

Studie 013
(CTN013-FCE20124)

Studienbericht

Pharmacia

Document 9550077

Reboxetine

CLINICAL STUDY
013

December 15, 1995

Multicentre, Multinational Double-blind Study of the Activity and Tolerability of Reboxetine vs Placebo in the Continuation Therapy of Major Depressive Episodes (Phase III)

Final report of study
CTN013-FCE20124

Authors

Ban TA, Dubini A, Petroccione A, Castiglioni RA,
Gaszner P, Mehilane L, Versiani M

1 (2598)

Pharmacia

Document 9550077

STUDY CO-ORDINATION, MANAGEMENT AND REPORTING

Steering Committee

Thomas A Ban MD
Professor of Psychiatry Emeritus
Vanderbilt University
Nashville, Tennessee, USA

October 10, 1995 Thomas A. Ban
date signature

Study Director

Adriana Dubini Pharm.D
Pharmacia, CNS R&D
Milano, Italy

Dec 6, 95 Adriana Dubini
date signature

Statistics

Anna Petroccione MD
Pharmacia, Oncology R&D
Biometrics and Data Management
Milano, Italy

Dec 6, 95 Anna Petroccione
date signature


Pharmacia

Document 9550077

CLINICAL INVESTIGATORS:

Dr RA Castiglioni
Hôpital Sainte Marguerite,
Service de Psychiatrie,
Marseille, Cedex, France

25.11.05
date


signature

Pharmacia

Document 9550077

CLINICAL INVESTIGATORS:

Dr P Gaszner
National Institute for
Nervous and Mental Diseases,
Budapest, Hungary

06.11.1995 , Peter Gaszner
date signature


090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

Pharmacia

Document 9550077

CLINICAL INVESTIGATORS:

Prof L Mehilane
Department of Psychiatry,
Tartu University,
Tartu, Estonia

07.11.95 
date signature

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

Pharmacia

Document 9550077

CLINICAL INVESTIGATORS:

Prof M Versiani
Institute of Psychiatry, Federal University
Rio de Janeiro, Brazil

November 14/95 *M Versiani*
date signature

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

TABLE OF CONTENTS

STUDY CO-ORDINATION, MANAGEMENT AND REPORTING	2
CLINICAL INVESTIGATORS	3
TABLE OF CONTENTS	7
LIST OF ABBREVIATIONS AND TERMS	23
SYNOPSIS	24
1. INTRODUCTION	28
2. STUDY OBJECTIVES	29
3. INVESTIGATIONAL PLAN	29
3.1 Study Design and Plan - Description and Rationale	29
3.1.1 Overview and Justification	29
3.1.2 Protocol Amendments	30
3.2 Ethics	31
3.2.1 Ethics Committee	31
3.2.2 Declaration of Helsinki	31
3.2.3 Patient Information	31
3.3 Study Population	32
3.3.1 Inclusion Criteria	32
3.3.2 Exclusion Criteria	32
3.3.3 Withdrawal Criteria	33
3.3.4 Sample Size - Number of Patients Planned	33
3.4 Treatments	34
3.4.1 Treatments to be Compared	34
3.4.2 Identity of Test Treatments	34
3.4.3 Dose Selection and Timing	34
3.4.4 Method of Assigning Patients to Treatment Groups	34
3.4.5 Treatment Packaging and Blinding	35
3.4.6 Concomitant Therapy	35
3.4.7 Treatment Supply, Accountability and Compliance	36
3.5 Efficacy and Safety Variables	36
3.5.1 Efficacy	36
3.5.1.1 Hamilton Depression Rating Scale	36
3.5.1.2 Clinical Global Impression	38
3.5.1.3 Montgomery and Asberg Depression Rating Scale	39
3.5.1.4 Zung Self-Rating Depression Scale	39
3.5.2 Safety	40
3.5.2.1 Adverse Events	40

Pharmacia

Document 9550077

3.5.2.2 Clinical and Laboratory Tests	41
3.6 Study Procedures and Flow Chart	42
3.6.1 Schedule of Assessments	42
3.6.1.1 Schedule of Assessments - Open Treatment Phase	42
3.6.1.2 Schedule of Assessments - Double-blind Treatment Phase	43
3.7 GCP Compliance and Data Quality Assurance	43
3.8 Statistical Analysis	44
3.8.1 Power Considerations	44
3.8.2 Planned Analysis	44
3.8.3 Analysis Carried Out	45
3.8.3.1 Baseline Comparability of Treatment Groups	45
3.8.3.2 Efficacy Analyses	45
3.8.3.3 Safety Analyses	47
3.9 Data Management	49
4. STUDY PATIENTS	50
4.1 Disposition of Patients	50
4.2 Protocol Deviations	52
4.2.1 Compliance with Entry Criteria	52
4.2.2 Concomitant Medications	52
4.2.3 Response criterion (HAMD total score decreased by 50% or more) for admission to double-blind phase	52
4.2.4 Randomisation	52
4.2.5 Assessment Intervals	53
4.2.6 Withdrawals for Protocol Violation	53
4.3 Demographic Data	53
4.3.1 Severity of Depression	54
4.3.2 Previous History of Depression	56
4.3.3 Medical History	57
5. STUDY MEDICATION AND COMPLIANCE	58
6. CONCOMITANT MEDICATION	58
7. EFFICACY RESULTS	58
7.1 Open Phase of the Study	58
7.1.1 Hamilton Depression Rating Scale	58
7.1.2 Clinical Global Impression	59
7.1.2.1 Severity of Illness	59
7.1.2.2 Global Improvement	59
7.1.2.3 Efficacy Index	59
7.1.3 Montgomery-Asberg Depression Rating Scale	59
7.1.4 Zung Self-Rating Depression Scale	59
7.2 Double-blind Phase	60

7.2.1 Hamilton Depression Rating Scale	60
7.2.1.1 HAMD Total Score	60
7.2.1.2 HAMD Factors	61
7.2.2 Clinical Global Impression	62
7.2.2.1 Severity of Illness	62
7.2.2.2 Global Improvement	62
7.2.2.3 Efficacy Index	62
7.2.3 Montgomery-Asberg Depression Rating Scale	62
7.2.4 Zung Self-Rating Depression Scale	63
7.3 Efficacy Conclusions	63
8. SAFETY RESULTS	63
8.1 Safety Population and Extent of Exposure	63
8.1.1 Number of Patients in Safety Analysis	63
8.1.2 Total Drug Exposure	63
8.2 Adverse Events	64
8.2.1 Analysis of Adverse Events	64
8.2.1.1 Open Phase	64
8.2.1.2 Double-blind Phase	66
8.2.2 Adverse Event Summary	69
8.2.2.1 Severity of Adverse Events	69
8.2.2.2 Age- and Gender-Related Effects	69
8.2.2.3 Frequently Reported Adverse Events	70
8.2.3 Serious Adverse Events, Deaths and Adverse Events Leading to Withdrawal	72
8.2.3.1 Serious Adverse Events and Deaths	72
8.2.3.2 Adverse Events Leading to Withdrawal	72
8.3 Laboratory Tests	73
8.3.1 Open Phase of the Study	73
8.3.1.1 Summary Statistics of Laboratory Values	73
8.3.1.2 Urinalysis	73
8.3.1.3 Abnormal Laboratory Values	73
8.3.1.4 Abnormal Laboratory Values of Clinical Relevance	74
8.3.2 Double-blind Phase	74
8.3.2.1 Summary Statistics of Laboratory Values	74
8.3.2.2 Urinalysis	75
8.3.2.3 Abnormal Laboratory Values	75
8.3.2.4 Abnormal Laboratory Values of Clinical Relevance	75
8.4 Vital Signs	75
8.4.1 Blood Pressure and Heart Rate	75
8.4.1.1 Open Phase	75
8.4.1.2 Double-blind Phase	76
8.4.2 Body Weight	77
8.4.3 Body Temperature	77
8.5 Ophthalmological Examination	77
8.6 Electrocardiogram	78

Pharmacia

Document 9550077

8.6.1 Open Phase	78
8.6.2 Double-blind Phase	78
8.7 Safety Conclusions	79
9. DISCUSSION	80
10. CONCLUSION	82
11. REFERENCES	83

TABLES	86
Table 1 Open phase: number of patients in each centre	87
Table 2 Patient disposition	88
Table 3 End of study: reasons for discontinuation - open phase	89
Table 4 Number of patients in each centre: double-blind phase	90
Table 5 End of study: reasons for discontinuation and visit at which discontinuation occurred - double-blind phase	91
Table 6 Frequency of protocol violations at admission	93
Table 7 Frequency of patients receiving concomitant drugs not allowed by protocol, by active principle	94
Table 8 Patients not responder at Visit 6 but entered double-blind phase	95
Table 9 Randomisation error: analysis of the assigned treatment vs randomised treatment	96
Table 10 Randomisation: Assigned treatment vs randomised treatment	97
Table 11 Compliance to schedule time as per protocol	98
Table 12 Demographic data of patients in open phase	100
Table 13 Demographic data of randomised patients	101
Table 14 Diagnosis and history of mental disorder of patients in open phase	102
Table 15 Diagnosis and history of mental disorders of randomised patients	103
Table 16 Previous antidepressive treatment by active principle	104
Table 17 Medical history findings of screened patients	105
Table 18 Medical history findings of screened patients by body system	107
Table 19 Experimental treatment: number of patients according to dose taken on each day and on days of assessment during therapy by phase and assigned treatment - open phase	108
Table 20 Experimental treatment: number of patients according to dose taken on each day and on days of assessment during therapy by phase and assigned treatment - phase: double-blind - treatment: reboxetine	109

Pharmacia

Document 9550077

Table 21	Experimental treatment: number of patients according to dose taken on each day and on days of assessment during therapy by phase and assigned treatment - phase: double-blind treatment: placebo	116
Table 22	Experimental treatment: distribution of patients according to capsules taken by phase and assigned treatment	122
Table 23	Concomitant drugs by active principle: number of patients receiving a concomitant drug at least once during the study by initial period of administration - open phase	123
Table 24	Concomitant drugs by active principle: number of patients receiving a concomitant drug at least once during the study by initial period of administration - double-blind phase	125
Table 25	Hamilton Depression Rating Scale - open phase	127
Table 26	Statistical analysis of factors of Hamilton Depression Rating Scale at each visit as compared to Day 0	128
Table 27	Hamilton Depression Rating Scale - summary statistics at last assessment of open phase	130
Table 28	Response during open phase	131
Table 29	Clinical Global Impression: severity - open phase	132
Table 30	Clinical Global Impression: severity - last assessment of open phase	133
Table 31	Shift table (last value vs Day 0) severity - open phase	134
Table 32	Clinical Global Impression: global improvement - open phase	135
Table 33	Clinical Global Impression: global improvement - last assessment of open phase	136
Table 34	Statistical analysis of efficacy index - open phase	137
Table 35	Montgomery-Asberg Depression Rating Scale - open phase	138
Table 36	Montgomery-Asberg Depression Rating Scale - summary statistics at last assessment of open phase	139
Table 37	Zung scale: summary statistics on total score according to time interval - open phase 140	140
Table 38	Zung scale - summary statistics on total score at last assessment - open phase	141
Table 39	Hamilton Depression Rating Scale considering only the patients responder at Visit 6 - treatment: reboxetine	142

Pharmacia

Document 9550077

Table 40 Hamilton Depression Rating Scale considering only the patients responder at Visit 6 - treatment: placebo	143
Table 41 Hamilton Depression Rating Scale - summary statistics at last assessment of randomised patients considering only the patients responder at Visit 6	144
Table 42 Proportion of patients who relapsed at least once during the double-blind phase	146
Table 43 Proportion of relapse-free patients during the first and the last 6 months of treatment - double-blind phase	147
Table 44 Patients in remission at last assessment by treatment (patients not responders at the end of run-in phase have not been considered)	148
Table 45 Statistical analysis of factors of Hamilton Depression Rating Scale at each visit as compared to Day 0 considering only the patients responder at Visit 6 - treatment: reboxetine	149
Table 46 Statistical analysis of factors of Hamilton Depression Rating Scale at each visit as compared to Day 0 considering only the patients responder at Visit 6 - treatment: placebo	155
Table 47 Clinical Global Impression: Severity considering only the patients responder at Visit 6	161
Table 48 Clinical Global Impression: Severity - last assessment considering only the patients responder at Visit 6	165
Table 49 Shift table - (last value vs Day 0) Severity considering only the patients responder at Visit 6	168
Table 50 Clinical Global Impression: Global Improvement considering only the patients responder at Visit 6	169
Table 51 Clinical Global Impression: Global Improvement - last assessment considering only the patients responder at Visit 6	173
Table 52 Statistical analysis of Efficacy Index considering only the patients responder at Visit 6 - treatment: reboxetine	176
Table 53 Statistical analysis of Efficacy Index considering only the patients responder at Visit 6 - treatment: placebo	177
Table 54 Montgomery-Asberg Depression Rating Scale considering only the patients responder at Visit 6	178
Table 55 Montgomery-Asberg Depression Rating Scale - last assessment considering only the patients responder at Visit 6	179

Pharmacia

Document 9550077

Table 56 Zung scale: summary statistics on total score according to time interval by assigned treatment - double-blind phase	180
Table 57 Zung scale: summary statistics on total score at last assessment by assigned treatment - double-blind phase	183
Table 58 Experimental treatment: number of patient exposed	185
Table 59 Adverse events: number of patients who complained of at least one adverse event during therapy - sex	186
Table 60 Adverse events: number of patients who complained of at least one adverse event during therapy - age	187
Table 61 Adverse events: number of adverse events and patients who complained of them during open phase by sex	188
Table 62 Adverse events: number of adverse events and patients who complained of them during open phase by body system and sex	191
Table 63 Adverse events: number of adverse events and patients who complained of them during open phase grouped by body system	205
Table 64 Adverse events: occurrence of adverse events according to time of onset - open phase	206
Table 65 Adverse events: occurrence of adverse events according to time of onset grouped by body system - open phase	209
Table 66 Adverse events: number of adverse events by maximal severity level and sex - open phase	210
Table 67 Adverse events: number of adverse events, grouped by body system, by maximal severity level and sex - open phase	216
Table 68 Adverse events: duration of episodes - open phase	219
Table 69 Adverse events: number of adverse events by symptomatic treatment and assigned treatment - open phase	222
Table 70 Adverse events by action on study drug - open phase	225
Table 71 Adverse events: disappeared after action on study drug and reappeared on resuming treatment - open phase	228
Table 72 Adverse events: outcome of events at the end of the therapy by action on study drug - open phase	230
Table 73 Adverse events by relationship to the experimental treatment - open phase	236

Pharmacia

Document 9550077

Table 74 Adverse events: number of randomised patients who complained of at least one adverse event during the study by sex and assigned treatment	239
Table 75 Adverse events: number of randomised patients who complained of at least one adverse event during the study by age and assigned treatment	240
Table 76 Adverse events: number of adverse events and patients who complained of them during therapy by sex, assigned treatment and phase	241
Table 77 Adverse events: number of adverse events and patients who complained of them during therapy by assigned treatment and grouped by body system	247
Table 78 Adverse events: occurrence of adverse events according to time of onset by assigned treatment	250
Table 79 Adverse events: occurrence of adverse events according to time of onset by assigned treatment and grouped by body system	257
Table 80 Adverse events: number of adverse events by maximal severity level, sex and assigned treatment	263
Table 81 Adverse events: number of adverse events, grouped by body system, by maximal severity level, sex and assigned treatment	271
Table 82 Adverse events: duration of episodes by assigned treatment	276
Table 83 Adverse events: number of adverse events by symptomatic treatment and assigned treatment	280
Table 84 Adverse events by action on study drug and assigned treatment	284
Table 85 Adverse events: disappeared after action on study drug and reappeared on resuming treatment by assigned treatment	289
Table 86 Adverse events: outcome of events at the end of the therapy by action on study drug assigned treatment	291
Table 87 Adverse events by relationship to the experimental treatment and assigned treatment	296
Table 88 Adverse events: frequency (95% C.I.) of patients who complained of adverse events during therapy according to time interval by sex and assigned treatment	301
Table 89 Adverse events: prevalence of adverse events according to time interval by assigned treatment	304
Table 90 Adverse events: prevalence of adverse events according to the interval by assigned treatment and grouped by body system	313

Pharmacia

Document 9550077

Table 91 Haematology and blood chemistry: mean and median values at each visit as compared to Visit -1 during the open phase	319
Table 92 Haematology and blood chemistry: number of subjects with values below, within or above the normal range at each evaluation time as compared to Visit -1 during the open phase	328
Table 93 Number and percentage of subjects with laboratory abnormalities of clinical relevance according to selected criteria - open phase	334
Table 94 Haematology and blood chemistry: mean and median values at each visit as compared to Visit -1 - randomised patients only	336
Table 95 Haematology and blood chemistry: number of subjects with values below, within or above the normal range at each evaluation time as compared to Visit -1	372
Table 96 Number and percentage of subjects with laboratory abnormalities of clinical relevance according to selected criteria - randomised patients only	408
Table 97a Vital signs: 5min lying systolic blood pressure - open phase	416
Table 97b Vital signs: 5min lying diastolic blood pressure - open phase	417
Table 97c Vital signs: 5min lying heart rate - open phase	418
Table 97d Vital signs: 2min standing systolic blood pressure - open phase	419
Table 97e Vital signs: 2min standing diastolic blood pressure - open phase	420
Table 97f Vital signs: 2min standing heart rate - open phase	421
Table 98 Vital signs changes from Visit -1 during the open phase	422
Table 99 Number and percentage of subjects with blood pressure and heart rate changes of clinical relevance as compared to Visit -1, in the open phase	423
Table 100 Number and percentage of subjects with vital signs changes of clinical relevance ($\geq 20\%$) as compared to Visit -1, in the open phase, associated with critical values	424
Table 101 Number and percentage of subjects with orthostatic hypotension during the open phase	426
Table 102a Vital signs: 5min lying systolic blood pressure - randomised patients only	427
Table 102b Vital signs: 5min lying diastolic blood pressure - randomised patients only	429
Table 102c Vital signs: 5min lying heart rate - randomised patients only	431

Pharmacia

Document 9550077

Table 102d	Vital signs: 2min standing systolic blood pressure - randomised patients only	433
Table 102e	Vital signs: 2min standing diastolic blood pressure - randomised patients only	435
Table 102f	Vital signs: 2min standing heart rate - randomised patients only	437
Table 103	Vital signss changes from Visit -I: randomised patients only	439
Table 104	Number and percentage of subjects with blood pressure and heart rate changes of clinical relevance as compared to Visit -I, in the double-blind phase	445
Table 105	Number and percentage of subjects with vital signs changes of clinical relevance ($\geq 20\%$) as compared to Visit -I, in the double-blind phase, associated with critical values	451
Table 106	Number and percentage of subjects with orthostatic hypotension - randomised patients only	463
Table 107	Vital signs: body weight - open phase	464
Table 108	Vital signs: body weight - randomised patients only	465
Table 109	Vital signs: body temperature - open phase	467
Table 110	Vital signs: body temperature - randomised patients only	468
Table 111	E.C.G.: Number and percentage of patients with abnormal E.C.G. according to time intervals by sex - open phase	470
Table 112	E.C.G.: shift table - number of patients with normal or abnormal E.C.G. value at each evaluation time as compared to pretreatment evaluation - open phase	471
Table 113	E.C.G.: shift table - number of patients with normal or abnormal E.C.G. value at last assessment as compared to pretreatment evaluation - open phase	472
Table 114	E.C.G.: Number and percentage of E.C.G. abnormalities observed during the study - open phase	473
Table 115	E.C.G.: Shift table - number of patients with absent or present E.C.G. abnormalities at last assessment as compared to pretreatment evaluation - open phase	474
Table 116	E.C.G.: Number and percentage of patients with at least one abnormality by abnormality group, observed during the study - open phase	477
Table 117	E.C.G.: shift table - number of patients with absent or present E.C.G. abnormalities grouped by type at last assessment as compared to pretreatment evaluation - open phase	478

Pharmacia

Document 9550077

Table 118	E.C.G.: Number and percentage of patients with abnormal E.C.G. according to time intervals by assigned treatment and sex - double-blind phase	479
Table 119	E.C.G.: shift table - number of patients with normal or abnormal E.C.G. value at each evaluation time as compared to pretreatment evaluation - double-blind phase	481
Table 120	E.C.G.: shift table - number of patients with normal or abnormal E.C.G. value at last assessment as compared to pretreatment evaluation - double-blind phase	482
Table 121	E.C.G.: Number and percentage of E.C.G. abnormalities observed during the study - double-blind phase	483
Table 122	E.C.G.: shift table - number of patients with absent or present E.C.G. abnormalities at last assessment as compared to pretreatment evaluation - double-blind phase	485
Table 123	E.C.G.: number and percentages of E.C.G. abnormalities, collected by group, observed during the study - double-blind phase	489
Table 124	E.C.G.: shift table - number of patients with absent or present E.C.G. abnormalities grouped by type at last assessment as compared to pretreatment evaluation - double-blind phase	491

Pharmacia

Document 9550077

FIGURES	495
Figure 1 Time to relapse (excluding the patients not responder at Week 6)	494
Figure 2 Censoring pattern	495
Figure 3 Maintenance of the response	496
Figure 4 Time to relapse (considering only the patients remitted at the end of the open phase)	497
Figure 5 Cumulative risk of developing the first adverse event during treatment - open phase	498
Figure 6 Percentage of patients with at least one adverse event when exposed to treatment according to time intervals - double-blind phase	499

Pharmacia

Document 9550077

12.	APPENDICES	500
12.1	Study Information	501
12.1.1	Protocol and Protocol Amendment	502
12.1.2	CRF Sample	572
12.1.3	Ethics Committees or Investigational Review Boards: Approvals, List of Members, Patient Information and Consent Forms	573
12.1.4	Clinical Investigators List, Signatures and Curricula Vitae	574
12.1.5	Certificates of Analysis	575
12.1.6	Audit Certificate	580
12.1.7	Randomisation List	582
12.1.8	Laboratory Reference Values and Criteria Used to Judge Abnormalities as Clinically Relevant	596
12.1.9	ECG Codes	599
12.1.10	Statistical Analysis Programs Listings	601
12.1.11	Selection of Statistical Analysis Outputs	609
12.2	Patient Information	657
12.2.1	Serious Adverse Events - Case Histories	658
12.2.2	Individual Data Listings	662
	Listing No. 1.0 Patient identification	
	Listing No. 2.0 Diagnosis and history of mental disorder	
	Listing No. 3.0 Chest X-ray and medical history	
	Listing No. 4.0 Previous treatments	
	Listing No. 5.0 Assessment dates and number of treatment days - open phase	
	Assessment dates and number of treatment days - double-blind phase	
	Listing No. 6.0 Concomitant drugs: open-phase	
	Concomitant drugs: double-blind phase	

Pharmacia

Document 9550077

Listing No. 7.0	Experimental treatment
Listing No. 8.0	Assigned vs randomised treatment
Listing No. 9.1	Reasons for discontinuation of the treatment - open phase Reasons for discontinuation of the treatment - double-blind phase
Listing No. 9.2	Patients not evaluable for efficacy
Listing No. 10. 1	Hamilton Depression Rating Scale - open phase Hamilton Depression Rating Scale - double-blind phase - treatment: reboxetine Hamilton Depression Rating Scale - double-blind phase - treatment: placebo
Listing No. 10.2	Montgomery Asberg Depression Rating Scale - open phase Montgomery Asberg Depression Rating Scale - double-blind phase - treatment: reboxetine Montgomery Asberg Depression Rating Scale - double-blind phase - treatment: placebo
Listing No. 10.3	Clinical Global Impression (CGI) - open phase Clinical Global Impression (CGI) - double-blind phase - treatment: reboxetine Clinical Global Impression (CGI) - double-blind phase - treatment: placebo
Listing No. 10.4	Zung Self Rating Depression Scale - open phase Zung Self Rating Depression Scale - double-blind phase - treatment: reboxetine Zung Self Rating Depression Scale - double-blind phase - treatment: placebo
Listing No. 11.0	Adverse Events - open phase Adverse Events - double-blind phase
Listing No. 12.1	Laboratory data - open phase Laboratory data - double-blind phase - treatment: reboxetine Laboratory data - double-blind phase - treatment: placebo
Listing No. 12.2	Laboratory data - clinically relevant abnormalities - open phase laboratory data - clinically relevant abnormalities - double-blind phase
Listing No. 12.3	Urinalysis - open phase

Pharmacia

Document 9550077

	Urinalysis - double-blind phase - treatment: reboxetine	
	Urinalysis - double-blind phase - treatment: placebo	
Listing No. 13.1	Vital signs - open phase	
	Vital signs - double-blind phase - treatment: reboxetine	
	Vital signs - double-blind phase - treatment: placebo	
Listing No. 13.2	Orthostatic hypotension - open phase	
	Orthostatic hypotension - double-blind phase - treatment: reboxetine	
	Orthostatic hypotension - double-blind phase - treatment: placebo	
Listing No. 13.3	Vital signs changes of clinical relevance - open phase	
	Vital signs changes of clinical relevance - double-blind phase - treatment: reboxetine	
	Vital signs changes of clinical relevance - double-blind phase - treatment: placebo	
Listing No. 14.1	ECG tracings: patients always normal - open phase	
	ECG tracings: patients always normal - double-blind phase	
Listing No. 14.2	ECG tracings: patients with at least one abnormality - open phase	
	ECG tracings: patients with at least one abnormality - double-blind phase	
Listing No. 15	Ophthalmologic examination at baseline and at last assessment (randomised patients) - treatment: reboxetine	
	Ophthalmologic examination at baseline and at last assessment (randomised - patients) - treatment: placebo	
12.2.3 CRFs		2598

LIST OF ABBREVIATIONS AND TERMS

AUC	Area under the plasma levels curve
b.i.d.	twice daily
BP	blood pressure
BUN	blood urea nitrogen
CGI	clinical global impression
CRF	case record form
CV	cardio-vascular system
DSM-III-R	diagnostic and statistical manual - 3rd edition - revised
ECG	electrocardiogram
ECT	Electroconvulsive therapy
GI	gastro-intestinal system
HAMD	Hamilton depression rating scale
HR	heart rate
MADRS	Montgomery-Asberg depression rating scale
NS	nervous system
R&D	research and development
REM	rapid eye movement
SD	standard deviation
SEM	standard error of the mean
Zung SDS	Zung self-rating depression scale

Pharmacia

Document 9550077

REBOXETINE - PROTOCOL 20124/013

SYNOPSIS

Name of Company: Pharmacia	Individual study table referring to part IV of the dossier Ref.: Vol.: Page:	(For national authority use only)
Name of finished product: Name of active ingredient(s): Reboxetine		
Title of study: Multicentre, multinational double-blind study of the activity and tolerability of reboxetine vs placebo in the continuation therapy of major depressive episodes		
Investigators: Prof M Versiani, Dr R Castiglioni, Prof K Ernst, Prof A Lipcey, Prof P Gaszner, Dr L Mehilanc, Dr Osztorharies, Prof A Szucs, Dr T Hortobagyi.		
Study centres: Federal University, Rio de Janeiro, Brazil; Hôpital Sainte Marguerite, Marseille, France; Neurologische Universitätsklinik, Rostok, Germany; Janos General Hospital, Budapest, Hungary; National Institute for Nervous and Mental Diseases, Budapest, Hungary; Tartu University, Estonia; Megyei Kórház Pszichiatriai, Győr, Hungary; Hollos Jozsef Megyei Kórház, Kecskemét, Hungary; Városi Kórház Pszichiatriai, Osztálya, Nagykanizsa, Hungary.		
Publication (reference): None		
Study period: May 90 - March 93	Clinical Phase: III	
Objectives: To assess the activity and tolerability of reboxetine in comparison with placebo in the maintenance therapy of Major Depressive Disorders.		
Methodology: In this prospective, double-blind, randomised, placebo-controlled, parallel group, multicentre and multinational trial, patients underwent an initial wash-out period of 1-2 weeks, after which they received reboxetine 4 mg b.i.d. for six weeks. Responders (50% decrease of the total Hamilton Depression Rating Scale (HAMD) score) were randomised to treatment with either reboxetine 4 mg b.i.d. or placebo for a maximum of one year or until relapse (total HAMD score increased by at least 50% and of at least 18). The response to treatment was assessed using the HAMD scale, Clinical Global Impression (CGI), the Montgomery and Asberg Depression Rating Scale (MADRS) and the Zung Self-Rating Depression Scale (Zung SDS). Safety and tolerability were assessed by the reporting of any adverse events and assessment of vital signs (supine and standing blood pressure and heart rate), laboratory tests, ECG and ophthalmological examination.		
Number of subjects (planned and analysed): 300 patients were to be recruited for the double-blind phase of the study. 358 patients from 9 centres entered the open phase and 286 patients from 8 centres were randomised to treatment with either reboxetine (145) or placebo (141). Three patients were randomised to treatment with either reboxetine (2) or placebo (1) but never received it. They were excluded from the analysis. Thus, 283 patients received randomised treatment.		
Diagnosis and main criteria for inclusion : Patients were diagnosed according to the DSM-III-R classification and were also assessed by the Composite Diagnostic Evaluation of Depressive Disorders (CODE-DD). The severity of depression was quantified using the HAMD scale. Criteria for inclusion were as follows: (1) Patients of either sex, of any race, aged 18 to 65 years, with a diagnosis of acute recurrence of Major Depressive Disorders, not accompanied by psychotic features (DSM-III-R) and not chronic in course, as shown by the CODE-DD variables: 'Acute onset' or 'Subacute onset' present and 'Prolonged duration' absent; (2) Initial (pre-treatment) total score for the 21-item HAMD and the Day 0 total score had to be ≥ 18 .		

Pharmacia

Document 9550077

<p>Name of Company: Pharmacia</p> <p>Name of finished product:</p> <p>Name of active ingredient(s): Reboxetine</p>	<p>Individual study table referring to part IV of the dossier</p> <p>Ref:</p> <p>Vol:</p> <p>Page:</p>	<p>(For national authority use only)</p>
<p>Test product: tablets containing reboxetine methanesulphonate unit dose: 4 mg reboxetine (free base) mode of administration: by oral route, b.i.d. batch no.: SF1032, SF1106</p>		
<p>Duration of treatment: Open phase: 6 weeks; double-blind phase : maximum period of one year or until relapse</p>		
<p>Reference therapy: Placebo (excipients alone) indistinguishable tablets unit dose: mode of administration: by oral route batch no.: SF1030, SF1111</p>		
<p>Criteria for evaluation:</p> <p>Efficacy</p> <p><i>Response:</i> HAM-D total score decreases equal to or greater than 50% compared to the baseline value (Visit 0). <i>Remission:</i> HAM-D total score lower than or equal to 10 (absolute value). <i>Relapse:</i> Increase in HAM-D total score equal to or greater than 50% compared with the value at randomisation (Visit 6) and HAM-D total score equal to or greater than 18 (absolute value). <i>Time to relapse:</i> Number of days elapsing between the randomisation date (Visit 6) and the date when the patient was first classified as "relapse". <i>Time to treatment failure:</i> Number of days elapsing between randomisation date (Visit 6) and date of relapse or of withdrawal from the study for any reason other than improvement. <i>Maintenance of the response:</i> Cumulative probability of the long lasting effect of the treatment based on the time to treatment failure</p> <p>Safety</p> <p>Reporting of adverse events, measurements of vital signs (supine and standing blood pressure and heart rate), laboratory tests, ECG, and ophthalmological examination.</p>		
<p>Statistical Method: The primary analysis of treatment effectiveness (main end-point) was based on the comparison of the proportion of patients experiencing at least one relapse in the long-term treatment period following randomisation, out of the total number of randomised patients, in each of the two treatment groups. A chi-square test was applied in order to test the null hypothesis.</p> <p>The time patterns of relapses in the two treatment groups, were described by the Kaplan-Meier method and compared by the log-rank test.</p> <p>The crude rate of patients who did not relapse at least once and who did not withdraw (unless because of improvement) during the first six and the following six months of the double-blind period, respectively, were compared between the two treatment groups by chi-square test, in order to test the maintenance of the response achieved in the open phase in the two periods separately. In addition, the relapse-free time pattern in the two groups was described according to the Kaplan-Meier method and between-treatment difference was tested by the log-rank test. The remission rate at the last assessment of the double-blind phase was calculated and the between-treatment difference tested (chi-square test).</p>		

Pharmacia

Document 9550077

<p>Name of Company: Pharmacia</p> <p>Name of finished product:</p> <p>Name of active ingredient(s): Reboxetine</p>	<p>Individual study table referring to part IV of the dossier</p> <p>Ref.:</p> <p>Vol.:</p> <p>Page:</p>	<p>(For national authority use only)</p>
<p>The cumulative risk of developing the first adverse event during the treatment period was estimated by the Kaplan-Meier method (open phase only). Furthermore, the weekly (run-in phase) or monthly (double-blind phase) frequency of patients presenting adverse events (either because of the onset of new events or because of the persistence of those previously developed) was assessed.</p>		
<p>Results</p> <p>358 patients entered the open phase of the study, 263 females and 95 males, with a mean age of 43.2 years. During the double-blind phase of the study, 143 patients received reboxetine and 140 received placebo. 79 reboxetine and 65 placebo recipients completed the study.</p>		
<p>Efficacy At the end of open reboxetine, 76% of patients were responders and 50% of patients were in remission (HAMDD total score 10 or less). At the last assessment of the open reboxetine treatment, the HAMDD total score was reduced from 29.6 at baseline to 12.9, the MADRS total score from 18.4 to 7.8, while the percentage of patients whose condition was "very much improved" and "much improved" according to CGI scores was 45.8 and 31.3, respectively.</p> <p>Among the 133 responder patients randomised to reboxetine, 21.8% relapsed during the long-term treatment, while 56.1% of the 132 responder patients randomised to placebo relapsed, the between-treatment difference being highly significant ($p < 0.01$). The time pattern of the relapse rate analysed according to the Kaplan-Meier method indicates a significantly increased risk of relapse on placebo compared with reboxetine ($p = 0.0001$). The proportion of patients in remission at the last assessment of the double-blind treatment phase was significantly higher on reboxetine (78.2%) than on placebo (44.7%) ($p < 0.001$).</p> <p>These results are confirmed by the analysis of the secondary efficacy variables. In the 133 responder patients randomised to reboxetine, the mean HAMDD score was reduced from 29.2 at baseline to 8.8 at week 6 and to 5.9 at Week 52 in the 76 assessed patients still on maintenance reboxetine. In the 132 responder patients randomised to placebo, HAMDD scores fell from 30.1 to 9.1 at Week 6 but increased to 11.1 at Week 52 in the 62 assessed patients still on treatment. Similarly, the mean total MADRS scores fell from 5.3 at Week 6 to 3.1 at Week 52 in the 76 assessed patients still on maintenance reboxetine, compared with a rise from 5.3 to 7.0 in the 62 patients on placebo. The percentage of patients whose CGI score was "very much improved" increased from 62.4% at Week 6 to 94.7% at Week 52 on reboxetine in contrast to a marginal increase from 57.6% to 64.5% at Week 52 on placebo.</p> <p>The additional analysis of the frequency of absence of relapse during the initial six months and subsequent six months of treatment indicates that the advantage over placebo in the maintenance of the response is present also in the second half of the one year treatment period (88.0 vs 59.2% of the reboxetine- and placebo-treated patients, respectively).</p> <p>Safety: All the patients who received study treatment were included in the safety analysis, i.e. 358 patients in the open phase and 283 patients (143 reboxetine, 140 placebo) in the double-blind phase of the study.</p> <p>During the open phase of the study, 52% of the patients reported adverse events and 3.6% discontinued reboxetine medication due to adverse events. Most frequently reported were dry mouth (19% of the patients), constipation (17%), urinary hesitancy/retention and increased sweating (8%), tachycardia and insomnia (6% each), and decreased libido (5%). The occurrence of newly reported adverse events was similar on reboxetine and placebo during the double-blind phase of the study; 40/143 reboxetine recipients reported 56 adverse events compared with 32/140 placebo recipients who reported 48 adverse events; however, the prevalence of adverse events was higher in the reboxetine than in the placebo group and discontinuation due to adverse event was more frequent on reboxetine (4.2%) than on placebo (1.4%). Most frequently reported was constipation (8% on reboxetine, 4% on placebo). The majority of adverse events were mild. Adverse events were reported more frequently by men than women, particularly on reboxetine. This was particularly the case for urinary hesitancy, urinary retention and decreased libido. There were three serious adverse events during the study (suicide and generalised convulsive episode on open reboxetine, hallucinations on placebo). The one death was the result of suicide.</p>		

Pharmacia

Document 9550077

Name of Company: Pharmacia Name of finished product: Name of active ingredient(s): Reboxetine	Individual study table referring to part IV of the dossier Ref.: Vol.: Page:	(For national authority use only)
<p>There was no indication of modifications in laboratory tests that were of clinical significance.</p> <p>Vital signs were not modified to any significant extent, with the exception of heart rate, which was significantly increased (20% or more) under reboxetine to values of 100 beats/min or higher in approximately 10 to 15% of the patients, also on long-term treatment and particularly on standing.</p> <p>No indication of effect on cardiac function emerged from ECG recordings. The ophthalmological examination did not provide indications of treatment related changes.</p>		
<p>Conclusions: The efficacy of reboxetine maintenance therapy in responders, as measured by HAM-D, MADRS and CGI scales, was markedly superior to that of placebo in patients with major depression, when administered for up to one year. The tolerability of reboxetine administered on a long-term basis was highly acceptable, as shown by the safety profile which was marginally superior to placebo for the incidence of adverse events and clinically significant tachycardia and similar to placebo for modifications of other vital signs, haematology and blood chemistry tests, ophthalmological and ECG examinations.</p>		

1. INTRODUCTION

Reboxetine (FCE 20124 or (2RS, α RS)- 2-[α -(2-ethoxy-phenoxy) benzyl] morpholine) is a new chemical compound which is highly potent in the pharmacological and biochemical tests predictive of antidepressant efficacy such as reserpine antagonism, norepinephrine reuptake inhibition and REM sleep latency increase [1]. Reboxetine also demonstrates the ability to prevent the effects of clonidine, an α_2 noradrenergic receptors agonist, after a single oral dose, in an animal model where tricyclic antidepressants were active only upon repeated administration [1]. Therefore, reboxetine was hypothesised to exert antidepressant efficacy of faster onset than the antidepressants currently available in depressed patients. In addition, comparison with imipramine 75 mg in a Q-EEG study in healthy volunteers revealed that reboxetine does not possess the marked sedative activity of imipramine, but rather psychostimulating properties [2, 3].

The pharmacokinetic properties of reboxetine have been evaluated following administration of single oral doses to healthy volunteers [4]. Average peak levels were observed 2 hours after administration, with remarkably stable levels 1-6 hours after administration; reboxetine plasma half-life was estimated as 13.2 hours and circulating radioactivity was accounted for principally (73% of AUC) by unchanged reboxetine.

An early phase II, 4-week, multicentre study in 98 patients in which reboxetine was administered at fixed-dosing doses, with maximum doses between 4 and 12 mg, showed that the compound was well tolerated at doses of up to 10 mg/day [5].

A double-blind parallel group multicentre study in 258 patients hospitalised due to a major depressive episode compared maximum doses of 8 mg of reboxetine with 200 mg of desipramine and placebo administered over a period of 4 weeks [6]. Reboxetine was found to be more effective than placebo with decreases $\geq 50\%$ in Hamilton Depression Rating Scale (HAM-D) at the end of treatment in 63% of patients (36% under placebo and 46% under desipramine). These decreases were present after 14 days of treatment in 31% of reboxetine patients and 22% of desipramine patients. More reboxetine patients complained of headache and urinary retention, whereas more desipramine patients experienced dry mouth, sweating and blurred vision. Cardiovascular adverse events were relatively rare but appeared with slightly higher frequency in the desipramine group (hypotension and tachycardia).

Phase II results obtained in controlled conditions in short-term studies in patients suffering from Major Depressive Disorders indicate that reboxetine is an effective antidepressant agent with a favourable therapeutic index with respect to desipramine. It is, however, recognised that the treatment of the depressive episode up to apparent resolution of symptoms is insufficient and long-term treatment is recommended, particularly in the case of recurrent depression [7, 8]. The present study was designed to evaluate the efficacy of

reboxetine in the long-term, continuation therapy of major depressive episodes, and its tolerability during long-term administration.

2. STUDY OBJECTIVES

To assess the activity and tolerability of reboxetine in comparison with placebo in the maintenance therapy of Major Depressive Disorders.

3. INVESTIGATIONAL PLAN

3.1 Study Design and Plan - Description and Rationale

3.1.1 OVERVIEW AND JUSTIFICATION

This phase III study was designed as a prospective, double-blind, randomised, placebo-controlled, parallel group, multicentre and multinational trial of the long-term efficacy and tolerability of reboxetine administered orally for up to one year to adult patients with a major depressive episode who had previously responded to a 6-week course of reboxetine. The design of the study is shown overleaf.

A total of 300 patients with Major Depressive Disorders was to be recruited according to the inclusion and exclusion criteria, and an informed consent obtained from each patient before screening.

At screening, a full medical history and physical examination (including ophthalmological examination, chest X-ray and electrocardiogram (ECG)) were carried out together with measurement of vital signs and laboratory tests. Patients were classified according to the Diagnostic and Statistical Manual - 3rd edition - revised (DSM-III-R) classification and the severity of depression was quantified using the HAMD score. Patients were also assessed by the Composite Diagnostic Evaluation of Depressive Disorders (CODE-DD), a psychiatric composite diagnostic system, the results of which are reported separately in the Addendum 1 and 2 to the present report.

After an initial wash-out period of 1-2 weeks, patients received reboxetine 4 mg b.i.d. for 6 weeks. Responders ($\geq 50\%$ decrease of the total HAMD score) were randomised to treatment with either reboxetine 4 mg b.i.d. or placebo for a maximum of one year or until relapse (total HAMD score increased by at least 50% and of at least 18). Relapse rate and time was defined as the study end-point; the between-treatment difference in relapse rate and cumulative risk of relapse were statistically analysed by the chi-square test and the log-rank test, respectively.

Other variables used for measuring efficacy were the Clinical Global Impression (CGI), the Montgomery and Asberg Depression Rating Scale (MADRS) and the Zung Self-Rating Depression Scale (Zung SDS).

Pharmacia

Document 9550077


Safety and tolerability were assessed by the reporting of any adverse events and assessment of vital signs (supine and standing blood pressure and heart rate), laboratory tests, ECG and ophthalmological examination.

Patients willing to continue receiving the test treatment after completion of a one year treatment period could be maintained on the same medication under blind conditions until the completion of the last patient in the centre.

A follow-up visit was carried out in each patient one month after treatment discontinuation in order to monitor possible withdrawal reactions and collect information on any events since treatment discontinuation.

A copy of the final protocol can be found in Appendix 12.1.1.

Overall Design



3.1.2 PROTOCOL AMENDMENTS

A protocol amendment was introduced (January 24, 1991) to extend the wash-out period to 3-4 weeks in patients who had had previous treatment with fluoxetine.

Four centres initially expected to participate were not active in the study for organizational reasons which prevented the possibility of long-term patient follow-up (Laboratoire de Pharmacologie Clinique, Centre Hospitalier Ponchaillou, Rennes, France and Klinika Psychiatrikzna, Szczecin, Poland) or due to political emergencies (two centres at the National Psychiatric Hospital, Panama). To make up the deficiency in patient numbers, the study was extended to include centre numbers 11, 12 and 13 (See Appendix 12.1.4) in Hungary, while the population expected to be recruited was increased in centre numbers 1 and 10, in order to maintain the recruitment capacity needed for the proposed sample size.

Pharmacia

Document 9550077

3.2 Ethics

3.2.1 ETHICS COMMITTEE

Approval from the Ethics Committees or Institutional Review Boards (IRBs) of the participating centres, in accordance with the regulations and requirements of individual countries, had to be obtained before the study could be undertaken. It was the responsibility of each of the investigators to submit the study protocol with its attachments to the Ethics Committee or IRB. A central approval allowing the clinical evaluation of the product was required and obtained in Hungary and Estonia (for the specific protocol), while local approvals were required and obtained in Germany, Brazil and France. In the latter case, the approval was obtained on a draft version of the protocol, marginally different from the final one.

The investigators were responsible, in accordance with local requirements, for informing the Ethics Committee/IRB of any emergent problems, serious adverse reactions or protocol amendments.

The notifications of approval are kept in the Pharmacia's trial master file.

3.2.2 DECLARATION OF HELSINKI

The study was carried out according to the principles embodied in the Declaration of Helsinki, adopted by the 18th World Medical Assembly, Helsinki, June 1964, and amended by the 29th World Medical Assembly, Tokyo, October 1975, by the 35th World Medical Assembly, Venice, October 1983 and the 41st World Medical Assembly, Hong Kong, 1989. A copy of the Declaration of Helsinki can be found in Enclosure 10 of Appendix 12.1.1.

3.2.3 PATIENT INFORMATION

Before entering the study, an explanation of the nature, duration, purpose of the study and action of the compound had to be given to each patient in such a manner that he/she was made aware of the potential risks, inconveniences or adverse events that could occur, and could express his/her informed consent to participation. The proposed consent form is enclosed (Enclosure 1 of Appendix 12.1.1); local translations and/or the forms adopted in response to individual Ethical Committee suggestions can be found in the trial master file. The forms were signed by the patient or the investigator. In the latter case, the signature of a witness was required to testify that full information was given to the patient.

3.3 Study Population

Adult patients who were attending out-patient clinics or were newly admitted (within 2 weeks) to the Psychiatric departments of the participating centres were selected in accordance with the following inclusion and exclusion criteria.

3.3.1 INCLUSION CRITERIA

The criteria for participation in this study were as follows:

- Patients of either sex, of any race, aged 18 to 65 years
- A diagnosis of acute recurrence of Major Depressive Disorders, not accompanied by psychotic features (DSM-III-R) [9] and not chronic in course, as shown by the CODE - DD [10] variables: 'Acute onset' or 'Subacute onset' present and 'Prolonged duration' absent
- The initial (pre-treatment) total score for the 21-item HAMD [11] and the Day 0 total score had to be ≥ 18
- Informed consent was obtained from the patient and/or next of kin (see Section 3.2.3).

3.3.2 EXCLUSION CRITERIA

Exclusion criteria for patients recruited to this study were as follows:

- Patients with a first episode of Major Depressive Disorder
- History of Major Depressive Disorder associated with endocrine disorders: hypo- or hyperthyroidism (confirmed by rT_3 , followed by T_3 and T_4 in the case of negative findings on admission), adrenal insufficiency, etc
- Pregnancy (excluded by a pregnancy test at the end of the wash-out period)
- Refusal to use contraception during the study period
- Past history of drug hypersensitivity
- Participation in a clinical study with an investigational compound in the four weeks preceding the study
- Evidence of substance or drug abuse presently or within the past six months
- Chronic respiratory insufficiency

Pharmacia

Document 9550077

-
- History or presence of gastrointestinal, hepatic or renal disease, or other conditions known to interfere with the absorption, distribution, metabolism and excretion of drugs
 - History of seizures or serious brain injury; current evidence of clinically important haematopoietic or cardiovascular diseases; current evidence of urinary retention or glaucoma
 - Symptoms of any other important clinical illness in the four weeks preceding the study
 - Clinically relevant abnormal findings in the physical examination, laboratory tests and ECG at admission
 - Electroconvulsive therapy (ECT) in the previous six months.

3.3.3 WITHDRAWAL CRITERIA

Patients could be withdrawn from the study at any time for the following reasons:

- Voluntary withdrawal by the patient
- Unacceptable toxicity, defined as the occurrence of serious and unexpected adverse events or the persistence of non-tolerable signs or symptoms which were not alleviated by reducing the dose to the lower dosage level
- Lack of efficacy during the open initial treatment phase, which applied to patients who after completion of at least two weeks of treatment showed worsening of the global clinical picture (Clinical Global Improvement - CGI - see Section 3.5.1.2).

In the case of treatment discontinuation, the final complete battery of tests was carried out wherever possible.

3.3.4 SAMPLE SIZE - NUMBER OF PATIENTS PLANNED

Each of the 10 centres participating in the study were to recruit, within a period of one year, enough patients to collect a sample of 30 patients who fulfilled the criteria for entering the double-blind phase of the study, so that a total of 300 patients was to be recruited overall.

As already mentioned in Section 3.1.2., in 4 centres the study never started for logistical reasons, 3 new centers were included and recruitment was extended in centre numbers 1 and 10 to well above the foreseen patient sample. Recruitment was stopped after randomisation of 286 patients of the 358 recruited. The sample size was consistent with the one calculated for an "intent to treat" analysis.

3.4 Treatments

3.4.1 TREATMENTS TO BE COMPARED

After an initial wash-out period of 7 days (14 days in the case of monoamine oxidase inhibitors' administration, 3-4 weeks in case of fluoxetine following the protocol amendment), patients received reboxetine 4 mg b.i.d. for 6 weeks. Responders ($\geq 50\%$ decrease of the total HAMD score) were randomised to treatment with either reboxetine 4 mg b.i.d. or placebo (one tablet b.i.d.) for a maximum of one year or until relapse (total HAMD score increased by at least 50% and of at least 18).

3.4.2 IDENTITY OF TEST TREATMENTS

Indistinguishable scored tablets containing either reboxetine 4 mg plus excipients (Batch No: SF1032, SF1106) or excipients only (placebo, Batch No: SF1030, SF1111) were supplied by the Sponsor. Copies of certificates of analysis for the test treatments are presented in Appendix 12.1.5.

3.4.3 DOSE SELECTION AND TIMING

All patients recruited for the study received one tablet of reboxetine 4 mg b.i.d. from Day 1 to Day 42 (i.e., for 6 weeks). The daily dose of reboxetine was chosen on the basis of the results of the previously mentioned open dose finding study [5], in which daily doses of 8 to 10 mg were found to be associated with the best therapeutic index, and of the controlled phase II study vs desimipramine and placebo [6], where the 8 mg/day dose was proved to possess antidepressant efficacy. At the end of this open treatment phase, patients showing a response were randomised to treatment with either reboxetine 4 mg b.i.d. or placebo (one tablet b.i.d.) for a maximum period of one year or until relapse.

The treatment was administered in the morning (10 a.m.) and in the evening (6 p.m.). Treatment had to be taken at least 2 hours before or after meals.

The daily dose could be reduced to half a tablet (2 mg b.i.d. for reboxetine) in the case of emergence of non-tolerable signs or symptoms.

3.4.4 METHOD OF ASSIGNING PATIENTS TO TREATMENT GROUPS

A randomisation list balanced within each centre and every 4 assignments was originally generated for patient allocation either to reboxetine or placebo. In the list in order to make the patient unequivocally identifiable across centres by his assignment number, a progressive number from 1 to 390 was generated. The test treatments were labelled according to the randomisation sequence number. Each randomised patient was then identified by corresponding treatment number. In spite of the anticipated break down by centre of such a

sequential list, in order to minimize the waste of drug supply, the latter was shipped to the centres by complete blocks of four treatment each. This led to the utilization of study medication by centers other than those to which it was initially allocated.

At the end of the 6-week open treatment of the acute episode of major depression, patients eligible for the double-blind phase of the study were given by investigators an independent sequence number from the one assigned during the open phase, according to the time they complete it. Assignment of treatment was done in a double-blind fashion by matching this sequence number and the treatment box number.

3.4.5 TREATMENT PACKAGING AND BLINDING

For the initial open treatment of the acute episode, six amber glass bottles showing the patient number and the appropriate week of treatment (Week 1 to 6) were prepared for each patient. Each bottle contained the medication necessary for each of the first six weeks of treatment with reboxetine (i.e. 16 tablets, one 4 mg tablet b.i.d. and 2 additional tablets for possible losses).

For the double-blind continuation therapy in patients who responded, glass amber bottles showing the patient number and the treatment period Week 7-8, Week 9-10, Week 11-12, and so on up to Week 51-52 were prepared for all the patients. These bottles contained the medication necessary for the two-week treatment periods between visits up to a maximum of one year (i.e. 32 tablets of either reboxetine 4 mg or placebo, representing one tablet b.i.d. and 4 additional tablets for possible losses).

To ensure the double-blind nature of the study, indistinguishable test treatment in identical amber bottles was identified using double labels indicating the protocol number, patient number, treatment period, batch number and expiry date (Enclosure 2 of Appendix 12.1.1). The detachable half of the label was to be included in the appropriate place in the CRF when used.

The investigators were given individual sealed envelopes containing the information on patient's treatment, and these were to be opened only in case of emergency necessitating treatment identification. In the event of an emergency, the investigators were to notify the study monitor immediately (within 24 hours), and were to report a full description of the reasons for opening the code on the Adverse Event Form in the CRF. The sealed individual codes were to be returned to the Sponsor at the end of the study.

3.4.6 CONCOMITANT THERAPY

No concomitant medication was allowed during the study. In the case of events arising during the course of the study, non-psychotropic medications which were considered necessary for the patient's welfare could be administered and were not considered protocol

Pharmacia

Document 9550077

violations. The medication, dosage and frequency of administration were recorded on the CRF. Chloral hydrate was permitted at bed-time as a sleep inducer on an 'as required' basis.

3.4.7 TREATMENT SUPPLY, ACCOUNTABILITY AND COMPLIANCE

All drug supplies were handled under the direct responsibility of the investigators and held by the Hospital Pharmacy. The study monitors checked drug storage conditions during site visits.

The investigators were responsible for drug accountability and kept a record of the test compounds received from the Sponsor as well as the drugs dispensed to each patient on the occasion of each visit. The upper label from each of the weekly cartons dispensed to each patient was detached and fixed in the appropriate space in the CRF. On the same occasion, cartons of the previous supply were returned by the patient and remaining capsules were counted (and the resulting figure reported in the CRF) to estimate compliance. These used cartons were returned to the study monitors during site visits. All unused medication was to be returned to the Sponsor at the end of the study.

3.5 Efficacy and Safety Variables

At screening, a full medical history and physical examination (including ophthalmologic examination, chest X-ray and ECG) were carried out including a measurement of vital signs and laboratory tests. Patients were classified according to the DSM-III-R classification [9], and the severity of depression was quantified using the HAMD scale [11]. Patients were also assessed by the Composite Diagnostic Evaluation of Depressive Disorders (CODE-DD) [10], a psychiatric composite diagnostic system, the results of which are reported separately in an 'ad hoc' report.

3.5.1 EFFICACY

Patients were classified according to the CODE-DD at screening, on Day 42 (Week 6), after 6 and 12 months of treatment and/or at the time of withdrawal.

Patients were seen at regular intervals throughout the study and the following efficacy assessments carried out at the specified intervals. All psychiatric evaluations and ratings were to be carried out by the same observer for a given patient and in the same setting and at the same time of day if possible.

3.5.1.1 Hamilton Depression Rating Scale

The severity of depression was measured using the HAMD at screening, Days 0, 7, 14, 21, 28, 35, 42 and every two weeks during double-blind phase study.

The HAMD scale contained 21 items, each of which was scored (0-2, 0-3 or 0-4) to reflect whether the symptom was absent, trivial, mild, moderate or severe. Some of the items were more heavily weighted than others. The scores for all the symptoms were added together to give a global judgement of the severity of the depression.

The 21-item list of the HAMD used in this study is as follows:

<u>Item</u>	<u>Score range</u>	<u>Factor</u>
1. Depressed mood	(0-4)	V
2. Feelings of guilt	(0-4)	III
3. Suicide	(0-4)	III
4. Insomnia early	(0-2)	VI
5. Insomnia middle	(0-2)	VI
6. Insomnia late	(0-2)	VI
7. Work and activities	(0-4)	V
8. Retardation	(0-4)	V
9. Agitation	(0-4)	III
10. Anxiety (psychic)	(0-4)	I
11. Anxiety (somatic)	(0-4)	I
12. Somatic symptoms gastrointestinal	(0-2)	I
13. Somatic symptoms general	(0-2)	I
14. Genital symptoms	(0-2)	V
15. Hypochondriasis	(0-4)	I
16. Loss of weight	(0-2)	II
17. Insight	(0-2)	I
18. Diurnal variation	(0-2)	IV
19. Depersonalization and Derealization	(0-4)	III
20. Paranoid symptoms	(0-3)	III
21. Obsessional symptoms	(0-2)	III

More detailed definitions of the items included in the scale can be found in Enclosure 4 of Appendix 12.1.1

Pharmacia

Document 9550077

Factorialisation was carried out according to the ECDEU manual [12], to yield six factors: anxiety/somatisation (I), weight (II), cognitive disturbances (III), diurnal variation (IV), retardation (V) and sleep disturbances (VI).

3.5.1.2 Clinical Global Impression

The Clinical Global Impression (severity of illness, global improvement and efficacy index) was administered according to the ECDEU manual [12]. Severity of illness was assessed by the investigator at Days 0, 7, 14, 21, 28, 35, 42 and every two weeks during the double-blind treatment period. The following scale was used:

- 1 = normal, not at all ill
- 2 = borderline mentally ill
- 3 = mildly ill
- 4 = moderately ill
- 5 = markedly ill
- 6 = severely ill
- 7 = among the most extremely ill patients

In addition, the investigator evaluated the global improvement at each visit, with reference to the baseline assessment, according to the following scale:

- 1 = very much improved
- 2 = much improved
- 3 = minimally improved
- 4 = no change
- 5 = minimally worse
- 6 = much worse
- 7 = very much worse

An Efficacy Index was then assessed in accordance with the degree of improvement of a patient and the disability deriving from the side effects experienced. Details of the CGI and its Efficacy Index can be found in Enclosure 5 of Appendix 12.1.1.

3.5.1.3 Montgomery and Asberg Depression Rating Scale

The MADRS [13] was measured at Days 0, 7, 14, 21, 28, 35, 42 and at monthly intervals thereafter.

This scale consists of ten items relating to depression selected from the 67 items in the Comprehensive Psychopathological Rating Scale [14] in view of their sensitivity to change [13]. The ten items are as follows:

1. Reported sadness
2. Inner tension
3. Apparent sadness
4. Suicidal thoughts
5. Inertia
6. Inability to feel
7. Pessimistic thoughts
8. Concentration difficulties
9. Reduced sleep
10. Reduced appetite

The scale requires a structured interview for completion. A score of 0 to 3 for each item was used, as in reference 14. More detailed definitions of the items included in the scale can be found in Enclosure 6 of Appendix 12.1.1.

3.5.1.4 Zung Self-Rating Depression Scale

The Zung SDS [15] was measured at Days 0, 7, 14, 21, 28, 35, 42 and at monthly intervals thereafter.

The scale consisted of 20 statements which patients were asked to choose the appropriate answer for out of the following:

- None or a little of the time
- Some of the time
- A good part of the time
- Most or all of the time

A score of between 0-4 or 4-0, depending on the statements, was awarded to the answers and the score for all the answers was totaled in order to give the Zung SDS score. The 20 statements used are shown in Enclosure 7 of Appendix 12.1.1

Pharmacia

Document 9550077

3.5.2 SAFETY

3.5.2.1 Adverse Events

Spontaneously Reported

Patients were notified of any possible adverse events they might experience and were instructed to report any such adverse event to the investigators immediately.

The occurrence of adverse events was recorded at Day 0, 7, 14, 21, 28, 35, 42 and every two week thereafter.

Any adverse event, noticed by the investigators or reported by the patients was reported, regardless of presumed relationship to the study medication, in the appropriate section of the CRF (Adverse Event Report Form - Enclosure 8 of Appendix 12.1.1).

For each adverse event, the following information was entered the CRF: description, date of onset, date of stopping, severity, drug cause-effect relationship, outcome, effect of withdrawal of treatment and rechallenge. The investigators also had to note if the double-blind code had been broken, the action taken regarding the test drug (none, dose reduced or discontinued) and any treatment given as a result of the adverse event.

Severity was coded as follows:

- 1 = mild - awareness of sign or symptom, but easily tolerated
- 2 = moderate - discomfort enough to cause interference with usual activity
- 3 = severe - incapacitating with inability to work or due usual activity
- 4 = unknown

Relationship to test drug was coded by the physician as definite, probable, possible, doubtful, unknown or not related, according to Karch and Lasagna modified criteria as shown in Enclosure 9 of Appendix 12.1.1.

All serious* and/or unexpected** adverse events had to be reported to study monitors in the Sponsor subsidiary immediately (within 24 hours), and the details recorded on an Adverse Event Report Form. Serious adverse event was defined as any experience that was (potentially) fatal or life-threatening, disabling, incapacitating, requiring inpatient hospitalisation, causing a congenital anomaly or cancer, or due to an overdose.

* Code of Federal Regulation, Vol 21, Part 312. Revised as of April 1 1987, page 75.

** Bem JL, Breckenridge AM, Mann RD, Rawlins MD. Review of yellow cards (1986): report to the Committee on the Safety of Medicines. Br J Clin Pharmac 1988; 26: 679-690.

Unexpected Adverse Event

Unexpected adverse event was defined as any adverse experience that was not identified in nature, severity or frequency in the current Investigator's brochure for the study.

The same procedure applied for all patients who died during the course of the study or within 30 days of completion, irrespective of whether the event was judged as related to treatment. If an autopsy was performed, a copy of the pathological report was to be sent to the Sponsor.

Adverse Events Reported Through a Check-List

The presence or absence of selected adverse events was solicited through a check list especially designed for the identifying events frequently reported in patients on antidepressant medication. These events could be either reported by the patient or observed by the investigator.

For each adverse event, the same procedure as for spontaneously reported adverse events was followed in terms of recording of information in the CRF (Adverse Event Report Form) and reporting of the 'serious' or 'unexpected' adverse event to the Sponsor.

3.5.2.2 Clinical and Laboratory Tests

Vital Signs

Blood pressure and heart rate (supine and standing) were measured at screening, on Days 0, 7, 14, 21, 28, 35, 42 and every two weeks thereafter.

Supine blood pressure and heart rate were measured in the morning after 5 minutes in the supine position and standing blood pressure and heart rate were measured 1 to 2 minutes after standing up.

ECG

An ECG was recorded at screening, on Days 14, 28, 42 and every two months in the double-blind period of the trial.

Ophthalmological examination

A standard ophthalmological examination, including assessment of visual acuity, colour vision, intraocular pressure, visual field, slit lamp examination of lens and cornea, and dilated fundus examination was performed at screening and the end of the double-blind period of the trial.

Laboratory Tests

Laboratory tests were recorded at screening, on Days 14, 28, 42 and every two months in the double-blind period of the trial.

Pharmacia

Document 9550077

The laboratory tests comprised the following: full blood count, serum electrolytes, liver enzymes, blood sugar, serum alkaline phosphatase, blood urea nitrogen (BUN), serum creatinine, uric acid, total and direct bilirubin, total serum protein and electrophoresis, serum cholesterol and triglycerides, rT₃, T₃ and T₄ (at screening only), and urinalysis.

Laboratory tests were also measured for patients who withdrew prematurely because of a serious adverse event.

3.6 Study Procedures and Flow Chart

3.6.1 SCHEDULE OF ASSESSMENTS

3.6.1.1 Schedule of Assessments - Open Treatment Phase

Assessment	Pre-treatment screening	Treatment day						
		0	7	14	21	28	35	42
Medical history	x							
Physical examination	x							
Ophthalmological examination	x							
Chest X-ray	x							
ECG	x			x		x		x
DSM-III-R/CODE-DD	x							x
21-item HAMD	x	x	x	x	x	x	x	x
CGI		x	x	x	x	x	x	x
MADRS		x	x	x	x	x	x	x
Zung SDS		x	x	x	x	x	x	x
Adverse events		x	x	x	x	x	x	x
Vital signs	x	x	x	x	x	x	x	x
Laboratory tests	x*			x		x		x
Dispensing medication		x	x	x	x	x	x	x
Compliance check		x	x	x	x	x	x	x

* rT₃, T₃ and T₄ at screening only

3.6.1.2 Schedule of Assessments - Double-blind Treatment Phase

Assessment	End of week							
	8	52
Ophthalmological examination								*
ECG	■	■	■	■	■	■	■	■
DSMIII-R/CODE- DD								*
21-item HAMD	x	x	x	x	x	x	x	x
CGI	x	x	x	x	x	x	x	x
MADRS	☒	☒	☒	☒	☒	☒	☒	☒
Zung SDS	☒	☒	☒	☒	☒	☒	☒	☒
Adverse events	x	x	x	x	x	x	x	x
Vital signs	x	x	x	x	x	x	x	x
Laboratory tests	■	■	■	■	■	■	■	■
Dispensing medication	x	x	x	x	x	x	x	
Compliance check	x	x	x	x	x	x	x	x

x.....x every two weeks
 ☒.....☒ every month
 ■.....■ every two months

3.7 GCP Compliance and Data Quality Assurance

The study was initiated before the formal adoption of Good Clinical Practice guidelines by European Regulatory Authorities and in the absence of Company Standard Operating Procedures. However, operating procedures for study monitoring and co-ordination were defined and are described in Attachment A of Appendix 12.1.1.

Training on diagnostic assessment was carried out during the first investigator meeting and during the site visit performed by the Scientific Co-ordinator of the study. Inter-rater reliability sessions on the instrument used for the assessment of change, particularly on the HAMD, were carried out during monitoring visits for training purposes by employing four videotaped interviews.

During the monitoring visits, which were made at regular intervals, the monitor validated the content of the CRF against source documents on the basis of the agreed procedures.

Site, trial master file and report audits were carried out by the Company Quality Assurance Unit.

3.8 Statistical Analysis

3.8.1 POWER CONSIDERATIONS

The main evaluation of treatment effectiveness was based on the comparison of the proportion of patients experiencing relapse (see below for definition) during the double-blind phase in each of the two treatment arms (reboxetine and placebo) out of the number of randomised patients.

In agreement with this goal, the following system of hypotheses was set up:

$$H_0: \pi_{RBX} \geq \pi_{PLC}$$

$$H_a: \pi_{RBX} < \pi_{PLC}$$

where π_{RBX} and π_{PLC} are the true relapse rates in the reboxetine and the placebo treated population, respectively.

Given the fact that a 15% difference in relapse rate was considered as a clinically relevant difference and assuming that 50% of placebo-treated patients were expected to relapse within one year, 135 patients in each arm were required to reject the null hypothesis at a one-tail α -level = 0.05 and with a power $(1 - \beta) = 0.80$ for the alternative hypothesis of a difference ($\delta = \pi_{PLC} - \pi_{RBX}$) as high as, or higher than, 15%.

Taking into account that 20% of the patients entering the run-in phase could not have achieved the response at the end of this phase, 358 patients were to be recruited.

3.8.2 PLANNED ANALYSIS

The main comparison was to be carried out on the basis of the rate of relapse (% of randomised patients experiencing relapse (as defined in Section 3.8.3.2)) using a test based on binomial distribution. The relapse time within each treatment group was to be estimated by the Kaplan-Meier method and compared by the log-rank test.

In addition, the remission rate (% of randomised patients experiencing remission at the last assessment and at the end of the 1-year treatment period) was to be compared between the two treatment groups.

The frequency of patients showing a clinically relevant decrease (≥ 20 mmHg) in standing systolic blood pressure was to be compared between the two groups.

Adverse events were to be presented by listing, patient-by-patient, all events and the cumulative frequencies of occurrence by treatment. If there were clinically significant differences in the occurrence of adverse events between treatment groups, these were to be compared.

Laboratory data was to be classified as normal or abnormal according to the normal ranges of the performing laboratory and the frequency of the abnormal results after treatment compared between the two treatment groups.

3.8.3 ANALYSIS CARRIED OUT

3.8.3.1 Baseline Comparability of Treatment Groups

Baseline characteristics (e.g. age, diagnosis, age at onset, number of previous episodes) which might have influenced the main end-point of the study were summarised considering both all the patients entered into the run-in phase and only the patients subsequently randomised either to reboxetine or placebo in the double-blind phase. In this latter presentation, patients were grouped according to the treatment they were allocated to afterwards, in order to verify the comparability of the two treatment groups.

3.8.3.2 Efficacy Analyses

Efficacy Criteria

The following definition and selection applies to the set of data analysed at the end of open phase:

- | | |
|------------|---|
| Remission: | HAMD total score lower than or equal to 10 (absolute value). |
| Response: | HAMD total score decrease equal to or greater than 50% compared to the baseline value (Visit 0). According to this definition, and based on the inclusion criterion which required a total score of HAMD at entry of at least 18, not all patients who achieved remission (as defined above), were included in the broader category of response ($18 \cdot 0.5 = 9$). |

Pharmacia

Document 9550077

The following definition and selection applies to the set of data analysed during double-blind phase:

- Relapse:** Increase in HAMD total score equal to or greater than 50% compared with the value at randomisation (Visit 6) and HAMD total score equal to or greater than 18 (absolute value).
- Time to relapse:** Number of days elapsing between the randomisation date (Visit 6) and the date when the patient was first classified as "relapse" according to the above definition.
- Time to censoring:** Number of days elapsing between randomisation (Visit 6) and withdrawal from the study for reasons other than occurrence of relapse or deterioration requiring study treatment discontinuation (classified in the end-of-treatment summary as deterioration).
- Time to treatment failure:** Number of days elapsing between randomization date (visit 6) and date of relapse or of withdrawal from the study for any reason other than improvement.
- Maintenance of the response:** Cumulative probability of the long lasting effect of the treatment based on the time to treatment failure.

Double-blind Phase

Patients who entered the double-blind phase of the study but who did not fulfil the criterion of response were excluded from efficacy analysis.

The primary analysis of treatment efficacy (main end-point) was based on the comparison of the proportion of patients experiencing at least one relapse in the long-term treatment period following randomisation, out of the total number of randomised patients, in each of the two treatment groups. In this analysis, patients withdrawing for any reason were classified according to whether or not they had relapsed during the observation period. A chi-square test [16] was applied in order to test the null hypothesis.

The cumulative probabilities of relapsing in the two treatment groups were described by the Kaplan-Meier method and compared by the log-rank test [17].

The same analysis was carried out for the sub-group of patients in remission at the end of the initial 6 weeks of treatment.

In both analyses, patients withdrawn for any reason were considered censored at the time of withdrawal. In order to ensure that the censoring patterns in the two treatment groups were comparable and independent of the treatment, the Kaplan-Meier curves of time to censoring were provided.

The crude rate of patients who did not relapse at least once and who did not withdraw (unless because of improvement) during the first six and the following six months of the double-blind period, respectively, were compared between the two treatment groups by chi-square test, in order to test the maintenance of the response achieved in the open phase in the two periods separately. The denominator of the analysis in the last six months includes all the patients who did not relapse or withdraw in the preceding six months. In addition, maintenance of the response including both the total observation period of 52 weeks and the first 6 months after randomisation (up to week 26) in the two groups was described according to the Kaplan-Meier method and between-treatment difference was tested by the log-rank test.

As planned in the protocol, the remission rate at the last assessment of the double-blind phase was calculated and the between-treatment difference tested (chi-square test).

Moreover, the total scores for HAMD, MADRS, Zung SDS, and CGI variables have been summarised by descriptive statistics at each visit and considering the last valid observation, in the two treatment groups.

3.8.3.3 Safety Analyses

All the analyses were carried out on two sets of data, according to the study design. The first set refers to the run-in phase and includes all the patients entered into the study, while the second set includes only the randomised patients and considers the assessments performed during both run-in and double-blind period, in order to give an overview of the safety of the whole study period (randomised patients who did not receive any dose in the double-blind phase have been excluded). In both cases, the values collected before the start of run-in phase were considered as reference values for the comparison vs baseline.

Vital Signs

Vital signs as measured at each assessment time were summarised by descriptive statistics. Patients with orthostatic hypotension (a decrease > 20 mmHg of the systolic blood pressure from lying to standing) were described. Finally, the frequency of patients showing clinically relevant changes ($\geq 20\%$ or more vs baseline) or such a modification accompanied by absolute critical values (≥ 160 or ≤ 100 mmHg for systolic blood pressure; ≥ 100 or ≤ 70 mmHg for diastolic blood pressure; ≥ 100 or ≤ 50 beats/min for heart rate) at each evaluation time were tabulated.

ECG

ECG results have been summarised in frequency tables showing normal/abnormal findings at each visit. Changes from baseline (i.e. normal to abnormal and vice versa, or changes in type of abnormality) have been displayed.

Pharmacia

Document 9550077

Laboratory Examinations

For all the laboratory examinations and within each of the two treatment groups, the following analyses have been provided:

- frequency and percentage of patients whose values were below, within or above the normal range at baseline and shifted to values below, within or above the normal ranges at each visit. Either the MacNemar test or Stuart Maxwell test [18] has been applied in order to test if the distribution across categories at baseline differs from the distribution at each visit.
- continuous values of laboratory tests were standardized according to the method proposed by Chuang-Stein [19], using as reference values the one reported in the Cecil Textbook of Medicine [20]; the Wilcoxon Rank Signed test for paired data [21] was applied in order to compare the values during treatment with those recorded at baseline.

The usage of statistical tests in this framework aimed mainly at providing screening tools for selecting relevant changes within each single examination, which were to be considered clinically relevant on the basis of the concordance with other examinations evaluating the same organ function. As an arbitrary pragmatic criterion statistical significance was claimed when p value was lower than 0.01.

Moreover, abnormal values of laboratory tests defined as clinically relevant by pre-defined criteria (Appendix 12.1.8) were specially considered and frequencies of clinically relevant abnormalities calculated.

Adverse Events

In the analysis of adverse events, attention has been focused on treatment-emergent signs and symptoms, i.e. events that were not present at baseline that appeared during treatment or, if present at baseline, that became more severe during treatment. The analyses were essentially descriptive and, for each set of patients (see above) and each treatment group, they were performed both in terms of the number of patients complaining of adverse events and the number of events.

Each event has been classified as occurring during the run-in phase or the double-blind phase depending on its onset. In the assessment of the frequency of patients with adverse events, each patient was counted once in any given phase, provided that he/she complained of one or more events occurring during that phase. The analyses were performed taking into account the occurrence of at least one sign or symptom, the occurrence of at least one event for each body system and, in detail, the occurrence of each type of sign or symptom. When severity of the events was considered, the worst reported degree was selected. In order to explore possible differences, patients were also classified by sex and age.

The cumulative risk of developing the first adverse event during the treatment period was estimated by the Kaplan-Meier method (open phase only). Furthermore, the weekly (run-in phase) or monthly (double-blind phase) frequency of patients presenting adverse events (either because of the onset of new events or because of the persistence of those previously developed) was assessed.

The events have been described by frequency tables according to duration, onset time, symptomatic treatment, relationship to study medication, study drug adjustment and outcome. The duration of any event was computed as the number of days from its onset up to its recovery or, in the absence of a recovery date, up to the last reporting date (approximate duration).

3.9 Data Management

Data management was carried out in the Biometrics and Data Management Department of Pharmacia, Milan.

CRFs data were entered into an IBM 3090 computer (according to the arrival flow) through data entry masks generated by SAS FSP release 6.06 and 6.07.

ECG tracings were classified and subsequently grouped according to the codes reported in Appendix 12.1.9. Previous and concomitant diseases were coded according to ICD9 dictionary [22]; concomitant drugs were coded according to the Drug Reference List [23]; and adverse events according to the WHO-ART dictionary [24]. In the absence of an adequate code and preferred term, "urinary hesitancy" was coded as "micturition disorder", and "blurred vision" as "vision abnormal". The mentioned events therefore appear in the tables under the indicated terms.

Subsequently, data were scrubbed by an electronic procedure set up to this purpose which generates listings of discrepancies between the actual value entered and pre-defined algorithms. Computer programs generated for this purpose are archived in the Biometrics and Data Management Department. These listings were reviewed by clinical personnel and editing of CRFs was requested at the Investigator site, whenever appropriate. Corrections were entered, repeating the loop until the files were completely clean.

Reporting, as well as statistical analyses, were carried out with SAS PROCs (version 6.07), apart from the Stuart-Maxwell test. The programs relevant to the latter are appended in Appendix 12.1.10. A selection of statistical analyses outputs is shown in Appendix 12.1.11.

4. STUDY PATIENTS

4.1 Disposition of Patients

Three hundred and fifty-eight patients were recruited to the open phase of this study at nine centres. Recruitment by centre is shown in Table 1. Centre numbers 1 and 10 recruited the majority of the patients, 41.9% and 21.2% respectively, while patient inclusion was minimal in centre numbers 2 (4 patients), 3 (10 patients), and 8 (7 patients). The remaining centres admitted 20-38 patients each to the study. Patient disposition is summarised in Table 2. A total of 322 patients (89.9%) completed the open phase of the study in accordance with the protocol and 36 patients (10.1%) withdrew. The main reasons for withdrawal are shown in Table 3.

One patient committed suicide. The narrative summary of the event is enclosed (Appendix 12.2.1); 13 patients (3.6% of the population admitted) dropped out due to adverse events (see Section 8.2.3.2); deterioration and unco-operativeness caused discontinuation in 10 and 11 cases, respectively (approximately 3% of the admitted patients).

Two hundred and eighty-six patients from 8 centres were randomised to treatment with either reboxetine (145) or placebo (141) as shown in Table 4. Three patients (centre 10: no. 36/36, 83/60, 18/283) were randomised to treatment with either reboxetine (2 cases) or placebo (1 case) but never received it. They were excluded from the analysis.

The frequency and timing of withdrawals, according to protocol provisions or for other reasons, during the double-blind phase is indicated by reason in Table 5.


Lack of efficacy was given as a reason for withdrawal twice as often by placebo recipients (36 patients, 25.7% of the randomised and treated cases) compared with reboxetine recipients (17 patients, 11.9%). Adverse events were associated with withdrawal in six patients under reboxetine (4.2% of the randomised and treated patients) and two patients under placebo (1.4%). In total, 64 patients (44.8% of the randomised and treated cases) discontinued the double-blind treatment in the reboxetine group and 75 (53.6% of the randomised and treated cases) in the placebo group. Discontinuations were mainly apparent within the seventh months of treatment.

Pharmacia

Document 9550077

The overall picture of patient disposition is shown below.

Disposition of patients



4.2 Protocol Deviations

4.2.1 COMPLIANCE WITH ENTRY CRITERIA

The frequency of non-compliance with inclusion/exclusion criteria of relevance for inferential purposes is given in Table 6. The most frequent reason (8.7% of the patients) for possible non-compliance with the exclusion criteria was related to abnormalities of thyroid function tests, suggestive of possible underlying, undiagnosed, endocrine disorder. Psychotropic medication with a possible influence on baseline assessments that was not allowed was administered during the wash-out period in 2.5% of the patients.

4.2.2 CONCOMITANT MEDICATIONS

The frequency of administration of concomitant drugs not allowed by the protocol due to their psychotropic properties during the open and double-blind phase is given in Table 7. This refers mainly to long-acting benzodiazepines, rarely administered and with similar frequency in the placebo and reboxetine groups.

4.2.3 RESPONSE CRITERION (HAMD TOTAL SCORE DECREASED BY 50% OR MORE) FOR ADMISSION TO DOUBLE-BLIND PHASE

The frequency of non-compliance with the response criterion is given in Table 8. As already mentioned, this applied to 18 cases, 10 randomised to reboxetine and 8 to placebo. All but two cases were improved in comparison with baseline, the improvement being superior to 40% in seven cases. As mentioned, these patients were excluded from efficacy analyses.

4.2.4 RANDOMISATION

Distribution and use of study medication were to be done, as previously mentioned, in blocks of 4 treatments, used in sequence from the smallest to the highest number according to patient temporal entry into the study; each centre was supposed to receive and use only complete blocks. In order to provide a discrepancy log with respect to the randomisation sequence, patients were listed according to their study entry date and the treatment foreseen to be assigned according to the random sequence of the blocks available at the center was matched by a sequential criterion. Mismatching between the foreseen treatment and the treatment actually received was identified as a randomisation error.

As reported in Table 9, errors in randomisation led to administration of the alternative experimental treatment in 49 patients (17.3%), but the within-centre error rate was highly variable (0-50%). However, as shown in Table 10, this randomisation error was evenly distributed in the reboxetine and the placebo groups (24 and 25 cases, respectively). In addition, in eight cases, four per group, problems in material supply led to utilization of the

Pharmacia

Document 9550077

material left by drop-out cases, which was therefore “out of randomisation” and they were analysed as for the actual treatment received.

4.2.5 ASSESSMENT INTERVALS

The summary statistics of the efficacy and safety assessment intervals are shown in Table 11. The range of days from treatment start indicates little, if any, deviation from the protocol time-schedule for the majority of assessment intervals.

4.2.6 WITHDRAWALS FOR PROTOCOL VIOLATION

Ten patients (6 reboxetine, 4 placebo) were withdrawn from the double-blind phase of the study because of protocol deviations as shown overleaf:

Protocol Deviations Causing Withdrawal from the Double-blind Phase of the Study

Protocol deviation	Reboxetine	Placebo	Total
Anxiolytic intake	2	1	3
Pregnancy	1	0	1
Misuse of study medication supply	3	1	4
Other	0	2	2
Total	6	4	10

4.3 Demographic Data

Demographic data of the whole sample admitted to the open phase and of the two subsamples subsequently randomised to reboxetine and placebo treatments for the double-blind phase of the study are given in Table 12 and 13 respectively and are presented below:

Summary of Demographic Data

		Open phase Reboxetine		Double-blind phase			
		n	(%)	Reboxetine		Placebo	
		n	(%)	n	(%)	n	(%)
Sex	female	263	73.5	115	79.3	95	67.4
	male	95	26.5	30	20.7	46	32.6
Total		358	100	145	100	141	100
		Mean	SD	Mean	SD	Mean	SD
Age (years)		43.2	11.8	43.4	11.6	42.3	12.2
Height (cm)		165.6	8.4	165.3	7.5	165.4	8.9
Weight (kg)		66.7	13.0	67.2	13.4	66.0	11.8

Female patients were prevalent in both treatment groups, and particularly so in the reboxetine group. The reboxetine and placebo treatment groups were well matched for age, height and weight.

4.3.1 SEVERITY OF DEPRESSION

The severity of depression, according to the HAMD, CGI and MADRS scales, at entry and at the different time intervals during the open phase of the study, is described in Tables 25, 29 and 35. As shown below, the severity of depression at entry in the total population was similar to the one of randomised patients and, among randomised patients, there was no important difference between the treatment groups at Day 0.

Pharmacia

Document 9550077

Severity of Depression at Day 0 in all patients

	n	Mean	SD
HAMD	358	29.6	5.6
MADRS	358	18.4	4.1

	n	(%)
CGI severity		
Normal	0	
Borderline mentally ill	0	
Mildly ill	3	(0.8)
Moderately ill	30	(8.4)
Markedly ill	223	(62.3)
Severely ill	87	(24.3)
Extremely ill	15	(4.2)

Pharmacia

Document 9550077

Severity of Depression at Day 0 in Randomised Patients

	Reboxetine			Placebo		
	n	Mean	SD	n	Mean	SD
HAMD	145	29.1	5.5	141	29.7	5.7
MADRS	145	17.9	4.0	141	18.6	4.2
	n	(%)		n	(%)	
CGI severity						
Normal	0			0		
Borderline mentally ill	0			0		
Mildly ill	1	(0.7)		1	(0.7)	
Moderately ill	12	(8.3)		13	(9.2)	
Markedly ill	89	(61.4)		91	(64.5)	
Severely ill	37	(25.2)		32	(22.7)	
Extremely ill	6	(4.2)		4	(2.8)	

4.3.2 PREVIOUS HISTORY OF DEPRESSION

Frequency of DSMIII-R diagnostic classifications and summary statistics (including mean with SD as well as median values with range) of features of the history of the mental disorder in the total population and in the randomised patients are shown in Tables 14 and 15 respectively.

The median age at onset of the depressive disorder, the median number of previous episodes of depression, the median duration of the last episode and the median duration of the present episode in the total population and in the randomised patients at entry are presented for each treatment group in the following table:

Previous History of Depression in the Total Population and in Randomised Patients

	All patients			Reboxetine			Placebo		
	n	Median	(range)	n	Median	(range)	n	Median	(range)
Age at onset (years)	356	34	(11-63)	145	34	(13-60)	139	32	(11-62)
Number of previous episodes	356	3	(1-15)	145	3	(1-15)	139	3	(1-10)
Duration of the last episode (weeks)	354	24	(2-364)	143	24	(3-364)	139	24	(2-364)
Duration of the present episode (weeks)	354	8	(0.1-364)	144	8	(0.1-364)	139	10	(0.6-208)

The treatment groups were well matched and similar to the admitted population for all aspects.

The frequency of previous antidepressant therapy by active principle is described in Table 16. As expected, tricyclic antidepressants were the most frequently prescribed and were similarly represented in the reboxetine and placebo groups.

4.3.3 MEDICAL HISTORY

Medical history in the total population and in the two groups of patients randomised to reboxetine and placebo is given in Table 17 and summarized by body system in Table 18. Worth noting is the slightly higher frequency of diseases of the circulatory system in the reboxetine group.

5. STUDY MEDICATION AND COMPLIANCE

The frequency of each dose of the experimental treatment administered in each study day is given in Tables 19 (open phase), 20 and 21 (double-blind phase, reboxetine and placebo, respectively). The per protocol dose was reportedly administered to almost all patients during the whole treatment period. The few exceptions mainly concerned instances of decrease of the daily dose or temporary treatment interruption in a maximum of 7 patients per treatment day during the open phase and of 2 and 3 patients in the reboxetine- and placebo-treated patients, respectively, during the double blind phase.

Comparison of the administered dose, as reported in the compliance section of the CRF, with the expected dose, as indicated in the experimental treatment section of the CRF, allowed calculation of the compliance with the treatment regimen; full compliance was defined in the case of correspondence between the dose prescribed (the per protocol one or a lower one prescribed by the physician, e.g. in case of adverse events) and the dose reportedly taken. A global compliance over the treatment period was calculated and patients were classified accordingly, as reported in Table 22. In 99% of the cases during the open phase and in 97 and 98% of the reboxetine- and placebo-treated cases during the double-blind phase, the reported compliance was 100%.

6. CONCOMITANT MEDICATION

The frequency of patients receiving a concomitant medication at least once is indicated by active principle in Table 23 (open phase) and 24 (double-blind phase). Most frequently newly administered was chloral hydrate as sleep inducer. In addition to the psychotropic medications not allowed by protocol administered in few cases in both treatment groups, already commented in Section 4.2.2, other drugs were only seldom administered, generally following the emergence of adverse events, with no major differences in frequency of administration between reboxetine and placebo.

7. EFFICACY RESULTS

7.1 Open Phase of the Study

7.1.1 HAMILTON DEPRESSION RATING SCALE

Summary statistics of total HAMD scores at each visit in the observed cases are shown in Table 25 and for individual HAMD factors in Table 26. The last assessment of the open phase is summarised in Table 27.

At the last assessment, the mean total HAMD score was reduced from 29.6 at baseline to 12.9. Among HAMD factors, the median of the differences vs baseline indicates maximal improvement for the factors 'retardation' (1.5 points), 'diurnal variation' and 'anxiety/somatisation' (1 point), corresponding to those most severely effected at baseline.

Pharmacia

Document 9550077

As summarised in Table 28, a total of 272 patients (76.0% of the admitted) were responders at Week 6 and of them 179 patients (50.0% of the admitted) were seen to be in remission.

7.1.2 CLINICAL GLOBAL IMPRESSION

7.1.2.1 Severity of Illness

The distribution of the CGI severity scores at each visit of the open phase in the observed cases is presented in Table 29, while the distribution of the scores at last assessment is summarised in Table 30. A clear-cut modification of the overall picture is apparent, with the majority of the patients being markedly to severely ill at baseline (90.8%) and normal to mildly ill at last assessment (69.8%).

The shift table of the last value vs Day 0 (Table 31) showed that the majority of patients had the severity of illness decreased (87.7%) and only 2.0% increased.

7.1.2.2 Global Improvement

The distribution of the CGI global improvement scores at each visit of the open phase in the observed cases are shown in Table 32. The last assessment of CGI improvement during the open phase of the study is summarised in Table 33.

The proportion of patients who were 'very much improved' increased from 0.8% at Week 1 to 50.5% at Week 6 and patients who were 'much improved' increased from 10.3% at Week 1 to 33.4% at Week 6. At the last assessment the majority of patients was classified as significantly improved, either very much (45.8%) or much (31.3%).

7.1.2.3 Efficacy Index

Summary statistics of the efficacy index, which attempts to weigh up the therapeutic benefit i.e. therapeutic effect vs side effects, are shown in Table 34. The mean and median efficacy index indicate a therapeutic effect outweighing side effects (1.5 or above) from Week 2 onwards.

7.1.3 MONTGOMERY-ASBERG DEPRESSION RATING SCALE

Summary statistics of MADRS total scores at each visit in the observed cases and at last assessment are shown in Table 35 and 36, respectively. The average MADRS total score was reduced from 18.4 at baseline to 7.8 at the last assessment.

7.1.4 ZUNG SELF-RATING DEPRESSION SCALE

Summary statistics of the Zung SDS total scores at each visit in the observed cases and at the last assessment are given in Tables 37 and 38, respectively. Complete data were obtained at baseline and at least one visit in only 317 of the 358 admitted patients. In this

subset of cases, the average Zung SDS total score was reduced from 57.1 at baseline to 41.3 at the last assessment.

7.2 Double-blind Phase

As mentioned, efficacy results have been analysed and are presented at each visit during the open and double-blind phases of the study for those patients who received randomised treatment, after exclusion of the 18 patients (10 of the reboxetine and 8 of the placebo group) admitted to randomised treatment while not complying with admission response criteria.

7.2.1 HAMILTON DEPRESSION RATING SCALE

7.2.1.1 HAMD Total Score

Summary statistics of total HAMD scores at each visit are shown in Table 39 for the reboxetine group and in Table 40 for the placebo group. Summary statistics of the HAMD total scores at the last assessment in the two treatment groups are given in Table 41.

In the 133 responder patients subsequently randomised to reboxetine, the mean HAMD total score was reduced from 29.2 at Week 0 to 8.8 at Week 6. This improvement was slightly increased in the patients continuing to receive the experimental treatment, with an average score of 5.9 at Week 52 in the 76 assessed patients still on treatment. The mean HAMD total score in the 132 responder patients subsequently randomised to placebo was reduced from 30.1 at Week 0 to 9.1 at Week 6, i.e. similarly to the above. This improvement was maintained in the patients continuing to receive the experimental treatment, a marginal deterioration being apparent in the 62 assessed patients still on treatment at Week 52 (11.1 points). Last assessment mean HAMD scores were 7.9 and 13.9 in reboxetine and placebo arm respectively. This unbiased comparison confirmed the difference between the two treatments.

Study End-Points

The number of randomised responder patients who relapsed at least once is shown by treatment group in Table 42. Among the 133 responder patients randomised to reboxetine, 21.8% fulfilled the criterion for relapse at least once during the study, while 56.1% of the 132 responder patients randomised to placebo did, the between-treatment difference being highly significant ($p < 0.001$).

The pattern of the time to relapse according to the Kaplan-Meier method in the two treatment groups is shown in Figure 1. The cumulative risk of relapse is clinically and statistically significantly higher under placebo than under reboxetine ($p = 0.0001$); under reboxetine, the relapses mainly occur within the first 3-4 months of follow-up, while under placebo, the cumulative probability of relapse increases almost steadily up to the end of the observation period.

In order to exclude the influence of the missed observations, due to possible differences between the two groups in drop-out rate, on the above findings, the censoring pattern was calculated, and is reported in Figure 2. No difference between the two groups is apparent.

When the results are considered in terms of maintenance of the response (defined as absence of relapse or relapse-free) (Figure 3), the cumulative probability is clinically and statistically significantly higher under reboxetine than under placebo ($p=0.0001$).

A further analysis was carried out that tested separately the differences between the two groups in the proportion of relapse-free patients during the first six months and the last six months of the study. As shown in Table 43, again a clinically and statistically significant difference between the two groups is apparent in both treatment periods ($p\leq 0.001$), with 60.9 vs 40.2% of the patients being relapse-free under reboxetine and placebo respectively in the initial six months and 88.0 vs 59.2% of the reboxetine- and placebo-treated patients who entered the last six months of treatment being relapse-free at all available observations.

In addition, the time pattern of relapse was described according to the Kaplan-Meier method on the subset of patients in remission at the end of the open phase (Figure 4). In this subset of patients, the rate of relapse was lower than in responder patients in both treatment groups, but particularly so in the initial three months after randomisation in the placebo group. In any case, the between-treatment difference was again highly significant ($p<0.001$).

The number of randomised responder patients in remission at the last assessment is shown by treatment group in Table 44; 78.2% of the reboxetine-treated patients and 44.7% of the placebo-treated patients were in remission at the last assessment, the between-treatment difference being highly significant ($p<0.001$).

7.2.1.2 HAMD Factors

Summary statistics of the HAMD factors in the responder patients randomised to reboxetine or placebo at the different assessment intervals in the observed cases are given in Tables 45 and 46, respectively. The pattern of the medians of the differences vs baseline indicates that the factors maximally improved in the first six weeks of open reboxetine treatment, i.e. retardation, diurnal variation and anxiety/somatisation. Retardation and anxiety/somatisation had a further marginal improvement in the patients continuing to receive reboxetine upon long-term treatment, but not in those receiving placebo.

In addition, sleep disturbances also appeared to be more clearly ameliorated in the patients continuing to receive reboxetine than in those under placebo medication.

7.2.2 CLINICAL GLOBAL IMPRESSION

7.2.2.1 Severity of Illness

The distribution of the CGI severity scores at each visit is given in Table 47 and the summary of last assessment values is presented in Table 48. The distributions of the scores at Week 6 were similar in the two groups, with 20.3 and 25.0% of the responder patients randomised to reboxetine and placebo, respectively, being judged normal, 39.1 and 34.8% borderline and 29.3 and 28.0 mildly ill. With continuation of treatment, the most clear-cut difference between the two groups is related to the proportion of patients classified as normal, relatively stable up to a maximum level of 33.9% in the placebo group and steadily increasing up to 73.7% at Week 52 in the reboxetine group. At the last assessment, 48.1% of the reboxetine-treated cases were judged normal, compared to 22.7% of the placebo-treated cases. A shift table of the last value vs Day 0 (Table 49) showed that the severity of illness under reboxetine had decreased in 95.5% of patients, increased in 2.3% of patients and remained the same for 2.3% of patients, whereas under placebo, severity of illness had decreased in 83.3% of patients, increased in 6.1% of patients and remained the same in 10.6% of patients.

7.2.2.2 Global Improvement

The distribution of CGI scores at the different weeks of treatment is shown by treatment group in Table 50 and the summary of last assessment values is given in Table 51. At Week 6 the proportion of much to very much improved patients was similar in the two groups. With continuation of treatment, the proportion of very much improved cases tended to remain stable (between 50 and 60%, 64.5% at Week 52) under placebo, while a progressive increase was apparent under reboxetine, up to a maximum of 94.7% at Week 52. At last assessment very much improved cases were 72.9 and 42.4% in the reboxetine and placebo groups, respectively.

7.2.2.3 Efficacy Index

Summary statistics of the efficacy index at each visit are shown in Table 52 and 53 for the reboxetine- and placebo-treated patients, respectively. No major differences between the two groups are apparent.

7.2.3 MONTGOMERY-ASBERG DEPRESSION RATING SCALE

Summary statistics of the total MADRS scores at each visit are shown in Table 54 and summarised for the last assessment in Table 55. The total MADRS score was reduced from 17.9 and 18.7 at Week 0 in the responder patients subsequently randomised to reboxetine and placebo, respectively, to 5.3 at Week 6 in both groups.

A further progressive improvement was apparent in the patients continuing to receive reboxetine, up to 3.1 on average in the 76 patients assessed at Week 52, while a slight

progressive deterioration was observed in the patients continuing to receive placebo, up to 7.0 on average in the 62 patients assessed at Week 52.

7.2.4 ZUNG SELF-RATING DEPRESSION SCALE

Summary statistics of the total Zung SDS scores at each visit are shown in Table 56 and summarized for the last assessment in Table 57. In the placebo and reboxetine groups 124 and 128 patients, respectively, had a complete assessment of the scale at their last assessment of the double-blind phase. Among these patients, 122 and 123, respectively, had a full assessment at Week 6. The total Zung SDS score was similar in the two treatment groups both at baseline (58.1 and 55.8 in the placebo and reboxetine group, respectively) and at Week 6 (38.8 and 36.3, respectively). A further progressive slight improvement was apparent in the patients continuing to receive reboxetine, up to 32.0 on average in the 75 patients with complete assessment at Week 52, while this was not the case in the patients continuing to receive placebo, with an average score of 40.6 points in the 58 patients with full assessment at Week 52.

7.3 Efficacy Conclusions

The planned analyses of the study end-points, i.e. frequency and rate of relapse, indicates that reboxetine is effective in the maintenance therapy of Major Depressive Disorders. These results are confirmed by the analysis of the secondary efficacy variables.

The additional analysis of the frequency of absence of relapse during the initial six months and subsequent six months of treatment indicates that reboxetine is effective in both situations, thus suggesting that the observed findings could be connected with prevention not only of relapse of the index episode, but also of recurrence of new episodes.

8. SAFETY RESULTS

8.1 Safety Population and Extent of Exposure

8.1.1 NUMBER OF PATIENTS IN SAFETY ANALYSIS

All the patients who received study treatment were included in the safety analysis, i.e. 358 patients in the open phase and 283 patients (143 reboxetine, 140 placebo) in the double-blind phase of the study.

8.1.2 TOTAL DRUG EXPOSURE

The number of patients exposed for six weeks, 2, 3, 6, 9 and 12 months is given in Table 58. Of the 358 patients entered, 285 were exposed to reboxetine at least for six

Pharmacia

Document 9550077

weeks, 124 at least for three months, 101 at least for 6 months, and 79 at least for 12 months.

8.2 Adverse Events

8.2.1 ANALYSIS OF ADVERSE EVENTS

8.2.1.1 Open Phase

The number of patients with adverse events and the number of adverse events during the open phase of the study are grouped by sex in Table 59 and by age classes in Table 60; 51.9% of the patients exposed had at least one, and an average of 2, adverse events; males suffered from adverse events more frequently (62.1%, 95% C.I. 51.6-71.9%) than females (48.3%, 95% C.I. 42.1-54.5%); patients 31 to 45 years old had adverse events more frequently, though not statistically significantly so, (59.0%, 95% C.I. 50.5-67.1%) than patients over 45 years (43.6%, 95% C.I. 35.7-51.7%).

Absolute and Per Cent Frequency

The absolute and percentage frequency of patients suffering from adverse events and of adverse events is grouped by event and sex in Tables 61 (all events) and 62 (aggregated by body system), and by body system and sex in Table 63. Most frequently reported were dry mouth (19.0% of the patients) and constipation (16.8%). Reported in 1 to 10% of the patients were increased sweating (8.1%), tachycardia and insomnia (6.1% each), micturition disorder (corresponding to urinary hesitancy, 5.6%), decreased libido (5.0%), dizziness (4.5%), abnormal vision (corresponding to blurred vision) and paresthesia (3.4 and 3.1%, respectively), tremor and headache (2.8 and 2.5%, respectively), and urinary retention (2.2%). The most relevant between-gender difference was related to the frequency of micturition disorders (urinary hesitancy) and urinary retention, complained of mainly by male patients (18.9 and 7.4% respectively) and of decreased libido, again complained of mainly by males (11.6%).

Most frequently affected, therefore, was the autonomic nervous system (26.5% of the patients, most frequently affected system in female patients with adverse events, 57.4%), and the gastro-intestinal (GI) system (18.7%). Psychiatric and cardiovascular (CV) disorders affected 12.6 and 10.9% of the patients, respectively, while central and peripheral nervous system (NS) and vision disorders appeared in 8.7 and 3.9% of the patients, respectively. Urinary system disorders affected 8.1% of the overall population, but 26.3% of male patients, and corresponded to the most frequently affected system in male patients with adverse events (42.3%).

Occurrence

The occurrence of adverse events is grouped by week of onset and event or body system in Tables 64 and 65, respectively. The cumulative risk of developing the first adverse event

64 (2598)

during treatment is described according to the Kaplan-Meier method in Figure 5. The majority of events emerged initially during treatment, within the first week (autonomic NS disorders, 78.1% of the cases; psychiatric disorders, 60.4%; central and peripheral NS disorders, 58.3%; GI system, 56.9%;) or within the second week of treatment (urinary system disorders, 68.8%; CV disorders, 55.4%; vision disorders, 62.5%).

Maximal Severity

The maximal severity of adverse events is grouped by sex and event or body system in Tables 66 and 67, respectively. The majority of events (61.3% of the patients with events), particularly in females (63.8%), but also in males (55.9%) were of mild severity, severe events being reported in 10.2% of the patients. Mildness characterised the severity of events for the vast majority of the affected body system: 81.1% of the patients for the autonomic NS disorders; 79.1% for the GI system disorders; 72.4% for the urinary system disorders; 71.4% for the vision disorders; 67.7% for the central and peripheral NS disorders, 59.0% for the CV disorders; 57.8% for the psychiatric disorders. However, among above commented events, most frequently reported as severe were urinary system disorders, severe in 5 cases (17.2%).

Duration

Summary statistics of the duration of adverse events are described in Table 68. Overall the median duration was of 22 days. Among the most frequent events (8 or more episodes), the median duration was above the overall median figure and up to 39 days for dry mouth, constipation, increased sweating, insomnia, decreased libido, abnormal vision (blurred vision), and tremor; it was below the overall median figure (minimum of 6 days) for headache, urinary retention, tachycardia and paresthesia.

Symptomatic Treatment

As shown in Table 69, 5.3% of the events required symptomatic treatment in 8.6% of the affected patients. Insomnia was the most frequent event leading to symptomatic treatment.

Modification of Study Medication and Patient Outcome

As shown in Table 70, no change in study medication was applied for 89.6% of the events, while the daily dose was reduced in 2.4% of the cases, or the treatment temporarily interrupted in 0.5%. Adverse events were the main reason of treatment withdrawal or contributed to it in 7.2% of the cases. This was most frequently seen for tachycardia (4 cases) and for dry mouth, constipation, libido decreased and urinary hesitancy (2 events each). The individual cases of patients withdrawn due to adverse events are described in Section 8.2.3.2. As shown in Table 71, of the 38 events requiring modification of the study medication, the vast majority (81.6%) disappeared following the modification of the regimen. In fact the patient outcome, grouped by event and action taken on study medication in Table 72, corresponds to full recovery in 78.9% of the cases following modification of the treatment regimen, and in 51.2% of the cases of unchanged study

medication, the event being still present at last assessment in 45.8% of the latter cases or incompletely recovered (recovered with sequelae) in 2.7%.

Relationship Between Adverse Events and Study Medication

The relationship between adverse events and study medication, as judged by the investigators on the basis of Karch and Lasagna modified criteria (Enclosure 9 of Appendix 12.1.1) is described in Table 73. The majority of events (63.6%) were judged possibly related, while 12.8% and 9.9% were judged probably and definitely related, respectively. Among the most frequent events, the maximal frequency of definite/probable relationship was present for dry mouth (36.2%), decreased libido (36.9%), dizziness (33.3%), and urinary retention (37.5%).

8.2.1.2 Double-blind Phase

Absolute and Per Cent Frequency

The absolute and per cent frequency of patients with adverse events and the total number of adverse events newly reported during the run-in open treatment with reboxetine in the two groups of patients subsequently randomised to reboxetine and placebo and those newly reported during the controlled phase of the study are grouped by treatment and sex in Table 74 and by treatment and age classes in Table 75. During the run-in phase, the frequency of adverse events in the females was higher in the patients subsequently randomised to placebo (57.4%) than in those subsequently randomised to reboxetine (50.0%). In contrast, in males the frequency of adverse events was higher in patients subsequently randomised to reboxetine (65.5%) than in those randomised to placebo (58.7%). During the controlled phase, the overall frequency of newly reported adverse event episodes was marginally different in the two treatment groups: 22.8% of the exposed patients in the placebo group (95% C.I. 16.2-30.7%) and 28.0% in the reboxetine group (95% C.I. 20.8-36.1). However in double-blind phase, in males the difference was somewhat more marked (though with largely overlapping C.I.s): 41.4% of the male patients exposed to reboxetine had at least one event, compared with 28.3% of the male patients exposed to placebo. As shown in Table 75, the marginally higher frequency of adverse events under reboxetine is due to the higher frequency of events in patients over 45 years (31.2%, 95% C.I. 20.2-44.1% in the reboxetine group, vs 19.3%, 95% C.I. 10.0-31.9% in the placebo group).

The frequency of patients suffering from adverse events and the frequency of adverse events are grouped by treatment, event and sex in Table 76 and by treatment, body system and sex in Table 77. Most frequently newly reported during the double-blind phase were constipation (8.4 and 4.3% of the patients under reboxetine and placebo, respectively), insomnia (4.9 and 5.0% under reboxetine and placebo), micturition disorder (corresponding to urinary hesitancy, 2.8 and 1.4% under reboxetine and placebo), tachycardia (2.8 and 2.9% under reboxetine and placebo), headache (2.8 and 2.9% under reboxetine and placebo), hypertension (2.8 and 1.4% under reboxetine and placebo), rash (2.1% under reboxetine). The most relevant between-gender difference is related to the frequency of micturition disorders (urinary hesitancy), complained of mainly by male patients (10.3 and

Pharmacia

Document 9550077

2.2% under reboxetine and placebo, respectively). As shown in Table 77, the only between-treatment difference for the most frequently affected body system was related to urinary system disorders, affecting 3.5 and 1.4% of the reboxetine- and placebo-treated patients, and 13.8 and 2.2% of male patients under reboxetine and placebo, respectively.

Occurrence

The time of occurrence of newly reported adverse events in the different time intervals during the run-in reboxetine treatment and double-blind reboxetine or placebo treatment is reported by event in Table 78 and by body system in Table 79. During the double-blind phase, newly reported events mainly emerged initially after randomisation and within the eighth month of therapy, consistently with the selection of the responder and tolerant population with treatment continuation.

Maximal Severity

The maximal severity of newly reported adverse events during the run-in and double-blind phase is grouped by sex and event or body system in Tables 80 and 81, respectively. Similarly to the open phase, during the double-blind phase the majority of patients (72.5% of the patients with events under reboxetine, 81.3% under placebo), particularly females (75.0 and 89.5% in the two groups, respectively), but also males (66.7 and 69.2%, respectively) suffered from events of mild severity. Severe events, however, were reported only under reboxetine in four patients (constipation, tachycardia, perineal pain, chest pain). As for the open phase, mildness characterised the severity of events for the vast majority of the affected body systems in both treatment groups. This was also the case of urinary system disorders, mild in four of the five affected patients under reboxetine (two out of two under placebo).

Duration

Summary statistics of the duration of newly reported adverse events in the run-in and double-blind phase in the two treatment groups are described in Table 82. During the double-blind phase, the overall median duration was 28 days in the reboxetine and 19 days in the placebo group. Among most frequent events, the median duration was higher in the reboxetine than in the placebo group for constipation (91 vs 43 days) and micturition disorders (urinary hesitancy) (118 vs 25 days).

Symptomatic Treatment

As shown in Table 83, during the double-blind phase under reboxetine, 21.4% of the newly emerged events required symptomatic treatment (6.3% under placebo) in 17.5% of the affected patients (6.3% under placebo).

Modification of Study Medication and Patient Outcome

As shown in Table 84, 8 adverse events emerged in the run-in phase caused or contributed to treatment discontinuation after randomisation in the reboxetine group: dry mouth (2 cases), constipation (3 cases), libido decreased (2 cases) and urinary retention (1 case). The

same holds for one case of constipation under placebo. During the double-blind phase, no change in study medication was applied for 87.5% of the events newly emerged in both the reboxetine and placebo groups; reduction of the daily dose was applied in one case of tachycardia in the reboxetine group and treatment was temporarily interrupted in two cases under placebo (headache and hypertension) and one case under reboxetine (perineal pain). Newly emerged adverse events were the main reason for treatment withdrawal or contributed to it in 5 cases under reboxetine (constipation, two events; tachycardia, rash and angina, one event each) and in four cases under placebo (constipation, two events; hypertension and hallucinations, one event each). The individual cases of patients withdrawn due to adverse events during the double-blind treatment are described in Section 8.2.3.2.

As shown in Table 85, the vast majority of the events requiring modification of the study medication disappeared following the change of the regimen. In fact the patient outcome, grouped by event and action taken on study medication in Table 86, for the events occurred during the double-blind phase, corresponds to full recovery in 85.7 and 97.6% of unchanged treatment regimens in the reboxetine and placebo group and in 57.1 and 66.7% of the cases following modification of the reboxetine or placebo treatment, the event still being present at the last assessment in the remaining cases.

Relationship Between Adverse Events and Study Medication

The relationship between adverse events and study medication, as judged by the investigators on the basis of Karch and Lasagna modified criteria (Enclosure 9 of 12.1.1) are described in Table 87. Of the 56 newly emerged events in the reboxetine group, 25.0% were judged probably and definitely related; this was the case for 4.2% of the 48 events newly emerged under placebo. Among most frequent events, the maximal frequency of definite/probable relationship is present for constipation (50.0%, 33.3% under placebo).

Prevalence

The prevalence of patients complaining of adverse events and the prevalence of adverse events in the different time intervals during the run-in reboxetine treatment and double-blind reboxetine or placebo treatment is reported in Table 88. Prevalence of patients with adverse events in the different weeks of treatment of the run-in and double-blind phase is given in Figure 6.

The proportion of patients with adverse events is relatively stable on long-term reboxetine treatment, with a pattern consistent with the selection of the responder and tolerant populations and minimal figures of 25% in the 81 and 79 patients still on treatment at Weeks 50 and 52. On the contrary, it decreases steadily under placebo, up to a minimum of 3% in the 65 patients still on treatment at Week 52.

The prevalence of adverse events in the different time intervals during the run-in reboxetine treatment and double-blind reboxetine or placebo treatment is reported by event in Table 89 and by body system in Table 90. During the double-blind phase, all events have a maximal

prevalence during the first month after randomisation, to decrease steadily thereafter under placebo, while remaining relatively stable under reboxetine. In the 79 patients still on treatment with reboxetine during the twelfth month, maximal prevalence was observed for dry mouth (8.9%, absent under placebo), constipation (8.9%, 1.5% under placebo), micturition disorders (urinary hesitancy, 6.3%, absent under placebo), decreased libido, increased sweating and abnormal vision (blurred vision) (2.5% each, absent under placebo).

8.2.2 ADVERSE EVENT SUMMARY

Of the 358 patients exposed to reboxetine during the open phase of the study, 186 patients (51.9%) reported a total of 374 adverse events (2.0 per patient) (Table 59). The occurrence of adverse events was similar on reboxetine and placebo during the double-blind phase of the study; 40/143 reboxetine recipients (28%) reported 56 adverse events and 32/140 placebo recipients (22.8%) reported 48 adverse events (Table 74). The prevalence of adverse events during the double-blind phase indicates a higher proportion of patients with adverse events in the reboxetine than in the placebo group up to the 1-year assessment (Figure 5).

8.2.2.1 Severity of Adverse Events

The maximum severity of adverse events is presented in Tables 66, 67, 80 and 81 and summarised as follows:

	No. of patients							
	Reboxetine				Placebo			
	Mild	Moderate	Severe	Total	Mild	Moderate	Severe	Total
Open phase	114	53	19	186	-	-	-	
Randomised patients								
Run-in phase	47	24	5	76	52	24	5	81
Double-blind phase	29	7	4	40	26	6	0	32

The majority of adverse events were mild.

8.2.2.2 Age- and Gender-Related Effects

During the open phase of the study, adverse events were reported more frequently in male (62%) than in female patients (48%) (Table 59). More frequent in males were urinary hesitancy (19% vs 1%), urinary retention (7% vs 0.4%) and decreased libido (12% vs 3%) (Table 61). During the double-blind phase of the study also adverse events emerged more

Pharmacia

Document 9550077

frequently in males, particularly under reboxetine (41%, 28% under placebo), than in females (25%, 20% under placebo) (Table 74). Again, urinary hesitancy and retention were more frequent in males (10% and 3%, 2% and 0% under reboxetine and placebo, respectively) than in females (1% hesitancy, under both reboxetine and placebo) (Table 76).

The proportion of patients reporting adverse events during the open phase of the study was minimal for patients aged 46 and over; 57% of patients aged 18-30 years, 59% of patients aged 31-45 years and 44% patients aged 46 years and over reported adverse events (Table 60). This was not confirmed for the events newly emerged during the double-blind phase (Table 75).

8.2.2.3 Frequently Reported Adverse Events

Adverse events which occurred in 5% or more of the patients during the open phase of the study are presented by body system in the following table:

Adverse Events Occurring in 5% of Patients or More - Open Phase (Table 62)

		Reboxetine	
Body system	Adverse event	No. of patients with event	% of patients exposed
Autonomic nervous system disorders	Mouth dry	68	19
	Sweating increased	29	8
Gastrointestinal system disorders	Constipation	60	17
Urinary system disorders	Urinary hesitancy/retention	28	8
Cardiovascular disorders	Tachycardia	22	6
Psychiatric disorders	Insomnia	22	6
	Libido decreased	18	5

Constipation and dry mouth were the most common adverse events during the open phase of the study.

The incidence of adverse events in randomised patients occurring during the double-blind phase of the study is presented overleaf, by body system, for those events that occurred in 2% of patients or more under reboxetine.

Pharmacia

Document 9550077

Adverse Events Occurring in 2% or More of Randomised Patients - Double-blind Phase

Body system	Adverse event	Reboxetine (n=143)		Placebo (n=140)	
		No. of patients with event	% of patients exposed	No. of patients with event	% of patients exposed
Gastrointestinal system disorders	Constipation	12	8	6	4
Psychiatric disorders	Insomnia	7	5	7	5
Urinary system disorders	Urinary hesitancy/retention	5	3	2	1
Cardiovascular disorders	Tachycardia	4	3	4	3
	Hypertension	4	3	2	1
Central and peripheral nervous system disorders	Headache	4	3	4	3
Skin and appendages	Rash	3	2	-	-

Constipation was the most common newly emerged adverse event with 8% of reboxetine recipients and 4% of placebo recipients reporting this event.

Pharmacia

Document 9550077

8.2.3 SERIOUS ADVERSE EVENTS, DEATHS AND ADVERSE EVENTS LEADING TO WITHDRAWAL

8.2.3.1 Serious Adverse Events and Deaths

Three adverse events (suicide and generalized convulsive episode on open reboxetine, hallucinations on placebo) were reported as serious. Case histories for these patients are provided in Appendix 12.2.1.

8.2.3.2 Adverse Events Leading to Withdrawal

Thirteen patients (3.6%) withdrew from the open phase of the study because of adverse events (Table 3). Eight patients (6 on reboxetine, 4.2%, 2 on placebo, 1.4%) withdrew from the double-blind phase of the study because of adverse events (Table 5). The nature of the adverse events present at withdrawal in these patients is summarised as follows:

Adverse Events Leading To Withdrawal

Study period	Treatment	Patient no.	Adverse event	Relationship to study drug
Open phase	Reboxetine	1-103; 3-5; 3-9; 1-49	Tachycardia	Probable, definite, probable, probable
		10-6; 13-12*	Urinary hesitancy	Possible, unknown
		1-63;10-6	Constipation	Possible, probable
		1-7; 1-63	Libido decreased	Probable, definite
		1-7; 3-6	Dry mouth	Definite
		1-63	Urinary retention	Probable
		10-6	Increased sweating	Possible
		1-49	Vomiting	Definite
		1-103	Dizziness	Probable
			Postural Hypotension	Probable
		1-54	Rash	Probable
		1-57	Diarrhoea	Probable
		1-147	Tremor	Probable
			Agitation	Probable
		3-5	Anxiety	Possible
		3-6	Fatigue	Definite
	Headache	Possible		
3-11	Convulsions	None		
12-30	Suicide	Unknown		

Pharmacia

Document 9550077

Double-blind	Reboxetine	1-90/134;	Constipation	Probable, probable
		10-49/43		
		1-18/15;	Libido decreased	Definite, probable
		1-56/319		
		3-7/71	Tachycardia	Probable
	Placebo	1-90/134	Urinary retention	Probable
		10-26/290	Angina pectoris	None
			Chest pain	Unknown
		12-18/109	Hallucinations	Unknown
		10-4/272	Hypertension	Doubtful
	Oedema	Doubtful		

* prostatic malignancy subsequently diagnosed

8.3 Laboratory Tests

8.3.1 OPEN PHASE OF THE STUDY

8.3.1.1 Summary Statistics of Laboratory Values

Summary statistics of the laboratory values after standardization according to the method proposed by Chuang-Stein (19), are shown by variable and week of treatment in Table 91. Differences vs baseline indicate a significant ($p < 0.01$, Wilcoxon rank signed test) decrease of white blood cells at Week 6 in males (median difference $0.07 \times 10^3/\text{mm}^3$), of gamma GT in males and females at Weeks 2 and 4, and in males at Week 6 (median differences 0.05-0.12 U/l), and of total cholesterol in females at Week 2 and 6 (median differences 0.06-0.08 mg/dl), and a significant increase of phosphate in males and females at Week 2 (median differences 0.11-0.13 mEq/l).

8.3.1.2 Urinalysis

Urinalysis results for each patient are given in Appendix 12.2.2. No abnormalities were detected during the open phase of treatment.

8.3.1.3 Abnormal Laboratory Values

The number and percentage of patients whose values shifted from within, below, or above the normal range to values within, below or above the normal range are given by week in Table 92. A statistically significant shift in the distribution of the frequencies toward lower values was found at Week 2 for neutrophils and at Week 4 for chlorides, while a statistically

significant shift in the distribution of the frequencies toward higher values was found at Week 4 for total proteins and at Week 6 for calcium ($p < 0.01$; Maxwell's test).

8.3.1.4 Abnormal Laboratory Values of Clinical Relevance

The distribution pattern of patients with clinically relevant abnormal values, as defined on the basis of selected criteria (Appendix 12.1.8) are given by variable and week of assessment in Table 93. The frequency of clinically relevant abnormal values was low and similar to baseline, with the possible exception of direct bilirubin which increased more than 100% and up to 191% over the upper limit of the normal range in 2.7% of the patients at Week 4 (1.6% at baseline), but in only 0.7% of the patients at Week 6.

8.3.2 DOUBLE-BLIND PHASE

8.3.2.1 Summary Statistics of Laboratory Values

Summary statistics of laboratory values after standardization according to the method proposed by Chuang-Stein (19), are shown by variable and week of treatment in Table 94.

In the reboksetine group differences vs baseline indicate a significant ($p < 0.01$) increase of red blood cells at Week 42 and 52 in females (median differences $0.06-0.07 \times 10^6/\text{mm}^3$), of monocytes at Week 42 and 52 in females (median differences 0.25%), of beta-globulins at Week 26 and 42 in males (median differences 0.33-0.54 g/dl), of gamma-globulins in females at Week 52 (median difference 0.24 g/dl), of sodium at Week 26, 34 and 42 in females (median differences 0.09-0.10 mEq/l), of phosphates at Week 52 in females (median difference 0.07 mEq/l); and a significant decrease of eosinophils in females at Week 10, 18, 26 and 42 (median differences 0.25%), of gamma-GT in females at Weeks 26, 34, 42 and 52 (median differences 0.10-0.27 U/l), of alkaline phosphatase in females at Weeks 10, 18, 26, 34, 42 (median differences 0.04-0.10 U/l), of alpha I-globulins in females at Weeks 10, 18, 26, 42, 52 (median differences 0.13-0.24 g/dl).

On placebo, differences vs baseline indicate a significant ($p < 0.01$) increase of monocytes at Week 34, 42 and 52 in females and at Week 42 in males (median differences 0.16-0.42%), of total proteins at Week 26 and 34 in males (median differences 0.15-0.20 g/dl), of gamma-globulins in males at Week 18, 26, 34, 42 and 52 (median difference 0.23- 0.50 g/dl), of sodium at Week 26, 42 and 52 in males (median differences 0.18-0.24 mEq/l), of potassium at Week 26, 34 and 42 in males (median differences 0.15-0.20 mEq/l), of phosphates at Week 34 and 42 in females (median difference 0.13-0.25 mEq/l); and a significant decrease of white blood cells in females at Week 10 and 18, and in males at Week 10 (already present at Week 6, on reboksetine), (median differences $0.06-0.08 \times 10^3/\text{mm}^3$), of gamma-GT in females at Weeks 26, 34, 42 and 52 and in males at Weeks 18, 34, 42 and 52 (median differences 0.12-0.22 U/l), of alkaline phosphatase in females and males at Weeks 10, 18, 26, 34, 42 and 52 (median differences 0.13-0.23 U/l), of alpha I-globulins in females at Week 10, 18 and 26 (median difference 0.08-0.18 g/dl), of total cholesterol in females at

Week 34 and 42 (median differences 0.06-0.20 mg/dl), and of triglycerides at Week 26 in males (median difference 0.14 mg/dl).

8.3.2.2 Urinalysis

Urinalysis data for each patient at each visit is presented in Appendix 12.2.2. No abnormalities were detected on randomised treatment.

8.3.2.3 Abnormal Laboratory Values

The number and percentage of patients shifted from values within, below or above the normal range to values within, below or above the latter are given by week in Table 95. In the reboxetine group, a statistically significant shift in the distribution of the frequencies toward lower values was found at Week 26, 42 and 52 for alpha1-globulins (shifted however toward higher values at Week 10), and at Week 10, 18 and 42 for chlorides, while a statistically significant shift in the distribution of the frequencies toward higher values was found at Week 26 and 42 for sodium ($p < 0.01$; Maxwell's test).

In the placebo group, a statistically significant shift in the distribution of the frequencies toward lower values was found at Week 10, 18 and 52 for alpha1-globulins, and at Week 10 and 42 for chlorides, while a statistically significant shift in the distribution of the frequencies toward higher values was found for eosinophils at Week 26 and 42, for monocytes at Week 34, 42 and 52 and for alpha2-globulins at Week 42.

8.3.2.4 Abnormal Laboratory Values of Clinical Relevance

The distribution pattern of patients with clinically relevant abnormal values is given by variable and week of assessment in Table 96. Frequency of clinically relevant abnormal values was similarly low in the two treatment groups over the study period; no significantly increased frequency over baseline was present for any of the variables measured in both reboxetine and placebo recipients.

8.4 Vital Signs

8.4.1 BLOOD PRESSURE AND HEART RATE

8.4.1.1 Open Phase

Summary statistics of blood pressure and heart rate values and changes vs baseline at each visit during the open phase of the study are presented in Table 97a-f and 98, respectively. There were no important trends apparent in mean and median vital signs values and changes during the open phase of the study.

The frequency of patients at each visit of the open phase who showed a modification of 20% or more vs baseline or such a modification accompanied by absolute critical values

(≥ 160 or ≤ 100 mmHg for systolic blood pressure; ≥ 100 or ≤ 70 mmHg for diastolic blood pressure; ≥ 100 or ≤ 50 beats/min for heart rate) are given in Tables 99 and 100, respectively. Similar proportions of patients (maximum 6%) showed an increase and a decrease of possible clinical relevance for the systolic blood pressure in lying and standing position and for the diastolic blood pressure in standing position. For the lying diastolic blood pressure, the proportion of patients with an increase of possible clinical relevance was slightly higher (6-10%) than the proportion of patients with a decrease (3-4%). For the heart rate, the proportion of patients with at least 20% increased values (13-21% and 18-21% in lying and standing position, respectively) was always higher than the proportion of patients with at least 20% decreased values (5-6% and 3-6% in lying and standing positions, respectively).

Similar proportions of patients (maximum 3%) showed an increase and a decrease of possible clinical relevance associated to critical values for the systolic blood pressure in lying position. For the lying diastolic blood pressure and for the standing systolic and diastolic blood pressure, the proportion of patients showing a decrease was always higher than those showing the opposite, the maximal difference being observed in standing position (0.3-0.8% vs 1.8-3.7% for the systolic; 0.3-2.4 % vs 4-5.7 % for the diastolic). Almost no patient showed a clinically relevant decrease of heart rate to values of 50 beats/min or lower, while 5-8% in lying and 9-13% in standing had an increase of at least a 20% associated with values of 100 beats/min or higher.

The number and percentage of patients with orthostatic hypotension (a decrease of > 20 mmHg in the standing systolic blood pressure as compared to the lying pressure) at each visit are presented in Table 101. The event had a low frequency at all visits, affecting a maximum of 2% of the patients at Week 3, with no major changes in frequency vs baseline.

8.4.1.2 Double-blind Phase

Summary statistics of blood pressure and heart rate values and changes vs baseline at each visit during the double-blind phase of the study are presented in Table 102a-f and 103, respectively. There were no important trends apparent in mean and median blood pressure values and changes during the double-blind phase as compared to the run-in reboxetine treatment, while the heart rate mean and median values and changes indicate maintenance on reboxetine of the small increase observed in the run-in phase, while a slight decrease was apparent on placebo.

The frequency of patients at each visit of the double-blind phase showing a modification of 20% or more vs baseline or such a modification accompanied by absolute critical values (≥ 160 or ≤ 100 mmHg for systolic blood pressure; ≥ 100 or ≤ 70 mmHg for diastolic blood pressure; ≥ 100 or ≤ 50 beats/min for heart rate) are given in Tables 104 and 105, respectively.

During the run-in phase, the proportion of patients with an increase of possible clinical relevance of the lying diastolic blood pressure was slightly higher than the proportion of

patients with a decrease in the group subsequently randomised to reboxetine. During the double-blind phase, the proportions of patients showing an increase and a decrease of possible clinical relevance for the systolic and diastolic blood pressure in lying and standing position were similar to the one apparent in the run-in phase in both reboxetine and placebo groups. As for the lying and standing heart rate, the higher proportion of patients with at least 20% increased values apparent in the run-in phase continued to be observed during the double-blind phase in the reboxetine-treated patients, but not in the placebo-treated ones.

The proportions of patients showing a decrease of possible clinical relevance of blood pressure associated with critical values tended to be slightly higher than those showing the opposite for all blood pressure measurements in the run-in and double-blind phase on both reboxetine and placebo. The proportions of patients with an increase of heart rate of at least 20% associated with critical values were always more prevalent than the opposite during the run-in and double-blind phase in both treatment groups and particularly on standing. However, during the double-blind phase a progressive decrease of the proportion of patients with this event was observed on placebo (present in 0 to 7% of the patients at the different visits), but not on reboxetine (present in 8 to 18%).

The number and percentage of patients with orthostatic hypotension at each visit are presented in Table 106. As reported for the open phase, the event had a low frequency at all visits, affecting a maximum of 3.6% of the patients on reboxetine and of 2.1% of the patients on placebo.

8.4.2 BODY WEIGHT

Summary statistics of the body weight values (Kg) during the open and double-blind phase of the study are given in Tables 107 and 108, respectively. No trends toward modification and no difference between the reboxetine and placebo groups were apparent.

8.4.3 BODY TEMPERATURE

Summary statistics of the body temperature values (°C) during the open and double-blind phase of the study are given in Tables 109 and 110, respectively. No trends toward modification and no difference between the two treatment groups were apparent.

8.5 Ophthalmological Examination

The results of the intraocular pressure measurement and of the global assessment of the detected abnormalities at baseline and at the last control visit of the double-blind treatment in the randomised patients are listed in Appendix 12.2.2. No modifications of note were apparent in either treatment group.

8.6 Electrocardiogram

8.6.1 OPEN PHASE

As shown in Table 111, among the 355 patients with ECG recorded at baseline and at least once during the open phase, 56 (15.8%) showed at least one ECG abnormality at entry into the study. This percentage frequency remained stable at the assessments made every two weeks up to Week 6, when 14.1% of the 319 evaluated cases had at least one abnormality. As shown in Table 112, during the fortnightly assessments of the open phase, frequency of normalisation of ECG recordings in patients with at least one abnormality at entry was always consistently higher (52.8, 43.4 and 54.9%) than frequency of at least one newly emerged abnormality in patients with normal tracing at baseline (7.4, 7.5 and 8.2%). At the last assessment of the open phase, of the 56 patients with at least one abnormality at baseline, 53.6% were reportedly normal, while among the 299 patients with normal tracings at baseline, 9.0% showed at least one abnormality (Table 113).

The frequency of individual abnormalities at admission and every two weeks during the study is shown in Table 114. In baseline conditions, individual abnormalities are present in a maximum of 5.1% of the 355 evaluated cases (sinus tachycardia). During treatment the frequencies of all observed abnormalities were not modified to any significant extent. As shown in Table 115, at the last assessment of the open phase, for all abnormalities the proportion of newly observed cases among normal baseline cases is lower than the proportion of normalised cases among abnormal baseline cases. Newly emerged abnormalities never reported at baseline include left bundle branch block and repolarisation disturbances, recorded in one and two cases, respectively.

The frequencies of patients with at least one abnormality by abnormality group are shown in Table 116. At baseline, from 2.8% (other disorders) to 6.2% (rhythm disorders) of the evaluated patients showed at least one abnormality of the indicated groups. The percentage frequencies were not modified to any significant extent up to Week 6. As shown in Table 117, at the last assessment of the open phase, for all abnormality groups, the proportion of newly emerged cases was far lower than the proportion of normalised cases.

8.6.2 DOUBLE-BLIND PHASE

As shown in Table 118, among the 135 patients with ECG recorded at baseline and at least once during the double-blind phase in each treatment group, 14.2 and 16.3% in the reboxetine and placebo group, respectively, had at least one ECG abnormality recorded at the end of the reboxetine open treatment. At the two-monthly assessments up to Week 52, the proportion of abnormal ECG recordings was similar in the two treatment groups, in the range of 13.4 to 6.4% in the reboxetine- and 15.4 to 7.0% in the placebo-treated patients.

As shown in Table 119, during the two-monthly assessments of the double-blind phase, the frequency of normalisation of ECG recordings in patients with at least one abnormality at entry was always consistently higher than the frequency of at least one newly emerged abnormality in patients with normal tracing at baseline in both treatment groups. At the last assessment of the double-blind phase (Table 120), of the 22 patients with at least one abnormality at baseline in either treatment group, 72.7 and 59.1% were reportedly normal in the reboxetine and placebo groups, respectively, while among the 113 patients with normal tracings at baseline in either treatment group, 6.2 and 4.4% of the reboxetine and placebo recipients showed at least one abnormality.

The frequency of individual abnormalities at admission and during the open reboxetine and double-blind treatment phases in randomised patients is shown by treatment group in Table 121. At the end of the open reboxetine treatment individual abnormalities are present in a maximum of 4.5% (non-specific ST-T wave changes and sinus tachycardia) of the 134 evaluated cases of the reboxetine and in 5.9% (sinus tachycardia) of the 135 evaluated cases of the placebo group. During the double-blind treatment, the percentage frequencies of all observed abnormalities were not modified to any significant extent in either treatment group. As shown in Table 122, at the last assessment of the double-blind phase, for all abnormalities and both treatment groups, the proportion of newly observed cases among normal baseline cases is lower than the proportion of normalised cases among abnormal baseline cases. Abnormalities never reported at baseline newly emerged in rare cases and with similar frequency in the reboxetine and placebo groups.

The frequencies of randomised patients with at least one abnormality by abnormality group during the open reboxetine and double-blind treatment are shown in Table 123. At the end of the open reboxetine treatment, from 2.2% (other disorders) to 6.7% (ischemic signs and rhythm disorders) of the evaluated patients in the reboxetine group and from 1.5 (other disorders) to 8.1 (rhythm disorders) in the placebo group showed at least one abnormality of the indicated groups. During the double-blind phase, the proportion of patients with at least one of each group of abnormalities was not modified to any significant extent in either treatment group. As shown in Table 124, at the last assessment of the double-blind phase, for all groups of abnormalities, the proportion of newly emerged cases was similar in the two treatment groups, and in both groups far lower than the proportion of normalised cases.

8.7 Safety Conclusions

All the patients who received study treatment were included in the safety analysis, i.e. 358 patients in the open phase and 283 patients (143 reboxetine, 140 placebo) in the double-blind phase of the study.

During the open phase of the study, 52% of the patients reported adverse events and 3.6% discontinued reboxetine medication due to adverse events. Most frequently reported were dry mouth (19% of the patients), constipation (17%), urinary hesitancy/retention and increased sweating (8%), tachycardia and insomnia (6%), and decreased libido (5%). The

occurrence of newly reported adverse events was similar on reboxetine and placebo during the double-blind phase of the study; 40/143 reboxetine recipients reported 56 adverse events compared with 32/140 placebo recipients who reported 48 adverse events; however, the prevalence of adverse events was higher in the reboxetine than in the placebo group and discontinuation due to adverse event was more frequent on reboxetine (4.2%) than on placebo (1.4%). Most frequently newly reported was constipation (8% on reboxetine, 4% on placebo). The majority of adverse events were mild. Adverse events were reported more frequently by men than women, particularly on reboxetine. This was particularly the case for urinary hesitancy, urinary retention and decreased libido. There were three serious adverse events during the study (suicide and generalized convulsive episode on open reboxetine, hallucinations on placebo). The one death was the result of suicide.

There was no indication of modifications in laboratory tests that were of clinical significance.

Vital signs were not modified to any significant extent, with the exception of heart rate, which was significantly increased (20% or more) under reboxetine to values of 100 beats/min. or higher in approximately 10 to 15% of the patients, also on long-term treatment and particularly on standing.

No indication of effect on cardiac function emerged from ECG recordings. The ophthalmologic examination did not provide indications of treatment related changes.

9. DISCUSSION

This was a multicentre, double-blind study to investigate the efficacy and tolerability of reboxetine compared with placebo in patients with a DSM-III-R diagnosis of Major Depressive Disorder and an HAMD total score of at least 18. After an initial period during which patients received reboxetine 4 mg bid for six weeks, responders (50% or greater decrease of the HAMD total score) were randomised to receive maintenance therapy with reboxetine 4 mg bid or placebo for up to one year. The study end-points were frequency and time to relapse and frequency of remission at last assessment of the double-blind treatment phase and these were to be compared between treatment groups. Three hundred and fifty-eight patients entered the open phase of the study, 286 entered the randomised phase of the study, 143 received reboxetine and 140 placebo; among whom 133 and 132 were responders at Week 6 and were considered evaluable for efficacy; 79 reboxetine and 65 placebo recipients completed the 1-year treatment period. Of the 36 patients withdrawn from the open phase, one patient committed suicide, 13 dropped out due to adverse events, and 10 for lack of efficacy. During the double-blind phase of the study, 6 reboxetine recipients and 2 placebo recipients withdrew due to adverse events. Thirty-six and 17 discontinued placebo and reboxetine medication, respectively, according to protocol provisions, due to deterioration of the clinical picture, the time pattern of discontinuations not related to deterioration being similar in the two treatment groups.

Efficacy. At the end of open reboxetine, 76% of patients were responders and 50% of patients were in remission (HAMD total score 10 or less). At the last assessment of the open reboxetine treatment, the HAMD total score was reduced from 29.6 at baseline to 12.9, the MADRS total score from 18.4 to 7.8, while the percentage of patients whose condition was “very much improved” and “much improved” according to CGI scores was 45.8 and 31.3, respectively. These results, though obtained in uncontrolled conditions, strongly support the antidepressant efficacy of reboxetine in the therapy of acute depressive episodes.

Among the 133 responder patients randomised to reboxetine, 21.8% relapsed during the long-term treatment, while 56.1% of the 132 responder patients randomised to placebo relapsed, the between-treatment difference being highly significant. The time pattern of the relapse rate analysed according to the Kaplan-Meier method indicates a significantly increased risk of relapse on placebo compared with reboxetine. The proportion of patients in remission at the last assessment of the double-blind treatment phase was significantly higher on reboxetine (78.2%) than on placebo (44.7%). The analysis of the study end-points proves the efficacy of reboxetine in the maintenance therapy of Major Depressive Disorders, the between-treatment difference being statistically and clinically highly significant.

These results are confirmed by the analysis of the secondary efficacy variables. In the 133 responder patients randomised to reboxetine, the mean HAMD score was reduced from 29.2 at baseline to 8.8 at Week 6 and to 5.9 at Week 52 in the 76 assessed patients still on maintenance reboxetine. In the 132 responder patients randomised to placebo, HAMD scores fell from 30.1 to 9.1 at Week 6 but increased to 11.1 at Week 52 in the 62 assessed patients still on treatment. Similarly, the mean total MADRS scores fell from 5.3 at Week 6 to 3.1 at Week 52 in the 76 assessed patients still on maintenance reboxetine, compared with a rise from 5.3 to 7.0 in the 62 patients on placebo. The percentage of patients whose CGI score was “very much improved” increased from 62.4% at Week 6 to 94.7% at Week 52 on reboxetine in contrast to a marginal increase from 57.6% to 64.5% at Week 52 on placebo.

The additional analysis of the frequency of maintenance of the response during the initial six months and subsequent six months of treatment indicates that the advantage over placebo in the maintenance of the response is present also in the second half of the one year treatment period (88.0 vs 59.2% of the reboxetine- and placebo-treated patients, respectively). As reported for imipramine [25], sertraline [26] and paroxetine [27], the observed findings can be interpreted as indicative of a preventive effect, not only of relapse of the index episode, but also of the recurrence of new episodes.

The additional analysis on the subset of patients in remission at the end of the open phase confirmed literature data [28] on the increased risk of relapse in patients with residual

depressive symptoms, as well as the advantage of reboxetine over placebo in the population in remission at randomisation.

Safety. Reboxetine had no effect of clinical significance on either laboratory tests, ECG, ophthalmoscopic examination or vital signs during either the acute or the long-term treatment phase, with the exception of the heart rate, which was significantly increased (20% or more) under reboxetine to values of 100 beats/min or higher in approximately 10 to 15% of the patients, also on long-term treatment and particularly on standing.

During the open phase of the study, 52% of the patients reported adverse events and 3.6% discontinued reboxetine medication due to adverse events. Most frequently reported were dry mouth (19% of the patients), constipation (17%), urinary hesitancy/retention and increased sweating (8%), tachycardia and insomnia (6%), libido decreased (5%).

The occurrence of newly reported adverse events was similar on reboxetine and placebo during the double-blind phase of the study: 40/143 reboxetine recipients reported 56 adverse events compared with 32/140 placebo recipients who reported 48 adverse events. Prevalence of adverse events was higher in the reboxetine than in the placebo group. Discontinuation due to adverse event was infrequent, but more frequent on reboxetine (4.2%) than on placebo (1.4%). The most frequently newly reported event was constipation (8% on reboxetine, 4% on placebo).

The majority of adverse events were mild. Adverse events were reported more frequently by men than women, particularly on reboxetine. This was particularly the case for urinary hesitancy, urinary retention and decreased libido. Three serious adverse events were reported during the study (suicide and generalized convulsive episode on open reboxetine, hallucinations on placebo). The one death was the result of suicide.

10. CONCLUSION

The efficacy of reboxetine maintenance therapy in responders, as measured by HAMD, MADRS and CGI scales, was markedly superior to that of placebo in patients with major depression, when administered for up to one year. The tolerability of reboxetine administered on a long-term basis was highly acceptable, as shown by the safety profile which was marginally superior to that of placebo for the incidence of adverse events and for clinically significant tachycardia and similar to placebo for modifications of other vital signs, haematology and blood chemistry tests, ophthalmologic and ECG examinations.

11. REFERENCES

1. Reboxetine Investigator Brochure, Farmitalia Carlo Erba, CNS Line, 1988.
2. Herrman WM et al (AFB - Berlin). Safety and tolerance of reboxetine in healthy male volunteer - A single rising dose tolerance study. Pharmacia Internal Report FCE 20124/602i, June 1984.
3. Herrman WM et al (AFB - Berlin). Reboxetine - Quantitative pharmaco EEG and pharmaco-psychological study. Pharmacia Internal Report FCE 20124/603i, January 1985.
4. Dubini A, Goldaniga GC, Montesanti L, Savoia L, Tamassia V, Vicario GP. Disposition and fate of ¹⁴C-reboxetine administered orally to healthy volunteers. Pharmacia Internal Report FCE 20124/604i, March 1985.
5. Dubini A, Ban T. Open dose range finding study in patients hospitalised for Major Depressive Disorders. Pharmacia Internal Report FCE 20124/701i, April 1989.
6. Dubini A, Ban T, Morey LC. Phase II controlled study of the activity and tolerability of reboxetine in comparison with placebo and desipramine in patients hospitalized for Major Depressive Disorders. Pharmacia Internal Report FCE 20124/702i, February 1991.
7. U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. Depression in Primary Care: Volume 2. Treatment of Major Depression. Rockville, Maryland: AHCPR Publication No. 93-0551, April 1993.
8. Kamlet MS, Paul N, Greenhouse J, Kupfer D, Frank E, Wade M. Cost Utility Analysis of Maintenance Treatment for Recurrent Depression. *Controlled Clinical Trials* 1995; 16:17-40.
9. American Psychiatric Association. Mood disorders. In: *Williams JBW (Ed). Diagnostic and Statistical Manual of Mental Disorder. Third edition revised*, American Psychiatric Association, Washington DC, 1987.
10. Ban TA. CODE DD. Composite Diagnostic Evaluation of Depressive Disorders. Brentwood, TN: JM Productions, Inc., 1989.
11. Hamilton M. A rating scale for depression. *J Neurol Neurosurg Psychiatry* 1960; 23: 56-62.

-
12. Guy W. ECDEU Assessment Manual for Psychopharmacology. U.S. Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration. Rockville, Maryland: 1976.
 13. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. *Br J Psychiatry* 1979; 134: 382-389.
 14. Asberg M, Montgomery SA, Perris C, Schalling D, Sedvall G. A comprehensive psychopathological psychiatric rating scale (CPRS). *Acta Psychiatrica Scand (Suppl)* 1978; 271: 5-27.
 15. Zung WWK. A Self-Rating Depression Scale. *Arch Gen. Psychiatry* 1965; 12: 63.
 16. Snedecor GW. *Statistical Methods*. Ames, Iowa, USA: The Iowa State University Press, 1964: 1-34, 217-219.
 17. Kalbfleisch JD, Prentice RL. *The Statistical Analysis of Failure Time Data*. New York: John Wiley & Sons, 1980: 16-19.
 18. Fleiss JL. *Statistical Methods for Rates and Proportions*. New York: John Wiley & Sons, 1973: 72-80.
 19. Chuang-Stein C. Summarizing laboratory data with different reference ranges in multi-center clinical trials. *Drug Information Journal* 1992; 26: 77-84.
 20. Wyngaarden JB, Smith LH, Bennett JC, Editors. *Cecil Textbook of Medicine*. Philadelphia: Saunders, 1988.
 21. Hollander M, Wolfe DA. *Nonparametric Statistical Methods*. New York: John Wiley & Sons, 1973: 26-38.
 22. Collaborating Center for International Drug Monitoring. *Manual of the international statistical classification of diseases, injuries, and causes of death*. Geneva: World Health Organization, 1977.
 23. Collaborating Center for International Drug Monitoring. *Drug Reference List*. Geneva: World Health Organization, 1989.
 24. Collaborating Center for International Drug Monitoring. *Adverse Reactions Terminology. International monitoring of adverse reactions to drugs*. Geneva: World Health Organization, 1989.
 25. Prien RF, Klett J, Caffey EM. Lithium Carbonate and Imipramine in Prevention of Affective Episodes. *Arch Gen. Psychiatry* 1973; 29: 420-5.

Pharmacia

Document 9550077

-
26. Doogan DP, Caillard V. Sertraline in the Prevention of Depression. *Br J of Psychiatry* 1992; 160: 217-222.
 27. Montgomery SA, Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. *International Clinical Psychopharmacology* 1993; 8: 189-195.
 28. Montgomery SA, Montgomery DB. Prophylactic treatment in recurrent unipolar depression. In: Montgomery SA, and Rouillon F, editors. *Long Term Treatment of Depression*. Chichester, England: John Wiley &

Pharmacia

Document 9550077

TABLES

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 1

OPEN PHASE : NUMBER OF PATIENTS IN EACH CENTRE

CENTRE NO.	number of patients
1	150
2	4
3	10
6	7
9	30
10	76
11	20
12	38
13	23
TOTAL	358

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBONETINE - PROTOCOL 20124/013

TABLE No.: 2

PATIENT DISPOSITION

	TREATMENT		TOTAL
	REBONETINE	PLACERO	
ENTERED OPEN	358		358
NOT COMPLETED OPEN AS PER PROTOCOL	36		36
COMPLETED OPEN AS PER PROTOCOL	322		322
COMPLETING OPEN NOT ENTERED DB	36		36
RANDOMIZED	145	141	286
DROPPED DB	64	75	139
COMPLETING 1-YR DB	79	65	144

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Table No.: 3

END OF STUDY: REASONS FOR DISCONTINUATION
OPEN PHASE

Reasons	No	%
ADVERSE EVENT (*)	13	36.11
DEATH	1	2.78
LOST TO FOLLOW UP	1	2.78
DETERIORATION	10	27.78
PATIENT UNCOOPERATIVE	11	30.56
Total	36	100.00

(*) ADVERSE EVENT: to be considered as adverse event or intercurrent medical problems

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 4

NUMBER OF PATIENTS IN EACH CENTRE

CENTRE	TREATMENT		TOTAL PER CENTRE
	REBOXETINE NUMBER OF PATIENTS	PLACEBO NUMBER OF PATIENTS	
1	60	61	121
3	1	3	4
8	3	3	6
9	10	9	19
10	37	34	71
11	9	8	17
12	16	16	32
13	9	7	16
TOTAL PER TREATMENT	145	141	286

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Table No.: 5

END OF STUDY: REASONS FOR DISCONTINUATION AND VISIT AT WHICH DISCONTINUATION OCCURRED
DOUBLE BLIND PHASE

ADVERSE EVENT (*)	Total	Last visit														Week 30											
		Week 8		Week 9		Week 10		Week 12		Week 14		Week 16		Week 18			Week 20		Week 22		Week 24		Week 25		Week 28		
		No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z		No	Z	No								
Placebo																											
ADVERSE EVENT (*)	2																										
PROTOCOL VIOLATION	4																										
LOST TO FOLLOW UP	9																										
DETERIORATION	36																										
IMPROVEMENT	7																										
PATIENT UNCOOPERATIVE	17																										
Total	75	100	4	5.3	3	4.0	8	10.7	2	2.7	6	8.0	9	12.0	7	9.3	6	8.0	4	5.3	3	4.0	5	6.7	3		
ADVERSE EVENT (*)	6																										
PROTOCOL VIOLATION	6																										
LOST TO FOLLOW UP	17																										
DETERIORATION	17																										
IMPROVEMENT	6																										
PATIENT UNCOOPERATIVE	12																										
Total	64	100	5	7.8	1	1.6	9	14.1	4	6.3	2	3.1	8	12.5	5	7.8	4	6.3	3	4.7	1	1.6	4	6.3	7	10.9	2

(CONTINUED)

(*) ADVERSE EVENT: to be considered as adverse event or intercurrent medical problems

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Table No.: 5

END OF STUDY: REASONS FOR DISCONTINUATION AND VISIT AT WHICH DISCONTINUATION OCCURRED
DOUBLE BLIND PHASE

	Week 30	Last visit																				
		Week 32		Week 34		Week 36		Week 38		Week 40		Week 42		Week 44		Week 46		Week 48		Week 50		
		Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	Z	No	
Placebo																						
ADVERSE EVENT (*)	50.0																					
PROTOCOL VIOLATION																						
LOST TO FOLLOW UP		1	11.1																			
DETERIORATION	2.8				2	5.6		2	5.6			1	2.8		1	2.8						
IMPROVEMENT										1	14.3											
PATIENT UNCOOPERATIVE	5.9											1	5.9									
Total	4.0	1	1.3	1	1.3	2	2.7	2	2.7	1	1.3	3	4.0	1	1.3	3	4.0					
ADVERSE EVENT (*)																						
PROTOCOL VIOLATION																						
LOST TO FOLLOW UP	5.9	1	5.9	2	11.8	1	5.9															
DETERIORATION																						
IMPROVEMENT																						
PATIENT UNCOOPERATIVE	8.3																					
Total	3.1	1	1.6	3	4.7	1	1.6	1	1.6													
Reboxetine																						
ADVERSE EVENT (*)																						
PROTOCOL VIOLATION																						
LOST TO FOLLOW UP																						
DETERIORATION																						
IMPROVEMENT																						
PATIENT UNCOOPERATIVE																						
Total																						

(*) ADVERSE EVENT: to be considered as adverse event or intercurrent medical problems

9550077

PHARMACIA CNS R&D
REBOXETINE PROTOCOL 013
TABLE NO: 6
FREQUENCY OF PROTOCOL VIOLATIONS AT ADMISSION

	NO.	%
PATIENTS EXPOSED	358	100.00
HAMD TOTAL SCORE < 18	1	0.28
THYROID TESTS ABNORMALITIES (*)	31	8.68
NOT ALLOWED MEDICATION DURING WASH-OUT	9	2.51
DSM IIIR 296.2	1	0.28

(*) > 10% deviaton from normal range limits

9550077

PHARMACIA CNS R&D
 REBOXETINE PROTOCOL 013
 TABLE NO: 7
 FREQUENCY OF PATIENTS RECEIVING CONCOMITANT DRUGS NOT ALLOWED BY PROTOCOL,
 BY ACTIVE PRINCIPLE

CLASS	ACTIVE PRINCIPLE	BASELINE	NEWLY ADMINISTERED		
			OPEN		DOUBLE BLIND
			REBOXETINE	REBOXETINE	PLACEBO
BENZODIAZEPINES	OXAZEPAM	1	1		
	LOPRAZOLAM	1	1		1
	NITRAZEPAM			1	1
	DIAZEPAM			1	
	FLUNITRAZEPAM	1			
	LORMETAZEPAM		1		
CENTRAL CV	CLONIDINE			1	1
PHENOTHIAZINES	ALIMEMAZINE	1			
	CYAMEMAZINE		1		
	THIORIDAZINE		1		
OTHER SEDATIVES	HYDROXYZINE	1			
	MEPROBAMATE		1		1
	K CLORAZEPATE + ACEPROMAZINE + ACEPROMETAZINE	2			

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 8

PATIENTS NOT RESPONDER AT VISIT 6 BUT ENTERED IN DOUBLE BLIND PHASE

	N
TREATMENT	
REBOXETINE	10
PLACEBO	8
TOTAL	18

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 RESOMETINE - PROTOCOL 20124/01S
 TABLE No.: 9
 RANDOMIZATION ERROR: ANALYSIS OF THE ASSIGNED TREATMENT vs RANDOMIZED TREATMENT

Centre	Patients randomized 283 Excluding out of randomization		Randomization error	
	No.	%	No.	%
1				
10	19	27.94		
11	6	35.29		
12	10	31.25		
13	8	50.00		
3	2	50.00		
8				
9			4	21.05
Total	49		49	17.31

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE – PROTOCOL 20124/013
 TABLE No.: 10
 RANDOMIZATION: ASSIGNED TREATMENT vs RANDOMIZED TREATMENT

Assigned treatment	Randomized treatment			Total
	Out of Random.	Placebo	Reboxetine	
Placebo	4	112	24	140
Reboxetine	4	25	114	143
Total	8	137	138	283

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

BEXOMETINE - PROTOCOL 20124/013
TABLE No.: 11

COMPLIANCE TO SCHEDULE TIME AS PER PROTOCOL

	Screen	Day 0	Open Phase					
			Week 0	Week 1	Week 2	Week 3	Week 4	Week 5
Assessment visit	No.	358	354	349	337	328	324	322
	Min	-28	7	14	20	27	34	41
	Max	1	12	17	24	30	38	44
	Median	-6	7	14	21	28	35	42
	95%	1	8	15	22	29	36	43
Laboratory test	No.	358	346			326		316
	Min	-28	7			21		35
	Max	1	23			31		45
	Median	-7	14			28		42
	95%	0	16			29		43
E.C.G.	No.	358	349			328		322
	Min	-21	9			21		35
	Max	1	23			37		51
	Median	-7	14			28		42
	95%	0	16			30		44

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R2D
REBOXETINE - PROTOCOL 20124/013
TABLE No.: 11

COMPLIANCE TO SCHEDULE TIME AS PER PROTOCOL

		Double Blind Phase																							
		Week 8	Week 10	Week 12	Week 14	Week 16	Week 18	Week 20	Week 22	Week 24	Week 26	Week 28	Week 30	Week 32	Week 34	Week 36	Week 38	Week 40	Week 42	Week 44	Week 46	Week 48	Week 50	Week 52	
Assessment visit	No.	274	261	249	245	231	217	206	197	192	185	173	168	166	162	159	156	155	152	150	147	146	144	144	
	Min	55	69	83	96	111	122	133	149	167	181	195	208	223	237	251	265	279	293	307	321	335	349	363	
	Max	70	84	98	112	126	140	154	168	182	196	203	217	231	245	259	273	287	301	315	329	343	357	371	
	Median	56	70	84	98	112	126	140	154	168	182	196	210	224	238	252	266	280	294	308	322	336	350	364	
Laboratory test	95%	57	71	85	99	113	127	141	155	169	183	197	211	225	239	253	267	281	295	309	323	337	351	365	
	No.	260					211				180				161				151					142	
	Min	56					96				167				230				288					363	
	Max	85					145				199				258				309					402	
E.C.G.	Median	70					126				182				238				294					364	
	95%	72					127				183				240				296					366	
	No.	261					216				185				162				152					144	
	Min	56					91				167				230				288					385	
	Max	86					142				205				258				302					487	
	Median	70					126				182				238				294					364	
	95%	72					128				183				240				295					366	

PHARMACIA C0550077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 12

DEMOGRAPHIC DATA OF PATIENTS IN OPEN PHASE

SEX: MALE	N	95
	%	26.54
SEX: FEMALE	N	263
	%	73.46
AGE(years):	mean	43.18
	stdev	11.83
	median	43.00
	min	18
	max	65
	N	358
	unk.	0
HEIGHT(cm):	mean	165.59
	stdev	8.38
	median	165.00
	min	150
	max	200
	N	358
	unk.	0
WEIGHT(kg):	mean	66.68
	stdev	13.00
	median	65.00
	min	41
	max	126
	N	358
	unk.	0

PHARMACIA CS 50077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 13

DEMOGRAPHIC DATA OF RANDOMIZED PATIENTS

		TREATMENT	
		REBOXETINE	PLACEBO
SEX: MALE	N	30	46
	Z	20.69	32.62
SEX: FEMALE	N	115	95
	Z	79.31	67.38
AGE(years):	mean	43.38	42.33
	stdev	11.58	12.23
	median	42.00	41.00
	min	18	21
	max	64	65
	N	145	141
	unk.	0	0
HEIGHT(cm):	mean	165.32	165.35
	stdev	7.53	8.88
	median	165.00	164.00
	min	150	150
	max	184	198
	N	145	141
	unk.	0	0
HEIGHT(kg):	mean	67.19	66.02
	stdev	13.35	11.84
	median	67.00	65.00
	min	41	42
	max	120	108
	N	145	141
	unk.	0	0

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA C5580077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 14

DIAGNOSIS AND HISTORY OF MENTAL DISORDERS OF PATIENTS IN OPEN PHASE

DIAGNOSIS	296.2	N	1
		Z	0.28
	296.3	N	357
		Z	99.72
AGE OF ONSET (years)		mean	34.65
		stdev	10.62
		median	34.00
		min	11
		max	63
		N	356
		unk.	2
NUMBER OF PREVIOUS EPISODES		mean	3.17
		stdev	2.14
		median	3.00
		min	1
		max	15
		N	356
		unk.	2
DURATION OF LAST EPISODE (weeks)		mean	30.29
		stdev	34.81
		median	24.00
		min	2
		max	364
		N	354
		unk.	4
DURATION OF PRESENT EPISODE (weeks)		mean	13.91
		stdev	25.11
		median	8.00
		min	0.14
		max	364
		N	354
		unk.	4
CHARACT. OF PRESENT EPISODE	exacerbation	N	38
	recurrence	N	308
	different	N	11
	unk.	N	0
ONSET OF PRESENT EPISODE	acute	N	89
	subacute	N	224
	insidious	N	43
	unk.	N	2
PRECIPIT. EXTERNAL STRESS	absent	N	254
	prob.present	N	59
	def.present	N	45
	unk.	N	0

DIAGNOSIS: 296.2=Major Depressive Disorder,First Episode
296.3=Major Depressive Disorder,Recurrent Episode

PHARMACIA C850077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 15

DIAGNOSIS AND HISTORY OF MENTAL DISORDERS OF RANDOMIZED PATIENTS

			TREATMENT	
			REBOXETINE	PLACEBO
DIAGNOSIS	296.2	N	0	1
		Z	0.00	0.71
	296.3	N	145	140
		Z	100.00	99.29
AGE OF ONSET (years)	mean	34.39	33.81	
	stdev	10.28	10.08	
	median	34.00	32.00	
	min	13	11	
	max	60	62	
	N	145	139	
	unk.	0	2	
NUMBER OF PREVIOUS EPISODES	mean	3.39	2.95	
	stdev	2.49	1.77	
	median	3.00	3.00	
	min	1	1	
	max	15	10	
	N	145	139	
DURATION OF LAST EPISODE (weeks)	mean	30.51	31.57	
	stdev	36.74	37.64	
	median	24.00	24.00	
	min	3	2	
	max	364	364	
	N	143	139	
	unk.	2	2	
DURATION OF PRESENT EPISODE (weeks)	mean	13.93	14.96	
	stdev	31.48	21.71	
	median	8.00	10.00	
	min	0.14	0.57	
	max	364	208	
	N	144	139	
CHARACT. OF PRESENT EPISODE	exacerbation	N	13	15
	recurrence	N	129	117
	different	N	3	8
	unk.	N	0	0
	ONSET OF PRESENT EPISODE	acute	N	36
subacute		N	97	82
insidious		N	10	22
unk.		N	2	0
PRECIPIT. EXTERNAL STRESS	absent	N	96	102
	prob.present	N	30	16
	def.present	N	19	23
	unk.	N	0	0

DIAGNOSIS: 296.2=Major Depressive Disorder,First Episode
296.3=Major Depressive Disorder,Recurrent Episode

PHARMACIA C8580077

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 16

PREVIOUS ANTIDEPRESSIVE TREATMENT BY ACTIVE PRINCIPLE

	Open Phase		Randomised Patients			
	All patients		Placebo		Reboxetine	
	No	%	No	%	No	%
Patients	358	100.0	140	100.0	143	100.0
AMITRIPTYLINE	76	21.2	29	20.7	31	21.7
MAPROTIline	74	20.7	30	21.4	26	18.2
IMIPRAMINE	49	13.7	15	10.7	21	14.7
DIBENZEPIN	34	9.5	15	10.7	12	8.4
CLOMIPRAMINE	14	3.9	6	4.3	5	3.5
TRIMIPRAMINE	14	3.9	6	4.3	5	3.5
FLUOXETINE	11	3.1	4	2.9	3	2.1
FLUVOXAMINE	8	2.2	4	2.9	2	1.4
MOCLOBEMIDE	6	1.7	3	2.1	2	1.4
TRAZODONE	4	1.1	2	1.4	1	0.7
TRANVLCYPROMINE	3	0.8	1	0.7	2	1.4
NORTRIPTYLINE	2	0.6	1	0.7	1	0.7
PAROXETINE	2	0.6	1	0.7	1	0.7
MIANSERIN	2	0.6	1	0.7		
NIALAMIDE	2	0.6			1	0.7
VILOXAZINE	2	0.6			1	0.7
DESIPRAMINE	2	0.6				
DOSULEPIN	2	0.6				
TIANEPTINE	1	0.3			1	0.7
AMINEPTINE	1	0.3				
MEDIFOXAMINE	1	0.3				
PIPOFEZINE	1	0.3				

PHARMACIA C9580077

REBOXETINE - PROTOCOL 20124/013

TABLE No.: 17

MEDICAL HISTORY FINDINGS OF SCREENED PATIENTS

Previous diseases	Open Phase		Randomised Patients			
	All patients		Reboxetine		Placebo	
	No	% on Pt.	No	% on Pt.	No	% on Pt.
Patients	358	100.0	143	100.0	140	100.0
NEURALGIA/NEURITIS NOS	10	2.8	8	5.6	2	1.4
APPENDICITIS NOS	9	2.5	2	1.4	7	5.0
OTHER SOFT TISSUE DIS	6	1.7	3	2.1	3	2.1
ANGINA PECTORIS	5	1.4	4	2.8	1	0.7
PNEUMONIA, ORGANISM NOS	4	1.1	1	0.7	2	1.4
MEASLES UNCOMPLICATED	4	1.1	1	0.7	3	2.1
ACUTE TONSILLITIS	3	0.8	1	0.7	1	0.7
PULMONARY TB NOS	2	0.6			2	1.4
UTERINE LEIOMYOMA	2	0.6	2	1.4		
HYPERTENSION NOS	3	0.8	2	1.4	1	0.7
MYOCARDITIS NOS	4	1.1	2	1.4	2	1.4
ASTHMA NOS	2	0.6			1	0.7
CHOLELITHIASIS	2	0.6				
NEPHRITIS NOS	2	0.6	1	0.7	1	0.7
OTHER PYELONEPHRITIS	2	0.6	1	0.7	1	0.7
FEMALE PELVIC INFLAM DIS	2	0.6	1	0.7		
CHRONIC ULCER OF SKIN	2	0.6	1	0.7		
RHEUMATISM NOS	3	0.8	1	0.7	2	1.4
GASTRITIS/DUODENITIS NOS	2	0.6	1	0.7	1	0.7
INFECTIOUS ENTERITIS NOS	1	0.3			1	0.7
VIRAL HEPATITIS	1	0.3			1	0.7
HEPATITIS A W/O COMA	2	0.6				
SARCOIDOSIS	1	0.3	1	0.7		
MALIG NEO FEMALE BREAST	1	0.3	1	0.7		
OTHER GU NEOPLASM NOS	1	0.3				
ENDOCRINE/NERV NEO NOS	1	0.3	1	0.7		
OPEN-ANGLE GLAUCOMA	1	0.3				
OTITIS MEDIA NOS	1	0.3				
RHEUM HEART DIS NEC/NOS	1	0.3	1	0.7		
ESSENTIAL HYPERTENSION	1	0.3				
ACUTE MYOCARDIAL INFARCT	1	0.3				
CHR ISCHEMIC HRT DIS NOS	1	0.3	1	0.7		
PERICARDIAL DISEASE NOS	1	0.3				
CHRONIC SINUSITIS NOS	1	0.3			1	0.7
INFLUENZA	1	0.3	1	0.7		

(CONTINUED)

PHARMACIA C9550077

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 17

MEDICAL HISTORY FINDINGS OF SCREENED PATIENTS

Previous diseases	Open Phase		Randomised Patients			
	All patients		Reboxetine		Placebo	
	No	% on Pt.	No	% on Pt.	No	% on Pt.
CHRONIC BRONCHITIS NOS	1	0.3	1	0.7		
STOMACH ULCER NOS	2	0.6			1	0.7
PARALYTIC ILEUS	1	0.3	1	0.7		
HEPATITIS IN VIRAL DIS	2	0.6	2	1.4		
CHOLECYSTITIS NEC	2	0.6	1	0.7	1	0.7
KIDNEY INFECTION	1	0.3	1	0.7		
CALCULUS OF KIDNEY	2	0.6	1	0.7		
CYSTITIS NOS	1	0.3			1	0.7
SALPINGO-OOPHORITIS NOS	1	0.3			1	0.7
CERVICITIS	1	0.3			1	0.7
VAGINITIS	1	0.3			1	0.7
MUCOUS POLYP OF CERVIX	1	0.3			1	0.7
OTH FEMALE GENITAL DIS	1	0.3				
ECTOPIC PREGNANCY NOS	1	0.3			1	0.7
POLYARTHRITIS NOS	1	0.3	1	0.7		
MONOARTHRITIS NOS	1	0.3	1	0.7		
BRACHIAL NEURITIS NOS	1	0.3	1	0.7		
POLYMYALGIA RHEUMATICA	2	0.6	1	0.7		
PALPITATIONS	2	0.6	1	0.7		
PULMONARY TUBERCULOSIS	1	0.3	1	0.7		
SCARLET FEVER	1	0.3			1	0.7
CHICKENPOX	1	0.3				
DIS BILIRUBIN EXCRETION	1	0.3				
THROMBOCYTOPENIA NOS	1	0.3			1	0.7
DISORDERS OF THE GLOBE	1	0.3			1	0.7
DIS TYMPANIC MEMB NEC	1	0.3	1	0.7		
THROMBOPHLEBITIS LEG NOS	1	0.3			1	0.7
CHR T A DIS	1	0.3			1	0.7
VIRAL PNEUMONIA	1	0.3	1	0.7		
INGUINAL HERNIA NOS	1	0.3	1	0.7		
HYPERPLASIA OF PROSTATE	1	0.3			1	0.7
PSORIASIS/LIKE DISORDERS	1	0.3	1	0.7		
RHEUMATOID ARTHRITIS	1	0.3			1	0.7
LUMBOSACRAL NEURITIS NOS	1	0.3	1	0.7		
TACHYCARDIA NOS	1	0.3	1	0.7		

PHARMACIA CIP 0077

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 18

MEDICAL HISTORY FINDINGS OF SCREENED PATIENTS BY BODY SYSTEM

Previous diseases (body system)	Open Phase		Randomised Patients			
	All patients		Reboxetine		Placebo	
	No	% on Pt.	No	% on Pt.	No	% on Pt.
Patients	358	100.0	143	100.0	140	100.0
MUSCULOSKELETAL SYS. AND CONNETIVE TISSUE	26	7.3	17	11.9	8	5.7
GASTRO-INTESTINAL SYSTEM	21	5.9	8	5.6	10	7.1
CARDIOVASCULAR SYSTEM	18	5.0	10	7.0	5	3.6
RESPIRATORY SYSTEM	14	3.9	5	3.5	6	4.3
INFECTIOUS AND PARASTITIC DISEASE	14	3.9	3	2.1	8	5.7
NEOPLASH	5	1.4	4	2.8		
GENITOURINARY SYSTEM	16	4.5	5	3.5	8	5.7
SKIN AND SUBCUTANEOUS TISSUE	3	0.8	2	1.4		
NERVOUS SYSTEM AND SENSE ORGANS	4	1.1	1	0.7	1	0.7
PREGNANCY, CHILDBIRTH AND PUERPERIUM	1	0.3			1	0.7
SYMPTONS, SIGNS AND ILL DEFINED CONDITIONS	3	0.8	2	1.4		
ENDOCR., NUTRIT. AND METAB. DISEASES	1	0.3				
BLOOD AND BLOOD-FORMING ORGANS	1	0.3			1	0.7

PHARMACIA CUS 0077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 19

EXPERIMENTAL TREATMENT: NUMBER OF PATIENTS ACCORDING TO DOSE TAKEN ON EACH DAY AND ON DAYS OF ASSESSMENT DURING THERAPY BY PHASE AND ASSIGNED TREATMENT

PHASE: OPEN

VISIT/DAYS OF TREATMENT	DOSE (mg/day)								Total		
	0		4		6		8		No	%	
	No	%	No	%	No	%	No	%			
1	1							358	100	358	100
2	2			1	0.3			357	99.7	358	100
3	3			1	0.3			357	99.7	358	100
4	4			1	0.3			356	99.7	357	100
5	5							357	100	357	100
6	6			1	0.3			354	99.7	355	100
7	7							354	100	354	100
8	8							8	100	8	100
2	1			4	1.1			350	98.9	354	100
2	2			4	1.1			350	98.9	354	100
3	3			4	1.1			350	98.9	354	100
4	4			4	1.1			350	98.9	354	100
5	5			4	1.1			350	98.9	354	100
6	6			4	1.1			350	98.9	354	100
7	7			4	1.1			344	98.9	348	100
8	8			1	12.5			7	87.5	8	100
9	9							1	100	1	100
3	1			3	0.9			346	99.1	349	100
2	2			2	0.6			347	99.4	349	100
3	3	1	0.3	3	0.9			344	98.9	348	100
4	4	1	0.3	3	0.9			343	98.8	347	100
5	5			2	0.6			343	99.4	345	100
6	6			2	0.6			343	99.4	345	100
7	7			2	0.6			334	99.4	336	100
8	8							8	100	8	100
4	1			4	1.2			333	98.8	337	100
2	2			3	0.9	1	0.3	332	98.8	336	100
3	3	1	0.3	4	1.2			331	98.5	336	100
4	4	1	0.3	4	1.2			331	98.5	336	100
5	5			5	1.5			331	98.5	336	100
6	6			5	1.5	1	0.3	329	98.2	335	100
7	7			7	2.2			312	97.8	319	100
8	8			1	25.0			3	75.0	4	100
5	1			4	1.2			324	98.8	328	100
2	2			3	0.9	1	0.3	324	98.8	328	100
3	3			3	0.9			323	99.1	326	100
4	4			3	0.9			323	99.1	326	100
5	5			3	0.9			323	99.1	326	100
6	6			3	0.9			323	99.1	326	100
7	7			3	0.9			316	99.1	319	100
8	8							14	100	14	100
6	1			3	0.9			321	99.1	324	100
2	2			3	0.9			321	99.1	324	100
3	3			3	0.9			321	99.1	324	100
4	4			3	0.9			321	99.1	324	100
5	5			3	0.9			319	99.1	322	100
6	6			3	0.9			319	99.1	322	100
7	7			3	1.0			312	99.0	315	100
8	8							17	100	17	100
9	9							1	100	1	100
10	10							1	100	1	100
11	11							1	100	1	100
12	12							1	100	1	100
13	13							1	100	1	100
14	14							1	100	1	100
15	15							1	100	1	100
16	16							1	100	1	100
17	17							1	100	1	100
18	18							1	100	1	100
19	19							1	100	1	100
20	20							1	100	1	100
21	21							1	100	1	100

PHARMACIA CNS 580077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 20

EXPERIMENTAL TREATMENT: NUMBER OF PATIENTS ACCORDING TO DOSE TAKEN ON EACH DAY AND ON DAYS OF ASSESSMENT DURING THERAPY BY PHASE AND ASSIGNED TREATMENT

PHASE: D.B.
AND TREATMENT: REBOXETINE

VISIT/DAYS OF TREATMENT	DOSE (mg/day)										Total			
	0		2		4		6		8		No	%		
	No	%	No	%	No	%	No	%	No	%				
8	1				1	0.7					142	99.3	143	100
2					1	0.7					142	99.3	143	100
3					1	0.7					142	99.3	143	100
4					1	0.7					142	99.3	143	100
5					1	0.7					142	99.3	143	100
6					1	0.7					142	99.3	143	100
7					2	1.4					141	98.6	143	100
8					1	0.7					142	99.3	143	100
9					1	0.7					142	99.3	143	100
10					1	0.7					142	99.3	143	100
11					1	0.7					142	99.3	143	100
12					1	0.7					142	99.3	143	100
13					1	0.7					142	99.3	143	100
14					1	0.7					140	99.3	141	100
15										5	100		5	100
16										2	100		2	100
17										1	100		1	100
18										1	100		1	100
19										1	100		1	100
20										1	100		1	100
21										1	100		1	100
9	1									1	100		1	100
2										1	100		1	100
3										1	100		1	100
4										1	100		1	100
5										1	100		1	100
6										1	100		1	100
7										1	100		1	100
10					1	0.7		1	0.7	135	98.5		137	100
2								1	0.7	135	99.3		136	100
3								1	0.7	135	99.3		136	100
4					1	0.7				135	99.3		136	100
5					1	0.7				135	99.3		136	100
6					1	0.7				135	99.3		136	100
7										135	99.3		136	100
8		1	0.7							135	99.3		136	100
9		1	0.7							135	99.3		136	100
10		1	0.7							135	99.3		136	100
11					1	0.7				135	99.3		136	100
12					1	0.7				135	99.3		136	100
13					1	0.7				135	99.3		136	100
14										129	98.5		131	100
15					1	0.8		1	0.8	3	100		3	100
12	1									128	100		128	100
2										128	100		128	100
3										128	100		128	100
4										128	100		128	100
5										128	100		128	100
6										128	100		128	100
7										128	100		128	100
8										128	100		128	100
9										128	100		128	100
10										128	100		128	100
11										128	100		128	100
12										128	100		128	100
13										128	100		128	100
14										122	100		122	100
15										5	100		5	100
14	1									124	100		124	100
2										124	100		124	100
3										124	100		124	100
4										124	100		124	100
5										124	100		124	100
6										124	100		124	100
7										124	100		124	100

(CONTINUED)

PHARMACIA C8580077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 20

EXPERIMENTAL TREATMENT: NUMBER OF PATIENTS ACCORDING TO DOSE TAKEN ON EACH DAY AND ON DAYS OF ASSESSMENT DURING THERAPY BY PHASE AND ASSIGNED TREATMENT

PHASE: D.B.
AND TREATMENT: REBOXETINE

VISIT/DAYS OF TREATMENT	DOSE (mg/day)										Total		
	0		2		4		6		8		No	%	
	No	%	No	%	No	%	No	%	No	%			
14	8									124	100	124	100
	9									124	100	124	100
	10									124	100	124	100
	11									124	100	124	100
	12									124	100	124	100
	13									123	100	123	100
	14									120	100	120	100
	15									5	100	5	100
16	1									122	100	122	100
	2									122	100	122	100
	3									122	100	122	100
	4									122	100	122	100
	5									122	100	122	100
	6									122	100	122	100
	7									122	100	122	100
	8									122	100	122	100
	9									122	100	122	100
	10									122	100	122	100
	11									122	100	122	100
	12									121	100	121	100
	13									121	100	121	100
	14									121	100	121	100
	15									1	100	1	100
18	1									114	100	114	100
	2									114	100	114	100
	3									114	100	114	100
	4									114	100	114	100
	5									114	100	114	100
	6									114	100	114	100
	7									114	100	114	100
	8									114	100	114	100
	9									114	100	114	100
	10									114	100	114	100
	11									114	100	114	100
	12					1	0.9			113	99.1	114	100
	13					1	0.9			112	99.1	113	100
	14					2	1.8			109	98.2	111	100
20	1									109	100	109	100
	2									109	100	109	100
	3									109	100	109	100
	4									109	100	109	100
	5									109	100	109	100
	6									109	100	109	100
	7									109	100	109	100
	8									109	100	109	100
	9									109	100	109	100
	10									109	100	109	100
	11									109	100	109	100
	12									109	100	109	100
	13									109	100	109	100
	14									109	100	109	100
	15									3	100	3	100
22	1									105	100	105	100
	2									105	100	105	100
	3									105	100	105	100
	4									105	100	105	100
	5									105	100	105	100
	6									105	100	105	100
	7									105	100	105	100
	8									105	100	105	100
	9									105	100	105	100
	10									105	100	105	100
	11									105	100	105	100
	12									105	100	105	100
	13									105	100	105	100

(CONTINUED)

PHARMACIA 0959077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 20

EXPERIMENTAL TREATMENT: NUMBER OF PATIENTS ACCORDING TO DOSE TAKEN ON EACH DAY AND ON DAYS OF ASSESSMENT DURING THERAPY BY PHASE AND ASSIGNED TREATMENT

PHASE: D.B.
AND TREATMENT: REBOXETINE

VISIT/DAYS OF TREATMENT	DOSE (mg/day)										Total		
	0		2		4		6		8		No	%	
	No	%	No	%	No	%	No	%	No	%			
22	14									103	100	103	100
	15									2	100	2	100
24	1									102	100	102	100
	2									102	100	102	100
	3									102	100	102	100
	4									102	100	102	100
	5									102	100	102	100
	6									102	100	102	100
	7									102	100	102	100
	8									102	100	102	100
	9									102	100	102	100
	10									102	100	102	100
	11									102	100	102	100
	12				1	1.0				101	99.0	102	100
	13									101	100	101	100
	14									97	100	97	100
	15									4	100	4	100
26	1									101	100	101	100
	2									101	100	101	100
	3									101	100	101	100
	4									101	100	101	100
	5									101	100	101	100
	6									101	100	101	100
	7									101	100	101	100
	8									101	100	101	100
	9									101	100	101	100
	10									101	100	101	100
	11									101	100	101	100
	12									101	100	101	100
	13									101	100	101	100
	14									99	100	99	100
	15									2	100	2	100
	16									1	100	1	100
	17									1	100	1	100
	18									1	100	1	100
	19									1	100	1	100
	20									1	100	1	100
	21									1	100	1	100
	22									1	100	1	100
	23									1	100	1	100
	24									1	100	1	100
	25									1	100	1	100
	26									1	100	1	100
	27									1	100	1	100
	28									1	100	1	100
28	1									97	100	97	100
	2									97	100	97	100
	3									97	100	97	100
	4									97	100	97	100
	5									97	100	97	100
	6									97	100	97	100
	7									97	100	97	100
	8									97	100	97	100
	9									97	100	97	100
	10									97	100	97	100
	11									97	100	97	100
	12									97	100	97	100
	13									97	100	97	100
	14									96	100	96	100
	15									2	100	2	100
	16									1	100	1	100
	17									1	100	1	100
	18									1	100	1	100
	19									1	100	1	100
	20									1	100	1	100

(CONTINUED)

PHARMACIA 0959077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 20

EXPERIMENTAL TREATMENT: NUMBER OF PATIENTS ACCORDING TO DOSE TAKEN ON EACH DAY AND ON DAYS OF ASSESSMENT DURING THERAPY BY PHASE AND ASSIGNED TREATMENT

PHASE: D.B.
AND TREATMENT: REBOXETINE

VISIT/DAYS OF TREATMENT	DOSE (mg/day)										Total		
	0		2		4		6		8		No	%	
	No	%	No	%	No	%	No	%	No	%			
28	21									1	100	1	100
	22									1	100	1	100
	23									1	100	1	100
	24									1	100	1	100
	25									1	100	1	100
	26									1	100	1	100
	27									1	100	1	100
	28									1	100	1	100
	29									1	100	1	100
	30									1	100	1	100
	31									1	100	1	100
	32									1	100	1	100
	33									1	100	1	100
	34									1	100	1	100
	35									1	100	1	100
	36									1	100	1	100
	37									1	100	1	100
	38									1	100	1	100
	39									1	100	1	100
	40									1	100	1	100
	41									1	100	1	100
	42									1	100	1	100
30	1									90	100	90	100
	2									90	100	90	100
	3									90	100	90	100
	4									90	100	90	100
	5									90	100	90	100
	6									90	100	90	100
	7									90	100	90	100
	8									90	100	90	100
	9									90	100	90	100
	10									90	100	90	100
	11									90	100	90	100
	12									90	100	90	100
	13									90	100	90	100
	14									89	100	89	100
	15									2	100	2	100
	16									1	100	1	100
	17									1	100	1	100
	18									1	100	1	100
	19									1	100	1	100
	20									1	100	1	100
	21									1	100	1	100
	22									1	100	1	100
	23									1	100	1	100
	24									1	100	1	100
	25									1	100	1	100
	26									1	100	1	100
	27									1	100	1	100
	28									1	100	1	100
32	1									88	100	88	100
	2									88	100	88	100
	3									88	100	88	100
	4									88	100	88	100
	5									88	100	88	100
	6									88	100	88	100
	7									88	100	88	100
	8									88	100	88	100
	9									88	100	88	100
	10									88	100	88	100
	11									88	100	88	100
	12									88	100	88	100
	13									88	100	88	100
	14									87	100	87	100
	15									1	100	1	100

(CONTINUED)

PHARMACIA 0953077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 20

EXPERIMENTAL TREATMENT: NUMBER OF PATIENTS ACCORDING TO DOSE TAKEN ON EACH DAY AND ON DAYS OF ASSESSMENT DURING THERAPY BY PHASE AND ASSIGNED TREATMENT

PHASE: D.B.
AND TREATMENT: REBOXETINE

VISIT/DAYS OF TREATMENT	DOSE (mg/day)										Total		
	0		2		4		6		8		No	%	
	No	%	No	%	No	%	No	%	No	%			
34	1									87	100	87	100
	2									87	100	87	100
	3									87	100	87	100
	4									87	100	87	100
	5									87	100	87	100
	6									87	100	87	100
	7									87	100	87	100
	8									87	100	87	100
	9									87	100	87	100
	10									87	100	87	100
	11									87	100	87	100
	12									87	100	87	100
	13									87	100	87	100
	14									86	100	86	100
	15									1	100	1	100
36	1									84	100	84	100
	2									84	100	84	100
	3									84	100	84	100
	4									84	100	84	100
	5									84	100	84	100
	6									84	100	84	100
	7									84	100	84	100
	8									84	100	84	100
	9									84	100	84	100
	10									84	100	84	100
	11									84	100	84	100
	12									84	100	84	100
	13									84	100	84	100
	14									82	100	82	100
38	1									83	100	83	100
	2									83	100	83	100
	3									83	100	83	100
	4									83	100	83	100
	5									83	100	83	100
	6									83	100	83	100
	7									83	100	83	100
	8									83	100	83	100
	9									83	100	83	100
	10									83	100	83	100
	11									83	100	83	100
	12									83	100	83	100
	13									83	100	83	100
	14									83	100	83	100
	15									1	100	1	100
40	1									82	100	82	100
	2									82	100	82	100
	3									82	100	82	100
	4									82	100	82	100
	5									82	100	82	100
	6									82	100	82	100
	7									82	100	82	100
	8									82	100	82	100
	9									82	100	82	100
	10									82	100	82	100
	11									82	100	82	100
	12									82	100	82	100
	13									82	100	82	100
	14									77	100	77	100
	15									1	100	1	100
42	1									82	100	82	100
	2									82	100	82	100
	3									82	100	82	100
	4									82	100	82	100
	5									82	100	82	100
	6									82	100	82	100

(CONTINUED)

PHARMACIA 0955077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 20

EXPERIMENTAL TREATMENT: NUMBER OF PATIENTS ACCORDING TO DOSE TAKEN ON EACH DAY AND ON DAYS OF ASSESSMENT DURING THERAPY BY PHASE AND ASSIGNED TREATMENT

PHASE: D.B.
AND TREATMENT: REBOXETINE

VISIT/DAYS OF TREATMENT	DOSE (mg/day)										Total		
	0		2		4		6		8		No	%	
	No	%	No	%	No	%	No	%	No	%			
42	7									82	100	82	100
	8									82	100	82	100
	9									82	100	82	100
	10									82	100	82	100
	11									82	100	82	100
	12									82	100	82	100
	13									82	100	82	100
	14									82	100	82	100
	15									4	100	4	100
44	1									82	100	82	100
	2									82	100	82	100
	3									82	100	82	100
	4									82	100	82	100
	5									82	100	82	100
	6									82	100	82	100
	7									82	100	82	100
	8									82	100	82	100
	9									82	100	82	100
	10									82	100	82	100
	11									82	100	82	100
	12									82	100	82	100
	13									82	100	82	100
	14									81	100	81	100
46	1									81	100	81	100
	2									81	100	81	100
	3									81	100	81	100
	4									81	100	81	100
	5									81	100	81	100
	6									81	100	81	100
	7									81	100	81	100
	8									81	100	81	100
	9									81	100	81	100
	10									81	100	81	100
	11									81	100	81	100
	12									81	100	81	100
	13									81	100	81	100
	14									78	100	78	100
48	1									81	100	81	100
	2									81	100	81	100
	3									81	100	81	100
	4									81	100	81	100
	5									81	100	81	100
	6									81	100	81	100
	7									81	100	81	100
	8									81	100	81	100
	9									81	100	81	100
	10									81	100	81	100
	11									81	100	81	100
	12									81	100	81	100
	13									81	100	81	100
	14									78	100	78	100
	15									8	100	8	100
50	1									80	100	80	100
	2									80	100	80	100
	3									80	100	80	100
	4									80	100	80	100
	5									80	100	80	100
	6									80	100	80	100
	7									80	100	80	100
	8									80	100	80	100
	9									80	100	80	100
	10									80	100	80	100
	11									80	100	80	100
	12									80	100	80	100
	13									80	100	80	100

(CONTINUED)

PHARMACIA OJ 58077
 REBOXETINE - PROTOCOL 20124/013

TABLE No.: 20

EXPERIMENTAL TREATMENT: NUMBER OF PATIENTS ACCORDING TO DOSE TAKEN ON EACH DAY AND ON DAYS OF ASSESSMENT DURING THERAPY BY PHASE AND ASSIGNED TREATMENT

PHASE: D.B.
 AND TREATMENT: REBOXETINE

VISIT/DAYS OF TREATMENT		DOSE (mg/day)										Total	
		0		2		4		6		8			
		No	%	No	%	No	%	No	%	No	%	No	%
50	14									75	100	75	100
	15									3	100	3	100
52	1									79	100	79	100
	2									79	100	79	100
	3									79	100	79	100
	4									79	100	79	100
	5									79	100	79	100
	6									79	100	79	100
	7									79	100	79	100
	8									79	100	79	100
	9									79	100	79	100
	10									79	100	79	100
	11									79	100	79	100
	12									79	100	79	100
	13									79	100	79	100
	14									78	100	78	100
	15									6	100	6	100

PHARMACIA 090177
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 21

EXPERIMENTAL TREATMENT: NUMBER OF PATIENTS ACCORDING TO DOSE TAKEN ON EACH DAY AND ON DAYS OF ASSESSMENT DURING THERAPY BY PHASE AND ASSIGNED TREATMENT (CAPSULES TAKEN)

PHASE: D.B.
AND TREATMENT: PLACEBO

VISIT/DAYS OF TREATMENT	DOSE (mg/day)						Total	
	0		4		8		No	%
	No	%	No	%	No	%		
8	1		1	0.7	139	99.3	140	100
	2		1	0.7	139	99.3	140	100
	3		1	0.7	139	99.3	140	100
	4		1	0.7	139	99.3	140	100
	5		1	0.7	139	99.3	140	100
	6		1	0.7	139	99.3	140	100
	7		1	0.7	139	99.3	140	100
	8		1	0.7	139	99.3	140	100
	9		1	0.7	139	99.3	140	100
	10		1	0.7	139	99.3	140	100
	11		1	0.7	139	99.3	140	100
	12		1	0.7	139	99.3	140	100
	13		1	0.7	139	99.3	140	100
	14		1	0.7	136	99.3	137	100
	15		1	14.3	6	85.7	7	100
10	1		1	0.7	135	99.3	136	100
	2		1	0.7	135	99.3	136	100
	3		1	0.7	135	99.3	136	100
	4		1	0.7	135	99.3	136	100
	5		1	0.7	135	99.3	136	100
	6		1	0.7	135	99.3	136	100
	7		1	0.7	135	99.3	136	100
	8		1	0.7	135	99.3	136	100
	9		1	0.7	135	99.3	136	100
	10		1	0.7	134	99.3	135	100
	11		1	0.7	134	99.3	135	100
	12		1	0.7	134	99.3	135	100
	13		1	0.7	134	99.3	135	100
	14		1	0.8	130	99.2	131	100
	15				2	100	2	100
12	1		1	0.8	132	99.2	133	100
	2		1	0.8	132	99.2	133	100
	3		1	0.8	131	99.2	132	100
	4		1	0.8	131	99.2	132	100
	5		1	0.8	131	99.2	132	100
	6		1	0.8	131	99.2	132	100
	7		1	0.8	131	99.2	132	100
	8		1	0.8	130	99.2	131	100
	9		1	0.8	130	99.2	131	100
	10		1	0.8	130	99.2	131	100
	11		1	0.8	130	99.2	131	100
	12		1	0.8	130	99.2	131	100
	13		1	0.8	130	99.2	131	100
	14		2	1.6	121	98.4	123	100
	15				2	100	2	100
14	1		1	0.8	124	99.2	125	100
	2		1	0.8	124	99.2	125	100
	3		1	0.8	124	99.2	125	100
	4		1	0.8	124	99.2	125	100
	5		1	0.8	124	99.2	125	100
	6		1	0.8	124	99.2	125	100
	7		1	0.8	124	99.2	125	100
	8		1	0.8	124	99.2	125	100
	9		1	0.8	124	99.2	125	100
	10		1	0.8	124	99.2	125	100
	11		1	0.8	124	99.2	125	100
	12		2	1.6	123	98.4	125	100
	13		1	0.8	122	99.2	123	100
	14		1	0.8	119	99.2	120	100
	15				4	100	4	100
16	1		1	0.8	122	99.2	123	100
	2		1	0.8	122	99.2	123	100
	3		1	0.8	122	99.2	123	100
	4		1	0.8	122	99.2	123	100
	5		1	0.8	122	99.2	123	100

(CONTINUED)

PHARMACIA 0958077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 21

EXPERIMENTAL TREATMENT: NUMBER OF PATIENTS ACCORDING TO DOSE TAKEN ON EACH DAY AND ON DAYS OF ASSESSMENT DURING THERAPY BY PHASE AND ASSIGNED TREATMENT (CAPSULES TAKEN)

PHASE: D.B.
AND TREATMENT: PLACEBO

VISIT/DAYS OF TREATMENT	DOSE (mg/day)						Total		
	0		4		8		No	%	
	No	%	No	%	No	%			
16	6		1	0.8	122	99.2	123	100	
	7		1	0.8	122	99.2	123	100	
	8		1	0.8	122	99.2	123	100	
	9	1	0.8	1	0.8	121	98.4	123	100
	10	1	0.8	1	0.8	121	98.4	123	100
	11		1	0.8	122	99.2	123	100	
	12		1	0.8	122	99.2	123	100	
	13		1	0.8	122	99.2	123	100	
	14		1	0.8	121	99.2	122	100	
	15				1	100	1	100	
18	1		2	1.7	115	98.3	117	100	
	2		2	1.7	115	98.3	117	100	
	3		2	1.7	115	98.3	117	100	
	4		2	1.7	115	98.3	117	100	
	5		2	1.7	115	98.3	117	100	
	6		2	1.7	115	98.3	117	100	
	7		2	1.7	115	98.3	117	100	
	8	1	0.9	2	1.7	114	97.4	117	100
	9		2	1.7	115	98.3	117	100	
	10		2	1.7	115	98.3	117	100	
	11		1	0.9	115	99.1	116	100	
	12		1	0.9	115	99.1	116	100	
	13		1	0.9	115	99.1	116	100	
	14		1	0.9	114	99.1	115	100	
	15				1	100	1	100	
20	1	1	0.9	1	0.9	106	98.1	108	100
	2	1	0.9	1	0.9	106	98.1	108	100
	3	1	0.9	1	0.9	106	98.1	108	100
	4	1	0.9	2	1.9	104	97.2	107	100
	5	1	0.9	1	0.9	104	98.1	106	100
	6	1	0.9	1	0.9	104	98.1	106	100
	7	1	0.9	1	0.9	104	98.1	106	100
	8	1	0.9	1	0.9	104	98.1	106	100
	9	1	0.9	1	0.9	104	98.1	106	100
	10	1	0.9	1	0.9	104	98.1	106	100
	11	1	0.9	1	0.9	104	98.1	106	100
	12	1	0.9	1	0.9	104	98.1	106	100
	13	1	0.9	1	0.9	104	98.1	106	100
	14	1	0.9	1	0.9	104	98.1	106	100
	15	1	33.3			2	66.7	3	100
	16	1	100					1	100
	17	1	100					1	100
	18	1	100					1	100
22	1		1	1.0	100	99.0	101	100	
	2		1	1.0	100	99.0	101	100	
	3		1	1.0	100	99.0	101	100	
	4		1	1.0	100	99.0	101	100	
	5		1	1.0	100	99.0	101	100	
	6		1	1.0	100	99.0	101	100	
	7		1	1.0	100	99.0	101	100	
	8		1	1.0	99	99.0	100	100	
	9		1	1.0	99	99.0	100	100	
	10		1	1.0	99	99.0	100	100	
	11		1	1.0	99	99.0	100	100	
	12		1	1.0	99	99.0	100	100	
	13		1	1.0	99	99.0	100	100	
	14		1	1.0	99	99.0	100	100	
	15				1	100	1	100	
24	1		1	1.1	94	98.9	95	100	
	2		1	1.1	94	98.9	95	100	
	3		1	1.1	94	98.9	95	100	
	4		1	1.1	94	98.9	95	100	
	5		1	1.1	94	98.9	95	100	
	6		1	1.1	94	98.9	95	100	
	7		1	1.1	94	98.9	95	100	

(CONTINUED)

PHARMACIA 09530077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 21

EXPERIMENTAL TREATMENT: NUMBER OF PATIENTS ACCORDING TO DOSE TAKEN ON EACH DAY AND ON DAYS OF ASSESSMENT DURING THERAPY BY PHASE AND ASSIGNED TREATMENT (CAPSULES TAKEN)

PHASE: D.B.
AND TREATMENT: PLACEBO

VISIT/DAYS OF TREATMENT	DOSE (mg/day)						Total	
	0		4		8		No	%
	No	%	No	%	No	%		
24	8		1	1.1	94	98.9	95	100
	9		1	1.1	94	98.9	95	100
	10		1	1.1	94	98.9	95	100
	11		1	1.1	94	98.9	95	100
	12		1	1.1	94	98.9	95	100
	13		1	1.1	94	98.9	95	100
	14		1	1.1	94	98.9	95	100
	15				7	100	7	100
26	1				91	100	91	100
	2				91	100	91	100
	3				91	100	91	100
	4				91	100	91	100
	5				91	100	91	100
	6				91	100	91	100
	7				91	100	91	100
	8	1	1.1		90	98.9	91	100
	9				91	100	91	100
	10				91	100	91	100
	11				91	100	91	100
	12				91	100	91	100
	13				91	100	91	100
	14				88	100	88	100
	15				2	100	2	100
	16				1	100	1	100
	17				1	100	1	100
	18				1	100	1	100
	19				1	100	1	100
	20				1	100	1	100
	21				1	100	1	100
	22				1	100	1	100
	23				1	100	1	100
	24				1	100	1	100
28	1				88	100	88	100
	2				88	100	88	100
	3				88	100	88	100
	4				88	100	88	100
	5				88	100	88	100
	6				88	100	88	100
	7				88	100	88	100
	8				88	100	88	100
	9				88	100	88	100
	10				88	100	88	100
	11				88	100	88	100
	12				88	100	88	100
	13				88	100	88	100
	14				87	100	87	100
	15				2	100	2	100
30	1				83	100	83	100
	2				83	100	83	100
	3				83	100	83	100
	4				83	100	83	100
	5				83	100	83	100
	6				83	100	83	100
	7				83	100	83	100
	8				83	100	83	100
	9				83	100	83	100
	10				83	100	83	100
	11				83	100	83	100
	12				83	100	83	100
	13				83	100	83	100
	14				83	100	83	100
	15				2	100	2	100
32	1				80	100	80	100
	2				80	100	80	100
	3				80	100	80	100

(CONTINUED)

PHARMACIA 0958077
 REBOXETINE - PROTOCOL 20124/013

TABLE No.: 21

EXPERIMENTAL TREATMENT: NUMBER OF PATIENTS ACCORDING TO DOSE TAKEN ON EACH DAY AND ON DAYS OF ASSESSMENT DURING THERAPY BY PHASE AND ASSIGNED TREATMENT (CAPSULES TAKEN)

PHASE: D.B.
 AND TREATMENT: PLACEBO

VISIT/DAYS OF TREATMENT	DOSE (mg/day)						Total		
	0		4		8		No	%	
	No	%	No	%	No	%			
32	4					80	100	80	100
	5					80	100	80	100
	6					80	100	80	100
	7					80	100	80	100
	8					80	100	80	100
	9					80	100	80	100
	10					80	100	80	100
	11					80	100	80	100
	12					80	100	80	100
	13					80	100	80	100
	14					78	100	78	100
34	1					79	100	79	100
	2					79	100	79	100
	3					79	100	79	100
	4					79	100	79	100
	5					79	100	79	100
	6					79	100	79	100
	7					79	100	79	100
	8					79	100	79	100
	9					79	100	79	100
	10					79	100	79	100
	11					79	100	79	100
	12					79	100	79	100
	13					79	100	79	100
	14					79	100	79	100
	15					2	100	2	100
36	1					78	100	78	100
	2					78	100	78	100
	3					78	100	78	100
	4					78	100	78	100
	5					78	100	78	100
	6					78	100	78	100
	7					78	100	78	100
	8					78	100	78	100
	9					78	100	78	100
	10					78	100	78	100
	11					78	100	78	100
	12					78	100	78	100
	13					78	100	78	100
	14					75	100	75	100
38	1					76	100	76	100
	2					76	100	76	100
	3					76	100	76	100
	4					76	100	76	100
	5					76	100	76	100
	6					76	100	76	100
	7					76	100	76	100
	8					76	100	76	100
	9					76	100	76	100
	10					76	100	76	100
	11					76	100	76	100
	12					76	100	76	100
	13					76	100	76	100
	14					75	100	75	100
40	1					74	100	74	100
	2					74	100	74	100
	3					74	100	74	100
	4					74	100	74	100
	5					74	100	74	100
	6					74	100	74	100
	7					74	100	74	100
	8					74	100	74	100
	9					74	100	74	100
	10					74	100	74	100
	11					74	100	74	100

(CONTINUED)

PHARMACIA 090177
 REBOXETINE - PROTOCOL 20124/013

TABLE No.: 21

EXPERIMENTAL TREATMENT: NUMBER OF PATIENTS ACCORDING TO DOSE TAKEN ON EACH DAY AND ON DAYS OF ASSESSMENT DURING THERAPY BY PHASE AND ASSIGNED TREATMENT (CAPSULES TAKEN)

PHASE: D.B.
 AND TREATMENT: PLACEBO

VISIT/DAYS OF TREATMENT	DOSE (mg/day)						Total	
	0		4		8		No	%
	No	%	No	%	No	%		
40	12				74	100	74	100
	13				74	100	74	100
	14				70	100	70	100
	15				1	100	1	100
42	1				73	100	73	100
	2				73	100	73	100
	3				73	100	73	100
	4				73	100	73	100
	5				73	100	73	100
	6				73	100	73	100
	7				73	100	73	100
	8				73	100	73	100
	9				73	100	73	100
	10				73	100	73	100
	11				73	100	73	100
	12				73	100	73	100
	13				73	100	73	100
	14				69	100	69	100
	15				3	100	3	100
44	1				70	100	70	100
	2				70	100	70	100
	3				70	100	70	100
	4				70	100	70	100
	5				70	100	70	100
	6				70	100	70	100
	7				70	100	70	100
	8				70	100	70	100
	9				70	100	70	100
	10				70	100	70	100
	11				70	100	70	100
	12				70	100	70	100
	13				70	100	70	100
	14				70	100	70	100
	15				2	100	2	100
46	1				68	100	68	100
	2				68	100	68	100
	3				68	100	68	100
	4				68	100	68	100
	5				68	100	68	100
	6				68	100	68	100
	7				68	100	68	100
	8				68	100	68	100
	9				68	100	68	100
	10				68	100	68	100
	11				68	100	68	100
	12				68	100	68	100
	13				68	100	68	100
	14				64	100	64	100
	15				1	100	1	100
48	1				66	100	66	100
	2				66	100	66	100
	3				66	100	66	100
	4				66	100	66	100
	5				66	100	66	100
	6				66	100	66	100
	7				66	100	66	100
	8				66	100	66	100
	9				66	100	66	100
	10				66	100	66	100
	11				66	100	66	100
	12				66	100	66	100
	13				66	100	66	100
	14				61	100	61	100
	15				6	100	6	100
50	1				66	100	66	100

(CONTINUED)

PHARMACIA ~~0530077~~
 REBOXETINE - PROTOCOL 20124/013

TABLE No.: 21

EXPERIMENTAL TREATMENT: NUMBER OF PATIENTS ACCORDING TO DOSE TAKEN ON EACH DAY AND ON DAYS OF ASSESSMENT DURING THERAPY BY PHASE AND ASSIGNED TREATMENT (CAPSULES TAKEN)

PHASE: D.B.
 AND TREATMENT: PLACEBO

VISIT/DAYS OF TREATMENT	DOSE (mg/day)						Total	
	0		4		8		No	%
	No	%	No	%	No	%		
50	2				66	100	66	100
	3				66	100	66	100
	4				66	100	66	100
	5				66	100	66	100
	6				66	100	66	100
	7				66	100	66	100
	8				66	100	66	100
	9				66	100	66	100
	10				66	100	66	100
	11				66	100	66	100
	12				66	100	66	100
	13				66	100	66	100
	14				63	100	63	100
	15				5	100	5	100
	52	1				65	100	65
2					65	100	65	100
3					65	100	65	100
4					65	100	65	100
5					65	100	65	100
6					65	100	65	100
7					65	100	65	100
8					65	100	65	100
9					65	100	65	100
10					65	100	65	100
11					65	100	65	100
12					65	100	65	100
13					65	100	65	100
14					63	100	63	100
15					2	100	2	100

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 22

EXPERIMENTAL TREATMENT: DISTRIBUTION OF PATIENTS ACCORDING TO CAPSULES TAKEN BY PHASE AND ASSIGNED TREATMENT

PHASE	TREATMENT	COMPLIANCE											
		90 - 95 %		95 - 99 %		100 %		TOTAL					
		No	%	No	%	No	%	No	%				
1-OPEN	REBOXETINE	1	0.3	2	0.6	355	99.2	358	100.0				
	TOTAL	1	0.3	2	0.6	355	99.2	358	100.0				
2-D.B.	TREATMENT												
	REBOXETINE			4	2.8	139	97.2	143	100.0				
	PLACEBO			3	2.1	137	97.9	140	100.0				
	TOTAL			7	2.5	276	97.5	283	100.0				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/013
 TABLE No.: 23
 CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS RECEIVING A CONCOMITANT DRUG AT LEAST ONCE DURING THE STUDY
 BY INITIAL PERIOD OF ADMINISTRATION - OPEN PHASE

Concomitant drugs	Newly		Started before treatment		Total	
	No	No	No	No	No	No
CHLORAL HYDRATE	41	30	71			
NIFEDIPINE	1	5	6			
ACETYSALICYLIC ACID	3	1	4			
VALERIANAE COMP.	2	1	3			
ZOLPIDEM	2	1	3			
TETRACYCLINE	2		2			
DICLOFENAC	1	1	2			
VALERIAN ROOT		2	2			
LIDOCAINE	1	1	2			
PAPAVERINE	1	1	2			
PROPRANOLOL	1	1	2			
OXAZEPAM	1	1	2			
MOCTRAM 10	1	1	2			
OXELADIN	1		1			
GENTAMICIN		1	1			
FUROSEMIDE		1	1			
BROMHEXINE	1		1			
HISTAMINE	1		1			
CAFFEINE AND SODIUM BENZOATE	1		1			
KETOTIFEN	1		1			
DROTAVERINE	1		1			
NETOPROLOL		1	1			

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOMETINE - PROTOCOL 20124/013
TABLE No.: 23

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE; NUMBER OF PATIENTS RECEIVING A CONCOMITANT DRUG AT LEAST ONCE DURING THE STUDY BY INITIAL PERIOD OF ADMINISTRATION - OPEN PHASE

Concomitant drugs	Newly		Started before treatment		Total	
	No	No	No	No	No	No
CEFALEXIN		1				1
CHLORMADINONE				1		1
FLUNITRAZEPAM				1		1
DUXOR				1		1
ALIMEMAZINE				1		1
CYANEMAZINE		1				1
HEPTAMINOL ADENOSINE PHOSPHATE				1		1
HYDROKIZINE				1		1
LOPRAZOLAM				1		1
MEPROBAMATE		1				1
MEPHENESIN		1				1
LORMETAZEPAM		1				1
TBIFLORIDAZINE		1				1

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
TABLE No.: 24

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS RECEIVING A CONCOMITANT DRUG AT LEAST ONCE DURING THE STUDY BY INITIAL PERIOD OF ADMINISTRATION - DOUBLE BLIND PHASE

Concomitant drugs	Reboxetine			Placebo		
	Started before D.B. Phase	Newly	Total	Started before D.B. Phase	Newly	Total
CHLORAL HYDRATE	19	2	21	24	3	27
NIFEDIPINE	3	3	6	1	1	2
VALERIAN ROOT		2	2	2	3	5
GLYCEROL		2	2			
PROPRANOLOL		1	1	1		1
CLONIDINE		1	1		1	1
VALERIANAE COMP.	2		2			
NITRAZEPAM		1	1		1	1
AMPICILLIN		1	1			
DIGITALIS		1	1			
PENTABRITHIYL TETRANITRATE		1	1			
DIAZEPAM		1	1			
PHENACETIN					1	1
PHENAZONE					1	1
ACETYLSALICYLIC ACID	1		1			
FUROSEMIDE	1		1			
DICLOFENAC	1		1			
METOPROLOL	1		1			
MEPROBAMATE					1	1
HEPTAHINOL					1	1
LOPRAZOLAM					1	1

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 TABLE No.: 24

CONCOMITANT DRUGS BY ACTIVE PRINCIPLE: NUMBER OF PATIENTS RECEIVING A CONCOMITANT DRUG AT LEAST ONCE DURING THE STUDY BY INITIAL PERIOD OF ADMINISTRATION - DOUBLE BLIND PHASE

Concomitant drugs	Reboxetine			Placebo		
	Started before D.B. Phase	Newly	Total	Started before D.B. Phase	Newly	Total
CHLORAL HYDRATE	19	2	21	24	3	27
NIFEDIPINE	3	3	6	1	1	2
VALERIAN ROOT		2	2	2	3	5
GLYCEROL		2	2			
PROPRANOLOL		1	1	1		1
CLONIDINE		1	1		1	1
VALERIANAE COMP.	2		2			
NITRAZEPAM		1	1		1	1
AMPICILLIN		1	1			
DIGITALIS		1	1			
PENTABRITHRITYL TETRANITRATE		1	1			
DIAZEPAM		1	1			
PHENACETIN					1	1
PHENAZONE					1	1
ACETYLSALICYLIC ACID	1		1			
FUROSEMIDE	1		1			
DICLOFENAC	1		1			
METOPROLOL	1		1			
MEPROBAMATE					1	1
HEPTAHINOL					1	1
LOPRAZOLAM					1	1

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 BEOBACHTUNG - PROTOKOLL 20124/013

TABLE No.: 25

HAMILTON DEPRESSION RATING SCALE - OPEN PHASE

	VISIT NO.							
	-1	0	1	2	3	4	5	6
N	358	358	358	354	349	335	328	323
MEAN	30.06	29.60	25.58	21.42	18.31	15.62	13.09	11.40
STDEV	5.50	5.59	7.19	7.65	7.97	7.35	7.33	7.31
MEDIAN	31.00	31.00	28.00	22.00	19.00	15.00	12.00	10.00
MIN	18	16	6	4	1	1	1	0
MAX	45	45	39	42	44	42	39	42

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 26

STATISTICAL ANALYSIS OF FACTORS OF HAMILTON DEPRESSION RATING SCALE AT EACH VISIT AS COMPARED TO DAY 0

	VISIT							
	0	1	2	3	4	5	6	
1: ANXIETY/SOMATIZATION	Evaluated	358	358	354	349	335	328	323
	Mean	1.64	1.42	1.22	1.05	0.92	0.77	0.67
	STD	0.45	0.50	0.51	0.50	0.46	0.47	0.47
	Min	0.50	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.67	2.67	2.83	2.50	2.33	2.50	2.50
	Median	1.67	1.50	1.25	1.00	0.83	0.67	0.50
	Median diff.	0.00	-0.17	-0.33	-0.67	-0.83	-1.00	-1.00
2: HEIGHT	Evaluated	358	358	354	349	335	328	323
	Mean	0.57	0.35	0.28	0.23	0.22	0.16	0.11
	STD	0.86	0.70	0.65	0.59	0.58	0.47	0.41
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Max	3.00	2.00	2.00	2.00	2.00	2.00	2.00
	Median	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Median diff.	0.00	0.00	0.00	0.00	0.00	0.00	0.00
3: COGNITIVE DISTURBANCE	Evaluated	358	358	354	349	335	328	323
	Mean	0.82	0.66	0.51	0.43	0.33	0.27	0.23
	STD	0.37	0.36	0.36	0.36	0.30	0.30	0.28
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.00	1.67	1.83	2.00	1.67	1.83	1.83
	Median	0.83	0.67	0.50	0.33	0.33	0.17	0.17
	Median diff.	0.00	-0.17	-0.33	-0.33	-0.50	-0.50	-0.67
4: DIURNAL VARIATION	Evaluated	358	358	354	349	335	328	323

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS RBD
REBOMETINE - PROTOCOL 20124/013

TABLE No.: 26

STATISTICAL ANALYSIS OF FACTORS OF HAMILTON DEPRESSION RATING SCALE AT EACH VISIT AS COMPARED TO DAY0

	VISIT							
	0	1	2	3	4	5	6	
4: DIURNAL VARIATION	Mean	1.18	1.05	0.86	0.72	0.62	0.54	0.46
	STD	0.73	0.73	0.70	0.67	0.65	0.64	0.63
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.00	2.00	2.00	2.00	2.00	2.00	2.00
	Median	1.00	1.00	1.00	1.00	1.00	1.00	1.00
	Median diff.	0.00	0.00	0.00	0.00	-1.00	-1.00	-1.00
5: RETARDATION	Evaluated	358	358	354	349	335	328	323
	Mean	2.18	1.93	1.61	1.36	1.14	0.95	0.83
	STD	0.47	0.58	0.63	0.64	0.60	0.57	0.59
	Min	0.75	0.25	0.00	0.00	0.00	0.00	0.00
	Max	3.25	3.25	3.00	3.25	3.00	3.00	3.25
	Median	2.25	2.00	1.75	1.25	1.00	1.00	0.75
Median diff.	0.00	-0.25	-0.50	-0.75	-1.00	-1.25	-1.50	
6: SLEEP DISTURBANCE	Evaluated	358	358	354	349	335	328	323
	Mean	1.45	1.31	1.15	1.02	0.92	0.77	0.71
	STD	0.45	0.45	0.48	0.53	0.52	0.49	0.47
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.00	2.00	2.00	2.00	2.00	2.00	2.00
	Median	1.67	1.33	1.33	1.00	1.00	0.67	0.67
Median diff.	0.00	0.00	-0.33	-0.33	-0.33	-0.67	-0.67	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD
REBOXETINE - PROTOCOL 20124/013

TABLE No. : 27

HAMILTON DEPRESSION RATING SCALE - SUMMARY STATISTICS AT LAST ASSESSMENT OF OPEN PHASE

	VISIT NO.						TOTAL
	1	2	3	4	5	6	
N	4	5	14	7	5	323	358
MEAN	29.00	32.20	27.86	21.71	21.00	11.40	12.87
STDEV	7.07	6.94	5.74	12.59	10.20	7.31	8.69
MEDIAN	26.50	34.00	27.50	23.00	21.00	10.00	10.00
MIN	24	20	17	4	5	0	0
MAX	39	37	37	34	33	42	42

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOMETINE - PROTOCOL 20124/013

TABLE No.: 28

RESPONSE DURING OPEN PHASE

	PATIENTS ENTERED		RESPONSE						REMISSION								
			withdrew- al			ABSENCE			withdrew- al			PRESENCE			ABSENCE		
			N	Z	N	Z	N	Z	N	Z	N	Z	N	Z	N	Z	
AT WEEK 6	358		35	9.8	272	76.0	51	14.2	35	9.8	179	50.0	144	40.2			
AT LAST ASSESSMENT	358		3	0.8	275	76.8	80	22.3	3	0.8	182	50.8	173	48.3			

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R00
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 29

CLINICAL GLOBAL IMPRESSION: SEVERITY - OPEN PHASE

VISIT NO.	SEVERITY OF ILLNESS																	
	NORMAL		BORDERLINE MENTALLY ILL		MILDLY ILL		MODERATELY ILL		MARKEDLY ILL		SEVERELY ILL		EXTREMELY ILL		TOTAL			
	N	ROZ	N	ROZ	N	ROZ	N	ROZ	N	ROZ	N	ROZ	N	ROZ	N	ROZ	N	ROZ
0					3	0.84			30	8.38	223	62.29	87	24.30	15	4.19	358	358
1			1	0.28	8	2.23	87	24.30	164	46.53	98	27.68	34	9.60	2	0.56	354	354
2			5	1.41	51	14.41	142	40.69	59	16.91	22	6.30	16	4.75	1	0.30	349	349
3	1	0.29	18	5.16	105	30.09	94	27.89	38	11.28	16	4.75	1	0.30	337	337	337	337
4	14	4.15	48	14.24	126	37.39	54	16.46	28	8.54	12	3.66	1	0.30	328	328	328	328
5	32	9.76	87	26.52	114	34.76	46	14.24	21	6.50	10	3.10					323	323
6	61	18.89	106	32.82	79	24.46												

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 30

CLINICAL GLOBAL IMPRESSION: SEVERITY - LAST ASSESSMENT OF OPEN PHASE

VISIT NO.	SEVERITY OF ILLNESS																						
	NORMAL			BORDERLINE MENTALLY ILL			MILDLY ILL			MODERATELY ILL			MARKEDLY ILL			SEVERELY ILL			EXTREMELY ILL			TOTAL	
	N	ROH	Z	N	ROH	Z	N	ROH	Z	N	ROH	Z	N	ROH	Z	N	ROH	Z	N	ROH	Z		
1																							
2							1	20.00															5
3							3	25.00															12
4	1	11.11					2	22.22															9
5																							5
6	61	18.89	106	32.82	79	24.46	46	14.24	21	6.50	10	3.10											323
TOTAL	62	17.32	108	30.17	80	22.35	52	14.53	36	10.06	18	5.03	2	0.56									358

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBONETINE - PROTOCOL 20124/013

TABLE No.: 31

SHIFT TABLE (LAST VALUE VS DAY) SEVERITY - OPEN PHASE

		SEVERITY				TOTAL	
DECREASED		NO CHANGE		INCREASED			
N	ROM %	N	ROM %	N	ROM %	N	N
314	87.71	37	10.34	7	1.96	358	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
REBOXYTINE - PROTOCOL 20124/013

TABLE No.: 32

CLINICAL GLOBAL IMPRESSION: GLOBAL IMPROVEMENT - OPEN PHASE

VISIT NO.	GLOBAL IMPROVEMENT																			
	VERY MUCH IMPROVED			MUCH IMPROVED			MINIMALLY IMPROVED			NO CHANGE			MINIMALLY WORSE			MUCH WORSE			TOTAL	
	N	ROH %	N	ROH %	N	ROH %	N	ROH %	N	ROH %	N	ROH %	N	ROH %	N	ROH %	N	ROH %		
1	3	0.84	37	10.34	100	27.93	201	56.15	16	4.47	1	0.28	358							
2	14	3.95	72	20.34	176	49.72	81	22.88	9	2.54	2	0.56	354							
3	28	8.02	128	36.68	150	42.98	33	9.46	8	2.29	2	0.57	349							
4	67	19.88	154	45.70	85	25.22	25	7.42	5	1.48	1	0.30	337							
5	121	36.89	138	42.07	45	13.72	19	5.79	4	1.22	1	0.30	328							
6	163	50.46	108	33.44	31	9.60	20	6.19	1	0.31			323							

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS R6D
REBOREXINE - PROTOCOL 20124/013

TABLE No.: 33

CLINICAL GLOBAL IMPRESSION: GLOBAL IMPROVEMENT - LAST ASSESSMENT OF OPEN PHASE

VISIT NO.	GLOBAL IMPROVEMENT												TOTAL					
	VERY MUCH IMPROVED			MUCH IMPROVED			MINIMALLY IMPROVED			NO CHANGE			MINIMALLY WORSE			MUCH WORSE		
	N	RO	%	N	RO	%	N	RO	%	N	RO	%	N	RO	%	N	RO	%
1						1	25.00				3	75.00						4
2						1	20.00				3	60.00	1	20.00				5
3				1	8.33		25.00	3	25.00	3	25.00	3	25.00	2	16.67			12
4	1	11.11		1	11.11	1	11.11	4	44.44	1	11.11	1	11.11	1	11.11			9
5				2	40.00	2	40.00	1	20.00									5
6	163	50.46		108	33.44	31	9.60	20	6.19	1	0.31							323
TOTAL	164	45.81		112	31.28	39	10.89	34	9.50	6	1.68	3	0.84					358

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 34

STATISTICAL ANALYSIS OF EFFICACY INDEX - OPEN PHASE

VISIT NO.	N	MEAN	MEDIAN	STDEV	MIN	MAX	MISSING
1	357	1.25	1.00	0.72	0.33	4.00	0
2	354	1.69	1.50	0.92	0.25	4.00	0
3	349	2.01	2.00	1.02	0.25	4.00	0
4	337	2.32	2.00	1.10	0.25	4.00	0
5	328	2.61	3.00	1.13	0.33	4.00	0
6	323	2.84	3.00	1.13	0.33	4.00	0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 35

MONTGOMERY ASBERG DEPRESSION RATING SCALE - OPEN PHASE

	VISIT NO.						
	0	1	2	3	4	5	6
N	358	358	354	349	335	328	323
MEAN	18.38	15.71	12.97	11.01	9.33	7.85	6.87
STDEV	4.07	5.05	5.26	5.27	4.95	4.88	5.15
MEDIAN	19.00	16.00	13.00	11.00	9.00	7.00	5.00
MIN	7	3	1	1	0	0	0
MAX	27	27	25	26	27	27	28

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS_R02
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 36

MONTGOMERY ASBERG DEPRESSION RATING SCALE - SUMMARY STATISTICS AT LAST ASSESSMENT OF OPEN PHASE

	VISIT NO.						TOTAL
	1	2	3	4	5	6	
N	4	5	14	7	5	323	358
MEAN	18.75	20.40	17.57	14.71	11.80	6.87	7.84
STDEV	2.50	5.86	4.13	8.34	7.16	5.15	6.00
MEDIAN	20.00	23.00	17.50	13.00	13.00	5.00	6.00
MIN	15	10	9	4	4	0	0
MAX	20	24	24	25	22	28	28

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/019
TABLE No.: 37

ZUNG SCALE: SUMMARY STATISTICS ON TOTAL SCORE ACCORDING TO TIME INTERVAL
OPEN PHASE

	Visit						
	Day 0	Week 1	Week 2	Week 3	Week 4	Week 5	Week 6
No	317	303	300	293	287	280	279
Mean	57.11	54.05	50.16	47.05	43.91	41.25	39.78
STD	8.24	8.27	9.36	10.34	11.06	11.93	12.62
Median	58	55	50	48	42	38	36
Min	28	26	23	21	21	21	21
Max	75	76	70	71	74	76	73

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 38

ZUNG SCALE: SUMMARY STATISTICS ON TOTAL SCORE AT LAST ASSESSMENT
OPEN PHASE

	Last assessment							Total
	Week 1	Week 2	Week 3	Week 4	Week 5	Week 6	Week 7	
No	2	8	10	7	11	279	317	
Mean	64.00	56.38	54.80	53.43	45.91	39.78	41.34	
STD	16.97	8.03	9.60	12.41	13.10	12.62	13.20	
Median	64	58	56	56	47	36	38	
Min	52	43	40	32	23	21	21	
Max	76	66	68	69	69	73	76	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No. : 39

HAMILTON DEPRESSION RATING SCALE
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

REBOXETINE	VISIT NO.																																			
	-1	0	1	2	3	4	5	6	8	9	10	12	14	16	18	20	22	24	26	28	30	32	34	36												
N	133	133	133	133	133	133	133	133	133	1	127	121	119	117	108	104	101	98	97	93	87	85	83	81												
MEAN	29.56	29.23	24.65	20.11	16.15	13.34	10.82	8.82	8.53	2.00	8.47	8.98	8.67	8.35	8.64	7.88	7.84	7.39	6.95	7.40	7.06	7.08	7.17	7.30												
STDEV	5.50	5.52	7.19	7.16	7.11	5.90	5.23	4.04	4.85	4.85	4.92	5.77	5.86	4.81	4.92	4.62	4.60	4.71	4.59	4.15	4.08	4.25	4.62	4.62												
MEDIAN	31.00	31.00	26.00	21.00	18.00	13.00	10.00	8.00	8.00	2.00	7.00	7.00	8.00	8.00	8.00	7.00	7.00	7.00	6.00	8.00	7.00	7.00	7.00	7.00												
MIN	18	18	7	4	1	1	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0												
MAX	45	43	38	33	31	31	19	24	24	2	27	34	32	25	24	28	26	29	31	22	18	19	19	18												

(CONTINUED)

	VISIT NO.											
	38	40	42	44	46	48	50	52				
N	80	79	79	79	78	77	77	76				
MEAN	7.55	6.73	6.86	6.97	6.50	6.51	6.36	5.86				
STDEV	5.20	4.43	4.40	4.54	3.88	4.13	3.91	3.84				
MEDIAN	7.00	6.00	7.00	7.00	7.00	6.00	6.00	6.00				
MIN	0	0	0	0	0	0	0	0				
MAX	24	21	22	22	19	17	16	19				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 40

HAMILTON DEPRESSION RATING SCALE
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

PLACEBO	VISIT NO.																															
	-1	0	1	2	3	4	5	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38								
N	132	132	132	132	132	132	132	132	132	128	125	119	116	110	104	97	92	88	85	80	77	76	75	73								
MEAN	30.47	30.05	25.99	21.06	17.67	14.52	11.41	9.13	9.67	10.56	10.76	10.71	11.16	11.40	11.11	11.35	10.98	10.56	10.91	11.64	11.40	11.25	11.56	11.40								
STDEV	5.54	5.56	7.09	7.16	6.77	5.49	4.50	3.65	4.51	6.06	6.58	6.05	7.42	6.97	7.27	7.12	6.76	6.39	6.12	6.14	6.05	6.14	6.42	6.88								
MEDIAN	32.00	31.00	28.00	21.50	18.00	14.00	11.00	9.00	10.00	10.00	10.00	10.00	9.00	10.00	10.00	11.00	10.00	10.00	11.00	12.00	12.00	11.00	13.00	12.00								
MIN	18	18	7	4	4	2	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0								
MAX	43	42	39	36	35	36	27	19	23	27	33	29	33	34	38	34	30	32	33	27	23	23	25	32								

(CONTINUED)

	VISIT NO.									
	40	42	44	46	48	50	52			
N	71	70	67	65	63	63	62			
MEAN	10.23	10.96	11.76	11.34	11.27	11.21	11.11			
STDEV	5.81	6.44	6.65	6.23	6.54	6.37	6.76			
MEDIAN	11.00	10.00	12.00	13.00	10.00	11.00	10.00			
MIN	0	0	0	0	0	0	0			
MAX	24	25	25	25	29	25	24			

143

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS_R02
REBEXETINE - PROTOCOL 20124/013

TABLE No. : 41

HAMILTON DEPRESSION RATING SCALE - SUMMARY STATISTICS AT LAST ASSESSMENT OF RANDOMIZED PATIENTS CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

REBEXE-TINE	VISIT NO.																															
	8	9	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	50	52									
N	5	1	6	2	2	9	4	3	3	1	4	6	2	2	2	1	1			1	1	1	1	75								
MEAN	10.00	2.00	11.67	26.00	27.50	10.44	9.25	8.67	13.67	20.00	9.25	6.50	5.00	8.00	2.50	0.00	24.00			15.00	0.00	10.00	5.86									
STDEV	7.78		8.66	11.31	0.71	10.11	10.31	3.21	10.79		10.28	4.72	2.83	1.41	2.12								3.84									
MEDIAN	10.00	2.00	11.50	26.00	27.50	8.00	6.50	10.00	9.00	20.00	7.00	6.00	5.00	8.00	2.50	0.00	24.00			15.00	0.00	10.00	6.00									
MIN	1	2	1	18	27	0	0	5	6	20	0	0	3	7	1	0	24			15	0	10	0									
MAX	20	2	21	34	28	25	24	11	26	20	23	14	7	9	4	0	24			15	0	10	19									
PLACERO N	4		3	6	3	6	6	7	5	4	3	5	3	1	1	2	2	1	3	2	2	1	62									
MEAN	12.75		15.67	22.50	8.33	19.50	18.83	13.29	22.40	25.00	21.67	6.80	14.33	0.00	4.00	22.00	30.50	5.00	9.00	15.50	12.50	12.00	11.11									
STDEV	4.50		14.01	11.54	8.74	14.18	12.02	12.96	8.79	5.10	15.37	4.76	11.37			2.83	2.12		12.29	13.44	17.68		6.76									
MEDIAN	11.50		20.00	25.00	6.00	22.50	20.50	8.00	22.00	26.00	29.00	8.00	11.00	0.00	4.00	22.00	30.50	5.00	4.00	15.50	12.50	12.00	10.00									
MIN	9		0	1	1	0	2	1	13	18	4	0	5	0	4	20	29	5	0	6	0	12	0									
MAX	19		27	33	18	33	33	38	34	30	32	13	27	0	4	24	32	5	23	25	25	12	24									

(CONTINUED)

144

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 41

HAMILTON DEPRESSION RATING SCALE - SUMMARY STATISTICS AT LAST ASSESSMENT OF RANDOMIZED PATIENTS
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

		VISIT NO.
TOTAL		
REBOXE- TIME	N	133
	MEAN	7.88
	STDEV	6.97
	MEDIAN	6.00
	MIN	0
	MAX	34
PLACEBO		N
		132
	MEAN	13.89
	STDEV	9.81
	MEDIAN	12.50
	MIN	0
	MAX	38

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS & RD
REBOXETINE - PROTOCOL 20124/013

TABLE N. 42

DOUBLE BLIND PHASE
PROPORTION OF PATIENTS WHO RELAPSED AT LEAST ONCE DURING THE DOUBLE BLIND PHASE

Treatment	Total N	Relapsed Patients N (%)
Reboxetine	133	29 (21.8 %)
Placebo	132	74 (56.1 %)

Chi-Square test: $\chi^2 = 32.7$ (D.F. = 1) P < 0.001

PHARMACIA CNS & RD
REBOXETINE - PROTOCOL 20124//013

TABLE N. 43

DOUBLE BLIND PHASE
PROPORTION OF RELAPSE-FREE PATIENTS DURING THE FIRST AND THE LAST 6 MONTHS OF TREATMENT

Months	Reboxetine			Placebo			Chi-Square Test
	Total	Relapse - Free Pts (*)		Total	Relapse - Free Pts (*)		
	N	N	(%)	N	N	(%)	
1 - 6	133	81	(60.9 %)	132	53	(40.2 %)	$\chi^2 = 11.4$ P = 0.001
7 -12	75	66	(88.0 %)	49	29	(59.2 %)	$\chi^2 = 13.7$ P < 0.001

(*) Patients who didn't relapse at least once during the indicated period and who didn't withdraw unless because improvement, are included.

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 44

PATIENTS IN REMISSION AT LAST ASSESSMENT BY TREATMENT
PATIENTS NOT RESPONDER AT THE END OF RUN-IN PHASE HAVE NOT BEEN CONSIDERED

	TREATMENT			
	REBOXETINE		PLACEBO	
	N	%	N	%
REMISSION				
NO	29	21.8	73	55.3
YES	104	78.2	59	44.7
TOTAL	133	100.0	132	100.0

REMISSION: HAMILTON RATING SCALE TOTAL SCORE <= 10
comparison between treatment : chi_square= 30.0 p<0.001

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 45

STATISTICAL ANALYSIS OF FACTORS OF HAMILTON DEPRESSION RATING SCALE AT EACH VISIT AS COMPARED TO DAY 0
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

TREATMENT	REBOXETINE	VISIT																								
		0	1	2	3	4	5	6	8	9	10	12	14	16	18	20	22	24								
1: ANXIETY/SOMATIZATION	Evaluated	133	133	133	133	133	133	133	133	1	127	121	119	117	108	104	101	96								
	Mean	1.61	1.36	1.14	0.93	0.81	0.65	0.51	0.53	0.17	0.53	0.58	0.55	0.54	0.56	0.51	0.50	0.45								
	STD	0.41	0.49	0.45	0.47	0.40	0.38	0.31	0.34		0.32	0.38	0.41	0.34	0.33	0.29	0.32	0.29								
	Min	0.50	0.17	0.00	0.00	0.00	0.00	0.00	0.00	0.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00								
	Max	2.33	2.33	1.83	1.83	1.67	1.67	1.33	1.50	0.17	1.50	2.00	2.00	1.83	1.67	1.50	2.00	1.50								
	Median	1.50	1.35	1.17	1.00	0.83	0.67	0.50	0.50	0.17	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50								
2: WEIGHT	Evaluated	133	133	133	133	133	133	133	133	1	127	121	119	117	108	104	101	98								
	Mean	0.61	0.37	0.26	0.22	0.20	0.13	0.07	0.23	0.00	0.20	0.19	0.22	0.16	0.19	0.06	0.11	0.15								
	STD	0.89	0.73	0.62	0.58	0.56	0.43	0.33	0.59		0.54	0.57	0.57	0.49	0.53	0.31	0.42	0.50								
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00								
	Max	3.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	0.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00								
	Median	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00								
3: COGNITIVE DISTURBANCE	Evaluated	133	133	133	133	133	133	133	133	1	127	121	119	117	108	104	101	98								
	Mean	0.78	0.63	0.44	0.34	0.25	0.21	0.16	0.14	0.00	0.16	0.17	0.15	0.14	0.15	0.13	0.14	0.15								
	STD	0.37	0.36	0.31	0.28	0.23	0.21	0.16	0.18		0.18	0.19	0.20	0.16	0.16	0.16	0.17	0.18								
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00								
	Max	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00								
	Median	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00								

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 45

STATISTICAL ANALYSIS OF FACTORS OF HAMILTON DEPRESSION RATING SCALE AT EACH VISIT AS COMPARED TO DAY 0
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

TREATMENT REBOXETINE	VISIT																							
	0	1	2	3	4	5	6	8	9	10	12	14	16	18	20	22	24							
3: COGNITIVE DISTURBANCE	Max	2.00	1.33	1.17	0.83	1.17	0.50	0.83	0.00	0.83	1.00	1.17	0.83	0.67	0.67	1.00	1.00							
	Median	0.83	0.67	0.33	0.33	0.17	0.17	0.17	0.00	0.17	0.17	0.17	0.17	0.00	0.17	0.17	0.17							
	Median diff.	0.00	-0.17	-0.33	-0.50	-0.50	-0.50	-0.67	-0.67	-0.83	-0.67	-0.67	-0.67	-0.67	-0.67	-0.67	-0.67							
4: DIURNAL VARIATION	Evaluated	133	133	133	133	133	133	133	1	127	121	119	117	108	104	101	98							
	Mean	1.31	1.08	0.86	0.69	0.53	0.47	0.38	0.32	0.00	0.28	0.28	0.30	0.25	0.25	0.25	0.22							
	STD	0.70	0.73	0.72	0.65	0.62	0.61	0.56	0.54		0.53	0.50	0.49	0.50	0.44	0.48	0.47							
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00							
	Max	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00							
	Median	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00							
5: RETARDATION	Median diff.	0.00	0.00	0.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00							
	Evaluated	133	133	133	133	133	133	133	1	127	121	119	117	108	104	101	98							
	Mean	2.15	1.85	1.53	1.17	0.94	0.75	0.64	0.53	0.00	0.51	0.56	0.53	0.55	0.54	0.48	0.47							
	STD	0.48	0.57	0.61	0.57	0.48	0.45	0.38	0.42		0.43	0.51	0.50	0.46	0.45	0.46	0.41							
	Min	0.75	0.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00							
	Max	3.25	3.00	3.00	2.75	2.00	1.75	1.50	2.00	0.00	1.75	2.25	2.50	2.25	2.00	2.25	2.25							
6: SLEEP DISTURBANCE	Median	2.00	2.00	1.50	1.25	1.00	0.75	0.75	0.50	0.00	0.50	0.50	0.50	0.50	0.50	0.50	0.50							
	Median diff.	0.00	-0.25	-0.50	-1.00	-1.25	-1.50	-1.50	-1.75	-2.00	-1.75	-1.75	-1.75	-1.75	-1.50	-1.75	-1.75							
	Evaluated	133	133	133	133	133	133	133	1	127	121	119	117	108	104	101	98							

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 45

STATISTICAL ANALYSIS OF FACTORS OF HAMILTON DEPRESSION RATING SCALE AT EACH VISIT AS COMPARED TO DAY 0
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

TREATMENT REBOXETINE	VISIT																								
	0	1	2	3	4	5	6	8	9	10	12	14	16	18	20	22	24								
6: SLEEP DISTURBANCE	1.45	1.29	1.12	0.97	0.82	0.69	0.61	0.61	0.33	0.62	0.59	0.57	0.57	0.58	0.52	0.56	0.51								
Mean	0.44	0.44	0.47	0.52	0.49	0.44	0.41	0.41		0.50	0.48	0.45	0.39	0.46	0.43	0.40	0.45								
STD	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.33	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00								
Min	2.00	2.00	2.00	2.00	2.00	2.00	1.67	2.00	0.33	2.00	1.67	1.67	1.67	2.00	2.00	1.67	2.00								
Max	1.67	1.33	1.33	1.00	1.00	0.67	0.67	0.67	0.33	0.67	0.67	0.67	0.67	0.50	0.33	0.67	0.33								
Median	0.00	0.00	-0.33	-0.33	-0.67	-0.67	-1.00	-1.00	-0.33	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00								
Median diff.																									

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 45

STATISTICAL ANALYSIS OF FACTORS OF HAMILTON DEPRESSION RATING SCALE AT EACH VISIT AS COMPARED TO DAY 0
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

TREATMENT	REBOXETINE	VISIT														
		26	28	30	32	34	36	38	40	42	44	46	48	50	52	
1: ANXIETY/SOMATIZATION	Evaluated	97	93	87	85	83	81	80	79	79	79	78	77	77	76	
	Mean	0.46	0.48	0.47	0.47	0.45	0.45	0.48	0.47	0.48	0.47	0.45	0.46	0.47	0.42	
	STD	0.30	0.26	0.27	0.30	0.29	0.30	0.35	0.34	0.34	0.34	0.35	0.29	0.30	0.32	
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	Max	1.83	1.33	1.00	1.17	1.00	1.33	1.67	1.33	1.50	1.50	1.17	1.00	1.17	1.33	
	Median	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.33	0.50	0.50	0.50	0.50	0.50	0.33	
2: WEIGHT	Median diff.	-1.17	-1.17	-1.33	-1.17	-1.17	-1.33	-1.25	-1.33	-1.33	-1.33	-1.33	-1.33	-1.33	-1.33	
	Evaluated	97	93	87	85	83	81	80	79	79	79	78	77	77	76	
	Mean	0.11	0.31	0.08	0.19	0.17	0.15	0.14	0.22	0.18	0.28	0.13	0.08	0.12	0.16	
	STD	0.43	0.72	0.35	0.57	0.51	0.50	0.47	0.55	0.53	0.68	0.47	0.31	0.46	0.54	
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	Max	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
3: COGNITIVE DISTURBANCE	Median	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	Median diff.	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	Evaluated	97	93	87	85	83	81	80	79	79	79	78	77	77	76	
	Mean	0.15	0.15	0.13	0.14	0.14	0.15	0.15	0.14	0.15	0.14	0.15	0.15	0.14	0.15	
	STD	0.19	0.21	0.17	0.18	0.17	0.19	0.20	0.15	0.17	0.17	0.16	0.17	0.16	0.16	
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 45

STATISTICAL ANALYSIS OF FACTORS OF HAMILTON DEPRESSION RATING SCALE AT EACH VISIT AS COMPARED TO DAY 0
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

TREATMENT REBOXETINE	VISIT															
	26	28	30	32	34	36	38	40	42	44	46	48	50	52		
3: COGNITIVE DISTURBANCE	Max	1.00	1.00	0.83	1.00	1.00	1.00	1.17	0.67	0.83	0.67	0.50	0.83	0.83	0.83	
	Median	0.17	0.00	0.00	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17	
	Median diff.	-0.67	-0.67	-0.67	-0.67	-0.67	-0.67	-0.67	-0.67	-0.67	-0.67	-0.67	-0.67	-0.67	-0.67	
4: DIURNAL VARIATION	Evaluated	97	93	87	85	83	81	80	79	79	79	78	77	77	76	
	Mean	0.21	0.18	0.16	0.12	0.12	0.15	0.13	0.16	0.14	0.10	0.09	0.08	0.09	0.09	
	STD	0.43	0.42	0.37	0.32	0.36	0.39	0.33	0.44	0.42	0.30	0.29	0.27	0.33	0.29	
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.00	2.00	1.00	1.00	2.00	2.00	1.00	2.00	2.00	1.00	1.00	1.00	2.00	1.00	1.00
	Median	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
5: RETARDATION	Median diff.	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	
	Evaluated	97	93	87	85	83	81	80	79	79	79	78	77	77	76	
	Mean	0.39	0.43	0.45	0.46	0.50	0.51	0.48	0.38	0.39	0.41	0.35	0.38	0.38	0.31	
6: SLEEP DISTURBANCE	STD	0.35	0.38	0.38	0.43	0.43	0.44	0.46	0.40	0.42	0.42	0.39	0.38	0.37	0.37	
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	Max	2.00	2.25	1.50	1.75	1.75	2.00	2.00	2.00	2.00	2.00	1.50	1.50	1.25	1.25	
6: SLEEP DISTURBANCE	Median	0.25	0.50	0.50	0.50	0.50	0.50	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25	
	Median diff.	-1.75	-1.75	-1.75	-1.75	-1.75	-1.75	-1.75	-1.75	-2.00	-1.75	-1.75	-1.75	-1.75	-2.00	
	Evaluated	97	93	87	85	83	81	80	79	79	79	78	77	77	76	

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 45

STATISTICAL ANALYSIS OF FACTORS OF HAMILTON DEPRESSION RATING SCALE AT EACH VISIT AS COMPARED TO DAY 0
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

TREATMENT REBOXETINE	VISIT														
	26	28	30	32	34	36	38	40	42	44	46	48	50	52	
6: SLEEP DISTURBANCE	0.47	0.49	0.49	0.44	0.44	0.44	0.46	0.52	0.40	0.41	0.42	0.44	0.40	0.32	
STD	0.41	0.37	0.38	0.36	0.37	0.40	0.44	0.36	0.34	0.39	0.36	0.39	0.33	0.35	
Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
Max	2.00	1.67	1.67	1.33	1.33	2.00	2.00	2.00	1.67	1.33	1.33	1.33	1.00	1.33	
Median	0.33	0.33	0.33	0.33	0.33	0.67	0.33	0.33	0.33	0.33	0.33	0.33	0.33	0.33	
Median diff.	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.17	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 46

STATISTICAL ANALYSIS OF FACTORS OF HAMILTON DEPRESSION RATING SCALE AT EACH VISIT AS COMPARED TO DAY 0
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

TREATMENT PLACEBO	VISIT																										
	0	1	2	3	4	5	6	8	10	12	14	16	18	20	22	24	26										
1: ANXIETY/SOMATIZATION	Evaluated	132	132	132	132	132	132	132	128	125	119	116	110	104	97	92	88										
	Mean	1.69	1.45	1.21	1.01	0.85	0.69	0.55	0.60	0.65	0.64	0.62	0.68	0.69	0.68	0.62	0.57										
	STD	0.47	0.49	0.48	0.40	0.37	0.33	0.30	0.33	0.39	0.41	0.38	0.44	0.43	0.46	0.40	0.36										
	Min	0.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00										
	Max	2.33	2.33	2.17	2.00	2.17	1.50	1.17	1.67	1.83	2.00	1.83	2.00	2.00	2.17	2.00	1.83	1.67									
	Median	1.83	1.50	1.25	1.00	0.83	0.67	0.50	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.50									
2: WEIGHT	Median diff.	0.00	-0.17	-0.50	-0.67	-0.83	-1.00	-1.17	-1.17	-1.00	-1.17	-1.08	-1.17	-1.17	-1.17	-1.17	-1.17										
	Evaluated	132	132	132	132	132	132	132	128	125	119	116	110	104	97	92	88										
	Mean	0.62	0.32	0.23	0.14	0.18	0.10	0.09	0.07	0.16	0.34	0.22	0.20	0.25	0.14	0.22	0.18	0.27									
	STD	0.88	0.68	0.60	0.44	0.54	0.37	0.36	0.33	0.53	0.72	0.55	0.56	0.62	0.49	0.60	0.55	0.67									
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00									
	Max	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00									
3: COGNITIVE DISTURBANCE	Median	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00										
	Median diff.	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00										
	Evaluated	132	132	132	132	132	132	132	128	125	119	116	110	104	97	92	88										
	Mean	0.84	0.67	0.49	0.40	0.28	0.21	0.15	0.19	0.20	0.20	0.20	0.25	0.23	0.22	0.24	0.24										
	STD	0.33	0.35	0.34	0.34	0.23	0.20	0.16	0.20	0.21	0.21	0.22	0.29	0.25	0.24	0.24	0.26	0.26									
	Min	0.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00									

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 46

STATISTICAL ANALYSIS OF FACTORS OF HAMILTON DEPRESSION RATING SCALE AT EACH VISIT AS COMPARED TO DAY 0
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

TREATMENT PLACEBO	VISIT																									
	0	1	2	3	4	5	6	8	10	12	14	16	18	20	22	24	26									
3: COGNITIVE DISTURBANCE	Max	1.83	1.67	1.50	1.00	0.83	0.67	0.83	1.00	1.00	1.00	1.00	1.50	1.33	1.00	1.00	1.17									
	Median	0.83	0.67	0.42	0.33	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17									
	Median diff.	0.00	-0.17	-0.33	-0.50	-0.50	-0.67	-0.67	-0.67	-0.67	-0.67	-0.67	-0.67	-0.67	-0.67	-0.67	-0.67									
4: DIURNAL VARIATION	Evaluated	132	132	132	132	132	132	132	128	128	125	119	116	110	104	97	88									
	Mean	1.13	1.05	0.82	0.66	0.56	0.47	0.33	0.33	0.32	0.39	0.38	0.38	0.32	0.37	0.40	0.48									
	STD	0.74	0.74	0.69	0.63	0.60	0.61	0.53	0.52	0.48	0.57	0.52	0.55	0.51	0.59	0.62	0.56									
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00									
	Max	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00									
	Median	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00									
5: RETARDATION	Evaluated	132	132	132	132	132	132	132	128	128	125	119	116	110	104	97	88									
	Mean	2.20	1.98	1.62	1.36	1.08	0.85	0.66	0.67	0.74	0.73	0.76	0.73	0.75	0.75	0.77	0.78									
	STD	0.46	0.59	0.61	0.58	0.48	0.39	0.36	0.42	0.54	0.55	0.50	0.59	0.59	0.60	0.59	0.49									
	Min	1.25	0.25	0.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00									
	Max	3.25	3.25	3.00	2.75	3.00	2.00	1.50	1.75	2.00	2.50	2.25	2.50	2.50	2.75	3.00	2.25									
	Median	2.25	2.00	1.75	1.25	1.00	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75									
6: SLEEP DISTURBANCE	Median diff.	0.00	-0.25	-0.50	-0.75	-1.00	-1.25	-1.50	-1.50	-1.50	-1.50	-1.50	-1.50	-1.50	-1.50	-1.50	-1.50									
	Evaluated	132	132	132	132	132	132	132	128	128	125	119	116	110	104	97	88									

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 46

STATISTICAL ANALYSIS OF FACTORS OF HAMILTON DEPRESSION RATING SCALE AT EACH VISIT AS COMPARED TO DAY 0
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

TREATMENT PLACEBO	VISIT																									
	0	1	2	3	4	5	6	8	10	12	14	16	18	20	22	24	26									
3: COGNITIVE DISTURBANCE	Max	1.83	1.67	1.50	1.00	0.83	0.67	0.83	1.00	1.00	1.00	1.00	1.50	1.33	1.00	1.00	1.17									
	Median	0.83	0.67	0.42	0.33	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17									
	Median diff.	0.00	-0.17	-0.33	-0.50	-0.50	-0.67	-0.67	-0.67	-0.67	-0.67	-0.67	-0.67	-0.67	-0.67	-0.67	-0.67									
4: DIURNAL VARIATION	Evaluated	132	132	132	132	132	132	132	128	128	125	119	116	110	104	97	88									
	Mean	1.13	1.05	0.82	0.66	0.56	0.47	0.33	0.33	0.32	0.39	0.38	0.38	0.32	0.37	0.40	0.48									
	STD	0.74	0.74	0.69	0.63	0.60	0.61	0.53	0.52	0.48	0.57	0.52	0.55	0.51	0.59	0.62	0.56									
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00									
	Max	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00									
	Median	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00									
5: RETARDATION	Evaluated	132	132	132	132	132	132	132	128	128	125	119	116	110	104	97	88									
	Mean	2.20	1.98	1.62	1.36	1.08	0.85	0.66	0.67	0.74	0.73	0.76	0.73	0.75	0.75	0.77	0.78									
	STD	0.46	0.59	0.61	0.58	0.48	0.39	0.36	0.42	0.54	0.55	0.50	0.59	0.59	0.60	0.59	0.49									
	Min	1.25	0.25	0.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00									
	Max	3.25	3.25	3.00	2.75	3.00	2.00	1.50	1.75	2.00	2.50	2.25	2.50	2.50	2.75	3.00	2.25									
	Median	2.25	2.00	1.75	1.25	1.00	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75									
6: SLEEP DISTURBANCE	Median diff.	0.00	-0.25	-0.50	-0.75	-1.00	-1.25	-1.50	-1.50	-1.50	-1.50	-1.50	-1.50	-1.50	-1.50	-1.50	-1.50									
	Evaluated	132	132	132	132	132	132	132	128	128	125	119	116	110	104	97	88									

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 46

STATISTICAL ANALYSIS OF FACTORS OF HAMILTON DEPRESSION RATING SCALE AT EACH VISIT AS COMPARED TO DAY 0
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

TREATMENT PLACEBO		VISIT												
		28	30	32	34	36	38	40	42	44	46	48	50	52
1: ANXIETY/SOMATIZATION	Evaluated	85	80	77	76	75	73	71	70	67	65	63	63	62
	Mean	0.60	0.66	0.66	0.64	0.64	0.65	0.65	0.65	0.70	0.66	0.69	0.68	0.70
	STD	0.36	0.36	0.37	0.36	0.39	0.39	0.37	0.38	0.40	0.37	0.40	0.37	0.40
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.00	1.50	1.67	1.33	1.67	1.83	1.50	1.33	1.50	1.50	1.50	1.33	1.50
	Median	0.50	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.83	0.67	0.67	0.67	0.75
2: WEIGHT	Median diff.	-1.17	-1.17	-1.17	-1.17	-1.17	-1.17	-1.17	-1.17	-1.17	-1.17	-1.17	-1.17	-1.17
	Evaluated	85	80	77	76	75	73	71	70	67	65	63	63	62
	Mean	0.29	0.20	0.18	0.18	0.15	0.10	0.10	0.30	0.27	0.28	0.21	0.14	0.16
	STD	0.69	0.58	0.56	0.56	0.48	0.41	0.42	0.71	0.69	0.67	0.60	0.50	0.52
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
3: COGNITIVE DISTURBANCE	Median	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Median diff.	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Evaluated	85	80	77	76	75	73	71	70	67	65	63	63	62
	Mean	0.26	0.24	0.24	0.26	0.28	0.28	0.23	0.25	0.29	0.29	0.28	0.31	0.27
	STD	0.26	0.27	0.23	0.27	0.25	0.26	0.22	0.27	0.27	0.26	0.26	0.27	0.28
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RRD
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 46

STATISTICAL ANALYSIS OF FACTORS OF HAMILTON DEPRESSION RATING SCALE AT EACH VISIT AS COMPARED TO DAY 0
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

TREATMENT PLACEBO	VISIT													
	28	30	32	34	36	38	40	42	44	46	48	50	52	
3: COGNITIVE DISTURBANCE	Max	1.00	1.17	1.00	1.33	1.17	1.17	0.83	1.17	0.83	1.17	1.17	1.17	1.00
	Median	0.17	0.17	0.17	0.17	0.17	0.33	0.17	0.33	0.17	0.33	0.33	0.33	0.17
	Median diff.	-0.67	-0.67	-0.67	-0.58	-0.50	-0.50	-0.67	-0.58	-0.50	-0.50	-0.50	-0.50	-0.50
4: DIURNAL VARIATION	Evaluated	85	80	77	76	75	73	71	70	67	65	63	63	62
	Mean	0.42	0.48	0.38	0.49	0.44	0.41	0.48	0.51	0.54	0.38	0.29	0.43	0.37
	STD	0.54	0.59	0.54	0.64	0.60	0.55	0.53	0.61	0.64	0.49	0.46	0.59	0.55
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
	Median	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
5: RETARDATION	Median diff.	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00
	Evaluated	85	80	77	76	75	73	71	70	67	65	63	63	62
	Mean	0.76	0.86	0.85	0.78	0.82	0.80	0.69	0.72	0.74	0.76	0.74	0.67	0.75
6: SLEEP DISTURBANCE	STD	0.51	0.52	0.55	0.52	0.53	0.60	0.49	0.49	0.53	0.52	0.54	0.50	0.55
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.50	2.50	2.00	1.75	1.75	2.50	2.00	1.75	2.25	2.50	2.25	1.75	2.00
6: SLEEP DISTURBANCE	Median	0.75	1.00	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75
	Median diff.	-1.50	-1.50	-1.50	-1.50	-1.50	-1.50	-1.50	-1.50	-1.50	-1.50	-1.50	-1.75	-1.50
	Evaluated	85	80	77	76	75	73	71	70	67	65	63	63	62

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 46

STATISTICAL ANALYSIS OF FACTORS OF HAMILTON DEPRESSION RATING SCALE AT EACH VISIT AS COMPARED TO DAY 0
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

TREATMENT PLACEBO	VISIT													
	28	30	32	34	36	38	40	42	44	46	48	50	52	
3: COGNITIVE DISTURBANCE	Max	1.00	1.17	1.00	1.33	1.17	1.17	0.83	1.17	0.83	1.17	1.17	1.17	1.00
	Median	0.17	0.17	0.17	0.17	0.17	0.33	0.17	0.33	0.17	0.33	0.33	0.33	0.17
	Median diff.	-0.67	-0.67	-0.67	-0.58	-0.50	-0.50	-0.67	-0.58	-0.50	-0.50	-0.50	-0.50	-0.50
4: DIURNAL VARIATION	Evaluated	85	80	77	76	75	73	71	70	67	65	63	63	62
	Mean	0.42	0.48	0.38	0.49	0.44	0.41	0.48	0.51	0.54	0.38	0.29	0.43	0.37
	STD	0.54	0.59	0.54	0.64	0.60	0.55	0.53	0.61	0.64	0.49	0.46	0.59	0.55
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
	Median	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
5: RETARDATION	Median diff.	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00
	Evaluated	85	80	77	76	75	73	71	70	67	65	63	63	62
	Mean	0.76	0.86	0.85	0.78	0.82	0.80	0.69	0.72	0.74	0.76	0.74	0.67	0.75
6: SLEEP DISTURBANCE	STD	0.51	0.52	0.55	0.52	0.53	0.60	0.49	0.49	0.53	0.52	0.54	0.50	0.55
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Max	2.50	2.50	2.00	1.75	1.75	2.50	2.00	1.75	2.25	2.50	2.25	1.75	2.00
6: SLEEP DISTURBANCE	Median	0.75	1.00	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75
	Median diff.	-1.50	-1.50	-1.50	-1.50	-1.50	-1.50	-1.50	-1.50	-1.50	-1.50	-1.50	-1.75	-1.50
	Evaluated	85	80	77	76	75	73	71	70	67	65	63	63	62

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 47

CLINICAL GLOBAL IMPRESSION: SEVERITY
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

VISIT NO.	TREATMENT	SEVERITY OF ILLNESS																	
		NORMAL		BORDERLINE MENTALLY ILL		MILDLY ILL		MODERATELY ILL		MARKEDLY ILL		SEVERELY ILL		EXTREMELY ILL		TOTAL			
		N	ROW Z	N	ROW Z	N	ROW Z	N	ROW Z	N	ROW Z	N	ROW Z	N	ROW Z	N	ROW Z		
0	REBOXETINE					1	0.75	12	9.02	83	62.41	33	24.81	4	3.01	133			
	PLACEBO							12	9.09	87	65.91	29	21.97	4	3.03	132			
1	REBOXETINE			4	3.01	39	29.32	75	56.39	14	10.53	1	0.75	1	0.75	133			
	PLACEBO			2	1.52	34	25.76	74	56.06	21	15.91	1	0.76	1	0.76	132			
2	REBOXETINE			25	18.80	69	51.88	32	24.06	7	5.26					133			
	PLACEBO			3	2.27	19	14.39	70	53.03	29	21.97	10	7.58	1	0.76	132			
3	REBOXETINE	1	0.75	9	6.77	47	35.34	61	45.86	12	9.02	3	2.26			133			
	PLACEBO			7	5.30	44	33.33	55	41.67	21	15.91	5	3.79			132			
4	REBOXETINE	7	5.26	25	18.80	57	42.86	36	27.07	7	5.26	1	0.75			133			
	PLACEBO	6	4.55	20	15.15	57	43.18	35	26.52	12	9.09	2	1.52			132			
5	REBOXETINE	19	14.29	40	30.08	52	39.10	17	12.78	4	3.01	1	0.75			133			
	PLACEBO	13	9.85	41	31.06	50	37.88	22	16.67	6	4.55					132			
6	REBOXETINE	27	20.30	52	39.10	39	29.32	13	9.77	2	1.50					133			
	PLACEBO	33	25.00	46	34.85	37	28.03	14	10.61	2	1.52					132			
8	REBOXETINE	45	33.83	39	29.32	35	26.32	12	9.02	2	1.50					133			
	PLACEBO	27	20.45	56	42.42	30	22.73	16	12.12	1	0.76	2	1.52			132			
9	REBOXETINE			1	100.00											1			
10	REBOXETINE	48	37.80	32	25.20	29	22.83	13	10.24	5	3.94					127			
	PLACEBO	30	23.44	43	33.59	37	28.91	13	10.16	2	1.56	2	1.56	1	0.78	128			
12	REBOXETINE	44	36.36	34	28.10	27	22.31	11	9.09	4	3.31	1	0.83			121			

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 47

CLINICAL GLOBAL IMPRESSION: SEVERITY
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

VISIT NO.	TREATMENT	SEVERITY OF ILLNESS																								
		NORMAL			BORDERLINE MENTALLY ILL			MILDLY ILL			MODERATELY ILL			MARKEDLY ILL			SEVERELY ILL			EXTREMELY ILL			TOTAL			
		N	ROM	Z	N	ROM	Z	N	ROM	Z	N	ROM	Z	N	ROM	Z	N	ROM	Z	N	ROM	Z	N	ROM	Z	
12	PLACEBO	28	22.40	42	33.60	45	36.00	6	4.80	3	2.40	1	0.80													125
14	REBOXETINE	42	35.29	38	31.93	24	20.17	10	8.40	4	3.36	1	0.84													119
16	PLACEBO	24	20.17	44	36.97	38	31.93	11	9.24	2	1.68															119
16	REBOXETINE	41	35.04	39	33.33	23	19.66	10	8.55	4	3.42															117
18	PLACEBO	29	25.00	38	32.76	34	29.31	9	7.76	6	5.17															116
18	REBOXETINE	44	40.74	31	28.70	21	19.44	6	5.56	4	3.70	2	1.85													108
20	PLACEBO	28	25.45	34	30.91	33	30.00	11	10.00	4	3.64															110
20	REBOXETINE	47	45.19	33	31.73	15	14.42	7	6.73	1	0.96	1	0.96													104
22	PLACEBO	27	25.96	36	34.62	24	23.08	12	11.54	4	3.85	1	0.96													104
22	REBOXETINE	46	45.54	29	28.71	18	17.82	8	7.92																	101
24	PLACEBO	29	29.90	25	25.77	30	30.93	8	8.25	4	4.12	1	1.03													97
24	REBOXETINE	49	50.00	26	26.53	16	16.33	4	4.08	2	2.04	1	1.02													98
26	PLACEBO	22	23.91	34	36.96	25	27.17	8	8.70	2	2.17	1	1.09													92
26	REBOXETINE	48	49.48	29	29.90	14	14.43	5	5.15																	97
28	PLACEBO	20	22.73	36	40.91	28	31.82	2	2.27	2	2.27															88
28	REBOXETINE	50	53.76	23	24.73	15	16.13	4	4.30																	93
30	PLACEBO	13	15.29	33	38.82	31	36.47	7	8.24																	85
30	REBOXETINE	51	58.62	22	25.29	12	13.79	1	1.15	1	1.15	1	1.15													87
	PLACEBO	14	17.50	28	35.00	28	35.00	9	11.25	1	1.25															80

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 47

CLINICAL GLOBAL IMPRESSION: SEVERITY
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

VISIT NO.	TREATMENT	SEVERITY OF ILLNESS															
		NORMAL		BORDERLINE MENTALLY ILL		MILDLY ILL		MODERATELY ILL		MARKEDLY ILL		SEVERELY ILL		EXTREMELY ILL		TOTAL	
		N	ROM Z	N	ROM Z	N	ROM Z	N	ROM Z	N	ROM Z	N	ROM Z	N	ROM Z	N	ROM Z
32	REBOXETINE	49	57.65	22	25.88	13	15.29	1	1.18								85
	PLACEBO	16	20.78	24	31.17	30	38.96	7	9.09								77
34	REBOXETINE	51	61.45	20	24.10	10	12.05	2	2.41								83
	PLACEBO	17	22.37	24	31.58	29	38.16	6	7.89								76
36	REBOXETINE	53	65.43	19	23.46	5	6.17	3	3.70	1	1.23						81
	PLACEBO	13	17.33	28	37.33	27	36.00	7	9.33								75
38	REBOXETINE	52	65.00	18	22.50	5	6.25	3	3.75	2	2.50						80
	PLACEBO	18	24.66	26	35.62	24	32.88	3	4.11	2	2.74						73
40	REBOXETINE	51	64.56	18	22.78	6	7.59	3	3.80	1	1.27						79
	PLACEBO	16	22.54	34	47.89	16	22.54	5	7.04								71
42	REBOXETINE	54	68.35	17	21.52	4	5.06	2	2.53	2	2.53						79
	PLACEBO	18	25.71	22	31.43	26	37.14	4	5.71								70
44	REBOXETINE	56	70.89	13	16.46	6	7.59	3	3.80	1	1.27						79
	PLACEBO	15	22.39	20	29.85	25	37.31	7	10.45								67
46	REBOXETINE	57	73.08	17	21.79	2	2.56	1	1.28	1	1.28						78
	PLACEBO	16	24.62	19	29.23	24	36.92	6	9.23								65
48	REBOXETINE	53	68.83	18	23.38	5	6.49	1	1.30								77
	PLACEBO	19	30.16	18	28.57	17	26.98	8	12.70	1	1.59						63
50	REBOXETINE	52	67.53	18	23.38	6	7.79	1	1.30								77

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 47

CLINICAL GLOBAL IMPRESSION: SEVERITY
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

VISIT NO.	TREATMENT	SEVERITY OF ILLNESS																	
		NORMAL		BORDERLINE MENTALLY ILL		MILDLY ILL		MODERATELY ILL		MARKEDLY ILL		SEVERELY ILL		EXTREMELY ILL		TOTAL			
		N	ROM %	N	ROM %	N	ROM %	N	ROM %	N	ROM %	N	ROM %	N	ROM %	N	ROM %		
32	REBOXETINE	49	57.65	22	25.88	13	15.29	1	1.18								85		
	PLACEBO	16	20.78	24	31.17	30	38.96	7	9.09								77		
34	REBOXETINE	51	61.45	20	24.10	10	12.05	2	2.41								83		
	PLACEBO	17	22.37	24	31.58	29	38.16	6	7.89								76		
36	REBOXETINE	53	65.43	19	23.46	5	6.17	3	3.70	1	1.23						81		
	PLACEBO	13	17.33	28	37.33	27	36.00	7	9.33								75		
38	REBOXETINE	52	65.00	18	22.50	5	6.25	3	3.75	2	2.50						80		
	PLACEBO	18	24.66	26	35.62	24	32.88	3	4.11	2	2.74						73		
40	REBOXETINE	51	64.56	18	22.78	6	7.59	3	3.80	1	1.27						79		
	PLACEBO	16	22.54	34	47.89	16	22.54	5	7.04								71		
42	REBOXETINE	54	68.35	17	21.52	4	5.06	2	2.53	2	2.53						79		
	PLACEBO	18	25.71	22	31.43	26	37.14	4	5.71								70		
44	REBOXETINE	56	70.89	13	16.46	6	7.59	3	3.80	1	1.27						79		
	PLACEBO	15	22.39	20	29.85	25	37.31	7	10.45								67		
46	REBOXETINE	57	73.08	17	21.79	2	2.56	1	1.28	1	1.28						78		
	PLACEBO	16	24.62	19	29.23	24	36.92	6	9.23								65		
48	REBOXETINE	53	68.83	18	23.38	5	6.49	1	1.30								77		
	PLACEBO	19	30.16	18	28.57	17	26.98	8	12.70	1	1.59						63		
50	REBOXETINE	52	67.53	18	23.38	6	7.79	1	1.30								77		

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 48

CLINICAL GLOBAL IMPRESSION: SEVERITY - LAST ASSESSMENT
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

VISIT NO.	TREATMENT	SEVERITY OF ILLNESS																
		NORMAL		BORDELINE MENTALLY ILL		MILDLY ILL		MODERATELY ILL		MARKEDLY ILL		SEVERELY ILL		EXTREMELY ILL		TOTAL		
		N	ROW Z	N	ROW Z	N	ROW Z	N	ROW Z	N	ROW Z	N	ROW Z	N	ROW Z	N	ROW Z	
8	REBOXETINE			2	40.00	2	40.00	1	20.00									5
	PLACEBO			1	25.00	2	50.00			1	25.00							4
9	REBOXETINE			1	100.00													1
10	REBOXETINE			2	33.33	1	16.67	2	33.33	1	16.67							6
	PLACEBO	1	33.33									1	33.33	1	33.33			3
12	REBOXETINE											2	100.00					2
	PLACEBO			1	16.67			1	16.67	3	50.00	1	16.67					6
14	REBOXETINE							2	100.00									2
	PLACEBO			2	66.67					1	33.33							3
16	REBOXETINE	1	11.11	3	33.33			4	44.44	1	11.11							9
	PLACEBO	1	16.67			1	16.67	1	16.67	3	50.00							6
18	REBOXETINE	1	25.00	1	25.00	1	25.00			1	25.00							4
	PLACEBO			2	33.33			2	33.33	2	33.33							6
20	REBOXETINE			2	66.67			1	33.33									3
	PLACEBO	1	14.29	3	42.86			2	28.57	1	14.29							7
22	REBOXETINE	1	33.33	1	33.33			1	33.33									3
	PLACEBO							3	60.00	1	20.00	1	20.00	1	20.00			5
24	REBOXETINE									1	100.00							1
	PLACEBO					1	25.00	1	25.00	1	25.00	1	25.00	1	25.00			4
26	REBOXETINE	1	25.00	1	25.00	1	25.00	1	25.00	1	25.00							4

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 48

CLINICAL GLOBAL IMPRESSION: SEVERITY - LAST ASSESSMENT
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

VISIT NO.	TREATMENT	SEVERITY OF ILLNESS																	
		NORMAL		BORDERLINE MENTALLY ILL		MILDLY ILL		MODERATELY ILL		MARKEDLY ILL		SEVERELY ILL		EXTREMELY ILL		TOTAL			
		N	ROZ %	N	ROZ %	N	ROZ %	N	ROZ %	N	ROZ %	N	ROZ %	N	ROZ %	N	ROZ %		
26	PLACEBO	1	33.33															3	
28	REBOXETINE			2	33.33	2	33.33	2	33.33									6	
	PLACEBO	1	20.00	2	40.00			2	40.00									5	
30	REBOXETINE			1	50.00	1	50.00											2	
	PLACEBO					1	33.33	1	33.33	1	33.33							3	
32	REBOXETINE	1	50.00			1	50.00											2	
	PLACEBO	1	100.00															1	
34	REBOXETINE	1	50.00	1	50.00													2	
	PLACEBO					1	100.00											1	
36	REBOXETINE	1	100.00															1	
	PLACEBO							2	100.00									2	
38	REBOXETINE							1	100.00									1	
	PLACEBO									2	100.00							2	
40	PLACEBO	1	100.00															1	
42	PLACEBO	1	33.33	1	33.33			1	33.33									3	
44	REBOXETINE							1	100.00									1	
	PLACEBO			1	50.00													2	
46	REBOXETINE	1	100.00															1	
	PLACEBO	1	50.00					1	50.00									2	

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 48

CLINICAL GLOBAL IMPRESSION: SEVERITY - LAST ASSESSMENT
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

VISIT NO.	TREATMENT	SEVERITY OF ILLNESS																	
		NORMAL		BORDERLINE MENTALLY ILL		MILDLY ILL		MODERATELY ILL		MARKEDLY ILL		SEVERELY ILL		EXTREMELY ILL		TOTAL			
		N	ROZ %	N	ROZ %	N	ROZ %	N	ROZ %	N	ROZ %	N	ROZ %	N	ROZ %	N	ROZ %		
26	PLACEBO	1	33.33																
28	REBOXETINE			2	33.33	2	33.33	2	33.33										
	PLACEBO	1	20.00	2	40.00			2	40.00										
30	REBOXETINE			1	50.00	1	50.00												
	PLACEBO					1	33.33	1	33.33	1	33.33								
32	REBOXETINE	1	50.00			1	50.00												
	PLACEBO	1	100.00																
34	REBOXETINE	1	50.00	1	50.00														
	PLACEBO					1	100.00												
36	REBOXETINE	1	100.00																
	PLACEBO							2	100.00										
38	REBOXETINE							1	100.00										
	PLACEBO									2	100.00								
40	PLACEBO	1	100.00																
42	PLACEBO	1	33.33	1	33.33														
44	REBOXETINE																		
	PLACEBO			1	50.00														
46	REBOXETINE	1	100.00																
	PLACEBO	1	50.00					1	50.00										

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS RED
REBOXETINE – PROTOCOL 20124/013

TABLE No.: 49

SHIFT TABLE (LAST VALUE VS DAY D) SEVERITY
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

TREATMENT	SEVERITY						TOTAL	
	DECREASED		NO CHANGE		INCREASED		N	N
	N	ROH %	N	ROH %	N	ROH %		
REBOXETINE	127	95.49	3	2.26	3	2.26	133	
PLACEBO	110	83.33	14	10.61	8	6.06	132	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 50

CLINICAL GLOBAL IMPRESSION: GLOBAL IMPROVEMENT
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

VISIT NO.	TREATMENT	GLOBAL IMPROVEMENT																							
		VERY MUCH IMPROVED			MUCH IMPROVED			MINIMALLY IMPROVED			NO CHANGE			MINIMALLY WORSE			MUCH WORSE			VERY MUCH WORSE			TOTAL		
		N	RO	Z	N	RO	Z	N	RO	Z	N	RO	Z	N	RO	Z	N	RO	Z	N	RO	Z	N	RO	Z
1	REBOXETINE	2	1.50	15	11.28	44	33.08	65	48.87	7	5.26														133
	PLACEBO			14	10.61	37	28.03	75	56.82	6	4.55														132
2	REBOXETINE	6	4.51	34	25.56	69	51.88	21	15.79	3	2.26														133
	PLACEBO	6	4.55	28	21.21	74	56.06	23	17.42	1	0.76														132
3	REBOXETINE	16	12.03	54	40.60	62	46.62			1	0.75														133
	PLACEBO	9	6.82	55	41.67	59	44.70	9	6.82																132
4	REBOXETINE	34	25.56	70	52.63	28	21.05			1	0.75														133
	PLACEBO	29	21.97	69	52.27	30	22.73	4	3.03																132
5	REBOXETINE	61	45.86	59	44.36	12	9.02	1	0.75																133
	PLACEBO	57	43.18	61	46.21	14	10.61																		132
6	REBOXETINE	83	62.41	43	32.33	7	5.26																		133
	PLACEBO	76	57.58	52	39.39	4	3.03																		132
8	REBOXETINE	91	68.42	34	25.56	7	5.26			1	0.75														133
	PLACEBO	82	62.12	39	29.55	9	6.82																		132
9	REBOXETINE	1	100.00																						1
10	REBOXETINE	86	67.72	28	22.05	12	9.45	1	0.79																127
	PLACEBO	70	54.69	42	32.81	14	10.94																		128
12	REBOXETINE	83	68.60	25	20.66	11	9.09	2	1.65																121
	PLACEBO	64	51.20	50	40.00	7	5.60	2	1.60	1	0.80														125
14	REBOXETINE	84	70.59	23	19.33	11	9.24																		119

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 50

CLINICAL GLOBAL IMPRESSION: GLOBAL IMPROVEMENT
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

VISIT NO.	TREATMENT	GLOBAL IMPROVEMENT																		TOTAL			
		VERY MUCH IMPROVED			MUCH IMPROVED			MINIMALLY IMPROVED			NO CHANGE			MINIMALLY WORSE			MUCH WORSE				VERY MUCH WORSE		
		N	RO	Z	N	RO	Z	N	RO	Z	N	RO	Z	N	RO	Z	N	RO	Z		N	RO	Z
14	PLACEBO	55	46.22	53	44.54	9	7.56	2	1.68													119	
16	REBOXETINE	79	67.52	27	23.08	10	8.55	1	0.85													117	
	PLACEBO	63	54.31	35	30.17	14	12.07	4	3.45													116	
18	REBOXETINE	70	64.81	29	26.85	7	6.48	1	0.93												1	108	
	PLACEBO	56	50.91	40	36.36	9	8.18	5	4.55													110	
20	REBOXETINE	79	75.96	19	18.27	4	3.85	1	0.96													104	
	PLACEBO	59	56.73	29	27.88	12	11.54	4	3.85													104	
22	REBOXETINE	76	75.25	19	18.81	6	5.94															101	
	PLACEBO	55	56.70	30	30.93	9	9.28	3	3.09													97	
24	REBOXETINE	76	77.55	17	17.35	3	3.06	1	1.02													98	
	PLACEBO	58	63.04	24	26.09	8	8.70	1	1.09												1	92	
26	REBOXETINE	78	80.41	14	14.43	4	4.12															97	
	PLACEBO	54	61.36	30	34.09	2	2.27	2	2.27													88	
28	REBOXETINE	71	76.34	19	20.43	2	2.15	1	1.06													93	
	PLACEBO	47	55.29	34	40.00	4	4.71															85	
30	REBOXETINE	74	85.06	13	14.94																		87
	PLACEBO	43	53.75	30	37.50	6	7.50													1	1.25		80
32	REBOXETINE	78	91.76	7	8.24																		85
	PLACEBO	40	51.95	30	38.96	7	9.09																77

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS RED
REBOXETINE - PROTOCOL 20124/013

TABLE No. : 50

CLINICAL GLOBAL IMPRESSION: GLOBAL IMPROVEMENT
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

VISIT NO.	TREATMENT	GLOBAL IMPROVEMENT															
		VERY MUCH IMPROVED		MUCH IMPROVED		MINIMALLY IMPROVED		NO CHANGE		MINIMALLY WORSE		MUCH WORSE		VERY MUCH WORSE		TOTAL	
		N	RO% Z	N	RO% Z	N	RO% Z	N	RO% Z	N	RO% Z	N	RO% Z	N	RO% Z	N	RO% Z
34	REBOXETINE	74	89.16	9	10.84												83
	PLACEBO	41	53.95	28	36.84	7	9.21										76
36	REBOXETINE	72	88.89	6	9.88	1	1.23										81
	PLACEBO	45	60.00	23	30.67	7	9.33										75
38	REBOXETINE	69	86.25	8	10.00	3	3.75										80
	PLACEBO	46	63.01	22	30.14	3	4.11	2	2.74								73
40	REBOXETINE	69	87.34	9	11.39	1	1.27										79
	PLACEBO	51	71.83	14	19.72	6	8.45										74
42	REBOXETINE	72	91.14	5	6.33	2	2.53										79
	PLACEBO	42	60.00	23	32.86	5	7.14										70
44	REBOXETINE	71	89.87	7	8.86	1	1.27										79
	PLACEBO	38	56.72	22	32.84	7	10.45										67
46	REBOXETINE	75	96.15	2	2.56	1	1.28										78
	PLACEBO	37	56.92	23	35.38	5	7.69										65
48	REBOXETINE	73	94.81	3	3.90	1	1.30										77
	PLACEBO	38	60.32	18	28.57	6	9.52	1	1.59								63
50	REBOXETINE	70	90.91	6	7.79	1	1.30										77
	PLACEBO	38	60.32	19	30.16	6	9.52										63
52	REBOXETINE	72	94.74	4	5.26												76

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 50

CLINICAL GLOBAL IMPRESSION: GLOBAL IMPROVEMENT
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

VISIT NO.	TREATMENT	GLOBAL IMPROVEMENT												TOTAL N			
		VERY MUCH IMPROVED		MUCH IMPROVED		MINIMALLY IMPROVED		NO CHANGE		MINIMALLY WORSE		MUCH WORSE			VERY MUCH WORSE		
		N	ROW %	N	ROW %	N	ROW %	N	ROW %	N	ROW %	N	ROW %		N	ROW %	
52	PLACEBO	40	64.52	15	24.19	7	11.29										62

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 51

CLINICAL GLOBAL IMPRESSION: GLOBAL IMPROVEMENT - LAST ASSESSMENT
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

VISIT NO.	TREATMENT	GLOBAL IMPROVEMENT																										
		VERY MUCH IMPROVED			MUCH IMPROVED			MINIMALLY IMPROVED			NO CHANGE			MINIMALLY WORSE			MUCH WORSE			VERY MUCH WORSE			TOTAL					
		N	ROH	Z	N	ROH	Z	N	ROH	Z	N	ROH	Z	N	ROH	Z	N	ROH	Z	N	ROH	Z	N	ROH	Z	N		
8	REBOXETINE	3	60.00	2	40.00																					5		
	PLACEBO	1	25.00	2	50.00	1	25.00																			4		
9	REBOXETINE	1	100.00																							1		
10	REBOXETINE	3	50.00	1	16.67	2	33.33																			6		
	PLACEBO	1	33.33			1	33.33																	1	33.33	3		
12	REBOXETINE					1	50.00	1	50.00																	2		
	PLACEBO	1	16.67			1	16.67	2	33.33	1	16.67														1	16.67	6	
14	REBOXETINE					2	100.00																			2		
	PLACEBO	1	33.33	1	33.33																						3	
16	REBOXETINE	4	44.44	1	11.11	4	44.44																			9		
	PLACEBO	1	16.67	1	16.67	1	16.67	3	50.00																		6	
18	REBOXETINE	1	25.00	2	50.00	1	25.00																			4		
	PLACEBO	1	16.67	1	16.67	1	16.67	3	50.00																		6	
20	REBOXETINE	1	33.33	1	33.33	1	33.33																				3	
	PLACEBO	2	28.57	2	28.57	2	28.57	1	14.29																		7	
22	REBOXETINE	2	66.67			1	33.33																				3	
	PLACEBO			1	20.00	2	40.00	2	40.00	2	40.00																5	
24	REBOXETINE																										1	
	PLACEBO					2	50.00	1	25.00																	1	25.00	4
26	REBOXETINE	2	50.00			2	50.00																				4	

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 51

CLINICAL GLOBAL IMPRESSION: GLOBAL IMPROVEMENT - LAST ASSESSMENT
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

VISIT NO.	TREATMENT	GLOBAL IMPROVEMENT																								
		VERY MUCH IMPROVED			MUCH IMPROVED			MINIMALLY IMPROVED			NO CHANGE			MINIMALLY WORSE			MUCH WORSE			VERY MUCH WORSE			TOTAL			
		N	ROM	Z	N	ROM	Z	N	ROM	Z	N	ROM	Z	N	ROM	Z	N	ROM	Z	N	ROM	Z	N	ROM	Z	
26	PLACEBO	1	33.33										2	66.67												3
28	REBOXETINE	2	33.33	2	33.33	2	33.33																			6
	PLACEBO	1	20.00	3	60.00	1	20.00																			5
30	REBOXETINE	1	50.00	1	50.00																					2
	PLACEBO			2	66.67																		1	33.33		3
32	REBOXETINE	1	50.00	1	50.00																					2
	PLACEBO	1	100.00																							1
34	REBOXETINE	2	100.00																							2
	PLACEBO			1	100.00																					1
36	REBOXETINE	1	100.00																							1
	PLACEBO																									1
38	REBOXETINE																									2
	PLACEBO																									1
40	PLACEBO	1	100.00																							1
42	PLACEBO	2	66.67																							3
44	REBOXETINE			1	100.00																					1
	PLACEBO	1	50.00																							2
46	REBOXETINE	1	100.00																							1
	PLACEBO	1	50.00																							2

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No. : 51

CLINICAL GLOBAL IMPRESSION: GLOBAL IMPROVEMENT - LAST ASSESSMENT
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

VISIT NO.	TREATMENT	GLOBAL IMPROVEMENT																								
		VERY MUCH IMPROVED			MUCH IMPROVED			MINIMALLY IMPROVED			NO CHANGE			MINIMALLY WORSE			MUCH WORSE			VERY MUCH WORSE			TOTAL			
		N	ROM %	Z	N	ROM %	Z	N	ROM %	Z	N	ROM %	Z	N	ROM %	Z	N	ROM %	Z	N	ROM %	Z	N	ROM %	Z	
50	REBOXETINE									1	100.00															1
	PLACEBO				1	100.00																				1
52	REBOXETINE	72	94.74		4	5.26																				76
	PLACEBO	40	64.52		15	24.19		7	11.29																	62
TOTAL	TREATMENT	97	72.93		16	12.03		18	13.53		2	1.50														133
	REBOXETINE	56	42.42		30	22.73		24	18.18		17	12.88		1	0.76											132
	PLACEBO																									

PHARMACIA CUS 58077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 52

STATISTICAL ANALYSIS OF EFFICACY INDEX
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

REBOXETINE	N	MEAN	MEDIAN	STDEV	MIN	MAX	MISSING
VISIT NO.							
1	133	1.32	1.00	0.79	0.50	4.00	0
2	133	1.83	2.00	0.95	0.50	4.00	0
3	133	2.22	2.00	1.05	1.00	4.00	0
4	133	2.58	3.00	1.07	1.00	4.00	0
5	133	2.90	3.00	1.07	1.00	4.00	0
6	133	3.09	4.00	1.01	1.00	4.00	0
8	133	3.03	3.00	1.05	0.67	4.00	0
9	1	4.00	4.00	.	4.00	4.00	0
10	127	3.03	3.00	1.03	0.67	4.00	0
12	121	3.02	3.00	1.02	0.50	4.00	0
14	119	3.12	4.00	1.01	1.00	4.00	0
16	117	3.11	4.00	1.01	0.67	4.00	0
18	108	3.14	4.00	1.01	1.00	4.00	0
20	104	3.29	4.00	0.99	1.00	4.00	0
22	101	3.33	4.00	0.94	1.00	4.00	0
24	98	3.22	4.00	1.00	1.00	4.00	0
26	97	3.27	4.00	1.00	1.00	4.00	0
28	93	3.28	4.00	0.97	1.00	4.00	0
30	87	3.40	4.00	0.88	1.50	4.00	0
32	85	3.43	4.00	0.89	1.50	4.00	0
34	83	3.40	4.00	0.93	1.50	4.00	0
36	81	3.33	4.00	0.93	1.50	4.00	0
38	80	3.33	4.00	0.93	1.50	4.00	0
40	79	3.37	4.00	0.91	1.50	4.00	0
42	79	3.35	4.00	0.93	1.50	4.00	0
44	79	3.35	4.00	0.92	1.50	4.00	0
46	78	3.45	4.00	0.89	2.00	4.00	0
48	77	3.49	4.00	0.88	1.50	4.00	0
50	77	3.47	4.00	0.88	1.50	4.00	0
52	76	3.49	4.00	0.87	1.50	4.00	0

PHARMACTA C558077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 53

STATISTICAL ANALYSIS OF EFFICACY INDEX
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

PLACEBO	N	MEAN	MEDIAN	STDEV	MIN	MAX	MISSING
VISIT NO.							
1	132	1.23	1.00	0.64	0.50	3.00	0
2	132	1.74	2.00	0.87	0.50	4.00	0
3	132	2.07	2.00	0.95	0.50	4.00	0
4	132	2.37	2.00	1.01	0.50	4.00	0
5	132	2.69	3.00	0.98	1.00	4.00	0
6	132	3.04	3.00	0.99	1.00	4.00	0
8	132	3.02	3.00	1.03	0.50	4.00	0
10	128	3.06	3.00	0.98	1.00	4.00	0
12	125	3.10	4.00	1.03	1.00	4.00	0
14	119	3.12	3.00	0.96	1.00	4.00	0
16	116	3.09	3.00	1.01	1.00	4.00	0
18	110	3.12	3.00	0.99	1.00	4.00	0
20	104	3.10	3.00	1.02	1.00	4.00	0
22	97	3.13	3.00	0.98	1.00	4.00	0
24	92	3.21	3.50	0.91	1.00	4.00	0
26	88	3.35	4.00	0.88	1.00	4.00	0
28	85	3.31	4.00	0.81	1.00	4.00	0
30	80	3.15	3.00	0.88	1.00	4.00	0
32	77	3.18	3.00	0.91	1.50	4.00	0
34	76	3.23	3.50	0.88	1.50	4.00	0
36	75	3.33	4.00	0.82	1.50	4.00	0
38	73	3.39	4.00	0.84	1.00	4.00	0
40	71	3.52	4.00	0.75	2.00	4.00	0
42	70	3.41	4.00	0.80	1.50	4.00	0
44	67	3.42	4.00	0.78	1.50	4.00	0
46	65	3.46	4.00	0.81	1.33	4.00	0
48	63	3.43	4.00	0.83	1.00	4.00	0
50	63	3.45	4.00	0.76	1.50	4.00	0
52	62	3.51	4.00	0.74	1.50	4.00	0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 54
MONTGOMERY ASBERG DEPRESSION RATING SCALE
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

	VISIT NO.																							
	0	1	2	3	4	5	6	8	9	10	12	15	16	18	20	24	28	30	32	36	40	44	48	52
N	133	133	133	133	133	133	133	133	1	1	1	121	117	1	104	98	93	1	85	80	79	79	77	76
MEAN	17.95	14.77	11.86	9.35	7.82	6.37	5.25	4.86	2.00	8.00	5.05	4.91	6.00	4.39	4.19	4.01	2.00	4.04	4.08	3.43	3.37	3.49	3.13	
STDEV	3.99	4.86	4.95	4.51	3.96	3.39	2.98	3.22			3.75	3.31		3.17	3.43	2.79		2.77	3.22	2.89	2.76	2.61	2.91	
MEDIAN	18.00	14.00	12.00	9.00	7.00	6.00	5.00	4.00	2.00	8.00	4.00	4.00	6.00	4.00	3.50	4.00	2.00	4.00	4.00	3.00	3.00	3.00	3.00	
MIN	7	3	1	1	0	0	0	0	2	8	0	0	6	0	0	0	0	2	0	0	0	0	0	
MAX	26	27	23	17	17	17	12	16	2	8	19	17	6	18	23	18	2	13	14	15	15	14	17	

TREATMENT: REBOXETINE

TREATMENT: PLACERO

	VISIT NO.																						
	0	1	2	3	4	5	6	8	9	10	12	14	16	20	22	24	28	32	36	40	44	48	52
N	132	132	132	132	132	132	132	132	132	125	1	116	104	1	92	85	77	75	71	67	63	62	
MEAN	18.74	16.00	12.64	10.55	8.62	6.77	5.25	5.58	6.34	16.00	6.36	6.70	17.00	6.45	6.46	6.46	6.99	7.39	5.92	7.49	7.11	6.98	
STDEV	4.22	5.04	4.81	4.36	3.49	3.09	2.65	3.28	4.42		4.71	4.66		4.49	4.13	4.83	4.97	4.48	5.43	5.33	5.64		
MEDIAN	19.00	17.00	13.00	11.00	8.50	6.00	5.00	5.00	6.00	16.00	5.00	5.50	17.00	6.00	7.00	7.00	8.00	8.00	5.00	5.00	5.00	5.00	
MIN	8	5	4	3	2	1	1	0	0	16	0	0	17	0	0	0	0	0	0	0	0	0	
MAX	27	25	24	22	24	17	14	17	22	16	24	20	17	18	18	16	16	16	17	18	20	18	20

120

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 55

MONTGOMERY ASBERG DEPRESSION RATING SCALE - LAST ASSESSMENT
CONSIDERING ONLY THE PATIENTS RESPONDER AT VISIT 6

TREATMENT	VISIT NO.																								TOTAL
	8	9	10	12	14	16	18	20	22	24	28	30	32	36	40	44	48	52							
REBOXETINE	10	1	1	4		12	1	6			5	7	1	4	2		2	1	76	133					
MEAN	5.30	2.00	8.00	15.00		6.67	6.00	6.00			8.60	3.86	2.00	3.00	7.00		2.50	9.00	3.13	4.47					
STDEV	4.14			4.97		5.97		3.69			6.19	2.79		2.94	9.90		3.54		2.91	4.34					
MEDIAN	4.00	2.00	8.00	16.50		7.00	6.00	4.50			7.00	4.00	2.00	3.00	7.00		2.50	9.00	3.00	3.00					
MIN	0	2	8	8		0	6	3			0	0	2	0	0		0	9	0	0					
MAX	12	2	8	19		17	6	12			16	8	2	6	14		5	9	17	19					
N	7			8	1	12		11			1	7	8	2	4	4	4	1	62	132					
MEAN	8.57			11.75	16.00	10.67		10.36	17.00	13.57	4.88		3.00	15.25	5.00	11.25	5.00	6.98	8.58						
STDEV	4.96			8.78		7.77		6.92		6.08	3.09		4.24	1.71	7.44	10.31		5.64	6.56						
MEDIAN	8.00			14.00	16.00	9.00		14.00	17.00	16.00	5.00		3.00	15.50	2.00	12.50	5.00	5.00	8.00						
MIN	2			0	16	0		1	17	1	0		0	13	0	0	0	5	0	0					
MAX	15			22	16	24		20	17	18	8		6	17	16	20	5	20	24	24					

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 56

ZUNG SCALE: SUMMARY STATISTICS ON TOTAL SCORE ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT DOUBLE BLIND PHASE

Phase: Run In Phase

	Day 0	Visit						
		Week 1	Week 2	Week 3	Week 4	Week 5	Week 6	
Placebo	No	124	119	119	118	120	117	122
	Mean	58.15	54.52	49.76	47.06	43.42	40.09	38.77
	STD	7.73	7.64	8.62	8.57	9.63	10.16	11.38
	Median	59	55	50	48	43	38	34
	Min	29	30	28	25	23	22	21
	Max	74	70	66	71	72	70	73
Reboxetine	No	128	122	120	120	122	123	123
	Mean	55.78	52.25	48.09	43.78	40.76	38.28	36.35
	STD	8.60	8.32	8.92	9.92	9.87	10.58	10.43
	Median	57	53	48	43	40	36	34
	Min	30	26	23	21	21	21	21
	Max	75	71	70	69	66	70	65

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOMETINE - PROTOCOL 20124/013
TABLE No.: 56

ZUNG SCALE: SUMMARY STATISTICS ON TOTAL SCORE ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT DOUBLE BLIND PHASE

	Visit																							
	Week 8	Week 9	Week 10	Week 12	Week 14	Week 16	Week 18	Week 19	Week 20	Week 21	Week 22	Week 24	Week 26	Week 28	Week 30	Week 32	Week 36	Week 40	Week 42	Week 44	Week 48	Week 50		
Placebo	No	120	5	115	5	108	7	1	91	1	3	84	75	1	70	69	65	2	61	58	1			
	Mean	39.99	42.54	42.20	42.62	49.43	71.00	41.34	54.00	39.00	39.50	40.56	67.00	38.99	40.75	38.20	23.50	41.02	40.78	31.00				
	STD	9.74	6.52	11.32	13.46	11.09	11.49	11.09	18.03	9.33	8.92	41	67	40	42	38	24	41	41	31				
	Median	40	34	41	46	41	52	71	39	54	34	39	41	21	21	21	20	21	20	21	20	20	31	
	Min	21	25	21	25	21	30	71	21	54	24	20	21	67	67	57	61	70	27	73	56	31		
	Max	63	41	75	58	69	62	71	70	54	59	60	63	85	82	76	76	75	74					
Rebometine	No	123	1	3	115	1	109	2	99			89	1	85	1	82	76	76	75	74				
	Mean	37.14	21.00	43.33	37.18	48.00	35.87	50.50	35.81			34.33	48.00	34.92	41.00	33.28	32.39	33.57	32.65	32.09				
	STD	10.25	11.72	10.60		9.66	6.36	10.10	10.10			9.62	8.83	7.40	7.65	8.04	8.33	7.46						
	Median	34	21	48	35	48	34	51	33			32	48	33	41	33	31	32	31	30				
	Min	20	21	30	20	48	20	46	22			21	48	20	41	20	20	20	20	20	20	20	20	
	Max	63	21	52	68	48	61	55	67			65	48	56	41	55	62	54	56	57				

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 TABLE No.: 56

ZUNG SCALE: SUMMARY STATISTICS ON TOTAL SCORE ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT
 DOUBLE BLIND PHASE

Phase: Double Blind Phase

	Visit	
	Week	
Placebo	No	58
	Mean	40.64
	STD	8.11
	Median	42
	Min	20
	Max	56
Reboxetine	No	75
	Mean	32.00
	STD	8.26
	Median	30
	Min	20
	Max	56

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
TABLE No.: 57
ZUNG SCALE: SUMMARY STATISTICS ON TOTAL SCORE AT LAST ASSESSMENT BY ASSIGNED TREATMENT
DOUBLE BLIND PHASE

		Last assessment																											
		Double Blind Phase																											
		Week 8	Week 9	Week 10	Week 12	Week 14	Week 16	Week 18	Week 19	Week 20	Week 22	Week 24	Week 26	Week 28	Week 30	Week 32	Week 36	Week 40	Week 42	Week 44	Week 48	Week 50	Week 52	Week 58					
Placebo	No	2			1	8	1	8	4	1	9	1	5		8	1	2	4	2	2	3		1	58					
	Mean	56.00		28.00	57.38	58.00	51.25	56.00	71.00	50.67	59.00	48.80		45.88	67.00	34.00	41.00	40.50	23.50	50.67	31.00	40.64							
	STD	2.83			12.07		15.19	6.98		12.35		10.89		9.98		12.73	10.74	16.26	4.95	2.31			8.11						
	Median	56		28	56	58	56	58	71	52	59	53		49	67	34	46	41	24	52	31	42							
	Min	54		28	37	58	22	46	71	25	59	30		23	67	25	25	29	20	48	31	20							
	Max	58		28	75	58	65	62	71	69	59	58		54	67	43	48	52	27	52	31	56							
Reboxetine	No	7	1	1	6		8	2		8		3	1	6	1	4	2			1	1		75						
	Mean	39.86	21.00	48.00	51.50		39.50	50.50	38.88		47.67	48.00	44.33	41.00	33.00	33.00			32.00	30.00			32.00						
	STD	13.25			10.07		14.50	6.36	8.71		15.01		12.39		10.68	9.90							8.26						
	Median	43	21	48	53		40	51	38		39	48	48	41	31	33			32	30			30						
	Min	23	21	48	36		20	46	24		39	48	23	41	23	26			32	30			20						
	Max	54	21	48	66		56	55	54		65	48	56	41	48	40			32	30			56						

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 57

ZUNG SCALE: SUMMARY STATISTICS ON TOTAL SCORE AT LAST ASSESSMENT BY ASSIGNED TREATMENT DOUBLE BLIND PHASE

	Last assessment	Double Blind Phase	Total
Placebo	No	124	124
	Mean	44.94	44.94
	STD	11.77	11.77
	Median	46	46
	Min	20	20
	Max	75	75
Reboxetine	No	128	128
	Mean	35.87	35.87
	STD	10.96	10.96
	Median	32	32
	Min	20	20
	Max	66	66

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 RESOXETINE - PROTOCOL 20124/013
 Table No.: 58

EXPERIMENTAL TREATMENT: NUMBER OF PATIENT EXPOSED

	Open Phase						Double Blind Phase					
	Day 0	Week 1	Week 2	Week 3	Week 4	Week 5	Week 6	Months 2	Months 3	Months 6	Months 9	Months 12
Placebo								136	125	91	74	65
Resoxetine	358	354	350	338	328	324	286	137	124	101	82	79
Total	358	354	350	338	328	324	286	273	249	192	156	144

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RRD

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 59

ADVERSE EVENTS: NUMBER OF PATIENTS WHO COMPLAINED OF AT LEAST ONE ADVERSE EVENT DURING THERAPY

	Open Phase		
	Female	Male	Total
Reboxetine			
Pt exposed	263	95	358
Pt with adverse events	127	59	186
% on exposed	48.28	62.10	51.95
95% L.L.	42.11	51.57	46.64
95% U.L.	54.51	71.86	57.24
No. of adverse events	256	118	374
Ratio A.E. on Pt with A.E.	2.01	2.00	2.01

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013

TABLE No.: 60

ADVERSE EVENTS: NUMBER OF PATIENTS WHO COMPLAINED OF AT LEAST ONE ADVERSE EVENT DURING THERAPY

	Open Phase				
	Total	AGE			
		18 - 30	31 - 45	> 45	
Reboxetine					
Pt exposed	358	58	144	156	
Pt with adverse events	186	33	85	68	
% on exposed	51.95	56.89	59.02	43.58	
95% L.L.	46.64	43.23	50.53	35.68	
95% U.L.	57.24	69.84	67.15	51.75	
No. of adverse events	374	65	172	137	
Ratio A.E. on Pt with A.E.	2.01	1.96	2.02	2.01	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 61

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING OPEN PHASE BY SEX

Adverse events	Female				Male				Total			
	No of Pt. exposed	% on exp.	No of AE with AE	Ratio (%)	No of Pt. exposed	% on exp.	No of AE with AE	Ratio (%)	No of Pt. exposed	% on exp.	No of AE with AE	Ratio (%)
Pt exposed	263	100.0			95	100.0			358	100.0		
Pt with a.e.	127	48.3	100.0	256	2.01	59	62.1	100.0	118	2.00	186	52.0
MOUTH DRY	52	19.8	40.9	56	1.07	16	16.8	27.1	16	1.00	68	19.0
CONSTIPATION	44	16.7	34.6	46	1.04	16	16.8	27.1	17	1.06	60	16.8
SWEATING INCREASED	24	9.1	18.8	26	1.08	5	5.3	8.4	6	1.20	29	8.1
TACHYCARDIA	16	6.1	12.5	17	1.06	6	6.3	10.1	6	1.00	22	6.1
INSOMNIA	16	6.1	12.5	16	1.00	6	6.3	10.1	6	1.00	22	6.1
HICTURITION DISORDER	2	0.8	1.5	2	1.00	18	18.9	30.5	21	1.16	20	5.6
LIBIDO DECREASED	7	2.7	5.5	7	1.00	11	11.6	18.6	12	1.09	18	5.0
DIZZINESS	13	4.9	10.2	15	1.15	3	3.2	5.0	3	1.00	16	4.5
VISION ABNORMAL	8	3.0	6.2	10	1.25	4	4.2	6.7	4	1.00	12	3.4
PARAESTHESIA	8	3.0	6.2	8	1.00	3	3.2	5.0	4	1.33	11	3.1
TREMOR	9	3.4	7.0	9	1.00	1	1.1	1.6	1	1.00	10	2.8
HEADACHE	6	2.3	4.7	7	1.16	3	3.2	5.0	4	1.33	9	2.5
URINARY RETENTION	1	0.4	0.7	1	1.00	7	7.4	11.8	7	1.00	8	2.2
RASH	3	1.1	2.3	3	1.00						3	0.8
VOMITING	3	1.1	2.3	3	1.00						3	0.8
FATIGUE	2	0.8	1.5	2	1.00	1	1.1	1.6	1	1.00	3	0.8
AGITATION	2	0.8	1.5	2	1.00						2	0.6
ANOREXIA	2	0.8	1.5	2	1.00						2	0.6
HYPERTENSION	2	0.8	1.5	2	1.00						2	0.6
HYPOTENSION POSTURAL	1	0.4	0.7	1	1.00	1	1.1	1.6	1	1.00	2	0.6

(CONTINUED)

(*) number of adverse events on patients who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
TABLE No.: 61

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING OPEN PHASE BY SEX

Adverse events	Female			Male			Total				
	No of Pt. exp.	Z on Pt. with AE	No of AE	No of Pt. exp.	Z on Pt. with AE	No of AE	No of Pt. exp.	Z on Pt. with AE	No of AE		
SOMNOLENCE	2	0.8	1.5	2	1.00		2	0.6	1.0	2	1.00
NAUSEA	1	0.4	0.7	1	1.00	1	1.1	1.6	1	2	1.00
INFECTION VIRAL	2	0.8	1.5	2	1.00		2	0.6	1.0	2	1.00
ACNE	1	0.4	0.7	1	1.00		1	0.3	0.5	1	1.00
CONVULSIONS	1	0.4	0.7	1	1.00		1	0.3	0.5	1	1.00
MUSCLE CONTRACTIONS INVOLUNTARY	1	0.4	0.7	1	1.00		1	0.3	0.5	1	1.00
VERTIGO	1	0.4	0.7	1	1.00		1	0.3	0.5	1	1.00
DIARRHOEA	1	0.4	0.7	1	1.00		1	0.3	0.5	1	1.00
EJACULATION FAILURE						1	1.1	1.6	1	1	1.00
PALPITATION	1	0.4	0.7	1	1.00		1	0.3	0.5	1	1.00
LACRIMAL GLAND DISORDER						1	1.1	1.6	1	1	1.00
CONJUNCTIVITIS	1	0.4	0.7	1	1.00		1	0.3	0.5	1	1.00
ANXIETY	1	0.4	0.7	1	1.00		1	0.3	0.5	1	1.00
NERVOUSNESS						1	1.1	1.6	1	1	1.00
SUICIDE ATTEMPT	1	0.4	0.7	1	1.00		1	0.3	0.5	1	1.00
FLATULENCE	1	0.4	0.7	1	1.00		1	0.3	0.5	1	1.00
COUGHING						1	1.1	1.6	1	1	1.00
UPPER RESP TRACT INFECTION	1	0.4	0.7	1	1.00		1	0.3	0.5	1	1.00
ALBUMINURIA	1	0.4	0.7	1	1.00		1	0.3	0.5	1	1.00
PERINEAL PAIN MALE						1	1.1	1.6	1	1	1.00
OVARIAN DISORDER	1	0.4	0.7	1	1.00		1	0.3	0.5	1	1.00

(CONTINUED)

(*) number of adverse events on patients who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 61

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING OPEN PHASE
BY SEX

Adverse events	Female			Male			Total		
	No of Pt.	Z on exp.	Pt. on AE with AE	No of Pt.	Z on exp.	Pt. on AE with AE	No of Pt.	Z on exp.	Pt. on AE with AE
VACINITIS	1	0.4	0.7	1	1.00		1	0.3	0.5
OEDEMA PERIPHERAL				1	1.1	1.6	1	0.3	0.5
BACK PAIN				1	1.1	1.6	1	0.3	0.5
RIGORS	1	0.4	0.7	1	1.00		1	0.3	0.5
FURUNCULOSIS				1	1.1	1.6	1	0.3	0.5
RHINITIS	1	0.4	0.7	1	1.00		1	0.3	0.5

(*) number of adverse events on patients who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 62

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING OPEN PHASE
BY BODY SYSTEM AND SEX

Body system: AUTONOMIC NERVOUS SYSTEM DISORDERS

Adverse events	Female				Male				Total			
	No of Pt	% on exp.	No of Pt with AE	Ratio (%)	No of Pt	% on exp.	No of Pt with AE	Ratio (%)	No of Pt	% on exp.	No of Pt with AE	Ratio (%)
MOUTH DRY	52	19.8	40.9	56	16	16.8	27.1	16	68	19.0	36.5	72
SWEATING INCREASED	24	9.1	18.8	26	5	5.3	8.4	6	29	8.1	15.5	32
EJACULATION FAILURE					1	1.1	1.6	1	1	0.3	0.5	1

(*) number of adverse events on patients who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 62

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING OPEN PHASE
BY BODY SYSTEM AND SEX

Body system: BODY AS A WHOLE-GENERAL DISORDERS

Adverse events	Female			Male			Total		
	No of Pt	% on exp.	Ratio with AE	No of Pt	% on exp.	Ratio with AE	No of Pt	% on exp.	Ratio with AE
FATIGUE	2	0.8	1.5	1	1.1	1.6	3	0.8	1.6
RIGORS	1	0.4	0.7	1	1.00	1	1	0.3	0.5

(*) number of adverse events on patients who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CHS RED

REBOMETINE - PROTOCOL 20124/013
TABLE No.: 62

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING OPEN PHASE
BY BODY SYSTEM AND SEX

Body system: CARDIOVASCULAR DISORDERS, GENERAL

Adverse events	Female				Male				Total						
	No of Pt	Z on exp.	No of Pt with AE	Ratio (%)	No of Pt	Z on exp.	No of Pt with AE	Ratio (%)	No of Pt	Z on exp.	No of Pt with AE	Ratio (%)			
TACHYCARDIA	16	6.1	12.5	17	1.06	6	6.3	10.1	6	1.00	22	6.1	11.8	23	1.04
DIZZINESS	13	4.9	10.2	15	1.15	3	3.2	5.0	3	1.00	16	4.5	8.6	18	1.12
HYPERTENSION	2	0.8	1.5	2	1.00						2	0.6	1.0	2	1.00
HYPOTENSION POSTURAL	1	0.4	0.7	1	1.00	1	1.1	1.6	1	1.00	2	0.6	1.0	2	1.00
PALPITATION	1	0.4	0.7	1	1.00						1	0.3	0.5	1	1.00
OEDEMA PERIPHERAL						1	1.1	1.6	1	1.00	1	0.3	0.5	1	1.00

193

(*) number of adverse events on patients who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013

TABLE No.: 62

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING OPEN PHASE BY BODY SYSTEM AND SEX

Body system: CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO

Adverse events	Female				Male				Total			
	No of Pt	% on exp.	No of Pt with AE	Ratio No of Pt AE (*)	No of Pt	% on exp.	No of Pt with AE	Ratio No of Pt AE (*)	No of Pt	% on exp.	No of Pt with AE	Ratio No of Pt AE (*)
PARAESTHESIA	8	3.0	6.2	8 1.00	3	3.2	5.0	4 1.33	11	3.1	5.9	12 1.09
TREMOR	9	3.4	7.0	9 1.00	1	1.1	1.6	1 1.00	10	2.8	5.3	10 1.00
HEADACHE	6	2.3	4.7	7 1.16	3	3.2	5.0	4 1.33	9	2.5	4.8	11 1.22
CONVULSIONS	1	0.4	0.7	1 1.00					1	0.3	0.5	1 1.00
MUSCLE CONTRACTIONS INVOLUNTARY	1	0.4	0.7	1 1.00					1	0.3	0.5	1 1.00
VERTIGO	1	0.4	0.7	1 1.00					1	0.3	0.5	1 1.00

(*) number of adverse events on patients who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 62

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING OPEN PHASE
BY BODY SYSTEM AND SEX

Body system: GASTRO-INTESTINAL SYSTEM DISORDERS

Adverse events	Female				Male				Total			
	No of Pt	% on exp.	% on Pt with AE	Ratio No of AE (*)	No of Pt	% on exp.	% on Pt with AE	Ratio No of AE (*)	No of Pt	% on exp.	% on Pt with AE	Ratio No of AE (*)
CONSTIPATION	44	16.7	34.6	4.6	16	16.8	27.1	1.7	60	16.8	32.2	6.3
VOMITING	3	1.1	2.3	3	3	1.00		1.00	3	0.8	1.6	3
ANOREXIA	2	0.8	1.5	2	2	1.00		1.00	2	0.6	1.0	2
NAUSEA	1	0.4	0.7	1	1	1.00	1.6	1.00	2	0.6	1.0	2
DIARRHOEA	1	0.4	0.7	1	1	1.00		1.00	1	0.3	0.5	1
FLATULENCE	1	0.4	0.7	1	1	1.00		1.00	1	0.3	0.5	1

195

(*) number of adverse events on patients who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 62

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING OPEN PHASE BY BODY SYSTEM AND SEX

Body system: MUSCULO-SKELETAL SYSTEM DISORDERS

Adverse events	Male			Total		
	No of Pt	% on exp.	Ratio of AE with AE (*)	No of Pt	% on exp.	Ratio of AE with AE (*)
BACK PAIN	1	1.1	1.00	1	0.3	1.00

(*) number of adverse events on patients who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 62

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING OPEN PHASE
BY BODY SYSTEM AND SEX

Body system: PSYCHIATRIC DISORDERS

Adverse events	Female				Male				Total					
	No of Pt	Z on exp.	No of AE with AE	Ratio No of AE (*)	No of Pt	Z on exp.	No of AE with AE	Ratio No of AE (*)	No of Pt	Z on exp.	No of AE with AE	Ratio No of AE (*)		
INSOMNIA	16	6.1	12.5	16	1.00	6	6.3	10.1	6	1.00	22	11.8	22	1.00
LIBIDO DECREASED	7	2.7	5.5	7	1.00	11	11.6	18.6	12	1.09	18	5.0	19	1.05
AGITATION	2	0.8	1.5	2	1.00						2	0.6	2	1.00
SOMNOLENCE	2	0.8	1.5	2	1.00						2	0.6	2	1.00
ANXIETY	1	0.4	0.7	1	1.00						1	0.3	1	1.00
NERVOUSNESS						1	1.1	1.6	1	1.00	1	0.3	1	1.00
SUICIDE ATTEMPT	1	0.4	0.7	1	1.00						1	0.3	1	1.00

(*) number of adverse events on patients who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 62

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING OPEN PHASE
BY BODY SYSTEM AND SEX

Body system: REPRODUCTIVE DISORDERS, FEMALE

Adverse events	Female				Total			
	No of Pt	% on exp.	No of AE with AE	Ratio No of AE (*)	No of Pt	% on exp.	No of AE with AE	Ratio No of AE (*)
OVARIAN DISORDER	1	0.4	0.7	1.00	1	0.3	0.5	1.00
VAGINITIS	1	0.4	0.7	1.00	1	0.3	0.5	1.00

(*) number of adverse events on patients who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 62

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING OPEN PHASE BY BODY SYSTEM AND SEX

Body system: REPRODUCTIVE DISORDERS, MALE

Adverse events	Male				Total			
	No of Pt	% on exp.	No of Pt with AE	Ratio of AE (*)	No of Pt	% on exp.	No of Pt with AE	Ratio of AE (*)
PERINEAL PAIN MALE	1	1.1	1.6	1.00	1	0.3	0.5	1.00

(*) number of adverse events on patients who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013

TABLE No.: 62

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING OPEN PHASE BY BODY SYSTEM AND SEX

Body system: RESISTANCE MECHANISM DISORDERS

Adverse events	Female			Male			Total		
	No of Pt	Z on exp.	Ratio No of AE (*)	No of Pt	Z on exp.	Ratio No of AE (*)	No of Pt	Z on exp.	Ratio No of AE (*)
INFECTION VIRAL	2	0.8	1.5	2	1.00	1.00	2	0.6	1.0
FURUNCULOSIS				1	1.1	1.6	1	0.3	0.5
						1	1		1
						1	1		1

(*) number of adverse events on patients who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 62

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING OPEN PHASE
BY BODY SYSTEM AND SEX

Body system: RESPIRATORY SYSTEM DISORDERS

Adverse events	Female			Male			Total		
	No of Pt	% on exp.	% on Pt with AE	No of Pt	% on exp.	% on Pt with AE	No of Pt	% on exp.	% on Pt with AE
COUGHING	1	0.4	0.7	1	1.1	1.6	1	0.3	0.5
UPPER RESP TRACT INFECTION	1	0.4	0.7	1	1.00	1	1	0.3	0.5
RHINITIS	1	0.4	0.7	1	1.00	1	1	0.3	0.5

201

(* number of adverse events on patients who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 TABLE No.: 62

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING OPEN PHASE
 BY BODY SYSTEM AND SEX

Body system: SKIN AND APPENDAGES DISORDERS

Adverse events	Female				Total			
	No of Pt	% on exp.	No on Pt with AE	Ratio No of AE (*)	No of Pt	% on exp.	No on Pt with AE	Ratio No of AE (*)
RASH	3	1.1	2.3	3 1.00	3	0.8	1.6	3 1.00
ACNE	1	0.4	0.7	1 1.00	1	0.3	0.5	1 1.00

(*) number of adverse events on patients who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No. : 62

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING OPEN PHASE
BY BODY SYSTEM AND SEX

Body system: URINARY SYSTEM DISORDERS

Adverse events	Female			Male			Total		
	No of Pt	% on exp.	Ratio of AE	No of Pt	% on exp.	Ratio of AE	No of Pt	% on exp.	Ratio of AE
MICTURITION DISORDER	2	0.8	1.5	18	18.9	30.5	20	5.6	10.7
URINARY RETENTION	1	0.4	0.7	7	7.4	11.8	8	2.2	4.3
ALBUMINURIA	1	0.4	0.7	1	1.00	1	1	0.3	0.5

(*) number of adverse events on patients who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 62

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING OPEN PHASE
BY BODY SYSTEM AND SEX

Body system: VISION DISORDERS

Adverse events	Female			Male			Total								
	No of Pt	% on exp.	No of Pt with AE	No of Pt	% on exp.	No of Pt with AE	No of Pt	% on exp.	No of Pt with AE						
VISION ABNORMAL	8	3.0	6.2	10	1.25	4	4.2	6.7	4	1.00	12	3.4	6.4	14	1.16
LACRIMAL GLAND DISORDER						1	1.1	1.6	1	1.00	1	0.3	0.5	1	1.00
CONJUNCTIVITIS	1	0.4	0.7	1	1.00						1	0.3	0.5	1	1.00

(*) number of adverse events on patients who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PEARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
TABLE No.: 63

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING OPEN PHASE GROUPED BY BODY SYSTEM

Body system	Female				Male				Total						
	No of Pt	Z on exp.	No of Pt with AE	Ratio (%)	No of Pt	Z on exp.	No of Pt with AE	Ratio (%)	No of Pt	Z on exp.	No of Pt with AE	Ratio (%)			
Pt exposed	263	100.0			95	100.0			358	100.0					
Pt with a.e.	127	48.3	100.0	256	2.01	59	62.1	100.0	118	2.00	186	52.0	100.0	374	2.01
AUTONOMIC NERVOUS SYSTEM DISORDERS	73	27.8	57.4	82	1.12	22	23.2	37.2	23	1.04	95	26.5	51.0	105	1.10
GASTRO-INTESTINAL SYSTEM DISORDERS	50	19.0	39.3	54	1.08	17	17.9	28.8	18	1.05	67	18.7	36.0	72	1.07
PSYCHIATRIC DISORDERS	27	10.3	21.2	29	1.07	18	18.9	30.5	19	1.05	45	12.6	24.1	48	1.06
CARDIOVASCULAR DISORDERS, GENERAL	30	11.4	23.6	36	1.20	9	9.5	15.2	11	1.22	39	10.9	20.9	47	1.20
CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO	24	9.1	18.8	27	1.12	7	7.4	11.8	9	1.28	31	8.7	16.6	36	1.16
URINARY SYSTEM DISORDERS	4	1.5	3.1	4	1.00	25	26.3	42.3	28	1.12	29	8.1	15.5	32	1.10
VISION DISORDERS	9	3.4	7.0	11	1.22	5	5.3	8.4	5	1.00	14	3.9	7.5	16	1.14
BODY AS A WHOLE-GENERAL DISORDERS	3	1.1	2.3	3	1.00	1	1.1	1.6	1	1.00	4	1.1	2.1	4	1.00
SKIN AND APPENDAGES DISORDERS	4	1.5	3.1	4	1.00						4	1.1	2.1	4	1.00
RESISTANCE MECHANISM DISORDERS	2	0.8	1.5	2	1.00	1	1.1	1.6	1	1.00	3	0.8	1.6	3	1.00
RESPIRATORY SYSTEM DISORDERS	2	0.8	1.5	2	1.00	1	1.1	1.6	1	1.00	3	0.8	1.6	3	1.00
REPRODUCTIVE DISORDERS, FEMALE	2	0.8	1.5	2	1.00						2	0.6	1.0	2	1.00
MUSCULO-SKELETAL SYSTEM DISORDERS						1	1.1	1.6	1	1.00	1	0.3	0.5	1	1.00
REPRODUCTIVE DISORDERS, MALE						1	1.1	1.6	1	1.00	1	0.3	0.5	1	1.00

(*) number of adverse events on patients who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 64

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET - OPEN PHASE

Adverse events	Total		Days of treatment											
	No of A.E.	%	0-7		8-14		15-21		22-28		29-35		36-42	
			No of A.E.	%	No of A.E.	%	No of A.E.	%	No of A.E.	%	No of A.E.	%	No of A.E.	%
MOUTH DRY	72	100.0	56	77.8	9	12.5	4	5.6	1	1.4			2	2.8
CONSTIPATION	63	100.0	36	57.1	7	11.1	10	15.9	5	7.9	2	3.2	3	4.8
SWEATING INCREASED	32	100.0	26	81.3	3	9.4			1	3.1	1	3.1	1	3.1
LIBIDO DECREASED	19	100.0	12	63.2	2	10.5	3	15.8			2	10.5		
INSOMNIA	22	100.0	13	59.1	5	22.7	1	4.5	2	9.1			1	4.5
MICTURITION DISORDER	23	100.0	11	47.8	6	26.1	3	13.0			2	8.7	1	4.3
TACHYCARDIA	23	100.0	10	43.5	2	8.7	4	17.4	6	26.1			1	4.3
DIZZINESS	18	100.0	8	44.4	4	22.2	1	5.6	5	27.8				
VISION ABNORMAL	14	100.0	5	35.7	4	28.6	2	14.3	3	21.4				
TREMOR	10	100.0	4	40.0	3	30.0	1	10.0	2	20.0				
PARAESTHESIA	12	100.0	8	66.7			1	8.3			3	25.0		
HEADACHE	11	100.0	6	54.5	2	18.2	1	9.1	1	9.1	1	9.1		
URINARY RETENTION	8	100.0	5	62.5			2	25.0	1	12.5				
ANOREXIA	2	100.0	1	50.0			1	50.0						
RASH	3	100.0	1	33.3			1	33.3			1	33.3		
NAUSEA	2	100.0	2	100.0										
FATIGUE	3	100.0	2	66.7			1	33.3						
HYPOTENSION POSTURAL	2	100.0	2	100.0										
RIGORS	1	100.0	1	100.0										
RHINITIS	1	100.0	1	100.0										
BACK PAIN	1	100.0	1	100.0										
EJACULATION FAILURE	1	100.0			1	100.0								

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 64

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET - OPEN PHASE

Adverse events	Total		Days of treatment													
			0-7		8-14		15-21		22-28		29-35		36-42			
			No of A.E.	%	No of A.E.	%	No of A.E.	%	No of A.E.	%	No of A.E.	%	No of A.E.	%		
PALPITATION	1	100.0					1	100.0								
AGITATION	2	100.0	2	100.0												
DIARRHOEA	1	100.0	1	100.0												
VOMITING	3	100.0	1	33.3	2	66.7										
LACRIMAL GLAND DISORDER	1	100.0	1	100.0												
NERVOUSNESS	1	100.0			1	100.0										
HYPERTENSION	2	100.0					2	100.0								
ACNE	1	100.0							1	100.0						
INFECTION VIRAL	2	100.0								2	100.0					
SOMNOLENCE	2	100.0	2	100.0												
PERINEAL PAIN MALE	1	100.0	1	100.0												
OVARIAN DISORDER	1	100.0			1	100.0										
FLATULENCE	1	100.0					1	100.0								
COUGHING	1	100.0					1	100.0								
OEDEMA PERIPHERAL	1	100.0									1	100.0				
CONVULSIONS	1	100.0	1	100.0												
MUSCLE CONTRACTIONS INVOLUNTARY	1	100.0	1	100.0												
VERTIGO	1	100.0	1	100.0												
FURUNCULOSIS	1	100.0	1	100.0												
VAGINITIS	1	100.0			1	100.0										
UPPER RESP TRACT INFECTION	1	100.0					1	100.0								
CONJUNCTIVITIS	1	100.0							1	100.0						

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD

REBOXETINE – PROTOCOL 20124/013
TABLE No.: 64

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET - OPEN PHASE

Adverse events	Total		Days of treatment												
	No of A.E.	%	0-7		8-14		15-21		22-28		29-35		36-42		
			No of A.E.	%	No of A.E.	%	No of A.E.	%	No of A.E.	%	No of A.E.	%	No of A.E.	%	
ANXIETY	1	100.0										1	100.0		
SUICIDE ATTEMPT	1	100.0												1	100.0
ALBUMINURIA	1	100.0												1	100.0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 65

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET
GROUPED BY BODY SYSTEM - OPEN PHASE

Body system	Total		Days of treatment											
	No of A.E.	Z	0-7		8-14		15-21		22-28		29-35		36-42	
			No of A.E.	Z	No of A.E.	Z	No of A.E.	Z	No of A.E.	Z	No of A.E.	Z	No of A.E.	Z
AUTONOMIC NERVOUS SYSTEM DISORDERS	105	100.0	82	78.1	13	12.4	4	3.8	2	1.9	1	1.0	3	2.9
GASTRO-INTESTINAL SYSTEM DISORDERS	72	100.0	41	56.9	9	12.5	12	16.7	5	6.9	2	2.8	3	4.2
PSYCHIATRIC DISORDERS	48	100.0	29	60.4	8	16.7	4	8.3	2	4.2	3	6.3	2	4.2
CARDIOVASCULAR DISORDERS, GENERAL	47	100.0	20	42.6	6	12.8	8	17.0	12	25.5			1	2.1
URINARY SYSTEM DISORDERS	32	100.0	16	50.0	6	18.8	5	15.6	1	3.1	2	6.3	2	6.3
CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO	36	100.0	21	58.3	5	13.9	3	8.3	3	8.3	4	11.1		
VISION DISORDERS	16	100.0	6	37.5	4	25.0	2	12.5	4	25.0				
BODY AS A WHOLE-GENERAL DISORDERS	4	100.0	3	75.0			1	25.0						
SKIN AND APPENDAGES DISORDERS	4	100.0	1	25.0			1	25.0	1	25.0	1	25.0		
RESPIRATORY SYSTEM DISORDERS	3	100.0	1	33.3			2	66.7						
MUSCULO-SKELETAL SYSTEM DISORDERS	1	100.0	1	100.0										
RESISTANCE MECHANISM DISORDERS	3	100.0	1	33.3					2	66.7				
REPRODUCTIVE DISORDERS, FEMALE	2	100.0			2	100.0								
REPRODUCTIVE DISORDERS, MALE	1	100.0	1	100.0										

209

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
TABLE No.: 66
ADVERSE EVENTS: NUMBER OF PATIENTS WITH ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL AND SEX - OPEN PHASE

Adverse events / Severity	Female			Male			Total			
	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	
All adverse events	Mild	81	63.8	63.8	33	55.9	55.9	114	61.3	61.3
	Moderate	33	26.0	26.0	20	33.9	33.9	53	28.5	28.5
	Severe	13	10.2	10.2	6	10.2	10.2	19	10.2	10.2
Total	127	100	100	59	100	100	186	100	100	
MOUTH DRY	Mild	44	84.6	34.6	12	75.0	20.3	56	82.4	30.1
	Moderate	7	13.5	5.5	3	18.8	5.1	10	14.7	5.4
	Severe	1	1.9	0.8	1	6.3	1.7	2	2.9	1.1
Total	52	100	40.9	16	100	27.1	68	100	36.6	
CONSTIPATION	Mild	39	88.6	30.7	10	62.5	16.9	49	81.7	26.3
	Moderate	5	11.4	3.9	5	31.3	8.5	10	16.7	5.4
	Severe				1	6.3	1.7	1	1.7	0.5
Total	44	100	34.6	16	100	27.1	60	100	32.3	
SWEATING INCREASED	Mild	19	79.2	15.0	4	80.0	6.8	23	79.3	12.4
	Moderate	5	20.8	3.9				5	17.2	2.7
	Severe				1	20.0	1.7	1	3.4	0.5
Total	24	100	18.9	5	100	8.5	29	100	15.6	
TACHYCARDIA	Mild	9	56.3	7.1	3	50.0	5.1	12	54.5	6.5
	Moderate	5	31.3	3.9	3	50.0	5.1	8	36.4	4.3
	Severe	2	12.5	1.6				2	9.1	1.1
Total	16	100	12.6	6	100	10.2	22	100	11.8	
INSOMNIA	Mild	8	50.0	6.3	2	33.3	3.4	10	45.5	5.4
	Moderate	7	43.8	5.5	4	66.7	6.8	11	50.0	5.9

(CONTINUED)

(*) Z on all patient with adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
TABLE No.: 66
ADVERSE EVENTS: NUMBER OF PATIENTS WITH ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL AND SEX - OPEN PHASE

Adverse events / Severity	Female			Male			Total			
	No. Pt.	(*) %	Z	No. Pt.	(*) %	Z	No. Pt.	(*) %	Z	
INSOMNIA	Severe	1	6.3	0.8			1	4.5	0.5	
	Total	16	100	12.6	6	100	10.2	22	100	11.8
MICTURITION DISORDER	Mild	1	50.0	0.8	15	83.3	25.4	16	80.0	8.5
	Moderate				2	11.1	3.4	2	10.0	1.1
Severe		1	50.0	0.8	1	5.6	1.7	2	10.0	1.1
	Total	2	100	1.6	18	100	30.5	20	100	10.8
LIBIDO DECREASED	Mild	6	85.7	4.7	8	72.7	13.6	14	77.8	7.5
	Moderate	1	14.3	0.8	2	18.2	3.4	3	16.7	1.6
Severe					1	9.1	1.7	1	5.6	0.5
	Total	7	100	5.5	11	100	18.6	18	100	9.7
DIZZINESS	Mild	9	69.2	7.1	1	33.3	1.7	10	62.5	5.4
	Moderate	1	7.7	0.8	1	33.3	1.7	2	12.5	1.1
Severe		3	23.1	2.4	1	33.3	1.7	4	25.0	2.2
	Total	13	100	10.2	3	100	5.1	16	100	8.6
VISION ABNORMAL	Mild	6	75.0	4.7	3	75.0	5.1	9	75.0	4.8
	Moderate	2	25.0	1.6	1	25.0	1.7	3	25.0	1.6
Total		8	100	6.3	4	100	6.8	12	100	6.5
	Mild	7	87.5	5.5	3	100	5.1	10	90.9	5.4
Moderate		1	12.5	0.8				1	9.1	0.5
	Total	8	100	6.3	3	100	5.1	11	100	5.9
TREMOR	Mild	8	88.9	6.3	1	100	1.7	9	90.0	4.8
	Moderate	1	11.1	0.8				1	10.0	0.5

(CONTINUED)

(*) % on all patient with adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 TABLE No.: 66
 ADVERSE EVENTS: NUMBER OF PATIENTS WITH ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL AND SEX - OPEN PHASE

Adverse events / Severity	Female			Male			Total		
	No. Pt.	(*) Z							
	9	100	7.1	1	100	1.7	10	100	5.4
TREMOR	3	50.0	2.4				3	33.3	1.6
HEADACHE	2	33.3	1.6	2	66.7	3.4	4	44.4	2.2
	1	16.7	0.8	1	33.3	1.7	2	22.2	1.1
Total	6	100	4.7	3	100	5.1	9	100	4.8
URINARY RETENTION				5	71.4	8.5	5	62.5	2.7
				1	14.3	1.7	1	12.5	0.5
Moderate	1	100	0.8	1	14.3	1.7	2	25.0	1.1
Severe	1	100	0.8	7	100	11.9	8	100	4.3
Total	2	66.7	1.6				2	66.7	1.1
RASH	1	33.3	0.8				1	33.3	0.5
Moderate	3	100	2.4				3	100	1.6
Total	1	33.3	0.8				1	33.3	0.5
VOMITING	1	33.3	0.8				1	33.3	0.5
Moderate	1	33.3	0.8				1	33.3	0.5
Severe	3	100	2.4				3	100	1.6
Total	1	50.0	0.8				1	33.3	0.5
FATIGUE	1	50.0	0.8	1	100	1.7	2	66.7	1.1
Severe	2	100	1.6	1	100	1.7	3	100	1.6
Total	1	50.0	0.8				1	50.0	0.5
AGITATION	1	50.0	0.8				1	50.0	0.5
Moderate	2	100	1.6				2	100	1.1
Total									

(CONTINUED)

(*) Z on all patient with adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/013
 TABLE No.: 66
 ADVERSE EVENTS: NUMBER OF PATIENTS WITH ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL AND SEX - OPEN PHASE

Adverse events / Severity	Female			Male			Total			
	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	
ANOREXIA	Mild	2	100	1.6			2	100	1.1	
	Total	2	100	1.6			2	100	1.1	
HYPERTENSION	Mild	1	50.0	0.8			1	50.0	0.5	
	Severe	1	50.0	0.8			1	50.0	0.5	
Total		2	100	1.6			2	100	1.1	
HYPOTENSION POSTURAL	Mild				1	100	1.7	1	50.0	0.5
	Moderate	1	100	0.8			1	100	0.5	
Total		1	100	0.8	1	100	1.7	2	100	1.1
SOMNOLENCE	Mild	2	100	1.6			2	100	1.1	
	Total	2	100	1.6			2	100	1.1	
NAUSEA	Mild	1	100	0.8	1	100	1.7	2	100	1.1
	Total	1	100	0.8	1	100	1.7	2	100	1.1
INFECTION VIRAL	Moderate	2	100	1.6			2	100	1.1	
	Total	2	100	1.6			2	100	1.1	
ACNE	Moderate	1	100	0.8			1	100	0.5	
	Total	1	100	0.8			1	100	0.5	
CONVULSIONS	Severe	1	100	0.8			1	100	0.5	
	Total	1	100	0.8			1	100	0.5	
MUSCLE CONTRACTIONS INVOLUNTARY	Moderate	1	100	0.8			1	100	0.5	
	Total	1	100	0.8			1	100	0.5	
VERTIGO	Mild	1	100	0.8			1	100	0.5	
	Total	1	100	0.8			1	100	0.5	

(CONTINUED)

(*) Z on all patient with adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS R&D

REBOMETINE - PROTOCOL 20124/013
TABLE No.: 66

ADVERSE EVENTS: NUMBER OF PATIENTS WITH ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL AND SEX - OPEN PHASE

Adverse events / Severity	Female			Male			Total			
	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	
DIARRHOEA	Moderate	1	100	0.8			1	100	0.5	
	Total	1	100	0.8			1	100	0.5	
EJACULATION FAILURE	Mild				1	100	1.7	1	100	0.5
	Total				1	100	1.7	1	100	0.5
PALPITATION	Moderate	1	100	0.8			1	100	0.5	
	Total	1	100	0.8			1	100	0.5	
LACRIMAL GLAND DISORDER	Severe				1	100	1.7	1	100	0.5
	Total				1	100	1.7	1	100	0.5
CONJUNCTIVITIS	Mild	1	100	0.8			1	100	0.5	
	Total	1	100	0.8			1	100	0.5	
ANXIETY	Severe	1	100	0.8			1	100	0.5	
	Total	1	100	0.8			1	100	0.5	
NERVOUSNESS	Moderate				1	100	1.7	1	100	0.5
	Total				1	100	1.7	1	100	0.5
SUICIDE ATTEMPT	Severe	1	100	0.8			1	100	0.5	
	Total	1	100	0.8			1	100	0.5	
FLATULENCE	Mild	1	100	0.8			1	100	0.5	
	Total	1	100	0.8			1	100	0.5	
COUGHING	Mild				1	100	1.7	1	100	0.5
	Total				1	100	1.7	1	100	0.5
UPPER RESP TRACT INFECTION	Mild	1	100	0.8			1	100	0.5	
	Total	1	100	0.8			1	100	0.5	

(CONTINUED)

(*) Z on all patient with adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REDOXYTINE - PROTOCOL 20124/013
TABLE No.: 66

ADVERSE EVENTS: NUMBER OF PATIENTS WITH ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL AND SEX - OPEN PHASE

Adverse events / Severity	Female			Male			Total		
	No. Pt.	(*) Z	(*) Z	No. Pt.	(*) Z	(*) Z	No. Pt.	(*) Z	(*) Z
ALBUMINURIA									
Severe	1	100	0.8				1	100	0.5
Total	1	100	0.8				1	100	0.5
PERINEAL PAIN MALE									
Mild				1	100	1.7	1	100	0.5
Total				1	100	1.7	1	100	0.5
OVARIAN DISORDER									
Moderate	1	100	0.8				1	100	0.5
Total	1	100	0.8				1	100	0.5
VAGINITIS									
Moderate	1	100	0.8				1	100	0.5
Total	1	100	0.8				1	100	0.5
OEDEMA PERIPHERAL									
Mild				1	100	1.7	1	100	0.5
Total				1	100	1.7	1	100	0.5
BACK PAIN									
Moderate				1	100	1.7	1	100	0.5
Total				1	100	1.7	1	100	0.5
RIGORS									
Moderate	1	100	0.8				1	100	0.5
Total	1	100	0.8				1	100	0.5
FURUNCULOSIS									
Mild				1	100	1.7	1	100	0.5
Total				1	100	1.7	1	100	0.5
RHINITIS									
Mild	1	100	0.8				1	100	0.5
Total	1	100	0.8				1	100	0.5

(*) Z on all patient with adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 TABLE No.: 67
 ADVERSE EVENTS: NUMBER OF PATIENTS WITH ADVERSE EVENTS, GROUPED BY BODY SYSTEM, BY MAXIMAL SEVERITY LEVEL AND SEX
 OPEN PHASE

Body system / Severity	Female			Male			Total			
	No. Pt.	(*) %	Z	No. Pt.	(*) %	Z	No. Pt.	(*) %	Z	
All adverse events	Mild	81	63.8	63.8	33	55.9	55.9	114	61.3	61.3
	Moderate	33	26.0	26.0	20	33.9	33.9	53	28.5	28.5
	Severe	13	10.2	10.2	6	10.2	10.2	19	10.2	10.2
	Total	127	100	100	59	100	100	186	100	100
AUTONOMIC NERVOUS SYSTEM DISORDERS	Mild	60	82.2	47.2	17	77.3	28.8	77	81.1	41.4
	Moderate	12	16.4	9.4	3	13.6	5.1	15	15.8	8.1
	Severe	1	1.4	0.8	2	9.1	3.4	3	3.2	1.6
	Total	73	100	57.5	22	100	37.3	95	100	51.1
GASTRO-INTESTINAL SYSTEM DISORDERS	Mild	42	84.0	33.1	11	64.7	18.6	53	79.1	28.5
	Moderate	7	14.0	5.5	5	29.4	8.5	12	17.9	6.5
	Severe	1	2.0	0.8	1	5.9	1.7	2	3.0	1.1
	Total	50	100	39.4	17	100	28.8	67	100	36.0
PSYCHIATRIC DISORDERS	Mild	16	59.3	12.6	10	55.6	16.9	26	57.8	14.0
	Moderate	8	29.6	6.3	7	38.9	11.9	15	33.3	8.1
	Severe	3	11.1	2.4	1	5.6	1.7	4	8.9	2.2
	Total	27	100	21.3	18	100	30.5	45	100	24.2
CARDIOVASCULAR DISORDERS, GENERAL	Mild	18	60.0	14.2	5	55.6	8.5	23	59.0	12.4
	Moderate	7	23.3	5.5	3	33.3	5.1	10	25.6	5.4
	Severe	5	16.7	3.9	1	11.1	1.7	6	15.4	3.2
	Total	30	100	23.6	9	100	15.3	39	100	21.0
CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO	Mild	17	70.8	13.4	4	57.1	6.8	21	67.7	11.3
	Moderate	5	20.8	3.9	2	28.6	3.4	7	22.6	3.8

(CONTINUED)

(*) % on all patient with adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS RED
REBOXETINE - PROTOCOL 20124/013
TABLE No.: 67
ADVERSE EVENTS: NUMBER OF PATIENTS WITH ADVERSE EVENTS, GROUPED BY BODY SYSTEM, BY MAXIMAL SEVERITY LEVEL AND SEX
OPEN PHASE

Body system / Severity	Female			Male			Total			
	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	
CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO	Severe	2	8.3	1.6	1	14.3	1.7	3	9.7	1.6
	Total	24	100	18.9	7	100	11.9	31	100	16.7
URINARY SYSTEM DISORDERS	Mild	1	25.0	0.8	20	80.0	33.9	21	72.4	11.3
	Moderate				3	12.0	5.1	3	10.3	1.6
Severe		3	75.0	2.4	2	8.0	3.4	5	17.2	2.7
	Total	4	100	3.1	25	100	42.4	29	100	15.6
VISION DISORDERS	Mild	7	77.8	5.5	3	60.0	5.1	10	71.4	5.4
	Moderate	2	22.2	1.6	1	20.0	1.7	3	21.4	1.6
Severe					1	20.0	1.7	1	7.1	0.5
	Total	9	100	7.1	5	100	8.5	14	100	7.5
BODY AS A WHOLE- GENERAL DISORDERS	Mild	1	33.3	0.8				1	25.0	0.5
	Moderate	1	33.3	0.8				1	25.0	0.5
Severe		1	33.3	0.8	1	100	1.7	2	50.0	1.1
	Total	3	100	2.4	1	100	1.7	4	100	2.2
SKIN AND APPENDAGES DISORDERS	Mild	2	50.0	1.6				2	50.0	1.1
	Moderate	2	50.0	1.6				2	50.0	1.1
Total		4	100	3.1				4	100	2.2
	Mild				1	100	1.7	1	33.3	0.5
RESISTANCE MECHANISM DISORDERS	Moderate	2	100	1.6				2	66.7	1.1
	Total	2	100	1.6	1	100	1.7	3	100	1.6
RESPIRATORY SYSTEM DISORDERS	Mild	2	100	1.6	1	100	1.7	3	100	1.6
	Total	2	100	1.6	1	100	1.7	3	100	1.6

(CONTINUED)

(*) Z on all patient with adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 67

ADVERSE EVENTS: NUMBER OF PATIENTS WITH ADVERSE EVENTS, GROUPED BY BODY SYSTEM, BY MAXIMAL SEVERITY LEVEL AND SEX OPEN PHASE

Body system / Severity	Female			Male			Total		
	No. Pt.	(*) %	(*) Z	No. Pt.	(*) %	(*) Z	No. Pt.	(*) %	(*) Z
REPRODUCTIVE DISORDERS, FEMALE									
Moderate	2	100	1.6				2	100	1.1
Total	2	100	1.6				2	100	1.1
MUSCULO-SKELETAL SYSTEM DISORDERS									
Moderate				1	100	1.7	1	100	0.5
Total				1	100	1.7	1	100	0.5
REPRODUCTIVE DISORDERS, MALE									
Mild				1	100	1.7	1	100	0.5
Total				1	100	1.7	1	100	0.5

(*) % on all patient with adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 68

ADVERSE EVENTS: DURATION OF EPISODES (*) - OPEN PHASE

Adverse events	No of Adverse events	Duration of episodes (days)		
		Min	50%	90% Max
ALL adverse events	374	1	22	41 44
MOUTH DRY	72	3	39	42 44
CONSTIPATION	63	2	27	41 43
SWEATING INCREASED	32	3	28	42 43
TACHYCARDIA	23	1	13	22 43
MICTURITION DISORDER	23	3	23	42 43
INSOMNIA	22	3	27	42 43
LIBIDO DECREASED	19	9	39	41 41
DIZZINESS	18	3	20	36 40
VISION ABNORMAL	14	3	27	41 41
PARAESTHESIA	12	4	14	39 39
HEADACHE	11	2	6	37 43
TREMOR	10	11	26	42 42
URINARY RETENTION	8	2	11	41 41
RASH	3	4	11	14 14
VOMITING	3	2	2	6 6
FATIGUE	3	4	14	23 23
ACITATION	2	5	10	14 14
ANOREXIA	2	22	27	32 32
HYPERTENSION	2	4	9	14 14
HYPOTENSION POSTURAL	2	15	16	16 16
SOMNOLENCE	2	1	2	3 3

(CONTINUED)

(*) adverse event present before start treatment: onset date = start treatment date of first report visit with changed severity
adverse event still present at end of study: end date = visit date of last report visit

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CHS RED

REOXETINE - PROTOCOL 20124/013
TABLE No.: 68

ADVERSE EVENTS: DURATION OF EPISODES (*) - OPEN PHASE

Adverse events	No of Adverse events	Duration of episodes (days)		
		Min	50%	Max
NAUSEA	2	11	21	30
INFECTION VIRAL	2	3	4	5
ACNE	1	16	16	16
CONVULSIONS	1	1	1	1
MUSCLE CONTRACTIONS INVOLUNTARY	1	4	4	4
VERTIGO	1	1	1	1
DIARRHOEA	1	20	20	20
EJACULATION FAILURE	1	36	36	36
PALPITATION	1	20	20	20
LACRIMAL GLAND DISORDER	1	11	11	11
CONJUNCTIVITIS	1	3	3	3
ANXIETY	1	3	3	3
NERVOUSNESS	1	11	11	11
SUICIDE ATTEMPT	1	1	1	1
FLATULENCE	1	14	14	14
COUGHING	1	2	2	2
UPPER RESP TRACT INFECTION	1	4	4	4
ALBUMINURIA	1	2	2	2
PERINEAL PAIN MALE	1	13	13	13
OVARIAN DISORDER	1	12	12	12
VAGINITIS	1	6	6	6
OEDEMA PERIPHERAL	1	9	9	9

(CONTINUED)

(*) adverse event present before start treatment: onset date = start treatment date of first report visit with changed severity
adverse event still present at end of study: end date = visit date of last report visit

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS RAD

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 68

ADVERSE EVENTS: DURATION OF EPISODES (*) - OPEN PHASE

Adverse events	No of Adverse events	Duration of episodes (days)		
		Min	50%	Max
BACK PAIN	1	31	31	31
RIGORS	1	43	43	43
FURUNCULOSIS	1	5	5	5
RHINITIS	1	40	40	40

221

(*) adverse event present before start treatment: onset date = start treatment date of first report visit with changed severity
adverse event still present at end of study: end date = visit date of last report visit

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 TABLE No.: 69
 ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY SYMPTOMATIC TREATMENT AND ASSIGNED TREATMENT
 OPEN PHASE

Adverse events	Symptomatic treatment						Total
	YES		NO		Total		
	No.	%	No.	%	No.	%	
No. of pt. with A.E.	16	8.6	170	91.4	186	100.0	
No. of adverse events	20	5.3	354	94.7	374	100.0	
MOUTH DRY			72	100.0	72	100.0	
CONSTIPATION			63	100.0	63	100.0	
SWEATING INCREASED			32	100.0	32	100.0	
TACHYCARDIA	1	4.3	22	95.7	23	100.0	
MICTURITION DISORDER			23	100.0	23	100.0	
INSOMNIA	8	36.4	14	63.6	22	100.0	
LIBIDO DECREASED			19	100.0	19	100.0	
DIZZINESS			18	100.0	18	100.0	
VISION ABNORMAL			14	100.0	14	100.0	
PARAESTHESIA			12	100.0	12	100.0	
HEADACHE	2	18.2	9	81.8	11	100.0	
TREMOR			10	100.0	10	100.0	
URINARY RETENTION	2	25.0	6	75.0	8	100.0	
RASH			3	100.0	3	100.0	
VOMITING			3	100.0	3	100.0	
FATIGUE			3	100.0	3	100.0	
AGITATION			2	100.0	2	100.0	
ANOREXIA			2	100.0	2	100.0	
HYPERTENSION	1	50.0	1	50.0	2	100.0	
HYPOTENSION POSTURAL			2	100.0	2	100.0	

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 69

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY SYMPTOMATIC TREATMENT AND ASSIGNED TREATMENT
OPEN PHASE

Adverse events	Symptomatic treatment					
	YES		NO		Total	
	No.	%	No.	%	No.	%
SOMNOLENCE			2	100.0	2	100.0
NAUSEA			2	100.0	2	100.0
INFECTION VIRAL	2	100.0			2	100.0
ACNE			1	100.0	1	100.0
CONVULSIONS			1	100.0	1	100.0
MUSCLE CONTRACTIONS INVOLUNTARY			1	100.0	1	100.0
VERTIGO			1	100.0	1	100.0
DIARRHOEA			1	100.0	1	100.0
PALPITATION			1	100.0	1	100.0
CONJUNCTIVITIS			1	100.0	1	100.0
ANXIETY			1	100.0	1	100.0
SUICIDE ATTEMPT			1	100.0	1	100.0
FLATULENCE			1	100.0	1	100.0
UPPER RESP TRACT INFECTION			1	100.0	1	100.0
ALBUMINURIA			1	100.0	1	100.0
OVARIAN DISORDER	1	100.0			1	100.0
VAGINITIS			1	100.0	1	100.0
RIGORS			1	100.0	1	100.0
RHINITIS			1	100.0	1	100.0
EJACULATION FAILURE			1	100.0	1	100.0
LACRIMAL GLAND DISORDER	1	100.0			1	100.0
NERVOUSNESS			1	100.0	1	100.0

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

PEROXETINE - PROTOCOL 20124/013

TABLE No.: 69

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY SYMPTOMATIC TREATMENT AND ASSIGNED TREATMENT OPEN PHASE

Adverse events	Symptomatic treatment					
	YES		NO		Total	
	No.	%	No.	%	No.	%
COUGHING	1	100.0			1	100.0
PERINEAL PAIN MALE			1	100.0	1	100.0
OEDEMA PERIPHERAL			1	100.0	1	100.0
BACK PAIN	1	100.0			1	100.0
FURUNCULOSIS			1	100.0	1	100.0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 70

ADVERSE EVENTS BY ACTION ON STUDY DRUG - OPEN PHASE

Adverse events	Study drug																	
	No change			Dose reduced			Temporarily interrupted			Definitively withdrawn			Unknown			Total		
	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%
ALL adverse events	335		89.6	9		2.4	2		0.5	27		7.2	1		0.3	374		100.0
MOUTH DRY	69		95.8	1		1.4				2		2.8				72		100.0
CONSTIPATION	61		96.8							2		3.2				63		100.0
SWEATING INCREASED	30		93.8	1		3.1				1		3.1				32		100.0
TACHYCARDIA	17		73.9	1		4.3	1		4.3	4		17.4				23		100.0
MICTURITION DISORDER	21		91.3							2		8.7				23		100.0
INSOMNIA	22		100.0													22		100.0
LIBIDO DECREASED	16		84.2	1		5.3				2		10.5				19		100.0
DIZZINESS	17		94.4							1		5.6				18		100.0
VISION ABNORMAL	13		92.9							1		7.1				14		100.0
PARAESTHESIA	12		100.0													12		100.0
HEADACHE	10		90.9							1		9.1				11		100.0
TREMOR	8		80.0	1		10.0				1		10.0				10		100.0
URINARY RETENTION	5		62.5	2		25.0				1		12.5				8		100.0
FATIGUE	2		66.7							1		33.3				3		100.0
VOMITING	2		66.7							1		33.3				3		100.0
RAASH	2		66.7							1		33.3				3		100.0
HYPERTENSION	1		50.0						1		50.0					2		100.0
HYPOTENSION POSTURAL	1		50.0							1		50.0				2		100.0
ANOREXIA	2		100.0													2		100.0
NAUSEA	2		100.0													2		100.0
AGITATION	1		50.0							1		50.0				2		100.0

(CONTINUED)

225

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
TABLE No.: 70

ADVERSE EVENTS BY ACTION ON STUDY DRUG - OPEN PHASE

Adverse events	Study drug																	
	No change			Dose reduced			Temporarily interrupted			Definitively withdrawn			Unknown			Total		
	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%
SOMNOLENCE	2		100.0													2		100.0
INFECTION VIRAL	2		100.0													2		100.0
EJACULATION FAILURE	1		100.0													1		100.0
RIGORS	1		100.0													1		100.0
OEDEMA PERIPHERAL	1		100.0													1		100.0
MUSCLE CONTRACTIONS INVOLUNTARY	1		100.0													1		100.0
FLATULENCE	1		100.0													1		100.0
BACK PAIN	1		100.0													1		100.0
OVARIAN DISORDER	1		100.0													1		100.0
VAGINITIS	1		100.0													1		100.0
PERINEAL PAIN MALE	1		100.0													1		100.0
FURUNCULOSIS	1		100.0													1		100.0
COUGHING	1		100.0													1		100.0
UPPER RESP TRACT INFECTION	1		100.0													1		100.0
RHINITIS	1		100.0													1		100.0
ACNE	1		100.0													1		100.0
ALBUMINURIA	1		100.0													1		100.0
LACRIMAL GLAND DISORDER	1		100.0													1		100.0
CONJUNCTIVITIS	1		100.0													1		100.0
PALPITATION				1		100.0												100.0
NERVOUSNESS				1		100.0												100.0
CONVULSIONS												1		100.0				100.0

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/013
 TABLE No.: 70

ADVERSE EVENTS BY ACTION ON STUDY DRUG - OPEN PHASE

Adverse events	Study drug												
	No change		Dose reduced		Temporarily interrupted		Definitively withdrawn		Unknown		Total		
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	
DIARRHOEA							1	100.0				1	100.0
ANXIETY							1	100.0				1	100.0
SUICIDE ATTEMPT							1	100.0				1	100.0
VERTIGO									1	100.0		1	100.0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 71

ADVERSE EVENTS: DISAPPEARED AFTER ACTION ON STUDY DRUG AND REAPPEARED ON RESUMING TREATMENT - OPEN PHASE

Adverse events	Modified study drug										Temporarily interrupted											
	Disappeared					Reappeared					Temporarily interrupted			Reappeared								
	NO		YES		Not applicable	Total		NO		YES		Not applicable	Total		NO		YES		Not applicable	Total		
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
All adverse events	6	15.8	31	81.6	1	2.6	38	100.0	2	100.0					2	100.0					2	100.0
TACHYCARDIA	1	16.7	5	83.3			6	100.0	1	100.0					1	100.0					1	100.0
MOUTH DRY	1	33.3	2	66.7			3	100.0														
LIBIDO DECREASED	1	33.3	2	66.7			3	100.0														
URINARY RETENTION	1	33.3	2	66.7			3	100.0														
SWEATING INCREASED	1	50.0	1	50.0			2	100.0														
TREMOR			2	100.0			2	100.0														
CONSTIPATION			2	100.0			2	100.0														
MICTURITION DISORDER	1	50.0	1	50.0			2	100.0														
FATIGUE			1	100.0			1	100.0														
DIZZINESS			1	100.0			1	100.0														
HYPERTENSION			1	100.0			1	100.0	1	100.0					1	100.0						
HYPOTENSION POSTURAL			1	100.0			1	100.0														
PALPITATION			1	100.0			1	100.0														
CONVULSIONS			1	100.0			1	100.0														
HEADACHE			1	100.0			1	100.0														
DIARRHOEA			1	100.0			1	100.0														
VOMITING			1	100.0			1	100.0														
AGITATION			1	100.0			1	100.0														
ANXIETY			1	100.0			1	100.0														
NERVOUSNESS			1	100.0			1	100.0														

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 71

ADVERSE EVENTS: DISAPPEARED AFTER ACTION ON STUDY DRUG AND REAPPEARED ON RESUMING TREATMENT - OPEN PHASE

Adverse events	Modified study drug														
	Disappeared					Temporarily interrupted									
	NO		YES		Not applicable	NO		YES		Not applicable	Total				
No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%		
SUICIDE ATTEMPT					1	100.0						1	100.0		
RASH			1	100.0								1	100.0		
VISION ABNORMAL			1	100.0								1	100.0		

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
TABLE No.: 72

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY BY ACTION ON STUDY DRUG - OPEN PHASE

Adverse events	Modified study drug												Unchanged study drug or Missing																									
	Recovered with sequelae			Still present			Death			Missing			Total			Recovered with sequelae			Still present			Death			Missing			Total										
	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z
All adverse events	30	78.9		7	18.4	1	2.6								38	100	172	51.2	9	2.7	154	45.8				1	0.3	336	100									
MOUTH DRY	2	66.7		1	33.3										3	100	30	43.5			39	56.5						69	100									
CONSTIPATION	2	100										2	100	24	39.3			37	60.7								61	100										
SWEATING INCREASED	1	50.0		1	50.0							2	100	18	60.0			12	40.0								30	100										
TACHYCARDIA	4	66.7		2	33.3							6	100	13	76.5			4	23.5								17	100										
MICTURITION DISORDER	1	50.0		1	50.0							2	100	9	42.9			12	57.1								21	100										
INSOMNIA															12	54.5	6	27.3			3	13.6				1	4.5	22	100									
LIBIDO DECREASED	2	66.7		1	33.3				3	100	2	12.5			14	87.5												16	100									
DIZZINESS	1	100							1	100	11	64.7			6	35.3												17	100									
VISION ABNORMAL	1	100							1	100	6	46.2			7	53.8												13	100									
PARESTHESIA												10	83.3			2	16.7											12	100									
HEADACHE	1	100							1	100	6	60.0			4	40.0												10	100									
TREMOR	2	100							2	100	2	25.0			6	75.0												8	100									
URINARY RETENTION	2	66.7		1	33.3				3	100	3	60.0			2	40.0												5	100									
FATIGUE	1	100							1	100			1	50.0			1	50.0									2	100										
VOMITING	1	100							1	100	2	100															2	100										
RASH	1	100							1	100	2	100															2	100										
HYPERTENSION	1	100							1	100																	1	100										
HYPOTENSION POSTURAL	1	100							1	100	1	100															1	100										
ANOREXIA											2	100															2	100										
NAUSEA											2	100															2	100										
ACITATION	1	100							1	100	1	100															1	100										

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
TABLE No. : 72

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY BY ACTION ON STUDY DRUG - OPEN PHASE

Adverse events	Modified study drug										Unchanged study drug or Missing														
	Recovered		Recovered with sequelae		Still present		Death		Missing		Total		Recovered with sequelae		Still present		Death		Missing		Total				
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%			
SOMNOLENCE													2	100									2	100	
INFECTION VIRAL													1	50.0										2	100
EJACULATION FAILURE																							1	100	
RIGORS																							1	100	
PALPITATION	1	100																							
OEDEMA PERIPHERAL																									
CONVULSIONS	1	100																							
MUSCLE CONTRACTIONS INVOLUNTARY																									
VERTIGO																									
DIARRHOEA	1	100																							
FLATULENCE																									
BACK PAIN																									
ANXIETY	1	100																							
NERVOUSNESS	1	100																							
SUICIDE ATTEMPT																									
OVARIAN DISORDER																									
VAGINITIS																									
PERINEAL PAIN MALE																									
FURUNCULOSIS																									
COUGHING																									
UPPER RESP TRACT INFECTION																									

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 72

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY BY ACTION ON STUDY DRUG - OPEN PHASE

Adverse events	Modified study drug						Unchanged study drug or Missing						
	Recovered with sequelae		Still present	Death	Missing	Total	Recovered with sequelae		Still present	Death	Missing	Total	
	No.	%					No.	%					No.
RHINITIS							1	100				1	100
ACNE						1	100					1	100
ALBUMINURIA									1	100		1	100
LACRIMAL GLAND DISORDER												1	100
CONJUNCTIVITIS							1	100				1	100

22
33
22

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 72

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY BY ACTION ON STUDY DRUG - OPEN PHASE

Adverse events	All adverse events											
	Recovered		Recovered with sequelae		Still present		Death		Missing		Total	
	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z
All adverse events	202	54.0	9	2.4	161	43.0	1	0.3	1	0.3	374	100.0
MOUTH DRY	32	44.4			40	55.6					72	100.0
CONSTIPATION	26	41.3			37	58.7					63	100.0
SWEATING INCREASED	19	59.4			13	40.6					32	100.0
TACHYCARDIA	17	73.9			6	26.1					23	100.0
MICTURITION DISORDER	10	43.5			13	56.5					23	100.0
INSOMNIA	12	54.5	6	27.3	3	13.6			1	4.5	22	100.0
LIBIDO DECREASED	4	21.1			15	78.9					19	100.0
DIZZINESS	12	66.7			6	33.3					18	100.0
VISION ABNORMAL	7	50.0			7	50.0					14	100.0
PARAESTHESIA	10	83.3			2	16.7					12	100.0
HEADACHE	7	63.6			4	36.4					11	100.0
TREMOR	4	40.0			6	60.0					10	100.0
URINARY RETENTION	5	62.5			3	37.5					8	100.0
FATIGUE	1	33.3	1	33.3	1	33.3					3	100.0
VOMITING	3	100.0									3	100.0
RASH	3	100.0									3	100.0
HYPERTENSION	1	50.0			1	50.0					2	100.0
HYPOTENSION POSTURAL	2	100.0									2	100.0
ANOREXIA	2	100.0									2	100.0
NAUSEA	2	100.0									2	100.0
AGITATION	2	100.0									2	100.0

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 72

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY BY ACTION ON STUDY DRUG - OPEN PHASE

Adverse events	All adverse events												
	Recovered		Recovered with sequelae		Still present		Death		Missing		Total		
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	
SOMNOLENCE	2	100.0										2	100.0
INFECTION VIRAL	1	50.0	1	50.0								2	100.0
EJACULATION FAILURE					1	100.0						1	100.0
RIGORS					1	100.0						1	100.0
PALPITATION	1	100.0										1	100.0
OEDEMA PERIPHERAL	1	100.0										1	100.0
CONVULSIONS	1	100.0										1	100.0
MUSCLE CONTRACTIONS INVOLUNTARY	1	100.0										1	100.0
VERTIGO	1	100.0										1	100.0
DIARRHOEA	1	100.0										1	100.0
FLATULENCE					1	100.0						1	100.0
BACK PAIN	1	100.0										1	100.0
ANXIETY	1	100.0										1	100.0
NERVOUSNESS	1	100.0										1	100.0
SUICIDE ATTEMPT								1	100.0			1	100.0
OVARIAN DISORDER	1	100.0										1	100.0
VAGINITIS	1	100.0										1	100.0
PERINEAL PAIN MALE	1	100.0										1	100.0
FURUNCULOSIS	1	100.0										1	100.0
COUGHING	1	100.0										1	100.0
UPPER RESP TRACT INFECTION	1	100.0										1	100.0

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013

TABLE No.: 72

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY BY ACTION ON STUDY DRUG - OPEN PHASE

Adverse events	All adverse events											
	Recovered		Recovered with sequelae		Still present		Death		Missing		Total	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
RHINITIS	1	100.0									1	100.0
ACNE	1	100.0									1	100.0
ALBUMINURIA					1	100.0					1	100.0
LACRIMAL GLAND DISORDER					1	100.0					1	100.0
CONJUNCTIVITIS	1	100.0									1	100.0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 73

ADVERSE EVENTS BY RELATIONSHIP TO THE EXPERIMENTAL TREATMENT - OPEN PHASE

Adverse events	Relationship																	
	Definite		Probable		Possible		Doubtful		None		Unknown		Missing		Total			
	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z		
Total adverse events	37	9.9	48	12.8	238	63.6	27	7.2	17	4.5	7	1.9			374	100.0		
MOUTH DRY	13	18.1	13	18.1	42	58.3	2	2.8	1	1.4	1	1.4			72	100.0		
CONSTIPATION	8	12.7	6	9.5	47	74.6	2	3.2							63	100.0		
SWEATING INCREASED			4	12.5	24	75.0	3	9.4	1	3.1					32	100.0		
TACHYCARDIA	2	8.7	4	17.4	13	56.5	4	17.4							23	100.0		
MICTURITION DISORDER	1	4.3	1	4.3	20	87.0			1	4.3					23	100.0		
INSOMNIA			1	4.5	10	45.5	5	22.7	4	18.2	2	9.1			22	100.0		
LIBIDO DECREASED	4	21.1	3	15.8	12	63.2									19	100.0		
DIZZINESS	2	11.1	4	22.2	11	61.1					1	5.6			16	100.0		
VISION ABNORMAL	2	14.3	2	14.3	10	71.4									14	100.0		
PARAESTHESIA	1	8.3			10	83.3	1	8.3							12	100.0		
HEADACHE			1	9.1	6	54.5	2	18.2	2	18.2					11	100.0		
TREMOR	1	10.0	1	10.0	8	80.0									10	100.0		
URINARY RETENTION	1	12.5	2	25.0	3	37.5	1	12.5	1	12.5					8	100.0		
FATIGUE	1	33.3	1	33.3	1	33.3									3	100.0		
VOMITING	1	33.3			1	33.3	1	33.3							3	100.0		
RASH			1	33.3	1	33.3	1	33.3							3	100.0		
HYPOTENSION POSTURAL			1	50.0	1	50.0									2	100.0		
AGITATION			1	50.0	1	50.0									2	100.0		
ANOREXIA					2	100.0									2	100.0		
NAUSEA					2	100.0									2	100.0		
SOMNOLENCE					2	100.0									2	100.0		
INFECTION VIRAL							1	50.0	1	50.0					2	100.0		

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 73

ADVERSE EVENTS BY RELATIONSHIP TO THE EXPERIMENTAL TREATMENT - OPEN PHASE

Adverse events	Relationship															
	Definite		Probable		Possible		Doubtful		None		Unknown		Missing		Total	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
HYPERTENSION									1	50.0	1	50.0			2	100.0
DIARRHOEA			1	100.0											1	100.0
NERVOUSNESS			1	100.0											1	100.0
EJACULATION FAILURE					1	100.0									1	100.0
RIGORS					1	100.0									1	100.0
PALPITATION					1	100.0									1	100.0
MUSCLE CONTRACTIONS INVOLUNTARY					1	100.0									1	100.0
VERTIGO					1	100.0									1	100.0
FLATULENCE					1	100.0									1	100.0
ANXIETY					1	100.0									1	100.0
PERINEAL PAIN MALE					1	100.0									1	100.0
FURUNCULOSIS					1	100.0									1	100.0
ACNE					1	100.0									1	100.0
CONJUNCTIVITIS					1	100.0									1	100.0
OEDEMA PERIPHERAL							1	100.0							1	100.0
OVARIAN DISORDER							1	100.0							1	100.0
RHINITIS							1	100.0							1	100.0
ALBUMINURIA							1	100.0							1	100.0
SUICIDE ATTEMPT										1	100.0				1	100.0
VAGINITIS														1	100.0	
COUGHING														1	100.0	
UPPER RESP TRACT INFECTION														1	100.0	

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 73

ADVERSE EVENTS BY RELATIONSHIP TO THE EXPERIMENTAL TREATMENT - OPEN PHASE

Adverse events	Relationship																	
	Definite		Probable		Possible		Doubtful		None		Unknown		Missing		Total			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%		
LACRIMAL GLAND DISORDER									1	100.0							1	100.0
CONVULSIONS																	1	100.0
BACK PAIN																	1	100.0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 TABLE No.: 74
 ADVERSE EVENTS: NUMBER OF RANDOMIZED PATIENTS WHO COMPLAINED OF AT LEAST ONE ADVERSE EVENTS DURING THE STUDY
 BY SEX AND ASSIGNED TREATMENT

	Run In Phase				Double Blind Phase			
	SEX		Total	Ratio A.E. on Pt with A.E.	SEX		Total	Ratio A.E. on Pt with A.E.
	Female	Male			Female	Male		
Placobo								
Pt exposed	94	46	140		94	46	140	
Pt with adverse events	54	27	81		19	13	32	
Z on exposed	57.44	58.69	57.85		20.21	28.26	22.85	
95% L.L.	46.82	43.23	49.23		12.63	15.99	16.19	
95% U.L.	67.59	73.00	66.15		29.75	43.46	30.71	
No. of adverse events	100	51	151		28	20	48	
Ratio A.E. on Pt with A.E.	1.85	1.88	1.86		1.47	1.53	1.50	
Reboxetine								
Pt exposed	114	29	143		114	29	143	
Pt with adverse events	57	19	76		28	12	40	
Z on exposed	50.00	65.51	53.14		24.56	41.37	27.97	
95% L.L.	40.49	45.67	44.63		16.98	23.52	20.79	
95% U.L.	59.51	82.06	61.53		33.51	61.07	36.09	
No. of adverse events	113	36	149		38	18	56	
Ratio A.E. on Pt with A.E.	1.98	1.89	1.96		1.35	1.50	1.40	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 75

ADVERSE EVENTS: NUMBER OF RANDOMIZED PATIENTS WHO COMPLAINED OF AT LEAST ONE ADVERSE EVENTS DURING THE STUDY BY AGE AND ASSIGNED TREATMENT

	Run In Phase					Double Blind Phase				
	AGE					AGE				
	Total	18 - 30	31 - 45	> 45	> 45	Total	18 - 30	31 - 45	> 45	> 45
Placebo										
Pt exposed	140	24	59	57	57	140	24	59	57	57
Pt with adverse events	81	16	40	25	25	32	1	20	11	11
% on exposed	57.85	66.66	67.79	43.85	43.85	22.85	4.16	33.89	19.29	19.29
95% L.L.	49.23	44.68	54.36	30.74	30.74	16.19	0.11	22.08	10.05	10.05
95% U.L.	66.15	84.37	79.38	57.64	57.64	30.71	21.12	47.39	31.91	31.91
No. of adverse events	151	28	80	43	43	48	1	30	17	17
Ratio A.E. on Pt with A.E.	1.86	1.75	2.00	1.72	1.72	1.50	1.00	1.50	1.54	1.54
Reboxetine										
Pt exposed	143	21	58	64	64	143	21	58	64	64
Pt with adverse events	76	9	36	31	31	40	5	15	20	20
% on exposed	53.14	42.85	62.06	48.43	48.43	27.97	23.80	25.86	31.25	31.25
95% L.L.	44.63	21.82	48.37	35.75	35.75	20.79	8.22	15.25	20.24	20.24
95% U.L.	61.53	65.98	74.49	61.27	61.27	36.09	47.17	39.04	44.06	44.06
No. of adverse events	149	21	64	64	64	56	7	20	29	29
Ratio A.E. on Pt with A.E.	1.96	2.33	1.77	2.06	2.06	1.40	1.40	1.33	1.45	1.45

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REOMETRINE - PROTOCOL 20124/013
TABLE No. 76

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY SEX ASSIGNED TREATMENT AND PHASE

Adverse event/Assigned treatment	Placebo						Robozentine														
	Run In Phase			Double Blind Phase			Run In Phase			Double Blind Phase											
	No. of Pt. with AE	% of Pt. with AE	No. of Pt. with AE	% of Pt. with AE	No. of Pt. with AE	% of Pt. with AE	No. of Pt. with AE	% of Pt. with AE	No. of Pt. with AE	% of Pt. with AE	No. of Pt. with AE	% of Pt. with AE									
Pt exposed	Female	94	100.0	94	100.0	46	100.0	46	100.0	114	100.0	114	100.0								
	Male	46	100.0	46	100.0	29	100.0	29	100.0	153	100.0	153	100.0								
	Total	140	100.0	140	100.0	75	100.0	75	100.0	267	100.0	267	100.0								
Pt with a.e.	Female	54	57.4	100.0	100.0	19	20.2	100.0	28	1.47	57	50.0	100.0	119	1.98	28	24.6	100.0	38	1.35	
	Male	27	58.7	100.0	100.0	13	28.3	100.0	20	1.53	19	65.5	100.0	36	1.89	12	41.4	100.0	18	1.50	
	Total	81	57.9	100.0	100.0	32	22.9	100.0	40	1.50	76	85.1	100.0	149	1.96	40	28.0	100.0	56	1.40	
CONSTIPATION	Female	19	20.2	35.1	20	1.05	5	5.3	26.3	5	1.00	20	17.5	38.0	22	1.10	9	7.9	30.1	11	1.22
	Male	7	15.2	25.9	7	1.00	1	2.2	7.6	1	1.00	4	33.8	21.0	4	1.00	3	10.3	25.0	3	1.00
	Total	26	18.6	32.0	27	1.05	6	4.3	18.7	6	1.00	24	16.8	31.5	26	1.06	12	8.4	30.0	14	1.16
MOUTH DRY	Female	18	19.1	33.3	18	1.00	1	1.00	2.2	1	1.00	23	20.2	40.3	23	1.21	1	0.7	2.5	1	1.00
	Male	9	19.6	33.3	9	1.00	1	2.2	7.6	1	1.00	3	10.3	15.7	3	1.00	1	0.7	2.5	1	1.00
	Total	27	19.3	33.3	27	1.00	2	0.7	3.1	2	1.00	26	18.2	36.0	26	1.19	2	1.4	4.4	2	1.00
INSOMNIA	Female	16	17.0	29.6	17	1.06	5	5.3	26.3	6	1.20	15	13.2	26.3	15	1.00	5	4.4	17.8	7	1.40
	Male	7	15.2	25.9	7	1.00	2	4.3	15.3	2	1.00	2	6.9	10.5	2	1.00	2	6.9	16.6	2	1.00
	Total	23	16.4	28.3	24	1.04	7	5.0	21.8	8	1.14	17	11.9	22.3	17	1.00	7	4.9	17.5	9	1.28
SWEATING INCREASED	Female	10	10.6	18.5	11	1.10	1	1.1	5.2	1	1.00	9	7.9	15.7	10	1.11	1	0.9	3.5	1	1.00
	Male	1	2.2	3.7	1	1.00	1	1.00	2.2	1	1.00	3	10.3	15.7	3	1.00	1	0.7	2.5	1	1.00
	Total	11	7.9	13.5	12	1.09	2	0.7	3.1	2	1.00	12	8.4	15.7	13	1.08	2	1.4	4.4	2	1.00
NICTURIATION DISORDER	Female	1	1.1	1.8	1	1.00	1	1.1	5.2	1	1.00	1	0.9	1.7	1	1.00	1	0.9	3.5	1	1.00
	Male	7	15.2	25.9	8	1.14	1	2.2	7.6	1	1.00	6	27.6	42.1	9	1.12	3	10.3	25.0	3	1.00
	Total	8	5.7	9.8	9	1.12	2	1.4	6.2	2	1.00	7	6.3	11.8	10	1.11	4	2.8	10.0	4	1.00

(*) number of adverse events on patients who complained of adverse events

(N2)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/019
TABLE No: 76

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
BY SEX ASSIGNED TREATMENT AND PHASE

Adverse events/Assigned treatment	Placebo												Reboxetine													
	Run In Phase						Double Blind Phase						Run In Phase						Double Blind Phase							
	No of Pt.	Z on exp.	% on AE	No of AE	Ratio (%)	No of Pt.	Z on exp.	% on AE	No of AE	Ratio (%)	No of Pt.	Z on exp.	% on AE	No of AE	Ratio (%)	No of Pt.	Z on exp.	% on AE	No of AE	Ratio (%)	No of Pt.	Z on exp.	% on AE	No of AE	Ratio (%)	
TACHYCARDIA	Female	5	5.3	9.2	5	1.00	3	3.2	15.7	3	1.00	5	4.4	8.7	5	1.00	3	2.6	10.7	4	1.33					
	Male	3	6.5	11.1	3	1.00	1	2.2	7.6	1	1.00	1	3.4	5.2	1	1.00	1	3.4	8.3	1	1.00					
	Total	8	5.7	9.8	8	1.00	4	2.9	12.5	4	1.00	6	4.2	7.8	6	1.00	4	2.8	10.0	5	1.25					
DIZZINESS	Female	6	6.4	11.1	7	1.16	1	1.1	5.2	1	1.00	6	5.3	10.5	7	1.16	1	0.9	3.5	1	1.00					
	Male	1	2.2	3.7	1	1.00	1	2.2	7.6	1	1.00															
	Total	7	5.0	8.6	8	1.14	2	1.4	6.2	2	1.00	6	4.2	7.8	7	1.16	1	0.7	2.5	1	1.00					
LIBIDO DECREASED	Female	1	1.1	1.8	1	1.00	1	1.1	5.2	1	1.00	5	4.4	8.7	5	1.00										
	Male	4	8.7	14.8	4	1.00						4	13.8	21.0	4	1.00	1	3.4	8.3	1	1.00					
	Total	5	3.6	6.1	5	1.00	1	0.7	3.1	1	1.00	9	6.3	11.8	9	1.00	1	0.7	2.5	1	1.00					
HEADACHE	Female						2	2.1	10.5	3	1.50	5	4.4	8.7	5	1.00	2	1.8	7.1	2	1.00					
	Male						2	4.3	15.3	2	1.00						2	6.9	16.6	2	1.00					
	Total						4	2.9	12.5	5	1.25	5	3.5	6.5	5	1.00	4	2.8	10.0	4	1.00					
VISION ABNORMAL	Female	2	2.1	3.7	2	1.00						2	1.8	3.5	3	1.50	1	0.9	3.5	1	1.00					
	Male	1	2.2	3.7	1	1.00	1	2.2	7.6	1	1.00	3	10.3	15.7	3	1.00										
	Total	3	2.1	3.7	3	1.00	1	0.7	3.1	1	1.00	5	3.5	6.5	6	1.20	1	0.7	2.5	1	1.00					
TREMOR	Female	5	5.3	9.2	5	1.00						1	0.9	1.7	1	1.00										
	Male	1	2.2	3.7	1	1.00	2	4.3	15.3	2	1.00															
	Total	6	4.3	7.4	6	1.00	2	1.4	6.2	2	1.00	1	0.7	1.3	1	1.00										
PARAESTHESIA	Female	3	3.2	5.5	3	1.00	1	1.1	5.2	2	2.00	1	0.9	1.7	1	1.00										
	Male	1	2.2	3.7	2	2.00						1	3.4	5.2	1	1.00										
	Total	4	2.9	4.9	5	1.25	1	0.7	3.1	2	2.00	2	1.4	2.6	2	1.00										

(*) number of adverse events on patients who complained of adverse events

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD
 REMOXYLINE - PROTOCOL 20124/013
 TABLE No: 76

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY
 BY SEX ASSIGNED TREATMENT AND PHASE

Adverse Events/Assigned treatment	Placebo						Reboxyline					
	Run In Phase			Double Blinded Phase			Run In Phase			Double Blinded Phase		
	No of X on Pt. with AE (%)	% on Pt. with AE	No of Ratio AE (%)	No of X on Pt. with AE (%)	% on Pt. with AE	No of Ratio AE (%)	No of X on Pt. with AE (%)	% on Pt. with AE	No of Ratio AE (%)	No of X on Pt. with AE (%)	% on Pt. with AE	No of Ratio AE (%)
URINARY RETENTION	Female	1 1.1	1.8	1 1.00			2 6.9	10.5	2 1.00	1 3.4	8.3	1 1.00
	Male	3 6.5	11.1	3 1.00			2 1.4	2.6	2 1.00	1 0.7	2.5	1 1.00
	Total	4 2.9	4.9	4 1.00						2 1.8	7.4	3 1.50
HYPERTENSION	Female				1 1.1	5.2	2 2.00			2 6.9	16.6	2 1.00
	Male				1 2.2	7.5	1 1.00			4 2.8	10.0	5 1.25
	Total				2 1.4	6.2	3 1.50					
DIARRHOEA	Female				1 1.1	5.2	1 1.00					
	Male				3 6.5	23.0	4 1.33			1 3.4	8.3	1 1.00
	Total				4 2.9	12.5	5 1.25			1 0.7	2.5	1 1.00
RASH	Female	1 1.1	1.8	1 1.00								
	Male	1 0.7	1.2	1 1.00								
	Total	2 1.4	1.5	2 1.00								
VOMITING	Female	1 1.1	1.8	1 1.00								
	Male				1 1.1	5.2	1 1.00			3 2.6	10.7	3 1.00
	Total	1 0.7	1.2	1 1.00						3 2.1	7.5	3 1.00
ANOREXIA	Female	1 1.1	1.8	1 1.00								
	Male				1 2.2	7.6	1 1.00			1 0.9	1.7	1 1.00
	Total	1 0.7	1.2	1 1.00						1 0.7	1.3	1 1.00
HYPOTENSION POSTURAL	Female											
	Male				1 2.2	7.6	1 1.00					
	Total				1 0.7	3.1	1 1.00			1 0.7	1.3	1 1.00
SONNOLENCE	Female											
	Male				2 1.4	6.2	2 1.00			2 1.8	3.5	2 1.00
	Total				2 1.4	2.6	2 1.00			2 1.4	2.6	2 1.00

(*) number of adverse events on patients who complained of adverse events

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOMETINE - PROTOCOL 20124/013
TABLE No: 76

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY SEX ASSIGNED TREATMENT AND PHASE

Adverse events/Assigned treatment	Placebo						Reboxetine						
	Run In Phase			Double Blind Phase			Run In Phase			Double Blind Phase			
	No of Pt. exp.	Z on exp. with AE	No of AE	No of Pt. exp.	Z on exp. with AE	No of AE	No of Pt. exp.	Z on exp. with AE	No of AE	No of Pt. exp.	Z on exp. with AE	No of AE	
NAUSEA	Female	1.1	1.8	1	1.00								
	Male						1	3.4	5.2	1	1.00		
	Total	1	0.7	1.2	1	1.00		0.7	1.3	1	1.00		
PERINEAL PAIN MALE	Male						1	3.4	5.2	1	1.00	1	3.4
	Total						1	0.7	1.3	1	1.00	1	0.7
	Total						1	0.7	1.3	1	1.00	1	0.7
DEDENA PERIPHERAL	Female						1	1.1	5.2	1	1.00		
	Male						1	3.4	5.2	1	1.00		
	Total						1	0.7	1.3	1	1.00		
ACNE	Female	1.1	1.8	1	1.00								
	Total	1	0.7	1.2	1	1.00							
	Female						1	0.9	1.7	1	1.00		
VERTIGO	Total						1	0.7	1.3	1	1.00		
	Male	2.2	3.7	1	1.00								
	Total	1	0.7	1.2	1	1.00							
EJACULATION FAILURE	Female												
	Total												
	Female						1	0.9	1.7	1	1.00		
PALPITATION	Total						1	0.7	1.3	1	1.00		
	Male												
	Total						1	0.7	1.3	1	1.00		
LACRIMAL GLAND DISORDER	Male												
	Total						1	3.4	5.2	1	1.00		
	Male						1	0.7	1.3	1	1.00		
HALUCINATION	Male						1	2.2	7.6	1	1.00		
	Total						1	0.7	1.3	1	1.00		
	Male						1	0.7	1.3	1	1.00		
NERVOUSNESS	Male	2.2	3.7	1	1.00								
	Total												
	Male												

(CONTINUED) 2
4
4

(*) number of adverse events on patients who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOMETINE - PROTOCOL 20124/013
TABLE No: 76

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY SEX ASSIGNED TREATMENT AND PHASE

Adverse events/Assigned treatment	Placebo						Reboxetine						
	Run In Phase			Double Blind Phase			Run In Phase			Double Blind Phase			
	No of Pt. exp.	Z on exp. with AE	No of AE	No of Pt. exp.	Z on exp. with AE	No of AE	No of Pt. exp.	Z on exp. with AE	No of AE	No of Pt. exp.	Z on exp. with AE	No of AE	
NAUSEA	Female	1.1	1.8	1	1.00								
	Male							3.4	5.2	1	1.00		
	Total	0.7	1.2	1	1.00			0.7	1.3	1	1.00		
PERINEAL PAIN MALE	Male							3.4	5.2	1	1.00	3.4	8.3
	Total							0.7	1.3	1	1.00	0.7	2.5
	Female												
DEDENA PERIPHERAL	Female					1	1.1	5.2	1	1.00			
	Male												
	Total					1	0.7	3.1	1	1.00			
ACNE	Female	1.1	1.8	1	1.00								
	Total	0.7	1.2	1	1.00								
	Female												
VERTIGO	Total												
	Male	2.2	3.7	1	1.00								
	Total	0.7	1.2	1	1.00								
EJACULATION FAILURE	Female												
	Total												
	Female												
PALPITATION	Total												
	Female												
	Total												
LACRIMAL GLAND DISORDER	Male												
	Total												
	Male					1	2.2	7.6	1	1.00			
HALUCINATION	Total					1	0.7	3.1	1	1.00			
	Male												
	Male	2.2	3.7	1	1.00								

(CONTINUED) 4

(*) number of adverse events on patients who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOMETINE - PROTOCOL 20124/013
TABLE No: 76

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY SEX ASSIGNED TREATMENT AND PHASE

Adverse events/Assigned treatment	Placebo								Reboxetine							
	Run In Phase				Double Blind Phase				Run In Phase				Double Blind Phase			
	No of Pt.	% on exp.	No of AE	Ratio No of Pt. (*)	No of Pt.	% on exp.	No of AE	Ratio No of Pt. (*)	No of Pt.	% on exp.	No of AE	Ratio No of Pt. (*)	No of Pt.	% on exp.	No of AE	Ratio No of Pt. (*)
FURUNCULOSIS	1	2.2	3.7	1	1.00											
Total	1	0.7	1.2	1	1.00											
PNEUMONIA																
Total																
RHINITIS																
Total																
INFECTION VIRAL																
Total																

246

(*) number of adverse events on patients who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No: 77

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT AND GROUPED BY BODY SYSTEM

Body system/Assigned treatment	Run In Phase						Double Blind Phase														
	Placebo			Reboxetine			Placebo			Reboxetine											
	No of Pt	% on exp.	No of AE	No of Pt	% on exp.	No of AE	No of Pt	% on exp.	No of AE	No of Pt	% on exp.	No of AE									
Pt exposed	Female	94	100.0				94	100.0				114	100.0								
	Male	46	100.0				46	100.0				29	100.0								
	Total	140	100.0				140	100.0				143	100.0								
Pt with a.e.	Female	51	54.3	100.0	95	1.86	55	48.2	100.0	106	1.92	18	19.1	100.0	28	24.6	100.0	38	1.35		
	Male	27	58.7	100.0	50	1.85	18	62.1	100.0	29	1.61	12	26.1	100.0	20	1.66	12	41.4	100.0	19	1.58
	Total	78	55.7	100.0	145	1.85	73	51.0	100.0	135	1.84	30	21.4	100.0	48	1.60	40	28.0	100.0	57	1.42
AUTONOMIC NERVOUS SYSTEM DISORDERS	Female	26	27.7	50.9	29	1.11	32	28.1	58.1	38	1.18	1	1.1	5.5	1	1.00	1	0.9	3.5	1	1.00
	Male	11	23.9	40.7	11	1.00	6	20.7	33.3	6	1.00	1	2.2	8.3	1	1.00					
	Total	37	26.4	47.4	40	1.08	38	26.6	52.0	44	1.15	2	1.4	6.6	2	1.00	1	0.7	2.5	1	1.00
GASTRO-INTESTINAL SYSTEM DISORDERS	Female	21	22.3	41.1	22	1.04	18	15.8	32.7	21	1.16	6	6.4	33.3	7	1.16	10	8.8	35.7	12	1.20
	Male	5	10.9	18.5	5	1.00	3	10.3	16.6	3	1.00	5	10.9	41.6	8	1.60	4	13.8	33.3	4	1.00
	Total	26	18.6	33.3	27	1.03	21	14.7	28.7	24	1.14	11	7.9	36.6	15	1.36	14	9.8	35.0	16	1.14
PSYCHIATRIC DISORDERS	Female	14	14.9	27.4	15	1.07	19	16.7	34.5	20	1.05	6	6.4	33.3	7	1.16	5	4.4	17.8	7	1.40
	Male	12	26.1	44.4	12	1.00	5	17.2	27.7	5	1.00	2	4.3	16.6	2	1.00	3	10.3	25.0	3	1.00
	Total	26	18.6	33.3	27	1.03	24	16.8	32.8	25	1.04	8	5.7	26.6	9	1.12	8	5.6	20.0	10	1.25
CARDIOVASCULAR DISORDERS, GENERAL	Female	10	10.6	19.6	12	1.20	10	8.8	18.1	11	1.10	5	5.3	27.7	7	1.40	7	6.1	25.0	9	1.28
	Male	4	8.7	14.8	5	1.25	2	6.9	11.1	2	1.00	3	6.5	25.0	3	1.00	3	10.3	25.0	3	1.00
	Total	14	10.0	17.9	17	1.21	12	8.4	16.4	13	1.08	8	5.7	26.6	10	1.25	10	7.0	25.0	12	1.20
URINARY SYSTEM DISORDERS	Female	3	3.2	5.8	3	1.00	1	0.9	1.8	1	1.00	1	1.1	5.5	1	1.00	1	0.9	3.5	1	1.00
	Male	10	21.7	37.0	11	1.10	7	24.1	38.8	8	1.14	1	2.2	8.3	1	1.00	4	13.8	33.3	6	1.50
	Total	13	9.3	16.6	14	1.07	8	5.6	10.9	9	1.12	2	1.4	6.6	2	1.00	5	3.5	12.5	7	1.40

(*) number of adverse events on patients who complained of adverse events
(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No: 77

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT AND GROUPED BY BODY SYSTEM

Body system/Assigned treatment	Run In Phase						Double Blind Phase														
	Placebo			Reboxetine			Placebo			Reboxetine											
	No of Pt	% on exp.	No of AE	No of Pt	% on exp.	No of AE	No of Pt	% on exp.	No of AE	No of Pt	% on exp.	No of AE									
Pt exposed	Female	94	100.0				94	100.0				114	100.0								
	Male	46	100.0				46	100.0				29	100.0								
	Total	140	100.0				140	100.0				143	100.0								
Pt with a.e.	Female	51	54.3	100.0	95	1.86	55	48.2	100.0	106	1.92	18	19.1	100.0	28	24.6	100.0	38	1.35		
	Male	27	58.7	100.0	50	1.85	18	62.1	100.0	29	1.61	12	26.1	100.0	20	1.66	12	41.4	100.0	19	1.58
	Total	78	55.7	100.0	145	1.85	73	51.0	100.0	135	1.84	30	21.4	100.0	48	1.60	40	28.0	100.0	57	1.42
AUTONOMIC NERVOUS SYSTEM DISORDERS	Female	26	27.7	50.9	29	1.11	32	28.1	58.1	38	1.18	1	1.1	5.5	1	1.00	1	0.9	3.5	1	1.00
	Male	11	23.9	40.7	11	1.00	6	20.7	33.3	6	1.00	1	2.2	8.3	1	1.00					
	Total	37	26.4	47.4	40	1.08	38	26.6	52.0	44	1.15	2	1.4	6.6	2	1.00	1	0.7	2.5	1	1.00
GASTRO-INTESTINAL SYSTEM DISORDERS	Female	21	22.3	41.1	22	1.04	18	15.8	32.7	21	1.16	6	6.4	33.3	7	1.16	10	8.8	35.7	12	1.20
	Male	5	10.9	18.5	5	1.00	3	10.3	16.6	3	1.00	5	10.9	41.6	8	1.60	4	13.8	33.3	4	1.00
	Total	26	18.6	33.3	27	1.03	21	14.7	28.7	24	1.14	11	7.9	36.6	15	1.36	14	9.8	35.0	16	1.14
PSYCHIATRIC DISORDERS	Female	14	14.9	27.4	15	1.07	19	16.7	34.5	20	1.05	6	6.4	33.3	7	1.16	5	4.4	17.8	7	1.40
	Male	12	26.1	44.4	12	1.00	5	17.2	27.7	5	1.00	2	4.3	16.6	2	1.00	3	10.3	25.0	3	1.00
	Total	26	18.6	33.3	27	1.03	24	16.8	32.8	25	1.04	8	5.7	26.6	9	1.12	8	5.6	20.0	10	1.25
CARDIOVASCULAR DISORDERS, GENERAL	Female	10	10.6	19.6	12	1.20	10	8.8	18.1	11	1.10	5	5.3	27.7	7	1.40	7	6.1	25.0	9	1.28
	Male	4	8.7	14.8	5	1.25	2	6.9	11.1	2	1.00	3	6.5	25.0	3	1.00	3	10.3	25.0	3	1.00
	Total	14	10.0	17.9	17	1.21	12	8.4	16.4	13	1.08	8	5.7	26.6	10	1.25	10	7.0	25.0	12	1.20
URINARY SYSTEM DISORDERS	Female	3	3.2	5.8	3	1.00	1	0.9	1.8	1	1.00	1	1.1	5.5	1	1.00	1	0.9	3.5	1	1.00
	Male	10	21.7	37.0	11	1.10	7	24.1	38.8	8	1.14	1	2.2	8.3	1	1.00	4	13.8	33.3	6	1.50
	Total	13	9.3	16.6	14	1.07	8	5.6	10.9	9	1.12	2	1.4	6.6	2	1.00	5	3.5	12.5	7	1.40

(* number of adverse events on patients who complained of adverse events)

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PRANACTA CNS 28D

REBOXETINE - PROTOCOL 20124/013
TABLE No: 77

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS AND PATIENTS WHO COMPLAINED OF THEM DURING THERAPY BY ASSIGNED TREATMENT AND GROUPED BY BODY SYSTEM

Body system/Assigned treatment	Run In Phase						Double Blind Phase									
	Placebo			Reboxetine			Placebo			Reboxetine						
	No of Pt	% on exp.	No of AE with AE	No of Pt	% on exp.	No of AE with AE	No of Pt	% on exp.	No of AE with AE	No of Pt	% on exp.	No of AE with AE				
MUSCULO-SKELETAL SYSTEM DISORDERS	1	2.2	3.7	1	1.00											
REPRODUCTIVE DISORDERS, MALE																
Male																
Total	1	0.7	1.2	1	1.00									1	3.4	5.3
Male														1	0.7	2.5
Total														1	0.7	2.5

249

(*) number of adverse events on patients who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 78

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT

Run In Phase

Adverse events / Assigned treatment	Total	Days of treatment																
		0-7		8-14		15-21		22-28		29-35		36-42						
		No A.E.	%	No A.E.	%	No A.E.	%	No A.E.	%	No A.E.	%	No A.E.	%					
MOUTH DRY		27	100	21	77.8	4	14.8	2	7.4									
		31	100	21	67.7	4	12.9	3	9.7	1	3.2					2	6.5	
CONSTIPATION		27	100	15	55.6	4	14.8	2	7.4	3	11.1	1	3.7	2	7.4			
		26	100	12	46.2	2	7.7	8	30.8	1	3.8	2	7.7	1	3.8			
INSOMNIA		24	100	18	75.0	4	16.7	1	4.2	1	4.2							
		17	100	10	58.8	3	17.6	1	5.9									
LIBIDO DECREASED		5	100	4	80.0											1	20.0	
		9	100	6	66.7	1	11.1	1	11.1							1	11.1	
MICTURITION DISORDER		9	100	3	33.3	4	44.4	1	11.1								1	11.1
		10	100	7	70.0	1	10.0	1	10.0							1	10.0	
SWEATING INCREASED		12	100	9	75.0	1	8.3									1	8.3	
		13	100	10	76.9	2	15.4									1	7.7	
VISION ABNORMAL		3	100	1	33.3	1	33.3	1	33.3									
		6	100	2	33.3	2	33.3	2	33.3									
TACHYCARDIA		8	100	3	37.5	1	12.5	1	12.5	3	37.5							
		6	100	2	33.3	1	16.7	1	16.7	1	16.7						1	16.7
DIZZINESS		8	100	5	62.5													
		7	100	1	14.3	3	42.9											
TREMOR		6	100	2	33.3	2	33.3											
		1	100			1	100											
PARAESTHESIA		5	100	3	60.0													
		2	100	2	100													

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
TABLE No.: 78

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT

Run In Phase

Adverse events / Assigned treatment	Total	Days of treatment														
		0-7		8-14		15-21		22-28		29-35		36-42				
		No A.E.	%	No A.E.	%	No A.E.	%	No A.E.	%	No A.E.	%	No A.E.	%			
URINARY RETENTION	4	100	3	75.0												
	2	100	1	50.0												
HEADACHE	5	100	3	60.0	1	20.0										
ANOREXIA	1	100	1	100												
	1	100					1	100								
EIGORS	1	100	1	100												
NAUSEA	1	100	1	100												
	1	100	1	100												
RHINITIS	1	100	1	100												
EJACULATION FAILURE	1	100					1	100								
RASH	1	100													1	100
BACK PAIN	1	100	1	100												
FATIGUE	1	100								1	100					
VOMITING	1	100	1	100												
HYPOTENSION POSTURAL	1	100	1	100												
PALPITATION	1	100								1	100					
LACRIMAL GLAND DISORDER	1	100	1	100												
PERINEAL PAIN MALE	1	100	1	100												
NERVOUSNESS	1	100								1	100					
ACNE	1	100													1	100
OEDEMA PERIPHERAL	1	100													1	100

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
TABLE No.: 78

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT

Run In Phase

Adverse events / Assigned treatment	Total		Days of treatment											
	No A.E.	%	0-7		8-14		15-21		22-28		29-35		36-42	
			No A.E.	%	No A.E.	%	No A.E.	%	No A.E.	%	No A.E.	%	No A.E.	%
SOMNOLENCE	2	100	2	100										
OVARIAN DISORDER	1	100			1	100								
INFECTION VIRAL	1	100							1	100				
ALBUMINURIA	1	100											1	100
FURUNCULOSIS	1	100	1	100										
VERTIGO	1	100	1	100										
VAGINITIS	1	100			1	100								
UPPER RESP TRACT INFECTION	1	100								1	100			

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 78

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT

Double Blind Phase

Adverse events / Assigned treatment	Total	Days of treatment																					
		43-70		71-98		99-126		127-154		155-182		183-210		211-238		239-266		267-294		295-322			
		No A.E.	%	No A.E.	%	No A.E.	%	No A.E.	%	No A.E.	%	No A.E.	%	No A.E.	%	No A.E.	%	No A.E.	%	No A.E.	%		
MOUTH DRY	1	100					1	100															
CONSTIPATION	6	100	2	33.3	1	16.7						1	16.7								2	33.3	
INSOMNIA	14	100	6	42.9	2	14.3				4	28.6												
LIBIDO DECREASED	8	100	2	25.0	1	12.5				1	12.5											1	11.1
MICTURITION DISORDER	9	100	2	22.2	2	22.2				2	22.2												
SWEATING INCREASED	1	100																					
VISION ABNORMAL	1	100																					
TACHYCARDIA	4	100	2	50.0																			
DIZZINESS	5	100	3	60.0																			
TREMOR	2	100																					
PARAESTHESIA	2	100																					
URINARY RETENTION	1	100																					
HEADACHE	5	100	1	20.0	1	20.0																	

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 78

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT

Double Blind Phase

Adverse events / Assigned treatment	Total	Days of treatment																			
		43-70		71-98		99-126		127-154		155-182		183-210		211-238		239-266		267-294		295-322	
		No A.E.	%	No A.E.	%	No A.E.	%	No A.E.	%	No A.E.	%	No A.E.	%	No A.E.	%	No A.E.	%	No A.E.	%	No A.E.	%
HEADACHE	4	100																			
HYPERTENSION	3	100	1	33.3			1	33.3													
	5	100	1	20.0			1	20.0	1	20.0											
RIGORS																					
EJACULATION FAILURE																					
	3	100	3	100																	
RASH	5	100	1	20.0																	
DIARRHOEA	1	100																			
	1	100																			
FATIGUE																					
	2	100																			
VOMITING	1	100																			
	1	100																			
HYPOTENSION POSTURAL	1	100																			
PERINEAL PAIN MALE	1	100	1	100																	
OEDEMA PERIPHERAL	1	100	1	100																	
HYPERTRIGLYCERIDAEMIA	1	100																			
ALBUMINURIA																					
ANGINA PECTORIS	1	100	1	100																	
CHEST PAIN	1	100	1	100																	
HALLUCINATION	1	100																			
	1	100																			
PNEUMONIA	1	100																			
	1	100																			

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 78

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT

Double Blind Phase

Adverse events / Assigned treatment	Days of treatment					
	323-350		351-364		> 364	
	No A.E.	% A.E.	No A.E.	% A.E.	No A.E.	% A.E.
MOUTH DRY	Placebo					
	Reboxetine					
CONSTIPATION	Placebo					
	Reboxetine					
INSOMNIA	Placebo	1	12.5			
	Reboxetine					
LIBIDO DECREASED	Placebo					
	Reboxetine					
MICTURITION DISORDER	Placebo					
	Reboxetine					
SWEATING INCREASED	Placebo					
	Reboxetine					
VISION ABNORMAL	Placebo					
	Reboxetine					
TACHYCARDIA	Placebo	1	25.0			
	Reboxetine					
DIZZINESS	Placebo					
	Reboxetine					
TREMOR	Placebo					
	Reboxetine					
PARAESTHESIA	Placebo	1	50.0			
	Reboxetine					
URINARY RETENTION	Placebo					
	Reboxetine					
HEADACHE	Placebo					
	Reboxetine					

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 TABLE No.: 78
 ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT
 Double Blind Phase

Adverse events / Assigned treatment	Days of treatment					
	323-350		351-364		> 364	
	No A.E.	%	No A.E.	%	No A.E.	%
HEADACHE	Reboxetine					
HYPERTENSION	Placebo					
	Reboxetine					
RIGORS	Reboxetine					
	Placebo					
EJACULATION FAILURE	Reboxetine					
	Placebo					
RASH	Reboxetine					
	Placebo					
DIARRHOEA	Reboxetine					
	Placebo					
FATIGUE	Reboxetine	1	100			
	Placebo					
VOMITING	Placebo					
	Reboxetine					
HYPOTENSION POSTURAL	Placebo					
	Reboxetine					
PERINEAL PAIN MALE	Placebo					
	Reboxetine					
OEDEMA PERIPHERAL	Placebo					
	Reboxetine					
ALBUMINURIA	Placebo					
	Reboxetine					
ANGINA PECTORIS	Placebo					
	Reboxetine					
CHEST PAIN	Placebo					
	Reboxetine					
HALLUCINATION	Placebo					
	Reboxetine					
PNEUMONIA	Placebo					
	Reboxetine					

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013

TABLE No.: 79

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND GROUPED BY BODY SYSTEM

Run In Phase

Body system / Assigned treatment	Total	Days of treatment													
		0-7		8-14		15-21		22-28		29-35		36-42			
		No A.E.	% Z	No A.E.	% Z	No A.E.	% Z	No A.E.	% Z	No A.E.	% Z	No A.E.	% Z		
AUTONOMIC NERVOUS SYSTEM DISORDERS	Placebo	40	100	30	75.0	6	15.0	2	5.0	1	2.5			1	2.5
	Reboxetine	44	100	31	70.5	6	13.6	3	6.8	1	2.3	1	2.3	2	4.5
GASTRO-INTESTINAL SYSTEM DISORDERS	Placebo	30	100	18	60.0	4	13.3	2	6.7	3	10.0	1	3.3	2	6.7
	Reboxetine	28	100	13	46.4	2	7.1	9	32.1	1	3.6	2	7.1	1	3.6
PSYCHIATRIC DISORDERS	Placebo	30	100	22	73.3	5	16.7	1	3.3	1	3.3	1	3.3		
	Reboxetine	28	100	18	64.3	4	14.3	4	14.3	1	3.6	1	3.6		
URINARY SYSTEM DISORDERS	Placebo	14	100	6	42.9	4	28.6	1	7.1	1	7.1			2	14.3
	Reboxetine	12	100	8	66.7	1	8.3	2	16.7			1	8.3		
CARDIOVASCULAR DISORDERS, GENERAL	Placebo	16	100	8	50.0	1	6.3	2	12.5	5	31.3				
	Reboxetine	16	100	4	25.0	4	25.0	2	12.5	5	31.3			1	6.3
CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO	Placebo	11	100	5	45.5	2	18.2	1	9.1	2	18.2	1	9.1		
	Reboxetine	9	100	6	66.7	2	22.2	1	11.1						
VISION DISORDERS	Placebo	3	100	1	33.3	1	33.3	1	33.3						
	Reboxetine	7	100	3	42.9	2	28.6							2	28.6
BODY AS A WHOLE-GENERAL DISORDERS	Placebo	1	100							1	100				
	Reboxetine	1	100	1	100										
SKIN AND APPENDAGES DISORDERS	Placebo	2	100											1	50.0
	Reboxetine	1	100												
RESPIRATORY SYSTEM DISORDERS	Placebo	1	100												
	Reboxetine	1	100	1	100										
MUSCULO-SKELETAL SYSTEM DISORDERS	Placebo	1	100	1	100										

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 79

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET
BY ASSIGNED TREATMENT AND GROUPED BY BODY SYSTEM

Run In Phase

Body system / Assigned treatment	Total		Days of treatment											
	No A.E.	Z	0-7		8-14		15-21		22-28		29-35		36-42	
			No A.E.	Z	No A.E.	Z	No A.E.	Z	No A.E.	Z	No A.E.	Z		
RESISTANCE MECHANISM DISORDERS	1	100	1	100										
	1	100						1	100					
REPRODUCTIVE DISORDERS, MALE	1	100	1	100										
	1	100			1	100								
REPRODUCTIVE DISORDERS, FEMALE	1	100			1	100								
	1	100			1	100								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
TABLE No.: 79

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET
BY ASSIGNED TREATMENT AND GROUPED BY BODY SYSTEM

Body system / Assigned treatment	Total	Days of treatment																							
		43-70		71-98		99-126		127-154		155-182		183-210		211-238		239-266		267-294		295-322					
		No A.E.	%	No A.E.	%	No A.E.	%	No A.E.	%	No A.E.	%	No A.E.	%	No A.E.	%	No A.E.	%	No A.E.	%	No A.E.	%				
AUTONOMIC NERVOUS SYSTEM DISORDERS	2	100																							
Placebo	2	100																							
Reboxetine	1	100																							
GASTRO-INTESTINAL SYSTEM DISORDERS	13	100	3	23.1	2	15.4															2	15.4			
Placebo	13	100	3	23.1	2	15.4																2	15.4		
Reboxetine	16	100	6	37.5	2	12.5																			
PSYCHIATRIC DISORDERS	10	100	2	20.0	2	20.0	3	30.0	1	10.0															
Placebo	10	100	2	20.0	2	20.0	2	20.0	2	20.0															
Reboxetine	10	100	2	20.0	2	20.0	2	20.0	2	20.0															
URINARY SYSTEM DISORDERS	2	100																							
Placebo	2	100																							
Reboxetine	5	100	2	40.0			1	20.0																	
CARDIOVASCULAR DISORDERS, GENERAL	11	100	2	18.2	1	9.1																	1	9.1	
Placebo	11	100	2	18.2	1	9.1																		1	9.1
Reboxetine	12	100	5	41.7			1	8.3	1	8.3															
CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO	9	100	1	11.1	2	22.2																			
Placebo	9	100	1	11.1	2	22.2																			
Reboxetine	4	100			1	25.0																			
VISION DISORDERS	1	100																							
Placebo	1	100																							
Reboxetine	1	100																							
BODY AS A WHOLE-GENERAL DISORDERS	1	100	1	100																					
Placebo	1	100	1	100																					
Reboxetine	3	100	3	100																					
SKIN AND APPENDAGES DISORDERS	1	100																							
Placebo	1	100																							
Reboxetine	1	100																							
REPRODUCTIVE DISORDERS, MALE	1	100	1	100																					
Placebo	1	100	1	100																					
Reboxetine																									

(CONTINUED) 21 6

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 79

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET
BY ASSIGNED TREATMENT AND GROUPED BY BODY SYSTEM

Double Blind Phase

Body system / Assigned treatment	Total		Days of treatment																				
	No A.E.	Z	43-70		71-98		99-126		127-154		155-182		183-210		211-238		239-266		267-294		295-322		
			No A.E.	Z	No A.E.	Z	No A.E.	Z	No A.E.	Z	No A.E.	Z	No A.E.	Z	No A.E.	Z	No A.E.	Z	No A.E.	Z	No A.E.	Z	
METABOLIC AND NUTRITIONAL DISORDERS	1	100																					
Reboxetine							1	100															

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 79

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND GROUPED BY BODY SYSTEM

Double Blind Phase

Body system / Assigned treatment	Days of treatment					
	323-350		351-364		> 364	
	No A.E.	%	No A.E.	%	No A.E.	%
AUTONOMIC NERVOUS SYSTEM DISORDERS						
Placebo						
Reboxetine						
GASTRO-INTESTINAL SYSTEM DISORDERS						
Placebo						
Reboxetine	1	6.3				
PSYCHIATRIC DISORDERS						
Placebo	1	10.0				
Reboxetine						
URINARY SYSTEM DISORDERS						
Placebo						
Reboxetine						
CARDIOVASCULAR DISORDERS, GENERAL						
Placebo	1	9.1				
Reboxetine						
CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO						
Placebo	1	11.1				
Reboxetine						
VISION DISORDERS						
Placebo						
Reboxetine						
BODY AS A WHOLE-GENERAL DISORDERS						
Placebo						
Reboxetine						
SKIN AND APPENDAGES DISORDERS						
Placebo						
Reboxetine						
RESISTANCE MECHANISM DISORDERS						
Placebo						
Reboxetine						
REPRODUCTIVE DISORDERS, MALE						
Placebo						
Reboxetine						

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 79

ADVERSE EVENTS: OCCURRENCE OF ADVERSE EVENTS ACCORDING TO TIME OF ONSET BY ASSIGNED TREATMENT AND GROUPED BY BODY SYSTEM

Double Blind Phase

Body system / Assigned treatment	Days of treatment					
	323-350		351-364		> 364	
	No A.E.	Z A.E.	No A.E.	Z A.E.	No A.E.	Z A.E.
METABOLIC AND NUTRITIONAL DISORDERS						
Reboxetine						

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
TABLE No.: 80

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Run In Phase

Adverse events / Severity	Placebo						Reboxetine												
	Female			Male			Female			Male			Total						
	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z				
All adverse events	Mild	36	66.7	66.7	16	59.3	59.3	52	64.2	64.2	35	61.4	61.4	12	63.2	63.2	47	61.8	61.8
	Moderate	13	24.1	24.1	11	40.7	40.7	24	29.6	29.6	19	33.3	33.3	5	26.3	26.3	24	31.6	31.6
	Severe	5	9.3	9.3				5	6.2	6.2	3	5.3	5.3	2	10.5	10.5	5	6.6	6.6
	Total	54	100.0	100.0	27	100.0	100.0	81	100.0	100.0	57	100.0	100.0	19	100.0	100.0	76	100.0	100.0
CONSTIPATION	Mild	17	89.5	31.5	4	57.1	14.8	21	80.8	25.9	16	80.0	28.1	2	50.0	10.5	18	75.0	23.7
	Moderate	2	10.5	3.7	3	42.9	11.1	5	19.2	6.2	4	20.0	7.0	2	50.0	10.5	6	25.0	7.9
	Total	19	100.0	35.2	7	100.0	25.9	26	100.0	32.1	20	100.0	35.1	4	100.0	21.1	24	100.0	31.6
	Mild	12	66.7	22.2	6	66.7	22.2	18	66.7	22.2	20	87.0	35.1	3	100.0	15.8	23	88.5	30.3
MOUTH DRY	Moderate	5	27.8	9.3	3	33.3	11.1	8	29.6	9.9	3	13.0	5.3				3	11.5	3.9
	Severe	1	5.6	1.9				1	3.7	1.2									
	Total	18	100.0	33.3	9	100.0	33.3	27	100.0	33.3	23	100.0	40.4	3	100.0	15.8	26	100.0	34.2
	Mild	10	62.5	18.5	4	57.1	14.8	14	60.9	17.3	9	60.0	15.8	1	50.0	5.3	10	58.8	13.2
INSOMNIA	Moderate	5	31.3	9.3	3	42.9	11.1	8	34.8	9.9	6	40.0	10.5	1	50.0	5.3	7	41.2	9.2
	Severe	1	6.3	1.9				1	4.3	1.2									
	Total	16	100.0	29.6	7	100.0	25.9	23	100.0	28.4	15	100.0	26.3	2	100.0	10.5	17	100.0	22.4
	Mild	9	90.0	16.7	1	100.0	3.7	10	90.9	12.3	5	55.6	8.8	3	100.0	15.8	8	66.7	10.5
SWEATING INCREASED	Moderate	1	10.0	1.9				1	9.1	1.2	4	44.4	7.0				4	33.3	5.3
	Total	10	100.0	18.5	1	100.0	3.7	11	100.0	13.6	9	100.0	15.8	3	100.0	15.8	12	100.0	15.8
	Mild				6	85.7	22.2	6	75.0	7.4	1	100.0	1.8	6	75.0	31.6	7	77.8	9.2
	Severe	1	100.0	1.9	1	14.3	3.7	1	12.5	1.2				1	12.5	5.3	1	11.1	1.3
HICTURITION DISORDER	Mild																		
	Moderate				1	14.3	3.7	1	12.5	1.2									
	Severe	1	100.0	1.9				1	12.5	1.2				1	12.5	5.3	1	11.1	1.3
	Total				1	14.3	3.7	1	12.5	1.2				1	12.5	5.3	1	11.1	1.3

(*) Z on all patient with adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 80

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Run In Phase

Adverse events / Severity	Placebo						Reboxetine												
	Female			Male			Female			Male			Total						
	No. Pt.	Z (%)	Z (%)	No. Pt.	Z (%)	Z (%)	No. Pt.	Z (%)	Z (%)	No. Pt.	Z (%)	Z (%)	No. Pt.	Z (%)	Z (%)				
MICTURITION DISORDER	Total	1	100.0	1.9	7	100.0	25.9	8	100.0	9.9	1	100.0	1.8	8	100.0	42.1	9	100.0	11.8
	Mild	1	20.0	1.9	1	33.3	3.7	2	25.0	2.5	4	80.0	7.0	1	100.0	5.3	5	83.3	6.6
	Moderate	4	80.0	7.4	2	66.7	7.4	6	75.0	7.4	1	20.0	1.8				1	16.7	1.3
	Total	5	100.0	9.3	3	100.0	11.1	8	100.0	9.9	5	100.0	8.8	1	100.0	5.3	6	100.0	7.9
DIZZINESS	Mild	4	66.7	7.4				4	57.1	4.9	4	66.7	7.0				4	66.7	5.3
	Moderate	1	16.7	1.9	1	100.0	3.7	2	28.6	2.5									
	Severe	1	16.7	1.9				1	14.3	1.2	2	33.3	3.5				2	33.3	2.6
	Total	6	100.0	11.1	1	100.0	3.7	7	100.0	8.6	6	100.0	10.5				6	100.0	7.9
LIBIDO DECREASED	Mild	1	100.0	1.9	4	100.0	14.8	5	100.0	6.2	4	80.0	7.0	2	50.0	10.5	6	66.7	7.9
	Moderate							1	20.0	1.8	1	20.0	1.8	1	25.0	5.3	2	22.2	2.6
	Severe												1	25.0	5.3	1	11.1	1.3	
	Total	1	100.0	1.9	4	100.0	14.8	5	100.0	6.2	5	100.0	8.8	4	100.0	21.1	9	100.0	11.8
HEADACHE	Mild																2	40.0	2.6
	Moderate																2	40.0	2.6
	Severe																1	20.0	1.3
	Total	2	100.0	3.7				2	66.7	2.5	1	50.0	1.8	3	100.0	15.8	4	80.0	5.3
VISION ABNORMAL	Mild																1	20.0	1.3
	Moderate																3	100.0	6.6
	Total	2	100.0	3.7	1	100.0	3.7	3	100.0	3.7	2	100.0	3.5	3	100.0	15.8	5	100.0	6.6
	Mild	5	100.0	9.3	1	100.0	3.7	6	100.0	7.4	1	100.0	1.8				1	100.0	1.3
Total	5	100.0	9.3	1	100.0	3.7	6	100.0	7.4	1	100.0	1.8	1	100.0	1.8	1	100.0	1.3	

264

(CONTINUED)

(*) Z on all patient with adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
TABLE No.: 80

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Run In Phase

Adverse events / Severity	Flacabio						Reboxetine													
	Female			Male			Total			Female			Male			Total				
	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z		
PARAESTHESIA	Mild	3	100.0	5.6	1	100.0	3.7	4	100.0	4.9	1	100.0	1.8	1	100.0	5.3	2	100.0	2.6	
	Total	3	100.0	5.6	1	100.0	3.7	4	100.0	4.9	1	100.0	1.8	1	100.0	5.3	2	100.0	2.6	
URINARY RETENTION	Mild				2	66.7	7.4	2	50.0	2.5					2	100.0	10.5	2	100.0	2.6
	Moderate				1	33.3	3.7	1	25.0	1.2										
Severe		1	100.0	1.9				1	25.0	1.2										
	Total	1	100.0	1.9	3	100.0	11.1	4	100.0	4.9					2	100.0	10.5	2	100.0	2.6
RASH	Mild	1	100.0	1.9				1	100.0	1.2										
	Total	1	100.0	1.9				1	100.0	1.2										
VOMITING	Mild	1	100.0	1.9				1	100.0	1.2										
	Total	1	100.0	1.9				1	100.0	1.2										
ANOREXIA	Mild	1	100.0	1.9				1	100.0	1.2										
	Total	1	100.0	1.9				1	100.0	1.2										
HYPOTENSION POSTURAL Moderate								1	100.0	1.2										
	Total							1	100.0	1.2										
SOMNOLENCE	Mild																			
	Total																			
NAUSEA	Mild	1	100.0	1.9				1	100.0	1.2										
	Total	1	100.0	1.9				1	100.0	1.2										
PERINEAL PAIN MALE	Mild																			
	Total																			
EDEMA PERIPHERAL	Mild																			
	Total																			

(CONTINUED)

(*) % on all patient with adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE NO.: 80

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Run In Phase

Adverse events / Severity	Placebo						Reboxetine									
	Female			Male			Female			Male			Total			
	No. Pt.	Z (%)	X Pt.	No. Pt.	Z (%)	X Pt.	No. Pt.	Z (%)	X Pt.	No. Pt.	Z (%)	X Pt.	No. Pt.	Z (%)	X Pt.	
OEDEMA PERIPHERAL																
Total																
Moderate	1	100.0	1.9			1	100.0	1.2								
Total	1	100.0	1.9			1	100.0	1.2								
VERTIGO																
Total																
Mild																
Total																
EJACULATION FAILURE																
Mild				1	100.0	3.7	1	100.0	1.2							
Total				1	100.0	3.7	1	100.0	1.2							
PALPITATION																
Moderate																
Total																
Severe																
Total																
LACRIMAL GLAND DISORDER																
Total																
Moderate																
Total																
NERVOUSNESS																
Moderate				1	100.0	3.7	1	100.0	1.2							
Total				1	100.0	3.7	1	100.0	1.2							
UPPER RESP TRACT INFECTION																
Mild	1	100.0	1.9													
Total	1	100.0	1.9													
Severe																
Total																
ALBUMINURIA																
Total																
Moderate																
Total																
OVARIAN DISORDER																
Moderate																
Total																
Moderate	1	100.0	1.9													
Total	1	100.0	1.9													

(*) Z on all patient with adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 80

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Run In Phase

Adverse events / Severity	Placebo						Reboxetine											
	Female			Male			Total			Female			Male			Total		
	No. Pt.	(*) %	Z	No. Pt.	(*) %	Z	No. Pt.	(*) %	Z	No. Pt.	(*) %	Z	No. Pt.	(*) %	Z	No. Pt.	(*) %	Z
BACK PAIN	Moderate			1	100.0	3.7	1	100.0	1.2									
	Total			1	100.0	3.7	1	100.0	1.2									
FATIGUE	Severe	1	100.0	1.9			1	100.0	1.2									
	Total	1	100.0	1.9			1	100.0	1.2									
RIGORS	Moderate																	
	Total									1	100.0	1.8				1	100.0	1.3
FURUNCULOSIS	Mild						1	100.0	3.7	1	100.0	1.2						
	Total				1	100.0	3.7	1	100.0	1.2								
RHINITIS	Mild																	
	Total									1	100.0	1.8				1	100.0	1.3
INFECTION VIRAL	Moderate																	
	Total									1	100.0	1.8				1	100.0	1.3

267

(*) % on all patient with adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACTA CMS RED

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 80

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Double Blind Phase	Placabo												Reboxetine																							
	Female						Male						Total						Female						Male						Total					
	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z						
All adverse events	Mild	17	89.5	89.5	9	69.2	69.2	26	81.3	81.3	21	75.0	75.0	8	66.7	66.7	29	72.5	72.5	29	72.5	72.5	7	17.5	17.5	4	10.0	10.0	40	100.0	100.0					
	Moderate	2	10.5	10.5	4	30.8	30.8	6	18.8	18.8	4	14.3	14.3	3	25.0	25.0	7	17.5	17.5	7	17.5	17.5	3	7.5	7.5	4	10.0	10.0	12	30.0	30.0					
	Severe																																			
	Total	19	100.0	100.0	13	100.0	100.0	32	100.0	100.0	28	100.0	100.0	12	100.0	100.0	40	100.0	100.0	40	100.0	100.0	40	100.0	100.0	10	25.0	25.0	100.0	100.0	100.0					
CONSTIPATION	Mild	4	80.0	21.1	1	100.0	7.7	5	83.3	15.6	7	77.8	25.0	2	66.7	16.7	9	75.0	22.5	9	75.0	22.5	2	16.7	5.0	2	16.7	5.0	1	8.3	2.5					
	Moderate	1	20.0	5.3				1	16.7	3.1	1	11.1	3.6	1	33.3	8.3	2	16.7	5.0	2	16.7	5.0	1	8.3	2.5	1	8.3	2.5	3	7.5	2.5					
	Severe																																			
MOUTH DRY	Total	5	100.0	26.3	1	100.0	7.7	6	100.0	18.8	9	100.0	32.1	3	100.0	25.0	12	100.0	30.0	12	100.0	30.0	3	100.0	25.0	12	100.0	30.0	12	100.0	30.0					
	Moderate							1	100.0	3.1																										
	Total				1	100.0	7.7	1	100.0	3.1																										
INSOMNIA	Mild	5	100.0	26.3				5	71.4	15.6	4	80.0	14.3	1	50.0	8.3	5	71.4	12.5	5	71.4	12.5	1	8.3	2.5	5	71.4	12.5	5	71.4	12.5					
	Moderate				2	100.0	15.4	2	28.6	6.3	1	20.0	3.6	1	50.0	8.3	2	28.6	6.3	2	28.6	6.3	1	8.3	2.5	2	28.6	6.3	2	28.6	6.3					
	Total	5	100.0	26.3	2	100.0	15.4	7	100.0	21.9	5	100.0	17.9	2	100.0	16.7	7	100.0	17.5	7	100.0	17.5	2	100.0	16.7	7	100.0	17.5	7	100.0	17.5					
SWEATING INCREASED	Mild	1	100.0	5.3				1	100.0	3.1	1	100.0	3.6				1	100.0	2.5	1	100.0	2.5				1	100.0	2.5	1	100.0	2.5					
	Total	1	100.0	5.3				1	100.0	3.1	1	100.0	3.6				1	100.0	2.5	1	100.0	2.5				1	100.0	2.5	1	100.0	2.5					
	Total	1	100.0	5.3				1	100.0	3.1	1	100.0	3.6				1	100.0	2.5	1	100.0	2.5				1	100.0	2.5	1	100.0	2.5					
MICTURITION DISORDER	Mild	1	100.0	5.3	1	100.0	7.7	2	100.0	6.3	1	100.0	3.6	2	66.7	16.7	3	75.0	7.5	3	75.0	7.5	1	8.3	2.5	3	75.0	7.5	3	75.0	7.5					
	Moderate																																			
	Total	1	100.0	5.3	1	100.0	7.7	2	100.0	6.3	1	100.0	3.6	2	66.7	16.7	3	75.0	7.5	3	75.0	7.5	1	8.3	2.5	3	75.0	7.5	3	75.0	7.5					
TACHYCARDIA	Mild	3	100.0	15.8	1	100.0	7.7	4	100.0	12.5	2	66.7	7.1	1	100.0	8.3	3	75.0	7.5	3	75.0	7.5	1	8.3	2.5	3	75.0	7.5	3	75.0	7.5					
	Severe										1	33.3	3.6				1	25.0	2.5	1	25.0	2.5				1	25.0	2.5	1	25.0	2.5					
	Total	3	100.0	15.8	1	100.0	7.7	4	100.0	12.5	3	100.0	10.7	1	100.0	8.3	4	100.0	10.0	4	100.0	10.0	1	8.3	2.5	4	100.0	10.0	4	100.0	10.0					

(*) Z on all patient with adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 80

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Double Blind Phase

Adverse events / Severity	Placebo						Reboxetine											
	Female			Male			Total			Female			Male			Total		
	No. Pt.	(*) %	Z	No. Pt.	(*) %	Z	No. Pt.	(*) %	Z	No. Pt.	(*) %	Z	No. Pt.	(*) %	Z	No. Pt.	(*) %	Z
DIZZINESS	Mild	1	100.0	5.3	1	100.0	7.7	2	100.0	6.3	1	100.0	3.6			1	100.0	2.5
	Total	1	100.0	5.3	1	100.0	7.7	2	100.0	6.3	1	100.0	3.6			1	100.0	2.5
LIBIDO DECREASED	Mild	1	100.0	5.3						3.1						1	100.0	2.5
	Total	1	100.0	5.3						3.1						1	100.0	2.5
HEADACHE	Mild	1	50.0	5.3	2	100.0	15.4	3	75.0	9.4	2	100.0	7.1	2	100.0	16.7	4	100.0
	Moderate	1	50.0	5.3				1	25.0	3.1								
VISION ABNORMAL	Total	2	100.0	10.5	2	100.0	15.4	4	100.0	12.5	2	100.0	7.1	2	100.0	16.7	4	100.0
	Mild				1	100.0	7.7	1	100.0	3.1	1	100.0	3.6			1	100.0	2.5
TREMOR	Total				1	100.0	7.7	1	100.0	3.1	1	100.0	3.6			1	100.0	2.5
	Mild				2	100.0	15.4	2	100.0	6.3								
PARAESTHESIA	Total				2	100.0	15.4	2	100.0	6.3								
	Mild	1	100.0	5.3				1	100.0	3.1								
URINARY RETENTION	Total	1	100.0	5.3				1	100.0	3.1								
	Mild																	
HYPERTENSION	Total															1	100.0	2.5
	Mild															1	100.0	2.5
DIARRHOEA	Mild	1	100.0	5.3	1	100.0	7.7	2	100.0	6.3	1	50.0	3.6	1	50.0	8.3	2	50.0
	Total	1	100.0	5.3	1	100.0	7.7	2	100.0	6.3	2	100.0	7.1	2	100.0	16.7	4	100.0
RASH	Mild	1	100.0	5.3	3	100.0	23.1	4	100.0	12.5						1	100.0	2.5
	Total	1	100.0	5.3	3	100.0	23.1	4	100.0	12.5	3	100.0	10.7	3	100.0	8.3	3	100.0

(*) % on all patient with adverse events

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
TABLE No.: 80

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Double Blind Phase

Adverse events / Severity	Placebo						Reboxetine										
	Female			Male			Female			Male			Total				
	No. Pt.	Z (%)	No. Pt.	Z (%)	No. Pt.	Z (%)	No. Pt.	Z (%)	No. Pt.	Z (%)	No. Pt.	Z (%)	No. Pt.	Z (%)	No. Pt.	Z (%)	
RASH																	
Total																	
VOMITING	1	100.0	5.3	1	100.0	7.7	2	100.0	6.3	1	100.0	3.6			3	100.0	7.5
Total	1	100.0	5.3	1	100.0	7.7	2	100.0	6.3	1	100.0	3.6			1	100.0	2.5
HYPOTENSION POSTURAL																	
Total																	
PERINEAL PAIN MALE																	
Total																	
OEDEMA PERIPHERAL	1	100.0	5.3														
Total	1	100.0	5.3														
HALLUCINATION																	
Total																	
HYPERTRIGLYCERIDEMIA																	
Total																	
ANGINA PECTORIS																	
Total																	
CHEST PAIN																	
Total																	
PNEUMONIA																	
Total																	

(*) Z on all patient with adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 81

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS, GROUPED BY BODY SYSTEM, BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Run In Phase

Body system / Severity	Placebo						Reboxetine													
	Female			Male			Female			Male			Total							
	No. Pt.	(*) %	Z	No. Pt.	(*) %	Z	No. Pt.	(*) %	Z	No. Pt.	(*) %	Z	No. Pt.	(*) %	Z					
All adverse events	Mild	36	66.7	66.7	16	59.3	59.3	64.2	64.2	35	61.4	61.4	12	63.2	63.2	47	61.8	61.8		
	Moderate	13	24.1	24.1	11	40.7	40.7	29.6	29.6	19	33.3	33.3	5	26.3	26.3	24	31.6	31.6		
	Severe	5	9.3	9.3				6.2	6.2	3	5.3	5.3	2	10.5	10.5	5	6.6	6.6		
	Total	54	100.0	100.0	27	100.0	100.0	81	100.0	100.0	57	100.0	100.0	19	100.0	100.0	76	100.0	100.0	
GASTRO-INTESTINAL SYSTEM DISORDERS	Mild	20	90.9	37.0	4	57.1	14.8	82.8	29.6	16	80.0	28.1	3	60.0	15.8	19	76.0	25.0		
	Moderate	2	9.1	3.7	3	42.9	11.1	17.2	6.2	4	20.0	7.0	2	40.0	10.5	6	24.0	7.9		
	Total	22	100.0	40.7	7	100.0	25.9	100.0	35.8	20	100.0	35.1	5	100.0	26.3	25	100.0	32.9		
	Mild	19	73.1	35.2	8	72.7	29.6	73.0	33.3	25	78.1	43.9	6	100.0	31.6	31	81.6	40.8		
AUTONOMIC NERVOUS SYSTEM DISORDERS	Moderate	6	23.1	11.1	3	27.3	11.1	24.3	11.1	7	21.9	12.3				7	18.4	9.2		
	Severe	1	3.8	1.9				2.7	1.2											
	Total	26	100.0	48.1	11	100.0	40.7	37	100.0	45.7	32	100.0	56.1	6	100.0	31.6	38	100.0	50.0	
	Mild	11	64.7	20.4	8	66.7	29.6	19	65.5	23.5	14	66.7	24.6	3	50.0	15.8	17	63.0	22.4	
PSYCHIATRIC DISORDERS	Moderate	5	29.4	9.3	4	33.3	14.8	9	31.0	11.1	7	33.3	12.3	2	33.3	10.5	9	33.3	11.8	
	Severe	1	5.9	1.9				3.4	1.2				1	16.7	5.3	1	3.7	1.3		
	Total	17	100.0	31.5	12	100.0	44.4	29	100.0	35.8	21	100.0	36.8	6	100.0	31.6	27	100.0	35.5	
	Mild	5	50.0	9.3	1	25.0	3.7	6	42.9	7.4	7	58.3	12.3	2	100.0	10.5	9	64.3	11.8	
CARDIOVASCULAR DISORDERS, GENERAL	Moderate	4	40.0	7.4	3	75.0	11.1	7	50.0	8.6	3	25.0	5.3				3	21.4	3.9	
	Severe	1	10.0	1.9				7.1	1.2	2	16.7	3.5				2	14.3	2.6		
	Total	10	100.0	18.5	4	100.0	14.8	14	100.0	17.3	12	100.0	21.1	2	100.0	10.5	14	100.0	18.4	
	Mild				8	80.0	29.6	8	61.5	9.9	1	100.0	1.8	8	80.0	42.1	9	81.8	11.8	
URINARY SYSTEM DISORDERS	Moderate				2	20.0	7.4	2	15.4	2.5						1	10.0	5.3	1	9.1

(*) % on all patient with adverse events

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 81

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS, GROUPED BY BODY SYSTEM, BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Run In Phase

Body system / Severity	Placebo						Reboxetine													
	Female			Male			Female			Male			Total							
	No. Pt.	(*) %	Z	No. Pt.	(*) %	Z	No. Pt.	(*) %	Z	No. Pt.	(*) %	Z	No. Pt.	(*) %	Z					
All adverse events	Mild	36	66.7	66.7	16	59.3	59.3	64.2	64.2	35	61.4	61.4	12	63.2	63.2	47	61.8	61.8		
	Moderate	13	24.1	24.1	11	40.7	40.7	29.6	29.6	19	33.3	33.3	5	26.3	26.3	24	31.6	31.6		
	Severe	5	9.3	9.3				6.2	6.2	3	5.3	5.3	2	10.5	10.5	5	6.6	6.6		
	Total	54	100.0	100.0	27	100.0	100.0	81	100.0	100.0	57	100.0	100.0	19	100.0	100.0	76	100.0	100.0	
GASTRO-INTESTINAL SYSTEM DISORDERS	Mild	20	90.9	37.0	4	57.1	14.8	82.8	29.6	16	80.0	28.1	3	60.0	15.8	19	76.0	25.0		
	Moderate	2	9.1	3.7	3	42.9	11.1	17.2	6.2	4	20.0	7.0	2	40.0	10.5	6	24.0	7.9		
	Total	22	100.0	40.7	7	100.0	25.9	100.0	35.8	20	100.0	35.1	5	100.0	26.3	25	100.0	32.9		
	Mild	19	73.1	35.2	8	72.7	29.6	73.0	33.3	25	78.1	43.9	6	100.0	31.6	31	81.6	40.8		
AUTONOMIC NERVOUS SYSTEM DISORDERS	Moderate	6	23.1	11.1	3	27.3	11.1	24.3	11.1	7	21.9	12.3				7	18.4	9.2		
	Severe	1	3.8	1.9				2.7	1.2											
	Total	26	100.0	48.1	11	100.0	40.7	37	100.0	45.7	32	100.0	56.1	6	100.0	31.6	38	100.0	50.0	
	Mild	11	64.7	20.4	8	66.7	29.6	19	65.5	23.5	14	66.7	24.6	3	50.0	15.8	17	63.0	22.4	
PSYCHIATRIC DISORDERS	Moderate	5	29.4	9.3	4	33.3	14.8	9	31.0	11.1	7	33.3	12.3	2	33.3	10.5	9	33.3	11.8	
	Severe	1	5.9	1.9				3.4	1.2				1	16.7	5.3	1	3.7	1.3		
	Total	17	100.0	31.5	12	100.0	44.4	29	100.0	35.8	21	100.0	36.8	6	100.0	31.6	27	100.0	35.5	
	Mild	5	50.0	9.3	1	25.0	3.7	6	42.9	7.4	7	58.3	12.3	2	100.0	10.5	9	64.3	11.8	
CARDIOVASCULAR DISORDERS, GENERAL	Moderate	4	40.0	7.4	3	75.0	11.1	7	50.0	8.6	3	25.0	5.3				3	21.4	3.9	
	Severe	1	10.0	1.9				7.1	1.2	2	16.7	3.5				2	14.3	2.6		
	Total	10	100.0	18.5	4	100.0	14.8	14	100.0	17.3	12	100.0	21.1	2	100.0	10.5	14	100.0	18.4	
	Mild				8	80.0	29.6	8	61.5	9.9	1	100.0	1.8	8	80.0	42.1	9	81.8	11.8	
URINARY SYSTEM DISORDERS	Moderate				2	20.0	7.4	2	15.4	2.5						1	10.0	5.3	1	9.1

(*) % on all patient with adverse events

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 81

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS, GROUPED BY BODY SYSTEM, BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Run In Phase

Body system / Severity	Placabo						Reboxetine												
	Female			Male			Total			Female			Male			Total			
	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	No. Pt.	Z	(*) Z	
REPRODUCTIVE DISORDERS, MALE																			
Mild																			
Total																			
RESPIRATORY SYSTEM DISORDERS																			
Mild	1	100.0	1.9				1	100.0	1.2	1	100.0	1.6							
Total	1	100.0	1.9				1	100.0	1.2	1	100.0	1.6							
MUSCULO-SKELETAL SYSTEM DISORDERS																			
Moderate				1	100.0	3.7	1	100.0	1.2										
Total				1	100.0	3.7	1	100.0	1.2										

273

(*) Z on all patient with adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REMOXTINE - PROTOCOL 20124/013
 TABLE No.: 81

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS, GROUPED BY BODY SYSTEM, BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Double Blind Phase

Body system / Severity	Placebo						Reboxetine										
	Female			Male			Female			Male			Total				
	No. Pt.	Z (%)	X (%)	No. Pt.	Z (%)	X (%)	No. Pt.	Z (%)	X (%)	No. Pt.	Z (%)	X (%)	No. Pt.	Z (%)	X (%)		
All adverse events	Mild	17	89.5	89.5	9	69.2	26	81.3	81.3	21	75.0	8	66.7	66.7	29	72.5	
	Moderate	2	10.5	10.5	4	30.8	6	18.8	18.8	4	14.3	3	25.0	25.0	7	17.5	
	Severe									3	10.7	1	8.3	8.3	4	10.0	
	Total	19	100.0	100.0	13	100.0	32	100.0	100.0	28	100.0	12	100.0	100.0	40	100.0	
GASTRO-INTESTINAL SYSTEM DISORDERS	Mild	6	85.7	31.6	5	100.0	38.5	91.7	34.4	8	80.0	3	75.0	25.0	11	78.6	
	Moderate	1	14.3	5.3				8.3	3.1	1	10.0	3.6	1	25.0	8.3	2	14.3
	Severe									1	10.0	3.6			1	7.1	
	Total	7	100.0	36.8	5	100.0	38.5	100.0	37.5	10	100.0	35.7	4	100.0	33.3	14	100.0
AUTONOMIC NERVOUS SYSTEM DISORDERS	Mild	1	100.0	5.3				50.0	3.1	1	100.0	3.6			1	100.0	
	Moderate				1	100.0	7.7	50.0	3.1								
	Total	1	100.0	5.3	1	100.0	7.7	100.0	6.3	1	100.0	3.6			1	100.0	
	Mild	6	100.0	31.6	1	33.3	7.7	77.8	21.9	4	80.0	14.3	2	66.7	16.7	6	75.0
PSYCHIATRIC DISORDERS	Moderate				2	66.7	15.4	22.2	6.3	1	20.0	3.6	1	33.3	8.3	2	25.0
	Total	6	100.0	31.6	3	100.0	23.1	100.0	28.1	5	100.0	17.9	3	100.0	25.0	8	100.0
	Mild	4	80.0	21.1	3	75.0	23.1	77.8	21.9	5	71.4	17.9	2	66.7	16.7	7	70.0
	Moderate	1	20.0	5.3	1	25.0	7.7	22.2	6.3	1	14.3	3.6	1	33.3	8.3	2	20.0
CARDIOVASCULAR DISORDERS, GENERAL	Severe									1	14.3	3.6			1	10.0	
	Total	5	100.0	26.3	4	100.0	30.8	100.0	28.1	7	100.0	25.0	3	100.0	25.0	10	100.0
	Mild	1	100.0	5.3	1	100.0	7.7	100.0	6.3	1	100.0	3.6	3	75.0	25.0	4	80.0
	Moderate												1	25.0	8.3	1	20.0
Total	1	100.0	5.3	1	100.0	7.7	100.0	6.3	1	100.0	3.6	4	100.0	33.3	5	100.0	

(*) % on all patient with adverse events

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 81

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS, GROUPED BY BODY SYSTEM, BY MAXIMAL SEVERITY LEVEL, SEX AND ASSIGNED TREATMENT

Double Blind Phase

Body system / Severity	Placebo						Reboxetine											
	Female			Male			Total			Female			Male			Total		
	No. Pt.	(*) %	Z	No. Pt.	(*) %	Z	No. Pt.	(*) %	Z	No. Pt.	(*) %	Z	No. Pt.	(*) %	Z	No. Pt.	(*) %	Z
CENTRAL & PERIPHERAL NERVOUS SYSTEM DISD	2	66.7	10.5	3	100.0	23.1	5	83.3	15.6	2	100.0	7.1	2	100.0	16.7	4	100.0	10.0
	1	33.3	5.3				1	16.7	3.1									
	3	100.0	15.8	3	100.0	23.1	6	100.0	18.8	2	100.0	7.1	2	100.0	16.7	4	100.0	10.0
VISION DISORDERS				1	100.0	7.7	1	100.0	3.1	1	100.0	3.6				1	100.0	2.5
				1	100.0	7.7	1	100.0	3.1	1	100.0	3.6				1	100.0	2.5
							3	100.0	10.7	3	100.0	10.7				3	100.0	7.5
SKIN AND APPENDAGES DISORDERS							3	100.0	10.7	3	100.0	10.7				3	100.0	7.5
							1	100.0	3.6	1	100.0	3.6				1	100.0	2.5
							1	100.0	3.6	1	100.0	3.6				1	100.0	2.5
RESISTANCE MECHANISM DISORDERS													1	100.0	8.3	1	100.0	2.5
													1	100.0	8.3	1	100.0	2.5
													1	100.0	8.3	1	100.0	2.5
REPRODUCTIVE DISORDERS, MALE													1	100.0	8.3	1	100.0	2.5
													1	100.0	8.3	1	100.0	2.5
													1	100.0	8.3	1	100.0	2.5
METABOLIC AND NUTRITIONAL DISORDERS							1	100.0	3.6							1	100.0	2.5
							1	100.0	3.6							1	100.0	2.5
							1	100.0	3.6							1	100.0	2.5

(*) % on all patient with adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CIS RED

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 82

ADVERSE EVENTS: DURATION OF EPISODES (*) BY ASSIGNED TREATMENT

Adverse events/Assigned treatment	Run In Phase						Double Blind Phase					
	No of Adverse events	Duration of episodes (days)			No of Adverse events	Duration of episodes (days)						
		Min	50%	90%		Max	Min	50%	90%	Max		
All adverse events	151	2	39	167	298	48	1	19	62	121		
	149	1	40	356	364	56	1	28	189	314		
CONSTIPATION	27	3	42	170	208	6	35	43	83	83		
	26	2	96	313	362	14	11	91	191	314		
MOUTH DRY	27	4	43	284	298	1	12	12	12	12		
	31	3	104	362	364							
INSOMNIA	24	3	58	141	208	8	8	18	57	57		
	17	8	47	170	196	9	14	21	84	84		
SWEATING INCREASED	12	8	40	62	75	1	47	47	47	47		
	13	3	20	299	362	1	286	286	286	286		
MICTURITION DISORDER	9	6	40	256	256	2	20	25	29	29		
	10	5	25	362	364	4	67	118	207	207		
TACHYCARDIA	8	5	31	105	105	4	6	6	8	8		
	6	7	12	22	22	5	2	9	32	32		
DIZZINESS	8	3	18	40	40	2	46	54	62	62		
	7	12	19	41	41	1	22	22	22	22		
LIBIDO DECREASED	5	38	168	283	283	1	33	33	33	33		
	9	54	295	360	360	1	123	123	123	123		
HEADACHE						5	8	18	46	46		
	5	2	6	122	122	4	3	9	13	13		
VISION ABNORMAL	3	32	40	132	132	1	20	20	20	20		

(CONTINUED)

(*) adverse event present before start treatment: onset date = start treatment date of first report visit with changed severity
adverse event still present at end of study: end date = visit date of last report visit

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS RED

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 82

ADVERSE EVENTS: DURATION OF EPISODES (*) BY ASSIGNED TREATMENT

Adverse events/Assigned treatment	Run In Phase						Double Blind Phase					
	No of Adverse events	Duration of episodes (days)			No of Adverse events	Duration of episodes (days)						
		Min	50Z	90Z		Max	Min	50Z	90Z	Max		
VISION ABNORMAL	Reboxetine	6	5	18	360	360	360	1	10	10	10	10
	Placebo	5	5	13	50	50	50	2	24	73	121	121
PARAESTHESIA	Reboxetine	2	19	29	39	39	39					
	Placebo	6	28	69	153	153	153	2	21	22	23	23
TREMOR	Reboxetine	1	11	11	11	11	11					
	Placebo							3	1	17	99	99
HYPERTENSION	Reboxetine							5	1	2	139	139
	Placebo	4	2	7	13	13	13					
URINARY RETENTION	Reboxetine	2	40	59	77	77	77	1	260	260	260	260
	Placebo							5	3	9	16	16
DIARRHOEA	Reboxetine							1	8	8	8	8
	Placebo	1	11	11	11	11	11					
RASH	Reboxetine							3	14	17	38	38
	Placebo	1	2	2	2	2	2	2	3	4	5	5
VOMITING	Reboxetine							1	9	9	9	9
	Placebo	1	32	32	32	32	32					
ANOREXIA	Reboxetine	1	22	22	22	22	22					
	Placebo							1	4	4	4	4
HYPOTENSION POSTURAL	Reboxetine	1	16	16	16	16	16					
	Placebo	2	1	2	3	3	3					
SOMNOLENCE	Reboxetine											
	Placebo	1	30	30	30	30	30					
NAUSEA												

(CONTINUED)

(*) adverse event present before start treatment: onset date = start treatment date of first report visit with changed severity
adverse event still present at end of study: end date = visit date of last report visit

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 82

ADVERSE EVENTS: DURATION OF EPISODES (*) BY ASSIGNED TREATMENT

Adverse events/Assigned treatment	Run In Phase						Double Blind Phase								
	No of Adverse events	Duration of episodes (days)			No of Adverse events	Duration of episodes (days)									
		Min	50Z	90Z		Max	Min	50Z	90Z	Max					
NAUSEA	1	11	11	11	11										
PERINEAL PAIN MALE	1	13	13	13	13					1	29	29	29	29	29
OEDEMA PERIPHERAL										1	15	15	15	15	15
	1	9	9	9	9										
ACNE	1	16	16	16	16										
VERTIGO	1	1	1	1	1										
EJACULATION FAILURE	1	60	60	60	60										
PALPITATION	1	20	20	20	20										
LACRIMAL GLAND DISORDER	1	11	11	11	11										
HALLUCINATION										1	2	2	2	2	2
NERVOUSNESS	1	11	11	11	11										
HYPERTRIGLYCERIDAEMIA										1	57	57	57	57	57
ANGINA PECTORIS										1	29	29	29	29	29
UPPER RESP TRACT INFECTION	1	4	4	4	4										
ALBUMINURIA	1	8	8	8	8										
OVARIAN DISORDER	1	12	12	12	12										
VAGINITIS	1	6	6	6	6										
BACK PAIN	1	31	31	31	31										
CHEST PAIN										1	13	13	13	13	13
FATIGUE	1	31	31	31	31										
RIGORS	1	124	124	124	124										

(CONTINUED)

(*) adverse event present before start treatment: onset date = start treatment date of first report visit with changed severity
adverse event still present at end of study: end date = visit date of last report visit

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS RED

REBOXETINE - PROTOCOL 20124-013
TABLE No.: 82

ADVERSE EVENTS: DURATION OF EPISODES (*) BY ASSIGNED TREATMENT

Adverse events/Assigned treatment	Run In Phase						Double Blind Phase						
	No of Adverse events	Duration of episodes (days)			No of Adverse events	Duration of episodes (days)							
		Min	50Z	90Z		Max	Min	50Z	90Z	Max			
FURUNCULOSIS	1	5	5	5	5								
PNEUMONIA													
RHINITIS	1	40	40	40	40			24	24			24	24
INFECTION VIRAL	1	3	3	3	3								

279

(*) adverse event present before start treatment: onset date = start treatment date of first report visit with changed severity
adverse event still present at end of study: end date = visit date of last report visit

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 83

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY SYMPTOMATIC TREATMENT AND ASSIGNED TREATMENT

Adverse events/Assigned treatment	Symptomatic treatment											
	Run In Phase						Double Blind Phase					
	YES		NO		Total		YES		NO		Total	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
No. of pt. with A.E.	10	12.3	71	87.7	81	100.0	2	6.3	30	93.8	32	100.0
	10	13.2	66	86.8	76	100.0	7	17.5	33	82.5	40	100.0
No. of adverse events	11	7.3	140	92.7	151	100.0	3	6.3	45	93.8	48	100.0
	11	7.4	138	92.6	149	100.0	12	21.4	44	78.6	56	100.0
CONSTIPATION			27	100.0	27	100.0					6	100.0
	1	3.8	25	96.2	26	100.0	1	7.1	13	92.9	14	100.0
MOUTH DRY			27	100.0	27	100.0					1	100.0
			31	100.0	31	100.0						
INSOMNIA	7	29.2	17	70.8	24	100.0	1	12.5	7	87.5	8	100.0
	6	35.3	11	64.7	17	100.0	4	44.4	5	55.6	9	100.0
SWEATING INCREASED			12	100.0	12	100.0					1	100.0
			13	100.0	13	100.0					1	100.0
MICTURITION DISORDER			9	100.0	9	100.0					2	100.0
			10	100.0	10	100.0					4	100.0
TACHYCARDIA	1	12.5	7	87.5	8	100.0					4	100.0
			6	100.0	6	100.0					5	100.0
DIZZINESS			8	100.0	8	100.0					2	100.0
			7	100.0	7	100.0					1	100.0
LIBIDO DECREASED			5	100.0	5	100.0					1	100.0
			9	100.0	9	100.0					1	100.0
HEADACHE							1	20.0	4	80.0	5	100.0
	1	20.0	4	80.0	5	100.0					4	100.0

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 83

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY SYMPTOMATIC TREATMENT AND ASSIGNED TREATMENT

Adverse events/Assigned treatment	Symptomatic treatment											
	Run In Phase						Double Blind Phase					
	YES		NO		Total		YES		NO		Total	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
VISION ABNORMAL	Placebo		3	100.0	3	100.0			1	100.0	1	100.0
	Reboxetine		6	100.0	6	100.0			1	100.0	1	100.0
PARESTHESIA	Placebo		5	100.0	5	100.0			2	100.0	2	100.0
	Reboxetine		2	100.0	2	100.0						
TREMOR	Placebo		6	100.0	6	100.0			2	100.0	2	100.0
	Reboxetine		1	100.0	1	100.0						
HYPERTENSION	Placebo						1	33.3	2	66.7	3	100.0
	Reboxetine						5	100.0			5	100.0
URINARY RETENTION	Placebo	2	50.0	2	50.0	4	100.0					
	Reboxetine			2	100.0	2	100.0			1	100.0	
DIARRHOEA	Placebo									5	100.0	
	Reboxetine									1	100.0	
RASH	Placebo			1	100.0	1	100.0					
	Reboxetine											
VOMITING	Placebo			1	100.0	1	100.0			2	100.0	
	Reboxetine									1	100.0	
ANOREXIA	Placebo			1	100.0	1	100.0			3	100.0	
	Reboxetine									2	100.0	
HYPOTENSION POSTURAL	Placebo			1	100.0	1	100.0			1	100.0	
	Reboxetine											
SOMNOLENCE	Placebo			1	100.0	1	100.0					
	Reboxetine			2	100.0	2	100.0					
NAUSEA	Placebo			1	100.0	1	100.0					
	Reboxetine											

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 83

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY SYMPTOMATIC TREATMENT AND ASSIGNED TREATMENT

Adverse events/Assigned treatment	Symptomatic treatment											
	Run In Phase						Double Blind Phase					
	YES		NO		Total		YES		NO		Total	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
NAUSEA												
OEDEMA PERIPHERAL												
PERINEAL PAIN MALE												
ACNE												
VERTIGO												
PALPITATION												
HYPERTRIGLYCERIDAEMIA												
ANGINA PECTORIS												
UPPER RESP TRACT INFECTION												
ALBUMINURIA												
OVARIAN DISORDER												
VAGINITIS												
CHEST PAIN												
FATIGUE												
RIGORS												
RHINITIS												
INFECTION VIRAL												
EJACULATION FAILURE												
LACRIMAL GLAND DISORDER												
HALLUCINATION												

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 83

ADVERSE EVENTS: NUMBER OF ADVERSE EVENTS BY SYMPTOMATIC TREATMENT AND ASSIGNED TREATMENT

Adverse events/Assigned treatment	Symptomatic treatment											
	Run In Phase						Double Blind Phase					
	YES		NO		Total		YES		NO		Total	
	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z
NERVOUSNESS			1	100.0	1	100.0						
BACK PAIN	1	100.0			1	100.0						
FURUNCULOSIS					1	100.0						
PNEUMONIA							1	100.0			1	100.0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124-013
TABLE No.: 84

ADVERSE EVENTS BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Run In Phase	Adverse events/Assigned treatment	Study drug											
		No change		Dose reduced		Temporarily interrupted		Definitively withdrawn		Unknown		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
All adverse events	Placebo	148	98.0	2	1.3			1	0.7			151	100.0
	Reboxetine	138	92.6	2	1.3			8	5.4	1	0.7	149	100.0
CONSTIPATION	Placebo	26	96.3					1	3.7			27	100.0
	Reboxetine	23	88.5					3	11.5			26	100.0
MOUTH DRY	Placebo	27	100.0									27	100.0
	Reboxetine	29	93.5					2	6.5			31	100.0
INSOMNIA	Placebo	24	100.0									24	100.0
	Reboxetine	17	100.0									17	100.0
SWEATING INCREASED	Placebo	12	100.0									12	100.0
	Reboxetine	12	92.3	1	7.7							13	100.0
MICTURITION DISORDER	Placebo	9	100.0									9	100.0
	Reboxetine	10	100.0									10	100.0
TACHICARDIA	Placebo	8	100.0									8	100.0
	Reboxetine	6	100.0									6	100.0
DIZZINESS	Placebo	8	100.0									8	100.0
	Reboxetine	7	100.0									7	100.0
LIBIDO DECREASED	Placebo	5	100.0									5	100.0
	Reboxetine	7	77.8					2	22.2			9	100.0
HEADACHE	Reboxetine	5	100.0									5	100.0
	Placebo	3	100.0									3	100.0
VISION ABNORMAL	Reboxetine	6	100.0									6	100.0
	Placebo	5	100.0									5	100.0

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOZETINE - PROTOCOL 20124/013
TABLE No.: 84

ADVERSE EVENTS BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Run In Phase

Adverse events/Assigned treatment	Study drug																			
	No change			Dose reduced			Temporarily interrupted			Definitively withdrawn			Unknown			Total				
	No.	Z	No. %	No.	Z	No. %	No.	Z	No. %	No.	Z	No. %	No.	Z	No. %	No.	Z	No. %		
PARAESTHESIA																				
	2		100.0																2	100.0
TREMOR																				
	6		100.0																6	100.0
URINARY RETENTION																				
	1		100.0																1	100.0
	3		75.0	1		25.0													4	100.0
VOMITING																				
	1		50.0						1		50.0								2	100.0
RASH																				
	1		100.0																1	100.0
HYPOTENSION POSTURAL																				
	1		100.0																1	100.0
DEDEMA PERIPHERAL																				
	1		100.0																1	100.0
ANOREXIA																				
	1		100.0																1	100.0
NAUSEA																				
	1		100.0																1	100.0
SOMNOLENCE																				
	1		100.0																1	100.0
PERINEAL PAIN MALE																				
	2		100.0																2	100.0
EJACULATION FAILURE																				
	1		100.0																1	100.0
FATIGUE																				
	1		100.0																1	100.0
RIGORS																				
	1		100.0																1	100.0
BACK PAIN																				
	1		100.0																1	100.0
OVARIAN DISORDER																				
	1		100.0																1	100.0
VAGINITIS																				
	1		100.0																1	100.0
FURUNCULOSIS																				
	1		100.0																1	100.0

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOZETINE - PROTOCOL 20124/013
TABLE No.: 84

ADVERSE EVENTS BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Run In Phase

Adverse events/Assigned treatment	Study drug																		
	No change			Dose reduced			Temporarily interrupted			Definitively withdrawn			Unknown			Total			
	No.	Z	No. %	No.	Z	No. %	No.	Z	No. %	No.	Z	No. %	No.	Z	No. %	No.	Z	No. %	
PARAESTHESIA																			
TRENDOR																			
URINARY RETENTION																			
VOMITING																			
RASH																			
HYPOTENSION POSTURAL																			
DEDEMA PERIPHERAL																			
ANOREXIA																			
NAUSEA																			
SOMNOLENCE																			
PERINEAL PAIN MALE																			
EJACULATION FAILURE																			
FATIGUE																			
RIGORS																			
BACK PAIN																			
OVARIAN DISORDER																			
VAGINITIS																			
FURUNCULOSIS																			

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 84

ADVERSE EVENTS BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Double Blind Phase

Adverse events/Assigned treatment	No change						Dose reduced						Temporarily interrupted						Definitively withdrawn						Total					
	No.		%		%		No.		%		%		No.		%		%		No.		%		%		No.		%		%	
All adverse events	Placebo	42	87.5																											
	Reboxetine	49	87.5	1	1.8																									
CONSTIPATION	Placebo	4	66.7																											
	Reboxetine	12	85.7																											
MOUTH DRY	Placebo	1	100.0																											
	Placebo	8	100.0																											
INSOMNIA	Reboxetine	9	100.0																											
	Placebo	1	100.0																											
SWEATING INCREASED	Reboxetine	1	100.0																											
	Reboxetine	1	100.0																											
MICTURITION DISORDER	Placebo	2	100.0																											
	Reboxetine	4	100.0																											
TACHYCARDIA	Placebo	4	100.0																											
	Reboxetine	3	60.0	1	20.0																									
DIZZINESS	Placebo	2	100.0																											
	Reboxetine	1	100.0																											
LIBIDO DECREASED	Placebo	1	100.0																											
	Reboxetine	1	100.0																											
HEADACHE	Placebo	4	80.0																											
	Reboxetine	4	100.0																											
VISION ABNORMAL	Placebo	1	100.0																											
	Reboxetine	1	100.0																											
PARAESTHESIA	Placebo	2	100.0																											

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R2D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 84

ADVERSE EVENTS BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Double Blind Phase

Adverse events/Assigned treatment	No change						Dose reduced						Temporarily interrupted						Definitively withdrawn						Total												
	No.			Z			No.			Z			No.			Z			No.			Z			No.			Z									
TREMOR		2	100.0																																		
HYPERTENSION	Placebo																																				
	Placebo	1	33.3							1	33.3																										
	Reboxetine	5	100.0																																		
URINARY RETENTION	Reboxetine	1	100.0																																		
DIARRHOEA	Placebo	5	100.0																																		
	Reboxetine	1	100.0																																		
VOMITING	Placebo	2	100.0																																		
	Reboxetine	1	100.0																																		
RASH	Reboxetine	2	66.7																																		
HYPOTENSION POSTURAL	Placebo	1	100.0																																		
OEDEMA PERIPHERAL	Placebo	1	100.0																																		
PERINEAL PAIN MALE	Reboxetine									1	100.0																										
CHEST PAIN	Reboxetine	1	100.0																																		
HYPERTRIGLYCERIDAEMIA	Reboxetine	1	100.0																																		
PNEUMONIA	Reboxetine	1	100.0																																		
ANGINA PECTORIS	Reboxetine																																				
HALLUCINATION	Placebo																																				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 TABLE No.: 85
 ADVERSE EVENTS: DISAPPEARED AFTER ACTION ON STUDY DRUG AND REAPPEARED ON RESUMING TREATMENT BY ASSIGNED TREATMENT

Run In Phase	Adverse events/Assigned treatment															
	Modified study drug						Temporarily interrupted									
	Disappeared			Reappeared			Disappeared			Temporarily interrupted						
All adverse events	NO		YES		Not applicable		Total		NO		YES		Not applicable		Total	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
REBOXETINE			10	100.0			10	100.0								
PLACEBO			3	100.0			3	100.0								
CONSTIPATION			3	100.0			3	100.0								
REBOXETINE			1	100.0			1	100.0								
PLACEBO			2	100.0			2	100.0								
MOUTH DRY			2	100.0			2	100.0								
REBOXETINE			2	100.0			2	100.0								
LIBIDO DECREASED			1	100.0			1	100.0								
REBOXETINE			1	100.0			1	100.0								
URINARY RETENTION			1	100.0			1	100.0								
REBOXETINE			1	100.0			1	100.0								
PLACEBO			1	100.0			1	100.0								
SWEATING INCREASED			1	100.0			1	100.0								
REBOXETINE			1	100.0			1	100.0								
PALPITATION			1	100.0			1	100.0								
REBOXETINE			1	100.0			1	100.0								
NERVOUSNESS			1	100.0			1	100.0								
PLACEBO			1	100.0			1	100.0								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 2012A/013
TABLE No.: 85

ADVERSE EVENTS: DISAPPEARED AFTER ACTION ON STUDY DRUG AND REAPPEARED ON RESUMING TREATMENT BY ASSIGNED TREATMENT

Double Blind Phase

Adverse events/Assigned treatment	Modified study drug												Temporarily interrupted					
	Disappeared						Reappeared											
	NO		YES		Not applicable		Total		NO		YES		Not applicable		Total			
	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z		
All adverse events	2	28.6	5	71.4			7	100.0			1	100.0			1	100.0		
	2	33.3	3	50.0	1	16.7	6	100.0	1	50.0			1	50.0	2	100.0		
CONSTIPATION	1	50.0	1	50.0			2	100.0										
			2	100.0			2	100.0										
HYPERTENSION	1	50.0			1	50.0	2	100.0					1	100.0	1	100.0		
			2	100.0			2	100.0										
TACHYCARDIA																		
	1	100.0					1	100.0										
ANGINA PECTORIS																		
			1	100.0			1	100.0	1	100.0					1	100.0		
HEADACHE																		
	1	100.0					1	100.0										
HALLUCINATION																		
			1	100.0			1	100.0										
PERINEAL PAIN MALE																		
			1	100.0			1	100.0						1	100.0	1	100.0	
RASH			1	100.0			1	100.0										

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 TABLE No.: 86
 ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Run In Phase	Adverse events/Assigned treatment	Unchanged study drug or Missing						Modified study drug											
		Recovered			Recovered with sequelae			Still present			Total			Recovered			Total		
		No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%
All adverse events	PLACEBO	139	93.9	6	4.1	3	2.0	148	100	3	100	3	100	3	100	3	100	3	100
	REBOXETINE	128	92.1	7	5.0	4	2.9	139	100	10	100	10	100	10	100	10	100	10	100
CONSTIPATION	PLACEBO	26	100					26	100	1	100	1	100	1	100	1	100	1	100
	REBOXETINE	21	91.3			2	8.7	23	100	3	100	3	100	3	100	3	100	3	100
MOUTH DRY	PLACEBO	25	92.6			2	7.4	27	100										
	REBOXETINE	29	100					29	100	2	100	2	100	2	100	2	100	2	100
INSOMNIA	PLACEBO	18	75.0	6	25.0			24	100										
	REBOXETINE	10	58.8	5	29.4	2	11.8	17	100										
SWEATING INCREASED	PLACEBO	12	100					12	100										
	REBOXETINE	12	100					12	100	1	100	1	100	1	100	1	100	1	100
MICTURITION DISORDER	PLACEBO	9	100					9	100										
	REBOXETINE	10	100					10	100										
TACHYCARDIA	PLACEBO	7	87.5			1	12.5	8	100										
	REBOXETINE	6	100					6	100										
DIZZINESS	PLACEBO	8	100					8	100										
	REBOXETINE	7	100					7	100										
LIBIDO DECREASED	PLACEBO	5	100					5	100										
	REBOXETINE	7	100					7	100	2	100	2	100	2	100	2	100	2	100
HEADACHE	REBOXETINE	5	100					5	100										
	PLACEBO	3	100					3	100										
VISION ABNORMAL	PLACEBO	6	100					6	100										
	REBOXETINE	6	100					6	100										

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 TABLE No.: 56
 ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT
 Run In Phase

Adverse events/Assigned treatment	Unchanged study drug or Missing						Modified study drug					
	Recovered		Recovered with sequelae		Still present		Recovered		Total			
	No.	%	No.	%	No.	%	No.	%	No.	%		
PARAESTHESIA	5	100							5	100		
REBOXETINE	2	100							2	100		
TREMOR	6	100							6	100		
REBOXETINE	1	100							1	100		
URINARY RETENTION	3	100							3	100	1	100
REBOXETINE	1	100							1	100	1	100
PLACERO	1	100							1	100		
VOMITING	1	100							1	100		
RASH	1	100							1	100		
HYPOTENSION	1	100							1	100		
POSTURAL	1	100							1	100		
OEDEMA PERIPHERAL	1	100							1	100		
REBOXETINE	1	100							1	100		
ANOREXIA	1	100							1	100		
REBOXETINE	1	100							1	100		
PLACERO	1	100							1	100		
REBOXETINE	1	100							1	100		
PLACERO	2	100							2	100		
SOMNOLENCE	1	100							1	100		
PERINEAL PAIN	1	100							1	100		
MALE	1	100							1	100		
EJACULATION	1	100							1	100		
FAILURE	1	100							1	100		
FATIGUE	1	100							1	100		
RIGORS	1	100							1	100		
PALPITATION	1	100							1	100	1	100
REBOXETINE											1	100

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
TABLE No.: 86
ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Run In Phase

Adverse events/Assigned treatment	Unchanged study drug or Missing						Modified study drug			
	Recovered		Still present		Total		Recovered		Total	
	No.	%	No.	%	No.	%	No.	%	No.	%
VERTIGO	1	100			1	100				
BACK PAIN	1	100			1	100				
NERVOUSNESS							1	100	1	100
OVARIAN DISORDER	1	100			1	100				
VAGINITIS	1	100			1	100				
FURUNCULOSIS	1	100			1	100				
INFECTION VIRAL			1	100						
UPPER RESP TRACT INFECTION	1	100			1	100				
RHINITIS	1	100			1	100				
ACNE	1	100			1	100				
ALBUMINURIA	1	100			1	100				
LACRIMAL GLAND DISORDER			1	100						

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124-013
TABLE No.: 86

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Double Blind Phase

Adverse events/Assigned treatment	Unchanged study drug or Missing												Modified study drug																						
	Recovered with sequelae			Still present			Death			Missing			Total			Recovered with sequelae			Still present			Death			Missing			Total							
	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z
All adverse events	PLACERO	41	97.6		1	2.4								42	100	4	66.7		2	33.3									6	100					
	REBOXETINE	42	85.7	1	2.0	6	12.2							43	100	4	57.1		3	42.9								7	100						
CONSTIPATION	PLACERO	4	100											4	100	2	100												2	100					
	REBOXETINE	11	91.7		1	8.3								12	100	1	50.0		1	50.0								2	100						
MOUTH DRY	PLACERO	1	100											1	100																				
	REBOXETINE	7	87.5		1	12.5								8	100																				
INSOMNIA	PLACERO	8	88.9	1	11.1									9	100																				
	REBOXETINE	1	100											1	100																				
SWEATING INCREASED	PLACERO	1	100											1	100																				
	REBOXETINE	1	100											1	100																				
MICTURITION DISORDER	PLACERO	2	100											2	100																				
	REBOXETINE	2	50.0		2	50.0								4	100																				
TACHYCARDIA	PLACERO	4	100											4	100																				
	REBOXETINE	3	100											3	100	2	100												2	100					
DIZZINESS	PLACERO	2	100											2	100																				
	REBOXETINE	1	100											1	100																				
LIBIDO DECREASED	PLACERO	1	100											1	100																				
	REBOXETINE	1	100											1	100																				
HEADACHE	PLACERO	4	100											4	100	1	100												1	100					
	REBOXETINE	4	100											4	100																				
VISION ABNORMAL	PLACERO	1	100											1	100																				
	REBOXETINE	1	100											1	100																				

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 86

ADVERSE EVENTS: OUTCOME OF EVENTS AT THE END OF THE THERAPY BY ACTION ON STUDY DRUG AND ASSIGNED TREATMENT

Double Blind Phase

Adverse events/Assigned treatment	Unchanged study drug or Missing												Modified study drug																					
	Recovered with sequelae			Still present			Death			Missing			Total			Recovered with sequelae			Still present			Death			Missing			Total						
	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%				
PARAESTHESIA	2	100																																
TREMOR	2	100																																
HYPERTENSION	1	100																																
REBOXETINE	4	80.0																																
URINARY RETENTION	1	100																																
DIARRHOEA	5	100																																
REBOXETINE	1	100																																
VOMITING	2	100																																
REBOXETINE	1	100																																
RASH	1	50.0																																
REBOXETINE	1	100																																
HYPOTENSION POSTURAL	1	100																																
PLACEBO	1	100																																
OEDEMA PERIPHERAL	1	100																																
PERINEAL PAIN MALE																																		
REBOXETINE																																		
CHEST PAIN																																		
REBOXETINE																																		
ANGINA PECTORIS																																		
REBOXETINE																																		
HYPERTRIGLYCERID-AEMIA	1	100																																
REBOXETINE																																		
HALLUCINATION																																		
PLACEBO																																		
REBOXETINE	1	100																																
PNEUMONIA																																		
REBOXETINE																																		

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: B7

ADVERSE EVENTS BY RELATIONSHIP TO THE EXPERIMENTAL TREATMENT AND ASSIGNED TREATMENT

Run In Phase

Adverse events/Assigned treatment	Relationship																								
	Definite			Probable			Possible			Doubtful			None			Unknown			Missing			Total			
	No.	%		No.	%		No.	%		No.	%		No.	%		No.	%		No.	%		No.	%		
Total adverse events	11	7.3	9	6.0	102	67.5	10	6.6	15	9.9	4	2.6									151	100.0			
	15	10.1	29	19.5	84	56.4	12	8.1	8	5.4	1	0.7									149	100.0			
CONSTIPATION	3	11.1	1	3.7	22	81.5	1	3.7													27	100.0			
	4	15.4	4	15.4	17	65.4	1	3.8													26	100.0			
MOUTH DRY	5	18.5	1	3.7	20	74.1			1	3.7											27	100.0			
	5	16.1	12	38.7	12	38.7	1	3.2			1	3.2									31	100.0			
INSOMNIA			1	4.2	6	25.0	4	16.7	11	45.8	2	8.3									24	100.0			
			1	5.9	8	47.1	2	11.8	6	35.3											17	100.0			
SWEATING INCREASED			1	8.3	10	83.3	1	8.3													12	100.0			
			2	15.4	9	69.2	2	15.4													13	100.0			
MICTURITION DISORDER					9	100.0															9	100.0			
	2	20.0	2	20.0	6	60.0															10	100.0			
TACHYCARDIA					7	87.5	1	12.5														8	100.0		
	1	16.7	1	16.7	3	50.0	1	16.7													6	100.0			
DIZZINESS	2	25.0	2	25.0	3	37.5															1	12.5			
					7	100.0																7	100.0		
LIBIDO DECREASED					5	100.0																5	100.0		
	2	22.2	3	33.3	4	44.4															9	100.0			
HEADACHE			1	20.0	2	40.0	2	40.0														5	100.0		
	1	33.3			2	66.7																3	100.0		
VISION ABNORMAL			2	33.3	4	66.7																6	100.0		
					6	100.0																6	100.0		
TREMOR					6	100.0																6	100.0		

(CONTINUED) 6

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CHS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 87

ADVERSE EVENTS BY RELATIONSHIP TO THE EXPERIMENTAL TREATMENT AND ASSIGNED TREATMENT

Run Ia Phase

Adverse events/Assigned treatment	Relationship																							
	Definite			Probable			Possible			Doubtful			None			Unknown			Missing			Total		
	No.	Z	No.	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	
TREMOR	1	100.0																					1	100.0
PARAESTHESIA								5	100.0														5	100.0
URINARY RETENTION								1	25.0	1	25.0	1	25.0	1	25.0								4	100.0
RAASH								1	50.0	1	50.0												2	100.0
VOMITING										1	100.0												1	100.0
HYPOTENSION POSTURAL										1	100.0												1	100.0
ANOREXIA										1	100.0												1	100.0
NAUSEA										1	100.0												1	100.0
SOMNOLENCE										2	100.0												2	100.0
PERINEAL PAIN MALE										1	100.0												1	100.0
OEDEMA PERIPHERAL												1	100.0										1	100.0
FATIGUE								1	100.0														1	100.0
NERVOUSNESS								1	100.0														1	100.0
EJACULATION FAILURE										1	100.0												1	100.0
RIGORS										1	100.0												1	100.0
PALPITATION										1	100.0												1	100.0
VERTIGO										1	100.0												1	100.0
FURUNCULOSIS										1	100.0												1	100.0

(CONTINUED) 29 7

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 87

ADVERSE EVENTS BY RELATIONSHIP TO THE EXPERIMENTAL TREATMENT AND ASSIGNED TREATMENT

Run In Phase

Adverse events/Assigned treatment	Relationship																
	Definite		Probable		Possible		Doubtful		None		Unknown		Missing		Total		
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	
ACNE					1	100.0										1	100.0
OVARIAN DISORDER							1	100.0								1	100.0
RHINITIS							1	100.0								1	100.0
ALBUMINURIA							1	100.0								1	100.0
VAGINITIS										1	100.0					1	100.0
INFECTION VIRAL										1	100.0					1	100.0
UPPER RESP TRACT INFECTION										1	100.0					1	100.0
LACRIMAL GLAND DISORDER										1	100.0					1	100.0
BACK PAIN													1	100.0		1	100.0

2008

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBEXETINE - PROTOCOL 20124/013
TABLE No.: 87

ADVERSE EVENTS BY RELATIONSHIP TO THE EXPERIMENTAL TREATMENT AND ASSIGNED TREATMENT

Double Blind Phase

Adverse events/Assigned treatment	Relationship																						
	Definite			Probable			Possible			Doubtful			None			Unknown			Total				
	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%	No.	Z	%		
Total adverse events	2	3.6	12	21.4	11	19.6	15	26.8	8	14.3	8	14.3	1	2.1	48	100.0							
CONSTIPATION	1	7.1	6	10.7	4	7.1	1	1.8							6	100.0							
MOUTH DRY																							
INSOMNIA	1	11.1													1	100.0							
SWEATING INCREASED																							
MICTURITION DISORDER																							
TACHYCARDIA																							
DIZZINESS																							
LIBIDO DECREASED																							
HEADACHE																							
VISION ABNORMAL																							
TREMOR																							

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 2012A/013
TABLE No.: 87

ADVERSE EVENTS BY RELATIONSHIP TO THE EXPERIMENTAL TREATMENT AND ASSIGNED TREATMENT

Adverse events/Assigned treatment	Relationship																					
	Definite			Probable			Possible			Doubtful			None			Unknown			Total			
	No.	%	Z	No.	%	Z	No.	%	Z	No.	%	Z	No.	%	Z	No.	%	Z	No.	%	Z	
PARAESTHESIA																						
HYPERTENSION																						
URINARY RETENTION																						
DIARRHOEA																						
RASH																						
VOMITING																						
HYPOTENSION POSTURAL																						
PERINEAL PAIN MALE																						
OEDEMA PERIPHERAL																						
PNEUMONIA																						
ANGINA PECTORIS																						
CHEST PAIN																						
HYPERTIGLYCAEMIA																						
HALLUCINATION																						

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOMETINE - PROTOCOL 20124/013
TABLE No.: 58

ADVERSE EVENTS: FREQUENCY (95% C.I.) OF PATIENT WHO COMPLAINED OF ADVERSE EVENTS DURING THERAPY ACCORDING TO TIME INTERVAL BY SEX AND ASSIGNED TREATMENT

Sex: Total

Assigned treatment	Days of treatment																			
	Run In Phase										Double Blind Phase									
	0-7	8-14	15-21	22-28	29-35	36-42	43-70	71-98	99-126	127-154	155-182	183-210	211-238	239-266	267-294	295-322	323-350	351-364	> 364	
Placebo	140	140	140	140	140	140	140	133	123	108	95	89	81	78	74	70	66	65		
Pt with a.e.	60	70	70	72	71	63	64	38	34	26	21	19	16	10	7	6	5	2		
% on exposed	42.9	50.0	50.0	51.4	50.7	45.0	45.7	28.6	27.6	24.1	22.1	21.3	19.8	12.8	9.5	8.6	7.6	3.1		
95% L.I.	34.5	41.4	41.4	42.8	42.1	36.6	37.3	21.1	20.0	16.4	14.2	13.4	11.7	6.3	3.9	3.2	2.5	0.4		
95% U.I.	51.5	58.6	58.6	60.0	59.3	53.6	54.3	37.0	36.4	33.3	31.8	31.3	30.1	22.3	18.5	17.7	16.8	10.7		
No. of A.E.	92	109	109	113	107	93	93	52	43	34	28	22	18	12	8	6	5	2		
Ratio A.E. on Pt	1.53	1.55	1.55	1.56	1.50	1.47	1.45	1.36	1.26	1.30	1.33	1.15	1.12	1.20	1.14	1.00	1.00	1.00		
Rebometine	143	143	143	143	143	143	143	128	122	109	102	98	90	84	82	82	81	79	0	
Pt with a.e.	57	60	67	60	59	56	62	47	42	34	34	29	27	25	24	24	20	20	1	
% on exposed	39.9	42.0	46.9	42.0	41.3	39.2	43.4	36.7	34.4	31.2	33.3	29.6	30.0	29.8	29.3	29.3	24.7	25.3		
95% L.I.	31.8	33.8	38.5	33.8	33.1	31.1	35.1	28.4	26.1	22.7	24.3	20.8	20.8	20.3	19.7	19.7	15.8	16.2		
95% U.I.	48.4	50.5	55.4	50.5	49.8	47.7	51.9	45.7	43.6	40.8	43.4	39.7	40.6	40.7	40.4	40.4	35.5	36.4		
No. of A.E.	86	96	106	101	98	92	103	74	66	53	53	47	42	38	36	35	29	28	1	
Ratio A.E. on Pt	1.50	1.60	1.58	1.68	1.66	1.64	1.66	1.57	1.57	1.55	1.55	1.52	1.55	1.52	1.50	1.45	1.45	1.40	1.00	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS RD

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 88

ADVERSE EVENTS: FREQUENCY (95% C.I.) OF PATIENT WHO COMPLAINED OF ADVERSE EVENTS DURING THERAPY ACCORDING TO TIME INTERVAL BY SEX AND ASSIGNED TREATMENT

Sex: Female

Assigned treatment	Days of treatment																			
	Run In Phase										Double Blind Phase									
	0-7	8-14	15-21	22-28	29-35	36-42	43-70	71-98	99-126	127-154	155-182	183-210	211-238	239-266	267-294	295-322	323-350	351-364	> 364	
Placebo	Pt exposed	94	94	94	94	94	94	91	84	73	67	63	58	57	53	50	47	46		
	Pt with a.o.	39	45	45	49	47	41	25	21	15	12	8	6	5	2	2	5	2		
	% on exposed	41.5	47.9	47.9	52.1	50.0	43.6	27.5	25.0	20.5	17.9	12.7	10.3	8.8	3.8	4.0	10.6	4.3		
	95% L.L.	31.4	37.5	37.5	41.6	39.5	33.4	18.6	16.2	12.0	9.6	5.6	3.9	2.9	0.5	0.5	3.5	0.5		
	95% U.L.	52.1	58.4	58.4	62.5	60.5	54.2	37.8	35.6	31.6	29.2	23.5	21.2	19.3	13.0	13.7	23.1	14.8		
	No. of A.E.	58	68	70	75	69	59	32	25	18	15	10	7	6	2	2	5	2		
	Ratio A.E. on Pt	1.48	1.51	1.55	1.53	1.46	1.43	1.37	1.28	1.19	1.20	1.25	1.16	1.20	1.00	1.00	1.00	1.00		
Reboxetine	Pt exposed	113	113	113	113	113	113	102	96	87	81	78	71	66	65	65	64	64	0	
	Pt with a.o.	43	45	49	45	46	44	37	31	26	25	21	18	16	15	15	13	13	1	
	% on exposed	38.1	39.8	43.4	39.8	40.7	38.9	34.4	32.3	29.9	30.9	26.9	25.4	24.2	23.1	23.1	20.3	20.3		
	95% L.L.	29.1	30.7	34.1	30.7	31.6	29.9	27.0	23.1	20.5	21.1	17.5	15.8	14.5	13.5	13.5	11.3	11.3		
	95% U.L.	47.7	49.5	53.0	49.5	50.4	48.6	46.4	42.6	40.6	42.1	38.2	37.1	36.4	35.2	35.2	32.2	32.2		
	No. of A.E.	61	68	77	76	77	74	60	51	41	40	35	28	26	24	23	18	18	1	
	Ratio A.E. on Pt	1.41	1.51	1.57	1.68	1.67	1.68	1.71	1.64	1.57	1.60	1.66	1.55	1.62	1.60	1.53	1.38	1.38	1.00	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 89

ADVERSE EVENTS: FREQUENCY (95% C.I.) OF PATIENT WHO COMPLAINED OF ADVERSE EVENTS DURING THERAPY ACCORDING TO TIME INTERVAL BY SEX AND ASSIGNED TREATMENT

Sex: Male

Assigned treatment	Days of treatment																			
	Run In Phase										Double Blind Phase									
	0-7	8-14	15-21	22-28	29-35	36-42	43-70	71-98	99-126	127-154	155-182	183-210	211-238	239-266	267-294	295-322	323-350	351-364		
Placebo																				
Pt exposed	46	46	46	46	46	46	46	42	39	35	28	26	23	21	21	20	19	19		
Pt with a.e.	21	25	25	23	24	22	21	13	13	11	9	11	10	5	5	4	0	0		
% on exposed	45.7	54.3	54.3	50.0	52.2	47.8	45.7	31.0	33.3	31.4	32.1	42.3	43.5	23.8	23.8	20.0	0.0	0.0		
95% L.L.	30.9	39.0	39.0	34.9	36.9	32.9	30.9	17.6	19.1	16.9	15.9	23.4	23.2	8.2	8.2	5.7	0.0	0.0		
95% U.L.	61.0	69.1	69.1	65.1	67.1	63.1	61.0	47.1	50.2	49.3	52.4	63.1	65.5	47.2	47.2	43.7	14.6	14.6		
No. of A.E.	34	41	39	38	38	34	34	20	18	16	13	12	11	6	6	4	0	0		
Ratio A.E. on Pt	1.61	1.64	1.56	1.65	1.58	1.54	1.61	1.53	1.38	1.45	1.44	1.09	1.10	1.20	1.20	1.00				
Reboxetine																				
Pt exposed	30	30	30	30	30	30	30	26	26	22	21	20	19	18	17	17	15	15		
Pt with a.e.	14	15	18	15	13	12	13	10	11	8	9	8	9	9	9	9	7	7		
% on exposed	46.7	50.0	60.0	50.0	43.3	40.0	43.3	38.5	42.3	36.4	42.9	40.0	47.4	50.0	52.9	52.9	46.7	46.7		
95% L.L.	28.3	31.3	40.6	31.3	25.5	22.7	25.5	20.2	23.4	17.2	21.8	19.1	24.4	26.0	27.8	27.8	18.4	21.3		
95% U.L.	65.7	68.7	77.3	68.7	62.6	59.4	62.6	59.4	63.1	59.3	66.0	63.9	71.1	74.0	77.0	77.0	67.1	73.4		
No. of A.E.	25	28	29	25	21	18	19	14	15	12	13	12	14	12	12	11	10	10		
Ratio A.E. on Pt	1.78	1.86	1.61	1.66	1.61	1.50	1.46	1.40	1.36	1.50	1.44	1.50	1.55	1.33	1.33	1.33	1.57	1.42		

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 89

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Run In Phase	Adverse events	Assigned treatment	Days of treatment														
			0-7		8-14		15-21		22-28		29-35		36-42				
			No Pt. exp. (*)	% on Pt. exp. (*)	No Pt. exp. (*)	% on Pt. exp. (*)	No Pt. exp. (*)	% on Pt. exp. (*)	No Pt. exp. (*)	% on Pt. exp. (*)	No Pt. exp. (*)	% on Pt. exp. (*)	No Pt. exp. (*)	% on Pt. exp. (*)			
	Pt exposed	140	100	1.53	140	100	1.55	140	100	1.56	140	100	1.50	140	100	1.47	
		143	100	1.50	143	100	1.60	143	100	1.68	143	100	1.66	143	100	1.64	
	MOUTH DRY		21	15.0	1.00	25	17.9	1.00	25	17.9	1.00	24	17.1	1.00	22	15.7	1.00
			21	14.7	1.00	23	16.1	1.00	21	14.7	1.00	21	14.7	1.00	20	14.0	1.05
	CONSTIPATION		15	10.7	1.00	18	12.9	1.00	18	12.9	1.00	18	12.9	1.00	17	12.1	1.00
			12	8.4	1.00	13	9.1	1.00	20	14.0	1.00	21	14.7	1.00	21	14.7	1.00
	INSOMNIA		18	12.9	1.00	21	15.0	1.00	21	15.0	1.00	20	14.3	1.05	19	13.6	1.05
			10	7.0	1.00	13	9.1	1.00	15	10.5	1.00	14	9.8	1.00	14	9.8	1.00
	LIBIDO DECREASED		4	2.9	1.00	4	2.9	1.00	4	2.9	1.00	4	2.9	1.00	5	3.6	1.00
			6	4.2	1.00	7	4.9	1.00	8	5.6	1.00	8	5.6	1.00	9	6.3	1.00
	MICTURITION DISORDER		3	2.1	1.00	7	5.0	1.00	7	5.0	1.00	7	5.0	1.00	7	5.0	1.00
			7	4.9	1.00	7	4.9	1.00	8	5.6	1.00	7	4.9	1.00	5	3.5	1.00
	SWEATING INCREASED		9	6.4	1.00	10	7.1	1.00	8	5.7	1.00	8	5.7	1.00	8	5.7	1.00
			10	7.0	1.00	8	5.6	1.00	8	5.6	1.00	6	4.2	1.00	6	4.2	1.00
	VISION ABNORMAL		1	0.7	1.00	2	1.4	1.00	3	2.1	1.00	3	2.1	1.00	3	2.1	1.00
			2	1.4	1.00	4	2.8	1.00	3	2.1	1.00	4	2.8	1.00	4	2.8	1.00
	TACHYCARDIA		3	2.1	1.00	3	2.1	1.00	4	2.9	1.00	7	5.0	1.00	6	4.3	1.00
			2	1.4	1.00	3	2.1	1.00	3	2.1	1.00	4	2.8	1.00	3	2.1	1.00
	BIZZINESS		5	3.6	1.00	4	2.9	1.00	3	2.1	1.00	5	3.6	1.00	4	2.9	1.00
			1	0.7	1.00	4	2.8	1.00	3	2.1	1.00	5	3.5	1.00	4	2.8	1.00

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 89

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Run In Phase

Adverse events	Assigned treatment	Days of treatment														
		0-7		8-14		15-21		22-28		29-35		36-42				
		No Pt.	% exp. (*)	No Pt.	% exp. (*)	No Pt.	% exp. (*)	No Pt.	% exp. (*)	No Pt.	% exp. (*)	No Pt.	% exp. (*)			
TREMOR	Placebo	2	1.4	1.00	4	2.9	1.00	6	4.3	1.00	6	4.3	1.00	6	4.3	1.00
	Reboxetine			1	0.7	1.00	1	0.7	1.00							
PARAESTHESIA	Placebo	3	2.1	1.00	3	2.1	1.00	4	2.9	1.00	2	1.4	1.00	2	1.4	1.00
	Reboxetine	2	1.4	1.00	2	1.4	1.00	2	1.4	1.00	1	0.7	1.00	1	0.7	1.00
URINARY RETENTION	Placebo	3	2.1	1.00	2	1.4	1.00	1	0.7	1.00	1	0.7	1.00			
	Reboxetine	1	0.7	1.00	1	0.7	1.00	2	1.4	1.00	2	1.4	1.00	2	1.4	1.00
HEADACHE	Reboxetine	3	2.1	1.00	3	2.1	1.00	4	2.8	1.00	1	0.7	1.00	1	0.7	1.00
ANOREXIA	Placebo	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00
	Reboxetine							1	0.7	1.00	1	0.7	1.00	1	0.7	1.00
RIGORS	Reboxetine	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00
NAUSEA	Placebo	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00
	Reboxetine	1	0.7	1.00	1	0.7	1.00									
RHINITIS	Reboxetine	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00
EJACULATION FAILURE	Placebo				1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00
	Placebo				1	0.7	1.00							1	0.7	1.00
BACK PAIN	Placebo	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00
FATIGUE	Placebo				1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00
VOMITING	Placebo	1	0.7	1.00												
HYPOTENSION POSTURAL	Reboxetine	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00						
PALPITATION	Reboxetine				1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 89

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Run In Phase

Adverse events	Assigned treatment	Days of treatment															
		0-7		8-14		15-21		22-28		29-35		36-42					
		No Pt.	% exp. (*)	No Pt.	% exp. (*)	No Pt.	% exp. (*)	No Pt.	% exp. (*)	No Pt.	% exp. (*)	No Pt.	% exp. (*)				
LACRIMAL GLAND DISORDER	Reboxetine	1	0.7	1.00	1	0.7	1.00										
PERINEAL PAIN MALE	Reboxetine	1	0.7	1.00	1	0.7	1.00										
NERVOUSNESS	Placebo				1	0.7	1.00										
ACNE	Placebo							1	0.7	1.00							
OEDEMA PERIPHERAL	Reboxetine							1	0.7	1.00							
SOMNOLENCE	Reboxetine	2	1.4	1.00													
OVARIAN DISORDER	Reboxetine				1	0.7	1.00										
INFECTION VIRAL	Reboxetine																
ALBUMINURIA	Placebo																
FURUNCULOSIS	Placebo	1	0.7	1.00													
VERTIGO	Reboxetine	1	0.7	1.00													
VAGINITIS	Placebo				1	0.7	1.00										
UPPER RESP TRACT INFECTION	Placebo							1	0.7	1.00							

(*) number of adverse events on number of patient who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

ROBOXETINE - PROTOCOL 20124/013
TABLE No.: 89

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Adverse events	Assigned treatment	Days of treatment																
		43-70		71-98		99-126		127-154		155-182		183-210		211-238		239-266		
		No Pt. exp. (*)	Z on Pt. exp. (*)	No Pt. exp. (*)	Z on Pt. exp. (*)	No Pt. exp. (*)	Z on Pt. exp. (*)	No Pt. exp. (*)	Z on Pt. exp. (*)	No Pt. exp. (*)	Z on Pt. exp. (*)	No Pt. exp. (*)	Z on Pt. exp. (*)	No Pt. exp. (*)	Z on Pt. exp. (*)	No Pt. exp. (*)	Z on Pt. exp. (*)	
Pt exposed	Placebo	140	1.45	133	1.36	123	1.26	108	1.30	95	1.33	89	1.15	81	1.12	78	1.20	
	Reboxetine	143	1.66	128	1.57	122	1.57	109	1.55	102	1.55	98	1.62	90	1.55	84	1.52	
MOUTH DRY	Placebo	17	12.1	9	6.8	9	7.3	1.00	8.3	1.00	8	8.4	1.00	6	6.7	1.00	3	3.8
	Reboxetine	21	14.7	1.04	20	15.6	1.00	14	12.8	1.00	17	13.9	1.00	14	12.8	1.00	9	10.0
CONSTIPATION	Placebo	18	12.9	1.00	15	11.3	1.00	12	9.8	1.00	10	9.3	1.00	8	8.4	1.00	2	2.2
	Reboxetine	25	17.5	1.04	22	17.2	1.00	20	16.4	1.00	14	12.8	1.00	15	14.7	1.00	13	13.3
INSOMNIA	Placebo	17	12.1	1.00	9	6.8	1.00	9	7.3	1.00	5	4.6	1.00	3	3.2	1.00	1	1.1
	Reboxetine	13	9.1	1.07	8	6.3	1.00	6	4.9	1.00	5	4.6	1.00	4	3.9	1.00	2	2.0
LIBIDO DECREASED	Placebo	5	3.6	1.00	5	3.8	1.00	5	4.1	1.00	5	4.1	1.00	3	2.8	1.00	3	3.2
	Reboxetine	9	6.3	1.00	8	6.3	1.00	8	6.6	1.00	7	6.4	1.00	7	6.9	1.00	7	7.1
MICTURITION DISORDER	Placebo	6	4.3	1.00	2	1.5	1.00	1	0.8	1.00	1	0.9	1.00	1	1.1	1.00	3	3.4
	Reboxetine	7	4.9	1.00	5	3.9	1.00	5	4.1	1.00	5	4.1	1.00	4	3.7	1.00	5	5.1
SWEATING INCREASED	Placebo	7	5.0	1.00	1	0.8	1.00										1	1.2
	Reboxetine	4	2.8	1.00	3	2.3	1.00	3	2.5	1.00	3	2.8	1.00	3	2.9	1.00	3	3.1
VISION ABNORMAL	Placebo	3	2.1	1.00	1	0.8	1.00	1	0.8	1.00	1	0.9	1.00				1	1.2
	Reboxetine	3	2.1	1.00	2	1.6	1.00	2	1.6	1.00	2	1.8	1.00	2	2.0	1.00	2	2.0
TACHYCARDIA	Placebo	4	2.9	1.00	1	0.8	1.00	1	0.8	1.00							1	1.1
	Reboxetine	2	1.4	2.00	1	0.8	1.00											
DIZZINESS	Placebo	2	1.4	1.00													2	2.2
	Reboxetine	3	2.1	1.00													1	1.1

307

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 89

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Double Blind Phase

Adverse events	Assigned treatment	Days of treatment																	
		43-70		71-98		99-126		127-154		155-182		183-210		211-238		239-266			
		No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)	No Pt.	% on exp. (*)		
TREMOR	Placebo	6	4.3	1.00	3	2.3	1.00	1	0.8	1.00	1	0.9	1.00	1	1.1	1.00	1	1.2	1.00
PARAESTHESIA	Placebo	1	0.7	1.00	1	0.8	1.00	1	0.8	1.00	1	0.9	1.00	1	1.1	1.00	1	1.2	1.00
URINARY RETENTION	Reboxetine	2	1.4	1.00	1	0.8	1.00	1	0.8	1.00	1	0.9	1.00	1	1.0	1.00	1	1.1	1.00
HEADACHE	Placebo	1	0.7	1.00	1	0.8	2.00	1	0.8	1.00	1	0.9	1.00	1	1.1	1.00	1	1.2	1.00
	Reboxetine	1	0.7	1.00	2	1.6	1.00	1	0.8	1.00				2	2.0	1.00	1	1.1	1.00
HYPERTENSION	Placebo	1	0.7	1.00	1	0.8	1.00	2	1.6	1.00	1	0.9	1.00	1	1.1	1.00	1	1.2	1.00
	Reboxetine	1	0.7	1.00				1	0.8	1.00	2	1.8	1.00	1	1.0	1.00	1	1.0	1.00
RIGORS	Reboxetine	1	0.7	1.00	1	0.8	1.00	1	0.8	1.00									
EJACULATION FAILURE	Placebo	1	0.7	1.00															
RASH	Reboxetine	3	2.1	1.00	1	0.8	1.00												
DIARRHOEA	Placebo	1	0.7	1.00	1	0.8	1.00												
	Reboxetine																		
FATIGUE	Placebo	1	0.7	1.00															
VOMITING	Placebo																		
	Reboxetine																		
HYPOTENSION POSTURAL	Placebo				1	0.8	1.00												
PERINEAL PAIN MALE	Reboxetine	1	0.7	1.00															
OEDEMA PERIPHERAL	Placebo	1	0.7	1.00															
HYPERTRIGLYCERIDAEMIA	Reboxetine				1	0.8	1.00	1	0.9	1.00	1	0.9	1.00	1	1.0	1.00			
ALBUMINURIA	Placebo	1	0.7	1.00															

(CONTINUED)

30

(*) number of adverse events on number of patient who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 89

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Adverse events	Assigned treatment	Days of treatment															
		43-70		71-98		99-126		127-154		155-182		183-210		211-238		239-266	
		No Pt. exp. (*)	% on Pt. exp. (*)	No Pt. exp. (*)	% on Pt. exp. (*)	No Pt. exp. (*)	% on Pt. exp. (*)	No Pt. exp. (*)	% on Pt. exp. (*)	No Pt. exp. (*)	% on Pt. exp. (*)	No Pt. exp. (*)	% on Pt. exp. (*)	No Pt. exp. (*)	% on Pt. exp. (*)	No Pt. exp. (*)	% on Pt. exp. (*)
ANGINA PECTORIS	Reboxetine	1	0.7	1.00													
CHEST PAIN	Reboxetine	1	0.7	1.00													
HALLUCINATION	Placebo				1	0.9	1.00										
PNEUMONIA	Reboxetine												1	1.1	1.00		

(CONTINUED)

309

(*) number of adverse events on number of patient who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 89

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Double Blind Phase

Adverse events	Assigned treatment	Days of treatment													
		267-294		295-322		323-350		351-364		> 364					
		No Pt.	Z on exp. (*)	No Pt.	Z on exp. (*)	No Pt.	Z on exp. (*)	No Pt.	Z on exp. (*)	No Pt.	Z on exp. (*)				
Pt exposed	Placebo	74	100	1.14	70	100	1.00	66	100	1.00	65	100	1.00	0	1.00
	Reboxetine	82	100	1.50	82	100	1.45	81	100	1.45	79	100	1.40		
MOUTH DRY	Placebo	3	4.1	1.00	1	1.4	1.00								
	Reboxetine	8	9.8	1.00	7	8.5	1.00	7	8.6	1.00	7	8.9	1.00		
CONSTIPATION	Placebo	1	1.4	1.00	2	2.9	1.00	2	3.0	1.00	1	1.5	1.00		
	Reboxetine	9	11.0	1.00	9	11.0	1.00	7	8.6	1.00	7	8.9	1.00	1	1.00
INSOMNIA	Placebo							1	1.5	1.00	1	1.5	1.00		
	Reboxetine	1	1.2	1.00	1	1.2	1.00	1	1.2	1.00	1	1.3	1.00		
LIBIDO DECREASED	Placebo	1	1.4	1.00											
	Reboxetine	6	7.3	1.00	6	7.3	1.00	2	2.5	1.00	2	2.5	1.00		
MICTURITION DISORDER	Placebo	1	1.4	1.00											
	Reboxetine	5	6.1	1.00	5	6.1	1.00	5	6.2	1.00	5	6.3	1.00		
SWEATING INCREASED	Placebo	1	1.4	1.00											
	Reboxetine	3	3.7	1.00	3	3.7	1.00	2	2.5	1.00	2	2.5	1.00		
VISION ABNORMAL	Placebo														
	Reboxetine	2	2.4	1.00	2	2.4	1.00	2	2.5	1.00	2	2.5	1.00		
TACHYCARDIA	Placebo				1	1.4	1.00	1	1.5	1.00					
	Reboxetine														
DIZZINESS	Placebo														
	Reboxetine														

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
TABLE No.: 89

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Double Blind Phase

Adverse events	Assigned treatment	Days of treatment												
		267-294		295-322		323-350		351-364		> 364				
		No Pt. exp. (*)	Z on Pt. exp. (*)	No Pt. exp. (*)	Z on Pt. exp. (*)	No Pt. exp. (*)	Z on Pt. exp. (*)	No Pt. exp. (*)	Z on Pt. exp. (*)	No Pt. exp. (*)	Z on Pt. exp. (*)			
TREMOR	Placebo	1	1.4	1.00	1	1.4	1.00							
PARAESTHESIA	Placebo							1	1.5	1.00				
URINARY RETENTION	Reboxetine	1	1.2	1.00	1	1.2	1.00	1	1.2	1.00	1	1.3	1.00	
HEADACHE	Placebo				1	1.4	1.00							
	Reboxetine													
HYPERTENSION	Placebo													
	Reboxetine	1	1.2	1.00	1	1.2	1.00	1	1.2	1.00	1	1.3	1.00	
RIGORS	Reboxetine													
EJACULATION FAILURE	Placebo													
RASH	Reboxetine													
DIARRHOEA	Placebo													
	Reboxetine							1	1.2	1.00				
FATIGUE	Placebo													
VOMITING	Placebo													
	Reboxetine													
HYPOTENSION POSTURAL	Placebo													
PERINEAL PAIN MALE	Reboxetine													
OEDEMA PERIPHERAL	Placebo													
HYPERTRIGLYCERIDAEMIA	Reboxetine													
ALBUMINURIA	Placebo													

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 89

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT

Double Blind Phase

Adverse events	Assigned treatment	Days of treatment													
		267-294		295-322		323-350		351-364		> 364					
		No Pt. exp. (*)	% on Pt. exp. (*)	No Pt. exp. (*)	% on Pt. exp. (*)	No Pt. exp. (*)	% on Pt. exp. (*)	No Pt. exp. (*)	% on Pt. exp. (*)	No Pt. exp. (*)	% on Pt. exp. (*)				
ANGINA PECTORIS	Reboxetine														
CHEST PAIN	Reboxetine														
HALLUCINATION	Placobo														
PNEUMONIA	Reboxetine														

(*) number of adverse events on number of patient who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 90

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL
BY ASSIGNED TREATMENT AND GROUPED BY BODY SYSTEM

Run In Phase

Body system	Assigned treatment	Days of treatment														
		0-7		8-14		15-21		22-28		29-35		36-42				
		No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)			
Pt exposed	Placebo	140	100	1.53	140	100	1.55	140	100	1.56	140	100	1.50	140	100	1.47
	Reboxetine	143	100	1.50	143	100	1.60	143	100	1.68	143	100	1.66	143	100	1.64
AUTONOMIC NERVOUS SYSTEM DISORDERS	Placebo	28	20.0	1.07	34	24.3	1.05	33	23.6	1.03	32	22.9	1.03	30	21.4	1.03
	Reboxetine	31	21.7	1.00	31	21.7	1.00	29	20.3	1.03	27	18.9	1.03	26	18.2	1.07
GASTRO-INTESTINAL SYSTEM DISORDERS	Placebo	18	12.9	1.00	20	14.3	1.00	20	14.3	1.00	20	14.3	1.00	19	13.6	1.00
	Reboxetine	13	9.1	1.00	14	9.8	1.00	20	14.0	1.05	21	14.7	1.04	21	14.7	1.09
PSYCHIATRIC DISORDERS	Placebo	22	15.7	1.00	26	18.6	1.00	26	18.6	1.00	25	17.9	1.04	24	17.1	1.04
	Reboxetine	18	12.6	1.00	20	14.0	1.00	23	16.1	1.00	22	15.4	1.00	23	16.1	1.00
URINARY SYSTEM DISORDERS	Placebo	6	4.3	1.00	9	6.4	1.00	8	5.7	1.00	8	5.7	1.00	7	5.0	1.00
	Reboxetine	8	5.6	1.00	8	5.6	1.00	10	7.0	1.00	9	6.3	1.00	7	4.9	1.00
CARDIOVASCULAR DISORDERS, GENERAL	Placebo	8	5.7	1.00	7	5.0	1.00	6	4.3	1.16	11	7.9	1.09	10	7.1	1.00
	Reboxetine	4	2.8	1.00	8	5.6	1.00	8	5.6	1.00	11	7.7	1.00	9	6.3	1.00
CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO	Placebo	5	3.6	1.00	7	5.0	1.00	8	5.7	1.00	8	5.7	1.00	8	5.7	1.00
	Reboxetine	6	4.2	1.00	6	4.2	1.00	7	4.9	1.00	2	1.4	1.00	2	1.4	1.00
VISION DISORDERS	Placebo	1	0.7	1.00	2	1.4	1.00	3	2.1	1.00	3	2.1	1.00	3	2.1	1.00
	Reboxetine	3	2.1	1.00	5	3.5	1.00	4	2.8	1.00	4	2.8	1.00	4	2.8	1.00
BODY AS A WHOLE-GENERAL DISORDERS	Placebo							1	0.7	1.00	1	0.7	1.00	1	0.7	1.00
	Reboxetine	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00
SKIN AND APPENDAGES DISORDERS	Placebo										1	0.7	1.00	2	1.4	1.00
	Reboxetine															

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 90

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL
BY ASSIGNED TREATMENT AND GROUPED BY BODY SYSTEM

Run In Phase

Body system	Assigned treatment	Days of treatment														
		0-7		8-14		15-21		22-28		29-35		36-42				
		No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)			
RESPIRATORY SYSTEM DISORDERS	Placebo	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00
	Reboxetine															
MUSCULO-SKELETAL SYSTEM DISORDERS	Placebo	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00	1	0.7	1.00
	Placebo	1	0.7	1.00												
	Reboxetine							1	0.7	1.00	1	0.7	1.00			
REPRODUCTIVE DISORDERS, MALE	Reboxetine	1	0.7	1.00	1	0.7	1.00									
	Placebo				1	0.7	1.00									
	Reboxetine				1	0.7	1.00									

(*) number of adverse events on number of patient who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 90

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL BY ASSIGNED TREATMENT AND GROUPED BY BODY SYSTEM

Double Blind Phase

Body system	Assigned treatment	Days of treatment																							
		43-70		71-98		99-126		127-154		155-182		183-210		211-238		239-266									
		No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)								
Pt exposed	Placebo	140	100	1.45	133	100	1.36	123	100	1.26	108	100	1.30	95	100	1.33	89	100	1.15	81	100	1.12	78	100	1.20
	Reboxetine	143	100	1.66	128	100	1.57	122	100	1.57	109	100	1.55	102	100	1.55	98	100	1.52	90	100	1.55	84	100	1.52
AUTONOMIC NERVOUS SYSTEM DISORDERS	Placebo	24	17	1.04	10	7	1.00	9	7	1.00	9	8	1.00	8	8	1.00	6	6	1.00	5	6	1.00	4	5	1.00
	Reboxetine	25	17	1.04	23	18	1.00	20	16	1.00	17	15	1.00	15	14	1.00	14	14	1.00	12	13	1.00	11	13	1.00
GASTRO-INTESTINAL SYSTEM DISORDERS	Placebo	18	12	1.05	16	12	1.00	12	9	1.00	10	9	1.00	8	8	1.00	4	4	1.00	1	1	1.00	3	3	1.00
	Reboxetine	25	17	1.04	22	17	1.00	20	16	1.00	14	12	1.00	15	14	1.00	13	13	1.00	10	10	1.00	9	10	1.00
PSYCHIATRIC DISORDERS	Placebo	22	15	1.00	14	10	1.00	14	11	1.00	8	7	1.00	6	6	1.00	3	3	1.00	2	2	1.00	1	1	1.00
	Reboxetine	22	15	1.04	16	12	1.00	14	11	1.00	12	11	1.00	11	10	1.00	9	9	1.00	7	7	1.00	6	7	1.00
URINARY SYSTEM DISORDERS	Placebo	7	5	1.00	2	1	1.00	1	0	1.00	1	0	1.00	1	1	1.00	1	1	1.00	3	3	1.00	1	1	1.00
	Reboxetine	9	6	1.00	6	4	1.00	6	4	1.00	5	4	1.00	6	5	1.00	6	6	1.00	5	5	1.00	5	6	1.00
CARDIOVASCULAR DISORDERS, GENERAL	Placebo	7	5	1.14	3	2	1.00	3	2	1.00	1	0	1.00	1	1	1.00	1	1	1.00	4	4	1.00	3	3	1.00
	Reboxetine	7	4	1.28	1	0	1.00	1	0	1.00	2	1	1.00	3	2	1.00	2	2	1.00	2	2	1.00	3	3	1.00
CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO	Placebo	8	5	1.00	5	3	1.00	3	2	1.00	3	2	1.00	3	3	1.00	3	3	1.00	2	2	1.00	3	3	1.00
	Reboxetine	1	0	1.00	2	1	1.00	1	0	1.00	1	0	1.00	2	2	1.00	2	2	1.00	1	1	1.00	1	1	1.00
VISION DISORDERS	Placebo	3	2	1.00	1	0	1.00	1	0	1.00	1	0	1.00	1	0	1.00	1	1	1.00	1	1	1.00	1	1	1.00
	Reboxetine	3	2	1.00	2	1	1.00	2	1	1.00	2	1	1.00	2	2	1.00	2	2	1.00	2	2	1.00	3	3	1.00
BODY AS A WHOLE- GENERAL DISORDERS	Placebo	1	0	1.00																					
	Reboxetine	2	1	1.00	1	0	1.00	1	0	1.00	1	0	1.00	1	0	1.00	1	1	1.00	1	1	1.00	1	1	1.00
SKIN AND APPENDAGES DISORDERS	Placebo	3	2	1.00	1	0	1.00																		
	Reboxetine	3	2	1.00	1	0	1.00																		

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 90

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL
BY ASSIGNED TREATMENT AND GROUPED BY BODY SYSTEM

Double Blind Phase

	Days of treatment															
	43-70		71-98		99-126		127-154		155-182		183-210		211-238		239-266	
Body system	No Pt	% on exp (*)	No Pt	% on exp (*)	No Pt	% on exp (*)	No Pt	% on exp (*)	No Pt	% on exp (*)	No Pt	% on exp (*)	No Pt	% on exp (*)	No Pt	% on exp (*)
Assigned treatment																
RESISTANCE MECHANISM DISORDERS																
Reboxetine																
REPRODUCTIVE DISORDERS, MALE																
Reboxetine	1	0.7	1.00										1	1.1	1.00	
METABOLIC AND NUTRITIONAL DISORDERS																
Reboxetine					1	0.8	1.00	1	0.9	1.00	1	1.0	1.00			

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 90

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL
BY ASSIGNED TREATMENT AND GROUPED BY BODY SYSTEM

Double Blind Phase

Body system	Assigned treatment	Days of treatment													
		267-294			295-322			323-350			351-364			> 364	
		No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)	No Pt	Z on exp (*)		
Pt exposed		74	100 1.14	70	100 1.00	66	100 1.00	65	100 1.00	100	1.40	0	1.00		
AUTONOMIC NERVOUS SYSTEM DISORDERS	Placebo	4	5.4 1.00	1	1.4 1.00										
	Reboxetine	11	13.4 1.00	10	12.2 1.00	9	11.1 1.00	9	11.4 1.00						
GASTRO-INTESTINAL SYSTEM DISORDERS	Placebo	1	1.4 1.00	2	2.9 1.00	2	3.0 1.00	1	1.5 1.00						
	Reboxetine	9	11.0 1.00	9	11.0 1.00	8	9.9 1.00	7	8.9 1.00	1	1.5 1.00				
PSYCHIATRIC DISORDERS	Placebo	1	1.4 1.00			1	1.5 1.00	1	1.5 1.00						
	Reboxetine	7	8.5 1.00	7	8.5 1.00	3	3.7 1.00	3	3.8 1.00						
URINARY SYSTEM DISORDERS	Placebo	1	1.4 1.00												
	Reboxetine	6	7.3 1.00	6	7.3 1.00	6	7.4 1.00	6	7.6 1.00						
CARDIOVASCULAR DISORDERS, GENERAL	Placebo			1	1.4 1.00	1	1.5 1.00								
	Reboxetine	1	1.2 1.00	1	1.2 1.00	1	1.2 1.00	1	1.3 1.00						
CENTRAL & PERIPHERAL NERVOUS SYSTEM DISO	Placebo	1	1.4 1.00	2	2.9 1.00	1	1.5 1.00								
	Reboxetine														
VISION DISORDERS	Placebo														
	Reboxetine	2	2.4 1.00	2	2.4 1.00	2	2.5 1.00	2	2.5 1.00						
BODY AS A WHOLE-GENERAL DISORDERS	Placebo														
	Reboxetine														
SKIN AND APPENDAGES DISORDERS	Reboxetine														

(CONTINUED)

(*) number of adverse events on number of patient who complained of adverse events

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS RED

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 90

ADVERSE EVENTS: PREVALENCE OF ADVERSE EVENTS ACCORDING TO TIME INTERVAL
BY ASSIGNED TREATMENT AND GROUPED BY BODY SYSTEM

Double Blind Phase

Body system	Assigned treatment	Days of treatment																			
		267-294		295-322		323-350		351-364		> 364											
		No Pt	% exp (*)	No Pt	% on exp (*)																
RESISTANCE MECHANISM DISORDERS	Reboxetine																				
REPRODUCTIVE DISORDERS, MALE	Reboxetine																				
METABOLIC AND NUTRITIONAL DISORDERS	Reboxetine																				

(*) number of adverse events on number of patient who complained of adverse events

PHARMACIA CNS 990077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 91

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1 DURING THE OPEN PHASE

		VISIT NO.											
		-1		1		2		3	4		5	6	
		F	M	F	M	F	M	F	F	M	M	F	M
HB	Evaluated	261	95	2	254	92	2	242	87	1	236	79	
	Mean	14.11	15.06	15.50	14.21	15.02	13.59	14.27	15.07	16.36	14.27	14.86	
	STD	1.95	2.15	0.71	1.86	1.76	2.81	1.96	1.76		1.93	1.91	
	Min	8.50	11.30	15.00	9.28	11.50	11.60	9.70	11.70	16.36	9.50	11.60	
	Max	21.40	24.83	16.00	20.80	20.21	15.57	22.00	20.21	16.36	21.20	20.82	
	Median	13.86	15.02	15.50	14.00	15.21	13.59	13.88	14.97	16.36	14.00	14.80	
	Diff. Median			-0.08	0.02	0.03	-0.05	0.03	0.05	-0.19	0.00	0.04	
	P value			1.0000	0.1930	0.1811	1.0000	0.1479	0.0714	1.0000	0.4859	0.2720	
HTC	Evaluated	261	93	2	254	91	2	242	87	1	235	79	
	Mean	38.73	44.08	38.22	38.62	43.89	37.33	38.64	44.07	44.43	38.55	43.48	
	STD	3.43	3.84	1.57	3.17	3.37	6.60	3.13	3.12		2.70	3.59	
	Min	24.50	37.57	37.11	27.75	37.57	32.67	29.00	38.43	44.43	28.00	37.57	
	Max	50.20	59.75	39.33	55.30	53.00	42.00	51.00	51.91	44.43	46.00	56.45	
	Median	39.00	43.57	38.22	38.94	43.57	37.33	39.00	43.57	44.43	39.00	43.40	
	Diff. Median			-0.11	0.00	0.00	-0.01	0.00	0.00	-0.07	0.00	0.00	
	P value			1.0000	0.9957	0.7098	1.0000	0.7058	0.4097	1.0000	0.7568	0.3520	
RBC	Evaluated	257	92	2	254	92	2	242	87	1	235	79	
	Mean	4.44	4.94	4.16	4.41	4.98	4.26	4.47	5.03	5.06	4.46	5.00	
	STD	0.66	0.75	0.23	0.51	0.56	0.48	0.50	0.61		0.45	0.57	
	Min	0.57	2.46	4.00	1.96	3.74	3.92	2.46	3.63	5.06	1.98	4.11	
	Max	11.20	7.89	4.32	6.78	7.72	4.60	6.98	7.69	5.06	7.24	7.92	
	Median	4.45	4.89	4.16	4.45	4.89	4.26	4.45	4.89	5.06	4.46	4.89	
	Diff. Median			-0.10	0.00	0.06	-0.03	0.02	0.06	-0.07	0.00	0.05	
	P value			1.0000	0.3401	0.0734	1.0000	0.1804	0.0151	1.0000	0.2402	0.2781	
PLATELETS	Evaluated	249	85	2	244	85	2	232	81	1	230	76	
	Mean	234.43	234.50	300.50	233.84	236.18	203.39	234.62	230.67	221.43	239.86	233.02	
	STD	54.87	41.55	99.70	60.64	41.17	37.63	67.03	38.23		67.56	44.22	
	Min	141.07	140.63	230.00	139.42	164.38	176.79	89.06	155.63	221.43	137.50	146.88	
	Max	466.00	392.19	371.00	487.50	375.00	230.00	650.00	386.00	221.43	612.00	462.50	
	Median	226.79	231.00	300.50	220.63	233.93	203.39	220.00	226.79	221.43	221.43	230.49	

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

PHARMACIA CNS 950077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 91

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1 DURING THE OPEN PHASE

		VISIT NO.													
		-1		1		2		3		4		5		6	
		F	N	F	N	F	N	F	N	F	N	F	N		
PLATELETS	Diff. Median			-0.05	-0.01	-0.01	0.12	0.00	-0.01	-0.11	0.01	0.01			
	P value			0.5000	0.3216	0.5737	0.5000	0.9511	0.5410	1.0000	0.1784	0.4992			
HBC	Evaluated	261	95	2	254	92	2	242	87	1	235	79			
	Mean	6.99	7.64	10.35	6.97	7.16	6.97	7.05	7.41	4.91	7.06	6.84			
	STD	1.94	3.04	0.66	1.99	2.30	2.54	1.85	2.10		1.76	2.09			
	Min	2.94	4.50	9.89	1.90	4.50	5.18	1.90	4.09	4.91	2.16	4.50			
	Max	16.39	25.11	10.81	14.45	19.91	8.77	13.38	16.39	4.91	13.60	20.47			
	Median	6.78	6.80	10.35	6.64	6.64	6.97	6.73	6.91	4.91	6.73	6.67			
	Diff. Median			-0.11	0.00	-0.02	0.04	0.01	-0.01	0.02	0.00	-0.07			
	P value			1.0000	0.7601	0.1213	1.0000	0.4728	0.4815	1.0000	0.5995	0.0001			
HBC: N	Evaluated	248	93	2	248	89	2	228	87	1	220	79			
	Mean	61.95	62.12	65.50	62.04	62.30	60.38	62.47	61.49	64.31	62.63	61.41			
	STD	5.14	5.32	4.95	5.02	3.99	3.37	4.92	4.61		4.90	5.69			
	Min	42.00	34.00	62.00	33.00	42.00	58.00	41.00	42.00	64.31	40.00	33.00			
	Max	79.00	72.00	69.00	84.00	69.33	62.77	78.00	71.00	64.31	81.00	68.15			
	Median	62.77	63.33	65.50	63.00	63.54	60.38	63.33	62.77	64.31	63.29	63.00			
	Diff. Median			0.10	0.03	0.02	0.28	0.07	-0.03	-0.08	0.05	-0.07			
	P value			1.0000	0.3635	0.9608	1.0000	0.0356	0.1634	1.0000	0.1034	0.6675			
HBC: E	Evaluated	245	89	2	242	87	2	224	87	1	216	78			
	Mean	2.02	2.17	1.50	1.97	2.16	1.50	1.91	2.37	1.50	2.10	2.20			
	STD	1.47	1.42	0.71	1.28	1.11	1.41	1.07	1.46		1.37	0.98			
	Min	0.00	0.50	1.00	0.00	0.50	0.50	0.33	0.50	1.50	0.33	0.50			
	Max	10.50	10.50	2.00	11.00	5.00	2.50	5.67	7.00	1.50	8.00	4.50			
	Median	1.67	2.00	1.50	1.50	2.00	1.50	1.67	2.00	1.50	1.67	2.00			
	Diff. Median			-0.25	0.00	0.00	0.00	0.00	0.00	-0.50	0.00	0.00			
	P value			0.5000	0.7183	0.5265	1.0000	0.2711	0.2735	1.0000	0.8531	0.7245			
HBC: B	Evaluated	232	88	2	233	84	2	217	81	1	208	75			
	Mean	0.13	0.19	0.75	0.12	0.07	0.38	0.12	0.10	0.00	0.13	0.13			
	STD	0.44	0.40	1.06	0.31	0.22	0.53	0.31	0.35		0.33	0.42			
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN950077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 91

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1 DURING THE OPEN PHASE

		VISIT NO.													
		-1		1		2		3		4		5		6	
		F	M	F	M	F	M	F	M	F	M	F	M		
HBC: B	Max	5.25	2.25	1.50	1.50	0.75	0.75	1.50	2.25	0.00	1.50	3.00			
	Median	0.00	0.00	0.75	0.00	0.00	0.38	0.00	0.00	0.00	0.00	0.00			
	Diff. Median			1.00	0.00	0.00	0.50	0.00	0.00	0.00	0.00	0.00			
	P value			1.0000	0.5918	0.0633	1.0000	0.7115	0.1121		0.9627	0.3060			
HBC: L	Evaluated	248	93	2	248	89	2	228	87	1	220	79			
	Mean	29.80	28.58	29.00	29.45	28.39	34.00	29.16	29.17	26.00	28.90	28.65			
	STD	4.87	4.16	4.24	4.81	3.06	8.49	4.57	3.55		4.89	3.21			
	Min	19.00	18.00	26.00	15.00	22.00	28.00	21.80	21.00	26.00	18.00	21.00			
	Max	49.00	52.00	32.00	45.00	40.00	40.00	52.00	39.00	26.00	55.00	40.00			
	Median	29.00	28.00	29.00	28.00	28.00	34.00	28.00	28.50	26.00	28.00	28.00			
	Diff. Median			-0.25	0.00	0.00	-0.28	-0.05	0.00	0.10	-0.05	0.05			
	P value			1.0000	0.3222	0.9405	1.0000	0.0619	0.4143	1.0000	0.0517	0.7072			
HBC: M	Evaluated	247	92	2	244	89	2	225	87	1	220	79			
	Mean	3.90	4.09	3.00	4.08	4.52	2.50	3.92	4.44	4.00	4.02	4.86			
	STD	2.15	1.97	1.41	2.16	2.33	0.71	2.29	2.16		2.21	2.15			
	Min	0.00	0.00	2.00	0.00	0.00	2.00	0.00	-1.00	4.00	0.00	-1.00			
	Max	11.00	9.00	4.00	10.00	13.00	3.00	10.00	9.00	4.00	10.00	13.00			
	Median	4.00	4.00	3.00	4.00	4.00	2.50	3.50	4.00	4.00	4.00	5.00			
	Diff. Median			0.25	0.00	0.00	0.00	0.00	0.00	0.25	0.00	0.00			
	P value			1.0000	0.1175	0.1755		0.9655	0.2439	1.0000	0.2870	0.0493			
CREATINI-NE	Evaluated	260	94	2	255	91	2	243	88	1	234	80			
	Mean	0.76	0.90	0.77	0.76	0.90	0.69	0.76	0.91	0.92	0.75	0.89			
	STD	0.14	0.15	0.25	0.13	0.14	0.11	0.15	0.21		0.14	0.13			
	Min	0.20	0.60	0.60	0.43	0.60	0.62	0.43	0.69	0.92	0.47	0.66			
	Max	1.16	1.61	0.94	1.14	1.41	0.77	1.33	2.12	0.92	1.31	1.34			
	Median	0.75	0.90	0.77	0.75	0.89	0.69	0.74	0.88	0.92	0.74	0.87			
	Diff. Median			0.10	0.00	0.00	-0.13	0.00	-0.00	0.09	0.00	0.00			
	P value			1.0000	0.3842	0.7876	1.0000	0.2191	0.5307	1.0000	0.1284	0.6140			
BUN	Evaluated	250	92	2	254	91	2	243	88	1	229	79			
	Mean	11.46	11.70	12.09	11.20	11.76	12.15	11.07	11.58	11.60	11.42	12.08			

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C0530077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 91

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1 DURING THE OPEN PHASE

		VISIT NO.													
		-1		1		2		3		4		5		6	
		F	M	F	M	F	M	F	M	F	M	F	M	F	M
BUN	STD	2.29	2.22	1.94	1.99	2.24	2.23	2.15	2.80					2.41	3.22
	Min	6.01	7.16	10.71	6.51	7.66	10.58	6.34	7.00	11.60	6.51	8.15			
	Max	20.67	17.45	13.46	15.80	18.14	13.73	18.00	23.23	11.60	27.52	34.09			
	Median	11.22	11.53	12.09	11.40	11.40	12.15	10.94	10.99	11.60	11.40	11.60			
	Diff. Median			0.06	-0.02	0.03	0.30	-0.04	-0.03	0.10	0.00	-0.03			
	P value			1.0000	0.1499	0.5170	0.5000	0.0367	0.5053	1.0000	0.6485	0.9469			
URIC ACID	Evaluated	260	95	2	255	92	2	242	88	1	233	80			
	Mean	4.11	5.36	3.18	4.04	5.28	4.23	4.09	5.38	6.48	4.04	5.32			
	STD	1.01	1.36	2.02	0.81	1.34	0.50	0.85	1.37		0.82	1.48			
	Min	2.08	2.27	1.76	1.98	2.99	3.88	1.78	2.88	6.48	1.78	3.29			
	Max	8.99	8.54	4.61	7.34	10.36	4.59	6.93	10.74	6.48	6.93	10.40			
	Median	3.95	5.27	3.18	4.04	5.04	4.23	4.04	5.49	6.48	4.04	5.11			
	Diff. Median			-0.19	-0.00	0.00	0.09	0.00	0.03	-0.07	-0.02	0.04			
P value			0.5000	0.4714	0.8706	1.0000	0.9739	0.6419	1.0000	0.2472	0.3758				
TOT. PROTEINS	Evaluated	260	95	2	253	92	2	244	88	1	235	80			
	Mean	7.38	7.37	7.59	7.43	7.47	7.73	7.42	7.43	8.11	7.47	7.51			
	STD	0.52	0.50	0.74	0.48	0.39	0.27	0.47	0.43		0.44	0.43			
	Min	5.74	6.27	7.07	6.31	6.40	7.54	6.21	6.50	8.11	6.32	6.50			
	Max	9.73	8.59	8.11	9.92	8.30	7.92	9.44	8.30	8.11	9.73	8.78			
	Median	7.35	7.35	7.59	7.45	7.54	7.73	7.35	7.45	8.11	7.45	7.54			
	Diff. Median			-0.05	0.05	0.07	-0.03	0.05	0.05	0.20	0.05	0.06			
P value			1.0000	0.1845	0.0255	1.0000	0.3822	0.1594	1.0000	0.0132	0.0351				
ALBUMINE	Evaluated	258	94	2	251	89	2	242	88	1	235	80			
	Mean	4.22	4.32	6.70	4.31	4.40	4.21	4.30	4.28	4.89	4.32	4.34			
	STD	0.50	0.44	3.39	0.44	0.36	0.02	0.43	0.36		0.40	0.39			
	Min	1.25	2.90	4.30	1.55	3.68	4.20	2.30	2.87	4.89	3.03	3.07			
	Max	5.77	5.87	9.10	5.73	5.66	4.23	5.65	5.05	4.89	5.98	5.30			
	Median	4.20	4.29	6.70	4.30	4.31	4.21	4.30	4.29	4.89	4.30	4.30			
	Diff. Median			1.70	0.00	0.03	-0.10	0.00	0.00	0.26	0.06	0.07			
P value			1.0000	0.1600	0.1449	0.5000	0.2782	0.7483	1.0000	0.1473	0.2349				

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN580077
REBOXETINE - PROTOCOL 20124/013

TABLE No. : 91

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1 DURING THE OPEN PHASE

		VISIT NO.													
		-1		1		2		3		4		5		6	
		F	M	F	M	F	M	F	M	F	M	F	M		
TOT BILIRUBIN	Evaluated	246	91	2	238	87	2	227	86	1	221	76			
	Mean	0.65	0.74	0.57	0.62	0.72	0.53	0.62	0.69	0.79	0.63	0.70			
	STD	0.26	0.31	0.08	0.28	0.26	0.16	0.29	0.23		0.24	0.23			
	Min	0.17	0.17	0.52	0.15	0.23	0.41	0.17	0.19	0.79	0.19	0.22			
	Max	2.28	2.20	0.63	3.27	1.43	0.64	2.67	1.30	0.79	1.80	1.48			
	Median	0.61	0.70	0.57	0.60	0.70	0.53	0.60	0.70	0.79	0.60	0.70			
	Diff. Median			0.10	0.00	0.00	0.12	0.00	0.00	-0.02	0.00	0.00			
	P value			1.0000	0.3283	0.9437	0.5000	0.2817	0.2126	1.0000	0.6255	0.7455			
DIR BILIRUBIN	Evaluated	224	84	2	222	79	2	215	80	1	212	70			
	Mean	0.13	0.15	0.12	0.13	0.14	0.11	0.13	0.15	0.04	0.14	0.15			
	STD	0.09	0.09	0.06	0.08	0.07	0.13	0.10	0.10		0.09	0.07			
	Min	0.00	0.00	0.08	-0.01	0.00	0.02	-0.01	0.00	0.04	-0.02	0.00			
	Max	0.60	0.53	0.16	0.36	0.30	0.20	0.58	0.56	0.04	0.48	0.32			
	Median	0.12	0.15	0.12	0.15	0.15	0.11	0.14	0.15	0.04	0.15	0.15			
	Diff. Median			0.20	0.00	0.00	-0.03	0.00	0.00	-0.22	0.00	0.00			
	P value			1.0000	0.6865	0.9802	1.0000	0.8350	0.7502	1.0000	0.0302	0.5139			
SGOT	Evaluated	262	95	2	255	90	2	244	88	1	234	79			
	Mean	20.16	21.51	32.33	19.55	20.74	24.55	19.97	21.14	17.27	19.78	20.51			
	STD	8.09	12.52	4.24	6.31	12.58	7.71	9.04	17.27		6.96	11.78			
	Min	-4.12	10.00	29.33	7.60	9.20	19.09	10.36	10.00	17.27	10.00	10.00			
	Max	78.00	129.29	35.33	74.00	127.86	30.00	85.20	174.29	17.27	68.00	117.14			
	Median	18.88	20.40	32.33	18.57	18.93	24.55	17.86	18.62	17.27	18.57	19.60			
	Diff. Median			0.10	0.00	-0.04	0.51	-0.04	-0.05	-0.23	-0.03	-0.05			
	P value			1.0000	0.4060	0.2200	0.5000	0.0917	0.1383	1.0000	0.0851	0.1577			
SGPT	Evaluated	262	95	2	255	92	2	244	88	1	234	80			
	Mean	19.74	22.97	33.33	17.96	22.53	27.71	19.29	22.89	31.25	19.38	22.22			
	STD	16.82	17.49	5.89	8.79	18.84	5.60	14.66	15.47		12.02	14.33			
	Min	-32.50	6.88	29.17	-1.25	2.41	23.75	5.00	5.00	31.25	5.00	6.25			
	Max	143.79	139.17	37.50	61.90	150.83	31.67	137.76	124.17	31.25	116.96	118.33			
	Median	15.89	19.66	33.33	16.67	18.33	27.71	16.61	20.00	31.25	17.50	20.00			

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN0530077
REBOXETINE - PROTOCOL 20124/013

TABLE No. : 91

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1 DURING THE OPEN PHASE

		VISIT NO.										
		-1		1	2		3	4		5	6	
		F	M	F	F	M	F	F	M	M	F	M
SGPT	Diff. Median			0.05	0.00	-0.06	0.36	0.00	0.00	0.55	0.00	0.00
	P value			1.0000	0.7660	0.1820	0.5000	0.4324	0.8143	1.0000	0.9927	0.7408
GAMMA-GT	Evaluated	257	95	2	252	90	2	241	87	1	231	76
	Mean	38.57	49.90	61.33	33.05	38.97	12.67	32.44	40.52	31.08	32.79	37.34
	STD	38.68	75.47	52.80	27.72	57.13	0.94	26.34	60.80		24.22	49.61
	Min	6.67	6.75	24.00	4.97	3.41	12.00	5.33	9.54	31.08	7.31	6.30
	Max	430.15	521.50	98.67	342.77	504.08	13.33	309.54	536.88	31.08	259.08	420.03
	Median	31.38	29.50	61.33	28.92	27.45	12.67	30.86	27.64	31.08	30.15	28.04
	Diff. Median			-0.17	-0.05	-0.08	-1.06	-0.07	-0.09	0.19	0.00	-0.12
	P value			1.0000	0.0012	0.0003	1.0000	0.0002	0.0011	1.0000	0.0793	0.0008
ALK. PHOSPH.	Evaluated	257	95	2	250	91	2	243	88	1	233	78
	Mean	106.97	132.29	68.13	105.68	126.39	108.25	105.01	126.75	120.27	105.80	126.11
	STD	35.22	44.16	23.45	34.99	50.19	82.29	33.72	47.03		34.04	44.46
	Min	44.12	48.32	51.55	40.60	52.88	50.06	33.87	44.77	120.27	36.70	44.27
	Max	242.91	352.91	84.71	324.66	377.04	166.44	300.42	377.04	120.27	299.19	400.22
	Median	103.65	127.28	68.13	101.10	121.28	108.25	100.37	121.39	120.27	102.42	123.73
	Diff. Median			0.07	-0.02	-0.01	0.31	0.00	-0.04	-0.51	-0.02	-0.03
	P value			1.0000	0.0918	0.2622	0.5000	0.2567	0.1339	1.0000	0.2127	0.0924
GLOBULIN-S: ALPHA 1	Evaluated	255	94	2	250	90	2	242	87	1	234	79
	Mean	0.15	0.14	0.25	0.14	0.13	0.23	0.16	0.15	0.28	0.15	0.14
	STD	0.15	0.12	0.07	0.12	0.11	0.10	0.18	0.15		0.13	0.12
	Min	-0.09	-0.10	0.20	-0.13	-0.11	0.16	-0.13	-0.06	0.28	-0.09	-0.13
	Max	1.07	0.68	0.30	0.80	0.57	0.30	1.36	0.78	0.28	0.65	0.56
	Median	0.12	0.12	0.25	0.12	0.11	0.23	0.12	0.11	0.28	0.12	0.10
	Diff. Median			-0.25	0.00	-0.04	-0.23	0.00	-0.04	0.66	0.00	-0.04
	P value			0.5000	0.6048	0.2347	1.0000	0.6220	0.7620	1.0000	0.7104	0.3521
GLOBULIN-S: ALPHA 2	Evaluated	255	94	2	250	90	2	242	87	1	234	79
	Mean	0.78	0.76	0.64	0.77	0.76	0.79	0.77	0.77	0.83	0.77	0.79
	STD	0.22	0.21	0.17	0.19	0.21	0.26	0.18	0.21		0.19	0.23
	Min	0.20	0.25	0.52	0.31	0.36	0.60	0.27	0.35	0.83	0.19	0.40

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

PHARMACIA CN9350077
REBOXETINE - PROTOCOL 20124/013

TABLE No. : 91

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1 DURING THE OPEN PHASE

		VISIT NO.													
		-1		1		2		3		4		5		6	
		F	M	F	M	F	M	F	M	F	M	F	M	F	M
GLOBULIN-S: ALPHA 2	Max	1.57	1.52	0.76	1.51	1.31	0.97	1.41	1.42	0.83	1.41	1.71			
	Median	0.75	0.73	0.64	0.75	0.74	0.79	0.75	0.74	0.83	0.75	0.74			
	Diff. Median			-0.20	0.00	0.02	-0.11	0.00	0.00	0.75	-0.01	0.02			
	P value			1.0000	0.7019	0.7363	0.5000	0.9566	0.5858	1.0000	0.3788	0.5350			
GLOBULIN-S: BETA	Evaluated	255	94	2	250	90	2	242	87	1	234	79			
	Mean	0.91	0.86	0.87	0.91	0.89	1.03	0.90	0.89	0.93	0.90	0.88			
	STD	0.22	0.21	0.05	0.21	0.21	0.09	0.22	0.24		0.23	0.21			
	Min	0.22	0.31	0.83	0.11	0.19	0.97	0.25	0.14	0.93	0.17	0.38			
	Max	1.82	1.55	0.90	1.75	1.78	1.10	1.73	1.71	0.93	1.54	1.46			
	Median	0.90	0.87	0.87	0.90	0.89	1.03	0.89	0.89	0.93	0.90	0.87			
	Diff. Median			0.17	-0.03	0.06	0.47	-0.03	-0.01	-0.11	0.00	0.00			
	P value			0.5000	0.6306	0.1349	0.5000	0.5553	0.7891	1.0000	0.7686	0.7312			
GLOBULIN-S: GAMMA	Evaluated	255	94	2	250	90	2	242	87	1	234	79			
	Mean	1.09	1.00	1.24	1.12	1.04	1.01	1.11	1.04	0.47	1.10	1.11			
	STD	0.40	0.35	0.28	0.36	0.31	0.07	0.39	0.33		0.36	0.36			
	Min	-0.01	0.09	1.04	0.16	0.32	0.96	0.01	0.27	0.47	0.11	0.34			
	Max	3.92	2.08	1.44	3.84	1.73	1.06	4.10	2.23	0.47	3.81	1.98			
	Median	1.04	1.00	1.24	1.12	1.02	1.01	1.11	1.02	0.47	1.08	1.15			
	Diff. Median			-0.35	0.06	0.00	0.29	0.04	0.01	-0.96	0.00	0.05			
	P value			0.5000	0.0533	0.2898	1.0000	0.0794	0.4315	1.0000	0.6617	0.0881			
TOT. CHOLEST.	Evaluated	259	95	2	255	91	2	242	86	1	234	79			
	Mean	217.10	209.93	210.00	208.21	207.49	207.82	210.92	209.66	260.77	205.28	204.38			
	STD	56.87	44.59	21.87	47.12	35.99	57.77	43.19	33.11		42.27	36.72			
	Min	123.45	64.09	194.53	132.37	142.57	166.97	107.38	152.55	260.77	122.55	140.75			
	Max	763.64	360.29	225.47	502.11	296.88	248.67	390.33	307.47	260.77	339.10	292.86			
	Median	207.11	208.57	210.00	199.29	199.87	207.82	202.12	204.75	260.77	196.62	201.57			
	Diff. Median			-0.32	-0.06	-0.03	-0.18	-0.05	0.02	0.32	-0.08	-0.04			
	P value			1.0000	0.0001	0.3130	0.5000	0.0657	0.8614	1.0000	0.0000	0.0777			
TRIGLYCERIDES	Evaluated	259	93	2	250	91	2	242	87	1	232	79			
	Mean	109.64	197.18	115.27	108.37	183.54	143.04	107.96	196.26	274.00	106.15	183.84			

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS 340077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 91

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1 DURING THE OPEN PHASE

		VISIT NO.													
		-1		1		2		3		4		5		6	
		F	M	F	M	F	M	F	M	F	M	F	M	F	M
TRIGLYCERIDES	STD	52.13	97.28	63.26	47.91	85.13	10.52	51.80	113.37					46.29	112.98
	Min	-20.25	21.48	70.53	19.32	40.53	135.60	6.13	40.53	274.00	29.87	-3.93			
	Max	387.56	522.33	160.00	358.64	458.57	150.48	374.28	673.43	274.00	347.07	670.07			
	Median	100.56	184.96	115.27	92.82	164.82	143.04	92.30	158.67	274.00	92.82	151.39			
	Diff. Median			0.30	0.00	-0.06	-0.28	-0.01	0.00	0.06	-0.02	-0.06			
	P value			1.0000	0.7606	0.0229	0.5000	0.1337	0.7768	1.0000	0.1017	0.1357			
GLUCOSE	Evaluated	261	95	2	256	90	2	244	88	1	235	79			
	Mean	93.16	95.96	95.38	91.44	93.80	78.75	91.40	96.16	84.00	91.50	94.18			
	STD	15.45	31.17	1.24	14.44	32.55	2.47	16.76	30.10		15.04	23.24			
	Min	63.64	65.23	94.50	58.33	61.25	77.00	57.27	60.45	84.00	54.25	63.64			
	Max	178.50	354.67	96.25	166.76	354.67	80.50	198.33	341.83	84.00	191.33	271.83			
	Median	92.17	89.25	95.38	89.54	91.00	78.75	89.83	93.04	84.00	90.68	91.67			
	Diff. Median			0.18	-0.05	0.00	-0.20	-0.04	-0.05	0.15	-0.05	-0.09			
	P value			0.5000	0.0329	0.2153	0.5000	0.1083	0.8678	1.0000	0.1195	0.1625			
NA+	Evaluated	262	95	2	256	92	2	244	88	1	235	80			
	Mean	138.82	138.57	140.50	138.46	139.00	139.83	138.48	138.54	138.67	138.44	138.63			
	STD	2.74	2.69	0.71	2.45	2.84	1.65	2.43	2.31		2.54	2.49			
	Min	134.24	134.67	140.00	132.00	134.24	138.67	132.67	134.00	138.67	132.00	134.82			
	Max	153.00	146.00	141.00	147.00	147.00	141.00	145.00	147.00	138.67	148.00	147.00			
	Median	138.35	138.35	140.50	138.00	138.35	139.83	138.00	138.18	138.67	138.00	138.35			
	Diff. Median			-0.15	0.00	0.06	0.07	-0.03	0.00	0.00	0.00	0.06			
	P value			0.5000	0.1099	0.0739	1.0000	0.1680	0.9787		0.3287	0.4094			
CL-	Evaluated	220	82	2	220	81	2	209	78	1	211	73			
	Mean	100.32	100.17	104.15	100.06	100.16	106.20	99.67	99.48	102.16	99.69	100.01			
	STD	3.00	2.73	2.61	2.93	3.09	2.32	3.61	3.26		3.64	2.67			
	Min	93.20	94.80	102.31	91.60	95.60	104.56	78.80	83.60	102.16	74.80	95.82			
	Max	110.80	108.24	106.00	110.80	112.40	107.85	110.00	108.40	102.16	111.60	107.23			
	Median	99.82	99.60	104.15	99.56	99.45	106.20	99.45	99.45	102.16	99.20	99.45			
	Diff. Median			-0.23	0.00	-0.03	0.68	0.00	-0.05	-0.41	0.00	0.00			
	P value			1.0000	0.5840	0.8170	0.5000	0.4093	0.2078	1.0000	0.7469	0.4368			

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS 9690077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 91

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1 DURING THE OPEN PHASE

		VISIT NO.										
		-1		1	2		3	4		5	6	
		F	M	F	F	M	F	F	M	M	F	M
K+	Evaluated	262	95	2	256	92	2	244	88	1	235	80
	Mean	4.13	4.05	4.35	4.13	4.07	4.19	4.14	4.06	4.10	4.10	3.99
	STD	0.44	0.38	0.91	0.42	0.38	0.83	0.41	0.43		0.41	0.31
	Min	2.30	3.40	3.71	3.10	3.30	3.60	3.10	3.10	4.10	3.10	3.40
	Max	6.70	5.20	4.99	5.60	5.10	4.78	5.67	5.90	4.10	5.79	5.21
	Median	4.07	4.00	4.35	4.06	3.98	4.19	4.06	3.98	4.10	4.00	3.98
	Diff. Median			-0.20	0.00	0.05	-0.16	0.05	0.05	0.00	0.00	0.00
	P value			0.5000	0.7376	0.2599	0.5000	0.2140	0.2665		0.8794	0.5954
CA++	Evaluated	211	69	2	200	63	1	197	63		189	59
	Mean	4.86	4.89	4.98	4.90	4.98	4.80	4.89	4.91		4.92	4.93
	STD	0.32	0.32	0.25	0.33	0.26		0.35	0.29		0.28	0.23
	Min	3.72	4.17	4.80	3.77	4.41	4.80	3.72	3.92		4.19	4.39
	Max	5.50	5.40	5.15	6.10	5.59	4.80	6.25	5.40		5.79	5.35
	Median	4.90	4.94	4.98	4.95	5.00	4.80	4.90	4.90		4.95	4.97
	Diff. Median			0.15	0.02	0.05	0.05	0.00	0.00		0.05	0.00
	P value			0.5000	0.0711	0.1553	1.0000	0.3881	0.6981		0.0202	0.8102
PO4-	Evaluated	255	94	2	249	88	2	240	88	1	233	80
	Mean	1.21	1.21	1.05	1.28	1.29	1.09	1.24	1.23	1.44	1.24	1.24
	STD	0.18	0.17	0.07	0.29	0.30	0.26	0.17	0.16		0.19	0.16
	Min	0.71	0.64	1.00	0.80	0.77	0.91	0.78	0.83	1.44	0.64	0.90
	Max	1.64	1.57	1.10	3.64	3.16	1.27	1.73	1.64	1.44	2.71	1.60
	Median	1.23	1.20	1.05	1.29	1.27	1.09	1.25	1.23	1.44	1.26	1.27
	Diff. Median			-0.37	0.11	0.13	-0.15	0.07	0.00	0.26	0.06	0.06
	P value			0.5000	0.0000	0.0023	0.5000	0.0207	0.3767	1.0000	0.0262	0.1476

P value: probability from Wilcoxon's rank signed test

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RRD
REBOMETINE - PROTOCOL 20124-013

TABLE No.: 92

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1 DURING THE OPEN PHASE

	VISIT NO.																				
	1			2			3			4			5			6					
	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H	P val	
HGB	LOW				24	16							20	20				21	18		
	NORMAL	1			14	250	6		1	1			10	240	4			13	220	9	
	HIGH																				
HTC	LOW				30	24			1				28	25				21	31		
	NORMAL	2			19	260	4		1	1			20	249	2			22	234	1	
	HIGH																				
RBC	LOW				15	18	1						10	21	2			9	23	1	
	NORMAL	2			13	270	4		1	1			11	259	9			8	254	4	
	HIGH																				
PLATELETS	LOW									1					2						2
	NORMAL	2			2	304	6		1	1			2	297	4			2	281	7	
	HIGH																				
HRC	LOW				4	10	1						5	8	1			3	11		
	NORMAL	1			5	303	7			2			8	286	7			4	277	5	
	HIGH																				
HRC: N	LOW				15	24			1				13	22	2			14	17	4	
	NORMAL				17	224	10		1	1			18	213	16			10	212	13	
	HIGH																				
HRC: E	LOW				11	37	5						13	36	1			11	31	5	
	NORMAL																				
	HIGH																				

P val: probability from Maxwell's test
L = Low N = Normal H = High

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBORETTINE - PROTOCOL 20124/013
TABLE No.: 92

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1 DURING THE OPEN PHASE

	VISIT NO.																		
	1			2			3			4			5			6			
	L	N	H	L	N	H	L	N	H	L	N	H	L	N	H	L	N	H	
HBC: E	2			26	166	22				15	171	22				20	151	26	
				1.000					1.000							1.000			
HBC: B																			
HBC: L	1																		
HBC: H																			
CREATININE																			
BUN																			
URIC ACID	1																		

P val: probability from Maxwell's test
L = Low N = Normal H = High

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 92

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1 DURING THE OPEN PHASE

	VISIT NO.																						
	1			2			3			4			5			6							
	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H	P val			
URIC ACID				1.000	14	5	0.340					11	8	0.112						13	6	0.226	
TOT. PROTEINS					10							1	9							8			
	2				2	318	4					2	310	4						1	294	4	
				1.000	5	3	0.066					7	1	0.007						1.000	7	1	0.044
ALBUMINE					2	6	1					3	5							2	5		
	1	1			2	301	11			2		5	292	11						1	2	281	12
				1.000	8	4	0.185					10	4	0.976						1.000	9	4	0.424
TOT BILIRUBIN					3							1	1								2		
	2				4	286	15			2		2	281	9							273	7	
				1.000	13	3	0.867					12	5	0.683						1.000	11	3	0.395
DIR BILIRUBIN																							
	2				1	236	16			2		1	228	23							1	217	23
				1.000	29	8	0.093					24	17	0.600						1.000	22	17	0.600
SGOT					1	1								1									
	1				2	307	9			2		2	296	11							1	281	9
				1.000	19	5	0.244					17	7	0.319						1.000	18	5	0.122
SGPT					1																		
	1				3	291	11			1		1	275	17							1	258	19
				1.000	1	21	18	0.078				22	18	0.522						1.000	22	15	0.755

(CONTINUED)

P val: probability from Maxwell's test
L = Low N = Normal H = High

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS, RED
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 92

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1 DURING THE OPEN PHASE

	VISIT NO.																			
	1			2			3			4			5			6				
	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H	P val
GAMMA-GT	LOH				2				1	1										
	NORMAL	1			2	232	19		1	225	21						5	207	20	
	HIGH			1	1	0.000	0.023	1	1	0.000	0.030					1	0.000	0.019		
ALK. PHOSPH.	LOW				8	9			1	6	10						9	5		
	NORMAL	1			6	283	8		1	6	273	11					9	260	6	
GLOBULINS: ALPHA 1	HIGH			1	10	14	0.663		1	10	15	0.592				1	1.000	0.418		
	LOW				91	22	2			86	23	2					72	31	3	
	NORMAL	1			34	145	11		1	46	121	18				1	42	115	18	
GLOBULINS: ALPHA 2	HIGH			1	1	15	0.323	1	1	1	17	15	0.031				1	1.000	0.376	
	LOW	1			23	31	1			23	28	3					21	26	2	
	NORMAL	1			26	188	16		2	21	193	16					24	184	12	
GLOBULINS: BETA	HIGH			1	1	0.000	0.149			1	0.000	0.199					1	1.000	0.173	
	LOW				21	22	2		1	21	19	4					18	21	3	
	NORMAL	2			9	204	26		1	15	198	23				1	18	180	27	
GLOBULINS: GAMMA	HIGH			1	1	0.000	0.056			1	0.000	0.591					3	29	14	0.863
	LOW				29	44			1	34	35						24	38		
	NORMAL	1			27	202	9		1	28	201	9			1		34	185	12	
TOT. CHOLEST. LOW	HIGH	1			12	10	0.105			1	0.000	0.613				1	1.000	0.792		
	LOW				8	12				6	13						6	12		

331

(CONTINUED)

P val: probability from Maxwell's test
L = Low N = Normal H = High

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 92

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1 DURING THE OPEN PHASE

	VISIT NO.																							
	1			2			3			4			5			6								
	L	N	H	L	N	H	L	N	H	L	N	H	L	N	H	L	N	H						
TOT. CHOLEST.	NORMAL	1		8	275	5			1			6	263	8			1			20	235	9		
	HIGH	1	1.000	14	21	0.080			1	1.000	16	16	0.073			1.000						16	15	0.138
TRIGLYCERIDES	LOW			1	1						2	1										2		
	NORMAL	2		1	273	20	1		1		259	26	1		1					4	246	20		
GLUCOSE	HIGH		1.000	18	21	0.949	1	1.000	18	23	0.293			1.000	1	1.000	1	19	19	0.525				
	LOW			1	6				1	6									1	5				
CA++	NORMAL	2		10	250	22	2		12	239	23			1					11	220	26			
	HIGH		1.000	30	25	0.328			1.000	28	23	0.288			1.000				29	22	0.299			
CA+-	LOW			12	18	1			8	23									7	21				
	NORMAL	2		19	294	1	2		23	275	1			1					23	261	2			
CL-	HIGH		1.000	2	2	1.000			1.000	2	0.846			1.000				1	0.809					
	LOW			43	19				39	21								32	32					
K+	NORMAL	2		32	186	6	1	1	44	164	6	1		1				35	164	10				
	HIGH		1.000	2	3	0.070			1.000	3	3	0.070			1.000				1	2	0.131			
K+-	LOW			12					12									1	9					
	NORMAL	1		8	320	5	2		7	304	7	1		1				4	294	5				
CA++	HIGH	1	1.000	2	2	0.352			1.000	2	0.129			1.000				2	0.201					
	LOW			7	28				9	27								5	30					
CA++	NORMAL	2		15	208	3	1		22	200	2							11	199	3				

(CONTINUED)

P val: probability from Maxwell's test
L = Low N = Normal H = High

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 92

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1 DURING THE OPEN PHASE

	VISIT NO.																				
	1			2			3			4			5			6					
	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H	P val	
CA++				1.000				0.031													0.003
PO4-					9	19				8	20						6	20	1		
NORMAL	2				12	264	17		1	1			15	260	11		1				
HIGH				1.000				0.090													1.000
					8	3				9	4										10
																					2
																					0.086

P val: probability from Maxwell's test
L = Low N = Normal H = High

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS RRD
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 93

NUMBER AND PERCENTAGE OF SUBJECTS WITH LABORATORY ABNORMALITIES OF CLINICAL RELEVANCE ACCORDING TO SELECTED CRITERIA
OPEN PHASE

	VISIT NO.																							
	-1		1		2		3		4		5		6											
	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z										
HB	7	1.97			2	0.58			3	0.91			3	0.95										
HTC	6	1.69			1	0.29			2	0.61			2	0.64										
RBC	6	1.72			3	0.87			1	0.30			2	0.64										
PLATELETS																								
HBC					1	0.29			1	0.30			1	0.32										
MBC: N	1	0.29			3	0.89			1	0.32			2	0.67										
MBC: E																								
MBC: B																								
MBC: L					1	0.30																		
MBC: X																								
CREATININE									1	0.30														
BUN																								
URIC ACID	3	0.85			1	0.29			2	0.61			3	0.96										
TOT. PROTEINS																								
ALBUMINE					1	50.00																		
TOT BILIRUBIN	2	0.59			1	0.31			2	0.64			2	0.71										
DIR BILIRUBIN	5	1.62							8	2.71			2	0.64										
SGOT	3	0.84			2	0.58			4	1.20			5	1.59										
SGPT	9	2.52			6	1.73			6	1.81			8	2.61										
GAMMA-GT	25	7.10			10	2.92			11	3.35			2	0.64										
ALK. PHOSPH.	1	0.28			2	0.59			2	0.60			2	0.64										

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 93

NUMBER AND PERCENTAGE OF SUBJECTS WITH LABORATORY ABNORMALITIES OF CLINICAL RELEVANCE ACCORDING TO SELECTED CRITERIA
OPEN PHASE

	VISIT NO.													
	-1		1		2		3		4		5		6	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
GLOBULINS: ALPHA 1	60	17.19			52	15.29			60	18.24			56	17.89
GLOBULINS: ALPHA 2	18	5.16			8	2.35			9	2.74			10	3.19
GLOBULINS: BETA	8	2.29			8	2.35			7	2.13			6	1.92
GLOBULINS: GAMMA	8	2.29			8	2.35			6	1.82			4	1.28
TOT. CHOLEST.	3	0.85			2	0.58			2	0.61			1	0.32
TRIGLYCERIDES	21	5.97			13	3.81			15	4.56			13	4.18
GLUCOSE	10	2.81			4	1.16			7	2.11			5	1.59
Na+														
CL-									4	1.39			2	0.70
K+	2	0.56												
CA++	2	0.71							1	0.38				
PO4-	9	2.58			13	3.86			10	3.05			7	2.24
T3														
T4														

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS 9580077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

REBOXETINE		VISIT NO.															
		-1		2		4		6		9		10		16		18	
		F	M	F	M	F	M	F	M	F	M	F	M	F	M		
HB	Evaluated	113	30	113	30	113	29	114	29	1	107	25	1	88	21		
	Mean	14.28	15.12	14.30	14.99	14.40	15.10	14.39	15.11	14.57	14.20	15.02	16.74	14.25	15.04		
	STD	2.02	1.69	1.92	1.53	2.11	1.52	2.04	1.80		2.00	1.69		1.82	1.80		
	Min	9.57	11.80	10.70	12.50	9.70	12.90	9.60	12.70	14.57	9.40	12.50	16.74	10.50	13.00		
	Max	21.40	18.78	20.80	18.07	22.00	19.10	21.20	20.82	14.57	22.60	19.84	16.74	19.33	20.52		
	Median	13.90	15.21	14.00	15.21	13.80	15.21	14.05	14.83	14.57	13.80	15.21	16.74	13.92	14.90		
	Diff. Median			0.01	0.00	0.02	0.05	0.00	0.00	-0.14	-0.03	0.00	0.52	0.03	-0.07		
	P value			0.7507	0.7971	0.3358	0.7791	0.3014	0.8345	1.0000	0.6570	0.7291	1.0000	0.6870	0.6624		
HTC	Evaluated	113	29	113	29	113	29	113	29	1	107	25	1	88	21		
	Mean	38.59	43.95	38.72	44.11	38.60	44.39	38.83	43.94	41.00	38.66	44.10	44.43	38.59	43.79		
	STD	3.63	3.28	3.26	3.66	3.13	3.10	2.91	3.13		3.17	4.05		2.63	3.29		
	Min	24.50	38.43	31.13	38.90	29.00	39.29	28.00	39.29	41.00	29.00	38.43	44.43	31.13	39.29		
	Max	46.50	51.50	48.25	53.00	48.22	51.91	46.00	53.30	41.00	49.53	57.80	44.43	44.00	53.60		
	Median	39.00	43.57	39.00	43.57	39.00	43.57	39.00	43.57	41.00	38.88	43.57	44.43	39.00	43.57		
	Diff. Median			0.00	0.04	0.00	0.07	0.00	0.00	0.00	0.00	-0.06	0.14	0.00	0.00		
	P value			0.7490	0.8651	0.9243	0.1855	0.4298	0.6670		0.8030	0.5555	1.0000	0.8262	0.7416		
RBC	Evaluated	110	29	113	30	113	29	114	29	1	107	25	1	88	21		
	Mean	4.46	5.01	4.39	4.98	4.45	5.02	4.50	4.97	4.54	4.51	4.99	5.03	4.55	5.22		
	STD	0.83	0.53	0.48	0.53	0.45	0.44	0.49	0.42		0.55	0.50		0.49	0.92		
	Min	0.57	4.42	2.15	3.97	2.46	4.58	3.06	4.42	4.54	2.87	4.50	5.03	3.30	4.58		
	Max	11.20	7.38	5.56	6.80	5.99	6.46	7.24	6.63	4.54	6.59	6.71	5.03	6.57	8.58		
	Median	4.45	4.89	4.45	4.89	4.48	4.89	4.48	4.89	4.54	4.53	4.88	5.03	4.50	4.87		
	Diff. Median			0.00	0.00	0.06	0.00	0.03	0.00	-0.02	0.00	-0.06	0.23	0.06	-0.02		
	P value			0.9621	0.4383	0.3215	0.7701	0.1960	0.3129	1.0000	0.8855	0.2943	1.0000	0.2291	0.5030		
PLATELETS	Evaluated	109	28	107	29	107	29	110	27	1	106	25	1	89	2		
	Mean	234.37	237.36	229.01	241.11	233.82	228.68	235.69	228.47	194.64	237.15	238.18	251.79	242.18	233.11		
	STD	51.99	49.01	48.87	38.74	69.76	30.44	55.64	23.46		62.63	46.22		53.46	39.41		
	Min	150.00	171.88	150.00	191.88	92.19	173.13	137.50	188.13	194.64	125.00	176.88	251.79	151.67	162.51		
	Max	460.94	392.19	437.50	375.00	650.00	300.00	439.06	275.00	194.64	542.19	396.87	251.79	417.50	337.00		
	Median	230.36	228.62	220.63	239.29	217.86	225.00	218.75	230.36	194.64	228.04	226.88	251.79	235.00	239.29		

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN9510077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

REBOXETINE		VISIT NO.															
		-1		2		4		6		9		10		16		18	
		F	M	F	M	F	M	F	M	F	M	F	M	F	M		
PLATELETS	Diff. Median			-0.01	0.02	0.00	-0.01	0.01	-0.00	-0.11	0.02	0.01	0.09	0.01	0.07		
	P value			0.1949	0.7345	0.8986	0.4624	0.5818	0.9534	1.0000	0.1292	0.9338	1.0000	0.1818	0.7372		
WBC	Evaluated	113	30	113	30	113	29	114	29	1	107	25	1	88	21		
	Mean	6.91	7.55	6.85	7.01	7.11	7.25	7.12	7.30	6.13	6.94	8.02	6.67	6.78	7.67		
	STD	1.74	3.67	2.11	2.60	1.95	2.11	1.74	2.90		2.06	3.45		1.77	3.21		
	Min	3.20	4.77	1.90	4.50	3.85	4.09	3.07	4.64	6.13	3.55	5.34	6.67	3.85	5.52		
	Max	13.11	25.11	14.45	19.91	13.38	15.64	12.86	20.47	6.13	16.20	21.03	6.67	12.84	18.99		
	Median	6.82	6.55	6.40	6.70	6.64	6.67	6.77	6.73	6.13	6.45	6.67	6.67	6.40	6.91		
	Diff. Median			-0.04	-0.03	0.01	-0.04	0.00	-0.04	0.17	-0.04	0.00	0.10	-0.06	-0.04		
	P value			0.3831	0.4025	0.5978	0.8745	0.3388	0.4396	1.0000	0.3604	0.8790	1.0000	0.1016	0.4896		
WBC: N	Evaluated	110	29	113	30	108	29	108	29	1	101	24	1	83	20		
	Mean	61.91	62.61	61.81	62.55	62.17	61.70	62.72	62.72	63.92	62.65	62.63	63.92	62.33	64.05		
	STD	5.09	3.27	6.08	2.53	5.06	2.94	5.12	2.95		4.80	5.56		4.32	3.11		
	Min	46.00	55.00	33.00	56.62	43.00	53.00	43.00	56.58	63.92	48.00	45.00	63.92	47.00	57.00		
	Max	79.00	70.00	84.00	67.00	78.00	67.00	81.00	68.15	63.92	87.00	74.00	63.92	69.08	71.00		
	Median	62.17	62.00	62.81	62.67	63.00	62.00	63.00	63.00	63.92	63.25	63.63	63.92	63.67	63.67		
	Diff. Median			0.07	-0.03	0.07	-0.03	0.07	-0.03	-0.12	0.03	0.12	-0.12	0.00	0.13		
	P value			0.4684	0.7791	0.2564	0.1704	0.2015	0.8413	1.0000	0.1513	0.2870	1.0000	0.4568	0.0990		
WBC: E	Evaluated	109	28	110	30	106	29	105	28	1	98	24	1	83	20		
	Mean	2.15	1.85	1.84	2.20	1.96	2.37	2.05	2.21	2.00	1.69	1.87	1.50	1.80	1.88		
	STD	1.48	0.97	1.07	1.05	1.14	1.37	1.29	1.04		0.91	0.99		0.85	0.81		
	Min	0.33	0.50	0.33	0.50	0.33	0.50	0.33	0.50	2.00	0.33	0.33	1.50	0.33	0.50		
	Max	9.67	5.00	6.00	4.50	5.67	7.00	6.50	4.50	2.00	5.00	4.50	1.50	3.50	3.50		
	Median	2.00	2.00	1.50	2.00	1.74	2.00	1.50	2.00	2.00	1.50	1.75	1.50	1.67	1.50		
	Diff. Median			-0.10	0.25	0.00	0.25	0.00	0.13	-0.25	-0.23	0.00	-0.25	-0.25	0.00		
	P value			0.0330	0.1132	0.3011	0.0221	0.1882	0.1029	1.0000	0.0062	0.7220	1.0000	0.0012	0.9720		
WBC: B	Evaluated	104	28	104	28	102	27	100	27	1	98	24	1	83	20		
	Mean	0.15	0.32	0.08	0.08	0.11	0.17	0.10	0.14	0.00	0.08	0.13	0.00	0.05	0.00		
	STD	0.58	0.52	0.23	0.24	0.29	0.52	0.31	0.30		0.28	0.29		0.21	0.20		
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CMO 580077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

REBOXETINE		VISIT NO.													
		-1		2		4		6		9	10		16	18	
		F	M	F	M	F	M	F	M	F	F	M	M	F	M
WBC: B	Max	5.25	2.25	0.75	0.75	1.50	2.25	1.50	0.75	0.00	1.50	0.75	0.00	1.50	0.75
	Median	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Diff. Median			0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P value			0.6814	0.0918	0.8621	0.4082	0.9577	0.3071		0.3960	0.0352		0.1447	0.0352
WBC: L	Evaluated	110	29	113	30	108	29	108	29	1	101	24	1	83	20
	Mean	29.65	28.41	29.55	28.31	29.38	29.27	28.69	27.71	26.00	29.25	28.52	28.00	29.14	27.47
	STD	4.75	3.89	4.62	2.86	4.18	3.21	4.11	2.81		3.81	2.57		4.90	2.27
	Min	19.00	18.00	15.00	24.00	22.00	25.00	18.00	21.00	26.00	13.00	23.80	28.00	20.00	23.00
	Max	49.00	34.25	45.00	36.00	43.00	37.00	46.00	33.00	26.00	43.00	33.40	28.00	49.00	33.00
	Median	29.45	28.00	29.00	27.75	28.35	28.50	28.00	28.00	26.00	29.00	28.25	28.00	28.00	27.50
	Diff. Median			-0.03	-0.10	-0.05	-0.05	-0.02	0.00	0.10	0.00	-0.08	0.30	-0.05	-0.13
	P value			0.8178	0.8061	0.3015	0.9294	0.1614	0.5208	1.0000	0.3899	0.9228	1.0000	0.2629	0.2570
WBC: M	Evaluated	109	28	109	30	106	29	108	29	1	100	24	1	83	20
	Mean	3.89	4.37	3.82	4.85	3.88	4.43	4.03	4.87	4.00	4.07	4.05	2.50	4.62	4.28
	STD	2.15	2.28	2.05	2.47	2.33	2.52	2.22	2.01		2.26	1.73		1.99	2.20
	Min	0.00	0.00	0.00	1.00	0.00	0.00	0.00	1.00	4.00	0.00	1.00	2.50	1.00	0.00
	Max	9.00	9.00	9.00	13.00	9.40	9.00	10.00	9.00	4.00	10.20	7.00	2.50	9.00	9.00
	Median	3.80	3.92	3.80	4.30	3.50	3.50	4.00	5.00	4.00	4.00	3.90	2.50	4.50	4.17
	Diff. Median			0.00	0.00	0.00	0.00	0.00	0.13	0.25	0.00	-0.06	-0.25	0.00	-0.33
	P value			0.7630	0.6001	0.9506	0.8548	0.4637	0.4231	1.0000	0.5705	0.1844	1.0000	0.0296	0.5001
CREATINI-NE	Evaluated	113	30	115	30	113	30	113	29	1	107	25	1	90	21
	Mean	0.77	0.91	0.76	0.87	0.75	0.87	0.74	0.90	0.83	0.75	0.92	0.89	0.75	0.90
	STD	0.13	0.18	0.13	0.10	0.15	0.10	0.13	0.11		0.15	0.14		0.13	0.13
	Min	0.46	0.66	0.50	0.72	0.43	0.69	0.47	0.72	0.83	0.50	0.72	0.89	0.50	0.72
	Max	1.46	1.61	1.44	1.04	1.30	1.08	1.10	1.10	0.83	1.50	1.26	0.89	1.15	1.10
	Median	0.75	0.90	0.74	0.86	0.74	0.88	0.74	0.90	0.83	0.74	0.91	0.89	0.70	0.89
	Diff. Median			0.00	0.00	-0.04	-0.02	0.00	0.00	0.12	0.00	0.00	-0.05	0.00	0.00
	P value			0.2570	0.1311	0.0228	0.3480	0.0162	0.9902	1.0000	0.1102	0.8946	1.0000	0.6549	0.7018
BUN	Evaluated	106	28	115	30	112	30	111	28	1	107	24	1	90	21
	Mean	11.26	12.09	11.07	11.24	10.95	11.37	11.30	12.58	15.70	11.33	12.15	12.58	11.40	12.12

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNO980077
REBOXETINE - PROTOCOL 20124/013

TABLE No. : 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

REBOXETINE		VISIT NO.															
		-1		2		4		6		9		10		16		18	
		F	M	F	M	F	M	F	M	F	M	F	M	F	M		
BUN	STD	2.22	2.58	2.12	2.18	2.15	2.43	2.30	4.52		2.05	2.45		2.07	2.44		
	Min	7.00	7.99	6.51	8.31	6.34	7.33	7.00	8.15	15.70	4.50	8.50	12.58	7.00	7.00		
	Max	18.00	17.45	15.80	17.67	18.00	19.10	17.92	34.09	15.70	18.00	19.31	12.58	18.55	17.51		
	Median	11.13	12.64	10.91	10.99	10.88	11.40	11.40	11.95	15.70	11.40	11.84	12.58	11.42	12.50		
	Diff. Median			-0.02	0.01	-0.03	-0.05	0.00	-0.05	0.36	0.03	-0.03	0.28	-0.01	-0.07		
	P value			0.5262	0.3069	0.5793	0.3127	0.7781	0.4692	1.0000	0.2449	0.8801	1.0000	0.9809	0.9202		
	Evaluated	114	30	115	30	113	30	112	29	1	106	25	1	89	20		
URIC ACID	Mean	4.09	5.65	4.04	5.39	4.06	5.53	4.08	5.48	3.61	4.00	5.34	7.34	3.91	5.10		
	STD	1.00	1.23	0.81	1.21	0.90	1.10	0.85	1.43		0.91	1.22		0.80	1.18		
	Min	2.27	3.29	2.19	3.29	2.29	3.29	2.08	3.50	3.61	0.93	3.50	7.34	2.04	3.60		
	Max	8.83	7.53	6.31	7.52	6.41	7.59	6.87	9.61	3.61	7.34	7.26	7.34	7.44	7.04		
	Median	3.94	5.65	3.95	5.17	4.05	5.54	4.04	5.38	3.61	3.93	5.31	7.34	3.84	5.27		
	Diff. Median			0.00	-0.06	0.00	-0.01	0.01	-0.02	-1.53	-0.02	-0.02	0.02	-0.02	-0.09		
	P value			0.5114	0.4622	0.9466	0.4873	0.6065	0.5757	1.0000	0.6061	0.5318	1.0000	0.2259	0.2305		
TOT. PROTEINS	Evaluated	113	30	113	30	113	30	113	29	1	106	25	1	89	21		
	Mean	7.38	7.49	7.46	7.60	7.45	7.50	7.51	7.52	7.64	7.50	7.68	7.92	7.50	7.42		
	STD	0.59	0.46	0.49	0.32	0.45	0.41	0.47	0.34		0.47	0.41		0.52	0.29		
	Min	5.74	6.59	6.45	6.69	6.40	6.59	6.32	6.59	7.64	6.31	6.86	7.92	6.21	6.97		
	Max	9.73	8.59	9.92	8.02	9.06	8.02	9.73	8.02	7.64	9.54	8.78	7.92	9.73	8.02		
	Median	7.45	7.49	7.45	7.68	7.35	7.64	7.50	7.56	7.64	7.54	7.64	7.92	7.45	7.45		
	Diff. Median			0.05	0.09	0.05	0.03	0.05	0.05	-0.25	0.05	0.10	0.13	0.10	-0.05		
P value			0.2325	0.2832	0.3499	0.6895	0.0356	0.7110	1.0000	0.0546	0.1238	1.0000	0.0274	0.7493			
ALBUMINE	Evaluated	112	29	114	30	113	30	113	29	1	106	25	1	88	21		
	Mean	4.27	4.37	4.29	4.56	4.29	4.35	4.26	4.42	4.37	4.27	4.49	4.96	4.21	4.20		
	STD	0.46	0.35	0.40	0.43	0.38	0.35	0.38	0.38		0.39	0.56		0.41	0.37		
	Min	2.25	3.49	3.35	3.80	3.10	3.52	3.03	3.53	4.37	3.20	3.90	4.96	2.90	3.61		
	Max	5.77	5.07	5.70	5.66	5.11	5.05	5.32	5.30	4.37	5.65	6.52	4.96	5.30	4.80		
	Median	4.22	4.36	4.26	4.61	4.30	4.37	4.20	4.40	4.37	4.20	4.47	4.96	4.20	4.20		
	Diff. Median			0.00	0.07	0.00	-0.04	0.00	0.00	-0.46	0.00	0.00	0.14	-0.01	-0.01		
P value			0.7111	0.0630	0.7080	0.3838	0.7674	0.6895	1.0000	0.9160	0.8801	1.0000	0.4404	0.1077			

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN9380077
REBOXETINE - PROTOCOL 20124/013

TABLE No. : 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

REBOXETINE		VISIT NO.													
		-1		2		4		6		9	10		16	18	
		F	M	F	M	F	M	F	M	F	F	M	M	F	M
TOT BILIRUBIN	Evaluated	107	29	106	29	105	30	105	28	1	99	24	1	82	20
	Mean	0.63	0.70	0.62	0.69	0.65	0.69	0.65	0.73	0.71	0.61	0.68	0.90	0.61	0.58
	STD	0.27	0.25	0.34	0.24	0.33	0.22	0.28	0.17		0.24	0.25		0.21	0.24
	Min	0.17	0.17	0.19	0.31	0.17	0.19	0.20	0.27	0.71	0.20	0.38	0.90	0.17	0.24
	Max	2.28	1.20	3.27	1.13	2.67	1.19	1.80	1.10	0.71	1.30	1.28	0.90	1.27	1.09
	Median	0.60	0.64	0.60	0.60	0.62	0.74	0.60	0.77	0.71	0.60	0.65	0.90	0.60	0.54
	Diff. Median			0.00	0.00	0.00	0.00	0.00	0.00	-0.15	0.00	0.03	0.38	0.00	-0.19
	P value			0.6846	0.8653	0.5845	0.8858	0.4743	0.6673	1.0000	0.8778	0.6907	1.0000	0.8703	0.0434
DIR BILIRUBIN	Evaluated	98	26	101	27	101	28	99	25	1	91	23	1	75	20
	Mean	0.13	0.13	0.13	0.14	0.14	0.15	0.14	0.13	0.04	0.13	0.13	0.05	0.13	0.12
	STD	0.09	0.10	0.08	0.08	0.10	0.11	0.09	0.07		0.08	0.08		0.08	0.08
	Min	0.00	0.00	-0.01	0.00	0.00	0.00	0.00	0.00	0.04	0.00	0.00	0.05	0.00	0.00
	Max	0.46	0.53	0.36	0.30	0.58	0.56	0.43	0.25	0.04	0.37	0.37	0.05	0.44	0.25
	Median	0.14	0.11	0.15	0.15	0.11	0.14	0.15	0.15	0.04	0.15	0.11	0.05	0.15	0.13
	Diff. Median			0.00	0.00	0.00	0.00	0.00	0.00	-0.21	0.00	-0.03	-0.33	0.00	-0.11
	P value			0.6263	0.4808	0.9894	0.8911	0.0165	0.9571	1.0000	0.9631	0.2573	1.0000	0.8225	0.2245
SGOT	Evaluated	114	30	114	30	113	30	112	29	1	106	25	1	89	21
	Mean	20.23	20.31	19.96	19.44	19.25	19.08	20.14	19.18	12.73	20.18	19.94	15.45	20.52	21.50
	STD	7.16	5.94	7.75	6.23	7.04	4.54	6.78	4.44		6.60	4.66		6.99	5.07
	Min	10.00	10.00	7.60	9.20	10.36	10.00	10.00	10.00	12.73	10.00	10.95	15.45	10.00	14.76
	Max	59.29	33.33	74.00	38.00	62.86	30.80	48.00	34.00	12.73	50.00	31.60	15.45	48.00	35.00
	Median	18.57	19.73	18.57	18.57	18.00	18.65	18.95	19.09	12.73	19.29	20.00	15.45	20.00	20.00
	Diff. Median			-0.02	-0.02	-0.05	-0.06	0.00	-0.05	-0.25	0.00	-0.04	-0.20	0.00	0.07
	P value			0.7195	0.5939	0.0982	0.2526	0.9169	0.3965	1.0000	0.8301	0.3339	1.0000	0.5469	0.6279
SGPT	Evaluated	114	30	114	30	113	30	112	29	1	105	25	1	89	21
	Mean	19.50	22.81	17.29	20.89	17.63	21.72	19.86	21.38	11.25	19.99	24.92	25.31	19.15	23.64
	STD	12.77	10.29	6.80	13.80	8.72	9.97	13.51	10.66		11.18	12.45		8.84	8.54
	Min	5.00	7.59	4.14	2.41	5.00	8.13	5.00	8.13	11.25	5.83	10.17	25.31	5.83	11.03
	Max	99.83	48.10	38.33	73.33	71.67	48.33	116.96	58.45	11.25	72.86	60.56	25.31	58.57	52.22
	Median	15.94	19.06	17.08	18.33	15.94	20.00	17.72	21.67	11.25	17.50	21.67	25.31	19.69	21.67

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN9340077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

REBOXETINE		VISIT NO.													
		-1		2		4		6		9	10		16	18	
		F	M	F	M	F	M	F	M	F	F	M	M	F	M
SCPT	Diff. Median			0.00	-0.13	0.00	-0.05	0.00	-0.03	-0.69	0.00	0.03	-0.10	0.07	0.13
	P value			0.3619	0.0857	0.1382	0.4377	0.7663	0.2978	1.0000	0.2737	0.4307	1.0000	0.2820	0.3882
GAMMA-GT	Evaluated	112	30	114	30	113	30	111	28	1	107	25	1	89	21
	Mean	37.00	31.69	31.83	30.77	31.09	27.77	31.92	30.60	10.86	32.44	34.97	4.67	32.96	30.17
	STD	30.44	16.90	21.36	15.11	21.64	15.33	19.47	26.45		22.26	26.51		19.48	19.01
	Min	8.00	10.35	8.00	9.45	8.00	11.70	7.31	7.14	10.86	6.67	5.27	4.67	10.67	5.27
	Max	255.27	78.70	120.00	75.63	165.54	88.27	152.00	144.30	10.86	138.91	118.33	4.67	112.53	79.04
	Median	31.38	27.69	27.48	27.94	28.92	23.86	28.92	23.22	10.86	28.00	25.72	4.67	28.92	25.40
	Diff. Median			-0.08	-0.08	-0.05	-0.12	0.04	-0.07	0.00	-0.04	0.01	-0.57	-0.12	-0.18
	P value			0.0046	0.4496	0.0023	0.0463	0.6165	0.1916		0.0619	0.9890	1.0000	0.0580	0.0973
ALK. PHOSPH.	Evaluated	114	30	113	30	113	30	111	29	1	107	25	1	90	21
	Mean	105.34	121.90	103.09	120.82	104.86	123.60	106.17	123.20	79.76	96.86	129.70	136.99	97.63	120.46
	STD	38.30	35.73	39.34	47.05	38.73	42.69	37.92	38.60		31.57	44.75		49.95	39.54
	Min	45.00	48.32	47.09	52.88	33.87	44.77	36.70	44.27	79.76	41.04	47.81	136.99	34.44	62.00
	Max	242.91	206.27	324.66	308.24	300.42	205.13	299.19	210.96	79.76	212.51	222.83	136.99	471.31	203.23
	Median	102.10	118.01	97.25	119.31	97.49	125.62	104.47	124.91	79.76	94.20	119.00	136.99	87.80	109.78
	Diff. Median			0.00	-0.06	0.00	0.03	0.01	0.02	0.00	-0.04	0.09	-0.27	-0.06	0.01
	P value			0.6119	0.7865	0.9856	0.9441	0.5473	0.9580		0.0042	0.2972	1.0000	0.0032	0.6261
GLOBULIN-S: ALPHA 1	Evaluated	112	29	114	30	112	30	113	29	1	104	25	1	86	20
	Mean	0.15	0.13	0.15	0.11	0.16	0.12	0.16	0.13	0.23	0.14	0.12	0.20	0.12	0.12
	STD	0.12	0.08	0.13	0.07	0.16	0.09	0.14	0.08		0.19	0.10		0.15	0.14
	Min	-0.09	-0.03	-0.13	-0.03	-0.06	-0.03	-0.06	-0.01	0.23	-0.10	-0.05	0.20	-0.05	-0.04
	Max	0.81	0.25	0.80	0.26	0.81	0.31	0.65	0.30	0.23	0.91	0.30	0.20	0.68	0.52
	Median	0.13	0.14	0.13	0.11	0.12	0.14	0.12	0.11	0.23	0.10	0.11	0.20	0.09	0.12
	Diff. Median			-0.03	-0.07	-0.03	-0.04	0.00	-0.02	0.30	-0.19	0.00	0.17	-0.19	0.02
	P value			0.5583	0.2496	0.4673	0.9920	0.6678	0.9907	1.0000	0.0058	0.3697	1.0000	0.0005	0.9530
GLOBULIN-S: ALPHA 2	Evaluated	112	29	114	30	112	30	113	29	1	104	25	1	86	20
	Mean	0.78	0.83	0.77	0.81	0.77	0.80	0.78	0.84	0.87	0.74	0.74	0.59	0.76	0.77
	STD	0.23	0.23	0.20	0.21	0.17	0.21	0.20	0.26		0.19	0.20		0.19	0.17
	Min	0.27	0.31	0.31	0.47	0.27	0.35	0.19	0.40	0.87	0.33	0.38	0.59	0.28	0.31

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN990077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

REBOXETINE		VISIT NO.													
		-1		2		4		6		9	10		16	18	
		F	M	F	M	F	M	F	M	F	F	M	M	F	M
GLOBULIN- S: ALPHA 2	Max	1.57	1.52	1.51	1.28	1.41	1.28	1.41	1.71	0.87	1.22	1.10	0.59	1.27	1.01
	Median	0.76	0.79	0.76	0.78	0.76	0.77	0.76	0.79	0.87	0.73	0.72	0.59	0.76	0.74
	Diff. Median			0.03	-0.02	0.00	-0.01	0.00	0.06	-0.35	-0.05	-0.06	-0.10	0.03	-0.10
	P value			0.6859	0.6172	0.6197	0.8911	0.9677	0.3840	1.0000	0.4055	0.1973	1.0000	0.5643	0.2126
GLOBULIN- S: BETA	Evaluated	112	29	114	30	112	30	113	29	1	104	25	1	86	20
	Mean	0.93	0.82	0.93	0.83	0.93	0.91	0.92	0.86	0.90	0.89	0.93	0.90	0.87	0.93
	STD	0.20	0.18	0.19	0.20	0.21	0.25	0.19	0.23		0.23	0.20		0.24	0.23
	Min	0.42	0.31	0.29	0.19	0.25	0.46	0.38	0.39	0.90	0.31	0.53	0.90	0.35	0.38
	Max	1.49	1.03	1.41	1.10	1.41	1.71	1.35	1.41	0.90	1.38	1.31	0.90	1.46	1.43
	Median	0.90	0.86	0.91	0.88	0.91	0.90	0.90	0.85	0.90	0.88	0.91	0.90	0.87	0.90
	Diff. Median			-0.03	0.00	-0.03	-0.01	-0.04	0.03	0.00	-0.09	0.10	0.34	-0.11	0.18
	P value			0.9406	0.5268	0.8931	0.2777	0.5114	0.4693		0.2147	0.0823	1.0000	0.1130	0.0663
GLOBULIN- S: GAMMA	Evaluated	112	29	114	30	112	30	113	29	1	104	25	1	86	20
	Mean	1.08	0.94	1.15	0.96	1.14	0.97	1.13	1.05	0.89	1.16	1.14	0.71	1.24	1.09
	STD	0.44	0.33	0.41	0.32	0.46	0.28	0.41	0.37		0.43	0.31		0.42	0.27
	Min	0.03	0.09	0.16	0.41	0.05	0.43	0.31	0.34	0.89	0.23	0.46	0.71	0.25	0.54
	Max	3.92	1.80	3.84	1.63	4.10	1.54	3.81	1.67	0.89	4.03	1.58	0.71	4.05	1.53
	Median	1.01	0.98	1.12	0.91	1.12	0.95	1.08	1.10	0.89	1.12	1.21	0.71	1.18	1.14
	Diff. Median			0.09	-0.06	0.09	-0.06	0.04	0.00	0.67	0.09	0.09	-0.51	0.10	0.10
	P value			0.0120	0.7791	0.0277	0.6369	0.2554	0.5740	1.0000	0.1224	0.0595	1.0000	0.0510	0.1650
TOT. CHOLEST.	Evaluated	114	30	115	30	113	30	112	28	1	105	25	1	89	21
	Mean	213.32	214.75	207.58	214.57	212.38	211.96	206.68	203.03	234.32	203.14	204.48	222.71	201.41	204.75
	STD	43.21	38.51	42.52	37.93	42.68	29.36	43.02	33.32		44.71	34.25		40.76	36.92
	Min	130.58	147.11	134.15	150.74	142.18	152.55	136.53	140.75	234.32	130.58	158.91	222.71	136.83	156.11
	Max	336.71	306.45	363.29	296.88	350.32	279.81	339.10	264.20	234.32	375.71	276.00	222.71	321.86	302.61
	Median	207.28	215.48	199.29	209.69	204.65	212.24	195.28	205.58	234.32	196.62	199.87	222.71	193.43	207.01
	Diff. Median			-0.04	-0.06	-0.03	-0.04	-0.07	-0.12	0.16	-0.09	-0.05	-0.19	-0.04	-0.01
P value			0.0372	0.4785	0.3457	0.6659	0.0117	0.0403	1.0000	0.0100	0.0921	1.0000	0.0313	0.1331	
TRIGLYCE- RIDES	Evaluated	114	30	112	30	112	29	110	29	1	104	24	1	88	2
	Mean	110.45	198.65	112.79	178.24	109.62	179.95	108.38	184.94	120.20	107.21	209.18	274.00	109.93	207.21

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNO580077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

REBOXETINE		VISIT NO.													
		-1		2		4		6		9	10		16	18	
		F	M	F	M	F	M	F	M	F	F	M	M	F	M
TRIGLYCE- RIDES	STD	50.77	92.16	54.86	90.24	53.86	82.22	49.60	110.60		54.86	108.32		70.39	133.57
	Min	39.73	80.89	36.27	50.67	38.87	62.33	38.00	24.00	120.20	38.00	87.33	274.00	29.87	49.00
	Max	387.56	522.33	358.64	390.67	363.33	369.61	332.54	604.00	120.20	389.19	545.86	274.00	526.00	595.67
	Median	102.78	183.68	93.77	145.52	91.95	154.45	92.03	151.39	120.20	88.54	163.14	274.00	92.03	154.75
	Diff. Median			0.00	-0.14	-0.02	-0.03	-0.01	-0.07	-0.24	0.00	-0.07	0.07	-0.06	-0.06
	P value			0.8991	0.1443	0.3518	0.5939	0.4833	0.2682	1.0000	0.4901	1.0000	1.0000	0.1524	0.7246
GLUCOSE	Evaluated	114	30	115	30	114	30	113	29	1	107	25	1	90	21
	Mean	93.81	97.97	91.73	90.86	93.15	94.68	90.73	94.39	92.75	93.15	97.70	91.00	92.66	96.85
	STD	16.19	15.79	15.88	11.85	17.85	16.46	16.69	12.57		17.82	21.45		16.18	17.33
	Min	65.00	74.91	58.33	71.59	58.86	68.41	54.25	79.55	92.75	42.95	65.23	91.00	62.24	70.00
	Max	178.50	144.67	166.76	126.00	198.33	141.17	191.33	138.25	92.75	200.67	155.91	91.00	175.00	135.23
	Median	92.17	93.63	91.00	92.00	91.00	92.51	89.25	92.75	92.75	90.00	92.75	91.00	91.00	96.83
	Diff. Median			-0.10	-0.15	-0.02	-0.13	-0.07	-0.18	0.60	-0.03	-0.07	0.05	-0.02	-0.09
	P value			0.0881	0.0070	0.8438	0.0427	0.0294	0.0774	1.0000	0.5661	0.2742	1.0000	0.7282	0.1564
NA+	Evaluated	114	30	115	30	113	30	113	29	1	106	25	1	90	21
	Mean	138.58	138.47	138.42	138.57	138.49	138.22	138.63	138.78	140.67	138.54	139.06	136.00	138.85	139.25
	STD	2.42	2.49	2.30	2.56	2.36	1.64	2.80	2.39		2.28	2.03		2.41	2.63
	Min	134.24	134.67	132.00	134.82	133.65	135.41	132.00	134.82	140.67	134.00	136.00	136.00	133.33	135.41
	Max	146.00	145.33	146.00	144.67	144.00	141.33	148.00	144.00	140.67	146.00	144.00	136.00	146.00	144.67
	Median	138.35	138.35	138.35	138.35	138.35	138.00	138.35	138.67	140.67	138.00	138.94	136.00	138.35	139.00
	Diff. Median			0.00	0.06	0.00	-0.05	0.00	0.06	0.27	0.00	0.06	0.00	0.00	0.00
	P value			0.4031	0.9161	0.6779	0.4682	0.7641	0.3218	1.0000	0.7250	0.3727		0.2081	0.3476
CL-	Evaluated	96	26	100	27	99	27	101	27	1	94	21	1	77	20
	Mean	100.16	100.21	100.11	99.81	99.58	99.19	100.11	100.40	102.24	99.99	99.85	97.68	99.67	98.60
	STD	2.69	2.74	3.13	2.56	3.68	4.06	3.07	2.91		3.70	3.15		4.02	3.10
	Min	93.20	96.91	93.76	95.60	81.20	83.60	95.60	97.20	102.24	90.80	96.08	97.68	81.20	90.80
	Max	106.00	108.24	110.80	105.84	109.20	107.12	111.60	107.23	102.24	113.20	106.00	97.68	107.44	105.60
	Median	99.82	99.53	99.56	99.04	99.45	98.08	99.45	99.45	102.24	99.09	98.73	97.68	99.04	97.80
	Diff. Median			-0.02	-0.04	-0.03	0.03	0.00	0.09	0.45	-0.05	0.00	-1.32	0.01	-0.00
	P value			0.2451	0.8142	0.2222	0.6757	0.3817	0.0667	1.0000	0.7294	0.9636	1.0000	0.6698	0.4410

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

PHARMACIA CN 0590077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

REBOXETINE		VISIT NO.													
		-1		2		4		6		9	10		16	18	
		F	M	F	M	F	M	F	M	F	F	M	M	F	M
K+	Evaluated	114	30	115	30	113	30	113	29	1	105	24	1	90	21
	Mean	4.10	4.08	4.14	3.95	4.14	3.98	4.12	3.94	4.90	4.12	4.09	4.40	4.15	4.14
	STD	0.45	0.40	0.44	0.34	0.44	0.32	0.44	0.26		0.42	0.32		0.42	0.31
	Min	2.30	3.50	3.30	3.30	3.34	3.10	3.10	3.60	4.90	3.18	3.40	4.40	3.26	3.80
	Max	5.10	5.20	5.60	4.83	5.67	4.54	5.79	4.57	4.90	5.44	4.70	4.40	5.80	4.80
	Median	4.06	4.05	4.06	3.90	4.00	4.00	4.00	3.90	4.90	4.06	4.07	4.40	4.06	4.06
	Diff. Median			0.00	0.00	0.05	-0.03	0.00	0.00	1.06	0.06	0.03	0.50	0.00	0.07
	P value			0.4390	0.1746	0.1738	0.2926	0.5718	0.2340	1.0000	0.3638	0.6622	1.0000	0.9444	0.5609
CA++	Evaluated	87	19	87	18	89	19	88	19		84	17		75	15
	Mean	4.81	4.88	4.88	4.91	4.84	4.92	4.91	4.92		4.87	4.88		4.85	5.00
	STD	0.34	0.30	0.36	0.20	0.39	0.16	0.28	0.23		0.35	0.32		0.33	0.28
	Min	3.72	4.40	3.77	4.56	3.72	4.60	4.30	4.39		3.77	4.30		3.81	4.52
	Max	5.50	5.40	6.10	5.20	6.25	5.15	5.54	5.20		5.56	5.63		5.50	5.35
	Median	4.85	4.90	4.90	4.94	4.88	4.90	4.95	4.90		4.90	4.92		4.90	5.00
	Diff. Median			0.05	0.07	0.00	0.10	0.06	0.05		0.05	-0.09		0.00	0.10
	P value			0.0801	0.6618	0.3755	0.5551	0.0020	0.5705		0.0524	0.4948		0.2718	0.3029
PO4-	Evaluated	112	30	115	29	112	30	112	29	1	106	25	1	89	20
	Mean	1.24	1.21	1.32	1.33	1.24	1.22	1.24	1.24	1.63	1.27	1.22	1.08	1.24	1.26
	STD	0.18	0.16	0.38	0.30	0.17	0.15	0.16	0.15		0.19	0.19		0.17	0.13
	Min	0.71	0.90	0.81	1.00	0.78	0.83	0.79	1.00	1.63	0.74	0.86	1.08	0.79	0.93
	Max	1.64	1.57	3.64	2.74	1.64	1.64	1.61	1.60	1.63	2.30	1.57	1.08	1.67	1.44
	Median	1.27	1.20	1.29	1.30	1.27	1.20	1.27	1.27	1.63	1.27	1.23	1.08	1.25	1.30
	Diff. Median			0.08	0.13	0.01	0.02	0.01	0.00	0.23	0.01	-0.07	-0.74	0.00	0.10
	P value			0.0198	0.0227	0.8467	0.7922	0.7743	0.4382	1.0000	0.2110	0.8756	1.0000	0.7326	0.1719

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN980077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

REBOXETINE		VISIT NO.										
		20	24	26		30	34		42		52	
		F	F	F	M	F	F	M	F	M	F	M
HB	Evaluated	1	1	79	19	1	68	17	66	16	63	13
	Mean	11.92	15.28	13.93	15.24	14.32	14.33	15.13	14.42	14.85	14.20	14.83
	STD			1.69	1.89		2.13	2.03	1.87	2.23	1.71	2.57
	Min	11.92	15.28	10.00	13.00	14.32	10.20	13.10	11.00	12.50	10.00	12.60
	Max	11.92	15.28	19.80	20.33	14.32	24.00	21.07	23.14	21.19	19.00	21.81
	Median	11.92	15.28	13.60	14.90	14.32	13.86	15.21	14.00	14.34	13.90	13.30
	Diff. Median	-0.13	0.08	-0.03	0.03	0.18	0.03	0.03	0.07	-0.06	0.03	-0.05
	P value	1.0000	1.0000	0.6517	0.5746	1.0000	0.3571	0.4037	0.0770	0.9799	0.1789	0.7251
HTC	Evaluated	1	1	79	19	1	68	17	66	16	63	13
	Mean	35.44	41.56	38.11	44.95	39.33	38.72	44.35	39.18	43.18	39.19	44.17
	STD			2.93	3.39		2.63	2.71	2.80	3.31	2.97	4.95
	Min	35.44	41.56	30.00	41.00	39.33	32.22	41.00	33.00	38.43	30.00	37.57
	Max	35.44	41.56	46.11	50.60	39.33	45.22	51.40	47.33	50.60	49.25	55.10
	Median	35.44	41.56	38.00	43.57	39.33	39.00	43.57	39.25	43.01	39.00	42.71
	Diff. Median	-0.06	-0.14	0.00	0.01	0.43	0.00	0.06	0.00	0.00	0.00	0.00
	P value	1.0000	1.0000	0.5667	0.3418	1.0000	0.7315	0.3988	0.4208	0.3867	0.5691	0.8647
RBC	Evaluated	1	1	79	19	1	67	17	66	16	63	13
	Mean	4.32	5.05	4.52	5.47	5.60	4.49	5.08	4.59	4.99	4.58	5.07
	STD			0.47	1.11		0.28	0.46	0.38	0.37	0.44	0.60
	Min	4.32	5.05	3.47	4.47	5.60	3.65	4.66	3.80	4.50	3.48	4.27
	Max	4.32	5.05	6.88	8.03	5.60	5.28	6.54	6.54	5.90	6.35	6.60
	Median	4.32	5.05	4.48	4.91	5.60	4.53	4.89	4.60	4.87	4.58	4.89
	Diff. Median	0.07	-0.21	0.06	0.06	0.59	0.02	0.00	0.06	0.00	0.06	0.00
	P value	1.0000	1.0000	0.1130	0.1160	1.0000	0.1185	0.4248	0.0039	1.0000	0.0073	0.6250
PLATELETS	Evaluated	1	1	79	18	1	68	17	65	16	62	13
	Mean	430.00	327.50	238.96	241.56	192.50	241.66	236.02	240.95	239.30	238.07	248.79
	STD			50.10	16.11		44.38	17.91	49.01	21.54	50.08	61.77
	Min	430.00	327.50	123.75	213.46	192.50	154.38	201.92	170.00	216.25	131.25	172.60
	Max	430.00	327.50	393.75	278.00	192.50	396.25	270.00	454.69	295.00	478.13	407.81
Median	430.00	327.50	230.36	242.99	192.50	231.25	234.38	228.75	230.80	228.13	232.50	

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS 390077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

REBOXETINE		VISIT NO.													
		20		24		26		30		34		42		52	
		F	F	F	M	F	F	M	F	M	F	M	F	M	
PLATELETS	Diff. Median	0.47	0.36	0.01	0.03	-0.08	0.03	0.01	0.03	0.01	0.03	0.01	0.03	-0.03	
	P value	1.0000	1.0000	0.1374	0.3289	1.0000	0.0406	0.8441	0.0439	0.6890	0.0841	0.7354			
HBC	Evaluated	1	1	79	19	1	68	17	66	16	63	13			
	Mean	7.75	10.78	7.22	7.92	6.02	6.98	7.75	7.11	7.98	7.31	7.81			
	STD			1.92	2.29		1.76	2.81	1.75	2.75	2.25	3.52			
	Min	7.75	10.78	4.18	5.34	6.02	3.96	4.78	4.28	5.61	4.50	5.43			
	Max	7.75	10.78	12.21	14.71	6.02	14.90	16.01	13.79	16.39	14.39	18.24			
	Median	7.75	10.78	6.54	7.53	6.02	6.59	6.61	6.68	6.93	6.45	6.26			
	Diff. Median	0.34	0.03	0.00	0.00	0.11	-0.01	-0.11	-0.01	0.00	0.00	-0.07			
	P value	1.0000	1.0000	0.4393	0.8446	1.0000	0.7473	0.5397	0.9768	0.9878	0.9012	0.3396			
HBC: N	Evaluated	1	1	76	17	1	65	16	64	15	62	13			
	Mean	60.75	64.92	62.78	64.10	54.08	63.43	63.51	63.25	64.96	63.22	64.06			
	STD			4.52	2.30		4.11	1.95	5.11	2.16	5.45	3.65			
	Min	60.75	64.92	50.46	60.00	54.08	52.00	58.92	36.00	60.08	35.00	55.00			
	Max	60.75	64.92	74.00	68.00	54.08	80.00	66.00	78.00	69.00	82.00	68.25			
	Median	60.75	64.92	63.67	64.08	54.08	64.00	63.67	64.00	64.33	64.00	64.33			
	Diff. Median	0.08	0.42	0.10	0.12	-0.33	0.10	0.00	0.10	0.13	0.09	0.07			
	P value	1.0000	1.0000	0.1104	0.0519	1.0000	0.1992	0.9460	0.0714	0.1722	0.4752	0.7480			
HBC: E	Evaluated	1	1	75	17	1	65	16	64	15	62	13			
	Mean	8.33	0.33	1.82	1.67	1.67	1.88	1.89	1.60	1.46	1.84	1.43			
	STD			1.39	0.77		1.42	0.78	0.71	0.71	0.96	0.54			
	Min	8.33	0.33	0.33	0.33	1.67	0.33	0.50	0.33	0.33	0.33	0.50			
	Max	8.33	0.33	10.50	3.00	1.67	9.67	3.50	3.50	2.50	5.00	2.50			
	Median	8.33	0.33	1.50	2.00	1.67	1.50	1.50	1.50	1.50	1.50	1.50			
	Diff. Median	0.67	0.00	-0.25	-0.25	-2.00	-0.25	-0.13	-0.25	-0.25	-0.25	-0.50			
	P value	1.0000		0.0019	0.7562	1.0000	0.0200	0.8203	0.0004	0.1899	0.0202	0.0273			
HBC: B	Evaluated	1	1	76	17	1	65	16	63	15	62	13			
	Mean	0.00	0.00	0.09	0.18	0.00	0.09	0.09	0.13	0.05	0.06	0.23			
	STD			0.32	0.33		0.28	0.37	0.37	0.19	0.25	0.47			
	Min	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

PHARMACIA CNS 959077
REBOXETINE - PROTOCOL 20124/013

TABLE No. : 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

REBOXETINE		VISIT NO.													
		20		24		26		30		34		42		52	
		F	F	F	M	F	F	M	F	M	F	M			
HBC: B	Max	0.00	0.00	1.50	0.75	0.00	1.50	1.50	1.50	0.75	1.50	1.50			
	Median	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
	Diff. Median	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
	P value			0.6279	0.2344		0.8066	0.2344	0.6172	0.0313	0.4316	0.3750			
HBC: L	Evaluated	1	1	76	17	1	65	16	64	15	62	13			
	Mean	25.00	26.00	29.01	27.25	39.00	28.64	27.79	28.11	26.92	28.65	26.72			
	STD			4.95	2.64		4.43	2.83	4.06	2.12	6.16	4.35			
	Min	25.00	26.00	20.50	22.50	39.00	19.00	21.00	19.25	23.00	17.00	20.00			
	Max	25.00	26.00	45.50	33.50	39.00	45.00	33.00	44.00	31.50	57.00	38.00			
	Median	25.00	26.00	27.90	27.00	39.00	28.00	27.75	27.50	27.00	27.50	26.50			
	Diff. Median	-0.40	-0.50	-0.08	-0.05	0.70	-0.10	0.03	-0.15	-0.10	-0.10	-0.10			
	P value	1.0000	1.0000	0.1988	0.4408	1.0000	0.1526	0.9892	0.0186	0.6584	0.1609	0.7869			
HBC: M	Evaluated	1	1	76	17	1	65	16	64	15	62	13			
	Mean	4.33	4.33	4.32	4.69	3.00	4.52	5.16	5.24	4.70	5.11	5.79			
	STD			1.98	2.51		2.33	2.08	2.39	2.56	2.40	1.88			
	Min	4.33	4.33	1.00	1.00	3.00	0.00	1.00	1.00	1.00	1.00	3.00			
	Max	4.33	4.33	9.00	9.00	3.00	9.00	9.00	9.00	9.00	15.00	9.00			
	Median	4.33	4.33	4.00	4.00	3.00	4.60	5.00	5.00	4.00	5.00	5.67			
	Diff. Median	-0.33	0.00	0.00	-0.25	0.00	0.00	0.00	0.25	0.00	0.25	0.25			
	P value	1.0000		0.1069	0.3968		0.0814	0.7026	0.0005	0.9326	0.0015	0.1553			
CREATININE	Evaluated	1	1	79	19	1	68	17	66	16	64	13			
	Mean	0.68	0.71	0.75	0.94	0.78	0.71	0.88	0.73	0.91	0.70	0.89			
	STD			0.14	0.17		0.13	0.15	0.11	0.15	0.11	0.15			
	Min	0.68	0.71	0.50	0.72	0.78	0.40	0.66	0.50	0.72	0.50	0.66			
	Max	0.68	0.71	1.15	1.30	0.78	1.23	1.20	1.05	1.18	1.03	1.20			
	Median	0.68	0.71	0.74	0.96	0.78	0.68	0.84	0.68	0.89	0.68	0.84			
	Diff. Median	-0.20	-0.32	0.00	0.10	-0.03	0.00	0.00	0.00	0.06	-0.07	0.10			
	P value	1.0000	1.0000	0.7482	0.0660	1.0000	0.2491	0.9180	0.9687	0.4124	0.0347	0.1289			
BUN	Evaluated	1	1	80	19	1	68	17	66	16	64	12			
	Mean	10.91	12.67	11.48	12.02	11.49	11.70	11.97	11.53	12.43	11.74	12.17			

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN0380077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

REBOXETINE		VISIT NO.													
		20		24		26		30		34		42		52	
		F	F	F	M	F	F	M	F	M	F	M	F	M	
BUN	STD			2.10	2.38			2.34	1.57	1.71	1.92	2.18	1.70		
	Min	10.91	12.67	7.00	7.00	11.49	7.14	8.83	7.66	8.57	7.63	8.57			
	Max	10.91	12.67	16.67	15.53	11.49	19.38	14.43	16.08	15.67	18.28	14.98			
	Median	10.91	12.67	11.76	12.50	11.49	11.95	12.23	11.95	13.05	12.02	12.36			
	Diff. Median	-0.16	0.03	0.00	0.00	0.11	0.01	0.03	-0.01	0.01	-0.01	-0.05			
	P value	1.0000	1.0000	0.4414	0.8176	1.0000	0.4156	0.8272	0.8871	0.8316	0.7656	0.5322			
	Evaluated	1	1	80	18	1	68	17	66	16	62	13			
URIC ACID	Mean	3.38	4.86	3.93	5.29	3.01	3.98	5.11	3.92	4.66	4.11	5.08			
	STD			0.87	1.14		0.73	0.94	0.86	1.09	1.06	0.87			
	Min	3.38	4.86	1.67	3.71	3.01	2.55	3.71	2.01	2.97	2.39	4.01			
	Max	3.38	4.86	5.90	7.36	3.01	6.21	6.99	7.55	7.51	9.09	6.67			
	Median	3.38	4.86	3.95	5.21	3.01	4.02	4.94	4.01	4.53	4.15	4.96			
	Diff. Median	-0.04	0.24	0.06	-0.07	0.01	0.03	0.03	-0.03	-0.10	0.08	0.03			
	P value	1.0000	1.0000	0.7131	0.6784	1.0000	0.9170	0.7467	0.4355	0.0443	0.2200	0.8523			
	Evaluated	1	1	80	19	1	68	17	66	16	64	13			
TOT. PROTEINS	Mean	7.16	7.08	7.41	7.51	7.46	7.48	7.38	7.44	7.54	7.52	7.30			
	STD			0.48	0.28		0.43	0.52	0.46	0.45	0.58	0.32			
	Min	7.16	7.08	6.28	6.97	7.46	6.02	6.59	6.40	6.50	6.69	6.59			
	Max	7.16	7.08	9.54	7.92	7.46	8.49	8.78	9.25	8.30	10.20	7.83			
	Median	7.16	7.08	7.45	7.54	7.46	7.54	7.35	7.45	7.64	7.45	7.35			
	Diff. Median	0.08	0.08	0.00	-0.05	0.48	0.04	-0.10	0.05	0.03	0.05	0.00			
	P value	1.0000	1.0000	0.5623	0.9233	1.0000	0.2099	0.5698	0.3407	0.6136	0.1455	0.6089			
	Evaluated	1	1	79	18	1	67	17	64	16	63	13			
ALBUMINE	Mean	3.90	3.50	4.19	4.20	4.00	4.20	4.21	4.13	4.39	4.10	4.18			
	STD			0.38	0.32		0.41	0.45	0.37	0.45	0.42	0.40			
	Min	3.90	3.50	3.50	3.70	4.00	3.60	3.64	3.50	3.90	3.00	3.90			
	Max	3.90	3.50	5.32	4.98	4.00	5.51	5.19	5.12	5.33	5.50	5.20			
	Median	3.90	3.50	4.13	4.13	4.00	4.10	4.15	4.00	4.21	4.00	4.09			
	Diff. Median	-0.13	-0.15	0.00	-0.07	0.07	-0.07	-0.10	-0.07	-0.07	-0.07	-0.13			
	P value	1.0000	1.0000	0.5267	0.0632	1.0000	0.6439	0.0419	0.1566	0.7138	0.0361	0.0996			
	Evaluated	1	1	79	18	1	67	17	64	16	63	13			

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

PHARMACIA CN9350077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

REBOXETINE		VISIT NO.													
		20		24		26		30		34		42		52	
		F	F	F	M	F	F	M	F	M	F	M	F	M	
TOT BILIRUBIN	Evaluated			76	18			65	16	63	15	61	13		
	Mean			0.58	0.64			0.60	0.55	0.65	0.55	0.63	0.67		
	STD			0.24	0.21			0.19	0.20	0.19	0.16	0.20	0.18		
	Min			0.15	0.30			0.17	0.19	0.27	0.25	0.20	0.42		
	Max			1.51	1.04			1.00	1.00	1.37	0.80	1.00	1.00		
	Median			0.55	0.64			0.60	0.51	0.68	0.60	0.68	0.68		
	Diff. Median			-0.13	-0.24			0.00	-0.06	0.00	-0.17	0.00	-0.13		
	P value			0.1546	0.1291			0.4382	0.1353	0.8199	0.0596	0.8247	0.3491		
DIR BILIRUBIN	Evaluated			70	18			58	15	57	13	54	13		
	Mean			0.14	0.14			0.13	0.10	0.13	0.12	0.14	0.13		
	STD			0.10	0.09			0.06	0.05	0.06	0.06	0.06	0.07		
	Min			0.00	0.00			0.00	0.00	0.00	0.00	0.00	0.00		
	Max			0.65	0.39			0.29	0.16	0.25	0.20	0.25	0.25		
	Median			0.15	0.10			0.15	0.10	0.15	0.15	0.15	0.15		
	Diff. Median			0.00	0.00			0.00	0.00	0.00	0.00	0.00	0.00		
	P value			0.2780	0.5322			0.3747	0.2891	0.8921	0.5703	0.7050	0.2578		
SGOT	Evaluated	1	1	80	18	1	68	17	66	16	62	13			
	Mean	32.00	56.00	20.57	18.87	32.00	20.15	22.15	19.79	22.78	20.97	21.40			
	STD			5.54	4.02		4.75	8.61	5.21	12.72	6.34	6.41			
	Min	32.00	56.00	11.82	12.73	32.00	11.82	10.95	12.73	12.86	12.14	11.90			
	Max	32.00	56.00	44.00	30.00	32.00	36.00	48.33	35.33	68.33	48.00	40.00			
	Median	32.00	56.00	20.00	19.09	32.00	20.00	20.00	18.57	20.96	20.00	20.00			
	Diff. Median	0.30	1.70	0.05	-0.03	0.00	0.04	0.11	0.04	0.10	0.02	0.05			
	P value	1.0000	1.0000	0.0526	0.4169		0.1827	0.4559	0.8790	0.4112	0.1153	1.0000			
SGPT	Evaluated	1	1	80	19	1	68	17	66	16	62	13			
	Mean	19.29	51.43	18.21	24.37	24.64	18.69	21.12	17.29	22.67	17.76	20.78			
	STD			7.29	19.69		6.37	6.31	6.34	10.01	8.11	8.05			
	Min	19.29	51.43	5.83	1.33	24.64	8.13	9.17	6.67	11.67	5.00	9.69			
	Max	19.29	51.43	42.07	97.24	24.64	47.50	31.39	35.00	55.00	52.50	39.17			
	Median	19.29	51.43	18.33	21.38	24.64	19.41	20.63	17.08	20.83	16.67	21.67			

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARNACIA CN0980077
REBOXETINE - PROTOCOL 20124/013

TABLE No. : 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

REBOXETINE		VISIT NO.													
		20		24		26		30		34		42		52	
		F	F	F	M	F	F	M	F	M	F	M			
SGPT	Diff. Median	0.14	0.93	0.02	0.13	0.07	0.06	-0.04	-0.02	0.16	-0.02	0.07			
	P value	1.0000	1.0000	0.5356	1.0000	1.0000	0.1896	0.3467	0.7962	0.7150	0.7443	0.5779			
GAMMA-GT	Evaluated	1	1	79	19	1	68	17	66	16	62	13			
	Mean	19.43	46.86	30.74	33.87	58.29	29.46	34.25	27.97	31.08	30.55	30.84			
	STD			15.98	27.11		14.05	19.67	13.81	19.66	14.44	25.80			
	Min	19.43	46.86	3.20	10.86	58.29	8.00	5.27	6.67	7.14	12.00	7.14			
	Max	19.43	46.86	102.40	120.82	58.29	78.15	92.71	76.92	94.42	90.46	109.79			
	Median	19.43	46.86	26.46	24.38	58.29	26.46	33.55	24.00	25.80	26.46	22.33			
	Diff. Median	0.14	0.79	-0.12	-0.11	-0.29	-0.18	-0.10	-0.25	-0.11	-0.18	-0.20			
	P value	1.0000	1.0000	0.0007	0.4233	1.0000	0.0005	1.0000	0.0000	0.2979	0.0005	0.0461			
ALK. PHOSPH.	Evaluated	1	1	80	19	1	67	17	64	16	62	13			
	Mean	81.37	115.40	96.86	129.15	77.04	89.92	116.75	88.19	112.72	94.28	115.11			
	STD			49.04	52.60		27.56	40.52	26.94	39.57	29.54	50.20			
	Min	81.37	115.40	43.68	52.88	77.04	39.17	53.45	36.70	52.31	34.88	56.30			
	Max	81.37	115.40	422.42	244.12	77.04	181.29	215.52	158.69	207.41	174.72	246.95			
	Median	81.37	115.40	87.37	117.37	77.04	88.79	104.57	87.01	108.12	89.89	103.15			
	Diff. Median	0.12	-0.11	-0.05	0.06	-0.25	-0.08	-0.01	-0.10	-0.10	-0.05	-0.12			
	P value	1.0000	1.0000	0.0066	0.5412	1.0000	0.0002	0.4947	0.0000	0.3225	0.0198	0.6355			
GLOBULIN-S: ALPHA 1	Evaluated	1	1	77	18	1	66	17	62	16	61	13			
	Mean	0.18	0.24	0.13	0.13	0.22	0.11	0.09	0.10	0.10	0.08	0.09			
	STD			0.18	0.11		0.12	0.10	0.12	0.11	0.10	0.12			
	Min	0.18	0.24	-0.12	-0.03	0.22	-0.10	-0.10	-0.06	-0.05	-0.07	-0.03			
	Max	0.18	0.24	1.28	0.40	0.22	0.50	0.30	0.45	0.40	0.45	0.35			
	Median	0.18	0.24	0.09	0.11	0.22	0.10	0.09	0.05	0.07	0.05	0.04			
	Diff. Median	0.06	0.09	-0.17	-0.05	0.04	-0.07	-0.09	-0.13	-0.23	-0.25	-0.13			
	P value	1.0000	1.0000	0.0004	0.9168	1.0000	0.0100	0.4657	0.0017	0.3481	0.0000	0.7354			
GLOBULIN-S: ALPHA 2	Evaluated	1	1	77	18	1	66	17	62	16	61	13			
	Mean	0.71	0.74	0.74	0.69	0.86	0.77	0.71	0.75	0.71	0.74	0.72			
	STD			0.17	0.22		0.17	0.24	0.18	0.14	0.19	0.14			
	Min	0.71	0.74	0.24	0.26	0.86	0.45	0.28	0.39	0.44	0.30	0.40			

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNO990077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

REBOXETINE		VISIT NO.													
		20		24		26		30		34		42		52	
		F	M	F	M	F	M	F	M	F	M	F	M	F	M
GLOBULIN- S: ALPHA 2	Max	0.71	0.74	1.22	1.13	0.86	1.33	1.06	1.17	0.97	1.21	0.98			
	Median	0.71	0.74	0.72	0.73	0.86	0.76	0.72	0.73	0.71	0.71	0.70			
	Diff. Median	-0.01	-0.24	0.00	-0.43	0.33	0.08	-0.25	0.03	-0.30	0.00	-0.16			
	P value	1.0000	1.0000	0.5202	0.1107	1.0000	0.1349	0.2742	0.5582	0.1330	0.8507	0.4973			
GLOBULIN- S: BETA	Evaluated	1	1	77	18	1	66	17	62	16	61	13			
	Mean	0.92	0.95	0.94	1.01	1.17	0.96	1.03	0.92	0.96	0.93	0.96			
	STD			0.20	0.27		0.22	0.31	0.25	0.10	0.25	0.16			
	Min	0.92	0.95	0.42	0.53	1.17	0.38	0.50	0.17	0.79	0.19	0.75			
	Max	0.92	0.95	1.35	1.53	1.17	1.43	1.66	1.55	1.19	1.55	1.22			
	Median	0.92	0.95	0.91	1.01	1.17	0.94	0.97	0.93	0.94	0.95	0.97			
	Diff. Median	0.01	-0.25	0.10	0.46	0.64	0.12	0.50	-0.05	0.27	0.13	0.47			
	P value	1.0000	1.0000	0.1067	0.0104	1.0000	0.0685	0.0300	0.3756	0.0020	0.3262	0.0171			
GLOBULIN- S: GAMMA	Evaluated	1	1	77	18	1	66	17	62	16	61	13			
	Mean	1.53	1.50	1.20	1.23	1.13	1.26	1.06	1.31	1.10	1.41	1.12			
	STD			0.51	0.41		0.37	0.28	0.31	0.31	0.63	0.25			
	Min	1.53	1.50	0.10	0.51	1.13	0.49	0.59	0.55	0.38	0.03	0.77			
	Max	1.53	1.50	4.23	2.16	1.13	2.53	1.44	2.00	1.49	5.51	1.45			
	Median	1.53	1.50	1.21	1.18	1.13	1.26	1.04	1.33	1.10	1.36	1.04			
	Diff. Median	0.00	0.67	0.00	0.24	0.14	0.02	0.06	0.09	0.11	0.24	-0.02			
	P value	1.0000	1.0000	0.4437	0.1084	1.0000	0.1620	0.5791	0.0262	0.2293	0.0004	0.6355			
TOT. CHOLEST.	Evaluated	1	1	80	19	1	66	17	64	16	62	13			
	Mean	201.71	276.29	201.23	207.54	197.57	206.60	198.23	197.20	187.85	202.45	193.62			
	STD			43.44	31.66		41.43	25.89	37.16	18.04	41.08	26.67			
	Min	201.71	276.29	133.29	158.00	197.57	136.53	154.19	123.45	145.36	148.13	148.92			
	Max	201.71	276.29	384.00	272.80	197.57	345.63	246.05	338.49	216.73	330.46	235.42			
	Median	201.71	276.29	194.34	199.75	197.57	198.85	193.40	190.37	189.86	191.26	199.75			
	Diff. Median	0.00	0.32	-0.04	0.04	0.21	0.02	-0.14	-0.07	-0.22	-0.06	-0.12			
	P value		1.0000	0.2801	0.9843	1.0000	0.8920	0.2389	0.0330	0.0507	0.0949	0.3757			
TRIGLYCE- RIDES	Evaluated	1	1	80	18	1	66	17	64	15	61	12			
	Mean	74.87	96.32	98.77	216.98	55.43	105.49	171.87	104.18	157.32	101.36	144.49			

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN990077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

REBOXETINE		VISIT NO.													
		20		24		26		30		34		42		52	
		F	F	F	M	F	F	M	F	M	F	M	F	M	
TRIGLYCE- RIDES	STD			42.34	192.97			64.09	75.75	69.48	66.01	50.13	53.44		
	Min	74.87	96.32	35.40	49.00	55.43	29.87	94.32	38.00	25.67	24.44	64.67			
	Max	74.87	96.32	263.70	877.53	55.43	411.84	299.11	566.09	280.67	301.04	280.64			
	Median	74.87	96.32	92.03	132.93	55.43	86.80	127.89	87.24	148.04	86.80	143.00			
	Diff. Median	0.20	-0.28	-0.05	-0.06	-0.19	-0.02	0.06	-0.07	0.01	-0.07	-0.02			
	P value	1.0000	1.0000	0.1132	0.9323	1.0000	0.4968	0.8637	0.1005	0.7959	0.0422	0.3013			
GLUCOSE	Evaluated	1	1	80	19	1	68	17	66	16	64	12			
	Mean	71.74	87.58	94.53	101.15	78.08	95.04	102.16	94.95	96.37	98.17	107.87			
	STD			13.78	25.57		12.09	21.45	12.70	13.20	15.15	18.66			
	Min	71.74	87.58	59.07	54.25	78.08	71.74	75.00	63.64	73.33	73.50	81.67			
	Max	71.74	87.58	136.50	165.67	78.08	128.33	155.17	147.00	126.00	171.50	142.33			
	Median	71.74	87.58	93.60	99.17	78.08	96.25	95.67	95.67	93.92	96.83	106.46			
	Diff. Median	-0.18	0.00	0.00	0.00	-0.41	-0.03	0.00	-0.03	-0.07	0.05	0.07			
	P value	1.0000		0.8315	0.8536	1.0000	0.6947	0.6593	0.3630	0.4332	0.4247	0.6221			
NA+	Evaluated	1	1	80	19	1	68	17	66	16	64	13			
	Mean	139.33	142.00	138.86	139.02	141.33	139.03	138.78	138.87	139.53	138.05	138.98			
	STD			2.03	2.07		2.29	2.03	1.68	3.15	1.72	2.20			
	Min	139.33	142.00	134.24	136.00	141.33	134.82	135.41	135.41	132.00	133.65	136.00			
	Max	139.33	142.00	145.00	145.00	141.33	146.00	143.33	144.00	146.00	142.67	144.67			
	Median	139.33	142.00	138.70	138.94	141.33	138.51	138.35	138.35	138.97	137.76	138.35			
	Diff. Median	-0.20	-0.33	0.08	0.12	-0.20	0.08	0.12	0.08	0.09	0.03	0.10			
	P value	1.0000	1.0000	0.0053	0.1857	1.0000	0.0055	0.3548	0.0001	0.1550	0.7117	0.4121			
CL-	Evaluated	1	1	74	16	1	61	16	61	15	58	12			
	Mean	99.60	99.60	99.40	98.83	102.80	99.57	99.27	99.47	99.09	99.13	98.14			
	STD			2.77	3.04		3.02	3.03	3.23	2.94	3.34	3.54			
	Min	99.60	99.60	94.40	94.00	102.80	94.80	95.09	92.40	95.09	91.60	91.60			
	Max	99.60	99.60	106.40	104.40	102.80	107.23	105.44	107.23	105.20	108.46	105.20			
	Median	99.60	99.60	98.18	98.16	102.80	98.36	98.00	98.00	97.64	98.00	97.82			
	Diff. Median	0.20	-0.70	-0.02	-0.09	0.50	0.00	0.02	-0.05	-0.05	-0.05	-0.11			
P value	1.0000	1.0000	0.1842	0.3231	1.0000	0.1755	0.8146	0.0469	0.6486	0.0374	0.2656				

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

PHARMACIA CN980077
REBOXETINE - PROTOCOL 20124/013

TABLE No. : 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

REBOXETINE		VISIT NO.													
		20		24		26		30		34		42		52	
		F	F	F	M	F	F	M	F	M	F	M			
K+	Evaluated	1	1	80	19		67	16	66	16	64	13			
	Mean	3.86	3.68	4.22	4.13		4.19	4.20	4.21	4.33	4.27	4.02			
	STD			0.42	0.39		0.41	0.24	0.34	0.41	0.41	0.19			
	Min	3.86	3.68	3.20	3.50		3.60	3.80	3.70	3.80	3.26	3.60			
	Max	3.86	3.68	6.17	5.31		6.01	4.60	5.33	5.53	5.33	4.41			
	Median	3.86	3.68	4.20	4.14		4.14	4.21	4.14	4.22	4.22	4.03			
	Diff. Median	-0.11	-0.28	0.06	0.11		0.10	0.13	0.05	0.23	0.11	0.06			
	P value	1.0000	1.0000	0.0704	0.5087		0.1342	0.2249	0.1531	0.0634	0.0147	0.5295			
CA++	Evaluated	1	1	66	15	1	59	13	58	12	56	12			
	Mean	3.80	4.00	4.86	4.92	4.60	4.91	4.84	4.84	4.84	4.88	4.92			
	STD			0.28	0.27		0.25	0.22	0.37	0.24	0.24	0.26			
	Min	3.80	4.00	4.08	4.65	4.60	4.30	4.33	2.70	4.34	4.30	4.50			
	Max	3.80	4.00	5.35	5.75	4.60	5.50	5.15	5.20	5.10	5.55	5.30			
	Median	3.80	4.00	4.89	4.90	4.60	4.90	4.88	4.90	4.93	4.90	4.98			
	Diff. Median	-1.00	-0.80	0.05	-0.05	0.44	0.05	0.00	0.00	-0.10	0.00	0.05			
	P value	1.0000	1.0000	0.2993	0.9220	1.0000	0.2945	0.3706	0.8534	0.0703	0.9595	0.6094			
PO4-	Evaluated	1	1	79	19		68	17	66	16	62	13			
	Mean	1.04	1.06	1.25	1.25		1.26	1.22	1.25	1.29	1.25	1.21			
	STD			0.19	0.23		0.30	0.16	0.19	0.15	0.18	0.19			
	Min	1.04	1.06	0.76	0.86		0.71	0.86	0.78	1.03	0.86	0.87			
	Max	1.04	1.06	1.61	1.79		3.24	1.43	1.83	1.50	1.65	1.50			
	Median	1.04	1.06	1.29	1.20		1.20	1.26	1.25	1.27	1.27	1.20			
	Diff. Median	-0.54	0.06	0.07	0.20		0.07	-0.03	0.07	0.24	0.07	0.00			
	P value	1.0000	1.0000	0.0615	0.3463		0.0525	0.5475	0.1433	0.0135	0.0198	0.7695			

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN950077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

PLACEBO		VISIT NO.													
		-1		2		4		6		10		12	14	16	18
		F	M	F	M	F	M	F	M	F	M	F	F	F	F
HB	Evaluated	95	46	95	46	93	46	94	44	94	41	1	1	1	76
	Mean	14.04	14.50	13.96	14.86	14.05	14.93	13.98	14.74	13.97	14.58	14.14	13.60	18.47	13.88
	STD	1.70	1.85	1.71	1.79	1.75	1.81	1.66	1.95	2.03	1.87				1.76
	Min	9.60	11.30	9.28	11.50	10.08	11.70	9.50	11.60	8.13	11.50	14.14	13.60	18.47	9.28
	Max	20.20	20.33	19.47	20.21	19.60	20.21	19.67	19.96	23.13	20.08	14.14	13.60	18.47	19.67
	Median	13.97	14.11	13.80	14.77	13.90	14.65	13.87	14.40	13.76	14.20	14.14	13.60	18.47	13.60
	Diff. Median			0.00	0.05	0.01	0.05	-0.03	0.06	0.00	-0.05	0.04	0.06	0.07	-0.03
	P value			0.6123	0.0180	0.7999	0.0120	0.2028	0.0589	0.3398	0.6823	1.0000	1.0000	1.0000	0.5809
HTC	Evaluated	95	45	95	46	93	46	94	44	94	41	1	1	1	76
	Mean	38.78	43.67	38.19	43.42	38.68	43.92	38.26	43.15	38.43	43.12	39.00	38.22	39.53	38.06
	STD	2.92	4.28	2.75	3.06	3.25	3.06	2.69	3.38	2.90	3.41				3.16
	Min	29.00	37.57	27.75	37.57	29.00	38.43	29.00	37.57	31.00	37.57	39.00	38.22	39.53	26.63
	Max	45.63	59.75	44.18	50.90	51.00	51.29	46.00	52.85	49.53	52.55	39.00	38.22	39.53	47.00
	Median	39.00	43.57	38.22	43.14	39.00	43.57	38.97	42.29	38.97	42.71	39.00	38.22	39.53	38.00
	Diff. Median			0.00	0.00	0.00	0.07	-0.05	-0.04	0.00	-0.07	-0.10	-0.28	0.06	-0.10
	P value			0.1092	0.9645	0.4715	0.2956	0.0417	0.4018	0.2286	0.8017	1.0000	1.0000	1.0000	0.0849
RBC	Evaluated	94	45	95	46	93	46	93	44	93	41	1	1	1	76
	Mean	4.43	4.82	4.38	4.89	4.47	4.90	4.40	4.96	4.41	4.90	4.28	4.49	4.47	4.47
	STD	0.58	0.83	0.52	0.41	0.54	0.38	0.43	0.43	0.51	0.35				0.46
	Min	1.72	2.46	1.96	3.74	2.51	3.63	1.98	4.11	1.86	4.33	4.28	4.49	4.47	2.66
	Max	6.93	7.89	5.39	5.90	6.57	6.04	5.75	6.54	6.26	6.07	4.28	4.49	4.47	6.33
	Median	4.45	4.85	4.43	4.90	4.45	4.89	4.45	4.89	4.41	4.87	4.28	4.49	4.47	4.47
	Diff. Median			0.00	0.08	0.00	0.06	-0.04	0.06	0.00	0.06	-0.12	-0.14	-0.06	0.04
	P value			0.7755	0.0046	0.3886	0.0048	0.4798	0.0660	0.6332	0.1657	1.0000	1.0000	1.0000	0.5062
PLATELETS	Evaluated	89	43	91	42	90	41	92	43	92	41	1	1	1	76
	Mean	238.88	234.08	245.58	230.26	240.10	234.64	251.61	240.95	237.16	240.08	194.64	360.00	197.12	227.84
	STD	59.15	41.28	73.67	38.44	66.44	43.12	82.85	52.58	65.67	44.29				61.28
	Min	154.81	140.63	157.21	164.38	89.06	155.63	166.67	172.60	112.50	175.48	194.64	360.00	197.12	110.30
	Max	466.00	362.00	487.50	352.00	559.00	386.00	612.00	462.50	550.00	379.69	194.64	360.00	197.12	586.50
	Median	221.43	239.29	222.00	229.46	223.27	230.36	227.72	233.93	224.06	229.38	194.64	360.00	197.12	217.90

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN950077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

PLACEBO		VISIT NO.													
		-1		2		4		6		10		12	14	16	18
		F	M	F	M	F	M	F	M	F	M	F	F	F	F
HB	Evaluated	95	46	95	46	93	46	94	44	94	41	1	1	1	76
	Mean	14.04	14.50	13.96	14.86	14.05	14.93	13.98	14.74	13.97	14.58	14.14	13.60	18.47	13.88
	STD	1.70	1.85	1.71	1.79	1.75	1.81	1.66	1.95	2.03	1.87				1.76
	Min	9.60	11.30	9.28	11.50	10.08	11.70	9.50	11.60	8.13	11.50	14.14	13.60	18.47	9.28
	Max	20.20	20.33	19.47	20.21	19.60	20.21	19.67	19.96	23.13	20.08	14.14	13.60	18.47	19.67
	Median	13.97	14.11	13.80	14.77	13.90	14.65	13.87	14.40	13.76	14.20	14.14	13.60	18.47	13.60
	Diff. Median			0.00	0.05	0.01	0.05	-0.03	0.06	0.00	-0.05	0.04	0.06	0.07	-0.03
	P value			0.6123	0.0180	0.7999	0.0120	0.2028	0.0589	0.3398	0.6823	1.0000	1.0000	1.0000	0.5809
HTC	Evaluated	95	45	95	46	93	46	94	44	94	41	1	1	1	76
	Mean	38.78	43.67	38.19	43.42	38.68	43.92	38.26	43.15	38.43	43.12	39.00	38.22	39.53	38.06
	STD	2.92	4.28	2.75	3.06	3.25	3.06	2.69	3.38	2.90	3.41				3.16
	Min	29.00	37.57	27.75	37.57	29.00	38.43	29.00	37.57	31.00	37.57	39.00	38.22	39.53	26.63
	Max	45.63	59.75	44.18	50.90	51.00	51.29	46.00	52.85	49.53	52.55	39.00	38.22	39.53	47.00
	Median	39.00	43.57	38.22	43.14	39.00	43.57	38.97	42.29	38.97	42.71	39.00	38.22	39.53	38.00
	Diff. Median			0.00	0.00	0.00	0.07	-0.05	-0.04	0.00	-0.07	-0.10	-0.28	0.06	-0.10
	P value			0.1092	0.9645	0.4715	0.2956	0.0417	0.4018	0.2286	0.8017	1.0000	1.0000	1.0000	0.0849
RBC	Evaluated	94	45	95	46	93	46	93	44	93	41	1	1	1	76
	Mean	4.43	4.82	4.38	4.89	4.47	4.90	4.40	4.96	4.41	4.90	4.28	4.49	4.47	4.47
	STD	0.58	0.83	0.52	0.41	0.54	0.38	0.43	0.43	0.51	0.35				0.46
	Min	1.72	2.46	1.96	3.74	2.51	3.63	1.98	4.11	1.86	4.33	4.28	4.49	4.47	2.66
	Max	6.93	7.89	5.39	5.90	6.57	6.04	5.75	6.54	6.26	6.07	4.28	4.49	4.47	6.33
	Median	4.45	4.85	4.43	4.90	4.45	4.89	4.45	4.89	4.41	4.87	4.28	4.49	4.47	4.47
	Diff. Median			0.00	0.08	0.00	0.06	-0.04	0.06	0.00	0.06	-0.12	-0.14	-0.06	0.04
	P value			0.7755	0.0046	0.3886	0.0048	0.4798	0.0660	0.6332	0.1657	1.0000	1.0000	1.0000	0.5062
PLATELETS	Evaluated	89	43	91	42	90	41	92	43	92	41	1	1	1	76
	Mean	238.88	234.08	245.58	230.26	240.10	234.64	251.61	240.95	237.16	240.08	194.64	360.00	197.12	227.84
	STD	59.15	41.28	73.67	38.44	66.44	43.12	82.85	52.58	65.67	44.29				61.28
	Min	154.81	140.63	157.21	164.38	89.06	155.63	166.67	172.60	112.50	175.48	194.64	360.00	197.12	110.30
	Max	466.00	362.00	487.50	352.00	559.00	386.00	612.00	462.50	550.00	379.69	194.64	360.00	197.12	586.50
	Median	221.43	239.29	222.00	229.46	223.27	230.36	227.72	233.93	224.06	229.38	194.64	360.00	197.12	217.90

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN 9590077
REBOXETINE - PROTOCOL 20124/013

TABLE No. : 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

PLACEBO		VISIT NO.													
		-1		2		4		6		10		12	14	16	18
		F	M	F	M	F	M	F	M	F	M	F	F	F	F
HBC: B	Max	1.50	1.50	1.50	0.75	1.50	0.75	1.50	3.00	1.50	0.07	0.75	0.00		2.25
	Median	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.75	0.00		0.00
	Diff. Median			0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	0.00		0.00
	P value			1.0000	0.3594	0.3131	0.1797	0.9859	0.6992	0.6267	0.0313	1.0000			0.5287
HBC: L	Evaluated	91	46	91	43	91	46	89	44	89	41	1	1		74
	Mean	29.74	28.77	29.10	28.60	29.09	29.19	29.43	29.20	29.59	28.06	26.50	28.00		28.94
	STD	4.34	4.34	4.50	3.33	4.68	3.79	5.83	3.43	4.52	3.57				5.25
	Min	21.00	22.00	21.00	22.00	22.50	21.00	22.00	24.00	19.00	21.00	26.50	28.00		20.00
	Max	40.50	52.00	42.00	40.00	52.00	39.00	55.00	40.00	50.00	43.00	26.50	28.00		57.00
	Median	28.60	28.00	28.00	28.14	28.00	28.50	27.50	28.25	29.00	27.50	26.50	28.00		28.00
	Diff. Median			0.00	0.05	-0.10	0.00	-0.10	0.05	0.00	0.00	-0.45	-0.10		-0.05
	P value			0.1284	0.7527	0.1143	0.3645	0.1232	0.2986	0.6025	0.3929	1.0000	1.0000		0.1573
HBC: M	Evaluated	91	46	91	43	90	46	89	44	89	41	1	1		74
	Mean	3.72	4.12	4.36	4.30	3.70	4.43	3.77	4.89	4.01	4.62	4.00	3.00		4.19
	STD	2.04	1.92	2.18	2.24	2.08	2.00	2.12	2.13	2.03	2.03				2.26
	Min	0.00	0.00	0.00	0.00	0.00	-1.00	0.00	-1.00	0.00	0.00	4.00	3.00		0.00
	Max	11.00	9.00	9.67	12.00	10.00	9.00	9.00	13.00	13.00	9.00	4.00	3.00		9.00
	Median	4.00	4.17	4.14	4.00	3.00	4.23	3.00	4.90	3.57	4.33	4.00	3.00		4.17
	Diff. Median			0.20	0.00	0.00	0.06	0.00	0.00	0.00	0.00	0.25	-0.33		0.00
	P value			0.0041	0.5312	0.8912	0.2113	0.9087	0.0615	0.4725	0.3885	1.0000	1.0000		0.1915
CREATINI-NE	Evaluated	94	45	94	45	94	46	93	44	94	41	1	1	1	75
	Mean	0.78	0.91	0.76	0.91	0.78	0.90	0.77	0.88	0.77	0.88	0.83	0.88	0.95	0.78
	STD	0.14	0.13	0.12	0.15	0.15	0.22	0.15	0.13	0.13	0.13				0.14
	Min	0.20	0.60	0.50	0.60	0.51	0.72	0.50	0.66	0.44	0.66	0.83	0.88	0.95	0.56
	Max	1.06	1.24	1.10	1.23	1.33	2.12	1.31	1.34	1.05	1.31	0.83	0.88	0.95	1.12
	Median	0.76	0.90	0.76	0.90	0.79	0.85	0.75	0.86	0.78	0.90	0.83	0.88	0.95	0.77
	Diff. Median			0.00	0.00	0.00	-0.04	0.00	-0.01	0.00	-0.01	-0.19	0.16	0.00	0.00
	P value			0.1910	0.8372	0.7483	0.1277	0.6262	0.2430	0.7509	0.5787	1.0000	1.0000		0.2751
BUN	Evaluated	93	45	94	45	95	46	90	44	94	40	1	1	1	75
	Mean	11.57	11.65	11.31	12.23	11.10	11.74	11.70	11.81	11.30	11.93	12.09	11.79	48.25	11.42

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS 950077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

PLACEBO		VISIT NO.													
		-1		2		4		6		10		12	14	16	18
		F	M	F	M	F	M	F	M	F	M	F	F	F	F
BUN	STD	2.37	2.10	1.90	2.46	2.26	2.95	2.73	2.28	2.17	2.37				2.14
	Min	6.01	7.16	7.00	7.66	6.84	7.00	6.51	8.15	5.69	7.00	12.09	11.79	48.25	6.51
	Max	20.67	16.49	15.80	18.14	16.69	23.23	27.52	17.96	17.17	16.35	12.09	11.79	48.25	20.33
	Median	11.35	11.40	11.40	11.76	10.85	10.85	11.40	11.40	11.17	12.36	12.09	11.79	48.25	11.61
	Diff. Median			-0.02	0.03	-0.06	0.00	0.00	-0.02	-0.03	0.00	0.22	0.08	3.50	-0.04
	P value			0.1241	0.1965	0.0245	0.8727	0.8661	0.7128	0.1885	0.4764	1.0000	1.0000	1.0000	0.0440
	Evaluated	95	46	95	46	94	46	93	44	92	41	1	1	1	76
URIC ACID	Mean	4.17	5.16	4.06	5.18	4.13	5.30	3.95	5.21	4.01	5.19	3.87	3.67	3.44	3.95
	STD	1.01	1.52	0.83	1.49	0.85	1.57	0.81	1.54	0.95	1.52				0.75
	Min	2.22	2.27	1.98	2.99	1.78	2.88	1.78	3.29	1.78	2.78	3.87	3.67	3.44	2.33
	Max	8.99	8.54	7.34	10.36	6.93	10.74	6.41	10.40	8.27	8.45	3.87	3.67	3.44	6.31
	Median	4.14	5.07	4.04	5.02	4.05	5.45	3.97	4.95	3.94	4.96	3.87	3.67	3.44	3.94
	Diff. Median			-0.02	0.01	-0.03	0.07	-0.06	0.09	-0.04	0.09	-0.18	0.38	-0.14	-0.06
	P value			0.4719	0.5975	0.5389	0.2006	0.0103	0.2130	0.1308	0.2729	1.0000	1.0000	1.0000	0.1340
TOT. PROTEINS	Evaluated	94	46	95	46	95	46	94	44	94	41	1	1	1	76
	Mean	7.45	7.35	7.46	7.41	7.44	7.40	7.47	7.51	7.43	7.45	7.73	7.08	6.65	7.48
	STD	0.52	0.49	0.46	0.42	0.45	0.42	0.41	0.50	0.45	0.48				0.45
	Min	6.12	6.27	6.31	6.40	6.21	6.50	6.59	6.50	6.31	6.46	7.73	7.08	6.65	6.50
	Max	8.68	8.30	8.49	8.30	8.49	8.30	8.43	8.78	8.40	9.06	7.73	7.08	6.65	8.78
	Median	7.40	7.30	7.54	7.35	7.45	7.35	7.45	7.54	7.54	7.54	7.73	7.08	6.65	7.49
	Diff. Median			0.05	0.05	0.00	0.05	0.05	0.10	0.05	0.05	0.45	-0.40	0.03	0.04
P value			0.4395	0.3123	0.9118	0.4751	0.3898	0.0529	0.8999	0.4131	1.0000	1.0000	1.0000	0.5593	
ALBUMINE	Evaluated	94	46	93	43	94	46	94	44	91	41	1	1	1	74
	Mean	4.25	4.34	4.36	4.29	4.31	4.26	4.36	4.30	4.38	4.22	4.74	3.90	4.54	4.28
	STD	0.44	0.53	0.41	0.30	0.40	0.37	0.39	0.41	0.59	0.48				0.41
	Min	1.78	2.90	3.40	3.68	3.07	2.87	3.68	3.07	3.47	3.18	4.74	3.90	4.54	3.44
	Max	5.21	5.87	5.73	5.08	5.20	4.93	5.39	5.07	6.97	6.43	4.74	3.90	4.54	5.65
	Median	4.30	4.20	4.30	4.30	4.30	4.23	4.30	4.30	4.20	4.10	4.74	3.90	4.54	4.20
	Diff. Median			0.00	0.00	0.00	0.00	0.06	0.07	0.00	-0.12	0.39	-0.40	-0.04	-0.07
P value			0.2339	0.3748	0.6335	0.6362	0.2735	0.2875	0.7897	0.0470	1.0000	1.0000	1.0000	0.4824	

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS 590077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

PLACEBO		VISIT NO.													
		-1		2		4		6		10		12	14	16	18
		F	M	F	M	F	M	F	M	F	M	F	F	F	F
TOT BILIRUBIN	Evaluated	88	44	88	43	88	45	88	41	87	39	1		1	71
	Mean	0.66	0.75	0.60	0.72	0.58	0.71	0.60	0.70	0.58	0.71	0.79		0.42	0.59
	STD	0.24	0.29	0.21	0.28	0.23	0.25	0.20	0.27	0.22	0.27				0.20
	Min	0.19	0.23	0.15	0.23	0.17	0.21	0.19	0.22	0.22	0.19	0.79		0.42	0.17
	Max	1.30	1.80	1.23	1.32	1.10	1.30	1.04	1.48	1.31	1.48	0.79		0.42	1.00
	Median	0.63	0.72	0.60	0.70	0.56	0.70	0.60	0.70	0.60	0.71	0.79		0.42	0.60
	Diff. Median			0.00	0.00	-0.04	0.00	0.00	0.00	-0.06	0.00	0.18		-0.22	0.00
	P value			0.1895	0.5319	0.0590	0.4497	0.0673	0.5017	0.0786	0.9764	1.0000		1.0000	0.1171
DIR BILIRUBIN	Evaluated	81	41	84	39	84	42	85	38	83	37	1		1	66
	Mean	0.13	0.14	0.13	0.14	0.13	0.15	0.14	0.16	0.12	0.16	0.02		0.00	0.11
	STD	0.10	0.08	0.08	0.08	0.10	0.09	0.09	0.07	0.08	0.09				0.08
	Min	0.00	0.00	0.00	0.00	-0.01	0.00	-0.02	0.02	0.00	0.01	0.02		0.00	0.00
	Max	0.60	0.31	0.33	0.30	0.53	0.47	0.48	0.32	0.33	0.52	0.02		0.00	0.35
	Median	0.10	0.15	0.15	0.15	0.14	0.15	0.15	0.15	0.10	0.15	0.02		0.00	0.10
	Diff. Median			0.00	0.00	0.00	0.00	0.00	0.03	0.00	0.00	-0.11		0.00	0.00
	P value			0.9570	0.8724	0.5815	0.7142	0.8265	0.2520	0.1811	0.9606	1.0000			0.1123
SGOT	Evaluated	95	46	95	45	95	46	94	43	94	41	1	1	1	75
	Mean	21.19	23.16	19.19	21.79	20.48	23.17	19.88	21.44	21.25	23.03	13.64	62.00	12.86	20.56
	STD	9.38	17.13	4.71	16.73	11.16	23.37	7.79	15.50	11.79	14.92				6.77
	Min	10.71	10.95	10.71	10.00	10.80	10.00	10.73	10.00	11.82	8.10	13.64	62.00	12.86	12.73
	Max	78.00	129.29	34.00	127.86	85.20	174.29	68.00	117.14	110.00	89.20	13.64	62.00	12.86	58.00
	Median	20.00	20.56	18.67	19.29	17.27	20.00	18.57	20.00	18.76	20.00	13.64	62.00	12.86	20.00
	Diff. Median			0.00	-0.07	-0.04	0.00	-0.05	-0.05	-0.02	-0.07	0.00	1.60	-0.19	0.00
	P value			0.1504	0.2047	0.2478	0.5112	0.0550	0.1563	0.6620	0.3342		1.0000	1.0000	0.7671
SGPT	Evaluated	95	46	95	46	95	46	94	44	94	41	1	1	1	75
	Mean	21.85	24.35	19.09	24.67	21.69	23.59	19.72	22.31	21.71	24.43	13.13	17.50	9.35	19.56
	STD	21.85	23.61	10.14	23.08	20.76	18.26	11.22	16.81	15.83	16.85				7.51
	Min	5.00	6.88	5.83	8.13	5.00	5.00	5.00	6.25	6.56	6.25	13.13	17.50	9.35	5.83
	Max	143.79	139.17	59.31	150.83	137.76	124.17	73.33	118.33	140.71	93.33	13.13	17.50	9.35	44.29
	Median	16.67	20.00	17.07	19.53	15.94	20.00	17.77	19.53	20.00	20.00	13.13	17.50	9.35	20.00

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN950077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

PLACEBO		VISIT NO.													
		-1		2		4		6		10		12	14	16	18
		F	M	F	M	F	M	F	M	F	M	F	F	F	F
SGPT	Diff. Median			0.00	-0.02	0.00	0.02	0.00	0.02	0.03	0.07	-0.18	0.14	0.09	0.07
	P value			0.9612	0.8937	0.9844	0.8724	0.9148	0.8987	0.0497	0.4464	1.0000	1.0000	1.0000	0.1601
GAMMA-GT	Evaluated	92	46	93	44	93	45	92	41	94	40	1	1	1	74
	Mean	43.73	65.25	35.48	44.34	34.75	47.66	34.31	39.83	34.25	38.40	14.29	33.14	17.33	32.46
	STD	53.22	104.53	38.17	79.63	34.30	81.46	31.47	62.86	28.44	41.07				26.63
	Min	8.00	6.75	4.97	3.41	6.67	9.54	7.66	6.30	7.31	7.65	14.29	33.14	17.33	8.00
	Max	430.15	521.50	342.77	504.08	309.54	536.88	259.08	420.03	213.54	248.85	14.29	33.14	17.33	223.38
	Median	31.38	30.13	28.92	25.40	30.37	28.48	28.64	28.48	26.46	25.08	14.29	33.14	17.33	27.96
	Diff. Median			-0.05	-0.10	-0.09	-0.07	-0.04	-0.13	-0.04	-0.14	0.16	-0.79	0.29	-0.09
	P value			0.0161	0.0000	0.0144	0.0180	0.0172	0.0015	0.1293	0.0181	1.0000	1.0000	1.0000	0.0147
ALK. PHOSPH.	Evaluated	94	46	94	45	95	46	94	42	93	41	1	1	1	75
	Mean	113.63	137.39	109.80	135.05	107.66	131.85	106.68	128.97	102.84	113.20	69.20	120.35	81.46	98.46
	STD	33.24	50.24	32.59	56.38	29.85	53.33	31.59	50.48	38.14	29.96				29.31
	Min	44.12	56.43	40.60	60.48	40.60	50.60	40.16	53.45	36.20	55.16	69.20	120.35	81.46	46.32
	Max	239.15	352.91	237.98	377.04	180.47	377.04	182.28	400.22	276.63	201.33	69.20	120.35	81.46	172.25
	Median	109.79	130.40	107.13	118.76	104.47	119.12	101.68	119.71	96.26	108.36	69.20	120.35	81.46	95.44
	Diff. Median			-0.08	0.00	-0.03	-0.05	-0.07	-0.05	-0.12	-0.17	-0.18	0.28	0.20	-0.12
	P value			0.0261	0.7091	0.1088	0.2249	0.0041	0.0393	0.0001	0.0000	1.0000	1.0000	1.0000	0.0000
GLOBULIN-S: ALPHA 1	Evaluated	93	46	93	44	95	45	93	43	91	41	1	1	1	72
	Mean	0.17	0.12	0.15	0.13	0.17	0.13	0.16	0.13	0.13	0.11	0.21	0.18	0.19	0.11
	STD	0.19	0.09	0.12	0.12	0.21	0.13	0.13	0.12	0.16	0.19				0.14
	Min	-0.05	-0.10	-0.04	-0.11	-0.13	-0.01	-0.09	-0.13	-0.12	-0.04	0.21	0.18	0.19	-0.09
	Max	1.07	0.40	0.73	0.57	1.36	0.78	0.65	0.56	0.96	0.86	0.21	0.18	0.19	0.56
	Median	0.13	0.11	0.14	0.10	0.13	0.10	0.14	0.10	0.09	0.05	0.21	0.18	0.19	0.07
	Diff. Median			0.00	-0.03	-0.03	-0.07	-0.07	-0.13	-0.08	-0.25	0.38	0.03	-0.07	-0.18
	P value			0.6233	0.7576	0.1960	0.6986	0.5047	0.2521	0.0079	0.0520	1.0000	1.0000	1.0000	0.0088
GLOBULIN-S: ALPHA 2	Evaluated	93	46	93	44	95	45	93	43	91	41	1	1	1	72
	Mean	0.79	0.77	0.77	0.76	0.78	0.75	0.77	0.77	0.75	0.77	0.59	0.68	0.97	0.75
	STD	0.21	0.19	0.16	0.19	0.18	0.21	0.18	0.21	0.18	0.21				0.20
	Min	0.39	0.47	0.51	0.36	0.39	0.36	0.39	0.41	0.11	0.29	0.59	0.68	0.97	0.13

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS 990077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

PLACEBO		VISIT NO.													
		-1		2		4		6		10		12	14	16	18
		F	M	F	M	F	M	F	M	F	M	F	F	F	F
GLOBULIN-S: ALPHA 2	Max	1.47	1.26	1.28	1.31	1.25	1.42	1.27	1.33	1.23	1.29	0.59	0.68	0.97	1.29
	Median	0.76	0.74	0.75	0.73	0.75	0.72	0.73	0.73	0.75	0.73	0.59	0.68	0.97	0.74
	Diff. Median			0.00	0.00	-0.07	-0.03	-0.07	-0.05	-0.03	0.05	-0.40	-0.23	0.07	-0.07
	P value			0.2502	0.8287	0.6450	0.7494	0.2559	0.8536	0.1218	0.7216	1.0000	1.0000	1.0000	0.1335
GLOBULIN-S: BETA	Evaluated	93	46	93	44	95	45	93	43	91	41	1	1	1	72
	Mean	0.90	0.90	0.88	0.90	0.88	0.85	0.90	0.88	0.89	0.92	0.86	0.93	1.36	0.89
	STD	0.24	0.22	0.23	0.22	0.23	0.24	0.25	0.21	0.25	0.34				0.23
	Min	0.22	0.42	0.11	0.42	0.30	0.14	0.17	0.38	0.13	0.49	0.86	0.93	1.36	0.29
	Max	1.82	1.38	1.75	1.78	1.47	1.34	1.54	1.46	1.63	2.31	0.86	0.93	1.36	1.47
	Median	0.89	0.89	0.89	0.89	0.87	0.85	0.90	0.87	0.89	0.87	0.86	0.93	1.36	0.90
	Diff. Median			-0.07	0.00	-0.05	-0.10	0.02	-0.06	0.02	-0.00	-0.03	-0.33	-0.13	-0.01
P value			0.2129	0.7942	0.4866	0.0808	0.5145	0.5793	0.9434	0.8787	1.0000	1.0000	1.0000	0.8583	
GLOBULIN-S: GAMMA	Evaluated	93	46	93	44	95	45	93	43	91	41	1	1	1	72
	Mean	1.10	1.03	1.08	1.08	1.07	1.08	1.05	1.14	1.07	1.10	0.88	1.22	0.82	1.17
	STD	0.34	0.39	0.31	0.31	0.31	0.37	0.30	0.38	0.40	0.38				0.37
	Min	0.46	0.32	0.21	0.38	0.01	0.27	0.11	0.34	0.14	0.34	0.88	1.22	0.82	-0.25
	Max	2.09	2.08	1.76	1.73	1.75	2.23	1.65	1.98	2.40	2.14	0.88	1.22	0.82	1.78
	Median	1.08	1.01	1.05	1.09	1.10	1.06	1.05	1.17	1.04	1.10	0.88	1.22	0.82	1.14
	Diff. Median			0.00	0.06	0.01	0.11	-0.03	0.07	-0.09	0.03	0.13	-0.15	-0.13	-0.01
P value			0.5594	0.2059	0.9615	0.3323	0.1701	0.1205	0.0952	0.3781	1.0000	1.0000	1.0000	0.7174	
TOT. CHOLEST.	Evaluated	94	46	95	45	94	45	94	44	93	40	1	1	1	76
	Mean	216.07	207.49	207.57	202.09	211.96	206.74	209.61	205.48	212.77	218.12	238.06	247.29	235.44	207.44
	STD	45.26	45.13	39.72	36.19	42.73	36.39	43.31	38.22	43.46	44.60				47.28
	Min	123.45	149.83	132.37	142.57	107.38	154.19	122.55	142.57	127.02	153.46	238.06	247.29	235.44	120.77
	Max	338.33	360.29	350.86	280.21	359.14	307.47	330.46	292.86	342.57	351.86	238.06	247.29	235.44	421.29
	Median	212.07	199.81	203.75	196.06	203.75	196.12	203.46	198.87	212.68	205.65	238.06	247.29	235.44	198.85
	Diff. Median			-0.08	0.00	-0.07	0.02	-0.08	0.01	-0.05	0.05	0.06	0.32	0.35	-0.10
P value			0.0031	0.5539	0.1512	0.9269	0.0140	0.7351	0.2833	0.1614	1.0000	1.0000	1.0000	0.0315	
TRIGLYCE- RIDES	Evaluated	93	45	94	45	95	46	94	43	93	41	1	1	1	75
	Mean	113.91	200.28	107.21	187.66	110.33	202.50	108.12	189.79	118.37	196.33	120.20	99.00	151.87	103.91

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS 9560077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

PLACEBO		VISIT NO.													
		-1		2		4		6		10		12	14	16	18
		F	M	F	M	F	M	F	M	F	M	F	F	F	F
TRIGLYCE- RIDES	STD	56.40	109.24	45.21	89.00	54.87	125.08	47.21	122.57	70.47	142.71				45.00
	Min	29.87	23.59	19.32	40.53	6.13	40.53	29.87	-3.93	29.87	23.59	120.20	99.00	151.87	17.12
	Max	322.09	520.68	241.33	458.57	374.28	673.43	347.07	670.07	439.73	690.21	120.20	99.00	151.87	256.97
	Median	101.68	173.21	91.16	164.82	94.64	158.39	99.22	153.44	98.57	141.32	120.20	99.00	151.87	94.64
	Diff. Median			-0.01	-0.06	0.00	0.02	-0.02	-0.01	0.00	-0.02	-0.18	-0.33	0.13	-0.01
	P value			0.3667	0.2027	0.4340	0.9622	0.2727	0.5364	0.9257	0.5564	1.0000	1.0000	1.0000	0.4425
GLUCOSE	Evaluated	94	46	95	45	95	46	94	44	93	41	1	1	1	76
	Mean	92.61	97.03	91.04	97.01	90.36	98.24	92.53	94.90	95.10	95.37	87.50	82.83	96.67	91.83
	STD	16.58	42.21	13.93	44.52	16.96	39.11	13.64	29.38	14.00	16.75				13.06
	Min	64.75	65.23	68.25	61.25	57.27	60.45	64.75	63.64	68.41	65.00	87.50	82.83	96.67	63.33
	Max	159.83	354.67	136.50	354.67	176.17	341.83	151.67	271.83	158.67	170.33	87.50	82.83	96.67	151.67
	Median	91.00	86.70	87.58	89.25	89.25	95.67	91.00	92.21	93.33	94.50	87.50	82.83	96.67	92.33
	Diff. Median			-0.05	0.05	-0.03	0.10	0.00	-0.06	0.07	0.13	-0.10	-0.32	-0.05	-0.03
	P value			0.2934	0.8170	0.2403	0.3016	0.6015	0.8032	0.0531	0.2283	1.0000	1.0000	1.0000	0.1673
HA+	Evaluated	95	46	95	46	95	46	94	44	94	41	1	1	1	76
	Mean	138.82	138.42	138.57	139.11	138.59	138.66	138.44	138.36	138.61	139.05	146.00	141.33	139.00	138.40
	STD	2.65	2.70	2.53	3.10	2.62	2.68	2.35	2.22	2.24	2.74				2.68
	Min	135.00	134.82	134.24	134.24	132.67	134.00	132.00	134.82	134.24	134.82	146.00	141.33	139.00	129.00
	Max	153.00	145.00	146.00	147.00	145.00	147.00	145.33	145.00	146.00	147.00	146.00	141.33	139.00	144.67
	Median	138.35	138.18	138.00	138.18	138.35	138.18	138.35	137.88	138.00	138.35	146.00	141.33	139.00	138.35
	Diff. Median			0.00	0.06	0.00	0.00	0.00	0.03	0.00	0.10	0.73	0.20	0.00	0.00
	P value			0.4015	0.1049	0.3358	0.3850	0.1777	0.3750	0.5777	0.0139	1.0000	1.0000		0.4164
CL-	Evaluated	81	40	82	40	83	40	88	39	80	38	1	1		69
	Mean	100.13	100.03	100.10	100.13	99.65	99.82	99.27	99.98	100.34	99.69	101.60	102.00		100.29
	STD	2.67	2.50	2.72	3.30	3.64	2.73	4.41	2.52	3.41	3.12				3.55
	Min	95.82	96.18	91.60	95.60	78.80	96.32	74.80	96.91	90.80	96.91	101.60	102.00		95.60
	Max	109.20	106.80	107.60	112.40	110.00	108.40	107.23	106.80	107.85	109.20	101.60	102.00		110.00
	Median	99.76	99.71	99.88	99.45	99.23	99.45	99.29	99.09	99.82	98.36	101.60	102.00		98.72
	Diff. Median			0.01	-0.05	0.00	-0.05	0.00	-0.05	0.00	-0.02	-0.03	0.00		0.00
	P value			0.5916	0.4747	0.7753	0.6850	0.9875	0.7348	0.4028	0.3023	1.0000			0.4276

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS 950077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

PLACEBO		VISIT NO.													
		-1		2		4		6		10		12	14	16	18
		F	M	F	M	F	M	F	M	F	M	F	F	F	F
K+	Evaluated	95	46	95	46	95	46	94	44	94	41	1	1	1	76
	Mean	4.18	4.00	4.13	4.15	4.17	4.11	4.10	4.04	4.09	4.09	4.20	4.12	4.30	4.15
	STD	0.45	0.36	0.39	0.42	0.40	0.50	0.36	0.35	0.38	0.35				0.37
	Min	3.39	3.40	3.40	3.50	3.10	3.30	3.30	3.40	3.10	3.30	4.20	4.12	4.30	3.40
	Max	6.70	4.87	5.20	5.10	5.10	5.90	4.87	5.21	5.02	5.21	4.20	4.12	4.30	5.44
	Median	4.20	3.98	4.10	4.08	4.20	3.98	4.06	4.03	4.09	4.00	4.20	4.12	4.30	4.06
	Diff. Median			0.00	0.06	0.00	0.06	-0.05	0.00	-0.05	0.10	0.19	0.06	0.21	-0.05
	P value			0.4667	0.0101	0.8502	0.0629	0.1615	0.5323	0.0842	0.0496	1.0000	1.0000	1.0000	0.0950
CA++	Evaluated	73	34	70	32	73	34	73	33	72	32		1	1	63
	Mean	4.88	4.92	4.92	5.00	4.93	4.91	4.91	4.92	4.92	4.92		4.00	4.38	4.92
	STD	0.27	0.35	0.33	0.27	0.30	0.35	0.30	0.24	0.33	0.21				0.30
	Min	4.17	4.17	4.03	4.41	3.94	3.92	4.19	4.43	4.10	4.48		4.00	4.38	3.94
	Max	5.30	5.40	5.38	5.50	5.50	5.40	5.79	5.35	5.70	5.35		4.00	4.38	5.95
	Median	4.95	5.05	5.00	5.05	5.00	4.97	4.92	4.99	4.91	4.88		4.00	4.38	5.00
	Diff. Median			0.04	0.02	0.05	-0.02	0.00	-0.03	0.07	-0.10		-0.80	-0.38	0.00
	P value			0.0899	0.3793	0.1541	0.8407	0.5693	0.8249	0.5543	0.5394		1.0000	1.0000	0.8594
PO4-	Evaluated	94	46	92	43	95	46	93	44	94	41	1	1	1	75
	Mean	1.22	1.23	1.27	1.29	1.24	1.23	1.25	1.26	1.24	1.24	1.46	0.99	1.14	1.24
	STD	0.18	0.18	0.18	0.34	0.18	0.17	0.24	0.16	0.18	0.15				0.15
	Min	0.86	0.83	0.82	0.77	0.80	0.90	0.64	0.90	0.86	0.83	1.46	0.99	1.14	0.86
	Max	1.60	1.53	1.80	3.16	1.73	1.63	2.71	1.53	1.71	1.50	1.46	0.99	1.14	1.58
	Median	1.25	1.27	1.29	1.26	1.23	1.26	1.25	1.27	1.23	1.26	1.46	0.99	1.14	1.27
	Diff. Median			0.13	0.07	0.06	0.00	0.07	0.06	0.02	0.06	0.17	-0.22	-0.14	0.14
	P value			0.0034	0.2081	0.0803	0.6389	0.1901	0.2619	0.1272	0.2820	1.0000	1.0000	1.0000	0.0599

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS 950077
REBOXETINE - PROTOCOL 2012a/013

TABLE No.: 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

PLACEBO		VISIT NO.															
		18		22		24		26		30		34		42		52	
		M	F	M	F	F	M	F	F	M	F	M	F	M	F	M	
HB	Evaluated	34	1	1	1	61	25	1	56	22	49	21	45	19			
	Mean	14.54	14.29	16.06	18.93	13.81	14.17	14.40	14.12	13.84	14.06	13.92	14.06	14.28			
	STD	1.64				1.63	1.64		1.61	1.43	1.40	1.09	1.56	1.67			
	Min	12.00	14.29	16.06	18.93	9.76	12.30	14.40	11.90	12.50	12.20	13.00	11.84	12.80			
	Max	19.28	14.29	16.06	18.93	19.00	17.66	14.40	19.27	17.18	18.67	16.93	19.20	18.45			
	Median	14.35	14.29	16.06	18.93	13.60	13.70	14.40	13.71	13.40	13.60	13.60	13.80	13.60			
	Diff. Median	0.07	0.11	0.40	0.97	-0.02	0.00	0.00	0.01	0.10	0.05	0.08	0.00	0.18			
	P value	0.2061	1.0000	1.0000	1.0000	0.7270	0.2718		0.6123	0.2609	0.7037	0.1698	0.7745	0.0134			
HTC	Evaluated	34	1	1	1	61	25	1	56	22	49	21	45	19			
	Mean	43.15	39.00	48.71	40.71	38.07	42.92	37.11	38.31	41.69	38.59	41.82	38.53	42.08			
	STD	3.29				2.42	3.56		2.13	2.61	3.12	1.83	2.49	1.85			
	Min	37.57	39.00	48.71	40.71	32.11	39.29	37.11	33.65	38.43	33.00	39.29	33.65	39.29			
	Max	53.15	39.00	48.71	40.71	43.00	53.45	37.11	44.63	48.47	52.75	45.29	45.88	47.00			
	Median	42.71	39.00	48.71	40.71	38.00	42.71	37.11	38.00	41.86	38.00	41.86	38.00	41.86			
	Diff. Median	0.00	0.30	0.71	0.06	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.07			
	P value	0.6029	1.0000	1.0000	1.0000	0.2673	0.9762		0.5554	0.8070	0.9594	0.7190	0.7564	0.1613			
RBC	Evaluated	34	1	1	1	61	25	1	56	22	49	21	45	19			
	Mean	5.10	4.30	5.46	4.40	4.48	5.07	4.29	4.48	4.79	4.44	4.84	4.40	4.89			
	STD	0.80				0.34	0.92		0.23	0.30	0.37	0.16	0.34	0.15			
	Min	4.42	4.30	5.46	4.40	3.93	4.50	4.29	3.87	4.21	3.29	4.58	3.57	4.58			
	Max	8.11	4.30	5.46	4.40	5.97	8.45	4.29	5.18	5.67	6.21	5.36	5.70	5.28			
	Median	4.89	4.30	5.46	4.40	4.45	4.78	4.29	4.48	4.73	4.45	4.81	4.49	4.89			
	Diff. Median	0.06	0.15	0.53	0.11	0.00	0.11	-0.23	0.00	0.14	0.00	0.17	-0.06	0.22			
	P value	0.0159	1.0000	1.0000	1.0000	0.8948	0.2027	1.0000	0.7072	0.1523	0.7770	0.0663	0.3954	0.0120			
PLATELETS	Evaluated	34	1	1	1	61	25	1	56	22	48	21	45	19			
	Mean	217.28	194.64	187.50	245.67	236.02	223.93	261.00	230.46	232.22	228.09	224.97	235.70	224.26			
	STD	39.03				67.37	44.03		41.04	27.41	46.13	24.92	43.92	18.75			
	Min	114.06	194.64	187.50	245.67	155.36	51.56	261.00	151.25	173.21	146.67	171.25	158.33	165.63			
	Max	322.00	194.64	187.50	245.67	645.00	258.12	261.00	355.00	281.25	363.00	275.00	332.50	243.75			
	Median	226.88	194.64	187.50	245.67	227.00	239.29	261.00	230.36	234.38	220.00	226.25	231.25	228.13			

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS 9350077
REBOXETINE - PROTOCOL 20124/013

TABLE No. : 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

PLACEBO		VISIT NO.															
		18		22		24		26		30		34		42		52	
		M	F	M	F	F	M	F	M	F	M	F	M	F	M		
PLATELETS	Diff. Median	-0.00	-0.14	-0.10	-0.16	-0.01	0.06	-0.01	0.00	0.09	0.00	0.05	0.02	0.06			
	P value	0.4538	1.0000	1.0000	1.0000	0.9884	0.1748	1.0000	0.6991	0.0650	0.8242	0.3251	0.2424	0.0955			
WBC	Evaluated	34	1	1	1	61	25	1	56	22	49	21	45	19			
	Mean	7.19	6.13	6.06	6.53	6.65	7.17	8.03	6.65	6.79	6.75	6.69	6.83	6.53			
	STD	2.09				1.64	2.10		1.34	1.54	2.29	1.59	2.00	1.18			
	Min	4.50	6.13	6.06	6.53	3.72	4.91	8.03	3.76	2.88	3.96	3.42	3.94	4.96			
	Max	12.95	6.13	6.06	6.53	11.81	15.06	8.03	10.05	11.54	15.06	11.27	12.35	9.24			
	Median	6.45	6.13	6.06	6.53	6.40	6.64	8.03	6.54	6.50	6.17	6.45	6.45	6.36			
	Diff. Median	-0.10	0.08	-0.16	-0.36	0.00	-0.04	0.11	-0.04	-0.03	-0.04	-0.17	-0.03	-0.10			
	P value	0.1284	1.0000	1.0000	1.0000	0.1119	0.5979	1.0000	0.0966	0.0321	0.2806	0.2188	0.3585	0.0976			
WBC: N	Evaluated	34	1	1	1	58	25	1	54	22	47	21	46	19			
	Mean	63.48	63.54	61.58	65.50	61.91	63.78	63.00	62.22	63.18	62.70	64.10	61.38	63.96			
	STD	3.19				5.00	3.06		3.75	2.52	5.37	1.99	5.83	1.86			
	Min	51.00	63.54	61.58	65.50	42.00	55.00	63.00	51.58	55.46	42.00	58.15	32.00	59.69			
	Max	69.00	63.54	61.58	65.50	69.67	73.00	63.00	68.92	65.67	73.00	68.33	68.15	67.00			
	Median	64.00	63.54	61.58	65.50	63.33	64.00	63.00	63.67	64.00	64.31	64.00	63.00	64.33			
	Diff. Median	0.03	0.38	-0.17	0.20	0.00	0.03	1.20	0.00	-0.02	0.10	0.03	-0.02	0.00			
	P value	0.0703	1.0000	1.0000	1.0000	0.8395	0.4778	1.0000	0.4672	0.6992	0.1840	0.5476	0.5271	0.5830			
WBC: E	Evaluated	34	1	1	1	57	25	1	54	22	46	21	45	19			
	Mean	2.19	2.50	1.67	2.20	1.72	2.23	1.50	1.87	1.92	1.80	1.74	1.91	1.68			
	STD	1.13				1.03	1.57		1.19	0.88	0.72	0.74	1.62	0.69			
	Min	0.33	2.50	1.67	2.20	0.33	0.50	1.50	0.50	1.00	0.33	0.50	0.33	0.50			
	Max	5.50	2.50	1.67	2.20	6.50	8.50	1.50	8.33	4.50	4.00	3.50	9.50	3.50			
	Median	2.00	2.50	1.67	2.20	1.50	2.00	1.50	1.50	1.50	1.50	1.50	1.50	1.50			
	Diff. Median	0.00	1.00	-2.67	0.40	0.00	-0.25	-1.25	0.00	-0.25	0.00	-0.25	0.00	-0.25			
	P value	0.6375	1.0000	1.0000	1.0000	0.2952	0.5199	1.0000	0.6963	0.1791	0.7143	0.1233	0.3447	0.2306			
WBC: B	Evaluated	34	1	1		57	25	1	54	22	46	21	45	19			
	Mean	0.03	0.00	0.00		0.07	0.06	0.75	0.07	0.10	0.03	0.04	0.03	0.04			
	STD	0.14				0.21	0.21		0.22	0.26	0.15	0.16	0.16	0.17			
	Min	0.00	0.00	0.00		0.00	0.00	0.75	0.00	0.00	0.00	0.00	0.00	0.00			

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS 0077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

PLACEBO		VISIT NO.															
		18		22		24		26		30		34		42		52	
		M	F	M	F	F	M	F	F	M	F	M	F	M	F	M	
WBC: B	Max	0.75	0.00	0.00		0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	
	Median	0.00	0.00	0.00		0.00	0.00	0.75	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	Diff. Median	0.00	0.00	0.00		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	P value	0.3125				0.4668	0.7500		0.2695	1.0000	0.1875	0.5000	0.1875	0.5000			
WBC: L	Evaluated	34	1	1	1	58	25	1	54	22	47	21	46	19			
	Mean	27.54	26.50	29.00	24.20	30.06	27.28	33.00	29.56	27.86	28.52	27.17	30.21	27.05			
	STD	2.47				5.83	2.34		4.46	2.96	6.17	2.23	7.34	2.22			
	Min	24.00	26.50	29.00	24.20	21.50	20.00	33.00	21.00	23.00	22.00	23.00	22.00	23.00			
	Max	37.00	26.50	29.00	24.20	53.00	32.00	33.00	42.00	37.50	52.00	33.00	67.00	33.00			
	Median	27.50	26.50	29.00	24.20	28.00	27.50	33.00	28.00	27.25	27.00	27.00	28.00	27.00			
	Diff. Median	0.00	-0.65	0.10	-0.16	0.00	-0.05	-0.70	0.00	0.00	-0.15	-0.10	-0.03	0.00			
	P value	0.1996	1.0000	1.0000	1.0000	0.3481	0.6367	1.0000	0.9337	0.8269	0.0325	0.6407	0.7940	0.5239			
WBC: M	Evaluated	34	1	1	1	58	25	1	54	22	47	21	46	19			
	Mean	4.59	3.50	4.33	3.80	4.54	5.31	2.00	4.58	6.02	5.19	6.07	5.18	6.24			
	STD	1.84				2.31	2.06		2.04	1.92	2.15	1.71	2.35	1.92			
	Min	1.00	3.50	4.33	3.80	0.00	2.00	2.00	0.00	3.00	1.00	2.00	1.00	2.00			
	Max	8.00	3.50	4.33	3.80	10.00	8.00	2.00	9.00	9.00	9.00	9.00	11.00	9.00			
	Median	5.00	3.50	4.33	3.80	4.53	5.00	2.00	4.67	5.50	5.00	6.00	5.20	6.00			
	Diff. Median	0.00	-0.13	0.00	-0.40	0.25	0.25	0.00	0.16	0.25	0.40	0.25	0.42	0.25			
	P value	0.9447	1.0000		1.0000	0.0101	0.1023		0.0083	0.0279	0.0002	0.0025	0.0002	0.0199			
CREATININE	Evaluated	34	1	1	1	61	25	1	56	22	49	21	46	19			
	Mean	0.92	0.80	1.20	0.75	0.77	0.85	0.72	0.75	0.83	0.75	0.83	0.75	0.84			
	STD	0.18				0.15	0.11		0.14	0.10	0.12	0.10	0.15	0.11			
	Min	0.72	0.80	1.20	0.75	0.56	0.72	0.72	0.51	0.72	0.56	0.72	0.50	0.66			
	Max	1.36	0.80	1.20	0.75	1.23	1.12	0.72	1.10	1.08	1.11	1.03	1.10	1.01			
	Median	0.86	0.80	1.20	0.75	0.71	0.84	0.72	0.69	0.78	0.74	0.78	0.74	0.83			
	Diff. Median	0.02	-0.20	0.51	0.00	0.00	0.00	-0.08	0.00	0.00	0.00	0.00	0.00	0.00			
	P value	0.2572	1.0000	1.0000		0.1951	0.6939	1.0000	0.4806	0.9614	0.7865	0.9737	0.9660	0.6532			
BUN	Evaluated	35	1	1	1	62	25	1	56	22	49	21	44	19			
	Mean	12.11	11.93	15.61	8.38	11.32	12.54	13.60	11.43	12.02	11.72	12.60	11.59	12.63			

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS 9540077
REBOXETINE - PROTOCOL 20124/013

TABLE No. : 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

PLACEBO		VISIT NO.															
		18		22		24		26		30		34		42		52	
		M	F	M	F	F	M	F	F	M	F	M	F	M	F	M	
BUN	STD	2.18				1.90	1.63			1.91	1.77	2.04	1.39	1.59	2.44		
	Min	7.83	11.93	15.61	8.38	6.51	8.15	13.60	6.18	7.82	6.51	9.46	8.38	7.05			
	Max	17.86	11.93	15.61	8.38	14.43	15.80	13.60	14.98	16.08	16.85	16.08	17.16	17.17			
	Median	12.23	11.93	15.61	8.38	11.11	12.78	13.60	11.81	12.23	11.95	12.50	11.61	12.50			
	Diff. Median	0.01	-0.04	0.16	-0.13	-0.03	0.08	0.06	-0.02	-0.04	0.03	0.08	0.03	0.05			
	P value	0.3508	1.0000	1.0000	1.0000	0.4247	0.0782	1.0000	0.5013	0.6483	0.8045	0.1432	0.9527	0.4833			
	Evaluated	35	1	1	1	62	25	1	55	21	49	21	45	19			
URIC ACID	Mean	5.20	5.07	5.45	4.19	3.98	4.77	2.84	4.08	4.48	4.27	4.47	4.06	4.60			
	STD	1.57				0.78	1.09		0.69	0.82	0.89	0.82	0.92	0.63			
	Min	2.99	5.07	5.45	4.19	1.81	3.29	2.84	2.65	3.50	1.84	3.71	1.86	3.71			
	Max	8.30	5.07	5.45	4.19	6.63	7.11	2.84	6.23	6.28	6.01	6.64	5.90	6.50			
	Median	4.70	5.07	5.45	4.19	3.85	4.43	2.84	4.04	4.32	4.35	4.22	4.35	4.43			
	Diff. Median	0.16	0.06	0.14	0.16	-0.04	0.00	-0.05	-0.03	0.00	0.00	0.01	0.03	0.14			
	P value	0.0468	1.0000	1.0000	1.0000	0.2232	0.9126	1.0000	0.7499	0.9922	0.3351	0.8517	0.9480	0.1707			
	Evaluated	34	1	1	1	62	25	1	56	22	49	21	46	19			
TOT. PROTEINS	Mean	7.49	7.64	7.16	7.38	7.52	7.71	7.83	7.39	7.62	7.43	7.56	7.31	7.49			
	STD	0.45				0.41	0.42		0.51	0.26	0.42	0.36	0.43	0.27			
	Min	6.52	7.64	7.16	7.38	6.32	6.78	7.83	5.93	6.97	6.32	7.16	5.93	7.26			
	Max	8.59	7.64	7.16	7.38	8.21	8.78	7.83	8.68	8.11	9.06	8.59	8.21	8.30			
	Median	7.54	7.64	7.16	7.38	7.54	7.64	7.83	7.45	7.68	7.35	7.45	7.35	7.35			
	Diff. Median	0.12	-0.30	-0.24	-0.52	0.00	0.20	0.10	0.00	0.15	0.00	0.05	-0.02	0.10			
	P value	0.0568	1.0000	1.0000	1.0000	0.3306	0.0034	1.0000	0.9411	0.0016	0.9700	0.0677	0.1571	0.0221			
	Evaluated	35	1	1	1	61	25	1	56	22	49	21	45	19			
ALBUMINE	Mean	4.22	4.57	4.30	5.78	4.25	4.18	4.30	4.23	4.08	4.19	4.03	4.13	4.06			
	STD	0.47				0.38	0.39		0.36	0.19	0.44	0.30	0.41	0.25			
	Min	3.18	4.57	4.30	5.78	3.23	3.80	4.30	3.80	3.80	3.60	3.60	2.90	3.70			
	Max	5.40	4.57	4.30	5.78	5.29	5.01	4.30	5.23	4.56	5.51	4.94	4.98	4.61			
	Median	4.10	4.57	4.30	5.78	4.20	4.03	4.30	4.13	4.00	4.00	4.00	4.02	4.00			
	Diff. Median	-0.07	-0.36	0.07	0.70	-0.06	-0.07	0.13	-0.07	-0.10	-0.07	-0.10	-0.11	-0.07			
	P value	0.2389	1.0000	1.0000	1.0000	0.4170	0.0117	1.0000	0.3927	0.0716	0.1077	0.0431	0.0574	0.2681			
	Evaluated	35	1	1	1	61	25	1	56	22	49	21	45	19			

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN930077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

PLACEBO		VISIT NO.															
		18		22		24		26		30		34		42		52	
		M	F	M	F	F	M	F	F	M	F	M	F	M	F	M	
TOT BILIRUBIN	Evaluated	33	1		1	59	24	1	53	21	46	21	43	19			
	Mean	0.73	0.76		0.64	0.61	0.66	0.36	0.62	0.60	0.70	0.73	0.67	0.77			
	STD	0.28				0.19	0.22		0.23	0.19	0.20	0.19	0.28	0.21			
	Min	0.30	0.76		0.64	0.21	0.21	0.36	0.28	0.24	0.30	0.40	0.19	0.47			
	Max	1.80	0.76		0.64	1.10	1.20	0.36	1.37	0.90	1.22	1.34	1.48	1.32			
	Median	0.79	0.76		0.64	0.64	0.60	0.36	0.60	0.60	0.70	0.70	0.69	0.70			
	Diff. Median	0.00	0.51		-0.17	-0.03	-0.06	-0.07	-0.13	-0.11	0.00	0.00	-0.13	0.13			
	P value	0.7278	1.0000		1.0000	0.1091	0.2998	1.0000	0.1816	0.0251	0.8981	0.9597	0.6515	0.5739			
DIR BILIRUBIN	Evaluated	30	1		1	53	24	1	49	21	41	21	40	19			
	Mean	0.16	0.04		0.00	0.12	0.15	0.16	0.12	0.13	0.14	0.16	0.13	0.18			
	STD	0.06				0.07	0.07		0.06	0.05	0.07	0.04	0.07	0.10			
	Min	0.02	0.04		0.00	0.00	0.02	0.16	0.00	0.03	0.00	0.05	0.00	0.05			
	Max	0.25	0.04		0.00	0.32	0.32	0.16	0.28	0.20	0.25	0.20	0.25	0.54			
	Median	0.20	0.04		0.00	0.15	0.15	0.16	0.11	0.15	0.15	0.15	0.15	0.15			
	Diff. Median	0.00	-0.37		0.00	0.00	-0.08	0.00	0.00	-0.25	0.00	0.00	0.00	0.00			
	P value	0.7455	1.0000			0.0732	0.1529		0.4339	0.1406	0.4279	0.9883	0.5445	0.9103			
SGOT	Evaluated	33	1	1	1	62	25	1	56	22	49	21	46	19			
	Mean	23.03	13.27	23.33	20.48	21.18	25.55	25.33	21.36	22.01	23.39	24.69	19.71	26.07			
	STD	15.69				8.90	20.40		5.87	10.21	16.71	17.78	6.66	28.28			
	Min	11.90	13.27	23.33	20.48	11.82	12.14	25.33	12.86	11.82	10.91	15.71	10.00	13.45			
	Max	102.86	13.27	23.33	20.48	66.00	96.40	25.33	44.00	62.86	129.20	101.43	56.00	142.14			
	Median	20.00	13.27	23.33	20.48	20.00	20.00	25.33	20.36	21.43	20.00	21.43	19.09	20.00			
	Diff. Median	-0.04	-0.29	-0.58	0.19	0.04	-0.04	0.20	0.07	0.02	0.03	0.07	0.02	0.09			
	P value	0.5517	1.0000	1.0000	1.0000	0.5355	0.6876	1.0000	0.0525	0.8014	0.3694	0.5274	0.6667	0.3406			
SGPT	Evaluated	35	1	1	1	62	25	1	56	22	49	21	46	19			
	Mean	24.78	36.25	11.94	22.39	18.69	29.10	15.00	18.80	22.69	22.44	31.20	17.74	30.75			
	STD	21.84				10.01	31.19		7.13	12.16	24.35	41.06	6.67	47.70			
	Min	9.17	36.25	11.94	22.39	5.83	7.50	15.00	5.00	10.00	5.00	17.50	5.00	9.69			
	Max	145.00	36.25	11.94	22.39	69.29	136.03	15.00	36.67	72.50	184.31	210.00	40.71	226.67			
	Median	20.83	36.25	11.94	22.39	18.33	21.67	15.00	20.00	21.67	21.25	21.67	18.12	21.67			

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN9580077
REBOXETINE - PROTOCOL 20124/013

TABLE No. : 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

PLACEBO		VISIT NO.															
		18		22		24		26		30		34		42		52	
		M	F	M	F	F	M	F	M	F	M	F	M	F	M	F	
SGPT	Diff. Median	0.00	0.16	-0.72	0.13	0.09	0.07	-0.20	0.06	0.03	0.10	0.13	0.03	0.00			
	P value	0.5872	1.0000	1.0000	1.0000	0.5911	0.9180	1.0000	0.2008	0.6719	0.1622	0.0670	0.7856	0.7555			
GAMMA-GT	Evaluated	34	1	1	1	61	25	1	56	22	49	21	46	19			
	Mean	41.12	12.57	17.54	12.00	30.89	43.52	19.73	30.54	28.40	29.06	36.50	26.83	46.28			
	STD	56.00				20.08	60.66		14.82	22.27	14.62	65.51	11.74	105.28			
	Min	12.60	12.57	17.54	12.00	10.13	14.13	19.73	2.40	7.11	10.06	13.05	7.31	13.59			
	Max	333.93	12.57	17.54	12.00	129.14	294.98	19.73	83.08	114.58	90.67	321.63	57.23	480.50			
	Median	24.38	12.57	17.54	12.00	26.46	22.33	19.73	27.45	22.33	26.46	22.33	25.23	22.33			
	Diff. Median	-0.20	0.14	-1.50	-0.75	-0.12	-0.14	-0.37	-0.15	-0.15	-0.15	-0.20	-0.22	-0.15			
	P value	0.0011	1.0000	1.0000	1.0000	0.0062	0.0380	1.0000	0.0054	0.0039	0.0035	0.0010	0.0001	0.0074			
	ALK. PHOSPH.	Evaluated	35	1	1	1	62	25	1	56	22	49	21	43	19		
Mean		121.03	104.40	128.98	155.00	94.64	114.30	58.48	93.38	108.82	92.16	108.29	87.83	108.55			
STD		55.99				29.43	49.19		28.61	33.09	25.94	30.31	26.31	47.39			
Min		62.00	104.40	128.98	155.00	38.84	69.60	58.48	43.13	78.21	46.10	73.65	33.37	67.57			
Max		343.45	104.40	128.98	155.00	177.44	273.44	58.48	199.33	232.76	151.48	228.98	151.48	295.20			
Median		101.27	104.40	128.98	155.00	92.97	97.95	58.48	89.07	98.19	89.27	98.90	88.04	97.95			
Diff. Median		-0.17	-0.09	0.38	0.34	-0.13	-0.21	-0.39	-0.18	-0.21	-0.19	-0.23	-0.19	-0.23			
P value		0.0084	1.0000	1.0000	1.0000	0.0000	0.0001	1.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000			
GLOBULIN-S: ALPHA 1	Evaluated	34	1	1	1	60	25	1	54	22	46	21	44	19			
	Mean	0.11	0.16	0.19	0.01	0.11	0.09	0.25	0.10	0.07	0.12	0.07	0.09	0.06			
	STD	0.15				0.13	0.09		0.10	0.06	0.13	0.08	0.09	0.07			
	Min	-0.05	0.16	0.19	0.01	-0.09	-0.05	0.25	-0.08	-0.03	-0.03	-0.02	-0.05	-0.03			
	Max	0.56	0.16	0.19	0.01	0.65	0.36	0.25	0.40	0.19	0.62	0.27	0.35	0.21			
	Median	0.03	0.16	0.19	0.01	0.09	0.09	0.25	0.09	0.07	0.07	0.05	0.06	0.05			
	Diff. Median	-0.20	0.09	0.09	-0.87	-0.13	-0.07	-0.75	-0.05	-0.11	-0.09	-0.07	-0.19	-0.11			
	P value	0.1558	1.0000	1.0000	1.0000	0.0080	0.1083	1.0000	0.1460	0.0331	0.1394	0.1484	0.0369	0.0314			
GLOBULIN-S: ALPHA 2	Evaluated	34	1	1	1	60	25	1	54	22	46	21	44	19			
	Mean	0.77	0.77	0.70	0.75	0.74	0.75	0.76	0.73	0.78	0.78	0.79	0.73	0.80			
	STD	0.18				0.17	0.17		0.19	0.17	0.24	0.13	0.14	0.18			
	Min	0.46	0.77	0.70	0.75	0.36	0.39	0.76	0.30	0.39	0.52	0.46	0.49	0.39			

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CND 950077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

PLACEBO		VISIT NO.															
		18		22		24		26		30		34		42		52	
		M	F	M	F	F	M	F	F	M	F	M	F	M	F	M	
GLOBULIN-S: ALPHA 2	Max	1.19	0.77	0.70	0.75	1.22	1.18	0.76	1.64	1.11	2.09	1.13	1.10	1.22			
	Median	0.74	0.77	0.70	0.75	0.72	0.76	0.76	0.71	0.76	0.75	0.76	0.72	0.80			
	Diff. Median	0.04	-0.13	-0.16	-0.80	-0.17	0.10	0.00	-0.13	0.04	0.00	0.02	-0.07	0.20			
	P value	0.8408	1.0000	1.0000	1.0000	0.2635	0.8247		0.2136	0.9251	0.7698	0.9199	0.2909	0.6155			
	Evaluated	34	1	1	1	60	25	1	54	22	46	21	44	19			
GLOBULIN-S: BETA	Mean	0.89	1.00	0.91	1.24	0.91	0.92	0.77	0.93	0.91	0.86	0.90	0.91	0.84			
	STD	0.23				0.21	0.23		0.23	0.20	0.20	0.23	0.22	0.27			
	Min	0.39	1.00	0.91	1.24	0.15	0.25	0.77	0.45	0.47	0.25	0.23	0.31	0.23			
	Max	1.29	1.00	0.91	1.24	1.42	1.20	0.77	1.62	1.23	1.30	1.30	1.42	1.29			
	Median	0.89	1.00	0.91	1.24	0.89	0.94	0.77	0.91	0.93	0.90	0.97	0.90	0.94			
	Diff. Median	0.16	0.28	-0.65	-0.02	0.02	0.17	-0.33	0.07	-0.02	0.00	0.13	0.05	-0.04			
	P value	0.2728	1.0000	1.0000	1.0000	0.8695	0.4788	1.0000	0.4826	0.9348	0.9527	0.8623	0.8298	0.6095			
	Evaluated	34	1	1	1	60	25	1	54	22	46	21	44	19			
GLOBULIN-S: GAMMA	Mean	1.25	0.63	1.19	1.33	1.12	1.32	1.12	1.14	1.34	1.25	1.36	1.21	1.34			
	STD	0.35				0.38	0.39		0.37	0.30	0.34	0.23	0.42	0.29			
	Min	0.61	0.63	1.19	1.33	0.09	0.64	1.12	0.19	0.77	0.52	0.98	0.32	0.69			
	Max	2.09	0.63	1.19	1.33	2.03	2.53	1.12	1.89	1.90	2.08	1.84	2.03	1.83			
	Median	1.29	0.63	1.19	1.33	1.17	1.28	1.12	1.22	1.34	1.25	1.36	1.29	1.36			
	Diff. Median	0.23	-0.23	-0.06	0.12	0.01	0.36	-0.10	0.04	0.40	0.09	0.40	-0.02	0.50			
	P value	0.0026	1.0000	1.0000	1.0000	0.9906	0.0010	1.0000	0.7171	0.0044	0.1218	0.0003	0.5246	0.0082			
	Evaluated	34	1	1	1	62	25	1	56	22	49	21	44	19			
TOT. CHOLEST.	Mean	205.50	249.29	305.50	235.44	206.89	201.01	167.47	199.37	201.54	197.86	188.71	199.74	190.10			
	STD	49.87				49.58	33.45		36.58	27.79	38.53	24.44	37.90	17.68			
	Min	145.29	249.29	305.50	235.44	147.86	150.39	167.47	146.65	157.09	148.26	154.19	152.00	160.72			
	Max	347.64	249.29	305.50	235.44	417.14	322.36	167.47	301.59	256.97	291.10	264.58	338.43	226.52			
	Median	189.65	249.29	305.50	235.44	192.87	201.57	167.47	190.96	198.39	187.69	187.05	189.65	189.77			
	Diff. Median	-0.10	-0.23	-0.46	-0.02	-0.07	-0.01	-0.27	-0.06	0.05	-0.20	-0.08	-0.12	-0.05			
	P value	0.1754	1.0000	1.0000	1.0000	0.2108	0.8859	1.0000	0.0070	0.6946	0.0069	0.3084	0.0554	0.6224			
	Evaluated	34	1	1	1	62	25	1	55	21	49	20	45	19			
TRIGLYCE- RIDES	Mean	172.67	128.85	326.61	111.20	101.09	167.77	38.00	103.47	172.28	110.19	160.39	90.40	164.77			
	Evaluated	34	1	1	1	62	25	1	55	21	49	20	45	19			

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS 9540077
REBOXETINE - PROTOCOL 20124/013

TABLE No. : 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

PLACEBO		VISIT NO.															
		18		22		24		26		30		34		42		52	
		M	F	M	F	F	M	F	M	F	M	F	M	F	M	F	
TRIGLYCE- RIDES	STD	70.54				46.82	97.73			48.94	80.17	62.90	63.57	39.11	62.11		
	Min	80.67	128.85	326.61	111.20	21.73	99.36	38.00	38.00	107.75	38.00	106.07	-2.67	107.75			
	Max	357.60	128.85	326.61	111.20	216.64	562.33	38.00	336.22	375.67	343.00	339.39	182.12	329.32			
	Median	149.36	128.85	326.61	111.20	88.54	137.96	38.00	89.41	141.32	89.41	139.64	85.06	141.32			
	Diff. Median	-0.09	0.21	-0.65	-0.20	0.04	-0.14	0.07	0.00	-0.06	0.07	-0.13	0.02	-0.11			
	P value	0.0297	1.0000	1.0000	1.0000	0.8084	0.0084	1.0000	0.7295	0.4272	0.3889	0.1108	0.8490	0.1786			
	Evaluated	34	1	1	1	62	25	1	55	22	49	21	46	19			
GLUCOSE	Mean	97.56	92.75	81.24	81.67	94.32	100.22	161.00	93.84	97.55	94.94	104.67	94.73	105.95			
	STD	25.40				14.24	16.94		14.55	9.56	10.65	12.93	10.08	18.96			
	Min	66.82	92.75	81.24	81.67	63.00	71.75	161.00	70.00	85.75	63.82	85.75	70.00	73.50			
	Max	207.67	92.75	81.24	81.67	133.00	147.00	161.00	165.00	126.00	123.67	144.67	116.67	164.50			
	Median	92.46	92.75	81.24	81.67	95.33	99.17	161.00	95.67	95.67	94.50	100.33	94.21	105.00			
	Diff. Median	0.05	-0.05	-0.23	0.00	0.07	0.05	2.25	0.03	0.10	0.05	0.07	0.05	0.07			
	P value	0.5574	1.0000	1.0000		0.2553	0.9688	1.0000	0.3325	0.6715	0.0731	0.7381	0.0400	0.5171			
	Evaluated	34	1	1	1	62	25	1	55	22	49	21	46	19			
NA+	Mean	138.41	142.00	142.67	138.50	138.98	139.16	138.00	139.41	138.59	139.42	138.60	138.81	138.82			
	STD	2.33				2.47	2.70		2.37	1.87	2.26	1.64	2.62	1.77			
	Min	132.67	142.00	142.67	138.50	133.65	134.24	138.00	136.00	134.24	134.50	136.00	134.82	137.18			
	Max	145.00	142.00	142.67	138.50	146.00	147.00	138.00	148.00	142.67	144.18	144.67	147.00	143.33			
	Median	138.35	142.00	142.67	138.50	138.94	138.94	138.00	138.94	138.65	138.94	138.35	138.35	138.35			
	Diff. Median	0.05	0.20	0.27	-0.20	0.05	0.20	0.00	0.07	0.22	0.12	0.18	0.00	0.24			
	P value	0.5199	1.0000	1.0000	1.0000	0.2817	0.0040		0.0082	0.0383	0.0316	0.0002	0.8727	0.0011			
	Evaluated	35	1	1	1	61	25	1	56	22	49	21	46	19			
CL-	Mean	99.17	106.00	97.20		99.81	98.66	101.08	100.34	99.03	100.47	98.85	99.70	98.88			
	STD	2.90				3.86	2.75		3.25	2.96	4.44	2.63	2.89	2.60			
	Min	95.09	106.00	97.20		86.80	92.40	101.08	96.91	96.40	91.60	96.91	95.09	97.27			
	Max	109.20	106.00	97.20		110.80	105.92	101.08	108.40	107.04	114.80	105.36	106.00	106.00			
	Median	98.58	106.00	97.20		98.36	97.64	101.08	98.36	98.18	98.36	98.00	98.36	98.00			
	Diff. Median	-0.09	0.12	-0.40		0.05	-0.05	-0.46	0.06	-0.05	0.00	-0.05	0.00	-0.05			
	P value	0.0994	1.0000	1.0000		0.5261	0.1305	1.0000	0.0319	0.5673	0.1579	0.5088	0.7306	0.3185			
	Evaluated	30	1	1		57	25	1	48	22	46	21	43	19			

(CONTINUED)

P value: probability from Wilcoxon's rank signed test

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS 09077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 94

HEMATOLOGY AND BLOOD CHEMISTRY : MEAN AND MEDIAN VALUES AT EACH VISIT AS COMPARED TO VISIT -1
RANDOMIZED PATIENTS ONLY

PLACEBO		VISIT NO.															
		18		22		24		26		30		34		42		52	
		M	F	M	F	F	M	F	M	F	M	F	M	F	M		
K+	Evaluated	35	1	1	1	61	25	1	56	22	49	21	46	19			
	Mean	4.06	4.40	4.66	4.87	4.19	4.14	4.14	4.23	4.17	4.20	4.17	4.18	4.14			
	STD	0.33				0.33	0.22		0.34	0.22	0.35	0.16	0.31	0.28			
	Min	3.40	4.40	4.66	4.87	3.30	3.60	4.14	3.50	3.70	3.70	3.90	3.60	3.60			
	Max	5.21	4.40	4.66	4.87	5.33	4.62	4.14	5.50	4.80	5.10	4.60	5.20	5.10			
	Median	4.00	4.40	4.66	4.87	4.14	4.14	4.14	4.14	4.14	4.14	4.14	4.10	4.14			
	Diff. Median	0.05	0.06	0.33	0.14	0.00	0.20	-0.20	0.02	0.17	0.00	0.15	0.00	0.15			
	P value	0.0745	1.0000	1.0000	1.0000	0.8948	0.0003	1.0000	0.4159	0.0009	0.7263	0.0001	0.7530	0.0017			
CA++	Evaluated	29		1	1	51	21	1	46	18	40	17	37	15			
	Mean	4.96		5.00	4.00	4.87	4.96	4.88	4.87	4.98	4.91	4.96	4.83	5.00			
	STD	0.29				0.27	0.32		0.25	0.20	0.25	0.12	0.27	0.11			
	Min	4.40		5.00	4.00	4.26	4.06	4.88	4.30	4.40	4.25	4.75	4.34	4.75			
	Max	5.75		5.00	4.00	5.50	5.46	4.88	5.30	5.40	5.70	5.15	5.50	5.20			
	Median	5.00		5.00	4.00	4.90	5.00	4.88	4.90	5.00	4.95	4.95	4.78	5.00			
	Diff. Median	0.00		0.60	-0.75	-0.02	-0.10	0.00	-0.02	-0.15	-0.02	-0.25	-0.10	-0.15			
	P value	0.5332		1.0000	1.0000	0.2484	0.1441		0.2106	0.0550	0.8589	0.0290	0.1032	0.1229			
PO4-	Evaluated	35	1	1	1	61	25	1	55	22	49	21	45	19			
	Mean	1.23	1.21	1.44	0.71	1.23	1.24	0.99	1.30	1.28	1.26	1.28	1.21	1.31			
	STD	0.16				0.21	0.17		0.18	0.12	0.17	0.12	0.23	0.17			
	Min	0.89	1.21	1.44	0.71	0.67	0.87	0.99	0.85	1.00	0.83	1.00	0.70	1.03			
	Max	1.58	1.21	1.44	0.71	1.55	1.50	0.99	1.70	1.47	1.55	1.43	1.73	1.73			
	Median	1.25	1.21	1.44	0.71	1.27	1.30	0.99	1.33	1.29	1.27	1.27	1.23	1.27			
	Diff. Median	0.09	-0.34	0.57	-0.86	0.13	-0.03	-0.04	0.25	0.10	0.13	0.19	0.11	0.13			
	P value	0.5307	1.0000	1.0000	1.0000	0.0267	0.3709	1.0000	0.0000	0.0975	0.0005	0.1361	0.2600	0.2386			

P value: probability from Wilcoxon's rank signed test

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS 98D
REBOXETINE - PROTOCOL 20124/013
TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT - 1

REBOXETINE	VISIT NO.																					
	2			4			6			9			10			16			18			
	L	N	H	L	N	H	L	N	H	L	N	H	L	N	H	L	N	H	L	N	H	
HB	LOH	8	5		6	7																
	NORMAL	8	100	3	4	106	1															
	HIGH																					
HTC	LOH	15	12		11	17																
	NORMAL	7	101	4	6	106	1															
	HIGH																					
RBC	LOH	4	6		3	8																
	NORMAL	6	114	2	6	114	5															
	HIGH	1	3	2	0.704	1	3	2	0.921	1	3	2	0.603									
PLATELETS	LOH																					
	NORMAL	129	2		130	2																
	HIGH																					
MBC	LOH	2	3	1	1	4	1															
	NORMAL	4	125	3	6	124	3															
	HIGH																					
MBC: N	LOH	4	9		5	8	1															
	NORMAL	9	96	4	9	96	4															
	HIGH	1	11	3	0.134	12	2	0.236	11	3	0.699											
MBC: E	LOH	6	15		7	13	1															
	NORMAL																					
	HIGH																					

(CONTINUED)

372

P val: probability from Maxwell's test
L = Low N = Normal H = High

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

REBOXETINE	VISIT NO.																					
	2			4			6			9			10			16			18			
	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H			
WBC: E	NORMAL	8	73	10		6	72	12		6	71	13		1	12	66	4		1	9	57	4
	HIGH	2	14	6	0.275	4	13	6	0.479	1	17	5	0.244		1	3	0.018		1	1	18	2
WBC: B	LOW																					
	NORMAL	123				122	3			121	3			1	115	2			1	100	1	
WBC: L	HIGH	3			0.250	3			1.000	3			1.000	3				1.000	3	2		
	LOW	1	6	1		1	4	2		7				1	5				1	5		
HBC: K	NORMAL	1	94	13		3	96	10		3	99	7		1	1	93	5		1	3	77	3
	HIGH	13	8	0.105		15	6	0.471		3	14	4	0.102		1	15	5	0.022		1	8	7
CREATININE	LOW	14	16	1		15	15	1		13	17	1			13	15	1			8	15	2
	NORMAL	19	66	6		26	59	10		16	72	8		1	20	60	6		1	11	56	3
BUN	HIGH	2	4	3	0.757	1	6	2	0.139	1	7	2	0.960		1	8	1	0.780		1	8	
	LOW	1				1				1					1					1		
URIC ACID	NORMAL	139	1			1	137	2		1	138			1	126	3			1	106	2	
	HIGH	2			0.513	2			0.607	2			0.223		1	2		0.549		1	2	
URIC ACID	LOW																					
	NORMAL	2	132			2	139	1		138	1			1	3	127	1		1	110	1	
URIC ACID	HIGH				0.500				0.223				1.000					0.195				
	LOW	1	5			1	5			6						6				1	4	
URIC ACID	NORMAL	3	121	6		4	121	4		4	117	6			3	114	2			3	95	2

P val: probability from Maxwell's test
L = Low N = Normal H = High

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

REBOXETINE	VISIT NO.																						
	2			4			6			9			10			16			18				
	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H
URIC ACID																							
	8			0.675	6	2	0.774	6	2	0.819	1	1.000	3	3	0.549	1	1.000						
TOT. PROTEINS	7				7								7										
	130	1			132	1		1	130	1		1	117	3		1	1.000						
ALBUMINE	2	1	0.026	2	1	0.026	2	1	0.089	2	1	0.089	2	1	0.095	2	1	0.095					
	1	1			1	2		1	2				1	119	3								
	128	3			2	129	2		2	128	2		1	119	3								
	3	3	0.368	4	3	0.717	5	2	0.526	1	1.000	6	0.783	5		1.000							
TOT BILIRUBIN	2				1			1					2										
	1	122	6		1	122	5		123	4		1	109	8									
	4		0.693	4	1	0.574	4	1	0.607	4	1	0.607	4	0.189	4	0.189							
DIR BILIRUBIN																							
	1	101	9		103	12			100	13		1	94	8									
	7	4	0.535	8	5	0.503	8	3	0.383	8	3	0.383	7	4	1.000								
SGOT																							
	2	125	5		129	3			125	5		1	114	7									
	7	4	0.311	8	3	0.227	8	3	0.561	8	3	0.561	9	1	0.804								
SGPT																							
	2	121	3		118	8			116	8		1	105	11									
	12	5	0.025	13	4	0.383	10	7	0.815	10	7	0.815	7	7	0.481								

(CONTINUED)

P val: probability from Maxwell's test
L = Low N = Normal H = High

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

REBOXETINE	VISIT NO.																						
	2		4		6		9		10		16		18										
	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H	P val							
GAMMA-GT	LOH																						
	NORMAL	104	6			105	7			2	101	8			1	86	14						
	HIGH	15	16	0.078	18	13	0.043	15	13	0.127	1.000	1	15	15	0.362	1.000	16	10					
ALK. PHOSPH.	LOH	5	6		4	6			7	3			6	4			5	3					
	NORMAL	4	113	4	3	115	4	6	112	2	4	105	5	4	105	5	3	89	4				
	HIGH	4	6	0.819	2	9	0.435	4	6	0.435	1.000	3	5	0.779	1.000	33	2	1					
GLOBULINS: ALPHA 1	LOH	32	11		35	10			30	14	1			36	3	1			24	30	4		
	NORMAL	18	63	5	21	54	8	20	54	9	1	23	50	2	1	23	50	2	1	24	30	4	
	HIGH	8	3	0.304	6	8	0.123	6	8	0.409	1.000	6	8	0.001	1.000	6	8	0.001	1.000	6	8	0.001	
GLOBULINS: ALPHA 2	LOH	12	8	1	10	12			9	11	2			7	11	2			6	7	3		
	NORMAL	9	79	10	9	82	9	9	83	8		16	68	7	1	16	68	7		10	60	5	
	HIGH	14	7	0.835	13	7	0.561	10	10	0.693	1	1.000	3	10	5	0.457	1.000	2	11	2			
GLOBULINS: BETA	LOH	8	8	1	6	8	3	5	10	2			5	9	2			4	8	3			
	NORMAL	5	85	9	7	84	9	8	80	12	1	1.000	10	63	17	1	10	63	17	1	10	56	7
	HIGH	14	10	0.385	14	10	0.613	2	17	6	0.585	1.000	3	14	6	0.846	1.000	3	8	7			
GLOBULINS: GAMMA	LOH	12	20		15	16			11	19			6	19	1			2	16	1			
	NORMAL	12	82	5	11	85	6	14	82	7		14	76	4	1	14	76	4		6	71	2	
	HIGH	3	6	0.287	5	4	0.601	7	2	0.685	1.000	5	4	0.588	1.000	5	4	0.588	1.000	5	3		
TOT. CHOLEST.	LOH	4	2		3	2			1	4			6		6			6		6		6	

(CONTINUED)

P val: probability from Maxwell's test
L = Low N = Normal H = High

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

	REBOXETINE																					
	VISIT NO.																					
	2		4		6		9		10		16		18									
TOT. CHOLEST.	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H			
NORMAL	3	118	4		4	114	6		12	104	5		1	11	95	6		5	85	3		
HIGH	5	8	0.856		9	5	0.531		8	6	0.096		1.000	7	5	0.461		1.000	6	5		
LOW																						
TRIGLYCERIDES	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H			
NORMAL	1	112	13		112	13			2	110	12		1	105	9		1	4	81	13		
HIGH	5	10	0.103		8	8	0.383		7	8	0.191		1.000	7	7	0.804		1.000	6	5		
LOW	1	2			1	2			1	2				3					2			
GLUCOSE	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H			
NORMAL	4	101	9		3	104	7		6	97	9		1	3	92	8		1	3	76	8	
HIGH	15	12	0.358		14	13	0.282		14	13	0.214		1.000	16	10	0.264		1.000	15	7		
LOW	8	8			3	13			2	14				1	15				15			
MA+	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H			
NORMAL	7	121			11	116			11	114	1		1	4	111			1	3	93		
HIGH			1.000				0.839				0.507		1.000			0.019		1.000				
CL-	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H			
NORMAL	19	6			17	8			16	12				17	9				16	11		
HIGH	14	77	4		19	74	3		16	75	7		1	19	61	7			17	49	3	
LOW	1		0.062		1		0.065		1		0.079		1.000	1		0.010		1.000				
K+	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H			
NORMAL	3	131	3		2	123	5		1	131	3			2	117	4		1	1	103	3	
HIGH	1		0.368		1		0.097		1		0.160		1.000	1		0.214		1.000			1	
LOW	3	14			5	14			4	15				3	15					2	14	
CA++	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H			
NORMAL	7	77	2		13	74	2		5	82	1			9	72	2				7	67	

(CONTINUED)

P val: probability from Maxwell's test
L = Low N = Normal H = High

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

	VISIT NO.																						
	2			4			6			9			10			16			18				
	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H				
CA++				0.115				0.361								0.174							
PO4-	4	6			3	7			2	8			1	7						3	4		
NORMAL	5	111	9		8	114	4		2	119	4		7	106	7				1		3	95	2
HIGH	4			0.365	4			2	0.967	6			1	1.000							1.000		2

(CONTINUED)

P val: probability from Maxwell's test
L = Low N = Normal H = High

100.00%

9550077

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CIS R&D
REBOXETINE - PROTOCOL 20124-013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

REBOXETINE	VISIT NO.																
	18		20		24		26		30		34		42		52		
	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	
HB	LOW						4	6				4	6			6	3
	NORMAL						4	68	4	1		2	57	5	1	59	3
	HIGH	0.946		1.000		1.000	6	6	0.670		1.000	4	7	0.348	1	3	6
HTC	LOW						4	17				2	13		4	10	
	NORMAL		1		1		7	68	1			5	64		5	61	1
	HIGH	0.082		1.000		1.000	1	1	0.125		1.000	1	1	0.103		1	0.435
RBC	LOW						1	8				1	5		5	1	
	NORMAL		1				3	76	5	1		3	72	2	2	70	3
	HIGH	0.344		1.000		1.000	1	1	0.307		1.000	1	1	0.659	1	1	0.194
PLATELETS	LOW																
	NORMAL		1		1		2	94					84			80	1
	HIGH	1.000		1.000		1.000	1	0.223		1.000	1	1	1.000			1.000	
WBC	LOW						1	3	1				3		3		2
	NORMAL		1		1		86	4				2	75	2	1	72	3
	HIGH	0.596		1.000		1.000	1	2	0.062		1.000	2	1	0.905	2	1	0.549
WBC: N	LOW						4	6	1				5	1		3	1
	NORMAL		1		1		6	61	5	1		4	59	2	2	60	2
	HIGH	0.478		1.000		1.000	5	5	0.925		1.000	8	2	0.237	1	8	2
WBC: E	LOW						2	7	1			1	7	1	2	6	
	HIGH																

(CONTINUED)

P val: probability from Maxwell's test
L = Low N = Normal H = High

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

REBOXETINE	VISIT NO.															
	18		20		24		26		30		34		42		52	
	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H
WBC: E	NORMAL															
	HIGH	0.015	1	1.000	9	50	5	1.000	1	1.000	5	50	4	8	49	1
	LOW															
WBC: B	NORMAL		1													
	HIGH	1.000		1.000			2	1.000		1.000			1	1.000		1
	LOW						4						1			4
WBC: L	NORMAL		1													
	HIGH	0.250		1.000			4	0.882		1.000			1	1.000		1
	LOW						6	16					5	15		2
WBC: N	NORMAL		1													
	HIGH	0.333		1.000			16	43		1			12	34		6
	LOW						1	3					5	3		5
CREATININE	NORMAL		1													
	HIGH	0.607		1.000			91	4		1			1	80		75
	LOW						2	0.435		1.000			2	0.846		2
BUN	NORMAL		1													
	HIGH	1.000		1.000				1.000		1.000			1	1.000		1
	LOW															
URIC ACID	NORMAL		1													
	HIGH						5						1	4		4
	LOW						4	85		1			76	1		4

P val: probability from Maxwell's test
L = Low N = Normal R = High

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

REBOXETINE	VISIT NO.															
	18		20		24		26		30		34		42		52	
	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H
URIC ACID	HIGH	0.667	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000
	LOW															
	NORMAL															
TOT. PROTEINS	HIGH															
	LOW															
	NORMAL															
ALBUMINE	HIGH	0.168	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000
	LOW															
	NORMAL															
TOT BILIRUBIN	HIGH	0.526	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000
	LOW															
	NORMAL															
DIR BILIRUBIN	HIGH	0.931														
	LOW															
	NORMAL															
SGOT	HIGH	1.000														
	LOW															
	NORMAL															
SGPT	HIGH	0.424	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000
	LOW															
	NORMAL															

(CONTINUED)

P val: probability from Maxwell's test
L = Low N = Normal H = High

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

REBOXETINE	VISIT NO.																
	18		20		24		26		30		34		42		52		
	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	
GAMMA-GT	LOW																
	NORMAL		1														
	HIGH	0.382		1.000		1.000		1.000		1.000		1.000		1.000		0.021	14
ALK. PHOSPH.	LOW																
	NORMAL		1														
	HIGH	0.931		1.000		1.000		1.000		1.000		1.000		0.350		3	4
GLOBULINS: ALPHA 1	LOW																
	NORMAL		1														
	HIGH																
GLOBULINS: ALPHA 2	LOW																
	NORMAL		1														
	HIGH	0.000		1.000		1.000		1.000		1.000		1.000		0.003		7	9
GLOBULINS: BETA	LOW																
	NORMAL		1														
	HIGH	0.543		1.000		1.000		1.000		1.000		1.000		0.577		1	7
GLOBULINS: GAMMA	LOW																
	NORMAL		1														
	HIGH	0.914		1.000		1.000		1.000		1.000		1.000		0.265		8	8
TOT. CHOLEST.	LOW																
	NORMAL		1														
	HIGH	0.049		1.000		1.000		1.000		1.000		1.000		0.834		4	4

(CONTINUED)

P val: probability from Maxwell's test
L = Low N = Normal H = High

03
00
11

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

REBOXETINE	VISIT NO.															
	18		20		24		26		30		34		42		52	
	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H
TOT. CHOLEST.		1		1	1	5 78 3		3	1		4 65 3		3 65 1		4 55	
	0.580		1.000		1.000	5 2 0.779		1.000		1.000	5 1 0.779		5 1 0.205		5	
TRIGLYCERIDES																
		1		1	1	2 81 6		6	1		1 68 7		1 69 2		1 62	
	0.037		1.000		1.000	5 4 0.352		4		1.000	5 2 0.513		5 2 0.319		2	
GLUCOSE																
		1		1	1	2 64 13		13	1		60 6		2 59 3		44	
	0.312		1.000		1.000	11 9 0.338		9		1.000	10 9 0.454		10 8 0.056		12	
NA+																
		1		1	1	2 83		83	1		6 65		2 66		3 62	
	0.008		1.000		1.000	0.004		0.004		1.000	0.115		0.004			
CL-																
		1		1	1	15 11		11			10 12		15 6		14 8	
		1		1	1	17 46 1		1	1		15 37 3		22 30 3		20 26	
	0.117		1.000		1.000	0.319		0.319		1.000	0.189		0.002			
K+																
		1		1	1	2		2			2		2		2	
		1		1	1	1 92 3		3			78 2		77 2		1 71	
	0.368		1.000		1.000	0.513		0.513			1 0.311		1 0.311			
CA++																
		1		1	1	1 14		14	1		1 10		2 9		8	
		1		1	1	6 59 1		1			4 57		3 56		4 55	

(CONTINUED)

P val: probability from Maxwell's test
L = Low N = Normal H = High

03
00
20

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

REBOXETINE	VISIT NO.															
	18		20		24		26		30		34		42		52	
	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H
CA++	0.189		1.000		1.000		0.122		1.000		0.180		0.146			
PO4-				2	5			2	5			4	3		3	4
		1		7	75	7		5	70	2		3	67	4	3	60
HIGH	0.931		1.000		1.000		0.211				1	0.846		1	0.407	1

(CONTINUED)

3 8 3

P val: probability from Maxwell's test
L = Low N = Normal H = High

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

REBOXETINE	VISIT NO.	
	52	H P val
HB	LOW	
	NORMAL	3
	HIGH	6 1.000
HTC	LOW	1
	NORMAL	1
	HIGH	0.261
RBC	LOW	1
	NORMAL	3
	HIGH	0.223
PLATELETS	LOW	
	NORMAL	2
	HIGH	0.223
MBC	LOW	
	NORMAL	5
	HIGH	2 0.097
MBC: N	LOW	1
	NORMAL	5
	HIGH	2 0.727
MBC: E	LOW	

(CONTINUED)

P val: probability from Maxwell's test
L = Low N = Normal H = High

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

REBOXETINE	VISIT NO.	
	H	P val
	52	
	2	
MBC: E	NORMAL	
	HIGH	4 0.102
	LOW	
MBC: B	NORMAL	2
	HIGH	1 0.000
	LOW	1
MBC: L	NORMAL	5
	HIGH	3 0.664
	LOW	
MBC: M	NORMAL	7
	HIGH	3 0.061
	LOW	
CREATININE	NORMAL	
	HIGH	0.368
	LOW	
BUN	NORMAL	1
	HIGH	1 0.000
	LOW	
URIC ACID	NORMAL	2

(CONTINUED)

P val: probability from Maxwell's test
L = Low N = Normal H = High

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

REBOXETINE	VISIT NO.	52	
		H	P val
URIC ACID	HIGH		1.000
	LOW		
TOT. PROTEINS	NORMAL	2	
	HIGH	1	0.189
	LOW		
ALBUMINE	NORMAL	4	
	HIGH		0.150
	LOW		
TOT BILIRUBIN	NORMAL		
	HIGH		0.500
	LOW		
DIR BILIRUBIN	NORMAL	3	
	HIGH	1	0.508
	LOW		
SGOT	NORMAL	2	
	HIGH	1	1.000
	LOW		
SGPT	NORMAL	4	
	HIGH	1	0.754

(CONTINUED)

P val: probability from Maxwell's test
L = Low N = Normal H = High

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

REBOXETINE	VISIT NO.	
	H	P val
	52	
	H	P val
GAMMA-GT	LOW	
	NORMAL	5
	HIGH	6 0.072
ALK. PROSPH.	LOW	
	NORMAL	2
	HIGH	2 0.905
GLOBULINS: ALPHA 1	LOW	
	NORMAL	3
	HIGH	0.000
GLOBULINS: ALPHA 2	LOW	1
	NORMAL	5
	HIGH	0.483
GLOBULINS: BETA	LOW	2
	NORMAL	10
	HIGH	4 0.248
GLOBULINS: GAMMA	LOW	
	NORMAL	8
	HIGH	4 0.081
TOT. CHOLEST.	LOW	

(CONTINUED)

P val: Probability from Maxwell's test
L = Low N = Normal H = High

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

REBOXETINE	VISIT NO.	
	52	
	H	P val
TOT. CHOLEST.		
	NORMAL	4
	HIGH	2
		0.946
TRIGLYCERIDES		
	LOW	
	NORMAL	4
	HIGH	4
		0.435
GLUCOSE		
	LOW	
	NORMAL	14
	HIGH	6
		0.845
NA+		
	LOW	
	NORMAL	
	HIGH	0.057
CL-		
	LOW	
	NORMAL	2
	HIGH	0.028
K+		
	LOW	
	NORMAL	3
	HIGH	0.189
CA++		
	LOW	1
	NORMAL	

(CONTINUED)

P val: probability from Maxwell's test
L = Low N = Normal H = High

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

REBOXETINE	VISIT NO.	
	H	P val
	52	
CA++	HIGH	0.311
	LOW	
PO4-	NORMAL	4
	HIGH	0.379

P val: probability from Maxwell's test
L = Low N = Normal H = High

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

PLACERSO	VISIT NO.																				
	2		4		6		10		12		14		16								
	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H	P val	
HB	LOW	13	8			12	9			9	12										
	NORMAL	5	105	1	5	102	2	6	99	3	10	93	2	1							
	HIGH													1							
HTC	LOW	11	8			13	5			11	8			6	13						
	NORMAL	10	109			10	108	1	13	104			16	96	2						
	HIGH	2			2			2			2			0.203							
RBC	LOW	9	9			6	10	1	5	13			5	12	1						
	NORMAL	5	108	1	3	110	2	3	109			3	105	1	1						
	HIGH	5			2			4			3			4			0.025				
PLATELETS	LOW	1			1			1			1										
	NORMAL	123	3			1	124	1	120	5			2	124	1						
	HIGH	1			2			2			2			3			0.160				
HBC	LOW	1	4			4	1			2	3			2	3						
	NORMAL	126	3			124	3			2	122	1		5	117	1					
	HIGH	5			5			5			5			2			0.239				
HBC: N	LOW	7	10			5	11	1	5	11	1		9	7	1						
	NORMAL	4	95	6	7	92	11			5	96	5		2	95	5					
	HIGH	9			1			4			4			4			0.354				
HBC: E	LOW	2	19	5	5	21			5	18	3		6	18	2						
	HIGH																				

(CONTINUED)

390

P val: probability from Maxwell's test
L = Low N = Normal H = High

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

PLACERO	VISIT NO.																												
	2		4		6		10		12		14		16																
	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H	P val									
WBC: E	NORMAL	16	63	7	7	77	7	12	67	9	12	64	7																
	HIGH	8	8	0.356	5	12	0.026	1	11	6	0.383	1	10	7	0.399										1.000				
WBC: B	LOW																												
	NORMAL	123			125	1		120	3					120	2											1			
WBC: L	HIGH	1	1	1.000	4	0.375		4	1.000		3	1.000											1.000						
	LOW	2			2			2			2																		
WBC: M	NORMAL	4	99	7	2	98	14	2	96	13	3	96	8																
	HIGH	9	11	0.652	13	8	0.982	10	10	0.822	11	9	0.714										1.000						
CREATININE	LOW	12	19	2	18	13	2	16	17		14	17	2																
	NORMAL	13	71	10	12	82	4	16	73	6	10	76	5																
BUN	HIGH	1	3	1	0.087	1	3	1	0.790	4	1	0.806	1	4	0.324										1.000				
	LOW	1			1			1			1																		
URIC ACID	NORMAL	132	1		131	4		131	1		130	1																	
	HIGH	2	1	0.513	3	1	0.565	3	1	0.368	2	1	0.368										1.000						
URIC ACID	LOW	1			1			1			1																		
	NORMAL	131	1		1	135	1	1	127	2	1	129	2																
URIC ACID	HIGH	3	0.368		3	0.607		3	0.905		3	0.223											1.000						
	LOW	3	5		1	7		3	5		8																		
URIC ACID	NORMAL	3	118	3	3	119	1	2	115	3	7	105	5																
	HIGH																												

(CONTINUED)

391

P val: probability from Maxwell's test
L = Low N = Normal H = High

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

PLACEBO		VISIT NO.															
		2		4		6		10		12		14		16			
		L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H	P val
URIC ACID	HIGH	5	4	0.607	4	5	0.183	6	3	0.319	5	3	0.967				1.000
TOT. PROTEINS	LOW	2			1	1		1			1						
	NORMAL	1	131	2	134	1		130	3		1	127	2			1	
	HIGH	2	2	0.846	4	0.247	4	0.565	4	0.717							1.000
ALBUMINE	LOW	3			1	3		1	3		1	2	1				
	NORMAL	1	120	5	2	123	4	122	6		1	114	7			1	
	HIGH	5	1	0.607	6	1	0.741	4	2	0.183	5	1	0.475				1.000
TOT BILIRUBIN	LOW	1			1	1		1	1		1	1					
	NORMAL	3	108	7	1	115	4	115	3		1	111	4				1
	HIGH	9	2	0.535	8	3	0.513	1	7	0.304	8	1	0.513				1.000
DIR BILIRUBIN	LOW																
	NORMAL	95	6		1	94	10	1	93	7		91	7				1
	HIGH	14	3	0.115	12	8	0.554	11	10	0.389	16	5	0.093				1.000
SGOT	LOW																
	NORMAL	125	3		123	6		121	4		1	117	5			1	
	HIGH	11	1	0.057	8	4	0.791	10	2	0.180	8	4	0.429				1.000
SGPT	LOW																
	NORMAL	118	4		115	7		111	8		108	8				1	
	HIGH	7	12	0.549	8	11	1.000	12	7	0.503	9	10	1.000				1.000

(CONTINUED)

P val: probability from Maxwell's test
L = Low N = Normal H = High

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

PLACED	VISIT NO.																			
	2		4		6		10		12		14		16							
	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H	P val
GAMMA-GT	LOH	1				1														
	NORMAL	2	85	7	1	88	8	3	82	9	3	77	12							
	HIGH	1	19	20	0.033	20	20	0.076	21	17	0.055	22	18	0.139	1	1.000				1.000
ALK. PHOSPH.	LOH	2				2														
	NORMAL	1	120	2	2	117	6	3	116	3	5	112	3							
	HIGH		5	8	0.319	7	6	0.815	5	7	0.174	6	6	0.050	1	1.000				1.000
GLOBULINS: ALPHA 1	LOH	38	7	2	37	8	2	32	12	2	39	6	2							
	NORMAL	11	63	4	17	59	4	16	55	6	28	43	3	1	1				1	
	HIGH		5	5	0.846	9	4	0.328	7	6	0.896	2	5	4	0.002	1	1.000			1.000
GLOBULINS: ALPHA 2	LOH	5	17		10	11	2	9	13		8	14	1							
	NORMAL	11	80	3	8	84	6	10	81	4	12	71	7	1	1				1	
	HIGH		11	8	0.053	2	10	7	0.484	10	9	0.227	1	16	2	0.173	1	1.000		
GLOBULINS: BETA	LOH	10	8		11	8	1	9	9	1	7	12	1							
	NORMAL	3	87	8	7	87	7	8	81	10	10	70	15							
	HIGH	1	11	7	0.320	1	10	8	0.749	1	10	7	0.974	2	10	5	0.747	1	1.000	
GLOBULINS: GAMMA	LOH	13	15		15	13		12	14		11	9	6							
	NORMAL	11	83	3	12	88	2	15	81	4	20	71	6						1	
	HIGH		8	2	0.236	6	4	0.361	1	7	2	0.490	2	7	0.304	1	1.000			1.000
TOT. CHOLEST.	LOH	4	7		2	9		4	6		3	6								

(CONTINUED)

P val: probability from Maxwell's test
L = Low N = Normal H = High

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

PLACERO	VISIT NO.															
	2		4		6		10		12		14		16			
	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H	P val
TOT. CHOLEST.	NORMAL	4	108	1	1	111	1	4	105	4	4	101	4	1		
	HIGH	6	9	0.111	5	10	0.011	6	9	0.670	2	13	0.587			1.000
TRIGLYCERIDES	LOW	1	1		2	1		2	2		1					
	NORMAL	110	4		106	10		2	103	8	2	102	7	1		
GLUCOSE	HIGH	9	11	0.232	8	14	0.543	1	10	11	0.735	7	15	0.368		1.000
	LOW	3			3			3			3					
NA+	NORMAL	6	101	9	7	98	13	4	98	13	3	94	14	1		
	HIGH	10	10	0.591	11	9	0.413	12	8	0.913	10	10	0.717			1.000
CL-	LOW	3	8		5	6		5	6		3	8				
	NORMAL	9	119	1	10	118	1	7	119		6	116	1	1		
K+	HIGH	1		0.971	1		0.607	1		0.584	1		0.867			1.000
	LOW	13	9		13	10		12	13		12	11				
CA++	NORMAL	15	80	1	21	72	2	16	75	3	24	63	5	1		
	HIGH	2		0.287	1	2	0.120	1		0.673	1		0.007			1.000
K+	LOW	4			4			4			4					
	NORMAL	3	132	1	5	129	2	3	129	1	5	124	1	1		
K+	HIGH	1		0.951	1		0.801	1		0.951	1		0.946			1.000
	LOW	4	10		4	11		1	14		2	13				
K+	NORMAL	5	83		5	87		5	84	2	6	81	2	1		
	HIGH															

P val: probability from Maxwell's test
L = Low N = Normal H = High

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

	VISIT NO.														
	2		4		6		10		12		14		16		
	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H
PLACERO															
CA++				0.302				0.210				0.107			1.000
P04--	3	9	4	9	3	8	1	5	8						
	6	104	7	4	112	5	5	111	3	5	106	5	1	1	1
	4	1	0.492	5	2	0.382	4	2	0.562	6	0.676	1.000			

(CONTINUED)

P val: probability from Maxwell's test
L = Low N = Normal H = High

333

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT - 1

PLACEBO	VISIT NO.																				
	16		18		22		24		26		30		34		42						
	P val	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N	H	P val	L	N		
HB	LOW		9	9																	
	NORMAL		9	73	3																
	HIGH	1.000		3	4	1.000															
HCT	LOW		6	10																	
	NORMAL		14	77	1																
	HIGH	1.000		1	1	0.717															
RBC	LOW		2	12	1																
	NORMAL		3	86																	
	HIGH	1.000		2	4	0.028															
PLATELETS	LOW			1																	
	NORMAL		5	101																	
	HIGH	1.000		1	0.219																
WBC	LOW		1	2																	
	NORMAL		2	92	5																
	HIGH	1.000		6	1	0.956															
WBC: N	LOW		3	8	4																
	NORMAL		2	82																	
	HIGH			5	4	0.011															
WBC: E	LOW		4	16																	

(CONTINUED)

P val: probability from Maxwell's test
L = Low N = Normal H = High

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

	VISIT NO.																				
	16		18		22		24		26		30		34		42						
	P val	L N	H N	P val	L N	H N	P val	L N	H N	P val	L N	H N	P val	L N	H N	P val	L N				
WBC: E	NORMAL	16	45	11						3	44	2			4	44	2	4	35		
	HIGH	1	13	2	0.826	1	0.368			1.000	3	8	3	0.004	1	1.000	8	2	0.013	10	
	LOW																				
WBC: B	NORMAL		102			2					80				1		73			65	
	HIGH		2	1	0.500		1.000			2	0.500					1.000	3	0.250	2		
	LOW		2						1	1						2			2		
WBC: L	NORMAL	1	85	3		2			1	2	63	3				57	6		1	53	
	HIGH	1	9	7	0.146		1.000			1.000	7	6	0.380	1	1.000	1	7	3	0.694	8	
	LOW	14	11	3						9	11	3		1		5	15			4	13
WBC: H	NORMAL	14	56	5		2			1	10	38	8			4	39	9		1	37	
	HIGH		5	0.701			1.000			1.000	3	1	0.091		1.000	3	1	0.009	2		
	LOW		1								1					1			1		
CREATININE	NORMAL	104	1			2			1		83	1				77			68		
	HIGH	1.000	1	2	0.607		1.000			1.000	1	0.607			1.000				1.000		
	LOW																				
BUN	NORMAL	1	107			2			1		85					1	76			1	68
	HIGH	1.000	2	1	0.223		1.000			1.000	1	0.368			1.000	1	0.368			1	
	LOW	1	6								7					7				7	
URIC ACID	NORMAL	4	93	2		2			1		2	72	1			65	1			1	56
	HIGH																				
	LOW																				

(CONTINUED)

P val: probability from Maxwell's test
L = Low N = Normal H = High

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

PLACERO	VISIT NO.															
	16		18		22		24		26		30		34		42	
	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H
URIC ACID	HIGH	1.000	3 2	0.741	1.000		1.000	5	0.066	1.000	3	0.018	4			
	LOW		1			1					1		1			
TOT. PROTEINS	NORMAL		104	2		1	82	1		1	73	2	64			
	HIGH	1.000	3	0.549	1.000	1	1.000	2	0.846	1.000	1	0.846	1			
ALBUMINE	LOW		1	2		1		1			1		1			
	NORMAL		2	95	5	1	1	78	3	1	74	3	65			
TOT BILIRUBIN	HIGH	1.000	3	1	0.779	1.000	3	1.000		1.000		0.135				
	LOW		1			1		1			1		1			
DIR BILIRUBIN	NORMAL		1	93		1		71	3	1	64	1	57			
	HIGH	1.000	8	1	0.018	1.000	8	0.195		1.000	6	0.102	7			
DIR BILIRUBIN	LOW															
	NORMAL		77	3		1		62	1	1	59	1	51			
SGOT	HIGH	1.000	14	2	0.013	1.000	10	4	0.012	1.000	10	0.012	9			
	LOW															
SGOT	NORMAL		95	4		1		78	4	1	69	4	63			
	HIGH	1.000	5	4	1.000	1	1.000	1	4	0.375	1.000	1	4	0.375	1	
SGPT	LOW															
	NORMAL		95	3		1		77	2	1	70	1	63			
SGPT	HIGH	1.000	8	4	0.227	1	1.000	5	3	0.453	1.000	5	2	0.219	5	

(CONTINUED)

33 39 88

P val: probability from Maxwell's test
L = Low N = Normal H = High

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

PLACEBO	VISIT NO.																
	16		18		22		24		26		30		34		42		
	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	
GAMMA-GT	LOW		1														
	NORMAL		66	9			1										
	HIGH	1.000	18	14	0.135	1	1.000										
ALK. PHOSPH.	LOW		1														
	NORMAL		7	92	2		1										
	HIGH	1.000	4	4	0.022		1.000										
GLOBULINS: ALPHA 1	LOW		34	7	1												
	NORMAL		27	25	2		1										
	HIGH	1.000	3	7	0.006		1.000										
GLOBULINS: ALPHA 2	LOW		7	10	2												
	NORMAL		9	56	7												
	HIGH	1.000	2	10	3	0.764		1.000									
GLOBULINS: BETA	LOW		6	11	1												
	NORMAL		7	57	10												
	HIGH	1.000	1	9	4	0.665	1	1.000									
GLOBULINS: GAMMA	LOW		4	13	4												
	NORMAL		8	64	6		1										
	HIGH	1.000	4	3	0.091		1.000										
TOT. CHOLEST.	LOW		1	8													

(CONTINUED)

P val: probability from Maxwell's test
L = Low N = Normal H = High

33
39
9

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

PLACEBO	VISIT NO.																	
	16		18		22		24		26		30		34		42			
	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H		
TOT. CHOLEST.	NORMAL	5	79	4				1	4	63	3			2	59	1	3	50
	HIGH	1.000	7	6	0.470	1	1	1.000	3	5	0.382			1.000	4	3	0.067	4
TRIGLYCERIDES	LOW	1	1						2			1						
	NORMAL		87	4		1			1	69	6				67	3		57
GLUCOSE	HIGH	1.000	7	9	0.403			1.000	4	5	0.693			1.000	3	3	1.000	4
	LOW		2							1					1			1
NA+	NORMAL		2	85	4			1	2	59	10				56	7		45
	HIGH	1.000	10	7	0.276			1.000	10	5	0.811			1.000	10	3	0.465	9
CL-	LOW		1	7						8					8			8
	NORMAL		8	94				1	6	70	1			1	66	2		61
K+	HIGH	1.000	1	0.587				1.000	1	0.867				1.000	1	0.056	1	
	LOW		12	9					12	7					3	13		9
K+	NORMAL		18	52	5	1	1		18	43	1			15	35	4		18
	HIGH		1	1	0.059			1.000		1	0.054			1.000		0.126		
K+	LOW		4							3					2			1
	NORMAL		2	102	2			1	1	81	1			1	75	1		69
CA++	HIGH	1.000	1	0.607				1.000		0.368				1.000		0.223		
	LOW		2	10					2	5					1	3		4
CA++	NORMAL		6	72	2			1	4	61				1	4	56		3
																		49

(CONTINUED)

P val: probability from Maxwell's test
L = Low N = Normal H = High

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT - 1

PLACEBO	VISIT NO.															
	16		18		22		24		26		30		34		42	
	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H	P val	L N H
HIGH	1.000		0.223		1.000		1.000		1.000		1.000		1.000		1.000	
LOW		2 10 1					3 8									2 7
NORMAL		6 56 1		1	2		9 61 2		1				3 57 4		3 53	
HIGH	1.000		0.308		1.000		1.000		1.000		0.879		1.000		0.141	

(CONTINUED)

401

P val: probability from Maxwell's test
L = Low N = Normal H = High

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

PLACEBO	VISIT NO.												
	42					52							
	H	P	val	L	N	H	P	val	L	N	H	P	val
HB	LOW				6	9	1						
	NORMAL	2			5	35	4						
	HIGH	2	0.177		2	2	0.260						
HTC	LOW				4	10							
	NORMAL	1			2	48							
	HIGH		0.587				0.039						
RBC	LOW				1	8							
	NORMAL				3	51							
	HIGH	1	0.232				1	0.227					
PLATELETS	LOW					1							
	NORMAL					63							
	HIGH		1.000				1.000						
MBC	LOW				1	2							
	NORMAL	2			2	52	2						
	HIGH	3	0.905		4	4	1	0.717					
MBC: N	LOW				2	3							
	NORMAL	3			2	51	1						
	HIGH	1	0.751		2	4	0.165						
MBC: E	LOW				3	12							

(CONTINUED)

P val: probability from Maxwell's test
L = Low N = Normal H = High

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOMETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

PLACEBO		VISIT NO.					
		42			52		
		H	P val	L	N	H	P val
HBC: E	NORMAL	3		6	32	3	
	HIGH		0.009		5	3	0.287
	LOW						
HBC: B	NORMAL				62		
	HIGH		0.500		2		0.500
	LOW				2		
HBC: L	NORMAL	3		1	48	5	
	HIGH	1	0.272		5	4	0.846
	LOW	1		4	11	2	
HBC: M	NORMAL	8		2	30	12	
	HIGH	2	0.001		2	2	0.001
	LOW				1		
CREATININE	NORMAL	1			64		
	HIGH		0.368				1.000
	LOW						
BUN	NORMAL				63		
	HIGH		0.368				1.000
	LOW				1	6	
URIC ACID	NORMAL	2		3	51		

(CONTINUED)

P val: probability from Maxwell's test
L = Low N = Normal H = High

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

PLACEBO		VISIT NO.												
		42					52							
		H	P	val	L	N	H	P	val	L	N	H	P	val
URIC ACID	HIGH			0.076					3					0.135
TOT. PROTEINS	LOW									1				
	NORMAL		3							1	62			
	HIGH			0.607										0.607
ALBUMINE	LOW													
	NORMAL		4							2	61			
	HIGH			0.082										1.000
TOT BILIRUBIN	LOW													
	NORMAL		2							2	47			5
	HIGH			0.151										0.717
DIR BILIRUBIN	LOW													
	NORMAL		1								47			2
	HIGH		1	0.021							9			1 0.065
SGOT	LOW													
	NORMAL		3								61			
	HIGH			0.625							2			2 0.500
SGPT	LOW													
	NORMAL		1								59			1
	HIGH		1	0.219							4			1 0.375

(CONTINUED)

P val: probability from Maxwell's test
L = Low N = Normal H = High

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20724/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

PLACERO	VISIT NO.	42						52					
		H		P val		L		N		H		P val	
GAMMA-GT	LOW												
	NORMAL	3		1	46	2							
	HIGH	4	0.013	12	4	0.017							
ALK. PHOSPH.	LOW												
	NORMAL			4	56								
	HIGH	1	0.018	1	1	0.082							
GLOBULINS: ALPHA 1	LOW	1		24	2								
	NORMAL	1		14	19	1							
	HIGH	2	0.037	3	3	0.007							
GLOBULINS: ALPHA 2	LOW			2	12								
	NORMAL	3		3	33	4							
	HIGH		0.009	1	8	0.042							
GLOBULINS: BETA	LOW				9	1							
	NORMAL	2		8	31	6							
	HIGH	2	0.212	1	6	1	0.974						
GLOBULINS: GAMMA	LOW	1		3	9	1							
	NORMAL	4		6	33	5							
	HIGH	2	0.193	2	4	0.250							
TOT. CHOLEST.	LOW				8								

(CONTINUED)

P val: probability from Maxwell's test
L = Low N = Normal H = High

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

PLACEBO	VISIT NO.	42				52			
		H	P	val	L	N	H	P	val
TOT. CHOLEST.	NORMAL	2				49			
	HIGH	3	0.322			3	3	0.004	
TRIGLYCERIDES	LOW								
	NORMAL	6			1	56	3		
GLUCOSE	HIGH	2	0.754		3	1	0.607		
	LOW					1			
NA+	NORMAL	11			43	12			
	HIGH	3	0.905		5	4	0.144		
CL-	LOW					8			
	NORMAL				4	51	1		
K+	HIGH		0.011		1		0.513		
	LOW				5	8			
CA++	NORMAL	5			17	32			
	HIGH		0.002				0.108		
K+	LOW								
	NORMAL					64	1		
CA++	HIGH		1.000				1.000		
	LOW					1	3		
CA++	NORMAL	1			3	45			

(CONTINUED)

P val: probability from Maxwell's test
L = Low N = Normal H = High

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 95

HEMATOLOGY AND BLOOD CHEMISTRY: NUMBER OF SUBJECTS WITH VALUES BELOW, WITHIN OR ABOVE THE NORMAL RANGE AT EACH EVALUATION TIME AS COMPARED TO VISIT -1

PLACEBO	VISIT NO.						
	42			52			
	H	P val	L	N	H	P val	
CA++		0.565				1.000	
PO4--	HIGH			2	5		
	LOW			6	45	3	
	NORMAL	2					
	HIGH	1	0.449	2	1	0.865	

P val: probability from Maxwell's test
L = Low N = Normal H = High

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 96

NUMBER AND PERCENTAGE OF SUBJECTS WITH LABORATORY ABNORMALITIES OF CLINICAL RELEVANCE ACCORDING TO SELECTED CRITERIA
RANDOMIZED PATIENTS ONLY

REBOXETINE	VISIT NO.																							
	-1		2		4		6		9		10		16		18		20		24					
	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z				
HB	2	1.40			2	1.41	1	0.70																
HTC	3	2.11			2	1.41	1	0.70																
RBC	2	1.44	2	1.40	1	0.70	1	0.70							1	0.92								
PLATELETS																								
HBC			1	0.70																				
MBC: N			2	1.40	1	0.73																		
MBC: E																								
MBC: B																								
MBC: L			1	0.70																				
MBC: M																								
CREATININE																								
BUN								1	0.72															
URIC ACID	2	1.39					1	0.71																
TOT. PROTEINS																								
ALBUMINE																								
TOT BILIRUBIN	1	0.74	1	0.74	2	1.48																		
DIR BILIRUBIN	3	2.42			5	3.88	1	0.81							1	1.05								
SGOT	1	0.69	1	0.69	1	0.70																		
SGPT	2	1.39	1	0.69	1	0.70	2	1.42																
GAMMA-GT	7	4.93	5	3.47	4	2.80	4	2.88													6	4.55		
ALK. PHOSPH.			1	0.70	1	0.70	1	0.71														1	0.90	

(CONTINUED) 408

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 96

NUMBER AND PERCENTAGE OF SUBJECTS WITH LABORATORY ABNORMALITIES OF CLINICAL RELEVANCE ACCORDING TO SELECTED CRITERIA
RANDOMIZED PATIENTS ONLY

REBOXETINE	VISIT NO.																							
	-1		2		4		6		9		10		16		18		20		24					
	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z				
GLOBULINS: ALPHA 1	21	14.89	20	13.89	28	19.72	27	19.01			40	31.01			36	33.96								
GLOBULINS: ALPHA 2	10	7.09	4	2.78	2	1.41	7	4.93			6	4.65			5	4.72								
GLOBULINS: BETA			2	1.39	3	2.11					1	0.78			1	0.94								
GLOBULINS: GAMMA	4	2.84	4	2.78	3	2.11	2	1.41			3	2.33			2	1.89								
TOT. CHOLEST.			1	0.69	1	0.70	1	0.71			1	0.77												
TRIGLYCERIDES	7	4.86	8	5.63	6	4.26	6	4.32			9	7.03			7	6.42								
GLUCOSE	5	3.47	2	1.38	4	2.78	3	2.11			5	3.79			3	2.70								
NA+																								
CL-					3	2.38									2	2.06								
K+	1	0.69																						
CA++	2	1.89			1	0.93														1	100.00			
PO4-	3	2.11	6	4.17	5	3.52	2	1.42			6	4.58			5	4.59								
T3																								
T4																								

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
TABLE No.: 96
NUMBER AND PERCENTAGE OF SUBJECTS WITH LABORATORY ABNORMALITIES OF CLINICAL RELEVANCE ACCORDING TO SELECTED CRITERIA
RANDOMIZED PATIENTS ONLY

REBOXETINE	VISIT NO.											
	26		30		34		42		52			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
HB	1	1.02								1	1.32	
HTC	1	1.02								1	1.32	
RBC	1	1.02								1	1.32	
PLATELETS												
WBC												
WBC: N	1	1.08					1	1.27	1	1.33		
WBC: E												
WBC: B												
WBC: L												
WBC: M												
CREATININE												
BUN												
URIC ACID										1	1.33	
TOT. PROTEINS												
ALBUMINE												
TOT BILIRUBIN												
DIR BILIRUBIN	2	2.27										
SGOT							1	1.22				
SGPT	1	1.01										
GAMMA-GT	4	4.08									2	2.67
ALK. PROSPH.	1	1.01										

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 96

NUMBER AND PERCENTAGE OF SUBJECTS WITH LABORATORY ABNORMALITIES OF CLINICAL RELEVANCE ACCORDING TO SELECTED CRITERIA
RANDOMIZED PATIENTS ONLY

	VISIT NO.											
	26		30		34		42		52		52	
	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z
REBOXETINE	24	25.26			19	22.89	21	26.92	18	24.32		
GLOBULINS: ALPHA 1	2	2.11			3	3.61	1	1.28	2	2.70		
GLOBULINS: ALPHA 2					1	1.20	2	2.56	2	2.70		
GLOBULINS: BETA					1	1.20	1	1.28	3	4.05		
GLOBULINS: GAMMA	5	5.26			1	1.20						
TOT. CHOLEST.	1	1.01			1	1.20						
TRIGLYCERIDES	4	4.08			3	3.61	2	2.53	2	2.74		
GLUCOSE	2	2.02			2	2.35	1	1.22	2	2.63		
NA+												
CL-												
K+	1	1.01			1	1.20						
CA++							1	1.43				
PO4-	6	6.12			4	4.71	5	6.10	2	2.67		
T3												
T4												

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REROXYTINE - PROTOCOL 20124/013
 TABLE No.: 96
 NUMBER AND PERCENTAGE OF SUBJECTS WITH LABORATORY ABNORMALITIES OF CLINICAL RELEVANCE ACCORDING TO SELECTED CRITERIA
 RANDOMIZED PATIENTS ONLY

PLACEBO	VISIT NO.																					
	-1		2		4		6		10		12		14		16		18		22			
	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z		
HB	3	2.13	2	1.42	1	0.72	2	1.45	1	0.74							1	0.91				
HTC	2	1.43	1	0.71			1	0.72									1	0.91				
RBC	3	2.16	1	0.71			1	0.73	1	0.75												
PLATELETS																						
HSC																						
HSC: N	1	0.73					1	0.73	1	0.74							1	0.93				
HSC: E							2	1.50														
HSC: B																						
HSC: L										1	0.77											
HSC: M																						
CREATININE																						
BUN																						
URIC ACID	1	0.71	1	0.71	2	1.43	2	1.46	1	0.75												
TOT. PROTEINS																						
ALBUMINE																						
TOT. BILIRUBIN																						
DIR. BILIRUBIN	2	1.64			3	2.38	1	0.81	1	0.83												
SGOT	2	1.42	1	0.71	3	2.13	2	1.46	3	2.22				1	100.00							
SGPT	6	4.26	4	2.84	4	2.84	3	2.17	5	3.70												
GAHHA-ST	15	10.87	5	3.65	5	3.62	4	3.01	6	4.48												
ALK. PHOSPH.	1	0.71	1	0.72	1	0.71	1	0.74														

(CONTINUED) 412

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 96

NUMBER AND PERCENTAGE OF SUBJECTS WITH LABORATORY ABNORMALITIES OF CLINICAL RELEVANCE ACCORDING TO SELECTED CRITERIA
RANDOMIZED PATIENTS ONLY

PLACEBO	VISIT NO.																					
	-1		2		4		6		10		12		14		16		18		22			
	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z		
GLOBULINS: ALPHA 1	23	16.55	22	16.06	25	17.86	23	16.91	42	31.82							44	41.51				
GLOBULINS: ALPHA 2	3	2.16	1	0.73	5	3.57	2	1.47	6	4.55							4	3.77				
GLOBULINS: BETA	6	4.32	5	3.65	3	2.14	5	3.68	7	5.30							1	0.94				
GLOBULINS: GAMMA	1	0.72	2	1.46	3	2.14	2	1.47	4	3.03							1	0.94				
TOT. CHOLEST.	2	1.43			1	0.72											1	0.91				
TRIGLYCERIDES	13	9.42	5	3.60	7	4.96	7	5.11	12	8.96							1	0.92				
GLUCOSE	5	3.57	2	1.43	3	2.13	2	1.45	3	2.24							3	2.73				
NA+																						
CL-					1	0.81	2	1.57														
K+	1	0.71																				
CA++																						
PO4-	2	1.43	6	4.44	3	2.13	4	2.92	5	3.70							2	1.82				
T3																						
T4																						

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 96

NUMBER AND PERCENTAGE OF SUBJECTS WITH LABORATORY ABNORMALITIES OF CLINICAL RELEVANCE ACCORDING TO SELECTED CRITERIA
RANDOMIZED PATIENTS ONLY

PLACERO	VISIT NO.											
	24		26		30		34		42		52	
	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z
HB			1	1.16								
HTC												
RBC												
PLATELETS			1	1.16								
WBC							1	1.28			1	1.54
WBC: N												
WBC: E												
WBC: B												
WBC: L			1	1.20								
WBC: H												
CREATININE												
BUN												
URIC ACID												
TOT. PROTEINS												
ALBUMINE												
TOT BILIRUBIN											1	1.69
DIR BILIRUBIN							1	1.28	2	2.86	1	1.54
SGOT			3	3.45								
SGPT			3	3.45			1	1.28	2	2.86	1	1.54
GAMMA-GT			5	5.81			2	2.56	2	2.86	1	1.54
ALK. PHOSPH.												

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No. : 96

NUMBER AND PERCENTAGE OF SUBJECTS WITH LABORATORY ABNORMALITIES OF CLINICAL RELEVANCE ACCORDING TO SELECTED CRITERIA
RANDOMIZED PATIENTS ONLY

PLACEBO	VISIT NO.											
	24		26		30		34		42		52	
	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z	No.	Z
GLOBULINS: ALPHA 1			24	28.24			15	19.74	15	22.39	16	25.40
GLOBULINS: ALPHA 2			2	2.35			3	3.95	1	1.49	1	1.59
GLOBULINS: BETA			3	3.53			2	2.63	2	2.99	1	1.59
GLOBULINS: GAMMA			3	3.53			2	2.63	1	1.49	1	1.59
TOT. CHOLEST.			1	1.15								
TRIGLYCERIDES			2	2.30			3	3.95	4	5.80		
GLUCOSE			2	2.30	1	100.00	1	1.30	1	1.43	1	1.54
NA+												
CL-			1	1.22					1	1.49		
K+												
CA++			1	100.00								
PO4-			1	100.00	3	3.49			1	1.30	2	2.86
T3												
T4												

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 97a

VITAL SIGN: 5m. LYING SYSTOLIC BLOOD PRESSURE - OPEN PHASE

	VISIT NO.						
	0	1	2	3	4	5	6
MEAN	121.97	120.89	119.72	121.09	121.46	120.96	120.04
STDEV	15.54	14.43	14.12	13.31	13.83	13.76	13.96
MEDIAN	120.00	120.00	120.00	120.00	120.00	120.00	120.00
MIN	80.00	80.00	85.00	85.00	90.00	90.00	80.00
MAX	180.00	180.00	170.00	160.00	160.00	190.00	165.00
N	358	358	354	349	357	328	322
MISS	0	0	0	0	0	0	2

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 97b

VITAL SIGN: 5m. LYING DIASTOLIC BLOOD PRESSURE - OPEN PHASE

	VISIT NO.						
	0	1	2	3	4	5	6
MEAN	78.22	77.91	77.43	78.22	78.68	79.05	77.94
STDEV	10.69	9.83	9.75	9.08	9.61	9.14	9.35
MEDIAN	80.00	80.00	80.00	80.00	80.00	80.00	80.00
MIN	50.00	50.00	54.00	55.00	56.00	58.00	50.00
MAX	110.00	100.00	120.00	100.00	120.00	120.00	115.00
N	358	358	354	349	357	328	322
MISS	0	0	0	0	0	0	2

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 97c

VITAL SIGN: 5m. LYING HEART RATE - OPEN PHASE

	VISIT NO.						
	0	1	2	3	4	5	6
MEAN	78.07	80.09	81.27	81.56	82.02	81.55	82.08
STDEV	11.17	12.02	13.09	12.53	12.64	11.05	12.71
MEDIAN	78.00	78.00	80.00	80.00	80.00	80.00	80.00
MIN	53.00	51.00	50.00	52.00	56.00	56.00	50.00
MAX	116.00	124.00	128.00	120.00	120.00	120.00	120.00
N	354	357	352	346	335	326	319
MISS	4	1	2	3	2	2	5

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 97d

VITAL SIGN: 2m. STANDING SYSTOLIC BLOOD PRESSURE - OPEN PHASE

	VISIT NO.						
	0	1	2	3	4	5	6
MEAN	120.15	118.02	117.32	118.03	119.03	117.97	117.86
STDEV	14.75	15.33	15.25	14.07	14.92	13.64	13.79
MEDIAN	120.00	120.00	120.00	120.00	120.00	120.00	120.00
MIN	80.00	75.00	80.00	85.00	80.00	85.00	80.00
MAX	180.00	180.00	180.00	170.00	180.00	190.00	160.00
N	358	358	354	349	357	328	322
MISS	0	0	0	0	0	0	2

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 97e

VITAL SIGN: 2m. STANDING DIASTOLIC BLOOD PRESSURE - OPEN PHASE

	VISIT NO.						
	0	1	2	3	4	5	6
MEAN	77.94	76.88	76.55	77.80	78.12	77.79	77.69
STDEV	11.11	10.20	10.67	10.48	10.41	9.53	10.43
MEDIAN	80.00	80.00	75.00	80.00	80.00	80.00	80.00
MIN	50.00	45.00	50.00	50.00	50.00	50.00	50.00
MAX	110.00	110.00	110.00	120.00	120.00	130.00	120.00
N	358	358	354	349	337	328	322
MISS	0	0	0	0	0	0	2

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 97f

VITAL SIGN: 2m. STANDING HEART RATE - OPEN PHASE

	VISIT NO.						
	0	1	2	3	4	5	6
MEAN	85.32	88.08	88.77	88.67	89.60	87.95	89.01
STDEV	12.81	14.17	15.11	14.79	13.80	12.43	14.09
MEDIAN	84.00	86.00	86.00	86.00	88.00	86.00	86.00
MIN	53.00	52.00	58.00	60.00	52.00	60.00	54.00
MAX	136.00	140.00	140.00	140.00	128.00	132.00	140.00
N	354	355	351	346	335	326	319
MISS	4	3	3	3	2	2	5

PHARMACIA C950077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 98

VITAL SIGN CHANGES FROM VISIT -1 DURING THE OPEN PHASE

REBOXETINE		VISIT NO.					
		1	2	3	4	5	6
LYING S.B.P.	NO.	354	354	349	337	328	322
	MEAN	-0.986	-2.034	-0.702	-0.237	-0.720	-1.705
	MEDIAN	0.000	0.000	0.000	0.000	0.000	0.000
	MIN	-40.00	-40.00	-60.00	-50.00	-50.00	-50.00
	MAX	55.000	60.000	50.000	50.000	50.000	45.000
LYING D.B.P.	NO.	354	354	349	337	328	322
	MEAN	-0.220	-0.689	0.043	0.534	1.034	-0.071
	MEDIAN	0.000	0.000	0.000	0.000	0.000	0.000
	MIN	-30.00	-25.00	-35.00	-40.00	-35.00	-30.00
	MAX	30.000	60.000	30.000	40.000	40.000	30.000
LYING H.R.	NO.	353	352	346	335	326	319
	MEAN	0.697	1.844	2.202	2.687	2.328	2.781
	MEDIAN	0.000	0.000	0.000	2.000	1.000	2.000
	MIN	-28.00	-48.00	-32.00	-40.00	-32.00	-32.00
	MAX	44.000	48.000	52.000	48.000	34.000	50.000
STANDING S.B.P.	NO.	354	354	349	337	328	322
	MEAN	-2.169	-2.701	-2.069	-1.009	-1.933	-2.006
	MEDIAN	0.000	0.000	0.000	0.000	0.000	0.000
	MIN	-50.00	-40.00	-40.00	-40.00	-40.00	-35.00
	MAX	55.000	50.000	45.000	45.000	50.000	46.000
STANDING D.B.P.	NO.	354	354	349	337	328	322
	MEAN	-1.017	-1.328	-0.120	0.341	0.159	0.087
	MEDIAN	0.000	0.000	0.000	0.000	0.000	0.000
	MIN	-28.00	-48.00	-32.00	-40.00	-32.00	-32.00
	MAX	34.000	50.000	50.000	40.000	40.000	30.000
STANDING H.R.	NO.	351	351	346	335	326	319
	MEAN	2.322	2.858	2.890	3.851	2.380	3.320
	MEDIAN	-1.000	0.000	0.000	2.000	0.000	1.000
	MIN	-45.00	-48.00	-38.00	-28.00	-30.00	-38.00
	MAX	54.000	56.000	54.000	54.000	40.000	52.000

PHARMACIA CN550077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 99

NUMBER AND PERCENTAGE OF SUBJECTS WITH BLOOD PRESSURE AND HEART RATE CHANGES OF CLINICAL RELEVANCE (*) AS COMPARED TO VISIT -1, OPEN PHASE

REBOXETINE			VISIT NO.					
			1	2	3	4	5	6
LYING S.B.P	INCREASE	Evaluated	354	354	349	337	328	322
		No.	17	12	20	23	15	18
		%	4.8	3.4	5.7	6.8	4.6	5.6
	DECREASE	Evaluated	354	354	349	337	328	322
		No.	11	12	11	10	10	15
		%	3.1	3.4	3.2	3.0	3.0	4.7
LYING D.B.P.	INCREASE	Evaluated	354	354	349	337	328	322
		No.	26	23	26	33	31	32
		%	7.3	6.5	7.4	9.8	9.5	9.9
	DECREASE	Evaluated	354	354	349	337	328	322
		No.	14	10	13	11	12	13
		%	4.0	2.8	3.7	3.3	3.7	4.0
LYING H.R.	INCREASE	Evaluated	353	352	346	335	326	319
		No.	46	52	65	62	52	66
		%	13.0	14.8	18.8	18.5	16.0	20.7
	DECREASE	Evaluated	353	352	346	335	326	319
		No.	18	16	23	16	15	19
		%	5.1	4.5	6.6	4.8	4.6	6.0
STANDING S.B.P	INCREASE	Evaluated	354	354	349	337	328	322
		No.	14	13	12	14	12	12
		%	4.0	3.7	3.4	4.2	3.7	3.7
	DECREASE	Evaluated	354	354	349	337	328	322
		No.	12	16	9	10	12	13
		%	3.4	4.5	2.6	3.0	3.7	4.0
STANDING D.B.P.	INCREASE	Evaluated	354	354	349	337	328	322
		No.	15	19	19	33	24	30
		%	4.2	5.4	5.4	9.8	7.3	9.3
	DECREASE	Evaluated	354	354	349	337	328	322
		No.	18	18	22	15	15	14
		%	5.1	5.1	6.3	4.5	4.6	4.3
STANDING H.R.	INCREASE	Evaluated	351	351	346	335	326	319
		No.	62	63	65	67	66	67
		%	17.7	17.9	18.8	20.0	20.2	21.0
	DECREASE	Evaluated	351	351	346	335	326	319
		No.	16	20	20	17	11	19
		%	4.6	5.7	5.8	5.1	3.4	6.0

* Increase or Decrease in SBP or DBP or HR => 20% as compared to visit -1

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C1950077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 100

NUMBER AND PERCENTAGE OF SUBJECTS WITH VITAL SIGNS CHANGES OF CLINICAL RELEVANCE (=> 20 %) AS COMPARED TO VISIT -1, OPEN PHASE, ASSOCIATED TO CRITICAL VALUES (*)

REBOXETINE			VISIT NO.					
			1	2	3	4	5	6
LYING S.B.P.	INCREASE	Evaluated	354	354	349	337	328	322
		No.	4	2	2	4	4	3
		%	1.1	0.6	0.6	1.2	1.2	0.9
	DECREASE	Evaluated	354	354	349	337	328	322
		No.	5	8	6	5	5	10
		%	1.4	2.3	1.7	1.5	1.5	3.1
LYING D.B.P.	INCREASE	Evaluated	354	354	349	337	328	322
		No.	3	5	2	7	6	4
		%	0.8	1.4	0.6	2.1	1.8	1.2
	DECREASE	Evaluated	354	354	349	337	328	322
		No.	11	10	12	10	11	13
		%	3.1	2.8	3.4	3.0	3.4	4.0
LYING H.R.	INCREASE	Evaluated	353	352	346	335	326	319
		No.	19	23	27	25	20	26
		%	5.4	6.5	7.8	7.5	6.1	8.2
	DECREASE	Evaluated	353	352	346	335	326	319
		No.	0	1	0	0	0	1
		%	0.0	0.3	0.0	0.0	0.0	0.3
STANDING S.B.P.	INCREASE	Evaluated	354	354	349	337	328	322
		No.	3	1	0	1	1	2
		%	0.8	0.3	0.0	0.3	0.3	0.6
	DECREASE	Evaluated	354	354	349	337	328	322
		No.	9	13	8	6	6	10
		%	2.5	3.7	2.3	1.8	1.8	3.1
STANDING D.B.P.	INCREASE	Evaluated	354	354	349	337	328	322
		No.	1	4	3	8	3	6
		%	0.3	1.1	0.9	2.4	0.9	1.9
	DECREASE	Evaluated	354	354	349	337	328	322
		No.	16	16	20	14	14	13
		%	4.5	4.5	5.7	4.2	4.3	4.0
STANDING H.R.	INCREASE	Evaluated	351	351	346	335	326	319
		No.	37	39	44	39	31	36
		%	10.5	11.1	12.7	11.6	9.5	11.3
	DECREASE	Evaluated	351	351	346	335	326	319
		No.	0	0	0	0	0	0
		%	0.0	0.0	0.0	0.0	0.0	0.0

(CONTINUED)

* S.B.P. values => 160 mm Hg or <= 100 mm Hg
D.B.P. values => 100 mm Hg or <= 70 mm Hg
H.R. values => 100 beats/min or <= 50 beats/min

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CN 35077
 REBOXETINE - PROTOCOL 20124/013

TABLE No.: 100

NUMBER AND PERCENTAGE OF SUBJECTS WITH VITAL SIGNS CHANGES OF CLINICAL RELEVANCE (=> 20 %) AS COMPARED TO VISIT -1, OPEN PHASE, ASSOCIATED TO CRITICAL VALUES (*)

REBOXETINE			VISIT NO.					
			1	2	3	4	5	6
STANDING H.R.	DECREASE	%	0.0	0.0	0.0	0.0	0.0	0.0

* S.B.P. values => 160 mm Hg or <= 100 mm Hg
 D.B.P. values => 100 mm Hg or <= 70 mm Hg
 H.R. values => 100 beats/min or <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 101

NUMBER AND PERCENTAGE OF SUBJECTS WITH ORTHOSTATIC HYPOTENSION (*) DURING THE OPEN PHASE

	VISIT NO.							
	-1	0	1	2	3	4	5	6
EVALUATED	358	358	358	354	349	337	328	322
No.	2	5	5	6	7	2	4	2
%	0.6	1.4	1.4	1.7	2.0	0.6	1.2	0.6
MEAN	27.5	29.0	28.0	34.2	27.4	25.0	28.8	35.0
MAX	30	30	30	50	30	25	30	40

426

(*) ORTHOSTATIC HYPOTENSION: decrease of systolic blood pressure in Standing position > 20 mmHg as compared to Lying position

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
TABLE No.: 102a

VITAL SIGN: 5m. LYING SYSTOLIC BLOOD PRESSURE - RANDOMIZED PATIENTS ONLY

REBOXETINE	VISIT NO.																															
	0	1	2	3	4	5	6	8	9	10	12	14	16	18	20	22	24	26	28	30	32											
MEAN	122.39	120.09	119.62	121.92	122.54	120.26	121.18	121.26	132.00	120.26	121.46	120.52	120.29	120.11	119.73	122.33	120.35	120.74	119.79	121.39	119.57											
STDEV	15.92	14.54	15.17	13.43	14.14	13.48	14.59	14.31		13.58	13.64	11.79	14.01	13.20	13.97	15.55	14.71	14.18	13.71	13.64	13.64											
MEDIAN	120.00	120.00	120.00	120.00	120.00	120.00	120.00	120.00	132.00	120.00	120.00	120.00	120.00	120.00	120.00	120.00	120.00	120.00	120.00	120.00	120.00											
MIN	90.00	90.00	90.00	90.00	95.00	90.00	85.00	90.00	90.00	90.00	90.00	90.00	85.00	85.00	95.00	90.00	90.00	90.00	90.00	90.00	90.00											
MAX	180.00	160.00	170.00	160.00	160.00	165.00	170.00	170.00	132.00	160.00	170.00	150.00	170.00	160.00	160.00	180.00	160.00	160.00	150.00	160.00	160.00											
N	143	143	143	143	143	143	143	143	1	137	127	124	122	113	109	105	102	101	97	90	88											
MISS	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0											

(CONTINUED)

	VISIT NO.										
	34	36	38	40	42	44	46	48	50	52	
MEAN	119.24	119.92	120.28	119.76	120.00	120.40	120.43	119.69	121.44	119.43	
STDEV	16.04	13.70	14.09	13.03	15.36	13.00	13.09	13.60	11.89	11.55	
MEDIAN	120.00	120.00	120.00	120.00	120.00	120.00	120.00	120.00	120.00	120.00	
MIN	90.00	90.00	90.00	90.00	90.00	90.00	85.00	85.00	90.00	100.00	
MAX	170.00	155.00	165.00	160.00	190.00	160.00	160.00	160.00	150.00	150.00	
N	86	84	83	82	82	82	81	80	80	79	
MISS	1	0	0	0	0	0	0	1	0	0	

427

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CIS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 102a

VITAL SIGN: 5m. LYING SYSTOLIC BLOOD PRESSURE - RANDOMIZED PATIENTS ONLY

PLACEBO	VISIT NO.																																	
	0	1	2	3	4	5	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34													
MEAN	121.09	121.14	119.08	119.55	120.42	121.03	118.56	121.19	121.76	120.82	119.84	120.37	118.33	118.73	120.25	121.37	120.71	119.43	120.22	120.31	119.62													
STDEV	15.48	13.93	13.73	13.67	14.04	14.98	14.22	14.39	15.97	15.44	15.53	15.89	14.76	13.16	13.81	12.17	12.64	14.53	13.94	14.44	12.47													
MEDIAN	120.00	120.00	120.00	120.00	120.00	120.00	120.00	120.00	120.00	120.00	120.00	120.00	120.00	120.00	120.00	120.00	120.00	120.00	120.00	120.00	120.00													
MIN	80.00	80.00	85.00	85.00	90.00	90.00	80.00	90.00	85.00	85.00	90.00	85.00	85.00	85.00	85.00	90.00	90.00	80.00	80.00	80.00	85.00													
MAX	160.00	160.00	150.00	160.00	160.00	190.00	160.00	170.00	170.00	180.00	170.00	185.00	160.00	150.00	160.00	160.00	160.00	160.00	160.00	160.00	140.00													
N	140	140	140	140	140	140	140	140	136	132	125	122	114	106	100	95	91	88	83	80	79													
MISS	0	0	0	0	0	0	0	0	0	1	0	1	3	2	1	0	0	0	0	0	0													

(CONTINUED)

	VISIT NO.										
	36	38	40	42	44	46	48	50	52		
MEAN	118.78	120.26	120.74	120.21	121.36	120.50	121.67	122.12	119.69		
STDEV	13.70	14.65	11.84	12.62	13.72	11.59	13.05	13.07	12.50		
MEDIAN	120.00	120.00	120.00	120.00	120.00	120.00	120.00	120.00	120.00		
MIN	85.00	90.00	100.00	90.00	90.00	90.00	90.00	90.00	90.00		
MAX	150.00	165.00	150.00	150.00	160.00	150.00	150.00	160.00	160.00		
N	78	76	74	73	70	68	66	66	65		
MISS	0	0	0	0	0	1	0	0	0		

428

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 102b

VITAL SIGN: 5m. LYING DIASTOLIC BLOOD PRESSURE - RANDOMIZED PATIENTS ONLY

REBOXETINE	VISIT NO.																															
	0	1	2	3	4	5	6	8	9	10	12	14	16	18	20	22	24	26	28	30	32											
MEAN	78.36	77.23	78.45	78.63	79.67	78.87	79.45	79.70	74.00	78.83	79.76	78.94	79.78	78.36	79.17	81.24	78.92	78.42	77.68	78.78	79.09											
STDEV	11.21	10.44	10.38	9.63	10.19	9.12	9.67	9.64		9.30	10.00	9.48	11.02	10.57	11.21	12.26	11.05	10.49	9.92	10.47	9.61											
MEDIAN	80.00	80.00	80.00	80.00	80.00	80.00	80.00	80.00	74.00	80.00	80.00	80.00	80.00	80.00	80.00	80.00	80.00	80.00	80.00	80.00	80.00											
MIN	50.00	50.00	55.00	55.00	58.00	58.00	56.00	60.00	74.00	58.00	60.00	55.00	55.00	50.00	60.00	55.00	50.00	50.00	55.00	55.00	55.00											
MAX	110.00	100.00	120.00	100.00	110.00	115.00	115.00	143	143	143	137	127	124	122	113	109	105	102	101	97	90											
N	143	143	143	143	143	143	143	143	1	137	127	124	122	113	109	105	102	101	97	90	88											
MISS	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0											

(CONTINUED)

	VISIT NO.										
	34	36	38	40	42	44	46	48	50	52	
MEAN	78.95	79.26	78.80	77.93	78.66	78.60	77.53	79.19	78.75	79.05	
STDEV	10.12	10.57	9.52	9.29	9.53	9.10	8.95	9.92	9.63	9.17	
MEDIAN	80.00	80.00	80.00	80.00	80.00	80.00	80.00	80.00	80.00	80.00	
MIN	60.00	60.00	60.00	60.00	60.00	60.00	55.00	55.00	60.00	60.00	
MAX	110.00	110.00	105.00	100.00	105.00	105.00	105.00	110.00	110.00	100.00	
N	86	84	83	82	82	82	81	80	80	79	
MISS	1	0	0	0	0	0	0	1	0	0	

5
2
7

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD
REBOXETINE - PROTOCOL 20124/013
TABLE No.: 102b

VITAL SIGN: 5p. LYING DIASTOLIC BLOOD PRESSURE - RANDOMIZED PATIENTS ONLY

PLACEBO	VISIT NO.																				
	0	1	2	3	4	5	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34
MEAN	77.91	78.15	75.80	77.30	77.41	78.93	76.29	78.41	78.46	77.01	75.72	76.84	76.05	75.98	77.85	76.68	76.59	75.00	76.20	75.56	76.58
STDEV	9.80	9.78	9.76	8.94	9.62	9.76	9.52	10.37	10.45	10.93	10.62	9.84	10.27	10.20	9.46	8.83	9.00	9.38	8.82	9.55	8.61
MEDIAN	80.00	80.00	80.00	80.00	80.00	80.00	80.00	80.00	80.00	80.00	80.00	80.00	75.00	77.50	80.00	80.00	80.00	75.00	80.00	75.00	80.00
MIN	50.00	55.00	54.00	55.00	60.00	60.00	50.00	60.00	55.00	50.00	40.00	55.00	40.00	44.00	55.00	60.00	60.00	50.00	60.00	55.00	55.00
MAX	100.00	100.00	100.00	100.00	120.00	120.00	100.00	110.00	100.00	110.00	100.00	105.00	110.00	100.00	100.00	105.00	100.00	100.00	100.00	100.00	100.00
N	140	140	140	140	140	140	140	140	136	132	125	122	114	106	100	95	91	88	83	80	79
MISS	0	0	0	0	0	0	0	0	0	1	0	1	3	2	1	0	0	0	0	0	0

(CONTINUED)

	VISIT NO.											
	36	38	40	42	44	46	48	50	52	54	56	58
MEAN	75.38	75.39	76.49	76.25	75.90	77.00	76.82	76.97	76.31	76.31	76.31	76.31
STDEV	8.63	9.23	7.97	8.19	8.21	7.68	9.06	7.69	8.54	8.54	8.54	8.54
MEDIAN	80.00	77.50	80.00	80.00	75.00	78.00	75.00	80.00	75.00	80.00	75.00	80.00
MIN	55.00	50.00	60.00	60.00	55.00	60.00	60.00	60.00	60.00	60.00	60.00	60.00
MAX	95.00	110.00	95.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	105.00
N	78	76	74	73	70	68	66	66	66	65	65	65
MISS	0	0	0	0	0	1	0	0	0	0	0	0

430

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
TABLE No.: 102c

VITAL SIGN: 5m. LYING HEART RATE - RANDOMIZED PATIENTS ONLY

REBOXETINE	VISIT NO.																															
	0	1	2	3	4	5	6	8	9	10	12	14	16	18	20	22	24	26	28	30	32											
MEAN	77.77	79.62	80.92	81.35	82.00	81.69	82.03	81.29	90.00	82.07	82.05	82.56	82.73	82.43	82.69	82.09	83.51	81.73	81.78	82.52	82.88											
STDEV	10.63	12.51	13.43	13.48	11.67	10.78	11.98	12.07		13.15	13.15	13.30	12.55	14.54	13.58	13.00	13.04	13.62	11.80	13.14	12.87											
MEDIAN	76.00	76.00	80.00	80.00	80.00	80.00	80.00	80.00	90.00	80.00	80.00	80.00	80.00	80.00	80.00	79.00	80.00	80.00	80.00	80.00	80.00											
MIN	54.00	60.00	55.00	60.00	62.00	62.00	54.00	56.00	90.00	56.00	54.00	56.00	54.00	54.00	54.00	56.00	60.00	60.00	60.00	60.00	58.00											
MAX	102.00	124.00	128.00	120.00	112.00	120.00	120.00	120.00	90.00	120.00	120.00	120.00	134.00	120.00	120.00	120.00	120.00	120.00	120.00	120.00	120.00											
N	141	143	142	141	143	143	142	143	1	137	127	124	122	113	109	104	102	101	96	89	88											
MISS	2	0	1	0	0	0	1	0	0	0	1	0	0	1	0	1	0	0	1	0	1											

(CONTINUED)

	VISIT NO.											
	34	36	38	40	42	44	46	48	50	52		
MEAN	82.19	83.39	82.17	81.21	80.34	82.01	81.32	80.89	81.35	81.06		
STDEV	13.32	13.62	12.07	11.19	10.76	13.44	11.59	10.81	10.73	10.14		
MEDIAN	80.00	80.00	82.00	80.00	80.00	78.00	80.00	80.00	80.00	80.00		
MIN	58.00	60.00	60.00	58.00	58.00	60.00	60.00	58.00	62.00	58.00		
MAX	120.00	120.00	114.00	114.00	104.00	116.00	116.00	116.00	112.00	104.00		
N	86	83	83	82	82	82	81	79	80	79		
MISS	1	1	0	0	0	0	0	2	0	0		

431

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOMETINE - PROTOCOL 20124/013

TABLE No.: 102c

VITAL SIGN: 5m. LYING HEART RATE - RANDOMIZED PATIENTS ONLY

PLACERO	VISIT NO.																				
	0	1	2	3	4	5	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34
MEAN	78.18	80.65	82.28	82.71	83.43	82.69	83.59	78.41	78.86	78.65	78.67	78.31	77.40	78.12	78.87	77.96	75.83	75.94	75.40	75.60	74.45
STDEV	11.88	12.33	14.07	12.55	13.99	11.74	13.91	11.21	12.28	12.66	12.29	11.58	14.14	12.41	11.73	12.42	12.15	11.63	11.21	11.09	12.21
MEDIAN	78.00	80.00	80.00	80.00	80.00	80.00	80.00	78.00	78.00	78.00	77.00	76.00	76.00	76.00	78.00	76.00	75.00	74.00	74.00	74.50	72.00
MIN	53.00	51.00	50.00	60.00	52.00	56.00	48.00	48.00	48.00	48.00	52.00	50.00	48.00	49.00	52.00	52.00	54.00	51.00	54.00	54.00	54.00
MAX	116.00	120.00	124.00	120.00	120.00	120.00	120.00	116.00	116.00	116.00	124.00	120.00	136.00	132.00	120.00	120.00	112.00	112.00	120.00	128.00	120.00
N	139	139	140	140	138	139	138	138	134	130	124	121	114	106	99	94	90	87	82	80	78
MISS	1	1	0	0	2	1	2	2	2	3	1	2	3	2	2	1	1	1	1	0	1

(CONTINUED)

	VISIT NO.										
	36	38	40	42	44	46	48	50	52		
MEAN	75.99	77.14	75.76	75.37	75.99	75.65	75.88	76.65	74.80		
STDEV	10.60	11.80	10.87	12.54	13.24	11.84	11.70	10.63	13.10		
MEDIAN	76.00	75.50	75.50	72.00	72.00	76.00	73.00	76.00	74.00		
MIN	60.00	54.00	54.00	52.00	54.00	58.00	54.00	58.00	54.00		
MAX	116.00	120.00	112.00	114.00	120.00	128.00	124.00	120.00	124.00		
N	77	74	74	73	70	68	66	66	65		
MISS	1	2	0	0	0	1	0	0	0		

432

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 102d

VITAL SIGN: 2b. STANDING SYSTOLIC BLOOD PRESSURE - RANDOMIZED PATIENTS ONLY

REBOXETINE	VISIT NO.																															
	0	1	2	3	4	5	6	8	9	10	12	14	16	18	20	22	24	26	28	30	32											
MEAN	120.30	118.01	117.97	118.27	119.71	118.08	118.31	118.64	126.00	118.64	118.58	118.15	118.55	118.41	116.83	118.88	117.88	118.69	116.65	118.87	117.78											
STDEV	15.16	15.25	14.86	13.33	14.48	13.72	14.09	14.90	13.99	15.80	13.29	14.88	14.07	14.22	15.60	14.01	14.70	14.22	14.37	13.66	12.93											
MEDIAN	120.00	115.00	120.00	120.00	120.00	120.00	115.00	126.00	120.00	120.00	120.00	117.50	120.00	115.00	115.00	120.00	115.00	115.00	115.00	115.00	115.00											
MIN	90.00	80.00	85.00	90.00	90.00	85.00	90.00	90.00	126.00	90.00	85.00	90.00	90.00	90.00	90.00	90.00	80.00	90.00	90.00	95.00	95.00											
MAX	180.00	170.00	160.00	150.00	165.00	160.00	160.00	165.00	126.00	160.00	170.00	160.00	170.00	165.00	160.00	160.00	164.00	160.00	150.00	160.00	150.00											
N	143	143	143	143	143	143	143	143	1	137	127	124	122	113	109	105	102	101	97	90	88											
MISS	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0											

(CONTINUED)

	VISIT NO.										
	34	36	38	40	42	44	46	48	50	52	
MEAN	118.02	117.42	116.33	116.83	116.04	117.62	117.19	117.94	117.56	116.57	
STDEV	15.44	13.14	13.16	12.68	13.72	12.80	12.92	14.07	13.29	13.56	
MEDIAN	117.50	115.00	115.00	115.00	115.00	115.00	120.00	120.00	120.00	115.00	
MIN	90.00	90.00	80.00	90.00	90.00	90.00	90.00	90.00	90.00	90.00	
MAX	180.00	150.00	145.00	150.00	170.00	150.00	160.00	170.00	155.00	160.00	
N	86	84	83	82	82	82	81	80	80	79	
MISS	1	0	0	0	0	0	0	1	0	0	

433

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 102d

VITAL SIGN: 2m. STANDING SYSTOLIC BLOOD PRESSURE - RANDOMIZED PATIENTS ONLY

PLACEBO	VISIT NO.																																	
	0	1	2	3	4	5	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34													
MEAN	120.28	118.06	116.84	117.31	118.64	117.99	117.74	120.19	119.49	118.67	117.72	119.69	115.00	117.41	118.85	116.89	117.47	117.90	116.51	116.63	116.71													
STDEV	14.84	15.26	16.05	15.13	15.06	14.39	14.40	15.52	16.26	16.38	16.91	16.75	14.45	14.56	14.75	12.53	12.92	14.83	14.67	12.16	13.42													
MEDIAN	120.00	120.00	120.00	120.00	120.00	120.00	120.00	120.00	120.00	120.00	115.00	120.00	110.00	115.00	120.00	115.00	115.00	115.00	115.00	115.00	115.00													
MIN	80.00	75.00	80.00	85.00	80.00	90.00	80.00	85.00	80.00	85.00	85.00	80.00	85.00	90.00	90.00	90.00	90.00	80.00	80.00	80.00	80.00													
MAX	150.00	165.00	180.00	160.00	160.00	190.00	156.00	177.00	168.00	180.00	175.00	200.00	160.00	150.00	160.00	160.00	160.00	190.00	180.00	140.00	160.00													
N	140	140	140	140	140	140	140	140	136	132	125	122	114	106	100	95	91	88	83	80	79													
MISS	0	0	0	0	0	0	0	0	0	1	0	1	3	2	1	0	0	0	0	0	0													

(CONTINUED)

	VISIT NO.										
	36	38	40	42	44	46	48	50	52		
MEAN	115.91	118.74	118.80	117.53	118.00	116.59	116.59	117.52	116.05		
STDEV	11.87	12.78	10.89	12.70	13.84	12.68	14.50	12.91	14.35		
MEDIAN	115.00	120.00	115.00	115.00	117.50	115.00	115.00	115.00	115.00		
MIN	80.00	90.00	100.00	90.00	90.00	90.00	90.00	85.00	85.00		
MAX	145.00	150.00	150.00	150.00	170.00	150.00	160.00	150.00	160.00		
N	76	76	74	73	70	68	66	66	65		
MISS	0	0	0	0	0	1	0	0	0		

434

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
TABLE No.: 102a

VITAL SIGN: 2m. STANDING DIASTOLIC BLOOD PRESSURE - RANDOMIZED PATIENTS ONLY

REBOXETINE	VISIT NO.																															
	0	1	2	3	4	5	6	8	9	10	12	14	16	18	20	22	24	26	28	30	32											
MEAN	78.56	76.64	77.24	77.79	79.59	78.17	78.85	79.69	90.00	78.86	79.99	79.03	79.59	79.12	78.58	79.31	77.94	78.81	77.63	78.41	79.49											
STDEV	11.57	10.59	11.30	11.16	10.98	9.79	10.91	10.91		10.22	11.34	11.17	11.72	12.18	12.71	11.82	12.36	11.05	11.23	11.63	11.37											
MEDIAN	80.00	80.00	75.00	80.00	80.00	80.00	80.00	80.00	90.00	80.00	80.00	80.00	80.00	80.00	80.00	80.00	80.00	80.00	80.00	80.00	80.00											
MIN	50.00	45.00	50.00	50.00	60.00	50.00	50.00	55.00	90.00	60.00	60.00	60.00	60.00	60.00	60.00	60.00	50.00	50.00	50.00	50.00	50.00											
MAX	110.00	100.00	110.00	110.00	120.00	105.00	120.00	120.00	90.00	110.00	110.00	110.00	115.00	130.00	130.00	120.00	115.00	115.00	110.00	110.00	115.00											
N	143	143	143	143	143	143	143	143	1	137	127	124	122	113	109	105	102	101	97	90	88											
MISS	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0											

(CONTINUED)

	VISIT NO.										
	34	36	38	40	42	44	46	48	50	52	
MEAN	79.31	79.32	77.59	77.54	76.65	78.32	77.35	79.00	78.38	77.72	
STDEV	11.66	11.71	11.11	11.35	11.39	11.38	10.61	10.66	10.93	10.85	
MEDIAN	80.00	80.00	80.00	80.00	75.00	75.00	80.00	80.00	75.00	75.00	
MIN	60.00	60.00	55.00	60.00	60.00	60.00	60.00	60.00	60.00	60.00	
MAX	110.00	110.00	110.00	110.00	110.00	110.00	110.00	110.00	110.00	115.00	
N	86	84	83	82	82	82	81	80	80	79	
MISS	1	0	0	0	0	0	0	1	0	0	

435

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 1026

VITAL SIGN: 2m. STANDING DIASTOLIC BLOOD PRESSURE - RANDOMIZED PATIENTS ONLY

PLACEBO	VISIT NO.																																	
	0	1	2	3	4	5	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34													
MEAN	77.72	76.88	75.55	77.38	76.79	77.76	77.04	79.04	77.81	77.05	75.48	76.92	75.92	75.94	78.90	75.22	75.00	75.06	74.63	74.24														
STDEV	11.27	10.25	10.47	10.00	10.36	9.67	10.59	10.18	11.07	11.27	10.78	11.24	11.12	10.85	12.03	9.76	10.00	9.86	10.23	9.57	9.03													
MEDIAN	80.00	77.00	75.00	80.00	75.00	80.00	80.00	80.00	80.00	75.00	75.00	80.00	75.00	70.00	80.00	70.00	70.00	70.00	70.00	70.00	75.00													
MIN	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	40.00	50.00	50.00	50.00	55.00	60.00	60.00	60.00	55.00	60.00	60.00	50.00													
MAX	110.00	110.00	110.00	100.00	120.00	130.00	110.00	110.00	100.00	120.00	100.00	105.00	115.00	105.00	110.00	110.00	105.00	105.00	105.00	105.00	100.00													
N	140	140	140	140	140	140	140	140	136	132	125	122	114	106	100	95	91	88	83	80	79													
MISS	0	0	0	0	0	0	0	0	0	1	0	1	3	2	1	0	0	0	0	0	0													

(CONTINUED)

	VISIT NO.											
	36	38	40	42	44	46	48	50	52			
MEAN	74.37	75.22	75.62	75.16	75.14	75.35	75.23	74.77	74.77			
STDEV	8.03	9.71	8.76	10.46	9.59	8.21	9.74	9.86	10.29			
MEDIAN	70.00	75.00	75.00	75.00	70.00	75.00	75.00	70.00	70.00			
MIN	55.00	60.00	60.00	60.00	60.00	60.00	60.00	60.00	60.00			
MAX	100.00	105.00	100.00	100.00	110.00	95.00	100.00	110.00	105.00			
N	78	76	74	73	70	68	66	66	65			
MISS	0	0	0	0	0	1	0	0	0			

436

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 102F

VITAL SIGN: 2b. STANDING HEART RATE - RANDOMIZED PATIENTS ONLY

REBOXETINE	VISIT NO.																															
	0	1	2	3	4	5	6	8	9	10	12	14	16	18	20	22	24	26	28	30	32											
MEAN	84.83	87.10	88.65	88.20	89.71	88.04	89.07	88.31	90.00	89.42	90.01	89.69	90.39	89.16	90.69	89.56	90.75	88.52	88.95	89.46	89.16											
STDEV	11.47	12.81	15.33	15.89	13.57	12.47	13.18	12.90	-	13.81	14.54	14.52	14.05	15.32	15.38	14.29	13.53	14.21	13.13	14.15	13.22											
MEDIAN	84.00	84.00	86.00	86.00	88.00	86.00	86.00	86.00	90.00	88.00	88.00	88.00	89.00	86.00	88.00	88.00	88.00	88.00	86.00	86.00	88.00											
MIN	60.00	60.00	60.00	60.00	60.00	65.00	64.00	62.00	90.00	60.00	62.00	62.00	62.00	58.00	62.00	62.00	68.00	64.00	64.00	66.00	62.00											
MAX	112.00	120.00	140.00	140.00	128.00	120.00	120.00	120.00	90.00	124.00	130.00	148.00	140.00	130.00	135.00	125.00	126.00	126.00	124.00	140.00	124.00											
N	141	142	142	141	143	143	142	143	1	137	127	124	122	113	109	104	102	101	96	89	88											
MISS	2	1	1	2	0	0	1	0	0	0	1	0	0	1	0	1	0	0	1	1	0											

(CONTINUED)

	VISIT NO.										
	34	36	38	40	42	44	46	48	50	52	
MEAN	89.20	89.39	88.78	88.40	87.17	88.95	87.77	88.38	88.75	86.63	
STDEV	14.53	13.70	12.02	12.15	13.40	13.49	12.04	12.40	12.89	11.14	
MEDIAN	87.00	86.00	86.00	86.00	86.00	86.00	86.00	86.00	86.00	86.00	
MIN	64.00	62.00	68.00	62.00	62.00	68.00	66.00	62.00	64.00	62.00	
MAX	120.00	125.00	121.00	124.00	120.00	124.00	128.00	120.00	132.00	116.00	
N	86	83	83	82	82	82	81	79	80	79	
MISS	1	1	0	0	0	0	0	2	0	0	

437

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 102f

VITAL SIGN: 2m. STANDING HEART RATE - RANDOMIZED PATIENTS ONLY

PLACERO	VISIT NO.																																	
	0	1	2	3	4	5	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34													
MEAN	86.00	89.35	89.41	89.74	90.78	89.40	90.42	86.01	86.73	85.08	85.03	85.26	85.02	85.40	86.26	84.63	83.31	82.84	82.89	81.98	81.23													
STDEV	13.81	15.35	15.77	14.49	14.64	12.62	15.23	12.69	13.10	12.88	12.69	11.35	14.18	11.75	12.26	12.56	13.18	12.94	11.29	10.12	11.74													
MEDIAN	84.00	88.00	87.00	88.00	88.00	88.00	88.00	84.00	86.00	84.00	84.00	82.00	82.00	84.00	84.00	82.00	81.50	80.00	82.00	80.00	81.00													
MIN	53.00	52.00	58.00	60.00	52.00	60.00	54.00	58.00	56.00	58.00	58.00	56.00	58.00	58.00	58.00	60.00	62.00	60.00	60.00	58.00	60.00													
MAX	136.00	140.00	140.00	140.00	126.00	132.00	129.00	132.00	132.00	124.00	128.00	124.00	140.00	136.00	120.00	124.00	128.00	120.00	120.00	124.00	120.00													
N	139	139	140	140	138	138	138	134	130	124	121	114	106	99	94	90	87	81	80	78														
MISS	1	1	0	0	2	1	2	2	2	3	1	2	3	2	2	1	1	1	2	0	1													

(CONTINUED)

	VISIT NO.										
	36	38	40	42	44	46	48	50	52		
MEAN	82.32	84.12	82.08	80.82	81.66	81.59	81.77	83.56	80.83		
STDEV	10.70	11.65	10.74	11.98	13.92	10.38	11.07	10.56	12.16		
MEDIAN	80.00	82.00	82.00	78.00	80.00	80.00	80.00	84.00	80.00		
MIN	64.00	64.00	62.00	60.00	58.00	64.00	60.00	62.00	58.00		
MAX	116.00	120.00	132.00	126.00	125.00	132.00	124.00	128.00	128.00		
N	77	74	74	73	70	68	66	66	65		
MISS	1	2	0	0	0	1	0	0	0		

438

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS 985 0077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 103

VITAL SIGNS CHANGES FROM VISIT -1: RANDOMIZED PATIENTS ONLY

REBOXETINE		VISIT NO.											
		1	2	3	4	5	6	8	9	10	12	14	16
LYING S.B.P.	NO.	143	143	143	143	143	143	143	1	137	127	124	122
	MEAN	-0.664	-1.140	1.168	1.783	-0.497	0.427	0.503	22.000	-1.255	0.472	-0.323	-0.697
	MEDIAN	0.000	0.000	0.000	0.000	0.000	0.000	0.000	22.000	0.000	0.000	0.000	0.000
	MIN	-40.00	-31.00	-60.00	-50.00	-40.00	-50.00	-40.00	22.000	-60.00	-60.00	-60.00	-40.00
	MAX	45.000	60.000	50.000	50.000	40.000	45.000	40.000	22.000	35.000	35.000	35.000	30.000
LYING D.B.P.	NO.	143	143	143	143	143	143	143	1	137	127	124	122
	MEAN	-0.252	0.972	1.350	2.189	1.392	1.972	2.217	-4.000	1.044	1.717	0.976	1.730
	MEDIAN	0.000	0.000	0.000	0.000	0.000	0.000	0.000	-4.000	0.000	0.000	0.000	0.000
	MIN	-30.00	-20.00	-30.00	-40.00	-35.00	-20.00	-20.00	-4.000	-30.00	-30.00	-30.00	-20.00
	MAX	30.000	60.000	30.000	40.000	30.000	30.000	38.000	-4.000	30.000	35.000	30.000	35.000
LYING H.R.	NO.	143	142	141	143	143	142	143	1	137	127	124	122
	MEAN	0.448	1.761	2.177	2.832	2.517	2.873	2.119	28.000	2.533	2.307	2.944	3.082
	MEDIAN	0.000	0.000	0.000	4.000	4.000	2.000	2.000	28.000	2.000	0.000	2.000	2.000
	MIN	-28.00	-48.00	-32.00	-32.00	-32.00	-32.00	-36.00	28.000	-56.00	-58.00	-56.00	-48.00
	MAX	44.000	44.000	52.000	44.000	34.000	50.000	50.000	28.000	50.000	48.000	44.000	54.000
STANDING S.B.P.	NO.	143	143	143	143	143	143	143	1	137	127	124	122
	MEAN	-1.014	-1.056	-0.755	0.685	-0.944	-0.706	-0.385	6.000	-1.080	-0.551	-0.726	-0.467
	MEDIAN	0.000	0.000	0.000	0.000	0.000	0.000	0.000	6.000	0.000	0.000	0.000	0.000
	MIN	-50.00	-35.00	-30.00	-40.00	-30.00	-35.00	-35.00	6.000	-40.00	-40.00	-40.00	-30.00
	MAX	50.000	50.000	45.000	45.000	35.000	40.000	40.000	6.000	35.000	50.000	40.000	50.000
STANDING D.B.P.	NO.	143	143	143	143	143	143	143	1	137	127	124	122
	MEAN	-0.853	-0.259	0.294	2.098	0.671	1.350	2.189	10.000	1.146	2.165	1.339	1.770
	MEDIAN	0.000	0.000	0.000	0.000	0.000	0.000	0.000	10.000	0.000	0.000	0.000	0.000
	MIN	-28.00	-48.00	-32.00	-32.00	-32.00	-32.00	-36.00	28.000	-56.00	-58.00	-56.00	-48.00
	MAX	30.000	50.000	50.000	40.000	40.000	30.000	40.000	10.000	30.000	35.000	35.000	40.000
STANDING H.R.	NO.	142	142	141	143	143	142	143	1	137	127	124	122
	MEAN	2.014	3.556	3.121	4.636	2.965	3.979	3.231	22.000	4.058	4.740	4.427	5.197
	MEDIAN	0.000	2.000	1.000	4.000	0.000	1.500	2.000	22.000	3.000	2.000	3.500	2.000
	MIN	-42.00	-36.00	-36.00	-26.00	-30.00	-30.00	-34.00	22.000	-40.00	-36.00	-38.00	-38.00
	MAX	42.000	56.000	50.000	54.000	40.000	50.000	54.000	22.000	52.000	52.000	60.000	56.000

(CONTINUED)

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS 0590077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 103

VITAL SIGNS CHANGES FROM VISIT -1: RANDOMIZED PATIENTS ONLY

REBOXETINE		VISIT NO.											
		18	20	22	24	26	28	30	32	34	36	38	40
LYING S.B.P.	NO.	113	109	105	102	101	97	90	88	86	84	83	82
	MEAN	-1.177	-1.780	1.524	-0.186	0.198	-0.670	0.833	-1.000	-1.802	-1.393	-1.048	-1.280
	MEDIAN	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	-5.000	0.000	0.000
	MIN	-50.00	-60.00	-35.00	-30.00	-30.00	-35.00	-20.00	-40.00	-35.00	-35.00	-30.00	-30.00
	MAX	30.000	30.000	70.000	30.000	30.000	40.000	40.000	35.000	60.000	40.000	45.000	45.000
LYING D.B.P.	NO.	113	109	105	102	101	97	90	88	86	84	83	82
	MEAN	0.071	0.991	3.505	1.255	0.772	0.340	1.533	1.795	1.372	1.500	0.940	0.220
	MEDIAN	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
	MIN	-25.00	-30.00	-20.00	-20.00	-20.00	-20.00	-20.00	-20.00	-25.00	-25.00	-30.00	-30.00
	MAX	30.000	35.000	70.000	40.000	40.000	30.000	35.000	35.000	50.000	40.000	40.000	40.000
LYING H.R.	NO.	113	109	104	102	101	96	89	88	86	83	83	82
	MEAN	2.761	2.917	2.221	3.529	1.792	1.865	2.787	2.898	2.186	3.361	1.855	1.183
	MEDIAN	2.000	4.000	0.000	2.000	2.000	0.000	1.000	0.000	0.000	0.000	1.000	0.000
	MIN	-46.00	-56.00	-60.00	-40.00	-28.00	-40.00	-40.00	-40.00	-32.00	-32.00	-32.00	-32.00
	MAX	50.000	46.000	42.000	50.000	52.000	46.000	48.000	48.000	40.000	44.000	38.000	42.000
STANDING S.B.P.	NO.	113	109	105	102	101	97	90	88	86	84	83	82
	MEAN	-0.796	-2.431	-0.029	-0.892	0.030	-1.753	0.422	-0.795	-1.047	-1.774	-2.711	-1.890
	MEDIAN	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	-5.000	0.000
	MIN	-30.00	-35.00	-35.00	-40.00	-30.00	-40.00	-25.00	-30.00	-30.00	-30.00	-35.00	-35.00
	MAX	40.000	40.000	45.000	45.000	40.000	40.000	40.000	40.000	50.000	50.000	30.000	50.000
STANDING D.B.P.	NO.	113	109	105	102	101	97	90	88	86	84	83	82
	MEAN	1.159	0.697	1.895	0.451	1.347	0.680	1.589	2.852	2.349	2.405	0.711	0.817
	MEDIAN	0.000	0.000	0.000	0.000	0.000	0.000	0.000	5.000	5.000	5.000	0.000	0.000
	MIN	-46.00	-56.00	-60.00	-40.00	-28.00	-40.00	-40.00	-40.00	-32.00	-32.00	-32.00	-32.00
	MAX	40.000	40.000	40.000	40.000	40.000	40.000	40.000	40.000	40.000	50.000	40.000	50.000
STANDING H.R.	NO.	113	109	104	102	101	96	89	88	86	83	83	82
	MEAN	4.124	5.303	4.000	5.000	2.901	3.073	3.820	3.341	3.593	3.964	2.831	2.695
	MEDIAN	4.000	2.000	3.000	3.000	0.000	-2.000	0.000	2.000	0.000	2.000	0.000	0.000
	MIN	-42.00	-34.00	-38.00	-30.00	-30.00	-28.00	-26.00	-32.00	-30.00	-32.00	-28.00	-26.00
	MAX	64.000	56.000	48.000	52.000	56.000	52.000	62.000	56.000	52.000	42.000	34.000	60.000

(CONTINUED)

PHARMACIA CN9390077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 103

VITAL SIGNS CHANGES FROM VISIT -1: RANDOMIZED PATIENTS ONLY

REBOXETINE		VISIT NO.					
		42	44	46	48	50	52
LYING S.B.P.	NO.	82	82	81	80	80	79
	MEAN	-1.037	-0.634	-0.802	-1.438	0.313	-1.709
	MEDIAN	0.000	0.000	-5.000	0.000	0.000	0.000
	MIN	-40.00	-30.00	-25.00	-40.00	-50.00	-40.00
	MAX	50.000	40.000	40.000	40.000	30.000	40.000
LYING D.B.P.	NO.	82	82	81	80	80	79
	MEAN	0.951	0.890	-0.272	1.225	0.788	1.114
	MEDIAN	0.000	0.000	0.000	0.000	0.000	0.000
	MIN	-30.00	-25.00	-25.00	-20.00	-25.00	-30.00
	MAX	30.000	30.000	30.000	30.000	30.000	40.000
LYING H.R.	NO.	82	82	81	79	80	79
	MEAN	0.317	1.988	1.074	0.684	1.100	0.924
	MEDIAN	0.000	-2.000	0.000	-2.000	1.000	0.000
	MIN	-42.00	-32.00	-40.00	-44.00	-40.00	-40.00
	MAX	42.000	41.000	40.000	36.000	28.000	30.000
STANDING S.B.P.	NO.	82	82	81	80	80	79
	MEAN	-2.683	-1.098	-1.765	-0.875	-1.250	-2.101
	MEDIAN	0.000	0.000	0.000	0.000	0.000	0.000
	MIN	-30.00	-35.00	-30.00	-30.00	-30.00	-30.00
	MAX	35.000	50.000	40.000	50.000	55.000	60.000
STANDING D.B.P.	NO.	82	82	81	80	80	79
	MEAN	-0.073	1.598	0.667	2.175	1.550	1.063
	MEDIAN	0.000	0.000	0.000	0.000	0.000	0.000
	MIN	-42.00	-32.00	-40.00	-44.00	-40.00	-40.00
	MAX	50.000	40.000	30.000	40.000	35.000	40.000
STANDING H.R.	NO.	82	82	81	79	80	79
	MEAN	1.463	3.244	1.901	2.646	2.963	0.646
	MEDIAN	2.000	2.000	0.000	0.000	0.000	0.000
	MIN	-37.00	-32.00	-30.00	-30.00	-28.00	-34.00
	MAX	56.000	42.000	48.000	36.000	46.000	34.000

PHARMACIA CNS 0077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 103

VITAL SIGNS CHANGES FROM VISIT -1: RANDOMIZED PATIENTS ONLY

PLACEBO		VISIT NO.											
		1	2	3	4	5	6	8	10	12	14	16	18
LYING S.B.P.	NO.	140	140	140	140	140	140	140	136	132	125	122	114
	MEAN	-1.321	-3.386	-2.914	-2.043	-1.436	-3.900	-1.271	-0.037	-0.962	-2.360	-2.008	-3.860
	MEDIAN	0.000	0.000	-5.000	0.000	0.000	-0.500	0.000	0.000	0.000	-5.000	-5.000	-5.000
	MIN	-40.00	-40.00	-50.00	-40.00	-50.00	-50.00	-30.00	-30.00	-40.00	-40.00	-40.00	-40.00
	MAX	50.000	40.000	40.000	45.000	50.000	40.000	50.000	60.000	70.000	50.000	75.000	55.000
LYING D.B.P.	NO.	140	140	140	140	140	140	140	136	132	125	122	114
	MEAN	-0.029	-2.379	-0.879	-0.771	0.750	-1.893	0.229	0.154	-1.136	-2.480	-1.475	-2.105
	MEDIAN	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
	MIN	-25.00	-25.00	-35.00	-30.00	-25.00	-30.00	-20.00	-30.00	-25.00	-30.00	-30.00	-30.00
	MAX	30.000	30.000	20.000	30.000	40.000	30.000	40.000	36.000	40.000	35.000	30.000	20.000
LYING H.R.	NO.	139	140	140	138	139	138	138	134	130	124	121	114
	MEAN	1.576	3.179	3.607	4.341	3.583	4.572	-0.652	-0.381	-0.269	-0.331	-0.810	-2.211
	MEDIAN	0.000	0.000	0.000	2.000	2.000	4.000	0.000	0.000	0.000	0.000	0.000	-3.500
	MIN	-28.00	-40.00	-24.00	-40.00	-32.00	-32.00	-46.00	-34.00	-38.00	-30.00	-36.00	-38.00
	MAX	44.000	48.000	44.000	48.000	32.000	48.000	40.000	42.000	36.000	40.000	48.000	58.000
STANDING S.B.P.	NO.	140	140	140	140	140	140	140	136	132	125	122	114
	MEAN	-2.607	-3.821	-3.350	-2.021	-2.671	-2.921	-0.471	-0.684	-1.280	-2.704	-0.705	-5.132
	MEDIAN	0.000	0.000	-5.000	0.000	0.000	0.000	0.000	0.000	0.000	-5.000	0.000	-5.000
	MIN	-50.00	-35.00	-40.00	-35.00	-40.00	-35.00	-40.00	-50.00	-35.00	-45.00	-40.00	-40.00
	MAX	55.000	40.000	35.000	35.000	50.000	46.000	67.000	60.000	70.000	65.000	90.000	35.000
STANDING D.B.P.	NO.	140	140	140	140	140	140	140	136	132	125	122	114
	MEAN	-0.521	-1.850	-0.021	-0.607	0.364	-0.357	1.636	0.279	-0.447	-2.312	-0.902	-1.746
	MEDIAN	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	-5.000	0.000	0.000
	MIN	-28.00	-40.00	-24.00	-40.00	-32.00	-32.00	-46.00	-34.00	-38.00	-30.00	-36.00	-38.00
	MAX	34.000	30.000	30.000	40.000	40.000	30.000	45.000	40.000	40.000	40.000	40.000	30.000
STANDING H.R.	NO.	139	140	140	138	139	138	138	134	130	124	121	114
	MEAN	3.281	3.371	3.700	4.725	3.324	4.384	-0.022	0.216	-1.092	-1.024	-1.066	-1.842
	MEDIAN	0.000	1.000	0.500	2.000	0.000	3.000	0.000	0.000	-2.000	-2.000	-2.000	-3.000
	MIN	-45.00	-48.00	-38.00	-24.00	-30.00	-38.00	-50.00	-40.00	-38.00	-38.00	-40.00	-52.00
	MAX	54.000	50.000	54.000	46.000	38.000	52.000	42.000	48.000	48.000	40.000	46.000	60.000

(CONTINUED)

PHARMACIA CNS 9190077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 103

VITAL SIGNS CHANGES FROM VISIT -1: RANDOMIZED PATIENTS ONLY

PLACEBO		VISIT NO.											
		20	22	24	26	28	30	32	34	36	38	40	42
LYING S.B.P.	NO.	106	100	95	91	88	83	80	79	78	76	74	73
	MEAN	-3.066	-1.800	-0.316	-1.264	-2.443	-1.651	-1.375	-1.835	-2.692	-1.579	-1.419	-2.055
	MEDIAN	-2.500	0.000	0.000	-5.000	-5.000	0.000	-2.500	0.000	-5.000	-5.000	0.000	-5.000
	MIN	-40.00	-40.00	-35.00	-40.00	-50.00	-40.00	-40.00	-30.00	-30.00	-30.00	-20.00	-25.00
	MAX	50.000	50.000	55.000	55.000	50.000	55.000	55.000	50.000	55.000	55.000	50.000	55.000
LYING D.B.P.	NO.	106	100	95	91	88	83	80	79	78	76	74	73
	MEAN	-1.991	-0.600	-1.632	-1.868	-3.409	-2.229	-2.813	-1.646	-2.821	-2.961	-2.162	-2.589
	MEDIAN	0.000	0.000	0.000	0.000	-5.000	0.000	0.000	0.000	-5.000	-5.000	0.000	0.000
	MIN	-25.00	-25.00	-20.00	-20.00	-30.00	-20.00	-25.00	-20.00	-25.00	-25.00	-20.00	-30.00
	MAX	25.000	30.000	30.000	30.000	30.000	30.000	30.000	30.000	25.000	40.000	25.000	30.000
LYING H.R.	NO.	106	99	94	90	87	82	80	78	77	74	74	73
	MEAN	-1.651	-0.758	-1.798	-3.822	-3.632	-4.317	-4.200	-5.397	-4.130	-2.743	-4.041	-4.534
	MEDIAN	-2.000	-2.000	-4.000	-4.000	-4.000	-4.000	-5.000	-6.500	-4.000	-4.000	-4.500	-6.000
	MIN	-30.00	-32.00	-28.00	-32.00	-32.00	-32.00	-30.00	-30.00	-32.00	-32.00	-32.00	-30.00
	MAX	40.000	32.000	32.000	36.000	36.000	36.000	40.000	40.000	28.000	44.000	36.000	36.000
STANDING S.B.P.	NO.	106	100	95	91	88	83	80	79	78	76	74	73
	MEAN	-2.500	-1.250	-2.947	-2.582	-1.989	-2.952	-2.625	-2.278	-3.064	-0.474	-0.797	-2.192
	MEDIAN	-2.500	0.000	-5.000	-5.000	-5.000	-5.000	-5.000	-5.000	0.000	0.000	-2.500	-5.000
	MIN	-45.00	-40.00	-35.00	-30.00	-30.00	-35.00	-40.00	-30.00	-35.00	-32.00	-30.00	-40.00
	MAX	40.000	50.000	50.000	40.000	80.000	70.000	40.000	45.000	40.000	50.000	50.000	40.000
STANDING D.B.P.	NO.	106	100	95	91	88	83	80	79	78	76	74	73
	MEAN	-1.358	1.160	-1.726	-2.407	-2.602	-2.458	-2.613	-2.709	-2.667	-1.868	-1.730	-2.356
	MEDIAN	0.000	0.000	0.000	0.000	0.000	0.000	0.000	-5.000	-5.000	-4.500	0.000	0.000
	MIN	-30.00	-32.00	-28.00	-32.00	-32.00	-32.00	-30.00	-30.00	-32.00	-32.00	-32.00	-30.00
	MAX	25.000	40.000	40.000	25.000	40.000	40.000	40.000	40.000	40.000	40.000	30.000	40.000
STANDING H.R.	NO.	106	99	94	90	87	81	80	78	77	74	74	73
	MEAN	-1.009	0.000	-1.840	-3.256	-3.690	-3.679	-4.550	-5.128	-4.403	-2.378	-4.000	-5.288
	MEDIAN	-2.000	-2.000	-4.000	-4.000	-5.000	-4.000	-5.500	-4.500	-6.000	-5.500	-6.500	-6.000
	MIN	-38.00	-38.00	-28.00	-38.00	-24.00	-30.00	-32.00	-32.00	-28.00	-30.00	-28.00	-32.00
	MAX	38.000	34.000	40.000	46.000	46.000	46.000	40.000	40.000	40.000	40.000	44.000	38.000

(CONTINUED)

PHARMACIA CNS0150077
REBOXETINE - PROTOCOL 20124/013

TABLE No. : 103

VITAL SIGNS CHANGES FROM VISIT -1: RANDOMIZED PATIENTS ONLY

PLACEBO		VISIT NO.				
		44	46	48	50	52
LYING S.B.P.	NO.	70	68	66	66	65
	MEAN	-0.500	-0.971	0.076	0.530	-1.462
	MEDIAN	0.000	0.000	0.000	0.000	-5.000
	MIN	-40.00	-30.00	-40.00	-30.00	-30.00
	MAX	50.000	55.000	60.000	55.000	50.000
LYING D.B.P.	NO.	70	68	66	66	65
	MEAN	-2.886	-1.456	-1.439	-1.288	-1.769
	MEDIAN	-3.500	0.000	0.000	0.000	0.000
	MIN	-30.00	-20.00	-30.00	-20.00	-20.00
	MAX	30.000	30.000	30.000	25.000	35.000
LYING H.R.	NO.	70	68	66	66	65
	MEAN	-3.857	-4.132	-3.742	-2.970	-4.846
	MEDIAN	-6.000	-4.000	-4.000	-4.000	-4.000
	MIN	-32.00	-38.00	-32.00	-26.00	-30.00
	MAX	36.000	24.000	28.000	30.000	32.000
STANDING S.B.P.	NO.	70	68	66	66	65
	MEAN	-1.286	-2.309	-2.424	-1.500	-2.646
	MEDIAN	0.000	0.000	-5.000	0.000	-5.000
	MIN	-30.00	-40.00	-50.00	-45.00	-40.00
	MAX	50.000	35.000	50.000	40.000	45.000
STANDING D.B.P.	NO.	70	68	66	66	65
	MEAN	-2.271	-1.691	-1.727	-2.182	-1.985
	MEDIAN	-2.500	-0.500	0.000	0.000	-5.000
	MIN	-32.00	-38.00	-32.00	-26.00	-30.00
	MAX	35.000	30.000	40.000	30.000	30.000
STANDING H.R.	NO.	70	68	66	66	65
	MEAN	-4.486	-4.588	-4.439	-2.652	-5.477
	MEDIAN	-8.000	-6.000	-6.000	-4.000	-6.000
	MIN	-37.00	-27.00	-30.00	-28.00	-34.00
	MAX	38.000	26.000	30.000	32.000	34.000

PHARMACIA CNS 980077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 104

NUMBER AND PERCENTAGE OF SUBJECTS WITH BLOOD PRESSURE AND HEART RATE CHANGES OF CLINICAL RELEVANCE (*) AS COMPARED TO VISIT -1, DOUBLE BLIND PHASE

REBOXETINE			VISIT NO.									
			1	2	3	4	5	6	8	9	10	12
LYING S.B.P.	INCREASE	Evaluated	143	143	143	143	143	143	143	1	137	127
		No.	7	7	11	13	7	11	6		8	10
		%	4.9	4.9	7.7	9.1	4.9	7.7	4.2		5.8	7.9
	DECREASE	Evaluated	143	143	143	143	143	143	143	1	137	127
		No.	4	2	3	4	3	4	5		6	3
		%	2.8	1.4	2.1	2.8	2.1	2.8	3.5		4.4	2.4
LYING D.B.P.	INCREASE	Evaluated	143	143	143	143	143	143	143	1	137	127
		No.	16	15	18	20	16	24	17		18	18
		%	11.2	10.5	12.6	14.0	11.2	16.8	11.9		13.1	14.2
	DECREASE	Evaluated	143	143	143	143	143	143	143	1	137	127
		No.	9	1	6	6	6	8	3		5	6
		%	6.3	0.7	4.2	4.2	4.2	5.6	2.1		3.6	4.7
LYING H.R.	INCREASE	Evaluated	143	142	141	143	143	142	143	1	137	127
		No.	16	20	29	24	18	25	24	1	26	22
		%	11.2	14.1	20.6	16.8	12.6	17.6	16.8	100.0	19.0	17.3
	DECREASE	Evaluated	143	142	141	143	143	142	143	1	137	127
		No.	8	7	10	4	5	6	10		11	9
		%	5.6	4.9	7.1	2.8	3.5	4.2	7.0		8.0	7.1
STANDING S.B.P.	INCREASE	Evaluated	143	143	143	143	143	143	143	1	137	127
		No.	7	9	6	9	6	8	8		5	11
		%	4.9	6.3	4.2	6.3	4.2	5.6	5.6		3.6	8.7
	DECREASE	Evaluated	143	143	143	143	143	143	143	1	137	127
		No.	6	4	1	4	4	5	2		7	2
		%	4.2	2.8	0.7	2.8	2.8	3.5	1.4		5.1	1.6
STANDING D.B.P.	INCREASE	Evaluated	143	143	143	143	143	143	143	1	137	127
		No.	7	11	7	18	8	20	18		14	19
		%	4.9	7.7	4.9	12.6	5.6	14.0	12.6		10.2	15.0
	DECREASE	Evaluated	143	143	143	143	143	143	143	1	137	127
		No.	8	7	9	4	5	7	4		3	4
		%	5.6	4.9	6.3	2.8	3.5	4.9	2.8		2.2	3.1
STANDING H.R.	INCREASE	Evaluated	142	142	141	143	143	142	143	1	137	127
		No.	26	29	28	30	28	29	24	1	28	32
		%	18.3	20.4	19.9	21.0	19.6	20.4	16.8	100.0	20.4	25.2
	DECREASE	Evaluated	142	142	141	143	143	142	143	1	137	127
		No.	9	12	11	9	5	7	12		8	6
		%	6.3	8.5	7.8	6.3	3.5	4.9	8.4		5.8	4.7

(CONTINUED)

445

* Increase or Decrease in SBP or DBP or HR => 20% as compared to visit -1

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS 9800077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 104

NUMBER AND PERCENTAGE OF SUBJECTS WITH BLOOD PRESSURE AND HEART RATE CHANGES OF CLINICAL RELEVANCE (*) AS COMPARED TO VISIT -1, DOUBLE BLIND PHASE

REBOXETINE			VISIT NO.									
			1	2	3	4	5	6	8	9	10	12
LYING S.B.P.	INCREASE	Evaluated	143	143	143	143	143	143	143	1	137	127
		No.	7	7	11	13	7	11	6		8	10
		%	4.9	4.9	7.7	9.1	4.9	7.7	4.2		5.8	7.9
	DECREASE	Evaluated	143	143	143	143	143	143	143	1	137	127
		No.	4	2	3	4	3	4	5		6	3
		%	2.8	1.4	2.1	2.8	2.1	2.8	3.5		4.4	2.4
LYING D.B.P.	INCREASE	Evaluated	143	143	143	143	143	143	143	1	137	127
		No.	16	15	18	20	16	24	17		18	18
		%	11.2	10.5	12.6	14.0	11.2	16.8	11.9		13.1	14.2
	DECREASE	Evaluated	143	143	143	143	143	143	143	1	137	127
		No.	9	1	6	6	6	8	3		5	6
		%	6.3	0.7	4.2	4.2	4.2	5.6	2.1		3.6	4.7
LYING H.R.	INCREASE	Evaluated	143	142	141	143	143	142	143	1	137	127
		No.	16	20	29	24	18	25	24	1	26	22
		%	11.2	14.1	20.6	16.8	12.6	17.6	16.8	100.0	19.0	17.3
	DECREASE	Evaluated	143	142	141	143	143	142	143	1	137	127
		No.	8	7	10	4	5	6	10		11	9
		%	5.6	4.9	7.1	2.8	3.5	4.2	7.0		8.0	7.1
STANDING S.B.P.	INCREASE	Evaluated	143	143	143	143	143	143	143	1	137	127
		No.	7	9	6	9	6	8	8		5	11
		%	4.9	6.3	4.2	6.3	4.2	5.6	5.6		3.6	8.7
	DECREASE	Evaluated	143	143	143	143	143	143	143	1	137	127
		No.	6	4	1	4	4	5	2		7	2
		%	4.2	2.8	0.7	2.8	2.8	3.5	1.4		5.1	1.6
STANDING D.B.P.	INCREASE	Evaluated	143	143	143	143	143	143	143	1	137	127
		No.	7	11	7	18	8	20	18		14	19
		%	4.9	7.7	4.9	12.6	5.6	14.0	12.6		10.2	15.0
	DECREASE	Evaluated	143	143	143	143	143	143	143	1	137	127
		No.	8	7	9	4	5	7	4		3	4
		%	5.6	4.9	6.3	2.8	3.5	4.9	2.8		2.2	3.1
STANDING H.R.	INCREASE	Evaluated	142	142	141	143	143	142	143	1	137	127
		No.	26	29	28	30	28	29	24	1	28	32
		%	18.3	20.4	19.9	21.0	19.6	20.4	16.8	100.0	20.4	25.2
	DECREASE	Evaluated	142	142	141	143	143	142	143	1	137	127
		No.	9	12	11	9	5	7	12		8	6
		%	6.3	8.5	7.8	6.3	3.5	4.9	8.4		5.8	4.7

(CONTINUED)

445

* Increase or Decrease in SBP or DBP or HR => 20% as compared to visit -1

PHARMACIA CNS 350077
REBOXETINE - PROTOCOL 20124/013

TABLE No. 104

NUMBER AND PERCENTAGE OF SUBJECTS WITH BLOOD PRESSURE AND HEART RATE CHANGES OF CLINICAL RELEVANCE (*) AS COMPARED TO VISIT -1, DOUBLE BLIND PHASE

REBOXETINE			VISIT NO.									
			34	36	38	40	42	44	46	48	50	52
LYING S.B.P.	INCREASE	Evaluated	86	84	83	82	82	82	81	80	80	79
		No.	3	7	6	6	7	6	6	5	8	4
		%	3.5	8.3	7.2	7.3	8.5	7.3	7.4	6.3	10.0	5.1
	DECREASE	Evaluated	86	84	83	82	82	82	81	80	80	79
		No.	5	2	2	4	4	1		1	1	2
		%	5.8	2.4	2.4	4.9	4.9	1.2		1.2	1.2	2.5
LYING D.B.P.	INCREASE	Evaluated	86	84	83	82	82	82	81	80	80	79
		No.	10	15	11	13	10	12	11	13	7	11
		%	11.6	17.9	13.3	15.9	12.2	14.6	13.6	16.2	8.8	13.9
	DECREASE	Evaluated	86	84	83	82	82	82	81	80	80	79
		No.	6	6	6	8	3	5	8	2	6	4
		%	7.0	7.1	7.2	9.8	3.7	6.1	9.9	2.5	7.5	5.1
LYING H.R.	INCREASE	Evaluated	86	83	83	82	82	82	81	79	80	79
		No.	16	17	15	11	10	18	15	15	15	12
		%	18.6	20.5	18.1	13.4	12.2	22.0	18.5	19.0	18.8	15.2
	DECREASE	Evaluated	86	83	83	82	82	82	81	79	80	79
		No.	6	4	5	6	9	8	8	5	7	6
		%	7.0	4.8	6.0	7.3	11.0	9.8	9.9	6.3	8.8	7.6
STANDING S.B.P.	INCREASE	Evaluated	86	84	83	82	82	82	81	80	80	79
		No.	7	6	7	7	5	3	3	4	3	4
		%	8.1	7.1	8.4	8.5	6.1	3.7	3.7	5.0	3.8	5.1
	DECREASE	Evaluated	86	84	83	82	82	82	81	80	80	79
		No.	3	4	3	3	4	3	3	2	1	4
		%	3.5	4.8	3.6	3.7	4.9	3.7	3.7	2.5	1.2	5.1
STANDING D.B.P.	INCREASE	Evaluated	86	84	83	82	82	82	81	80	80	79
		No.	10	7	9	8	7	10	8	10	8	10
		%	11.6	8.3	10.8	9.8	8.5	12.2	9.9	12.5	10.0	12.7
	DECREASE	Evaluated	86	84	83	82	82	82	81	80	80	79
		No.	10	6	7	6	5	8	6	5	5	7
		%	11.6	7.1	8.4	7.3	6.1	9.8	7.4	6.3	6.3	8.9
STANDING H.R.	INCREASE	Evaluated	86	83	83	82	82	82	81	79	80	79
		No.	16	17	14	17	15	19	12	14	15	11
		%	18.6	20.5	16.9	20.7	18.3	23.2	14.8	17.7	18.8	13.9
	DECREASE	Evaluated	86	83	83	82	82	82	81	79	80	79
		No.	6	3	3	5	10	4	9	5	3	7
		%	7.0	3.6	3.6	6.1	12.2	4.9	11.1	6.3	3.8	8.9

447

* Increase or Decrease in SBP or DBP or HR => 20% as compared to visit -1

PHARMACIA C950077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 104

NUMBER AND PERCENTAGE OF SUBJECTS WITH BLOOD PRESSURE AND HEART RATE CHANGES OF CLINICAL RELEVANCE (*) AS COMPARED TO VISIT -1, DOUBLE BLIND PHASE

PLACEBO			VISIT NO.										
			1	2	3	4	5	6	8	10	12	14	
LYING S.B.P.	INCREASE	Evaluated	140	140	140	140	140	140	140	136	132	125	
		No.	5	2	5	7	6	6	3	8	8	6	
		%	3.6	1.4	3.6	5.0	4.3	4.3	2.1	5.9	6.1	4.8	
	DECREASE	Evaluated	140	140	140	140	140	140	140	140	136	132	125
		No.	5	7	7	4	6	10	2	7	5	7	
		%	3.6	5.0	5.0	2.9	4.3	7.1	1.4	5.1	3.8	5.6	
LYING D.B.P.	INCREASE	Evaluated	140	140	140	140	140	140	140	136	132	125	
		No.	7	4	6	10	14	7	12	10	11	5	
		%	5.0	2.9	4.3	7.1	10.0	5.0	8.6	7.4	8.3	4.0	
	DECREASE	Evaluated	140	140	140	140	140	140	140	136	132	125	
		No.	5	7	5	4	5	4	2	5	5	11	
		%	3.6	5.0	3.6	2.9	3.6	2.9	1.4	3.7	3.8	8.8	
LYING H.R.	INCREASE	Evaluated	139	140	140	138	139	138	138	134	130	124	
		No.	23	23	28	33	28	38	17	18	17	14	
		%	16.5	16.4	20.0	23.9	20.1	27.5	12.3	13.4	13.1	11.3	
	DECREASE	Evaluated	139	140	140	138	139	138	138	134	130	124	
		No.	9	6	7	8	5	8	10	10	13	10	
		%	6.5	4.3	5.0	5.8	3.6	5.8	7.2	7.5	10.0	8.1	
STANDING S.B.P.	INCREASE	Evaluated	140	140	140	140	140	140	140	136	132	125	
		No.	5	4	5	4	6	4	10	7	7	6	
		%	3.6	2.9	3.6	2.9	4.3	2.9	7.1	5.1	5.3	4.8	
	DECREASE	Evaluated	140	140	140	140	140	140	140	136	132	125	
		No.	3	8	5	3	8	6	6	7	5	6	
		%	2.1	5.7	3.6	2.1	5.7	4.3	4.3	5.1	3.8	4.8	
STANDING D.B.P.	INCREASE	Evaluated	140	140	140	140	140	140	140	136	132	125	
		No.	5	5	8	13	14	8	17	15	10	8	
		%	3.6	3.6	5.7	9.3	10.0	5.7	12.1	11.0	7.6	6.4	
	DECREASE	Evaluated	140	140	140	140	140	140	140	136	132	125	
		No.	7	7	8	7	6	2	1	7	8	12	
		%	5.0	5.0	5.7	5.0	4.3	1.4	0.7	5.1	6.1	9.6	
STANDING H.R.	INCREASE	Evaluated	139	140	140	138	139	138	138	134	130	124	
		No.	29	26	27	29	31	32	20	17	15	14	
		%	20.9	18.6	19.3	21.0	22.3	23.2	14.5	12.7	11.5	11.3	
	DECREASE	Evaluated	139	140	140	138	139	138	138	134	130	124	
		No.	6	6	3	5	4	8	12	10	11	12	
		%	4.3	4.3	2.1	3.6	2.9	5.8	8.7	7.5	8.5	9.7	

(CONTINUED)

448

* Increase or Decrease in SBP or DBP or HR => 20% as compared to visit -1

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS 350077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 104

NUMBER AND PERCENTAGE OF SUBJECTS WITH BLOOD PRESSURE AND HEART RATE CHANGES OF CLINICAL RELEVANCE (*) AS COMPARED TO VISIT -1, DOUBLE BLIND PHASE

PLACEBO			VISIT NO.									
			16	18	20	22	24	26	28	30	32	34
LYING S.B.P.	INCREASE	Evaluated	122	114	106	100	95	91	88	83	80	79
		No.	7	3	3	5	6	4	5	7	5	2
		%	5.7	2.6	2.8	5.0	6.3	4.4	5.7	8.4	6.3	2.5
	DECREASE	Evaluated	122	114	106	100	95	91	88	83	80	79
		No.	6	8	4	5	2	1	3	3	4	2
		%	4.9	7.0	3.8	5.0	2.1	1.1	3.4	3.6	5.0	2.5
LYING D.B.P.	INCREASE	Evaluated	122	114	106	100	95	91	88	83	80	79
		No.	6	6	8	8	6	8	8	5	5	5
		%	4.9	5.3	7.5	8.0	6.3	8.8	9.1	6.0	6.3	6.3
	DECREASE	Evaluated	122	114	106	100	95	91	88	83	80	79
		No.	5	3	8	5	6	4	5	3	4	3
		%	4.1	2.6	7.5	5.0	6.3	4.4	5.7	3.6	5.0	3.8
LYING H.R.	INCREASE	Evaluated	121	114	106	99	94	90	87	82	80	78
		No.	13	10	11	6	10	4	4	4	7	4
		%	10.7	8.8	10.4	6.1	10.6	4.4	4.6	4.9	8.8	5.1
	DECREASE	Evaluated	121	114	106	99	94	90	87	82	80	78
		No.	11	12	8	6	7	13	11	10	8	18
		%	9.1	10.5	7.5	6.1	7.4	14.4	12.6	12.2	10.0	23.1
STANDING S.B.P.	INCREASE	Evaluated	122	114	106	100	95	91	88	83	80	79
		No.	6	3	8	8	8	8	5	7	6	4
		%	4.9	2.6	7.5	8.0	8.4	8.8	5.7	8.4	7.5	5.1
	DECREASE	Evaluated	122	114	106	100	95	91	88	83	80	79
		No.	7	11	4	7	6	6	2	3	2	1
		%	5.7	9.6	3.8	7.0	6.3	6.6	2.3	3.6	2.5	1.3
STANDING D.B.P.	INCREASE	Evaluated	122	114	106	100	95	91	88	83	80	79
		No.	9	5	6	15	9	10	9	8	6	6
		%	7.4	4.4	5.7	15.0	9.5	11.0	10.2	9.6	7.5	7.6
	DECREASE	Evaluated	122	114	106	100	95	91	88	83	80	79
		No.	7	9	6	6	6	9	11	9	9	7
		%	5.7	7.9	5.7	6.0	6.3	9.9	12.5	10.8	11.3	8.9
STANDING H.R.	INCREASE	Evaluated	121	114	106	99	94	90	87	81	80	78
		No.	14	12	11	12	12	8	7	6	7	6
		%	11.6	10.5	10.4	12.1	12.8	8.9	8.0	7.4	8.8	7.7
	DECREASE	Evaluated	121	114	106	99	94	90	87	81	80	78
		No.	9	9	4	4	8	12	11	8	10	13
		%	7.4	7.9	3.8	4.0	8.5	13.3	12.6	9.9	12.5	16.7

449

(CONTINUED)

* Increase or Decrease in SBP or DBP or HR => 20% as compared to visit -1

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS 9590077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 104

NUMBER AND PERCENTAGE OF SUBJECTS WITH BLOOD PRESSURE AND HEART RATE CHANGES OF CLINICAL RELEVANCE (*) AS COMPARED TO VISIT -1, DOUBLE BLIND PHASE

PLACEBO			VISIT NO.								
			36	38	40	42	44	46	48	50	52
LYING S.B.P.	INCREASE	Evaluated	78	76	74	73	70	68	66	66	65
		No.	3	7	4	4	3	4	4	3	3
		%	3.8	9.2	5.4	5.5	4.3	5.9	6.1	4.5	4.6
	DECREASE	Evaluated	78	76	74	73	70	68	66	66	65
		No.	4	3			1	1	3	1	3
		%	5.1	3.9			1.4	1.5	4.5	1.5	4.6
LYING D.B.P.	INCREASE	Evaluated	78	76	74	73	70	68	66	66	65
		No.	5	5	6	4	4	4	6	4	6
		%	6.4	6.6	8.1	5.5	5.7	5.9	9.1	6.1	9.2
	DECREASE	Evaluated	78	76	74	73	70	68	66	66	65
		No.	4	5	5	2	4	2	5	4	5
		%	5.1	6.6	6.8	2.7	5.7	2.9	7.6	6.1	7.7
LYING H.R.	INCREASE	Evaluated	77	74	74	73	70	68	66	66	65
		No.	4	6	5	5	6	4	6	4	5
		%	5.2	8.1	6.8	6.8	8.6	5.9	9.1	6.1	7.7
	DECREASE	Evaluated	77	74	74	73	70	68	66	66	65
		No.	8	5	7	12	6	9	7	7	12
		%	10.4	6.8	9.5	16.4	8.6	13.2	10.6	10.6	18.5
STANDING S.B.P.	INCREASE	Evaluated	78	76	74	73	70	68	66	66	65
		No.	5	7	6	7	6	6	5	5	6
		%	6.4	9.2	8.1	9.6	8.6	8.8	7.6	7.6	9.2
	DECREASE	Evaluated	78	76	74	73	70	68	66	66	65
		No.	4	4		2		4	3	1	6
		%	5.1	5.3		2.7		5.9	4.5	1.5	9.2
STANDING D.B.P.	INCREASE	Evaluated	78	76	74	73	70	68	66	66	65
		No.	6	7	5	6	4	6	5	6	7
		%	7.7	9.2	6.8	8.2	5.7	8.8	7.6	9.1	10.8
	DECREASE	Evaluated	78	76	74	73	70	68	66	66	65
		No.	5	8	8	7	5	5	4	6	6
		%	6.4	10.5	10.8	9.6	7.1	7.4	6.1	9.1	9.2
STANDING H.R.	INCREASE	Evaluated	77	74	74	73	70	68	66	66	65
		No.	5	8	8	6	9	6	8	6	6
		%	6.5	10.8	10.8	8.2	12.9	8.8	12.1	9.1	9.2
	DECREASE	Evaluated	77	74	74	73	70	68	66	66	65
		No.	9	4	10	12	9	8	7	5	10
		%	11.7	5.4	13.5	16.4	12.9	11.8	10.6	7.6	15.4

* Increase or Decrease in SBP or DBP or HR => 20% as compared to visit -1

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNS 950077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 105

NUMBER AND PERCENTAGE OF SUBJECTS WITH VITAL SIGNS CHANGES OF CLINICAL RELEVANCE (=> 20 %) AS COMPARED TO VISIT -1, DOUBLE BLIND PHASE, ASSOCIATED TO CRITICAL VALUES (*)

REBOXETINE			VISIT NO.									
			1	2	3	4	5	6	8	9	10	12
LYING S.B.P.	INCREASE	Evaluated	143	143	143	143	143	143	143	1	137	127
		No.	1	1	1	2	1	2	1		2	2
		%	0.7	0.7	0.7	1.4	0.7	1.4	0.7		1.5	1.6
	DECREASE	Evaluated	143	143	143	143	143	143	143	1	137	127
		No.	2	2	0	2	1	2	2		4	1
		%	1.4	1.4	0.0	1.4	0.7	1.4	1.4		2.9	0.8
LYING D.B.P.	INCREASE	Evaluated	143	143	143	143	143	143	143	1	137	127
		No.	1	3	1	3	0	3	1		2	3
		%	0.7	2.1	0.7	2.1	0.0	2.1	0.7		1.5	2.4
	DECREASE	Evaluated	143	143	143	143	143	143	143	1	137	127
		No.	7	1	5	5	5	8	3		3	5
		%	4.9	0.7	3.5	3.5	3.5	5.6	2.1		2.2	3.9
LYING H.R.	INCREASE	Evaluated	143	142	141	143	143	142	143	1	137	127
		No.	9	11	14	10	10	12	11	0	14	15
		%	6.3	7.7	9.9	7.0	7.0	8.5	7.7	0.0	10.2	11.8
	DECREASE	Evaluated	143	142	141	143	143	142	143	1	137	127
		No.	0	0	0	0	0	0	0		0	0
		%	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.0	0.0
STANDING S.B.P.	INCREASE	Evaluated	143	143	143	143	143	143	143	1	137	127
		No.	1	1	0	1	0	2	2		1	4
		%	0.7	0.7	0.0	0.7	0.0	1.4	1.4		0.7	3.1
	DECREASE	Evaluated	143	143	143	143	143	143	143	1	137	127
		No.	4	3	1	2	3	3	1		5	1
		%	2.8	2.1	0.7	1.4	2.1	2.1	0.7		3.6	0.8
STANDING D.B.P.	INCREASE	Evaluated	143	143	143	143	143	143	143	1	137	127
		No.	1	4	2	5	0	5	5		3	4
		%	0.7	2.8	1.4	3.5	0.0	3.5	3.5		2.2	3.1
	DECREASE	Evaluated	143	143	143	143	143	143	143	1	137	127
		No.	6	7	8	3	5	6	3		3	4
		%	4.2	4.9	5.6	2.1	3.5	4.2	2.1		2.2	3.1
STANDING H.R.	INCREASE	Evaluated	142	142	141	143	143	142	143	1	137	127
		No.	16	17	19	19	15	17	13	0	18	23
		%	11.3	12.0	13.5	13.3	10.5	12.0	9.1	0.0	13.1	18.1
	DECREASE	Evaluated	142	142	141	143	143	142	143	1	137	127
		No.	0	0	0	0	0	0	0		0	0
		%	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.0	0.0

(CONTINUED)

451

* S.B.P. values => 160 mm Hg or <= 100 mm Hg
D.B.P. values => 100 mm Hg or <= 70 mm Hg
H.R. values => 100 beats/min or <= 50 beats/min

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CIB ~~5510077~~
 REBOXETINE - PROTOCOL 20124/013

TABLE No.: 105

NUMBER AND PERCENTAGE OF SUBJECTS WITH VITAL SIGNS CHANGES OF CLINICAL RELEVANCE (=> 20 %) AS COMPARED TO VISIT -1, DOUBLE BLIND PHASE, ASSOCIATED TO CRITICAL VALUES (*)

REBOXETINE			VISIT NO.										
			1	2	3	4	5	6	8	9	10	12	
STANDING H.R.	DECREASE	%	0.0	0.0	0.0	0.0	0.0	0.0	0.0			0.0	0.0

(CONTINUED)

* S.B.P. values => 160 mm Hg or <= 100 mm Hg
 D.B.P. values => 100 mm Hg or <= 70 mm Hg
 H.R. values => 100 beats/min or <= 50 beats/min

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN 550077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 105

NUMBER AND PERCENTAGE OF SUBJECTS WITH VITAL SIGNS CHANGES OF CLINICAL RELEVANCE (=> 20 %) AS COMPARED TO VISIT -1, DOUBLE BLIND PHASE, ASSOCIATED TO CRITICAL VALUES (*)

REBOXETINE			VISIT NO.									
			14	16	18	20	22	24	26	28	30	32
LYING S.B.P	INCREASE	Evaluated	124	122	113	109	105	102	101	97	90	88
		No.	0	1	0	0	4	1	1	0	0	0
		%	0.0	0.8	0.0	0.0	3.8	1.0	1.0	0.0	0.0	0.0
	DECREASE	Evaluated	124	122	113	109	105	102	101	97	90	88
		No.	0	1	1	1	1	2	2	0		2
		%	0.0	0.8	0.9	0.9	1.0	2.0	2.0	0.0		2.3
LYING D.B.P.	INCREASE	Evaluated	124	122	113	109	105	102	101	97	90	88
		No.	1	4	2	3	5	2	4	3	3	0
		%	0.8	3.3	1.8	2.8	4.8	2.0	4.0	3.1	3.3	0.0
	DECREASE	Evaluated	124	122	113	109	105	102	101	97	90	88
		No.	3	2	6	5	3	2	4	3	6	4
		%	2.4	1.6	5.3	4.6	2.9	2.0	4.0	3.1	6.7	4.5
LYING H.R.	INCREASE	Evaluated	124	122	113	109	104	102	101	96	89	88
		No.	14	13	17	11	9	11	12	7	11	11
		%	11.3	10.7	15.0	10.1	8.7	10.8	11.9	7.3	12.4	12.5
	DECREASE	Evaluated	124	122	113	109	104	102	101	96	89	88
		No.	0	0	0	0	0	0	0	0	0	0
		%	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
STANDING S.B.P	INCREASE	Evaluated	124	122	113	109	105	102	101	97	90	88
		No.	1	2	0	0	1	1	1	0	0	0
		%	0.8	1.6	0.0	0.0	1.0	1.0	1.0	0.0	0.0	0.0
	DECREASE	Evaluated	124	122	113	109	105	102	101	97	90	88
		No.	2	4		4	1	2	2	2		2
		%	1.6	3.3		3.7	1.0	2.0	2.0	2.1		2.3
STANDING D.B.P.	INCREASE	Evaluated	124	122	113	109	105	102	101	97	90	88
		No.	4	4	5	4	4	2	4	4	4	2
		%	3.2	3.3	4.4	3.7	3.8	2.0	4.0	4.1	4.4	2.3
	DECREASE	Evaluated	124	122	113	109	105	102	101	97	90	88
		No.	5	6	5	8	6	5	5	5	6	4
		%	4.0	4.9	4.4	7.3	5.7	4.9	5.0	5.2	6.7	4.5
STANDING H.R.	INCREASE	Evaluated	124	122	113	109	104	102	101	96	89	88
		No.	20	19	18	19	15	15	17	13	12	8
		%	16.1	15.6	15.9	17.4	14.4	14.7	16.8	13.5	13.5	9.1
	DECREASE	Evaluated	124	122	113	109	104	102	101	96	89	88
		No.	0	0	0	0	0	0	0	0	0	0
		%	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

(CONTINUED)

453

* S.B.P. values => 160 mm Hg or <= 100 mm Hg
D.B.P. values => 100 mm Hg or <= 70 mm Hg
H.R. values => 100 beats/min or <= 50 beats/min

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CIB50077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 105

NUMBER AND PERCENTAGE OF SUBJECTS WITH VITAL SIGNS CHANGES OF CLINICAL RELEVANCE (=> 20 %) AS COMPARED TO VISIT -1, DOUBLE BLIND PHASE, ASSOCIATED TO CRITICAL VALUES (*)

REBOXETINE			VISIT NO.											
			14	16	18	20	22	24	26	28	30	32		
STANDING H.R.	DECREASE	%	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

(CONTINUED)

454

* S.B.P. values => 160 mm Hg or <= 100 mm Hg
D.B.P. values => 100 mm Hg or <= 70 mm Hg
H.R. values => 100 beats/min or <= 50 beats/min

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CN 950077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 105

NUMBER AND PERCENTAGE OF SUBJECTS WITH VITAL SIGNS CHANGES OF CLINICAL RELEVANCE (=> 20 %) AS COMPARED TO VISIT -1, DOUBLE BLIND PHASE, ASSOCIATED TO CRITICAL VALUES (*)

REBOXETINE			VISIT NO.									
			34	36	38	40	42	44	46	48	50	52
LYING S.B.P	INCREASE	Evaluated	86	84	83	82	82	82	81	80	80	79
		No.	3	0	2	1	2	0	0	1	0	0
		%	3.5	0.0	2.4	1.2	2.4	0.0	0.0	1.2	0.0	0.0
	DECREASE	Evaluated	86	84	83	82	82	82	81	80	80	79
		No.	5	2	2	2	4	1		1	1	2
		%	5.8	2.4	2.4	2.4	4.9	1.2		1.2	1.2	2.5
LYING D.B.P.	INCREASE	Evaluated	86	84	83	82	82	82	81	80	80	79
		No.	2	3	2	3	2	2	0	2	1	2
		%	2.3	3.6	2.4	3.7	2.4	2.4	0.0	2.5	1.2	2.5
	DECREASE	Evaluated	86	84	83	82	82	82	81	80	80	79
		No.	5	5	6	7	3	4	7	2	5	4
		%	5.8	6.0	7.2	8.5	3.7	4.9	8.6	2.5	6.3	5.1
LYING H.R.	INCREASE	Evaluated	86	83	83	82	82	82	81	79	80	79
		No.	9	10	6	5	3	11	6	6	6	4
		%	10.5	12.0	7.2	6.1	3.7	13.4	7.4	7.6	7.5	5.1
	DECREASE	Evaluated	86	83	83	82	82	82	81	79	80	79
		No.	0	0	0	0	0	0	0	0	0	0
		%	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
STANDING S.B.P	INCREASE	Evaluated	86	84	83	82	82	82	81	80	80	79
		No.	2	0	0	0	1	0	0	1	0	1
		%	2.3	0.0	0.0	0.0	1.2	0.0	0.0	1.2	0.0	1.3
	DECREASE	Evaluated	86	84	83	82	82	82	81	80	80	79
		No.	2	1	3	2	3	1	1	2	1	2
		%	2.3	1.2	3.6	2.4	3.7	1.2	1.2	2.5	1.2	2.5
STANDING D.B.P.	INCREASE	Evaluated	86	84	83	82	82	82	81	80	80	79
		No.	5	3	2	2	3	3	1	2	1	2
		%	5.8	3.6	2.4	2.4	3.7	3.7	1.2	2.5	1.2	2.5
	DECREASE	Evaluated	86	84	83	82	82	82	81	80	80	79
		No.	10	6	7	6	4	8	5	5	3	5
		%	11.6	7.1	8.4	7.3	4.9	9.8	6.2	6.3	3.8	6.3
STANDING H.R.	INCREASE	Evaluated	86	83	83	82	82	82	81	79	80	79
		No.	13	10	8	12	8	14	8	10	10	7
		%	15.1	12.0	9.6	14.6	9.8	17.1	9.9	12.7	12.5	8.9
	DECREASE	Evaluated	86	83	83	82	82	82	81	79	80	79
		No.	0	0	0	0	0	0	0	0	0	0
		%	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

455

(CONTINUED)

* S.B.P. values => 160 mm Hg or <= 100 mm Hg
D.B.P. values => 100 mm Hg or <= 70 mm Hg
H.R. values => 100 beats/min or <= 50 beats/min

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA C550077
 REBOXETINE - PROTOCOL 20124/013

TABLE No.: 105

NUMBER AND PERCENTAGE OF SUBJECTS WITH VITAL SIGNS CHANGES OF CLINICAL RELEVANCE (=> 20 %) AS COMPARED TO VISIT -1, DOUBLE BLIND PHASE, ASSOCIATED TO CRITICAL VALUES (*)

REBOXETINE			VISIT NO.										
			34	36	38	40	42	44	46	48	50	52	
STANDING H.R.	DECREASE	%	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

* S.B.P. values => 160 mm Hg or <= 100 mm Hg
 D.B.P. values => 100 mm Hg or <= 70 mm Hg
 H.R. values => 100 beats/min or <= 50 beats/min

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA C9580077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 105

NUMBER AND PERCENTAGE OF SUBJECTS WITH VITAL SIGNS CHANGES OF CLINICAL RELEVANCE (=> 20 %) AS COMPARED TO VISIT -1, DOUBLE BLIND PHASE, ASSOCIATED TO CRITICAL VALUES (*)

PLACERO			VISIT NO.										
			1	2	3	4	5	6	8	10	12	14	
LYING S.B.P.	INCREASE	Evaluated	140	140	140	140	140	140	140	136	132	125	
		No.	1	0	1	2	3	1	1	4	2	3	
		%	0.7	0.0	0.7	1.4	2.1	0.7	0.7	2.9	1.5	2.4	
	DECREASE	Evaluated	140	140	140	140	140	140	140	136	132	125	
		No.	3	5	6	2	4	8	2	6	5	4	
		%	2.1	3.6	4.3	1.4	2.9	5.7	1.4	4.4	3.8	3.2	
LYING D.B.P.	INCREASE	Evaluated	140	140	140	140	140	140	140	136	132	125	
		No.	2	2	1	3	6	1	5	2	6	1	
		%	1.4	1.4	0.7	2.1	4.3	0.7	3.6	1.5	4.5	0.8	
	DECREASE	Evaluated	140	140	140	140	140	140	140	136	132	125	
		No.	4	7	5	4	5	4	2	5	5	10	
		%	2.9	5.0	3.6	2.9	3.6	2.9	1.4	3.7	3.8	8.0	
LYING H.R.	INCREASE	Evaluated	139	140	140	138	139	138	138	134	130	124	
		No.	9	10	10	14	10	13	6	5	4	5	
		%	6.5	7.1	7.1	10.1	7.2	9.4	4.3	3.7	3.1	4.0	
	DECREASE	Evaluated	139	140	140	138	139	138	138	134	130	124	
		No.	0	1	0	0	0	1	0	0	1	0	
		%	0.0	0.7	0.0	0.0	0.0	0.7	0.0	0.0	0.8	0.0	
STANDING S.B.P.	INCREASE	Evaluated	140	140	140	140	140	140	140	136	132	125	
		No.	1	0	0	0	1	0	2	3	1	3	
		%	0.7	0.0	0.0	0.0	0.7	0.0	1.4	2.2	0.8	2.4	
	DECREASE	Evaluated	140	140	140	140	140	140	140	136	132	125	
		No.	2	7	4	3	3	5	4	4	4	4	
		%	1.4	5.0	2.9	2.1	2.1	3.6	2.9	2.9	3.0	3.2	
STANDING D.B.P.	INCREASE	Evaluated	140	140	140	140	140	140	140	136	132	125	
		No.	0	0	1	2	3	1	4	4	4	1	
		%	0.0	0.0	0.7	1.4	2.1	0.7	2.9	2.9	3.0	0.8	
	DECREASE	Evaluated	140	140	140	140	140	140	140	136	132	125	
		No.	7	5	7	7	5	2	1	6	7	11	
		%	5.0	3.6	5.0	5.0	3.6	1.4	0.7	4.4	5.3	8.8	
STANDING H.R.	INCREASE	Evaluated	139	140	140	138	139	138	138	134	130	124	
		No.	16	18	18	17	15	17	10	9	7	11	
		%	11.5	12.9	12.9	12.3	10.8	12.3	7.2	6.7	5.4	8.9	
	DECREASE	Evaluated	139	140	140	138	139	138	138	134	130	124	
		No.	0	0	0	0	0	0	0	0	0	0	
		%	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	

(CONTINUED)

457

* S.B.P. values => 160 mm Hg or <= 100 mm Hg
D.B.P. values => 100 mm Hg or <= 70 mm Hg
H.R. values => 100 beats/min or <= 50 beats/min

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA C1580077
 REBOXETINE - PROTOCOL 20124/013

TABLE No.: 105

NUMBER AND PERCENTAGE OF SUBJECTS WITH VITAL SIGNS CHANGES OF CLINICAL RELEVANCE (\Rightarrow 20 %) AS COMPARED TO VISIT -1, DOUBLE BLIND PHASE, ASSOCIATED TO CRITICAL VALUES (*)

PLACEBO			VISIT NO.											
			1	2	3	4	5	6	8	10	12	14		
STANDING H.R.	DECREASE	%	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

(CONTINUED)

* S.B.P. values \Rightarrow 160 mm Hg or \leq 100 mm Hg
 D.B.P. values \Rightarrow 100 mm Hg or \leq 70 mm Hg
 H.R. values \Rightarrow 100 beats/min or \leq 50 beats/min

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

PHARMACIA CNE530077
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 105

NUMBER AND PERCENTAGE OF SUBJECTS WITH VITAL SIGNS CHANGES OF CLINICAL RELEVANCE (=> 20 %) AS COMPARED TO VISIT -1, DOUBLE BLIND PHASE, ASSOCIATED TO CRITICAL VALUES (*)

PLACERO			VISIT NO.									
			16	18	20	22	24	26	28	30	32	34
LYING S.B.P	INCREASE	Evaluated	122	114	106	100	95	91	88	83	80	79
		No.	2	1	0	1	2	1	1	1	0	0
		%	1.6	0.9	0.0	1.0	2.1	1.1	1.1	1.2	0.0	0.0
	DECREASE	Evaluated	122	114	106	100	95	91	88	83	80	79
		No.	4	5	2	4	2	1	3	2	4	2
		%	3.3	4.4	1.9	4.0	2.1	1.1	3.4	2.4	5.0	2.5
LYING D.B.P.	INCREASE	Evaluated	122	114	106	100	95	91	88	83	80	79
		No.	1	2	1	2	2	2	2	2	2	1
		%	0.8	1.8	0.9	2.0	2.1	2.2	2.3	2.4	2.5	1.3
	DECREASE	Evaluated	122	114	106	100	95	91	88	83	80	79
		No.	5	3	8	5	6	4	5	3	4	3
		%	4.1	2.6	7.5	5.0	6.3	4.4	5.7	3.6	5.0	3.8
LYING H.R.	INCREASE	Evaluated	121	114	106	99	94	90	87	82	80	78
		No.	3	5	3	1	4	2	2	1	3	2
		%	2.5	4.4	2.8	1.0	4.3	2.2	2.3	1.2	3.8	2.6
	DECREASE	Evaluated	121	114	106	99	94	90	87	82	80	78
		No.	1	1	1	0	0	0	0	0	0	0
		%	0.8	0.9	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0
STANDING S.B.P	INCREASE	Evaluated	122	114	106	100	95	91	88	83	80	79
		No.	2	0	0	1	1	0	1	1	0	0
		%	1.6	0.0	0.0	1.0	1.1	0.0	1.1	1.2	0.0	0.0
	DECREASE	Evaluated	122	114	106	100	95	91	88	83	80	79
		No.	4	6	2	5	4	3	2	1	1	1
		%	3.3	5.3	1.9	5.0	4.2	3.3	2.3	1.2	1.2	1.3
STANDING D.B.P.	INCREASE	Evaluated	122	114	106	100	95	91	88	83	80	79
		No.	3	2	1	5	2	1	2	2	1	1
		%	2.5	1.8	0.9	5.0	2.1	1.1	2.3	2.4	1.2	1.3
	DECREASE	Evaluated	122	114	106	100	95	91	88	83	80	79
		No.	7	8	5	5	4	8	10	7	7	6
		%	5.7	7.0	4.7	5.0	4.2	8.8	11.4	8.4	8.8	7.6
STANDING H.R.	INCREASE	Evaluated	121	114	106	99	94	90	87	81	80	78
		No.	4	7	4	5	4	4	3	2	3	2
		%	3.3	6.1	3.8	5.1	4.3	4.4	3.4	2.5	3.8	2.6
	DECREASE	Evaluated	121	114	106	99	94	90	87	81	80	78
		No.	0	0	0	0	0	0	0	0	0	0
		%	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

459

(CONTINUED)

* S.B.P. values => 160 mm Hg or <= 100 mm Hg
D.B.P. values => 100 mm Hg or <= 70 mm Hg
H.R. values => 100 beats/min or <= 50 beats/min

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA C5530077
 REBOXETINE - PROTOCOL 20124/013

TABLE No.: 105

NUMBER AND PERCENTAGE OF SUBJECTS WITH VITAL SIGNS CHANGES OF CLINICAL RELEVANCE (=> 20 %) AS COMPARED TO VISIT -1, DOUBLE BLIND PHASE, ASSOCIATED TO CRITICAL VALUES (*)

PLACEBO			VISIT NO.										
			16	18	20	22	24	26	28	30	32	34	
STANDING H.R.	DECREASE	%	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

(CONTINUED)

* S.B.P. values => 160 mm Hg or <= 100 mm Hg
 D.B.P. values => 100 mm Hg or <= 70 mm Hg
 H.R. values => 100 beats/min or <= 50 beats/min

PHARMACIA C550077
REBOXETINE - PROTOCOL 20124/013

TABLE No. : 105

NUMBER AND PERCENTAGE OF SUBJECTS WITH VITAL SIGNS CHANGES OF CLINICAL RELEVANCE (\Rightarrow 20 %) AS COMPARED TO VISIT -1, DOUBLE BLIND PHASE, ASSOCIATED TO CRITICAL VALUES (*)

PLACEBO			VISIT NO.									
			36	38	40	42	44	46	48	50	52	
LYING S.B.P	INCREASE	Evaluated	78	76	74	73	70	68	66	66	65	
		No.	0	1	0	0	1	0	0	0	1	
		%	0.0	1.3	0.0	0.0	1.4	0.0	0.0	0.0	1.5	
	DECREASE	Evaluated	78	76	74	73	70	68	66	66	65	
		No.	4	3			0	1	1	1	2	
		%	5.1	3.9			0.0	1.5	1.5	1.5	3.1	
LYING D.B.P.	INCREASE	Evaluated	78	76	74	73	70	68	66	66	65	
		No.	0	1	0	1	0	1	2	0	1	
		%	0.0	1.3	0.0	1.4	0.0	1.5	3.0	0.0	1.5	
	DECREASE	Evaluated	78	76	74	73	70	68	66	66	65	
		No.	4	5	5	2	4	2	5	4	5	
		%	5.1	6.6	6.8	2.7	5.7	2.9	7.6	6.1	7.7	
LYING H.R.	INCREASE	Evaluated	77	74	74	73	70	68	66	66	65	
		No.	1	2	1	2	1	1	1	1	1	
		%	1.3	2.7	1.4	2.7	1.4	1.5	1.5	1.5	1.5	
	DECREASE	Evaluated	77	74	74	73	70	68	66	66	65	
		No.	0	0	0	0	0	0	0	0	0	
		%	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
STANDING S.B.P	INCREASE	Evaluated	78	76	74	73	70	68	66	66	65	
		No.	0	0	0	0	1	0	0	0	0	
		%	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	
	DECREASE	Evaluated	78	76	74	73	70	68	66	66	65	
		No.	2	3		1		3	2	0	4	
		%	2.6	3.9		1.4		4.4	3.0	0.0	6.2	
STANDING D.B.P.	INCREASE	Evaluated	78	76	74	73	70	68	66	66	65	
		No.	1	1	0	2	1	0	1	1	1	
		%	1.3	1.3	0.0	2.7	1.4	0.0	1.5	1.5	1.5	
	DECREASE	Evaluated	78	76	74	73	70	68	66	66	65	
		No.	4	6	8	7	5	3	4	5	5	
		%	5.1	7.9	10.8	9.6	7.1	4.4	6.1	7.6	7.7	
STANDING H.R.	INCREASE	Evaluated	77	74	74	73	70	68	66	66	65	
		No.	3	4	2	3	5	0	1	1	1	
		%	3.9	5.4	2.7	4.1	7.1	0.0	1.5	1.5	1.5	
	DECREASE	Evaluated	77	74	74	73	70	68	66	66	65	
		No.	0	0	0	0	0	0	0	0	0	
		%	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	

(CONTINUED)

461

* S.B.P. values \Rightarrow 160 mm Hg or \leq 100 mm Hg
D.B.P. values \Rightarrow 100 mm Hg or \leq 70 mm Hg
H.R. values \Rightarrow 100 beats/min or \leq 50 beats/min

PHARMACIA CIPRO 0077
 REBOXETINE - PROTOCOL 20124/013

TABLE No.: 105

NUMBER AND PERCENTAGE OF SUBJECTS WITH VITAL SIGNS CHANGES OF CLINICAL RELEVANCE (=> 20 %) AS COMPARED TO VISIT -1, DOUBLE BLIND PHASE, ASSOCIATED TO CRITICAL VALUES (*)

PLACEBO			VISIT NO.								
			36	38	40	42	44	46	48	50	52
STANDING H.R.	DECREASE	%	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

* S.B.P. values => 160 mm Hg or <= 100 mm Hg
 D.B.P. values => 100 mm Hg or <= 70 mm Hg
 H.R. values => 100 beats/min or <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 106

NUMBER AND PERCENTAGE OF SUBJECTS WITH ORTHOSTATIC HYPOTENSION (*) - RANDOMIZED PATIENTS ONLY

TREATMENT REBOXETINE	VISIT NO.																			
	-1	0	1	2	3	4	5	6	8	10	16	20	22	24	38	42	44	50	52	
143	143	143	143	143	143	143	143	143	143	137	122	109	105	102	83	82	82	81	79	
No.	1	3	3	4	2	1	1	3	2	1	1	1	1	1	3	1	1	1	1	
Z	0.7	2.1	2.1	2.8	1.4	0.7	0.7	2.1	1.5	0.8	0.9	1.0	1.0	3.6	1.2	1.2	1.2	1.2	1.3	
MEAN	30.0	30.0	28.3	25.5	25.0	25.0	30.0	31.7	25.0	25.0	25.0	40.0	30.0	33.3	25.0	25.0	25.0	25.0	25.0	
MAX	30	30	30	30	25	25	30	40	25	25	25	40	30	50	25	25	25	25	25	

TREATMENT PLACEBO	VISIT NO.																			
	-1	0	1	2	3	5	6	8	10	14	20	22	24	30	38	46				
140	140	140	140	140	140	140	140	140	136	125	106	100	95	83	76	68				
No.	1	2	1	1	3	2	1	1	2	1	2	2	2	1	1	1				
Z	0.7	1.4	0.7	0.7	2.1	1.4	0.7	0.7	1.5	0.8	1.9	2.0	2.1	1.2	1.3	1.5				
MEAN	25.0	27.5	30.0	50.0	30.0	30.0	40.0	25.0	27.5	30.0	26.0	27.5	27.5	25.0	22.0	30.0				
MAX	25	30	30	50	30	30	40	25	30	30	30	30	30	25	22	30				

463

(*) ORTHOSTATIC HYPOTENSION: decrease of systolic blood pressure in Standing position > 20 mmHg as compared to Lying position

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CHS RED
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 107

VITAL SIGN: BODY WEIGHT - OPEN PHASE

	VISIT NO.						
	0	1	2	3	4	5	6
MEAN	66.73	66.57	68.74	66.42	66.31	65.38	66.39
STDEV	12.91	12.93	47.42	12.90	12.75	12.60	12.53
MEDIAN	65.00	65.00	65.00	65.00	65.00	65.00	65.50
MIN	41.00	41.00	40.00	41.00	41.00	41.00	41.00
MAX	126.00	126.00	925.00	123.00	122.00	121.00	121.00
N	358	358	354	349	337	328	322
MISS	0	0	0	0	0	0	2

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 108

VITAL SIGN: BODY WEIGHT - RANDOMIZED PATIENTS ONLY

REBOXETINE	VISIT NO.																				
	0	8	9	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44
MEAN	67.16	67.16	54.00	67.11	67.12	66.61	66.61	66.48	66.69	66.75	66.74	66.70	66.84	66.88	66.28	66.60	66.88	66.61	66.33	66.24	66.22
STDEV	13.38	13.40		13.47	13.35	13.15	13.24	13.32	13.29	13.12	13.20	13.24	13.32	13.41	12.44	12.40	12.57	12.42	12.19	12.18	12.08
MEDIAN	67.00	67.00	54.00	67.00	67.00	67.00	67.00	67.00	67.00	67.00	67.00	67.00	67.00	67.00	66.50	67.00	67.00	67.00	67.00	67.00	66.50
MIN	41.00	42.00	54.00	41.00	41.00	41.00	41.00	41.00	41.00	41.00	41.00	42.00	42.00	42.00	41.00	41.00	41.00	41.00	41.00	41.00	41.00
MAX	120.00	119.00	54.00	120.00	123.00	119.00	120.00	119.00	119.00	119.00	120.00	120.00	119.00	119.00	119.00	119.00	119.00	119.00	119.00	119.00	119.00
N	143	143	1	137	127	124	122	113	109	105	102	101	97	90	88	86	84	83	82	82	82
MISS	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0

(CONTINUED)

	VISIT NO.				
	46	48	50	52	
MEAN	66.44	66.56	66.60	66.51	
STDEV	12.00	12.09	12.05	11.97	
MEDIAN	67.00	67.00	67.00	67.00	
MIN	42.00	42.00	42.00	42.00	
MAX	119.00	118.00	118.00	118.00	
N	81	80	80	79	
MISS	0	1	0	0	

465

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 108

VITAL SIGN: BODY WEIGHT - RANDOMIZED PATIENTS ONLY

PLACEBO	VISIT NO.																				
	0	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46
MEAN	66.14	65.96	65.68	65.51	65.02	64.90	64.97	64.94	65.12	65.32	65.13	64.82	64.76	65.10	64.63	64.46	64.62	64.68	64.53	64.11	63.85
STDEV	11.64	11.90	11.62	11.70	11.16	11.24	11.54	11.62	11.64	11.13	11.32	11.31	11.28	11.18	10.28	10.27	10.30	10.40	10.38	10.31	10.50
MEDIAN	65.00	65.00	65.00	65.00	65.00	65.00	66.00	65.50	66.00	65.00	65.00	63.00	64.00	64.00	64.00	63.50	64.00	64.00	64.00	64.00	64.00
MIN	42.00	42.00	42.00	41.00	41.00	41.00	41.00	41.00	41.00	41.00	41.00	40.00	40.00	41.00	41.00	40.00	40.00	40.00	40.00	40.00	40.00
MAX	106.00	106.00	105.00	106.00	105.00	105.00	105.00	105.00	105.00	105.00	105.00	105.00	105.00	105.00	90.00	90.00	90.00	90.00	88.00	88.00	88.00
N	140	140	136	132	125	122	114	106	100	95	91	88	83	80	79	78	76	74	73	70	68
MISS	0	0	0	1	0	1	3	2	1	0	0	0	0	0	0	0	0	0	0	0	1

(CONTINUED)

	VISIT NO.		
	48	50	52
MEAN	63.83	63.77	63.91
STDEV	10.57	10.60	10.69
MEDIAN	64.00	63.50	64.00
MIN	40.00	41.00	41.00
MAX	88.00	88.00	88.00
N	66	66	65
MISS	0	0	0

466

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 109

VITAL SIGN: BODY TEMPERATURE - OPEN PHASE

	VISIT NO.						
	0	1	2	3	4	5	6
MEAN	36.40	36.41	36.40	36.41	36.40	36.42	36.39
STDEV	0.33	0.35	0.32	0.33	0.36	0.31	0.34
MEDIAN	36.40	36.40	36.40	36.40	36.40	36.40	36.40
MIN	35.40	35.30	35.30	35.20	35.00	35.20	35.00
MAX	37.70	38.00	37.30	37.30	37.30	37.70	37.50
N	356	358	354	349	337	328	321
MISS	0	0	0	0	0	0	3

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 110

VITAL SIGN: BODY TEMPERATURE - RANDOMIZED PATIENTS ONLY

REBOXETINE	VISIT NO.																																					
	0	1	2	3	4	5	6	8	9	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38														
MEAN	36.40	36.38	36.39	36.38	36.42	36.40	36.37	36.35	36.50	36.37	36.38	36.38	36.37	36.40	36.39	36.31	36.38	36.32	36.31	36.32	36.32	36.32	36.35	36.36	36.34													
STDEV	0.35	0.34	0.29	0.32	0.34	0.31	0.33	0.33	0.31	0.38	0.30	0.27	0.33	0.29	0.26	0.31	0.32	0.30	0.31	0.31	0.33	0.40	0.33	0.34														
MEDIAN	36.40	36.40	36.40	36.40	36.40	36.40	36.40	36.40	36.50	36.40	36.40	36.40	36.40	36.40	36.40	36.40	36.40	36.30	36.30	36.30	36.30	36.40	36.40															
MIN	35.40	35.50	35.60	35.20	35.40	35.20	35.00	35.20	36.50	35.20	35.20	35.30	35.40	35.40	35.30	35.60	35.30	35.30	35.30	35.30	35.30	35.60	35.60	35.50														
MAX	37.70	37.30	37.10	37.20	37.20	37.20	37.00	37.20	36.50	37.10	37.80	37.10	37.00	37.40	37.00	37.00	37.10	37.20	37.10	37.00	36.90	39.00	37.20	37.40														
N	143	143	143	143	143	143	142	143	1	137	127	124	122	113	109	104	102	101	97	90	88	86	84	83														
MISS	0	0	0	0	0	0	1	0	0	0	1	0	0	1	0	1	0	0	0	0	0	1	0	0														

(CONTINUED)

	VISIT NO.									
	40	42	44	46	48	50	52			
MEAN	36.32	36.34	36.30	36.32	36.30	36.28	36.28			
STDEV	0.36	0.31	0.34	0.33	0.33	0.33	0.32			
MEDIAN	36.30	36.40	36.30	36.40	36.30	36.30	36.30			
MIN	35.00	35.40	35.00	35.00	35.50	35.60	35.40			
MAX	37.20	37.00	37.10	37.00	37.20	37.20	37.00			
N	82	82	82	81	80	80	79			
MISS	0	0	0	0	1	0	0			

468

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD
REBOXETINE - PROTOCOL 20124/013

TABLE No.: 110

VITAL SIGN: BODY TEMPERATURE - RANDOMIZED PATIENTS ONLY

PLACEBO	VISIT NO.																							
	0	1	2	3	4	5	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40
MEAN	36.39	36.42	36.43	36.42	36.39	36.45	36.41	36.41	36.44	36.39	36.43	36.36	36.36	36.35	36.36	36.35	36.36	36.30	36.34	36.27	36.34	36.29	36.32	36.31
STDEV	0.32	0.35	0.35	0.34	0.37	0.33	0.39	0.37	0.38	0.32	0.33	0.31	0.35	0.35	0.35	0.33	0.34	0.30	0.29	0.35	0.29	0.34	0.38	0.31
MEDIAN	36.40	36.40	36.40	36.40	36.40	36.50	36.50	36.40	36.50	36.40	36.50	36.40	36.35	36.40	36.40	36.40	36.30	36.30	36.30	36.30	36.30	36.30	36.30	36.30
MIN	35.40	35.30	35.30	35.40	35.00	35.30	35.00	35.00	35.10	35.20	35.20	35.20	35.20	35.20	35.20	35.50	35.50	35.50	35.50	34.50	35.60	35.30	35.40	35.50
MAX	37.10	38.00	37.30	37.10	37.30	37.70	37.50	37.40	37.20	37.50	37.20	37.10	37.00	37.00	37.00	37.00	37.30	37.00	37.60	37.10	37.00	37.00	38.00	37.00
N	140	140	140	140	140	140	140	140	136	132	125	122	114	106	100	95	91	88	83	80	79	78	76	74
MISS	0	0	0	0	0	0	0	0	0	1	0	1	3	2	1	0	0	0	0	0	0	0	0	0

(CONTINUED)

	VISIT NO.					
	42	44	46	48	50	52
MEAN	36.30	36.29	36.30	36.27	36.25	36.29
STDEV	0.27	0.27	0.28	0.29	0.26	0.29
MEDIAN	36.30	36.30	36.30	36.30	36.20	36.30
MIN	35.60	35.60	35.60	35.50	35.60	35.50
MAX	37.00	36.90	36.80	36.80	36.80	36.80
N	73	70	68	66	66	65
MISS	0	0	1	0	0	0

469

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 TABLE No.: 111
 E.C.G.: NUMBER AND PERCENTAGE OF PATIENTS WITH ABNORMAL E.C.G. ACCORDING TO TIME INTERVALS BY SEX
 OPEN PHASE

Sex	Eval.	Screen		weeks 0-2	weeks 3-4	weeks 5-6
		No.	%			
Female	Eval.	262		260	243	236
	Normal	219		230	205	200
	%	83.59		88.46	84.36	84.75
Male	Abnormal	43		30	38	36
	Eval.	16.41		11.54	15.64	15.25
	%	93		90	89	83
Total	Normal	80		73	76	74
	Eval.	86.02		81.11	85.39	89.16
	%	13		17	13	9
Total	Abnormal	13.98		18.89	14.61	10.84
	Eval.	355		350	332	319
	Normal	299		303	281	274
Total	Abnormal	84.23		86.57	84.64	85.89
	Eval.	56		47	51	45
	%	15.77		13.43	15.36	14.11

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 112

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH NORMAL OR ABNORMAL E.C.G. VALUE AT EACH EVALUATION TIME AS COMPARED TO PRETREATMENT EVALUATION OPEN PHASE

E.C.G. at Baseline	Time interval									
	weeks 0-2		weeks 3-4		weeks 3-4		weeks 5-6		weeks 5-6	
	Abnormal	Normal	Abnormal	Normal	Abnormal	Normal	Abnormal	Normal	Abnormal	Normal
No.	25	28	30	23	23	23	28	28		
%	47.2	52.8	56.6	43.4	43.4	45.1	54.9	54.9		
No.	22	275	21	258	22	246	246	246		
%	7.4	92.6	7.5	92.5	8.2	91.8	91.8	91.8		
No.	47	303	51	281	45	274	274	274		
%	13.4	86.6	15.4	84.6	14.1	85.9	85.9	85.9		

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 TABLE No.: 113
 E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH NORMAL OR ABNORMAL E.C.G. VALUE AT LAST ASSESSMENT AS COMPARED TO PRETREATMENT EVALUATION OPEN PHASE

E.C.G. at Baseline	Last assessment							
	Abnormal			Normal			Total	
	No.	%	No.	%	No.	%	No.	%
Abnormal	26	46.4	30	53.6	56	100.0		
Normal	27	9.0	272	91.0	299	100.0		
Total	53	14.9	302	85.1	355	100.0		

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013

TABLE No.: 114

E.C.G.: NUMBER AND PERCENTAGE OF E.C.G. ABNORMALITIES OBSERVED DURING THE STUDY OPEN PHASE

E.C.G. abnormality type	Screen		weeks 0-2		weeks 3-4		weeks 5-6	
	No	Z	No	Z	No	Z	No	Z
Evaluated Pt	355	100.0	350	100.0	332	100.0	319	100.0
A-V BLOCK 1ST DEGREE	1	0.3	4	1.1	3	0.9	1	0.3
CONDUCTION DISORDER			2	0.6				
LEFT AXIAL DEVIATION	1	0.3			1	0.3	1	0.3
LEFT BUNDLE BRANCH BLOCK			1	0.3	1	0.3	1	0.3
LEFT POSTERIOR HEMIBLOCK	1	0.3						
LEFT VENTRICULAR HYPERTROPHY	1	0.3	1	0.3	1	0.3	1	0.3
MYOCARDIAL ISCHEMIA	4	1.1	1	0.3	2	0.6	1	0.3
NON SPECIFIC ST-T WAVE CHANGES	14	3.9	15	4.3	16	4.8	12	3.8
OTHER	4	1.1	2	0.6	2	0.6	2	0.6
PREVIOUS MYOCARDIAL INFARCTION	1	0.3	1	0.3	1	0.3	1	0.3
RIGHT AXIAL DEVIATION	1	0.3	1	0.3	1	0.3		
RIGHT BUNDLE BRANCH BLOCK	2	0.6						
RIGHT INCOMPLETE BUNDLE BRANCH	10	2.8	8	2.3	9	2.7	10	3.1
RIGHT VENTRICULAR HYPERTROPHY	3	0.8	1	0.3	1	0.3	1	0.3
RIPOLARIZATION DISTURBANCES			1	0.3	2	0.6	2	0.6
SINUS BRADYCARDIA (< 60)	3	0.8	1	0.3	3	0.9	3	0.9
SINUS TACHYCARDIA (> 100)	18	5.1	15	4.3	13	3.9	14	4.4
VENTRICULAR ECTOPIC BEATS - OC	1	0.3	2	0.6	1	0.3	2	0.6

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013

TABLE No.: 115

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT AS COMPARED TO PRETREATMENT EVALUATION OPEN PHASE

E.C.G. Abnormality at Baseline	Last assessment									
	Absent			Present			Total			
	No	%	z	No	%	z	No	%	z	
A-V BLOCK 1ST DEGREE	Absent	352	99.4	2	0.6	100.0	354	100.0		
	Present	1	100.0			1	100.0			
	Total	353	99.4	2	0.6	355	100.0			
LEFT AXIAL DEVIATION	Absent	354	100.0			354	100.0			
	Present			1	100.0	1	100.0			
	Total	354	99.7	1	0.3	355	100.0			
LEFT BUNDLE BRANCH BLOCK	Absent	354	99.7	1	0.3	355	100.0			
	Present									
	Total	354	99.7	1	0.3	355	100.0			
LEFT POSTERIOR HEMIBLOCK	Absent	354	100.0			354	100.0			
	Present	1	100.0			1	100.0			
	Total	355	100.0			355	100.0			
LEFT VENTRICULAR HYPERTROPHY	Absent	354	100.0			354	100.0			
	Present			1	100.0	1	100.0			
	Total	354	99.7	1	0.3	355	100.0			
MYOCARDIAL ISCHEMIA	Absent	351	100.0			351	100.0			
	Present	3	75.0	1	25.0	4	100.0			
	Total	354	99.7	1	0.3	355	100.0			
NON SPECIFIC ST-T WAVE CHANGES	Absent	337	98.8	4	1.2	341	100.0			
	Present	5	35.7	9	64.3	14	100.0			
	Total	342	96.3	13	3.7	355	100.0			
OTHER	Absent	351	100.0			351	100.0			

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R2D
 REBOXETINE - PROTOCOL 20124/013
 TABLE No.: 115
 E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT AS COMPARED TO PRETREATMENT EVALUATION OPEN PHASE

E.C.G. Abnormality at Baseline	Last assessment						Total		
	Absent			Present			No	%	Z
	No	%	Z	No	%	Z			
OTHER	Present	2	50.0	2	50.0	4	100.0		
	Total	353	99.4	2	0.6	355	100.0		
PREVIOUS MYOCARDIAL INFARCTION	Absent	354	100.0			354	100.0		
	Present			1	100.0	1	100.0		
	Total	354	99.7	1	0.3	355	100.0		
RIGHT AXIAL DEVIATION	Absent	354	100.0			354	100.0		
	Present			1	100.0	1	100.0		
	Total	354	99.7	1	0.3	355	100.0		
RIGHT BUNDLE BRANCH BLOCK	Absent	353	100.0			353	100.0		
	Present	2	100.0			2	100.0		
	Total	355	100.0			355	100.0		
RIGHT INCOMPLETE BUNDLE BRANCH BLOCK	Absent	342	99.1	3	0.9	345	100.0		
	Present	1	10.0	9	90.0	10	100.0		
	Total	343	96.6	12	3.4	355	100.0		
RIGHT VENTRICULAR HYPERTROPHY	Absent	352	100.0			352	100.0		
	Present	2	66.7	1	33.3	3	100.0		
	Total	354	99.7	1	0.3	355	100.0		
RIPOLARIZATION DISTURBANCES	Absent	353	99.4	2	0.6	355	100.0		
	Present								
	Total	353	99.4	2	0.6	355	100.0		
SINUS BRADYCARDIA (< 60)	Absent	350	99.4	2	0.6	352	100.0		
	Present	2	66.7	1	33.3	3	100.0		

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 115

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT AS COMPARED TO PRETREATMENT EVALUATION OPEN PHASE

E.C.G. Abnormality at Baseline	Last assessment							
	Absent		Present		Total			
	No	%	No	%	No	%		
SINUS BRADYCARDIA (< 60)	Total	352	99.2	3	0.8	355	100.0	
	Absent	321	95.3	16	4.7	337	100.0	
	Present	16	88.9	2	11.1	18	100.0	
SINUS TACHYCARDIA (> 100)	Total	337	94.9	18	5.1	355	100.0	
	Absent	352	99.4	2	0.6	354	100.0	
	Present	1	100.0			1	100.0	
VENTRICULAR ECTOPIC BEATS - OCCASIONAL	Total	353	99.4	2	0.6	355	100.0	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
 REBOXETINE - PROTOCOL 20124/013
 TABLE No.: 116
 E.C.G.: NUMBER AND PERCENTAGE PATIENTS WITH AT LEAST ONE ABNORMALITY BY ABNORMALITY GROUP, OBSERVED DURING THE STUDY
 OPEN PHASE

Group of abnormalities	Screen		weeks 0-2		weeks 3-4		weeks 5-6	
	No	%	No	%	No	%	No	%
Evaluated Pt.	355	100.0	350	100.0	332	100.0	319	100.0
Rhythm disorders	22	6.2	18	5.1	17	5.1	19	6.0
Conduction disorders	15	4.2	14	4.0	13	3.9	12	3.8
Ischemic signs	18	5.1	17	4.9	20	6.0	15	4.7
Other disorders	10	2.8	6	1.7	6	1.8	5	1.6

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 2012A/013
TABLE No.: 117

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES GROUPED BY TYPE AT LAST ASSESSMENT AS COMPARED TO PRETREATMENT EVALUATION OPEN PHASE

E.C.G. Abnormality at Baseline	Last Assessment						
	Absent		Present		Total		
	No	%	No	%	No	%	
Rhythm disorders	Absent	313	94.0	20	6.0	333	100.0
	Present	19	86.4	3	13.6	22	100.0
	Total	332	93.5	23	6.5	355	100.0
Conduction disorders	Absent	335	98.5	5	1.5	340	100.0
	Present	5	33.3	10	66.7	15	100.0
	Total	340	95.8	15	4.2	355	100.0
Ischemic signs	Absent	331	98.2	6	1.8	337	100.0
	Present	8	44.4	10	55.6	18	100.0
	Total	339	95.5	16	4.5	355	100.0
Other disorders	Absent	345	100.0			345	100.0
	Present	4	40.0	6	60.0	10	100.0
	Total	349	98.3	6	1.7	355	100.0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 TABLE No.: 11B
 E.C.G.: NUMBER AND PERCENTAGE OF PATIENTS WITH ABNORMAL E.C.G. ACCORDING TO TIME INTERVALS BY ASSIGNED TREATMENT AND SEX
 DOUBLE BLIND PHASE

Treatments: Roboxetine

Sex	Eval.	No.	Run In Phase					Double Blind Phase				
			Screen	weeks 0-2	3-4	5-6	7-10	11-18	19-26	27-34	35-42	43-52
Female	Eval.	110	109	108	109	109	109	87	78	70	66	64
	Normal	No.	92	99	98	95	94	81	73	63	56	60
	%	83.64	90.83	90.74	87.16	86.24	93.10	93.59	90.00	84.85	93.75	
Male	Abnormal	No.	18	10	10	14	15	6	5	7	10	4
	Eval.	No.	16.36	9.17	9.26	12.84	13.76	6.90	6.41	10.00	15.15	6.25
	%	14.73	8.17	8.28	11.68	12.52	6.70	6.41	6.70	10.00	15.15	6.25
Total	Normal	No.	25	25	25	25	24	21	19	17	16	14
	Eval.	No.	21	18	20	20	22	17	17	16	15	13
	%	84.00	72.00	80.00	80.00	91.67	80.95	89.47	94.12	93.75	92.86	
Total	Abnormal	No.	4	7	5	5	2	4	2	1	1	1
	Eval.	No.	16.00	28.00	20.00	20.00	8.33	19.05	10.53	5.88	6.25	7.14
	%	14.55	24.44	17.78	17.78	7.41	16.67	14.29	12.50	5.56	6.25	7.14
Total	Normal	No.	135	134	133	134	133	108	97	87	82	78
	Eval.	No.	113	117	118	115	116	98	90	79	71	73
	%	83.70	87.31	88.72	85.82	87.22	90.74	92.78	90.80	86.59	93.59	
Total	Abnormal	No.	22	17	15	19	17	10	7	8	11	5
	Eval.	No.	16.30	12.69	11.28	14.18	12.78	9.26	7.22	9.20	13.41	6.41
	%	14.55	10.99	8.53	10.56	9.19	7.99	6.41	5.56	4.76	6.25	7.14

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 TABLE No.: 118
 E.C.G.: NUMBER AND PERCENTAGE OF PATIENTS WITH ABNORMAL E.C.G. ACCORDING TO TIME INTERVALS BY ASSIGNED TREATMENT AND SEX
 DOUBLE BLIND PHASE

Treatments: Placebo

Sex	Eval.	No.	Run In Phase						Double Blind Phase					
			Screen	weeks 0-2	weeks 3-4	weeks 5-6	weeks 7-10	weeks 11-18	weeks 19-26	weeks 27-34	weeks 35-42	weeks 43-52		
Female	Eval.	93	92	90	93	92	76	62	57	50	46			
	Normal	No.	75	78	69	74	83	69	54	49	41			
	%	80.65	84.78	76.67	79.57	90.22	90.79	87.10	85.96	94.00	89.13			
Male	Abnormal	No.	18	14	21	19	9	7	8	3	5			
	Eval.	No.	19.35	15.22	23.33	20.43	9.78	9.21	12.90	14.04	6.00			
	%	42	41	42	42	41	33	29	21	21	19			
Total	Normal	No.	38	37	38	39	37	30	24	17	16			
	Eval.	%	90.48	90.24	90.48	92.86	90.24	90.91	82.76	80.95	90.48			
	%	4	4	4	3	4	3	5	4	2	3			
Total	Abnormal	%	9.52	9.76	9.52	7.14	9.76	9.09	17.24	19.05	9.52			
	Eval.	No.	135	133	132	135	133	109	91	78	65			
	%	113	115	107	113	120	99	78	66	66	57			
Total	Abnormal	%	83.70	86.47	81.06	83.70	90.23	90.83	85.71	84.62	92.96			
	Eval.	No.	22	18	25	22	13	10	13	12	8			
	%	16.30	13.53	18.94	16.30	9.77	9.17	14.29	15.38	7.04	12.31			

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 119

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH NORMAL OR ABNORMAL E.C.G. VALUE AT EACH EVALUATION TIME AS COMPARED TO PRETREATMENT EVALUATION DOUBLE BLIND PHASE

E.C.G. at Baseline		Time Interval																							
		Run In Phase												Double Blind Phase											
		weeks 0-2		weeks 3-4		weeks 5-6		weeks 7-10		weeks 11-18		weeks 19-26		weeks 27-34		weeks 35-42		weeks 43-52							
	No.	Abno.	Norm.	Abno.	Norm.	Abno.	Norm.	Abno.	Norm.	Abno.	Norm.	Abno.	Norm.	Abno.	Norm.	Abno.	Norm.	Abno.	Norm.	Abno.	Norm.	Abno.	Norm.		
Placebo	Abnormal	10	10	15	6	12	10	8	13	8	8	7	7	7	5	4	7	5	4	7	5	4	5	4	
	%	50.0	50.0	71.4	28.6	54.5	45.5	38.1	61.9	50.0	50.0	50.0	58.3	41.7	36.4	63.6	55.6	44.4	44.4	55.6	44.4	55.6	44.4	44.4	
	Normal	8	105	10	101	10	103	5	107	2	91	6	71	5	61	1	59	3	53	3	53	3	53	3	
Total	No.	18	115	25	107	22	113	13	120	10	99	13	78	12	66	5	66	8	57	8	57	8	57	8	
	%	13.5	86.5	18.9	81.1	16.3	83.7	9.8	90.2	9.2	90.8	14.3	85.7	15.4	84.6	7.0	93.0	12.3	87.7	7.0	93.0	12.3	87.7	7.0	
	Abnormal	9	13	10	12	9	13	9	13	6	10	3	9	6	7	6	5	2	7	6	5	2	7	6	
Reboxetine	No.	40.9	59.1	45.5	54.5	40.9	59.1	40.9	59.1	37.5	62.5	25.0	75.0	46.2	53.8	54.5	45.5	22.2	77.8	54.5	45.5	22.2	77.8	54.5	
	%	40.9	59.1	45.5	54.5	40.9	59.1	40.9	59.1	37.5	62.5	25.0	75.0	46.2	53.8	54.5	45.5	22.2	77.8	54.5	45.5	22.2	77.8	54.5	
	Normal	8	104	5	106	10	102	8	103	4	88	4	81	2	72	5	66	3	66	5	66	3	66	3	
Total	No.	17	117	15	118	19	115	17	116	10	98	7	90	8	79	11	71	5	73	11	71	5	73	11	
	%	12.7	87.3	11.3	88.7	14.2	85.8	12.8	87.2	9.3	90.7	7.2	92.8	9.2	90.8	13.4	86.6	6.4	93.6	9.2	90.8	13.4	86.6	6.4	
	Abnormal	17	117	15	118	19	115	17	116	10	98	7	90	8	79	11	71	5	73	11	71	5	73	11	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 TABLE No.: 120
 E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH NORMAL OR ABNORMAL E.C.G. VALUE AT LAST ASSESSMENT AS COMPARED TO PRETREATMENT EVALUATION DOUBLE BLIND PHASE

E.C.G. at Baseline	Last assessment						Total	
	Abnormal		Normal				No.	%
	No.	%	No.	%	No.	%		
Placebo	9	40.9	13	59.1	22	100.0		
	5	4.4	108	95.6	113	100.0		
Total	14	10.4	121	89.6	135	100.0		
Reboxetine	6	27.3	16	72.7	22	100.0		
	7	6.2	106	93.8	113	100.0		
Total	13	9.6	122	90.4	135	100.0		

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
TABLE No.: 121

E.C.G.: NUMBER AND PERCENTAGE OF E.C.G. ABNORMALITIES OBSERVED DURING THE STUDY
DOUBLE BLIND PHASE

Assigned treatment: Reboxetine

E.C.G. abnormality type	Run In Phase												Double Blind Phase											
	Screen		weeks 0-2		weeks 3-4		weeks 5-6		weeks 7-10		weeks 11-18		weeks 19-26		weeks 27-34		weeks 35-42		weeks 43-52					
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%				
Evaluated Pt	135	100.0	134	100.0	133	100.0	134	100.0	133	100.0	108	100.0	97	100.0	87	100.0	82	100.0	78	100.0				
A-V BLOCK 1ST DEGREE			1	0.7	1	0.8																		
LEFT VENTRICULAR HYPERTROPHY	1	0.7	1	0.7	1	0.8	1	0.7	1	0.8	1	0.9												
MYOCARDIAL ISCHEMIA	3	2.2	1	0.7	1	0.8	1	0.7	1	0.8	1	0.9	1	1.0	1	1.1	1	1.2						
NON SPECIFIC ST-T WAVE CHANGES	6	4.4	5	3.7	6	4.5	6	4.5	5	3.8	2	1.9	1	1.0	4	4.6	4	4.9	1	1.3				
OTHER	2	1.5			1	0.8	1	0.7	1	0.8	1	0.9	1	1.0			1	1.2						
PREVIOUS MYOCARDIAL INFARCTION	1	0.7	1	0.7	1	0.8	1	0.7	1	0.8	1	0.9	1	1.0	1	1.1	1	1.2						
RIGHT BUNDLE BRANCH BLOCK	1	0.7																						
RIGHT INCOMPLETE BUNDLE BRANCH	2	1.5	2	1.5	4	3.0	4	3.0	3	2.3			2	2.1	1	1.1	2	2.4	2	2.6				
RIGHT VENTRICULAR HYPERTROPHY	1	0.7																						
BIPOHARIZATION DISTURBANCES			1	0.7	1	0.8	2	1.5	1	0.8	1	0.9					1	1.2						
SINUS BRADYCARDIA (< 60)	1	0.7					1	0.7	1	0.8	1	0.9												
SINUS TACHYCARDIA (> 100)	7	5.2	8	6.0	2	1.5	6	4.5	6	4.5	2	1.9	3	3.1	2	2.5	2	2.4	2	2.6				
VENTRICULAR ECTOPIC BEATS OC	1	0.7																						

1-
CO
CS

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 121

E.C.G.: NUMBER AND PERCENTAGE OF E.C.G. ABNORMALITIES OBSERVED DURING THE STUDY
DOUBLE BLIND PHASE

Assigned treatment: Placebo

E.C.G. abnormality type	Run In Phase												Double Blind Phase											
	Screen		weeks 0-2		weeks 3-4		weeks 5-6		weeks 7-10		weeks 11-18		weeks 19-26		weeks 27-34		weeks 35-42		weeks 43-52					
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%				
Evaluated Pt	135	100.0	133	100.0	132	100.0	135	100.0	133	100.0	109	100.0	91	100.0	78	100.0	71	100.0	65	100.0				
A-V BLOCK 1ST DEGREE	1	0.7	1	0.8	1	0.8							1	1.1	1	1.3								
CONDUCTION DISORDER								1	0.8										1	1.5				
LEFT AXIAL DEVIATION	1	0.7			1	0.8	1	0.7	1	0.8	1	0.9	1	1.1	1	1.3	1	1.4	1	1.5				
LEFT BUNDLE BRANCH BLOCK									1	0.8	1	0.9												
MYOCARDIAL ISCHEMIA																	1	1.4						
NON SPECIFIC ST-T WAVE CHANGES	5	3.7	6	4.5	8	6.1	4	3.0	3	2.3	1	0.9					1	1.3		1				
OTHER	1	0.7	2	1.5	1	0.8	1	0.7	1	0.8	1	0.9	1	1.1	1	1.3	1	1.4	1	1.5				
RIGHT AXIAL DEVIATION																								
RIGHT BUNDLE BRANCH BLOCK	1	0.7							1	0.8														
RIGHT INCOMPLETE BUNDLE BRANCH	5	3.7	4	3.0	4	3.0	6	4.4	2	1.5	4	3.7	3	3.3	3	3.8	2	2.8	3	4.6				
RIGHT VENTRICULAR HYPERTROPHY	1	0.7	1	0.8	1	0.8	1	0.7									1	1.3	1	1.5				
BIPOLARIZATION DISTURBANCES					1	0.8							1	1.1	1	1.3			1	1.5				
SICK SINUS SYNDROME									1	0.8														
SINUS BRADYCARDIA (< 60)	2	1.5	1	0.8	2	1.5	2	1.5	2	1.5	2	1.8	5	5.5	2	2.6								
SINUS TACHYCARDIA (> 100)	6	4.4	4	3.0	7	5.3	8	5.9	2	1.5			2	2.2	1	1.3								
VENTRICULAR ECTOPIC BEATS																								
OC			1	0.8	1	0.8	1	0.7																

121

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 122

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT AS COMPARED TO PRETREATMENT EVALUATION
DOUBLE BLIND PHASE

Assigned treatment: Reboxetine

E.C.G. Abnormality at Baseline	Last Assessment						
	Absent		Present		Total		
	No	%	No	%	No	%	
A-V BLOCK 1ST DEGREE	Absent	135	100.0			135	100.0
	Total	135	100.0			135	100.0
CONDUCTION DISORDER	Absent	135	100.0			135	100.0
	Total	135	100.0			135	100.0
LEFT AXIAL DEVIATION	Absent	135	100.0			135	100.0
	Total	135	100.0			135	100.0
LEFT VENTRICULAR HYPERTROPHY	Absent	134	100.0			134	100.0
	Present			1	100.0	1	100.0
Total		134	99.3	1	0.7	135	100.0
	Absent	132	100.0			132	100.0
MYOCARDIAL ISCHEMIA	Present	2	66.7	1	33.3	3	100.0
	Total	134	99.3	1	0.7	135	100.0
NON SPECIFIC ST-T WAVE CHANGES	Absent	129	100.0			129	100.0
	Present	4	66.7	2	33.3	6	100.0
Total		133	98.5	2	1.5	135	100.0
	Absent	132	99.2	1	0.8	133	100.0
OTHER	Present	2	100.0			2	100.0
	Total	134	99.3	1	0.7	135	100.0
PREVIOUS MYOCARDIAL INFARCTION	Absent	134	100.0			134	100.0
	Present			1	100.0	1	100.0
Total	134	99.3	1	0.7	135	100.0	

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 TABLE No.: 122
 E.C.G.: SHEFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT AS COMPARED TO PRETREATMENT EVALUATION DOUBLE BLIND PHASE

Assigned treatment: Reboxetine

E.C.G. Abnormality at Baseline	Last Assessment					
	Absent			Present		
	No	Z	%	No	Z	%
RIGHT BUNDLE BRANCH BLOCK	Absent	134	100.0			
	Present	1	100.0			
	Total	135	100.0			
RIGHT INCOMPLETE BUNDLE BRANCH BLOCK	Absent	131	98.5	2	1.5	
	Present			2	100.0	
	Total	131	97.0	4	3.0	
RIGHT VENTRICULAR HYPERTROPHY	Absent	134	100.0			
	Present	1	100.0			
	Total	135	100.0			
RIPOLARIZATION DISTURBANCES	Absent	134	99.3	1	0.7	
	Present					
	Total	134	99.3	1	0.7	
SINUS BRADYCARDIA (< 60)	Absent	134	100.0			
	Present	1	100.0			
	Total	135	100.0			
SINUS TACHYCARDIA (> 100)	Absent	125	97.7	3	2.3	
	Present	7	100.0			
	Total	132	97.8	3	2.2	
VENTRICULAR ECTOPIC BEATS - OCCASIONAL	Absent	134	100.0			
	Present	1	100.0			
	Total	135	100.0			

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
TABLE No.: 122

E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT AS COMPARED TO PRETREATMENT EVALUATION DOUBLE BLIND PHASE

Assigned treatment: Placebo

E.C.G. Abnormality at Baseline	Last Assessment						Total		
	Absent		Present		Total		Total		
	No	Z	No	Z	No	Z	No	Z	
A-V BLOCK 1ST DEGREE	Absent	134	100.0					134	100.0
	Present			1	100.0			1	100.0
	Total	134	99.3	1	0.7	135	100.0	135	100.0
CONDUCTION DISORDER	Absent	134	99.3	1	0.7	135	100.0		
	Present								
	Total	134	99.3	1	0.7	135	100.0		
LEFT AXIAL DEVIATION	Absent	134	99.3	1	0.7	135	100.0		
	Present								
	Total	134	99.3	1	0.7	135	100.0		
LEFT VENTRICULAR HYPERTROPHY	Absent	135	100.0			135	100.0		
	Present			1	100.0			1	100.0
	Total	135	100.0	1	0.7	135	100.0	135	100.0
MYOCARDIAL ISCHEMIA	Absent	135	100.0			135	100.0		
	Present								
	Total	135	100.0			135	100.0		
NON SPECIFIC ST-T WAVE CHANGES	Absent	129	99.2	1	0.8	130	100.0		
	Present	3	60.0	2	40.0	5	100.0		
	Total	132	97.8	3	2.2	135	100.0		
OTHER	Absent	133	99.3	1	0.7	134	100.0		
	Present			1	100.0			1	100.0
	Total	133	98.5	2	1.5	135	100.0		
PREVIOUS MYOCARDIAL INFARCTION	Absent	135	100.0			135	100.0		
	Present								
	Total	135	100.0			135	100.0		

(CONTINUED)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 TABLE No.: 122
 E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES AT LAST ASSESSMENT AS COMPARED TO PRETREATMENT EVALUATION DOUBLE BLIND PHASE

Assigned treatment: Placebo

E.C.G. Abnormality at Baseline	Last Assessment						Total		
	Absent		Present		Total		Total		
	No	%	No	%	No	%	No	%	
RIGHT BUNDLE BRANCH BLOCK	Absent	134	100.0			134	100.0		
	Present	1	100.0			1	100.0		
	Total	135	100.0			135	100.0		
RIGHT INCOMPLETE BUNDLE BRANCH BLOCK	Absent	129	99.2	1	0.8	130	100.0		
	Present	3	60.0	2	40.0	5	100.0		
	Total	132	97.8	3	2.2	135	100.0		
RIGHT VENTRICULAR HYPERTROPHY	Absent	134	100.0			134	100.0		
	Present			1	100.0	1	100.0		
	Total	134	99.3	1	0.7	135	100.0		
RIPOLARIZATION DISTURBANCES	Absent	134	99.3	1	0.7	135	100.0		
	Present								
	Total	134	99.3	1	0.7	135	100.0		
SINUS BRADYCARDIA (< 60)	Absent	132	99.2	1	0.8	133	100.0		
	Present	1	50.0	1	50.0	2	100.0		
	Total	133	98.5	2	1.5	135	100.0		
SINUS TACHYCARDIA (> 100)	Absent	129	100.0			129	100.0		
	Present	6	100.0			6	100.0		
	Total	135	100.0			135	100.0		
VENTRICULAR ECTOPIC BEATS - OCCASIONAL	Absent	135	100.0			135	100.0		
	Present								
	Total	135	100.0			135	100.0		

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 TABLE No.: 123
 E.C.G.: NUMBER AND PERCENTAGE OF E.C.G. ABNORMALITIES, COLLECTED BY GROUP, OBSERVED DURING THE STUDY
 DOUBLE BLIND PHASE

Assigned treatment: Reboxetine

Group of abnormalities	Run In Phase												Double Blind Phase											
	Screen		weeks 0-2		weeks 3-4		weeks 5-6		weeks 7-10		weeks 11-18		weeks 19-26		weeks 27-34		weeks 35-42		weeks 43-52					
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%				
Evaluated Pt.	135	100.0	134	100.0	133	100.0	134	100.0	133	100.0	108	100.0	97	100.0	87	100.0	82	100.0	78	100.0				
Rhythm disorders	9	6.7	8	6.0	2	1.5	7	5.2	7	5.3	3	2.8	3	3.1	2	2.3	2	2.4	2	2.6				
Conduction disorders	3	2.2	3	2.2	5	3.8	4	3.0	3	2.3			2	2.1	1	1.1	2	2.4	2	2.6				
Ischemic signs	9	6.7	7	5.2	8	6.0	9	6.7	7	5.3	4	3.7	2	2.1	5	5.7	6	7.3	1	1.3				
Other disorders	5	3.7	2	1.5	3	2.3	3	2.2	3	2.3	3	2.8	2	2.1	1	1.1	2	2.4						

687

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 TABLE No.: 123
 E.C.G.: NUMBER AND PERCENTAGE OF E.C.G. ABNORMALITIES, COLLECTED BY GROUP, OBSERVED DURING THE STUDY
 DOUBLE BLIND PHASE

Assigned treatment: Placebo

Group of abnormalities	Run In Phase												Double Blind Phase											
	Screen		weeks 0-2		weeks 3-4		weeks 5-6		weeks 7-10		weeks 11-18		weeks 19-26		weeks 27-34		weeks 35-42		weeks 43-52					
	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%	No	%				
Evaluated Pt.	135	100.0	133	100.0	132	100.0	135	100.0	133	100.0	109	100.0	91	100.0	78	100.0	71	100.0	65	100.0				
Rhythm disorders	8	5.9	6	4.5	10	7.6	11	8.1	5	3.8	2	1.8	7	7.7	3	3.8								
Conduction disorders	8	5.9	5	3.8	6	4.5	7	5.2	5	3.8	6	5.5	5	5.5	5	6.4	3	4.2	5	7.7				
Ischemic signs	5	3.7	6	4.5	9	6.8	4	3.0	3	2.3	1	0.9	1	1.1	2	2.6	1	1.4	2	3.1				
Other disorders	2	1.5	3	2.3	2	1.5	2	1.5	2	1.5	1	0.9	1	1.1	2	2.6	2	2.8	2	3.1				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 TABLE No.: 124
 E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES GROUPED BY TYPE AT LAST ASSESSMENT AS COMPARED TO PRETREATMENT EVALUATION
 DOUBLE BLIND PHASE

Assigned treatment: Reboxetine

E.C.G. Abnormality at Baseline	Last Assessment						
	Absent		Present		Total		
	No	%	No	%	No	%	
Rhythm disorders	Absent	123	97.6	3	2.4	126	100.0
	Present	9	100.0			9	100.0
	Total	132	97.8	3	2.2	135	100.0
Conduction disorders	Absent	130	98.5	2	1.5	132	100.0
	Present	1	33.3	2	66.7	3	100.0
	Total	131	97.0	4	3.0	135	100.0
Ischemic signs	Absent	125	99.2	1	0.8	126	100.0
	Present	6	66.7	3	33.3	9	100.0
	Total	131	97.0	4	3.0	135	100.0
Other disorders	Absent	129	99.2	1	0.8	130	100.0
	Present	3	60.0	2	40.0	5	100.0
	Total	132	97.8	3	2.2	135	100.0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 TABLE No.: 124
 E.C.G.: SHIFT TABLE - NUMBER OF PATIENTS WITH ABSENT OR PRESENT E.C.G. ABNORMALITIES GROUPED BY TYPE AT LAST ASSESSMENT AS COMPARED TO PRETREATMENT EVALUATION
 DOUBLE BLIND PHASE

Assigned treatment: Placebo

E.C.G. Abnormality at Baseline	Last Assessment						
	Absent		Present		Total		
	No	%	No	%	No	%	
Rhythm disorders	Absent	126	99.2	1	0.8	127	100.0
	Present	7	87.5	1	12.5	8	100.0
	Total	133	98.5	2	1.5	135	100.0
Conduction disorders	Absent	125	98.4	2	1.6	127	100.0
	Present	4	50.0	4	50.0	8	100.0
	Total	129	95.6	6	4.4	135	100.0
Ischemic signs	Absent	128	98.5	2	1.5	130	100.0
	Present	3	60.0	2	40.0	5	100.0
	Total	131	97.0	4	3.0	135	100.0
Other disorders	Absent	132	99.2	1	0.8	133	100.0
	Present			2	100.0	2	100.0
	Total	132	97.8	3	2.2	135	100.0

9550077

Pharmacia

Document 9550077


FIGURES

493

9550077

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

FIG. 1
TIME TO RELAPSE
(EXCLUDING THE PATIENTS NOT RESPONDER AT WEEK 6)




9550077

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

FIG. 2

CENSORING PATTERN




9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

FIG. 3


MAINTENANCE OF THE RESPONSE



PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

FIG. 4

TIME TO RELAPSE
(CONSIDERING ONLY THE PATIENTS REMITTED AT THE END OF THE OPEN PHASE)




LOG RANK TEST: CHI-SQUARE = 23.09 D.F.=1 P = 0.0001

PHARMACIA CNS R&D
REBOXETINE – PROTOCOL 20124/013

FIG. 5


CUMULATIVE RISK OF DEVELOPING THE FIRST ADVERSE EVENT DURING TREATMENT
OPEN PHASE



PHARMACIA CNS R&D
REBOXETINE – PROTOCOL 20124/013

FIG. 6

% OF PATIENTS WITH AT LEAST ONE ADVERSE EVENT ON EXPOSED ACCORDING TO TIME INTERVAL
DOUBLE BLIND PHASE



9550077

Pharmacia

Document 9550077

12. APPENDICES

9550077

Pharmacia

Document 9550077

12.1 Study Information

9550077

Pharmacia

Document 9550077

12.1.1 PROTOCOL AND PROTOCOL AMENDMENT

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

9550077

FARMITALIA CARLO ERBA
ERRAMONT GROUP
CNS LINE

**AMENDMENT 1 to the
REBOXETINE PROTOCOL 20124/013**

The paragraph 9.1 will be as follow:

9.1. Pre-treatment period

Patients will be checked for eligibility according to the inclusion and exclusion criteria. A washout period of 4-7 days (14 days in case of MAOI administration, and 3-4 weeks in case of previous fluoxetine treatment) will then be undertaken, during which only chloral hydrate (0.5 - 1.0 g) as sleep inducer on p.r.n. basis will be allowed. Informed consent will be obtained from each patient and/or next of kin.

Eligible patients will be then randomized to one of the treatment groups and will undergo baseline assessments.

Information on patients screened for the study and found not to be eligible will be collected in the appropriate form (screening form, enclosure 3).

Signatures:

Investigator _____

Study Monitor _____

Product Leader Julia Jansen

Line Medical Head Edoardo Debin

Biostatisticians Riccardo Spezia

20124/013

Date: January 24, 1991

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CNS Line - Medical Research

9550077

FARMITALIA CARLO ERBA
R&D - C.N.S. LINE

COMPOUND: REBOXETINE
PROTOCOL No.: 20124/013
VERSION: Final: 28/2/90
PHASE: III
TITLE: MULTICENTER, MULTINATIONAL DOUBLE-BLIND STUDY
OF THE ACTIVITY AND TOLERABILITY OF REBOXETINE
VS PLACEBO IN THE CONTINUATION THERAPY OF
MAJOR DEPRESSIVE EPISODES
INVESTIGATORS: See page 5 and 6
PRODUCT LEADER: Adriana Dubini
Farmitalia Carlo Erba
C.N.S. Line
Via Carlo Imbonati, 24
20159 Milano
Phone: 039-2-69952749
STUDY MONITOR: See page 17
DATA MANAGEMENT
CENTER: BIOSTATISTICS AND DATA MANAGEMENT FICE MILAN

This protocol contains strictly confidential information which is not to be communicated or published unless previously authorized by Farmitalia Carlo Erba R&D.

20124/013

Date: 28/2/90

504.

I N D E X

1.0	PROTOCOL SUMMARY	Page	1
2.0	INTRODUCTION	"	1
3.0	RATIONALE	"	4
4.0	OBJECTIVES	"	4
5.0	DESIGN	"	5
5.1	Description	"	5
5.2	Number of Subjects Proposed	"	5
5.3	Logistics	"	5
6.0	STUDY POPULATION	"	6
6.1	Source of Subjects	"	6
6.2	Inclusion Criteria	"	6
6.3	Exclusion Criteria	"	6
6.4	Subjects of Identification	"	7
7.0	RANDOMIZATION PROCEDURES	"	7
8.0	EXPERIMENTAL TREATMENTS	"	8
8.1	Test Preparation	"	8
8.2	Labelling	"	8
8.3	Packaging	"	8
8.4	Drug Supplies Storage	"	8
8.5	Dispensing, Use and Disposal of the Test Preparation during and at the End of the Study	"	9
9.0	STUDY CONDUCT	"	9
9.1	Pre-treatment Period	"	9
9.2	Treatment Period	"	9
9.2.1	Dose/Route ad Administration/Treatment Schedule	"	9
9.2.2	Duration of Treatment	"	10
9.2.3	Indications for Early Termination of Test Therapy	"	10
9.2.4	Dropouts/Replacement of Subjects	"	10
9.2.5	Concomitant Therapy	"	11
9.2.6	Indications for Opening the Code	"	11
9.3	Follow-up	"	11
9.4	Study timetable	"	12

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CNS Line - Medical Research

9550077

10.0	EFFICACY ASSESSMENTS	Page	12
10.1	Variables to be Measured for Efficacy Assessment	"	12
10.2	Efficacy Definition	"	12
10.3	Criteria for Subject Evaluability	"	13
11.0	SAFETY ASSESSMENT	"	13
11.1	Variables to be measured for Safety Assessment	"	13
11.2.	Criteria for Subject Evaluability	"	13
12.0	ADVERSE EVENTS	"	13
13.0	EVALUATION SCHEDULE	"	14
14.0	STATISTICAL CONSIDERATIONS	"	14
14.1	Sample Size	"	15
15.0	ETHICAL ASPECTS	"	16
15.1	Ethical Committee	"	16
15.2	Informed Consent	"	16
16.0	PROTOCOL AMENDMENTS	"	17
17.0	STUDY MONITORING	"	17
18.0	SUPPLY AND INVENTORY	"	17
19.0	ADMINISTRATIVE ASPECTS	"	18
19.1	Insurance Policy	"	18
19.2	Curriculum vitae	"	18
19.3	Data Collection in the Case Record Form	"	18
19.4	Use and Publication of the Data obtained from the Study	"	18
20.0	STUDY REPORT	"	19
20.1	Clinical Study Final Report	"	19
20.2	Use and Publication of Study Results	"	19
21.0	END OF THE STUDY	"	19
22.0	STUDY COORDINATION	"	19
23.0	REFERENCES	"	19
24.0	SIGNATURES	"	20
	TABLES 1-2		
	ENCLOSURES 1-10		
	ATTACHMENT A E B		

20124/013

Date: 28/2/90

11

FARMUTUAL CARLO ERBA
ERBAMONT GROUP
CNS Line - Medical Research

9550077

1.0 PROTOCOL SUMMARY

The study, aimed at the evaluation of the efficacy of reboxetine in comparison with placebo in the maintenance therapy of acute episodes of Major Depressive Disorders and the tolerability of the compound upon long term administration, will be carried out on a multicenter, multinational basis, according to a double-blind parallel group design, in 300 patients. After an initial washout period of 1-2 weeks, patients will receive reboxetine 4 mg b.i.d. for 6 weeks. Responders (50% decrease of the total score of the Hamilton Depression Rating Scale, HAMD-Encl.4) will be randomized to treatment with either reboxetine or placebo, administered according to a fixed dose regimen, up to relapse (HAMD total score increased of at least 50% and greater than 18) or up to a maximum treatment period of one year. Efficacy (HAMD, Montgomery-Asberg Depression Rating Scale-Encl.6, Zung self-rating Depression scale-Encl.7) and tolerability (newly observed signs and symptoms, lab tests and ECG) will be assessed at weekly, or weekly-monthly intervals. A long-term follow-up could then be undertaken.

2.0 INTRODUCTION

Reboxetine (FCE 20124 or RS, RS 2-[α -(2-ethoxy-phenoxy) benzyl] morpholine methanesulphonate is a chemically new compound highly potent in pharmacological and biochemical tests predictive of antidepressant effectiveness: reserpine antagonism, norepinephrine reuptake inhibition, REM sleep latency increase. In addition reboxetine has been found to be able to prevent clonidine effects in rodents after single oral administration, in contrast with what observed following tricyclic monoamine uptake inhibitors, which were found to be active only upon repeated doses: these results indicate that the compound is able to decrease the sensitivity of α_2 noradrenergic receptors, one of the biochemical correlates of chronic antidepressant treatment, after single oral dose: therefore it may be expected to exert antidepressant effectiveness of faster onset with respect to available antidepressants in patients (1).

In phase I studies healthy volunteers (2, 3) were orally administered single doses of 0.5 - 5 mg of compound. After 5mg orthostatic hypotension, accompanied by tachycardia and by subjective symptomatology consistent with the disturbed circulatory regulation was observed.

In these studies single doses of 1 & 3 mg of the compound showed dose-dependent CNS effects with EEG modifications (decreased power of theta and fast-beta waves in the fronto-central derivative), performance improvement

FARMUTAJA CARLO ERBA
ERBAMONT GROUP
CNS Line - Medical Research

9550077

(peg-board test) and growth hormone increase, the latter reportedly sensitive to hypothalamic noradrenergic stimulation by norepinephrine reuptake inhibitors.

The comparison with the positive control, imipramine 75 mg, associated to similar EEG modifications in the fronto-central derivative, to modifications indicative of sedative activity in the occipito-temporal derivative and to deterioration of the Pauli performance test, in the absence of growth hormone modifications, indicate that reboxetine does not possess the marked sedative activity of imipramine, but rather psychostimulating properties. After all treatment standing heart rate increase and salivation decrease was apparent. No other modifications of tolerability parameters were observed.

The pharmacokinetics of the compound was evaluated in the above mentioned studies as well as after administration of 2 mg ¹⁴C-FCE 20124 to 3 healthy volunteers (4). Most of the radioactivity circulating in plasma (73% in terms of AUC) was accounted for by unchanged reboxetine; the average peak levels were observed at 2 h, with remarkably stable levels 1-6 hours after administration; its plasma half-life was estimated as 13.2 h, slightly lower than that of total radioactivity.

In addition the autonomic effects of the compound have been evaluated in a study carried out in 16 healthy volunteers according to a double-blind, latin square experimental design. Single doses of reboxetine 1, 2 & 4 mg, desipramine 25, 50 and 100 mg and placebo were administered at weekly intervals. Both reboxetine and desipramine were found to be similarly active in reducing salivation and antagonizing carbachol-evoked sweating, activities consistent with anticholinergic properties, and in increasing heart rate (consistent with muscarinic receptor blockade and/or noradrenergic stimulation); reboxetine, but not desipramine, was found to increase resting pupil diameter (consistent with muscarinic receptor blockade and/or α -stimulation) and to antagonize light evoked-miosis (consistent with anticholinergic activity).

Neither reboxetine nor desipramine were found to modify phenylephrine evoked sweating (no evidence of α -adrenoceptor blockade); following reboxetine a reduction of phenylephrine-evoked mydriasis was apparent, possibly due to a "ceiling effect" (due to the mydriatic effect of reboxetine) rather than α -adrenoceptor blockade. No evidence of noradrenaline-uptake blockade could be observed, since noradrenaline failed to evoke measurable pupillary response.

20124/013

Date: 28/2/90

Page: 2 of 22

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CNS Line
FARMITALIA CARLO ERBA
ERBAMONT GROUP
CNS Line - Medical Research

9550077

On the basis of the results of the phase I studies, a 6-center early phase II study was carried out aimed at assessing tolerability and activity of progressively increased doses of reboxetine, administered over a 4-week period to hospitalized patients suffering from Major Depressive Disorders.

Ninety-eight patients were admitted to the study to be treated with maximum reboxetine daily doses of 4 mg (29 pts), 6 mg (27 pts), 8 mg (18 pts), 10 mg (12 pts) and 12 mg (12 pts). Treatment was discontinued in 4 patients in the 4 mg group due to deterioration of the clinical picture (with a manic syndrome in one case); in 2 patients of the 6 mg group due to the development of a manic episode; in one patient of the 6 mg group due to a convulsive episode, under associated treatment with levomepromazine. Dosage decrease was almost only present in the 12 mg group where in 5/12 cases, due to hypotension and tachycardia, the daily dose was decreased to 10 mg up to completion of the treatment period.

The rating scales applied showed dose related improvement of the clinical picture both as average changes vs basal conditions as well as frequencies of relevant modifications (defined as 50% decrease of HAMD) up to the 10 mg/day dose, whereas slight deterioration, concomitant to the intolerance signs/symptoms, was observed in the highest dose group.

The compound was well tolerated when administered up to the dose of 10 mg/day, as shown by newly observed signs and symptoms, mainly of mild to moderate severity and transient, and by vital signs and lab tests assessments, ECG included.

A double blind parallel group study was subsequently carried out in 10 centers (Hungary, Italy, France and Latin America) in 258 patients hospitalized due to a Major Depressive Episode. The experimental treatment had to be administered for 4 weeks, with maximum doses of 8 mg reboxetine(RBX) or 200 mg desipramine(DMI). The experimental treatment was discontinued in 26 patients (10%): in 18 cases (5, 6 e 7 of the RBX, DMI and P group respectively) for inefficacy; in 3 cases for adverse events (2 of the RBX group due to deterioration of the ventricular extrasystoles present before study start and hypertensive episodes respectively and 1 of the placebo group due to a cutaneous rash); in 5 cases (2, 1 and 2 in the RBX, DMI and P group respectively) for reasons unrelated to the experimental treatment.

FARMITALIA CARLO ERBA
ERRAMONT GROUP
CNS Line - Medical Research

9550077

Of the 80, 82 and 81 cases evaluable for efficacy in the RBX, DMI and P group (after exclusion of protocol violations, mainly related to associated treatments) 63%, 46% and 36% respectively showed a decrease >50% of the HAMD total score at the end of treatment; in 31%, 22% and 21% of these patients respectively the decrease was present within the 14th day at treatment. As to within-center results, the highest frequency of response was observed in the RBX group in all but 3 of the participating centers. After 2 and 4 weeks of treatment an average decrease of 23% and 34% of the HAMD was present in the P group; the corresponding figures were 34% and 49% in the DMI group and 39% e 57% in the RBX group.

As to signs/symptoms, more frequent in the RBX group were headache, complained of by 33% of the patients (20% and 21% in the DMI e P group respectively), and urinary hesitancy/retention, present in 12% vs 4% vs 1% of the cases, RBX vs DMI vs P. More frequent in the DMI group were dry mouth (45% vs 26% vs 21%, DMI vs RBX vs P), sweating (28% vs 18% vs 22%), blurred vision (17% vs 4% in both RBX and P groups). Cardiovascular signs/symptoms were relatively rare, and appeared with slightly higher frequency in the DMI group: hypotension 13%, vs 6% in the RBX and 8% in the P group and tachycardia 19% vs 12% and 8% in the RBX and P group respectively.

3.0 RATIONALE

Phase II results obtained in controlled conditions in patients suffering from Major Depressive Disorders indicate that reboxetine is an effective antidepressant agent, with a favourable therapeutic index with respect to desipramine. The efficacy of the compound in the continuation therapy of Major Depressive Episodes needs now to be tested in controlled conditions vs placebo. In addition the tolerability of the compound upon long-term administration has to be evaluated.

4.0 OBJECTIVES

To assess activity and tolerability of reboxetine in comparison with placebo in the continuation therapy following response in patients suffering from Major Depressive Disorders.

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CNS Line - Medical Research

9550077

5.0 DESIGN

5.1 Description

This phase III study will be carried out according to a double blind parallel group design, controlled vs placebo, with random allocation of patients to one of the two treatments. The study will be organized on a multicentre, multinational basis.

5.2 Number of Subjects Proposed

Each center will recruit enough patients to collect a sample of 30 patients, fulfilling the criteria for entering the double blind phase within a period of one year, for a total of 300 patients overall.

5.3 Logistics

The following 10 centers will participate in the study:

1° BRAZIL - Institute of Psychiatry, Federal University
Rio de Janeiro
Principal Investigator: Prof. M. Versiani
Associate Investigator: Dr. A.E. Nardi

2° DDR - Wilhelm Pieck Universität Rostock
Rostock
Principal Investigator: Prof. K. Ernst

3° FRANCE - Université Aix-Marseille Laboratoire de
Traitement des Connaissances - Faculté de Médecine
Marseille Cedex
Principal Investigator: Prof. M. Ohayon

4° FRANCE - Laboratoire de Pharmacologie Clinique
Centre Hospitalier Ponchaillou
Rennes
Principal Investigator: Prof. H. Allain
Associate Investigators: Dr. J.M. Gandon, Dr. J.P. Martinet

5° PANAMA - National Psychiatric Hospital.
Panama
Principal Investigator: Dr. L. Vergara

6° PANAMA - National Psychiatric Hospital.
Panama
Principal Investigator: Dr. R. Batista

7° POLAND - Klinika Psychiatryczna

FARMUTALIA CARLO ERBA
ERBAMONT GROUP
CNS Line - Medical Research

9550077

Szczecin
Principal Investigator: Dr. M. Jarema

8° HUNGARY - Psychiatric Dept. "Janos" General Hospital
Budapest
Principal Investigator: Dr. A. Lipcsey
Associate Investigator: Dr. E. Nagy

9° HUNGARY - National Institute for Nervous and Mental
Diseases
Budapest
Principal Investigator: Dr. P. Gaszner
Associate Investigator: Dr. A. Tar

10° USSR - Dept. of Psychiatric, University
Tartu Estonia
Principal Investigator: Prof. L. Mehilane
Associate Investigator: Dr. P. Laame

6.0 STUDY POPULATION

6.1 Source of Subjects

Adult patients selected from the population attending out-patient clinics or newly admitted (within 2 weeks) to the Psychiatric Dpt of the participating centers will be studied.

6.2 Inclusion Criteria

- Patients affected by acute recurrences of Major Depressive Disorders, not accompanied by psychotic features (DSM IIIr) with the CODE DD variables: "Acute onset" or "Subacute onset" present and "Prolonged duration" absent.
- Patients of either sex, of any race, aged 18 to 65 years.
- A total score of 18 or above in the 21-HAMD.
- Patient's consent: informed consent will be obtained from the patient and/or next of kin (proposed consent form: Enclosure 1).

6.3 Exclusion Criteria

- First episodes of Major Depressive Disorders
- History of Major Depressive Disorders associated to

20124/013

Date: 28/2/90

Page: 6 of 22

Endocrine Disorders: hypo and hyper-thyroidism tested by rT3, followed by T3 and T4 in case of negative finding at admission; adrenal insufficiency, etc.

- Pregnancy (tested by pregnancy test at the end of the wash-out period).
- Refusal of contraceptive use during the study period.
- Past history of drug hypersensitivity.
- Participation in a clinical study with an investigational compound in the 4 weeks preceding the study.
- Evidence of Substance Use Disorder within past 6 months or currently.
- Chronic respiratory insufficiency
- History or presence of gastrointestinal, liver, or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism and excretion of drugs.
- History of seizures or serious brain injury; current evidence of clinically important hematopoietic or cardiovascular diseases. Current evidence of urinary retention or glaucoma.
- Symptoms of any other important clinical illness in the 4 weeks preceding the study.
- Clinically relevant abnormal findings in the physical examination, laboratory tests and ECG at admission.
- ECT in the previous 6 months.

6.4 Identification of Subjects

Patients will be identified by their initials and by the number in the trial.

7.0 RANDOMIZATION PROCEDURES

A randomization list balanced within center will be prepared for patient allocation to one of the 2 possible treatments (reboxetine or placebo). On this basis the experimental treatments will be prepared and labelled with the corresponding patient number.

FARMITALIA CARLO ERBA
ERRAMONT GROUP
CNS Line - Medical Research

9550077

Patient allocation to treatment will be done at the end of the 6 weeks open treatment of the acute episode (see Study Conduct) by the principal Investigator on the basis of the patient's temporal entry into the study.

8.0 EXPERIMENTAL TREATMENTS

8.1 Test Preparation

Indistinguishable scored tablets containing either reboxetine 4 mg plus excipients (batch no SF1030) or excipients only (placebo, batch no SF1032) will be used.

8.2 Labelling

The experimental treatment will be labelled by using the labels in enclosure 2. Double labels will be used (see point 8.5).

8.3 Packaging

For the open initial treatment of the acute episode (see Study Conduct) 6 glass amber bottles labelled with the patient number and the indication week 1 to 6 will be prepared for each patient. Each bottle will contain the medication necessary for each of the first 6 weeks of treatment with reboxetine, i.e. 16 tablets (1 tab 4 mg b.i.d. plus 2 additional for possible losses).

In addition for the double blind continuation therapy following response (see Study Conduct) 30 glass amber bottles labelled with the patient number and the indication week 7-8, week 9-10, week 11-12, etc, up to week 51-52 will be prepared for each patient. Each bottle will contain the medication necessary for each of the two-week treatment periods between visits up to the maximum of one year , i.e. 32 tablets of either reboxetine 4 mg or placebo (1 tab b.i.d. plus 4 additional for possible losses).

8.4 Drug Supplies Storage

Drug supplies will be stored at room temperature. All drug supplies will be handled under the direct responsibility of the Investigator and held by the Hospital Pharmacy. The study Monitor will check drug storage conditions during site visits.

20124/013

Date: 28/2/90

Page: 8 of 22

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CNS Line - Medical Research

9550077

The Investigator will be also responsible for drug accountability and will keep a record of the test compounds received from the Sponsor as well as of the dispensed drug.

8.5 Dispensing, Use and Disposal of the Test Preparation during and at the End of the Study

Medication will be dispensed to the patient on the occasion of each visit; the Investigator will detach the upper label from each of the weekly cartons he is dispensing to the patient and will attach them in the appropriate space in the Case Record Form. On the same occasion cartons of the possible previous supply will be returned by the patient.

Used cartons will be returned to the study Monitor during site visits.

All unused medication has to be returned to Farmitalia Carlo Erba at the end of the study.

9.0 STUDY CONDUCT

9.1 Pre-Treatment Period

Patients will be checked for eligibility according to the inclusion and exclusion criteria. A washout period of 7 days (14 days in case of MAOI administration) will then be undertaken, during which only chloral hydrate as sleep inducer on p.r.n. basis will be allowed. Informed consent will be obtained from each patient.

Eligible patients will then undergo baseline assessments.

Information on patients screened for the study, including those not eligible, will be collected in the appropriate form (screening form, enclosure 3).

9.2 Treatment Period

9.2.1 Dose/Route of Administration/Treatment Schedule

Patients will receive 1 tablet of reboxetine 4 mg b.i.d. from day 1 to day 42, i.e. for 6 weeks. At the end of this open treatment phase patients showing response (see Efficacy Definitions) will be randomized to treatment with either reboxetine or placebo (1 tab b.i.d.) for a maximum period of one year or up to relapse (see Efficacy Definitions).

20124/013

Date: 28/2/90

Page: 9 of 22

The daily dose can be reduced by half tablet (2 mg for reboxetine) in case of emergence of non tolerable signs or symptoms.

The treatments will be administered in the morning (10 a.m.) and in the evening (6 p.m.). Treatment intake will take place at least 2 hours before or after meals.

9.2.2 Duration of Treatment

Following the initial open treatment with reboxetine for 6 weeks, the experimental treatment with either reboxetine or placebo will be administered for a maximum period of one year.

9.2.3 Indications for Early Termination of Test Therapy

Termination of test therapy prior to completion of the treatment period may be considered under the following circumstances:

- Patient's request.
- Unacceptable toxicity: this is defined as the occurrence of serious and unexpected (see Adverse Events) adverse events or the persistence of non tolerable signs or symptoms which are not alleviated by reducing the dose to the lower dosage level.
- Inefficacy during the open initial treatment phase: this will apply to patients who after completion of at least 2 weeks of treatment will show worsening of the global clinical picture (CGI - Global Improvement, see assessments).

In case of treatment discontinuation the final complete battery of assessments will be carried out wherever possible.

9.2.4 Dropouts/Replacement of Subjects

Patients who drop out of the study for any reason during the open treatment phase will be substituted in order to have in each Center a sample of 30 patients entering the double blind treatment phase.

Patients who drop out of the study for any reason during the double blind treatment phase will not be substituted.

For those patients who have been selected for the study who drop out at any time, even if it is before entrance to the treatment period, documentation will be provided.

9.2.5 Concomitant Therapy

No concomitant medications are allowed during the study. In case of events arising during the course of the study non psychotropic medications which are considered necessary for the patient's welfare may be administered and will not be considered protocol violations. The drugs, dosage and frequency of administration will be recorded on CRF. Chloral hydrate as a sleep inducer on p.r.n. basis at bed-time is allowed.

9.2.6 Indications for Opening the Code

The Investigator will be given individual sealed envelopes containing the information on patient's treatment. These latter may be opened only in case of emergency necessitating treatment identification; the Investigator will immediately (within 24 hours) inform the study Monitor at FICE Subsidiaries and will report full description of reasons for opening the code in the CRF (Adverse Event Form).

The sealed individual codes will be returned to Farmitalia Carlo Erba at the end of the study.

9.3 Follow-up

Patients willing to continue receiving the experimental treatment after completion of the one year treatment period will be maintained under the same medication in blind conditions until completion of the last patient of the center.

A follow up visit will be carried out in each patient one month after treatment discontinuation in order to monitor possible withdrawal reactions and collect information on interval events.

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CNS Line - Medical Research

9550077

9.4 Study Timetable

Foreseen start date: March 90
Duration of accrual: 12 months
Foreseen end date (date of the last visit of the last patient): March 92.

10.0 EFFICACY ASSESSMENTS

10.1 Variables to be measured for Efficacy Assessment

At admission and on day 42, after 6 and 12 months of treatment and/or at the time of treatment termination patients will be classified according to the Composite Diagnostic Classification for Depressive Disorders (CODE DD).

On days 0, 7, 14, 21, 28, 35, 42, at bi-weekly intervals afterwards and monthly during follow-up:

- Hamilton Depression Rating Scale (21-item HAMD, enclosure 4); as above plus under screening for entry.
- Clinical Global Impression (Enclosure 5).
- On days 0, 7, 14, 21, 28, 35, 42 and at monthly interval afterwards:
- Montgomery-Asberg Depression Rating Scale (Enclosure 6)
- Zung self-rating Depression Scale (Enclosure 7)

All psychiatric evaluations and ratings will be carried out by the same observer for a given patient, preferably in the same setting and at the same time of the day.

10.2 Efficacy Definitions

Decreases of at least 50 % in the total HAMD score vs day 0 will be considered index of response whereas total HAMD score of 10 or less will be considered index of remission.

Fifty percent increase of HAMD total score with respect to the end of the 6-week open treatment associated with a total score of at least 18 will be considered index of relapse.

10.3 Criteria for Subject Evaluability

Every randomized patient will be included in the analysis.

11.0 SAFETY ASSESSMENT

11.1 Variables to be measured for Safety Assessment

- Standard medical history: at admission.
- Standard clinical examination: full physical examination; chest X-ray: at admission.
- Blood pressure and pulse will be measured in the lying (after 5 minutes lying) and in the standing position (1 - 2 minutes after standing up) in the morning: at admission and at each visit.
- ECG: at admission, day 14, day 28, day 42 and every two months during the double blind treatment phase.
- Ophthalmologic examination: at admission and end of treatment.
- Laboratory tests (Full blood count, serum electrolytes, liver enzymes, blood sugar, SAP, BUN, serum creatinine, uric acid, total and direct bilirubin, total serum proteins and electrophoresis, serum cholesterol and triglycerides; only at admission rT₃, T₃, T₄; urinalysis): at admission, day 14, day 28, day 42 and every two months during the double blind treatment phase.
- Adverse events: a check-list will be administered at baseline and at each visit (Enclosure 8).

11.2 Criteria for Subject Evaluability

Every patient who has received one dose of the experimental treatment will be included in the safety evaluation.

12.0 ADVERSE EVENTS

Patients will be notified of possible adverse events they could experience and instructed to immediately report them to the Investigator.

Any adverse event, noticed by the Investigator or complained of by the patient, including clinically relevant lab abnormalities, will be recorded in the appropriate section of the CRF, regardless of presumed relationship to study medication.

FARMITALIA CARLO ERBA
ERRAMONT GROUP
CNS Line - Medical Research

9550077

For each event, the following information will be entered in the CRF: description, onset date, disappearance date, severity (1 = mild, awareness of sign or symptom, but easily tolerated; 2 = moderate, discomfort enough to cause interference with usual activity; 3 = severe, incapacitating with inability to work or do usual activity; 4 = unknown), drug cause-effect relationship (according to Karch and Lasagna modified criteria; see enclosure 9), outcome, dechallenge (what happened to the adverse event when the drug was stopped or the dose decreased?) rechallenge (what happened when the drug was restarted after the adverse event had disappeared?). The Investigator will also note if the double-blind code has been opened, the action taken regarding the test drug (none, discontinued, dosage reduced) and any treatment applied because of the adverse reactions.

All serious* ("any experience that is (potentially) fatal or life-threatening, disabling, incapacitating, requires inpatient hospitalization, or causes a congenital anomaly or cancer or is due to overdose") and/or unexpected* ("any adverse experience that is not identified in nature, severity or frequency in the current investigator's brochure for the study") adverse events must be immediately (within 24 hours) reported by telephone to FICE Subsidiaries Monitors and the Adverse Event Report Form must be filled in immediately. The same applies to all patients who died, irrespective of whether the event was judged as related to treatment, during the course of the study or within 30 days of completion of treatment.

In case of death, if an autopsy is performed, copy of the pathological report should be sent to the Sponsor.

13.0 EVALUATION SCHEDULE

Is reported in table 1 and table 2.

14.0 STATISTICAL CONSIDERATIONS

Randomized patients will be classified according to the

* Code of Federal Regulation, Vol 21 Part 312. Revised as of April 1, 1987, pg. 75. * J.L.Bem et al.: Review of yellow cards (1986): report to the Committee on the Safety of Medicines. Br.J. Clin. Pharmac. (1988), 26, 679-689.

following criteria:

- Relapse (see 10.2)
- Remission (see 10.2) at the last assessment and at the end of the 1-yr double blind treatment period
- No change (it will be applied to those patients who will complete the one year period of treatment but will not fulfill the above criterion)
- Early termination (see 9.2.3) i.e. patient's request and/or unacceptable toxicity
- Lost to follow-up

The main comparison between treatments will be done on the basis of relapse rate (% of randomized patients experiencing relapse) by using a test based on the binomial distribution. Relapse time will be analysed by Kaplan-Meyer method and the comparison between treatments performed by the log-rank test.

In addition remission rate (% of randomized patients experiencing remission at the last assessment and at the 1-yr interval) in the two treatment groups will be compared.

Frequencies of patients showing maximum decrease ≥ 20 mmHg in the standing systolic blood pressure in the two treatment groups will be compared.

Adverse events will be presented by listing, patient-by-patient, all events encountered and the cumulative frequencies of occurrence by treatment. The latter, if clinically significant, will be submitted to non parametric test of the differences between treatment groups.

Laboratory data will be classified as normal or abnormal on the basis of the normal ranges of the performing Laboratory and the frequency of abnormal results after treatment in the two groups compared.

14.1 Sample Size

Seventy % of the patients are expected to be classified as responders at the end of the initial 6 weeks of treatment and to enter the double blind placebo controlled treatment phase; during the latter 10% of the total patient sample is expected to drop out without reaching the study end point and 50% of the placebo-treated patients are expected to relapse within one year;

FARMACIA CARLO ERBA
ERBAMONT GROUP
CNS Line - Medical Research

9550077

Considering of clinical relevance a difference of 15% in the incidence of relapse with respect to the one expected for the placebo group, 135 patients per arm are necessary in order to have a power (1- β) of at least 0.80 for rejecting the null hypothesis (no difference between treatments) if the alternative hypothesis (relapse rate for placebo = 0.5, for reboxetine \leq 0.35) is true, with the α level fixed at 0.05 (one side).

15.0 ETHICAL ASPECTS

The study will be carried out according to the Helsinki Declaration (Venice revision, Enclosure 10)

15.1 Ethical Committee

This study will not be undertaken until approval is obtained from the Ethical Committee of the participating centres. It is responsibility of the Investigator to submit the study protocol with its attachments to the Ethical Committee.

The written approval of the Ethical Committee will report the name and profession of all its members and a copy of it will be sent to the Sponsor before the study begins.

The Investigator is committed, in compliance with local requirements, to inform the Ethical Committee of any emergent problems, serious adverse reactions or protocol amendments.

15.2 Informed Consent

Before entering the study each patient will be explained nature, duration, and purpose of the study and the action of the compound in such a manner that the patient is aware of the potential risks, inconveniences or adverse effects that may occur and can express his/her informed consent to participation. The consent form (enclosure 1) will be signed by the patient or by the Investigator. In the latter case, the signature of a witness will testify that full information was given to the patient.

FARMITALIA CARLO ERBA
ERBAMONT GROUP
CNS Line - Medical Research

9550077

16.0 PROTOCOL AMENDMENTS

After the protocol has been signed, no changes will be made without the agreement of both the Investigator and the Sponsor. Any change will be recorded on a written agreement which will be signed and dated by both parties and attached to the original protocol.

17.0 STUDY MONITORING

Monitors of the study are:

Dr. M. Bosc (Farmitalia Carlo Erba Tour Franklin Cedex 11 Paris La Defense - France - Phone: 49032000)

Dr. G. Fiorentino (Farmitalia Carlo Erba, Apartado 10744 Panama 4, Rep. Panama. Phone: 642133)

Dr. M. Geller (Farmitalia Carlo Erba, Rodovia Washington Luiz Br-040 Km 119, 293 Duque de Caxias, Rio de Janeiro, Brasil. Phone: 7715110)

Dr. L. Orlandini (Farmitalia Carlo Erba ROSCA, Karlsplatz 1, A 1010 Wien, Austria. Phone: 5054651)

Dr. F. Heteny (Farmitalia Carlo Erba, Képviselet Iroda Bajcsy Zsilinszky ut 12 VI S 1051 Budapest, Hungary. Phone: 1181376)

A pre-study visit will be made by the Monitor to the Investigator in order to discuss problems, if any, and the obligations of both the Sponsor and the Investigator. During the trial monitoring visits will be paid to the site by the study Monitor monthly to bi-monthly. During the visits the Monitor will assess the progress of the study, review the compliance with the study protocol, discuss any problem, check the CRFs for legibility, accuracy and completeness, validate CRFs content against source documents, assess the status of drug storage dispensing and retrieval.

Operating procedures for training on assessment instruments, study monitoring and coordination are described in attachment A.

18.0 SUPPLY AND INVENTORY

Test preparation will be supplied by Farmitalia Carlo Erba in the form described in 8.1. Records will be kept by the Investigator as to the disposition of study drug for each

FARMITALIA CARLO ERBA
ERRAMONT GROUP
CNS Line - Medical Research

9550077

patient. A disposition form accounting for all study supplies will be signed by the Investigator.

19.0 ADMINISTRATIVE ASPECTS

19.1 Insurance Policy

Farmitalia Carlo Erba Company declares to have a group insurance cover (policy NO. 4W8102 - Italia Assicurazioni) which provides indemnity to the Investigator, to the co-Investigators and to the subjects participating in the trial.

19.2 Curriculum Vitae

The Investigator will provide the Sponsor with signed copies of his/her and his/her co- Investigators CVs.

19.3 Data Collection in the Case Record Form

All study data will be recorded in the CRF supplied by the Sponsor (Attachment B). A black ink ball point pen should be used for entering the data to ensure the good quality of the reproduced CRFs copies.

Only the Principal Investigator and the duly authorized co-Investigators can make entries in the CRF.

In case of errors corrections must be made by crossing out the incorrect entry (that must remain legible) and entering the correction followed by the Investigator's initials and the date of the correction.

On the occasion of the monitoring visits the monitor will take away the original and one copy of each page, while the Investigator will retain a copy for his files, together with the drug disposition records, for ten years after the discontinuation of the investigation.

19.4 Use of the Information related to the Study

All unpublished documentation including the protocol, the CRF and the Investigator's Brochure, given to the Investigator is confidential. These documents cannot be disclosed to a third party without the written consent of FICE R&D. The submission of these documents to the Ethical Committee is expressly permitted.

The Investigator agrees that FICE R&D maintains the right to utilize the results of this study, in their original form and/or in a global report, for submission to the governmental and regulatory authorities of any country.

20.0 STUDY REPORT

20.1 Clinical Study Final Report

The final Medical Study Report will be written by the Product Leader and will be submitted to the Investigators for approval and signature.

20.2 Publication of Study Results

The results of the study will be published in a common publication, agreed upon between all Investigators and FICE R&D.

The Investigators, whilst free to use the data resulting from this study for individual publications (subsequent to the common one), are asked to discuss any paper with Farmitalia Carlo Erba prior to submission; to this purpose copy of manuscript/abstract has to be available for FICE R&D Approval Procedure 30 days prior to publication.

The results of the study may be submitted for a common publication, agreed upon between the Investigator and FICE R&D.

21.0 END OF THE STUDY

Either the Investigator or FICE R&D could terminate this study at any time for well documented reasons. In this event the other party will be immediately notified.

22.0 STUDY COORDINATION

A Steering Committee in charge of the coordination of the study will be settled, as described in Attachment A.

23.0 REFERENCES

1. Reboxetine Investigator Brochure, FICE, CNS Line, June 1988

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

FARMILIA CARLO ERBA
ERBAMONT GROUP
CRS Line - Medical Research

9550077

2. /602i - Herrmann W.M. et al. (AFB - Berlin)
Safety and tolerance of reboxetine in healthy male volunteers - A single rising dose tolerance study.
June 15, 1984.
3. /603i - Herrmann W.M. (AFB - Berlin)
Reboxetine - Quantitative pharmaco EEG and pharmacopsychological study.
January, 1985.
4. /604i - Dubini A. et al.
Disposition and fate of ¹⁴C-reboxetine administered orally to healthy volunteers.
March, 1985.
5. /608i - Dubini A., Ban T. Open dose-range finding study in patients hospitalized for Mayor Depressive Disorders
April, 1989

24.0 SIGNATURES

Signatures of the:

Investigator _____

Study Monitor _____

Product Leader Adriano Rubin

Line Medical Head Adriano Rubin

Biostatisticians Francesca Sperti

FARMITALIA CARLO ERBA
 ERBAMONT GROUP
 CNS Line - Medical Research

9550077

TABLE 1

EVALUATION SCHEDULE: OPEN TREATMENT PHASE

DAY	PRE-TREATMENT			TREATMENT				
	SCREEN	0	7	14	21	28	35	42
ASSESSMENT:								
MEDICAL HISTORY	X							
PHYSICAL EXAMINATION	X							
OPHTHALMOLOGIC EXAM.	X							
CHEST-X-RAY	X							
VITAL SIGNS	X	X	X	X	X	X	X	X
ECG	X			X		X		X
LABORATORY	X			X		X		X
CODE-DD	X							X
CGI		X	X	X	X	X	X	X
21-ITEM HAMD	X	X	X	X	X	X	X	X
MONTGOMERY-ASBERG DEPRESSION RS		X	X	X	X	X	X	X
ZUNG SELF-RDS		X	X	X	X	X	X	X
COMPLIANCE		X	X	X	X	X	X	X
DISPENSING MED.		X	X	X	X	X	X	X
ADVERSE EVENTS		X	X	X	X	X	X	X

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

FARMITALIA CERIAL ERBA
 LEBAMONT GROUP
 CNS Line - Medical Research

9550077

TABLE 2

EVALUATION SCHEDULE: DOUBLE BLIND TREATMENT PHASE

END OF WEEK	8	10	18	24	26	34	42	52
ASSESSMENT:								
ECG		X	X		X	X	X	X
OPHTHALMOLOGIC EXAM.								X
VITAL SIGNS *	X	X	X	X	X	X	X	X
LABORATORY		X	X		X	X	X	X
CODE-DD				X				X
CGI *	X	X	X	X	X	X	X	X
21-ITEM HAMD *	X	X	X	X	X	X	X	X
MONTGOMERY-ASBERG ** DEPRESSION RS	X	X	X	X	X	X	X	X
ZUNG SELF-RDS **	X	X	X	X	X	X	X	X
COMPLIANCE *	X	X	X	X	X	X	X	X
DISPENSING MED.*	X	X	X	X	X	X	X	X
ADVERSE EVENTS *	X	X	X	X	X	X	X	X

* X.....X = bi-weekly intervals
 ** x.....x = monthly intervals

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

9550077

ENCLOSURE Nº 1

REBOXETINE PROTOCOL 20124/013

Phase III controlled study of the activity and tolerability of reboxetine in comparison with placebo in the continuation therapy of patients suffering for major depressive disorders.

CONSENT FORM

Principal Investigator:

EXPLANATION

Purpose of the study

Reboxetine, a new potential antidepressant agent, has effects in animals which suggest that it may exert therapeutic efficacy of faster onset, in comparison with established antidepressant drugs, in patients suffering from depressive disorders. The trial is proposed in order to learn about the antidepressant effectiveness of the compound and about the maintenance of its activity.

Plan of the study

After a six-weeks treatment course with reboxetine at the daily dose of 8 mg, patients responding to the treatment will receive either reboxetine or a harmless inactive treatment (placebo). Neither patients nor doctors will know which treatment will be administered in individual cases until after the study is completed. The identity of the treatments can anyhow be determined immediately if any medical problem will develop and it will become important to learn which of the two possible treatments is being given.

Treatment will be administered for a maximum period of one year. It will be discontinued in case of re-emergence of psychiatric symptomatology or in case of significant side-effects. In addition patients participating in the study may withdraw their consent at any time without prejudice to their continued medical treatment.

During treatment, physical and psychiatric examinations will be done on frequent occasions, in order to determine

9550077

PROT.Nº 20124/013

CONT' ENCLOSURE Nº1

possible side-effects and benefits of treatments. Blood tests, urinalysis, ECG will be undertaken bi-weekly during the initial phase or every two months during the long-term treatment phase. Blood pressure and pulse will be taken very frequently, particularly in the first two weeks of treatment.

Possible discomforts and risks

Antidepressant drugs can cause dry mouth, blurred vision, dizziness, mild difficulty in voiding urine, postural hypotension and electrocardiographic changes.

Reboxetine has been so far administered for 28 days to about 180 patients and was well tolerated up to the dose of 5 mg twice daily. In the dose range of 3-5 mg twice daily clinically relevant improvement of depressive condition was present in the majority of patients; symptoms complained off by patients were mainly mild and transient and included most frequently headache, sweating, lassitude, nasal congestion, constipation and urinary hesitancy. At higher doses orthostatic hypotension, tachycardia, dizziness, blurred vision and nausea were reported.

Patients participating in the study will be carefully monitored to detect early signs of such side-effects.

Possible benefits

Other drugs are available for treatment of depressive disorders but none has been of proven value in all cases. This study will allow the evaluation of the antidepressant activity of reboxetine in comparison with placebo upon long-term administration. Under the latter treatment, 50% maintenance of response can be expected upon long-term administration. The evaluation of patient response under placebo could be useful in deciding the most appropriate treatment approach in individual cases.

Alternative treatment

Patients would receive alternative pharmacological therapy with an antidepressant drug chosen on the basis of response during previous episodes, if any. Risks and benefits of receiving treatment with any of the available antidepressant drugs can be explained by.....

Confidentiality

Participation in the study will be kept confidential to the extent permitted by law.

9550077

PROT. N°20124/013

CONT'. ENCLOSURE N° 1

Problems and questions

Should any problem or question arise with regard to the study, patients can contact the Principal Investigator:

.....
or the other staff members also involved in the study:

.....

.....

.....

In addition any problem or question can be discussed with a member of the Institutional Review Board (.....), the Committee which has evaluated the potential risks and possible benefits of the study.

Payments and policy regarding research-related injuries.

Patients will not be paid for the participation in the study. The Clinical Center will provide short-term medical care for any physical injury resulting from participation in the study. No long-term medical care or financial compensation for such injuries will be provided except as it may be through whatever remedies are normally available under law. Insurance coverage is granted through the Sponsor Company.

PATIENTS CONSENT

I have read the explanation about this study and I have been given the opportunity to discuss it and to ask questions. I hereby consent to take part in this study.

Patient Signature

date

Investigator Signature

date

9550077

ENCLOSURE N° 2

REBOXETINE PROTOCOL 20124/013
EXPERIMENTAL TREATMENT LABELLING

OPEN TREATMENT PHASE :

reboxetine protocol 20124/013
patient no.....
week 1 - week 6
reboxetine 4 mg tablets
batch no.....
expiry.....
drug for investigational use

DOUBLE BLIND TREATMENT PHASE :

reboxetine protocol 20124/013
patient no.....
week 7-8 ; 51-52
expiry.....
drug for investigational use

532

9550077

ENCLOSURE N°3



Patient initials

Birth date
D M Y

Sex M F

Age (years)

Weight (kg)

Height (cm)

Phase III

**Multicenter, multinational
double-blind study
of the activity and
tolerability of reboxetine
vs placebo in the
continuation therapy of
major depressive
episodes**

PROTOCOL 20124/013

SCREENING FORM

Investigator's signature _____

533 ERBAMONT GROUP

FARMITALIA CARLO ERBA
Edamont Group

Compound **REBOXETINE** 9550077 Protocol No. 2|0|1|2|4|0|1|3

Centre No.

Patient No.

Initials

Visit/cycle S|C|R|E|N

Investigator's name _____

Monitor's name: _____

Date / /
D M Y

PRE-STUDY CHECKLIST

CCAT. ENCLOSURE N°3

THE PATIENT:

ARE THE FOLLOWING CONDITIONS PRESENT?

YES NO

Aged between 18 and 65 years inclusive? YES NO

Affected by Acute Recurrences of Major Depressive Disorders (DSM-III-R), not complicated by psychotic features with the code-DD: "Acute Onset" or "Subacute Onset" present and "Prolonged Duration" absent? YES NO

With a total score of 18 or above in the 21-HAMD? YES NO

Able and willing (he or the next of kin) to give Informed Consent? YES NO

ARE THE FOLLOWING CONDITIONS ABSENT?

First episodes of Major Depressive Disorders? YES NO

History of Major Depressive Disorders, associated to Endocrine Disorders? YES NO

Pregnancy? (if applicable) YES NO

Refusal of contraceptive use during the study period? YES NO

Clinically significant hematopoietic abnormality? YES NO

Clinically significant lab values abnormality? YES NO

Current evidence of urinary retention? YES NO

Current evidence of thyroid disease (by rT₃ followed by T₃, T₄)? YES NO

Current evidence of glaucoma? YES NO

Clinically significant physical abnormality? YES NO

NO, please cross and detail:

Hepatic function : _____

Renal function : _____

Gastrointestinal function : _____

Cardiovascular function : _____

Investigator's signature 534

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE** 550077

Protocol No. 20124013

Centre No. [][][][]

Patient No. [][][]

Initials [][][]

Visit/cycle [S][C][R][E][N]

Date [][][][][][]
D M Y

(CONT')

CONT. ENCLOSURE Nº3

YES NO

Participation in a clinical trial with an investigational compound in the 4 weeks preceding the study?

- Evidence of substance use disorder within past 6 months or currently?

Chronic respiratory insufficiency?

History of drug hypersensitivity?

Any history of seizures or brain injury?

Any other important clinical illness in the 4 weeks preceding the study?

ECT in the previous 6 months?

the answer to any of the above questions is NO the patient is unsuitable for entry into the study and should proceed further.

INCLUSION

I, _____ confirm that the available informations on the patient agree with inclusion and inclusion criteria and that the patient is suitable to be included in this study.

535

Investigator's signature _____

9550077

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 20124013

Centre No.

Patient No.

Initials

Visit/cycle SCREEN

Date
 D M Y

ADMISSION EXAMINATION

CONT. ENCLOSURE Nº 3

CHEST X-RAY taken on
 D M Y

normal abnormal

If abnormal, detail _____

VITAL SIGNS

- Body temperature (°C)
- Respiratory rate (breaths/min)
- 5 min lying arterial blood pressure (mmHg) systolic diastolic
- 5 min lying heart rate (beats/min)
- 2 min standing arterial blood pressure (mmHg) systolic diastolic
- 2 min standing heart rate (beats/min)

MEDICAL HISTORY

- Important previous diseases _____

536

Investigator's signature _____

9550077

FARMITALIA CARLO ERBA
Erbamont Group

Compound REBOXETINE

Protocol No. 20124013

Centre No. [][][][] Patient No. [][][] Initials [][][] Visit/cycle S|C|E|E|N|

Date [][][][][][]
D M Y

CONT. ENCLOSURE N°3

DIAGNOSIS

- DSM III-AXIS I _____ [][][][]

HISTORY OF THE MENTAL DISORDER: Unknown if known:

- Age of onset of disease years [][]

- Number of previous episodes [][]

- Approximate duration of last episode weeks [][] months [][] years [][]

PRESENT EPISODE

- Approximate duration at the time of admission to the study days [][] weeks [][] months [][] years [][]

THE PRESENT EPISODE IS BEST CHARACTERIZED AS:

- Exacerbation of chronic condition [1]
- Recurrence of similar previous conditions [2]
- Significantly different from any previous conditions [3]
- First occurrence, no previous psychiatric diagnosis [4]

ONSET OF PRESENT EPISODE WAS:

- Acute (<2 weeks) [1]
- Subacute (≥ 2 weeks) [2]
- Insidious (≥ 3 months) [3]

RECIPIATING EXTERNAL STRESS WAS:

- Absent [1]
- Probably present [2]
- Definitely present [3]

537

Investigator's signature _____

9550077

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. 2|0|1|2|4|0|1|3|

Centre No.

Patient No.

Initials

Visit/cycle S|C|R|E|N|

Date
D M Y

LABORATORY TESTS

CONT. ENCLOSURE N°3

Tests	Value	Clinically Significant abnormality*	Tests	Value*	Clinically Significant abnormality**
BLOOD TESTS			BUN		<input type="checkbox"/>
HGB		<input type="checkbox"/>	Creatinine		<input type="checkbox"/>
MCT		<input type="checkbox"/>	Uric acid		<input type="checkbox"/>
RBC		<input type="checkbox"/>	Total bilirubin		<input type="checkbox"/>
WBC		<input type="checkbox"/>	Direct bilirubin		<input type="checkbox"/>
Neutrophils		<input type="checkbox"/>	Total protein		<input type="checkbox"/>
Lymphocytes		<input type="checkbox"/>	Blood albumin		<input type="checkbox"/>
Eosinophils		<input type="checkbox"/>	Cholesterol		<input type="checkbox"/>
Monocytes		<input type="checkbox"/>	Triglycerides		<input type="checkbox"/>
Basophils		<input type="checkbox"/>	Globulins: α 1		<input type="checkbox"/>
Platelets		<input type="checkbox"/>	α 2		<input type="checkbox"/>
Na ⁺		<input type="checkbox"/>	β		<input type="checkbox"/>
K ⁺		<input type="checkbox"/>	γ		<input type="checkbox"/>
CL ⁻		<input type="checkbox"/>	rT ₃		<input type="checkbox"/>
Ca ⁺⁺		<input type="checkbox"/>	T ₃		<input type="checkbox"/>
PO ₄		<input type="checkbox"/>	T ₄		<input type="checkbox"/>
SGOT		<input type="checkbox"/>	URINALYSIS		
SGPT		<input type="checkbox"/>	Specific gravity		
γ-GT		<input type="checkbox"/>	Albumin		<input type="checkbox"/>
			Sugar		<input type="checkbox"/>
BLOOD SUGAR			RBC		<input type="checkbox"/>
Alkaline phosphatase		<input type="checkbox"/>	WBC		<input type="checkbox"/>

Observation: _____

* Cross in case of clinically significant abnormality

538

Investigator's signature _____

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

FARMITALIA CARLO ERBA
Erbamont Group

Compound REBOXETINE ⁹⁵⁵⁰⁰⁷⁷

Protocol No. 2|0|1|2|4|0|1|3

Centre No. [][][][] Patient No. [][][] Initials [][][]


Visit/cycle SK|RE|EN

Date [][][][][][]
D M Y

CONT' ECG

CONT. ENCLOSURE Nº3

Please, add here the ORIGINAL TRACING AND MEDICAL REPORT



Investigator's signature _____

FARMITALIA CARLO ERBA
Erbarmont Group

Compound **REBOXETINE** 9550077

Protocol No. 2|0|1|2|4|0|1|3

Centre No. [][][][]

Patient No. [][][]

Initials [][][]

Visit/cycle [S][C][R][E][W]

Date [][][][][][]
D M Y

HAMD: HAMILTON DEPRESSION RATING SCALE

CONT. ENCLOSURE N°3

1. Depressed mood (*Sadness, hopeless, helpless, worthless*)

- 0 Absent 1 These feeling states indicated only on questioning
 2 These feeling states spontaneously reported verbally
 3 Communicates feeling states non-verbally - i.e., through facial expression, posture, voice, and tendency to weep
 4 Patient reports VIRTUALLY ONLY these feeling states in his spontaneous verbal and non-verbal communication

2. Feelings of guilt

- 0 Absent 1 Self reproach, feels he has let people down
 2 Ideas of guilt or rumination over past errors or sinful deeds
 3 Present illness is a punishment. Delusions of guilt
 4 Hears accusatory or denunciatory voices and/or experiences threatening visual hallucinations

3. Suicide

- 0 Absent 1 Feels life is not worth living
 2 Wishes he were dead or any thoughts of possible death to self
 3 Suicide ideas or gesture
 4 Attempts at suicide (*any serious attempt rates 4*)

4. Insomnia early

- 0 No difficulty falling asleep 1 Complains of occasional difficulty falling asleep - i.e., more than ½ hour
 2 Complains of nightly difficulty falling asleep

5. Insomnia middle

- 0 No difficulty 1 Patient complains of being restless and disturbed during the night
 2 Waking during the night - any getting out of bed rates 2 (*except for purposes of voiding*)

6. Insomnia late

- 0 No difficulty 1 Waking in early hours of the morning but goes back to sleep
 2 Unable to fall asleep again if he gets out of bed

7. Work and activities

- 0 No difficulty
 1 Thoughts and feelings of incapacity, fatigue or weakness related to activities; work or hobbies
 2 Loss of interest in activity; hobbies or work - either directly reported by patient, or indirect in listlessness, indecision and vacillation (*feels he has to push self to work or activities*)
 3 Decrease in actual time spent in activities or decrease in productivity. In hospital, rate 3 if patient does not spend at least three hours a day in activities (*hospital job or hobbies*) exclusive of ward chores
 4 Stopped working because of present illness. In hospital, rate 4 if patient engages in no activities except ward chores, or if patient fails to perform ward chores unassisted

9550077

FARMITALIA CARLO ERBA
Erbamont Group

Compound **REBOXETINE**

Protocol No. **2|0|1|2|4|0|1|3**

Centre No.

Patient No.

Initials

Visit/cycle **5|C|R|E|E|N**

Date
D M Y

CONT. ENCLOSURE N°3

8. Retardation (Slowness of thought and speech; Impaired ability to concentrate; decreased motor activity)

0 Normal speech and thought

1 Slight retardation at interview

2 Obvious retardation at interview

3 Interview difficult

4 Complete stupor

3. Agitation

0 None

1 Fidgetiness

2 Playing with hands, hair, etc.

3 Moving about, can't sit still

4 Hand wringing, nail biting, hair-pulling, biting of lips

1. Anxiety psychic

0 No difficulty

1 Subjective tension and irritability

2 Worrying about minor matters

3 Apprehensive attitude apparent in face or speech

4 Fears expressed without questioning

Anxiety somatic

Physiological concomitants of anxiety, such as: Gastro-intestinal (*dry mouth, wind, indigestion, diarrhea, cramps, belching*); Cardio-vascular (*palpitations, headaches*); Respiratory (*hyperventilation, sighing*); Urinary frequency; Sweating

0 Absent

1 Mild

2 Moderate

3 Severe

4 Incapacitating

Somatic symptoms gastrointestinal

0 None

1 Loss of appetite but eating without staff encouragement. Heavy feelings in abdomen

2 Difficulty eating without staff urging. Requests or requires laxatives or medication for bowels or medication for G.I. symptoms

Somatic symptoms general

0 None

1 Heaviness in limbs, back or head. Backaches, headache, muscle aches. Loss of energy and fatigability

2 Any clear-cut symptoms rates 2

Genital symptoms (Such as: Loss of libido; Menstrual disturbances)

0 Absent

1 Mild

2 Severe

Hypochondriasis

0 Not present

1 Self-absorption (bodily)

2 Preoccupation with health

3 Frequent complaints, requests for help, etc.

4 Hypochondriacal delusions

542

FARMITALIA CARLO ERBA
Erbarmont Group

Compound REBOXETINE 9550077

Protocol No. 20124013

Centre No. [][][][]

Patient No. [][][]

Initials [][][]

Visit/cycle [S][C][R][E][E][N]

Date [][][][][][]
D M Y

CONT. ENCLOSURE N°3

16. Loss of weight Rate either A or B

A. When Rating By History:

- 0 No weight loss
- 1 Probable weight loss associated with present illness
- 2 Definite (according to patient) weight loss
- 3 Not assessed

B. On Weekly Ratings By Ward Psychiatrist, When Actual Weight Changes Are Measured:

- 0 Less than 1 lb. weight loss in week
- 1 Greater than 1 lb. weight loss in week
- 2 Greater than 2 lb. weight loss in week
- 3 Not assessed

7. Insight

- 0 Acknowledges being depressed and ill
- 1 Acknowledges illness but attributes cause to bad food, climate, overwork, virus, need for rest, etc.
- 2 Denies being ill at all

9. Diurnal variation

A. Note Whether Symptoms Are Worse In Morning Or Evening. If NO Diurnal Variation, Mark "none":

- 0 No variation
- 1 Worse in A.M.
- 2 Worse in P.M.

B. When Present, Mark The Severity Of The Variation. Mark "None" If NO Variation:

- 0 None
- 1 Mild
- 2 Severe

7. Depersonalization and derealization (Such as: Feelings of unreality, Nihilistic Ideas)

- 0 Absent
- 1 Mild
- 2 Moderate
- 3 Severe
- 4 Incapacitating

7. Paranoid symptoms

- 0 None
- 1 Suspicious
- 2 Ideas of reference
- 3 Delusions of reference and persecution

7. Obsessional and compulsive symptoms

- 0 Absent
- 1 Mild
- 2 Severe

Total score [][]

543

Investigator's signature _____

9550077

FARMITALIA CARLO ERBA
Erbamont Group

Compound REBOXETINE

Protocol No. 2|0|1|2|4|0|1|3

Centre No. [][][][] Patient No. [][][] Initials [][][] Visit/cycle S|C|R|E|E|M

Date [][][][][][]
D M Y

CONT. ENCLOSURE N°3

REVIOUS TREATMENTS

NAME*	EFFICACY (Very poor, Poor, Fair, Good, Very good)	SIDE EFFECTS (if any)
	VP P F G VG	[]
	VP P F G VG	[]
	VP P F G VG	[]
	VP P F G VG	[]
	VP P F G VG	[]

—ast treatment taken: name* _____ Last day of treatment [][][][][][]
D M Y

Drug free, Wash-Out Period: from [][][][][][] to [][][][][][]
D M Y D M Y

CONCOMITANT DRUGS (during the drug free, wash-out period)

NAME*	Daily Dose (mg)	Started on (date)			Discontinued on (date)			Reason for the administration
		D	M	Y	D	M	Y	

Whenever possible use non-proprietary name instead of trade name

Observations: _____

5 4 4

Investigator's signature _____

9550077

ARMITALIA CARLO ERBA
Erbamont Group

Compound REBOXETINE

Protocol No. 2|0|1|2|4|0|1|3

Centre No. [][][][]

Patient No. [][][]

Initials [][][]

Visit/cycle [][][][]

Date [][][][][][]
D M Y

ENCLOSURE N°4

HAMD: HAMILTON DEPRESSION RATING SCALE

1. Depressed mood (*Sadness, hopeless, helpless, worthless*)

- 0 Absent 1 These feeling states indicated only on questioning
 2 These feeling states spontaneously reported verbally
 3 Communicates feeling states non-verbally - i.e., through facial expression, posture, voice, and tendency to weep
 4 Patient reports VIRTUALLY ONLY these feeling states in his spontaneous verbal and non-verbal communication

2. Feelings of guilt

- 0 Absent 1 Self reproach, feels he has let people down
 2 Ideas of guilt or rumination over past errors or sinful deeds
 3 Present illness is a punishment. Delusions of guilt
 4 Hears accusatory or denunciatory voices and/or experiences threatening visual hallucinations

3. Suicide

- 0 Absent 1 Feels life is not worth living
 2 Wishes he were dead or any thoughts of possible death to self
 3 Suicide ideas or gesture
 4 Attempts at suicide (*any serious attempt rates 4*)

4. Insomnia early

- 0 No difficulty falling asleep 1 Complains of occasional difficulty falling asleep - i.e., more than ½ hour
 2 Complains of nightly difficulty falling asleep

5. Insomnia middle

- 0 No difficulty 1 Patient complains of being restless and disturbed during the night
 2 Waking during the night - any getting out of bed rates 2 (*except for purposes of voiding*)

6. Insomnia late

- 0 No difficulty 1 Waking in early hours of the morning but goes back to sleep
 2 Unable to fall asleep again if he gets out of bed

7. Work and activities

- 0 No difficulty
 1 Thoughts and feelings of incapacity, fatigue or weakness related to activities; work or hobbies
 2 Loss of interest in activity; hobbies or work - either directly reported by patient, or indirect in listlessness, indecision and vacillation (*feels he has to push self to work or activities*)
 3 Decrease in actual time spent in activities or decrease in productivity. In hospital, rate 3 if patient does not spend at least three hours a day in activities (*hospital job or hobbies*) exclusive of ward chores
 4 Stopped working because of present illness. In hospital, rate 4 if patient engages in no activities except ward chores, or if patient fails to perform ward chores unassisted

Investigator's signature _____

5 4 5

9550077

FARMITALIA CARLO ERBA
Erbament Group

Compound **REBOXETINE**

Protocol No. 20124013

Centre No.

Patient No.

Initials

Visit/cycle

Date
D M Y

CONT. ENCLOSURE N°4

8. Retardation (*Slowness of thought and speech; Impaired ability to concentrate; decreased motor activity*)

0 Normal speech and thought

1 Slight retardation at interview

2 Obvious retardation at interview

3 Interview difficult

4 Complete stupor

9. Agitation

0 None

1 Fidgetiness

2 Playing with hands, hair, etc.

3 Moving about, can't sit still

4 Hand wringing, nail biting, hair-pulling, biting of lips

10. Anxiety psychic

0 No difficulty

1 Subjective tension and irritability

2 Worrying about minor matters

3 Apprehensive attitude apparent in face or speech

4 Fears expressed without questioning

1. Anxiety somatic

Physiological concomitants of anxiety, such as: Gastro-intestinal (*dry mouth, wind, indigestion, diarrhea, cramps, belching*); Cardio-vascular (*palpitations, headaches*); Respiratory (*hyperventilation, sighing*); Urinary frequency; Sweating

0 Absent

1 Mild

2 Moderate

3 Severe

4 Incapacitating

2. Somatic symptoms gastrointestinal

0 None

1 Loss of appetite but eating without staff encouragement. Heavy feelings in abdomen

2 Difficulty eating without staff urging. Requests or requires laxatives or medication for bowels or medication for G.I. symptoms

3. Somatic symptoms general

0 None

1 Heaviness in limbs, back or head. Backaches, headache, muscle aches. Loss of energy and fatigability

2 Any clear-cut symptoms rates 2

1. Genital symptoms (Such as: *Loss of libido; Menstrual disturbances*)

0 Absent

1 Mild

2 Severe

5. Hypochondriasis

0 Not present

1 Self-absorption (bodily)

2 Preoccupation with health

3 Frequent complaints, requests for help, etc.

4 Hypochondriacal delusions

546

Investigator's signature _____

FARMITALIA CARDI ERBA
Erbamont Group

Compound **REBOXETINE**⁹⁵⁵⁰⁰⁷⁷

Protocol No. 20124013

Centre No.

Patient No.

Initials

Visit/cycle

Date
D M Y

CONT. ENCLOSURE N°4

16. Loss of weight Rate either A or B

A. When Rating By History:

- 0 No weight loss
 1 Probable weight loss associated with present illness
 2 Definite (according to patient) weight loss
 3 Not assessed

B. On Weekly Ratings By Ward Psychiatrist, When Actual Weight Changes Are Measured:

- 0 Less than 1 lb. weight loss in week
 1 Greater than 1 lb. weight loss in week
 2 Greater than 2 lb. weight loss in week
 3 Not assessed

17. Insight

- 0 Acknowledges being depressed and ill
 1 Acknowledges illness but attributes cause to bad food, climate, overwork, virus, need for rest, etc.
 2 Denies being ill at all

8. Diurnal variation

A. Note Whether Symptoms Are Worse In Morning Or Evening. If NO Diurnal Variation, Mark "none":

- 0 No variation 1 Worse in A.M. 2 Worse in P.M.

B. When Present, Mark The Severity Of The Variation. Mark "None" If NO Variation:

- 0 None 1 Mild 2 Severe

9. Depersonalization and derealization (Such as: Feelings of unreality, Nihilistic ideas)

- 0 Absent 1 Mild 2 Moderate
 3 Severe 4 Incapacitating

20. Paranoid symptoms

- 0 None
 1 Suspicious
 2 Ideas of reference
 3 Delusions of reference and persecution

1. Obsessional and compulsive symptoms

- 0 Absent 1 Mild 2 Severe

Total score

547

Investigator's signature _____

FARMITALIA CARLO ERBA
Erbamont Group

Compound REBOXERIN 5077

Protocol No. 201124013

Centre No. () () () ()

Patient No. () () () ()

Initials () () () ()

Visit/cycle () () () () () () () ()

Date () () () () () ()
D M Y

CLINICAL GLOBAL IMPRESSION (CGI)

ENCLOSURE N°5

A. SEVERITY OF ILLNESS

Considering your clinical experience with this particular population, how mentally ill is the patient at this time?

- 1 Normal, not at all ill
- 2 Borderline mentally ill
- 3 Mildly ill
- 4 Moderately ill
- 5 Markedly ill
- 7 Severely ill
- 8 Among the most extremely ill patients

B. GLOBAL IMPROVEMENT (rate total improvement whether or not, in your judgement, it is due entirely to drug treatment)

Compared to this condition at admission to the study, how much has he changed?

- 1 Very much improved
- 2 Much improved
- 3 Minimally improved
- 4 No change
- 5 Minimally worse
- 6 Much worse
- 7 Very much worse

C. EFFICACY INDEX (rate this item on the basis of drug effect only)

Activity	Tolerability: side effects			
	None	Do not significantly interfere with patient's functioning	Significantly interfere with patient's functioning	Outweigh therapeutic effect
MARKED Vast improvement, complete or nearly complete remission of all symptoms	1	2	3	4
MODERATE Decided improvement, partial remission of symptoms	5	6	7	8
MINIMAL Slight improvement which does not alter status of care of patient	9	10	11	12
UNCHANGED OR WORSE	13	14	15	16

548 Investigator's signature _____

FARMITALIA CARLO ERBA
Ebamont Group

Compound REBOXETINE ⁹⁵⁵⁰⁰⁷⁷

Protocol No. [2][0][1][2][4][0][1]

Centre No. [][][][][]

Patient No. [][][][]

Initials [][][]

Visit/cycle [][][][][][]

Date [][][][][][][]
D M Y

ENCLOSURE No 6

MADRS: MONTGOMERY ASBERG DEPRESSION RATING SCALE

1. Reported sadness

- Representing subjectively experienced mood, regardless of whether it is reflected in appearance or not. Includes depressed mood, low spirits, despondency, and the feeling of being beyond help and without hope.
- Rate according to intensity, duration and the extent to which the mood is influenced by events.
- Elated mood is scored zero on this item.

Occasional sadness may occur in the circumstances [0]; Predominant feelings of sadness, but brighter moments occur [1]; Pervasive feelings of sadness or gloominess, the mood is hardly influenced by external circumstances [2]; Continuous experience of misery or extreme despondency [3].

2. Inner tension

- Representing feelings of ill-defined discomfort, edginess, inner turmoil, mental tension mounting to panic, dread and anguish.
- Rate according to intensity, frequency, duration and the extent of reassurance called for.
- Distinguish from sadness, worrying and muscular tension.

Placid, only fleeting inner tension [0]; Occasional feelings of edginess and ill-defined discomfort [1]; Continuous feelings of inner tension, or intermittent panic which the patient can only master with some difficulty [2]; Unrelenting dread or anguish, overwhelming panic [3].

3. Apparent sadness

- Representing despondency, gloom, and despair (more than just ordinary transient low spirits) reflected in speech, facial expression, and posture, rate by depth and inability to brighten up.

No sadness [0]; Looks dispirited but brightens up occasionally [1]; Appears sad and unhappy all of the time [2]; Extreme and continuous gloom and despondency [3].

4. Suicidal thoughts

- Representing the feeling that life is not worth living, that a natural death would be welcome, suicidal thoughts, and preparations for suicide.
- Suicidal attempts should not in themselves influence the rating.

Enjoys life or takes it as it comes [0]; Weary of life, only fleeting suicidal thoughts [1]; Much better off dead. Suicidal thoughts are common, and suicide is considered as a possible solution, but without specific plans or intention [2]; Explicit plans for suicide when there is an opportunity, active preparation for suicide [3].

5. Inertia

- Representing a difficulty getting started or slowness initiating and performing everyday activities
- Distinguish from indecision and fatigability.

No difficulty in getting started. No sluggishness [0]; Difficulties in starting new activities [1]; Difficulties in starting very simple routine activities, which are carried out only with effort [2]; Complete inertia, unable to start any activity without help [3].

6. Inability to feel

- Representing the subjective experience of reduced interest in the surroundings, or activities that normally give pleasure. The ability to react with adequate emotion to circumstances or people is produced.
- Distinguish from inertia

Normal interest in the surroundings and in other people [0]; Reduced ability to enjoy usual interests. Reduced ability to feel anger [1]; loss of interest in the surroundings. Loss of feelings for friends and acquaintances [2]; The experience of being emotionally paralyzed, inability to feel anger or grief, and a complete or even painful failure to feel for close relatives and friends [3].

Investigator's signature _____

FARMITALIA CARLO ERBA
Erbamont Group

Compound REBOXETINE 0550077

Protocol No. 20124011

Centre No. [][][][]

Patient No. [][][][]

Initials [][][]

Visit/cycle [][][][][]

Date [][][][][][][]
D M Y

CONT. ENCLOSURE N°6

7. Pessimistic thoughts

- Representing thoughts of guilt, inferiority, self-reproach, sinfulness, remorse and ruin.

No pessimistic thoughts [0]; fluctuating ideas of failure, self-reproach or self-depreciation [1]; Persistent self-accusations, or definite but still rational ideas of guilt or sin. Increasingly pessimistic about the future [2];

Delusions of ruin, remorse and unredeemable sin. Absurd self-accusations [3].

8. Concentration difficulties

- Representing difficulties in collecting one's thoughts amounting to incapacitating lack of concentration.

- Rate according to intensity, frequency, and degree of incapacity recorded.

- Distinguish from failing memory and disrupted thought.

No difficulties in concentrating [0]; Occasional difficulties in collecting one's thoughts [1]; Difficulties in concentrating and sustaining thoughts which interfere with reading or conversation [2]; Incapacitating lack of concentration [3].

9. Reduced sleep

- Representing a subjective experience of reduced duration or depth of sleep compared to the subject's own fitful sleep.

Sleep as usual [0]; Slight difficulty dropping off to sleep or slightly reduced, light or fitful sleep [1]; sleep reduced or broken by at least 2 hours [2]; Less than two or three hours sleep [3].

10. Reduced appetite

- Representing the feeling of a loss of appetite compared with when well.

Normal or increased appetite [0]; Slightly reduced appetite [1]; No appetite. Food is tasteless. Need to force oneself to eat [2]; Must be forced to eat. Food refusal [3].

Total score [][][]

550
Investigator's signature _____

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

9550077

Enclosure N°7

FARMITALIA CARLO ERBA
Erbamont Group

Compound REBOXETINE

Protocol No. 121011241013

CENTER No. _____

PATIENT No. _____

INITIALS _____

VISIT/CYCLE _____

INVESTIGATOR'S NAME: _____ MONITOR'S NAME: _____ DATE _____
D M Y

ZUNG S.D.S.

STATEMENT	NONE OR A LITTLE OF THE TIME	SOME OF THE TIME	A GOOD PART OF THE TIME	MOST OR ALL OF THE TIME
1) I feel down hearted and blue	1	2	3	4
2) Morning is when I feel the best	4	3	2	1
3) I have crying spells or feel like it	1	2	3	4
4) I have trouble sleeping at night	1	2	3	4
5) I eat as much as I used to	4	3	2	1
6) I still enjoy sex	4	3	2	1
7) I notice that I am losing weight	1	2	3	4
8) I have trouble with constipation	1	2	3	4
9) My heart beats faster than usual	1	2	3	4
10) I get tired for no reason	1	2	3	4
11) My mind is as clear as it used to be	4	3	2	1
12) I find it easy to do the things I used to do	4	3	2	1
13) I am restless and can't keep still	1	2	3	4
14) I feel hopeful about the future	4	3	2	1
15) I am more irritable than usual	1	2	3	4
16) I find it easy to make decisions	4	3	2	1
17) I feel that I am useful and needed	4	3	2	1
18) My life is pretty full	4	3	2	1
19) I feel that others would be better off if I were dead	1	2	3	4
20) I still enjoy the things I used to do	4	3	2	1

TOTAL SCORE _____

SIGNATURE _____

9550077

FARMITALIA CARLO ERBA Erbarmont Group Compound **REBOXETINE** Protocol No. 2|0|1|2|4|0|1|3|
 Centre No. Patient No. Initials Visit/cycle
 Date _{D M Y}

ENCLOSURE Nº 8

ADVERSE EVENT REPORT FORM*

REPORT STATUS 1 initial 2 follow-up 3 final

1. DESCRIPTION/DURATION			
Adverse event (verbatim): _____			
<u>Report:</u>		<u>Onset date:</u>	<u>Still present:</u>
1 <input type="checkbox"/> spontaneously		<u> </u> <u> </u> <u> </u> d m y	1 <input type="checkbox"/> no 2 <input type="checkbox"/> yes
2 <input type="checkbox"/> non-leading question			<u> </u> <u> </u> <u> </u> d m y
3 <input type="checkbox"/> check list		<u>Onset time:</u>	<u>Last dosing before:</u>
		<u> </u> <u> </u> h m	<u> </u> <u> </u> <u> </u> <u> </u> d a y h
			<u>End time:</u>
			<u> </u> <u> </u> h m
In case of multiple episodes, give mean duration: days: <u> </u> hours: <u> </u> min.: <u> </u>			
2. CHARACTERIZATION			
<u>Severity:</u>	<u>Source:</u>	<u>Frequency:</u>	<u>History:</u>
1 <input type="checkbox"/> mild	1 <input type="checkbox"/> physician	1 <input type="checkbox"/> single episode	1 <input type="checkbox"/> observed before the current treatment
2 <input type="checkbox"/> moderate	2 <input type="checkbox"/> patient	2 <input type="checkbox"/> continuous	2 <input type="checkbox"/> not observed before
3 <input type="checkbox"/> severe	3 <input type="checkbox"/> others, specify _____	3 <input type="checkbox"/> multiple episodes, specify No. of episodes: <input type="checkbox"/>	3 <input type="checkbox"/> unknown
4 <input type="checkbox"/> unknown			
3. ACTION TAKEN			
<u>Hospitalization:</u>	<u>Study drug:</u>	<u>Other actions:</u>	
1 <input type="checkbox"/> required	1 <input type="checkbox"/> no change	1 <input type="checkbox"/> discontinuation of other medication: _____	
2 <input type="checkbox"/> not required	2 <input type="checkbox"/> dose reduced	2 <input type="checkbox"/> symptomatic treatment: _____	
	3 <input type="checkbox"/> definitively withdrawn	3 <input type="checkbox"/> other action: _____	
<u>Code opened:</u>	4 <input type="checkbox"/> temporarily interrupted, specify No. of days: <u> </u>		
1 <input type="checkbox"/> no 2 <input type="checkbox"/> yes			
4. DECHALLENGE/RECHALLENGE			
Did the adverse event disappear after treatment withdrawal or dose reduction?	1 <input type="checkbox"/> no 2 <input type="checkbox"/> yes 3 <input type="checkbox"/> not applicable	Did the adverse event reappear on resuming treatment?	1 <input type="checkbox"/> no 2 <input type="checkbox"/> yes 3 <input type="checkbox"/> not applicable
5. PREDISPOSING OR CONTRIBUTING CONDITIONS			
1 <input type="checkbox"/> no 2 <input type="checkbox"/> yes, specify: _____			

* FILL IN ONE FORM BY SINGLE EVENT (if serious or unexpected promptly inform the Study Monitor)

552 Investigator's signature _____

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

9550077

FARMITALIA CARLO ERBA
Erbamont Group

Compound REBOXETINE

Protocol No. 2|0|1|2|4|0|1|3

Centre No. [][][][][]

Patient No. [][][][]

Initials [][][][]

Visit/cycle [][][][][][][]

Date [][][][][][][]
D M Y

CONT: ENCLOSURE Nº6

6. RELATIONSHIP TO STUDY MEDICATION (according to modified Karch and Lasagna criteria, see protocol)		1 <input type="checkbox"/> definite	4 <input type="checkbox"/> doubtful
		2 <input type="checkbox"/> probable	5 <input type="checkbox"/> none
		3 <input type="checkbox"/> possible	6 <input type="checkbox"/> unknown
7. OUTCOME OF EVENT TO DATE (if patient died, fill in the Death Report Form)		1 <input type="checkbox"/> recovered	3 <input type="checkbox"/> still present
		2 <input type="checkbox"/> recovered with sequelae	4 <input type="checkbox"/> death
8. ADDITIONAL INVESTIGATIONS			
Specific laboratory tests performed?		Other diagnostic procedures?	
1 <input type="checkbox"/> no	if yes, date: [][][][][][][]	1 <input type="checkbox"/> no	if yes, specify: _____
2 <input type="checkbox"/> yes	d m y	2 <input type="checkbox"/> yes	and attach the results
9. DESCRIPTIVE SUMMARY/OTHER RELEVANT MEDICAL DATA			

Investigator's signature _____			

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

9550077

Attachment A

REBOXETINE PROTOCOL 20124/013: OPERATING PROCEDURES FOR TRAINING ON ASSESSMENT INSTRUMENTS, STUDY MONITORING AND COORDINATION.

Aim

The purpose of these procedures is to provide standardization of the study conduct in the different clinical centers and to assure data uniformity and compatibility by appropriate interventions during data gathering.

Inter-rater reliability

Prior to commencement of the clinical trial:

- training on diagnostic assessments will be conducted during the first Investigator-meeting and first site visit.

During the clinical trial:

- inter-rater agreement for the instruments used in the assessment of change will be tested on the occasion of the monitoring visits by employing 4 videotaped interviews.

Study monitoring

During the course of the study (24-months) one monitoring visit will be conducted by the Scientific Coordinator of the study (Prof. T. Ban) and monthly to bi-monthly monitoring visits will be conducted by Study Monitors from Farmitalia Carlo Erba.

The start-up visit will take place after approval of the protocol by the Institutional Review Board (IRB) or Ethical Committee. On this visit the following documents will be collected:

- copy of the protocol signed by the Principal Investigator;
- CV of Principal Investigator and Co-Investigators;
- the written approval of the study (typed on the Institute's letter head) by the Hospital or University Center Review Board and the IRB members list;

9550077

Prot. N° 20124/013 Cont. Attachment A

- an IRB approved blank copy of the consent form;
- the list of the laboratory normal values or ranges of the lab. tests.

These documents will be sent to FICE-Milan (A. Faja). On the occasion of this visit the monitor will also check that the CRFs and the drug supply have been delivered to the Clinical Investigator and the accompanying letter, signed by the Clinical Investigator, will be collected. In addition the Monitor will identify the staff members who will be involved in the study conduct and the monitoring visits schedule will be agreed.

Following the start-up visit the form A (enclosed) will be filled in. Copy of it will be sent to A. Faja in Milan.

The first monitoring visit will be done immediately after the recruitment of the first two, three patients.

The periodic monitoring visits are carried out in order to:

- 1 verify protocol adherence: patient eligibility (page 1 of the CRF), times of assessments, completeness of data, pill count;
 - 2 verify data consistency looking for inconsistencies or errors in the data recorded on the CRF;
 - 3 verify the accuracy of data collection in CRFs against the original clinic or hospital records for:
 - pt initials and hospital record no
 - signed informed consent
 - study medication administration and concomitant medications
 - physician notes on adverse events
 - 20% of data for laboratory tests, patient history and vital signs; in case of an error rate > 15% all data need to be monitored;
 - total Hamilton score reported in the hospital record.
- Source-verified data can be initialled by the study monitor in the CRF.
- 4 review all adverse events including laboratory abnormalities, occurred since the previous visit. Should the information of a serious, or unexpected adverse event newly emerge, the local study Monitor

9550077

Prot. N° 20124/013

Cont. Attachment A

must immediately (within two working days) inform the Product Leader in Milan;

- 5 evaluate patient recruitment rate and treatment discontinuations;
- 6 verify study medication storage and accountability and collect bottles of completed treatments;
- 7 ensure continued acceptability of the facilities and of the staff.

CRFs will be completed in black ink and corrections, if needed, made only by the Clinical Investigator with a single line throughout; the corrections will be initialled by Clinical Investigator and dated. Each page of each completed CRF will be signed by Clinical Investigator.

After review for accuracy and completeness, the original and first copy of each page of the CRF will be removed (leaving the second copy with the Investigator). The first copy will be sent to Milan by Special Delivery Service for review and data processing while the original will be retained by the Monitor in the subsidiary until completion of the whole treatment period of the individual patient.

After each monitoring visit the periodic site visit report and the patients progress report form (form B and C enclosed) will be filled in. Copy of them will be sent to A. Faja in Milan.

The study termination visit will be performed upon Investigator's completion of all CRFs of treated patients. During this visit:

- 1 the monitor will check and collect the remaining completed CRFs and will perform a final data review;
- 2 a final check and review of drug accounting, inventorying of remaining drug supplies and arrangement to send them to FICE will be done;
- 3 a time frame for study reporting will be discussed;
- 4 appropriate follow-up of patients under long-term treatment will be assured and monitoring and collection of data from these patients discussed and agreed

The study termination visit form (form D) will be filled in and copy of it sent to A. Faja.

9550077

Prot. N° 20124/013

Cont. Attachment A

Study coordination

In order to obtain uniformity and standardization in the carrying out of the study a Steering Committee is established. All questions arising during the conduct of the study will be submitted to the Committee for advice and action taking.

In particular the Committee will take care of:

- queries about patients acceptability
- possible need of protocol amendments
- possible need of premature termination of the study
- acceptability of particular cases of protocol violations
- evaluation of clinically relevant adverse events and their scientific and ethical consequences in terms of issues raised or study discontinuation.

Members of the Committee will be: Prof. T. Ban (Vanderbilt University), Chairman; Dr. I. Cohen, legal aspects; Dr. L. Morey (biometric aspects).

Any problem or issue arising during the conduct of the study will be submitted to the Committee in writing by the Clinical Investigators or by the study Monitors. "Ad hoc" meetings of the Committee will be organized when needed. File note of the meeting with conclusions about action taking will be circulated to Clinical Investigators and study Monitors.

- 4 -

557



9550077

FORM A 1*

START-UP VISIT

PRODUCT: REBOXETINE PROTOCOL N.: 20124/013 DATE OF THE VISIT: _____
CENTER N.: _____ PREVIOUS VISIT: _____

INVESTIGATOR AND SITE: _____

NUMBER OF PATIENTS: _____ START DATE: [] [] [] [] [] []

STAFF MEMBERS

NAME	RESPONSIBILITY
_____	_____
_____	_____
_____	_____
_____	_____
_____	_____

FACILITIES (Lab/Clinical) adequate YES NO

List and comments:

MONITOR'S NAME: _____ SIGNATURE: _____ DATE: _____

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

START-UP VISIT (cont'd)

PRODUCT: REBOXETINE

PROTOCOL N.: 20124/013

DATE: _____

CENTER N.: _____

CHECK OF DOCUMENTS

Document	Obtained	
	YES	NO
Signed protocol	<input type="checkbox"/>	<input type="checkbox"/>
CV of investigator	<input type="checkbox"/>	<input type="checkbox"/>
CV of co-investigator	<input type="checkbox"/>	<input type="checkbox"/>
IRB approval	<input type="checkbox"/>	<input type="checkbox"/>
IRB member list	<input type="checkbox"/>	<input type="checkbox"/>
Consent form	<input type="checkbox"/>	<input type="checkbox"/>
Laboratory licence (if applicable)	<input type="checkbox"/>	<input type="checkbox"/>
Normal lab. values	<input type="checkbox"/>	<input type="checkbox"/>

COMMENTS

CHECK OF STUDY MATERIAL

Test drug supply: delivered on

CRFs : delivered on N. of copies:

Written receipt obtained YES NO

MONITOR'S NAME: _____

SIGNATURE: _____

DATE: _____



9550077

FORM A 3*

START-UP VISIT (cont'd)

PRODUCT: REBOXETINE

PROTOCOL N.: 20124/013

DATE:

CENTER N.:

DISCUSSED TOPICS

	YES	NO	Comments (if need fill in the form A 4)
Protocol	<input type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>
CRF (signature, corrections, storage)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>
Consent form	<input type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>
Investigator's brochure	<input type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>
Monitoring schedule	<input type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>
Audit agreed	<input type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>
Drug accountability	<input type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>
Source documents available	<input type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>
Reporting of adverse events	<input type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>
Procedure for amending protocol	<input type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>
IRB reporting requirements	<input type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>
Start and completion dates	<input type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>
Visit to pharmacy (if applicable)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>

COMMENTS:

MONITOR'S NAME:

SIGNATURE:

DATE:

 **FARMITALIA CARLO ERBA**
ERBAMONT GROUP

9550077

FORM A 4*

START-UP VISIT (cont'd)

PRODUCT: REBOXETINE

PROTOCOL N.: 20124/013

DATE:

CENTER N.:

OVERALL IMPRESSION AND COMMENTS

MONITOR'S NAME:

SIGNATURE:

DATE:



9550077

FORM B 1*

TRIAL PROGRESS REPORT

PRODUCT: REBOXETINE VISIT
 TELEPHONE DATE:
 DATE OF PREV. VISIT:

INVESTIGATOR ADDRESS PROT. N. 20124/013 CENTER N.

START DATE: SCHEDULED END DATE:

NUMBER OF CASES

To be recruited	Entered	Entered after last contact	Still under treatment	Completed	Discontinued (drop-out)
					Total
					Adv. events
					Other

STUDY REVIEW

	YES	NO
1. Changes in key staff member	<input type="checkbox"/>	<input type="checkbox"/>
2. Changes lab. facilities/normal values	<input type="checkbox"/>	<input type="checkbox"/>
3. Is protocol (incl./excl. criteria, randomization, blinding etc.) adhered to?	<input type="checkbox"/>	<input type="checkbox"/>
4. CRF's properly completed (legibility, missing data, signature, corrections)	<input type="checkbox"/>	<input type="checkbox"/>
5. Have CRF's checked against source documents?	<input type="checkbox"/>	<input type="checkbox"/>
6. Have any serious or unexpected adverse events been observed?	<input type="checkbox"/>	<input type="checkbox"/>
7. If yes, are they duly reported?	<input type="checkbox"/>	<input type="checkbox"/>
8. Have all informed consents been obtained?	<input type="checkbox"/>	<input type="checkbox"/>
9. Is there adequate documentation regarding drop outs?	<input type="checkbox"/>	<input type="checkbox"/>
10. Are adequate drug accountability record being obtained?	<input type="checkbox"/>	<input type="checkbox"/>
11. Are investigational drug supplies being stored properly?	<input type="checkbox"/>	<input type="checkbox"/>
12. Does the investigator have sufficient supplies of the test articles?	<input type="checkbox"/>	<input type="checkbox"/>
* Comment "no" box checked above in monitor's finding and corrective actions form (if applicable) Properly fill, for each subject, the Study Progress form		

SCHEDULED DATE FOR NEXT VISIT:

MONITOR'S NAME: SIGNATURE: DATE:

FARMITALIA CARLO ERBA
ERBAMONT GROUP

9550077

FORM B 2*

TRIAL PROGRESS REPORT (cont'd)

PRODUCT: REBOXETINE VISIT DATE:
TELEPHONE DATE OF PREV. VISIT:

INVESTIGATOR ADDRESS PROT. N. 20124/013 CENTER N.

MONITOR'S FINDING AND CORRECTIVE ACTIONS

MONITOR'S NAME: SIGNATURE: DATE:

PRODUCT: REBOXETINE PROTOCOL N.: 20124/013 DATE OF VISIT: _____
CENTER N.: _____

INVESTIGATOR: _____

REASON FOR TERMINATION

STUDY COMPLETED

STUDY INTERRUPTED : indicate the reason _____

STORAGE OF INVESTIGATOR'S RECORDS:

(Signed protocol and amendments, Informed Consent Forms, CRF, Ethical Committee Approval, Correspondence)

- Is the investigator's file concerning this study complete? yes no

- Where are stored these records? _____

- Which duration for storage has been indicated to the investigator? _____

HAS THE FINAL DRUG ACCOUNTABILITY FORM BEEN COMPLETED?

Yes No

DISCUSSED TOPICS:

Preliminary Report Yes No if yes, when: _____

Statistical Report: Availability date: _____

Final Report: Scheduled date of submission for signature _____

Publication

Congress

Payment

Other topics: _____

MONITOR'S NAME: _____

SIGNATURE: _____

DATE: _____

FARMIVALIA CARLO ERBA
ERBAMONT GROUP

9550077

CORPORATE MEDICAL COORDINATION

Enclosure 9

APPENDIX 2

ADVERSE DRUG REACTION - A CRITICAL REVIEW

GUIDELINES FOR DETERMINING CAUSE-EFFECT RELATIONSHIP
(According to Karch and Lasagna, JAMA 234: 1236-41,1975, modified)

1. DEFINITE (or CERTAIN)

A reaction that follows a reasonable temporal sequence from administration of the drug or in which the drug level has been established in body fluids or tissues; that follows a known response pattern to the suspected drug; and that is confirmed by improvement on stopping the drug (dechallenge), and reappearance of the reaction on repeated exposure (rechallenge).

2. PROBABLE

A reaction that follows a reasonable temporal sequence from administration of the drug; that follows a known response pattern to the suspected drug; that is confirmed by dechallenge; and that could not be reasonably explained by the known characteristics of the patient's clinical state.

3. POSSIBLE

A reaction that follows a reasonable temporal sequence from administration of the drug; that follows a known response pattern to the suspected drug; but that could have been produced by the patient's clinical state or other modes of therapy administered to the patient.

4. DOUBTFUL

Any reaction that does not meet the criteria above and is not judged as not drug related or unknown.

5. UNKNOWN

Relationship for which no evaluation can be made.

6. NOT DRUG RELATED

Any reaction that is judged as definitely due to conditions (causes) different from the drug.

FARMUTALLA CARLO ERBA
ERBAMONT GROUP

9550077

CORPORATE MEDICAL COORDINATION

Enclosure 10

DECLARATION OF HELSINKI

Recommendations guiding physicians in biomedical research involving human subjects

Adopted by the 18th World Medical Assembly, Helsinki, Finland, June 1964, amended by the 29th World Medical Assembly, Tokyo, Japan, October 1975, and the 35th World Medical Assembly, Venice, Italy, October 1983.

INTRODUCTION

It is the mission of the physician to safeguard the health of the people. His or her knowledge and conscience are dedicated to the fulfilment of this mission.

The declaration of Geneva of the World Medical Association binds the physician with the words, "The health of my patient will be my first consideration", and The International Code of Medical Ethics declares that, "A physician shall act only in the patient's interest when providing medical care which might have the effect of weakening the physical and mental condition of the patient".

The purpose of biomedical research involving human subjects must be to improve diagnostic, therapeutic and prophylactic procedures and the understanding of the aetiology and pathogenesis of disease.

In current medical practice most diagnostic, therapeutic or prophylactic procedures involve hazards. This applies especially to biomedical research.

Medical progress is based on research which ultimately must rest in part on experimentation involving human subjects.

In the field of biomedical research a fundamental distinction must be recognized between medical research in which the aim is essentially diagnostic or therapeutic for a patient, and medical research the essential object of which is purely scientific and without implying direct diagnostic or therapeutic value to the person subjected to the research.

Special caution must be exercised in the conduct of research which may affect the environment, and the welfare of animals used for research must be respected.

- 1 -

568

FARMITALIA CARLO ERBA
ERBAMONT GROUP

9550077

CORPORATE MEDICAL COORDINATION

cont. Encl. 10

Because it is essential that the results of laboratory experiments be applied to human beings to further scientific knowledge and to help suffering humanity, The World Medical Association has prepared the following recommendations as a guide to every physician in biomedical research involving human subjects. They should be kept under review in the future. It must be stressed that the standards as drafted are only a guide to physicians all over the world. Physicians are not relieved from criminal, civil and ethical responsibilities under the law of their own countries.

I. BASIC PRINCIPLES

1. Biomedical research involving human subjects must conform to generally accepted scientific principles and should be based on adequately performed laboratory and animal experimentation and on a thorough knowledge of the scientific literature.
2. The design and performance of each experimental procedure involving human subjects should be clearly formulated in an experimental protocol which should be transmitted to a specially appointed independent committee for consideration, comment and guidance.
3. Biomedical research involving human subjects should be conducted only by scientifically qualified persons and under the supervision of a clinically competent medical person. The responsibility for the human subject must always rest with a medically qualified person and never rest on the subject of the research, even though the subject has given his or her consent.
4. Biomedical research involving human subjects cannot legitimately be carried out unless the importance of the objective is in proportion to the inherent risk to the subject.
5. Every biomedical research project involving human subjects should be preceded by careful assessment of predictable risks in comparison with foreseeable benefits to the subject or to others. Concern for the interests of the subject must always prevail over the interests of science and society.
6. The right of the research subject to safeguard his or her integrity must always be respected. Every precaution should be taken to respect the privacy of the subject and to minimize the impact of the study on the subject's physical and mental integrity and on the personality of the subject.
7. Physicians should abstain from engaging in research projects involving human subjects unless they are satisfied that the hazards involved are believed to be predictable. Physicians should cease any investigation if the hazards are found to outweigh the potential benefits.

FACULTY LIAISON
MONTMONT GROUP

9550077

CORPORATE MEDICAL COORDINATION

cont. Encl. 10

8. In publication of the results of this or her research, the physician is obliged to preserve the accuracy of the results. Reports of experimentation not in accordance with the principles laid down in this Declaration should not be accepted for publication.

9. In any research on human beings, each potential subject must be adequately informed of the aims, methods, anticipated benefits and potential hazards of the study and the discomfort it may entail. He or she should be informed that he or she is at liberty to abstain from participation in the study and that he or she is free to withdraw his or her consent to participation at any time. The physician should then obtain the subject's freely given informed consent, preferably in writing.

10. When obtaining informed consent for the research project the physician should be particularly cautious if the subject is in a dependent relationship to him or her or may consent under duress. In that case the informed consent should be obtained by a physician who is not engaged in the investigation and who is completely independent of this official relationship.

11. In case of legal incompetence, informed consent should be obtained from the legal guardian in accordance with national legislation. Where physical or mental incapacity makes it impossible to obtain informed consent, or when the subject is a minor, permission from the responsible relative replaces that of the subject in accordance with national legislation. Whenever the minor child is in fact able to give a consent, the minor's consent must be obtained in addition to the consent of the minor's legal guardian.

12. The research protocol should always contain a statement of the ethical considerations involved and should indicate that the principles enunciated in the present declaration are complied with.

II. MEDICAL RESEARCH COMBINED WITH PROFESSIONAL CARE (Clinical research)

1. In the treatment of the sick person, the physician must be free to use a new diagnostic and therapeutic measure, if in his or her judgement it offers hope of saving life, reestablishing health or alleviating suffering.

2. The potential benefits, hazards and discomfort of a new method should be weighed against the advantages of the best current diagnostic and therapeutic methods.

3. In any medical study, every patient - including those of a control group, if any - should be assured of the best proven diagnostic and therapeutic method.

4. The refusal of the patient to participate in a study must never interfere with the physician-patient relationship.

FARMITALIA CARLO ERBA
ERBAMONT GROUP

9550077

CORPORATE MEDICAL COORDINATION

Cont. Encl. 10

5. If the physician considers it essential not to obtain informed consent, the specific reasons for this proposal should be stated in the experimental protocol for transmission to the independent committee (1,2).

6. The physician can combine medical research with professional care, the objective being the acquisition of new medical knowledge, only to the extent that medical research is justified by its potential diagnostic or therapeutic value for the patient.

III. NON-THERAPEUTIC BIOMEDICAL RESEARCH INVOLVING HUMAN SUBJECTS

(Non-clinical biomedical research)

1. In the purely scientific application of medical research carried out on a human being, it is the duty of the physician to remain the protector of the life and health of that person on whom biomedical research is being carried out.

2. The subjects should be volunteers - either healthy persons or patients for whom the experimental design is not related to the patient's illness.

3. The investigator or the investigating team should discontinue the research if in his/her or their judgement it may, if continued, be harmful to the individual.

4. In research on man, the interest of science and society should never take precedence over considerations related to the well-being of the subject.

- 4 -

571

9550077

Pharmacia

Document 9550077

12.1.2 CRF SAMPLE

A complete CRF sample is filed in the Study Master File

9550077

Pharmacia

Document 9550077

12.1.3 ETHICS COMMITTEES OR INVESTIGATIONAL REVIEW BOARDS:
APPROVALS, LIST OF MEMBERS, PATIENT INFORMATION AND
CONSENT FORMS

Investigational Review Boards and Ethics Committees approvals were obtained according to local regulations and laws: copy of the approval documents and , in case of Ethics Committees, list of members is filed in the Study Master File.

The proposed consent form is enclosed (Enclosure 1 of Appendix 12.1.1). Copy of forms approved by Ethics Committees and local translations are filed in the Study Master File.

9550077

Pharmacia

Document 9550077

12.1.4 CLINICAL INVESTIGATORS LIST, SIGNATURES AND CURRICULA VITAE

PRINCIPAL INVESTIGATORS AND AFFILIATIONS

- Centre 1: Professor M Versiani (Principal investigator)
Dr AE Nardi, Dr IL Figueira (Co-investigators)
Institute of Psychiatry, Federal University, Rio de Janeiro,
Brazil
- Centre 2: Professor K Ernst (Principal investigator)
Dr Schläfhe (Co-investigators)
W. Pieck Universität, Rostock, Germany
- Centre 3: Dr RA Castiglioni (Principal investigator)
Dr I Note (Co-investigator)
Hôpital Sainte Marguerite, Service de Psychiatrie, Marseille,
Cedex, France
- Centre 8: Dr A Lipcsey (Principal investigator)
Dr E Nagy (Co-investigator)
Neuro-Psychiatric Department, Janos General Hospital,
Budapest, Hungary
- Centre 9: Dr P Gaszner (Principal investigator)
Dr A Tar (Co-investigator)
National Institute for Nervous and Mental Diseases, Budapest,
Hungary
- Centre 10: Professor L Mehilane (Principal investigator)
Dr Shlik, Dr Jakou (Co-investigators)
Department of Psychiatry, University Tartu, Tartu, Estonia
- Centre 11: Dr G Osztorharics (Principal investigator)
Dr E Timea, Dr K Vilma (Co-investigators)
Megyei Korház Pszichiatriai, Osztálya, Győr, Hungary
- Centre 12: Professor A Szucs (Principal investigator)
Dr S Kalmár (Co-investigator)
Hollós József Megyei Korház, Pszichiatriai Osztálya,
Kecskemét, Hungary
- Centre 13: Dr T Hortobagyi (Principal investigator)
Városi Korház Pszichiatriai, Osztálya, Nagykanizsa, Hungary

Investigators' signatures and Curricula vitae are filed in the Study Master File.

9550077

Pharmacia

Document 9550077

12.1.5 CERTIFICATES OF ANALYSIS

9550077

VIA CARLO IMBONATI, 24
20159 MILANO



TELEFONO (02) 69961 (CENTRALINO)
TELEGRAMMI: ERBACAR MILANO
CASSELLA POSTALE 10519
C.C. POSTALE 619205
TELEX 330314 ERBA I

DATA November 18th, 1992

VS RIF.

NS RIF.

CERTIFICATE OF ANALYSIS

TEL. DIRETTO

REBOXETINE 4 mg tablets

Batch SF 1032

Manufacturing date : June, 1989
Expiry date : May, 1993
Active drug substance : RR 16N055
Appearance : round, convex, 8 mm diameter,
white tablet with a breakline
on one surface, and marked S.F.
on the other
Identification : positive
Average weight : mg 199.33
Uniformity of content : within the limits, according to Eur.
Ph. 2nd Ed., section V.5.2.2
Assay : mg 3.967 of Reboxetine/tablet
Related substances : 0.72%
Dissolution : 92.86% of the L.A. after 15 minutes
Microbial contamination : total viable aerobic count < 1000
moulds and yeasts < 100
E. Coli and Salmonellae : absent
Reanalysis date : November 18th, 1992

NOTE : this certificate replaces the previous one, edited on
April 27th 1992, owing to the extension of the shelf-life

Approved by

: Virginio Busnelli

S.R.L. - SEDE LEGALE IN MILANO
CAPITALE L. 528.732.127.000 I.V.
TRIBUNALE DI MILANO R.S. N. 238246
VOL. 6366 FASC. 46 C.C.I.A.A. N. 1171077
COD. FISC. E PART. IVA N. 07608290156

GRUPPO ERBAMONT

576

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

9550077

VIA CARLO IMBONATI, 24
20159 MILANO

TELEFONO (02) 69961 (CENTRALINO)
TELEGRAMMI ERBACAP-MILANO
CASELLA POSTALE 10519
C.C. POSTALE 819205
TELEX 330314 ERBA-I

 **FARMITALIA CARLO ERBA**

November 16th, 1992

DATA

VS RIF

NS RIF

TEL DIRETTO

CERTIFICATE OF ANALYSIS

REBOXETINE 4 mg tablets


Batch SF 1106

Manufacturing date	: July, 1990
Expiry date	: June, 1993
Active drug substance	: RR 17L015
Appearance	: white, round, convex, 8 mm diameter tablet, with a breakline on one surface
Identification	: positive
Average weight	: mg 200.80
Assay	: mg 3.880 of Reboxetine/tablet
Related substances	: 0.61%
Uniformity of content	: complies, according to Eur. Ph., 2nd Ed., requirements
Dissolution	: 93.9% of the L.A. after 15 minutes
Microbial contamination	: total viable aerobic count < 1000 moulds and yeasts < 100 E. Coli and Salmonellae : absent

Note : this certificate replaces the previous one, in order to extend the shelf-life, having already obtained stability data after 36 months storage at 25°C, for two other 4 mg batches

Approved by

: Virginio Busnelli



S.R.L. - SEDE LEGALE IN MILANO
CAPITALE L. 528.732.127.000 IV
TRIBUNALE DI MILANO R.S. N. 238246
VOL. 6366 - FASC. 46 - C.C.I.A.A. N. 1171077
COD. FISC. E PART. IVA N. 07608290158

GRUPPO ERBAMONT

577

9550077

VIA CARLO IMBONATI, 24
20159 MILANO

TELEFONO (02) 69651 (CENTRALINO)
TELEGRAMMI ERBACAR-MILANO
CABINETTA POSTALE 10519
C.C. POSTALE 619205
TELEFAX 330314 ERBA I.



DATA April 26, 1990

VS FIF

NS FIF

TELEMEFITO

ANALYSIS CERTIFICATE

Placebo for Reboxetine 4 mg tablets

Batch SF 1030

Manufacturing date : May, 1989


Appearance : round, convex, 8 mm diameter,
white tablet with a breakline
on one surface, and marked S.F.
on the other

Identification : negative

Average weight : mg 202.47

Uniformity of weight : complies, according to Eur. Ph.
2nd Ed., Section V.5.2.1

Disintegration time : 25 seconds

Approved by : Virginio Busnelli 

578
SITI: 578 LEGALE IN MILANO
CANTIERI L. 533 712 617 000 IV
TIBERIALI DI MILANO P.S. N. 238246
VIA ROME 1ASC. 46 - C.C.I.A.A. N. 1371077
C.N. ERBA F. PART. IVA N. 0760290156

GRUPPO ERBAMONT
LABORATORI DI CONTROLLO QUALITÀ DELLA SAIUTE

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

9550077

CENTRO RICERCHE
VIA GIOVANNI XXIII, 23
20014 NERVIANO
TELEFONO (0331) 587250
TELEGRAMMI: FARMITALIA CARLO ERBA NERVIANO
CASSELLA POSTALE 2
TELEX 310678 MONTED PER FARMITALIA NERVIANO



DATA July 26, 1990

ANALYSIS CERTIFICATE

Placebo for Reboxetine 4 mg tablets

Batch SF 1111

Manufacturing date : July, 1990

Appearance : round, convex, 8 mm diameter,
white tablet with a breakline
on one surface, and marked S.F.
on the other

Identification : negative

Average weight : mg 200.67

Uniformity of weight : complies, according to Eur. Ph.
2nd Ed., Section V.5.2.1

Disintegration time : 35 seconds

Microbial contamination
(USP XXII) : total viable aerobic count < 1000
moulds and yeasts < 100
E. Coli and Salmonella : absent

Approved by : V. Busnelli *Busnelli*

579

SRL SEDE LEGALE IN MILANO
CAPITALE SOC. L. 528.732.127.000 IV
TRIBUNALE MILANO RS N. 2330/94
VOL. 8306 - FASC. 46 - C.C.I.A.A. N. 1171077
COD. FISC. E PART. IVA N. 07698220166

9550077

Pharmacia

Document 9550077

12.1.6 AUDIT CERTIFICATE

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

9550077

Pharmacia
Pharmaceuticals Milan R&D/GCP-QA

R&D/Q.A. AUDIT CERTIFICATE

Product **REBOXETINE**

Protocol N°: **FCE 20124/013** N° GCP: **18**

Study title: Multicenter, multinational double-blind study of the activity and tolerability of Reboxetine vs Placebo in the continuation therapy of major depressive disorders.

Type of Audit	Site	Audit date(s)	Reporting date
Study Master File	Pharmacia	28.10.1992	02.11.1992
Study Master File	Pharmacia	18.05.1993	25.05.1993
Investigator Site	Centre N.8 (Hungary)	18.10.1993	04.11.1993
Investigator Site	Centre N.9 (Hungary)	19.10.1993	04.11.1993
Audit at subsidiary	Hungary	19.10.1993	04.11.1993
Investigator Site	Centre N.12 (Hungary)	20.10.1993	04.11.1993
Investigator Site and CRO	Centre 01 (Brazil)	02-09.05.1995	31.05.1995
Study Master File	Pharmacia	30.08-08.09.1995	28.09.1995
Data Listings vs CRFs	Pharmacia	13-27.09.1995	06.10.1995
Draft Final Report	Pharmacia	09-13.10.1995	16.10.1995
Final Report	Pharmacia	11.01.1996	11.01.1996

Signature of the Head of R&D/GCP-Q.A. Ollet. Kova

Date: Jan 11th 1996

9550077

Pharmacia

Document 9550077

12.1.7 RANDOMISATION LIST

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

REBOXETINE PROT. 9550077/013
RANDOMIZATION LIST

74

18:45 Saturday, October 21, 1989

----- CENTRE= 1 BRAZIL -----

PTS N.	TREATMENT
1	placebo
2	reboxetine
3	reboxetine
4	reboxetine
5	placebo
6	placebo
7	reboxetine
8	reboxetine
9	placebo
10	placebo
11	reboxetine
12	placebo
13	placebo
14	reboxetine
15	reboxetine
16	placebo
17	reboxetine
18	placebo
19	reboxetine
20	reboxetine
21	reboxetine
22	placebo
23	placebo "
24	placebo
25	placebo
26	placebo
27	reboxetine
28	reboxetine
29	placebo
30	reboxetine

9550077
REBOXETINE PROT. 20124/013
RANDOMIZATION LIST

76

18:45 Saturday, October 21, 1989

----- CENTRE= 2 DDR -----

PTS N.	TREATMENT
31	reboxetine
32	placebo
33	placebo
34	placebo
35	reboxetine
36	reboxetine
37	reboxetine
38	placebo
39	placebo
40	reboxetine
41	placebo
42	reboxetine
43	reboxetine
44	placebo
45	placebo
46	placebo
47	reboxetine
48	reboxetine
49	placebo
50	reboxetine
51	reboxetine
52	placebo
53	reboxetine
54	placebo
55	placebo
56	placebo
57	reboxetine
58	placebo
59	reboxetine
60	reboxetine

REBOXETINE PROT. 955007/013
RANDOMIZATION LIST

77

18:45 Saturday, October 21, 1989

----- CENTRE= 3 FRANCE -----

PTS N.	TREATMENT
61	placebo
62	placebo
63	reboxetine
64	reboxetine
65	placebo
66	reboxetine
67	placebo
68	placebo
69	reboxetine
70	reboxetine
71	reboxetine
72	placebo
73	placebo
74	reboxetine
75	placebo
76	reboxetine
77	placebo
78	reboxetine
79	placebo
80	reboxetine
81	placebo
82	reboxetine
83	placebo
84	reboxetine
85	placebo
86	reboxetine
87	placebo
88	reboxetine
89	reboxetine
90	placebo

REBOXETINE PROT. 20124/013
RANDOMIZATION LIST

78

18:45 Saturday, October 21, 1989

----- CENTRE= 4 FRANCE -----

PTS N.	TREATMENT
91	reboxetine
92	reboxetine
93	reboxetine
94	placebo
95	placebo
96	placebo
97	placebo
98	placebo
99	reboxetine
100	reboxetine
101	placebo
102	reboxetine
103	placebo
104	reboxetine
105	reboxetine
106	reboxetine
107	placebo
108	placebo
109	placebo
110	reboxetine
111	placebo
112	placebo
113	reboxetine
114	reboxetine
115	reboxetine
116	placebo
117	reboxetine
118	reboxetine
119	placebo
120	placebo

REBOXETINE PROT~~95507~~20124/013
RANDOMIZATION LIST

79

18:45 Saturday, October 21, 1989

----- CENTRE= 5 PANAMA -----

PTS N.	TREATMENT
121	reboxetine
122	placebo
123	reboxetine
124	placebo
125	reboxetine
126	placebo
127	placebo
128	reboxetine
129	reboxetine
130	placebo
131	placebo
132	reboxetine
133	reboxetine
134	reboxetine
135	placebo
136	placebo
137	placebo
138	reboxetine
139	reboxetine
140	placebo
141	reboxetine
142	placebo
143	reboxetine
144	placebo
145	placebo
146	placebo
147	reboxetine
148	placebo
149	reboxetine
150	reboxetine

REBOXETINE PROT. 20124/013
RANDOMIZATION LIST

81

18:45 Saturday, October 21, 1989

----- CENTRE= 6 PANAMA -----

PTS N.	TREATMENT
151	placebo
152	reboxetine
153	reboxetine
154	reboxetine
155	placebo
156	placebo
157	placebo
158	reboxetine
159	reboxetine
160	placebo
161	reboxetine
162	placebo
163	placebo
164	reboxetine
165	placebo
166	reboxetine
167	reboxetine
168	placebo
169	placebo
170	reboxetine
171	reboxetine
172	placebo
173	reboxetine
174	placebo
175	placebo
176	placebo
177	placebo
178	reboxetine
179	reboxetine
180	reboxetine

REBOXETINE PROT. 955997013
RANDOMIZATION LIST

82

18:45 Saturday, October 21, 1989

----- CENTRE= 7 POLAND -----

PTS N.	TREATMENT
181	placebo
182	reboxetine
183	placebo
184	reboxetine
185	placebo
186	reboxetine
187	placebo
188	reboxetine
189	reboxetine
190	placebo
191	placebo
192	reboxetine
193	placebo
194	placebo
195	reboxetine
196	placebo
197	reboxetine
198	reboxetine
199	placebo
200	placebo
201	placebo
202	reboxetine
203	reboxetine
204	reboxetine
205	reboxetine
206	reboxetine
207	reboxetine
208	placebo
209	placebo
210	placebo

REBOXETINE PROT. 20124/010 9550072 83
RANDOMIZATION LIST
18:45 Saturday, October 21, 1989

----- CENTRE= ' 8 HUNGARY' -----

PTS N.	TREATMENT
211	placebo
212	reboxetine
213	reboxetine
214	placebo
215	placebo
216	reboxetine
217	placebo
218	placebo
219	reboxetine
220	reboxetine
221	reboxetine
222	placebo
223	reboxetine
224	placebo
225	placebo
226	reboxetine
227	reboxetine
228	placebo
229	placebo
230	reboxetine
231	reboxetine
232	reboxetine
233	placebo
234	placebo
235	placebo
236	placebo
237	reboxetine
238	reboxetine
239	placebo
240	reboxetine

REBOXETINE PROT. 15121/019 9550047 84
RANDOMIZATION LIST
18:45 Saturday, October 21, 1989

----- CENTRE= 9 HUNGARY -----

PTS N.	TREATMENT
241	placebo
242	placebo
243	reboxetine
244	placebo
245	reboxetine
246	reboxetine
247	placebo
248	placebo
249	reboxetine
250	reboxetine
251	placebo
252	reboxetine
253	placebo
254	placebo
255	reboxetine
256	reboxetine
257	placebo
258	reboxetine
259	reboxetine
260	reboxetine
261	placebo
262	placebo
263	reboxetine
264	placebo
265	reboxetine
266	placebo
267	placebo
268	placebo
269	reboxetine
270	reboxetine

REBOXETINE PROT 2012/013
RANDOMIZATION LIST

955044

86

18:45 Saturday, October 21, 1989

----- CENTRE=10 USSR -----

PTS N.	TREATMENT
271	reboxetine
272	placebo
273	placebo
274	reboxetine
275	reboxetine
276	placebo
277	reboxetine
278	reboxetine
279	placebo
280	reboxetine
281	placebo
282	placebo
283	placebo
284	placebo
285	reboxetine
286	reboxetine
287	reboxetine
288	placebo
289	placebo
290	reboxetine
291	reboxetine
292	reboxetine
293	placebo
294	placebo
295	placebo
296	placebo
297	reboxetine
298	placebo
299	reboxetine
300	reboxetine

REBOXETINE PROT. 20124/013
RANDOMIZATION LIST

80

18:45 Saturday, October 21, 1989

----- CENTRE= 5b PANAMA -----

PTS N.	TREATMENT
331	placebo
332	placebo
333	placebo
334	reboxetine
335	reboxetine
336	reboxetine
337	placebo
338	reboxetine
339	placebo
340	reboxetine
341	placebo
342	reboxetine
343	reboxetine
344	placebo
345	placebo
346	placebo
347	reboxetine
348	reboxetine
349	placebo
350	placebo
351	reboxetine
352	reboxetine
353	placebo
354	reboxetine
355	placebo
356	reboxetine
357	placebo
358	reboxetine
359	reboxetine
360	placebo

593

9550077
REBOXETINE PROT.20124/013
RANDOMIZATION LIST

75

18:45 Saturday, October 21, 1989

----- CENTRE= ' 1b BRAZIL ' -----

PTS N.	TREATMENT
301	reboxetine
302	placebo
303	reboxetine
304	placebo
305	reboxetine
306	placebo
307	placebo
308	placebo
309	reboxetine
310	reboxetine
311	reboxetine
312	placebo
313	reboxetine
314	placebo
315	placebo
316	reboxetine
317	placebo
318	reboxetine
319	reboxetine
320	reboxetine
321	placebo
322	placebo ..
323	reboxetine
324	placebo
325	placebo
326	reboxetine
327	placebo
328	placebo
329	reboxetine
330	reboxetine

9550077
REBOXETINE PROT.20124/013 85
RANDOMIZATION LIST
18:45 Saturday, October 21, 1989

----- CENTRE= ' 9b HUNGARY ' -----

PTS N.	TREATMENT
361	reboxetine
362	placebo
363	reboxetine
364	placebo
365	reboxetine
366	placebo
367	reboxetine
368	reboxetine
369	placebo
370	reboxetine
371	placebo
372	placebo
373	reboxetine
374	reboxetine
375	placebo
376	placebo
377	reboxetine
378	placebo
379	placebo
380	reboxetine
381	reboxetine
382	placebo ..
383	placebo
384	reboxetine
385	reboxetine
386	placebo
387	placebo
388	reboxetine
389	reboxetine
390	placebo

Pharmacia

Document 9550077

12.1.8 LABORATORY REFERENCE VALUES AND CRITERIA USED TO
JUDGE LABORATORY ABNORMALITIES AS CLINICALLY RELEVANT

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA C9590077

REBOXETINE - PROTOCOL 20124/013
APPENDIX No.: 12.1.8

LABORATORY REFERENCE VALUES

		Range values			
		Female		Male	
		Min	Max	Min	Max
Laboratory test	Units				
HB	g/dl	12.00	16.00	13.50	17.50
HT	%	36.00	46.00	41.00	53.00
RBC	10 ⁶ /mm ³	4.00	5.20	4.50	5.90
PLATELETS	10 ³ /mm ³	150.00	400.00	150.00	400.00
ESR/SEDIMENT. RATE 1st h	mm	0.00	10.00	0.00	10.00
ESR/SEDIMENT. RATE 2nd h	mm	0.00	20.00	0.00	20.00
WBC	10 ³ /mm ³	4.50	11.00	4.50	11.00
WBC: N	%	57.00	67.00	57.00	67.00
WBC: E	%	1.00	3.00	1.00	3.00
WBC: B	%	0.00	0.75	0.00	0.75
WBC: L	%	23.00	33.00	23.00	33.00
WBC: M	%	3.00	7.00	3.00	7.00
CREATININE	mg/dl	0.50	1.10	0.60	1.20
CREATININE CLEARANCE	ml/min	88.00	128.00	97.00	137.00
UREA	mg/dl	15.00	35.00	15.00	35.00
BUN	mg/dl	7.00	18.00	7.00	18.00
URIC ACID	mg/dl	2.60	6.00	3.50	7.20
TOT. PROTEINS	g/dl	6.40	8.30	6.40	8.30
ALBUMINE	g/dl	3.50	5.00	3.50	5.00
TOT BILIRUBIN	mg/dl	0.20	1.00	0.20	1.00
DIR BILIRUBIN	mg/dl	0.00	0.20	0.00	0.20
SGOT	U/l	10.00	30.00	10.00	30.00
SGPT	U/l	5.00	30.00	5.00	30.00
GAMMA GT	U/l	8.00	40.00	9.00	50.00
LDH	U/l	210.00	420.00	210.00	420.00
ALK. PHOSPH.	U/l	56.00	155.00	62.00	176.00
GLOBULINS ALPHA 1	g/dl	0.10	0.30	0.10	0.30
GLOBULINS ALPHA 2	g/dl	0.60	1.00	0.60	1.00
GLOBULINS BETA	g/dl	0.70	1.10	0.70	1.10
GLOBULINS GAMMA	g/dl	0.80	1.60	0.80	1.60
SEDIMENT.	mm/h	0.00	20.00	0.00	15.00
TOT. CHOLEST.	mg/dl	152.00	268.00	158.00	276.00
HDL	mg/dl	35.00	65.00	29.00	60.00
TRIGLYCERIDES	mg/dl	38.00	160.00	49.00	284.00
GLUCOSE	mg/dl	70.00	105.00	70.00	105.00
NA+	mEq/l	136.00	146.00	136.00	146.00
CL-	mEq/l	98.00	106.00	98.00	106.00
K+	mEq/l	3.50	5.10	3.50	5.10
Ca++	mEq/l	4.50	5.50	4.50	5.50
PO4--	mEq/l	1.00	1.50	1.00	1.50
T4	ug/dl	5.00	12.00	5.00	12.00
TSH	mU/l	2.00	10.00	2.00	10.00

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

APPENDIX No.: 12.1.8

CRITERIA USED TO CONSIDER LABORATORY ABNORMALITIES CLINICALLY RELEVANT

Laboratory test	Percent variation above or below normal range (*)
HB	- 15
HTC	- 15
PBC	- 15
PLATELETS	- 30
HBC	- 30
HBC: N	- 30
HBC: E	not defined
HBC: B	not defined
HBC: L	- 30
HBC: H	not defined
CREATININE	+ 50
BUN	+ 50
URIC ACID	+ 30
TOT. PROTEINS	-- 30
ALBUMINE	-- 30
TOT BILIRUBIN	+ 100
DIR BILIRUBIN	+ 100
SGOT	+ 100
SGPT	+ 100
GAMMA-GT	+ 100
ALK. PHOSPH.	+ 100
GLOBULINS: ALPHA 1	-- 30
GLOBULINS: ALPHA 2	-- 30
GLOBULINS: BETA	-- 30
GLOBULINS: GAMMA	-- 30
TOT. CHOLEST.	+ 30
TRIGLYCERIDES	+ 30
GLUCOSE	-- 30
NA+	-- 10
CL-	-- 10
K+	-- 15
CA++	-- 15
PO4--	-- 15

598

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

Pharmacia

Document 9550077

12.1.9 ECG CODES

ECG CODES

0 Normal

1 Rhythm disorders

- 10 Sinus bradycardia (< 60)
- 20 Sinus tachycardia (> 100)
- 30 Sick Sinus Syndrome
- 40
 - Atrial ectopic beats:
 - 41 - Occasional
 - 42 - Frequent (> 6/mm)
 - 43 - Couplets
 - 44 - Supraventricular Tachycardia
- 50
 - Ventricular ectopic beats:
 - 51 - Occasional
 - 52 - Frequent (> 6/mm)
 - 53 - Polymorphic
 - 54 - Couplets
 - 55 - Ventricular Tachycardia
- 60
 - Atrial fibrillation/flutter
- 105
 - Vagotonia
- 108
 - Atrial-ventricular dissociation

2 Conduction disorders

- 70
 - A-V Block
 - 71 - 1st degree
 - 72 - 2nd degree - Mobitz 1
 - 73 - Complete - Mobitz 2
- 85
 - Right bundle branch block
- 86
 - Left bundle branch block
- 87
 - Left anterior hemiblock
- 88
 - Left posterior hemiblock
- 89
 - Bifascicular Block (specify)
- 90
 - Trifascicular Block (specify)
- 91
 - Conduction disorders
- 103
 - Left axial deviation
- 106
 - Right incomplete bundle branch block

3 Ischemic signs

- 102
 - Repolarization disturbances
- 107
 - Non specific ST-T changes
- 82
 - Myocardial ischemia
- 84
 - Acute Myocardial infarction

4 Other

- 80
 - Left ventricular hypertrophy
- 81
 - Right ventricular hypertrophy
- 83
 - Previous Myocardial infarction
- 93
 - Other (specify) _____
- 104
 - Right axial deviation

9550077

Pharmacia

Document 9550077

12.1.10 STATISTICAL ANALYSIS PROGRAMS LISTINGS

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA QUS RED
REBOMETINE - PROTOCOL 21124/013
APPENDIX No. 1 12.1.10

```
*****  
* Procedure for laboratory data subjects whose values are lower,  
* - frequency and percent of their baseline (Sioe test)  
* equal or higher than their baseline (Sioe test)  
* - Frequency and percentage of subjects whose values fall below,  
* within or above the normal ranges, before and after treatment;  
* - Shift tables end of treatment vs baseline of values below;  
* above and within the normal ranges (Mc Nemar/Stuart-Maxwell  
* test)  
*****  
* INPUT MACRO VARIABLES  
* CENTRE = ;  
* LASTVIS = ;  
* ACOPPE = ;  
* DATIN = ;  
* DATOUT = ;  
* TABIN = ;  
* TLAB = ;  
* RMIN = ;  
* RMAX = ;  
* GROU = ;  
* ACOTRT = ;  
* BASE = ;  
* TRT = ;  
* SCHED = ;  
* DOSE = ;  
* NTAB1 = ;  
* *****  
* MACRO MACLAB1  
* *****  
* OPTIONS ps=60 ls=160;  
* *****  
-----  
LASTVIS=1 : ONLY BASELINE AND LAST VISIT FOR EACH PATIENT  
-----  
%IF %LASTVIS=1 %THEN %DO;  
PROC FORMAT VALUE BASLAST &BASE="BASELINE" 99999="LAST VISIT";  
RUN; %END;  
%LET EGAR= B&B 1- B&B &NLAB;  
PROC SORT DATA=&DATA IN OUT=&DATOUT; BY &PCODE &TEMPO;  
DATA &DATOUT; SET &DATOUT; IF &TEMPO >= &BASE; RUN;  
DATA &DATOUT; SET &DATOUT; BY &PCODE;  
RETAIN &LAB; ARRAY B (&NLAB) &LAB; ARRAY T (&NLAB) &TLAB;  
IF FIRST.&PCODE THEN DO I=1 TO &NLAB; B (I)=.; END;  
IF &TEMPO = &BASE THEN DO I=1 TO &NLAB; B (I)= T (I); END;  
%IF %LASTVIS=1 %THEN %STR(OUTPUT);  
%ELSE %IF %LASTVIS=1 %THEN  
%DO;  
IF &TEMPO >= &BASE THEN &TEMPO=99999;  
%IF %ACOPPE=1 %THEN %DO;  
%IF %ACOPPE=1 %THEN %DO;  
%ELSE %IF %ACOPPE=1 %THEN %DO;  
IF LAST.&PCODE; CUM=.;  
DO I=1 TO &NLAB; CUM=SUM(CUM, ( B (I)+ T (I))); END;  
IF CUM = .;  
OUTPUT;  
DO I=1 TO &NLAB; T (I)= B (I); END;  
OUTPUT; %END;  
%END;
```

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

```

&END;
RUN;
DATA &DATOUT; SET &DATOUT;
** INDIV-SHIFT LABORATORY EXAMINATIONS * * *
**-----*
ARRAY LL(&LABAB,ARRAY ARRAY BB(&UG) &LAB;
DO I=1 TO &NLAB; DO J=1 TO &NUG;
SU(I)=0; SU(I)=0; UG(I)=0;
&IF &LASTVIS=1 AND &ACOPPIE=1 &THEN &DO;
IF S= THEN DO;
LL(I)=.; BB(I)=.; SU(I)=.; GIU(I)=.; UG(I)=.; END;
&END;
IF S=0 THEN SU(I)=1;
ELSE IF <S<0 THEN GIU(I)=1;
ELSE IF S=0 THEN UG(I)=1;
END;
** EXAMINATIONS OUT OF THE NORMAL RANGES * * *
**-----*
ARRAY MN(*) &RMIN; ARRAY MX(*) &RMAX;
ARRAY LMIN(&NLAB); ARRAY LMAX(&NLAB); ARRAY LNOR (&NLAB);
DO I=1 TO &NLAB;
IF LL(I)^=, THEN
DO; IF MN(I)^=, OR MX(I)^=, THEN
DO; IF MX(I)=, THEN MX =99999; ELSE MX =MX(I);
LMIN(I)=0*(LL(I)>=MN(I))+1*(LL(I)< MN(I));
LMAX(I)=0*(LL(I)<= MX )+1*(LL(I) >
LNOR(I)=1-MAX(LMIN(I),LMAX(I));
F(I)=1*(LMAX(I)=1)-1*(LMIN(I)=1);
&END;
ELSE DO; LMIN(I)=.; LMAX(I)=.; LNOR(I)=.; F(I)=.; END;
&END;
DO; LMIN(I)=.; LMAX(I)=.; LNOR(I)=.; F(I)=.; END;
&END;
IF SUM(OF SU-LINLAB GIU-GIUNLAB UG-UG&NLAB) >0
THEN OKSHIF="EVALUABLE"; ELSE OKSHIF="NOT EVAL.";
IF SUM(OF LNOR-LNLAB LMAX-LMAX&NLAB LNOR-LNOR&NLAB) >0
THEN OKRANGE="EVALUABLE" OR OKSHIF="EVALUABLE";
IF OKRANGE="EVALUABLE" OR OKSHIF="EVALUABLE"
THEN EVALSRJ=1; ELSE EVALSRJ=0;
DROP &TLAB &ELAB &RMIN &RMAX;
RUN;
&IF &NTAB1^= &THEN &DO;
TITLE7
TABLE &NTAB1 HAEMATOLOGY AND BLOOD CHEMISTRY";
&LET NTAB1=&EVAL(&NTAB1+1);
&END;
&IF &NTAB1=7
TITLE7
HAEMATOLOGY AND BLOOD CHEMISTRY";
&END;
&PROC TABULATE; FORMCHAR=; F&F&ACCC&C&B&C&BB' X F=10.;
CLASS &TRT &TEMPO OKRANGE OKSHIF; KEY LABEL ALL=&TOTAL;
TABLE (&TRT ALL) * (OKRANGE= / SUBJECTS= ALL), &TEMPO N= /
&RTS=25 BOX=
/ NORMAL AND ABNORMAL LAB VALUES: EVALUABLE SUBJECTS AT EACH VISIT;
TABLE (&TRT ALL) * (OKSHIF= / SUBJECTS= ALL), &TEMPO N= /
&RTS=25 BOX=
/ SHIFT SUBJECTS EVALUABLE SUBJECTS AT EACH VISIT;
&IF &LASTVIS=1 &THEN

```

```

%DO; LABEL &TEMPO='VISIT'; FORMAT &TEMPO BASLAST.; %END;
%MEND MACLAB1;

* *****
%MACRO TABELLE1;
* *****
* DATA SET FOR EXAMINATIONS OUT OF THE NORMAL RANGES
* *****
DATA _LAB_ ; SET &TABIN;
KEEP LMNI-LMIN&NLAB LNORI-LNOR&NLAB LMAXI-LMAX&NLAB
&PCODE &BYVAR;
RUN;

%IF &BYVAR ^= %THEN %DO; PROC SORT DATA=_LAB_ BY &BYVAR; RUN; %END;
PROC SUMMARY DATA=_LAB_ ; IF &BYVAR ^= %THEN %STR(BY &BYVAR.);
VAR LMNI-LMIN&NLAB LNORI-LNOR&NLAB LMAXI-LMAX&NLAB;
OUTPUT OUT=PIPPO
SUM=SMINI-SMIN&NLAB SNORI-SNOR&NLAB SMAXI-SMAX&NLAB;
RUN;
* *****
DATA PIPPO; SET PIPPO;
KEEP &BYVAR DUMMY LNU NT PERC EVAL TEST;
DUMMY=' ';
LABEL DUMMY='=====' %IF &GROUP ^= %THEN &GROUP='=====';
ARRAY SMIN(&NLAB) SMINI-SMIN&NLAB;
ARRAY SNOR(&NLAB) SNORI-SNOR&NLAB;
ARRAY SMAX(&NLAB) SMAXI-SMAX&NLAB;
DO TEST=1 TO &NLAB;
NT=SMIN(TEST); SNOR(TEST)+SMAX(TEST);
IF SNOR THEN DO;
EVAL=NN;
LNU=-1; NT=SMIN(TEST); PERC=ROUND(NT*100./NN,.1); OUTPUT;
EVAL=0;
LNU=0; NT=SNOR(TEST); PERC=ROUND(NT*100./NN,.1); OUTPUT;
LNU=1; NT=SMAX(TEST); PERC=ROUND(NT*100./NN,.1); OUTPUT;
END;
END;
RUN;
* *****
* TABLES EXAMINATIONS OUT OF THE NORMAL RANGES
* *****
**OPTIONS PS=55 LS=165;
TITLE7
'FREQUENCY AND PERCENTAGE OF SUBJECTS WHOSE VALUES FELL BELOW, WITHIN';
TITLE8
'OR ABOVE THE NORMAL RANGES, BEFORE AND AFTER TREATMENT';
PROC TABULATE DATA=PIPPO FORMCHAR=' ' ;
%IF &LASTVIS=1 %THEN %DO; FORMAT &TEMPO BASLAST.; %END;
%IF &GROUP ^= %THEN %STR(BY &GROUP DUMMY);
CLASS TEST &CODE &DOSE &TEMPO TEST LNU &CENTRE;
VAR NT PERC EVAL;
TABLE
%IF &CENTRE ^= %THEN %STR(&CENTRE.); %ELSE;
TEST*TEMPO=" " &&DIM3
* (EVAL=' EVAL.' *SUM= ' *F=EVAL. LNU=' '
* (NT=' N' * SUM= ' *F=4*0
PERC=' (%) * SUM= ' *F=XCENTO. )
/ BOX= _PAGE_
RTS=33;
%END;
%MEND TABELLE1;
* *****

```

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

```

** *****
** MACRO TABLE2;
** -----
** DATA SET FOR SHIFT TABLES;
** -----
DATA SHIFT; SET $TABIN; IF $TEMPO=$BASE;
KEEP $BYVAR $UI-$SU&NLAB $UI1-$GIU&NLAB $UI-$UG&NLAB;
RUN;

%IF $BYVAR ^= %THEN %DO; PROC SORT DATA=SHIFT; BY $BYVAR; RUN; %END;

PROC SUMMARY DATA=SHIFT; %IF $BYVAR ^= %THEN %STR(BY $BYVAR);
VAR $UI-$SU&NLAB $UI1-$GIU&NLAB $UI-$UG&NLAB;
OUTPUT OUT=SHIFT $SUM=$UI-$SU&NLAB $UI1-$GIU&NLAB $UI-$UG&NLAB;
RUN;

DATA SHIFT; SET SHIFT;
DUMMY=''; LABEL DUMMY=''; %IF $GROUP ^= %THEN $GROUP='';
SPAZIO=''; LABEL SPAZIO='';
LABEL P_VALUE='2 TAILED SIGN TEST';
ARRAY SU($NLAB) $UI-$SU&NLAB; ARRAY GIU($NLAB) $UI1-$GIU&NLAB;
ARRAY UG($NLAB) $UI-$UG&NLAB;
DO TEST=1 TO $NLAB;
  SOMMA=$U(TEST)+GIU(TEST);
  NN=$U(TEST)+GIU(TEST)+UG(TEST);
  IF SOMMA= THEN P_VALUE='';
  ELSE IF (SU(TEST)=GIU(TEST)) THEN P_VALUE=1.00;
  ELSE P_VALUE=2.*PROBNML(0.5,SOMMA,MIN(SU(TEST),GIU(TEST)));
  IF NN= THEN DO;
    P_VALUE=ROUND(P_VALUE,.001);
    LNU=1; NT=GIU(TEST); PERC=ROUND(NT*100./NN,.1); OUTPUT;
    EVAL=0; P_VALUE=0;
    LNU=0; NT=UG(TEST); PERC=ROUND(NT*100./NN,.1); OUTPUT;
    LNU=1; NT=$U(TEST); PERC=ROUND(NT*100./NN,.1); OUTPUT;
  END;
END;
KEEP $BYVAR TEST LNU NT PERC P_VALUE SPAZIO DUMMY EVAL;
RUN;
** -----
** TABULATE: SHIFT TABLES;
** -----
OPTIONS PS=55 LS=163;

TITLE7
'FREQUENCY AND PERCENTAGE OF SUBJECTS WHOSE VALUES ARE LOWER, EQUAL OR;
' HIGHER THAN THEIR BASELINE';
PROC TABULATE DATA=SHIFT FORMCHAR=' ' MISSING;
%IF $GROUP ^= %THEN %STR(BY $GROUP $MPO $ASLAST); %END;
%IF $GROUP ^= %THEN %STR(BY $GROUP DUMMY);
FORMAT TEST $TEST $LNU $SHIFT;
CLASS $RT $SCHED $DOSE $TEMPO TEST LNU $CENTRE;
VAR NT PERC EVAL P_VALUE SPAZIO;
LABEL EVAL='EVAL.' 'NT=' 'N' 'PERC=' ('%');
%IF $LASTVIS=1
%THEN %STR(LABEL TEST='TEST (LAST VISIT VS BASELINE)');
%ELSE;
TABLE
%IF $CENTRE ^= %THEN %STR($CENTRE); %ELSE;
%IF $LASTVIS ^=1 %THEN %STR('&TEMPO=" '); %ELSE;
%$&DIM3
*(EVAL*$SUM= ' *F=EVAL.
LNU= ' * (NT*$SUM= ' *F=4.0

```

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

```

P VALUE*SUM= ' ' *F=XCENTO. )
SFATIO= ' ' *SUM= ' ' *F=FVALUE.
/ MISSTEXT= ' ' BOX= _PAGE_ RTS=28;

RUN;
%END TABLE2;
* *****
** $MACRO LABELLE3; *****
** *****
** DATA SET OUT OF RANGE *****
** -----
DATA CERRANGE; SET &TABIN;
KEEP &BYVAR TEST BNU LNU DUMMY INCROCI CONTA;
ARRAY L(*) F1-F&NLAB;
DUMMY=.; LABEL DUMMY= '===='; %IF &GROUP=.; %THEN &GROUP= '====';
LABEL LNU= '00' X BNU= 'BASELINE';
CONTA=.;
IF TEST=0; BASE THEN
DO TEST=1 TO &NLAB; B (TEST)=L (TEST); END;
ELSE
DO TEST=1 TO &NLAB;
IF (L (TEST)^=. AND B (TEST)^=.) THEN
DO;
BNU=B (TEST); LNU=L (TEST); INCROCI= (BNU=1) *3+ (LNU=2);
OUTPUT;
END;
END;
RUN;

PROC SORT; BY &BYVAR TEST INCROCI;
PROC SUMMARY DATA=CERRANGE; BY &BYVAR TEST INCROCI; ID BNU LNU;
VAR CONTA; OUTPUT OUT=CERRANGE SUM=CONTA; RUN;
DATA MAXWELL; SET CERRANGE; BY &BYVAR TEST;
KEEP &BYVAR TEST PROB INCROCI BNU LNU;
BNU=1; LNU=1;
LABEL LNU= '00' X BNU= 'BASELINE';
ARRAY _A (9) A1 A2 A3 A21 A22 A23 A31 A32 A33;
RETAIN A1 A2 A3 A21 A22 A23 A31 A32 A33;
IF FIRST THEN DO I=1 TO 9; _A (I)=0; END;
IF LAST TEST THEN
DO; N12= (A12+A21) /2; N13= (A13+A31) /2; N23= (A23+A32) /2;
D1=A12+A13-A21-A31; D2=A21+A23-A12-A32; D3=A31+A32-A13-A23;
D1=D1*D1; D2=D2*D2; D3=D3*D3;
NUMX2=N23*D1+N13*D2+N12*D3;
DENX2=N12*(N13-N23)+N13*N23; DENX2=DENX2*2;
IF DENX2>0 THEN DO; X2=NUMX2/DENX2;
PROB=1-PROBCHI (X2, 2);
ELSE DO;
X2= A12+ A21
IF A32>0 OR A23>0 THEN
DO; IF A32=A23 THEN PROB=1;
ELSE DO; DENX2=A32+A23; NUMX2=MIN (A32, A23);
PROB=2.*PROBNML (0.5, DENX2, NUMX2);
END;
END;
ELSE
END;
IF A21>0 OR A12>0 THEN
DO; IF A21=A12 THEN PROB=1;
ELSE DO; DENX2=A21+A12; NUMX2=MIN (A21, A12);
PROB=2.*PROBNML (0.5, DENX2, NUMX2);
END;
END;
```

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

```

END;
ELSE
  IF A13>0 OR A31>0 THEN
    DO; IF A31=0 THEN PROB=1;
      ELSE DO; DENX2=A313; NUMX2=MIN(A31, A13);
        PROB=2.*PROB*NL(0.5, DENX2, NUMX2);
      END;
    ELSE
      DO; PROB=1;
      END;
  END;
  INCR0CI=0;
  OUTPUT;
END;
END;
END;

RUN; CRRANGE=MERGE CRRANGE MAXWELL;
DATA=FRANGE;
IF FIRST THEN INCR0CI=1;
IF LAST THEN INCR0CI=0;
IF FIRST THEN P=PROB;
IF LAST THEN P=PROB;
IF BNU=1 AND LNU=1
  THEN DO; PROB=P; OUTPUT; END;
ELSE DO; OUTPUT; BNU=1; LNU=1; CONTA=.; PROB=P; OUTPUT; END;
RUN;
%*-----*
%* TABULATE: OUT OF RANGE: BASELINE VS END OF TREATMENT ;
%*-----*
OPTIONS RS=87 IS=120;
TITLE7 SHEW/TABLE END OF TREATMENT VS. BASELINE;
TITLE8 'OF VALUES BELOW ABOVE AND WITHIN THE NORMAL RANGES';
%IF %GROUP^= %THEN %STR(PROC SORT DATA=CRRANGE; BY %GROUP;);
%* for mainframe : FORMCHAR='FABFACCCBCEBFCACBCEB'X;
PROC TABULATE
  DATA=FRANGE MISSING;
  %IF %LASTVIS=1 %THEN %DO; FORMAT %TEMPO BASLAST.; %END;
  %IF %GROUP^= %THEN %STR(BY %GROUP DUMMY.);
  %FORMAT BNU LNU LNU. TEST FTEST.;
  CLASS %TEST BNU LNU %DOSE %SCHED %TEMPO %CENTRE;
  TABLE %IF %CENTRE^= %THEN %CENTRE*
    %IF %ACCTR=1 %THEN %STR(%TEMPO= ' '); %ELSE %&&DIM3;
    %IF %ACCTR=1 %THEN %&&DIM3; %ELSE %STR(%TEMPO= ' ');
    * (LNU=%IF LASTVIS=1 %THEN %STR("LAST VISIT");
    * %ELSE %STR(" ");
    * CONTA=, *SUM=, *F=XN.
  PROB= P (*), *SUM=, *F=6.3)
  / ROW=FLOAT RUS=40 PRINTMISS MISSTXT=,
  BOX=%IF LASTVIS=1 %THEN %STR(" ");
  %ELSE %STR(_PAGE_);
FOOTNOTE
/ (4) MC NEMAR (Binomial Distribution) / STUART-MAXWELL TEST;
RUN;
TITLE7 ' '; FOOTNOTE ' ';
%MEND TABLE3;
%MACRO MACLAB2;
%*-----*
%* SHIF TABLES
%*-----*
%* FORMAT
%*-----*

```


9550077

Pharmacia

Document 9550077

12.1.11 SELECTION OF STATISTICAL ANALYSIS OUTPUTS

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS R&D
REBOXETINE - PROTOCOL 20124/013

APPENDIX No.: 12.1.11

PATIENTS IN REMISSION AT LAST ASSESSMENT BY TREATMENT
PATIENTS NOT RESPONDER AT THE END OF RUN-IN PHASE HAVE NOT BEEN CONSIDERED

TABLE OF TREAT BY REM

TREAT(TREATMENT)	REM	0	1	Total
Frequency				
Percent				
Row Pct				
Col Pct				
REBOXETINE		29	104	133
		10.94	39.25	50.19
		21.80	76.20	
		28.53	63.80	
PLACEBO		73	59	132
		27.55	22.26	49.81
		55.50	44.70	
		71.57	56.20	
Total		102	165	265
		38.49	61.51	100.00

Frequency Missing = 72

STATISTICS FOR TABLE OF TREAT BY REM

Statistic	DF	Value	Prob
Chi-Square	1	31.400	0.000
Likelihood Ratio Chi-Square	1	32.200	0.000
Continuity Adj. Chi-Square	1	30.001	0.000
Mantel-Haenszel Chi-Square	1	31.282	0.000
Fisher's Exact Test (Left)		1.50E-08	1.000
Fisher's Exact Test (Right)		1.000	2.08E-08
Phi Coefficient (2-Tail)		-0.344	
Contingency Coefficient		0.325	
Cramer's V		-0.344	
Effective Sample Size =		265	
Frequency Missing =		72	

WARNING: 21% of the data are missing.

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS 980
 REMONETIM - PROTOCOL 20124/013
 APPENDIX No.: 12.1.1.11

DOUBLE BLIND PHASE
 PROPORTION OF PATIENTS WHO RELAPSED AT LEAST ONCE DURING THE DOUBLE BLIND PHASE

TABLE OF FAIL BY TREAT

FAIL(RELAPSED)	TREAT(TREATMENT)
Frequency	
Percent	
Row Pct	
Col Pct	REMONETIM(PLACEBO) NE
Total	
NO	104 50 162 39.25 21.09 51.15 66.20 35.80
YES	78.20 63.94 29 74 103 10.94 27.92 38.87 26.18 71.64 21.88 58.06
Total	189 132 265 58.15 49.81 100.00

STATISTICS FOR TABLE OF FAIL BY TREAT

Statistic	DF	Value	Prob
Chi-Square	1	32.719	0.000
Likelihood Ratio Chi-Square	1	33.578	0.000
Continuity Adj. Chi-Square	1	31.293	0.000
Nantal-Hannszel Chi-Square	1	32.595	0.000
Fisher's Exact Test (Left)			1.000
Fisher's Exact Test (Right)			7.51E-09
Fisher's Exact Test (2-Tail)			1.04E-08
Phi Coefficient		0.351	
Contingency Coefficient		0.332	
Cramer's V		0.351	
Sample Size =	265		

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 RENOXYTINE - PROTIDON. 2012/013
 APPENDIX No.: 12.1.1.1

DOUBLE BLIND PHASE
 PROPORTION OF RELAPSED-FREE PATIENTS DURING THE FIRST AND THE LAST 6 MONTHS OF TREATMENT

TABLE OF RELAPSED BY TREAT

RELAPSED	TREAT(TREATMENT)		Total
Frequency	Percent	Row Pct	Col Pct
		RENOXYTINE/PLACEBO	IME
NO	80	53	133
	30.19	20.00	50.19
	80.15	39.65	
	60.15	40.15	
YES	55	70	132
	20.00	29.61	49.61
	40.18	59.85	
	39.85	59.85	
Total	135	132	265
	50.19	49.81	100.00

STATISTICS FOR TABLE OF RELAPSED BY TREAT

Statistic	DF	Value	Prob
Chi-Square	1	10.589	0.001
Likelihood Ratio Chi-Square	1	10.571	0.001
Continuity Adj. Chi-Square	1	9.814	0.002
Mantel-Haenszel Chi-Square	1	10.589	0.001
Fisher's Exact Test (Left)		8.40E-04	1.000
Fisher's Exact Test (2-Tail)		1.39E-03	
Phi Coefficient		0.200	
Contingency Coefficient		0.196	
Cramer's V		0.200	
Sample Size = 265			

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
 REMONETIM - PROTOCOL 20124/013
 APPENDIX No.: 12.1.11

DOUBLE BLIND PHASE
 PROPORTION OF RELAPSED-FREE PATIENTS DURING THE FIRST AND THE LAST 6 MONTHS OF TREATMENT

TABLE OF RELAPSED BY TREAT

RELAPSED	TREAT(TREATMENT)	Frequency	Percent	Row Pct	Col Pct	REMONETIM/PLACEBO	Total
	LINE					LINE	
NO		64	29	95			
		53.23	23.39	76.41			
		69.47	30.53				
		96.00	59.18				
YES		9	20	29			
		7.26	16.13	23.39			
		31.03	59.37				
		12.00	40.62				
TOTAL		75	49	124			
		69.46	39.52	100.00			

STATISTICS FOR TABLE OF RELAPSED BY TREAT

Statistic	DF	Value	Prob
Chi-Square	1	15.735	0.000
Likelihood Ratio Chi-Square	1	15.565	0.000
Continuity Adj. Chi-Square	1	12.174	0.000
Nominal Homogeneity Chi-Square	1	13.424	0.000
Fisher's Exact Test (Left (Right) (2-tail))		2.62E-04	3.69E-04
Phi Coefficient		0.333	
Contingency Coefficient		0.316	
Cramer's V		0.333	
Sample Size =		124	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R2D
REGIMETIME - PROTOCOL 20124/013

APPENDIX No.: 12.1.1.1

TIME TO RELAPSE
(EXCLUDING THE PATIENTS NOT RESPONDER AT WEEK 6)

The LIFEEST Procedure

Product-Limit Survival Estimates
TREAT = PLACEBO

TIME	Survival	Failure	Survival Standard Error	Number Failed	Number Left
0.000	1.0000	0	0	0	132
15.000	0.9924	0.0076	0.00755	1	131
15.000*				1	130
15.000*				1	129
15.000*				1	128
16.000	0.9847	0.0153	0.0108	2	127
25.000*				2	126
28.000	0.9769	0.0231	0.0132	3	125
29.000				4	124
29.000				5	123
29.000				6	122
29.000				7	121
29.000				8	120
29.000				9	119
29.000				10	118
29.000				11	117
29.000				12	116
29.000				13	115
29.000				14	114
29.000				15	113
29.000	0.8783	0.1217	0.0272	16	112
42.000*				17	111
43.000				18	110
43.000				19	109
43.000				20	108
43.000	0.8355	0.1645	0.0328	21	106
43.000*				21	105
56.000	0.8279	0.1721	0.0334	22	104
57.000				23	103
57.000	0.8040	0.1960	0.0352	24	102
57.000*				25	101
57.000*				25	100
71.000				26	99
71.000				27	97
71.000				28	96
71.000				29	95
71.000				30	94
71.000				31	93
71.000				32	92
71.000				33	91

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS BRD
 REMOETINE - PROTOCOL 20124/013
 APPENDIX No.: 12.1.11

TIME TO RELAPSE
 (EXCLUDING THE PATIENTS NOT RESPONDER AT WEEK 6)

The LIFETEST Procedure

TIME	Survival	Failure	Survival Standard Error	Number Failed	Number Left
71.000	0.7309	0.2691	0.0395	34	90
71.000*				34	89
71.003*				34	88
71.003*				34	87
71.003*				34	86
71.003*				34	85
71.003*				34	84
71.003*				34	83
71.003*				34	82
71.003*				34	81
71.003*				34	80
71.003*				34	79
71.003*				34	78
71.003*				34	77
71.003*				34	76
71.003*				34	75
71.003*				34	74
71.003*				34	73
71.003*				34	72
71.003*				34	71
71.003*				34	70
71.003*				34	69
71.003*				34	68
71.003*				34	67
71.003*				34	66
71.003*				34	65
71.003*				34	64
71.003*				34	63
71.003*				34	62
71.003*				34	61
71.003*				34	60
71.003*				34	59
71.003*				34	58
71.003*				34	57
71.003*				34	56
71.003*				34	55
71.003*				34	54
71.003*				34	53
71.003*				34	52
71.003*				34	51
71.003*				34	50
71.003*				34	49
71.003*				34	48
71.003*				34	47
71.003*				34	46
71.003*				34	45
71.003*				34	44
71.003*				34	43
71.003*				34	42
71.003*				34	41
71.003*				34	40
71.003*				34	39
71.003*				34	38
71.003*				34	37
71.003*				34	36
71.003*				34	35
71.003*				34	34
71.003*				34	33
71.003*				34	32
71.003*				34	31
71.003*				34	30
71.003*				34	29
71.003*				34	28
71.003*				34	27
71.003*				34	26
71.003*				34	25
71.003*				34	24
71.003*				34	23
71.003*				34	22
71.003*				34	21
71.003*				34	20
71.003*				34	19
71.003*				34	18
71.003*				34	17
71.003*				34	16
71.003*				34	15
71.003*				34	14
71.003*				34	13
71.003*				34	12
71.003*				34	11
71.003*				34	10
71.003*				34	9
71.003*				34	8
71.003*				34	7
71.003*				34	6
71.003*				34	5
71.003*				34	4
71.003*				34	3
71.003*				34	2
71.003*				34	1

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS 880
 REMOETINE - PROTOCOL 2016/113
 APPENDIX No.: 12.1.11

TIME TO RELAPSE
 (EXCLUDING THE PATIENTS NOT RESPONDER AT WEEK 6)

The LIFEEST Procedure

TIME	Survival	Failure	Survival Standard Error	Number Failed	Number Left
197.000				61	65
197.000	0.4656	0.5462	0.0478	62	64
197.000M				63	63
211.000				64	62
211.000M	0.4322	0.5678	0.0479	65	61
225.000				66	60
225.000M	0.4106	0.5894	0.0479	67	59
239.000				67	58
239.000M	0.3992	0.6008	0.0479	68	57
253.000				68	56
253.000M				69	55
267.000				70	54
267.000M	0.3840	0.6160	0.0478	71	53
280.000				72	52
280.000M	0.3622	0.6378	0.0477	72	51
295.000				73	50
295.000M	0.3279	0.6721	0.0474	74	49
322.000				74	48
322.000M				74	47
325.000				74	46
325.000M				74	45
325.000M				74	44
325.000M				74	43
325.000M				74	42
325.000M				74	41
325.000M				74	40
325.000M				74	39
325.000M				74	38
325.000M				74	37
325.000M				74	36
325.000M				74	35
325.000M				74	34
325.000M				74	33
325.000M				74	32
325.000M				74	31
325.000M				74	30
325.000M				74	29
325.000M				74	28
325.000M				74	27
325.000M				74	26
325.000M				74	25
325.000M				74	24
325.000M				74	23
325.000M				74	22
325.000M				74	21
325.000M				74	20
325.000M				74	19
325.000M				74	18
325.000M				74	17
325.000M				74	16
325.000M				74	15
325.000M				74	14
325.000M				74	13
325.000M				74	12
325.000M				74	11
325.000M				74	10
325.000M				74	9
325.000M				74	8
325.000M				74	7
325.000M				74	6
325.000M				74	5
325.000M				74	4
325.000M				74	3
325.000M				74	2
325.000M				74	1

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
 RESOMETINE - PROTOCOL 20124/013
 APPENDIX No.: 12.1.11

TIME TO RELAPSE
 (EXCLUDING THE PATIENTS NOT RESPONDER AT WEEK 6)

The LIFETEST Procedure

TIME	Survival	Failure	Survival Standard Error	Number Failed	Number Left
324.000*				74	0
* Censored Observation					
Quantiles	75%	Mean		179.829	
	50%	163.000	Standard Error	9.738	
	25%	71.000			

NOTE: The last observation was censored so the estimate of the mean is biased.

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

APPENDIX No.: 12.1.1.11

TIME TO RELEASE
(EXCLUDING THE PATIENTS NOT RESPONDER AT WEEK 6)

The LIFEEST Procedure

Product-Limit Survival Estimates
TREAT = REBOXETINE

TIME	Survival	Failure	Survival Standard Error	Number Failed	Number Left
0.000	1.0000	0	0	0	133
15.000				1	132
15.000				2	131
15.000				3	130
15.000				4	129
15.000	0.9624	0.0376	0.0165	5	128
15.000*				5	127
15.000*				5	126
15.000*				5	125
15.000*				5	124
20.000*				5	123
20.000*				5	122
20.000*				6	121
20.000*				7	120
20.000*	0.9387	0.0613	0.0210	8	119
20.000*				8	118
20.000*				8	117
20.000*				8	116
20.000*				9	115
45.000				10	114
45.000				11	113
45.000				12	112
45.000				13	111
45.000*	0.8983	0.1017	0.0266	13	110
45.000*				14	109
57.000				15	108
57.000	0.8726	0.1274	0.0295	16	107
57.000*				16	106
71.000	0.8455	0.1545	0.0304	17	105
71.000*				17	104
71.000*				17	103
71.000*				17	102
71.000*				17	101
71.000*				17	100
71.000*				17	99
71.000*				17	98
86.000				18	97
86.000	0.8390	0.1610	0.0331	19	96
86.000*				20	95
99.000	0.8301	0.1699	0.0339	21	94
99.000*				21	93
99.000*				21	92

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

APPENDIX No.: 12.1.11

TIME TO RELEASE
(EXCLUDING THE PATIENTS NOT RESPONDER AT WEEK 6)

The LIFETEST Procedure

TIME	Survival	Failure	Survival Standard Error	Number Failed	Number Left
99.000*				21	91
99.000*				21	90
112.000	0.8299	0.1791	0.0548	22	89
112.000*				22	88
112.000*				22	87
125.000	0.6115	0.1685	0.0356	23	86
127.000	0.6020	0.1580	0.0384	24	85
134.000	0.7926	0.2074	0.0572	25	84
141.000	0.7831	0.2169	0.0580	26	83
141.000*				26	82
141.000*				26	81
155.000*				26	80
155.000*				26	79
155.000*				26	78
166.000*				26	77
166.000*				26	76
166.000*				26	75
166.000*				26	74
183.000*				26	73
197.000	0.7724	0.2276	0.0589	27	72
197.000*				27	71
197.000*				27	70
211.000*				27	69
211.000*				27	68
225.000	0.7500	0.2500	0.0409	29	67
225.000*				29	66
225.000*				29	65
225.000*				29	64
225.000*				29	63
225.000*				29	62
225.000*				29	61
225.000*				29	60
225.000*				29	59
225.000*				29	58
225.000*				29	57
225.000*				29	56
225.000*				29	55
225.000*				29	54
225.000*				29	53
225.000*				29	52
225.000*				29	51
225.000*				29	50
225.000*				29	49
225.000*				29	48
225.000*				29	47

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RAD
 REMONETIME - PROTOCOL 20126/013
 APPENDIX No.: 12.1.1.11

TIME TO RELAPSE
 (EXCLUDING THE PATIENTS NOT RESPONDER AT WEEK 6)

The LIFETEST Procedure

TIME	Survival		Standard Error		Number Failed	Number Left
	Survival	Failure	Survival	Error		
322.000*	29	46			29	46
322.000*	29	45			29	45
322.000*	29	44			29	44
322.000*	29	43			29	43
322.000*	29	42			29	42
322.000*	29	41			29	41
322.000*	29	40			29	40
322.000*	29	39			29	39
322.000*	29	38			29	38
322.000*	29	37			29	37
322.000*	29	36			29	36
322.000*	29	35			29	35
322.000*	29	34			29	34
322.000*	29	33			29	33
322.000*	29	32			29	32
322.000*	29	31			29	31
322.000*	29	30			29	30
322.000*	29	29			29	29
322.000*	29	28			29	28
322.000*	29	27			29	27
322.000*	29	26			29	26
322.000*	29	25			29	25
322.000*	29	24			29	24
322.000*	29	23			29	23
322.000*	29	22			29	22
322.000*	29	21			29	21
322.000*	29	20			29	20
322.000*	29	19			29	19
322.000*	29	18			29	18
322.000*	29	17			29	17
322.000*	29	16			29	16
322.000*	29	15			29	15
322.000*	29	14			29	14
322.000*	29	13			29	13
322.000*	29	12			29	12
322.000*	29	11			29	11
322.000*	29	10			29	10
322.000*	29	9			29	9
322.000*	29	8			29	8
322.000*	29	7			29	7
322.000*	29	6			29	6
322.000*	29	5			29	5
322.000*	29	4			29	4
322.000*	29	3			29	3
322.000*	29	2			29	2

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD
 REDNETINE - PROTOCOL 20124/013
 APPENDIX No.: 12.1.1.11

TIME TO RELAPSE
 (EXCLUDING THE PATIENTS NOT RESPONDER AT WEEK 6)

The LIFETEST Procedure

TIME	Survival	Failure	Survival Standard Error	Number Failed	Number Left
324,000*		29		29	1
324,000*		29		29	0

* Censored Observation

Quantiles	75%	Mean	50%	Standard Error	25%
		199.030		6.287	

NOTE: The last observation was censored so the estimate of the mean is biased.

Summary of the Number of Censored and Uncensored Values

TREAT	Total	Failed	Censored	XCensored
PLACEBO	132	74	58	45.9394
REDNETINE	133	29	104	78.1955
Total	265	103	162	61.1321

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

9550077


PHARMACIA DNS R&D
REBOXetine - PROTOCOL 20124/013

APPENDIX No.: 12.1.1.11

TIME TO RELAPSE
(EXCLUDING THE PATIENTS NOT RESPONDER AT WEEK 6)

The LIFEEST Procedure

Survival Function Estimates



DAYS BETWEEN RELAPSE AND WEEKS TIME

9550077

PHARMACIA DMS R&D
REBONETINE - PROTOCOL 20124/013

APPENDIX No.: 12.1.1.1

TIME TO RELAPSE
(EXCLUDING THE PATIENTS NOT RESPONDER AT WEEK 6)

The LIFE/TEST Procedure

Censored Observations



Legend for Strata Symbols

P:TREAT=PLACEBO R:TREAT=REBONETINE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

APPENDIX No.: 12-1-11

TIME TO RELAPSE
(EXCLUDING THE PATIENTS NOT RESPONDER AT WEEK 6)

The LIFE TEST Procedure

Testing Homogeneity of Survival Curves over Strata
Time Variable TIME

Rank Statistics			
TREAT	Log-Rank	Milcozen	
PLACEBO	27.579	4352.0	
REBOXETINE	-27.579	-4352.0	

Covariance Matrix for the Log-Rank Statistics

TREAT	PLACEBO	REBOXETINE
PLACEBO	24.4975	-24.4975
REBOXETINE	-24.4975	24.4975

Covariance Matrix for the Milcozen Statistics

TREAT	PLACEBO	REBOXETINE
PLACEBO	921955	-921955
REBOXETINE	-921955	921955

Test of Equality over Strata

Test	Chi-Square	DF	Pr >
Log-Rank	30.5993	1	0.0001
Milcozen	20.5432	1	0.0001
-2Log(LR)	35.6470	1	0.0001

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS MSD
REBOXETINE - PROTOCOL 20124/013

APPENDIX No.: 12.1.1.11

CENSORING PATTERN

The LIFEEST Procedure

Product-Limit Survival Estimates
TREAT = PLACEBO

TIME	Survival		Survival Standard Error	Number Failed	Number Left
	Survival	Failure			
0.000	1.0000	0	0	0	132
15.000				1	131
15.000				2	130
15.000	0.9772	0.0227	0.0130	3	129
15.000*				3	126
16.000	0.9596	0.0304	0.0149	4	127
25.000	0.9420	0.0380	0.0167	5	126
26.000	0.9564	0.0456	0.0182	6	125
29.000	0.9467	0.0533	0.0196	7	124
29.000*				7	123
29.000*				7	122
29.000*				7	121
29.000*				7	120
29.000*				7	119
29.000*				7	118
29.000*				7	117
29.000*				7	116
29.000*				7	115
29.000*				7	114
29.000*				7	113
29.000*				7	112
42.000	0.9363	0.0417	0.0212	8	111
43.000	0.9298	0.0702	0.0226	9	110
43.000*				9	109
43.000*				9	108
43.000*				9	107
43.000*				9	106
43.000*				9	105
56.000*				9	104
57.000	0.9119	0.0681	0.0255	10	103
57.000*				11	102
57.000*				11	101
57.000*				11	100
57.000*				11	99
71.000				12	98
71.000	0.8845	0.1157	0.0293	13	97
71.000*				14	96
71.000*				14	95
71.000*				14	94
71.000*				14	93
71.000*				14	92

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REMOXETINE - PROTOCOL 20124/013

APPENDIX No.: 12.1.11

CENSORING PATTERN

The LIFEEST Procedure

TIME	Survival	Failure	Survival Standard Error	Number Failed	Number Left
71.000*				14	91
71.000*				14	90
71.000*				14	89
71.000*				14	88
71.000*				14	87
84.000*				14	86
85.000				15	85
85.000				16	84
85.000	0.0535	0.1465	0.0332	17	83
85.000*				17	82
85.000*				17	81
85.000*	0.0429	0.1571	0.0544	18	80
99.000				19	79
99.000				20	78
99.000				21	77
99.000				22	76
99.000				23	75
99.000	0.7737	0.2293	0.0404	24	74
99.000				24	73
99.000				24	72
99.000				24	71
99.000				24	70
100.000*				24	69
100.000*				25	68
112.000	0.7686	0.2214	0.0413	25	67
112.000*				25	66
112.000*				25	65
127.000	0.7569	0.2431	0.0423	26	64
128.000*				26	63
128.000*				27	62
141.000	0.7449	0.2551	0.0433	27	61
141.000*				28	60
155.000				29	59
155.000				30	58
155.000	0.6961	0.3039	0.0468	31	57
155.000*				31	56
155.000*				31	55
155.000*				31	54
169.000*				31	53
169.000*				31	52
169.000*				31	51
169.000*				31	50
170.000*				31	49
163.000	0.6019	0.3101	0.0480	32	48

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REDOXETINE - PROTOCOL 2012/013

APPENDIX No.: 12.1.11

CENSORING PATTERN

The LIFETEST Procedure

TIME	Survival	Failure	Survival Standard Error	Number Failed	Number Left
163.000*				32	47
163.000*				32	46
163.000*				33	45
163.000*				34	44
163.000*	0.4532	0.3470	0.0503	34	43
163.000*				34	42
163.000*				34	41
163.000*				34	40
163.000*				34	39
163.000*				34	38
163.000*	0.4550	0.3650	0.0518	35	37
163.000*	0.4179	0.3821	0.0532	36	36
163.000*	0.4007	0.3933	0.0544	37	35
163.000*				37	34
163.000*				37	33
163.000*				37	32
163.000*				37	31
163.000*	0.4913	0.4167	0.0560	38	30
163.000*				38	29
163.000*				38	28
163.000*				38	27
163.000*				38	26
163.000*				38	25
163.000*				38	24
163.000*				38	23
163.000*				38	22
163.000*				38	21
163.000*				38	20
163.000*				38	19
163.000*				38	18
163.000*				38	17
163.000*				38	16
163.000*				38	15
163.000*				38	14
163.000*				38	13
163.000*				38	12
163.000*				38	11
163.000*				38	10
163.000*				38	9
163.000*				38	8
163.000*				38	7
163.000*				38	6
163.000*				38	5
163.000*				38	4

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS MSD
REBOXETINE - PROTOCOL 20124/013

APPENDIX No.: 12.1.1.11

CENSORING PATTERN

The LIFETEST Procedure

TIME	Survival	Failure	Survival Standard Error	Number Failed	Number Left
323,000*				36	3
323,000*				36	2
324,000*				36	1
324,000*				36	0

* Censored Observation

Quantiles	Mean
75%	216,106
50%	Standard Error 9,322
25%	141,000

NOTE: The last observation was censored so the estimate of the mean is biased.

9550077

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD
REBOMETINE - PROTOCOL 20124/013

APPENDIX No.: 12.1.1.11

CENSORING PATTERN

The LIFETEST Procedure

Product-Limit Survival Estimates
TREAT = REBOMETINE

TIME	Survival	Failure	Survival Standard Error	Number Failed	Number Left
0.000	1.0000	0	0	0	135
16.000				1	132
16.000				2	131
16.000				3	130
16.000				4	129
16.000				5	128
16.000				6	127
16.000	0.9474	0.0526	0.0194	7	126
16.000*				7	125
16.000*				7	124
23.000	0.9397	0.0603	0.0207	8	123
26.000	0.9321	0.0679	0.0219	9	122
29.000				10	121
29.000				11	120
29.000	0.9092	0.0908	0.0250	12	119
29.000*				12	118
29.000*				12	117
29.000*				12	116
63.000				13	115
63.000	0.8935	0.1065	0.0269	14	114
63.000*				14	113
63.000*				14	112
63.000*				14	111
63.000*				14	110
57.000*				14	109
57.000*				14	108
57.000*				14	107
67.000	0.8651	0.1149	0.0279	15	106
71.000				16	105
71.000				17	104
71.000				18	103
71.000	0.8434	0.1266	0.0323	20	102
71.000*				20	101
72.000	0.8250	0.1350	0.0330	21	99
84.000	0.8265	0.1725	0.0357	22	98
85.000				23	97
85.000	0.8057	0.1993	0.0351	24	96
85.000*				24	95
85.000*				24	94
99.000				25	93

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CUS BRD
RENOMETINE - PROTOCOL 20124/013

APPENDIX No.: 12.1.11

CENSORING PATTERN

The LIFETEST Procedure*

TIME	Survival	Failure	Survival Standard Error	Number Failed	Number Left
99.000	0.7924	0.2076	0.0384	26	92
99.000*				26	91
99.000*				26	90
113.000				27	89
113.000				28	88
113.000	0.7440	0.2560	0.0303	29	87
125.000*				29	86
127.000*				29	85
134.000*				29	84
141.000				30	83
141.000*	0.7476	0.2522	0.0395	31	82
141.000*				31	81
155.000				32	80
155.000				33	79
155.000	0.7201	0.2799	0.0411	34	78
168.000	0.7108	0.2892	0.0416	35	77
169.000				36	76
169.000	0.6924	0.3076	0.0425	37	75
169.000				38	74
183.000	0.6739	0.3261	0.0433	39	73
197.000				40	72
197.000	0.6555	0.3445	0.0441	41	71
211.000	0.6461	0.3539	0.0444	42	69
225.000*				42	68
225.000*				42	67
241.000	0.6365	0.3635	0.0448	43	66
242.000*				43	65
242.000*				43	64
242.000*				43	63
242.000*				43	62
242.000*				43	61
242.000*				43	60
242.000*				43	59
242.000*				43	58
242.000*				43	57
242.000*				43	56
242.000*				43	55
242.000*				43	54
242.000*				43	53
242.000*				43	52
242.000*				43	51
242.000*				43	50
242.000*				43	49

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA GUS R&D
REBOXETINE - PROTOCOL 20124/013

APPENDIX No.: 12.1.11

CENSORING PATTERN

The LIFETEST Procedure

TIME	Survival	Failure	Survival Standard Error	Number Failed	Number Left
323.000*				43	48
323.000*				43	47
323.000*				43	46
323.000*				43	45
323.000*				43	44
323.000*				43	43
323.000*				43	42
323.000*				43	41
323.000*				43	40
323.000*				43	39
323.000*				43	38
323.000*				43	37
323.000*				43	36
323.000*				43	35
323.000*				43	34
323.000*				43	33
323.000*				43	32
323.000*				43	31
323.000*				43	30
323.000*				43	29
323.000*				43	28
323.000*				43	27
323.000*				43	26
323.000*				43	25
323.000*				43	24
323.000*				43	23
323.000*				43	22
323.000*				43	21
323.000*				43	20
323.000*				43	19
323.000*				43	18
323.000*				43	17
323.000*				43	16
323.000*				43	15
323.000*				43	14
323.000*				43	13
323.000*				43	12
323.000*				43	11
323.000*				43	10
323.000*				43	9
323.000*				43	8
323.000*				43	7
323.000*				43	6
324.000*				43	5

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

9550077

PHARMACIA CVS RSD
REBOMETINE - PROTOCOL 20124/013

APPENDIX No.: 12.1.11

CENSORING PATTERN

The LIFETEST Procedure

TIME	Survival	Failure	Survival Standard Error	Number Failed	Number Left
324.000*				43	4
324.000*				45	3
324.000*				45	2
324.000*				43	1
324.000*				43	0

* Censored Observation

Quantiles 75% Mean 215.561
50% Standard Error 8.752
25% 141.800

NOTE: The last observation was censored so the estimate of the mean is biased.


Summary of the Number of Censored and Uncensored Values

TREAT	Total	Failed	Censored	XCensored
PLACEMO	132	36	94	71.2121
REBOMETINE	133	43	90	67.6692
Total	265	81	184	69.4540

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOINETIME - PROTOCOL 20124/013
 APPENDIX No.: 12.1.11
 CENSORING PATTERN
 The LIFE TEST Procedure
 Survival Function Estimates



633

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOZETINE - PROTOCOL 20126/013

APPENDIX No.: 12.1.1.11

CENSORING PATTERN

The LIFETEST Procedure

Censored Observations

Strata	0	10	20	30	40	50	60	70	80	90	100	110	120	130	140	150	160	170	180	190	200	210	220	230	240	250	260	270	280	290	300	310	320	330			
R+																																					
P+																																					
P																																					
R																																					
M																																					
WP																																					
PM																																					

DAYS BETWEEN RELAPSE AND WEEK TIME

Legend for Strata Symbols

P:TREAT=PLACEBO R:TREAT=REBOZETINE

PHARMACIA CNS RSD
 REBONETIME - PROTOCOL 20126/013
 APPENDIX No.: 12.1.1.11
 CENSORING PATTERN
 The LIFE TEST Procedure
 Testing Homogeneity of Survival Curves over Strata
 Time Variable TIME

Rank Statistics

TREAT	Log-Rank	Milcoxon
PLACEBO	1.2594	-1.53.00
REBONETIME	-1.2594	1.53.00

Covariance Matrix for the Log-Rank Statistics

TREAT	PLACEBO	REBONETIME
PLACEBO	19.4716	-19.4716
REBONETIME	-19.4716	19.4716

Covariance Matrix for the Milcoxon Statistics

TREAT	PLACEBO	REBONETIME
PLACEBO	727733	-727733
REBONETIME	-727733	727733

Test of Equality over Strata

Test	Chi-Square	Df	Pr >
Log-Rank	0.0815	1	0.7753
Milcoxon	0.0243	1	0.8741
-2Log(LR)	0.5694	1	0.4505

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
 REBONETINE - PROTOCOL 20124/013
 APPENDIX No.: 12.1.1.11
 MAINTENANCE OF THE RESPONSE

The LIFE TEST Procedure
 Product-Limit Survival Estimates
 TREAT = PLACEBO

TIME	Survival	Failure	Survival Standard Error	Number Failed	Number Left
0.000	1.0000	0	0	0	132
15.000				1	131
15.000				2	130
15.000				3	129
15.000	0.9697	0.0303	0.0149	4	128
16.000	0.9621	0.0379	0.0164	5	127
25.000*				6	126
26.000	0.9545	0.0455	0.0182	7	125
26.000				8	124
26.000				9	123
26.000				10	122
26.000				11	120
26.000				12	119
26.000				13	118
26.000				14	117
26.000				15	116
26.000				16	115
26.000				17	114
26.000				18	113
26.000	0.8652	0.1348	0.0507	19	112
42.000*				19	111
43.000				20	110
43.000				21	109
43.000				22	108
43.000				23	107
43.000				24	106
43.000	0.6090	0.3910	0.0546	25	105
56.000	0.6013	0.3987	0.0549	26	104
57.000				27	103
57.000				28	102
57.000				29	101
57.000	0.7705	0.2295	0.0566	30	100
57.000*				30	99
71.000				31	98
71.000				32	97
71.000				32	96
71.000				34	95
71.000				35	94
71.000				36	93

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMONETINE - PROTOCOL 20126/013
 APPENDIX No.: 12.1.11
 MAINTENANCE OF THE RESPONSE

The LIFETEST Procedure

TIME	Survival	Failure	Survival Standard Error	Number Failed	Number Left
71.000				37	92
71.000				36	91
71.000				39	90
71.000				40	89
71.000	0.4849	0.3151	0.0408	41	88
71.000*				41	87
84.000	0.4770	0.3230	0.0411	42	86
85.000				43	85
85.000				44	84
85.000				45	83
85.000				46	82
85.000	0.4374	0.3426	0.0423	47	81
97.000	0.4290	0.3710	0.0425	48	80
99.000				49	79
99.000				50	78
99.000				51	77
99.000				52	76
99.000				53	75
99.000				54	74
99.000				55	73
99.000	0.5665	0.4332	0.0437	56	72
100.000	0.5589	0.4411	0.0438	57	71
107.000	0.5510	0.4490	0.0439	58	70
113.000				59	69
113.000				60	68
113.000				61	67
113.000	0.5195	0.4805	0.0441	62	66
127.000	0.5117	0.4883	0.0441	63	65
128.000				64	64
128.000	0.4959	0.5041	0.0441	65	63
141.000				66	62
141.000	0.4892	0.5108	0.0441	67	61
155.000				68	60
155.000				69	59
155.000				70	58
155.000				71	57
155.000				72	56
155.000	0.4330	0.5670	0.0438	73	55
159.000				74	54
159.000				75	53
169.000				76	52
169.000				77	51
169.000	0.3936	0.6064	0.0432	78	50

637

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOOTING - PROTOCOL 20124/013
 APPENDIX No.: 12.1.1.11
 MAINTENANCE OF THE RESPONSE

The LIFETEST Procedure

TIME	Survival	Failure	Survival Standard Error	Number Failed	Number Left
170.000	0.3857	0.6143	0.0431	79	49
185.000				80	48
185.000				81	47
185.000	0.3621	0.6379	0.0425	82	46
197.000				83	45
197.000				84	44
197.000				85	43
197.000	0.3306	0.6694	0.0416	86	42
211.000				87	41
211.000	0.3149	0.6851	0.0411	88	40
225.000				89	39
225.000	0.2991	0.7009	0.0405	90	38
239.000*				91	37
253.000				92	36
253.000	0.2825	0.7175	0.0400	93	35
267.000				94	34
267.000	0.2576	0.7424	0.0389	95	33
280.000				96	32
280.000	0.2416	0.7590	0.0382	97	31
295.000				98	30
295.000	0.2244	0.7756	0.0373	99	29
325.000*				99	28
325.000*				99	27
325.000*				99	26
325.000*				99	25
325.000*				99	24
325.000*				99	23
325.000*				99	22
325.000*				99	21
325.000*				99	20
325.000*				99	19
325.000*				99	18
325.000*				99	17
325.000*				99	16
325.000*				99	15
325.000*				99	14
325.000*				99	13
325.000*				99	12
325.000*				99	11
325.000*				99	10
325.000*				99	9
325.000*				99	8
325.000*				99	7

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RAD
 REMOETINE - PROTOCOL 2016/013
 APPENDIX No.: 12.1.11
 MAINTENANCE OF THE RESPONSE

The LIFEEST Procedure

TIME	Survival	Failure	Survival Standard Error	Number Failed	Number Left
323.000*				99	6
323.000*				99	5
323.000*				99	4
323.000*				99	3
323.000*				99	2
324.000*				99	1
324.000*				99	0

* Censored Observation

Quantiles 75% 289.000 Mean 156.649
 50% 128.000 Standard Error 6.961
 25% 71.000

NOTE: The last observation was censored so the estimate of the mean is biased.

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS 880
 REMOETINE - PROTOCOL 20124/013
 APPENDIX No.: 12.1.11
 MAINTENANCE OF THE RESPONSE

The LIFEEST Procedure
 Product-Limit Survival Estimates
 TREAT = REMOETINE

TIME	Survival	Failure	Survival Standard Error	Number Failed	Number Left
0.000	1.0000	0	0	0	133
15.000				1	132
15.000				2	131
15.000				3	130
15.000				4	129
15.000				5	128
15.000				6	127
15.000				7	126
15.000	0.9396	0.0602	0.0206	6	125
15.000*				8	124
23.000*				8	122
29.000				9	121
29.000				10	120
29.000				11	119
29.000				12	118
29.000				13	117
29.000	0.8936	0.1064	0.0269	14	116
42.000				15	115
42.000				16	114
42.000				17	113
42.000				18	112
42.000				19	111
42.000	0.8474	0.1526	0.0314	20	110
57.000				21	109
57.000				22	108
57.000	0.8243	0.1757	0.0333	23	107
67.000*				24	106
71.000				25	104
71.000				26	103
71.000				27	102
71.000				28	101
71.000	0.7776	0.2224	0.0364	29	100
72.000*				30	99
84.000	0.7496	0.2502	0.0369	31	97
85.000				32	96
85.000				33	95
85.000	0.7354	0.2616	0.0366	34	94

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013

APPENDIX No. 12.1.1.1

MAINTENANCE OF THE RESPONSE

The LIFETEST Procedure

TIME	Survival	Failure	Survival Standard Error	Number Failed	Number Left
99.000				35	93
99.000				36	92
99.000				37	91
99.000	0.7019	0.2931	0.0400	38	90
113.000				39	89
113.000				40	88
113.000	0.6836	0.3164	0.0409	41	87
125.000	0.6765	0.3235	0.0412	42	86
127.000	0.6677	0.3323	0.0415	43	85
136.000	0.6598	0.3402	0.0417	44	84
141.000				45	83
141.000				46	82
141.000	0.6382	0.3618	0.0424	47	81
155.000				48	80
155.000				49	79
155.000	0.6127	0.3873	0.0430	50	78
166.000	0.6045	0.3955	0.0431	51	77
169.000				52	76
169.000	0.5891	0.4109	0.0434	53	75
185.000				54	74
185.000	0.5754	0.4266	0.0438	55	73
197.000				56	72
197.000				57	71
197.000	0.5498	0.4502	0.0439	58	70
211.000	0.5420	0.4580	0.0440	59	69
225.000				60	68
225.000	0.5243	0.4737	0.0441	61	67
281.000	0.5184	0.4816	0.0441	62	66
322.000*				62	65
322.000*				62	64
322.000*				62	63
323.000*				62	62
323.000*				62	61
323.000*				62	60
323.000*				62	59
323.000*				62	58
323.000*				62	57
323.000*				62	56
323.000*				62	55
323.000*				62	54
323.000*				62	53
323.000*				62	52
323.000*				62	51

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA RNS RED
REBOXETINE - PROTOCOL 20124/013

APPENDIX No.: 12.1.11

MAINTENANCE OF THE RESPONSE

The LIFETEST Procedure

TIME	Survival	Failure	Survival Standard Error	Number Failed	Number Left
325.000*				62	50
325.000*				62	49
325.000*				62	48
325.000*				62	47
325.000*				62	46
325.000*				62	45
325.000*				62	44
325.000*				62	43
325.000*				62	42
325.000*				62	41
325.000*				62	40
325.000*				62	39
325.000*				62	38
325.000*				62	37
325.000*				62	36
325.000*				62	35
325.000*				62	34
325.000*				62	33
325.000*				62	32
325.000*				62	31
325.000*				62	30
325.000*				62	29
325.000*				62	28
325.000*				62	27
325.000*				62	26
325.000*				62	25
325.000*				62	24
325.000*				62	23
325.000*				62	22
325.000*				62	21
325.000*				62	20
325.000*				62	19
325.000*				62	18
325.000*				62	17
325.000*				62	16
325.000*				62	15
325.000*				62	14
325.000*				62	13
325.000*				62	12
325.000*				62	11
325.000*				62	10
325.000*				62	9
325.000*				62	8

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBONETINE - PROTOCOL 20124/013
 APPENDIX No.: 12.1.1.11
 MAINTENANCE OF THE RESPONSE

The LIFETEST Procedure

TIME	Survival	Failure	Survival Standard Error	Number Failed	Number Left
323.000*		62		62	7
323.400*		62		62	4
324.000*		62		62	5
324.000*		62		62	4
324.000*		62		62	3
324.000*		62		62	2
324.000*		62		62	1
324.000*		62		62	0

* Censored Observation

Quantiles	75%	Mean	192.560
50%		Standard Error	9.105
25%	85.000		

NOTE: The last observation was censored so the estimate of the mean is biased.

Summary of the Number of Censored and Uncensored Values

TREAT	Total	Failed	Censored	XCensored
PLACEBO	132	99	33	25.0000
REBONETINE	133	62	71	53.4835
Total	265	161	104	78.4835

9550077

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17


PHARMACIA CUS IBD
REBOOTING - PROTOCOL 20124/013

APPENDIX No.: 12.1.11

MAINTENANCE OF THE RESPONSE

The LIFE TEST Procedure

Survival Function Estimates



9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS 880
REBOUNDING - PROTOCOL 20124/013

APPENDIX No.: 12.1.11

MAINTENANCE OF THE RESPONSE

The LIFETEST Procedure

Censored Observations



Legend for Strata Symbols

P+: TREAT=PLACEBO R: TREAT=REBOUNDING

645

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACTA GUS BRD
REBONETINE - PROTOCOL 20124/913

APPENDIX No.: 12.1.11

MAINTENANCE OF THE RESPONSE

The LIFE TEST Procedure

Testing Homogeneity of Survival Curves over Strata
Time Variable TIME

Rank Statistics

TREAT	Log-Rank	Mileston
PLACEBO	26.495	4660.0
REBONETINE	-26.495	-4660.0

Covariance Matrix for the Log-Rank Statistics

TREAT	PLACEBO	REBONETINE
PLACEBO	37.6528	-37.6528
REBONETINE	-37.6528	37.6528

Covariance Matrix for the Mileston Statistics

TREAT	PLACEBO	REBONETINE
PLACEBO	1357631	-1357631
REBONETINE	-1357631	1357631

Test of Equality over Strata

Test	Chi-Square	DF	Chi-Square	P >
Log-Rank	18.6440	1	0.0001	
Mileston	12.1597	1	0.0005	
-2log(LR)	22.8036	1	0.0001	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 RIBONETTINE - PROTOCOL 20126/013
 APPENDIX No.: 12.1.11

TIME TO RELAPSE
 (CONSIDERING ONLY THE PATIENTS REMITTED AT THE END OF THE OPEN PHASE)

TABLE OF TREAT BY FAIL

TREAT(TREATMENT)	FAIL (RELAISE)
Frequency	
Percent	
Row Pct	
Col Pct	
IND	YES Total
-----	-----
RIBONETTINE	74 16 60
	42.29 8.00 50.29
	86.99 15.91
	62.18 25.06
-----	-----
PLACEBO	65 42 87
	25.71 24.00 49.71
	51.72 66.28
	57.82 75.00
-----	-----
Total	119 56 175
	66.00 32.00 100.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBONETINE - PROTOCOL 20126/013
APPENDIX No.: 12.1.11

TIME TO RELEASE
(CONSIDERING ONLY THE PATIENTS REMITTED AT THE END OF THE OPEN PHASE)

The LIFETEST Procedure
Product-Limit Survival Estimates
TREAT = PLACEBO

TIME	Survival	Failure	Survival Standard Error	Number Failed	Number Left
0.000	1.0000	0	0	0	87
15.000	0.9805	0.0115	0.0114	1	86
15.000*				1	85
15.000*				1	84
15.000*				1	83
16.000	0.9766	0.0234	0.0184	2	82
25.000*				2	81
29.000				3	80
29.000				4	79
29.000				5	78
29.000				6	77
29.000				7	76
29.000	0.9843	0.0957	0.0522	8	75
42.000*				8	74
45.000				9	73
45.000	0.8798	0.1202	0.0557	10	72
57.000	0.8676	0.1324	0.0572	11	71
57.000*				11	70
57.000*				11	69
71.000				12	68
71.000				13	67
71.000				14	66
71.000				15	65
71.000				16	64
71.000				17	63
71.000	0.7796	0.2204	0.0460	18	62
71.000*				18	61
71.000*				18	60
71.000*				19	59
85.000				19	58
85.000	0.7399	0.2601	0.0498	20	57
85.000*				21	56
97.000*				21	55
99.000				22	54
99.000	0.7125	0.2875	0.0509	23	53
99.000*				23	52
99.000*				23	51
99.000*				23	50
107.000*				23	49
				23	48

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 RENOVETINE - PROTOCOL 2016/013
 APPENDIX No.: 12.1.11

TIME TO RELAPSE
 (CONSIDERING ONLY THE PATIENTS REMITTED AT THE END OF THE OPEN PHASE)

The LIFETEST Procedure

TIME	Survival	Failure	Survival Standard Error	Number Failed	Number Left
113.000	0.6828	0.3172	0.0529	24	47
113.000				25	46
113.000*				25	45
128.000				26	44
128.000	0.4525	0.5475	0.0547	27	43
141.000	0.4373	0.5627	0.0555	28	42
141.000*				28	41
155.000*				28	40
155.000*				28	39
155.000*				28	38
155.000*				28	37
155.000*				28	36
155.000*				28	35
159.000				31	34
159.000	0.5792	0.4208	0.0589	32	33
169.000	0.5585	0.4415	0.0595	33	32
170.000				33	31
181.000*				34	30
197.000				35	29
197.000	0.5016	0.4984	0.0610	36	28
197.000*				36	27
211.000	0.4637	0.5363	0.0614	37	26
225.000				38	25
225.000	0.4478	0.5522	0.0619	39	24
252.000*				39	23
252.000*	0.4292	0.5708	0.0621	40	22
252.000*				40	21
267.000	0.4017	0.5983	0.0622	41	20
286.000	0.3902	0.6098	0.0622	42	19
286.000*				42	18
322.000*				42	17
323.000*				42	16
323.000*				42	15
323.000*				42	14
323.000*				42	13
323.000*				42	12
323.000*				42	11
323.000*				42	10
323.000*				42	9
323.000*				42	8
323.000*				42	7
323.000*				42	6
323.000*				42	5

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
REBOXETINE - PROTOCOL 20126/013

APPENDIX No.: 12.1.1.11

TIME TO RELAPSE
(CONSIDERING ONLY THE PATIENTS REMITTED AT THE END OF THE OPEN PHASE)

The LIFETEST Procedure

TIME	Survival	Failure	Survival Standard Error	Number Failed	Number Left
325.000*				42	4
325.000*				42	3
325.000*				42	2
325.000*				42	1
325.000*				42	0

* Censored Observation

Quantiles	75%	Mean	100.00%
50%	211.000	Standard Error	11.181
25%	65.000		

NOTE: The last observation was censored so the estimate of the mean is biased.

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS MSD
REBOZETINE - PROTOCOL 20124/013

APPENDIX No.: 12.1.1.11

TIME TO RELEASE
(CONSIDERING ONLY THE PATIENTS REQUITED AT THE END OF THE OPEN PHASE)

The LIFETEST Procedure

Product-Limit Survival Estimates
TREAT = REBOZETINE

TIME	Survival	Failure	Survival Standard Error	Number Failed	Number Left
0.000	1.0000	0	0	0	86
15.000	0.9886	0.0114	0.0113	1	87
15.000*				1	86
15.000*				1	85
25.000*				1	84
26.000*				1	83
29.000*				1	82
29.000*				1	81
43.000				2	80
43.000				2	79
43.000				4	78
43.000	0.9398	0.0602	0.0261	5	77
57.000*				5	76
71.000*				5	75
71.000*				5	74
72.000*				5	73
72.000*				5	72
85.000				5	71
85.000				5	70
85.000	0.9001	0.0999	0.0336	7	69
99.000	0.8819	0.1181	0.0356	8	68
99.000*				9	67
99.000*				9	66
99.000*				9	65
113.000	0.6730	0.3270	0.0577	9	64
113.000				10	63
113.000*				10	62
125.000	0.6589	0.3411	0.0396	11	61
136.000	0.6446	0.3554	0.0416	12	60
141.000*				12	59
141.000*				12	58
155.000*				12	57
155.000*				12	56
168.000*				12	55
168.000*				12	54
169.000*				12	53
183.000*				12	52
197.000*				12	51
197.000*				12	50
211.000*				12	49

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS 80D
 REBOMETINE - PROTOCOL 20124/013
 APPENDIX No.: 12.1.1.11

TIME TO RELAPSE
 (CONSIDERING ONLY THE PATIENTS REMITTED AT THE END OF THE OPEN PHASE)

The LIFETEST Procedure

TIME	Survival	Failure	Survival Standard Error	Number Failed	Number Left
225.000	0.8104	0.1896	0.0463	13	48
225.000				14	47
231.000*				14	46
322.000*				14	45
322.000*				14	44
323.000*				14	43
323.000*				14	42
323.000*				14	41
323.000*				14	40
323.000*				14	39
323.000*				14	38
323.000*				14	37
323.000*				14	36
323.000*				14	35
323.000*				14	34
323.000*				14	33
323.000*				14	32
323.000*				14	31
323.000*				14	30
323.000*				14	29
323.000*				14	28
323.000*				14	27
323.000*				14	26
323.000*				14	25
323.000*				14	24
323.000*				14	23
323.000*				14	22
323.000*				14	21
323.000*				14	20
323.000*				14	19
323.000*				14	18
323.000*				14	17
323.000*				14	16
323.000*				14	15
323.000*				14	14
323.000*				14	13
323.000*				14	12
323.000*				14	11
323.000*				14	10
323.000*				14	9
323.000*				14	8
323.000*				14	7
323.000*				14	6
323.000*				14	5

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

9550077

PHARMACIA CNS RED
 REDOXETINE - PROTOCOL 20124/013
 APPENDIX No.: 12.1.11

TIME TO RELAPSE
 (CONSIDERING ONLY THE PATIENTS REMITTED AT THE END OF THE OPEN PHASE)

The LIFETEST Procedure

TIME	Survival	Failure	Survival Standard Error	Number Failed	Number Left
323.000*		14		14	5
323.000*		14		14	4
323.000*		14		14	3
324.000*		14		14	2
324.000*		14		14	1
324.000*		14		14	0

* Censored Observation

Quantiles	75%	Mean	202.259
50%		Standard Error	4.401
25%			

NOTE: The last observation was censored so the estimate of the mean is biased.

Summary of the Number of Censored and Uncensored Values

TREAT	Total	Failed	Censored	Xensored
PLACEBO	87	42	45	51.7241
REDOXETINE	88	14	74	84.0999
Total	175	56	119	68.0000


090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

9550077

PHARMACIA CNS 86D
 REBOMETINE - PROTOCOL 2012/013
 APPENDIX No.: 12.1.11

TIME TO RELAPSE
 (CONSIDERING ONLY THE PATIENTS REMITTED AT THE END OF THE OPEN PHASE)

The LIFETEST Procedure
 Survival Function Estimates



9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA RUS OAD
REBORETIME - PROTOCOL 20124/013
APPENDIX No.: 12.1.11

TIME TO RELAPSE
(CONSIDERING ONLY THE PATIENTS REMITTED AT THE END OF THE OPEN PHASE)

The LIFE TEST Procedure

Censored Observations



Legend for Strata Symbols

P+TREAT=PLACEBO R+TREAT=REBORETIME

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS BAD
 REMOXTINE – PROTOCOL 2012/4/013
 APPENDIX No.: 12.1.11

TIME TO RELAPSE
 (CONSIDERING ONLY THE PATIENTS REMITTED AT THE END OF THE OPEN PHASE)

The LIFETEST Procedure

Testing Homogeneity of Survival Curves over Strata
 Time Variable TIME

Rank Statistics		
TREAT	Log-Rank	Wilcoxon
PLACEBO	17.510	2015.0
REMOXTINE	-17.510	-2015.0

Covariance Matrix for the Log-Rank Statistics

TREAT	PLACEBO	REMOXTINE
PLACEBO	13.2920	-13.2920
REMOXTINE	-13.2920	13.2920

Covariance Matrix for the Wilcoxon Statistics

TREAT	PLACEBO	REMOXTINE
PLACEBO	218763	-218763
REMOXTINE	-218763	218763

Test of Equality over Strata

Test	Chi-Square	DF	Pr >
Log-Rank	23.0689	1	0.0001
Wilcoxon	10.5599	1	0.0001
-2log(LR)	25.5812	1	0.0001

9550077

Pharmacia

Document 9550077

12.2 Patient Information

9550077

Pharmacia

Document 9550077

12.2.1 SERIOUS ADVERSE EVENTS - CASE HISTORIES

9550077

Pharmacia

Document 9550077

Narrative of Event no. HU 001 Protocol no. 20124/013 Patient no. 18/109

Center no. 12, Kecskemet (Hungary)

Investigator: E. Kovacs

Adverse event: hallucinations (date of the event: 23.05.92)

Patient's history: the patient was a 51 years old male and he was suffering from a Major Depressive Episode for 8 months when he entered in the 20124/013 study on January 9th, 1992. He had had the onset of depressive disorder at the age of 47 years. His previous antidepressive treatments were represented by trimipramine, dibenzepin hydrochloride and maprotiline.

The patient had had a gastroduodenostomia in 1988.

Baseline ECG showed sinus bradycardia while chest X-ray was normal. Laboratory tests did not show any clinical relevant abnormalities.

Experimental period: the patient entered the 20124/013 study on January 9th, 1992 and received the experimental treatment as follows:

treatment	days	dose	remarks
from - to		(mg/day)	
15.01.92 - 28.01.92	14	8	
29.01.92 - 25.02.92	28	4	
26.02.92 - 22.05.92	87	0	
23.05.92 - 23.05.92	1	0	

On January 15th, 1992 he started a therapy with chloral hydrate (1500 mg/day) for insomnia.

On January 17th, 1992 a picture of urinary retention of moderate severity appeared, treated with drotaverine hydrochloride (40 mg/day) till 30.01.92. The dosage of the experimental treatment was reduced with full recovery on 29.01.92.

On February 25th, 1992, according to the protocol, the patient completed the open phase of treatment with reboxetine. At this moment the Hamilton Depression Rating scale (HAMD) was performed and the total score was of 16 points. In comparison with the baseline score (29 points) an improvement was observed.

On February 26th, 1992 he was included in a double-blind treatment period. The improvement in depressive symptomatology was maintained till the middle of May.

On May 23rd, 1992 the patient suffered from hallucinations that led to his hospitalization. The experimental treatment, which happened to be placebo, was stopped.

During the study the patient had received the experimental treatment for 42 days, taking a cumulative amount of 224 mg of reboxetine.

Comments: the Investigator judged the event as probably drug related.

9550077

Pharmacia

Document 9550077

Narrative of Event no. HU 002 Protocol no. 20124/013 Patient no. 30
Center no. 12, Kecskemet (Hungary) Investigator: A. Szucs
Adverse event: suicide by overdose of multiple drugs (date of the event: 03.04.92)

Patient's history: the patient was a 36 years old female and she was suffering from a Major Depressive Episode for 2 months when she entered in the 20124/013 study on February 24th, 1992. She had had the onset of depressive disorder at the age of 34 years. Her previous antidepressive treatments were represented by amitriptyline, lithium carbonate and maprotiline till February 18th, 1992 with very poor results. In addition she was treated with levomepromazine (75 mg/day) from January 9th, 1992 to February 18th, 1992.

Baseline ECG and chest X-ray were normal. Laboratory tests did not show any clinical relevant abnormalities.

Experimental period: the patient entered the 20124/013 study on February 24th, 1992 and received the experimental treatment as follows:

treatment	days	dose	remarks
from - to		(mg/day)	
25.02.92 03.04.92	39	8	

On February 25th, 1992 she started a therapy with chloral hydrate (1000 mg/day) and valerianae comp. (400 mg/day) for insomnia.

At the baseline visit the Hamilton Depression Rating scale (HAM-D) was performed and the total score was of 42 points. While she was on therapy a progressive improvement was observed in the severity of the depressive syndrome until March 3rd, 1992 when the HAM-D total score of 21 points was reported. At the same time no suicidal intent was detected.

On April 3rd, 1992 was at home and committed suicide by taking alcohol and drugs (levomepromazine, promethazine, amitriptyline and maprotiline). Autopsy was performed according to the request of local police department and death was ascribed to respiratory paralysis due to drug intoxication. The results of toxicology examination confirmed that the drugs ingested were those mentioned. The blood alcoholemia was of 1.75 g/l %.

At the moment of the event the patient had been under the experimental treatment for 39 days and she had received a cumulative amount of 312 mg of reboxetine, while being treated with 8 mg/day of the compound.

Comments: the Investigator judged the adverse event as not drug related.

9550077

Pharmacia

Document 9550077

Narrative of Event No. **FR 0075** Protocol no. **20124/013** Patient no. **11**

Center no. **3, Marseille (France)** Investigator: **d'Arnaud Castiglioni**

Adverse event: **generalized epilepsy fit** (date of the event: **27.05.91**)

Patient's history: the patient was a 56 years old female and she was suffering from a Major Depressive Episode for 5 months when she entered in the 20124/013 study on May 17th, 1991. She had had the onset of depressive disorder at the age of 49 years.

The patient had suffered from moderate hallucinatory delirium between 1988 and February 1991 and for this reason she has been treated with haloperidol (6 mg/day). She complained of insomnia treated with meprazine (410 mg/day) and clorazepate/ promazine/promazine (10 mg/day) from February 15th, 1991 to May 23rd, 1991.

Baseline ECG and chest X-ray were normal. Laboratory tests did not show any clinical relevant abnormalities.

Experimental period: the patient entered the 20124/013 study on May 17th, 1991 and received the experimental treatment as follows:

treatment	days	dose	remarks
from - to		(mg/day)	
25.05.91 - 27.05.91	3	8	

From May 24th, to May 27th, 1991 she was treated with chloral hydrate (500 mg/day) for insomnia.

On May 27th, 1991, four hours after the last dose of reboxetine, the patient suffered from a single episode of generalized epilepsy fit, recovering spontaneously in a few minutes.

The experimental treatment was definitively discontinued.

On May 28th, 1991 an EEG was performed and slow waves (delta intermittent activity) in the anterior and average temporal region of the left hemisphere were found.

On June 6th, 1991 another EEG was done and the result was normal. Also a neurological examination was performed showing a normal clinical picture with the exception for an extrapyramidal hypertonia that was considered as probably correlated with the previous therapy with haloperidol.

At the moment of the event the patient had been under the experimental treatment for 3 days and she had received a cumulative amount of 24 mg of reboxetine, while being treated with 8 mg/day of the compound.

Comments: the Investigator judged the adverse event as not drug related. Among psychotropic drugs tricyclic antidepressant and neuroleptics are known to be associated with convulsions. The sudden stopping of benzodiazepine treatment is probably the main factor responsible of the epilepsy fit.

9550077

Pharmacia

Document 9550077

12.2.2 Individual Data Listings

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 1.0

PATIENT IDENTIFICATION

Contre Patient	Initials	D.R.	Patient Sex	Age (years)	Height (cm)	Weight (kg)	Height DSK-III-R Screening date	Screening date	open start	open end	Double B. start	Double B. end
1	1 NGA		Female	39	154.0	59.0	09/11/90	09/11/90	17/11/90	28/12/90	29/12/90	22/03/91
2	2 RAQ		Male	58	165.0	78.0	09/11/90	09/11/90	17/11/90	07/12/90	07/12/90	14/11/91
3	3 TA		Female	52	168.0	2963	09/11/90	09/11/90	17/11/90	28/12/90	29/12/90	14/11/91
4	4 DNC		Female	54	63.0	168.0	13/11/90	13/11/90	21/11/90	02/01/91	03/01/91	20/11/91
5	5 DB		Female	58	61.0	159.0	27/11/90	27/11/90	05/12/90	15/01/91	16/01/91	03/12/91
6	6 CFM		Female	63	60.0	161.0	27/11/90	27/11/90	05/12/90	15/01/91	16/01/91	09/04/91
7	7 JSA		Male	58	74.0	172.0	30/11/90	30/11/90	08/12/90	26/12/90	16/01/91	09/04/91
8	8 WVB		Male	25	67.0	174.0	30/11/90	30/11/90	08/12/90	18/01/91	19/01/91	07/06/91
9	9 CCR		Male	52	68.0	168.0	19/12/90	19/12/90	27/12/90	06/02/91	07/02/91	26/12/91
10	10 LDL		Female	60	60.0	153.0	01/03/91	01/03/91	09/03/91	18/03/91	16/03/91	31/01/92
11	11 VRT		Female	53	52.0	160.0	29/03/91	29/03/91	19/04/91	19/04/91	20/04/91	14/11/91
12	12 SLT		Female	24	42.0	152.0	12/03/91	12/03/91	20/03/91	30/04/91	01/05/91	17/03/92
13	13 JR		Female	52	50.0	157.0	23/04/91	23/04/91	01/05/91	14/05/91	14/05/91	17/03/92
14	14 MLC		Female	61	57.0	166.0	30/04/91	30/04/91	08/05/91	14/06/91	19/06/91	30/07/91
15	15 MAO		Female	57	65.0	162.0	30/04/91	30/04/91	09/05/91	19/06/91	20/06/91	06/05/92
16	16 NHC		Female	64	65.0	165.0	10/05/91	10/05/91	18/05/91	28/06/91	29/06/91	21/02/92
17	17 CEC		Female	29	51.0	160.0	14/05/91	14/05/91	22/05/91	02/07/91	03/07/91	31/12/91
18	18 TTH		Female	28	51.0	155.0	15/05/91	15/05/91	23/05/91	03/07/91	04/07/91	25/09/91
19	19 SR		Female	54	60.0	157.0	21/05/91	21/05/91	29/05/91	09/07/91	10/07/91	18/02/92
20	20 EFC		Female	49	52.0	156.0	24/05/91	24/05/91	01/06/91	12/07/91	13/07/91	23/08/91
21	21 VNC		Female	29	60.0	168.0	28/05/91	28/05/91	05/06/91	16/07/91	17/07/91	02/06/92
22	22 SK		Female	49	51.0	163.0	04/06/91	04/06/91	12/06/91	23/07/91	24/07/91	09/06/92
23	23 AR		Female	41	48.0	160.0	14/06/91	14/06/91	22/06/91	19/07/91	19/07/91	30/06/92
24	24 LVF		Female	63	46.0	167.0	25/06/91	25/06/91	03/07/91	13/08/91	14/08/91	30/06/92
25	25 ANR		Female	29	72.0	159.0	28/06/91	28/06/91	06/07/91	16/08/91	17/08/91	03/07/92
26	26 OC		Female	37	55.0	162.0	02/07/91	02/07/91	10/07/91	20/08/91	21/08/91	07/07/92
27	27 RK		Male	32	80.0	181.0	05/07/91	05/07/91	13/07/91	23/08/91	24/08/91	04/10/91
28	28 RHM		Female	52	75.0	176.0	09/07/91	09/07/91	17/07/91	27/08/91	28/08/91	31/12/91
29	29 AFO		Female	43	56.0	158.0	09/07/91	09/07/91	17/07/91	27/08/91	28/08/91	14/07/92
30	30 ERV		Male	51	65.0	160.0	10/07/91	10/07/91	18/07/91	28/08/91	29/08/91	06/11/91
31	31 MAM		Female	35	41.0	150.0	16/07/91	16/07/91	24/07/91	03/09/91	04/09/91	21/07/92
32	32 DKM		Female	48	65.0	168.0	17/07/91	17/07/91	25/07/91	04/09/91	05/09/91	22/07/92
33	33 OFC		Male	30	62.0	173.0	17/07/91	17/07/91	25/07/91	04/09/91	05/09/91	16/10/91
34	34 CHH		Female	58	56.0	155.0	31/07/91	31/07/91	08/08/91	18/09/91	19/09/91	12/08/92
35	35 ERP		Female	51	58.0	158.0	20/08/91	20/08/91	28/08/91	08/10/91	09/10/91	25/08/92
36	36 LH		Female	53	78.0	155.0	27/08/91	27/08/91	15/10/91	15/10/91	16/10/91	17/12/91
37	37 RF		Female	59	76.0	155.0	27/08/91	27/08/91	15/10/91	15/10/91	16/10/91	01/09/92
38	38 DBF		Female	53	65.0	163.0	10/09/91	10/09/91	04/09/91	15/10/91	16/10/91	15/09/92
39	39 ASS		Female	50	60.0	167.0	17/09/91	17/09/91	25/09/91	05/11/91	06/11/91	22/09/92
40	40 EN		Female	52	53.0	150.0	17/09/91	17/09/91	25/09/91	05/11/91	06/11/91	22/09/92
41	41 SFS		Female	59	70.0	165.0	17/09/91	17/09/91	25/09/91	05/11/91	06/11/91	28/07/92
42	42 ICC		Female	62	50.0	158.0	25/09/91	25/09/91	03/10/91	13/11/91	14/11/91	30/09/92
43	43 ARN		Female	41	92.0	178.0	25/09/91	25/09/91	03/10/91	13/11/91	14/11/91	30/09/92
44	44 MAL		Female	55	65.0	160.0	01/10/91	01/10/91	09/10/91	19/11/91	20/11/91	06/10/92
45	45 DPS		Female	61	65.0	164.0	01/10/91	01/10/91	09/10/91	19/11/91	20/11/91	06/10/92

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
296.5=Major Depressive Disorder, Bipolar
300.4=Dysthymia

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Patient	D.B. Initials	Patient Sex	Age (years)	Weight (kg)	Height (cm)	DSM-III-R Screening (*)	Date	open start	open end	treatment Double B. and Treatment	Double B. start	Double B. end
1	46	SP	311 Female	36	51.0	165.0	2963	08/10/91	16/10/91	26/10/91	Reboxetine	27/11/91	13/10/92
	47	MCS	312 Female	49	65.0	159.0	2963	15/10/91	23/10/91	03/12/91	Placebo	04/12/91	08/09/92
	48	SAM	313 Female	41	66.0	150.0	2963	18/10/91	24/10/91	04/12/91	Reboxetine	05/12/91	21/10/92
	49	DAS	314 Female	48	62.0	157.0	2963	18/10/91	26/10/91	08/11/91	Reboxetine		
	50	MFA	315 Female	35	54.0	165.0	2963	18/10/91	26/10/91	06/12/91	Placebo	07/12/91	23/10/92
	51	ASA	316 Female	24	49.0	161.0	2963	18/10/91	26/10/91	06/12/91	Placebo	07/12/91	23/10/92
	52	HIS	317 Female	43	52.0	163.0	2963	23/10/91	31/10/91	11/12/91	Reboxetine	12/12/91	28/10/92
	53	JFT	318 Female	53	68.0	156.0	2963	23/10/91	31/10/91	11/12/91	Placebo	12/12/91	01/04/92
	54	JD	319 Female	43	72.0	158.0	2963	29/10/91	06/11/91	17/12/91	Reboxetine	18/12/91	11/02/92
	55	DNG	320 Female	46	75.0	170.0	2963	29/10/91	06/11/91	17/12/91	Reboxetine	18/12/91	31/12/91
	56	IAL	321 Female	25	42.0	162.0	2963	03/12/91	11/12/91	21/01/92	Reboxetine	22/01/92	31/03/92
	57	SNC	322 Female	42	53.0	160.0	2963	03/12/91	11/12/91	28/01/92	Placebo	29/01/92	15/12/92
	58	ARM	323 Female	26	48.0	162.0	2963	13/12/91	21/12/91	31/01/92	Placebo	01/02/92	18/12/92
	59	SFF	324 Female	54	62.0	177.0	2963	13/12/91	21/12/91	31/01/92	Reboxetine	19/02/92	18/12/92
	60	EM	325 Female	64	62.0	168.0	2963	13/12/91	08/01/92	18/02/92	Placebo	19/02/92	05/01/93
	61	RVC	326 Female	56	53.0	154.0	2963	31/12/91	09/01/92	29/01/92	Placebo		
	62	MEA	327 Female	34	86.0	171.0	2963	10/01/92	18/01/92	28/02/92	Placebo	29/02/92	15/01/93
	63	JCL	328 Female	61	60.0	160.0	2963	14/01/92	22/01/92	04/03/92	Reboxetine	05/03/92	19/01/93
	64	ENF	329 Female	40	62.0	162.0	2963	14/01/92	22/01/92	04/03/92	Placebo	05/03/92	31/07/92
	65	FS	330 Female	33	68.0	160.0	2963	14/01/92	22/01/92	04/03/92	Placebo		
	66	TCG	331 Female	63	85.0	155.0	2963	14/01/92	22/01/92	04/03/92	Placebo		
	67	MAA	332 Female	52	52.0	160.0	2963	14/01/92	22/01/92	04/03/92	Placebo		
	68	NGS	333 Female	52	52.0	160.0	2963	14/01/92	22/01/92	04/03/92	Placebo		
	69	RFA	334 Female	39	52.0	180.0	2963	17/01/92	25/01/92	06/03/92	Placebo	07/03/92	26/06/92
	70	MLM	335 Female	62	72.0	155.0	2963	21/01/92	29/01/92	10/03/92	Reboxetine	11/03/92	26/01/93
	71	OHV	336 Female	45	52.0	170.0	2963	21/01/92	29/01/92	10/03/92	Reboxetine	11/03/92	30/06/92
	72	RLJ	337 Female	41	68.0	170.0	2963	21/01/92	29/01/92	10/03/92	Reboxetine	11/03/92	28/07/92
	73	FMA	338 Female	28	60.0	160.0	2963	21/01/92	29/01/92	10/03/92	Reboxetine	11/03/92	26/01/93
	74	IVL	339 Female	39	62.0	160.0	2963	21/01/92	29/01/92	10/03/92	Reboxetine	11/03/92	29/01/93
	75	ELF	340 Female	47	57.0	160.0	2963	24/01/92	01/02/92	13/03/92	Reboxetine	14/03/92	29/01/93
	76	SFA	341 Female	42	70.0	174.0	2963	31/01/92	08/02/92	20/03/92	Placebo	21/03/92	05/02/93
	77	ACG	342 Female	36	70.0	172.0	2963	31/01/92	08/02/92	20/03/92	Reboxetine	21/03/92	05/02/93
	78	SD	343 Female	39	80.0	176.0	2963	31/01/92	08/02/92	20/03/92	Placebo	21/03/92	05/02/93
	79	JCM	344 Female	48	70.0	168.0	2963	31/01/92	08/02/92	20/03/92	Placebo	21/03/92	30/04/92
	80	MEL	345 Female	52	62.0	165.0	2963	31/01/92	08/02/92	20/03/92	Reboxetine	21/03/92	05/02/93
	81	HFB	346 Female	33	66.0	168.0	2963	31/01/92	08/02/92	20/03/92	Reboxetine	21/03/92	05/02/93
	82	MDS	347 Female	35	65.0	170.0	2963	31/01/92	08/02/92	20/03/92	Reboxetine	21/03/92	05/02/93
	83	LFN	348 Female	51	69.0	162.0	2963	31/01/92	08/02/92	20/03/92	Placebo	21/03/92	05/02/93
	84	IN	349 Male	34	75.0	172.0	2963	31/01/92	08/02/92	20/03/92	Placebo	21/03/92	05/02/93
	85	HLF	350 Male	53	71.0	175.0	2963	31/01/92	08/02/92	20/03/92	Placebo	21/03/92	05/02/93
	86	MTF	351 Female	45	73.0	160.0	2963	31/01/92	08/02/92	20/03/92	Reboxetine	21/03/92	10/07/92
	87	MDO	352 Female	21	75.0	162.0	2963	31/01/92	08/02/92	20/03/92	Reboxetine	21/03/92	05/02/93
	88	VRL	353 Female	48	60.0	170.0	2963	04/02/92	12/02/92	24/03/92	Reboxetine	25/03/92	19/05/92
	89	NIV	354 Female	46	68.0	160.0	2963	04/02/92	12/02/92	24/03/92	Reboxetine	25/03/92	07/04/92
	90	JSS	355 Male	42	65.0	169.0	2963	04/02/92	12/02/92	24/03/92	Reboxetine	25/03/92	07/04/92

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
296.5=Major Depressive Disorder, Bipolar
300.4=Dysthymia

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124-013
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Patient	Initials	D.B. Sex	Age (years)	Weight (kg)	Height (cm)	DSM-III-R Screening data (*)	treatment		Double B. start	Double B. end		
								open start	open end				
1	91	MSC	135 Female	51	66.0	163.0	2963	04/02/92	12/02/92	24/03/92	Placebo	25/03/92	09/02/93
	92	PSS	Female	52	65.0	170.0	2963	04/02/92	12/02/92	24/03/92	Placebo	26/03/92	10/02/93
	93	AL	136 Female	31	88.0	178.0	2963	05/02/92	13/02/92	25/03/92	Placebo	26/03/92	10/02/93
	94	RAB	38 Male	70.0	172.0	2963	05/02/92	13/02/92	25/03/92	Placebo	26/03/92	10/02/93	
	95	GHT	138 Female	37	66.0	174.0	2963	05/02/92	13/02/92	25/03/92	Reboxetine	26/03/92	10/02/93
	96	SFN	139 Male	33	68.0	175.0	2963	05/02/92	13/02/92	25/03/92	Reboxetine	26/03/92	10/02/93
	97	MND	140 Male	26	60.0	169.0	2963	05/02/92	13/02/92	25/03/92	Placebo	26/03/92	10/02/93
	98	YTT	141 Female	60	72.0	168.0	2963	05/02/92	13/02/92	25/03/92	Reboxetine	26/03/92	10/02/93
	99	LGD	Female	30	60.0	165.0	2963	05/02/92	13/02/92	25/03/92	Placebo	26/03/92	10/02/93
	100	JWA	142 Male	34	83.0	180.0	2963	05/02/92	13/02/92	25/03/92	Placebo	26/03/92	10/02/93
	101	JLL	143 Female	28	53.0	155.0	2963	11/02/92	19/02/92	31/03/92	Reboxetine	01/04/92	16/02/93
	102	ESF	Female	41	69.0	160.0	2963	11/02/92	19/02/92	31/03/92	Placebo	01/04/92	17/02/93
	103	JRA	Male	32	79.0	177.0	2963	11/02/92	19/02/92	31/03/92	Placebo	01/04/92	17/02/93
	104	MTF	144 Female	48	72.0	170.0	2963	11/02/92	19/02/92	31/03/92	Placebo	01/04/92	17/02/93
	105	ABS	145 Female	32	62.0	168.0	2963	11/02/92	19/02/92	31/03/92	Placebo	01/04/92	16/02/93
	106	MRN	146 Male	32	65.0	174.0	2963	12/02/92	20/02/92	01/04/92	Reboxetine	02/04/92	16/02/93
	107	LAN	147 Female	40	70.0	167.0	2963	12/02/92	20/02/92	01/04/92	Placebo	02/04/92	17/02/93
	108	STB	148 Female	43	59.0	165.0	2963	12/02/92	20/02/92	01/04/92	Reboxetine	02/04/92	17/02/93
	109	IPL	149 Female	36	71.0	169.0	2963	12/02/92	20/02/92	01/04/92	Reboxetine	02/04/92	17/02/93
	110	TQO	150 Female	46	66.0	171.0	2963	12/02/92	20/02/92	01/04/92	Placebo	02/04/92	17/02/93
	111	JRF	331 Male	33	70.0	162.0	2963	12/02/92	20/02/92	01/04/92	Placebo	02/04/92	17/02/93
	112	PSA	Female	30	70.0	178.0	2963	12/02/92	20/02/92	01/04/92	Placebo	08/04/92	24/02/93
	113	LPS	Male	48	75.0	178.0	2963	12/02/92	20/02/92	01/04/92	Placebo	08/04/92	24/02/93
	114	CLF	332 Female	31	45.0	152.0	2963	18/02/92	26/02/92	07/04/92	Placebo	08/04/92	24/02/93
	115	ELS	333 Female	58	65.0	150.0	2963	18/02/92	26/02/92	07/04/92	Placebo	08/04/92	24/02/93
	116	RGA	334 Female	36	56.0	161.0	2963	18/02/92	26/02/92	07/04/92	Reboxetine	08/04/92	24/02/93
	117	FSL	335 Female	50	120.0	153.0	2963	18/02/92	26/02/92	07/04/92	Reboxetine	08/04/92	24/02/93
	118	RWH	Female	51	47.0	156.0	2963	18/02/92	26/02/92	31/03/92	Placebo	09/04/92	24/02/93
	119	RWH	Female	46	68.0	172.0	2963	18/02/92	26/02/92	07/04/92	Placebo	09/04/92	24/02/93
	120	JLB	Female	41	80.0	170.0	2963	19/02/92	27/02/92	08/04/92	Reboxetine	09/04/92	24/02/93
	121	LAC	336 Female	39	74.0	180.0	2963	19/02/92	27/02/92	08/04/92	Placebo	09/04/92	24/02/93
	122	HSS	337 Male	33	82.0	171.0	2963	19/02/92	27/02/92	08/04/92	Reboxetine	09/04/92	24/02/93
	123	MLL	338 Female	35	60.0	168.0	2963	19/02/92	27/02/92	08/04/92	Placebo	09/04/92	24/02/93
	124	PPC	339 Male	49	65.0	165.0	2963	19/02/92	27/02/92	08/04/92	Reboxetine	09/04/92	24/02/93
	125	FDP	340 Female	43	76.0	174.0	2963	19/02/92	27/02/92	08/04/92	Placebo	09/04/92	24/02/93
	126	SHB	341 Female	42	65.0	162.0	2963	19/02/92	27/02/92	08/04/92	Placebo	09/04/92	24/02/93
	127	VFD	342 Female	40	80.0	176.0	2963	19/02/92	27/02/92	08/04/92	Reboxetine	09/04/92	24/02/93
	128	LAM	343 Male	30	72.0	180.0	2963	19/02/92	27/02/92	08/04/92	Reboxetine	09/04/92	24/02/93
	129	MNS	344 Male	31	85.0	175.0	2963	19/02/92	27/02/92	08/04/92	Placebo	09/04/92	24/02/93
	130	EGA	345 Female	23	42.0	158.0	2963	21/02/92	29/02/92	11/03/92	Placebo	11/04/92	31/07/92
	131	RMR	Female	37	62.0	165.0	2963	04/03/92	11/03/92	29/04/92	Placebo	01/05/92	19/03/93
	132	MAT	Female	21	55.0	160.0	2963	11/03/92	19/03/92	30/06/92	Placebo	06/05/92	23/03/93
	133	JPM	346 Male	53	70.0	173.0	2963	13/03/92	21/03/92	05/05/92	Reboxetine	06/05/92	23/03/93
	134	LMS	347 Female	42	80.0	178.0	2963	17/03/92	25/03/92	05/05/92	Reboxetine	06/05/92	23/03/93
	135	HMS	348 Female	38	65.0	162.0	2963	17/03/92	25/03/92	05/05/92	Reboxetine	06/05/92	23/03/93

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
296.5=Major Depressive Disorder, Bipolar
300.4=Dysthymia

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Patient	Initials	D.B. Patient Sex	Age (years)	Weight (kg)	Height (cm)	DSM-III-R Screening date	(*)	treatment		Double B. start	Double B. end	
									open start	open end			
1	136	AVP	349 Male	31	60.0	162.0	17/03/92	2963	25/03/92	05/05/92	Placebo	06/05/92	23/03/93
	137	CNE	Female	40	63.0	170.0	17/03/92	2963	25/03/92	05/05/92	Placebo	06/05/92	23/03/93
	138	LRV	350 Female	32	60.0	168.0	17/03/92	2963	25/03/92	05/05/92	Placebo	06/05/92	23/03/93
	139	RA	351 Male	44	70.0	175.0	17/03/92	2963	25/03/92	05/05/92	Reboxetine	06/05/92	23/03/93
	140	MCA	352 Female	52	65.0	166.0	17/03/92	2963	25/03/92	05/05/92	Reboxetine	06/05/92	23/03/93
	141	ANG	353 Female	42	68.0	162.0	17/03/92	2963	25/03/92	05/05/92	Reboxetine	06/05/92	23/03/93
	142	SCC	354 Female	42	62.0	164.0	17/03/92	2963	25/03/92	05/05/92	Reboxetine	06/05/92	23/03/93
	143	JEP	355 Male	32	58.0	166.0	17/03/92	2963	25/03/92	05/05/92	Placebo	06/05/92	11/08/92
	144	ARF	356 Male	58	87.0	169.0	18/03/92	2963	26/03/92	06/05/92	Reboxetine	07/05/92	16/12/92
	145	SLD	357 Male	30	51.0	168.0	20/03/92	2963	28/03/92	08/05/92	Placebo	09/05/92	26/03/93
	146	LRH	358 Male	54	75.0	170.0	20/03/92	2963	28/03/92	08/05/92	Reboxetine	09/05/92	26/03/93
	147	JOH	Female	59	61.0	156.0	20/03/92	2963	28/03/92	10/04/92	Placebo	09/05/92	26/03/93
	148	CAS	359 Male	41	72.0	175.0	20/03/92	2963	28/03/92	08/05/92	Reboxetine	09/05/92	26/03/93
	149	SC	360 Female	33	70.0	168.0	20/03/92	2963	28/03/92	08/05/92	Placebo	09/05/92	26/03/93
	150	VA	151 Female	22	65.0	165.0	20/03/92	2963	28/03/92	08/05/92	Placebo	09/05/92	18/12/92
2	31	IK	Female	64	56.0	160.0	09/11/90	2963	10/11/90	06/12/90			
	32	GE	Female	60	72.0	164.0	09/12/90	2963	10/12/90	26/12/90			
	33	HS	Female	62	94.0	176.0	14/01/91	2963	15/01/91	30/01/91			
	34	EH	Female	56	126.0	180.0	27/03/91	2963	28/03/91	24/04/91			
3	1	AMR	Female	35	49.0	171.0	09/11/90	2963	16/11/90	13/12/90	Placebo	29/12/90	05/09/91
	2	FIL	61 Female	41	71.0	161.0	02/11/90	2962	17/11/90	28/12/90	Placebo	15/05/91	18/09/91
	3	DUS	62 Male	57	68.0	172.0	25/03/91	2963	03/04/91	14/05/91	Placebo		
	4	AUD	Female	49	57.0	160.0	29/11/90	2963	08/12/90	15/01/91			
	5	MHA	Female	35	60.0	170.0	18/12/90	2963	24/12/90	24/01/91			
	6	AJP	Male	27	69.0	175.0	29/11/90	2963	20/12/90	24/01/91			
	7	GRI	Female	61	57.0	168.0	05/12/90	2963	11/12/90	22/01/91	Reboxetine	23/01/91	06/02/91
	9	DEI	Female	37	43.0	151.0	10/01/91	2963	19/01/91	05/02/91			
	10	TOR	72 Male	31	73.0	172.0	03/04/91	2963	11/04/91	22/05/91	Placebo	23/05/91	11/09/91
	11	PIE	Female	56	71.0	161.0	17/05/91	2963	25/05/91	27/05/91			
	8	1	HJ	Female	60	73.0	163.0	03/12/90	2963	04/12/90	14/01/91	Placebo	15/01/91
2		TE	212 Female	34	63.0	166.0	13/12/90	2963	14/12/90	24/01/91	Reboxetine	25/01/91	12/12/91
3		JL	213 Male	42	77.0	181.0	20/12/90	2963	21/12/90	30/01/91	Reboxetine	01/02/91	11/04/91
4		BA	214 Female	47	65.0	154.0	10/01/91	2963	11/01/91	21/02/91	Placebo	22/02/91	09/01/92
5		SL	215 Male	52	77.0	180.0	08/01/91	2963	15/01/91	25/02/91	Placebo	26/02/91	11/03/91
6		TL	216 Female	44	45.0	158.0	21/01/91	2963	22/01/91	04/03/91	Reboxetine	05/03/91	20/01/92
7		SZT	Female	42	48.0	164.0	21/03/91	2963	22/03/91	11/04/91			
9	1	US	Female	47	73.0	161.0	28/05/90	2963	29/05/90	09/07/90			

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
296.5=Major Depressive Disorder, Bipolar
300.4=Dysthymia

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Patient	Initials	D.B.	Age (years)	Sex	Weight (kg)	Height (cm)	DSM-III-R Screening data (*)	open start	open end	Double B. start	Double B. end
9	2	VCF	241	35	Female	73.0	175.0	2963	28/05/90	09/07/90	10/07/90	27/05/91
	3	SF	43	55.0	Female	58.0	158.0	2963	14/08/90	15/08/90	09/07/90	27/05/91
	4	SA	57	57.0	Female	62.0	162.0	2963	24/08/90	01/09/90	04/11/90	13/07/91
	5	MF	64	68.0	Female	62.0	162.0	2963	15/09/90	23/09/90	03/11/90	05/11/91
	6	SD	64	65.0	Female	65.0	163.0	2963	08/11/90	07/11/90	19/12/90	07/11/91
	7	RP	29	85.0	Male	82.0	182.0	2963	08/11/90	09/11/90	20/12/90	07/11/91
	8	KTH	37	75.0	Female	64.0	164.0	2963	23/11/90	22/11/90	03/01/91	08/05/91
	9	PL	64	45.0	Female	156.0	156.0	2963	23/11/90	22/11/90	04/01/91	08/05/91
	10	RG	30	54.0	Female	150.0	150.0	2963	10/01/91	11/01/91	21/02/91	13/03/91
	11	KE	246	64.0	Female	164.0	164.0	2963	29/01/91	30/01/91	12/03/91	28/04/92
	12	GXT	247	64.0	Female	152.0	152.0	2963	05/03/91	06/03/91	16/04/91	25/06/91
	13	BP	248	65.0	Female	159.0	159.0	2963	13/03/91	14/03/91	24/04/91	11/05/92
	14	SZF	57	59.0	Female	164.0	164.0	2963	24/03/91	25/03/91	05/05/91	17/05/92
	15	BI	249	60.0	Female	161.0	161.0	2963	12/05/91	20/05/91	30/06/91	01/07/91
	16	UGY	250	61.0	Female	152.0	152.0	2963	02/07/91	10/07/91	20/08/91	01/07/91
	17	NL	29	78.0	Male	185.0	185.0	2963	27/06/91	05/07/91	18/07/91	07/07/92
	18	NEM	42	62.0	Female	171.0	171.0	2963	08/07/91	15/07/91	25/08/91	17/12/91
	19	KF	251	61.0	Female	158.0	158.0	2963	06/08/91	14/08/91	24/09/91	17/12/91
	20	GVE	252	76.0	Female	165.0	165.0	2963	17/08/91	24/08/91	04/10/91	27/12/91
	21	TA	25	67.0	Female	178.0	178.0	2963	18/10/91	26/10/91	06/12/91	27/12/91
	22	RRE	34	61.0	Female	162.0	162.0	2963	22/10/91	30/10/91	10/12/91	27/03/92
	23	SZN	18	51.0	Female	157.0	157.0	2963	01/11/91	09/11/91	20/12/91	27/03/92
	24	LGY	44	57.0	Male	178.0	178.0	2963	04/11/91	12/11/91	23/12/91	30/03/92
	25	PH	254	65.0	Female	157.0	157.0	2963	15/11/91	20/11/91	31/12/91	03/11/92
	26	CP	62	51.0	Female	158.0	158.0	2963	17/11/91	22/11/91	02/01/92	23/04/92
	27	ZSL	62	71.0	Male	170.0	170.0	2963	27/03/92	28/03/92	08/05/92	19/10/92
	28	HI	36	65.0	Male	176.0	176.0	2963	06/04/92	07/04/92	18/05/92	19/10/92
	29	SZF	258	53.0	Female	161.0	161.0	2963	06/04/92	07/04/92	18/05/92	19/10/92
	30	NF	259	56.0	Female	158.0	158.0	2963	06/04/92	07/04/92	18/05/92	15/06/92
	10	1	VK	271	83.0	Male	168.0	168.0	2963	03/10/90	16/10/90	27/11/90
4		ZSD	52	64.0	Female	158.0	158.0	2963	24/10/90	31/10/90	11/12/90	29/05/91
5		AN	40	89.0	Female	170.0	170.0	2963	07/11/90	14/11/90	26/12/90	06/02/91
6		RS	43	86.0	Male	187.0	187.0	2963	09/11/90	16/11/90	15/12/90	06/02/91
7		RK	47	87.0	Male	162.0	162.0	2963	13/11/90	20/11/90	17/12/90	15/01/91
8		VP	56	65.0	Female	160.0	160.0	2963	26/11/90	27/11/90	14/01/91	04/02/91
9		RT	37	54.0	Female	161.0	161.0	2963	03/12/90	04/12/90	14/01/91	06/02/91
10		MH	34	67.0	Female	160.0	160.0	2963	03/12/90	14/01/91	15/01/91	06/02/91
11		TH	36	73.0	Female	160.0	160.0	2963	27/12/90	27/12/90	13/01/91	15/01/91
12		EP	38	73.0	Female	159.0	159.0	2963	09/01/91	10/01/91	02/02/91	20/03/91
13		HU	40	62.0	Female	165.0	165.0	2963	11/02/91	12/02/91	25/03/91	08/04/91
14		AA	36	85.3	Male	185.0	185.0	2963	11/02/91	12/02/91	25/03/91	10/02/92
15	HT	280	50	Female	166.0	166.0	2963	20/02/91	21/02/91	03/04/91	30/04/91	
16	AJ	281	39	Female	63.0	164.0	2963	04/03/91	04/03/91	15/04/91	02/03/92	

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
296.5=Major Depressive Disorder, Bipolar
300.4=Hypothyria

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Patient	Initials	D.B.	Age	Weight	Height	DSK-III-R	Screening	open	treatment	Double B.	Double B.
			Patient	(years)	(kg)	(cm)	(*)	date	start	end	start	end
10	17	MM	282	Female	59	77.0	161.0	2963	14/03/91	14/03/91	24/04/91	10/03/92
	18	SS	28	Female	46.0	157.0	2963	18/03/91	18/03/91	29/04/91	25/04/91	06/09/92
	19	TN	284	Female	33	66.0	160.0	2963	01/04/91	02/04/91	14/05/91	30/03/92
	20	EJ	285	Female	35	60.0	167.0	2963	22/04/91	23/04/91	03/06/91	04/11/91
	21	AK	288	Female	29	45.0	158.0	2963	29/04/91	29/04/91	10/06/91	29/09/91
	22	AA	286	Male	37	82.0	178.0	2963	22/04/91	23/04/91	03/06/91	20/04/92
	23	LT	287	Female	34	58.0	168.0	2963	23/04/91	24/04/91	04/06/91	25/02/92
	24	AI	289	Male	26	46.0	182.0	2963	30/04/91	01/05/91	11/06/91	28/04/92
	25	ES	28	Male	25	79.0	178.0	2963	13/05/91	14/05/91	03/06/91	05/08/91
	26	JIF	280	Female	60	93.0	159.0	2963	27/05/91	28/05/91	08/07/91	01/06/92
	27	HK	282	Female	51	71.0	156.0	2963	03/06/91	03/06/91	14/07/91	13/05/92
	28	LL	291	Male	55	82.0	170.0	2963	30/05/91	30/05/91	10/07/91	06/01/92
	29	JJ	293	Male	28	63.0	178.0	2963	19/08/91	19/08/91	29/09/91	14/09/92
	30	VK	294	Female	36	51.0	151.0	2963	16/09/91	17/09/91	28/10/91	14/09/92
	31	RK	297	Female	32	72.0	160.0	2963	16/09/91	16/09/91	27/10/91	14/09/92
	32	LK	299	Female	29	63.0	161.0	2963	16/09/91	16/09/91	27/10/91	14/09/92
	33	EK	300	Male	52	82.0	179.0	2963	19/09/91	19/09/91	30/10/91	21/01/92
	34	TK	31	Male	29	78.0	184.0	2963	23/09/91	23/09/91	03/11/91	12/01/92
	35	IN	35	Female	28	51.0	166.0	2963	23/09/91	23/09/91	03/11/91	12/01/92
	36	AK	19	Female	72.0	168.0	2963	14/10/91	14/10/91	25/11/91	04/11/91	12/01/92
	37	HK	37	Female	61	58.0	165.0	2963	14/10/91	14/10/91	24/11/91	26/04/92
	38	LL	41	Female	41	53.0	164.0	2963	14/10/91	14/10/91	24/11/91	03/02/92
	39	VH	40	Female	42	52.0	158.0	2963	15/10/91	15/10/91	25/11/91	13/10/92
	40	AP	33	Female	32	67.0	165.0	2963	24/10/91	24/10/91	04/12/91	28/01/92
	41	VP	42	Female	54	72.0	165.0	2963	30/10/91	30/10/91	10/12/91	27/10/92
	42	TT	295	Male	28	69.0	175.0	2963	13/11/91	14/11/91	25/12/91	24/01/92
	43	IK	296	Female	27	65.0	170.0	2963	14/11/91	15/11/91	26/12/91	14/05/92
	44	AB	298	Male	21	64.0	162.0	2963	17/11/91	18/11/91	29/12/91	08/03/92
	45	KJ	34	Female	43	71.0	161.0	2963	19/11/91	20/11/91	31/12/91	10/03/92
	46	TH	38	Male	37	95.0	191.0	2963	28/11/91	03/12/91	13/01/92	27/01/92
	47	TN	46	Female	46	62.0	170.0	2963	04/12/91	05/12/91	15/01/92	02/12/92
	48	JP	39	Female	39	53.0	152.0	2963	04/12/91	05/12/91	15/01/92	22/04/92
	49	VH	47	Female	47	69.0	172.0	2963	10/12/91	11/12/91	21/01/92	23/06/92
	50	EE	44	Male	43	84.0	170.0	2963	18/12/91	19/12/91	29/01/92	16/12/92
	51	UL	45	Female	41	65.0	158.0	2963	18/12/91	19/12/91	29/01/92	16/12/92
	52	HP	48	Female	46	65.0	171.0	2963	13/01/92	14/01/92	10/02/92	06/09/92
	53	HA	49	Female	49	56.0	164.0	2963	12/01/92	13/01/92	23/02/92	06/09/92
	54	UN	48	Female	52	52.0	168.0	2963	12/01/92	13/01/92	23/02/92	06/09/92
	55	TP	49	Male	31	85.0	185.0	2963	13/01/92	14/01/92	24/02/92	11/01/93
	56	JP	50	Male	52	82.0	187.0	2963	13/01/92	14/01/92	24/02/92	23/03/92
	57	AG	51	Female	47	95.0	176.0	2963	14/01/92	15/01/92	25/02/92	12/01/93
	58	KK	52	Female	27	68.0	182.0	2963	14/01/92	14/01/92	25/02/92	11/01/93
	59	TA	53	Female	22	47.0	167.0	2963	20/01/92	20/01/92	01/03/92	29/03/92
	60	JH	54	Male	28	63.0	174.0	2963	20/01/92	20/01/92	01/03/92	16/03/92
	61	JT	55	Male	21	80.0	198.0	2963	21/01/92	22/01/92	03/03/92	26/05/92

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
296.5=Major Depressive Disorder, Bipolar
300.4=Dysthymia

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Patient	Initials	D.B. Patient Sex	Age (years)	Height (kg)	Height (cm)	DSM-III-R Screening date	open start	open end	treatment Double B. end Treatment	Double B. start	Double B. end		
													(*)	
10	62	RK	56 Male	55	105.0	174.0	21/01/92	22/01/92	03/03/92	Placebo	04/03/92	01/09/92		
	63	NS	57 Male	55	67.0	178.0	03/02/92	04/02/92	16/03/92	Reboxetine	17/03/92	01/02/93		
	64	LT	58 Female	31	48.0	158.0	05/02/92	06/02/92	16/03/92	Placebo	19/03/92	24/06/92		
	81	JN	46 Female	25	67.0	2963	20/02/92	21/02/92	02/04/92	Placebo	03/04/92	06/01/93		
	82	LS	59 Male	24	67.0	176.0	20/02/92	25/02/92	06/04/92	Reboxetine	07/04/92	25/01/93		
	83	KL	Male	49	83.0	174.0	02/03/92	03/03/92	13/04/92					
	84	RV	63 Female	49	68.0	163.0	2963	10/03/92	21/04/92	Reboxetine	22/04/92	30/06/92		
	85	AK	272 Male	28	65.0	173.0	2963	10/03/92	11/03/92	Placebo	22/04/92	05/05/92		
	86	NR	274 Female	45	74.0	165.0	2963	18/03/92	19/03/92	29/04/92	Reboxetine	30/04/92	22/07/92	
	87	AN	275 Female	54	68.0	168.0	2963	18/03/92	19/03/92	29/04/92	Reboxetine	30/04/92	17/03/93	
	88	AR	276 Female	65	68.0	160.0	2963	18/03/92	19/03/92	29/04/92	Placebo	30/04/92	17/03/93	
	89	SK	277 Female	18	68.0	172.0	2963	19/03/92	20/03/92	30/04/92	Reboxetine	01/05/92	14/03/92	
	90	SV	70 Female	31	55.0	161.0	2963	23/03/92	24/03/92	04/05/92	Reboxetine	05/05/92	02/11/92	
	91	HI	74 Male	46	74.0	175.0	2963	31/03/92	01/04/92	12/05/92	Placebo	13/05/92	30/05/93	
	92	LA	73 Female	27	64.0	176.0	2963	01/04/92	09/04/92	20/05/92	Reboxetine	21/05/92	16/12/92	
	93	AN	285 Female	53	85.0	167.0	2963	08/04/92	09/04/92	20/05/92	Placebo	21/05/92	12/08/92	
	94	PV	273 Female	25	60.0	158.0	2963							
	11	1	DF	372 Male	50	92.0	160.0	07/10/91	12/10/91	22/11/91	Placebo	23/11/91	05/06/92	
		2	HB	373 Female	60	116.0	164.0	2963	07/10/91	14/10/91	24/11/91	Reboxetine	25/11/91	10/05/92
		3	RF	374 Female	49	83.0	153.0	2963	07/10/91	15/10/91	25/11/91	Reboxetine	26/11/91	23/12/91
4		BA	375 Male	61	71.0	170.0	2963	11/10/91	18/10/91	28/11/91	Placebo	29/11/91	13/03/92	
5		ZM	Male	45	77.0	171.0	2963	14/10/91	16/10/91	12/11/91				
6		VP	376 Male	34	80.0	178.0	2963	12/10/91	16/10/91	26/11/91	Reboxetine	27/11/91	13/10/92	
7		KK	Female	49	55.0	150.0	2963	16/10/91	24/10/91	04/12/91	Placebo	05/12/91	21/10/92	
8		KF	Female	59	59.0	160.0	2963	04/11/91	11/11/91	02/12/91				
9		FI	362 Female	49	108.0	164.0	2963	05/11/91	12/11/91	23/12/91	Placebo	24/12/91	03/02/92	
10		BJ	363 Female	49	79.0	180.0	2963	19/11/91	26/11/91	06/01/92	Reboxetine	07/01/92	23/11/92	
11		NGY	361 Female	63	71.0	155.0	2963	21/11/91	06/12/91	16/01/92	Reboxetine	17/01/92	19/05/92	
12		PJ	364 Female	62	57.0	175.0	2963	09/12/91	16/12/91	26/01/92	Placebo	27/01/92	13/12/92	
13		GM	365 Female	22	48.0	158.0	2963	08/01/92	15/01/92	25/02/92	Reboxetine	26/02/92	02/06/92	
14		RJ	Female	58	67.0	163.0	2963	19/01/92	20/01/92	16/02/92				
15		NR	366 Female	40	82.0	163.0	2963	02/01/92	03/02/92	15/03/92	Placebo	11/03/92	02/06/92	
16		NA	367 Female	40	51.0	166.0	2963	02/01/92	03/02/92	15/03/92	Reboxetine	16/03/92	05/06/92	
17		UZ	368 Female	35	75.0	164.0	2963	06/02/92	07/02/92	19/03/92	Reboxetine	20/03/92	04/02/93	
18		EI	369 Female	43	60.0	156.0	2963	27/02/92	28/02/92	22/03/92	Placebo	23/03/92	07/02/93	
19		FX	370 Female	52	63.0	156.0	2963	27/02/92	28/02/92	22/03/92	Reboxetine	10/04/92	25/02/93	
20		LJ	371 Female	52	70.0	163.0	2963	01/03/92	02/03/92	12/04/92	Placebo	13/04/92	05/06/92	
12	1	IB	92 Male	53	72.0	176.0	2963	28/10/91	31/10/91	11/12/91	Reboxetine	12/12/91	28/10/92	
	2	EFC	99 Female	43	78.0	163.0	2963	29/10/91	05/11/91	16/12/91	Reboxetine	17/12/91	27/01/92	
	3	IF	93 Female	35	66.0	170.0	2963	28/10/91	30/10/91	10/12/91	Reboxetine	11/12/91	27/10/92	
	4	EG	100 Female	28	71.0	153.0	2963	30/10/91	05/11/91	16/12/91	Reboxetine	17/12/91	18/05/92	

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episode
296.5=Major Depressive Disorder, Bipolar
300.4=Dysthymia

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Patient	D.B. Initials	Sex	Age (years)	Weight (kg)	Height (cm)	DSM-III-R Screening date	open start	open end	treatment end	treatment start	Double B. start	Double B. end
12	5	ZSH	95	Male	66.0	170.0	04/11/91	05/11/91	16/12/91	Placebo	17/12/91	09/03/92	
	6	MR	98	Female	51.0	150.0	31/10/91	02/11/91	12/12/91	Placebo	13/12/91	28/05/92	
	7	LK	42	Male	85.0	160.0	30/10/91	05/11/91	16/12/91	Reboxetine	17/12/91	18/05/92	
	8	FN	102	Female	90.0	165.0	31/10/91	01/11/91	12/12/91	Reboxetine			
	9	KBP	31	Female	48.0	152.0	30/10/91	31/10/91	11/12/91	Reboxetine	12/12/91	10/06/92	
	10	IP	96	Female	64.0	172.0	04/11/91	05/11/91	16/12/91	Placebo	17/12/91	20/06/92	
	11	ER	47	Female	62.0	165.0	31/10/91	31/10/91	16/12/91	Placebo	17/12/91	15/01/92	
	12	FSZ	38	Female	56.0	160.0	04/11/91	05/11/91	16/12/91	Placebo	17/12/91	13/01/92	
	13	ISZ	103	Female	54.0	156.0	04/11/91	05/11/91	16/12/91	Placebo	17/12/91	27/01/92	
	14	GSZ	101	Female	36	87.0	155.0	06/11/91	16/12/91	Placebo	18/12/91	14/01/92	
	15	GB	104	Male	51	75.0	176.0	05/11/91	26/11/91	Reboxetine	07/01/92	25/05/92	
	16	FN	105	Female	54.0	162.0	10/12/91	15/12/91	21/01/92	Reboxetine	22/01/92	23/06/92	
	17	TK	108	Male	51	85.0	171.0	14/01/92	15/01/92	25/02/92	Placebo	26/02/92	23/05/92
	18	LS	106	Female	56	68.0	168.0	15/01/92	16/01/92	26/02/92	Reboxetine	27/02/92	06/05/92
	19	SSZ	20	Male	44	70.0	167.0	16/01/92	17/01/92	27/02/92	Placebo	28/02/92	30/07/92
	20	KSZ	42	Male	81.0	164.0	30/01/92	31/01/92	12/03/92	Reboxetine	13/03/92	18/06/92	
	21	FL	110	Female	63	60.0	155.0	24/01/92	28/01/92	09/03/92	Placebo	10/03/92	25/01/93
	22	RV	112	Female	46	53.0	167.0	06/02/92	07/02/92	19/03/92	Placebo	20/03/92	20/08/92
	23	EN	113	Female	63	79.0	155.0	07/02/92	08/02/92	20/03/92	Reboxetine	04/04/92	04/09/92
	24	MF	25	Female	53	76.0	160.0	10/02/92	11/02/92	23/03/92	Reboxetine	24/03/92	08/02/93
	25	FS	35	Male	105.0	200.0	04/02/92	05/02/92	17/03/92				
	26	LB	58	Female	55.0	163.0	06/02/92	08/02/92	20/03/92	Reboxetine	21/03/92	02/10/92	
	27	VCS	28	IV	38	50.0	165.0	07/02/92	08/02/92	20/03/92	Placebo	21/03/92	29/05/92
	28	IV	116	Female	38	50.0	165.0	10/02/92	11/02/92	23/03/92	Reboxetine	24/03/92	08/02/93
	29	AK	35	Female	71.0	167.0	24/02/92	25/02/92	03/04/92				
	30	FS	36	Female	56.0	154.0	23/03/92	25/03/92	05/05/92				
	31	FN	52	Male	82.0	175.0	01/04/92	02/04/92	13/05/92				
	32	LN	43	Male	85.0	180.0	01/04/92	02/04/92	13/05/92	Reboxetine	14/05/92	19/08/92	
	33	LN	41	Female	78.0	165.0	27/03/92	28/03/92	08/05/92	Placebo	09/05/92	26/03/93	
	34	TGB	120	Female	44	59.0	160.0	27/03/92	28/03/92	08/05/92	Placebo	09/05/92	31/07/92
	35	LP	119	Female	43	69.0	162.0	30/03/92	31/03/92	11/05/92	Reboxetine	12/05/92	22/06/92
	36	FB	385	Female	46	85.0	174.0	03/04/92	04/04/92	15/05/92	Placebo	16/05/92	07/08/92
	37	EK	52	Female	52	75.0	163.0	06/04/92	07/04/92	18/05/92			
	38	FG	37	Female	55.0	162.0	06/04/92	07/04/92	18/05/92				
13	1	PZ	219	Female	58.0	163.0	09/10/91	16/10/91	26/11/91	Reboxetine	27/11/91	13/10/92	
	2	TCS	26	Female	54.0	166.0	08/10/91	17/10/91	27/11/91	Placebo	28/11/91	14/10/92	
	3	AI	25	Female	69.0	164.0	08/10/91	16/10/91	26/11/91	Reboxetine	27/11/91	13/10/92	
	4	SZJ	55	Male	66.0	170.0	09/10/91	16/10/91	26/11/91				
	5	HF	43	Female	50.0	158.0	10/10/91	18/10/91	22/10/91				
	6	KE	28	Female	44.0	168.0	11/10/91	18/10/91	28/11/91	Reboxetine	29/11/91	15/10/92	
	7	BL	220	Female	55	68.0	158.0	09/10/91	25/10/91	05/12/91	Reboxetine	06/12/91	21/10/92
	8	PK	228	Female	55	59.0	160.0	15/10/91	22/10/91	02/12/91	Placebo	03/12/91	18/05/92
	9	SZS	64	Male	76.0	170.0	15/10/91	22/10/91	02/12/91	Placebo	03/12/91	27/02/92	

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
296.3=Major Depressive Disorder, Multiple Episodes
296.5=Major Depressive Disorder, Bipolar
300.4=Disthymia

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 1.0

PATIENT IDENTIFICATION

Centre	Patient Initials	D.B. Patient Sex	Age (years)	Height (kg)	Height (cm)	DSM-III-R Screening (x)	date	open start	open end	treatment Double B. Treatment	Double B. start	Double B. end
13	10 BM	Female	57	81.0	165.0	2963	18/10/91	18/10/91	24/10/91	Placebo	27/12/91	12/11/92
	11 HS	Female	46	84.0	167.0	2963	17/10/91	15/11/91	26/12/91	Placebo		
	12 BF	Male	54	75.0	165.0	2963	21/10/91	31/10/91	04/12/91	Placebo		
	13 HM	Male	53	80.0	172.0	2963	28/10/91	02/11/91	13/12/91	Reboxetine	14/12/91	30/10/92
	14 DF	Female	63	66.0	172.0	2963	28/10/91	07/11/91	18/12/91	Placebo	14/12/91	30/10/92
	15 KG	Female	45	80.0	160.0	2963	28/10/91	07/11/91	18/12/91	Placebo	19/12/91	03/11/92
	16 SZL	Female	65	76.0	160.0	2963	14/11/91	20/11/91	31/12/91	Placebo		
	17 GSM	Female	50	47.0	158.0	2963	15/11/91	20/11/91	31/12/91	Placebo	01/01/92	17/11/92
	18 VT	Female	41	59.0	158.0	2963	26/11/91	04/12/91	14/01/92	Reboxetine	15/01/92	01/12/92
	19 XK	Female	49	64.0	169.0	2963	23/01/92	24/01/92	13/02/92	Placebo		
	20 NL	Female	41	65.0	172.0	2963	24/01/92	29/01/92	10/03/92	Reboxetine	11/03/92	26/01/93
	21 CL	Female	30	58.0	156.0	2963	19/02/92	19/02/92	31/03/92	Reboxetine	01/04/92	16/02/93
	22 NKN	Female	52	79.0	175.0	2963	05/05/92	06/05/92	16/06/92	Reboxetine	17/06/92	14/07/92
	23 BSB	Female	26	56.0	164.0	2963	05/05/92	07/05/92	17/06/92	Reboxetine		

(*) DIAGNOSIS: 296.2=Major Depressive Disorder, First Episode
 296.3=Major Depressive Disorder, Multiple Episode
 296.5=Major Depressive Disorder, Bipolar
 300.4=Dysthymia

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOETINE - PROTOCOL 20124/013
Listing No.: 2.0

DIAGNOSIS AND HISTORY OF MENTAL DISORDER

Patient Centre	No.	Initials	Visit Date	DSM III Men. Axis 1	Dis. Unknown	Onset Age (years)	Number of Prev. Epis.	Last Episode Duration	Present Episode Duration at Admission	Present Episode Characterization	Present Episode Onset	Present Episode Precip. Stress
1	1	MGA	09NOV90	296.3		30	3	6months	4days	rec. prev. cond.	acute	absent
	2	RAQ	09NOV90	296.3		50	5	10months	4months	rec. prev. cond.	subacute	absent
	3	TA	09NOV90	296.3		33	6	10months	12weeks	rec. prev. cond.	subacute	absent
	4	DNC	13NOV90	296.3		46	4	12months	2months	rec. prev. cond.	subacute	absent
	5	DB	27NOV90	296.3		57	2	3months	2months	rec. prev. cond.	acute	absent
	6	CPM	27NOV90	296.3		55	5	2years	21months	rec. prev. cond.	acute	absent
	7	JSA	30NOV90	296.3		45	6	8months	6months	rec. prev. cond.	acute	absent
	8	MVB	30NOV90	296.3		18	3	18months	9months	rec. prev. cond.	subacute	absent
	9	CCR	19DEC90	296.3		25	3	3months	12months	rec. prev. cond.	acute	absent
	10	LDL	25JAN91	296.3		51	3	3months	6weeks	rec. prev. cond.	acute	absent
	11	VBT	01MAR91	296.3		22	2	6months	2months	rec. prev. cond.	acute	absent
	12	SLT	12MAR91	296.3		22	1	12months	4months	rec. prev. cond.	acute	absent
	13	JR	30APR91	296.3		49	2	18months	4months	rec. prev. cond.	acute	absent
	14	MLC	30APR91	296.3		45	2	6weeks	3weeks	rec. prev. cond.	acute	absent
	15	HAO	30APR91	296.3		45	4	10months	4months	rec. prev. cond.	acute	absent
	16	HCC	10MAY91	296.3		28	3	10weeks	8months	rec. prev. cond.	subacute	absent
	17	CEC	14MAY91	296.3		13	2	2years	8months	rec. prev. cond.	acute	absent
	18	TTM	15MAY91	296.3		52	4	2months	3months	rec. prev. cond.	subacute	absent
	19	SR	21MAY91	296.3		28	3	4months	4months	rec. prev. cond.	subacute	absent
	20	EFC	24MAY91	296.3		27	2	2years	4months	rec. prev. cond.	subacute	absent
	21	VNC	28MAY91	296.3		28	3	12months	4months	rec. prev. cond.	subacute	absent
	22	SK	04JUN91	296.3		28	4	6months	2months	rec. prev. cond.	acute	absent
	23	AR	14JUN91	296.3		58	2	18months	6weeks	rec. prev. cond.	acute	absent
	24	LVF	25JUN91	296.3		30	3	3months	6weeks	rec. prev. cond.	acute	absent
	25	AMR	02JUL91	296.3		25	3	18months	6weeks	rec. prev. cond.	acute	absent
	26	OC	05JUL91	296.3		30	2	12months	2months	rec. prev. cond.	acute	absent
	27	RK	09JUL91	296.3		25	2	18months	2months	rec. prev. cond.	acute	absent
	28	RHM	09JUL91	296.3		38	4	12months	2months	rec. prev. cond.	subacute	absent
	29	AF0	10JUL91	296.3		40	2	6months	2months	rec. prev. cond.	acute	absent
	30	ERV	09JUL91	296.3		38	4	12months	2months	rec. prev. cond.	acute	absent
	31	MAM	16JUL91	296.3		27	3	3months	2months	rec. prev. cond.	acute	absent
	32	DGM	17JUL91	296.3		38	4	8months	2months	rec. prev. cond.	acute	absent
	33	DFC	17JUL91	296.3		50	2	3years	4months	rec. prev. cond.	acute	absent
	34	GKH	31JUL91	296.3		50	3	2months	2months	rec. prev. cond.	acute	absent
	35	EMP	20AUG91	296.3		25	3	10months	3months	rec. prev. cond.	acute	absent
	36	LM	20AUG91	296.3		30	3	6months	3months	rec. prev. cond.	acute	absent
	37	RF	27AUG91	296.3		33	3	12months	3months	rec. prev. cond.	subacute	absent
	38	DBF	10SEP91	296.3		43	3	12months	3months	rec. prev. cond.	subacute	absent
	39	ASS	17SEP91	296.3		40	2	1years	3months	rec. prev. cond.	subacute	absent
	40	EM	17SEP91	296.3		41	2	2years	6months	rec. prev. cond.	subacute	absent
	41	SFS	17SEP91	296.3		37	3	18months	10months	rec. prev. cond.	subacute	absent
	42	ICC	25SEP91	296.3		48	2	6months	8months	rec. prev. cond.	subacute	absent
	43	ARN	25SEP91	296.3		30	2	2years	3months	rec. prev. cond.	subacute	absent
	44	HAL	01OCT91	296.3		20	5	18months	10months	rec. prev. cond.	acute	absent
	45	DPS	01OCT91	296.3		40	6	6months	2months	rec. prev. cond.	acute	absent
	46	SP	08OCT91	296.3		20	3	20months	20months	rec. prev. cond.	acute	absent
	47	NCS	15OCT91	296.3		40	2	4months	1months	rec. prev. cond.	subacute	absent

DSM Axis 1: 296.2=Major Depressive Disorder, First Episode

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 2.0

DIAGNOSIS AND HISTORY OF MENTAL DISORDER

Patient Centre	No.	Initials	Visit Date	DSM III Axis 1	Men. Dis. Unknown	Dis. Onset (years)	Age	Number of Prev. Epis.	Duration of Last Episode (years)	Duration at Admission	Present Episode Characterization	Present Episode Onset	Present Episode Precip. External Stress
1	48	SKM	16OCT91	296.3			36	6	8months	1years	rec. prev. cond.	subacute	absent
	49	DAS	18OCT91	296.3			38	4	6months	2months	rec. prev. cond.	acute	absent
	50	MFA	18OCT91	296.3			40	2	4months	2months	rec. prev. cond.	acute	absent
	51	ASA	18OCT91	296.3			28	3	7months	1months	rec. prev. cond.	subacute	absent
	52	MTS	23OCT91	296.3			40	3	8months	2months	rec. prev. cond.	subacute	absent
	53	JFT	23OCT91	296.3			40	3	15months	2months	rec. prev. cond.	subacute	absent
	54	JD	29OCT91	296.3			32	3	18months	3months	rec. prev. cond.	acute	absent
	55	DMG	29OCT91	296.3			50	10	10months	4months	rec. prev. cond.	subacute	absent
	56	IAL	29OCT91	296.3			42	2	9months	1months	rec. prev. cond.	subacute	absent
	57	SMC	03DEC91	296.3			30	2	12months	3months	rec. prev. cond.	subacute	absent
	58	ARM	10DEC91	296.3			23	2	10months	3months	rec. prev. cond.	acute	absent
	59	SFF	13DEC91	296.3			50	3	8months	4months	rec. prev. cond.	subacute	absent
	60	EH	15DEC91	296.3			58	6	5months	2months	rec. prev. cond.	subacute	absent
	61	NYC	15DEC91	296.3			50	3	10months	3months	rec. prev. cond.	subacute	absent
	62	HEA	31DEC91	296.3			30	2	10months	3months	rec. prev. cond.	subacute	absent
	63	JCL	31DEC91	296.3			50	6	12months	3months	rec. prev. cond.	subacute	absent
	64	EMF	10JAN92	296.3			36	3	9months	2months	rec. prev. cond.	acute	absent
	65	FS	16JAN92	296.3			29	5	6months	1months	rec. prev. cond.	acute	absent
	66	TCG	16JAN92	296.3			40	8	18months	2months	rec. prev. cond.	subacute	absent
	67	WAA	16JAN92	296.3			46	4	8months	3months	rec. prev. cond.	subacute	absent
	68	GSS	16JAN92	296.3			36	3	10months	2months	rec. prev. cond.	subacute	absent
	69	RFA	17JAN92	296.3			58	2	6months	2months	rec. prev. cond.	subacute	absent
	70	MLN	21JAN92	296.3			40	3	8months	4months	rec. prev. cond.	subacute	absent
	71	OMV	21JAN92	296.3			35	3	18months	2months	rec. prev. cond.	subacute	absent
	72	RLJ	21JAN92	296.3			24	2	6months	1months	rec. prev. cond.	subacute	absent
	73	FMA	21JAN92	296.3			36	2	4months	1months	rec. prev. cond.	subacute	absent
	74	IVL	24JAN92	296.3			28	3	2years	3months	rec. prev. cond.	acute	absent
	75	ELF	31JAN92	296.3			26	3	18months	2months	rec. prev. cond.	subacute	absent
	76	SFA	31JAN92	296.3			31	2	16months	3months	rec. prev. cond.	subacute	absent
	77	ACG	31JAN92	296.3			48	2	1years	2months	rec. prev. cond.	subacute	absent
	78	SD	31JAN92	296.3			27	3	8months	2months	rec. prev. cond.	acute	absent
	79	JCN	31JAN92	296.3			42	2	16months	3months	rec. prev. cond.	subacute	absent
	80	MEL	31JAN92	296.3			48	2	1years	2months	rec. prev. cond.	subacute	absent
	81	MFB	31JAN92	296.3			30	4	6months	2months	rec. prev. cond.	subacute	absent
	82	MDS	31JAN92	296.3			41	3	2years	3months	rec. prev. cond.	subacute	absent
	83	LFM	31JAN92	296.3			28	3	16months	2months	rec. prev. cond.	subacute	absent
	84	IN	31JAN92	296.3			40	4	9months	2months	rec. prev. cond.	subacute	absent
	85	MLP	31JAN92	296.3			40	4	5months	2months	rec. prev. cond.	subacute	absent
	86	RIF	31JAN92	296.3			19	2	6months	2months	rec. prev. cond.	subacute	absent
	87	RDO	04FEB92	296.3			38	5	10months	2months	rec. prev. cond.	subacute	absent
	88	VRL	04FEB92	296.3			37	4	14months	2months	rec. prev. cond.	subacute	absent
	89	NHY	04FEB92	296.3			22	8	10months	2months	rec. prev. cond.	subacute	absent
	90	JSS	04FEB92	296.3			41	4	6months	2months	rec. prev. cond.	subacute	absent
	91	MSC	04FEB92	296.3			48	3	10months	2months	rec. prev. cond.	subacute	absent
	92	PSS	04FEB92	296.3			28	2	6months	2months	rec. prev. cond.	subacute	absent
	93	AL	05FEB92	296.3			35	2	10months	1months	rec. prev. cond.	subacute	absent
	94	RAB	05FEB92	296.3									

DSM3 Axis 1: 296.2=Major Depressive Disorder, First Episode

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 2.0

DIAGNOSIS AND HISTORY OF MENTAL DISORDER

Centre	Patient No.	Initials	Visit Date	DSM III Axis 1	Men.	Dis.	Onset (years)	Number of Prevs.	Last Episode Duration	Present Episode Duration at Admission	Present Episode Characterization	Present Episode Onset	Present Episode Precip. Stress
1	95	GHT	05FEB92	296.3			32	3	2months	3months	rec. prev. cond.	subacute	absent
	96	SPN	05FEB92	296.3			27	3	6months	2months	rec. prev. cond.	subacute	absent
	97	HND	05FEB92	296.3			24	2	8months	2months	rec. prev. cond.	subacute	absent
	98	YTT	05FEB92	296.3			40	10	8months	2months	rec. prev. cond.	subacute	absent
	99	LGD	05FEB92	296.3			25	2	18months	2months	rec. prev. cond.	subacute	absent
	100	JVA	11FEB92	296.3			30	2	10months	1months	rec. prev. cond.	acute	absent
	101	JLL	11FEB92	296.3			24	2	6months	2months	rec. prev. cond.	subacute	absent
	102	ESF	11FEB92	296.3			36	3	5months	1months	rec. prev. cond.	subacute	absent
	103	JRA	11FEB92	296.3			27	3	2years	3months	rec. prev. cond.	subacute	absent
	104	KFE	11FEB92	296.3			42	3	10months	1months	rec. prev. cond.	subacute	absent
	105	ARS	11FEB92	296.3			28	4	14months	1months	rec. prev. cond.	subacute	absent
	106	KRN	11FEB92	296.3			26	4	6months	1months	rec. prev. cond.	subacute	absent
	107	LAN	12FEB92	296.3			30	5	3months	1months	rec. prev. cond.	subacute	absent
	108	SIB	12FEB92	296.3			37	4	3months	1months	rec. prev. cond.	subacute	absent
	109	IPL	12FEB92	296.3			32	3	4months	4weeks	rec. prev. cond.	subacute	absent
	110	IQD	12FEB92	296.3			43	2	8months	1months	rec. prev. cond.	subacute	absent
	111	JBF	12FEB92	296.3			30	3	3months	1months	rec. prev. cond.	subacute	absent
	112	PSA	12FEB92	296.3			25	3	12months	2months	rec. prev. cond.	subacute	absent
	113	LPS	12FEB92	296.3			38	4	2years	3months	rec. prev. cond.	subacute	absent
	114	CLF	18FEB92	296.3			25	3	8months	12months	rec. prev. cond.	subacute	absent
	115	ELS	18FEB92	296.3			30	8	7months	6months	rec. prev. cond.	subacute	absent
	116	KGA	18FEB92	296.3			28	4	2years	2months	rec. prev. cond.	subacute	absent
	117	PSL	18FEB92	296.3			38	6	18months	1months	rec. prev. cond.	subacute	absent
	118	KVN	18FEB92	296.3			26	2	9months	2months	rec. prev. cond.	subacute	absent
	119	KVN	18FEB92	296.3			40	2	8months	2months	rec. prev. cond.	subacute	absent
	120	JLB	18FEB92	296.3			38	2	10months	1months	rec. prev. cond.	subacute	absent
	121	LAC	19FEB92	296.3			30	3	18months	1months	rec. prev. cond.	subacute	absent
	122	HSS	19FEB92	296.3			30	2	8months	1months	rec. prev. cond.	subacute	absent
	123	MLL	19FEB92	296.3			29	3	10months	1months	rec. prev. cond.	subacute	absent
	124	PPC	19FEB92	296.3			30	6	4months	1months	rec. prev. cond.	subacute	absent
	125	FDP	19FEB92	296.3			40	2	8months	1months	rec. prev. cond.	subacute	absent
	126	SNB	19FEB92	296.3			32	3	4months	1months	rec. prev. cond.	subacute	absent
	127	VPD	19FEB92	296.3			32	3	4months	1months	rec. prev. cond.	subacute	absent
	128	LAM	19FEB92	296.3			25	3	4months	1months	rec. prev. cond.	subacute	absent
	129	KNS	19FEB92	296.3			26	3	8months	4months	rec. prev. cond.	subacute	absent
	130	EGA	21FEB92	296.3			19	2	9months	1months	rec. prev. cond.	subacute	absent
	131	RWR	04MAR92	296.3			32	3	7months	1months	rec. prev. cond.	subacute	absent
	132	KAT	11MAR92	296.3			40	5	18months	2months	rec. prev. cond.	subacute	absent
	133	JPR	13MAR92	296.3			39	2	8months	1months	rec. prev. cond.	subacute	absent
	134	LNS	17MAR92	296.3			32	3	7months	2months	rec. prev. cond.	subacute	absent
	135	KNS	17MAR92	296.3			28	2	4months	1months	rec. prev. cond.	subacute	absent
	136	ANP	17MAR92	296.3			28	2	4months	1months	rec. prev. cond.	subacute	absent
	137	CNE	17MAR92	296.3			26	3	6months	1months	rec. prev. cond.	subacute	absent
	138	LBY	17MAR92	296.3			36	6	7months	1months	rec. prev. cond.	subacute	absent
	139	RA	17MAR92	296.3			48	2	4months	1months	rec. prev. cond.	subacute	absent
	140	MCA	17MAR92	296.3			36	3	4months	1months	rec. prev. cond.	subacute	absent
	141	ANG	17MAR92	296.3			36	3	4months	1months	rec. prev. cond.	subacute	absent

DSM3 Axis 1: 296.2=Major Depressive Disorder, First Episode

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXYETINE - PROTOCOL 20124/013
Listing No.: 2.0

DIAGNOSIS AND HISTORY OF MENTAL DISORDER

Patient Centre No.	Initials	Visit Date	DSM III Men. Axis 1	Dis. Unknown	Onset Age (years)	Number of Prev. Epis.	Last Episode Duration	Present Episode Duration at Admission	Present Episode Characterization	Present Episode Onset	Present Episode Precip. External Stress	
1	142	17MAR92	296.3		34	3	6months	1months	rec. prev. cond.	acute	absent	
	143	17MAR92	296.3		28	2	10months	1months	rec. prev. cond.	acute	absent	
	144	18MAR92	296.3		48	3	7months	1months	rec. prev. cond.	acute	absent	
	145	20MAR92	296.3		25	3	8months	1months	rec. prev. cond.	acute	absent	
	146	20MAR92	296.3		50	3	7months	1months	rec. prev. cond.	acute	absent	
	147	20MAR92	296.3		52	2	8months	1months	rec. prev. cond.	subacute	absent	
	148	20MAR92	296.3		30	2	5months	1months	rec. prev. cond.	subacute	absent	
	149	20MAR92	296.3		28	2	14months	1months	rec. prev. cond.	acute	absent	
	150	20MAR92	296.3		19	2	8months	8months	rec. prev. cond.	acute	absent	
	2	31	08NOV90	296.3		35	1	14weeks	6weeks	rec. prev. cond.	subacute	absent
		32	08DEC90	296.3		39	4	3months	3weeks	rec. prev. cond.	subacute	absent
		33	14JAN91	296.3		61	1	3months	3months	rec. prev. cond.	subacute	absent
		34	27MAR91	296.3		42	4	3months	3months	rec. prev. cond.	subacute	absent
	3	1	09NOV90	296.3		33	1	2months	3weeks	rec. prev. cond.	subacute	absent
		2	02NOV90	296.2	Y		2	3months	3weeks	first occ.	subacute	defin. pres.
3		25MAR91	296.3		38	2	3months	4months	rec. prev. cond.	acute	prob. pres.	
4		AUD	299NOV90	296.3	43	3	1months	2weeks	exac. chron. cond.	acute	absent	
5		HMA	18DEC90	296.3	29	3	3months	4weeks	rec. prev. cond.	subacute	prob. pres.	
6		AJP	29NOV90	296.3	20	6	4months	3weeks	exac. chron. cond.	insidious	prob. pres.	
7		GRI	05DEC90	296.3	41	15	2months	3months	rec. prev. cond.	subacute	prob. pres.	
9		DEN	10JAN91	296.3	26	3	3months/1weeks	3months	exac. chron. cond.	insidious	prob. pres.	
10		TOR	03APR91	296.3	31	1	3months	3months	exac. chron. cond.	subacute	prob. pres.	
11		PIE	17MAY91	296.3	49	5	1months	5months	exac. chron. cond.	subacute	absent	
8		1	HJ	03DEC90	296.3	30	4	3months	3weeks	rec. prev. cond.	subacute	absent
	2	TE	13DEC90	296.3	33	2	2months	2weeks	rec. prev. cond.	subacute	absent	
	3	JL	20DEC90	296.3	39	2	3months	10days	rec. prev. cond.	acute	absent	
	4	BA	10JAN91	296.3	34	6	3months	12days	rec. prev. cond.	acute	absent	
	5	SL	08JAN91	296.3	44	4	3months	10days	rec. prev. cond.	acute	absent	
	6	TL	21JAN91	296.3	34	4	2months	1weeks	rec. prev. cond.	acute	absent	
	7	SZT	21MAR91	296.3	38	3	6weeks	1weeks	rec. prev. cond.	acute	absent	
9	1	US	28MAY90	296.3	37	5	6months	1months	rec. prev. cond.	subacute	absent	
	2	VCF	28MAY90	296.3	30	2	4months	2months	rec. prev. cond.	subacute	absent	
	3	SF	14AUG90	296.3	40	2	10months	2months	rec. prev. cond.	subacute	absent	
	4	BA	24AUG90	296.3	43	2	6months	4months	rec. prev. cond.	subacute	absent	
	5	HF	15SEP90	296.3	40	5	4months	2months	rec. prev. cond.	insidious	absent	
	6	SD	06NOV90	296.3	41	3	4months	2months	rec. prev. cond.	subacute	absent	
	7	PP	08NOV90	296.3	27	2	5months	2months	rec. prev. cond.	subacute	absent	
	8	KTM	21NOV90	296.3	36	2	6months	2months/2weeks	rec. prev. cond.	subacute	absent	
	9	PL	23NOV90	296.3	63	1	3months	9months	rec. prev. cond.	insidious	absent	
	10	BG	10JAN91	296.3	27	2	4months	8months	rec. prev. cond.	insidious	absent	

DSM3 Axis 1: 296.2=Major Depressive Disorder, First Episode

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 2.0

DIAGNOSIS AND HISTORY OF MENTAL DISORDER

Centre	Patient No.	Initials	Visit Date	DSM III Men. Dis. Axis 1	Onset Age (years)	Number of Prev. Epis.	Last Episode Duration	Duration at Admission	Present Episode Characterization	Present Episode Onset	Present Episode Precip. Stress	External Stress
9	11	KE	25JAN91	296.3	31	4	6months	11months	rec. prev. cond.	insidious	absent	absent
	12	GYT	05MAR91	296.3	52	5	4months	12months	rec. prev. cond.	subacute	absent	absent
	13	BP	13MAR91	296.3	33	1	3months	3months	rec. prev. cond.	subacute	absent	absent
	14	SZF	24MAR91	296.3	55	2	3months	5weeks	rec. prev. cond.	insidious	absent	absent
	15	BI	12MAY91	296.3	28	15	5months	3weeks	rec. prev. cond.	subacute	prob. pres.	prob. pres.
	16	UGY	02JUL91	296.3	54	1	9months	2weeks	rec. prev. cond.	subacute	absent	absent
	17	NL	27JUN91	296.3	24	1	10weeks	3months	rec. prev. cond.	subacute	prob. pres.	prob. pres.
	18	MBM	08JUL91	296.3	32	10	5months	3months	rec. prev. cond.	subacute	absent	absent
	19	KF	06AUG91	296.3	49	2	1years	2months	rec. prev. cond.	insidious	absent	absent
	20	GVE	17AUG91	296.3	39	4	4weeks	2months	rec. prev. cond.	acute	absent	absent
	21	TA	18OCT91	296.3	15	5	3months	2months	rec. prev. cond.	insidious	absent	absent
	22	RKE	22OCT91	296.3	30	1	2months	2months	rec. prev. cond.	insidious	absent	absent
	23	SZN	01NOV91	296.3	15	2	2months	4months	rec. prev. cond.	subacute	absent	absent
	24	LCY	04NOV91	296.3	34	6	3months	2months	rec. prev. cond.	subacute	absent	absent
	25	PH	15NOV91	296.3	60	3	3months	2months	rec. prev. cond.	subacute	absent	absent
	26	CF	17NOV91	296.3	60	1	4months	5months	rec. prev. cond.	subacute	prob. pres.	prob. pres.
	27	ZSL	27MAR92	296.3	59	2	4months	4weeks	rec. prev. cond.	subacute	prob. pres.	prob. pres.
	28	HI	06APR92	296.3	26	1	1years	5weeks	rec. prev. cond.	subacute	prob. pres.	prob. pres.
	29	SZF	06APR92	296.3	51	1	2months	5months	rec. prev. cond.	subacute	prob. pres.	prob. pres.
	30	NF	06APR92	296.3	22	4	2months	5months	rec. prev. cond.	subacute	prob. pres.	prob. pres.
	1	VK	03OCT90	296.3	36	3	7months	3months	rec. prev. cond.	subacute	defin. pres.	defin. pres.
	4	ZSD	24OCT90	296.3	11	4	2months	4months/1weeks	exac. chron. cond.	acute	prob. pres.	prob. pres.
	5	AN	07NOV90	296.3	-32	4	7months	7months	rec. prev. cond.	subacute	defin. pres.	defin. pres.
	6	RS	09NOV90	296.3	38	2	3months	1months/3weeks	rec. prev. cond.	acute	defin. pres.	defin. pres.
	7	KK	13NOV90	296.3	42	4	2months	2months/2weeks	rec. prev. cond.	subacute	absent	absent
	8	VP	26NOV90	296.3	33	8	3months	5months	rec. prev. cond.	subacute	defin. pres.	defin. pres.
	9	RT	03DEC90	296.3	35	1	1years/10months	7months	exac. chron. cond.	subacute	defin. pres.	defin. pres.
	10	MH	03DEC90	296.3	25	4	4months	36days	rec. prev. cond.	acute	defin. pres.	defin. pres.
	11	TM	27DEC90	296.3	28	2	1months	3months/3weeks	rec. prev. cond.	subacute	defin. pres.	defin. pres.
	12	EP	09JAN91	296.3	26	4	8months	4months	rec. prev. cond.	subacute	prob. pres.	prob. pres.
	13	HU	11FEB91	296.3	32	4	6months	2months	rec. prev. cond.	subacute	defin. pres.	defin. pres.
	14	AA	11FEB91	296.3	21	5	1months	5months	rec. prev. cond.	subacute	absent	absent
	15	HT	20FEB91	296.3	46	2	1months	1months	rec. prev. cond.	subacute	prob. pres.	prob. pres.
	16	AJ	04MAR91	296.3	37	1	9months	4months	diff. from prev. cond.	subacute	prob. pres.	prob. pres.
	17	MM	14MAR91	296.3	35	7	2months	3months	rec. prev. cond.	subacute	defin. pres.	defin. pres.
	18	SS	18MAR91	296.3	28	1	4months	1months	rec. prev. cond.	acute	defin. pres.	defin. pres.
	19	TN	01APR91	296.3	24	1	2months	2months	diff. from prev. cond.	subacute	absent	absent
	20	EJ	22APR91	296.3	34	1	4months	3months	rec. prev. cond.	subacute	defin. pres.	defin. pres.
	21	AK	22APR91	296.3	27	1	5months	85days	rec. prev. cond.	acute	defin. pres.	defin. pres.
	22	AA	22APR91	296.3	17	10	6months	1months	rec. prev. cond.	subacute	prob. pres.	prob. pres.
	23	LT	30APR91	296.3	33	1	5months	4months	rec. prev. cond.	subacute	defin. pres.	defin. pres.
	24	AL	30APR91	296.3	24	1	14months	5months	rec. prev. cond.	subacute	prob. pres.	prob. pres.
	25	ES	13MAY91	296.3	24	1	8months	1months	rec. prev. cond.	subacute	prob. pres.	prob. pres.

DSM3 Axis 1: 296.2-Major Depressive Disorder, First Episode

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 2.0

DIAGNOSIS AND HISTORY OF MENTAL DISORDER

Patient Centre	No.	Initials	Visit Date	DSM Axis 1	Men. Dis.	Onset (years)	Age	Number of Prev. Epis.	Last Episode Duration	Present Episode Duration at Admission	Present Episode Characterization	Present Episode Onset	Present Episode Precip. External Stress
10	26	JIF	27MAY91	296.3		37	4	8months	3months	exac. chron. cond.	subacute	prob. pres.	
	27	MK	03JUN91	296.3		48	2	3months	6months	rec. prev. cond.	subacute	defin. pres.	
	28	LL	30MAY91	296.3		39	8	4weeks	4months	rec. prev. cond.	acute	prob. pres.	
	29	JJ	19AUG91	296.3		27	1	3months	3months	rec. prev. cond.	subacute	prob. pres.	
	30	VK	16SEP91	296.3		31	2	2months	3weeks/2days	rec. prev. cond.	acute	defin. pres.	
	31	RK	16SEP91	296.3		16	5	8months	4months	rec. prev. cond.	subacute	prob. pres.	
	32	LK	16SEP91	296.3		26	2	8months	5months	rec. prev. cond.	subacute	defin. pres.	
	33	EK	19SEP91	296.3		42	9	3months	3months	rec. prev. cond.	subacute	prob. pres.	
	34	TK	23SEP91	296.3		23	3	8months	12months	rec. prev. cond.	subacute	prob. pres.	
	35	JH	23SEP91	296.3		23	4	6months	5months/1weeks	exac. chron. cond.	acute	prob. pres.	
	36	AK	14OCT91	296.3		18	6	4months	2months	exac. chron. cond.	subacute	prob. pres.	
	37	HK	14OCT91	296.3		27	6	8months	3months	exac. chron. cond.	subacute	defin. pres.	
	38	LL	14OCT91	296.3		39	1	1years/6months	8months	rec. prev. cond.	subacute	prob. pres.	
	39	VH	15OCT91	296.3		22	2	6months	4months	rec. prev. cond.	subacute	defin. pres.	
	40	AP	24OCT91	296.3		31	1	6months	3months	rec. prev. cond.	subacute	prob. pres.	
	41	VP	30OCT91	296.3		51	1	3years	3months	rec. prev. cond.	subacute	defin. pres.	
	42	TT	13NOV91	296.3		28	1	2months	2months	diff. from prev. cond.	subacute	defin. pres.	
	43	IK	14NOV91	296.3		23	1	3months	4months	rec. prev. cond.	subacute	defin. pres.	
	44	AB	17NOV91	296.3		18	2	6months	2months	rec. prev. cond.	subacute	prob. pres.	
	45	KJ	19NOV91	296.3		43	1	2weeks	12days	rec. prev. cond.	acute	defin. pres.	
	46	TN	28NOV91	296.3		16	10	5months	8months	rec. prev. cond.	insidious	defin. pres.	
	47	TM	04DEC91	296.3		39	3	7years	3months	rec. prev. cond.	insidious	prob. pres.	
	48	IP	04DEC91	296.3		28	10	4months	2weeks	rec. prev. cond.	acute	defin. pres.	
	49	VH	10DEC91	296.3		43	1	1years/6months	4months	exac. chron. cond.	insidious	defin. pres.	
	50	EE	18DEC91	296.3		18	3	3months	8months	exac. chron. cond.	subacute	defin. pres.	
	51	UL	18DEC91	296.3		37	4	3months	3months	rec. prev. cond.	subacute	defin. pres.	
	52	MP	12JAN92	296.3		16	2	1years/2months	4months	rec. prev. cond.	acute	defin. pres.	
	53	MA	12JAN92	296.3		45	3	7years	2weeks	exac. chron. cond.	insidious	defin. pres.	
	54	UN	12JAN92	296.3		23	1	4months	7years	diff. from prev. cond.	subacute	defin. pres.	
	55	TP	13JAN92	296.3		20	3	3months	1months	rec. prev. cond.	subacute	absent	
	56	JP	13JAN92	296.3		31	4	10months	9months	rec. prev. cond.	subacute	prob. pres.	
	57	AG	14JAN92	296.3		26	4	4months	4months	rec. prev. cond.	subacute	defin. pres.	
	58	EK	16JAN92	296.3		47	2	4months	7months	rec. prev. cond.	subacute	defin. pres.	
	59	TA	20JAN92	296.3		21	2	4months	1months	rec. prev. cond.	subacute	defin. pres.	
	60	JH	20JAN92	296.3		20	4	4months	1months	exac. chron. cond.	insidious	prob. pres.	
	61	JT	21JAN92	296.3		43	2	3months	3months	diff. from prev. cond.	insidious	prob. pres.	
	62	RK	05FEB92	296.3		35	1	6months	6months	diff. from prev. cond.	subacute	defin. pres.	
	63	MS	05FEB92	296.3		29	1	2years	2weeks	diff. from prev. cond.	subacute	defin. pres.	
	64	LT	20FEB92	296.3		22	1	2years	2years	exac. chron. cond.	subacute	defin. pres.	
	65	JN	20FEB92	296.3		23	1	5months	2months	rec. prev. cond.	subacute	absent	
	66	LS	20FEB92	296.3		28	14	6months	4months/2weeks	rec. prev. cond.	subacute	absent	
	67	KL	02MAR92	296.3		31	1	3months	2months/2weeks	rec. prev. cond.	subacute	defin. pres.	
	68	HV	10MAR92	296.3		25	1	3months	2months/2weeks	rec. prev. cond.	subacute	defin. pres.	
	69	AK	10MAR92	296.3		25	1	3months	2months/2weeks	rec. prev. cond.	subacute	defin. pres.	

677

DSMB Axis 1: 296.2=Major Depressive Disorder, First Episode

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXYETINE - PROTOCOL 20124/013
Listing No.: 2.0

DIAGNOSIS AND HISTORY OF MENTAL DISORDER

Centre	Patient No.	Initials	Visit Date	DSM III Axis 1	Men. Dis. Unknown	Onset Age (years)	Number of Prev. Epis.	Last Episode Duration	Present Episode Duration at Admission	Present Episode Characterization	Present Episode Onset	Present Episode Precip. Stress	
10	86	NP	16MAR92	296.3		40	1	1years	2months/2weeks	diff. from prev. cond.	subacute	defin. pres.	
	87	AN	18MAR92	296.3		40	5	3months	2months	exac. chron. cond.	subacute	prob. pres.	
	88	AH	18MAR92	296.3		41	5	3months	6months	rec. prev. cond.	insidious	defin. pres.	
	89	SK	19MAR92	296.3		16	1	6months	3months	diff. from prev. cond.	insidious	defin. pres.	
	90	SV	23MAR92	296.3		29	1	8months	7months	rec. prev. cond.	subacute	defin. pres.	
	91	HI	23MAR92	296.3		33	8	6months	8months	rec. prev. cond.	subacute	prob. pres.	
	92	LA	31MAR92	296.3		25	1	1years	8months	rec. prev. cond.	subacute	defin. pres.	
	93	AN	01APR92	296.3		43	3	1years	5months	rec. prev. cond.	insidious	defin. pres.	
	94	PV	08APR92	296.3		20	2	6months	4months	diff. from prev. cond.	subacute	defin. pres.	
	11	1	DF	07OCT91	296.3		64	1	1months	4months	rec. prev. cond.	insidious	absent
		2	BB	07OCT91	296.3		57	1	2months	10weeks	rec. prev. cond.	subacute	absent
		3	BE	07OCT91	296.3		18	5	2months	2months	exac. chron. cond.	subacute	prob. pres.
		4	BA	11OCT91	296.3		27	5	2months	9weeks	rec. prev. cond.	subacute	absent
		5	ZH	14OCT91	296.3		43	1	6months	1months	exac. chron. cond.	subacute	prob. pres.
6		VP	12OCT91	296.3		32	1	4months	3weeks	rec. prev. cond.	subacute	absent	
7		KK	16OCT91	296.3		30	3	6months	10weeks	exac. chron. cond.	subacute	prob. pres.	
8		KF	04NOV91	296.3		54	2	1months	1months	exac. chron. cond.	subacute	prob. pres.	
9		FI	05NOV91	296.3		36	4	6months	6weeks	exac. chron. cond.	subacute	absent	
10		BJ	19NOV91	296.3		31	4	6months	11weeks	rec. prev. cond.	subacute	prob. pres.	
11		NGY	21NOV91	296.3		46	4	6months	10weeks	rec. prev. cond.	subacute	absent	
12		PJ	09DEC91	296.3		51	6	5months	1months	exac. chron. cond.	subacute	absent	
13		GK	08JAN92	296.3		14	3	5months	2months	exac. chron. cond.	subacute	absent	
14		BJ	19JAN92	296.3		58	1	4months	1months	exac. chron. cond.	subacute	absent	
15	NF	26JAN92	296.3		38	2	4months	1months	exac. chron. cond.	subacute	absent		
16	NA	02FEB92	296.3		39	1	3months	1months	exac. chron. cond.	subacute	absent		
17	UZ	06FEB92	296.3		35	2	4months	1months	exac. chron. cond.	subacute	absent		
18	EI	03FEB92	296.3		41	2	5months	1months	exac. chron. cond.	subacute	absent		
19	FK	27FEB92	296.3		35	5	5months	1months	exac. chron. cond.	subacute	absent		
20	LJ	01MAR92	296.3		42	5	5months	2months	exac. chron. cond.	subacute	absent		
12	1	IB	28OCT91	296.3		50	4	3months/2weeks	2months/2weeks	exac. chron. cond.	insidious	absent	
	2	EFC	29OCT91	296.3		41	1	2months	3months	rec. prev. cond.	insidious	prob. pres.	
	3	IF	28OCT91	296.3		30	2	1years	4months	rec. prev. cond.	subacute	absent	
	4	EG	30OCT91	296.3		24	1	1years	2months	rec. prev. cond.	subacute	absent	
	5	ZSH	04NOV91	296.3		18	5	3months	4months	rec. prev. cond.	insidious	prob. pres.	
	6	MK	31OCT91	296.3		36	3	3months	6weeks	rec. prev. cond.	subacute	absent	
	7	LK	30OCT91	296.3		42	1	2months	2months	rec. prev. cond.	subacute	absent	
	8	FN	31OCT91	296.3		47	5	7months	2months	exac. chron. cond.	insidious	prob. pres.	
	9	KBP	30OCT91	296.3		30	3	2months	1months	rec. prev. cond.	subacute	prob. pres.	
	10	IP	04NOV91	296.3	Y			3months	4years	rec. prev. cond.	insidious	absent	
	11	ER	31OCT91	296.3		36	1	2months	3months	rec. prev. cond.	subacute	absent	
	12	FSZ	04NOV91	296.3		36	1	2months	3months	rec. prev. cond.	insidious	absent	
	13	ISZ	04NOV91	296.3		35	3	2months	4months	rec. prev. cond.	insidious	prob. pres.	

678

DSM Axis 1: 296.2-Major Depressive Disorder, First Episode

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXYTINE - PROTOCOL 20124/013
Listing No.: 2.0

DIAGNOSIS AND HISTORY OF MENTAL DISORDER

Centre	Patient No.	Initials	Visit Date	DSM III Men. Axis 1	Dis. Unknown	Onset Age (years)	Number of Prev. Epis.	Duration of Last Episode	Duration at Admission	Present Episode Characterization	Present Episode Onset	Present Episode Precip. Stress
12	14	GSZ	05NOV91	296.3		35	4	3months	2weeks	rec. prev. cond.	subacute	absent
	15	GB	25NOV91	296.3		37	5	3months	2months	rec. prev. cond.	subacute	absent
	16	FN	10DEC91	296.3		34	2	3weeks	2months	rec. prev. cond.	subacute	absent
	17	TK	14JAN92	296.3		47	3	9months	10months	rec. prev. cond.	subacute	absent
	18	LS	14JAN92	296.3		47	2	3months	8months	exac. chron. cond.	insidious	absent
	19	SSZ	15JAN92	296.3		33	2	2months	2months	rec. prev. cond.	subacute	absent
	20	KSZ	16JAN92	296.3		36	5	1months	11months	rec. prev. cond.	insidious	absent
	21	FL	30JAN92	296.3		37	3	4months	3months/2weeks	exac. chron. cond.	insidious	absent
	22	MV	24JAN92	296.3		53	4	3months	3months	rec. prev. cond.	subacute	absent
	23	EN	06FEB92	296.3		36	3	4months	3months	rec. prev. cond.	subacute	absent
	24	MF	07FEB92	296.3		45	4	4months	2weeks/7days	rec. prev. cond.	acute	prob. pres.
	25	FS	10FEB92	296.3		50	2	3months	1months	rec. prev. cond.	subacute	absent
	26	LB	04FEB92	296.3		33	2	2months	1months	rec. prev. cond.	subacute	absent
	27	VCS	04FEB92	296.3		53	3	3months	2months	rec. prev. cond.	subacute	absent
	28	IV	07FEB92	296.3		20	6	5months	3months	rec. prev. cond.	insidious	absent
	29	AK	10FEB92	296.3		30	5	6months	3months	rec. prev. cond.	subacute	absent
	30	FS	24FEB92	296.3		34	2	8months	2months	exac. chron. cond.	subacute	absent
	31	FR	23MAR92	296.3		40	4	3months	3months	exac. chron. cond.	subacute	absent
	32	LN	07APR92	296.3		25	2	2months	3months	rec. prev. cond.	insidious	absent
	33	LN	07APR92	296.3		25	2	2months	3months	rec. prev. cond.	insidious	absent
	34	TGB	27MAR92	296.3		34	4	6months	8months	exac. chron. cond.	insidious	absent
	35	LP	27MAR92	296.3		40	2	4months	5months	rec. prev. cond.	insidious	absent
	36	FB	30MAR92	296.3		35	3	4months	5months	exac. chron. cond.	insidious	absent
	37	EK	03APR92	296.3		47	2	3months	5months	rec. prev. cond.	insidious	absent
	38	FG	06APR92	296.3		34	3	4months	8months	rec. prev. cond.	insidious	absent
13	1	PZ	09OCT91	296.3		28	5	6weeks	1months	rec. prev. cond.	subacute	absent
	2	TCS	08OCT91	296.3		25	1	2months	3weeks	rec. prev. cond.	subacute	absent
	3	AI	08OCT91	296.3		23	1	3months	2weeks	rec. prev. cond.	subacute	absent
	4	SZJ	09OCT91	296.3		54	1	2months	3weeks	rec. prev. cond.	subacute	absent
	5	MF	10OCT91	296.3		23	8	3months	3weeks	rec. prev. cond.	subacute	absent
	6	KE	11OCT91	296.3		26	2	3months	2weeks	rec. prev. cond.	subacute	absent
	7	BL	09OCT91	296.3		54	1	2months	3weeks	rec. prev. cond.	subacute	absent
	8	PK	15OCT91	296.3		46	2	2months	2weeks	rec. prev. cond.	subacute	prob. pres.
	9	SZS	15OCT91	296.3		29	2	2months	3weeks	rec. prev. cond.	subacute	absent
	10	BM	18OCT91	296.3		57	2	2months	4weeks	rec. prev. cond.	subacute	absent
	11	RS	17OCT91	296.3		22	3	3months	2weeks	rec. prev. cond.	subacute	absent
	12	RF	21OCT91	296.3		49	3	1months	2weeks	rec. prev. cond.	subacute	absent
	13	HM	28OCT91	296.3		28	6	3months	2weeks	rec. prev. cond.	subacute	absent
	14	DF	28OCT91	296.3		62	1	2months	3weeks	rec. prev. cond.	acute	absent
	15	KG	28OCT91	296.3		42	4	2months	1months	rec. prev. cond.	subacute	absent
	16	SZL	14NOV91	296.3		62	2	2months	6weeks	rec. prev. cond.	subacute	absent
	17	GSM	15NOV91	296.3		49	1	2months	1months	rec. prev. cond.	subacute	absent
	18	VT	26NOV91	296.3		41	6	1months/2weeks	1days	rec. prev. cond.	acute	absent

DSM Axis 1: 296.2-Major Depressive Disorder, First Episode

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 2.0

DIAGNOSIS AND HISTORY OF MENTAL DISORDER

Centre	Patient No.	Initials	Visit Date	DSM III Men. Axis 1	Dis. Unknown	Onset Age (years)	Number of Prev. Epis.	Duration of Last Episode	Present Episode Duration at Admission	Present Episode Characterization	Present Episode Onset	Present Episode Precip. Stress
13	19	KK	23JAN92	296.3		30	4	2months	10days	rec. prev. cond.	acute	prob. pres.
	20	NL	24JAN92	296.3		34	3	2months	3days	rec. prev. cond.	subacute	prob. pres.
	21	CL	13FEB92	296.3		26	3	2months	2weeks	rec. prev. cond.	subacute	prob. pres.
	22	NYM	05MAY92	296.3		36	4	2months	2months	rec. prev. cond.	subacute	prob. pres.
	23	BSB	05MAY92	296.3		24	1	3months	2weeks	rec. prev. cond.	acute	prob. pres.

680

DSM3 Axis 1: 296.2=Major Depressive Disorder, First Episode

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 3.0

CHEST X-RAY AND MEDICAL HISTORY

Centre	Patient No.	Initials	Screening Date	X-Ray N/A	Medical history
1	1	MGA	09NOV90	normal	
	2	RAQ	09NOV90	normal	
	3	TA	09NOV90	normal	
	4	DNC	13NOV90	normal	
	5	DB	27NOV90	normal	
	6	CPM	27NOV90	normal	
	7	JSA	30NOV90	normal	
	8	MVB	30NOV90	normal	
	9	CCR	19DEC90	normal	
	10	LDL	25JAN91	normal	
	11	VPT	01MAR91	normal	
	12	SIT	02MAR91	normal	
	13	JF	23APR91	normal	
	14	HLC	30APR91	normal	
	15	HAO	30APR91	normal	
	16	RHC	10MAY91	normal	
	17	CEC	14MAY91	normal	
	18	TYM	15MAY91	normal	
	19	SR	21MAY91	normal	
	20	EFC	24MAY91	normal	
	21	VHC	28MAY91	normal	
	22	SK	04JUN91	normal	
	23	AR	14JUN91	normal	
	24	LVF	25JUN91	normal	
	25	AMR	28JUN91	normal	
	26	OC	02JUL91	normal	
	27	RK	05JUL91	normal	
	28	RHM	09JUL91	normal	
	29	AFO	09JUL91	normal	
	30	ERV	10JUL91	normal	
	31	MAM	16JUL91	normal	
	32	DGM	17JUL91	normal	
	33	OFC	17JUL91	normal	
	34	GHH	31JUL91	normal	
	35	EMP	20AUG91	normal	
	36	LM	20AUG91	normal	
	37	BF	27AUG91	normal	
	38	DRF	10SEP91	normal	
	39	ASS	17SEP91	normal	
	40	EM	17SEP91	normal	
	41	SFS	17SEP91	normal	
	42	ICC	25SEP91	normal	
	43	ARN	25SEP91	normal	
	44	MAL	01OCT91	normal	
	45	DPS	01OCT91	normal	
	46	SP	08OCT91	normal	
	47	MCS	15OCT91	normal	
	48	SCM	16OCT91	normal	
	49	DAS	18OCT91	normal	
	50	MFA	18OCT91	normal	
	51	ASA	18OCT91	normal	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 3.0
 CHEST X-RAY AND MEDICAL HISTORY

Centre	Patient No.	Initials	Screening Date	X-Ray N/A	Medical history
1	52	MTS	23OCT91	normal	
1	53	JFT	23OCT91	normal	
1	54	JD	29OCT91	normal	
1	55	DNG	29OCT91	normal	
1	56	IAL	29OCT91	normal	
1	57	SNC	03DEC91	normal	
1	58	ARM	03DEC91	normal	
1	59	SPF	10DEC91	normal	
1	60	EN	13DEC91	normal	
1	61	HVC	13DEC91	normal	
1	62	NEA	31DEC91	normal	
1	63	JCL	31DEC91	normal	
1	64	ENF	10JAN92	normal	
1	65	FS	14JAN92	normal	
1	66	TCG	14JAN92	normal	
1	67	MAA	14JAN92	normal	
1	68	MCS	14JAN92	normal	
1	69	RFA	14JAN92	normal	
1	70	RLH	17JAN92	normal	
1	71	ORV	21JAN92	normal	
1	72	RLJ	21JAN92	normal	
1	73	FRA	21JAN92	normal	
1	74	IVL	21JAN92	normal	
1	75	ELF	24JAN92	normal	
1	76	SFA	31JAN92	normal	
1	77	ACG	31JAN92	normal	
1	78	SD	31JAN92	normal	
1	79	JCH	31JAN92	normal	
1	80	MEL	31JAN92	normal	
1	81	NFB	31JAN92	normal	
1	82	NDS	31JAN92	normal	
1	83	LFM	31JAN92	normal	
1	84	IN	31JAN92	normal	
1	85	MLP	31JAN92	normal	
1	86	MTF	31JAN92	normal	
1	87	NDO	31JAN92	normal	
1	88	VBL	04FEB92	normal	
1	89	NHV	04FEB92	normal	
1	90	JSS	04FEB92	normal	
1	91	MSC	04FEB92	normal	
1	92	PRS	04FEB92	normal	
1	93	AL	05FEB92	normal	
1	94	RAB	05FEB92	normal	
1	95	GHI	05FEB92	normal	
1	96	SPK	05FEB92	normal	
1	97	MND	05FEB92	normal	
1	98	YTT	05FEB92	normal	
1	99	LGD	05FEB92	normal	
1	100	JNA	05FEB92	normal	
1	101	JLL	11FEB92	normal	
1	102	ESF	11FEB92	normal	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 3.0

CHEST X-RAY AND MEDICAL HISTORY

Centre	Patient No.	Initials	Screening Date	X-Ray N/A	Medical history
1	103	JRA	11FEB92	normal	
	104	MTF	11FEB92	normal	
	105	ABS	11FEB92	normal	
	106	MRN	11FEB92	normal	
	107	LAN	12FEB92	normal	
	108	STB	12FEB92	normal	
	109	IPL	12FEB92	normal	
	110	TQO	12FEB92	normal	
	111	JBF	12FEB92	normal	
	112	PSA	12FEB92	normal	
	113	LPS	12FEB92	normal	
	114	CLP	18FEB92	normal	
	115	ELS	18FEB92	normal	
	116	RGA	18FEB92	normal	
	117	FSL	18FEB92	normal	
	118	RYN	18FEB92	normal	
	119	RYN	18FEB92	normal	
	120	JLB	19FEB92	normal	
	121	LAC	19FEB92	normal	
	122	HSS	19FEB92	normal	
	123	MLL	19FEB92	normal	
	124	PPC	19FEB92	normal	
	125	FDP	19FEB92	normal	
	126	SMB	19FEB92	normal	
	127	VPD	19FEB92	normal	
	128	LAN	19FEB92	normal	
	129	MNS	19FEB92	normal	
	130	EGA	21FEB92	normal	
	131	RMR	04MAR92	normal	
	132	MAT	11MAR92	normal	
	133	JFM	13MAR92	normal	
	134	LMS	17MAR92	normal	
	135	MMS	17MAR92	normal	
	136	AVP	17MAR92	normal	
	137	CNE	17MAR92	normal	
	138	LBV	17MAR92	normal	
	139	RA	17MAR92	normal	
	140	RCA	17MAR92	normal	
	141	ARG	17MAR92	normal	
	142	SCC	17MAR92	normal	
	143	JEP	17MAR92	normal	
	144	ARF	18MAR92	normal	
	145	SLD	20MAR92	normal	
	146	LRH	20MAR92	normal	
	147	JGM	20MAR92	normal	
	148	CAS	20MAR92	normal	
	149	SC	20MAR92	normal	
	150	VA	20MAR92	normal	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 3.0

Centre	Patient No.	Initials	Screening Date	X-Ray N/A	Medical history
2	31	IK	09NOV90	normal	
	32	GE	09DEC90	normal	CHOLELITHIASIS
	33	HS	14JAN91	normal	OTH FEMALE GENITAL DIS
	34	EH	27MAR91	normal	
3	1	AMR	09NOV90	normal	
	2	FTL	02NOV90	normal	
	3	DUB	25MAR91	normal	
	4	AUD	29NOV90	normal	OPEN-ANGLE GLAUCOMA
	5	WMA	18DEC90	normal	
	6	ALP	29NOV90	normal	
	7	GBI	05DEC90	normal	MALIG NEO FEMALE BREAST
	9	DEN	10JAN91	normal	STOMACH ULCER NOS
	10	TOR	03APR91	normal	
	11	PLE	17MAY91	normal	
	8	1	HJ	03DEC90	abnormal
2		TE	13DEC90	normal	
3		JL	20DEC90	normal	
4		BA	10JAN91	normal	
5		SL	06JAN91	normal	DISORDERS OF THE GLOBE
6		TL	21JAN91	normal	
7		SZT	21MAR91	normal	
9	1	US	28MAY90	normal	
	2	VCF	28MAY90	normal	
	3	SF	14AUG90	normal	ESSENTIAL HYPERTENSION
	4	SA	24AUG90	normal	
	5	NF	15SEP90	normal	
	6	SD	06NOV90	normal	
	7	PP	08NOV90	normal	
	8	KTM	21NOV90	normal	
	9	PL	23NOV90	normal	
	10	RG	10JAN91	normal	
	11	VE	29JAN91	normal	
	12	CVT	05MAR91	normal	
	13	BF	13MAR91	normal	
	14	SZF	24MAR91	normal	ACUTE MYOCARDIAL INFARCT
	15	RI	12MAY91	normal	CHRONIC ULCER OF SKIN
	16	UGY	02JUL91	normal	
	17	NL	27JUN91	normal	
	18	HBM	06JUL91	normal	
	19	KF	06AUG91	normal	
	20	GYE	17AUG91	normal	
	21	TA	18OCT91	normal	
	22	RKE	22OCT91	normal	
	23	SZN	01NOV91	normal	
	24	LGY	04NOV91	normal	
	25	PM	15NOV91	normal	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 3.0

CHEST X-RAY AND MEDICAL HISTORY

Centre	Patient No.	Initials	Screening Date	X-Ray N/A	Medical history
9	26	CP	17NOV91	normal	
	27	ZSL	27MAR92	normal	
	28	HI	06APR92	normal	
	29	SZF	06APR92	normal	
	30	NF	06APR92	normal	
	10	1	VK	03OCT90	abnormal
4		ZSD	24OCT90	normal	PULMONARY TUBERCULOSIS
5		AN	07NOV90	normal	OTHER SOFT TISSUE DIS
6		ES	09NOV90	normal	OTHER SOFT TISSUE DIS
7		BK	13NOV90	normal	POLYMYALGIA RHEUMATICA
8		VP	24NOV90	normal	OTHER SOFT TISSUE DIS
9		RT	03DEC90	not done	PNEUMONIA, ORGANISM NOS
10		HR	03DEC90	normal	VASINITIS
11		TR	27DEC90	not done	
12		EP	09JAN91	not done	
13		HU	11FEB91	not done	KIDNEY INFECTION
14		AA	20FEB91	not done	APPENDICITIS NOS
15		HT	04MAR91	normal	ECTOPIC PREGNANCY NOS
16		AJ	14MAR91	normal	HEPATITIS A W/O COMA
17		MM	18MAR91	normal	
18		SS	01APR91	normal	
19		TN	22APR91	normal	
20		EJ	29APR91	normal	
21		AK	22APR91	normal	
22		AA	23APR91	normal	
23		LT	30APR91	normal	
24		AL	19MAY91	normal	
25		ES	27MAY91	normal	
26		JIF	03JUN91	normal	
27		HK	19AUG91	normal	
28		LI	30MAY91	normal	
29		JJ	19AUG91	normal	
30		VK	16SEP91	normal	
31		PK	16SEP91	normal	
32		LK	16SEP91	normal	
33		EK	19SEP91	normal	
34		TK	23SEP91	normal	
35		JH	23SEP91	normal	
36		AK	14OCT91	normal	
37		HK	14OCT91	normal	
38		LL	14OCT91	normal	
39		VH	15OCT91	normal	
40		AP	24OCT91	normal	
41		VP	30OCT91	abnormal	
42		TT	13NOV91	normal	
43		IK	14NOV91	normal	
44		AB	17NOV91	normal	
45		KJ	19NOV91	normal	

6 8 5

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXYETINE - PROTOCOL 20124/013
Listing No.: 3.0

CHEST X-RAY AND MEDICAL HISTORY

Centre	Patient No.	Initials	Screening Date	X-Ray N/A	Medical history
10	46	TN	28NOV91	normal	
	47	TM	04DEC91	normal	ACUTE TONSILLITIS
	48	IP	04DEC91	normal	NEURALGIA/NEURITIS NOS
	49	VH	10DEC91	normal	RHEUMATISM NOS
	50	EE	18DEC91	normal	NEURALGIA/NEURITIS NOS
	51	UL	18DEC91	normal	NEURALGIA/NEURITIS NOS
	52	NP	13JAN92	normal	RHEUMATOID ARTHRITIS
	53	MA	12JAN92	normal	SALPINGO-OOPHORITIS NOS
	54	UN	12JAN92	normal	CHICKENPOX
	55	TP	13JAN92	normal	PARALYTIC ILEUS
	56	JP	13JAN92	normal	MYOCARDITIS NOS
	57	AG	14JAN92	normal	MYOCARDITIS NOS
	58	EK	14JAN92	normal	LUMBOSACRAL NEURITIS NOS
	59	TA	20JAN92	normal	ACUTE TONSILLITIS
	60	JR	21JAN92	normal	OTHER PNEUMOPHRYTIS
	61	JT	21JAN92	normal	CYSTITIS NOS
	62	RK	21JAN92	normal	ANGINA PECTORIS
	63	RS	03FEB92	abnormal	MYOCARDITIS NOS
	64	LI	05FEB92	normal	THROMBOCYTOPENIA NOS
	81	JN	20FEB92	normal	NEURALGIA/NEURITIS NOS
	82	LS	20FEB92	normal	MEASLES UNCOMPLICATED
	83	KL	02MAR92	normal	ACUTE TONSILLITIS
	84	RV	10MAR92	normal	HEPATITIS IN VIRAL DIS
	85	AK	10MAR92	normal	HEPATITIS IN VIRAL DIS
	86	NP	16MAR92	normal	UTERINE LEIOMYOMA
	87	AN	18MAR92	normal	NEURALGIA/NEURITIS NOS
	88	AH	18MAR92	normal	PULMONARY TB NOS
	89	SK	19MAR92	normal	HEPATITIS IN VIRAL DIS
	90	SV	23MAR92	normal	PNEUMONIA, ORGANISM NOS
	91	HI	23MAR92	normal	NEURALGIA/NEURITIS NOS
	92	LA	31MAR92	normal	HEPATITIS IN VIRAL DIS
	93	AN	01APR92	normal	NEURALGIA/NEURITIS NOS
	94	PV	08APR92	normal	CERVICITIS
	11	1	DF	07OCT91	normal
2		HR	07OCT91	abnormal	HYPERTENSION NOS
3		RF	07OCT91	normal	POLYARTHRITIS NOS
4		BA	11OCT91	normal	
5		ZR	14OCT91	normal	
6		VP	12OCT91	normal	
7		KK	16OCT91	normal	
8		RF	04NOV91	normal	CHRONIC ULCER OF SKIN
9		FI	05NOV91	normal	
10		BJ	19NOV91	normal	
11		NGY	21NOV91	normal	
12		FJ	09DEC91	normal	
13		CK	08JAN92	normal	
14		BJ	19JAN92	normal	
15		NF	28JAN92	normal	

6 8 6

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXYETINE - PROTOCOL 20124/013
 Listing No.: 3.0

CHEST X-RAY AND MEDICAL HISTORY

Centre	Patient No.	Initials	Screening Date	X-Ray N/A	Medical history	
11	16	NA	02FEB92	normal		
	17	UZ	06FEB92	normal		
	18	EI	03FEB92	normal		
	19	FK	27FEB92	normal		
	20	LJ	01MAR92	normal		
	12	1	IB	28OCT91	normal	
		2	EFC	29OCT91	normal	
		3	IF	28OCT91	normal	
		4	EG	30OCT91	normal	
		5	ZSH	04NOV91	normal	
		6	WK	31OCT91	normal	
		7	LK	30OCT91	normal	TACHYCARDIA NOS
		8	FN	30OCT91	normal	
		9	KBP	30OCT91	normal	
		10	IP	04NOV91	normal	
		11	ER	31OCT91	normal	
		12	FSZ	04NOV91	normal	
		13	ISZ	04NOV91	normal	
		14	GSS	05NOV91	normal	
		15	GB	25NOV91	normal	
16		FN	10DEC91	normal		
17		TK	14JAN92	normal		
18		LS	14JAN92	normal		
19	SSZ	15JAN92	normal			
20	KSZ	16JAN92	normal			
21	FL	30JAN92	normal			
22	HV	24JAN92	normal			
23	EN	06FEB92	normal			
24	MF	07FEB92	normal			
25	FS	10FEB92	normal			
26	LB	04FEB92	normal			
27	VCS	06FEB92	normal			
28	IV	07FEB92	normal			
29	AK	10FEB92	normal			
30	FS	24FEB92	normal			
31	FN	23MAR92	normal			
32	LN	01APR92	normal			
33	LN	01APR92	normal			
34	TGB	27MAR92	normal			
35	LP	27MAR92	normal			
36	PB	30MAR92	normal			
37	EK	03APR92	normal			
38	FC	06APR92	normal			
13	1	PZ	09OCT91	normal		
	2	TCS	06OCT91	normal		
	3	AI	06OCT91	normal		
	4	SZJ	09OCT91	abnormal		

687

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED		REBOXETINE - PROTOCOL 20124/013		Listing No.: 3.0		CHEST X-RAY AND MEDICAL HISTORY	
Centre	Patient No.	Initials	Screening Date	X-Ray N/A	Medical history		
13	5	MF	10OCT91	normal			
	6	ME	11OCT91	normal			
	7	BL	09OCT91	normal			
	8	PK	15OCT91	normal			
	9	SZS	15OCT91	normal			
	10	BM	18OCT91	normal			HYPERPLASIA OF PROSTATE
	11	HS	17OCT91	normal			
	12	BF	21OCT91	normal			
	13	HM	28OCT91	normal			
	14	DF	28OCT91	normal			
	15	KG	28OCT91	normal			
	16	SZL	14NOV91	normal			
	17	GSM	16NOV91	normal			
	18	VT	26NOV91	normal			
	19	KX	23JAN92	normal			OTHER GU NEOPLASIA NOS
	20	NL	24JAN92	normal			
	21	CL	13FEB92	normal			
	22	NYH	05MAY92	normal			
	23	BSB	05MAY92	normal			

9550077

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 4.0

PREVIOUS TREATMENTS

Centre	Patient No.	Initials	Visit Date	Treatment	Efficacy	Side Effects	Last Treatments Taken	Date of Discontinuation (1)	Treatment Start (2)	(2)-(1)
1	1	HGA	09NOV90	IMIPRAMINE TRAZODONE	poor poor	Y Y	TRAZODONE	01NOV90	17NOV90	16
1	2	RAQ	09NOV90	IMIPRAMINE FLUOXETINE	fair poor	Y Y	FLUOXETINE	14OCT90	17NOV90	34
1	3	TA	09NOV90	AMITRIPTYLINE ALPRAZOLAM	poor very poor	Y Y	ALPRAZOLAM	03NOV90	17NOV90	14
1	4	DNC	13NOV90	CLOMIPRAMINE IMIPRAMINE	poor poor	Y Y	CLOMIPRAMINE	01NOV90	21NOV90	20
1	5	DB	27NOV90	TRANLYCYPROMINE IMIPRAMINE	fair poor	Y Y	IMIPRAMINE	20NOV90	05DEC90	15
1	6	CFH	27NOV90	BROMAZEPAM FLUOXETINE	poor poor	Y	FLUOXETINE	30OCT90	05DEC90	36
1	7	JSA	30NOV90	IMIPRAMINE TRAZODONE FLUOXETINE	good poor poor	Y Y Y	FLUOXETINE	20NOV90	05DEC90	15
6	8	HVB	30NOV90	DIAZEPAM AMITRIPTYLINE	poor fair	Y	AMITRIPTYLINE	06NOV90	08DEC90	32
9	9	CCR	19DEC90	IMIPRAMINE CLOMIPRAMINE	good poor	Y Y	CLOMIPRAMINE	01DEC90	27DEC90	26
1	10	LDL	25JAN91	TRANLYCYPROMINE MOCLOBEMIDE	fair poor		MOCLOBEMIDE	05JAN91	02FEB91	28
1	12	SLT	12MAR91	IMIPRAMINE	very poor		IMIPRAMINE	26FEB91	20MAR91	22
1	14	MLC	30APR91	IMIPRAMINE	good	Y	IMIPRAMINE	10APR91	08MAY91	28
1	16	HBC	10MAY91	IMIPRAMINE	poor	Y	IMIPRAMINE	20APR91	18MAY91	28
1	17	CEC	14MAY91	IMIPRAMINE	poor		IMIPRAMINE	10MAR91	22MAY91	73
1	18	THH	15MAY91	FLUOXETINE	very poor	Y	FLUOXETINE	25APR91	23MAY91	28
1	19	SR	21MAY91	TRANLYCYPROMINE	good		TRANLYCYPROMINE	15DEC91	29MAY91	-200
1	21	VHC	28MAY91	TRAZODONE	very poor		TRAZODONE	20APR91	05JUN91	46
1	22	SK	04JUN91	IMIPRAMINE	good	Y	IMIPRAMINE	21FEB91	12JUN91	111

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 4.0

PREVIOUS TREATMENTS

Centre	Patient No.	Initials	Visit Date	Treatment	Efficacy	Side Effects	Last Treatments Taken	Date of Discontinuation (1)	Treatment Start (2)	(2)-(1)
1	23	AR	14JUN91	ALPRAZOLAM	very poor	Y	ALPRAZOLAM	14MAY91	22JUN91	39
1	24	LVF	25JUN91	IMIPRAMINE	good	Y	IMIPRAMINE	02MAY91	03JUL91	62
1	25	AMR	28JUN91	FLUOXETINE	fair	Y	FLUOXETINE	10JAN91	06JUL91	177
1	26	OC	02JUL91	NOCLOBENIDE	good		NOCLOBENIDE	19MAR91	10JUL91	113
1	27	RK	05JUL91	FLUOXETINE ALPRAZOLAM	fair fair	Y Y	FLUOXETINE	01APR91	13JUL91	103
1	28	RHM	09JUL91	IMIPRAMINE	poor		IMIPRAMINE	03JUN91	17JUL91	44
1	29	AFO	09JUL91	NORTRIPTYLIN	very poor	Y	NORTRIPTYLIN	01JUN91	17JUL91	46
1	30	ERV	10JUL91	MIANSERIN	fair	Y	MIANSERIN	25JUN91	18JUL91	23
1	31	HAM	16JUL91	IMIPRAMINE	poor		IMIPRAMINE	10JUN91	24JUL91	44
1	32	DGM	17JUL91	FLUOXETINE	poor	Y	FLUOXETINE	01JUL91	25JUL91	24
1	33	QFC	17JUL91	MAPROTILIN	poor		MAPROTILIN	01JUL91	25JUL91	24
1	34	GMH	31JUL91	NORTRIPTYLIN	poor	Y	NORTRIPTYLIN	10MAY91	08AUG91	90
1	35	EMP	20AUG91	NOCLOBENIDE	good	Y	NOCLOBENIDE	12FEB91	28AUG91	197
1	36	LM	20AUG91	NOCLOBENIDE	poor		NOCLOBENIDE	01AUG91	27AUG91	26
1	37	RF	27AUG91	TRAZODON	good		TRAZODON	19JAN91	04SEP91	228
1	38	DBF	10SEP91	NOCLOBENIDE	poor		NOCLOBENIDE	10SEP91	18SEP91	8
1	39	ASS	17SEP91	CLOMIPRAMIN	good		CLOMIPRAMIN	10AUG91	25SEP91	46
1	41	SFS	17SEP91	CLOMIPRAMIN	good		CLOMIPRAMIN	20JAN91	25SEP91	248
1	43	ARN	25SEP91	IMIPRAMINE	good		IMIPRAMINE	10JUL90	03OCT91	450
1	44	MAL	01OCT91	IMIPRAMINE	very poor		IMIPRAMINE	15SEP91	09OCT91	24
1	45	DPS	01OCT91	IMIPRAMINE	good	Y	IMIPRAMINE	01MAR91	09OCT91	222
1	49	DAS	18OCT91	IMIPRAMINE	poor		IMIPRAMINE	01OCT91	26OCT91	25
1	50	MFA	18OCT91	FLUOXETINE	fair		FLUOXETINE	13APR91	26OCT91	196

9550077

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 4.0

PREVIOUS TREATMENTS

Centre	Patient No.	Initials	Visit Date	Treatment	Efficacy	Side Effects	Last Treatments Taken	Date of Discontinuation (1)	Treatment Start (2)	(2)-(1)
1	60	EM	13DEC91	IMIPRAMINE	fair		IMIPRAMINE	13JUN91	21DEC91	191
1	108	STB	12FEB92	FLUOXETINE	fair		FLUOXETINE	12AUG91	20FEB92	192
1	113	LPS	12FEB92	NOCLOBENDE	good		NOCLOBENDE	07SEP91	20FEB92	166
2	31	IK	09NOV90	TRIMIPRAMINE DESIPRAMINE	poor poor	Y Y	AMITRIPTYLINE	02NOV90	10NOV90	8
2	32	GE	09DEC90	AMITRIPTYLINE CARMAZEPINE	good good		AMITRIPTYLINE	02DEC90	10DEC90	8
2	33	HS	14JAN91	AMITRIPTYLINE TRIMIPRAMINE THIORIDAZIN	poor very good good	Y Y Y	TRIMIPRAMINE	07JAN91	15JAN91	8
2	34	EH	27MAR91	AMITRIPTYLINE TRIMIPRAMINE IMIPRAMINE DESIPRAMINE	good good good good		AMITRIPTYLINE	20MAR91	28MAR91	8
3	2	FTL	02NOV90	MAPROTILINE	very poor		MAPROTILINE	22OCT90	17NOV90	26
3	3	DUB	25MAR91	TRIMIPRAMINE	fair		TRIMIPRAMINE	20MAR91	03APR91	14
3	4	AUD	29NOV90	VILOXAZINE TOFRANIL ANAFRANIL SURVECTOR PROTHIADEN	good fair fair poor poor		VILOXAZINE	28NOV90	08DEC90	10
3	5	MMA	18DEC90	FLUOXETINE	good		FLUOXETINE	15NOV90	24DEC90	39
3	6	AJP	29NOV90	FLUOXETINE	fair		FLUOXETINE	15SEP90	20DEC90	96
3	7	GRI	05DEC90	VIVALAN STABLON	poor very poor		STABLON	04DEC90	11DEC90	7
3	9	DEN	10JAN91	PROTHIADEN CLELDIAL	good very good	Y Y	PROTHIADEN	10JAN91	19JAN91	9
3	10	TOR	03APR91	CLOMIPRAMINE	fair	Y	CLOMIPRAMINE	29MAR91	11APR91	13
8	1	HJ	03DEC90	THIORIDAZINE IMIPRAMINE DIBENZEPIN MEPROBAMAT	very poor very poor very poor very poor		DIBENZEPIN MEPROBAMAT	26NOV90	04DEC90	8

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOMETINE - PROTOCOL 20124/013
Listing No.: 4.0

PREVIOUS TREATMENTS

Contre	Patient No.	Initials	Visit Date	Treatment	Efficacy	Side Effects	Last Treatments Taken	Date of Discontinuation (1)	Treatment Start (2)	(2)-(1)
8	2	TE	13DEC90	INIPRAMINE HEPROBAMAT	very poor fair		INIPRAMINE HEPROBAMAT	06DEC90	14DEC90	8
8	3	JL	20DEC90	DIBENZEPIN DIAZEPAM	very poor poor		DIBENZEPIN DIAZEPAM	13DEC90	21DEC90	8
8	4	BA	10JAN91	THIORIDAZIN MAPROTILINE	very poor very poor		THIORIDAZIN MAPROTILINE	05JAN91	11JAN91	8
8	5	SL	08JAN91	MAPROTILINE THIORIDAZIN	very poor poor		MAPROTILINE THIORIDAZIN	29DEC90	15JAN91	17
8	6	TL	21JAN91	MAPROTILINE THIORIDAZIN	very poor poor		MAPROTILINE THIORIDAZIN	16JAN91	22JAN91	8
8	7	SZT	21MAR91	MAPROTILINE DIAZEPAM	poor poor		MAPROTILINE	14MAR91	22MAR91	8
9	1	US	28MAY90	INIPRAMINE MAPROTILINE NOVERIL	poor fair poor		NOVERIL	20MAY90	29MAY90	9
9	2	VCF	28MAY90	LUDIONIL	poor		LUDIONIL	20MAY90	29MAY90	9
9	3	SF	14AUG90	LUDIONIL TOLYON	poor poor		TOLYON	25JUN90	15AUG90	51
9	4	SA	24AUG90	LUDIONIL AMITRIPTYLINE	fair poor		LUDIONIL	10MAY88	01SEP90	844
9	5	MF	15SEP90	NOVERIL AMITRIPTYLINE LUDIONIL	fair poor good		LUDIONIL	10FEB90	23SEP90	225
9	6	SD	06NOV90	TRIMIPRAMINE	poor		TRIMIPRAMINE	15SEP90	07NOV90	53
9	7	PP	08NOV90	LUDIONIL NOVERIL PAROXETINE LITHIUM	poor poor poor poor		NOVERIL	31OCT90	09NOV90	9
9	8	KTM	21NOV90	NOVERIL PAROXETINE INIPRAMINE LUDIONIL	poor fair poor poor		NOVERIL	21NOV90	22NOV90	1
9	9	PL	23NOV90	LUDIONIL	very poor		LUDIONIL	15NOV90	24NOV90	9

9550077

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 4.0

PREVIOUS TREATMENTS

Centre	Patient No.	Initials	Visit Date	Treatment	Efficacy	Side Effects	Last Treatments Taken	Dates of Discontinuation (1)	Treatment Start (2)	(2)-(1)
9	9	PL	23NOV98	NOVERIL	very poor					
9	10	BG	16JAN91	LUDIOMIL HALOPERIDOL SEDUXEN PIPOFEZINE	poor very poor very poor very poor		LUDIOMIL	18MAY87	11JAN91	1334
9	11	KE	29JAN91	MELLERIL	poor		MELLERIL	21JAN91	30JAN91	9
9	12	GYT	05MAR91	TRIMIPRAMINE LUDIOMIL NOVERIL	poor good poor		NOVERIL	10FEB91	06MAR91	24
9	13	BP	13MAR91	AMITRIPTYLINE NOVERIL	poor poor		NOVERIL	06MAR91	14MAR91	8
9	14	SZF	24MAR91	NOVERIL	poor		NOVERIL	15FEB91	25MAR91	38
9	15	BI	12MAY91	NOVERIL LUDIOMIL TEPERIN	fair fair poor		TEPERIN	12DEC90	20MAY91	159
9	16	UGY	02JUL91	LUDIOMIL	good		LUDIOMIL	10OCT87	10JUL91	1369
9	18	MBM	08JUL91	TEPERIN LUDIOMIL NOVERIL FEVARIN	poor fair poor fair		FEVARIN	02JUL91	15JUL91	13
9	20	GVE	17AUG91	AMITRIPTYLINE NOVERIL	fair fair		NOVERIL	16AUG91	24AUG91	8
9	22	RKE	22OCT91	TEPERIN IMIPRAMINE LUDIOMIL	fair poor poor		LUDIOMIL	18SEP91	30OCT91	50
9	23	SZN	01NOV91	NOVERIL	good		NOVERIL	16OCT91	09NOV91	24
9	24	LGY	04NOV91	FEVARIN	fair		FEVARIN	31OCT91	12NOV91	12
9	25	PH	15NOV91	LUDIOMIL FEVARIN	poor fair		FEVARIN	15SEP91	20NOV91	66
9	29	SZF	06APR92	IMIPRAMINE	poor		IMIPRAMINE	30MAR92	07APR92	8
9	30	NF	06APR92	LUDIOMIL NOVERIL	poor poor		NOVERIL	30MAR92	07APR92	8

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 4,0

PREVIOUS TREATMENTS

Centre	Patient No.	Initials	Visit Date	Treatment	Efficacy	Side Effects	Last Treatments Taken	Date of Discontinuation (1)	Treatment Start (2)	(2)-(1)
10	1	VK	03OCT90	HALOPERIDOL	poor	Y	HALOPERIDOL	03OCT90	16OCT90	13
10	4	2SD	24OCT90	RELANIUM ANAFRANIL	fair fair		ANAFRANIL	23OCT90	31OCT90	8
10	5	AN	07NOV90	AMITRIPTYLINE	fair		AMITRIPTYLINE	01NOV90	14NOV90	13
10	6	RS	09NOV90	AMITRIPTYLINE	poor		AMITRIPTYLINE	07NOV90	16NOV90	9
10	7	RK	13NOV90	AMITRIPTYLINE	good	Y	AMITRIPTYLINE	01JAN89	20NOV90	688
10	8	VP	26NOV90	AMITRIPTYLINE	poor		AMITRIPTYLINE	18NOV90	27NOV90	9
10	9	RT	03DEC90	AMITRIPTYLINE	poor		AMITRIPTYLINE	26NOV90	04DEC90	8
10	10	MH	03DEC90	ANAFRANIL	poor	Y	ANAFRANIL	25NOV90	04DEC90	9
10	11	TM	27DEC90	THIORIDAZINE	poor		THIORIDAZINE	16DEC90	27DEC90	11
10	12	EP	09JAN91	NOOTROPIL	poor		NOOTROPIL	15NOV90	10JAN91	56
10	14	AA	11FEB91	AMITRIPTYLINE	good					
10	15	HT	20FEB91	AMITRIPTYLINE	fair	Y	AMITRIPTYLINE	01MAY90	21FEB91	296
10	16	AJ	04MAR91	AMITRIPTYLINE	poor	Y				
10	17	MH	14MAR91	IMIPRAMINE	good					
10	19	TM	01APR91	ANAFRANIL	poor	Y	ANAFRANIL	02MAR91	02APR91	31
10	22	AA	22APR91	AMITRIPTYLINE	very poor	Y	AMITRIPTYLINE	14APR91	23APR91	9
10	23	LT	23APR91	AMITRIPTYLINE	very poor		AMITRIPTYLINE	16APR91	24APR91	8
10	24	AL	30APR91	AMITRIPTYLINE	poor	Y				
10	25	ES	13MAY91	AMITRIPTYLINE	good					
10	26	JIF	27MAY91	ANAFRANIL AMITRIPTYLINE AMITRIPTYLINE	good poor poor	Y Y				
10	27	MK	03JUN91	AMITRIPTYLINE	poor		AMITRIPTYLINE	23MAY91	03JUN91	11
10	28	LL	30MAY91	IMIPRAMINE AMITRIPTYLINE	good very poor		AMITRIPTYLINE	22MAY91	30MAY91	8

9550077

1/69

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 4.0

PREVIOUS TREATMENTS

Centre	Patient No.	Initials	Visit Date	Treatment	Efficacy	Side Effects	Last Treatments Taken	Date of Discontinuation (1)	Treatment Start (2)-(1)
10	28	LL	30MAY91	NIALAMIDE	very poor				
10	29	JJ	19AUG91	AMITRIPTYLINE	fair		AMITRIPTYLINE	11AUG91	19AUG91
10	30	VK	16SEP91	AMITRIPTYLINE	fair		AMITRIPTYLINE	09SEP91	17SEP91
10	31	RK	16SEP91	AMITRIPTYLINE	very poor		NOOTROPIL	08SEP91	16SEP91
10	32	LK	16SEP91	TAZEPAM	fair		TAZEPAM	08SEP91	16SEP91
10	33	EK	19SEP91	NOOTROPIL AMITRIPTYLINE	fair good		AMITRIPTYLINE	11SEP91	19SEP91
10	34	TK	23SEP91	AMITRIPTYLINE NOOTROPIL		Y	AMITRIPTYLINE	13SEP91	23SEP91
10	35	IH	23SEP91	NOOTROPIL AMITRIPTYLINE	poor fair		AMITRIPTYLINE	10SEP91	23SEP91
10	36	AK	14OCT91	ANAFRANIL	poor	Y			
10	37	HK	14OCT91	IMIPRAMINE AMITRIPTYLINE ANAFRANIL	very poor very poor very poor	Y			
10	38	LL	14OCT91	NOOTROPIL			NOOTROPIL	06OCT91	14OCT91
10	40	AP	24OCT91	AMITRIPTYLINE AMITRIPTYLINE	very poor poor	Y	AMITRIPTYLINE	01MAR91	24OCT91
10	42	TT	13NOV91	TRYPTIZOL NOOTROPIL	very poor very poor		TRYPTIZOL	06NOV91	14NOV91
10	45	KJ	19NOV91	AMITRIPTYLINE	poor		AMITRIPTYLINE	12NOV91	20NOV91
10	47	TH	04DEC91	AMITRIPTYLINE	good		AMITRIPTYLINE	06SEP89	05DEC91
10	48	IP	04DEC91	AMITRIPTYLINE RADEDOHR	good good		AMITRIPTYLINE	14NOV91	05DEC91
10	49	VH	10DEC91	AMITRIPTYLINE	fair		AMITRIPTYLINE	02DEC91	11DEC91
10	50	EE	18DEC91	PIRACETAM	fair				
10	56	JP	13JAN92	AMITRIPTYLINE	good	Y	AMITRIPTYLINE	06JAN92	14JAN92
10	57	AG	14JAN92	AMITRIPTYLINE	fair		AMITRIPTYLINE	01MAY89	15JAN92

9550077

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 4.0

PREVIOUS TREATMENTS

Centre	Patient No.	Initials	Visit Date	Treatment	Efficacy	Side Effects	Last Treatments Taken	Date of Discontinuation (1)	Treatment Start (2)	(2)-(1)
10	57	AG	14JAN92	NOOTROPIL	fair					
10	58	KK	14JAN92	AMITRIPTYLINE	fair		AMITRIPTYLINE	07JAN92	14JAN92	7
10	61	JT	21JAN92	RADEDORM NOOTROPIL	very poor poor		RADEDORM	14JAN92	22JAN92	8
10	62	RK	21JAN92	AMITRIPTYLINE SONAPAX RADEDORM	very poor poor fair	Y	AMITRIPTYLINE	13JAN92	22JAN92	9
10	81	JN	20FEB92	TRIPTIZOL	poor		TRIPTIZOL	10FEB92	21FEB92	11
10	83	KL	02MAR92	IMIPRAMINE AMITRIPTYLINE NIALAMIDE ANAFRANIL	fair fair fair fair	Y	NIALAMIDE	16FEB92	03MAR92	16
10	87	AN	18MAR92	AMITRIPTYLINE	good	Y	AMITRIPTYLINE	30APR90	19MAR92	689
10	90	SV	23MAR92	AMITRIPTYLINE	fair		AMITRIPTYLINE	01JAN89	24MAR92	1178
10	91	HI	23MAR92	ANAFRANIL AMITRIPTYLINE IMIPRAMINE	fair fair fair		ANAFRANIL	01JUN92	24MAR92	-69
10	94	PV	08APR92	IMIPRAMINE RADEDORM	fair fair		IMIPRAMINE	29FEB92	09APR92	40
11	1	DF	07OCT91	MAPROTILINE	poor		MAPROTILINE	18MAY85	12OCT91	2338
11	2	HB	07OCT91	MAPROTILINE	good		MAPROTILINE	06OCT91	14OCT91	8
11	3	RF	07OCT91	IMIPRAMINE TRIPRAMINE THIORDAZINE CARBAMAZEPINE LITHIUM	good fair fair good good		IMIPRAMINE CARBAMAZEPINE	06OCT91	15OCT91	9
11	4	BA	11OCT91	IMIPRAMINE MAPROTILINE DIBENZEPIN	fair fair fair		DIBENZEPIN	10OCT91	18OCT91	8
11	5	ZH	14OCT91	IMIPRAMINE	poor		IMIPRAMINE	10OCT91	18OCT91	8
11	6	VP	12OCT91	AMITRIPTYLINE	fair		AMITRIPTYLINE	14OCT89	16OCT91	732

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 4.0

PREVIOUS TREATMENTS

Centre	Patient No.	Initials	Visit Date	Treatment	Efficacy	Side Effects	Last Treatments Taken	Date of Discontinuation (1)	Treatment Start (2)	(2)-(1)
11	7	KK	16OCT91	CARBAMAZEPINE DIBENZEPIN	good good		DIBENZEPIN	16OCT91	24OCT91	8
11	8	KF	04NOV91	MAPROTIline IMIPRAMINE DIBENZEPIN	good fair good		DIBENZEPIN	03NOV91	11NOV91	8
11	9	FI	05NOV91	IMIPRAMINE TRIMIPRAMINE AMITRIPTYLINE FEVARI	poor good fair good		AMITRIPTYLINE	03NOV91	12NOV91	9
11	10	BJ	19NOV91	MAPROTIline IMIPRAMINE CARBAMAZEPINE LITHIUM DIBENZEPIN	poor poor poor poor good		DIBENZEPIN	18NOV91	26NOV91	8
11	11	NGY	27NOV91	MAPROTIline IMIPRAMINE FEVARI	fair good fair		MAPROTIline	27NOV91	06DEC91	15
11	12	FJ	09DEC91	MAPROTIline THIORIDAZINE DIBENZEPIN AMITRIPTYLINE	good fair good good		MAPROTIline	08DEC91	16DEC91	8
11	13	GK	06JAN92	MAPROTIline METOFENAZATE ALPRAZOLAM IMIPRAMINE	fair fair good good		IMIPRAMINE	06JAN92	15JAN92	9
11	14	BJ	19JAN92	MAPROTIline	good		MAPROTIline	12JAN92	20JAN92	8
11	15	NF	26JAN92	IMIPRAMINE	good		IMIPRAMINE	24JAN92	29JAN92	8
11	16	NA	02FEB92	MAPROTIline	fair					
11	17	UZ	06FEB92	MAPROTIline IMIPRAMINE DIBENZEPIN HYDROCHLORIDE FLUVOXAMINE	fair good fair good		DIBENZEPINHYDROCHLORIDE	30JAN92	07FEB92	8
11	18	EI	03FEB92	DIBENZEPIN MAPROTIline FLUVOXAMINE	fair fair good		FLUVOXAMINE	26JAN92	10FEB92	15

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 4.0

PREVIOUS TREATMENTS

Centre No.	Patient No.	Initials	Visit Date	Treatment	Efficacy	Side Effects	Last Treatments Taken	Date of Discontinuation (1)	Treatment Start (2)	(2)-(1)
11	19	FK	27FEB92	MAPROTILINE DIBENZEPIN HYDROCHLORIDE	fair		DIBENZEPINHYDROCHLORIDE	20FEB92	28FEB92	8
11	20	LJ	01MAR92	MAPROTILINE DIBENZEPIN HYDROCHLORIDE	good					
12	1	IB	28OCT91	THIORIDAZINE NOVERIL TEPERIN	fair fair poor		TEPERIN	22OCT91	31OCT91	9
12	2	EFC	29OCT91	PERPHENAZINE AMITRIPTYLINE	very poor		PERPHENAZINE AMITRIPTYLINE	28OCT91	05NOV91	8
12	3	IF	28OCT91	MEPROBAMATE TOFISOPAM	good good		MEPROBAMATE	21OCT91	30OCT91	9
12	4	EG	30OCT91	NOVERIL	good		NOVERIL	29OCT91	05NOV91	7
12	5	ZSH	04NOV91	CARBAMAZEPINE	poor		CARBAMAZEPINE	26OCT91	05NOV91	10
12	6	MK	31OCT91	LUDIONIL AMITRIPTYLINE IMIPRAMINE LEVOPROMAZIN	good good very poor fair		LUDIONIL	26OCT91	02NOV91	7
12	7	LK	30OCT91	MEPROBAMATE AMITRIPTYLINE TRIMIPRAMINE	poor good fair		AMITRIPTYLINE	28OCT91	05NOV91	8
12	8	FH	31OCT91	AMITRIPTYLINE FEVARIN	fair		FEVARIN	25OCT91	01NOV91	7
12	9	KBP	30OCT91	IMIPRAMINE AMITRIPTYLINE	good good		IMIPRAMINE AMITRIPTYLINE	17OCT91	31OCT91	14
12	10	IP	04NOV91	LEVOPROMAZIN MAPROTILINE HYDROCHLORIDE	very poor poor		MAPROTILINEHYDROCHLORIDE	27OCT91	05NOV91	9
12	11	ER	31OCT91	NOVERIL LUDIONIL	good poor		LUDIONIL	26OCT91	31OCT91	5
12	12	FSZ	04NOV91	MEPROBAMATE PINDOLIDE LEVOPROMAZIN	fair poor fair		MEPROBAMATE	27OCT91	05NOV91	9
12	13	ISZ	04NOV91	AMITRIPTYLINE	poor		AMITRIPTYLINE	27OCT91	05NOV91	9

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 4.0

PREVIOUS TREATMENTS

Centre	Patient No.	Initials	Visit Date	Treatment	Efficacy	Side Effects	Last Treatments Taken	Date of Discontinuation (1)	Treatment Start (2)	(2)-(1)
12	14	GSZ	05NOV91	MAPROTIILINE CHLORPROTHIXENE	poor poor		MAPROTIILINE CHLORPROTHIXENE	30OCT91	06NOV91	7
12	15	GB	25NOV91	NEPRAMATE CARBAMAZEPINE	poor fair		CARBAMAZEPINE	11NOV91	26NOV91	15
12	16	FN	10DEC91	ALPRAZOLAM MAPROTIILINE	poor fair		MAPROTIILINE	27NOV91	11DEC91	14
12	17	TK	14JAN92	CHLORPROTHIXENE TRIMIPRAMINE	fair fair		TRIMIPRAMINE	07JAN92	15JAN92	8
12	18	LS	14JAN92	TRIMIPRAMINE DIBENZEPIN HYDROCHLORIDE MAPROTIILINE	good fair good		MAPROTIILINE	01JAN92	15JAN92	14
12	19	SSZ	15JAN92	MAPROTIILINE	good		MAPROTIILINE	08JAN92	16JAN92	8
12	20	KSZ	16JAN92	AMITRIPTYLINE MAPROTIILINE	fair fair		MAPROTIILINE	28DEC91	17JAN92	20
12	21	FL	30JAN92	THIORIDAZIN MAPROTIILINE	poor poor		MAPROTIILINE	24JAN92	31JAN92	7
12	22	HV	24JAN92	MAPROTIILINE AMITRIPTYLINE INIPRAMINE	fair good fair		AMITRIPTYLINE INIPRAMINE	19JAN92	28JAN92	9
12	23	EN	06FEB92	DIBENZEPIN MAPROTIILINE	poor very poor		DIBENZEPIN	30JAN92	07FEB92	8
12	24	HF	07FEB92	TRIMIPRAMINE MAPROTIILINE AMITRIPTYLINE	poor poor fair		AMITRIPTYLINE	31JAN92	08FEB92	8
12	25	FS	10FEB92	MAPROTIILINE TRIMIPRAMINE	good fair		TRIMIPRAMINE	05FEB92	11FEB92	6
12	26	LB	04FEB92	MAPROTIILINE	poor		MAPROTIILINE	30JAN92	05FEB92	6
12	27	VCS	06FEB92	MAPROTIILINE	fair		MAPROTIILINE	24DEC91	08FEB92	46
12	28	IV	07FEB92	AMITRIPTYLINE	fair		AMITRIPTYLINE	23DEC92	08FEB92	-319
12	29	AK	10FEB92	MAPROTIILINE	poor		MAPROTIILINE	03FEB92	11FEB92	8
12	30	FS	24FEB92	AMITRIPTYLINE	very poor		AMITRIPTYLINE LITHIUMCARBONATE	18FEB92	25FEB92	7

693

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 4.0

PREVIOUS TREATMENTS

Centre	Patient No.	Initials	Visit Date	Treatment	Efficacy	Side Effects	Last Treatments Taken	Dates of Discontinuation (1)	Treatment Start (2)	(2)-(1)
12	30	FS	24FEB92	LITHIUM CARBONATE IMIPRAMINE	very poor very poor					
12	31	FM	23MAR92	AMITRIPTYLINE DIBENZEPIN	poor		DIBENZEPIN	09MAR92	25MAR92	16
12	32	LM	01APR92	IMIPRAMINE	very poor		IMIPRAMINE	11MAR92	02APR92	22
12	33	LN	01APR92	MAPROTILINE	poor		MAPROTILINE	25MAR92	02APR92	8
12	34	TGB	27MAR92	AMITRIPTYLINE	poor		AMITRIPTYLINE	22MAR92	28MAR92	6
12	35	LP	27MAR92	TRIMIPRAMINE AMITRIPTYLINE MAPROTILINE	poor fair fair		MAPROTILINE	22MAR92	28MAR92	6
12	36	FB	30MAR92	AMITRIPTYLINE IMIPRAMINE	fair fair		IMIPRAMINE	27MAR92	31MAR92	10
12	37	EK	03APR92	MAPROTILINE AMITRIPTYLINE	poor fair		AMITRIPTYLINE	25MAR92	04APR92	10
12	38	FG	06APR92	MAPROTILINE AMITRIPTYLINE	poor poor		AMITRIPTYLINE	28MAR92	07APR92	10
13	1	P2	09OCT91	AMITRIPTYLINE MAPROTILINE	poor good		MAPROTILINE	08OCT91	16OCT91	8
13	2	TCS	08OCT91	MAPROTILINE	very poor		MAPROTILINE	10OCT91	17OCT91	7
13	3	AI	08OCT91	MAPROTILINE	very poor		MAPROTILINE	08OCT91	16OCT91	8
13	4	SZJ	09OCT91	MAPROTILINE	very poor		MAPROTILINE	10OCT91	16OCT91	6
13	5	HF	10OCT91	MAPROTILINE	very poor		MAPROTILINE	09OCT91	18OCT91	9
13	6	HE	11OCT91	MAPROTILINE	poor		MAPROTILINE	10OCT91	18OCT91	8
13	7	BL	09OCT91	AMITRIPTYLINE	very poor		AMITRIPTYLINE	18OCT91	25OCT91	7
13	8	PK	15OCT91	MAPROTILINE	fair		MAPROTILINE	15OCT91	22OCT91	7
13	9	SZS	15OCT91	DIBENZEPIN	poor		DIBENZEPIN	14OCT91	22OCT91	8
13	10	BH	18OCT91	MAPROTILINE	very poor		MAPROTILINE	12OCT91	18OCT91	6
13	11	HS	17OCT91	DIBENZEPIN	poor		DIBENZEPIN	07NOV91	15NOV91	8

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 4.0

PREVIOUS TREATMENTS

Centre	Patient No.	Initials	Visit Date	Treatment	Efficacy	Side Effects	Last Treatments Taken	Date of Discontinuation (1)	Treatment Start (2)	(2)-(1)
13	11	HS	17OCT91	MAPROTIline	poor					
13	12	BF	21OCT91	DIBENZEPIN	fair		DIBENZEPIN	23OCT91	31OCT91	8
13	13	HM	28OCT91	DIBENZEPIN	poor		DIBENZEPIN	27OCT91	02NOV91	6
13	14	DF	28OCT91	MAPROTIline	poor		MAPROTIline	27OCT91	02NOV91	6
13	15	KG	28OCT91	MAPROTIline	poor		MAPROTIline	28OCT91	07NOV91	10
13	16	SZL	14NOV91	MAPROTIline	poor		MAPROTIline	13NOV91	20NOV91	7
13	17	GSM	15NOV91	AMITRIPTYline MAPROTIline	fair poor		MAPROTIline	12NOV91	20NOV91	8
13	18	VT	26NOV91	AMITRIPTYline	poor		AMITRIPTYline	25NOV91	04DEC91	9
13	19	KK	23JAN92	MAPROTIline AMITRIPTYline	poor very poor		MAPROTIline	17JAN92	24JAN92	7
13	20	NL	24JAN92	MAPROTIline	poor		MAPROTIline	22JAN92	29JAN92	7
13	21	CL	13FEB92	MAPROTIline	very poor		MAPROTIline	10FEB92	19FEB92	9
13	22	NVM	05MAY92	MAPROTIline	poor		MAPROTIline	27APR92	06MAY92	9
13	23	BSB	05MAY92	MAPROTIline	very poor		MAPROTIline	29APR92	07MAY92	8

9550077

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS RED

REBOMETINE - PROTOCOL 201247/13
Listine No.: 5.0

ASSESSMENT DATES AND NUMBER OF TREATMENT DAYS
OPEN PHASE

Centre 1

Patient No.	Initials	Screen	Screen-Day0	Day0	Week1	Week1-Day0	Week2	Week2-Day0	Week3	Week3-Day0	Week4	Week4-Day0	Week5	Week5-Day0	Week6	Week6-Day0	Weeks	Weeks-Day0
1	MEA	09NOV90	-7	16NOV90	23NOV90	7	30NOV90	14	07DEC90	21	14DEC90	28	21DEC90	35	28DEC90	42	28DEC90	42
2	RAO	09NOV90	-7	16NOV90	23NOV90	7	30NOV90	14	07DEC90	21	14DEC90	28	21DEC90	35	28DEC90	42	28DEC90	42
3	TA	09NOV90	-7	16NOV90	23NOV90	7	30NOV90	14	07DEC90	21	14DEC90	28	21DEC90	35	28DEC90	42	28DEC90	42
4	DAK	13NOV90	-7	20NOV90	27NOV90	7	05DEC90	15	12DEC90	22	19DEC90	29	26DEC90	36	02JAN91	45	02JAN91	45
5	DB	27NOV90	-7	04DEC90	11DEC90	7	18DEC90	14	24DEC90	22	02JAN91	29	06JAN91	35	15JAN91	42	15JAN91	42
6	CPH	27NOV90	-7	04DEC90	11DEC90	7	18DEC90	14	24DEC90	22	02JAN91	29	06JAN91	35	15JAN91	42	15JAN91	42
7	JSA	30NOV90	-4	04DEC90	11DEC90	7	18DEC90	14	24DEC90	22	02JAN91	29	06JAN91	35	15JAN91	42	15JAN91	42
8	HUS	30NOV90	-7	07DEC90	14DEC90	7	21DEC90	14	28DEC90	21	25JAN91	28	30JAN91	35	06FEB91	42	06FEB91	42
9	CCR	19DEC90	-7	26DEC90	02JAN91	7	09JAN91	14	16JAN91	21	23JAN91	28	30JAN91	35	06FEB91	42	06FEB91	42
10	LDL	25JAN91	-7	01FEB91	08FEB91	7	15FEB91	14	22FEB91	21	01MAR91	28	08MAR91	35	15MAR91	42	15MAR91	42
11	VRT	01MAR91	-7	08MAR91	15MAR91	7	22MAR91	14	29MAR91	20	05APR91	28	12APR91	35	19APR91	42	19APR91	42
12	SLT	12MAR91	-7	19MAR91	26MAR91	7	02APR91	14	09APR91	21	16APR91	28	23APR91	35	30APR91	42	30APR91	42
13	JR	23APR91	-7	30APR91	07MAY91	7	14MAY91	14	21MAY91	21	28MAY91	28	04JUN91	35	11JUN91	42	11JUN91	42
14	MLC	30APR91	-7	07MAY91	14MAY91	7	21MAY91	14	28MAY91	21	04JUN91	28	11JUN91	35	18JUN91	42	18JUN91	42
15	HAD	30APR91	-6	08MAY91	15MAY91	7	22MAY91	14	29MAY91	21	05JUN91	28	12JUN91	35	19JUN91	42	19JUN91	42
16	MHC	10MAY91	-7	17MAY91	24MAY91	7	31MAY91	14	07JUN91	21	14JUN91	28	21JUN91	35	28JUN91	42	28JUN91	42
17	CEC	10MAY91	-7	17MAY91	24MAY91	7	31MAY91	14	07JUN91	21	14JUN91	28	21JUN91	35	28JUN91	42	28JUN91	42
18	TTM	15MAY91	-7	22MAY91	29MAY91	7	05JUN91	14	12JUN91	21	19JUN91	28	26JUN91	35	03JUL91	42	03JUL91	42
19	SR	21MAY91	-7	28MAY91	04JUN91	7	11JUN91	14	18JUN91	21	25JUN91	28	02JUL91	35	09JUL91	42	09JUL91	42
20	EFC	24MAY91	-7	31MAY91	07JUN91	7	14JUN91	14	21JUN91	21	28JUN91	28	05JUL91	35	12JUL91	42	12JUL91	42
21	VHC	28MAY91	-7	04JUN91	11JUN91	7	18JUN91	14	25JUN91	21	02JUL91	28	09JUL91	35	16JUL91	42	16JUL91	42
22	SK	04JUN91	-7	11JUN91	18JUN91	7	25JUN91	14	02JUL91	21	09JUL91	28	16JUL91	35	23JUL91	42	23JUL91	42
23	AR	14JUN91	-7	21JUN91	28JUN91	7	05JUL91	14	12JUL91	21	19JUL91	28	26JUL91	35	02AUG91	42	02AUG91	42
24	LVP	25JUN91	-7	02JUL91	09JUL91	7	16JUL91	14	23JUL91	21	30JUL91	28	06AUG91	35	13AUG91	42	13AUG91	42
25	AKR	28JUN91	-7	05JUL91	12JUL91	7	19JUL91	14	26JUL91	21	02AUG91	28	09AUG91	35	16AUG91	42	16AUG91	42
26	DC	02JUL91	-7	09JUL91	16JUL91	7	23JUL91	14	30JUL91	21	06AUG91	28	13AUG91	35	20AUG91	42	20AUG91	42
27	RK	05JUL91	-7	12JUL91	19JUL91	7	26JUL91	14	02AUG91	21	09AUG91	28	16AUG91	35	23AUG91	42	23AUG91	42
28	AFO	09JUL91	-7	16JUL91	23JUL91	7	30JUL91	14	06AUG91	21	13AUG91	28	20AUG91	35	27AUG91	42	27AUG91	42
29	RHM	09JUL91	-7	16JUL91	23JUL91	7	30JUL91	14	06AUG91	21	13AUG91	28	20AUG91	35	27AUG91	42	27AUG91	42
30	EDV	10JUL91	-7	17JUL91	24JUL91	7	31JUL91	14	07AUG91	21	14AUG91	28	21AUG91	35	28AUG91	42	28AUG91	42
31	MMR	14JUL91	-7	21JUL91	28JUL91	7	04AUG91	14	11AUG91	21	18AUG91	28	25AUG91	35	01SEP91	42	01SEP91	42
32	DBR	17JUL91	-7	24JUL91	31JUL91	7	07AUG91	14	14AUG91	21	21AUG91	28	28AUG91	35	04SEP91	42	04SEP91	42
33	DFC	17JUL91	-7	24JUL91	31JUL91	7	07AUG91	14	14AUG91	21	21AUG91	28	28AUG91	35	04SEP91	42	04SEP91	42
34	GHI	31JUL91	-7	07AUG91	14AUG91	7	11AUG91	14	18AUG91	21	25AUG91	28	01SEP91	35	08SEP91	42	08SEP91	42
35	ERP	20AUG91	-7	27AUG91	03SEP91	7	10SEP91	14	17SEP91	21	24SEP91	28	01OCT91	35	08OCT91	42	08OCT91	42
36	LH	20AUG91	-7	27AUG91	03SEP91	7	10SEP91	14	17SEP91	21	24SEP91	28	01OCT91	35	08OCT91	42	08OCT91	42
37	RF	27AUG91	-7	03SEP91	10SEP91	7	17SEP91	14	24SEP91	21	01OCT91	28	08OCT91	35	15OCT91	42	15OCT91	42
38	DBF	10SEP91	-7	17SEP91	24SEP91	7	01OCT91	14	08OCT91	21	15OCT91	28	22OCT91	35	29OCT91	42	29OCT91	42
39	ASS	17SEP91	-7	24SEP91	01OCT91	7	08OCT91	14	15OCT91	21	22OCT91	28	29OCT91	35	05NOV91	42	05NOV91	42
40	EH	17SEP91	-7	24SEP91	01OCT91	7	08OCT91	14	15OCT91	21	22OCT91	28	29OCT91	35	05NOV91	42	05NOV91	42
41	SFS	17SEP91	-7	24SEP91	01OCT91	7	08OCT91	14	15OCT91	21	22OCT91	28	29OCT91	35	05NOV91	42	05NOV91	42
42	ICC	25SEP91	-7	02OCT91	09OCT91	7	16OCT91	14	23OCT91	21	30OCT91	28	06NOV91	35	13NOV91	42	13NOV91	42
43	ARN	25SEP91	-7	02OCT91	09OCT91	7	16OCT91	14	23OCT91	21	30OCT91	28	06NOV91	35	13NOV91	42	13NOV91	42
44	MAL	01OCT91	-7	08OCT91	15OCT91	7	22OCT91	14	29OCT91	21	05NOV91	28	12NOV91	35	19NOV91	42	19NOV91	42
45	DPS	01OCT91	-7	08OCT91	15OCT91	7	22OCT91	14	29OCT91	21	05NOV91	28	12NOV91	35	19NOV91	42	19NOV91	42
46	SP	08OCT91	-7	15OCT91	22OCT91	7	29OCT91	14	05NOV91	21	12NOV91	28	19NOV91	35	26NOV91	42	26NOV91	42

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBROXETINE - PROTOCOL 20126/013
 List:ing No.: 5.0
 ASSESSMENT DATES AND NUMBER OF TREATMENT DAYS
 OPEN PHASE

Continued

Patient No.	Initials	Screen	Screen-Day0	Day0	Week1	Week1-Day0	Week2	Week2-Day0	Week3	Week3-Day0	Week4	Week4-Day0	Week5	Week5-Day0	Week6	Week6-Day0
47	MCS	15OCT91	-7	25OCT91	29OCT91	7	08NOV91	14	13NOV91	21	19NOV91	28	26NOV91	35	03DEC91	42
48	SDH	14OCT91	-7	25OCT91	30OCT91	7	08NOV91	14	13NOV91	21	20NOV91	28	27NOV91	35	04DEC91	42
49	DMS	16OCT91	-7	25OCT91	01NOV91	7	08NOV91	14	13NOV91	21	22NOV91	29	29NOV91	35	06DEC91	42
50	MFA	18OCT91	-7	25OCT91	01NOV91	7	08NOV91	14	14NOV91	20	22NOV91	29	29NOV91	35	06DEC91	42
51	ASA	18OCT91	-7	25OCT91	01NOV91	7	08NOV91	14	14NOV91	20	22NOV91	29	29NOV91	35	06DEC91	42
52	RTS	23OCT91	-7	30OCT91	06NOV91	7	13NOV91	14	20NOV91	21	27NOV91	28	04DEC91	35	11DEC91	42
53	JFT	23OCT91	-7	30OCT91	06NOV91	7	13NOV91	14	20NOV91	21	27NOV91	28	04DEC91	35	11DEC91	42
54	JD	29OCT91	-7	05NOV91	12NOV91	7	19NOV91	14	26NOV91	21	03DEC91	28	10DEC91	35	17DEC91	42
55	DWG	29OCT91	-7	05NOV91	12NOV91	7	19NOV91	14	26NOV91	21	03DEC91	28	10DEC91	35	17DEC91	42
56	IAL	29OCT91	-7	05NOV91	12NOV91	7	19NOV91	14	26NOV91	21	03DEC91	28	10DEC91	35	17DEC91	42
57	SNC	03DEC91	-7	10DEC91	17DEC91	7	24DEC91	14	31DEC91	21	07JAN92	28	14JAN92	35	21JAN92	42
58	ARM	05DEC91	-7	10DEC91	17DEC91	7	24DEC91	14	31DEC91	21	07JAN92	28	14JAN92	35	21JAN92	42
59	SPF	10DEC91	-7	17DEC91	24DEC91	7	31DEC91	14	07JAN92	21	14JAN92	28	21JAN92	35	28JAN92	42
60	EM	13DEC91	-7	20DEC91	27DEC91	7	03JAN92	14	10JAN92	21	17JAN92	28	24JAN92	35	31JAN92	42
61	HVC	13DEC91	-7	20DEC91	27DEC91	7	03JAN92	14	10JAN92	21	17JAN92	28	24JAN92	35	31JAN92	42
62	MCA	31DEC91	-7	07JAN92	14JAN92	7	22JAN92	14	29JAN92	21	04FEB92	28	11FEB92	35	18FEB92	42
63	JCL	01JAN92	-8	08JAN92	15JAN92	7	22JAN92	14	29JAN92	21	04FEB92	28	11FEB92	35	18FEB92	42
64	EMF	10JAN92	-7	17JAN92	24JAN92	7	31JAN92	14	07FEB92	21	14FEB92	28	21FEB92	35	28FEB92	42
65	FS	14JAN92	-7	21JAN92	28JAN92	7	04FEB92	14	11FEB92	21	18FEB92	28	25FEB92	35	04MAR92	43
66	TCG	14JAN92	-7	21JAN92	28JAN92	7	04FEB92	14	11FEB92	21	18FEB92	28	25FEB92	35	04MAR92	43
67	MAA	14JAN92	-7	21JAN92	28JAN92	7	04FEB92	14	11FEB92	21	18FEB92	28	25FEB92	35	04MAR92	43
68	MCS	14JAN92	-7	21JAN92	28JAN92	7	04FEB92	14	11FEB92	21	18FEB92	28	25FEB92	35	04MAR92	43
69	RPA	14JAN92	-7	24JAN92	31JAN92	7	07FEB92	14	14FEB92	21	21FEB92	28	28FEB92	35	06MAR92	42
70	HLH	17JAN92	-7	26JAN92	02FEB92	7	11FEB92	14	18FEB92	21	25FEB92	28	04MAR92	36	10MAR92	42
71	DMW	21JAN92	-7	28JAN92	04FEB92	7	11FEB92	14	18FEB92	21	25FEB92	28	04MAR92	36	10MAR92	42
72	RLJ	21JAN92	-7	28JAN92	04FEB92	7	11FEB92	14	18FEB92	21	25FEB92	28	04MAR92	36	10MAR92	42
73	FMA	21JAN92	-7	28JAN92	04FEB92	7	11FEB92	14	18FEB92	21	25FEB92	28	04MAR92	36	10MAR92	42
74	IVL	21JAN92	-7	28JAN92	04FEB92	7	11FEB92	14	18FEB92	21	25FEB92	28	04MAR92	36	10MAR92	42
75	ELF	24JAN92	-7	31JAN92	07FEB92	7	14FEB92	14	21FEB92	21	28FEB92	28	06MAR92	36	13MAR92	42
76	SFA	31JAN92	-7	07FEB92	14FEB92	7	21FEB92	14	28FEB92	21	28FEB92	28	06MAR92	36	13MAR92	42
77	ACG	31JAN92	-7	07FEB92	14FEB92	7	21FEB92	14	28FEB92	21	28FEB92	28	06MAR92	36	13MAR92	42
78	SD	31JAN92	-7	07FEB92	14FEB92	7	21FEB92	14	28FEB92	21	28FEB92	28	06MAR92	36	13MAR92	42
79	JCH	31JAN92	-7	07FEB92	14FEB92	7	21FEB92	14	28FEB92	21	28FEB92	28	06MAR92	36	13MAR92	42
80	MEL	31JAN92	-7	07FEB92	14FEB92	7	21FEB92	14	28FEB92	21	28FEB92	28	06MAR92	36	13MAR92	42
81	HPB	31JAN92	-7	07FEB92	14FEB92	7	21FEB92	14	28FEB92	21	28FEB92	28	06MAR92	36	13MAR92	42
82	HDS	31JAN92	-7	07FEB92	14FEB92	7	21FEB92	14	28FEB92	21	28FEB92	28	06MAR92	36	13MAR92	42
83	LFH	31JAN92	-7	07FEB92	14FEB92	7	21FEB92	14	28FEB92	21	28FEB92	28	06MAR92	36	13MAR92	42
84	IN	31JAN92	-7	07FEB92	14FEB92	7	21FEB92	14	28FEB92	21	28FEB92	28	06MAR92	36	13MAR92	42
85	MLP	31JAN92	-7	07FEB92	14FEB92	7	21FEB92	14	28FEB92	21	28FEB92	28	06MAR92	36	13MAR92	42
86	KTF	31JAN92	-7	07FEB92	14FEB92	7	21FEB92	14	28FEB92	21	28FEB92	28	06MAR92	36	13MAR92	42
87	HDO	04FEB92	-7	11FEB92	18FEB92	7	25FEB92	14	04MAR92	22	10MAR92	28	17MAR92	35	24MAR92	42
88	VRJ	04FEB92	-7	11FEB92	18FEB92	7	25FEB92	14	04MAR92	22	10MAR92	28	17MAR92	35	24MAR92	42
89	MPV	04FEB92	-7	11FEB92	18FEB92	7	25FEB92	14	04MAR92	22	10MAR92	28	17MAR92	35	24MAR92	42
90	JSS	04FEB92	-7	11FEB92	18FEB92	7	25FEB92	14	04MAR92	22	10MAR92	28	17MAR92	35	24MAR92	42
91	MSC	04FEB92	-7	11FEB92	18FEB92	7	25FEB92	14	04MAR92	22	10MAR92	28	17MAR92	35	24MAR92	42

703

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REDNET/IME - PROTOCOL 20124/013
 Listing No.: 5.0
 ASSESSMENT DATES AND NUMBER OF TREATMENT DAYS
 OPEN PHASE

(continued)

Patient No.	Initials	Screen	Screen-Days	Day0	Week1	Week1-Day0	Week2	Week2-Day0	Week3	Week3-Day0	Week4	Week4-Day0	Week5	Week5-Day0	Week6	Week6-Day0
92	PSS	04FEB92	-7	11FEB92	18FEB92	7	25FEB92	14	04MAR92	22	10MAR92	26	17MAR92	35	24MAR92	42
93	AL	05FEB92	-7	12FEB92	19FEB92	7	26FEB92	14	04MAR92	21	11MAR92	26	18MAR92	35	25MAR92	42
94	RAB	05FEB92	-7	12FEB92	19FEB92	7	26FEB92	14	04MAR92	21	11MAR92	26	18MAR92	35	25MAR92	42
95	GRT	05FEB92	-7	12FEB92	19FEB92	7	26FEB92	14	04MAR92	21	11MAR92	26	18MAR92	35	25MAR92	42
96	SPM	05FEB92	-7	12FEB92	19FEB92	7	26FEB92	14	04MAR92	21	11MAR92	26	18MAR92	35	25MAR92	42
97	MAD	05FEB92	-7	12FEB92	19FEB92	7	26FEB92	14	04MAR92	21	11MAR92	26	18MAR92	35	25MAR92	42
98	YTT	05FEB92	-7	12FEB92	19FEB92	7	26FEB92	14	04MAR92	21	11MAR92	26	18MAR92	35	25MAR92	42
99	LGD	06FEB92	-7	12FEB92	19FEB92	7	26FEB92	14	04MAR92	21	11MAR92	26	18MAR92	35	25MAR92	42
100	JMA	06FEB92	-7	12FEB92	19FEB92	7	26FEB92	14	04MAR92	21	11MAR92	26	18MAR92	35	25MAR92	42
101	JLL	11FEB92	-7	18FEB92	25FEB92	7	04MAR92	15	10MAR92	21	17MAR92	26	24MAR92	35	31MAR92	42
102	ESF	11FEB92	-7	18FEB92	25FEB92	7	04MAR92	15	10MAR92	21	17MAR92	26	24MAR92	35	31MAR92	42
103	JSA	11FEB92	-7	18FEB92	25FEB92	7	04MAR92	15	10MAR92	21	17MAR92	26	24MAR92	35	31MAR92	42
104	MTF	11FEB92	-7	18FEB92	25FEB92	7	04MAR92	15	10MAR92	21	17MAR92	26	24MAR92	35	31MAR92	42
105	ABS	11FEB92	-7	18FEB92	25FEB92	7	04MAR92	15	10MAR92	21	17MAR92	26	24MAR92	35	31MAR92	42
106	MEN	11FEB92	-7	18FEB92	25FEB92	7	04MAR92	15	10MAR92	21	17MAR92	26	24MAR92	35	31MAR92	42
107	LAN	12FEB92	-7	19FEB92	26FEB92	7	04MAR92	14	11MAR92	21	18MAR92	26	25MAR92	35	01APR92	42
108	STB	12FEB92	-7	19FEB92	26FEB92	7	04MAR92	14	11MAR92	21	18MAR92	26	25MAR92	35	01APR92	42
109	IPL	12FEB92	-7	19FEB92	26FEB92	7	04MAR92	14	11MAR92	21	18MAR92	26	25MAR92	35	01APR92	42
110	TQO	12FEB92	-7	19FEB92	26FEB92	7	04MAR92	14	11MAR92	21	18MAR92	26	25MAR92	35	01APR92	42
111	JBF	12FEB92	-7	19FEB92	26FEB92	7	04MAR92	14	11MAR92	21	18MAR92	26	25MAR92	35	01APR92	42
112	PSA	12FEB92	-7	19FEB92	26FEB92	7	04MAR92	14	11MAR92	21	18MAR92	26	25MAR92	35	01APR92	42
113	LPS	12FEB92	-7	19FEB92	26FEB92	7	04MAR92	14	11MAR92	21	18MAR92	26	25MAR92	35	01APR92	42
114	CLF	18FEB92	-7	25FEB92	04MAR92	8	10MAR92	14	17MAR92	21	24MAR92	26	31MAR92	35	07APR92	42
115	ELS	18FEB92	-7	25FEB92	04MAR92	8	10MAR92	14	17MAR92	21	24MAR92	26	31MAR92	35	07APR92	42
116	MSA	18FEB92	-7	25FEB92	04MAR92	8	10MAR92	14	17MAR92	21	24MAR92	26	31MAR92	35	07APR92	42
117	PBL	18FEB92	-7	25FEB92	04MAR92	8	10MAR92	14	17MAR92	21	24MAR92	26	31MAR92	35	07APR92	42
118	MMH	18FEB92	-7	25FEB92	04MAR92	8	10MAR92	14	17MAR92	21	24MAR92	26	31MAR92	35	07APR92	42
119	MMH	18FEB92	-7	25FEB92	04MAR92	8	10MAR92	14	17MAR92	21	24MAR92	26	31MAR92	35	07APR92	42
120	JLB	18FEB92	-7	25FEB92	04MAR92	8	10MAR92	14	17MAR92	21	24MAR92	26	31MAR92	35	07APR92	42
121	LAC	18FEB92	-7	25FEB92	04MAR92	8	10MAR92	14	17MAR92	21	24MAR92	26	31MAR92	35	07APR92	42
122	HSS	18FEB92	-7	25FEB92	04MAR92	8	10MAR92	14	17MAR92	21	24MAR92	26	31MAR92	35	07APR92	42
123	HLL	18FEB92	-7	25FEB92	04MAR92	8	10MAR92	14	17MAR92	21	24MAR92	26	31MAR92	35	07APR92	42
124	PPC	18FEB92	-7	25FEB92	04MAR92	8	10MAR92	14	17MAR92	21	24MAR92	26	31MAR92	35	07APR92	42
125	FDP	18FEB92	-7	25FEB92	04MAR92	8	10MAR92	14	17MAR92	21	24MAR92	26	31MAR92	35	07APR92	42
126	SMB	18FEB92	-7	25FEB92	04MAR92	8	10MAR92	14	17MAR92	21	24MAR92	26	31MAR92	35	07APR92	42
127	VFD	18FEB92	-7	25FEB92	04MAR92	8	10MAR92	14	17MAR92	21	24MAR92	26	31MAR92	35	07APR92	42
128	LAM	18FEB92	-7	25FEB92	04MAR92	8	10MAR92	14	17MAR92	21	24MAR92	26	31MAR92	35	07APR92	42
129	MMS	18FEB92	-7	25FEB92	04MAR92	8	10MAR92	14	17MAR92	21	24MAR92	26	31MAR92	35	07APR92	42
130	EGA	21FEB92	-6	28FEB92	06MAR92	7	13MAR92	14	20MAR92	21	27MAR92	26	03APR92	35	10APR92	42
131	RHR	04MAR92	-6	11MAR92	17MAR92	7	04APR92	14	11APR92	21	18APR92	26	25APR92	35	02MAY92	42
132	MAT	11MAR92	-7	18MAR92	24MAR92	7	05APR92	14	12APR92	21	19APR92	26	26APR92	35	03MAY92	42
133	JPM	13MAR92	-7	20MAR92	27MAR92	7	07APR92	14	14APR92	21	21APR92	26	28APR92	35	05MAY92	42
134	LHS	17MAR92	-7	24MAR92	31MAR92	7	07APR92	14	14APR92	21	21APR92	26	28APR92	35	05MAY92	42
135	MMS	17MAR92	-7	24MAR92	31MAR92	7	07APR92	14	14APR92	21	21APR92	26	28APR92	35	05MAY92	42
136	AVP	17MAR92	-7	24MAR92	31MAR92	7	07APR92	14	14APR92	21	21APR92	26	28APR92	35	05MAY92	42

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA DNS RED
REBOMETINE - PROTOCOL 20124/015
Listing No.: B.0

ASSESSMENT DATES AND NUMBER OF TREATMENT DAYS
OPEN PHASE

Centre#8

Patient No.	Initials	Screen	Screen-Day0	Day0	Week1	Week1-Day0	Week2	Week2-Day0	Week3	Week3-Day0	Week4	Week4-Day0	Week5	Week5-Day0	Week6	Week6-Day0
1	HJ	08DEC90	0	08DEC90	18DEC90	7	17DEC90	14	24DEC90	21	31DEC90	28	07JAN91	35	14JAN91	42
2	TE	13DEC90	0	13DEC90	20DEC90	7	27DEC90	14	03JAN91	21	10JAN91	28	17JAN91	35	24JAN91	42
3	JL	20DEC90	0	20DEC90	27DEC90	7	03JAN91	14	10JAN91	21	17JAN91	28	24JAN91	35	31JAN91	42
4	BA	10JAN91	0	10JAN91	17JAN91	7	24JAN91	14	31JAN91	21	07FEB91	28	14FEB91	35	21FEB91	42
5	SL	06JAN91	-6	14JAN91	21JAN91	7	28JAN91	14	04FEB91	21	11FEB91	28	18FEB91	35	25FEB91	42
6	TL	21JAN91	0	21JAN91	28JAN91	7	04FEB91	14	11FEB91	21	18FEB91	28	25FEB91	35	04MAR91	42
7	SZT	21MAR91	8	21MAR91	28MAR91	7	04APR91	14	11APR91	21						

Centre#9

Patient No.	Initials	Screen	Screen-Day0	Day0	Week1	Week1-Day0	Week2	Week2-Day0	Week3	Week3-Day0	Week4	Week4-Day0	Week5	Week5-Day0	Week6	Week6-Day0
1	US	28MAY90	0	28MAY90	04JUN90	7	11JUN90	14	18JUN90	21	25JUN90	28	02JUL90	35	09JUL90	42
2	VCF	28MAY90	0	28MAY90	04JUN90	7	11JUN90	14	18JUN90	21	25JUN90	28	02JUL90	35	09JUL90	42
3	SF	14AUG90	0	14AUG90	21AUG90	7	28AUG90	14	04SEP90	21	11SEP90	28	18SEP90	35	25SEP90	42
4	SA	24AUG90	-7	31AUG90	07SEP90	7	14SEP90	14	21SEP90	21	28SEP90	28	05OCT90	35	12OCT90	42
5	HK	15SEP90	-7	22SEP90	29SEP90	7	06OCT90	14	13OCT90	21	20OCT90	28	27OCT90	35	03NOV90	42
6	SD	08NOV90	8	08NOV90	15NOV90	7	22NOV90	14	29NOV90	21	06DEC90	28	13DEC90	35	20DEC90	42
7	PP	08NOV90	0	08NOV90	15NOV90	7	22NOV90	14	29NOV90	21	06DEC90	28	13DEC90	35	20DEC90	42
8	KTH	21NOV90	0	21NOV90	28NOV90	7	05DEC90	14	12DEC90	21	19DEC90	28	26DEC90	35	02JAN91	42
9	PL	30NOV90	1	28NOV90	30NOV90	8	07DEC90	15	14DEC90	22	21DEC90	29	28DEC90	35	04JAN91	43
10	BB	10JAN91	0	10JAN91	17JAN91	7	24JAN91	14	31JAN91	21	07FEB91	28	14FEB91	35	21FEB91	42
11	ME	24JAN91	0	29JAN91	05FEB91	7	12FEB91	14	19FEB91	21	26FEB91	28	05MAR91	35	12MAR91	42
12	DTT	18MAR91	-1	16MAR91	23MAR91	6	30MAR91	13	26MAR91	20	02APR91	27	09APR91	34	16APR91	41
13	BP	18MAR91	-1	16MAR91	23MAR91	6	30MAR91	13	26MAR91	20	02APR91	27	09APR91	34	16APR91	41
14	SZF	24MAR91	0	29MAR91	31MAR91	7	07APR91	14	14APR91	21	21APR91	28	28APR91	35	05MAY91	42
15	BI	12MAY91	-7	19MAY91	26MAY91	7	02JUN91	14	09JUN91	21	16JUN91	28	23JUN91	35	30JUN91	42
16	UGY	02JUL91	-7	09JUL91	16JUL91	7	23JUL91	14	30JUL91	21	06AUG91	28	13AUG91	35	20AUG91	42
17	NL	27JUN91	-7	04JUL91	11JUL91	7	18JUL91	14	06AUG91	21	13AUG91	28	20AUG91	35	27AUG91	42
18	MMH	06JUL91	-6	13JUL91	20JUL91	7	26JUL91	14	02SEP91	21	09SEP91	28	16SEP91	35	23SEP91	42
19	KF	06AUG91	-7	13AUG91	20AUG91	7	27AUG91	14	03SEP91	21	10SEP91	28	17SEP91	35	24SEP91	42
20	QVE	17AUG91	-6	24AUG91	31AUG91	7	06SEP91	14	13SEP91	21	20SEP91	28	27SEP91	35	04OCT91	42
21	TA	16OCT91	-7	23OCT91	30OCT91	7	06NOV91	14	13NOV91	21	20NOV91	28	27NOV91	35	04DEC91	42
22	RKE	28OCT91	-7	29OCT91	05NOV91	7	12NOV91	14	19NOV91	21	26NOV91	28	03DEC91	35	10DEC91	42
23	SZN	01NOV91	-7	08NOV91	15NOV91	7	22NOV91	14	29NOV91	21	06DEC91	28	13DEC91	35	20DEC91	42
24	LEV	04NOV91	-7	11NOV91	18NOV91	7	25NOV91	14	02DEC91	21	09DEC91	28	16DEC91	35	23DEC91	42
25	PM	15NOV91	-4	19NOV91	26NOV91	7	03DEC91	14	10DEC91	21	17DEC91	28	24DEC91	35	31DEC91	42
26	CP	17NOV91	-4	21NOV91	28NOV91	7	05DEC91	14	12DEC91	21	19DEC91	28	26DEC91	35	02JAN92	42
27	ZSL	27MAR92	0	27MAR92	03APR92	7	10APR92	14	17APR92	21	24APR92	28	01MAY92	35	08MAY92	42
28	HI	06APR92	0	06APR92	13APR92	7	20APR92	14	27APR92	21	04MAY92	28	11MAY92	35	18MAY92	42
29	SZF	06APR92	0	06APR92	13APR92	7	20APR92	14	27APR92	21	04MAY92	28	11MAY92	35	18MAY92	42
30	MF	06APR92	0	06APR92	13APR92	7	20APR92	14	27APR92	21	04MAY92	28	11MAY92	35	18MAY92	42

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CIS R&D

REMOETINE - PROTOCOL 2012/4/013
Listing No.: 5.0

ASSESSMENT DATES AND NUMBER OF TREATMENT DAYS
OPEN PHASE

Centre=10

Table with columns: Patient No., Initials, Screen, Screen-Day0, Day0, Week1, Week1-Days, Week2, Week2-Day0, Week3, Week3-Day0, Week4, Week4-Day0, Week5, Week5-Day0, Week6, Week6-Day0, Week7, Week7-Day0. Contains patient data for 45 patients, including initials like UK, ZSD, AN, RS, RK, VP, RT, MH, HH, EP, HU, AA, HT, AJ, MM, SS, TN, EJ, AA, LT, AL, ES, JIF, LL, VK, RK, LK, EK, TK, IH, AK, HK, LL, VH, AP, VP, TT, IK, KJ, KB, TN, TH, IP and corresponding dates and week numbers.

707

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 5.0

ASSESSMENT DATES AND NUMBER OF TREATMENT DAYS
 OPEN PHASE

Centres I

Patient No.	Initials	Screen	Screen-Day0	Day0	Week1	Week1-Day0	Week2	Week2-Day0	Week3	Week3-Day0	Week4	Week4-Day0	Week5	Week5-Day0	Week6	Week6-Day0
49	VM	10DEC91	0	10DEC91	7	24DEC91	14	31DEC91	21	07JAN92	28	14JAN92	35	21JAN92	42	28JAN92
50	EE	10DEC91	0	10DEC91	7	01JAN92	14	08JAN92	21	15JAN92	28	22JAN92	35	29JAN92	42	29JAN92
51	UL	10DEC91	0	10DEC91	7	01JAN92	14	08JAN92	21	15JAN92	28	22JAN92	35	29JAN92	42	29JAN92
52	HP	15JAN92	0	13JAN92	7	27JAN92	14	03FEB92	21	10FEB92	28	14FEB92	35	20FEB92	42	20FEB92
53	MA	15JAN92	0	12JAN92	7	26JAN92	14	02FEB92	21	09FEB92	28	13FEB92	35	19FEB92	42	19FEB92
54	UN	15JAN92	0	12JAN92	7	26JAN92	14	02FEB92	21	09FEB92	28	13FEB92	35	19FEB92	42	19FEB92
55	TP	15JAN92	0	12JAN92	7	26JAN92	14	02FEB92	21	09FEB92	28	13FEB92	35	19FEB92	42	19FEB92
56	JP	15JAN92	0	13JAN92	7	27JAN92	14	03FEB92	21	10FEB92	28	14FEB92	35	20FEB92	42	20FEB92
57	AB	15JAN92	0	13JAN92	7	27JAN92	14	03FEB92	21	10FEB92	28	14FEB92	35	20FEB92	42	20FEB92
58	KA	15JAN92	1	13JAN92	7	27JAN92	14	03FEB92	21	10FEB92	28	14FEB92	35	20FEB92	42	20FEB92
59	TA	21JAN92	1	19JAN92	7	04FEB92	14	09FEB92	21	16FEB92	28	20FEB92	35	23FEB92	42	23FEB92
60	JH	21JAN92	1	19JAN92	7	04FEB92	14	09FEB92	21	16FEB92	28	20FEB92	35	23FEB92	42	23FEB92
61	JT	21JAN92	0	21JAN92	7	04FEB92	14	11FEB92	21	18FEB92	28	22FEB92	35	25FEB92	42	25FEB92
62	RK	21JAN92	0	21JAN92	7	04FEB92	14	11FEB92	21	18FEB92	28	22FEB92	35	25FEB92	42	25FEB92
63	MS	05FEB92	0	05FEB92	7	12FEB92	14	19FEB92	21	26FEB92	28	03MAR92	35	09MAR92	42	09MAR92
64	LT	05FEB92	0	05FEB92	7	12FEB92	14	19FEB92	21	26FEB92	28	03MAR92	35	09MAR92	42	09MAR92
65	LN	20FEB92	0	20FEB92	7	05MAR92	14	12MAR92	21	19MAR92	28	26MAR92	35	02APR92	42	02APR92
66	LS	20FEB92	-4	02MAR92	7	09MAR92	14	16MAR92	21	23MAR92	28	30MAR92	35	06APR92	42	06APR92
67	KL	02MAR92	0	02MAR92	7	09MAR92	14	16MAR92	21	23MAR92	28	30MAR92	35	06APR92	42	06APR92
68	HV	10MAR92	0	10MAR92	7	17MAR92	14	24MAR92	21	31MAR92	28	07APR92	35	14APR92	42	14APR92
69	AK	10MAR92	0	10MAR92	7	17MAR92	14	24MAR92	21	31MAR92	28	07APR92	35	14APR92	42	14APR92
70	NP	16MAR92	0	16MAR92	9	24MAR92	16	00APR92	23	15APR92	30	22APR92	37	29APR92	44	29APR92
71	AN	16MAR92	0	16MAR92	9	24MAR92	16	00APR92	23	15APR92	30	22APR92	37	29APR92	44	29APR92
72	SK	19MAR92	0	19MAR92	7	02APR92	14	09APR92	21	16APR92	28	23APR92	35	30APR92	42	30APR92
73	SV	25MAR92	0	23MAR92	7	06APR92	14	13APR92	21	20APR92	28	27APR92	35	04MAY92	42	04MAY92
74	MI	25MAR92	0	23MAR92	7	06APR92	14	13APR92	21	20APR92	28	27APR92	35	04MAY92	42	04MAY92
75	LA	01APR92	0	31MAR92	7	14APR92	14	21APR92	21	28APR92	28	05MAY92	35	12MAY92	42	12MAY92
76	AN	06APR92	-7	06APR92	7	14APR92	14	21APR92	21	28APR92	28	05MAY92	35	12MAY92	42	12MAY92
77	PV	06APR92	0	06APR92	7	22APR92	14	29APR92	21	06MAY92	28	13MAY92	35	20MAY92	42	20MAY92

9550077

108

Centres II

Patient No.	Initials	Screen	Screen-Day0	Day0	Week1	Week1-Day0	Week2	Week2-Day0	Week3	Week3-Day0	Week4	Week4-Day0	Week5	Week5-Day0	Week6	Week6-Day0
1	DF	07OCT91	-4	11OCT91	7	25OCT91	14	01NOV91	21	08NOV91	28	15NOV91	35	22NOV91	42	29NOV91
2	HB	07OCT91	-6	13OCT91	7	27OCT91	14	03NOV91	21	10NOV91	28	17NOV91	35	24NOV91	42	31NOV91
3	RF	07OCT91	-7	14OCT91	7	28OCT91	14	04NOV91	21	11NOV91	28	18NOV91	35	25NOV91	42	02DEC91
4	BA	11OCT91	-6	17OCT91	7	31OCT91	14	07NOV91	21	14NOV91	28	21NOV91	35	28NOV91	42	05DEC91
5	ZM	16OCT91	-5	17OCT91	7	31OCT91	14	07NOV91	21	14NOV91	28	21NOV91	35	28NOV91	42	05DEC91
6	VP	12OCT91	-8	15OCT91	7	29OCT91	14	06NOV91	21	13NOV91	28	20NOV91	35	27NOV91	42	04DEC91
7	KK	16OCT91	-7	23OCT91	7	36NOV91	14	13NOV91	21	20NOV91	28	27NOV91	35	04DEC91	42	11DEC91
8	KF	04NOV91	-6	11NOV91	7	24NOV91	14	01DEC91	21	02DEC91	28	09DEC91	35	16DEC91	42	23DEC91

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA OHS R&D
 REBOOTLINE - PROTOCOL 2012/4/013
 Listing No.: 5.0
 ASSESSMENT DATES AND NUMBER OF TREATMENT DAYS
 OPEN PHASE

Patient No.	Initials	Screen	Screen-Day0	Day0	Week1	Week1-Day0	Week2	Week2-Day0	Week3	Week3-Day0	Week4	Week4-Day0	Week5	Week5-Day0	Week6	Week6-Day0
9	FI	05NOV91	-6	11NOV91	18NOV91	7	25NOV91	14	02DEC91	21	09DEC91	28	16DEC91	35	23DEC91	42
10	BJ	19NOV91	-6	26NOV91	03DEC91	7	09DEC91	14	16DEC91	21	23DEC91	30	30DEC91	35	06JAN92	42
11	NGV	21NOV91	-14	05DEC91	12DEC91	7	19DEC91	14	26DEC91	21	02JAN92	28	09JAN92	35	16JAN92	42
12	PJ	09DEC91	-6	15DEC91	22DEC91	14	29DEC91	14	05JAN92	21	12JAN92	28	19JAN92	35	26JAN92	42
13	GC	06JAN92	-6	14JAN92	21JAN92	7	28JAN92	14	06FEB92	21	11FEB92	28	18FEB92	35	25FEB92	42
14	BJ	19JAN92	0	19JAN92	26JAN92	7	02FEB92	14	09FEB92	21	16FEB92	28	23FEB92	35	03MAR92	42
15	MF	26JAN92	0	02FEB92	09FEB92	7	16FEB92	14	23FEB92	21	03MAR92	28	09MAR92	35	16MAR92	42
16	NA	02FEB92	0	08FEB92	15FEB92	7	20FEB92	14	27FEB92	21	06MAR92	28	13MAR92	35	20MAR92	42
17	UZ	08FEB92	-6	09FEB92	16FEB92	7	23FEB92	14	01MAR92	21	08MAR92	28	15MAR92	35	22MAR92	42
18	EI	09FEB92	0	27FEB92	05MAR92	7	12MAR92	14	19MAR92	21	26MAR92	28	02APR92	35	09APR92	42
19	FK	27FEB92	0	01MAR92	08MAR92	7	15MAR92	14	22MAR92	21	29MAR92	28	05APR92	35	12APR92	42
20	LJ	01MAR92	0													

(continued)

Patient No.	Initials	Screen	Screen-Day0	Day0	Week1	Week1-Day0	Week2	Week2-Day0	Week3	Week3-Day0	Week4	Week4-Day0	Week5	Week5-Day0	Week6	Week6-Day0
1	IB	28OCT91	-2	30OCT91	06NOV91	7	13NOV91	14	20NOV91	21	27NOV91	28	04DEC91	35	11DEC91	42
2	EFC	29OCT91	-6	04NOV91	11NOV91	7	18NOV91	14	25NOV91	21	02DEC91	28	09DEC91	35	16DEC91	42
3	IF	26OCT91	-1	29OCT91	05NOV91	7	12NOV91	14	19NOV91	21	26NOV91	28	03DEC91	35	10DEC91	42
4	EG	30OCT91	-5	04NOV91	11NOV91	7	18NOV91	14	25NOV91	21	02DEC91	28	09DEC91	35	16DEC91	42
5	ZSH	04NOV91	0	04NOV91	08NOV91	7	15NOV91	14	22NOV91	21	29NOV91	28	06DEC91	35	13DEC91	41
6	HK	31OCT91	-1	01NOV91	08NOV91	7	15NOV91	14	22NOV91	21	29NOV91	28	06DEC91	35	13DEC91	42
7	LK	30OCT91	-5	04NOV91	11NOV91	7	18NOV91	14	25NOV91	21	02DEC91	28	09DEC91	35	16DEC91	42
8	PH	31OCT91	0	31OCT91	07NOV91	7	14NOV91	14	21NOV91	21	28NOV91	28	05DEC91	35	12DEC91	42
9	KBP	30OCT91	0	04NOV91	11NOV91	7	18NOV91	14	25NOV91	21	02DEC91	28	09DEC91	35	16DEC91	42
10	JP	04NOV91	0	30OCT91	06NOV91	7	13NOV91	14	20NOV91	21	27NOV91	28	04DEC91	35	11DEC91	42
11	ER	31OCT91	1	04NOV91	11NOV91	7	18NOV91	14	25NOV91	21	02DEC91	28	09DEC91	35	16DEC91	42
12	FSZ	04NOV91	0	04NOV91	11NOV91	7	18NOV91	14	25NOV91	21	02DEC91	28	09DEC91	35	16DEC91	42
13	ISZ	04NOV91	0	04NOV91	11NOV91	7	18NOV91	14	25NOV91	21	02DEC91	28	09DEC91	35	16DEC91	42
14	GSZ	05NOV91	0	05NOV91	12NOV91	7	19NOV91	14	26NOV91	21	03DEC91	28	10DEC91	35	17DEC91	42
15	GB	25NOV91	0	25NOV91	02DEC91	7	09DEC91	14	16DEC91	21	23DEC91	28	30DEC91	35	06JAN92	42
16	FN	10DEC91	0	14JAN92	21JAN92	7	28JAN92	14	04FEB92	21	11FEB92	28	18FEB92	35	25FEB92	42
17	TK	14JAN92	0	14JAN92	21JAN92	7	28JAN92	14	04FEB92	21	11FEB92	28	18FEB92	35	25FEB92	42
18	LS	15JAN92	0	15JAN92	22JAN92	7	29JAN92	14	05FEB92	21	12FEB92	28	19FEB92	35	26FEB92	42
19	SSZ	15JAN92	0	15JAN92	22JAN92	7	29JAN92	14	05FEB92	21	12FEB92	28	19FEB92	35	26FEB92	42
20	KSZ	16JAN92	0	16JAN92	23JAN92	7	30JAN92	14	06FEB92	21	13FEB92	28	20FEB92	35	27FEB92	42
21	FL	30JAN92	-3	27JAN92	06FEB92	7	17FEB92	14	24FEB92	21	03MAR92	28	10MAR92	35	17MAR92	42
22	MV	26JAN92	0	06FEB92	13FEB92	7	20FEB92	14	27FEB92	21	06MAR92	28	13MAR92	35	20MAR92	42
23	EW	04FEB92	0	07FEB92	14FEB92	7	21FEB92	14	28FEB92	21	06MAR92	28	13MAR92	35	20MAR92	42
24	MF	07FEB92	0	10FEB92	17FEB92	7	24FEB92	14	02MAR92	21	09MAR92	28	16MAR92	35	23MAR92	42
25	FS	14FEB92	0	17FEB92	24FEB92	7	03MAR92	14	10MAR92	21	17MAR92	28	24MAR92	35	31MAR92	42
26	LB	04FEB92	0	04FEB92	11FEB92	7	18FEB92	14	25FEB92	21	03MAR92	28	10MAR92	35	17MAR92	42

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REDDMETINE - PROTOCOL 2012/01/13
 Listing No.: 5.9

ASSESSMENT DATES AND NUMBER OF TREATMENT DAYS
 OPEN PHASE

Centrales12
 (continued)

Patient No.	Initials	Screen	Screen-Day0	Day0	Week1	Week1-Day0	Week2	Week2-Day0	Week3	Week3-Day0	Week4	Week4-Day0	Week5	Week5-Day0	Week6	Week6-Day0
27	VCS	06FEB92	-1	07FEB92	14FEB92	7	21FEB92	14	28FEB92	21	06MAR92	28	13MAR92	35	20MAR92	42
28	IV	07FEB92	0	07FEB92	14FEB92	7	21FEB92	14	28FEB92	21	06MAR92	28	13MAR92	35	20MAR92	42
29	AK	10FEB92	0	10FEB92	17FEB92	7	24FEB92	14	02MAR92	21	09MAR92	28	16MAR92	35	23MAR92	42
30	FS	24FEB92	0	24FEB92	02MAR92	7	09MAR92	14	16MAR92	21	23MAR92	28	30MAR92	35	06APR92	42
31	FR	29MAR92	-1	29MAR92	31MAR92	7	07APR92	14	14APR92	21	21APR92	28	28APR92	35	05MAY92	42
32	LN	01APR92	0	01APR92	08APR92	7	15APR92	14	22APR92	21	29APR92	28	06MAY92	35	13MAY92	42
33	LN	01APR92	0	01APR92	08APR92	7	15APR92	14	22APR92	21	29APR92	28	06MAY92	35	13MAY92	42
34	TGB	27MAR92	0	27MAR92	03APR92	7	10APR92	14	17APR92	21	24APR92	28	01MAY92	35	08MAY92	42
35	LP	27MAR92	0	27MAR92	03APR92	7	10APR92	14	17APR92	21	24APR92	28	01MAY92	35	08MAY92	42
36	FB	30MAR92	0	30MAR92	06APR92	7	13APR92	14	20APR92	21	27APR92	28	04MAY92	35	11MAY92	42
37	EK	05APR92	0	05APR92	12APR92	7	17APR92	14	24APR92	21	01MAY92	28	08MAY92	35	15MAY92	42
38	FG	06APR92	0	06APR92	13APR92	7	20APR92	14	27APR92	21	04MAY92	28	11MAY92	35	18MAY92	42

Centrales13

Patient No.	Initials	Screen	Screen-Day0	Day0	Week1	Week1-Day0	Week2	Week2-Day0	Week3	Week3-Day0	Week4	Week4-Day0	Week5	Week5-Day0	Week6	Week6-Day0
1	PZ	09OCT91	-6	15OCT91	22OCT91	7	29OCT91	14	05NOV91	21	12NOV91	28	19NOV91	35	26NOV91	42
2	TCS	08OCT91	-8	14OCT91	21OCT91	8	31OCT91	15	06NOV91	21	13NOV91	28	20NOV91	35	27NOV91	42
3	AI	08OCT91	-7	15OCT91	22OCT91	7	29OCT91	14	05NOV91	21	12NOV91	28	19NOV91	35	26NOV91	42
4	SZJ	09OCT91	-6	15OCT91	22OCT91	7	29OCT91	14	05NOV91	21	12NOV91	28	19NOV91	35	26NOV91	42
5	HF	10OCT91	-7	17OCT91	24OCT91	7	31OCT91	14	07NOV91	21	14NOV91	28	21NOV91	35	28NOV91	42
6	KE	11OCT91	-6	17OCT91	24OCT91	12	31OCT91	14	07NOV91	21	14NOV91	28	21NOV91	35	28NOV91	42
7	BL	09OCT91	-15	24OCT91	31OCT91	7	06NOV91	14	13NOV91	21	20NOV91	28	27NOV91	35	02DEC91	42
8	PK	15OCT91	-6	21OCT91	28OCT91	7	04NOV91	14	11NOV91	21	18NOV91	28	25NOV91	35	02DEC91	42
9	SZS	15OCT91	-6	21OCT91	28OCT91	7	04NOV91	14	11NOV91	21	18NOV91	28	25NOV91	35	02DEC91	42
10	BM	16OCT91	1	17OCT91	24OCT91	7	30OCT91	14	06NOV91	21	13NOV91	28	20NOV91	35	27NOV91	42
11	HS	17OCT91	-28	16NOV91	23NOV91	7	23NOV91	14	01DEC91	21	08DEC91	28	15DEC91	35	22DEC91	42
12	BF	21OCT91	-9	30OCT91	06NOV91	7	13NOV91	14	20NOV91	21	27NOV91	28	04DEC91	35	11DEC91	42
13	PH	20OCT91	-4	01NOV91	08NOV91	7	15NOV91	14	22NOV91	21	29NOV91	28	06DEC91	35	13DEC91	42
14	DF	28OCT91	-4	05NOV91	12NOV91	7	15NOV91	14	22NOV91	21	29NOV91	28	06DEC91	35	13DEC91	42
15	KG	28OCT91	-9	04NOV91	11NOV91	7	15NOV91	14	22NOV91	21	29NOV91	28	06DEC91	35	13DEC91	42
16	SZL	14NOV91	-5	19NOV91	26NOV91	7	03DEC91	14	10DEC91	21	17DEC91	28	24DEC91	35	31DEC91	42
17	GSM	15NOV91	-4	19NOV91	26NOV91	7	03DEC91	14	10DEC91	21	17DEC91	28	24DEC91	35	31DEC91	42
18	VT	26NOV91	-7	03DEC91	10DEC91	7	17DEC91	14	23DEC91	20	30DEC91	28	07JAN92	35	14JAN92	42
19	KK	25JAN92	0	25JAN92	01JAN92	7	08FEB92	14	15FEB92	21	22FEB92	28	01MAR92	35	08MAR92	42
20	NL	24JAN92	-5	26JAN92	02FEB92	7	11FEB92	14	18FEB92	21	25FEB92	28	04MAR92	35	11MAR92	42
21	CL	18FEB92	-5	18FEB92	25FEB92	7	03MAR92	14	10MAR92	21	17MAR92	28	24MAR92	35	31MAR92	42
22	NYM	08MAY92	0	08MAY92	15MAY92	7	19MAY92	14	26MAY92	21	02JUN92	28	09JUN92	35	16JUN92	42
23	BSB	08MAY92	-1	08MAY92	15MAY92	7	20MAY92	14	27MAY92	21	03JUN92	28	10JUN92	35	17JUN92	42

9550077

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBONETINE - PROTOCOL 20124/013
 Listing No.: 5.0
 ASSESSMENT DATES AND NUMBER OF TREATMENT DAYS
 DOUBLE BLIND PHASE

(continued)

Pat. No. (*)	Instit.	Week6	Week10	Week12	Week14	Week16	Week18	Week20	Week22	Week24
81/315	ASA	14	28	42	56	70	84	98	112	126
82/316	RIS	15	30	45	60	75	90	105	120	135
83/317	JFT	15	30	45	60	75	90	105	120	135
84/318	DWG	14	28	42	56	70	84	98	112	126
85/319	TAL	14	28	42	56	70	84	98	112	126
86/320	ASH	14	28	42	56	70	84	98	112	126
87/321	SPF	14	28	42	56	70	84	98	112	126
88/322	EH	14	28	42	56	70	84	98	112	126
89/323	HWC	14	28	42	56	70	84	98	112	126
90/324	MEA	14	28	42	56	70	84	98	112	126
91/325	EHF	14	28	42	56	70	84	98	112	126
92/326	TCG	13	27	41	55	69	83	97	111	125
93/327	MAA	14	28	42	56	70	84	98	112	126
94/328	MLH	14	28	42	56	70	84	98	112	126
95/329	OMV	14	28	42	56	70	84	98	112	126
96/330	RLJ	14	28	42	56	70	84	98	112	126
97/331	FMA	14	28	42	56	70	84	98	112	126
98/332	ELF	14	28	42	56	70	84	98	112	126
99/333	ACD	14	28	42	56	70	84	98	112	126
100/334	SFA	14	28	42	56	70	84	98	112	126
101/335	ACD	14	28	42	56	70	84	98	112	126
102/336	JCH	14	28	42	56	70	84	98	112	126
103/337	MEL	14	28	42	56	70	84	98	112	126
104/338	MEB	14	28	42	56	70	84	98	112	126
105/339	HDS	14	28	42	56	70	84	98	112	126
106/340	IN	14	28	42	56	70	84	98	112	126
107/341	RLP	14	28	42	56	70	84	98	112	126
108/342	HDD	14	28	42	56	70	84	98	112	126
109/343	MNV	14	28	42	56	70	84	98	112	126
110/344	JSS	14	28	42	56	70	84	98	112	126
111/345	MSC	14	28	42	56	70	84	98	112	126
112/346	AL	14	28	42	56	70	84	98	112	126
113/347	RAB	14	28	42	56	70	84	98	112	126
114/348	GHT	14	28	42	56	70	84	98	112	126
115/349	SPM	14	28	42	56	70	84	98	112	126
116/350	HMD	14	28	42	56	70	84	98	112	126
117/351	YTT	14	28	42	56	70	84	98	112	126
118/352	JNA	14	28	42	56	70	84	98	112	126
119/353	JLL	14	28	42	56	70	84	98	112	126
120/354	MTF	14	28	42	56	70	84	98	112	126
121/355	MTF	14	28	42	56	70	84	98	112	126
122/356	AS5	14	28	42	56	70	84	98	112	126
123/357	AS5	14	28	42	56	70	84	98	112	126
124/358	MKN	14	28	42	56	70	84	98	112	126
125/359	LAN	14	28	42	56	70	84	98	112	126

(*) PATIENT NO.: OPEN / DOUBLE BLIND

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBDMETINE - PROTOCOL 20124/013
Listing No.: 5.0

ASSESSMENT DATES AND NUMBER OF TREATMENT DAYS
DOUBLE BLIND PHASE

Centre=1
(continued)

Pat. No. (*)	Init.	Week8	Week10	Week12	Week14	Week16	Week18	Week20	Week22	Week24
108/148	STB	15APR92	20APR92	28APR92						
109/149	IPL	15APR92	20APR92	28APR92						
110/150	TOP	15APR92	20APR92	28APR92						
111/331	JBF	15APR92	20APR92	28APR92						
114/332	CLF	22APR92	28APR92							
115/335	ELS	22APR92	28APR92							
116/334	MR	22APR92	28APR92							
117/335	PSL	22APR92	28APR92							
121/336	LAC	22APR92	28APR92							
122/337	HSS	22APR92	28APR92							
123/338	HLI	22APR92	28APR92							
124/339	PPC	22APR92	28APR92							
125/340	FDP	22APR92	28APR92							
126/341	SMB	22APR92	28APR92							
127/342	VFD	22APR92	28APR92							
128/343	LAM	22APR92	28APR92							
129/344	MMS	22APR92	28APR92							
130/345	EGA	22APR92	28APR92							
131/346	JPH	15MAY92	29MAY92							
132/347	LPS	19MAY92	14JUN92							
133/348	AVP	19MAY92	14JUN92							
134/349	LVV	19MAY92	14JUN92							
135/350	RA	19MAY92	14JUN92							
136/351	MCA	19MAY92	14JUN92							
137/352	AMB	19MAY92	14JUN92							
138/353	SCC	19MAY92	14JUN92							
139/354	SEP	19MAY92	14JUN92							
140/355	ARF	20MAY92	28MAY92							
141/356	SUD	20MAY92	28MAY92							
142/357	LHR	20MAY92	28MAY92							
143/358	CAS	20MAY92	28MAY92							
144/359	SC	20MAY92	28MAY92							
145/360	VA	20MAY92	28MAY92							

Centre=3

Pat. No. (*)	Init.	Week8	Week10	Week12	Week14	Week16	Week18	Week20	Week22	Week24
2/41	FIL	11JAN91	20JAN91	28JAN91						
5/42	DUB	29MAY91	15JUN91	22JUN91						

(*) PATIENT NO.: OPEN / DOUBLE BLIND

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD
 REBOMETINE - PROTOCOL 20124/913
 Listing No.: 5.0
 ASSESSMENT DATES AND NUMBER OF TREATMENT DAYS
 DOUBLE BLIND PHASE

----- Centres 5 -----
 (continued)

Pat.No. (*)	Init.	Week0	Week2-Week6	Week10	Week10-Week6	Week12	Week12-Week6	Week14	Week14-Week6	Week16	Week16-Week6	Week18	Week18-Week6	Week20	Week20-Week6
2/71	OR	05FEB91	14	12FEB91	21	05JUL91	42	17JUL91	56	31JUL91	70	14AUG91	84	28AUG91	98
18/72	TR	05JUN91	14	15JUN91	26										

Pat.No. (*)	Init.	Week0	Week2-Week6	Week10	Week10-Week6	Week12	Week12-Week6	Week14	Week14-Week6	Week16	Week16-Week6	Week18	Week18-Week6	Week20	Week20-Week6
1/211	HJ	26JAN91	14	11FEB91	26	25FEB91	42	11MAR91	56	25MAR91	70	08APR91	84	22APR91	98
2/212	TE	07FEB91	14	21FEB91	26	07MAR91	42	21MAR91	56	04APR91	70	18APR91	84	02MAY91	98
3/213	JL	14FEB91	14	28FEB91	26	14MAR91	42	28MAR91	56	11APR91	70	25APR91	84	13MAY91	98
4/214	BA	07MAR91	14	21MAR91	26	06APR91	42	18APR91	56	09MAY91	70	19MAY91	84	30MAY91	98
5/215	SL	11MAR91	14												
6/216	TL	18MAR91	14	02APR91	27	15APR91	42	29APR91	56	13MAY91	70	27MAY91	84	10JUN91	98

9550077

----- Centres 8 -----

Pat.No. (*)	Init.	Week0	Week2-Week6	Week10	Week10-Week6	Week12	Week12-Week6	Week14	Week14-Week6	Week16	Week16-Week6	Week18	Week18-Week6	Week20	Week20-Week6
2/241	VGF	23JUL90	14	06AUG90	23	20AUG90	42	03SEP90	56	17SEP90	70	01OCT90	84	15OCT90	98
5/242	WF	17NOV90	14	01DEC90	26	15DEC90	42	29DEC90	56	12JAN91	70	26JAN91	84	09FEB91	98
6/245	SD	01JAN91	14	15JAN91	26	29JAN91	42	12FEB91	56	24FEB91	70	12MAR91	84	26MAR91	98
7/243	PP	03JAN91	14	17JAN91	26	31JAN91	42	14FEB91	56	28FEB91	70	14MAR91	84	28MAR91	98
8/244	KTM	14JAN91	14	30JAN91	26	13FEB91	42	27FEB91	56	13MAR91	70	27MAR91	84	10APR91	98
11/244	KE	24MAR91	14	08APR91	28	23APR91	42	07MAY91	56	21MAY91	70	06JUN91	84	16JUN91	98
12/242	GYT	20APR91	14	14MAY91	26	28MAY91	42	11JUN91	56	25JUN91	70	12JUL91	84	31JUL91	98
13/248	BP	08MAY91	14	22MAY91	26	05JUN91	42	19JUN91	56	03JUL91	70	22SEP91	84	06OCT91	98
15/249	BI	14JUL91	14	28JUL91	26	11AUG91	42	25AUG91	56	08SEP91	70	12NOV91	84	26NOV91	98
16/250	UBV	03SEP91	14	17SEP91	26	01OCT91	42	15OCT91	56	29OCT91	70	17DEC91	84	20NOV91	98
19/251	KP	08OCT91	14	22OCT91	26	05NOV91	42	19NOV91	56	13DEC91	70	27DEC91	84	20NOV91	98
20/252	DVE	16OCT91	14	01NOV91	26	15NOV91	42	29NOV91	56	13DEC91	70	27DEC91	84	20NOV91	98
23/254	SZN	03JAN92	14	17JAN92	26	31JAN92	42	14FEB92	56	28FEB92	70	16MAR92	84	27MAR92	98
24/253	LEV	06JAN92	14	20JAN92	26	03FEB92	42	17FEB92	56	02MAR92	70	16MAR92	84	30MAR92	98
25/254	PH	14JAN92	14	28JAN92	26	11FEB92	42	25FEB92	56	10MAR92	70	24MAR92	84	07APR92	98
26/255	CP	16JAN92	14	30JAN92	26	13FEB92	42	27FEB92	56	12MAR92	70	26MAR92	84	09APR92	98
28/257	HI	01JUN92	14	15JUN92	26	29JUN92	42	13JUL92	56	27JUL92	70	10AUG92	84	24AUG92	98
29/258	SZF	01JUN92	14	15JUN92	26	29JUN92	42	13JUL92	56	27JUL92	70	10AUG92	84	24AUG92	98
30/259	NF	01JUN92	14	15JUN92	26										

(*) PATIENT NO.: OPEN / DOUBLE BLIND

9550077

PHARMACIA CNS R&D
REBOWITINE - PROTODOL 2012/4/013
Listing No.: S.0
ASSESSMENT DATES AND NUMBER OF TREATMENT DAYS
DOUBLE BLIND PHASE

Centre#10

Table with columns: Pat. No., Initt., Week0-Week20, Week10-Week10, Week11-Week11, Week12-Week12, Week13-Week13, Week14-Week14, Week15-Week15, Week16-Week16, Week17-Week17, Week18-Week18, Week19-Week19, Week20-Week20, Week21-Week21, Week22-Week22. Rows list patient IDs and treatment dates.

(*): PATIENT NO.: OPEN / DOUBLE BLIND

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOMETINE - PROTOCOL 20124/013
Listing No.: E.9

ASSESSMENT DATES AND NUMBER OF TREATMENT DAYS
DOUBLE BLIND PHASE

Centre 10
(continued)

Pat. No. (*)	In.Lt.	Week0	Week1	Week2	Week3	Week4	Week5	Week6	Week7	Week8	Week9	Week10	Week11	Week12	Week13	Week14	Week15	Week16	Week17	Week18	Week19	Week20	Week21	Week22
56/46	UN	08MAR92	14	05APR92	28	15APR92	56	03MAY92	70	17MAY92	84	31MAY92	98											
56/49	TP	09MAR92	14	06APR92	28	20APR92	56	04MAY92	70	18MAY92	84	01JUN92	98											
56/50	JP	09MAR92	14	06APR92	28	20APR92	56	04MAY92	70	18MAY92	84	01JUN92	98											
57/51	AG	10MAR92	14	07APR92	28	21APR92	56	05MAY92	70	19MAY92	84	02JUN92	98											
56/52	KK	09MAR92	14	06APR92	28	20APR92	56	04MAY92	70	18MAY92	84	01JUN92	98											
57/53	TA	16MAR92	15	03MAY92	29																			
60/54	JM	16MAR92	15	03MAY92	29																			
61/55	JT	17MAR92	14	04MAY92	28	14APR92	42	28APR92	56	20MAY92	84	03JUN92	98											
62/56	RK	17MAR92	14	04MAY92	28	14APR92	42	28APR92	56	20MAY92	84	03JUN92	98											
63/57	RS	30MAR92	14	15APR92	28	27APR92	42	11MAY92	56	00JUN92	84	22JUN92	98											
64/58	LT	01APR92	14	19APR92	28	13MAY92	56	27MAY92	70	10JUN92	84	22JUN92	98											
61/46	JN	16APR92	14	30APR92	28	14MAY92	42	28MAY92	56	11JUN92	84	09JUL92	98											
62/59	LS	26APR92	14	04MAY92	28	18MAY92	42	01JUN92	56	15JUN92	84	15JUL92	98											
64/63	HV	05MAY92	14	19MAY92	28	02JUN92	42	18JUN92	58	30JUN92	84													
65/272	AK	05MAY92	14	19MAY92	28	02JUN92	42	18JUN92	58	30JUN92	84													
66/274	NP	13MAY92	14	27MAY92	28	13JUN92	42	24JUN92	56	08JUL92	84	05AUG92	98											
67/275	AN	13MAY92	14	27MAY92	28	13JUN92	42	24JUN92	56	08JUL92	84	05AUG92	98											
68/276	AM	13MAY92	14	27MAY92	28	13JUN92	42	24JUN92	56	08JUL92	84	05AUG92	98											
69/277	SK	14MAY92	14																					
90/70	SV	18MAY92	14	01JUN92	28	16JUN92	43	29JUN92	56	13JUL92	85	18AUG92	98											
91/74	PH	18MAY92	13	02JUN92	28	16JUN92	44	29JUN92	55	13JUL92	84	18AUG92	97											
92/73	LA	20MAY92	14	05JUN92	28	23JUN92	42	07JUL92	56	21JUL92	84	18AUG92	98											
93/285	AM	05JUN92	14	17JUN92	28	01JUL92	42	15JUL92	56	29JUL92	84	26AUG92	98											
94/273	PV	05JUN92	14	17JUN92	28	01JUL92	42	15JUL92	56	29JUL92	84	26AUG92	98											

716

Centre 11

Pat. No. (*)	In.Lt.	Week0	Week1	Week2	Week3	Week4	Week5	Week6	Week7	Week8	Week9	Week10	Week11	Week12	Week13	Week14	Week15	Week16	Week17	Week18	Week19	Week20	Week21	Week22
1/372	DF	05DEC91	14	20DEC91	28	05JAN92	42	17JAN92	56	31JAN92	84	14FEB92	98											
2/373	HB	05DEC91	14	20DEC91	28	05JAN92	42	17JAN92	56	02FEB92	70	16FEB92	84	01MAR92	98									
3/374	RF	09DEC91	14	23DEC91	28	09JAN92	42	23JAN92	56	06FEB92	70	20FEB92	84	05MAR92	98									
4/375	BA	12DEC91	14	26DEC91	28	07JAN92	42	21JAN92	56	09FEB92	70	18FEB92	84	03MAR92	98									
6/377	VP	18DEC91	14	02JAN92	28	15JAN92	42	25JAN92	56	12FEB92	70	24FEB92	84	11MAR92	98									
7/376	KK	18DEC91	14	02JAN92	28	15JAN92	42	25JAN92	56	12FEB92	70	24FEB92	84	11MAR92	98									
9/382	FI	06JAN92	14	20JAN92	28	03FEB92	42																	
10/383	BJ	26JAN92	14	09FEB92	28	17FEB92	42	02MAR92	56	16MAR92	70	30MAR92	84	13APR92	98									
11/381	MY	30JAN92	14	13FEB92	28	27FEB92	42	12MAR92	56	26MAR92	70	09APR92	84	23APR92	98									
12/384	PJ	09FEB92	14	23FEB92	28	08MAR92	42	22MAR92	56	05APR92	70	19APR92	84	03MAY92	98									
13/385	CK	10MAR92	14	24MAR92	28	07APR92	42	21APR92	56	08MAY92	70	19MAY92	84	02JUN92	98									
15/386	NF	24MAR92	14	07APR92	28	21APR92	42	05MAY92	56	19MAY92	70	02JUN92	84											

(*) PATIENT NO.: OPEN / DOUBLE BLIND

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOETINE - PROTOCOL 2012/013
 Listing No.: 5.0
 ASSESSMENT DATES AND NUMBER OF TREATMENT DAYS
 DOUBLE BLIND PHASE

Centre=11 (continued)

Pac.No. (*)	Init.	Week8	Week8-Week6	Week10	Week10-Week6	Week12	Week12-Week6	Week14	Week14-Week6	Week16	Week16-Week6	Week18	Week18-Week6	Week20	Week20-Week6
16/567	NA	29MAR92	14	12APR92	28	26APR92	42	10MAY92	56	20MAY92	70	07JUN92	84		
17/568	UZ	02APR92	14	16APR92	28	30APR92	42	14MAY92	56	24MAY92	70	11JUN92	84		
18/569	EL	05APR92	14	19APR92	28	03MAY92	42	17MAY92	56	31MAY92	70	14JUN92	84	25JUN92	98
19/570	FK	23APR92	14	07MAY92	28	21MAY92	42	06JUN92	56	18JUN92	70	02JUL92	84	16JUL92	98
20/571	LJ	26APR92	14	10MAY92	28	24MAY92	42	07JUN92	56						

Centre=12

Pac.No. (*)	Init.	Week8	Week8-Week6	Week10	Week10-Week6	Week12	Week12-Week6	Week14	Week14-Week6	Week16	Week16-Week6	Week18	Week18-Week6	Week20	Week20-Week6
1/92	IB	25DEC91	14	06JAN92	28	22JAN92	42	05FEB92	56	19FEB92	70	06MAR92	84	10MAR92	98
2/99	EFC	30DEC91	14	13JAN92	28	27JAN92	42	04FEB92	56	18FEB92	70	03MAR92	84	17MAR92	98
3/95	IF	24DEC91	14	07JAN92	28	21JAN92	42	04FEB92	56	20FEB92	70	09MAR92	84	23MAR92	98
4/100	EG	30DEC91	14	13JAN92	28	27JAN92	42	10FEB92	56	24FEB92	70	09MAR92	84		
5/95	ZSH	30DEC91	14	13JAN92	28	27JAN92	42	08FEB92	56	22FEB92	70	05MAR92	84		
6/96	HK	30DEC91	14	09JAN92	28	23JAN92	42	08FEB92	56	20FEB92	70	05MAR92	84	19MAR92	98
7/102	LK	30DEC91	14	15JAN92	28	27JAN92	42	10FEB92	56	24FEB92	70	09MAR92	84	23MAR92	98
9/91	KBP	25DEC91	14	06JAN92	28	22JAN92	42	05FEB92	56	19FEB92	70	04MAR92	84	18MAR92	98
10/96	IP	30DEC91	14	13JAN92	28	27JAN92	42	10FEB92	56	24FEB92	70	09MAR92	84	23MAR92	98
11/94	ER	25DEC91	14	06JAN92	28	22JAN92	42	10FEB92	56	24FEB92	70	09MAR92	84	23MAR92	98
12/97	FSZ	30DEC91	14	13JAN92	28	15JAN92	35								
13/103	ISZ	30DEC91	14	13JAN92	28	27JAN92	42								
14/101	GSZ	31DEC91	14	14JAN92	28	27JAN92	42								
15/104	OB	20JAN92	14	08FEB92	28	17FEB92	42	02MAR92	56	14MAR92	70	30MAR92	84	13APR92	98
16/105	FN	04FEB92	14	08FEB92	28	03MAR92	42	17MAR92	56	31MAR92	70	14APR92	84	28APR92	98
17/106	TK	10MAR92	14	24MAR92	28	09APR92	44	21APR92	58	05MAY92	72	19MAY92	86	02JUN92	98
18/109	LS	10MAR92	14	24MAR92	28	09APR92	42	21APR92	56	05MAY92	70	19MAY92	84	25MAY92	98
19/106	SSZ	11MAR92	14	25MAR92	28	09APR92	42	22APR92	56	07MAY92	70	21MAY92	84	06JUN92	98
20/107	KSZ	12MAR92	14	26MAR92	28	09APR92	42	23APR92	56	07MAY92	70	21MAY92	84	06JUN92	98
21/110	FL	21MAR92	14	05APR92	28	23APR92	42	07MAY92	56	21MAY92	70	04JUN92	84	18JUN92	98
22/111	MV	28MAR92	14	06APR92	28	23APR92	42	07MAY92	56	21MAY92	70	04JUN92	84	18JUN92	98
23/112	EN	02APR92	14	16APR92	28	30APR92	42	04MAY92	56	18MAY92	70	01JUN92	84	15JUN92	98
24/113	MF	17APR92	14	01MAY92	28	15MAY92	42	04MAY92	56	20MAY92	70	11JUN92	84	25JUN92	98
25/114	FS	06APR92	14	01MAY92	28	15MAY92	42	04MAY92	56	20MAY92	70	11JUN92	84	25JUN92	98
27/115	VCS	05APR92	14	20APR92	28	04MAY92	42	18MAY92	56	01JUN92	70	15JUN92	84	29JUN92	98
28/116	IV	05APR92	14	17APR92	28	01MAY92	42	15MAY92	56	29MAY92	70	12JUN92	84	26JUN92	98
29/117	AK	06APR92	14	20APR92	28	04MAY92	42	18MAY92	56	29MAY92	70	15JUN92	84	29JUN92	98
33/586	LN	27MAY92	14	19JUN92	28	04MAY92	42	18MAY92	56	29MAY92	70	15JUN92	84	29JUN92	98
34/120	TBB	22MAY92	14	15JUN92	28	24JUN92	42	08JUL92	56	22JUL92	70	05AUG92	84	19AUG92	98
35/119	LP	22MAY92	14	05JUN92	28	19JUN92	42	05JUL92	56	17JUL92	70	31JUL92	84	14AUG92	98
36/585	FB	25MAY92	14	08JUN92	28	22JUN92	42								

(*) PATIENT NO.: OPEN / DOUBLE BLIND

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD

REDBUQUETINE - PROTOCOL 20124/013
Listing No.: 5.0

ASSESSMENT DATES AND NUMBER OF TREATMENT DAYS
DOUBLE BLIND PHASE

Pat.No. (*)	Init.	Centre=12										Centre=13									
		Week8	Week8-Week6	Week10	Week10-Week8	Week12	Week12-Week10	Week14	Week14-Week12	Week16	Week16-Week14	Week18	Week18-Week16	Week20	Week20-Week18	Week22	Week22-Week20				
37/584	EK	29MAY92	14	12JUN92	28	26JUN92	42	18JUL92	56	26JUL92	70	07AUG92	84								
1/219	PZ	10DEC91	14	20DEC91	28	07JAN92	42	21JAN92	56	04FEB92	70	18FEB92	84	03MAR92	98						
2/224	TES	11DEC91	14	20DEC91	28	06JAN92	42	22JAN92	56	05FEB92	70	19FEB92	84	04MAR92	98						
3/221	AI	10DEC91	14	20DEC91	28	07JAN92	42	21JAN92	56	04FEB92	70	18FEB92	84	03MAR92	98						
6/226	KE	12DEC91	14	20DEC91	28	09JAN92	42	23JAN92	56	06FEB92	70	20FEB92	84	05MAR92	98						
7/220	BL	19DEC91	14	02JAN92	28	16JAN92	42	30JAN92	56	13FEB92	70	27FEB92	84	12MAR92	98						
8/228	PK	16DEC91	14	30DEC91	28	15JAN92	42	27JAN92	56	10FEB92	70	24FEB92	84	09MAR92	98						
9/229	SZS	16DEC91	14	30DEC91	28	15JAN92	42	27JAN92	56	10FEB92	70	24FEB92	84	09MAR92	98						
11/225	HS	09JAN92	14	25JAN92	28	08FEB92	42	20FEB92	56	05MAR92	70	19MAR92	84	02APR92	98						
13/225	HH	27DEC91	14	10JAN92	28	26JAN92	42	07FEB92	56	21FEB92	70	06MAR92	84	20MAR92	98						
14/217	DF	27DEC91	14	10JAN92	28	26JAN92	42	07FEB92	56	21FEB92	70	06MAR92	84	20MAR92	98						
15/222	KG	01JAN92	14	15JAN92	28	29JAN92	42	12FEB92	56	24FEB92	70	11MAR92	84	25MAR92	98						
17/218	GSH	14JAN92	14	28JAN92	28	11FEB92	42	25FEB92	56	10MAR92	70	24MAR92	84	07APR92	98						
18/227	VT	28JAN92	14	11FEB92	28	25FEB92	42	10MAR92	56	24MAR92	70	07APR92	84	21APR92	98						
20/230	NL	24MAR92	14	07APR92	28	21APR92	42	05MAY92	56	19MAY92	70	02JUN92	84	14JUN92	98						
21/231	CL	14APR92	14	28APR92	28	12MAY92	42	26MAY92	56	09JUN92	70	23JUN92	84	07JUL92	98						
22/232	NYH	30JUN92	14	14JUL92	28																

(continued)

(*) PATIENT NO.: OPEN / DOUBLE BLIND

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOMETINE - PROTOCOL 20124/013
Listing No.: 5.0

ASSESSMENT DATES AND NUMBER OF TREATMENT DAYS
DOUBLE BLIND PHASE

Centret1

Pct.No.	Init.	Week22	Week22	Week24	Week24	Week26	Week26	Week28	Week28	Week30	Week30	Week32	Week32	Week34	Week34	Week36	Week36
(*)		-Week6	-Week6	-Week6	-Week6												
1/1	MEA																
3/2	TA	19APR91	112	03MAY91	140	17MAY91	140	31MAY91	154	14JUN91	165	28JUN91	162	12JUL91	196	26JUL91	210
4/5	DA	24APR91	126	08MAY91	140	22MAY91	140	05JUN91	154	19JUN91	165	05JUL91	162	17JUL91	196	31JUL91	210
5/4	DB	09MAY91	113	31MAY91	140	04JUN91	140	18JUN91	154	02JUL91	165	16JUL91	162	30JUL91	196	13AUG91	210
6/5	CPM																
8/6	M05	10MAY91	112	26MAY91	140	07JUN91	140	21JUN91	154	09JUL91	165	07AUG91	162	21AUG91	196	04SEPT91	210
9/7	CRS	29MAY91	112	12JUN91	140	26JUN91	140	10JUL91	154	26JUL91	165	09AUG91	162	23AUG91	196	11OCT91	210
10/8	L0L	05JUL91	112	19JUL91	140	02AUG91	140	16AUG91	154	30AUG91	165	13SEP91	162	27SEP91	196	11OCT91	210
11/9	VRT	09AUG91	112	25AUG91	140	08SEP91	140	22SEP91	154	06OCT91	165	10OCT91	162	24OCT91	196	14NOV91	209
12/10	SLT	20AUG91	112	03SEP91	140	17SEP91	140	01OCT91	154	15OCT91	165	29OCT91	162	12NOV91	196	26NOV91	210
14/11	MIC																
15/12	MAD	09OCT91	112	25OCT91	140	08NOV91	140	22NOV91	154	06DEC91	165	10DEC91	162	24DEC91	197	16JAN92	211
16/13	MHC	16OCT91	112	01NOV91	139	14NOV91	139	29NOV91	154	13DEC91	165	27DEC91	162	10JAN92	196	24JAN92	210
17/14	CEC	22OCT91	112	05NOV91	140	19NOV91	140	03DEC91	154	17DEC91	165	31DEC91	162				
18/15	TTM																
19/16	SR	29OCT91	112	12NOV91	140	26NOV91	140	10DEC91	154	24DEC91	165	07JAN92	162	21JAN92	196	04FEB92	210
20/17	EFC																
21/18	VHC	09NOV91	112	19NOV91	140	03DEC91	140	17DEC91	154	31DEC91	165	14JAN92	162	28JAN92	196	11FEB92	210
22/19	SK	12NOV91	112	26NOV91	140	10DEC91	140	24DEC91	154	07JAN92	165	21JAN92	162	04FEB92	196	18FEB92	210
24/20	LVF	03DEC91	112	17DEC91	140	31DEC91	140	14JAN92	154	28JAN92	165	11FEB92	162	28FEB92	196	09MAR92	209
25/21	AHR	04DEC91	112	20DEC91	140	03JAN92	140	17JAN92	154	31JAN92	165	14FEB92	162	28FEB92	196	13MAR92	210
26/22	OC	10DEC91	112	24DEC91	140	07JAN92	140	21JAN92	154	04FEB92	165	18FEB92	162	04MAR92	197	17MAR92	210
27/23	RK																
28/24	RHM	17DEC91	112	31DEC91	140												
29/25	AFO	17DEC91	112	31DEC91	140	14JAN92	140	28JAN92	154	11FEB92	165	25FEB92	162	10MAR92	196	24MAR92	210
30/26	ERV																
31/27	MAM	24DEC91	112	07JAN92	140	21JAN92	140	04FEB92	154	18FEB92	165	04MAR92	162	17MAR92	196	31MAR92	210
32/28	DM	20DEC91	115	03JAN92	140	22JAN92	140	05FEB92	154	19FEB92	165	04MAR92	162	18MAR92	196	01APR92	210
33/29	OFC																
34/30	GHI	15JAN92	119	28JAN92	133	12FEB92	140	26FEB92	154	11MAR92	175	25MAR92	169	08APR92	203	22APR92	217
35/301	EMP	26JAN92	112	11FEB92	128	25FEB92	140	10MAR92	154	24MAR92	165	07APR92	162	22APR92	197	05MAY92	210
36/302	LM																
37/303	RF	04FEB92	112	18FEB92	128	05MAR92	140	17MAR92	154	31MAR92	165	14APR92	162	28APR92	196	12MAY92	210
38/304	DFE	18FEB92	112	04MAR92	127	17MAR92	140	31MAR92	154	14APR92	165	28APR92	162	16MAY92	196	29MAY92	210
39/305	ASB	25FEB92	112	10MAR92	126	24MAR92	140	07APR92	154	22APR92	165	05MAY92	162	19MAY92	196	02JUN92	210
40/306	EH	25FEB92	112	10MAR92	126	24MAR92	140	07APR92	154	22APR92	165	05MAY92	162	19MAY92	196	02JUN92	210
41/307	SFS	25FEB92	112	10MAR92	126	24MAR92	140	07APR92	154	22APR92	165	05MAY92	162	19MAY92	196	02JUN92	210
42/308	ICC	04MAR92	112	18MAR92	126	01APR92	140	15APR92	154	29APR92	165	13MAY92	162	27MAY92	196	10JUN92	210
43/309	ARN	04MAR92	112	18MAR92	126	01APR92	140	15APR92	154	29APR92	165	13MAY92	162	27MAY92	196	10JUN92	210
44/310	DPS	10MAR92	112	24MAR92	126	07APR92	140	22APR92	154	05MAY92	165	19MAY92	162	02JUN92	196	16JUN92	210
45/311	SP	17MAR92	112	31MAR92	126	14APR92	140	28APR92	154	12MAY92	165	26MAY92	162	09JUN92	196	25JUN92	210
47/312	MES	24MAR92	112	07APR92	126	22APR92	140	10MAY92	154	19MAY92	165	06JUN92	162	16JUN92	196	01JUL92	210
48/313	SDH	25MAR92	112	08APR92	126	22APR92	140	10MAY92	154	19MAY92	165	06JUN92	162	17JUN92	196	01JUL92	210
50/314	MFA	27MAR92	112	10APR92	126	24APR92	140	08MAY92	154	22MAY92	165	05JUN92	162	15JUN92	196	02JUL92	210

(*) PATIENT NO.: OPEN / DOUBLE BLIND

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD

REDBUETINE - PROTOCOL 20124/013

Listing No.: 5.0

ASSESSMENT DATES AND NUMBER OF TREATMENT DAYS
DOUBLE BLIND PHASE

(continued)

Pat. No. (*)	Init.	Week22		Week24		Week26		Week28		Week30		Week32		Week34		Week36	
		-Week6	Week22	-Week6	Week24	-Week6	Week26	-Week6	Week28	-Week6	Week30	-Week6	Week32	-Week6	Week34	-Week6	Week36
51/015	ASA	27MAR92	112	10APR92	125	26APR92	140	09MAY92	154	22MAY92	168	05JUN92	182	19JUN92	196	05JUL92	210
52/016	MTS	01APR92	112	15APR92	125	29APR92	140	13MAY92	154	27MAY92	168	10JUN92	182	24JUN92	196	08JUL92	210
53/017	JFT	01APR92	112														
55/018	DWG																
56/019	IAL																
58/020	ARM																
59/021	SFF	19MAY92	112	02JUN92	125	16JUN92	140	30JUN92	154	14JUL92	168	28JUL92	182	11AUG92	196	25AUG92	210
60/022	EH	22MAY92	112	05JUN92	125	19JUN92	140	03JUL92	154	17JUL92	168	31JUL92	182	14AUG92	196	28AUG92	210
61/023	HOC	28MAY92	112	05JUN92	125	19JUN92	140	03JUL92	154	17JUL92	168	31JUL92	182	14AUG92	196	28AUG92	210
62/024	HEA	05JUN92	112	25JUN92	125	09JUL92	140	21JUL92	154	04AUG92	168	18AUG92	182	01SEP92	196	15SEP92	210
64/025	EDF	13JUN92	112	05JUL92	125	17JUL92	140	31JUL92	154	14AUG92	168	28AUG92	182	11SEP92	196	25SEP92	210
66/026	TGD	25JUN92	111	07JUL92	125	21JUL92	139	04AUG92	153	18AUG92	167	01SEP92	181	15SEP92	195	29SEP92	209
67/027	MMA	25JUN92	111	07JUL92	125	21JUL92	139										
70/028	MLH	26JUN92	112														
71/029	DNV	30JUN92	112	14JUL92	125	28JUL92	140	11AUG92	154	25AUG92	168	08SEP92	182	22SEP92	196	06OCT92	210
72/030	RLJ	30JUN92	112														
73/031	FPA	30JUN92	112	14JUL92	125	28JUL92	140										
74/032	IVL	30JUN92	112	14JUL92	125	28JUL92	140										
75/033	ELF	03JUL92	112	17JUL92	125	31JUL92	140	14AUG92	154	28AUG92	168	11SEP92	182	25SEP92	196	09OCT92	210
76/034	SFA	10JUL92	112	24JUL92	125	07AUG92	140	21AUG92	154	04SEP92	168	18SEP92	182	02OCT92	196	16OCT92	210
77/035	ACD	10JUL92	112	24JUL92	125	07AUG92	140	21AUG92	154	04SEP92	168	18SEP92	182	02OCT92	196	16OCT92	210
79/036	JCH	10JUL92	112	24JUL92	125	07AUG92	140	21AUG92	154	04SEP92	168	18SEP92	182	02OCT92	196	16OCT92	210
80/037	HEL																
81/038	MFH	10JUL92	112	24JUL92	125	07AUG92	140	21AUG92	154	04SEP92	168	18SEP92	182	02OCT92	196	16OCT92	210
82/039	MDS	10JUL92	112	24JUL92	125	07AUG92	140	21AUG92	154	04SEP92	168	18SEP92	182	02OCT92	196	16OCT92	210
84/040	IN	10JUL92	112	24JUL92	125	07AUG92	140	21AUG92	154	04SEP92	168	18SEP92	182	02OCT92	196	16OCT92	210
85/041	MLP	10JUL92	112	24JUL92	125	07AUG92	140	21AUG92	154	04SEP92	168	18SEP92	182	02OCT92	196	16OCT92	210
87/042	MDD	10JUL92	112														
89/043	NMV																
90/044	JSS																
91/045	NSC	14JUL92	112	26JUL92	125	11AUG92	140	25AUG92	154	08SEP92	168	22SEP92	182	06OCT92	196	20OCT92	210
93/046	AL	15JUL92	112	29JUL92	125	12AUG92	140	26AUG92	154	09SEP92	168	23SEP92	182	07OCT92	196	21OCT92	210
94/047	RAB	15JUL92	112	29JUL92	125	12AUG92	140	26AUG92	154	09SEP92	168	23SEP92	182	07OCT92	196	21OCT92	210
95/048	GMT	15JUL92	112	29JUL92	125	12AUG92	140	26AUG92	154	09SEP92	168	23SEP92	182	07OCT92	196	21OCT92	210
96/049	SPM	15JUL92	112	29JUL92	125	12AUG92	140	26AUG92	154	09SEP92	168	23SEP92	182	07OCT92	196	21OCT92	210
97/050	MDD	15JUL92	112	29JUL92	125	12AUG92	140	26AUG92	154	09SEP92	168	23SEP92	182	07OCT92	196	21OCT92	210
98/051	YTT	15JUL92	112	29JUL92	125	12AUG92	140	26AUG92	154	09SEP92	168	23SEP92	182	07OCT92	196	21OCT92	210
100/052	JNA	15JUL92	112	29JUL92	125	12AUG92	140	26AUG92	154	09SEP92	168	23SEP92	182	07OCT92	196	21OCT92	210
101/053	JLL	21JUL92	112	04AUG92	125	18AUG92	141	01SEP92	154	15SEP92	168	30SEP92	182	15OCT92	196	27OCT92	210
104/054	HTF	21JUL92	112	04AUG92	125	18AUG92	141	01SEP92	154	15SEP92	168	30SEP92	182	15OCT92	196	27OCT92	210
105/055	ABS	21JUL92	112	04AUG92	125	18AUG92	141	01SEP92	154	15SEP92	168	30SEP92	182	15OCT92	196	27OCT92	210
106/056	MKN	21JUL92	112	04AUG92	125	18AUG92	141	01SEP92	154	15SEP92	168	30SEP92	182	15OCT92	196	27OCT92	210
107/057	LAN	22JUL92	112	04AUG92	125	18AUG92	139	01SEP92	153	15SEP92	167	29SEP92	181	15OCT92	195	27OCT92	209

(*) PATIENT NO.: OPEN / DOUBLE BLIND

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REDBETINE - PROTOCOL 20124/115
Listing No.: 5.0

ASSESSMENT DATES AND NUMBER OF TREATMENT DAYS
DOUBLE BLIND PHASE

(continued)

Pat.No. (*)	Init.	Week22		Week24		Week26		Week28		Week30		Week32		Week34		Week36	
		-Week6	Week22	-Week6	Week24	-Week6	Week26	-Week6	Week28	-Week6	Week30	-Week6	Week32	-Week6	Week34	-Week6	Week36
180/140	STB	22JUL92	112	05AUG92	126	19AUG92	140	02SEP92	154	16SEP92	168	30SEP92	182	14OCT92	196	28OCT92	210
189/149	IFL	22JUL92	112	05AUG92	126	19AUG92	140	02SEP92	154	16SEP92	168	30SEP92	182	14OCT92	196	28OCT92	210
110/150	TOO	22JUL92	112	05AUG92	126	19AUG92	140	02SEP92	154	16SEP92	168	30SEP92	182	14OCT92	196	28OCT92	210
111/151	JBF	22JUL92	112	05AUG92	126	19AUG92	140	02SEP92	154	16SEP92	168	30SEP92	182	14OCT92	196	28OCT92	210
114/152	CLF	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
115/153	ELS	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
116/154	MEA	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
117/155	PSL	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
120/156	LAC	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
122/157	MS	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
123/158	PHL	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
124/159	PPC	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
125/160	FDP	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
126/161	SHB	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
127/162	VFD	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
128/163	LAM	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
129/164	MNS	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
130/165	EGA	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
131/166	JPM	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
132/167	LHS	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
133/168	LHS	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
134/169	LHS	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
135/170	MNS	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
136/171	AVP	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
137/172	LBV	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
138/173	RA	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
139/174	RA	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
140/175	MCA	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
141/176	AMG	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
142/177	SCC	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
143/178	JEP	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
144/179	ANF	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
145/180	SLD	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
146/181	LBW	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
146/182	CAS	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
146/183	SCS	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
146/184	SC	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211
146/185	VA	28JUL92	127	24AUG92	141	07SEP92	155	23SEP92	169	07OCT92	183	21OCT92	197	04NOV92	211	04NOV92	211

Centre=1

Centre=3

Pat.No. (*)	Init.	Week24		Week26		Week28		Week30		Week32		Week34		Week36			
		-Week6	Week24	-Week6	Week26	-Week6	Week28	-Week6	Week30	-Week6	Week32	-Week6	Week34	-Week6	Week36		
2/61	FIL	18APR91	111	02MAY91	125	16MAY91	139	30MAY91	153	15JUN91	169	27JUN91	181	11JUL91	195	25JUL91	209
3/62	DUB	04SEP91	113	18SEP91	127												

(*): PATIENT NO.: OPEN / DOUBLE BLIND

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS 18D

REBOMETINE - PROTOCOL 20124/013
Listing No.: 5.0

ASSESSMENT DATES AND NUMBER OF TREATMENT DAYS
DOUBLE BLIND PHASE

Pat.No. (*)	Init.	Week22		Week24		Week26		Week28		Week30		Week32		Week34		Week36	
		-Week6	-Week6														
7/71	ORI	11SEP91	112
10/72	TOK
----- Centres3 -----																	
(continued)																	
----- Centres8 -----																	
1/211	HJ	06MAY91	112	20MAY91	126	05JUN91	140	17JUN91	154	01JUL91	168	15JUL91	182	29JUL91	196	12AUG91	210
2/212	TE	10MAY91	112	30MAY91	126	13JUN91	140	27JUN91	154	11JUL91	168	25JUL91	182	08AUG91	196	22AUG91	210
3/213	JL
4/214	BA	13JUN91	112	27JUN91	126	11JUL91	140	25JUL91	154	08AUG91	168	22AUG91	182	05SEP91	196	19SEP91	210
5/215	SL
6/216	TL	24JUN91	112	08JUL91	126	22JUL91	140	05AUG91	154	19AUG91	168	02SEP91	182	16SEP91	196	30SEP91	210
----- Centres9 -----																	
2/241	VCF	29OCT90	112	12NOV90	126	26NOV90	140	10DEC90	154	24DEC90	168	07JAN91	182	21JAN91	196	04FEB91	210
5/242	MF	23FEB91	112	09MAR91	126	23MAR91	140	06APR91	154	20APR91	168	04MAY91	182	18MAY91	196	01JUN91	210
6/245	SD	09APR91	112	23APR91	126	07MAY91	140	21MAY91	154	04JUN91	168	18JUN91	182	02JUL91	196	16JUL91	210
7/243	PP	11APR91	112	25APR91	126	09MAY91	140	23MAY91	154	06JUN91	168	20JUN91	182	04JUL91	196	18JUL91	210
8/244	KTM	24APR91	112	08MAY91	126
11/246	KE	02JUL91	112	16JUL91	126	30JUL91	140	13AUG91	154	27AUG91	168	10SEP91	182	24SEP91	196	08OCT91	210
12/247	OVT
13/248	BP	14AUG91	.	.	126	11SEP91	140	25SEP91	154	09OCT91	168	23OCT91	182	06NOV91	196	20NOV91	210
15/249	BI	20OCT91	112	03NOV91	126	17NOV91	140	01DEC91	154	15DEC91	168	29DEC91	182	12JAN92	196	26JAN92	210
16/250	URY	10DEC91	112	24DEC91	126	07JAN92	140	21JAN92	154	04FEB92	168	18FEB92	182	03MAR92	196	17MAR92	210
19/251	KF
20/252	OYE
23/253	SZN
24/254	LVY
25/254	PH	21APR92	112	05MAY92	126	19MAY92	140	02JUN92	154	16JUN92	168	30JUN92	182	14JUL92	196	28JUL92	210
26/255	CP	23APR92	112
28/257	HI	07SEP92	112	21SEP92	126	05OCT92	140	19OCT92	154
29/258	SZF	07SEP92	112	21SEP92	126	05OCT92	140	19OCT92	154
30/259	NF

(*) PATIENT NO.: OPEN / DOUBLE BLIND

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOMETINE - PROTOCOL 20124/913

Listing No.: 5.0

ASSESSMENT DATES AND NUMBER OF TREATMENT DAYS
DOUBLE BLIND PHASE

Centre#18

Pat. No. (*)	Init.	Week22		Week24		Week26		Week28		Week30		Week32		Week34		Week36	
		-Week6	Week6														
1/271	VK																
4/222	ZSD																
5/225	AN																
7/224	RK																
9/225	RT																
10/226	MH																
12/227	EP																
15/228	HU																
16/229	AA																
15/230	HT																
16/281	AJ																
17/282	MH																
19/284	TN																
20/285	EJ																
21/286	AK																
22/286	AA																
23/287	LT																
24/289	AL																
26/290	JIF																
27/292	MK																
28/291	LL																
29/293	JJ																
30/294	VK																
31/297	RK																
32/299	LK																
33/300	EK																
34/31	TK																
35/35	JH																
37/32	MK																
38/37	LL																
39/40	VH																
40/33	AP																
41/42	VP																
42/45	TT																
43/296	JK																
44/296	AB																
45/34	KJ																
46/28	TH																
47/39	TH																
48/41	IP																
49/43	VH																
50/44	EE																
51/45	UL																
55/47	MA																

(*) PATIENT NO.: OPEN / DOUBLE BLIND

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS 880

REBOWETINE - PROTOCOL 20124/013

Listing No.: 5.0

ASSESSMENT DATES AND NUMBER OF TREATMENT DAYS
DOUBLE BLIND PHASE

(continued)

Pat.No. (*)	Init.	Week22		Week24		Week26		Week28		Week30		Week32		Week34		Week36	
		-Week6	Week22	-Week6	Week24	-Week6	Week26	-Week6	Week28	-Week6	Week30	-Week6	Week32	-Week6	Week34	-Week6	Week36
54/48	UN	14JUN92	112	26JUN92	126	12JUL92	140	26JUL92	154	09AUG92	168	23AUG92	182	06SEP92	196	20SEP92	210
55/49	TP	15JUN92	112	29JUN92	126	13JUL92	140	27JUL92	154	10AUG92	168	24AUG92	182	07SEP92	196	21SEP92	210
56/50	JP																
57/51	AK	14JUN92	112	30JUN92	126	14JUN92	140	28JUL92	154	11AUG92	168	25AUG92	182	08SEP92	196	22SEP92	210
58/52	KK	15JUN92	115	30JUN92	127	15JUL92	140	29JUL92	155	11AUG92	169	25AUG92	183	08SEP92	197	21SEP92	210
59/53	TA																
60/54	JH																
61/55	JT																
62/56	RK	23JUN92	112	07JUL92	126	21JUL92	140	04AUG92	154	18AUG92	168	01SEP92	182				
63/57	MS	06JUL92	112	20JUL92	126	05AUG92	140	17AUG92	154	31AUG92	168	14SEP92	182	28SEP92	196	12OCT92	210
64/58	LT																
61/46	JN	23JUL92	112	06AUG92	126	20AUG92	140	03SEP92	154	17SEP92	168	01OCT92	182	15OCT92	196	29OCT92	210
62/59	LS	27JUL92	112	19AUG92	126	24AUG92	140	07SEP92	154	21SEP92	168	05OCT92	182	19OCT92	196	02NOV92	210
64/63	HV																
65/272	AK																
66/274	NP																
67/275	AN	19AUG92	112	02SEP92	126	16SEP92	140	30SEP92	154	14OCT92	168	28OCT92	182	11NOV92	196	25NOV92	210
68/276	AH	19AUG92	112	02SEP92	126	16SEP92	140	30SEP92	154	14OCT92	168	28OCT92	182	11NOV92	196	25NOV92	210
69/277	SK																
90/78	SV	24AUG92	112	07SEP92	126	21SEP92	140	21SEP92	154	19OCT92	167						
91/74	HI	24AUG92	111	08SEP92	126	22SEP92	140	05OCT92	153	19OCT92	167						
92/73	LA	01SEP92	112	15SEP92	126	29SEP92	140	13OCT92	154	27OCT92	168	10NOV92	182	24NOV92	196	08DEC92	210
93/285	AN	09SEP92	112	23SEP92	126	07OCT92	140	21OCT92	154	04NOV92	168	18NOV92	182	02DEC92	196	16DEC92	210
94/273	PV																

(continued)

Pat.No. (*)	Init.	Week22		Week24		Week26		Week28		Week30		Week32		Week34		Week36	
		-Week6	Week22	-Week6	Week24	-Week6	Week26	-Week6	Week28	-Week6	Week30	-Week6	Week32	-Week6	Week34	-Week6	Week36
1/322	DF	13MAR92	112	27MAR92	126	10APR92	140	24APR92	154	08MAY92	168	22MAY92	182	05JUN92	196		
2/323	HB	13MAR92	112	29MAR92	126	12APR92	140	26APR92	154	10MAY92	168						
3/324	RF																
4/325	BA	15MAR92	106														
6/327	VP	17MAR92	112	31MAR92	126	14APR92	140	26APR92	154	12MAY92	168	24MAY92	182	07JUN92	196	25JUN92	210
7/326	KK	28MAR92	112	09APR92	126	22APR92	140	06MAY92	154	20MAY92	168	03JUN92	182	17JUN92	196	01JUL92	210
9/362	FI																
10/363	BJ	27APR92	112	11MAY92	126	25MAY92	140	08JUN92	154	22JUN92	168	06JUL92	182	20JUL92	196	05AUG92	210
11/361	NSY	07MAY92	112	19MAY92	124												
12/364	PJ	17MAY92	112	31MAY92	126	14JUN92	140	28JUN92	154	12JUL92	168	26JUL92	182	09AUG92	196	25AUG92	210
13/365	GK																
15/366	NF																

(*) PATIENT NO.: OPEN / DOUBLE BLIND

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOMETINE - PROTOCOL 20124/113

Listing No.: 5.0

ASSESSMENT DATES AND NUMBER OF TREATMENT DAYS
DOUBLE BLIND PHASE

Centre=11

(continued)

Pat.No. (*)	Init.	Week22		Week24		Week26		Week28		Week30		Week32		Week34		Week36	
		-Weeks	Week22	-Weeks	Week24	-Weeks	Week26	-Weeks	Week28	-Weeks	Week30	-Weeks	Week32	-Weeks	Week34	-Weeks	Week36
16/257	NA																
17/256	UZ	09JUL92	112	23JUL92	126	06AUG92	140	20AUG92	154	03SEP92	168	17SEP92	182	01OCT92	196	15OCT92	210
18/269	EI	12JUL92	112	26JUL92	126	09AUG92	140	23AUG92	154	06SEP92	168	20SEP92	182	04OCT92	196	18OCT92	210
19/270	PK	30JUL92	112	13AUG92	126	27AUG92	140	10SEP92	154	24SEP92	168	08OCT92	182	22OCT92	196	05NOV92	210
20/271	LJ																

Centre=12

Pat.No. (*)	Init.	Week22		Week24		Week26		Week28		Week30		Week32		Week34		Week36	
		-Weeks	Week22	-Weeks	Week24	-Weeks	Week26	-Weeks	Week28	-Weeks	Week30	-Weeks	Week32	-Weeks	Week34	-Weeks	Week36
1/92	IB	01APR92	112	15APR92	126	29APR92	140	13MAY92	154	27MAY92	168	10JUN92	182	24JUN92	196	08JUL92	210
2/99	EFC																
3/95	IF	31MAR92	112	14APR92	126	28APR92	140	12MAY92	154	26MAY92	168	09JUN92	182	23JUN92	196	07JUL92	210
4/100	EG	06APR92	112	21APR92	127	06MAY92	140	18MAY92	154								
5/95	ZSH																
6/95	MK	02APR92	112	16APR92	126	30APR92	140	14MAY92	154	28MAY92	168						
7/102	LK	06APR92	112	20APR92	126	04MAY92	140	18MAY92	154								
9/91	KBP	01APR92	112	15APR92	126	29APR92	140	13MAY92	154								
10/96	IP	06APR92	112	20APR92	126												
11/94	ER																
12/97	F52																
13/103	I52																
14/101	6S2																
15/104	0B	27APR92	112	11MAY92	126	25MAY92	140										
16/105	FN	12MAY92	112	26MAY92	126	09JUN92	140										
17/106	TK	16JUN92	112	30JUN92	126	14JUL92	140	28JUL92	154								
18/109	LS																
19/106	SS2																
20/107	K52	16JUN92	112	02JUL92	126	16JUL92	140	30JUL92	154								
21/110	FL																
22/111	MV	29JUN92	112	13JUL92	126	27JUL92	140	10AUG92	154	24AUG92	168	07SEP92	182	21SEP92	196	05OCT92	210
23/112	EN	09JUL92	112	23JUL92	126	06AUG92	140	20AUG92	154								
24/113	WF	24JUL92	126	07AUG92	140	21AUG92	154	04SEP92	168								
25/114	PS	18JUL92	112	01AUG92	126	15AUG92	140	29AUG92	154	07SEP92	168	21SEP92	182	05OCT92	196	19OCT92	210
27/115	VCS	16JUL92	112	24JUL92	126	07AUG92	140	21AUG92	154	04SEP92	168	18SEP92	182	02OCT92	196		
28/116	IV																
29/117	AK	13JUL92	112	27JUL92	126	10AUG92	140	24AUG92	154	07SEP92	168	21SEP92	182	09OCT92	196	19OCT92	210
33/286	LN																
34/120	T6B	28AUG92	112	11SEP92	126	25SEP92	140	09OCT92	154	23OCT92	168	16NOV92	182	20NOV92	196	04DEC92	210
35/119	LP																
36/385	FB																

(*) PATIENT NO.: OPEN / DOUBLE BLIND

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CIS RBD

REDBUXTINE - PROTOCOL 2012/4/013

Listing No.: 5.0

ASSESSMENT DATES AND NUMBER OF TREATMENT DAYS
DOUBLE BLIND PHASE

Pat. No. (*)	Init.	Centrep12										Centrep13									
		Week22 -Week6	Week22	Week24 -Week6	Week24	Week26 -Week6	Week26	Week28 -Week6	Week28	Week30 -Week6	Week30	Week32 -Week6	Week32	Week34 -Week6	Week34	Week36 -Week6	Week36	Week38 -Week6	Week38		
37/256	EX																				
1/219	PZ	17MAR92	112	31MAR92	126	14APR92	140	28APR92	154	12MAY92	168	26MAY92	182	09JUN92	196	23JUN92	210				
2/224	TCS	18MAR92	112	01APR92	126	15APR92	140	29APR92	154	13MAY92	168	27MAY92	182	10JUN92	196	24JUN92	210				
3/221	AI	17MAR92	112	31MAR92	126	14APR92	140	28APR92	154	12MAY92	168	26MAY92	182	09JUN92	196	23JUN92	210				
6/226	KE	19MAR92	112	02APR92	126	16APR92	140	30APR92	154	14MAY92	168	28MAY92	182	11JUN92	196	25JUN92	210				
7/220	BL	26MAR92	112	06APR92	126	22APR92	139	06MAY92	153	20MAY92	167	03JUN92	181	17JUN92	195	01JUL92	209				
8/226	PK	23MAR92	112	06APR92	126	20APR92	140	04MAY92	154	18MAY92	168										
9/223	SZS																				
11/225	HS	16APR92	112	30APR92	126	14MAY92	140	28MAY92	154	11JUN92	168	25JUN92	182	09JUL92	196	23JUL92	210				
13/233	HH	03APR92	112	17APR92	126	01MAY92	140	15MAY92	154	29MAY92	168	12JUN92	182	26JUN92	196	10JUL92	210				
14/217	DF	03APR92	112	17APR92	126	01MAY92	140	15MAY92	154	29MAY92	168	12JUN92	182	26JUN92	196	10JUL92	210				
15/222	KG	06APR92	112	22APR92	126	06MAY92	140	20MAY92	154	03JUN92	168	17JUN92	182	01JUL92	196	15JUL92	210				
17/218	GSM	21APR92	112	05MAY92	126	19MAY92	140	02JUN92	154	16JUN92	168	30JUN92	182	14JUL92	196	28JUL92	210				
18/227	VT	05MAY92	112	19MAY92	126	02JUN92	140	16JUN92	154	30JUN92	168	14JUL92	182	28JUL92	196	11AUG92	210				
20/230	NL	30JUN92	112	14JUL92	126	28JUL92	140	11AUG92	154	25AUG92	168	08SEP92	182	22SEP92	196	06OCT92	210				
21/231	CL	21JUL92	112	04AUG92	126	18AUG92	140	01SEP92	154	15SEP92	168	29SEP92	182	18OCT92	196	27OCT92	210				
22/232	NYM																				

(*) PATIENT NO.: OPEN / DOUBLE BLIND

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBNETINE - PROTOCOL 20124/013
Listing No.: 5.0

ASSESSMENT DATES AND NUMBER OF TREATMENT DAYS
DOUBLE BLIND PHASE

Pat.No. [*]	Init.	Week35		Week40		Week42		Week44		Week46		Week48		Week50		Week52	
		Week35	-Week35	Week40	-Week40	Week42	-Week42	Week44	-Week44	Week46	-Week46	Week48	-Week48	Week50	-Week50	Week52	-Week52
1/1	MGA	09AUG91	224	23AUG91	258	06SEP91	252	20SEP91	266	04OCT91	280	18OCT91	294	01NOV91	308	14NOV91	322
5/2	TA	14AUG91	224	26AUG91	258	11SEP91	252	25SEP91	266	09OCT91	280	23OCT91	294	06NOV91	308	20NOV91	322
4/3	DNC	27AUG91	224	10SEP91	258	26SEP91	252	09OCT91	266	22OCT91	280	05NOV91	294	19NOV91	308	03DEC91	322
6/4	CPH																
8/6	MUS																
9/7	CCR	14SEP91	224	02OCT91	258	16OCT91	252	30OCT91	266	13NOV91	280	27NOV91	294	11DEC91	308	24DEC91	322
10/8	LDL	25OCT91	224	08NOV91	258	22NOV91	252	06DEC91	266	20DEC91	280	03JAN92	294	17JAN92	308	31JAN92	322
11/9	VKT	10DEC91	224	20DEC91	258	07JAN92	252	21JAN92	266	04FEB92	280	18FEB92	294	04MAR92	308	17MAR92	322
14/11	PLC	30JAN92	224	12FEB92	258	26FEB92	252	11MAR92	266	28MAR92	280	05APR92	294	22APR92	308	06MAY92	322
15/12	MAD	07FEB92	224	21FEB92	258												
16/13	MHC																
17/14	CEC																
18/15	TTM																
19/16	SR	10FEB92	224														
20/17	EFC																
21/18	VMC	25FEB92	224	10MAR92	258	24MAR92	252	07APR92	266	22APR92	280	06MAY92	294	19MAY92	308	02JUN92	322
22/19	SK	04MAR92	224	17MAR92	258	31MAR92	252	14APR92	266	26APR92	280	12MAY92	294	26MAY92	308	09JUN92	322
26/20	LVF	23MAR92	224	07APR92	258	22APR92	252	05MAY92	266	19MAY92	280	02JUN92	294	16JUN92	308	03JUL92	322
25/21	AMR	27MAR92	224	10APR92	258	24APR92	252	08MAY92	266	22MAY92	280	05JUN92	294	19JUN92	308	03JUL92	322
26/22	OC	31MAR92	224	14APR92	258	28APR92	252	12MAY92	266	26MAY92	280	09JUN92	294	23JUN92	308	07JUL92	322
27/23	RK																
28/24	RHM																
29/25	AFO	07APR92	224	22APR92	258	05MAY92	252	19MAY92	266	02JUN92	280	16JUN92	294	30JUN92	308	14JUL92	322
30/26	ERV																
31/27	MAM	14APR92	224	26APR92	258	12MAY92	252	26MAY92	266	09JUN92	280	23JUN92	294	07JUL92	308	21JUL92	322
32/28	DBM	15APR92	224	29APR92	258	13MAY92	252	27MAY92	266	10JUN92	280	24JUN92	294	08JUL92	308	22JUL92	322
33/29	DFC																
34/30	GMI	09MAY92	224	20MAY92	258	03JUN92	252	17JUN92	266	01JUL92	280	15JUL92	301	29JUL92	315	12AUG92	329
35/301	EPH	19MAY92	224	02JUN92	258	16JUN92	252	01JUL92	266	14JUL92	280	28JUL92	294	11AUG92	308	25AUG92	322
36/302	LH																
37/303	RF	26MAY92	224	07JUN92	258	23JUN92	252	07JUL92	266	21JUL92	280	04AUG92	294	18AUG92	308	01SEP92	322
38/304	DBF	09JUN92	224	25JUN92	258	07JUL92	252	21JUL92	266	04AUG92	280	18AUG92	294	01SEP92	308	15SEP92	322
39/305	ASB	16JUN92	224	03JUN92	258	14JUL92	252	28JUL92	266	11AUG92	280	25AUG92	294	08SEP92	308	22SEP92	322
40/306	EH	16JUN92	224	03JUN92	258	14JUL92	252	28JUL92	266	11AUG92	280	25AUG92	294	08SEP92	308	22SEP92	322
41/307	SFS	16JUN92	224	03JUN92	258	14JUL92	252	28JUL92	266	11AUG92	280	25AUG92	294	08SEP92	308	22SEP92	322
42/308	ICC	24JUN92	224	08JUL92	258	22JUL92	252	05AUG92	266	19AUG92	280	02SEP92	294	16SEP92	308	30SEP92	322
43/309	ARN	24JUN92	224	08JUL92	258	22JUL92	252	05AUG92	266	19AUG92	280	02SEP92	294	16SEP92	308	30SEP92	322
45/310	DPS	30JUN92	224	14JUL92	258	28JUL92	252	11AUG92	266	25AUG92	280	09SEP92	294	23SEP92	308	06OCT92	322
46/311	SP	07JUL92	224	21JUL92	258	04AUG92	252	18AUG92	266	01SEP92	280	15SEP92	294	29SEP92	308	13OCT92	322
47/312	MCS	14JUL92	224	28JUL92	258	11AUG92	252	05SEP92	266	08SEP92	280	22SEP92	294	16SEP92	308	09OCT92	322
48/313	SDM	15JUL92	224	29JUL92	258	12AUG92	252	26AUG92	266	09SEP92	280	23SEP92	294	07OCT92	308	21OCT92	322
50/314	MFA	17JUL92	224	31JUL92	258	14AUG92	252	28AUG92	266	11SEP92	280	25SEP92	294	09OCT92	308	23OCT92	322

(*): PATIENT NO.: OPEN / DOUBLE BLIND

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD

REBOMETINE - PROTOCOL 20126/013
Listing No.: 5.0

ASSESSMENT DATES AND NUMBER OF TREATMENT DAYS
DOUBLE BLIND PHASE

(continued)

Pac.No. (*)	Init.	Week35 -Week6	Week35	Week30 -Week6	Week30	Week40 -Week6	Week40	Week42 -Week6	Week42	Week44 -Week6	Week44	Week46 -Week6	Week46	Week48 -Week6	Week48	Week50 -Week6	Week50	Week52 -Week6	Week52
51/315	ASA	17JUL92	224	31JUL92	238	14AUG92	252	28AUG92	266	11SEP92	280	25SEP92	294	30SEP92	308	01OCT92	308	23OCT92	322
52/316	MIS	22JUL92	224	05AUG92	238	19AUG92	252	02SEP92	266	16SEP92	280	30SEP92	294	30SEP92	308	14OCT92	308	28OCT92	322
53/317	JFT																		
55/318	DHO																		
56/319	TAL																		
58/320	ABM																		
59/321	SDF	05SEP92	224	22SEP92	238	06OCT92	252	20OCT92	266	08NOV92	280	17NOV92	294	17NOV92	308	01DEC92	308	15DEC92	322
60/322	EH	11SEP92	224	28SEP92	238	09OCT92	252	23OCT92	266	09NOV92	280	20NOV92	294	20NOV92	308	04DEC92	308	18DEC92	322
61/323	HC	11SEP92	224	28SEP92	238	09OCT92	252	23OCT92	266	09NOV92	280	20NOV92	294	20NOV92	308	04DEC92	308	18DEC92	322
62/324	HEA	23SEP92	224	10OCT92	238	27OCT92	252	10NOV92	266	24NOV92	280	05DEC92	294	05DEC92	308	20DEC92	308	03JAN93	322
64/325	EPF	09OCT92	224	26OCT92	238	09NOV92	252	20NOV92	266	09DEC92	280	18DEC92	294	18DEC92	308	01JAN93	308	15JAN93	322
65/326	TCO	15OCT92	223	27OCT92	237	11NOV92	251	24NOV92	265	09DEC92	279	22DEC92	293	22DEC92	307	05JAN93	307	19JAN93	321
67/327	MAA																		
70/328	HLH																		
71/329	OMV	20OCT92	224	03NOV92	238	17NOV92	252	01DEC92	266	15DEC92	280	29DEC92	294	29DEC92	308	12JAN93	308	26JAN93	322
72/330	RLJ																		
73/331	FMA																		
74/332	IVL	20OCT92	224	03NOV92	238	17NOV92	252	01DEC92	266	15DEC92	280	29DEC92	294	29DEC92	308	12JAN93	308	26JAN93	322
75/333	ELF	28OCT92	224	04NOV92	238	20NOV92	252	04DEC92	266	18DEC92	280	31DEC92	294	31DEC92	308	15JAN93	308	29JAN93	322
76/334	SFA	30OCT92	224	13NOV92	238	27NOV92	252	11DEC92	266	24DEC92	279	05JAN93	294	05JAN93	308	19JAN93	308	05FEB93	322
77/335	ADG	30OCT92	224	13NOV92	238	27NOV92	252	11DEC92	266	24DEC92	279	05JAN93	294	05JAN93	308	19JAN93	308	05FEB93	322
79/336	JDM	30OCT92	224	13NOV92	238	27NOV92	252	11DEC92	266	24DEC92	279	05JAN93	294	05JAN93	308	19JAN93	308	05FEB93	322
80/337	MEL																		
81/338	MFB	30OCT92	224	13NOV92	238	27NOV92	252	11DEC92	266	24DEC92	279	05JAN93	294	05JAN93	308	19JAN93	308	05FEB93	322
82/339	MDS	30OCT92	224	13NOV92	238	27NOV92	252	11DEC92	266	24DEC92	279	05JAN93	294	05JAN93	308	19JAN93	308	05FEB93	322
84/339	IN	30OCT92	224	13NOV92	238	27NOV92	252	11DEC92	266	24DEC92	279	05JAN93	294	05JAN93	308	19JAN93	308	05FEB93	322
85/339	WLP	30OCT92	224	13NOV92	238	27NOV92	252	11DEC92	266	24DEC92	279	05JAN93	294	05JAN93	308	19JAN93	308	05FEB93	322
87/332	MDO																		
89/335	MWV																		
90/336	JSS																		
91/336	KSC	03NOV92	224	17NOV92	238	01DEC92	252	15DEC92	266	29DEC92	280	12JAN93	294	12JAN93	308	09FEB93	308	09FEB93	322
93/336	AL	04NOV92	224	18NOV92	238	02DEC92	252	16DEC92	266	30DEC92	280	13JAN93	294	13JAN93	308	10FEB93	308	10FEB93	322
94/337	ROB	04NOV92	224	18NOV92	238	02DEC92	252	16DEC92	266	30DEC92	280	13JAN93	294	13JAN93	308	10FEB93	308	10FEB93	322
95/338	GHT	04NOV92	224	18NOV92	238	02DEC92	252	16DEC92	266	30DEC92	280	13JAN93	294	13JAN93	308	10FEB93	308	10FEB93	322
96/339	SPM	04NOV92	224	18NOV92	238	02DEC92	252	16DEC92	266	30DEC92	280	13JAN93	294	13JAN93	308	10FEB93	308	10FEB93	322
97/140	IND	04NOV92	224	18NOV92	238	02DEC92	252	16DEC92	266	30DEC92	280	13JAN93	294	13JAN93	308	10FEB93	308	10FEB93	322
98/141	YTT	04NOV92	224	18NOV92	238	02DEC92	252	16DEC92	266	30DEC92	280	13JAN93	294	13JAN93	308	10FEB93	308	10FEB93	322
100/142	JMA	04NOV92	224	18NOV92	238	02DEC92	252	16DEC92	266	30DEC92	280	13JAN93	294	13JAN93	308	10FEB93	308	10FEB93	322
101/143	JLL	11NOV92	224	24NOV92	239	08DEC92	252	23DEC92	266	05JAN93	280	19JAN93	294	19JAN93	308	16FEB93	308	16FEB93	322
104/144	MIF	11NOV92	225	25NOV92	239	09DEC92	253	23DEC92	267	06JAN93	281	19JAN93	294	19JAN93	309	17FEB93	309	17FEB93	323
105/145	ABS	11NOV92	225	25NOV92	239	09DEC92	253	23DEC92	267	06JAN93	281	19JAN93	294	19JAN93	309	17FEB93	309	17FEB93	323
106/146	MKN	18NOV92	224	24NOV92	238	08DEC92	252	22DEC92	266	05JAN93	280	19JAN93	294	19JAN93	308	16FEB93	308	16FEB93	322
107/147	LAM	18NOV92	223	24NOV92	237	08DEC92	251	22DEC92	265	05JAN93	279	19JAN93	293	19JAN93	307	16FEB93	307	16FEB93	321

(*) PATIENT NO.: OPEN / DOUBLE BLIND

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R0D

REBOMETINE - PROTOCOL 2012/4/113
Listing No.: 5.0

ASSESSMENT DATES AND NUMBER OF TREATMENT DAYS
DOUBLE BLIND PHASE

(continued)

Pac.No. (*)	Init.	Week30		Week40		Week42		Week44		Week46		Week48		Week50		Week52	
		Week30 -Week6	Week40 -Week6	Week42 -Week6	Week44 -Week6	Week46 -Week6	Week48 -Week6	Week50 -Week6	Week52 -Week6	Week30 -Week6	Week40 -Week6	Week42 -Week6	Week44 -Week6	Week46 -Week6	Week48 -Week6	Week50 -Week6	Week52 -Week6
106/140	STB	11NOV92	224	28NOV92	238	01DEC92	252	23DEC92	266	06JAN93	280	19JAN93	294	08FEB93	308	17FEB93	322
109/149	IFL	11NOV92	224	28NOV92	238	01DEC92	252	23DEC92	266	06JAN93	280	19JAN93	294	08FEB93	308	17FEB93	322
110/150	TOO	11NOV92	224	28NOV92	238	01DEC92	252	23DEC92	266	06JAN93	280	19JAN93	294	08FEB93	308	17FEB93	322
111/331	JBF	18NOV92	224	28NOV92	238	01DEC92	252	23DEC92	266	06JAN93	280	19JAN93	294	08FEB93	308	17FEB93	322
116/332	CLF	18NOV92	225	02DEC92	239	15DEC92	252	30DEC92	267	13JAN93	281	27JAN93	295	14FEB93	309	24FEB93	323
116/333	ELS	18NOV92	225	02DEC92	239	15DEC92	252	30DEC92	267	13JAN93	281	27JAN93	295	14FEB93	309	24FEB93	323
116/334	MCA	18NOV92	225	02DEC92	238	15DEC92	252	30DEC92	266	12JAN93	280	26JAN93	294	07FEB93	308	24FEB93	322
117/335	PSL	18NOV92	225	02DEC92	238	15DEC92	252	30DEC92	266	12JAN93	280	26JAN93	294	07FEB93	308	24FEB93	322
121/336	LAC	18NOV92	224	02DEC92	238	15DEC92	252	30DEC92	266	12JAN93	280	26JAN93	294	07FEB93	308	24FEB93	322
122/337	HSS	18NOV92	224	02DEC92	238	15DEC92	252	30DEC92	266	12JAN93	280	26JAN93	294	07FEB93	308	24FEB93	322
124/338	HLL	18NOV92	224	02DEC92	238	15DEC92	252	30DEC92	266	12JAN93	280	26JAN93	294	07FEB93	308	24FEB93	322
124/339	PHC	18NOV92	224	02DEC92	238	15DEC92	252	30DEC92	266	12JAN93	280	26JAN93	294	07FEB93	308	24FEB93	322
125/340	FDP	18NOV92	224	02DEC92	238	15DEC92	252	30DEC92	266	12JAN93	280	26JAN93	294	07FEB93	308	24FEB93	322
126/341	SHB	18NOV92	224	02DEC92	238	15DEC92	252	30DEC92	266	12JAN93	280	26JAN93	294	07FEB93	308	24FEB93	322
127/342	VPD	18NOV92	224	02DEC92	238	15DEC92	252	30DEC92	266	12JAN93	280	26JAN93	294	07FEB93	308	24FEB93	322
128/343	LAM	18NOV92	224	02DEC92	238	15DEC92	252	30DEC92	266	12JAN93	280	26JAN93	294	07FEB93	308	24FEB93	322
129/344	MNS	18NOV92	224	02DEC92	238	15DEC92	252	30DEC92	266	12JAN93	280	26JAN93	294	07FEB93	308	24FEB93	322
130/345	EGA	11DEC92	225	24DEC92	239	08JAN93	253	22JAN93	267	08FEB93	281	19FEB93	295	08MAR93	309	19MAR93	323
135/346	JPH	15DEC92	224	29DEC92	238	12JAN93	252	26JAN93	266	09FEB93	280	24FEB93	294	09MAR93	308	25MAR93	322
136/347	LMS	15DEC92	224	29DEC92	238	12JAN93	252	26JAN93	266	09FEB93	280	24FEB93	294	09MAR93	308	25MAR93	322
135/348	MMS	15DEC92	224	29DEC92	238	12JAN93	252	26JAN93	266	09FEB93	280	24FEB93	294	09MAR93	308	25MAR93	322
136/349	AVP	15DEC92	224	29DEC92	238	12JAN93	252	26JAN93	266	09FEB93	280	24FEB93	294	09MAR93	308	25MAR93	322
136/350	LBV	15DEC92	224	29DEC92	238	12JAN93	252	26JAN93	266	09FEB93	280	24FEB93	294	09MAR93	308	25MAR93	322
139/351	RA	15DEC92	224	29DEC92	238	12JAN93	252	26JAN93	266	09FEB93	280	24FEB93	294	09MAR93	308	25MAR93	322
140/352	MCA	15DEC92	224	29DEC92	238	12JAN93	252	26JAN93	266	09FEB93	280	24FEB93	294	09MAR93	308	25MAR93	322
141/353	AMQ	15DEC92	224	29DEC92	238	12JAN93	252	26JAN93	266	09FEB93	280	24FEB93	294	09MAR93	308	25MAR93	322
142/354	SCC	15DEC92	224	29DEC92	238	12JAN93	252	26JAN93	266	09FEB93	280	24FEB93	294	09MAR93	308	25MAR93	322
143/355	JEP	16DEC92	224	30DEC92	237	13JAN93	252	27JAN93	266	10FEB93	280	25FEB93	294	10MAR93	308	26MAR93	322
144/356	ARF	16DEC92	224	30DEC92	237	13JAN93	252	27JAN93	266	10FEB93	280	25FEB93	294	10MAR93	308	26MAR93	322
145/357	SID	16DEC92	224	30DEC92	237	13JAN93	252	27JAN93	266	10FEB93	280	25FEB93	294	10MAR93	308	26MAR93	322
146/358	LPM	16DEC92	224	30DEC92	237	13JAN93	252	27JAN93	266	10FEB93	280	25FEB93	294	10MAR93	308	26MAR93	322
148/359	CAS	16DEC92	224	30DEC92	237	13JAN93	252	27JAN93	266	10FEB93	280	25FEB93	294	10MAR93	308	26MAR93	322
149/360	SC	16DEC92	224	30DEC92	237	13JAN93	252	27JAN93	266	10FEB93	280	25FEB93	294	10MAR93	308	26MAR93	322
150/151	VA	16DEC92	224	30DEC92	237	13JAN93	252	27JAN93	266	10FEB93	280	25FEB93	294	10MAR93	308	26MAR93	322

(*) PATIENT NO.: OPEN / DOUBLE BLIND

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS RED

REBOMETINE - PROTOCOL 20124/013
Listing No.: 5.0

ASSESSMENT DATES AND NUMBER OF TREATMENT DAYS
DOUBLE BLIND PHASE

Pat.No. (*)	Initt.	Week33		Week40		Week42		Week44		Week46		Week48		Week50		Week52	
		-Week33	Week33	-Week40	Week40	-Week42	Week42	-Week44	Week44	-Week46	Week46	-Week48	Week48	-Week50	Week50	-Week52	Week52
7/71	GRJ
10/72	TOR
----- Centres3 ----- (continued)																	
1/211	HJ	25AUG91	224	09SEP91	235	23SEP91	252	07OCT91	266	21OCT91	280	14NOV91	294	28NOV91	308	12DEC91	322
2/212	TE	05SEP91	224	19SEP91	235	03OCT91	252	17OCT91	266	31OCT91	280	14NOV91	294	28NOV91	308	12DEC91	322
3/213	JL
4/214	BA	05OCT91	224	17OCT91	238	31OCT91	252	14NOV91	266	28NOV91	280	12DEC91	294	26DEC91	308	09JAN92	322
5/215	SL
6/216	TL	14OCT91	224	28OCT91	238	11NOV91	252	25NOV91	266	09DEC91	280	23DEC91	294	06JAN92	308	20JAN92	322
----- Centres3 -----																	
----- Centres4 -----																	
2/241	VCF	18FEB91	224	06MAY91	238	19MAY91	252	01APR91	266	15APR91	280	29APR91	294	13MAY91	308	27MAY91	322
5/242	MF	15JUN91	224	29JUN91	238	13JUL91	252	27JUL91	266	10SEP91	280	06OCT91	294	22OCT91	308	05NOV91	322
6/243	SD	31JUL91	224	13AUG91	238	27AUG91	252	10SEP91	266	24SEP91	280	08OCT91	294	22OCT91	308	07NOV91	322
7/243	PP	01AUG91	224	15AUG91	238	29AUG91	252	12SEP91	266	26SEP91	280	10OCT91	294	24OCT91	308	07NOV91	322
8/244	KTM
11/246	KE	22OCT91	224	05NOV91	238	19NOV91	252	03DEC91	266	17DEC91	280	31DEC91	294	14JAN92	308	28JAN92	322
12/247	GVT
13/248	BP	04DEC91	224	10DEC91	238	01JAN92	252	15JAN92	266	29JAN92	280	12FEB92	294	26FEB92	308	11MAR92	322
15/249	BI	09FEB92	224	23FEB92	238	09MAR92	252	22MAR92	266	05APR92	280	19APR92	294	03MAY92	308	17MAY92	322
16/250	UGY	31MAR92	224	14APR92	238	28APR92	252	12MAY92	266	26MAY92	280	09JUN92	294	23JUN92	308	07JUL92	322
19/251	RF
20/252	GVE
23/253	SZN
24/253	LVY
25/254	PH	11AUG92	224	25AUG92	238	08SEP92	252	22SEP92	266	06OCT92	280	20OCT92	294	03NOV92	308	17NOV92	322
26/255	CP
28/257	HI
29/258	SZF
30/259	MF

(*): PATIENT NO.: OPEN / DOUBLE BLIND

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REGIMETIME - PROTOCOL 20124/813

Listing No.: 5.0

ASSESSMENT DATES AND NUMBER OF TREATMENT DAYS
DOUBLE BLIND PHASE

Centre=10

Pat.No. (*)	Init.	Week35		Week40		Week42		Week44		Week46		Week48		Week50		Week52	
		-Week5	Week5														
1/271	VK																
4/272	ZSD																
5/273	AN																
7/274	RK																
9/275	RT																
10/276	MI																
12/277	EP																
15/278	HU																
15/279	AA	04NOV91	224	18NOV91	238	02DEC91	252	17DEC91	267	30DEC91	280	13JAN92	294	27JAN92	308	10FEB92	322
15/280	HT																
16/281	AJ	25NOV91	225	09DEC91	237	23DEC91	251	07JAN92	266	20JAN92	279	03FEB92	293	17FEB92	307	03MAR92	322
17/282	HH	04DEC91	224	18DEC91	236	02JAN92	250	15JAN92	265	29JAN92	278	12FEB92	292	26FEB92	306	10MAR92	321
19/284	TN	23DEC91	223	06JAN92	237	21JAN92	252	03FEB92	265	17FEB92	279	02MAR92	293	16MAR92	307	31MAR92	322
20/285	EJ																
21/286	AK																
22/286	AA	13JAN92	224	27JAN92	238	10FEB92	252	24FEB92	266	09MAR92	280	23MAR92	294	06APR92	308	21APR92	323
25/287	LT	14JAN92	224	28JAN92	238	11FEB92	252	25FEB92	266	11FEB92	280	31MAR92	294	14APR92	308	28APR92	322
26/289	AL	21JAN92	224	04FEB92	238	18FEB92	252	03MAR92	266	17MAR92	280	31MAR92	294	14APR92	308	28APR92	322
26/290	JIF																
27/292	PK	25FEB92	225	09MAR92	239	24MAR92	253	08APR92	267	20APR92	280	04MAY92	294	18MAY92	308	02JUN92	323
28/291	LL	19FEB92	224	04MAR92	238	18MAR92	252	01APR92	266	15APR92	280	29APR92	294	13MAY92	308	02JUN92	323
29/293	JJ																
30/294	VK	05JUN92	224	22JUN92	238	06JUL92	252	20JUL92	266	05AUG92	280	17AUG92	294	31AUG92	308	14SEP92	322
31/297	RK	08JUN92	224	25JUN92	241	07JUL92	253	20JUL92	266	05AUG92	280	17AUG92	294	31AUG92	308	15SEP92	323
32/299	LK	07JUN92	223	21JUN92	237	07JUL92	251	20JUL92	266	05AUG92	280	17AUG92	294	31AUG92	308	15SEP92	323
35/300	EK																
36/31	TK																
35/35	IM																
37/32	HK																
38/37	LL																
39/40	VH	06JUL92	224	20JUL92	238	06AUG92	253	17AUG92	266	31AUG92	280	14SEP92	294	28SEP92	308	13OCT92	323
40/43	AP																
41/42	VP	21JUL92	224	04AUG92	238	18AUG92	252	01SEP92	266	15SEP92	280	29SEP92	294	13OCT92	308	27OCT92	322
42/295	IT																
42/296	IK																
44/298	AB																
45/34	KJ																
46/38	TN																
47/39	TH	26AUG92	224	09SEP92	238	23SEP92	252	07OCT92	266	21OCT92	280	04NOV92	294	18NOV92	308	02DEC92	322
48/41	IP																
49/43	VH																
50/44	EE	03SEP92	224	25SEP92	238	07OCT92	252	21OCT92	266	04NOV92	280	18NOV92	294	02DEC92	308	16DEC92	322
51/45	UL	03SEP92	224	25SEP92	238	07OCT92	252	21OCT92	266	04NOV92	280	18NOV92	294	02DEC92	308	16DEC92	322
55/47	MA																

(*): PATIENT NO.: OPEN / DOUBLE BLIND

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA ONS R&D

REBOMETINE - PROTOCOL 20124/013

Listing No.: 5.9

ASSESSMENT DATES AND NUMBER OF TREATMENT DAYS
DOUBLE BLIND PHASE

Centre#10 (continued)

Pat.No. (*)	Init.	Week38		Week40		Week42		Week44		Week46		Week48		Week50		Week52	
		-Weeks	Week38	-Weeks	Week40	-Weeks	Week42	-Weeks	Week44	-Weeks	Week46	-Weeks	Week48	-Weeks	Week50	-Weeks	Week52
56/48	UN
56/49	TP	05OCT92	224	19OCT92	238	02NOV92	252	16NOV92	266	30NOV92	280	14DEC92	294	28DEC92	308	11JAN93	322
56/50	JP
57/51	AB	04OCT92	224	20OCT92	238	03NOV92	252	17NOV92	266	01DEC92	280	15DEC92	294	29DEC92	308	12JAN93	322
58/52	KK	05OCT92	224	19OCT92	238	02NOV92	252	16NOV92	266	30NOV92	280	14DEC92	294	28DEC92	308	12JAN93	322
59/53	TA
60/54	JM
61/55	JT
62/56	RK
63/57	HS	26OCT92	224	09NOV92	238	23NOV92	252	07DEC92	266	21DEC92	280	04JAN93	294	18JAN93	308	01FEB93	322
64/58	LT
81/46	JN	11NOV92	224	25NOV92	237	09DEC92	251	23DEC92	265	06JAN93	279
82/59	LS	16NOV92	224	30NOV92	238	14DEC92	252	28DEC92	266	11JAN93	280	25JAN93	294
84/63	HV
85/272	AK
86/274	NP
87/275	AN	09DEC92	224	23DEC92	238	06JAN93	252	20JAN93	266	03FEB93	280	17FEB93	294	03MAR93	308	17MAR93	322
88/276	AH	09DEC92	224	23DEC92	238	06JAN93	252	20JAN93	266	03FEB93	280	17FEB93	294	03MAR93	308	17MAR93	322
89/277	SK
90/70	SV
91/74	HI
92/73	LA	22DEC92	224	05JAN93	238	19JAN93	252	02FEB93	266	16FEB93	280	02MAR93	294	16MAR93	308	30MAR93	322
93/285	AN
94/273	PV

Centre#11

Pat.No. (*)	Init.	Week38		Week40		Week42		Week44		Week46		Week48		Week50		Week52	
		-Weeks	Week38	-Weeks	Week40	-Weeks	Week42	-Weeks	Week44	-Weeks	Week46	-Weeks	Week48	-Weeks	Week50	-Weeks	Week52
1/372	DF
2/373	HB
3/374	RF
4/375	BA
6/377	VP	07JUL92	224	21JUL92	238	04AUG92	252	18AUG92	266	01SEP92	280	15SEP92	294	29SEP92	308	13OCT92	322
7/376	KK	15JUL92	224	29JUL92	238	12AUG92	252	26AUG92	266	09SEP92	280	23SEP92	294	07OCT92	308	21OCT92	322
9/382	FI
10/383	BJ	17AUG92	224	31AUG92	238	14SEP92	252	28SEP92	266	12OCT92	280	26OCT92	294	09NOV92	308	23NOV92	322
11/381	NGV
12/384	PJ	04SEP92	224	20SEP92	238	04OCT92	252	18OCT92	266	01NOV92	280	15NOV92	294	29NOV92	308	13DEC92	322
13/385	GK
15/386	NF

(*) PATIENT NO.: OPEN / DOUBLE BLIND

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOMETINE - PROTOCOL 20124/913
Listing No.: 5.0

ASSESSMENT DATES AND NUMBER OF TREATMENT DAYS
DOUBLE BLIND PHASE

Pat.No. (*)	Init.	Week38		Week40		Week42		Week44		Week46		Week48		Week50		Week52	
		-Week	Week38	-Week	Week40	-Week	Week42	-Week	Week44	-Week	Week46	-Week	Week48	-Week	Week50	-Week	Week52
16/357	WA																
17/368	UZ	224	29OCT92	224	12NOV92	224	26NOV92	224	10DEC92	224	24DEC92	224	07JAN93	224	21JAN93	224	04FEB93
18/369	EI	224	01NOV92	224	15NOV92	224	29NOV92	224	13DEC92	224	27DEC92	224	10JAN93	224	24JAN93	224	07FEB93
19/370	FX	224	19NOV92	224	03DEC92	224	17DEC92	224	31DEC92	224	14JAN93	224	28JAN93	224	11FEB93	224	25FEB93
20/371	LJ																

----- Centref=11 -----
(continued)

Pat.No. (*)	Init.	Week38		Week40		Week42		Week44		Week46		Week48		Week50		Week52	
		-Week	Week38	-Week	Week40	-Week	Week42	-Week	Week44	-Week	Week46	-Week	Week48	-Week	Week50	-Week	Week52
1/92	IB																
2/99	EFC	224	22JUL92	224	05AUG92	224	19AUG92	224	02SEP92	224	16SEP92	224	30SEP92	224	14OCT92	224	28OCT92
3/93	IF	224	21JUL92	224	04AUG92	224	18AUG92	224	01SEP92	224	15SEP92	224	29SEP92	224	13OCT92	224	27OCT92
4/100	EG																
5/95	ZSH																
5/96	HK																
7/102	LK																
9/91	KBP																
10/96	IP																
11/94	ER																
12/97	FSZ																
13/103	ISZ																
14/101	GSZ																
15/104	GB																
16/105	FN																
17/106	TK																
18/109	LS																
19/104	SSZ																
20/107	KSZ																
21/110	FL																
22/111	MU	224	19OCT92	224	02NOV92	224	16NOV92	224	30NOV92	224	14DEC92	224	28DEC92	224	11JAN93	224	25JAN93
23/112	EN																
24/113	MF																
25/114	FS	224	02NOV92	224	16NOV92	224	30NOV92	224	14DEC92	224	28DEC92	224	11JAN93	224	25JAN93	224	08FEB93
27/115	VCS																
28/116	IV																
29/117	AK	224	02NOV92	224	16NOV92	224	30NOV92	224	14DEC92	224	28DEC92	224	11JAN93	224	25JAN93	224	08FEB93
33/306	LN																
34/120	T69	224	10DEC92	224	01JAN93	224	15JAN93	224	29JAN93	224	12FEB93	224	26FEB93	224	12MAR93	224	26MAR93
35/119	LP																
36/386	FB																

(*): PATIENT NO.: OPEN / DOUBLE BLIND

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOMETINE - PROTOCOL 20124/013

Listing No.: 5.0

ASSESSMENT DATES AND NUMBER OF TREATMENT DAYS
DOUBLE BLIND PHASE

Pat. No. (*)	Init.	Week35		Week40		Week42		Week44		Week46		Week48		Week50		Week52	
		Week35 -Week6	Week35	Week40 -Week6	Week40	Week42 -Week6	Week42	Week44 -Week6	Week44	Week46 -Week6	Week46	Week48 -Week6	Week48	Week50 -Week6	Week50	Week52 -Week6	Week52
37/386	EX																
----- Centre#12 ----- (continued)																	
----- Centre#13 -----																	
1/219	PZ	07/JUL/92	224	21/JUL/92	238	06/AUG/92	252	16/AUG/92	266	01/SEP/92	280	15/SEP/92	294	29/SEP/92	308	13/OCT/92	322
2/224	TS	06/JUL/92	224	25/JUL/92	238	05/AUG/92	252	19/AUG/92	266	02/SEP/92	280	16/SEP/92	294	30/SEP/92	308	14/OCT/92	322
3/221	AI	07/JUL/92	224	21/JUL/92	238	06/AUG/92	252	16/AUG/92	266	01/SEP/92	280	15/SEP/92	294	29/SEP/92	308	13/OCT/92	322
6/226	KE	09/JUL/92	224	23/JUL/92	238	06/AUG/92	252	20/AUG/92	266	03/SEP/92	280	17/SEP/92	294	01/OCT/92	308	15/OCT/92	322
7/220	BL	15/JUL/92	225	29/JUL/92	237	12/AUG/92	251	26/AUG/92	265	09/SEP/92	279	23/SEP/92	293	07/OCT/92	307	21/OCT/92	321
8/228	PK																
9/229	SZS																
11/225	HS	06/AUG/92	224	20/AUG/92	238	03/SEP/92	252	17/SEP/92	266	01/OCT/92	280	15/OCT/92	294	29/OCT/92	308	12/NOV/92	322
13/223	HH	24/JUL/92	224	07/AUG/92	238	04/SEP/92	252	04/SEP/92	266	16/SEP/92	280	02/OCT/92	294	16/OCT/92	308	30/OCT/92	322
14/217	DF	24/JUL/92	224	07/AUG/92	238	21/AUG/92	252	04/SEP/92	266	16/SEP/92	280	02/OCT/92	294	16/OCT/92	308	30/OCT/92	322
15/222	KG	29/JUL/92	224	12/AUG/92	238	25/AUG/92	251	08/SEP/92	265	22/SEP/92	279	06/OCT/92	293	20/OCT/92	307	03/NOV/92	321
17/216	GSH	11/AUG/92	224	25/AUG/92	238	08/SEP/92	252	22/SEP/92	266	06/OCT/92	280	20/OCT/92	294	03/NOV/92	308	17/NOV/92	322
18/227	VT	25/AUG/92	224	08/SEP/92	238	22/SEP/92	252	06/OCT/92	266	20/OCT/92	280	03/NOV/92	294	17/NOV/92	308	01/DEC/92	322
20/230	NL	20/OCT/92	224	03/NOV/92	238	17/NOV/92	252	01/DEC/92	266	15/DEC/92	280	29/DEC/92	294	12/JAN/93	308	24/JAN/93	322
21/231	CL	19/NOV/92	224	24/NOV/92	238	09/DEC/92	252	22/DEC/92	266	05/JAN/93	280	19/JAN/93	294	02/FEB/93	308	16/FEB/93	322
22/232	NYK																

(*) PATIENT NO.: OPEN / DOUBLE BLIND

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 6.0
 CONCOMITANT DRUGS
 OPEN PHASE

Centre	Patient	Initial	Sex	Treatment	Concomitant drug	Start date	End date	days of administr.	interval conc_drug - start treat
2	31	IK	Female	Reboxetine	CHLORAL HYDRATE	03/11/90	06/12/90(*)	34	-7
					NIFEDIPINE	26/11/90	06/12/90(*)	11	16
	32	GE	Female	Reboxetine	CHLORAL HYDRATE	03/12/90	26/12/90(*)	24	-7
	33	HS	Female	Reboxetine	CHLORAL HYDRATE	08/01/91	30/01/91(*)	23	-7
	34	EH	Female	Reboxetine	CHLORAL HYDRATE	21/03/91	24/04/91(*)	35	-7
3	2	FIL	Female	Reboxetine	OXAZEPAN	13/11/90	21/11/90	9	-4
					STILNOX	07/12/90	10/12/90	4	20
	3	DUB	Male	Reboxetine	HYDROXYZINE	26/03/91	09/04/91	15	-8
	4	AUD	Female	Reboxetine	DUXIL	29/11/90	15/01/91	48	-9
					LUTERAN	06/12/90	16/12/90	11	-2
					ROHIPNOL	29/11/90	15/01/91	48	-9
					STILNOX	29/11/90	15/01/91	48	-9
7	681		Female	Reboxetine	LOPRAZOLAM	05/12/90	09/01/91	30	-6
					NOCTRAN 10	18/01/91	21/01/91	4	38
9	DEN		Female	Reboxetine	AMPECYCLAL	25/01/91	29/01/91	5	6
					NOZINAN	13/01/91	16/01/91	4	-6

(*) - start date missing = screening date
 (*) - end date missing = last dose taken date

735

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 6.0
 CONCOMITANT DRUGS
 OPEN PHASE

9550077

Centre	Patient	Initial	Sex	Treatment	Concomitant drug	Start date	End date	days of administr.	interval conc drug - start treat
3	9	DEN	Female	Reboxetine	SERESTA	30/01/91	30/01/91	1	11
					TERCIAN	27/01/91	27/01/91	1	8
					THERALENE	10/01/91	05/02/91	27	-9
					URBANYL	10/01/91	17/01/91	8	-9
	10	TDR	Male	Reboxetine	AVLOCARDYL	17/05/91	22/05/91	6	36
					DICLOFENAC	15/04/91	25/04/91	11	4
					EQUANIL	22/05/91	22/05/91	1	41
					MEPHENESIN	15/04/91	15/05/91	31	4
					NOCTAMID	22/04/91	17/05/91	26	11
					NOCTRAN 10	02/04/91	22/04/91	21	-9
					STILNOX	17/05/91	22/05/91	6	36
	11	PIE	Female	Reboxetine	MEPRONIZINE	15/02/91	23/05/91	98	-99
					NOCTRAN 10	15/02/91	23/05/91	98	-99
	9	SZF	Female	Reboxetine	MELLERIL	01/05/91	05/05/91	5	37
	10	VR	Male	Reboxetine	CHLORAL HYDRATE	04/10/90	15/10/90	12	-12

736

(\$) - start date missing = screening date
 (*) - end date missing = last dose taken date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 6.0
 CONCOMITANT DRUGS
 OPEN PHASE

Centre	Patient	Initial	Sex	Treatment	Concomitant drug	Start date	End date	days of administr.	interval conc. drug - start treat
10	1	VK	Male	Reboxetine	TETRACICLINA	24/10/90	29/10/90	6	8
	4	ZSD	Female	Reboxetine	CHLORAL HYDRATE	24/10/90	30/10/90	7	-7
	8	VP	Female	Reboxetine	CHLORAL HYDRATE	21/11/90 11/12/90	26/11/90 17/12/90	6 7	-6 14
	9	RT	Female	Reboxetine	ACEYLSALICYLIC ACID	20/12/90	21/12/90	2	16
	10	MH	Female	Reboxetine	TETRACYCLINE	12/12/90	16/12/90	5	8
	11	TH	Female	Reboxetine	CHLORAL HYDRATE	18/12/90	09/01/91	23	-9
	13	HU	Female	Reboxetine	GENTAMICIN	26/01/91	04/03/91	38	-17
	14	AA	Male	Reboxetine	CHLORAL HYDRATE	12/02/91	18/03/91	35	0
	15	HT	Female	Reboxetine	ASPIRINE	20/03/91	25/03/91	6	27
					CHLORAL HYDRATE	14/03/91 27/03/91	25/03/91 03/04/91	12 8	21 34
	18	SS	Female	Reboxetine	ASPIRINA	08/04/91	11/04/91	4	21
	20	EJ	Female	Reboxetine	CHLORAL HYDRATE	22/04/91	29/04/91	8	35
					CHLORAL HYDRATE	02/05/91	03/06/91(*)	33	9

737

(\$) - start date missing = screening date
 (*) - end date missing = last dose taken date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 6.0
 CONCOMITANT DRUGS
 OPEN PHASE

Centre	Patient	Initial	Sex	Treatment	Concomitant drug	Start date	End date	days of administr.	interval conc.drug - start treat
10	23	LT	Female	Reboxetine	CHLORAL HYDRATE	10/05/91	04/06/91(*)	26	16
	27	NK	Female	Reboxetine	CHLORAL HYDRATE	10/06/91	17/06/91	8	7
	29	JJ	Male	Reboxetine	CHLORAL HYDRATE	26/08/91	06/09/91	12	7
	30	VK	Female	Reboxetine	CHLORAL HYDRATE	20/09/91	28/10/91(*)	39	3
	37	HK	Female	Reboxetine	CHLORAL HYDRATE	07/10/91	24/11/91(*)	49	-7
	41	VP	Female	Reboxetine	CHLORAL HYDRATE	13/11/91	10/12/91(*)	28	14
	42	TT	Male	Reboxetine	CHLORAL HYDRATE	11/11/91	25/12/91(*)	45	-3
	45	KJ	Female	Reboxetine	CHLORAL HYDRATE	21/11/91	31/12/91(*)	41	1
	47	TK	Female	Reboxetine	CHLORAL HYDRATE	26/11/91	05/12/91	10	-9
	48	IP	Female	Reboxetine	CHLORAL HYDRATE	28/11/91	04/12/91	7	-7
	54	UN	Female	Reboxetine	CHLORAL HYDRATE	08/01/91	23/02/92(*)	412	-370
	56	JP	Male	Reboxetine	CHLORAL HYDRATE	08/01/92	24/02/92(*)	48	-6
	62	RK	Male	Reboxetine	CHLORAL HYDRATE	23/01/92	03/03/92(*)	41	1
	63	MS	Male	Reboxetine	CHLORAL HYDRATE	05/02/92	16/03/92	43	-1
	64	LT	Female	Reboxetine	CHLORAL HYDRATE	10/02/92	14/03/92	34	4
	81	JN	Female	Reboxetine	CHLORAL HYDRATE	19/02/92	02/04/92(*)	44	-2

(#) - start date missing = screening date
 (*) - end date missing = last dose taken date

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 6.0
 CONCOMITANT DRUGS
 OPEN PHASE

9550077

Centre	Patient	Initial	Sex	Treatment	Concomitant drug	Start date	End date	days of administr.	interval conc. drug - start treat
10	83	KL	Male	Reboxetine	CHLORAL HYDRATE	04/03/92	11/04/92	39	1
	86	NP	Female	Reboxetine	CHLORAL HYDRATE	18/03/92	29/04/92(*)	43	-1
	90	SV	Female	Reboxetine	CHLORAL HYDRATE	30/03/92	04/05/92(*)	36	6
	92	LA	Female	Reboxetine	CHLORAL HYDRATE	08/04/92	14/04/92	7	7
11	1	DF	Male	Reboxetine	CHLORAL HYDRATE	12/10/91	22/11/91(*)	42	0
	2	HB	Female	Reboxetine	ACETYSALICYLIC ACID	06/10/91(\$)	24/11/91(*)	50	-8
					DICLOFENAC SODIUM	06/10/91(\$)	24/11/91(*)	50	-8
					FUROSEMIDE	06/10/91(\$)	24/11/91(*)	50	-8
					NIFEDIPINE	06/10/91(\$)	24/11/91(*)	50	-8
	3	RF	Female	Reboxetine	CHLORAL HYDRATE	07/10/91	25/11/91(*)	50	-8
	4	BA	Male	Reboxetine	CHLORAL HYDRATE	19/10/91	08/11/91	21	1
	5	ZH	Male	Reboxetine	CHLORAL HYDRATE	14/10/91	12/11/91(*)	30	-4
	6	VP	Male	Reboxetine	CHLORAL HYDRATE	17/10/91	05/11/91	20	1
	7	KK	Female	Reboxetine	CHLORAL HYDRATE	17/10/91	04/12/91(*)	49	-7
	8	KF	Female	Reboxetine	CHLORAL HYDRATE	04/11/91	02/12/91(*)	29	-7

(\$) - start date missing = screening date
 (*) - end date missing = last dose taken date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 6.0
 CONCOMITANT DRUGS
 OPEN PHASE

Centre	Patient	Initial	Sex	Treatment	Concomitant drug	Start date	End date	days of administr.	interval conc_drug - start treat
11	9	FI	Female	Reboxetine	CHLORAL HYDRATE	11/01/91	23/12/91(*)	347	-305
	10	BJ	Female	Reboxetine	CHLORAL HYDRATE	25/11/91	06/01/92(*)	43	-1
	11	NGY	Female	Reboxetine	CHLORAL HYDRATE	05/12/91	16/01/92(*)	43	-1
	12	PJ	Female	Reboxetine	CHLORAL HYDRATE	15/12/91	26/01/92(*)	43	-1
	13	GK	Female	Reboxetine	CHLORAL HYDRATE	14/01/92	25/02/92(*)	43	-1
	14	BJ	Female	Reboxetine	CHLORAL HYDRATE	19/01/92	16/02/92(*)	29	-1
	15	NF	Female	Reboxetine	CHLORAL HYDRATE	25/01/92	09/03/92(*)	45	-4
	16	NA	Female	Reboxetine	CHLORAL HYDRATE	02/02/92	15/03/92(*)	43	-1
	17	UZ	Female	Reboxetine	CHLORAL HYDRATE	31/01/92	19/03/92(*)	49	-7
	18	EI	Female	Reboxetine	CHLORAL HYDRATE	03/02/92	22/03/92(*)	49	-7
	19	FK	Female	Reboxetine	CHLORAL HYDRATE	21/02/92	09/04/92(*)	49	-7
	20	LJ	Female	Reboxetine	CHLORAL HYDRATE	24/02/92	12/04/92(*)	49	-7
12	2	EFC	Female	Reboxetine	CHLORAL HYDRATE	05/11/91	16/12/91(*)	42	0
	3	IF	Female	Reboxetine	CHLORAL HYDRATE	30/10/91	10/12/91(*)	42	0
	4	EG	Female	Reboxetine	CHLORAL HYDRATE	05/11/91	16/12/91(*)	42	0

(*) - start date missing = screening date
 (*) - end date missing = last dose taken date

740

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 6.0
 CONCOMITANT DRUGS
 OPEN PHASE

9550077

Centre	Patient	Initial	Sex	Treatment	Concomitant drug	Start date	End date	days of administr.	interval conc.drug - start treat
12	5	ZSH	Male	Reboxetine	DISULFIRAM	10/09/91	26/10/91	47	-56
					NICOTINAMIDE	11/10/91	30/10/91	20	-25
	6	HK	Female	Reboxetine	CHLORAL HYDRATE	02/11/91	12/12/91(*)	41	0
	7	LK	Male	Reboxetine	PROPRANOLOL	17/06/91	28/10/91	134	-141
	8	FN	Female	Reboxetine	CHLORAL HYDRATE	01/11/91	12/12/91(*)	42	0
	9	KBP	Female	Reboxetine	CLONAZEPAM	04/08/91	16/10/91	74	-88
	10	IP	Female	Reboxetine	CHLORAL HYDRATE	05/11/91	16/12/91(*)	42	0
					DISULFIRAM	15/07/91	27/10/91	105	-113
	11	ER	Female	Reboxetine	CHLORAL HYDRATE	31/10/91	11/12/91(*)	42	0
					LEVOPROMAZIN	06/04/91	26/10/91	204	-208
					XANAX	06/04/91	26/10/91	204	-208
	12	FSZ	Female	Reboxetine	CHLORAL HYDRATE	07/11/91	16/12/91(*)	40	2
	13	ISZ	Female	Reboxetine	CHLORAL HYDRATE	12/11/91	16/12/91(*)	35	7
	14	GSZ	Female	Reboxetine	CHLORAL HYDRATE	06/11/91	17/12/91(*)	42	0
					NIFEDIPINE	04/11/91(\$)	17/12/91(*)	44	-2

(\$) - start date missing = screening date
 (*) - end date missing = last dose taken date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 6.0
 CONCOMITANT DRUGS
 OPEN PHASE

Centre	Patient	Initial	Sex	Treatment	Concomitant drug	Start date	End date	days of administr.	interval conc.drug - start treat
12	14	GS2	Female	Reboxetine	PROPRANOLOL	04/11/91(\$)	17/12/91(*)	44	-2
	15	GS	Male	Reboxetine	NIFEDIPINE	06/03/90	06/01/92(*)	672	-630
	16	FN	Female	Reboxetine	CHLORAL HYDRATE	12/12/91	21/01/92(*)	41	1
					RIVOTRIL	09/12/91(\$)	02/12/91	-6	-2
	17	TK	Male	Reboxetine	CARBAMAZEPINE	30/07/91	08/01/92	163	-169
					CHLORAL HYDRATE	15/01/92	25/02/92(*)	42	0
	18	LS	Male	Reboxetine	CHLORAL HYDRATE	15/01/92	25/02/92(*)	42	0
					DROTAVERINE HYDROCHLORIDE	17/01/92	30/01/92	14	2
	19	SS2	Female	Reboxetine	CHLORAL HYDRATE	16/01/92	27/01/92	12	0
					DIAZEPAM	31/12/91	08/01/92	9	-16
	21	FL	Female	Reboxetine	VALERIANAE COMP.	01/02/92	12/03/92(*)	41	1
	22	NV	Female	Reboxetine	CHLORAL HYDRATE	28/01/92	09/03/92(*)	42	0
					PROMETHAZINE	06/07/91	07/01/92	186	-206
	23	EN	Female	Reboxetine	CHLORAL HYDRATE	10/02/92	19/03/92(*)	39	3
	24	MF	Female	Reboxetine	CHLORPROTHIXENE	20/12/89	31/01/92	773	-780

(\$) - start date missing = screening date
 (*) - end date missing = last dose taken date

742

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 6.0
 CONCOMITANT DRUGS
 OPEN PHASE

Centre	Patient	Initial	Sex	Treatment	Concomitant drug	Start date	End date	days of administr.	interval conc drug - start treat
12	24	MF	Female	Reboxetine	METOPROLOL TARTRATE	01/01/91	20/03/92(*)	445	-403
					NIFEDIPINE	01/01/91	20/03/92(*)	445	-403
					PROMETHAZINE HYDROCHLORID	01/01/80	31/01/92	4414	-4421
	26	LB	Male	Reboxetine	CHLORPROTHIXENE	22/10/91	30/01/92	101	-106
	27	VCS	Female	Reboxetine	CHLORAL HYDRATE	28/02/92	20/03/92(*)	22	20
					VALERIANAE COMP.	01/02/92	20/03/92(*)	49	-7
	28	IV	Female	Reboxetine	ALPRAZOLAM	01/07/91	31/01/92	215	-222
					VALERIAN EXTRACT	04/02/92	20/03/92(*)	46	-4
	29	AK	Female	Reboxetine	ALPRAZOLAM	10/11/91	03/02/92	86	-93
					VALERIAN EXTRACT	07/02/92	20/03/92	43	-4
	30	FS	Female	Reboxetine	CHLORAL HYDRATE	25/02/92	03/04/92	39	0
					LEVOPROMAZIN	09/01/92	18/02/92	41	-47
					VALERIANAE COMP.	25/02/92	03/04/92	39	0
	31	FM	Male	Reboxetine	BROMHEXINE HYDROCHLORIDE	14/04/92	15/04/92	2	20
					COFFEINUM NATRIUM BENZOIC	21/04/92	30/04/92	10	27

(*) - start date missing = screening date
 (*) - end date missing = last dose taken date

9550077

372

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 6.0
 CONCOMITANT DRUGS
 OPEN PHASE

9550077

Centre	Patient	Initial	Sex	Treatment	Concomitant drug	Start date	End date	days of administr.	interval conc_drug - start treat
12	31	FM	Male	Reboxetine	HISTAMINE HYDROCHLORIDE	21/04/92	30/04/92	10	27
					RETOTIFEN	27/04/92	04/05/92	8	33
					LIDOCAINE	24/03/92	03/04/92	11	-1
						07/04/92	08/04/92	2	13
						21/04/92	27/04/92	7	27
					NIFEDIPINE	22/01/91	05/05/92(*)	470	-428
					PAPAVERINE HYDROCHLORIDE	24/03/92	03/04/92	11	-1
						07/04/92	08/04/92	2	13
						21/04/92	30/04/92	10	27
	33	LN	Female	Reboxetine	CHLORAL HYDRATE	25/03/92	13/05/92(*)	50	-8
	34	TGB	Female	Reboxetine	CHLORAL HYDRATE	29/03/92	03/05/92	36	1
	35	LP	Female	Reboxetine	CHLORAL HYDRATE	29/03/92	08/05/92(*)	41	1
	36	FB	Female	Reboxetine	CHLORAL HYDRATE	31/03/92	11/05/92(*)	42	0
	38	FG	Female	Reboxetine	CHLORAL HYDRATE	07/04/92	18/05/92(*)	42	0
13	12	BF	Male	Reboxetine	CEFALEXIN	19/11/91	04/12/91(*)	16	19

744

(#) - start date missing = screening date
 (*) - end date missing = last dose taken date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 6.0

CONCOMITANT DRUGS
DOUBLE BLIND PHASE

Centre	Patient	D.B.	Patient	Initial	Sex	Treatment	Concomitant drug	Start date	End date	days of administr.	interval conc_drug - start treat
1	58	320	ARM		Female	Reboxetine	GLYCERIN	28/03/92	31/03/92	4	108
	90	134	JSS		Male	Reboxetine	GLYCERIN	05/04/92	07/04/92	3	53
3	10	72	TOR		Male	Placebo	EQUANIL	23/05/91	31/05/91	9	42
							HAYLANE	15/08/91	28/08/91	14	126
							HEPTAMINOL	28/06/91	17/07/91	20	78
7	45						STILNOX	23/05/91 18/07/91	31/05/91 13/08/91	9 27	42 98
9	20	252	GYE		Female	Reboxetine	NITRAZEPAM	05/10/91 16/11/91 14/12/91	18/10/91 29/11/91 27/12/91	14 14 14	42 84 112
	24	253	LGY		Male	Placebo	NITRAZEPAM	04/03/92	15/03/92	12	113
10	4	272	ZSD		Female	Placebo	ANTIPYRINE	24/12/90	08/01/91	16	54
							CLONIDINE	23/01/91	31/03/91	68	84
							PHENACETIN	24/12/90	08/01/91	16	54
	20	285	EJ		Female	Reboxetine	CHLORAL HYDRATE	02/05/91	17/06/91	47	9
	22	286	AA		Male	Reboxetine	AMPICILIN	22/11/91	15/12/91	24	213
							CHLORAL HYDRATE	26/08/91	23/09/91	29	125
							OBSIDAN	13/08/91	29/12/91	139	112

(§) - start date missing = screening date
(*) - end date missing = last dose taken date

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 6.0

CONCOMITANT DRUGS
DOUBLE BLIND PHASE

Centre	Patient	D.B.	Patient Initial	Sex	Treatment	Concomitant drug	Start date	End date	days of administr.	interval conc_drug - start treat
10	23	287	LT	Female	Reboxetine	CHLORAL HYDRATE	10/05/91	18/06/91	40	16
						DIAZEPAN	13/02/92	25/02/92(*)	13	295
	26	290	JIF	Female	Reboxetine	DIGILANID	09/07/91	05/08/91(*)	28	42
						PENTITTAE	09/07/91	05/08/91(*)	28	42
	27	292	MK	Female	Reboxetine	CLONIDINE	06/08/91	05/08/91	3	64
						NIFEDIPINE	05/08/91	05/08/91	1	63
	30	294	VK	Female	Placebo	CHLORAL HYDRATE	01/10/91	18/11/91	49	14
	37	32	HK	Female	Placebo	CHLORAL HYDRATE	15/10/91	18/02/92	127	1
	41	42	VP	Female	Reboxetine	CHLORAL HYDRATE	13/11/91	29/12/91	47	14
	42	295	TT	Male	Placebo	CHLORAL HYDRATE	11/11/91	24/01/92(*)	75	-3
	45	34	EJ	Female	Placebo	CHLORAL HYDRATE	21/11/91	28/01/92	69	1
	62	56	RK	Male	Placebo	CHLORAL HYDRATE	23/01/92	05/03/92	43	1
	81	46	JN	Female	Placebo	CHLORAL HYDRATE	19/02/92	07/04/92	49	-2
	86	274	NP	Female	Reboxetine	CHLORAL HYDRATE	18/03/92	10/06/92	85	-1
	90	70	SV	Female	Reboxetine	CHLORAL HYDRATE	30/03/92	18/05/92	50	6

(\$) - start date missing = screening date
(*) - end date missing = last dose taken date

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 6.0

CONCOMITANT DRUGS
DOUBLE BLIND PHASE

Centre	Patient	D. B.	Patient	Initial	Sex	Treatment	Concomitant drug	Start date	End date	days of administr.	interval conc_drug - start treat
11	1	372	DF		Male	Placebo	CHLORAL HYDRATE	12/10/91	06/12/91	56	0
	2	373	HB		Female	Reboxetine	ACETYSALICYLIC ACID	06/10/91(\$)	10/05/92	218	-8
							DICLOFENAC SODIUM	06/10/91(\$)	10/05/92	218	-8
							FUROSEHIDE	06/10/91(\$)	10/05/92	218	-8
							NIFEDIPINE	06/10/91(\$)	10/05/92	218	-8
	3	374	RF		Female	Reboxetine	CHLORAL HYDRATE	07/10/91	23/12/91(*)	78	-8
	4	375	BA		Male	Placebo	CHLORAL HYDRATE	21/02/92	12/03/92	21	126
	7	376	KK		Female	Placebo	CHLORAL HYDRATE	17/10/91	20/05/92	217	-7
	9	362	FI		Female	Placebo	CHLORAL HYDRATE	11/01/91	05/02/92(*)	389	-305
	10	363	BJ		Female	Reboxetine	CHLORAL HYDRATE	25/11/91	29/06/92	218	-1
	11	361	NGY		Female	Reboxetine	CHLORAL HYDRATE	05/12/91	18/05/92	166	-1
	12	364	PJ		Female	Placebo	CHLORAL HYDRATE	15/12/91	02/05/92	140	-1
	13	365	GK		Female	Reboxetine	CHLORAL HYDRATE	14/01/92	05/05/92	113	-1
	15	366	NF		Female	Placebo	CHLORAL HYDRATE	28/01/92	02/06/92	127	-1
	16	367	NA		Female	Reboxetine	CHLORAL HYDRATE	02/02/92	04/06/92	124	-1

9550077

747

(\$) - start date missing = screening date
(*) - end date missing = last dose taken date

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013

Listing No.: 6.0

CONCOMITANT DRUGS
DOUBLE BLIND PHASE

9550077

Centre	Patient	D.B.	Patient Initial	Sex	Treatment	Concomitant drug	Start date	End date	days of administr.	interval conc_drug - start treat
11	17	368	UZ	Female	Reboxetine	CHLORAL HYDRATE	31/01/92	09/06/92	131	-7
	18	369	EI	Female	Placebo	CHLORAL HYDRATE	03/02/92	17/05/92	105	-7
	19	370	FK	Female	Reboxetine	CHLORAL HYDRATE	21/02/92	22/04/92	62	-7
	20	371	LJ	Female	Placebo	CHLORAL HYDRATE	24/02/92	04/06/92	102	-7
12	1	92	IB	Male	Reboxetine	NIFEDIPINE	23/06/92	28/10/92(*)	128	236
	2	99	EFC	Female	Reboxetine	CHLORAL HYDRATE	05/11/91	27/01/92(*)	84	0
	3	93	IF	Female	Reboxetine	CHLORAL HYDRATE	30/10/91	20/12/91	52	0
	4	100	EG	Female	Reboxetine	CHLORAL HYDRATE	05/11/91	18/05/92(*)	196	0
	6	98	MK	Female	Placebo	CHLORAL HYDRATE	02/11/91	27/05/92	208	0
	10	96	IP	Female	Placebo	CHLORAL HYDRATE	05/11/90	20/04/92	533	-365
	11	94	ER	Female	Placebo	CHLORAL HYDRATE	31/10/91	15/01/92	77	0
	12	97	FSZ	Female	Placebo	CHLORAL HYDRATE	07/11/91	13/01/92(*)	68	2
	13	103	ISZ	Female	Placebo	CHLORAL HYDRATE	12/11/91	27/01/92	77	7
	14	101	OSZ	Female	Placebo	CHLORAL HYDRATE	06/11/91	14/01/92(*)	70	0
						NIFEDIPINE	06/11/91	14/01/92(*)	70	0

(*) - start date missing = screening date
(*) - end date missing = last dose taken date

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 6.0

CONCOMITANT DRUGS
DOUBLE BLIND PHASE

9550077

Centre	Patient	D.B.	Patient	Initial	Sex	Treatment	Concomitant drug	Start date	End date	days of administr.	interval conc_drug - start treat
12	14	101	GSZ		Female	Placebo	PROPRANOLOL	06/11/91	14/01/92(*)	70	0
15	15	104	GB		Male	Reboxetine	NIFEDIPINE	06/03/90	25/05/92(*)	812	-630
16	16	105	FN		Female	Reboxetine	CHLORAL HYDRATE	12/12/91	23/06/92(*)	195	1
17	17	108	TK		Male	Placebo	CHLORAL HYDRATE	15/01/92	20/04/92	97	0
18	18	109	LS		Male	Placebo	CHLORAL HYDRATE	15/01/92	23/05/92	130	0
21	21	110	FL		Female	Reboxetine	VALERIANAE COMP.	01/02/92	17/06/92	138	1
22	22	111	NV		Female	Placebo	CHLORAL HYDRATE	28/01/92	20/03/92	53	0
23	23	112	EN		Female	Placebo	CHLORAL HYDRATE	10/02/92	29/06/92	141	3
24	24	113	MF		Female	Reboxetine	VALERIAN EXTRACT	26/07/92	02/08/92	8	170
25	25	114	FS		Female	Reboxetine	METOPROLOL TARTRATE	01/01/91	04/09/92(*)	613	-403
							NIFEDIPINE	01/01/91	04/09/92(*)	613	-403
							NIFEDIPINE	13/07/92	13/07/92	1	153
							NIFEDIPINE	05/10/92	05/10/92	1	237
27	27	115	VCS		Female	Reboxetine	VALERIAN EXTRACT	16/11/92	07/02/93	84	279
							CHLORAL HYDRATE	28/02/92	27/06/92	121	20
							CHLORAL HYDRATE	24/07/92	20/08/92	28	167

(*) - start date missing = screening date
(*) - end date missing = last dose taken date

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 6.0

CONCOMITANT DRUGS
DOUBLE BLIND PHASE

Centre	Patient	D.B.	Patient	Initial	Sex	Treatment	Concomitant drug	Start date	End date	days of administr.	interval conc_drug - start treat
12	27	115	VCS		Female	Reboxetine	VALERIANAE COMP.	17/03/92	27/06/92	103	38
	28	116	IV		Female	Placebo	CHLORAL HYDRATE	18/05/92	28/05/92	11	100
	33	388	LN		Female	Reboxetine	VALERIAN EXTRACT	04/02/92	28/05/92	115	-4
	34	120	TGB		Female	Placebo	CHLORAL HYDRATE	25/03/92	19/08/92	148	-8
	35	119	LP		Female	Placebo	CHLORAL HYDRATE	12/03/93	26/03/93	15	349
	36	385	FB		Female	Reboxetine	VALERIAN EXTRACT	04/05/92 12/02/93	30/07/92 26/03/93	88 43	37 321
	13	9	SZS		Male	Placebo	NIFEDIPINE	29/03/92	05/06/92	69	1
								06/06/92	30/07/92	55	70
								31/03/92	22/06/92(*)	84	0
								26/05/92	21/06/92	27	56
								10/02/92	10/02/92	1	111

9550077

750

(\$) - start date missing = screening date
(*) - end date missing = last dose taken date

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

9550077

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Patient No. Open-Blind Centre	Phase	Treatment	From date	To date	Treat. days	Protocol dose (ng/d)	Daily dose (ng/d)	% Compl. period	% Compl. cumulat.	Reason (*)	Morning dose (ng)	Evening dose (ng)
1	1-OPEN	REBOXETINE	17/11/90	28/12/90	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	PLACEBO	29/12/90	22/03/91	84	8	8	100.0	100.0		4	4
					84							
2	1-OPEN	REBOXETINE	17/11/90	23/11/90	7	8	8	100.0	100.0	3m 3e	4	4
					14							
					21							
3-2	1-OPEN	REBOXETINE	17/11/90	28/12/90	42	8	8	100.0	100.0		4	4
					42							
4-3	2-D.B.	REBOXETINE	29/12/90	14/11/91	321	8	8	100.0	100.0		4	4
					321							
					43							
5-4	2-D.B.	REBOXETINE	03/01/91	20/11/91	322	8	8	100.0	100.0		4	4
					322							
					42							
6-5	2-D.B.	REBOXETINE	16/01/91	03/12/91	322	8	8	100.0	100.0		4	4
					322							
					42							
7	1-OPEN	REBOXETINE	05/12/90	15/01/91	42	8	8	100.0	100.0	3m 3e	4	4
					42							
					84							
	2-D.B.	PLACEBO	16/01/91	09/04/91	84	8	8	100.0	100.0		4	4
					84							
	1-OPEN	REBOXETINE	05/12/90	11/12/90	7	8	8	100.0	100.0	3m 3e	4	4
					7							
					7							

(*) 1=forget to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	% Compl. period	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
1	7	1-OPEN	REBOXETINE	19/12/90	26/12/90	8	8	8	100.0	100.0		4	4
						22							
8-6		1-OPEN	REBOXETINE	08/12/90	18/01/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	19/01/91	07/06/91	140	8	8	100.0	100.0		4	4
						140							
9-7		1-OPEN	REBOXETINE	27/12/90	06/02/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	07/02/91	26/12/91	323	8	8	100.0	100.0		4	4
						323							
10-8		1-OPEN	REBOXETINE	02/02/91	15/03/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	16/03/91	31/01/92	322	8	8	100.0	100.0		4	4
						322							
11-9		1-OPEN	REBOXETINE	09/03/91	19/04/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	20/04/91	14/11/91	209	8	8	100.0	100.0		4	4
						209							
12-10		1-OPEN	REBOXETINE	20/03/91	30/04/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	01/05/91	17/03/92	322	8	8	100.0	100.0		4	4
						322							
13		1-OPEN	REBOXETINE	01/05/91	14/05/91	14	8	8	100.0	100.0		4	4

752

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	Z Compl. period	Z Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
						14							
1	14-11	1-OPEN	REBOXETINE	08/05/91	18/06/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	19/06/91	30/07/91	42	8	8	100.0	100.0		4	4
						42							
15-12		1-OPEN	REBOXETINE	09/05/91	19/06/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	20/06/91	06/05/92	322	8	8	100.0	100.0		4	4
						322							
16-13		1-OPEN	REBOXETINE	18/05/91	28/06/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	29/06/91	21/02/92	238	8	8	100.0	100.0		4	4
						238							
17-14		1-OPEN	REBOXETINE	22/05/91	02/07/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	03/07/91	31/12/91	182	8	8	100.0	100.0		4	4
						182							
18-15		1-OPEN	REBOXETINE	23/05/91	03/07/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	04/07/91	25/09/91	84	8	8	100.0	100.0		4	4
						84							
19-16		1-OPEN	REBOXETINE	29/05/91	09/07/91	42	8	8	100.0	100.0		4	4
						42							

753

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

9550077

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	% Compl. period	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
1	19-16	2-D.B.	PLACEBO	10/07/91	18/02/92	224	8	8	100.0	100.0		4	4
						224							
20-17		1-OPEN	REBOXETINE	01/06/91	12/07/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	13/07/91	23/08/91	42	8	8	100.0	100.0		4	4
						42							
21-18		1-OPEN	REBOXETINE	05/06/91	16/07/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	17/07/91	02/06/92	322	8	8	100.0	100.0		4	4
						322							
22-19		1-OPEN	REBOXETINE	12/06/91	23/07/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	24/07/91	09/06/92	322	8	8	100.0	100.0		4	4
						322							
23		1-OPEN	REBOXETINE	22/06/91	19/07/91	28	8	8	100.0	100.0		4	4
						28							
24-20		1-OPEN	REBOXETINE	03/07/91	13/08/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	14/08/91	30/06/92	322	8	8	100.0	100.0		4	4
						322							
25-21		1-OPEN	REBOXETINE	06/07/91	16/08/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	17/08/91	03/07/92	322	8	8	100.0	100.0		4	4

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	Compl. period	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
1	26-22	1-OPEN	REBOXETINE	10/07/91	20/08/91	42	8	8	100.0	100.0		4	4
		2-D.B.	PLACEBO	21/08/91	07/07/92	42	8	8	100.0	100.0		4	4
27-23		1-OPEN	REBOXETINE	19/07/91	23/08/91	42	8	8	100.0	100.0		4	4
		2-D.B.	PLACEBO	24/08/91	04/10/91	42	8	8	100.0	100.0		4	4
28-24		1-OPEN	REBOXETINE	17/07/91	27/08/91	42	8	8	100.0	100.0		4	4
		2-D.B.	PLACEBO	28/08/91	31/12/91	126	8	8	100.0	100.0		4	4
29-25		1-OPEN	REBOXETINE	17/07/91	27/08/91	42	8	8	100.0	100.0		4	4
		2-D.B.	PLACEBO	28/08/91	14/07/92	322	8	8	100.0	100.0		4	4
30-26		1-OPEN	REBOXETINE	18/07/91	28/08/91	42	8	8	100.0	100.0		4	4
		2-D.B.	PLACEBO	29/08/91	06/11/91	70	8	8	100.0	100.0		4	4
31-27		1-OPEN	REBOXETINE	24/07/91	03/09/91	42	8	8	100.0	100.0		4	4
		2-D.B.	PLACEBO	04/10/91	03/09/91	42	8	8	100.0	100.0		4	4

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Patient No. Open-Blind Centre	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	Compl. period	X Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
1	31-27	2-D.B.	REBOXETINE	04/09/91	21/07/92	322	8	8	100.0	100.0	4	4
					322							
	32-28	1-OPEN	REBOXETINE	25/07/91	04/09/91	42	8	8	100.0	100.0	4	4
					42							
	2-D.B.	REBOXETINE	05/09/91	22/07/92	322	8	8	8	100.0	100.0	4	4
					322							
	33-29	1-OPEN	REBOXETINE	25/07/91	04/09/91	42	8	8	100.0	100.0	4	4
					42							
	2-D.B.	PLACEBO	05/09/91	16/10/91	42	8	8	8	100.0	100.0	4	4
					42							
	34-30	1-OPEN	REBOXETINE	08/08/91	11/09/91	35	8	8	100.0	100.0	4	4
				12/09/91	18/09/91	7	8	4	50.0	91.7	4e	4
					42							
	2-D.B.	REBOXETINE	19/09/91	25/09/91	7	8	4	50.0	50.0	4e	4	4
				26/09/91	12/08/92	322	8	8	100.0	98.9	4	4
					329							
	35-301	1-OPEN	REBOXETINE	28/08/91	08/10/91	42	8	8	100.0	100.0	4	4
					42							
	2-D.B.	REBOXETINE	09/10/91	25/08/92	322	8	8	8	100.0	100.0	4	4
					322							
	36-302	1-OPEN	REBOXETINE	27/08/91	08/10/91	43	8	8	100.0	100.0	4	4
					43							
	2-D.B.	PLACEBO	09/10/91	17/12/91	70	8	8	8	100.0	100.0	4	4
					70							
	37-303	1-OPEN	REBOXETINE	04/09/91	15/10/91	42	8	8	100.0	100.0	4	4

(*) 1=forget to take the medication, 2=last medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	X Compl. period	X Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
						42							
1	37-303	2-D.B.	REBOXETINE	16/10/91	01/09/92	322	8	8	100.0	100.0		4	4
						322							
	38-304	1-OPEN	REBOXETINE	18/09/91	29/10/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	30/10/91	15/09/92	322	8	8	100.0	100.0		4	4
						322							
	39-305	1-OPEN	REBOXETINE	25/09/91	05/11/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	06/11/91	22/09/92	322	8	8	100.0	100.0		4	4
						322							
	40-306	1-OPEN	REBOXETINE	25/09/91	05/11/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	06/11/91	22/09/92	322	8	8	100.0	100.0		4	4
						322							
	41-307	1-OPEN	REBOXETINE	25/09/91	05/11/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	06/11/91	28/07/92	266	8	8	100.0	100.0		4	4
						266							
	42-308	1-OPEN	REBOXETINE	03/10/91	13/11/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	14/11/91	30/09/92	322	8	8	100.0	100.0		4	4
						322							

757

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Patient No.	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	Compl. period	Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
1	43-309	1-OPEN	REBOXETINE	03/10/91	13/11/91	42	8	8	100.0	100.0	4	4
					42							
	2-D.B.	REBOXETINE	14/11/91	30/09/92	322	8	8	100.0	100.0		4	4
					322							
44	1-OPEN	REBOXETINE	09/10/91	19/11/91	42	8	8	100.0	100.0		4	4
					42							
45-310	1-OPEN	REBOXETINE	09/10/91	19/11/91	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	REBOXETINE	20/11/91	06/10/92	322	8	8	100.0	100.0		4	4
					322							
46-311	1-OPEN	REBOXETINE	16/10/91	26/11/91	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	REBOXETINE	27/11/91	13/10/92	322	8	8	100.0	100.0		4	4
					322							
47-312	1-OPEN	REBOXETINE	23/10/91	03/12/91	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	PLACEBO	04/12/91	08/09/92	280	8	8	100.0	100.0		4	4
					280							
48-313	1-OPEN	REBOXETINE	24/10/91	04/12/91	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	REBOXETINE	05/12/91	21/10/92	322	8	8	100.0	100.0		4	4
					322							
49	1-OPEN	REBOXETINE	26/10/91	08/11/91	14	8	8	100.0	100.0		4	4

(*) 1=forget to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	Compl. period	Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
1	50-314	1-OPEN	REBOXETINE	26/10/91	06/12/91	42	8	8	100.0	100.0		4	4
		2-D.B.	PLACEBO	07/12/91	23/10/92	322	8	8	100.0	100.0		4	4
51-315		1-OPEN	REBOXETINE	26/10/91	06/12/91	42	8	8	100.0	100.0		4	4
		2-D.B.	PLACEBO	07/12/91	23/10/92	322	8	8	100.0	100.0		4	4
52-316		1-OPEN	REBOXETINE	31/10/91	11/12/91	42	8	8	100.0	100.0		4	4
		2-D.B.	PLACEBO	12/12/91	28/10/92	322	8	8	100.0	100.0		4	4
53-317		1-OPEN	REBOXETINE	31/10/91	11/12/91	42	8	8	100.0	100.0		4	4
		2-D.B.	PLACEBO	12/12/91	01/04/92	112	8	8	100.0	100.0		4	4
54		1-OPEN	REBOXETINE	06/11/91	26/11/91	21	8	8	100.0	100.0		4	4
		2-D.B.	PLACEBO	27/11/91	03/12/91	7	8	4	100.0	100.0	3m 3e	2	2
55-318		1-OPEN	REBOXETINE	06/11/91	17/12/91	42	8	8	100.0	100.0		4	4
		2-D.B.	PLACEBO	18/12/91	11/02/92	56	8	8	100.0	100.0		4	4

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Patient No. Centre Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol Daily dose (mg/d)	X Compl. period	X Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
1 56-319	1-OPEN	REBOXETINE	06/11/91	17/12/91	42	8	8	100.0		4	4
					42						
	2-D.B.	REBOXETINE	18/12/91	31/12/91	14	8	8	100.0		4	4
					14						
57	1-OPEN	REBOXETINE	11/12/91	31/12/91	21	8	8	100.0		4	4
					21						
58-320	1-OPEN	REBOXETINE	11/12/91	21/01/92	42	8	8	100.0		4	4
					42						
	2-D.B.	REBOXETINE	22/01/92	31/03/92	70	8	8	100.0		4	4
					70						
59-321	1-OPEN	REBOXETINE	18/12/91	28/01/92	42	8	8	100.0		4	4
					42						
	2-D.B.	PLACEBO	29/01/92	15/12/92	322	8	8	100.0		4	4
					322						
60-322	1-OPEN	REBOXETINE	21/12/91	31/01/92	42	8	8	100.0		4	4
					42						
	2-D.B.	PLACEBO	01/02/92	18/12/92	322	8	8	100.0		4	4
					322						
61-323	1-OPEN	REBOXETINE	21/12/91	31/01/92	42	8	8	100.0		4	4
					42						
	2-D.B.	REBOXETINE	01/02/92	18/12/92	322	8	8	100.0		4	4
					322						

(*) 1=forget to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Patient No. Centre Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	Compl. period	X Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
1 62-324	1-OPEN	REBOXETINE	08/01/92	18/02/92	42	8	8	100.0	100.0		4	4
					42							
63	2-D.B.	PLACEBO	19/02/92	05/01/93	322	8	8	100.0	100.0		4	4
					322							
64-325	1-OPEN	REBOXETINE	09/01/92	29/01/92	21	8	8	100.0	100.0		4	4
					21							
65	2-D.B.	PLACEBO	29/02/92	15/01/93	322	8	8	100.0	100.0		4	4
					322							
66-326	1-OPEN	REBOXETINE	22/01/92	04/03/92	43	8	8	100.0	100.0		4	4
					43							
67-327	2-D.B.	REBOXETINE	05/03/92	19/01/93	321	8	8	100.0	100.0		4	4
					321							
68	1-OPEN	REBOXETINE	22/01/92	04/03/92	43	8	8	100.0	100.0		4	4
					43							
69	2-D.B.	PLACEBO	05/03/92	31/07/92	149	8	8	100.0	100.0		4	4
					149							
69	1-OPEN	REBOXETINE	22/01/92	04/03/92	43	8	8	100.0	100.0		4	4
					43							

761

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Patient No. Centre Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	Compl. period	X Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
1 70-328	1-OPEN	REBOXETINE	25/01/92	06/03/92	42	8	8	100.0	100.0		4	4
					42							
71-329	2-D.B.	PLACEBO	07/03/92	26/06/92	112	8	8	100.0	100.0		4	4
					112							
72-330	1-OPEN	REBOXETINE	29/01/92	10/03/92	42	8	8	100.0	100.0		4	4
					42							
73-121	2-D.B.	REBOXETINE	11/03/92	30/06/92	112	8	8	100.0	100.0		4	4
					112							
74-122	1-OPEN	REBOXETINE	29/01/92	10/03/92	42	8	8	100.0	100.0		4	4
					42							
75-123	2-D.B.	PLACEBO	11/03/92	26/01/93	140	8	8	100.0	100.0		4	4
					140							
	1-OPEN	REBOXETINE	01/02/92	13/03/92	42	8	8	100.0	100.0		4	4
					42							

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBEXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Patient No. Centre	Open-Blind Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	x Compl. period	x Compl. cumulat.	Reason (*)	Morning dose (ng)	Evening dose (ng)
1	75-123	2-D.B.	REBEXETINE	14/03/92	29/01/93	322	8	8	100.0	100.0	4	4
					322							
	76-124	1-OPEN	REBEXETINE	08/02/92	20/03/92	42	8	8	100.0	100.0	4	4
					42							
	77-125	2-D.B.	PLACEBO	21/03/92	05/02/93	322	8	8	100.0	100.0	4	4
					322							
	79-126	1-OPEN	REBEXETINE	08/02/92	20/03/92	42	8	8	100.0	100.0	4	4
					42							
	80-127	2-D.B.	PLACEBO	21/03/92	05/02/93	322	8	8	100.0	100.0	4	4
					322							
	81-128	1-OPEN	REBEXETINE	08/02/92	20/03/92	42	8	8	100.0	100.0	4	4
					42							
		2-D.B.	PLACEBO	21/03/92	30/04/92	41	8	8	100.0	100.0	4	4
					41							
		1-OPEN	REBEXETINE	08/02/92	20/03/92	42	8	8	100.0	100.0	4	4
					42							
		2-D.B.	REBEXETINE	21/03/92	05/02/93	322	8	8	100.0	100.0	4	4

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (ng/d)	Daily dose (ng/d)	Compl. period	X Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
1	82-129	1-OPEN	REBOXETINE	08/02/92	20/03/92	322	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	21/03/92	05/02/93	322	8	8	100.0	100.0		4	4
						42							
83		1-OPEN	REBOXETINE	08/02/92	20/03/92	322	8	8	100.0	100.0		4	4
						42							
84-130		1-OPEN	REBOXETINE	08/02/92	20/03/92	42	8	8	100.0	100.0		4	4
						42							
764		2-D.B.	PLACEBO	21/03/92	05/02/93	322	8	8	100.0	100.0		4	4
						42							
85-131		1-OPEN	REBOXETINE	08/02/92	20/03/92	322	8	8	100.0	100.0		4	4
						42							
86		1-OPEN	REBOXETINE	08/02/92	20/03/92	322	8	8	100.0	100.0		4	4
						42							
87-132		1-OPEN	REBOXETINE	08/02/92	20/03/92	42	8	8	100.0	100.0		4	4
						42							
88		1-OPEN	REBOXETINE	12/02/92	24/03/92	42	8	8	100.0	100.0		4	4
						42							

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

9550077

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (ng/d)	Daily dose (ng/d)	X Compl. period	X Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
1	89-133	1-OPEN	REBOXETINE	12/02/92	24/03/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	25/03/92	19/05/92	56	8	8	100.0	100.0		4	4
						56							
90	134	1-OPEN	REBOXETINE	12/02/92	24/03/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	25/03/92	07/04/92	14	8	8	100.0	100.0		4	4
						14							
91	135	1-OPEN	REBOXETINE	12/02/92	24/03/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	25/03/92	09/02/93	322	8	8	100.0	100.0		4	4
						322							
92		1-OPEN	REBOXETINE	12/02/92	24/03/92	42	8	8	100.0	100.0		4	4
						42							
93	136	1-OPEN	REBOXETINE	13/02/92	25/03/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	26/03/92	10/02/93	322	8	8	100.0	100.0		4	4
						322							
94	137	1-OPEN	REBOXETINE	13/02/92	25/03/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	26/03/92	10/02/93	322	8	8	100.0	100.0		4	4
						322							
95	138	1-OPEN	REBOXETINE	13/02/92	25/03/92	42	8	8	100.0	100.0		4	4

(*) 1=forget to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (ng/d)	Daily dose (ng/d)	% Compl. period	% Compl. cumulat.	Reason (*)	Morning dose (ng)	Evening dose (ng)
	1	95-138	2-D.B.	REBOXETINE	26/03/92	10/02/93	322	8	8	100.0	100.0	4	4
						42							
						322							
	96-139	1-OPEN	REBOXETINE	13/02/92	25/03/92	42	8	8	8	100.0	100.0	4	4
						42							
	97-140	2-D.B.	REBOXETINE	26/03/92	10/02/93	322	8	8	8	100.0	100.0	4	4
						42							
						322							
	98-141	1-OPEN	REBOXETINE	13/02/92	25/03/92	42	8	8	8	100.0	100.0	4	4
						42							
						322							
	99	2-D.B.	REBOXETINE	26/03/92	10/02/93	322	8	8	8	100.0	100.0	4	4
						42							
						322							
	100-142	1-OPEN	REBOXETINE	13/02/92	25/03/92	42	8	8	8	100.0	100.0	4	4
						42							
						322							
	101-143	2-D.B.	REBOXETINE	26/03/92	10/02/93	322	8	8	8	100.0	100.0	4	4
						42							
						322							
	101-143	1-OPEN	REBOXETINE	19/02/92	31/03/92	42	8	8	8	100.0	100.0	4	4
						42							

(*) 1=forget to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (ng/d)	Daily dose (ng/d)	% Compl. period	% Compl. cumulat.	Reason (*)	Morning dose (ng)	Evening dose (ng)
1	101-143	2-D.B.	REBOXETINE	01/04/92	16/02/93	322	8	8	100.0	100.0		4	4
						322							
	102	1-OPEN	REBOXETINE	19/02/92	31/03/92	42	8	8	100.0	100.0		4	4
						42							
	103	1-OPEN	REBOXETINE	19/02/92	25/02/92	7	8	8	100.0	100.0		4	4
				26/02/92	04/03/92	8	8	4	100.0	100.0	3m 3e	2	2
						15							
	104-144	1-OPEN	REBOXETINE	19/02/92	31/03/92	42	8	8	100.0	100.0		4	4
						42							
	105-145	2-D.B.	PLACEBO	01/04/92	17/02/93	323	8	8	100.0	100.0		4	4
						323							
	106-146	1-OPEN	REBOXETINE	19/02/92	31/03/92	42	8	8	100.0	100.0		4	4
						42							
	107-147	2-D.B.	PLACEBO	01/04/92	16/02/93	322	8	8	100.0	100.0		4	4
						322							
	108-148	1-OPEN	REBOXETINE	20/02/92	01/04/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	02/04/92	16/02/93	321	8	8	100.0	100.0		4	4
						321							
		1-OPEN	REBOXETINE	20/02/92	01/04/92	42	8	8	100.0	100.0		4	4

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	% Compl. period	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
						42							
1	108-148	2-D.B.	PLACEBO	02/04/92	17/02/93	322	8	8	100.0	100.0		4	4
						322							
	109-149	1-OPEN	REBOXETINE	20/02/92	01/04/92	42	8	8	100.0	100.0		4	4
						42							
	2-D.B.		REBOXETINE	02/04/92	17/02/93	322	8	8	100.0	100.0		4	4
						322							
	110-150	1-OPEN	REBOXETINE	20/02/92	01/04/92	42	8	8	100.0	100.0		4	4
						42							
	2-D.B.		REBOXETINE	02/04/92	17/02/93	322	8	8	100.0	100.0		4	4
						322							
	111-331	1-OPEN	REBOXETINE	20/02/92	01/04/92	42	8	8	100.0	100.0		4	4
						42							
	2-D.B.		PLACEBO	02/04/92	17/02/93	322	8	8	100.0	100.0		4	4
						322							
	112	1-OPEN	REBOXETINE	20/02/92	01/04/92	42	8	8	100.0	100.0		4	4
						42							
	113	1-OPEN	REBOXETINE	20/02/92	01/04/92	42	8	8	100.0	100.0		4	4
						42							
	114-332	1-OPEN	REBOXETINE	26/02/92	07/04/92	42	8	8	100.0	100.0		4	4
						42							
	2-D.B.		PLACEBO	08/04/92	24/02/93	323	8	8	100.0	100.0		4	4
						323							

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

9550077

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	X Compl. period	X Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
1	115-333	1-OPEN	REBOXETINE	26/02/92	07/04/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	08/04/92	24/02/93	323	8	8	100.0	100.0		4	4
						323							
	116-334	1-OPEN	REBOXETINE	26/02/92	07/04/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	08/04/92	24/02/93	323	8	8	100.0	100.0		4	4
						323							
	117-335	1-OPEN	REBOXETINE	26/02/92	07/04/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	08/04/92	24/02/93	323	8	8	100.0	100.0		4	4
						323							
	118	1-OPEN	REBOXETINE	26/02/92	31/03/92	35	8	8	100.0	100.0		4	4
						35							
	119	1-OPEN	REBOXETINE	26/02/92	07/04/92	42	8	8	100.0	100.0		4	4
						42							
	120	1-OPEN	REBOXETINE	27/02/92	08/04/92	42	8	8	100.0	100.0		4	4
						42							
	121-336	1-OPEN	REBOXETINE	27/02/92	08/04/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	09/04/92	24/02/93	322	8	8	100.0	100.0		4	4
						322							
	122-337	1-OPEN	REBOXETINE	27/02/92	08/04/92	42	8	8	100.0	100.0		4	4

769

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	Compl. period	Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
	1	122-337	2-D.B.	PLACEBO	09/04/92	24/02/93	322	8	8	100.0	100.0	4	4
						42							
						322							
	123-338	1-OPEN	REBOXETINE	27/02/92	08/04/92	42	8	8	8	100.0	100.0	4	4
						42							
	2-D.B.	REBOXETINE	09/04/92	24/02/93	322	8	8	8	8	100.0	100.0	4	4
						322							
	124-339	1-OPEN	REBOXETINE	27/02/92	08/04/92	42	8	8	8	100.0	100.0	4	4
						42							
	2-D.B.	PLACEBO	09/04/92	24/02/93	322	8	8	8	8	100.0	100.0	4	4
						322							
	125-340	1-OPEN	REBOXETINE	27/02/92	08/04/92	42	8	8	8	100.0	100.0	4	4
						42							
	2-D.B.	REBOXETINE	09/04/92	24/02/93	322	8	8	8	8	100.0	100.0	4	4
						322							
	126-341	1-OPEN	REBOXETINE	27/02/92	08/04/92	42	8	8	8	100.0	100.0	4	4
						42							
	2-D.B.	PLACEBO	09/04/92	24/02/93	322	8	8	8	8	100.0	100.0	4	4
						322							
	127-342	1-OPEN	REBOXETINE	27/02/92	08/04/92	42	8	8	8	100.0	100.0	4	4
						42							
	2-D.B.	REBOXETINE	09/04/92	24/02/93	322	8	8	8	8	100.0	100.0	4	4
						322							

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	Z Compl. period	Z Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
1	128-343	1-OPEN	REBOXETINE	27/02/92	08/04/92	42	42	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	09/04/92	24/02/93	322	322	8	100.0	100.0		4	4
						322							
	129-344	1-OPEN	REBOXETINE	27/02/92	08/04/92	42	42	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	09/04/92	16/12/92	252	252	8	100.0	100.0		4	4
						252							
	130-345	1-OPEN	REBOXETINE	29/02/92	10/04/92	42	42	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	11/04/92	31/07/92	112	112	8	100.0	100.0		4	4
						112							
	131	1-OPEN	REBOXETINE	11/03/92	20/04/92	41	41	8	100.0	100.0		4	4
						41							
	132	1-OPEN	REBOXETINE	19/03/92	29/04/92	42	42	8	100.0	100.0		4	4
						42							
	133-346	1-OPEN	REBOXETINE	21/03/92	30/04/92	41	41	8	100.0	100.0		4	4
						41							
		2-D.B.	PLACEBO	01/05/92	19/03/93	323	323	8	100.0	100.0		4	4
						323							
	134-347	1-OPEN	REBOXETINE	25/03/92	05/05/92	42	42	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	06/05/92	23/03/93	322	322	8	100.0	100.0		4	4

(*) 1=forget to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Patient No. Centre Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	z Compl. period	x Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
1 135-348	1-OPEN	REBOXETINE	25/03/92	05/05/92	42	8	8	100.0	100.0		4	4
					42							
136-349	2-D.B.	REBOXETINE	06/05/92	23/03/93	322	8	8	100.0	100.0		4	4
					322							
137	1-OPEN	REBOXETINE	25/03/92	05/05/92	42	8	8	100.0	100.0		4	4
					42							
138-350	2-D.B.	PLACEBO	06/05/92	23/03/93	322	8	8	100.0	100.0		4	4
					322							
139-351	1-OPEN	REBOXETINE	25/03/92	05/05/92	42	8	8	100.0	100.0		4	4
					42							
140-352	2-D.B.	PLACEBO	06/05/92	23/03/93	322	8	8	100.0	100.0		4	4
					322							
	1-OPEN	REBOXETINE	25/03/92	05/05/92	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	REBOXETINE	06/05/92	23/03/93	322	8	8	100.0	100.0		4	4
					322							
	1-OPEN	REBOXETINE	25/03/92	05/05/92	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	REBOXETINE	06/05/92	23/03/93	322	8	8	100.0	100.0		4	4
					322							

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	Compl. period	Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
1	141-353	1-OPEN	REBOXETINE	25/05/92	05/05/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	06/05/92	01/12/92	210	8	8	100.0	100.0		4	4
						210							
142-354		1-OPEN	REBOXETINE	25/03/92	05/05/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	06/05/92	23/03/93	322	8	8	100.0	100.0		4	4
						322							
143-355		1-OPEN	REBOXETINE	25/05/92	05/05/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	06/05/92	11/08/92	98	8	8	100.0	100.0		4	4
						98							
144-356		1-OPEN	REBOXETINE	26/03/92	06/05/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	07/05/92	16/12/92	224	8	8	100.0	100.0		4	4
						224							
145-357		1-OPEN	REBOXETINE	28/03/92	08/05/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	09/05/92	26/03/93	322	8	8	100.0	100.0		4	4
						322							
146-358		1-OPEN	REBOXETINE	28/03/92	08/05/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	09/05/92	26/03/93	322	8	8	100.0	100.0		4	4

773

(*) 1=forget to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Patient No. Centre	Open-Blind Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	X Compl. period	X Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
1	1-OPEN	REBOXETINE	28/03/92	03/04/92	7	8	8	100.0	100.0		4	4
			04/04/92	10/04/92	7	8	4	100.0	100.0	3m 3a	2	2
148-359	1-OPEN	REBOXETINE	28/03/92	08/05/92	42	8	8	100.0	100.0		4	4
					14							
149-360	2-D.B.	REBOXETINE	09/05/92	26/03/93	322	8	8	100.0	100.0		4	4
					42							
150-151	1-OPEN	REBOXETINE	28/03/92	08/05/92	42	8	8	100.0	100.0		4	4
					42							
2	2-D.B.	PLACEBO	09/05/92	26/03/93	322	8	8	100.0	100.0		4	4
					42							
31	1-OPEN	REBOXETINE	09/05/92	18/12/92	224	8	8	100.0	100.0		4	4
					224							
32	1-OPEN	REBOXETINE	10/12/90	25/12/90	16	8	8	100.0	100.0		4	4
			26/12/90	26/12/90	1	8	4	100.0	100.0	6a	4	4
33	1-OPEN	REBOXETINE	15/01/91	30/01/91	16	8	8	100.0	100.0		4	4
					17							
34	1-OPEN	REBOXETINE	28/03/91	24/04/91	28	8	8	100.0	100.0		4	4
					16							

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	z Compl. period	z Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
3	1	1-OPEN	REBOXETINE	16/11/90	13/12/90	28	8	8	100.0	100.0		4	4
						28							
2-61	1-OPEN	REBOXETINE	17/11/90	28/12/90	42	8	8	100.0	100.0		4	4	
					42								
3-62	1-OPEN	REBOXETINE	18/09/91	22/04/91	20	8	8	100.0	100.0		4	4	
					22			0.0	96.9	1m 1e	4	4	
					42			100.0	99.2		4	4	
					251								
7-75	1-OPEN	REBOXETINE	23/04/91	14/05/91	20	8	8	100.0	100.0		4	4	
					42					3m 3e	2	2	
4	1-OPEN	REBOXETINE	08/12/90	02/01/91	26	8	8	100.0	100.0		4	4	
					127					3e	4	2	
5	1-OPEN	REBOXETINE	26/12/90	10/01/91	18	8	8	100.0	100.0		4	4	
					39					3m 3e	4	4	
6	1-OPEN	REBOXETINE	20/12/90	24/12/90	5	8	8	100.0	100.0		4	4	
					5					3e	4	2	
7-71	1-OPEN	REBOXETINE	11/12/90	02/01/91	23	8	8	100.0	100.0		4	4	
					1					3e	4	2	

(*) 1=forget to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS RSD

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	% Compl. period	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)		
3	7-71	1-OPEN	REBOXETINE	04/01/91	09/01/91	6	8	4	100.0	100.0	3m 3e	2	2		
				10/01/91	10/01/91	1	8	6	100.0	100.0	3m	2	4		
				11/01/91	22/01/91	12	8	8	100.0	100.0		4	4		
						43									
	2-D.B.		REBOXETINE	23/01/91	28/01/91	6	8	8	100.0	100.0		4	4		
				29/01/91	06/02/91	9	8	4	100.0	100.0	3m 3e	2	2		
						15									
9	1-OPEN		REBOXETINE	19/01/91	04/02/91	17	8	8	100.0	100.0		4	4		
				05/02/91	05/02/91	1	8	4	100.0	100.0	6e	4	4		
						18									
10-72	1-OPEN		REBOXETINE	11/04/91	22/05/91	42	8	8	100.0	100.0		4	4		
						42									
11	2-D.B.		PLACEBO	23/05/91	11/09/91	112	8	8	100.0	100.0		4	4		
						112									
8	1-OPEN		REBOXETINE	25/05/91	27/05/91	3	8	8	100.0	100.0		4	4		
						3									
1-OPEN		REBOXETINE	04/12/90	14/01/91	42	8	8	100.0	100.0		4	4			
						42									
2-D.B.		PLACEBO	15/01/91	07/10/91	266	8	8	100.0	100.0		4	4			
						266									
2-212	1-OPEN		REBOXETINE	14/12/90	24/01/91	42	8	8	100.0	100.0		4	4		
						42									
2-D.B.		REBOXETINE	25/01/91	12/12/91	322	8	8	100.0	100.0		4	4			
						322									
3-213	1-OPEN		REBOXETINE	21/12/90	31/01/91	42	8	8	100.0	100.0		4	4		

(*) 1=forget to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	Compl. period	Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
8 3-213	2-D.B.	REBOXETINE	01/02/91	11/04/91	70	8	8	100.0	100.0		4	4
					42							
					70							
4-214	1-OPEN	REBOXETINE	11/01/91	21/02/91	42	8	8	100.0	100.0		4	4
					42							
2-D.B.		PLACERO	22/02/91	09/01/92	322	8	8	100.0	100.0		4	4
					322							
5-215	1-OPEN	REBOXETINE	15/01/91	25/02/91	42	8	8	100.0	100.0		4	4
					42							
2-D.B.		PLACERO	26/02/91	11/03/91	14	8	8	100.0	100.0		4	4
					14							
6-216	1-OPEN	REBOXETINE	22/01/91	04/03/91	42	8	8	100.0	100.0		4	4
					42							
2-D.B.		REBOXETINE	05/03/91	20/01/92	322	8	8	100.0	100.0		4	4
					322							
7	1-OPEN	REBOXETINE	22/03/91	11/04/91	21	8	8	100.0	100.0		4	4
					21							
9 1	1-OPEN	REBOXETINE	29/05/90	09/07/90	42	8	8	100.0	100.0		4	4
					42							
2-241	1-OPEN	REBOXETINE	29/05/90	09/07/90	42	8	8	100.0	100.0		4	4
					42							
2-D.B.		PLACERO	10/07/90	27/05/91	322	8	8	100.0	100.0		4	4
					322							

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	% Compl. period	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
9	1-OPEN	REBOXETINE	15/08/90	25/09/90	42	8	8	100.0	100.0		4	4
					42							
4	1-OPEN	REBOXETINE	01/09/90	12/10/90	42	8	8	100.0	100.0		4	4
					42							
5-242	1-OPEN	REBOXETINE	23/09/90	03/11/90	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	PLACEBO	04/11/90	13/07/91	252	8	8	100.0	100.0		4	4
					252							
6-245	1-OPEN	REBOXETINE	07/11/90	18/12/90	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	REBOXETINE	19/12/90	05/11/91	322	8	8	100.0	100.0		4	4
					322							
7-243	1-OPEN	REBOXETINE	09/11/90	20/12/90	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	REBOXETINE	21/12/90	07/11/91	322	8	8	100.0	100.0		4	4
					322							
8-244	1-OPEN	REBOXETINE	22/11/90	02/01/91	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	PLACEBO	03/01/91	08/05/91	126	8	8	100.0	100.0		4	4
					126							
9	1-OPEN	REBOXETINE	24/11/90	04/01/91	42	8	8	100.0	100.0		4	4
					42							
10	1-OPEN	REBOXETINE	11/01/91	21/02/91	42	8	8	100.0	100.0		4	4

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	Z Compl. period	Z Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
9	11-246	1-OPEN	REBOXETINE	30/01/91	12/03/91	42	8	8	100.0	100.0		4	4
		2-D.B.	REBOXETINE	13/03/91	28/01/92	322	8	8	100.0	100.0		4	4
		1-OPEN	REBOXETINE	06/03/91	16/04/91	42	8	8	100.0	100.0		4	4
		2-D.B.	PLACEBO	17/04/91	25/06/91	70	8	8	100.0	100.0		4	4
13-248	779	1-OPEN	REBOXETINE	14/03/91	24/04/91	42	8	8	100.0	100.0		4	4
		2-D.B.	PLACEBO	25/04/91	11/03/92	322	8	8	100.0	100.0		4	4
		1-OPEN	REBOXETINE	25/03/91	05/05/91	42	8	8	100.0	100.0		4	4
		1-OPEN	REBOXETINE	20/05/91	30/06/91	42	8	8	100.0	100.0		4	4
15-249		2-D.B.	REBOXETINE	01/07/91	17/05/92	322	8	8	100.0	100.0		4	4
		1-OPEN	REBOXETINE	10/07/91	20/08/91	42	8	8	100.0	100.0		4	4
		2-D.B.	REBOXETINE	21/08/91	07/07/92	322	8	8	100.0	100.0		4	4
		1-OPEN	REBOXETINE	07/07/92		42	8	8	100.0	100.0		4	4

(*) 1=forget to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (ng/d)	Daily dose (ng/d)	Z Compl. period	Z Compl. cumulat.	Reason (*)	Morning dose (ng)	Evening dose (ng)
9	17	1-OPEN	REBOXETINE	05/07/91	18/07/91	14	8	8	100.0	100.0		4	4
						14							
18		1-OPEN	REBOXETINE	15/07/91	25/08/91	42	8	8	100.0	100.0		4	4
						42							
19-251		1-OPEN	REBOXETINE	14/08/91	24/09/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	25/09/91	17/12/91	84	8	8	100.0	100.0		4	4
						84							
20-252		1-OPEN	REBOXETINE	24/08/91	18/09/91	26	8	8	100.0	100.0		4	4
				19/09/91	20/09/91	2	8	4	50.0	96.4	1e	4	4
				21/09/91	04/10/91	14	8	8	100.0	97.6		4	4
						42							
		2-D.B.	REBOXETINE	05/10/91	26/12/91	83	8	8	100.0	100.0		4	4
				27/12/91	27/12/91	1	8	4	50.0	99.4	1e	4	4
						84							
21		1-OPEN	REBOXETINE	26/10/91	06/12/91	42	8	8	100.0	100.0		4	4
						42							
22		1-OPEN	REBOXETINE	30/10/91	10/12/91	42	8	8	100.0	100.0		4	4
						42							
23-256		1-OPEN	REBOXETINE	09/11/91	20/12/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	21/12/91	27/03/92	98	8	8	100.0	100.0		4	4
						98							
24-253		1-OPEN	REBOXETINE	12/11/91	23/12/91	42	8	8	100.0	100.0		4	4
						42							

(*) 1=Forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	z Compl. period	z Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
9	24-253	2-D.B.	PLACEBO	24/12/91	30/03/92	98	8	8	100.0	100.0		4	4
						98							
	25-254	1-OPEN	REBOXETINE	20/11/91	31/12/91	42	8	8	100.0	100.0		4	4
						42							
	26-255	2-D.B.	PLACEBO	01/01/92	03/11/92	308	8	8	100.0	100.0		4	4
						308							
	27	1-OPEN	REBOXETINE	22/11/91	02/01/92	42	8	8	100.0	100.0		4	4
						42							
	28-257	2-D.B.	REBOXETINE	03/01/92	23/04/92	112	8	8	100.0	100.0		4	4
						112							
	29-258	1-OPEN	REBOXETINE	28/03/92	08/05/92	42	8	8	100.0	100.0		4	4
						42							
	30-259	2-D.B.	PLACEBO	19/05/92	19/10/92	154	8	8	100.0	100.0		4	4
						154							
	31-260	1-OPEN	REBOXETINE	07/04/92	18/05/92	42	8	8	100.0	100.0		4	4
						42							
	32-261	2-D.B.	REBOXETINE	19/05/92	19/10/92	154	8	8	100.0	100.0		4	4
						154							
	33-262	1-OPEN	REBOXETINE	07/04/92	18/05/92	42	8	8	100.0	100.0		4	4
						42							
	34-263	2-D.B.	REBOXETINE	19/05/92	15/06/92	28	8	8	100.0	100.0		4	4

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBEXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	x Compl. period	x Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
10	1-271	1-OPEN	REBEXETINE	16/10/90	26/11/90	28	8	8	100.0	100.0		4	4
						42							
	2-D.B.		REBEXETINE	27/11/90	01/02/91	42	8	8	100.0	100.0		4	4
						67							
4-272	1-OPEN		REBEXETINE	31/10/90	11/12/90	67	8	8	100.0	100.0		4	4
						42							
	2-D.B.		PLACEBO	12/12/90	19/02/91	42	8	8	100.0	100.0		4	4
						70							
	1-OPEN		REBEXETINE	14/11/90	26/12/90	10	8	8	100.0	100.0		4	4
						43							
	2-D.B.		PLACEBO	27/12/90	06/02/91	42	8	8	100.0	100.0		4	4
						43							
6	1-OPEN		REBEXETINE	16/11/90	15/12/90	42	8	8	100.0	100.0		4	4
						30							
7-274	1-OPEN		REBEXETINE	20/11/90	01/01/91	30	8	8	100.0	100.0		4	4
						43							
8	2-D.B.		REBEXETINE	02/01/91	15/01/91	43	8	8	100.0	100.0		4	4
						14							
	1-OPEN		REBEXETINE	27/11/90	17/12/90	14	8	8	100.0	100.0		4	4
						21							
9-275	1-OPEN		REBEXETINE	04/12/90	14/01/91	21	8	8	100.0	100.0		4	4
						42							

(*) 1=Forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	X Compl. period	X Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
						42							
10	9-275	2-D.B.	REBOXETINE	15/01/91	04/02/91	21	8	8	100.0	100.0		4	4
						21							
10	276	1-OPEN	REBOXETINE	04/12/90	14/01/91	42	8	8	100.0	100.0		4	4
						42							
2-D.B.			PLACEBO	15/01/91	06/02/91	23	8	8	100.0	100.0		4	4
						23							
11		1-OPEN	REBOXETINE	27/12/90	13/01/91	18	8	8	100.0	100.0		4	4
						18							
12-277		1-OPEN	REBOXETINE	10/01/91	20/02/91	42	8	8	100.0	100.0		4	4
						42							
2-D.B.			REBOXETINE	21/02/91	20/03/91	28	8	8	100.0	100.0		4	4
						28							
13-278		1-OPEN	REBOXETINE	12/02/91	25/03/91	42	8	8	100.0	100.0		4	4
						42							
2-D.B.			REBOXETINE	26/03/91	08/04/91	14	8	8	100.0	100.0		4	4
						14							
14-279		1-OPEN	REBOXETINE	12/02/91	25/03/91	42	8	8	100.0	100.0		4	4
						42							
2-D.B.			PLACEBO	26/03/91	10/02/92	322	8	8	100.0	100.0		4	4
						322							
15-280		1-OPEN	REBOXETINE	21/02/91	03/04/91	42	8	8	100.0	100.0		4	4
						42							

(*) 1=forget to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

9550077

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	% Compl. period	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
10	15-280	2-D.B.	REBOXETINE	04/04/91	30/04/91	27	8	8	100.0	100.0		4	4
						27							
	16-281	1-OPEN	REBOXETINE	04/03/91	15/04/91	43	8	8	100.0	100.0		4	4
						43							
		2-D.B.	PLACEBO	16/04/91	02/03/92	322	8	8	100.0	100.0		4	4
						322							
	17-282	1-OPEN	REBOXETINE	14/03/91	24/04/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	25/04/91	10/03/92	321	8	8	100.0	100.0		4	4
						321							
	18-283	1-OPEN	REBOXETINE	18/03/91	29/04/91	43	8	8	100.0	100.0		4	4
						43							
	19-284	1-OPEN	REBOXETINE	02/04/91	14/05/91	43	8	8	100.0	100.0		4	4
						43							
		2-D.B.	PLACEBO	15/05/91	30/03/92	321	8	8	100.0	100.0		4	4
						321							
	20-285	1-OPEN	REBOXETINE	23/04/91	03/06/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	04/06/91	04/11/91	154	8	8	100.0	100.0		4	4
						154							
	21-288	1-OPEN	REBOXETINE	29/04/91	09/06/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	10/06/91	29/09/91	112	8	8	100.0	100.0		4	4

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	z Compl. period	z Compl. cumulat.	Reason (*)	Morning dose (ng)	Evening dose (ng)
10	22-286	1-OPEN	REBOXETINE	23/04/91	03/06/91	112	8	100.0	100.0		4	4
						42	8	100.0	100.0		4	4
	2-D.B.	REBOXETINE	04/06/91	20/04/92	322	8	100.0	100.0			4	4
					42	8	100.0	100.0		4	4	
23-287	1-OPEN	REBOXETINE	24/04/91	04/06/91	322	8	100.0	100.0			4	4
					42	8	100.0	100.0		4	4	
	2-D.B.	REBOXETINE	05/06/91	25/02/92	266	8	100.0	100.0			4	4
					266	8	100.0	100.0		4	4	
24-289	1-OPEN	REBOXETINE	01/05/91	11/06/91	42	8	100.0	100.0			4	4
					42	8	100.0	100.0		4	4	
	2-D.B.	PLACERO	12/06/91	28/04/92	322	8	100.0	100.0			4	4
					322	8	100.0	100.0		4	4	
25	1-OPEN	REBOXETINE	14/05/91	03/06/91	21	8	100.0	100.0			4	4
					21	8	100.0	100.0		4	4	
26-290	1-OPEN	REBOXETINE	28/05/91	08/07/91	42	8	100.0	100.0			4	4
					42	8	100.0	100.0		4	4	
	2-D.B.	REBOXETINE	09/07/91	05/08/91	28	8	100.0	100.0			4	4
					28	8	100.0	100.0		4	4	
27-292	1-OPEN	REBOXETINE	03/06/91	14/07/91	42	8	100.0	100.0			4	4
					42	8	100.0	100.0		4	4	
	2-D.B.	REBOXETINE	15/07/91	01/06/92	323	8	100.0	100.0			4	4
					323	8	100.0	100.0		4	4	

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4= regimen modified by patient.

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	% Compl. period	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
10	28-291	1-OPEN	REBOXETINE	30/05/91	10/07/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	11/07/91	13/05/92	308	8	8	100.0	100.0		4	4
						308							
29-293		1-OPEN	REBOXETINE	19/08/91	29/09/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	30/09/91	06/01/92	99	8	8	100.0	100.0		4	4
						99							
30-294		1-OPEN	REBOXETINE	17/09/91	28/10/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	29/10/91	14/09/92	322	8	8	100.0	100.0		4	4
						322							
31-297		1-OPEN	REBOXETINE	16/09/91	27/10/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	28/10/91	14/09/92	323	8	8	100.0	100.0		4	4
						323							
32-299		1-OPEN	REBOXETINE	16/09/91	27/10/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	28/10/91	14/09/92	323	8	8	100.0	100.0		4	4
						323							
33-300		1-OPEN	REBOXETINE	19/09/91	30/10/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	31/10/91	21/01/92	83	8	8	100.0	100.0		4	4

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	X Compl. period	X Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
10	34-31	1-OPEN	REBOXETINE	23/09/91	03/11/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	04/11/91	12/01/92	70	8	8	100.0	100.0		4	4
						70							
	35-35	1-OPEN	REBOXETINE	23/09/91	03/11/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	04/11/91	12/01/92	70	8	8	100.0	100.0		4	4
						70							
	36-36	1-OPEN	REBOXETINE	14/10/91	25/11/91	43	8	8	100.0	100.0		4	4
						43							
27 00 7	37-32	1-OPEN	REBOXETINE	14/10/91	24/11/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	25/11/91	26/04/92	154	8	8	100.0	100.0		4	4
						154							
38-37	1-OPEN		REBOXETINE	14/10/91	14/10/91	1	8	8	100.0	100.0		4	4
						3							
						3							
						38							
		2-D.B.	REBOXETINE	25/11/91	03/02/92	71	8	8	100.0	100.0		4	4
						71							
39-40	1-OPEN		REBOXETINE	15/10/91	25/11/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	26/11/91	13/10/92	323	8	8	100.0	100.0		4	4
						42							

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

9550077

EXPERIMENTAL TREATMENT

Patient No. Centre Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	% Compl. period	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
10 40-33	1-OPEN	REBOXETINE	24/10/91	04/12/91	323	8	8	100.0	100.0		4	4
					42							
	2-D.B.	PLACEBO	05/12/91	28/01/92	55	8	8	100.0	100.0		4	4
					55							
41-42	1-OPEN	REBOXETINE	30/10/91	10/12/91	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	REBOXETINE	11/12/91	27/10/92	322	8	8	100.0	100.0		4	4
					322							
42-295	1-OPEN	REBOXETINE	14/11/91	25/12/91	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	PLACEBO	26/12/91	24/01/92	30	8	8	100.0	100.0		4	4
					30							
43-296	1-OPEN	REBOXETINE	15/11/91	26/12/91	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	PLACEBO	27/12/91	14/05/92	140	8	8	100.0	100.0		4	4
					140							
44-298	1-OPEN	REBOXETINE	18/11/91	29/12/91	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	PLACEBO	30/12/91	08/03/92	70	8	8	100.0	100.0		4	4
					70							
45-34	1-OPEN	REBOXETINE	20/11/91	31/12/91	42	8	8	100.0	100.0		4	4
					42							

(*) 1=forgot to take the medication, 2=last medication, 3=adverse event, 4=regimen modified by patient.

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Patient No. Open-Blind Centre	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	z Compl. period	z Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
10	2-D.B.	PLACEBO	01/01/92	10/03/92	70	8	8	100.0	100.0		4	4
					70							
46-38	1-OPEN	REBOXETINE	03/12/91	13/01/92	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	PLACEBO	14/01/92	27/01/92	14	8	8	100.0	100.0		4	4
					14							
47-39	1-OPEN	REBOXETINE	05/12/91	15/01/92	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	PLACEBO	16/01/92	02/12/92	322	8	8	100.0	100.0		4	4
					322							
48-41	1-OPEN	REBOXETINE	05/12/91	15/01/92	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	PLACEBO	16/01/92	22/04/92	98	8	8	100.0	100.0		4	4
					98							
49-43	1-OPEN	REBOXETINE	11/12/91	21/01/92	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	REBOXETINE	22/01/92	23/06/92	154	8	8	100.0	100.0		4	4
					154							
	1-OPEN	REBOXETINE	19/12/91	29/01/92	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	PLACEBO	30/01/92	16/12/92	322	8	8	100.0	100.0		4	4
					322							
51-45	1-OPEN	REBOXETINE	19/12/91	29/01/92	42	8	8	100.0	100.0		4	4

789

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RAD

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Patient No. Centre Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	% Compl. period	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
					42							
10 51-45	2-D.B.	PLACEBO	30/01/92	10/06/92	133	8	8	100.0	100.0		4	4
			11/06/92	11/06/92	1	8	8	0.0	99.3	1m 1e	4	4
			12/06/92	16/12/92	188	8	8	100.0	99.7			
					322							
52	1-OPEN	REBOXETINE	14/01/92	10/02/92	28	8	8	100.0	100.0		4	4
					28							
53-47	1-OPEN	REBOXETINE	13/01/92	23/02/92	42	8	8	100.0	100.0		4	4
					42							
54-48	2-D.B.	REBOXETINE	24/02/92	06/09/92	196	8	8	100.0	100.0		4	4
					196							
			13/01/92	23/02/92	42	8	8	100.0	100.0		4	4
					42							
55-49	1-OPEN	REBOXETINE	14/01/92	24/02/92	42	8	8	100.0	100.0		4	4
					42							
			25/02/92	11/01/93	322	8	8	100.0	100.0		4	4
					322							
56-50	1-OPEN	REBOXETINE	14/01/92	24/02/92	42	8	8	100.0	100.0		4	4
					42							
2-D.B.	REBOXETINE	25/02/92	09/03/92	14	8	8	100.0	100.0		4	4	
			10/03/92	12/03/92	3	8	6	100.0	100.0	3e	4	2
			13/03/92	15/03/92	3	8	4	100.0	100.0	3m 3e	2	2
			16/03/92	19/03/92	4	8	4	100.0	100.0	3m 3e	2	2
			20/03/92	22/03/92	3	8	4	100.0	100.0	3m 3e	2	2
			23/03/92	23/03/92	1	8	2	100.0	100.0	3m 3e	2	2

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	z Compl. period	x Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
10	57-51	1-OPEN	REBOXETINE	15/01/92	25/02/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	26/02/92	12/01/93	322	8	8	100.0	100.0		4	4
						322							
58-52		1-OPEN	REBOXETINE	14/01/92	24/02/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	25/02/92	11/01/93	322	8	8	100.0	100.0		4	4
						322							
59-53		1-OPEN	REBOXETINE	20/01/92	01/03/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	02/03/92	29/03/92	28	8	8	100.0	100.0		4	4
						28							
60-54		1-OPEN	REBOXETINE	20/01/92	01/03/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	02/03/92	16/03/92	15	8	8	100.0	100.0		4	4
						15							
61-55		1-OPEN	REBOXETINE	22/01/92	03/03/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	04/03/92	26/05/92	84	8	8	100.0	100.0		4	4
						84							
62-56		1-OPEN	REBOXETINE	22/01/92	03/03/92	42	8	8	100.0	100.0		4	4
						42							

(*) 1=forget to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient, 5=...

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Patient No. Centre Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	% Compl. period	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
10	2-D.B.	PLACEBO	04/03/92	19/05/92	77	8	8	100.0	100.0		4	4
			20/05/92	20/05/92	1	8	8	0.0	98.7		4	4
			21/05/92	01/09/92	104	8	8	100.0	99.5	1m 1o	4	4
					182							
63-57	1-OPEN	REBOXETINE	04/02/92	16/03/92	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	REBOXETINE	17/03/92	06/06/92	82	8	8	100.0	100.0		4	4
			07/06/92	08/06/92	2	8	4	50.0	96.8	1o	4	4
			09/06/92	01/02/93	238	8	8	100.0	99.7		4	4
					322							
64-58	1-OPEN	REBOXETINE	06/02/92	18/03/92	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	PLACEBO	19/03/92	24/06/92	98	8	8	100.0	100.0		4	4
					98							
81-46	1-OPEN	REBOXETINE	21/02/92	02/04/92	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	PLACEBO	03/04/92	06/01/93	279	8	8	100.0	100.0		4	4
					279							
82-59	1-OPEN	REBOXETINE	25/02/92	06/04/92	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	REBOXETINE	07/04/92	25/01/93	294	8	8	100.0	100.0		4	4
					294							
83-60	1-OPEN	REBOXETINE	03/03/92	13/04/92	42	8	8	100.0	100.0		4	4
					42							
84-63	1-OPEN	REBOXETINE	11/03/92	21/04/92	42	8	8	100.0	100.0		4	4

9550077

792

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Patient No. Open-Blind Centre	Phase	Treatment	From date	To date	Treat. days	Protocol dose (ng/d)	Daily dose (ng/d)	Compl. period	Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
10 84-63	2-D.B.	REBOXETINE	22/04/92	30/06/92	42	8	8	100.0	100.0		4	4
					70							
85-272	1-OPEN	REBOXETINE	11/03/92	21/04/92	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	PLACEBO	22/04/92	05/05/92	14	8	8	100.0	100.0		4	4
					14							
86-274	1-OPEN	REBOXETINE	19/03/92	29/04/92	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	REBOXETINE	30/04/92	22/07/92	84	8	8	100.0	100.0		4	4
					84							
87-275	1-OPEN	REBOXETINE	19/03/92	29/04/92	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	REBOXETINE	30/04/92	17/03/93	322	8	8	100.0	100.0		4	4
					322							
88-276	1-OPEN	REBOXETINE	19/03/92	29/04/92	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	PLACEBO	30/04/92	17/03/93	322	8	8	100.0	100.0		4	4
					322							
89-277	1-OPEN	REBOXETINE	20/03/92	30/04/92	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	REBOXETINE	01/05/92	14/05/92	14	8	8	100.0	100.0		4	4
					14							

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	% Compl. period	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)										
10	90-70	1-OPEN	REBOXETINE	24/03/92	04/05/92	42	8	8	100.0	100.0		4	4										
						42																	
		2-D.B.	REBOXETINE	05/05/92	21/09/92	140	8	8	100.0	100.0		4	4										
						140																	
91-74	1-OPEN	REBOXETINE	24/03/92	04/05/92	42	8	8	100.0	100.0		4	4											
					42																		
					2-D.B.								REBOXETINE	05/05/92	02/11/92	182	8	8	100.0	100.0		4	4
																182							
92-73	1-OPEN	REBOXETINE	01/04/92	12/05/92	42	8	8	100.0	100.0		4	4											
					42																		
					2-D.B.								PLACEBO	13/05/92	30/03/93	322	8	8	100.0	100.0		4	4
																322							
93-285	1-OPEN	REBOXETINE	09/04/92	20/05/92	42	8	8	100.0	100.0		4	4											
					42																		
					2-D.B.								REBOXETINE	21/05/92	16/12/92	210	8	8	100.0	100.0		4	4
																210							
94-273	1-OPEN	REBOXETINE	09/04/92	20/05/92	42	8	8	100.0	100.0		4	4											
					42																		
					2-D.B.								PLACEBO	21/05/92	12/08/92	84	8	8	100.0	100.0		4	4
																84							
11	1-OPEN	REBOXETINE	12/10/91	22/11/91	42	8	8	100.0	100.0		4	4											
					42																		
					2-D.B.								PLACEBO	23/11/91	05/06/92	196	8	8	100.0	100.0		4	4
																196							

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Patient No. Centre Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	% Compl. period	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
11	2-373	1-OPEN	REBOXETINE	14/10/91	24/11/91	42	8	100.0	100.0		4	4
	2-D.B.	REBOXETINE	25/11/91	10/05/92	168	8	8	100.0	100.0		4	4
3-374	1-OPEN	REBOXETINE	15/10/91	25/11/91	42	8	8	100.0	100.0		4	4
4-375	2-D.B.	REBOXETINE	26/11/91	22/12/91	27	8	8	100.0	100.0		4	4
5	1-OPEN	REBOXETINE	18/10/91	28/11/91	42	8	8	100.0	100.0	6e	4	4
6-377	2-D.B.	PLACEBO	29/11/91	12/03/92	105	8	8	100.0	100.0		4	4
7-376	1-OPEN	REBOXETINE	18/10/91	11/11/91	25	8	8	100.0	100.0		4	4
8-378	1-OPEN	REBOXETINE	16/10/91	26/11/91	42	8	8	100.0	100.0		4	4
9-379	2-D.B.	REBOXETINE	27/11/91	13/10/92	322	8	8	100.0	100.0		4	4
10-380	1-OPEN	REBOXETINE	24/10/91	04/12/91	42	8	8	100.0	100.0		4	4
11-381	2-D.B.	PLACEBO	05/12/91	21/10/92	322	8	8	100.0	100.0		4	4

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (ng/d)	Daily dose (ng/d)	X Compl. period	X Compl. cumulat.	Reason (*)	Morning dose (ng)	Evening dose (ng)
						322							
	11	1-OPEN	REBOXETINE	11/11/91	01/12/91	21	8	8	100.0	100.0		4	4
				02/12/91	02/12/91	1	8	4	100.0	100.0	6e	4	4
	9-362	1-OPEN	REBOXETINE	12/11/91	23/12/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	24/12/91	02/02/92	41	8	8	100.0	100.0		4	4
				03/02/92	03/02/92	1	8	4	100.0	100.0	6e	4	4
	10-363	1-OPEN	REBOXETINE	26/11/91	06/01/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	07/01/92	23/11/92	322	8	8	100.0	100.0		4	4
						322							
	11-361	1-OPEN	REBOXETINE	06/12/91	16/01/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	17/01/92	18/05/92	123	8	8	100.0	100.0		4	4
				19/05/92	19/05/92	1	8	4	100.0	100.0	6e	4	4
	12-364	1-OPEN	REBOXETINE	16/12/91	26/01/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	27/01/92	13/12/92	322	8	8	100.0	100.0		4	4
						322							
	13-365	1-OPEN	REBOXETINE	15/01/92	25/02/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	26/02/92	02/06/92	98	8	8	100.0	100.0		4	4

9550077

796

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	Compl. period	Compl. cumulat.	Reason (x)	Morning dose (mg)	Evening dose (mg)
						98							
11	14	1-OPEN	REBOXETINE	20/01/92	15/02/92	27	8	8	100.0	100.0		4	4
				16/02/92	16/02/92	1	8	4	100.0	100.0	6c	4	4
						28							
15-366		1-OPEN	REBOXETINE	29/01/92	10/03/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	11/03/92	02/06/92	84	8	8	100.0	100.0		4	4
						84							
16-367		1-OPEN	REBOXETINE	09/02/92	15/03/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	16/03/92	04/06/92	81	8	8	100.0	100.0		4	4
				05/06/92	05/06/92	1	8	4	50.0	99.4	1e	4	4
						82							
17-368		1-OPEN	REBOXETINE	07/02/92	19/03/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	20/03/92	04/02/93	322	8	8	100.0	100.0		4	4
						322							
18-369		1-OPEN	REBOXETINE	10/02/92	22/03/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	23/03/92	07/02/93	322	8	8	100.0	100.0		4	4
						322							
19-370		1-OPEN	REBOXETINE	28/02/92	09/04/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	10/04/92	25/02/93	322	8	8	100.0	100.0		4	4

9550077

797

(x) 1=forget to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CIS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	% Compl. period	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
11	20-371	1-OPEN	REBOXETINE	02/03/92	12/04/92	322	8	8	100.0	100.0		4	4
						42							
12	1-92	2-D.B.	PLACEBO	13/04/92	04/06/92	53	8	8	100.0	100.0	60	4	4
						1							
						54							
12	1-92	1-OPEN	REBOXETINE	31/10/91	11/12/91	42	8	8	100.0	100.0		4	4
						42							
2	2-99	2-D.B.	REBOXETINE	12/12/91	28/10/92	322	8	8	100.0	100.0		4	4
						322							
						42							
3	3-93	1-OPEN	REBOXETINE	30/10/91	12/11/91	14	8	8	100.0	100.0	10	4	4
						1							
4	4-100	1-OPEN	REBOXETINE	05/11/91	16/12/91	27	8	8	100.0	98.8		4	4
						42							
5	5-95	1-OPEN	REBOXETINE	17/12/91	27/01/92	42	8	8	100.0	100.0		4	4
						322							
5	5-95	1-OPEN	REBOXETINE	11/12/91	27/10/92	322	8	8	100.0	100.0		4	4
						322							
5	5-95	1-OPEN	REBOXETINE	05/11/91	16/12/91	42	8	8	100.0	100.0		4	4
						42							
5	5-95	1-OPEN	REBOXETINE	17/12/91	18/05/92	154	8	8	100.0	100.0		4	4
						154							

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	Compl. period	X Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
12	5-95	2-D.B.	PLACEBO	17/12/91	09/03/92	84	8	8	100.0	100.0		4	4
						84							
6-98		1-OPEN	REBOXETINE	02/11/91	12/12/91	41	8	8	100.0	100.0		4	4
						41							
2-D.B.			PLACEBO	13/12/91	28/05/92	168	8	8	100.0	100.0		4	4
						168							
7-102		1-OPEN	REBOXETINE	05/11/91	16/12/91	42	8	8	100.0	100.0		4	4
						42							
2-D.B.			REBOXETINE	17/12/91	18/05/92	154	8	8	100.0	100.0		4	4
						154							
8		1-OPEN	REBOXETINE	01/11/91	12/12/91	42	8	8	100.0	100.0		4	4
						42							
9-91		1-OPEN	REBOXETINE	31/10/91	11/12/91	42	8	8	100.0	100.0		4	4
						42							
2-D.B.			REBOXETINE	12/12/91	10/06/92	182	8	8	100.0	100.0		4	4
						182							
10-96		1-OPEN	REBOXETINE	05/11/91	16/12/91	42	8	8	100.0	100.0		4	4
						42							
2-D.B.			PLACEBO	17/12/91	20/04/92	126	8	8	100.0	100.0		4	4
						126							
11-94		1-OPEN	REBOXETINE	31/10/91	11/12/91	42	8	8	100.0	100.0		4	4
						42							

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

9550077

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	Z Compl. period	Z Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
12	11-94	2-D.B.	PLACEBO	12/12/91	15/01/92	35	8	8	100.0	100.0		4	4
						35							
	12-97	1-OPEN	REBOXETINE	05/11/91	16/12/91	42	8	8	100.0	100.0		4	4
						42							
	2-D.B.		PLACEBO	17/12/91	13/01/92	28	8	8	100.0	100.0		4	4
						28							
	13-103	1-OPEN	REBOXETINE	05/11/91	16/12/91	42	8	8	100.0	100.0		4	4
						42							
	2-D.B.		PLACEBO	17/12/91	27/01/92	42	8	8	100.0	100.0		4	4
						42							
	14-101	1-OPEN	REBOXETINE	06/11/91	17/12/91	42	8	8	100.0	100.0		4	4
						42							
	2-D.B.		PLACEBO	18/12/91	14/01/92	28	8	8	100.0	100.0		4	4
						28							
	15-104	1-OPEN	REBOXETINE	26/11/91	06/01/92	42	8	8	100.0	100.0		4	4
						42							
	2-D.B.		REBOXETINE	07/01/92	25/05/92	140	8	8	100.0	100.0		4	4
						140							
	16-105	1-OPEN	REBOXETINE	11/12/91	21/01/92	42	8	8	100.0	100.0		4	4
						42							
	2-D.B.		REBOXETINE	22/01/92	23/06/92	154	8	8	100.0	100.0		4	4
						154							
	17-108	1-OPEN	REBOXETINE	15/01/92	25/02/92	42	8	8	100.0	100.0		4	4
						42							

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Patient No. Open-Blind Centre	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	Compl. period	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
12	2-D.B.	PLACEBO	26/02/92	23/07/92	42	8	8	100.0	100.0		4	4
					154							
18-109	1-OPEN	REBOXETINE	15/01/92	28/01/92	14	8	8	100.0	100.0	3m 3e	4	4
					28							
	2-D.B.	PLACEBO	26/02/92	22/05/92	87	8	8	100.0	100.0	6e	4	4
					1							
19-106	1-OPEN	REBOXETINE	16/01/92	26/02/92	42	8	8	100.0	100.0		4	4
					88							
	2-D.B.	REBOXETINE	27/02/92	06/05/92	70	8	8	100.0	100.0		4	4
					70							
20-107	1-OPEN	REBOXETINE	17/01/92	27/02/92	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	PLACEBO	28/02/92	30/07/92	154	8	8	100.0	100.0		4	4
					154							
21-110	1-OPEN	REBOXETINE	31/01/92	12/03/92	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	REBOXETINE	13/03/92	18/06/92	98	8	8	100.0	100.0		4	4
					98							
22-111	1-OPEN	REBOXETINE	28/01/92	09/03/92	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	PLACEBO	10/03/92	25/01/93	322	8	8	100.0	100.0		4	4
					42							

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From data	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	Compl. period	X Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
12	23-112	1-OPEN	REBOXETINE	07/02/92	19/03/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	20/03/92	20/08/92	154	8	8	100.0	100.0		4	4
						154							
24	113	1-OPEN	REBOXETINE	08/02/92	03/04/92	56	8	8	100.0	100.0		4	4
						56							
		2-D.B.	REBOXETINE	04/04/92	04/09/92	154	8	8	100.0	100.0		4	4
						154							
25	114	1-OPEN	REBOXETINE	11/02/92	23/03/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	24/03/92	08/02/93	322	8	8	100.0	100.0		4	4
						322							
26		1-OPEN	REBOXETINE	05/02/92	17/03/92	42	8	8	100.0	100.0		4	4
						42							
27	115	1-OPEN	REBOXETINE	08/02/92	20/03/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	21/03/92	02/10/92	196	8	8	100.0	100.0		4	4
						196							
28	116	1-OPEN	REBOXETINE	08/02/92	20/03/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	21/03/92	29/05/92	70	8	8	100.0	100.0		4	4
						70							

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Patient No. Centre	Open-Blind Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	z Compl. period	x Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
12	29-117	1-OPEN	REBOXETINE	11/02/92	23/03/92	42	8	8	100.0	100.0	4	4
					42							
		2-D.B.	REBOXETINE	24/03/92	08/02/93	322	8	8	100.0	100.0	4	4
					322							
30	1-OPEN	REBOXETINE	25/02/92	03/04/92	39	8	8	8	100.0	100.0	4	4
					39							
31	1-OPEN	REBOXETINE	25/03/92	05/05/92	42	8	8	8	100.0	100.0	4	4
					42							
32	1-OPEN	REBOXETINE	02/04/92	13/05/92	42	8	8	8	100.0	100.0	4	4
					42							
33-388	1-OPEN	REBOXETINE	02/04/92	13/05/92	42	8	8	8	100.0	100.0	4	4
					42							
34-120	1-OPEN	REBOXETINE	14/05/92	19/08/92	98	8	8	8	100.0	100.0	4	4
					98							
	2-D.B.	PLACEBO	09/05/92	26/03/93	322	8	8	8	100.0	100.0	4	4
					322							
35-119	1-OPEN	REBOXETINE	28/03/92	08/05/92	42	8	8	8	100.0	100.0	4	4
					42							
	2-D.B.	PLACEBO	09/05/92	31/07/92	84	8	8	8	100.0	100.0	4	4
					84							
36-385	1-OPEN	REBOXETINE	31/03/92	11/05/92	42	8	8	8	100.0	100.0	4	4

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Patient No. Centre	Open-Blind Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	Compl. period	X Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
12	36-385	2-D.B.	REBOXETINE	12/05/92	22/06/92	42	8	8	100.0	100.0	4	4
					42							
37	386	1-OPEN	REBOXETINE	04/04/92	15/05/92	42	8	8	100.0	100.0	4	4
					42							
		2-D.B.	PLACEBO	16/05/92	07/08/92	84	8	8	100.0	100.0	4	4
					84							
38		1-OPEN	REBOXETINE	07/04/92	18/05/92	42	8	8	100.0	100.0	4	4
					42							
13	1-219	1-OPEN	REBOXETINE	16/10/91	26/11/91	42	8	8	100.0	100.0	4	4
					42							
		2-D.B.	REBOXETINE	27/11/91	13/10/92	322	8	8	100.0	100.0	4	4
					322							
2-224		1-OPEN	REBOXETINE	17/10/91	27/11/91	42	8	8	100.0	100.0	4	4
					42							
		2-D.B.	PLACEBO	28/11/91	14/10/92	322	8	8	100.0	100.0	4	4
					322							
3-221		1-OPEN	REBOXETINE	16/10/91	26/11/91	42	8	8	100.0	100.0	4	4
					42							
		2-D.B.	REBOXETINE	27/11/91	13/10/92	322	8	8	100.0	100.0	4	4
					322							
4		1-OPEN	REBOXETINE	16/10/91	26/11/91	42	8	8	100.0	100.0	4	4
					42							

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Patient No.	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	Compl. period	Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
13	1-OPEN	REBOXETINE	18/10/91	22/10/91	5	8	8	100.0	100.0		4	4
					5							
6-226	1-OPEN	REBOXETINE	18/10/91	28/11/91	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	REBOXETINE	29/11/91	15/10/92	322	8	8	100.0	100.0		4	4
					322							
7-220	1-OPEN	REBOXETINE	25/10/91	05/12/91	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	REBOXETINE	06/12/91	21/10/92	321	8	8	100.0	100.0		4	4
					321							
8-228	1-OPEN	REBOXETINE	22/10/91	02/12/91	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	PLACEBO	03/12/91	18/05/92	168	8	8	100.0	100.0		4	4
					168							
9-229	1-OPEN	REBOXETINE	22/10/91	02/12/91	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	PLACEBO	03/12/91	27/02/92	87	8	8	100.0	100.0		4	4
					87							
10	1-OPEN	REBOXETINE	18/10/91	22/10/91	5	8	8	100.0	100.0		4	4
			23/10/91	23/10/91	1	8	4	100.0	100.0	60	4	4
					6							
11-225	1-OPEN	REBOXETINE	15/11/91	26/12/91	42	8	8	100.0	100.0		4	4
					42							
	2-D.B.	PLACEBO	27/12/91	12/11/92	322	8	8	100.0	100.0		4	4

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	% Compl. period	% Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
13	12	1-OPEN	REBOXETINE	31/10/91	04/12/91	35	8	8	100.0	100.0		4	4
						35							
13-223		1-OPEN	REBOXETINE	02/11/91	13/12/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	14/12/91	30/10/92	322	8	8	100.0	100.0		4	4
						322							
14-217		1-OPEN	REBOXETINE	02/11/91	13/12/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	14/12/91	30/10/92	322	8	8	100.0	100.0		4	4
						322							
15-222		1-OPEN	REBOXETINE	07/11/91	18/12/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	19/12/91	03/11/92	321	8	8	100.0	100.0		4	4
						321							
16		1-OPEN	REBOXETINE	20/11/91	31/12/91	42	8	8	100.0	100.0		4	4
						42							
17-218		1-OPEN	REBOXETINE	20/11/91	31/12/91	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	PLACEBO	01/01/92	17/11/92	322	8	8	100.0	100.0		4	4
						322							
18-227		1-OPEN	REBOXETINE	04/12/91	14/01/92	42	8	8	100.0	100.0		4	4
						42							

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 7.0

EXPERIMENTAL TREATMENT

Centre	Patient No. Open-Blind	Phase	Treatment	From date	To date	Treat. days	Protocol dose (mg/d)	Daily dose (mg/d)	x Compl. period	x Compl. cumulat.	Reason (*)	Morning dose (mg)	Evening dose (mg)
13	18-227	2-D.B.	REBOXETINE	15/01/92	01/12/92	322	8	8	100.0	100.0		4	4
						322							
	19	1-OPEN	REBOXETINE	24/01/92	13/02/92	21	8	8	100.0	100.0		4	4
						21							
	20-230	1-OPEN	REBOXETINE	29/01/92	10/03/92	42	8	8	100.0	100.0		4	4
						42							
						42							
		2-D.B.	REBOXETINE	11/03/92	26/01/93	322	8	8	100.0	100.0		4	4
						322							
	21-231	1-OPEN	REBOXETINE	19/02/92	31/03/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	01/04/92	16/02/93	322	8	8	100.0	100.0		4	4
						322							
	22-232	1-OPEN	REBOXETINE	06/05/92	16/06/92	42	8	8	100.0	100.0		4	4
						42							
		2-D.B.	REBOXETINE	17/06/92	14/07/92	28	8	8	100.0	100.0		4	4
						28							
	23	1-OPEN	REBOXETINE	07/05/92	17/06/92	42	8	8	100.0	100.0		4	4
						42							

9550077

807

(*) 1=forgot to take the medication, 2=lost medication, 3=adverse event, 4=regimen modified by patient,

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 8.0

ASSIGNED vs RANDOMIZED TREATMENT

Centre	Sequen. block	Treatment	Given Start treat. date	Initial Patient	Randomized		Error (*)
					Treatment	Sequen. block	
1	1	Placebo	29/12/90	MGA	1	1	1
	1	Reboxetine	03/01/91	TA	2	2	1
	1	Reboxetine	16/01/91	DNC	3	3	1
	1	Reboxetine	16/01/91	DR	4	4	1
	1	Placebo	16/01/91	CPM	5	5	1
	2	Reboxetine	19/01/91	MVB	6	6	1
	2	Reboxetine	07/02/91	CCR	7	7	2
	2	Reboxetine	16/03/91	LDL	8	8	2
	2	Placebo	20/04/91	VPT	9	9	2
	2	Placebo	01/05/91	SLT	10	10	2
	2	Reboxetine	19/06/91	RLC	11	11	2
	2	Placebo	20/06/91	RAO	12	12	2
	3	Placebo	29/06/91	MHC	13	13	2
	3	Reboxetine	03/07/91	CEC	14	14	3
	3	Reboxetine	04/07/91	TYN	15	15	3
	3	Placebo	10/07/91	SR	16	16	3
	3	Reboxetine	13/07/91	EFC	17	17	3
	4	Placebo	17/07/91	VHC	18	18	3
	4	Reboxetine	24/07/91	SK	19	19	4
	4	Reboxetine	14/08/91	LVF	20	20	4
	4	Reboxetine	17/08/91	AHR	21	21	4
	4	Placebo	21/08/91	OC	22	22	4
	4	Placebo	24/08/91	RK	23	23	4
	4	Placebo	28/08/91	RHM	24	24	4
	5	Placebo	28/08/91	AFO	25	25	5
	5	Placebo	29/08/91	ERV	26	26	5
	5	Reboxetine	04/09/91	HAN	27	27	5
	5	Reboxetine	05/09/91	DCM	28	28	5
	5	Placebo	05/09/91	OFC	29	29	5
	5	Reboxetine	19/09/91	GNH	30	30	5
	6	Reboxetine	09/10/91	EMP	301	301	6
6	Placebo	16/10/91	LM	302	302	6	
6	Placebo	16/10/91	BF	303	303	6	
6	Reboxetine	30/10/91	DBF	304	304	6	
6	Reboxetine	06/11/91	ASS	305	305	6	
6	Placebo	06/11/91	EH	306	306	6	
7	Placebo	06/11/91	SFS	307	307	7	
7	Placebo	14/11/91	ICC	308	308	7	
7	Reboxetine	14/11/91	ARN	309	309	7	
7	Reboxetine	20/11/91	DPS	310	310	7	
7	Reboxetine	27/11/91	SP	311	311	7	
8	Placebo	04/12/91	MCS	312	312	7	
8	Reboxetine	05/12/91	SCH	313	313	8	
8	Placebo	07/12/91	MFA	314	314	8	
8	Placebo	07/12/91	ASA	315	315	8	
8	Reboxetine	12/12/91	MTS	316	316	8	
8	Placebo	12/12/91	JFT	317	317	8	
8	Reboxetine	18/12/91	DMG	318	318	8	
9	Reboxetine	18/12/91	IAL	319	319	9	

(*): Assigned treatment different from randomized

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 8.0

ASSIGNED vs RANDOMIZED TREATMENT

Centre	Sequen.	block	Treatment	Given		Randomized		Error (%)
				Start treat. date	Initial Patient	Patient	Treatment	
1	9	9	Reboxetine	22/01/92	ARM	320	Reboxetine	9
	9	9	Placebo	29/01/92	SPF	321	Placebo	9
	9	9	Placebo	01/02/92	EM	322	Placebo	9
	9	9	Reboxetine	01/02/92	HVC	323	Reboxetine	9
	10	10	Placebo	19/02/92	HEA	324	Placebo	10
	10	10	Reboxetine	29/02/92	ENF	325	Placebo	10
	10	10	Placebo	05/03/92	TCG	326	Reboxetine	10
	10	10	Placebo	05/03/92	MAA	327	Placebo	10
	10	10	Placebo	07/03/92	MLK	328	Placebo	10
	10	10	Reboxetine	11/03/92	ONV	329	Reboxetine	10
	10	10	Reboxetine	11/03/92	RLJ	330	Reboxetine	10
	11	11	Reboxetine	11/03/92	FMA	121	Reboxetine	11
	11	11	Placebo	14/03/92	IYL	122	Placebo	11
	11	11	Placebo	14/03/92	IVL	123	Reboxetine	11
	11	11	Placebo	21/03/92	SFA	124	Placebo	11
	11	11	Reboxetine	21/03/92	ACG	125	Reboxetine	11
	11	11	Placebo	21/03/92	JCM	126	Placebo	11
	12	12	Placebo	21/03/92	NEL	127	Placebo	12
	12	12	Reboxetine	21/03/92	HFB	128	Reboxetine	12
	12	12	Reboxetine	21/03/92	HDS	129	Reboxetine	12
	12	12	Placebo	21/03/92	IN	130	Placebo	12
	12	12	Placebo	21/03/92	MLP	131	Placebo	12
	13	13	Reboxetine	21/03/92	HDO	132	Reboxetine	13
	13	13	Reboxetine	25/03/92	NHV	133	Reboxetine	13
	13	13	Reboxetine	25/03/92	JSS	134	Reboxetine	13
	13	13	Placebo	25/03/92	NSC	135	Placebo	13
	13	13	Placebo	26/03/92	AL	136	Placebo	13
	13	13	Placebo	26/03/92	RAB	137	Placebo	13
	13	13	Reboxetine	26/03/92	GMT	138	Reboxetine	13
	14	14	Reboxetine	26/03/92	SPH	139	Reboxetine	14
	14	14	Placebo	26/03/92	MND	140	Placebo	14
	14	14	Reboxetine	26/03/92	YIT	141	Reboxetine	14
	14	14	Placebo	01/04/92	JMA	142	Placebo	14
14	14	Reboxetine	01/04/92	JLL	143	Reboxetine	14	
15	15	Placebo	01/04/92	HIF	144	Reboxetine	15	
15	15	Placebo	01/04/92	ABS	145	Placebo	15	
15	15	Reboxetine	01/04/92	RRN	146	Placebo	15	
15	15	Placebo	02/04/92	LAN	147	Reboxetine	15	
15	15	Reboxetine	02/04/92	STB	148	Placebo	15	
15	15	Reboxetine	02/04/92	IPL	149	Reboxetine	15	
16	16	Placebo	02/04/92	TQO	150	Reboxetine	16	
16	16	Placebo	02/04/92	JBF	331	Placebo	16	
16	16	Placebo	08/04/92	CLF	332	Placebo	16	
16	16	Placebo	08/04/92	ELS	333	Placebo	16	
16	16	Reboxetine	08/04/92	MGA	334	Reboxetine	16	
16	16	Reboxetine	08/04/92	FSL	335	Reboxetine	16	
17	17	Placebo	09/04/92	LAC	336	Reboxetine	17	
17	17	Placebo	09/04/92	HSS	337	Placebo	17	
17	17	Reboxetine	09/04/92	NLL	338	Reboxetine	17	

(*) Assigned treatment different from randomized

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 8.0
ASSIGNED vs RANDOMIZED TREATMENT

Centre	Sequen. block	Treatment	Given		Randomized		Error (*)
			Start treat. date	Initial Patient	Treatment	Sequen. block	
1	17	Placebo	09/04/92	PPC	339	Placebo	17
	17	Reboxetine	09/04/92	FDP	340	Reboxetine	17
	17	Placebo	09/04/92	SNB	341	Placebo	17
	17	Reboxetine	09/04/92	VPD	342	Reboxetine	17
	18	Placebo	09/04/92	LAM	343	Reboxetine	18
	18	Reboxetine	09/04/92	HNS	344	Placebo	18
	18	Placebo	11/04/92	EGA	345	Placebo	18
	18	Reboxetine	01/05/92	JPM	346	Placebo	18
	18	Placebo	06/05/92	LMS	347	Reboxetine	18
	18	Reboxetine	06/05/92	MMS	348	Reboxetine	18
	19	Placebo	06/05/92	AVP	349	Placebo	19
	19	Reboxetine	06/05/92	LEV	350	Placebo	19
	19	Placebo	06/05/92	RA	351	Reboxetine	19
	19	Reboxetine	06/05/92	RCA	352	Reboxetine	19
	19	Placebo	06/05/92	AMG	353	Placebo	19
	19	Reboxetine	06/05/92	SCC	354	Reboxetine	19
	20	Placebo	06/05/92	JEP	355	Placebo	20
	20	Reboxetine	07/05/92	ARF	356	Reboxetine	20
	20	Placebo	09/05/92	SLD	357	Placebo	20
	20	Reboxetine	09/05/92	LRM	358	Reboxetine	20
	20	Placebo	09/05/92	CAS	359	Reboxetine	20
20	Reboxetine	09/05/92	SC	360	Placebo	20	
21	Placebo	09/05/92	VA	151	Placebo	21	
10	1	Reboxetine	27/11/90	VK	271	Reboxetine	1
	1	Placebo	12/12/90	ZSD	272	Placebo	1
	1	Placebo	27/12/90	AN	273	Placebo	1
	1	Reboxetine	02/01/91	RK	274	Reboxetine	1
	1	Placebo	15/01/91	RT	275	Reboxetine	1
	2	Reboxetine	15/01/91	MR	276	Placebo	1
	2	Placebo	21/02/91	EP	277	Reboxetine	2
	2	Reboxetine	26/03/91	HU	278	Reboxetine	2
	2	Placebo	06/04/91	AA	279	Placebo	2
	2	Reboxetine	16/04/91	HT	280	Reboxetine	2
	2	Placebo	16/04/91	AJ	281	Placebo	2
	2	Reboxetine	25/04/91	NR	282	Placebo	2
	3	Placebo	15/05/91	YN	284	Placebo	3
	3	Reboxetine	04/06/91	EJ	285	Reboxetine	3
	3	Placebo	04/06/91	AA	286	Reboxetine	3
	3	Reboxetine	05/06/91	LT	287	Reboxetine	3
	3	Placebo	10/06/91	AK	288	Placebo	3
	4	Reboxetine	12/06/91	AL	289	Placebo	4
	4	Placebo	09/07/91	JIF	290	Reboxetine	4
	4	Reboxetine	11/07/91	LL	291	Reboxetine	4
	4	Placebo	15/07/91	MK	292	Reboxetine	4
4	Reboxetine	30/09/91	JJ	293	Placebo	4	
5	Placebo	28/10/91	RK	297	Placebo	4	
5	Reboxetine	28/10/91	LK	299	Placebo	5	

(*) Assigned treatment different from randomized

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 8.0

ASSIGNED vs RANDOMIZED TREATMENT

Centro	Given		Randomized		Error (*)
	Sequen. block	Treatment	Sequen. block	Treatment	
10	4	Placebo	294	296	
	5	Reboxetine	300	297	
	6	Placebo	31	298	*
	6	Reboxetine	35	299	
	6	Placebo	32	300	*
	7	Reboxetine	37	31	
	7	Placebo	40	32	*
	6	Reboxetine	33	33	
	7	Placebo	42	34	*
	5	Reboxetine	295	35	*
	5	Placebo	296	37	*
	5	Reboxetine	34	38	
	6	Placebo	298	39	
	7	Reboxetine	38	40	*
	7	Placebo	39	41	
	7	Reboxetine	41	42	*
	8	Placebo	43	43	
	8	Reboxetine	44	44	
	8	Placebo	45	45	*
	8	Reboxetine	47	46	
	8	Placebo	48	47	*
	9	Reboxetine	49	48	*
	9	Placebo	50	49	*
	9	Reboxetine	52	50	*
	9	Placebo	51	51	*
	9	Reboxetine	53	52	*
	9	Placebo	54	53	*
	10	Reboxetine	55	54	
	10	Placebo	56	55	*
	10	Reboxetine	57	56	*
	10	Placebo	58	57	*
	8	Reboxetine	46	58	
	11	Placebo	59	59	
11	Reboxetine	65	70		
12	Placebo	70	71	*	
13	Reboxetine	74	72		
1	Placebo	73	73		
1	Reboxetine	272	74		
1	Placebo	273	75		
1	Reboxetine	274	272		
1	Placebo	275	273		
1	Reboxetine	276	274		
1	Placebo	277	275		
2	Reboxetine	277	276		
3	Placebo	285	277		
3	Reboxetine	285	285		
11	1	Placebo	372	367	*
	2	Reboxetine	373	368	*
	2	Placebo	374	369	*

(*): Assigned treatment different from randomized

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 8.0

ASSIGNED vs RANDOMIZED TREATMENT

Centre	Sequen. block	Treatment	Given Start treat. date	Initial Patient	Patient	Randomized		Error (*)		
						Treatment	Sequen. block			
11	2	Reboxetine	27/11/91	VP	377	370	Reboxetine	1		
	2	Placebo	29/11/91	BA	375	371	Placebo	1		
	2	Placebo	05/12/91	KK	376	372	Placebo	1		
	3	Placebo	24/12/91	FT	362	373	Reboxetine	2	*	
	3	Reboxetine	07/01/92	RJ	363	374	Reboxetine	2		
	3	Reboxetine	17/01/92	NGY	361	375	Placebo	2	*	
	3	Placebo	27/01/92	PJ	364	376	Placebo	2		
	3	Reboxetine	26/02/92	CK	365	377	Reboxetine	2		
	3	Placebo	11/03/92	NP	366	361	Reboxetine	3	*	
	1	Reboxetine	18/03/92	NA	367	362	Placebo	3	*	
	1	Reboxetine	20/03/92	UZ	368	363	Reboxetine	3		
	1	Placebo	23/03/92	EI	369	364	Placebo	3		
	1	Reboxetine	10/04/92	FK	370	365	Reboxetine	3		
	1	Placebo	13/04/92	LJ	371	366	Placebo	3		
	12	1	Reboxetine	11/12/91	IF	93	91	Reboxetine	1	
		1	Reboxetine	12/12/91	KBP	91	92	Reboxetine	1	
		1	Reboxetine	12/12/91	IR	92	93	Reboxetine	1	
1		Placebo	12/12/91	ER	94	94	Placebo	1		
2		Placebo	13/12/91	NK	98	95	Placebo	1		
1		Placebo	17/12/91	ZSH	95	96	Placebo	1		
1		Placebo	17/12/91	IP	96	97	Placebo	2		
2		Placebo	17/12/91	FSZ	97	98	Placebo	2		
2		Reboxetine	17/12/91	ERC	99	99	Reboxetine	2		
2		Reboxetine	17/12/91	EG	100	100	Reboxetine	2		
2		Placebo	17/12/91	LK	102	101	Placebo	2	*	
3		Placebo	18/12/91	ISZ	103	102	Reboxetine	2	*	
3		Placebo	18/12/91	GSZ	101	103	Placebo	3		
3		Reboxetine	07/01/92	GR	104	104	Reboxetine	3		
3		Reboxetine	22/01/92	FN	105	105	Reboxetine	3		
3		Placebo	26/02/92	TK	108	106	Reboxetine	3	*	
4		Placebo	26/02/92	LS	109	107	Reboxetine	3	*	
3		Reboxetine	27/02/92	SSZ	106	108	Placebo	3	*	
3		Placebo	28/02/92	RSZ	107	109	Placebo	4	*	
4		Placebo	10/03/92	RY	111	110	Reboxetine	4	*	
4	Reboxetine	13/03/92	FL	110	111	Placebo	4	*		
4	Placebo	20/03/92	EN	112	112	Placebo	4			
5	Reboxetine	21/03/92	VCS	115	113	Reboxetine	4			
5	Placebo	21/03/92	IV	116	114	Reboxetine	4	*		
5	Reboxetine	24/03/92	FS	114	115	Reboxetine	5			
5	Reboxetine	24/03/92	AK	117	116	Placebo	5	*		
4	Reboxetine	04/04/92	MF	113	117	Reboxetine	5			
5	Placebo	09/05/92	LP	119	119	Placebo	5			
5	Placebo	09/05/92	TGB	120	120	Placebo	5			
6	Reboxetine	12/05/92	FB	385	385	Reboxetine	6			
6	Reboxetine	14/05/92	LN	388	386	Placebo	6	*		
6	Placebo	16/05/92	EK	386	388	Reboxetine	6	*		

(*) Assigned treatment different from randomized

∞ 1 2

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 8.0

ASSIGNED vs RANDOMIZED TREATMENT

Centre	Given		Initial Patient	Patient	Randomized Treatment	Sequen. block	Error (*)
	Sequen. block	Treatment					
13	1	Reboxetine	27/11/91	PZ	217 Placebo	1	*
	1	Reboxetine	27/11/91	AI	221 Placebo	1	*
	2	Placebo	28/11/91	TCS	218 Reboxetine	1	*
	2	Reboxetine	29/11/91	KE	224 Reboxetine	1	*
	2	Placebo	03/12/91	PK	220 Reboxetine	1	*
	3	Placebo	03/12/91	SZS	221 Reboxetine	1	*
	1	Reboxetine	06/12/91	BL	222 Placebo	1	
	1	Placebo	14/12/91	DF	223 Reboxetine	2	
	2	Reboxetine	14/12/91	HH	217 Placebo	2	*
	1	Placebo	19/12/91	KG	225 Placebo	2	*
	2	Placebo	27/12/91	HS	222 Reboxetine	2	*
	2	Placebo	01/01/92	GSH	227 Reboxetine	2	*
	3	Reboxetine	15/01/92	VI	228 Placebo	2	*
3	Reboxetine	11/03/92	NL	227 Placebo	3	*	
3	Reboxetine	01/04/92	CL	230 Reboxetine	3		
3	Reboxetine	17/06/92	NYH	231 Reboxetine	3		
3	1	Placebo	29/12/90	FIL	61 Placebo	1	*
	2	Reboxetine	23/01/91	GRI	62 Placebo	1	*
	2	Placebo	15/05/91	DUB	63 Reboxetine	1	*
8	1	Placebo	15/01/91	HJ	211 Placebo	1	
	1	Reboxetine	25/01/91	TE	212 Reboxetine	1	
	1	Reboxetine	01/02/91	JL	213 Reboxetine	1	
	1	Placebo	22/02/91	BA	214 Placebo	1	
	1	Placebo	26/02/91	SL	215 Placebo	1	
	1	Reboxetine	05/03/91	TL	216 Reboxetine	1	
	1	Placebo	10/07/90	VCF	241 Placebo	1	
9	1	Placebo	06/11/90	MF	242 Placebo	1	
	1	Reboxetine	19/12/90	SD	243 Reboxetine	1	*
	1	Reboxetine	21/12/90	PP	244 Placebo	1	*
	1	Placebo	02/01/91	KTH	245 Reboxetine	1	*
	2	Reboxetine	13/03/91	KE	246 Reboxetine	1	
	2	Placebo	17/04/91	GT	247 Placebo	2	
	2	Placebo	25/04/91	BP	248 Reboxetine	2	
	2	Reboxetine	01/07/91	BI	249 Placebo	2	
	2	Reboxetine	21/08/91	UGY	250 Reboxetine	2	
	2	Placebo	25/09/91	KF	251 Placebo	2	
	2	Reboxetine	05/10/91	GVE	252 Reboxetine	2	
	3	Reboxetine	21/12/91	S2N	253 Placebo	3	*
	3	Placebo	24/12/91	LGY	254 Placebo	3	*
3	Placebo	01/01/92	PH	255 Reboxetine	3	*	

(*) Assigned treatment different from randomized

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 8.0

ASSIGNED vs RANDOMIZED TREATMENT

Centre	Given		Start treat. date	Initial	Patient	Patient	Randomized		Error (*)
	Sequen. block	Treatment					Sequen. block	Treatment	
9	3	Reboxetine	03/01/92	CP	255	256	Reboxetine	3	
	3	Placebo	19/05/92	HI	257	257	Placebo	3	
	3	Reboxetine	19/05/92	SZF	258	258	Reboxetine	3	
	4	Reboxetine	19/05/92	NF	259	259	Reboxetine	4	

814

(* Assigned treatment different from randomized)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOMETINE - PROTOCOL 20124-013
Listing No.: 9.1

REASON FOR DISCONTINUATION OF THE TREATMENT
OPEN PHASE

Centre	Patient	Initial	Centre	Patient	Initial	Sex	Last visit	Decision to	Reason
							discontinue		
1	2	RAQ	1	2	RAQ	Male	Week 3	PHYSICIAN	PATIENT UNCOOPERATIVE
	7	JSA	1	7	JSA	Male	Week 3	PATIENT	ADVERSE EVENT (*)
	13	JR	1	13	JR	Female	Week 2	OTHERS	PATIENT UNCOOPERATIVE
	23	AR	1	23	AR	Female	Week 4	PHYSICIAN	PATIENT UNCOOPERATIVE
	49	DMS	1	49	DAS	Female	Week 2	PATIENT	ADVERSE EVENT (*)
	54	JD	1	54	JD	Female	Week 4	PHYSICIAN	ADVERSE EVENT (*)
	57	SMC	1	57	SMC	Female	Week 3	PHYSICIAN	ADVERSE EVENT (*)
	63	JCL	1	63	JCL	Male	Week 3	PHYSICIAN	ADVERSE EVENT (*)
	103	JRA	1	103	JRA	Male	Week 2	PHYSICIAN	ADVERSE EVENT (*)
	118	NVH	1	118	NVH	Female	Week 5	PATIENT	PATIENT UNCOOPERATIVE
	147	JGH	1	147	JGH	Female	Week 2	PATIENT	ADVERSE EVENT (*)
2	31	IK	2	31	IK	Female	Week 4	PHYSICIAN	DETERIORATION
	32	GE	2	32	GE	Female	Week 3	PHYSICIAN	DETERIORATION
	33	HS	2	33	HS	Female	Week 3	PHYSICIAN	DETERIORATION
	34	EH	2	34	EH	Female	Week 4	PATIENT	PATIENT UNCOOPERATIVE
3	1	AMR	3	1	AMR	Female	Week 4	PATIENT	PATIENT UNCOOPERATIVE

(*) ADVERSE EVENT: to be considered as adverse event or intercurrent medical problems

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 3.1

REASON FOR DISCONTINUATION OF THE TREATMENT
OPEN PHASE

Centre	Patient	Initial	Centre	Patient	Initial	Sex	Last visit	Decision to discontinue	Reason
3	4	AUD	3	4	AUD	Female	Week 6	PHYSICIAN	DETERIORATION
	5	MMA	3	5	MMA	Female	Week 5	PATIENT	ADVERSE EVENT (*)
	6	AJP	3	6	AJP	Male	Week 1	PATIENT	ADVERSE EVENT (*)
	9	DEN	3	9	DEN	Female	Week 3	PATIENT	ADVERSE EVENT (*)
	11	PIE	3	11	PIE	Female	Week 1	PATIENT	ADVERSE EVENT (*)
8	7	SZT	8	7	SZT	Female	Week 3	PHYSICIAN	DETERIORATION
9	17	NL	9	17	NL	Male	Week 2	PATIENT	PATIENT UNCOOPERATIVE
10	6	RS	10	6	RS	Male	Week 5		ADVERSE EVENT (*)
	8	VP	10	8	VP	Female	Week 3	PHYSICIAN	DETERIORATION
	11	TH	10	11	TH	Female	Week 3	PHYSICIAN	DETERIORATION
	25	ES	10	25	ES	Male	Week 3	PHYSICIAN	DETERIORATION
	52	MP	10	52	MP	Male	Week 4	PATIENT	LOST TO FOLLOW UP
11	5	ZK	11	5	ZK	Male	Week 4	PHYSICIAN	DETERIORATION
	8	KF	11	8	KF	Female	Week 4	PATIENT	PATIENT UNCOOPERATIVE
	14	BJ	11	14	BJ	Female	Week 4	PHYSICIAN	DETERIORATION
12	30	FS	12	30	FS	Female	Week 6		DEATH

816

(*) ADVERSE EVENT: to be considered as adverse event or intercurrent medical problems

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 9.1

REASON FOR DISCONTINUATION OF THE TREATMENT
 OPEN PHASE

Centre	Patient	Initial	Centre	Patient	Initial	Sex	Last visit	Decision to	Reason
								discontinue	
13	5	MF	13	5	MF	Female	Week 1	PATIENT	PATIENT UNCOOPERATIVE
	10	BH	13	10	BH	Female	Week 1	PATIENT	PATIENT UNCOOPERATIVE
	12	BF	13	12	BF	Male	Week 5	PHYSICIAN	ADVERSE EVENT (*)
	19	KK	13	19	KK	Female	Week 3	PATIENT	PATIENT UNCOOPERATIVE

9550077

817

(*) ADVERSE EVENT: to be considered as adverse event or intercurrent medical problems

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 9.1

REASON FOR DISCONTINUATION OF THE TREATMENT
DOUBLE BLIND PHASE

Centre	Patient	D.B.	Patient Initial	Sex	Treatment	Last visit	Decision to discontinue	Reason
1	1	1	MGA	Female	Placebo	Week 18	PHYSICIAN	DETERIORATION
	6	5	CPM	Female	Placebo	Week 18	PATIENT	DETERIORATION
	8	6	KVB	Male	Placebo	Week 26	PHYSICIAN	DETERIORATION
	11	9	VRT	Female	Placebo	Week 36	PATIENT	DETERIORATION
	14	11	MLC	Female	Reboxetine	Week 12	PHYSICIAN	DETERIORATION
	16	13	MHC	Female	Placebo	Week 40	PATIENT	IMPROVEMENT
	17	14	CEC	Female	Reboxetine	Week 32	PHYSICIAN	LOST TO FOLLOW UP
	18	15	TTM	Female	Reboxetine	Week 18	PHYSICIAN	ADVERSE EVENT (*)
	19	16	SR	Female	Placebo	Week 38	PATIENT	DETERIORATION
	20	17	EFC	Female	Reboxetine	Week 12	PATIENT	DETERIORATION
	27	23	RK	Male	Placebo	Week 12	PATIENT	DETERIORATION
	28	24	RMM	Female	Placebo	Week 24	PATIENT	DETERIORATION
	30	26	ERV	Male	Placebo	Week 16	PHYSICIAN	DETERIORATION
	33	29	OFC	Male	Placebo	Week 12	PATIENT	DETERIORATION
	36	302	LH	Female	Placebo	Week 16	PHYSICIAN	DETERIORATION
	41	307	SFS	Male	Placebo	Week 44	PHYSICIAN	DETERIORATION

(*) ADVERSE EVENT: to be considered as adverse event or intercurrent medical problems

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 9.1

REASON FOR DISCONTINUATION OF THE TREATMENT
DOUBLE BLIND PHASE

Centre	Patient	D.B. Patient	Initial	Sex	Treatment	Last visit	Decision to discontinue	Reason
1	47	312	MCS	Female	Placebo	Week 46	PHYSICIAN	DETERIORATION
	53	317	JFT	Female	Placebo	Week 22	PHYSICIAN	DETERIORATION
	55	318	DMG	Female	Reboxetine	Week 14	PHYSICIAN	DETERIORATION
	56	319	IAL	Male	Reboxetine	Week 8	PATIENT	ADVERSE EVENT (*)
	58	320	ARM	Female	Reboxetine	Week 16	PATIENT	DETERIORATION
	67	327	MAA	Female	Placebo	Week 26	PHYSICIAN	DETERIORATION
	70	328	MLM	Female	Placebo	Week 22	PHYSICIAN	DETERIORATION
	72	330	RLJ	Male	Reboxetine	Week 22	PATIENT	PATIENT UNCOOPERATIVE
	73	121	FMA	Female	Reboxetine	Week 26	PATIENT	DETERIORATION
	80	127	MEL	Female	Placebo	Week 12	PHYSICIAN	DETERIORATION
	87	132	KDO	Female	Reboxetine	Week 22	PATIENT	DETERIORATION
	89	133	MHV	Female	Reboxetine	Week 14	PHYSICIAN	DETERIORATION
	90	134	JSS	Male	Reboxetine	Week 8	PATIENT	ADVERSE EVENT (*)
	129	344	MNS	Male	Placebo	Week 42	PATIENT	DETERIORATION
	130	345	ECA	Female	Placebo	Week 22	PATIENT	DETERIORATION
	141	353	AMG	Female	Placebo	Week 36	PATIENT	DETERIORATION

(*) ADVERSE EVENT: to be considered as adverse event or intercurrent medical problems

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 9.1

REASON FOR DISCONTINUATION OF THE TREATMENT
DOUBLE BLIND PHASE

Centre	Patient	D.B.	Patient	Initial	Sex	Treatment	Last visit	Decision to discontinue	Reason
1	143	355	JEP		Male	Placebo	Week 20	PHYSICIAN	DETERIORATION
	144	356	ARF		Male	Reboxetine	Week 38	PATIENT	DETERIORATION
	150	151	VA		Female	Placebo	Week 38	PATIENT	DETERIORATION
3	2	61	FIL		Female	Placebo	Week 42	PATIENT	IMPROVEMENT
	3	62	DUB		Male	Placebo	Week 24	PATIENT	DETERIORATION
	7	71	GRI		Female	Reboxetine	Week 10	PATIENT	ADVERSE EVENT (*)
10		72	TOR		Male	Placebo	Week 22	PATIENT	PATIENT UNCOOPERATIVE
8	1	211	HJ		Female	Placebo	Week 46	PHYSICIAN	PATIENT UNCOOPERATIVE
	3	213	JL		Male	Reboxetine	Week 16	PHYSICIAN	DETERIORATION
	5	215	SL		Male	Placebo	Week 8	PHYSICIAN	PATIENT UNCOOPERATIVE
9	5	242	MF		Female	Placebo	Week 42	PATIENT	PATIENT UNCOOPERATIVE
	8	244	KTM		Female	Placebo	Week 24	PHYSICIAN	DETERIORATION
12		247	GYT		Female	Placebo	Week 16	PATIENT	PATIENT UNCOOPERATIVE
19		251	KF		Female	Placebo	Week 18	PATIENT	IMPROVEMENT
20		252	GVE		Female	Reboxetine	Week 18	PATIENT	IMPROVEMENT
23		256	SZN		Female	Reboxetine	Week 20	PATIENT	PATIENT UNCOOPERATIVE

(*) ADVERSE EVENT: to be considered as adverse event or intercurrent medical problems

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 9.1

REASON FOR DISCONTINUATION OF THE TREATMENT
DOUBLE BLIND PHASE

Centre	Patient	D.B.	Patient	Initial	Sex	Treatment	Last visit	Decision to discontinue	Reason
9	24	253	IGY	Male	Placebo	Week 20	PATIENT	PATIENT UNCOOPERATIVE	
	25	254	PM	Female	Placebo	Week 50	PATIENT	PATIENT UNCOOPERATIVE	
	26	255	CP	Female	Reboxetine	Week 22	PATIENT	PATIENT UNCOOPERATIVE	
	28	257	HI	Male	Placebo	Week 28	PATIENT	PATIENT UNCOOPERATIVE	
	29	258	SZF	Female	Reboxetine	Week 28	PATIENT	PATIENT UNCOOPERATIVE	
	30	259	NF	Female	Reboxetine	Week 10	PATIENT	PATIENT UNCOOPERATIVE	
10	1	271	VK	Male	Reboxetine	Week 16	PATIENT	IMPROVEMENT	
	4	272	ZSD	Female	Placebo	Week 30	PHYSICIAN	ADVERSE EVENT (*)	
	5	273	AN	Female	Placebo	Week 12	PATIENT	IMPROVEMENT	
	7	274	RK	Male	Reboxetine	Week 8	PATIENT	IMPROVEMENT	
	9	275	RT	Female	Reboxetine	Week 9	PATIENT	IMPROVEMENT	
	10	276	MH	Female	Placebo	Week 10	PATIENT	IMPROVEMENT	
	12	277	EP	Female	Reboxetine	Week 10	PATIENT	DETERIORATION	
	13	278	HU	Female	Reboxetine	Week 8	PATIENT	LOST TO FOLLOW UP	
	15	280	HT	Female	Reboxetine	Week 10	PATIENT	IMPROVEMENT	
	20	285	EJ	Female	Reboxetine	Week 28	PATIENT	LOST TO FOLLOW UP	

(*) ADVERSE EVENT: to be considered as adverse event or intercurrent medical problems

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 9.1

REASON FOR DISCONTINUATION OF THE TREATMENT
DOUBLE BLIND PHASE

Centre	Patient	D.B.	Patient Initial	Sex	Treatment	Last visit	Decision to discontinue	Reason
10	21	288	AK	Female	Placebo	Week 22	PATIENT	LOST TO FOLLOW UP
	23	287	LT	Female	Reboxetine	Week 44	PHYSICIAN	PROTOCOL VIOLATION
	26	290	JIF	Female	Reboxetine	Week 10	PATIENT	ADVERSE EVENT (*)
	28	291	LL	Male	Reboxetine	Week 50	PHYSICIAN	PROTOCOL VIOLATION
	29	293	JJ	Male	Placebo	Week 20	PATIENT	LOST TO FOLLOW UP
	33	300	EK	Male	Reboxetine	Week 18	PATIENT	LOST TO FOLLOW UP
	34	31	TK	Male	Reboxetine	Week 16	PATIENT	LOST TO FOLLOW UP
	35	35	IN	Female	Reboxetine	Week 16	PATIENT	LOST TO FOLLOW UP
	37	32	HK	Female	Placebo	Week 28	PHYSICIAN	PROTOCOL VIOLATION
	38	37	LL	Female	Reboxetine	Week 16	PATIENT	IMPROVEMENT
	40	33	AP	Female	Placebo	Week 14	PATIENT	IMPROVEMENT
	42	295	TT	Male	Placebo	Week 12	PHYSICIAN	DETERIORATION
	43	296	IK	Female	Placebo	Week 26	PATIENT	PATIENT UNCOOPERATIVE
	44	298	AB	Male	Placebo	Week 16	PATIENT	IMPROVEMENT
	45	34	KJ	Female	Placebo	Week 16	PATIENT	LOST TO FOLLOW UP
	46	38	TN	Male	Placebo	Week 8	PHYSICIAN	PATIENT UNCOOPERATIVE

(*) ADVERSE EVENT: to be considered as adverse event or intercurrent medical problems

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXYTINE - PROTOCOL 20124/013
Listing No.: 9.1

REASON FOR DISCONTINUATION OF THE TREATMENT
DOUBLE BLIND PHASE

Centre	Patient	D.B.	Patient	Initial	Sex	Treatment	Last visit	Decision to	Reason
							discontinue		
10	48	41	IP	Female	Placebo	Week 20	PATIENT	LOST TO FOLLOW UP	
	49	43	VM	Female	Reboxetine	Week 28	PATIENT	ADVERSE EVENT (*)	
	53	47	MA	Female	Reboxetine	Week 34	PATIENT	LOST TO FOLLOW UP	
	54	48	UN	Female	Reboxetine	Week 34	PATIENT	LOST TO FOLLOW UP	
	56	50	JP	Male	Reboxetine	Week 10	PATIENT	PATIENT UNCOOPERATIVE	
	59	53	TA	Female	Reboxetine	Week 10	PATIENT	LOST TO FOLLOW UP	
	60	54	JM	Male	Placebo	Week 8	PATIENT	PATIENT UNCOOPERATIVE	
	61	55	JT	Male	Placebo	Week 18	PATIENT	LOST TO FOLLOW UP	
	62	56	RK	Male	Placebo	Week 32	PATIENT	LOST TO FOLLOW UP	
	64	58	LT	Female	Placebo	Week 20	PATIENT	LOST TO FOLLOW UP	
	81	46	JN	Female	Placebo	Week 46	PATIENT	LOST TO FOLLOW UP	
	82	59	LS	Male	Reboxetine	Week 48	PATIENT	LOST TO FOLLOW UP	
	84	63	HV	Female	Reboxetine	Week 16	PATIENT	LOST TO FOLLOW UP	
	85	272	AK	Male	Placebo	Week 8	PHYSICIAN	PATIENT UNCOOPERATIVE	
	86	274	NP	Female	Reboxetine	Week 18	PATIENT	LOST TO FOLLOW UP	
	89	277	SK	Female	Reboxetine	Week 8	PATIENT	LOST TO FOLLOW UP	

(*) ADVERSE EVENT: to be considered as adverse event or intercurrent medical problems

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 9.1

REASON FOR DISCONTINUATION OF THE TREATMENT
DOUBLE BLIND PHASE

Centre	Patient	D.B.	Patient	Initial	Sex	Treatment	Last visit	Decision to discontinue	Reason
10	90	70	SV		Female	Reboxetine	Week 26	PATIENT	LOST TO FOLLOW UP
	91	74	HI		Male	Reboxetine	Week 30	PATIENT	LOST TO FOLLOW UP
	93	285	AN		Female	Reboxetine	Week 36	PATIENT	LOST TO FOLLOW UP
	94	273	PV		Female	Placebo	Week 18	PATIENT	LOST TO FOLLOW UP
11	1	372	DF		Male	Placebo	Week 34	PATIENT	PATIENT UNCOOPERATIVE
	2	373	HB		Female	Reboxetine	Week 30	PATIENT	PATIENT UNCOOPERATIVE
	3	374	RF		Female	Reboxetine	Week 10	PHYSICIAN	DETERIORATION
	4	375	EA		Male	Placebo	Week 22	PHYSICIAN	DETERIORATION
	9	362	FI		Female	Placebo	Week 12	PHYSICIAN	DETERIORATION
	11	361	NGY		Female	Reboxetine	Week 24	PHYSICIAN	DETERIORATION
	13	365	OK		Female	Reboxetine	Week 20	PHYSICIAN	PROTOCOL VIOLATION
	15	366	NF		Female	Placebo	Week 18	PHYSICIAN	DETERIORATION
	16	367	NA		Female	Reboxetine	Week 18	PATIENT	PATIENT UNCOOPERATIVE
	20	371	LJ		Female	Placebo	Week 14	PHYSICIAN	DETERIORATION
12	2	99	EFC		Female	Reboxetine	Week 12	PATIENT	DETERIORATION
	4	100	EG		Female	Reboxetine	Week 28	PHYSICIAN	PROTOCOL VIOLATION

(*) ADVERSE EVENT: to be considered as adverse event or intercurrent medical problems

024

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 9.1

REASON FOR DISCONTINUATION OF THE TREATMENT
DOUBLE BLIND PHASE

Centre	Patient	D.B. Patient	Initial Sex	Treatment	Last visit	Decision to discontinue	Reason
12	5	95 ZSH	Male	Placebo	Week 18	PATIENT	DETERIORATION
	6	98 NK	Female	Placebo	Week 30	PATIENT	PATIENT UNCOOPERATIVE
	7	102 LK	Male	Reboxetine	Week 28	PATIENT	PROTOCOL VIOLATION
	9	91 KBP	Female	Reboxetine	Week 28	PATIENT	DETERIORATION
	10	96 IP	Female	Placebo	Week 24	PATIENT	PATIENT UNCOOPERATIVE
	11	94 ER	Female	Placebo	Week 12	PATIENT	DETERIORATION
	12	97 FSZ	Female	Placebo	Week 10	PATIENT	DETERIORATION
	13	103 IS2	Female	Placebo	Week 12	PATIENT	PATIENT UNCOOPERATIVE
	14	101 GS2	Female	Placebo	Week 10	PHYSICIAN	DETERIORATION
	15	104 GB	Male	Reboxetine	Week 26	PATIENT	PATIENT UNCOOPERATIVE
	16	105 FN	Female	Reboxetine	Week 26	PHYSICIAN	PATIENT UNCOOPERATIVE
	17	108 TK	Male	Placebo	Week 28	PHYSICIAN	PROTOCOL VIOLATION
	18	109 LS	Male	Placebo	Week 20	PHYSICIAN	ADVERSE EVENT (*)
	19	106 SS2	Female	Reboxetine	Week 16	PATIENT	PATIENT UNCOOPERATIVE
	20	107 KS2	Male	Placebo	Week 28	PHYSICIAN	PROTOCOL VIOLATION
	21	110 FL	Female	Reboxetine	Week 20	PATIENT	DETERIORATION

(*) ADVERSE EVENT: to be considered as adverse event or intercurrent medical problems

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 9.1

REASON FOR DISCONTINUATION OF THE TREATMENT
DOUBLE BLIND PHASE

Centre	Patient	D.B.	Patient	Initial	Sex	Treatment	Last visit	Decision to discontinue	Reason
12	23	112	EN		Female	Placebo	Week 28	PHYSICIAN	PROTOCOL VIOLATION
	24	113	MF		Female	Reboxetine	Week 28	PHYSICIAN	PROTOCOL VIOLATION
	27	115	VCS		Female	Reboxetine	Week 34	PATIENT	PATIENT UNCOOPERATIVE
	28	116	IV		Female	Placebo	Week 16	PATIENT	DETERIORATION
	33	368	LN		Female	Reboxetine	Week 20	PATIENT	LOST TO FOLLOW UP
	35	119	LP		Female	Placebo	Week 18	PATIENT	DETERIORATION
	36	385	FB		Female	Reboxetine	Week 12	PATIENT	DETERIORATION
	37	386	EK		Female	Placebo	Week 18	PATIENT	PATIENT UNCOOPERATIVE
13	8	228	PK		Female	Placebo	Week 30	PHYSICIAN	DETERIORATION
	9	229	SZS		Male	Placebo	Week 20	PATIENT	DETERIORATION
	22	232	NYM		Female	Reboxetine	Week 10	PHYSICIAN	DETERIORATION

(* ADVERSE EVENT: to be considered as adverse event or intercurrent medical problems

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
LISTING No.: 9.2

PATIENTS NOT EVALUABLE FOR EFFICACY

TREATMENT	CENTRE	PATIENT	BASELINE	LAST OPEN	VARIA- TION %	LAST DOUBLE BLIND	AT LEAST ONE RELAPSE- YES_NO	DISCONTINUATION FOR
PLACERO	10	19/284	21	11	47.	0	NO	
		50/44	25	13	48.	10	NO	
	11	12/364	19	13	31.	4	NO	
		15/364	18	21	-16.	18	NO	
		9/362	31	19	58.	28	NO	
	12	12/797	20	17	15.	22	NO	
		18/109	29	16	44.	17	NO	
		5/95	23	12	47.	10	NO	
		14/111	55	17	49.	37	YES	
		59/53	18	12	35.	4	NO	
REBOXETINE	10	59/53	18	12	35.	4	NO	
		13/365	20	24	-20.	1	NO	
	11	3/374	28	17	59.	34	YES	
		2/99	31	22	29.	25	NO	
		25/114	29	16	44.	9	NO	
	12	4/100	25	19	24.	12	NO	
		1/219	32	20	37.	3	NO	
	13	22/232	31	16	48.	34	YES	
		6/226	30	19	36.	8	NO	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Patient	Centre No.	Initials	Visit	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score	
1	1	MGA	-1	3	1	2	1	2	1	3	2	0	4	3	1	2	1	3	1	1	1	2	0	0	34	
			0	3	2	2	1	2	2	1	3	1	4	3	1	2	1	3	2	1	2	2	0	0	37	
			1	3	2	2	1	2	2	3	2	0	2	3	2	2	1	2	0	1	2	2	0	0	34	
			2	2	1	1	1	1	2	2	1	0	3	3	2	2	1	2	0	1	1	1	0	0	27	
			3	2	1	1	1	1	2	1	0	2	2	2	2	1	2	0	0	1	1	1	0	0	21	
			4	1	0	0	1	1	1	2	1	0	2	1	0	2	1	1	0	0	1	1	0	0	16	
			5	1	0	0	1	1	0	1	0	2	1	0	2	1	1	0	0	1	1	1	0	0	14	
			6	1	0	0	1	1	1	1	1	0	2	1	0	2	0	1	0	0	1	1	0	0	14	
1	2	RAQ	-1	3	2	2	1	2	2	3	2	0	3	2	2	1	2	1	2	1	0	0	2	1	34	
			0	3	2	2	1	2	2	3	2	0	3	2	2	2	1	2	0	0	2	1	1	1	36	
			1	3	1	1	1	2	1	3	2	0	3	3	2	2	2	0	0	1	2	1	1	1	34	
			2	2	1	1	1	1	1	2	1	0	2	2	1	2	1	2	0	0	1	2	1	1	27	
			3	2	0	0	1	1	1	2	1	2	0	2	1	2	2	1	0	0	0	1	1	1	21	
1	3	TA	-1	3	2	1	2	1	1	2	2	0	4	2	2	2	0	2	1	1	1	1	1	0	31	
			0	3	1	1	2	2	1	2	2	0	4	2	2	2	0	2	0	0	1	2	1	0	28	
			1	4	2	2	1	2	2	3	2	0	3	2	2	2	2	2	0	1	1	1	1	0	36	
			2	3	1	1	2	1	2	3	1	0	2	2	2	1	1	1	0	0	0	1	0	1	25	
			3	2	0	0	1	1	2	1	0	2	2	2	1	2	1	1	0	0	0	1	0	1	20	
			4	2	0	0	1	1	1	2	1	0	2	2	1	2	1	1	0	0	0	1	0	1	20	
			5	1	0	0	1	1	1	2	1	0	2	1	0	2	1	1	0	0	0	1	0	1	16	
			6	1	0	0	1	1	1	1	1	0	1	2	0	2	0	1	0	0	0	1	0	1	14	
4		DNC	-1	3	2	1	2	1	2	2	1	0	4	3	2	2	1	3	1	1	0	2	0	1	34	
			0	3	2	2	1	2	1	3	2	0	4	2	2	2	1	2	0	1	1	2	0	1	34	
			1	3	2	1	2	1	2	4	2	0	4	3	2	2	1	3	2	0	1	2	0	1	38	
			2	3	1	1	1	1	2	3	1	0	2	2	2	1	1	1	0	0	1	1	0	1	26	
			3	2	1	0	1	1	1	2	1	0	2	1	0	2	1	1	0	0	1	1	0	1	19	
			4	2	1	0	1	1	1	1	1	0	2	2	2	1	1	0	0	1	1	1	0	1	19	
			5	1	0	0	1	1	0	1	1	0	2	1	0	2	1	1	0	0	1	1	0	1	16	
			6	1	0	0	1	1	1	1	1	0	1	1	0	2	1	1	0	0	0	1	0	1	13	
1	5	DB	-1	3	1	1	2	2	1	3	2	0	3	3	2	2	3	2	0	0	2	0	0	0	34	
			0	3	2	1	2	2	1	3	2	0	3	2	2	2	3	0	0	0	2	0	0	0	32	
			1	3	2	1	2	1	1	3	1	0	3	2	1	2	2	0	0	0	2	0	0	0	28	
			2	2	1	0	1	0	2	2	1	0	2	2	0	2	1	2	0	1	0	2	0	0	21	
			3	2	1	0	1	1	1	2	1	0	2	2	0	2	1	0	0	0	1	0	0	0	18	
			4	1	0	0	1	1	1	0	0	1	1	1	1	2	0	1	0	0	0	1	0	0	11	
			5	1	0	0	1	1	0	1	0	1	1	1	0	0	1	0	0	0	1	0	0	0	10	
			6	1	0	0	1	1	1	1	1	0	1	1	0	2	1	1	0	0	0	1	0	0	13	
1	6	CPH	-1	3	1	3	1	1	1	3	0	2	4	2	2	1	1	2	1	1	1	0	0	1	31	
			0	3	2	3	1	2	1	3	0	2	4	2	2	2	1	2	1	1	1	1	0	1	35	
			1	4	2	1	1	1	1	3	0	2	2	2	1	2	1	2	0	0	1	1	0	1	29	
			2	2	1	1	1	2	1	2	0	2	2	2	0	3	1	1	0	0	1	2	1	0	24	
			3	2	1	1	2	1	2	2	1	0	2	2	2	1	1	0	0	1	1	1	1	0	23	
			4	1	0	0	2	0	2	1	1	0	2	2	1	2	1	2	0	0	1	1	1	1	0	20

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit No.	Hamilton Depression Rating Scale																				Total Score	
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20		It.21
1	6	CPH	5	1	0	0	2	0	1	1	1	0	2	2	1	2	1	1	0	0	1	1	0	18	
			6	1	1	0	2	0	1	1	0	0	1	1	0	2	1	0	0	1	1	1	0	13	
	7	JSA	-1	4	2	2	2	2	1	3	2	0	3	3	2	2	2	2	2	0	2	1	1	40	
			0	4	2	2	2	2	2	0	4	3	2	2	2	2	2	2	0	1	0	2	1	38	
			1	4	2	1	2	1	3	1	0	4	3	2	2	2	2	2	0	0	2	1	1	1	35
			2	3	1	1	2	1	1	2	1	0	2	1	1	2	1	1	0	0	0	1	1	1	23
1	8	MYB	3	3	1	1	2	1	2	3	1	0	2	2	2	2	2	3	2	1	0	2	1	34	
			-1	3	1	1	2	2	2	3	0	2	3	3	2	2	1	1	2	1	1	2	0	0	34
			0	3	2	1	2	2	3	1	0	3	3	2	2	2	2	2	0	0	1	1	0	0	35
			1	3	2	1	2	2	3	2	0	3	3	2	2	2	2	2	0	0	1	1	0	0	33
			2	2	1	0	1	0	2	2	1	0	2	2	2	2	1	1	0	0	1	1	0	0	21
			3	2	0	0	1	1	1	1	1	0	2	1	1	2	1	1	0	0	1	1	0	0	17
1	9	CCR	4	1	0	0	1	1	1	2	1	1	1	1	1	2	0	1	0	0	1	1	0	16	
			5	1	0	0	1	1	0	1	1	0	1	2	0	1	1	0	0	1	1	0	0	1	16
			6	1	0	0	1	1	1	1	1	0	1	2	0	2	1	2	0	0	0	1	0	1	13
			-1	4	2	2	1	2	2	4	3	0	2	3	2	2	2	2	3	2	2	1	3	0	43
			0	3	2	2	2	1	2	4	2	0	3	3	2	2	2	2	2	2	1	2	0	1	41
			1	3	2	2	1	2	3	2	0	2	3	2	2	2	2	2	0	2	1	2	0	1	36
1	10	LDL	2	2	1	1	1	1	3	1	0	2	2	2	2	2	2	1	1	0	1	1	0	24	
			3	2	1	0	1	2	1	1	1	0	2	2	2	2	1	1	0	0	1	1	0	1	20
			4	1	0	0	1	0	0	1	0	0	1	1	0	0	1	1	0	0	1	1	0	0	8
			5	1	0	0	1	0	0	1	0	0	1	1	0	0	1	1	0	0	0	1	0	0	8
			6	1	0	0	1	0	0	1	0	0	1	1	0	0	1	1	0	0	0	1	0	1	8
			-1	4	2	2	2	1	1	3	2	0	3	3	2	2	1	3	2	0	2	2	1	1	39
1	11	VRT	0	4	2	1	2	1	2	4	2	0	3	3	2	2	1	2	2	0	2	2	1	39	
			1	4	2	1	2	1	2	3	2	0	2	3	2	2	1	2	0	0	2	2	1	1	35
			2	3	1	1	1	1	2	2	0	1	2	2	2	1	1	1	0	0	1	2	1	1	27
			3	2	1	1	1	1	2	1	1	0	1	1	0	1	1	1	0	0	1	1	1	1	19
			4	1	0	0	1	1	0	0	0	0	2	2	0	0	0	1	0	0	0	1	0	1	11
			5	0	0	0	1	0	0	1	0	0	1	1	0	0	1	1	0	0	0	1	0	1	6
1	12	SLT	6	0	0	0	1	1	0	0	0	1	1	0	0	0	1	0	0	0	1	0	1	7	
			-1	4	0	2	2	2	3	2	0	4	3	1	2	2	2	0	1	0	2	1	1	34	
			0	4	0	2	2	1	2	3	2	0	3	3	2	2	0	3	0	1	0	1	1	1	36
			1	4	0	2	2	1	2	3	0	2	3	2	2	1	1	0	1	0	1	1	1	1	32
			2	4	1	1	2	1	2	3	0	2	3	3	1	2	2	1	2	0	1	2	0	1	33
			3	4	1	2	1	1	2	3	0	2	3	3	1	2	2	2	0	0	1	2	0	0	32
1	13	SLT	4	3	0	0	1	1	1	2	0	1	2	0	1	2	1	2	0	0	1	1	0	21	
			5	2	0	0	1	1	1	2	0	1	2	2	1	2	1	2	0	0	1	1	0	0	13
			6	1	0	0	1	1	0	1	1	0	1	2	2	1	2	1	1	0	0	1	1	0	14
			-1	3	1	1	2	1	2	3	0	3	3	2	2	1	3	2	0	2	0	2	2	0	35
			0	3	1	2	2	1	2	3	0	3	3	2	2	1	3	0	0	2	2	0	2	0	34
			1	3	1	2	1	1	2	3	0	2	3	2	2	1	2	0	0	2	2	0	2	0	31

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REMOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Patient Centre No.	Initials	Visit No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score
1	12	SLT	2	3	1	1	1	2	3	0	2	2	2	1	2	1	2	0	0	1	1	1	0	27
			3	2	1	1	1	2	2	0	1	2	1	1	1	1	1	2	0	0	1	1	0	22
			4	1	0	0	2	1	1	1	0	1	2	1	1	1	0	0	0	1	1	1	0	14
			5	1	0	0	1	1	0	1	2	1	0	1	0	1	1	0	0	1	1	0	0	12
			6	1	0	0	1	1	0	1	1	1	1	0	2	1	0	0	0	1	0	0	0	11
1	13	JR	-1	4	2	2	1	1	2	4	2	0	3	3	2	2	1	2	0	2	1	0	1	37
			0	3	1	2	1	2	3	2	0	3	2	1	2	2	3	0	2	1	1	1	0	33
			1	4	2	2	2	2	3	2	0	3	3	2	2	1	3	0	1	2	1	0	0	37
			2	4	2	2	2	2	3	2	0	2	3	2	2	1	3	0	0	1	1	0	0	34
1	14	MLC	-1	3	2	2	2	1	2	3	0	3	3	3	2	2	1	1	1	1	2	0	0	37
			0	4	1	1	2	1	2	3	0	3	3	3	1	2	1	0	0	1	1	1	0	33
			1	4	1	1	2	1	2	3	0	2	3	3	1	2	1	0	0	1	1	1	0	31
			2	4	2	1	2	1	2	3	0	2	3	3	1	2	1	0	0	1	1	1	0	28
			3	3	1	1	2	1	2	3	0	3	3	2	2	1	2	2	1	1	1	1	0	32
			4	4	1	1	2	1	2	2	0	3	3	2	2	1	2	2	0	1	2	1	0	32
			5	2	1	0	1	2	1	2	0	2	3	3	1	2	2	0	1	2	1	0	0	32
			6	1	0	1	1	2	1	2	0	2	3	3	1	2	1	1	0	0	1	0	0	21
1	15	MAO	-1	4	2	2	1	1	2	4	1	2	2	2	1	2	1	1	0	0	1	0	0	17
			0	4	2	2	1	2	4	3	0	2	2	2	2	2	1	1	0	2	2	0	0	36
			1	4	2	2	2	2	3	3	0	3	2	2	2	2	1	0	0	1	2	0	0	35
			2	3	1	1	2	1	2	3	0	2	2	2	2	2	1	0	0	1	2	0	0	34
			3	2	1	1	2	1	2	2	0	2	2	2	2	2	1	0	0	1	1	1	0	25
			4	2	1	0	1	1	2	3	0	2	2	2	2	1	1	0	0	1	1	0	0	23
			5	1	1	0	1	1	2	2	0	1	1	2	0	2	1	1	0	0	1	1	0	19
			6	1	0	0	1	1	1	2	0	1	2	2	1	1	0	0	0	1	1	0	0	16
1	16	MHC	-1	4	2	2	2	1	3	2	0	3	3	2	2	3	1	0	0	1	2	0	0	37
			0	4	2	2	2	2	3	2	0	3	3	2	2	2	2	0	0	2	2	0	0	37
			1	4	2	1	1	2	2	3	2	0	3	2	2	2	2	0	0	2	2	0	0	34
			2	3	1	1	2	1	2	3	0	2	3	2	1	1	0	0	0	2	2	0	0	29
			3	2	1	0	2	1	2	3	1	0	2	2	1	1	0	0	0	1	1	1	0	23
			4	1	1	0	1	1	2	1	0	2	2	1	1	1	0	0	0	1	2	0	0	16
			5	2	1	0	1	1	2	1	0	2	2	1	1	1	0	0	0	1	1	0	0	18
			6	1	0	0	1	1	1	2	0	1	2	2	1	1	0	0	0	1	1	0	0	13
1	17	CEC	-1	3	2	1	1	2	2	3	0	3	3	3	2	1	1	2	0	1	2	0	0	34
			0	3	2	1	2	2	3	0	3	3	3	2	2	1	2	0	0	1	2	0	0	36
			1	3	2	1	2	1	2	3	0	2	3	3	1	2	1	2	0	1	2	0	0	32
			2	3	2	1	2	1	2	3	0	2	3	3	1	2	0	0	0	1	1	0	0	29
			3	2	1	2	1	2	3	0	2	2	2	2	1	2	0	0	0	1	2	0	0	27
			4	2	1	0	2	1	2	2	0	2	2	2	1	2	0	0	0	1	2	0	0	24
			5	1	1	0	1	1	2	1	0	2	2	1	1	1	0	0	0	1	1	0	0	17
			6	1	1	0	1	1	2	0	1	2	2	0	0	1	2	0	0	1	1	0	0	16
1	18	TTM	-1	4	2	1	2	2	3	2	0	3	3	2	2	2	2	2	0	1	2	0	0	37

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Total Score																							
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21			
1	18	TTH	0	4	2	1	2	2	2	3	2	0	3	3	2	2	2	3	0	0	2	2	0	1	38		
			1	4	2	1	2	2	3	0	2	3	3	2	2	1	3	2	0	0	2	2	0	0	38		
			2	3	2	0	2	2	3	0	1	2	2	1	2	1	2	1	2	0	0	1	1	0	0	27	
			3	2	2	0	2	1	2	3	0	1	2	2	1	1	1	2	0	0	0	1	1	1	0	25	
			4	2	2	0	2	1	1	2	0	1	2	2	1	1	1	2	0	0	0	1	1	1	0	23	
			5	1	1	0	1	1	2	0	1	1	2	0	2	1	2	1	1	0	0	1	1	1	0	18	
1	19	SR	-1	4	1	2	2	2	1	3	2	0	3	3	1	2	2	3	1	0	2	2	0	0	36		
			0	4	1	2	1	2	2	3	0	2	3	3	1	2	2	2	0	0	1	2	0	0	33		
			1	4	1	2	1	2	3	0	2	3	2	1	2	2	2	2	2	0	0	2	1	0	1	35	
			2	4	1	1	1	2	2	3	0	1	3	2	1	2	2	2	2	0	0	2	1	0	0	33	
			3	3	1	1	1	2	2	3	0	2	3	3	1	2	2	2	2	0	0	2	1	0	0	31	
			4	2	1	0	1	1	2	2	0	2	2	2	1	2	1	1	2	0	0	1	1	0	0	24	
1	20	EFC	5	1	0	0	2	1	1	2	0	2	2	2	0	1	1	1	0	0	2	1	0	0	19		
			6	1	0	0	1	1	1	1	1	0	1	2	2	0	2	1	1	0	0	2	1	0	0	15	
			-1	3	2	2	1	2	2	3	0	2	3	3	2	2	2	2	1	1	1	2	1	1	0	36	
			0	3	2	2	2	1	2	3	0	2	3	2	2	2	2	2	1	2	0	2	1	1	0	35	
			1	3	2	2	2	1	2	3	0	2	3	2	2	2	2	2	1	2	0	2	1	1	0	31	
			2	3	1	1	2	1	2	1	2	2	2	2	2	2	2	2	1	2	0	2	1	0	0	32	
1	21	VHC	3	2	1	1	2	1	1	2	1	0	2	2	1	1	1	1	0	0	1	1	1	0	24		
			4	2	1	1	2	1	1	2	2	0	2	2	1	1	1	1	0	0	1	1	1	0	23		
			5	1	2	2	1	2	2	3	0	2	3	1	2	1	1	1	0	0	1	1	1	0	29		
			6	2	1	0	1	1	0	1	1	0	2	2	1	1	1	1	0	0	1	1	1	0	0	17	
			-1	4	2	1	2	1	1	3	0	2	2	3	2	2	2	2	1	1	1	1	1	1	0	33	
			0	3	2	1	2	2	1	3	0	2	3	2	2	2	2	2	0	0	0	1	1	1	0	31	
1	22	SK	1	3	2	1	2	1	1	3	2	0	3	2	2	2	2	2	0	0	2	1	1	0	30		
			2	3	2	1	2	1	1	3	2	0	3	2	1	2	1	2	1	0	0	1	2	1	0	28	
			3	3	2	1	2	1	1	3	2	0	2	3	2	1	2	1	1	0	0	1	2	1	0	28	
			4	2	1	0	2	1	2	2	1	2	2	0	2	2	1	2	1	1	0	0	2	1	1	0	23
			5	1	0	0	1	0	0	1	0	0	1	0	2	2	0	2	1	0	0	1	1	1	0	12	
			6	1	0	0	1	0	0	1	0	0	1	2	1	0	2	1	0	0	0	0	1	0	0	10	
1	23	AR	-1	3	1	1	1	1	2	2	0	2	2	2	2	2	1	1	0	0	1	2	0	0	26		
			0	3	1	1	2	1	2	1	2	0	1	2	3	1	2	1	1	0	0	2	2	0	1	28	
			1	3	1	1	2	1	1	2	0	1	2	2	1	2	1	1	1	0	0	1	2	0	1	25	
			2	3	1	1	2	1	1	2	0	2	2	2	1	2	1	1	0	0	0	1	1	1	0	25	
			3	2	1	1	1	2	2	2	0	1	2	2	1	2	1	1	1	0	0	2	1	1	0	25	
			4	1	0	0	1	0	1	0	1	0	0	2	2	0	2	1	0	0	0	0	0	0	0	12	
1	29	AR	5	1	0	0	1	0	0	1	0	1	2	2	0	1	0	0	0	0	1	1	0	0	12		
			6	1	0	0	1	1	1	1	1	0	1	2	1	0	0	1	0	0	0	1	1	0	11		
			-1	3	1	1	1	1	2	2	2	0	3	3	2	2	1	1	1	2	0	1	1	0	0	29	
			0	3	1	2	1	2	2	3	2	0	3	3	2	2	1	1	1	0	0	1	1	0	0	30	
			1	3	1	1	2	2	3	2	0	3	3	2	2	2	1	1	1	0	0	1	1	0	0	29	
			2	3	2	1	2	1	2	4	2	0	3	3	2	2	1	1	1	0	0	1	1	1	0	32	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit No.	Total Score																						
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21		
1	23	AR	3	3	2	1	2	1	2	3	0	3	3	2	2	2	1	1	0	1	1	1	0	0	31	
			4	3	1	2	1	2	4	2	0	3	3	2	2	2	1	2	0	0	2	1	0	0	35	
			-1	3	2	2	1	2	1	3	0	2	3	2	1	2	1	1	2	0	1	1	0	1	31	
			0	3	2	2	1	2	1	3	0	3	3	2	1	2	2	1	0	0	1	1	0	1	31	
1	24	LVF	1	3	1	1	2	1	2	3	0	2	3	1	2	2	1	1	0	0	1	1	0	0	28	
			2	2	1	0	2	1	1	2	2	1	2	0	2	1	1	0	0	1	1	1	0	0	20	
			3	2	1	0	2	1	1	2	0	1	2	0	1	1	1	1	0	0	1	1	0	0	18	
			4	1	0	0	1	1	1	2	0	1	2	0	0	1	1	1	0	0	1	1	0	0	15	
			5	1	0	0	1	0	0	1	0	1	2	1	0	0	1	1	0	0	1	1	0	0	9	
			6	1	0	0	0	1	0	0	1	0	2	1	0	0	1	0	0	0	0	0	1	0	0	9
1	25	ANR	-1	3	1	2	2	1	2	3	2	0	3	2	2	1	2	1	1	0	0	1	0	1	33	
			0	3	2	1	2	1	2	4	2	0	3	3	2	2	1	0	2	1	2	1	0	0	34	
			1	3	1	1	2	1	1	3	2	0	3	3	2	2	1	2	0	1	1	2	1	0	0	31
			2	2	0	0	2	1	0	1	0	1	2	1	0	1	1	1	0	0	1	1	0	0	16	
			3	2	0	0	2	1	0	1	0	1	1	0	1	1	1	1	0	0	1	0	0	0	0	13
			4	2	1	0	1	2	2	2	1	0	2	0	2	0	2	0	0	2	0	1	0	0	0	20
1	26	OC	5	1	1	0	1	0	1	0	1	0	2	2	0	1	1	0	0	1	0	0	1	0	14	
			6	1	0	0	0	0	1	1	0	1	1	0	1	1	1	0	0	0	1	0	0	1	8	
			-1	2	2	1	2	2	3	0	3	2	0	3	2	2	1	2	2	0	2	1	0	1	37	
			0	4	1	1	1	2	3	2	0	3	3	1	2	2	2	0	1	1	1	2	0	0	32	
			1	3	1	1	1	2	3	2	0	3	2	2	1	2	1	1	2	0	1	1	2	0	0	29
			2	3	1	1	0	1	2	3	2	0	3	2	2	1	1	2	0	1	1	2	0	1	0	27
3	33	33	3	2	1	0	2	1	1	2	0	2	3	1	0	2	0	1	0	0	1	2	0	0	22	
			4	1	1	1	0	0	1	0	1	2	1	1	0	1	1	0	0	0	0	1	0	0	12	
			5	1	0	0	1	0	0	1	0	1	1	1	0	1	1	0	0	0	1	0	1	0	11	
			6	1	0	0	1	0	1	1	0	0	2	1	0	1	1	0	0	1	0	1	0	1	0	11
			-1	4	2	1	2	1	2	3	0	3	3	2	2	2	2	0	2	2	0	2	1	1	0	37
			0	3	2	1	1	2	2	4	3	0	3	3	2	2	2	0	0	1	1	2	1	1	1	36
1	27	RK	1	3	2	1	2	2	1	4	3	0	3	3	2	2	1	0	2	1	1	2	0	1	37	
			2	2	1	1	2	0	2	2	0	0	3	2	0	2	1	2	0	0	1	2	0	0	23	
			3	2	1	1	1	1	1	1	2	0	2	3	1	0	2	0	1	0	0	1	2	0	1	19
			4	2	1	0	1	1	0	2	1	0	2	2	0	2	1	1	0	0	1	1	2	0	1	21
			5	1	1	0	1	2	0	2	1	0	2	1	0	1	0	1	1	0	0	1	1	0	0	15
			6	1	0	0	1	0	0	1	0	0	1	2	0	1	0	0	0	0	0	1	0	0	0	9
1	28	RHM	-1	3	1	1	1	0	2	3	2	0	3	3	1	1	2	3	1	0	1	1	0	0	29	
			0	4	1	1	2	1	1	3	2	0	3	2	1	2	1	1	2	0	2	2	0	1	32	
			1	4	1	1	2	1	1	3	2	0	3	2	1	2	1	1	0	0	2	1	1	0	28	
			2	3	2	1	2	1	1	3	2	0	3	3	0	2	2	0	0	0	2	1	1	0	29	
			3	3	1	1	2	1	1	3	2	0	3	2	0	2	2	0	0	2	1	1	0	1	0	30
			4	2	1	0	1	2	1	2	0	1	2	0	2	1	1	0	0	1	0	0	1	1	0	21
1	29	32	5	1	0	1	0	1	2	0	1	2	2	0	2	1	1	0	0	1	1	0	1	0	15	
			6	1	0	0	1	0	0	1	0	1	2	0	1	0	0	0	0	0	1	0	0	0	9	
			-1	3	1	1	1	0	2	3	2	0	3	3	1	1	2	3	1	0	1	1	0	0	29	
			0	4	1	1	2	1	1	3	2	0	3	2	1	2	1	1	2	0	2	2	0	1	0	32
			1	4	1	1	2	1	1	3	2	0	3	2	1	2	1	1	0	0	2	1	1	0	1	28
			2	3	2	1	2	1	1	3	2	0	3	3	0	2	2	0	0	0	2	1	1	0	1	30

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.1

HAMILTON DEPRESSION RATING SCALE
OPEN PHASE

Centre No.	Patient No.	Initials	Visit No.	Total Score																						
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21		
1	29	AFD	-1	4	1	1	2	1	1	3	2	0	3	3	1	1	2	2	0	2	2	0	1	33		
			0	4	2	1	1	1	3	2	0	4	2	2	2	1	3	1	1	2	0	1	1	0	35	
			1	4	2	1	2	1	1	3	2	0	4	2	2	1	2	1	2	0	1	2	0	1	0	32
			2	3	1	2	1	2	2	3	2	0	3	3	1	2	1	1	0	0	2	1	1	0	0	31
			3	2	1	1	2	0	2	2	2	0	2	2	1	1	1	0	0	1	1	2	0	0	0	23
			4	2	0	0	2	0	0	2	0	1	2	1	1	0	1	1	0	0	0	1	1	0	0	14
1	30	ERV	5	1	0	1	2	0	1	2	0	1	2	1	1	2	1	0	0	1	1	0	0	17		
			6	1	0	0	1	1	0	0	1	2	1	1	0	0	1	0	0	0	1	1	0	0	10	
			-1	4	1	1	2	1	1	3	1	0	3	3	2	1	2	1	1	0	2	2	1	1	35	
			0	3	2	1	1	2	1	2	3	0	2	3	2	1	2	1	0	0	1	1	0	0	30	
			1	3	2	1	1	2	2	1	2	0	4	3	2	1	2	0	1	1	1	1	1	0	0	30
			2	3	2	1	2	2	1	2	2	1	0	4	3	2	1	0	0	0	1	1	0	0	0	25
1	31	MAN	3	2	1	0	2	2	1	0	2	2	0	2	2	1	0	0	1	1	1	1	1	0	22	
			4	2	1	0	2	2	1	3	0	1	1	1	0	0	1	0	0	1	1	1	0	0	17	
			5	2	1	0	2	2	1	3	0	1	1	1	0	0	1	1	0	0	1	1	0	0	16	
			6	1	0	0	1	2	1	2	1	0	1	2	2	0	0	0	0	0	1	1	0	1	0	11
			-1	3	2	1	1	2	2	2	2	0	3	3	2	1	1	1	1	1	1	1	1	0	0	30
			1	3	2	2	1	2	1	2	2	0	3	2	1	2	2	1	0	0	2	1	0	1	0	30
1	32	DGM	2	2	0	0	2	2	1	3	2	0	4	3	1	2	1	0	0	2	0	1	1	0	20	
			3	2	1	0	2	1	2	1	2	0	2	1	0	1	1	0	0	2	0	1	0	1	20	
			4	1	0	0	1	1	2	1	0	2	3	3	1	2	1	1	0	0	1	0	1	0	0	12
			5	1	0	0	1	0	0	1	1	0	1	1	0	0	1	0	0	0	0	0	0	0	0	6
			6	1	0	0	1	0	0	1	0	0	1	2	0	0	0	0	0	0	0	0	0	0	0	8
			-1	4	1	1	2	1	1	4	3	0	4	3	2	2	2	3	2	0	2	3	1	0	0	41
1	33	DGM	0	4	2	2	2	2	4	3	0	4	2	2	2	2	1	0	1	2	2	1	0	0	40	
			1	4	2	1	2	2	3	3	0	3	2	2	2	2	1	0	1	1	1	1	1	0	35	
			2	2	1	0	1	1	1	2	1	0	2	0	1	1	0	0	1	0	1	1	0	0	18	
			3	2	1	1	1	1	1	2	1	0	2	2	1	1	0	0	1	1	0	0	1	0	0	20
			4	1	0	0	1	0	0	1	0	2	2	1	0	1	1	0	0	0	0	0	1	0	0	12
			5	1	0	0	1	0	0	2	1	0	2	2	2	1	0	0	0	0	0	1	1	0	0	13
1	33	DGM	6	1	0	0	1	0	0	1	0	1	2	0	0	0	0	0	0	0	0	1	0	0	8	
			-1	3	1	1	2	1	1	4	3	0	4	3	2	2	2	3	2	0	2	3	1	0	41	
			0	4	2	2	2	2	4	3	0	4	2	2	2	2	1	0	1	2	2	1	0	0	40	
			1	4	2	1	2	2	3	3	0	3	2	2	2	2	1	0	1	1	1	1	1	1	0	35
			2	2	1	0	1	1	1	2	1	0	2	0	1	1	0	0	1	0	1	1	0	0	0	18
			3	2	1	1	1	1	1	2	1	0	2	2	1	1	0	0	1	0	0	1	0	0	0	20
1	33	DGM	4	1	0	0	1	0	0	1	0	2	2	1	0	1	1	0	0	0	0	1	0	0	12	
			5	1	0	0	1	0	0	2	1	0	2	2	2	1	0	0	0	0	1	1	0	0	13	
			6	1	0	0	1	0	0	1	0	1	1	1	0	0	1	1	0	0	0	1	1	0	0	8
			-1	3	1	1	2	1	1	4	3	0	4	3	2	2	2	3	2	0	2	3	1	0	0	41
			0	3	2	1	1	1	2	2	0	2	0	2	3	1	2	1	0	1	1	1	1	1	2	30
			1	3	2	1	1	1	1	3	2	0	3	3	1	2	1	0	1	0	1	1	1	1	2	31
1	34	GHH	2	3	0	2	1	1	1	3	2	0	3	3	1	2	1	0	1	1	2	1	1	2	29	
			3	3	1	1	1	1	2	0	2	2	0	3	3	1	2	1	0	1	1	1	1	2	29	
			4	2	0	0	1	1	1	2	0	2	2	2	1	1	1	0	0	0	0	1	1	1	2	25
			5	1	0	0	1	1	1	2	1	0	2	2	1	0	1	0	0	0	0	1	0	0	0	15
			6	1	0	0	1	0	0	1	1	0	1	1	0	0	2	0	0	0	0	0	1	0	1	11
			-1	4	2	1	2	1	1	3	2	0	4	3	2	2	1	1	1	0	1	1	1	0	0	9
1	34	GHH	0	4	1	2	1	2	1	3	2	0	3	3	2	2	1	1	0	1	2	0	0	0	33	
			1	4	1	2	2	1	2	3	2	0	3	3	2	2	0	0	1	2	2	0	1	2	34	
			2	4	1	2	2	1	2	3	2	1	0	2	2	1	1	0	0	1	2	1	2	1	0	30
			3	4	1	2	2	1	2	3	2	1	0	2	2	1	1	0	0	1	2	1	2	1	0	30
			4	1	1	2	2	1	2	3	2	0	3	3	2	2	0	0	1	2	2	1	2	1	0	30
			5	4	1	2	2	1	2	3	2	1	0	2	2	1	1	0	0	1	2	2	1	2	1	0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit																					Total Score		
			It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21			
1	34	GMH	2	3	1	1	2	1	2	3	1	0	2	2	1	2	1	1	0	0	2	1	1	0	27	
			3	2	1	1	2	1	2	3	2	0	3	2	2	1	1	2	0	1	1	0	0	0	28	
			4	2	1	1	2	1	1	2	0	1	2	2	2	1	1	1	0	0	1	1	0	0	23	
			5	1	0	0	1	2	0	1	1	2	0	1	2	0	0	1	0	1	0	1	0	0	0	14
			6	0	0	1	1	1	1	1	0	1	1	0	1	0	0	0	0	0	0	0	1	0	0	9
1	35	EHP	-1	4	2	1	2	1	2	3	2	0	3	4	2	2	1	1	2	0	2	1	1	1	37	
			0	4	2	2	1	1	4	2	0	4	2	1	2	2	0	0	0	2	2	1	1	1	35	
			1	2	1	0	1	1	1	2	0	2	2	1	1	1	1	0	0	1	2	0	0	0	21	
			2	2	1	0	2	1	0	2	2	2	0	2	1	1	1	0	0	1	1	1	1	0	1	21
			3	1	0	0	1	1	1	1	0	1	0	1	0	1	0	0	1	0	0	1	1	0	1	14
			4	1	0	0	1	1	0	1	0	1	1	0	1	1	1	0	0	0	0	0	0	0	0	10
1	36	LM	5	0	1	0	1	0	1	0	1	1	2	1	0	1	1	0	0	0	0	0	0	1	8	
			6	0	0	1	0	0	1	0	0	1	0	0	1	0	0	0	0	0	0	1	0	0	5	
			-1	3	2	1	2	1	2	4	2	0	3	2	2	2	1	1	1	1	1	2	0	0	0	36
			0	4	1	2	1	2	1	4	2	0	4	2	2	2	1	0	0	1	1	2	0	1	1	34
			1	3	1	1	2	1	2	5	1	0	5	2	2	1	1	2	0	1	1	1	1	0	0	30
			2	2	1	0	2	1	2	2	0	2	5	2	1	1	1	2	1	1	0	1	1	0	0	26
1	37	RF	3	2	1	1	2	1	2	2	0	2	2	2	2	1	0	2	0	1	1	0	0	0	17	
			4	1	0	0	1	1	1	2	0	1	2	2	1	1	0	0	0	0	1	0	0	1	14	
			5	1	0	1	1	1	1	1	1	1	0	2	1	1	1	0	0	0	0	1	0	0	17	
			6	1	0	0	1	1	0	1	1	0	2	2	0	1	1	0	0	0	0	1	0	1	13	
			-1	4	2	2	1	2	1	2	3	0	3	4	1	1	1	2	0	0	2	2	0	0	0	35
			0	4	2	2	1	2	1	2	3	0	2	3	3	0	1	1	2	0	2	2	0	0	0	34
1	38	DBF	1	3	1	1	2	2	2	3	0	2	3	0	2	1	1	1	0	0	2	1	1	0	27	
			2	3	1	1	2	2	0	2	0	1	2	2	0	2	1	1	0	0	1	1	0	0	22	
			3	0	0	1	1	1	1	0	1	0	1	2	0	0	1	2	0	0	0	1	0	0	13	
			4	0	0	1	1	0	1	1	0	1	2	1	0	0	1	1	0	0	0	0	0	0	0	8
			5	1	0	0	1	1	0	1	0	1	0	1	1	1	1	1	1	0	0	1	1	0	0	13
			6	0	0	1	1	0	1	0	1	0	1	2	1	0	0	1	1	0	0	1	1	0	0	9
1	39	ASS	-1	4	2	2	2	1	2	4	0	4	3	3	1	2	1	3	0	0	1	2	0	0	37	
			0	4	2	2	1	2	1	2	4	0	3	4	1	2	1	3	0	0	1	2	0	0	38	
			1	3	2	1	2	1	1	3	0	4	3	3	1	2	1	3	0	0	1	1	0	0	32	
			2	3	1	1	2	1	0	2	0	1	2	2	0	1	1	2	0	0	1	1	0	0	21	
			3	2	1	0	1	1	0	2	0	1	1	2	0	1	0	1	0	0	0	1	1	0	0	14
			4	2	1	0	1	1	0	1	0	1	1	1	0	1	1	1	0	0	1	1	0	0	0	15
1	34	ASS	5	1	1	0	1	1	0	1	0	0	2	1	0	0	1	1	0	0	0	0	0	0	10	
			6	1	0	0	1	0	0	1	0	0	1	1	0	0	1	1	0	0	0	1	0	0	8	
			-1	3	2	2	1	2	1	3	3	0	3	3	1	2	2	1	0	1	1	1	1	1	1	34
			0	3	2	1	2	1	1	3	3	0	3	3	1	2	2	0	1	1	1	1	0	0	1	33
			1	3	1	1	2	1	1	3	0	3	3	1	2	1	1	0	1	0	1	2	1	0	0	30
			2	3	1	1	1	1	1	3	0	2	3	1	2	1	1	0	1	0	1	2	1	0	0	27

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit																					Total Score			
			It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21				
1	39	ASS	5	1	1	1	1	1	0	0	1	1	0	1	1	1	1	0	0	0	1	0	0	13			
			6	1	0	0	1	1	0	1	1	1	1	1	1	1	1	1	0	0	0	1	0	0	11		
1	40	EH	-1	3	2	1	2	1	2	3	2	0	3	4	1	2	1	2	1	1	0	1	0	32			
			0	4	2	1	2	1	3	3	0	3	4	1	2	1	2	0	1	1	1	1	0	0	34		
			1	4	2	1	2	1	3	2	0	2	4	1	2	1	2	1	2	0	1	1	2	0	0	33	
			2	2	1	1	2	1	1	2	0	2	3	2	0	2	1	1	0	0	1	1	2	0	0	24	
			3	2	1	0	1	1	1	1	0	2	2	0	1	1	1	1	0	0	1	1	1	0	0	16	
			4	2	1	0	1	1	0	1	1	0	1	3	2	2	1	1	2	0	0	1	1	0	0	18	
1	41	SFS	5	0	0	0	1	1	0	1	0	0	2	1	0	0	0	0	0	0	0	0	0	6			
			6	1	0	0	1	1	0	1	0	1	2	1	0	0	0	0	0	0	0	0	0	0	9		
			-1	4	2	1	2	1	1	3	0	3	4	2	1	2	2	1	1	0	2	1	0	1	34		
			0	3	2	1	2	1	3	2	0	4	3	1	1	1	1	2	0	1	1	1	1	0	2	33	
			1	3	2	1	2	1	3	2	0	2	2	1	1	1	1	2	0	0	1	1	1	0	2	23	
			2	2	1	0	2	1	0	2	1	0	2	2	0	2	2	1	0	0	0	0	0	0	0	1	15
1	42	ICC	3	2	1	0	1	1	0	2	0	0	2	2	1	0	0	1	0	0	1	0	0	0	16		
			4	1	0	0	1	1	1	1	0	1	2	1	0	1	0	1	0	0	0	0	1	0	12		
			5	1	0	0	1	1	1	1	0	1	2	1	0	1	0	1	0	0	0	0	0	0	1	11	
			6	0	0	0	1	0	1	1	0	0	1	2	0	0	2	0	0	0	0	0	0	0	0	8	
			-1	4	2	2	1	1	1	4	2	0	3	3	1	2	1	0	2	1	2	1	0	1	0	1	35
			0	4	2	1	1	1	1	4	2	0	3	4	1	2	1	0	0	1	2	1	0	1	0	1	34
1	43	ARN	1	4	2	1	1	1	1	4	2	0	3	4	1	2	1	0	0	1	1	1	0	1	30		
			2	3	2	1	1	1	1	4	2	0	2	4	1	2	1	0	0	1	1	1	0	0	28		
			3	3	1	0	2	1	0	3	0	2	3	2	0	2	1	0	0	0	1	2	0	0	1	24	
			4	1	0	0	1	1	0	1	1	0	2	1	0	2	1	0	0	0	1	1	0	0	0	13	
			5	1	0	0	1	1	0	1	1	0	2	2	0	1	1	0	0	0	0	0	0	0	0	1	12
			6	0	0	1	1	0	1	0	1	0	0	2	1	0	0	1	0	0	0	0	0	0	0	1	8
1	44	MAL	-1	3	1	1	2	2	1	2	3	2	0	4	3	0	2	2	0	0	2	1	1	1	34		
			0	3	1	1	2	1	2	3	2	0	4	3	0	2	2	2	0	0	2	1	1	1	1	33	
			1	3	1	1	2	1	1	3	2	0	3	3	0	2	2	1	0	0	1	1	1	1	1	29	
			2	3	1	1	2	1	1	2	0	1	2	3	0	2	2	1	1	0	0	1	1	0	1	24	
			3	2	0	0	2	2	0	2	3	0	2	3	3	0	2	2	1	0	0	1	0	0	1	28	
			4	2	0	0	2	0	0	2	2	1	0	2	2	0	2	1	2	0	1	1	1	0	0	19	
1	44	MAL	5	1	0	0	2	0	0	1	0	0	2	2	0	2	1	1	0	0	0	0	0	0	15		
			6	1	0	0	1	1	0	1	1	0	1	1	0	0	1	1	0	0	0	0	0	0	8		
			-1	4	2	2	1	1	2	4	3	0	3	4	0	2	2	3	0	0	2	3	0	0	0	39	
			0	4	2	2	1	1	4	3	3	0	3	4	0	2	2	3	0	0	2	3	0	0	0	36	
			1	4	2	2	1	1	4	3	3	0	4	4	0	2	2	1	0	0	2	1	0	0	0	0	35
			2	2	1	1	2	1	1	3	2	0	3	3	0	2	2	2	0	1	2	2	0	0	0	0	32
1	44	MAL	3	2	1	1	2	0	1	3	2	0	2	2	0	2	2	2	0	1	2	2	0	0	0	28	
			4	2	1	0	1	1	1	3	2	0	2	2	0	2	1	0	0	2	1	0	0	0	0	24	
			5	2	0	1	1	1	1	3	2	0	2	2	0	2	1	2	1	0	2	1	0	0	0	20	
			6	3	2	2	1	1	4	3	0	3	4	0	2	2	1	0	0	0	2	1	0	0	0	0	20
			-1	4	2	2	1	1	2	4	3	0	3	4	0	2	2	3	0	0	2	3	0	0	0	0	38
			0	4	2	2	1	1	4	3	3	0	3	4	0	2	2	3	0	0	2	3	0	0	0	0	36

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Patient Centre	No.	Initials	Visit No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score			
1	45	DPS	-1	3	2	1	2	2	1	4	0	3	3	3	3	1	2	2	2	1	0	1	2	0	0	35		
			0	3	2	1	2	1	4	0	2	3	3	3	3	3	1	2	2	2	0	0	1	2	0	0	33	
			1	2	0	1	1	1	0	1	0	1	3	2	0	1	3	2	2	1	2	0	0	1	1	0	0	18
			2	3	1	1	2	1	1	3	2	0	3	3	0	3	0	2	2	1	0	0	0	0	0	0	0	25
			3	0	0	1	1	1	1	1	0	2	2	1	0	0	1	0	0	0	0	0	0	0	0	0	0	11
			4	0	0	0	0	1	0	1	0	1	0	1	2	1	0	0	0	0	2	0	0	0	1	0	0	9
1	46	SP	6	0	0	0	0	0	0	1	0	1	1	1	1	0	2	0	2	0	0	0	0	0	0	8		
			-1	4	1	2	2	1	1	4	2	0	3	2	2	2	2	1	2	1	2	1	0	2	1	0	0	33
			0	4	1	2	2	1	1	4	2	0	3	2	2	2	2	2	1	2	0	0	0	2	1	0	0	33
			1	4	1	2	2	1	2	4	2	0	3	2	2	2	2	2	2	2	0	0	0	1	2	0	0	34
			2	4	1	2	2	1	2	3	2	0	2	2	2	2	2	2	2	2	0	0	0	1	1	0	0	34
			3	2	0	1	1	1	2	3	2	0	2	2	2	2	2	2	2	2	0	0	0	1	1	0	0	23
1	47	MCS	4	1	0	0	1	1	2	0	2	2	2	2	2	2	1	0	0	0	0	1	2	0	0	0	17	
			5	1	0	0	1	1	1	2	0	1	2	2	2	2	2	0	0	0	0	0	1	2	0	0	14	
			6	1	0	0	1	1	1	1	0	1	2	2	2	2	2	0	0	0	0	0	1	0	0	0	0	14
			-1	3	2	1	2	2	1	3	2	0	4	3	1	2	1	2	1	2	0	0	1	2	1	1	0	34
			0	4	1	2	2	1	2	3	2	0	2	3	4	1	2	2	2	2	0	0	0	2	1	0	0	34
			1	4	1	2	1	1	1	3	0	1	2	3	1	2	3	1	2	2	2	0	0	1	1	0	0	28
1	48	SCM	2	2	1	1	1	1	1	2	0	1	1	2	1	2	1	2	1	2	0	0	0	0	0	0	19	
			3	1	1	1	1	1	1	1	0	0	2	1	1	2	0	2	1	1	2	0	0	0	0	0	14	
			4	1	0	0	1	1	1	1	0	0	1	2	0	2	1	2	2	1	1	2	0	0	0	0	0	10
			5	1	0	0	1	1	1	1	1	0	0	1	2	0	1	1	1	1	0	0	0	0	0	0	0	6
			6	0	0	0	0	1	1	0	0	1	1	0	1	1	0	1	1	0	0	0	0	0	0	0	0	6
			-1	3	2	1	1	1	1	2	3	0	3	4	0	2	2	2	3	0	1	1	1	0	0	0	1	34
1	49	DAS	0	3	2	1	1	1	2	3	0	1	3	4	0	2	2	2	3	0	1	2	0	0	1	1	32	
			1	3	1	1	1	1	2	3	0	1	2	3	0	2	2	2	2	2	0	1	1	0	0	1	27	
			2	2	0	0	2	2	2	2	0	1	2	3	0	2	2	2	2	2	0	0	1	2	0	0	0	25
			3	1	0	0	2	2	2	2	0	1	2	3	0	2	2	2	2	2	0	0	1	2	0	0	0	22
			4	1	0	0	2	2	2	2	1	0	1	2	1	0	1	2	2	2	0	0	0	1	1	0	0	18
			5	1	0	0	1	1	1	1	0	0	1	2	1	0	0	2	2	2	0	0	0	1	0	0	0	13
1	50	MFA	6	1	0	0	1	1	0	0	1	1	1	1	0	1	0	2	2	0	0	0	0	1	0	0	11	
			-1	3	2	1	2	0	2	3	0	3	4	3	1	2	2	2	2	2	0	1	1	1	1	1	1	36
			0	3	2	2	2	0	2	3	0	3	4	3	1	2	2	2	2	2	0	0	1	1	1	1	1	35
			1	2	2	2	2	0	2	3	0	2	3	3	1	2	2	2	2	2	0	0	2	1	1	1	0	32
			2	3	2	1	2	0	2	4	0	4	3	4	2	2	2	2	2	2	0	0	0	2	1	1	0	37
			-1	4	1	2	1	2	1	2	3	0	4	2	2	2	1	1	1	1	1	1	1	0	1	0	1	33
1	50	MFA	0	4	2	1	2	2	1	2	3	0	3	3	2	2	2	1	1	0	1	1	0	1	1	1	33	
			1	3	2	1	2	2	1	2	3	0	3	2	2	2	2	2	2	1	0	0	1	0	1	1	1	32
			2	3	2	1	2	2	1	2	2	1	2	2	2	2	2	2	2	2	0	0	1	0	1	1	1	30
			3	2	1	1	2	1	1	2	2	0	2	2	2	2	2	2	2	2	1	0	0	1	0	1	1	25
			4	2	0	0	1	1	1	1	1	1	1	0	2	2	2	2	2	2	1	0	0	1	0	1	1	19
			5	1	0	0	1	1	1	1	1	1	1	0	2	2	0	2	1	1	1	0	0	1	0	1	1	17

836

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score	
1	50	MFA	6	0	0	1	1	0	1	0	0	2	1	0	1	0	1	0	1	0	0	0	1	1	10	
1	51	ASA	-1	3	1	2	1	2	1	3	0	2	4	1	2	1	1	1	1	2	2	0	1	0	34	
			0	3	1	2	1	2	1	3	0	3	3	4	1	2	2	1	0	1	1	2	0	1	0	33
			1	3	1	1	2	1	2	1	3	0	3	4	1	2	2	1	0	1	1	1	0	1	0	30
			2	3	2	1	2	0	2	2	2	2	2	2	1	2	2	1	0	0	1	1	0	0	0	27
			3	2	1	1	2	0	2	1	0	2	1	0	2	1	1	0	0	1	1	1	0	0	0	18
			4	1	0	0	1	1	1	1	0	2	2	2	2	2	2	0	0	0	0	1	0	0	0	14
			5	1	0	0	1	0	1	1	0	2	1	1	0	2	1	1	0	0	0	0	0	0	0	10
			6	1	0	0	1	0	1	1	0	1	2	0	2	1	0	0	0	0	0	0	0	0	0	10
1	52	HTS	-1	4	2	2	2	2	1	3	3	0	4	3	2	2	1	1	0	0	2	2	0	0	0	37
			0	4	2	2	2	1	3	3	0	3	3	2	2	1	0	0	2	3	0	2	0	0	0	37
			1	3	1	2	2	1	2	3	2	0	3	3	2	2	1	1	0	0	2	1	0	0	0	32
			2	3	1	1	2	1	1	3	2	0	2	2	2	1	1	0	0	2	2	2	0	0	0	28
			3	2	1	1	1	2	1	2	1	0	2	2	1	1	0	0	0	1	1	1	0	0	0	22
			4	2	1	0	1	2	1	2	1	0	2	1	1	1	1	0	0	0	1	1	0	0	0	15
			5	1	0	0	1	1	1	1	0	2	1	1	1	1	1	0	0	0	0	1	0	0	0	12
			6	1	0	0	2	1	1	1	0	2	1	0	0	0	0	1	0	0	0	1	0	0	0	12
1	53	JFT	-1	4	2	2	2	2	1	4	0	3	3	4	1	2	2	2	0	1	2	0	0	0	0	37
			0	4	1	2	2	2	1	4	0	3	3	3	1	2	2	1	0	1	1	0	0	0	0	34
			1	4	1	2	2	1	1	4	0	3	2	3	1	2	2	1	0	0	1	1	0	0	0	31
			2	3	2	1	1	1	1	3	2	0	2	2	2	2	2	1	0	0	2	1	0	0	0	26
			3	2	1	1	1	1	1	3	1	0	2	2	2	2	1	1	0	0	1	1	0	0	0	22
			4	1	1	0	1	1	1	2	1	0	2	2	2	1	1	1	2	0	0	1	0	0	0	18
			5	0	0	0	1	1	1	1	0	2	1	0	0	1	1	0	0	0	0	2	0	0	0	11
			6	0	0	0	1	1	1	1	0	2	1	0	0	0	0	1	0	0	0	2	0	0	0	10
1	54	JD	-1	3	2	1	2	1	2	3	2	0	3	2	1	2	1	2	2	1	2	1	2	1	0	33
			0	3	2	1	2	2	1	3	2	0	3	3	1	2	1	2	1	0	1	2	1	1	0	33
			1	4	2	1	2	1	2	3	2	0	3	2	1	2	1	2	0	0	2	1	1	0	0	32
			2	3	1	2	2	2	1	3	1	0	3	3	1	2	2	2	0	0	2	2	1	1	0	32
			3	4	2	2	2	1	1	3	2	0	3	3	1	2	2	1	0	0	2	2	1	0	0	34
			4	3	2	2	2	1	2	3	2	0	3	3	1	2	2	1	0	1	2	1	1	1	0	34
1	55	DMG	-1	4	1	2	2	1	2	4	3	0	3	2	0	2	2	1	1	2	0	2	0	1	0	34
			0	4	1	2	2	1	2	4	3	0	3	2	0	2	1	1	0	0	1	1	1	0	0	31
			1	4	1	2	2	1	2	4	1	0	2	3	1	2	2	1	0	0	1	1	0	0	0	30
			2	3	1	1	2	1	2	3	1	0	2	2	1	2	2	1	0	0	1	1	0	0	0	26
			3	2	1	1	2	1	1	3	0	2	2	2	1	1	0	0	1	0	0	1	0	0	0	20
			4	2	1	1	0	1	0	2	0	2	2	2	0	2	2	1	0	0	0	0	0	0	0	16
			5	1	1	1	0	1	1	1	0	2	2	2	0	2	2	1	0	0	0	0	0	0	0	15
			6	1	0	0	1	0	1	0	0	1	2	0	2	2	1	0	0	0	0	0	0	0	0	11
1	56	IAL	-1	3	2	2	1	1	2	3	2	0	3	3	1	2	2	1	1	0	2	0	1	1	0	33
			0	3	1	2	1	2	1	4	1	0	2	3	1	2	0	1	0	1	2	2	1	1	0	31
			1	3	1	2	2	1	1	4	0	1	2	2	1	2	1	1	0	0	2	2	1	1	0	30

9550077

090177e1803f2135\Approved\Approved On: 11-11-2012 09:17

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.1

HAMILTON DEPRESSION RATING SCALE
OPEN PHASE

Patient No.	Initials	Visit No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score		
56	IAL	2	1	1	1	1	1	3	1	0	2	2	1	1	1	1	0	0	0	1	1	1	1	1	24	
		3	1	0	1	0	1	2	1	0	2	1	0	2	1	1	1	0	0	1	1	1	1	1	17	
		4	1	0	0	1	0	1	0	0	2	1	0	0	2	1	0	0	0	0	1	1	1	1	13	
		5	0	0	0	1	0	1	1	0	0	2	1	0	0	0	2	1	0	0	0	1	1	1	12	
		6	0	0	0	1	0	1	1	0	0	1	1	0	0	0	2	1	0	0	0	1	1	1	11	
		-1	4	2	1	2	1	2	3	2	0	3	3	1	2	2	2	2	0	0	2	1	1	0	0	33
57	SMC	0	4	2	1	2	2	3	2	0	2	3	1	2	2	2	0	0	0	1	1	0	0	0	32	
		1	3	2	1	2	1	2	3	2	0	3	3	1	2	2	3	0	0	1	1	0	0	0	32	
		2	3	1	2	2	1	1	3	0	2	2	3	1	2	2	2	0	0	1	2	1	2	0	0	30
		3	3	1	2	1	2	1	2	3	0	2	3	1	2	2	2	0	0	0	2	1	0	0	0	28
		-1	4	1	1	2	1	1	3	1	0	3	3	1	2	2	2	2	2	0	1	1	0	0	0	31
		0	4	1	1	2	1	2	3	1	0	3	3	1	2	2	2	0	0	2	2	1	0	0	0	31
58	ARM	1	3	2	2	1	2	3	2	0	3	3	1	2	2	2	0	0	0	2	1	0	0	0	33	
		2	3	2	2	1	2	3	2	0	3	3	1	2	2	2	0	0	0	2	1	0	0	0	33	
		3	3	1	1	2	1	1	2	2	0	2	2	1	2	1	2	0	0	0	0	2	0	0	0	25
		4	2	2	1	2	1	1	2	2	0	2	3	1	2	2	2	0	0	0	0	0	0	0	0	25
		5	1	1	1	0	1	1	2	1	0	1	2	0	2	1	1	0	0	0	1	1	0	0	0	17
		6	1	0	0	1	1	1	0	1	1	0	2	2	0	2	1	1	0	0	1	1	0	0	0	15
59	SPF	-1	3	1	2	1	2	1	3	0	2	2	3	2	2	1	1	0	2	1	1	0	0	0	29	
		0	3	1	2	2	1	3	0	2	2	3	2	2	1	1	0	1	1	1	0	0	0	0	29	
		1	3	1	2	1	2	1	3	0	1	2	3	2	2	2	1	0	0	1	2	0	0	0	28	
		2	3	1	1	2	1	1	3	1	0	2	3	1	2	1	2	1	0	0	1	1	0	0	0	26
		3	3	1	0	2	1	1	3	1	0	2	2	1	2	1	1	0	0	1	1	1	0	0	0	23
		4	2	0	0	2	1	0	2	0	1	2	2	0	0	0	0	0	0	0	0	1	0	0	0	15
60	EM	5	1	0	0	1	0	1	0	1	1	1	1	0	0	0	1	0	0	2	1	1	1	0	11	
		6	0	0	0	1	1	1	1	0	1	2	1	2	1	1	0	0	0	0	2	1	0	0	10	
		-1	4	2	2	1	2	1	2	4	0	4	3	3	1	2	2	2	0	2	1	1	0	0	2	40
		0	4	2	2	1	2	4	0	3	3	3	3	1	2	2	3	0	0	1	2	0	0	2	2	39
		1	4	2	1	2	1	2	4	0	3	3	2	1	2	2	2	0	0	0	1	2	0	0	2	36
		2	4	2	1	2	0	2	4	0	3	3	3	1	2	2	2	0	0	1	2	0	0	2	2	36
61	HVC	3	4	2	1	2	1	1	4	0	3	2	3	1	2	2	2	0	0	2	2	0	0	1	35	
		4	2	1	0	1	1	2	0	2	2	2	1	0	2	1	0	0	0	1	0	0	0	2	18	
		5	2	1	0	0	1	1	2	0	2	2	1	1	1	1	1	0	0	1	0	0	0	2	18	
		6	1	1	0	1	1	1	1	2	0	2	1	1	1	1	1	0	0	0	1	0	0	0	2	18
		-1	3	1	2	2	1	2	3	0	2	3	2	0	2	2	2	0	0	2	2	0	0	1	1	17
		0	3	1	1	2	2	3	0	2	3	3	0	2	2	2	0	0	0	0	2	2	0	0	1	32
61	HVC	1	3	1	1	2	2	1	3	0	2	3	3	0	2	2	2	0	0	2	2	0	0	1	33	
		2	3	1	1	2	2	1	3	0	2	3	3	0	2	2	0	0	0	2	1	0	0	1	31	
		3	2	1	0	1	1	2	3	0	2	3	3	0	2	2	1	0	0	2	2	0	0	1	31	
		4	1	0	0	1	1	1	3	0	2	2	2	0	2	1	0	0	0	2	1	0	0	1	24	
		5	1	0	0	1	1	1	2	0	0	1	1	2	2	1	1	0	0	1	1	0	0	0	17	
		6	1	0	0	2	1	1	0	2	0	1	1	1	0	2	1	1	0	2	0	0	0	0	0	14

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXYLINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Patient No.	Centre	Initials	Visit No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score				
67	1	WAA	5	1	0	0	1	1	1	1	2	0	0	2	2	0	2	1	0	0	0	0	0	0	0	13			
			6	1	0	0	1	1	1	2	0	2	1	0	2	1	0	2	1	0	0	0	0	0	0	0	12		
			-1	3	1	2	1	2	1	3	0	2	3	3	3	2	2	2	3	1	1	0	1	0	0	0	0	33	
			1	3	1	2	2	1	2	2	3	0	2	2	2	2	2	2	2	2	0	1	0	1	0	0	0	32	
			2	3	1	1	2	2	2	3	0	2	2	2	2	2	2	2	2	2	0	1	1	0	0	0	0	30	
			3	3	1	1	2	2	2	3	0	2	3	2	1	2	1	2	2	2	0	1	1	0	0	0	0	29	
68	1	MGS	4	3	1	1	2	2	1	2	3	0	2	3	2	1	2	2	1	2	1	1	0	0	0	0	31		
			5	3	1	1	2	1	2	3	0	2	3	2	1	2	2	1	2	1	2	1	1	0	0	0	0	30	
			6	3	1	1	2	1	2	3	0	2	3	2	1	2	2	1	2	2	1	2	1	1	0	0	0	31	
			7	3	1	1	2	1	2	3	0	2	3	2	1	2	2	1	2	2	1	2	1	1	0	0	0	30	
			8	3	1	1	2	1	2	3	0	2	3	2	1	2	2	1	2	2	1	2	1	1	0	0	0	31	
			9	3	1	1	2	1	2	3	0	2	3	2	1	2	2	0	2	2	0	1	1	0	0	0	0	31	
69	1	RFA	-1	4	1	2	2	2	4	0	4	3	1	2	2	1	2	1	0	2	1	1	0	0	0	0	34		
			0	4	1	2	2	1	2	4	0	4	3	1	2	2	1	2	1	0	0	1	1	0	0	0	31		
			1	4	1	1	2	1	2	4	0	4	3	1	2	2	1	2	1	0	0	1	1	0	0	0	0	30	
			2	4	1	1	2	1	2	4	0	3	4	2	1	2	1	2	2	0	0	1	1	0	0	1	0	31	
			3	4	1	1	2	1	2	4	0	3	3	2	1	2	1	2	2	0	0	1	1	0	0	0	0	28	
			4	2	0	0	2	1	0	3	0	2	3	4	1	0	1	0	1	0	0	1	1	0	0	1	0	24	
70	1	MLM	5	2	0	1	2	1	0	3	0	2	3	4	1	2	2	0	0	0	1	0	0	1	0	0	24		
			6	3	0	1	2	1	0	3	0	2	3	4	1	2	2	1	2	2	0	1	0	0	0	0	0	23	
			-1	4	2	1	2	1	1	3	0	1	4	3	1	2	1	2	1	3	0	1	1	2	0	0	0	33	
			0	4	2	3	2	1	2	4	2	0	3	2	2	2	2	1	2	1	3	0	0	2	1	1	0	37	
			1	4	2	2	2	1	2	4	2	0	3	2	2	2	2	1	2	1	2	0	0	2	1	1	0	35	
			2	4	2	1	2	1	1	4	2	0	3	2	2	2	1	2	1	3	0	0	1	1	1	1	0	33	
71	1	OMV	3	3	2	1	2	1	1	4	2	0	3	2	2	2	1	2	0	1	1	1	1	1	0	0	32		
			4	3	2	1	2	2	1	4	2	0	3	3	2	2	1	1	1	1	0	1	1	0	0	0	32		
			5	2	1	1	2	2	1	2	2	1	2	2	1	2	1	1	1	1	1	0	0	0	0	0	0	23	
			6	2	0	0	2	1	1	2	1	2	1	0	2	2	1	1	1	1	0	0	0	0	0	0	0	16	
			-1	3	1	2	2	1	2	1	3	2	0	3	3	1	2	2	1	3	0	1	1	2	0	0	0	32	
			0	3	1	1	2	2	1	3	2	0	3	3	1	2	2	1	2	2	1	2	1	0	2	0	0	32	
72	1	RLJ	1	3	1	0	2	1	1	3	2	0	3	2	1	2	2	2	2	2	0	0	3	0	0	0	32		
			2	4	1	1	2	2	2	3	2	0	3	3	2	2	2	2	2	2	2	0	1	0	0	0	0	30	
			3	3	1	1	2	1	1	2	2	0	2	3	2	2	2	2	2	2	2	0	0	0	0	0	0	0	26
			4	2	1	1	2	1	1	2	1	1	2	1	2	1	2	1	1	2	1	1	0	0	0	0	0	0	20
			5	2	1	0	2	1	0	2	1	0	2	1	0	3	1	0	2	1	0	0	0	0	0	0	0	0	17
			6	1	1	0	1	1	0	1	1	0	2	1	0	2	1	0	2	1	0	0	0	0	0	0	0	0	12

840

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Patient Centre No.	Initials	Visit No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score	
1	73	FMA	-1	3	1	1	2	2	1	3	0	0	2	1	1	2	2	3	2	1	2	0	1	0	30
			0	3	1	1	2	1	2	3	0	0	2	2	2	2	2	2	0	1	2	0	1	0	28
			1	3	1	1	2	1	3	0	0	3	3	1	2	2	2	2	0	1	2	1	1	0	31
			2	3	0	1	2	2	1	3	0	3	3	1	2	2	2	2	0	0	2	1	1	0	29
			3	2	0	0	2	1	2	0	0	3	3	0	2	1	1	1	2	0	2	0	0	0	24
			4	2	0	0	2	2	0	2	0	2	2	0	2	1	1	1	0	0	1	0	1	0	18
			5	2	0	0	2	2	0	2	1	0	2	1	1	1	1	0	0	1	0	0	1	0	16
			6	1	0	0	2	2	0	1	0	2	1	0	2	1	0	0	0	0	0	0	1	0	13
1	74	IVL	-1	4	2	1	2	1	2	3	0	0	3	3	2	2	2	3	0	1	1	0	0	0	32
			0	3	1	1	2	1	2	4	0	1	3	3	2	2	2	2	0	1	1	0	0	0	31
			1	4	1	1	2	1	2	4	0	1	3	3	2	2	2	3	0	1	1	0	0	0	33
			2	4	1	1	2	0	2	4	0	1	3	3	2	2	1	2	1	1	1	0	1	0	33
			3	3	1	0	2	0	2	3	0	0	3	3	2	2	1	1	2	1	1	0	1	0	27
			4	2	1	0	2	0	1	2	0	0	2	1	0	2	1	0	0	1	1	0	0	0	16
			5	1	2	1	0	0	1	2	0	0	1	1	0	2	1	0	0	1	1	0	0	0	12
			6	1	2	0	0	0	1	1	0	0	2	1	0	2	1	0	1	0	0	0	0	0	12
1	75	ELF	-1	4	2	2	2	2	0	3	0	3	4	3	2	1	2	1	2	1	1	0	1	0	35
			0	4	2	2	2	0	3	0	4	4	4	2	1	2	1	2	1	1	1	0	1	0	35
			1	4	2	1	2	0	4	0	3	4	2	1	2	1	2	0	1	1	1	0	0	0	32
			2	4	2	1	2	0	4	0	3	4	2	1	2	1	2	0	1	1	1	0	0	0	30
			3	3	2	1	2	1	0	3	0	2	4	2	0	2	1	1	0	1	1	0	0	0	26
			4	2	1	1	2	0	0	3	0	2	2	2	0	2	1	1	0	1	1	0	0	0	21
			5	2	1	1	2	0	0	2	0	2	1	1	0	1	1	1	0	1	1	0	0	0	17
			6	2	1	0	0	0	2	1	0	2	1	1	0	1	1	1	0	1	1	0	0	0	16
1	76	SFA	-1	4	2	1	2	2	1	3	0	3	3	4	1	2	2	2	2	1	0	1	0	0	36
			0	4	2	1	2	1	2	1	3	0	3	4	1	2	2	2	0	1	0	1	0	0	33
			1	3	2	1	1	2	1	3	0	3	3	3	1	2	2	2	0	0	0	0	0	0	29
			2	2	2	1	1	2	1	3	0	2	2	3	1	2	2	1	0	0	0	0	0	0	25
			3	2	1	1	1	1	1	3	0	2	2	2	1	2	1	1	0	0	0	0	0	0	21
			4	1	0	0	2	1	0	2	0	1	2	2	1	0	1	1	0	0	1	0	0	0	15
			5	1	0	0	1	1	0	1	0	1	1	1	0	0	1	1	0	0	1	0	0	0	10
			6	0	0	0	1	0	0	0	0	1	1	1	0	0	1	0	0	0	0	0	0	0	4
1	77	ACG	-1	4	2	1	2	1	2	4	2	0	4	3	2	1	2	2	1	1	1	0	0	0	35
			0	4	2	1	2	0	2	4	2	0	4	3	2	1	2	2	0	1	1	0	0	0	34
			1	4	1	1	2	0	2	4	2	0	4	2	1	2	1	1	1	1	0	0	0	0	31
			2	4	1	1	2	1	2	4	2	0	4	2	1	2	1	1	2	1	0	0	0	0	31
			3	3	1	1	1	1	1	2	4	2	0	3	2	1	0	1	0	0	1	0	0	0	25
			4	2	1	1	2	0	1	3	0	0	3	2	0	1	2	1	0	0	0	0	0	0	18
			5	1	1	0	2	0	0	2	1	0	2	2	0	1	2	0	0	0	0	0	0	0	13
			6	1	0	0	1	0	1	1	0	2	1	0	2	0	1	2	0	0	0	0	0	0	12
1	78	SD	-1	4	1	1	2	1	1	3	0	4	3	4	2	1	1	0	1	0	1	0	0	0	32
			0	4	1	1	2	1	1	3	0	3	4	4	2	2	0	2	0	1	0	1	0	0	32
			1	3	2	1	1	1	1	3	0	3	3	1	2	0	2	2	1	0	0	2	0	0	30

841

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.1

HAMILTON DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	HAMILTON DEPRESSION RATING SCALE																	Total Score					
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17		It.18	It.19	It.20	It.21	
1	78	SD	2	4	1	1	2	1	1	3	0	3	3	4	2	0	1	2	0	1	0	1	0	0	32	
			3	4	2	1	1	3	0	2	4	4	2	2	2	2	0	0	0	0	1	0	0	0	34	
			4	3	2	1	2	1	3	0	3	4	4	2	2	2	1	0	0	0	0	0	0	0	0	32
			5	3	2	1	2	2	1	3	0	3	4	3	2	2	2	1	2	0	0	0	0	0	0	33
			6	4	2	1	2	1	2	3	0	3	4	3	2	2	2	1	0	0	0	0	0	0	0	32
			-1	4	2	2	1	1	1	4	0	3	4	4	2	2	1	2	0	1	1	0	0	0	0	35
1	79	JCH	0	4	2	2	1	1	2	4	0	3	4	3	2	2	1	2	0	1	1	0	0	0	35	
			1	4	2	1	1	1	2	4	0	2	4	4	2	2	1	1	0	1	1	0	0	0	33	
			2	3	1	1	1	1	4	0	2	3	3	1	2	1	1	0	0	0	0	0	0	0	26	
			3	2	0	1	1	1	4	0	1	2	3	1	2	1	1	0	0	0	0	0	0	0	21	
			4	2	0	0	1	1	3	0	1	2	3	1	2	1	1	0	0	0	0	0	0	0	18	
			5	0	0	0	1	1	2	0	0	1	1	2	1	1	1	0	0	0	0	0	0	0	0	9
1	80	MEL	6	0	0	0	1	1	0	2	0	0	1	1	1	1	0	0	0	0	0	0	0	0	10	
			-1	4	1	1	2	0	2	3	2	0	3	3	1	2	1	2	1	1	2	0	1	1	33	
			0	4	1	1	2	0	2	3	1	0	3	4	1	2	1	1	0	1	2	0	1	1	1	31
			1	4	1	1	2	1	1	3	1	0	2	4	1	2	1	1	0	1	2	0	1	1	1	30
			2	3	0	1	1	1	1	3	1	0	3	3	1	2	1	1	0	1	2	0	1	1	1	27
			3	3	0	1	1	1	1	2	1	0	3	2	1	2	1	1	0	1	1	0	1	1	1	24
1	81	MFB	4	2	0	0	1	1	1	1	2	1	0	2	2	1	0	1	1	0	1	0	0	1	19	
			5	2	0	0	1	1	1	2	0	0	2	1	1	0	1	1	0	1	1	0	0	1	16	
			6	1	0	0	1	1	1	1	0	0	1	2	1	0	1	1	0	1	1	0	0	0	1	13
			-1	4	2	2	1	2	2	4	0	3	3	3	1	2	2	3	0	1	2	1	0	0	0	38
			0	4	2	1	2	2	2	4	0	3	3	3	1	2	2	3	0	1	2	1	0	0	0	38
			1	4	1	2	1	2	2	4	0	2	3	3	1	2	2	2	2	1	2	1	0	0	0	37
1	82	MDS	2	3	1	1	1	2	1	4	0	1	2	3	1	2	2	1	0	1	1	0	0	0	27	
			3	2	0	1	1	1	1	4	0	1	2	3	1	2	1	1	0	0	1	0	0	0	22	
			4	2	0	0	1	1	1	4	0	1	3	3	1	2	1	1	0	0	0	0	0	0	0	17
			5	1	0	0	1	1	1	2	0	1	2	1	2	1	1	1	0	0	0	0	0	0	0	12
			6	1	0	0	1	1	1	1	0	0	1	2	1	0	1	1	0	0	0	0	0	0	0	10
			-1	3	2	1	2	1	2	4	2	0	4	3	1	2	1	1	1	1	0	0	0	0	0	32
1	83	LFM	0	3	1	2	1	2	1	4	3	0	4	3	1	2	1	2	0	0	0	1	0	1	32	
			1	3	1	2	2	1	1	4	0	4	4	2	1	2	1	2	0	0	0	2	0	1	33	
			2	2	1	1	2	1	1	4	3	0	3	3	1	2	1	1	2	0	0	0	0	0	1	27
			3	2	1	1	2	1	1	4	2	0	3	3	1	2	1	1	1	0	0	0	0	0	1	23
			4	1	0	1	1	1	1	3	2	0	2	2	1	2	1	1	0	0	0	0	0	0	1	19
			5	1	0	1	1	1	1	3	1	0	2	2	1	2	1	1	0	0	0	0	1	0	1	17
1	84	LFM	6	0	0	0	1	1	1	1	1	0	1	1	0	1	1	0	0	0	0	0	0	0	10	
			-1	3	1	2	2	1	1	4	0	3	3	4	1	2	1	2	1	1	1	1	1	1	36	
			0	3	1	2	2	1	1	4	0	4	4	4	1	2	1	2	2	1	2	1	1	1	1	40
			1	3	1	2	2	1	1	4	0	4	4	4	1	2	1	2	0	1	2	1	1	1	1	36
			2	4	1	1	2	1	2	4	0	4	3	3	1	2	1	2	2	0	1	1	1	1	1	36
			3	4	1	2	2	1	2	4	0	4	3	3	1	2	1	2	2	1	2	1	1	1	1	39
1	85	LFM	4	4	2	2	2	1	2	4	0	3	4	2	2	1	2	0	1	2	1	1	1	1	42	
			5	4	2	2	2	1	2	4	0	3	4	3	2	2	1	2	0	1	2	1	1	1	42	

842

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit																					Total Score	
				It. 1	It. 2	It. 3	It. 4	It. 5	It. 6	It. 7	It. 8	It. 9	It. 10	It. 11	It. 12	It. 13	It. 14	It. 15	It. 16	It. 17	It. 18	It. 19	It. 20	It. 21		
1	83	LFM	5	4	4	2	1	2	1	2	4	0	4	3	3	2	1	1	0	1	2	2	1	1	39	
			6	4	2	2	1	2	4	0	3	4	2	2	1	2	1	2	0	1	2	2	1	2	42	
1	84	IN	-1	4	1	1	2	0	2	4	3	0	3	4	1	2	1	1	0	0	2	1	0	0	32	
			0	4	1	1	2	0	3	3	4	3	1	2	1	2	1	2	0	0	2	0	0	0	31	
			1	4	1	1	2	0	2	3	0	3	3	0	2	2	1	2	1	0	0	2	0	1	0	30
			2	3	1	1	2	0	1	3	2	0	4	3	0	2	2	1	0	0	1	0	0	0	0	26
			3	2	1	0	2	0	0	3	2	0	2	2	1	0	2	2	1	0	0	0	0	0	0	19
			4	0	0	0	2	0	1	1	0	2	1	0	0	2	1	0	0	0	0	0	0	0	0	10
1	85	MLP	5	0	0	0	2	0	0	1	0	0	2	2	0	0	0	0	0	0	0	0	0	0	9	
			6	0	0	0	2	0	0	1	0	0	2	0	0	0	0	0	0	0	0	0	0	0	7	
			-1	4	1	1	1	1	2	3	0	3	4	3	1	2	1	3	1	1	0	1	0	1	0	34
			0	4	1	2	1	1	2	3	0	3	3	2	2	1	2	1	3	2	1	0	1	0	1	34
			1	4	1	2	1	1	2	3	0	2	3	2	2	1	2	1	2	0	1	0	1	0	1	33
			2	3	1	1	1	1	2	3	0	2	2	2	1	2	1	2	0	0	0	0	0	0	0	1
1	86	MTF	3	2	1	0	1	1	2	3	0	2	2	2	2	1	2	1	1	0	0	0	0	1	22	
			4	2	1	0	1	1	2	3	0	1	2	1	1	0	1	0	0	0	0	0	0	0	17	
			5	1	0	0	1	1	2	3	0	1	2	1	1	0	1	0	0	0	0	0	0	0	1	17
			6	1	0	0	1	1	2	2	0	1	2	1	1	0	1	0	0	0	0	0	0	0	1	18
			-1	3	1	2	2	1	1	2	2	0	1	1	1	0	1	1	0	0	0	0	0	0	0	14
			0	3	1	2	2	1	3	2	0	4	1	1	1	1	1	1	1	0	1	0	0	1	0	30
1	87	MDO	-1	4	1	2	2	1	2	4	0	2	3	3	2	1	2	1	1	0	0	1	1	0	32	
			0	4	1	2	2	0	2	4	0	2	4	3	2	1	2	1	0	0	0	1	1	0	32	
			1	4	2	1	2	0	2	4	0	3	4	3	2	2	1	1	0	0	0	1	1	0	33	
			2	4	2	1	2	0	1	4	0	3	3	3	2	2	1	1	0	0	0	1	1	0	31	
			3	3	2	1	2	0	0	4	0	3	2	2	2	1	1	1	0	0	0	1	1	0	0	25
			4	2	1	1	2	0	0	3	0	2	2	1	0	2	1	1	0	0	0	0	0	0	0	18
1	88	VRL	5	1	1	1	2	0	0	1	0	0	1	1	0	2	1	1	0	0	0	0	0	0	13	
			6	1	1	1	1	0	0	1	0	0	1	1	0	1	1	1	0	0	0	0	0	0	10	
			-1	4	2	2	1	1	2	3	2	0	3	2	1	2	2	1	1	1	0	0	0	0	0	34
			0	4	2	2	1	1	2	3	2	0	4	2	1	2	2	0	1	2	0	1	2	0	1	34
			1	4	2	1	1	1	2	3	2	0	4	2	1	2	2	2	0	1	2	1	2	1	0	34
			2	3	2	1	1	1	2	2	1	0	3	2	1	2	1	0	1	0	1	2	1	0	0	27
1	89	VRL	3	3	2	1	2	1	2	2	1	0	3	2	1	2	1	0	1	2	1	2	1	0	30	
			4	3	2	1	2	1	2	2	1	0	3	2	1	2	1	2	0	1	2	1	0	0	30	
			5	3	2	1	2	1	2	2	1	2	2	1	2	1	2	1	2	0	1	2	0	0	0	32
			6	3	2	1	2	1	2	2	1	2	2	1	2	1	2	1	2	0	1	2	0	0	0	31
			-1	4	2	1	2	1	2	4	2	0	3	4	1	2	1	2	1	1	0	0	1	2	0	31
			0	4	2	1	2	1	2	4	2	0	3	4	1	2	1	2	1	1	0	0	1	2	0	31

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Patient Centre No.	Initials	Visit No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score					
1	89	MHV	-1	4	1	1	0	2	2	3	1	0	4	3	1	2	2	3	0	0	2	0	1	0	32				
			0	4	1	2	0	2	4	2	0	4	3	1	2	2	3	0	0	2	0	1	0	1	0	35			
			1	4	1	2	0	2	4	2	0	4	3	1	2	2	3	0	0	2	0	1	0	1	0	35			
			2	4	1	1	1	2	1	4	2	0	3	2	1	2	2	2	0	0	2	0	1	0	1	0	31		
			3	3	1	1	1	2	1	3	1	0	2	2	1	2	1	1	0	0	1	0	1	0	1	0	24		
			4	1	1	1	1	2	1	2	1	0	2	2	0	2	1	1	0	0	1	0	1	0	1	0	20		
1	90	JSS	5	1	1	1	1	2	1	1	0	0	2	2	0	2	1	1	0	0	1	0	1	0	17				
			6	1	0	1	1	2	1	2	1	0	2	1	0	2	1	1	0	0	0	0	0	1	0	17			
			-1	3	1	2	2	1	3	1	0	4	3	2	2	2	1	2	2	0	0	1	0	1	0	33			
			0	3	1	2	1	2	3	2	0	4	3	2	2	1	2	0	0	0	1	0	1	0	1	0	33		
			1	3	1	2	1	1	3	2	0	4	3	2	2	2	1	2	0	0	1	0	1	1	0	30			
			2	3	1	2	1	2	3	0	3	2	2	2	1	1	1	0	0	1	0	1	1	1	0	0	25		
1	91	MSC	3	1	1	1	2	1	2	3	1	0	2	2	1	1	1	0	0	0	1	0	1	0	21				
			4	1	1	1	2	1	2	1	1	0	2	2	1	2	1	1	0	0	1	0	1	0	1	0	19		
			5	1	1	1	2	1	2	1	1	0	2	1	1	2	1	0	0	0	0	1	0	1	0	1	0	15	
			6	1	1	1	2	1	1	0	1	0	1	1	1	1	1	1	0	0	0	0	0	0	1	0	15		
			-1	4	1	2	1	0	2	4	2	0	4	3	1	2	1	2	1	2	0	1	2	0	0	0	34		
			0	4	1	2	1	0	2	4	2	0	4	3	1	2	2	2	2	2	0	1	2	0	1	0	35		
1	92	PSS	1	4	1	1	1	0	2	4	1	0	3	3	1	2	2	2	2	0	0	1	0	0	0	31			
			2	3	1	1	1	0	2	3	1	0	3	3	1	2	2	2	0	0	0	0	1	0	0	26			
			3	2	1	1	1	0	2	2	1	0	2	2	1	2	2	1	0	0	0	0	0	0	0	0	20		
			4	2	1	0	1	0	2	2	1	0	2	2	0	2	1	0	0	0	0	0	0	0	0	0	16		
			5	1	1	0	1	0	2	1	1	0	2	1	0	2	1	0	0	0	0	0	0	0	0	0	13		
			6	1	1	0	1	0	2	1	1	0	2	1	0	2	0	0	0	0	0	0	0	0	0	0	12		
1	93	AL	-1	4	0	2	2	0	2	3	0	4	4	1	2	1	1	1	0	0	1	0	0	0	0	31			
			0	4	0	2	2	0	2	4	0	3	4	4	1	2	1	1	0	0	2	0	0	0	0	0	28		
			1	4	0	2	2	0	2	3	0	4	4	4	3	2	1	1	2	0	1	1	0	0	0	0	0	24	
			2	3	0	2	1	1	4	0	1	2	2	0	2	2	0	1	0	1	0	1	0	0	0	0	0	17	
			3	2	0	0	2	1	1	2	0	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	14	
			4	1	0	0	2	1	1	2	0	1	1	1	1	1	0	0	1	0	0	0	0	0	0	0	0	12	
1	94	RAB	5	1	0	0	2	1	1	1	0	1	1	1	1	0	0	0	1	0	0	1	0	0	0	11			
			6	1	0	0	2	1	1	1	0	1	1	1	1	0	0	0	1	0	0	0	1	0	0	0	10		
			-1	3	2	1	0	2	1	4	2	0	3	1	1	2	2	2	2	2	1	2	0	1	2	0	1	0	32
			0	4	2	1	0	2	1	4	2	1	4	2	2	2	0	1	2	0	1	2	0	1	2	0	1	0	32
			1	4	2	1	0	2	1	4	1	0	2	2	2	2	2	2	2	0	1	2	0	1	2	0	1	0	30
			4	2	1	0	2	1	4	1	0	2	2	2	2	2	2	2	2	0	1	2	0	1	2	0	1	0	30

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score		
1	94	RAB	2	4	2	1	0	1	1	4	1	0	2	2	0	2	2	1	0	1	2	0	1	0	27		
			3	2	1	1	0	2	1	0	2	2	2	2	2	1	0	2	1	0	0	1	0	1	0	22	
			4	2	1	0	0	1	1	3	1	0	2	1	0	2	1	0	2	1	0	0	1	0	1	0	18
			5	1	1	0	0	1	1	2	0	0	2	1	0	0	1	0	0	1	0	0	1	0	1	0	13
			6	1	1	0	0	1	1	1	0	0	1	1	0	0	1	0	0	1	0	0	1	0	1	0	11
			-1	3	2	0	2	1	1	3	2	0	3	3	1	2	1	2	2	0	2	0	0	0	0	1	31
1	95	OHT	1	3	2	0	2	1	1	3	2	0	4	3	1	2	0	2	0	1	2	0	0	1	0	30	
			2	3	2	0	2	1	1	3	2	0	3	3	1	2	2	2	0	0	0	1	2	0	0	1	30
			3	2	1	0	2	1	1	3	2	0	3	3	1	2	2	2	1	0	0	0	2	0	0	1	28
			4	2	1	0	2	1	1	3	2	0	3	2	1	2	2	1	0	0	0	2	1	0	0	1	23
			5	1	1	0	2	1	1	2	1	0	2	1	1	2	2	1	0	0	1	0	0	0	0	1	21
			6	0	0	2	1	1	1	2	1	1	1	0	0	1	2	2	1	0	0	0	0	0	0	1	16
1	96	SPH	-1	4	1	2	1	1	2	3	0	2	3	4	1	2	1	1	2	0	2	0	0	0	1	33	
			0	4	1	2	1	1	2	3	0	2	3	4	1	2	0	1	2	0	2	0	0	0	1	32	
			1	3	1	1	1	1	2	4	0	2	3	4	1	2	0	1	2	0	0	2	0	0	1	31	
			2	3	1	1	1	1	2	4	0	2	3	4	1	2	0	1	0	0	0	2	0	0	1	29	
			3	2	1	1	1	1	2	3	0	2	4	1	2	2	1	0	0	0	0	2	0	0	1	25	
			4	2	1	1	1	1	2	2	0	1	2	3	1	2	2	1	0	0	0	2	0	0	0	1	22
1	97	HND	5	1	1	0	1	1	2	2	0	0	2	2	1	2	2	1	0	0	2	0	0	0	1	17	
			6	1	1	0	1	1	2	1	0	0	1	1	1	2	2	0	0	0	1	0	0	0	1	17	
			-1	4	1	2	0	1	1	2	1	0	0	1	1	0	2	0	2	0	0	0	0	0	0	1	13
			0	4	1	2	0	0	3	0	1	4	3	2	2	1	2	1	2	1	1	2	0	0	0	0	31
			1	4	1	2	0	0	2	4	3	2	2	1	2	1	2	0	1	2	0	1	2	0	0	0	31
			2	3	1	1	2	0	0	2	0	1	3	3	2	2	1	2	0	1	2	0	0	0	0	0	28
1	98	YTT	3	2	1	1	1	0	0	2	0	0	2	2	2	2	2	1	2	0	0	1	0	0	0	21	
			4	1	1	0	2	0	0	2	0	1	1	0	2	1	2	0	0	0	0	0	0	0	0	12	
			5	0	0	0	2	0	0	0	0	1	1	0	0	1	1	0	2	1	2	0	0	0	0	0	10
			6	0	0	0	2	0	0	0	0	1	1	0	0	1	1	0	2	1	2	0	0	0	0	0	9
			-1	4	0	2	2	0	2	3	2	0	4	4	1	2	1	1	2	1	1	0	2	0	1	0	32
			0	4	0	2	2	0	2	3	2	0	4	3	1	2	1	0	0	2	1	1	2	0	1	0	31
1	99	LGD	1	4	0	2	2	0	2	2	0	4	3	3	2	1	2	1	0	0	0	2	1	1	0	30	
			2	3	0	2	2	0	2	2	0	3	3	2	1	2	1	0	0	2	1	0	0	1	0	24	
			3	2	0	2	2	0	2	1	0	2	2	1	2	2	1	0	0	1	0	0	1	0	1	0	21
			4	1	0	2	2	0	2	1	0	0	1	1	1	2	1	0	0	1	0	0	1	0	1	0	17
			5	1	0	2	2	0	2	1	0	0	1	1	1	1	2	1	0	0	0	0	1	0	1	0	16
			6	1	0	1	2	0	2	1	0	0	1	1	1	0	2	1	0	0	0	0	0	0	1	0	14
1	99	LGD	-1	3	2	1	1	1	1	4	0	2	3	2	1	2	1	3	2	0	2	0	0	0	0	31	
			0	3	2	1	1	1	1	4	0	2	3	2	2	1	3	0	0	2	0	0	0	0	0	0	30
			1	3	2	1	1	1	1	4	0	3	3	2	2	1	3	0	0	2	0	0	0	0	0	0	31
			2	4	2	1	1	1	1	4	0	3	3	2	2	1	3	0	0	2	0	0	0	0	0	0	36
			3	4	2	1	1	1	1	4	0	3	3	4	2	2	1	3	2	0	2	0	0	0	0	0	30
			4	4	2	1	1	1	1	4	0	2	3	3	3	2	1	1	2	0	2	0	0	0	0	0	33

8451

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Patient Centre No.	Initials	Visit No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score	
1	99	LGD	5	3	2	1	1	1	4	0	2	2	3	2	2	1	3	0	0	1	0	0	0	0	29
1	100	JWA	-1	4	1	1	2	0	2	4	0	4	3	1	2	1	1	0	1	1	0	0	0	1	33
			0	4	1	2	0	2	4	0	4	3	3	1	2	1	1	2	1	1	0	0	0	1	35
			1	4	1	1	2	0	2	4	0	3	3	1	2	1	1	0	1	1	0	0	0	1	32
			2	3	1	1	2	0	2	4	0	3	3	2	1	1	0	0	1	1	0	0	0	1	28
			3	2	1	0	2	0	2	2	0	2	2	1	2	1	1	0	0	0	0	0	0	1	21
			4	1	1	0	2	0	2	2	0	1	1	1	2	1	1	0	0	0	0	0	0	1	17
			5	1	0	0	2	0	2	1	0	1	1	1	2	1	1	0	0	0	0	0	0	1	15
			6	0	0	0	2	0	2	1	0	0	1	1	0	1	0	0	0	0	0	0	0	0	9
1	101	JLL	-1	3	1	2	1	1	3	0	2	3	3	2	2	1	2	2	0	1	0	0	0	0	31
			0	3	0	1	2	0	3	0	3	4	4	2	1	2	0	0	0	2	1	0	0	0	32
			1	3	0	1	2	0	2	0	3	3	3	1	2	1	2	0	0	2	1	0	0	0	27
			2	1	0	0	2	0	1	0	1	2	2	1	1	1	1	0	0	0	0	0	0	0	15
			3	0	0	0	2	0	1	0	0	1	2	1	1	1	1	2	0	0	0	0	0	0	12
			4	0	0	0	2	0	1	0	0	2	1	0	0	0	1	0	0	0	0	0	0	0	5
			5	0	0	0	2	0	1	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	7
			6	0	0	0	1	0	1	0	1	1	1	0	0	1	0	0	0	0	0	0	0	0	8
1	102	ESF	-1	4	2	2	2	1	4	3	0	2	3	1	2	2	1	1	0	2	0	0	0	0	34
			0	4	0	2	1	1	3	2	0	3	4	1	2	1	0	0	1	1	2	0	1	1	30
			1	4	0	2	1	1	4	2	0	3	3	1	2	1	0	2	1	1	1	1	0	0	31
			2	3	0	2	1	1	3	3	0	3	4	1	2	1	0	0	1	1	1	0	0	0	29
			3	3	0	1	2	1	1	3	2	0	3	3	1	2	1	0	2	1	1	0	0	0	27
			4	2	0	1	2	1	1	3	2	0	3	2	1	2	1	0	0	1	1	0	0	0	24
			5	2	0	1	2	1	1	3	2	0	2	2	1	2	1	0	0	1	2	0	0	0	23
			6	2	0	2	1	1	3	2	0	2	3	1	2	1	0	0	1	2	0	0	0	0	25
1	103	JRA	-1	3	0	2	2	0	3	1	0	4	3	0	2	1	2	2	0	2	0	1	1	1	31
			0	3	0	2	2	0	3	2	0	4	4	0	2	1	2	2	0	2	0	1	1	1	33
			1	3	0	2	2	0	4	2	0	4	4	0	2	1	3	2	0	2	0	1	1	1	35
			2	3	0	2	2	0	4	1	0	4	4	0	2	1	3	2	0	2	0	1	1	1	34
1	104	MTF	-1	3	0	2	2	0	1	3	2	0	4	2	1	2	2	1	2	0	1	0	1	1	30
			0	3	0	2	2	0	1	3	2	0	4	3	1	2	1	0	0	2	0	1	1	1	30
			1	3	0	1	2	0	1	3	2	0	3	3	1	2	2	1	2	0	0	1	1	1	30
			2	2	0	1	2	1	0	3	1	0	2	2	1	2	1	0	0	2	0	1	1	1	24
			3	2	0	1	2	1	0	2	1	0	2	2	1	2	2	1	0	0	1	0	1	1	21
			4	1	0	0	1	1	0	2	1	0	1	2	0	2	1	0	0	1	0	0	1	1	15
			5	1	0	0	1	1	0	1	0	1	2	0	2	1	0	0	0	1	0	0	1	1	11
			6	0	0	0	1	1	0	0	1	1	1	0	0	1	0	0	0	0	0	0	1	1	8
1	105	ABS	-1	4	2	0	2	1	2	3	2	0	3	4	2	1	1	1	0	1	0	0	0	2	33
			0	4	2	0	2	1	2	4	2	0	3	4	2	2	1	2	0	0	1	0	0	2	34
			1	4	2	0	2	1	2	4	2	0	3	3	2	2	1	0	0	1	0	0	2	35	
			2	4	1	0	2	1	2	4	2	0	3	3	1	2	1	0	0	1	0	0	0	2	31

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBORETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score		
1	105	ABS	3	3	0	0	2	1	2	3	2	0	2	2	1	2	2	1	0	0	1	0	0	0	2	26	
			4	2	0	2	1	1	2	2	1	2	0	2	2	1	2	2	1	0	0	1	0	0	2	23	
			5	1	0	0	2	1	1	1	0	1	1	0	1	0	0	2	1	0	0	1	0	0	2	15	
			6	0	0	0	2	1	1	1	0	1	1	0	1	0	0	2	0	0	0	0	0	0	0	1	11
			-1	4	0	2	1	0	2	4	2	4	2	0	4	4	1	2	1	2	1	0	2	0	0	0	32
			1	4	0	2	1	0	2	4	2	4	2	0	4	4	1	2	1	2	2	0	2	0	0	0	33
1	106	MRN	1	4	0	2	1	0	2	4	2	0	3	4	1	2	1	2	0	0	0	2	0	0	0	30	
			2	4	0	2	1	0	2	4	2	4	2	0	3	4	1	2	1	2	0	0	0	0	0	30	
			3	2	0	1	2	1	0	2	4	2	0	3	3	3	1	2	1	1	0	0	0	0	0	0	26
			4	2	0	1	2	1	0	2	2	2	0	2	2	1	2	1	1	0	0	0	0	0	0	0	19
			5	1	0	0	1	2	1	0	2	2	0	2	2	0	2	0	1	1	0	0	0	0	0	0	16
			6	0	0	0	1	1	0	0	1	2	0	1	1	0	0	1	1	0	0	0	0	0	0	0	10
1	107	LAN	-1	3	1	0	2	0	2	4	3	0	2	4	2	2	0	3	2	0	2	0	0	0	1	33	
			0	3	1	0	2	0	2	4	3	0	2	4	2	2	0	2	0	0	2	0	0	0	1	30	
			1	3	2	0	2	0	2	4	3	0	2	4	2	2	0	2	0	2	0	0	2	0	0	1	32
			2	3	2	0	2	0	1	3	5	0	2	4	2	2	2	2	0	2	0	0	2	0	0	1	30
			3	2	0	2	0	1	3	2	0	2	3	2	2	2	2	1	2	0	1	0	0	0	0	1	25
			4	2	0	2	0	1	1	0	2	2	1	0	2	2	2	1	0	0	0	2	0	0	0	0	20
1	108	STB	1	2	0	1	1	0	1	1	0	1	2	1	2	1	2	2	1	0	2	0	2	0	0	21	
			2	1	0	1	1	0	1	1	0	1	1	0	1	1	0	0	2	1	0	0	1	0	0	12	
			-1	4	2	0	0	1	0	3	0	4	3	0	4	3	1	2	2	2	2	1	0	0	1	0	32
			0	4	2	0	0	1	0	3	0	4	4	4	4	4	1	2	2	2	2	1	0	0	1	0	33
			1	4	2	0	2	2	0	3	0	4	3	4	4	4	1	2	2	2	2	1	0	0	1	0	34
			2	4	2	0	2	2	0	3	0	4	3	4	4	4	1	2	2	1	1	0	0	0	1	0	29
1	109	IPL	3	3	2	0	2	2	0	3	0	3	3	3	3	1	2	1	1	0	1	0	0	1	0	25	
			4	2	2	0	2	2	0	2	0	2	2	2	2	1	2	1	1	1	0	0	0	0	1	0	22
			5	2	2	0	2	2	0	2	0	2	1	2	2	2	1	2	1	1	0	0	0	0	1	0	20
			6	1	1	0	2	2	0	1	0	1	1	0	1	1	1	2	1	0	0	0	0	0	1	0	15
			-1	4	0	0	2	1	2	4	0	2	4	3	1	2	0	0	2	0	2	0	2	0	1	0	30
			0	4	0	0	2	1	2	4	0	2	4	3	1	2	0	1	0	0	1	0	2	0	1	0	29
1	110	TQO	1	4	0	0	2	1	2	4	0	2	4	3	1	2	0	0	1	0	0	1	0	0	1	0	33
			2	4	0	0	2	1	2	4	0	2	3	3	1	2	0	1	0	0	1	0	1	2	1	0	34
			3	3	0	0	2	1	2	3	0	2	3	3	1	2	2	1	1	0	0	1	1	1	1	0	29
			4	2	0	0	2	1	2	3	0	1	2	2	2	2	2	0	0	0	0	0	1	0	0	0	22
			5	1	0	0	2	1	2	3	0	0	2	2	2	2	2	0	0	0	0	0	1	0	0	0	19
			6	1	0	0	1	1	1	1	0	0	1	1	0	0	1	0	0	0	0	0	1	0	0	0	12
1	111	TQO	-1	3	1	0	2	1	1	3	0	4	3	1	2	2	2	1	3	2	1	2	0	1	0	33	
			0	3	1	0	2	1	1	4	0	3	3	2	2	2	1	3	2	1	2	1	2	0	1	0	34
			1	3	1	0	2	1	1	4	0	3	3	2	2	2	1	3	0	1	0	1	2	0	1	0	29
			2	3	1	0	2	1	1	4	0	3	2	2	2	2	1	1	0	1	0	1	2	0	1	0	26
			3	2	1	0	2	1	1	2	0	1	2	2	2	2	1	1	0	1	0	1	1	0	1	0	23
			4	2	1	0	2	0	1	1	1	1	1	2	2	2	1	1	0	1	0	1	1	0	1	0	18
5	0	0	0	2	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8			

847

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score			
1	110	TQO	6	0	0	0	2	0	1	0	0	0	1	0	0	2	1	0	0	0	0	0	1	0	0	8		
			-1	4	0	1	2	1	2	4	2	0	4	3	1	2	1	2	1	2	0	1	2	0	0	1	33	
			1	4	0	1	2	3	2	0	4	4	1	2	1	2	1	2	1	2	0	1	2	0	0	0	1	33
			2	4	0	1	2	3	2	0	3	4	1	2	1	2	1	2	1	2	0	1	2	0	0	0	1	32
			3	2	0	0	2	1	2	2	0	2	3	1	2	1	2	1	2	1	1	0	0	1	0	0	1	28
			4	2	0	0	2	1	2	2	0	2	2	1	2	1	2	1	2	1	1	0	0	1	0	0	1	22
1	111	JBF	5	1	0	0	2	1	1	2	2	0	2	1	2	1	2	1	1	0	0	1	0	0	0	1	21	
			6	1	0	0	1	1	1	1	1	1	1	0	1	1	0	1	1	1	0	0	1	0	0	1	13	
			-1	4	0	1	1	1	2	4	0	3	4	2	1	2	1	2	1	2	1	0	1	0	0	0	1	30
			1	4	0	1	1	2	4	0	3	4	2	1	2	1	1	2	1	1	0	1	2	0	0	0	1	30
			2	4	0	1	1	2	4	0	4	3	2	1	2	1	1	2	1	1	0	2	0	0	0	0	1	29
			3	3	0	1	2	1	1	3	0	3	4	1	2	1	1	2	1	1	0	0	2	0	0	0	0	29
1	112	PSA	4	2	0	0	2	1	1	3	0	2	4	3	1	2	1	2	1	2	0	1	0	0	0	0	25	
			5	2	0	0	1	1	1	3	0	2	4	3	1	2	1	2	1	2	0	0	1	0	0	0	23	
			6	2	0	0	1	1	1	3	0	3	3	3	1	2	1	2	1	2	0	0	1	0	0	0	24	
			-1	4	1	0	2	1	0	4	2	0	4	3	1	2	1	2	1	2	0	0	2	1	0	0	30	
			1	4	1	0	2	1	0	4	2	0	4	3	1	2	1	2	1	2	2	0	2	1	0	0	31	
			2	3	1	0	2	1	0	4	2	0	3	3	1	2	2	2	2	2	2	0	2	1	0	0	32	
1	113	LPS	3	4	1	0	2	1	1	4	2	0	3	4	1	2	2	2	2	2	0	2	1	0	0	0	32	
			4	3	1	0	2	1	1	4	2	0	3	4	1	2	2	2	2	2	0	2	1	0	0	0	32	
			5	4	1	0	2	1	0	4	1	0	3	3	1	2	2	2	2	2	0	0	2	1	0	0	0	27
			6	3	1	0	2	1	0	4	1	0	3	3	1	2	2	2	2	2	0	0	2	1	0	0	0	27
			-1	4	1	0	2	1	0	4	1	0	4	2	3	1	2	2	2	2	0	0	2	1	0	0	0	29
			1	4	1	0	2	1	0	4	2	0	4	3	1	2	1	2	1	2	0	0	2	1	0	0	0	26
1	114	CLF	-1	4	1	2	0	2	4	0	2	3	3	2	2	1	2	1	1	2	1	1	0	0	0	0	33	
			0	3	1	1	2	1	1	3	0	3	3	4	2	2	1	0	2	1	0	2	1	0	0	0	32	
			1	3	1	1	2	1	1	3	0	2	3	2	2	2	1	0	0	0	0	2	1	0	0	0	27	
			2	2	1	0	2	1	1	2	0	2	2	2	2	2	1	0	0	0	0	0	1	1	0	0	0	22
			3	1	1	0	2	1	1	1	0	1	2	2	2	2	1	0	0	0	0	0	0	0	0	0	0	17
			4	0	0	0	2	1	1	1	0	1	1	2	0	1	0	0	1	0	0	0	0	0	0	0	0	11
1	115	ELS	5	0	0	0	2	1	1	1	0	1	1	2	0	1	0	0	0	0	0	0	0	0	0	0	9	
			6	0	0	0	2	0	1	1	0	1	1	1	0	2	0	0	0	0	0	0	0	0	0	0	0	9
			-1	4	1	1	2	0	1	3	0	2	4	4	0	2	1	2	1	2	1	1	0	3	0	0	0	32
			0	4	1	2	2	0	1	3	0	3	4	4	0	2	2	0	2	1	0	1	2	1	1	0	0	31
			1	4	1	2	2	0	1	3	2	0	4	4	0	2	2	0	2	0	2	0	2	1	0	0	0	32
			2	3	1	2	2	0	0	2	2	0	3	3	0	2	0	0	0	0	0	0	0	1	0	0	0	25
1	116	MGA	3	2	1	1	2	0	0	2	2	0	3	2	0	2	2	2	0	0	0	1	0	0	0	0	12	
			4	1	1	0	2	0	0	2	2	0	2	2	0	2	2	0	2	0	0	0	0	0	0	0	16	
			5	1	1	0	2	0	0	2	2	0	2	2	0	2	2	0	2	1	0	0	0	0	0	0	0	15
			6	1	0	0	2	0	0	2	2	0	2	2	0	2	1	0	2	1	0	0	0	0	0	0	0	13
			-1	4	1	1	2	0	2	3	2	0	3	3	2	2	1	1	1	1	1	1	1	0	0	0	0	30
			1	4	1	1	2	0	2	3	2	0	3	3	2	2	1	1	1	1	1	1	1	0	0	0	0	30

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Patient	Centre	Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total		
1	121	LAC	4	1	0	0	2	1	0	1	0	0	1	1	0	0	1	1	0	0	0	1	0	1	0	11	
			5	0	0	1	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	1	0	6	
			6	0	0	0	1	1	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	1	0	7
			-1	3	2	1	2	1	1	4	2	0	4	3	2	2	1	2	1	2	1	0	1	0	0	0	32
			1	4	1	1	2	1	1	4	2	0	3	3	2	2	1	2	0	1	2	0	1	0	0	0	31
			1	4	1	1	2	1	1	3	0	3	3	2	2	2	1	2	0	1	2	0	1	0	0	0	31
1	122	HSS	2	3	1	1	2	1	2	1	0	1	2	2	1	2	2	1	2	1	0	0	2	0	0	25	
			3	2	0	1	1	1	1	1	0	0	2	2	2	1	2	1	0	0	0	0	1	0	0	18	
			4	1	0	0	1	1	1	1	1	0	0	1	1	2	2	1	1	0	0	1	0	0	0	0	14
			5	0	0	0	1	1	1	1	0	0	1	1	1	2	2	1	1	0	0	0	1	0	0	0	7
			6	0	0	0	1	1	1	1	0	0	0	0	1	1	0	0	1	0	0	1	0	0	0	0	6
			-1	4	1	0	2	1	1	2	3	0	2	3	1	2	1	2	1	2	0	1	2	0	1	1	32
1	123	MLL	0	4	1	0	2	1	2	3	0	2	3	4	1	2	1	2	0	0	1	2	0	1	1	33	
			1	4	1	0	2	1	2	3	0	2	3	4	1	2	1	2	0	1	2	0	1	2	0	1	33
			2	3	1	0	2	1	2	3	0	2	3	3	1	2	1	2	0	1	2	0	1	2	0	1	32
			3	2	1	0	2	1	1	3	0	2	2	2	1	2	1	2	0	0	2	0	0	2	0	1	28
			4	1	0	0	2	1	1	1	1	0	1	2	2	1	2	1	2	0	0	0	2	0	1	1	24
			5	0	0	0	2	0	1	1	0	0	1	2	1	2	1	2	1	0	0	0	1	0	1	1	16
1	124	PPC	0	0	0	0	1	1	0	0	0	0	0	1	1	0	2	0	0	0	0	0	0	0	0	9	
			1	4	1	1	2	1	1	4	3	0	4	3	1	2	0	2	0	2	0	1	0	1	0	2	33
			1	4	1	1	2	1	1	4	3	0	4	3	1	2	0	2	2	1	0	1	0	1	0	2	35
			2	3	1	1	2	1	1	4	3	0	3	3	1	2	2	2	1	0	0	1	0	1	0	2	34
			3	2	1	0	2	1	1	3	2	0	3	3	1	2	2	1	0	0	0	0	0	0	0	0	26
			4	1	0	0	1	1	1	2	0	0	2	2	1	2	2	1	0	0	0	0	0	0	0	0	19
1	125	FDP	5	1	0	0	1	1	1	1	0	0	1	1	1	0	2	2	1	0	0	0	0	0	0	10	
			6	1	0	0	1	1	1	1	1	0	1	1	0	1	2	0	0	0	0	0	0	0	0	11	
			-1	4	1	1	2	1	1	4	3	0	4	3	1	2	0	2	0	2	0	1	0	1	0	2	33
			0	4	0	1	0	0	2	4	0	4	4	3	2	2	2	2	1	0	2	2	0	2	1	0	34
			1	2	0	1	2	1	2	4	0	4	4	3	2	2	2	2	1	0	0	2	1	0	1	0	32
			2	2	0	0	2	1	2	3	0	4	4	3	2	2	2	2	1	0	0	2	0	2	0	0	32
1	126	SMB	3	2	0	0	2	1	2	3	0	1	3	2	2	2	2	1	0	0	0	1	0	0	0	24	
			3	2	0	0	2	1	2	3	0	1	3	2	2	2	2	1	0	0	0	0	0	0	0	19	
			4	1	0	0	2	1	2	1	0	0	1	1	0	2	2	0	0	0	0	0	0	0	0	0	13
			5	1	0	0	2	1	2	1	0	1	1	0	2	2	1	0	0	0	0	0	0	1	0	0	14
			6	1	1	0	2	1	2	1	0	1	1	1	0	2	2	1	0	0	0	0	0	1	0	0	14
			-1	3	2	1	2	1	2	3	2	0	4	3	1	2	1	2	0	2	1	0	1	0	0	0	32
1	126	SMB	0	3	2	1	2	1	2	3	2	0	4	3	1	2	1	3	1	0	0	1	0	0	0	32	
			1	3	2	1	2	1	2	3	2	0	4	3	1	2	1	2	0	0	0	1	1	0	0	31	
			2	3	1	1	2	1	2	3	2	0	4	3	1	2	1	2	0	0	0	1	1	0	0	0	24
			3	2	1	1	1	1	2	1	0	3	2	1	2	2	0	2	0	2	0	1	0	0	0	0	22
			4	1	1	1	1	1	1	1	1	1	1	0	2	1	0	2	1	0	2	0	1	0	0	0	17
			5	1	1	0	1	1	1	1	1	1	0	0	2	1	0	2	2	0	0	0	1	0	0	0	13
6	0	0	0	1	1	1	1	0	0	1	1	0	0	1	0	2	2	0	0	0	0	0	0	6			

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.1

HAMILTON DEPRESSION RATING SCALE
OPEN PHASE

Patient Centre No.	Initials	Visit No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score	
1	127	VPD	-1	3	2	1	2	1	1	3	0	3	4	3	0	2	0	2	1	1	2	0	1	0	32
			0	3	2	1	2	1	1	4	0	2	4	3	1	2	0	2	1	2	0	0	0	0	33
			1	3	2	1	2	1	1	3	0	2	3	3	1	2	0	2	0	1	2	0	0	0	29
			2	2	2	1	1	1	2	0	1	2	2	1	2	0	2	0	2	0	2	0	0	0	23
			3	2	1	1	1	1	2	0	1	2	1	2	1	2	0	1	0	0	1	0	0	0	18
			4	1	1	1	1	1	1	0	0	1	1	1	0	0	0	0	0	2	0	0	0	0	11
			5	0	0	1	1	1	1	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	6
			6	0	0	0	1	1	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	5
1	128	LAM	-1	4	1	0	0	2	2	4	0	4	4	1	0	2	0	3	0	1	2	0	1	2	33
			0	4	2	0	0	2	4	0	3	4	2	0	2	0	3	0	1	2	0	0	1	2	33
			1	4	2	0	0	2	3	0	3	3	2	0	2	0	3	0	1	2	0	0	2	2	31
			2	4	1	0	0	2	2	0	2	2	2	0	2	0	1	3	0	1	2	0	0	0	26
			3	2	1	0	0	2	2	0	1	2	2	0	2	1	1	0	1	1	2	0	0	1	22
			4	1	0	0	2	2	2	0	2	2	1	1	0	1	3	0	1	1	1	0	0	0	21
			5	2	1	0	0	2	2	1	0	2	1	1	0	2	1	3	0	1	2	0	0	1	21
			6	0	0	0	2	1	0	1	0	1	0	1	0	2	1	0	0	0	0	0	0	0	9
1	129	MNS	-1	3	1	0	2	0	2	3	2	0	4	3	0	2	1	0	0	1	2	3	0	1	30
			0	4	1	0	2	0	3	2	0	3	3	3	0	2	1	0	2	1	2	1	1	1	33
			1	4	1	0	2	0	2	2	0	3	3	3	0	2	2	1	1	1	2	1	0	1	30
			2	4	1	0	2	0	2	2	0	2	2	2	0	2	2	0	0	0	1	0	0	0	18
			3	2	0	0	2	0	2	1	0	2	1	0	2	2	0	0	0	0	1	0	0	0	12
			4	1	0	0	2	0	0	1	0	2	1	0	2	0	0	0	0	1	0	0	0	0	9
			5	0	0	0	2	0	0	0	1	0	1	1	0	0	0	0	2	0	0	0	0	0	7
			6	0	0	0	2	1	0	0	1	0	1	1	0	0	0	0	0	0	0	0	0	0	7
1	130	EGA	-1	3	2	2	1	2	1	3	2	0	3	3	2	2	1	1	2	0	1	0	1	0	32
			0	4	2	2	2	1	1	3	2	0	3	3	2	2	1	0	2	0	2	0	1	0	33
			1	4	2	2	2	1	1	3	2	0	3	3	2	2	1	0	0	0	2	0	1	0	30
			2	3	2	2	2	1	1	3	1	0	2	2	2	2	1	0	0	0	2	0	1	0	27
			3	3	1	1	2	1	1	3	2	0	2	2	1	2	1	0	0	0	1	0	1	0	24
			4	2	1	1	2	1	1	2	1	0	2	2	1	2	1	0	0	0	1	0	1	0	21
			5	1	0	1	2	1	0	1	1	0	2	1	2	1	0	0	0	1	0	1	0	1	16
			6	1	0	1	2	1	0	1	1	0	1	1	0	1	0	0	0	1	0	1	0	1	12
1	131	RMR	-1	4	1	0	2	2	1	3	0	2	4	4	1	2	1	3	1	0	1	0	0	0	32
			0	4	1	0	2	2	1	3	0	2	4	4	1	2	1	2	2	0	1	0	0	0	32
			1	4	1	0	2	2	1	3	0	2	4	3	1	2	1	0	0	2	0	0	0	0	30
			2	4	1	0	2	2	1	3	0	2	4	3	1	2	2	2	0	0	1	0	0	0	29
			3	4	1	0	2	1	1	4	0	2	3	4	1	2	2	2	0	0	2	0	0	0	31
			4	4	1	0	2	1	1	4	0	2	3	4	1	2	2	2	0	0	2	0	0	0	29
			5	3	1	0	2	1	1	3	0	2	2	3	1	2	2	2	0	0	2	0	0	0	30
			6	3	1	0	2	2	1	3	0	2	3	3	1	2	2	2	0	0	2	0	0	0	29
1	132	MAT	-1	3	1	1	2	1	1	3	2	0	3	4	2	1	2	1	2	0	0	0	1	1	33
			0	4	1	1	2	1	1	3	2	0	3	4	2	1	1	0	0	2	2	0	1	1	30
			1	4	1	1	2	1	1	3	2	0	2	3	1	2	2	1	1	0	2	2	1	0	32

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.1

HAMILTON DEPRESSION RATING SCALE
OPEN PHASE

Patient No.	Centre No.	Initials	Visit No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score			
1	132	MAT	2	4	1	1	2	1	1	3	1	0	2	2	1	2	1	1	1	0	0	1	1	0	0	1	26	
			3	3	1	1	2	1	1	3	1	0	2	2	2	1	2	2	1	0	0	1	0	0	0	1	25	
			4	3	1	1	2	1	1	2	1	0	2	2	1	2	1	2	1	1	0	0	1	0	0	1	23	
			5	3	1	1	1	1	1	2	1	2	1	0	2	3	1	2	1	1	0	0	1	0	0	1	23	
			6	3	1	1	2	0	1	2	0	1	0	2	2	1	2	2	1	0	0	0	1	0	0	1	23	
			-1	3	2	0	2	1	1	3	2	0	3	2	0	3	2	2	1	1	2	0	2	2	0	0	0	31
1	133	JPH	0	4	2	0	2	1	1	3	2	0	3	4	2	2	2	1	1	0	0	2	0	0	0	0	31	
			1	4	1	0	2	1	1	3	2	0	3	4	2	2	2	1	1	0	0	2	0	0	0	0	29	
			2	4	1	0	2	1	1	3	2	0	3	3	3	2	2	2	1	0	0	2	0	0	0	0	0	29
			3	2	1	0	2	1	1	2	0	3	2	0	3	3	1	2	2	1	0	0	1	0	0	0	21	
			4	1	1	0	2	1	1	1	1	2	0	2	1	1	2	2	1	0	0	1	0	0	0	0	18	
			5	1	1	0	1	1	1	1	1	1	0	1	1	1	1	2	2	1	0	0	1	0	0	0	15	
1	134	LMS	6	1	1	0	1	0	1	0	1	0	1	1	1	1	2	1	1	0	0	1	0	0	0	11		
			-1	4	0	2	2	0	4	0	2	4	3	2	2	2	2	1	1	1	0	0	0	1	1	0	32	
			0	4	0	2	2	0	4	0	2	4	3	2	2	2	2	1	2	2	0	0	0	0	1	1	0	33
			1	4	0	2	2	0	4	0	2	3	3	2	2	2	2	1	1	0	0	0	1	0	0	1	0	30
			2	3	0	1	2	0	3	0	2	2	2	2	2	2	2	1	1	0	0	0	0	0	0	1	0	24
			3	2	0	1	2	0	2	0	2	2	2	2	2	2	2	1	1	0	0	0	0	0	0	1	0	16
1	135	MNS	4	1	0	0	2	1	0	2	0	2	1	0	2	1	0	2	1	0	0	0	0	0	0	0	7	
			5	0	0	0	2	1	0	0	2	1	0	2	1	0	2	1	0	0	0	0	0	0	0	0	7	
			6	0	0	0	2	1	0	0	2	1	0	2	1	0	0	0	1	0	0	0	0	0	0	0	0	7
			-1	3	1	0	2	2	1	3	0	4	3	0	2	2	2	2	2	0	0	2	0	0	1	0	0	31
			0	3	1	0	2	2	1	3	0	4	3	0	4	3	0	2	2	2	0	0	2	0	1	0	1	32
			1	3	1	0	2	2	1	3	0	3	3	0	3	3	0	2	2	2	1	0	0	2	0	0	0	28
1	136	AVP	2	3	1	0	2	1	1	2	0	1	2	2	0	2	2	1	0	0	0	2	0	0	0	0	22	
			3	2	1	0	2	1	1	1	0	1	2	1	0	1	0	2	2	1	0	0	1	0	0	0	15	
			4	1	0	1	1	1	1	1	0	1	1	0	1	1	1	0	2	2	0	0	1	0	0	0	14	
			5	0	0	0	1	1	1	1	0	0	1	1	1	1	0	0	1	0	0	0	0	0	0	0	0	7
			6	0	0	0	1	1	1	0	0	1	0	1	0	1	0	0	2	1	0	0	0	0	0	0	0	6
			-1	4	2	2	2	0	2	2	0	3	4	1	2	0	3	2	0	3	1	0	1	1	0	0	1	33
1	137	CHE	0	4	2	2	0	2	0	2	3	0	3	4	1	2	0	0	3	1	0	1	1	0	0	1	32	
			1	4	2	2	0	2	3	0	3	4	1	2	0	3	2	2	2	1	2	0	1	1	0	0	1	34
			2	3	1	2	0	2	2	1	0	2	2	2	2	2	2	1	0	0	0	1	0	0	0	0	1	26
			3	2	1	1	2	0	2	1	0	2	2	2	2	2	2	2	2	2	0	0	1	0	0	0	1	22
			4	1	0	1	2	0	1	1	0	1	1	0	1	1	0	2	2	0	0	0	1	1	0	0	1	16
			5	1	0	1	2	0	1	1	0	1	0	1	0	1	0	2	2	0	0	0	1	0	0	0	1	13
1	137	CHE	6	0	0	0	2	0	1	0	1	0	1	0	1	0	0	2	2	0	0	0	0	0	0	0	9	
			-1	3	0	2	1	1	2	3	0	3	4	2	2	1	0	1	0	1	1	1	1	0	0	0	0	30
			0	3	0	2	1	1	2	3	0	3	4	2	2	1	0	2	1	1	0	2	1	1	0	0	0	29
			1	3	0	2	1	1	2	4	0	3	4	2	2	2	2	1	0	1	0	2	1	1	0	0	0	31
			2	4	0	2	1	1	2	4	0	2	4	2	2	2	2	1	1	0	1	1	0	1	0	0	0	30
			3	3	0	1	1	1	2	3	0	2	2	2	2	2	2	2	2	2	0	2	1	1	0	0	0	26
4	4	0	1	1	1	2	3	0	2	2	2	2	2	2	2	2	0	0	0	1	0	0	0	0	26			

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD
 REBEXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Hamilton Depression Rating Scale																				Total Score		
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20		It.21	
1	137	CHE	5	4	0	2	1	1	1	2	4	0	2	3	3	2	2	2	2	0	0	1	0	0	30	
			6	3	0	1	1	1	2	3	0	2	2	2	2	2	2	0	2	0	1	0	0	0	26	
			-1	3	2	0	1	1	4	2	0	4	4	2	2	1	1	2	0	0	0	2	0	0	32	
	1	138	LBV	1	3	2	0	1	2	1	4	2	0	4	4	2	2	1	1	0	0	0	3	0	0	32
				2	1	1	0	1	2	1	4	2	0	3	3	1	2	1	1	0	0	0	2	0	0	28
				3	1	1	0	1	1	3	2	0	3	2	0	2	1	1	0	0	0	0	1	0	0	19
1	139	RA	4	0	0	0	1	1	1	2	1	1	0	2	2	1	1	0	0	0	0	1	0	0	9	
			5	0	0	0	1	1	0	0	1	1	0	1	0	0	1	0	0	0	0	1	0	0	6	
			6	0	0	0	1	1	0	0	1	0	0	2	0	0	1	0	0	0	0	0	2	0	0	7
			-1	4	0	1	1	0	2	4	0	4	3	4	1	0	2	1	0	1	0	1	0	1	0	31
			0	4	0	1	1	0	2	4	0	3	3	4	1	0	2	3	2	0	1	0	1	0	1	32
			1	4	0	1	1	0	2	4	0	3	3	4	2	0	2	3	0	0	2	0	1	0	1	31
1	140	MCA	2	4	0	1	1	0	2	4	0	3	2	4	2	0	2	0	0	0	1	0	1	0	25	
			3	2	0	1	1	0	2	4	0	1	2	2	0	2	1	2	0	0	1	0	1	0	19	
			4	1	0	0	1	1	0	1	1	0	1	2	1	0	2	1	0	0	2	0	1	0	13	
			5	0	0	0	1	0	1	0	1	0	1	1	0	0	2	1	0	0	2	0	0	1	0	8
			6	0	0	0	1	0	1	0	0	1	1	0	0	0	2	1	0	0	0	0	0	1	0	8
			-1	3	2	0	2	1	1	3	0	2	3	3	0	2	2	1	0	0	1	0	1	1	0	27
1	141	ANG	0	3	2	0	2	1	1	3	0	3	3	4	0	2	2	1	0	0	1	1	0	0	29	
			1	4	2	0	2	1	1	4	0	3	3	1	0	2	2	1	0	0	1	2	0	0	29	
			2	2	0	1	1	1	1	4	0	1	2	2	0	2	2	1	0	0	1	0	0	0	22	
			3	1	1	0	1	1	1	3	0	2	2	0	2	2	2	1	2	0	1	0	0	0	22	
			4	1	1	0	1	1	1	1	1	0	1	1	1	1	1	1	1	0	0	1	0	0	0	13
			5	1	1	0	1	1	1	1	1	0	1	1	0	0	1	1	0	0	1	0	0	0	0	12
1	142	SCC	0	4	1	2	1	1	2	3	2	0	4	3	1	2	2	1	0	1	0	1	0	0	31	
			1	4	1	2	1	1	2	3	0	3	2	1	2	2	1	0	0	2	0	1	0	1	0	31
			2	4	1	1	1	1	2	3	0	3	2	1	2	2	1	0	0	2	0	1	0	1	0	28
			3	2	1	1	1	1	1	2	0	2	2	1	1	2	2	1	0	0	2	0	0	0	0	22
			4	2	1	1	1	1	1	1	0	2	1	1	2	2	1	0	0	0	1	0	1	0	0	20
			5	1	0	0	1	1	1	1	1	0	2	1	1	0	0	2	1	0	0	2	0	1	0	15
1	143	SCC	-1	3	1	0	2	2	2	4	0	4	3	1	2	1	1	0	1	1	0	1	1	0	33	
			0	3	1	0	2	2	2	4	0	3	4	3	1	2	1	2	0	1	1	1	0	0	34	
			1	4	1	0	2	2	1	4	0	3	3	1	2	1	2	0	0	1	1	0	1	0	30	
			2	3	1	0	2	2	1	4	0	2	3	2	1	2	1	1	2	0	0	1	0	0	25	
			3	1	1	0	2	1	1	2	0	2	2	1	2	1	1	0	0	0	0	0	0	0	0	15
			4	1	1	0	2	1	1	1	1	0	1	1	1	1	1	1	0	0	0	0	0	0	0	14
1	144	SCC	5	0	0	0	1	1	1	0	0	1	1	1	1	2	1	1	0	0	0	0	0	0	11	
			6	0	0	0	1	1	0	1	0	0	1	1	1	2	1	1	0	0	0	0	0	0	10	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Patient	Centre	No.	Initials	Visit	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total				
1	143	JEP		-1	4	0	2	1	2	1	4	3	0	3	4	2	2	1	2	1	2	0	1	0	0	0	1	35			
				0	3	2	1	1	1	2	3	2	0	3	4	1	2	1	1	1	1	1	0	0	2	0	1	0	30		
				1	3	1	1	1	1	2	3	1	0	2	3	1	2	1	1	1	1	1	1	0	0	2	0	1	0	26	
				2	2	1	0	1	1	2	2	1	0	2	1	1	0	2	1	0	2	1	0	0	0	2	0	1	0	21	
				3	1	1	0	1	1	2	2	1	0	2	1	1	0	2	1	0	2	0	0	0	0	1	0	0	0	16	
				4	0	0	0	1	1	2	1	0	0	1	2	1	0	2	0	0	2	0	0	0	0	0	0	0	0	11	
1	144	ARF		6	0	0	0	1	1	2	0	0	1	1	1	0	1	0	2	0	0	0	0	0	0	0	0	8			
				-1	4	2	1	2	2	0	4	0	2	4	2	0	2	2	2	2	3	0	0	0	2	0	1	1	33		
				0	4	2	1	2	2	1	3	0	4	3	3	0	2	2	2	2	3	0	0	0	0	1	0	0	0	34	
				1	4	2	1	2	1	3	0	2	3	3	0	1	2	2	2	2	2	0	0	0	0	1	0	0	0	30	
				2	3	2	1	1	2	1	3	0	1	2	2	0	2	2	2	2	2	2	0	0	0	1	0	0	0	25	
				3	2	2	1	1	2	1	2	0	1	2	2	0	1	2	2	2	2	2	0	0	0	1	0	0	0	21	
1	145	SLD		5	1	2	1	1	2	1	1	0	1	1	1	1	1	0	2	2	1	0	0	0	1	0	0	17			
				6	1	2	0	1	1	0	0	1	1	1	1	1	1	1	0	2	1	0	0	0	0	1	0	0	15		
				-1	4	0	2	1	0	2	4	3	0	4	3	0	4	3	1	2	1	1	1	1	1	2	0	1	0	32	
				0	4	1	1	2	1	1	3	1	0	4	4	1	2	1	2	1	2	1	2	0	1	1	0	0	0	0	30
				1	4	1	1	2	1	1	3	1	0	3	3	1	2	1	2	2	1	0	1	0	0	1	2	0	0	1	30
				2	3	1	1	2	1	0	2	1	0	2	3	1	2	1	2	1	1	0	0	1	0	0	1	0	0	0	22
1	146	LRM		4	2	1	0	2	0	0	1	0	0	1	1	1	1	1	1	0	1	1	0	0	1	0	0	0	18		
				5	1	1	0	2	0	0	1	1	0	1	1	0	1	1	1	1	1	0	1	0	0	1	0	0	0	12	
				6	1	1	0	2	0	0	1	1	0	0	2	0	0	1	0	0	1	0	1	0	0	1	0	0	0	11	
				-1	3	1	0	2	1	1	3	0	2	4	3	1	2	1	1	1	1	1	1	0	1	2	0	1	0	29	
				0	4	2	1	2	2	0	3	0	2	3	3	0	2	2	2	2	2	2	1	2	0	2	0	1	0	32	
				1	4	2	1	2	2	0	3	0	1	2	2	0	2	2	2	2	2	1	0	0	0	2	0	1	0	26	
1	147	JGM		2	3	2	1	2	2	0	3	0	1	2	2	2	2	2	2	2	2	0	0	0	1	0	0	0	23		
				3	2	2	1	2	1	0	2	0	1	2	2	0	2	2	2	2	2	0	0	0	0	1	0	0	0	19	
				4	2	2	1	2	1	0	2	0	1	1	1	0	2	2	2	2	2	0	0	2	0	1	0	0	0	20	
				5	1	1	1	2	1	0	1	1	1	1	0	1	1	1	1	1	2	2	0	0	0	1	0	0	0	15	
				6	1	1	1	2	0	0	1	0	1	1	0	2	0	2	2	2	2	2	0	0	0	0	1	0	0	0	13
				-1	4	0	0	2	2	1	3	2	0	4	3	0	4	3	0	2	1	1	1	1	1	2	0	1	0	30	
1	148	CAS		0	3	0	0	2	2	1	4	2	0	4	3	0	2	1	2	1	1	2	0	1	2	0	1	0	30		
				1	4	0	1	2	2	1	4	0	4	3	2	2	1	2	2	1	1	2	2	1	1	1	0	1	0	37	
				2	4	0	1	2	2	1	4	0	4	3	3	2	2	1	2	2	1	1	2	2	1	1	0	1	0	36	
				-1	3	1	1	2	1	1	3	0	4	3	1	2	1	2	1	2	0	1	2	0	1	1	0	0	0	30	
				0	4	1	1	2	1	1	3	0	4	3	1	2	1	2	1	1	1	0	0	0	0	2	0	0	0	30	
				1	3	1	1	2	1	1	3	0	4	3	1	2	1	2	1	1	1	0	0	0	0	0	2	0	0	0	29
1	149	JGM		2	2	1	1	1	1	2	0	2	0	2	2	0	2	2	2	2	2	1	0	0	2	0	0	0	22		
				3	1	1	0	1	1	1	1	1	1	2	0	2	2	2	2	2	2	2	1	0	0	0	0	0	0	19	
				4	1	1	0	1	1	1	1	1	2	0	2	2	2	2	2	2	2	2	1	0	0	0	0	0	0	0	16
				5	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	2	2	1	0	0	0	0	0	0	0	9
				6	0	0	0	1	1	2	0	0	1	1	0	1	1	0	2	0	0	0	0	0	0	0	0	0	0	0	8
				-1	4	0	0	1	1	2	2	1	4	3	0	4	3	0	2	1	1	1	1	1	1	2	0	1	0	30	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBORETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit																				Total Score			
			It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20		It.21		
1	148	CAS	6	0	0	0	1	1	1	1	2	0	1	1	0	0	2	0	0	0	0	0	0	10		
1	149	SC	-1	4	0	0	2	2	1	4	1	0	4	3	2	2	1	1	2	1	1	0	0	32		
			0	4	0	0	2	2	2	4	2	0	4	3	2	2	1	1	0	1	1	0	0	32		
			1	4	0	0	2	2	1	4	2	0	4	3	1	2	2	1	1	1	0	0	1	33		
			2	3	0	0	2	2	1	3	2	0	3	2	2	2	1	0	0	1	1	0	0	28		
			3	2	0	0	2	2	0	2	2	0	2	2	2	2	1	0	0	1	1	0	1	22		
			4	1	0	0	2	2	0	1	1	0	2	1	0	2	2	1	1	0	0	1	1	18		
			5	1	0	0	2	2	1	1	1	0	2	1	0	2	1	1	0	0	1	2	0	14		
			6	0	0	0	2	2	0	0	1	0	1	1	0	0	1	1	0	0	0	0	1	10		
1	150	VA	-1	3	1	2	2	0	2	4	0	3	4	3	1	2	1	2	1	1	2	0	1	0	35	
			0	3	1	2	2	0	2	4	0	3	4	3	1	2	2	2	0	2	0	1	0	1	0	36
			1	4	1	2	2	0	2	4	0	3	4	3	2	2	1	2	0	2	0	1	0	1	0	37
			2	4	1	1	2	0	2	4	0	3	4	3	2	2	1	0	0	1	0	1	0	1	0	31
			3	2	1	1	2	0	2	4	0	3	3	3	1	2	2	0	0	1	0	1	0	1	0	27
			4	2	0	0	2	0	2	2	0	2	2	2	0	2	2	0	0	0	2	0	1	0	0	21
			5	1	0	0	2	0	1	1	0	2	1	1	0	2	2	0	0	0	2	0	1	0	0	16
			6	0	0	0	2	0	1	0	0	1	1	0	0	2	1	0	0	0	0	0	1	0	0	9
2	001	IK	-1	2	1	2	1	1	2	3	2	1	3	0	1	1	1	1	0	0	2	0	0	0	0	24
			0	3	0	2	1	1	2	3	2	1	3	0	1	1	1	1	0	0	2	0	0	0	0	24
			1	3	0	1	1	1	2	3	2	1	3	0	1	1	1	0	0	0	2	0	0	0	0	22
			2	2	1	1	1	0	0	3	2	0	2	1	0	1	1	0	0	1	0	0	1	0	0	16
			3	1	0	0	1	0	0	3	1	1	2	1	0	0	1	0	0	1	0	0	1	0	0	12
			4	2	0	1	0	0	1	3	1	1	2	1	0	0	0	1	0	0	1	0	0	0	0	15
2	32	BE	-1	2	0	1	1	1	2	3	2	1	3	2	1	1	1	2	0	0	2	0	0	0	0	25
			0	3	0	0	1	1	2	4	3	1	3	3	2	2	1	2	0	0	2	0	0	0	0	30
			1	3	1	1	1	2	2	3	2	1	2	2	1	1	0	1	0	0	1	0	0	0	0	24
			2	3	1	1	1	2	2	3	2	1	2	2	1	1	0	1	0	0	1	0	0	0	0	24
			3	3	1	3	1	2	2	3	2	1	2	2	1	1	0	1	0	0	1	0	0	0	0	26
2	33	HS	-1	3	1	1	0	1	2	3	2	2	2	2	0	1	0	2	0	0	1	0	0	1	0	24
			0	3	2	2	0	1	2	3	3	2	2	2	0	2	0	2	0	0	1	0	0	2	2	29
			1	3	2	2	1	2	2	3	3	2	2	2	0	2	0	1	0	0	1	0	0	2	2	30
			2	3	3	2	1	2	2	3	3	2	2	1	2	0	2	0	0	0	0	0	0	2	2	33
			3	4	3	3	1	2	2	3	3	2	3	3	1	2	0	2	0	0	0	0	1	0	2	37
2	34	EH	-1	3	1	3	1	2	2	3	2	2	1	1	0	2	0	2	0	0	1	0	0	2	0	28
			0	3	1	3	1	2	2	3	2	2	1	1	0	2	0	1	0	0	1	0	0	2	2	27
			1	3	0	2	1	1	1	3	2	2	1	1	0	2	0	1	0	0	1	0	0	2	2	22
			2	2	1	1	1	1	1	3	1	2	1	1	0	2	0	1	0	0	1	0	0	2	2	25
			3	2	1	1	1	1	1	2	1	1	2	1	0	1	0	1	0	0	1	0	0	2	2	18
			4	2	1	1	1	1	1	2	1	2	2	2	0	1	1	1	0	1	0	1	0	2	2	23
3	1	AHR	-1	3	1	3	1	1	1	4	2	2	1	1	1	2	2	0	1	1	0	0	1	0	0	28
			0	3	2	1	1	2	1	4	2	2	1	1	1	2	3	0	1	1	0	0	0	0	0	28

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOMETINE - PROTOCOL 20124/013
Listing No.: 10.1

HAMILTON DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	HAMILTON DEPRESSION RATING SCALE																				Total Score	
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20		It.21
3	1	ANR	1	2	2	1	1	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	9	
			2	0	1	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	4	
			3	0	1	0	0	1	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	3	
			4	0	1	0	1	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	4	
3	2	FIL	-1	2	3	1	1	1	1	3	2	2	0	1	1	0	2	0	1	0	0	0	1	24	
			0	3	2	1	1	2	1	1	2	1	0	0	0	0	0	0	0	1	0	0	0	22	
			1	2	1	1	2	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	10	
			2	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	4	
			3	0	1	0	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	
			4	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	2
3	3	DUB	5	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	
			6	0	0	0	1	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	3	
			-1	3	2	2	1	1	4	1	3	2	1	0	1	1	3	0	0	0	0	0	0	1	28
			0	3	2	3	2	1	1	4	2	2	1	1	2	1	3	1	0	0	0	0	0	0	31
			1	2	3	0	2	1	1	2	1	1	1	0	0	0	2	0	0	0	0	0	0	0	16
			2	1	1	0	2	1	1	2	1	1	0	0	0	0	0	0	1	0	0	0	0	0	11
3	00	CJL	3	0	0	0	2	1	1	1	0	3	0	0	0	0	0	0	0	0	0	0	0	8	
			4	0	0	0	1	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	5	
			5	1	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	
			6	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
			-1	3	0	1	2	2	2	4	3	1	3	2	1	1	0	0	0	0	0	0	0	1	26
			0	4	1	1	2	2	4	2	4	2	3	2	1	2	1	0	0	0	0	0	0	0	27
3	05	AUD	1	1	1	1	1	0	1	3	3	0	2	1	1	1	0	0	2	0	0	0	0	18	
			2	0	0	0	1	0	1	1	2	0	1	0	0	0	0	0	0	0	0	0	0	6	
			3	1	0	0	0	1	2	2	1	1	0	0	0	0	0	0	1	0	0	0	0	10	
			4	1	0	0	0	2	2	3	1	1	1	1	0	0	0	0	0	0	0	0	0	14	
			5	1	0	1	0	0	1	1	1	1	0	0	1	0	0	0	0	0	0	1	0	0	7
			6	3	1	4	1	1	2	3	3	0	3	3	1	2	0	0	0	0	0	2	0	0	29
3	5	MMA	-1	2	2	1	1	1	0	3	0	2	4	2	1	1	1	2	1	0	0	0	1	25	
			0	2	1	0	1	0	3	0	2	4	2	0	1	1	1	1	0	0	0	0	0	1	22
			1	2	2	1	1	0	2	3	0	2	4	2	1	0	1	0	1	0	0	0	0	1	23
			2	0	0	0	1	0	1	0	0	2	1	0	0	0	1	0	0	0	0	0	0	1	5
			3	0	0	0	1	0	0	1	0	0	2	0	0	0	1	0	0	0	0	0	0	0	8
3	6	AJP	4	1	1	0	0	1	0	1	0	0	4	1	0	0	0	0	0	0	0	0	1	11	
			5	1	0	0	0	1	0	0	1	0	0	4	1	0	0	0	0	0	0	0	0	1	5
			-1	3	2	1	0	2	0	2	1	1	3	3	1	1	1	1	0	0	0	0	1	1	25
			0	3	2	1	1	2	2	1	1	3	3	1	1	1	0	0	0	0	0	0	1	1	26
			1	3	1	1	1	2	2	1	1	3	2	2	1	1	0	0	0	0	0	0	1	0	24
3	7	GRI	-1	3	1	3	2	0	1	3	1	1	1	0	1	0	1	0	1	0	0	0	0	23	
			0	2	2	1	1	1	2	1	1	3	1	1	1	1	1	1	0	2	0	0	0	0	25
			1	1	1	1	0	0	2	1	0	2	1	1	0	1	0	0	0	0	0	0	0	0	12
			2	1	1	0	1	0	0	1	1	0	1	0	1	0	0	0	1	0	0	0	9		

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	HAMILTON DEPRESSION RATING SCALE																								Total Score
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	It.22			
8	3	JL	5	2	1	0	1	0	1	1	0	1	0	0	1	2	0	0	0	1	0	0	0	0	11			
			6	2	1	0	1	1	0	1	0	0	1	0	0	1	2	0	0	1	0	0	0	0	12			
	4	BA	-1	3	2	2	2	2	3	2	2	3	2	0	1	2	1	0	0	1	0	0	0	0	30			
			0	2	2	1	2	4	2	3	2	0	1	2	1	0	0	1	0	0	1	0	0	0	31			
			1	2	2	1	2	3	2	1	2	1	0	1	0	0	1	0	0	1	0	0	0	0	24			
			2	1	0	0	1	1	2	1	0	1	0	1	2	1	0	0	1	0	0	1	0	0	0	13		
5	0	3	1	0	0	1	1	1	1	0	1	0	0	1	2	1	0	0	1	0	0	0	0	12				
		4	0	0	1	1	1	1	1	0	1	0	0	2	0	0	0	0	0	0	0	0	0	7				
		5	0	0	0	1	1	1	1	0	0	0	0	2	0	0	0	0	0	0	0	0	0	5				
		6	0	0	0	1	0	1	1	0	0	0	0	2	0	0	0	0	0	0	0	0	0	4				
8	5	SL	-1	2	4	2	2	2	4	1	1	2	2	1	2	2	2	0	0	0	0	0	0	0	33			
			0	2	2	2	2	4	1	1	2	2	1	2	2	2	2	0	0	0	0	0	0	0	32			
			1	2	4	2	2	4	1	1	2	2	1	2	2	1	2	2	0	0	0	0	0	0	31			
			2	1	2	0	1	1	3	1	0	1	1	1	1	2	1	0	0	0	0	0	0	0	0	17		
			3	1	2	0	1	1	3	1	0	1	1	1	1	2	1	0	0	0	0	0	0	0	0	17		
			4	1	1	0	1	1	1	2	1	0	0	1	1	2	1	0	0	0	0	0	0	0	0	12		
8	CO	CT6	5	1	0	0	1	1	1	2	1	0	0	0	1	2	1	0	0	0	0	0	0	0	11			
			6	1	0	0	1	0	0	1	1	0	0	0	1	2	1	0	0	0	0	0	0	0	0	8		
			-1	3	2	1	1	1	2	4	1	1	2	1	2	1	2	1	2	0	1	0	0	0	0	28		
			0	3	2	1	2	2	4	2	2	1	2	1	2	1	2	1	2	0	1	0	0	0	0	32		
			1	2	2	1	1	1	2	4	1	1	2	1	1	1	2	1	1	1	0	1	0	0	0	25		
			2	1	1	0	1	0	1	3	1	0	1	1	1	0	2	0	0	0	1	0	0	0	0	14		
8	7	SZT	3	1	1	0	1	0	0	2	0	0	1	1	0	2	0	0	0	1	0	0	0	0	10			
			4	1	0	0	1	0	0	2	0	0	1	1	0	2	0	0	0	1	0	0	0	0	9			
			5	1	0	0	1	0	0	2	0	0	1	1	0	0	0	0	0	0	1	0	0	0	8			
			6	1	0	0	1	0	0	2	0	0	1	1	0	0	1	0	0	0	1	0	0	0	8			
			-1	2	2	1	2	2	1	2	1	1	2	1	2	1	2	1	2	0	1	0	0	0	0	22		
			0	2	2	1	2	2	1	2	1	1	2	1	2	1	2	1	2	0	1	0	0	0	0	23		
9	1	US	1	2	1	1	2	1	2	2	1	2	0	1	0	2	1	0	0	1	0	0	0	0	21			
			2	1	1	2	1	2	2	1	2	0	1	1	0	2	1	0	0	1	0	0	0	0	23			
			3	2	1	1	2	2	1	2	2	1	2	0	1	0	2	1	0	0	1	0	0	0	21			
			-1	3	3	3	1	2	1	3	2	0	2	1	1	2	3	0	1	0	1	0	0	0	0	29		
			0	3	3	3	1	2	2	3	0	3	3	1	1	1	3	0	1	1	0	2	0	0	0	34		
			1	3	3	2	1	1	2	3	0	3	3	1	1	1	3	0	1	1	0	2	0	0	0	32		
9	2	VCF	2	3	3	2	1	1	2	3	0	2	1	1	1	2	0	1	1	0	2	0	0	0	27			
			3	3	2	2	1	1	3	3	0	2	1	1	1	2	0	1	1	0	2	0	0	0	28			
			4	3	2	2	1	1	2	2	0	1	1	1	1	2	0	1	1	0	1	0	0	0	25			
			5	3	3	2	1	1	1	3	2	0	1	1	1	2	0	1	1	2	0	1	1	0	0	25		
			6	3	2	2	1	1	1	3	2	0	2	1	1	2	0	1	1	2	0	1	1	0	0	27		
			-1	3	2	2	1	1	1	3	2	0	2	1	1	1	2	0	1	1	0	2	0	0	0	27		
9	2	VCF	0	3	2	2	1	1	1	2	1	0	2	1	1	2	0	1	0	0	0	0	0	0	23			
			1	2	2	1	1	1	2	1	0	2	1	1	1	2	0	1	1	0	1	0	0	0	25			
			2	3	2	2	1	1	2	1	1	2	1	1	1	1	2	0	1	1	0	0	0	0	1	0		
			3	2	2	1	1	1	2	1	1	2	1	1	1	1	2	0	1	1	0	0	0	0	0	26		
			4	3	2	2	1	1	1	2	0	1	1	1	1	1	2	0	1	1	0	0	0	0	0	26		
			5	3	3	2	1	1	1	3	2	0	1	1	1	1	2	0	1	1	0	2	0	0	0	27		

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 RESOMETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score	
9	7	PP	5	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	4
			6	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3
9	8	KTM	-1	3	1	2	1	2	3	2	0	2	3	2	1	2	1	0	1	2	0	0	0	0	0	30
			0	3	2	2	1	2	3	1	2	3	1	2	3	1	2	2	0	1	1	0	0	0	0	30
			1	3	2	2	1	2	3	2	0	2	3	1	2	1	0	1	0	1	1	0	0	0	0	29
			2	2	1	1	1	1	3	3	0	2	3	2	2	1	1	2	0	2	0	1	0	0	0	32
			3	3	2	1	1	1	3	3	0	2	3	2	2	1	1	2	0	1	2	0	0	0	0	28
			4	3	2	1	1	1	3	3	0	2	2	2	2	1	1	2	0	1	0	0	0	0	0	28
			5	3	2	1	1	1	3	3	0	2	2	2	2	1	1	1	0	1	0	0	0	0	0	28
			6	3	3	2	1	1	3	3	0	3	2	2	2	2	1	2	2	1	1	0	0	0	0	32
9	10	BG	-1	3	2	3	1	1	0	3	2	0	1	2	1	1	2	2	0	1	1	0	0	0	0	27
			0	3	2	3	1	1	1	2	3	0	3	2	1	1	2	1	0	1	1	0	0	0	0	29
			1	3	2	2	1	1	1	2	2	0	2	2	1	1	2	2	0	1	1	0	0	0	0	27
			2	3	2	2	1	1	1	2	2	0	2	2	1	1	2	0	1	1	1	0	0	0	0	26
			3	3	3	2	1	1	1	3	3	0	2	2	1	1	1	2	0	1	1	0	0	0	0	28
			4	3	2	3	1	1	2	3	3	0	2	2	2	2	2	0	1	1	1	0	0	0	0	33
			5	3	2	2	2	1	1	3	2	0	2	2	2	2	2	0	1	1	1	0	0	0	0	29
			6	3	2	2	2	1	1	3	2	0	2	2	2	2	1	1	0	1	1	0	0	0	0	28
9	11	KE	-1	3	2	2	1	1	1	2	2	0	1	2	2	1	2	1	0	1	1	0	0	0	0	25
			0	3	2	2	1	1	1	2	2	0	2	2	1	1	1	1	0	1	1	0	0	0	0	25
			1	2	2	1	1	1	1	2	2	0	1	1	1	1	1	1	0	1	1	0	0	0	0	20
			2	1	1	0	1	0	0	1	0	0	1	1	0	0	0	1	0	1	0	0	0	0	0	8
			3	1	0	0	1	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	5
			4	0	0	0	1	0	0	0	0	0	1	1	1	0	0	0	0	1	0	0	0	0	0	5
			5	0	0	0	1	0	0	1	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	4
			6	0	0	0	1	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	3
9	12	GYT	-1	3	2	2	2	1	1	3	2	0	2	2	2	1	1	2	0	1	1	0	0	0	0	28
			0	3	2	2	1	1	1	3	2	0	1	2	2	1	2	0	1	1	1	0	0	0	0	27
			1	2	2	1	1	0	2	2	0	1	2	2	1	1	2	0	2	1	2	0	0	0	0	25
			2	2	2	1	1	0	2	2	0	1	1	1	1	1	0	1	0	1	1	0	0	0	0	19
			3	1	1	1	1	0	0	1	0	0	1	1	1	1	0	0	1	0	1	0	0	0	0	11
			4	1	1	1	0	0	1	1	0	0	1	1	1	0	0	1	0	1	0	0	0	0	0	11
			5	1	1	1	1	0	1	1	0	0	1	1	1	0	1	0	0	1	1	0	0	0	0	10
			6	1	1	1	1	0	1	1	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	6

860

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	HAMILTON DEPRESSION RATING SCALE																				Total Score		
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20		It.21	
9	13	BP	-1	2	2	2	1	1	3	2	0	1	2	1	1	1	2	0	1	1	0	0	0	25		
			0	2	2	1	1	1	2	0	1	1	1	1	1	1	1	1	0	1	1	0	0	22		
			1	2	2	1	1	1	3	2	0	1	2	2	1	1	1	1	0	1	1	0	0	24		
			2	2	2	1	1	1	3	1	0	1	2	1	1	1	1	2	0	1	1	0	0	23		
			3	2	2	1	0	1	2	2	0	2	2	1	1	1	1	1	0	2	1	0	0	0	18	
			4	2	1	1	1	0	2	2	0	1	1	1	1	1	1	1	0	1	1	0	0	0	8	
9	14	SZF	5	1	0	0	1	0	1	0	0	1	1	1	1	0	0	0	0	0	0	0	6			
			6	0	0	0	1	0	0	1	1	0	1	1	0	0	0	0	0	0	0	0	0	6		
			-1	3	3	2	1	2	2	4	3	0	2	2	1	2	1	3	0	2	1	0	0	34		
			0	3	3	2	1	2	2	5	3	0	3	3	1	2	1	3	0	2	1	0	0	35		
			1	3	3	3	1	1	1	3	3	0	3	3	2	2	2	2	0	2	1	0	1	0	36	
			2	3	3	3	1	1	1	3	3	0	3	3	2	2	2	2	0	2	1	0	1	0	36	
8	61		3	3	3	3	1	1	1	4	4	0	3	3	2	2	2	0	2	1	0	1	0	44		
			4	3	3	3	1	1	1	4	4	0	3	3	2	2	2	3	0	2	1	4	2	0	44	
			5	3	3	3	1	1	1	4	3	0	3	3	2	2	2	1	3	0	1	1	1	2	0	38
			6	3	3	3	1	1	1	3	3	0	3	3	2	2	2	1	3	0	1	1	1	2	0	39
			1	3	3	3	2	1	1	1	3	3	0	3	3	1	1	1	2	0	1	1	1	2	0	33
			2	3	2	2	2	2	2	3	3	0	3	2	1	1	1	3	0	1	1	0	0	0	32	
9	15	BI	-1	3	2	2	2	2	3	3	0	3	2	1	1	1	3	0	1	1	0	0	0	32		
			0	3	2	2	2	2	3	3	0	2	2	2	2	2	2	0	2	1	1	1	0	33		
			1	3	2	2	2	1	1	2	2	0	2	2	1	1	1	2	0	1	1	1	0	28		
			2	2	2	2	2	1	1	2	2	0	2	2	1	1	1	3	0	1	1	0	0	26		
			3	2	2	1	1	1	1	2	1	1	0	1	1	1	1	1	0	1	1	0	0	0	19	
			4	1	1	1	1	1	0	1	1	0	1	1	1	1	0	1	0	0	0	0	0	0	12	
9	16	UGY	5	1	1	0	0	1	1	0	1	0	1	1	0	0	0	0	0	0	0	0	0	8		
			6	1	0	0	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	5		
			-1	3	2	1	1	1	1	3	2	0	2	2	1	1	1	3	0	1	1	0	0	26		
			0	3	2	2	1	2	1	3	3	0	2	2	1	1	1	1	3	1	1	0	0	0	30	
			1	3	2	2	1	1	2	3	3	0	1	2	1	1	1	1	3	0	1	1	0	0	28	
			2	2	1	1	1	1	1	3	2	0	1	1	1	1	1	2	1	1	1	0	0	0	21	
9	17	NL	3	1	1	0	1	1	0	2	1	0	1	1	0	1	1	2	0	1	0	0	0	14		
			4	1	0	0	1	0	0	1	1	0	0	1	1	0	1	0	0	0	0	0	0	8		
			5	1	0	0	1	0	0	1	0	0	1	1	0	1	1	0	0	0	0	0	0	8		
			6	1	0	0	1	0	0	1	0	0	1	1	0	1	1	0	0	0	0	0	0	9		
			-1	3	2	1	2	1	1	3	2	0	1	1	1	1	1	3	0	1	1	0	0	0	23	
			0	3	2	2	1	1	1	3	2	0	1	1	1	1	1	3	0	1	1	0	0	0	26	
9	18	HBH	1	3	2	2	1	1	1	3	2	0	1	1	1	1	1	2	0	1	1	0	0	24		
			2	2	2	1	1	1	1	2	2	0	1	1	1	1	1	1	0	1	1	0	0	20		
			-1	3	2	2	1	1	1	3	2	0	1	2	1	1	1	3	0	1	1	0	0	26		
			0	3	2	3	1	1	1	3	3	0	2	3	1	1	1	2	0	1	1	0	0	0	29	
			1	3	2	3	1	1	1	3	3	0	3	2	1	1	1	3	0	1	1	0	0	0	30	
			2	2	2	2	1	1	0	2	2	0	1	2	1	1	1	1	0	0	1	0	0	0	20	
9	14		3	1	1	0	1	1	0	1	1	0	1	1	1	1	1	0	1	1	0	0	0	14		
			4	1	1	0	1	1	0	1	1	0	1	1	1	1	1	1	0	1	1	0	0	10		
			5	1	1	0	1	1	0	1	1	0	1	1	1	1	1	1	0	1	1	0	0	10		
			4	1	1	0	1	1	0	1	1	0	1	1	1	1	1	1	0	0	0	0	0	0	8	
			5	1	1	0	1	1	0	1	1	0	0	1	1	1	1	1	0	0	0	0	0	0	8	
			6	1	1	0	1	1	0	1	1	0	0	1	1	1	1	1	0	0	0	0	0	0	8	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Patient Centre No.	Initials	Visit No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score	
9	18	MBH	6	3	2	3	1	1	3	3	0	3	2	1	1	1	2	0	0	1	2	0	0	0	30
9	19	KF	-1	3	2	2	1	1	3	2	0	1	2	1	1	1	2	0	0	1	1	0	0	0	25
			0	3	2	2	1	1	3	2	0	2	2	1	1	1	2	0	0	1	1	0	0	0	26
			1	3	2	1	1	0	2	2	0	1	1	1	1	1	2	0	0	1	1	0	0	0	21
			2	1	0	1	0	1	1	0	1	0	1	1	0	0	0	0	0	1	0	0	0	0	9
			3	1	0	0	1	0	1	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0	6
			4	0	0	0	1	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	6
			5	0	0	0	1	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	5
			6	0	0	0	1	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	4
9	20	CYE	-1	3	3	3	1	1	3	3	0	2	3	1	1	1	3	0	1	1	2	0	0	0	32
			0	3	3	1	1	1	3	2	0	2	2	1	1	1	3	0	1	1	1	0	0	0	31
			1	3	2	2	1	1	2	2	0	1	1	1	1	1	1	0	0	1	0	0	0	0	21
			2	2	2	1	1	0	2	2	0	2	1	1	1	1	1	0	0	1	0	0	0	0	18
			3	1	1	0	1	0	2	2	0	1	1	1	0	0	1	0	0	1	0	0	0	0	11
			4	1	0	0	1	0	1	1	0	0	1	1	0	0	1	0	0	0	0	0	0	0	7
			5	0	0	0	1	0	1	1	0	0	1	1	0	0	1	0	0	0	0	0	0	0	6
			6	1	0	0	1	0	1	1	0	1	1	1	0	0	1	0	0	0	0	0	0	0	8
9	22	TA	-1	3	2	2	1	1	2	2	0	1	2	1	1	1	2	0	1	1	1	0	0	0	24
			0	2	2	1	1	1	2	2	0	1	1	2	1	1	2	0	0	1	1	0	0	0	24
			1	2	2	1	1	1	2	1	0	1	1	1	1	1	2	0	0	1	2	0	0	0	22
			2	2	1	1	1	0	2	1	0	1	2	1	1	1	2	0	0	1	2	0	0	0	22
			3	1	1	0	1	1	1	1	0	1	1	1	0	0	1	0	0	1	0	0	0	0	15
			4	1	1	0	1	0	1	1	0	1	1	1	1	1	2	0	0	1	0	0	0	0	14
			5	1	0	0	1	0	2	1	0	1	1	1	0	0	1	0	0	0	0	0	0	0	9
			6	1	0	0	1	0	1	1	0	0	1	1	0	1	0	0	0	0	0	0	0	0	7
9	23	SZN	-1	2	2	2	1	1	2	2	0	1	1	2	1	1	2	0	1	1	1	0	0	0	23
			0	2	2	1	1	1	2	2	0	1	1	1	1	1	2	0	0	1	1	0	0	0	22
			1	2	2	1	1	1	2	2	0	1	1	1	1	1	2	0	0	1	2	0	0	0	21
			2	2	1	0	1	1	2	2	0	1	1	1	1	1	2	0	0	1	1	0	0	0	19
			3	1	1	0	1	1	1	0	2	2	2	1	1	1	1	0	0	1	0	0	0	0	16
			4	2	1	0	1	1	0	2	0	1	2	1	1	1	1	0	0	1	0	0	0	0	16
			5	1	1	0	1	1	0	1	2	0	1	2	1	1	2	0	0	1	0	0	0	0	16
			6	1	1	0	1	0	1	2	0	1	2	1	1	1	1	0	0	1	0	0	0	0	15
9	24	LCY	-1	2	2	2	1	1	2	2	0	1	2	1	1	1	3	0	0	1	1	0	0	0	25

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Patient No.	Centre No.	Initials	Visit	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score		
9	29	SZF	3	1	1	0	1	1	2	0	1	2	0	1	1	1	0	0	1	0	0	0	0	0	0	12	
			4	1	1	0	1	0	0	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	9	
			5	1	1	0	0	0	1	1	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	5
			6	1	0	0	0	0	1	1	0	0	1	0	0	0	1	0	0	0	0	1	0	0	0	0	5
			-1	3	2	2	1	1	1	2	2	0	1	2	0	1	1	1	1	0	1	0	0	0	0	0	21
			1	2	2	1	1	2	0	1	1	1	1	1	1	1	1	0	0	2	1	0	0	0	0	0	21
9	30	NF	2	2	2	0	1	1	1	1	1	1	1	1	1	1	0	0	2	1	0	0	0	0	0	22	
			1	2	2	0	1	1	1	1	1	1	1	1	1	1	0	0	1	0	0	0	0	0	0	15	
			3	1	1	0	1	0	1	1	1	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0	9
			4	1	1	0	1	0	1	1	1	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0	8
			5	1	1	0	1	0	0	1	1	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0	6
			6	1	0	0	1	0	1	1	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	6
10	1	VK	-1	4	1	3	1	2	2	0	2	3	2	1	2	2	1	2	1	2	0	1	0	1	0	32	
			0	3	1	1	2	2	0	1	2	1	2	1	0	2	1	0	0	0	0	0	0	0	0	21	
			1	3	1	0	1	2	1	2	2	1	2	1	0	1	0	1	0	0	0	0	0	0	0	0	18
			2	3	1	0	0	2	1	2	0	2	2	1	0	1	0	0	0	0	0	0	0	0	0	0	15
			4	3	0	0	1	2	1	2	0	2	1	0	0	2	1	0	1	0	0	1	0	0	0	0	20
			5	3	0	0	1	2	0	2	0	2	1	0	0	1	0	1	0	1	0	0	1	0	0	0	15
10	4	ZSD	6	3	0	0	0	1	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	10	
			-1	4	1	1	2	0	4	1	2	4	2	1	1	2	1	2	1	2	0	1	0	0	0	0	30
			0	4	1	1	2	2	4	1	2	4	3	1	2	1	2	1	1	1	1	0	0	0	0	0	33
			1	3	1	1	2	2	4	1	2	3	3	0	1	2	1	0	0	0	0	0	0	0	0	0	28
			2	3	1	1	2	2	3	0	1	1	2	0	1	2	1	0	0	0	0	0	0	0	0	0	22
			3	3	1	1	2	2	3	0	1	1	2	0	1	2	1	0	0	0	0	0	0	0	0	0	23
10	5	AN	4	3	1	1	2	2	1	2	0	1	2	2	0	1	1	1	1	0	0	0	0	0	0	20	
			5	3	1	0	2	2	0	2	0	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	18
			6	3	0	0	2	1	0	2	0	0	1	1	0	1	1	0	1	1	0	0	0	0	0	0	12
			-1	4	2	3	0	0	0	3	1	2	2	3	0	2	2	3	0	1	2	2	1	2	1	0	33
			0	4	2	3	0	0	0	3	1	2	2	3	0	2	2	3	0	1	2	3	0	1	2	0	31
			1	4	2	3	0	0	1	0	2	0	2	2	1	1	0	2	2	3	0	1	2	0	0	0	27
10	6	RS	2	3	1	0	0	0	0	2	1	1	1	1	1	0	2	2	0	0	1	1	0	0	0	18	
			3	2	0	0	0	0	1	0	1	0	1	1	1	0	2	0	1	2	0	1	1	0	0	0	14
			4	2	0	0	0	0	1	0	1	1	1	1	1	0	2	1	2	0	1	1	0	0	0	0	14
			5	0	0	0	0	0	1	1	0	0	1	1	1	0	1	1	1	0	1	1	0	0	0	0	7
			6	0	0	0	0	0	1	1	0	0	1	1	0	0	1	1	0	1	1	0	0	0	0	0	7
			-1	3	2	2	2	2	3	1	1	2	3	1	1	2	3	1	2	1	2	1	1	1	1	0	0
10	30	0	3	2	2	2	2	3	0	1	2	3	1	1	2	1	0	1	0	1	1	1	0	0	0	30	
			1	3	1	1	0	1	1	2	1	1	3	1	1	2	1	0	1	0	1	1	0	0	0	0	20
			2	3	1	1	0	1	1	2	0	1	1	1	1	2	0	0	1	0	0	1	0	0	0	0	18
			3	1	1	0	1	1	2	0	1	1	0	1	1	1	0	1	2	0	0	1	1	0	0	0	13
			4	1	1	0	1	1	2	0	0	1	1	0	0	1	0	0	1	0	0	0	1	0	0	0	11
			5	3	1	0	1	1	2	1	1	2	1	0	0	2	1	0	0	1	1	0	0	0	0	0	11

864

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 2012A/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit																				Total Score			
			It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20		It.21		
10	13	HU	-1	4	1	2	2	1	2	4	2	0	3	3	1	2	2	0	1	0	1	2	1	1	35	
			0	3	1	1	2	1	1	4	2	0	3	3	1	2	2	0	1	0	1	2	1	1	32	
			1	3	1	1	2	1	1	3	1	0	3	2	1	2	2	0	2	0	1	2	1	1	30	
			2	3	0	0	2	1	1	3	0	0	1	2	0	2	2	0	2	0	1	0	1	0	21	
			3	3	0	0	2	1	1	2	0	0	2	3	0	2	2	0	0	0	1	0	1	0	0	20
			4	1	0	0	2	1	1	1	0	0	1	2	0	2	2	0	0	0	1	0	1	0	0	15
10	14	AA	5	1	0	0	1	1	1	1	0	0	2	2	0	2	1	0	1	0	1	0	0	14		
			6	1	0	0	1	1	0	1	0	0	1	0	2	1	1	0	0	1	0	0	0	11		
			-1	3	1	1	2	1	1	2	1	0	4	3	1	2	1	0	0	0	1	1	0	1	26	
			0	3	1	1	2	1	1	2	1	0	4	3	1	2	0	0	0	1	1	0	1	0	25	
			1	4	2	1	1	1	3	1	1	4	2	1	2	0	0	0	0	1	0	1	0	1	26	
			2	3	0	0	1	1	2	0	1	2	1	0	2	0	0	0	0	0	1	0	0	1	15	
10	15	HT	3	1	0	0	1	1	2	0	1	2	1	0	2	0	0	0	0	0	1	0	0	12		
			4	1	0	0	1	1	2	0	0	2	1	0	1	0	0	0	0	0	0	0	0	10		
			5	1	0	0	1	1	2	0	0	2	1	0	1	0	0	1	0	0	1	0	0	0	8	
			6	1	0	0	1	1	1	0	0	1	0	0	1	0	0	1	0	0	0	0	0	0	7	
			-1	4	0	3	2	1	2	3	2	1	2	2	3	0	2	2	0	1	1	1	0	1	35	
			0	4	0	2	2	1	2	3	2	2	2	3	0	2	2	0	1	1	1	0	1	1	33	
10	16	AJ	1	3	0	2	2	1	2	3	1	1	2	2	0	2	0	2	1	1	1	0	1	23		
			2	3	0	0	1	2	2	1	1	2	2	0	2	0	2	0	2	1	1	0	1	0	23	
			3	1	0	0	1	0	0	1	0	0	1	0	2	0	1	1	0	1	1	0	0	0	11	
			4	2	0	0	0	0	1	0	0	1	0	0	1	0	2	0	1	1	1	0	0	0	11	
			5	3	0	2	0	0	0	2	0	0	1	1	0	2	0	0	1	0	0	0	0	0	13	
			6	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	2	
10	17	MH	-1	4	1	2	1	1	2	3	1	2	3	4	0	2	1	3	2	1	2	2	1	1	39	
			0	4	1	2	1	1	2	3	1	2	3	4	0	2	1	3	0	1	2	2	1	1	37	
			1	1	0	0	1	1	2	0	1	2	0	1	2	0	2	0	1	1	1	1	1	1	18	
			2	1	0	0	0	1	2	1	0	0	4	3	0	2	1	2	0	1	0	0	1	1	20	
			3	1	0	0	0	2	1	0	0	1	0	2	1	1	1	0	1	1	0	1	0	1	1	15
			4	1	0	0	0	2	1	0	0	2	1	0	1	1	1	0	1	1	1	0	0	0	0	12
10	18	SS	5	1	0	0	1	1	0	0	2	1	0	2	3	0	2	1	1	0	1	1	0	0	14	
			6	0	0	0	1	1	0	0	0	0	1	0	0	2	0	1	0	1	1	0	0	0	8	
			-1	3	1	0	1	1	2	3	1	1	1	2	0	1	1	0	0	0	1	0	0	0	19	
			0	3	1	0	1	1	2	3	1	1	1	2	0	1	1	0	0	0	2	0	0	0	20	
			1	2	1	0	0	2	0	3	0	0	0	2	0	1	0	0	0	0	0	0	0	0	0	11
			2	3	0	0	1	0	3	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	10
10	19	SS	3	1	0	0	0	2	0	1	0	0	1	0	1	0	1	0	0	0	0	0	0	0	8	
			4	3	0	0	0	2	0	1	0	0	1	0	1	0	0	2	0	0	0	0	0	0	10	
			5	2	0	0	2	0	1	0	0	1	1	0	1	0	0	1	0	0	0	0	0	0	9	
			6	1	0	0	2	1	1	0	0	1	0	0	1	0	0	0	1	0	0	0	0	0	6	
			-1	3	0	3	2	1	2	3	1	2	4	3	0	2	1	1	2	0	1	1	1	1	1	34
			1	2	0	1	2	1	2	3	0	2	1	2	2	0	2	1	0	0	1	1	1	1	1	32

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score		
10	18	SS	2	1	0	1	1	1	2	2	0	0	2	2	0	1	1	0	0	0	0	0	0	0	1	15	
			3	1	0	1	0	1	0	0	1	1	1	1	1	0	1	1	0	0	0	0	0	0	1	9	
			4	3	0	2	0	1	2	2	0	1	3	3	0	2	1	0	0	0	0	1	1	1	1	1	24
			5	4	1	2	0	2	2	2	2	2	3	1	2	1	1	1	1	1	1	0	1	1	1	1	31
			6	3	0	1	0	1	0	1	0	1	2	2	2	1	2	1	0	0	0	0	0	0	0	0	16
			-1	3	0	1	2	1	1	2	1	0	2	1	1	2	1	2	1	0	2	1	0	0	0	0	23
10	19	TN	0	3	0	1	2	1	1	2	1	0	2	1	1	2	1	0	0	0	0	0	0	0	0	21	
			1	2	0	0	1	1	1	1	0	1	1	0	1	1	0	0	1	1	0	0	0	0	0	14	
			2	1	0	0	0	1	1	0	0	1	0	0	1	0	2	0	1	0	0	0	0	0	0	10	
			3	1	0	0	0	1	1	0	0	1	1	0	2	0	1	0	1	0	0	0	0	0	0	0	10
			4	1	0	0	0	0	1	0	0	1	1	0	1	0	0	0	1	0	0	0	0	0	0	0	6
			5	1	0	0	0	0	0	1	0	0	1	1	0	0	0	0	1	0	1	0	0	0	0	0	7
10	20	EJ	6	2	0	0	0	0	0	1	0	0	1	2	0	2	0	0	0	0	1	0	0	0	0	11	
			-1	3	1	1	1	0	0	2	1	1	2	2	0	2	0	0	0	0	0	0	1	0	1	0	18
			0	3	1	1	0	0	2	1	1	2	2	0	2	0	0	0	0	0	0	0	1	0	1	0	18
			1	2	0	0	1	1	0	0	1	1	2	0	1	0	2	0	0	2	0	0	1	0	1	0	13
			2	1	0	0	0	1	1	0	0	1	1	0	1	0	2	0	0	0	0	0	1	0	1	0	11
			3	1	0	0	0	1	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4
10	21	AK	4	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	
			-1	4	1	4	0	0	1	2	1	0	2	1	0	2	2	0	2	1	1	0	0	1	0	25	
			0	4	1	4	0	0	1	2	1	0	2	1	0	2	2	0	2	1	1	0	1	0	1	0	25
			1	3	1	2	0	1	2	2	0	0	3	0	1	0	2	2	0	2	1	1	0	0	0	0	23
			2	3	1	3	0	1	2	2	0	0	1	0	0	2	2	0	0	0	0	1	1	0	0	0	19
			3	2	0	0	0	1	1	2	1	0	2	0	0	1	2	2	0	0	1	1	0	0	0	0	15
10	22	AA	4	2	0	0	0	0	1	0	0	2	0	0	1	2	2	0	0	1	0	1	0	0	0	13	
			5	3	0	2	0	1	0	2	0	1	0	1	0	1	2	1	0	0	0	1	1	0	0	15	
			6	1	0	1	0	1	0	1	0	0	1	1	0	1	1	0	1	0	0	0	1	0	0	0	9
			-1	3	2	2	2	2	1	3	1	1	3	4	1	2	1	1	0	1	0	1	2	2	0	0	34
			0	3	2	2	2	1	3	1	3	4	1	3	4	1	2	1	1	0	1	2	2	2	0	0	34
			1	2	1	1	0	1	0	2	0	0	1	2	0	0	2	0	0	2	1	2	0	0	0	0	17
10	23	LT	2	3	1	1	1	1	1	2	0	0	2	1	0	2	0	0	0	0	0	2	0	0	0	11	
			3	2	1	0	1	1	0	0	1	1	0	0	1	0	1	0	0	0	0	0	2	0	0	0	7
			4	1	1	0	0	1	0	0	1	0	0	0	0	0	2	0	0	0	0	0	1	0	0	0	6
			5	1	1	0	0	0	0	1	0	0	1	0	0	1	0	0	0	0	0	0	1	0	0	0	8
			6	0	1	0	0	0	1	0	0	1	0	0	1	1	0	2	0	0	0	0	1	0	0	0	7
			-1	3	0	0	0	0	0	1	1	0	2	2	0	2	0	2	1	0	2	1	1	0	0	0	18
10	23	LT	0	3	0	0	0	0	1	1	0	2	2	0	2	0	2	1	2	2	1	1	0	0	0	18	
			1	2	0	0	1	0	0	2	0	0	2	2	1	2	1	2	2	1	1	0	0	0	0	19	
			2	3	0	0	1	0	2	0	0	1	3	1	2	1	2	1	1	1	1	1	0	0	0	0	20
			3	2	0	0	1	0	2	0	0	2	2	1	2	1	1	0	1	1	0	1	1	0	0	0	16
			4	3	0	0	1	0	1	0	0	2	2	2	2	1	1	0	1	1	0	1	1	0	0	0	16
			-1	3	0	0	0	0	1	0	0	2	2	2	2	1	2	1	1	2	1	1	1	0	0	0	16

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Patient Centre No.	Initials	Visit No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score	
10	23	LT	5	2	0	0	0	0	1	0	0	3	3	1	2	1	1	0	0	0	0	0	0	0	14
10	24	AL	-1	3	0	0	0	1	3	1	2	4	3	2	0	0	1	2	0	1	0	0	0	1	25
			0	1	0	0	0	0	2	0	1	1	1	0	2	0	0	0	0	0	1	0	0	0	31
			1	1	0	0	0	0	0	0	0	1	1	0	2	0	0	0	0	0	1	0	0	0	9
			2	2	0	0	0	0	0	0	0	1	1	0	2	0	0	0	0	0	1	0	0	0	7
			3	1	0	0	0	0	1	0	1	1	1	0	2	0	0	0	0	0	1	0	0	0	8
			4	1	0	0	0	0	0	0	1	1	1	0	2	0	0	0	0	0	1	0	0	0	6
			5	2	0	0	0	0	1	0	1	3	1	1	2	0	0	0	0	0	0	0	0	0	12
			6	3	0	0	0	1	0	0	4	1	0	2	0	0	0	0	0	0	1	0	0	0	13
10	25	ES	-1	4	0	3	2	1	2	2	1	1	3	3	0	0	3	2	1	0	0	0	0	0	28
			0	4	0	3	2	1	2	2	1	1	3	3	0	0	3	2	1	0	0	0	0	0	26
			1	3	0	2	2	1	2	2	0	1	2	2	0	0	3	2	1	0	0	0	0	0	23
			2	4	0	2	2	1	2	2	1	0	3	4	1	0	0	3	0	1	0	0	0	0	26
			3	4	0	2	2	1	0	2	0	1	3	4	1	0	3	0	2	1	0	0	0	0	27
10	26	JIF	-1	3	0	1	2	2	2	3	1	2	3	3	1	2	2	1	0	0	0	0	0	0	32
			0	3	0	1	2	2	2	3	1	0	3	3	1	2	2	1	0	0	0	0	0	0	30
			1	2	0	0	2	2	2	3	0	0	3	3	2	1	2	1	2	0	1	0	0	0	30
			2	3	0	2	1	2	2	3	0	1	3	3	2	1	2	1	2	0	1	0	0	0	30
			3	3	0	2	2	2	2	3	1	0	3	3	1	1	2	1	0	1	0	0	0	0	29
			4	3	0	2	2	2	2	3	0	0	3	3	1	2	2	1	2	0	1	1	0	0	31
			5	2	0	1	1	2	2	3	0	0	2	1	1	2	2	1	1	0	1	0	0	0	22
			6	1	0	0	1	2	2	2	0	0	1	1	2	2	1	1	0	0	1	0	0	0	14
10	27	MK	-1	4	0	1	1	2	2	2	1	0	1	2	0	0	1	0	0	0	1	0	0	0	18
			0	4	0	1	1	2	2	2	1	0	1	2	0	0	1	0	0	0	1	0	0	0	18
			1	4	0	2	0	2	2	1	0	1	2	1	0	0	1	0	0	0	1	0	0	0	17
			2	2	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	6
			3	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	3
			4	1	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	5
			5	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	2
			6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	3
10	28	LL	-1	4	2	3	2	1	1	4	1	1	2	1	0	2	2	0	0	0	1	0	1	0	28
			0	4	2	3	2	1	1	4	1	1	3	1	0	2	2	0	0	0	1	0	1	0	29
			1	3	1	1	1	0	1	2	0	0	2	1	0	2	2	0	0	0	1	0	1	0	18
			2	0	0	0	0	0	2	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	4
			3	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
			4	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	10
			5	0	0	0	0	0	0	0	0	0	2	2	0	0	0	0	0	0	1	0	0	0	5
			6	1	0	0	0	0	0	0	0	0	1	1	0	1	0	0	2	0	1	0	0	0	6
10	29	JJ	-1	4	2	1	2	1	2	2	2	0	2	1	1	0	0	2	1	1	0	1	0	0	26
			0	3	2	1	2	1	2	2	1	1	1	0	0	0	0	0	0	1	1	0	1	0	23
			1	3	1	1	2	2	2	2	1	0	0	1	1	0	0	0	0	0	1	0	0	0	16

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit																				Total Score				
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20		It.21			
10	34	TK	5	1	0	0	1	2	0	0	1	1	0	0	1	0	0	1	0	0	0	0	0	0	0	0	8	
			6	1	1	0	0	1	2	0	0	1	1	0	0	1	0	0	0	0	0	1	0	0	0	0	0	8
10	35	IN	-1	3	0	1	2	1	0	4	3	0	2	3	0	2	1	0	0	1	0	0	1	2	0	0	25	
			1	3	0	0	0	1	0	4	3	0	1	1	0	0	1	0	0	1	0	0	1	2	0	0	0	25
			2	2	0	0	0	0	3	1	0	1	1	0	0	1	0	0	1	0	0	1	0	0	0	0	0	15
			3	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	10
			4	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	5
10	36	AK	5	1	0	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	5	
			6	1	0	0	0	0	0	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	
			-1	3	2	2	0	2	2	1	0	2	2	0	0	0	0	2	0	0	1	1	2	1	2	1	0	27
			0	3	2	2	1	2	2	1	0	2	2	0	0	0	0	2	2	0	1	1	2	1	2	1	0	28
			1	2	1	0	0	1	0	0	1	0	0	0	0	0	0	2	1	0	1	0	0	0	0	0	0	9
10	37	HK	2	1	1	0	0	0	0	0	0	1	1	0	0	0	0	0	2	0	0	0	0	0	0	0	10	
			3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	
			4	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	0	0	0	0	0	0	3
			5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
			6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10	38	LL	-1	4	1	3	2	1	0	3	1	1	4	3	1	2	2	0	2	0	0	2	0	0	0	2	34	
			0	4	1	3	2	1	0	3	1	1	4	3	1	2	2	0	2	0	2	0	0	0	0	0	2	34
			1	2	1	0	2	1	2	0	1	1	4	3	1	2	2	0	0	0	0	1	0	0	0	0	0	17
			2	1	1	0	2	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	10
			3	2	0	0	0	0	0	1	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	7
10	39	VH	4	2	0	0	0	1	1	1	0	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	13	
			5	1	0	0	0	1	1	1	0	1	1	1	1	1	2	1	0	0	0	0	0	0	0	0	0	10
			6	1	1	0	0	0	1	1	0	0	1	1	1	1	2	1	0	0	0	0	0	0	0	0	0	12
			-1	3	0	0	2	2	2	1	0	3	1	1	4	3	1	2	1	0	2	0	1	0	0	0	0	24
			0	3	0	0	2	2	2	1	0	3	1	1	4	3	1	2	1	0	2	0	1	0	0	0	0	24
10	36	VH	1	2	0	0	0	2	2	1	1	0	1	0	0	1	2	1	0	2	0	1	0	0	0	0	16	
			2	0	0	0	0	2	2	1	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	7
			3	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
			4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
			5	1	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
10	35	VH	6	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	
			-1	4	0	2	1	1	1	3	1	1	4	3	1	2	2	3	2	1	3	0	1	3	0	1	0	36
			0	4	0	2	1	2	1	1	3	1	1	4	3	1	2	3	2	1	1	1	0	1	0	0	0	35
			1	3	0	1	0	1	1	2	0	0	2	2	1	2	2	2	1	1	1	1	0	0	0	0	0	22
			2	0	0	1	2	1	2	1	2	0	0	2	2	0	2	2	0	0	1	1	0	0	0	0	0	20
10	36	VH	3	2	0	0	1	2	1	2	0	0	2	2	0	2	2	1	0	1	1	0	0	0	0	0	14	
			4	1	0	0	0	1	1	1	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	11
			5	2	0	0	1	1	1	0	0	0	1	1	0	0	2	2	1	0	0	0	0	0	0	0	0	22
			6	1	0	1	0	1	1	1	1	1	1	1	1	1	2	1	0	0	1	1	0	0	0	0	0	11
			6	1	0	1	0	1	1	1	1	1	1	1	1	1	2	1	2	2	1	1	0	1	1	0	0	16

870

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit																				Total			
			It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20		It.21	Scores	
10	45	KJ	2	2	1	0	0	0	2	0	0	1	1	0	2	0	0	0	0	0	0	0	0	0	11	
			3	3	2	3	0	0	2	0	1	0	2	0	0	1	0	0	1	0	1	0	0	0	15	
			4	2	2	1	1	0	0	1	0	0	1	0	2	0	0	0	0	0	1	0	0	0	11	
			5	1	2	0	2	0	0	1	0	0	1	0	2	0	0	0	0	0	0	1	0	0	10	
			6	1	2	0	2	0	0	0	0	0	0	1	0	2	0	0	0	0	0	1	0	0	0	9
10	46	TN	-1	3	2	2	0	0	0	3	1	1	2	2	0	2	1	0	0	0	0	0	0	19		
			0	3	2	0	0	0	3	1	1	2	2	0	2	1	0	0	0	0	0	0	0	0	19	
			1	1	2	1	0	0	2	1	0	0	2	2	0	2	1	0	0	0	0	0	0	0	14	
			2	1	2	0	0	0	2	1	0	0	2	2	0	2	1	0	0	0	0	0	0	0	13	
			3	1	1	0	0	0	2	1	0	0	2	2	0	2	1	0	0	0	0	0	0	0	12	
			4	1	2	1	0	0	2	1	0	0	2	2	0	2	1	0	0	0	0	0	0	0	0	14
10	47	TH	5	1	2	1	0	0	2	1	0	0	2	2	0	2	1	0	0	0	0	0	0	11		
			6	1	2	0	0	0	1	0	0	2	2	0	2	0	1	0	0	0	0	0	0	0	9	
			-1	3	1	0	2	2	2	1	0	0	1	1	0	2	1	3	0	0	1	0	0	0	20	
			0	3	1	0	2	2	2	1	0	0	1	1	0	2	1	3	0	0	1	0	0	0	20	
			1	2	1	0	2	1	0	0	1	0	1	1	0	2	1	2	0	0	1	0	0	0	0	16
			2	2	1	0	2	1	1	0	0	0	1	0	2	1	2	0	0	0	1	0	0	0	0	16
10	48	IP	3	1	1	0	2	1	1	0	0	1	1	0	2	0	2	0	0	0	1	0	0	0	14	
			4	1	1	0	2	1	1	0	0	1	1	0	2	0	2	0	0	0	1	0	0	0	14	
			5	1	1	0	2	1	1	0	0	1	1	0	2	0	2	0	0	0	1	0	0	0	11	
			6	0	0	0	0	0	0	0	0	0	0	2	0	2	0	2	0	0	1	0	0	0	7	
			-1	4	1	2	2	2	2	2	0	0	1	2	1	0	0	0	2	0	0	0	0	0	0	21
			0	4	1	2	2	2	2	2	0	0	2	2	1	0	0	0	2	0	0	0	0	0	0	22
10	49	VH	1	4	2	2	2	2	2	2	0	0	2	2	1	1	0	0	0	0	0	0	0	1	23	
			2	3	2	3	2	2	2	1	0	0	2	2	1	1	0	0	0	0	0	0	0	0	21	
			3	2	0	2	2	2	2	1	0	0	2	2	1	1	0	0	0	0	0	0	0	0	17	
			4	2	0	2	2	2	2	1	0	0	2	2	1	1	0	0	0	0	0	0	0	0	15	
			5	3	0	1	1	1	0	0	0	0	2	2	0	1	0	0	0	0	0	0	0	0	0	11
			6	1	2	1	2	0	0	0	0	0	0	1	0	2	0	0	0	0	1	0	0	0	0	11
10	50	EE	-1	4	2	2	2	0	0	3	0	1	2	3	0	2	1	2	2	0	1	0	0	0	27	
			0	4	2	2	1	0	0	3	0	1	2	3	0	2	1	2	2	0	1	0	0	0	27	
			1	3	2	1	2	1	0	2	0	0	2	3	0	2	0	1	0	0	1	0	0	0	19	
			2	3	2	1	2	1	0	2	0	0	2	2	0	2	0	1	0	0	1	0	0	0	19	
			3	2	1	1	2	1	0	1	0	0	2	2	0	2	0	1	0	0	1	0	0	0	16	
			4	1	1	0	2	1	0	1	0	0	1	2	0	2	0	1	0	0	1	0	0	0	0	13
10	50	EE	5	1	0	0	1	1	0	1	0	0	1	2	0	2	0	1	0	0	1	0	0	0	10	
			6	2	0	0	1	1	0	1	0	0	2	2	0	2	0	1	0	0	1	0	0	0	13	
			-1	4	0	3	1	2	2	4	1	0	2	2	0	2	1	2	0	0	0	0	0	0	26	
			0	4	0	2	1	2	2	4	1	0	2	2	0	2	1	2	0	0	0	0	0	0	0	25
			1	3	2	1	1	2	1	3	0	0	2	2	0	2	1	2	0	0	0	0	0	0	0	22
			2	3	1	1	1	2	1	3	0	0	2	2	0	2	1	1	0	0	0	0	0	0	0	20
10	50	EE	3	3	1	1	1	2	1	2	0	1	1	0	1	1	1	0	0	0	0	0	0	16		
			4	3	2	1	1	2	1	3	0	0	1	1	0	2	1	1	0	0	0	0	0	0	19	

872

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Patient No.	Centre	Initials	Visit No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score			
10	50	EE	5	3	1	1	0	0	0	2	0	0	1	1	0	2	1	1	0	0	0	0	0	0	0	13		
			6	2	2	1	2	0	0	0	2	0	0	1	1	0	2	1	0	0	0	0	0	0	0	0	13	
10	51	UL	-1	3	2	1	0	0	0	2	0	0	2	2	1	2	2	0	2	0	1	0	0	0	0	20		
			1	2	2	1	0	0	2	2	1	2	1	2	2	1	2	1	0	1	0	1	0	0	0	0	20	
			2	3	2	1	0	0	2	2	1	2	1	2	2	1	2	1	0	1	0	1	0	0	0	0	17	
			3	2	0	0	2	2	1	0	0	2	1	2	1	1	0	1	0	1	0	1	0	0	0	0	19	
			4	1	1	0	0	2	1	0	0	2	1	1	1	1	1	0	1	0	1	0	1	0	0	0	15	
			5	1	0	0	1	0	1	0	0	1	2	1	1	0	2	1	1	0	0	0	0	0	0	0	0	12
10	52	HP	6	1	0	0	1	0	0	0	0	0	1	1	0	0	2	1	1	1	0	0	0	0	0	0	9	
			-1	2	2	1	2	1	2	1	0	0	2	2	0	2	0	0	0	0	0	0	0	0	0	0	0	5
			0	2	2	1	2	1	2	1	0	0	2	2	0	2	0	0	0	0	0	0	1	0	0	0	0	18
			1	1	1	0	2	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	18
			2	1	0	0	1	0	0	1	0	0	2	0	0	0	0	0	0	0	0	0	2	0	0	0	0	6
			3	1	0	0	1	0	0	1	0	0	2	0	0	0	0	1	0	0	0	0	2	0	0	0	0	7
10	53	NA	4	1	1	0	0	0	1	0	0	1	0	0	1	0	2	0	0	0	0	0	0	0	0	0	8	
			-1	3	2	2	2	1	0	0	0	2	2	1	2	0	0	0	0	0	0	0	0	0	0	0	0	9
			0	3	2	2	2	1	0	0	0	2	2	1	2	1	0	0	0	0	0	0	0	0	0	0	0	20
			1	2	2	1	1	2	1	0	0	1	2	1	0	0	0	0	0	0	0	0	0	1	0	0	0	20
			2	2	2	1	1	1	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	1	0	0	0	14
			3	1	0	1	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	12
10	54	UN	4	1	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	3	
			5	1	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	3
			6	1	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	3
			-1	3	2	2	2	1	0	0	0	2	2	1	2	0	0	0	0	0	0	0	0	0	0	0	0	28
			0	3	2	1	2	2	1	4	0	0	2	3	0	2	0	2	0	2	2	0	2	0	0	0	0	28
			1	2	0	0	0	0	3	0	0	2	2	0	2	0	2	0	2	0	2	0	2	0	0	0	0	15
10	55	TP	2	2	2	0	0	1	3	0	0	2	2	0	2	0	2	0	2	0	0	0	0	0	0	0	18	
			3	1	1	0	0	1	2	0	0	1	1	0	1	0	1	0	1	0	0	0	1	0	0	0	10	
			4	2	1	0	0	1	1	2	0	0	1	1	0	1	0	1	0	0	0	0	1	0	0	0	0	12
			5	1	1	0	0	0	2	2	0	0	1	1	0	1	0	1	0	1	0	0	1	0	0	0	0	11
			6	1	1	0	0	0	2	2	0	0	1	1	0	1	0	1	0	1	0	0	0	0	0	0	0	9
			-1	3	3	3	2	2	2	2	0	1	3	2	0	1	1	3	0	0	0	0	1	0	0	0	0	29
10	56	JP	0	3	3	3	2	2	2	0	1	3	2	0	1	1	3	0	0	0	0	1	0	0	0	0	29	
			1	2	0	0	0	2	2	0	1	3	2	0	1	1	3	0	0	0	0	0	0	0	0	0	15	
			2	1	2	0	0	1	1	0	0	2	1	0	0	1	2	0	0	0	0	0	0	0	0	0	0	11
			3	1	2	0	0	1	1	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	8
			4	1	1	0	0	0	1	1	0	0	1	0	0	1	1	0	0	1	1	0	0	0	0	0	0	7
			5	1	1	0	0	0	1	1	0	0	2	1	0	0	1	1	0	0	0	0	1	0	0	0	0	9
10	56	JP	6	1	1	0	0	0	1	0	0	1	0	0	1	1	0	1	0	0	0	0	0	0	0	0	6	
			-1	4	1	1	2	2	1	2	1	0	3	3	0	0	0	0	0	0	0	0	2	0	0	0	1	23
			0	4	1	1	2	2	1	2	1	0	3	3	0	0	0	0	0	0	2	0	0	0	0	1	22	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXYLINE - PROTOCOL 2012A/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score				
10	88	AH	2	1	0	0	0	2	1	2	0	0	1	1	0	2	2	0	0	0	0	0	0	0	0	12			
			3	1	0	0	1	2	1	1	0	0	1	1	0	2	2	0	0	0	0	0	0	0	0	0	11		
			4	2	0	0	1	2	1	1	0	0	2	1	0	0	2	2	0	0	0	0	0	0	0	0	0	14	
			5	1	0	0	0	2	0	1	0	0	2	1	0	2	2	0	0	0	0	0	0	0	0	0	0	11	
			6	1	0	0	0	2	0	0	0	0	2	1	0	0	1	0	0	0	0	0	0	0	0	0	0	7	
			-1	3	2	0	1	0	0	1	0	0	3	0	0	2	2	1	0	0	2	0	1	0	0	0	0	18	
10	89	SK	1	2	0	1	0	0	2	0	3	0	0	2	2	1	1	0	0	2	0	1	0	0	0	0	18		
			2	1	2	0	2	0	0	0	2	0	0	2	2	0	2	0	0	0	0	0	1	0	0	0	0	15	
			3	1	2	0	1	0	0	1	0	2	0	1	2	0	0	0	0	0	0	0	1	0	0	0	0	12	
			4	1	2	0	0	0	0	1	0	0	1	1	1	1	1	1	0	0	0	0	1	0	0	0	0	9	
			5	1	2	0	0	0	0	0	0	1	0	0	2	1	1	2	0	0	1	0	1	0	0	0	0	12	
			6	1	0	0	0	0	0	0	0	0	0	2	1	1	1	1	0	0	0	0	1	0	0	0	0	9	
10	90	SV	-1	3	1	2	1	2	2	3	2	0	2	2	1	2	2	0	2	1	1	1	0	1	1	31			
			0	3	1	2	1	2	2	3	2	0	2	2	1	2	2	0	2	1	1	1	0	1	1	1	31		
			1	2	0	0	2	2	1	2	2	1	0	2	2	1	2	2	0	0	1	1	0	1	1	1	22		
			2	1	0	0	1	2	2	2	0	0	1	1	0	1	2	0	0	0	1	1	0	0	1	1	22		
			3	0	0	0	1	2	2	2	0	0	1	1	0	1	2	0	0	2	0	2	0	1	0	0	0	14	
			4	0	0	0	1	1	1	1	0	0	1	1	0	1	2	0	0	2	0	2	0	1	0	0	0	13	
10	91	HI	5	3	0	0	0	1	1	1	0	0	1	1	0	1	2	0	0	0	0	0	0	0	0	8			
			6	0	0	0	0	1	1	1	0	0	0	0	1	2	0	0	0	0	0	0	0	0	0	0	9		
			-1	3	1	2	0	1	2	2	1	0	0	1	2	2	0	2	2	0	0	0	0	0	0	0	0	10	
			0	3	1	2	0	1	2	2	1	0	0	0	1	2	2	1	2	0	1	2	0	1	0	1	0	22	
			1	3	1	1	0	2	2	2	1	0	0	1	1	2	2	2	2	2	2	2	1	1	0	1	0	22	
			2	2	0	0	0	2	2	2	1	0	0	1	1	2	2	2	2	2	2	2	1	1	0	1	0	26	
10	92	LA	3	1	0	0	0	2	1	0	0	0	1	1	0	2	2	2	2	2	2	1	1	0	0	0	19		
			4	0	0	0	0	2	1	0	0	0	0	0	0	1	2	2	1	2	2	1	0	0	0	0	9		
			5	0	0	0	0	1	1	0	0	0	0	0	0	0	1	1	1	2	0	1	0	0	0	0	0	6	
			6	0	0	0	0	1	1	0	0	0	0	0	0	0	0	1	2	0	1	0	1	0	0	0	0	6	
			-1	3	1	2	0	1	2	2	1	0	0	0	0	0	1	2	0	1	2	0	1	0	0	0	0	4	
			23	3	1	1	2	2	1	2	0	0	4	2	1	2	2	1	2	1	2	1	2	1	0	0	1	0	23
10	93	AN	0	3	1	1	0	0	0	2	0	2	0	1	2	2	0	0	1	2	0	0	1	0	0	0	18		
			1	2	0	0	1	0	0	2	0	0	1	0	0	1	2	1	2	0	0	0	1	0	0	0	0	10	
			2	1	0	0	0	0	0	1	0	0	0	0	0	0	2	0	1	1	0	0	0	0	0	0	0	7	
			3	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	1	0	0	0	0	0	0	0	0	4	
			4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
			-1	3	1	1	0	0	0	2	0	2	0	1	2	1	2	1	2	0	0	1	0	0	0	0	0	0	18

877

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REMOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit No.	Total Score																					
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	
10	93	AN	5	0	0	0	0	0	0	0	0	1	1	2	0	0	0	0	0	0	0	0	4		
			6	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	3	
10	94	PV	-1	3	2	2	1	2	3	1	0	2	2	1	2	1	2	2	0	0	0	0	28		
			0	3	2	2	1	2	3	1	0	2	2	1	2	1	2	2	0	0	0	0	0	28	
			1	3	2	1	1	0	1	2	0	0	2	1	1	2	1	2	0	0	0	0	0	19	
			2	2	2	1	1	0	0	1	0	0	2	1	1	0	2	1	1	0	0	0	0	14	
			3	1	2	1	1	0	0	1	0	0	2	1	1	0	2	1	1	0	0	0	0	13	
			4	2	2	1	1	0	0	1	0	0	2	1	1	0	1	1	1	0	0	0	0	13	
11	1	DF	5	1	1	0	0	1	0	0	1	1	1	1	1	1	1	0	0	0	0	0	9		
			6	1	1	0	1	1	0	0	1	1	0	1	1	1	1	1	0	0	0	0	0	10	
			-1	2	3	4	2	2	3	2	1	3	3	1	1	2	0	1	0	1	1	0	0	34	
			0	2	1	4	2	1	2	2	1	1	2	1	1	2	0	1	0	1	0	0	0	26	
			1	2	1	0	1	1	1	1	1	1	2	1	1	1	2	1	0	0	1	0	0	0	18
			2	1	1	0	0	2	1	1	1	1	1	1	1	1	2	0	0	1	0	0	0	0	16
11	2	HB	3	1	1	0	0	1	1	1	1	2	0	0	0	0	0	1	0	0	0	0	9		
			4	2	0	0	1	1	2	1	0	0	1	1	0	1	2	0	0	1	0	0	0	12	
			5	0	0	0	1	1	1	1	0	0	1	0	1	0	1	2	0	0	0	0	0	7	
			6	1	0	0	1	1	1	1	0	1	0	0	1	2	0	0	1	0	0	0	0	8	
			-1	3	0	4	2	1	1	3	1	0	1	2	1	1	1	2	3	0	1	0	0	27	
			0	3	0	3	2	1	1	2	1	0	1	2	1	1	1	2	3	0	1	0	0	0	25
11	3	RF	1	2	0	1	1	1	2	1	0	1	1	0	1	1	0	0	0	0	0	0	13		
			2	1	0	0	1	1	1	0	0	1	1	0	1	0	1	0	0	0	0	0	0	10	
			3	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	2	
			4	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
			5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	
			6	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	
11	4	BA	-1	3	2	4	1	1	1	3	2	0	3	3	1	1	0	2	0	0	1	0	28		
			0	3	2	3	2	1	1	3	2	0	3	3	1	1	0	2	0	0	1	0	0	28	
			1	2	1	1	0	1	1	1	1	1	0	1	1	1	1	0	1	1	0	1	0	0	16
			2	2	1	0	1	1	1	1	1	0	1	1	1	1	0	1	1	0	1	0	0	0	15
			3	0	0	0	1	1	1	1	0	0	0	0	0	0	0	0	2	0	0	1	0	0	6
			4	2	0	1	1	1	2	1	1	0	2	1	1	1	2	0	0	1	0	0	0	0	17
11	5	1	5	1	1	1	1	1	1	1	1	0	0	1	1	1	1	0	0	1	0	0	12		
			6	1	1	1	1	1	1	1	0	0	1	2	0	1	1	0	0	1	0	1	0	17	
			-1	3	0	0	2	1	2	3	1	0	2	2	1	1	0	2	0	0	2	0	0	22	
			0	3	0	1	1	1	1	3	1	0	2	2	1	1	0	0	0	0	2	0	0	20	
			1	3	0	1	2	1	1	2	1	0	2	2	1	2	0	3	0	0	2	0	0	0	23
			2	1	0	0	0	1	1	1	2	0	0	1	1	1	0	0	0	0	2	0	0	0	15
11	6	1	3	1	0	0	0	1	1	2	0	1	2	0	1	0	2	0	0	0	0	0	11		
			4	1	0	0	1	0	1	1	0	0	1	1	1	0	1	0	0	0	0	0	0	11	
			5	1	0	0	1	0	1	1	0	0	1	1	1	1	0	1	0	0	2	0	0	11	
			6	1	0	0	1	1	1	1	0	0	1	1	1	1	0	1	0	0	1	0	0	9	
			-1	0	0	0	1	1	1	1	0	0	1	1	0	1	0	1	0	0	0	1	0	0	9
			0	0	0	0	1	1	1	1	0	0	1	1	0	1	0	1	0	0	0	1	0	0	9

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.1
HAMILTON DEPRESSION RATING SCALE
OPEN PHASE

Patient No.	Centre No.	Initials	Visit No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score		
11	5	ZH	-1	3	2	3	1	1	1	3	1	3	2	2	0	1	1	0	3	0	2	0	1	1	31		
			0	3	3	1	1	1	3	2	1	1	1	1	1	1	1	1	0	0	0	0	0	1	1	29	
			1	3	3	1	1	1	3	3	2	0	1	1	2	0	0	0	0	0	0	0	0	0	1	0	29
			2	3	2	3	1	1	1	1	0	1	1	2	0	0	0	1	2	0	0	0	0	0	1	0	24
			3	3	3	3	2	1	1	3	2	2	0	1	0	2	0	0	2	0	0	0	2	2	1	0	32
11	6	VP	-1	2	1	1	2	2	3	2	2	2	3	1	1	0	0	2	1	1	3	0	0	0	31		
			0	2	1	1	2	2	4	1	1	2	3	2	1	0	0	2	1	1	3	0	0	0	31		
			1	0	2	0	1	0	1	2	1	1	2	1	0	1	1	0	0	0	0	1	0	1	0	15	
			2	1	0	0	1	1	1	1	0	1	1	0	1	0	0	1	0	0	1	0	1	0	0	10	
			3	1	0	0	1	1	1	1	1	0	1	1	0	0	0	0	0	0	0	1	0	0	0	9	
			4	0	0	0	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	1	0	0	0	8
11	7	KK	5	0	0	0	0	1	1	1	0	1	1	0	0	0	0	0	0	0	0	0	0	0	5		
			6	0	0	0	1	1	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	5	
			-1	3	2	3	1	1	2	3	1	1	2	2	1	2	1	2	1	3	0	1	0	1	0	1	33
			0	3	2	0	0	1	1	2	1	1	2	2	1	1	0	1	0	1	0	2	0	0	1	1	22
			1	2	0	0	1	1	1	0	1	1	1	1	1	1	0	1	0	1	1	0	2	0	0	1	15
11	8	RF	2	0	0	0	1	0	2	1	0	1	1	1	1	1	1	1	2	0	0	0	0	0	16		
			3	1	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	0	0	1	0	0	0	10	
			4	2	0	0	0	0	1	1	0	1	2	0	1	1	1	2	0	0	0	0	1	0	0	0	11
			5	1	0	0	1	0	0	1	1	1	1	1	1	1	1	1	2	1	0	0	1	0	0	0	11
			6	1	0	0	0	0	1	0	0	1	1	1	1	1	1	1	1	0	2	0	1	0	0	0	10
			-1	3	0	1	2	1	2	3	1	0	3	2	1	1	0	3	1	0	3	1	0	2	0	0	26
11	9	FI	0	3	0	2	1	2	3	1	1	3	3	1	2	1	1	0	3	2	0	2	0	0	0	31	
			1	3	0	0	2	1	2	2	1	0	2	2	1	1	0	3	2	0	1	0	0	1	0	23	
			2	2	0	0	1	1	1	2	0	0	2	2	1	2	0	3	0	0	2	0	2	0	0	19	
			3	3	0	1	2	1	2	3	2	0	2	1	1	2	0	3	0	0	3	0	0	2	0	0	25
			-1	3	3	3	2	1	2	3	1	2	4	2	1	1	1	1	1	2	0	0	0	0	1	2	34
11	10	BJ	0	3	3	2	2	1	2	3	2	1	2	3	2	1	1	1	1	0	0	1	0	1	1	31	
			1	2	2	1	1	1	1	1	2	2	1	1	2	1	1	1	0	0	2	0	0	0	0	1	20
			2	2	1	1	2	2	0	0	1	1	1	1	1	1	1	2	0	0	0	0	2	0	1	1	20
			3	1	2	0	0	1	2	1	1	0	0	1	1	1	1	1	0	2	0	0	1	0	1	1	17
			4	1	1	1	0	1	1	1	0	0	1	1	1	1	1	1	0	0	0	0	1	0	0	0	11
			5	2	1	0	0	1	2	1	0	0	1	1	1	1	1	1	0	1	0	1	0	0	1	0	16
11	10	BJ	-1	3	0	2	2	1	2	2	1	0	2	2	0	1	1	0	0	2	0	2	0	1	0	23	
			0	3	0	1	2	1	2	2	1	0	3	2	0	1	1	1	0	0	1	0	1	0	0	0	21
			1	1	0	0	1	1	1	2	0	0	2	1	1	1	1	1	0	2	0	1	0	0	0	0	15
			2	1	0	0	1	0	1	0	0	0	1	1	1	1	1	1	0	0	0	0	1	0	0	0	8
			3	1	0	0	1	1	1	0	0	1	0	0	1	0	1	0	0	0	0	1	0	0	0	0	6
			4	1	0	0	1	1	1	1	1	0	0	1	1	1	1	0	0	0	2	0	1	0	0	0	11
5	1	0	0	1	1	1	2	0	0	1	1	0	0	1	0	0	0	0	0	1	0	0	0	8			
6	0	0	0	1	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	3		

879

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Patient No.	Centre No.	Initials	Visit	Total Score																						
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score	
11	11	NGY	-1	3	0	2	2	1	2	3	2	0	2	2	1	1	0	0	0	0	0	0	0	0	23	
			0	3	0	1	2	1	2	3	2	0	3	1	0	1	0	0	1	0	0	0	0	1	0	21
			1	3	2	1	2	1	1	2	2	0	2	0	0	1	0	0	0	0	0	0	0	1	0	18
			2	1	0	0	2	1	2	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	8
			3	1	0	0	2	1	2	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
			4	0	0	0	2	1	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
11	12	PJ	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
			-1	3	2	1	1	0	1	2	1	2	3	2	1	1	1	3	0	0	1	0	0	0	0	25
			1	3	0	1	1	0	1	1	2	1	1	2	2	1	1	0	3	0	0	0	0	1	0	19
			2	3	0	0	2	1	1	4	2	0	2	1	2	0	0	3	0	0	0	0	0	1	0	23
			3	1	0	0	1	1	1	3	1	0	1	2	1	1	0	1	1	0	1	0	0	0	0	19
			4	2	0	0	2	1	1	2	0	0	1	1	2	1	0	1	2	0	1	0	0	0	0	14
11	13	GK	5	2	0	0	2	1	1	2	0	0	1	1	1	0	1	0	0	0	0	0	0	0	15	
			6	2	0	0	2	1	1	2	0	1	1	1	0	1	0	0	0	0	0	0	0	0	12	
			-1	3	2	0	2	1	1	2	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0	13
			0	3	2	0	2	1	1	2	3	1	1	2	2	1	0	2	0	0	0	1	0	0	0	25
			1	2	1	1	1	1	1	3	1	1	2	2	0	1	0	0	0	0	0	0	0	0	0	20
			2	1	1	0	1	1	2	0	1	1	1	1	2	1	0	0	0	0	0	0	0	0	0	15
11	14	BJ	3	3	2	3	1	1	1	2	0	1	1	1	0	0	0	0	0	0	0	0	0	0	25	
			4	3	2	3	1	1	1	4	2	2	3	1	1	1	0	0	1	0	0	0	0	0	28	
			5	3	2	2	2	2	2	3	2	2	2	1	1	0	1	0	2	0	1	0	0	0	28	
			6	3	1	2	1	1	1	3	1	2	3	2	2	0	1	0	0	0	0	0	0	0	0	24
			-1	2	1	1	2	1	1	3	1	2	2	1	1	2	1	0	1	0	0	1	0	0	0	25
			0	2	1	1	1	1	1	3	1	2	2	2	1	1	2	1	0	1	1	0	0	0	0	22
11	15	NF	1	2	1	0	1	1	2	2	1	1	1	1	0	2	0	0	0	0	0	0	0	0	16	
			2	1	0	0	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	5	
			3	2	1	0	2	1	1	2	0	0	1	1	0	0	2	0	0	0	0	0	0	0	14	
			4	3	1	1	2	2	2	4	3	4	3	3	2	1	0	0	2	0	1	0	0	0	34	
			-1	3	2	2	0	2	2	3	1	1	2	2	1	2	0	0	0	0	0	0	0	0	0	26
			1	2	0	0	1	1	1	2	0	0	1	1	1	1	0	0	1	0	0	0	0	0	0	18
11	16	NA	2	1	0	0	1	1	1	2	0	0	1	1	1	0	0	0	1	0	0	0	0	0	14	
			3	1	1	1	1	1	0	0	1	1	1	1	0	0	0	2	0	0	1	0	0	0	13	
			4	1	0	0	2	2	2	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	9	
			5	3	0	1	2	2	2	2	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	12
			6	3	1	1	2	2	1	2	2	0	1	2	2	1	1	2	0	0	0	0	0	0	0	20
			-1	3	2	2	2	2	2	3	1	1	2	2	1	1	1	0	0	0	0	0	0	0	0	21
11	17	MA	0	3	2	2	2	2	2	3	1	1	2	2	1	0	0	1	0	0	0	0	0	0	27	
			1	1	2	0	2	1	2	2	0	2	2	2	1	2	0	0	0	0	0	0	0	0	26	
			2	3	2	1	1	1	2	0	0	2	2	1	1	2	0	0	2	0	0	0	0	0	19	
			3	2	1	1	1	1	3	0	2	2	2	2	1	2	0	2	0	0	0	0	0	0	25	
			4	2	1	0	2	2	2	2	0	1	1	1	1	1	0	0	1	0	0	0	0	0	0	19
			5	2	1	0	2	2	2	2	0	1	1	1	1	1	0	0	1	0	0	0	0	0	0	19

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBEXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score				
11	16	NA	4	2	1	0	1	1	1	2	0	2	2	1	1	1	1	0	0	0	1	0	0	0	0	17			
			5	3	1	1	2	2	2	2	2	2	2	2	1	1	1	1	0	0	0	1	0	0	0	0	23		
			6	2	1	1	1	2	1	0	0	1	0	1	0	1	1	1	0	0	0	0	1	0	0	0	0	13	
	11	17	UZ	-1	2	2	2	2	2	2	3	0	1	2	2	2	2	1	2	0	1	0	1	0	0	0	0	27	
				0	2	2	0	2	1	0	3	0	1	2	2	1	2	2	1	0	0	1	0	2	0	0	0	0	24
				1	2	1	0	1	1	1	1	1	1	1	1	1	1	0	1	2	0	0	1	0	0	0	0	0	16
2				1	1	0	1	1	0	1	1	1	1	1	1	1	1	1	1	0	0	1	0	0	0	0	0	11	
3				2	0	0	1	1	0	1	1	1	1	2	0	1	1	1	0	0	1	0	1	0	0	0	0	11	
4				1	1	1	0	0	1	0	0	1	0	0	1	1	1	1	1	0	0	0	0	0	0	0	0	7	
11	18	EI	5	1	0	1	1	1	1	2	0	1	1	1	1	1	1	1	0	0	0	1	0	0	0	0	13		
			6	2	1	0	1	1	1	0	0	1	0	1	0	1	1	1	0	0	0	0	2	0	0	0	0	12	
			-1	3	2	1	2	2	2	3	1	2	3	2	2	2	2	2	2	1	0	1	0	0	0	0	0	32	
			0	2	1	1	1	1	1	2	0	1	2	2	1	2	1	1	1	0	0	1	0	0	0	0	0	23	
			1	1	1	0	1	1	1	2	0	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	12	
			2	1	0	0	1	1	0	1	1	1	1	1	1	1	1	1	1	0	0	0	1	0	0	0	0	9	
11	19	FK	3	2	0	0	1	1	2	0	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	13		
			4	2	0	0	1	1	0	0	2	0	1	1	1	1	1	1	0	0	0	0	1	0	0	0	11		
			5	1	0	0	1	0	0	1	1	1	1	1	1	1	1	1	1	0	0	0	1	0	0	0	0	7	
			6	1	0	0	1	0	0	2	0	0	1	1	1	1	1	1	1	0	0	0	1	0	0	0	0	10	
			-1	2	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	1	0	2	0	1	0	0	0	25	
			0	2	1	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	0	0	0	1	0	0	0	0	24
11	20	LJ	1	2	1	1	1	1	1	2	0	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	14		
			2	1	0	0	1	1	0	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	7		
			3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	
			4	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	
			5	1	0	0	1	0	0	1	0	0	1	0	0	1	0	0	1	0	0	0	0	0	0	0	0	7	
			6	1	0	0	0	0	0	1	1	0	1	1	1	1	1	1	1	0	0	0	0	1	0	0	0	7	
12	1	IB	-1	2	1	1	2	2	2	2	1	2	2	3	2	2	2	1	1	0	1	0	1	0	0	0	26		
			0	3	1	1	2	1	2	2	1	2	2	2	2	2	2	2	1	1	0	0	1	0	0	0	0	24	
			1	2	0	0	1	1	2	2	0	1	2	1	2	1	1	1	1	0	0	0	1	0	0	0	0	17	
			2	2	0	1	2	2	2	3	0	1	2	1	1	1	1	1	0	0	0	0	1	0	0	0	0	19	
			3	2	0	0	1	1	2	0	0	2	1	1	1	1	1	1	0	0	0	0	2	0	0	0	0	13	
			4	2	0	0	1	1	1	1	0	1	1	1	1	1	1	1	1	0	0	0	2	0	0	0	0	14	
12	1	IB	5	2	0	0	1	1	1	2	1	1	2	1	1	2	0	1	0	0	0	2	0	0	0	0	14		
			6	2	0	0	1	1	2	1	0	1	2	1	0	0	0	0	0	0	0	0	1	0	0	0	0	12	
			-1	4	0	0	0	1	0	4	1	0	4	1	0	2	3	1	0	2	0	1	2	0	0	0	0	23	
			1	4	0	0	0	1	0	4	1	0	4	1	0	2	3	1	0	2	0	1	2	0	0	0	0	23	
			2	1	0	0	0	0	2	1	0	1	1	0	1	1	1	1	0	1	2	0	1	2	0	0	0	14	
			3	1	0	0	0	0	1	1	0	1	2	0	1	0	0	0	1	0	0	0	1	2	0	0	0	12	
12	1	IB	4	1	0	0	0	0	1	1	0	1	1	0	1	1	0	0	1	0	0	1	0	0	0	0	8		
			5	2	0	0	0	0	0	2	0	0	1	1	0	1	1	0	1	0	0	1	1	0	0	0	10		
			6	2	0	0	0	0	0	2	0	0	1	1	1	0	1	1	1	1	0	0	1	1	0	0	0	10	
			-1	2	0	0	0	0	0	0	0	0	2	1	1	1	1	1	1	1	1	0	0	0	0	0	0	10	
			2	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	10	
			3	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	10	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit No.	Total Score																							
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21			
12	2	EFC	-1	3	1	1	2	2	2	2	0	0	3	3	2	2	1	3	1	2	1	0	0	31			
			0	3	1	1	2	2	2	0	0	3	3	2	1	2	1	3	1	2	1	0	0	31			
			1	3	1	1	2	2	2	0	0	2	3	1	2	1	3	1	2	1	0	0	0	0	29		
			2	3	1	1	2	2	2	0	0	2	2	1	2	1	2	1	2	1	0	0	0	0	27		
			3	3	1	1	2	2	2	0	0	3	2	1	2	1	2	1	2	1	0	0	0	0	28		
			4	2	2	2	1	1	2	2	1	1	2	2	1	1	1	1	2	0	2	0	0	0	26		
12	3	IF	2	2	2	1	1	2	2	1	1	2	2	1	1	1	1	1	1	1	0	0	0	22			
			-1	3	2	0	2	2	2	0	2	3	2	1	1	1	1	1	2	0	1	0	0	27			
			0	1	2	0	2	2	2	0	1	3	2	1	1	1	1	1	2	0	1	0	0	24			
			1	2	1	0	1	2	2	0	1	2	2	1	1	1	1	1	0	0	1	0	0	20			
			2	2	0	0	2	2	2	1	0	1	2	2	0	1	1	1	0	0	1	0	0	0	18		
			3	2	0	0	2	2	1	0	1	2	0	1	1	1	1	1	0	0	0	0	0	0	10		
12	4	EG	4	1	0	0	0	1	1	0	0	2	0	0	1	1	1	0	0	0	0	0	0	8			
			5	1	0	0	0	1	0	0	0	1	0	0	1	1	1	1	0	0	0	0	0	5			
			6	0	0	0	1	0	0	0	0	1	0	0	1	1	1	1	0	0	0	0	0	0	5		
			-1	3	2	1	2	1	1	2	2	3	2	2	1	2	0	0	2	2	1	0	0	0	2		
			0	1	2	0	2	2	2	0	1	3	2	1	1	1	1	1	2	0	1	0	0	0	24		
			1	2	1	0	1	2	2	1	2	2	1	1	1	1	1	1	0	0	1	0	0	0	20		
12	5	ZSH	2	3	0	0	1	1	1	3	0	1	2	4	2	1	0	0	0	0	1	0	0	16			
			3	1	0	1	1	1	1	1	1	2	3	2	1	1	1	1	1	0	0	1	0	1	14		
			4	1	1	0	1	1	1	2	1	1	1	1	1	1	0	0	0	0	1	1	0	0	11		
			5	1	1	0	1	1	1	2	1	1	1	1	1	1	0	0	0	0	1	1	0	0	15		
			6	1	1	0	1	1	0	1	0	1	1	0	1	1	0	0	0	0	1	1	0	0	1	10	
			-1	3	1	1	2	1	1	0	1	1	1	1	1	1	0	0	0	0	1	1	0	0	12		
12	6	MK	-1	4	2	1	1	1	1	1	1	1	4	4	0	1	2	0	0	1	2	0	1	0	28		
			0	4	2	1	2	2	1	1	2	4	1	2	4	0	1	2	0	0	1	2	0	1	0	32	
			1	4	0	0	1	0	0	1	1	0	2	3	0	1	2	0	0	1	2	0	1	0	1	0	19
			2	1	0	0	1	0	0	1	1	0	2	3	0	1	2	0	0	1	1	1	0	1	0	1	16
			3	0	1	0	0	0	1	1	0	2	1	0	0	0	0	0	1	0	1	1	0	1	0	0	11
			4	1	1	1	0	0	0	1	1	0	2	2	1	1	1	0	1	2	0	1	1	0	1	0	16
12	7	LK	5	2	1	0	0	0	1	1	0	2	3	0	1	1	1	1	1	0	1	0	1	0	10		
			6	1	1	0	0	0	2	3	0	1	1	1	1	1	1	1	0	0	1	0	1	0	1	16	
			-1	2	0	0	2	2	2	2	2	3	1	0	0	0	0	2	0	0	1	0	0	0	0	8	
			0	2	0	0	2	2	2	2	3	2	3	1	0	0	2	0	0	1	1	0	1	0	1	26	
			1	1	0	0	1	1	1	2	2	1	2	2	1	0	0	2	0	0	1	1	0	0	1	0	27
			1	1	0	0	1	1	1	2	2	1	2	2	1	0	0	2	0	0	1	1	0	0	1	0	18

00
22

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Patient No.	Centre No.	Initials	Visit No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score	
	12	7	LK	2	1	0	0	1	1	1	1	2	1	2	2	1	0	0	2	0	0	1	1	0	0	17
				3	2	0	0	1	2	2	0	0	2	1	1	2	0	0	1	0	2	0	0	0	0	16
				4	2	0	0	1	2	2	0	0	2	1	0	2	0	0	1	0	2	0	0	0	0	15
				5	2	0	0	1	2	2	0	1	2	1	0	1	0	0	0	0	1	0	0	0	0	13
				6	2	0	0	1	2	1	1	0	1	1	0	1	0	0	0	0	0	1	0	0	0	12
	12	8	FM	-1	4	2	1	2	2	2	2	1	3	3	0	1	1	2	0	0	2	1	1	1	1	33
				0	4	2	1	2	2	2	1	1	3	2	0	1	2	2	0	0	2	1	1	1	1	32
				1	3	2	1	2	2	2	1	2	2	1	0	1	2	0	0	0	2	0	1	1	1	27
				2	3	1	0	2	2	2	1	1	2	2	0	1	1	1	0	0	2	0	0	0	0	23
				3	2	2	0	2	2	2	1	1	2	2	0	1	1	1	0	0	2	0	0	0	0	23
				4	2	2	0	2	2	2	1	1	2	2	0	1	1	1	0	0	2	0	0	0	0	23
				5	3	2	1	2	2	2	1	1	2	2	0	1	1	1	0	0	2	0	0	0	0	23
				6	3	2	1	2	2	2	1	1	2	2	0	1	2	1	0	0	2	0	0	0	0	23
	12	9	KBP	-1	2	1	1	2	2	2	1	1	2	1	1	1	2	1	0	0	2	0	0	0	0	26
				0	2	1	1	2	2	2	4	2	1	3	2	0	1	1	2	2	0	0	0	0	0	30
				1	2	0	0	0	1	4	2	0	2	2	0	1	1	1	2	2	0	0	0	0	0	30
				2	2	0	0	0	1	4	2	0	2	2	0	1	1	0	0	0	2	0	0	0	0	17
				3	2	0	0	1	0	2	0	2	2	0	1	1	0	0	0	0	0	0	0	0	0	17
				4	2	0	0	1	0	2	0	2	2	0	1	1	0	0	0	0	2	0	0	0	0	16
				5	2	0	0	1	1	2	2	0	2	1	0	1	1	0	0	0	0	0	0	0	0	17
				6	2	0	0	0	2	2	2	1	0	2	1	0	1	1	0	0	2	0	0	0	0	15
	12	10	IP	-1	4	2	2	2	2	1	1	0	2	0	0	0	1	0	0	0	0	0	0	0	0	11
				0	4	3	2	2	2	2	1	0	1	3	3	1	1	1	0	0	2	1	1	0	0	30
				1	2	2	1	2	2	1	1	1	2	2	0	1	0	0	0	0	1	0	0	0	1	26
				2	2	2	0	1	1	1	1	1	1	1	2	1	1	0	0	0	1	0	0	0	1	21
				3	2	2	1	1	1	1	1	1	1	1	2	1	1	0	0	0	1	0	0	0	1	17
				4	1	1	0	0	1	1	1	1	1	1	2	1	0	0	0	0	1	0	0	0	1	18
				5	1	1	0	0	1	1	1	0	1	1	1	1	0	0	0	0	1	0	0	0	0	11
				6	1	1	0	0	1	1	1	0	1	1	1	1	1	0	1	0	1	0	0	0	0	11
	12	11	ER	-1	2	0	0	1	1	2	3	1	2	3	2	2	0	2	0	2	1	2	0	0	0	26
				0	2	0	0	2	1	2	2	1	2	3	1	2	0	2	0	2	1	2	0	0	0	25
				1	2	0	0	1	1	2	3	1	2	2	2	0	2	0	2	0	2	1	1	0	0	24
				2	2	0	0	1	1	2	3	1	1	2	0	2	0	2	0	2	1	1	0	0	0	22
				3	1	0	0	0	1	2	3	1	2	0	2	0	2	0	2	0	2	1	2	0	0	22
				4	1	0	0	0	1	2	2	1	1	1	0	1	1	0	0	2	1	1	1	0	0	15
				5	1	0	0	0	1	1	1	1	1	1	1	0	2	0	1	1	1	0	0	0	0	12
				6	1	0	0	0	1	1	1	0	1	1	1	1	1	0	2	0	1	1	0	0	0	12
	12	12	FSZ	-1	2	2	2	2	2	1	2	0	3	0	0	1	0	0	0	0	0	0	0	0	0	22
				0	2	1	1	2	1	2	1	0	3	0	0	1	0	0	0	0	1	2	0	0	1	20
				1	2	1	0	1	1	1	2	1	0	2	0	0	1	0	0	1	1	2	0	0	1	15
				2	1	2	1	1	1	1	0	0	1	0	0	1	0	0	1	0	2	0	0	0	0	13
				3	2	2	1	1	1	1	1	0	1	0	0	1	0	0	1	0	2	0	0	0	0	13
				4	2	2	1	0	1	1	1	0	0	1	0	0	1	0	0	0	1	0	0	0	0	11

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Patient Centre No.	Initials	Visit No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score	
12	FSZ	5	2	2	1	0	0	1	1	0	2	2	0	0	1	0	0	0	0	1	0	0	0	0	13
		6	3	1	2	0	1	1	0	0	2	3	0	0	1	1	1	0	0	1	0	0	0	0	17
12	ISZ	-1	3	0	1	2	2	2	2	3	0	2	2	1	2	2	4	1	2	2	0	0	0	0	33
		1	2	0	0	2	0	2	2	2	2	2	2	0	2	2	4	1	2	2	0	0	0	0	33
		2	3	0	0	2	0	2	2	2	0	2	2	0	2	1	3	0	2	2	0	0	0	0	24
		3	2	0	0	2	0	2	2	0	2	2	0	2	1	3	0	2	2	0	2	0	0	0	25
		4	1	0	0	2	1	2	2	1	0	2	1	0	1	1	2	1	0	2	0	0	0	0	20
		5	1	0	0	1	1	2	2	2	1	0	2	1	0	1	1	0	0	2	0	0	0	0	18
		6	1	0	0	1	1	2	2	1	0	2	1	0	1	1	1	0	0	1	0	0	0	0	15
12	GSZ	-1	3	1	1	1	1	1	2	1	0	2	4	0	2	0	1	0	1	0	0	0	0	0	21
		0	4	1	2	1	1	1	2	1	0	2	3	0	2	0	2	0	2	0	1	0	0	0	23
		1	1	1	0	1	0	2	1	0	1	3	0	1	0	1	0	1	0	1	0	0	0	0	13
		2	1	1	0	0	0	2	1	0	1	3	0	1	0	1	0	1	0	1	0	0	0	0	12
		3	2	0	0	0	0	2	1	0	0	2	1	0	0	0	1	0	0	1	0	0	0	0	7
		4	3	0	1	1	2	2	2	0	1	2	2	0	1	0	0	0	0	0	0	0	0	0	17
		5	2	0	0	0	0	0	1	0	0	2	1	0	1	0	0	0	0	0	0	0	0	0	7
		6	2	0	0	0	0	1	0	0	2	1	0	1	0	0	0	0	0	0	0	0	0	0	6
12	GB	-1	3	3	2	1	1	1	1	2	2	2	2	1	1	0	1	0	1	2	0	0	0	0	27
		0	3	3	1	1	1	1	1	2	2	2	2	1	1	0	0	1	0	1	2	0	0	1	25
		1	3	3	1	1	2	1	1	2	2	2	2	1	1	0	0	0	1	2	0	0	0	1	27
		2	3	3	0	1	2	1	1	2	2	2	2	1	1	0	0	0	1	1	0	0	0	1	23
		3	2	2	0	1	2	1	1	1	1	1	2	1	1	0	0	0	1	1	0	0	0	1	19
		4	2	2	0	1	1	1	1	1	1	1	2	1	1	0	0	0	1	1	0	0	0	1	18
		5	2	0	0	1	1	1	1	1	1	1	0	0	0	0	0	0	1	1	0	0	0	1	10
		6	2	0	0	1	1	1	0	0	1	1	0	0	0	0	0	0	0	1	2	0	0	0	9
12	FN	-1	4	0	0	2	2	2	3	0	2	3	3	2	0	0	3	2	0	2	0	0	0	0	30
		0	4	0	0	2	2	2	3	0	2	3	3	2	0	0	3	2	0	2	0	0	0	0	28
		1	3	0	0	2	1	2	2	0	2	2	2	0	0	0	3	1	0	2	0	0	0	0	22
		2	2	0	0	0	0	0	1	0	1	1	1	0	0	0	2	0	0	0	0	0	0	0	8
		3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	2
		4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	2
		5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	3
		6	2	0	0	0	1	0	0	0	2	0	0	0	0	0	1	0	0	0	0	0	0	0	8
12	TK	-1	2	2	1	2	2	1	2	2	2	2	1	1	0	2	1	2	0	1	0	0	0	0	26
		0	2	1	0	2	2	1	2	1	2	1	1	1	1	1	2	2	1	0	1	0	0	0	25
		1	2	1	0	2	1	1	2	1	1	2	1	1	2	2	2	1	0	1	0	0	0	0	25
		2	1	0	2	1	1	1	2	1	1	2	1	1	2	2	2	1	0	1	0	0	0	0	25
		3	1	2	0	0	0	2	1	1	0	2	2	2	2	2	2	1	2	0	1	0	0	0	20
		4	1	1	0	0	0	2	1	0	0	1	1	1	2	2	2	2	0	1	0	0	0	0	14
		5	1	1	0	0	0	2	1	0	1	1	1	1	2	2	2	2	0	1	0	0	0	0	14
		6	1	1	0	0	0	1	1	0	1	0	1	0	1	2	2	0	0	1	0	0	0	0	9

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
 RESOMETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Patient Centre No.	Initials	Visit No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score
12	LS	-1	3	2	2	2	2	2	4	2	2	3	3	2	2	2	2	2	0	2	2	0	0	41
		0	2	2	2	2	2	2	3	2	2	2	2	2	1	1	1	0	0	1	1	0	0	29
		1	2	2	2	2	2	2	3	1	2	2	2	2	1	1	1	0	0	1	1	0	0	25
		2	2	2	2	2	2	2	3	1	2	1	1	1	1	1	1	0	0	1	0	0	0	23
		3	2	1	0	2	2	2	3	1	1	2	1	1	1	1	1	0	0	1	0	0	0	21
		4	2	1	0	2	2	2	3	1	1	2	1	0	1	1	1	1	1	0	1	0	0	22
		5	1	0	0	2	2	2	2	0	1	1	1	1	1	1	1	1	1	0	1	0	0	16
		6	1	0	0	2	2	2	2	0	1	1	1	1	1	1	1	0	0	1	0	0	0	16
12	SSZ	-1	3	3	1	2	2	1	3	1	2	3	0	0	0	1	0	0	0	0	0	0	0	22
		0	3	3	1	2	2	1	3	1	2	3	0	0	0	1	0	0	0	0	0	0	0	22
		1	3	3	0	2	2	0	2	0	2	3	0	0	0	1	0	0	0	0	0	0	0	18
		2	3	3	0	2	2	0	1	0	2	3	0	0	0	1	0	0	0	0	0	0	0	17
		3	1	1	0	0	1	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	5
		4	2	0	0	1	1	2	0	1	2	0	0	0	1	1	0	0	0	0	0	0	0	11
		5	1	0	0	1	1	1	1	0	1	2	0	0	1	1	0	0	0	0	0	0	0	8
		6	1	0	0	1	1	2	0	1	2	0	0	0	1	0	0	0	0	0	0	0	0	8
12	MSZ	-1	3	0	2	2	2	2	4	0	4	4	4	2	2	0	3	2	0	0	0	0	0	36
		0	3	0	2	2	2	2	4	0	4	4	4	2	1	0	3	1	0	0	0	0	0	35
		1	3	0	2	2	2	1	3	0	4	4	2	1	0	3	1	0	0	0	0	0	0	23
		2	0	0	1	2	1	3	0	2	3	0	0	0	0	0	0	0	0	0	0	0	0	14
		3	2	0	0	2	2	2	2	0	2	2	0	0	0	0	0	0	0	0	0	0	0	11
		4	3	0	2	2	2	2	2	0	2	3	0	0	1	0	0	0	0	0	0	0	0	19
		5	2	0	0	1	1	0	1	0	1	2	0	0	1	0	0	0	0	0	0	0	0	9
		6	1	0	0	1	1	0	0	0	1	2	0	0	0	0	0	0	0	0	0	0	0	6
12	FL	-1	3	0	1	2	2	2	3	0	3	3	2	1	1	2	3	0	0	0	0	0	0	28
		0	3	0	0	2	2	2	3	0	3	2	2	1	1	2	3	0	0	0	0	0	0	26
		1	0	0	0	2	2	2	0	1	2	2	2	1	1	2	3	1	1	0	0	0	0	19
		2	0	0	0	1	0	0	2	0	1	1	2	0	2	2	2	1	1	0	0	0	0	14
		3	1	0	0	1	0	0	2	0	1	1	2	0	2	2	2	1	0	0	0	0	0	15
		4	1	0	0	1	0	0	2	0	1	1	2	0	0	2	2	2	0	0	0	0	0	12
		5	0	0	0	1	0	0	2	0	1	1	2	0	0	2	2	0	0	0	0	0	0	10
		6	0	0	0	0	0	0	2	0	0	1	2	0	0	2	2	0	0	0	0	0	0	8
12	HV	-1	2	2	2	2	2	2	2	1	2	3	4	1	2	2	3	1	0	0	0	0	0	33
		0	2	2	1	2	2	2	2	1	2	3	4	1	2	2	3	1	0	0	0	0	0	32
		1	2	1	2	2	2	2	2	1	2	3	3	1	2	2	2	0	0	0	0	0	0	29
		2	2	1	2	2	1	1	1	0	2	3	3	1	1	2	2	2	0	0	0	0	0	26
		3	1	0	0	1	0	1	0	1	1	1	1	0	1	2	1	2	1	0	0	0	0	12
		4	2	0	0	1	0	1	0	1	0	1	2	1	0	1	2	1	0	0	0	0	0	12
		5	2	0	0	1	0	1	0	1	0	1	2	1	0	1	2	1	0	0	0	0	0	11
		6	2	0	0	1	0	0	1	0	1	1	1	0	1	2	0	0	0	0	0	0	0	8
12	EN	-1	4	3	2	2	2	2	4	2	3	4	3	2	2	2	3	2	0	0	0	0	0	43
		0	4	3	2	2	2	2	4	2	3	4	3	2	2	2	3	2	0	0	0	0	0	42
		1	3	2	2	2	2	2	4	2	3	4	3	2	2	2	3	0	0	0	0	0	0	39

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit No.	Visit																				Total Score	
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20		It.21
12	34	TGR	0	3	2	1	1	2	2	3	1	3	3	2	1	2	2	0	0	0	0	0	0	31	
			1	2	1	1	2	2	3	1	3	3	2	1	1	2	1	0	0	0	0	0	0	26	
			2	2	1	0	1	2	1	2	0	2	3	1	1	1	2	1	0	0	0	0	0	20	
			3	2	0	0	1	1	1	0	1	2	1	1	0	0	2	1	0	0	0	0	0	14	
			4	2	0	0	0	1	1	0	0	1	1	1	0	0	2	0	0	0	0	0	0	0	9
			5	1	0	0	0	1	0	0	1	1	0	0	1	1	2	1	0	0	0	0	0	0	8
12	35	LP	-1	4	2	2	2	2	2	3	1	3	3	0	2	2	3	0	0	1	0	0	0	35	
			0	4	2	2	2	2	2	1	3	3	0	2	2	3	0	0	0	1	0	0	0	34	
			1	4	2	2	2	2	2	2	1	3	3	0	2	2	3	0	0	1	0	0	0	34	
			2	4	2	1	1	2	2	1	2	3	3	0	2	2	3	0	0	0	1	0	0	0	31
			3	3	1	1	1	2	1	1	2	2	1	2	3	0	2	3	0	0	1	0	0	0	25
			4	3	1	0	1	1	2	1	1	2	2	1	0	1	2	2	0	0	0	0	0	0	20
12	CO36 OO OO	FB	6	1	0	0	1	1	0	0	1	1	0	1	1	2	1	0	0	0	0	0	0	13	
			-1	3	2	1	2	2	3	0	3	3	1	0	1	2	2	0	0	0	0	0	0	27	
			0	3	2	1	2	2	2	3	0	3	3	1	0	1	2	2	0	0	0	0	0	0	27
			1	2	2	0	2	2	2	3	0	3	3	1	0	1	2	2	0	0	0	0	0	0	25
			2	3	1	1	1	2	1	2	3	0	2	3	2	0	0	2	2	0	0	0	0	0	24
			3	3	1	1	1	1	1	3	0	2	2	2	0	0	2	2	0	0	0	0	0	0	21
12	37	EK	4	3	0	0	2	1	1	2	0	2	2	1	0	1	2	1	0	0	0	0	0	18	
			5	3	0	0	2	1	1	2	0	2	2	1	0	1	2	1	0	0	0	0	0	17	
			6	2	0	0	1	0	0	2	2	2	2	0	2	2	2	0	0	0	0	0	0	0	13
			-1	3	0	0	2	1	1	2	3	3	0	0	0	2	0	0	0	0	0	0	0	0	18
			0	2	0	0	2	2	1	1	2	3	3	0	0	0	2	0	0	0	0	0	0	0	18
			1	2	0	0	1	1	0	1	2	2	3	0	0	0	2	0	0	0	0	0	0	0	14
12	38	FG	2	2	0	0	1	1	0	1	1	2	3	0	0	0	0	0	0	0	0	0	0	12	
			3	2	0	0	0	1	0	1	1	2	2	0	0	0	2	0	0	0	0	0	0	11	
			4	1	0	0	0	0	1	1	2	2	0	0	0	0	2	0	0	0	0	0	0	9	
			5	1	0	0	0	0	1	1	1	2	2	1	1	1	2	0	0	0	0	0	0	0	7
			6	0	0	0	0	0	1	1	1	1	1	0	0	0	2	0	0	0	0	0	0	0	5
			-1	3	0	1	1	1	2	1	2	2	2	3	1	2	1	2	1	0	1	0	0	0	26
13	1	PZ	0	3	0	0	1	2	2	1	1	2	2	2	1	0	1	1	1	0	0	0	0	22	
			1	3	0	0	1	2	2	1	1	2	2	1	1	0	1	1	0	1	0	0	0	20	
			2	2	0	0	0	2	2	1	1	2	1	2	1	1	0	1	1	0	1	0	0	18	
			3	2	0	0	0	2	2	1	1	2	1	2	1	1	0	1	1	0	1	0	0	19	
			4	4	2	0	1	2	2	2	2	0	3	3	2	1	0	1	1	0	1	0	0	0	28
			5	4	2	2	1	2	1	2	1	2	1	2	1	1	0	1	0	1	0	0	0	0	24
13	1	PZ	6	4	2	2	1	2	1	2	1	3	1	1	0	1	1	0	1	0	0	0	0	24	
			-1	4	1	1	2	1	2	4	2	2	3	2	1	1	2	1	2	0	2	0	0	1	34
			0	4	1	1	2	1	2	4	2	2	1	1	2	1	2	1	2	0	2	0	0	1	32
			1	3	0	0	2	2	2	1	1	1	3	3	2	1	1	3	1	0	1	0	0	0	27
			2	2	0	0	1	0	1	1	0	1	2	1	0	1	1	0	0	0	1	0	0	0	13

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Patient No.	Centre No.	Initials	Visit No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score
13	1	P2	3	2	1	0	1	0	1	3	1	2	2	2	1	1	2	3	1	0	1	0	1	1	26
			4	2	0	0	1	1	1	2	1	2	2	1	1	1	1	2	0	0	1	0	1	1	21
			5	1	0	0	0	0	1	1	0	1	0	1	0	0	0	1	1	1	0	1	0	0	8
			6	3	0	0	1	0	1	1	2	2	1	1	2	1	1	2	1	2	1	0	0	0	20
13	2	TCS	-1	3	3	3	2	2	3	4	3	4	3	3	2	1	2	2	2	0	2	0	0	1	42
			0	4	1	3	2	2	3	3	3	3	3	3	2	1	2	3	2	0	2	0	0	1	41
			1	2	0	2	2	1	1	2	2	3	3	3	1	1	2	2	2	0	2	0	1	1	34
			2	2	0	1	2	2	1	1	1	2	3	2	0	1	1	2	0	0	1	0	1	1	24
			3	2	0	1	2	2	1	1	1	2	3	2	0	1	1	2	0	0	1	0	1	1	23
			4	2	0	2	2	2	0	2	2	3	3	3	1	1	1	1	1	0	1	0	0	0	26
			5	1	0	1	0	0	1	1	0	2	2	2	0	1	1	1	1	1	1	0	0	0	14
			6	2	0	1	0	1	1	1	0	2	2	2	0	1	1	2	0	1	2	0	0	0	17
13	3	AI	-1	4	2	3	2	2	1	4	3	0	3	0	1	1	2	0	1	0	2	0	1	0	32
			0	4	2	3	2	2	2	4	3	0	3	0	1	2	2	0	1	0	2	0	1	0	36
			1	3	3	0	1	2	2	3	3	2	3	0	1	2	1	0	2	0	0	1	1	0	30
			2	2	0	0	0	2	2	1	2	1	2	1	2	1	0	0	0	0	0	0	0	0	18
			3	2	0	0	0	1	1	1	2	1	1	1	1	1	1	0	0	0	0	0	0	0	12
			4	1	0	0	1	1	1	1	1	2	1	1	1	1	1	1	0	0	0	0	0	0	13
			5	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
			6	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
13	4	SZJ	-1	4	0	3	2	2	2	4	3	4	3	3	2	1	2	3	2	0	0	2	0	1	43
			0	4	0	3	2	2	2	4	3	4	3	3	2	2	2	3	2	0	0	2	0	2	45
			1	3	0	0	1	2	1	3	3	4	3	2	1	1	2	3	0	1	1	0	1	0	32
			2	1	0	1	1	2	1	2	2	1	1	1	2	1	2	2	2	0	2	0	0	0	24
			3	2	0	0	2	2	2	1	2	2	1	2	2	1	2	2	2	0	2	0	1	0	28
			4	3	0	0	2	2	2	4	3	1	2	2	2	0	2	2	1	0	0	1	0	0	27
			5	2	0	2	2	2	2	4	2	3	2	3	2	2	2	3	1	1	2	0	1	1	39
			6	4	0	2	1	0	2	4	3	3	3	3	2	1	2	2	0	2	1	2	1	1	37
13	5	HF	-1	4	2	3	2	2	1	3	2	3	3	3	2	1	2	3	2	0	2	2	1	1	44
			0	4	2	3	2	2	1	3	2	3	3	3	2	1	2	3	2	0	2	2	1	1	44
			1	3	2	2	2	1	1	3	2	2	3	3	2	1	2	3	2	0	2	1	1	1	39
13	6	KE	-1	3	0	2	2	0	0	3	2	1	3	3	1	1	2	3	3	0	2	0	0	1	31
			0	3	0	2	2	0	0	3	2	1	3	3	1	1	2	3	3	0	2	0	0	1	30
			1	3	0	1	2	1	0	3	2	1	3	2	1	1	2	2	0	0	2	0	0	1	27
			2	2	0	1	2	1	2	3	1	2	2	1	1	1	2	2	0	0	2	0	0	1	25
			3	2	1	1	1	1	1	1	1	2	2	0	1	1	2	2	0	0	1	1	0	1	21
			4	2	1	0	1	1	1	1	2	1	2	3	1	1	1	2	0	0	1	1	0	1	25
			5	2	1	0	1	1	1	1	2	1	2	3	1	1	1	2	0	0	1	2	0	1	26
			6	2	0	0	1	1	1	1	3	0	2	2	2	1	1	2	0	0	1	0	0	1	19
13	7	BL	-1	3	1	2	1	2	2	1	3	2	1	1	1	1	2	1	1	0	1	0	0	1	29
			0	3	1	1	2	0	2	3	2	2	1	2	2	1	2	2	2	0	2	0	0	1	39
			1	1	0	0	2	1	0	2	1	0	1	1	1	1	2	2	1	0	1	0	0	0	17

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Patient No.	Centre No.	Initials	Visit	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score		
7	13	BL	2	1	0	0	1	1	1	1	1	1	1	1	0	0	2	1	0	0	0	0	0	0	13		
			3	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	14		
			4	0	0	0	1	1	1	1	1	1	1	1	1	1	2	1	0	0	0	0	0	0	14		
			5	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2	0	0	0	0	5		
			6	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2	0	0	0	0	4		
8	13	PK	-1	2	1	1	2	2	0	2	1	1	3	3	1	1	2	3	2	0	2	1	2	1	33		
			0	2	1	2	2	2	2	3	2	2	3	3	1	2	3	2	2	0	1	1	2	1	39		
			1	1	0	0	2	2	2	1	1	2	2	1	1	1	2	0	0	0	1	0	0	0	20		
			2	1	0	0	1	2	2	1	1	2	1	1	1	1	2	1	0	0	1	0	0	0	21		
			3	2	0	0	1	2	2	2	2	2	2	1	1	2	1	1	0	1	1	0	0	0	24		
			4	2	0	0	2	2	1	2	1	2	3	1	2	2	1	2	0	1	1	0	0	0	24		
			5	1	0	0	2	2	1	2	1	2	3	1	2	2	1	2	0	1	1	0	0	0	25		
			6	1	0	0	2	2	1	1	1	1	1	1	1	2	1	2	0	1	0	0	0	0	15		
			7	1	0	0	2	1	1	1	1	1	1	2	1	1	2	1	2	0	1	0	0	0	19		
9	13	SZS	-1	3	2	3	2	2	2	3	1	1	3	3	2	1	1	2	1	0	1	2	0	1	36		
			0	3	1	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1	1	0	28	
			1	3	0	0	2	2	2	2	2	2	2	2	2	2	2	2	1	1	0	2	0	0	0	28	
			2	3	1	0	2	2	2	2	2	2	2	2	2	2	2	3	2	0	0	0	0	0	0	32	
			3	2	0	1	2	2	2	2	2	2	2	2	2	2	2	2	0	0	0	0	0	0	0	28	
			4	3	0	0	2	2	2	4	3	2	3	3	2	2	2	2	2	1	1	0	0	0	0	35	
			5	2	1	0	2	2	2	2	2	2	2	2	2	2	2	2	0	0	1	0	1	0	0	27	
			6	2	0	1	2	2	1	1	1	1	1	1	0	0	1	2	1	1	0	1	0	0	0	18	
10	13	BH	-1	3	0	1	1	1	2	3	2	1	2	3	1	1	2	3	1	0	1	0	1	0	0	29	
			0	3	0	1	1	1	2	3	2	1	2	3	1	1	2	3	1	0	1	0	1	0	0	29	
			1	3	0	1	1	1	2	3	2	1	2	3	1	1	2	3	1	0	1	0	1	0	0	29	
11	13	HS	-1	3	0	4	2	2	2	4	2	2	3	3	2	2	2	3	2	1	2	0	1	0	0	42	
			0	3	0	2	2	2	2	4	2	2	3	3	2	2	2	3	2	1	1	0	1	0	0	37	
			1	3	0	1	1	2	2	4	2	2	3	3	2	2	2	2	0	0	1	0	1	0	0	31	
			2	2	0	0	1	1	1	4	2	2	3	2	1	1	2	3	0	0	1	0	1	1	1	28	
			3	2	0	0	1	1	1	3	1	1	2	2	0	1	1	2	0	0	1	0	1	1	1	20	
			4	2	0	0	1	1	1	2	0	1	1	1	1	1	1	1	1	1	0	1	0	1	1	18	
			5	2	0	0	1	1	1	2	0	1	1	1	1	1	1	1	1	0	1	0	0	0	0	10	
			6	1	0	0	0	0	0	1	0	1	1	1	1	1	1	1	1	0	0	1	0	0	0	9	
12	13	BF	-1	4	1	2	2	1	1	4	2	2	3	3	1	1	1	2	2	0	2	1	0	1	0	36	
			0	3	1	2	2	2	2	3	3	3	3	3	1	2	2	2	0	0	0	1	0	1	0	35	
			1	3	1	0	2	2	2	1	3	3	3	3	1	2	2	3	0	0	1	1	0	1	0	35	
			2	3	3	2	2	2	2	3	3	3	3	3	2	2	2	3	1	1	1	1	1	1	1	42	
			3	3	0	1	2	2	2	3	3	3	3	3	2	2	2	3	1	1	1	1	1	1	1	36	
			4	3	2	1	2	2	2	3	3	3	3	3	1	1	2	3	0	0	1	1	1	1	1	36	
			5	1	1	1	1	1	1	3	1	2	1	1	1	1	2	2	2	0	2	1	0	0	0	25	
13	13	HH	-1	3	0	0	2	2	2	4	3	3	3	3	2	1	2	2	2	0	1	0	0	0	0	37	
			0	2	0	0	2	1	2	1	2	2	3	1	1	2	2	2	2	0	1	0	0	0	0	28	
			1	2	0	0	1	1	1	3	1	2	1	2	0	1	2	2	2	0	0	0	0	0	0	0	21

890

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit No.	Hamilton Depression Rating Scale																				Total Score		
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20		It.21	
13	13	HK	2	2	0	0	2	2	2	2	2	2	2	1	1	2	2	2	0	1	0	0	1	29		
			3	2	0	0	2	2	2	3	3	3	3	1	0	2	3	0	0	1	1	0	0	1	31	
			4	2	0	0	2	2	1	2	0	1	2	2	0	1	2	2	0	0	0	0	0	0	19	
			5	2	0	0	1	1	1	1	1	1	1	1	0	2	1	0	0	1	0	0	0	0	14	
			6	1	0	0	1	0	0	1	1	1	1	0	0	0	1	1	0	0	1	0	0	0	0	8
			-1	3	0	0	2	2	2	3	2	3	2	3	1	2	2	2	2	0	1	0	0	1	33	
13	14	DF	0	3	0	1	2	2	3	2	3	3	3	1	2	2	3	2	0	2	1	0	1	38		
			1	2	0	1	1	2	2	2	1	3	2	3	1	2	2	3	0	1	1	1	0	1	31	
			2	2	0	0	2	2	2	2	2	1	3	2	3	1	2	2	3	0	2	0	1	1	31	
			3	2	0	1	0	2	2	2	2	2	3	1	2	2	2	3	0	0	1	1	0	1	29	
			4	2	0	0	1	2	2	1	1	2	2	2	0	1	2	2	0	1	2	0	0	0	23	
			5	1	0	0	1	1	1	1	1	1	2	1	1	1	1	2	1	0	1	1	1	1	17	
13	15	KG	6	1	0	0	1	2	1	0	1	1	2	1	1	1	1	2	0	1	1	0	0	16		
			-1	4	1	1	2	1	1	4	3	0	3	3	1	1	2	2	1	0	2	2	1	0	35	
			0	4	1	1	2	1	1	4	3	0	3	3	1	1	2	2	1	0	2	1	0	1	35	
			1	3	0	0	2	2	2	3	3	0	3	3	1	1	2	2	1	0	1	2	1	0	32	
			2	3	0	0	2	2	2	3	3	0	3	3	1	1	2	2	0	1	0	1	2	1	0	32
			3	3	0	0	2	2	2	3	3	0	3	3	1	1	2	2	0	1	0	1	0	1	0	31
13	16	SZL	4	2	0	0	1	2	1	2	2	0	1	1	1	1	2	0	0	0	0	1	0	16		
			5	2	0	0	1	1	1	2	2	0	1	1	1	1	1	0	0	0	0	1	0	0	16	
			6	1	0	0	1	1	1	2	2	0	1	1	0	1	1	1	0	0	0	0	0	0	12	
			-1	3	1	1	2	2	2	3	2	3	2	3	2	2	2	3	2	0	1	0	1	0	37	
			0	3	1	1	2	2	2	3	2	3	3	3	2	2	2	3	0	1	1	0	1	0	37	
			1	3	0	0	2	2	2	2	2	2	2	3	2	2	2	3	0	0	1	0	1	0	31	
13	17	GSM	2	3	0	1	1	1	1	1	0	1	1	2	1	1	1	3	2	0	1	0	1	0	22	
			3	2	0	1	1	1	1	2	0	2	1	1	1	1	1	2	0	0	1	0	1	0	21	
			4	2	0	0	1	1	1	1	1	0	1	1	1	0	1	1	0	0	1	0	0	0	13	
			5	2	0	0	2	2	2	1	0	0	1	1	1	1	2	3	0	0	1	0	0	0	19	
			6	3	1	0	1	0	2	3	1	1	3	3	2	1	2	3	2	0	2	0	1	1	1	32
			-1	3	2	0	2	2	2	3	3	3	3	3	3	1	2	2	2	1	1	1	1	0	1	39
13	18	VT	0	3	2	0	2	2	2	3	2	2	3	3	1	2	2	2	2	1	1	0	0	1	37	
			1	2	1	0	2	2	2	3	3	2	2	3	1	2	2	1	0	0	0	0	0	0	28	
			2	1	0	0	2	2	1	2	1	2	1	1	1	1	0	0	0	0	0	0	0	0	19	
			3	1	0	0	0	1	0	1	1	1	1	1	0	1	1	0	0	0	0	0	0	0	8	
			4	1	0	0	0	0	1	1	0	1	1	1	1	1	1	0	0	0	0	0	0	0	0	9
			5	1	0	0	0	0	0	2	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	7
13	19	VT	6	1	0	0	1	0	1	1	0	1	1	1	1	1	0	0	1	0	1	0	0	0	11	
			-1	3	0	0	2	2	1	1	2	2	3	3	0	1	2	3	0	0	2	0	1	2	30	
			0	3	0	0	2	2	1	2	2	1	2	3	3	0	1	2	3	0	0	2	0	1	2	32
			1	3	0	0	2	2	1	1	1	1	2	3	3	0	1	2	3	0	0	2	0	1	1	26
			2	2	0	0	2	1	1	1	1	1	2	2	2	0	1	1	1	0	0	1	0	1	0	17
			3	1	0	0	1	1	0	2	1	0	1	0	0	0	0	2	0	0	1	0	1	0	0	10
13	20	VT	4	1	0	0	2	2	2	1	1	0	1	1	0	0	0	0	0	0	1	0	0	0	14	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.1

HAMILTON DEPRESSION RATING SCALE
OPEN PHASE

Centre No.	Patient No.	Initials	Visit No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score			
13	18	VT	5	1	0	0	1	1	1	1	1	1	1	2	0	1	0	1	0	0	1	0	0	0	0	13		
			6	1	0	0	1	0	1	1	1	1	1	1	1	1	0	1	0	1	0	1	0	0	0	9		
13	19	KK	-1	3	2	3	2	1	2	4	2	1	2	1	1	1	2	1	2	0	2	1	1	1	1	35		
			1	3	2	0	2	1	1	3	1	1	1	1	2	1	1	1	2	1	1	0	2	1	1	1	28	
			2	3	0	3	1	1	2	3	2	1	3	2	2	1	2	0	1	0	0	0	0	0	0	0	27	
			3	2	0	1	2	2	2	2	2	2	2	2	2	2	2	1	2	2	0	0	0	2	2	1	28	
13	20	NL	-1	3	1	2	2	2	2	3	2	3	3	3	2	2	2	3	2	1	2	2	2	3	1	45		
			0	3	1	2	1	2	3	2	3	2	2	3	3	2	2	3	0	0	1	2	2	3	1	43		
			1	3	0	0	1	1	2	1	2	2	2	2	2	2	0	1	2	3	0	0	1	1	3	1	26	
			2	3	0	0	1	1	1	1	1	1	2	1	2	1	1	1	1	1	0	0	0	0	2	1	19	
			3	1	0	0	2	1	1	1	1	1	2	1	2	1	0	1	0	0	2	1	1	0	0	2	1	18
			4	2	0	0	0	1	1	1	1	2	2	2	0	0	0	0	0	1	1	0	0	0	2	1	18	
13	21	CL	5	1	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	1	1	11		
			6	1	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	1	1	11	
			-1	2	3	0	1	2	2	1	2	2	3	3	3	1	2	2	2	0	0	1	1	0	1	0	0	32
			0	3	3	0	1	2	2	2	2	2	3	3	3	1	2	2	2	2	2	2	2	1	2	0	0	55
			1	2	3	1	1	2	1	1	0	2	2	3	1	2	2	2	2	2	2	2	2	0	2	0	0	32
			2	2	2	0	1	1	1	0	2	1	2	1	1	1	1	1	1	1	1	1	1	2	0	2	0	23
13	22	NYH	3	1	1	0	0	0	0	0	0	2	0	1	1	0	1	1	1	1	1	1	2	0	0	12		
			4	1	1	0	0	0	0	0	0	0	2	0	1	1	0	0	1	1	2	1	1	2	0	0	12	
			5	1	0	0	0	0	0	0	0	0	2	0	0	0	0	1	1	1	1	1	2	0	0	0	7	
			6	1	0	0	0	0	0	0	0	0	2	0	0	0	0	1	1	1	1	1	2	0	0	0	7	
			-1	3	0	0	2	2	2	2	2	1	3	2	1	2	2	3	2	0	0	0	0	0	0	0	29	
			0	3	0	1	2	2	2	2	2	2	3	3	3	1	2	2	2	0	1	1	1	0	2	0	0	31
13	23	BSB	1	2	2	0	1	1	0	2	2	3	1	1	2	2	2	2	3	0	0	0	0	0	0	20		
			2	2	0	1	2	2	1	1	1	1	1	1	1	1	1	1	2	1	0	0	1	0	0	1	20	
			3	2	0	1	2	2	1	1	1	1	1	1	1	1	1	1	1	2	1	0	0	1	0	0	1	22
			4	2	0	2	2	2	2	2	2	0	1	2	0	1	1	2	2	1	0	0	1	0	0	1	22	
			5	1	0	1	1	2	2	2	2	2	0	1	1	1	1	1	2	1	0	0	1	0	0	1	18	
			6	1	0	1	1	2	1	1	2	1	1	1	1	1	1	1	2	1	0	0	1	0	0	1	16	
13	25	BSB	-1	3	0	0	2	1	1	3	1	1	2	2	1	2	0	2	0	0	0	0	0	0	0	25		
			0	3	0	1	2	2	1	2	3	1	2	2	1	2	2	1	2	0	1	1	2	1	2	1	32	
			1	2	1	1	2	1	1	2	2	2	2	1	1	2	2	2	2	2	2	2	2	0	1	0	1	25
			2	2	1	1	2	1	1	1	2	1	1	1	1	1	1	1	1	2	0	0	1	0	1	0	1	19
			3	1	1	0	2	1	1	0	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	1	17
			4	1	0	0	2	1	1	0	1	1	2	1	1	1	1	2	1	0	0	1	0	0	0	1	21	
13	26	BSB	5	1	0	0	2	1	1	0	1	1	2	1	1	1	1	2	1	0	0	1	0	0	0	9		
			6	1	0	0	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	11

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

D.B.		Visit																					Total	
Centre	Patient Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score
1	3	2	TA	8	1	0	0	1	1	0	0	1	1	0	0	1	0	0	0	0	1	0	0	8
				10	1	0	1	1	0	1	0	1	1	0	1	0	1	0	0	0	1	1	0	10
				12	0	0	1	1	0	0	1	1	1	0	1	0	1	0	0	0	0	1	0	8
				14	0	0	1	1	0	1	0	1	1	0	1	0	1	0	0	0	0	1	0	9
				16	0	0	1	1	0	1	0	1	1	0	0	0	1	0	0	0	1	0	0	8
				18	0	0	1	1	0	1	0	1	1	0	0	0	1	0	0	0	1	0	0	7
				20	0	0	1	1	0	1	0	1	1	0	0	1	0	0	0	0	0	0	0	7
				22	0	0	1	1	0	0	1	1	1	0	1	0	1	0	0	0	1	0	0	7
				24	1	0	0	1	0	0	1	1	1	0	1	0	1	0	0	0	1	0	0	8
				26	1	0	0	1	0	1	0	1	1	0	1	0	1	0	0	0	1	0	0	9
				28	0	0	0	1	0	1	0	1	1	0	1	0	1	0	0	0	1	0	0	8
				30	0	0	0	1	0	1	0	1	2	0	1	0	1	0	0	0	1	0	0	9
				32	0	0	0	1	0	1	0	2	1	0	1	0	1	0	0	0	0	0	0	7
				34	0	0	0	1	0	0	2	1	0	1	0	1	0	0	0	0	0	0	0	10
				36	1	0	0	1	0	0	1	1	0	1	0	1	0	0	0	0	0	0	0	7
				38	0	0	0	1	0	0	1	0	1	0	0	1	0	0	0	0	1	0	0	6
				40	0	0	0	1	1	1	0	2	1	0	0	1	0	0	0	0	1	0	0	7
				42	1	0	0	1	1	1	0	2	1	1	0	0	1	0	0	0	1	0	0	12
				44	0	0	0	1	0	1	0	2	2	1	0	0	0	0	0	0	0	0	0	11
				46	0	0	0	1	0	1	0	2	2	0	1	0	0	0	0	0	0	0	0	8
				48	1	0	0	1	0	1	0	1	0	1	0	0	0	0	0	0	0	0	0	6
				50	0	0	0	1	0	1	0	1	0	1	0	0	0	0	0	0	0	0	0	5
				52	0	0	0	1	0	1	0	1	1	0	1	0	0	0	0	0	1	0	0	6
1	4	3	DNC	8	1	0	0	1	1	0	0	1	1	0	0	0	1	0	0	0	1	0	0	9
				10	0	0	1	0	0	0	0	1	1	0	0	1	0	0	0	0	1	0	0	6
				12	0	0	1	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	4
				14	0	0	0	0	0	1	0	1	1	0	0	0	1	0	0	0	0	0	0	5
				16	0	0	0	1	0	0	1	1	1	0	1	0	0	0	0	0	0	0	0	6
				18	0	0	0	1	0	0	0	1	1	0	1	0	0	0	0	0	0	0	0	4
				20	0	0	0	1	0	0	0	1	1	0	1	0	0	0	0	0	0	0	0	4
				22	0	0	0	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	6
				24	0	0	0	1	0	0	0	1	1	0	1	1	0	0	0	0	0	0	0	8
				26	0	0	0	1	0	1	0	0	1	0	0	1	1	0	0	0	0	0	0	6
				28	0	0	0	1	0	0	0	2	1	0	0	0	1	0	0	0	0	0	0	4
				30	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	5
				32	0	0	0	1	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	6
				34	0	0	0	1	0	0	0	1	2	0	0	0	1	0	0	0	0	0	0	7
				36	0	0	0	1	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	6
				38	0	0	0	1	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	7
				40	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	4
				42	0	0	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	3
				44	0	0	0	1	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	4
				46	0	0	0	1	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	4
				48	0	0	0	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	3
				50	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	5
				52	0	0	0	1	0	0	0	1	1	0	0	1	0	0	0	0	0	0	0	6

893

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXETINE - PROTOCOL 2012A/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REMOXETINE

D.B.		Visit		Hamilton Depression Rating Scale																				Total	
Centro Patient Initials		No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score	
1	5	4	DB	8	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	6
				10	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	5
				12	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	6
				14	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	5
				16	0	0	0	0	0	0	0	2	1	0	0	0	0	0	0	0	0	0	0	0	6
				18	0	0	0	0	0	0	0	2	1	0	0	0	0	0	0	0	0	0	0	0	5
				20	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	6
				22	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	6
				24	0	0	0	0	0	0	0	1	2	0	0	0	0	0	0	0	0	0	0	0	7
				26	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	6
				28	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	4
				30	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	6
				32	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	4
				34	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	4
				36	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	4
				38	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	4
				40	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	4
				42	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	4
				44	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	4
				46	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	5
				48	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	5
				50	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	4
				52	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	5
1	9	7	CCR	8	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	10
				10	1	0	0	0	0	0	0	1	2	1	1	0	0	0	0	0	0	0	0	0	13
				12	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	5
				14	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	6
				16	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	6
				18	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	6
				20	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	5
				22	0	0	0	0	0	0	0	1	2	1	0	0	0	0	0	0	0	0	0	0	7
				24	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	6
				26	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	5
				28	1	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	6
				30	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	4
				32	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	5
				34	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	4
				36	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	5
				38	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	4
				40	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	4
				42	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	4
				44	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	4
				46	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	4
				48	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	2
				50	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	3
				52	0	0	0	0	0	0	0	0	2	1	0	0	0	0	0	0	0	0	0	0	4

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.1

HAMILTON DEPRESSION RATING SCALE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient No.	Visit																					Total Score	
		It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21		
1	10	LDL	8	0	0	0	1	1	0	1	0	1	2	0	1	0	0	0	0	0	0	0	8	
			10	0	0	1	0	1	0	1	1	1	1	1	0	0	0	0	0	0	0	0	0	9
			12	0	0	1	1	1	0	0	1	1	1	1	0	0	0	0	0	0	0	0	0	6
			14	0	0	1	1	1	0	0	1	1	2	0	1	0	0	0	0	0	0	0	0	9
			16	0	0	0	1	0	1	0	0	1	1	0	1	0	0	0	0	0	0	0	0	5
			18	0	0	0	1	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	4
			20	0	0	0	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	5
			22	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	5
			24	0	0	0	1	1	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	6
			26	0	0	0	1	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	6
			28	0	0	0	0	0	0	1	0	0	1	2	1	0	0	0	0	0	0	0	0	6
			30	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	6
			32	0	0	0	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	5
			34	0	0	0	0	0	0	0	1	0	1	1	0	0	0	0	0	0	0	0	0	5
			36	0	0	0	0	0	0	1	0	1	1	0	0	0	0	0	0	0	0	0	0	5
			38	0	0	0	0	0	0	0	0	0	1	2	1	0	0	0	0	0	0	0	0	4
40	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	7			
42	0	0	0	1	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	7			
44	0	0	0	1	0	1	0	0	0	2	0	0	0	0	0	0	0	0	0	0	5			
46	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	5			
48	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	6			
50	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	6			
52	0	0	0	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	6			
1	14	MLC	8	2	0	0	1	1	1	2	1	0	2	1	0	1	0	0	0	0	0	15		
			10	2	0	1	1	1	1	2	2	2	1	2	1	1	0	0	0	1	1	0	21	
			12	3	1	2	2	2	3	3	0	4	3	2	2	1	3	0	0	1	2	1	0	37
			14	1	0	0	1	2	1	2	0	1	2	0	2	1	2	0	0	0	0	1	0	18
1	17	CEC	10	1	0	0	1	1	0	1	1	1	0	0	1	0	0	0	0	0	0	0	9	
			12	1	0	0	1	1	0	0	2	1	2	0	2	1	1	0	0	0	1	1	0	16
			14	1	0	0	1	0	0	0	0	2	0	0	1	1	1	0	0	0	1	0	0	10
			16	0	0	0	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	6
			18	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	7
			20	1	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	12
			22	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	9
			24	0	0	0	0	1	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	8
			26	0	0	0	0	1	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	6
			28	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	7
			30	0	0	0	0	1	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	6
			32	0	0	0	0	1	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	9
1	18	TTH	8	1	0	0	1	0	2	2	1	0	2	1	0	0	0	0	0	1	0	0	16	
			10	1	1	0	1	0	1	1	0	2	1	0	2	0	1	0	0	0	1	1	0	14
			12	1	1	0	1	1	1	2	1	0	2	1	0	1	1	0	0	0	0	1	0	16
			14	1	0	0	1	1	0	1	1	0	1	0	0	1	1	0	0	0	1	1	0	11
			16	1	0	0	1	0	1	2	1	0	0	2	1	0	0	0	0	0	0	0	0	12
			18	1	0	0	1	0	1	2	1	0	0	2	1	0	1	1	0	0	0	0	0	12

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

D.B.		Visit																				Total		
Centre	Patient Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score
1	18	15	ITM	18	0	0	0	1	0	0	1	0	0	1	1	0	0	1	1	0	0	0	0	6
1	20	17	EFC	8	2	1	1	2	1	2	1	0	2	2	1	1	2	0	0	0	0	0	0	20
				10	2	1	2	2	1	2	2	2	2	1	2	1	0	1	2	1	2	1	0	27
				12	3	1	2	2	1	2	3	2	0	3	2	1	2	0	0	2	2	1	0	34
1	22	19	SK	8	0	0	0	0	1	0	1	1	1	1	0	0	1	0	0	0	0	1	1	8
				10	0	0	0	0	1	0	1	1	1	1	0	0	0	0	0	0	0	0	1	6
				12	0	0	1	0	0	1	0	1	2	1	0	0	1	0	0	0	0	0	0	7
				14	1	0	1	1	0	0	1	1	1	1	0	0	1	1	0	0	1	1	0	10
				16	0	0	0	0	1	1	0	1	2	0	0	1	0	0	0	0	0	0	0	6
				18	0	0	0	0	1	0	0	1	0	0	1	0	1	0	0	0	0	0	0	4
				20	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	1	0	5
				22	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	5
				24	0	0	0	0	1	0	0	1	1	1	0	0	0	0	1	0	0	0	0	4
				26	0	0	0	1	0	0	0	1	1	1	0	0	0	0	1	0	0	0	0	5
				28	0	0	0	1	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	3
				30	0	0	0	1	0	0	1	1	0	1	0	0	0	0	0	0	0	0	0	7
				32	0	0	0	0	1	0	0	2	2	1	1	0	0	0	0	0	0	0	0	7
				34	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3
				36	0	0	0	1	1	0	0	0	2	0	0	0	0	0	0	0	0	0	0	6
				38	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	3
				40	0	0	0	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	4
				42	0	0	0	1	0	0	0	0	1	1	0	0	1	0	0	0	0	0	0	5
				44	0	0	0	1	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	5
				46	0	0	0	1	0	0	0	0	1	1	0	0	0	1	2	0	0	0	0	7
				48	0	0	0	1	0	0	0	1	1	1	0	0	0	1	1	0	0	0	0	6
				50	0	0	0	0	0	0	0	1	1	1	0	0	0	1	1	0	0	0	0	7
				52	0	0	0	0	0	0	0	1	1	1	0	0	1	1	0	0	0	0	0	5
1	24	20	LVF	8	1	0	0	1	0	0	1	1	1	1	0	0	1	0	0	0	0	0	0	8
				10	1	0	0	1	1	0	1	0	0	2	1	1	1	0	0	0	0	1	0	11
				12	1	0	0	1	1	0	1	0	1	2	1	0	1	0	0	0	0	1	0	11
				14	1	0	0	1	0	0	1	0	0	1	2	1	0	0	1	0	0	1	0	10
				16	1	0	1	1	0	0	1	0	1	2	1	0	1	1	0	0	0	0	0	10
				18	1	0	1	1	0	0	1	0	1	2	0	0	0	0	0	0	0	0	0	15
				20	1	0	0	1	0	0	1	0	0	1	2	0	0	0	0	0	0	0	0	8
				22	1	0	0	1	0	0	1	2	0	0	0	0	0	0	0	0	0	0	0	11
				24	1	0	0	2	0	0	2	1	0	2	1	0	0	0	0	0	0	0	0	11
				26	2	0	0	2	0	0	2	0	1	2	1	0	0	0	0	0	0	0	0	12
				28	0	0	0	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	6
				30	1	0	0	1	0	0	1	1	0	1	1	0	0	0	0	0	0	0	0	11
				32	1	0	0	1	0	0	1	1	0	1	1	0	0	0	0	0	0	0	0	6
				34	0	0	0	1	0	0	1	1	1	1	0	0	0	0	0	0	0	0	0	11
				36	1	0	0	1	0	0	1	1	1	1	0	0	0	0	0	0	0	0	0	7
				38	1	0	0	1	1	0	1	0	0	1	1	0	0	0	0	0	0	0	0	10
				40	1	0	0	1	1	0	1	0	0	1	1	0	0	0	0	0	0	0	0	7
				42	0	0	0	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	6
				44	0	0	0	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	5
				46	0	0	0	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	7
				48	0	0	0	1	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	6
				50	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	5
				52	0	0	0	0	0	0	0	1	1	1	0	0	1	1	0	0	0	0	0	4

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient Initials	D.S.	Visit No.	Visit																					Total Score	
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21		
1	LVF		42	1	1	1	2	0	0	1	0	2	2	1	0	2	1	0	0	0	0	0	0	14		
			44	1	1	1	2	0	0	1	0	2	2	1	0	2	1	1	0	0	0	0	0	15		
			46	1	0	0	1	0	1	0	2	2	0	0	2	1	0	0	0	0	0	0	0	10		
			48	0	0	0	1	0	1	0	2	1	0	0	2	0	1	0	0	0	0	0	0	8		
			50	0	1	0	0	1	1	0	2	1	0	0	2	0	0	0	0	0	0	0	0	8		
			52	0	1	0	0	1	1	0	2	1	0	0	0	0	0	0	0	0	0	0	0	7		
			1	AMR		8	0	0	0	1	0	1	1	0	2	1	0	0	0	0	0	0	0	0	0	7
						10	0	0	0	1	0	1	0	1	2	0	0	1	0	0	0	0	0	0	0	0
12	0	0				0	1	0	1	0	1	0	1	1	0	0	0	0	0	0	0	0	0	7		
14	0	0				0	1	0	0	0	0	1	1	0	0	1	0	0	0	0	0	0	0	4		
16	0	0				0	1	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	4		
18	0	0				0	1	0	0	0	1	0	0	2	0	0	1	0	0	0	0	0	0	6		
20	0	0				0	1	1	1	0	0	1	1	0	0	1	0	0	0	0	0	0	0	8		
22	0	0				0	1	1	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	6		
24	0	0				0	1	1	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	7		
26	0	0				0	1	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	7		
28	0	0				0	1	0	0	1	0	0	2	0	1	0	0	0	0	2	0	0	0	8		
30	0	0				0	1	0	0	1	0	0	1	0	0	1	0	0	0	0	0	0	0	6		
32	0	0				0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	5		
34	0	0				0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	5		
36	0	0				0	0	0	0	0	0	0	1	0	2	0	0	0	0	0	0	0	0	4		
38	0	0				0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	3		
40	0	0				0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	4		
42	0	0				0	0	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	5		
44	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	5					
46	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	6					
48	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	6					
50	0	0	0	0	0	0	0	0	0	1	0	2	0	0	0	0	0	0	0	0	6					
52	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	6					
1	HAM		8	1	0	0	2	0	0	1	1	0	0	1	0	0	1	0	0	0	0	0	8			
			10	1	0	0	1	0	0	1	0	1	2	0	0	1	0	0	1	0	0	0	8			
			12	1	1	0	0	1	0	0	1	1	0	2	1	0	1	1	0	0	1	0	0	12		
			14	0	0	0	1	0	1	1	1	0	2	1	0	0	0	0	0	0	0	1	0	9		
			16	1	0	0	1	0	0	1	0	1	0	2	1	0	0	0	0	0	0	1	0	9		
			18	1	0	0	1	0	0	1	1	0	2	1	0	0	0	0	0	0	0	1	0	11		
			20	1	0	0	1	0	1	1	1	0	1	2	0	0	1	0	0	0	0	0	0	11		
			22	1	0	0	0	2	1	1	1	0	1	2	0	0	1	0	0	0	0	0	0	12		
			24	0	0	0	0	0	1	0	1	0	2	2	1	0	0	0	0	0	0	1	0	8		
			26	1	1	0	0	1	0	1	1	0	2	2	1	1	0	0	0	0	0	1	0	11		
			28	1	1	0	1	1	0	1	1	0	1	1	1	0	0	0	0	0	0	1	0	14		
			30	1	0	0	1	1	0	0	1	1	0	2	0	0	1	0	0	0	0	0	0	11		
32	0	0	0	0	1	1	0	0	1	0	2	1	0	0	0	0	2	0	0	0	10					
34	0	0	0	0	2	1	0	0	1	0	2	0	0	0	0	0	0	0	0	0	9					
36	1	0	0	1	1	0	1	0	1	0	2	0	0	0	0	0	0	0	0	0	9					
38	0	0	0	0	2	1	0	0	0	1	0	2	0	0	0	0	0	0	0	0	9					

0001

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

D.B.	Centre	Patient	Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score
		1	31	27	MAM	40	0	0	0	1	1	0	1	0	0	1	0	0	0	0	0	0	0	0	0	5
						42	0	0	1	1	0	1	1	0	0	1	2	0	0	0	0	0	0	0	0	8
						44	0	0	2	0	0	1	1	0	1	1	2	1	0	0	0	0	0	0	0	9
						46	0	0	0	1	0	0	1	0	1	0	2	1	0	0	0	0	0	0	0	7
						48	0	0	0	1	2	0	0	0	1	0	2	1	0	0	0	0	1	0	0	8
						50	0	0	1	1	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	6
						52	0	0	0	1	0	1	0	0	1	0	0	1	0	0	0	0	0	0	0	4
		1	32	28	DGX	8	0	0	0	1	0	1	1	1	1	0	0	1	0	0	0	0	0	0	0	7
						10	0	0	1	1	0	2	2	2	0	1	1	1	0	0	0	1	1	0	0	12
						12	1	1	0	1	1	0	2	1	1	1	1	0	0	1	1	0	1	1	0	14
						14	1	1	0	1	1	0	0	1	2	0	2	1	1	1	1	0	0	1	1	15
						16	1	1	1	1	0	2	0	2	1	0	1	1	0	0	1	1	0	0	0	16
						18	2	0	1	2	1	2	2	0	2	2	0	2	1	0	0	1	0	0	0	19
						20	2	0	1	1	2	2	2	0	2	1	0	2	1	0	0	2	1	0	0	20
						22	2	0	1	1	1	2	2	0	2	2	1	2	1	0	0	0	1	1	0	21
						24	1	0	1	0	1	1	0	1	2	1	0	0	0	0	0	1	1	0	0	11
						26	1	0	0	1	0	1	1	0	1	0	0	1	0	0	2	0	1	1	0	11
						28	1	0	0	1	0	1	2	1	0	1	1	0	0	0	0	1	0	0	0	13
						30	1	0	0	1	1	0	1	0	1	0	1	2	1	0	0	1	0	0	0	11
						32	1	0	0	1	1	0	2	1	0	1	1	2	1	0	0	0	0	0	0	12
						34	2	0	0	1	1	1	0	0	1	1	1	2	1	0	0	0	0	0	0	12
						36	1	0	0	2	1	0	2	0	1	2	1	2	1	0	0	0	1	0	0	16
						38	2	0	0	2	2	0	2	0	1	2	1	2	1	0	0	0	0	0	0	17
						40	0	0	0	2	0	2	0	1	0	0	0	0	0	0	0	0	0	0	0	9
						42	0	0	0	1	0	1	1	0	1	0	2	0	0	0	0	0	0	0	0	7
						44	0	0	0	1	0	1	1	0	1	1	0	2	1	0	0	0	0	0	0	9
						46	0	0	0	1	0	1	0	0	2	0	0	0	0	0	0	0	0	0	0	8
						48	0	0	0	1	0	0	1	2	0	2	1	0	0	0	0	0	0	0	0	9
						50	0	0	0	2	0	1	0	1	1	0	2	1	0	0	0	0	0	0	0	8
						52	0	0	0	1	0	1	0	1	0	2	0	1	0	0	0	0	0	0	0	7
		1	34	30	GHI	8	1	0	1	0	0	1	1	0	1	0	0	1	0	0	0	0	1	1	0	9
						10	1	0	0	1	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	7
						12	1	1	0	0	0	2	1	0	2	1	0	1	1	0	0	0	0	1	0	12
						14	1	1	1	1	2	1	1	0	0	1	1	0	0	0	0	0	0	0	0	12
						16	1	0	0	1	1	1	0	0	1	1	0	1	1	0	0	0	1	1	0	11
						18	1	0	0	1	1	1	1	0	0	1	1	0	0	0	0	0	1	0	0	12
						20	1	0	0	1	2	1	1	0	0	1	1	0	0	0	0	1	0	0	0	11
						22	0	0	0	1	1	1	0	0	1	0	0	1	1	0	0	0	0	0	0	7
						24	2	0	0	1	1	1	2	0	2	1	1	0	0	0	0	0	0	0	0	15
						26	0	0	0	1	1	0	0	1	1	1	0	0	0	0	0	0	0	0	0	5
						28	1	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	14
						30	0	0	1	1	0	1	0	0	1	1	0	2	1	0	0	0	0	0	0	10
						32	1	1	1	2	1	0	2	1	0	2	1	0	0	0	0	0	0	0	0	15
						34	2	0	1	2	1	0	1	0	2	0	0	2	1	0	0	0	0	0	0	13
						36	2	0	1	2	1	0	1	0	2	0	0	2	1	0	0	0	0	0	0	14

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

D.B.		Visit																					Total		
Centre	Patient	Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score
1	34	GMH	38	2	1	1	2	2	0	2	1	0	2	1	0	2	1	0	0	0	0	0	0	0	17
			40	1	1	1	1	1	1	2	0	1	2	0	1	0	0	0	0	0	0	0	0	0	15
			42	0	0	0	2	1	1	2	0	0	2	0	0	0	0	0	0	0	0	0	0	0	9
			44	0	0	0	1	1	2	1	0	1	2	0	0	0	0	0	0	0	0	0	0	0	9
			46	0	0	1	1	1	1	2	2	0	2	1	1	2	1	0	0	0	0	0	0	0	14
			48	1	0	1	2	1	1	2	2	0	2	1	1	2	1	0	0	0	0	0	0	0	17
			50	1	0	0	2	1	0	1	1	0	1	1	1	2	1	0	0	0	0	0	0	0	12
			52	1	0	0	1	1	1	1	1	0	1	0	1	1	1	0	0	0	0	0	0	0	11
			8	0	0	0	1	1	0	1	0	1	2	1	1	0	0	1	0	0	0	1	0	0	10
			10	0	0	0	1	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	4
			12	0	0	0	1	0	1	0	0	2	1	0	2	1	0	0	0	0	0	0	0	0	10
			14	0	0	0	1	0	1	0	0	1	1	0	1	0	1	0	0	0	0	0	0	0	9
			16	0	0	0	1	0	1	1	0	1	1	0	1	0	1	0	0	0	0	0	0	0	10
			18	0	0	0	1	0	1	1	0	1	1	0	1	0	1	0	0	0	0	0	0	0	9
			20	0	0	0	1	0	0	0	0	0	1	1	0	0	1	0	0	0	0	0	0	0	4
			22	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	4
			24	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	2
			26	0	0	0	1	0	0	0	0	0	2	1	0	0	0	0	0	0	0	0	0	0	8
			28	0	0	0	1	0	0	0	0	1	1	0	0	2	1	0	0	0	0	0	0	0	8
			30	0	0	0	2	0	0	0	1	0	2	0	0	2	1	0	0	0	0	0	0	0	11
			32	1	0	1	2	0	0	1	1	0	2	0	0	2	1	0	0	0	0	0	0	0	11
			34	1	0	0	2	0	0	0	1	0	2	0	0	2	1	0	0	0	0	0	0	0	7
			36	0	0	0	2	0	0	0	0	1	0	1	0	0	1	0	0	0	0	0	0	0	5
			38	0	0	0	2	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	5
			40	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	5
			42	0	0	0	1	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	5
			44	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	6
			46	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	6
			48	0	0	0	1	0	0	0	0	0	2	0	0	2	1	0	0	0	0	0	0	0	7
			50	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	5
			52	0	0	0	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	6
			8	0	0	0	1	0	0	1	0	1	2	1	1	0	0	0	0	0	0	0	0	0	7
			10	0	0	0	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	4
			12	0	0	0	1	0	0	1	0	0	2	1	0	0	0	0	0	0	0	0	0	0	4
			14	0	0	0	1	0	0	1	0	0	2	1	0	0	0	0	0	0	0	0	0	0	11
			16	0	0	0	1	0	0	1	0	0	1	2	1	0	0	0	0	0	0	0	0	0	9
			18	0	0	0	1	0	0	1	0	0	2	1	0	0	0	0	0	0	0	0	0	0	10
			20	0	0	0	1	0	0	1	0	0	1	2	0	0	1	0	0	0	0	0	0	0	8
			22	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	5
			24	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	5
			26	0	0	0	0	0	0	0	0	0	2	1	0	0	0	0	0	0	0	0	0	0	4
			28	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	4
			30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4
			32	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
			34	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
			26	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	6
			28	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	6
			30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
			32	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
			34	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7

899

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

D. B.		Centre Patient		Initials	Visit No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score	
1	37	303	RF		36	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	6
					38	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	8
					40	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	6
					42	0	0	0	0	0	0	0	0	0	1	1	2	0	0	0	0	0	0	0	0	0	0	8
					44	0	0	0	0	0	0	0	0	0	2	1	1	0	0	0	0	0	0	0	0	0	0	8
					46	0	0	0	0	0	0	0	0	0	2	1	1	0	0	0	0	0	0	0	0	0	0	7
					48	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	6
					50	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	7
					52	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	6
1	39	305	ASS		8	1	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	11
					10	1	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	9
					12	1	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	7
					14	1	0	0	0	0	0	0	0	0	2	1	0	0	0	0	0	0	0	0	0	0	0	10
					16	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	10
					18	1	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	11
					20	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	8
					22	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	8
					24	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	9
					26	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	8
					28	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	9
					30	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	10
					32	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	10
					34	1	0	0	0	0	0	0	0	0	2	1	0	0	0	0	0	0	0	0	0	0	0	13
					36	1	0	0	0	0	0	0	0	0	2	1	0	0	0	0	0	0	0	0	0	0	0	13
					38	1	0	0	0	0	0	0	0	0	2	1	0	0	0	0	0	0	0	0	0	0	0	14
					40	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	17
					42	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	10
					44	1	0	0	0	0	0	0	0	0	2	1	0	0	0	0	0	0	0	0	0	0	0	11
					46	1	0	0	0	0	0	0	0	0	2	1	0	0	0	0	0	0	0	0	0	0	0	14
					48	1	0	0	0	0	0	0	0	0	2	1	0	0	0	0	0	0	0	0	0	0	0	12
					50	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	12
					52	1	0	0	0	0	0	0	0	0	2	0	2	0	0	0	0	0	0	0	0	0	0	16
1	43	309	ARN		8	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	16
					10	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	5
					12	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	6
					14	1	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	6
					16	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	7
					18	0	0	0	0	0	0	0	0	0	2	1	0	0	0	0	0	0	0	0	0	0	0	11
					20	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	6
					22	0	0	0	0	0	0	0	0	0	2	1	0	0	0	0	0	0	0	0	0	0	0	6
					24	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	7
					26	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	7
					28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
					30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
					32	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6

900

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	Initials	Visit No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score
1	43	309	ARN	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	0	0	0	0	5
				36	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	0	0	0	0	6
				38	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	0	0	0	0	7
				40	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				42	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				44	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				48	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				52	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
1	45	310	DPS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4
				16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4
				18	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4
				20	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4
				22	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10
				28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
				30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				32	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				34	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10
				36	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				38	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				40	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				42	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				44	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				48	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10
				50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				52	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
1	46	311	SP	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				8	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	12
				10	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
				12	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	11
				14	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4
				16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				18	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				20	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
				22	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3
				24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
				26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
				28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.1

HAMILTON DEPRESSION RATING SCALE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

D.B.		Visit																				Total		
Centre	Patient Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score
1	46	311	SP	32	0	0	0	1	0	0	1	1	1	0	0	1	0	0	0	0	0	0	0	6
				34	0	0	1	1	0	0	1	1	1	0	0	1	1	0	0	0	0	0	0	7
				36	0	0	2	0	0	0	0	2	1	0	0	1	1	0	0	0	0	0	0	7
				38	0	0	1	0	0	0	1	0	0	0	0	1	1	0	0	0	0	0	0	4
				40	0	0	0	1	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	5
				42	0	0	1	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	5
				44	0	0	0	0	0	1	0	0	0	0	1	1	0	0	0	0	0	0	0	5
				46	0	0	2	0	0	0	1	1	0	1	0	1	0	0	0	0	0	0	0	7
				48	0	0	1	0	1	0	0	1	1	0	1	1	0	0	0	0	0	0	0	9
				50	0	0	1	1	0	1	0	1	1	0	1	1	0	0	0	0	0	0	0	9
				52	0	0	0	0	2	0	1	0	2	0	0	1	1	0	0	0	1	0	0	8
1	48	313	SCX	8	1	0	0	0	1	0	1	2	2	0	2	1	1	0	0	0	1	0	0	14
				10	1	0	1	0	0	1	1	2	1	0	2	1	1	0	0	0	1	0	0	12
				12	2	1	0	2	1	0	2	2	2	0	2	1	0	1	0	1	1	0	0	20
				14	2	1	0	1	0	0	1	1	2	1	0	0	0	0	1	1	2	0	0	13
				16	1	0	1	1	0	1	1	2	2	0	2	1	0	0	0	2	1	0	0	16
				18	0	0	1	1	0	1	0	2	2	0	0	1	0	0	0	0	0	0	0	8
				20	1	0	0	1	1	0	1	0	1	0	0	1	0	0	0	0	0	0	0	10
				22	1	0	0	1	1	0	2	1	0	0	2	1	0	0	0	0	0	0	0	10
				24	0	0	0	1	1	1	1	0	0	1	2	0	2	1	0	0	0	0	0	12
				26	0	0	0	2	1	1	0	0	2	2	0	2	1	0	0	0	0	0	0	10
				28	0	0	0	2	1	1	2	0	0	1	0	2	0	0	0	0	0	0	0	12
				30	0	0	0	1	1	2	0	0	1	0	2	1	1	0	0	0	0	0	0	9
				32	0	0	0	1	1	1	0	0	1	0	2	0	0	0	0	0	0	0	0	10
				34	0	0	0	1	1	2	0	0	2	1	0	2	0	0	0	0	0	0	0	10
				36	0	0	0	1	1	0	0	2	1	0	2	0	0	0	0	0	0	0	0	9
				38	0	0	0	1	1	2	0	0	2	1	0	2	0	0	0	0	0	0	0	13
				40	1	0	0	1	0	1	0	0	2	0	2	1	1	0	0	0	0	0	0	12
				42	1	0	0	1	0	1	2	0	1	2	0	2	1	1	0	0	0	0	0	12
				44	1	0	0	1	1	0	1	2	0	1	2	0	1	0	0	0	0	0	0	11
				46	2	0	0	1	0	0	1	1	0	1	0	1	1	0	0	0	0	0	0	11
				48	2	0	1	2	0	0	1	0	1	1	0	1	1	0	0	0	0	0	0	13
				50	1	0	0	2	0	1	0	1	2	0	0	1	1	0	0	0	0	0	0	14
				52	1	0	0	2	1	0	1	2	2	0	1	1	0	2	0	0	1	0	0	14
1	52	316	MTS	8	1	0	0	1	1	1	0	2	0	1	2	1	0	0	0	0	1	0	0	12
				10	0	0	0	1	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	5
				12	0	0	0	1	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	5
				14	1	0	0	1	0	0	1	1	0	1	0	1	0	0	0	0	0	0	0	11
				16	1	0	1	1	0	1	1	0	2	1	1	2	0	1	0	0	0	0	0	13
				18	1	1	0	1	1	0	2	1	1	2	1	1	0	0	0	0	0	0	0	17
				20	1	0	0	0	2	0	1	0	1	0	0	1	1	0	0	0	0	0	0	10
				22	1	0	0	1	2	0	1	0	1	2	0	0	2	1	0	0	0	0	0	12
				24	1	0	0	1	1	0	1	0	1	1	1	0	1	0	0	0	0	0	0	10
				26	1	0	0	1	1	0	1	1	0	1	1	1	0	0	0	0	0	0	0	10
				28	0	0	0	2	0	0	0	2	1	0	1	1	1	0	0	0	0	0	0	10

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

D.B.		Visit																				Total			
Centre	Patient Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score	
1	52	316	NTS	30	1	0	0	1	1	0	1	0	1	1	0	2	0	0	0	0	0	0	1	0	9
				32	1	0	0	2	0	1	1	0	1	0	2	1	0	0	0	0	0	0	0	0	9
				34	0	0	1	2	0	1	0	2	0	1	2	0	0	0	0	0	0	0	0	0	8
				36	1	0	0	1	1	0	2	0	0	1	1	0	0	0	0	0	0	0	1	0	9
				38	1	0	0	1	0	1	0	2	0	0	2	0	0	0	0	0	0	0	0	0	7
				40	0	0	0	1	0	1	0	1	1	0	2	0	0	0	0	0	0	0	0	0	9
				42	0	0	0	1	0	1	1	2	1	0	2	0	0	0	0	0	0	0	0	0	8
				44	0	0	0	2	0	1	0	1	2	1	0	1	0	0	0	0	0	0	0	0	6
				46	1	0	0	1	0	1	2	0	1	0	2	1	0	0	0	0	0	0	0	0	13
				48	1	0	0	2	1	0	2	1	1	0	2	1	0	0	0	0	0	0	0	0	7
				50	0	0	0	1	0	1	0	1	0	1	0	2	1	0	0	0	0	0	0	0	7
				52	0	0	0	1	0	0	1	1	1	0	2	0	0	0	0	0	0	0	0	0	7
1	55	318	DMG	8	1	0	0	1	0	1	1	0	1	0	0	1	0	0	0	0	0	0	0	0	7
				10	2	0	1	2	1	1	2	1	0	2	1	0	2	1	0	1	1	0	0	0	18
				12	2	1	1	2	1	1	2	0	2	1	0	2	1	0	1	1	0	0	0	0	24
				14	3	1	1	2	1	1	3	2	0	3	1	2	2	1	0	1	1	0	0	0	28
1	56	319	IAL	8	2	1	0	2	1	0	2	2	2	0	1	2	1	0	0	0	0	0	1	1	20
1	58	320	ARM	8	1	0	0	1	0	1	1	1	1	1	0	1	1	0	0	0	0	2	0	0	12
				10	0	0	0	1	0	1	0	0	2	1	0	0	0	0	0	0	0	0	0	0	7
				12	0	0	0	1	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	8
				14	2	0	1	2	1	1	2	0	1	2	3	1	1	2	2	0	1	0	0	0	23
				16	2	1	0	2	2	0	2	2	2	2	0	2	1	2	2	0	2	0	0	0	25
1	61	323	HVC	8	1	0	0	1	1	0	1	0	1	2	1	0	1	0	0	0	1	0	0	0	10
				10	0	0	0	1	1	1	0	0	1	0	2	0	0	0	0	0	0	0	0	0	7
				12	0	0	0	2	0	1	0	2	0	0	0	0	1	0	0	0	0	0	0	0	7
				14	0	0	0	2	0	1	0	0	2	1	0	0	1	0	0	0	0	0	0	0	8
				16	1	0	0	1	1	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	6
				18	1	0	0	2	2	0	0	1	2	0	0	0	1	0	0	0	0	0	0	0	8
				20	0	0	0	2	2	0	0	2	2	0	0	2	0	0	0	0	0	0	0	1	10
				22	0	0	0	1	1	0	0	2	2	0	0	1	0	0	0	0	0	0	0	0	5
				24	0	0	0	1	1	0	0	0	1	0	1	0	1	0	0	0	0	0	0	0	6
				26	0	0	0	1	1	0	0	0	1	1	1	0	1	0	0	0	0	0	0	0	8
				28	0	0	0	2	0	1	0	0	0	2	1	1	1	0	0	0	0	1	0	0	9
				30	0	0	0	1	0	2	0	0	1	1	1	1	0	0	0	0	0	0	0	0	7
				32	0	0	0	1	1	1	0	0	1	1	0	1	0	1	0	0	0	0	0	0	8
				34	0	0	0	1	0	1	0	0	1	2	0	1	0	0	1	0	0	0	0	0	8
				36	0	0	0	1	0	1	0	0	1	2	0	1	0	0	0	0	1	0	0	0	10
				38	0	0	0	1	0	1	0	0	1	0	0	2	1	0	0	0	0	0	0	0	9
				40	0	0	0	1	1	1	0	0	1	1	0	0	1	1	2	0	0	0	0	0	6
				42	0	0	0	1	1	1	0	0	1	1	0	0	1	0	0	0	0	0	0	0	6
				44	0	0	0	1	1	1	0	0	0	1	0	0	1	0	0	0	0	0	0	0	5
				46	0	0	0	2	2	0	0	0	0	0	1	0	1	1	0	0	0	0	0	0	6
				48	0	0	0	1	1	1	0	0	0	0	1	0	1	1	0	0	0	0	0	0	8

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

D.B.		Centre Patient		Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score	
1	61	323	HVC	50	0	0	0	1	1	1	1	0	0	2	2	1	0	1	0	1	1	0	0	0	0	0	0	9
1	66	326	TCG	8	1	0	0	1	1	0	1	0	1	0	1	2	1	0	2	0	0	1	0	0	0	0	0	11
				10	0	0	0	1	0	1	0	0	1	1	0	2	1	0	2	0	0	0	0	0	0	0	0	10
				12	0	0	0	2	0	0	0	0	1	2	0	2	0	2	0	0	0	0	0	1	0	0	0	10
				14	1	0	0	2	0	0	0	1	1	0	2	0	1	0	2	0	1	0	0	0	0	0	0	8
				16	1	0	0	2	1	0	0	0	1	0	2	0	1	0	2	0	1	0	0	0	0	0	0	9
				18	0	0	0	2	0	0	0	0	2	0	0	1	0	2	0	1	0	0	0	0	0	0	0	8
				20	0	0	0	1	1	0	0	0	1	1	0	2	0	1	0	1	0	0	0	0	0	0	0	7
				22	0	0	0	1	0	0	0	0	1	1	0	1	0	1	0	1	1	2	0	0	0	0	0	6
				24	0	0	0	1	0	0	0	0	1	1	0	1	0	1	0	1	1	2	0	0	0	0	0	8
				26	0	0	0	1	0	0	0	0	1	1	0	1	0	1	0	1	1	2	0	0	0	0	0	5
				28	0	0	0	1	0	0	0	0	1	1	0	1	0	2	0	0	0	2	0	0	0	0	0	9
				30	0	0	0	1	0	0	0	0	1	1	0	1	0	1	0	1	0	0	0	0	0	0	0	6
				32	0	0	0	2	0	0	0	0	2	0	2	0	1	0	2	0	0	0	0	0	0	0	0	9
				34	0	0	0	2	0	0	0	0	1	2	0	1	0	2	0	0	0	0	0	0	0	0	0	7
				36	0	0	0	2	0	0	0	1	2	0	1	0	2	0	0	1	0	0	0	0	0	0	0	8
				38	0	0	0	1	1	0	0	1	1	0	1	0	1	0	1	0	1	0	0	0	0	0	0	7
				40	0	0	0	1	1	0	0	0	1	1	0	1	0	1	0	1	0	2	0	0	0	0	0	7
				42	0	0	0	1	1	0	0	0	1	1	1	0	1	0	0	0	1	0	0	0	0	0	0	6
				44	0	0	0	0	1	0	0	1	2	0	2	0	1	0	0	0	0	0	0	0	1	0	0	8
				46	0	0	0	2	0	0	0	1	2	0	2	0	1	0	0	0	0	0	0	0	1	0	0	8
				50	0	0	0	1	0	0	1	0	1	2	0	1	0	0	1	0	0	0	0	0	1	0	0	8
				52	0	0	0	0	0	0	1	0	0	0	2	2	1	0	0	0	0	0	0	0	0	1	0	7
1	71	329	DMY	8	1	0	0	2	0	0	1	0	1	0	1	1	0	1	1	0	0	0	0	1	0	0	0	11
				10	1	0	0	2	1	0	1	0	2	1	0	2	0	2	1	0	0	0	0	1	0	0	0	13
				12	0	0	0	1	2	0	1	0	1	2	0	0	0	2	1	0	0	0	0	1	0	0	0	12
				14	1	0	0	2	0	0	1	0	1	2	0	0	0	2	1	0	0	0	0	0	2	0	0	12
				16	1	0	0	1	0	0	1	0	1	2	0	0	0	2	1	0	0	0	0	0	1	0	0	10
				18	1	0	0	2	0	0	2	0	1	1	0	0	0	2	1	0	0	0	0	0	1	0	0	11
				20	2	0	0	1	0	0	2	0	1	1	0	0	2	1	0	0	0	0	0	0	0	0	0	10
				22	1	0	0	2	0	0	1	0	1	1	0	1	0	2	1	0	0	0	0	0	0	0	0	12
				24	1	0	0	1	0	0	1	0	1	1	0	1	0	2	0	0	0	0	0	0	0	0	0	8
				26	1	0	0	1	0	0	1	0	1	1	0	0	1	0	2	0	0	0	0	0	0	0	0	9
				28	1	0	0	1	0	0	1	0	1	1	0	0	2	1	0	0	0	0	0	0	0	0	0	9
				30	1	0	0	1	0	0	1	0	1	1	0	0	1	0	2	0	1	0	0	0	0	0	0	8
				32	1	0	0	1	0	0	1	0	1	1	0	0	2	0	1	0	0	0	0	0	0	0	0	8
				34	1	0	0	2	0	0	1	0	2	1	0	2	0	0	1	0	0	0	1	0	0	0	0	12
				36	2	0	0	2	0	0	2	0	1	1	0	0	2	0	1	0	0	0	1	0	0	0	0	13
				38	2	0	0	2	0	0	1	1	2	0	1	0	0	2	1	0	0	0	1	0	0	0	0	14
				40	0	0	0	1	0	0	1	1	0	0	1	0	2	1	0	0	0	0	1	0	0	0	0	13
				42	0	0	0	0	0	0	1	1	0	0	1	1	0	2	0	1	0	0	0	0	0	0	0	9
				44	0	0	0	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	8
				46	0	0	0	1	0	0	1	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	8
				48	0	0	0	1	0	0	0	0	1	2	0	1	0	0	0	0	0	0	0	0	0	0	0	8
				50	0	0	0	1	0	0	1	0	1	2	0	1	0	0	1	0	0	0	0	0	0	0	0	8
				52	0	0	0	0	0	0	1	0	0	0	2	2	1	0	0	0	0	0	0	0	0	0	0	7

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

D.B.		Visit																				Total		
Centre	Patient Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score
1	71	329	ONV	48	0	0	0	1	1	2	0	2	0	0	0	0	0	0	0	0	0	0	0	9
				50	1	0	0	1	1	1	1	1	0	0	0	1	2	0	0	0	0	0	0	11
				52	1	0	0	1	2	0	1	2	0	0	1	1	0	0	0	0	0	0	0	12
1	72	330	RLJ	8	1	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	10
				10	0	0	0	1	1	0	0	1	1	1	0	0	0	0	0	0	0	0	0	6
				12	0	0	0	1	0	1	0	1	0	2	0	1	1	0	0	0	0	0	0	7
				14	0	0	0	1	0	0	0	1	1	0	0	2	0	0	0	0	0	0	0	7
				16	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	8
				18	0	0	0	1	1	0	0	1	2	0	0	0	0	0	0	0	0	0	0	8
				20	0	0	0	2	0	0	1	0	1	2	0	0	0	0	0	0	0	0	0	8
				22	0	0	0	2	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	9
				24	0	0	0	2	0	1	0	1	2	0	0	2	1	0	0	0	0	0	0	9
				26	2	0	2	2	1	1	2	0	2	1	2	1	0	0	0	0	0	0	0	9
				28	0	0	0	1	0	0	1	0	2	0	0	0	0	0	0	0	0	0	0	7
1	73	121	FMA	8	1	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	7
				10	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	6
				12	1	0	0	0	1	0	1	0	2	0	0	0	0	0	0	0	0	0	0	8
				14	0	0	0	2	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	7
				16	0	0	0	2	0	0	1	0	1	0	0	2	1	0	0	0	0	0	0	9
				18	0	0	0	2	0	0	1	1	0	2	0	0	0	0	0	0	0	0	0	8
				20	0	0	0	2	0	0	1	1	0	2	0	0	0	0	0	0	0	0	0	11
				22	0	0	0	2	1	1	2	0	0	1	1	0	0	0	0	0	0	0	0	10
				24	2	0	2	2	0	2	1	2	0	1	0	2	0	0	0	0	0	0	0	17
				26	2	0	2	2	1	1	2	0	2	1	2	1	0	0	0	0	0	0	0	23
1	75	123	ELF	8	1	1	0	2	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	8
				10	1	2	0	2	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	13
				12	1	1	0	1	0	0	1	0	2	1	1	2	1	0	0	0	0	0	0	13
				14	1	0	0	1	0	0	1	0	1	0	0	1	0	0	0	0	0	0	0	7
				16	0	0	0	2	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	6
				18	0	0	0	2	0	0	1	0	1	0	0	1	0	0	0	0	0	0	0	8
				20	1	0	0	2	0	0	1	1	0	1	0	0	0	0	0	0	0	0	0	11
				22	0	0	0	2	0	1	1	0	2	0	0	0	0	0	0	0	0	0	0	7
				24	0	0	0	2	0	0	1	0	2	0	0	0	0	0	0	0	0	0	0	5
				26	0	0	0	1	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	7
				28	1	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	13
				30	1	0	0	2	0	0	2	0	0	1	0	0	0	0	0	0	0	0	0	16
				32	2	0	0	2	0	0	2	0	2	0	1	2	1	0	0	0	0	0	0	11
				34	1	0	0	2	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	12
				36	1	0	0	2	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	13
				38	1	0	0	2	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	8
				40	1	0	0	2	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	13
				42	1	0	0	2	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	13
				44	2	0	0	2	0	0	2	0	0	1	1	0	0	0	0	0	0	0	0	14
				46	1	1	0	1	0	0	2	0	0	1	1	0	0	0	0	0	0	0	0	14
				48	1	1	0	1	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	13
				50	2	0	0	0	0	0	1	0	2	0	0	0	0	0	0	0	0	0	0	12
				52	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8

905

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score			
D.B.	125	ACG	8	1	0	0	2	0	0	1	1	0	0	1	0	0	2	1	0	0	0	1	0	0	0	10		
			10	1	0	2	1	0	1	0	1	1	0	1	0	1	0	2	0	0	0	0	1	0	0	0	12	
			12	1	0	0	2	1	0	1	0	2	1	1	0	1	1	0	2	0	0	0	1	0	0	0	0	12
			14	1	0	0	1	2	0	1	0	1	0	0	2	0	1	0	2	0	0	0	1	0	0	0	0	11
			16	2	0	0	1	1	0	1	0	2	0	1	0	2	0	0	2	0	0	0	0	0	0	0	0	11
			18	2	0	0	1	1	0	1	0	2	0	1	0	2	0	0	2	0	0	0	0	0	0	0	0	7
			20	0	0	0	1	1	0	0	1	0	0	2	0	1	0	0	2	0	0	0	0	0	0	0	0	11
			22	1	0	0	1	1	0	1	0	1	1	0	2	1	1	0	0	2	0	0	0	0	0	0	0	11
			24	0	0	0	1	1	0	1	0	1	0	1	0	2	0	0	0	2	0	0	0	0	0	0	0	8
			26	0	0	0	2	1	0	0	1	0	1	0	2	0	0	0	0	2	0	0	0	0	0	0	0	11
			28	0	0	0	1	2	0	0	0	0	0	0	1	2	0	0	0	2	0	0	0	0	0	0	0	8
			30	0	0	0	1	2	0	0	1	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	8
			32	0	0	0	1	1	0	0	1	0	0	1	1	0	1	0	1	0	0	0	0	0	0	0	0	9
			34	0	0	0	2	1	0	0	1	0	1	1	1	0	1	0	1	0	0	0	0	0	0	0	0	8
			36	0	0	0	2	1	0	0	1	0	1	0	2	0	1	0	1	1	0	0	0	0	0	0	0	10
			38	0	0	0	2	1	0	0	1	0	1	1	1	0	1	0	1	0	0	0	0	0	0	0	0	9
			40	0	0	0	0	0	0	0	0	0	1	2	2	0	0	0	1	0	0	0	0	0	0	0	0	7
			42	0	0	0	0	2	0	0	0	0	0	0	2	1	0	0	2	1	0	0	0	0	0	0	0	8
			44	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	2	0	0	0	0	0	0	0	0	10
			46	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	2	0	0	0	0	0	0	0	0	8
			48	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	4
			50	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	5
			52	0	0	0	0	0	0	0	0	0	0	0	2	2	2	0	0	0	0	0	0	0	0	0	0	8
			MFB	81	128	8	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0
10	0	0				0	1	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	6		
12	0	0				0	1	1	0	0	0	1	1	0	1	0	1	0	1	1	0	0	0	0	0	0	7	
14	0	0				0	2	0	0	0	0	0	1	0	1	0	0	1	0	0	0	0	0	0	0	0	5	
16	0	0				0	1	1	0	0	0	0	1	1	0	1	1	0	1	0	0	0	0	0	0	0	6	
18	0	0				0	1	1	0	0	0	0	1	1	0	0	1	0	0	1	0	0	0	0	0	0	7	
20	0	0				0	1	1	0	0	0	0	1	2	0	1	0	0	0	1	0	0	0	0	0	0	6	
22	0	0				0	1	1	0	0	0	1	1	0	1	0	1	0	0	1	0	0	0	0	0	0	0	7
24	0	0				0	1	1	0	0	1	0	1	0	1	0	0	0	1	0	0	0	0	0	0	0	0	12
26	1	0				0	1	1	1	1	0	1	0	2	2	0	1	0	1	1	0	0	0	0	0	0	0	11
28	0	0				0	1	2	0	0	1	1	0	0	2	1	0	0	1	1	0	0	0	0	0	0	0	11
30	0	0				0	1	2	0	0	1	1	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	7
32	0	0				0	1	2	0	0	1	1	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	9
34	0	0				0	1	2	0	0	1	1	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	9
36	0	0				0	1	2	0	0	1	1	0	0	2	0	0	0	1	0	0	0	0	0	0	0	0	8
38	0	0				0	1	2	0	0	1	1	0	0	2	0	0	0	1	0	0	0	0	0	0	0	0	8
40	0	0				0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
42	0	0				0	0	0	0	0	0	0	1	2	0	0	0	0	1	0	0	0	0	0	0	0	0	8
44	0	0				0	0	0	0	0	0	0	1	1	1	0	1	0	0	0	0	0	0	0	0	0	0	8
46	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
48	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
50	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
52	0	0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOMETINE

D.B.		Visit																					Total			
Centre	Patient	Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score	
1	82	129	MDS	8	1	0	0	0	1	0	1	0	1	1	0	1	0	1	1	1	2	0	0	0	0	11
				10	0	0	0	2	0	0	1	1	1	0	1	0	1	1	1	0	0	0	0	0	0	8
				12	0	0	0	0	1	0	1	1	0	1	0	1	0	1	1	0	0	0	1	0	0	9
				14	1	1	0	2	0	0	1	0	1	2	0	1	0	1	1	0	0	1	0	0	0	12
				16	1	0	0	1	0	1	0	1	2	0	1	0	1	1	0	0	1	0	0	0	0	11
				18	1	1	0	1	0	1	0	1	2	0	1	0	1	1	1	2	0	1	0	0	0	15
				20	0	0	0	1	0	1	0	1	0	0	0	0	1	2	0	0	0	0	0	0	1	8
				22	0	0	0	1	0	1	0	1	2	0	0	0	0	1	1	0	0	0	0	0	0	7
				24	0	0	0	1	0	1	0	1	1	1	0	0	2	1	0	0	0	0	0	0	0	8
				26	0	0	0	1	0	0	1	1	1	1	0	0	2	1	0	0	0	0	0	0	0	8
				28	0	0	0	1	0	1	0	1	1	0	0	1	0	1	0	0	0	0	0	0	0	10
				30	0	0	0	1	0	1	0	1	2	1	0	0	1	0	0	0	0	0	0	0	0	7
				32	0	0	0	1	0	1	0	1	2	1	0	0	1	0	0	0	0	0	0	0	0	8
				34	0	0	0	1	0	1	0	0	2	1	0	0	1	0	0	0	0	0	0	0	0	8
				36	0	0	0	2	0	0	1	0	2	1	0	0	2	0	0	0	0	0	0	0	0	9
				38	0	0	0	1	1	1	0	1	2	0	0	1	0	0	0	0	0	0	0	0	0	5
				40	0	0	0	1	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	6
				42	0	0	0	2	0	0	0	2	0	0	0	1	0	0	1	0	0	0	0	0	0	9
				44	0	0	0	0	0	0	2	0	0	0	0	1	0	0	1	0	0	0	0	0	0	6
				46	0	0	0	0	0	0	1	0	0	0	0	1	0	0	1	0	0	0	0	0	0	7
				48	0	0	0	2	0	0	1	1	0	0	0	1	0	0	1	0	0	0	0	0	0	6
				50	0	0	0	0	0	0	2	1	0	1	1	0	1	0	1	0	0	0	0	0	0	7
				52	0	0	0	0	0	0	0	0	0	0	1	0	1	0	1	0	0	0	0	0	5	
1	87	132	MDO	8	0	0	0	2	0	1	0	0	2	1	0	1	0	0	2	0	0	0	0	0	0	11
				10	1	0	0	2	1	0	1	1	0	2	1	0	2	1	0	0	0	0	0	0	0	12
				12	1	0	0	2	1	0	0	1	0	2	0	0	2	1	0	0	0	0	1	0	0	12
				14	1	0	0	2	2	0	1	0	0	2	1	0	0	2	1	0	0	0	0	0	0	14
				16	2	0	0	2	1	0	1	1	0	2	0	0	2	1	0	0	0	0	0	0	0	14
				18	2	0	0	1	2	0	1	0	0	1	1	0	2	1	1	0	0	0	1	0	0	13
				20	2	0	0	1	2	0	0	1	0	0	1	0	2	1	1	0	0	1	0	0	0	16
				22	2	0	0	2	2	0	2	0	2	0	2	1	0	2	1	1	0	0	1	0	0	20
1	89	133	MMV	8	1	1	1	2	1	0	1	2	0	2	2	1	0	2	1	0	2	0	0	0	0	20
				10	2	1	1	2	1	1	2	0	2	1	2	2	1	0	2	0	1	0	0	0	0	24
				12	2	1	1	2	1	1	2	0	2	1	2	2	1	0	0	1	0	0	0	0	0	22
				14	2	1	2	2	1	1	2	0	2	3	2	2	1	1	1	2	0	0	0	0	0	27
1	90	134	JSS	8	1	0	0	1	1	0	1	0	2	3	2	0	1	1	0	0	0	0	0	1	0	15
1	95	138	GHT	8	1	0	0	0	1	0	0	2	1	1	0	2	1	0	0	0	0	0	1	0	0	10
				10	0	0	0	0	0	0	0	1	1	1	0	0	2	0	0	0	0	0	0	0	0	6
				12	0	0	0	2	0	0	0	0	1	2	1	0	0	0	0	0	0	0	0	0	0	8
				14	0	0	0	1	0	1	0	0	1	2	0	0	2	0	0	0	0	0	0	0	0	9
				16	0	0	0	2	0	0	0	0	2	2	0	0	0	0	0	0	0	0	0	0	0	10
				18	0	0	0	2	0	0	1	1	2	2	0	0	2	1	0	0	0	0	0	0	0	9
				20	0	0	0	0	2	0	0	0	1	1	2	1	0	2	1	0	0	0	0	0	0	9

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre Patient Initials		Visit																					Total
		It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score
1	95	138	CNT	22	0	0	0	0	1	1	0	0	0	2	1	0	0	0	0	0	0	0	6
				24	0	0	1	1	1	1	0	0	1	0	0	0	0	0	0	0	0	0	7
				26	0	0	0	1	1	1	1	1	0	1	1	0	0	0	0	0	0	0	9
				28	0	0	0	0	1	2	0	1	0	0	1	0	0	0	0	0	0	0	7
				30	0	0	0	2	0	1	1	0	0	0	0	2	0	0	0	0	0	0	8
				32	0	0	0	1	1	1	1	0	0	0	1	0	0	0	0	0	0	0	7
				34	0	0	0	1	1	0	2	1	0	0	1	0	0	0	0	0	0	0	8
				36	0	0	0	1	0	1	1	0	0	1	1	0	0	0	0	0	0	0	7
				38	0	0	0	0	1	1	2	0	0	0	1	1	0	0	0	0	0	0	8
				40	0	0	0	2	0	1	0	0	0	2	0	0	0	0	0	0	0	0	7
				42	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	5
				44	0	0	0	2	0	0	0	1	2	1	0	0	0	0	0	0	0	0	8
				46	0	0	0	2	0	0	0	1	1	0	2	0	0	0	0	0	0	0	8
				48	0	0	0	1	0	1	0	0	1	2	0	0	0	0	0	0	0	0	6
				50	0	0	0	2	0	0	0	0	2	0	0	0	0	0	0	0	0	0	7
				52	0	0	0	1	1	0	0	1	1	1	0	0	0	0	0	0	0	0	6
1	96	139	SPH	8	0	0	0	1	1	2	0	0	1	1	0	1	2	0	0	0	0	0	11
				10	0	0	0	2	1	1	0	0	0	2	0	0	0	0	0	0	0	0	10
				12	0	0	0	1	2	0	0	0	1	2	0	0	0	0	0	0	0	0	10
				14	0	0	0	1	1	2	0	0	0	0	1	0	0	0	0	0	0	0	9
				16	0	0	0	1	1	1	0	0	0	0	2	1	0	0	0	0	0	0	11
				18	0	0	0	2	0	2	1	0	0	2	0	0	0	0	0	0	0	0	10
				20	0	0	0	1	1	1	0	0	0	1	0	0	0	0	0	0	0	0	11
				22	0	0	0	1	2	0	1	0	0	2	0	0	0	0	0	0	0	0	11
				24	1	0	0	1	1	0	0	1	0	0	1	0	0	0	0	0	0	0	11
				26	1	1	1	1	0	0	1	0	0	1	0	0	1	0	0	0	0	0	11
				28	1	1	1	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	11
				30	1	2	1	2	0	0	1	1	0	0	1	1	0	0	0	0	0	0	13
				32	1	2	1	2	0	0	1	1	0	0	2	1	0	0	0	0	0	0	14
				34	1	2	1	1	0	1	2	1	0	1	1	1	0	0	0	0	0	0	14
				36	1	2	1	2	0	2	1	0	0	1	1	1	0	0	0	0	0	0	13
				38	1	1	1	1	0	1	1	0	0	1	1	1	0	0	0	0	0	0	12
				40	1	0	1	1	0	1	1	0	0	1	1	0	0	0	0	0	0	0	11
				42	2	0	0	0	2	0	0	2	1	0	0	1	0	0	0	0	0	0	12
				44	0	0	0	0	2	0	0	1	0	0	1	0	0	0	0	0	0	0	9
				46	0	0	0	0	1	0	0	1	0	0	1	1	0	0	0	0	0	0	8
				48	0	0	0	1	0	2	1	0	0	2	1	0	0	0	0	0	0	0	9
				50	0	0	0	1	0	1	0	0	0	2	1	0	0	0	0	0	0	0	6
				52	0	0	0	1	0	0	0	1	2	0	0	0	0	0	0	0	0	0	6
1	98	141	YTT	8	0	0	0	1	2	1	1	0	0	1	0	2	0	0	0	0	0	0	11
				10	0	0	0	1	2	1	1	0	0	1	0	0	1	0	0	0	0	0	10
				12	0	0	0	1	1	2	1	0	0	0	0	0	0	0	0	0	0	0	10
				14	0	0	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	9
				16	0	0	0	2	1	1	1	0	0	0	0	0	0	0	0	0	0	0	11
				18	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	9

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

D.B.		Centre Patient		Initials		Visit		It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total	
1	98	141	YTT	20	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				22	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	12
				30	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	11
				32	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				34	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				36	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				38	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				40	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				42	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				44	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				48	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				52	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
1	101	163	JLL	8	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				18	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				20	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10
				22	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
				26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
				32	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				34	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				36	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				38	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				40	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				42	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
				44	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				48	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				52	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
1	107	147	LAN	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10
				14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 40.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score
1	107	LAN	18	0	0	1	1	0	0	0	0	0	2	1	0	0	2	1	0	0	0	1	1	0	10
			20	0	0	1	1	0	0	0	0	1	1	1	0	0	2	1	0	0	0	1	1	0	9
			22	0	0	1	1	0	0	0	0	1	1	1	0	0	2	1	0	0	0	0	1	0	9
			24	0	0	2	1	0	1	0	1	1	1	1	0	0	2	1	0	0	0	0	0	0	8
			26	0	0	1	1	1	0	0	1	2	1	2	1	0	1	0	0	0	0	1	0	0	9
			28	0	0	1	1	1	1	0	0	2	1	0	0	1	0	0	0	0	0	0	0	0	9
			30	0	0	0	0	2	1	0	0	2	1	0	1	1	1	0	0	0	0	0	0	0	7
			32	0	0	0	0	2	1	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	8
			34	0	0	0	2	0	0	1	1	1	1	1	0	0	1	0	0	0	0	0	0	0	8
			36	0	0	0	1	1	0	0	1	1	1	1	0	0	1	0	0	0	0	0	0	0	7
			38	0	0	0	1	0	0	0	0	0	2	0	0	0	1	0	0	0	0	0	0	0	6
			40	0	0	0	1	0	0	0	0	0	0	1	1	0	1	0	0	0	0	0	0	0	7
			42	0	0	0	1	0	0	0	0	0	0	2	0	0	1	0	0	0	0	0	0	0	6
			44	0	0	0	0	2	0	0	0	0	0	1	1	1	1	0	0	0	0	0	0	0	7
			46	0	0	0	0	0	0	0	0	0	2	0	1	2	0	0	0	0	0	0	0	0	6
			48	0	0	0	0	0	0	1	0	2	1	1	0	1	0	0	0	0	0	0	0	0	8
			50	1	0	0	1	0	0	1	0	2	2	2	1	2	0	0	0	0	0	0	0	0	12
			52	0	0	0	0	0	0	0	2	1	1	1	0	0	0	1	0	0	0	0	0	0	6
1	109	IPL	8	0	0	0	1	1	0	1	1	0	1	0	0	0	2	1	0	0	0	0	0	0	10
			10	0	0	0	2	1	0	1	1	0	2	0	0	2	2	0	0	0	0	0	0	0	11
			12	1	0	0	2	1	0	1	1	0	2	1	0	2	2	1	0	0	0	0	0	0	14
			14	1	1	0	2	1	0	1	1	0	1	1	0	2	2	0	0	0	0	0	0	0	13
			16	1	1	0	1	2	0	1	1	0	1	1	0	2	2	0	0	0	0	0	0	0	14
			18	1	1	0	2	1	0	1	1	0	2	0	0	2	2	0	0	0	0	0	0	0	13
			20	1	1	0	1	1	0	1	1	0	1	1	0	2	2	1	0	0	0	0	0	0	12
			22	1	1	0	1	1	0	1	1	0	1	1	0	0	2	1	0	0	0	0	0	0	13
			24	0	0	0	2	0	0	1	1	0	2	0	0	0	1	0	0	0	0	0	0	0	9
			26	0	0	0	1	1	0	2	0	0	0	0	0	2	1	0	0	0	0	0	0	0	8
			28	0	0	0	0	0	0	2	1	0	1	1	0	0	1	0	0	0	0	0	0	0	8
			30	1	0	0	2	0	0	2	1	0	1	1	0	1	1	0	0	0	0	0	0	0	14
			32	1	0	0	1	1	0	0	2	0	2	0	0	1	1	0	0	0	0	0	0	0	12
			34	1	0	0	1	1	0	1	1	0	1	1	2	0	0	1	0	0	0	0	0	0	11
			36	1	0	0	1	0	0	2	0	1	1	1	0	0	1	0	0	0	0	0	0	0	10
			38	1	0	1	2	1	0	0	1	0	1	2	0	1	0	0	0	0	0	0	0	0	14
			40	0	0	0	1	0	0	1	0	0	2	0	0	2	1	0	0	0	0	0	0	0	9
			42	0	0	0	2	0	0	0	1	0	0	2	0	1	0	0	0	0	0	0	0	0	8
			44	0	0	0	2	0	0	0	0	0	0	2	1	0	1	0	0	0	0	0	0	0	8
			46	0	0	0	0	2	0	0	1	0	1	1	0	0	1	0	0	0	0	0	0	0	7
			48	0	0	0	0	2	0	0	1	0	1	1	0	0	1	0	0	0	0	0	0	0	7
			50	0	0	0	0	0	0	1	0	2	1	1	0	0	1	0	0	0	0	0	0	0	8
			52	0	0	0	0	0	0	0	0	1	0	1	2	0	1	0	0	0	0	0	0	0	1
1	110	TQO	8	0	0	0	1	1	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	7
			10	0	0	0	2	1	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	6
			12	0	0	0	1	0	1	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	6
			14	0	0	0	1	0	1	0	0	0	0	1	0	0	1	1	0	0	0	0	0	0	6

9550077

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient No.	Visit	Initials	It.																				Total Score		
				1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20		21	
1	110	TQO	16	0	0	0	1	1	0	0	0	2	0	0	2	0	1	0	0	0	0	0	0	0	1	8
			18	0	0	1	1	1	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	1	7
			20	0	0	0	1	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	1	7
			22	0	0	0	1	2	0	0	1	0	0	1	0	0	1	0	0	0	0	0	0	0	1	6
			24	0	0	0	1	0	0	1	1	0	0	1	0	0	1	0	0	0	0	0	0	0	1	5
			26	0	0	0	2	0	0	0	2	2	1	0	0	2	1	0	0	0	0	0	0	0	1	9
			28	0	0	0	0	0	2	0	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	8
			30	0	0	0	0	1	0	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	10
			32	0	0	0	0	2	0	0	1	1	2	1	0	1	0	1	0	0	0	0	0	0	0	7
			34	0	0	0	0	1	1	1	0	1	1	0	1	1	0	1	0	0	0	0	0	0	0	8
			36	0	0	0	1	1	0	0	1	0	1	1	1	1	1	1	1	0	0	0	0	0	1	8
			38	0	0	0	1	0	0	1	0	0	1	1	1	1	1	1	1	0	0	0	0	0	1	6
			40	0	0	0	0	0	0	0	0	1	0	0	0	0	1	2	0	0	0	0	0	0	1	5
			42	0	0	0	2	1	0	0	0	0	0	1	2	0	0	1	0	0	0	0	0	0	1	7
			44	0	0	0	2	1	0	1	0	0	1	1	0	0	1	2	0	0	0	0	0	0	0	9
			46	0	0	0	2	0	0	0	0	0	0	2	0	0	2	0	0	0	0	0	0	0	0	6
48	0	0	0	0	0	0	0	0	0	2	2	0	0	0	0	2	0	0	0	0	0	0	8			
50	0	0	0	0	0	0	1	0	0	1	0	2	0	0	0	0	0	0	0	0	0	1	7			
52	0	0	0	0	1	0	0	0	0	0	2	0	0	2	0	0	0	0	0	0	0	1	6			
1	116	MGA	8	0	0	0	1	1	0	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	5	
			10	0	0	0	1	1	0	0	0	0	2	0	0	1	1	0	0	0	0	0	0	1	7	
			12	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	7	
			14	0	0	0	1	0	0	0	0	1	0	1	0	0	1	1	0	0	0	0	0	1	0	6
			16	0	0	0	1	0	0	0	0	1	0	0	0	2	1	1	0	0	0	0	0	0	0	7
			18	0	0	0	1	0	0	0	1	0	0	0	1	0	0	1	1	0	0	0	0	0	1	6
			20	0	0	0	0	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	1	5
			22	0	0	0	0	1	0	0	0	0	1	1	0	0	1	0	0	0	0	0	0	0	1	5
			24	0	0	0	0	0	0	0	0	0	2	1	1	0	0	1	0	0	0	0	0	0	0	5
			26	0	0	0	0	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	8
			28	0	0	0	1	0	0	1	0	0	2	1	1	0	1	1	0	0	0	0	0	0	0	6
			30	0	0	0	1	1	0	1	0	1	1	1	1	0	1	1	0	0	0	0	0	0	1	8
			32	0	0	0	0	1	0	1	0	1	0	2	1	1	0	1	1	0	0	0	0	0	0	6
			34	0	0	0	0	1	0	1	0	1	0	1	1	0	1	1	1	0	0	0	0	0	0	9
			36	0	0	0	1	0	1	0	1	0	1	1	1	0	1	1	1	0	0	0	0	0	0	9
			38	0	0	0	1	0	1	0	0	0	1	1	1	0	1	1	1	0	0	0	0	0	0	8
40	0	0	0	2	1	0	1	0	0	0	1	1	0	0	1	0	0	0	0	0	0	0	4			
42	0	0	0	2	0	0	0	0	0	1	1	1	0	0	1	1	1	2	0	0	0	1	10			
44	0	0	0	2	0	0	0	0	1	2	1	0	0	1	1	0	0	0	0	0	1	0	10			
46	0	0	0	0	0	0	1	0	0	1	1	0	0	1	1	0	0	0	0	0	1	0	7			
48	0	0	0	1	0	0	1	0	0	1	2	2	1	0	0	0	0	0	0	0	0	0	9			
50	0	0	0	1	0	0	1	0	0	2	2	0	0	1	0	0	0	0	0	0	0	0	8			
52	0	0	0	0	0	0	1	0	1	1	1	1	1	1	0	1	0	0	0	0	0	0	7			
1	117	PSL	8	0	0	0	1	1	0	1	0	0	1	0	0	2	1	0	0	0	0	0	0	10		
			10	0	0	0	1	2	0	0	0	2	0	0	1	1	0	0	0	0	0	0	0	0	7	
			12	0	0	0	1	1	0	0	0	1	0	0	2	0	0	0	0	0	0	0	0	0	7	

911

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 ROXETINE - PROTOCOL 20124/013
 Listing No.: 10.1

HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: ROXETINE

D.B.		Visit																				Total			
Centre	Patient Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score	
1	117	335	PSL	14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10	
				16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10	
				18	1	0	0	1	0	1	1	0	1	1	0	2	1	0	0	1	0	0	0	0	12
				20	0	0	0	1	0	1	1	0	0	1	0	2	1	0	0	0	0	0	0	0	8
				22	0	0	0	0	1	1	0	1	1	0	0	2	1	0	0	0	0	0	0	0	9
				24	1	0	0	0	1	1	1	0	2	0	0	2	0	0	0	0	0	1	0	0	10
				26	0	0	0	1	0	1	1	0	1	0	0	2	0	0	0	0	0	0	0	0	7
				28	0	0	0	1	0	1	1	0	2	0	0	2	0	0	0	0	0	0	0	0	9
				30	0	0	0	2	0	0	2	0	0	2	0	0	0	0	0	0	0	0	0	0	8
				32	2	0	1	2	0	0	2	0	0	1	0	2	1	0	0	0	0	0	0	0	14
				34	2	0	1	2	0	0	2	0	2	1	0	2	1	0	0	0	0	0	0	0	16
				36	0	0	0	2	1	0	1	0	2	1	0	0	1	0	0	0	0	0	0	0	10
				38	0	0	0	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	8
				40	0	0	0	1	0	1	0	1	2	0	0	1	0	0	0	0	0	0	0	0	7
				42	0	0	0	0	0	2	0	0	1	2	2	0	0	0	0	0	0	0	0	0	8
				44	0	0	0	1	1	0	1	2	0	0	0	2	1	0	0	0	0	0	0	0	10
				46	1	1	0	1	1	0	1	2	0	0	0	0	2	1	0	0	0	0	0	0	12
				48	1	2	0	0	0	1	1	2	0	1	1	0	0	1	1	0	0	0	0	0	11
				50	1	0	0	0	2	0	1	1	0	0	2	0	2	1	1	0	0	0	0	0	10
				52	1	1	0	0	2	0	1	0	0	2	0	2	1	0	0	0	0	0	0	0	10
1	121	336	LAC	8	0	0	0	1	0	1	0	0	1	0	0	1	0	0	0	0	0	0	0	0	6
				10	0	0	0	1	1	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	7
				12	0	0	0	0	1	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	5
				14	0	0	0	0	1	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	4
				16	0	0	0	1	1	0	0	1	0	1	0	1	0	0	0	0	0	0	0	0	6
				18	0	0	0	0	1	0	0	1	1	1	0	1	0	0	0	0	0	0	0	0	6
				20	0	0	0	0	1	0	0	0	1	1	0	1	0	0	0	0	0	0	0	0	7
				22	0	0	0	0	1	0	0	0	1	0	1	0	1	0	0	0	0	0	0	0	6
				24	0	0	0	0	0	0	1	0	0	1	0	2	0	0	0	0	0	0	0	0	7
				26	0	0	0	0	0	0	1	0	0	1	0	1	0	0	0	0	0	0	0	0	8
				28	0	0	0	1	0	1	0	0	1	1	0	1	0	0	0	0	0	0	0	0	5
				30	0	0	0	0	0	0	1	0	0	2	0	0	0	0	0	0	0	0	0	0	8
				32	0	0	0	0	0	0	1	0	0	2	0	0	0	0	0	0	0	0	0	0	10
				34	2	0	1	2	0	0	2	0	2	1	0	0	0	0	0	0	0	0	0	0	8
				36	0	0	0	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	7
				38	0	0	0	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	10
				40	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	7
				42	0	0	0	0	0	0	0	0	1	2	2	0	0	0	0	0	0	0	0	0	10
				44	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	7
				46	0	0	0	0	0	0	1	0	1	0	2	0	0	0	0	0	0	0	0	0	6
				48	0	0	0	0	0	0	1	0	1	0	2	0	0	0	0	0	0	0	0	0	5
				50	0	0	0	0	0	0	0	1	1	2	1	0	0	0	0	0	0	0	0	0	5
				52	0	0	0	0	2	0	0	1	1	1	0	2	0	0	0	0	0	0	0	0	9
1	123	338	MLL	8	0	0	0	1	1	1	0	0	1	0	0	2	1	0	0	0	0	0	0	0	7
				10	0	0	0	1	1	1	0	0	1	0	0	2	1	0	0	0	0	0	0	0	10

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient No.	D.B. Initials	Visit No.	Total Score																							
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21			
1	123	338	MLL	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7			
				14	0	0	1	1	1	1	1	0	0	1	0	0	2	0	0	0	0	0	0	1	0	10	
				16	0	0	0	1	2	0	1	1	0	0	1	2	0	0	0	0	0	0	0	0	0	7	
				18	0	0	0	1	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	7	
				20	0	0	0	1	2	0	2	2	0	1	0	0	2	0	0	0	0	0	0	0	1	0	11
				22	0	0	0	1	1	0	1	1	0	0	1	0	2	1	0	0	0	0	0	0	1	0	10
				24	0	0	0	1	1	0	1	1	0	0	1	0	1	1	0	0	0	0	0	0	2	0	8
				26	0	0	0	2	0	0	0	0	1	1	0	0	1	0	0	0	0	0	0	0	1	0	7
				28	0	0	0	1	0	1	1	1	0	0	2	1	0	0	0	2	2	0	0	0	0	0	11
				30	0	0	0	1	0	1	0	2	0	1	2	0	0	2	0	0	0	0	0	0	0	0	10
				32	0	0	0	1	0	1	0	0	2	0	2	1	1	0	0	1	2	0	0	0	0	0	13
				34	0	0	0	1	0	1	0	0	0	0	2	1	1	0	0	0	0	0	0	0	0	0	7
				36	0	0	0	0	0	2	1	2	0	1	2	0	1	0	0	1	0	0	0	0	0	0	9
				38	0	0	0	1	0	0	1	1	0	1	1	0	0	1	1	0	0	0	0	0	0	0	8
				40	0	0	0	1	1	1	0	0	2	3	3	0	2	0	0	0	0	0	0	0	0	0	13
				42	1	0	0	2	1	1	1	0	1	0	1	0	0	2	0	0	1	0	0	0	0	0	14
				44	0	0	0	1	1	1	2	0	1	2	2	0	1	0	0	0	0	0	0	0	0	0	12
				46	1	0	1	2	1	0	1	0	0	1	2	0	0	1	0	0	0	0	0	0	2	0	12
				48	1	1	0	2	1	0	2	0	0	2	1	0	2	0	1	0	0	0	0	0	1	0	14
				50	2	1	1	2	0	0	1	0	0	2	1	0	2	0	1	0	0	0	0	0	1	0	16
				52	2	1	1	1	0	0	1	0	2	2	0	2	0	2	0	2	0	0	0	0	0	0	17
1	125	340	FDP	8	1	0	1	1	1	2	1	1	0	0	1	0	0	0	0	0	0	0	1	0	15		
				10	0	0	0	2	1	2	0	1	0	2	1	0	2	0	0	0	0	0	0	1	0	12	
				12	1	0	1	2	2	1	2	1	0	2	0	0	2	1	0	0	0	0	0	1	0	16	
				14	1	0	1	2	2	1	2	1	0	2	1	0	2	1	0	0	0	0	0	1	0	17	
				16	2	0	0	2	2	1	2	2	0	1	2	0	2	0	0	0	0	0	0	1	0	17	
				18	1	1	1	2	2	2	1	1	0	0	1	0	0	2	0	0	0	0	0	0	0	0	16
				20	2	1	1	2	2	2	2	2	1	1	0	0	1	0	0	0	0	0	0	1	0	0	18
				22	2	1	1	2	2	1	2	2	2	2	0	0	2	0	0	0	0	0	0	1	0	0	19
				24	1	0	1	2	1	1	1	1	0	0	2	0	0	0	0	0	0	0	0	1	0	0	14
				26	1	0	1	0	0	0	2	0	1	2	2	1	1	0	0	0	0	0	0	1	2	0	14
				28	1	0	1	0	0	0	2	0	2	2	2	1	0	1	1	0	0	0	0	2	0	0	17
				30	1	0	2	1	0	0	0	1	1	1	0	0	1	1	0	0	0	0	0	1	2	0	15
				32	1	1	1	0	0	0	2	0	2	2	1	1	0	2	1	0	0	0	0	2	0	0	17
				34	2	0	2	0	0	0	1	0	1	2	1	0	0	2	1	0	0	0	0	1	1	0	13
				36	1	0	2	0	0	0	0	1	0	1	2	1	0	0	0	0	0	0	0	1	1	0	18
				38	1	0	2	0	0	0	1	0	1	1	1	0	2	1	1	0	0	0	0	2	1	0	13
				40	1	0	2	0	0	0	2	0	2	2	1	1	0	2	0	0	0	0	0	2	1	0	17
				42	1	0	0	0	0	2	0	1	0	0	1	2	1	0	0	0	0	0	0	1	2	0	11
				44	0	0	0	0	0	0	1	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	14
				46	0	0	0	0	0	0	0	1	0	0	1	1	1	2	0	0	2	0	0	0	0	0	8
				48	0	0	0	0	0	0	0	1	0	2	0	0	1	1	0	0	0	0	0	0	0	0	8
50	0	0	0	0	0	0	1	0	2	0	1	1	1	0	0	0	0	0	0	0	0	0	10				
52	0	0	0	2	0	0	1	0	0	1	1	1	1	2	0	1	0	0	0	0	1	0	12				
1	127	342	VPD	8	0	0	0	1	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0			
				9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 2012A/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

D.B.		Centre Patient		Visit		Total																						
		Initials		No.		It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score	
1	127	342	VPD	10	0	0	0	0	1	2	0	0	0	0	1	0	2	1	0	1	1	0	0	0	0	0	0	9
				12	1	0	0	2	1	0	1	0	0	2	1	2	1	0	0	1	1	2	0	0	0	0	0	16
				14	1	0	0	2	2	0	1	0	1	1	1	2	1	0	0	1	1	0	0	1	0	0	0	13
				16	1	0	0	2	2	0	1	0	1	1	2	1	2	1	2	0	0	0	0	1	0	0	0	14
				18	1	0	0	2	2	0	1	0	1	1	2	1	2	0	0	0	0	0	0	1	1	0	0	14
				20	1	0	0	1	2	1	1	0	1	2	1	2	1	2	0	0	0	0	1	1	0	0	0	16
				22	1	0	0	2	2	0	2	0	1	1	2	1	2	1	2	0	1	0	0	1	0	0	0	16
				24	1	0	0	1	2	1	1	0	1	1	1	0	0	1	0	0	1	0	0	1	0	1	0	12
				26	0	0	0	1	1	1	0	0	2	1	1	1	0	0	0	1	1	0	0	0	1	0	0	9
				28	0	0	0	1	1	1	0	0	1	1	1	1	0	0	1	1	0	0	0	0	2	0	0	9
				30	0	0	0	1	2	0	1	1	0	2	0	1	0	0	1	1	0	0	0	0	0	0	1	10
				32	0	0	0	0	2	0	1	2	0	1	1	0	0	2	1	0	0	0	0	0	0	0	0	10
				34	0	0	0	2	1	0	0	0	2	0	2	0	0	0	0	0	0	0	0	0	0	0	0	8
				36	0	0	0	1	1	0	1	2	0	0	0	0	0	0	2	1	0	0	0	0	0	0	0	8
				38	0	0	0	1	1	1	1	0	0	2	1	0	0	1	0	1	0	0	0	0	0	0	0	10
				40	0	0	0	1	0	1	0	0	0	2	1	1	0	0	0	0	0	0	0	0	0	0	0	7
				42	0	0	0	2	1	0	0	0	1	1	1	1	1	0	0	0	1	0	0	0	0	0	0	8
				44	0	0	0	2	1	1	0	0	0	2	2	2	1	0	0	0	0	0	0	0	0	0	0	8
				46	0	0	0	2	1	1	0	0	2	2	2	2	1	0	0	0	0	0	0	0	1	0	0	12
				48	0	0	0	1	1	2	0	0	2	2	2	2	1	0	0	0	1	0	0	0	2	0	0	14
				50	0	0	0	1	1	1	0	0	1	2	1	1	0	0	0	0	0	0	0	0	0	0	0	8
				52	0	0	0	1	2	1	0	0	1	2	1	1	1	0	0	0	0	0	0	0	1	0	0	10
1	128	343	LAM	8	0	0	0	1	2	1	0	1	0	1	0	1	0	1	0	1	0	0	0	0	0	0	0	10
				10	0	0	0	2	2	1	0	0	1	1	0	1	1	0	1	0	0	0	0	0	0	0	0	9
				12	0	0	0	2	2	1	0	1	0	0	1	1	1	0	1	0	0	0	0	0	0	0	0	11
				14	0	0	0	2	2	1	1	0	0	0	1	1	1	0	1	0	0	0	0	0	0	0	0	7
				16	0	0	0	2	2	1	0	0	0	1	0	2	1	0	0	1	0	0	0	0	1	0	0	10
				18	0	0	0	1	2	1	0	0	1	0	2	1	0	0	1	0	0	0	0	0	0	0	0	7
				20	0	0	0	2	2	0	0	0	1	0	1	0	0	2	1	0	0	0	0	0	0	0	0	9
				22	0	0	0	2	2	0	0	0	1	0	1	2	1	0	0	0	0	0	0	0	0	0	0	10
				24	0	0	0	0	0	0	1	1	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	6
				26	0	0	0	1	1	2	0	0	1	1	0	0	2	1	0	0	0	0	0	0	0	0	0	7
				28	0	0	0	0	1	1	0	0	1	1	0	0	0	2	0	1	0	0	0	0	0	0	0	8
				30	0	0	0	2	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				32	1	1	1	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	7
				34	0	0	0	0	0	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	8
				36	0	0	0	0	0	0	0	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				38	1	1	1	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	11
				40	0	0	0	0	1	1	0	0	0	2	0	0	0	1	0	0	0	0	0	0	0	0	0	7
				42	0	0	0	0	1	1	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	11
				44	0	0	0	0	1	1	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	7
				46	0	0	0	1	1	1	0	0	0	2	0	0	1	0	0	0	0	0	0	0	0	0	0	8
				48	0	0	0	2	1	2	0	1	0	1	0	1	2	0	0	0	0	0	0	0	0	0	0	10
				50	0	0	0	1	2	0	1	1	0	1	1	2	0	0	0	0	0	0	0	0	0	0	0	9
				52	0	0	0	1	1	1	0	0	1	2	1	1	0	0	0	0	0	0	0	0	0	0	0	10
				54	0	0	0	1	1	1	0	0	1	2	1	1	0	0	0	0	0	0	0	0	0	0	0	7

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

D.R.		Centre Patient Initials		Visit		It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score	
1	134	347	LMS	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
				12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				18	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				20	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				22	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				32	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				34	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				36	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				38	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				40	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				42	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				44	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				48	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
				52	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
1	135	348	MMS	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				18	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				20	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				22	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
				32	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				34	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
				36	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				38	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				40	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				42	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				44	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				48	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
				52	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	D.B.	Patient Initials	Visit No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score
1			8	0	0	0	1	1	0	0	0	1	1	0	0	1	0	0	0	0	0	0	1	0	6
			10	0	0	0	1	1	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	4
			12	0	0	0	1	1	0	0	0	1	0	0	0	2	0	0	0	0	0	0	0	0	4
			14	0	0	0	1	1	0	0	0	0	0	1	0	0	0	1	0	0	0	1	0	0	5
			16	0	0	0	0	1	0	0	0	0	0	0	1	0	0	1	2	0	0	0	0	4	
			18	0	0	0	1	1	0	0	0	1	1	0	0	0	0	1	0	0	0	1	0	0	5
			20	0	0	0	0	0	2	2	0	0	0	0	0	2	0	1	0	0	0	0	0	5	
			22	0	0	0	0	1	0	1	0	0	1	0	0	1	0	1	0	0	0	0	0	7	
			24	0	0	0	0	1	0	1	0	0	1	0	0	1	0	0	0	0	0	0	0	5	
			26	0	0	0	0	2	0	1	1	0	1	2	0	0	1	0	0	0	0	1	0	7	
			28	0	0	0	1	1	0	1	0	1	0	0	1	0	0	1	0	0	0	0	0	8	
			30	0	0	0	1	1	0	1	0	1	2	1	0	0	1	0	0	0	0	2	0	7	
			32	0	0	0	1	1	1	0	0	2	2	1	0	0	0	0	0	0	0	0	0	8	
			34	0	0	0	1	1	1	0	0	2	0	0	1	0	0	0	0	0	0	0	1	8	
			36	0	0	0	1	1	1	0	0	1	2	0	0	2	1	0	0	0	0	0	0	11	
			38	0	0	0	0	1	1	0	0	0	1	2	0	0	1	0	0	0	0	0	0	7	
			40	0	0	0	0	0	2	1	0	0	0	0	0	1	0	0	0	0	0	0	0	4	
			42	0	0	0	0	0	0	2	1	0	0	0	0	0	1	0	0	0	0	0	0	4	
			44	0	0	0	1	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	6	
			46	0	0	0	0	2	0	0	0	0	0	0	1	0	0	1	0	0	0	1	0	6	
			48	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2	0	0	0	1	0	5	
			50	0	0	0	0	0	0	0	0	0	1	0	2	0	1	0	1	2	0	0	0	6	
			52	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	4	
			8	1	0	0	1	1	0	1	0	1	2	3	0	0	0	0	0	0	0	1	0	11	
			10	2	2	0	2	0	0	1	0	0	2	1	1	0	0	0	0	0	0	1	0	12	
			12	1	1	0	1	1	0	0	0	0	2	2	0	0	1	0	0	0	0	1	0	10	
			14	1	0	0	1	0	0	1	0	0	2	2	3	0	0	1	0	0	0	1	0	12	
			16	1	0	0	1	0	0	0	0	2	2	2	0	0	1	0	0	0	0	1	0	10	
			18	1	0	0	1	0	0	0	0	1	2	2	0	0	1	1	0	0	0	1	0	9	
			22	1	0	0	1	0	0	0	0	2	2	3	0	0	1	1	0	0	0	1	0	12	
			24	1	1	1	2	1	0	0	0	2	2	3	0	0	1	1	2	0	0	1	0	15	
			26	1	1	1	1	2	0	0	1	1	1	1	0	0	1	1	0	0	0	1	0	19	
			28	1	1	1	1	1	2	0	0	2	0	1	0	0	2	1	0	0	0	1	0	15	
			30	1	1	1	1	2	0	1	2	0	2	1	0	2	1	0	0	0	0	1	0	17	
			32	1	2	1	1	0	2	0	0	2	3	1	0	2	1	0	0	0	1	0	0	19	
			34	1	2	2	1	1	0	1	3	0	2	3	1	0	1	1	0	0	1	0	0	19	
			36	1	2	2	1	1	1	2	0	1	2	1	0	1	1	0	0	0	1	0	0	17	
			38	2	2	2	2	1	1	3	0	3	3	1	0	2	1	1	0	0	0	1	0	24	
			8	1	1	1	2	1	1	2	0	0	2	1	0	0	2	1	0	0	1	0	1	19	
			10	1	1	1	1	2	1	1	2	0	1	0	0	2	1	0	0	1	0	0	0	14	
			12	2	1	1	2	1	1	0	0	1	0	0	2	1	0	2	0	1	0	0	0	15	
			14	1	1	1	2	1	1	0	0	2	1	0	0	2	1	0	0	0	1	0	0	18	
			16	2	1	1	2	1	0	2	0	0	2	0	0	2	1	0	2	0	1	0	0	17	
			18	1	1	1	2	1	1	2	0	0	0	0	0	2	1	1	0	0	1	0	0	15	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient No.	Initials	Visit																				Total It.21 Score			
			It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20		It.21		
1	146	358	LRM	20	2	1	1	2	1	1	0	2	1	0	0	1	0	0	0	2	1	0	0	0	0	14
				22	2	1	1	1	1	1	0	0	2	0	0	1	0	0	0	0	0	0	0	0	0	15
				24	1	0	0	1	0	1	1	0	0	1	0	1	1	0	0	0	0	0	0	0	0	8
				26	1	0	0	2	0	1	1	0	2	0	0	2	1	0	0	0	0	0	0	0	0	11
				28	1	0	0	1	1	1	1	0	0	1	0	2	1	1	0	0	0	0	0	0	0	11
				30	1	0	0	2	1	1	1	0	0	2	0	1	1	0	0	0	1	1	0	0	0	13
				32	2	0	0	1	1	2	2	0	0	2	0	2	1	0	0	0	2	1	0	0	0	16
				34	2	0	0	1	1	1	2	1	0	0	2	0	1	0	0	1	1	1	0	0	0	16
				36	2	0	0	1	1	1	2	1	0	1	2	0	1	0	0	0	1	0	0	0	0	13
				38	2	0	0	1	1	0	2	1	0	1	2	0	1	0	0	0	1	0	0	0	0	12
				40	1	0	0	2	0	1	0	0	2	1	2	0	2	1	0	0	0	0	0	0	0	16
				42	1	0	0	1	1	0	2	1	0	1	2	0	2	1	0	0	0	0	0	0	0	15
				44	1	0	0	2	0	0	2	0	1	2	1	0	2	1	0	0	0	0	0	0	0	16
				46	1	0	1	2	0	0	1	0	2	1	0	2	1	1	0	0	0	1	0	0	0	14
				48	2	1	2	1	0	1	2	0	1	2	0	1	2	1	0	0	0	0	0	0	0	17
				50	1	1	2	2	0	0	2	1	0	2	1	0	2	1	0	0	0	0	0	0	0	16
				52	2	1	2	1	1	1	2	0	2	2	1	0	2	1	0	0	0	0	0	0	0	19
				8	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	5
				10	0	0	0	0	0	0	0	2	2	2	0	0	1	1	0	0	0	0	0	0	0	8
				12	0	0	0	0	0	0	0	2	2	2	2	0	1	1	2	0	0	0	0	0	0	12
				14	0	0	0	1	0	0	0	0	2	1	0	0	2	1	0	0	0	0	0	0	0	7
				16	0	0	0	1	1	0	0	0	1	2	1	0	0	1	0	0	0	0	0	0	0	4
				18	0	0	0	1	1	0	0	0	0	2	0	0	0	1	0	0	0	0	0	0	0	9
				20	0	0	0	1	1	0	0	0	0	1	2	2	1	1	0	0	0	0	0	0	0	8
				22	0	0	0	2	0	0	0	0	2	2	1	0	0	1	1	0	0	0	0	0	0	6
				24	0	0	0	0	0	0	0	0	1	1	1	0	0	1	1	0	0	0	0	0	0	8
				26	0	0	0	0	0	0	0	0	1	1	1	0	1	0	0	0	0	0	0	0	0	9
				28	0	0	0	1	0	0	0	1	1	1	1	0	1	0	0	0	0	0	0	0	0	6
				30	0	0	0	1	0	0	0	1	0	2	0	1	0	1	0	0	0	0	0	0	0	6
				32	0	0	0	1	0	0	1	0	0	2	0	1	0	1	0	0	0	0	0	0	0	6
				34	0	0	0	1	0	0	1	0	1	1	0	0	1	0	0	0	0	0	0	0	0	6
				36	0	0	0	1	1	0	1	0	0	1	0	0	2	1	0	0	0	0	0	0	0	7
				38	0	0	0	0	0	0	0	0	1	2	1	0	0	0	0	0	0	0	0	0	0	3
				40	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	5
				42	0	0	0	0	0	0	0	0	0	2	2	0	1	0	0	0	0	0	0	0	0	6
				44	0	0	0	1	0	0	1	0	0	1	0	0	1	0	0	0	0	0	0	0	0	7
				46	0	0	0	1	0	0	1	0	0	2	2	0	2	1	0	0	0	0	0	0	0	7
				48	0	0	0	1	0	0	0	0	0	1	1	0	0	1	0	0	0	0	0	0	0	7
				50	0	0	0	1	0	0	1	0	0	1	1	0	1	0	0	0	0	0	0	0	0	7
				52	0	0	0	2	0	0	0	0	1	2	2	0	1	0	0	0	0	0	0	0	0	8
3	7	71	GRI	8	2	1	1	2	2	2	1	0	1	2	1	1	1	0	0	0	1	0	0	0	0	19
				10	2	1	1	2	2	2	1	0	1	2	1	1	1	0	0	0	2	0	0	0	0	20
8	2	212	TE	8	0	0	0	1	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	4
				10	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	D. B.	Visit	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score	
8	2	212	TE	12	0	0	0	1	0	0	1	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	4
				14	0	0	1	0	0	1	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	4
				16	0	0	1	0	0	1	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	4
				18	1	0	0	1	0	0	1	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	5
				20	1	0	0	1	0	0	1	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	4
				22	1	0	0	1	0	0	1	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	4
				24	1	0	0	0	0	1	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	4
				26	0	0	0	0	0	1	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3
				28	0	0	0	0	0	1	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3
				30	0	0	0	0	0	1	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3
				32	0	0	0	0	0	1	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3
				34	0	0	0	0	0	1	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3
				36	0	0	0	0	0	1	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3
				38	0	0	0	0	0	1	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3
				40	0	0	0	0	0	1	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3
				42	0	0	0	0	0	1	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3
				44	0	0	0	0	0	1	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3
				46	0	0	0	0	0	1	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3
				48	0	0	0	0	0	1	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3
				50	0	0	0	0	0	1	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3
				52	0	0	0	0	0	1	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3
8	3	213	JL	8	2	1	0	1	1	0	1	1	0	1	1	0	0	2	2	0	0	1	0	0	0	0	14
				10	2	1	0	1	1	0	2	1	0	1	1	0	0	2	2	0	0	1	0	0	0	0	15
				12	2	1	0	2	1	1	2	1	0	1	1	0	0	2	2	0	0	1	0	0	0	0	19
				14	2	1	0	2	2	1	3	2	0	2	1	0	0	2	2	2	0	0	1	0	0	0	21
8	6	216	TL	8	1	0	0	1	0	0	1	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	5
				10	1	0	0	1	0	0	1	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	6
				12	1	0	0	1	0	0	1	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	6
				14	1	0	0	1	0	0	1	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	6
				16	1	0	0	1	0	0	1	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	6
				18	1	0	0	1	0	0	1	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	6
				20	1	0	0	1	0	0	1	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	6
				22	1	0	0	1	0	0	1	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	6
				24	0	0	0	1	0	0	1	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	6
				26	0	0	0	1	0	0	1	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	6
				28	0	0	0	1	0	0	1	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	6
				30	0	0	0	1	0	0	1	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	6
				32	0	0	0	1	0	0	1	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	6
				34	0	0	0	1	0	0	1	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	6
				36	0	0	0	0	0	0	1	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	6
				38	0	0	0	0	0	0	1	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	6
				40	0	0	0	0	0	0	1	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	6
				42	0	0	0	0	0	0	1	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	6
				44	0	0	0	0	0	0	1	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	6
				46	0	0	0	0	0	0	1	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	6
				48	0	0	0	0	0	0	1	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	6
				50	0	0	0	0	0	0	1	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	6
				52	0	0	0	0	0	0	1	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	6

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOMETINE

D.B.		Visit																					Total		
Centre	Patient	Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score
8	6	216	TL	46	0	0	0	0	0	1	1	0	0	0	0	0	2	0	0	0	0	0	0	0	4
				48	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	4
				50	0	0	0	0	0	1	1	0	0	0	0	0	2	0	0	0	0	0	0	0	4
				52	0	0	0	0	0	1	1	0	0	0	0	0	2	0	0	0	0	0	0	0	4
9	6	245	SD	8	1	0	0	1	0	1	0	0	1	0	0	1	0	0	0	0	0	0	0	0	6
				10	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	4
				12	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	4
				14	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	4
				16	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	4
				18	0	0	0	1	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	5
				20	0	0	0	1	1	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	4
				22	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	3
				24	0	0	0	1	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	5
				26	0	0	0	1	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	4
				28	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	5
				30	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	4
				32	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	4
				34	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	3
				36	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	2
				38	0	0	0	1	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	3
				40	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	3
				42	0	0	0	1	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	2
				44	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
				46	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				48	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				50	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				52	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
9	7	243	PP	8	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
				10	1	1	0	1	1	1	0	0	2	0	1	0	1	0	0	0	0	0	0	0	4
				12	1	0	0	1	1	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	12
				14	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	5
				16	0	0	0	1	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	4
				18	0	0	0	1	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	5
				20	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	5
				22	0	0	0	1	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	4
				24	0	0	0	1	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	5
				26	0	0	0	1	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	4
				28	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
				30	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				32	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				34	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				36	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				38	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				40	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				42	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				44	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				46	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				48	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				50	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				52	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score					
9	7	243	PP	44	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
				46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				48	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
9	11	246	KE	52	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
				8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
				10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
				12	3	3	1	1	0	0	2	2	0	1	2	1	1	1	1	1	2	0	1	1	0	0	0	3	
9	15	249	BI	14	3	3	2	1	0	3	3	0	3	1	1	1	1	3	0	1	1	0	0	2	0	22			
				16	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9		
				18	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7	
				20	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	
9	15	249	BI	22	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5		
				24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	
				26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
				28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
9	15	249	BI	30	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7		
				32	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	
				34	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	
				36	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	
9	15	249	BI	38	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3		
				40	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3		
				42	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	
				44	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
9	15	249	BI	46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2		
				48	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2		
				50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	
				52	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	
9	15	249	BI	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4		
				10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	
				12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	
				14	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7	
9	15	249	BI	16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5		
				18	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8	
				20	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8	
				22	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8	
9	15	249	BI	24	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10		
				26	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9	
				28	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8	
				30	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8	
9	15	249	BI	32	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8		
				34	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8	
				36	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8	
				38	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8	
9	15	249	BI	40	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9		
				42	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8	
				44	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8	
				46	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8	
9	15	249	BI	48	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9		
				50	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9	
				52	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9	
				40	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

D.B.		Visit																				Total		
Centre	Patient Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score
10	20	285	EJ	18	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
				20	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				22	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10	22	286	AA	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3
				14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
				16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18	3	1	2	2	1	0	0	1	1	1	2	1	0	0	2	0	1	0	0	22
				20	3	1	1	0	2	0	1	1	1	1	0	0	0	0	0	1	0	0	0	13
				22	1	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	9
				24	0	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	4
				26	0	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	3
				28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				32	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				34	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				36	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				38	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				40	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				42	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				44	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				48	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				52	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10	23	287	LT	8	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				10	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3
				12	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4
				14	3	0	0	0	0	0	0	0	0	0	2	1	1	1	0	0	0	0	0	15
				16	3	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	15
				18	3	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	15
				20	3	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	11
				22	2	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	18
				24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3
				26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3
				32	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				34	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				36	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				38	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	16
				40	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				42	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				44	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				48	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				52	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

D.B.		Visit																					Total			
Centre	Patient Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score		
10	23	287	LT	40	0	0	0	2	1	1	2	0	0	0	3	3	1	0	0	0	0	0	0	0	14	
				42	0	0	0	0	1	1	0	0	0	3	3	1	0	1	0	1	0	2	0	0	13	
				44	1	0	0	1	1	0	0	0	4	3	1	1	0	2	0	0	0	0	0	0	15	
10	26	290	JIF	8	2	0	0	1	1	2	3	0	0	1	1	1	1	0	0	0	0	0	0	0	12	
				10	3	0	0	2	2	2	3	0	0	1	1	1	1	2	0	1	0	0	0	0	21	
10	27	292	MK	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
				10	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	
				12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
				18	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
				20	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	
				22	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
				24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				32	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				34	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				36	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				38	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				40	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				42	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				44	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				48	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				52	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
10	28	291	LL	8	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10	
				10	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	11	
				12	3	1	2	1	1	3	1	0	0	4	2	1	2	0	1	0	1	0	0	0	0	26
				14	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	4
				16	2	1	1	0	1	1	1	1	0	2	2	0	0	0	0	0	0	0	0	0	0	15
				18	4	1	3	1	1	0	3	0	0	3	3	1	2	1	0	0	0	0	0	0	0	24
				20	4	1	3	2	2	2	3	0	0	2	2	1	2	1	0	0	0	0	0	0	0	28
				22	2	1	1	1	1	1	1	0	0	1	1	0	1	1	0	0	0	0	0	0	0	13
				24	4	2	3	2	2	2	3	1	0	2	2	1	1	0	0	0	0	0	0	0	0	29
				26	4	2	3	2	2	3	1	0	0	2	2	1	1	2	0	0	1	0	0	0	0	31
				28	4	2	2	1	1	0	3	0	0	1	1	0	1	2	1	0	0	0	0	0	0	22
				30	2	1	1	0	1	0	3	0	0	1	1	0	1	2	1	0	0	0	0	0	0	15
				32	1	0	0	0	0	0	1	0	0	1	1	0	0	1	0	0	0	0	0	0	0	6
				34	2	1	2	1	0	1	2	0	0	2	2	0	1	1	0	0	0	0	0	0	0	18
				36	4	2	1	0	1	0	3	0	0	2	2	0	1	1	0	0	1	0	0	0	0	18
				38	4	1	1	1	0	0	3	0	0	2	2	0	1	1	0	0	1	0	0	0	0	18

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOMETINE

D.B.		Visit																				Total				
Centre	Patient	Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score	
10	28	291	LL	40	3	1	2	1	0	0	3	1	0	2	2	0	2	1	0	0	0	1	0	0	21	
				42	4	1	2	1	1	0	3	1	0	2	2	0	1	1	0	0	1	0	1	0	20	
				44	4	1	1	1	1	1	3	0	0	2	2	0	1	1	0	2	0	1	0	1	0	22
				46	3	1	1	1	1	1	2	0	0	2	2	0	1	1	0	1	0	1	0	1	0	19
				48	2	1	1	0	0	1	2	0	1	1	0	0	1	0	2	0	0	1	0	1	0	14
				50	2	1	0	0	0	1	1	0	0	1	1	0	0	1	0	0	0	1	0	1	0	10
10	31	297	RK	8	0	0	0	0	1	0	0	0	0	1	2	1	2	0	0	0	1	2	0	0	10	
				10	1	1	0	0	0	0	0	0	2	2	0	2	0	1	0	0	0	0	0	0	10	
				12	1	0	0	0	0	0	0	0	2	2	0	2	0	2	0	1	1	0	0	0	11	
				14	1	0	0	0	1	0	0	0	2	2	1	1	2	0	2	1	1	1	0	0	14	
				16	0	0	0	1	1	0	0	0	1	1	1	2	0	2	1	1	1	0	0	0	12	
				18	0	0	0	1	2	0	0	0	1	1	1	2	0	2	1	0	1	0	0	0	14	
				20	0	0	0	1	1	0	0	0	1	1	0	1	0	1	0	0	0	0	0	0	7	
				22	0	0	0	1	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	2	
				24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				28	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	0	0	0	0	
				30	1	1	0	0	0	0	1	0	0	1	1	0	2	1	0	0	0	0	0	0	0	
				32	1	1	0	1	0	0	0	0	2	2	1	1	1	1	0	0	0	0	0	0	0	
				34	1	1	0	0	0	0	0	0	2	2	1	1	1	1	0	1	0	0	0	0	11	
				36	1	1	0	0	0	0	0	0	1	1	1	1	1	1	0	0	0	0	0	0	0	
				38	1	1	0	2	2	2	1	0	0	2	2	1	2	1	0	2	0	0	0	0	0	
				40	0	0	0	2	1	1	0	0	1	1	2	1	2	0	0	0	0	0	0	0	0	
				42	1	1	0	2	1	1	0	0	2	2	0	0	0	0	0	0	0	0	0	0	0	
				44	1	1	0	2	1	1	0	0	2	2	0	2	0	0	0	0	0	0	0	0	0	
				46	1	1	0	1	0	0	0	0	2	2	0	0	0	0	0	0	0	0	0	0	0	
				48	1	0	0	1	0	0	0	0	2	2	0	0	0	0	0	0	0	0	0	0	0	
				50	0	0	0	0	0	0	0	0	2	2	0	2	0	0	0	0	0	0	0	0	0	
				52	0	0	0	0	0	0	0	0	2	2	0	2	0	0	0	0	0	0	0	0	0	
10	32	299	LK	8	1	0	0	0	2	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	7	
				10	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	5	
				12	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	
				14	3	1	1	0	0	0	0	0	1	1	0	2	0	0	0	0	0	0	0	0	9	
				16	1	1	0	0	0	0	0	0	1	2	0	0	0	1	0	0	0	0	0	0	7	
				18	1	1	0	0	0	0	0	0	1	2	0	0	0	0	0	0	0	0	0	0	6	
				20	1	0	0	0	0	0	0	0	1	2	0	0	0	0	0	0	0	0	0	0	5	
				22	1	0	0	0	0	0	0	0	1	2	0	0	0	0	0	0	0	0	0	0	7	
				24	0	1	0	0	0	0	1	0	0	1	0	0	1	0	0	0	0	0	0	0	0	
				26	0	0	0	0	0	0	0	0	1	1	0	0	1	0	0	0	0	0	0	0	6	
				28	0	0	0	0	0	0	0	0	1	1	0	1	0	0	0	0	0	0	0	0	5	
				30	0	0	0	0	0	0	0	0	1	1	0	1	0	0	0	0	0	0	0	0	4	
				32	0	0	0	0	0	0	0	0	1	1	0	1	0	0	0	0	0	0	0	0	3	
				34	0	0	0	0	0	0	0	0	1	1	0	1	0	0	0	0	0	0	0	0	3	
				36	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
				38	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

D.B.		Visit																					Total	
Centre	Patient Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score
10	32	299	LK	40	0	0	0	0	0	0	0	1	1	0	2	0	0	0	0	0	0	0	0	4
				42	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	2
				44	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
				46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				48	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				52	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10	33	300	EK	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				18	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10	34	31	TK	8	1	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	5
				10	0	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	4
				12	2	1	0	0	1	0	2	1	1	1	0	2	0	0	0	0	1	0	0	12
				14	2	1	0	0	1	0	1	1	1	0	2	0	0	0	0	0	1	0	0	11
				16	2	1	1	0	0	1	0	0	1	0	0	0	0	0	0	0	1	0	0	8
10	35	35	IM	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
				10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3
				12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3
				16	2	0	1	0	2	0	2	0	1	0	1	0	0	0	0	0	1	0	0	11
10	38	37	LL	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10	39	40	VM	8	1	0	0	1	1	0	0	1	1	0	2	1	1	0	1	0	0	1	0	13
				10	2	0	1	1	2	2	0	1	1	1	0	1	1	0	1	0	0	1	0	19
				12	2	0	0	2	2	1	0	0	1	1	1	0	1	0	1	0	1	0	0	16
				14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3
				16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4
				18	1	0	0	0	1	0	0	0	2	0	0	0	0	0	0	0	0	0	0	12
				20	1	0	0	0	1	0	0	2	2	1	0	1	0	1	0	1	0	0	0	13
				22	1	0	0	1	1	0	0	2	2	1	0	2	1	0	0	1	0	0	0	14
				24	1	0	0	0	1	1	0	0	2	2	1	0	2	1	0	0	0	0	0	15
				26	1	0	0	1	1	0	0	1	1	1	0	1	0	1	0	0	0	0	0	15
				28	2	1	0	0	1	1	0	0	1	2	1	1	0	1	0	1	0	0	0	18
				30	1	1	0	0	1	1	0	0	1	2	0	1	0	0	0	1	0	0	0	13
				32	0	0	0	0	1	1	0	0	1	2	0	2	1	0	0	0	0	0	0	11
				34	0	0	0	0	0	0	0	0	1	2	0	2	1	0	0	0	0	0	0	8

927

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

D.B.		Visit		Centre Patient Initials No.																					Total
		It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score		
10	53	47	MA	10	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4		
				12	1	1	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	7		
				14	1	1	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	4		
				16	1	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	4		
				18	1	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	3		
				20	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	3		
				22	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2		
				24	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	2		
				26	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	2		
				28	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	2		
				30	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	2		
				32	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1		
				34	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1		
				36	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1		
				38	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1		
10	54	48	UN	8	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9		
				10	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8		
				12	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8		
				14	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4		
				16	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4		
				18	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9		
				20	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	16		
				22	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	12		
				24	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10		
				26	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	11		
				28	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	11		
				30	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9		
				32	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7		
				34	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7		
10	56	50	JP	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5		
				10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6		
10	57	51	AG	8	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5		
				10	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10		
				12	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6		
				14	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7		
				16	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8		
				18	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	13		
				20	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10		
				22	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9		
				24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7		
				26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5		
				28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6		
				30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5		
				32	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10		
				34	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7		
				36	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	12		
				38	3	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	18		

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013

Listing No.: 10.1

HAMILTON DEPRESSION RATING SCALE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

D.B.		Centre Patient		Visit	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total	
10	57	51	AG	40	3	1	2	1	0	0	2	1	0	3	3	0	2	1	0	0	0	0	0	0	0	0	20
				42	3	1	1	0	0	2	1	0	4	3	0	2	1	0	0	0	0	0	0	0	0	0	22
				44	3	1	1	0	0	2	1	0	4	3	0	2	1	0	0	0	0	0	0	0	0	0	20
				46	1	0	0	0	0	1	0	0	0	0	0	0	2	1	0	0	0	0	0	0	0	0	5
				48	1	0	0	0	0	1	0	0	0	0	0	0	2	1	0	0	0	0	0	0	0	0	4
				50	1	0	0	0	0	1	0	0	0	0	0	2	1	0	0	0	0	0	0	0	0	0	5
				52	1	0	2	0	0	1	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	6
10	59	53	TA	8	0	0	0	2	2	1	0	0	1	1	1	1	1	0	0	0	0	0	0	0	0	0	12
				10	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	0	0	0	0	0	0	4
10	63	57	MS	8	0	0	0	0	0	1	0	0	0	1	1	0	1	0	0	0	0	0	0	0	0	0	6
				10	0	0	0	0	0	1	0	0	0	1	1	0	1	0	0	0	0	0	0	0	0	0	6
				12	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	6
				14	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	3
				16	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	3
				18	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	2
				20	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	2
				22	0	0	0	0	0	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	3
				24	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	2
				26	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	2
				28	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	2
				30	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	2
				32	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	2
				34	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	2
				36	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	2
				38	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	2
				40	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	2
				42	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1
				44	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1
				46	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1
				48	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1
				50	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1
				52	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1
10	82	59	LS	8	1	1	0	0	0	0	2	0	0	1	0	0	2	1	0	0	0	0	0	0	0	0	8
				10	1	1	0	0	0	0	2	0	0	2	0	0	2	1	0	0	0	0	0	0	0	0	9
				12	1	1	0	0	0	0	1	0	0	1	0	0	2	1	0	0	0	0	0	0	0	0	9
				14	1	1	0	0	0	0	1	0	0	1	0	0	2	1	0	0	0	0	0	0	0	0	7
				16	1	1	0	0	0	0	1	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	5
				18	1	0	0	0	0	0	1	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	4
				20	1	0	0	0	0	0	1	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	4
				22	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	3
				24	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

D.B.		Visit																					Total	
Centre	Patient Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20		It.21
10	82	59	LS	32	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				34	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				36	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				38	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				40	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				42	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				44	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10	84	63	HV	8	2	1	1	0	2	2	0	0	1	1	1	1	0	1	0	1	0	0	0	18
				10	1	1	1	1	1	2	2	0	1	1	1	0	0	2	0	1	0	0	0	15
				12	1	1	0	0	2	1	1	0	1	1	0	1	0	0	0	1	0	0	0	10
				14	3	1	1	1	2	2	0	0	3	3	1	2	0	1	0	1	1	0	0	24
				16	3	1	0	1	1	2	2	0	0	3	1	2	0	1	1	1	1	0	0	23
10	86	274	NP	8	1	0	0	0	1	0	1	0	0	2	0	1	0	1	0	0	0	0	0	9
				10	0	0	0	0	1	0	0	0	1	1	1	0	0	1	0	0	0	0	0	6
				12	0	0	0	0	1	0	0	0	1	1	1	0	0	1	0	0	0	0	0	6
				14	0	0	0	0	0	0	0	0	1	1	1	0	0	1	0	0	0	0	0	5
				16	0	0	0	0	0	0	0	0	1	1	1	0	0	1	0	0	0	0	0	4
10	87	275	AN	8	1	0	0	1	0	0	1	0	0	2	1	0	2	0	0	0	0	0	0	8
				10	1	0	0	1	0	0	1	0	0	2	1	0	2	0	0	0	0	0	0	8
				12	1	0	0	1	0	0	1	0	0	2	1	0	2	0	0	0	0	0	0	8
				14	1	0	0	2	0	0	1	0	0	2	1	0	2	0	0	1	0	0	0	10
				16	1	0	0	2	0	0	1	0	0	2	2	0	2	0	0	1	0	0	0	11
				18	1	0	0	2	0	0	1	0	0	2	1	0	1	0	0	0	0	0	0	8
				20	1	0	0	1	0	0	1	0	0	2	1	0	1	0	0	0	0	0	0	7
				22	0	0	0	1	0	0	1	0	0	2	0	0	1	0	0	0	0	0	0	5
				24	0	0	0	1	0	0	1	0	0	2	0	0	1	0	0	0	0	0	0	5
				26	0	0	0	1	0	0	1	0	0	1	0	0	0	0	1	0	0	0	0	4
				28	0	0	0	1	0	0	1	0	0	1	0	0	0	0	1	0	0	0	0	4
				30	0	0	0	2	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	4
				32	0	0	0	0	2	0	1	0	0	1	0	0	0	0	0	0	0	0	0	4
				34	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	3
				36	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	3
				38	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	3
				40	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	2
				42	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	2
				44	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	2
				46	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	2
				48	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	2
				50	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	2
				52	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	2
10	89	277	SK	8	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	4

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	D.B.	Initials	No.	Visit																					Total
					It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	
11	2	373	HB	22	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
				24	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				26	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	3
				28	0	0	1	1	1	0	0	1	0	0	0	0	0	0	0	0	2	0	0	0	0	8
				30	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	3
11	3	374	RF	8	1	0	1	1	1	1	1	0	1	0	1	1	0	0	0	0	1	0	1	0	11	
				10	3	0	2	2	2	3	2	2	2	3	1	2	2	1	2	0	2	0	2	0	34	
				8	0	0	0	0	0	0	1	0	2	1	0	0	0	0	0	0	0	0	0	0	0	4
				10	1	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	4
				12	0	0	0	2	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	4
				14	0	0	0	0	1	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3
				16	0	0	0	0	2	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	4
				18	1	0	0	0	2	2	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	7
				20	0	0	0	0	2	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	2
				22	0	0	0	0	2	0	0	1	0	1	1	2	0	1	0	0	0	1	0	0	0	10
11	10	363	BJ	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	
				10	2	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
				12	2	1	1	1	2	2	0	0	1	1	1	1	1	0	0	0	0	0	0	0	0	14
				14	1	0	1	1	1	0	1	0	0	0	1	1	0	1	0	0	2	0	0	1	0	17
				16	1	0	0	1	0	0	1	0	0	0	1	0	1	0	0	0	0	0	1	0	0	7
				18	2	0	0	1	0	0	1	0	0	0	1	0	0	0	0	0	0	0	1	0	0	6
				20	1	0	0	0	1	1	1	0	0	0	1	0	0	1	0	0	0	0	1	0	0	8
				22	1	0	0	0	1	1	1	0	0	1	1	0	0	1	0	0	0	0	0	0	0	7
				24	1	0	0	0	0	0	0	1	0	0	1	0	0	1	0	0	0	0	0	0	0	6
				26	1	0	0	0	0	0	0	1	0	0	1	0	0	1	0	0	0	0	0	0	0	5
				28	1	0	0	0	1	0	0	1	0	0	1	2	0	0	0	0	0	0	0	0	0	9
				30	1	0	0	0	1	0	0	1	0	0	1	1	0	0	1	0	0	0	1	0	0	9
				32	1	0	0	0	1	0	0	1	0	0	1	1	0	1	0	0	0	0	0	0	0	5
				34	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	5
				36	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3
				38	0	0	0	1	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	2
				40	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
				42	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
44	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1				
46	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1				
48	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1				
50	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2				
52	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1				

09
03
03

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

D.B.		Visit																				Total		
Centre	Patient Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score
11	2	373	HB	22	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1
				24	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				26	0	0	0	1	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	3
				28	0	0	1	1	1	0	0	1	0	0	1	0	0	2	0	0	0	0	0	8
				30	0	0	0	0	1	0	0	1	0	0	1	0	0	0	0	0	0	0	0	3
11	3	374	RF	8	1	0	1	1	1	1	0	1	0	1	1	0	0	0	0	1	0	1	0	11
				10	3	0	2	2	3	2	2	3	1	2	2	1	2	1	2	0	2	0	0	34
11	6	377	VP	8	0	0	0	0	1	0	2	1	0	0	0	0	0	0	0	0	0	0	0	4
				10	1	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	4
				12	0	0	0	2	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	4
				14	0	0	0	1	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3
				16	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4
				18	1	0	0	2	2	0	0	1	0	1	0	0	0	0	0	0	0	0	0	7
				20	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	2
				22	0	0	0	2	0	0	1	0	1	2	0	1	0	0	1	0	0	0	0	10
				24	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	2
				26	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	2
				28	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1
				30	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
				32	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
				34	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
				36	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
				38	0	0	0	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	3
				40	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	2
				42	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
				44	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
				46	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
				48	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
				50	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				52	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
11	10	363	BJ	8	1	0	0	1	1	1	0	1	1	1	1	1	0	0	1	0	0	0	0	10
				10	2	0	0	1	1	3	0	1	2	1	1	1	0	0	1	0	0	0	0	14
				12	2	1	1	1	2	2	0	0	1	1	1	1	0	0	2	0	1	0	0	17
				14	1	0	0	1	1	0	0	0	1	0	1	0	0	0	0	0	1	0	0	7
				16	1	0	0	1	0	0	0	1	0	0	1	0	0	0	0	0	1	0	0	6
				18	2	0	0	1	0	0	0	1	0	0	1	1	0	0	0	0	1	0	0	8
				20	1	0	0	1	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	7
				22	1	0	0	0	1	0	0	1	1	0	1	0	0	0	0	0	0	0	0	6
				24	1	0	0	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	5
				26	1	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	4
				28	1	0	0	0	1	0	0	1	0	0	1	0	0	0	0	0	0	0	0	4
				30	1	0	0	0	1	0	0	1	1	0	1	0	0	0	0	0	0	0	0	4
				32	1	0	0	0	0	1	0	0	1	1	0	1	0	0	0	0	0	0	0	5
				34	1	0	0	0	0	0	0	0	1	1	0	1	0	0	0	0	0	0	0	5

933

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

D.B.		Centre Patient		Visit	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total	
11	17	368	UZ	32	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	2
				34	2	0	0	0	0	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	6
				36	2	0	0	0	0	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	6
				38	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				40	2	0	0	0	0	1	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	5
				42	2	0	0	1	0	0	2	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	7
				44	1	0	0	0	0	2	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	5
				46	1	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	3
				48	1	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	3
				50	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	2
				52	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	2
11	19	370	FK	8	2	0	0	0	1	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	6
				10	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1
				12	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1
				14	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1
				16	1	0	0	1	0	0	0	0	1	1	0	0	1	0	0	0	1	0	0	0	0	0	6
				18	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	2
				20	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	4
				22	1	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1
				24	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	5
				26	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	1
				28	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1
				30	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1
				32	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1
				34	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1
				36	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1
				38	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1
				40	2	0	0	0	1	0	0	0	1	1	1	1	1	0	0	0	1	0	0	0	0	0	10
				42	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	2
				44	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1
				46	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1
				48	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1
				50	2	0	0	0	1	0	1	2	0	0	2	0	0	0	0	0	0	0	0	0	0	0	8
				52	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1
12	1	92	IB	8	1	0	0	0	0	0	1	1	0	1	1	0	1	1	0	0	0	0	1	0	0	0	8
				10	1	0	0	0	0	0	1	1	0	1	0	0	0	1	0	0	0	0	1	0	0	0	6
				12	1	0	0	0	0	0	1	1	0	1	1	0	0	1	0	0	0	0	1	0	0	0	7
				14	1	0	0	0	0	0	1	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	5
				16	2	0	0	0	0	0	2	1	1	0	1	1	0	1	0	0	0	0	1	0	0	0	10
				18	2	0	0	0	0	0	2	1	1	0	1	1	1	0	0	0	0	0	1	0	0	0	10
				20	2	0	0	0	0	0	2	1	1	0	1	0	0	1	0	0	0	0	1	0	0	0	9
				22	1	0	0	0	0	0	1	0	1	0	1	0	0	1	0	0	0	0	1	0	0	0	7
				24	0	0	0	0	0	0	1	1	0	1	0	0	1	0	0	0	0	0	1	0	0	0	6
				26	0	0	0	0	0	0	1	1	0	1	0	0	1	0	0	0	0	0	1	0	0	0	6
				28	0	0	0	0	0	0	1	1	0	1	0	0	1	0	0	0	0	0	1	0	0	0	5

935

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CVS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient No.	D.B. Initials	Visit No.	It. 1 It. 2 It. 3 It. 4 It. 5 It. 6 It. 7 It. 8 It. 9 It. 10 It. 11 It. 12 It. 13 It. 14 It. 15 It. 16 It. 17 It. 18 It. 19 It. 20 It. 21																					Total Score				
				It. 1	It. 2	It. 3	It. 4	It. 5	It. 6	It. 7	It. 8	It. 9	It. 10	It. 11	It. 12	It. 13	It. 14	It. 15	It. 16	It. 17	It. 18	It. 19	It. 20	It. 21					
12	4	100	EG	20	1	1	0	0	0	2	2	0	1	1	1	1	0	1	0	0	0	0	0	1	0	0	11		
				22	2	1	0	0	0	2	0	1	1	1	1	1	1	0	1	0	0	0	0	1	0	0	12		
				24	1	0	0	0	0	2	0	0	1	1	1	1	1	0	1	0	0	0	0	1	0	0	9		
				26	0	0	0	1	1	0	1	0	1	1	1	1	1	0	1	0	0	0	0	1	0	0	12		
12	7	102	LK	28	3	0	0	0	0	2	1	2	1	1	0	1	0	0	0	1	0	0	0	0	0	0	16		
				8	2	0	0	0	2	2	0	0	2	2	1	0	0	1	1	0	1	0	0	0	0	0	0	17	
				10	2	0	0	0	2	2	0	1	2	2	1	0	0	0	0	0	1	0	0	0	0	0	0	15	
				12	2	0	0	0	2	2	0	1	2	2	1	0	1	0	1	0	1	0	0	0	0	0	0	15	
				14	2	0	0	0	2	2	0	1	2	2	1	0	1	0	1	0	1	0	0	0	0	0	0	18	
				16	2	0	0	0	2	2	0	2	2	2	0	0	2	0	0	0	1	0	0	0	0	0	0	14	
				18	1	0	0	0	2	2	0	2	0	2	1	1	0	0	0	0	0	1	0	0	0	0	0	8	
				20	1	0	0	0	1	2	1	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	11	
				22	2	0	0	1	2	1	0	1	1	0	0	1	0	1	0	0	0	1	0	0	0	0	0	11	
				24	2	0	0	1	2	1	0	2	1	0	2	1	0	1	0	0	0	1	0	0	0	0	0	0	16
				26	2	0	0	1	2	2	1	0	2	1	0	2	1	0	1	0	0	1	0	0	0	0	0	0	14
				28	2	0	0	1	2	2	1	0	1	2	1	0	1	0	1	0	0	1	0	0	0	0	0	0	14
12	9	91	KBP	8	3	0	0	1	1	2	3	1	1	3	1	0	1	0	0	0	0	2	0	0	0	0	20		
				10	3	0	0	1	1	2	2	1	0	2	1	0	1	1	0	0	0	2	0	0	0	0	17		
				12	3	0	0	1	0	2	2	1	0	2	1	0	1	1	0	0	0	2	0	0	0	0	0	16	
				14	2	0	0	0	1	1	1	0	2	1	0	0	1	1	0	0	0	2	0	0	0	0	0	12	
				16	2	0	0	0	1	1	1	0	2	1	0	0	1	1	0	0	0	0	0	0	0	0	0	9	
				18	3	0	0	1	1	2	2	0	3	1	0	0	1	0	0	2	0	0	0	0	0	0	0	18	
				20	2	0	0	1	2	2	2	0	2	1	0	0	1	0	0	0	0	2	0	0	0	0	0	13	
				22	1	0	0	0	0	0	0	1	0	1	1	0	0	1	0	0	0	0	2	0	0	0	0	7	
				24	1	0	0	0	0	0	0	0	1	0	1	1	0	0	1	0	0	0	2	0	0	0	0	7	
				26	1	0	0	0	0	0	0	1	0	1	1	0	0	1	0	0	0	0	2	0	0	0	0	7	
				28	1	0	0	0	0	0	0	0	0	1	1	0	0	1	0	0	0	0	2	0	0	0	0	0	6
				12	15	104	GB	8	1	2	1	1	0	0	1	0	1	1	0	0	0	1	0	0	0	0	0	0	0
10	1	2	1					1	1	0	0	1	0	1	1	0	0	0	1	0	0	0	0	0	0	0	11		
12	1	2	1					1	1	0	0	1	1	1	0	0	0	0	1	0	0	0	0	0	0	0	12		
14	1	2	1					1	1	0	0	1	1	1	1	0	0	0	1	0	0	0	0	0	0	0	0	12	
16	1	1	1					1	1	0	0	1	1	1	1	0	0	0	1	0	0	0	0	0	0	0	0	11	
18	1	1	0					1	0	0	0	1	1	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	10
12	16	105	FN	20	1	1	0	1	0	0	0	1	1	1	0	0	0	1	0	0	0	0	0	0	0	0	9		
				22	1	1	0	1	0	0	1	1	1	1	0	0	0	1	0	0	0	0	0	0	0	0	9		
				24	1	1	0	1	0	0	1	1	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	10	
				26	1	1	0	1	0	0	1	1	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	10	
12	16	105	FN	8	1	1	0	0	1	1	0	1	1	1	0	0	0	1	0	0	0	0	0	0	0	0	11		
				10	1	0	0	0	0	0	0	1	2	0	0	1	0	2	1	0	0	0	0	0	0	0	9		
				12	3	0	0	1	1	0	0	2	2	3	0	1	0	3	0	0	0	0	0	0	0	0	0	12	
				14	1	0	0	0	1	1	0	0	2	0	1	0	3	2	0	0	0	0	0	0	0	0	0	18	
				16	2	0	0	1	1	0	0	0	1	2	3	0	1	0	3	0	0	0	0	0	0	0	0	11	
				18	2	0	0	1	1	0	2	0	2	3	0	1	0	3	0	0	0	0	0	0	0	0	0	17	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	D.B.	Initials	Visit No.	Visit																				Total Score					
					It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20		It.21				
12	33	388	LN	8	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	4	
				10	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	5	
				12	2	0	0	1	1	0	0	1	0	1	0	0	0	0	0	0	2	0	1	0	0	0	0	0	9	
				14	2	0	0	1	1	1	0	1	0	1	0	0	0	0	0	0	2	0	1	0	0	0	0	0	11	
				16	2	0	0	0	0	1	1	0	1	0	0	0	0	0	0	0	2	0	1	1	0	0	0	0	10	
				18	2	0	0	0	1	1	1	0	1	0	0	0	0	0	0	0	2	0	1	1	0	0	0	0	10	
				20	2	0	0	0	0	1	1	0	1	0	0	0	0	0	0	0	2	0	1	1	0	0	0	0	10	
12	36	385	FB	8	2	0	0	1	1	1	0	1	2	2	0	1	2	2	0	0	1	0	0	0	0	0	0	0	16	
				10	2	0	0	1	2	1	1	0	2	2	1	1	2	2	0	1	2	2	0	0	0	0	0	0	19	
				12	2	0	0	1	2	1	1	0	2	2	0	1	2	2	0	0	0	0	0	0	0	0	0	0	18	
13	1	219	PZ	8	1	0	0	0	0	0	0	1	1	0	1	1	1	0	0	1	1	0	0	1	0	0	0	0	9	
				10	1	0	0	1	0	0	1	2	0	1	1	0	1	1	0	0	1	1	0	0	1	0	0	0	14	
				12	2	0	0	1	0	0	1	0	1	1	0	1	1	0	0	1	1	0	0	1	0	0	0	0	10	
				14	2	0	0	1	1	0	1	2	2	2	1	0	1	1	0	0	1	1	0	0	1	0	0	0	18	
				16	2	0	0	2	1	2	3	2	2	1	1	1	1	1	0	1	1	1	1	0	0	1	1	24		
				18	1	0	0	1	0	0	2	1	0	2	1	1	2	1	0	0	0	0	0	0	0	0	0	0	14	
				20	2	0	0	1	0	1	2	1	0	2	1	0	1	0	1	0	1	2	0	0	0	0	0	0	16	
				22	2	0	0	1	1	1	2	2	2	2	1	0	1	0	1	0	1	0	1	0	0	0	0	0	21	
				24	1	0	0	0	0	1	1	1	1	1	1	2	1	1	0	0	1	1	0	0	0	0	0	0	12	
				26	1	0	0	0	1	1	1	1	1	1	1	2	1	1	0	0	0	0	0	0	0	0	0	0	15	
				30	2	0	0	1	1	1	1	2	1	1	1	2	1	0	0	0	0	0	0	0	0	0	0	0	17	
				32	1	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	6	
				34	1	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	6	
				36	1	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	6	
				38	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	
				40	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	
				42	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	
				44	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	
				46	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	
				48	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	
				50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	
				52	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	
13	3	221	AI	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	
				10	1	0	0	0	0	0	0	1	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
				12	1	1	0	0	0	0	0	1	1	2	1	1	0	0	0	0	0	0	0	0	0	0	0	0	8	
				14	2	0	0	0	0	0	0	1	1	3	2	1	1	0	0	0	0	0	0	0	0	0	0	0	11	
				16	1	0	0	0	0	0	0	1	1	1	2	1	1	0	0	0	0	0	0	0	0	0	0	0	10	
				18	1	0	0	0	0	0	0	0	0	1	1	2	2	1	0	0	0	0	0	0	0	0	0	0	9	
				20	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5		
				22	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	
				24	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	
				26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	
				28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBONETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBONETINE

D.B.		Centre Patient Initials		Visit																				Total
		It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score	
13	7	220	BL	28	1	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	6
				30	1	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	4
				32	1	0	0	1	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	6
				34	1	0	0	1	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	6
				36	1	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	7
				38	1	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	5
				40	1	0	0	1	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	6
				42	1	0	0	1	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	6
				44	1	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	6
				46	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	3
				48	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3
				50	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				52	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4
13	13	223	HM	8	1	0	0	1	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	7
				10	1	0	0	1	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	7
				12	1	0	0	0	0	2	0	2	0	0	0	1	0	0	0	1	0	0	0	5
				14	1	0	0	0	0	2	0	2	0	0	0	1	2	0	0	0	2	0	0	12
				16	1	0	0	1	1	0	0	2	2	0	1	1	0	0	0	1	0	0	0	11
				18	1	0	0	0	1	0	1	0	1	1	0	1	0	1	0	1	0	0	0	11
				20	1	0	0	0	1	0	1	1	0	1	1	0	1	0	0	1	0	0	0	11
				22	1	0	0	0	1	0	2	1	1	0	0	1	1	2	0	0	1	0	0	11
				24	1	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	8
				26	1	0	0	0	0	1	0	2	1	0	0	0	1	0	0	1	0	0	0	8
				28	1	0	0	0	0	0	1	0	2	1	1	0	0	0	0	1	0	0	0	8
				30	1	0	0	0	0	0	1	1	0	0	1	1	2	0	0	1	0	0	0	9
				32	1	0	0	0	0	0	1	1	0	1	1	0	0	0	0	1	0	0	0	11
				34	1	0	0	0	0	1	0	1	1	0	1	1	1	1	0	0	0	0	0	11
				36	1	0	0	0	1	0	1	1	0	0	1	1	1	1	0	0	0	0	0	12
				38	1	0	0	0	1	0	1	1	0	1	1	1	1	2	0	1	0	0	0	13
				40	1	0	0	0	1	0	1	1	0	1	1	1	1	1	1	0	0	0	0	13
				42	1	0	0	0	0	1	1	0	1	1	0	0	0	1	2	0	0	0	0	13
				44	1	0	0	0	1	1	0	1	1	0	0	1	1	0	0	1	0	0	0	9
				46	1	0	0	0	1	1	0	1	1	0	0	1	1	0	0	1	0	0	0	11
				48	1	0	0	0	1	0	1	0	1	0	0	1	1	0	0	1	0	0	0	11
				50	1	0	0	0	1	0	1	0	1	0	0	1	1	0	0	1	0	0	0	9
				52	0	0	0	0	1	1	0	1	0	0	0	1	0	0	0	1	0	0	0	9
13	18	227	VT	8	1	0	0	1	0	0	1	1	0	1	0	0	0	0	0	1	0	0	0	6
				10	2	0	0	1	0	1	1	1	1	0	1	0	1	0	0	2	1	0	0	11
				12	2	0	0	2	1	2	1	2	0	1	0	0	0	0	0	0	0	0	0	13
				14	1	0	0	2	0	1	2	2	1	2	3	0	1	0	0	0	0	0	0	16
				16	1	0	0	2	0	1	2	2	1	1	0	0	1	0	0	0	0	0	0	12
				18	1	0	0	2	1	2	2	2	1	2	0	1	0	0	0	0	0	0	0	17
				20	2	0	0	2	2	2	2	2	1	2	1	1	1	0	0	0	0	0	0	20
				22	2	0	0	2	2	2	3	2	2	0	1	0	1	0	0	0	1	0	0	22
				24	1	0	0	2	1	1	2	2	2	0	1	1	1	0	0	1	0	0	0	16

942

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total	
13	18	227	VT	26	1	0	0	1	1	0	2	1	1	1	1	1	1	1	1	1	0	0	0	0	1	14
				28	1	0	1	1	1	1	1	1	1	2	1	1	1	1	1	1	0	0	0	0	1	16
				30	1	0	0	2	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	18
				32	1	0	0	1	2	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	15
				34	1	0	0	1	0	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	11
				36	1	0	0	0	0	1	1	1	1	1	1	1	1	1	1	2	0	0	0	0	0	13
				38	1	0	0	0	1	0	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	10
				40	1	0	0	2	1	0	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	12
				42	1	0	0	0	1	0	0	1	1	1	1	1	1	1	1	0	0	0	0	0	0	10
				44	1	0	0	0	0	0	1	1	1	1	2	0	1	1	2	2	0	0	0	0	0	14
				46	1	0	0	0	0	0	0	1	1	1	1	1	1	0	0	0	0	0	0	0	0	7
				48	1	0	0	0	0	0	0	1	1	1	1	1	1	0	1	0	0	0	0	0	0	8
				50	0	0	0	0	0	0	1	1	1	1	2	0	1	0	1	0	0	0	0	0	0	6
				52	0	0	0	1	0	0	1	1	1	1	1	0	1	0	0	0	0	0	0	0	0	6
13	20	230	NL	8	2	0	0	2	1	1	2	3	3	2	0	1	0	1	1	0	1	0	0	0	1	24
				10	1	0	0	1	1	1	1	2	1	1	1	0	1	0	2	0	0	0	0	0	0	14
				12	2	0	0	2	2	1	2	2	2	2	2	0	1	0	2	0	0	0	0	0	0	21
				14	2	0	0	1	2	1	1	2	2	2	2	0	1	0	1	0	0	0	0	0	0	19
				16	1	0	0	0	0	0	0	1	1	1	1	0	0	0	2	0	0	0	0	0	0	10
				18	1	0	0	0	0	0	1	1	1	1	1	0	0	1	0	0	0	0	0	0	0	9
				20	1	0	0	0	0	0	1	1	1	1	1	0	0	0	1	0	0	0	0	0	0	10
				22	1	0	0	0	0	0	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	10
				24	1	0	0	0	0	0	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	6
				26	1	0	0	0	0	0	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	8
				28	1	0	0	0	0	0	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	4
				30	1	0	0	0	0	0	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0	5
				32	1	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	5
				34	1	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	3
				36	1	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	4
				38	1	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	3
				40	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4
				42	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3
				44	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4
				46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4
				48	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3
				50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				52	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4
13	21	231	CL	8	1	0	0	0	1	1	0	0	1	0	1	1	1	2	1	1	0	0	0	0	0	13
				10	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	8
				12	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	7
				14	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				16	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				18	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10
				20	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	12
				22	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	13

943

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	Initials	D.B.	Visit	Total																				
					No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20
13	21	231	CL	24	1	0	1	1	1	1	1	0	2	0	1	1	0	1	1	1	0	0	0	0	13
				26	1	0	1	1	1	0	0	2	1	1	1	0	1	0	0	1	0	0	0	0	10
				28	1	0	1	0	0	0	0	1	0	1	1	0	0	1	1	0	0	1	0	0	9
				30	1	0	0	0	0	0	0	1	1	1	1	0	0	2	1	0	0	1	0	0	9
				32	1	0	0	0	1	1	0	0	1	0	1	1	0	1	1	2	0	1	0	0	11
				34	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	2
				36	1	0	0	0	0	0	0	2	0	1	1	0	0	1	1	0	0	0	0	0	6
				38	1	0	0	0	0	0	0	1	1	1	1	0	0	1	1	0	0	0	0	0	6
				40	1	0	0	0	0	0	0	2	0	1	1	0	0	1	1	0	0	1	0	0	7
				42	0	0	0	0	0	0	0	1	1	1	1	0	0	1	1	0	0	1	0	0	8
				44	0	0	0	0	0	0	0	1	0	1	1	0	0	1	1	0	0	1	0	0	5
				46	1	0	0	0	0	0	0	2	1	0	1	1	0	1	1	0	0	1	0	0	8
				48	0	0	0	0	0	0	1	0	0	1	0	0	1	1	0	0	1	0	0	0	5
				50	1	0	0	0	0	0	0	1	0	0	1	1	0	1	2	1	0	0	0	0	7
				52	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	2
13	22	232	NYM	8	2	1	2	2	2	1	2	0	1	2	0	1	2	1	0	1	0	0	1	0	1
				10	3	0	3	2	2	2	3	2	1	3	2	1	2	1	0	1	2	1	0	0	2

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
 REROXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACERO

Centre	Patient	D. B.	Visit	Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total	
1	1	1	8	MGA	1	0	1	1	0	1	0	2	2	1	1	1	0	0	1	1	0	0	1	1	0	0	1	14
			10		2	1	1	1	0	2	2	1	1	1	1	1	1	1	1	1	1	0	0	1	0	0	0	17
			12		2	0	0	1	1	2	2	2	2	2	2	2	2	2	2	2	2	0	0	0	2	0	0	19
			14		2	0	0	1	0	1	2	0	2	1	1	0	1	0	1	0	1	0	0	0	2	0	0	14
			16		2	1	0	1	1	2	1	2	1	1	2	2	2	2	2	2	2	1	1	2	1	2	0	23
			18		3	1	1	2	1	2	3	2	0	2	2	2	2	2	2	2	2	1	1	2	0	0	0	29
1	6	5	8	CPM	1	0	0	1	1	1	2	0	0	2	1	1	2	1	1	1	0	0	0	1	0	0	0	15
			10		1	0	0	1	2	1	2	0	0	2	1	1	2	1	2	1	2	0	0	1	0	0	0	17
			12		1	0	0	2	2	1	2	0	1	2	2	2	2	2	2	2	2	0	0	1	1	0	0	20
			14		2	0	0	2	2	1	2	0	3	2	2	2	2	2	2	2	2	0	0	1	1	1	1	29
			16		2	1	1	2	2	1	2	0	3	2	2	2	2	2	2	2	2	0	0	1	2	1	0	29
			18		3	1	1	2	2	1	3	0	3	3	3	3	3	3	3	3	3	2	2	1	2	1	0	33
1	8	6	8	MVB	1	0	0	1	1	0	1	0	0	1	1	1	0	2	1	1	0	0	0	1	0	0	0	11
			10		1	0	0	1	1	1	1	0	0	1	1	1	0	2	1	1	1	0	0	0	0	0	0	10
			12		1	0	0	1	1	1	1	0	0	1	1	1	1	0	1	1	1	0	0	1	1	0	0	14
			14		1	0	0	1	1	1	2	0	0	1	1	1	0	2	1	1	0	0	0	1	1	0	0	14
			16		1	0	0	1	2	1	0	2	1	0	2	2	0	1	1	1	0	0	0	0	1	0	0	17
			18		2	0	0	1	1	2	2	1	0	2	2	1	1	1	1	1	0	0	0	1	0	0	0	17
			20		1	0	0	1	1	2	1	0	2	2	2	2	2	2	2	2	2	1	1	0	0	1	1	20
			22		1	0	0	1	1	2	1	0	2	2	2	2	2	2	2	2	2	1	1	0	0	1	1	18
			24		2	0	0	1	1	2	1	0	2	2	2	2	2	2	2	2	2	1	1	0	0	1	1	22
			26		2	1	2	2	1	3	2	0	3	2	2	2	2	2	2	2	2	0	2	1	2	0	0	32
1	11	9	8	VRT	1	0	0	1	1	1	0	0	2	1	1	1	0	1	1	1	0	0	0	1	0	0	0	11
			10		1	0	0	1	1	1	1	0	2	1	1	1	1	1	1	1	1	0	0	0	1	0	0	14
			12		1	0	0	1	1	0	0	2	1	1	1	0	0	0	0	0	1	0	0	0	1	1	0	10
			14		1	0	0	1	1	0	2	0	1	1	1	0	2	1	0	0	1	0	0	1	0	0	0	12
			16		1	0	0	1	2	0	0	1	1	0	0	2	1	0	1	0	1	0	0	1	1	0	0	13
			18		1	0	0	1	1	1	1	0	2	1	1	1	0	1	1	1	0	0	0	0	0	0	0	10
			20		1	0	0	1	1	1	0	0	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	10
			22		1	0	0	1	1	0	1	2	1	2	1	2	1	2	2	2	1	0	0	0	0	0	0	10
			24		2	0	0	1	1	2	1	0	2	2	2	2	2	2	2	2	2	1	1	0	0	1	1	18
			26		2	1	2	2	1	3	2	0	3	2	2	2	2	2	2	2	2	0	2	1	2	0	0	32
1	12	10	8	SIT	1	0	0	1	1	1	0	0	2	1	1	1	0	1	1	1	0	0	0	1	0	0	0	11
			10		1	0	0	1	2	1	1	0	1	2	2	1	0	1	1	1	0	0	0	1	0	0	0	14
			12		1	0	0	1	1	2	0	1	2	1	1	1	0	1	1	1	1	0	0	1	1	0	0	15
			14		1	0	0	1	1	1	2	0	1	2	1	0	1	0	1	1	1	0	0	1	1	0	0	15
			16		1	0	0	1	1	1	2	1	0	2	1	0	2	1	0	2	1	0	0	1	1	0	0	16
			18		1	0	0	1	1	0	0	2	0	1	2	1	0	1	0	1	0	0	1	1	1	0	0	13

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

D.B.		Visit																				Total			
Centre	Patient	Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score
1	16	13	MHC	18	1	1	0	1	1	0	2	1	0	2	2	1	0	1	0	0	0	1	0	0	15
				20	1	1	0	1	1	1	2	1	0	2	1	0	1	0	0	0	0	0	0	0	14
				22	2	1	0	0	2	0	2	2	1	1	1	1	1	0	0	0	0	0	0	0	14
				24	1	0	0	1	1	0	0	1	1	1	1	1	1	0	0	0	0	0	0	0	8
				26	1	0	0	1	0	1	0	1	1	1	1	0	1	0	0	0	0	0	0	0	8
				28	1	0	0	1	0	1	0	1	1	1	1	1	1	0	0	0	0	0	0	0	12
				30	1	0	0	1	1	1	2	0	2	1	1	1	1	0	0	0	0	0	0	0	12
				32	2	0	0	1	1	1	0	2	2	1	1	1	1	0	0	0	0	0	0	0	13
				34	1	0	0	1	1	1	2	1	0	1	0	1	1	0	0	0	0	0	0	0	9
				36	1	0	0	1	1	0	1	0	1	2	1	0	1	0	0	0	0	0	0	0	9
				38	0	0	0	1	1	0	1	0	1	2	1	0	1	0	0	0	0	0	0	0	8
				40	0	0	0	1	1	0	0	1	2	1	0	1	0	0	0	0	0	0	0	0	8
1	19	16	SR	8	1	1	1	1	1	0	1	2	2	0	0	0	1	1	0	0	1	0	0	0	14
				10	1	1	0	1	1	1	2	1	0	2	2	0	2	0	1	0	0	0	0	0	16
				12	1	1	0	1	1	1	0	2	2	1	0	1	1	1	0	0	0	1	0	0	13
				14	1	1	0	1	1	1	0	2	2	2	0	2	1	1	0	0	0	1	0	0	15
				16	1	1	1	1	1	0	2	0	1	2	2	1	1	1	0	0	0	1	0	0	15
				18	2	1	1	1	1	0	2	0	1	2	2	1	2	0	1	0	0	0	0	0	18
				20	2	1	1	2	1	0	2	1	0	2	1	0	1	1	0	0	0	1	0	0	19
				22	2	1	1	2	0	1	2	0	0	2	2	0	2	1	1	0	0	2	1	0	19
				24	2	1	1	1	1	0	2	0	1	2	2	0	1	1	2	0	0	1	2	0	21
				26	2	0	1	2	1	1	2	0	1	2	0	1	1	2	0	0	0	2	0	0	18
				28	2	0	1	1	0	2	0	1	2	2	0	1	1	1	2	0	0	1	1	0	18
				30	2	0	1	2	1	0	2	0	1	2	2	0	1	1	1	0	0	0	0	0	20
				32	2	1	1	2	1	0	2	0	2	2	0	2	2	1	0	0	0	0	0	0	17
				34	1	1	1	1	1	0	2	1	0	2	2	1	1	1	0	0	0	1	1	0	25
				36	2	1	1	2	1	0	2	0	2	2	2	1	2	2	0	0	1	1	1	0	17
				38	4	2	1	2	1	2	4	1	0	3	3	1	2	2	0	0	1	2	1	0	32
1	21	18	VHC	8	1	0	0	1	0	1	1	0	0	1	2	0	1	1	0	0	0	1	0	0	11
				10	1	0	0	0	0	1	1	0	2	1	0	0	1	1	0	0	0	1	1	0	9
				12	1	0	0	0	0	1	1	0	2	1	1	1	1	1	0	0	0	0	0	1	11
				14	1	0	0	1	1	1	1	0	2	1	0	0	1	0	0	0	0	1	1	0	13
				16	1	0	0	1	1	0	1	0	2	1	0	0	1	0	0	0	0	0	0	1	9
				18	0	0	0	1	1	0	0	1	2	2	0	0	1	0	0	0	0	0	0	0	10
				20	1	1	0	1	1	0	2	0	1	2	2	0	1	1	0	0	0	0	0	0	10
				22	1	0	0	1	1	0	1	0	2	1	1	1	1	0	0	0	0	0	1	0	12
				24	1	0	0	1	0	1	1	0	1	1	0	1	1	0	0	0	0	0	0	0	10
				26	1	0	0	1	1	0	1	1	0	1	1	0	1	0	0	0	0	0	0	0	10
				28	1	0	0	2	1	1	1	0	1	1	1	0	1	0	0	0	0	0	0	0	11
				30	1	0	0	2	1	1	1	0	1	1	0	1	1	0	0	0	0	0	0	0	10
				32	1	0	0	1	1	1	1	0	1	1	0	1	1	0	0	0	0	0	0	0	10
				34	1	0	0	2	1	1	1	0	1	1	0	1	1	0	0	0	0	0	0	0	10
				36	1	0	0	1	1	0	1	0	2	2	1	1	1	0	0	0	0	0	0	0	11
				38	1	1	1	1	1	0	2	2	2	2	1	1	1	1	0	0	0	0	0	0	11
				40	1	1	1	2	1	1	2	0	2	1	1	0	1	1	0	0	0	0	0	0	11

947

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

D.B.		Visit																				Total			
Centre	Patient	Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score
1	21	18	VMC	42	1	1	1	1	1	1	1	1	0	2	1	2	1	0	0	0	1	0	0	1	18
				44	1	1	1	1	1	1	1	1	0	2	0	2	1	0	0	1	1	0	1	0	17
				46	2	1	1	1	1	1	1	1	0	2	0	1	2	1	0	0	1	1	0	0	17
				48	2	1	1	1	1	1	1	1	0	2	1	1	2	0	1	0	1	1	0	0	18
				50	1	1	1	1	1	1	1	1	0	2	1	1	2	1	0	0	1	1	0	0	17
				52	2	1	1	1	1	1	1	1	0	2	1	1	2	1	0	0	1	1	0	0	17
1	26	22	OC	8	1	0	0	1	1	0	1	0	1	2	1	0	0	1	0	0	1	0	0	1	11
				10	1	1	0	2	1	0	1	0	1	2	1	0	1	0	0	0	1	0	0	0	13
				12	1	1	0	1	1	0	1	0	2	1	1	1	1	1	2	0	1	1	0	0	18
				14	1	1	0	1	1	0	1	1	0	2	1	1	1	0	0	0	1	1	0	0	12
				16	2	0	0	2	1	0	1	0	2	2	0	2	1	1	0	0	0	1	0	0	18
				18	0	0	0	1	1	0	2	0	1	1	1	1	1	0	0	0	0	0	0	0	10
				20	1	0	1	1	1	2	0	1	2	2	0	2	1	0	0	0	1	0	0	0	17
				22	1	0	1	2	1	2	2	0	1	2	2	0	1	0	0	0	0	0	0	0	18
				24	2	0	0	2	0	2	0	1	2	1	0	2	2	1	0	0	2	1	0	0	18
				26	1	0	0	1	1	1	0	2	3	2	0	2	2	1	0	0	0	0	0	0	15
				28	2	1	0	1	1	1	0	2	3	2	0	2	2	1	0	0	0	0	0	0	17
				30	2	0	0	1	1	2	1	0	2	2	1	1	1	0	0	0	0	0	0	0	15
				32	2	0	0	1	1	1	0	0	2	1	1	2	1	0	0	0	0	0	0	0	15
				34	1	1	0	1	1	1	0	0	2	1	1	2	1	0	0	0	0	0	0	0	13
				36	1	1	0	2	1	0	2	0	0	2	0	0	2	1	0	0	0	0	0	0	12
				38	2	1	0	2	1	0	2	0	0	2	0	0	2	1	0	0	0	0	0	0	15
				40	1	0	0	1	0	0	1	0	0	2	0	0	2	1	0	0	0	0	0	0	10
				42	1	1	0	2	1	0	2	0	1	2	1	1	2	1	0	0	0	0	0	0	14
				44	1	1	0	2	1	0	2	0	1	1	1	1	2	1	0	0	0	0	0	0	15
				46	2	0	0	2	0	0	2	0	1	2	2	1	0	0	0	0	0	0	0	0	16
				48	2	1	0	2	1	0	2	0	1	2	1	1	2	1	0	0	0	0	0	0	18
				50	1	1	0	2	2	0	2	0	1	2	1	1	2	1	0	0	0	0	0	0	16
				52	2	1	0	2	1	0	2	0	1	2	1	1	2	1	1	0	0	1	0	0	18
1	27	23	RK	8	1	1	0	1	1	1	1	0	2	1	1	2	1	0	0	0	1	0	0	0	14
				10	2	1	1	2	2	1	2	0	2	2	1	2	1	0	0	0	1	0	0	0	22
				12	3	1	2	2	1	1	3	0	3	3	2	2	1	1	2	0	1	0	0	0	31
1	28	24	RHM	8	1	1	0	1	1	1	1	0	2	1	0	2	0	0	0	0	1	0	0	0	13
				10	1	0	1	1	1	1	1	0	2	1	0	2	1	0	0	0	0	0	0	0	12
				12	1	1	1	1	1	1	0	2	0	2	1	0	1	1	0	0	0	0	0	0	14
				14	2	1	1	1	1	1	2	0	1	2	1	1	1	1	0	0	0	1	1	0	20
				16	2	1	0	1	1	1	2	0	2	2	0	2	1	1	0	0	1	1	0	0	20
				18	2	1	1	2	1	1	2	0	2	3	0	2	1	1	0	0	1	1	0	0	24
				20	2	1	1	2	1	1	2	0	2	3	0	2	1	1	0	0	2	0	0	0	25
				22	2	1	1	2	1	1	2	0	2	3	0	2	1	1	1	2	0	1	0	0	26
				24	2	0	1	2	1	2	2	0	2	3	0	2	2	1	1	2	0	2	1	0	27
1	29	25	AFO	8	1	0	0	1	1	0	1	0	1	2	1	0	1	1	0	0	0	0	0	0	12
				10	1	0	1	0	0	1	0	1	2	1	0	1	1	1	0	0	0	0	0	0	9

848

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.1
HAMILTON DEPRESSION RATING SCALE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	Initials	No.	Visit																				Total	
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20		It.21
1	29	25	AFO	12	2	1	0	0	1	1	0	0	1	1	0	0	1	1	0	0	0	0	0	0	11
				14	1	0	0	1	1	0	1	1	1	0	1	1	0	0	0	0	0	0	0	0	8
				16	1	0	0	1	1	0	1	1	1	0	0	1	0	0	0	0	0	0	0	0	7
				18	1	0	0	1	1	0	1	1	1	0	0	1	1	0	0	0	0	0	0	0	8
				20	1	0	0	1	1	0	1	1	0	0	1	1	0	0	1	0	0	0	0	0	9
				22	1	0	0	1	1	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	7
				24	1	0	0	1	1	1	1	1	0	0	1	1	0	0	0	0	1	1	0	0	11
				26	1	0	0	1	1	0	1	1	0	0	1	1	0	0	0	0	1	1	0	0	9
				28	1	0	0	1	1	1	1	1	0	0	1	1	0	0	2	1	1	1	0	0	13
				30	2	1	0	2	1	0	2	1	1	1	1	1	0	0	2	1	1	1	0	0	20
				32	2	1	0	2	1	0	2	1	1	1	2	1	0	0	2	0	0	0	0	0	16
				34	2	1	0	2	1	0	2	0	1	2	1	0	0	2	0	0	0	0	0	0	15
				36	1	1	0	2	1	1	2	0	2	2	0	0	2	1	0	0	0	0	0	0	17
				38	1	1	0	2	1	0	2	0	1	2	1	0	0	0	0	0	0	0	0	0	16
				40	1	1	0	2	1	0	2	0	1	2	0	1	0	0	0	0	1	1	0	0	14
				42	1	1	0	2	0	1	2	0	1	2	0	1	0	0	0	0	1	1	0	0	14
				44	1	1	0	2	0	0	3	0	2	1	0	1	0	0	0	1	1	0	0	0	15
				46	2	1	0	2	0	1	2	0	1	2	0	1	0	0	0	0	0	0	0	0	12
				48	1	1	0	2	0	0	2	0	1	2	0	1	0	0	0	0	0	0	0	0	13
				50	1	0	0	2	0	1	1	0	1	2	0	1	0	0	0	0	0	0	0	0	8
				52	1	0	0	2	0	0	1	0	1	1	0	0	1	0	0	0	0	0	0	0	8
1	30	26	ERV	8	2	0	0	2	0	0	1	1	0	2	1	0	0	0	0	0	0	0	0	0	13
				10	2	1	0	2	2	0	2	0	2	2	1	2	1	0	0	0	0	0	0	0	19
				12	2	1	1	1	2	2	0	2	1	1	1	2	0	0	0	0	0	0	0	0	20
				14	2	1	1	2	2	1	3	2	0	2	2	1	1	0	0	0	0	0	0	0	24
				16	3	2	1	2	2	1	3	0	3	2	0	2	2	0	0	0	0	2	1	0	33
1	33	29	OFC	8	1	0	0	1	1	1	1	0	0	2	1	0	0	0	0	0	0	0	0	0	11
				10	1	1	0	1	1	0	2	1	0	2	1	1	0	0	0	0	0	0	0	0	16
				12	3	2	1	2	2	1	3	2	0	3	2	1	2	1	0	0	1	2	1	0	33
1	36	302	LM	8	1	1	1	1	1	0	1	0	1	1	2	0	0	0	0	0	0	0	0	0	11
				10	1	0	0	1	1	0	2	1	0	2	1	0	0	0	0	0	0	0	0	0	15
				12	2	1	1	2	2	1	3	0	2	2	1	2	1	2	0	0	1	0	0	0	27
				14	2	1	2	2	1	2	2	0	2	2	1	2	1	1	0	0	0	0	0	0	27
				16	3	1	2	2	1	2	3	0	4	2	2	1	1	1	0	0	0	0	0	0	32
1	38	304	DBF	8	0	0	0	0	1	1	0	0	1	2	1	0	0	0	0	0	0	0	0	0	8
				10	0	0	0	1	1	0	0	0	1	2	1	0	0	0	0	0	0	0	0	0	6
				12	0	0	0	1	1	0	0	1	1	1	0	1	0	0	0	0	0	0	0	0	10
				14	0	0	0	1	1	0	0	1	1	1	0	1	1	0	0	0	0	0	0	0	9
				16	2	0	0	2	0	0	1	0	0	2	1	0	0	0	0	0	0	0	0	0	10
				18	2	0	0	1	1	1	2	0	1	2	1	0	0	0	0	0	0	0	0	0	18
				20	2	1	0	1	1	1	2	0	1	2	1	1	1	0	0	0	0	0	0	0	18
				22	1	1	0	1	1	1	1	0	2	2	1	1	0	0	0	0	0	0	0	0	15
				24	1	1	0	2	1	1	0	2	2	1	0	1	1	0	0	0	0	0	0	0	17

07
05

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score
1	38	DBF	26	1	1	0	2	1	0	2	0	2	2	1	1	2	1	0	2	0	1	0	1	0	20
			28	1	1	0	1	1	0	2	0	2	2	1	1	0	0	1	1	0	1	1	1	0	15
			30	2	1	0	2	1	0	2	0	1	2	1	1	0	2	1	1	0	1	1	0	0	18
			32	1	0	0	1	1	0	1	0	1	1	1	1	0	1	1	1	0	1	1	0	0	13
			34	0	0	0	1	1	0	0	0	2	2	1	0	0	1	1	0	0	1	0	0	0	10
			36	1	0	0	2	1	0	1	0	2	1	1	0	2	1	1	0	0	1	0	0	0	14
			38	1	1	0	1	0	1	0	1	2	2	1	1	0	2	1	1	0	0	1	0	0	17
			40	0	0	0	1	1	0	0	1	2	2	2	0	2	1	1	0	0	0	1	1	0	14
			42	1	1	1	2	1	1	0	2	2	1	1	1	2	1	1	0	0	0	2	0	0	19
			44	1	2	1	1	2	1	1	1	2	1	1	1	2	1	2	0	1	0	0	0	0	21
			46	2	1	1	2	1	0	2	2	0	2	0	2	1	2	1	0	0	0	0	0	0	19
			48	2	1	1	2	1	0	3	1	0	0	0	2	1	3	0	0	0	1	0	0	0	22
			50	2	1	1	2	1	2	3	0	2	1	1	1	0	2	1	0	0	1	0	0	0	21
			52	2	1	1	2	1	0	3	0	3	2	1	1	0	1	3	0	0	2	1	0	0	24
1	40	EX	8	1	0	0	1	1	1	1	1	0	2	1	0	1	0	1	0	0	1	1	0	0	13
			10	1	0	0	1	1	1	1	1	0	2	1	0	1	1	1	0	0	1	1	0	0	14
			12	1	0	0	1	1	1	1	0	2	2	0	1	0	1	0	0	0	1	1	0	0	13
			14	1	0	1	1	2	0	1	1	0	2	1	0	2	0	0	0	0	1	1	0	0	15
			16	0	0	0	1	0	0	0	1	0	1	0	0	2	0	0	0	0	0	0	1	0	7
			18	1	1	0	1	1	0	1	1	1	1	1	1	1	1	1	2	0	0	0	0	0	15
			20	2	1	0	1	0	1	2	0	1	1	1	0	2	0	0	0	0	0	0	0	0	20
			22	2	1	0	2	1	0	2	0	2	2	1	0	2	1	0	0	0	2	0	0	0	14
			24	1	1	1	1	0	0	2	1	0	2	1	0	2	1	0	2	0	0	0	0	0	16
			26	1	1	1	1	0	0	2	1	0	2	1	0	2	1	0	2	0	0	0	0	0	8
			28	1	1	0	1	0	0	1	0	1	1	1	0	2	1	0	0	0	0	0	0	0	12
			30	0	0	0	2	0	0	1	0	1	2	0	0	2	0	0	0	0	0	0	0	0	10
			32	0	0	0	2	0	0	2	0	2	2	0	0	2	0	0	0	0	0	0	0	0	8
			34	1	1	1	1	0	0	1	0	1	2	0	0	2	0	0	0	0	0	0	0	0	10
			36	2	1	1	2	0	0	2	0	2	2	0	0	2	1	0	2	0	0	0	0	0	17
			38	2	1	1	2	0	0	2	0	2	2	2	1	2	1	0	2	0	0	0	0	0	19
			40	1	1	1	2	1	1	2	1	0	2	1	1	2	1	0	0	0	1	0	0	0	20
			42	2	1	1	2	1	1	2	1	0	2	1	1	2	2	1	0	0	0	1	0	0	22
			44	1	1	1	2	1	2	3	0	0	1	1	2	2	1	0	0	0	0	0	0	0	19
			46	1	1	1	2	1	2	3	0	0	2	1	1	2	2	1	0	0	0	0	0	0	22
			48	2	1	1	2	1	2	3	0	0	2	1	1	2	2	2	0	0	0	0	0	0	19
			50	1	1	1	2	1	1	3	2	0	2	1	2	1	2	0	0	0	0	0	0	0	23
			52	2	1	1	2	1	1	3	2	0	2	2	1	2	1	0	0	0	0	2	0	0	20
																									23
1	41	SFS	8	1	0	0	1	0	1	1	0	1	2	1	0	2	1	0	0	0	1	1	0	0	14
			10	1	0	0	1	1	1	2	0	1	2	1	0	2	1	1	0	0	0	1	0	0	16
			12	1	0	1	1	1	1	1	0	1	2	1	1	2	1	0	0	0	1	0	0	0	16
			14	1	0	1	1	1	1	1	0	1	2	1	1	2	1	0	0	0	1	1	0	0	19
			16	1	1	0	1	1	1	1	0	2	2	1	0	2	1	1	0	0	0	0	0	0	14
			18	0	0	0	1	0	1	0	0	1	0	2	1	0	0	1	0	0	0	0	0	0	8
			20	1	0	1	1	0	1	0	1	0	1	2	1	1	0	0	0	0	1	0	0	0	12
			22	2	0	0	2	1	0	2	0	1	2	1	0	2	1	0	0	0	0	1	0	0	15

9550

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient Initials	Visit No.	It. 1 It. 2 It. 3 It. 4 It. 5 It. 6 It. 7 It. 8 It. 9 It. 10 It. 11 It. 12 It. 13 It. 14 It. 15 It. 16 It. 17 It. 18 It. 19 It. 20 It. 21																				Total Score							
			SFS	SFS	SFS	SFS	SFS	SFS	SFS	SFS	SFS	SFS	SFS	SFS	SFS	SFS	SFS	SFS	SFS	SFS	SFS	SFS								
1	41	307	24	1	1	0	2	1	0	2	0	1	2	1	0	2	1	1	0	0	0	1	0	0	0	0	0	16		
			26	2	1	0	2	0	0	2	0	1	1	2	1	0	1	1	0	0	0	1	0	0	0	0	0	15		
			28	2	1	0	2	0	0	2	0	1	1	1	0	0	1	1	0	0	0	1	0	0	0	0	0	15		
			30	2	1	0	2	0	0	2	0	1	2	0	0	2	1	0	0	0	0	1	0	0	0	0	0	14		
			32	2	1	0	2	1	0	1	0	1	1	1	0	2	1	0	0	0	0	1	0	0	0	0	0	15		
			34	2	1	0	2	1	0	1	0	1	2	1	0	2	1	0	0	0	0	2	0	0	0	0	0	16		
			36	2	1	0	2	1	0	1	0	2	2	1	0	2	1	0	0	0	0	1	0	0	0	0	0	17		
			38	2	1	0	2	1	0	2	1	0	2	2	1	0	2	1	0	0	0	1	0	0	0	0	0	18		
			40	2	2	1	2	1	1	2	0	1	2	1	2	2	1	0	2	0	0	1	0	0	0	0	0	23		
			42	2	2	1	2	1	1	3	0	1	2	2	1	2	2	1	0	2	0	1	0	0	0	0	0	24		
			44	3	2	1	2	1	1	3	0	1	2	1	2	2	1	0	2	0	1	0	0	0	0	0	0	25		
			1	42	308	8	1	0	1	1	1	1	1	1	1	1	1	0	2	1	1	0	0	0	0	0	0	0	0	13
						10	1	0	1	2	0	0	1	1	0	2	1	0	0	2	1	0	0	0	0	0	0	0	0	12
						12	1	0	1	1	2	0	1	0	2	2	0	2	1	0	0	0	0	0	0	0	0	0	0	0
14	1	1				0	1	1	0	1	1	0	2	1	1	0	0	1	0	0	0	1	0	0	0	0	0	12		
16	1	1				0	0	1	0	1	0	1	0	2	1	1	0	0	0	0	0	1	0	0	0	0	0	11		
18	0	0				0	1	0	0	1	0	1	0	1	0	1	0	0	0	0	0	2	0	0	0	0	0	7		
20	1	1				0	1	0	1	0	1	0	1	1	0	1	0	2	0	0	0	1	0	0	0	0	0	11		
22	2	0				0	1	2	0	1	2	0	1	2	1	1	2	1	0	0	0	0	0	0	0	0	0	18		
24	0	0				0	2	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	6		
26	0	0				0	1	2	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	6		
28	0	0				0	1	1	0	0	0	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	6		
30	0	0				0	1	1	0	0	0	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	7		
32	0	0				0	1	1	0	0	0	0	0	1	2	1	0	0	0	0	0	0	0	0	0	0	0	8		
34	0	0				0	1	1	0	0	0	0	0	2	1	1	0	0	0	0	0	0	0	0	0	0	0	7		
36	0	0	0	2	2	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	8					
38	0	0	0	2	1	0	0	0	0	0	2	1	0	0	1	0	0	0	0	0	0	0	0	0	7					
40	0	0	0	1	1	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	10					
42	1	1	0	0	1	0	1	1	0	0	1	2	1	0	0	0	0	0	0	0	0	0	0	0	11					
44	1	1	0	1	1	0	1	1	0	0	0	1	2	1	0	0	0	0	0	0	0	0	0	0	14					
46	1	0	1	1	1	0	2	1	0	0	2	1	0	0	2	0	0	0	0	0	0	0	0	0	5					
48	0	0	0	2	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7					
50	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1					
52	0	0	0	1	1	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6					
1	47	312	8	1	0	0	1	0	1	1	0	1	1	0	1	1	0	0	0	0	0	0	0	0	0	0	10			
			10	1	0	0	1	1	0	1	0	1	1	1	0	1	0	0	0	0	0	0	0	0	0	0	11			
			12	0	0	0	1	0	1	1	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	7			
			14	2	1	0	1	1	1	1	1	0	2	1	1	1	1	1	0	0	1	1	0	0	0	0	17			
			16	2	1	1	2	0	0	2	1	0	2	3	0	2	1	0	0	0	0	2	0	0	0	0	0	20		
			18	2	1	1	2	1	1	2	1	0	2	1	1	2	1	0	0	0	0	0	0	0	0	0	0	19		
			20	1	1	1	2	1	1	2	1	0	1	1	1	0	0	1	0	0	0	1	0	0	0	0	0	19		
			22	1	1	1	1	1	1	1	1	0	1	1	0	1	0	2	2	1	0	0	1	0	0	0	0	17		
			24	1	0	1	1	2	0	0	2	1	0	2	1	0	0	0	0	0	0	0	0	0	0	0	0	14		
			26	2	0	1	2	0	0	2	1	0	2	1	0	2	1	0	0	0	0	0	0	0	0	0	0	0	17	
			28	2	0	1	1	1	1	1	1	0	2	1	1	0	2	1	0	0	0	0	0	0	0	0	0	0	16	

CC
 CR
 I-1

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

9550077

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

D.B.		Visit																					Total	
Centre	Patient Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score
1	51	315	ASA	34	1	1	0	1	2	0	0	1	1	0	0	2	0	0	0	0	0	0	0	13
				36	2	1	0	2	1	0	3	0	1	1	2	1	1	0	0	0	0	1	0	17
				38	2	0	1	2	1	0	2	1	0	2	1	0	0	0	0	0	0	2	0	17
				40	2	0	1	2	1	0	2	0	2	1	1	2	1	0	0	0	1	0	0	17
				42	2	0	1	2	0	1	2	0	1	1	1	2	1	0	0	0	1	0	0	17
				44	3	1	1	2	1	1	2	0	1	2	1	1	1	0	0	0	1	1	0	21
				46	2	1	1	2	1	1	2	0	1	1	1	1	1	0	0	0	1	0	0	18
				48	2	1	1	2	0	2	1	1	0	2	1	1	0	0	0	0	1	0	0	18
				50	2	1	1	2	1	0	2	0	1	1	1	1	1	0	0	0	1	0	0	18
				52	3	1	1	2	1	0	2	0	1	1	1	1	1	0	1	0	1	0	0	19
1	53	317	JFT	8	0	0	0	1	0	1	1	0	1	1	0	0	0	0	0	0	0	1	0	7
				10	1	0	0	1	1	1	1	0	1	1	0	1	0	0	0	0	1	1	0	12
				12	2	1	1	1	0	2	1	0	1	1	2	0	0	0	0	1	1	0	0	17
				14	2	1	0	2	0	0	2	1	0	0	2	1	0	0	0	0	1	1	0	15
				16	3	1	1	2	1	1	3	0	3	3	1	0	1	0	0	0	0	0	0	19
				18	3	1	1	2	1	1	3	2	0	3	2	2	2	0	0	1	2	0	0	28
				20	3	1	1	2	1	1	4	2	0	3	3	2	2	0	0	1	2	0	0	30
				22	3	1	1	2	1	1	4	3	0	4	3	2	2	0	2	1	2	0	0	34
1	59	321	SPF	8	1	1	0	1	0	0	0	0	2	1	1	0	0	0	0	0	0	1	0	11
				10	1	1	0	2	1	0	1	0	1	2	2	1	0	0	0	0	0	0	0	14
				12	0	0	0	2	1	0	1	0	1	1	0	2	1	0	0	0	0	0	0	10
				14	0	0	0	2	2	0	1	0	2	1	1	0	0	0	2	0	0	0	0	13
				16	0	0	0	1	1	0	0	1	1	1	0	0	1	0	0	0	0	0	0	6
				18	1	0	0	1	1	0	1	0	1	2	1	0	0	0	0	0	0	0	0	11
				20	1	0	0	2	1	0	1	0	1	2	0	2	0	1	0	0	0	0	0	12
				22	1	0	0	1	2	0	1	0	0	2	1	0	0	0	0	0	0	1	0	16
				26	2	2	0	2	1	1	2	2	0	2	2	0	1	0	0	0	0	0	0	19
				28	1	1	1	1	1	1	2	2	0	2	2	1	0	0	0	0	0	1	0	19
				30	2	1	1	2	1	1	2	2	0	1	1	2	1	0	0	0	0	0	0	18
				32	1	2	1	1	0	2	2	0	3	1	2	2	1	0	0	0	0	0	0	20
				34	2	2	1	1	2	0	2	1	0	2	1	1	0	0	0	0	0	0	0	19
				36	1	1	1	1	2	0	2	1	0	2	1	1	0	0	0	0	0	1	0	20
				38	2	2	1	1	1	2	1	0	1	1	2	1	1	0	0	0	0	1	0	20
				40	2	1	1	1	1	2	1	0	1	1	2	1	0	0	0	0	1	1	0	20
				42	1	1	1	1	1	1	2	0	1	2	2	1	1	0	0	0	1	1	0	19
				44	2	1	1	1	1	1	2	0	1	2	2	1	1	0	0	0	1	1	0	19
				46	2	1	0	2	1	0	2	0	2	1	1	1	0	0	0	0	1	1	0	21
				48	2	0	2	1	0	2	0	1	2	3	2	1	1	0	0	0	1	0	0	20
				50	1	2	1	1	2	1	2	0	1	2	0	2	1	1	0	0	1	0	0	19
				52	2	2	1	2	1	1	2	0	1	2	2	0	2	1	1	0	0	2	0	22
1	60	322	EM	8	2	1	1	2	1	1	3	0	1	3	2	1	1	0	0	0	1	0	0	23
				10	2	0	1	1	1	1	2	0	1	2	1	0	0	0	0	0	1	0	0	18
				12	2	0	1	1	1	0	2	0	1	1	2	1	0	0	0	0	0	1	0	15

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

D.B.		Visit																				Total			
Centre	Patient	Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score
1	60	322	EM	14	1	0	1	1	2	0	2	0	2	2	0	1	2	1	0	0	0	1	0	0	16
				16	2	0	1	2	2	0	1	0	2	2	0	1	2	1	0	2	0	0	2	0	17
				18	2	0	1	2	2	0	1	0	2	2	0	1	2	1	0	2	0	0	1	0	19
				20	2	0	1	1	0	2	0	1	2	1	1	2	1	0	0	0	0	1	0	0	15
				22	1	0	0	2	1	0	2	0	2	1	0	2	1	0	0	0	0	0	2	0	15
				24	2	1	1	1	2	2	0	2	3	1	1	0	1	1	0	0	1	0	0	2	22
				26	1	1	1	2	1	1	3	0	2	1	1	0	1	1	0	0	1	0	0	2	19
				28	1	0	1	1	2	1	3	0	2	1	1	0	1	1	0	0	1	1	0	2	21
				30	2	1	1	2	1	1	3	0	2	1	1	2	0	1	1	0	0	1	0	2	22
				32	2	1	1	1	2	1	1	2	1	1	1	1	0	2	1	0	0	1	0	2	20
				34	2	1	1	1	1	2	0	3	2	1	1	0	2	1	0	0	0	1	0	2	22
				36	2	1	1	1	2	0	3	0	2	1	1	0	2	1	0	0	0	1	1	0	21
				38	2	1	1	1	1	0	3	0	1	1	0	2	1	0	0	0	0	1	0	2	18
				40	2	1	1	1	0	2	0	1	1	0	1	2	1	0	0	0	0	1	0	2	20
				42	1	2	0	1	1	2	0	2	2	2	0	2	0	1	1	2	0	1	0	2	24
				44	2	0	1	1	2	0	3	1	2	1	1	2	1	1	2	0	1	0	0	2	24
				46	1	2	0	1	1	2	0	1	2	1	1	2	1	1	2	0	1	0	0	2	25
				48	3	2	0	2	1	1	2	0	3	2	1	2	1	1	2	0	1	0	0	2	25
				50	1	2	0	1	1	3	0	3	2	2	1	2	1	1	2	0	1	0	0	2	25
				52	2	2	0	1	1	0	2	0	2	1	1	2	1	1	2	0	0	0	0	1	21
				8	1	1	0	2	1	0	2	2	0	2	1	1	2	1	0	0	0	0	0	0	16
				10	1	0	0	1	1	0	0	1	2	1	1	1	1	0	0	1	0	1	1	0	12
				12	0	0	0	2	0	0	0	1	2	1	1	1	0	0	1	0	0	0	0	0	9
				14	0	0	0	2	1	0	1	0	1	2	1	1	0	1	0	0	0	1	0	0	11
				16	0	0	0	1	2	0	0	1	1	1	1	0	0	0	0	0	0	1	0	0	8
				18	0	0	0	1	1	0	0	0	1	1	1	0	1	1	0	0	0	0	1	0	8
				20	0	0	0	2	1	0	0	1	1	1	0	1	0	1	0	0	0	0	1	0	8
				22	0	0	0	2	1	0	1	0	1	2	1	0	2	0	1	0	0	0	0	0	10
				24	2	0	1	2	0	0	2	0	2	1	1	0	2	1	0	0	0	0	0	0	14
				26	1	1	0	1	2	0	1	2	1	1	1	0	2	1	0	0	0	1	0	0	14
				28	2	0	1	2	0	0	2	2	2	0	1	1	1	2	1	0	0	1	0	0	15
				30	1	1	0	2	1	0	1	0	2	1	0	1	2	2	1	0	0	1	0	0	16
				32	1	1	0	2	1	0	2	0	2	1	0	1	2	2	1	0	0	1	0	0	16
				34	1	0	2	1	1	0	1	0	2	1	1	2	2	1	0	0	0	1	0	0	17
				36	2	1	0	1	2	0	2	1	1	1	2	2	1	1	0	0	0	1	0	0	18
				38	2	1	1	1	2	0	1	2	1	2	1	1	2	1	0	0	0	1	0	0	18
				40	1	0	1	0	2	0	1	1	0	2	1	1	0	0	2	2	0	1	1	0	17
				42	2	0	0	2	0	1	1	0	2	1	1	2	0	1	1	0	0	1	2	0	17
				44	1	2	0	1	1	1	2	0	1	2	1	1	0	0	1	1	0	1	2	0	17
				46	1	1	1	2	0	1	1	2	0	1	2	1	0	1	1	0	0	1	0	0	18
				48	1	2	0	1	0	2	1	2	0	1	2	1	1	2	0	0	0	2	0	0	18
				50	2	0	1	1	2	0	2	1	2	1	1	2	1	1	2	0	0	1	0	0	19
				52	2	1	1	1	2	0	2	1	0	2	2	1	2	1	0	0	0	1	0	0	19
				8	1	0	0	1	1	0	1	0	0	2	1	0	2	0	0	0	0	0	0	0	9
				10	1	1	0	2	1	0	1	0	2	1	2	1	2	0	1	2	0	0	0	0	18

LD
 UT

MEA

324

62

325

EMF

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

D.B.		Visit																					Total			
Centre	Patient	Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score	
1	64	325	ENF	12	2	0	0	2	1	0	1	1	0	2	1	1	1	1	0	0	0	1	0	0	0	15
				14	1	1	0	2	1	0	1	1	0	2	0	1	1	0	2	0	1	0	0	0	0	15
				16	1	0	0	2	1	0	1	0	1	2	1	1	2	1	0	0	0	1	0	0	0	14
				18	2	1	0	2	1	0	1	0	1	2	1	1	2	1	1	0	0	2	0	0	0	18
				20	1	0	0	1	2	0	1	0	2	1	2	0	2	1	1	0	0	1	0	0	0	15
				22	0	0	0	2	0	1	0	0	2	2	0	2	1	0	0	0	2	0	0	0	0	14
				24	1	1	2	2	1	1	0	2	1	2	1	2	1	1	1	0	0	1	0	0	0	20
				26	1	2	1	1	2	0	3	1	0	1	1	0	1	1	1	0	0	1	0	0	0	17
				28	1	2	2	2	2	0	2	0	1	2	1	2	1	1	0	0	0	1	0	0	0	22
				30	2	1	1	1	1	0	3	2	0	2	2	1	2	1	0	0	0	1	0	0	0	19
				32	2	1	2	1	0	2	2	0	2	2	1	2	2	1	1	0	0	1	0	0	0	23
				34	1	1	1	2	1	0	3	2	0	2	1	2	1	1	0	0	0	1	0	0	0	20
				36	2	1	2	1	2	0	2	1	0	1	2	1	2	1	1	0	0	0	0	0	0	18
				38	2	1	2	1	2	0	3	2	0	2	2	1	2	1	1	0	0	1	0	0	0	23
				40	1	0	0	2	1	0	2	0	1	2	1	0	0	1	1	0	0	0	0	0	0	13
				42	0	0	0	1	1	0	0	0	2	1	1	0	0	1	0	0	0	0	0	0	0	10
				44	0	0	0	0	2	2	0	0	2	1	2	0	0	1	0	0	0	0	0	0	0	11
				46	0	0	0	1	1	1	0	0	2	0	2	0	0	1	0	0	0	0	0	0	0	9
				48	0	0	0	1	1	0	0	2	1	2	1	1	0	0	0	0	0	1	0	0	0	10
				50	0	0	0	1	0	0	1	0	2	2	1	0	0	0	0	0	0	0	0	0	0	9
				52	0	0	0	2	1	0	0	2	1	1	0	2	1	0	0	0	0	0	0	0	0	10
1	67	327	HAA	8	1	0	0	1	1	0	1	1	0	2	1	0	2	1	0	0	0	1	0	0	0	12
				10	1	1	1	1	1	0	1	1	0	2	2	0	2	1	0	0	0	1	0	0	0	15
				12	2	1	1	1	2	0	1	1	0	2	2	0	2	1	0	0	0	1	0	0	0	17
				14	2	1	0	2	1	0	1	1	0	2	1	0	2	1	0	2	0	1	0	0	0	17
				16	2	1	0	1	2	0	1	1	0	2	1	0	2	1	0	0	0	2	0	0	0	16
				18	2	1	1	2	0	1	1	0	2	2	1	0	2	1	0	2	0	0	0	0	0	19
				20	1	1	0	1	1	0	1	1	0	1	1	0	2	1	0	0	2	0	0	0	0	14
				22	1	1	1	2	1	0	1	1	0	2	1	0	2	1	0	0	0	1	0	0	0	15
				24	2	1	1	2	2	0	1	3	0	3	2	1	0	2	1	0	2	1	0	0	0	25
				26	2	2	2	2	2	1	1	3	0	3	3	1	2	1	0	2	0	1	0	0	0	29
1	70	328	MLM	8	1	0	0	2	1	0	1	1	0	2	2	1	0	2	1	0	0	1	0	0	0	16
				10	2	1	0	2	2	0	1	2	0	2	1	0	2	1	1	2	0	0	1	0	0	21
				12	2	1	0	2	1	0	1	1	0	2	2	0	2	1	0	0	0	1	1	0	0	19
				14	2	1	1	2	1	0	1	2	0	2	1	0	2	1	1	2	0	1	1	0	0	24
				16	2	1	1	2	1	1	2	0	2	2	1	0	2	2	1	0	0	1	1	0	0	25
				18	2	1	1	2	1	1	1	2	0	2	2	1	2	2	1	0	0	1	1	0	0	22
				20	2	1	1	2	1	1	1	2	0	2	2	1	2	1	1	0	0	1	1	0	0	25
				22	5	1	1	2	1	1	2	0	3	2	1	2	1	1	1	0	0	2	1	0	0	28
1	74	122	IVL	8	1	0	0	2	0	0	1	0	0	2	0	2	1	1	2	0	0	0	1	0	0	12
				10	2	1	0	2	0	0	1	0	1	2	1	0	2	1	0	0	0	0	1	0	0	14
				12	1	1	0	1	1	1	1	0	1	1	0	2	1	0	0	0	0	0	0	0	0	12
				14	2	1	0	1	2	0	2	1	0	2	1	0	2	1	0	0	0	0	0	0	0	16
				16	2	1	0	2	1	1	2	1	0	2	1	0	2	1	1	0	0	0	1	0	0	17

955

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

D.B.		Centre Patient		Visit		D.B.																					Total
1	79	126	JCH	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score	
16	0	0	0	0	1	1	0	0	1	0	0	2	1	0	2	0	0	1	1	0	0	0	0	0	0	0	7
18	0	0	0	0	2	1	0	0	1	1	0	2	1	0	2	1	1	0	1	1	2	0	0	0	0	0	12
20	0	0	0	1	1	0	1	1	1	0	1	0	1	0	1	0	1	1	1	1	0	0	0	1	0	0	9
22	0	0	0	2	0	1	1	1	0	2	0	0	1	0	1	1	0	1	0	0	0	0	0	0	0	0	9
24	1	2	0	2	0	1	2	0	0	2	1	1	1	0	1	1	0	1	1	1	0	0	1	0	0	0	16
26	2	1	0	2	0	1	2	0	1	2	1	1	1	0	1	2	0	0	0	0	0	0	1	1	0	0	16
28	1	1	0	1	0	1	1	1	1	1	1	1	1	1	1	1	1	0	1	0	0	0	1	1	0	0	12
30	2	0	0	2	0	1	1	1	1	0	2	1	1	0	1	0	1	0	1	1	0	0	1	1	0	0	14
32	2	0	0	1	1	0	2	0	2	0	2	0	1	1	1	1	1	1	1	0	0	1	1	0	0	0	15
34	1	1	0	1	2	0	1	2	0	1	2	0	1	1	1	1	1	1	1	0	0	1	1	0	0	0	15
36	2	0	0	2	1	0	1	0	1	2	0	1	1	0	1	1	0	0	1	1	0	0	1	0	0	0	13
38	1	1	0	2	1	0	1	0	2	1	1	0	1	1	0	1	1	0	0	1	1	0	0	1	0	0	14
40	1	0	0	2	0	1	1	1	0	2	1	1	0	1	1	0	1	1	1	0	0	1	1	0	0	0	11
42	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	0	1	1	0	0	0	1	1	0	0	11
44	1	0	0	2	1	0	1	0	0	1	0	0	1	1	1	1	1	0	0	0	0	0	0	0	0	0	9
46	0	0	0	2	1	0	1	0	0	1	0	0	0	0	0	0	2	0	0	0	0	0	1	0	0	0	11
48	1	0	0	2	0	0	1	2	0	1	2	0	1	2	0	0	0	0	0	0	0	0	0	0	0	0	7
50	0	0	0	1	0	0	1	2	0	1	2	0	1	2	1	1	2	0	1	0	0	0	0	0	0	0	12
52	0	0	0	1	0	0	1	2	0	1	2	0	1	1	0	2	1	1	0	0	0	0	0	0	0	0	8
8	1	1	0	2	1	0	1	0	0	2	2	1	2	1	2	1	1	2	1	1	0	0	0	0	1	0	15
10	2	1	0	1	1	0	2	2	0	3	3	2	2	1	3	2	2	1	1	2	0	0	1	0	0	0	24
12	3	1	0	2	1	0	2	2	0	3	3	2	2	1	3	2	2	1	2	0	0	0	2	0	0	0	26
8	1	0	1	1	1	0	1	0	1	1	1	1	0	2	1	0	2	1	1	0	0	0	1	0	0	0	12
10	1	0	1	2	0	0	2	0	1	2	1	1	0	2	1	0	2	1	1	0	0	0	1	0	0	0	14
12	1	0	1	1	1	0	2	0	0	2	1	1	0	2	1	1	0	2	1	1	0	2	0	1	0	0	16
14	1	0	1	2	0	0	2	1	0	2	0	1	1	0	2	0	1	2	0	0	0	0	0	0	0	0	16
16	0	0	1	2	0	0	2	1	0	2	0	1	1	0	2	0	1	2	0	0	0	0	0	0	0	0	12
18	0	0	0	2	0	0	1	1	0	2	0	1	1	0	2	0	0	0	0	0	0	0	0	0	0	0	8
20	1	0	1	2	1	0	2	0	1	1	0	2	1	1	1	0	2	0	0	0	0	0	0	0	0	0	9
22	2	0	1	2	1	0	1	2	1	1	2	1	1	2	1	1	2	1	1	0	0	0	1	0	0	0	19
24	1	0	1	2	1	0	1	1	0	2	1	1	0	2	1	1	0	1	1	0	0	0	0	0	0	0	17
26	1	0	1	2	1	1	2	2	0	2	1	0	1	1	1	1	0	1	1	1	0	0	0	0	0	0	12
28	1	0	1	2	1	1	1	2	0	2	0	1	0	1	1	2	0	0	0	0	0	0	0	0	0	0	16
30	1	0	1	2	1	1	1	1	1	1	0	1	1	1	1	2	0	1	1	1	0	0	0	0	0	0	15
32	1	0	1	2	0	1	1	1	1	1	1	0	1	1	1	1	1	0	1	1	0	0	0	0	0	0	11
34	1	0	0	1	1	1	1	1	1	1	1	0	1	1	1	1	0	1	1	0	0	0	0	0	0	0	11
36	1	0	0	1	1	1	1	1	1	1	1	0	1	1	1	1	0	1	1	0	0	0	0	0	0	0	11
38	0	0	0	2	1	1	1	1	1	1	1	0	1	1	1	1	0	0	1	0	0	0	0	0	0	0	7
40	1	0	0	2	1	0	1	1	1	1	1	0	1	1	1	1	0	0	1	0	0	0	0	0	0	0	11
42	1	2	0	2	0	0	1	0	1	1	0	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	11
44	1	2	0	2	0	0	1	0	1	1	0	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	11
46	1	2	0	1	1	1	2	0	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	11
48	2	2	0	1	1	2	0	2	0	2	1	1	1	1	1	1	2	1	1	0	0	0	0	0	0	0	13
50	2	2	0	1	1	2	0	2	0	1	1	1	1	1	1	1	1	2	1	1	0	0	0	0	0	0	15
52	2	2	1	1	1	0	2	0	2	1	1	1	1	1	1	1	1	2	1	1	0	0	0	0	0	0	20
52	2	2	1	1	1	0	2	0	2	1	1	1	1	1	1	1	1	2	1	1	0	0	0	0	0	0	18
52	2	2	1	1	1	0	2	0	2	1	1	1	1	1	1	1	1	2	1	1	0	0	0	0	0	0	19

957

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

D.B.		Centre Patient Initials		Visit																				Total
		It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score	
1	93	136	AL	8	0	0	0	0	2	1	0	1	0	0	0	1	0	0	0	0	0	0	0	10
				10	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	8
				12	0	0	0	2	1	0	0	0	2	0	1	0	0	0	0	0	0	0	0	8
				14	0	0	0	0	2	1	0	0	0	1	2	1	0	0	0	0	0	0	0	9
				16	0	0	1	2	1	0	0	0	2	1	0	0	0	0	0	0	0	0	0	12
				18	0	0	0	1	1	1	0	0	0	2	1	0	0	0	0	0	0	0	0	9
				20	1	0	0	2	0	1	1	0	0	2	1	1	2	0	0	0	0	0	0	12
				22	1	0	0	2	0	1	1	0	0	2	1	1	2	0	0	0	0	0	0	11
				24	0	0	0	1	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	6
				26	0	0	0	2	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	7
				28	1	0	1	1	2	0	1	0	0	1	1	0	0	0	0	0	0	0	0	11
				30	1	0	1	2	1	0	1	0	0	2	0	1	0	0	0	0	0	0	0	13
				32	1	0	1	2	1	0	1	0	0	2	0	0	0	0	0	0	0	0	0	14
				34	1	0	1	2	1	0	0	2	0	0	2	0	0	0	0	0	0	0	0	11
				36	1	0	1	2	0	2	0	2	2	1	1	2	0	0	0	0	0	0	0	17
				38	1	0	1	2	0	0	2	0	2	1	1	2	0	0	0	0	0	0	0	16
				40	1	0	1	2	1	0	0	1	0	2	2	0	0	0	0	0	0	0	0	17
				42	2	1	0	2	1	0	1	0	1	1	2	0	1	2	0	1	0	0	0	19
				44	2	1	0	2	1	0	2	0	2	3	2	0	1	0	2	1	0	0	0	22
				46	1	2	1	0	2	2	0	1	1	2	2	1	0	0	1	1	0	0	0	22
				48	2	1	1	0	2	1	2	0	1	1	2	2	1	0	2	1	1	0	0	22
				50	1	2	2	1	1	2	3	0	1	1	2	2	1	0	1	1	0	0	0	23
				52	1	2	2	1	1	1	3	0	1	1	3	1	1	0	1	1	1	0	0	24
1	94	137	RAB	8	1	0	0	2	1	0	0	0	0	2	1	0	0	0	0	0	0	0	0	10
				10	1	0	0	2	1	0	0	1	2	1	0	0	0	0	0	0	0	0	0	13
				12	1	0	1	2	1	0	0	1	0	2	0	0	0	0	0	0	0	0	0	11
				14	1	0	0	2	0	1	1	0	0	2	0	0	0	0	0	0	0	0	0	8
				16	0	0	2	1	1	0	0	0	2	1	0	0	0	0	0	0	0	0	0	8
				18	1	0	0	2	1	1	0	0	2	1	0	0	0	0	0	0	0	0	0	11
				20	1	0	0	2	1	1	1	0	0	2	1	0	0	0	0	0	0	0	0	13
				22	1	0	0	1	1	1	2	1	0	2	1	0	0	0	0	0	0	0	0	13
				24	0	0	0	1	1	1	1	2	0	0	1	0	0	0	0	0	0	0	0	8
				26	0	0	0	2	1	0	2	0	1	1	0	0	0	0	0	0	0	0	0	9
				28	1	0	1	2	1	0	2	0	1	2	1	0	0	0	0	0	0	0	0	17
				30	1	0	1	2	1	0	0	2	1	1	0	0	0	0	0	0	0	0	0	15
				32	2	0	1	2	1	0	0	2	2	0	1	1	0	0	0	0	0	0	0	16
				34	2	0	0	2	1	0	0	2	0	1	1	0	0	0	0	0	0	0	0	10
				36	1	0	0	1	1	0	0	1	1	0	0	1	2	0	0	0	0	0	0	9
				38	0	0	0	0	1	2	0	2	1	0	0	0	0	0	0	0	0	0	0	11
				40	0	0	0	0	0	2	1	0	0	2	3	1	0	0	0	0	0	0	0	15
				42	1	0	0	2	1	1	2	1	0	2	2	1	0	0	0	0	0	0	0	18
				44	1	0	1	2	0	1	1	2	0	2	2	0	0	0	0	0	0	0	0	15
				46	1	0	1	2	0	1	1	2	0	2	1	0	0	0	0	0	0	0	0	13
				48	1	0	1	2	0	1	1	0	1	1	2	0	0	0	0	0	0	0	0	14
				50	2	0	1	2	0	0	2	1	1	1	2	1	0	0	0	0	0	0	0	17
				52	1	0	1	1	1	1	0	3	0	1	1	2	1	0	0	0	0	0	0	14

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

D.B.		Centre Patient Initials																					Total
Visit		It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score
1	97	140	MND	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10
				10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	11
				12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10
				14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10
				16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10
				18	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10
				20	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				22	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	11
				24	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	12
				26	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	13
				30	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	18
				32	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	19
				34	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	14
				36	1	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	14
				38	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	14
				40	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	11
				42	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	12
				44	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				48	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				52	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
1	100	142	JWA	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10
				12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10
				14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				18	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				20	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				22	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				24	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	11
				26	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				28	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	12
				30	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	17
				32	1	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	12
				34	1	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	11
				36	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	11
				38	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				40	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	12
				42	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				44	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10
				46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				48	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				52	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8

960

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score			
D.B.	331	JBF	8	1	0	1	2	1	0	1	0	0	1	0	0	0	2	1	0	0	0	1	0	0	0	12		
			10	1	0	1	2	1	1	0	2	0	0	2	0	0	0	2	1	0	0	0	1	0	0	0	13	
			12	1	0	1	2	2	0	1	2	0	1	2	0	0	0	2	1	0	0	0	1	0	1	0	16	
			14	1	1	1	2	1	0	1	0	0	2	0	1	0	0	2	0	0	2	0	1	0	1	0	17	
			16	1	1	1	2	2	0	1	0	2	0	2	0	0	0	2	1	0	0	0	1	0	0	0	14	
			18	1	1	1	1	1	0	1	0	0	1	1	0	0	0	2	1	0	0	0	1	0	0	0	12	
			20	1	1	1	1	1	0	2	1	0	2	1	0	2	1	0	2	1	0	0	1	0	0	0	15	
			22	1	1	1	2	0	1	1	0	2	1	0	2	1	0	2	1	0	0	0	1	0	1	0	0	16
			24	1	1	0	0	1	1	0	0	2	1	0	2	1	1	0	0	1	0	0	1	0	1	0	0	10
			26	1	0	1	1	1	0	1	1	0	2	1	1	1	1	0	0	1	0	0	2	1	0	0	0	12
			28	2	1	0	0	1	2	1	2	0	1	1	0	1	1	0	0	1	0	0	2	1	0	0	0	17
			30	1	2	0	1	1	1	1	1	0	1	0	1	1	1	0	2	1	0	0	2	1	0	0	0	15
			32	1	2	0	1	1	1	1	1	1	1	0	2	1	1	0	2	0	1	0	0	2	0	0	0	16
			34	2	1	1	2	0	1	2	0	1	1	0	1	1	1	1	0	1	0	0	2	0	0	0	0	17
			36	1	1	1	2	0	0	1	0	1	1	2	1	0	1	2	0	1	0	0	0	2	0	0	0	14
			38	2	1	1	2	0	0	2	0	1	1	2	0	1	1	0	0	1	0	0	0	1	0	0	0	14
			40	1	0	0	1	1	0	1	0	1	0	1	2	0	1	2	1	1	0	0	0	1	0	0	0	12
			42	2	0	1	0	0	2	1	0	0	2	1	0	2	1	1	0	1	0	0	0	1	0	0	0	14
			44	1	1	0	0	0	1	1	0	1	1	1	1	1	1	1	2	1	0	0	0	1	0	0	0	9
			46	1	0	0	0	1	1	0	0	1	1	0	2	1	0	0	1	1	0	0	0	0	1	0	0	11
			48	1	0	0	2	0	0	1	0	2	1	0	1	2	1	0	2	1	0	0	0	0	1	0	0	12
			50	1	0	0	2	0	0	1	0	1	2	0	1	2	0	1	1	1	0	0	0	0	2	0	0	13
			52	1	0	0	2	0	0	2	0	1	1	1	1	1	1	1	2	0	1	0	0	0	1	0	0	13
			D.B.	332	CLF	8	1	1	0	2	1	0	2	0	1	2	1	1	1	2	1	0	0	0	1	0	0	0
10	1	1				0	2	2	0	2	0	1	2	1	1	1	1	2	1	0	1	1	0	0	0	18		
12	1	1				0	2	1	0	2	0	1	2	1	1	1	1	2	1	1	1	1	0	0	1	0	17	
14	1	1				0	2	2	0	2	0	2	2	2	2	2	2	2	1	1	1	1	0	0	0	0	20	
16	1	1				1	1	1	1	1	1	1	2	2	2	2	2	2	1	0	0	0	0	0	1	0	0	19
18	1	1				1	1	2	1	1	0	2	2	2	2	2	2	1	2	1	0	0	0	0	1	0	0	18
20	1	1				1	1	2	1	1	0	2	0	1	2	1	1	2	2	1	0	0	1	1	0	0	0	18
22	1	1				0	2	1	0	2	1	0	2	2	2	2	2	1	2	1	1	0	1	1	0	0	0	20
24	1	1				0	2	1	0	1	0	1	0	1	2	0	1	1	2	0	1	0	0	1	0	0	0	14
26	1	0				0	1	1	0	1	0	1	0	0	1	1	2	0	1	1	0	0	0	1	0	0	0	12
28	2	0				0	1	1	0	1	1	0	1	1	2	0	1	1	1	1	0	0	0	1	1	0	0	14
30	1	0				1	2	0	1	1	0	1	2	0	1	1	1	1	1	1	0	2	0	0	1	1	0	0
32	2	0	1	1	1	1	1	1	1	1	2	2	2	2	2	2	2	0	0	0	1	2	0	0	0	17		
34	1	0	1	1	1	1	1	1	1	1	0	2	2	2	2	2	0	0	0	0	1	1	0	0	16			
36	2	1	0	2	0	0	2	0	1	1	1	1	1	1	1	2	0	0	1	2	0	0	1	0	0	11		
38	1	0	0	1	0	2	0	0	1	0	0	2	1	1	0	2	0	0	0	0	0	1	2	0	0	15		
40	1	0	0	1	0	2	1	0	2	1	1	0	0	2	1	0	0	0	0	0	1	2	0	0	0	15		
42	2	0	1	1	1	0	0	1	1	0	1	1	1	1	1	0	2	0	1	1	0	0	0	0	15			
44	1	1	1	2	0	0	1	0	1	1	2	0	1	1	1	0	0	1	0	0	1	1	0	0	0	15		
46	1	1	1	2	0	0	1	0	1	1	2	0	2	1	1	0	0	1	0	0	1	1	0	0	0	16		
48	2	0	1	1	0	2	1	1	2	0	2	1	0	2	1	0	0	0	0	0	1	1	0	0	0	16		
50	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	1	1	0	1	2	0	0	18			
52	1	1	1	1	1	1	0	0	2	1	0	1	2	1	1	2	1	1	0	0	1	2	0	0	0	15		

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initials	No.	Visit	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score		
1	115	333	ELS	8	1	0	0	0	2	1	0	0	1	1	1	1	0	1	0	0	1	0	0	1	0	13		
				10	0	0	0	2	2	0	0	1	2	1	1	0	0	1	0	0	0	0	1	0	0	10		
				12	0	0	0	1	1	0	1	1	1	1	2	0	0	0	1	1	0	0	0	0	0	0	10	
				14	0	0	0	1	1	0	1	1	1	1	1	0	0	0	1	0	0	0	0	0	0	0	8	
				16	1	0	0	2	1	0	1	1	1	1	2	0	2	0	1	0	0	0	0	0	0	0	12	
				18	1	0	0	2	1	0	1	1	1	1	1	0	0	1	1	0	0	0	0	0	0	0	11	
				20	1	0	0	1	2	0	0	2	1	1	2	0	0	1	1	0	0	0	1	0	0	0	12	
				22	1	0	0	2	0	1	0	1	1	1	2	0	0	1	1	0	0	0	1	0	0	0	13	
				24	1	0	0	1	1	0	0	2	0	2	1	1	1	1	1	0	0	0	1	0	0	0	14	
				26	1	0	0	2	0	1	1	2	1	1	2	1	0	0	1	1	0	0	2	0	0	0	14	
				28	2	1	1	2	1	1	2	2	2	2	1	1	0	0	1	1	0	0	1	0	0	0	19	
				30	1	0	0	2	0	1	0	1	1	1	1	0	2	1	0	0	0	1	1	0	0	0	12	
				32	0	0	0	0	0	0	1	0	1	1	1	0	2	1	0	0	0	0	0	0	0	0	7	
				34	1	0	0	2	0	1	2	0	1	1	1	0	0	2	1	0	0	0	1	0	0	0	16	
				36	1	1	0	1	1	0	2	1	1	1	1	0	2	1	0	0	1	1	1	0	0	0	15	
				38	2	0	1	1	1	0	1	1	1	1	1	0	2	1	0	0	1	1	0	0	0	0	16	
				40	1	0	0	2	0	0	2	0	0	0	0	0	2	1	0	0	0	0	1	0	0	0	16	
				42	0	0	0	2	1	0	0	2	1	0	0	0	2	1	0	0	0	0	0	1	0	0	12	
				44	0	0	0	2	0	1	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	9	
				46	0	0	0	1	1	0	1	0	0	0	0	0	1	2	1	0	0	0	0	0	0	0	7	
				48	0	0	0	1	1	0	1	1	0	0	1	0	2	0	0	0	0	0	2	0	0	0	8	
				50	0	0	0	2	0	1	1	0	0	1	1	0	2	0	0	0	0	0	0	1	0	0	8	
				52	0	0	0	1	0	1	1	0	0	2	2	0	0	1	0	0	0	0	0	0	0	0	8	
1	122	337	HSS	8	0	0	0	1	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	1	6	
				10	0	0	0	1	0	0	0	0	1	1	1	0	0	1	0	0	0	0	0	0	0	0	5	
				12	0	0	0	1	1	0	0	1	1	1	1	0	0	1	1	0	0	0	0	0	0	0	7	
				14	0	0	0	2	1	0	0	1	0	1	1	0	0	1	0	0	0	0	0	0	0	0	1	7
				16	0	0	0	2	1	0	0	0	2	0	2	0	0	1	1	0	0	0	0	0	0	0	1	8
				18	0	0	0	1	2	0	0	0	0	2	1	1	0	0	1	0	0	0	0	0	0	0	1	8
				20	0	0	0	1	1	0	0	0	0	2	1	0	0	1	1	0	0	0	0	0	0	0	6	
				22	0	0	0	1	1	0	0	0	1	1	1	0	0	1	1	0	0	0	0	0	0	0	7	
				24	0	0	0	1	1	0	0	2	0	2	1	0	0	1	1	0	0	0	0	0	0	0	7	
				26	0	0	0	0	0	1	0	1	1	1	2	2	0	0	1	1	0	0	0	0	0	0	11	
				28	1	1	0	0	1	0	1	0	1	1	1	0	0	0	1	0	0	0	0	0	0	0	7	
				30	0	0	0	2	1	0	1	1	0	1	1	0	2	1	0	0	0	0	0	0	0	0	10	
				32	0	0	0	1	1	0	0	2	2	0	1	1	0	0	1	0	0	0	0	0	0	0	9	
				34	0	0	0	1	1	0	0	2	0	0	1	1	0	2	1	1	0	0	0	0	0	0	8	
				36	0	0	0	2	2	0	0	1	1	1	0	0	1	1	0	0	0	0	0	0	0	0	10	
				38	0	0	0	1	1	0	0	2	2	0	1	1	0	0	1	0	0	0	0	0	0	0	7	
				40	0	0	0	1	1	0	0	2	0	1	1	0	0	1	0	0	0	0	0	0	0	0	10	
				42	0	0	0	1	0	0	1	1	0	1	1	1	0	0	1	0	0	0	0	0	0	0	7	
				44	0	0	0	1	0	0	1	1	0	2	2	0	0	1	0	0	0	0	0	0	0	0	12	
				46	0	0	0	0	1	0	0	1	0	2	2	0	0	2	0	0	0	0	0	0	0	0	7	
				48	0	0	0	0	1	0	1	0	0	2	1	2	0	1	0	0	0	0	0	0	0	0	8	
				50	0	0	0	1	0	1	0	0	2	1	1	0	2	1	0	0	0	0	0	0	0	0	9	
				52	0	0	0	1	0	1	1	0	0	2	2	0	0	1	0	0	0	0	0	0	0	0	10	
				54	0	0	0	2	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	6	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

D.B.		Visit																						Total							
Centre	Patient Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score							
1	129	344	WNS	8	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	3						
				10	0	0	0	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	4					
				12	0	0	0	1	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	4					
				14	0	0	0	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	4					
				16	0	0	0	1	0	0	1	0	0	2	0	0	0	0	0	0	0	0	0	0	0	1	5				
				18	0	0	0	1	0	0	1	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	6				
				20	0	0	0	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	1	4				
				22	0	0	0	1	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	5				
				24	0	0	0	1	0	0	1	0	0	1	0	2	0	0	0	0	0	0	0	0	0	0	8				
				26	1	0	0	2	1	0	1	0	1	1	0	1	1	0	0	1	0	0	0	1	0	0	12				
				28	2	1	0	1	1	1	1	0	1	1	1	1	0	2	1	1	0	0	1	1	0	0	16				
				30	1	2	1	1	1	1	1	0	1	1	1	2	1	1	1	1	2	1	1	0	0	0	21				
				32	2	2	1	1	2	0	2	0	2	2	2	1	2	1	1	0	0	0	0	0	0	0	19				
				34	2	2	1	1	2	0	2	0	2	2	2	1	1	1	1	0	0	0	0	0	0	0	23				
36	2	1	1	1	2	1	1	2	0	2	1	3	1	1	1	1	2	0	1	1	0	0	24								
38	2	0	2	1	1	2	1	1	2	3	0	2	1	1	2	1	1	0	0	1	0	0	22								
40	2	1	1	2	1	1	2	1	2	2	2	2	1	1	2	1	2	0	0	1	1	0	24								
42	2	1	1	2	1	1	0	2	1	0	2	1	2	1	2	1	2	0	0	1	2	0	23								
1	130	345	EGA	8	1	0	1	2	1	0	1	0	1	0	2	2	1	0	0	0	0	1	0	0	14						
				10	1	1	1	2	1	0	1	1	0	1	1	1	2	2	1	0	0	0	1	0	1	18					
				12	1	1	1	2	2	0	1	1	0	1	1	1	2	2	1	0	0	0	2	0	1	19					
				14	2	1	1	2	0	1	0	1	0	2	1	1	1	2	1	0	0	0	1	0	1	17					
				16	2	1	0	2	1	0	1	0	1	0	2	1	2	2	1	0	0	0	0	1	0	1	18				
				18	2	1	0	2	1	0	1	0	1	0	2	1	2	2	1	0	0	0	1	0	1	0	19				
				20	2	1	1	2	1	0	1	0	1	1	0	2	2	2	1	0	0	0	1	0	1	0	21				
				22	2	1	1	2	1	0	1	2	0	1	2	2	2	2	2	0	0	0	1	0	1	0	22				
				1	133	346	JPM	8	1	0	0	1	2	1	1	0	1	1	0	1	2	1	0	2	0	0	0	0	15		
								10	1	0	0	2	1	1	1	1	1	0	1	1	1	2	1	0	0	0	1	0	0	14	
								12	1	0	0	2	1	1	1	1	0	1	1	1	1	2	1	0	0	0	1	0	0	14	
								14	1	0	0	1	1	1	1	1	0	2	0	1	1	2	1	0	0	0	1	0	0	13	
								16	1	0	1	2	1	1	2	0	2	0	1	2	0	1	2	0	0	0	1	0	0	0	17
								18	1	0	0	2	1	2	1	2	0	2	0	1	1	2	0	0	0	0	1	0	0	0	15
20	1	0	1					2	1	1	2	0	0	1	1	1	1	2	1	0	2	0	0	0	0	0	18				
22	1	0	0					1	2	1	2	2	0	2	1	1	2	1	0	0	0	0	1	0	0	0	19				
24	1	0	0					1	0	0	1	0	0	0	2	1	1	2	1	0	0	0	0	0	1	0	11				
26	1	0	0					0	0	2	1	1	0	1	0	1	1	0	2	1	0	0	0	2	0	0	11				
28	1	0	0					0	0	2	0	1	0	1	1	1	1	0	2	1	0	2	0	1	0	0	14				
30	1	0	0					0	0	2	0	2	0	1	1	1	0	0	1	2	0	0	2	0	0	0	13				
32	0	0	0					0	0	2	1	0	2	0	2	0	0	1	0	0	0	0	0	0	0	0	8				
34	0	0	0					1	1	0	2	0	1	2	1	2	1	0	0	0	0	0	0	0	0	0	10				
36	2	0	0	2	0	0	1	0	0	1	0	2	1	1	0	0	2	0	0	1	0	0	14								
38	2	0	0	2	0	0	1	0	0	1	1	1	1	1	2	1	0	0	0	1	0	0	13								
40	1	0	0	2	0	0	1	2	0	1	1	1	1	0	2	1	1	0	0	1	0	0	14								
42	2	0	0	2	0	0	1	2	0	1	1	1	1	0	2	1	0	0	1	1	0	0	15								
44	2	0	1	1	1	1	2	0	0	2	2	1	2	1	2	1	0	0	0	2	1	0	16								

966

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REMOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACERO

D.B.		Visit																					Total		
Centre	Patient Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score	
1	133	346	JPM	46	1	0	1	1	2	0	0	2	2	0	0	1	1	0	0	0	0	1	0	0	13
				48	1	1	0	0	2	1	0	0	2	0	0	2	0	0	0	0	0	0	0	0	10
				50	1	0	0	2	0	0	0	2	3	0	2	1	1	0	0	0	1	0	0	1	14
				52	1	0	0	2	0	0	2	1	1	1	2	0	0	0	0	0	1	0	0	0	12
1	136	349	AVP	8	1	0	0	1	0	0	2	2	0	1	0	2	2	0	0	0	0	1	0	0	13
				10	2	1	0	1	0	0	2	2	0	1	0	2	2	0	0	0	0	0	0	0	14
				12	2	1	0	2	0	0	1	1	1	2	2	2	0	2	0	0	0	0	0	0	17
				14	2	1	0	2	0	1	1	1	1	2	2	0	0	0	0	0	0	0	0	0	16
				16	2	1	0	1	0	0	2	2	2	1	1	2	0	0	0	0	0	0	0	0	18
				18	1	2	0	1	1	1	2	2	0	1	1	2	2	0	0	0	0	0	0	0	17
				20	1	2	0	1	1	1	3	2	0	1	1	2	2	0	0	0	0	0	0	0	18
				22	2	2	0	2	1	1	2	0	2	0	1	2	2	0	0	0	0	0	0	0	19
				24	1	0	1	2	0	0	2	0	1	1	0	1	1	0	0	0	0	0	0	0	12
				26	2	0	1	1	0	1	0	1	1	1	2	0	0	0	0	0	1	0	0	0	13
				28	2	0	1	1	0	2	0	1	1	1	0	0	0	0	0	0	1	0	0	0	15
				30	2	0	2	1	1	1	2	0	2	2	1	0	0	1	2	0	1	0	0	0	17
				32	2	1	0	2	0	1	2	0	1	1	1	2	0	0	0	0	1	0	0	0	15
				34	2	1	0	2	0	1	2	0	1	1	2	0	0	1	0	0	2	1	0	0	17
				36	2	0	1	2	1	0	2	0	1	0	2	0	1	1	0	0	2	1	0	0	18
				38	2	0	1	1	1	1	2	0	0	2	2	0	1	0	0	0	2	0	0	0	13
				40	0	0	1	0	2	1	0	2	1	0	2	1	0	0	0	0	0	0	0	0	15
				42	1	1	0	2	1	0	2	1	0	2	2	1	0	1	2	0	0	0	0	0	13
				44	1	1	0	2	1	0	2	1	0	2	1	0	0	1	2	0	0	0	0	0	13
				46	1	1	0	2	1	0	2	1	0	1	1	0	0	1	2	0	0	0	0	0	12
				48	1	1	0	1	1	1	0	0	1	2	1	0	1	0	0	0	0	1	0	0	13
				50	1	1	0	0	2	1	0	0	2	1	1	0	1	0	0	0	0	0	0	0	12
				52	1	0	0	2	1	0	1	1	0	2	1	2	0	1	2	0	0	1	0	0	17
1	138	350	LBV	8	0	0	0	2	0	0	1	0	1	0	2	2	0	0	2	0	0	0	0	0	11
				10	0	0	0	2	0	0	0	1	1	2	2	0	0	2	0	0	0	0	0	0	10
				12	0	0	0	1	1	0	0	1	0	1	2	0	0	0	0	0	0	0	0	0	6
				14	0	0	0	2	0	0	1	0	1	0	1	2	0	0	0	0	0	0	0	0	9
				16	0	0	0	2	1	0	0	2	0	1	2	0	0	0	0	0	0	0	0	0	8
				18	0	0	0	1	1	0	1	1	1	1	2	0	0	2	0	0	0	0	0	0	13
				20	0	0	0	2	1	0	2	0	1	2	2	0	0	0	0	0	0	0	0	0	13
				22	0	0	0	2	1	0	2	0	1	2	1	1	2	0	0	0	0	0	0	0	12
				24	1	0	0	2	1	0	1	0	1	1	0	0	0	0	0	0	1	0	0	0	12
				26	1	0	0	2	0	2	0	1	1	1	0	0	0	0	0	0	0	0	0	0	14
				28	2	0	0	2	0	1	2	0	1	2	1	0	0	0	0	0	1	0	0	0	17
				30	2	0	1	2	0	0	2	0	2	3	1	0	0	0	0	0	1	0	0	0	17
				32	0	1	1	2	0	0	1	2	1	0	1	0	0	0	0	0	1	0	0	0	17
				34	2	0	1	2	0	1	0	0	2	3	1	0	0	0	0	0	1	0	0	0	15
				36	2	0	1	2	0	1	0	0	2	3	1	0	0	0	0	0	2	0	0	0	18
				38	2	0	2	1	1	2	0	1	2	3	1	0	0	0	0	0	1	0	0	0	19
				40	1	1	0	0	2	1	0	0	2	2	0	0	1	0	0	0	1	0	0	0	12
				42	2	0	0	1	1	0	0	1	1	1	0	2	1	1	0	0	1	0	0	0	12

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REMOXYLINE - PROTOCOL 20124/013
 Listing No.: 10-1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

D.B.		Centre Patient		Visit	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total	
1	138	350	LBV	44	1	1	1	1	0	2	1	0	2	1	1	2	0	2	0	0	1	0	0	0	0	0	17
				46	2	0	1	2	0	2	1	0	2	2	2	1	1	1	0	0	1	0	1	0	0	0	19
				48	1	1	0	2	0	0	2	0	1	1	1	1	2	0	0	0	0	1	0	0	0	0	13
				50	2	0	1	1	1	1	1	1	1	1	1	0	2	0	1	0	0	1	0	0	0	0	14
				52	1	1	0	1	1	0	2	1	0	2	1	1	2	0	1	0	0	0	0	0	0	0	14
1	141	353	ANG	8	2	0	1	2	0	0	2	0	0	2	0	0	2	0	0	0	0	1	0	0	0	0	13
				10	2	1	1	2	1	0	2	0	1	0	0	1	0	0	1	0	0	1	0	0	0	0	16
				12	2	1	0	2	1	0	1	1	0	2	0	0	2	0	0	2	0	1	0	0	0	0	16
				14	2	1	0	2	0	0	1	1	0	2	0	0	1	0	0	0	0	1	0	0	0	0	13
				16	1	1	0	2	0	0	1	1	0	2	0	0	2	1	0	0	0	0	0	0	0	0	12
				18	0	0	0	2	0	0	1	1	0	2	0	0	0	1	0	0	0	0	0	0	0	0	7
				20	0	0	0	2	1	1	0	1	0	1	0	0	0	0	1	0	0	0	1	0	0	0	7
				22	0	0	0	2	0	1	1	1	0	1	0	0	1	1	0	0	0	0	0	0	0	0	8
				24	0	0	0	2	1	1	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	9
				26	1	0	0	1	1	1	1	1	0	0	1	1	2	1	0	0	0	0	0	0	0	0	12
				28	1	1	0	2	1	1	2	1	0	2	1	1	1	0	0	0	0	1	0	0	0	0	18
				30	1	2	0	2	1	2	1	0	2	2	1	1	2	1	0	0	0	1	0	0	0	0	19
				32	2	2	0	2	1	1	2	2	0	1	1	2	1	0	0	2	0	1	0	0	0	0	21
				34	2	2	1	2	1	1	2	2	0	2	1	1	2	1	0	0	0	1	1	0	0	0	22
				36	2	2	0	2	1	1	2	2	0	2	1	1	2	1	0	0	1	2	1	0	0	0	24
1	143	355	JEP	8	0	0	0	2	0	0	0	0	0	2	0	1	0	2	0	0	0	0	0	0	0	0	7
				10	1	0	0	1	1	0	0	0	0	2	1	1	2	1	0	2	0	0	0	0	0	0	42
				12	1	0	0	2	1	0	1	1	0	2	2	1	2	1	0	2	0	0	0	0	0	0	16
				14	1	0	0	2	1	0	2	0	2	2	2	1	2	1	0	0	0	0	0	0	0	0	16
				16	2	0	0	2	0	0	2	2	0	2	2	1	2	1	0	2	0	0	0	0	0	0	18
				18	2	0	0	2	0	1	2	2	0	2	2	1	2	1	0	2	0	0	0	0	0	0	18
				20	2	0	1	2	2	0	1	2	2	0	2	3	2	2	1	0	2	0	0	0	0	0	18
				22	2	0	0	2	2	0	2	2	0	2	3	2	2	1	0	2	1	0	0	0	0	0	23
1	145	357	SLD	8	0	0	0	1	2	0	1	0	1	3	1	0	0	1	0	1	0	0	0	0	0	0	11
				10	0	0	0	2	1	0	1	1	0	2	1	0	2	1	0	0	0	0	0	0	0	0	11
				12	1	1	0	2	2	0	1	0	1	3	1	0	1	1	0	1	0	0	0	0	0	0	15
				14	1	1	0	2	1	0	0	0	2	1	1	0	2	1	0	0	0	0	0	0	0	0	13
				16	1	1	0	2	1	0	1	0	1	3	1	1	1	1	0	1	0	0	0	0	0	0	15
				18	1	1	0	1	1	0	1	1	0	1	3	1	2	2	1	0	0	0	0	0	0	0	16
				20	1	1	0	2	0	2	0	1	0	1	3	1	2	2	1	0	0	0	0	0	0	0	17
				22	2	1	0	2	1	0	2	0	1	3	1	2	2	1	0	0	0	0	0	0	0	0	17
				24	1	0	0	1	1	0	2	0	1	2	1	1	2	1	0	0	0	0	1	1	0	0	12
				26	1	0	0	2	0	0	1	1	0	2	1	1	0	1	0	0	0	0	1	0	0	0	16
				28	2	0	0	2	0	0	2	0	2	2	1	1	2	1	1	0	0	0	0	0	0	0	17
				30	1	0	0	2	0	0	1	0	2	2	1	1	0	2	1	1	2	1	0	0	0	0	16
				32	2	0	0	2	1	1	2	2	0	1	1	1	2	1	0	0	0	1	1	0	0	0	12
				34	2	0	0	1	1	1	3	0	2	0	1	1	2	1	0	0	0	1	0	0	0	0	17
				36	2	0	0	1	1	1	3	0	2	3	0	1	2	1	0	0	0	1	0	0	0	0	17
				38	2	0	0	2	1	1	3	0	2	3	0	1	2	1	0	0	0	1	0	0	0	0	19
				40	1	2	0	1	1	0	2	0	1	2	0	0	2	1	1	0	0	1	1	0	0	0	16

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXETINE - PROTOCOL 2012A/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

D.B.		Visit																					Total		
Centre	Patient Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score	
1	145	357	SLD	42	1	1	0	2	0	0	2	1	0	2	1	0	0	0	0	0	0	0	0	1	15
				44	1	2	0	1	1	1	3	0	2	2	2	1	1	0	0	0	1	0	0	0	18
				46	2	0	0	1	0	0	1	1	2	0	2	1	1	0	0	1	0	0	0	0	13
				48	1	1	1	1	0	0	1	1	0	1	0	2	1	1	1	0	0	0	0	0	13
				50	1	1	1	1	1	0	1	1	0	2	0	1	1	0	0	0	0	0	0	0	14
				52	2	1	0	2	0	0	1	2	0	1	2	0	1	0	0	1	0	0	0	0	15
1	149	360	SC	8	0	0	0	1	1	1	2	0	0	1	2	1	0	0	0	0	0	0	0	0	10
				10	0	0	2	1	1	2	2	0	1	1	2	1	0	0	0	0	0	0	0	0	14
				12	0	0	2	1	2	2	1	0	2	1	1	1	0	2	0	0	0	1	0	0	17
				14	1	1	2	1	0	2	0	1	1	1	2	0	0	0	0	1	0	0	0	0	16
				16	2	1	1	2	0	2	0	2	1	1	2	0	0	0	2	0	0	0	0	0	19
				18	2	1	1	2	0	2	2	0	2	1	0	2	0	0	0	0	0	0	0	0	17
				20	1	0	0	1	1	0	2	1	0	1	0	2	0	0	0	0	0	0	0	0	12
				22	0	0	0	2	0	2	1	0	1	1	0	2	0	0	0	0	0	0	0	0	10
				24	1	0	1	2	0	0	1	0	0	2	1	0	0	0	0	0	0	0	0	0	12
				26	1	0	0	2	0	0	1	0	0	2	1	0	0	0	0	0	1	0	0	0	11
				28	1	0	0	2	0	0	1	0	0	2	0	0	0	0	0	0	0	0	0	0	11
				30	1	0	0	1	2	0	1	0	1	2	0	0	0	0	0	0	0	0	0	0	14
				32	1	0	0	1	1	0	2	0	1	1	0	2	0	1	0	0	0	0	0	0	12
				34	1	0	0	1	1	0	1	0	2	2	1	1	0	0	0	0	0	0	0	0	14
				36	0	0	0	0	1	1	0	0	2	2	2	1	0	0	0	0	0	0	0	0	9
				38	0	0	0	0	1	1	0	0	1	1	1	0	0	0	0	0	0	0	0	0	9
				40	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				42	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				44	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10
				48	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10
				50	0	0	0	2	0	0	1	0	0	2	0	0	1	0	0	0	0	0	0	0	10
				52	0	0	0	1	0	0	0	0	2	2	0	0	2	0	0	0	0	0	0	0	10
1	150	151	VA	8	0	0	0	1	2	1	0	0	0	2	0	2	1	0	0	0	0	0	0	0	12
				10	0	0	1	1	1	0	0	1	1	1	0	1	0	0	0	0	0	0	0	0	8
				12	0	0	0	2	1	1	0	0	1	1	1	2	0	0	0	0	0	0	0	0	10
				14	1	0	0	1	1	1	0	0	2	0	1	1	0	0	0	0	1	0	0	0	11
				16	1	0	0	2	1	1	2	0	1	2	0	1	0	0	0	0	0	0	0	0	13
				18	1	0	0	1	1	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				20	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				22	0	0	0	0	2	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	11
				24	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	16
				26	0	0	0	1	0	0	0	0	1	2	1	1	1	2	0	0	0	0	0	0	17
				28	2	0	0	1	0	0	0	2	0	1	2	1	1	0	0	0	0	0	0	0	19
				30	3	0	0	1	2	0	0	1	2	3	1	2	1	2	0	0	0	0	0	0	22
				32	3	0	0	2	0	0	1	2	2	3	1	2	1	2	0	0	0	0	0	0	22
				34	2	0	0	1	2	1	1	1	1	2	1	1	2	1	0	0	0	0	0	0	20
				36	3	0	0	2	1	1	2	0	1	1	1	2	1	1	0	0	0	0	0	0	25
				38	4	0	0	3	1	1	1	1	3	3	1	2	1	1	1	1	1	1	1	0	0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

D.B.		Visit																					Total				
Centre	Patient	Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score		
3	2	61	FIL	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
				10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				18	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				20	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				22	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				32	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				34	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				36	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				38	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				40	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				42	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
3	3	62	DUB	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				16	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				18	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				20	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				22	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				24	3	3	2	1	1	1	3	2	0	2	1	0	1	1	2	1	1	0	0	0	0	0	25
3	10	72	TOR	8	1	0	1	0	0	0	1	1	0	2	1	0	1	0	0	0	0	0	0	0	0	0	
				10	0	1	0	0	0	0	1	1	0	2	1	0	0	0	0	0	0	0	0	0	0	0	
				12	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				14	1	1	0	0	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				16	1	1	0	2	0	0	1	1	0	2	1	0	0	0	0	0	0	0	0	0	0	0	
				18	1	1	1	1	1	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	
				20	1	1	2	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
3	1	211	HJ	8	1	0	0	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	
				10	2	0	1	2	1	1	2	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	
				12	1	0	0	1	0	0	2	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	
				14	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				16	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				18	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				20	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				22	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				24	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				26	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

970

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 2012A/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

D.B.		Centre		Patient		Initials		No.		It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total
8	1	211	HJ	28	1	0	0	0	1	0	0	1	0	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	7
				30	1	0	0	1	0	0	1	1	0	0	1	0	0	0	0	1	0	0	0	1	0	0	1	0	0	0	7
				32	1	0	0	1	0	0	1	1	0	0	1	0	0	0	0	1	0	0	0	2	1	0	0	0	0	0	9
				34	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	1	0	0	7
				36	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	1	0	0	7
				38	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	1	0	0	7
				40	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	2	0	0	0	1	0	0	0	7
				42	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	2	0	0	0	1	0	0	0	7
				44	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	6
8	4	214	RA	8	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	4
				10	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	4
				12	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	4
				14	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	5
				16	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	4
				18	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	6
				20	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	6
				22	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	6
				24	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	6
				26	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	5
				28	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	5
				30	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	5
				32	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	5
				34	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	5
				36	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	5
				38	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	5
				40	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	5
				42	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	5
				44	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	5
				50	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	5
				52	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	5
8	5	215	SL	8	2	0	0	1	0	0	2	1	0	0	0	0	1	0	0	1	0	1	2	1	0	0	0	0	0	0	13
9	2	241	VCF	8	1	0	0	1	0	1	0	1	0	0	0	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	6
				10	0	0	0	1	0	1	0	1	0	0	0	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	5
				12	0	0	0	1	0	0	1	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	3
				14	1	0	0	1	0	0	1	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	5
				16	1	0	0	1	0	0	1	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	4
				18	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	4
				20	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	5
				22	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	5
				24	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	5
				26	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	5
				28	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	5

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

D.B.		Centre Patient		Visit	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total	
9	2	241	VCF	30	1	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	4
				32	1	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	5
				34	1	0	0	1	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	3
				36	1	0	0	0	1	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	3
				38	0	0	0	0	1	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	4
				40	0	0	0	0	1	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	7
				42	1	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	3
				44	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	4
				46	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	2
				48	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1
				50	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
				52	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
9	5	242	MF	8	1	0	0	0	0	1	1	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	6
				10	1	0	0	1	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	8
				12	0	0	0	1	1	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	7
				14	0	0	0	1	1	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	6
				16	1	0	0	1	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	6
				18	0	0	0	1	1	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	7
				20	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	3
				22	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	4
				24	0	0	0	1	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	4
				26	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	2
				28	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	2
				30	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
				32	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				34	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				36	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	4
				38	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	2
				40	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3
				42	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4
9	8	244	KTM	8	2	1	1	1	1	1	1	1	0	1	2	1	1	1	1	0	0	0	0	0	0	0	16
				10	2	2	1	1	1	1	3	2	0	1	2	2	2	2	1	1	2	0	1	0	0	0	25
				12	2	2	1	1	1	1	2	0	0	2	2	1	1	1	1	0	1	1	0	0	0	0	22
				14	3	2	1	1	1	1	2	0	0	1	2	2	2	2	1	1	0	1	1	0	0	0	24
				16	2	2	1	1	1	1	2	0	0	1	1	1	1	1	1	1	1	1	0	0	0	0	22
				18	2	2	2	1	1	1	3	2	0	1	1	1	1	1	1	2	0	1	1	0	0	0	22
				20	2	3	2	1	2	1	3	2	0	1	2	2	2	2	1	1	2	0	1	0	0	0	29
				22	3	3	2	1	1	0	3	3	0	3	3	1	1	1	1	2	0	1	1	0	0	0	29
				24	3	3	2	1	1	0	3	3	0	2	4	1	1	1	1	2	0	1	2	0	0	0	30
9	12	247	GTT	8	0	0	0	1	1	1	2	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	9
				10	0	0	0	1	1	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	7
				12	0	0	0	1	1	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	6
				14	1	1	0	1	1	0	2	1	0	1	1	1	1	1	1	1	0	1	1	0	0	0	15
				16	3	3	2	2	1	1	3	3	0	2	2	1	1	1	1	1	0	1	1	0	0	0	30

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REMOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

D.B.		Visit																				Total			
Centre Patient Initials		No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score	
9	13	248	BP	8	1	0	0	0	1	0	1	1	0	0	1	1	0	0	0	0	0	0	0	7	
				10	0	0	0	1	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	4	
				12	0	0	0	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	4	
				14	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	2	
				16	1	0	0	0	1	0	1	1	0	0	1	0	0	0	0	0	0	0	0	7	
				18	0	0	0	1	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	4	
				20	0	0	0	1	1	0	1	1	1	1	0	0	0	0	0	0	0	0	0	7	
				22	1	1	1	1	1	2	1	0	1	1	1	0	0	0	0	1	0	0	0	14	
				24	1	0	0	1	0	0	1	1	0	1	0	0	0	0	0	0	0	0	0	7	
				26	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	6	
				28	1	0	0	1	1	0	1	1	0	1	0	0	0	0	0	0	0	0	0	8	
				30	1	1	0	1	1	0	1	1	1	1	1	0	0	0	0	0	0	0	0	12	
				32	1	0	0	1	0	0	1	0	1	1	0	0	0	0	0	0	0	0	0	6	
				34	1	0	0	1	1	0	1	1	0	1	1	0	0	0	0	0	0	0	0	11	
				36	1	0	0	1	1	0	1	1	0	1	0	0	0	0	0	0	0	0	0	6	
				38	1	0	0	1	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	8	
				40	1	0	0	1	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	6	
				42	0	0	0	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	5	
				44	1	1	1	1	1	0	2	1	1	1	1	0	0	0	0	0	0	0	0	14	
				46	1	1	0	1	1	0	1	1	0	0	1	0	0	0	0	0	0	0	0	8	
				48	1	0	0	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	5	
				50	2	1	1	1	1	0	2	1	1	1	1	0	0	0	0	0	0	0	0	16	
				52	2	1	1	1	1	0	2	0	1	1	1	0	0	0	0	0	0	0	0	17	
9	19	251	KF	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
				10	1	2	0	1	1	0	1	1	0	1	1	0	0	0	0	0	0	0	0	0	12
				12	1	1	0	1	0	1	1	0	1	1	1	0	0	0	0	0	0	0	0	0	11
				14	2	1	0	1	0	1	1	2	0	1	1	0	0	0	0	0	0	0	0	0	13
				16	2	2	1	1	1	0	1	2	0	2	1	1	0	0	0	0	0	0	0	0	17
				18	2	2	1	2	1	1	2	0	1	2	1	1	0	0	0	0	0	0	0	0	23
9	24	253	LGZ	8	1	1	0	0	1	0	1	0	1	1	1	0	0	0	0	0	0	0	0	0	7
				10	1	1	0	1	1	0	1	0	1	1	0	0	0	0	0	0	0	0	0	0	9
				12	1	1	0	1	1	0	1	1	0	1	0	0	0	0	0	0	0	0	0	0	8
				14	1	1	0	1	1	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	10
				16	1	0	0	1	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	5
				18	1	1	0	2	1	1	1	0	1	1	0	0	0	0	0	0	0	0	0	0	13
				20	1	0	0	1	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	5
9	25	254	PH	8	1	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	4
				10	0	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	4
				12	1	0	0	1	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	4
				14	1	0	0	1	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	5
				16	0	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	6
				18	1	1	0	1	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	7
				20	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	5
				22	1	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	5

973

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 2012A/013
Listing No.: 10.1

HAMILTON DEPRESSION RATING SCALE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	Initials	No.	Visit																				Total			
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20		It.21	Score	
9	25	254	PH	1	1	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	6
				26	1	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	5
				28	1	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	7
				30	1	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	9
				32	1	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	20
				34	2	2	1	1	1	1	2	2	0	1	1	2	0	2	0	1	0	0	0	0	0	0	15
				36	2	1	0	1	1	1	2	0	1	1	1	1	0	1	0	1	0	0	0	0	0	0	10
				38	1	1	0	1	1	1	1	1	0	0	1	1	0	1	0	0	0	0	0	0	0	0	9
				40	1	0	0	1	1	1	1	1	0	1	1	0	1	0	0	0	0	0	0	0	0	0	8
				42	1	0	0	1	1	1	1	1	0	1	1	0	0	1	0	0	0	0	0	0	0	0	8
				44	1	0	0	1	1	1	1	1	0	1	1	0	0	1	0	0	0	0	0	0	0	0	10
				46	1	0	0	1	1	1	1	1	0	2	1	0	0	1	0	0	0	0	0	0	0	0	10
				48	1	0	0	1	1	1	1	1	0	2	1	0	0	1	0	0	0	0	0	0	0	0	10
				50	1	1	0	1	1	1	1	1	0	2	1	0	0	1	0	0	0	0	0	0	0	0	12
9	28	257	HI	8	1	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	5
				10	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	3
				12	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	3
				14	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	4
				16	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	3
				18	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	3
				20	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	3
				22	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	2
				24	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	3
				26	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	5
				28	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	5
10	4	272	2SD	8	2	0	0	0	2	1	0	2	0	0	1	1	0	0	0	0	0	0	0	0	0	0	12
				10	2	0	0	0	2	1	0	2	0	0	1	1	0	0	0	0	0	0	0	0	0	0	12
				12	2	0	0	0	2	1	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	11
				14	2	0	0	0	2	1	0	2	0	0	1	1	0	0	0	0	0	0	0	0	0	0	12
				16	3	0	0	0	2	1	0	1	0	0	1	2	0	0	0	0	0	0	0	0	0	0	14
				18	3	0	0	0	2	1	0	1	0	0	1	2	0	0	0	0	0	0	0	0	0	0	14
				20	3	0	0	0	2	1	0	1	0	0	1	2	0	0	0	0	0	0	0	0	0	0	14
				22	1	0	0	0	1	2	0	0	2	0	4	2	0	0	0	0	0	0	0	0	0	0	22
				24	3	0	0	0	2	0	1	0	2	3	1	0	0	0	0	0	0	0	0	0	0	0	16
				26	1	0	0	0	2	2	0	1	0	1	1	0	0	0	0	0	0	0	0	0	0	0	15
				28	1	0	0	0	2	1	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	10
				30	1	0	0	0	2	1	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	10
10	5	273	AN	8	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	3
				10	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1
				12	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1
10	10	276	MH	8	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	3
				10	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0

974

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS 88D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACERO

Centre	Patient	Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score			
	10	14	279	AA	8	2	0	0	1	1	2	1	0	0	0	0	0	0	0	0	0	0	0	0	1	12		
					10	1	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	1	6	
					12	1	0	0	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	1	6
					14	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	1	6
					16	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	1	6
					18	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	1	8
					20	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	1	7
					22	2	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	1	7
					24	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	1	7
					26	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	1	6
					28	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	1	6
					30	3	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	1	10
					32	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	5
					34	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	4
					36	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	3	
					38	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	3	
					40	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	3	
					42	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	3	
					44	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	3	
					46	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	3	
					48	2	1	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	12	
					50	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	7	
					52	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	7	
	10	16	281	AJ	8	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	9	
					10	2	0	0	0	0	0	0	0	2	2	0	0	0	0	0	0	0	0	0	0	0	13	
					12	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	13	
					14	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	11	
					16	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	9	
					18	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	7	
					20	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	5	
					22	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	6	
					24	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	6	
					26	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	5	
					28	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	6	
					30	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	8	
					32	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	9	
					34	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	7	
					36	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	6	
					38	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	5	
					40	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	7	
					42	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	7	
					44	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	6	
					46	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	6	
					48	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	7	
					50	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	6	
					52	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	6	

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

9550077

PHARMACIA CNS R&D
RESOJETINE - PROTOCOL 2012A/013
Listing No.: 10.1
HAMILTON DEPRESSION RATING SCALE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

D.B.		Centre Patient Initials		Visit	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score
10	17	282	MM	B	1	0	0	0	1	1	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	5
				10	2	0	0	0	1	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	5
				12	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				14	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				16	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
				18	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
				20	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				22	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
				24	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
				26	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				28	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				30	3	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
				32	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
				34	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				36	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				38	0	0	0	0	1	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	2
				40	1	0	0	0	0	1	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	4
				42	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4
				44	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
				46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				48	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				52	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10	19	284	TN	B	1	0	0	0	0	0	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	4
				10	0	0	0	0	0	0	0	0	0	0	1	1	0	2	0	1	0	0	0	0	0	5
				12	2	0	0	0	0	0	0	0	0	1	1	0	2	0	2	0	1	1	0	0	0	11
				14	1	0	0	0	0	0	0	0	0	1	1	0	2	0	1	0	0	1	0	0	0	7
				16	2	0	0	0	0	0	0	0	0	2	1	0	2	1	2	0	2	0	0	0	0	11
				18	2	0	0	0	0	0	0	0	0	2	1	0	2	0	1	0	0	1	0	0	0	10
				20	3	0	0	0	0	0	0	0	0	2	2	0	2	0	2	0	2	0	1	0	0	12
				22	1	0	0	0	0	0	0	0	0	1	1	0	2	0	1	0	0	1	0	0	0	8
				24	0	0	0	0	0	0	0	0	0	0	0	0	2	0	2	0	1	0	0	0	0	5
				26	0	0	0	0	0	0	0	0	0	0	1	1	0	2	0	2	0	1	0	0	0	8
				28	0	0	0	0	0	0	0	0	0	0	1	1	0	2	0	2	0	1	0	0	0	7
				30	0	0	0	0	0	0	0	0	0	0	1	1	0	2	0	2	0	1	0	0	0	8
				32	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	1	0	1	0	0	0	4
				34	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	1	0	0	0	2
				36	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	3
				38	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1
				40	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1
				42	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	2
				44	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	2
				46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				48	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	2
				50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1
				52	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

D.B.		Visit																				Total				
Centre	Patient	Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score	
10	21	288	AK	8	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	
				10	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				12	1	0	0	0	0	1	0	0	1	1	0	2	0	0	0	0	1	0	0	0	0	7
				14	3	0	0	1	1	0	2	0	0	0	0	1	1	1	1	1	0	0	0	0	0	14
				16	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	0	0	0	0	5
				18	1	0	0	0	0	0	2	0	0	1	1	0	2	0	1	0	1	0	0	0	0	9
				20	1	0	0	0	0	2	0	0	2	1	0	2	0	1	0	0	1	0	0	0	0	10
				22	3	0	1	0	1	0	0	0	3	2	1	2	0	0	0	1	0	0	0	0	0	15
10	24	289	AL	8	2	0	0	0	1	0	0	0	2	1	0	2	0	0	0	0	0	0	0	0	0	10
				10	2	0	0	0	0	0	2	0	1	4	2	0	0	1	0	0	1	0	0	0	0	15
				12	1	0	0	0	0	0	0	0	2	1	0	2	0	1	0	0	1	0	0	0	0	10
				14	2	0	0	0	0	0	2	0	0	2	1	1	2	0	2	0	1	1	0	0	0	14
				16	2	0	0	0	0	0	3	0	0	2	1	1	2	0	0	1	1	0	0	0	0	18
				18	1	0	0	0	0	0	0	0	4	2	1	0	2	0	1	0	1	0	0	0	0	8
				20	0	0	0	0	0	0	0	0	0	1	1	0	2	0	1	0	1	0	0	0	0	5
				22	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	1	0	0	0	0	3
				24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3
				26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3
				28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				32	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				34	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				36	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				38	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				40	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				42	1	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	10
				44	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	6
				46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				48	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				52	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
10	29	293	JJ	8	1	1	0	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	5
				10	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	2
				12	1	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	4
				14	2	0	0	2	2	0	2	1	0	0	2	2	0	0	0	0	1	1	0	0	0	17
				16	1	1	0	2	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	7
				18	2	1	1	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	8
				20	3	2	2	1	0	1	2	0	0	1	0	0	0	0	0	0	0	0	0	0	0	12
10	30	294	VK	8	1	2	1	2	2	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	20
				10	2	1	1	1	1	1	0	0	1	2	0	0	0	1	0	0	0	0	0	0	0	15
				12	1	1	1	1	2	2	0	0	1	2	0	1	1	0	0	0	0	0	0	0	0	18
				14	2	0	0	2	2	2	1	0	0	1	2	1	1	0	0	0	0	0	0	0	0	16
				16	1	1	2	2	2	2	1	0	1	2	2	1	0	0	0	0	0	0	0	0	0	20
				18	1	1	2	0	2	2	1	0	0	2	2	0	2	1	0	0	0	0	0	0	0	19

977

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

D.B.		Centre Patient Initials		Visit		It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total	
10	43	296	IK	26	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4
10	44	298	AB	8	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10	45	34	KJ	8	1	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9
				10	1	2	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
				12	2	2	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	11
				14	1	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
10	46	38	TH	8	1	2	0	0	0	0	0	0	0	0	2	2	0	1	0	0	0	0	0	0	0	0	0	10
10	47	39	TM	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
				10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
				16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4
				18	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3
				20	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				22	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
				24	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4
				26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4
				28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
				30	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4
				32	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4
				34	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
				36	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4
				38	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4
				40	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4
				42	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4
				44	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4
				46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
				48	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
				50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
				52	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5
10	48	41	IP	8	1	2	1	1	2	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	12
				10	1	1	1	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10
				12	1	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				14	1	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				16	1	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7
				18	1	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				20	1	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6

629

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.1
HAMILTON DEPRESSION RATING SCALE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

D.B.		Visit																						Total		
Centre	Patient	Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20		It.21	Score
10	50	44	EE	8	1	1	1	1	2	1	0	3	0	0	0	2	0	2	1	1	0	0	0	0	0	15
				10	1	0	0	0	0	0	3	0	0	2	2	0	2	1	1	0	0	0	0	0	0	13
				12	1	1	1	1	2	0	2	3	0	0	1	1	0	2	1	0	0	0	0	0	0	15
				14	1	1	1	2	0	2	3	0	0	1	1	0	2	1	0	0	0	0	0	0	0	15
				16	1	1	1	1	0	2	3	0	0	1	1	0	2	1	0	0	0	0	0	0	0	14
				18	1	1	1	1	1	1	2	3	0	0	1	1	0	2	1	0	1	0	0	0	0	16
				20	0	1	1	1	0	2	2	3	0	0	1	1	0	2	1	0	1	0	0	0	0	17
				22	1	1	1	1	1	0	2	0	0	1	1	0	2	1	0	1	0	0	0	0	0	12
				24	2	1	1	2	0	1	2	0	0	1	1	1	2	1	0	0	0	0	0	0	0	15
				26	1	0	0	1	2	0	1	2	0	0	1	0	0	2	1	0	0	0	0	0	0	10
				28	2	0	0	2	0	1	2	0	0	1	0	0	2	1	0	0	0	0	0	0	0	11
				30	1	0	0	1	0	2	0	1	2	0	0	1	1	1	0	0	0	0	0	0	0	9
				32	1	0	0	1	0	2	0	1	2	0	1	0	0	2	1	0	0	0	0	0	0	11
				34	1	0	0	1	0	2	1	2	1	0	1	0	1	1	0	1	0	0	0	0	0	11
				36	1	0	0	0	1	2	1	2	1	0	1	0	1	1	0	1	0	0	0	0	0	12
				38	1	0	0	0	1	2	2	1	0	1	0	0	2	1	0	1	0	0	0	0	0	10
				40	1	0	0	0	1	2	2	1	0	1	0	0	1	1	0	0	0	0	0	0	0	10
				42	1	0	0	0	1	1	2	1	0	1	0	0	1	1	0	0	0	0	0	0	0	9
				44	1	0	0	1	1	1	2	1	0	1	0	0	2	1	0	0	0	0	0	0	0	11
				46	1	0	0	1	1	2	1	0	1	1	0	0	2	1	0	0	0	0	0	0	0	11
				48	1	0	0	1	1	2	1	0	1	1	1	0	2	1	0	0	0	0	0	0	0	11
				50	1	0	0	1	1	2	1	0	1	1	0	2	1	1	0	0	0	0	0	0	0	10
				52	1	0	0	0	1	0	2	1	0	1	1	0	2	1	0	0	0	0	0	0	0	10
10	51	45	UL	8	1	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	3	
				10	1	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	3
				12	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	3
				14	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	2
				16	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	2
				18	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	2
				20	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1
				22	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1
				24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1
				26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1
				28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1
				30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1
				32	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1
				34	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1
				36	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1
				38	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1
				40	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1
				42	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1
				44	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
				46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				48	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
				50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
				52	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

D.B.		Visit																					Total		
Centre	Patient	Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score
10	92	73	LA	40	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				42	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				44	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
				46	1	0	0	1	0	0	0	0	0	0	0	1	2	1	0	0	0	0	0	0	7
				48	1	0	0	1	0	0	0	1	1	1	1	0	0	1	2	1	0	0	0	0	9
				50	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	2
				52	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1
10	94	273	PV	8	1	1	0	1	0	0	1	1	1	1	1	1	1	1	0	0	0	0	0	0	10
				10	1	0	2	0	1	0	1	1	1	1	1	2	1	1	0	0	0	0	0	0	10
				12	1	0	0	2	0	0	1	1	1	1	1	0	0	0	0	0	0	0	0	0	9
				14	1	0	0	1	0	0	1	1	1	1	1	0	0	0	0	0	0	0	0	0	8
				16	1	0	0	1	0	0	1	1	1	1	1	1	1	1	0	0	0	0	0	0	7
11	1	372	DF	8	0	0	0	0	1	1	0	0	1	2	1	0	1	1	0	0	0	0	0	0	8
				10	0	0	0	0	1	1	0	0	1	0	1	0	0	0	0	0	0	0	0	0	5
				12	1	0	0	1	2	1	0	1	0	0	0	0	2	1	0	0	0	0	0	0	10
				14	0	0	0	1	1	2	0	1	1	0	1	0	0	0	0	0	0	0	0	0	8
				16	0	0	0	1	1	1	0	1	1	0	1	0	0	0	0	0	0	0	0	0	7
				18	1	0	1	2	3	0	1	2	2	1	0	1	0	0	0	0	0	0	0	0	17
				20	0	0	1	1	2	1	0	1	1	1	2	0	1	0	0	0	0	0	0	0	13
				22	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
				24	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3
				26	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3
				28	0	0	0	0	1	1	0	0	1	1	1	0	1	0	1	0	0	0	0	0	8
				30	2	1	1	1	1	1	0	0	1	1	1	0	1	0	0	0	0	0	0	0	10
				32	1	0	0	1	1	1	0	0	1	0	1	0	0	0	0	0	0	0	0	0	7
				34	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	4
11	4	375	BA	8	2	0	0	0	1	0	0	1	1	1	0	1	0	1	0	0	1	0	0	0	9
				10	2	0	0	0	1	0	2	0	1	1	0	1	0	0	0	0	1	0	0	0	10
				12	2	0	0	1	0	1	2	0	0	1	0	0	0	0	0	0	0	0	0	0	9
				14	2	0	0	0	0	2	0	0	1	1	0	0	0	0	0	0	0	0	0	0	10
				16	1	0	0	0	0	1	2	0	0	2	0	0	1	0	0	0	0	0	0	0	8
				18	1	0	0	0	1	1	2	0	1	1	1	0	0	0	0	0	0	0	0	0	10
				20	3	1	0	0	2	1	1	2	0	1	1	0	0	0	0	0	0	0	0	0	16
				22	2	0	0	0	0	2	2	0	2	0	0	1	0	0	0	0	0	0	0	0	13
11	7	376	MK	8	1	0	0	0	0	1	0	0	1	1	1	1	0	0	0	0	0	0	0	0	7
				10	2	0	0	0	0	0	2	1	0	2	1	1	0	0	0	0	0	0	0	0	13
				12	1	0	0	1	0	0	2	0	1	1	0	0	0	0	0	0	0	0	0	0	11
				14	2	0	0	0	0	0	1	1	1	2	0	1	0	0	0	0	0	0	0	0	11
				16	2	0	0	0	0	0	2	0	1	1	1	0	0	0	0	0	0	0	0	0	9
				18	2	0	0	1	1	1	2	0	1	1	1	0	0	0	0	0	0	0	0	0	16
				20	1	0	0	0	1	1	2	0	1	1	1	1	0	0	0	0	0	0	0	0	13
				22	1	0	0	0	0	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	10
				24	1	0	0	0	0	1	2	0	1	1	1	1	1	0	0	0	0	0	0	0	9

984

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

D.B.		Visit																					Total			
Centre	Patient	Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score	
11	15	366	NF	16	2	1	1	1	1	0	0	1	0	2	0	0	0	0	0	0	0	0	0	0	2	18
11	18	369	EI	8	2	0	0	1	0	0	2	0	0	1	0	0	0	0	0	0	0	0	0	0	0	7
				10	2	0	0	1	1	1	0	0	1	1	0	2	0	0	0	0	0	0	0	0	0	10
				12	2	0	0	0	0	1	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	6
				14	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	3
				16	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	3
				18	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	3
				20	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	2
				22	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	3
				24	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	2
				26	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	2
				28	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	2
				30	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	2
				32	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	2
				34	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	2
				36	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	2
				38	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	2
				40	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	2
				42	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	2
				44	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	3
				46	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	4
				48	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	3
				50	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	3
				52	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	4
11	20	371	LJ	8	1	0	0	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	7
				10	1	0	0	1	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	8
				12	1	0	0	1	1	0	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	7
				14	2	0	0	2	2	2	0	0	2	2	1	1	0	0	0	0	1	0	0	0	0	18
12	5	95	ZSH	8	1	1	0	0	1	1	1	0	1	1	0	0	0	0	0	0	0	0	0	0	0	11
				10	1	1	0	0	1	2	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	13
				12	1	1	0	0	1	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	9
				14	1	1	0	0	1	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	10
				16	1	0	0	1	1	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	9
				18	1	1	0	1	1	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	10
12	6	98	MK	8	2	3	0	0	0	0	1	1	0	2	1	0	0	0	0	0	0	0	0	0	0	11
				10	1	2	0	0	0	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	10
				12	0	1	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	4
				14	0	1	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	6
				16	0	0	0	0	0	0	1	0	1	1	0	0	0	0	0	0	0	0	0	0	0	6
				18	1	0	1	2	1	1	2	1	1	1	1	0	0	0	0	0	0	0	0	0	0	17
				20	2	1	1	0	0	0	3	1	0	2	1	0	0	0	0	0	0	0	0	0	0	21
				22	1	1	1	0	0	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	12

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

D.B.		Visit		Centres Patient Initials																				Total	
		No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score	
12	6	98	MX	24	0	1	1	0	0	1	1	1	2	0	1	0	2	1	0	0	0	0	0	12	
				26	0	1	0	0	0	1	0	1	0	0	1	0	1	0	1	0	0	0	0	5	
				28	0	1	0	0	0	1	1	0	1	0	0	1	0	0	0	0	0	0	0	5	
				30	0	1	0	0	0	1	1	0	1	0	0	1	0	0	0	0	0	0	0	5	
12	10	96	IP	8	1	1	0	0	1	0	0	1	1	1	1	0	1	0	1	0	0	0	0	10	
				10	2	1	0	0	1	1	0	1	2	1	1	0	1	0	1	0	0	0	0	13	
				12	1	1	0	1	0	0	1	0	1	1	1	0	0	0	0	0	0	0	0	7	
				14	1	1	0	2	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	10	
				16	1	1	0	1	0	0	0	1	1	1	1	0	0	0	0	0	0	0	0	8	
				18	1	1	0	1	0	0	1	1	1	1	1	0	0	0	0	0	0	0	0	8	
				20	1	1	0	2	0	1	1	1	1	1	1	0	0	0	0	0	0	0	0	8	
				22	2	1	0	2	1	0	1	2	2	1	1	1	0	0	0	0	0	0	0	15	
				24	2	1	0	2	2	1	0	2	2	1	1	0	0	0	0	0	0	0	0	18	
12	11	94	ER	8	2	0	0	2	1	1	0	1	2	1	2	0	2	0	0	0	1	0	0	16	
				10	3	0	0	2	2	2	0	2	2	1	2	0	0	0	0	0	1	0	0	22	
				12	3	0	0	2	2	3	0	2	2	2	1	2	0	0	0	0	1	0	0	24	
12	12	97	FSZ	8	3	1	2	0	2	1	0	0	2	3	1	1	1	2	0	0	1	0	0	21	
				10	3	2	2	0	2	1	0	0	2	3	1	1	1	2	0	0	1	0	0	22	
12	13	103	ISZ	8	2	0	0	2	2	2	0	1	0	0	0	0	0	0	0	1	0	0	0	12	
				10	1	0	0	2	2	2	1	0	1	0	0	0	0	0	0	0	0	0	0	9	
				12	2	0	0	2	2	1	1	1	1	1	1	0	2	2	1	0	0	0	0	20	
12	14	101	GSZ	8	3	2	1	1	1	0	2	0	1	2	0	1	0	1	0	0	0	0	0	17	
				10	4	2	3	2	2	3	1	1	3	2	0	1	0	1	0	0	0	0	0	27	
12	17	108	TK	8	0	1	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	4	
				10	0	1	0	0	0	1	0	0	1	1	0	0	1	0	0	0	0	0	0	6	
				12	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	2	
				14	0	0	0	0	0	0	0	1	1	1	0	0	1	0	0	0	0	0	0	4	
				16	0	0	0	0	0	0	0	0	1	1	0	1	0	0	0	0	0	0	0	4	
				18	0	0	0	0	1	0	0	0	1	1	0	1	0	0	0	0	0	0	0	5	
				20	0	0	0	0	0	0	0	1	1	1	0	1	0	0	0	0	0	0	0	5	
				22	0	0	0	0	0	0	0	1	1	1	0	1	0	0	0	0	0	0	0	4	
				24	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	1	
				26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
				28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
12	18	109	LS	8	1	0	0	2	2	1	1	0	1	1	1	2	1	1	0	0	0	0	0	15	
				10	1	0	0	2	1	1	0	1	1	1	1	2	1	1	0	0	0	0	0	14	
				12	1	0	0	2	1	1	0	1	1	1	1	2	1	0	0	0	0	0	0	13	
				14	1	0	1	2	1	0	1	0	0	0	1	2	1	0	0	0	0	0	0	13	
				16	2	0	1	2	1	0	1	0	1	2	0	1	2	0	0	0	0	0	0	14	
				18	2	0	1	2	1	1	0	1	2	0	1	2	1	2	0	0	0	0	0	17	

987

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

D.B.		Visit																					Total	
Centre	Patient Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Score
12	28	116	IV	8	1	0	0	0	0	0	1	0	1	1	0	1	2	1	0	0	0	0	0	10
				10	0	0	1	0	1	0	1	1	1	1	0	1	2	1	0	0	0	0	0	10
				12	0	0	0	0	0	1	0	1	1	0	1	2	1	0	0	0	0	0	0	8
				14	0	0	0	0	0	1	1	1	1	0	1	2	1	0	0	0	0	0	0	8
				16	2	0	1	1	1	1	0	2	1	0	1	2	1	0	0	0	0	0	0	15
12	34	120	TGB	8	0	0	0	0	0	0	1	1	0	1	0	2	0	0	0	0	0	0	0	5
				10	0	0	0	0	0	0	1	1	0	0	0	2	0	0	0	0	0	0	0	4
				12	1	0	0	0	1	0	1	1	0	1	0	2	0	0	0	0	0	0	0	4
				14	1	1	0	0	1	0	1	2	0	1	0	2	0	0	0	0	0	0	0	9
				16	1	0	0	0	0	0	1	1	0	1	0	2	0	0	0	0	0	0	0	6
				18	0	0	0	0	0	0	0	1	1	2	0	2	0	1	0	0	0	0	0	7
				20	0	0	0	0	0	0	0	1	1	0	2	0	0	0	0	0	0	0	0	4
				22	0	0	0	0	0	0	0	0	0	1	0	2	0	0	0	0	0	0	0	2
				24	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	2
				26	0	1	1	1	1	0	0	2	2	0	0	2	0	0	0	0	0	0	0	10
				28	0	0	0	0	0	0	0	1	1	0	0	2	0	0	0	0	0	0	0	4
				30	0	0	0	0	1	0	0	1	1	0	0	2	0	0	0	0	0	0	0	6
				32	0	0	0	0	1	0	0	1	1	0	0	2	0	0	0	0	0	0	0	5
				34	0	0	0	0	0	0	0	1	1	0	0	2	0	0	0	0	0	0	0	3
				36	0	0	0	0	0	0	0	1	0	0	0	2	0	0	0	0	0	0	0	2
				38	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	2
				40	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	2
				42	0	0	0	0	0	0	0	1	1	0	0	2	0	0	0	0	0	0	0	6
				44	0	0	0	0	0	0	0	1	0	0	1	2	0	0	0	0	0	0	0	5
				46	1	1	0	1	1	1	0	0	1	0	0	2	0	0	0	0	0	0	0	3
				48	0	0	0	1	0	0	0	1	2	0	0	2	0	0	0	0	0	0	0	10
				50	1	1	0	1	1	1	0	0	1	0	0	2	0	0	0	0	0	0	0	4
				52	1	1	0	0	1	1	0	0	1	2	1	0	2	0	0	0	0	0	0	11
				54	1	1	0	0	1	0	0	1	0	0	0	2	0	0	0	0	0	0	0	6
12	35	119	LP	8	1	0	1	1	0	0	1	1	0	0	0	2	0	0	0	0	0	0	0	7
				10	0	0	0	0	0	0	1	1	1	0	1	2	0	0	0	0	0	0	0	6
				12	0	0	0	1	0	0	0	1	0	1	1	2	0	2	0	0	0	0	0	8
				14	0	0	0	2	0	0	0	1	1	0	1	2	0	0	0	0	0	0	0	7
				16	1	0	1	1	2	1	1	0	1	0	1	2	1	0	0	0	0	0	0	15
				18	2	0	0	2	2	1	2	2	1	0	1	2	1	0	0	0	0	0	0	18
12	37	386	EK	8	0	0	0	0	1	0	0	1	2	0	0	2	0	0	0	0	0	0	0	7
				10	0	0	0	0	0	0	1	1	2	0	0	2	0	0	0	0	0	0	0	8
				12	0	0	0	0	1	0	1	1	2	0	1	2	0	2	0	0	0	0	0	11
				14	0	0	0	0	1	0	1	1	2	0	0	2	0	0	0	0	0	0	0	7
				16	0	0	0	0	0	0	1	1	2	0	0	2	0	0	0	0	0	0	0	5
				18	0	0	0	1	1	1	1	1	1	0	0	2	0	0	0	0	0	0	0	8
13	2	224	TCS	8	2	0	1	0	0	0	2	3	3	1	1	2	0	0	0	0	1	0	0	19
				10	1	0	0	0	1	0	1	2	0	0	1	1	0	0	0	1	0	0	0	8
				12	2	0	1	0	1	1	1	2	3	2	1	1	0	0	0	1	0	0	1	19

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

D.B.		Centre Patient		Initials	No.	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total	
13	2	224	TCS	14	2	0	1	0	0	1	1	1	1	1	2	3	2	1	1	1	0	0	0	1	0	0	0	17
				16	1	1	0	0	1	1	1	1	1	1	2	2	0	1	1	1	0	0	1	0	1	1	1	15
				18	1	1	0	0	1	1	1	1	1	1	2	2	0	1	1	1	0	0	1	0	1	1	1	14
				20	1	1	0	0	1	1	0	2	2	2	2	2	0	2	1	1	0	0	1	1	0	0	0	15
				22	2	1	0	0	2	2	2	2	2	2	2	2	2	1	1	1	2	2	2	1	1	1	1	26
				24	2	0	1	1	2	2	2	2	2	2	2	2	2	1	2	1	2	0	2	1	0	1	1	27
				26	2	0	1	1	2	1	2	2	2	2	2	2	2	1	1	1	1	1	1	1	0	1	1	25
				28	2	1	1	1	2	1	2	1	1	1	2	1	1	0	1	2	1	0	2	0	1	1	1	19
				30	1	0	1	0	1	0	1	1	1	1	1	1	1	1	1	1	1	0	0	1	0	1	1	14
				32	1	0	0	0	1	0	2	2	1	1	2	2	1	0	1	1	1	0	0	1	0	0	0	11
				34	1	0	1	0	0	1	0	1	1	1	1	1	1	1	1	1	1	1	0	1	0	0	0	11
				36	1	0	1	0	0	1	0	1	1	1	1	1	1	1	1	1	1	1	0	1	0	0	0	11
				38	1	0	1	0	0	1	0	1	1	1	1	1	1	1	1	1	1	1	0	1	0	0	0	12
				40	1	0	1	0	0	1	0	1	1	1	1	1	1	0	1	1	1	0	0	1	0	0	0	8
				42	1	0	1	0	0	1	0	1	1	1	1	1	1	0	1	1	0	0	0	1	0	0	0	8
				44	1	0	0	1	0	0	1	1	1	1	1	1	1	0	1	0	1	0	0	1	0	0	0	7
				46	1	0	0	1	0	0	1	1	1	1	1	1	1	1	1	1	1	0	0	1	0	0	0	9
				48	1	0	0	1	0	0	1	1	1	1	1	1	1	0	1	1	1	0	0	0	0	1	0	10
				50	1	0	0	1	0	0	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	1	8
				52	1	0	0	1	0	0	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	7
13	8	228	PK	8	1	0	0	1	1	1	0	0	0	0	0	0	1	0	0	1	0	0	1	0	0	0	0	7
				10	1	0	0	0	0	1	1	1	1	1	1	1	1	0	0	1	0	0	1	0	0	0	0	6
				12	1	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	1	0	0	0	13
				14	1	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	2	0	0	0	0	0	0	11
				16	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	3
				18	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	5
				20	0	0	0	0	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	3
				22	0	0	0	0	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	4
				24	1	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	0	2	0	1	0	0	10
				26	1	0	0	0	1	2	1	1	1	1	1	1	1	1	1	1	1	2	0	0	1	0	0	16
				28	3	0	0	2	2	3	2	2	2	2	2	2	2	2	2	2	2	2	0	2	0	2	1	33
				30	3	1	1	1	2	3	2	2	2	2	2	2	2	2	2	2	2	2	0	2	0	0	0	27
13	9	229	SZS	8	2	0	1	0	1	1	1	1	1	1	1	1	2	1	1	1	1	0	0	1	0	0	0	17
				10	2	0	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	1	0	0	0	16
				12	1	0	0	1	1	0	1	1	1	1	1	1	1	1	1	1	1	2	0	0	1	0	0	12
				14	1	0	0	1	2	2	1	0	1	1	1	1	1	1	1	1	1	0	1	0	0	0	0	19
				16	3	0	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	3	1	0	0	0	0	33
				18	3	0	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	3	2	0	0	0	0	34
				20	3	0	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	3	2	0	0	0	0	38
13	11	225	HS	8	2	0	1	1	0	0	1	0	1	1	2	1	1	1	1	1	1	2	0	0	1	0	0	17
				10	1	0	0	0	1	0	1	0	1	1	1	1	1	1	1	1	1	1	0	0	1	0	0	8
				12	2	0	0	1	2	2	2	2	2	2	2	2	2	2	2	2	2	3	0	0	1	0	0	28
				14	2	0	0	2	2	2	2	2	2	2	2	2	2	2	2	2	2	3	1	1	1	1	1	24
				16	2	0	0	2	2	2	2	2	2	2	2	2	2	2	2	2	2	3	1	1	1	1	1	24

990

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.1
 HAMILTON DEPRESSION RATING SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient No.	D.B.	Initials	Visit	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	It.21	Total Score
	13	11			2	0	0	1	2	1	0	0	2	2	2	0	1	2	2	0	0	0	1	1	1	20
				18	2	0	1	1	1	0	2	1	1	1	1	2	0	1	2	1	0	0	0	1	1	18
				20	1	0	1	1	0	0	2	1	1	1	1	2	0	1	2	1	0	0	0	1	1	19
				22	2	0	1	1	0	0	2	1	1	1	1	2	0	1	2	2	1	0	0	1	1	19
				24	1	0	0	0	0	0	1	0	1	1	1	0	1	2	2	0	0	0	0	1	1	13
				26	1	0	0	0	0	0	1	0	1	0	1	0	1	2	1	1	1	0	0	1	1	12
				28	1	0	0	0	0	0	0	1	0	1	0	1	0	1	2	1	0	0	1	1	1	13
				30	1	0	0	1	1	0	0	2	1	1	1	0	1	2	1	0	0	1	1	1	1	16
				32	1	0	0	1	1	0	1	1	1	1	1	0	0	1	2	1	0	0	1	1	1	14
				34	1	0	1	1	1	0	1	0	2	1	1	1	0	1	2	1	0	0	0	1	1	10
				36	1	0	0	1	1	0	1	1	1	1	1	0	1	2	1	0	0	0	0	1	1	13
				38	1	0	0	1	0	0	1	0	2	1	1	1	0	1	2	1	0	0	0	0	1	13
				40	1	0	1	1	0	0	1	0	2	1	1	1	0	1	2	1	0	0	0	0	2	16
				42	1	0	1	1	0	0	1	0	1	1	1	0	1	2	1	2	1	0	0	0	1	13
				44	1	0	0	1	1	0	1	1	0	2	1	1	0	1	2	1	0	0	0	0	1	12
				46	1	0	0	1	0	0	1	0	2	1	1	1	0	2	1	0	0	0	0	1	1	11
				48	1	0	0	1	0	0	1	0	1	0	1	0	1	2	1	0	0	0	0	1	1	12
				50	1	0	1	0	0	0	1	0	1	1	1	0	1	2	1	1	0	0	0	1	1	12
				52	1	0	0	0	0	1	1	1	1	1	1	1	0	1	1	1	1	0	0	0	1	11
	13	14	217	DF	8	2	0	0	0	1	1	0	1	1	1	0	1	1	1	1	0	0	1	0	0	12
				10	2	0	1	1	1	1	3	1	2	2	2	2	2	1	2	1	1	1	1	0	0	24
				12	1	0	0	0	0	2	2	1	1	1	1	1	0	1	0	1	0	0	1	0	0	13
				14	1	1	0	0	0	2	1	1	1	1	1	2	1	0	1	1	1	1	1	0	0	16
				16	1	0	0	0	0	2	1	1	1	0	1	1	1	1	1	1	1	0	0	1	0	13
				18	2	0	0	1	1	2	1	1	1	2	2	1	1	2	1	1	0	0	1	0	0	19
				20	2	0	0	1	1	2	2	2	2	3	3	2	1	2	1	2	1	1	0	0	0	27
				22	2	0	1	2	2	2	2	1	2	3	2	1	1	2	2	2	0	2	0	1	0	28
				24	2	0	1	1	2	2	2	1	1	1	1	1	1	2	2	0	0	0	2	0	1	23
				26	1	0	0	1	1	2	2	1	2	2	2	2	0	0	2	1	0	0	1	0	1	17
				28	1	0	0	1	1	2	1	1	1	1	1	1	0	1	2	1	0	0	1	0	1	14
				30	1	0	0	1	1	2	1	1	1	1	0	0	0	2	1	0	0	1	0	0	0	12
				32	1	0	0	1	1	2	1	1	1	1	1	0	0	1	2	0	0	1	0	0	1	13
				34	1	0	0	1	1	1	1	1	1	0	0	1	1	0	2	1	0	0	1	0	1	15
				36	1	0	0	0	1	1	1	1	1	1	1	1	1	0	2	1	0	0	1	0	1	12
				40	1	0	0	0	1	1	1	1	1	1	1	0	0	2	1	0	0	0	1	0	0	9
				42	1	0	0	0	1	1	1	1	1	1	1	1	0	0	2	1	0	0	0	1	0	13
				44	1	0	0	1	1	2	1	1	1	1	1	0	1	2	1	0	0	0	1	0	1	15
				46	1	0	0	1	1	1	1	1	1	1	1	1	0	0	2	1	0	0	1	0	1	11
				48	1	0	0	0	1	1	1	1	1	1	1	1	0	0	0	0	0	0	1	0	1	11
				50	1	0	0	0	1	0	0	1	0	1	1	1	0	0	0	0	0	0	0	1	1	9
				52	1	0	0	0	1	2	1	1	1	1	1	0	0	1	1	0	0	0	0	0	1	11
	13	15	222	KG	8	1	0	0	1	1	1	1	0	1	1	0	1	1	1	0	0	0	0	1	0	12
				10	2	0	0	0	1	1	2	2	1	2	2	1	0	1	2	1	0	1	0	0	2	18
				12	2	0	0	0	1	1	2	1	1	1	2	1	0	1	2	1	0	1	0	0	1	16
				14	1	0	0	0	1	1	1	1	1	1	0	1	1	1	1	0	2	1	0	0	1	16

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

9550077

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
1	1	MGA	0	2	2	2	1	2	2	1	2	2	3	19		
			1	2	2	1	2	2	2	2	2	3	1	2	19	
			2	2	1	1	1	1	1	1	2	1	1	1	13	
			3	2	1	1	1	0	1	1	1	1	1	1	12	
			4	1	1	1	0	1	1	1	1	1	1	1	9	
			5	1	1	0	1	1	1	1	1	1	1	1	0	7
1	2	BAQ	6	1	1	1	0	1	1	0	1	1	1	0	7	
			0	2	2	3	1	2	2	2	2	2	1	3	21	
			1	3	2	3	1	2	2	2	2	2	2	3	23	
			2	1	1	2	1	2	2	2	2	2	2	2	1	15
			3	1	1	1	0	1	1	1	1	1	2	1	0	9
			0	2	2	3	1	2	2	2	2	1	1	3	3	20
1	3	TA	1	2	2	3	1	2	2	2	1	1	3	3	22	
			2	2	2	3	2	2	2	2	2	2	2	3	22	
			1	2	1	1	1	1	1	1	2	1	2	1	2	14
			2	1	1	1	1	1	1	1	2	1	2	1	2	14
			3	1	1	2	0	1	1	1	1	1	1	1	0	7
			4	1	1	1	0	1	1	1	1	1	1	1	0	7
1	4	DNC	5	1	1	1	0	1	1	0	1	1	1	0	7	
			6	1	1	1	0	1	1	0	1	1	1	1	0	7
			0	2	3	2	1	2	2	2	2	2	2	3	1	20
			1	2	2	2	2	2	2	2	2	1	3	3	3	22
			2	2	1	1	1	2	1	1	1	2	2	2	1	15
			3	1	1	2	0	1	1	1	1	1	1	2	0	10
1	5	DB	4	1	1	1	0	1	2	1	1	1	1	0	9	
			5	1	1	1	0	1	1	1	1	1	1	1	0	7
			6	1	1	1	0	1	1	1	1	1	1	1	0	8
			0	3	2	3	1	2	2	2	2	2	3	2	2	22
			1	3	2	1	1	2	2	2	2	2	3	2	2	21
			2	3	1	1	0	2	2	2	2	2	2	2	0	13
1	6	CPH	3	2	1	1	0	1	1	0	1	1	1	0	10	
			4	1	1	0	0	1	0	0	0	1	1	0	4	
			5	1	1	0	0	0	1	1	1	0	1	1	0	6
			6	1	1	1	0	0	1	1	1	0	1	1	0	7
			0	3	2	3	1	2	2	2	2	2	3	2	2	22
			1	2	2	2	1	1	2	2	2	2	2	2	2	18
1	7	JSA	2	2	2	2	1	2	2	2	2	2	2	0	17	
			3	1	1	1	2	2	2	2	1	1	1	1	12	
			4	2	1	1	0	2	1	1	1	1	2	2	1	13
			5	1	1	1	0	1	1	1	1	1	2	2	1	11
			6	1	1	1	0	1	1	1	1	1	2	2	0	10
			0	3	2	3	2	2	2	2	2	2	3	3	3	25
1	2		1	3	2	3	1	2	3	2	2	3	2	24		
			2	2	1	1	2	2	1	1	1	2	2	2	16	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
1	7	JSA	3	2	3	2	1	2	2	2	2	2	3	21
1	8	MVB	0	3	2	3	1	2	2	2	3	2	3	23
			1	3	2	2	0	2	3	2	3	2	2	22
			2	2	1	1	0	2	1	1	1	2	3	15
			3	1	1	1	0	2	1	1	1	1	1	10
			4	1	1	1	0	1	1	0	1	1	1	8
			5	1	1	1	0	1	1	1	1	1	0	8
			6	1	1	1	0	1	1	0	1	2	0	8
1	9	CCR	0	3	3	3	1	2	2	2	3	2	3	24
			1	2	2	3	1	2	2	2	3	2	3	22
			2	1	2	1	0	2	1	1	2	1	1	13
			3	2	2	1	0	1	1	1	2	2	0	12
			4	1	1	1	0	1	1	0	1	1	0	7
			5	1	1	0	0	1	0	0	1	1	0	5
			6	0	1	0	0	1	0	0	1	1	0	4
1	10	LDL	0	3	2	3	1	3	2	2	2	3	3	24
			1	3	2	2	1	3	2	2	2	2	2	21
			2	2	1	1	0	2	1	2	1	2	1	14
			3	1	1	1	0	1	1	1	2	1	0	9
			4	1	2	0	0	0	0	0	1	1	0	5
			5	0	1	0	0	0	0	0	0	1	0	2
			6	0	1	0	0	0	0	0	0	1	0	2
1	11	VRT	0	3	2	3	2	2	3	1	2	3	2	23
			1	2	3	3	2	2	3	2	2	3	2	24
			2	3	2	2	2	2	3	2	2	3	2	24
			3	2	2	2	2	2	2	2	2	2	2	21
			4	2	2	1	0	2	2	1	2	2	1	15
			5	2	2	1	0	2	2	1	1	1	1	12
			6	1	1	0	0	1	0	0	1	1	0	5
1	12	SLT	0	3	3	2	2	2	2	1	2	2	3	22
			1	3	3	2	2	2	2	2	2	2	2	22
			2	3	3	2	2	2	1	1	2	2	1	19
			3	2	1	2	1	2	1	1	2	1	1	13
			4	1	2	1	0	1	1	0	1	1	0	8
			5	1	1	0	0	1	1	0	1	1	0	6
			6	1	1	0	0	1	0	0	1	1	0	5
1	13	JR	0	3	3	3	2	2	2	1	2	3	2	23
			1	3	3	3	2	2	2	2	2	2	2	23
			2	2	3	2	2	2	3	2	2	2	2	22
1	14	MLC	0	3	3	3	2	2	2	1	2	2	2	22
			1	3	3	2	2	3	2	2	2	2	2	23

994

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.2
 MONTGOMERY ASBERG DEPRESSION RATING SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
1	20	EFC	2	2	2	2	1	2	2	1	2	2	2	18		
			3	2	2	1	2	2	2	1	2	1	1	15		
			4	2	2	1	2	2	2	2	2	1	2	1	16	
			5	2	2	1	2	2	2	2	2	1	2	1	17	
			6	1	2	1	0	1	1	1	1	0	1	1	9	
			0	2	2	2	1	2	3	2	3	1	3	2	2	20
1	21	VMC	1	3	2	1	2	2	2	2	1	2	2	2	19	
			2	2	2	1	2	2	2	2	1	1	2	1	15	
			3	2	2	1	2	2	2	2	2	1	2	1	17	
			4	2	1	0	2	2	2	2	2	1	2	1	0	12
			5	1	2	1	0	1	1	1	1	0	1	1	0	8
			6	1	1	0	1	1	1	1	1	0	0	1	0	6
1	22	SK	0	3	2	1	2	2	2	2	1	2	2	1	17	
			1	3	2	1	2	2	2	2	2	1	2	2	1	16
			2	2	2	2	2	2	2	2	2	1	2	2	2	17
			3	2	2	1	2	2	2	2	2	1	2	2	2	14
			4	1	2	0	1	1	0	0	0	0	2	1	0	7
			5	1	2	0	0	1	1	1	1	0	1	1	0	7
1	23	AR	0	2	2	1	2	2	2	2	1	2	1	1	15	
			1	2	2	1	2	2	2	2	2	2	2	2	1	18
			2	2	3	1	2	2	2	2	2	1	2	2	2	19
			3	2	3	2	2	2	2	2	2	1	2	2	1	18
			4	2	3	2	1	2	3	3	3	1	2	2	2	20
			0	2	2	1	2	2	2	2	2	1	2	2	1	18
1	24	LVF	1	2	2	2	2	2	3	3	1	2	2	2	19	
			2	2	2	1	1	0	1	1	1	1	2	0	11	
			3	2	1	0	1	1	1	1	1	1	1	1	0	9
			4	1	2	1	0	1	1	1	1	1	1	2	0	10
			5	1	2	0	1	1	1	1	1	1	1	1	0	8
			6	1	1	0	0	1	1	1	1	0	1	1	0	6
1	25	AMR	0	3	2	1	3	3	2	2	1	2	2	2	20	
			1	2	2	1	2	2	2	2	2	1	2	2	18	
			2	1	2	0	1	1	1	1	1	1	1	1	0	9
			3	2	1	0	1	1	1	1	1	1	1	2	1	11
			4	2	2	1	0	2	2	2	2	1	1	2	0	13
			5	1	2	1	0	1	1	1	1	1	1	1	0	9
1	26	OC	0	3	2	2	3	3	3	3	2	2	2	2	24	
			1	2	2	1	2	2	1	2	1	2	2	1	15	
			2	1	2	1	1	1	0	1	1	0	1	1	12	
			3	2	2	1	0	2	2	2	2	1	1	2	0	13

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOMETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
1	26	OC	4	1	1	0	1	1	1	1	0	1	0	7
			5	1	1	0	0	1	1	0	0	1	0	5
			6	1	1	0	0	1	1	0	0	1	0	5
1	27	RK	0	2	3	2	1	3	2	2	2	3	2	22
			1	3	3	2	1	2	2	1	2	3	2	21
			2	2	2	1	1	1	2	2	2	2	0	15
			3	2	2	1	1	1	1	1	1	1	1	12
			4	2	2	1	0	1	1	1	0	1	0	9
			5	1	2	1	0	1	1	0	1	1	0	8
			6	1	1	0	0	0	1	0	0	1	0	4
1	28	RHM	0	2	3	2	1	2	2	1	2	2	1	18
			1	2	2	2	1	2	2	2	2	2	1	18
			2	2	2	1	1	2	2	1	1	2	0	15
			3	2	2	1	1	2	2	1	2	2	1	16
			4	2	2	1	0	2	1	1	1	2	0	12
			5	1	2	1	0	1	1	0	1	1	0	8
			6	1	1	1	0	1	1	0	1	1	0	7
1	29	AFO	0	3	2	2	2	2	2	1	2	2	2	20
			1	2	2	2	1	2	2	2	2	2	1	19
			2	2	2	2	1	2	2	1	2	2	1	17
			3	2	2	2	1	2	2	1	3	1	1	17
			4	2	1	1	0	1	1	0	1	1	0	8
			5	1	2	1	1	2	1	1	1	2	1	13
			6	1	1	1	0	1	0	1	1	2	0	8
1	30	ERV	0	2	3	2	2	3	2	2	2	2	1	20
			1	2	3	2	1	2	2	2	2	2	1	18
			2	2	2	2	1	2	2	1	2	3	0	17
			3	2	2	1	0	1	1	1	2	1	0	10
			4	2	2	1	0	1	1	0	1	2	0	9
			5	2	2	1	1	1	1	0	1	1	1	11
			6	1	1	0	0	1	1	1	0	0	0	5
1	31	MAM	0	2	2	3	2	2	2	1	1	2	1	18
			1	3	2	2	1	2	2	1	2	2	0	18
			2	2	2	1	0	1	0	1	3	2	0	12
			3	2	2	1	0	2	1	1	1	2	0	13
			4	0	1	0	0	1	0	1	1	2	0	9
			5	1	1	0	0	1	0	0	1	1	0	5
			6	1	1	0	0	1	0	0	1	1	0	5
1	32	DGM	0	3	3	3	2	2	3	2	2	3	2	25
			1	3	3	2	1	2	3	1	2	2	1	20
			2	2	1	1	0	1	1	1	1	2	1	11
			3	2	2	1	1	2	1	1	1	2	1	14

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
1	32	DCH	4	1	2	0	0	1	1	0	1	1	0	7		
			5	1	2	1	0	1	1	1	1	1	0	9		
			6	1	1	1	0	1	0	0	0	0	1	0	6	
			0	2	2	1	2	2	2	2	2	1	2	1	17	
			1	3	2	1	2	2	2	2	2	2	2	2	20	
			2	2	1	2	2	2	2	2	2	1	2	2	1	16
1	33	OFC	3	2	2	1	1	1	1	1	1	2	0	0	13	
			4	1	2	1	1	1	0	1	1	2	2	0	9	
			5	1	1	0	1	1	1	1	1	0	1	0	6	
			6	1	1	0	0	1	1	1	1	0	1	0	6	
			0	3	2	2	2	2	2	2	2	1	3	2	23	
			1	3	2	2	2	2	2	2	2	1	3	1	21	
1	34	GNH	2	3	3	2	1	2	2	1	2	2	3	1	20	
			3	2	3	2	1	2	2	2	1	2	2	1	16	
			4	2	2	1	2	2	2	2	1	1	2	2	3	16
			5	1	2	1	1	2	1	1	1	0	2	2	2	11
			6	0	1	0	0	1	1	1	1	1	1	2	0	7
			0	3	2	2	2	2	2	2	2	2	2	2	1	21
1	35	EMP	1	2	2	1	1	1	1	1	1	1	2	1	14	
			2	2	2	1	1	1	1	1	1	1	2	0	11	
			3	1	2	0	1	0	0	0	0	0	1	0	8	
			4	1	2	0	1	1	1	1	1	1	1	1	0	6
			5	0	1	0	0	1	1	1	1	0	1	2	0	6
			6	0	1	0	0	1	1	1	1	0	0	1	0	3
1	36	LM	0	3	3	2	3	3	2	2	2	2	3	0	22	
			1	3	2	1	2	2	2	2	1	2	2	3	20	
			2	2	2	1	2	2	2	2	2	2	1	2	2	16
			3	2	2	1	2	2	2	2	1	2	2	2	2	15
			4	1	2	0	0	2	1	1	1	1	1	2	0	9
			5	1	2	0	0	1	1	1	1	0	1	2	0	8
1	37	RF	6	1	1	0	0	1	0	0	1	1	1	0	6	
			0	3	3	2	3	2	2	2	2	2	1	2	0	18
			1	2	2	1	2	2	2	2	2	1	1	2	0	14
			2	2	2	1	2	2	2	2	2	1	2	2	0	14
			3	0	2	0	2	2	1	2	1	0	2	2	0	9
			4	0	1	0	0	0	0	0	0	0	1	2	0	4
1	38	DBF	5	1	2	0	1	1	1	1	1	1	2	0	9	
			6	0	2	0	0	1	1	0	0	0	1	0	4	
			0	3	3	2	3	2	2	2	2	2	2	3	1	23
			1	3	3	2	2	2	2	2	2	2	2	2	1	21
			2	2	2	1	2	2	2	2	2	1	2	2	0	14
			3	1	1	1	0	1	1	1	1	1	1	2	0	9

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASEBEG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
1	38	DBF	4	2	2	1	0	1	1	0	1	2	0	10		
			5	1	2	0	1	1	0	0	1	1	0	7		
			6	1	1	0	0	1	0	0	0	1	1	0	5	
			0	3	3	2	2	2	2	2	2	1	2	1	20	
			1	2	2	1	2	2	2	2	2	2	2	1	19	
			2	2	2	1	2	2	2	2	2	2	2	1	17	
1	39	ASS	3	1	2	1	0	1	2	1	2	1	0	9		
			4	2	2	0	1	1	2	1	1	1	0	11		
			5	1	1	1	1	1	1	1	1	1	1	0	9	
			6	1	1	1	0	1	1	1	1	1	1	0	9	
			0	3	3	2	2	2	2	2	2	2	2	1	24	
			1	3	2	1	2	2	2	2	2	2	2	2	17	
1	40	EM	2	2	2	1	1	2	1	1	1	2	0	13		
			3	2	2	1	1	1	1	1	1	2	0	11		
			4	1	2	1	1	1	1	1	1	1	2	0	10	
			5	0	1	0	0	1	1	1	1	1	1	0	4	
			6	1	1	0	0	1	0	1	0	0	0	1	0	4
			0	3	3	2	2	2	2	2	2	2	2	2	23	
1	41	SFS	1	3	2	1	1	2	1	1	1	2	1	1	16	
			2	2	2	1	1	1	1	1	1	1	2	0	9	
			3	1	2	1	0	2	1	1	1	0	0	1	11	
			4	1	2	0	0	1	1	1	1	0	1	1	7	
			5	1	1	0	0	1	1	1	1	0	1	1	6	
			6	0	1	0	0	1	0	1	0	0	1	1	0	4
1	42	ICC	0	3	3	2	2	3	2	2	2	2	3	1	22	
			1	3	2	1	2	2	1	1	1	2	2	1	17	
			2	2	2	1	2	2	2	2	2	2	2	2	1	16
			3	2	2	1	0	1	1	1	1	1	2	1	1	12
			4	1	2	1	0	1	1	1	1	1	1	2	0	9
			5	1	2	0	0	1	0	1	0	0	1	1	0	6
1	43	ARN	0	3	3	1	1	2	2	2	2	3	3	0	20	
			1	3	2	1	1	2	2	1	1	2	2	0	15	
			2	2	2	1	1	2	1	1	1	2	1	2	1	14
			3	2	2	1	0	1	1	1	1	1	1	1	0	9
			4	2	2	1	0	2	1	1	1	1	1	2	0	12
			5	1	2	0	0	2	1	1	1	1	1	2	0	9
1	44	MAL	0	3	3	2	2	3	3	2	3	2	0	23		
			1	3	3	2	2	3	2	2	2	2	0	21		
			2	3	2	1	2	2	2	2	2	2	0	19		
3	2	2	2	1	2	2	1	2	2	2	2	0	16			

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.2
 MONTGOMERY ASBERG DEPRESSION RATING SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
1	44	MAL	4	2	2	2	0	2	1	1	1	2	0	13		
			5	2	2	1	0	2	1	1	1	1	2	0	12	
			6	3	3	2	2	3	3	3	2	2	2	0	22	
			0	3	3	2	1	3	2	3	2	1	2	1	21	
			1	2	2	0	1	1	1	1	0	0	1	2	0	9
			2	2	0	1	1	1	1	1	0	0	1	2	0	10
1	45	DPS	3	0	2	0	0	1	0	0	0	1	0	5		
			4	0	2	0	0	1	0	0	0	1	1	0	5	
			5	0	2	0	0	1	0	1	0	0	1	0	4	
			6	0	1	0	0	1	0	0	0	0	0	0	3	
			0	3	2	2	3	2	2	2	1	1	2	2	2	21
			1	3	1	1	2	2	2	2	3	2	2	2	1	19
1	46	SP	2	3	3	2	1	2	2	2	2	2	2	3	21	
			3	2	2	2	1	2	2	2	2	2	2	2	19	
			4	2	2	1	2	2	1	2	1	1	2	0	13	
			5	1	1	0	0	2	1	1	0	0	1	2	0	10
			6	1	2	0	0	2	1	2	0	0	0	2	0	8
			0	1	2	0	1	1	1	1	1	0	1	2	0	8
1	47	MCS	0	3	3	1	1	2	3	3	1	2	2	1	19	
			1	3	2	0	1	2	1	2	1	1	2	1	18	
			2	2	2	0	1	2	1	2	1	0	1	2	1	12
			3	1	2	0	1	2	1	2	1	0	1	2	1	11
			4	1	1	0	0	1	1	1	1	0	1	1	0	6
			5	1	1	0	0	1	1	1	1	0	1	1	0	5
1	48	SCM	6	0	1	0	0	1	0	0	0	0	1	0	3	
			0	3	2	1	3	2	2	3	2	1	2	0	19	
			1	3	2	1	2	2	2	2	2	1	2	0	15	
			2	2	1	0	2	2	2	2	2	0	2	3	0	14
			3	1	2	0	2	2	1	2	1	0	2	3	0	10
			4	1	2	0	1	1	1	1	1	0	0	3	0	8
1	49	DAS	5	1	1	0	0	0	0	0	0	0	2	0	4	
			6	1	1	0	0	0	0	0	0	0	1	0	3	
			0	3	2	2	2	2	3	2	3	2	2	2	1	21
			1	3	2	1	1	2	2	2	2	2	2	2	1	17
			2	3	2	1	2	3	3	3	2	2	3	3	3	23
			3	3	2	1	2	2	2	2	2	2	2	2	2	22
1	50	MFA	0	3	3	2	1	2	3	3	2	2	2	2	22	
			1	3	2	2	2	2	2	2	2	1	2	3	21	
			2	2	2	1	1	2	2	2	2	1	2	2	3	16
			3	2	2	1	1	2	1	1	1	1	2	2	1	14
			4	2	2	1	0	1	1	1	1	0	1	2	0	10
			5	1	2	1	0	1	1	1	1	0	1	1	0	7
6	0	1	2	0	0	1	1	0	0	1	1	0	4			

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASEBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
1	57	SMC	2	3	2	2	1	2	2	1	2	2	1	18
			3	3	2	1	1	2	2	1	2	2	1	17
1	58	ARM	0	3	3	2	1	2	2	1	2	2	1	19
			1	3	2	1	1	2	2	1	2	2	1	17
			2	3	2	1	1	2	2	1	2	2	1	17
			3	2	2	1	1	2	2	1	2	2	1	15
			4	2	2	1	1	2	2	1	2	2	1	17
			5	1	1	1	1	1	2	1	2	1	0	10
			6	1	2	1	0	1	1	1	1	1	0	9
1	59	SPF	0	3	3	2	1	2	2	1	2	2	1	19
			1	3	2	1	1	2	2	1	2	2	1	18
			2	2	2	1	1	2	2	1	2	2	1	16
			3	2	2	1	0	2	2	1	2	2	1	15
			4	1	2	1	0	2	1	0	1	2	0	10
			5	1	1	0	0	1	1	1	1	1	0	7
			6	0	2	0	0	1	1	0	1	2	0	7
1	60	EM	0	3	3	2	1	2	3	2	2	3	2	23
			1	3	3	3	1	3	3	2	2	3	2	25
			2	3	3	2	1	3	2	2	2	3	2	23
			3	2	2	2	1	3	2	2	2	3	1	20
			4	2	2	1	0	2	1	1	1	2	0	12
			5	2	2	1	0	2	1	1	1	1	1	11
			6	1	2	1	0	2	1	1	1	2	1	12
1	61	HVC	0	2	2	2	1	2	2	1	2	3	0	17
			1	2	2	1	1	2	2	2	1	3	0	17
			2	2	2	1	1	2	2	2	1	3	0	16
			3	1	2	1	0	2	2	1	2	2	0	13
			4	1	2	0	0	1	1	1	1	2	2	11
			5	1	1	0	0	1	1	0	0	2	0	6
			6	1	1	0	0	1	1	1	2	2	2	11
1	62	MEA	0	3	3	2	1	2	2	2	2	2	1	21
			1	3	2	2	1	2	3	1	2	2	1	19
			2	2	2	1	1	2	2	2	2	2	2	19
			3	2	2	1	1	1	2	1	2	2	2	16
			4	1	2	1	1	2	1	1	1	2	1	13
			5	1	1	1	0	2	1	0	1	1	1	9
			6	0	1	0	0	1	0	0	0	1	0	3
1	63	JCL	0	3	3	3	2	1	2	1	2	2	0	19
			1	3	3	2	2	2	2	2	1	2	0	19
			2	2	2	1	1	2	2	2	1	2	1	17
			3	2	2	1	1	2	2	2	2	3	2	19

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD

REBOMETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
1	64	ENF	0	3	3	2	2	3	2	2	2	3	2	24		
			1	3	2	2	3	3	2	2	2	2	2	23		
			2	1	1	0	1	0	0	0	0	0	1	0	5	
			3	0	1	0	0	0	0	0	0	0	1	0	5	
			4	1	1	0	0	0	0	0	0	0	1	0	4	
			5	0	1	0	0	0	0	0	0	0	1	0	5	
1	65	FS	6	0	1	0	0	0	0	0	0	1	0	2		
			0	3	3	2	1	3	3	2	2	2	3	3	25	
			1	3	3	2	1	3	3	2	2	2	3	3	25	
			2	2	2	2	1	2	2	2	2	2	2	2	22	
			3	2	2	1	1	2	2	2	2	1	2	1	16	
			4	1	2	1	0	1	1	1	1	1	1	2	1	11
1	66	TCG	5	2	2	2	2	2	2	2	1	2	2	2	19	
			6	3	3	2	1	2	2	2	1	1	3	2	20	
			0	3	3	2	2	3	3	3	3	2	3	2	26	
			1	2	2	1	1	2	2	2	2	2	2	2	21	
			2	2	2	1	1	2	2	2	2	1	2	1	16	
			3	2	2	1	1	2	2	2	2	1	2	1	14	
1	67	MAA	4	1	2	0	0	1	0	0	0	1	2	0	7	
			5	1	1	0	0	1	1	1	1	1	2	0	7	
			6	0	1	0	0	1	1	1	0	0	1	1	0	4
			0	2	3	2	1	2	2	2	3	1	2	3	0	19
			1	2	2	1	2	2	2	2	2	2	2	3	0	18
			2	3	2	1	2	2	2	2	3	2	2	3	0	20
1	68	MGS	3	2	2	2	1	2	3	3	2	2	2	0	17	
			4	2	2	1	1	1	1	1	1	2	2	0	13	
			5	1	2	0	0	2	2	1	1	1	1	2	0	10
			6	1	2	0	0	2	2	2	1	0	1	2	0	9
			0	2	3	1	2	2	2	2	3	1	2	3	2	21
			1	2	2	1	2	2	2	2	2	2	1	3	2	19
1	69	RFA	2	3	3	2	2	3	3	3	2	2	3	1	19	
			3	3	3	1	3	3	3	3	2	2	3	1	22	
			4	3	3	2	2	2	2	2	2	2	2	2	2	22
			5	3	3	2	2	2	2	2	2	2	2	2	2	21
			6	3	3	2	1	2	2	2	3	2	1	2	2	20
			0	3	3	2	2	3	3	3	3	2	3	3	2	27
1	69	RFA	1	3	3	3	1	3	3	3	2	3	3	1	25	
			2	3	3	2	2	2	2	2	2	2	2	2	1	23
			3	3	3	2	2	2	2	2	2	1	2	2	1	20
			4	1	2	1	0	2	1	2	1	2	1	2	1	13
			5	2	2	1	1	2	2	2	3	2	3	2	1	21
			6	3	3	2	1	2	2	2	3	2	2	2	1	19

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
1	70	MLK	0	3	3	2	2	3	3	2	2	3	2	25		
			1	3	2	2	1	3	2	2	2	3	2	22		
			2	3	2	2	1	3	3	2	2	2	3	2	22	
			3	2	2	3	1	3	3	2	2	2	2	2	22	
			4	3	3	2	1	3	3	2	2	2	3	2	24	
			5	2	2	1	1	3	2	2	2	2	1	2	1	17
1	71	ONV	6	2	2	1	0	2	2	1	1	2	1	1	14	
			0	3	2	2	1	2	2	2	1	2	2	1	18	
			1	2	2	2	1	2	2	2	2	1	2	1	17	
			2	2	2	2	0	2	2	2	2	1	2	1	15	
			3	2	2	1	0	3	2	2	1	2	2	1	17	
			4	1	2	1	0	1	2	2	0	0	1	2	1	11
1	72	RLJ	5	1	2	0	0	1	2	1	1	1	2	0	9	
			6	1	1	0	0	1	1	1	0	1	2	0	7	
			0	3	2	2	1	3	3	2	2	2	2	3	2	23
			1	2	2	2	1	2	2	2	2	2	2	3	2	20
			2	2	2	2	1	2	2	1	2	2	2	2	2	19
			3	2	2	1	1	2	1	2	1	1	1	2	1	14
1	73	FMA	4	2	2	1	1	2	1	1	1	2	2	1	15	
			5	2	2	1	0	2	1	2	1	1	2	0	12	
			6	1	2	0	0	1	1	1	1	0	1	1	0	7
			0	2	2	2	1	2	3	2	3	2	1	3	1	19
			1	2	2	1	1	2	2	2	2	1	2	2	1	17
			2	3	2	2	0	1	3	3	3	2	1	3	2	22
1	74	IVL	3	2	2	0	0	1	2	2	2	1	3	0	13	
			4	2	2	0	0	1	1	1	0	1	2	0	9	
			5	2	2	1	0	1	1	1	1	1	2	0	11	
			6	1	2	0	0	1	1	1	1	0	1	2	0	8
			0	3	2	2	1	3	3	3	3	2	2	3	2	23
			1	3	2	2	1	3	2	2	2	2	2	3	2	23
1	75	ELF	2	3	2	0	0	2	2	2	2	2	2	1	21	
			3	2	2	0	0	2	2	2	2	2	2	2	17	
			4	2	2	1	0	2	1	1	1	1	2	0	12	
			5	1	1	1	0	2	1	1	1	1	2	0	10	
			6	1	2	0	0	1	1	1	1	1	1	1	0	8
			0	3	3	2	2	3	3	3	3	2	2	2	2	25
1	75	ELF	1	3	3	2	1	3	3	3	2	1	2	2	22	
			2	3	3	2	1	2	2	2	2	2	2	1	20	
			3	2	2	2	1	2	3	1	2	1	2	0	17	
			4	2	2	1	1	2	2	2	2	1	2	1	14	
			5	2	2	1	1	2	1	2	1	1	1	1	0	13
			6	2	2	1	0	2	2	1	1	1	2	1	0	11

1004

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD

REBOMETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
1	76	SFA	0	3	3	2	1	3	2	2	2	2	2	22		
			1	2	3	2	1	2	2	2	1	2	2	1	18	
			2	2	3	1	2	1	2	2	2	1	2	1	1	15
			3	2	2	1	2	1	2	2	2	1	2	1	1	16
			4	2	2	1	1	1	1	1	1	1	2	1	1	12
			5	1	1	1	0	1	0	1	0	0	1	1	0	6
1	77	ACG	0	0	1	0	0	0	0	0	1	1	1	0	3	
			1	3	3	2	3	2	3	3	1	2	2	2	2	23
			2	3	3	1	3	2	3	3	2	2	2	2	1	20
			3	3	3	1	3	2	3	3	2	1	3	2	2	22
			4	2	2	1	3	2	1	2	2	1	2	0	0	16
			5	2	2	1	1	2	1	2	2	1	1	2	0	14
1	78	SD	0	1	2	1	0	1	1	1	1	1	1	0	9	
			1	3	3	2	2	3	3	3	2	2	2	2	2	23
			2	3	3	2	2	3	3	3	3	2	3	2	3	25
			3	3	3	1	3	3	1	3	2	1	3	2	3	25
			4	3	3	1	3	3	2	3	2	2	2	2	3	24
			5	3	3	2	1	3	2	3	2	2	2	2	3	23
1	79	JCM	0	3	3	3	1	2	3	3	2	2	2	3	24	
			1	3	3	2	3	3	3	3	1	2	2	2	2	24
			2	2	2	1	3	2	3	3	2	1	2	2	2	23
			3	2	2	1	3	2	3	3	2	1	2	2	1	18
			4	2	2	0	0	2	2	2	2	1	2	2	1	17
			5	0	1	0	0	2	2	2	2	1	1	2	1	13
1	80	MEL	0	0	2	0	0	2	1	1	0	1	2	1	9	
			1	3	3	1	2	2	3	3	2	2	2	2	1	20
			2	3	3	1	2	2	2	2	2	1	2	2	1	21
			3	2	3	1	2	2	2	2	2	0	2	2	1	17
			4	2	3	1	1	2	0	2	2	0	2	2	1	16
			5	2	2	1	0	2	1	2	1	0	1	2	1	12
1	81	HFB	0	1	1	1	0	1	1	1	0	1	2	1	11	
			1	3	3	2	3	2	3	3	3	1	2	2	1	24
			2	3	3	2	3	2	3	3	3	1	3	3	1	23
			3	2	2	1	3	2	1	3	2	0	2	2	1	18
			4	2	2	1	1	3	2	2	2	0	1	2	1	15
			5	2	2	1	0	2	1	2	1	0	1	2	1	12
1			6	1	1	0	1	1	1	0	1	1	1	9		
			6	1	1	0	1	0	1	1	0	1	1	1	7	

1005

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
1	82	MDS	0	3	3	2	1	3	2	2	2	3	1	22		
			1	3	3	2	1	3	2	1	2	2	2	1	20	
			2	2	2	1	3	1	3	2	2	1	2	1	17	
			3	2	1	1	2	2	2	2	2	2	2	1	15	
			4	1	1	0	2	1	2	1	1	1	2	1	11	
			5	1	1	0	1	1	1	1	1	1	1	2	0	10
1	83	LFM	0	3	3	2	0	1	1	0	0	1	2	0	7	
			1	3	3	2	2	3	3	3	2	2	2	2	25	
			2	3	3	2	3	2	3	3	2	2	2	2	2	24
			3	3	3	2	3	3	3	3	3	2	2	2	2	25
			4	3	3	3	2	3	3	3	2	2	2	2	2	26
			5	3	3	3	2	3	3	3	3	2	2	2	2	27
1	84	IN	0	3	3	3	2	3	3	2	2	3	3	3	28	
			1	3	3	1	2	3	2	2	1	2	2	2	1	19
			2	2	2	1	2	1	2	2	2	1	2	2	0	17
			3	2	2	0	2	1	2	2	1	1	1	1	0	15
			4	0	2	0	0	1	1	1	0	0	0	1	0	4
			5	0	2	0	0	1	0	0	0	0	0	1	0	4
1	85	MLP	0	3	3	0	0	1	0	0	0	0	1	0	4	
			1	3	2	2	2	2	2	2	2	2	2	2	24	
			2	2	2	1	2	2	2	2	2	2	2	2	2	22
			3	2	1	1	2	2	2	2	2	1	2	2	1	16
			4	2	1	0	0	2	1	1	1	1	1	2	1	13
			5	1	1	0	0	2	1	1	1	1	1	2	1	11
1	86	MTF	0	1	1	0	0	2	1	1	1	1	2	1	10	
			1	1	1	0	1	1	1	1	1	1	1	2	1	9
			2	2	2	2	2	2	2	2	2	2	2	2	2	19
			3	2	3	1	2	3	3	3	3	3	3	3	3	19
			4	3	3	2	2	3	2	2	2	2	2	3	2	22
			5	3	3	2	2	3	2	2	2	2	2	2	2	24
1	87	MDO	0	3	3	3	2	3	3	2	2	2	3	1	24	
			1	3	3	2	3	3	3	3	3	3	3	3	1	26
			2	3	3	2	3	3	3	3	3	3	3	3	2	27
			3	2	2	1	3	2	2	2	2	2	2	2	3	23
			4	2	2	1	1	3	1	1	1	1	1	1	2	15
			5	1	1	1	1	2	1	1	1	1	2	1	0	13
1	88	MDO	0	1	1	1	1	1	1	1	1	1	1	1	9	
			1	1	1	1	1	1	1	1	1	1	1	1	0	
			2	1	1	1	1	1	1	1	1	1	1	1	0	
			3	1	1	1	1	1	1	1	1	1	1	1	0	
			4	1	1	1	1	1	1	1	1	1	1	1	0	
			5	1	1	1	1	1	1	1	1	1	1	1	0	

1006

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
1	88	VRL	0	3	3	3	2	2	3	2	3	3	2	2	26	
			1	3	3	2	1	2	3	2	2	3	2	1	22	
			2	2	2	1	2	2	1	2	1	2	1	2	1	16
			3	2	2	1	2	2	1	2	2	1	2	1	1	17
			4	2	2	1	3	3	1	3	3	2	2	3	1	21
			5	2	2	1	3	2	2	2	2	1	2	3	1	20
1	89	NHV	6	2	3	2	1	3	2	2	2	3	3	1	21	
			0	3	3	2	3	3	3	3	2	3	2	2	1	25
			1	3	3	1	3	3	2	3	2	2	2	2	1	23
			2	3	2	1	3	1	3	2	3	1	2	2	1	18
			3	2	2	1	2	2	1	2	2	1	2	2	1	16
			4	1	2	1	1	2	1	1	1	1	1	2	0	12
1	90	JSS	5	1	2	1	1	2	1	1	1	1	2	0	11	
			6	1	2	1	1	2	1	1	1	1	2	0	12	
			0	2	3	1	2	2	1	2	3	2	2	2	2	21
			1	2	3	2	2	3	2	2	3	1	2	2	2	21
			2	3	3	1	2	2	2	2	2	1	2	2	2	18
			3	2	3	1	2	2	2	2	2	1	3	3	1	16
1	91	MSC	4	1	2	1	1	1	1	1	1	1	3	1	13	
			5	1	1	1	1	1	1	1	1	1	3	1	12	
			6	1	1	1	1	0	1	1	1	1	1	2	1	10
			0	3	3	2	3	3	2	3	2	2	3	2	1	24
			1	3	2	2	2	3	2	2	2	2	2	2	1	21
			2	2	2	1	2	2	2	2	2	1	2	2	1	17
1	92	PSS	3	2	2	1	2	2	1	1	1	2	2	1	14	
			4	2	2	1	1	1	1	1	1	1	2	0	11	
			5	1	2	0	0	1	1	1	1	0	1	2	0	8
			6	1	1	1	0	1	1	1	1	1	1	2	0	9
			0	3	3	2	3	3	2	3	3	2	3	2	1	23
			1	3	3	2	2	3	2	2	2	2	3	2	2	25
1	93	AL	2	2	3	2	2	2	2	2	2	2	2	2	20	
			3	3	3	1	2	2	2	2	2	2	2	2	21	
			4	3	3	2	2	2	2	2	3	2	2	2	2	23
			5	3	3	2	2	2	2	2	3	2	2	2	2	22
			6	3	3	2	2	2	2	2	2	1	2	2	2	20
			0	2	3	2	2	2	2	2	2	2	2	2	2	23
1	93	AL	1	2	1	1	2	3	2	2	2	2	3	2	19	
			2	2	1	1	2	2	1	2	1	1	2	3	0	14
			3	2	1	0	1	1	0	1	1	0	1	3	0	10
			4	1	1	1	1	1	1	1	1	1	1	3	0	9
			5	1	1	0	0	1	1	1	1	0	1	3	0	8
			6	1	1	1	0	1	1	1	1	0	1	3	0	9

1007

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.2
 MONTGOMERY ASBERG DEPRESSION RATING SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
1	94	RAB	0	2	3	2	1	3	2	2	2	2	1	20		
			1	3	2	2	1	3	2	2	2	2	2	1	19	
			2	3	1	1	3	1	3	2	2	1	2	0	16	
			3	2	1	1	2	1	2	2	2	1	2	0	13	
			4	2	2	1	2	1	2	1	1	1	2	0	13	
			5	1	1	0	0	1	1	1	1	0	1	2	0	8
1	95	GNT	6	1	1	1	0	1	1	1	1	2	0	8		
			0	2	3	3	0	2	3	3	2	3	2	1	21	
			1	2	3	2	0	2	2	2	2	2	2	1	18	
			2	2	2	2	0	2	2	2	2	2	2	0	16	
			3	2	2	1	0	2	2	2	2	1	2	0	14	
			4	2	2	1	0	1	2	1	1	1	1	0	12	
1	96	SPW	5	1	1	0	0	1	1	1	0	1	2	0	7	
			6	0	1	0	0	1	1	1	0	0	1	2	6	
			0	3	3	2	2	2	3	2	2	2	2	1	22	
			1	3	2	1	3	2	3	2	2	2	2	1	22	
			2	2	3	2	1	2	2	2	2	1	2	1	18	
			3	2	2	1	2	1	2	1	1	1	1	1	14	
1	97	MND	4	2	1	1	0	2	1	1	1	1	2	1	12	
			5	1	1	1	0	1	1	1	1	1	2	1	10	
			6	1	1	1	0	1	1	1	1	1	1	1	10	
			0	3	3	2	2	2	2	2	2	2	2	1	20	
			1	3	3	1	2	2	2	2	2	1	1	2	2	19
			2	2	2	1	2	2	2	2	2	1	1	1	2	15
1	98	YTT	3	2	2	1	1	2	1	1	1	1	1	1	13	
			4	1	1	1	1	2	1	1	1	1	1	0	10	
			5	0	1	0	0	1	1	1	1	0	1	1	5	
			6	0	1	0	0	0	1	1	1	0	1	1	4	
			0	3	3	2	2	2	3	2	3	2	3	2	23	
			1	3	3	2	2	2	2	2	2	2	2	2	20	
1	99	LGD	2	2	2	1	2	2	1	1	1	1	2	1	15	
			3	2	2	1	2	1	2	1	1	2	1	1	15	
			4	1	1	1	2	1	1	1	1	1	1	1	12	
			5	1	1	1	1	1	1	1	1	1	1	1	11	
			6	1	1	1	1	1	1	1	1	1	1	2	1	11
			0	3	2	3	1	3	3	3	3	2	3	2	2	23
1	100	∞	1	3	3	3	1	3	2	2	2	3	2	2	23	
			2	3	3	3	1	3	2	2	2	2	2	2	20	
			3	3	3	2	1	2	2	2	2	2	2	2	22	
			4	3	3	3	1	3	2	2	2	2	2	2	22	
			5	3	3	3	2	1	3	2	2	2	2	2	20	
			6	3	3	1	1	3	2	2	2	2	2	2	20	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
1	100	JHA	0	3	3	2	2	3	2	1	3	2	1	22		
			1	3	3	2	3	2	1	2	1	1	2	1	19	
			2	3	3	1	3	1	3	1	1	1	2	1	17	
			3	2	2	1	1	0	1	1	1	1	2	1	12	
			4	1	1	0	0	1	1	1	1	1	2	1	10	
			5	1	1	0	0	1	1	1	1	1	2	1	10	
1	101	JLL	0	0	1	0	0	1	1	0	1	2	1	1	7	
			1	2	3	2	2	1	2	3	2	2	2	2	21	
			2	1	2	1	2	1	1	1	1	2	2	1	15	
			3	0	2	0	1	0	1	0	1	1	2	1	10	
			4	0	2	0	0	1	0	0	1	0	2	0	6	
			5	0	2	0	0	1	0	0	1	1	1	0	0	7
1	102	ESF	0	0	1	0	0	1	0	0	0	1	1	0	4	
			1	3	3	2	2	2	2	3	2	2	2	1	22	
			2	3	3	2	3	2	3	3	3	2	2	2	2	24
			3	2	2	2	2	2	2	2	2	2	2	2	1	22
			4	2	2	1	1	2	2	2	2	1	2	2	1	17
			5	2	2	2	1	2	2	2	2	2	2	2	1	17
1	103	JRA	0	3	3	2	2	2	2	2	2	1	2	1	15	
			1	3	3	2	2	2	2	2	2	2	2	2	2	18
			2	3	3	2	2	2	2	2	2	2	2	2	2	20
			3	3	3	2	2	2	2	2	2	2	2	2	2	22
			4	3	3	2	2	2	2	2	2	2	2	2	2	23
			5	3	3	2	2	2	2	2	2	2	2	2	2	23
1	104	MTF	0	3	3	2	2	2	2	3	2	2	2	1	22	
			1	3	2	1	2	1	2	2	3	2	2	1	19	
			2	2	2	1	2	1	2	2	2	1	2	1	15	
			3	2	2	1	0	2	1	2	1	1	2	1	13	
			4	1	1	1	0	1	1	1	1	1	1	1	0	8
			5	1	1	1	0	1	1	1	1	0	1	1	0	7
1	105	ABS	0	0	1	0	0	1	1	0	0	1	1	0	4	
			1	3	3	2	2	2	2	2	2	2	3	2	22	
			2	3	3	1	3	2	3	2	2	2	2	3	2	22
			3	2	2	1	0	2	2	2	2	2	2	3	1	20
			4	2	2	1	0	2	2	2	2	2	2	3	1	17
			5	1	1	1	0	1	1	1	1	2	2	3	1	13
1	106	MRN	0	0	1	0	0	1	0	0	0	1	2	0	10	
			1	3	3	1	2	2	3	2	2	2	2	2	2	22
			2	3	2	1	2	2	3	2	2	1	2	2	1	21
			3	2	2	1	2	2	2	2	2	1	2	2	1	19
			4	2	2	1	1	1	1	1	1	1	1	1	1	14
			5	0	0	0	0	1	0	0	0	0	1	2	0	5

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
1	106	MRN	4	2	2	1	1	1	1	1	1	2	0	12		
			5	1	1	1	0	1	1	1	1	1	0	8		
			6	0	1	0	0	0	0	0	0	0	1	0	3	
			1	3	3	1	0	3	2	3	2	2	2	2	20	
			2	2	3	1	0	2	3	2	3	1	2	2	17	
			3	2	2	1	0	2	2	2	2	1	1	2	2	14
1	107	LAN	4	2	2	1	0	1	2	1	1	2	1	13		
			5	1	2	1	0	1	1	1	1	1	1	1	10	
			6	1	1	1	0	1	1	1	1	1	1	0	8	
			1	3	3	1	0	3	2	3	2	2	2	2	18	
			2	3	3	1	0	2	3	2	3	1	2	2	17	
			3	2	2	1	0	2	2	2	2	1	1	2	2	15
1	108	STB	4	2	2	1	0	2	1	1	1	3	1	14		
			5	1	2	1	0	2	1	1	1	1	3	1	14	
			6	1	1	1	0	1	1	1	1	1	3	1	11	
			1	3	3	1	0	2	3	2	3	2	3	2	20	
			2	3	3	1	0	2	3	2	3	1	3	1	19	
			3	2	2	1	0	2	2	2	2	1	3	1	15	
1	109	IPL	4	2	2	1	0	2	1	1	1	3	1	12		
			5	1	1	0	0	1	1	1	0	1	2	0	7	
			6	1	1	0	0	0	1	1	1	0	1	0	6	
			1	3	3	1	0	3	3	3	3	2	3	1	20	
			2	3	3	1	0	3	2	3	2	1	3	1	19	
			3	2	2	1	0	3	2	2	2	1	3	1	15	
1	110	TQD	4	2	2	1	0	2	1	1	1	3	1	12		
			5	1	1	0	0	1	1	1	0	1	2	0	7	
			6	1	1	0	0	0	1	1	1	0	1	0	6	
			1	3	3	1	0	3	3	3	3	2	3	2	20	
			2	2	2	0	2	2	3	2	3	1	2	3	18	
			3	2	2	0	2	2	2	2	2	1	2	2	16	
1	111	JBF	4	1	2	1	0	1	1	1	1	1	0	10		
			5	0	1	0	0	0	0	0	0	0	2	0	4	
			6	0	1	0	0	0	0	0	0	0	1	2	0	4
			1	3	3	1	1	2	2	2	2	2	2	3	1	21
			2	3	3	1	1	2	3	2	3	1	2	3	1	20
			3	2	2	1	1	2	2	2	2	1	1	3	1	17
1	112	PSA	4	1	2	1	0	1	1	1	1	2	1	1	15	
			5	1	1	1	0	1	0	1	0	1	2	1	11	
			6	1	1	0	0	1	1	1	1	0	1	2	1	9
			1	3	3	1	1	3	2	3	2	2	2	1	1	20
			2	3	3	1	1	3	1	3	3	1	2	2	1	22
			3	3	3	1	1	3	2	3	2	2	2	2	1	21

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
1	118	MVR	4	3	3	2	1	2	2	2	2	2	2	21
			5	3	3	2	0	3	3	2	2	2	2	22
1	119	MVR	0	3	3	2	1	2	3	2	2	3	2	23
			1	3	2	2	1	2	3	1	2	3	2	21
			2	3	2	2	1	2	3	2	1	3	2	21
			3	2	2	2	1	2	3	2	2	3	2	21
			4	2	2	1	1	2	2	1	2	2	1	16
			5	2	2	1	1	2	2	1	2	3	1	17
			6	2	2	1	1	2	2	1	2	2	1	16
1	120	JLB	0	3	3	3	1	2	3	2	3	3	1	24
			1	3	3	1	1	2	3	2	2	2	1	20
			2	3	3	2	1	2	3	2	2	2	1	21
			3	3	2	1	1	2	3	1	2	2	1	18
			4	2	2	1	1	2	2	1	1	2	1	15
			5	2	2	1	1	2	2	1	2	2	1	16
			6	2	2	1	1	2	2	1	3	3	1	18
1	121	LAC	0	3	3	3	2	2	3	1	2	2	1	22
			1	3	2	2	1	2	3	1	2	3	2	22
			2	2	2	2	1	2	2	1	1	2	2	17
			3	2	2	1	1	2	2	1	1	2	2	15
			4	1	1	0	0	1	1	0	1	1	0	7
			5	0	1	0	0	0	0	0	1	1	0	3
			6	0	1	0	0	0	0	0	1	1	0	3
1	122	HSS	0	3	3	2	1	3	3	2	2	2	2	23
			1	3	3	2	1	2	3	2	1	3	1	21
			2	3	2	1	1	1	2	1	2	3	1	17
			3	1	1	1	0	1	2	1	1	2	1	12
			4	1	1	1	0	1	1	0	1	2	1	9
			5	0	1	0	0	0	0	0	1	2	0	4
			6	0	1	0	0	0	0	0	2	2	0	5
1	123	MLL	0	3	3	2	0	2	3	1	3	3	1	21
			1	3	2	2	0	2	3	1	2	3	1	20
			2	2	2	2	0	2	2	1	2	3	1	17
			3	2	2	1	0	1	2	1	1	2	1	15
			4	1	2	1	0	1	1	0	1	2	1	10
			5	0	1	0	0	1	1	0	1	2	0	5
			6	0	1	0	0	0	1	0	0	1	0	3
1	124	PPC	0	3	3	3	1	3	3	1	3	2	1	23
			1	3	2	2	1	3	3	1	2	3	1	21
			2	2	2	1	1	2	2	1	1	2	1	15
			3	2	2	1	0	1	1	0	1	2	1	11
			4	1	1	0	0	1	1	0	1	2	1	8

1012

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 40.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
1	124	PPC	5	1	1	0	0	1	1	0	1	2	0	7
			6	1	1	0	0	0	1	0	1	2	0	6
1	125	FDP	0	3	3	2	1	3	2	2	2	1	2	21
			1	2	2	1	1	3	2	1	2	3	3	21
			2	2	2	0	0	2	2	0	1	3	3	15
			3	2	2	0	0	1	2	0	2	3	1	12
			4	1	1	0	0	1	1	0	1	3	0	8
			5	1	1	0	0	1	1	0	1	3	0	8
			6	1	1	0	0	1	1	0	1	3	0	9
1	126	SMB	0	2	3	3	1	2	3	2	3	3	1	23
			1	2	3	2	1	2	3	2	2	3	1	21
			2	2	2	1	1	2	2	1	3	3	1	19
			3	1	1	1	1	2	2	1	2	2	1	15
			4	1	1	1	1	1	1	1	2	2	0	11
			5	1	1	1	0	1	1	1	0	2	0	8
			6	0	1	0	0	0	0	0	0	2	0	3
1	127	VPD	0	3	3	1	1	3	2	2	2	2	1	20
			1	3	2	1	1	2	3	1	1	2	1	17
			2	2	2	1	1	1	2	1	1	2	1	14
			3	1	1	1	1	1	1	1	1	2	1	11
			4	1	1	0	1	1	1	1	1	2	1	10
			5	0	1	0	0	0	0	0	1	2	0	4
			6	0	1	0	0	1	0	0	1	1	0	4
1	128	LAM	0	3	3	2	0	3	3	2	2	2	0	20
			1	3	3	2	0	2	2	2	2	2	0	18
			2	3	2	1	0	1	2	1	1	2	0	16
			3	2	2	1	0	1	1	1	1	2	0	13
			4	2	2	1	0	1	1	1	1	2	0	11
			5	2	1	1	0	2	1	1	1	2	0	11
			6	2	1	1	0	1	1	1	1	2	0	12
1	129	MNS	0	0	1	1	0	0	0	0	1	2	0	10
			1	0	2	2	0	0	3	1	3	2	0	18
			2	3	2	1	0	2	2	1	2	2	0	16
			3	2	2	1	0	1	1	1	1	2	0	13
			4	1	1	1	0	0	1	1	1	2	0	11
			5	0	1	0	0	0	1	1	1	2	0	8
			6	0	1	0	0	0	0	0	1	2	0	4
1	130	EGA	0	3	3	2	2	2	3	2	2	2	2	23
			1	3	3	2	2	2	3	1	2	2	2	22
			2	2	2	2	2	2	3	1	1	2	2	19
			3	2	2	1	1	2	2	1	1	2	1	16
			4	1	2	1	1	2	1	1	1	2	1	13

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
1	130	EGA	5	1	1	1	1	1	1	1	1	2	1	11
			6	0	1	0	1	1	1	0	1	2	0	8
1	131	RMR	0	3	3	2	0	2	3	1	3	3	1	20
			1	3	3	2	0	2	3	1	2	3	1	20
			2	3	3	2	0	3	2	1	2	3	1	19
			3	3	3	2	0	3	3	1	2	3	1	21
			4	3	2	1	0	2	2	1	2	3	1	17
			5	2	2	2	0	2	2	1	2	3	1	17
			6	2	2	2	0	2	3	1	2	3	1	18
1	132	MAF	0	3	3	1	1	2	3	1	2	2	0	18
			1	3	2	1	1	2	3	1	2	2	1	18
			2	3	2	1	1	2	3	1	2	2	1	16
			3	2	2	1	1	2	2	1	1	2	1	15
			4	2	2	1	1	2	2	1	1	2	1	15
			5	2	2	1	1	2	2	1	2	2	1	16
			6	2	2	1	1	2	2	1	2	2	1	15
1	133	JPH	0	3	3	2	0	2	3	2	2	2	2	21
			1	3	2	2	0	2	3	1	2	2	2	19
			2	3	2	1	0	2	2	1	1	2	1	15
			3	2	2	1	0	1	1	1	1	2	1	12
			4	1	1	1	0	1	1	1	1	2	1	10
			5	1	1	1	0	1	1	1	1	1	1	9
			6	1	1	1	0	0	1	1	1	1	1	7
1	134	LMS	0	3	3	3	2	3	3	0	2	2	3	24
			1	3	3	2	2	3	3	0	2	2	3	24
			2	2	2	2	1	2	2	0	2	2	3	18
			3	2	2	1	0	2	2	0	2	2	2	15
			4	1	1	1	0	1	1	0	1	1	0	7
			5	0	1	0	0	0	0	0	1	1	0	3
			6	0	1	0	0	0	0	0	1	1	0	3
1	135	MMS	0	3	3	2	0	2	2	1	3	2	0	18
			1	2	2	2	0	2	2	1	1	2	0	14
			2	1	1	1	0	1	1	1	1	2	0	10
			3	1	1	1	0	1	1	1	1	2	0	10
			4	1	1	0	0	1	1	1	1	2	0	8
			5	0	1	0	0	0	0	0	1	2	0	4
			6	0	1	0	0	0	0	0	0	1	0	2
1	136	AVP	0	3	3	1	2	1	2	2	3	2	1	20
			1	2	2	1	2	2	2	2	2	2	2	21
			2	2	2	1	2	1	2	1	1	2	2	16
			3	2	1	1	1	1	1	1	1	2	1	12
			4	1	1	1	1	1	1	0	1	2	0	9

1014

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
1	136	AVP	5	1	1	0	1	0	0	0	1	2	0	6
			6	0	1	0	0	0	0	0	1	2	0	4
1	137	CNE	0	2	3	1	2	2	3	0	3	2	2	19
			1	2	3	2	2	3	3	0	3	2	2	22
			2	3	3	1	2	3	3	0	2	2	2	21
			3	2	2	1	2	2	2	0	1	2	2	16
			4	3	2	2	1	2	2	0	1	2	2	17
			5	3	2	2	2	3	3	0	1	2	2	20
			6	3	2	2	1	2	2	0	1	2	2	16
1	138	LBV	0	2	3	2	0	3	3	2	3	2	2	22
			1	2	2	2	0	3	3	2	2	2	1	19
			2	1	2	1	0	2	2	1	2	2	0	13
			3	1	2	1	0	2	1	1	1	2	0	10
			4	0	1	0	0	0	0	0	1	2	0	4
			5	0	1	0	0	0	0	0	1	1	0	3
			6	0	2	0	0	0	0	0	1	1	0	4
1	139	RA	0	3	3	2	1	3	3	0	2	2	1	20
			1	3	3	2	1	3	3	0	2	2	3	22
			2	3	2	2	1	3	2	0	2	2	3	20
			3	2	2	1	1	1	1	0	1	1	1	11
			4	1	1	1	0	1	1	0	1	1	0	7
			5	0	1	0	0	0	0	0	2	1	0	4
			6	0	1	0	0	0	0	0	1	1	0	3
1	140	MCA	0	2	3	2	0	2	3	2	2	2	0	18
			1	3	3	2	0	3	3	2	2	2	0	20
			2	2	2	1	0	3	1	2	2	1	0	14
			3	1	2	1	0	2	1	1	1	1	0	10
			4	1	1	1	0	1	1	1	1	1	0	8
			5	1	1	1	0	1	1	1	1	1	0	8
			6	1	1	1	0	1	1	1	1	1	0	8
1	141	AMG	0	3	3	2	2	2	3	1	2	2	1	21
			1	3	2	2	2	2	3	1	1	2	1	19
			2	3	2	1	1	2	2	1	1	2	1	17
			3	2	2	1	1	1	1	1	1	2	1	13
			4	2	2	1	1	1	1	0	1	2	1	13
			5	1	1	0	0	1	1	0	1	2	0	7
			6	1	1	0	0	1	1	0	1	2	0	7
1	142	SCC	0	2	3	2	0	3	3	1	1	3	1	19
			1	3	3	2	0	3	1	1	1	3	1	20
			2	2	2	1	0	2	2	1	1	3	1	15
			3	1	1	1	0	1	1	1	1	2	1	10
			4	1	1	1	0	1	1	1	0	2	1	9

101

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTCOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
1	142	SCC	5	0	1	0	0	0	0	0	1	2	1	5
			6	0	1	0	0	0	0	0	1	1	1	4
1	143	JEP	0	2	3	2	1	2	3	1	2	2	1	19
			1	2	2	1	1	2	3	1	1	2	1	16
			2	2	2	1	0	2	2	1	1	2	1	14
			3	1	1	1	0	1	1	1	1	2	1	10
			4	0	1	1	0	1	0	0	1	2	1	6
			5	0	1	0	0	0	0	0	1	2	1	5
			6	0	1	0	0	0	0	0	0	2	1	4
1	144	ARF	0	3	3	2	1	2	3	2	1	3	0	20
			1	3	3	2	1	2	3	2	1	3	0	20
			2	2	2	1	1	2	2	2	1	2	0	16
			3	2	2	1	1	2	2	2	1	2	0	15
			4	1	2	1	1	1	1	2	1	2	0	12
			5	1	1	1	1	1	1	2	1	2	0	11
			6	1	1	1	0	0	1	2	1	1	0	8
1	145	SLD	0	3	3	2	1	2	2	1	1	2	1	18
			1	3	2	1	1	2	2	1	2	2	1	17
			2	3	2	1	1	1	2	1	1	1	1	14
			3	2	2	0	1	1	1	1	1	1	0	10
			4	1	1	1	0	1	1	1	1	1	0	8
			5	1	1	1	0	1	1	1	1	1	0	8
			6	1	0	1	0	1	1	1	0	1	0	6
1	146	LRM	0	3	2	2	1	2	3	2	3	2	0	20
			1	3	2	2	1	2	2	2	1	2	0	17
			2	2	2	2	1	2	2	2	1	2	0	16
			3	2	2	1	1	2	2	2	1	2	0	15
			4	2	2	1	1	2	2	2	1	2	0	14
			5	1	1	1	1	1	1	1	1	1	0	9
			6	1	1	1	1	1	1	1	1	1	0	9
1	147	JGM	0	2	3	2	0	3	3	2	2	3	0	20
			1	3	3	2	1	3	2	2	2	3	2	23
			2	3	3	2	1	3	3	2	2	3	2	24
1	148	CAS	0	3	3	2	1	2	2	2	2	2	1	20
			1	3	3	2	1	2	2	1	2	2	1	19
			2	2	2	1	1	2	1	1	2	0	0	13
			3	1	2	1	0	1	1	1	1	2	0	10
			4	1	2	1	0	1	1	1	1	2	0	10
			5	0	1	0	0	1	0	0	0	2	0	4
			6	0	1	0	0	1	0	0	1	2	0	5
1	149	SC	0	3	3	3	0	3	3	0	3	3	3	24

1016

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASEBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
1	149	SC	1	3	3	3	0	3	3	0	2	3	2	22		
			2	3	2	2	0	2	2	0	2	3	2	18		
			3	2	2	1	0	1	1	1	1	0	1	0	10	
			4	1	2	1	0	1	1	1	1	0	2	0	9	
			5	1	1	1	0	1	1	1	1	0	2	0	8	
			6	0	1	0	0	0	0	0	0	0	1	2	0	4
1	150	VA	0	3	3	2	2	3	2	2	1	2	2	1	21	
			1	3	3	2	2	3	2	2	1	2	2	2	22	
			2	3	3	1	3	2	2	3	2	1	2	2	1	19
			3	2	2	1	1	3	1	3	1	1	1	2	1	15
			4	1	2	1	0	1	1	2	1	1	2	0	0	10
			5	1	1	1	0	1	1	1	1	0	1	1	0	7
2	31	IK	0	2	1	2	2	2	1	1	1	2	2	1	16	
			1	2	1	2	1	2	2	2	1	0	2	2	1	14
			2	2	1	2	2	1	2	2	2	1	2	2	1	14
			3	1	2	1	0	2	1	2	1	1	1	0	0	10
			4	2	1	2	0	2	2	2	2	1	1	1	0	13
			5	2	2	2	0	3	2	2	2	1	2	2	2	18
2	32	GE	0	2	2	2	0	3	2	2	2	2	2	2	18	
			1	2	1	2	1	2	2	2	2	1	2	2	2	17
			2	2	1	2	2	2	2	2	2	1	2	2	2	17
2	33	HS	0	3	2	2	2	2	3	2	3	2	2	0	21	
			1	2	2	3	2	2	2	2	2	2	2	0	20	
			2	3	2	3	2	2	2	2	2	3	2	1	23	
2	34	EH	0	2	2	2	3	2	2	3	3	3	2	1	24	
			1	2	1	2	2	2	2	2	1	2	2	0	18	
			2	2	2	1	2	1	2	2	1	2	2	0	15	
			3	2	1	1	2	1	2	2	1	2	2	0	16	
3	1	AMR	0	2	2	2	1	2	1	2	1	1	2	0	12	
			1	2	2	1	2	1	2	1	2	1	1	2	13	
			2	1	1	0	0	0	0	0	0	0	0	0	0	0
			3	1	0	0	1	1	1	1	1	1	1	1	0	16
3	2	FIL	0	2	1	1	1	2	2	2	2	0	1	0	13	
			1	1	0	1	1	0	1	1	0	1	1	0	5	
			2	1	1	0	1	0	1	1	0	1	1	0	5	
			3	0	1	0	0	1	0	1	0	0	1	0	4	
3	2	FIL	4	0	0	0	1	0	0	0	1	1	0	0	4	
			3	0	0	0	0	0	0	0	0	0	0	0	0	
			2	1	1	1	0	1	1	1	0	1	1	0	0	4
			1	0	0	0	0	0	0	0	0	0	0	0	0	

1017

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score	
3	2	FIL	5	0	1	0	0	0	0	0	1	0	0	2	
			6	0	1	0	0	0	0	0	0	0	0	0	1
	3	DUB	0	2	2	2	2	3	1	1	2	1	1	0	16
			1	2	1	1	2	2	1	1	2	1	1	0	13
			2	1	1	1	1	1	1	0	0	1	2	0	11
			3	0	1	1	1	0	0	0	0	1	2	0	4
3	AUD	4	0	0	0	0	0	1	0	0	0	1	0	2	
		5	0	1	0	0	1	0	0	0	0	1	0	4	
		6	0	0	0	0	0	0	0	0	0	1	0	0	1
		0	3	2	2	2	2	2	2	2	2	2	3	2	22
		1	2	1	1	2	1	2	1	1	1	1	2	1	15
		2	0	1	1	1	1	1	1	1	1	1	1	0	8
3	MMA	3	1	1	1	1	0	1	0	1	0	2	1	1	8
		4	1	1	2	0	1	1	1	1	1	1	2	2	12
		5	1	0	1	1	1	1	1	1	0	1	1	1	7
		6	2	2	3	3	3	2	2	2	2	3	2	1	23
		0	1	2	2	1	1	1	1	2	2	2	0	0	13
		1	1	2	2	0	1	1	1	2	1	1	1	1	12
3	AJP	2	0	1	1	0	0	0	1	1	0	0	0	0	5
		3	0	1	0	0	0	0	1	1	1	1	1	0	5
		4	1	1	0	0	0	0	1	1	1	2	0	0	6
		5	1	1	0	0	0	0	0	1	0	1	0	0	4
		0	1	2	2	1	1	1	1	2	2	1	1	1	13
3	GRI	1	1	2	2	2	2	1	1	2	1	1	2	1	15
		0	2	2	1	1	1	2	2	2	2	1	1	2	16
		1	1	1	1	1	1	1	2	1	1	1	1	2	12
		2	1	1	0	0	0	1	1	0	1	0	1	1	6
		3	1	1	0	0	1	1	1	0	0	0	1	0	5
		4	1	1	1	1	1	1	1	1	0	0	1	1	9
3	DEN	5	0	0	0	0	1	0	1	0	0	3	1	1	6
		6	0	1	0	1	1	1	0	1	0	0	1	0	5
		0	1	2	1	1	1	2	1	2	2	1	2	1	15
		1	1	1	2	1	1	1	1	1	1	1	2	1	12
		2	1	1	1	1	1	1	1	1	1	1	0	1	9
		3	1	1	1	1	1	1	1	1	1	1	2	1	12
3	TOR	0	2	2	2	2	2	2	2	2	2	2	2	1	19
		1	0	2	2	1	1	2	2	2	2	2	2	1	18
		2	0	1	0	0	2	1	1	1	1	1	1	0	7
		3	2	1	2	1	2	2	2	2	2	2	2	0	15
		4	1	2	1	0	1	1	1	0	1	1	2	0	9
5	1	1	0	0	1	0	1	0	1	1	1	0	5		

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD

RESOMETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
3	10	TOR	6	0	1	0	0	0	0	0	1	1	0	3
3	11	PIE	0	2	2	2	0	2	3	2	2	1	1	17
			1	2	3	3	0	3	3	3	1	2	0	20
8	1	HJ	0	2	2	2	1	2	2	2	2	2	0	17
			1	2	1	2	1	2	2	1	2	2	0	15
			2	1	1	0	0	1	1	1	1	1	0	7
			3	1	0	0	0	1	1	1	1	1	0	6
			4	1	0	0	0	1	1	1	1	1	0	6
			5	1	0	0	0	1	1	1	1	1	0	5
			6	0	0	0	0	1	1	0	1	1	0	4
8	2	TE	0	3	2	2	0	2	2	2	2	2	1	18
			1	1	1	1	0	1	1	1	2	2	0	10
			2	1	1	0	0	1	1	1	1	2	0	8
			3	1	0	0	0	1	1	0	1	2	0	6
			4	0	0	0	0	1	1	0	1	1	0	3
			5	0	0	0	0	1	0	0	1	1	0	3
			6	0	0	0	0	1	0	0	1	1	0	3
8	3	JL	0	2	2	2	2	2	2	2	2	2	0	18
			1	1	1	1	1	2	2	1	1	1	0	11
			2	0	1	1	1	2	1	1	1	1	0	9
			3	0	1	1	0	1	1	0	1	1	0	6
			4	0	1	1	0	1	1	0	1	1	0	5
			5	0	1	1	0	1	1	0	1	1	0	5
			6	1	1	1	0	1	0	0	1	1	0	6
8	4	BA	0	2	1	2	2	3	2	1	2	2	0	17
			1	1	1	1	1	2	2	1	2	2	0	13
			2	0	1	0	0	1	1	0	1	2	0	6
			3	0	1	0	0	1	0	0	1	2	0	5
			4	0	1	0	0	1	0	0	1	1	0	4
			5	0	1	0	0	1	0	0	1	1	0	4
			6	0	0	0	0	1	0	0	1	1	0	3
8	5	SL	0	2	1	2	2	3	2	2	2	2	1	19
			1	1	1	2	1	2	2	1	2	2	1	15
			2	1	0	1	1	2	1	1	1	1	1	10
			3	1	0	1	1	2	1	1	1	1	1	10
			4	1	0	1	0	2	0	1	1	1	0	7
			5	1	0	1	0	1	0	1	1	1	0	6
			6	1	0	1	0	1	0	1	1	1	0	6
8	6	TL	0	2	1	2	1	3	1	2	2	1	1	16
			1	2	1	2	1	2	1	1	2	1	1	14
			2	1	1	1	0	2	1	1	1	1	1	10

1019

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
8	6	TL	3	0	1	0	0	1	0	0	1	1	0	4		
			4	0	1	0	0	1	0	0	1	1	1	0	4	
			5	0	1	0	0	1	0	0	0	1	1	0	4	
			6	0	1	0	0	1	0	0	0	1	1	0	4	
			0	2	1	2	1	2	2	2	2	2	1	2	1	16
			2	2	1	2	1	2	2	2	2	2	2	2	1	17
9	1	US	3	2	1	2	1	2	2	2	1	2	2	1	16	
			4	2	1	2	1	2	2	2	2	2	2	1	16	
			5	2	1	2	1	2	2	2	2	2	2	1	15	
			6	2	1	2	1	2	2	2	2	2	2	2	1	17
			0	3	2	3	2	3	2	2	2	2	2	2	1	21
			2	2	2	2	2	2	2	2	2	2	3	1	1	19
9	2	VCF	0	2	2	2	2	1	2	2	2	2	2	1	16	
			1	2	2	2	2	1	2	2	2	1	1	1	16	
			2	1	1	1	0	0	1	1	1	1	1	0	7	
			3	1	1	1	0	0	1	1	1	0	0	0	5	
			4	1	1	1	0	0	0	0	0	1	1	1	0	3
			5	0	0	0	0	0	0	0	0	1	1	1	0	4
9	3	SF	6	1	1	0	0	0	0	0	1	0	0	0	3	
			0	2	2	2	1	2	2	1	2	2	2	1	0	16
			1	2	2	2	1	2	2	1	2	2	1	1	0	15
			2	2	1	1	1	1	0	1	0	1	1	1	0	9
			3	2	1	2	1	1	1	1	1	1	1	1	0	11
			4	2	2	2	2	1	2	2	2	2	2	2	1	18
9	4	SA	5	2	2	2	2	1	2	2	2	2	2	1	18	
			6	2	1	2	1	1	2	2	2	2	1	1	14	
			0	3	2	3	2	1	3	2	3	3	2	2	2	23
			1	3	2	2	1	2	2	2	2	2	2	2	1	20
			2	3	2	2	1	3	2	2	2	2	2	2	1	20
			3	3	2	2	2	2	2	2	2	2	2	2	1	20
9	5	MF	4	3	2	3	2	2	2	2	3	2	2	1	20	
			5	3	2	3	2	2	2	2	2	2	2	1	20	
			0	2	1	1	1	1	1	1	1	1	1	1	1	11
			1	2	1	2	1	1	2	1	2	1	1	1	1	13
			2	1	1	1	1	1	1	1	1	1	1	1	1	10
			3	1	1	1	0	1	1	1	1	1	1	1	0	9
9	4	5	4	1	1	1	0	1	1	0	0	1	0	5		
			5	1	0	1	0	0	1	0	1	0	1	0	4	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS RBD
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.2
 MONTGOMERY ASBERG DEPRESSION RATING SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
9	5	MF	6	1	0	1	0	0	1	0	1	0	0	4
9	6	SD	0	2	2	2	1	1	2	2	2	1	0	16
			1	2	2	2	1	1	2	2	2	1	0	15
			2	2	1	2	1	1	2	2	1	1	0	13
			3	1	1	1	0	0	1	1	1	0	0	7
			4	1	0	1	0	0	0	0	0	0	0	2
			5	1	1	1	0	0	0	0	0	1	0	4
			6	1	0	1	0	0	0	0	0	1	0	3
9	7	PP	0	2	2	2	1	1	2	2	2	2	1	17
			1	2	2	2	1	1	2	2	2	2	1	18
			2	1	0	1	0	0	1	1	1	1	0	6
			3	1	0	1	0	0	0	0	0	1	0	3
			4	1	0	1	0	0	1	1	0	1	0	5
			5	1	0	1	0	0	1	1	0	0	0	2
			6	1	0	0	0	0	1	0	0	0	0	2
9	8	KTH	0	2	2	3	2	1	2	2	2	2	1	19
			1	2	2	2	1	1	2	2	2	2	1	18
			2	2	1	1	0	0	1	1	1	1	0	9
			3	1	0	1	0	0	1	1	1	1	0	6
			4	1	0	1	0	0	1	0	1	1	0	5
			5	1	0	1	0	0	0	0	1	1	0	3
			6	1	0	1	0	1	0	1	0	1	0	5
9	9	PL	0	2	2	3	2	2	2	2	2	2	2	21
			1	2	2	2	2	2	2	2	2	2	2	19
			2	2	2	2	2	2	2	2	2	1	0	17
			3	2	2	3	2	2	2	2	2	1	1	19
			4	2	2	2	2	1	2	2	2	1	1	17
			5	2	2	3	2	2	2	2	2	1	1	19
			6	2	2	3	2	2	2	2	2	1	2	20
9	10	BG	0	2	2	2	2	1	2	2	2	1	1	17
			1	2	2	2	2	1	2	2	2	1	0	16
			2	2	2	2	1	1	2	2	2	1	0	16
			3	3	2	2	2	2	2	2	2	1	1	19
			4	3	2	3	2	1	2	2	2	1	1	19
			5	2	2	2	2	1	2	2	2	1	1	17
			6	2	2	2	2	1	2	2	2	1	1	17
9	11	RE	0	2	2	2	2	1	2	2	2	1	0	16
			1	2	2	2	2	1	1	1	1	1	0	13
			2	1	1	1	0	0	1	1	0	1	0	6
			3	1	0	0	0	0	0	0	0	0	0	3
			4	0	0	0	0	1	0	1	0	1	0	3
			5	0	0	0	0	0	1	1	0	0	0	2

1021

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 70.2

MONTGOMERY ASEBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
9	18	MBM	2	2	2	1	2	1	1	1	2	1	0	13		
			3	1	1	1	0	1	1	1	0	0	0	6		
			4	1	1	1	0	1	1	1	1	1	0	0	5	
			5	1	0	0	0	1	1	1	1	1	0	0	4	
			6	2	2	2	2	2	2	2	2	2	2	1	1	18
9	19	KF	0	2	2	2	2	1	2	1	2	1	0	0	15	
			1	2	1	1	1	1	2	1	2	1	1	0	13	
			2	1	0	1	0	1	0	1	1	0	1	0	0	4
			3	1	0	0	0	1	0	1	0	0	0	0	0	3
			4	0	0	0	0	0	1	1	1	1	1	0	0	3
			5	0	0	0	0	0	1	1	1	1	1	0	0	3
9	20	GYE	6	0	0	0	0	0	1	0	0	1	0	0	2	
			0	2	2	2	2	2	2	3	2	2	2	1	20	
			1	2	2	2	2	1	1	1	1	1	1	1	0	13
			2	1	1	1	1	1	1	1	1	1	1	0	0	9
			3	1	0	1	0	0	1	1	1	1	1	0	0	5
			4	1	0	0	0	0	1	1	1	1	0	0	0	3
9	21	TA	5	0	0	0	0	0	1	1	1	1	0	0	3	
			6	1	1	1	0	0	0	0	1	1	0	0	5	
			0	2	2	2	2	2	2	2	2	2	2	1	1	18
			1	2	1	1	1	1	1	1	1	1	1	1	1	15
			2	2	1	1	1	1	1	1	1	1	1	1	0	15
			3	1	1	1	0	0	1	1	1	1	1	1	0	8
9	22	RRE	4	1	1	1	1	0	1	1	1	0	0	0	6	
			5	1	1	1	0	0	1	1	1	1	0	0	4	
			6	1	0	1	0	1	1	1	1	1	0	0	0	4
			0	2	2	2	1	1	1	1	2	2	2	1	1	16
			1	2	2	1	1	1	1	1	2	1	1	1	0	16
			2	2	1	1	1	1	1	1	1	1	1	1	0	11
9	23	SZN	3	1	1	1	0	0	1	1	1	1	0	0	7	
			4	1	1	1	0	0	1	1	1	1	0	0	6	
			5	1	0	1	0	0	1	1	1	1	1	0	0	5
			6	1	0	1	0	1	1	1	1	1	0	0	0	4
			0	2	2	2	1	1	1	1	2	2	1	1	0	14
			1	2	2	1	1	1	1	1	2	1	1	1	0	13
9	24	LGY	2	1	1	1	0	0	1	1	1	1	0	0	10	
			3	1	1	1	0	1	1	1	1	1	1	0	8	
			4	2	1	1	2	1	1	1	1	1	1	1	0	10
			5	1	1	1	0	1	1	1	1	1	1	1	0	8
			6	1	1	1	0	0	1	1	1	1	0	0	0	5
			0	2	2	2	2	2	2	2	2	2	2	1	0	15
1	2	1	1	1	1	1	1	2	1	1	1	0	13			

1023

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
9	24	LGY	2	2	2	2	1	1	1	1	1	2	0	13		
			3	1	1	1	0	1	1	1	1	1	1	0	8	
			4	1	1	1	0	1	1	1	1	1	1	1	0	8
			5	1	0	1	0	1	1	1	1	1	1	0	0	6
			6	1	0	1	0	1	1	1	1	1	0	0	0	5
			0	2	2	0	0	2	1	1	1	1	1	1	0	11
9	25	PH	1	2	2	2	0	1	1	1	1	1	1	0	11	
			2	2	1	2	1	1	1	1	1	1	1	0	11	
			3	1	1	1	0	1	1	1	1	1	1	0	0	11
			4	1	0	1	0	1	1	1	1	1	0	0	0	7
			5	1	0	1	0	1	1	1	1	1	0	0	0	5
			6	1	0	1	0	1	1	1	1	1	0	0	0	4
9	26	CP	0	2	2	2	0	0	0	0	0	0	0	0	3	
			1	2	2	1	1	1	1	1	2	2	1	0	14	
			2	2	2	1	1	1	1	1	1	2	1	1	0	13
			3	1	1	2	0	1	1	1	1	1	1	1	0	11
			4	1	1	1	0	1	1	1	1	1	0	0	0	6
			5	1	0	1	0	1	1	1	1	1	0	0	0	5
9	27	ZSL	0	1	1	1	0	0	0	0	0	0	0	0	3	
			1	2	1	2	0	1	1	1	1	1	1	1	0	10
			2	2	1	1	0	1	1	1	1	1	1	1	0	10
			3	2	1	1	0	1	1	1	1	1	1	1	0	9
			4	1	1	1	0	1	1	1	1	1	0	0	0	7
			5	1	1	1	0	1	1	1	1	1	0	0	0	6
9	28	HI	0	1	1	1	0	0	0	0	0	0	0	0	4	
			1	2	1	2	0	1	1	1	1	1	1	1	0	10
			2	2	1	2	0	1	1	1	1	1	1	1	0	9
			3	1	1	2	0	1	1	1	1	1	1	1	0	10
			4	1	1	1	0	0	1	1	1	0	0	0	0	5
			5	1	1	1	0	0	1	1	1	0	0	0	0	4
9	29	SZF	0	1	0	1	0	0	0	0	0	0	0	0	3	
			1	2	1	2	0	1	1	1	1	1	1	1	0	11
			2	2	1	2	0	1	1	1	1	1	1	1	0	10
			3	1	1	2	0	1	1	1	1	1	1	1	0	10
			4	1	1	1	0	0	1	1	1	1	0	0	0	7
			5	1	1	1	0	0	1	1	1	1	0	0	0	6
9	30	NF	0	2	1	1	0	0	1	1	0	0	0	0	4	
			1	2	1	2	1	2	1	2	2	1	1	1	0	13
			2	2	1	2	1	2	1	2	2	1	1	1	0	12

1024

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
9	30	NF	2	2	1	2	0	1	1	1	1	1	0	10		
			3	1	0	1	0	1	1	1	1	1	0	7		
			4	1	0	1	0	1	1	1	1	1	0	0	6	
			5	1	0	1	0	0	1	1	0	0	1	0	4	
			6	1	0	1	0	0	0	1	1	0	1	0	4	
10	1	VK	0	2	2	2	1	1	1	2	3	2	0	16		
			1	2	2	2	0	1	1	2	2	3	2	0	15	
			2	2	2	1	0	1	1	1	2	2	2	1	0	12
			3	2	2	1	0	1	1	1	2	2	1	1	0	12
			4	1	1	1	0	1	1	1	1	1	1	1	0	8
			5	1	1	1	0	1	1	1	1	1	1	1	0	8
10	4	ZSD	0	3	2	3	1	1	1	1	3	2	2	2	19	
			1	3	2	2	1	1	1	1	1	3	2	2	1	17
			2	2	1	1	1	1	1	1	1	2	2	0	0	12
			3	2	2	1	1	1	1	1	1	2	2	0	0	13
			4	1	2	1	1	1	1	1	1	2	2	0	0	12
			5	1	1	1	0	1	1	1	1	1	2	2	0	10
10	5	AN	0	3	2	3	0	1	1	0	1	1	1	0	6	
			1	1	1	2	1	1	1	1	1	2	0	0	16	
			2	1	1	1	0	1	1	1	1	1	1	0	0	11
			3	1	1	1	0	0	0	0	1	1	1	0	0	7
			4	1	1	1	0	0	0	0	0	1	1	0	0	5
			5	0	1	1	0	0	0	0	0	1	1	1	0	2
10	6	RS	0	0	1	0	0	0	0	0	0	0	1	0	2	
			1	2	2	1	1	1	1	1	1	1	2	1	1	14
			2	1	1	2	1	1	1	1	1	1	1	1	0	12
			3	1	1	1	1	1	1	1	1	1	1	1	0	10
			4	1	2	0	1	1	1	1	1	1	1	1	0	8
			5	2	2	2	0	1	1	1	1	1	1	2	1	13
10	7	RK	0	1	2	1	1	1	0	0	1	0	2	1	10	
			1	1	1	1	1	1	1	1	1	1	0	0	8	
			2	1	1	1	1	1	1	1	1	1	2	0	0	8
			3	1	1	1	0	1	1	1	1	0	0	1	0	4
			4	1	1	0	0	1	0	0	0	0	0	1	0	3
			5	0	0	0	0	0	0	0	0	0	0	1	0	1
10	8	VP	0	2	2	1	1	2	1	1	3	2	1	1	16	
			1	2	2	1	2	1	1	1	1	1	3	2	1	16
			2	3	2	1	2	1	1	1	1	1	3	2	1	18

1020

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
10	8	VP	3	3	3	2	2	3	1	1	3	2	1	21
10	9	RT	0	1	2	1	1	1	1	1	3	2	2	15
			1	1	1	1	1	1	1	1	3	2	1	14
			2	1	1	1	1	1	0	1	2	2	0	10
			3	2	2	2	1	1	1	1	2	2	1	15
			4	1	1	1	1	1	0	1	1	1	1	5
			5	1	0	1	1	1	0	1	0	0	1	5
			6	1	0	0	0	0	0	0	0	0	1	2
10	10	MI	0	1	2	1	0	1	1	1	3	1	1	12
			1	1	1	1	0	1	1	1	2	1	1	10
			2	1	1	1	0	0	0	0	1	1	0	5
			3	0	1	0	0	0	0	0	1	1	0	3
			4	0	1	0	0	0	0	0	1	1	0	3
			5	1	1	0	0	0	0	0	0	0	0	2
			6	1	1	0	0	0	0	0	0	0	0	2
10	11	TM	0	2	1	2	1	1	1	1	2	2	2	15
			1	2	2	2	2	1	1	1	3	2	2	18
			2	2	2	2	2	1	1	1	3	1	1	16
			3	3	2	3	3	1	2	1	3	2	1	21
10	12	EP	0	1	1	1	1	1	1	1	2	1	0	10
			1	1	1	1	1	1	1	1	2	2	1	12
			2	1	1	1	1	1	1	1	2	2	1	12
			3	2	1	2	1	1	1	1	2	2	1	14
			4	1	1	1	1	1	1	0	2	1	0	9
			5	1	1	1	1	1	1	0	2	1	0	9
			6	1	1	1	0	1	0	0	1	1	0	6
10	13	HU	0	2	2	2	1	2	1	1	3	2	2	18
			1	1	2	1	1	1	1	1	2	2	1	13
			2	1	1	1	0	0	0	0	2	2	0	8
			3	1	1	1	0	0	0	0	2	2	0	7
			4	1	1	0	0	0	0	0	1	2	0	5
			5	1	1	0	0	0	0	0	1	1	0	4
			6	1	1	0	0	0	0	0	1	1	0	4
10	14	AA	0	1	1	2	1	1	1	1	1	2	1	12
			1	2	2	2	1	1	1	2	2	2	1	16
			2	1	1	1	0	1	1	0	1	1	0	7
			3	1	1	0	0	1	1	0	0	1	0	5
			4	1	1	0	0	1	1	0	0	1	0	5
			5	1	1	0	0	1	1	0	0	1	0	5
			6	1	1	0	0	1	1	0	0	1	0	5
10	15	HT	0	2	1	2	2	1	1	1	2	2	0	14

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
10	15	HT	1	1	1	1	2	1	1	1	2	2	0	12		
			2	1	1	0	1	0	0	0	1	1	0	7		
			3	1	0	0	1	0	0	0	0	0	1	0	4	
			4	1	1	0	1	0	1	0	0	1	0	0	4	
			5	1	1	1	1	1	1	1	1	0	0	0	8	
			6	1	0	0	0	0	0	0	0	0	0	0	1	
10	16	AJ	0	1	2	1	1	0	1	1	2	2	0	11		
			1	1	1	0	0	0	1	0	0	1	1	0	5	
			2	1	2	0	0	0	0	0	0	0	2	0	6	
			3	1	1	0	0	0	0	0	0	1	1	0	4	
			4	1	2	0	0	0	0	0	0	0	1	1	0	5
			5	1	2	0	0	0	0	0	0	0	0	2	0	6
10	17	MK	0	2	1	0	0	1	1	1	0	0	1	0	8	
			1	1	0	0	1	1	1	1	1	0	1	0	5	
			2	1	0	1	1	1	1	1	0	0	1	1	0	5
			3	1	0	0	1	1	1	1	1	0	0	1	0	4
			4	1	0	1	1	1	1	1	1	0	0	1	0	5
			5	1	1	0	1	1	1	1	1	0	0	1	0	5
10	18	SS	0	2	2	1	1	1	2	2	1	3	2	0	16	
			1	1	1	0	1	1	1	2	1	2	2	0	11	
			2	1	1	1	1	1	1	1	1	0	0	1	0	6
			3	1	1	0	1	0	1	1	1	0	0	1	0	5
			4	2	1	1	1	1	1	2	1	0	1	1	0	11
			5	2	3	2	2	1	2	1	2	1	2	1	1	17
10	19	TN	0	2	2	1	1	1	2	1	1	2	2	2	16	
			1	1	1	0	1	1	1	1	1	1	1	2	0	8
			2	1	0	0	1	0	1	1	0	1	1	1	0	4
			3	1	1	0	0	1	0	1	0	0	0	0	0	4
			4	1	1	0	0	1	0	0	0	0	0	0	0	2
			5	1	1	0	0	0	0	0	0	0	0	0	0	2
10	20	EJ	0	1	1	1	1	1	1	1	1	2	0	0	9	
			1	1	1	0	0	1	1	1	1	1	1	0	6	
			2	1	1	0	0	1	1	1	1	1	1	1	0	6
			3	1	0	0	0	0	0	0	0	0	1	1	0	3
			4	1	0	0	0	0	0	0	0	0	1	1	0	3
			5	0	0	0	0	0	0	0	0	0	1	1	0	2
10	21	AK	0	2	1	2	3	2	1	1	1	2	1	0	15	
			1	1	1	0	1	1	1	1	1	1	1	1	0	11
			2	1	1	0	0	0	0	0	0	0	0	0	0	0
			3	1	0	0	0	0	0	0	0	0	0	0	0	0
			4	1	0	0	0	0	0	0	0	0	0	0	0	0
			5	0	0	0	0	0	0	0	0	0	0	0	0	0

1027

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASEBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
10	21	AK	1	1	1	1	2	1	1	1	1	1	1	11		
			2	2	1	3	2	1	1	1	1	1	0	13		
			3	1	1	0	2	1	1	1	1	1	1	0	8	
			4	1	1	0	1	1	1	1	1	1	1	1	7	
			5	1	1	1	1	2	2	2	2	1	1	1	12	
			6	1	1	0	1	1	1	1	1	1	2	1	1	10
10	22	AA	0	1	2	1	1	2	2	2	3	2	1	1	17	
			1	1	1	0	1	1	1	1	1	2	1	0	9	
			2	1	1	1	1	1	1	1	1	1	1	1	0	10
			3	1	1	1	0	0	0	0	0	1	0	0	0	4
			4	1	1	0	0	0	0	0	0	1	0	1	0	3
			5	1	1	1	0	0	0	0	0	1	0	0	0	3
10	23	LT	0	1	1	1	0	1	1	1	1	1	0	0	7	
			1	1	1	0	1	1	1	1	1	1	1	1	7	
			2	1	1	0	1	1	1	1	1	0	1	1	8	
			3	1	1	0	0	0	0	0	0	0	0	1	4	
			4	1	1	1	0	0	0	0	0	0	0	1	1	5
			5	1	1	1	0	0	0	0	0	0	0	1	1	4
10	24	AL	0	2	2	2	0	2	1	1	3	2	2	2	17	
			1	1	1	0	1	0	1	0	0	3	0	0	6	
			2	1	1	0	1	0	1	0	0	2	0	0	5	
			3	1	1	0	0	1	0	0	0	2	0	0	5	
			4	1	1	0	0	1	0	0	0	1	0	0	4	
			5	1	1	2	0	1	1	1	1	2	2	1	1	10
10	25	ES	0	2	2	2	0	2	1	1	2	2	1	0	8	
			1	1	1	0	1	0	1	0	2	1	1	0	15	
			2	2	2	1	1	0	1	1	2	1	2	1	15	
			3	2	2	2	1	1	1	1	1	1	2	2	1	15
			0	1	1	0	1	2	1	2	2	1	2	2	2	15
			1	1	1	1	1	2	2	2	2	1	2	2	2	15
10	26	JIF	0	1	1	1	1	2	2	2	1	2	2	2	16	
			1	1	1	0	1	1	2	1	1	1	2	2	11	
			2	1	1	1	2	2	2	2	2	1	2	2	11	
			3	1	1	1	1	2	2	2	2	1	2	2	11	
			4	1	1	1	1	2	2	2	2	1	2	2	11	
			5	1	1	1	0	1	2	2	2	1	1	2	0	8
10	MK	0	2	1	2	1	1	1	1	2	0	1	0	11		
		1	2	2	2	1	1	1	1	1	2	0	0	13		
		2	1	0	0	1	0	0	0	0	0	0	0	2		
		3	1	0	0	0	0	0	0	0	0	0	0	0	1	

1028

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
10	27	MK	4	1	0	0	0	0	0	0	0	1	0	2
			5	1	0	0	0	0	0	0	0	0	0	1
			6	0	0	0	0	0	0	0	0	0	0	0
10	28	LL	0	2	2	3	2	2	1	1	2	2	0	17
			1	1	1	1	1	1	1	1	1	1	0	9
			2	0	1	0	0	0	0	0	1	1	0	3
			3	0	0	0	0	0	0	0	1	1	0	2
			4	1	1	0	0	0	1	1	1	1	0	5
			5	0	1	0	0	0	0	0	1	0	0	2
			6	1	1	0	0	0	0	0	0	0	0	2
10	29	JJ	0	1	1	1	1	1	0	2	1	1	1	10
			1	1	1	1	1	1	0	1	1	1	0	9
			2	1	1	1	1	1	0	1	1	1	0	8
			3	1	1	0	0	0	0	0	1	1	0	4
			4	1	1	1	0	1	0	1	1	1	0	7
			5	1	1	1	1	1	0	1	1	1	0	8
			6	1	1	0	1	0	0	1	1	1	0	6
10	30	VK	0	1	2	1	2	1	2	1	2	1	1	14
			1	1	2	1	2	1	1	1	1	2	1	13
			2	1	2	0	1	1	1	1	1	2	1	11
			3	1	2	0	1	1	1	1	1	1	0	9
			4	1	2	0	1	1	1	1	1	2	0	10
			5	1	2	0	1	2	1	1	1	1	0	11
			6	1	1	0	2	1	0	1	0	1	0	7
10	31	RK	0	1	3	1	1	1	2	0	2	1	2	13
			1	1	1	0	0	0	1	0	1	2	1	8
			2	1	1	1	0	0	0	0	0	1	1	4
			3	1	1	1	0	0	0	0	0	1	1	5
			4	1	2	0	0	0	0	1	0	2	1	7
			5	1	2	0	1	0	0	1	0	1	1	7
			6	1	1	0	1	0	0	0	0	1	0	4
10	32	LK	0	2	2	2	1	1	2	2	2	1	0	16
			1	1	1	1	1	1	1	1	2	1	0	11
			2	1	1	0	0	0	1	1	2	1	0	7
			3	1	1	0	0	0	1	1	2	1	0	8
			4	1	2	1	1	0	2	1	2	1	1	12
			5	1	1	0	0	0	1	1	1	1	0	6
			6	1	1	1	0	0	1	1	1	1	0	7
10	33	EK	0	1	1	1	0	1	2	1	0	1	1	9
			1	1	0	0	0	0	0	0	0	1	1	3
			2	0	0	0	0	0	0	0	0	1	0	1
			3	0	0	0	0	0	0	0	0	1	0	1

1029

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASEBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
10	33	EK	4	0	0	0	0	0	0	0	0	1	0	1
			5	0	0	0	0	0	0	0	0	1	0	1
			6	0	0	0	0	0	0	0	0	0	0	0
10	34	TK	0	2	2	2	1	1	2	2	3	2	0	17
			1	1	1	1	1	1	2	1	3	2	0	13
			2	1	1	0	0	1	2	1	2	1	0	9
			3	1	1	1	1	1	2	1	2	1	0	11
			4	1	1	1	0	0	1	0	1	1	0	5
			5	1	1	0	0	0	1	0	1	1	0	5
			6	1	1	0	0	0	1	1	0	1	0	5
10	35	IM	0	1	2	1	1	3	2	1	3	1	0	15
			1	1	1	1	0	3	1	1	2	1	0	11
			2	1	1	0	0	2	1	1	2	0	0	8
			3	1	0	0	0	1	1	1	2	0	0	6
			4	1	0	0	0	1	1	1	1	1	0	6
			5	1	0	0	1	1	1	1	1	1	0	7
			6	1	0	0	0	1	0	0	1	0	0	3
10	36	AK	0	1	2	1	2	1	1	1	3	2	0	14
			1	1	0	0	0	0	1	1	3	1	0	7
			2	1	1	0	0	0	0	1	3	0	0	6
			3	0	0	0	0	0	0	0	1	0	0	1
			4	0	0	0	0	0	0	0	0	0	0	0
			5	0	0	0	0	0	0	0	0	0	0	0
			6	0	0	0	0	0	0	0	0	0	0	0
10	37	HK	0	2	2	2	2	2	1	1	3	2	2	19
			1	1	0	0	0	1	1	1	1	2	1	8
			2	1	1	0	0	0	1	1	1	2	0	7
			3	1	0	0	0	0	0	0	1	0	1	3
			4	1	1	0	0	1	1	0	1	0	1	7
			5	1	1	0	0	1	0	0	1	1	1	6
			6	1	1	0	0	0	0	1	1	1	1	5
10	38	LL	0	1	2	1	0	2	0	0	3	2	1	12
			1	1	1	0	0	1	0	0	3	2	1	9
			2	0	0	0	0	1	0	0	1	1	0	3
			3	0	0	0	0	0	0	0	0	1	0	0
			4	0	0	0	0	0	0	0	0	0	0	0
			5	1	0	0	0	0	0	0	0	1	0	2
			6	0	0	0	0	0	0	0	0	1	0	1
10	39	VH	0	2	2	2	1	2	2	0	2	2	2	17
			1	2	1	1	1	1	2	0	2	2	1	13
			2	1	1	0	0	0	2	0	2	1	0	7
			3	1	1	0	0	0	1	0	1	1	0	5

1030

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
10	39	VN	4	1	1	0	0	0	1	0	1	1	0	5		
			5	1	1	0	0	1	2	1	2	2	1	11		
			6	1	1	0	1	1	2	2	0	2	1	1	10	
			0	1	1	1	0	1	1	1	1	1	1	1	9	
			1	1	0	0	0	1	1	1	1	1	1	0	7	
			2	1	0	0	0	1	1	1	1	0	1	0	4	
10	40	AP	3	1	0	1	0	0	1	0	1	0	0	4		
			4	1	0	1	0	0	1	0	0	1	0	4		
			5	0	0	0	0	0	0	0	0	0	0	0	2	
			6	1	0	0	0	0	0	0	0	0	1	0	1	
			0	1	0	0	0	0	0	0	0	0	0	1	0	2
			1	1	1	1	2	2	2	3	2	0	3	2	0	12
10	41	VP	2	1	1	1	0	1	2	0	0	2	2	0	10	
			3	1	1	1	0	1	2	0	0	2	2	0	10	
			4	1	1	1	0	1	2	1	2	1	2	0	11	
			5	1	1	1	0	1	1	1	1	1	1	2	0	9
			6	0	1	0	0	1	1	1	1	0	1	2	0	7
			0	3	3	2	3	3	2	3	2	2	2	2	2	24
10	42	TT	1	3	2	3	2	3	2	2	2	2	2	2	23	
			2	3	2	3	2	3	2	2	1	1	0	2	19	
			3	2	1	2	1	2	2	2	1	1	1	0	1	13
			4	2	1	1	1	2	2	2	1	1	1	0	1	12
			5	2	1	1	1	2	2	2	2	1	1	1	0	12
			6	1	1	1	0	2	2	2	2	2	1	1	0	11
10	43	IK	0	3	2	3	2	3	2	2	2	2	2	2	21	
			1	2	1	1	1	1	1	1	1	1	2	1	11	
			2	2	1	1	2	1	1	1	1	1	0	0	1	11
			3	1	1	0	0	1	1	1	0	0	1	0	2	13
			4	1	1	0	0	1	0	1	0	0	0	0	1	5
			5	0	1	0	0	1	0	1	0	0	0	0	0	4
10	44	AB	6	0	0	0	0	1	0	0	0	0	0	0	2	
			0	2	1	2	1	1	1	1	1	1	1	2	1	14
			1	2	1	0	1	1	1	1	1	1	0	2	1	11
			2	1	1	0	0	1	1	1	1	0	0	2	1	6
			3	1	1	0	0	0	1	0	0	0	0	2	2	7
			4	2	1	1	1	1	1	1	1	0	0	2	1	8
10	45	KJ	5	1	1	0	0	0	0	0	0	0	0	0	3	
			6	0	0	0	0	0	0	0	0	0	1	0	2	
			0	3	1	2	3	2	2	2	0	2	3	0	0	18
			1	1	1	1	2	1	1	0	1	1	1	0	0	8
			2	1	1	0	1	1	1	0	1	1	1	0	0	6
			3	1	1	1	1	1	1	1	1	1	1	0	0	8

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
10	45	KJ	4	2	0	0	1	1	0	1	1	1	0	7		
			5	1	0	0	0	1	0	1	0	0	1	0	4	
			6	1	0	0	0	0	0	0	1	1	0	0	3	
			0	2	2	2	2	2	2	2	2	2	3	0	0	17
			1	1	1	0	1	1	1	1	1	1	1	2	0	9
			2	1	2	0	1	1	1	1	1	1	2	2	0	10
10	46	TN	3	1	1	0	0	1	1	1	1	1	1	0	7	
			4	1	1	0	0	1	1	1	1	1	1	0	7	
			5	1	1	0	0	1	1	1	1	1	1	0	7	
			6	1	1	0	0	1	1	1	1	1	1	0	6	
			0	2	1	0	1	1	1	1	1	1	1	0	0	6
			1	1	1	0	1	1	1	1	1	1	1	0	0	6
10	47	TH	0	2	1	2	0	1	0	0	1	1	3	0	11	
			1	1	0	1	0	1	1	1	1	1	2	0	7	
			2	1	0	1	0	1	1	1	1	1	2	0	7	
			3	1	1	0	1	0	1	1	1	1	2	0	7	
			4	1	1	0	0	1	1	1	1	1	2	0	7	
			5	1	1	0	0	1	1	1	1	1	2	0	5	
10	48	IP	6	0	0	0	0	1	0	0	1	1	0	0	3	
			0	3	2	2	2	2	2	2	2	2	2	2	22	
			1	2	2	2	2	2	2	2	2	2	2	2	1	18
			2	2	2	2	2	2	2	2	2	2	2	2	1	17
			3	1	2	2	1	1	1	1	1	2	2	2	1	12
			4	1	2	1	1	0	0	0	0	0	2	2	1	11
10	49	VM	5	2	2	1	1	0	1	1	0	2	1	0	9	
			6	1	1	0	1	0	0	0	0	2	1	0	6	
			0	3	2	2	2	2	2	2	2	2	2	2	0	17
			1	2	2	1	1	1	1	1	1	2	2	1	0	12
			2	2	2	1	1	1	1	1	1	2	1	1	0	12
			3	1	2	0	1	1	1	1	0	1	1	1	0	8
10	50	EE	4	1	1	0	0	1	0	0	1	1	1	0	6	
			5	1	1	0	0	1	1	1	1	1	1	1	0	6
			6	1	1	1	0	1	1	1	1	1	1	0	0	6
			0	3	2	2	2	2	2	2	2	2	3	3	0	19
			1	2	2	1	2	2	2	2	2	2	3	2	0	18
			2	2	2	1	2	2	2	2	2	2	3	2	0	17
10	51	UL	3	2	1	2	1	2	2	2	2	2	2	0	14	
			4	2	2	1	2	1	2	2	2	2	2	0	13	
			5	2	2	2	0	1	2	2	2	2	2	1	1	13
			6	1	1	0	0	1	2	2	2	2	3	1	0	9
			0	2	2	2	1	2	2	2	2	2	2	0	1	14
			1	2	2	1	2	1	2	2	2	2	2	0	1	13

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
10	51	UL	4	1	1	0	0	1	0	1	1	1	1	7		
			5	1	0	0	0	0	0	0	0	1	0	1	4	
			6	0	1	0	0	0	0	0	0	0	0	0	0	1
			0	2	2	1	1	1	1	1	1	1	1	2	0	12
			1	1	1	0	1	0	1	1	1	0	1	1	0	6
			2	1	1	0	1	0	1	1	0	0	1	1	0	5
10	52	MP	3	0	1	0	1	1	0	0	1	1	0	4		
			4	1	1	0	1	1	1	0	1	0	0	0	5	
			0	2	2	1	1	1	1	1	1	1	1	2	0	14
			1	2	1	1	1	1	0	0	1	1	2	1	1	10
10	53	MA	2	1	1	1	1	0	0	1	1	1	1	1	8	
			3	1	1	1	1	0	0	1	1	1	1	0	4	
			4	1	0	0	0	0	0	0	0	1	1	0	0	3
			5	1	0	0	0	0	0	0	0	1	1	0	0	3
			6	1	0	0	0	0	0	0	0	1	0	0	0	2
			0	2	2	1	2	1	1	2	1	1	2	2	0	15
10	54	UN	1	2	2	1	0	2	1	1	2	2	0	0	10	
			2	2	2	1	0	2	1	1	1	2	1	1	0	12
			3	1	1	0	1	1	1	1	1	1	2	1	0	8
			4	2	1	1	0	1	1	1	1	1	2	1	0	10
			5	1	1	1	0	1	1	1	0	1	2	1	0	7
			6	1	0	0	0	1	1	1	0	1	1	1	0	5
10	55	TP	0	3	3	3	2	1	1	2	2	2	3	0	20	
			1	2	2	1	0	1	1	1	1	2	2	1	0	12
			2	1	1	1	0	0	0	0	1	2	2	1	0	9
			3	1	1	0	0	0	0	0	1	2	2	1	0	8
			4	1	1	0	0	0	0	0	1	1	2	0	0	5
			5	1	2	0	0	0	1	1	1	1	2	1	0	8
10	56	JP	6	1	0	0	0	0	0	0	1	2	0	0	4	
			0	1	1	1	1	1	2	1	1	1	2	2	0	12
			1	1	1	0	0	1	1	0	0	0	2	1	0	6
			2	0	0	0	0	0	0	0	0	0	1	2	0	4
			3	0	0	0	0	0	0	0	0	0	1	2	0	3
			4	0	0	0	0	0	0	0	0	0	1	1	0	3
10	57	AG	5	0	0	0	0	1	0	0	0	0	1	0	4	
			0	2	2	2	1	2	2	1	1	1	3	1	0	16
			1	1	0	0	1	1	0	0	0	0	3	1	0	6
			2	1	0	0	1	1	0	0	0	1	2	1	0	7
			3	1	1	0	0	0	0	0	0	0	1	1	0	4
10	58	AG	4	0	2	0	0	0	0	0	3	1	0	0	6	
			5	1	2	1	0	0	0	0	0	0	3	1	0	9

1033

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD

REBOXETINE - PROTOCOL 20124/013
Listing No.: 40.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
10	57	AG	6	1	0	0	1	0	0	1	3	2	0	8
10	58	RK	0	2	1	2	2	2	2	2	3	2	1	19
			1	1	0	0	2	1	1	2	3	2	1	13
			2	1	1	1	1	1	1	2	3	2	1	14
			3	1	1	0	0	0	0	1	2	1	1	7
			4	1	1	0	0	0	0	1	1	2	1	7
			5	0	1	0	0	0	0	0	1	0	1	3
			6	0	0	0	0	0	0	0	1	0	0	1
10	59	TA	0	1	1	1	0	2	2	0	3	1	1	12
			1	1	2	0	0	0	2	0	3	1	1	10
			2	1	1	0	0	0	1	0	3	1	1	9
			3	1	1	0	0	0	1	0	3	1	0	7
			4	1	1	0	0	1	1	0	3	1	0	6
			5	1	2	0	1	2	2	0	3	2	1	14
			6	1	1	0	0	1	1	1	3	1	0	9
10	60	JH	0	1	1	1	0	2	2	1	3	1	1	13
			1	1	1	0	0	0	1	1	1	1	0	6
			2	1	1	0	0	0	1	1	1	1	0	6
			3	1	1	1	2	1	2	2	1	2	0	13
			4	1	1	0	0	0	0	1	0	2	0	5
			5	0	0	0	0	0	0	0	0	1	0	1
			6	0	1	0	0	0	0	0	0	1	0	2
10	61	JT	0	2	2	2	2	2	2	1	2	3	1	19
			1	2	2	1	1	2	2	1	2	3	1	18
			2	2	2	1	1	2	2	1	2	2	1	16
			3	2	2	1	1	2	2	1	2	2	1	16
			4	2	1	1	1	2	2	1	2	2	1	15
			5	1	2	1	1	2	2	1	2	2	0	13
			6	1	1	0	1	1	1	1	2	1	0	9
10	62	RK	0	2	2	2	0	1	1	1	2	2	0	13
			1	1	1	0	0	1	1	1	2	2	0	11
			2	1	1	0	0	1	1	1	2	1	0	8
			3	1	1	0	0	1	1	1	2	1	0	7
			4	1	1	0	0	0	1	1	2	0	0	6
			5	0	1	0	0	1	1	1	2	0	0	5
			6	0	1	0	0	0	0	1	1	1	0	4
10	63	MS	0	2	2	1	1	1	1	0	1	3	0	12
			1	2	2	1	0	1	1	0	1	3	0	11
			2	1	1	0	0	1	1	0	1	2	0	7
			3	1	1	0	0	0	1	0	0	3	0	6
			4	1	1	0	0	0	1	0	0	1	0	4
			5	0	1	0	0	0	0	0	0	1	0	2

1034

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.2
 MONTGOMERY ASBERG DEPRESSION RATING SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
10	53	MS	6	0	1	0	0	0	0	0	0	0	0	1
10	64	LT	0	3	1	3	3	2	2	1	2	3	2	22
			1	2	1	2	2	2	2	1	2	3	2	19
			2	1	1	1	1	1	2	0	2	2	1	12
			3	1	1	1	1	2	1	0	2	1	1	11
			4	1	1	0	0	1	1	0	1	1	0	6
			5	1	1	0	0	1	1	0	1	1	0	6
			6	0	1	0	0	1	1	0	1	1	0	5
10	81	JN	0	2	2	2	1	2	1	1	2	2	0	15
			1	2	1	1	0	1	0	1	2	1	1	10
			2	1	1	0	0	0	0	0	1	1	1	5
			3	1	1	0	0	0	0	0	1	1	0	4
			4	1	1	0	0	0	0	0	0	1	1	4
			5	1	1	0	0	0	0	0	0	0	0	2
			6	1	1	0	0	0	0	0	0	0	0	2
10	82	LS	0	2	2	2	1	2	2	2	2	1	0	16
			1	2	2	0	0	2	2	2	2	2	0	14
			2	2	2	0	0	1	2	1	2	2	1	13
			3	2	2	0	0	1	2	1	2	1	1	12
			4	2	2	0	0	1	2	1	2	1	1	12
			5	1	1	0	0	1	2	1	2	1	0	9
			6	1	1	0	0	1	2	1	2	1	0	8
10	83	KL	0	2	1	2	2	2	3	1	3	2	2	20
			1	0	1	0	0	1	1	0	1	1	1	6
			2	1	1	0	1	1	1	1	1	2	1	10
			3	1	0	0	1	1	1	1	1	0	1	7
			4	1	1	1	2	2	2	2	1	1	1	14
			5	1	1	0	0	0	1	0	1	1	0	4
			6	1	1	0	1	1	1	1	1	2	1	10
10	84	HV	0	2	2	2	2	3	2	2	3	1	1	20
			1	1	1	1	1	2	2	2	3	2	0	15
			2	1	2	1	1	2	2	2	3	2	1	17
			3	1	1	1	1	1	2	2	3	2	1	15
			4	1	1	1	1	1	1	1	3	2	1	13
			5	1	1	0	1	1	1	1	3	2	1	12
			6	1	1	0	1	1	1	1	3	2	1	12
10	85	AK	0	2	2	1	1	0	1	1	2	0	0	10
			1	2	2	1	0	0	1	1	2	1	0	10
			2	1	2	0	0	0	1	0	2	1	0	7
			3	1	2	0	0	0	1	0	1	1	0	6
			4	1	2	1	0	0	1	0	1	1	0	6
			5	1	2	0	0	0	0	0	1	0	0	4

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.2
 MONTGOMERY ASBERG DEPRESSION RATING SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
10	85	AK	6	1	2	0	0	0	0	0	1	0	0	4
10	86	NP	0	3	2	2	2	2	1	2	2	3	2	21
			1	1	2	1	0	1	0	1	2	2	1	11
			2	1	1	0	0	0	0	1	1	2	1	7
			3	1	1	1	0	0	0	1	1	2	1	8
			4	1	1	1	0	1	1	1	2	1	1	10
			5	1	1	1	1	0	0	1	1	2	1	9
			6	1	2	1	0	1	0	1	1	2	0	9
10	87	AN	0	2	1	2	1	2	1	0	2	2	0	13
			1	1	1	0	0	1	1	0	2	2	0	8
			2	1	1	0	0	1	1	0	2	2	0	7
			3	1	1	0	0	1	1	0	2	1	0	7
			4	1	1	1	0	1	1	0	1	1	0	7
			5	1	1	1	0	1	0	0	1	1	0	5
			6	1	1	0	0	1	0	0	1	1	0	5
10	88	AH	0	2	2	2	0	1	0	1	2	2	0	12
			1	1	2	1	0	1	0	1	2	1	0	9
			2	1	1	0	0	1	0	0	2	1	0	6
			3	1	1	0	0	1	0	0	2	1	0	5
			4	1	1	1	0	0	0	0	1	2	0	6
			5	1	1	1	0	0	0	0	1	1	0	4
			6	1	1	0	0	0	0	0	1	1	0	4
10	89	SK	0	2	2	1	0	2	1	1	2	1	1	13
			1	1	2	1	0	1	1	1	2	1	0	10
			2	1	1	0	0	1	0	1	2	1	0	7
			3	1	1	0	0	0	0	1	2	0	1	6
			4	1	1	0	0	0	0	1	1	0	1	5
			5	1	1	0	0	0	0	1	1	0	1	4
			6	0	1	0	0	0	0	0	1	0	0	2
10	90	SV	0	1	2	2	1	2	2	1	2	2	1	16
			1	1	2	0	0	1	1	0	2	2	1	9
			2	1	1	0	0	1	0	0	2	1	0	6
			3	0	1	0	0	0	0	0	2	1	0	4
			4	0	1	0	0	0	0	0	2	1	0	4
			5	1	0	1	0	0	0	0	1	1	0	5
			6	0	1	0	0	1	1	0	1	1	0	5
10	91	HI	0	1	0	2	1	1	1	1	2	1	1	11
			1	2	1	2	1	1	1	1	2	1	1	13
			2	1	1	0	0	0	0	0	1	1	0	4
			3	1	1	0	0	0	0	0	0	1	0	3
			4	0	0	0	0	0	0	0	0	2	0	2
			5	0	0	0	0	0	0	0	0	1	0	1

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASEBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
10	91	HI	6	0	0	0	0	0	0	0	0	1	0	1
10	92	LA	0	1	2	1	1	2	2	1	1	2	2	15
			1	1	1	0	0	1	1	1	1	1	1	9
			2	1	1	0	0	0	0	0	0	1	0	4
			3	1	1	0	0	0	0	0	0	1	1	4
			4	1	1	0	0	0	0	0	1	1	0	4
			5	0	0	0	0	0	0	0	1	1	0	4
			6	0	0	0	0	1	0	0	1	1	0	2
10	93	AN	0	2	1	1	1	2	1	1	2	0	0	11
			1	1	1	1	0	1	1	0	1	0	0	6
			2	1	1	0	0	0	0	0	0	0	0	3
			3	0	1	0	0	0	0	0	0	0	0	1
			4	0	1	0	0	0	0	0	0	0	0	1
			5	0	1	0	0	0	0	0	0	0	0	1
			6	0	0	0	0	0	0	0	0	0	1	2
10	94	PV	0	2	2	2	1	2	2	1	2	2	2	18
			1	2	1	2	1	1	1	2	2	1	1	14
			2	2	1	1	1	1	2	1	2	1	0	12
			3	1	1	1	1	1	2	1	2	1	0	11
			4	1	1	1	1	1	2	1	2	1	0	11
			5	1	1	1	0	1	2	1	2	1	0	10
			6	1	1	1	0	1	2	1	2	1	0	9
11	1	DF	0	2	2	2	1	2	1	1	1	2	1	15
			1	1	1	1	1	2	1	1	2	2	1	13
			2	1	1	1	1	1	1	1	2	2	0	10
			3	0	1	1	1	1	1	0	1	2	0	8
			4	1	1	0	0	1	0	0	1	2	0	7
			5	0	0	0	0	1	1	1	1	2	0	6
			6	0	1	0	0	1	0	1	0	1	0	4
11	2	HB	0	2	2	1	3	2	1	1	1	2	1	16
			1	1	1	1	1	1	1	1	1	2	0	10
			2	0	1	1	0	1	1	0	1	1	0	6
			3	0	0	0	0	0	0	0	0	1	0	1
			4	0	0	0	0	0	0	0	0	1	0	1
			5	0	0	0	0	0	0	0	0	0	0	0
			6	0	0	0	0	0	0	0	0	0	0	0
11	3	RF	0	2	2	2	3	2	1	2	1	2	1	18
			1	1	1	1	1	1	1	1	1	2	1	11
			2	1	1	1	0	1	1	1	1	2	1	10
			3	0	0	0	0	0	0	1	1	1	0	3
			4	1	1	1	1	1	1	1	1	2	0	10
			5	1	1	1	1	1	0	1	0	1	0	7

1037

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASEBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
11	3	RF	6	0	2	1	1	1	0	1	2	2	0	10
11	4	BA	0	2	2	2	1	2	1	1	2	2	1	16
			1	2	2	2	1	2	1	1	1	2	1	15
			2	1	1	1	0	2	1	1	1	2	1	11
			3	1	1	1	0	1	0	1	1	1	0	7
			4	1	1	1	0	1	0	1	1	1	1	8
			5	1	1	1	0	1	0	1	1	1	1	7
			6	1	1	1	0	1	0	1	1	1	0	6
11	5	ZM	0	3	2	2	2	2	2	2	2	2	1	20
			1	3	2	2	2	2	2	2	2	2	0	19
			2	3	1	3	2	2	3	2	1	1	0	18
			3	3	3	3	3	2	2	2	2	2	0	22
11	6	VP	0	2	2	1	1	1	2	2	2	3	2	18
			1	0	1	0	0	1	0	1	1	1	0	5
			2	0	1	1	0	1	0	1	1	0	0	5
			3	0	1	1	0	0	0	1	0	1	0	3
			4	0	1	0	0	0	0	1	0	1	0	3
			5	0	0	0	0	1	0	1	1	0	0	3
			6	0	0	0	0	0	0	0	0	1	0	1
11	7	KK	0	2	2	2	1	2	2	1	1	2	1	16
			1	1	1	1	0	1	0	1	0	1	1	7
			2	1	1	1	0	1	0	1	0	1	1	7
			3	0	1	1	0	0	0	1	0	0	0	3
			4	1	1	1	0	0	0	1	0	0	1	5
			5	1	1	1	0	0	0	1	1	1	1	7
			6	1	1	1	0	0	0	1	1	1	1	5
11	8	KF	0	2	2	2	1	2	2	1	1	2	2	17
			1	1	1	1	0	1	0	1	1	2	2	10
			2	2	2	1	0	1	0	1	0	2	2	11
			3	2	1	2	1	2	1	2	1	2	2	16
11	9	FI	0	2	2	2	2	1	2	2	1	2	1	17
			1	1	1	1	1	1	0	1	1	2	1	10
			2	1	2	1	1	0	0	1	1	3	2	12
			3	1	1	1	0	1	0	1	1	1	1	8
			4	1	1	1	1	1	1	1	1	1	1	10
			5	1	1	1	0	1	1	1	1	2	1	9
			6	1	1	1	0	1	1	1	1	2	2	11
11	10	BJ	0	2	2	2	0	2	1	2	1	2	0	14
			1	1	1	1	0	1	1	1	1	2	1	10
			2	0	1	1	0	1	1	1	1	1	1	8
			3	1	1	0	0	1	1	1	1	1	0	7

1038

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
11	10	BJ	4	0	1	0	0	1	1	1	1	1	0	6		
			5	0	1	1	0	0	1	1	1	1	2	0	7	
			6	0	1	0	0	0	0	1	0	0	0	1	0	3
			0	2	2	1	2	1	2	2	2	2	2	2	0	17
			2	1	1	0	0	0	0	0	2	1	1	3	0	13
			3	0	1	0	0	0	0	0	0	1	1	3	1	9
11	11	NGY	4	0	1	0	0	0	0	0	0	0	0	0	6	
			5	0	0	0	0	0	0	0	0	0	0	0	4	
			6	0	0	0	0	0	0	0	0	0	0	1	0	4
			0	1	2	1	2	1	2	2	2	2	2	2	0	1
			1	1	1	0	0	0	0	0	0	0	0	1	0	1
			2	1	2	0	0	1	1	1	1	1	1	1	0	8
11	12	PJ	0	1	2	1	1	1	0	1	1	0	1	1	8	
			1	2	2	0	3	2	2	2	2	2	2	2	1	19
			2	1	2	0	2	1	1	1	1	1	1	2	1	13
			3	1	1	1	2	1	1	1	1	1	1	1	2	11
			4	1	2	1	0	0	1	1	1	0	1	2	1	9
			5	1	1	1	0	0	1	1	1	1	0	2	0	7
11	13	GK	0	2	2	2	1	2	2	2	2	2	2	1	5	
			1	1	1	1	1	1	1	1	1	1	1	1	1	16
			2	1	2	1	1	1	1	1	1	1	1	1	1	11
			3	2	2	1	0	0	2	2	2	2	2	2	0	9
			4	2	2	2	2	3	2	2	2	2	2	3	2	19
			5	2	2	2	2	2	2	2	2	2	2	3	1	20
11	14	BJ	0	2	1	2	2	3	2	2	2	2	2	2	22	
			1	2	1	1	2	2	2	2	2	2	2	2	1	13
			2	0	0	0	1	1	1	1	1	1	1	0	0	12
			3	1	1	1	2	1	2	1	1	1	1	1	0	3
			4	3	2	3	1	3	3	3	3	2	2	3	3	25
			0	2	2	1	1	2	2	2	2	2	2	2	1	15
11	15	NF	1	1	1	1	1	1	2	2	1	1	2	1	11	
			2	1	1	1	2	1	1	1	1	1	1	0	11	
			3	1	1	1	0	2	1	1	1	1	0	1	0	8
			4	1	1	1	0	1	1	1	1	1	0	3	0	8
			5	2	1	1	0	1	1	1	1	1	1	2	1	12
			6	3	2	2	1	2	1	2	1	1	1	2	1	16
11	16	NA	0	3	2	2	2	2	2	2	2	2	3	2	22	
			1	2	1	2	1	1	1	1	1	1	1	1	1	13
			2	3	2	3	1	2	2	2	2	2	2	1	2	19
			3	1	2	2	1	1	1	1	1	1	0	2	1	13
			4	2	2	2	0	2	2	2	2	2	2	2	1	14
			5	2	2	3	1	2	1	1	1	1	1	2	1	16

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 40.2

MONTGOMERY ASEBerg DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
11	16	NA	6	2	1	1	1	1	1	1	1	1	1	11
11	17	UZ	0	2	2	2	1	2	3	2	2	1	1	18
			1	1	1	1	1	1	1	1	1	1	0	10
			2	1	1	1	0	1	1	0	1	1	1	8
			3	1	1	1	0	1	1	1	2	1	0	9
			4	1	1	0	1	1	1	0	1	0	0	5
			5	1	1	1	1	1	1	1	0	1	1	9
			6	1	1	1	0	1	1	1	0	2	1	9
11	18	EI	0	2	2	2	1	2	2	1	1	1	1	15
			1	1	1	1	0	2	1	1	0	1	1	9
			2	1	1	1	0	1	1	0	0	1	1	7
			3	1	1	1	0	2	1	0	0	1	1	7
			4	1	1	2	0	2	1	1	1	2	1	10
			5	1	1	1	0	2	1	2	1	1	1	12
			6	1	1	1	0	1	0	0	0	1	0	5
11	19	FK	0	2	2	2	1	1	1	0	0	1	1	7
			1	1	1	2	1	2	2	1	1	2	1	16
			2	1	1	2	1	1	2	1	1	1	1	12
			3	1	0	1	0	0	1	1	0	0	1	8
			4	0	0	0	0	0	0	0	0	0	0	2
			5	0	0	0	0	1	1	1	0	1	0	3
			6	1	1	0	1	1	0	0	0	1	0	5
11	20	LJ	0	2	2	2	1	2	2	1	1	2	2	17
			1	2	1	2	1	2	2	1	1	1	1	14
			2	2	1	2	1	0	1	1	1	2	1	12
			3	1	1	2	0	1	1	1	0	2	1	9
			4	1	1	1	0	1	1	1	0	2	1	9
			5	1	1	2	1	2	1	1	1	2	0	12
			6	2	1	1	0	0	1	1	1	1	1	9
12	1	IB	0	3	1	1	0	2	2	1	2	2	2	16
			1	2	1	1	0	2	1	1	2	1	1	11
			2	1	1	1	0	1	1	1	1	0	1	8
			3	1	1	1	0	1	1	1	1	0	1	8
			4	1	2	1	1	2	1	1	1	0	1	11
			5	1	1	2	0	2	2	0	0	0	1	9
			6	0	1	1	0	1	1	0	1	0	0	5
12	2	BFC	0	3	3	2	2	2	2	2	1	3	2	22
			1	3	2	2	2	2	2	2	1	3	2	21
			2	3	2	3	2	2	2	2	1	3	2	22
			3	3	2	3	2	2	2	2	1	3	2	22
			4	2	2	2	1	2	2	2	1	2	1	16
			5	2	2	2	2	2	1	2	1	2	1	17

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.2
 MONTGOMERY ASBERG DEPRESSION RATING SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
12	2	EFC	6	2	2	2	1	2	1	2	1	2	1	16
12	3	IF	0	2	2	2	0	2	2	1	0	2	0	13
			1	1	2	2	0	2	2	1	0	3	0	13
			2	1	1	1	0	2	2	1	0	2	0	10
			3	1	1	1	0	1	2	1	0	2	0	9
			4	0	1	0	0	1	1	1	0	1	0	5
			5	0	1	0	0	0	0	0	0	1	0	2
			6	0	0	0	0	0	0	0	0	0	0	0
12	4	EG	0	2	2	2	2	2	1	2	1	2	2	18
			1	2	2	2	2	2	1	2	1	2	2	18
			2	2	1	2	1	2	1	2	1	2	2	17
			3	1	1	1	1	1	2	1	0	1	2	11
			4	0	1	2	1	0	0	1	0	1	1	7
			5	0	1	1	1	0	1	1	0	1	1	7
			6	1	2	1	1	1	2	1	0	1	1	11
12	5	ZSH	0	1	1	2	1	2	2	2	1	2	1	15
			1	1	1	2	1	2	2	2	1	2	1	15
			2	1	1	2	1	2	2	2	1	2	0	14
			3	1	1	2	1	2	2	2	1	2	0	14
			4	1	1	2	1	2	2	2	1	2	0	14
			5	1	1	2	1	1	1	1	1	2	0	12
			6	1	1	2	1	1	1	1	2	2	0	12
12	6	MK	0	3	2	3	1	1	2	2	2	2	1	19
			1	2	2	2	0	1	2	2	2	2	1	16
			2	1	1	1	0	1	1	1	1	1	1	9
			3	0	1	0	0	1	1	1	1	0	1	6
			4	1	2	1	1	2	1	1	1	0	1	11
			5	1	1	2	1	2	2	1	1	2	2	14
			6	1	0	0	0	1	1	1	1	1	0	6
12	7	LK	0	2	2	2	0	2	1	2	2	3	2	18
			1	1	2	2	0	1	1	1	2	2	1	13
			2	1	2	1	0	1	0	1	0	2	1	9
			3	1	1	0	0	2	1	0	1	2	0	10
			4	1	1	1	0	2	1	0	1	1	0	8
			5	1	1	1	0	2	1	1	1	1	0	8
			6	1	2	2	0	1	1	1	1	1	0	10
12	8	FM	0	2	2	2	2	2	3	2	2	2	2	21
			1	2	2	2	1	2	2	2	2	2	2	19
			2	2	2	2	2	2	2	2	2	2	2	20
			3	2	2	2	1	2	2	2	2	2	0	17
			4	2	2	2	2	2	2	2	2	2	2	20
			5	2	2	2	1	2	2	2	2	2	2	19

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
12	8	FM	6	2	2	2	1	2	2	2	2	2	2	19
12	9	KBP	0	2	2	2	0	2	2	1	1	2	0	14
			1	2	2	1	0	2	2	1	1	2	0	13
			2	2	2	1	0	2	1	1	1	2	0	12
			3	2	2	1	0	2	1	1	1	2	0	12
			4	2	2	1	0	2	1	1	1	2	0	12
			5	2	2	1	0	2	1	1	1	2	0	12
			6	2	2	1	0	2	1	1	1	2	0	11
12	10	IP	0	3	2	3	2	2	3	2	2	3	2	24
			1	3	2	3	2	2	3	2	2	3	2	24
			2	2	1	2	1	2	2	1	1	2	2	16
			3	3	2	1	1	2	2	1	1	2	2	18
			4	3	1	1	2	2	2	1	1	2	2	17
			5	3	1	1	1	2	2	1	1	2	1	14
			6	3	1	1	1	1	2	1	1	2	1	14
12	11	ER	0	1	2	2	0	1	1	1	2	2	2	14
			1	1	1	1	0	1	1	1	2	2	1	12
			2	1	1	1	0	1	0	1	1	2	1	9
			3	1	2	2	0	1	0	1	1	2	2	12
			4	1	1	2	0	1	0	1	1	2	2	11
			5	1	1	1	0	1	0	1	1	2	1	9
			6	1	1	1	0	0	0	1	1	1	2	8
12	12	FSZ	0	2	2	2	2	2	2	2	3	2	1	20
			1	2	2	2	1	2	2	2	2	2	2	20
			2	2	1	2	1	1	2	2	2	1	1	15
			3	1	1	2	1	1	1	2	2	1	1	13
			4	1	1	2	1	1	1	2	2	1	1	13
			5	1	1	2	1	1	2	2	1	1	1	13
			6	2	2	2	2	1	2	3	1	0	0	15
12	13	ISZ	0	3	1	2	1	1	2	2	1	2	2	17
			1	2	1	2	1	1	2	1	1	1	2	14
			2	1	1	1	1	1	2	1	1	1	2	12
			3	1	1	1	1	1	2	1	1	1	2	12
			4	1	1	1	0	1	1	1	0	2	1	9
			5	0	1	1	0	0	1	1	0	1	1	6
			6	0	1	1	0	0	1	1	0	1	1	6
12	14	GSZ	0	2	2	2	1	1	2	1	2	2	0	15
			1	2	1	1	1	1	2	1	1	1	0	11
			2	1	0	1	0	1	1	1	1	1	0	7
			3	1	0	1	0	1	1	0	1	1	0	6
			4	2	1	2	1	1	1	1	1	2	1	13
			5	1	0	1	0	1	1	0	0	1	0	5

1042

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.2
 MONTGOMERY ASBERG DEPRESSION RATING SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
12	14	GSZ	6	1	0	1	0	1	1	1	0	0	0	5
12	15	GB	0	1	1	2	1	2	2	2	1	2	1	15
			1	1	1	2	1	2	2	2	1	2	1	15
			2	1	1	2	2	1	2	2	1	2	1	15
			3	1	1	2	2	1	2	2	1	2	1	15
			4	1	1	2	2	1	2	2	1	2	1	15
			5	1	1	1	0	0	1	2	0	2	1	7
			6	1	1	2	1	1	1	1	0	1	0	9
12	16	FN	0	2	2	2	0	2	2	0	0	2	2	14
			1	2	1	2	0	2	2	0	0	2	2	13
			2	1	1	1	0	1	1	0	0	0	0	5
			3	1	0	1	0	0	0	0	0	0	0	2
			4	1	0	1	0	0	0	0	0	0	0	2
			5	0	1	1	0	0	0	0	0	0	0	2
			6	1	1	1	0	1	0	0	0	1	0	5
12	17	TK	0	1	0	1	0	2	2	1	1	1	1	10
			1	1	0	1	0	2	2	1	1	1	1	10
			2	1	0	2	1	2	2	1	1	1	1	12
			3	1	0	1	0	2	1	1	1	0	2	9
			4	1	0	1	0	1	1	1	1	0	1	7
			5	1	0	1	0	1	1	1	1	0	1	6
			6	1	0	0	0	1	0	1	1	0	0	4
12	18	LS	0	1	1	2	1	1	2	1	1	2	2	15
			1	1	1	2	1	1	2	1	1	2	2	14
			2	1	1	1	1	1	2	1	1	2	2	14
			3	1	1	1	1	1	2	1	1	2	1	12
			4	1	1	1	0	2	1	1	1	2	0	10
			5	0	0	1	0	1	1	0	0	2	0	5
			6	0	0	1	0	1	1	0	0	1	1	5
12	19	SSZ	0	2	2	2	1	2	3	1	2	2	0	17
			1	1	2	2	0	2	2	1	1	2	0	13
			2	1	2	2	0	2	2	1	1	2	0	13
			3	1	0	1	0	0	0	1	0	0	0	3
			4	1	1	1	0	1	1	1	0	0	0	8
			5	1	1	1	0	0	1	1	0	1	0	5
			6	0	1	0	0	0	0	1	0	1	0	3
12	20	KSZ	0	3	2	2	3	3	2	2	0	3	3	23
			1	3	2	2	2	3	2	2	0	3	2	21
			2	2	1	2	1	2	1	1	0	2	0	12
			3	1	1	1	0	0	0	0	0	1	0	4
			4	2	2	2	2	1	1	0	0	3	0	13
			5	1	1	1	0	1	0	1	0	2	0	7

1043

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.2
 MONTGOMERY ASBERG DEPRESSION RATING SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
12	20	KSZ	6	1	1	1	0	0	0	0	0	1	0	4
12	21	FL	0	2	2	2	1	2	1	0	0	3	1	14
			1	0	1	1	0	1	1	0	0	3	1	8
			2	0	1	0	0	1	1	0	0	0	1	4
			3	0	1	1	0	1	1	0	0	1	0	5
			4	0	1	1	0	1	1	0	0	1	0	5
			5	0	1	1	0	1	1	0	0	1	0	4
			6	0	1	0	0	0	1	0	0	0	0	2
12	22	MV	0	2	2	2	2	3	2	1	1	3	2	20
			1	2	2	2	1	2	1	1	1	3	0	15
			2	2	2	2	2	2	2	1	1	2	2	18
			3	1	1	1	0	1	0	0	1	1	2	8
			4	1	1	2	0	1	0	0	0	1	0	6
			5	1	1	1	0	0	0	0	0	1	0	4
			6	1	1	1	0	0	0	0	0	1	0	4
12	23	EN	0	3	3	3	2	3	3	3	2	3	2	27
			1	3	2	2	2	2	2	3	2	3	2	25
			2	3	2	2	2	2	2	2	2	2	2	22
			3	3	2	2	1	1	1	3	2	1	2	19
			4	2	2	2	1	0	2	2	1	0	1	13
			5	0	1	1	0	0	1	2	1	0	0	6
			6	0	1	0	0	0	1	1	1	0	0	4
12	24	MF	0	1	2	2	2	2	2	1	2	2	2	18
			1	1	2	2	1	2	2	1	2	2	2	17
			2	1	1	1	0	1	1	1	1	1	1	9
			3	0	0	0	0	1	0	0	1	0	0	2
			4	0	0	0	0	1	0	0	1	0	0	2
			5	0	0	0	0	1	0	0	1	1	0	3
			6	0	0	0	0	1	0	0	1	0	0	2
12	25	FS	0	2	2	3	1	2	3	2	2	3	2	22
			1	2	1	2	1	2	1	1	2	3	1	17
			2	1	1	1	1	2	2	1	1	3	0	13
			3	1	0	1	0	1	1	1	1	3	0	9
			4	1	0	1	0	1	0	1	0	2	0	6
			5	1	1	1	1	1	0	1	0	1	0	7
			6	1	1	1	1	1	0	1	1	1	0	8
12	26	LB	0	2	2	2	1	1	1	1	1	3	1	15
			1	2	2	2	1	1	1	1	1	2	1	14
			2	2	2	2	1	1	1	1	1	2	1	14
			3	1	2	1	1	1	1	1	1	1	1	11
			4	1	2	1	1	1	1	1	1	1	1	11
			5	1	2	1	1	1	1	1	1	2	1	12

1044

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOMETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
12	26	LB	6	1	2	1	1	1	1	1	1	2	1	12		
			0	3	2	3	2	2	2	3	0	3	2	22		
			1	2	2	2	2	2	0	1	1	0	1	0	13	
			2	2	2	2	2	0	0	0	0	2	1	0	11	
			3	1	1	1	0	0	0	0	0	2	1	0	8	
			4	0	1	1	0	0	0	0	0	2	0	1	0	5
12	27	VCS	5	0	1	1	0	0	0	1	0	1	0	4		
			6	0	1	0	0	0	0	0	0	0	1	0	2	
			0	1	2	1	2	2	2	2	1	1	1	2	15	
			1	1	1	0	2	1	2	2	1	0	2	2	9	
			2	1	1	0	2	1	1	1	1	0	2	1	1	8
			3	1	1	0	0	0	0	0	0	0	0	2	1	7
12	28	IV	4	1	1	1	0	0	0	0	0	1	0	5		
			5	1	1	1	0	0	0	0	0	0	1	0	4	
			6	1	1	1	0	0	0	0	0	0	1	0	4	
			0	3	2	1	2	3	2	2	2	1	2	2	18	
			1	3	2	2	2	2	2	2	2	1	2	1	0	13
			2	3	2	2	2	2	2	2	2	1	2	1	0	12
12	29	AK	3	2	2	1	2	2	2	1	0	0	0	0	10	
			4	1	1	1	1	1	0	0	0	0	0	0	4	
			5	0	1	1	0	0	0	0	0	0	0	0	1	
			6	1	1	1	0	0	1	1	1	0	0	1	0	5
			0	3	3	2	3	3	3	3	3	2	2	3	2	26
			1	3	2	2	2	2	2	2	2	2	2	2	1	24
12	30	FS	2	2	2	2	2	2	2	2	2	2	2	1	19	
			3	2	2	2	2	2	2	2	2	2	2	1	18	
			4	2	2	2	2	2	2	2	2	2	2	1	0	16
			5	2	2	2	2	2	2	2	2	2	2	0	0	14
			0	2	2	1	2	2	2	2	2	2	2	2	2	17
			1	2	2	1	2	2	2	2	2	1	2	1	1	15
12	31	FH	2	2	1	2	2	2	2	2	1	2	1	0	13	
			3	2	1	2	2	2	2	2	2	2	1	0	13	
			4	2	1	2	1	2	2	2	2	1	1	0	0	13
			5	1	1	1	2	2	2	2	2	1	1	0	0	13
			6	1	1	1	0	1	1	1	1	1	1	1	0	11
			0	1	1	2	2	2	2	2	2	1	2	1	1	13
12	32	LM	1	1	0	1	2	2	2	2	1	1	2	1	13	
			2	1	1	0	2	2	2	2	2	1	2	1	1	13
			3	2	1	2	2	2	2	2	2	1	2	1	0	12
			4	2	0	2	0	2	2	2	2	1	1	0	0	10
			5	2	2	2	0	2	2	2	2	2	1	1	1	14
			6	2	2	2	0	2	2	2	2	2	1	1	1	15

1045

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
12	33	LN	0	2	1	2	2	2	2	2	2	1	0	16		
			1	2	1	2	2	2	2	2	2	2	0	0	15	
			2	2	1	2	2	2	2	2	2	2	0	0	13	
			3	1	0	1	1	1	1	1	1	1	1	0	0	6
			4	1	0	1	0	1	1	1	1	1	1	0	0	6
			5	0	0	1	0	1	1	1	1	1	1	0	0	5
12	34	TGS	6	0	0	1	0	1	0	1	1	0	0	0	4	
			0	2	2	2	2	2	2	2	2	2	3	2	21	
			1	2	2	1	1	1	1	1	1	1	2	2	2	19
			2	1	2	1	1	1	1	1	1	1	2	2	2	16
			3	1	1	1	0	1	1	1	1	1	1	2	2	12
			4	1	1	1	0	0	1	1	1	1	1	2	1	9
12	35	LP	5	0	1	1	0	0	1	1	1	1	0	0	5	
			6	0	1	0	0	0	0	0	0	0	0	1	0	2
			0	3	3	2	2	2	2	2	1	2	1	3	0	19
			1	3	2	1	1	1	1	1	1	2	1	2	0	16
			2	3	2	1	1	1	1	1	1	2	1	2	0	16
			3	2	2	1	1	1	1	1	1	2	1	1	0	13
12	36	FB	4	2	2	2	0	1	1	1	1	1	1	0	11	
			5	1	1	1	0	0	1	1	0	1	1	0	5	
			6	1	1	1	1	0	1	0	1	0	0	1	0	6
			0	3	2	1	3	2	2	2	2	1	0	3	0	17
			1	2	2	0	3	2	2	2	2	1	0	3	0	15
			2	2	2	0	2	2	2	2	2	1	0	3	0	14
12	37	EK	3	1	1	2	0	2	2	2	1	0	2	0	12	
			4	1	1	2	0	2	1	1	1	0	2	0	10	
			5	1	1	2	0	1	1	1	1	1	0	2	0	9
			6	1	1	2	0	1	1	1	1	1	0	1	0	8
			0	1	2	1	1	1	1	1	1	0	1	2	0	9
			1	1	2	1	1	1	1	1	1	0	1	2	0	9
12	38	FG	2	1	1	1	0	1	1	1	0	1	2	0	9	
			3	1	1	1	0	1	1	1	0	1	2	0	9	
			4	1	1	0	0	1	0	0	0	0	1	1	0	5
			5	1	1	0	0	1	0	0	0	0	1	1	0	5
			6	0	1	1	0	1	0	0	0	0	1	0	0	5
			0	3	2	1	2	2	2	2	2	1	2	2	2	19
12	38	FG	1	3	1	2	1	1	1	2	0	2	2	2	16	
			2	2	1	1	1	1	1	1	1	0	2	2	2	13
			3	2	1	1	1	1	1	1	1	0	2	2	2	13
			4	3	2	1	1	1	1	1	1	0	2	2	2	20
			5	2	1	3	2	2	2	2	2	2	2	2	2	20
			6	3	1	3	2	2	2	2	2	2	2	2	2	21

1046

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
13	1	P2	0	2	2	2	2	2	2	2	1	2	2	19		
			1	2	1	1	2	2	1	2	1	1	1	13		
			2	1	1	1	1	0	2	2	1	1	2	1	14	
			3	2	2	1	1	1	1	1	1	2	1	2	15	
			4	1	1	1	0	1	1	1	1	0	0	0	6	
			5	1	1	0	0	1	0	1	0	0	1	0	0	4
13	2	TCS	0	3	3	2	2	2	2	2	2	1	2	2	22	
			1	2	2	2	2	2	2	2	0	1	1	1	15	
			2	1	1	1	2	1	1	1	0	1	1	1	10	
			3	1	1	1	1	1	1	1	1	2	1	1	1	11
			4	2	1	1	0	1	0	1	1	1	1	1	1	9
			5	0	1	1	0	1	0	1	1	1	1	0	0	5
13	3	AI	0	0	1	0	0	1	0	0	1	0	1	0	4	
			1	2	2	2	2	2	2	2	2	3	2	2	21	
			2	1	1	1	1	1	1	1	1	1	1	1	1	13
			3	1	1	1	1	1	1	1	1	1	1	1	1	10
			4	1	1	0	0	1	1	1	1	1	0	0	0	4
			5	0	1	0	0	1	0	0	0	1	0	0	0	4
13	4	S2J	0	3	2	3	3	3	2	2	2	2	2	2	24	
			1	1	1	1	1	0	1	1	1	1	2	1	11	
			2	1	1	1	2	1	2	2	2	1	1	2	14	
			3	2	1	1	0	1	1	1	1	1	2	1	2	12
			4	2	2	2	0	1	1	1	1	1	1	2	1	13
			5	1	2	2	0	2	1	1	1	1	1	2	2	14
13	5	MF	0	2	2	2	2	3	2	2	2	2	1	2	21	
			1	2	2	2	2	1	2	2	2	2	2	2	18	
			2	2	2	2	2	2	2	2	2	2	2	2	20	
			3	1	2	1	0	2	2	2	2	2	2	1	2	16
			4	1	1	1	0	2	1	1	1	1	2	1	1	12
			5	1	2	1	0	1	1	1	1	1	2	1	1	11
13	6	KE	0	2	2	1	1	1	1	1	1	2	1	1	11	
			1	2	1	1	1	1	1	1	1	1	2	1	11	
			2	1	1	1	1	1	1	1	1	1	2	1	11	
			3	1	2	1	0	1	0	1	0	1	1	0	1	7
			4	1	1	1	0	1	1	1	1	1	1	1	1	10
			5	1	2	1	0	1	0	1	1	1	1	1	0	6
13	7	BL	0	2	2	2	2	2	2	2	2	2	2	2	18	
			1	1	1	1	1	0	1	1	1	1	1	1	9	
			2	1	1	0	1	0	1	1	1	1	1	1	7	
			3	1	1	0	0	1	1	1	1	1	1	1	1	6
			4	1	1	0	0	1	0	1	1	1	1	1	1	6
			5	1	1	0	0	0	0	0	0	1	0	1	0	5

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
13	7	BL	5	1	0	1	0	1	0	1	0	0	0	4
			6	1	0	0	0	1	1	0	0	0	0	3
13	8	PR	0	2	2	2	2	2	2	1	2	2	2	19
			1	2	2	2	0	2	2	1	1	0	0	14
			2	1	1	1	0	1	1	1	2	1	1	11
			3	1	1	1	0	1	1	1	2	1	1	10
			4	1	1	1	0	1	1	1	1	1	0	9
			5	2	1	1	0	1	0	1	1	1	1	6
			6	0	0	1	0	0	0	1	0	0	1	3
13	9	SZS	0	2	2	2	1	2	2	2	2	2	1	18
			1	2	1	1	2	1	2	1	2	1	1	14
			2	1	2	1	0	1	1	1	1	1	2	11
			3	1	1	1	0	1	1	1	2	1	1	10
			4	1	1	0	0	1	1	1	1	1	0	7
			5	2	1	1	0	1	1	1	1	1	1	10
			6	1	0	0	0	0	0	1	0	1	1	4
13	10	BH	0	2	2	2	1	1	1	2	2	1	1	15
			1	2	2	2	2	2	2	2	2	2	2	20
13	1011	HS	0	3	2	3	2	2	2	2	2	3	1	22
			1	2	2	2	1	2	1	2	2	2	1	17
			2	1	1	1	0	1	0	1	0	1	0	6
			3	1	1	1	0	0	1	1	0	1	0	7
			4	1	1	1	0	2	1	1	1	0	0	8
			5	1	0	0	0	1	1	1	1	0	0	5
			6	1	1	0	0	1	1	0	0	0	1	4
13	12	BF	0	2	2	2	2	2	2	2	2	2	2	20
			1	1	1	1	0	1	0	1	1	1	1	9
			2	2	2	1	0	1	0	1	1	1	1	10
			3	1	1	1	0	1	0	1	1	1	0	7
			4	1	2	1	0	1	2	1	2	1	0	11
			5	1	1	1	1	0	0	1	1	0	0	6
13	13	HK	0	2	2	2	1	2	2	2	1	2	2	18
			1	1	1	1	0	1	1	1	2	1	0	9
			2	1	1	1	0	1	0	1	1	0	0	6
			3	1	1	1	0	2	1	1	1	0	1	12
			4	1	1	1	0	1	0	1	0	1	0	6
			5	1	0	1	0	1	0	1	0	1	1	6
			6	1	0	1	0	0	0	1	0	0	0	3
13	14	DF	0	2	2	2	2	2	2	2	2	2	2	20
			1	1	1	1	0	2	1	1	1	2	1	11
			2	1	1	1	0	1	0	1	1	1	1	8

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
13	14	DF	3	2	2	2	0	1	1	2	1	2	2	15		
			4	1	1	1	0	1	1	1	0	1	1	6		
			5	1	1	1	0	1	1	1	1	1	1	1	8	
			6	0	1	1	0	1	0	0	0	0	1	0	4	
			0	3	2	2	2	2	2	2	2	2	2	2	1	20
			1	1	1	1	0	2	2	2	2	2	2	2	1	10
13	15	KG	2	0	1	1	0	1	1	1	1	1	0	0	6	
			3	1	1	1	0	1	1	1	1	1	0	0	9	
			4	1	1	1	0	2	1	1	1	1	1	0	0	9
			5	1	0	1	0	1	0	1	0	1	0	1	0	5
			6	1	0	1	0	1	0	1	0	1	0	0	0	4
			0	2	2	2	1	2	2	2	2	2	2	2	1	17
13	16	SZL	1	1	1	1	0	2	1	1	1	1	1	1	10	
			2	2	1	1	0	1	0	1	1	1	1	1	8	
			3	2	2	2	0	1	1	1	1	1	1	0	0	12
			4	1	1	1	0	0	0	0	0	1	0	0	0	4
			5	1	1	1	0	0	0	0	0	1	0	1	0	5
			6	3	2	2	0	2	2	2	2	2	2	2	2	18
13	17	GSM	0	1	2	2	0	2	1	1	1	2	1	1	13	
			1	1	1	1	0	1	1	1	1	1	1	1	9	
			2	1	1	1	0	1	1	1	1	1	0	0	0	6
			3	1	1	1	0	1	1	1	1	1	1	1	1	9
			4	1	0	0	0	1	1	1	1	1	1	1	0	5
			5	1	1	1	0	1	1	1	0	0	0	0	0	3
13	18	VT	0	2	3	2	0	1	1	1	2	2	2	0	15	
			1	1	2	1	0	1	1	1	1	1	1	1	10	
			2	1	1	1	0	1	1	1	1	1	0	0	0	8
			3	1	1	1	0	0	0	0	0	1	0	0	0	2
			4	0	1	1	0	0	0	0	0	0	0	0	0	2
			5	1	1	1	0	0	0	0	0	0	0	0	0	2
13	19	KK	0	2	3	2	0	1	1	2	2	2	3	2	20	
			1	1	0	1	0	1	1	1	1	1	1	1	7	
			2	1	1	1	0	1	1	1	1	1	0	0	0	6
			3	2	2	2	1	1	2	2	2	2	1	1	1	15
			0	2	2	2	1	2	2	2	2	2	2	2	2	17
			1	1	1	0	0	2	1	1	1	1	1	0	0	7
13	20	NL	2	1	1	1	0	2	1	1	1	1	0	0	8	
			3	1	1	1	0	2	1	1	1	0	0	0	4	
			4	1	1	1	0	1	1	1	0	1	0	0	0	5
			5	1	1	1	0	1	1	1	0	1	0	0	0	5
			0	1	1	1	0	1	1	1	1	1	1	0	0	8

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE
OPEN PHASE

Centre No.	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
13	20	NL	6	1	1	1	0	1	1	1	1	0	0	7
13	21	CL	0	2	3	3	0	0	0	2	2	2	1	15
			1	1	2	1	0	1	1	1	1	1	0	10
			2	1	1	1	0	0	0	0	0	0	0	3
			3	1	1	1	0	1	0	1	1	0	0	6
			4	1	1	1	0	1	0	1	1	0	0	6
			5	0	1	1	0	0	0	1	0	0	0	2
			6	1	1	1	0	0	0	1	0	0	0	4
13	22	NYH	0	2	2	2	0	1	0	1	1	1	1	11
			1	2	2	1	0	2	0	2	1	2	0	13
			2	1	2	1	0	0	0	1	1	0	0	8
			3	2	1	1	0	1	0	1	0	0	0	6
			4	1	1	1	0	1	0	1	0	0	0	5
			5	1	1	1	0	1	0	1	1	0	0	5
			6	1	1	1	0	1	0	0	0	0	0	4
13	23	BSB	0	2	2	2	0	1	0	1	1	0	0	9
			1	2	2	2	0	1	0	1	0	1	0	9
			2	1	2	1	0	1	0	1	0	0	0	6
			3	1	1	1	0	1	0	1	1	0	0	6
			4	0	1	0	0	0	0	1	1	0	0	3
			5	0	1	0	0	1	0	0	1	0	0	3
			6	0	1	0	0	0	0	0	0	0	0	1

1050

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
1	3	TA	8	1	1	0	0	1	0	0	1	1	0	5
			12	0	1	0	0	1	0	0	1	1	0	3
			16	0	1	0	0	1	0	0	1	1	0	4
			20	0	1	0	0	1	0	0	1	1	0	4
			24	1	1	0	0	0	1	0	1	1	0	5
			28	0	1	0	0	1	1	0	1	1	0	5
			32	0	1	0	0	1	1	0	1	1	1	6
			36	1	1	0	0	1	1	0	1	0	0	5
			40	0	2	0	0	1	0	0	1	2	0	6
			44	0	2	0	0	1	1	0	0	2	0	6
			48	1	1	1	0	1	0	0	1	1	0	6
			52	0	1	0	0	1	0	0	1	1	0	4
1	4	DNC	8	1	1	0	0	0	1	0	1	1	0	5
			12	0	0	0	0	0	1	0	1	1	0	3
			16	0	1	0	0	1	0	0	1	1	0	4
			20	0	1	0	0	0	0	0	1	1	0	3
			24	0	1	0	0	0	0	0	1	2	0	4
			28	0	1	0	0	1	1	0	1	0	0	4
			32	0	1	0	0	1	1	0	1	1	0	4
			36	0	1	1	0	1	0	0	1	0	0	3
			40	0	1	0	0	1	0	0	0	0	0	2
			44	0	1	0	0	0	0	0	1	0	0	2
			48	0	1	0	0	0	0	0	1	2	0	4
			52	0	1	0	0	1	0	0	0	1	0	3
1	5	DB	8	0	1	0	0	0	0	0	1	1	0	3
			12	0	1	0	0	0	0	0	1	1	0	3
			16	0	1	0	0	0	0	0	1	1	0	3
			20	0	1	0	0	0	0	0	1	2	0	4
			24	0	1	0	0	0	0	0	1	1	0	3
			28	0	1	0	0	0	0	0	1	0	1	3
			32	0	1	0	0	0	0	0	1	1	0	3
			36	0	1	0	0	0	0	0	0	1	0	2
			40	0	1	1	0	0	0	0	0	1	0	4
			44	0	1	0	0	0	0	0	1	2	0	4
			48	0	1	0	0	1	0	0	0	1	0	3
			52	0	1	0	0	1	0	0	0	1	0	3
1	9	CCR	8	0	1	0	0	1	1	0	1	2	0	6
			12	0	1	0	0	0	0	0	1	1	0	3
			16	0	1	0	0	0	0	0	1	1	0	3
			20	0	1	0	0	0	0	0	1	1	0	3
			24	0	1	0	0	0	0	0	1	1	0	3
			28	1	1	0	0	0	0	0	1	2	0	4
			32	0	1	0	0	0	0	0	1	1	0	4
			36	0	1	0	0	0	0	0	1	0	0	2

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inability to Feel Inertia	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
1	9	CCR	40	0	1	0	0	0	0	0	1	0	2		
			44	0	1	0	0	0	0	0	0	1	0	2	
			48	0	1	0	0	0	0	0	0	0	0	2	
			52	0	2	0	0	0	0	0	1	0	0	3	
1	10	LDL	8	0	1	0	0	1	0	0	1	1	0	4	
			12	0	1	0	0	1	0	0	1	1	0	4	
			16	0	1	0	0	0	0	0	1	1	0	3	
			20	0	1	0	0	1	0	0	1	1	0	4	
			24	0	1	0	0	1	1	0	1	1	0	5	
			28	0	1	0	0	0	0	0	1	0	0	2	
			32	0	1	0	0	0	0	0	0	1	0	3	
			36	0	1	0	0	1	0	0	1	0	0	3	
			40	0	1	0	0	0	0	0	0	2	0	3	
			44	0	2	0	0	1	0	0	1	1	0	5	
			48	0	1	0	0	1	0	0	1	1	0	4	
			52	0	1	0	0	0	0	0	0	0	1	0	2
			1	11	MLC	8	2	1	1	0	1	1	2	2	0
12	3	3				2	2	3	2	2	2	2	24		
1	14	CEC	8	2	1	1	0	1	0	0	1	2	0	9	
			12	1	1	0	0	1	1	0	0	1	0	5	
			16	0	1	0	0	0	0	0	0	1	0	3	
			20	1	1	0	0	1	1	0	0	1	1	6	
			24	0	1	0	0	1	0	0	0	1	1	0	4
1	15	TTM	8	2	2	1	1	2	1	1	2	1	15		
			12	2	2	2	2	3	2	1	2	2	19		
1	17	EFC	8	0	1	0	0	1	0	0	1	1	0	5	
			12	0	2	0	0	1	0	0	0	1	0	4	
			16	0	1	0	0	0	0	0	1	0	0	3	
			20	0	0	0	0	0	0	0	0	0	0	1	
			24	0	1	0	0	0	0	0	0	1	0	3	
1	19	SK	8	0	1	0	0	0	0	1	1	0	3		
			12	0	2	0	0	0	0	0	1	0	0	3	
			16	0	1	0	0	0	0	0	1	0	0	2	
1	20	EFC	8	0	1	0	0	0	0	0	1	1	0	3	
			12	0	2	0	0	0	0	0	1	0	0	3	
			16	0	1	0	0	0	0	0	1	1	0	4	
			20	0	0	0	0	0	0	0	0	1	1	3	
			24	0	1	0	0	0	0	0	1	1	0	3	
1	22	SK	8	0	1	0	0	0	0	0	1	1	0	3	
			12	0	0	0	0	0	0	0	1	1	0	3	
			16	0	1	0	0	0	0	0	1	1	0	3	
1	44		8	0	1	0	0	0	0	0	1	1	0	3	
			12	0	1	0	0	0	0	0	1	1	0	2	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
1	22	19	SK	52	0	1	0	0	0	0	0	1	0	0	2
1	24	20	LVF	8	1	1	1	0	1	0	0	0	1	0	5
				12	1	2	0	0	1	0	0	1	1	0	6
				16	1	1	0	0	1	0	0	1	1	0	6
				20	1	1	0	0	2	0	0	1	1	0	6
				24	1	2	0	0	2	0	0	1	2	0	9
				28	0	1	0	0	2	1	0	1	1	0	5
				32	1	1	0	0	1	1	1	1	1	0	8
				36	1	1	0	0	1	1	1	1	1	0	8
				40	1	1	0	0	1	1	1	0	1	0	7
				44	1	2	1	0	1	1	0	0	2	0	9
				48	1	2	1	1	1	1	1	2	1	0	11
				52	0	1	0	0	1	0	0	1	1	0	4
1	25	21	AMR	8	0	1	0	0	1	0	0	1	1	0	5
				12	0	1	0	0	1	1	0	1	1	0	5
				16	0	0	0	0	1	0	0	1	2	0	5
				20	0	1	0	0	1	0	0	1	1	0	2
				24	0	1	0	0	1	1	0	1	2	0	6
				28	0	1	0	0	1	1	0	1	1	0	5
				32	0	2	0	0	1	0	0	0	1	1	5
				36	0	1	0	0	0	0	0	1	1	0	3
				40	0	1	0	0	0	0	0	1	0	0	2
				44	0	1	0	0	0	0	0	1	1	0	3
				48	0	1	0	0	0	0	0	1	1	0	3
				52	0	1	0	0	1	0	0	1	0	0	3
1	31	27	MAM	8	1	1	0	0	1	0	1	1	1	0	6
				12	2	1	1	0	1	0	1	0	1	0	7
				16	1	1	1	0	1	1	1	1	1	0	7
				20	1	1	1	0	1	1	1	1	1	0	8
				24	0	1	0	0	1	1	0	1	2	0	8
				28	1	1	0	1	1	1	1	1	0	0	4
				32	0	1	0	1	1	1	1	1	2	1	11
				36	1	1	0	0	1	0	0	1	1	0	4
				40	0	1	0	0	1	0	0	1	1	0	4
				44	0	1	0	0	1	0	0	0	1	0	2
				48	0	1	0	0	1	0	0	0	1	0	2
				52	0	1	0	0	0	0	0	1	2	0	4
1	52	28	DGH	8	0	1	0	0	0	0	0	0	1	0	3
				12	1	2	1	0	1	0	0	0	1	0	3
				16	2	2	1	0	1	1	1	1	1	1	10
				20	2	2	1	1	2	1	1	1	2	0	13
				24	1	2	1	1	2	1	1	2	2	0	14
				28	1	1	1	0	1	1	1	1	1	0	8
				32	1	1	1	0	1	1	1	1	2	1	10

1053

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score					
1	39	305	ASS	12	1	1	0	0	0	0	1	1	0	4					
				16	1	1	1	0	2	1	1	1	1	0	9				
				20	0	1	0	0	1	1	0	0	0	1	0	5			
				24	0	1	0	0	1	1	0	0	1	1	0	4			
				28	0	1	0	0	1	1	0	0	0	1	0	5			
				32	0	2	0	0	1	1	0	0	2	2	1	8			
				36	1	1	1	0	1	1	1	1	1	2	2	1	11		
				40	0	1	1	0	1	1	0	0	1	1	1	0	4		
				44	1	1	1	1	0	1	1	1	1	1	1	0	6		
				48	1	1	1	1	1	1	1	1	1	1	1	1	7		
				52	1	2	1	2	1	1	1	1	1	1	2	1	13		
				1	43	309	ARN	8	0	1	0	0	0	0	1	1	0	0	3
								12	0	1	0	0	0	0	0	0	1	0	0
16	1	2	0					0	1	1	0	1	0	0	1	0	6		
20	0	1	0					0	0	0	0	0	0	1	0	1	3		
24	0	1	0					0	0	0	0	0	1	0	2	0	4		
28	0	1	0					0	0	0	0	0	0	0	1	0	2		
32	0	1	0					0	0	0	0	0	0	1	1	0	3		
36	0	0	0					0	0	0	0	0	0	1	1	0	2		
40	0	1	0					0	0	0	0	0	0	1	1	0	2		
44	0	1	0					0	0	0	0	0	0	1	1	0	3		
48	0	1	0					0	0	0	0	0	0	1	1	0	3		
52	0	1	0					0	0	0	0	0	0	0	1	0	2		
1	45	310	DPS					8	0	1	0	0	0	0	1	1	0	0	4
				12	0	1	0	0	1	1	0	0	1	1	0	3			
				16	0	1	0	0	0	0	0	0	0	0	0	1			
				20	0	1	0	0	0	1	0	0	0	0	0	0	2		
				24	0	1	0	0	0	0	0	0	0	0	1	0	2		
				28	0	1	0	0	0	0	0	0	0	0	1	0	2		
				32	0	1	0	0	0	0	0	0	0	1	1	0	3		
				36	0	1	0	0	0	0	0	0	0	1	1	0	3		
				40	0	0	0	0	0	0	0	0	0	1	1	1	3		
				44	0	1	0	0	0	0	0	0	0	1	1	0	3		
				48	1	1	0	0	0	0	1	1	0	1	1	1	6		
				52	0	0	0	0	0	0	0	0	0	2	1	1	4		
				1	46	311	SP	8	1	1	0	0	0	0	1	1	0	0	5
12	1	1	0					0	1	0	0	0	0	1	0	4			
16	0	1	0					0	1	0	0	0	0	0	0	0	3		
20	0	2	0					0	1	0	0	0	0	1	1	0	6		
24	0	1	0					0	0	0	0	0	0	0	1	0	2		
28	0	1	0					0	0	0	0	0	0	0	1	0	2		
32	0	1	0					0	0	0	0	0	0	1	1	0	3		
36	0	1	0					0	0	0	0	0	0	1	1	0	3		
40	0	1	0					0	0	0	0	0	0	1	1	1	4		

1055

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score			
1	46	311	SP	44	0	0	0	1	0	0	1	0	0	2			
				48	0	1	0	0	0	0	0	1	1	1	4		
				52	0	1	0	0	0	0	0	0	1	1	0	3	
1	48	313	SCM	8	1	2	0	1	1	1	1	1	0	8			
				12	2	1	0	2	2	1	2	2	0	0	14		
				16	1	2	1	1	1	1	1	1	1	1	0	10	
				20	1	1	1	0	1	1	0	0	0	1	0	6	
				24	0	1	0	0	1	1	0	0	0	2	0	4	
				28	0	1	0	0	1	1	0	0	0	1	2	0	5
				32	0	1	0	0	1	1	0	0	0	1	2	0	5
				36	0	1	0	0	1	1	0	0	0	0	2	0	4
				40	1	1	0	1	1	1	1	0	0	0	1	0	5
				44	1	1	0	0	1	1	1	0	0	0	1	0	4
1	52	316	MTS	48	1	1	0	1	1	0	0	0	1	0	6		
				52	1	2	0	0	1	1	0	0	0	2	0	7	
				8	1	2	1	0	1	1	1	1	1	2	1	11	
				12	0	0	0	0	1	1	0	0	0	0	1	1	4
				16	1	2	1	1	1	1	1	1	1	2	1	1	11
				20	1	1	1	0	1	1	1	1	0	1	1	0	7
				24	1	1	1	0	1	1	1	1	0	0	1	1	7
1	55	318	DMG	28	0	1	0	1	0	0	1	1	1	0	4		
				32	1	1	0	0	1	0	0	0	1	1	0	5	
				36	1	1	0	0	1	0	0	0	0	1	0	4	
				40	0	1	0	0	1	0	0	0	0	1	0	4	
				44	0	1	0	0	1	1	0	0	0	1	0	3	
				48	1	1	1	0	1	1	1	1	0	1	2	0	8
				52	0	1	1	0	0	1	1	0	0	1	1	0	4
				8	1	1	0	0	1	1	1	1	0	1	1	0	6
				12	2	2	1	1	2	1	1	1	1	2	2	1	15
				1	56	319	IAL	8	2	2	1	0	2	1	1	2	0
16	2	2	1					1	2	1	1	1	2	2	0	17	
1	58	320	ARM	8	1	1	0	1	1	1	1	1	1	9			
				16	0	2	0	0	0	0	0	0	1	2	0	5	
1	61	323	HVC	8	1	1	0	1	1	0	0	0	1	1	7		
				12	0	1	0	0	1	0	0	0	1	2	0	5	
				16	1	1	0	0	0	0	0	0	0	1	1	0	4
				20	0	2	0	0	0	0	0	0	0	1	2	0	5
				24	0	1	0	0	0	0	0	0	0	1	1	1	4
				28	0	1	0	0	0	0	0	0	0	1	2	1	5
32	0	1	0	0	0	0	0	0	0	0	2	0	3				
36	0	1	0	0	0	0	0	0	0	1	1	0	4				

1056

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 40.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient No.	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
1	61	323	HVC	40	0	1	0	0	0	0	2	1	0	4	
				44	0	0	0	0	0	1	1	1	1	3	
				48	0	1	0	0	0	1	2	1	1	5	
				52	0	1	0	0	0	1	1	1	0	3	
					0	0	0	0	0	0	0	0	0	0	0
1	66	326	TCG	8	1	1	1	1	0	1	1	1	0	7	
				12	0	1	0	0	0	1	1	1	1	3	
				16	1	1	1	0	0	1	1	1	1	2	
				20	0	1	0	0	0	0	1	1	1	2	
				24	0	1	0	0	0	0	1	1	1	1	
				28	0	1	0	0	0	0	1	1	1	2	
				32	0	1	0	0	0	0	1	1	1	2	
				36	0	1	0	0	0	0	1	1	1	2	
				40	0	1	0	0	0	0	1	1	1	1	
				44	0	1	0	0	0	0	1	1	1	1	
				48	0	2	0	0	0	0	1	1	1	1	
				52	0	2	0	0	0	0	1	1	1	1	
					0	0	0	0	0	0	0	0	0	0	0
					0	0	0	0	0	0	0	0	0	0	0
					0	0	0	0	0	0	0	0	0	0	0
1	71	329	ORV	8	1	1	1	1	0	1	1	1	0	6	
				12	1	1	1	0	1	1	2	1	0	8	
				16	1	1	1	1	1	1	1	1	1	0	
				20	1	1	1	1	1	1	1	1	1	0	
				24	1	1	1	1	1	1	1	1	1	0	
				28	1	1	1	1	1	1	1	1	1	0	
				32	1	1	1	1	1	1	1	1	1	0	
				36	2	1	2	0	0	1	1	1	1	0	
				40	0	1	0	0	0	1	1	1	1	0	
				44	0	1	0	0	0	0	1	1	1	1	
48	0	0	0	0	0	1	1	1	1	2					
52	1	0	1	0	0	1	1	1	1	2					
	0	0	0	0	0	0	0	0	0	0					
	0	0	0	0	0	0	0	0	0	0					
	0	0	0	0	0	0	0	0	0	0					
1	72	330	RLJ	8	1	1	0	0	0	1	1	1	0	5	
				12	0	1	0	0	1	1	1	1	0	4	
				16	0	2	0	0	1	1	1	1	0	4	
				20	0	1	0	0	1	1	1	1	0	5	
					0	0	0	0	0	0	0	0	0	0	
1	73	121	FMA	8	1	1	1	0	0	1	1	1	0	6	
				12	1	2	1	0	1	1	1	1	0	6	
				16	0	1	0	0	1	1	1	1	0	4	
				20	0	1	0	0	1	1	1	1	0	4	
				24	2	2	2	2	1	1	1	2	0	13	
					0	0	0	0	0	0	0	0	0	0	
1	75	123	ELF	8	1	1	1	0	0	1	1	1	1	7	
				12	1	1	1	0	1	1	1	1	1	8	
				16	0	1	0	0	1	1	1	1	0	3	
				20	1	1	1	0	1	1	1	1	1	8	
				24	0	0	0	0	0	0	0	0	0	2	

1057

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE

DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score						
1	75	123	ELF	28	1	1	0	1	0	0	0	1	1	6						
				32	2	1	0	1	1	0	0	0	0	1	1	8				
				36	1	1	0	1	0	1	0	0	0	1	1	7				
				40	1	0	0	1	0	1	0	0	0	1	1	5				
				44	2	1	1	0	1	1	0	0	0	1	1	9				
				48	1	1	0	0	1	1	1	0	1	0	0	7				
				52	0	0	0	0	2	0	0	0	0	1	0	1	4			
				1	77	125	ACG	8	1	1	0	1	1	0	1	1	0	0	7	
								12	1	1	0	1	1	0	1	1	1	1	1	8
								16	2	1	0	1	1	0	1	1	1	1	1	9
20	0	1	0					0	0	0	0	0	0	1	1	4				
24	0	1	0					0	1	0	0	0	0	1	0	4				
28	0	1	0					0	0	0	0	0	0	1	0	4				
32	0	1	0					0	0	0	0	0	0	1	2	0	4			
36	0	1	0					0	0	0	0	0	0	1	2	1	5			
40	0	2	0					0	0	0	0	0	0	1	0	0	3			
44	0	1	0					0	0	0	0	0	0	1	1	0	3			
1	81	128	MFB	8	0	0	0	0	0	0	0	0	0	0	3					
				12	0	1	0	0	0	0	0	0	1	1	1	4				
				16	0	1	0	0	0	0	0	0	0	1	1	1	4			
				20	0	1	0	0	0	0	0	0	0	1	1	1	4			
				24	0	1	0	0	1	0	0	0	0	1	2	0	5			
				28	0	1	0	0	0	0	0	0	0	1	2	0	5			
				32	0	1	0	0	0	1	0	0	0	1	0	0	4			
				36	0	1	0	0	0	0	0	0	0	1	2	0	4			
				40	0	1	0	0	0	0	0	0	0	0	0	1	3			
				44	0	1	0	0	0	1	0	0	0	0	0	1	4			
1	82	129	MBS	8	0	0	0	0	0	0	0	0	0	0	3					
				12	0	0	0	0	0	0	0	0	0	0	0	3				
				16	1	1	0	0	1	1	0	1	0	1	1	1	8			
				20	0	1	0	0	1	0	0	0	0	1	1	1	5			
				24	0	1	0	0	1	0	0	0	0	0	1	0	7			
				28	0	1	0	0	1	0	0	0	0	0	1	0	3			
				32	0	1	0	0	1	0	0	0	0	1	0	0	4			
				36	0	1	0	0	0	1	0	0	0	2	1	0	5			
				40	0	0	0	0	0	0	0	0	0	1	1	0	4			
				44	0	0	0	0	0	0	2	0	0	1	0	1	3			
1	48	48	48	0	0	0	0	0	0	0	0	0	0	0	4					
				0	0	0	0	0	0	0	0	0	0	0	0	4				
				0	0	0	0	0	0	0	0	0	0	0	0	4				
				0	0	0	0	0	0	0	0	0	0	0	0	4				
				0	0	0	0	0	0	0	0	0	0	0	0	4				
				0	0	0	0	0	0	0	0	0	0	0	0	4				
				0	0	0	0	0	0	0	0	0	0	0	0	4				
				0	0	0	0	0	0	0	0	0	0	0	0	4				
				0	0	0	0	0	0	0	0	0	0	0	0	4				
				0	0	0	0	0	0	0	0	0	0	0	0	4				

1058

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient No.	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score			
1	87	132	MDO	8	0	2	0	0	1	0	0	1	2	0	6		
				12	1	1	1	0	1	0	1	2	0	0	7		
				16	1	1	0	0	1	1	1	2	0	1	0	7	
				20	2	1	1	1	1	1	1	2	0	2	0	12	
				24	2	1	1	1	1	1	1	2	0	2	0	12	
1	89	133	RMV	8	2	2	1	1	1	1	2	2	2	2	16		
				12	2	3	1	1	2	2	2	2	2	2	18		
				16	2	2	1	1	1	1	1	1	1	1	1	9	
				20	1	1	0	0	1	1	1	1	1	1	1	0	5
1	95	138	GNT	8	1	1	0	0	1	0	0	1	1	1	0	4	
				12	0	2	0	0	0	0	0	0	0	1	1	0	4
				16	0	2	0	0	0	0	0	0	0	2	1	0	5
				20	0	1	0	0	0	0	0	0	0	1	1	0	3
				24	0	1	0	0	0	0	0	0	0	1	1	0	4
				28	0	0	0	0	0	1	0	0	0	0	2	1	5
				32	0	0	0	0	0	0	0	0	0	0	2	1	4
				36	0	0	0	0	0	0	0	0	0	0	1	1	3
				40	0	1	0	0	0	0	0	0	0	0	1	0	2
				44	0	1	0	0	0	0	0	0	0	1	1	0	3
				48	0	1	0	0	0	0	0	0	0	1	1	0	3
				52	0	1	0	0	0	0	0	0	0	0	1	1	3
1	96	139	SPH	8	0	1	0	0	0	0	0	1	2	1	5		
				12	0	1	0	0	0	0	0	0	1	3	0	5	
				16	0	0	0	0	2	0	0	0	1	2	0	5	
				20	0	1	0	0	0	1	0	0	1	1	0	4	
				24	1	0	1	0	0	1	0	0	1	1	1	1	7
				28	1	0	1	1	1	1	1	1	1	1	1	1	9
				32	1	0	1	1	1	1	1	1	2	1	1	0	10
				36	1	0	1	1	1	1	1	1	1	1	1	1	10
				40	1	0	1	1	1	1	1	0	0	1	1	0	7
				44	0	1	1	0	0	0	0	0	0	1	1	0	4
				48	0	1	0	0	0	0	0	0	0	0	1	0	3
				52	0	1	0	0	0	0	0	0	0	0	1	0	3
1	98	141	YTT	8	0	1	0	0	0	0	0	0	0	0	0	4	
				12	0	1	0	0	0	1	0	0	0	0	2	0	5
				16	0	1	0	0	0	1	0	0	0	1	2	0	5
				20	0	1	0	0	0	1	0	0	0	1	1	0	4
				24	0	1	0	0	0	0	0	0	0	1	1	0	3
				28	0	1	0	0	0	0	0	0	0	1	1	0	3
				32	0	0	2	0	0	0	0	0	0	1	2	0	5
				36	0	0	1	0	0	0	0	0	0	1	0	1	2
				40	0	1	0	0	0	0	0	0	0	1	0	0	4
				44	0	1	0	0	0	0	0	0	0	0	1	0	2
				48	0	1	0	0	0	0	0	0	0	0	0	0	1
				52	0	2	0	0	0	0	0	0	0	0	1	0	3

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient No.	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feas	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
1	98	141	YTT	52	0	0	0	0	0	0	0	1	0	2
1	101	143	JLL	8	0	0	0	0	0	0	0	1	1	3
				12	0	0	0	0	0	0	0	1	0	3
				16	0	0	0	0	0	0	0	1	0	3
				20	0	0	0	1	0	0	1	1	0	5
				24	0	0	0	0	0	0	0	1	0	2
				28	0	0	0	0	0	0	0	1	1	4
				32	0	0	0	0	0	0	0	1	1	5
				36	0	0	0	0	0	0	0	1	1	5
				40	0	0	0	0	0	0	0	1	1	5
				44	0	0	0	0	0	0	0	1	1	5
				48	0	0	0	0	0	0	0	0	0	2
				52	0	0	0	0	0	0	0	0	0	2
1	107	147	LAN	8	0	0	0	0	0	0	0	2	0	4
				12	0	0	0	0	0	0	0	3	0	6
				16	0	0	0	0	0	0	0	1	0	3
				20	0	0	0	0	0	0	0	1	0	3
				24	0	0	0	0	0	0	0	2	0	5
				28	0	0	0	1	0	0	1	1	1	5
				32	0	0	0	0	0	0	0	1	1	5
				36	0	0	0	0	0	0	0	1	1	4
				40	0	0	0	0	0	0	0	1	1	4
				44	0	0	0	0	0	0	0	1	1	4
				48	0	0	0	0	0	0	0	0	0	2
				52	0	0	0	0	0	0	0	0	0	2
1	109	149	IPL	8	0	0	0	1	0	0	1	1	0	4
				12	1	0	0	0	0	0	1	2	0	6
				16	1	0	0	1	1	1	0	2	0	8
				20	1	0	0	1	1	1	1	1	0	8
				24	0	0	0	0	0	0	1	1	0	4
				28	0	0	0	0	0	0	1	1	0	4
				32	0	0	0	0	0	0	1	1	0	4
				36	1	1	0	1	1	0	1	2	0	8
				40	0	0	0	0	0	0	1	1	1	7
				44	0	0	0	0	0	0	1	1	1	5
				48	0	0	0	0	0	0	1	1	1	5
				52	0	0	0	0	0	0	0	0	0	3
1	110	150	TQO	8	0	0	0	0	0	0	0	1	0	2
				12	0	0	0	0	0	0	0	1	0	3
				16	0	0	0	0	0	0	1	1	0	3
				20	0	0	0	0	0	0	0	2	0	3
				24	0	0	0	0	0	0	1	1	1	4
				28	0	0	0	1	0	0	1	1	0	3

1060

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
1	110	T00	32	0	1	0	0	0	0	0	1	1	1	4		
			36	0	0	0	0	0	0	0	1	1	1	3		
			40	0	0	0	0	0	0	0	0	1	0	1	2	
			44	0	1	0	0	1	0	0	0	0	2	0	4	
			48	0	2	0	0	0	0	0	0	0	0	0	2	
			52	0	1	0	0	0	0	0	0	0	1	1	0	3
1	116	MGA	8	0	1	0	0	0	0	0	0	0	1	0	2	
			12	0	1	0	0	0	0	0	0	1	0	0	2	
			16	0	1	0	0	0	0	0	0	1	1	0	3	
			20	0	1	0	0	0	0	0	0	0	0	0	0	1
			24	0	1	0	0	0	0	0	0	1	1	1	0	3
			28	0	1	0	0	0	0	0	0	1	1	1	1	4
			32	0	1	0	0	0	0	0	0	0	0	1	1	3
			36	0	1	0	0	0	0	0	0	0	2	1	1	5
			40	0	0	0	0	0	0	0	0	0	1	2	1	4
			44	0	1	0	0	0	0	0	0	0	0	1	0	2
			48	0	2	0	0	0	0	0	0	0	1	1	1	5
			52	0	1	0	0	0	0	1	0	0	0	0	1	3
1	117	FSL	8	0	1	0	0	0	0	0	0	1	1	0	4	
			12	0	1	0	0	0	0	0	0	0	1	1	3	
			16	0	1	0	0	0	1	0	0	0	1	1	0	4
			20	0	1	0	0	0	1	0	0	0	1	1	0	4
			24	1	1	1	0	0	1	0	0	0	1	1	0	6
			28	0	1	0	0	0	1	0	0	0	1	1	0	4
			32	2	1	1	1	1	2	1	1	0	1	2	0	11
			36	0	2	0	0	0	1	0	0	0	1	2	0	6
			40	0	1	0	0	0	1	0	0	0	1	1	0	4
			44	0	0	0	0	0	1	0	0	0	1	1	0	3
			48	1	1	1	0	0	1	1	1	2	0	1	0	8
			52	1	1	1	0	0	1	1	1	1	1	1	0	8
1	121	LAC	8	0	1	0	0	0	0	0	0	0	1	0	2	
			12	0	1	0	0	0	0	0	0	0	0	0	2	
			16	0	1	0	0	0	0	0	0	0	1	1	0	4
			20	0	1	0	0	0	0	0	0	0	1	1	1	4
			24	0	1	0	0	0	1	0	0	0	1	0	1	3
			28	0	0	0	0	0	0	0	0	0	1	0	1	3
			32	0	0	0	0	0	1	0	0	0	1	1	1	4
			36	0	0	0	0	0	1	0	0	0	1	1	1	4
			40	0	1	0	0	0	1	0	0	0	0	1	1	3
			44	0	2	0	0	0	1	0	0	0	0	0	0	3
			48	0	1	0	0	0	1	0	0	0	1	1	0	4
			52	0	1	0	0	0	1	0	0	0	0	1	0	3
1	123	MLL	8	0	1	0	0	0	0	0	0	0	2	0	3	
			12	0	1	0	0	0	0	0	0	0	0	0	2	
			16	0	1	0	0	0	0	0	0	0	0	0	2	
			20	0	1	0	0	0	0	0	0	0	1	1	0	3
			24	0	1	0	0	0	1	0	0	0	1	0	1	3
			28	0	0	0	0	0	0	0	0	0	1	0	1	3
			32	0	0	0	0	0	1	0	0	0	1	1	1	4
			36	0	0	0	0	0	1	0	0	0	1	1	1	4
			40	0	1	0	0	0	1	0	0	0	0	1	1	3
			44	0	2	0	0	0	1	0	0	0	0	0	0	3
			48	0	1	0	0	0	1	0	0	0	1	1	0	4
			52	0	1	0	0	0	1	0	0	0	0	1	0	3

1061

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient No.	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inability to Feel	Possinistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score			
1	123	338	MLL	12	0	1	0	0	0	0	1	2	0	4		
				16	0	1	0	0	0	0	0	1	2	0	5	
				20	0	1	0	0	0	0	0	0	1	2	0	6
				24	0	0	0	0	0	0	0	0	1	1	1	4
				28	0	2	0	0	0	0	0	0	0	1	1	5
				32	0	2	0	0	0	0	0	0	1	1	1	5
				36	0	2	0	0	0	0	0	0	1	1	0	6
				40	0	2	0	0	0	0	0	0	1	2	0	5
				44	0	1	0	0	0	0	0	0	0	3	0	5
				48	1	1	1	1	1	1	1	1	1	1	0	8
				52	2	1	1	1	1	1	2	1	2	1	0	12
				1	125	340	FDP	8	1	1	1	0	0	0	1	2
12	1	1	1					1	1	1	1	3	0	0	11	
16	2	1	1					0	1	1	1	1	3	0	11	
20	2	1	2					1	1	2	1	1	3	0	14	
24	1	1	1					1	1	1	1	1	2	0	9	
28	1	2	1					1	1	2	1	1	0	0	1	10
32	1	1	1					1	1	1	1	1	2	0	0	9
36	1	1	1					2	1	1	1	2	2	0	0	9
40	1	1	1					1	0	0	0	0	1	1	1	7
44	0	1	0					0	0	0	0	0	0	0	1	3
48	0	1	0					0	0	0	0	0	0	0	1	3
52	0	1	0					0	0	0	2	1	0	1	1	5
1	127	342	VPD	8	0	1	0	0	0	0	0	1	1	1	3	
				12	1	2	1	0	0	0	0	1	2	1	9	
				16	1	1	1	0	0	1	1	1	2	1	1	9
				20	1	2	1	0	0	1	1	0	1	2	1	10
				24	1	1	1	1	1	1	0	0	1	2	0	8
				28	0	1	0	1	0	0	0	0	1	2	0	4
				32	0	1	0	0	0	0	0	0	1	1	0	5
				36	0	0	0	0	0	0	0	0	1	1	0	3
				40	0	1	0	0	0	0	0	0	0	1	1	3
				44	0	2	0	0	0	0	0	0	1	2	1	6
				48	0	2	0	0	0	0	0	0	1	2	1	6
				52	0	2	0	0	0	0	0	0	1	2	1	6
1	128	343	LAM	8	0	1	0	0	0	0	1	2	1	1	5	
				12	0	1	0	0	0	0	0	1	2	1	5	
				16	0	1	0	0	0	0	0	1	2	1	5	
				20	0	1	0	0	0	0	0	1	2	1	5	
				24	0	0	0	0	0	0	0	0	0	0	0	4
				28	0	0	0	0	0	0	0	0	0	0	0	1
				32	1	0	1	1	1	1	1	1	2	0	1	4
				36	0	0	0	0	0	0	0	0	0	0	0	6
				40	1	1	0	0	0	2	0	0	1	0	1	3

1062

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient No.	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Inner Suicidal Thoughts	Inability to Feel Inertia	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score			
1	128	343	LAM	44	0	1	0	0	0	0	1	2	0	4		
				48	0	1	0	0	0	0	0	0	2	0	5	
				52	0	1	0	0	0	0	0	0	1	0	2	
1	134	347	LMS	8	0	1	0	0	0	0	1	1	0	3		
				12	0	2	0	0	0	0	0	0	1	0	4	
				16	0	2	0	0	0	0	0	0	0	1	0	4
				20	0	1	0	0	0	0	0	0	0	1	0	3
				24	0	1	0	0	0	0	0	0	0	1	1	3
				28	0	1	0	0	0	2	0	0	1	0	0	4
				32	0	2	0	0	0	0	0	0	1	1	0	4
				36	0	1	0	0	0	1	0	0	0	1	0	4
				40	0	1	0	0	0	0	0	0	0	1	0	2
				44	0	1	0	0	0	0	0	0	1	1	1	4
				48	0	1	0	0	0	0	0	0	1	0	1	4
				52	0	1	0	0	0	0	1	0	0	1	0	3
1	135	348	MMS	8	0	1	0	0	0	0	0	1	1	0	3	
				12	0	1	0	0	0	0	0	0	1	1	4	
				16	0	1	0	0	0	0	0	0	0	1	0	2
				20	0	1	0	0	0	0	0	0	1	1	0	3
				24	0	1	0	0	0	0	0	0	1	1	1	4
				28	0	1	0	0	0	0	0	0	1	1	1	4
				32	1	1	0	0	0	0	0	0	1	1	0	4
				36	0	1	0	0	0	0	0	0	1	1	1	4
				40	0	1	0	0	0	1	0	0	1	1	0	4
				44	0	1	0	0	0	0	0	0	1	1	0	2
				48	0	2	0	0	0	0	0	0	1	2	1	6
				52	0	2	0	0	0	0	0	0	1	1	1	5
1	139	351	RA	8	0	0	0	0	0	0	0	2	1	3		
				12	0	0	0	0	0	0	0	1	1	1	3	
				16	0	0	0	0	0	0	0	0	0	2	4	
				20	0	0	0	0	0	0	0	0	0	2	4	
				24	0	1	0	0	0	0	0	0	1	0	3	
				28	0	2	0	0	0	1	0	0	1	2	0	6
				32	0	1	0	0	0	1	0	0	1	2	0	5
				36	0	0	0	0	0	2	0	0	1	2	1	6
				40	0	1	0	0	0	1	0	0	1	0	2	2
				44	0	1	0	0	0	1	0	0	1	1	1	5
				48	0	1	0	0	0	1	0	0	1	1	1	5
				52	0	1	0	0	0	0	0	0	0	1	0	2
1	140	352	MCA	8	1	1	0	0	0	0	1	2	0	5		
				12	0	1	0	0	0	0	1	2	0	4		
				16	1	1	0	0	2	1	1	2	1	10		
				20	0	1	0	0	0	0	0	0	0	0	3	

1063

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CIS R&D		REBOMETINE - PROTOCOL 20124/013		Listing No.: 10.2		MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE														Total
		DOUBLE BLIND PHASE		DOUBLE BLIND PHASE		TREATMENT: REBOMETINE														Total
Centre	Patient	D.B. Patient	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Reduced Total Score					
1	140	352	MCA	24	0	1	0	0	2	0	0	0	0	0	3					
				28	0	1	0	0	2	0	0	1	0	0	4					
				32	1	1	1	0	0	0	1	1	0	1	6					
				36	0	0	0	0	0	0	0	1	0	1	4					
				40	0	1	0	0	2	0	0	0	0	0	4					
				44	0	1	0	0	0	0	0	0	0	0	1					
				48	0	1	0	0	1	0	0	0	0	0	2					
				52	0	0	0	0	0	0	0	0	0	0	1					
				54	0	0	0	0	1	0	0	0	0	0	2					
1	142	354	SCC	8	0	1	0	0	0	0	0	0	1	1	3					
				12	0	0	0	0	0	0	0	1	0	0	2					
				16	0	0	0	0	0	0	0	0	1	0	2					
				20	0	0	0	0	2	0	0	1	0	0	3					
				24	0	1	0	0	1	0	0	0	0	0	2					
				28	0	0	0	0	1	0	0	0	1	1	4					
				32	0	2	0	0	0	0	0	1	2	0	6					
				36	0	1	0	0	0	0	0	1	0	0	4					
				40	0	0	0	0	0	0	0	1	0	1	2					
				44	0	1	0	0	0	0	0	1	0	0	2					
				48	0	1	0	0	0	0	0	1	0	0	2					
				52	0	1	0	0	0	0	0	1	0	0	2					
1	144	356	ARF	8	1	2	1	0	0	1	0	1	1	0	7					
				12	1	2	0	0	0	0	0	1	1	0	5					
				16	1	2	0	0	0	0	0	0	1	0	4					
				20	1	2	0	0	0	0	0	1	1	0	5					
				24	1	1	1	1	2	1	1	1	2	0	11					
				28	1	1	1	1	2	1	1	2	2	0	12					
				32	1	2	1	2	2	1	2	1	1	0	13					
				36	1	2	1	2	2	1	2	1	2	0	14					
1	146	358	LRM	8	1	2	1	1	2	1	1	1	2	0	12					
				12	1	1	1	1	2	2	1	1	2	0	12					
				16	2	1	1	1	1	1	1	2	0	0	11					
				20	2	1	1	1	2	1	1	0	2	0	11					
				24	1	1	1	0	1	0	0	1	1	0	6					
				28	1	1	1	0	1	0	0	0	1	0	5					
				32	1	1	1	0	2	1	0	1	1	0	8					
				36	1	1	1	0	2	1	0	1	1	0	9					
				40	1	2	1	1	1	2	1	1	1	2	12					
				44	2	2	1	1	2	1	0	1	1	0	11					
				48	1	2	2	2	1	2	1	1	1	1	14					
				52	2	2	2	2	2	1	1	1	2	2	17					
1	148	359	CAS	8	0	1	0	0	0	0	0	1	1	0	3					
				12	0	2	0	0	0	0	0	1	0	2	5					
				16	0	1	0	0	0	0	0	1	1	0	3					

1064

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient No.	Initials	D.B.	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Apparent Suicidal Thoughts	Inability to Feel Inertia	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score			
1	148	359	CAS	20	0	1	0	0	0	0	1	1	0	3			
				24	0	2	0	0	0	0	0	0	1	1	0	3	
				28	0	1	0	0	0	0	0	0	0	0	1	1	3
				32	0	1	0	0	0	0	0	0	0	1	1	1	4
				36	0	1	0	0	1	0	0	0	0	0	0	0	3
				40	0	1	0	0	0	0	0	0	0	1	0	0	2
				44	0	1	0	0	0	0	0	0	0	1	1	0	3
				48	0	1	0	0	0	0	0	0	0	1	1	0	3
				52	0	1	0	0	0	0	0	0	0	1	1	0	3
				3	7	71	GRI	8	1	1	1	1	1	0	0	3	1
8	2	212	TE	8	0	0	0	0	0	0	1	1	0	0	3		
				12	0	0	0	0	0	1	0	0	1	1	0	3	
				16	0	0	0	0	0	1	0	0	1	1	0	0	3
				20	1	0	0	0	0	1	0	0	1	1	0	0	4
				24	1	0	0	0	0	1	0	0	1	1	0	0	3
				28	0	0	0	0	0	0	0	0	1	1	0	0	2
				32	0	0	0	0	0	0	0	0	1	1	0	0	2
				36	0	0	0	0	0	0	0	0	1	1	0	0	2
				40	0	0	0	0	0	0	0	0	1	1	0	0	2
				44	0	0	0	0	0	0	0	0	1	1	0	0	2
8	3	213	JL	8	1	1	1	0	0	0	1	1	1	0	6		
				12	1	1	1	0	0	2	1	1	1	1	0	9	
				16	1	1	1	0	0	2	1	2	2	1	1	0	11
				8	1	1	0	0	0	1	0	0	1	1	1	0	5
				12	1	1	0	0	0	1	0	0	1	1	1	0	5
				16	1	1	0	0	0	1	0	0	1	1	1	0	5
				20	1	1	0	0	0	1	0	0	1	1	1	0	5
				24	0	0	0	0	0	1	0	0	1	1	0	0	3
				28	0	0	0	0	0	1	0	0	1	1	0	0	3
				32	0	0	0	0	0	1	0	0	1	1	0	0	2
9	6	245	SD	8	1	0	1	0	0	0	0	1	1	0	3		
				12	0	0	0	0	0	1	1	1	1	0	0	3	
				16	0	0	0	0	0	1	1	1	1	0	0	3	
				20	0	0	0	0	0	0	0	0	0	0	1	0	2
				24	0	0	0	0	0	0	0	0	0	0	0	0	3

1065

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score	
9	6	245	SD	28	0	0	0	0	1	0	0	1	0	2	
			32	0	0	0	0	0	0	0	0	1	0	1	
			36	0	0	0	0	0	0	0	0	0	0	0	0
			40	0	0	0	0	0	0	0	0	0	1	0	1
			44	0	0	0	0	0	0	0	0	0	0	0	0
			48	0	0	0	0	0	0	0	0	0	0	0	0
9	7	243	PP	8	0	0	0	0	1	0	1	0	0	2	
			12	1	0	0	0	0	1	0	0	1	0	3	
			16	0	0	0	0	0	0	1	0	0	0	2	
			20	0	0	0	0	0	0	1	0	0	0	2	
			24	0	0	0	0	0	0	1	0	1	0	0	2
			28	0	0	0	0	0	0	0	0	0	0	0	0
9	11	246	KE	8	0	0	0	0	0	0	0	0	0	2	
			12	2	2	2	1	1	2	2	1	1	1	14	
			16	1	0	1	0	0	1	1	1	0	0	0	4
			20	1	0	1	0	0	1	0	1	0	0	0	4
			24	1	0	0	0	0	0	1	0	1	0	0	3
			28	1	0	0	0	0	0	1	0	0	0	0	2
9	15	249	BI	8	0	0	0	0	0	0	0	0	0	0	
			12	0	0	0	0	0	1	0	0	0	0	2	
			16	0	0	0	0	0	0	1	0	0	0	0	
			20	1	0	0	0	0	0	1	0	0	0	0	
			24	1	1	1	0	1	1	1	1	1	0	0	7
			28	1	1	1	1	1	1	1	1	1	0	0	6
9	16	250	UCY	8	1	0	0	0	1	0	0	0	0	0	
			12	1	0	0	0	0	1	0	0	0	0	3	
			16	0	0	0	0	0	0	1	0	0	0	0	
			20	1	0	0	0	0	0	1	0	0	0	0	
			24	1	1	1	0	1	1	1	1	1	0	0	6
			28	1	1	1	1	1	1	1	1	1	1	0	4
9	16	250	UCY	40	1	0	0	0	0	0	1	0	0	0	
			44	0	0	0	0	0	0	0	0	1	0	0	
			48	1	0	0	0	0	0	1	0	0	1	0	
			52	1	0	0	0	0	0	0	0	0	0	0	
			8	1	0	0	0	0	1	0	0	0	0	0	
			16	1	0	0	0	0	0	0	0	0	0	0	

1066

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient No.	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
9	16	UCY	12	0	0	0	0	0	1	1	1	0	0	3
			16	1	0	1	0	0	1	1	0	0	0	4
			20	1	0	1	0	0	0	1	0	0	0	3
			24	1	0	1	0	0	0	1	0	0	0	3
			28	1	0	1	0	0	0	1	0	0	0	2
			32	0	0	0	0	0	0	1	0	0	0	2
			36	0	0	1	0	0	0	1	0	0	0	2
			40	1	0	1	0	0	1	0	0	0	0	3
			44	1	0	1	0	0	1	0	1	0	0	4
			48	0	0	0	0	0	1	0	0	0	0	2
			52	1	0	0	0	0	1	1	0	0	0	3
9	20	GVE	8	1	0	1	0	1	1	1	0	1	0	6
			12	1	1	1	0	1	1	1	1	1	0	8
			16	1	1	1	0	1	1	1	1	0	0	7
9	23	SZN	8	1	1	1	0	0	1	1	0	0	0	5
			12	1	0	1	0	0	1	1	1	0	0	5
			16	1	0	1	0	0	1	1	1	0	0	5
			20	1	0	1	0	0	1	0	0	0	0	3
9	26	CP	8	0	0	0	0	0	0	0	1	0	0	1
			12	1	0	1	0	0	0	1	0	0	0	3
			16	1	0	1	0	0	0	1	0	0	0	3
			20	1	0	1	0	0	1	0	0	0	0	3
9	29	SZF	8	1	0	1	0	0	1	0	0	0	0	3
			12	0	0	0	0	1	1	0	1	0	0	3
			16	1	0	0	0	1	1	1	0	0	0	3
			20	1	0	0	0	1	1	1	0	0	0	3
			24	0	0	0	0	0	1	1	0	0	0	3
			28	0	0	0	0	0	1	0	1	1	0	3
9	30	NF	8	1	0	1	0	0	1	1	0	0	0	4
10	1	VK	8	0	1	0	0	1	0	0	0	1	0	3
			12	1	1	0	0	1	0	0	0	1	0	4
			16	0	0	0	0	0	0	0	0	1	0	1
10	7	RK	8	0	0	0	0	0	0	0	0	1	0	1
10	9	RT	8	0	0	0	0	0	0	0	0	1	1	2
			9	0	0	0	0	0	0	0	0	1	1	2
10	12	EP	8	1	1	1	0	0	0	0	1	1	0	6
			10	1	1	1	0	1	0	1	1	1	0	8

1007

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient No.	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
10	13	278	RU	8	1	1	0	0	0	0	1	1	0	4
10	15	280	HT	8	0	0	0	0	0	0	0	0	0	0
10	20	285	EJ	8	0	0	0	0	0	0	0	1	0	1
				12	0	0	0	0	0	0	0	0	0	0
				16	0	0	0	0	0	0	0	1	0	1
				20	0	0	0	0	0	0	0	0	0	0
				24	0	0	0	0	0	0	0	0	0	0
				28	0	0	0	0	0	0	0	0	0	0
				32	0	0	0	0	0	0	0	0	0	0
				36	0	0	0	0	0	0	0	0	0	0
				40	0	0	0	0	0	0	0	0	0	0
				44	0	0	0	0	0	0	0	0	0	0
				48	0	0	0	0	0	0	0	0	0	0
				52	0	0	0	0	0	0	0	0	0	0
10	22	286	AA	8	0	0	0	0	0	0	0	1	0	1
				12	0	0	0	0	0	0	0	1	0	1
				16	0	0	0	0	0	0	0	0	0	0
				20	1	1	1	1	1	1	2	1	1	11
				24	0	1	0	0	0	1	0	1	0	3
				28	0	0	0	0	0	0	1	0	0	2
				32	0	0	0	0	0	0	0	0	0	0
				36	0	0	0	0	0	0	0	0	0	0
				40	0	0	0	0	0	0	0	0	0	0
				44	0	0	0	0	0	0	0	0	0	0
				48	0	0	0	0	0	0	0	0	0	0
				52	0	0	0	0	0	0	0	0	0	0
10	23	287	LT	8	1	1	0	0	0	0	0	1	1	4
				12	1	0	0	0	0	0	0	0	2	2
				16	1	2	2	1	0	1	2	0	0	11
				20	1	1	1	1	0	1	0	0	0	6
				24	0	0	0	0	0	1	0	0	0	1
				28	0	1	0	0	0	0	0	0	0	1
				32	0	0	0	0	0	0	0	0	0	0
				36	1	1	0	0	0	1	0	0	0	5
				40	0	0	0	0	0	0	0	2	1	5
				44	1	2	0	0	0	0	0	1	1	5
10	26	290	JIF	8	1	1	0	0	1	0	1	2	1	8
10	27	292	NK	8	0	0	0	0	0	0	0	1	0	1
				12	0	0	0	0	0	0	0	0	0	0
				16	0	0	0	0	0	0	0	1	0	1
				20	0	0	0	0	0	0	0	0	0	0
				24	0	0	0	0	0	0	0	0	0	0
				28	0	0	0	0	0	0	0	0	0	0
				32	0	0	0	0	0	0	0	0	0	0
				36	0	0	0	0	0	0	0	0	0	0
				40	0	0	0	0	0	0	0	0	0	0
				44	0	0	0	0	0	0	0	0	0	0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient No.	D.B. Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
10	27	292	MK	68	0	0	0	0	0	0	0	0	0	0	0
				52	0	0	0	0	0	0	0	0	0	0	0
10	28	291	LL	8	1	1	0	0	0	0	1	1	1	0	5
				12	2	1	2	2	2	1	1	2	2	2	17
				16	1	1	0	1	0	0	1	2	1	0	7
				20	2	1	2	2	2	2	1	2	2	2	18
				24	3	2	3	2	2	3	2	3	2	1	23
				28	3	1	3	2	2	3	2	2	1	0	18
				32	1	1	0	0	2	0	0	0	0	0	2
				36	2	1	2	1	2	1	1	3	1	0	14
				40	2	1	2	2	2	2	1	2	1	0	15
				44	2	1	2	2	2	2	1	2	1	1	13
				48	1	1	0	1	1	1	1	2	1	0	9
10	31	297	RK	8	0	1	0	0	0	0	0	0	1	1	3
				12	1	1	0	0	1	0	0	0	0	0	3
				16	0	1	0	0	0	0	0	0	1	1	3
				20	0	1	0	0	0	0	0	0	1	0	2
				24	0	0	0	0	0	0	0	0	0	0	0
				28	0	0	0	0	0	0	0	0	0	0	0
				32	1	1	0	0	1	1	1	0	1	1	7
				36	1	1	0	0	0	0	1	0	0	1	4
				40	0	1	0	0	0	0	0	0	1	1	3
				44	1	1	0	0	0	0	1	1	1	0	5
				48	1	1	0	0	0	0	0	1	1	0	4
				52	0	1	0	0	0	0	0	2	0	0	3
10	32	299	LK	8	1	1	0	0	0	1	0	1	2	0	6
				12	1	0	0	1	0	2	1	0	0	0	5
				16	1	1	0	0	0	1	1	0	0	0	4
				20	1	1	0	0	0	1	0	0	0	0	4
				24	0	1	0	0	1	1	1	2	0	0	3
				28	0	1	0	0	1	1	1	2	0	0	6
				32	0	1	0	0	0	0	0	1	0	0	2
				36	0	1	0	0	0	0	0	0	0	0	1
				40	0	0	0	0	0	0	0	0	0	0	0
				44	0	0	0	0	0	0	0	1	0	0	2
				48	0	0	0	0	0	0	0	0	1	0	1
				52	0	0	0	0	0	0	0	0	0	0	0
10	33	300	EK	8	0	0	0	0	0	0	0	0	0	0	0
				12	0	0	0	0	0	0	0	0	0	0	0
				16	0	0	0	0	0	0	0	0	0	0	0
10	34	31	TK	8	1	1	0	0	0	1	0	1	1	0	5
				12	1	1	0	0	1	1	1	2	1	0	8

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient No.	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inability to Feel Inertia	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
10	34	TK	16	1	1	0	1	1	1	2	1	0	9
10	35	IM	8	0	0	0	0	0	0	0	0	0	1
			12	0	0	0	0	0	0	0	0	0	1
			16	1	1	0	1	1	1	0	1	0	7
10	36	LL	8	0	0	0	0	0	0	0	1	0	1
			12	0	1	0	0	0	0	0	0	0	1
			16	0	0	0	0	0	0	0	0	0	0
10	39	VX	8	1	1	0	0	0	0	1	1	0	4
			12	1	1	0	0	1	0	1	1	1	7
			16	0	1	0	0	0	0	1	0	0	2
			20	1	1	0	0	0	0	1	1	1	5
			24	1	1	0	0	1	0	1	1	1	7
			28	1	1	0	1	1	1	1	1	1	8
			32	0	1	0	0	0	0	1	1	0	4
			36	1	1	0	1	2	1	2	2	1	11
			40	1	1	0	0	0	0	2	1	0	5
			44	1	1	0	0	1	0	1	1	0	5
			48	1	1	0	0	1	0	1	1	0	5
			52	2	1	0	0	1	0	1	1	0	6
10	41	VP	8	0	0	0	0	1	0	1	1	0	3
			12	0	1	0	0	1	0	1	1	0	4
			16	0	1	0	0	0	0	1	0	0	2
			20	0	1	0	0	0	0	0	0	0	1
			24	0	1	0	0	0	0	0	1	0	2
			28	0	0	0	0	0	0	1	1	0	2
			32	0	0	0	0	0	0	1	0	0	1
			36	0	0	0	0	0	0	0	0	0	0
			40	0	1	0	0	0	0	0	0	0	1
			44	0	1	0	0	0	0	0	0	0	1
			48	0	0	0	0	0	0	0	0	0	0
			52	0	1	0	0	0	0	0	0	0	1
10	43	VW	8	1	1	0	0	1	1	1	1	0	6
			12	1	1	1	1	1	0	2	1	0	8
			16	1	1	1	1	1	0	2	1	0	8
			20	1	1	1	1	1	0	2	1	0	8
			24	1	1	1	0	0	0	2	0	0	5
			28	1	2	0	0	0	0	2	0	0	5
10	47	MA	8	0	1	0	0	0	1	0	0	0	2
			12	1	1	0	0	0	1	0	1	0	4
			16	0	1	0	0	0	1	0	0	0	2
			20	0	1	0	0	0	0	0	1	0	2

1070

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient No.	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inability to Feel Inertia	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
10	53	47	MA	24	0	1	0	0	0	0	1	0	2
				28	0	1	0	0	0	0	1	0	2
				32	0	1	0	0	0	0	0	0	1
10	54	48	UN	8	1	0	0	1	1	1	2	0	6
				12	0	0	0	0	0	1	1	0	2
				16	1	1	0	1	0	1	1	0	5
				20	1	1	0	1	0	1	1	0	6
				24	1	1	0	1	0	1	1	0	6
				28	1	1	0	1	0	1	1	0	5
				32	1	1	0	1	0	1	1	0	5
10	56	50	JP	8	0	1	0	0	0	1	1	0	3
10	57	51	AG	8	1	1	0	0	0	1	1	0	4
				12	1	1	0	0	0	1	0	0	3
				16	1	1	0	0	0	1	1	0	5
				20	0	1	0	0	1	1	1	0	5
				24	0	1	0	0	1	1	0	0	4
				28	0	0	0	1	0	2	0	0	3
				32	1	1	0	1	0	2	0	0	5
				36	1	1	0	1	1	2	1	0	8
				40	1	3	1	2	1	3	1	0	15
				44	1	3	1	2	1	3	1	0	15
				48	0	0	0	1	0	3	0	0	4
				52	1	0	0	2	1	0	3	0	7
10	59	53	TA	8	0	1	0	1	0	3	2	1	9
10	63	57	MS	8	0	1	0	0	0	0	0	0	1
				12	0	1	0	0	0	0	0	0	1
				16	0	1	0	0	0	0	0	0	1
				20	0	1	0	0	0	0	0	0	1
				24	0	0	0	0	0	0	1	0	1
				28	0	0	0	0	0	0	1	0	1
				32	0	0	0	0	0	0	1	0	1
				36	0	0	0	0	0	0	1	0	1
				40	0	0	0	0	0	0	1	0	1
				44	0	0	0	0	0	0	0	0	0
				48	0	0	0	0	0	0	0	0	0
				52	0	0	0	0	0	0	0	0	0
10	82	59	LS	8	1	1	0	0	1	2	0	0	6
				12	0	1	0	0	1	1	0	0	4
				16	0	1	0	0	1	1	0	0	4
				20	0	1	0	0	1	1	0	0	4
				24	0	0	0	0	0	1	0	0	2

1071

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
10	82	59	LS	28	0	0	0	0	0	0	0	0	0	0	0
				32	0	0	0	0	0	0	0	0	0	0	0
				36	0	0	0	0	0	0	0	0	0	0	0
				40	0	0	0	0	0	0	0	0	0	0	0
				44	0	0	0	0	0	0	0	0	0	0	0
10	84	63	HV	8	1	1	0	1	1	1	1	3	2	1	12
				12	1	1	0	0	1	1	1	2	1	0	8
				16	1	2	1	0	2	2	2	3	2	1	16
10	86	274	NP	8	1	2	0	0	1	0	0	1	1	0	6
				12	0	1	0	0	0	0	0	2	1	1	5
				16	0	1	0	0	0	0	0	2	0	1	4
10	87	275	AN	8	0	1	0	0	1	0	0	1	1	0	4
				12	0	1	0	0	1	0	0	1	1	0	4
				16	0	2	0	0	1	0	0	1	1	0	5
				20	0	1	0	0	1	0	0	1	1	0	4
				24	0	1	0	0	1	0	0	0	1	0	3
				28	0	1	0	0	1	0	0	0	1	0	3
				32	0	1	0	0	1	0	0	0	1	0	3
				36	0	1	0	0	1	0	0	0	1	0	2
				40	0	1	0	0	1	0	0	0	0	0	2
				44	0	1	0	0	1	0	0	0	0	0	2
				48	0	1	0	0	1	0	0	0	0	0	2
				52	0	1	0	0	1	0	0	0	0	0	2
10	89	277	SK	8	0	1	0	0	0	0	0	1	0	0	2
10	90	70	SV	8	0	0	0	0	0	0	0	2	1	0	3
				12	2	1	0	0	1	0	0	1	1	0	7
				16	2	1	0	0	1	0	0	1	1	0	7
				20	1	0	0	0	0	0	0	0	0	0	1
				24	0	0	0	0	0	0	0	0	0	0	0
10	91	74	HI	8	1	1	0	0	0	1	0	0	1	0	4
				12	0	1	0	0	0	1	0	0	1	0	3
				16	0	1	0	0	0	1	0	0	1	0	3
				20	0	1	0	0	0	0	0	0	1	0	2
				24	1	1	0	0	0	0	0	0	1	1	4
				28	1	1	0	0	0	0	0	0	1	1	4
10	93	285	AN	8	0	0	0	0	0	0	0	0	0	0	0
				12	0	0	0	0	0	0	0	0	0	0	0
				16	0	0	0	0	0	0	0	0	0	0	0
				20	0	0	0	0	0	0	0	0	0	0	0
				24	0	0	0	0	0	0	0	0	0	0	0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient No.	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score			
10	93	285	AN	28	0	0	0	0	0	0	0	0	0	0			
				32	0	0	0	0	0	0	0	0	0	0			
				36	0	0	0	0	0	0	0	0	0	0	0		
11	2	373	HB	8	0	0	0	0	0	0	0	1	0	1			
				12	0	0	0	0	0	0	0	0	0	1	1		
				16	0	0	0	0	0	0	0	0	0	1	0	1	
				20	0	0	0	0	0	0	0	0	0	1	0	1	
				24	0	0	0	0	0	0	0	0	0	1	0	1	
				28	0	1	0	0	1	0	1	0	1	0	0	4	1
30	0	1	0	0	0	0	0	0	1	0	1	0	2				
11	3	374	RF	8	1	1	0	1	0	1	1	2	1	9			
				9	1	1	0	1	0	1	2	1	1	9			
11	6	377	VP	8	0	1	0	0	0	0	0	0	0	0	1		
				12	0	1	0	0	0	0	0	0	0	0	1	3	
				16	0	1	0	0	0	0	0	0	0	0	2	1	
				20	0	0	0	0	0	0	0	0	0	0	0	0	0
				24	0	1	0	0	0	0	0	0	0	0	0	0	1
				28	0	0	0	0	0	0	0	0	1	0	1	0	2
				32	0	0	0	0	0	0	0	0	0	0	1	0	1
				36	0	1	0	0	0	0	0	0	0	0	1	0	1
				40	0	0	0	0	0	0	0	0	1	0	0	0	1
				44	0	0	0	0	0	0	0	0	1	0	0	0	1
48	0	0	0	0	0	0	0	0	1	0	0	0	1				
52	0	0	0	0	0	0	0	0	1	0	0	0	1				
11	10	363	BJ	8	1	1	0	1	1	1	1	1	2	1	7		
				12	2	2	1	1	1	1	2	1	1	2	1	15	
				16	1	1	1	0	1	1	1	1	0	1	1	6	
				20	1	1	1	0	1	1	0	0	0	0	1	0	5
				24	1	1	0	0	1	1	0	0	0	0	0	0	3
				28	1	1	0	0	1	1	1	1	1	0	1	0	7
				32	1	1	1	0	1	1	1	0	1	0	0	0	5
				36	0	1	0	0	0	0	0	0	0	0	0	0	1
				40	1	1	0	0	0	0	0	0	0	0	0	0	2
				44	1	1	1	0	0	0	0	0	1	0	0	0	4
48	0	1	0	0	0	0	0	0	1	0	0	0	1				
52	0	1	0	0	0	0	0	0	0	0	0	0	1				
11	11	361	NGY	8	0	0	0	0	0	0	0	0	1	0	1		
				12	0	0	0	0	0	0	0	0	0	1	0	1	
				16	0	0	0	0	0	0	0	0	0	0	2	0	2
				20	0	0	0	0	0	0	0	0	0	0	1	0	2
24	2	-2	2	1	2	1	1	2	1	1	3	1	16				
11	13	365	GK	8	1	1	1	1	1	1	1	1	1	8			
				9	1	1	1	1	1	1	1	1	1	1	8		

1073

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD

REBOMETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE

DOUBLE BLIND PHASE
TREATMENT: REBOMETINE

Centre	Patient	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score			
11	13	365	CK	12	1	0	0	1	0	0	0	1	0	4			
				15	1	0	0	0	0	0	0	0	0	0	2		
	16	367	NA	20	0	1	0	0	0	0	0	0	0	0	1		
				8	2	2	1	1	1	1	1	1	1	2	14		
				12	1	1	1	1	1	1	1	1	1	1	1	9	
				16	1	1	1	1	1	1	1	1	1	1	1	6	
11	17	368	UZ	18	1	1	0	0	1	1	1	1	0	0	6		
				8	1	1	1	1	1	1	1	1	1	1	1	11	
				12	1	1	1	1	1	1	1	1	1	1	1	5	
				16	1	1	0	0	0	0	0	0	0	0	0	3	
				20	1	1	0	0	0	0	0	0	0	0	0	2	
				24	1	1	1	0	1	1	1	1	1	1	0	1	7
				28	1	1	0	0	0	0	0	0	0	0	0	0	3
				32	0	1	0	0	0	0	0	0	0	0	0	0	1
				36	1	1	1	0	0	0	0	0	0	0	0	0	4
				40	1	1	1	0	1	0	0	0	0	0	0	0	4
11	19	370	FK	44	1	1	0	0	0	0	0	0	0	0	4		
				48	0	1	1	0	0	0	0	0	0	0	0	2	
				52	1	1	1	0	0	0	0	0	0	0	0	3	
				8	2	1	1	0	0	0	0	1	0	0	0	1	6
				12	0	1	0	0	0	0	0	0	0	0	0	0	1
				16	1	1	1	0	0	0	0	0	0	0	1	1	5
12	1	92	IB	20	0	1	0	0	0	0	0	0	0	0	1		
				24	0	1	0	0	0	0	0	0	0	0	0	1	
				28	0	0	0	0	0	0	0	0	0	0	0	0	
				32	0	0	0	0	0	0	0	0	0	0	0	0	
				36	0	0	0	0	0	0	0	0	0	0	0	0	
				40	1	1	1	0	0	0	0	0	0	0	0	0	4
				44	0	1	0	0	0	0	0	0	0	0	0	0	1
				48	0	1	0	0	0	0	0	0	0	0	0	0	1
				52	0	1	0	0	0	0	0	0	0	0	0	0	1
				8	0	1	0	0	0	0	0	0	0	0	0	0	0
				12	0	0	0	0	0	0	0	0	0	0	0	0	0
				16	1	1	1	0	0	0	0	0	0	0	0	0	3

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/073
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient No.	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inability to Feel Inertia	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
12	2	99	8	2	2	2	1	2	1	1	2	1	16		
			12	2	2	2	1	2	1	1	2	1	16		
12	3	93	8	0	1	0	0	0	0	0	0	0	0	1	
			12	0	0	0	0	0	0	0	0	0	0	0	0
			16	0	1	0	0	0	0	0	0	0	1	0	2
			20	0	0	0	0	0	0	0	0	0	0	0	0
			24	0	0	0	0	0	0	0	0	0	0	0	0
			28	0	1	0	0	0	0	0	0	0	1	0	2
			32	0	0	0	0	0	0	0	0	0	0	0	0
			36	0	0	0	0	0	0	0	0	0	0	0	0
			40	0	0	0	0	0	0	0	0	0	0	0	0
			44	0	0	0	0	0	0	0	0	0	0	0	0
12	4	100	8	0	1	0	0	0	0	0	0	0	0	2	
			12	0	2	2	1	2	1	2	1	2	1	13	
			16	0	1	1	1	1	1	1	1	0	0	5	
			20	0	1	1	1	0	1	0	0	0	0	3	
			24	0	1	1	0	1	0	0	0	0	0	3	
			28	0	0	1	0	2	1	0	0	0	0	1	5
			32	2	1	2	1	2	1	1	1	0	0	0	10
			36	2	2	2	0	1	2	0	0	1	2	1	13
			40	1	1	1	0	1	2	0	0	0	2	0	8
			44	0	1	1	0	1	1	2	0	0	2	0	8
12	9	91	8	2	2	2	0	1	0	1	1	0	15		
			12	1	1	1	0	1	2	1	1	0	0	11	
			16	2	2	2	0	1	2	1	1	1	0	11	
			20	1	2	1	1	1	2	1	1	0	0	10	
			24	0	1	1	1	1	1	1	1	1	0	6	
			28	0	1	1	0	1	1	1	1	1	0	6	
12	15	104	8	1	1	1	1	0	1	0	1	1	7		
			12	1	1	1	1	0	0	1	1	1	1	7	
			16	1	1	1	1	1	0	1	1	0	1	8	
			20	1	1	1	1	0	0	1	1	0	1	7	
			24	1	1	1	1	0	0	1	1	0	1	7	
			28	1	1	1	1	0	0	1	1	0	1	7	
12	16	105	8	0	1	1	0	0	0	0	0	0	2		
			12	2	2	2	0	0	1	1	0	1	0	9	
			16	2	2	2	0	1	1	1	0	1	0	10	
			20	2	2	2	0	1	1	1	0	1	0	10	
			24	2	2	2	0	1	1	1	0	1	0	10	
			28	2	2	2	0	1	1	1	0	1	0	10	

1075

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE

DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient No.	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
12	16	105	24	2	2	0	0	0	0	1	0	0	0	7
12	19	106	8	0	0	0	0	0	1	1	0	0	1	3
			12	0	0	1	0	0	0	1	0	0	0	2
			16	0	0	0	0	0	0	0	0	0	0	0
12	21	110	8	0	1	0	0	1	1	0	0	0	0	3
			12	0	1	0	0	0	0	0	0	0	0	2
			16	0	1	0	0	0	0	0	0	0	0	1
			20	1	2	1	1	1	0	1	0	1	1	9
12	24	113	8	0	0	0	0	0	0	0	1	0	1	2
			12	0	0	0	0	0	0	0	1	0	0	1
			16	0	0	0	0	0	0	0	1	0	0	1
			20	0	0	0	0	0	0	0	1	0	0	1
			24	0	0	0	0	0	0	0	1	0	0	1
			28	0	0	0	0	0	0	0	1	0	0	1
12	25	114	8	1	1	1	0	1	0	1	1	1	0	7
			12	0	1	0	1	1	0	1	1	1	0	6
			16	0	1	0	0	1	0	1	1	1	0	5
			20	0	1	1	0	0	0	1	1	2	0	6
			24	1	1	1	1	1	0	1	1	0	0	7
			28	0	1	0	0	1	0	1	1	1	0	5
			32	0	1	0	0	1	0	1	1	0	0	4
			36	0	1	0	0	1	0	1	1	1	0	4
			40	0	1	0	0	1	0	1	1	1	0	5
			44	1	1	0	0	1	0	1	1	1	0	6
			48	1	1	0	0	1	0	0	1	1	0	4
			52	1	1	1	0	1	0	1	0	1	0	6
12	27	115	8	0	1	0	0	0	0	0	0	1	0	2
			12	0	1	0	0	0	0	0	0	0	0	1
			16	0	1	0	0	0	0	0	0	1	0	2
			20	0	1	0	0	0	0	0	0	0	1	2
			24	0	1	0	0	0	0	0	0	1	0	2
			28	0	1	0	0	0	0	0	0	1	1	3
			32	0	0	0	0	0	0	0	0	0	0	0
12	29	117	8	1	0	0	0	0	0	0	0	0	0	1
			12	0	0	1	0	0	0	0	0	0	0	1
			16	0	1	0	0	0	0	0	0	0	0	1
			20	0	1	0	0	0	0	1	0	0	0	2
			24	0	1	0	0	0	0	0	0	1	0	2
			28	0	1	1	0	0	0	0	0	1	0	3
			32	0	1	0	0	0	0	0	0	0	0	1
			36	0	1	0	0	0	0	0	0	0	0	1

1076

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Inner Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score			
12	29	117	AK	40	0	0	0	0	0	0	0	0	0	0			
				44	0	0	0	0	0	0	0	0	0	0	0		
				48	0	0	0	0	0	0	0	0	0	0	0	0	
12	33	388	LN	52	0	0	0	0	0	0	0	0	0	0			
				8	0	0	1	0	1	1	0	0	0	0	4		
				12	0	0	1	0	1	1	0	0	0	0	0	4	
12	36	385	FB	16	0	0	1	0	1	1	0	0	0	0	4		
				20	0	0	1	0	1	1	0	0	0	0	0	4	
				8	1	2	2	0	1	0	0	0	0	1	0	7	
13	1	219	PZ	12	1	2	2	0	1	0	0	0	0	0	8		
				8	1	0	0	0	1	0	0	0	1	0	0	4	
				12	1	1	0	0	1	0	0	0	1	0	0	4	
13	3	221	AI	16	2	2	1	0	1	0	1	0	0	0	8		
				20	1	1	0	0	0	1	0	0	1	0	0	5	
				24	1	1	0	0	1	1	0	0	1	0	0	5	
				28	1	1	1	0	0	0	0	0	1	2	0	0	6
				32	1	1	0	0	0	0	0	0	1	0	0	0	3
				36	0	1	1	0	0	1	0	0	0	0	0	0	3
				40	0	1	1	0	0	0	0	0	1	0	0	0	2
				44	0	1	1	0	0	0	0	0	0	0	0	0	2
				48	0	1	1	1	0	0	0	0	0	0	0	0	3
				52	0	1	1	0	0	0	0	0	1	0	0	0	3
				8	0	1	1	0	0	0	0	0	0	0	0	0	1
				12	0	1	1	0	0	1	0	0	0	0	0	0	3
				16	1	1	1	0	0	1	0	0	1	0	0	0	3
20	0	1	1	0	0	0	0	0	1	0	0	0	4				
24	0	1	0	0	0	1	0	0	1	0	0	0	3				
28	1	1	0	0	0	0	0	0	1	0	0	0	2				
32	0	1	0	0	0	0	0	0	1	0	0	0	3				
36	0	1	0	0	0	1	0	0	1	0	0	0	3				
40	0	1	0	0	0	0	0	0	1	0	0	0	2				
44	0	1	0	0	0	0	0	0	0	1	0	0	2				
48	0	1	1	0	0	0	0	0	0	0	1	0	3				
52	0	1	0	0	0	0	0	0	0	0	0	0	1				
13	6	226	KE	8	0	1	0	0	0	0	0	0	0	0	3		
				12	0	1	0	0	1	1	0	0	0	0	0	4	
				16	0	1	1	0	0	0	0	0	1	0	0	4	
				20	1	0	0	0	0	1	0	0	0	0	0	3	
				24	0	1	0	0	0	1	0	0	0	0	0	0	4
				28	0	1	0	0	0	0	0	0	0	0	0	0	1
32	1	1	0	0	0	0	0	0	0	0	0	0	3				
36	1	1	1	0	0	0	0	0	0	0	0	0	3				
40	1	1	1	0	0	0	0	0	0	0	0	0	5				

1077

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient No.	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inability to Feel Inertia	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score			
13	6	226	RE	40	1	1	1	0	0	0	0	0	4			
				44	1	1	1	0	0	0	0	0	0	4		
				48	1	1	1	0	0	0	0	0	0	0	5	
				52	1	1	1	0	0	0	0	0	0	0	5	
13	7	220	BL	8	1	0	0	0	0	0	0	0	3			
				12	0	1	0	0	1	0	0	0	0	0	2	
				16	0	1	1	0	0	0	0	0	0	0	3	
				20	0	1	1	0	0	0	0	0	0	0	2	
				24	0	0	1	0	0	0	0	0	0	0	0	1
				28	0	1	0	0	0	0	0	0	0	0	0	2
				32	0	0	0	0	1	0	0	0	0	0	0	3
				36	0	0	0	0	1	0	0	0	0	0	0	3
				40	0	1	0	0	0	0	0	0	0	0	0	1
				44	1	1	0	0	0	0	0	0	0	0	0	2
				48	1	1	0	0	0	0	0	0	0	0	0	2
				52	0	0	0	0	0	0	0	0	0	0	0	2
				13	13	223	HM	8	1	1	0	0	0	0	0	0
12	0	1	1					0	0	0	0	0	0	0	4	
16	1	1	2					0	0	0	0	0	0	0	6	
20	1	1	0					0	0	0	0	0	0	0	4	
24	1	0	0					0	0	0	0	0	0	0	0	5
28	1	1	0					0	0	0	0	0	0	0	0	3
32	0	1	0					0	0	0	0	0	0	0	0	3
36	0	1	0					0	0	0	0	0	0	0	0	3
40	1	1	0					0	0	0	0	0	0	0	0	5
44	1	1	0					0	0	0	0	0	0	0	0	2
48	1	1	0					0	0	0	0	0	0	0	0	3
52	0	1	0					0	0	0	0	0	0	0	0	2
13	18	227	VT					8	1	0	0	0	0	0	0	0
				12	1	1	1	0	0	0	0	0	0	0	5	
				16	1	1	1	0	0	0	0	0	0	0	5	
				20	1	1	0	0	0	0	0	0	0	0	4	
				24	1	1	0	0	0	0	0	0	0	0	0	3
				28	1	1	0	0	0	0	0	0	0	0	0	4
				32	1	1	1	0	0	0	0	0	0	0	0	4
				36	0	1	1	0	0	0	0	0	0	0	0	5
				40	1	1	0	0	0	0	0	0	0	0	0	5
				44	1	1	1	0	0	0	0	0	0	0	0	5
				48	1	1	1	0	0	0	0	0	0	0	0	5
				52	0	0	0	0	0	0	0	0	0	0	0	2
				13	20	230	NL	8	1	2	1	0	0	0	0	0
12	1	2	1					0	0	0	0	0	0	6		
16	1	1	1					0	0	0	0	0	0	5		

1078

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient No.	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score	
13	20	NL	20	1	1	0	0	0	0	1	0	0	0	3	
			24	1	1	1	0	0	0	0	0	1	0	0	4
			28	1	1	1	0	0	0	0	0	0	0	0	3
			32	1	1	1	0	0	0	0	0	0	0	0	3
			36	0	1	0	0	1	0	0	0	0	0	0	2
			40	0	1	0	0	0	0	0	0	1	0	0	2
			44	0	1	0	0	0	0	0	0	1	0	0	3
			48	0	1	0	0	0	0	0	0	1	0	0	2
			52	0	1	0	0	0	0	0	0	0	0	0	1
			13	21	CL	8	1	0	0	0	1	0	1	0	1
12	0	0				0	0	1	0	0	0	0	0	0	2
16	1	1				0	0	0	0	0	0	1	0	0	3
20	0	1				1	0	0	0	0	0	0	0	0	3
24	1	1				0	0	0	0	0	0	0	0	0	2
28	1	1				1	0	0	0	0	0	0	0	0	3
32	0	1				1	0	0	0	0	0	0	0	0	3
36	0	1				1	0	0	0	0	0	1	0	0	3
40	0	1				1	0	0	0	0	0	1	0	0	4
44	0	1				0	0	0	0	0	0	1	0	0	3
13	22	NYM	8	2	2	2	1	2	1	2	1	1	1	1	15
			12	0	0	0	0	0	0	0	0	0	0	0	0
			16	1	1	0	0	0	0	0	0	0	0	0	0
			20	0	1	1	0	0	0	0	0	0	0	0	0
			24	1	1	0	0	0	0	0	0	0	0	0	0
			28	1	1	1	0	0	0	0	0	0	0	0	0
			32	0	1	1	0	0	0	0	0	0	0	0	0
			36	0	1	1	0	0	0	0	0	0	0	0	0
			40	0	1	1	0	0	0	0	0	0	0	0	0
			44	0	1	0	0	0	0	0	0	0	0	0	0
48	0	1	0	0	0	0	0	0	0	0	0	0			
52	0	1	0	0	0	0	0	0	0	0	0	0			

1079

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Centre	Patient	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
1	1	NGA	8	1	2	0	0	1	0	0	1	1	0	6		
			12	1	2	1	0	1	1	1	2	2	1	2	13	
			16	2	2	2	0	2	1	2	2	2	2	2	17	
			8	1	1	0	0	2	1	1	1	1	2	1	10	
			12	1	2	1	0	1	1	1	0	2	2	2	1	11
			16	2	2	2	1	2	2	2	2	1	2	2	1	17
1	8	MYB	8	1	1	0	0	1	0	0	1	1	1	0	5	
			12	1	1	1	0	1	1	1	1	0	1	1	8	
			16	1	2	1	0	2	1	1	1	1	1	1	0	10
			20	1	2	1	0	1	1	1	1	1	1	2	1	11
			24	2	2	1	1	2	1	1	1	1	2	2	0	14
			8	1	2	2	1	2	2	2	2	1	1	2	0	13
1	11	VRT	8	1	2	0	0	1	1	1	1	1	1	0	8	
			12	1	1	1	0	1	1	1	1	1	1	1	0	7
			16	1	2	1	0	1	1	1	1	0	1	2	0	9
			20	1	1	1	0	1	1	1	1	0	1	1	1	8
			24	1	1	2	1	1	1	1	0	0	0	1	0	6
			28	1	2	0	0	2	0	0	0	0	1	2	0	8
			32	2	2	2	1	2	1	2	1	2	1	2	1	15
			36	2	2	2	1	0	2	2	2	1	1	2	0	13
			8	1	2	0	0	1	1	1	1	0	1	2	0	8
			12	1	2	0	0	2	2	2	2	1	1	2	0	11
			16	1	2	1	1	1	1	1	1	0	1	1	0	9
			20	1	2	0	0	1	1	1	1	0	1	0	0	6
24	1	2	1	1	0	1	1	0	0	1	1	0	7			
28	1	2	1	1	1	1	2	1	1	1	2	0	11			
32	1	2	1	1	1	1	1	1	1	1	1	0	10			
36	1	2	1	1	1	2	2	1	1	2	2	1	13			
40	1	2	1	1	1	2	1	1	1	1	2	1	14			
44	1	1	1	1	1	2	1	1	1	1	2	1	14			
48	1	2	1	1	1	1	1	1	1	1	2	1	12			
52	2	2	1	1	1	0	1	1	1	1	1	1	9			
1	15	MAO	8	1	2	0	0	1	1	1	1	1	2	0	8	
			12	1	2	1	0	1	1	1	1	1	2	0	9	
			16	1	1	1	0	1	1	1	1	0	1	1	0	7
			20	1	2	1	0	1	1	1	1	0	1	2	0	9
			24	1	2	1	0	1	1	1	1	0	1	1	1	12
			28	1	2	1	1	1	2	1	1	1	1	1	1	14
			32	2	2	1	1	1	2	1	1	1	2	2	1	14
			36	1	1	1	1	1	1	1	1	1	1	1	0	9
			40	2	1	1	1	1	1	0	2	1	1	2	1	12
			44	1	2	1	1	1	1	1	1	1	1	2	0	11
			48	2	1	1	1	1	1	1	1	1	1	2	0	11
			8	1	2	0	0	1	1	1	1	1	1	2	0	8
12	1	2	1	0	1	1	1	1	1	1	1	0	9			
16	1	1	1	0	1	1	1	1	1	1	1	0	7			
20	1	2	1	0	1	1	1	1	0	1	2	0	9			
24	1	2	1	1	1	1	1	1	1	1	1	1	12			
28	1	2	1	1	1	2	1	1	1	2	2	1	14			
32	2	2	1	1	1	2	1	1	1	1	2	1	14			
36	1	1	1	1	1	1	1	1	1	1	1	0	9			
40	2	1	1	1	1	1	1	1	1	1	2	1	12			
44	1	2	1	1	1	1	1	1	1	1	2	0	11			
48	2	1	1	1	1	1	1	1	1	1	2	0	11			

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
1	15	MAO	52	2	1	1	1	2	1	1	1	2	1	13
1	16	MHC	8	1	2	0	0	2	1	0	1	1	0	8
			12	1	2	1	1	1	1	1	1	1	0	10
			16	1	2	1	0	1	1	1	1	1	1	10
			20	1	2	1	0	1	1	1	1	2	1	11
			24	1	1	0	0	1	1	1	1	1	0	6
			28	1	1	0	0	1	1	0	1	1	1	7
			32	2	2	0	0	1	1	1	1	2	1	11
			36	1	1	0	0	1	1	0	1	1	0	5
			40	0	1	0	0	0	0	0	1	1	0	3
1	19	SR	8	1	2	1	1	1	1	0	1	1	0	9
			12	1	1	1	0	1	0	1	1	1	0	7
			16	1	2	0	1	2	1	1	0	2	0	10
			20	2	2	1	1	2	1	1	1	2	0	13
			24	2	2	1	1	1	1	1	1	2	0	12
			28	2	2	1	1	2	1	1	1	2	0	13
			32	2	2	1	1	2	1	1	1	2	0	13
			36	2	2	1	1	2	1	1	2	2	1	15
1	21	VNC	8	1	2	0	0	1	1	1	0	1	0	7
			12	1	1	1	0	1	0	0	0	1	1	7
			16	1	2	0	0	1	0	0	1	1	0	6
			20	1	2	1	0	1	1	1	1	2	0	10
			24	1	1	1	0	1	0	0	1	1	0	6
			28	2	1	1	0	2	0	0	1	2	0	10
			32	0	1	0	0	1	1	0	1	1	0	5
			36	1	1	1	0	2	1	0	1	2	1	11
			40	1	1	1	1	1	1	1	2	2	1	11
			44	1	1	1	1	1	1	1	1	2	1	12
			48	1	1	1	1	1	1	1	1	2	1	11
			52	2	2	1	1	2	1	1	1	1	1	13
1	26	OC	8	1	2	0	0	1	1	1	0	1	0	9
			12	1	2	1	0	1	1	1	1	2	0	11
			16	1	2	1	0	1	1	1	1	2	0	10
			20	1	2	1	1	2	1	1	1	2	0	12
			24	2	2	1	0	2	1	1	1	1	0	11
			28	2	2	1	0	1	0	1	1	2	1	11
			32	2	2	0	0	1	0	0	1	2	1	9
			36	1	1	1	0	1	1	1	1	2	0	9
			40	1	1	0	0	1	1	0	1	1	0	6
			44	1	1	1	0	2	0	1	1	1	1	9
			48	2	2	1	1	2	1	1	1	2	1	13
			52	2	2	1	0	2	1	1	1	2	1	13

1081

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient No.	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
1	27	RK	8	1	2	1	0	1	2	1	1	2	0	10
			12	3	3	2	2	2	1	2	1	2	3	22
1	28	RMN	8	1	2	1	0	1	1	0	1	2	0	9
			12	1	2	1	0	1	1	1	1	2	0	10
			16	2	2	1	0	2	1	1	1	2	0	12
			20	2	2	1	1	2	1	1	2	2	0	14
			24	2	2	2	2	2	2	1	1	2	0	16
1	29	AF0	8	1	2	0	0	1	0	0	1	1	0	6
			12	1	2	0	0	1	0	1	1	1	0	7
			16	0	1	0	0	1	0	0	1	1	0	4
			20	1	1	0	0	1	0	0	1	1	0	5
			24	1	1	0	0	1	1	0	1	2	0	7
			28	1	1	1	1	1	1	1	0	2	1	9
			32	2	2	1	0	2	1	1	1	2	1	13
			36	1	1	1	0	2	1	1	2	2	0	11
			40	1	1	1	0	2	1	1	2	2	1	11
			44	1	1	1	0	2	1	1	0	1	1	9
			48	2	2	1	0	2	1	1	1	2	1	12
			52	1	1	0	0	1	0	0	0	1	1	5
1	30	ERV	8	1	2	1	0	1	0	1	1	1	0	8
			12	2	2	1	1	2	1	1	1	2	2	15
			16	3	2	1	1	2	2	1	2	3	0	17
1	33	OFC	8	1	2	0	0	1	0	1	1	2	0	8
			12	3	2	2	1	2	2	2	2	3	1	20
1	36	LK	8	1	2	0	1	1	1	0	1	1	0	8
			12	2	2	1	1	2	2	1	1	2	2	17
			16	3	2	2	2	2	3	2	2	3	3	24
1	38	DBF	8	0	1	0	0	0	1	0	0	1	0	3
			12	0	1	0	0	0	0	0	0	1	0	3
			16	2	1	1	0	1	0	0	1	1	0	7
			20	2	2	1	0	1	0	1	1	2	1	13
			24	1	2	1	0	1	2	1	2	2	1	13
			28	1	2	1	0	1	1	1	2	1	0	10
			32	1	1	1	0	1	0	0	1	1	1	7
			36	1	1	1	0	1	0	0	1	1	0	6
			40	0	2	0	0	1	0	0	0	2	0	5
			44	1	2	2	1	2	2	2	1	2	1	16
			48	2	2	2	2	2	2	2	1	2	0	15
			52	2	2	2	1	2	1	1	2	2	1	16
1	40	EN	8	1	2	1	0	1	1	1	1	2	0	10

1082

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient No.	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score				
1	40	306	EH	12	1	2	0	0	1	1	1	2	0	9				
				16	0	1	0	0	1	1	1	1	1	1	0	3		
				20	1	1	1	0	1	1	1	1	1	1	0	8		
				24	1	2	1	1	1	1	1	1	1	1	0	10		
				28	1	1	1	0	1	1	1	1	1	1	0	8		
				32	0	2	0	0	2	0	0	0	0	0	0	5		
				36	2	2	1	1	2	1	1	1	1	0	1	0	11	
				40	1	2	1	1	2	1	1	1	1	1	1	1	13	
				44	2	2	2	1	2	1	1	1	1	1	3	2	17	
				48	2	2	2	1	2	2	1	2	2	1	3	2	18	
				52	2	2	3	2	2	2	1	2	2	2	3	1	20	
				1	41	307	SFS	8	1	2	0	0	1	1	1	2	0	8
12	1	2	1					1	1	1	1	1	1	2	1	12		
16	1	2	1					0	1	1	1	1	1	1	0	8		
20	1	1	1					1	1	1	1	1	1	1	0	9		
24	1	2	1					0	2	1	1	1	1	2	0	11		
28	2	1	1					0	2	1	1	1	1	2	0	10		
32	2	1	1					1	0	1	1	1	1	2	0	11		
36	2	2	2					1	0	1	1	1	1	2	0	11		
40	2	2	2					1	1	2	1	2	2	2	2	2	18	
44	3	2	2					1	2	2	2	2	2	2	2	2	20	
1	42	308	ICC					8	1	1	0	0	1	1	1	2	0	8
								12	1	2	0	1	1	1	1	1	1	2
				16	1	2	1	0	0	1	1	1	1	1	1	8		
				20	1	1	1	0	1	1	1	1	1	2	0	8		
				24	0	1	0	0	0	0	0	0	0	0	0	3		
				28	0	1	0	0	0	0	0	0	0	1	1	0	3	
				32	0	1	0	0	0	0	0	0	0	0	0	0	2	
				36	0	1	0	0	0	0	0	0	0	0	2	0	3	
				40	0	1	0	0	1	1	1	1	1	1	1	1	5	
				44	1	0	1	0	1	1	1	1	1	1	1	1	7	
				48	0	0	0	0	1	1	1	1	1	0	1	0	5	
				52	0	0	0	0	1	1	1	1	1	1	1	0	5	
1	47	312	MCS	8	1	1	1	0	1	0	1	2	0	7				
				12	0	1	0	0	1	1	1	1	1	1	0	5		
				16	2	2	1	1	1	1	1	1	1	2	0	13		
				20	1	1	1	1	2	1	1	1	1	2	0	11		
				24	1	1	1	1	1	1	0	0	0	1	0	9		
				28	1	1	1	1	1	1	1	2	1	2	1	11		
				32	1	1	2	1	2	1	1	2	1	2	2	2	13	
				36	1	1	2	1	2	1	1	2	1	2	2	1	12	
				40	2	2	2	2	2	2	3	2	2	1	2	1	18	
				44	2	2	3	2	3	2	3	2	2	2	2	1	20	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
1	50	MFA	8	1	2	0	0	2	1	0	1	1	0	8		
			12	2	1	1	1	1	2	2	2	2	2	15		
			16	2	1	1	1	1	2	1	1	1	2	0	13	
			20	1	1	1	1	1	1	1	1	1	2	0	11	
			24	1	1	2	1	2	1	1	1	0	1	2	13	
			28	2	2	2	1	2	1	2	1	0	2	2	16	
			32	2	2	2	2	2	1	2	1	0	1	2	15	
			36	2	2	2	2	2	1	2	1	0	0	2	15	
			40	2	2	2	2	2	1	1	1	0	1	2	12	
			44	1	1	1	1	1	1	1	1	0	0	2	0	8
			48	0	1	1	1	1	1	1	1	0	1	2	0	5
			52	0	1	0	0	1	0	1	0	0	1	2	0	5
1	51	ASA	8	0	1	0	0	0	0	0	0	0	1	0	2	
			12	1	1	0	0	1	1	1	1	1	1	1	8	
			16	1	2	1	1	2	2	1	1	1	0	1	1	12
			20	1	1	1	0	1	1	1	1	0	2	1	0	8
			24	1	1	0	0	0	0	0	0	1	1	2	0	6
			28	0	1	0	0	0	0	0	0	0	0	2	0	3
			32	1	1	1	0	1	1	1	1	1	1	2	0	8
			36	1	1	2	0	1	1	1	1	1	1	2	0	10
			40	2	1	1	1	2	1	2	1	0	1	2	1	12
			44	2	2	2	1	2	2	2	2	1	1	2	1	16
			48	2	2	2	1	1	1	1	1	1	1	2	1	14
			52	3	2	1	1	1	1	1	2	1	1	2	1	15
1	53	JFT	8	0	1	0	0	1	0	0	1	1	1	0	4	
			12	1	2	1	1	2	1	1	1	1	1	1	13	
			16	2	2	1	1	2	1	2	1	1	1	2	1	15
			20	2	3	1	1	3	2	2	2	2	2	2	2	20
1	59	SPF	8	1	1	1	1	0	1	1	0	1	1	1	8	
			12	0	1	0	0	0	0	0	0	0	1	2	0	5
			16	0	1	0	0	0	0	0	0	0	1	1	0	3
			20	1	2	0	0	1	1	1	1	0	1	1	0	7
			24	1	1	1	0	2	1	1	1	0	0	2	2	11
			28	1	1	1	0	2	1	1	1	1	1	2	2	13
			32	1	1	1	1	2	1	2	1	2	1	2	2	15
			36	1	1	2	1	2	1	2	1	1	1	2	1	13
			40	2	2	2	1	1	1	1	2	1	1	2	0	13
			44	2	2	2	1	1	1	1	1	1	1	2	1	14
			48	2	2	2	0	2	1	2	1	1	2	2	0	15
			52	2	2	2	1	2	1	2	2	2	1	2	0	16
1	60	EM	8	2	2	2	1	2	2	2	1	2	1	1	17	
			12	1	1	1	1	1	1	1	1	0	2	1	11	
			16	1	2	1	1	1	1	1	1	0	2	1	12	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013

Listing No.: 40.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient No.	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score						
1	60	322	EM	20	2	1	0	2	1	0	2	1	1	12						
				24	2	1	1	2	1	1	1	1	2	1	14					
				28	1	1	2	1	1	1	1	1	1	3	1	12				
				32	2	1	1	1	1	1	1	1	1	2	1	12				
				36	2	1	1	2	2	2	2	2	1	2	1	15				
				40	1	1	0	2	1	1	1	1	1	1	0	11				
				44	2	1	0	2	2	2	2	2	2	2	2	1	15			
				48	3	2	0	2	2	2	2	2	2	2	2	0	17			
				52	1	2	1	0	2	2	2	2	2	1	1	0	13			
				1	62	324	NEA	8	1	1	0	1	1	1	1	2	1	11		
								12	0	2	0	0	0	0	0	0	1	1	1	5
								16	0	1	0	0	0	0	0	0	1	1	1	0
20	0	1	0					0	0	0	0	0	1	1	1	0	3			
24	2	1	1					0	1	1	1	1	1	1	1	0	8			
28	2	1	1					0	1	1	1	1	1	1	1	1	9			
32	1	1	1					0	1	1	1	1	1	1	1	1	9			
36	2	2	2					0	1	1	1	1	1	1	1	2	13			
40	1	1	1					1	1	1	1	1	1	1	1	1	9			
44	1	1	2					2	2	2	2	2	2	2	2	0	14			
48	2	2	1					0	2	2	2	2	2	2	2	1	15			
52	1	2	2					1	2	2	2	2	2	1	2	1	14			
1	64	325	ENF	8	1	0	0	1	1	0	0	1	1	0	5					
				12	1	1	1	0	1	1	1	1	0	1	1	7				
				16	1	1	1	0	1	1	1	1	1	1	1	1	7			
				20	1	1	1	0	1	1	1	1	1	1	1	0	8			
				24	2	2	2	1	2	2	2	2	2	2	2	1	15			
				28	2	2	2	2	2	2	2	2	2	2	2	1	16			
				32	2	2	2	2	2	2	2	2	2	2	2	1	16			
				36	2	2	2	2	2	2	2	2	2	2	2	1	16			
				40	1	1	0	1	1	0	1	1	1	1	2	0	6			
				44	0	2	0	0	0	0	0	0	0	1	2	0	5			
				48	0	2	0	0	0	0	0	0	0	1	1	1	5			
				52	0	1	0	0	0	0	0	0	0	1	2	0	4			
1	67	327	MAA	8	1	1	0	1	1	0	1	1	0	7						
				12	1	2	1	1	1	1	1	1	2	0	11					
				16	2	1	1	0	1	1	1	1	2	2	0	11				
				20	1	1	1	0	1	1	1	1	1	1	1	0	8			
1	70	328	MLX	8	1	2	2	2	2	2	2	2	2	1	17					
				12	2	2	1	1	1	1	1	1	2	0	9					
				16	2	2	1	1	1	1	1	1	1	2	0	11				
				20	2	2	1	1	2	2	2	2	2	2	1	14				

1085

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
1	74	IVL	8	1	1	1	0	1	1	0	1	1	0	7		
			12	1	1	1	0	1	0	1	1	1	2	0	8	
			16	2	1	1	0	1	1	1	1	1	1	1	0	9
			20	1	2	1	1	1	1	1	1	0	1	2	0	10
			24	1	1	1	1	1	1	1	1	1	1	1	0	8
			28	0	2	0	0	0	0	0	0	0	0	1	0	3
			32	0	1	0	0	0	1	1	0	0	1	1	0	4
			36	2	1	1	0	1	1	1	1	1	0	2	0	9
			40	1	1	1	0	1	1	1	1	0	1	1	0	7
			44	1	2	1	1	1	1	1	1	1	1	2	0	10
			48	1	1	1	1	1	1	1	1	1	0	1	0	7
			52	1	0	1	0	1	0	2	1	1	1	2	0	9
1	76	SFA	8	0	1	0	0	0	0	0	0	0	1	0	2	
			12	0	1	0	0	0	0	0	0	0	1	1	0	3
			16	0	1	0	0	0	0	0	0	0	1	1	0	3
			20	0	1	0	0	0	0	0	0	0	1	1	1	4
			24	1	1	1	0	1	1	1	1	0	1	1	1	8
			28	1	1	1	0	1	1	1	1	0	1	1	1	8
			32	1	1	1	1	1	1	1	1	0	1	2	0	10
			36	2	2	1	1	1	1	2	1	0	1	2	0	11
			40	1	1	1	1	1	1	1	1	0	1	1	0	8
			44	1	1	1	2	1	2	1	1	0	1	1	2	11
			48	1	2	1	2	1	2	1	1	0	1	2	1	12
			52	1	1	1	1	2	1	1	0	0	0	1	1	8
1	79	JCM	8	1	1	1	0	1	1	0	0	1	2	1	9	
			12	1	1	1	0	0	1	1	0	1	1	1	8	
			16	0	1	0	0	0	0	0	0	0	1	1	0	3
			20	0	1	0	0	0	0	0	0	0	0	1	0	4
			24	1	1	1	0	1	1	1	1	2	1	1	1	10
			28	1	1	1	0	1	1	1	1	0	0	2	1	9
			32	2	1	1	0	1	1	1	1	0	1	2	1	10
			36	2	1	1	0	1	1	1	1	0	1	2	1	10
			40	1	1	1	0	1	1	1	1	0	1	1	1	7
			44	1	1	1	0	0	0	0	0	0	0	1	2	5
			48	1	2	1	0	1	0	1	1	0	1	1	1	8
			52	0	1	0	0	1	0	1	0	0	0	0	0	2
1	80	MEL	8	1	2	1	0	1	1	1	1	2	1	11		
			12	2	2	2	0	2	2	2	2	2	2	18		
1	84	IN	8	1	1	1	1	1	1	1	0	1	1	1	9	
			12	1	1	1	1	2	1	1	0	0	1	1	9	
			16	0	2	0	0	1	0	0	0	1	1	0	5	
			20	2	2	1	1	2	1	2	1	1	2	2	14	
24	1	2	1	1	1	1	1	0	0	1	1	1	9			

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CHS R8D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score				
1	84	IN	28	1	2	1	1	2	1	0	1	2	1	12				
			32	1	1	0	0	1	1	0	0	0	2	1	7			
			36	0	1	0	0	0	0	0	0	0	1	0	4			
			40	1	1	0	0	1	1	0	0	0	1	1	1	5		
			44	2	2	1	0	2	2	1	2	2	2	2	1	14		
			48	2	2	2	0	2	2	2	1	2	1	2	1	15		
			52	2	2	2	1	2	2	2	1	2	1	2	1	16		
			1	85	MLP	8	1	1	1	0	1	1	0	0	0	0	0	5
						12	0	1	0	0	1	0	0	0	1	1	0	4
						16	0	2	0	0	0	0	0	0	0	0	0	3
20	0	2				0	0	0	0	0	0	0	1	1	0	4		
24	0	0				0	0	0	0	0	0	0	1	1	0	3		
28	1	1				1	0	1	1	1	1	0	1	2	1	9		
32	1	1				1	0	1	1	1	1	0	1	1	1	7		
36	0	1				0	0	0	0	0	0	0	0	2	0	4		
40	1	1				1	0	1	1	1	0	0	0	1	1	6		
44	1	1				1	2	1	1	1	1	0	1	1	1	10		
1	91	NSC	48	2	2	2	2	2	2	1	2	2	2	2	16			
			52	2	2	2	2	2	2	1	0	3	2	2	18			
			8	1	2	1	0	1	0	1	0	1	1	2	1	10		
			12	1	1	1	0	1	1	1	1	1	0	2	0	8		
			16	0	2	0	0	0	0	0	0	1	2	0	0	5		
			20	0	2	0	0	2	0	2	0	1	2	0	0	7		
			24	1	1	1	0	1	1	1	1	0	1	1	1	7		
			28	1	1	1	0	1	1	1	1	1	0	1	1	8		
			32	1	1	1	0	1	1	1	1	1	0	2	0	8		
			36	1	2	1	0	1	1	1	1	1	0	2	0	9		
1	93	AL	40	1	2	1	1	1	1	1	1	1	1	1	11			
			44	2	1	1	1	2	2	1	1	1	1	1	12			
			48	1	2	1	1	2	2	1	1	1	1	2	1	14		
			52	2	2	2	2	2	1	1	2	1	1	2	1	16		
			8	0	1	0	0	1	0	1	0	0	0	2	0	4		
			12	0	1	0	0	0	0	0	0	0	1	2	1	5		
			16	0	1	0	1	0	0	0	0	0	1	2	0	5		
			20	1	1	0	0	1	0	1	0	0	1	1	1	7		
			24	0	1	0	0	0	0	0	0	0	1	1	0	3		
			28	1	1	1	1	1	0	0	0	0	1	2	0	7		
32	1	2	1	1	1	1	1	1	0	1	2	1	11					
36	1	2	2	1	1	2	1	1	0	1	2	1	13					
40	1	2	1	0	1	1	2	1	1	1	2	1	11					
44	2	2	2	0	2	2	2	2	1	1	2	3	17					
48	2	2	2	1	2	2	2	2	1	1	2	2	16					
52	2	2	3	2	2	3	2	2	2	1	2	2	19					

1087

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/073
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient No.	Patient Initials	D.B.	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score			
1	94	RAB		8	1	2	1	0	0	0	0	1	2	0	7			
				12	1	1	1	1	0	0	0	0	0	2	0	7		
				16	0	2	0	0	0	0	0	0	0	0	2	0	5	
				20	1	2	1	0	2	1	0	0	0	0	2	0	9	
				24	0	1	0	0	1	0	0	0	0	0	2	0	4	
				28	1	1	1	1	1	1	0	0	0	0	2	1	10	
				32	2	1	1	1	2	1	0	0	0	0	2	1	12	
				36	1	1	1	0	1	1	0	0	0	0	1	1	1	8
				40	0	2	0	0	0	0	0	0	0	0	0	2	1	5
				44	2	2	1	2	1	2	1	0	0	0	0	2	1	13
				48	1	1	1	1	1	1	0	0	0	0	0	2	1	10
				52	1	1	1	1	2	1	0	0	0	0	0	2	1	10
				1	97	MND		8	0	2	0	0	0	0	0	1	2	0
12	0	2	0					0	0	0	0	0	0	2	0	6		
16	0	2	0					0	0	0	0	0	0	0	2	0	5	
20	0	1	0					0	0	0	0	0	0	0	2	0	4	
24	1	1	1					0	2	1	0	0	0	0	2	0	9	
28	0	1	0					0	1	0	0	0	0	0	2	0	5	
32	2	1	1					1	2	1	1	1	1	1	2	2	14	
36	1	1	1					0	0	0	0	0	0	0	2	1	7	
40	1	1	1					0	0	0	0	0	0	0	1	1	5	
44	0	1	0					0	2	0	0	0	0	0	1	1	5	
48	0	1	0					0	1	0	0	0	0	0	1	1	5	
52	0	1	0					0	2	0	0	0	0	0	0	2	1	6
1	100	JWA						8	0	1	0	0	0	0	0	0	0	2
				12	0	2	0	0	0	0	0	0	0	0	2	0	4	
				16	0	1	0	0	0	0	0	0	0	0	1	0	4	
				20	0	1	0	0	0	0	0	0	0	0	1	0	2	
				24	0	1	0	0	0	0	0	0	0	0	1	0	3	
				28	1	1	1	0	1	0	0	0	0	0	1	1	8	
				32	1	1	1	0	0	1	1	1	1	1	2	0	8	
				36	0	1	1	0	1	0	0	0	0	0	1	2	11	
				40	1	1	1	0	1	0	0	0	0	0	1	2	7	
				44	0	1	0	0	1	0	0	0	0	0	0	1	0	5
				48	0	0	0	0	2	0	0	0	0	0	1	0	0	5
				52	0	2	0	0	0	0	0	0	0	0	2	0	0	4
				1	104	MTF		8	0	1	0	0	0	0	0	0	0	2
12	0	2	0					0	0	0	0	0	0	0	2	0	3	
16	0	1	0					0	0	0	0	0	0	0	1	0	6	
20	0	1	0					0	0	0	0	0	0	0	1	2	1	6
24	1	2	0					0	0	0	0	0	0	0	1	2	1	7
28	1	2	2					1	1	1	0	0	0	0	2	2	1	14
32	1	1	1					1	1	1	1	1	1	1	2	1	1	11
36	1	2	1					2	1	2	0	0	0	0	1	2	1	11
40	1	0	1					0	1	1	0	0	0	0	1	1	1	13
44	1	0	1					1	1	1	0	0	0	0	1	2	1	13
48	0	1	0					0	0	0	0	0	0	0	0	0	0	6
52	0	2	0					0	0	0	0	0	0	0	2	0	0	6

1088

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Centre	Patient No.	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score				
1	104	MTF	40	1	1	1	0	2	0	0	0	1	1	7				
			44	2	1	1	1	1	1	0	1	2	1	11				
			48	2	1	1	1	1	1	1	1	1	1	1	13			
			52	2	1	2	2	0	2	0	0	1	2	0	12			
			1	105	ABS	8	0	1	0	0	1	0	0	0	2	0	4	
						12	1	1	1	0	1	0	0	1	2	0	7	
						16	1	1	1	0	1	0	1	1	2	0	7	
						20	1	1	1	0	1	1	1	1	2	0	8	
1	106	MRN	24	1	1	1	0	1	2	0	2	0	0	8				
			28	1	1	1	0	1	1	1	1	2	0	9				
			32	1	1	1	0	2	2	0	1	1	1	1	11			
			36	1	1	1	0	1	1	1	1	2	1	1	10			
			40	0	0	0	0	1	0	1	0	1	1	1	4			
			44	0	2	2	0	1	0	0	0	0	0	1	0	4		
			48	0	1	0	0	2	0	0	0	0	1	0	0	4		
			52	0	0	0	0	2	0	0	0	0	2	0	1	5		
1	108	STB	8	0	1	0	0	0	0	0	0	0	1	1	3			
			12	0	2	0	0	0	0	0	0	0	2	2	6			
			16	0	2	0	0	0	0	0	0	0	1	2	5			
			20	0	2	0	0	0	0	0	0	0	1	2	5			
			24	0	1	0	0	0	0	0	0	0	1	0	4			
			28	1	1	1	1	1	1	1	1	1	1	1	0	8		
			32	1	1	1	0	1	1	1	1	1	2	2	0	10		
			36	1	1	1	0	1	1	1	1	0	1	2	0	8		
			40	1	1	1	0	1	0	1	0	0	1	0	1	6		
			44	2	2	2	1	1	1	1	1	1	1	2	1	15		
			48	1	1	1	0	1	1	1	1	1	1	1	1	9		
			52	1	1	1	0	1	1	1	1	0	0	1	1	7		
1	108	STB	8	1	1	1	1	1	1	1	0	1	2	0	9			
			12	1	1	1	1	2	1	1	1	0	1	0	9			
			16	1	1	1	0	1	0	0	0	0	0	1	0	5		
			20	1	1	1	0	1	0	0	0	0	0	0	4			
			24	1	1	1	0	1	1	0	1	1	1	1	1	8		
			28	1	0	1	0	1	0	1	0	1	0	0	1	6		
			32	0	1	0	0	1	0	1	0	2	0	0	1	5		
			36	1	1	1	1	1	1	1	1	1	1	0	1	9		
1	111	JBF	40	1	1	1	0	1	1	1	1	1	0	2	8			
			44	1	1	1	0	1	1	1	1	1	0	1	8			
			48	1	1	1	1	2	1	2	1	1	1	0	11			
			52	1	1	1	1	1	1	1	1	0	0	1	8			
			1	111	JBF	8	1	1	1	1	1	1	1	0	2	0	7	
						12	1	1	1	1	2	1	1	0	0	2	0	8
						16	1	1	1	1	1	1	1	1	0	0	0	8
						20	1	1	1	1	1	1	1	1	0	0	0	9

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Inability to Feel Inertia	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score				
1	111	JBF	20	1	2	1	1	1	0	2	0	10				
			24	1	1	1	1	1	1	1	1	0	8			
			28	1	1	2	0	1	1	1	1	2	1	12		
			32	2	1	2	0	1	1	1	0	2	0	11		
			36	1	2	1	1	2	1	1	1	1	1	12		
			40	1	1	1	0	1	0	1	1	2	0	7		
			44	1	1	1	1	2	1	1	0	2	1	10		
			48	1	1	1	0	1	1	1	1	1	0	7		
			52	1	1	1	0	2	1	0	1	1	1	9		
			1	114	CLF	8	1	1	1	1	0	1	1	2	1	10
						12	1	2	1	1	1	1	1	2	0	10
						16	1	1	1	1	1	1	1	1	2	1
20	1	2				1	2	1	1	1	1	2	1	13		
24	1	1				1	2	1	1	1	0	2	1	9		
28	1	1				1	0	1	1	0	1	1	0	7		
32	1	1				1	0	2	1	1	1	1	1	10		
36	1	2				1	0	2	1	1	2	2	0	12		
40	1	2				1	0	1	1	0	1	1	1	9		
44	1	2				1	1	1	2	0	1	1	0	10		
48	2	2				1	1	1	0	0	1	1	0	11		
52	1	1				1	1	1	1	1	1	2	0	10		
1	115	ELS	8	1	1	0	1	0	0	0	2	1	7			
			12	0	1	0	1	0	0	1	2	0	5			
			16	1	1	0	1	0	0	1	2	0	6			
			20	1	2	0	0	1	0	0	2	0	6			
			24	1	2	1	0	1	0	1	1	1	1	8		
			28	2	2	1	1	1	1	1	1	2	1	14		
			32	2	1	0	1	0	0	0	0	0	0	2		
			36	1	1	0	1	1	1	1	1	1	0	8		
			40	1	0	1	2	1	0	0	1	1	1	7		
			44	0	0	0	0	0	0	0	1	1	0	4		
			48	0	1	0	1	0	0	0	1	1	0	4		
			52	0	2	0	0	1	0	0	0	1	0	4		
1	122	HSS	8	0	1	0	0	0	0	0	1	0	2			
			12	0	1	0	0	0	0	0	0	1	0	2		
			16	0	1	0	0	0	0	0	1	2	0	4		
			20	0	1	0	0	0	0	0	1	2	0	4		
			24	0	1	0	0	0	0	0	0	1	0	2		
			28	1	1	0	0	1	1	1	1	0	0	7		
			32	0	0	0	0	0	0	0	1	2	0	5		
			36	0	0	0	0	0	0	0	2	2	0	6		
			40	0	2	0	0	0	0	0	1	1	0	6		
			44	0	2	0	0	0	0	0	1	1	0	3		
			48	0	1	0	0	0	0	0	0	1	0	2		

1090

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient No.	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
1	122	HSS	52	0	2	0	0	1	0	0	0	1	0	4
1	124	PPC	8	0	1	0	0	0	0	0	1	2	0	4
			12	0	1	0	0	2	0	0	1	2	0	6
			16	0	1	0	0	1	0	0	1	2	1	6
			20	0	1	0	0	1	0	0	1	2	0	5
			24	1	1	1	1	1	1	0	1	2	1	10
			28	1	1	1	0	1	1	0	1	2	1	9
			32	1	1	1	0	1	1	1	1	1	1	9
			36	1	2	1	0	1	1	1	1	2	1	11
			40	0	1	0	0	0	0	0	1	1	0	3
			44	0	1	0	0	0	0	0	1	1	0	3
			48	1	2	1	0	2	1	1	1	2	0	11
			52	1	2	2	0	1	1	1	1	1	1	11
1	126	SMB	8	0	1	0	0	0	0	0	0	2	0	3
			12	0	2	0	0	0	0	0	0	2	0	4
			16	0	2	0	0	0	0	0	1	2	0	5
			20	0	2	0	0	0	0	0	1	1	0	4
			24	0	1	0	0	1	0	0	1	1	1	5
			28	0	1	0	0	1	1	0	1	1	1	7
			32	1	1	1	0	0	1	0	1	2	1	8
			36	0	1	0	0	1	0	0	2	1	0	5
			40	0	2	0	0	2	0	0	1	0	0	3
			44	0	2	0	0	0	0	0	1	1	0	4
			48	0	1	0	0	1	0	0	1	2	0	5
			52	0	1	0	0	2	0	0	1	2	0	4
1	129	MNS	8	0	1	0	0	0	0	0	0	1	0	2
			12	0	1	0	0	0	0	0	1	1	0	3
			16	0	1	0	0	1	1	0	0	1	0	4
			20	0	1	0	0	0	0	0	1	1	0	3
			24	0	1	0	0	1	0	0	1	1	0	3
			28	1	1	1	0	1	1	1	1	2	0	9
			32	2	2	1	1	2	2	2	1	2	1	16
			36	2	2	2	1	2	2	1	1	2	1	16
			40	2	2	2	1	2	1	1	2	2	1	16
1	130	EGA	8	1	1	1	1	1	1	0	1	2	2	11
			12	1	1	1	1	1	1	1	1	2	2	12
			16	2	2	1	1	1	1	1	1	2	2	13
			20	2	2	1	1	1	2	1	2	2	2	16
1	133	JPH	8	1	1	1	0	1	1	0	1	2	1	9
			12	1	1	1	0	1	1	0	1	2	1	9
			16	1	1	1	1	2	1	0	1	2	1	11
			20	1	1	1	1	2	1	0	2	2	1	12

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Centre	Patient	D.B. Patient	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score					
1	133	346	JPH	24	1	1	1	0	1	1	0	1	1	1	8					
				28	1	1	1	0	1	1	0	0	1	1	0	7				
				32	0	0	0	0	1	0	1	0	1	1	1	1	4			
				36	1	1	1	0	1	0	1	1	0	1	1	1	8			
				40	1	1	1	0	1	0	1	0	1	1	0	0	6			
				44	2	2	2	1	1	1	0	1	0	1	1	2	1	13		
				48	2	2	2	0	1	1	0	1	0	1	0	0	0	8		
				52	1	1	1	0	1	1	0	1	1	0	0	1	1	7		
				1	136	349	AVP	8	1	1	1	0	2	1	0	0	0	1	0	6
								12	1	1	1	0	2	1	1	1	1	1	2	11
16	2	2	2					1	2	1	1	1	1	1	1	1	12			
20	1	1	1					0	2	1	0	1	1	2	0	0	11			
24	1	1	1					1	1	1	0	0	0	0	0	0	7			
28	1	1	1					1	1	1	0	1	1	0	1	1	0	9		
32	2	2	2					1	1	1	1	1	1	0	1	0	0	11		
36	2	2	2					1	1	1	0	2	1	0	1	2	2	13		
40	0	0	0					0	2	0	0	2	0	0	2	1	1	9		
44	1	2	2					1	1	1	0	1	1	1	1	2	1	11		
1	138	350	LBV	8	1	1	1	0	2	1	0	1	1	2	1	10				
				12	0	0	0	0	1	0	0	0	0	0	0	0	11			
				16	0	1	0	0	0	0	0	0	0	0	0	1	1	3		
				20	0	2	0	0	2	0	0	1	1	0	1	2	1	8		
				24	1	1	1	0	1	0	0	1	0	1	1	2	0	8		
				28	1	1	1	0	1	1	1	1	1	1	1	2	0	9		
				32	2	2	2	1	1	1	1	1	1	1	1	2	1	12		
				36	2	2	2	1	1	1	0	1	1	1	1	2	2	14		
				40	1	1	1	0	1	1	0	1	1	1	1	1	0	8		
				44	2	2	2	1	1	1	1	2	1	1	1	2	1	13		
1	141	353	AMG	8	1	1	1	0	2	1	0	1	1	2	1	12				
				12	1	1	1	0	2	1	0	1	1	1	1	0	7			
				16	1	1	1	0	1	1	1	1	0	0	0	2	0	8		
				20	1	1	1	0	1	0	0	1	0	0	0	0	0	6		
				24	0	0	0	0	0	0	0	0	0	0	1	2	1	4		
				28	1	1	1	0	1	0	0	1	0	0	1	2	1	5		
				32	1	1	1	2	2	2	1	2	2	1	0	2	1	12		
				36	2	2	2	0	2	2	0	2	2	2	1	2	2	15		
				1	143	355	JEP	8	0	1	1	0	0	0	0	1	1	0	0	3
								12	1	2	1	0	0	1	1	1	0	1	1	2
16	1	2	1					0	2	1	0	0	0	0	0	1	1	9		

1092

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Centre	Patient	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
1	143	JEP	20	2	2	1	1	2	1	0	2	2	2	15
1	145	SLD	8	0	2	0	0	1	0	0	1	2	0	6
			12	1	2	1	0	1	1	1	1	2	0	10
			16	1	2	1	0	1	1	1	1	2	1	11
			20	1	2	2	0	2	1	1	2	2	2	15
			24	1	1	1	0	1	0	0	1	1	1	7
			28	1	1	1	0	2	0	0	1	1	1	8
			32	1	1	2	0	2	1	0	0	1	1	9
			36	2	2	1	0	2	1	0	1	2	1	12
			40	1	1	1	0	2	1	1	1	1	0	8
			44	2	2	1	0	2	1	1	1	2	2	14
			48	1	1	1	1	1	1	1	1	1	0	9
			52	1	1	1	0	1	2	1	0	1	1	9
1	149	SC	8	0	0	0	0	2	0	0	1	2	1	6
			12	0	2	0	0	1	0	0	1	2	1	7
			16	2	2	2	1	2	1	1	1	2	1	15
			20	1	1	1	1	1	1	0	1	1	0	7
			24	1	1	1	0	1	0	0	1	1	0	6
			28	1	1	1	0	1	1	0	1	1	0	6
			32	1	1	1	0	1	1	0	1	1	0	7
			36	0	2	0	0	1	0	0	1	1	1	6
			40	0	2	0	0	0	0	0	1	1	0	4
			44	0	2	0	0	0	0	0	1	0	1	4
			48	0	1	0	0	0	0	0	1	0	0	2
			52	0	1	0	0	0	0	0	1	1	0	3
1	150	VA	8	0	2	0	0	0	0	0	1	2	0	5
			12	0	1	0	0	0	0	0	1	2	1	5
			16	1	1	1	0	1	0	0	0	2	1	7
			20	0	1	0	0	0	0	0	0	1	0	3
			24	0	2	0	0	1	0	0	1	0	0	4
			28	2	1	1	0	1	1	0	1	1	1	9
			32	2	2	2	0	2	2	0	1	1	1	13
			36	3	2	2	2	2	2	0	1	2	1	17
3	2	FIL	8	0	0	0	0	0	0	0	0	0	0	0
			12	1	1	0	0	0	0	0	0	0	0	2
			16	0	0	0	0	0	0	0	0	0	0	0
			20	0	1	0	0	0	0	0	0	0	0	1
			24	0	0	0	0	0	0	0	0	0	0	0
			28	0	0	0	0	0	0	0	0	0	0	0
			32	0	0	0	0	0	0	0	0	0	0	0
			36	0	0	0	0	0	0	0	0	0	0	0
			40	0	0	0	0	0	0	0	0	0	0	0

1093

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
3	3	62	BUB	8	0	0	0	0	0	0	0	0	0	0
				12	0	0	0	0	0	0	0	0	0	0
				16	0	0	0	0	0	0	0	0	0	0
				20	0	0	0	0	0	0	0	0	0	0
				24	2	2	2	2	1	2	3	1	1	18
3	10	72	TOR	8	1	1	1	1	0	1	0	0	0	6
				12	0	1	0	0	0	1	0	0	0	2
				16	1	1	0	1	0	1	0	1	0	6
				20	1	0	1	1	0	1	0	0	0	5
8	1	211	HJ	8	1	1	0	1	1	1	2	2	0	10
				12	1	1	0	1	1	1	1	1	0	7
				16	1	1	0	0	1	0	1	1	0	5
				20	1	1	0	0	1	0	1	1	0	5
				24	1	1	0	0	1	0	1	1	0	5
				28	1	1	0	0	1	0	1	1	0	5
				32	1	1	0	0	1	0	1	1	0	5
				36	1	1	0	0	1	0	1	1	0	5
				40	1	1	0	0	1	0	1	1	0	5
				44	1	1	0	0	1	0	1	1	0	5
8	4	214	BA	8	0	0	0	1	0	0	1	1	0	3
				12	0	0	0	1	0	0	1	1	0	3
				16	0	0	0	1	0	0	1	1	0	3
				20	0	0	0	1	0	0	1	1	0	3
				24	0	0	0	1	0	0	1	1	0	3
				28	0	0	0	1	0	0	1	1	0	3
				32	0	0	0	1	0	0	1	1	0	3
				36	0	0	0	1	0	0	1	1	0	3
				40	0	0	0	1	0	0	1	1	0	3
				44	0	0	0	1	0	0	1	1	0	3
				48	0	0	0	1	0	0	1	1	0	3
				52	0	0	0	1	0	0	1	1	0	3
8	5	215	SL	8	1	0	1	0	2	1	1	1	0	8
9	2	241	VCF	8	1	0	0	0	0	1	0	0	0	3
				12	0	0	1	0	0	0	0	1	0	1
				16	0	0	1	0	0	0	0	1	0	1
				20	0	0	1	0	0	0	0	1	0	2
				24	1	0	1	0	0	0	0	1	0	3
				28	1	0	1	0	0	0	0	1	0	3
				32	1	0	1	0	0	0	0	1	0	3
				36	1	0	1	0	0	0	0	1	0	2
				40	0	0	0	0	0	0	0	0	0	1
				44	0	0	0	0	0	0	0	0	0	1

1094

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
 RESOMETINE - PROTOCOL 20124/013
 Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
9	2	241	VCF	48	0	0	0	0	0	0	0	1	0	1
				52	0	0	0	0	0	0	0	0	0	0
9	5	242	MF	8	1	0	1	0	0	0	1	0	0	3
				12	0	0	1	0	0	1	1	0	0	3
				16	1	0	0	0	1	0	0	1	0	3
				20	0	0	0	0	0	0	1	0	0	2
				24	0	0	0	0	0	0	0	1	0	2
				28	0	0	0	0	1	0	0	0	0	1
				32	0	0	0	0	0	0	0	0	0	0
				36	0	0	0	0	0	0	0	0	0	1
				40	0	0	0	0	1	0	0	0	0	1
9	8	244	KTM	8	1	0	1	1	1	1	1	1	0	7
				12	2	1	2	1	1	1	1	1	1	12
				16	2	2	2	1	2	1	1	1	0	13
				20	2	2	2	2	2	2	1	1	0	16
				24	2	2	2	2	2	2	2	1	1	18
9	12	247	GVT	8	1	0	0	0	1	1	0	0	0	4
				12	0	0	0	0	1	0	0	0	0	2
				16	2	2	2	2	2	2	2	1	1	18
9	13	248	BP	8	0	0	0	0	1	1	1	0	0	4
				12	1	0	0	0	0	0	0	0	0	2
				16	1	0	1	0	0	1	0	0	0	4
				20	1	0	1	0	1	1	0	0	0	4
				24	1	0	1	0	1	0	0	0	0	4
				28	1	0	1	0	0	1	0	0	0	4
				32	1	0	1	0	1	1	0	0	0	4
				36	1	0	1	0	0	1	0	0	0	5
				40	0	0	1	0	0	0	1	0	0	2
				44	1	1	1	1	1	1	0	1	0	7
				48	1	0	0	0	1	1	0	0	0	3
				52	1	1	1	1	1	1	1	1	0	8
9	19	251	KF	8	0	0	0	0	0	0	1	0	0	1
				12	1	1	1	1	1	1	1	0	0	7
				16	2	1	2	1	1	1	1	0	0	10
9	24	253	LGY	8	1	0	1	0	1	1	0	0	0	4
				12	1	0	1	0	1	1	0	0	0	4
				16	1	0	1	0	0	1	0	0	0	3
				20	1	0	1	0	0	1	0	0	0	3
9	25	254	PM	8	1	0	1	0	0	1	0	0	0	3
				12	1	0	0	0	0	1	0	0	0	2

1095

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Centre	Patient No.	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inability to Feel Inertia	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
9	25	254	PK	16	0	0	0	0	1	0	0	0	3		
				20	1	0	1	0	0	0	0	0	0	4	
				24	1	0	1	0	0	0	0	0	0	0	3
				28	1	0	1	0	0	0	0	0	0	0	3
				32	1	0	0	0	1	0	0	0	0	0	4
				36	1	1	1	0	1	0	0	0	0	0	4
				40	1	0	0	1	0	0	0	0	0	0	5
				44	1	0	0	1	0	0	0	0	0	0	4
				48	1	0	0	0	0	0	0	0	0	0	5
				48	1	0	0	0	0	0	0	0	0	0	5
9	28	257	HI	8	1	0	1	0	0	0	0	0	3		
				12	0	0	0	0	0	0	0	0	0	2	
				16	0	0	0	0	0	0	0	0	0	2	
				20	0	0	0	0	0	0	0	0	0	0	1
				24	0	0	0	0	0	0	0	0	0	0	1
				28	0	0	0	0	0	0	0	0	0	0	2
				8	1	1	1	0	0	0	0	0	0	0	6
				12	1	1	1	0	0	0	0	0	0	0	6
				16	1	1	1	0	0	0	0	0	0	0	8
				20	2	2	2	1	0	0	0	0	0	0	13
10	4	272	ZSD	24	1	1	1	0	0	0	0	0	7		
				28	1	1	1	0	0	0	0	0	0	4	
				8	0	1	1	0	0	0	0	0	0	1	
				12	0	1	1	0	0	0	0	0	0	0	1
				16	0	1	1	0	0	0	0	0	0	0	1
				20	0	1	1	0	0	0	0	0	0	0	1
				24	0	1	1	0	0	0	0	0	0	0	1
				28	0	1	1	0	0	0	0	0	0	0	1
				8	0	1	1	0	0	0	0	0	0	0	1
				12	0	1	1	0	0	0	0	0	0	0	1
10	5	273	AN	8	1	1	1	0	0	0	0	0	2		
				12	0	1	1	0	0	0	0	0	0	0	
				8	1	1	1	0	0	0	0	0	0	0	
				12	0	1	1	0	0	0	0	0	0	0	
				8	1	1	1	0	0	0	0	0	0	0	
				12	0	1	1	0	0	0	0	0	0	0	
				8	1	1	1	0	0	0	0	0	0	0	
				12	0	1	1	0	0	0	0	0	0	0	
				8	1	1	1	0	0	0	0	0	0	0	
				12	0	1	1	0	0	0	0	0	0	0	
10	10	276	MR	8	1	1	1	0	0	0	0	0	0		
				8	1	2	0	0	1	1	0	0	0	0	
				12	1	1	0	0	0	0	0	0	0	0	
				16	1	1	0	0	0	0	0	0	0	0	
				20	1	1	0	0	0	0	0	0	0	0	
				24	1	1	0	0	0	0	0	0	0	0	
				28	1	1	0	0	0	0	0	0	0	0	
				32	1	1	0	0	0	0	0	0	0	0	
				36	0	1	0	0	0	0	0	0	0	0	
				40	0	1	0	0	0	0	0	0	0	0	
10	16	281	AJ	44	0	1	0	0	0	0	0	0	0		
				48	0	1	0	0	0	0	0	0	0	0	
				52	1	1	0	0	0	0	0	0	0	0	
				8	1	1	0	0	0	0	0	0	0	0	
				12	1	1	0	0	0	0	0	0	0	0	
				16	0	1	0	0	0	0	0	0	0	0	
				20	0	1	0	0	0	0	0	0	0	0	
				24	1	1	0	0	0	0	0	0	0	0	
				8	1	1	0	0	0	0	0	0	0	0	
				12	1	1	0	0	0	0	0	0	0	0	

1096

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient No.	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
10	16	AJ	28	0	1	0	0	0	0	0	0	1	0	2		
			32	1	1	0	0	0	0	0	0	0	1	0	4	
			36	0	1	0	0	0	0	0	0	0	0	0	0	2
			40	0	1	0	0	0	0	0	0	0	0	0	0	2
			44	0	1	0	0	0	0	0	0	0	0	0	0	1
			48	0	1	0	0	0	0	0	0	0	0	0	0	1
			52	0	1	0	0	0	0	0	0	0	0	0	0	1
10	17	MM	8	1	0	0	0	0	1	0	0	0	1	0	3	
			12	1	0	0	0	1	0	0	0	0	0	0	0	2
			16	0	0	0	0	1	0	0	0	0	0	0	0	1
			20	1	0	0	0	1	0	0	0	0	0	0	0	2
			24	0	0	0	0	0	0	0	0	1	0	0	0	2
			28	0	0	0	0	0	0	0	0	0	0	0	0	1
			32	0	0	0	0	0	0	0	0	0	0	0	0	1
			36	0	1	0	0	0	0	0	0	0	0	0	0	1
			40	1	0	0	0	0	0	1	0	0	0	0	0	2
			44	0	0	0	0	0	0	1	0	0	0	0	0	1
			48	0	0	0	0	0	0	1	0	0	0	0	0	1
			52	0	0	0	0	0	0	0	0	0	0	0	0	0
			10	19	TN	8	1	1	0	0	0	0	0	0	0	0
12	1	1				0	0	0	0	0	0	0	0	0	0	3
16	1	2				0	0	0	0	0	0	0	0	0	0	3
20	1	1				1	0	0	0	0	0	0	0	0	0	3
24	0	0				0	0	0	0	0	0	0	0	0	0	0
28	0	1				0	0	0	0	0	0	0	0	0	0	1
32	0	0				0	0	0	0	0	0	0	0	0	0	0
36	0	0				0	0	0	0	0	0	0	0	0	0	0
40	0	0				0	0	0	0	0	0	0	0	0	0	0
44	0	0				0	0	0	0	0	0	0	0	0	0	0
48	0	0				0	0	0	0	0	0	0	0	0	0	0
52	0	0	0	0	0	0	0	0	0	0	0	0	0			
10	21	AK	8	1	0	0	0	1	1	0	0	0	0	0	3	
			12	1	1	0	0	0	0	0	0	0	0	0	2	
			16	0	0	0	0	0	0	0	0	0	0	0	1	
			20	1	1	0	0	0	0	0	0	0	0	0	0	3
10	24	AL	8	1	1	0	0	1	0	0	0	0	1	0	4	
			12	1	1	0	0	1	0	0	0	0	0	0	3	
			16	1	2	0	0	1	0	0	0	0	2	0	1	8
			20	0	0	0	0	1	0	0	0	0	0	0	0	1
			24	0	0	0	0	0	0	0	0	0	0	0	0	0
			28	0	0	0	0	0	0	0	0	0	0	0	0	0
			32	0	0	0	0	0	0	0	0	0	0	0	0	0
36	0	0	0	0	0	0	0	0	0	0	0	0	0			

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REMEXIME - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient No.	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score			
10	24	289	AL	40	0	0	0	0	0	0	0	0	0	0			
				44	0	1	0	0	0	0	0	0	0	0	1		
				48	0	0	0	0	0	0	0	0	0	0	0	0	
				52	0	0	0	0	0	0	0	0	0	0	0	0	
10	29	293	JJ	8	1	1	0	0	0	1	1	0	0	4			
				12	1	1	0	0	1	0	0	0	0	4			
				16	1	1	0	0	1	0	0	1	0	0	5		
				20	1	1	0	0	1	0	0	1	0	0	5		
				24	1	1	2	2	1	2	2	1	1	0	0	14	
10	30	294	VK	8	1	1	0	1	0	2	1	2	0	0	9		
				12	1	1	0	1	1	0	1	0	0	0	7		
				16	1	1	0	1	1	1	1	1	1	0	0	9	
				20	1	1	0	0	1	0	0	0	0	0	0	7	
				24	1	1	0	0	1	0	0	0	0	0	0	7	
				28	0	1	0	0	0	0	0	0	0	0	0	2	
				32	0	1	0	0	0	0	0	0	0	0	0	2	
				36	0	1	0	0	0	0	0	0	0	0	0	2	
				40	0	1	0	0	0	0	0	0	0	0	0	2	
				44	1	2	0	1	1	1	1	1	0	0	2	0	9
				48	1	1	0	0	1	1	1	0	0	0	1	0	5
				52	0	1	0	0	0	0	0	0	0	0	1	0	2
10	37	32	HK	8	1	1	0	0	0	0	0	1	1	4			
				12	1	1	0	0	1	0	1	0	1	6			
				16	1	1	0	0	1	1	1	1	1	7			
				20	1	2	0	0	1	1	0	0	2	2	9		
				24	1	1	0	0	1	0	1	0	2	2	0	8	
10	40	33	AP	8	0	0	0	0	0	0	0	0	0	0			
				12	0	0	0	0	0	0	0	0	0	0	0		
				16	0	0	0	0	0	0	0	0	0	0	0		
				20	1	1	1	0	2	2	2	1	1	0	0	11	
				24	1	1	0	0	1	1	1	1	1	1	1	0	11
10	42	295	YT	8	1	0	0	1	0	2	2	0	0	0	3		
				12	1	0	0	1	1	0	0	0	0	0	0	2	
				16	1	0	0	0	0	0	0	0	0	0	0	1	
				20	1	0	0	0	0	0	0	0	0	0	0	1	
				24	1	0	0	0	0	0	0	0	0	0	0	0	1
10	43	296	IK	8	0	0	0	0	0	0	0	0	0	0			
				12	0	0	0	0	0	0	0	0	0	0	0		
				16	0	0	0	0	0	0	0	0	0	0	0		
				20	0	0	0	0	0	0	0	0	0	0	0		
				24	1	0	0	0	0	0	0	0	0	0	0	2	
10	44	298	AB	8	0	0	0	0	0	0	0	0	0	0			
				12	0	0	0	0	0	0	0	0	0	0	0		
				16	0	0	0	0	0	0	0	0	0	0	0		
				20	0	0	0	0	0	0	0	0	0	0	0		
				24	0	0	0	0	0	0	0	0	0	0	0		
10	45	34	KJ	8	1	0	0	0	0	1	1	0	1	0	3		
				12	1	0	0	0	1	1	0	0	0	1	0	5	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient No.	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Inner Tension	Apparent Suicidal Thoughts	Inability to Feel Inertia	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
10	46	38	TN	8	1	1	0	0	1	1	1	0	0	6
10	47	39	TM	8	0	0	0	0	0	1	1	0	0	2
				12	0	0	0	0	0	1	1	0	0	3
				16	0	0	0	0	0	0	0	0	0	0
				20	0	1	0	0	0	0	0	0	0	1
				24	0	1	0	0	0	0	0	0	0	1
				28	0	1	0	0	0	0	0	0	0	1
				32	0	1	0	0	0	0	0	0	0	1
				36	0	1	0	0	0	0	0	0	0	1
				40	0	1	0	0	0	0	0	0	0	1
				44	0	1	0	0	0	0	0	0	0	1
				48	0	1	0	0	0	0	0	0	0	1
				52	0	1	0	0	0	0	0	0	0	1
10	48	41	IP	8	1	1	0	1	0	0	2	1	0	6
				12	1	1	0	0	0	0	1	1	0	4
				16	0	1	0	0	0	0	1	1	0	3
				20	1	1	0	0	0	0	2	1	0	5
10	50	44	EE	8	1	1	0	1	2	1	3	2	0	13
				12	1	1	1	1	2	1	3	2	0	14
				16	0	1	1	1	2	1	3	2	0	12
				20	0	1	1	1	2	0	3	2	0	11
				24	1	1	1	0	2	1	2	2	0	10
				28	1	1	1	0	2	1	2	2	0	10
				32	1	1	1	0	2	1	2	2	0	10
				36	1	1	1	0	2	1	2	2	0	10
				40	1	1	0	0	2	1	2	2	0	9
				44	1	1	0	0	2	1	2	2	0	9
				48	1	1	0	0	2	1	2	2	0	9
				52	1	1	0	0	2	1	2	2	0	8
10	51	45	UL	8	0	0	0	0	0	0	0	0	0	0
				12	0	0	0	0	0	0	0	0	0	0
				16	0	0	0	0	0	0	0	0	0	0
				20	0	0	0	0	0	0	0	0	0	0
				24	0	0	0	0	0	0	0	0	0	0
				28	0	0	0	0	0	0	0	0	0	0
				32	0	0	0	0	0	0	0	0	0	0
				36	0	0	0	0	0	0	0	0	0	0
				40	0	0	0	0	0	0	0	0	0	0
				44	1	0	1	0	0	0	0	0	0	2
				48	0	0	0	0	0	0	0	0	0	0
				52	0	0	0	0	0	0	0	0	0	0
10	55	49	TP	8	1	0	0	0	0	1	1	0	0	4

1099

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score			
10	55	49	TP	12	1	1	1	1	0	1	2	1	1	0	0	9		
				16	1	1	0	0	0	0	0	0	1	0	1	0	4	
				20	1	1	0	0	0	0	0	0	0	1	1	0	5	
				24	1	1	0	0	0	0	0	0	0	1	1	0	6	
				28	1	1	0	0	0	0	0	0	0	1	1	0	6	
				32	1	1	0	0	0	0	0	0	0	1	1	0	5	
				36	1	1	0	0	1	1	1	1	1	1	1	0	0	6
				40	1	1	0	0	1	1	1	1	1	1	1	0	0	6
				44	1	1	0	0	1	1	1	1	1	1	1	0	0	5
				48	1	1	0	0	1	1	1	1	1	1	1	0	0	5
10	58	52	KK	8	0	0	0	0	0	0	0	1	0	1	1	2		
				12	0	0	0	0	0	0	0	0	0	0	0	1	1	
				16	0	1	0	0	0	0	0	0	0	0	0	0	0	1
				20	0	1	0	0	0	0	0	0	0	0	0	2	1	3
				24	1	1	0	0	0	0	0	0	0	0	0	2	1	5
				28	1	1	0	0	0	0	0	0	0	0	0	2	1	4
				32	0	1	0	0	0	0	0	0	0	0	0	1	0	2
				36	1	1	0	0	0	0	0	0	0	0	0	2	0	4
				40	0	0	0	0	0	0	0	0	0	0	0	1	0	0
				44	0	0	0	0	0	0	0	0	0	0	0	1	0	2
10	60	54	JM	8	2	1	2	1	2	1	1	2	1	1	1	14		
				12	1	1	0	0	1	1	1	1	1	2	1	0	8	
				16	0	0	0	0	0	0	0	1	0	0	2	0	3	
				8	0	1	0	0	0	0	0	0	0	0	1	0	0	3
				12	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				16	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				8	0	0	0	0	0	0	0	0	0	0	1	0	0	0
				12	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				16	0	0	0	0	0	0	0	0	0	0	0	0	0	0
				10	64	58	LT	8	0	1	0	0	0	0	0	0	0	0
12	1	1	1					0	2	0	0	0	0	0	0	0	1	6
16	0	1	0					0	0	0	0	0	0	0	0	0	1	2
20	0	1	0					0	0	0	0	0	0	0	0	0	0	1
8	0	1	0					0	0	0	0	0	0	0	0	0	0	1
12	0	1	0					0	0	0	0	0	0	0	0	0	0	0
16	0	1	0					0	0	0	0	0	0	0	0	0	0	0
8	0	1	0					0	0	0	0	0	0	0	0	0	0	0
12	0	1	0					0	0	0	0	0	0	0	0	0	0	0
16	0	1	0					0	0	0	0	0	0	0	0	0	0	0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score											
10	55	49	TP	12	1	1	1	1	0	1	2	1	1	0	9											
				16	1	1	0	0	0	1	0	0	1	0	0	4										
				20	1	1	0	0	0	1	0	0	1	1	0	0	5									
				24	1	1	0	0	0	1	0	0	1	1	0	0	6									
				28	1	1	0	0	0	1	0	0	1	1	0	0	6									
				32	1	1	0	0	0	1	0	0	1	1	0	0	5									
				36	1	1	0	0	1	1	0	0	1	1	0	0	6									
				40	1	1	0	0	1	1	0	0	1	1	0	0	6									
				44	1	1	0	0	1	1	0	0	1	1	0	0	5									
				48	1	1	0	0	1	1	0	0	1	1	0	0	5									
				52	1	1	0	0	1	1	0	0	1	1	0	0	5									
				10	58	52	KK	8	0	0	0	0	0	0	0	1	0	1	2							
12	0	0	0					0	0	0	0	0	0	0	1	1										
16	0	1	0					0	0	0	0	0	0	0	0	0	1									
20	0	1	0					0	0	0	0	0	0	0	0	2	1	3								
24	1	1	0					0	0	0	0	0	0	0	0	2	1	5								
28	1	1	0					0	0	0	0	0	0	0	0	2	1	4								
32	0	1	0					0	0	0	0	0	0	0	0	1	0	2								
36	1	1	0					0	0	0	0	0	0	0	0	2	0	4								
40	0	0	0					0	0	0	0	0	0	0	0	0	0	0								
44	0	0	0					0	0	0	0	0	0	0	0	1	0	2								
48	0	0	0					0	0	0	0	1	0	0	0	0	0	1								
52	0	0	0					0	0	0	0	0	0	0	0	0	0	0								
10	60	54	JM	8	2	1	2	1	2	1	1	2	1	1	14											
				12	1	1	0	0	1	1	2	1	0	0	8											
				16	0	0	0	0	0	0	2	0	0	0	0	6										
				10	61	55	JT	8	0	0	0	0	1	1	2	1	0	0	3							
								12	0	0	0	0	0	0	2	0	0	0	0							
								16	0	0	0	0	1	0	2	0	0	0	0	0						
								10	62	56	RK	8	0	1	0	0	0	0	1	1	0	0	3			
												12	0	0	0	0	0	0	0	0	0	0	0	0		
												16	0	0	0	0	0	0	0	0	0	0	0	0	0	
												20	0	0	0	0	0	0	0	0	0	0	0	0	0	0
												24	0	0	0	0	0	0	0	0	0	0	0	0	0	0
												28	0	0	0	0	0	0	0	0	0	0	0	0	0	0
32	0	0	0									0	0	0	0	0	0	0	0	0	0	0				
10	64	58	LT									8	0	1	0	0	0	0	0	0	0	0	0	2		
												12	1	1	1	0	2	0	0	0	0	0	0	1	6	
				16	0	1	0					0	0	0	0	0	0	0	0	0	1					
				20	0	1	0					0	0	0	0	0	0	0	0	0	0	1				
				10	81	66	JN					8	0	1	0	0	0	0	0	0	0	0	0	1		
								12	0	0	0	0	0	0	0	0	0	0	0	0	0					
								16	0	1	0	0	0	0	0	0	0	0	0	0	0	1				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Face	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
11	4	375	BA	8	1	1	0	1	0	1	0	1	0	6
				12	1	1	0	2	1	1	0	2	0	9
				16	1	1	1	0	1	0	1	2	0	7
				20	2	2	0	2	1	1	1	2	1	14
11	7	376	KK	22	2	2	0	2	2	2	2	2	1	17
				8	1	1	0	1	0	1	0	0	1	6
				12	1	2	1	0	2	1	1	1	1	11
				16	2	1	2	0	1	1	1	1	1	11
11	9	362	FI	20	1	1	0	1	0	1	0	1	1	7
				24	1	1	0	1	0	1	0	1	0	5
				28	0	1	0	0	1	0	0	0	0	2
				32	0	1	0	0	1	0	0	0	0	1
11	12	364	PJ	36	1	1	0	2	1	0	1	0	0	7
				40	0	1	0	0	2	1	0	0	0	1
				44	0	1	0	0	0	0	0	0	0	1
				48	0	1	0	0	0	0	0	0	0	1
11	15	366	NF	52	0	1	0	0	0	0	0	0	0	1
				8	1	1	1	0	0	1	0	1	1	6
				12	2	2	2	2	2	2	2	2	2	20
				16	1	1	2	1	2	1	1	1	1	14
11	18	369	EI	20	1	1	0	2	2	1	1	1	1	12
				24	1	1	0	2	1	1	1	1	1	8
				28	0	1	0	0	0	0	0	0	0	2
				32	0	1	0	0	0	0	0	0	0	2

1102

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Centre	Patient	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inability to Feel Inertia	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score
11	18	369	EI	36	0	0	0	0	0	0	0	0	1
				40	0	0	0	0	0	0	0	0	1
				44	0	0	0	0	0	0	0	0	1
				48	1	1	0	0	0	0	0	0	3
				52	1	1	0	0	0	0	0	0	3
11	20	371	LJ	8	0	1	0	1	0	0	1	1	5
				12	1	1	0	1	1	0	1	0	6
				14	2	2	0	2	1	2	3	1	16
12	5	95	ZSH	8	1	1	1	1	1	2	2	0	12
				12	1	1	1	1	1	2	2	0	12
				16	1	1	1	1	1	2	2	0	12
12	6	98	MK	8	1	1	0	1	1	1	0	0	7
				12	0	1	0	0	0	1	0	1	3
				16	0	1	0	0	0	1	0	1	3
				20	1	1	1	1	1	1	0	2	10
				24	0	1	0	1	1	1	0	0	6
				28	0	1	0	1	1	1	0	0	6
12	10	96	IP	8	2	1	1	1	1	1	2	0	12
				12	2	1	1	1	1	1	2	0	12
				16	2	1	1	1	1	1	1	0	10
				20	1	1	0	0	1	2	1	1	9
				24	1	2	1	0	1	2	2	1	11
12	11	94	ER	8	1	2	1	0	1	1	2	2	11
				12	2	2	2	0	2	2	2	2	17
12	12	97	FSZ	8	2	2	2	1	2	1	0	0	14
12	13	103	ISZ	8	0	1	1	0	0	1	3	0	6
				12	1	1	2	0	1	1	3	1	11
12	14	101	GSZ	8	2	2	1	2	1	1	2	0	15
12	17	108	TK	8	0	0	0	0	1	0	0	0	2
				12	0	0	0	0	1	0	1	0	2
				16	0	0	0	0	1	0	0	0	2
				20	0	0	0	0	1	0	0	0	2
				24	0	0	0	0	1	0	0	0	1
				28	0	0	0	0	0	0	0	0	0
12	18	109	LS	8	1	1	1	0	1	1	0	0	6
				12	1	1	1	0	0	1	0	0	5
				16	0	1	1	0	1	1	1	0	6

1103

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.2

MONTGOMERY ASBERS DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient No.	Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score						
12	20	107	KSZ	8	0	0	0	0	0	0	0	0	0	2						
				12	0	0	0	0	0	0	0	0	0	0	0					
				16	1	1	1	0	0	0	0	0	0	0	0	5				
				20	1	1	1	0	0	0	0	0	0	0	0	4				
				24	1	2	1	0	0	0	0	0	0	0	2	9				
				28	1	2	1	1	0	0	0	0	0	0	2	1	8			
				12	22	111	MV	8	1	1	0	0	0	0	0	0	1	0	4	
								12	1	1	0	0	0	0	0	0	0	0	0	3
16	1	0	1					0	0	0	0	0	0	0	1	0	3			
20	1	1	1					1	0	1	0	0	0	0	0	0	6			
24	2	1	2					1	0	0	0	0	0	0	0	0	7			
28	0	1	0					0	0	0	0	0	0	0	0	1	2			
32	0	1	1					0	0	0	0	0	0	0	0	1	4			
36	0	0	0					0	0	0	0	0	0	0	0	0	0			
12	23	112	EN	8	1	1	0	0	0	0	0	0	0	0	4					
				12	0	0	0	0	0	0	0	0	0	0	0	3				
				16	0	0	0	0	0	0	0	0	0	0	0	1				
				20	0	0	0	0	0	0	0	0	0	0	0	0				
				24	0	0	0	0	0	0	0	0	0	0	0	0				
				28	0	1	0	0	0	0	0	0	0	0	1	0	3			
				12	28	116	IV	8	1	1	0	0	0	0	0	0	0	0	3	
								12	1	0	1	0	0	0	0	0	0	1	0	3
16	1	2	1					1	0	0	0	0	0	0	2	1	8			
12	34	120	TGB					8	0	0	0	0	0	0	0	0	0	0	1	
								12	1	0	0	0	0	0	0	0	0	0	1	3
								16	1	0	0	0	0	0	0	0	0	0	1	3
								20	0	0	0	0	0	0	0	0	0	0	0	0
								24	0	0	0	0	0	0	0	0	0	0	0	0
				28	0	0	0	0	0	0	0	0	0	0	0	0				
				32	0	0	0	0	0	0	0	0	0	0	0	0				
				36	0	0	0	0	0	0	0	0	0	0	0	0				
12	35	119	LP	8	0	1	1	0	0	0	0	0	0	0	0	4				
				12	0	1	0	0	0	0	0	0	0	0	0	2				
				16	1	1	2	1	1	0	0	0	0	0	0	1	8			

1104

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOMETINE - PROTOCOL 20124/013
Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient No.	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score	
12	37	386 EK	8	0	1	1	0	0	0	0	1	0	1	4	
			12	1	1	1	0	0	0	0	1	0	0	5	
			16	1	0	0	0	0	0	0	0	0	0	1	
13	2	224 TCS	8	1	2	0	0	0	0	0	1	0	1	5	
			12	0	1	1	0	1	0	0	1	0	0	5	
			16	0	1	1	0	0	0	0	0	0	0	3	
			20	1	1	1	0	0	0	0	0	1	0	0	5
			24	1	2	1	0	0	0	0	0	1	0	0	6
			28	1	2	1	0	0	0	0	0	1	0	0	6
			32	1	1	1	0	0	0	0	0	0	0	0	3
			36	0	1	0	0	1	0	0	0	0	0	0	3
			40	1	1	0	0	0	0	0	0	1	0	0	4
			44	1	1	1	0	0	0	0	0	1	0	0	4
13	8	228 PK	8	0	1	0	0	0	0	0	1	0	0	4	
			12	1	0	0	0	1	0	0	1	0	0	3	
			16	0	0	0	0	1	1	0	0	0	0	2	
			20	1	0	1	0	0	0	0	0	0	0	2	
			24	0	0	1	0	0	0	0	0	0	0	0	2
13	9	229 S2S	8	2	2	0	0	1	0	0	0	0	0	8	
			12	1	0	1	0	1	0	0	0	0	0	4	
			16	2	2	1	0	1	1	1	1	1	1	0	7
			20	2	2	3	1	2	1	2	2	2	1	1	13
13	11	225 HS	8	1	0	1	0	1	0	0	1	0	0	0	4
			12	1	1	2	0	1	1	1	1	0	0	0	7
			16	2	1	1	0	0	0	0	0	1	0	0	6
			20	1	1	1	0	0	0	0	0	1	0	0	4
			24	1	1	1	0	0	0	0	0	0	0	0	4
			28	1	1	0	0	0	0	0	0	1	0	0	4
			32	1	0	0	0	1	0	0	0	0	0	0	3
			36	1	1	1	0	0	0	0	0	0	0	0	3
			40	1	1	1	0	1	0	1	0	0	0	0	5
			44	1	1	1	0	1	0	1	0	0	0	0	5
13	14	217 DF	8	1	1	1	0	1	0	0	0	0	0	0	4
			12	1	1	2	0	0	0	0	0	0	0	0	4
			16	1	1	0	0	1	0	0	0	0	0	0	4
			20	2	2	2	0	1	1	1	1	1	1	0	10
24	1	2	2	0	1	1	1	0	0	1	1	0	10		

1105

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 10.2

MONTGOMERY ASBERG DEPRESSION RATING SCALE - DOUBLE BLIND PHASE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient No.	D.B. Patient Initials	Visit No.	Reported Sadness	Inner Tension	Apparent Sadness	Suicidal Thoughts	Inertia	Inability to Feel	Pessimistic Thoughts	Concentration Difficulties	Reduced Sleep	Reduced Appetite	Total Score		
13	14	DF	28	1	2	2	0	1	0	1	0	0	0	7		
			32	1	1	0	0	1	0	0	1	0	0	4		
			36	1	0	1	0	1	0	0	0	1	0	0	4	
			40	1	1	0	0	0	0	0	0	0	0	0	3	
			44	1	1	1	0	1	0	0	0	1	0	0	5	
			48	1	1	0	0	0	0	0	0	0	0	0	2	
13	15	KG	52	1	1	0	0	0	0	1	0	0	0	3		
			8	1	0	1	0	0	0	0	0	0	0	2		
			12	0	1	1	0	1	0	0	0	1	0	0	4	
			16	1	1	0	0	0	1	0	0	1	0	0	3	
			20	1	0	1	0	1	0	0	0	1	0	0	4	
			24	0	1	1	0	0	0	0	0	0	1	0	3	
13	17	GSM	28	1	1	1	0	0	0	0	0	0	0	3		
			32	0	1	0	0	0	0	0	1	1	0	0	3	
			36	0	0	1	0	0	0	0	0	1	0	0	2	
			40	1	1	0	0	0	0	0	0	0	0	0	3	
			44	0	1	1	0	1	0	0	0	0	0	0	2	
			48	0	1	0	0	0	0	0	0	0	1	0	2	
13	218	GSM	52	0	1	0	0	0	0	0	0	1	0	0	2	
			8	1	1	0	0	1	0	0	0	1	0	0	4	
			12	0	0	1	0	0	0	0	0	0	0	0	2	
			16	1	1	1	0	0	0	0	0	1	0	0	3	
			20	1	1	0	0	0	0	0	0	0	0	0	2	
			24	1	0	0	0	0	0	0	0	1	1	0	0	2
13	218	GSM	28	1	1	1	0	0	0	0	1	0	0	0	3	
			32	0	1	0	0	0	0	0	0	0	0	0	4	
			36	0	1	0	0	0	0	0	0	0	0	0	2	
			40	0	1	0	0	0	0	0	0	0	0	0	1	
			44	0	0	1	0	0	0	0	0	0	0	0	2	
			48	0	1	0	0	0	0	0	0	0	0	0	1	
13	218	GSM	52	0	0	0	0	0	0	0	0	0	0	0	1	
			8	1	1	0	0	0	0	0	0	0	0	0	1	
			12	0	1	1	0	0	0	0	0	0	0	0	0	1
			16	1	1	0	0	0	0	0	0	0	0	0	0	1
			20	1	1	0	0	0	0	0	0	0	0	0	0	1
			24	1	0	0	0	0	0	0	0	0	0	0	0	1

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	1	MGA	0	16NOV90	Markedly ill	No change	0.50
			1	23NOV90	Markedly ill	Minimally improved	1.00
			2	30NOV90	Moderately ill	Minimally improved	1.00
			3	07DEC90	Mildly ill	Much improved	1.50
			4	14DEC90	Mildly ill	Very much improved	2.00
			6	28DEC90	Borderline mentally ill	Very much improved	2.00
1	2	RAQ	0	16NOV90	Severely ill	No change	0.33
			1	23NOV90	Markedly ill	Minimally improved	1.00
			2	30NOV90	Moderately ill	Much improved	1.50
			3	07DEC90	Moderately ill	No change	1.00
			0	16NOV90	Markedly ill	Minimally improved	2.00
			1	23NOV90	Markedly ill	Moderately improved	2.00
1	3	TA	0	16NOV90	Markedly ill	No change	1.00
			1	23NOV90	Markedly ill	Minimally improved	2.00
			2	30NOV90	Moderately ill	Much improved	3.00
			3	07DEC90	Mildly ill	Much improved	3.00
			4	14DEC90	Mildly ill	Very much improved	4.00
			5	21DEC90	Borderline mentally ill	Very much improved	4.00
1	4	DNC	0	20NOV90	Severely ill	No change	1.00
			1	27NOV90	Severely ill	Minimally improved	1.00
			2	05DEC90	Moderately ill	Much improved	1.50
			3	12DEC90	Mildly ill	Much improved	1.50
			4	19DEC90	Mildly ill	Very much improved	2.00
			5	26DEC90	Borderline mentally ill	Very much improved	2.00
1	5	DB	0	04DEC90	Markedly ill	No change	1.00
			1	11DEC90	Markedly ill	Much improved	1.50
			2	18DEC90	Mildly ill	Very much improved	2.00
			3	26DEC90	Mildly ill	Very much improved	4.00
			4	02JAN91	Borderline mentally ill	Very much improved	4.00
			5	09JAN91	Normal	Very much improved	4.00
1	6	CPM	0	04DEC90	Severely ill	Minimally improved	1.00
			1	11DEC90	Markedly ill	Much improved	1.50
			2	18DEC90	Moderately ill	Much improved	1.50
			3	26DEC90	Mildly ill	Much improved	1.50
			4	02JAN91	Mildly ill	Much improved	1.50
			5	09JAN91	Mildly ill	Much improved	1.50
1	7	JSA	0	04DEC90	Severely ill	Very much improved	2.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	7	JSA	1	11DEC90	Severely ill	No change	0.50
			2	18DEC90	Moderately ill	Minimally improved	1.00
			3	26DEC90	Markedly ill	No change	0.25
1	8	MVB	0	07DEC90	Markedly ill	No change	1.00
			1	14DEC90	Markedly ill	Much improved	3.00
			2	21DEC90	Moderately ill	Much improved	3.00
			3	28DEC90	Mildly ill	Much improved	3.00
			4	04JAN91	Mildly ill	Much improved	4.00
			5	11JAN91	Borderline mentally ill	Very much improved	4.00
1	9	CCR	6	18JAN91	Borderline mentally ill	Very much improved	4.00
			0	26DEC90	Severely ill	No change	1.00
			1	02JAN91	Severely ill	Minimally improved	3.00
			2	09JAN91	Moderately ill	Much improved	1.50
			3	16JAN91	Mildly ill	Very much improved	2.00
			4	23JAN91	Normal	Very much improved	2.00
1	10	LDL	5	30JAN91	Normal	Very much improved	2.00
			6	06FEB91	Normal	Very much improved	2.00
			0	01FEB91	Severely ill	No change	1.00
			1	08FEB91	Severely ill	Minimally improved	2.00
			2	15FEB91	Markedly ill	Much improved	3.00
			3	22FEB91	Mildly ill	Much improved	4.00
1	11	VRT	4	01MAR91	Borderline mentally ill	Very much improved	4.00
			5	08MAR91	Normal	Very much improved	4.00
			6	15MAR91	Normal	Very much improved	4.00
			0	08MAR91	Severely ill	No change	0.50
			1	15MAR91	Severely ill	No change	0.50
			2	22MAR91	Severely ill	No change	1.00
1	12	SLT	3	29MAR91	Severely ill	No change	1.00
			4	05APR91	Moderately ill	Minimally improved	1.50
			5	12APR91	Mildly ill	Much improved	1.50
			6	19APR91	Borderline mentally ill	Very much improved	2.00
			0	19MAR91	Markedly ill	No change	0.50
			1	26MAR91	Markedly ill	No change	0.50
1	13	JR	2	02APR91	Markedly ill	Minimally improved	1.00
			3	09APR91	Moderately ill	Much improved	1.50
			4	16APR91	Mildly ill	Much improved	1.50
			5	23APR91	Borderline mentally ill	Very much improved	2.00
			6	30APR91	Borderline mentally ill	Very much improved	2.00
			0	30APR91	Markedly ill	No change	0.50
1	07MAY91	Markedly ill	No change	0.50			

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	13	JR	2	14MAY91	Markedly ill	No change	0.50
1	14	MLC	0	07MAY91	Markedly ill	No change	1.00
			1	14MAY91	Markedly ill	Minimally improved	0.50
			2	21MAY91	Moderately ill	No change	1.50
			3	28MAY91	Markedly ill	No change	0.50
			4	04JUN91	Markedly ill	Much improved	1.50
			5	11JUN91	Moderately ill	Very much improved	2.00
			6	18JUN91	Borderline mentally ill		
1	15	MAO	0	08MAY91	Markedly ill	No change	1.00
			1	15MAY91	Markedly ill	Minimally improved	2.00
			2	22MAY91	Moderately ill	Much improved	3.00
			3	29MAY91	Moderately ill	Much improved	3.00
			4	05JUN91	Mildly ill	Very much improved	4.00
			5	12JUN91	Mildly ill		
			6	19JUN91	Borderline mentally ill		
1	16	MHC	0	17MAY91	Severely ill	No change	0.50
			1	24MAY91	Markedly ill	Minimally improved	1.00
			2	31MAY91	Markedly ill	Much improved	1.50
			3	07JUN91	Moderately ill	Much improved	1.50
			4	14JUN91	Mildly ill	Much improved	1.50
			5	21JUN91	Mildly ill	Very much improved	2.00
			6	28JUN91	Borderline mentally ill		
1	17	CEC	0	21MAY91	Markedly ill	No change	1.00
			1	28MAY91	Markedly ill	Minimally improved	2.00
			2	04JUN91	Markedly ill	Minimally improved	2.00
			3	11JUN91	Moderately ill	Much improved	3.00
			4	18JUN91	Moderately ill	Much improved	3.00
			5	25JUN91	Mildly ill	Much improved	3.00
			6	02JUL91	Mildly ill		
1	18	TTH	0	22MAY91	Markedly ill	No change	0.50
			1	29MAY91	Markedly ill	Minimally improved	1.00
			2	05JUN91	Moderately ill	Minimally improved	1.00
			3	12JUN91	Moderately ill	Minimally improved	1.00
			4	19JUN91	Moderately ill	Much improved	1.50
			5	26JUN91	Mildly ill	Much improved	1.50
			6	03JUL91	Mildly ill		
1	19	SR	0	28MAY91	Markedly ill	No change	1.00
			1	04JUN91	Markedly ill	No change	1.00
			2	11JUN91	Markedly ill	No change	1.00
			3	18JUN91	Markedly ill	No change	1.00

1109

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	19	SR	4	25JUN91	Moderately ill	Much improved	3.00
			5	02JUL91	Mildly ill	Much improved	3.00
			6	09JUL91	Borderline mentally ill	Much improved	3.00
1	20	EFC	0	31MAY91	Markedly ill	No change	0.50
			1	07JUN91	Markedly ill	No change	0.50
			2	14JUN91	Markedly ill	Minimally improved	2.00
			3	21JUN91	Moderately ill	Much improved	1.50
			4	28JUN91	Moderately ill	Minimally improved	1.00
			5	05JUL91	Markedly ill	Much improved	1.50
1	21	VMC	0	12JUL91	Mildly ill	Much improved	1.50
			0	04JUN91	Markedly ill	No change	1.00
			1	11JUN91	Markedly ill	No change	1.00
			2	18JUN91	Markedly ill	Minimally improved	1.00
			3	25JUN91	Moderately ill	Minimally improved	1.00
			4	02JUL91	Moderately ill	Very much improved	4.00
1	22	SK	0	09JUL91	Borderline mentally ill	Very much improved	4.00
			1	16JUL91	Borderline mentally ill	Very much improved	4.00
			0	11JUN91	Moderately ill	No change	1.00
			1	18JUN91	Moderately ill	No change	1.00
			2	25JUN91	Moderately ill	Minimally improved	2.00
			3	02JUL91	Moderately ill	Very much improved	4.00
1	23	AR	0	09JUL91	Borderline mentally ill	Very much improved	4.00
			1	16JUL91	Borderline mentally ill	Very much improved	4.00
			0	21JUN91	Markedly ill	No change	1.00
			1	28JUN91	Markedly ill	No change	1.00
			2	05JUL91	Markedly ill	No change	0.50
			3	12JUL91	Markedly ill	No change	0.50
1	24	LNF	0	19JUL91	Markedly ill	No change	0.50
			1	02JUL91	Markedly ill	Minimally improved	2.00
			2	09JUL91	Moderately ill	Much improved	3.00
			3	16JUL91	Mildly ill	Much improved	3.00
			4	23JUL91	Mildly ill	Much improved	3.00
			5	30JUL91	Borderline mentally ill	Very much improved	4.00
1	25	AMR	0	06AUG91	Normal	Very much improved	4.00
			1	13AUG91	Normal	Very much improved	4.00
			0	05JUL91	Markedly ill	No change	1.00
			1	12JUL91	Markedly ill	Much improved	3.00
			2	19JUL91	Mildly ill	Much improved	3.00
			3	26JUL91	Borderline mentally ill	Much improved	3.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	25	AMR	4	02AUG91	Mildly ill	Much improved	3.00
			5	09AUG91	Borderline mentally ill	Very much improved	4.00
			6	16AUG91	Normal	Very much improved	4.00
			0	09JUL91	Markedly ill	Minimally improved	2.00
			1	16JUL91	Moderately ill	Minimally improved	2.00
			2	23JUL91	Moderately ill	Much improved	3.00
1	26	OC	3	30JUL91	Mildly ill	Much improved	4.00
			4	06AUG91	Borderline mentally ill	Very much improved	4.00
			5	13AUG91	Borderline mentally ill	Very much improved	4.00
			6	20AUG91	Borderline mentally ill	Very much improved	4.00
			0	12JUL91	Markedly ill	No change	1.00
			1	19JUL91	Markedly ill	Minimally improved	2.00
1	27	RK	2	26JUL91	Moderately ill	Much improved	3.00
			3	02AUG91	Mildly ill	Minimally improved	2.00
			4	09AUG91	Moderately ill	Very much improved	4.00
			5	16AUG91	Borderline mentally ill	Very much improved	4.00
			6	23AUG91	Normal	Very much improved	4.00
			0	16JUL91	Markedly ill	Minimally improved	2.00
1	28	RMH	1	23JUL91	Moderately ill	Minimally improved	2.00
			2	30JUL91	Moderately ill	No change	1.00
			3	06AUG91	Markedly ill	Much improved	3.00
			4	13AUG91	Moderately ill	Much improved	3.00
			5	20AUG91	Mildly ill	Very much improved	4.00
			6	27AUG91	Borderline mentally ill	Very much improved	4.00
1	29	AFO	0	16JUL91	Markedly ill	No change	1.00
			1	23JUL91	Markedly ill	No change	0.50
			2	30JUL91	Markedly ill	Minimally improved	1.00
			3	06AUG91	Moderately ill	Very much improved	2.00
			4	13AUG91	Borderline mentally ill	Much improved	1.50
			5	20AUG91	Mildly ill	Very much improved	2.00
1	30	ERV	0	17JUL91	Markedly ill	No change	1.00
			1	24JUL91	Markedly ill	Minimally improved	2.00
			2	31JUL91	Moderately ill	Minimally improved	2.00
			3	07AUG91	Moderately ill	Much improved	3.00
			4	14AUG91	Mildly ill	Much improved	3.00
			5	21AUG91	Mildly ill	Very much improved	4.00
1	31	MAN	0	23JUL91	Markedly ill	No change	1.00
			1	30JUL91	Markedly ill	No change	1.00

11111

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	31	MAH	2	06AUG91	Mildly ill	Much improved	3.00
			3	13AUG91	Moderately ill	Minimally improved	2.00
			4	20AUG91	Borderline mentally ill	Very much improved	4.00
			5	27AUG91	Normal	Very much improved	4.00
			6	03SEP91	Normal	Very much improved	4.00
			0	24JUL91	Markedly ill	No change	0.50
1	32	DGN	1	31JUL91	Markedly ill	Much improved	1.50
			2	07AUG91	Mildly ill	Much improved	1.50
			3	14AUG91	Mildly ill	Much improved	2.00
			4	21AUG91	Borderline mentally ill	Very much improved	2.00
			5	28AUG91	Borderline mentally ill	Very much improved	2.00
			6	04SEP91	Normal	Very much improved	2.00
1	33	OFC	0	24JUL91	Markedly ill	No change	1.00
			1	31JUL91	Markedly ill	Minimally improved	1.00
			2	07AUG91	Moderately ill	Minimally improved	1.00
			3	14AUG91	Moderately ill	Very much improved	2.00
			4	21AUG91	Mildly ill	Very much improved	2.00
			5	28AUG91	Borderline mentally ill	Very much improved	2.00
1	34	GMH	0	04SEP91	Normal	Very much improved	2.00
			1	11SEP91	Markedly ill	No change	0.50
			2	18SEP91	Markedly ill	Minimally improved	1.00
			3	25SEP91	Moderately ill	Minimally improved	1.00
			4	02OCT91	Moderately ill	Minimally improved	1.00
			5	09OCT91	Borderline mentally ill	Much improved	1.50
1	35	EMP	0	16SEP91	Normal	Very much improved	2.00
			1	23SEP91	Moderately ill	Minimally improved	2.00
			2	30SEP91	Moderately ill	Minimally improved	2.00
			3	07OCT91	Borderline mentally ill	Very much improved	4.00
			4	14OCT91	Normal	Very much improved	4.00
			5	21OCT91	Normal	Very much improved	4.00
1	36	LM	0	08OCT91	Markedly ill	No change	0.50
			1	15OCT91	Markedly ill	Minimally improved	1.00
			2	22OCT91	Moderately ill	Minimally improved	1.00
			3	29OCT91	Moderately ill	Much improved	1.50
			4	05NOV91	Mildly ill	Very much improved	2.00
			5	12NOV91	Borderline mentally ill	Very much improved	2.00
6	19NOV91	Borderline mentally ill	Very much improved	4.00			

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124-013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	37	RF	0	03SEP91	Markedly ill		
			1	10SEP91	Moderately ill	Minimally improved	2.00
			2	17SEP91	Moderately ill	Minimally improved	2.00
			3	24SEP91	Borderline mentally ill	Much improved	3.00
			4	01OCT91	Normal	Very much improved	4.00
			5	08OCT91	Borderline mentally ill	Very much improved	4.00
1	38	DBF	0	17SEP91	Markedly ill		
			1	24SEP91	Markedly ill	No change	1.00
			2	01OCT91	Moderately ill	Minimally improved	2.00
			3	08OCT91	Borderline mentally ill	Very much improved	4.00
			4	15OCT91	Mildly ill	Much improved	3.00
			5	22OCT91	Borderline mentally ill	Very much improved	4.00
1	39	ASS	0	24SEP91	Markedly ill		
			1	01OCT91	Markedly ill	No change	1.00
			2	08OCT91	Moderately ill	Minimally improved	2.00
			3	15OCT91	Mildly ill	Much improved	1.50
			4	22OCT91	Mildly ill	Much improved	1.50
			5	29OCT91	Borderline mentally ill	Much improved	3.00
1	40	EM	0	05NOV91	Borderline mentally ill	Very much improved	4.00
			1	24SEP91	Markedly ill		
			2	01OCT91	Markedly ill	No change	1.00
			3	08OCT91	Moderately ill	Minimally improved	1.00
			4	15OCT91	Mildly ill	Much improved	1.50
			5	22OCT91	Mildly ill	Much improved	1.50
1	41	SFS	0	05NOV91	Normal	Very much improved	2.00
			1	24SEP91	Markedly ill	Minimally improved	1.00
			2	01OCT91	Moderately ill	Much improved	1.50
			3	08OCT91	Mildly ill	Much improved	1.50
			4	15OCT91	Mildly ill	Much improved	2.00
			5	22OCT91	Borderline mentally ill	Very much improved	2.00
1	42	ICC	0	05NOV91	Normal	Very much improved	2.00
			1	24SEP91	Markedly ill	Minimally improved	1.00
			2	01OCT91	Moderately ill	Much improved	1.50
			3	08OCT91	Mildly ill	Much improved	1.50
			4	15OCT91	Borderline mentally ill	Very much improved	2.00
			5	22OCT91	Borderline mentally ill	Very much improved	2.00
1	42	ICC	0	02OCT91	Markedly ill		
			1	09OCT91	Markedly ill	No change	1.00
			2	16OCT91	Moderately ill	Minimally improved	2.00
			3	23OCT91	Moderately ill	Minimally improved	2.00
			4	30OCT91	Borderline mentally ill	Very much improved	4.00
5	06NOV91	Borderline mentally ill	Very much improved	4.00			

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	42	ICC	6	13NOV91	Normal	Very much improved	4.00
1	43	ARN	0	02OCT91	Markedly ill	Minimally improved	1.00
			1	09OCT91	Moderately ill	Minimally improved	1.00
			2	16OCT91	Moderately ill	Minimally improved	1.00
			3	23OCT91	Moderately ill	Much improved	1.50
			4	30OCT91	Borderline mentally ill	Very much improved	2.00
			5	06NOV91	Borderline mentally ill	Very much improved	2.00
			6	13NOV91	Normal	No change	1.00
1	44	MAL	0	08OCT91	Markedly ill	No change	1.00
			1	15OCT91	Markedly ill	Minimally improved	2.00
			2	22OCT91	Markedly ill	Minimally improved	2.00
			3	29OCT91	Moderately ill	Much improved	3.00
			4	05NOV91	Mildly ill	No change	1.00
			5	12NOV91	Markedly ill	No change	1.00
1	45	DPS	0	08OCT91	Markedly ill	Much improved	3.00
			1	15OCT91	Mildly ill	Minimally improved	2.00
			2	22OCT91	Moderately ill	Very much improved	4.00
			3	29OCT91	Borderline mentally ill	Very much improved	4.00
			4	05NOV91	Normal	Very much improved	4.00
			5	12NOV91	Normal	Very much improved	4.00
			6	19NOV91	Normal	No change	1.00
1	46	SP	0	15OCT91	Markedly ill	No change	1.00
			1	22OCT91	Markedly ill	No change	1.00
			2	29OCT91	Markedly ill	Minimally improved	2.00
			3	05NOV91	Moderately ill	Much improved	3.00
			4	12NOV91	Mildly ill	Much improved	3.00
			5	19NOV91	Borderline mentally ill	Much improved	3.00
			6	26NOV91	Mildly ill	Much improved	3.00
1	47	MCS	0	22OCT91	Markedly ill	Minimally improved	2.00
			1	29OCT91	Moderately ill	Much improved	1.50
			2	05NOV91	Mildly ill	Much improved	1.50
			3	12NOV91	Mildly ill	Very much improved	2.00
			4	19NOV91	Borderline mentally ill	Very much improved	2.00
			5	26NOV91	Borderline mentally ill	Very much improved	2.00
			6	03DEC91	Normal	Very much improved	2.00
1	48	SCM	0	23OCT91	Markedly ill	Minimally improved	2.00
			1	30OCT91	Moderately ill	Minimally improved	1.00
			2	06NOV91	Moderately ill	Minimally improved	1.00
			3	13NOV91	Moderately ill	Minimally improved	1.00

11114

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	48	SCK	4	20NOV91	Mildly ill	Much improved	1.50
			5	27NOV91	Borderline mentally ill	Very much improved	2.00
			6	04DEC91	Borderline mentally ill	Very much improved	4.00
			0	25OCT91	Markedly ill	No change	0.50
			1	01NOV91	Markedly ill	No change	0.25
			2	08NOV91	Markedly ill	No change	1.00
1	50	MFA	1	01NOV91	Markedly ill	No change	1.00
			2	08NOV91	Markedly ill	Minimally improved	2.00
			3	14NOV91	Moderately ill	Much improved	3.00
			4	22NOV91	Mildly ill	Much improved	3.00
			5	29NOV91	Mildly ill	Much improved	3.00
			6	06DEC91	Borderline mentally ill	Very much improved	4.00
1	51	ASA	0	25OCT91	Markedly ill	No change	1.00
			1	01NOV91	Markedly ill	Minimally improved	1.00
			2	08NOV91	Moderately ill	Much improved	1.50
			3	14NOV91	Mildly ill	Much improved	1.50
			4	22NOV91	Borderline mentally ill	Very much improved	2.00
			5	29NOV91	Borderline mentally ill	Very much improved	2.00
1	52	MTS	0	30OCT91	Markedly ill	No change	1.00
			1	06NOV91	Markedly ill	Minimally improved	2.00
			2	13NOV91	Moderately ill	Minimally improved	2.00
			3	20NOV91	Moderately ill	Much improved	3.00
			4	27NOV91	Mildly ill	Much improved	4.00
			5	04DEC91	Borderline mentally ill	Very much improved	4.00
1	53	JFT	0	30OCT91	Markedly ill	No change	1.00
			1	06NOV91	Markedly ill	Minimally improved	2.00
			2	13NOV91	Moderately ill	Minimally improved	2.00
			3	20NOV91	Moderately ill	Much improved	3.00
			4	27NOV91	Mildly ill	Much improved	4.00
			5	04DEC91	Borderline mentally ill	Very much improved	4.00
1	54	JD	0	05NOV91	Markedly ill	No change	1.00
			1	12NOV91	Markedly ill	No change	1.00
			2	19NOV91	Markedly ill	No change	1.00
			3	26NOV91	Markedly ill	No change	0.33
			4	03DEC91	Markedly ill	No change	0.25
			5	10DEC91	Normal	No change	0.25

11115

Small text at the bottom right edge of the page, likely a page number or reference code.

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	55	DMG	0	05NOV91	Markedly ill	No change	1.00
			1	12NOV91	Markedly ill	Minimally improved	2.00
			2	19NOV91	Moderately ill	Minimally improved	2.00
			3	26NOV91	Moderately ill	Much improved	3.00
			4	03DEC91	Mildly ill	Much improved	3.00
			5	10DEC91	Mildly ill	Very much improved	4.00
1	56	IAL	0	05NOV91	Borderline mentally ill	No change	0.50
			1	12NOV91	Markedly ill	Minimally improved	1.00
			2	19NOV91	Moderately ill	Much improved	1.50
			3	26NOV91	Mildly ill	Very much improved	1.50
			4	03DEC91	Borderline mentally ill	Very much improved	1.50
			5	10DEC91	Borderline mentally ill	Very much improved	1.50
1	57	SMC	0	10DEC91	Markedly ill	No change	0.33
			1	17DEC91	Markedly ill	No change	0.33
			2	24DEC91	Markedly ill	Minimally improved	0.67
			3	31DEC91	Moderately ill		
			0	10DEC91	Markedly ill	No change	0.50
			1	17DEC91	Markedly ill	No change	0.50
1	58	ARH	2	24DEC91	Markedly ill	Minimally improved	1.00
			3	31DEC91	Moderately ill	Minimally improved	1.00
			4	07JAN92	Moderately ill	Much improved	1.50
			5	14JAN92	Mildly ill	Much improved	3.00
			6	21JAN92	Mildly ill		
			0	17DEC91	Markedly ill	No change	0.50
1	59	SPF	1	24DEC91	Markedly ill	Minimally improved	1.00
			2	31DEC91	Moderately ill	Minimally improved	1.00
			3	07JAN92	Moderately ill	Much improved	3.00
			4	14JAN92	Mildly ill	Very much improved	4.00
			5	21JAN92	Borderline mentally ill	Very much improved	4.00
			6	28JAN92	Normal		
1	60	EH	0	20DEC91	Markedly ill	No change	1.00
			1	27DEC91	Markedly ill	No change	1.00
			2	03JAN92	Markedly ill	Much improved	3.00
			3	10JAN92	Markedly ill	Much improved	3.00
			4	17JAN92	Mildly ill	Much improved	3.00
			5	24JAN92	Mildly ill	Much improved	3.00
1	61	HVC	0	20DEC91	Markedly ill		

1116

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	61	HVC	1	27DEC91	Markedly ill	No change	0.50
			2	03JAN92	Markedly ill	No change	0.50
			3	10JAN92	Moderately ill	Minimally improved	1.00
			4	17JAN92	Mildly ill	Much improved	1.50
			5	24JAN92	Borderline mentally ill	Very much improved	2.00
			6	31JAN92	Mildly ill	Much improved	1.50
1	62	MEA	0	07JAN92	Markedly ill	No change	1.00
			1	14JAN92	Markedly ill	No change	1.00
			2	21JAN92	Markedly ill	Minimally improved	2.00
			3	28JAN92	Moderately ill	Much improved	1.50
			4	04FEB92	Mildly ill	Much improved	1.50
			5	11FEB92	Mildly ill	Very much improved	2.00
1	63	JCL	0	08JAN92	Markedly ill	No change	0.50
			1	15JAN92	Markedly ill	Minimally improved	1.00
			2	22JAN92	Moderately ill	Minimally improved	0.50
			3	29JAN92	Moderately ill	No change	0.50
			4	05FEB92	Markedly ill	Very much improved	2.00
			5	12FEB92	Borderline mentally ill	Very much improved	2.00
1	64	EHF	0	17JAN92	Markedly ill	No change	0.50
			1	24JAN92	Markedly ill	Very much improved	2.00
			2	31JAN92	Borderline mentally ill	Very much improved	2.00
			3	07FEB92	Borderline mentally ill	Very much improved	2.00
			4	14FEB92	Normal	Very much improved	2.00
			5	21FEB92	Normal	Very much improved	2.00
1	65	FS	0	21JAN92	Markedly ill	No change	0.50
			1	28JAN92	Markedly ill	No change	0.50
			2	04FEB92	Markedly ill	Minimally improved	1.00
			3	11FEB92	Moderately ill	Much improved	1.50
			4	18FEB92	Mildly ill	No change	0.50
			5	25FEB92	Markedly ill	No change	0.50
1	66	TCG	0	04MAR92	Markedly ill	No change	0.50
			1	11MAR92	Markedly ill	No change	0.50
			2	18MAR92	Moderately ill	Minimally improved	1.00
			3	25MAR92	Moderately ill	Minimally improved	1.00
			4	01APR92	Borderline mentally ill	Very much improved	2.00
			5	08APR92	Borderline mentally ill	Very much improved	2.00
1	67	MAA	0	21JAN92	Markedly ill	No change	1.00
			1	28JAN92	Markedly ill	No change	1.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	67	WAA	2	04FEB92	Moderately ill	Minimally improved	2.00
			3	11FEB92	Moderately ill	Minimally improved	2.00
			4	18FEB92	Moderately ill	Minimally improved	2.00
			5	25FEB92	Borderline mentally ill	Very much improved	4.00
			6	04MAR92	Borderline mentally ill	Very much improved	4.00
			0	21JAN92	Markedly ill	No change	0.50
1	68	MGS	1	28JAN92	Markedly ill	Minimally improved	1.00
			2	04FEB92	Moderately ill	No change	0.50
			3	11FEB92	Markedly ill	No change	0.50
			4	18FEB92	Markedly ill	No change	0.50
			5	25FEB92	Markedly ill	No change	0.50
			6	04MAR92	Markedly ill	No change	0.50
1	69	RFA	0	21JAN92	Markedly ill	No change	0.50
			1	28JAN92	Markedly ill	No change	0.50
			2	04FEB92	Markedly ill	Minimally improved	1.00
			3	11FEB92	Moderately ill	Minimally improved	1.00
			4	18FEB92	Moderately ill	Minimally improved	1.00
			5	25FEB92	Moderately ill	Minimally improved	1.00
1	70	MLM	0	04MAR92	Moderately ill	Minimally improved	1.00
			1	24JAN92	Markedly ill	No change	0.50
			2	31JAN92	Markedly ill	No change	0.50
			3	07FEB92	Markedly ill	No change	0.50
			4	14FEB92	Markedly ill	No change	0.50
			5	21FEB92	Markedly ill	No change	0.50
1	71	ONV	0	28FEB92	Mildly ill	Much improved	3.00
			1	04FEB92	Markedly ill	No change	0.50
			2	11FEB92	Moderately ill	Minimally improved	1.00
			3	18FEB92	Moderately ill	Minimally improved	1.00
			4	25FEB92	Mildly ill	Much improved	1.50
			5	04MAR92	Borderline mentally ill	Very much improved	4.00
1	72	RLJ	0	10MAR92	Normal	Very much improved	4.00
			1	28JAN92	Markedly ill	No change	1.00
			2	04FEB92	Markedly ill	No change	1.00
			3	11FEB92	Markedly ill	Minimally improved	2.00
			4	18FEB92	Moderately ill	Minimally improved	2.00
			5	25FEB92	Moderately ill	Much improved	3.00
1	73	RFA	0	04MAR92	Borderline mentally ill	Very much improved	4.00
			1	24JAN92	Markedly ill	No change	1.00
			2	31JAN92	Markedly ill	No change	1.00
			3	07FEB92	Markedly ill	Minimally improved	2.00
			4	14FEB92	Markedly ill	Minimally improved	2.00
			5	21FEB92	Markedly ill	Much improved	3.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	73	FMA	0	28JAN92	Markedly ill	No change	0.50
			1	04FEB92	Markedly ill	No change	0.50
			2	11FEB92	Markedly ill	Minimally improved	1.00
			3	18FEB92	Moderately ill	Much improved	1.50
			4	25FEB92	Mildly ill	Much improved	1.50
			5	04MAR92	Mildly ill	Very much improved	2.00
1	74	IVL	0	28JAN92	Borderline mentally ill	No change	1.00
			1	04FEB92	Markedly ill	No change	1.00
			2	11FEB92	Markedly ill	Minimally improved	2.00
			3	18FEB92	Moderately ill	Much improved	3.00
			4	25FEB92	Mildly ill	Very much improved	4.00
			5	04MAR92	Borderline mentally ill	Much improved	4.00
1	75	ELF	0	31JAN92	Markedly ill	No change	1.00
			1	07FEB92	Markedly ill	No change	1.00
			2	14FEB92	Markedly ill	Minimally improved	2.00
			3	21FEB92	Moderately ill	Minimally improved	2.00
			4	28FEB92	Moderately ill	Much improved	3.00
			5	06MAR92	Mildly ill	Much improved	3.00
1	76	SFA	0	13MAR92	Mildly ill	No change	1.00
			1	07FEB92	Markedly ill	Minimally improved	2.00
			2	14FEB92	Moderately ill	Minimally improved	2.00
			3	21FEB92	Moderately ill	Much improved	3.00
			4	28FEB92	Mildly ill	Very much improved	4.00
			5	06MAR92	Borderline mentally ill	Very much improved	4.00
1	77	ACC	0	20MAR92	Normal	No change	1.00
			1	07FEB92	Markedly ill	No change	1.00
			2	14FEB92	Markedly ill	Minimally improved	1.00
			3	21FEB92	Moderately ill	Much improved	1.50
			4	28FEB92	Mildly ill	Very much improved	2.00
			5	06MAR92	Borderline mentally ill	Very much improved	2.00
1	78	SD	0	07FEB92	Markedly ill	No change	0.50
			1	14FEB92	Markedly ill	No change	0.50
			2	21FEB92	Markedly ill	No change	0.33
			3	28FEB92	Markedly ill	No change	0.33
			4	06MAR92	Markedly ill	No change	0.33

11119

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	78	SD	6	20MAR92	Markedly ill	No change	0.33
1	79	JCM	0	07FEB92	Markedly ill	No change	0.50
			1	14FEB92	Markedly ill	Minimally improved	1.00
			2	21FEB92	Moderately ill	Minimally improved	1.00
			3	28FEB92	Moderately ill	Much improved	1.50
			4	06MAR92	Mildly ill	Very much improved	2.00
			5	13MAR92	Normal	Very much improved	2.00
			6	20MAR92	Normal		
1	80	MEL	0	07FEB92	Markedly ill	No change	1.00
			1	14FEB92	Markedly ill	Minimally improved	2.00
			2	21FEB92	Moderately ill	Minimally improved	2.00
			3	28FEB92	Moderately ill	Much improved	3.00
			4	06MAR92	Mildly ill	Much improved	3.00
			5	13MAR92	Mildly ill	Very much improved	4.00
			6	20MAR92	Borderline mentally ill	Very much improved	4.00
1	81	HFB	0	07FEB92	Markedly ill	No change	0.50
			1	14FEB92	Markedly ill	Minimally improved	1.00
			2	21FEB92	Moderately ill	Minimally improved	1.00
			3	28FEB92	Moderately ill	Much improved	1.50
			4	06MAR92	Mildly ill	Very much improved	2.00
			5	13MAR92	Borderline mentally ill	Very much improved	2.00
			6	20MAR92	Borderline mentally ill		
1	82	MDS	0	07FEB92	Markedly ill	No change	0.50
			1	14FEB92	Markedly ill	Minimally improved	1.00
			2	21FEB92	Moderately ill	Minimally improved	1.00
			3	28FEB92	Moderately ill	Much improved	1.50
			4	06MAR92	Mildly ill	Much improved	1.50
			5	13MAR92	Mildly ill	Very much improved	2.00
			6	20MAR92	Borderline mentally ill	Very much improved	2.00
1	83	LFK	0	07FEB92	Markedly ill	No change	1.00
			1	14FEB92	Markedly ill	Minimally worse	1.00
			2	21FEB92	Severely ill	Minimally worse	1.00
			3	28FEB92	Severely ill	Minimally worse	1.00
			4	06MAR92	Severely ill	Minimally worse	1.00
			5	13MAR92	Severely ill	Minimally worse	1.00
			6	20MAR92	Severely ill	Minimally worse	1.00
1	84	IN	0	07FEB92	Markedly ill	No change	0.50
			1	14FEB92	Markedly ill	Minimally improved	1.00
			2	21FEB92	Moderately ill	Much improved	1.50
			3	28FEB92	Mildly ill		

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	84	IN	4	06MAR92	Normal	Very much improved	2.00
			5	13MAR92	Normal	Very much improved	2.00
			6	20MAR92	Normal	Very much improved	2.00
			0	07FEB92	Markedly ill	No change	1.00
			1	14FEB92	Markedly ill	Minimally improved	2.00
			2	21FEB92	Moderately ill	Minimally improved	2.00
1	85	MLP	3	28FEB92	Moderately ill	Much improved	3.00
			4	06MAR92	Mildly ill	Much improved	3.00
			5	13MAR92	Mildly ill	Much improved	3.00
			6	20MAR92	Borderline mentally ill	Very much improved	4.00
			0	07FEB92	Markedly ill	No change	0.50
			1	14FEB92	Markedly ill	No change	0.50
1	86	MTF	2	21FEB92	Markedly ill	No change	0.50
			3	28FEB92	Markedly ill	No change	0.50
			4	06MAR92	Markedly ill	No change	0.50
			5	13MAR92	Markedly ill	No change	0.50
			6	20MAR92	Markedly ill	No change	0.50
			0	07FEB92	Markedly ill	No change	0.50
1	87	MDO	1	14FEB92	Markedly ill	No change	1.00
			2	21FEB92	Markedly ill	No change	0.50
			3	28FEB92	Moderately ill	Minimally improved	1.00
			4	06MAR92	Mildly ill	Much improved	1.50
			5	13MAR92	Borderline mentally ill	Very much improved	2.00
			6	20MAR92	Borderline mentally ill	Very much improved	2.00
1	88	VRL	0	11FEB92	Markedly ill	No change	1.00
			1	18FEB92	Markedly ill	Minimally improved	2.00
			2	25FEB92	Moderately ill	No change	1.00
			3	04MAR92	Markedly ill	No change	1.00
			4	10MAR92	Markedly ill	No change	1.00
			5	17MAR92	Markedly ill	No change	1.00
1	89	NMV	6	24MAR92	Markedly ill	No change	1.00
			0	11FEB92	Markedly ill	No change	0.50
			1	18FEB92	Markedly ill	No change	1.00
			2	25FEB92	Markedly ill	Minimally improved	2.00
			3	04MAR92	Moderately ill	Much improved	3.00
			4	10MAR92	Mildly ill	Much improved	3.00
1	90	JSS	5	17MAR92	Mildly ill	Much improved	3.00
			6	24MAR92	Mildly ill	Much improved	3.00
1	90	JSS	0	11FEB92	Markedly ill	No change	1.00
			1	18FEB92	Markedly ill	No change	1.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3
CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	90	JES	2	25FEB92	Markedly ill	No change	1.00
			3	04MAR92	Moderately ill	Minimally improved	1.00
			4	10MAR92	Moderately ill	Minimally improved	1.00
			5	17MAR92	Mildly ill	Much improved	1.50
			6	24MAR92	Borderline mentally ill	Very much improved	2.00
1	91	MSC	0	11FEB92	Markedly ill	No change	1.00
			1	18FEB92	Markedly ill	Minimally improved	2.00
			2	25FEB92	Moderately ill	Minimally improved	2.00
			3	04MAR92	Moderately ill	Much improved	3.00
			4	10MAR92	Mildly ill	Very much improved	4.00
			5	17MAR92	Borderline mentally ill	Very much improved	4.00
6	24MAR92	Borderline mentally ill	Very much improved	4.00			
1	92	PSS	0	11FEB92	Markedly ill	No change	0.50
			1	18FEB92	Markedly ill	Minimally improved	1.00
			2	25FEB92	Moderately ill	Minimally improved	1.00
			3	04MAR92	Moderately ill	No change	0.50
			4	10MAR92	Markedly ill	No change	0.50
			5	17MAR92	Markedly ill	Minimally improved	1.00
6	24MAR92	Moderately ill					
1	93	AL	0	12FEB92	Markedly ill	Minimally improved	1.00
			1	19FEB92	Moderately ill	Much improved	1.50
			2	26FEB92	Mildly ill	Very much improved	2.00
			3	04MAR92	Borderline mentally ill	Very much improved	2.00
			4	11MAR92	Borderline mentally ill	Very much improved	2.00
			5	18MAR92	Borderline mentally ill	Very much improved	2.00
6	25MAR92	Borderline mentally ill	Very much improved	2.00			
1	94	RAB	0	12FEB92	Markedly ill	No change	0.50
			1	19FEB92	Markedly ill	Minimally improved	1.00
			2	26FEB92	Moderately ill	Minimally improved	1.00
			3	04MAR92	Moderately ill	Much improved	1.50
			4	11MAR92	Mildly ill	Very much improved	2.00
			5	18MAR92	Borderline mentally ill	Very much improved	2.00
6	25MAR92	Borderline mentally ill	Very much improved	2.00			
1	95	GMT	0	12FEB92	Markedly ill	No change	0.50
			1	19FEB92	Markedly ill	Minimally improved	1.00
			2	26FEB92	Moderately ill	Minimally improved	1.00
			3	04MAR92	Moderately ill	Minimally improved	1.00
			4	11MAR92	Moderately ill	Much improved	1.50
			5	18MAR92	Mildly ill	Very much improved	2.00
6	25MAR92	Borderline mentally ill	Very much improved	2.00			

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	96	SPW	0	12FEB92	Markedly ill	No change	0.50
			1	19FEB92	Markedly ill	No change	0.50
			2	26FEB92	Markedly ill	Minimally improved	1.00
			3	04MAR92	Moderately ill	Minimally improved	1.00
			4	11MAR92	Moderately ill	Much improved	1.50
			5	18MAR92	Mildly ill	Very much improved	2.00
1	97	MND	0	12FEB92	Borderline mentally ill	No change	1.00
			1	19FEB92	Markedly ill	Minimally improved	2.00
			2	26FEB92	Moderately ill	Much improved	3.00
			3	04MAR92	Mildly ill	Very much improved	4.00
			4	11MAR92	Borderline mentally ill	Very much improved	4.00
			5	18MAR92	Normal	Very much improved	4.00
1	98	YTT	0	12FEB92	Markedly ill	No change	0.50
			1	19FEB92	Markedly ill	Minimally improved	1.00
			2	26FEB92	Moderately ill	Minimally improved	1.00
			3	04MAR92	Moderately ill	Much improved	1.50
			4	11MAR92	Markedly ill	Much improved	1.50
			5	18MAR92	Mildly ill	Very much improved	2.00
1	99	LCD	0	12FEB92	Borderline mentally ill	No change	0.50
			1	19FEB92	Markedly ill	Minimally worse	0.50
			2	26FEB92	Markedly ill	No change	0.50
			3	04MAR92	Markedly ill	No change	0.50
			4	11MAR92	Markedly ill	No change	0.50
			5	18MAR92	Markedly ill	Minimally improved	1.00
1	100	JWA	0	12FEB92	Markedly ill	No change	1.00
			1	19FEB92	Markedly ill	Minimally improved	2.00
			2	26FEB92	Moderately ill	Minimally improved	2.00
			3	04MAR92	Moderately ill	Much improved	3.00
			4	11MAR92	Mildly ill	Much improved	3.00
			5	18MAR92	Mildly ill	Very much improved	4.00
1	101	JLL	0	12FEB92	Normal	Very much improved	4.00
			1	19FEB92	Markedly ill	Minimally improved	2.00
			2	26FEB92	Moderately ill	Much improved	3.00
			3	04MAR92	Mildly ill	Very much improved	4.00
			4	11MAR92	Normal	Very much improved	4.00
			5	18MAR92	Normal	Very much improved	4.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	101	JLL	6	31MAR92	Normal	Very much improved	4.00
1	102	ESF	0	18FEB92	Markedly ill	No change	1.00
			1	25FEB92	Markedly ill	Minimally improved	2.00
			2	04MAR92	Markedly ill	Minimally improved	2.00
			3	10MAR92	Moderately ill	Minimally improved	2.00
			4	17MAR92	Moderately ill	Minimally improved	2.00
			5	24MAR92	Moderately ill	Minimally improved	2.00
			6	31MAR92	Moderately ill	Minimally improved	2.00
1	103	JRA	0	18FEB92	Markedly ill	No change	0.33
			1	25FEB92	Markedly ill	No change	0.25
			2	04MAR92	Markedly ill	No change	0.25
1	104	MIF	0	18FEB92	Markedly ill	No change	0.50
			1	25FEB92	Markedly ill	Minimally improved	1.00
			2	04MAR92	Moderately ill	Minimally improved	1.00
			3	10MAR92	Moderately ill	Much improved	1.50
			4	17MAR92	Mildly ill	Very much improved	2.00
			5	24MAR92	Borderline mentally ill	Very much improved	2.00
			6	31MAR92	Normal	Very much improved	2.00
1	105	ABS	0	18FEB92	Markedly ill	No change	0.50
			1	25FEB92	Markedly ill	No change	0.50
			2	04MAR92	Markedly ill	Minimally improved	1.00
			3	10MAR92	Moderately ill	Minimally improved	1.00
			4	17MAR92	Moderately ill	Very much improved	2.00
			5	24MAR92	Borderline mentally ill	Very much improved	2.00
			6	31MAR92	Normal	Very much improved	2.00
1	106	MEN	0	18FEB92	Markedly ill	No change	0.50
			1	25FEB92	Markedly ill	Minimally improved	1.00
			2	04MAR92	Moderately ill	Much improved	1.50
			3	10MAR92	Mildly ill	Much improved	1.50
			4	17MAR92	Mildly ill	Very much improved	2.00
			5	24MAR92	Borderline mentally ill	Very much improved	2.00
			6	31MAR92	Normal	Very much improved	2.00
1	107	LAN	0	19FEB92	Markedly ill	No change	0.50
			1	26FEB92	Markedly ill	No change	0.50
			2	04MAR92	Markedly ill	Minimally improved	1.00
			3	11MAR92	Moderately ill	Minimally improved	1.00
			4	18MAR92	Moderately ill	Minimally improved	1.00
			5	25MAR92	Moderately ill	Minimally improved	1.00
			6	01APR92	Borderline mentally ill	Very much improved	2.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	108	STB	0	19FEB92	Markedly ill	No change	0.50
			1	26FEB92	Markedly ill	No change	0.50
			2	04MAR92	Markedly ill	Minimally improved	1.00
			3	11MAR92	Moderately ill	Minimally improved	1.00
			4	18MAR92	Moderately ill	Much improved	1.50
			5	25MAR92	Mildly ill	Much improved	1.50
1	109	IPL	0	19FEB92	Markedly ill	No change	1.00
			1	26FEB92	Markedly ill	No change	0.50
			2	04MAR92	Markedly ill	Minimally improved	1.00
			3	11MAR92	Moderately ill	Much improved	1.50
			4	18MAR92	Mildly ill	Very much improved	2.00
			5	25MAR92	Borderline mentally ill	Very much improved	2.00
1	110	TQD	0	19FEB92	Markedly ill	No change	1.00
			1	26FEB92	Markedly ill	Minimally improved	2.00
			2	04MAR92	Moderately ill	Minimally improved	2.00
			3	11MAR92	Moderately ill	Much improved	3.00
			4	18MAR92	Mildly ill	Very much improved	4.00
			5	25MAR92	Normal	Very much improved	4.00
1	111	JBF	0	19FEB92	Markedly ill	No change	1.00
			1	26FEB92	Markedly ill	Minimally improved	1.00
			2	04MAR92	Moderately ill	Minimally improved	1.00
			3	11MAR92	Moderately ill	Minimally improved	1.00
			4	18MAR92	Moderately ill	Very much improved	2.00
			5	25MAR92	Borderline mentally ill	Very much improved	2.00
1	112	PSA	0	19FEB92	Markedly ill	No change	0.50
			1	26FEB92	Markedly ill	No change	0.50
			2	04MAR92	Markedly ill	No change	0.50
			3	11MAR92	Markedly ill	Minimally improved	1.00
			4	18MAR92	Moderately ill	Minimally improved	1.00
			5	25MAR92	Moderately ill	Minimally improved	1.00
1	113	LFS	0	19FEB92	Markedly ill	No change	0.50
			1	26FEB92	Markedly ill	No change	0.50
			2	04MAR92	Markedly ill	No change	0.50
			3	11MAR92	Markedly ill	Minimally improved	1.00
			4	18MAR92	Moderately ill	Minimally improved	1.00
			5	25MAR92	Moderately ill	Minimally improved	1.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	113	LPS	6	07APR92	Moderately ill	Minimally improved	1.00
1	114	CLF	0	25FEB92	Markedly ill	No change	0.50
			1	04MAR92	Markedly ill	Minimally improved	1.00
			2	10MAR92	Moderately ill	Much improved	1.50
			3	17MAR92	Mildly ill	Very much improved	2.00
			4	24MAR92	Borderline mentally ill	Very much improved	2.00
			5	31MAR92	Normal	Very much improved	2.00
			6	07APR92	Normal	Very much improved	2.00
1	115	ELS	0	25FEB92	Markedly ill	No change	1.00
			1	04MAR92	Markedly ill	Minimally improved	2.00
			2	10MAR92	Moderately ill	Much improved	3.00
			3	17MAR92	Mildly ill	Much improved	1.50
			4	24MAR92	Mildly ill	Very much improved	2.00
			5	31MAR92	Borderline mentally ill	Very much improved	4.00
			6	07APR92	Borderline mentally ill	Very much improved	4.00
1	116	MGA	0	25FEB92	Markedly ill	Minimally improved	2.00
			1	04MAR92	Moderately ill	Minimally improved	1.00
			2	10MAR92	Moderately ill	Minimally improved	1.00
			3	17MAR92	Moderately ill	Much improved	1.50
			4	24MAR92	Mildly ill	Much improved	1.50
			5	31MAR92	Mildly ill	Much improved	1.50
			6	07APR92	Borderline mentally ill	Very much improved	2.00
1	117	PSL	0	25FEB92	Markedly ill	No change	1.00
			1	04MAR92	Markedly ill	Minimally improved	2.00
			2	10MAR92	Moderately ill	Minimally improved	2.00
			3	17MAR92	Moderately ill	Much improved	3.00
			4	24MAR92	Mildly ill	Very much improved	4.00
			5	31MAR92	Borderline mentally ill	Very much improved	4.00
			6	07APR92	Borderline mentally ill	Very much improved	4.00
1	118	MVN	0	25FEB92	Markedly ill	No change	1.00
			1	04MAR92	Markedly ill	No change	1.00
			2	10MAR92	Markedly ill	No change	1.00
			3	17MAR92	Markedly ill	No change	1.00
			4	24MAR92	Markedly ill	No change	1.00
			5	31MAR92	Markedly ill	No change	1.00
1	119	MVN	0	25FEB92	Markedly ill	No change	0.50
			1	04MAR92	Markedly ill	No change	0.50
			2	10MAR92	Markedly ill	No change	0.50
			3	17MAR92	Markedly ill	Minimally improved	1.00
			4	24MAR92	Moderately ill	Minimally improved	1.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	119	MVM	5	31MAR92	Moderately ill	Minimally improved	1.00
			6	07APR92	Moderately ill	Minimally improved	1.00
1	120	JLB	0	26FEB92	Markedly ill	No change	0.50
			1	04MAR92	Markedly ill	No change	0.50
			2	11MAR92	Markedly ill	Minimally improved	1.00
			3	18MAR92	Moderately ill	Minimally improved	1.00
			4	25MAR92	Moderately ill	Minimally improved	1.00
			5	01APR92	Moderately ill	Minimally improved	1.00
1	121	LAC	6	08APR92	Moderately ill	Minimally improved	1.00
			0	26FEB92	Markedly ill	No change	1.00
			1	04MAR92	Markedly ill	Minimally improved	2.00
			2	11MAR92	Moderately ill	Minimally improved	2.00
			3	18MAR92	Moderately ill	Very much improved	4.00
			4	25MAR92	Borderline mentally ill	Very much improved	4.00
1	122	HSS	5	01APR92	Normal	Very much improved	4.00
			6	08APR92	Normal	Very much improved	4.00
			0	26FEB92	Markedly ill	No change	0.50
			1	04MAR92	Markedly ill	Minimally improved	1.00
			2	11MAR92	Moderately ill	Much improved	1.50
			3	18MAR92	Mildly ill	Very much improved	2.00
1	123	MLL	4	25MAR92	Borderline mentally ill	Very much improved	2.00
			5	01APR92	Normal	Very much improved	2.00
			6	08APR92	Normal	Very much improved	2.00
			0	26FEB92	Markedly ill	No change	1.00
			1	04MAR92	Markedly ill	Minimally improved	2.00
			2	11MAR92	Moderately ill	Minimally improved	2.00
1	124	PPC	3	18MAR92	Moderately ill	Much improved	3.00
			4	25MAR92	Mildly ill	Very much improved	4.00
			5	01APR92	Normal	Very much improved	4.00
			6	08APR92	Normal	Very much improved	4.00
			0	26FEB92	Markedly ill	No change	0.50
			1	04MAR92	Markedly ill	Minimally improved	1.00
1	125	FDP	2	11MAR92	Moderately ill	Much improved	1.50
			3	18MAR92	Mildly ill	Very much improved	2.00
			4	25MAR92	Borderline mentally ill	Very much improved	2.00
			5	01APR92	Borderline mentally ill	Very much improved	2.00
			6	08APR92	Borderline mentally ill	Very much improved	2.00
			0	26FEB92	Markedly ill	No change	0.50
1	04MAR92	Markedly ill	Minimally improved	1.00			
2	11MAR92	Moderately ill	Minimally improved	1.00			

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	125	FDP	3	18MAR92	Mildly ill	Much improved	1.50
			4	25MAR92	Borderline mentally ill	Very much improved	2.00
			5	01APR92	Borderline mentally ill	Very much improved	2.00
			6	08APR92	Borderline mentally ill	Very much improved	2.00
			0	26FEB92	Markedly ill	No change	1.00
			1	04MAR92	Markedly ill	Minimally improved	2.00
1	126	SMB	2	11MAR92	Moderately ill	Minimally improved	2.00
			3	18MAR92	Moderately ill	Much improved	3.00
			4	25MAR92	Mildly ill	Very much improved	2.00
			5	01APR92	Borderline mentally ill	Very much improved	2.00
			6	08APR92	Normal	Very much improved	4.00
			1	127	VPD	0	26FEB92
1	04MAR92	Markedly ill				Minimally improved	1.00
2	11MAR92	Moderately ill				Much improved	1.50
3	18MAR92	Mildly ill				Very much improved	2.00
4	25MAR92	Borderline mentally ill				Very much improved	2.00
5	01APR92	Normal				Very much improved	2.00
1	128	LAN	0	26FEB92	Markedly ill	No change	0.50
			1	04MAR92	Markedly ill	Minimally improved	1.00
			2	11MAR92	Moderately ill	Minimally improved	1.00
			3	18MAR92	Moderately ill	Minimally improved	1.00
			4	25MAR92	Moderately ill	Minimally improved	1.00
			5	01APR92	Moderately ill	Minimally improved	1.00
1	129	WNS	6	08APR92	Normal	Very much improved	2.00
			0	26FEB92	Markedly ill	No change	1.00
			1	04MAR92	Markedly ill	Minimally improved	2.00
			2	11MAR92	Moderately ill	Much improved	3.00
			3	18MAR92	Mildly ill	Very much improved	4.00
			4	25MAR92	Borderline mentally ill	Very much improved	4.00
1	130	EGA	5	01APR92	Normal	Very much improved	4.00
			6	08APR92	Normal	Very much improved	4.00
			0	26FEB92	Markedly ill	No change	1.00
			1	06MAR92	Markedly ill	Minimally improved	2.00
			2	13MAR92	Moderately ill	Minimally improved	2.00
			3	20MAR92	Moderately ill	Minimally improved	1.00
1	131	RMR	4	27MAR92	Moderately ill	Much improved	1.50
			5	03APR92	Mildly ill	Very much improved	2.00
			6	10APR92	Borderline mentally ill	Very much improved	2.00
			0	10MAR92	Markedly ill	No change	1.00
			1	17MAR92	Moderately ill	Minimally improved	2.00
			2	24MAR92	Moderately ill	Minimally improved	2.00

1123

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	131	RMR	1	17MAR92	Markedly ill	No change	0.50
			2	24MAR92	Markedly ill	No change	0.50
			3	31MAR92	Markedly ill	No change	0.50
			4	07APR92	Markedly ill	No change	0.50
			5	14APR92	Markedly ill	No change	0.50
			6	20APR92	Markedly ill	No change	0.50
1	132	MAT	0	18MAR92	Markedly ill	No change	0.50
			1	25MAR92	Markedly ill	Minimally improved	1.00
			2	01APR92	Moderately ill	Minimally improved	1.00
			3	08APR92	Moderately ill	Minimally improved	1.00
			4	15APR92	Moderately ill	Minimally improved	1.00
			5	22APR92	Moderately ill	Minimally improved	1.00
1	133	JPM	0	20MAR92	Markedly ill	No change	0.50
			1	27MAR92	Markedly ill	No change	0.50
			2	03APR92	Markedly ill	No change	0.50
			3	10APR92	Moderately ill	Minimally improved	1.00
			4	17APR92	Mildly ill	Much improved	1.50
			5	24APR92	Mildly ill	Much improved	1.50
1	134	LMS	0	30APR92	Borderline mentally ill	Very much improved	2.00
			1	24MAR92	Markedly ill	No change	1.00
			2	31MAR92	Markedly ill	Minimally improved	2.00
			3	07APR92	Moderately ill	Minimally improved	2.00
			4	14APR92	Moderately ill	Much improved	3.00
			5	20APR92	Mildly ill	Very much improved	4.00
1	135	MMS	0	28APR92	Normal	Very much improved	4.00
			1	05MAY92	Normal	Very much improved	4.00
			2	24MAR92	Markedly ill	Minimally improved	1.00
			3	31MAR92	Moderately ill	Minimally improved	1.00
			4	07APR92	Moderately ill	Much improved	1.50
			5	14APR92	Mildly ill	Very much improved	2.00
1	136	AVP	0	20APR92	Borderline mentally ill	Very much improved	2.00
			1	28APR92	Normal	Very much improved	2.00
			2	05MAY92	Normal	Very much improved	2.00
			3	24MAR92	Markedly ill	No change	0.50
			4	31MAR92	Markedly ill	Minimally improved	1.00
			5	07APR92	Moderately ill	Minimally improved	1.00
1	137	AVP	0	14APR92	Moderately ill	Much improved	1.50
			1	20APR92	Moderately ill	Much improved	1.50
			2	28APR92	Moderately ill	Much improved	1.50
			3	05MAY92	Moderately ill	Much improved	1.50
			4	23APR92	Moderately ill	Much improved	1.50
			5	30APR92	Moderately ill	Much improved	1.50

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/073
Listing No.: 10.3
CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	137	CME	0	24MAR92	Markedly ill	No change	0.50
			1	31MAR92	Markedly ill	No change	0.50
			2	07APR92	Markedly ill	Minimally improved	1.00
			3	14APR92	Moderately ill	Minimally improved	1.00
			4	20APR92	Moderately ill	No change	0.50
			5	28APR92	Markedly ill	Minimally improved	1.00
1	138	LBV	0	24MAR92	Markedly ill	No change	1.00
			1	31MAR92	Markedly ill	Much improved	3.00
			2	07APR92	Mildly ill	Very much improved	4.00
			3	14APR92	Mildly ill	Very much improved	4.00
			4	20APR92	Normal	Very much improved	4.00
			5	28APR92	Normal	Very much improved	4.00
1	139	RA	0	24MAR92	Markedly ill	No change	1.00
			1	31MAR92	Markedly ill	Minimally improved	1.00
			2	07APR92	Moderately ill	Much improved	1.50
			3	14APR92	Mildly ill	Very much improved	2.00
			4	20APR92	Borderline mentally ill	Very much improved	2.00
			5	28APR92	Normal	Very much improved	2.00
1	140	MCA	0	24MAR92	Markedly ill	No change	1.00
			1	31MAR92	Markedly ill	Minimally improved	2.00
			2	07APR92	Moderately ill	Minimally improved	2.00
			3	14APR92	Moderately ill	Very much improved	4.00
			4	20APR92	Borderline mentally ill	Very much improved	4.00
			5	28APR92	Borderline mentally ill	Very much improved	4.00
1	141	ANG	0	24MAR92	Markedly ill	No change	0.50
			1	31MAR92	Markedly ill	Minimally improved	1.00
			2	07APR92	Moderately ill	Minimally improved	1.00
			3	14APR92	Moderately ill	Minimally improved	1.00
			4	20APR92	Moderately ill	Much improved	1.50
			5	28APR92	Mildly ill	Very much improved	2.00
1	142	SCC	0	24MAR92	Markedly ill	No change	1.00
			1	31MAR92	Markedly ill	Minimally improved	2.00
			2	07APR92	Moderately ill	Much improved	3.00
			3	14APR92	Mildly ill	Very much improved	4.00
			4	20APR92	Borderline mentally ill	Very much improved	4.00
			5	28APR92	Normal	Very much improved	4.00

1130

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REROMETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	142	SCC	6	05MAY92	Normal	Very much improved	4.00
1	143	JEP	0	24MAR92	Markedly ill	Minimally improved	2.00
			1	31MAR92	Moderately ill	Minimally improved	1.00
			2	07APR92	Moderately ill	Much improved	1.50
			3	14APR92	Mildly ill	Very much improved	2.00
			4	20APR92	Borderline mentally ill	Very much improved	2.00
			5	28APR92	Normal	Very much improved	2.00
			6	05MAY92	Normal	Very much improved	2.00
1	144	ARF	0	25MAR92	Markedly ill	No change	1.00
			1	01APR92	Markedly ill	Minimally improved	2.00
			2	08APR92	Moderately ill	Minimally improved	2.00
			3	15APR92	Moderately ill	Much improved	3.00
			4	22APR92	Mildly ill	Much improved	3.00
			5	29APR92	Mildly ill	Much improved	3.00
			6	06MAY92	Borderline mentally ill	Very much improved	4.00
1	145	SLD	0	27MAR92	Markedly ill	No change	1.00
			1	03APR92	Markedly ill	Minimally improved	2.00
			2	10APR92	Moderately ill	Much improved	3.00
			3	17APR92	Mildly ill	Very much improved	4.00
			4	24APR92	Borderline mentally ill	Very much improved	4.00
			5	30APR92	Borderline mentally ill	Very much improved	4.00
			6	08MAY92	Borderline mentally ill	Very much improved	4.00
1	146	LRM	0	27MAR92	Markedly ill	Minimally improved	1.00
			1	03APR92	Moderately ill	Minimally improved	1.00
			2	10APR92	Moderately ill	Much improved	1.50
			3	17APR92	Mildly ill	Much improved	1.50
			4	24APR92	Mildly ill	Much improved	1.50
			5	30APR92	Mildly ill	Very much improved	2.00
			6	08MAY92	Borderline mentally ill	Very much improved	2.00
1	147	JGM	0	27MAR92	Markedly ill	Minimally worse	0.33
			1	03APR92	Markedly ill	Minimally worse	0.25
			2	10APR92	Markedly ill	Minimally worse	0.25
1	148	CAS	0	27MAR92	Markedly ill	No change	0.50
			1	03APR92	Markedly ill	Minimally improved	1.00
			2	10APR92	Moderately ill	Much improved	1.50
			3	17APR92	Mildly ill	Much improved	1.50
			4	24APR92	Mildly ill	Very much improved	2.00
			5	30APR92	Normal	Very much improved	2.00
			6	08MAY92	Normal	Very much improved	2.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	149	SC	0	27MAR92	Markedly ill	No change	0.50
			1	03APR92	Markedly ill	Minimally improved	1.00
			2	10APR92	Moderately ill	Minimally improved	1.00
			3	17APR92	Moderately ill	Much improved	1.50
			4	24APR92	Mildly ill	Very much improved	2.00
			6	08MAY92	Borderline mentally ill Normal	Very much improved	2.00
1	150	VA	0	27MAR92	Markedly ill	No change	0.50
			1	03APR92	Markedly ill	No change	0.50
			2	10APR92	Markedly ill	Minimally improved	1.00
			3	17APR92	Moderately ill	Minimally improved	1.00
			4	24APR92	Moderately ill	Much improved	1.50
			5	30APR92	Mildly ill	Very much improved	2.00
2	31	IK	0	09NOV90	Severely ill	No change	1.00
			1	16NOV90	Markedly ill	Minimally improved	1.00
			2	23NOV90	Moderately ill	Minimally improved	1.00
			3	30NOV90	Mildly ill	Minimally improved	1.00
			4	07DEC90	Moderately ill	No change	0.50
			0	10DEC90	Severely ill	No change	1.00
2	32	GE	1	17DEC90	Severely ill	No change	1.00
			2	24DEC90	Severely ill	No change	1.00
			3	27DEC90	Severely ill	Much worse	1.00
2	33	HS	0	14JAN91	Severely ill	No change	1.00
			1	21JAN91	Severely ill	Much worse	1.00
			2	28JAN91	Severely ill	Minimally worse	1.00
			3	31JAN91	Extremely ill	Minimally worse	1.00
			0	27MAR91	Moderately ill	No change	1.00
2	34	EH	1	03APR91	Markedly ill	No change	1.00
			2	10APR91	Markedly ill	Minimally improved	1.00
			3	17APR91	Moderately ill	Minimally improved	2.00
			4	24APR91	Moderately ill	Minimally improved	2.00
3	1	AMR	0	16NOV90	Markedly ill	Much improved	3.00
			1	23NOV90	Mildly ill	Very much improved	4.00
			2	29NOV90	Borderline mentally ill	Very much improved	4.00
			3	06DEC90	Borderline mentally ill	Very much improved	4.00
3	2	FIL	0	13DEC90	Normal	Very much improved	4.00
			1	16NOV90	Markedly ill	Much improved	3.00
			2	23NOV90	Mildly ill	Much improved	3.00
			4	30NOV90	Mildly ill	Much improved	3.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
3	2	FIL	2	30NOV90	Borderline mentally ill	Very much improved	4.00
			3	07DEC90	Borderline mentally ill	Very much improved	4.00
			4	14DEC90	Normal	Very much improved	4.00
			5	21DEC90	Normal	Very much improved	4.00
			6	28DEC90	Normal	Very much improved	4.00
			0	03APR91	Markedly ill	Minimally improved	2.00
3	3	DUB	1	10APR91	Moderately ill	Much improved	4.00
			2	17APR91	Moderately ill	Much improved	4.00
			3	23APR91	Mildly ill	Very much improved	4.00
			4	30APR91	Normal	Very much improved	4.00
			5	07MAY91	Normal	Very much improved	4.00
			6	14MAY91	Normal	Very much improved	4.00
3	4	AUD	0	07DEC90	Severely ill	Minimally improved	1.00
			1	14DEC90	Markedly ill	Much improved	3.00
			2	21DEC90	Mildly ill	Much improved	3.00
			3	28DEC90	Mildly ill	Minimally improved	0.67
			4	04JAN91	Moderately ill	Much improved	1.50
			5	11JAN91	Mildly ill	No change	1.00
3	5	MHA	0	23DEC90	Markedly ill	No change	1.00
			1	30DEC90	Markedly ill	Minimally improved	3.00
			2	06JAN91	Markedly ill	Much improved	1.33
			3	13JAN91	Mildly ill	Minimally improved	1.50
			4	20JAN91	Moderately ill	Much improved	1.00
			5	27JAN91	Borderline mentally ill	Minimally improved	0.50
3	6	AJP	0	18DEC90	Markedly ill	Minimally improved	1.00
			1	27DEC90	Markedly ill	Minimally improved	1.00
			0	11DEC90	Markedly ill	Much improved	3.00
			1	18DEC90	Mildly ill	Much improved	1.50
			2	25DEC90	Mildly ill	Minimally improved	3.00
			3	01JAN91	Mildly ill	Much improved	1.50
3	7	GRI	4	08JAN91	Mildly ill	Minimally improved	3.00
			5	15JAN91	Mildly ill	Much improved	1.50
			6	22JAN91	Moderately ill	Much improved	3.00
			7	29JAN91	Borderline mentally ill	Much improved	1.50
			8	05FEB91	Moderately ill	Much improved	1.50
			9	12FEB91	Borderline mentally ill	Much improved	1.50
3	9	DEN	0	18JAN91	Markedly ill	No change	0.33
			1	25JAN91	Markedly ill	Minimally improved	1.00
			2	01FEB91	Moderately ill	No change	0.25
3	10	TOR	0	05FEB91	Markedly ill	No change	0.25
			1	12FEB91	Markedly ill	No change	0.25
			2	19FEB91	Markedly ill	No change	0.25

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
3	2	FIL	2	30NOV90	Borderline mentally ill	Very much improved	4.00
			3	07DEC90	Borderline mentally ill	Very much improved	4.00
			4	14DEC90	Normal	Very much improved	4.00
			5	21DEC90	Normal	Very much improved	4.00
			6	28DEC90	Normal	Very much improved	4.00
			0	03APR91	Markedly ill	Minimally improved	2.00
3	3	DUB	1	10APR91	Moderately ill	Much improved	4.00
			2	17APR91	Moderately ill	Much improved	4.00
			3	23APR91	Mildly ill	Very much improved	4.00
			4	30APR91	Normal	Very much improved	4.00
			5	07MAY91	Normal	Very much improved	4.00
			6	14MAY91	Normal	Very much improved	4.00
3	4	AUD	0	07DEC90	Severely ill	Minimally improved	1.00
			1	14DEC90	Markedly ill	Much improved	3.00
			2	21DEC90	Mildly ill	Much improved	3.00
			3	28DEC90	Mildly ill	Minimally improved	0.67
			4	04JAN91	Moderately ill	Much improved	1.50
			5	11JAN91	Mildly ill	No change	1.00
3	5	MHA	0	23DEC90	Markedly ill	No change	1.00
			1	30DEC90	Markedly ill	Minimally improved	3.00
			2	06JAN91	Markedly ill	Much improved	1.33
			3	13JAN91	Mildly ill	Minimally improved	1.50
			4	22JAN91	Moderately ill	Much improved	1.00
			5	29JAN91	Borderline mentally ill	Minimally improved	0.50
3	6	AJP	0	18DEC90	Markedly ill	Minimally improved	1.00
			1	27DEC90	Markedly ill	Minimally improved	1.00
			0	11DEC90	Markedly ill	Much improved	3.00
			1	18DEC90	Mildly ill	Much improved	1.50
			2	25DEC90	Mildly ill	Minimally improved	3.00
			3	01JAN91	Mildly ill	Much improved	1.50
3	7	GRI	4	08JAN91	Mildly ill	Minimally improved	3.00
			5	15JAN91	Mildly ill	Much improved	1.50
			6	22JAN91	Moderately ill	Much improved	3.00
			7	29JAN91	Borderline mentally ill	Much improved	1.50
			8	05FEB91	Moderately ill	Much improved	1.50
			9	12FEB91	Borderline mentally ill	Much improved	1.50
3	9	DEN	0	18JAN91	Markedly ill	No change	0.33
			1	25JAN91	Markedly ill	Minimally improved	1.00
			2	01FEB91	Moderately ill	No change	0.25
3	10	TOR	0	05FEB91	Markedly ill	No change	0.25
			1	12FEB91	Markedly ill	No change	0.25
			2	19FEB91	Markedly ill	No change	0.25

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
8	5	SL	4	11FEB91	Mildly ill	Much improved	4.00
			5	18FEB91	Borderline mentally ill	Very much improved	4.00
			6	25FEB91	Borderline mentally ill	Very much improved	4.00
8	6	TL	0	21JAN91	Severely ill	Minimally improved	2.00
			1	28JAN91	Severely ill	Much improved	4.00
			2	04FEB91	Mildly ill	Very much improved	4.00
			3	11FEB91	Borderline mentally ill	Very much improved	4.00
			4	18FEB91	Borderline mentally ill	Very much improved	4.00
			5	25FEB91	Borderline mentally ill	Very much improved	4.00
8	7	SZT	6	04MAR91	Borderline mentally ill	Very much improved	4.00
			0	21MAR91	Markedly ill	No change	1.00
			1	28MAR91	Markedly ill	No change	1.00
			2	04APR91	Markedly ill	No change	1.00
			3	11APR91	Markedly ill	No change	1.00
			0	28MAY90	Severely ill	No change	1.00
9	1	US	1	04JUN90	Severely ill	No change	1.00
			2	11JUN90	Severely ill	No change	1.00
			3	18JUN90	Severely ill	No change	1.00
			4	25JUN90	Severely ill	No change	1.00
			5	02JUL90	Severely ill	No change	1.00
			6	09JUL90	Severely ill	No change	1.00
9	2	VCF	0	28MAY90	Markedly ill	No change	1.00
			1	04JUN90	Markedly ill	Much improved	4.00
			2	11JUN90	Mildly ill	Much improved	4.00
			3	18JUN90	Mildly ill	Very much improved	4.00
			4	25JUN90	Borderline mentally ill	Much improved	4.00
			5	02JUL90	Borderline mentally ill	Very much improved	4.00
9	3	SF	6	09JUL90	Borderline mentally ill	Very much improved	4.00
			0	16AUG90	Markedly ill	No change	1.00
			1	21AUG90	Markedly ill	Minimally improved	2.00
			2	28AUG90	Moderately ill	Minimally improved	2.00
			3	04SEP90	Moderately ill	No change	1.00
			4	11SEP90	Markedly ill	No change	1.00
9	4	SA	5	18SEP90	Markedly ill	No change	1.00
			6	25SEP90	Markedly ill	No change	1.00
9	4	SA	0	31AUG90	Severely ill	No change	1.00
			1	07SEP90	Severely ill	No change	1.00
			2	14SEP90	Severely ill	No change	1.00
			3	21SEP90	Severely ill	No change	1.00
			4	28SEP90	Severely ill	No change	1.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
9	4	SA	5	05OCT90	Severely ill	No change	1.00
			6	12OCT90	Severely ill	No change	1.00
9	5	HF	0	22SEP90	Moderately ill	No change	1.00
			1	26SEP90	Moderately ill	Minimally improved	2.00
			2	06OCT90	Mildly ill	Much improved	3.00
			3	13OCT90	Mildly ill	Much improved	4.00
			4	20OCT90	Mildly ill	Much improved	4.00
			5	27OCT90	Mildly ill	Much improved	4.00
9	6	SD	0	03NOV90	Borderline mentally ill	Much improved	4.00
			1	06NOV90	Markedly ill	No change	1.00
			2	13NOV90	Markedly ill	Minimally improved	2.00
			3	20NOV90	Moderately ill	Much improved	4.00
			4	27NOV90	Mildly ill	Much improved	4.00
			5	04DEC90	Mildly ill	Much improved	4.00
9	7	PP	0	18DEC90	Borderline mentally ill	Much improved	4.00
			1	08NOV90	Markedly ill	No change	1.00
			2	15NOV90	Markedly ill	Minimally improved	2.00
			3	22NOV90	Moderately ill	Much improved	3.00
			4	29NOV90	Mildly ill	Much improved	3.00
			5	06DEC90	Mildly ill	Very much improved	4.00
9	8	KTM	0	13DEC90	Borderline mentally ill	Very much improved	4.00
			1	20DEC90	Borderline mentally ill	No change	1.00
			2	27NOV90	Markedly ill	Minimally improved	2.00
			3	05DEC90	Moderately ill	Much improved	4.00
			4	12DEC90	Mildly ill	Much improved	4.00
			5	19DEC90	Mildly ill	Very much improved	4.00
9	9	PL	0	26DEC90	Borderline mentally ill	Much improved	4.00
			1	02JAN91	Mildly ill	No change	1.00
			2	22NOV90	Severely ill	Minimally improved	2.00
			3	30NOV90	Severely ill	No change	1.00
			4	07DEC90	Severely ill	No change	1.00
			5	14DEC90	Severely ill	No change	1.00
9	10	BG	0	21DEC90	Severely ill	No change	1.00
			1	28DEC90	Severely ill	No change	1.00
9	10	BG	0	04JAN91	Severely ill	No change	1.00
			1	10JAN91	Markedly ill	No change	0.50
9	10	BG	1	17JAN91	Markedly ill	No change	0.50
			2	24JAN91	Markedly ill	No change	0.50

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
9	10	BG	3	31JAN91	Severely ill	No change	1.00
			4	07FEB91	Severely ill	No change	1.00
			5	14FEB91	Markedly ill	No change	1.00
			6	21FEB91	Markedly ill	No change	1.00
			0	29JAN91	Moderately ill	Minimally improved	2.00
			1	05FEB91	Moderately ill	Much improved	4.00
9	11	KE	2	12FEB91	Mildly ill	Much improved	4.00
			3	19FEB91	Borderline mentally ill	Much improved	4.00
			4	26FEB91	Borderline mentally ill	Very much improved	4.00
			5	05MAR91	Borderline mentally ill	Very much improved	4.00
			6	12MAR91	Borderline mentally ill	Very much improved	4.00
			0	06MAR91	Markedly ill	No change	1.00
9	12	GYT	1	12MAR91	Markedly ill	Minimally improved	2.00
			2	19MAR91	Moderately ill	Much improved	4.00
			3	26MAR91	Mildly ill	Much improved	4.00
			4	02APR91	Moderately ill	Much improved	4.00
			5	09APR91	Mildly ill	Much improved	4.00
			6	16APR91	Mildly ill	Very much improved	4.00
9	13	BP	0	14MAR91	Markedly ill	No change	1.00
			1	20MAR91	Markedly ill	No change	1.00
			2	27MAR91	Markedly ill	No change	1.00
			3	03APR91	Markedly ill	Minimally improved	2.00
			4	10APR91	Moderately ill	Much improved	4.00
			5	17APR91	Mildly ill	Much improved	4.00
9	14	SZF	6	24APR91	Mildly ill	Much improved	4.00
			0	24MAR91	Severely ill	No change	1.00
			1	31MAR91	Severely ill	No change	1.00
			2	07APR91	Severely ill	Minimally worse	1.00
			3	14APR91	Severely ill	Minimally worse	1.00
			4	21APR91	Severely ill	Minimally worse	1.00
9	15	BI	5	28APR91	Severely ill	No change	1.00
			6	05MAY91	Severely ill	No change	1.00
			0	19MAY91	Severely ill	Minimally improved	2.00
			1	26MAY91	Markedly ill	Minimally improved	2.00
			2	02JUN91	Markedly ill	Much improved	3.00
			3	09JUN91	Moderately ill	Much improved	4.00
9	16	UGY	4	16JUN91	Mildly ill	Much improved	4.00
			5	23JUN91	Mildly ill	Much improved	4.00
			6	30JUN91	Borderline mentally ill	Very much improved	4.00
			0	09JUL91	Markedly ill		

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
9	16	UGY	1	16JUL91	Markedly ill	No change	1.00
			2	23JUL91	Moderately ill	Minimally improved	2.00
			3	30JUL91	Mildly ill	Much improved	3.00
			4	06AUG91	Mildly ill	Much improved	4.00
			5	13AUG91	Borderline mentally ill	Very much improved	4.00
			6	20AUG91	Borderline mentally ill	Very much improved	4.00
9	17	NL	0	04JUL91	Markedly ill	Minimally improved	2.00
			1	11JUL91	Moderately ill	Minimally improved	2.00
9	18	MBN	0	14JUL91	Markedly ill	No change	1.00
			1	21JUL91	Markedly ill	Minimally improved	2.00
9	19	KF	2	28JUL91	Moderately ill	Much improved	3.00
			3	04AUG91	Mildly ill	Much improved	4.00
			4	11AUG91	Mildly ill	Much improved	4.00
			5	18AUG91	Borderline mentally ill	Much improved	4.00
			6	25AUG91	Markedly ill	No change	1.00
			0	13AUG91	Markedly ill	Minimally improved	2.00
9	20	GVE	1	20AUG91	Moderately ill	Minimally improved	2.00
			2	27AUG91	Mildly ill	Much improved	4.00
			3	03SEP91	Borderline mentally ill	Very much improved	4.00
			4	10SEP91	Borderline mentally ill	Very much improved	4.00
			5	17SEP91	Borderline mentally ill	Very much improved	4.00
			6	24SEP91	Borderline mentally ill	Very much improved	4.00
9	21	TA	0	23AUG91	Severely ill	Minimally improved	2.00
			1	30AUG91	Moderately ill	Minimally improved	3.00
			2	06SEP91	Moderately ill	Much improved	4.00
			3	13SEP91	Mildly ill	Much improved	4.00
			4	20SEP91	Mildly ill	Very much improved	4.00
			5	27SEP91	Borderline mentally ill	Much improved	4.00
9	22	RKE	0	04OCT91	Mildly ill	Much improved	4.00
			0	25OCT91	Moderately ill	No change	1.00
			1	01NOV91	Moderately ill	No change	1.00
			2	08NOV91	Moderately ill	Minimally improved	2.00
			3	15NOV91	Mildly ill	Much improved	4.00
			4	22NOV91	Borderline mentally ill	Much improved	4.00
9	22	RKE	5	29NOV91	Borderline mentally ill	Much improved	4.00
			6	06DEC91	Borderline mentally ill	Much improved	4.00
9	22	RKE	0	29OCT91	Moderately ill	No change	1.00
			1	05NOV91	Moderately ill	Minimally improved	2.00
9	22	RKE	2	12NOV91	Mildly ill	Minimally improved	2.00
			2	12NOV91	Mildly ill	Minimally improved	2.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
9	22	RHE	3	19NOV91	Mildly ill	Minimally improved	2.00
			4	26NOV91	Mildly ill	Much improved	3.00
			5	03DEC91	Borderline mentally ill	Much improved	4.00
			6	10DEC91	Borderline mentally ill	Much improved	4.00
			0	08NOV91	Moderately ill	No change	1.00
			1	15NOV91	Moderately ill	Minimally improved	2.00
9	23	SZN	2	22NOV91	Mildly ill	Minimally improved	2.00
			3	29NOV91	Mildly ill	Minimally improved	2.00
			4	06DEC91	Mildly ill	Minimally improved	2.00
			5	13DEC91	Mildly ill	Minimally improved	3.00
			6	20DEC91	Borderline mentally ill	Much improved	4.00
			9	24	LEY	0	11NOV91
1	18NOV91	Moderately ill				No change	1.00
2	25NOV91	Moderately ill				Minimally improved	3.00
3	02DEC91	Mildly ill				Minimally improved	3.00
4	09DEC91	Mildly ill				Minimally improved	3.00
5	16DEC91	Mildly ill				Minimally improved	3.00
9	25	PM	6	23DEC91	Borderline mentally ill	Much improved	4.00
			0	19NOV91	Moderately ill	No change	1.00
			1	26NOV91	Moderately ill	Minimally improved	2.00
			2	03DEC91	Mildly ill	Much improved	3.00
			3	10DEC91	Borderline mentally ill	Much improved	4.00
			4	17DEC91	Borderline mentally ill	Much improved	4.00
9	26	CP	5	24DEC91	Borderline mentally ill	Much improved	3.00
			6	31DEC91	Borderline mentally ill	Much improved	4.00
			0	21NOV91	Moderately ill	No change	1.00
			1	28NOV91	Moderately ill	Minimally improved	2.00
			2	05DEC91	Mildly ill	Much improved	4.00
			3	12DEC91	Borderline mentally ill	Much improved	4.00
9	27	ZSL	4	19DEC91	Borderline mentally ill	Much improved	4.00
			5	26DEC91	Borderline mentally ill	Very much improved	4.00
			6	02JAN92	Borderline mentally ill	Very much improved	4.00
			0	27MAR92	Moderately ill	No change	1.00
			1	03APR92	Moderately ill	No change	1.00
			2	10APR92	Moderately ill	Minimally improved	2.00
9	28	HI	3	17APR92	Mildly ill	Much improved	4.00
			4	24APR92	Borderline mentally ill	Much improved	4.00
			5	01MAY92	Borderline mentally ill	Much improved	4.00
			6	08MAY92	Borderline mentally ill	Much improved	4.00
			0	06APR92	Moderately ill	No change	1.00
			0	06APR92	Moderately ill	No change	1.00

1139

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
9	28	HI	1	13APR92	Moderately ill	No change	1.00
			2	20APR92	Moderately ill	No change	1.00
			3	27APR92	Mildly ill	Minimally improved	3.00
			4	04MAY92	Borderline mentally ill	Much improved	4.00
			5	11MAY92	Borderline mentally ill	Much improved	4.00
			6	18MAY92	Borderline mentally ill	Much improved	4.00
9	29	SZF	0	06APR92	Moderately ill	No change	1.00
			1	13APR92	Moderately ill	No change	1.00
			2	20APR92	Moderately ill	Much improved	3.00
			3	27APR92	Mildly ill	Much improved	3.00
			4	04MAY92	Mildly ill	Much improved	4.00
			5	11MAY92	Borderline mentally ill	Much improved	4.00
9	30	NF	0	06APR92	Markedly ill	No change	1.00
			1	13APR92	Markedly ill	Minimally improved	2.00
			2	20APR92	Moderately ill	Much improved	4.00
			3	27APR92	Mildly ill	Much improved	4.00
			4	04MAY92	Mildly ill	Very much improved	4.00
			5	11MAY92	Borderline mentally ill	Very much improved	4.00
10	1	VK	0	16OCT90	Markedly ill	Minimally improved	1.00
			1	23OCT90	Markedly ill	Much improved	1.50
			2	30OCT90	Moderately ill	Minimally improved	1.00
			3	06NOV90	Markedly ill	Much improved	1.50
			4	13NOV90	Moderately ill	Much improved	3.00
			5	20NOV90	Mildly ill	Much improved	3.00
10	4	ZSD	0	31OCT90	Severely ill	Minimally improved	2.00
			1	07NOV90	Severely ill	Minimally improved	2.00
			2	14NOV90	Markedly ill	Minimally improved	2.00
			3	21NOV90	Markedly ill	Minimally improved	2.00
			4	28NOV90	Markedly ill	Much improved	3.00
			5	05DEC90	Moderately ill	Much improved	3.00
10	5	AN	0	12DEC90	Mildly ill	Much improved	3.00
			1	14NOV90	Severely ill	Minimally improved	2.00
			2	21NOV90	Severely ill	Much improved	3.00
			3	28NOV90	Markedly ill	Much improved	1.00
			4	05DEC90	Moderately ill	Much improved	1.50
			5	12DEC90	Moderately ill	Very much improved	2.00
10	6	AN	0	19DEC90	Mildly ill	Very much improved	4.00
			1	26DEC90	Mildly ill	Very much improved	4.00

1140

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
10	6	RS	0	16NOV90	Markedly ill		
			1	23NOV90	Markedly ill	Minimally improved	1.50
			2	30NOV90	Markedly ill	Minimally improved	1.50
			3	07DEC90	Moderately ill	Much improved	1.50
			4	14DEC90	Moderately ill	Much improved	1.50
10	7	RK	5	19DEC90	Markedly ill	Minimally improved	0.50
			0	20NOV90	Moderately ill		
			1	27NOV90	Moderately ill	Minimally improved	1.00
			2	04DEC90	Moderately ill	Minimally improved	1.00
			3	11DEC90	Moderately ill	Much improved	1.50
10	8	VP	4	18DEC90	Moderately ill	Much improved	1.50
			5	27DEC90	Mildly ill	Very much improved	2.00
			6	02JAN91	Borderline mentally ill	Very much improved	2.00
			0	26NOV90	Markedly ill		
			1	03DEC90	Markedly ill	Minimally improved	1.00
10	9	RT	2	10DEC90	Markedly ill	Minimally worse	1.00
			3	17DEC90	Severely ill	Minimally worse	1.00
			0	03DEC90	Markedly ill		
10	10	MH	1	10DEC90	Markedly ill	Minimally improved	2.00
			2	17DEC90	Markedly ill	Minimally improved	2.00
			3	27DEC90	Markedly ill	Minimally improved	1.00
			4	02JAN91	Moderately ill	Much improved	3.00
			5	07JAN91	Mildly ill	Very much improved	4.00
			6	14JAN91	Mildly ill	Very much improved	4.00
10	11	TH	0	03DEC90	Markedly ill		
			1	10DEC90	Markedly ill	Much improved	1.50
			2	17DEC90	Mildly ill	Very much improved	2.00
			3	27DEC90	Mildly ill	Very much improved	4.00
			4	02JAN91	Mildly ill	Very much improved	4.00
			5	07JAN91	Mildly ill	Very much improved	4.00
10	12	EP	6	14JAN91	Mildly ill	Very much improved	4.00
			0	27DEC90	Moderately ill		
			1	02JAN91	Severely ill	Much worse	0.50
10	13	EP	2	09JAN91	Severely ill	Much worse	0.50
			3	14JAN91	Severely ill	Much worse	1.00
			0	09JAN91	Markedly ill		
10	14	EP	1	16JAN91	Markedly ill	Minimally worse	1.00
			2	23JAN91	Markedly ill	Minimally worse	1.00
			3	30JAN91	Markedly ill	Minimally worse	1.00
			4	06FEB91	Moderately ill	Minimally improved	2.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
10	12	EP	5	13FEB91	Moderately ill	Much improved	3.00
			6	20FEB91	Moderately ill	Much improved	3.00
10	13	HU	0	11FEB91	Markedly ill	Minimally improved	1.00
			1	18FEB91	Moderately ill	Minimally improved	1.00
			2	25FEB91	Markedly ill	Much improved	1.50
			3	04MAR91	Moderately ill	Much improved	1.50
			4	11MAR91	Moderately ill	Much improved	1.50
			5	18MAR91	Moderately ill	Much improved	1.50
10	14	AA	6	25MAR91	Moderately ill	Very much improved	2.00
			0	11FEB91	Markedly ill	Minimally worse	0.50
			1	18FEB91	Markedly ill	Minimally improved	1.00
			2	25FEB91	Moderately ill	Minimally improved	1.50
			3	04MAR91	Mildly ill	Minimally improved	1.50
			4	12MAR91	Mildly ill	Much improved	1.50
10	15	HT	5	18MAR91	Mildly ill	Much improved	1.50
			6	25MAR91	Mildly ill	Much improved	1.50
			0	20FEB91	Severely ill	Minimally improved	2.00
			1	27FEB91	Severely ill	Minimally improved	1.50
			2	06MAR91	Markedly ill	Much improved	1.50
			3	13MAR91	Moderately ill	Much improved	1.50
10	16	AJ	4	20MAR91	Moderately ill	Minimally improved	1.00
			5	27MAR91	Markedly ill	Minimally improved	1.00
			6	03APR91	Mildly ill	Very much improved	2.00
			0	04MAR91	Markedly ill	Minimally improved	1.00
			1	11MAR91	Moderately ill	Minimally improved	1.00
			2	18MAR91	Moderately ill	Much improved	1.50
10	17	MM	3	25MAR91	Moderately ill	Very much improved	2.00
			4	01APR91	Mildly ill	Very much improved	2.00
			5	08APR91	Mildly ill	Very much improved	2.00
			6	16APR91	Mildly ill	Very much improved	2.00
			0	13MAR91	Markedly ill	Much improved	3.00
			1	20MAR91	Markedly ill	Minimally improved	2.00
10	18	SS	2	27MAR91	Moderately ill	Much improved	3.00
			3	03APR91	Moderately ill	Much improved	3.00
			4	10APR91	Moderately ill	Much improved	3.00
			5	17APR91	Moderately ill	Much improved	3.00
			6	24APR91	Mildly ill	Very much improved	4.00
			0	18MAR91	Markedly ill	Minimally improved	1.00
10	18	SS	1	25MAR91	Moderately ill	Much improved	1.50
			2	03APR91	Moderately ill	Much improved	1.50

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index			
10	18	SS	3	08APR91	Moderately ill	Much improved	3.00			
			4	15APR91	Moderately ill	Minimally improved	2.00			
			5	22APR91	Severely ill	Minimally worse	1.00			
			6	30APR91	Moderately ill	Much improved	3.00			
			10	19	TN	0	04APR91	Markedly ill	Minimally improved	1.50
						1	08APR91	Moderately ill	Much improved	1.50
2	15APR91	Mildly ill				Much improved	1.50			
3	22APR91	Mildly ill				Very much improved	4.00			
4	29APR91	Mildly ill				Very much improved	4.00			
5	06MAY91	Mildly ill				Very much improved	4.00			
10	20	EJ	0	22APR91	Moderately ill	Minimally improved	1.00			
			1	29APR91	Moderately ill	Much improved	1.00			
			2	06MAY91	Moderately ill	Very much improved	2.00			
			3	13MAY91	Mildly ill	Very much improved	2.00			
			4	20MAY91	Mildly ill	Very much improved	4.00			
			5	27MAY91	Mildly ill	Very much improved	4.00			
10	21	AK	0	03JUN91	Mildly ill	Very much improved	4.00			
			1	06MAY91	Markedly ill	Minimally improved	2.00			
			2	13MAY91	Markedly ill	Minimally improved	2.00			
			3	20MAY91	Moderately ill	Much improved	3.00			
			4	27MAY91	Moderately ill	Much improved	3.00			
			5	03JUN91	Moderately ill	Much improved	1.50			
10	22	AA	0	10JUN91	Moderately ill	Much improved	1.50			
			1	22APR91	Severely ill	Much improved	1.50			
			2	29APR91	Moderately ill	Much improved	3.00			
			3	06MAY91	Moderately ill	Very much improved	4.00			
			4	13MAY91	Mildly ill	Very much improved	4.00			
			5	20MAY91	Mildly ill	Very much improved	4.00			
10	23	LT	0	05JUN91	Mildly ill	Very much improved	4.00			
			1	23APR91	Markedly ill	Minimally worse	1.00			
			2	30APR91	Markedly ill	Minimally worse	1.00			
			3	07MAY91	Markedly ill	Minimally improved	2.00			
			4	14MAY91	Moderately ill	Minimally improved	2.00			
			5	21MAY91	Moderately ill	Much improved	3.00			
10	24	AL	0	04JUN91	Moderately ill	Very much improved	4.00			
			1	30APR91	Markedly ill	Very much improved	4.00			

1143

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 40.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
10	24	AL	1	07MAY91	Moderately ill	Much improved	1.50
			2	14MAY91	Moderately ill	Much improved	3.00
			3	21MAY91	Moderately ill	Much improved	1.50
			4	28MAY91	Mildly ill	Very much improved	4.00
			5	04JUN91	Moderately ill	Much improved	1.50
			6	11JUN91	Moderately ill	Much improved	3.00
10	25	ES	0	13MAY91	Severely ill	Minimally improved	2.00
			1	20MAY91	Markedly ill	Minimally worse	0.50
			2	27MAY91	Severely ill	Minimally worse	0.50
10	26	JIF	0	27MAY91	Markedly ill	Minimally improved	1.00
			1	03JUN91	Markedly ill	Minimally worse	0.50
			2	10JUN91	Markedly ill	Minimally improved	1.00
			3	17JUN91	Markedly ill	Minimally worse	1.00
			4	24JUN91	Severely ill	Much improved	3.00
			5	01JUL91	Moderately ill	Much improved	3.00
10	27	MK	0	08JUL91	Moderately ill	Much improved	3.00
			1	03JUN91	Markedly ill	Minimally worse	0.50
			2	10JUN91	Markedly ill	Much improved	3.00
			3	17JUN91	Moderately ill	Very much improved	4.00
			4	25JUN91	Mildly ill	Very much improved	4.00
			5	01JUL91	Mildly ill	Very much improved	4.00
10	28	LL	0	08JUL91	Mildly ill	Very much improved	4.00
			1	15JUL91	Mildly ill	Very much improved	4.00
			2	29MAY91	Severely ill	Much improved	3.00
			3	05JUN91	Markedly ill	Very much improved	4.00
			4	13JUN91	Mildly ill	Very much improved	4.00
			5	19JUN91	Mildly ill	Much improved	1.50
10	29	JJ	0	26JUN91	Moderately ill	Very much improved	2.00
			1	03JUL91	Mildly ill	Very much improved	4.00
			2	10JUL91	Mildly ill	Very much improved	4.00
			3	17JUL91	Mildly ill	Very much improved	4.00
			4	24JUL91	Mildly ill	Very much improved	4.00
			5	31JUL91	Mildly ill	Very much improved	4.00
10	30	VK	0	19AUG91	Markedly ill	Minimally improved	2.00
			1	26AUG91	Moderately ill	Much improved	3.00
			2	02SEP91	Moderately ill	Much improved	3.00
			3	09SEP91	Mildly ill	Much improved	3.00
			4	16SEP91	Mildly ill	Much improved	3.00
			5	23SEP91	Moderately ill	Much improved	3.00
10	30	VK	0	30SEP91	Mildly ill	Much improved	3.00
			1	16SEP91	Markedly ill	Minimally improved	2.00

1144

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
10	30	VK	2	30SEP91	Moderately ill	Minimally improved	2.00
			3	07OCT91	Moderately ill	Much improved	3.00
			4	14OCT91	Moderately ill	Minimally improved	2.00
			5	21OCT91	Markedly ill	Minimally improved	2.00
			6	28OCT91	Moderately ill	Much improved	3.00
			10	31	RK	0	16SEP91
1	23SEP91	Moderately ill				Much improved	3.00
2	30SEP91	Moderately ill				Much improved	3.00
3	07OCT91	Moderately ill				Much improved	3.00
4	14OCT91	Moderately ill				Much improved	3.00
5	21OCT91	Moderately ill				Much improved	3.00
10	32	LK	0	28OCT91	Mildly ill	Very much improved	2.00
			1	16SEP91	Severely ill		
			2	23SEP91	Markedly ill	Minimally improved	2.00
			3	30SEP91	Moderately ill	Much improved	3.00
			4	07OCT91	Moderately ill	Much improved	3.00
			5	14OCT91	Markedly ill	Minimally improved	2.00
10	33	EK	0	21OCT91	Moderately ill	Much improved	3.00
			1	28OCT91	Moderately ill	Much improved	3.00
			2	18SEP91	Moderately ill		
			3	25SEP91	Mildly ill	Very much improved	4.00
			4	02OCT91	Mildly ill	Very much improved	4.00
			5	09OCT91	Mildly ill	Very much improved	4.00
10	34	TK	0	16OCT91	Mildly ill	Very much improved	4.00
			1	23OCT91	Mildly ill	Very much improved	4.00
			2	30OCT91	Mildly ill	Very much improved	4.00
			3	06SEP91	Severely ill		
			4	13SEP91	Markedly ill	Much improved	3.00
			5	20SEP91	Moderately ill	Much improved	3.00
10	35	IM	0	27OCT91	Mildly ill	Very much improved	4.00
			1	03NOV91	Mildly ill	Very much improved	4.00
			2	10SEP91	Severely ill	Minimally improved	2.00
			3	17SEP91	Markedly ill	Much improved	3.00
			4	24SEP91	Moderately ill	Much improved	3.00
			5	01OCT91	Mildly ill	Very much improved	4.00
10	36	IM	0	21OCT91	Mildly ill	Very much improved	4.00
			1	28OCT91	Mildly ill	Very much improved	4.00
			2	04NOV91	Mildly ill	Very much improved	4.00
			3	11NOV91	Mildly ill	Very much improved	4.00
			4	18NOV91	Mildly ill	Very much improved	4.00
			5	25NOV91	Mildly ill	Very much improved	4.00

1145

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
10	36	AK	0	14OCT91	Markedly ill		
			1	21OCT91	Moderately ill	Much improved	3.00
			2	28OCT91	Mildly ill	Very much improved	4.00
			3	04NOV91	Mildly ill	Very much improved	4.00
			4	12NOV91	Mildly ill	Very much improved	4.00
			5	18NOV91	Mildly ill	Very much improved	4.00
10	37	HK	0	28NOV91	Borderline mentally ill		
			1	14OCT91	Severely ill	Much improved	1.50
			2	21OCT91	Moderately ill	Very much improved	2.00
			3	28OCT91	Moderately ill	Very much improved	4.00
			4	04NOV91	Moderately ill	Very much improved	4.00
			5	11NOV91	Moderately ill	Very much improved	4.00
10	38	LL	0	18NOV91	Moderately ill		
			1	14OCT91	Markedly ill	Minimally improved	0.67
			2	21OCT91	Moderately ill	Very much improved	4.00
			3	28OCT91	Mildly ill	Very much improved	4.00
			4	04NOV91	Mildly ill	Very much improved	4.00
			5	11NOV91	Mildly ill	Very much improved	2.00
10	39	VM	0	25NOV91	Mildly ill		
			1	14OCT91	Markedly ill	Very much improved	4.00
			2	21OCT91	Moderately ill	Much improved	1.50
			3	28OCT91	Moderately ill	Much improved	1.50
			4	04NOV91	Moderately ill	Much improved	3.00
			5	11NOV91	Moderately ill	Much improved	3.00
10	40	AP	0	18NOV91	Moderately ill		
			1	28OCT91	Moderately ill	Minimally improved	1.00
			2	04NOV91	Moderately ill	Much improved	1.50
			3	11NOV91	Moderately ill	Very much improved	2.00
			4	18NOV91	Moderately ill	Very much improved	2.00
			5	27NOV91	Moderately ill	Very much improved	2.00
10	41	VP	0	04DEC91	Mildly ill		
			1	29OCT91	Mildly ill	Minimally improved	1.00
			2	05NOV91	Mildly ill	Minimally improved	1.00
			3	12NOV91	Mildly ill	Minimally improved	1.00
			4	19NOV91	Mildly ill	Minimally improved	1.00
5	26NOV91	Mildly ill	Much improved	1.50			

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3
CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
10	41	VP	6	10DEC91	Mildly ill	Much improved	1.50
10	42	TT	0	13NOV91	Severely ill	No change	1.00
			1	20NOV91	Severely ill	Minimally improved	2.00
			2	27NOV91	Markedly ill	Minimally improved	2.00
			3	04DEC91	Markedly ill	Minimally improved	2.00
			4	11DEC91	Markedly ill	Much improved	3.00
			5	18DEC91	Moderately ill	Much improved	3.00
			6	25DEC91	Moderately ill	Much improved	3.00
10	43	IK	0	14NOV91	Markedly ill	Much improved	1.50
			1	21NOV91	Moderately ill	Minimally improved	1.00
			2	28NOV91	Markedly ill	Much improved	1.50
			3	05DEC91	Mildly ill	Much improved	1.50
			4	12DEC91	Mildly ill	Very much improved	4.00
			5	19DEC91	Borderline mentally ill	Very much improved	4.00
			6	26DEC91	Normal	Very much improved	4.00
10	44	AB	0	17NOV91	Moderately ill	Minimally improved	1.00
			1	24NOV91	Moderately ill	Much improved	1.50
			2	01DEC91	Mildly ill	Much improved	1.50
			3	08DEC91	Mildly ill	Much improved	1.50
			4	15DEC91	Mildly ill	Much improved	1.50
			5	22DEC91	Mildly ill	Much improved	1.50
			6	29DEC91	Borderline mentally ill	Very much improved	2.00
10	45	KJ	0	19NOV91	Markedly ill	Minimally improved	2.00
			1	26NOV91	Moderately ill	Much improved	3.00
			2	03DEC91	Moderately ill	Minimally improved	2.00
			3	10DEC91	Markedly ill	Much improved	3.00
			4	17DEC91	Moderately ill	Much improved	3.00
			5	24DEC91	Moderately ill	Much improved	3.00
			6	31DEC91	Mildly ill	Much improved	3.00
10	46	TN	0	02DEC91	Markedly ill	Much improved	1.50
			1	09DEC91	Moderately ill	Much improved	1.50
			2	16DEC91	Moderately ill	Much improved	1.50
			3	23DEC91	Moderately ill	Much improved	1.50
			4	30DEC91	Moderately ill	Much improved	1.50
			5	06JAN92	Mildly ill	Much improved	1.50
			6	13JAN92	Borderline mentally ill	Much improved	1.50
10	47	TM	0	04DEC91	Moderately ill	Minimally improved	1.00
			1	11DEC91	Moderately ill	Minimally improved	1.00
			2	18DEC91	Moderately ill	Much improved	1.50
			3	25DEC91	Mildly ill	Much improved	1.50

1147

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
10	47	TM	4	01JAN92	Mildly ill	Much improved	1.50
			5	08JAN92	Mildly ill	Much improved	1.50
			6	15JAN92	Mildly ill	Much improved	1.50
10	48	IP	0	04DEC91	Severely ill	No change	0.50
			1	11DEC91	Severely ill	Minimally improved	1.00
			2	18DEC91	Severely ill	Minimally improved	1.00
			3	25DEC91	Markedly ill	Much improved	1.50
			4	01JAN92	Moderately ill	Much improved	1.50
			5	08JAN92	Moderately ill	Much improved	1.50
10	49	VH	0	10DEC91	Severely ill	Much improved	3.00
			1	17DEC91	Markedly ill	Minimally improved	1.00
			2	24DEC91	Markedly ill	Minimally improved	1.50
			3	31DEC91	Moderately ill	Much improved	1.50
			4	07JAN92	Moderately ill	Much improved	1.50
			5	14JAN92	Mildly ill	Much improved	1.50
10	50	EE	0	21JAN92	Moderately ill	Much improved	1.50
			1	18DEC91	Severely ill	Minimally improved	2.00
			2	25DEC91	Severely ill	Minimally improved	1.00
			3	01JAN92	Severely ill	Minimally improved	1.00
			4	08JAN92	Markedly ill	Minimally improved	1.00
			5	15JAN92	Markedly ill	Minimally improved	1.50
10	51	UL	0	22JAN92	Markedly ill	Minimally improved	1.50
			1	29JAN92	Moderately ill	Minimally improved	1.50
			2	18DEC91	Markedly ill	Minimally improved	2.00
			3	25DEC91	Markedly ill	Minimally improved	1.00
			4	01JAN92	Markedly ill	Minimally improved	1.00
			5	08JAN92	Markedly ill	Much improved	1.50
10	52	MP	0	15JAN92	Mildly ill	Much improved	1.50
			1	22JAN92	Mildly ill	Much improved	1.50
			2	29JAN92	Borderline mentally ill	Much improved	1.50
			3	13JAN92	Mildly ill	Much improved	3.00
			4	20JAN92	Borderline mentally ill	Much improved	3.00
			5	27JAN92	Borderline mentally ill	Much improved	3.00
10	53	MA	0	03FEB92	Borderline mentally ill	Much improved	3.00
			1	10FEB92	Borderline mentally ill	Much improved	3.00
			2	17FEB92	Borderline mentally ill	Much improved	1.50
			3	24FEB92	Borderline mentally ill	Much improved	1.50

1148

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTDCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
10	53	MA	4	09FEB92	Borderline mentally ill	Much improved	1.50
			5	16FEB92	Borderline mentally ill	Much improved	1.50
			6	23FEB92	Borderline mentally ill	Much improved	1.50
10	54	UN	0	12JAN92	Severely ill	Minimally improved	1.00
			1	19JAN92	Markedly ill	Minimally improved	1.00
			2	26JAN92	Markedly ill	Much improved	1.50
			3	02FEB92	Moderately ill	Much improved	1.50
			4	09FEB92	Moderately ill	Much improved	1.50
			5	16FEB92	Moderately ill	Much improved	1.50
6	23FEB92	Mildly ill	Much improved	1.50			
10	55	TP	0	13JAN92	Moderately ill	Minimally improved	1.00
			1	20JAN92	Moderately ill	Minimally improved	1.00
			2	27JAN92	Moderately ill	Much improved	1.50
			3	03FEB92	Mildly ill	Much improved	1.50
			4	10FEB92	Mildly ill	Much improved	1.50
			5	17FEB92	Mildly ill	Much improved	1.50
6	24FEB92	Mildly ill	Much improved	3.00			
10	56	JP	0	13JAN92	Markedly ill	Much improved	1.50
			1	20JAN92	Moderately ill	Very much improved	2.00
			2	27JAN92	Mildly ill	Very much improved	2.00
			3	03FEB92	Mildly ill	Very much improved	4.00
			4	10FEB92	Mildly ill	Much improved	3.00
			5	17FEB92	Moderately ill	Much improved	4.00
6	24FEB92	Mildly ill	Very much improved	4.00			
10	57	AG	0	14JAN92	Severely ill	Very much improved	2.00
			1	21JAN92	Moderately ill	Very much improved	4.00
			2	28JAN92	Moderately ill	Very much improved	4.00
			3	04FEB92	Mildly ill	Much improved	3.00
			4	11FEB92	Moderately ill	Much improved	3.00
			5	18FEB92	Moderately ill	Much improved	3.00
6	25FEB92	Moderately ill	Very much improved	4.00			
10	58	KK	0	13JAN92	Severely ill	Minimally improved	1.00
			1	20JAN92	Markedly ill	Minimally improved	1.00
			2	27JAN92	Markedly ill	Much improved	1.50
			3	03FEB92	Moderately ill	Much improved	1.50
			4	10FEB92	Moderately ill	Very much improved	2.00
			5	17FEB92	Mildly ill	Very much improved	2.00
6	24FEB92	Mildly ill	Very much improved	4.00			
10	59	TA	0	20JAN92	Markedly ill	Minimally improved	1.00
			1	26JAN92	Markedly ill	Minimally improved	1.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 RIBOZEMINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
10	59	TA	2	02FEB92	Moderately ill	Much improved	1.50
			3	09FEB92	Mildly ill	Much improved	3.00
			4	16FEB92	Mildly ill	Very much improved	2.00
			5	23FEB92	Severely ill	Minimally worse	0.50
			6	01MAR92	Moderately ill	Much improved	1.00
			10	60	JM	0	19JAN92
1	26JAN92	Mildly ill				Much improved	1.50
2	02FEB92	Mildly ill				Much improved	1.00
3	09FEB92	Markedly ill				No change	1.00
4	16FEB92	Mildly ill				Much improved	3.00
5	23FEB92	Borderline mentally ill				Very much improved	4.00
10	61	JT	6	01MAR92	Borderline mentally ill	Very much improved	4.00
			0	21JAN92	Severely ill		
			1	28JAN92	Severely ill	Minimally improved	2.00
			2	04FEB92	Severely ill	Minimally improved	2.00
			3	11FEB92	Severely ill	Minimally improved	2.00
			4	18FEB92	Markedly ill	Minimally improved	2.00
10	62	RK	5	25FEB92	Markedly ill	Minimally improved	2.00
			6	03MAR92	Moderately ill	Much improved	3.00
			0	21JAN92	Moderately ill		
			1	28JAN92	Moderately ill	Minimally improved	2.00
			2	04FEB92	Moderately ill	Minimally improved	2.00
			3	11FEB92	Moderately ill	Minimally improved	2.00
10	63	MS	4	18FEB92	Mildly ill	Much improved	1.50
			5	25FEB92	Mildly ill	Much improved	1.50
			6	03MAR92	Mildly ill	Much improved	1.50
			0	03FEB92	Moderately ill		
			1	10FEB92	Moderately ill	Minimally improved	1.00
			2	17FEB92	Moderately ill	Minimally improved	1.00
10	64	LT	3	24FEB92	Moderately ill	Minimally improved	1.00
			4	02MAR92	Moderately ill	Minimally improved	1.00
			5	09MAR92	Mildly ill	Much improved	3.00
			6	16MAR92	Borderline mentally ill	Much improved	3.00
			0	05FEB92	Extremely ill		
			1	12FEB92	Severely ill	Minimally improved	1.00
10	64	LT	2	19FEB92	Markedly ill	Minimally improved	1.00
			3	26FEB92	Moderately ill	Much improved	1.50
			4	04MAR92	Mildly ill	Much improved	1.50
			5	11MAR92	Mildly ill	Much improved	1.50
			6	18MAR92	Mildly ill	Much improved	1.50

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS R&D
 REXOETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
10	81	JN	0	20FEB92	Moderately ill		
			1	27FEB92	Moderately ill	Minimally improved	2.00
			2	05MAR92	Mildly ill	Much improved	3.00
			3	12MAR92	Mildly ill	Much improved	3.00
			4	19MAR92	Mildly ill	Much improved	3.00
			5	26MAR92	Mildly ill	Much improved	3.00
10	82	LS	0	02APR92	Mildly ill		
			1	24FEB92	Markedly ill	Minimally improved	1.00
			2	02MAR92	Markedly ill	Minimally improved	1.00
			3	09MAR92	Moderately ill	Minimally improved	1.00
			4	16MAR92	Moderately ill	Minimally improved	1.00
			5	23MAR92	Moderately ill	Much improved	1.50
10	83	KL	0	06APR92	Mildly ill		
			1	02MAR92	Severely ill	Very much improved	2.00
			2	09MAR92	Moderately ill	Minimally improved	1.00
			3	16MAR92	Markedly ill	Very much improved	2.00
			4	23MAR92	Mildly ill	Very much improved	2.00
			5	30MAR92	Markedly ill	Very much improved	2.00
10	84	HV	0	06APR92	Mildly ill		
			1	13APR92	Moderately ill	Much improved	1.50
			2	10MAR92	Severely ill	Minimally improved	2.00
			3	17MAR92	Markedly ill	Minimally improved	2.00
			4	24MAR92	Markedly ill	Minimally improved	2.00
			5	31MAR92	Markedly ill	Minimally improved	1.00
10	85	AK	0	07APR92	Markedly ill		
			1	14APR92	Markedly ill	Minimally improved	1.00
			2	21APR92	Markedly ill	Minimally improved	1.00
			3	28APR92	Markedly ill	Minimally improved	1.00
			4	05MAY92	Markedly ill	Minimally improved	1.00
			5	12MAY92	Markedly ill	Minimally improved	1.00
10	86	NP	0	10MAR92	Moderately ill		
			1	17MAR92	Moderately ill	No change	0.50
			2	24MAR92	Mildly ill	Much improved	1.50
			3	31MAR92	Mildly ill	Much improved	1.50
			4	07APR92	Mildly ill	Much improved	1.50
10	86	NP	0	14APR92	Mildly ill		
			1	21APR92	Mildly ill	Much improved	1.50
			2	28APR92	Mildly ill	Much improved	1.50
			3	05MAY92	Mildly ill	Much improved	1.50
			4	12MAY92	Mildly ill	Much improved	1.50
10	86	NP	0	16MAR92	Severely ill		
			1	23MAR92	Moderately ill	Minimally improved	2.00
			2	30MAR92	Moderately ill	Minimally improved	2.00
			3	06APR92	Moderately ill	Minimally improved	1.00
			4	13APR92	Moderately ill	Minimally improved	1.00
10	86	NP	5	22APR92	Moderately ill	Minimally improved	1.00

1 1 1 1 1

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMDEXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
10	86	NP	6	29APR92	Moderately ill	Minimally improved	1.00
10	87	AN	0	18MAR92	Moderately ill	Minimally improved	1.00
			1	25MAR92	Moderately ill	Much improved	1.50
			2	01APR92	Mildly ill	Much improved	1.50
			3	08APR92	Mildly ill	Much improved	1.50
			4	15APR92	Mildly ill	Much improved	1.50
			5	22APR92	Mildly ill	Much improved	1.50
			6	29APR92	Mildly ill	Much improved	1.50
10	88	AH	0	18MAR92	Moderately ill	Minimally improved	2.00
			1	25MAR92	Moderately ill	Much improved	3.00
			2	01APR92	Mildly ill	Much improved	3.00
			3	08APR92	Mildly ill	Minimally improved	2.00
			4	15APR92	Moderately ill	Much improved	3.00
			5	22APR92	Mildly ill	Much improved	3.00
			6	29APR92	Mildly ill	Much improved	3.00
10	89	SK	0	19MAR92	Moderately ill	Minimally improved	1.00
			1	26MAR92	Moderately ill	Much improved	1.50
			2	02APR92	Mildly ill	Much improved	1.50
			3	09APR92	Mildly ill	Much improved	3.00
			4	16APR92	Mildly ill	Much improved	3.00
			5	23APR92	Mildly ill	Much improved	3.00
			6	30APR92	Borderline mentally ill	Much improved	3.00
10	90	SV	0	23MAR92	Severely ill	Much improved	1.50
			1	30MAR92	Moderately ill	Much improved	1.50
			2	06APR92	Moderately ill	Much improved	1.50
			3	13APR92	Moderately ill	Very much improved	4.00
			4	20APR92	Mildly ill	Very much improved	4.00
			5	27APR92	Mildly ill	Very much improved	4.00
			6	04MAY92	Mildly ill	Very much improved	4.00
10	91	HI	0	23MAR92	Markedly ill	Minimally worse	0.50
			1	30MAR92	Markedly ill	Much improved	1.50
			2	06APR92	Moderately ill	Much improved	1.50
			3	13APR92	Moderately ill	Very much improved	4.00
			4	20APR92	Mildly ill	Very much improved	4.00
			5	27APR92	Mildly ill	Very much improved	4.00
			6	05MAY92	Mildly ill	Very much improved	4.00
10	92	LA	0	31MAR92	Markedly ill	Much improved	1.50
			1	07APR92	Moderately ill	Very much improved	2.00
			2	14APR92	Mildly ill	Very much improved	2.00
			3	21APR92	Mildly ill	Very much improved	2.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
10	92	LA	4	28APR92	Mildly ill	Very much improved	2.00
			5	05MAY92	Mildly ill	Very much improved	2.00
			6	12MAY92	Mildly ill	Very much improved	4.00
			0	08APR92	Moderately ill	Minimally improved	1.00
			1	15APR92	Moderately ill	Much improved	1.50
			2	22APR92	Mildly ill	Much improved	1.50
10	93	AN	3	29APR92	Mildly ill	Much improved	1.50
			4	06MAY92	Mildly ill	Much improved	1.50
			5	13MAY92	Mildly ill	Much improved	1.50
			6	20MAY92	Mildly ill	Much improved	1.50
			0	08APR92	Severely ill	Minimally improved	2.00
			1	15APR92	Severely ill	Minimally improved	2.00
10	94	PV	2	22APR92	Markedly ill	Minimally improved	2.00
			3	29APR92	Markedly ill	Minimally improved	1.00
			4	06MAY92	Markedly ill	Minimally improved	1.50
			5	13MAY92	Moderately ill	Much improved	1.50
			6	20MAY92	Moderately ill	Much improved	1.50
			0	08APR92	Severely ill	Minimally improved	2.00
11	1	DF	0	11OCT91	Markedly ill	Minimally improved	2.00
			1	18OCT91	Markedly ill	Minimally improved	2.00
			2	25OCT91	Moderately ill	Much improved	3.00
			3	01NOV91	Moderately ill	Much improved	3.00
			4	08NOV91	Moderately ill	Much improved	3.00
			5	15NOV91	Mildly ill	Much improved	3.00
11	2	HB	6	22NOV91	Mildly ill	Much improved	3.00
			0	13OCT91	Markedly ill	Much improved	3.00
			1	20OCT91	Moderately ill	Much improved	3.00
			2	27OCT91	Mildly ill	Very much improved	4.00
			3	03NOV91	Borderline mentally ill	Very much improved	4.00
			4	10NOV91	Normal	Very much improved	4.00
11	3	RF	5	17NOV91	Normal	Very much improved	4.00
			6	24NOV91	Normal	Very much improved	4.00
			0	14OCT91	Markedly ill	Much improved	3.00
			1	21OCT91	Moderately ill	Much improved	3.00
			2	28OCT91	Moderately ill	Much improved	3.00
			3	04NOV91	Moderately ill	Much improved	3.00
11	4	BA	4	11NOV91	Moderately ill	Much improved	3.00
			5	18NOV91	Mildly ill	Much improved	3.00
			6	25NOV91	Moderately ill	Much improved	3.00
			0	17OCT91	Markedly ill	No change	1.00
			1	24OCT91	Markedly ill	No change	1.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Data	Severity of Illness	Global Improvement	Efficacy Index
11	4	BA	2	31OCT91	Moderately ill	Minimally improved	2.00
			3	07NOV91	Moderately ill	Minimally improved	2.00
			4	14NOV91	Mildly ill	Much improved	3.00
			5	21NOV91	Mildly ill	Much improved	3.00
			6	28NOV91	Mildly ill	Much improved	3.00
			0	17OCT91	Markedly ill	No change	1.00
11	5	ZH	1	24OCT91	Markedly ill	No change	1.00
			2	31OCT91	Markedly ill	Minimally worse	1.00
			3	07NOV91	Markedly ill	Minimally worse	1.00
			4	14NOV91	Severely ill	Much worse	1.00
11	6	VP	0	15OCT91	Markedly ill	Minimally improved	2.00
			1	22OCT91	Moderately ill	Much improved	3.00
			2	29OCT91	Moderately ill	Much improved	3.00
			3	05NOV91	Mildly ill	Much improved	3.00
			4	12NOV91	Mildly ill	Much improved	3.00
			5	19NOV91	Borderline mentally ill	Much improved	3.00
11	7	EK	0	23OCT91	Mildly ill	Much improved	3.00
			1	30OCT91	Markedly ill	Much improved	3.00
			2	06NOV91	Moderately ill	Much improved	3.00
			3	13NOV91	Mildly ill	Much improved	3.00
			4	20NOV91	Mildly ill	Much improved	3.00
			5	27NOV91	Mildly ill	Much improved	3.00
11	8	KF	0	04DEC91	Mildly ill	Much improved	3.00
			1	10NOV91	Markedly ill	Minimally improved	2.00
			2	17NOV91	Markedly ill	Minimally improved	2.00
			3	24NOV91	Moderately ill	Minimally improved	2.00
			4	01DEC91	Markedly ill	No change	1.00
			5	08DEC91	Markedly ill	No change	1.00
11	9	FI	0	11NOV91	Severely ill	Minimally improved	2.00
			1	18NOV91	Markedly ill	Minimally improved	2.00
			2	25NOV91	Moderately ill	Minimally improved	2.00
			3	02DEC91	Moderately ill	Much improved	3.00
			4	09DEC91	Moderately ill	Much improved	3.00
			5	16DEC91	Moderately ill	Much improved	3.00
11	10	BJ	0	23DEC91	Moderately ill	Minimally improved	2.00
			1	29NOV91	Markedly ill	Minimally improved	2.00
			2	06DEC91	Moderately ill	Much improved	3.00
			3	13DEC91	Mildly ill	Much improved	3.00
			4	20DEC91	Mildly ill	Much improved	3.00
			5	27DEC91	Mildly ill	Much improved	3.00

1154

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
11	10	BJ	4	23DEC91	Mildly ill	Much improved	3.00
			5	30DEC91	Mildly ill	Much improved	3.00
			6	06JAN92	Mildly ill	Much improved	3.00
11	11	NGY	0	05DEC91	Markedly ill	No change	1.00
			1	12DEC91	Markedly ill	Much improved	3.00
			2	19DEC91	Moderately ill	Much improved	3.00
			3	26DEC91	Moderately ill	Much improved	3.00
			4	02JAN92	Borderline mentally ill	Much improved	4.00
			5	09JAN92	Borderline mentally ill	Very much improved	4.00
11	12	PJ	0	15DEC91	Moderately ill	No change	1.00
			1	22DEC91	Markedly ill	Minimally improved	2.00
			2	29DEC91	Markedly ill	Much improved	3.00
			3	05JAN92	Moderately ill	Much improved	3.00
			4	12JAN92	Mildly ill	Much improved	3.00
			5	19JAN92	Mildly ill	Much improved	3.00
11	13	GK	0	14JAN92	Markedly ill	Minimally improved	2.00
			1	21JAN92	Moderately ill	Much improved	3.00
			2	28JAN92	Mildly ill	Minimally improved	2.00
			3	04FEB92	Moderately ill	Minimally improved	2.00
			4	11FEB92	Severely ill	No change	1.00
			5	18FEB92	Severely ill	No change	1.00
11	14	BJ	0	19JAN92	Markedly ill	No change	1.00
			1	26JAN92	Markedly ill	Much improved	3.00
			2	02FEB92	Mildly ill	Much improved	3.00
			3	09FEB92	Mildly ill	Minimally worse	1.00
11	15	NF	0	28JAN92	Markedly ill	Minimally improved	2.00
			1	04FEB92	Moderately ill	Minimally improved	2.00
			2	11FEB92	Moderately ill	Much improved	3.00
			3	18FEB92	Mildly ill	Much improved	3.00
			4	25FEB92	Mildly ill	Much improved	3.00
			5	03MAR92	Mildly ill	Much improved	3.00
11	16	NA	0	02FEB92	Severely ill	Minimally improved	2.00
			1	09FEB92	Markedly ill	No change	1.00
			2	16FEB92	Severely ill	Minimally improved	2.00
11	17	NA	0	02FEB92	Severely ill	Minimally improved	2.00
			1	09FEB92	Markedly ill	No change	1.00
			2	16FEB92	Severely ill	Minimally improved	2.00
11	18	NA	0	02FEB92	Severely ill	Minimally improved	2.00
			1	09FEB92	Markedly ill	No change	1.00
			2	16FEB92	Severely ill	Minimally improved	2.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index	
11	16	NA	4	01MAR92	Moderately ill	Minimally improved	2.00	
			5	08MAR92	Severely ill	No change	1.00	
			6	15MAR92	Markedly ill	Minimally improved	2.00	
	11	17	UZ	0	06FEB92	Severely ill	Minimally improved	2.00
				1	13FEB92	Moderately ill	Much improved	3.00
				2	20FEB92	Mildly ill	Much improved	3.00
3				27FEB92	Mildly ill	Much improved	3.00	
4				05MAR92	Mildly ill	Much improved	3.00	
5				12MAR92	Mildly ill	Much improved	3.00	
11	18	EI	0	09FEB92	Markedly ill	Much improved	3.00	
			1	16FEB92	Moderately ill	Much improved	3.00	
			2	23FEB92	Mildly ill	Much improved	3.00	
			3	01MAR92	Mildly ill	Much improved	3.00	
			4	08MAR92	Mildly ill	Much improved	3.00	
			5	15MAR92	Mildly ill	Much improved	3.00	
11	19	FK	0	27FEB92	Severely ill	Minimally improved	2.00	
			1	05MAR92	Markedly ill	Much improved	3.00	
			2	12MAR92	Mildly ill	Very much improved	4.00	
			3	19MAR92	Borderline mentally ill	Very much improved	4.00	
			4	26MAR92	Borderline mentally ill	Much improved	3.00	
			5	02APR92	Mildly ill	Much improved	3.00	
11	20	LJ	0	01MAR92	Severely ill	Minimally improved	2.00	
			1	08MAR92	Markedly ill	Minimally improved	2.00	
			2	15MAR92	Moderately ill	Much improved	3.00	
			3	22MAR92	Mildly ill	Much improved	3.00	
			4	29MAR92	Mildly ill	Much improved	3.00	
			5	05APR92	Mildly ill	Much improved	3.00	
12	1	IB	0	30OCT91	Extremely ill	No change	1.00	
			1	06NOV91	Severely ill	Minimally improved	2.00	
			2	13NOV91	Moderately ill	Much improved	3.00	
			3	20NOV91	Mildly ill	Much improved	3.00	
			4	27NOV91	Mildly ill	Much improved	3.00	
			5	04DEC91	Borderline mentally ill	Much improved	4.00	
12	2	EFC	0	04NOV91	Severely ill	Minimally worse	1.00	
			1	11NOV91	Severely ill			

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
12	2	EFC	2	18NOV91	Severely ill	No change	1.00
			3	25NOV91	Severely ill	Minimally worse	0.50
			4	02DEC91	Severely ill	No change	1.00
			5	09DEC91	Markedly ill	Minimally improved	2.00
			6	16DEC91	Markedly ill	Minimally improved	2.00
			12	3	IF	0	29OCT91
1	05NOV91	Severely ill				No change	1.00
2	12NOV91	Severely ill				Minimally improved	2.00
3	19NOV91	Markedly ill				Minimally improved	3.00
4	26NOV91	Moderately ill				Much improved	4.00
5	03DEC91	Mildly ill				Very much improved	4.00
12	4	EG	0	04NOV91	Extremely ill	Minimally worse	1.00
			1	11NOV91	Severely ill	Minimally improved	2.00
			2	18NOV91	Severely ill	Minimally improved	2.00
			3	25NOV91	Severely ill	Minimally improved	2.00
			4	02DEC91	Severely ill	Minimally improved	3.00
			5	09DEC91	Moderately ill	Much improved	3.00
12	5	ZSH	0	04NOV91	Mildly ill	Minimally improved	2.00
			1	11NOV91	Mildly ill	Minimally improved	2.00
			2	18NOV91	Mildly ill	Minimally improved	3.00
			3	25NOV91	Mildly ill	Minimally improved	3.00
			4	02DEC91	Mildly ill	Minimally improved	3.00
			5	09DEC91	Mildly ill	Minimally improved	3.00
12	6	MK	0	01NOV91	Severely ill	Minimally improved	2.00
			1	08NOV91	Severely ill	Minimally improved	2.00
			2	15NOV91	Markedly ill	Minimally improved	2.00
			3	22NOV91	Moderately ill	Much improved	3.00
			4	29NOV91	Mildly ill	Minimally improved	2.00
			5	06DEC91	Moderately ill	Much improved	4.00
12	7	LK	0	04NOV91	Severely ill	Much improved	3.00
			1	11NOV91	Moderately ill	Much improved	3.00
			2	18NOV91	Moderately ill	Minimally improved	2.00
			3	25NOV91	Markedly ill	Minimally improved	2.00
			4	02DEC91	Markedly ill	Minimally improved	3.00
			5	09DEC91	Moderately ill	Minimally improved	3.00
12	8	LH	0	04NOV91	Severely ill	Much improved	3.00
			1	11NOV91	Moderately ill	Much improved	3.00
			2	18NOV91	Moderately ill	Minimally improved	2.00
			3	25NOV91	Markedly ill	Minimally improved	2.00
			4	02DEC91	Markedly ill	Minimally improved	3.00
			5	09DEC91	Moderately ill	Minimally improved	3.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
12	8	FM	0	31OCT91	Extremely ill	No change	1.00
			1	07NOV91	Severely ill	Minimally improved	2.00
			2	14NOV91	Severely ill	Minimally improved	2.00
			3	21NOV91	Markedly ill	Minimally improved	2.00
			4	28NOV91	Severely ill	Much worse	1.00
			5	05DEC91	Severely ill	Minimally improved	2.00
12	9	KBP	0	12DEC91	Severely ill	No change	1.00
			1	30OCT91	Severely ill	Minimally improved	2.00
			2	06NOV91	Markedly ill	Minimally improved	2.00
			3	13NOV91	Markedly ill	Minimally improved	2.00
			4	20NOV91	Markedly ill	Minimally improved	2.00
			5	27NOV91	Markedly ill	Minimally improved	3.00
12	10	IP	0	04NOV91	Moderately ill	No change	1.00
			1	11NOV91	Severely ill	No change	1.00
			2	18NOV91	Severely ill	Minimally improved	2.00
			3	25NOV91	Markedly ill	Much improved	3.00
			4	02DEC91	Markedly ill	Much improved	3.00
			5	09DEC91	Moderately ill	Much improved	4.00
12	11	ER	0	16DEC91	Mildly ill	Minimally worse	0.50
			1	30OCT91	Severely ill	Minimally improved	1.00
			2	06NOV91	Severely ill	Minimally improved	1.00
			3	13NOV91	Severely ill	Minimally improved	1.00
			4	20NOV91	Severely ill	Minimally improved	1.00
			5	27NOV91	Severely ill	Minimally improved	1.00
12	12	FSZ	0	04NOV91	Markedly ill	No change	1.00
			1	11NOV91	Markedly ill	Minimally improved	2.00
			2	18NOV91	Moderately ill	Minimally improved	2.00
			3	25NOV91	Moderately ill	Minimally improved	1.00
			4	02DEC91	Moderately ill	Minimally improved	2.00
			5	09DEC91	Moderately ill	Minimally improved	2.00
12	13	ISZ	0	16DEC91	Markedly ill	Minimally improved	2.00
			1	04NOV91	Severely ill	Minimally worse	1.00
			2	11NOV91	Severely ill	Minimally worse	1.00
			3	18NOV91	Severely ill	No change	1.00
			4	25NOV91	Markedly ill	No change	1.00
5	02DEC91	Markedly ill	Minimally improved	3.00			

1153

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 40.3
CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
12	13	ISZ	6	16DEC91	Moderately ill	Minimally improved	2.00
12	14	GSZ	0	05NOV91	Severely ill	Minimally worse	1.00
			1	12NOV91	Severely ill	No change	1.00
			2	19NOV91	Severely ill	Minimally improved	1.50
			3	26NOV91	Markedly ill	No change	1.00
			4	03DEC91	Severely ill	Minimally improved	1.50
			5	10DEC91	Markedly ill	Minimally improved	1.50
			6	17DEC91	Markedly ill	Minimally improved	1.50
12	15	GB	0	25NOV91	Markedly ill	Minimally worse	1.00
			1	02DEC91	Markedly ill	Minimally improved	2.00
			2	09DEC91	Moderately ill	Minimally improved	3.00
			3	16DEC91	Mildly ill	Minimally improved	3.00
			4	23DEC91	Mildly ill	Minimally improved	3.00
			5	30DEC91	Mildly ill	Minimally improved	3.00
			6	06JAN92	Mildly ill	Minimally improved	3.00
12	16	FN	0	10DEC91	Severely ill	Minimally worse	1.00
			1	17DEC91	Severely ill	Minimally improved	2.00
			2	24DEC91	Markedly ill	Much improved	4.00
			3	31DEC91	Mildly ill	Very much improved	4.00
			4	07JAN92	Borderline mentally ill	Much improved	4.00
			5	14JAN92	Borderline mentally ill	Very much improved	4.00
			6	21JAN92	Mildly ill	Much improved	4.00
12	17	TK	0	14JAN92	Markedly ill	Minimally worse	1.00
			1	21JAN92	Markedly ill	No change	1.00
			2	28JAN92	Markedly ill	Minimally improved	2.00
			3	04FEB92	Markedly ill	Minimally improved	3.00
			4	11FEB92	Moderately ill	Minimally improved	3.00
			5	18FEB92	Moderately ill	Much improved	4.00
			6	25FEB92	Mildly ill	Much improved	4.00
12	18	LS	0	14JAN92	Severely ill	No change	1.00
			1	21JAN92	Markedly ill	No change	1.00
			2	28JAN92	Markedly ill	Minimally improved	2.00
			3	04FEB92	Moderately ill	Minimally improved	2.00
			4	11FEB92	Moderately ill	Much improved	3.00
			5	18FEB92	Moderately ill	Much improved	3.00
			6	25FEB92	Moderately ill	Much improved	3.00
12	19	SSZ	0	15JAN92	Markedly ill	No change	1.00
			1	22JAN92	Markedly ill	No change	1.00
			2	29JAN92	Markedly ill	Minimally improved	3.00
			3	05FEB92	Mildly ill	Minimally improved	3.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
12	19	SSZ	4	12FEB92	Moderately ill	Minimally improved	3.00
			5	19FEB92	Mildly ill	Much improved	4.00
			6	26FEB92	Mildly ill	Much improved	4.00
12	20	KSZ	0	16JAN92	Severely ill	No change	1.00
			1	23JAN92	Severely ill	Minimally improved	2.00
			2	30JAN92	Severely ill	Much improved	3.00
			3	06FEB92	Moderately ill	No change	1.00
			4	13FEB92	Moderately ill	Minimally improved	3.00
			5	20FEB92	Moderately ill	Much improved	4.00
12	21	FL	0	27FEB92	Mildly ill	Much improved	4.00
			1	30JAN92	Severely ill	No change	1.00
			2	06FEB92	Severely ill	Minimally improved	2.00
			3	13FEB92	Markedly ill	Minimally improved	2.00
			4	20FEB92	Markedly ill	Much improved	3.00
			5	27FEB92	Moderately ill	Much improved	4.00
12	22	NV	0	05MAR92	Mildly ill	Much improved	4.00
			1	12MAR92	Borderline mentally ill	Much improved	4.00
			2	27JAN92	Severely ill	No change	1.00
			3	03FEB92	Severely ill	No change	1.00
			4	10FEB92	Severely ill	Minimally improved	2.00
			5	17FEB92	Markedly ill	Minimally improved	2.00
12	23	EN	0	24FEB92	Markedly ill	Much improved	4.00
			1	02MAR92	Moderately ill	Much improved	4.00
			2	09MAR92	Moderately ill	Much improved	4.00
			3	06FEB92	Extremely ill	Minimally worse	1.00
			4	13FEB92	Extremely ill	No change	1.00
			5	20FEB92	Extremely ill	Minimally improved	2.00
12	24	MF	0	05MAR92	Markedly ill	Much improved	3.00
			1	12MAR92	Moderately ill	Much improved	3.00
			2	19MAR92	Moderately ill	Much improved	4.00
			3	07FEB92	Severely ill	No change	1.00
			4	14FEB92	Severely ill	Minimally improved	3.00
			5	21FEB92	Severely ill	Much improved	3.00
12	25	FS	0	28FEB92	Markedly ill	Much improved	3.00
			1	06MAR92	Moderately ill	Much improved	3.00
			2	13MAR92	Mildly ill	Much improved	4.00
			3	20MAR92	Mildly ill	Much improved	4.00
			4	10FEB92	Extremely ill	No change	1.00
			5	17FEB92	Severely ill	Minimally improved	3.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
12	25	FS	2	24FEB92	Markedly ill	Minimally improved	2.00
			3	02MAR92	Moderately ill	Much improved	3.00
			4	09MAR92	Moderately ill	Much improved	3.00
			5	16MAR92	Moderately ill	Much improved	3.00
			6	23MAR92	Moderately ill	Much improved	3.00
			12	26	LB	0	04FEB92
1	11FEB92	Severely ill				No change	1.00
2	18FEB92	Severely ill				Minimally improved	2.00
3	25FEB92	Markedly ill				Minimally improved	2.00
4	03MAR92	Markedly ill				Minimally improved	2.00
5	10MAR92	Markedly ill				Minimally improved	2.00
12	27	VCS	0	07FEB92	Extremely ill	No change	1.00
			1	14FEB92	Extremely ill	Minimally improved	2.00
			2	21FEB92	Severely ill	Minimally improved	2.00
			3	28FEB92	Severely ill	Much improved	3.00
			4	06MAR92	Markedly ill	Much improved	3.00
			5	13MAR92	Moderately ill	Much improved	3.00
12	28	IV	0	07FEB92	Mildly ill	Much improved	4.00
			1	14FEB92	Severely ill	No change	1.00
			2	21FEB92	Markedly ill	Minimally improved	2.00
			3	28FEB92	Markedly ill	Minimally improved	2.00
			4	06MAR92	Markedly ill	Minimally improved	2.00
			5	13MAR92	Moderately ill	Minimally improved	3.00
12	29	AK	0	20MAR92	Moderately ill	Minimally improved	3.00
			1	10FEB92	Extremely ill	No change	1.00
			2	17FEB92	Severely ill	No change	1.00
			3	24FEB92	Severely ill	Minimally improved	2.00
			4	02MAR92	Severely ill	Minimally improved	3.00
			5	09MAR92	Moderately ill	Much improved	4.00
12	30	FS	0	23MAR92	Borderline mentally ill	Much improved	4.00
			1	24FEB92	Extremely ill	No change	1.00
			2	02MAR92	Extremely ill	No change	1.00
			3	09MAR92	Extremely ill	No change	1.00
			4	16MAR92	Extremely ill	Minimally improved	2.00
			5	23MAR92	Extremely ill	Minimally improved	2.00
12	30	APR92	0	06APR92	Extremely ill	Minimally improved	2.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/073
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
12	31	FM	0	24MAR92	Extremely ill	No change	1.00
			1	31MAR92	Severely ill	No change	1.00
			2	07APR92	Severely ill	Minimally improved	2.00
			3	14APR92	Markedly ill	Minimally improved	2.00
			4	21APR92	Markedly ill	Minimally improved	2.00
			5	28APR92	Markedly ill	Minimally improved	2.00
12	32	LM	0	05MAY92	Markedly ill	Minimally improved	2.00
			1	01APR92	Extremely ill	No change	1.00
			2	08APR92	Severely ill	No change	1.00
			3	15APR92	Severely ill	No change	1.00
			4	22APR92	Severely ill	No change	1.00
			5	29APR92	Severely ill	No change	1.00
12	33	LN	0	06MAY92	Severely ill	No change	1.00
			1	13MAY92	Severely ill	No change	1.00
			2	01APR92	Severely ill	Minimally improved	2.00
			3	08APR92	Severely ill	Minimally improved	2.00
			4	15APR92	Markedly ill	Minimally improved	3.00
			5	22APR92	Markedly ill	Much improved	4.00
12	34	TGB	0	29APR92	Borderline mentally ill	Much improved	4.00
			1	06MAY92	Borderline mentally ill	Much improved	4.00
			2	13MAY92	Severely ill	No change	1.00
			3	20MAY92	Severely ill	Minimally improved	2.00
			4	27MAY92	Markedly ill	Much improved	3.00
			5	03APR92	Moderately ill	Much improved	4.00
12	35	LP	0	10APR92	Moderately ill	Much improved	4.00
			1	17APR92	Moderately ill	Much improved	4.00
			2	24APR92	Mildly ill	Much improved	4.00
			3	01MAY92	Mildly ill	Much improved	4.00
			4	08MAY92	Mildly ill	No change	1.00
			5	15MAY92	Extremely ill	No change	1.00
12	36	FB	0	22APR92	Severely ill	Minimally improved	2.00
			1	29APR92	Markedly ill	Minimally improved	2.00
			2	06MAY92	Markedly ill	Much improved	3.00
			3	13MAY92	Moderately ill	No change	1.00
			4	20MAY92	Extremely ill	No change	1.00
			5	27MAY92	Severely ill	Minimally improved	2.00

1163

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
12	36	FB	6	11MAY92	Moderately ill	Minimally improved	2.00
12	37	EK	0	03APR92	Moderately ill	No change	1.00
			1	10APR92	Moderately ill	Minimally improved	2.00
			2	17APR92	Moderately ill	Much improved	4.00
			3	24APR92	Mildly ill	Much improved	4.00
			4	01MAY92	Borderline mentally ill	Much improved	4.00
			5	08MAY92	Borderline mentally ill	Much improved	4.00
			6	15MAY92	Borderline mentally ill	Much improved	4.00
12	38	FG	0	06APR92	Extremely ill	No change	1.00
			1	13APR92	Severely ill	No change	1.00
			2	20APR92	Severely ill	No change	1.00
			3	27APR92	Severely ill	Minimally worse	1.00
			4	04MAY92	Markedly ill	No change	1.00
			5	11MAY92	Severely ill	No change	1.00
			6	18MAY92	Markedly ill	No change	1.00
13	1	PZ	0	15OCT91	Severely ill	Much improved	3.00
			1	22OCT91	Markedly ill	Much improved	3.00
			2	29OCT91	Markedly ill	Minimally improved	2.00
			3	05NOV91	Markedly ill	Much improved	4.00
			4	12NOV91	Mildly ill	Much improved	4.00
			5	19NOV91	Mildly ill	Much improved	4.00
			6	26NOV91	Borderline mentally ill	Much improved	4.00
13	2	TCS	0	16OCT91	Severely ill	Minimally improved	2.00
			1	24OCT91	Markedly ill	Much improved	3.00
			2	31OCT91	Moderately ill	Much improved	3.00
			3	06NOV91	Moderately ill	Minimally improved	2.00
			4	13NOV91	Moderately ill	Much improved	4.00
			5	20NOV91	Moderately ill	Very much improved	4.00
			6	27NOV91	Borderline mentally ill		
13	3	AI	0	15OCT91	Severely ill	Much improved	3.00
			1	22OCT91	Markedly ill	Much improved	3.00
			2	29OCT91	Moderately ill	Much improved	4.00
			3	05NOV91	Moderately ill	Much improved	4.00
			4	12NOV91	Mildly ill	Much improved	4.00
			5	19NOV91	Mildly ill	Much improved	4.00
			6	26NOV91	Borderline mentally ill	Much improved	4.00
13	4	SZJ	0	15OCT91	Severely ill	Much improved	3.00
			1	22OCT91	Moderately ill	Minimally improved	3.00
			2	29OCT91	Markedly ill	Much improved	3.00
			3	05NOV91	Moderately ill	Much improved	3.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
13	4	SZJ	4	12NOV91	Markedly ill	Minimally improved	2.00
			5	19NOV91	Markedly ill	Minimally improved	2.00
			6	26NOV91	Severely ill	No change	1.00
13	5	HF	0	17OCT91	Severely ill	No change	1.00
			1	24OCT91	Severely ill	No change	1.00
13	6	KE	0	17OCT91	Markedly ill	Minimally improved	2.00
			1	29OCT91	Markedly ill	Minimally improved	2.00
			2	31OCT91	Markedly ill	Minimally improved	2.00
			3	07NOV91	Markedly ill	Much improved	3.00
			4	14NOV91	Moderately ill	Minimally improved	2.00
			5	21NOV91	Moderately ill	Much improved	4.00
13	7	BL	0	24OCT91	Borderline mentally ill	Much improved	4.00
			1	31OCT91	Severely ill	Much improved	4.00
			2	07NOV91	Moderately ill	Very much improved	4.00
			3	14NOV91	Mildly ill	Much improved	4.00
			4	21NOV91	Mildly ill	Much improved	3.00
			5	28NOV91	Borderline mentally ill	Much improved	4.00
13	8	PK	0	05DEC91	Borderline mentally ill	Very much improved	4.00
			1	21OCT91	Severely ill	Much improved	3.00
			2	28OCT91	Markedly ill	Much improved	3.00
			3	04NOV91	Moderately ill	Much improved	3.00
			4	11NOV91	Moderately ill	Minimally improved	2.00
			5	18NOV91	Moderately ill	Much improved	3.00
13	9	SZS	0	25NOV91	Mildly ill	Much improved	3.00
			1	02DEC91	Borderline mentally ill	Much improved	4.00
			2	21OCT91	Severely ill	Much improved	3.00
			3	28OCT91	Markedly ill	Minimally improved	3.00
			4	04NOV91	Moderately ill	Minimally improved	3.00
			5	11NOV91	Markedly ill	Much improved	3.00
13	10	BM	0	25NOV91	Markedly ill	Minimally improved	2.00
			1	02DEC91	Borderline mentally ill	Much improved	4.00
			2	17OCT91	Severely ill	No change	1.00
			3	24OCT91	Severely ill	No change	1.00
			4	14NOV91	Severely ill	Minimally improved	2.00
			5	21NOV91	Severely ill	Much improved	3.00
13	11	HS	0	28NOV91	Moderately ill	Minimally improved	2.00
			1	05DEC91	Moderately ill	Much improved	3.00
			2	12DEC91	Moderately ill	Minimally improved	2.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
13	11	HS	4	12DEC91	Markedly ill	Minimally improved	2.00
			5	19DEC91	Moderately ill	Minimally improved	3.00
			6	26DEC91	Moderately ill	Much improved	3.00
13	12	BF	0	30OCT91	Severely ill	Much improved	3.00
			1	06NOV91	Moderately ill	Minimally improved	2.00
			2	13NOV91	Markedly ill	Much improved	3.00
			3	20NOV91	Moderately ill	Minimally improved	2.00
			5	04DEC91	Mildly ill	Much improved	3.00
13	13	HM	0	01NOV91	Severely ill	Minimally improved	3.00
			1	08NOV91	Markedly ill	Minimally improved	2.00
			2	15NOV91	Moderately ill	Minimally improved	3.00
			3	22NOV91	Moderately ill	Much improved	3.00
			4	29NOV91	Moderately ill	Much improved	3.00
			5	06DEC91	Moderately ill	Much improved	3.00
13	14	DF	0	01NOV91	Severely ill	Minimally improved	2.00
			1	08NOV91	Markedly ill	Minimally improved	2.00
			2	15NOV91	Moderately ill	Minimally improved	2.00
			3	22NOV91	Markedly ill	Minimally improved	2.00
			4	29NOV91	Moderately ill	Minimally improved	1.50
			5	06DEC91	Mildly ill	Much improved	1.50
13	15	KG	0	13DEC91	Mildly ill	Much improved	2.00
			1	06NOV91	Severely ill	Minimally improved	2.00
			2	13NOV91	Moderately ill	Minimally improved	2.00
			3	20NOV91	Moderately ill	Minimally improved	3.00
			4	27NOV91	Moderately ill	Minimally improved	2.00
			5	04DEC91	Moderately ill	Much improved	4.00
13	16	SZL	0	18DEC91	Mildly ill	Much improved	4.00
			1	19NOV91	Markedly ill	Minimally improved	2.00
			2	26NOV91	Markedly ill	Minimally improved	2.00
			3	03DEC91	Moderately ill	Minimally improved	1.00
			4	10DEC91	Markedly ill	Minimally improved	3.00
			5	17DEC91	Moderately ill	Minimally improved	2.00
13	17	GSM	0	24DEC91	Moderately ill	Minimally improved	2.00
			1	31DEC91	Markedly ill	No change	1.00
			0	19NOV91	Markedly ill	Minimally improved	2.00
			1	26NOV91	Moderately ill	Minimally improved	2.00
			2	03DEC91	Moderately ill	Minimally improved	2.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
RESOMETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index			
13	17	GSM	3	10DEC91	Moderately ill	Much improved	3.00			
			4	17DEC91	Moderately ill	Much improved	1.50			
			5	24DEC91	Moderately ill	Much improved	3.00			
			6	31DEC91	Mildly ill	Much improved	4.00			
			13	18	VT	0	03DEC91	Markedly ill	Much improved	1.50
						1	10DEC91	Markedly ill	Minimally improved	1.50
2	17DEC91	Markedly ill				Minimally improved	2.00			
3	23DEC91	Markedly ill				Much improved	3.00			
4	31DEC91	Borderline mentally ill				Much improved	3.00			
5	07JAN92	Mildly ill				Much improved	3.00			
6	14JAN92	Moderately ill	Much improved	3.00						
13	19	KK	0	23JAN92	Severely ill	Much improved	3.00			
			1	30JAN92	Moderately ill	Minimally improved	2.00			
			2	06FEB92	Markedly ill	Minimally improved	2.00			
13	20	NL	3	13FEB92	Markedly ill	Much improved	2.00			
			0	28JAN92	Markedly ill	Minimally improved	2.00			
			1	04FEB92	Moderately ill	Much improved	3.00			
			2	11FEB92	Moderately ill	Minimally improved	2.00			
			3	18FEB92	Moderately ill	Much improved	3.00			
			4	25FEB92	Mildly ill	Much improved	3.00			
13	21	CL	5	03MAR92	Mildly ill	Much improved	3.00			
			6	10MAR92	Borderline mentally ill	Very much improved	4.00			
			0	18FEB92	Severely ill	Much improved	3.00			
			1	25FEB92	Moderately ill	Much improved	3.00			
			2	03MAR92	Mildly ill	Much improved	3.00			
			3	10MAR92	Moderately ill	Much improved	3.00			
13	22	NYM	4	17MAR92	Mildly ill	Much improved	3.00			
			5	24MAR92	Borderline mentally ill	Very much improved	4.00			
			6	31MAR92	Borderline mentally ill	Very much improved	4.00			
			0	05MAY92	Severely ill	Minimally improved	2.00			
			1	12MAY92	Markedly ill	Minimally improved	2.00			
			2	19MAY92	Moderately ill	Much improved	3.00			
13	23	BSB	3	26MAY92	Moderately ill	Minimally improved	3.00			
			4	02JUN92	Mildly ill	Minimally improved	3.00			
			5	09JUN92	Mildly ill	Minimally improved	3.00			
			6	16JUN92	Mildly ill	Much improved	3.00			
			0	06MAY92	Markedly ill	Minimally improved	2.00			
			1	13MAY92	Markedly ill	Much improved	3.00			
13	23	BSB	2	20MAY92	Moderately ill	Much improved	3.00			
			3	27MAY92	Moderately ill	Much improved	3.00			

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
 OPEN PHASE

Centre	Patient No.	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
13	23	BSB	4	03JUN92	Mildly ill	Much improved	4.00
			5	10JUN92	Borderline mentally ill	Much improved	4.00
			6	17JUN92	Normal	Very much improved	4.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
1	3	2	TA	8	11JAN91	Normal	Very much improved	4.00				
				10	25JAN91	Normal	Very much improved	4.00				
				12	08FEB91	Normal	Very much improved	4.00				
				14	22FEB91	Normal	Very much improved	4.00				
				16	08MAR91	Normal	Very much improved	4.00				
				18	22MAR91	Normal	Very much improved	4.00				
				20	05APR91	Normal	Very much improved	4.00				
				22	19APR91	Normal	Very much improved	4.00				
				24	03MAY91	Normal	Very much improved	4.00				
				26	17MAY91	Normal	Very much improved	4.00				
				28	31MAY91	Normal	Very much improved	4.00				
				30	14JUN91	Normal	Very much improved	4.00				
				32	28JUN91	Normal	Very much improved	4.00				
				34	12JUL91	Normal	Very much improved	4.00				
				36	26JUL91	Normal	Very much improved	4.00				
				38	09AUG91	Normal	Very much improved	4.00				
				40	23AUG91	Borderline mentally ill	Very much improved	4.00				
				42	06SEP91	Borderline mentally ill	Very much improved	4.00				
				44	20SEP91	Normal	Very much improved	4.00				
				46	04OCT91	Normal	Very much improved	4.00				
				48	18OCT91	Normal	Very much improved	4.00				
				50	01NOV91	Normal	Very much improved	4.00				
				52	14NOV91	Normal	Very much improved	4.00				
				1	4	3	DNC	8	16JAN91	Normal	Very much improved	2.00
								10	30JAN91	Normal	Very much improved	2.00
								12	13FEB91	Normal	Very much improved	2.00
								14	27FEB91	Normal	Very much improved	4.00
								16	13MAR91	Normal	Very much improved	4.00
								18	27MAR91	Normal	Very much improved	4.00
								20	10APR91	Normal	Very much improved	4.00
								22	24APR91	Normal	Very much improved	4.00
								24	08MAY91	Normal	Very much improved	4.00
26	22MAY91	Normal	Very much improved					4.00				
28	05JUN91	Normal	Very much improved					4.00				
30	19JUN91	Normal	Very much improved					4.00				
32	03JUL91	Normal	Very much improved					4.00				
34	17JUL91	Normal	Very much improved					4.00				
36	31JUL91	Normal	Very much improved					4.00				
38	14AUG91	Normal	Very much improved					4.00				
40	28AUG91	Normal	Very much improved	4.00								
42	11SEP91	Normal	Very much improved	4.00								
44	25SEP91	Normal	Very much improved	4.00								
46	09OCT91	Normal	Very much improved	4.00								
48	23OCT91	Normal	Very much improved	4.00								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	4	3	DNC	50	06NOV91	Normal	Very much improved	4.00
	5	4	DB	52	20NOV91	Normal	Very much improved	4.00
1	8			8	29JAN91	Normal	Very much improved	4.00
	10			10	19FEB91	Normal	Very much improved	4.00
	12			12	27FEB91	Normal	Very much improved	4.00
	14			14	13MAR91	Normal	Very much improved	4.00
	16			16	27MAR91	Normal	Very much improved	4.00
	18			18	10APR91	Normal	Very much improved	4.00
	20			20	24APR91	Normal	Very much improved	4.00
	22			22	08MAY91	Normal	Very much improved	4.00
	24			24	31MAY91	Normal	Very much improved	4.00
	26			26	04JUN91	Normal	Very much improved	4.00
	28			28	18JUN91	Normal	Very much improved	4.00
	30			30	02JUL91	Normal	Very much improved	4.00
	32			32	16JUL91	Normal	Very much improved	4.00
	34			34	30JUL91	Normal	Very much improved	4.00
	36			36	13AUG91	Normal	Very much improved	4.00
	38			38	27AUG91	Normal	Very much improved	4.00
	40			40	10SEP91	Normal	Very much improved	4.00
	42			42	24SEP91	Normal	Very much improved	4.00
	44			44	08OCT91	Normal	Very much improved	4.00
	46			46	22OCT91	Normal	Very much improved	4.00
48			48	05NOV91	Normal	Very much improved	4.00	
50			50	19NOV91	Normal	Very much improved	4.00	
52			52	03DEC91	Normal	Very much improved	4.00	
1	8		CCR	8	20FEB91	Normal	Very much improved	2.00
	10			10	06MAR91	Normal	Very much improved	2.00
	12			12	20MAR91	Normal	Very much improved	2.00
	14			14	03APR91	Normal	Very much improved	2.00
	16			16	17APR91	Normal	Very much improved	2.00
	18			18	30APR91	Normal	Very much improved	2.00
	20			20	15MAY91	Normal	Very much improved	2.00
	22			22	29MAY91	Normal	Very much improved	2.00
	24			24	12JUN91	Normal	Very much improved	2.00
	26			26	26JUN91	Normal	Very much improved	2.00
	28			28	10JUL91	Normal	Very much improved	2.00
	30			30	24JUL91	Normal	Very much improved	2.00
32			32	07AUG91	Normal	Very much improved	2.00	
34			34	21AUG91	Normal	Very much improved	2.00	
36			36	04SEP91	Normal	Very much improved	2.00	
38			38	18SEP91	Normal	Very much improved	2.00	
40			40	02OCT91	Normal	Very much improved	2.00	
42			42	16OCT91	Normal	Very much improved	2.00	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index					
1	9	7	CCR		44	30OCT91	Normal	Very much improved	4.00					
					46	13NOV91	Normal	Very much improved	4.00					
					48	27NOV91	Normal	Very much improved	4.00					
					50	11DEC91	Normal	Very much improved	4.00					
					52	26DEC91	Normal	Very much improved	4.00					
1	10	8	LDL		8	28MAR91	Normal	Very much improved	4.00					
					10	12APR91	Normal	Very much improved	4.00					
					12	26APR91	Normal	Very much improved	4.00					
					14	10MAY91	Normal	Very much improved	4.00					
					16	24MAY91	Normal	Very much improved	4.00					
					18	07JUN91	Normal	Very much improved	4.00					
					20	21JUN91	Normal	Very much improved	4.00					
					22	05JUL91	Normal	Very much improved	4.00					
					24	19JUL91	Normal	Very much improved	4.00					
					26	02AUG91	Normal	Very much improved	4.00					
					28	16AUG91	Normal	Very much improved	4.00					
					30	30AUG91	Normal	Very much improved	4.00					
					32	13SEP91	Normal	Very much improved	4.00					
					34	27SEP91	Normal	Very much improved	4.00					
					36	11OCT91	Normal	Very much improved	4.00					
					38	25OCT91	Normal	Very much improved	4.00					
					40	08NOV91	Normal	Very much improved	4.00					
					42	22NOV91	Normal	Very much improved	4.00					
					44	06DEC91	Normal	Very much improved	4.00					
					46	20DEC91	Normal	Very much improved	4.00					
					48	03JAN92	Normal	Very much improved	4.00					
					50	17JAN92	Normal	Very much improved	4.00					
					52	31JAN92	Normal	Very much improved	4.00					
					1	14	11	MLC		8	02JUL91	Borderline mentally ill	Much improved	1.50
										10	16JUL91	Mildly ill	Much improved	1.50
										12	30JUL91	Markedly ill	No change	0.50
					1	17	14	CEC		8	16JUL91	Mildly ill	Much improved	3.00
										10	30JUL91	Normal	Very much improved	4.00
12	13AUG91	Mildly ill	Much improved	3.00										
14	27AUG91	Borderline mentally ill	Very much improved	4.00										
16	10SEP91	Normal	Very much improved	4.00										
18	24SEP91	Normal	Very much improved	4.00										
20	08OCT91	Borderline mentally ill	Very much improved	4.00										
22	22OCT91	Normal	Very much improved	4.00										
24	05NOV91	Normal	Very much improved	4.00										
26	19NOV91	Normal	Very much improved	4.00										
28	03DEC91	Normal	Very much improved	4.00										

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	17	14	CEC	30	17DEC91	Normal	Very much improved	4.00
				32	31DEC91	Normal	Very much improved	4.00
1	18	15	TTM	8	17JUL91	Mildly ill	Much improved	1.50
				10	31JUL91	Borderline mentally ill	Very much improved	2.00
				12	14AUG91	Mildly ill	Much improved	1.50
				14	28AUG91	Borderline mentally ill	Very much improved	2.00
				16	11SEP91	Borderline mentally ill	Much improved	1.50
				18	25SEP91	Normal	Much improved	1.33
1	20	17	EFC	8	26JUL91	Mildly ill	Much improved	1.50
				10	09AUG91	Moderately ill	Minimally improved	1.00
				12	23AUG91	Markedly ill	No change	0.50
1	22	19	SK	8	06AUG91	Normal	Very much improved	4.00
				10	20AUG91	Normal	Very much improved	4.00
				12	03SEP91	Normal	Very much improved	4.00
				14	17SEP91	Borderline mentally ill	Very much improved	4.00
				16	01OCT91	Normal	Very much improved	4.00
				18	15OCT91	Normal	Very much improved	4.00
				20	29OCT91	Normal	Very much improved	4.00
				22	12NOV91	Normal	Very much improved	4.00
				24	26NOV91	Normal	Very much improved	4.00
				26	10DEC91	Normal	Very much improved	4.00
				28	24DEC91	Normal	Very much improved	4.00
				30	07JAN92	Normal	Very much improved	4.00
				32	21JAN92	Normal	Very much improved	4.00
				34	04FEB92	Normal	Very much improved	4.00
				36	18FEB92	Normal	Very much improved	4.00
				38	04MAR92	Normal	Very much improved	4.00
				40	17MAR92	Normal	Very much improved	4.00
				42	31MAR92	Normal	Very much improved	4.00
				44	14APR92	Normal	Very much improved	4.00
				46	28APR92	Normal	Very much improved	4.00
				48	12MAY92	Normal	Very much improved	4.00
				50	26MAY92	Normal	Very much improved	4.00
				52	09JUN92	Normal	Very much improved	4.00
1	24	20	LVF	8	27AUG91	Normal	Very much improved	4.00
				10	10SEP91	Borderline mentally ill	Very much improved	4.00
				12	24SEP91	Borderline mentally ill	Very much improved	4.00
				14	08OCT91	Borderline mentally ill	Very much improved	4.00
				16	22OCT91	Normal	Much improved	3.00
				18	05NOV91	Mildly ill	Very much improved	3.00
				20	19NOV91	Normal	Very much improved	4.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOMETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOMETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
1	24	20	LVF	22	03DEC91	Borderline mentally ill	Very much improved	4.00				
				24	17DEC91	Borderline mentally ill	Very much improved	4.00				
				26	31DEC91	Borderline mentally ill	Very much improved	4.00				
				28	14JAN92	Normal	Very much improved	4.00				
				30	28JAN92	Borderline mentally ill	Very much improved	4.00				
				32	11FEB92	Borderline mentally ill	Very much improved	4.00				
				34	25FEB92	Normal	Very much improved	4.00				
				36	09MAR92	Borderline mentally ill	Very much improved	4.00				
				38	23MAR92	Normal	Very much improved	4.00				
				40	07APR92	Borderline mentally ill	Very much improved	4.00				
				42	22APR92	Borderline mentally ill	Very much improved	4.00				
				44	05MAY92	Mildly ill	Much improved	3.00				
				46	19MAY92	Borderline mentally ill	Very much improved	4.00				
				48	02JUN92	Normal	Very much improved	4.00				
				50	16JUN92	Normal	Very much improved	4.00				
				52	30JUN92	Normal	Very much improved	4.00				
				1	25	21	AHR	8	30AUG91	Normal	Very much improved	4.00
								10	13SEP91	Normal	Very much improved	4.00
								12	27SEP91	Normal	Very much improved	4.00
								14	11OCT91	Normal	Very much improved	4.00
16	25OCT91	Normal	Very much improved					4.00				
18	08NOV91	Normal	Very much improved					4.00				
20	22NOV91	Normal	Very much improved					4.00				
22	06DEC91	Normal	Very much improved					4.00				
24	20DEC91	Normal	Very much improved					4.00				
26	03JAN92	Normal	Very much improved					4.00				
28	17JAN92	Normal	Very much improved					4.00				
30	31JAN92	Normal	Very much improved					4.00				
32	14FEB92	Normal	Very much improved					4.00				
34	28FEB92	Normal	Very much improved					4.00				
36	13MAR92	Normal	Very much improved					4.00				
38	27MAR92	Normal	Very much improved					4.00				
40	10APR92	Normal	Very much improved					4.00				
42	24APR92	Normal	Very much improved					4.00				
44	08MAY92	Normal	Very much improved					4.00				
46	22MAY92	Normal	Very much improved					4.00				
48	05JUN92	Normal	Very much improved	4.00								
50	19JUN92	Normal	Very much improved	4.00								
52	03JUL92	Normal	Very much improved	4.00								
1	31	27	MAN	8	17SEP91	Normal	Very much improved	4.00				
				10	01OCT91	Normal	Very much improved	4.00				
				12	15OCT91	Borderline mentally ill	Very much improved	4.00				
				14	29OCT91	Normal	Very much improved	4.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Date	Severity of Illness	Global Improvement	Efficacy Index
1	31	27	HAM	16	12NOV91	Normal	Very much improved	4.00
				18	26NOV91	Borderline mentally ill	Very much improved	4.00
				20	10DEC91	Borderline mentally ill	Very much improved	4.00
				22	24DEC91	Borderline mentally ill	Very much improved	4.00
				24	07JAN92	Normal	Very much improved	4.00
				26	21JAN92	Borderline mentally ill	Very much improved	4.00
				28	04FEB92	Borderline mentally ill	Very much improved	4.00
				30	18FEB92	Borderline mentally ill	Very much improved	4.00
				32	04MAR92	Normal	Very much improved	4.00
				34	17MAR92	Normal	Very much improved	4.00
				36	31MAR92	Normal	Very much improved	4.00
				38	14APR92	Normal	Very much improved	4.00
				40	28APR92	Normal	Very much improved	4.00
				42	12MAY92	Normal	Very much improved	4.00
				44	26MAY92	Normal	Very much improved	4.00
				46	09JUN92	Normal	Very much improved	4.00
				48	23JUN92	Normal	Very much improved	4.00
				50	07JUL92	Normal	Very much improved	4.00
				52	21JUL92	Normal	Very much improved	4.00
				1	32	28	DGM	8
10	02OCT91	Borderline mentally ill	Very much improved					4.00
12	16OCT91	Borderline mentally ill	Very much improved					4.00
14	30OCT91	Borderline mentally ill	Very much improved					4.00
16	13NOV91	Mildly ill	Much improved					3.00
18	27NOV91	Mildly ill	Much improved					3.00
20	14DEC91	Mildly ill	Much improved					3.00
22	28DEC91	Mildly ill	Much improved					3.00
24	08JAN92	Borderline mentally ill	Very much improved					4.00
26	22JAN92	Borderline mentally ill	Very much improved					4.00
28	05FEB92	Borderline mentally ill	Very much improved					4.00
30	19FEB92	Borderline mentally ill	Very much improved					4.00
32	04MAR92	Borderline mentally ill	Very much improved					4.00
34	18MAR92	Borderline mentally ill	Very much improved					4.00
36	01APR92	Mildly ill	Much improved					3.00
38	15APR92	Mildly ill	Much improved					3.00
40	29APR92	Normal	Very much improved					4.00
42	13MAY92	Normal	Very much improved					4.00
44	27MAY92	Normal	Very much improved					4.00
46	10JUN92	Normal	Very much improved					4.00
48	24JUN92	Normal	Very much improved	4.00				
50	08JUL92	Normal	Very much improved	4.00				
52	22JUL92	Normal	Very much improved	4.00				
1	34	30	GMH	8	09OCT91	Normal	Very much improved	2.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOMETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOMETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
1	34	30	GMH	10	23OCT91	Normal	Very much improved	2.00				
				12	06NOV91	Borderline mentally ill	Very much improved	2.00				
				14	20NOV91	Borderline mentally ill	Very much improved	2.00				
				16	04DEC91	Borderline mentally ill	Very much improved	4.00				
				18	18DEC91	Borderline mentally ill	Very much improved	4.00				
				20	02JAN92	Borderline mentally ill	Very much improved	4.00				
				22	15JAN92	Normal	Very much improved	4.00				
				24	29JAN92	Mildly ill	Much improved	1.50				
				26	12FEB92	Normal	Very much improved	2.00				
				28	26FEB92	Borderline mentally ill	Much improved	2.00				
				30	11MAR92	Normal	Very much improved	2.00				
				32	25MAR92	Mildly ill	Much improved	2.00				
				34	08APR92	Borderline mentally ill	Very much improved	4.00				
				36	22APR92	Borderline mentally ill	Very much improved	4.00				
				38	06MAY92	Mildly ill	Much improved	3.00				
				40	20MAY92	Mildly ill	Much improved	3.00				
				42	03JUN92	Normal	Very much improved	4.00				
				44	17JUN92	Normal	Very much improved	4.00				
				46	01JUL92	Borderline mentally ill	Very much improved	4.00				
				48	15JUL92	Mildly ill	Much improved	3.00				
				50	29JUL92	Borderline mentally ill	Much improved	3.00				
				52	12AUG92	Borderline mentally ill	Very much improved	4.00				
				1	35	301	EMP	8	22OCT91	Normal	Very much improved	4.00
								10	05NOV91	Normal	Very much improved	4.00
								12	19NOV91	Normal	Very much improved	4.00
								14	03DEC91	Normal	Very much improved	4.00
16	17DEC91	Normal	Very much improved					4.00				
18	31DEC91	Normal	Very much improved					4.00				
20	14JAN92	Normal	Very much improved					4.00				
22	28JAN92	Normal	Very much improved					4.00				
24	11FEB92	Normal	Very much improved					4.00				
26	23FEB92	Normal	Very much improved					4.00				
28	08MAR92	Normal	Very much improved					4.00				
30	24MAR92	Normal	Very much improved					4.00				
32	07APR92	Borderline mentally ill	Very much improved					4.00				
34	22APR92	Borderline mentally ill	Very much improved					4.00				
36	05MAY92	Normal	Very much improved					4.00				
38	19MAY92	Normal	Very much improved					4.00				
40	02JUN92	Normal	Very much improved					4.00				
42	16JUN92	Normal	Very much improved					4.00				
44	30JUN92	Normal	Very much improved	4.00								
46	14JUL92	Normal	Very much improved	4.00								
48	28JUL92	Normal	Very much improved	4.00								
50	11AUG92	Normal	Very much improved	4.00								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	35	301	ENP	52	25AUG92	Normal	Very much improved	4.00
1	37	303	RF	8	29OCT91	Normal	Very much improved	4.00
				10	12NOV91	Normal	Very much improved	4.00
				12	26NOV91	Borderline mentally ill	Very much improved	4.00
				14	10DEC91	Normal	Very much improved	4.00
				16	24DEC91	Normal	Very much improved	4.00
				18	07JAN92	Normal	Very much improved	4.00
				20	21JAN92	Normal	Very much improved	4.00
				22	04FEB92	Normal	Very much improved	4.00
				24	18FEB92	Normal	Very much improved	4.00
				26	04MAR92	Normal	Very much improved	4.00
				28	17MAR92	Normal	Very much improved	4.00
				30	31MAR92	Normal	Very much improved	4.00
				32	14APR92	Normal	Very much improved	4.00
				34	28APR92	Normal	Very much improved	4.00
				36	12MAY92	Normal	Very much improved	4.00
				38	26MAY92	Normal	Very much improved	4.00
				40	09JUN92	Normal	Very much improved	4.00
				42	23JUN92	Normal	Very much improved	4.00
				44	07JUL92	Normal	Very much improved	4.00
				46	21JUL92	Normal	Very much improved	4.00
				48	04AUG92	Normal	Very much improved	4.00
				50	18AUG92	Normal	Very much improved	4.00
				52	01SEP92	Normal	Very much improved	4.00
1	39	305	ASS	8	19NOV91	Borderline mentally ill	Very much improved	4.00
				10	03DEC91	Normal	Very much improved	4.00
				12	17DEC91	Normal	Very much improved	4.00
				14	31DEC91	Normal	Very much improved	4.00
				16	14JAN92	Borderline mentally ill	Very much improved	4.00
				18	28JAN92	Borderline mentally ill	Very much improved	4.00
				20	11FEB92	Normal	Very much improved	4.00
				22	25FEB92	Normal	Very much improved	4.00
				24	09MAR92	Normal	Very much improved	4.00
				26	24MAR92	Normal	Very much improved	4.00
				28	07APR92	Normal	Very much improved	4.00
				30	22APR92	Normal	Very much improved	4.00
				32	06MAY92	Borderline mentally ill	Very much improved	4.00
				34	19MAY92	Mildly ill	Much improved	3.00
				36	02JUN92	Mildly ill	Much improved	3.00
				38	16JUN92	Mildly ill	Much improved	3.00
				40	30JUN92	Normal	Very much improved	4.00
				42	14JUL92	Normal	Very much improved	4.00
				44	28JUL92	Borderline mentally ill	Very much improved	4.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
1	39	305	ASS	46	11AUG92	Borderline mentally ill	Very much improved	4.00				
				48	25AUG92	Borderline mentally ill	Very much improved	4.00				
				50	08SEP92	Mildly ill	Much improved	3.00				
				52	22SEP92	Mildly ill	Much improved	3.00				
				8	27NOV91	Normal	Very much improved	2.00				
1	43	309	ARN	10	11DEC91	Normal	Very much improved	2.00				
				12	26DEC91	Normal	Very much improved	2.00				
				14	07JAN92	Normal	Very much improved	2.00				
				16	21JAN92	Borderline mentally ill	Very much improved	2.00				
				18	04FEB92	Normal	Very much improved	2.00				
				20	18FEB92	Normal	Very much improved	2.00				
				22	04MAR92	Normal	Very much improved	2.00				
				24	18MAR92	Normal	Very much improved	2.00				
				26	01APR92	Normal	Very much improved	2.00				
				28	15APR92	Normal	Very much improved	2.00				
				30	29APR92	Normal	Very much improved	2.00				
				32	13MAY92	Normal	Very much improved	2.00				
				34	27MAY92	Normal	Very much improved	2.00				
				36	10JUN92	Normal	Very much improved	2.00				
				38	24JUN92	Normal	Very much improved	2.00				
				40	08JUL92	Normal	Very much improved	2.00				
				42	22JUL92	Normal	Very much improved	2.00				
				44	05AUG92	Normal	Very much improved	2.00				
				46	19AUG92	Normal	Very much improved	2.00				
				48	02SEP92	Normal	Very much improved	2.00				
				50	16SEP92	Normal	Very much improved	2.00				
				52	30SEP92	Normal	Very much improved	2.00				
				1	45	310	DPS	8	09DEC91	Normal	Very much improved	4.00
								10	17DEC91	Normal	Very much improved	4.00
								12	31DEC91	Normal	Very much improved	4.00
								14	14JAN92	Normal	Very much improved	4.00
								16	28JAN92	Normal	Very much improved	4.00
								18	11FEB92	Normal	Very much improved	4.00
20	25FEB92	Normal	Very much improved					4.00				
22	10MAR92	Normal	Very much improved					4.00				
24	24MAR92	Normal	Very much improved					4.00				
26	07APR92	Normal	Very much improved					4.00				
28	22APR92	Normal	Very much improved					4.00				
30	05MAY92	Normal	Very much improved					4.00				
32	19MAY92	Normal	Very much improved	4.00								
34	02JUN92	Normal	Very much improved	4.00								
36	16JUN92	Normal	Very much improved	4.00								
38	30JUN92	Normal	Very much improved	4.00								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXYETINE - PROTOCOL 20124/013
 Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
 DOUBLE BLIND PHASE
 TREATMENT: REBOXYETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
1	45	310	DFS	40	14JUL92	Normal	Very much improved	4.00				
				42	28JUL92	Normal	Very much improved	4.00				
				44	11AUG92	Normal	Very much improved	4.00				
				46	25AUG92	Normal	Very much improved	4.00				
				48	08SEP92	Borderline mentally ill	Very much improved	4.00				
				50	22SEP92	Normal	Very much improved	4.00				
				52	06OCT92	Normal	Very much improved	4.00				
				1	46	311	SP	8	10DEC91	Normal	Very much improved	4.00
								10	24DEC91	Borderline mentally ill	Very much improved	4.00
								12	07JAN92	Normal	Very much improved	4.00
14	21JAN92	Borderline mentally ill	Very much improved					4.00				
16	04FEB92	Normal	Very much improved					4.00				
18	18FEB92	Normal	Very much improved					4.00				
20	04MAR92	Normal	Very much improved					4.00				
22	17MAR92	Normal	Very much improved					4.00				
24	31MAR92	Normal	Very much improved					4.00				
26	14APR92	Normal	Very much improved					4.00				
1	48	313	SCH	8	18DEC91	Borderline mentally ill	Very much improved	4.00				
				10	02JAN92	Borderline mentally ill	Very much improved	4.00				
				12	15JAN92	Mildly ill	Much improved	3.00				
				14	29JAN92	Borderline mentally ill	Very much improved	4.00				
				16	12FEB92	Mildly ill	Much improved	3.00				
				18	26FEB92	Normal	Very much improved	4.00				
				20	11MAR92	Borderline mentally ill	Very much improved	4.00				
				22	25MAR92	Borderline mentally ill	Very much improved	4.00				
				24	08APR92	Normal	Very much improved	4.00				
				26	22APR92	Borderline mentally ill	Very much improved	4.00				
1	48	313	SCH	28	06MAY92	Normal	Very much improved	4.00				
				30	20MAY92	Normal	Very much improved	4.00				
				32	03JUN92	Normal	Very much improved	4.00				
				34	17JUN92	Normal	Very much improved	4.00				
				36	01JUL92	Normal	Very much improved	4.00				
				38	15JUL92	Normal	Very much improved	4.00				
				40	29JUL92	Normal	Very much improved	4.00				
				42	12AUG92	Normal	Very much improved	4.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	D.S. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
1	48	313	SCH	34	17JUN92	Normal	Very much improved	4.00				
				36	01JUL92	Normal	Very much improved	4.00				
				38	15JUL92	Borderline mentally ill	Very much improved	4.00				
				40	29JUL92	Borderline mentally ill	Very much improved	4.00				
				42	12AUG92	Borderline mentally ill	Very much improved	4.00				
				44	26AUG92	Borderline mentally ill	Very much improved	4.00				
				46	09SEP92	Normal	Very much improved	4.00				
				48	23SEP92	Borderline mentally ill	Very much improved	4.00				
				50	07OCT92	Borderline mentally ill	Very much improved	4.00				
				52	21OCT92	Borderline mentally ill	Very much improved	4.00				
				1	52	316	MIS	8	26DEC91	Borderline mentally ill	Very much improved	4.00
								10	08JAN92	Normal	Very much improved	4.00
								12	22JAN92	Normal	Very much improved	2.00
								14	05FEB92	Borderline mentally ill	Very much improved	2.00
16	19FEB92	Borderline mentally ill	Very much improved					2.00				
18	04MAR92	Mildly ill	Much improved					1.50				
20	18MAR92	Borderline mentally ill	Very much improved					2.00				
22	01APR92	Borderline mentally ill	Very much improved					2.00				
24	15APR92	Borderline mentally ill	Very much improved					2.00				
26	29APR92	Borderline mentally ill	Very much improved					2.00				
28	13MAY92	Normal	Very much improved					2.00				
30	27MAY92	Normal	Very much improved					2.00				
32	10JUN92	Normal	Very much improved					2.00				
34	24JUN92	Normal	Very much improved					2.00				
36	08JUL92	Normal	Very much improved	2.00								
38	22JUL92	Normal	Very much improved	2.00								
40	05AUG92	Normal	Very much improved	2.00								
42	19AUG92	Normal	Very much improved	2.00								
44	02SEP92	Normal	Very much improved	2.00								
46	16SEP92	Normal	Very much improved	2.00								
48	30SEP92	Borderline mentally ill	Very much improved	2.00								
50	14OCT92	Normal	Very much improved	2.00								
52	28OCT92	Normal	Very much improved	2.00								
1	55	318	DMG	8	31DEC91	Normal	Very much improved	4.00				
				10	14JAN92	Mildly ill	Much improved	1.50				
				12	28JAN92	Moderately ill	Minimally improved	1.00				
				14	11FEB92	Moderately ill	Minimally improved	1.00				
1	56	319	IAL	8	31DEC91	Mildly ill	Much improved	0.75				
				8	04FEB92	Borderline mentally ill	Very much improved	2.00				
1	58	320	ARM	10	18FEB92	Normal	Very much improved	2.00				
				12	04MAR92	Normal	Very much improved	2.00				

Source: www.clinicaltrials.gov

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	58	320	ARM	14	17MAR92	Moderately ill	Minimally improved	1.00
				16	31MAR92	Moderately ill	Minimally improved	0.67
1	61	323	HVC	8	14FEB92	Borderline mentally ill	Very much improved	2.00
				10	28FEB92	Normal	Very much improved	2.00
				12	13MAR92	Normal	Very much improved	2.00
				14	27MAR92	Normal	Very much improved	2.00
				16	10APR92	Normal	Very much improved	2.00
				18	24APR92	Normal	Very much improved	2.00
				20	08MAY92	Normal	Very much improved	2.00
				22	22MAY92	Normal	Very much improved	2.00
				24	05JUN92	Normal	Very much improved	2.00
				26	19JUN92	Normal	Very much improved	2.00
				28	03JUL92	Normal	Very much improved	2.00
				30	17JUL92	Normal	Very much improved	2.00
				32	31JUL92	Normal	Very much improved	2.00
				34	14AUG92	Normal	Very much improved	2.00
				36	28AUG92	Normal	Very much improved	2.00
				38	11SEP92	Normal	Very much improved	2.00
				40	25SEP92	Normal	Very much improved	2.00
				42	09OCT92	Normal	Very much improved	2.00
				44	23OCT92	Normal	Very much improved	2.00
				46	06NOV92	Normal	Very much improved	2.00
				48	20NOV92	Normal	Very much improved	2.00
				50	04DEC92	Normal	Very much improved	2.00
				52	18DEC92	Normal	Very much improved	2.00
1	66	326	TCG	8	17MAR92	Borderline mentally ill	Very much improved	2.00
				10	31MAR92	Normal	Very much improved	4.00
				12	14APR92	Normal	Very much improved	2.00
				14	28APR92	Normal	Very much improved	2.00
				16	12MAY92	Normal	Very much improved	2.00
				18	26MAY92	Normal	Very much improved	2.00
				20	09JUN92	Normal	Very much improved	2.00
				22	23JUN92	Normal	Very much improved	2.00
				24	07JUL92	Normal	Very much improved	2.00
				26	21JUL92	Normal	Very much improved	2.00
				28	04AUG92	Normal	Very much improved	2.00
				30	18AUG92	Normal	Very much improved	2.00
				32	01SEP92	Normal	Very much improved	2.00
				34	15SEP92	Normal	Very much improved	2.00
				36	29SEP92	Normal	Very much improved	2.00
				38	13OCT92	Normal	Very much improved	2.00
				40	27OCT92	Normal	Very much improved	2.00
				42	10NOV92	Normal	Very much improved	2.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	66	326	TCG	44	24NOV92	Normal	Very much improved	2.00
				46	06DEC92	Normal	Very much improved	2.00
				48	22DEC92	Normal	Very much improved	2.00
				50	05JAN93	Normal	Very much improved	2.00
				52	19JAN93	Normal	Very much improved	2.00
1	71	329	OKV	8	24MAR92	Borderline mentally ill	Very much improved	4.00
				10	07APR92	Borderline mentally ill	Very much improved	4.00
				12	22APR92	Borderline mentally ill	Very much improved	4.00
				14	05MAY92	Borderline mentally ill	Very much improved	4.00
				16	19MAY92	Borderline mentally ill	Very much improved	4.00
				18	02JUN92	Borderline mentally ill	Very much improved	4.00
				20	16JUN92	Borderline mentally ill	Very much improved	4.00
				22	30JUN92	Borderline mentally ill	Very much improved	4.00
				24	14JUL92	Normal	Very much improved	4.00
				26	28JUL92	Normal	Very much improved	4.00
				28	11AUG92	Normal	Very much improved	4.00
				30	25AUG92	Normal	Very much improved	4.00
				32	08SEP92	Borderline mentally ill	Very much improved	4.00
				34	22SEP92	Borderline mentally ill	Very much improved	4.00
				36	06OCT92	Borderline mentally ill	Very much improved	4.00
				38	20OCT92	Borderline mentally ill	Very much improved	4.00
				40	03NOV92	Normal	Very much improved	4.00
				42	17NOV92	Normal	Very much improved	4.00
				44	01DEC92	Normal	Very much improved	4.00
				46	15DEC92	Normal	Very much improved	4.00
				48	29DEC92	Normal	Very much improved	4.00
				50	12JAN93	Borderline mentally ill	Very much improved	4.00
52	26JAN93	Borderline mentally ill	Very much improved	4.00				
1	72	330	RLJ	8	24MAR92	Borderline mentally ill	Very much improved	4.00
				10	07APR92	Normal	Very much improved	4.00
				12	20APR92	Normal	Very much improved	2.00
				14	05MAY92	Normal	Very much improved	2.00
				16	19MAY92	Normal	Very much improved	2.00
1	73	121	FMA	18	02JUN92	Normal	Very much improved	2.00
				20	16JUN92	Normal	Very much improved	2.00
				22	30JUN92	Normal	Very much improved	4.00
				8	24MAR92	Normal	Very much improved	2.00
				10	07APR92	Normal	Very much improved	2.00
				12	22APR92	Normal	Very much improved	2.00
1	14	05MAY92	Normal	14	05MAY92	Normal	Very much improved	2.00
				16	19MAY92	Normal	Very much improved	2.00
				18	02JUN92	Normal	Very much improved	2.00
				20	16JUN92	Normal	Very much improved	2.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
1	73	121	FMA	20	16JUN92	Normal	Very much improved	2.00				
				22	30JUN92	Normal	Very much improved	2.00				
				24	14JUL92	Mildly ill	Much improved	1.50				
				26	28JUL92	Moderately ill	Minimally improved	1.00				
				8	27MAR92	Normal	Very much improved	4.00				
				10	10APR92	Borderline mentally ill	Very much improved	4.00				
1	75	123	ELF	12	24APR92	Borderline mentally ill	Very much improved	4.00				
				14	08MAY92	Normal	Very much improved	4.00				
				16	22MAY92	Normal	Very much improved	4.00				
				18	05JUN92	Normal	Very much improved	4.00				
				20	19JUN92	Borderline mentally ill	Very much improved	4.00				
				22	03JUL92	Normal	Very much improved	4.00				
				24	17JUL92	Normal	Very much improved	4.00				
				26	31JUL92	Normal	Very much improved	4.00				
				28	14AUG92	Borderline mentally ill	Very much improved	4.00				
				30	28AUG92	Mildly ill	Much improved	3.00				
				32	11SEP92	Mildly ill	Much improved	3.00				
				34	25SEP92	Borderline mentally ill	Very much improved	4.00				
				36	09OCT92	Borderline mentally ill	Very much improved	4.00				
				38	23OCT92	Borderline mentally ill	Very much improved	4.00				
				40	06NOV92	Normal	Very much improved	4.00				
				42	20NOV92	Borderline mentally ill	Very much improved	4.00				
				44	04DEC92	Borderline mentally ill	Very much improved	4.00				
				46	18DEC92	Borderline mentally ill	Very much improved	4.00				
				48	31DEC92	Borderline mentally ill	Very much improved	4.00				
				50	15JAN93	Borderline mentally ill	Very much improved	4.00				
				52	29JAN93	Normal	Very much improved	4.00				
				1	77	125	ACG	8	03APR92	Borderline mentally ill	Very much improved	1.33
								10	17APR92	Borderline mentally ill	Very much improved	1.33
								12	30APR92	Borderline mentally ill	Very much improved	1.33
								14	15MAY92	Borderline mentally ill	Very much improved	1.33
								16	29MAY92	Borderline mentally ill	Very much improved	1.33
18	12JUN92	Borderline mentally ill	Very much improved					1.33				
20	26JUN92	Normal	Very much improved					1.33				
22	10JUL92	Borderline mentally ill	Very much improved					1.33				
24	24JUL92	Normal	Very much improved					1.33				
26	07AUG92	Borderline mentally ill	Very much improved					1.33				
28	21AUG92	Normal	Very much improved					1.33				
30	04SEP92	Normal	Very much improved					2.00				
32	18SEP92	Normal	Very much improved					2.00				
34	02OCT92	Normal	Very much improved					2.00				
36	16OCT92	Normal	Very much improved					2.00				
38	30OCT92	Normal	Very much improved					2.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 RESOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
 DOUBLE BLIND PHASE
 TREATMENT: RESOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
1	77	125	ACG	40	13NOV92	Normal	Very much improved	2.00				
				42	27NOV92	Normal	Very much improved	2.00				
				44	11DEC92	Normal	Very much improved	2.00				
				46	24DEC92	Normal	Very much improved	2.00				
				48	08JAN93	Normal	Very much improved	4.00				
				50	22JAN93	Normal	Very much improved	4.00				
				52	05FEB93	Normal	Very much improved	4.00				
				1	81	128	MFS	8	03APR92	Normal	Very much improved	2.00
								10	17APR92	Normal	Very much improved	2.00
								12	30APR92	Normal	Very much improved	2.00
								14	15MAY92	Normal	Very much improved	2.00
								16	29MAY92	Normal	Very much improved	2.00
								18	12JUN92	Normal	Very much improved	2.00
								20	19JUN92	Normal	Very much improved	2.00
								22	10JUL92	Normal	Very much improved	2.00
								24	24JUL92	Normal	Very much improved	2.00
26	07AUG92	Borderline mentally ill	Very much improved					2.00				
28	21AUG92	Normal	Very much improved					2.00				
30	04SEF92	Borderline mentally ill	Very much improved					2.00				
32	18SEF92	Normal	Very much improved					2.00				
34	02OCT92	Normal	Very much improved					2.00				
36	16OCT92	Normal	Very much improved					2.00				
38	30OCT92	Normal	Very much improved					2.00				
40	13NOV92	Normal	Very much improved	2.00								
42	27NOV92	Normal	Very much improved	2.00								
44	11DEC92	Normal	Very much improved	2.00								
46	24DEC92	Normal	Very much improved	2.00								
48	08JAN93	Normal	Very much improved	4.00								
50	22JAN93	Normal	Very much improved	4.00								
52	05FEB93	Normal	Very much improved	4.00								
1	82	129	MDS	8	03APR92	Borderline mentally ill	Very much improved	2.00				
				10	17APR92	Normal	Very much improved	2.00				
				12	30APR92	Normal	Very much improved	2.00				
				14	15MAY92	Borderline mentally ill	Very much improved	2.00				
				16	29MAY92	Borderline mentally ill	Very much improved	2.00				
				18	12JUN92	Borderline mentally ill	Much improved	1.50				
				20	26JUN92	Normal	Very much improved	2.00				
				22	10JUL92	Normal	Very much improved	2.00				
				24	24JUL92	Normal	Very much improved	2.00				
				26	07AUG92	Normal	Very much improved	2.00				
				28	21AUG92	Normal	Very much improved	2.00				
				30	04SEF92	Normal	Very much improved	4.00				
				32	18SEF92	Normal	Very much improved	4.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
1	82	129	MDS	34	02OCT92	Normal	Very much improved	2.00				
				36	16OCT92	Normal	Very much improved	2.00				
				38	30OCT92	Normal	Very much improved	2.00				
				40	13NOV92	Normal	Very much improved	2.00				
				42	27NOV92	Normal	Very much improved	2.00				
				44	10DEC92	Normal	Very much improved	2.00				
				46	24DEC92	Normal	Very much improved	2.00				
				48	08JAN93	Normal	Very much improved	2.00				
				50	22JAN93	Normal	Very much improved	2.00				
				52	05FEB93	Normal	Very much improved	2.00				
				1	87	152	MDO	8	03APR92	Normal	Very much improved	2.00
								10	17APR92	Borderline mentally ill	Very much improved	2.00
								12	30APR92	Borderline mentally ill	Very much improved	2.00
								14	15MAY92	Borderline mentally ill	Very much improved	2.00
16	29MAY92	Borderline mentally ill	Very much improved					2.00				
18	12JUN92	Mildly ill	Much improved					1.50				
20	26JUN92	Mildly ill	Much improved					1.50				
22	10JUL92	Moderately ill	Minimally improved					1.00				
1	89	133	NHV					8	07APR92	Mildly ill	Much improved	3.00
								10	20APR92	Moderately ill	Minimally improved	2.00
				12	05MAY92	Moderately ill	Minimally improved	2.00				
				14	19MAY92	Moderately ill	Minimally improved	2.00				
				1	90	134	JSS	8	07APR92	Mildly ill	Much improved	1.00
								1	95	GNT	8	08APR92
10	22APR92	Normal	Very much improved	2.00								
				12	06MAY92	Normal	Very much improved	2.00				
				14	20MAY92	Normal	Very much improved	2.00				
				16	03JUN92	Normal	Very much improved	2.00				
				18	17JUN92	Normal	Very much improved	2.00				
				20	01JUL92	Normal	Very much improved	2.00				
				22	15JUL92	Normal	Very much improved	2.00				
				24	29JUL92	Normal	Very much improved	2.00				
				26	12AUG92	Normal	Very much improved	2.00				
				28	26AUG92	Normal	Very much improved	2.00				
				30	09SEF92	Normal	Very much improved	2.00				
				32	23SEF92	Normal	Very much improved	2.00				
				34	07OCT92	Normal	Very much improved	2.00				
				36	21OCT92	Normal	Very much improved	2.00				
				38	04NOV92	Normal	Very much improved	2.00				
				40	18NOV92	Normal	Very much improved	2.00				
				42	02DEC92	Normal	Very much improved	2.00				

11882

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 70.3

CLINICAL GLOBAL IMPRESSION (CGI)
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
1	95	138	GMT	44	16DEC92	Normal	Very much improved	2.00				
				46	30DEC92	Normal	Very much improved	2.00				
				48	13JAN93	Normal	Very much improved	2.00				
				50	27JAN93	Normal	Very much improved	2.00				
				52	10FEB93	Normal	Very much improved	2.00				
				1	96	139	SPH	8	08APR92	Normal	Very much improved	2.00
								10	22APR92	Normal	Very much improved	2.00
								12	06MAY92	Normal	Very much improved	2.00
								14	20MAY92	Normal	Very much improved	4.00
								16	03JUN92	Normal	Very much improved	2.00
18	17JUN92	Normal	Very much improved					2.00				
20	01JUL92	Normal	Very much improved					2.00				
22	15JUL92	Normal	Very much improved					2.00				
24	29JUL92	Borderline mentally ill	Very much improved					2.00				
26	12AUG92	Borderline mentally ill	Very much improved					2.00				
28	26AUG92	Borderline mentally ill	Very much improved	2.00								
30	09SEP92	Borderline mentally ill	Very much improved	2.00								
32	23SEP92	Borderline mentally ill	Very much improved	2.00								
34	07OCT92	Borderline mentally ill	Very much improved	2.00								
36	21OCT92	Borderline mentally ill	Very much improved	2.00								
38	04NOV92	Borderline mentally ill	Very much improved	2.00								
40	18NOV92	Borderline mentally ill	Very much improved	2.00								
42	02DEC92	Borderline mentally ill	Very much improved	2.00								
44	16DEC92	Normal	Very much improved	2.00								
46	30DEC92	Normal	Very much improved	2.00								
48	13JAN93	Normal	Very much improved	2.00								
50	27JAN93	Normal	Very much improved	2.00								
52	10FEB93	Normal	Very much improved	2.00								
1	98	141	YTT	8	08APR92	Normal	Very much improved	2.00				
				10	22APR92	Normal	Very much improved	2.00				
				12	06MAY92	Normal	Very much improved	2.00				
				14	20MAY92	Normal	Very much improved	2.00				
				16	03JUN92	Normal	Very much improved	2.00				
				18	17JUN92	Normal	Very much improved	2.00				
				20	01JUL92	Normal	Very much improved	2.00				
				22	15JUL92	Normal	Very much improved	2.00				
				24	29JUL92	Normal	Very much improved	2.00				
				26	12AUG92	Normal	Very much improved	2.00				
28	26AUG92	Borderline mentally ill	Very much improved	2.00								
30	09SEP92	Borderline mentally ill	Very much improved	2.00								
32	23SEP92	Normal	Very much improved	2.00								
34	07OCT92	Normal	Very much improved	2.00								
36	21OCT92	Normal	Very much improved	2.00								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centro	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
1	98	141	VTT	38	04NOV92	Normal	Very much improved	2.00				
				40	18NOV92	Normal	Very much improved	2.00				
				42	02DEC92	Normal	Very much improved	2.00				
				44	16DEC92	Normal	Very much improved	2.00				
				46	30DEC92	Normal	Very much improved	2.00				
				48	13JAN93	Normal	Very much improved	2.00				
				50	27JAN93	Normal	Very much improved	2.00				
				52	10FEB93	Normal	Very much improved	2.00				
				1	101	143	JLL	8	14APR92	Normal	Very much improved	4.00
								10	28APR92	Normal	Very much improved	4.00
								12	12MAY92	Normal	Very much improved	4.00
								14	26MAY92	Normal	Very much improved	4.00
16	09JUN92	Normal	Very much improved					4.00				
18	23JUN92	Normal	Very much improved					4.00				
20	07JUL92	Normal	Very much improved					4.00				
22	21JUL92	Normal	Very much improved					4.00				
24	04AUG92	Normal	Very much improved					2.00				
26	18AUG92	Normal	Very much improved					2.00				
28	01SEP92	Normal	Very much improved					2.00				
30	15SEP92	Normal	Very much improved					2.00				
32	29SEP92	Normal	Very much improved	4.00								
34	13OCT92	Normal	Very much improved	4.00								
36	27OCT92	Normal	Very much improved	4.00								
38	10NOV92	Normal	Very much improved	4.00								
40	24NOV92	Normal	Very much improved	4.00								
42	08DEC92	Normal	Very much improved	4.00								
44	22DEC92	Normal	Very much improved	4.00								
46	05JAN93	Normal	Very much improved	4.00								
48	19JAN93	Normal	Very much improved	4.00								
50	02FEB93	Normal	Very much improved	4.00								
52	16FEB93	Normal	Very much improved	4.00								
1	107	147	LAN	8	15APR92	Normal	Very much improved	2.00				
				10	29APR92	Normal	Very much improved	2.00				
				12	13MAY92	Normal	Very much improved	2.00				
				14	27MAY92	Normal	Very much improved	2.00				
				16	10JUN92	Normal	Very much improved	2.00				
				18	24JUN92	Normal	Very much improved	2.00				
				20	08JUL92	Normal	Very much improved	2.00				
				22	22JUL92	Normal	Very much improved	2.00				
				24	04AUG92	Normal	Very much improved	2.00				
				26	18AUG92	Normal	Very much improved	2.00				
				28	01SEP92	Normal	Very much improved	2.00				
				30	15SEP92	Normal	Very much improved	2.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
1	107	147	LAN	32	29SEP92	Normal	Very much improved	2.00				
				34	13OCT92	Normal	Very much improved	2.00				
				36	27OCT92	Normal	Very much improved	2.00				
				38	10NOV92	Normal	Very much improved	2.00				
				40	24NOV92	Normal	Very much improved	2.00				
				42	08DEC92	Normal	Very much improved	2.00				
				44	22DEC92	Normal	Very much improved	2.00				
				46	05JAN93	Normal	Very much improved	2.00				
				48	19JAN93	Normal	Very much improved	2.00				
				50	02FEB93	Borderline mentally ill	Very much improved	2.00				
				52	16FEB93	Normal	Very much improved	2.00				
				1	109	149	IPL	8	15APR92	Normal	Very much improved	2.00
								10	29APR92	Normal	Very much improved	2.00
								12	13MAY92	Borderline mentally ill	Very much improved	2.00
								14	27MAY92	Borderline mentally ill	Very much improved	2.00
								16	10JUN92	Borderline mentally ill	Very much improved	2.00
18	24JUN92	Borderline mentally ill	Very much improved					2.00				
20	08JUL92	Borderline mentally ill	Very much improved					2.00				
22	22JUL92	Borderline mentally ill	Very much improved					2.00				
24	05AUG92	Normal	Very much improved					2.00				
26	19AUG92	Normal	Very much improved					2.00				
28	02SEP92	Normal	Very much improved					2.00				
30	16SEP92	Borderline mentally ill	Very much improved					2.00				
32	30SEP92	Borderline mentally ill	Very much improved					2.00				
34	14OCT92	Borderline mentally ill	Very much improved					2.00				
36	28OCT92	Borderline mentally ill	Very much improved					2.00				
38	11NOV92	Borderline mentally ill	Very much improved					2.00				
40	25NOV92	Normal	Very much improved	2.00								
42	09DEC92	Normal	Very much improved	2.00								
44	23DEC92	Normal	Very much improved	2.00								
46	06JAN93	Normal	Very much improved	2.00								
48	19JAN93	Normal	Very much improved	2.00								
50	03FEB93	Normal	Very much improved	2.00								
52	17FEB93	Normal	Very much improved	2.00								
1	110	150	TQO	8	15APR92	Normal	Very much improved	4.00				
				10	29APR92	Normal	Very much improved	4.00				
				12	13MAY92	Normal	Very much improved	4.00				
				14	27MAY92	Normal	Very much improved	4.00				
				16	10JUN92	Normal	Very much improved	4.00				
				18	24JUN92	Normal	Very much improved	4.00				
				20	08JUL92	Normal	Very much improved	4.00				
				22	22JUL92	Normal	Very much improved	4.00				
24	05AUG92	Normal	Very much improved	4.00								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOMETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOMETINE

Centre	Patient	D.S. Patient	Initials	Visit No.	Date	Severity of Illness	Global Improvement	Efficacy Index				
1	110	150	TQO	26	19AUG92	Normal	Very much improved	4.00				
				28	02SEP92	Normal	Very much improved	4.00				
				30	16SEP92	Normal	Very much improved	4.00				
				32	30SEP92	Normal	Very much improved	4.00				
				34	14OCT92	Normal	Very much improved	4.00				
				36	28OCT92	Normal	Very much improved	4.00				
				38	11NOV92	Normal	Very much improved	4.00				
				40	25NOV92	Normal	Very much improved	4.00				
				42	09DEC92	Normal	Very much improved	4.00				
				44	23DEC92	Normal	Very much improved	4.00				
				46	06JAN93	Normal	Very much improved	4.00				
				48	19JAN93	Normal	Very much improved	4.00				
				50	03FEB93	Normal	Very much improved	4.00				
				52	17FEB93	Normal	Very much improved	4.00				
				1	116	354	MGA	8	22APR92	Normal	Very much improved	2.00
								10	05MAY92	Normal	Very much improved	2.00
								12	19MAY92	Normal	Very much improved	2.00
								14	02JUN92	Normal	Very much improved	2.00
16	16JUN92	Normal	Very much improved					2.00				
18	30JUN92	Normal	Very much improved					2.00				
20	14JUL92	Normal	Very much improved					2.00				
22	28JUL92	Normal	Very much improved					2.00				
24	12AUG92	Normal	Very much improved					2.00				
26	26AUG92	Normal	Very much improved					2.00				
28	09SEP92	Normal	Very much improved					2.00				
30	23SEP92	Normal	Very much improved					2.00				
32	07OCT92	Normal	Very much improved					2.00				
34	21OCT92	Normal	Very much improved					2.00				
36	04NOV92	Normal	Very much improved					2.00				
38	18NOV92	Normal	Very much improved					2.00				
40	01DEC92	Normal	Very much improved					2.00				
42	15DEC92	Normal	Very much improved					2.00				
44	29DEC92	Normal	Very much improved	2.00								
46	12JAN93	Normal	Very much improved	2.00								
48	26JAN93	Normal	Very much improved	2.00								
50	09FEB93	Normal	Very much improved	2.00								
52	24FEB93	Normal	Very much improved	2.00								
1	117	355	PSL	8	22APR92	Normal	Very much improved	4.00				
				10	05MAY92	Normal	Very much improved	4.00				
				12	19MAY92	Normal	Very much improved	4.00				
				14	02JUN92	Normal	Very much improved	4.00				
				16	16JUN92	Normal	Very much improved	4.00				
18	30JUN92	Borderline mentally ill	Very much improved	4.00								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOMETINE - PROTOCOL 20124-013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOMETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
1	117	335	PSL	20	14JUL92	Normal	Very much improved	4.00				
				22	28JUL92	Normal	Very much improved	4.00				
				24	12AUG92	Borderline mentally ill	Very much improved	4.00				
				26	26AUG92	Normal	Very much improved	4.00				
				28	09SEP92	Normal	Very much improved	4.00				
				30	25SEP92	Normal	Very much improved	4.00				
				32	07OCT92	Borderline mentally ill	Very much improved	4.00				
				34	27OCT92	Mildly ill	Much improved	3.00				
				36	04NOV92	Normal	Very much improved	4.00				
				38	18NOV92	Normal	Very much improved	4.00				
				40	01DEC92	Normal	Very much improved	4.00				
				42	15DEC92	Normal	Very much improved	4.00				
				44	29DEC92	Normal	Very much improved	4.00				
				46	12JAN93	Borderline mentally ill	Very much improved	4.00				
				48	26JAN93	Borderline mentally ill	Very much improved	4.00				
				50	09FEB93	Borderline mentally ill	Very much improved	4.00				
				52	24FEB93	Borderline mentally ill	Very much improved	4.00				
				1	121	336	LAC	8	22APR92	Normal	Very much improved	4.00
								10	06MAY92	Normal	Very much improved	4.00
								12	20MAY92	Normal	Very much improved	4.00
14	03JUN92	Normal	Very much improved					4.00				
16	17JUN92	Normal	Very much improved					4.00				
18	01JUL92	Normal	Very much improved					4.00				
20	15JUL92	Normal	Very much improved					4.00				
22	29JUL92	Normal	Very much improved					4.00				
24	12AUG92	Normal	Very much improved					4.00				
26	26AUG92	Normal	Very much improved					4.00				
28	09SEP92	Normal	Very much improved					4.00				
30	23SEP92	Normal	Very much improved					4.00				
32	07OCT92	Normal	Very much improved					4.00				
34	21OCT92	Borderline mentally ill	Very much improved					4.00				
36	04NOV92	Normal	Very much improved					4.00				
38	18NOV92	Normal	Very much improved					4.00				
40	02DEC92	Normal	Very much improved					4.00				
42	16DEC92	Normal	Very much improved					4.00				
44	30DEC92	Normal	Very much improved					4.00				
46	13JAN93	Normal	Very much improved					4.00				
48	27JAN93	Normal	Very much improved	4.00								
50	10FEB93	Normal	Very much improved	4.00								
52	24FEB93	Normal	Very much improved	4.00								
1	123	338	MLL	8	22APR92	Normal	Very much improved	4.00				
				10	06MAY92	Normal	Very much improved	4.00				
				12	20MAY92	Normal	Very much improved	4.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
1	123	338	MLL	14	03JUN92	Normal	Very much improved	4.00				
				16	17JUN92	Normal	Very much improved	4.00				
				18	04JUL92	Normal	Very much improved	4.00				
				20	15JUL92	Normal	Very much improved	4.00				
				22	29JUL92	Normal	Very much improved	4.00				
				24	12AUG92	Normal	Very much improved	4.00				
				26	26AUG92	Normal	Very much improved	2.00				
				28	09SEP92	Borderline mentally ill	Very much improved	4.00				
				30	23SEP92	Normal	Very much improved	4.00				
				32	07OCT92	Borderline mentally ill	Very much improved	2.00				
				34	21OCT92	Normal	Very much improved	4.00				
				36	04NOV92	Normal	Very much improved	2.00				
				38	18NOV92	Normal	Very much improved	4.00				
				40	02DEC92	Borderline mentally ill	Very much improved	4.00				
				42	16DEC92	Borderline mentally ill	Very much improved	4.00				
				44	30DEC92	Borderline mentally ill	Very much improved	4.00				
				46	13JAN93	Borderline mentally ill	Very much improved	4.00				
				48	27JAN93	Borderline mentally ill	Very much improved	4.00				
				50	10FEB93	Mildly ill	Much improved	4.00				
				52	24FEB93	Mildly ill	Much improved	3.00				
				1	125	340	FDP	8	22APR92	Borderline mentally ill	Very much improved	2.00
								10	06MAY92	Borderline mentally ill	Very much improved	2.00
								12	20MAY92	Mildly ill	Much improved	1.50
								14	03JUN92	Mildly ill	Much improved	1.50
								16	17JUN92	Mildly ill	Much improved	1.50
								18	01JUL92	Mildly ill	Much improved	1.50
								20	15JUL92	Mildly ill	Much improved	1.50
								22	29JUL92	Mildly ill	Much improved	1.50
								24	12AUG92	Borderline mentally ill	Very much improved	2.00
								26	26AUG92	Borderline mentally ill	Very much improved	2.00
28	09SEP92	Mildly ill	Much improved					1.50				
30	23SEP92	Mildly ill	Much improved					1.50				
32	07OCT92	Borderline mentally ill	Very much improved					2.00				
34	21OCT92	Mildly ill	Much improved					1.50				
36	04NOV92	Borderline mentally ill	Very much improved					2.00				
38	18NOV92	Mildly ill	Much improved					1.50				
40	02DEC92	Borderline mentally ill	Very much improved	2.00								
42	16DEC92	Borderline mentally ill	Very much improved	2.00								
44	30DEC92	Borderline mentally ill	Very much improved	2.00								
46	13JAN93	Normal	Very much improved	2.00								
48	27JAN93	Normal	Very much improved	2.00								
50	10FEB93	Normal	Very much improved	2.00								
52	24FEB93	Normal	Very much improved	2.00								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
1	127	342	VPD	8	22APR92	Normal	Very much improved	2.00				
				10	06MAY92	Normal	Very much improved	2.00				
				12	20MAY92	Mildly ill	Much improved	1.50				
				14	03JUN92	Borderline mentally ill	Very much improved	2.00				
				16	17JUN92	Borderline mentally ill	Very much improved	2.00				
				18	01JUL92	Borderline mentally ill	Very much improved	2.00				
				20	15JUL92	Mildly ill	Much improved	1.50				
				22	29JUL92	Mildly ill	Much improved	1.50				
				24	13AUG92	Borderline mentally ill	Very much improved	2.00				
				26	26AUG92	Normal	Very much improved	2.00				
				28	09SEP92	Normal	Very much improved	2.00				
				30	23SEP92	Normal	Very much improved	2.00				
				32	07OCT92	Normal	Very much improved	2.00				
				34	21OCT92	Normal	Very much improved	2.00				
				36	04NOV92	Normal	Very much improved	2.00				
				38	18NOV92	Normal	Very much improved	2.00				
				40	02DEC92	Normal	Very much improved	2.00				
				42	16DEC92	Normal	Very much improved	2.00				
				44	30DEC92	Normal	Very much improved	2.00				
				46	13JAN93	Borderline mentally ill	Very much improved	2.00				
				48	27JAN93	Borderline mentally ill	Very much improved	2.00				
				50	10FEB93	Normal	Very much improved	2.00				
				52	24FEB93	Normal	Very much improved	2.00				
				1	128	343	LAM	8	22APR92	Normal	Very much improved	2.00
								10	06MAY92	Normal	Very much improved	2.00
								12	20MAY92	Normal	Very much improved	2.00
								14	03JUN92	Normal	Very much improved	2.00
								16	17JUN92	Normal	Very much improved	2.00
18	01JUL92	Normal	Very much improved					2.00				
20	15JUL92	Normal	Very much improved					2.00				
22	29JUL92	Normal	Very much improved					2.00				
24	12AUG92	Normal	Very much improved					2.00				
26	26AUG92	Normal	Very much improved					2.00				
28	09SEP92	Normal	Very much improved					2.00				
30	23SEP92	Normal	Very much improved					2.00				
32	07OCT92	Normal	Very much improved					2.00				
34	21OCT92	Normal	Very much improved					2.00				
36	04NOV92	Normal	Very much improved					2.00				
38	18NOV92	Normal	Very much improved					2.00				
40	02DEC92	Borderline mentally ill	Very much improved	2.00								
42	16DEC92	Normal	Very much improved	2.00								
44	30DEC92	Normal	Very much improved	2.00								
46	13JAN93	Normal	Very much improved	2.00								
48	27JAN93	Normal	Very much improved	2.00								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	128	343	LAM	50	10FEB93	Normal	Very much improved	2.00
				52	24FEB93	Normal	Very much improved	2.00
1	134	347	LMS	8	19MAY92	Normal	Very much improved	4.00
				10	02JUN92	Normal	Very much improved	4.00
				12	16JUN92	Normal	Very much improved	4.00
				14	30JUN92	Normal	Very much improved	4.00
				16	14JUL92	Normal	Very much improved	4.00
				18	28JUL92	Normal	Very much improved	4.00
				20	11AUG92	Normal	Very much improved	4.00
				22	25AUG92	Normal	Very much improved	4.00
				24	08SEP92	Normal	Very much improved	4.00
				26	22SEP92	Normal	Very much improved	4.00
				28	06OCT92	Normal	Very much improved	4.00
				30	20OCT92	Normal	Very much improved	4.00
				32	03NOV92	Normal	Very much improved	4.00
				34	17NOV92	Normal	Very much improved	4.00
				36	01DEC92	Normal	Very much improved	4.00
				38	15DEC92	Normal	Very much improved	4.00
				40	29DEC92	Normal	Very much improved	4.00
				42	12JAN93	Normal	Very much improved	4.00
				44	26JAN93	Normal	Very much improved	4.00
				46	09FEB93	Normal	Very much improved	4.00
48	24FEB93	Normal	Very much improved	4.00				
50	09MAR93	Normal	Very much improved	4.00				
52	23MAR93	Normal	Very much improved	4.00				
1	135	348	MMS	8	19MAY92	Normal	Very much improved	2.00
				10	02JUN92	Normal	Very much improved	2.00
				12	16JUN92	Normal	Very much improved	2.00
				14	30JUN92	Normal	Very much improved	2.00
				16	14JUL92	Normal	Very much improved	2.00
				18	28JUL92	Normal	Very much improved	2.00
				20	11AUG92	Normal	Very much improved	2.00
				22	25AUG92	Normal	Very much improved	2.00
				24	08SEP92	Normal	Very much improved	2.00
				26	22SEP92	Normal	Very much improved	2.00
				28	06OCT92	Normal	Very much improved	2.00
				30	20OCT92	Normal	Very much improved	2.00
32	03NOV92	Normal	Very much improved	2.00				
34	17NOV92	Normal	Very much improved	2.00				
36	01DEC92	Normal	Very much improved	2.00				
38	15DEC92	Normal	Very much improved	2.00				
40	29DEC92	Normal	Very much improved	2.00				
42	12JAN93	Normal	Very much improved	2.00				

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
1	135	348	MMS	44	26JAN93	Normal	Very much improved	2.00				
				46	08FEB93	Normal	Very much improved	4.00				
				48	24FEB93	Normal	Very much improved	4.00				
				50	09MAR93	Normal	Very much improved	4.00				
				52	23MAR93	Normal	Very much improved	4.00				
				1	139	351	RA	8	19MA92	Normal	Very much improved	2.00
								10	02JUN92	Normal	Very much improved	2.00
								12	16JUN92	Normal	Very much improved	2.00
								14	30JUN92	Normal	Very much improved	2.00
								16	14JUL92	Normal	Very much improved	2.00
18	28JUL92	Normal	Very much improved					2.00				
20	11AUG92	Normal	Very much improved					2.00				
22	25AUG92	Normal	Very much improved					2.00				
24	08SEP92	Normal	Very much improved					2.00				
26	22SEP92	Normal	Very much improved					2.00				
1	140	352	MCA	28	06OCT92	Normal	Very much improved	2.00				
				30	20OCT92	Normal	Very much improved	2.00				
				32	03NOV92	Normal	Very much improved	2.00				
				34	17NOV92	Normal	Very much improved	2.00				
				36	01DEC92	Normal	Very much improved	2.00				
				38	15DEC92	Normal	Very much improved	2.00				
				40	29DEC92	Normal	Very much improved	2.00				
				42	12JAN93	Normal	Very much improved	2.00				
				44	26JAN93	Normal	Very much improved	2.00				
				46	09FEB93	Normal	Very much improved	2.00				
1	140	352	MCA	48	24FEB93	Normal	Very much improved	2.00				
				50	09MAR93	Normal	Very much improved	2.00				
				52	23MAR93	Normal	Very much improved	2.00				
				8	19MA92	Normal	Very much improved	4.00				
				10	02JUN92	Normal	Very much improved	4.00				
				12	16JUN92	Normal	Very much improved	4.00				
				14	30JUN92	Mildly ill	Much improved	3.00				
				16	14JUL92	Borderline mentally ill	Much improved	4.00				
				18	28JUL92	Normal	Very much improved	4.00				
				20	11AUG92	Normal	Very much improved	4.00				
1	140	352	MCA	22	25AUG92	Normal	Very much improved	4.00				
				24	08SEP92	Normal	Very much improved	4.00				
				26	22SEP92	Normal	Very much improved	4.00				
				28	06OCT92	Normal	Very much improved	4.00				
				30	20OCT92	Normal	Very much improved	4.00				
				32	03NOV92	Normal	Very much improved	4.00				
				34	17NOV92	Normal	Very much improved	4.00				
				36	01DEC92	Normal	Very much improved	4.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
1	140	352	MCA	38	15DEC92	Normal	Very much improved	4.00				
				40	29DEC92	Normal	Very much improved	4.00				
				42	12JAN93	Normal	Very much improved	4.00				
				44	26JAN93	Normal	Very much improved	4.00				
				46	09FEB93	Normal	Very much improved	4.00				
				48	24FEB93	Normal	Very much improved	4.00				
				50	09MAR93	Normal	Very much improved	4.00				
				52	23MAR93	Normal	Very much improved	4.00				
				1	142	354	SCC	8	19MAY92	Normal	Very much improved	4.00
								10	02JUN92	Normal	Very much improved	4.00
								12	16JUN92	Normal	Very much improved	4.00
								14	30JUN92	Normal	Very much improved	4.00
								16	14JUL92	Normal	Very much improved	4.00
								18	28JUL92	Normal	Very much improved	4.00
								20	11AUG92	Normal	Very much improved	4.00
								22	25AUG92	Normal	Very much improved	4.00
								24	08SEP92	Normal	Very much improved	4.00
26	22SEP92	Normal	Very much improved					4.00				
28	06OCT92	Normal	Very much improved					4.00				
30	20OCT92	Normal	Very much improved					4.00				
32	03NOV92	Normal	Very much improved					4.00				
34	17NOV92	Normal	Very much improved					4.00				
36	01DEC92	Normal	Very much improved					4.00				
38	15DEC92	Normal	Very much improved					4.00				
40	29DEC92	Normal	Very much improved					4.00				
42	12JAN93	Normal	Very much improved	4.00								
44	09FEB93	Normal	Very much improved	4.00								
46	24FEB93	Normal	Very much improved	4.00								
48	09MAR93	Normal	Very much improved	4.00								
50	23MAR93	Normal	Very much improved	4.00								
52	23MAR93	Normal	Very much improved	4.00								
1	144	356	ARF	8	20MAY92	Borderline mentally ill	Very much improved	4.00				
				10	03JUN92	Borderline mentally ill	Very much improved	4.00				
				12	17JUN92	Borderline mentally ill	Very much improved	4.00				
				14	01JUL92	Borderline mentally ill	Very much improved	4.00				
				16	15JUL92	Borderline mentally ill	Very much improved	4.00				
				18	29JUL92	Normal	Very much improved	4.00				
				20	12AUG92	Borderline mentally ill	Very much improved	4.00				
				22	26AUG92	Borderline mentally ill	Very much improved	4.00				
				24	09SEP92	Mildly ill	Much improved	3.00				
				26	23SEP92	Mildly ill	Much improved	3.00				
28	07OCT92	Mildly ill	Much improved	3.00								
30	21OCT92	Mildly ill	Much improved	3.00								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of illness	Global Improvement	Efficacy Index
1	144	356	ARF	32	04NOV92	Mildly ill	Much improved	3.00
				34	18NOV92	Mildly ill	Much improved	3.00
				36	02DEC92	Mildly ill	Much improved	3.00
				38	16DEC92	Moderately ill	Minimally improved	2.00
				8	22MAY92	Mildly ill	Much improved	1.50
				10	05JUN92	Borderline mentally ill	Very much improved	2.00
				12	19JUN92	Borderline mentally ill	Very much improved	2.00
				14	03JUL92	Mildly ill	Very much improved	2.00
1	146	358	LRH	16	17JUL92	Mildly ill	Much improved	1.50
				18	31JUL92	Mildly ill	Much improved	3.00
				20	14AUG92	Borderline mentally ill	Very much improved	4.00
				22	28AUG92	Mildly ill	Much improved	3.00
				24	11SEF92	Normal	Very much improved	2.00
				26	25SEF92	Borderline mentally ill	Very much improved	2.00
				28	09OCT92	Normal	Very much improved	2.00
				30	23OCT92	Borderline mentally ill	Very much improved	2.00
				32	06NOV92	Borderline mentally ill	Very much improved	2.00
				34	20NOV92	Mildly ill	Much improved	1.50
				36	04DEC92	Borderline mentally ill	Very much improved	2.00
				38	18DEC92	Borderline mentally ill	Very much improved	2.00
				40	31DEC92	Mildly ill	Much improved	1.50
				42	15JAN93	Mildly ill	Much improved	1.50
				44	29JAN93	Mildly ill	Much improved	1.50
				46	12FEB93	Normal	Very much improved	2.00
48	26FEB93	Mildly ill	Much improved	1.50				
50	12MAR93	Mildly ill	Much improved	1.50				
52	26MAR93	Mildly ill	Much improved	1.50				
1	148	359	CMS	8	22MAY92	Normal	Very much improved	2.00
				10	05JUN92	Normal	Very much improved	2.00
				12	19JUN92	Normal	Very much improved	2.00
				14	03JUL92	Normal	Very much improved	2.00
				16	17JUL92	Normal	Very much improved	2.00
				18	31JUL92	Normal	Very much improved	2.00
				20	14AUG92	Normal	Very much improved	2.00
				22	28AUG92	Normal	Very much improved	2.00
				24	11SEF92	Normal	Very much improved	2.00
				26	25SEF92	Normal	Very much improved	2.00
				28	09OCT92	Normal	Very much improved	2.00
				30	23OCT92	Normal	Very much improved	2.00
				32	06NOV92	Normal	Very much improved	2.00
				34	20NOV92	Normal	Very much improved	2.00
				36	04DEC92	Normal	Very much improved	2.00
				38	18DEC92	Normal	Very much improved	2.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	148	359	CAS	40	31DEC92	Normal	Very much improved	2.00
				42	15JAN93	Normal	Very much improved	2.00
				44	29JAN93	Normal	Very much improved	2.00
				46	12FEB93	Normal	Very much improved	4.00
				48	26FEB93	Normal	Very much improved	4.00
				50	12MAR93	Normal	Very much improved	4.00
				52	26MAR93	Normal	Very much improved	4.00
3	7	71	GRI	8	05FEB91	Moderately ill	Minimally improved	0.67
				10	12FEB91	Moderately ill	Minimally improved	0.67
8	212	212	TE	8	07FEB91	Normal	Very much improved	4.00
				10	21FEB91	Normal	Very much improved	4.00
				12	07MAR91	Normal	Very much improved	4.00
				14	21MAR91	Normal	Very much improved	4.00
				16	04APR91	Normal	Very much improved	4.00
				18	18APR91	Normal	Very much improved	4.00
				20	02MAY91	Normal	Very much improved	4.00
				22	16MAY91	Normal	Very much improved	4.00
				24	30MAY91	Normal	Very much improved	4.00
				26	13JUN91	Normal	Very much improved	4.00
				28	27JUN91	Normal	Very much improved	4.00
				30	11JUL91	Normal	Very much improved	4.00
				32	25JUL91	Normal	Very much improved	4.00
				34	08AUG91	Normal	Very much improved	4.00
36	22AUG91	Normal	Very much improved	4.00				
38	05SEP91	Normal	Very much improved	4.00				
40	19SEP91	Normal	Very much improved	4.00				
42	03OCT91	Normal	Very much improved	4.00				
44	17OCT91	Normal	Very much improved	4.00				
46	31OCT91	Normal	Very much improved	4.00				
48	14NOV91	Normal	Very much improved	4.00				
50	28NOV91	Normal	Very much improved	4.00				
52	12DEC91	Normal	Very much improved	4.00				
8	3	213	JL	8	14FEB91	Borderline mentally ill	Much improved	4.00
				10	28FEB91	Moderately ill	Minimally improved	3.00
				12	14MAR91	Moderately ill	Minimally improved	3.00
				14	28MAR91	Moderately ill	Minimally improved	3.00
				16	11APR91	Moderately ill	Minimally improved	2.00
8	6	216	TL	8	18MAR91	Borderline mentally ill	Very much improved	4.00
				10	02APR91	Borderline mentally ill	Very much improved	4.00
				12	15APR91	Borderline mentally ill	Very much improved	4.00
				14	29APR91	Borderline mentally ill	Very much improved	4.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOMETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOMETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
8	6	216	TL	16	13MAY91	Borderline mentally ill	Very much improved	4.00				
				18	27MAY91	Borderline mentally ill	Very much improved	4.00				
				20	10JUN91	Borderline mentally ill	Very much improved	4.00				
				22	24JUN91	Borderline mentally ill	Very much improved	4.00				
				24	08JUL91	Normal	Very much improved	4.00				
				26	22JUL91	Normal	Very much improved	4.00				
				28	05AUG91	Normal	Very much improved	4.00				
				30	19AUG91	Normal	Very much improved	4.00				
				32	02SEP91	Normal	Very much improved	4.00				
				34	16SEP91	Normal	Very much improved	4.00				
				36	30SEP91	Normal	Very much improved	4.00				
				38	14OCT91	Normal	Very much improved	4.00				
				42	11NOV91	Normal	Very much improved	4.00				
				44	25NOV91	Normal	Very much improved	4.00				
				46	09DEC91	Normal	Very much improved	4.00				
				48	23DEC91	Normal	Very much improved	4.00				
				50	06JAN92	Normal	Very much improved	4.00				
				52	20JAN92	Normal	Very much improved	4.00				
				9	6	245	SD	8	01JAN91	Borderline mentally ill	Much improved	4.00
								10	15JAN91	Borderline mentally ill	Very much improved	4.00
12	29JAN91	Borderline mentally ill	Very much improved					4.00				
14	12FEB91	Borderline mentally ill	Very much improved					4.00				
16	26FEB91	Borderline mentally ill	Very much improved					4.00				
18	12MAR91	Borderline mentally ill	Very much improved					4.00				
20	26MAR91	Borderline mentally ill	Very much improved					4.00				
22	09APR91	Borderline mentally ill	Very much improved					4.00				
24	23APR91	Borderline mentally ill	Very much improved					4.00				
26	07MAY91	Borderline mentally ill	Very much improved					4.00				
28	21MAY91	Borderline mentally ill	Very much improved					4.00				
30	04JUN91	Borderline mentally ill	Very much improved					4.00				
32	18JUN91	Normal	Very much improved					4.00				
34	02JUL91	Normal	Very much improved					4.00				
36	16JUL91	Normal	Very much improved					4.00				
38	30JUL91	Normal	Very much improved					4.00				
40	13AUG91	Normal	Very much improved					4.00				
42	27AUG91	Normal	Very much improved					4.00				
44	10SEP91	Normal	Very much improved					4.00				
46	24SEP91	Normal	Very much improved					4.00				
48	08OCT91	Normal	Very much improved	4.00								
50	22OCT91	Normal	Very much improved	4.00								
52	05NOV91	Normal	Very much improved	4.00								
9	7	243	PP	8	03JAN91	Borderline mentally ill	Very much improved	4.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
9	7	243	PP	10	17JAN91	Mildly ill	Much improved	4.00				
				12	31JAN91	Borderline mentally ill	Very much improved	4.00				
				14	14FEB91	Borderline mentally ill	Very much improved	4.00				
				16	28FEB91	Borderline mentally ill	Very much improved	4.00				
				18	14MAR91	Normal	Very much improved	4.00				
				20	28MAR91	Borderline mentally ill	Very much improved	4.00				
				22	11APR91	Borderline mentally ill	Very much improved	4.00				
				24	25APR91	Borderline mentally ill	Very much improved	4.00				
				26	09MAY91	Normal	Very much improved	4.00				
				28	23MAY91	Normal	Very much improved	4.00				
				30	06JUN91	Normal	Very much improved	4.00				
				32	20JUN91	Normal	Very much improved	4.00				
				34	04JUL91	Normal	Very much improved	4.00				
				36	18JUL91	Normal	Very much improved	4.00				
				38	01AUG91	Normal	Very much improved	4.00				
				40	15AUG91	Normal	Very much improved	4.00				
				42	29AUG91	Normal	Very much improved	4.00				
				44	12SEF91	Normal	Very much improved	4.00				
				46	26SEF91	Normal	Very much improved	4.00				
				48	10OCT91	Normal	Very much improved	4.00				
				50	24OCT91	Normal	Very much improved	4.00				
				52	07NOV91	Normal	Very much improved	4.00				
				9	11	246	KE	8	26MAR91	Borderline mentally ill	Very much improved	4.00
								10	09APR91	Borderline mentally ill	Very much improved	4.00
								12	23APR91	Moderately ill	Minimally improved	2.00
								14	07MAY91	Severely ill	Minimally worse	1.00
								16	21MAY91	Mildly ill	Much improved	3.00
								18	04JUN91	Borderline mentally ill	Much improved	3.00
								20	18JUN91	Borderline mentally ill	Very much improved	4.00
								22	02JUL91	Borderline mentally ill	Very much improved	4.00
								24	16JUL91	Borderline mentally ill	Very much improved	4.00
								26	30JUL91	Borderline mentally ill	Very much improved	4.00
28	13AUG91	Borderline mentally ill	Very much improved					4.00				
30	27AUG91	Borderline mentally ill	Very much improved					4.00				
32	10SEF91	Borderline mentally ill	Very much improved					4.00				
34	24SEF91	Borderline mentally ill	Very much improved					4.00				
36	08OCT91	Normal	Very much improved					4.00				
38	22OCT91	Normal	Very much improved					4.00				
40	05NOV91	Normal	Very much improved	4.00								
42	19NOV91	Normal	Very much improved	4.00								
44	03DEC91	Normal	Very much improved	4.00								
46	17DEC91	Normal	Very much improved	4.00								
48	31DEC91	Normal	Very much improved	4.00								
50	14JAN92	Normal	Very much improved	4.00								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
9	11	246	KE	52	28JAN92	Normal	Very much improved	4.00
9	15	249	BI	8	14JUL91	Borderline mentally ill	Very much improved	4.00
				10	28JUL91	Borderline mentally ill	Very much improved	4.00
				12	11AUG91	Borderline mentally ill	Very much improved	4.00
				14	25AUG91	Mildly ill	Much improved	4.00
				16	08SEP91	Borderline mentally ill	Very much improved	4.00
				18	22SEP91	Borderline mentally ill	Much improved	4.00
				20	06OCT91	Borderline mentally ill	Much improved	4.00
				22	20OCT91	Borderline mentally ill	Much improved	4.00
				24	03NOV91	Mildly ill	Much improved	4.00
				26	17NOV91	Mildly ill	Much improved	4.00
				28	01DEC91	Mildly ill	Much improved	4.00
				30	15DEC91	Mildly ill	Much improved	4.00
				32	29DEC91	Mildly ill	Much improved	4.00
				34	12JAN92	Mildly ill	Much improved	4.00
				36	26JAN92	Mildly ill	Much improved	4.00
				38	09FEB92	Borderline mentally ill	Very much improved	4.00
				40	23FEB92	Mildly ill	Much improved	4.00
				42	08MAR92	Borderline mentally ill	Very much improved	4.00
				44	22MAR92	Mildly ill	Very much improved	4.00
				46	05APR92	Borderline mentally ill	Very much improved	4.00
				48	19APR92	Borderline mentally ill	Very much improved	4.00
				50	03MAY92	Borderline mentally ill	Much improved	4.00
				52	17MAY92	Borderline mentally ill	Very much improved	4.00
9	16	250	UGV	8	03SEP91	Mildly ill	Much improved	3.00
				10	17SEP91	Borderline mentally ill	Much improved	4.00
				12	01OCT91	Borderline mentally ill	Very much improved	4.00
				14	15OCT91	Borderline mentally ill	Very much improved	4.00
				16	29OCT91	Borderline mentally ill	Much improved	4.00
				18	12NOV91	Borderline mentally ill	Much improved	4.00
				20	26NOV91	Borderline mentally ill	Much improved	4.00
				22	10DEC91	Borderline mentally ill	Much improved	4.00
				24	24DEC91	Borderline mentally ill	Much improved	4.00
				26	07JAN92	Borderline mentally ill	Much improved	4.00
				28	21JAN92	Borderline mentally ill	Much improved	4.00
				30	04FEB92	Normal	Very much improved	4.00
				32	18FEB92	Borderline mentally ill	Very much improved	4.00
				34	03MAR92	Borderline mentally ill	Very much improved	4.00
				36	17MAR92	Borderline mentally ill	Very much improved	4.00
				38	31MAR92	Borderline mentally ill	Very much improved	4.00
				40	14APR92	Borderline mentally ill	Very much improved	4.00
				42	28APR92	Borderline mentally ill	Very much improved	4.00
				44	12MAY92	Borderline mentally ill	Very much improved	4.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of illness	Global Improvement	Efficacy Index
9	16	250	UGY	46	26MAY92	Borderline mentally ill	Very much improved	4.00
				48	09JUN92	Borderline mentally ill	Very much improved	4.00
				50	23JUN92	Borderline mentally ill	Much improved	4.00
				52	07JUL92	Borderline mentally ill	Very much improved	4.00
9	20	252	GVE	8	18OCT91	Mildly ill	Much improved	3.00
				10	01NOV91	Mildly ill	Much improved	3.00
				12	15NOV91	Mildly ill	Much improved	3.00
				14	29NOV91	Moderately ill	Minimally improved	3.00
				16	13DEC91	Mildly ill	Much improved	3.00
				18	27DEC91	Markedly ill	Minimally improved	2.00
9	23	256	SZN	8	03JAN92	Borderline mentally ill	Much improved	3.00
				10	17JAN92	Mildly ill	Much improved	4.00
				12	31JAN92	Mildly ill	Much improved	3.00
				14	14FEB92	Mildly ill	Much improved	3.00
				16	28FEB92	Mildly ill	Much improved	3.00
				18	13MAR92	Mildly ill	Much improved	4.00
				20	27MAR92	Borderline mentally ill	Very much improved	4.00
				8	16JAN92	Borderline mentally ill	Very much improved	4.00
				10	30JAN92	Borderline mentally ill	Very much improved	4.00
				12	13FEB92	Borderline mentally ill	Very much improved	4.00
9	26	255	CP	14	27FEB92	Borderline mentally ill	Very much improved	4.00
				16	12MAR92	Borderline mentally ill	Very much improved	4.00
				18	26MAR92	Borderline mentally ill	Much improved	4.00
				20	09APR92	Borderline mentally ill	Very much improved	4.00
				22	23APR92	Borderline mentally ill	Very much improved	4.00
				8	01JUN92	Borderline mentally ill	Very much improved	4.00
				10	15JUN92	Borderline mentally ill	Very much improved	4.00
				12	29JUN92	Borderline mentally ill	Very much improved	4.00
				14	13JUL92	Borderline mentally ill	Very much improved	4.00
				16	27JUL92	Borderline mentally ill	Very much improved	4.00
9	29	258	SZF	18	10AUG92	Borderline mentally ill	Very much improved	4.00
				20	24AUG92	Borderline mentally ill	Very much improved	4.00
				22	07SEP92	Borderline mentally ill	Very much improved	4.00
				24	21SEP92	Borderline mentally ill	Very much improved	4.00
				26	05OCT92	Borderline mentally ill	Much improved	4.00
				28	19OCT92	Borderline mentally ill	Very much improved	4.00
9	30	259	NF	8	01JUN92	Borderline mentally ill	Very much improved	4.00
				10	15JUN92	Borderline mentally ill	Very much improved	4.00
10	1	271	VK	8	10DEC90	Borderline mentally ill	Very much improved	2.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D			REBOXETINE - PROTOCOL 20124/013		Listing No.: 10.3		CLINICAL GLOBAL IMPRESSION (CGI)			DOUBLE BLIND PHASE		TREATMENT: REBOXETINE		Efficacy Index
Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement					Efficacy Index		
10	1	271	VK	10	27DEC90	Mildly ill	Very much improved					2.00		
				12	07JAN91	Mildly ill	Very much improved					2.00		
				14	21JAN91	Borderline mentally ill	Very much improved					2.00		
				16	04FEB91	Borderline mentally ill	Very much improved					2.00		
10	7	274	RK	8	16JAN91	Borderline mentally ill	Very much improved					2.00		
10	9	275	RT	8	28JAN91	Mildly ill	Very much improved					4.00		
				9	05FEB91	Borderline mentally ill	Very much improved					4.00		
10	12	277	EP	8	06MAR91	Moderately ill	Much improved					3.00		
				10	20MAR91	Moderately ill	Much improved					3.00		
10	13	278	HU	8	08APR91	Moderately ill	Very much improved					2.00		
10	15	280	HT	8	17APR91	Borderline mentally ill	Very much improved					2.00		
				10	30APR91	Borderline mentally ill	Very much improved					2.00		
10	20	285	EJ	8	17JUN91	Mildly ill	Very much improved					4.00		
				10	01JUL91	Mildly ill	Very much improved					4.00		
				12	15JUL91	Borderline mentally ill	Very much improved					4.00		
				14	29JUL91	Borderline mentally ill	Very much improved					4.00		
				16	12AUG91	Borderline mentally ill	Very much improved					4.00		
				18	26AUG91	Borderline mentally ill	Very much improved					4.00		
				20	09SEP91	Borderline mentally ill	Very much improved					4.00		
				22	23SEP91	Borderline mentally ill	Very much improved					4.00		
				24	07OCT91	Borderline mentally ill	Very much improved					4.00		
				26	21OCT91	Borderline mentally ill	Very much improved					4.00		
				28	04NOV91	Borderline mentally ill	Very much improved					4.00		
10	22	286	AA	8	17JUN91	Mildly ill	Very much improved					4.00		
				10	01JUL91	Mildly ill	Very much improved					4.00		
				12	15JUL91	Mildly ill	Very much improved					4.00		
				14	29JUL91	Mildly ill	Very much improved					4.00		
				16	12AUG91	Mildly ill	Very much improved					4.00		
				18	26AUG91	Mildly ill	Very much improved					4.00		
				20	09SEP91	Moderately ill	Minimally improved					2.00		
				22	23SEP91	Moderately ill	Much improved					3.00		
				24	07OCT91	Mildly ill	Much improved					3.00		
				26	21OCT91	Mildly ill	Much improved					3.00		
				28	04NOV91	Mildly ill	Much improved					3.00		
				30	18NOV91	Mildly ill	Very much improved					4.00		
				32	02DEC91	Borderline mentally ill	Very much improved					4.00		
				34	16DEC91	Mildly ill	Very much improved					4.00		
				36	30DEC91	Borderline mentally ill	Very much improved					4.00		

1200

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
10	22	286	AA	38	13JAN92	Borderline mentally ill	Very much improved	4.00				
				40	27JAN92	Borderline mentally ill	Very much improved	4.00				
				42	10FEB92	Borderline mentally ill	Very much improved	4.00				
				44	24FEB92	Borderline mentally ill	Very much improved	4.00				
				46	09MAR92	Borderline mentally ill	Very much improved	4.00				
				48	23MAR92	Borderline mentally ill	Very much improved	4.00				
				50	06APR92	Borderline mentally ill	Very much improved	4.00				
				52	21APR92	Borderline mentally ill	Very much improved	4.00				
				10	23	287	LT	8	18JUN91	Moderately ill	Very much improved	4.00
								10	02JUL91	Mildly ill	Very much improved	4.00
								12	16JUL91	Mildly ill	Very much improved	4.00
								14	30JUL91	Moderately ill	Much improved	3.00
16	13AUG91	Moderately ill	Much improved					3.00				
18	26AUG91	Moderately ill	Much improved					3.00				
20	10SEP91	Moderately ill	Much improved					3.00				
22	24SEP91	Moderately ill	Minimally improved					2.00				
24	08OCT91	Mildly ill	Very much improved					4.00				
26	23OCT91	Mildly ill	Very much improved					4.00				
28	05NOV91	Mildly ill	Very much improved					4.00				
30	19NOV91	Mildly ill	Very much improved					4.00				
32	03DEC91	Mildly ill	Very much improved	4.00								
34	17DEC91	Mildly ill	Very much improved	4.00								
36	30DEC91	Moderately ill	Much improved	3.00								
38	14JAN92	Markedly ill	Minimally improved	2.00								
40	28JAN92	Moderately ill	Much improved	3.00								
42	11FEB92	Moderately ill	Much improved	3.00								
44	25FEB92	Moderately ill	Much improved	3.00								
10	26	290	JIF	8	22JUL91	Mildly ill	Very much improved	4.00				
				10	05AUG91	Markedly ill	Minimally improved	2.00				
10	27	292	MK	8	29JUL91	Mildly ill	Very much improved	4.00				
				10	12AUG91	Mildly ill	Very much improved	2.00				
				12	26AUG91	Mildly ill	Very much improved	4.00				
				14	09SEP91	Mildly ill	Very much improved	4.00				
				16	23SEP91	Mildly ill	Very much improved	4.00				
				18	07OCT91	Mildly ill	Very much improved	4.00				
				20	21OCT91	Mildly ill	Very much improved	4.00				
				22	04NOV91	Mildly ill	Very much improved	4.00				
				24	18NOV91	Mildly ill	Very much improved	4.00				
				26	02DEC91	Borderline mentally ill	Very much improved	4.00				
				28	17DEC91	Borderline mentally ill	Very much improved	4.00				
				30	30DEC91	Borderline mentally ill	Very much improved	4.00				
32	13JAN92	Mildly ill	Very much improved	4.00								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
10	27	292	MK	34	28JAN92	Borderline mentally ill	Very much improved	4.00				
				36	10FEB92	Borderline mentally ill	Very much improved	4.00				
				38	25FEB92	Borderline mentally ill	Very much improved	4.00				
				40	09MAR92	Borderline mentally ill	Very much improved	4.00				
				42	24MAR92	Borderline mentally ill	Very much improved	4.00				
				44	06APR92	Borderline mentally ill	Very much improved	4.00				
				46	20APR92	Borderline mentally ill	Very much improved	4.00				
				48	04MAY92	Borderline mentally ill	Very much improved	4.00				
				50	18MAY92	Borderline mentally ill	Very much improved	4.00				
				52	02JUN92	Borderline mentally ill	Very much improved	4.00				
				10	28	291	LL	8	24JUL91	Moderately ill	Much improved	3.00
								10	07AUG91	Moderately ill	Much improved	3.00
								12	21AUG91	Severely ill	No change	1.00
								14	04SEP91	Mildly ill	Very much improved	4.00
16	18SEP91	Moderately ill	Much improved					3.00				
18	02OCT91	Severely ill	No change					1.00				
20	16OCT91	Moderately ill	Minimally worse					1.00				
22	30OCT91	Moderately ill	Minimally improved					2.00				
24	13NOV91	Severely ill	Minimally worse					1.00				
26	27NOV91	Severely ill	Minimally worse					1.00				
28	11DEC91	Severely ill	No change					1.00				
30	23DEC91	Moderately ill	Much improved					3.00				
32	06JAN92	Mildly ill	Very much improved					4.00				
34	22JAN92	Moderately ill	Much improved					3.00				
10	31	297	RK	8	11NOV91	Mildly ill	Very much improved	2.00				
				10	26NOV91	Mildly ill	Very much improved	2.00				
				12	09DEC91	Mildly ill	Very much improved	4.00				
				14	23DEC91	Mildly ill	Very much improved	4.00				
				16	07JAN92	Mildly ill	Very much improved	4.00				
				18	21JAN92	Moderately ill	Much improved	3.00				
				20	03FEB92	Mildly ill	Very much improved	4.00				
				22	17FEB92	Mildly ill	Very much improved	4.00				
				24	02MAR92	Borderline mentally ill	Very much improved	4.00				
				26	17MAR92	Borderline mentally ill	Very much improved	4.00				
				28	30MAR92	Borderline mentally ill	Very much improved	4.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
10	31	297	RK	30	13APR92	Mildly ill	Very much improved	4.00				
				32	28APR92	Mildly ill	Very much improved	4.00				
				34	12MAY92	Mildly ill	Very much improved	4.00				
				36	26MAY92	Mildly ill	Very much improved	4.00				
				38	08JUN92	Moderately ill	Much improved	3.00				
				40	25JUN92	Moderately ill	Much improved	3.00				
				42	07JUL92	Moderately ill	Much improved	3.00				
				44	20JUL92	Moderately ill	Much improved	3.00				
				46	03AUG92	Moderately ill	Much improved	3.00				
				48	17AUG92	Mildly ill	Very much improved	4.00				
				50	31AUG92	Mildly ill	Very much improved	4.00				
				52	15SEP92	Mildly ill	Very much improved	4.00				
				10	32	299	LK	8	11NOV91	Mildly ill	Very much improved	2.00
								10	25NOV91	Mildly ill	Very much improved	2.00
								12	09DEC91	Mildly ill	Very much improved	2.00
								14	23DEC91	Moderately ill	Much improved	1.50
								16	07JAN92	Mildly ill	Very much improved	2.00
								18	20JAN92	Mildly ill	Very much improved	2.00
20	04FEB92	Mildly ill	Very much improved					4.00				
22	17FEB92	Mildly ill	Very much improved					4.00				
24	01MAR92	Mildly ill	Very much improved					4.00				
26	15MAR92	Mildly ill	Very much improved					4.00				
28	29MAR92	Mildly ill	Very much improved					4.00				
30	12APR92	Mildly ill	Very much improved					4.00				
32	26APR92	Mildly ill	Very much improved					4.00				
34	10MAY92	Borderline mentally ill	Very much improved					4.00				
36	24MAY92	Borderline mentally ill	Very much improved					4.00				
38	07JUN92	Borderline mentally ill	Very much improved					4.00				
40	21JUN92	Mildly ill	Very much improved					4.00				
42	07JUL92	Mildly ill	Very much improved					4.00				
44	20JUL92	Mildly ill	Very much improved	4.00								
46	03AUG92	Borderline mentally ill	Very much improved	4.00								
48	17AUG92	Borderline mentally ill	Very much improved	4.00								
50	31AUG92	Borderline mentally ill	Very much improved	4.00								
52	15SEP92	Borderline mentally ill	Very much improved	4.00								
10	33	300	EK	8	13NOV91	Borderline mentally ill	Very much improved	4.00				
				10	26NOV91	Borderline mentally ill	Very much improved	4.00				
				12	10DEC91	Borderline mentally ill	Very much improved	4.00				
				14	23DEC91	Borderline mentally ill	Very much improved	4.00				
10	34	31	TK	16	08JAN92	Borderline mentally ill	Very much improved	4.00				
				18	21JAN92	Borderline mentally ill	Very much improved	4.00				
				8	18NOV91	Mildly ill	Very much improved	4.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of illness	Global Improvement	Efficacy Index
10	34	31	TK	10	03DEC91	Mildly ill	Very much improved	4.00
				12	17DEC91	Moderately ill	Much improved	3.00
				14	30DEC91	Moderately ill	Much improved	3.00
				16	13JAN92	Moderately ill	Much improved	3.00
10	35	35	IH	8	18NOV91	Mildly ill	Very much improved	4.00
				10	03DEC91	Mildly ill	Very much improved	4.00
				12	16DEC91	Mildly ill	Very much improved	4.00
				14	30DEC91	Mildly ill	Very much improved	4.00
				16	13JAN92	Moderately ill	Minimally improved	2.00
				8	09DEC91	Mildly ill	Very much improved	4.00
10	38	37	LL	10	23DEC91	Mildly ill	Very much improved	4.00
				12	06JAN92	Mildly ill	Very much improved	4.00
				14	20JAN92	Borderline mentally ill	Very much improved	4.00
				16	04FEB92	Borderline mentally ill	Very much improved	4.00
				8	09DEC91	Moderately ill	Much improved	3.00
				10	39	40	VH	10
12	06JAN92	Moderately ill	Much improved					3.00
14	20JAN92	Mildly ill	Much improved					4.00
16	03FEB92	Mildly ill	Very much improved					4.00
18	18FEB92	Moderately ill	Much improved					3.00
20	02MAR92	Moderately ill	Much improved					3.00
22	16MAR92	Moderately ill	Much improved					3.00
24	30MAR92	Moderately ill	Much improved					3.00
26	13APR92	Moderately ill	Much improved					3.00
28	27APR92	Moderately ill	Much improved					3.00
30	14MAY92	Moderately ill	Much improved					3.00
32	28MAY92	Mildly ill	Very much improved					4.00
34	08JUN92	Mildly ill	Much improved					4.00
36	22JUN92	Moderately ill	Much improved					3.00
38	06JUL92	Mildly ill	Very much improved					4.00
40	20JUL92	Mildly ill	Very much improved					4.00
42	04AUG92	Mildly ill	Very much improved					4.00
44	17AUG92	Mildly ill	Very much improved					4.00
46	31AUG92	Mildly ill	Very much improved					4.00
48	14SEP92	Mildly ill	Very much improved					4.00
50	28SEP92	Mildly ill	Very much improved	4.00				
52	13OCT92	Mildly ill	Very much improved	4.00				
10	41	42	VP	8	24DEC91	Mildly ill	Much improved	1.50
				10	07JAN92	Mildly ill	Much improved	1.50
				12	21JAN92	Mildly ill	Much improved	1.50
				14	04FEB92	Borderline mentally ill	Very much improved	2.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	Patient	D.B.	Patient	Initials	Visit	Severity of Illness	Global Improvement	Efficacy Index				
						No.	Date						
10	41	42	VP	16	18FEB92	16	Borderline mentally ill	Very much improved	2.00				
				18	03MAR92	18	Borderline mentally ill	Very much improved	2.00				
				20	17MAR92	20	Borderline mentally ill	Very much improved	2.00				
				22	31MAR92	22	Borderline mentally ill	Very much improved	2.00				
				24	14APR92	24	Borderline mentally ill	Very much improved	2.00				
				26	28APR92	26	Borderline mentally ill	Very much improved	2.00				
				28	12MAY92	28	Borderline mentally ill	Very much improved	2.00				
				30	26MAY92	30	Borderline mentally ill	Very much improved	2.00				
				32	09JUN92	32	Borderline mentally ill	Very much improved	2.00				
				34	23JUN92	34	Normal	Very much improved	4.00				
				36	07JUL92	36	Normal	Very much improved	4.00				
				38	21JUL92	38	Normal	Very much improved	4.00				
				40	04AUG92	40	Normal	Very much improved	4.00				
				42	18AUG92	42	Normal	Very much improved	4.00				
				44	01SEP92	44	Normal	Very much improved	4.00				
				46	15SEP92	46	Normal	Very much improved	4.00				
				48	29SEP92	48	Normal	Very much improved	4.00				
				50	13OCT92	50	Normal	Very much improved	4.00				
				52	27OCT92	52	Normal	Very much improved	4.00				
				10	49	43	VM	8	04FEB92	8	Moderately ill	Much improved	1.50
								10	18FEB92	10	Moderately ill	Much improved	1.50
								12	03MAR92	12	Moderately ill	Much improved	1.50
								14	17MAR92	14	Mildly ill	Much improved	1.50
								16	31MAR92	16	Moderately ill	Much improved	1.50
								18	14APR92	18	Moderately ill	Much improved	1.50
								20	28APR92	20	Moderately ill	Much improved	1.50
								22	12MAY92	22	Moderately ill	Much improved	1.50
								24	26MAY92	24	Moderately ill	Much improved	1.00
								26	09JUN92	26	Mildly ill	Much improved	1.00
								28	23JUN92	28	Mildly ill	Much improved	1.00
								10	53	47	MA	8	08MAR92
				10	22MAR92	10	Borderline mentally ill					Very much improved	2.00
12	05APR92	12	Borderline mentally ill	Very much improved	2.00								
14	19APR92	14	Borderline mentally ill	Very much improved	4.00								
16	03MAY92	16	Borderline mentally ill	Very much improved	4.00								
18	17MAY92	18	Borderline mentally ill	Very much improved	4.00								
20	31MAY92	20	Borderline mentally ill	Very much improved	4.00								
22	14JUN92	22	Borderline mentally ill	Very much improved	4.00								
24	28JUN92	24	Borderline mentally ill	Very much improved	4.00								
26	12JUL92	26	Borderline mentally ill	Very much improved	4.00								
28	26JUL92	28	Borderline mentally ill	Very much improved	4.00								
30	09AUG92	30	Borderline mentally ill	Very much improved	4.00								
32	23AUG92	32	Borderline mentally ill	Very much improved	4.00								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
10	53	47	MA	34	06SEP92	Borderline mentally ill	Very much improved	4.00
10	54	48	UN	8	08MAR92	Mildly ill	Much improved	1.50
				10	22MAR92	Mildly ill	Much improved	1.50
				12	05APR92	Borderline mentally ill	Very much improved	2.00
				14	19APR92	Borderline mentally ill	Very much improved	2.00
				16	03MAY92	Mildly ill	Much improved	1.50
				18	17MAY92	Mildly ill	Much improved	1.50
				20	31MAY92	Mildly ill	Much improved	1.50
				22	14JUN92	Mildly ill	Much improved	3.00
				24	28JUN92	Mildly ill	Much improved	3.00
				26	12JUL92	Mildly ill	Much improved	3.00
				28	26JUL92	Mildly ill	Much improved	3.00
				30	09AUG92	Mildly ill	Much improved	3.00
				32	23AUG92	Mildly ill	Much improved	3.00
				34	06SEP92	Mildly ill	Much improved	3.00
10	56	50	JP	8	09MAR92	Mildly ill	Very much improved	1.33
				10	23MAR92	Mildly ill	Very much improved	1.33
10	57	51	AG	8	10MAR92	Mildly ill	Very much improved	4.00
				10	24MAR92	Moderately ill	Much improved	3.00
				12	07APR92	Mildly ill	Very much improved	4.00
				14	21APR92	Mildly ill	Very much improved	4.00
				16	05MAY92	Moderately ill	Very much improved	4.00
				18	19MAY92	Moderately ill	Much improved	3.00
				20	02JUN92	Moderately ill	Very much improved	4.00
				22	16JUN92	Moderately ill	Very much improved	4.00
				24	30JUN92	Mildly ill	Very much improved	4.00
				26	14JUL92	Mildly ill	Very much improved	4.00
				28	28JUL92	Mildly ill	Very much improved	4.00
				30	11AUG92	Mildly ill	Very much improved	4.00
				32	25AUG92	Moderately ill	Very much improved	4.00
				34	08SEP92	Moderately ill	Much improved	1.50
				36	22SEP92	Moderately ill	Much improved	1.50
				38	06OCT92	Moderately ill	Much improved	3.00
				40	20OCT92	Moderately ill	Much improved	3.00
				42	03NOV92	Markedly ill	Minimally improved	2.00
				44	17NOV92	Moderately ill	Much improved	3.00
				46	01DEC92	Mildly ill	Very much improved	4.00
				48	15DEC92	Mildly ill	Very much improved	4.00
				50	29DEC92	Mildly ill	Very much improved	4.00
				52	12JAN93	Mildly ill	Very much improved	4.00
10	59	53	TA	8	16MAR92	Moderately ill	Much improved	1.50

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
10	59	53	TA	10	30MAR92	Mildly ill	Very much improved	4.00
10	63	57	MS	8	30MAR92	Borderline mentally ill	Much improved	3.00
				10	13APR92	Borderline mentally ill	Much improved	3.00
				12	27APR92	Borderline mentally ill	Very much improved	4.00
				14	14MAY92	Borderline mentally ill	Very much improved	4.00
				16	25MAY92	Borderline mentally ill	Very much improved	4.00
				18	08JUN92	Borderline mentally ill	Very much improved	4.00
				20	22JUN92	Normal	Very much improved	4.00
				22	06JUL92	Borderline mentally ill	Very much improved	4.00
				24	20JUL92	Borderline mentally ill	Very much improved	4.00
				26	03AUG92	Borderline mentally ill	Very much improved	4.00
				28	17AUG92	Borderline mentally ill	Very much improved	4.00
				30	31AUG92	Borderline mentally ill	Very much improved	4.00
				32	14SEP92	Borderline mentally ill	Very much improved	4.00
				34	28SEP92	Borderline mentally ill	Very much improved	4.00
				36	12OCT92	Borderline mentally ill	Very much improved	4.00
				38	26OCT92	Borderline mentally ill	Very much improved	4.00
				40	09NOV92	Borderline mentally ill	Very much improved	4.00
				42	23NOV92	Normal	Very much improved	4.00
				44	07DEC92	Normal	Very much improved	4.00
				46	21DEC92	Normal	Very much improved	4.00
				48	04JAN93	Normal	Very much improved	4.00
				50	18JAN93	Normal	Very much improved	4.00
				52	01FEB93	Normal	Very much improved	4.00
10	82	59	LS	8	20APR92	Borderline mentally ill	Much improved	3.00
				10	04MAY92	Borderline mentally ill	Much improved	3.00
				12	18MAY92	Borderline mentally ill	Much improved	3.00
				14	01JUN92	Borderline mentally ill	Much improved	3.00
				16	15JUN92	Borderline mentally ill	Much improved	3.00
				18	29JUN92	Borderline mentally ill	Much improved	3.00
				20	13JUL92	Borderline mentally ill	Much improved	3.00
				22	27JUL92	Borderline mentally ill	Much improved	3.00
				24	10AUG92	Borderline mentally ill	Very much improved	4.00
				26	24AUG92	Normal	Very much improved	4.00
				28	07SEP92	Normal	Very much improved	4.00
				30	21SEP92	Normal	Very much improved	4.00
				32	05OCT92	Normal	Very much improved	4.00
				34	19OCT92	Normal	Very much improved	4.00
				36	02NOV92	Normal	Very much improved	4.00
				38	16NOV92	Normal	Very much improved	4.00
				40	30NOV92	Normal	Very much improved	4.00
				42	14DEC92	Normal	Very much improved	4.00
				44	28DEC92	Normal	Very much improved	4.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

Control	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
10	82	59	LS	46	11JAN93	Normal	Very much improved	4.00
				48	25JAN93			
10	84	63	HV	8	05MAY92	Moderately ill	Much improved	1.50
				10	19MAY92	Moderately ill	Much improved	1.50
				12	02JUN92	Mildly ill	Very much improved	2.00
				14	16JUN92	Markedly ill	Minimally improved	1.00
				16	30JUN92	Markedly ill	Minimally improved	1.00
10	86	274	NP	8	13MAY92	Mildly ill	Much improved	1.50
				10	27MAY92	Mildly ill	Much improved	1.50
				12	10JUN92	Mildly ill	Much improved	3.00
				14	24JUN92	Mildly ill	Much improved	3.00
				16	08JUL92	Borderline mentally ill	Very much improved	4.00
				18	22JUL92			
10	87	275	AN	8	13MAY92	Mildly ill	Much improved	1.50
				10	27MAY92	Mildly ill	Much improved	1.50
				12	10JUN92	Mildly ill	Much improved	1.50
				14	24JUN92	Mildly ill	Much improved	1.50
				16	08JUL92	Mildly ill	Much improved	1.50
				18	22JUL92	Mildly ill	Much improved	1.50
				20	05AUG92	Mildly ill	Much improved	1.50
				22	19AUG92	Borderline mentally ill	Much improved	1.50
				24	02SEP92	Borderline mentally ill	Much improved	1.50
				26	16SEP92	Borderline mentally ill	Much improved	1.50
				28	30SEP92	Borderline mentally ill	Much improved	1.50
				30	14OCT92	Borderline mentally ill	Much improved	3.00
				32	28OCT92	Borderline mentally ill	Much improved	1.50
				34	11NOV92	Borderline mentally ill	Much improved	1.50
				36	25NOV92	Borderline mentally ill	Much improved	1.50
				38	09DEC92	Borderline mentally ill	Much improved	2.00
				40	23DEC92	Borderline mentally ill	Very much improved	2.00
				42	06JAN93	Borderline mentally ill	Very much improved	2.00
				44	20JAN93	Borderline mentally ill	Very much improved	2.00
				46	03FEB93	Borderline mentally ill	Very much improved	2.00
				48	17FEB93	Borderline mentally ill	Very much improved	2.00
				50	03MAR93	Borderline mentally ill	Very much improved	2.00
				52	17MAR93	Borderline mentally ill	Very much improved	2.00
10	89	277	SK	8	14MAY92	Borderline mentally ill	Very much improved	4.00
10	90	70	SV	8	18MAY92	Mildly ill	Very much improved	4.00
				10	01JUN92	Mildly ill	Very much improved	4.00
				12	16JUN92	Moderately ill	Much improved	3.00

1203

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
10	90	70	SV	14	29JUN92	Moderately ill	Much improved	3.00				
				16	13JUL92	Moderately ill	Much improved	3.00				
				18	28JUL92	Mildly ill	Very much improved	4.00				
				20	10AUG92	Mildly ill	Very much improved	4.00				
				22	24AUG92	Mildly ill	Very much improved	4.00				
				24	07SEP92	Borderline mentally ill	Very much improved	4.00				
				26	21SEP92	Borderline mentally ill	Very much improved	4.00				
				10	91	74	HI	8	18MAY92	Mildly ill	Much improved	3.00
								10	02JUN92	Mildly ill	Very much improved	4.00
								12	18JUN92	Mildly ill	Very much improved	4.00
14	29JUN92	Mildly ill	Very much improved					4.00				
16	13JUL92	Mildly ill	Very much improved					4.00				
18	28JUL92	Mildly ill	Very much improved					4.00				
20	10AUG92	Mildly ill	Very much improved					4.00				
22	24AUG92	Mildly ill	Very much improved					4.00				
24	08SEP92	Mildly ill	Much improved					3.00				
26	22SEP92	Mildly ill	Much improved					3.00				
10	93	285	AN	8	03JUN92	Borderline mentally ill	Very much improved	2.00				
				10	17JUN92	Borderline mentally ill	Very much improved	2.00				
				12	01JUL92	Borderline mentally ill	Very much improved	2.00				
				14	15JUL92	Borderline mentally ill	Very much improved	2.00				
				16	29JUL92	Borderline mentally ill	Very much improved	2.00				
				18	12AUG92	Normal	Very much improved	4.00				
				20	26AUG92	Normal	Very much improved	4.00				
				22	09SEP92	Normal	Very much improved	4.00				
				24	23SEP92	Normal	Very much improved	4.00				
				26	07OCT92	Normal	Very much improved	4.00				
11	2	373	HB	8	08DEC91	Normal	Very much improved	4.00				
				10	22DEC91	Normal	Very much improved	4.00				
				12	05JAN92	Normal	Very much improved	4.00				
				14	19JAN92	Normal	Very much improved	4.00				
				16	02FEB92	Normal	Very much improved	4.00				
				18	16FEB92	Borderline mentally ill	Very much improved	4.00				
				20	01MAR92	Normal	Very much improved	4.00				
				22	15MAR92	Normal	Very much improved	4.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
11	2	373	HB	24	29MAR92	Normal	Very much improved	4.00				
				26	12APR92	Normal	Very much improved	4.00				
				28	26APR92	Moderately ill	Much improved	3.00				
11	3	374	RF	30	10MAY92	Borderline mentally ill	Very much improved	4.00				
				8	09DEC91	Moderately ill	Much improved	3.00				
				10	23DEC91	Markedly ill	No change	1.00				
11	6	377	VP	8	10DEC91	Mildly ill	Much improved	3.00				
				10	24DEC91	Mildly ill	Much improved	3.00				
				12	07JAN92	Mildly ill	Much improved	3.00				
				14	21JAN92	Mildly ill	Much improved	3.00				
				16	04FEB92	Mildly ill	Much improved	3.00				
				18	18FEB92	Mildly ill	Much improved	3.00				
				20	03MAR92	Normal	Very much improved	4.00				
				22	17MAR92	Mildly ill	Minimally improved	3.00				
				24	31MAR92	Mildly ill	Much improved	3.00				
				26	14APR92	Mildly ill	Very much improved	4.00				
				28	28APR92	Mildly ill	Much improved	4.00				
				30	12MAY92	Normal	Very much improved	4.00				
				32	26MAY92	Normal	Very much improved	4.00				
				34	09JUN92	Normal	Very much improved	4.00				
				36	23JUN92	Normal	Very much improved	4.00				
				38	07JUL92	Normal	Very much improved	4.00				
				40	21JUL92	Normal	Very much improved	4.00				
				42	04AUG92	Normal	Very much improved	4.00				
				44	18AUG92	Normal	Very much improved	4.00				
				46	01SEP92	Normal	Very much improved	4.00				
				48	15SEP92	Normal	Very much improved	4.00				
				50	29SEP92	Normal	Very much improved	4.00				
				52	13OCT92	Normal	Very much improved	4.00				
				11	10	363	BJ	8	20JAN92	Mildly ill	Much improved	3.00
								10	03FEB92	Moderately ill	Much improved	3.00
								12	17FEB92	Moderately ill	Minimally improved	2.00
								14	02MAR92	Mildly ill	Much improved	3.00
								16	16MAR92	Mildly ill	Much improved	3.00
								18	30MAR92	Mildly ill	Much improved	3.00
								20	13APR92	Mildly ill	Much improved	3.00
								22	27APR92	Mildly ill	Much improved	3.00
								24	11MAY92	Borderline mentally ill	Very much improved	4.00
26	25MAY92	Borderline mentally ill	Very much improved					4.00				
28	08JUN92	Mildly ill	Much improved					3.00				
30	22JUN92	Borderline mentally ill	Very much improved					4.00				
32	06JUL92	Borderline mentally ill	Very much improved	4.00								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
11	10	363	BJ	34	20JUL92	Normal	Very much improved	4.00				
				36	03AUG92	Normal	Very much improved	4.00				
				38	17AUG92	Normal	Very much improved	4.00				
				40	31AUG92	Normal	Very much improved	4.00				
				42	14SEP92	Normal	Very much improved	4.00				
				44	28SEP92	Borderline mentally ill	Very much improved	4.00				
				46	12OCT92	Normal	Very much improved	4.00				
				48	26OCT92	Normal	Very much improved	4.00				
				50	09NOV92	Normal	Very much improved	4.00				
				52	23NOV92	Normal	Very much improved	4.00				
				11	11	361	NEY	8	30JAN92	Borderline mentally ill	Very much improved	4.00
								10	13FEB92	Mildly ill	Much improved	3.00
12	27FEB92	Normal	Very much improved					4.00				
14	12MAR92	Normal	Very much improved					4.00				
16	26MAR92	Borderline mentally ill	Very much improved					4.00				
18	09APR92	Mildly ill	Much improved					3.00				
20	23APR92	Borderline mentally ill	Very much improved					4.00				
22	07MAY92	Borderline mentally ill	Very much improved					4.00				
24	19MAY92	Markedly ill	No change					1.00				
11	13	365	GR					8	10MAR92	Mildly ill	Much improved	3.00
								10	24MAR92	Mildly ill	Much improved	3.00
								12	07APR92	Borderline mentally ill	Very much improved	4.00
				14	21APR92	Borderline mentally ill	Very much improved	4.00				
				16	05MAY92	Borderline mentally ill	Very much improved	4.00				
				18	19MAY92	Borderline mentally ill	Very much improved	4.00				
				20	02JUN92	Normal	Very much improved	4.00				
				11	16	367	NA	8	29MAR92	Markedly ill	Minimally improved	2.00
								10	12APR92	Markedly ill	Minimally improved	2.00
								12	26APR92	Mildly ill	Much improved	3.00
								14	10MAY92	Mildly ill	Much improved	3.00
								16	24MAY92	Mildly ill	Much improved	3.00
18	07JUN92	Mildly ill	Much improved					3.00				
11	17	368	UZ					8	02APR92	Mildly ill	Much improved	3.00
								10	16APR92	Mildly ill	Much improved	3.00
								12	30APR92	Borderline mentally ill	Very much improved	4.00
								14	14MAY92	Borderline mentally ill	Very much improved	4.00
								16	28MAY92	Borderline mentally ill	Very much improved	4.00
								18	11JUN92	Borderline mentally ill	Very much improved	4.00
				20	25JUN92	Borderline mentally ill	Very much improved	4.00				
				22	09JUL92	Borderline mentally ill	Very much improved	4.00				
				24	23JUL92	Mildly ill	Much improved	3.00				

1211

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
11	17	368	UZ	26	06AUG92	Borderline mentally ill	Very much improved	4.00				
				28	20AUG92	Normal	Very much improved	4.00				
				30	03SEP92	Normal	Very much improved	4.00				
				32	17SEP92	Normal	Very much improved	4.00				
				34	01OCT92	Borderline mentally ill	Very much improved	4.00				
				36	15OCT92	Borderline mentally ill	Very much improved	4.00				
				38	29OCT92	Normal	Very much improved	4.00				
				40	12NOV92	Borderline mentally ill	Very much improved	4.00				
				42	26NOV92	Mildly ill	Much improved	3.00				
				44	09DEC92	Borderline mentally ill	Very much improved	4.00				
				46	24DEC92	Normal	Very much improved	4.00				
				48	07JAN93	Normal	Very much improved	4.00				
				50	21JAN93	Normal	Very much improved	4.00				
				52	04FEB93	Normal	Very much improved	4.00				
				11	19	370	FK	8	23APR92	Borderline mentally ill	Very much improved	4.00
								10	07MAY92	Normal	Very much improved	4.00
								12	21MAY92	Normal	Very much improved	4.00
								14	04JUN92	Normal	Very much improved	4.00
								16	18JUN92	Borderline mentally ill	Very much improved	4.00
								18	02JUL92	Normal	Very much improved	4.00
								20	16JUL92	Normal	Very much improved	4.00
								22	30JUL92	Borderline mentally ill	Very much improved	4.00
								24	13AUG92	Normal	Very much improved	4.00
								26	27AUG92	Borderline mentally ill	Very much improved	4.00
								28	10SEP92	Normal	Very much improved	4.00
								30	24SEP92	Normal	Very much improved	4.00
32	08OCT92	Normal	Very much improved					4.00				
34	22OCT92	Normal	Very much improved					4.00				
36	05NOV92	Normal	Very much improved					4.00				
38	19NOV92	Normal	Very much improved					4.00				
40	03DEC92	Mildly ill	Much improved					3.00				
42	17DEC92	Normal	Very much improved					4.00				
44	31DEC92	Normal	Very much improved					4.00				
46	14JAN93	Normal	Very much improved					4.00				
48	28JAN93	Normal	Very much improved					4.00				
50	11FEB93	Borderline mentally ill	Very much improved					4.00				
52	25FEB93	Normal	Very much improved					4.00				
12	1	92	IB					8	25DEC91	Moderately ill	Minimally improved	3.00
								10	08JAN92	Mildly ill	Minimally improved	3.00
								12	22JAN92	Mildly ill	Much improved	4.00
				14	05FEB92	Borderline mentally ill	Much improved	4.00				
				16	19FEB92	Mildly ill	Minimally improved	2.00				
				18	04MAR92	Mildly ill	Minimally improved	2.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
12	1	92	IB	20	18MAR92	Mildly ill	Minimally improved	2.00				
				22	01APR92	Mildly ill	Much improved	3.00				
				24	15APR92	Mildly ill	Much improved	4.00				
				26	29APR92	Mildly ill	Much improved	4.00				
				28	13MAY92	Mildly ill	Much improved	4.00				
				30	27MAY92	Mildly ill	Much improved	4.00				
				32	10JUN92	Mildly ill	Much improved	4.00				
				34	24JUN92	Normal	Very much improved	4.00				
				36	08JUL92	Normal	Very much improved	4.00				
				38	22JUL92	Normal	Very much improved	4.00				
				40	05AUG92	Normal	Very much improved	4.00				
				42	19AUG92	Normal	Very much improved	4.00				
				44	02SEP92	Normal	Very much improved	4.00				
				46	16SEP92	Normal	Very much improved	4.00				
				48	30SEP92	Normal	Very much improved	4.00				
				50	14OCT92	Normal	Very much improved	4.00				
				52	28OCT92	Normal	Very much improved	4.00				
				12	2	99	EFC	8	30DEC91	Severely ill	No change	1.00
								10	13JAN92	Severely ill	No change	1.00
								12	27JAN92	Severely ill	No change	1.00
				12	3	93	IF	8	24DEC91	Normal	Very much improved	4.00
								10	07JAN92	Normal	Very much improved	4.00
12	21JAN92	Normal	Very much improved					4.00				
14	04FEB92	Normal	Very much improved					4.00				
16	18FEB92	Normal	Very much improved					4.00				
18	03MAR92	Normal	Very much improved					4.00				
20	17MAR92	Normal	Very much improved					4.00				
22	31MAR92	Normal	Very much improved					4.00				
24	14APR92	Normal	Very much improved					4.00				
26	28APR92	Normal	Very much improved					4.00				
28	12MAY92	Normal	Very much improved					4.00				
30	26MAY92	Normal	Much improved					3.00				
32	09JUN92	Normal	Very much improved					4.00				
34	23JUN92	Normal	Very much improved					4.00				
36	07JUL92	Normal	Very much improved					4.00				
38	21JUL92	Normal	Very much improved					4.00				
40	04AUG92	Normal	Very much improved					4.00				
42	18AUG92	Normal	Very much improved					4.00				
44	01SEP92	Normal	Very much improved					4.00				
46	15SEP92	Normal	Very much improved					4.00				
48	29SEP92	Normal	Very much improved					4.00				
50	13OCT92	Normal	Very much improved					4.00				
52	27OCT92	Normal	Very much improved	4.00								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD

REBOMETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOMETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
12	4	100	EG	8	30DEC91	Markedly ill	No change	1.00
				10	13JAN92	Moderately ill	Minimally improved	2.00
				12	27JAN92	Moderately ill	Minimally improved	2.00
				14	10FEB92	Mildly ill	Minimally improved	3.00
				16	24FEB92	Mildly ill	Minimally improved	3.00
				18	09MAR92	Moderately ill	Much improved	3.00
				20	23MAR92	Moderately ill	Minimally improved	3.00
				22	06APR92	Moderately ill	Minimally improved	3.00
	7	402	LK	24	27APR92	Moderately ill	Minimally improved	3.00
				26	04MAY92	Moderately ill	Minimally improved	3.00
				28	18MAY92	Moderately ill	Minimally improved	3.00
				8	30DEC91	Moderately ill	Minimally improved	3.00
				10	13JAN92	Markedly ill	Minimally improved	2.00
				12	27JAN92	Moderately ill	Minimally improved	3.00
				14	10FEB92	Markedly ill	Minimally improved	2.00
				16	24FEB92	Markedly ill	No change	1.00
12	9	91	RBP	18	09MAR92	Markedly ill	Minimally improved	2.00
				20	23MAR92	Mildly ill	Much improved	4.00
				22	06APR92	Mildly ill	Much improved	4.00
				24	20APR92	Markedly ill	Minimally improved	2.00
				26	04MAY92	Moderately ill	Minimally improved	2.00
				28	18MAY92	Mildly ill	Minimally improved	2.00
				8	25DEC91	Markedly ill	Minimally worse	1.00
				10	08JAN92	Markedly ill	No change	1.00
	15	104	GB	12	22JAN92	Markedly ill	Minimally improved	2.00
				14	05FEB92	Markedly ill	Minimally improved	2.00
				16	19FEB92	Markedly ill	Minimally improved	2.00
				18	04MAR92	Severely ill	Very much worse	1.00
				20	18MAR92	Markedly ill	No change	1.00
				22	01APR92	Moderately ill	Much improved	4.00
				24	15APR92	Moderately ill	Much improved	4.00
				26	29APR92	Moderately ill	Much improved	4.00
12	15	104	GB	28	13MAY92	Moderately ill	Much improved	4.00
				8	20JAN92	Mildly ill	Minimally improved	2.00
				10	03FEB92	Mildly ill	Minimally improved	2.00
				12	17FEB92	Mildly ill	Minimally improved	2.00
				14	02MAR92	Mildly ill	Minimally improved	2.00
				16	16MAR92	Mildly ill	Minimally improved	2.00
				18	30MAR92	Mildly ill	Minimally improved	2.00
				20	13APR92	Mildly ill	Minimally improved	3.00
22	27APR92	Mildly ill	Minimally improved	3.00				
24	11MAY92	Mildly ill	Minimally improved	3.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
12	15	104	GB	26	25MAY92	Mildly ill	Minimally improved	3.00
12	16	105	FN	8	04FEB92	Mildly ill	Much improved	4.00
				10	18FEB92	Moderately ill	Minimally improved	3.00
				12	03MAR92	Markedly ill	Minimally improved	2.00
				14	17MAR92	Markedly ill	Minimally improved	2.00
				16	31MAR92	Markedly ill	Minimally improved	2.00
				18	14APR92	Markedly ill	Minimally improved	2.00
				20	28APR92	Borderline mentally ill	Much improved	4.00
				22	12MAY92	Normal	Very much improved	4.00
				24	26MAY92	Normal	Very much improved	4.00
				26	09JUN92	Normal	Very much improved	4.00
12	19	106	SS2	8	11MAR92	Normal	Very much improved	4.00
				10	25MAR92	Normal	Very much improved	4.00
				12	08APR92	Normal	Much improved	4.00
				14	22APR92	Normal	Very much improved	4.00
				16	06MAY92	Normal	Very much improved	4.00
12	21	110	FL	8	26MAR92	Borderline mentally ill	Much improved	4.00
				10	09APR92	Borderline mentally ill	Much improved	4.00
				12	23APR92	Borderline mentally ill	Much improved	4.00
				14	07MAY92	Borderline mentally ill	Much improved	4.00
				16	21MAY92	Borderline mentally ill	Much improved	4.00
				18	04JUN92	Borderline mentally ill	Much improved	4.00
				20	18JUN92	Moderately ill	Minimally improved	3.00
12	24	113	NF	8	17APR92	Moderately ill	Minimally improved	3.00
				10	01MAY92	Moderately ill	Minimally improved	3.00
				12	15MAY92	Moderately ill	Minimally improved	3.00
				14	29MAY92	Moderately ill	Minimally improved	3.00
				16	12JUN92	Moderately ill	Minimally improved	3.00
				18	26JUN92	Moderately ill	Minimally improved	3.00
				20	10JUL92	Moderately ill	Minimally improved	3.00
				22	24JUL92	Moderately ill	Minimally improved	3.00
				24	07AUG92	Moderately ill	Minimally improved	3.00
				26	21AUG92	Moderately ill	Minimally improved	3.00
				28	04SEP92	Moderately ill	Minimally improved	3.00
12	25	114	FS	8	06APR92	Moderately ill	Much improved	3.00
				10	20APR92	Moderately ill	Much improved	3.00
				12	04MAY92	Moderately ill	Much improved	3.00
				14	18MAY92	Moderately ill	Much improved	3.00
				16	01JUN92	Mildly ill	Much improved	3.00
				18	15JUN92	Mildly ill	Much improved	3.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index								
12	25	114	FS	20	29JUN92	Mildly ill	Much improved	3.00								
				22	13JUL92	Mildly ill	Much improved	3.00								
				24	27JUL92	Moderately ill	Much improved	3.00								
				26	10AUG92	Moderately ill	Much improved	3.00								
				28	24AUG92	Mildly ill	Much improved	3.00								
				30	07SEP92	Mildly ill	Much improved	4.00								
				32	21SEP92	Mildly ill	Much improved	3.00								
				34	05OCT92	Mildly ill	Much improved	3.00								
				36	19OCT92	Mildly ill	Much improved	3.00								
				38	02NOV92	Mildly ill	Much improved	3.00								
				40	16NOV92	Mildly ill	Much improved	3.00								
				42	30NOV92	Moderately ill	Much improved	3.00								
				44	14DEC92	Moderately ill	Much improved	3.00								
				46	28DEC92	Mildly ill	Much improved	3.00								
				48	11JAN93	Mildly ill	Much improved	3.00								
				50	25JAN93	Mildly ill	Much improved	3.00								
				52	08FEB93	Moderately ill	Much improved	3.00								
				12	27	115	VCS	8	03APR92	Mildly ill	Much improved	4.00				
								10	17APR92	Mildly ill	Much improved	4.00				
								12	01MAY92	Borderline mentally ill	Much improved	4.00				
								14	15MAY92	Borderline mentally ill	Much improved	4.00				
								16	29MAY92	Borderline mentally ill	Much improved	4.00				
								18	12JUN92	Borderline mentally ill	Much improved	4.00				
								20	26JUN92	Borderline mentally ill	Very much improved	4.00				
								22	10JUL92	Borderline mentally ill	Very much improved	4.00				
								24	24JUL92	Borderline mentally ill	Much improved	4.00				
								26	07AUG92	Borderline mentally ill	Much improved	4.00				
								28	21AUG92	Borderline mentally ill	Much improved	4.00				
								30	04SEP92	Borderline mentally ill	Much improved	4.00				
								32	18SEP92	Normal	Very much improved	4.00				
								34	02OCT92	Normal	Very much improved	4.00				
								12	29	117	AK	8	06APR92	Normal	Very much improved	4.00
												10	20APR92	Normal	Very much improved	4.00
												12	04MAY92	Normal	Very much improved	4.00
14	18MAY92	Normal	Very much improved									4.00				
16	01JUN92	Normal	Very much improved	4.00												
18	15JUN92	Normal	Very much improved	4.00												
20	29JUN92	Normal	Very much improved	4.00												
22	13JUL92	Normal	Very much improved	4.00												
24	27JUL92	Normal	Very much improved	4.00												
26	10AUG92	Normal	Very much improved	4.00												
28	24AUG92	Normal	Very much improved	4.00												
30	07SEP92	Normal	Very much improved	4.00												

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
12	29	117	AK	32	21SEP92	Normal	Very much improved	4.00
				34	05OCT92	Normal	Very much improved	4.00
				36	19OCT92	Normal	Very much improved	4.00
				38	02NOV92	Normal	Very much improved	4.00
				40	16NOV92	Normal	Very much improved	4.00
				42	30NOV92	Normal	Very much improved	4.00
				44	14DEC92	Normal	Very much improved	4.00
				46	28DEC92	Normal	Very much improved	4.00
				48	11JAN93	Normal	Very much improved	4.00
				50	25JAN93	Normal	Very much improved	4.00
				52	08FEB93	Normal	Very much improved	4.00
				12	33	368	LN	8
10	10JUN92	Borderline mentally ill	Much improved					4.00
12	24JUN92	Borderline mentally ill	Much improved					4.00
14	08JUL92	Borderline mentally ill	Much improved					4.00
16	22JUL92	Borderline mentally ill	Much improved					4.00
18	05AUG92	Borderline mentally ill	Much improved					4.00
20	19AUG92	Borderline mentally ill	Much improved					4.00
8	25MAY92	Moderately ill	Minimally improved					2.00
12	36	365	FB	10	08JUN92	Markedly ill	Minimally improved	2.00
				12	22JUN92	Markedly ill	Minimally improved	2.00
13	1	219	PZ	8	10DEC91	Borderline mentally ill	Much improved	4.00
				10	24DEC91	Moderately ill	Much improved	3.00
				12	07JAN92	Mildly ill	Much improved	3.00
				14	21JAN92	Borderline mentally ill	Very much improved	4.00
				16	04FEB92	Moderately ill	Much improved	3.00
				18	18FEB92	Mildly ill	Much improved	3.00
				20	03MAR92	Mildly ill	Much improved	3.00
				22	17MAR92	Mildly ill	Much improved	3.00
				24	31MAR92	Borderline mentally ill	Much improved	3.00
				26	14APR92	Mildly ill	Much improved	3.00
				28	28APR92	Mildly ill	Much improved	3.00
				30	12MAY92	Borderline mentally ill	Very much improved	4.00
				32	26MAY92	Borderline mentally ill	Very much improved	4.00
				34	09JUN92	Borderline mentally ill	Very much improved	4.00
				36	23JUN92	Borderline mentally ill	Very much improved	4.00
				38	07JUL92	Borderline mentally ill	Very much improved	4.00
40	21JUL92	Borderline mentally ill	Very much improved	4.00				
42	04AUG92	Normal	Very much improved	4.00				
44	18AUG92	Borderline mentally ill	Very much improved	4.00				
46	01SEF92	Normal	Very much improved	4.00				
48	15SEF92	Borderline mentally ill	Very much improved	4.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
13	1	249	PZ	50	29SEP92	Normal	Very much improved	4.00
				52	13OCT92	Normal	Very much improved	4.00
13	3	224	AI	8	10DEC91	Borderline mentally ill	Much improved	4.00
				10	24DEC91	Borderline mentally ill	Very much improved	4.00
				12	07JAN92	Borderline mentally ill	Very much improved	4.00
				14	21JAN92	Mildly ill	Much improved	3.00
				16	04FEB92	Borderline mentally ill	Much improved	4.00
				18	18FEB92	Borderline mentally ill	Very much improved	4.00
				20	03MAR92	Borderline mentally ill	Very much improved	4.00
				22	17MAR92	Borderline mentally ill	Much improved	4.00
				24	31MAR92	Borderline mentally ill	Very much improved	4.00
				26	14APR92	Mildly ill	Much improved	4.00
				28	28APR92	Borderline mentally ill	Very much improved	4.00
				30	12MAY92	Borderline mentally ill	Very much improved	4.00
				32	26MAY92	Borderline mentally ill	Very much improved	4.00
				34	09JUN92	Normal	Very much improved	4.00
				36	23JUN92	Normal	Very much improved	4.00
				38	07JUL92	Borderline mentally ill	Very much improved	4.00
				40	21JUL92	Borderline mentally ill	Very much improved	4.00
				42	04AUG92	Borderline mentally ill	Very much improved	4.00
				44	18AUG92	Normal	Very much improved	4.00
				46	01SEP92	Normal	Very much improved	4.00
48	15SEP92	Normal	Very much improved	4.00				
50	29SEP92	Borderline mentally ill	Very much improved	4.00				
52	13OCT92	Normal	Very much improved	4.00				
13	6	226	KE	8	12DEC91	Mildly ill	Much improved	4.00
				10	26DEC91	Mildly ill	Much improved	4.00
				12	09JAN92	Mildly ill	Much improved	4.00
				14	23JAN92	Borderline mentally ill	Very much improved	4.00
				16	06FEB92	Borderline mentally ill	Very much improved	4.00
				18	20FEB92	Mildly ill	Minimally improved	3.00
				20	05MAR92	Borderline mentally ill	Very much improved	4.00
				22	19MAR92	Borderline mentally ill	Very much improved	4.00
				24	02APR92	Normal	Very much improved	4.00
				26	16APR92	Borderline mentally ill	Very much improved	4.00
				28	30APR92	Borderline mentally ill	Very much improved	4.00
				30	14MAY92	Borderline mentally ill	Very much improved	4.00
32	28MAY92	Borderline mentally ill	Very much improved	4.00				
34	11JUN92	Mildly ill	Much improved	3.00				
36	25JUN92	Mildly ill	Much improved	3.00				
38	09JUL92	Borderline mentally ill	Much improved	4.00				
40	23JUL92	Borderline mentally ill	Much improved	4.00				
42	06AUG92	Borderline mentally ill	Very much improved	4.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
13	6	226	KE	44	20AUG92	Borderline mentally ill	Very much improved	4.00				
				46	03SEP92	Borderline mentally ill	Very much improved	4.00				
				48	17SEP92	Borderline mentally ill	Very much improved	4.00				
				50	04OCT92	Borderline mentally ill	Very much improved	4.00				
				52	15OCT92	Borderline mentally ill	Very much improved	4.00				
				13	7	220	BL	8	19DEC91	Borderline mentally ill	Very much improved	4.00
								10	02JAN92	Borderline mentally ill	Very much improved	4.00
								12	16JAN92	Borderline mentally ill	Very much improved	4.00
								14	30JAN92	Normal	Very much improved	4.00
								16	13FEB92	Borderline mentally ill	Very much improved	4.00
18	27FEB92	Borderline mentally ill	Very much improved					4.00				
20	12MAR92	Normal	Very much improved					4.00				
22	26MAR92	Normal	Very much improved					4.00				
24	08APR92	Normal	Very much improved					4.00				
26	22APR92	Normal	Very much improved					4.00				
13	13	223	HM	8	27DEC91	Mildly ill	Much improved	4.00				
				10	10JAN92	Borderline mentally ill	Much improved	4.00				
				12	24JAN92	Borderline mentally ill	Much improved	3.00				
				14	07FEB92	Borderline mentally ill	Much improved	4.00				
				16	21FEB92	Mildly ill	Minimally improved	3.00				
				18	06MAR92	Borderline mentally ill	Very much improved	4.00				
				20	20MAR92	Borderline mentally ill	Much improved	4.00				
				22	03APR92	Borderline mentally ill	Much improved	3.00				
				24	17APR92	Mildly ill	Much improved	3.00				
				26	01MAY92	Mildly ill	Much improved	3.00				
13	13	223	HM	28	15MAY92	Mildly ill	Much improved	3.00				
				30	29MAY92	Mildly ill	Much improved	3.00				
				32	12JUN92	Borderline mentally ill	Very much improved	4.00				
				34	26JUN92	Borderline mentally ill	Very much improved	4.00				
				36	10JUL92	Borderline mentally ill	Very much improved	4.00				
				38	24JUL92	Borderline mentally ill	Very much improved	4.00				
				40	07AUG92	Borderline mentally ill	Very much improved	4.00				
				42	21AUG92	Borderline mentally ill	Very much improved	4.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
13	13	223	HM	38	24JUL92	Borderline mentally ill	Much improved	4.00				
				40	07AUG92	Borderline mentally ill	Much improved	4.00				
				42	21AUG92	Borderline mentally ill	Very much improved	2.00				
				44	04SEP92	Borderline mentally ill	Very much improved	2.00				
				46	18SEP92	Borderline mentally ill	Very much improved	2.00				
				48	02OCT92	Borderline mentally ill	Very much improved	2.00				
				50	16OCT92	Borderline mentally ill	Very much improved	2.00				
				52	30OCT92	Borderline mentally ill	Very much improved	2.00				
				13	18	227	VT	8	28JAN92	Borderline mentally ill	Very much improved	4.00
								10	10FEB92	Mildly ill	Much improved	3.00
12	25FEB92	Mildly ill	Much improved					3.00				
14	10MAR92	Mildly ill	Much improved					3.00				
16	24MAR92	Mildly ill	Much improved					3.00				
18	07APR92	Mildly ill	Much improved					3.00				
20	21APR92	Borderline mentally ill	Much improved					3.00				
22	05MAY92	Mildly ill	Much improved					4.00				
24	19MAY92	Borderline mentally ill	Very much improved					4.00				
26	02JUN92	Borderline mentally ill	Much improved					4.00				
13	20	230	NL	28	16JUN92	Borderline mentally ill	Much improved	4.00				
				30	30JUN92	Borderline mentally ill	Much improved	4.00				
				32	14JUL92	Borderline mentally ill	Very much improved	4.00				
				34	28JUL92	Borderline mentally ill	Very much improved	4.00				
				36	11AUG92	Borderline mentally ill	Very much improved	4.00				
				38	25AUG92	Borderline mentally ill	Very much improved	4.00				
				40	08SEP92	Borderline mentally ill	Very much improved	4.00				
				42	22SEP92	Borderline mentally ill	Very much improved	4.00				
				44	06OCT92	Mildly ill	Much improved	3.00				
				46	20OCT92	Borderline mentally ill	Very much improved	4.00				
13	20	230	NL	48	03NOV92	Borderline mentally ill	Very much improved	4.00				
				50	17NOV92	Borderline mentally ill	Very much improved	4.00				
				52	01DEC92	Borderline mentally ill	Very much improved	4.00				
				8	24MAR92	Mildly ill	Much improved	3.00				
				10	07APR92	Mildly ill	Much improved	3.00				
				12	21APR92	Mildly ill	Much improved	3.00				
				14	05MAY92	Mildly ill	Much improved	3.00				
				16	19MAY92	Mildly ill	Much improved	3.00				
				18	02JUN92	Borderline mentally ill	Very much improved	4.00				
				20	16JUN92	Borderline mentally ill	Very much improved	4.00				
13	20	230	NL	22	30JUN92	Borderline mentally ill	Very much improved	4.00				
				24	14JUL92	Borderline mentally ill	Very much improved	4.00				
				26	28JUL92	Borderline mentally ill	Very much improved	4.00				
				28	11AUG92	Borderline mentally ill	Very much improved	4.00				
				30	25AUG92	Borderline mentally ill	Very much improved	4.00				
				32	08SEP92	Borderline mentally ill	Very much improved	4.00				
				34	22SEP92	Borderline mentally ill	Very much improved	4.00				
				36	06OCT92	Mildly ill	Much improved	3.00				
				38	20OCT92	Borderline mentally ill	Very much improved	4.00				
				40	03NOV92	Borderline mentally ill	Very much improved	4.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of illness	Global Improvement	Efficacy Index				
13	20	230	NL	32	08SEP92	Borderline mentally ill	Very much improved	4.00				
				34	22SEP92	Borderline mentally ill	Very much improved	4.00				
				36	06OCT92	Borderline mentally ill	Very much improved	4.00				
				38	20OCT92	Borderline mentally ill	Very much improved	4.00				
				40	03NOV92	Borderline mentally ill	Very much improved	4.00				
				42	17NOV92	Borderline mentally ill	Very much improved	4.00				
				44	01DEC92	Borderline mentally ill	Very much improved	4.00				
				46	15DEC92	Borderline mentally ill	Very much improved	4.00				
				48	29DEC92	Borderline mentally ill	Very much improved	4.00				
				50	12JAN93	Borderline mentally ill	Very much improved	4.00				
				52	26JAN93	Borderline mentally ill	Very much improved	4.00				
				13	21	231	CL	8	14APR92	Borderline mentally ill	Very much improved	4.00
								10	28APR92	Borderline mentally ill	Much improved	4.00
								12	12MAY92	Borderline mentally ill	Very much improved	4.00
								14	26MAY92	Mildly ill	Very much improved	4.00
								16	09JUN92	Borderline mentally ill	Much improved	4.00
18	23JUN92	Borderline mentally ill	Very much improved					4.00				
20	07JUL92	Borderline mentally ill	Very much improved					4.00				
22	21JUL92	Borderline mentally ill	Very much improved					4.00				
24	04AUG92	Borderline mentally ill	Very much improved					4.00				
26	18AUG92	Borderline mentally ill	Very much improved					4.00				
28	01SEP92	Borderline mentally ill	Much improved					4.00				
30	15SEP92	Normal	Very much improved					4.00				
32	29SEP92	Borderline mentally ill	Very much improved					4.00				
34	13OCT92	Borderline mentally ill	Very much improved					4.00				
36	27OCT92	Borderline mentally ill	Very much improved	4.00								
38	10NOV92	Borderline mentally ill	Very much improved	4.00								
40	24NOV92	Borderline mentally ill	Much improved	4.00								
42	08DEC92	Borderline mentally ill	Much improved	4.00								
44	22DEC92	Borderline mentally ill	Much improved	4.00								
46	05JAN93	Borderline mentally ill	Much improved	4.00								
48	19JAN93	Borderline mentally ill	Much improved	4.00								
50	02FEB93	Borderline mentally ill	Much improved	4.00								
52	16FEB93	Borderline mentally ill	Much improved	4.00								
13	22	232	NYM	8	30JUN92	Moderately ill	Minimally improved	2.00				
				10	14JUL92	Severely ill	Much worse	1.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 RESOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index		
1	1	1	MGA	8	11JAN91	Borderline mentally ill	Very much improved	2.00		
				10	25JAN91	Borderline mentally ill	Very much improved	4.00		
				12	08FEB91	Mildly ill	Much improved	3.00		
				14	22FEB91	Borderline mentally ill	Much improved	3.00		
				16	08MAR91	Mildly ill	Minimally improved	2.00		
				18	22MAR91	Markedly ill	No change	1.00		
	1	6	CPM	8	29JAN91	Borderline mentally ill	Very much improved	2.00		
				10	13FEB91	Borderline mentally ill	Much improved	4.00		
				12	26FEB91	Mildly ill	Minimally improved	2.00		
				14	12MAR91	Markedly ill	No change	1.00		
				16	28MAR91	Markedly ill	No change	1.00		
				18	09APR91	Markedly ill	No change	1.00		
	1	8	MYB	8	01FEB91	Normal	Very much improved	4.00		
				10	15FEB91	Normal	Very much improved	4.00		
				12	01MAR91	Mildly ill	Much improved	3.00		
				14	15MAR91	Mildly ill	Much improved	3.00		
				16	28MAR91	Mildly ill	Much improved	3.00		
				18	12APR91	Mildly ill	Much improved	3.00		
20				26APR91	Moderately ill	Minimally improved	2.00			
22				10MAY91	Mildly ill	Much improved	3.00			
24				24MAY91	Moderately ill	Minimally improved	2.00			
26				07JUN91	Markedly ill	No change	1.00			
1				11	VRT	8	03MAY91	Borderline mentally ill	Very much improved	2.00
						10	17MAY91	Normal	Very much improved	2.00
	12	31MAY91	Borderline mentally ill			Very much improved	4.00			
	14	14JUN91	Borderline mentally ill			Very much improved	4.00			
	16	28JUN91	Borderline mentally ill			Very much improved	4.00			
	18	12JUL91	Borderline mentally ill			Very much improved	4.00			
	20	26JUL91	Borderline mentally ill			Very much improved	4.00			
	22	09AUG91	Borderline mentally ill			Very much improved	4.00			
	24	23AUG91	Normal			Very much improved	4.00			
	26	06SEP91	Borderline mentally ill			Very much improved	4.00			
	28	20SEP91	Borderline mentally ill			Very much improved	4.00			
	30	04OCT91	Borderline mentally ill			Very much improved	4.00			
	32	18OCT91	Moderately ill			Minimally improved	2.00			
	34	01NOV91	Mildly ill			Much improved	3.00			
	36	14NOV91	Moderately ill			Minimally improved	2.00			
	1	12	SLT			8	14MAY91	Borderline mentally ill	Very much improved	2.00
						10	28MAY91	Mildly ill	Much improved	1.50
						12	11JUN91	Mildly ill	Much improved	3.00
14				25JUN91	Mildly ill	Much improved	3.00			

1 2 2 2

PHARMACIA CNS R&D

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	12	10	SLT	16	09JUL91	Borderline mentally ill	Very much improved	4.00
				18	23JUL91	Borderline mentally ill	Very much improved	4.00
				20	06AUG91	Borderline mentally ill	Very much improved	4.00
				22	20AUG91	Mildly ill	Much improved	3.00
				24	03SEP91	Mildly ill	Much improved	3.00
				26	17SEP91	Mildly ill	Much improved	3.00
				28	01OCT91	Mildly ill	Much improved	3.00
				30	15OCT91	Mildly ill	Much improved	3.00
				32	29OCT91	Mildly ill	Much improved	3.00
				34	12NOV91	Borderline mentally ill	Very much improved	4.00
				36	26NOV91	Mildly ill	Much improved	3.00
				38	10DEC91	Mildly ill	Much improved	3.00
				40	24DEC91	Mildly ill	Much improved	3.00
				42	07JAN92	Normal	Very much improved	4.00
				44	21JAN92	Borderline mentally ill	Very much improved	4.00
				46	04FEB92	Borderline mentally ill	Very much improved	4.00
				48	18FEB92	Borderline mentally ill	Very much improved	4.00
				50	04MAR92	Borderline mentally ill	Very much improved	4.00
				52	17MAR92	Mildly ill	Much improved	3.00
				1	15	12	MAO	8
10	17JUL91	Borderline mentally ill	Very much improved					4.00
12	31JUL91	Borderline mentally ill	Much improved					1.50
14	14AUG91	Borderline mentally ill	Much improved					2.00
16	28AUG91	Borderline mentally ill	Very much improved					2.00
18	11SEP91	Mildly ill	Much improved					3.00
20	25SEP91	Borderline mentally ill	Very much improved					4.00
22	09OCT91	Borderline mentally ill	Very much improved					4.00
24	23OCT91	Mildly ill	Much improved					3.00
26	06NOV91	Borderline mentally ill	Very much improved					4.00
28	20NOV91	Mildly ill	Much improved					3.00
30	04DEC91	Mildly ill	Much improved					3.00
32	18DEC91	Moderately ill	Minimally improved					2.00
34	02JAN92	Mildly ill	Minimally improved					2.00
36	16JAN92	Borderline mentally ill	Much improved					4.00
38	30JAN92	Borderline mentally ill	Very much improved					4.00
40	12FEB92	Mildly ill	Much improved					3.00
42	26FEB92	Mildly ill	Much improved					3.00
44	11MAR92	Mildly ill	Much improved					3.00
46	25MAR92	Mildly ill	Much improved					3.00
48	08APR92	Mildly ill	Much improved	3.00				
50	22APR92	Mildly ill	Much improved	3.00				
52	06MAY92	Mildly ill	Much improved	3.00				
1	16	13	MHC	8	12JUL91	Borderline mentally ill	Very much improved	2.00

1 2 3

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
1	16	13	HHC	10	26JUL91	Borderline mentally ill	Very much improved	2.00				
				12	09AUG91	Borderline mentally ill	Much improved	1.50				
				14	23AUG91	Borderline mentally ill	Much improved	1.50				
				16	06SEP91	Mildly ill	Minimally improved	1.00				
				18	20SEP91	Mildly ill	Much improved	1.50				
				20	04OCT91	Borderline mentally ill	Much improved	1.50				
				22	18OCT91	Borderline mentally ill	Very much improved	4.00				
				24	01NOV91	Normal	Very much improved	4.00				
				26	14NOV91	Normal	Very much improved	4.00				
				28	29NOV91	Borderline mentally ill	Very much improved	4.00				
				30	13DEC91	Borderline mentally ill	Very much improved	4.00				
				32	27DEC91	Borderline mentally ill	Very much improved	4.00				
				34	09JAN92	Normal	Very much improved	4.00				
				36	24JAN92	Normal	Very much improved	4.00				
				38	07FEB92	Normal	Very much improved	4.00				
				40	21FEB92	Normal	Very much improved	4.00				
				1	19	16	SR	8	23JUL91	Borderline mentally ill	Very much improved	4.00
								10	06AUG91	Mildly ill	Much improved	3.00
								12	20AUG91	Borderline mentally ill	Very much improved	4.00
								14	03SEP91	Mildly ill	Much improved	3.00
								16	17SEP91	Mildly ill	Much improved	3.00
								18	01OCT91	Mildly ill	Much improved	3.00
								20	15OCT91	Mildly ill	Much improved	3.00
								22	29OCT91	Mildly ill	Much improved	3.00
								24	12NOV91	Mildly ill	Much improved	3.00
								26	26NOV91	Moderately ill	Minimally improved	2.00
								28	10DEC91	Mildly ill	Much improved	3.00
								30	24DEC91	Mildly ill	Much improved	3.00
								32	07JAN92	Mildly ill	Much improved	3.00
								34	21JAN92	Mildly ill	Much improved	3.00
								36	04FEB92	Moderately ill	Minimally improved	2.00
								38	18FEB92	Markedly ill	No change	1.00
				1	21	18	VMC	6	30JUL91	Borderline mentally ill	Very much improved	4.00
								10	13AUG91	Normal	Very much improved	4.00
								12	27AUG91	Borderline mentally ill	Very much improved	4.00
								14	10SEP91	Borderline mentally ill	Very much improved	4.00
								16	24SEP91	Normal	Very much improved	4.00
								18	08OCT91	Borderline mentally ill	Very much improved	4.00
								20	22OCT91	Borderline mentally ill	Much improved	3.00
								22	05NOV91	Borderline mentally ill	Very much improved	4.00
24	19NOV91	Borderline mentally ill	Very much improved					4.00				
26	03DEC91	Borderline mentally ill	Very much improved					4.00				
28	17DEC91	Borderline mentally ill	Very much improved					4.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D			REBOXETINE - PROTOCOL 20124/013			Listing No.: 10.3			CLINICAL GLOBAL IMPRESSION (CGI)			DOUBLE BLIND PHASE			TREATMENT: PLACEBO		
Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index									
1	21	18	VHC	30	31DEC91	Borderline mentally ill	Very much improved	4.00									
				32	16JAN92	Normal	Much improved	4.00									
				34	28JAN92	Mildly ill	Much improved	3.00									
				36	11FEB92	Mildly ill	Much improved	3.00									
				38	25FEB92	Mildly ill	Much improved	3.00									
				40	10MAR92	Mildly ill	Much improved	3.00									
				42	24MAR92	Mildly ill	Much improved	3.00									
				44	07APR92	Mildly ill	Much improved	3.00									
				46	22APR92	Mildly ill	Much improved	3.00									
				48	05MAY92	Mildly ill	Much improved	3.00									
				50	19MAY92	Mildly ill	Much improved	3.00									
				52	02JUN92	Mildly ill	Much improved	3.00									
				1	26	22	OC	8	03SEP91	Borderline mentally ill	Very much improved	4.00					
								10	17SEP91	Borderline mentally ill	Much improved	3.00					
								12	01OCT91	Mildly ill	Much improved	3.00					
								14	15OCT91	Borderline mentally ill	Very much improved	4.00					
								16	29OCT91	Mildly ill	Much improved	3.00					
								18	12NOV91	Normal	Very much improved	4.00					
20	26NOV91	Mildly ill	Much improved					3.00									
22	10DEC91	Mildly ill	Much improved					3.00									
24	24DEC91	Mildly ill	Much improved					3.00									
26	07JAN92	Mildly ill	Much improved					3.00									
28	21JAN92	Mildly ill	Much improved					3.00									
30	04FEB92	Mildly ill	Much improved					3.00									
32	18FEB92	Borderline mentally ill	Much improved					3.00									
34	04MAR92	Borderline mentally ill	Very much improved					4.00									
36	17MAR92	Borderline mentally ill	Very much improved					4.00									
38	31MAR92	Borderline mentally ill	Very much improved					4.00									
40	14APR92	Borderline mentally ill	Very much improved					4.00									
42	28APR92	Borderline mentally ill	Very much improved					4.00									
44	12MAY92	Mildly ill	Much improved	3.00													
46	26MAY92	Mildly ill	Much improved	3.00													
48	09JUN92	Mildly ill	Much improved	3.00													
50	23JUN92	Mildly ill	Much improved	3.00													
52	07JUL92	Mildly ill	Much improved	3.00													
1	27	23	RK	8	06SEP91	Borderline mentally ill	Much improved	3.00									
				10	20SEP91	Moderately ill	Minimally improved	2.00									
				12	04OCT91	Markedly ill	No change	1.00									
1	28	24	RMH	8	10SEP91	Borderline mentally ill	Very much improved	4.00									
				10	24SEP91	Borderline mentally ill	Much improved	3.00									
				12	08OCT91	Borderline mentally ill	Very much improved	4.00									
				14	22OCT91	Mildly ill	Much improved	3.00									

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	28	24	RMH	8	05NOV91	Mildly ill	Much improved	3.00
				10	19NOV91	Moderately ill	Minimally improved	2.00
				18	03DEC91	Moderately ill	Minimally improved	2.00
				20	17DEC91	Moderately ill	Minimally improved	2.00
1	29	25	AF0	22	31DEC91	Moderately ill	Minimally improved	2.00
				8	10SEP91	Borderline mentally ill	Very much improved	2.00
				10	24SEP91	Normal	Very much improved	2.00
				12	08OCT91	Borderline mentally ill	Very much improved	2.00
1	30	26	ERV	14	22OCT91	Normal	Very much improved	4.00
				16	05NOV91	Normal	Very much improved	4.00
				18	19NOV91	Normal	Very much improved	4.00
				20	03DEC91	Normal	Very much improved	4.00
				22	17DEC91	Normal	Very much improved	4.00
				24	31DEC91	Borderline mentally ill	Very much improved	4.00
				26	14JAN92	Normal	Very much improved	4.00
				28	28JAN92	Borderline mentally ill	Very much improved	4.00
				30	11FEB92	Borderline mentally ill	Very much improved	4.00
				32	25FEB92	Mildly ill	Much improved	3.00
				34	10MAR92	Mildly ill	Much improved	3.00
				36	24MAR92	Mildly ill	Much improved	3.00
				38	07APR92	Mildly ill	Much improved	3.00
				40	22APR92	Mildly ill	Much improved	3.00
				42	05MAY92	Borderline mentally ill	Very much improved	4.00
				44	19MAY92	Borderline mentally ill	Very much improved	4.00
46	02JUN92	Borderline mentally ill	Very much improved	4.00				
48	16JUN92	Borderline mentally ill	Very much improved	4.00				
50	30JUN92	Mildly ill	Very much improved	4.00				
52	14JUL92	Normal	Very much improved	4.00				
1	33	29	OFC	8	11SEP91	Borderline mentally ill	Very much improved	4.00
				10	25SEP91	Mildly ill	Much improved	3.00
				12	09OCT91	Mildly ill	Minimally improved	2.00
				14	23OCT91	Moderately ill	Minimally improved	2.00
1	36	302	LM	16	06NOV91	Markedly ill	No change	1.00
				8	18SEP91	Borderline mentally ill	Much improved	1.50
				10	02OCT91	Mildly ill	Much improved	1.50
				12	16OCT91	Markedly ill	No change	1.00
1	36	302	LM	8	22OCT91	Borderline mentally ill	Very much improved	4.00
				10	05NOV91	Mildly ill	Much improved	3.00
				12	19NOV91	Moderately ill	Minimally improved	2.00
				14	03DEC91	Moderately ill	Minimally improved	2.00
1	36	302	LM	16	17DEC91	Markedly ill	No change	1.00
				16	17DEC91	Markedly ill	No change	1.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Centre	Patient	D.B. Patient	Initials	Visit No.	Date	Severity of Illness	Global Improvement	Efficacy Index				
1	38	304	DBF	8	12NOV91	Normal	Very much improved	4.00				
				10	26NOV91	Normal	Very much improved	4.00				
				12	10DEC91	Normal	Very much improved	4.00				
				14	24DEC91	Normal	Very much improved	4.00				
				16	07JAN92	Borderline mentally ill	Very much improved	4.00				
				18	21JAN92	Mildly ill	Much improved	3.00				
				20	04FEB92	Mildly ill	Much improved	3.00				
				22	18FEB92	Mildly ill	Much improved	3.00				
				24	04MAR92	Mildly ill	Much improved	3.00				
				26	17MAR92	Mildly ill	Much improved	3.00				
				28	31MAR92	Mildly ill	Much improved	3.00				
				30	14APR92	Mildly ill	Much improved	3.00				
				32	28APR92	Borderline mentally ill	Much improved	3.00				
				34	12MAY92	Normal	Very much improved	4.00				
				36	26MAY92	Borderline mentally ill	Very much improved	4.00				
				38	09JUN92	Mildly ill	Much improved	3.00				
				40	23JUN92	Borderline mentally ill	Much improved	3.00				
				42	07JUL92	Mildly ill	Much improved	3.00				
				44	21JUL92	Mildly ill	Minimally improved	2.00				
				46	04AUG92	Mildly ill	Much improved	3.00				
				48	18AUG92	Moderately ill	Minimally improved	2.00				
				50	01SEP92	Mildly ill	Minimally improved	2.00				
				52	15SEP92	Moderately ill	Minimally improved	2.00				
				1	40	306	EM	8	19NOV91	Borderline mentally ill	Very much improved	4.00
								10	03DEC91	Borderline mentally ill	Very much improved	4.00
								12	17DEC91	Borderline mentally ill	Very much improved	4.00
								14	31DEC91	Mildly ill	Much improved	3.00
								16	14JAN92	Normal	Much improved	3.00
								18	28JAN92	Borderline mentally ill	Much improved	3.00
								20	11FEB92	Borderline mentally ill	Very much improved	4.00
								22	25FEB92	Moderately ill	Minimally improved	2.00
								24	10MAR92	Borderline mentally ill	Very much improved	4.00
26	24MAR92	Borderline mentally ill	Very much improved					4.00				
28	07APR92	Borderline mentally ill	Very much improved					4.00				
30	22APR92	Normal	Very much improved					4.00				
32	05MAY92	Normal	Very much improved					4.00				
34	19MAY92	Borderline mentally ill	Much improved					3.00				
36	02JUN92	Mildly ill	Much improved					3.00				
38	16JUN92	Mildly ill	Minimally improved					2.00				
40	30JUN92	Mildly ill	Minimally improved	2.00								
42	14JUL92	Mildly ill	Minimally improved	2.00								
44	28JUL92	Moderately ill	Much improved	3.00								
46	11AUG92	Mildly ill	Much improved	3.00								
48	25AUG92	Moderately ill	Minimally improved	2.00								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOMETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centro	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	40	306	EM	50	08SEP92	Mildly ill	Minimally improved	2.00
				52	22SEP92	Moderately ill	Minimally improved	2.00
1	41	307	SFS	8	19NOV91	Borderline mentally ill	Very much improved	2.00
				10	03DEC91	Mildly ill	Much improved	1.50
				12	17DEC91	Mildly ill	Much improved	1.50
				14	30DEC91	Mildly ill	Much improved	1.50
				16	14JAN92	Borderline mentally ill	Very much improved	4.00
				18	28JAN92	Normal	Very much improved	4.00
				20	17FEB92	Borderline mentally ill	Very much improved	4.00
				22	25FEB92	Mildly ill	Much improved	3.00
				24	10MAR92	Mildly ill	Much improved	3.00
				26	24MAR92	Mildly ill	Much improved	3.00
				28	07APR92	Mildly ill	Much improved	3.00
				30	22APR92	Borderline mentally ill	Very much improved	4.00
				32	05MAY92	Mildly ill	Much improved	3.00
				34	19MAY92	Mildly ill	Much improved	3.00
				36	02JUN92	Mildly ill	Much improved	3.00
				38	16JUN92	Mildly ill	Much improved	3.00
				40	30JUN92	Moderately ill	Minimally improved	2.00
				42	14JUL92	Moderately ill	Minimally improved	2.00
				44	28JUL92	Moderately ill	Minimally improved	2.00
1	42	308	ICC	8	27NOV91	Borderline mentally ill	Very much improved	4.00
				10	10DEC91	Borderline mentally ill	Very much improved	4.00
				12	26DEC91	Borderline mentally ill	Very much improved	4.00
				14	07JAN92	Borderline mentally ill	Very much improved	4.00
				16	21JAN92	Borderline mentally ill	Very much improved	4.00
				18	04FEB92	Normal	Very much improved	4.00
				20	18FEB92	Borderline mentally ill	Very much improved	4.00
				22	04MAR92	Mildly ill	Much improved	3.00
				24	18MAR92	Normal	Very much improved	4.00
				26	01APR92	Normal	Very much improved	4.00
				28	15APR92	Normal	Very much improved	4.00
				30	29APR92	Normal	Very much improved	4.00
				32	13MAY92	Normal	Very much improved	4.00
				34	27MAY92	Normal	Very much improved	4.00
				36	10JUN92	Normal	Very much improved	4.00
				38	24JUN92	Normal	Very much improved	4.00
				40	08JUL92	Normal	Very much improved	4.00
				42	22JUL92	Borderline mentally ill	Very much improved	4.00
				44	05AUG92	Borderline mentally ill	Very much improved	4.00
				46	19AUG92	Borderline mentally ill	Very much improved	4.00
				48	02SEP92	Normal	Very much improved	4.00
				50	16SEP92	Normal	Very much improved	4.00

1 2 2 3

PHARMACIA CNS RED - REBOMETINE - PROTOCOL 20124/013 - Listing No.: 10.3 - CLINICAL GLOBAL IMPRESSION (CGI) - DOUBLE BLIND PHASE - TREATMENT: PLACEBO

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	42	308	ICC	52	30SEP92	Normal	Very much improved	4.00
1	47	312	MCS	8	17DEC91	Borderline mentally ill	Very much improved	2.00
				10	31DEC91	Borderline mentally ill	Very much improved	4.00
				12	14JAN92	Normal	Very much improved	4.00
				14	28JAN92	Mildly ill	Much improved	3.00
				16	11FEB92	Moderately ill	Minimally improved	2.00
				18	25FEB92	Mildly ill	Much improved	3.00
				20	10MAR92	Mildly ill	Much improved	3.00
				22	24MAR92	Mildly ill	Very much improved	4.00
				24	07APR92	Mildly ill	Much improved	3.00
				26	22APR92	Mildly ill	Much improved	3.00
				28	05MAY92	Mildly ill	Much improved	3.00
				30	19MAY92	Mildly ill	Much improved	3.00
				32	02JUN92	Mildly ill	Much improved	3.00
				34	16JUN92	Mildly ill	Much improved	3.00
				36	30JUN92	Mildly ill	Much improved	3.00
				38	14JUL92	Mildly ill	Much improved	3.00
				40	28JUL92	Moderately ill	Minimally improved	2.00
				42	11AUG92	Moderately ill	Minimally improved	2.00
				44	25AUG92	Moderately ill	Minimally improved	2.00
				46	08SEP92	Moderately ill	Minimally improved	2.00
1	50	314	MFA	8	20DEC91	Borderline mentally ill	Very much improved	4.00
				10	03JAN92	Borderline mentally ill	Very much improved	4.00
				12	17JAN92	Mildly ill	Much improved	3.00
				14	31JAN92	Mildly ill	Much improved	3.00
				16	14FEB92	Mildly ill	Much improved	3.00
				18	28FEB92	Mildly ill	Much improved	3.00
				20	13MAR92	Mildly ill	Much improved	3.00
				22	27MAR92	Mildly ill	Much improved	3.00
				24	10APR92	Mildly ill	Much improved	3.00
				26	24APR92	Mildly ill	Much improved	3.00
				28	08MAY92	Mildly ill	Much improved	3.00
				30	22MAY92	Moderately ill	Minimally improved	2.00
				32	05JUN92	Mildly ill	Much improved	3.00
				34	19JUN92	Moderately ill	Minimally improved	2.00
				36	03JUL92	Moderately ill	Minimally improved	2.00
				38	17JUL92	Moderately ill	Minimally improved	2.00
				40	31JUL92	Mildly ill	Much improved	3.00
				42	14AUG92	Mildly ill	Much improved	3.00
				44	28AUG92	Borderline mentally ill	Very much improved	4.00
				46	11SEP92	Borderline mentally ill	Very much improved	4.00
				48	25SEP92	Normal	Very much improved	4.00
				50	09OCT92	Normal	Very much improved	4.00

1229

REBOXETINE - PROTOCOL 20124/013 Listing No.: 10.3

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTICOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 DOUBLE BLIND PHASE
 TREATMENT: PLACERO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	50	314	MFA	52	23OCT92	Normal	Very much improved	4.00
1	51	315	ASA	8	20DEC91	Normal	Very much improved	2.00
				10	03JAN92	Normal	Very much improved	4.00
				12	17JAN92	Normal	Very much improved	4.00
				14	31JAN92	Normal	Very much improved	4.00
				16	14FEB92	Mildly ill	Much improved	3.00
				18	28FEB92	Mildly ill	Much improved	3.00
				20	13MAR92	Borderline mentally ill	Very much improved	4.00
				22	27MAR92	Borderline mentally ill	Very much improved	4.00
				24	10APR92	Borderline mentally ill	Very much improved	4.00
				26	24APR92	Borderline mentally ill	Very much improved	4.00
				28	08MAY92	Normal	Very much improved	4.00
				30	22MAY92	Normal	Very much improved	4.00
				32	05JUN92	Borderline mentally ill	Very much improved	4.00
				34	19JUN92	Borderline mentally ill	Very much improved	4.00
				36	03JUL92	Mildly ill	Much improved	3.00
				38	17JUL92	Mildly ill	Much improved	3.00
				40	31JUL92	Mildly ill	Much improved	3.00
				42	14AUG92	Mildly ill	Much improved	3.00
				44	28AUG92	Moderately ill	Minimally improved	2.00
				46	11SEF92	Mildly ill	Much improved	3.00
				48	25SEF92	Mildly ill	Much improved	3.00
				50	09OCT92	Mildly ill	Much improved	3.00
				52	23OCT92	Mildly ill	Much improved	3.00
1	53	317	JFT	8	26DEC91	Normal	Very much improved	4.00
				10	08JAN92	Borderline mentally ill	Very much improved	4.00
				12	22JAN92	Mildly ill	Much improved	3.00
				14	05FEB92	Mildly ill	Much improved	3.00
				16	19FEB92	Mildly ill	Much improved	3.00
				18	04MAR92	Moderately ill	Minimally improved	2.00
				20	18MAR92	Moderately ill	No change	1.00
				22	01APR92	Moderately ill	No change	1.00
1	59	321	SPF	8	14FEB92	Borderline mentally ill	Very much improved	4.00
				10	28FEB92	Borderline mentally ill	Very much improved	4.00
				12	10MAR92	Normal	Very much improved	4.00
				14	24MAR92	Normal	Very much improved	4.00
				16	07APR92	Normal	Very much improved	4.00
				18	20APR92	Borderline mentally ill	Very much improved	4.00
				20	05MAY92	Borderline mentally ill	Very much improved	4.00
				22	19MAY92	Borderline mentally ill	Very much improved	4.00
				24	02JUN92	Mildly ill	Much improved	3.00
				26	16JUN92	Mildly ill	Much improved	3.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient No.	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
1	59	321	SPF	28	30JUN92	Mildly ill	Much improved	3.00				
				30	14JUL92	Mildly ill	Much improved	3.00				
				32	28JUL92	Mildly ill	Much improved	3.00				
				34	11AUG92	Mildly ill	Much improved	3.00				
				36	25AUG92	Mildly ill	Much improved	3.00				
				38	08SEP92	Mildly ill	Much improved	3.00				
				40	22SEP92	Moderately ill	Minimally improved	2.00				
				42	06OCT92	Mildly ill	Much improved	3.00				
				44	20OCT92	Mildly ill	Much improved	3.00				
				46	03NOV92	Moderately ill	Minimally improved	2.00				
				48	17NOV92	Moderately ill	Minimally improved	2.00				
				50	04DEC92	Mildly ill	Much improved	3.00				
				52	15DEC92	Moderately ill	Minimally improved	2.00				
				1	60	322	EM	8	14FEB92	Moderately ill	Minimally improved	2.00
								10	28FEB92	Mildly ill	Much improved	3.00
								12	13MAR92	Mildly ill	Much improved	3.00
								14	27MAR92	Mildly ill	Much improved	3.00
								16	10APR92	Mildly ill	Much improved	3.00
18	24APR92	Mildly ill	Much improved					3.00				
20	08MAY92	Mildly ill	Much improved					3.00				
22	22MAY92	Mildly ill	Much improved					3.00				
24	05JUN92	Moderately ill	Minimally improved					2.00				
26	19JUN92	Mildly ill	Much improved					3.00				
28	03JUL92	Moderately ill	Minimally improved					2.00				
30	17JUL92	Moderately ill	Minimally improved					2.00				
32	31JUL92	Moderately ill	Minimally improved					2.00				
34	14AUG92	Moderately ill	Minimally improved					2.00				
36	28AUG92	Moderately ill	Much improved					3.00				
38	11SEP92	Mildly ill	Minimally improved					2.00				
40	25SEP92	Moderately ill	Minimally improved					2.00				
42	09OCT92	Moderately ill	Minimally improved					2.00				
44	23OCT92	Moderately ill	Minimally improved	2.00								
46	06NOV92	Moderately ill	Minimally improved	2.00								
48	20NOV92	Moderately ill	No change	1.00								
50	04DEC92	Moderately ill	Minimally improved	2.00								
52	18DEC92	Moderately ill	Minimally improved	2.00								
1	62	324	MEA	8	04MAR92	Mildly ill	Much improved	1.50				
				10	17MAR92	Borderline mentally ill	Very much improved	2.00				
				12	31MAR92	Normal	Very much improved	4.00				
				14	14APR92	Borderline mentally ill	Very much improved	4.00				
				16	28APR92	Normal	Very much improved	4.00				
				18	12MAY92	Normal	Very much improved	4.00				
20	26MAY92	Normal	Very much improved	4.00								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXYLINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Contro	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	62	324	MEA	22	09JUN92	Normal	Very much improved	4.00
				24	23JUN92	Borderline mentally ill	Very much improved	4.00
				26	07JUL92	Borderline mentally ill	Very much improved	4.00
				28	21JUL92	Borderline mentally ill	Very much improved	4.00
				30	04AUG92	Mildly ill	Much improved	3.00
				32	18AUG92	Mildly ill	Much improved	3.00
				34	01SEP92	Mildly ill	Much improved	3.00
				36	15SEP92	Mildly ill	Much improved	3.00
				38	29SEP92	Mildly ill	Much improved	3.00
				40	13OCT92	Mildly ill	Much improved	3.00
				42	27OCT92	Mildly ill	Much improved	3.00
				44	10NOV92	Mildly ill	Much improved	3.00
				46	24NOV92	Mildly ill	Much improved	3.00
				48	08DEC92	Mildly ill	Much improved	3.00
				50	22DEC92	Mildly ill	Much improved	3.00
				52	05JAN93	Mildly ill	Much improved	3.00
1	64	325	EMF	8	13MAR92	Normal	Very much improved	2.00
				10	27MAR92	Mildly ill	Much improved	1.50
				12	10APR92	Mildly ill	Much improved	1.50
				14	24APR92	Mildly ill	Much improved	1.50
				16	08MAY92	Borderline mentally ill	Very much improved	2.00
				18	22MAY92	Mildly ill	Much improved	3.00
				20	05JUN92	Mildly ill	Much improved	3.00
				22	19JUN92	Borderline mentally ill	Very much improved	4.00
				24	03JUL92	Mildly ill	Much improved	3.00
				26	17JUL92	Mildly ill	Much improved	3.00
				28	31JUL92	Mildly ill	Kinimally improved	2.00
				30	14AUG92	Mildly ill	Much improved	3.00
				32	28AUG92	Moderately ill	Kinimally improved	2.00
				34	11SEP92	Mildly ill	Kinimally improved	2.00
				36	25SEP92	Mildly ill	Much improved	3.00
				38	09OCT92	Moderately ill	Minimally improved	2.00
				40	23OCT92	Borderline mentally ill	Very much improved	4.00
				42	06NOV92	Normal	Very much improved	4.00
				44	20NOV92	Normal	Very much improved	4.00
				46	04DEC92	Normal	Very much improved	4.00
				48	18DEC92	Normal	Very much improved	4.00
				50	31DEC92	Normal	Very much improved	4.00
				52	15JAN93	Normal	Very much improved	4.00
1	67	327	MAA	8	17MAR92	Borderline mentally ill	Very much improved	4.00
				10	31MAR92	Mildly ill	Much improved	3.00
				12	14APR92	Mildly ill	Much improved	3.00
				14	28APR92	Mildly ill	Much improved	3.00

REBOXYLINE - PROTOCOL 20124/013 Listing No.: 10.3

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
1	67	327	MAA	16	12MAY92	Mildly ill	Much improved	3.00				
				18	26MAY92	Mildly ill	Much improved	3.00				
				20	09JUN92	Borderline mentally ill	Very much improved	4.00				
				22	23JUN92	Mildly ill	Much improved	3.00				
				24	07JUL92	Moderately ill	Minimally improved	2.00				
				26	21JUL92	Markedly ill	No change	1.00				
1	70	328	MLM	8	20MAR92	Mildly ill	Much improved	3.00				
				10	03APR92	Moderately ill	Minimally improved	2.00				
				12	17APR92	Mildly ill	Much improved	1.50				
				14	30APR92	Moderately ill	Minimally improved	1.00				
				16	15MAY92	Moderately ill	Minimally improved	1.00				
				18	29MAY92	Moderately ill	Minimally improved	1.00				
				20	12JUN92	Moderately ill	Minimally improved	1.00				
				22	26JUN92	Moderately ill	Minimally improved	1.00				
				1	74	122	IVL	8	24MAR92	Borderline mentally ill	Very much improved	4.00
								10	07APR92	Borderline mentally ill	Very much improved	4.00
12	22APR92	Borderline mentally ill	Very much improved					4.00				
14	05MAY92	Mildly ill	Much improved					3.00				
16	19MAY92	Mildly ill	Much improved					3.00				
18	02JUN92	Borderline mentally ill	Very much improved					4.00				
20	16JUN92	Borderline mentally ill	Very much improved					4.00				
22	30JUN92	Borderline mentally ill	Very much improved					4.00				
24	14JUL92	Borderline mentally ill	Very much improved					4.00				
26	28JUL92	Borderline mentally ill	Very much improved					4.00				
28	11AUG92	Normal	Very much improved					4.00				
30	25AUG92	Borderline mentally ill	Very much improved					4.00				
32	08SEP92	Normal	Very much improved					4.00				
34	22SEP92	Normal	Very much improved					4.00				
36	06OCT92	Borderline mentally ill	Very much improved	4.00								
38	20OCT92	Borderline mentally ill	Very much improved	4.00								
40	03NOV92	Borderline mentally ill	Very much improved	4.00								
42	17NOV92	Borderline mentally ill	Very much improved	4.00								
44	01DEC92	Mildly ill	Much improved	3.00								
46	15DEC92	Mildly ill	Much improved	3.00								
48	29DEC92	Borderline mentally ill	Very much improved	4.00								
50	12JAN93	Borderline mentally ill	Very much improved	4.00								
52	26JAN93	Borderline mentally ill	Very much improved	4.00								
1	76	124	SFA	8	03APR92	Normal	Very much improved	4.00				
				10	17APR92	Normal	Very much improved	4.00				
				12	30APR92	Normal	Very much improved	4.00				
				14	15MAY92	Normal	Very much improved	4.00				
				16	29MAY92	Normal	Very much improved	4.00				

1233

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
1	76	124	SFA	18	12JUN92	Normal	Very much improved	4.00				
				20	26JUN92	Normal	Very much improved	4.00				
				22	10JUL92	Normal	Very much improved	4.00				
				24	24JUL92	Borderline mentally ill	Very much improved	4.00				
				26	07AUG92	Mildly ill	Much improved	3.00				
				28	21AUG92	Borderline mentally ill	Very much improved	4.00				
				30	04SEP92	Mildly ill	Much improved	3.00				
				32	18SEP92	Mildly ill	Much improved	3.00				
				34	02OCT92	Borderline mentally ill	Very much improved	4.00				
				36	16OCT92	Borderline mentally ill	Very much improved	4.00				
				38	30OCT92	Mildly ill	Much improved	3.00				
				40	13NOV92	Borderline mentally ill	Very much improved	4.00				
				42	27NOV92	Mildly ill	Much improved	3.00				
				44	10DEC92	Mildly ill	Much improved	3.00				
				46	24DEC92	Mildly ill	Much improved	1.50				
				48	08JAN93	Mildly ill	Much improved	1.50				
				50	22JAN93	Mildly ill	Much improved	3.00				
				52	05FEB93	Borderline mentally ill	Very much improved	4.00				
				1	79	126	JCM	8	03APR92	Borderline mentally ill	Very much improved	2.00
								10	17APR92	Borderline mentally ill	Very much improved	2.00
								12	30APR92	Borderline mentally ill	Very much improved	2.00
								14	15MAY92	Borderline mentally ill	Very much improved	2.00
								16	29MAY92	Normal	Very much improved	2.00
								18	12JUN92	Borderline mentally ill	Very much improved	2.00
								20	26JUN92	Normal	Very much improved	2.00
								22	10JUL92	Normal	Much improved	1.50
								24	24JUL92	Mildly ill	Much improved	1.50
								26	07AUG92	Mildly ill	Very much improved	2.00
				28	21AUG92	Borderline mentally ill	Very much improved	2.00				
				30	04SEP92	Borderline mentally ill	Much improved	1.50				
				32	18SEP92	Mildly ill	Much improved	3.00				
				34	02OCT92	Mildly ill	Very much improved	4.00				
				36	16OCT92	Borderline mentally ill	Very much improved	4.00				
				38	30OCT92	Borderline mentally ill	Very much improved	4.00				
				40	13NOV92	Borderline mentally ill	Very much improved	4.00				
				42	27NOV92	Normal	Very much improved	4.00				
				44	10DEC92	Borderline mentally ill	Very much improved	4.00				
				46	24DEC92	Normal	Very much improved	4.00				
				48	08JAN93	Borderline mentally ill	Very much improved	4.00				
				50	22JAN93	Normal	Very much improved	4.00				
				52	05FEB93	Normal	Very much improved	4.00				
				1	80	127	MEL	8	03APR92	Borderline mentally ill	Very much improved	2.00
								10	17APR92	Moderately ill	Minimally improved	1.00

1234

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXENTINE - PROTOCOL 20124/013
 Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
 DOUBLE BLIND PHASE
 TREATMENT: PLACERO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	80	127	MEL	12	30APR92	Moderately ill	Minimally improved	1.00
1	84	130	IN	8	03APR92	Borderline mentally ill	Very much improved	2.00
				10	17APR92	Borderline mentally ill	Very much improved	2.00
				12	30APR92	Mildly ill	Much improved	1.50
				14	15MAY92	Borderline mentally ill	Much improved	2.00
				16	29MAY92	Normal	Very much improved	2.00
				18	12JUN92	Normal	Much improved	2.00
				20	26JUN92	Borderline mentally ill	Much improved	1.50
				22	10JUL92	Mildly ill	Much improved	1.50
				24	24JUL92	Borderline mentally ill	Much improved	2.00
				26	07AUG92	Mildly ill	Much improved	3.00
				28	21AUG92	Mildly ill	Much improved	3.00
				30	04SEP92	Borderline mentally ill	Very much improved	2.00
				32	18SEP92	Borderline mentally ill	Very much improved	2.00
				34	02OCT92	Borderline mentally ill	Very much improved	2.00
				36	16OCT92	Normal	Very much improved	4.00
				38	30OCT92	Normal	Very much improved	4.00
				40	13NOV92	Borderline mentally ill	Very much improved	2.00
				42	27NOV92	Borderline mentally ill	Very much improved	2.00
				44	11DEC92	Mildly ill	Much improved	3.00
				46	24DEC92	Mildly ill	Much improved	1.50
				48	08JAN93	Moderately ill	Minimally improved	2.00
				50	22JAN93	Mildly ill	Minimally improved	3.00
				52	05FEB93	Mildly ill	Much improved	3.00
1	85	131	MEL	8	03APR92	Normal	Very much improved	4.00
				10	17APR92	Borderline mentally ill	Very much improved	4.00
				12	30APR92	Normal	Very much improved	4.00
				14	15MAY92	Normal	Very much improved	4.00
				16	29MAY92	Normal	Very much improved	4.00
				18	12JUN92	Normal	Very much improved	4.00
				20	26JUN92	Normal	Very much improved	4.00
				22	10JUL92	Normal	Very much improved	4.00
				24	24JUL92	Normal	Very much improved	4.00
				26	07AUG92	Normal	Very much improved	4.00
				28	21AUG92	Borderline mentally ill	Very much improved	2.00
				30	04SEP92	Mildly ill	Much improved	1.50
				32	18SEP92	Borderline mentally ill	Very much improved	4.00
				34	02OCT92	Borderline mentally ill	Very much improved	4.00
				36	16OCT92	Normal	Very much improved	4.00
				38	30OCT92	Normal	Very much improved	4.00
				40	13NOV92	Borderline mentally ill	Very much improved	4.00
				42	27NOV92	Mildly ill	Much improved	4.00
				44	11DEC92	Mildly ill	Much improved	3.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
 DOUBLE BLIND PHASE
 TREATMENT: PLACERO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
1	85	131	MLP	46	24DEC92	Moderately ill	Minimally improved	2.00				
				48	08JAN93	Moderately ill	Minimally improved	2.00				
				50	22JAN93	Moderately ill	Minimally improved	2.00				
				52	05FEB93	Moderately ill	Minimally improved	2.00				
				1	91	135	MSC	8	07APR92	Borderline mentally ill	Very much improved	4.00
								10	22APR92	Borderline mentally ill	Very much improved	4.00
								12	05MAY92	Borderline mentally ill	Very much improved	4.00
								14	19MAY92	Borderline mentally ill	Very much improved	4.00
								16	02JUN92	Normal	Very much improved	4.00
								18	16JUN92	Normal	Very much improved	4.00
								20	30JUN92	Normal	Very much improved	4.00
								22	14JUL92	Normal	Very much improved	4.00
24	28JUL92	Borderline mentally ill	Very much improved					4.00				
26	17AUG92	Borderline mentally ill	Very much improved					4.00				
28	25AUG92	Borderline mentally ill	Very much improved					4.00				
30	08SEP92	Borderline mentally ill	Very much improved					4.00				
32	22SEP92	Borderline mentally ill	Very much improved	4.00								
34	06OCT92	Borderline mentally ill	Very much improved	4.00								
36	20OCT92	Borderline mentally ill	Very much improved	4.00								
38	03NOV92	Borderline mentally ill	Very much improved	4.00								
40	17NOV92	Borderline mentally ill	Very much improved	4.00								
42	01DEC92	Mildly ill	Much improved	3.00								
44	15DEC92	Mildly ill	Much improved	3.00								
46	29DEC92	Mildly ill	Much improved	3.00								
48	12JAN93	Mildly ill	Much improved	3.00								
50	26JAN93	Moderately ill	Minimally improved	2.00								
52	09FEB93	Moderately ill	Minimally improved	2.00								
1	93	136	AL	8	06APR92	Normal	Very much improved	2.00				
				10	22APR92	Normal	Very much improved	2.00				
				12	06MAY92	Normal	Very much improved	4.00				
				14	20MAY92	Normal	Very much improved	4.00				
				16	03JUN92	Borderline mentally ill	Very much improved	4.00				
				18	17JUN92	Normal	Very much improved	4.00				
				20	01JUL92	Borderline mentally ill	Very much improved	4.00				
				22	15JUL92	Borderline mentally ill	Very much improved	4.00				
				24	29JUL92	Normal	Very much improved	4.00				
				26	12AUG92	Normal	Very much improved	4.00				
				28	26AUG92	Borderline mentally ill	Very much improved	4.00				
				30	09SEP92	Borderline mentally ill	Very much improved	4.00				
32	23SEP92	Borderline mentally ill	Very much improved	4.00								
34	07OCT92	Borderline mentally ill	Very much improved	4.00								
36	21OCT92	Mildly ill	Much improved	4.00								
38	04NOV92	Mildly ill	Much improved	3.00								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
1	93	136	AL	40	18NOV92	Mildly ill	Much improved	3.00				
				42	02DEC92	Mildly ill	Much improved	3.00				
				44	16DEC92	Moderately ill	Minimally improved	2.00				
				46	30DEC92	Moderately ill	Minimally improved	2.00				
				48	13JAN93	Moderately ill	Minimally improved	2.00				
				50	27JAN93	Moderately ill	Minimally improved	2.00				
				52	10FEB93	Moderately ill	Minimally improved	2.00				
				1	94	137	RAB	8	08APR92	Borderline mentally ill	Very much improved	2.00
								10	22APR92	Borderline mentally ill	Very much improved	2.00
								12	06MAY92	Borderline mentally ill	Very much improved	2.00
14	20MAY92	Normal	Very much improved					2.00				
16	03JUN92	Normal	Very much improved					2.00				
18	17JUN92	Borderline mentally ill	Very much improved					2.00				
20	01JUL92	Borderline mentally ill	Very much improved					2.00				
22	15JUL92	Borderline mentally ill	Very much improved					2.00				
24	29JUL92	Normal	Very much improved					2.00				
26	12AUG92	Normal	Very much improved					2.00				
28	26AUG92	Mildly ill	Much improved	3.00								
30	09SEP92	Mildly ill	Much improved	1.50								
32	23SEP92	Mildly ill	Much improved	1.50								
34	07OCT92	Mildly ill	Much improved	3.00								
36	21OCT92	Borderline mentally ill	Very much improved	4.00								
38	04NOV92	Normal	Very much improved	4.00								
40	18NOV92	Normal	Very much improved	4.00								
42	02DEC92	Mildly ill	Much improved	1.50								
44	16DEC92	Mildly ill	Much improved	1.50								
46	30DEC92	Borderline mentally ill	Very much improved	4.00								
48	13JAN93	Borderline mentally ill	Very much improved	4.00								
50	27JAN93	Mildly ill	Much improved	3.00								
52	10FEB93	Borderline mentally ill	Very much improved	4.00								
1	97	140	HND	8	08APR92	Normal	Very much improved	4.00				
				10	22APR92	Normal	Very much improved	4.00				
				12	06MAY92	Normal	Very much improved	4.00				
				14	20MAY92	Normal	Very much improved	4.00				
				16	03JUN92	Normal	Very much improved	4.00				
				18	17JUN92	Normal	Very much improved	4.00				
				20	01JUL92	Normal	Very much improved	4.00				
				22	15JUL92	Normal	Very much improved	4.00				
				24	29JUL92	Borderline mentally ill	Very much improved	4.00				
				26	12AUG92	Borderline mentally ill	Very much improved	4.00				
28	26AUG92	Normal	Much improved	3.00								
30	09SEP92	Mildly ill	Much improved	3.00								
32	23SEP92	Mildly ill	Much improved	3.00								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBEXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
1	97	140	MND	8	07OCT92	Mildly ill	Much improved	3.00				
				36	21OCT92	Borderline mentally ill	Very much improved	4.00				
				38	04NOV92	Borderline mentally ill	Very much improved	4.00				
				40	18NOV92	Borderline mentally ill	Very much improved	4.00				
				42	02DEC92	Borderline mentally ill	Very much improved	4.00				
				44	16DEC92	Normal	Very much improved	4.00				
				46	30DEC92	Normal	Very much improved	4.00				
				48	13JAN93	Normal	Very much improved	4.00				
				50	27JAN93	Normal	Very much improved	4.00				
				52	10FEB93	Normal	Very much improved	4.00				
				1	100	142	JWA	8	08APR92	Normal	Very much improved	4.00
								10	22APR92	Normal	Very much improved	4.00
								12	06MAY92	Normal	Very much improved	4.00
								14	20MAY92	Normal	Very much improved	4.00
16	03JUN92	Normal	Very much improved					4.00				
18	17JUN92	Normal	Very much improved					4.00				
20	01JUL92	Normal	Very much improved					4.00				
22	15JUL92	Normal	Very much improved					4.00				
24	29JUL92	Borderline mentally ill	Very much improved					4.00				
26	12AUG92	Normal	Very much improved					4.00				
28	26AUG92	Borderline mentally ill	Very much improved					4.00				
30	09SEP92	Borderline mentally ill	Very much improved					4.00				
32	23SEP92	Mildly ill	Much improved					1.50				
34	07OCT92	Borderline mentally ill	Very much improved					4.00				
36	21OCT92	Borderline mentally ill	Very much improved	4.00								
38	04NOV92	Normal	Very much improved	4.00								
40	18NOV92	Borderline mentally ill	Very much improved	4.00								
42	02DEC92	Normal	Very much improved	4.00								
44	16DEC92	Normal	Very much improved	4.00								
46	30DEC92	Normal	Very much improved	4.00								
48	13JAN93	Normal	Very much improved	4.00								
50	27JAN93	Normal	Very much improved	4.00								
52	10FEB93	Normal	Very much improved	4.00								
1	104	144	MTF	8	14APR92	Normal	Very much improved	2.00				
				10	28APR92	Normal	Very much improved	2.00				
				12	12MAY92	Normal	Very much improved	2.00				
				14	26MAY92	Borderline mentally ill	Very much improved	2.00				
				16	09JUN92	Normal	Very much improved	2.00				
				18	23JUN92	Normal	Very much improved	2.00				
				20	07JUL92	Borderline mentally ill	Very much improved	2.00				
				22	21JUL92	Borderline mentally ill	Very much improved	2.00				
				24	05AUG92	Mildly ill	Much improved	1.50				
				26	19AUG92	Mildly ill	Much improved	1.50				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 RESOMETINE - PROTOCOL 20124/013
 Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centro	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
1	104	144	MTF	28	02SEP92	Borderline mentally ill	Very much improved	4.00				
				30	16SEP92	Moderately ill	Minimally improved	2.00				
				32	30SEP92	Borderline mentally ill	Very much improved	4.00				
				34	14OCT92	Normal	Very much improved	4.00				
				36	28OCT92	Borderline mentally ill	Very much improved	2.00				
				38	11NOV92	Borderline mentally ill	Very much improved	2.00				
				40	25NOV92	Borderline mentally ill	Very much improved	4.00				
				42	09DEC92	Mildly ill	Much improved	3.00				
				44	23DEC92	Mildly ill	Much improved	3.00				
				46	06JAN93	Borderline mentally ill	Very much improved	4.00				
				48	19JAN93	Mildly ill	Much improved	3.00				
				50	03FEB93	Borderline mentally ill	Very much improved	4.00				
				52	17FEB93	Borderline mentally ill	Very much improved	4.00				
				1	105	145	ABS	8	14APR92	Normal	Very much improved	2.00
								10	28APR92	Borderline mentally ill	Very much improved	2.00
								12	12MAY92	Borderline mentally ill	Very much improved	2.00
								14	26MAY92	Borderline mentally ill	Very much improved	2.00
16	09JUN92	Borderline mentally ill	Very much improved					2.00				
18	23JUN92	Borderline mentally ill	Very much improved					2.00				
20	07JUL92	Borderline mentally ill	Very much improved					2.00				
22	21JUL92	Borderline mentally ill	Very much improved					2.00				
24	05AUG92	Borderline mentally ill	Very much improved					2.00				
26	19AUG92	Borderline mentally ill	Very much improved					2.00				
28	02SEP92	Mildly ill	Much improved					1.50				
30	16SEP92	Borderline mentally ill	Much improved					2.00				
32	30SEP92	Mildly ill	Much improved					1.50				
34	14OCT92	Normal	Very much improved					2.00				
36	28OCT92	Borderline mentally ill	Very much improved					4.00				
38	11NOV92	Borderline mentally ill	Very much improved					2.00				
40	25NOV92	Normal	Very much improved					4.00				
42	09DEC92	Normal	Very much improved	4.00								
44	23DEC92	Borderline mentally ill	Very much improved	4.00								
46	06JAN93	Normal	Very much improved	4.00								
48	19JAN93	Normal	Very much improved	4.00								
50	03FEB93	Normal	Very much improved	4.00								
52	17FEB93	Normal	Very much improved	4.00								
1	106	146	MRN	8	14APR92	Normal	Very much improved	2.00				
				10	28APR92	Normal	Very much improved	2.00				
				12	12MAY92	Normal	Very much improved	2.00				
				14	26MAY92	Normal	Very much improved	2.00				
				16	09JUN92	Normal	Very much improved	2.00				
				18	23JUN92	Normal	Very much improved	2.00				
				20	07JUL92	Normal	Very much improved	2.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
1	106	146	MRN	22	21JUL92	Normal	Very much improved	2.00				
				24	04AUG92	Normal	Very much improved	2.00				
				26	18AUG92	Borderline mentally ill	Very much improved	2.00				
				28	01SEP92	Borderline mentally ill	Very much improved	2.00				
				30	15SEP92	Normal	Very much improved	4.00				
				32	29SEP92	Borderline mentally ill	Very much improved	2.00				
				34	13OCT92	Mildly ill	Much improved	1.50				
				36	27OCT92	Borderline mentally ill	Very much improved	4.00				
				38	10NOV92	Borderline mentally ill	Very much improved	4.00				
				40	24NOV92	Borderline mentally ill	Very much improved	4.00				
				42	08DEC92	Mildly ill	Much improved	3.00				
				44	22DEC92	Mildly ill	Much improved	3.00				
				46	05JAN93	Borderline mentally ill	Very much improved	4.00				
				48	19JAN93	Borderline mentally ill	Very much improved	4.00				
				50	02FEB93	Mildly ill	Much improved	3.00				
				52	16FEB93	Borderline mentally ill	Very much improved	4.00				
				1	108	148	STB	8	15APR92	Borderline mentally ill	Very much improved	2.00
								10	29APR92	Borderline mentally ill	Very much improved	2.00
								12	13MAY92	Borderline mentally ill	Very much improved	2.00
								14	27MAY92	Normal	Very much improved	2.00
								16	10JUN92	Normal	Very much improved	2.00
								18	24JUN92	Normal	Very much improved	2.00
20	08JUL92	Normal	Very much improved					2.00				
22	22JUL92	Normal	Very much improved					2.00				
24	05AUG92	Borderline mentally ill	Very much improved					2.00				
26	19AUG92	Borderline mentally ill	Very much improved					4.00				
28	02SEP92	Borderline mentally ill	Very much improved					4.00				
30	16SEP92	Normal	Very much improved					4.00				
32	30SEP92	Normal	Very much improved					4.00				
34	14OCT92	Mildly ill	Much improved					1.50				
36	28OCT92	Borderline mentally ill	Very much improved					2.00				
38	11NOV92	Borderline mentally ill	Very much improved					2.00				
40	25NOV92	Borderline mentally ill	Very much improved					2.00				
42	09DEC92	Mildly ill	Much improved					3.00				
44	23DEC92	Mildly ill	Much improved					3.00				
46	06JAN93	Mildly ill	Much improved					1.50				
48	19JAN93	Mildly ill	Much improved					1.50				
50	03FEB93	Mildly ill	Much improved					1.50				
52	17FEB93	Mildly ill	Much improved	1.50								
1	111	331	JBF	8	15APR92	Borderline mentally ill	Very much improved	2.00				
				10	29APR92	Borderline mentally ill	Very much improved	2.00				
				12	13MAY92	Mildly ill	Much improved	1.50				
				14	27MAY92	Mildly ill	Much improved	1.50				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REMOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
1	111	331	JBF	16	10JUN92	Borderline mentally ill	Very much improved	4.00				
				18	24JUN92	Borderline mentally ill	Very much improved	4.00				
				20	08JUL92	Mildly ill	Much improved	3.00				
				22	22JUL92	Mildly ill	Much improved	3.00				
				24	05AUG92	Borderline mentally ill	Very much improved	4.00				
				26	19AUG92	Borderline mentally ill	Very much improved	4.00				
				28	02SEP92	Mildly ill	Much improved	3.00				
				30	16SEP92	Mildly ill	Much improved	3.00				
				32	30SEP92	Mildly ill	Much improved	3.00				
				34	14OCT92	Mildly ill	Much improved	3.00				
				36	28OCT92	Mildly ill	Much improved	3.00				
				38	11NOV92	Borderline mentally ill	Very much improved	4.00				
				40	25NOV92	Borderline mentally ill	Very much improved	4.00				
				42	09DEC92	Borderline mentally ill	Very much improved	4.00				
				44	23DEC92	Borderline mentally ill	Very much improved	4.00				
				46	06JAN93	Normal	Very much improved	4.00				
				48	19JAN93	Borderline mentally ill	Very much improved	4.00				
				50	03FEB93	Borderline mentally ill	Very much improved	4.00				
				52	17FEB93	Borderline mentally ill	Very much improved	4.00				
				1	114	332	CLF	8	22APR92	Mildly ill	Much improved	1.50
								10	05MAY92	Mildly ill	Much improved	1.50
								12	19MAY92	Mildly ill	Much improved	1.50
								14	02JUN92	Mildly ill	Much improved	1.50
								16	16JUN92	Mildly ill	Much improved	1.50
								18	30JUN92	Mildly ill	Much improved	1.50
								20	14JUL92	Mildly ill	Minimally improved	1.50
								22	28JUL92	Mildly ill	Much improved	1.50
								24	12AUG92	Borderline mentally ill	Very much improved	2.00
								26	26AUG92	Borderline mentally ill	Very much improved	2.00
								28	09SEP92	Borderline mentally ill	Very much improved	2.00
								30	23SEP92	Borderline mentally ill	Very much improved	2.00
								32	07OCT92	Mildly ill	Very much improved	2.00
34	21OCT92	Mildly ill	Much improved					1.50				
36	04NOV92	Mildly ill	Much improved					1.50				
38	18NOV92	Mildly ill	Much improved					1.50				
40	02DEC92	Borderline mentally ill	Very much improved	2.00								
42	16DEC92	Mildly ill	Much improved	1.50								
44	30DEC92	Mildly ill	Much improved	1.50								
46	13JAN93	Mildly ill	Much improved	3.00								
48	27JAN93	Mildly ill	Much improved	3.00								
50	10FEB93	Mildly ill	Much improved	3.00								
52	24FEB93	Borderline mentally ill	Very much improved	4.00								
1	115	333	ELS	8	22APR92	Borderline mentally ill	Very much improved	4.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	115	333	ELS	10	05MAY92	Normal	Very much improved	4.00
				12	19MAY92	Normal	Very much improved	4.00
				14	02JUN92	Normal	Very much improved	4.00
				16	16JUN92	Borderline mentally ill	Very much improved	4.00
				18	30JUN92	Borderline mentally ill	Very much improved	4.00
				20	14JUL92	Borderline mentally ill	Very much improved	4.00
				22	28JUL92	Borderline mentally ill	Very much improved	4.00
				24	12AUG92	Borderline mentally ill	Very much improved	4.00
				26	26AUG92	Borderline mentally ill	Very much improved	4.00
				28	09SEP92	Hidly ill	Much improved	3.00
				30	23SEP92	Borderline mentally ill	Very much improved	4.00
				32	07OCT92	Normal	Very much improved	4.00
				34	21OCT92	Hidly ill	Much improved	3.00
				36	04NOV92	Hidly ill	Much improved	3.00
				38	18NOV92	Borderline mentally ill	Very much improved	4.00
				40	02DEC92	Borderline mentally ill	Very much improved	4.00
				42	15DEC92	Normal	Very much improved	4.00
				44	30DEC92	Normal	Very much improved	4.00
				46	13JAN93	Normal	Very much improved	4.00
				48	27JAN93	Normal	Very much improved	4.00
				50	10FEB93	Normal	Very much improved	4.00
				52	24FEB93	Normal	Very much improved	4.00
1	122	337	HSS	8	22APR92	Normal	Very much improved	2.00
				10	06MAY92	Normal	Very much improved	2.00
				12	20MAY92	Normal	Very much improved	2.00
				14	03JUN92	Normal	Very much improved	2.00
				16	17JUN92	Normal	Very much improved	2.00
				18	01JUL92	Normal	Very much improved	2.00
				20	15JUL92	Normal	Very much improved	2.00
				22	29JUL92	Normal	Very much improved	2.00
				24	12AUG92	Normal	Very much improved	2.00
				26	26AUG92	Normal	Very much improved	2.00
				28	09SEP92	Borderline mentally ill	Very much improved	2.00
				30	23SEP92	Normal	Very much improved	2.00
				32	07OCT92	Normal	Very much improved	2.00
				34	21OCT92	Normal	Very much improved	2.00
				36	04NOV92	Normal	Very much improved	2.00
				38	18NOV92	Normal	Very much improved	2.00
				40	02DEC92	Borderline mentally ill	Very much improved	2.00
				42	16DEC92	Normal	Very much improved	2.00
				44	30DEC92	Normal	Very much improved	2.00
				46	13JAN93	Normal	Very much improved	2.00
				48	27JAN93	Normal	Very much improved	2.00
				50	10FEB93	Normal	Very much improved	2.00

1242

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	122	397	HSS	52	24FEB93	Normal	Very much improved	4.00
1	124	339	PPC	8	22APR92	Normal	Very much improved	2.00
				10	06MAY92	Normal	Very much improved	2.00
				12	20MAY92	Normal	Very much improved	2.00
				14	03JUN92	Borderline mentally ill	Very much improved	2.00
				16	17JUN92	Borderline mentally ill	Very much improved	2.00
				18	01JUL92	Borderline mentally ill	Very much improved	2.00
				20	15JUL92	Borderline mentally ill	Very much improved	2.00
				22	29JUL92	Normal	Very much improved	2.00
				24	12AUG92	Borderline mentally ill	Very much improved	2.00
				26	26AUG92	Mildly ill	Much improved	1.50
				28	09SEF92	Borderline mentally ill	Very much improved	2.00
				30	23SEF92	Borderline mentally ill	Very much improved	2.00
				32	07OCT92	Borderline mentally ill	Very much improved	2.00
				34	21OCT92	Normal	Very much improved	2.00
				36	04NOV92	Mildly ill	Much improved	1.50
				38	18NOV92	Borderline mentally ill	Very much improved	2.00
				40	02DEC92	Normal	Very much improved	2.00
				42	16DEC92	Normal	Very much improved	2.00
				44	30DEC92	Normal	Very much improved	2.00
				46	13JAN93	Mildly ill	Very much improved	4.00
				48	27JAN93	Mildly ill	Much improved	3.00
				50	10FEB93	Mildly ill	Much improved	3.00
				52	24FEB93	Mildly ill	Much improved	3.00
1	126	341	SMB	8	22APR92	Normal	Very much improved	4.00
				10	06MAY92	Normal	Very much improved	4.00
				12	20MAY92	Normal	Very much improved	4.00
				14	03JUN92	Normal	Very much improved	4.00
				16	17JUN92	Normal	Very much improved	4.00
				18	01JUL92	Normal	Very much improved	4.00
				20	15JUL92	Normal	Very much improved	4.00
				22	29JUL92	Normal	Very much improved	4.00
				24	12AUG92	Normal	Very much improved	4.00
				26	26AUG92	Normal	Very much improved	4.00
				28	09SEF92	Borderline mentally ill	Very much improved	4.00
				30	23SEF92	Borderline mentally ill	Very much improved	4.00
				32	07OCT92	Borderline mentally ill	Very much improved	4.00
				34	21OCT92	Borderline mentally ill	Very much improved	4.00
				36	04NOV92	Normal	Very much improved	4.00
				38	18NOV92	Normal	Very much improved	4.00
				40	02DEC92	Normal	Very much improved	4.00
				42	16DEC92	Normal	Very much improved	4.00
				44	30DEC92	Normal	Very much improved	4.00

1243

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
-TREATMENT: PLACERO

Centre	Patient No.	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
1	126	341	SMB	46	13JAN93	Normal	Very much improved	4.00
				48	27JAN93	Normal	Very much improved	4.00
				50	10FEB93	Normal	Very much improved	4.00
				52	24FEB93	Normal	Very much improved	4.00
				8	22APR92	Normal	Very much improved	4.00
				10	06MAY92	Normal	Very much improved	4.00
				12	20MAY92	Normal	Very much improved	4.00
				14	03JUN92	Normal	Very much improved	4.00
				16	17JUN92	Normal	Very much improved	4.00
				18	01JUL92	Normal	Very much improved	4.00
1	129	344	MNS	20	15JUL92	Normal	Very much improved	4.00
				22	29JUL92	Normal	Very much improved	4.00
				24	12AUG92	Normal	Very much improved	4.00
				26	26AUG92	Borderline mentally ill	Very much improved	4.00
				28	09SEP92	Mildly ill	Very much improved	4.00
				30	23SEP92	Moderately ill	Much improved	3.00
				32	07OCT92	Mildly ill	Much improved	3.00
				34	21OCT92	Moderately ill	Minimally improved	2.00
				36	04NOV92	Moderately ill	Minimally improved	2.00
				38	18NOV92	Moderately ill	Minimally improved	2.00
1	130	345	EGA	40	02DEC92	Moderately ill	Minimally improved	2.00
				42	16DEC92	Moderately ill	Minimally improved	2.00
				8	24APR92	Borderline mentally ill	Very much improved	2.00
				10	08MAY92	Mildly ill	Much improved	1.50
				12	22MAY92	Mildly ill	Much improved	1.50
				14	05JUN92	Mildly ill	Much improved	1.50
				16	19JUN92	Mildly ill	Much improved	1.50
				18	03JUL92	Mildly ill	Much improved	1.50
				20	17JUL92	Moderately ill	Minimally improved	1.00
				22	31JUL92	Moderately ill	Minimally improved	1.00
1	133	346	JPK	8	15MAY92	Mildly ill	Much improved	1.50
				10	29MAY92	Borderline mentally ill	Very much improved	2.00
				12	12JUN92	Borderline mentally ill	Very much improved	2.00
				14	26JUN92	Borderline mentally ill	Very much improved	2.00
				16	10JUL92	Mildly ill	Much improved	1.50
				18	24JUL92	Mildly ill	Much improved	1.50
				20	07AUG92	Mildly ill	Much improved	1.50
				22	21AUG92	Mildly ill	Much improved	1.50
				24	04SEP92	Borderline mentally ill	Very much improved	2.00
				26	18SEP92	Borderline mentally ill	Very much improved	2.00
28	02OCT92	Borderline mentally ill	Very much improved	2.00				
30	16OCT92	Borderline mentally ill	Very much improved	2.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
1	133	346	JPH	32	30OCT92	Normal	Very much improved	2.00				
				34	13NOV92	Normal	Very much improved	2.00				
				36	27NOV92	Borderline mentally ill	Very much improved	2.00				
				38	11DEC92	Borderline mentally ill	Very much improved	2.00				
				40	24DEC92	Borderline mentally ill	Very much improved	2.00				
				42	08JAN93	Mildly ill	Much improved	1.50				
				44	22JAN93	Mildly ill	Much improved	3.00				
				46	05FEB93	Borderline mentally ill	Very much improved	1.53				
				48	19FEB93	Normal	Very much improved	4.00				
				50	05MAR93	Borderline mentally ill	Very much improved	4.00				
				52	19MAR93	Borderline mentally ill	Very much improved	4.00				
				1	136	349	AJP	8	19MA92	Borderline mentally ill	Very much improved	2.00
								10	02JUN92	Borderline mentally ill	Very much improved	2.00
								12	16JUN92	Mildly ill	Much improved	1.50
								14	30JUN92	Mildly ill	Much improved	1.50
								16	14JUL92	Mildly ill	Much improved	1.50
								18	28JUL92	Mildly ill	Much improved	1.50
20	11AUG92	Mildly ill	Much improved					1.50				
22	25AUG92	Mildly ill	Much improved					2.00				
24	08SEF92	Borderline mentally ill	Very much improved					2.00				
26	22SEF92	Borderline mentally ill	Very much improved					2.00				
28	06OCT92	Mildly ill	Much improved					1.00				
30	20OCT92	Mildly ill	Much improved					1.50				
32	03NOV92	Mildly ill	Much improved					1.50				
34	17NOV92	Mildly ill	Much improved					1.50				
36	01DEC92	Mildly ill	Much improved					3.00				
38	15DEC92	Mildly ill	Much improved					3.00				
40	29DEC92	Borderline mentally ill	Very much improved					4.00				
42	12JAN93	Mildly ill	Much improved	3.00								
44	26JAN93	Borderline mentally ill	Very much improved	4.00								
46	09FEB93	Borderline mentally ill	Very much improved	4.00								
48	24FEB93	Borderline mentally ill	Very much improved	4.00								
50	09MAR93	Normal	Very much improved	4.00								
52	23MAR93	Mildly ill	Much improved	3.00								
1	138	350	LBV	8	19MA92	Normal	Very much improved	4.00				
				10	02JUN92	Normal	Very much improved	4.00				
				12	16JUN92	Normal	Very much improved	4.00				
				14	30JUN92	Normal	Very much improved	4.00				
				16	14JUL92	Normal	Very much improved	4.00				
				18	28JUL92	Borderline mentally ill	Very much improved	4.00				
				20	11AUG92	Borderline mentally ill	Very much improved	4.00				
				22	25AUG92	Borderline mentally ill	Very much improved	4.00				
				24	08SEF92	Borderline mentally ill	Very much improved	4.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

PEROMETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
1	138	350	LBV	26	22SEP92	Borderline mentally ill	Very much improved	4.00				
				28	06OCT92	Mildly ill	Much improved	3.00				
				30	20OCT92	Mildly ill	Much improved	3.00				
				32	03NOV92	Mildly ill	Much improved	3.00				
				34	17NOV92	Mildly ill	Much improved	3.00				
				36	01DEC92	Mildly ill	Much improved	3.00				
				38	15DEC92	Borderline mentally ill	Much improved	3.00				
				40	29DEC92	Borderline mentally ill	Very much improved	4.00				
				42	12JAN93	Borderline mentally ill	Very much improved	4.00				
				44	26JAN93	Mildly ill	Much improved	3.00				
				46	09FEB93	Mildly ill	Much improved	3.00				
				48	24FEB93	Borderline mentally ill	Very much improved	4.00				
				50	09MAR93	Borderline mentally ill	Very much improved	4.00				
				52	23MAR93	Borderline mentally ill	Very much improved	4.00				
				1	141	353	ANG	8	19MAY92	Borderline mentally ill	Very much improved	2.00
								10	02JUN92	Mildly ill	Much improved	1.50
								12	16JUN92	Mildly ill	Much improved	1.50
								14	30JUN92	Borderline mentally ill	Very much improved	2.00
16	14JUL92	Borderline mentally ill	Very much improved					2.00				
18	28JUL92	Normal	Very much improved					2.00				
20	11AUG92	Normal	Very much improved					2.00				
22	25AUG92	Normal	Very much improved					2.00				
24	08SEP92	Normal	Very much improved					2.00				
26	22SEP92	Normal	Very much improved					2.00				
28	06OCT92	Mildly ill	Much improved					1.50				
30	20OCT92	Mildly ill	Much improved					1.50				
32	03NOV92	Moderately ill	Minimally improved	2.00								
34	17NOV92	Moderately ill	Minimally improved	2.00								
36	01DEC92	Moderately ill	Minimally improved	2.00								
1	143	355	JEP	8	19MAY92	Normal	Very much improved	2.00				
				10	02JUN92	Borderline mentally ill	Very much improved	2.00				
				12	16JUN92	Mildly ill	Much improved	3.00				
				14	30JUN92	Mildly ill	Much improved	3.00				
				16	14JUL92	Mildly ill	Much improved	3.00				
				18	28JUL92	Mildly ill	Much improved	3.00				
				20	11AUG92	Moderately ill	Minimally improved	2.00				
				1	145	357	SLD	8	22MAY92	Normal	Very much improved	4.00
								10	05JUN92	Normal	Very much improved	4.00
								12	19JUN92	Borderline mentally ill	Very much improved	4.00
								14	03JUL92	Borderline mentally ill	Very much improved	4.00
								16	17JUL92	Borderline mentally ill	Very much improved	4.00
18	31JUL92	Mildly ill	Much improved					3.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
1	145	357	SLD	20	16AUG92	Mildly ill	Much improved	3.00				
				22	28AUG92	Mildly ill	Much improved	3.00				
				24	11SEP92	Borderline mentally ill	Very much improved	4.00				
				26	25SEP92	Mildly ill	Much improved	3.00				
				28	09OCT92	Mildly ill	Much improved	3.00				
				30	23OCT92	Mildly ill	Much improved	3.00				
				32	06NOV92	Mildly ill	Much improved	3.00				
				34	20NOV92	Borderline mentally ill	Very much improved	4.00				
				36	04DEC92	Mildly ill	Much improved	3.00				
				38	18DEC92	Mildly ill	Much improved	3.00				
				40	31DEC92	Mildly ill	Much improved	3.00				
				42	15JAN93	Mildly ill	Much improved	3.00				
				44	29JAN93	Mildly ill	Much improved	3.00				
				46	12FEB93	Borderline mentally ill	Very much improved	4.00				
				48	26FEB93	Borderline mentally ill	Very much improved	4.00				
				50	12MAR93	Borderline mentally ill	Very much improved	4.00				
				52	26MAR93	Mildly ill	Much improved	3.00				
				1	149	360	SC	8	22MAY92	Normal	Very much improved	2.00
								10	05JUN92	Borderline mentally ill	Very much improved	2.00
								12	19JUN92	Mildly ill	Much improved	1.50
								14	03JUL92	Mildly ill	Much improved	1.50
								16	17JUL92	Mildly ill	Much improved	1.50
								18	31JUL92	Mildly ill	Much improved	1.50
								20	14AUG92	Borderline mentally ill	Very much improved	2.00
								22	28AUG92	Normal	Very much improved	2.00
								24	11SEP92	Borderline mentally ill	Very much improved	2.00
								26	25SEP92	Borderline mentally ill	Very much improved	2.00
								28	09OCT92	Borderline mentally ill	Very much improved	2.00
								30	23OCT92	Borderline mentally ill	Very much improved	2.00
								32	06NOV92	Borderline mentally ill	Very much improved	2.00
								34	20NOV92	Borderline mentally ill	Very much improved	2.00
								36	04DEC92	Normal	Very much improved	4.00
38	18DEC92	Normal	Very much improved					4.00				
40	31DEC92	Normal	Very much improved	4.00								
42	15JAN93	Normal	Very much improved	4.00								
44	29JAN93	Normal	Very much improved	4.00								
46	12FEB93	Normal	Very much improved	4.00								
48	26FEB93	Normal	Very much improved	4.00								
50	12MAR93	Normal	Very much improved	4.00								
52	26MAR93	Normal	Very much improved	4.00								
1	150	151	VA	8	22MAY92	Borderline mentally ill	Very much improved	2.00				
				10	05JUN92	Borderline mentally ill	Very much improved	2.00				
				12	19JUN92	Normal	Very much improved	2.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 70.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
1	150	151	VA	14	03JUL92	Borderline mentally ill	Very much improved	2.00				
				16	17JUL92	Borderline mentally ill	Very much improved	2.00				
				18	31JUL92	Borderline mentally ill	Very much improved	2.00				
				20	14AUG92	Normal	Very much improved	2.00				
				22	28AUG92	Normal	Very much improved	2.00				
				24	11SEP92	Borderline mentally ill	Very much improved	2.00				
				26	25SEP92	Borderline mentally ill	Very much improved	2.00				
				28	09OCT92	Mildly ill	Much improved	3.00				
				30	23OCT92	Mildly ill	Much improved	3.00				
				32	06NOV92	Moderately ill	Minimally improved	2.00				
				34	20NOV92	Moderately ill	Minimally improved	2.00				
				36	04DEC92	Moderately ill	Minimally improved	2.00				
				38	18DEC92	Markedly ill	No change	1.00				
				3	2	61	FLL	8	11JAN91	Normal	Very much improved	4.00
								10	25JAN91	Normal	Very much improved	4.00
								12	07FEB91	Normal	Very much improved	4.00
								14	21FEB91	Normal	Very much improved	4.00
								16	07MAR91	Normal	Very much improved	4.00
18	21MAR91	Normal	Much improved					4.00				
20	04APR91	Normal	Very much improved					4.00				
22	18APR91	Normal	Very much improved					4.00				
24	02MAY91	Normal	Very much improved					4.00				
26	16MAY91	Normal	Very much improved					4.00				
28	30MAY91	Normal	Very much improved					4.00				
30	15JUN91	Normal	Very much improved					4.00				
32	27JUN91	Normal	Very much improved					4.00				
34	11JUL91	Normal	Very much improved					4.00				
36	25JUL91	Normal	Very much improved					4.00				
38	08AUG91	Normal	Very much improved					4.00				
40	22AUG91	Normal	Very much improved					4.00				
42	05SEP91	Normal	Very much improved					4.00				
3	3	62	DUB	8	29MAY91	Normal	Very much improved	4.00				
				10	12JUN91	Normal	Very much improved	4.00				
				12	26JUN91	Normal	Very much improved	4.00				
				14	10JUL91	Normal	Very much improved	4.00				
				16	24JUL91	Normal	Very much improved	4.00				
				18	07AUG91	Normal	Very much improved	4.00				
3	10	72	TOR	22	21AUG91	Normal	Very much improved	4.00				
				24	04SEP91	Severely ill	Very much worse	1.00				
				8	05JUN91	Mildly ill	Much improved	1.33				
				10	19JUN91	Borderline mentally ill	Much improved	2.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
3	10	72	TOR	12	03JUL91	Borderline mentally ill	Much improved	2.00				
				14	17JUL91	Borderline mentally ill	Much improved	4.00				
				16	31JUL91	Borderline mentally ill	Much improved	2.00				
				18	14AUG91	Borderline mentally ill	Much improved	2.00				
8	1	211	HJ	20	28AUG91	Borderline mentally ill	Much improved	2.00				
				22	11SEP91	Borderline mentally ill	Much improved	2.00				
				8	28JAN91	Mildly ill	Much improved	4.00				
				10	17FEB91	Moderately ill	Minimally improved	3.00				
8	4	214	BA	12	23FEB91	Borderline mentally ill	Much improved	4.00				
				14	11MAR91	Borderline mentally ill	Much improved	4.00				
				16	25MAR91	Borderline mentally ill	Very much improved	4.00				
				18	08APR91	Borderline mentally ill	Very much improved	4.00				
				20	22APR91	Borderline mentally ill	Very much improved	4.00				
				22	06MAY91	Borderline mentally ill	Very much improved	4.00				
				24	20MAY91	Borderline mentally ill	Very much improved	4.00				
				26	03JUN91	Borderline mentally ill	Very much improved	4.00				
				28	17JUN91	Severely ill	Very much improved	4.00				
				30	01JUL91	Borderline mentally ill	Very much improved	4.00				
				32	15JUL91	Borderline mentally ill	Very much improved	4.00				
				34	29JUL91	Borderline mentally ill	Very much improved	4.00				
				36	12AUG91	Borderline mentally ill	Very much improved	4.00				
				38	26AUG91	Borderline mentally ill	Very much improved	4.00				
				40	09SEP91	Borderline mentally ill	Very much improved	4.00				
				42	23SEP91	Borderline mentally ill	Very much improved	4.00				
				44	07OCT91	Borderline mentally ill	Very much improved	4.00				
				46	21OCT91	Borderline mentally ill	Very much improved	4.00				
				8	4	214	BA	8	07MAR91	Normal	Very much improved	4.00
								10	21MAR91	Normal	Very much improved	4.00
								12	04APR91	Normal	Very much improved	4.00
								14	18APR91	Normal	Very much improved	4.00
								16	02MAY91	Normal	Very much improved	4.00
								18	16MAY91	Normal	Very much improved	4.00
20	30MAY91	Normal	Very much improved					4.00				
22	13JUN91	Normal	Very much improved					4.00				
24	27JUN91	Normal	Very much improved					4.00				
26	11JUL91	Normal	Very much improved					4.00				
28	25JUL91	Normal	Very much improved					4.00				
30	08AUG91	Normal	Very much improved					4.00				
32	22AUG91	Normal	Very much improved					4.00				
34	05SEP91	Normal	Very much improved					4.00				
36	19SEP91	Normal	Very much improved					4.00				
38	03OCT91	Normal	Very much improved					4.00				
40	17OCT91	Normal	Very much improved	4.00								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 RENDYETINE - PROTOCOL 20124/013
 Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
8	4	214	BA	42	31OCT91	Normal	Very much improved	4.00				
				44	14NOV91	Normal	Very much improved	4.00				
				46	28NOV91	Normal	Very much improved	4.00				
				48	12DEC91	Normal	Very much improved	4.00				
				50	26DEC91	Normal	Very much improved	4.00				
				52	09JAN92	Normal	Very much improved	4.00				
				8	5	215	SL	8	11MAR91	Mildly ill	Very much improved	4.00
				9	2	241	VCF	8	23JUL90	Borderline mentally ill	Very much improved	4.00
								10	06AUG90	Borderline mentally ill	Very much improved	4.00
								12	20AUG90	Normal	Very much improved	4.00
14	03SEP90	Borderline mentally ill	Very much improved					4.00				
16	17SEP90	Borderline mentally ill	Very much improved					4.00				
18	01OCT90	Borderline mentally ill	Very much improved					4.00				
20	15OCT90	Borderline mentally ill	Very much improved					4.00				
22	29OCT90	Borderline mentally ill	Very much improved					4.00				
24	12NOV90	Borderline mentally ill	Very much improved					4.00				
26	26NOV90	Borderline mentally ill	Very much improved					4.00				
28	10DEC90	Borderline mentally ill	Very much improved					4.00				
30	24DEC90	Borderline mentally ill	Very much improved					4.00				
32	07JAN91	Borderline mentally ill	Very much improved					4.00				
34	21JAN91	Borderline mentally ill	Very much improved					4.00				
36	04FEB91	Borderline mentally ill	Very much improved					4.00				
38	18FEB91	Borderline mentally ill	Very much improved					4.00				
40	04MAR91	Borderline mentally ill	Very much improved					4.00				
42	18MAR91	Borderline mentally ill	Very much improved					4.00				
44	01APR91	Borderline mentally ill	Very much improved	4.00								
46	15APR91	Borderline mentally ill	Very much improved	4.00								
48	29APR91	Borderline mentally ill	Very much improved	4.00								
50	13MAY91	Normal	Very much improved	4.00								
52	27MAY91	Normal	Very much improved	4.00								
9	5	242	MF	8	17NOV90	Borderline mentally ill	Much improved	4.00				
				10	01DEC90	Borderline mentally ill	Much improved	4.00				
				12	15DEC90	Borderline mentally ill	Much improved	4.00				
				14	29DEC90	Borderline mentally ill	Much improved	4.00				
				16	12JAN91	Borderline mentally ill	Very much improved	4.00				
				18	26JAN91	Borderline mentally ill	Very much improved	4.00				
				20	09FEB91	Borderline mentally ill	Very much improved	4.00				
				22	23FEB91	Borderline mentally ill	Very much improved	4.00				
				24	09MAR91	Borderline mentally ill	Very much improved	4.00				
				26	23MAR91	Borderline mentally ill	Very much improved	4.00				
28	06APR91	Normal	Very much improved	4.00								
30	20APR91	Normal	Very much improved	4.00								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBEXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
9	5	242	NF	32	04MAY91	Normal	Very much improved	4.00				
				34	18MAY91	Borderline mentally ill	Very much improved	4.00				
				36	04JUN91	Borderline mentally ill	Very much improved	4.00				
				38	15JUN91	Normal	Very much improved	4.00				
				40	28JUN91	Normal	Very much improved	4.00				
				42	15JUL91	Borderline mentally ill	Very much improved	4.00				
				9	8	244	KTH	8	16JAN91	Moderately ill	Minimally improved	3.00
								10	30JAN91	Markedly ill	Minimally improved	2.00
								12	19FEB91	Moderately ill	Minimally improved	2.00
								14	27FEB91	Moderately ill	Minimally improved	2.00
16	13MAR91	Moderately ill	Minimally improved					2.00				
18	27MAR91	Moderately ill	Minimally improved					2.00				
9	12	247	GYT	20	10APR91	Markedly ill	No change	1.00				
				22	24APR91	Markedly ill	No change	1.00				
				24	08MAY91	Markedly ill	No change	1.00				
				8	30APR91	Mildly ill	Much improved	4.00				
				10	14MAY91	Borderline mentally ill	Very much improved	4.00				
				12	28MAY91	Borderline mentally ill	Very much improved	4.00				
9	13	248	BP	14	11JUN91	Mildly ill	Much improved	3.00				
				16	25JUN91	Markedly ill	No change	1.00				
				8	08MAY91	Borderline mentally ill	Very much improved	4.00				
				10	22MAY91	Borderline mentally ill	Very much improved	4.00				
				12	05JUN91	Borderline mentally ill	Very much improved	4.00				
				14	19JUN91	Borderline mentally ill	Very much improved	4.00				
				16	03JUL91	Borderline mentally ill	Very much improved	4.00				
				18	17JUL91	Borderline mentally ill	Very much improved	4.00				
				20	31JUL91	Borderline mentally ill	Very much improved	4.00				
				22	14AUG91	Mildly ill	Much improved	3.00				
9	13	248	BP	24	28AUG91	Borderline mentally ill	Much improved	4.00				
				26	11SEP91	Borderline mentally ill	Much improved	4.00				
				28	25SEP91	Borderline mentally ill	Much improved	4.00				
				30	09OCT91	Mildly ill	Very much improved	3.00				
				32	23OCT91	Mildly ill	Much improved	3.00				
				34	06NOV91	Mildly ill	Much improved	3.00				
				36	20NOV91	Borderline mentally ill	Much improved	4.00				
				38	04DEC91	Borderline mentally ill	Much improved	4.00				
				40	18DEC91	Borderline mentally ill	Much improved	4.00				
				42	01JAN92	Borderline mentally ill	Much improved	4.00				
9	13	248	BP	44	15JAN92	Mildly ill	Much improved	4.00				
				46	29JAN92	Mildly ill	Much improved	4.00				
				48	12FEB92	Borderline mentally ill	Much improved	4.00				
				50	26FEB92	Mildly ill	Much improved	3.00				

1251

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
9	13	248	BP	52	11MAR92	Moderately ill	Much improved	3.00
9	19	251	KF	8	08OCT91	Normal	Very much improved	4.00
				10	22OCT91	Mildly ill	Minimally improved	3.00
				12	05NOV91	Mildly ill	Minimally improved	2.00
				14	19NOV91	Mildly ill	Minimally improved	2.00
				16	03DEC91	Mildly ill	Minimally improved	2.00
				18	17DEC91	Moderately ill	No change	1.00
9	24	253	LGJ	8	06JAN92	Borderline mentally ill	Much improved	4.00
				10	20JAN92	Mildly ill	Much improved	4.00
				12	03FEB92	Mildly ill	Much improved	4.00
				14	17FEB92	Mildly ill	Much improved	4.00
				16	02MAR92	Borderline mentally ill	Very much improved	4.00
				18	16MAR92	Moderately ill	Much improved	3.00
				20	30MAR92	Borderline mentally ill	Very much improved	4.00
9	25	254	PM	8	14JAN92	Borderline mentally ill	Very much improved	4.00
				10	28JAN92	Borderline mentally ill	Very much improved	4.00
				12	11FEB92	Borderline mentally ill	Very much improved	4.00
				14	25FEB92	Borderline mentally ill	Very much improved	4.00
				16	10MAR92	Borderline mentally ill	Very much improved	4.00
				18	24MAR92	Borderline mentally ill	Very much improved	4.00
				20	07APR92	Borderline mentally ill	Very much improved	4.00
				22	21APR92	Borderline mentally ill	Very much improved	4.00
				24	05MAY92	Borderline mentally ill	Very much improved	4.00
				26	19MAY92	Borderline mentally ill	Very much improved	4.00
				28	02JUN92	Borderline mentally ill	Very much improved	4.00
				30	16JUN92	Borderline mentally ill	Very much improved	4.00
				32	30JUN92	Mildly ill	Much improved	3.00
				34	14JUL92	Moderately ill	Minimally improved	2.00
				36	28JUL92	Mildly ill	Much improved	3.00
				38	11AUG92	Mildly ill	Much improved	4.00
				40	25AUG92	Borderline mentally ill	Much improved	4.00
				42	08SEP92	Borderline mentally ill	Much improved	4.00
				44	22SEP92	Borderline mentally ill	Much improved	4.00
				46	06OCT92	Mildly ill	Much improved	4.00
				48	20OCT92	Mildly ill	Much improved	4.00
				50	03NOV92	Mildly ill	Much improved	4.00
9	28	257	HI	8	01JUN92	Borderline mentally ill	Very much improved	4.00
				10	15JUN92	Normal	Very much improved	4.00
				12	29JUN92	Normal	Very much improved	4.00
				14	13JUL92	Borderline mentally ill	Very much improved	4.00
				16	27JUL92	Normal	Very much improved	4.00

1252

REPRODUCTION OF THIS DOCUMENT IS PROHIBITED WITHOUT THE WRITTEN PERMISSION OF THE INSTITUT FÜR QUALITÄT UND WIRTSCHAFTLICHKEIT IM GESUNDHEITSWESEN (IQWiG)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient No.	D.B. Patient	Initials	Visit No.	Date	Severity of Illness	Global Improvement	Efficacy Index				
9	28	257	HI	18	10AUG92	Normal	Very much improved	4.00				
				20	24AUG92	Normal	Very much improved	4.00				
				22	07SEP92	Normal	Very much improved	4.00				
				24	24SEP92	Normal	Very much improved	4.00				
				26	05OCT92	Borderline mentally ill	Very much improved	4.00				
				28	19OCT92	Borderline mentally ill	Much improved	4.00				
				10	4	272	ZSD	8	27DEC90	Mildly ill	Much improved	1.50
								10	08JAN91	Mildly ill	Much improved	1.50
12	22JAN91	Mildly ill	Much improved					1.50				
14	05FEB91	Mildly ill	Much improved					2.00				
16	19FEB91	Moderately ill	Much improved					2.00				
18	01MAR91	Moderately ill	Minimally improved					1.00				
20	20MAR91	Severely ill	Much improved					1.50				
22	28MAR91	Markedly ill	Much improved					1.50				
24	17APR91	Markedly ill	Much improved					1.50				
26	01MAY91	Moderately ill	Much improved					3.00				
28	15MAY91	Moderately ill	Much improved					3.00				
30	29MAY91	Moderately ill	Much improved					3.00				
10	5	273	AN	8	09JAN91	Borderline mentally ill	Very much improved	4.00				
				10	23JAN91	Borderline mentally ill	Very much improved	4.00				
				12	06FEB91	Borderline mentally ill	Very much improved	4.00				
10	10	276	MH	8	28JAN91	Mildly ill	Very much improved	4.00				
				10	07FEB91	Normal	Very much improved	4.00				
10	14	279	AA	8	08APR91	Mildly ill	Minimally improved	1.00				
				10	22APR91	Mildly ill	Much improved	3.00				
				12	06MAY91	Mildly ill	Much improved	3.00				
				14	20MAY91	Mildly ill	Much improved	3.00				
				16	03JUN91	Mildly ill	Much improved	3.00				
				18	17JUN91	Mildly ill	Much improved	3.00				
				20	01JUL91	Mildly ill	Much improved	3.00				
				22	15JUL91	Mildly ill	Much improved	3.00				
				24	29JUL91	Mildly ill	Much improved	3.00				
				26	12AUG91	Mildly ill	Much improved	3.00				
				28	26AUG91	Mildly ill	Much improved	3.00				
				30	09SEP91	Moderately ill	Much improved	3.00				
				32	23SEP91	Mildly ill	Much improved	3.00				
				34	07OCT91	Mildly ill	Much improved	3.00				
				36	21OCT91	Mildly ill	Very much improved	4.00				
				38	04NOV91	Mildly ill	Very much improved	4.00				
40	18NOV91	Mildly ill	Very much improved	4.00								
42	02DEC91	Mildly ill	Very much improved	4.00								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
10	14	279	AA	44	17DEC91	Mildly ill	Very much improved	4.00				
				46	30DEC91	Mildly ill	Very much improved	4.00				
				48	13JAN92	Moderately ill	Much improved	3.00				
				50	27JAN92	Mildly ill	Much improved	3.00				
				52	10FEB92	Mildly ill	Much improved	3.00				
				10	16	281	AJ	8	29APR91	Mildly ill	Very much improved	2.00
								10	13MAY91	Mildly ill	Very much improved	4.00
								12	27MAY91	Mildly ill	Very much improved	4.00
								14	10JUN91	Mildly ill	Very much improved	2.00
								16	24JUN91	Mildly ill	Very much improved	2.00
18	08JUL91	Mildly ill	Very much improved					2.00				
20	22JUL91	Mildly ill	Very much improved					2.00				
22	05AUG91	Mildly ill	Very much improved					2.00				
24	19AUG91	Mildly ill	Very much improved					2.00				
26	02SEP91	Mildly ill	Very much improved					2.00				
28	16SEP91	Mildly ill	Very much improved	2.00								
30	30SEP91	Mildly ill	Very much improved	2.00								
32	14OCT91	Mildly ill	Very much improved	2.00								
34	29OCT91	Mildly ill	Very much improved	4.00								
36	11NOV91	Mildly ill	Very much improved	4.00								
38	25NOV91	Mildly ill	Very much improved	4.00								
40	09DEC91	Mildly ill	Very much improved	4.00								
42	23DEC91	Mildly ill	Very much improved	4.00								
44	07JAN92	Mildly ill	Very much improved	4.00								
46	20JAN92	Mildly ill	Very much improved	4.00								
48	03FEB92	Mildly ill	Very much improved	2.00								
50	17FEB92	Mildly ill	Very much improved	2.00								
52	03MAR92	Mildly ill	Very much improved	4.00								
10	17	282	MH	8	08MAY91	Mildly ill	Very much improved	4.00				
				10	22MAY91	Mildly ill	Very much improved	4.00				
				12	05JUN91	Mildly ill	Very much improved	4.00				
				14	19JUN91	Mildly ill	Very much improved	4.00				
				16	03JUL91	Mildly ill	Very much improved	4.00				
				18	15JUL91	Mildly ill	Very much improved	4.00				
				20	31JUL91	Mildly ill	Very much improved	4.00				
				22	14AUG91	Mildly ill	Very much improved	4.00				
				24	28AUG91	Mildly ill	Very much improved	4.00				
				26	11SEP91	Borderline mentally ill	Very much improved	4.00				
28	25SEP91	Mildly ill	Very much improved	4.00								
30	09OCT91	Moderately ill	Much improved	3.00								
32	23OCT91	Mildly ill	Very much improved	4.00								
34	05NOV91	Mildly ill	Very much improved	4.00								
36	20NOV91	Mildly ill	Very much improved	4.00								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

Centre	Patient No.	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
10	17	282	MH	38	04DEC91	Mildly ill	Very much improved	4.00				
				40	18DEC91	Mildly ill	Very much improved	4.00				
				42	02JAN92	Borderline mentally ill	Very much improved	4.00				
				44	15JAN92	Mildly ill	Very much improved	4.00				
				46	29JAN92	Mildly ill	Very much improved	4.00				
				48	12FEB92	Borderline mentally ill	Very much improved	4.00				
				50	26FEB92	Borderline mentally ill	Very much improved	4.00				
				52	10MAR92	Normal	Very much improved	4.00				
				10	19	284	TN	8	27MAY91	Mildly ill	Very much improved	4.00
								10	10JUN91	Mildly ill	Very much improved	4.00
								12	25JUN91	Moderately ill	Much improved	3.00
								14	08JUL91	Mildly ill	Much improved	3.00
16	22JUL91	Moderately ill	Much improved					3.00				
18	05AUG91	Moderately ill	Much improved					3.00				
20	19AUG91	Moderately ill	Much improved					3.00				
22	02SEP91	Mildly ill	Much improved					3.00				
24	16SEP91	Mildly ill	Much improved					3.00				
26	30SEP91	Mildly ill	Much improved					3.00				
28	14OCT91	Mildly ill	Much improved					3.00				
30	28OCT91	Mildly ill	Much improved					3.00				
32	11NOV91	Mildly ill	Very much improved	4.00								
34	25NOV91	Mildly ill	Very much improved	4.00								
36	10DEC91	Mildly ill	Very much improved	4.00								
38	23DEC91	Borderline mentally ill	Very much improved	4.00								
40	06JAN92	Borderline mentally ill	Very much improved	4.00								
42	21JAN92	Borderline mentally ill	Very much improved	4.00								
44	03FEB92	Mildly ill	Very much improved	4.00								
46	17FEB92	Mildly ill	Very much improved	4.00								
48	02MAR92	Mildly ill	Very much improved	4.00								
50	16MAR92	Mildly ill	Very much improved	4.00								
52	31MAR92	Borderline mentally ill	Very much improved	4.00								
10	21	288	AK	8	26JUN91	Mildly ill	Very much improved	2.00				
				10	08JUL91	Mildly ill	Very much improved	4.00				
				12	22JUL91	Mildly ill	Very much improved	4.00				
				14	05AUG91	Moderately ill	Much improved	3.00				
				16	19AUG91	Mildly ill	Very much improved	4.00				
				18	02SEP91	Mildly ill	Very much improved	4.00				
20	16SEP91	Moderately ill	Much improved	3.00								
22	30SEP91	Moderately ill	Much improved	3.00								
10	24	289	AL	8	25JUN91	Moderately ill	Much improved	3.00				
				10	09JUL91	Moderately ill	Minimally improved	2.00				
				12	23JUL91	Moderately ill	Much improved	3.00				

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

RESOMETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient No.	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index		
10	24	289	AL	14	06AUG91	Moderately ill	Minimally improved	2.00		
				16	20AUG91	Moderately ill	Minimally improved	2.00		
				18	02SEP91	Mildly ill	Very much improved	4.00		
				20	17SEP91	Mildly ill	Very much improved	4.00		
				22	01OCT91	Mildly ill	Very much improved	4.00		
				24	15OCT91	Mildly ill	Very much improved	4.00		
				26	29OCT91	Mildly ill	Very much improved	4.00		
				28	12NOV91	Mildly ill	Very much improved	4.00		
				30	26NOV91	Mildly ill	Very much improved	4.00		
				32	10DEC91	Mildly ill	Very much improved	4.00		
				34	23DEC91	Mildly ill	Very much improved	4.00		
				36	07JAN92	Mildly ill	Very much improved	4.00		
				38	21JAN92	Mildly ill	Very much improved	4.00		
				40	04FEB92	Mildly ill	Very much improved	4.00		
				42	18FEB92	Mildly ill	Very much improved	4.00		
				44	03MAR92	Mildly ill	Very much improved	4.00		
				46	17MAR92	Mildly ill	Very much improved	4.00		
				48	31MAR92	Mildly ill	Very much improved	4.00		
				50	14APR92	Mildly ill	Very much improved	4.00		
				52	28APR92	Mildly ill	Very much improved	4.00		
	10	29	293	JJ	8	14OCT91	Mildly ill	Very much improved	4.00	
					10	28OCT91	Mildly ill	Very much improved	4.00	
					12	11NOV91	Mildly ill	Very much improved	4.00	
					14	25NOV91	Moderately ill	Minimally improved	2.00	
					16	09DEC91	Mildly ill	Much improved	3.00	
					18	23DEC91	Mildly ill	Much improved	3.00	
					20	06JAN92	Moderately ill	Minimally improved	2.00	
		10	30	294	VK	8	11NOV91	Moderately ill	Minimally improved	3.00
						10	25NOV91	Moderately ill	Much improved	3.00
						12	09DEC91	Moderately ill	Much improved	3.00
						14	23DEC91	Moderately ill	Much improved	3.00
						16	07JAN92	Moderately ill	Minimally improved	2.00
				18	21JAN92	Moderately ill	Much improved	3.00		
				20	05FEB92	Moderately ill	Much improved	3.00		
				22	17FEB92	Moderately ill	Much improved	3.00		
				24	02MAR92	Moderately ill	Much improved	3.00		
				26	16MAR92	Mildly ill	Very much improved	4.00		
				28	30MAR92	Mildly ill	Very much improved	4.00		
				30	13APR92	Mildly ill	Very much improved	4.00		
			32	27APR92	Mildly ill	Very much improved	4.00			
			34	11MAY92	Mildly ill	Very much improved	4.00			
			36	25MAY92	Mildly ill	Very much improved	4.00			
			38	08JUN92	Mildly ill	Very much improved	4.00			

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
10	30	294	VK	40	22JUN92	Mildly ill	Very much improved	4.00				
				42	06JUL92	Mildly ill	Very much improved	4.00				
				44	20JUL92	Moderately ill	Much improved	3.00				
				46	03AUG92	Moderately ill	Much improved	3.00				
				48	17AUG92	Moderately ill	Much improved	3.00				
				50	31AUG92	Mildly ill	Very much improved	4.00				
				52	14SEP92	Mildly ill	Very much improved	4.00				
				10	37	32	HK	8	09DEC91	Moderately ill	Very much improved	4.00
								10	23DEC91	Markedly ill	Minimally improved	2.00
								12	06JAN92	Mildly ill	Very much improved	4.00
14	20JAN92	Moderately ill	Much improved					3.00				
16	03FEB92	Markedly ill	Minimally improved					2.00				
18	18FEB92	Markedly ill	Minimally improved					2.00				
20	02MAR92	Markedly ill	Minimally improved					2.00				
22	17MAR92	Markedly ill	Minimally improved					2.00				
24	30MAR92	Moderately ill	Much improved					3.00				
26	13APR92	Mildly ill	Much improved					3.00				
28	27APR92	Moderately ill	Much improved	3.00								
10	40	33	AP	8	18DEC91	Mildly ill	Very much improved	4.00				
				10	02JAN92	Borderline mentally ill	Very much improved	4.00				
				12	15JAN92	Borderline mentally ill	Very much improved	4.00				
				14	29JAN92	Borderline mentally ill	Very much improved	4.00				
10	42	295	TT	8	08JAN92	Moderately ill	Much improved	3.00				
				12	05FEB92	Severely ill	Minimally improved	2.00				
10	43	296	IK	8	09JAN92	Borderline mentally ill	Very much improved	4.00				
				10	23JAN92	Normal	Very much improved	4.00				
				12	06FEB92	Borderline mentally ill	Very much improved	4.00				
				14	20FEB92	Borderline mentally ill	Very much improved	4.00				
				16	05MAR92	Normal	Very much improved	4.00				
				18	19MAR92	Normal	Very much improved	4.00				
				20	02APR92	Normal	Very much improved	4.00				
				22	16APR92	Normal	Very much improved	4.00				
				24	30APR92	Normal	Very much improved	4.00				
				26	14MAY92	Normal	Very much improved	4.00				
10	44	298	AB	8	12JAN92	Borderline mentally ill	Very much improved	2.00				
				10	26JAN92	Normal	Very much improved	4.00				
				12	09FEB92	Normal	Very much improved	4.00				
				14	23FEB92	Normal	Very much improved	4.00				
				16	08MAR92	Normal	Very much improved	4.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
10	45	34	KJ	8	14JAN92	Mildly ill	Much improved	3.00
				10	28JAN92	Mildly ill	Much improved	3.00
				12	11FEB92	Mildly ill	Much improved	3.00
				14	25FEB92	Borderline mentally ill	Much improved	3.00
				16	10MAR92	Borderline mentally ill	Much improved	3.00
				8	27JAN92	Borderline mentally ill	Much improved	1.50
				8	29JAN92	Borderline mentally ill	Much improved	1.50
				10	12FEB92	Borderline mentally ill	Much improved	3.00
				12	26FEB92	Borderline mentally ill	Much improved	3.00
				14	11MAR92	Borderline mentally ill	Much improved	3.00
				16	25MAR92	Borderline mentally ill	Much improved	3.00
				18	08APR92	Borderline mentally ill	Much improved	3.00
				20	22APR92	Borderline mentally ill	Much improved	3.00
				22	06MAY92	Borderline mentally ill	Much improved	3.00
				24	20MAY92	Borderline mentally ill	Much improved	3.00
				26	03JUN92	Borderline mentally ill	Much improved	3.00
28	17JUN92	Borderline mentally ill	Much improved	3.00				
30	01JUL92	Borderline mentally ill	Much improved	3.00				
32	15JUL92	Borderline mentally ill	Much improved	3.00				
34	29JUL92	Borderline mentally ill	Much improved	3.00				
36	12AUG92	Borderline mentally ill	Much improved	3.00				
38	26AUG92	Borderline mentally ill	Much improved	3.00				
40	09SEP92	Borderline mentally ill	Much improved	3.00				
42	23SEP92	Borderline mentally ill	Much improved	3.00				
44	07OCT92	Borderline mentally ill	Much improved	3.00				
46	21OCT92	Borderline mentally ill	Much improved	3.00				
48	04NOV92	Borderline mentally ill	Much improved	3.00				
50	18NOV92	Borderline mentally ill	Much improved	3.00				
52	02DEC92	Borderline mentally ill	Much improved	3.00				
10	48	41	IP	8	29JAN92	Moderately ill	Much improved	1.50
				10	12FEB92	Mildly ill	Much improved	1.50
				12	26FEB92	Borderline mentally ill	Very much improved	2.00
				14	11MAR92	Borderline mentally ill	Much improved	3.00
				16	25MAR92	Borderline mentally ill	Much improved	3.00
				18	08APR92	Borderline mentally ill	Much improved	3.00
				20	22APR92	Borderline mentally ill	Much improved	3.00
				8	12FEB92	Moderately ill	Minimally improved	1.50
				10	26FEB92	Moderately ill	Minimally improved	3.00
				12	11MAR92	Moderately ill	Minimally improved	3.00
				14	25MAR92	Moderately ill	Minimally improved	3.00
				16	08APR92	Moderately ill	Minimally improved	3.00

1258

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED			REBOXETINE - PROTOCOL 20124/013			Listing No.: 10.3			CLINICAL GLOBAL IMPRESSION (CGI)			DOUBLE BLIND PHASE			TREATMENT: PLACEBO		
Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index	Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
10	50	44	EE	18	22APR92	Moderately ill	Minimally improved	3.00	10	51	45	UL	8	12FEB92	Borderline mentally ill	Very much improved	4.00
				20	06MAY92	Moderately ill	Minimally improved	3.00					10	26FEB92	Borderline mentally ill	Very much improved	4.00
				22	20MAY92	Moderately ill	Much improved	3.00					12	11MAR92	Normal	Very much improved	4.00
				24	03JUN92	Moderately ill	Much improved	3.00					14	25MAR92	Normal	Very much improved	4.00
				26	17JUN92	Moderately ill	Much improved	3.00					16	08APR92	Normal	Very much improved	4.00
				28	01JUL92	Moderately ill	Much improved	3.00					18	22APR92	Normal	Very much improved	4.00
				30	15JUL92	Moderately ill	Much improved	3.00					20	06MAY92	Normal	Very much improved	4.00
				32	29JUL92	Moderately ill	Much improved	3.00					22	20MAY92	Normal	Very much improved	4.00
				34	12AUG92	Moderately ill	Much improved	3.00					24	03JUN92	Normal	Very much improved	4.00
				36	26AUG92	Moderately ill	Much improved	3.00					26	17JUN92	Normal	Very much improved	4.00
				38	09SEP92	Moderately ill	Much improved	3.00					28	01JUL92	Normal	Very much improved	4.00
				40	23SEP92	Moderately ill	Much improved	3.00					30	15JUL92	Normal	Very much improved	4.00
				42	07OCT92	Moderately ill	Much improved	3.00					32	29JUL92	Normal	Very much improved	4.00
				44	21OCT92	Moderately ill	Much improved	3.00					34	12AUG92	Normal	Very much improved	4.00
				46	04NOV92	Moderately ill	Much improved	3.00					36	26AUG92	Normal	Very much improved	4.00
				48	18NOV92	Moderately ill	Much improved	3.00					38	09SEP92	Normal	Very much improved	4.00
				50	02DEC92	Moderately ill	Much improved	3.00					40	23SEP92	Normal	Very much improved	4.00
				52	16DEC92	Moderately ill	Much improved	3.00					42	07OCT92	Normal	Very much improved	4.00
													44	21OCT92	Normal	Very much improved	4.00
													46	04NOV92	Normal	Very much improved	4.00
													48	18NOV92	Normal	Very much improved	4.00
													50	02DEC92	Normal	Very much improved	4.00
													52	16DEC92	Normal	Very much improved	4.00
10	55	49	TP	8	09MAR92	Borderline mentally ill	Much improved	3.00	10	51	45	UL	8	12FEB92	Borderline mentally ill	Very much improved	4.00
				10	23MAR92	Moderately ill	Much improved	3.00					10	26FEB92	Borderline mentally ill	Very much improved	4.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REMEXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
10	55	49	TP	12	06APR92	Mildly ill	Much improved	3.00				
				14	20APR92	Mildly ill	Much improved	3.00				
				16	04MAY92	Borderline mentally ill	Much improved	3.00				
				18	18MAY92	Borderline mentally ill	Much improved	3.00				
				20	01JUN92	Mildly ill	Much improved	3.00				
				22	15JUN92	Mildly ill	Much improved	3.00				
				24	29JUN92	Mildly ill	Much improved	3.00				
				26	13JUL92	Mildly ill	Much improved	3.00				
				28	27JUL92	Mildly ill	Much improved	3.00				
				30	10AUG92	Mildly ill	Much improved	3.00				
				32	24AUG92	Mildly ill	Much improved	3.00				
				34	07SEP92	Borderline mentally ill	Much improved	3.00				
				36	21SEP92	Mildly ill	Much improved	3.00				
				38	05OCT92	Mildly ill	Much improved	3.00				
				40	19OCT92	Mildly ill	Much improved	3.00				
				42	02NOV92	Mildly ill	Much improved	3.00				
				44	16NOV92	Mildly ill	Much improved	3.00				
				46	30NOV92	Mildly ill	Much improved	3.00				
				48	14DEC92	Mildly ill	Much improved	3.00				
				50	28DEC92	Mildly ill	Much improved	3.00				
				52	11JAN93	Mildly ill	Much improved	3.00				
				10	58	52	KK	8	09MAR92	Mildly ill	Very much improved	4.00
								10	23MAR92	Mildly ill	Very much improved	4.00
								12	06APR92	Mildly ill	Very much improved	4.00
								14	20APR92	Mildly ill	Very much improved	4.00
								16	04MAY92	Mildly ill	Very much improved	4.00
								18	18MAY92	Mildly ill	Very much improved	4.00
								20	02JUN92	Mildly ill	Very much improved	4.00
								22	16JUN92	Mildly ill	Very much improved	4.00
								24	30JUN92	Mildly ill	Much improved	3.00
								26	13JUL92	Mildly ill	Much improved	3.00
								28	28JUL92	Mildly ill	Much improved	3.00
30	11AUG92	Mildly ill	Much improved					3.00				
32	25AUG92	Mildly ill	Much improved					3.00				
34	08SEP92	Mildly ill	Much improved					3.00				
36	21SEP92	Mildly ill	Much improved					3.00				
38	05OCT92	Mildly ill	Very much improved					4.00				
40	19OCT92	Borderline mentally ill	Very much improved	4.00								
42	02NOV92	Mildly ill	Very much improved	4.00								
44	16NOV92	Mildly ill	Very much improved	4.00								
46	30NOV92	Mildly ill	Very much improved	4.00								
48	14DEC92	Mildly ill	Very much improved	4.00								
50	28DEC92	Borderline mentally ill	Very much improved	4.00								
52	12JAN93	Borderline mentally ill	Very much improved	4.00								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
10	60	54	JM	8	16MAR92	Markedly ill	Minimally improved	2.00
10	61	55	JT	8	17MAR92	Moderately ill	Much improved	3.00
				10	31MAR92	Mildly ill	Much improved	3.00
				12	14APR92	Mildly ill	Much improved	3.00
				14	28APR92	Borderline mentally ill	Very much improved	4.00
				16	12MAY92	Borderline mentally ill	Very much improved	4.00
				18	26MAY92	Borderline mentally ill	Very much improved	4.00
10	62	56	RK	8	17MAR92	Mildly ill	Much improved	1.50
				10	31MAR92	Mildly ill	Much improved	3.00
				12	14APR92	Normal	Very much improved	4.00
				14	28APR92	Normal	Very much improved	4.00
				16	13MAY92	Normal	Very much improved	4.00
				18	27MAY92	Normal	Very much improved	4.00
				20	09JUN92	Normal	Very much improved	4.00
				22	23JUN92	Normal	Very much improved	4.00
				24	07JUL92	Normal	Very much improved	4.00
				26	21JUL92	Normal	Very much improved	4.00
				28	04AUG92	Normal	Very much improved	4.00
				30	18AUG92	Normal	Very much improved	4.00
				32	01SEP92	Normal	Very much improved	4.00
10	64	58	LT	8	01APR92	Borderline mentally ill	Very much improved	4.00
				10	15APR92	Normal	Very much improved	4.00
				12	29APR92	Borderline mentally ill	Very much improved	4.00
				14	13MAY92	Borderline mentally ill	Very much improved	4.00
				16	27MAY92	Borderline mentally ill	Very much improved	4.00
				18	10JUN92	Borderline mentally ill	Very much improved	4.00
				20	22JUN92	Normal	Very much improved	4.00
10	81	46	JN	8	16APR92	Mildly ill	Much improved	3.00
				10	30APR92	Mildly ill	Much improved	3.00
				12	14MAY92	Borderline mentally ill	Very much improved	4.00
				14	28MAY92	Borderline mentally ill	Very much improved	4.00
				16	11JUN92	Borderline mentally ill	Very much improved	4.00
				18	25JUN92	Borderline mentally ill	Very much improved	4.00
				20	09JUL92	Borderline mentally ill	Very much improved	4.00
				22	23JUL92	Borderline mentally ill	Very much improved	4.00
				24	06AUG92	Borderline mentally ill	Very much improved	4.00
				26	20AUG92	Borderline mentally ill	Very much improved	4.00
				28	03SEP92	Borderline mentally ill	Very much improved	4.00
				30	17SEP92	Borderline mentally ill	Very much improved	4.00
				32	01OCT92	Borderline mentally ill	Very much improved	4.00
				34	15OCT92	Borderline mentally ill	Very much improved	4.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
10	81	46	JN	36	29OCT92	Borderline mentally ill	Very much improved	4.00				
				38	11NOV92	Normal	Very much improved	4.00				
				40	25NOV92	Normal	Very much improved	4.00				
				42	09DEC92	Normal	Very much improved	4.00				
				44	23DEC92	Normal	Very much improved	4.00				
				46	06JAN93	Normal	Very much improved	4.00				
				10	85	272	AK	8	05MAY92	Mildly ill	Much improved	3.00
								8	13MAY92	Borderline mentally ill	Very much improved	4.00
								10	27MAY92	Borderline mentally ill	Very much improved	4.00
								12	10JUN92	Borderline mentally ill	Very much improved	4.00
14	24JUN92	Borderline mentally ill	Very much improved					4.00				
16	08JUL92	Normal	Very much improved					4.00				
18	22JUL92	Normal	Very much improved					4.00				
20	05AUG92	Normal	Very much improved					4.00				
22	19AUG92	Normal	Very much improved					4.00				
24	02SEP92	Normal	Very much improved					4.00				
10	88	276	AH	26	16SEP92	Normal	Very much improved	4.00				
				28	30SEP92	Normal	Very much improved	4.00				
				30	14OCT92	Normal	Very much improved	4.00				
				32	28OCT92	Borderline mentally ill	Very much improved	4.00				
				34	11NOV92	Borderline mentally ill	Very much improved	4.00				
				36	25NOV92	Borderline mentally ill	Very much improved	4.00				
				38	09DEC92	Borderline mentally ill	Very much improved	4.00				
				40	23DEC92	Borderline mentally ill	Very much improved	4.00				
				42	06JAN93	Borderline mentally ill	Very much improved	4.00				
				44	20JAN93	Borderline mentally ill	Very much improved	4.00				
10	92	73	LA	46	03FEB93	Normal	Very much improved	4.00				
				48	17FEB93	Normal	Very much improved	4.00				
				50	03MAR93	Normal	Very much improved	4.00				
				52	17MAR93	Normal	Very much improved	4.00				
				8	26MAY92	Borderline mentally ill	Very much improved	4.00				
				10	09JUN92	Borderline mentally ill	Very much improved	4.00				
				12	23JUN92	Borderline mentally ill	Very much improved	4.00				
				14	07JUL92	Borderline mentally ill	Very much improved	4.00				
				16	21JUL92	Mildly ill	Very much improved	4.00				
				18	04AUG92	Mildly ill	Very much improved	4.00				
10	92	73	LA	20	18AUG92	Mildly ill	Very much improved	4.00				
				22	01SEF92	Borderline mentally ill	Very much improved	4.00				
				24	15SEF92	Borderline mentally ill	Very much improved	4.00				
				26	29SEF92	Borderline mentally ill	Very much improved	4.00				
				28	13OCT92	Borderline mentally ill	Very much improved	4.00				
				30	27OCT92	Mildly ill	Very much improved	4.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
PHARMACIA CNS R&D REBOXETINE - PROTOCOL 20124/013 Listing No.: 10.3 CLINICAL GLOBAL IMPRESSION (CGI) DOUBLE BLIND PHASE TREATMENT: PLACEBO								
10	92	73	LA	32	10NOV92	Mildly ill	Very much improved	4.00
				34	24NOV92	Mildly ill	Very much improved	4.00
				36	08DEC92	Mildly ill	Very much improved	4.00
				38	22DEC92	Borderline mentally ill	Very much improved	4.00
				40	05JAN93	Borderline mentally ill	Very much improved	4.00
				42	19JAN93	Borderline mentally ill	Very much improved	4.00
				44	02FEB93	Borderline mentally ill	Very much improved	4.00
				46	16FEB93	Mildly ill	Much improved	4.00
				48	02MAR93	Mildly ill	Much improved	4.00
				50	16MAR93	Borderline mentally ill	Very much improved	4.00
				52	30MAR93	Borderline mentally ill	Very much improved	4.00
10	94	273	PV	8	03JUN92	Moderately ill	Much improved	1.50
				10	17JUN92	Mildly ill	Much improved	1.50
				12	01JUL92	Mildly ill	Much improved	1.50
				14	15JUL92	Mildly ill	Much improved	1.50
				16	29JUL92	Mildly ill	Much improved	1.50
				18	12AUG92			
11	1	372	DF	8	06DEC91	Moderately ill	Much improved	3.00
				10	20DEC91	Mildly ill	Much improved	3.00
				12	03JAN92	Mildly ill	Much improved	3.00
				14	17JAN92	Mildly ill	Minimally improved	3.00
				16	31JAN92	Mildly ill	Minimally improved	3.00
				18	14FEB92	Moderately ill	Minimally improved	3.00
				20	28FEB92	Moderately ill	Minimally improved	3.00
				22	13MAR92	Mildly ill	Much improved	3.00
				24	27MAR92	Mildly ill	Much improved	3.00
				26	10APR92	Mildly ill	Much improved	3.00
				28	24APR92	Moderately ill	Much improved	3.00
				30	08MAY92	Moderately ill	Minimally improved	3.00
				32	22MAY92	Moderately ill	Minimally improved	3.00
				34	05JUN92	Mildly ill	Much improved	3.00
11	4	375	BA	8	12DEC91	Mildly ill	Much improved	3.00
				10	26DEC91	Mildly ill	Much improved	3.00
				12	09JAN92	Mildly ill	Much improved	3.00
				14	23JAN92	Mildly ill	Much improved	3.00
				16	06FEB92	Mildly ill	Much improved	3.00
				18	20FEB92	Mildly ill	Much improved	3.00
				20	05MAR92	Mildly ill	Much improved	3.00
				22	13MAR92	Severely ill	No change	1.00
11	7	376	EK	8	18DEC91	Mildly ill	Much improved	3.00
				10	01JAN92	Moderately ill	Minimally improved	2.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
11	7	376	KK	12	15JAN92	Mildly ill	Much improved	3.00				
				14	29JAN92	Mildly ill	Much improved	3.00				
				16	12FEB92	Mildly ill	Much improved	3.00				
				18	26FEB92	Mildly ill	Much improved	3.00				
				20	11MAR92	Mildly ill	Much improved	3.00				
				22	25MAR92	Mildly ill	Much improved	3.00				
				24	08APR92	Mildly ill	Much improved	3.00				
				26	22APR92	Borderline mentally ill	Very much improved	4.00				
				28	06MAY92	Borderline mentally ill	Very much improved	4.00				
				30	20MAY92	Borderline mentally ill	Very much improved	4.00				
				32	03JUN92	Normal	Very much improved	4.00				
				34	17JUN92	Normal	Much improved	3.00				
				36	01JUL92	Mildly ill	Very much improved	4.00				
				38	15JUL92	Borderline mentally ill	Very much improved	4.00				
				40	29JUL92	Normal	Very much improved	4.00				
				42	12AUG92	Normal	Very much improved	4.00				
				44	26AUG92	Normal	Very much improved	4.00				
				46	09SEF92	Normal	Very much improved	4.00				
				48	23SEF92	Normal	Very much improved	4.00				
				50	07OCT92	Normal	Very much improved	4.00				
				52	21OCT92	Normal	Very much improved	4.00				
				11	9	362	FI	8	06JAN92	Moderately ill	Minimally improved	2.00
								10	20JAN92	Mildly ill	Much improved	3.00
								12	03FEB92	Severely ill	No change	1.00
				11	12	364	PJ	8	09FEB92	Markedly ill	Minimally improved	2.00
								10	23FEB92	Moderately ill	Minimally improved	2.00
								12	08MAR92	Mildly ill	Much improved	3.00
								14	22MAR92	Mildly ill	Much improved	3.00
								16	05APR92	Mildly ill	Much improved	3.00
								18	19APR92	Borderline mentally ill	Very much improved	4.00
								20	03MAY92	Borderline mentally ill	Very much improved	4.00
								22	17MAY92	Borderline mentally ill	Very much improved	4.00
24	31MAY92	Borderline mentally ill	Very much improved					4.00				
26	14JUN92	Mildly ill	Much improved					3.00				
28	28JUN92	Mildly ill	Much improved					3.00				
30	12JUL92	Borderline mentally ill	Very much improved					4.00				
32	26JUL92	Borderline mentally ill	Very much improved					4.00				
34	09AUG92	Borderline mentally ill	Very much improved					4.00				
36	23AUG92	Mildly ill	Much improved					3.00				
38	06SEF92	Borderline mentally ill	Very much improved					4.00				
40	20SEF92	Borderline mentally ill	Very much improved	4.00								
42	04OCT92	Mildly ill	Much improved	3.00								
44	18OCT92	Mildly ill	Much improved	3.00								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 70.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
11	12	364	PJ	46	01NOV92	Mildly ill	Much improved	3.00				
				48	15NOV92	Mildly ill	Much improved	3.00				
				50	29NOV92	Borderline mentally ill	Very much improved	4.00				
				52	13DEC92	Borderline mentally ill	Very much improved	4.00				
11	15	366	NF	8	24MAR92	Borderline mentally ill	Very much improved	4.00				
				10	07APR92	Mildly ill	Much improved	3.00				
				12	21APR92	Moderately ill	Minimally improved	2.00				
				14	05MAY92	Mildly ill	Much improved	3.00				
				16	19MAY92	Mildly ill	Much improved	3.00				
				18	02JUN92	Markedly ill	No change	1.00				
				11	18	369	EI	8	05APR92	Mildly ill	Much improved	3.00
								10	19APR92	Mildly ill	Much improved	3.00
12	03MAY92	Borderline mentally ill	Very much improved					4.00				
14	17MAY92	Borderline mentally ill	Very much improved					4.00				
16	31MAY92	Borderline mentally ill	Very much improved					4.00				
18	14JUN92	Normal	Very much improved					4.00				
20	28JUN92	Normal	Very much improved					4.00				
22	12JUL92	Normal	Very much improved					4.00				
24	26JUL92	Normal	Very much improved					4.00				
26	09AUG92	Normal	Very much improved					4.00				
28	23AUG92	Normal	Very much improved					4.00				
30	06SEP92	Normal	Very much improved					4.00				
32	20SEP92	Normal	Very much improved					4.00				
34	04OCT92	Normal	Very much improved					4.00				
36	18OCT92	Normal	Very much improved	4.00								
38	01NOV92	Normal	Very much improved	4.00								
40	15NOV92	Normal	Very much improved	4.00								
42	29NOV92	Normal	Very much improved	4.00								
44	13DEC92	Normal	Very much improved	4.00								
46	27DEC92	Normal	Very much improved	4.00								
48	10JAN93	Normal	Very much improved	4.00								
50	24JAN93	Normal	Very much improved	4.00								
52	07FEB93	Normal	Very much improved	4.00								
11	20	371	LJ	8	26APR92	Borderline mentally ill	Very much improved	4.00				
				10	10MAY92	Mildly ill	Much improved	3.00				
				12	24MAY92	Mildly ill	Much improved	3.00				
				14	07JUN92	Markedly ill	No change	1.00				
12	5	95	ZSH	8	30DEC91	Mildly ill	Minimally improved	3.00				
				10	13JAN92	Mildly ill	Minimally improved	3.00				
				12	27JAN92	Mildly ill	Minimally improved	3.00				
				14	10FEB92	Mildly ill	Minimally improved	3.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 40.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
12	5	95	ZSH	16	24FEB92	Mildly ill	Minimally improved	3.00
				18	09MAR92	Mildly ill	Minimally improved	3.00
12	6	98	MK	8	26DEC91	Moderately ill	Minimally improved	3.00
				10	09JAN92	Mildly ill	Much improved	3.00
				12	23JAN92	Borderline mentally ill	Much improved	4.00
				14	06FEB92	Borderline mentally ill	Much improved	4.00
				16	20FEB92	Mildly ill	Much improved	4.00
				18	05MAR92	Moderately ill	No change	1.00
				20	19MAR92	Moderately ill	No change	1.00
				22	02APR92	Moderately ill	Minimally improved	3.00
				24	16APR92	Mildly ill	Much improved	4.00
				26	30APR92	Mildly ill	Much improved	4.00
				28	14MAY92	Mildly ill	Much improved	4.00
				30	28MAY92	Mildly ill	Much improved	4.00
12	10	96	IP	8	30DEC91	Mildly ill	Minimally improved	2.00
				10	13JAN92	Mildly ill	Minimally improved	3.00
				12	27JAN92	Mildly ill	Much improved	3.00
				14	10FEB92	Mildly ill	Minimally improved	3.00
				16	24FEB92	Mildly ill	Minimally improved	3.00
				18	09MAR92	Mildly ill	Minimally improved	3.00
				20	23MAR92	Mildly ill	Minimally improved	3.00
				22	06APR92	Mildly ill	Minimally improved	3.00
				24	20APR92	Mildly ill	Minimally improved	3.00
12	11	94	ER	8	25DEC91	Severely ill	Much worse	0.50
				10	08JAN92	Severely ill	Very much worse	1.00
				12	15JAN92	Severely ill	Very much worse	1.00
12	12	97	FSZ	8	30DEC91	Markedly ill	Minimally worse	1.00
				10	13JAN92	Markedly ill	Minimally worse	1.00
12	13	103	ISZ	8	30DEC91	Moderately ill	Minimally improved	2.00
				10	13JAN92	Mildly ill	Much improved	4.00
				12	27JAN92	Markedly ill	Minimally worse	1.00
12	14	101	GSZ	8	31DEC91	Severely ill	Much worse	1.00
				10	14JAN92	Extremely ill	Much worse	1.00
12	17	108	TK	8	10MAR92	Borderline mentally ill	Much improved	4.00
				10	24MAR92	Borderline mentally ill	Much improved	4.00
				12	09APR92	Borderline mentally ill	Much improved	4.00
				14	21APR92	Borderline mentally ill	Much improved	4.00
				16	05MAY92	Borderline mentally ill	Much improved	4.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
12	17	108	TK	18	19MAY92	Borderline mentally ill	Much improved	4.00				
				20	02JUN92	Borderline mentally ill	Much improved	4.00				
				22	16JUN92	Borderline mentally ill	Much improved	4.00				
				24	30JUN92	Normal	Very much improved	4.00				
				26	14JUL92	Normal	Very much improved	4.00				
				28	28JUL92	Normal	Very much improved	4.00				
				12	18	109	LS	8	10MAR92	Mildly ill	Much improved	4.00
								10	24MAR92	Mildly ill	Much improved	4.00
12	07APR92	Mildly ill	Much improved					4.00				
14	21APR92	Mildly ill	Much improved					4.00				
16	05MAY92	Mildly ill	Much improved					4.00				
18	19MAY92	Moderately ill	Much improved					3.00				
20	25MAY92	Extremely ill	Very much worse					0.25				
12	20	107	MSZ					8	12MAR92	Normal	Very much improved	4.00
				10	26MAR92	Normal	Very much improved	4.00				
				12	09APR92	Normal	Very much improved	4.00				
				14	23APR92	Borderline mentally ill	Much improved	4.00				
				16	07MAY92	Borderline mentally ill	Much improved	4.00				
				18	21MAY92	Borderline mentally ill	Much improved	4.00				
				20	04JUN92	Borderline mentally ill	Much improved	4.00				
				22	18JUN92	Borderline mentally ill	Much improved	4.00				
12	22	111	MV	24	02JUL92	Moderately ill	Minimally improved	3.00				
				26	16JUL92	Mildly ill	Much improved	4.00				
				28	30JUL92	Moderately ill	Minimally improved	3.00				
				8	23MAR92	Mildly ill	Much improved	4.00				
				10	06APR92	Mildly ill	Much improved	4.00				
				12	20APR92	Borderline mentally ill	Much improved	4.00				
				14	04MAY92	Borderline mentally ill	Much improved	4.00				
				16	18MAY92	Borderline mentally ill	Much improved	4.00				
12	22	111	MV	18	01JUN92	Mildly ill	Much improved	4.00				
				20	15JUN92	Mildly ill	Much improved	4.00				
				22	29JUN92	Mildly ill	Much improved	4.00				
				24	13JUL92	Mildly ill	Minimally improved	3.00				
				26	27JUL92	Borderline mentally ill	Much improved	4.00				
				28	10AUG92	Borderline mentally ill	Very much improved	4.00				
				30	24AUG92	Borderline mentally ill	Very much improved	4.00				
				32	07SEF92	Borderline mentally ill	Much improved	4.00				
12	22	111	MV	34	21SEF92	Borderline mentally ill	Much improved	4.00				
				36	05OCT92	Normal	Very much improved	4.00				
				38	19OCT92	Normal	Very much improved	4.00				
				40	02NOV92	Borderline mentally ill	Very much improved	4.00				
12	22	111	MV	42	16NOV92	Borderline mentally ill	Very much improved	4.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
12	22	111	MV	44	30NOV92	Borderline mentally ill	Very much improved	4.00				
				46	14DEC92	Borderline mentally ill	Very much improved	4.00				
				48	28DEC92	Borderline mentally ill	Very much improved	4.00				
				50	11JAN93	Borderline mentally ill	Very much improved	4.00				
				52	25JAN93	Borderline mentally ill	Very much improved	4.00				
12	23	112	EN	8	02APR92	Moderately ill	Much improved	4.00				
				10	16APR92	Moderately ill	Much improved	4.00				
				12	30APR92	Moderately ill	Much improved	4.00				
				14	14MAY92	Moderately ill	Much improved	4.00				
				16	28MAY92	Mildly ill	Much improved	4.00				
				18	11JUN92	Borderline mentally ill	Much improved	4.00				
				20	25JUN92	Borderline mentally ill	Much improved	4.00				
				22	09JUL92	Normal	Very much improved	4.00				
				24	23JUL92	Normal	Very much improved	4.00				
				26	06AUG92	Borderline mentally ill	Much improved	4.00				
				28	20AUG92	Borderline mentally ill	Much improved	4.00				
				12	28	116	IV	8	03APR92	Moderately ill	Minimally improved	3.00
								10	17APR92	Moderately ill	Minimally improved	3.00
12	01MAY92	Mildly ill	Much improved					4.00				
14	15MAY92	Mildly ill	Much improved					4.00				
16	29MAY92	Moderately ill	Minimally improved					2.00				
12	34	120	TGB	8	22MAY92	Normal	Very much improved	4.00				
				10	05JUN92	Normal	Very much improved	4.00				
				12	19JUN92	Borderline mentally ill	Much improved	4.00				
				14	03JUL92	Borderline mentally ill	Much improved	4.00				
				16	17JUL92	Borderline mentally ill	Much improved	4.00				
				18	31JUL92	Borderline mentally ill	Much improved	4.00				
				20	14AUG92	Normal	Very much improved	4.00				
				22	28AUG92	Normal	Very much improved	4.00				
				24	11SEP92	Normal	Very much improved	4.00				
				26	25SEP92	Normal	Much improved	4.00				
				28	09OCT92	Borderline mentally ill	Much improved	4.00				
				30	23OCT92	Normal	Very much improved	4.00				
				32	06NOV92	Normal	Very much improved	4.00				
34	20NOV92	Normal	Very much improved	4.00								
36	04DEC92	Normal	Very much improved	4.00								
38	18DEC92	Normal	Very much improved	4.00								
40	01JAN93	Normal	Very much improved	4.00								
42	15JAN93	Normal	Very much improved	4.00								
44	29JAN93	Normal	Very much improved	4.00								
46	12FEB93	Borderline mentally ill	Much improved	4.00								
48	26FEB93	Normal	Very much improved	4.00								

1268

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 40.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
12	34	120	TGB	50	12MAR93	Borderline mentally ill	Much improved	4.00				
				52	26MAR93	Borderline mentally ill	Very much improved	4.00				
12	35	119	LP	8	22MAY92	Moderately ill	Much improved	3.00				
				10	05JUN92	Moderately ill	Much improved	3.00				
				12	19JUN92	Mildly ill	Much improved	4.00				
				14	03JUL92	Mildly ill	Much improved	4.00				
				16	17JUL92	Moderately ill	Minimally improved	3.00				
				18	31JUL92	Moderately ill	Minimally improved	3.00				
12	37	386	EK	8	29MAY92	Borderline mentally ill	Much improved	4.00				
				10	12JUN92	Mildly ill	Minimally improved	3.00				
				12	26JUN92	Mildly ill	Minimally improved	3.00				
				14	10JUL92	Mildly ill	Much improved	4.00				
				16	24JUL92	Borderline mentally ill	Much improved	4.00				
				18	07AUG92	Borderline mentally ill	Much improved	4.00				
				13	2	224	TCS	8	11DEC91	Mildly ill	Much improved	4.00
								10	25DEC91	Borderline mentally ill	Very much improved	4.00
12	08JAN92	Borderline mentally ill	Very much improved					4.00				
14	22JAN92	Borderline mentally ill	Much improved					4.00				
16	05FEB92	Borderline mentally ill	Very much improved					4.00				
18	19FEB92	Mildly ill	Much improved					4.00				
20	04MAR92	Moderately ill	Much improved					3.00				
22	18MAR92	Moderately ill	Minimally improved					2.00				
24	01APR92	Mildly ill	Much improved					3.00				
26	15APR92	Mildly ill	Much improved					3.00				
28	29APR92	Moderately ill	Much improved					3.00				
30	13MAY92	Moderately ill	Much improved					3.00				
32	27MAY92	Borderline mentally ill	Much improved					3.00				
34	10JUN92	Borderline mentally ill	Much improved					4.00				
36	24JUN92	Borderline mentally ill	Very much improved					4.00				
38	08JUL92	Borderline mentally ill	Much improved					4.00				
40	22JUL92	Borderline mentally ill	Much improved	4.00								
42	05AUG92	Borderline mentally ill	Very much improved	4.00								
44	19AUG92	Borderline mentally ill	Very much improved	4.00								
46	02SEP92	Borderline mentally ill	Very much improved	4.00								
48	16SEP92	Borderline mentally ill	Very much improved	4.00								
50	30SEP92	Borderline mentally ill	Very much improved	4.00								
52	14OCT92	Normal	Very much improved	4.00								
13	8	228	PK	8	16DEC91	Mildly ill	Much improved	4.00				
				10	30DEC91	Borderline mentally ill	Very much improved	4.00				
				12	13JAN92	Borderline mentally ill	Very much improved	4.00				
				14	27JAN92	Borderline mentally ill	Very much improved	4.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 DOUBLE BLIND PHASE
 TREATMENT: PLACERO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
13	8	228	PK	16	10FEB92	Borderline mentally ill	Very much improved	4.00				
				18	24FEB92	Borderline mentally ill	Very much improved	4.00				
				20	09MAR92	Borderline mentally ill	Very much improved	4.00				
				22	23MAR92	Normal	Very much improved	4.00				
				24	06APR92	Borderline mentally ill	Very much improved	4.00				
				26	20APR92	Borderline mentally ill	Very much improved	4.00				
				28	04MAY92	Moderately ill	Minimally improved	2.00				
				30	18MAY92	Markedly ill	Much worse	1.00				
				13	9	229	SZS	8	16DEC91	Mildly ill	Much improved	3.00
								10	30DEC91	Moderately ill	Minimally improved	3.00
12	13JAN92	Mildly ill	Much improved					3.00				
14	27JAN92	Borderline mentally ill	Much improved					4.00				
16	10FEB92	Markedly ill	Minimally improved					3.00				
18	24FEB92	Markedly ill	No change					1.00				
13	11	225	HS	8	09JAN92	Mildly ill	Much improved	3.00				
				10	23JAN92	Borderline mentally ill	Much improved	4.00				
				12	06FEB92	Mildly ill	Much improved	3.00				
				14	20FEB92	Mildly ill	Much improved	3.00				
				16	05MAR92	Moderately ill	Much improved	3.00				
				18	19MAR92	Mildly ill	Much improved	3.00				
				20	02APR92	Mildly ill	Much improved	3.00				
				22	16APR92	Mildly ill	Much improved	3.00				
				24	30APR92	Mildly ill	Much improved	3.00				
				26	14MAY92	Mildly ill	Much improved	3.00				
				28	28MAY92	Mildly ill	Much improved	4.00				
				30	11JUN92	Borderline mentally ill	Much improved	4.00				
				32	25JUN92	Borderline mentally ill	Much improved	4.00				
				34	09JUL92	Borderline mentally ill	Much improved	4.00				
36	23JUL92	Borderline mentally ill	Very much improved	4.00								
38	06AUG92	Borderline mentally ill	Very much improved	4.00								
40	20AUG92	Borderline mentally ill	Very much improved	4.00								
42	03SEP92	Borderline mentally ill	Very much improved	4.00								
44	17SEP92	Borderline mentally ill	Very much improved	4.00								
46	01OCT92	Borderline mentally ill	Much improved	4.00								
48	15OCT92	Borderline mentally ill	Very much improved	4.00								
50	29OCT92	Borderline mentally ill	Very much improved	4.00								
52	12NOV92	Borderline mentally ill	Very much improved	4.00								
13	14	217	DF	8	27DEC91	Moderately ill	Much improved	1.50				
				10	10JAN92	Moderately ill	Much improved	3.00				
				12	24JAN92	Borderline mentally ill	Much improved	4.00				
				14	07FEB92	Moderately ill	Much improved	3.00				

1270

PHARMACIA CNS R&D

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.3

CLINICAL GLOBAL IMPRESSION (CGI)
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index				
13	14	217	DF	16	24FEB92	Mildly ill	Much improved	3.00				
				18	06MAR92	Mildly ill	Minimally improved	3.00				
				20	20MAR92	Moderately ill	Minimally improved	2.00				
				22	03APR92	Mildly ill	Minimally improved	3.00				
				24	17APR92	Moderately ill	Minimally improved	3.00				
				26	04MAY92	Mildly ill	Minimally improved	3.00				
				28	15MAY92	Mildly ill	Much improved	3.00				
				30	29MAY92	Mildly ill	Much improved	3.00				
				32	12JUN92	Borderline mentally ill	Much improved	4.00				
				34	26JUN92	Borderline mentally ill	Very much improved	4.00				
				36	10JUL92	Borderline mentally ill	Much improved	4.00				
				38	24JUL92	Borderline mentally ill	Very much improved	4.00				
				40	07AUG92	Borderline mentally ill	Very much improved	4.00				
				42	21AUG92	Borderline mentally ill	Very much improved	4.00				
				44	04SEF92	Borderline mentally ill	Very much improved	4.00				
				46	18SEF92	Borderline mentally ill	Very much improved	4.00				
				48	02OCT92	Borderline mentally ill	Very much improved	4.00				
				50	16OCT92	Borderline mentally ill	Very much improved	4.00				
				52	30OCT92	Borderline mentally ill	Very much improved	4.00				
				13	15	222	KG	8	01JAN92	Borderline mentally ill	Very much improved	4.00
								10	15JAN92	Mildly ill	Much improved	4.00
								12	29JAN92	Borderline mentally ill	Much improved	4.00
								14	12FEB92	Mildly ill	Much improved	3.00
								16	26FEB92	Borderline mentally ill	Very much improved	4.00
								18	11MAR92	Borderline mentally ill	Much improved	3.00
								20	25MAR92	Borderline mentally ill	Very much improved	4.00
								22	08APR92	Borderline mentally ill	Very much improved	4.00
				13	17	218	GSM	24	22APR92	Borderline mentally ill	Very much improved	4.00
								26	06MAY92	Borderline mentally ill	Very much improved	4.00
								28	20MAY92	Borderline mentally ill	Very much improved	4.00
								30	03JUN92	Borderline mentally ill	Very much improved	4.00
								32	17JUN92	Borderline mentally ill	Very much improved	4.00
34	01JUL92	Borderline mentally ill	Very much improved					4.00				
36	15JUL92	Borderline mentally ill	Very much improved					4.00				
38	29JUL92	Borderline mentally ill	Very much improved					4.00				
40	12AUG92	Borderline mentally ill	Very much improved					4.00				
42	25AUG92	Borderline mentally ill	Very much improved					4.00				
44	08SEF92	Borderline mentally ill	Very much improved					4.00				
46	22SEF92	Borderline mentally ill	Very much improved					4.00				
48	06OCT92	Borderline mentally ill	Very much improved					4.00				
50	20OCT92	Borderline mentally ill	Very much improved					4.00				
52	03NOV92	Borderline mentally ill	Very much improved					4.00				
13	17	218	GSM					8	14JAN92	Borderline mentally ill	Much improved	4.00

1271

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.3
 CLINICAL GLOBAL IMPRESSION (CGI)
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Visit Date	Severity of Illness	Global Improvement	Efficacy Index
13	17	218	GSM	10	28JAN92	Normal	Very much Improved	4.00
				12	14FEB92	Borderline mentally ill	Very much Improved	4.00
				14	25FEB92	Normal	Very much Improved	4.00
				16	10MAR92	Borderline mentally ill	Very much Improved	4.00
				18	24MAR92	Borderline mentally ill	Very much Improved	4.00
				20	07APR92	Normal	Very much Improved	4.00
				22	21APR92	Borderline mentally ill	Very much Improved	4.00
				24	05MAY92	Borderline mentally ill	Very much Improved	4.00
				26	19MAY92	Normal	Very much Improved	4.00
				28	02JUN92	Borderline mentally ill	Much improved	4.00
				30	16JUN92	Borderline mentally ill	Very much Improved	4.00
				32	30JUN92	Borderline mentally ill	Very much Improved	4.00
				34	14JUL92	Normal	Very much Improved	4.00
				36	28JUL92	Normal	Very much Improved	4.00
				38	11AUG92	Normal	Very much Improved	4.00
				40	25AUG92	Normal	Very much Improved	4.00
				42	08SEP92	Normal	Very much Improved	4.00
				44	22SEP92	Normal	Very much Improved	4.00
				46	06OCT92	Normal	Very much Improved	4.00
				48	20OCT92	Normal	Very much Improved	4.00
				50	03NOV92	Normal	Very much Improved	4.00
				52	17NOV92	Normal	Very much Improved	4.00

1272

PHARMACIA CNS R&D

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 RESOMETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit	Date Performed	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (*)				
1	1	MGA	0	16NOV90	4	4	3	3	4	3	3	3	3	3	3	3	3	2	3	4	3	4	3	4	4	3	67			
			1	23NOV90	4	4	2	4	4	3	3	2	3	3	3	3	3	3	3	3	3	4	3	4	4	3	4	74		
			2	30NOV90	2	2	2	3	3	4	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	2	2	55	
			3	07DEC90	2	2	2	2	3	1	4	3	2	3	2	2	2	2	2	3	2	2	2	2	3	3	2	2	3	45
			4	14DEC90	2	2	2	2	1	2	4	3	2	1	2	2	3	3	3	2	2	3	3	4	2	3	1	2	46	
			5	21DEC90	1	2	1	2	1	1	1	3	2	3	2	3	3	3	3	3	3	3	3	2	2	2	1	2	40	
1	2	RAQ	6	28DEC90	1	2	2	1	1	1	3	3	1	1	3	3	1	1	2	2	2	3	2	2	1	1	1	36		
			0	16NOV90	4	3	3	4	4	4	2	3	4	4	4	4	4	4	3	2	4	4	3	3	3	3	3	4	67	
			1	23NOV90	4	3	3	4	4	4	3	2	4	4	4	4	4	4	3	3	3	3	3	3	4	4	3	4	70	
			2	30NOV90	3	3	2	3	3	4	2	4	3	4	4	4	4	4	3	2	4	3	3	2	3	2	3	3	61	
			3	07DEC90	2	2	2	2	2	3	1	4	3	2	3	2	3	3	3	2	3	3	2	2	2	1	3	45		
			0	16NOV90	4	1	3	4	4	4	2	3	3	2	2	2	2	2	2	1	4	4	4	4	4	3	4	3	62	
1	3	TA	1	23NOV90	4	2	4	4	4	4	3	2	3	4	4	4	4	4	2	2	4	4	4	4	4	3	4	69		
			2	30NOV90	4	2	3	3	4	4	2	3	2	3	4	4	4	4	4	2	2	4	4	4	3	2	2	4	63	
			3	07DEC90	2	2	3	3	4	4	1	2	3	3	3	3	3	3	3	2	2	4	3	3	3	2	2	2	55	
			4	14DEC90	2	2	1	2	1	3	1	3	2	3	3	3	3	3	3	2	2	2	2	2	2	2	2	2	3	43
			5	21DEC90	2	2	2	2	3	2	3	1	2	2	2	2	2	2	2	2	1	3	3	3	2	2	1	2	42	
			6	28DEC90	2	1	1	1	2	1	2	1	2	2	3	2	2	3	2	3	2	2	2	1	3	2	2	1	1	37
1	4	DNC	0	20NOV90	4	4	3	3	4	2	3	2	4	4	4	4	4	4	4	4	2	1	3	4	4	3	3	65		
			1	27NOV90	4	4	3	3	4	3	2	3	3	4	4	4	4	4	4	3	3	3	3	4	4	3	4	67		
			2	05DEC90	3	3	2	2	2	2	2	3	2	2	2	2	2	2	2	3	2	2	4	4	2	2	2	2	52	
			3	12DEC90	2	3	3	1	1	3	2	2	2	2	2	2	2	2	2	3	2	2	3	2	4	4	1	3	50	
			4	19DEC90	2	2	3	2	1	4	1	2	2	2	2	2	2	2	2	3	2	1	3	3	3	3	1	2	44	
			5	26DEC90	2	1	2	2	1	4	1	3	2	1	2	2	2	2	2	1	1	2	2	1	2	2	3	1	2	37
1	5	DB	6	02JAN91	1	1	2	2	1	2	1	1	3	2	2	2	2	3	2	2	2	1	2	2	2	1	2	34		
			0	06DEC90	4	2	4	4	3	4	3	2	4	4	4	4	4	4	3	3	2	4	3	4	3	3	3	3	65	
			1	13DEC90	4	2	2	2	2	2	2	4	2	4	3	3	3	3	3	3	3	3	3	3	2	2	2	2	3	54
			2	20DEC90	3	1	2	2	1	4	1	2	3	4	2	3	4	2	3	3	2	2	2	3	2	3	2	3	48	
			3	26DEC90	3	2	2	2	2	4	1	2	3	2	3	2	3	2	3	2	2	1	2	2	2	2	3	1	2	43
			4	02JAN91	1	1	1	2	1	2	1	2	1	2	1	2	1	2	1	1	2	1	2	2	2	2	1	1	2	29
1	6	CPK	5	08JAN91	2	1	1	2	1	2	1	2	2	3	1	2	2	2	2	2	1	2	2	2	3	1	1	36		
			6	15JAN91	2	1	2	3	3	1	2	1	2	2	2	2	2	2	4	2	1	3	2	2	2	1	2	40		
			0	04DEC90	4	2	4	4	4	4	3	2	4	4	4	4	4	4	3	4	4	4	4	4	4	4	4	3	72	
			1	11DEC90	4	2	3	4	4	3	2	2	3	2	3	3	3	3	3	3	3	3	3	3	4	4	4	4	64	
			2	18DEC90	3	1	2	4	4	3	1	2	4	3	2	2	4	3	3	2	4	3	3	3	4	4	2	3	57	
			3	26DEC90	2	1	3	3	2	2	1	2	3	2	2	2	2	2	2	2	2	2	3	3	3	2	3	1	3	46
1	4		4	02JAN91	3	2	2	2	3	3	1	2	1	2	2	2	3	2	2	2	2	3	1	4	4	1	1	44		

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Patient Centre No.	Initials	Visit	Date Performed	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (*)			
1	6	CFM	5	08JAN91	2	2	3	3	2	1	2	2	2	1	1	1	1	2	2	3	2	2	2	1	2	41		
			6	15JAN91	3	2	2	1	2	2	1	1	1	1	1	1	1	1	1	1	1	3	3	2	1	1	34	
1	7	JSA	0	04DEC90	3	3	3	2	3	4	2	3	3	3	3	4	4	4	4	4	4	4	3	2	3	62		
			1	11DEC90	3	4	3	4	3	3	4	4	2	2	3	4	4	4	4	4	4	4	4	2	3	63		
			2	18DEC90	4	2	3	4	3	2	2	3	1	2	4	3	4	4	4	4	4	4	4	3	3	4	59	
1	8	MYB	3	26DEC90	4	3	2	3	4	3	2	3	4	2	2	2	3	2	4	2	4	2	3	3	3	58		
			4	07DEC90	4	4	2	3	3	3	4	2	1	4	4	4	4	4	4	4	4	4	4	3	2	4	64	
			1	14DEC90	4	4	3	4	3	2	2	4	3	4	4	4	3	4	4	4	4	3	3	4	4	2	4	64
			2	21DEC90	2	3	2	3	2	2	2	2	2	3	1	3	1	3	2	1	3	2	4	3	2	1	2	47
			3	28DEC90	2	2	3	2	2	1	2	1	2	2	1	2	2	2	3	2	2	3	2	4	2	1	2	38
			4	04JAN91	2	2	1	2	1	2	1	2	4	2	1	3	3	1	3	3	1	3	2	2	1	1	1	38
1	9	CCR	5	11JAN91	2	3	1	2	1	2	2	1	1	4	2	1	4	2	1	4	2	2	2	1	1	34		
			6	18JAN91	2	2	1	2	2	1	1	2	2	1	1	3	2	1	1	3	2	1	2	2	1	1	34	
			0	26DEC90	4	4	3	4	4	4	2	2	4	4	4	4	4	3	4	4	4	3	4	4	4	3	4	72
			1	02JAN91	4	4	2	4	4	4	2	2	4	3	3	3	2	4	3	4	3	4	3	4	3	3	65	
			2	09JAN91	3	2	1	2	3	1	2	2	4	3	3	1	2	2	3	2	3	3	3	2	2	2	3	48
			3	16JAN91	3	2	2	1	2	1	3	2	2	2	2	2	2	1	2	2	3	2	4	2	2	1	2	41
1	10	LDL	4	23JAN91	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	28	
			5	30JAN91	1	2	1	1	2	2	1	4	2	1	1	3	2	2	1	1	2	2	1	1	2	1	1	32
			6	06FEB91	1	1	1	1	2	2	1	2	2	1	1	1	1	1	1	1	1	1	1	2	1	1	1	27
			0	01FEB91	3	4	3	3	4	4	3	2	4	3	3	3	3	3	3	3	4	3	4	3	3	3	4	67
			1	08FEB91	4	3	4	4	4	4	3	1	3	2	2	4	3	4	4	4	4	4	4	4	4	3	3	64
			2	15FEB91	3	4	2	4	3	1	3	3	4	3	3	4	3	4	3	4	3	4	3	4	4	3	3	62
1	11	VRT	3	22FEB91	2	2	1	2	2	2	2	1	2	3	3	2	1	2	2	3	2	3	2	3	1	2	40	
			4	01MAR91	1	2	2	2	1	1	2	2	1	1	2	2	1	1	2	2	1	2	2	2	1	2	35	
			5	08MAR91	1	1	1	1	2	1	1	1	2	2	1	1	1	1	2	2	1	1	1	1	1	1	1	26
			6	15MAR91	1	1	1	2	1	1	2	1	1	2	2	2	2	1	1	1	1	2	2	1	1	1	1	27
			0	08MAR91	4	2	2	4	4	3	3	2	3	4	4	4	4	4	4	4	4	3	4	4	3	3	4	73
			1	15MAR91	4	3	3	4	4	3	4	3	3	3	3	3	3	3	3	3	3	4	3	3	2	2	4	60
1	12	SLT	2	22MAR91	3	3	3	4	4	3	4	4	4	4	4	4	4	4	4	4	4	4	3	3	2	2	66	
			3	28MAR91	4	4	2	4	4	3	3	1	4	4	4	4	4	4	4	4	4	4	4	3	2	2	4	80
			4	05APR91	2	4	3	2	3	2	1	3	2	2	3	2	2	2	3	2	3	1	2	2	1	1	3	46
			5	12APR91	2	3	1	2	3	1	1	2	1	1	2	1	1	2	1	1	2	1	1	1	2	1	1	32
			6	19APR91	2	1	1	2	1	1	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	26
			0	19MAR91	4	4	3	4	4	3	4	2	3	4	4	4	4	4	4	4	4	4	4	4	3	3	4	69
1	26MAR91	3	4	3	3	2	2	1	3	4	3	3	3	3	3	3	3	3	3	2	3	3	1	2	51			

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Date Performed	Date																				Total Score (*)	
					ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19		IT.20
1	12	SILT	2	02APR91	4	4	2	2	2	3	3	1	2	3	2	2	4	4	3	3	3	3	1	3	53	
			3	09APR91	2	2	2	3	3	1	1	2	2	3	3	4	2	2	3	3	3	3	2	2	47	
			4	16APR91	2	3	1	2	2	1	1	2	2	2	2	3	2	2	3	2	2	2	2	1	3	40
			5	23APR91	1	2	1	2	1	1	1	1	2	2	2	2	2	2	3	2	1	3	2	1	2	33
			6	30APR91	1	1	1	2	1	2	1	1	2	1	1	1	2	1	1	1	2	1	3	2	1	28
			0	30APR91	4	3	3	3	3	2	2	2	3	3	3	4	4	4	4	3	2	4	4	4	4	61
1	13	JR	1	07MAY91	4	3	3	4	4	2	3	3	2	2	2	3	3	3	4	4	4	4	2	3	63	
			2	14MAY91	4	1	3	3	4	3	3	2	4	3	3	3	3	3	1	2	2	3	3	3	57	
1	14	MLC	0	07MAY91	4	2	2	4	3	3	1	1	3	2	3	2	4	4	2	3	3	3	3	3	55	
			1	14MAY91	3	2	2	3	3	3	1	2	2	2	2	2	2	2	2	4	4	2	3	3	51	
			2	21MAY91	4	4	2	4	2	2	3	4	4	4	4	4	4	3	3	3	3	4	3	3	3	52
			3	28MAY91	3	3	4	3	3	2	2	2	4	3	3	3	4	3	3	3	2	4	4	3	2	60
			4	04JUN91	3	3	3	2	2	2	3	4	3	3	3	3	3	4	4	4	4	4	4	3	4	63
			5	11JUN91	3	2	2	3	3	1	2	2	3	3	3	3	3	3	3	2	3	2	3	2	2	51
1	15	MAO	6	18JUN91	2	1	1	2	3	3	1	2	2	1	2	2	1	1	2	2	3	2	2	1	36	
			0	08MAY91	3	4	3	3	3	2	2	2	2	2	2	2	4	4	2	4	4	4	4	3	50	
			1	15MAY91	4	4	2	3	2	4	1	3	2	2	2	2	2	2	2	4	2	3	2	2	3	54
			2	22MAY91	3	4	3	3	4	2	4	4	4	4	4	4	4	4	4	4	4	4	4	2	2	65
			3	29MAY91	2	2	2	4	3	3	1	4	4	4	2	2	2	2	2	2	2	2	2	2	2	45
			4	05JUN91	3	2	3	3	4	4	1	2	4	4	4	4	4	2	2	2	2	3	3	2	2	56
1	16	MHC	5	12JUN91	2	2	1	3	2	2	4	1	2	1	2	2	2	2	1	1	1	2	1	2	40	
			6	19JUN91	2	2	2	3	3	1	1	2	2	3	2	1	2	2	1	2	3	1	2	1	39	
			0	17MAY91	4	2	3	4	4	2	2	3	2	3	3	3	3	4	2	4	3	3	3	3	3	62
			1	24MAY91	4	1	3	4	4	4	2	3	2	4	4	4	4	2	4	2	4	3	3	2	3	60
			2	31MAY91	3	3	3	4	4	2	3	3	3	4	3	3	3	3	3	1	2	4	3	3	4	61
			3	07JUN91	3	2	3	3	2	3	1	1	2	1	3	3	2	2	1	3	1	2	1	2	1	41
1	17	CEC	4	14JUN91	2	2	1	3	2	3	1	2	3	3	2	2	2	2	2	2	2	2	1	2	43	
			5	21JUN91	2	2	1	3	2	3	2	1	3	3	3	3	2	2	2	3	2	3	3	1	2	46
			6	28JUN91	2	1	1	3	2	3	2	3	2	1	2	2	2	2	2	2	1	3	2	1	1	38
			0	21MAY91	4	3	3	3	3	4	3	2	2	3	3	3	4	3	3	4	3	3	3	3	4	57
1	17	CEC	1	28MAY91	4	3	3	3	3	1	2	2	2	2	2	2	4	4	4	4	4	2	2	3	56	
			2	04JUN91	2	2	2	3	1	2	2	2	3	3	3	2	2	2	2	3	2	2	2	2	3	44
			3	11JUN91	2	2	1	3	1	2	3	2	2	2	2	3	3	4	4	4	4	4	2	4	2	52
			4	18JUN91	2	2	1	3	1	3	3	2	2	2	4	3	1	2	2	4	2	3	1	2	3	45
			5	25JUN91	2	3	2	1	2	3	2	1	2	2	1	2	2	2	1	4	2	2	2	1	2	38
6	02JUL91	2	2	2	1	3	2	2	2	2	2	2	3	3	2	2	2	2	2	2	2	1	3	44		

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit	Date Performed	ZUNG	IT.1 IT.2 IT.3 IT.4 IT.5 IT.6 IT.7 IT.8 IT.9 IT.10 IT.11 IT.12 IT.13 IT.14 IT.15 IT.16 IT.17 IT.18 IT.19 IT.20																				Total Score (*)
						IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	
1	23	AR	2	05JUL91	4	3	4	4	2	3	3	4	2	2	1	3	3	2	2	3	3	4	57			
			3	12JUL91	3	2	4	4	2	3	4	3	3	4	2	2	3	3	3	3	3	2	3	59		
			4	19JUL91	3	2	4	1	3	2	3	4	3	3	4	2	4	4	3	3	3	3	2	4	58	
			0	02JUL91	4	3	3	3	4	3	3	2	2	4	3	3	3	2	3	3	2	3	3	4	59	
1	24	LVF	1	09JUL91	4	2	2	2	2	2	4	4	3	3	2	2	4	3	3	4	3	3	56			
			2	16JUL91	3	3	1	2	2	2	2	4	3	2	2	1	3	3	2	2	1	3	4	56		
			3	23JUL91	3	1	2	3	3	1	2	3	3	3	2	2	1	3	3	2	2	1	1	3	43	
			4	30JUL91	3	3	2	2	2	2	2	1	2	2	2	2	2	2	3	3	1	1	1	43		
			5	06AUG91	3	1	2	2	2	2	2	1	2	2	3	1	2	2	2	2	2	1	1	2	42	
			6	13AUG91	2	1	1	1	2	3	1	1	2	2	1	1	2	1	1	2	3	1	1	1	32	
1	25	AMR	0	05JUL91	4	2	4	3	3	3	4	3	4	4	2	2	4	4	4	4	3	4	67			
			1	12JUL91	4	2	2	2	3	3	4	3	3	2	2	4	3	3	3	2	2	3	4	57		
			2	19JUL91	2	2	2	4	3	3	1	2	2	3	3	2	2	2	2	3	2	1	2	46		
			3	26JUL91	2	2	1	3	2	2	2	3	1	2	2	2	1	1	1	1	2	1	2	36		
			4	02AUG91	2	1	3	3	2	2	2	2	2	2	2	2	2	2	3	2	2	1	3	42		
			5	09AUG91	2	1	1	2	3	1	1	2	2	3	2	2	3	1	2	3	1	2	3	1	38	
1	26	OC	1	09JUL91	1	2	1	1	1	1	1	2	2	2	1	1	2	1	1	2	1	1	28			
			0	16JUL91	3	3	4	3	3	2	4	4	2	3	3	2	2	4	2	2	2	3	3	56		
			1	23JUL91	4	3	3	3	4	2	2	3	3	3	2	2	3	3	4	4	4	2	3	60		
			2	30JUL91	3	2	2	3	2	2	1	3	3	2	3	2	2	3	1	3	1	2	3	45		
			3	06AUG91	2	2	3	2	2	2	2	2	3	3	3	2	2	3	2	3	3	1	2	3	49	
			4	13AUG91	2	2	3	3	1	1	1	1	2	2	3	1	2	1	3	1	2	1	1	2	35	
1	27	RK	0	12JUL91	4	3	4	4	2	4	2	3	4	4	2	4	3	3	3	3	4	3	67			
			1	19JUL91	4	2	4	3	3	3	4	4	4	4	4	4	3	4	4	4	3	3	3	64		
			2	26JUL91	3	2	1	4	2	2	3	3	1	2	3	2	3	2	3	2	3	2	2	47		
			3	02AUG91	2	2	3	2	1	2	2	2	1	2	1	3	2	2	2	1	3	2	2	41		
			4	09AUG91	3	1	1	1	2	2	2	3	3	3	4	4	2	2	2	2	2	1	2	40		
			5	16AUG91	2	2	1	2	2	2	4	1	3	2	3	2	1	2	2	1	2	1	2	41		
1	28	RHK	0	16JUL91	4	4	2	3	3	4	1	3	3	3	1	2	3	4	3	3	2	4	53			
			1	23JUL91	4	3	3	3	2	2	1	3	4	2	4	3	4	3	3	4	3	4	3	60		
			2	30JUL91	4	3	3	2	2	3	3	2	3	1	4	4	2	4	2	3	2	3	2	52		
			3	06AUG91	4	3	4	3	4	2	2	4	2	2	3	3	1	3	1	2	2	3	3	56		
			4	13AUG91	3	2	3	2	3	1	2	2	2	2	2	1	2	1	2	2	2	1	2	37		
			5	20AUG91	3	3	2	2	3	3	2	2	3	3	1	2	3	4	2	2	2	2	1	3	47	

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit	Date Performed	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (*)	
1	28	RMH	6	27AUG91	2	1	2	2	1	2	1	3	2	2	2	1	1	1	2	1	2	2	2	1	1	32	
1	29	AFO	0	16JUL91	4	4	2	3	3	2	4	4	4	4	4	3	3	3	4	3	3	3	4	4	4	68	
			1	23JUL91	4	3	4	2	2	2	2	2	2	2	2	4	4	1	4	2	2	3	3	2	4	54	
			2	30JUL91	4	1	3	2	2	3	3	2	2	2	2	4	2	2	4	3	4	4	4	2	3	56	
			3	06AUG91	3	2	2	3	1	1	2	2	3	2	2	2	2	1	1	2	2	1	1	2	2	36	
			4	13AUG91	3	2	2	3	2	2	1	1	2	1	2	2	2	2	2	2	2	2	3	3	1	40	
			5	20AUG91	2	2	3	2	2	2	2	1	4	2	2	3	1	3	3	1	3	3	3	1	2	46	
			6	27AUG91	1	2	2	2	1	1	2	2	1	2	2	1	1	3	2	1	2	2	1	1	2	32	
1	30	ERV	0	17JUL91	4	3	1	3	3	2	2	4	2	2	2	3	3	3	2	2	3	3	3	3	4	57	
			1	24JUL91	4	4	2	2	2	2	1	3	4	4	4	4	4	3	2	4	3	2	2	2	3	57	
			2	31JUL91	4	1	2	3	2	2	2	3	3	2	2	3	3	2	2	3	3	2	3	2	3	50	
			3	07AUG91	3	2	2	1	2	2	2	3	3	4	4	2	2	2	2	2	2	1	4	1	4	50	
			4	14AUG91	3	2	3	4	3	2	1	2	2	2	2	2	3	2	2	2	2	3	1	1	2	42	
			5	21AUG91	3	2	1	2	2	2	2	2	2	2	2	2	2	1	1	2	2	2	2	2	2	35	
			6	28AUG91	1	1	2	2	2	2	1	1	1	1	1	1	1	3	3	3	1	2	2	1	1	32	
1	31	MAN	0	23JUL91	4	3	3	4	2	2	3	2	3	4	4	3	3	3	4	1	3	3	3	2	4	59	
			1	30JUL91	3	2	4	4	4	4	4	4	4	4	4	4	4	4	4	4	1	1	3	3	3	63	
			2	06AUG91	4	2	3	2	4	1	2	2	2	2	2	2	2	3	3	2	2	2	2	3	2	51	
			3	13AUG91	2	3	3	2	2	1	2	1	2	1	2	2	1	3	1	2	3	1	2	3	1	2	40
			4	20AUG91	2	1	1	3	3	2	2	1	3	1	1	2	2	2	2	2	2	2	2	2	2	3	40
			5	27AUG91	2	2	1	1	2	2	2	2	2	2	2	2	2	1	1	2	2	1	2	1	1	31	
			6	03SEP91	1	2	1	1	2	2	1	1	2	2	2	1	2	1	2	1	2	1	1	1	2	29	
1	32	DCM	0	24JUL91	4	4	4	4	3	4	2	2	4	3	4	4	4	4	1	3	4	3	4	4	4	69	
			1	31JUL91	4	1	3	3	2	2	1	1	1	1	1	3	3	3	2	3	3	3	4	3	3	60	
			2	07AUG91	3	1	4	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	47	
			3	14AUG91	2	2	1	2	2	1	4	4	4	4	4	4	4	4	4	2	3	2	2	2	2	38	
			4	27AUG91	2	1	1	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	34
			5	28AUG91	2	1	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	30
			6	04SEP91	1	2	1	1	2	2	1	2	2	2	2	2	1	2	1	2	1	2	1	1	1	28	
1	33	OFC	0	24JUL91	4	2	2	2	2	4	3	2	3	4	2	4	3	3	2	2	2	3	3	2	3	55	
			1	31JUL91	4	4	3	4	3	3	2	2	3	3	3	4	4	4	2	4	4	4	4	3	2	63	
			2	07AUG91	4	2	1	3	3	3	3	4	3	3	3	3	3	3	2	3	3	4	3	2	1	53	
			3	14AUG91	2	2	3	2	2	4	2	4	3	2	2	2	2	2	2	2	2	2	2	2	2	2	54
			4	27AUG91	3	1	2	3	3	3	1	4	3	2	2	2	2	2	2	1	1	2	3	2	1	2	43
			5	28AUG91	2	2	1	2	2	2	3	2	1	1	1	2	2	2	2	2	2	2	2	2	2	1	32
			6	04SEP91	1	2	2	2	1	1	1	1	1	1	2	1	2	1	2	1	2	1	1	1	1	2	29

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit	Date Performed	ZUNG																				Total Score (*)		
					IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20			
1	34	GMH	0	07AUG91	4	4	2	2	3	3	4	3	3	2	4	4	2	3	3	3	3	1	3	3	3	59	
			1	14AUG91	1	2	1	1	2	2	2	4	4	4	4	4	4	3	3	3	2	2	3	3	3	48	
			2	21AUG91	4	4	4	3	3	3	2	4	4	4	4	4	4	3	4	3	3	4	2	4	2	3	64
			3	28AUG91	3	2	2	3	2	3	2	1	3	3	2	2	3	2	3	2	2	3	2	2	1	2	64
			4	04SEP91	2	2	2	4	4	3	3	2	2	3	4	4	4	2	3	3	3	2	2	2	1	2	53
			5	11SEP91	2	2	2	2	2	2	2	2	4	1	1	1	1	1	2	1	1	1	1	1	1	2	33
1	35	ENP	0	27AUG91	4	3	3	4	2	3	3	2	4	2	3	4	3	2	2	3	3	3	3	3	60		
			1	03SEP91	2	2	2	1	2	2	2	1	3	1	3	3	3	1	2	3	3	2	3	2	2	42	
			2	10SEP91	2	2	2	3	1	1	2	2	3	2	2	2	2	2	2	2	2	3	1	2	3	42	
			3	17SEP91	2	2	1	2	1	1	2	2	3	1	4	3	2	2	1	3	2	2	2	3	1	4	42
			4	24SEP91	2	1	2	1	2	1	1	2	1	1	2	1	2	1	2	1	2	2	1	1	2	1	33
			5	01OCT91	1	2	1	1	3	1	1	2	2	1	3	1	1	1	2	1	2	1	1	2	2	1	30
1	36	LM	0	08OCT91	1	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	2	1	2	1	1	25	
			1	27AUG91	4	4	3	3	1	3	3	2	2	3	4	3	4	3	3	3	3	2	2	2	3	4	57
			2	03SEP91	3	3	2	4	3	2	2	2	3	2	2	3	3	4	4	4	4	2	2	2	2	2	54
			3	10SEP91	2	2	2	2	2	1	2	3	3	2	2	2	2	2	2	2	2	1	2	2	1	2	36
			4	17SEP91	3	3	2	2	4	3	3	2	2	2	2	2	2	2	2	2	3	1	1	1	1	1	45
			5	01OCT91	2	1	1	3	1	1	2	2	1	2	1	2	1	1	2	2	1	1	1	1	1	1	28
1	37	RF	0	08OCT91	3	2	1	1	2	2	2	2	1	2	2	2	1	3	2	2	1	2	1	2	2	35	
			1	03SEP91	4	4	2	3	2	3	2	2	4	2	2	4	2	4	3	3	3	3	3	3	4	2	58
			2	10JUL91	4	3	3	3	1	3	1	1	4	3	3	3	4	4	3	4	4	2	2	3	2	3	58
			3	17SEP91	3	2	2	1	3	2	1	3	2	2	2	3	2	2	3	2	2	3	2	2	3	2	45
			4	24SEP91	1	2	2	2	2	1	1	1	1	2	1	1	2	1	2	1	1	1	2	1	1	2	29
			5	01OCT91	1	2	1	2	1	1	2	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	25
1	38	DBF	0	08OCT91	2	1	1	2	2	1	1	2	1	1	2	1	1	2	1	1	2	3	1	1	1	29	
			1	15OCT91	1	1	1	2	1	1	2	1	1	2	1	1	1	1	2	1	1	2	1	2	1	1	29
			2	17SEP91	4	3	3	4	4	3	1	1	4	4	3	2	4	4	4	4	4	4	4	4	2	4	64
			3	24SEP91	4	4	4	4	4	4	3	3	1	2	2	1	2	1	1	1	2	2	2	2	2	1	48
			4	01OCT91	3	2	2	3	2	2	1	2	1	4	2	2	2	2	1	2	2	1	2	2	1	2	39
			5	08OCT91	2	2	1	3	1	3	2	2	2	1	4	2	2	1	2	2	1	3	3	1	2	2	38
1	39	ASS	0	15OCT91	3	2	1	2	2	1	1	2	3	1	2	1	2	1	2	1	2	1	1	1	2	34	
			1	22OCT91	1	1	2	2	1	1	2	1	1	2	1	1	2	1	1	3	2	1	2	2	1	1	31
			2	29OCT91	1	1	1	2	2	1	2	1	2	1	2	1	2	1	1	2	1	2	1	2	2	1	30
			3	05SEP91	4	4	2	3	3	3	1	3	3	3	2	2	4	4	4	4	4	1	3	3	3	3	56
			4	12OCT91	3	2	1	4	3	2	2	2	2	2	2	2	3	3	3	3	2	2	2	2	2	2	49
			5	08OCT91	4	2	2	3	3	1	2	3	3	2	2	2	2	2	2	2	2	1	2	2	2	1	47

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit	Date Performed	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (*)				
1	39	ASS	3	15OCT91	4	2	2	2	2	2	3	3	1	3	2	3	3	3	1	2	2	2	1	2	1	2	42			
			4	22OCT91	3	1	2	3	1	3	2	2	2	4	2	2	2	2	2	1	1	1	1	3	1	2	37			
			5	29OCT91	3	1	2	2	1	2	2	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	1	34		
			6	05NOV91	2	1	2	1	1	2	2	1	1	2	2	2	1	1	2	2	1	1	1	1	2	2	3	29		
			0	24SEP91	4	4	2	3	3	2	2	4	4	2	4	2	3	3	3	3	4	1	4	1	3	3	3	4	60	
			1	01OCT91	4	3	1	2	3	3	2	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	48	
1	40	EH	1	08OCT91	3	2	2	3	3	3	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	3	46		
			3	15OCT91	3	1	1	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	40		
			4	22OCT91	2	1	1	3	1	1	2	2	1	1	2	2	1	1	1	1	2	1	2	1	2	1	2	29		
			5	29OCT91	1	1	1	2	1	1	2	1	1	2	1	2	1	2	1	2	1	2	1	2	2	1	2	1	29	
			6	05NOV91	2	2	2	1	1	2	2	1	2	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	50	
			0	24SEP91	4	3	3	3	3	3	1	4	4	2	2	2	2	2	2	2	2	3	3	4	3	4	3	3	60	
1	41	SFS	1	01OCT91	4	3	3	3	2	4	1	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	4	53		
			2	08OCT91	3	2	2	3	3	3	4	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	56	
			3	15OCT91	2	3	3	1	4	3	4	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	46	
			4	22OCT91	2	1	2	1	2	2	2	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	43	
			5	29OCT91	2	2	1	2	1	2	2	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	30
			6	05NOV91	1	2	2	2	1	4	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1	30
1	42	ICC	0	02OCT91	4	4	4	4	2	4	3	2	4	2	3	3	2	2	2	4	4	4	3	3	3	3	4	65		
			1	09OCT91	3	4	4	3	3	2	4	2	3	4	2	3	4	3	2	2	4	3	4	2	2	2	2	4	61	
			2	16OCT91	3	2	2	3	3	3	1	3	3	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	44	
			3	23OCT91	4	2	1	3	3	2	2	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	42	
			4	30OCT91	2	1	2	1	1	2	2	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	30
			5	06NOV91	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	32
1	43	ARN	0	02OCT91	4	3	3	2	2	3	3	3	4	2	3	2	2	2	2	2	2	2	2	2	2	2	4	57		
			1	09OCT91	3	2	2	3	2	4	2	3	3	3	4	2	3	3	3	3	3	3	3	3	3	3	3	3	55	
			2	16OCT91	3	3	3	2	2	1	4	2	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	58	
			3	23OCT91	3	2	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	40	
			4	30OCT91	3	2	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	36	
			5	25SEP91	3	2	1	1	2	2	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	26
1	44	MAL	0	08OCT91	4	4	4	4	2	4	4	2	4	2	3	2	2	2	2	2	2	2	2	2	2	2	4	66		
			1	15OCT91	4	4	2	3	3	4	4	2	3	3	4	4	4	3	3	3	3	3	3	3	3	3	3	3	64	
			2	22OCT91	3	2	4	4	3	3	4	4	2	3	3	4	4	4	3	3	3	3	3	3	3	3	3	3	4	63
			3	29OCT91	3	2	1	3	1	3	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	42
			4	05NOV91	3	2	1	2	1	3	2	2	4	4	2	4	4	2	2	2	2	2	2	2	2	2	2	2	2	43
			0	24SEP91	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	66

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Date Performed	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (*)	
1	44	MAL	5	12NOV91	3	3	2	2	3	3	1	2	3	2	2	2	3	2	2	2	2	1	2	2	3	4	44
			6	19NOV91	4	4	2	3	3	3	1	2	3	3	3	2	4	4	4	2	2	3	3	3	4	58	
1	45	DPS	0	08OCT91	4	4	2	4	4	2	2	1	2	3	3	3	4	4	2	2	3	3	3	3	4	60	
			1	15OCT91	2	2	1	2	1	1	2	2	1	2	1	2	1	2	2	2	2	2	1	1	1	1	30
			2	22OCT91	3	2	2	1	3	1	2	2	2	1	3	1	2	1	2	2	2	1	2	1	1	2	37
			3	29OCT91	2	1	2	2	1	2	2	1	2	2	2	1	2	1	2	1	2	2	1	1	1	1	31
			4	05NOV91	1	1	1	2	2	1	2	2	1	2	1	2	1	2	2	1	2	1	1	2	1	1	28
			5	12NOV91	1	1	2	2	1	2	2	1	2	2	1	2	1	2	2	1	2	1	2	1	1	1	28
			6	19NOV91	1	1	2	1	2	1	1	2	2	2	2	1	2	1	1	1	1	1	1	3	1	1	29
1	46	SP	0	15OCT91	4	4	2	4	4	3	2	3	3	3	3	3	3	2	3	3	2	2	3	3	4	60	
			1	22OCT91	4	3	3	3	4	2	2	3	3	3	3	3	3	3	3	3	4	1	3	2	3	58	
			2	29OCT91	4	2	2	3	3	3	1	4	2	4	2	4	3	2	4	2	2	4	1	3	3	56	
			3	05NOV91	2	2	4	2	3	1	2	2	4	2	4	2	2	4	3	2	1	2	1	2	3	46	
			4	12NOV91	3	2	2	1	2	1	2	2	2	2	2	2	2	2	2	4	2	3	1	2	2	1	42
			5	19NOV91	2	2	1	2	2	1	2	1	2	2	1	2	1	2	2	1	2	1	1	2	2	2	42
			6	26NOV91	1	1	2	2	2	1	1	3	2	2	2	2	1	2	1	2	1	2	1	1	2	2	33
1	47	MCS	0	22OCT91	4	3	3	2	3	3	1	1	4	3	3	2	3	3	3	2	2	2	3	2	3	53	
			1	29OCT91	4	3	2	3	2	3	3	2	3	3	3	2	3	2	3	4	1	1	1	2	2	4	52
			2	05NOV91	3	2	1	3	2	3	1	2	3	1	2	1	2	1	2	1	3	3	2	2	1	39	
			3	12NOV91	3	1	2	2	1	2	2	2	1	2	1	2	1	2	2	1	3	2	2	2	1	35	
			4	19NOV91	2	1	2	2	1	2	1	2	1	2	1	2	1	2	1	2	1	3	1	3	1	1	32
			5	26NOV91	1	2	2	1	2	1	2	2	1	2	1	2	1	2	1	2	1	1	1	2	1	1	27
			6	03DEC91	1	2	2	1	2	2	1	2	1	1	2	1	2	1	2	1	1	1	3	2	1	1	31
1	48	SCN	0	23OCT91	4	3	3	4	1	4	1	2	2	4	2	3	3	3	3	1	3	2	2	3	4	54	
			1	30OCT91	3	2	1	4	2	3	1	4	3	2	3	2	3	2	2	1	3	3	3	2	2	50	
			2	06NOV91	3	3	4	2	3	2	3	2	3	2	3	2	2	2	1	2	2	2	1	2	2	46	
			3	13NOV91	2	2	4	3	2	1	2	2	3	2	3	2	2	2	2	2	3	2	2	1	2	42	
			4	20NOV91	2	2	3	1	3	2	2	1	2	2	1	2	2	2	2	2	2	2	2	1	2	38	
			5	27NOV91	2	1	1	2	2	1	2	3	2	1	1	2	1	1	2	2	1	1	3	2	1	2	34
			6	04DEC91	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	2	2	2	1	2	1	1	31
1	49	DAS	0	25OCT91	4	3	3	2	2	3	3	4	4	2	3	2	3	2	3	4	2	3	1	3	4	57	
			1	01NOV91	3	2	1	3	1	3	3	3	4	3	3	4	3	2	4	1	3	4	1	3	3	59	
			2	08NOV91	4	2	3	3	4	3	1	2	4	2	4	3	2	3	3	3	3	3	3	3	4	59	
1	50	MFA	0	25OCT91	4	4	4	4	4	4	2	3	3	4	2	2	2	2	4	3	4	4	4	4	4	68	
			1	01NOV91	4	3	3	3	4	2	2	3	3	4	4	4	3	2	1	4	2	4	2	2	3	58	
			2	08NOV91	4	2	2	4	3	2	3	3	3	2	2	2	2	2	2	2	3	3	2	2	3	52	

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Date Performed	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (*)				
1	50	MFA	3	14NOV91	3	2	2	3	1	1	2	1	2	1	2	2	1	2	1	2	1	2	2	2	2	2	35			
			4	22NOV91	2	2	2	1	1	2	2	1	2	1	2	1	2	1	1	2	2	1	1	2	1	1	31			
			5	29NOV91	3	2	2	1	3	2	4	2	2	2	2	2	2	1	1	2	2	2	1	2	2	2	2	39		
			6	06DEC91	1	1	1	2	1	2	2	3	2	3	1	1	1	2	3	1	1	1	1	2	1	2	1	2	32	
			0	25OCT91	4	4	2	3	3	3	4	3	3	4	4	4	2	2	4	4	2	2	2	3	3	2	3	4	63	
			1	01NOV91	4	2	2	2	3	3	1	2	3	3	3	4	2	2	2	1	2	2	2	1	3	3	2	3	50	
1	51	ASA	2	08NOV91	4	2	2	1	2	4	3	3	1	2	1	2	1	2	1	2	2	1	2	2	1	2	2	41		
			3	14NOV91	3	3	2	2	1	3	1	4	1	4	1	1	2	2	1	1	2	2	2	1	2	1	2	1	35	
			4	22NOV91	2	2	1	2	2	2	2	2	2	2	2	2	2	1	3	1	2	2	1	3	1	2	1	2	37	
			5	28NOV91	2	2	1	2	1	2	1	3	1	2	2	1	2	2	1	2	1	2	2	1	2	1	2	1	2	32
			6	06DEC91	2	1	2	2	1	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	1	30
			0	30OCT91	4	4	4	4	4	3	2	2	4	4	3	2	1	4	1	3	3	4	1	3	3	4	4	4	64	
1	52	MIS	1	30OCT91	3	2	2	1	2	3	3	2	3	3	2	4	2	2	3	2	4	2	2	3	3	3	4	57		
			2	13NOV91	3	2	2	1	2	3	3	4	2	3	4	1	3	3	2	2	3	3	2	2	2	2	3	50		
			3	20NOV91	3	2	2	2	3	1	2	2	4	2	2	3	3	2	2	3	2	2	3	2	2	2	2	3	47	
			4	27NOV91	2	2	2	2	1	1	2	2	4	2	2	4	3	3	1	3	3	1	3	3	1	1	2	2	41	
			5	04DEC91	3	2	2	2	1	1	2	2	1	2	2	2	1	2	2	2	2	1	2	2	2	2	1	1	36	
			6	11DEC91	2	1	2	2	1	1	2	1	2	1	2	1	2	1	2	1	2	2	3	2	1	2	1	1	32	
1	53	JFT	0	30OCT91	4	4	2	4	3	3	3	3	1	4	3	3	3	3	3	3	3	3	4	3	3	4	4	64		
			1	06NOV91	4	3	3	2	2	2	2	3	3	3	1	3	2	2	2	2	2	2	2	1	3	2	2	2	47	
			2	13NOV91	2	2	4	3	3	1	2	2	4	2	4	2	3	1	1	2	2	2	2	2	2	1	2	1	42	
			3	20NOV91	2	1	2	2	2	1	2	2	1	2	2	1	2	2	2	2	3	2	2	3	1	2	1	2	36	
			4	27NOV91	3	2	2	2	2	2	2	2	1	2	2	1	2	1	1	2	2	1	1	3	1	2	1	2	35	
			5	04DEC91	2	2	2	2	2	2	2	1	1	2	2	1	1	1	1	1	1	1	1	2	1	2	1	1	34	
1	54	JD	6	11DEC91	1	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	2	1	2	1	1	1	27		
			0	05NOV91	4	3	3	2	3	2	1	4	4	2	3	3	3	1	3	3	3	1	3	2	3	2	2	4	54	
			1	12NOV91	4	3	3	2	4	1	2	3	3	3	3	3	3	3	3	3	3	4	1	4	4	2	3	3	56	
			2	19NOV91	3	3	3	3	3	4	1	1	4	2	3	1	3	4	1	3	3	3	4	1	3	3	4	4	56	
			3	26NOV91	2	4	4	3	3	3	1	2	3	2	3	4	3	2	3	4	3	2	3	4	3	2	3	3	58	
			4	03DEC91	4	4	2	3	3	3	1	2	3	2	3	2	2	3	3	2	2	2	3	3	4	2	3	3	56	
1	55	DMG	0	05NOV91	4	4	2	3	3	4	3	4	3	3	3	3	3	3	3	3	3	3	2	2	3	3	3	4	57	
			1	12NOV91	4	3	3	3	3	4	3	5	4	2	2	3	2	3	2	2	3	2	2	1	2	2	2	3	54	
			2	19NOV91	4	2	1	2	1	3	2	1	3	2	1	4	2	1	4	2	2	4	3	2	4	3	2	2	45	
			3	26NOV91	2	2	1	3	2	1	2	3	2	2	2	2	2	2	2	2	2	2	1	2	3	1	2	2	2	34
			4	03DEC91	2	2	1	3	2	4	1	2	3	4	1	2	1	2	1	2	1	2	2	1	2	2	1	2	1	40
			5	10DEC91	4	3	3	3	2	4	1	1	2	3	2	2	2	2	2	2	2	2	1	3	1	2	2	1	1	44
6	17DEC91	2	1	2	2	1	1	2	2	1	1	2	1	1	1	1	2	1	2	1	2	2	1	1	1	1	29			

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit	ZUNG	Data Performed																				Total Score (*)		
					IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20			
1	56	IAL	0	05NOV91	4	3	2	4	2	1	2	3	3	4	1	1	2	3	2	4	2	3	3	3	52		
			1	12NOV91	4	2	1	3	2	3	2	2	2	2	2	1	2	2	3	4	2	2	1	2	2	45	
			2	19NOV91	4	2	2	3	2	2	2	2	2	2	2	1	2	2	1	2	2	2	3	1	2	2	42
			3	26NOV91	4	2	2	3	2	2	2	2	2	2	2	1	2	2	1	2	3	1	2	2	1	2	39
			4	03DEC91	2	1	1	2	2	4	3	2	2	2	2	1	2	2	1	1	1	1	2	2	2	2	37
			5	10DEC91	3	1	1	1	4	1	1	2	1	2	2	1	1	1	2	2	1	1	1	1	1	1	28
1	57	SMC	6	17DEC91	1	1	2	1	2	4	1	1	2	1	2	1	2	1	2	1	1	1	2	1	29		
			0	03DEC91	4	3	3	2	2	2	2	3	2	2	3	2	2	2	3	3	3	3	3	3	3	49	
			1	17DEC91	3	2	1	4	3	2	2	3	2	2	1	3	3	2	3	3	2	3	1	2	2	47	
			2	24DEC91	2	3	2	2	2	1	3	3	4	2	2	2	2	2	1	3	2	2	2	1	1	44	
			3	31DEC91	3	3	2	2	2	2	1	4	2	2	2	2	2	1	3	2	2	1	3	2	1	40	
			0	10DEC91	3	2	2	3	3	2	2	3	2	1	1	2	2	2	2	3	1	2	2	2	2	2	42
1	58	ARH	1	17DEC91	3	4	3	3	3	2	2	2	1	2	2	3	3	3	3	3	3	2	2	2	53		
			2	24DEC91	4	3	3	3	3	2	2	4	2	1	2	2	2	1	1	2	2	2	2	2	2	45	
			3	31DEC91	3	3	1	2	3	2	2	1	1	2	2	2	2	2	2	2	3	1	2	3	1	2	40
			4	07JAN92	3	2	1	4	2	2	3	1	2	4	3	2	2	2	2	2	3	4	2	3	4	2	51
			5	14JAN92	2	2	3	3	1	2	2	4	3	2	2	2	2	2	2	2	3	3	2	3	3	3	52
			6	21JAN92	2	2	2	3	2	3	1	4	2	3	1	2	2	2	1	3	2	2	1	2	2	1	40
1	59	SPF	0	17DEC91	4	3	2	3	2	3	3	2	3	3	2	2	1	2	3	1	2	3	1	2	37		
			1	24DEC91	3	2	2	3	2	2	2	1	2	2	2	2	2	4	2	2	1	4	2	2	2	45	
			2	31DEC91	4	3	3	2	2	2	1	3	1	2	3	4	1	3	3	3	2	2	4	2	2	50	
			3	07JAN92	3	2	2	3	2	2	2	2	2	3	1	2	2	2	2	2	3	3	1	2	2	44	
			4	14JAN92	2	2	1	2	2	2	1	2	2	2	2	2	2	2	2	2	2	3	1	2	2	44	
			5	21JAN92	2	1	2	1	2	2	1	3	3	2	2	2	1	2	2	2	2	3	1	2	1	2	38
1	60	EM	6	28JAN92	1	1	1	3	1	2	1	2	1	2	2	1	2	1	2	1	2	1	2	1	29		
			0	20DEC91	4	2	4	3	3	4	3	2	3	3	4	3	2	2	2	3	2	3	3	3	4	63	
			1	27DEC91	4	3	3	4	3	2	3	3	4	4	4	3	4	4	3	4	4	3	3	3	4	62	
			2	03JAN92	3	3	3	4	4	3	2	2	3	2	4	3	3	4	3	3	4	3	3	3	4	63	
			3	10JAN92	4	4	4	4	4	4	4	2	2	3	2	3	2	2	2	2	2	2	3	2	2	4	57
			4	17JAN92	4	3	3	3	2	3	1	1	2	2	2	2	2	2	2	2	2	2	3	1	2	2	42
1	61	HVC	5	24JAN92	3	2	2	2	3	2	1	1	2	1	2	1	2	2	1	2	2	2	1	2	34		
			6	31JAN92	3	3	2	2	2	3	2	1	2	3	2	3	2	1	2	2	2	3	1	2	2	44	
			0	20DEC91	4	4	3	3	1	1	2	2	3	4	3	3	2	3	3	3	3	3	2	2	3	53	
			1	27DEC91	3	3	4	4	1	4	2	3	3	4	2	3	3	3	3	3	4	2	3	4	2	3	56
			2	03JAN92	4	1	3	4	4	4	2	2	3	1	3	3	3	2	4	1	3	3	3	3	2	53	
			3	10JAN92	3	1	2	4	1	2	2	1	3	3	1	2	1	2	3	3	2	1	2	2	1	2	41
1	61	HVC	4	17JAN92	3	2	2	2	2	2	2	2	2	2	1	2	2	2	3	1	2	2	1	2	38		

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit	Date Performed	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (*)				
1	61	HVC	5	24JAN92	3	2	2	3	2	2	2	2	2	2	2	2	2	1	1	1	2	1	1	2	2	1	36			
			6	31JAN92	2	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1	33		
			0	07JAN92	3	4	3	3	3	3	3	3	3	3	3	3	3	3	2	2	3	3	4	3	3	3	3	4	60	
			1	14JAN92	4	3	4	4	4	4	4	4	4	4	4	4	4	4	3	3	4	4	4	4	4	4	4	4	55	
			2	21JAN92	4	2	4	4	4	4	4	4	4	4	4	4	4	4	3	3	4	4	4	4	4	4	4	4	50	
			3	28JAN92	4	2	4	4	4	4	4	4	4	4	4	4	4	4	3	3	4	4	4	4	4	4	4	4	52	
1	62	MEA	4	04FEB92	3	2	4	4	3	2	1	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	49		
			5	11FEB92	2	1	1	2	2	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	31	
			6	18FEB92	1	1	1	2	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	27	
			0	08JAN92	4	3	3	4	1	4	1	3	3	2	2	2	2	2	2	3	3	2	2	4	4	2	2	3	50	
			1	15JAN92	4	3	3	4	2	3	3	3	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	53	
			2	22JAN92	4	2	4	4	2	4	2	4	2	4	2	4	2	4	2	2	2	2	4	1	2	4	3	4	59	
1	64	ENF	3	29JAN92	4	2	1	4	1	4	1	4	2	3	2	3	2	4	3	3	2	3	2	3	2	3	3	56		
			0	17JAN92	4	3	2	3	2	3	4	2	2	2	2	2	2	2	2	4	4	2	2	4	4	3	3	4	60	
			1	24JAN92	4	4	2	2	2	2	3	4	2	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	56	
			2	31JAN92	1	1	1	3	1	2	2	4	2	1	2	1	2	1	2	2	2	2	2	2	2	2	2	2	33	
			3	07FEB92	1	1	1	3	2	1	2	2	1	2	2	1	2	2	2	2	2	2	2	2	2	2	2	2	33	
			4	14FEB92	2	1	2	1	2	2	1	2	2	1	2	2	1	2	2	2	2	2	2	2	2	2	2	2	28	
1	65	FS	5	21FEB92	1	2	1	2	1	2	1	2	1	2	1	2	1	2	2	2	2	2	2	2	2	2	2	26		
			6	28FEB92	1	2	1	2	1	2	1	2	2	1	2	1	2	1	2	2	2	2	2	2	2	2	2	2	27	
			0	21JAN92	4	2	3	4	3	3	4	4	3	3	4	4	3	3	2	2	2	3	4	1	3	3	3	59		
			1	28JAN92	3	3	3	3	2	2	1	2	4	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	54	
			2	04FEB92	3	3	2	3	2	2	1	4	3	3	3	3	3	3	3	3	3	3	4	4	3	3	3	3	55	
			3	11FEB92	4	4	2	3	2	2	2	4	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	56	
1	66	TCG	4	18FEB92	3	3	4	4	3	3	2	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	63		
			5	25FEB92	4	3	3	2	3	2	3	2	3	2	3	2	3	2	3	3	3	2	2	3	4	4	4	4	58	
			6	04MAR92	4	3	3	2	3	2	3	2	3	2	3	2	3	2	3	3	3	4	4	4	4	4	4	4	4	58
			0	21JAN92	4	3	3	3	2	3	2	4	2	2	4	2	4	2	4	3	4	3	4	3	3	4	4	4	60	
			1	28JAN92	3	3	4	3	4	3	4	2	2	4	2	2	4	2	4	3	3	4	1	4	4	4	4	4	64	
			2	04FEB92	4	1	3	4	2	2	1	2	2	4	3	3	3	3	3	3	3	4	3	4	3	4	4	4	53	
1	67	WAA	3	11FEB92	2	4	3	3	3	4	2	3	2	4	2	3	2	4	3	1	3	3	4	4	3	3	3	60		
			4	18FEB92	2	3	3	2	2	2	4	2	2	3	2	4	2	2	2	2	2	2	2	2	2	2	2	2	39	
			5	25FEB92	1	2	2	1	2	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	32	
			6	04MAR92	1	2	1	2	1	2	2	1	2	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	28
			0	21JAN92	4	4	2	3	1	2	1	3	2	4	3	2	4	2	4	3	2	4	2	4	4	2	3	3	55	
			1	28JAN92	4	3	1	4	1	4	1	2	4	2	4	2	4	2	3	2	2	3	3	3	3	3	4	4	4	54

(*) = Total score computed

1284

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REMOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit	Date Performed	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (*)				
1	67	WAA	2	04FEB92	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	60			
			3	11FEB92	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	40	
			4	18FEB92	2	1	2	4	1	2	2	3	4	2	3	4	2	4	2	4	4	2	1	1	1	1	1	1	1	39
			5	25FEB92	2	1	2	1	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	30
			6	04MAR92	2	1	2	2	2	1	2	2	2	1	1	2	1	1	1	1	1	1	2	1	1	1	1	2	29	
			0	21JAN92	4	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	62
1	68	MGS	1	28JAN92	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	57		
			2	04FEB92	4	3	3	2	3	2	3	4	4	3	3	4	2	4	3	4	4	2	4	4	4	4	4	4	57	
			3	11FEB92	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	62
			4	18FEB92	4	2	4	3	3	4	3	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	62
			5	25FEB92	4	2	4	3	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	66
			6	04MAR92	4	3	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	64
1	69	RFA	0	21JAN92	4	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	62		
			1	28JAN92	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	60	
			2	04FEB92	4	3	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	62
			3	11FEB92	4	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	54
			4	18FEB92	4	3	3	2	2	2	2	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	59
			5	25FEB92	4	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	60
1	70	MLM	0	24JAN92	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	68		
			1	31JAN92	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	67	
			2	07FEB92	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	60
			3	14FEB92	3	4	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	59
			4	21FEB92	4	3	3	2	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	60
			5	28FEB92	2	2	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	42
1	71	OMY	0	06MAR92	2	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	39		
			1	13JAN92	4	3	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	64	
			2	20JAN92	4	3	3	2	3	2	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	60
			3	27JAN92	4	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	56
			4	03FEB92	4	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	56
			5	10FEB92	4	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	54
1	72	RLJ	0	10MAR92	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	52		
			1	17MAR92	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25	
			2	24MAR92	4	2	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	62
			3	31MAR92	4	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	60
			4	07APR92	3	4	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	50
			5	14APR92	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	49

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit	Date Performed	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	Total Score (*)						
1	72	RLJ	4	25FEB92	2	1	2	2	1	4	2	2	2	1	2	1	2	3	2	1	2	1	2	1	1	2	36				
			5	04MAR92	2	2	2	1	1	2	2	1	2	2	1	2	1	2	2	1	2	1	2	1	2	1	1	31			
			6	10MAR92	1	2	1	2	2	1	2	1	1	2	1	2	1	2	1	1	2	1	2	1	2	1	1	2	29		
			1	73	FMA	0	28JAN92	4	2	3	3	2	4	2	1	2	3	3	3	2	3	4	4	2	4	2	2	2	4	56	
						1	04FEB92	4	2	2	4	3	3	1	4	3	4	3	3	2	2	3	2	3	4	3	2	2	2	3	59
						2	11FEB92	3	3	2	2	3	3	4	3	3	3	3	3	2	2	3	4	1	3	4	1	3	2	2	52
3	18FEB92	3				2	1	3	2	3	4	2	3	2	2	3	2	2	3	4	1	3	1	1	3	1	2	48			
1	74	IVL	4	25FEB92	2	2	2	2	1	3	4	2	2	2	2	2	2	4	2	2	3	3	3	2	1	1	44				
			5	04MAR92	2	2	1	2	2	2	2	4	2	2	2	2	2	2	2	2	2	3	3	2	1	2	1	1	36		
			6	10MAR92	2	2	1	2	1	2	1	4	2	3	3	2	1	2	1	2	1	2	1	2	1	2	1	1	36		
			0	28JAN92	4	3	2	2	3	2	2	3	2	2	2	3	3	3	1	2	2	4	3	4	3	4	5	55			
			1	04FEB92	2	1	2	3	2	2	1	4	3	3	1	3	3	4	3	3	2	4	3	4	3	4	2	2	52		
			2	11FEB92	3	3	4	3	3	2	2	1	1	2	2	3	1	3	2	1	1	2	1	1	2	1	2	2	43		
1	75	ELF	3	18FEB92	2	2	1	3	2	1	1	2	2	1	1	2	1	1	2	2	1	1	1	2	1	2	32				
			4	25FEB92	2	2	2	1	2	2	2	1	2	2	2	3	1	2	2	1	1	2	2	2	2	1	1	35			
			5	04MAR92	2	1	2	2	2	2	1	2	3	2	2	2	2	1	1	1	1	2	2	1	1	2	1	1	36		
			6	10MAR92	2	1	2	2	2	2	1	2	2	1	2	2	1	2	1	2	1	2	1	2	1	1	2	1	32		
			0	31JAN92	4	3	2	2	2	2	1	2	2	2	1	2	4	4	3	3	2	4	3	3	3	2	2	2	54		
			1	07FEB92	3	2	4	4	3	2	1	3	2	2	2	4	3	2	2	4	4	4	3	4	4	4	2	2	56		
1	76	SFA	2	14FEB92	4	3	3	2	3	2	3	2	3	2	2	2	2	3	2	2	2	3	2	2	2	1	3	52			
			3	21FEB92	3	4	3	4	2	4	1	1	3	2	3	2	3	2	3	2	2	3	2	2	2	2	1	2	50		
			4	28FEB92	3	4	3	4	2	4	1	1	3	2	3	2	3	2	3	2	2	3	2	2	2	3	1	1	42		
			5	06MAR92	2	1	2	2	3	1	2	2	2	2	4	2	2	2	2	1	2	2	1	2	2	2	1	2	37		
			6	13MAR92	2	2	1	3	1	2	1	2	2	1	2	2	4	2	2	2	1	2	2	1	2	2	1	1	36		
			0	07FEB92	4	2	4	4	2	2	4	2	2	4	2	2	4	3	3	4	3	2	4	4	3	4	3	2	64		
1	77	ACG	1	14FEB92	4	2	3	1	3	1	2	1	2	1	2	3	2	2	4	3	4	3	4	3	4	3	2	52			
			2	21FEB92	3	2	1	2	1	3	1	2	1	2	2	2	2	2	2	2	4	2	2	1	3	2	2	42			
			3	28FEB92	3	2	4	3	3	1	3	3	4	3	3	2	4	3	4	3	3	2	1	3	3	3	2	2	50		
			4	06MAR92	2	2	1	3	1	2	1	1	3	2	2	2	2	2	2	2	3	2	2	2	2	3	2	2	40		
			5	13MAR92	2	2	1	3	1	2	1	2	2	1	2	2	2	2	1	2	2	1	2	2	2	2	3	1	2	35	
			6	20MAR92	1	1	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	1	2	1	1	2	1	1	26		
1	77	ACG	0	07FEB92	4	2	4	4	3	2	4	1	3	4	4	4	4	4	1	3	4	3	1	3	4	4	2	62			
			1	14FEB92	4	2	3	3	2	2	1	3	4	2	4	2	4	2	4	1	4	2	1	3	2	3	4	3	55		
			2	21FEB92	3	2	1	3	3	2	1	2	4	2	4	2	4	2	4	2	1	4	2	2	3	4	3	3	50		
			3	28FEB92	4	1	1	3	3	4	1	1	2	3	4	3	3	4	3	2	2	3	3	2	2	1	2	1	2	47	
			4	06MAR92	3	1	2	4	2	4	1	1	3	2	4	1	1	3	2	3	1	1	1	1	2	1	1	2	39		
5	13MAR92	2	1	2	2	1	4	2	2	1	4	2	2	1	2	2	1	2	1	2	1	2	2	2	1	1	35				

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Date Performed	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (*)	
1	77	ACG	6	20MAR92	2	1	1	3	2	4	1	1	3	2	2	2	1	2	1	1	2	1	2	1	1	34	
1	78	SD	0	07FEB92	4	2	4	4	4	3	1	1	3	3	4	3	4	4	4	3	4	3	3	3	3	64	
			1	14FEB92	4	3	3	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	58	
			2	21FEB92	4	3	4	3	2	2	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	61	
			3	28FEB92	4	2	4	3	3	4	2	4	4	4	4	4	4	4	4	4	4	4	4	4	4	66	
			4	06MAR92	4	2	4	3	2	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	68	
			5	13MAR92	4	3	4	3	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	67	
			6	20MAR92	3	2	4	4	2	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	65	
1	79	JCH	0	07FEB92	4	4	3	4	3	3	1	1	2	4	4	4	4	4	4	4	4	4	4	4	4	62	
			1	14FEB92	4	3	2	3	3	4	1	2	4	4	4	4	4	4	4	4	4	4	4	4	4	62	
			2	21FEB92	3	3	1	3	2	3	1	2	3	3	3	3	3	3	3	3	3	3	3	3	3	47	
			3	28FEB92	3	2	3	4	3	2	2	2	2	3	2	2	4	3	2	2	2	2	2	2	2	49	
			4	06MAR92	2	2	1	2	1	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	32	
			5	13MAR92	2	1	1	2	1	1	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	34	
			6	20MAR92	1	1	1	2	1	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	28
1	80	HEL	0	07FEB92	4	4	4	4	3	2	2	4	4	4	4	4	4	4	4	4	4	4	4	4	4	66	
			1	14FEB92	4	3	3	4	4	4	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	63	
			2	21FEB92	4	3	2	3	3	4	1	1	3	4	4	4	4	4	4	4	4	4	4	4	4	58	
			3	28FEB92	3	2	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	45	
			4	06MAR92	2	1	1	3	2	2	1	1	2	3	1	2	2	2	2	2	2	2	2	2	2	35	
			5	13MAR92	2	1	1	2	2	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	32	
			6	20MAR92	2	1	1	3	3	2	1	2	2	3	1	2	2	2	2	2	2	2	2	2	2	35	
1	81	MFB	0	07FEB92	4	3	2	4	2	3	2	1	3	4	3	3	3	3	3	3	3	3	3	3	3	64	
			1	14FEB92	4	2	2	3	2	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	55	
			2	21FEB92	3	2	1	3	2	2	1	4	3	4	3	3	3	3	3	3	3	3	3	3	3	57	
			3	28FEB92	3	1	1	3	2	2	3	4	3	4	3	3	3	3	3	3	3	3	3	3	3	43	
			4	06MAR92	3	1	1	3	2	2	2	2	3	2	2	2	2	2	2	2	2	2	2	2	2	42	
			5	13MAR92	3	1	1	3	2	2	1	4	1	3	3	3	3	3	3	3	3	3	3	3	3	37	
			6	20MAR92	2	1	1	2	2	2	1	4	2	2	2	2	2	2	2	2	2	2	2	2	2	31	
1	82	HDS	0	07FEB92	4	2	1	4	2	3	1	2	2	3	2	2	1	2	3	3	3	3	3	3	3	51	
			1	14FEB92	4	1	2	3	2	3	4	1	2	3	4	3	3	3	3	3	3	3	3	3	3	59	
			2	21FEB92	2	1	1	4	3	2	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	41	
			3	28FEB92	3	2	1	3	2	3	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	42	
			4	06MAR92	2	2	2	2	2	3	2	1	1	4	4	4	4	4	4	4	4	4	4	4	4	41	
			5	13MAR92	3	1	1	4	1	3	1	2	2	3	2	2	2	2	2	2	2	2	2	2	2	37	
			6	20MAR92	2	1	1	3	2	2	1	2	2	3	1	2	2	2	2	2	2	2	2	2	2	34	

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit	Date Performed	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (*)				
1	83	LPH	0	07FEB92	4	4	1	3	4	4	3	1	3	1	3	1	4	4	4	3	1	4	4	1	4	4	3	63		
			1	14FEB92	4	4	4	4	2	2	4	4	4	4	4	4	4	4	4	4	4	3	1	1	4	4	4	2	62	
			2	21FEB92	4	3	3	4	2	3	4	4	2	3	2	3	2	3	2	2	3	2	3	3	2	2	4	4	60	
			3	28MAR92	4	3	3	2	3	3	4	4	4	4	4	4	4	4	4	3	4	4	4	3	4	4	4	4	64	
			4	06MAR92	4	3	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	3	74	
			5	13FEB92	4	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	76
1	84	IN	0	07FEB92	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	73		
			1	14FEB92	3	1	3	4	2	4	2	1	2	1	2	4	4	4	3	4	4	3	2	4	4	3	2	4	60	
			2	21FEB92	2	1	1	4	1	4	1	2	2	1	3	3	3	2	1	3	3	2	1	2	2	2	2	3	55	
			3	28FEB92	2	1	1	2	2	4	1	2	2	4	3	3	3	2	2	1	3	2	2	1	3	2	1	1	41	
			4	06MAR92	1	1	1	4	1	4	1	1	2	3	3	3	2	2	2	1	2	2	1	1	2	1	1	1	35	
			5	13MAR92	1	1	1	3	1	4	1	1	3	2	2	2	2	1	2	2	2	1	2	1	2	2	1	1	1	33
1	85	MLP	0	07FEB92	4	3	3	4	4	2	2	2	2	2	2	1	2	1	1	2	1	2	2	2	1	1	1	32		
			1	14FEB92	4	2	3	4	3	2	2	1	2	3	3	3	3	2	3	3	3	2	3	4	4	3	3	4	58	
			2	21FEB92	4	3	3	4	3	2	2	1	2	3	4	4	4	4	4	4	4	4	3	4	4	4	4	4	61	
			3	28FEB92	4	3	3	4	3	2	2	1	2	3	4	3	3	2	2	4	3	2	2	4	2	4	3	4	55	
			4	06MAR92	2	2	2	3	4	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	45	
			5	13MAR92	2	2	1	3	2	2	2	1	1	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	39	
1	86	MTF	0	07FEB92	4	3	4	4	4	4	2	2	1	4	3	1	4	4	4	1	3	4	4	4	3	3	4	64		
			1	14FEB92	4	4	3	4	3	4	3	2	4	4	4	4	4	4	4	3	1	3	3	4	3	3	3	4	65	
			2	21FEB92	4	3	3	4	4	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	64	
			3	28FEB92	4	2	4	4	3	4	3	2	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	79	
			4	06MAR92	4	3	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	58	
			5	13MAR92	3	2	4	4	3	2	3	2	1	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	60	
1	87	NDO	0	07FEB92	4	2	2	4	4	4	2	1	2	4	3	2	4	3	3	4	4	3	4	3	3	2	4	59		
			1	14FEB92	4	2	2	3	4	2	2	1	3	4	4	4	4	4	4	4	3	3	3	3	3	3	3	3	56	
			2	21FEB92	4	2	2	3	4	2	4	2	3	2	2	2	2	2	2	3	4	4	4	2	3	2	2	2	55	
			3	28FEB92	3	2	2	2	2	2	4	2	4	3	1	2	4	2	2	2	2	2	2	2	2	2	2	2	2	50
			4	06MAR92	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	44	
			5	13MAR92	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	38
1	88	VRL	0	11FEB92	4	4	2	3	2	3	2	2	2	3	1	2	3	4	3	1	2	4	4	4	4	4	60			
			1	18FEB92	4	2	2	4	2	2	3	2	2	4	4	4	4	4	4	4	4	4	4	3	4	4	4	4	58	

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
 REXOXYLINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit	Date Performed	ZUNG																				Total Score (*)
					IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	
1	88	VRL	2	25FEB92	4	4	2	4	4	3	3	4	2	2	3	3	4	4	4	4	2	64			
			3	04MAR92	4	3	3	2	2	4	4	3	3	4	2	2	3	3	3	4	4	4	60		
			4	10MAR92	3	4	3	2	2	3	3	4	3	4	3	2	2	3	3	4	4	4	62		
			5	17MAR92	3	4	3	2	2	4	2	2	3	3	3	2	2	3	3	4	4	4	58		
			6	24MAR92	4	4	2	3	3	4	2	3	2	4	4	2	3	4	3	1	3	3	3	60	
			0	11FEB92	3	1	1	4	2	4	2	2	3	3	2	3	2	3	2	1	3	3	3	50	
1	89	NHV	1	18FEB92	3	1	2	4	1	3	4	4	2	2	3	3	4	3	3	3	4	54			
			2	25FEB92	3	2	2	3	1	3	1	2	2	4	2	4	4	2	3	3	3	1	50		
			3	04MAR92	3	1	1	2	1	2	2	4	1	3	2	1	4	1	2	2	1	2	1	35	
			4	10MAR92	2	2	1	3	2	2	1	1	2	2	2	4	3	2	2	1	2	1	2	38	
			5	17MAR92	2	1	1	2	2	1	1	1	3	1	2	2	2	1	1	2	2	1	1	32	
			6	24MAR92	2	1	2	2	1	2	1	2	2	1	2	1	1	1	2	1	1	2	1	30	
1	90	JSS	0	11FEB93	3	2	1	4	3	3	2	1	2	1	3	2	4	2	4	3	2	50			
			1	18FEB92	4	3	2	4	2	3	3	1	2	3	4	2	2	2	2	4	2	3	55		
			2	25FEB92	3	1	1	4	1	2	1	1	3	3	4	2	4	3	2	4	1	3	3	49	
			3	04MAR92	3	1	2	4	2	1	2	4	2	2	1	2	1	2	2	2	2	3	2	43	
			4	10MAR92	2	2	4	2	1	3	1	2	1	2	1	2	3	3	2	2	3	1	2	40	
			5	17MAR92	2	1	1	3	1	2	1	2	2	4	2	2	1	3	2	1	3	2	1	37	
1	91	MSC	0	11FEB92	2	1	2	1	1	3	1	1	2	1	2	1	1	1	2	2	1	30			
			1	18FEB92	4	3	4	3	2	4	4	1	2	4	3	2	4	2	4	2	4	3	60		
			2	25FEB92	4	2	4	2	3	2	2	4	2	2	3	4	1	2	2	3	4	4	3	58	
			3	04MAR92	2	2	4	2	3	1	2	2	2	2	3	1	2	2	2	3	3	2	2	44	
			4	10MAR92	2	2	2	3	1	2	1	1	2	2	3	2	1	2	3	2	1	2	2	40	
			5	17MAR92	2	1	1	3	2	1	2	1	2	3	2	1	2	2	1	2	3	1	2	39	
1	92	PSS	0	11FEB92	1	2	1	2	2	1	2	1	2	1	1	1	2	1	2	1	2	31			
			1	18FEB92	4	3	4	4	2	4	4	1	4	3	4	3	2	4	4	4	2	4	64		
			2	25FEB92	4	3	3	2	4	2	4	3	4	4	3	3	3	3	3	4	4	3	3	66	
			3	04MAR92	4	2	3	3	4	2	4	4	4	3	3	3	3	3	4	4	2	3	3	65	
			4	10MAR92	3	3	4	4	3	3	4	4	3	4	2	4	3	4	3	4	3	2	4	65	
			5	17MAR92	4	3	3	4	3	4	4	3	2	3	4	3	4	3	4	3	2	4	3	64	
1	93	AL	0	12FEB92	4	1	2	3	2	1	1	2	3	2	4	3	3	3	1	4	3	3	50		
			1	19FEB92	4	1	3	3	1	2	3	4	2	2	3	4	3	2	4	4	2	3	54		
			2	26FEB92	3	1	2	2	1	2	2	1	2	2	1	2	2	2	4	4	2	3	40		
			3	04MAR92	2	1	1	3	1	1	1	2	3	4	2	2	2	2	2	2	1	2	1	36	

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
 REMOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Patient No.	Initials	Visit	Date Performed	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (*)		
93	AL	4	11MAR92	2	1	1	3	1	1	2	2	3	2	3	2	1	2	2	1	1	2	2	1	2	33		
		5	18MAR92	2	1	2	2	1	1	1	2	2	2	2	2	2	1	2	2	2	2	2	1	1	30		
		6	25MAR92	2	2	1	2	1	2	2	2	2	2	2	2	2	1	2	2	2	2	2	1	1	1	32	
		0	12MAR92	4	4	2	3	2	3	2	2	4	4	4	4	4	3	3	4	4	2	4	2	4	3	60	
		1	19FEB92	4	1	4	3	2	4	1	4	2	4	3	3	3	3	1	3	3	4	4	3	3	3	58	
		2	26FEB92	3	3	4	4	1	4	1	4	3	3	4	3	4	3	2	4	2	4	3	4	2	2	57	
94	RAB	3	04MAR92	3	1	2	3	2	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	62	
		4	11MAR92	2	1	1	3	1	3	1	4	2	3	2	2	2	2	2	1	2	2	2	3	2	2	42	
		5	18MAR92	2	1	2	3	1	3	1	4	2	3	3	3	3	1	2	1	3	1	3	1	2	1	40	
		6	25MAR92	2	1	1	2	1	2	1	4	2	2	2	2	2	1	2	1	2	1	2	1	1	1	31	
		0	12FEB92	4	1	3	4	3	1	2	3	4	4	4	4	4	4	4	3	4	2	3	3	4	1	61	
		1	19FEB92	4	1	2	4	2	4	2	4	4	4	4	4	4	4	4	4	4	2	4	4	2	1	59	
95	GMT	2	26FEB92	4	2	1	3	2	4	2	2	3	2	4	4	3	3	4	4	2	4	4	2	1	2	54	
		3	04MAR92	3	1	2	2	4	1	2	3	2	4	4	4	4	4	4	4	4	2	2	2	1	2	43	
		4	11MAR92	2	1	1	2	1	4	1	2	2	1	1	1	1	1	2	2	2	2	2	2	1	1	32	
		5	18MAR92	2	1	2	2	1	4	1	2	3	1	1	1	1	1	1	1	2	2	2	1	1	1	32	
		6	25MAR92	1	1	1	3	2	4	1	2	2	2	2	2	2	1	1	1	1	2	1	2	1	1	1	31
		0	12FEB92	4	2	3	4	3	2	3	1	3	2	4	4	4	4	4	4	4	3	3	4	4	3	4	64
96	SPH	1	19FEB92	3	2	2	4	2	4	2	4	4	4	4	4	4	4	4	4	3	3	4	4	2	2	54	
		2	26FEB92	3	2	1	3	3	4	2	3	4	3	4	3	3	2	2	3	2	2	3	3	2	2	54	
		3	04MAR92	4	3	3	4	4	3	2	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	51	
		4	11MAR92	2	1	1	2	4	1	1	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	39	
		5	18MAR92	3	3	2	3	4	1	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	40	
		6	25MAR92	2	1	1	3	2	4	1	1	3	2	2	2	2	1	1	1	2	2	1	3	1	2	1	36
97	MND	0	12FEB92	3	3	4	3	4	3	4	4	4	4	4	4	4	4	4	4	2	3	3	4	4	3	67	
		1	19MAR92	3	3	4	4	3	3	2	4	2	4	4	4	4	4	4	4	4	3	3	4	4	2	64	
		2	26FEB92	4	4	2	3	3	1	4	3	3	3	3	3	3	3	3	3	3	4	4	4	3	3	60	
		3	04MAR92	4	2	4	3	4	1	1	2	1	3	4	3	3	4	4	4	4	3	4	4	3	3	54	
		4	11MAR92	4	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	1	62
		5	18MAR92	2	2	1	3	1	3	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	32
98	YTT	6	25MAR92	1	1	2	1	3	1	2	2	2	2	2	2	1	2	1	2	1	2	2	1	1	1	31	
		0	12FEB92	4	4	2	4	3	4	2	1	3	4	4	4	4	3	3	4	4	2	4	3	4	4	64	
		1	19FEB92	4	4	3	3	4	1	4	2	4	2	4	4	4	4	4	4	4	4	4	4	4	4	66	
		2	26FEB92	4	4	2	4	1	3	3	3	3	3	3	3	3	3	3	3	3	4	4	4	3	3	59	
		3	04MAR92	4	4	1	4	4	3	1	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	60
		4	10MAR92	3	2	2	3	2	4	4	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	45
5	18MAR92	2	2	1	3	2	4	1	4	2	4	1	4	2	2	1	1	3	1	3	1	2	2	1	38		

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
 REBEXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Date Performed	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (*)
1	98	YIT	6	25MAR92	2	1	1	3	2	3	1	4	2	1	1	1	1	2	1	2	1	2	1	2	1	34
1	99	LGD	0	12FEB92	4	1	2	3	3	3	3	1	2	2	3	3	3	4	3	3	3	3	2	2	4	54
			1	19FEB92	4	2	3	2	3	4	4	4	3	4	4	4	4	3	4	2	2	4	2	3	4	61
			2	26FEB92	4	1	3	4	3	3	1	2	3	4	4	4	4	4	2	2	4	4	4	2	4	55
			3	04MAR92	3	1	3	4	3	2	1	2	3	3	3	3	3	3	3	3	4	2	4	4	2	55
			4	11MAR92	3	1	2	3	4	2	2	4	4	4	4	2	3	3	3	1	3	4	4	4	4	58
			5	18MAR92	3	1	2	3	4	3	3	1	4	4	4	2	3	4	4	2	3	4	4	3	4	59
			6	25MAR92	4	2	1	3	4	4	2	2	2	4	2	4	4	4	4	2	4	2	3	3	3	59
1	100	JMA	0	12FEB92	4	3	3	4	3	2	1	3	2	3	2	3	2	4	4	2	4	2	3	2	4	59
			1	19FEB92	4	2	2	1	2	1	2	2	3	2	3	2	2	2	2	2	2	3	3	2	2	42
			2	26FEB92	3	2	1	3	1	3	1	2	3	4	2	2	2	2	1	2	1	2	2	2	2	41
			3	04MAR92	4	2	2	4	1	3	1	2	2	3	2	2	2	2	2	2	1	2	2	1	2	42
			4	11MAR92	2	1	3	3	1	3	1	3	2	1	2	1	2	2	2	1	2	1	1	1	2	35
			5	18MAR92	2	1	1	3	1	2	1	1	3	1	2	2	2	2	1	2	2	1	1	1	1	32
			6	25MAR92	1	1	1	3	1	2	1	2	1	2	1	2	1	2	1	2	1	1	1	1	1	29
1	101	JLL	0	18FEB92	3	4	3	4	3	3	2	3	3	2	4	2	4	2	4	2	4	4	4	3	2	61
			1	25FEB92	3	3	1	3	3	3	1	2	2	3	2	3	3	3	4	2	4	2	2	2	2	50
			2	04MAR92	3	3	2	2	2	4	2	3	3	2	1	2	1	2	2	1	2	2	1	2	1	43
			3	10MAR92	3	2	2	3	2	2	2	2	2	1	2	2	2	2	3	3	2	3	1	2	1	42
			4	17MAR92	2	2	1	3	2	2	2	2	2	1	2	2	2	2	3	2	1	2	2	2	1	37
			5	24MAR92	2	2	1	2	2	2	2	2	2	2	1	2	2	2	2	2	1	2	1	1	1	32
			6	31MAR92	1	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	1	1	1	1	1	33
1	102	ESF	0	18FEB92	4	4	2	3	3	3	1	2	3	3	2	3	3	3	4	3	3	3	2	4	4	59
			1	25FEB92	4	3	2	4	4	3	2	4	4	4	4	4	4	4	4	2	4	4	4	4	3	65
			2	04MAR92	3	2	2	4	3	4	2	1	2	4	3	3	3	3	3	3	3	3	4	4	3	60
			3	10MAR92	3	4	3	4	3	3	4	4	4	4	3	3	4	4	4	4	4	4	4	4	3	62
			4	17MAR92	3	4	3	4	3	3	2	2	4	4	4	4	4	4	4	2	3	3	4	2	2	58
			5	24MAR92	3	4	3	4	3	3	2	2	3	4	4	4	4	4	4	1	2	3	3	4	3	62
			6	31MAR92	4	4	2	4	4	4	3	3	2	4	4	3	2	4	4	3	2	3	2	4	4	65
1	103	JRA	0	18FEB92	4	1	3	4	2	4	2	2	2	4	4	4	4	4	4	4	4	4	4	4	4	76
			1	25FEB92	4	2	4	4	2	4	2	2	4	4	4	4	4	4	4	3	3	4	4	4	4	66
			2	04MAR92	4	3	3	4	2	4	2	4	3	3	3	3	4	3	3	3	3	4	4	3	4	64
1	104	MTF	0	18FEB92	4	2	3	3	2	3	2	1	2	2	4	4	4	4	3	3	2	4	4	3	4	58
			1	25FEB92	4	4	2	2	3	2	1	4	2	3	2	4	4	4	2	3	3	2	2	2	2	56
			2	04MAR92	3	4	2	2	3	2	2	4	3	2	4	3	2	4	4	3	3	4	4	1	2	55
			3	10MAR92	2	2	1	2	2	2	2	2	4	2	2	1	2	2	2	3	1	1	2	2	1	37

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Date Performed	ZUNG																				Total Score (*)
					IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	
1	104	MTF	4	17MAR92	2	2	1	2	1	2	1	4	2	2	1	1	1	2	1	1	1	1	1	2	31
			5	24MAR92	2	2	1	2	2	1	2	4	2	2	1	2	1	2	1	2	1	1	1	1	33
			6	31MAR92	1	1	2	2	1	2	1	4	2	1	1	1	2	1	2	1	2	1	2	1	31
			0	18FEB92	4	3	1	4	4	2	2	1	3	4	4	3	2	3	3	4	4	1	1	3	57
			1	25FEB92	4	2	2	4	2	4	2	2	4	3	4	4	3	3	4	3	3	1	1	3	60
			2	04MAR92	4	2	3	5	4	2	1	2	3	4	3	3	3	2	4	3	3	1	2	2	53
1	105	ABS	3	10MAR92	3	3	1	2	4	1	2	2	4	3	1	2	2	1	1	2	1	1	2	42	
			4	17MAR92	2	2	4	1	4	1	1	3	2	2	1	2	3	1	2	1	1	1	1	39	
			5	24MAR92	3	3	1	4	1	4	2	2	1	2	2	1	2	2	1	2	1	1	1	2	38
			6	31MAR92	1	2	1	3	1	4	2	1	2	1	2	1	2	1	2	1	2	1	1	1	32
			0	18FEB92	4	2	2	4	2	3	1	2	2	1	2	1	4	2	4	1	4	4	4	4	52
			1	25FEB92	4	3	1	4	1	3	1	2	3	2	4	2	1	4	2	3	4	4	4	4	55
1	106	MRN	2	06MAR92	4	2	2	3	2	1	2	4	4	3	3	1	3	3	3	4	4	4	3	57	
			3	10MAR92	3	2	1	3	1	3	2	1	3	4	2	3	2	2	1	3	4	2	4	2	48
			4	17MAR92	2	1	1	2	1	2	1	1	2	4	3	1	2	2	1	3	2	2	2	2	37
			5	24MAR92	2	1	1	3	1	2	1	1	2	3	1	2	2	2	1	2	2	1	1	1	32
			6	31MAR92	1	1	1	2	1	2	1	1	2	2	1	2	1	2	1	2	2	1	1	1	28
			0	19FEB92	4	3	2	4	3	1	3	1	3	3	4	2	4	3	3	2	2	1	3	2	54
1	107	LAN	1	26FEB92	4	2	4	2	4	1	2	1	2	1	2	2	3	4	4	4	1	2	51		
			2	06MAR92	4	4	2	4	2	4	1	1	3	4	2	2	2	2	4	4	2	1	2	53	
			3	11MAR92	3	3	1	3	2	4	1	1	2	1	2	2	1	2	2	1	2	2	1	2	38
			4	18MAR92	3	3	1	3	2	4	1	1	2	2	2	1	2	2	2	1	1	1	1	2	38
			5	25MAR92	2	1	2	2	1	4	2	1	2	2	1	2	2	2	1	2	1	2	2	2	35
			6	01APR92	2	1	2	2	1	4	2	2	1	1	2	1	2	2	1	1	2	2	1	2	31
1	108	STB	0	19FEB92	4	2	3	2	2	3	2	2	4	2	4	3	1	4	4	2	1	4	55		
			1	26FEB92	4	2	1	4	2	3	1	2	4	2	4	2	3	3	3	4	4	1	2	53	
			2	04MAR92	3	3	1	4	2	3	2	2	4	3	1	3	4	2	2	3	1	2	2	48	
			3	11MAR92	3	1	2	4	1	4	2	2	4	2	4	4	3	4	2	2	2	1	1	2	50
			4	18MAR92	2	1	2	4	1	3	3	4	2	3	2	4	2	2	3	4	1	1	1	1	50
			5	25MAR92	2	1	1	4	2	3	2	2	4	2	2	2	2	2	2	1	2	1	1	1	38
1	109	IPL	0	19MAR92	4	2	1	4	2	1	2	1	4	4	3	2	4	4	2	3	3	1	4	54	
			1	26FEB92	4	3	1	4	3	1	3	1	3	3	4	2	4	3	2	4	4	1	2	52	
			2	04MAR92	4	2	1	4	1	4	1	2	1	1	2	3	4	3	2	2	3	4	1	4	47
			3	11MAR92	4	3	1	4	3	4	1	4	3	3	4	3	4	2	2	2	4	2	1	2	57
			4	18MAR92	3	2	1	4	1	4	1	4	1	4	1	3	2	1	3	2	2	1	2	1	45
			5	25MAR92	2	2	1	3	1	4	1	4	1	4	1	2	1	2	1	1	2	1	1	1	34

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Date Performed	ZUNG	IT.1 IT.2 IT.3 IT.4 IT.5 IT.6 IT.7 IT.8 IT.9 IT.10 IT.11 IT.12 IT.13 IT.14 IT.15 IT.16 IT.17 IT.18 IT.19 IT.20																				Total Score (*)			
						IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20				
1	109	IPL	6	01APR92	2	2	1	3	1	4	1	3	3	1	1	1	2	2	1	1	2	1	1	1	1	34			
			0	19FEB92	4	3	2	3	2	3	2	2	3	4	2	2	4	2	2	4	2	2	4	1	1	3	56		
			1	26FEB92	3	3	1	3	1	3	2	3	4	3	4	3	2	3	3	3	3	3	3	4	4	1	2	51	
			2	04MAR92	3	2	1	4	1	3	1	2	2	4	3	2	2	3	2	2	3	2	2	3	3	2	2	48	
			3	11MAR92	2	2	1	3	1	3	1	2	3	2	4	2	2	3	3	2	2	2	2	2	1	1	1	42	
			4	18MAR92	2	1	1	3	1	2	1	2	3	2	4	2	2	3	3	2	2	2	2	2	1	1	1	30	
1	110	TQO	5	25MAR92	2	1	1	2	1	2	1	2	1	2	1	2	1	1	2	1	1	1	1	1	2	28			
			6	01APR92	1	1	1	2	1	2	1	2	2	1	2	1	2	1	1	1	1	1	1	1	1	1	28		
			0	19FEB92	3	4	3	4	3	2	4	2	4	2	4	2	3	2	2	3	4	2	3	4	2	4	60		
			1	26FEB92	4	2	2	3	2	2	4	2	4	2	4	3	2	2	3	2	3	1	3	1	4	2	55		
			2	04MAR92	3	2	1	3	2	1	3	2	2	3	3	3	3	3	4	2	2	1	3	2	1	3	48		
			3	11MAR92	2	2	1	4	2	2	4	2	2	4	2	2	2	2	2	2	2	2	1	2	2	1	2	43	
1	111	JBF	4	18MAR92	3	1	2	3	2	1	2	2	1	2	2	3	2	2	3	2	2	1	1	1	1	2	40		
			5	25MAR92	2	1	2	2	2	1	2	2	2	2	2	2	1	2	1	2	1	1	2	1	1	2	31		
			6	01APR92	2	1	2	2	1	2	2	1	2	2	1	2	2	1	2	2	1	1	2	2	1	1	2	32	
			0	19FEB92	3	4	4	3	2	4	2	4	2	4	2	3	2	3	4	4	2	2	3	4	2	4	58		
			1	26FEB92	4	2	2	3	2	2	4	2	4	2	4	3	2	2	4	2	2	2	3	1	4	2	55		
			2	04MAR92	3	2	1	3	2	1	3	2	2	3	3	3	3	4	2	2	1	3	2	1	3	48			
1	112	PSA	3	11MAR92	3	1	2	3	1	2	2	1	2	2	2	2	2	2	2	2	2	2	2	1	1	2	40		
			4	18MAR92	2	2	1	2	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1	1	2	31	
			5	25MAR92	2	1	2	2	1	2	2	1	2	2	2	2	2	1	2	2	1	1	2	2	1	1	2	31	
			6	01APR92	2	1	2	2	1	2	2	1	2	2	1	2	2	1	2	2	1	1	2	2	1	1	2	32	
			0	19FEB92	3	4	4	4	4	2	2	1	4	2	2	3	3	2	4	4	2	2	3	4	2	2	2	58	
			1	26FEB92	4	3	2	2	3	1	4	2	4	2	4	3	3	2	4	2	2	2	4	2	2	2	2	58	
1	113	LPS	2	04MAR92	4	2	4	3	2	2	3	2	4	2	3	2	2	2	2	2	2	3	3	3	3	3	59		
			3	11MAR92	3	3	4	4	3	3	2	2	3	3	2	2	2	2	2	2	2	2	2	2	2	2	4	58	
			4	18MAR92	4	2	4	4	1	1	4	4	3	2	2	3	3	2	2	2	2	2	2	2	2	2	2	4	58
			5	25MAR92	2	2	1	2	2	4	2	2	4	2	4	2	3	4	1	4	4	4	3	3	3	3	3	51	
			6	01APR92	3	3	4	2	3	4	1	2	4	3	3	4	3	2	4	4	4	4	4	4	4	4	4	62	
			0	19FEB92	4	1	2	4	3	2	1	2	4	3	3	2	4	2	4	4	2	2	4	4	4	2	4	59	
1	114	CLF	1	26FEB92	4	1	2	4	2	2	4	2	4	2	3	2	3	2	4	4	2	3	4	2	2	4	54		
			2	04MAR92	4	2	3	3	2	4	2	4	2	4	2	2	2	3	2	4	2	2	4	2	2	2	4	56	
			3	11MAR92	4	1	2	3	2	4	2	4	2	3	2	2	2	4	4	2	3	1	2	3	2	2	2	54	
			4	18MAR92	3	1	1	4	2	4	1	3	3	2	4	3	3	4	4	2	3	3	2	3	2	2	2	52	
			5	25MAR92	3	1	1	2	2	4	1	4	3	2	4	2	3	3	3	3	3	1	2	3	1	2	2	43	
			6	01APR92	3	1	2	3	3	3	4	3	3	4	2	1	3	4	3	4	3	1	2	4	4	1	3	56	

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Date Performed	ZUNG																				Total Score (*)			
					IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20				
1	115	ELS	0	25FEB92	3	3	3	2	3	2	2	4	2	2	3	2	2	4	2	3	3	3	1	2	49			
			1	04MAR92	4	4	2	3	3	2	2	4	2	2	4	2	4	2	2	3	3	3	2	2	57			
			2	10MAR92	3	4	2	3	4	3	1	2	3	2	4	2	4	3	3	4	3	2	2	2	2	57		
			3	17MAR92	3	2	2	1	3	2	3	2	1	3	2	2	4	4	2	2	2	2	2	1	1	45		
			4	24MAR92	2	2	1	3	2	4	2	2	4	2	2	1	1	1	1	1	2	2	1	2	2	42		
			5	31MAR92	1	2	1	2	2	2	1	2	1	2	1	2	1	2	1	2	2	2	1	2	2	31		
1	116	MGA	0	25FEB92	3	1	3	4	2	3	2	1	4	2	4	2	3	4	2	4	2	2	2	2	54			
			1	04MAR92	3	1	1	4	2	2	3	3	4	4	2	4	2	4	3	2	4	3	2	2	3	54		
			2	10MAR92	4	1	1	2	2	3	4	2	2	4	4	3	3	2	4	4	2	4	2	2	2	3	55	
			3	17MAR92	3	1	2	3	2	4	4	3	2	2	4	2	3	1	2	3	1	2	3	3	2	2	52	
			4	24MAR92	2	2	1	3	2	2	4	2	2	2	3	1	2	1	1	2	2	2	1	2	1	2	39	
			5	31MAR92	2	2	2	2	2	2	1	4	2	1	2	2	1	2	1	2	2	2	1	2	2	1	2	36
1	117	PSL	0	25FEB92	4	3	3	2	3	2	2	4	2	2	3	2	2	3	1	1	2	2	2	2	2	48		
			1	04MAR92	4	2	4	3	1	4	2	2	2	3	2	4	3	3	1	2	3	2	2	2	2	1	50	
			2	10MAR92	3	1	3	3	1	3	2	2	4	3	3	2	2	2	1	1	1	2	2	2	2	2	2	43
			3	17MAR92	3	2	2	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1	3	42
			4	24MAR92	3	1	2	2	1	2	2	2	2	2	1	2	3	1	1	1	2	2	2	2	2	2	2	38
			5	31MAR92	2	1	2	2	1	2	2	1	2	2	4	2	3	2	1	3	1	2	1	2	2	1	2	37
1	118	MVM	0	25FEB92	4	4	2	3	3	2	2	1	2	2	1	2	2	2	2	1	2	3	1	2	2	35		
			1	04MAR92	4	3	3	3	4	2	4	4	3	3	3	3	3	3	3	4	2	4	3	4	4	3	63	
			2	10MAR92	4	4	2	3	3	4	2	3	3	2	4	3	4	3	3	4	3	3	3	3	3	3	3	62
			3	17MAR92	4	4	2	3	4	4	3	4	2	4	3	3	4	3	3	4	3	3	4	3	4	4	3	66
			4	24MAR92	4	3	3	2	4	4	3	3	4	3	3	2	2	4	4	2	3	3	3	3	4	4	4	64
			5	31MAR92	3	4	3	3	3	2	2	3	4	2	3	4	4	2	4	2	4	3	3	3	3	2	2	61
1	119	MVM	0	25FEB92	3	4	1	3	2	3	1	1	2	4	3	2	4	2	4	4	4	4	4	2	4	64		
			1	04MAR92	4	4	2	3	4	2	3	4	2	4	4	3	3	3	3	4	3	3	4	4	3	4	68	
			2	10MAR92	3	4	2	3	4	2	4	2	2	4	2	4	2	2	4	3	3	4	4	3	4	3	4	61
			3	17MAR92	3	4	3	4	2	4	2	4	2	4	2	4	1	2	2	4	3	4	4	3	2	2	2	60
			4	24MAR92	4	4	2	4	2	3	4	4	3	4	3	3	1	3	4	4	2	4	4	3	4	3	3	60
			5	31MAR92	3	3	3	4	1	3	4	1	1	3	3	4	4	1	4	4	2	3	1	3	1	3	3	59
1	120	JLB	0	26FEB92	4	1	2	4	2	3	1	1	3	4	4	4	4	2	3	3	3	3	3	3	3	52		
			1	04MAR92	4	3	1	3	2	4	1	3	2	4	3	4	4	3	2	3	4	3	2	3	4	3	58	
			2	11MAR92	4	1	1	4	2	4	1	4	3	2	4	4	3	4	2	4	4	4	2	4	4	2	3	56

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Date Performed	Date																				Total Score (*)			
					ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19		IT.20		
1	120	JLB	3	18MAR92	3	1	1	4	2	4	2	3	2	4	3	2	4	2	4	3	2	4	3	2	1	3	53	
			4	25MAR92	3	1	2	3	2	4	1	4	4	4	2	2	3	1	2	3	1	2	2	4	3	3	2	52
			5	01APR92	3	1	1	3	2	4	1	4	2	3	2	2	3	4	2	2	2	4	3	2	4	3	4	51
			6	08APR92	3	2	1	3	2	3	1	4	2	4	3	3	3	3	2	1	4	4	4	4	2	4	4	54
			0	26FEB92	4	3	3	3	4	3	2	2	3	4	2	2	2	2	2	4	4	4	4	4	3	3	4	57
			1	04MAR92	3	2	1	2	2	4	2	3	2	3	4	2	4	2	4	2	3	2	3	2	2	2	3	51
1	121	LAC	2	11MAR92	3	2	1	3	2	3	2	3	4	4	4	2	1	2	2	2	4	2	4	2	2	3	48	
			3	18MAR92	3	2	1	1	2	2	4	2	3	1	2	3	2	1	4	4	4	4	2	4	2	4	45	
			4	25MAR92	2	2	1	2	1	2	2	4	2	2	2	2	4	3	1	2	2	5	1	2	3	1	2	39
			5	01APR92	2	2	1	2	1	2	2	1	2	3	2	1	2	1	1	2	1	1	1	1	1	1	1	31
			6	08APR92	1	1	2	2	1	2	1	2	2	1	2	1	2	1	2	1	2	1	2	1	1	1	1	28
			0	26FEB92	4	4	2	3	3	4	2	2	3	3	1	3	3	3	4	4	2	3	3	2	2	3	4	60
1	122	HSS	1	04MAR92	3	4	3	4	2	2	4	3	3	3	3	4	2	2	4	2	2	2	2	2	2	2	56	
			2	11MAR92	4	2	4	3	2	3	4	3	2	1	2	1	2	1	2	1	4	4	4	4	3	3	53	
			3	18MAR92	2	2	1	3	2	4	1	2	3	4	2	2	2	4	4	2	3	3	3	2	2	2	2	50
			4	25MAR92	2	1	1	3	3	2	1	1	2	2	2	2	2	2	2	2	3	3	4	2	2	1	1	42
			5	01APR92	1	2	1	2	1	2	2	1	2	1	1	1	2	1	2	1	2	2	2	2	2	1	1	29
			6	08APR92	1	1	1	2	1	2	1	2	1	2	1	2	1	2	1	1	1	1	1	2	1	1	1	26
1	123	MLL	0	26FEB92	4	4	2	4	2	2	4	2	3	3	3	4	2	3	3	2	2	4	4	2	4	2	60	
			1	04MAR92	3	3	3	4	2	2	4	4	4	3	3	3	4	4	1	2	2	2	2	2	2	2	3	58
			2	11MAR92	3	2	2	4	2	2	1	1	2	4	2	3	3	3	1	3	4	2	2	1	2	1	2	47
			3	18MAR92	2	2	1	4	1	2	3	2	2	3	2	2	4	3	1	2	3	2	3	1	2	1	2	43
			4	25MAR92	2	1	1	3	1	2	1	2	3	4	3	3	2	2	1	1	2	1	1	2	1	1	2	38
			5	01APR92	1	1	1	2	1	2	2	2	2	1	2	1	2	1	1	1	1	1	2	1	1	1	1	28
1	124	PPC	0	26FEB92	3	2	3	4	2	1	2	1	4	2	3	3	2	4	4	4	4	2	4	2	2	4	56	
			1	04MAR92	4	1	1	4	2	4	3	4	2	3	3	3	2	1	2	4	2	4	4	2	4	2	2	54
			2	11MAR92	2	1	2	3	2	4	2	3	1	2	2	2	4	3	2	1	1	2	4	4	2	2	2	45
			3	18MAR92	2	3	3	2	4	3	4	2	1	2	2	2	3	1	1	1	2	1	2	4	2	1	2	42
			4	25MAR92	2	2	1	1	2	2	4	2	2	1	2	2	1	2	3	1	2	1	2	1	2	1	1	31
			5	01APR92	1	2	1	3	1	2	2	2	1	2	2	2	1	2	3	1	2	1	2	1	2	1	2	34
1	125	FDP	0	26FEB92	4	3	1	2	4	2	2	4	2	4	3	2	4	2	1	4	4	2	4	2	4	2	54	
			1	04MAR92	4	2	2	4	4	3	1	2	2	4	2	3	3	4	1	2	2	2	2	2	2	2	50	
			2	11FEB92	4	2	2	4	2	4	2	4	2	4	2	1	4	2	2	3	3	1	2	2	2	2	2	50
			3	18MAR92	2	2	2	4	1	2	4	1	2	4	2	2	3	1	2	2	2	1	1	2	1	1	2	41
			4	25MAR92	2	1	2	4	2	2	1	2	2	1	2	2	1	2	2	2	2	1	1	1	1	1	1	34
			0	26FEB92	4	3	1	2	4	2	2	4	2	4	2	3	2	4	2	1	4	4	2	4	2	4	2	54

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Date Performed	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (*)	
1	125	FDP	5	01APR92	2	2	4	1	1	2	3	1	1	2	3	1	2	1	2	2	1	2	1	2	1	34	
			6		1	1	2	4	1	2	2	1	2	3	1	2	3	1	2	2	1	2	2	1	2	34	
1	126	SNB	0	26FEB92	4	4	4	2	3	2	2	4	4	3	3	3	3	1	4	4	2	3	3	3	4	63	
			1	04MAR92	3	4	2	4	2	3	2	3	4	2	3	4	1	4	1	2	4	3	2	2	2	53	
			2	11MAR92	4	4	3	2	3	2	2	3	4	3	4	3	4	3	3	3	3	2	2	2	2	54	
			3	18MAR92	2	3	3	2	3	1	1	2	3	2	3	2	2	2	2	1	2	2	1	3	2	43	
			4	25MAR92	2	2	2	2	2	1	2	3	1	2	3	1	3	2	2	1	2	3	2	2	4	41	
			5	01APR92	2	1	1	2	1	2	1	2	3	3	4	1	2	1	2	1	2	1	3	2	1	35	
			6	08APR92	2	2	1	2	1	2	1	1	2	1	2	1	2	1	2	1	2	1	2	1	1	27	
1	127	VPD	0	26FEB92	4	2	4	2	2	1	4	2	2	2	2	3	2	3	2	3	4	2	3	1	2	51	
			1	04MAR92	4	3	3	2	2	4	3	2	2	2	2	3	3	2	4	1	2	2	4	3	2	55	
			2	11MAR92	3	4	3	2	4	4	2	2	4	4	3	3	4	3	3	3	2	2	3	3	4	60	
			3	18MAR92	2	1	3	2	2	1	2	4	2	2	4	2	2	2	2	2	2	2	2	2	2	47	
			4	25MAR92	2	1	2	2	4	3	2	2	1	2	2	2	1	1	1	2	2	1	2	3	2	39	
			5	01APR92	1	1	1	2	2	1	2	3	2	2	2	2	2	2	2	2	1	1	2	1	1	32	
			6	08APR92	1	1	1	1	2	4	2	2	1	2	2	1	1	1	2	2	1	1	1	1	1	28	
1	128	LAM	0	26FEB92	4	1	4	2	2	2	1	3	2	2	4	4	2	2	2	3	4	4	2	1	4	55	
			1	04MAR92	4	1	3	4	2	1	2	3	4	3	3	4	4	4	2	1	2	2	2	1	3	51	
			2	11MAR92	3	1	3	4	2	1	1	3	4	2	2	4	3	2	2	2	3	4	4	1	2	51	
			3	18MAR92	3	1	1	4	2	1	1	2	4	2	2	2	2	2	2	2	2	2	2	2	1	43	
			4	25MAR92	2	1	1	2	1	2	2	4	2	2	4	2	2	1	2	2	2	3	4	3	1	39	
			5	01APR92	2	1	1	3	1	1	2	2	2	3	2	2	1	1	1	1	1	2	1	3	1	32	
			6	08APR92	1	1	1	2	1	1	2	2	1	2	2	1	1	2	1	2	1	1	2	1	1	27	
1	129	WNS	0	26FEB92	4	4	3	4	2	3	4	2	3	4	4	1	2	4	3	2	2	3	4	2	4	60	
			1	04MAR92	4	4	2	3	2	2	2	4	2	2	2	4	2	4	2	4	3	2	2	3	2	56	
			2	11MAR92	4	4	2	3	3	1	2	2	3	3	3	3	4	2	2	2	2	2	3	2	4	54	
			3	18MAR92	3	2	2	3	4	4	2	1	4	3	2	2	2	2	2	2	1	3	1	1	2	47	
			4	25MAR92	3	2	2	2	4	2	2	2	2	2	2	1	2	3	2	2	1	1	2	2	2	40	
			5	01APR92	2	1	1	2	1	2	1	2	2	1	2	2	1	2	1	2	1	2	1	1	2	31	
			6	08APR92	1	1	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	1	1	2	27
1	130	EGA	0	26FEB92	4	2	2	3	2	3	1	4	3	1	4	3	1	2	4	2	2	4	4	2	2	51	
			1	04MAR92	3	2	2	4	4	2	1	3	2	2	2	3	2	3	2	3	4	3	4	2	2	50	
			2	11MAR92	3	1	2	3	2	1	1	4	2	2	2	3	2	3	2	4	3	4	3	2	2	47	
			3	18MAR92	3	1	2	3	2	1	2	1	2	2	4	2	2	3	3	2	3	3	2	3	1	2	43
			4	25MAR92	2	2	2	2	2	2	2	4	2	2	2	2	2	1	3	2	1	3	2	3	1	43	
			5	01APR92	2	2	1	3	1	3	1	3	1	2	4	2	2	4	3	2	2	2	2	2	1	2	42
			6	08APR92	3	1	1	2	1	2	1	4	1	2	1	2	1	1	2	2	1	2	1	1	1	1	31

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Data Performed	Date																				Total Score (*)			
					IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20				
1	131	RHR	0	10MAR92	4	1	4	3	4	4	4	2	3	2	3	4	2	3	2	1	2	3	2	2	4	56		
			1	17MAR92	4	1	2	4	2	3	2	2	3	4	4	4	3	3	3	3	3	2	2	3	2	4	56	
			2	24MAR92	4	1	3	3	3	4	4	4	4	4	4	4	3	3	2	2	2	2	1	1	3	1	4	54
			3	31MAR92	3	1	3	4	3	2	3	2	4	3	3	3	3	2	2	2	2	2	2	1	4	4	53	
			4	07APR92	4	1	3	4	2	4	2	4	2	4	4	4	4	3	2	2	2	2	2	2	1	4	58	
			5	14APR92	4	2	2	4	3	3	3	3	3	4	4	4	4	3	2	2	2	2	2	2	2	4	60	
1	132	MAT	0	16MAR92	3	2	1	4	3	2	2	4	4	2	3	2	1	4	1	4	1	4	2	3	3	53		
			1	23MAR92	3	1	1	4	3	4	3	4	4	3	2	3	3	2	4	3	4	2	4	4	4	2	60	
			2	07APR92	3	2	1	4	2	2	2	2	3	4	4	2	3	4	2	4	2	4	2	4	2	2	54	
			3	08APR92	2	2	2	4	4	4	4	4	4	4	4	4	3	4	3	4	3	4	3	3	2	4	60	
			4	15APR92	4	2	4	2	3	2	3	2	2	3	3	1	2	1	2	4	3	3	2	4	3	2	50	
			5	22APR92	3	3	4	2	3	2	3	2	2	4	2	3	2	2	1	2	2	1	2	2	4	3	52	
1	133	JPH	0	20MAR92	3	1	3	3	3	2	1	1	3	3	4	3	1	2	2	2	4	4	2	2	2	49		
			1	27MAR92	4	1	4	2	4	2	4	2	4	2	3	2	1	2	2	1	2	2	4	2	2	2	48	
			2	03APR92	3	3	4	2	2	4	2	4	3	2	2	3	2	2	3	1	2	2	2	1	2	1	3	50
			3	10APR92	4	1	2	3	1	2	2	4	2	2	2	2	1	2	2	2	2	2	1	1	2	1	2	40
			4	17APR92	2	1	3	3	2	3	1	4	2	2	2	2	3	2	2	1	1	2	2	1	2	1	2	41
			5	24APR92	2	1	2	2	2	2	2	2	2	2	2	4	4	3	2	1	3	1	2	2	1	2	3	42
1	134	LNS	0	24MAR92	4	2	4	3	4	3	2	2	2	2	2	2	2	1	1	1	1	1	2	2	1	34		
			1	31MAR92	4	3	4	2	4	4	4	4	4	4	4	4	4	4	3	3	3	4	3	3	3	4	64	
			2	07APR92	4	2	3	4	2	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	60	
			3	14APR92	3	2	2	3	4	4	4	4	4	4	4	4	4	4	3	3	2	2	2	2	4	2	4	60
			4	20APR92	2	3	3	2	1	2	3	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	54
			5	28APR92	1	2	2	2	1	2	1	2	1	2	4	3	2	1	2	2	1	3	4	4	2	2	2	44
1	135	MNS	0	24MAR92	4	4	1	4	3	2	2	2	3	4	4	3	2	2	2	2	2	2	2	1	1	2	26	
			1	31MAR92	4	4	2	4	2	3	2	2	4	3	4	4	4	3	3	3	3	3	4	1	2	4	57	
			2	07APR92	3	3	2	3	2	4	1	2	2	4	3	3	2	2	2	2	2	2	3	4	1	2	57	
			3	14APR92	2	1	3	1	4	1	2	3	2	2	4	2	3	2	4	2	4	2	4	1	1	1	3	51
			4	20APR92	2	1	3	2	4	2	2	2	2	2	2	2	2	2	2	2	2	2	2	4	1	2	38	
			5	28APR92	1	1	1	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1	2	1	2	41
1	136	AVP	0	24MAR92	3	4	2	3	2	1	2	2	4	3	4	3	2	4	3	2	4	1	2	4	56			
			1	31MAR92	3	4	3	2	3	2	3	2	4	2	4	2	4	2	4	2	4	2	3	3	2	3	59	

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.4

ZUNG SELF RATING DEPRESSION SCALE
OPEN PHASE

Centre No.	Patient No.	Initials	Date Performed	ZUNG	IT.1 IT.2 IT.3 IT.4 IT.5 IT.6 IT.7 IT.8 IT.9 IT.10 IT.11 IT.12 IT.13 IT.14 IT.15 IT.16 IT.17 IT.18 IT.19 IT.20																				Total Score (*)		
					IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20			
1	136	AVP	07APR92	4	2	4	3	4	2	4	4	3	2	3	3	4	4	1	1	2	1	2	1	3	56		
			14APR92	3	2	2	3	4	4	4	3	2	2	3	2	1	4	4	1	2	1	4	2	2	49		
			20APR92	3	3	3	3	4	1	2	4	4	3	1	1	1	2	2	2	1	4	2	2	2	48		
			28APR92	2	2	2	1	2	2	2	2	3	1	1	1	4	3	1	1	1	2	1	2	1	2	38	
				1	1	2	2	1	4	2	2	1	2	1	2	1	2	1	2	1	1	2	1	2	1	2	32
				6																							32
1	137	CHE	24MAR92	4	3	1	4	4	2	3	1	2	3	2	4	4	2	4	4	2	3	3	3	3	56		
			31MAR92	3	3	4	3	2	3	3	3	1	2	2	4	4	2	4	4	2	4	2	3	4	4	57	
			07APR92	3	2	4	3	1	4	2	4	3	2	2	4	4	2	3	2	4	3	2	4	2	4	56	
			14APR92	4	2	2	4	2	2	4	4	4	2	4	4	2	2	2	2	4	4	4	2	2	2	58	
			20APR92	4	2	2	4	2	2	4	4	4	2	2	4	4	2	2	2	4	4	2	4	2	4	60	
			28APR92	4	3	2	4	3	2	4	4	4	2	2	3	4	3	2	2	3	3	3	3	3	3	63	
1	138	LBV	05MAY92	3	2	2	3	2	4	2	4	2	2	4	3	3	4	2	4	4	3	3	3	3	59		
			24MAR92	4	2	4	4	2	4	2	2	2	4	3	2	2	2	4	4	2	4	4	3	3	60		
			31MAR92	4	2	4	4	2	3	2	2	4	3	4	4	2	1	2	1	1	4	4	4	3	3	56	
			07APR92	3	3	3	3	1	2	2	4	4	3	2	2	4	4	4	4	3	2	2	2	3	2	52	
			14APR92	3	1	2	3	2	2	4	4	2	2	2	4	4	2	4	4	4	1	1	1	1	1	47	
			20APR92	2	2	1	2	2	2	2	2	2	2	2	2	1	2	2	2	1	1	2	2	2	2	39	
1	139	RA	28APR92	2	2	1	2	1	2	2	1	2	2	2	2	2	2	1	1	2	2	1	1	1	31		
			05MAY92	1	2	1	2	1	2	1	1	2	1	2	1	2	1	2	1	2	3	1	1	1	31		
			24MAR92	4	1	3	4	2	2	4	2	4	2	4	4	1	3	3	4	2	4	4	4	2	2	57	
			31MAR92	4	1	2	3	3	1	3	2	2	2	3	2	1	3	4	2	2	2	2	2	4	4	52	
			07APR92	4	1	3	3	3	2	3	2	4	4	4	4	2	4	2	4	4	1	3	2	2	2	48	
			14APR92	2	2	1	3	2	2	1	3	2	2	1	2	2	4	2	2	3	2	2	2	2	4	48	
1	140	MCA	20APR92	2	3	4	4	3	4	3	2	4	3	2	4	3	2	1	3	1	1	1	2	1	51		
			28APR92	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	1	28	
			05MAY92	1	1	2	2	1	2	1	1	2	1	1	1	1	1	2	1	1	2	1	2	1	1	26	
			24MAR92	4	1	2	4	2	4	2	2	3	3	2	2	4	3	4	3	3	1	2	1	3	3	52	
			31MAR92	3	1	2	3	2	2	4	2	2	4	2	2	4	4	2	2	2	3	2	3	2	3	53	
			07APR92	3	3	2	2	3	1	1	3	2	2	2	2	3	3	4	2	1	2	2	1	2	2	45	
1	141	ANG	14APR92	3	1	2	4	3	2	4	2	2	4	4	2	4	2	1	2	3	1	2	3	1	2	43	
			20APR92	2	1	2	2	2	2	2	2	2	2	2	2	2	2	1	3	1	2	1	2	1	1	33	
			28APR92	2	1	2	2	1	2	2	1	2	2	1	2	2	2	2	2	1	3	1	2	1	2	36	
			05MAY92	2	1	2	2	1	2	1	2	1	2	1	2	2	2	2	1	2	3	1	2	1	1	32	
			24MAR92	4	1	2	3	3	4	2	1	4	3	3	4	3	3	1	2	2	4	3	4	3	4	56	
			31MAR92	4	2	4	4	3	4	4	3	3	4	4	4	2	4	2	1	3	2	3	3	2	2	60	
1	141	ANG	07APR92	4	1	4	2	4	3	4	4	4	4	4	2	4	2	1	2	4	2	3	2	2	56		
			14APR92	4	1	4	2	4	3	4	4	3	4	4	4	2	4	2	1	2	4	2	2	2	4	56	
			20APR92	4	1	2	3	2	2	4	4	3	4	4	4	2	4	2	1	1	3	2	3	2	3	49	

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.4

ZUNG SELF RATING DEPRESSION SCALE
OPEN PHASE

Patient No.	Centre	Initials	Date Performed	ZUNG	Date																				Total Score (x)	
					IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20		
141	1	ANG	20APR92	2	1	1	3	2	3	1	4	4	2	2	4	2	3	2	4	2	3	2	1	1	48	
			28APR92	2	2	1	2	1	4	2	3	2	3	2	4	2	4	2	4	2	4	2	1	1	37	
			05MAY92	2	1	2	1	2	2	4	2	2	1	3	2	2	2	1	2	2	1	1	1	1	1	34
			24MAR92	4	2	4	3	2	3	2	4	4	4	4	4	2	1	2	3	3	3	3	3	3	3	59
			31MAR92	4	1	2	4	1	3	2	4	3	4	3	4	3	3	3	3	3	3	1	1	1	3	54
			07APR92	3	1	1	3	2	3	1	2	3	1	2	3	2	2	1	1	4	2	1	1	1	1	3
142	1	SCC	14APR92	3	1	1	3	2	4	2	3	3	2	2	2	1	2	2	1	4	2	1	1	1	42	
			20APR92	2	1	2	3	3	2	2	1	2	2	3	1	2	1	2	1	2	3	1	1	1	37	
			28APR92	1	1	1	2	2	2	2	2	2	1	2	2	2	1	2	2	1	4	3	1	1	2	35
			05MAY92	1	2	1	2	3	2	1	2	3	1	2	2	1	4	2	1	4	2	1	1	1	2	36
			24MAR92	4	2	3	2	2	2	1	2	4	2	4	3	2	2	2	3	4	4	2	2	2	2	52
			31MAR92	3	2	3	3	2	3	4	3	2	3	3	4	2	2	3	4	2	2	2	2	2	2	51
143	1	JEP	07APR92	3	3	4	2	3	2	3	4	3	3	4	2	2	2	2	3	2	2	2	2	2	56	
			14APR92	3	2	2	3	3	2	1	2	3	4	3	3	4	4	4	4	2	2	1	1	1	50	
			20APR92	2	2	1	2	1	3	1	2	2	4	2	2	1	2	1	2	2	1	2	1	1	1	37
			28APR92	2	1	2	2	1	1	1	2	2	2	2	2	2	1	2	2	2	2	1	1	1	1	29
			05MAY92	2	1	3	2	2	2	1	1	2	2	1	1	1	2	2	2	1	2	1	1	1	1	32
			25MAR92	4	3	2	3	4	3	2	2	4	3	3	2	2	4	4	4	3	4	3	3	3	3	59
144	1	ARF	07APR92	3	2	2	1	4	2	4	3	2	2	2	2	2	2	2	4	3	4	2	2	2	51	
			08APR92	3	3	4	1	3	3	2	2	2	2	2	2	2	4	3	2	4	4	4	2	2	52	
			15APR92	3	2	2	1	3	3	4	2	2	4	2	2	3	3	2	4	4	4	4	2	2	4	54
			22APR92	2	2	1	3	2	3	2	4	2	1	1	1	1	3	1	2	3	1	2	3	1	2	42
			29APR92	2	2	1	2	2	4	2	3	2	4	2	4	1	2	2	2	2	1	1	1	1	1	41
			06MAY92	3	2	1	2	2	2	1	1	2	2	1	1	1	2	2	1	2	1	1	1	1	1	35
145	1	SLD	27MAR92	4	4	2	3	2	2	1	3	3	4	3	3	4	4	2	4	2	4	4	2	2	60	
			03APR92	3	3	4	2	3	2	3	2	4	2	4	3	3	3	2	1	3	2	2	2	2	4	54
			10APR92	3	1	2	3	3	2	1	2	3	2	4	2	4	4	4	2	3	4	4	3	3	3	50
			17APR92	4	3	3	2	3	2	3	1	2	1	2	1	2	2	4	3	2	4	3	3	3	3	50
			24APR92	2	2	2	4	4	4	2	1	2	3	2	2	2	4	2	1	2	1	2	2	2	2	46
			30APR92	2	2	1	2	2	2	2	1	2	4	2	3	1	2	4	2	4	2	3	2	2	2	41
146	1	LRM	05MAY92	2	1	2	2	1	2	2	1	2	2	1	2	2	2	2	2	1	2	1	1	1	31	
			27MAR92	3	4	3	4	1	4	3	1	4	2	4	3	4	2	4	4	2	2	2	2	2	2	60
			03APR92	3	3	1	3	3	2	2	4	3	4	1	2	2	2	2	2	4	1	2	2	2	2	52
			10APR92	3	3	3	3	2	2	4	2	2	2	2	2	3	3	2	2	4	4	4	2	3	3	53
			17APR92	2	2	2	4	3	3	4	2	2	2	2	3	3	3	2	4	3	2	1	2	2	1	50
			24APR92	2	2	1	2	2	4	2	4	2	1	2	2	3	2	1	2	1	3	2	2	2	2	42
30APR92	3	2	1	4	2	4	2	2	4	2	4	3	3	3	2	2	2	2	2	1	1	1	48			

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (*)	
1	146	LRM	6	08MAY92	2	1	2	1	2	1	4	1	2	1	2	2	2	2	4	2	1	1	1	2	35	
1	147	JGH	0	27MAR92	4	2	4	4	2	2	2	4	3	3	3	3	1	3	2	4	4	3	1	4	58	
			1	03APR92	4	2	4	4	2	4	2	3	4	4	4	4	4	4	2	3	4	4	2	4	64	
			2	10APR92	4	3	4	4	3	2	4	2	3	3	3	4	4	2	3	3	4	4	3	4	66	
1	148	CAS	0	27MAR92	4	2	2	3	3	1	2	2	1	2	2	4	2	4	1	4	2	2	2	4	49	
			1	03APR92	3	2	2	4	2	3	2	4	4	2	2	4	2	2	2	4	4	4	1	3	55	
			2	10APR92	3	1	1	3	1	3	4	1	3	4	1	3	3	3	3	4	4	4	1	3	46	
			3	17APR92	2	2	2	3	2	4	2	1	2	3	2	1	2	1	2	1	2	1	1	2	39	
			4	24APR92	2	1	2	2	1	3	4	2	2	1	2	4	2	2	1	1	1	2	1	2	38	
			5	30APR92	2	1	1	2	2	2	2	1	2	1	2	1	1	1	1	1	1	2	1	2	30	
			6	08MAY92	1	2	1	2	1	1	2	1	2	1	2	1	2	1	1	1	2	1	1	1	30	
1	149	SC	0	27MAR92	4	3	3	4	3	3	1	4	3	4	3	4	3	4	4	3	3	1	1	3	61	
			1	03APR92	4	3	3	4	3	3	4	4	2	2	2	4	3	3	3	3	3	4	1	2	61	
			2	10APR92	3	3	1	3	2	4	2	3	4	2	3	3	3	4	3	4	3	3	1	3	57	
			3	17APR92	3	3	1	4	3	3	4	2	4	4	2	2	2	2	2	2	2	2	1	2	54	
			4	24APR92	2	2	2	3	2	4	4	3	1	2	2	2	1	1	3	2	2	1	1	2	44	
			5	30APR92	1	2	1	2	1	2	2	1	2	2	1	1	1	1	1	1	1	2	2	1	32	
			6	08MAY92	1	1	2	2	1	1	2	2	4	1	2	3	4	4	1	1	2	1	1	1	30	
1	150	VA	0	27MAR92	4	3	1	4	3	4	4	1	1	2	4	4	4	4	2	4	4	2	4	4	63	
			1	03APR92	4	4	2	4	3	4	4	1	4	3	3	3	4	4	4	4	4	2	4	3	67	
			2	10APR92	4	4	1	3	3	4	4	1	4	2	2	3	3	4	1	2	2	2	4	3	56	
			3	17APR92	3	3	1	3	3	3	4	1	2	4	3	3	3	3	3	2	2	2	3	3	56	
			4	24APR92	2	3	2	3	3	3	4	1	2	4	3	3	2	3	3	4	4	4	2	2	52	
			5	30APR92	2	1	1	2	2	1	4	1	2	2	2	3	4	4	2	3	3	4	2	2	54	
			6	08MAY92	1	1	2	2	1	1	2	4	1	2	2	2	4	2	2	1	1	3	3	1	38	
2	31	IK	0	09NOV90	3	4	3	3	1	3	1	1	1	2	3	4	4	4	3	4	2	3	2	3	55	
			1	16NOV90	3	4	3	3	1	3	1	1	1	2	3	3	3	4	4	3	4	4	2	3	55	
			2	23NOV90	3	3	2	1	1	4	3	1	1	2	3	1	3	1	3	1	3	1	2	1	40	
			3	30NOV90	2	4	1	2	1	1	4	1	1	4	1	4	1	3	2	3	3	3	1	4	44	
			4	07DEC90	3	4	2	2	1	1	4	2	3	2	3	2	3	2	3	3	3	3	2	3	48	
2	32	GE	0	10DEC90	3	4	1	4	3	3	1	1	1	2	3	4	2	2	1	4	1	3	1	3	46	
			1	17DEC90	4	4	1	4	3	4	1	2	3	1	3	3	3	2	3	1	4	1	4	1	3	52
2	33	HS	0	16JAN91	4	4	2	4	1	4	1	3	2	3	1	3	4	3	4	3	3	1	1	3	54	
			1	21JAN91	4	3	3	4	1	1	3	1	4	1	4	1	4	4	1	3	4	1	4	1	4	52

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Date Performed	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (*)			
2	34	EH	0	27MAR91	4	3	3	4	2	4	1	3	2	4	4	4	4	3	3	3	1	4	1	4	1	3	58		
			1	03APR91	3	3	3	4	1	4	3	3	3	3	3	3	3	3	3	3	3	2	3	2	3	1	3	54	
			2	10APR91	4	3	3	4	2	3	2	1	3	3	2	4	2	3	3	2	3	2	4	2	3	2	3	54	
			3	17APR91	3	4	3	4	4	2	3	3	2	3	3	3	3	3	3	3	3	3	3	4	3	2	3	60	
3	1	ANR	4	24APR91	3	3	3	3	4	4	2	4	2	4	2	3	4	3	4	3	2	3	4	2	3	3	61		
			0	16NOV90	4	3	4	3	4	1	3	1	4	3	2	3	4	3	2	3	4	2	1	1	3	3	2	51	
			1	23NOV90	2	2	2	2	3	2	3	2	2	2	2	2	2	2	2	3	3	2	2	4	1	3	47		
			2	29NOV90	2	1	2	1	2	2	3	2	2	2	2	1	1	1	1	2	2	1	1	1	2	2	1	33	
3	2	FIL	3	06DEC90	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	27		
			4	13DEC90	2	1	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	32		
			0	16NOV90	4	3	2	3	3	4	3	1	2	3	4	3	4	4	3	4	4	3	4	4	3	4	4	65	
			1	23NOV90	3	3	2	3	3	4	3	1	2	3	3	3	3	3	3	3	3	3	2	2	2	3	2	52	
3	1301	DUB	2	30NOV90	2	3	2	3	3	2	3	3	2	3	3	3	3	3	3	3	2	2	3	2	2	2	53		
			3	07DEC90	1	1	2	1	1	2	1	2	3	1	3	2	2	2	2	2	2	2	2	2	3	3	2	37	
			4	14DEC90	2	1	1	1	1	3	2	1	2	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	32
			5	21DEC90	2	1	2	2	1	1	3	2	1	1	2	1	2	1	2	1	2	2	1	2	2	2	2	2	32
			6	28DEC90	1	4	1	2	4	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	31
			-1	25MAR91	4	4	2	2	1	3	1	2	4	4	4	2	4	3	4	2	4	3	4	2	3	4	3	56	
3	4	AUD	1	14DEC90	2	4	1	3	4	2	3	3	2	4	1	3	2	4	4	4	1	4	4	4	4	4	3	60	
			2	21DEC90	2	4	1	4	1	2	4	4	3	4	1	1	4	4	1	4	4	4	4	4	4	4	4	57	
			3	28DEC90	2	4	1	3	3	2	4	4	3	3	2	3	3	4	1	4	4	4	4	4	4	4	4	2	59
			4	04JAN91	4	4	1	4	1	2	3	4	4	4	4	4	4	4	4	3	3	4	4	4	4	4	4	3	63
			5	11JAN91	4	4	4	4	3	2	1	4	4	4	4	4	4	4	4	4	4	4	3	4	4	4	4	4	3
3	5	MMA	0	23DEC90	1	2	2	4	2	1	1	1	3	2	1	3	2	3	3	4	3	4	2	1	1	1	42		
			1	30DEC90	3	3	1	1	1	2	1	3	2	3	2	1	4	1	4	1	4	2	1	4	2	3	2	42	
			2	06JAN91	3	3	1	2	1	1	2	3	2	3	2	1	4	1	4	1	2	4	1	2	4	2	1	43	
			3	13JAN91	1	2	1	4	1	1	1	1	4	2	1	4	4	4	4	4	4	4	4	4	4	1	1	41	
			4	22JAN91	3	1	2	4	1	1	3	2	4	3	1	1	4	2	4	4	4	2	4	4	1	1	1	44	
3	6	AJP	5	23JAN91	1	2	1	4	1	1	1	1	1	1	2	3	2	3	2	3	2	2	3	1	1	1	35		
			1	18DEC90	3	3	2	3	4	1	2	2	3	3	1	4	3	4	3	4	4	4	4	4	4	1	4	57	
			1	18FEB90	3	4	3	1	4	4	1	3	1	3	1	3	2	2	2	2	2	2	1	3	1	3	4	50	
			2	25DEC90	2	2	1	1	4	4	1	3	1	1	1	4	1	4	1	4	4	4	4	1	4	2	3	44	
3	7	GRI	3	01JAN91	3	4	2	4	4	4	2	4	4	4	4	4	4	4	4	4	2	4	3	3	4	4	67		
			4	08JAN91	4	4	1	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	2	4	4	4	64	
			5	15JAN91	2	3	1	4	3	4	1	3	4	1	3	3	1	3	1	3	1	3	1	2	4	2	3	51	

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.4

ZUNG SELF RATING DEPRESSION SCALE
OPEN PHASE

Centre No.	Patient No.	Initials	Date Performed	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (*)			
																										0	1	2
8	6	TL	21JAN91	4	4	2	3	4	4	4	4	2	2	4	4	4	4	2	4	3	4	4	4	2	4	68		
			28JAN91	4	4	2	3	4	4	4	4	4	2	2	4	4	4	4	2	4	3	4	4	4	2	4	62	
			04FEB91	2	4	1	2	4	1	1	1	3	3	3	3	3	3	3	3	2	3	3	3	3	3	2	4	47
			11FEB91	2	3	1	2	4	1	2	2	2	3	3	3	3	3	3	3	2	2	2	2	3	1	3	43	
			18FEB91	2	3	1	2	4	1	1	1	2	2	2	2	2	2	2	2	1	2	2	2	2	3	1	2	37
			25FEB91	2	3	1	2	4	1	1	1	2	2	2	2	2	2	2	2	1	2	2	2	2	3	1	2	35
8	7	SZT	04MAR91	2	2	1	2	1	2	1	1	1	1	2	2	2	2	2	1	2	2	2	2	1	2	33		
			21MAR91	4	4	2	4	3	4	3	2	2	2	2	4	4	4	4	2	4	2	3	4	4	2	4	65	
			28MAR91	4	4	2	4	3	4	3	4	4	4	4	4	4	4	4	4	2	4	2	3	4	4	1	4	63
			04APR91	4	4	2	4	3	4	3	4	2	2	2	4	4	4	4	4	2	4	2	3	4	4	1	4	63
			11APR91	4	4	2	4	3	4	1	2	2	2	2	4	4	4	4	4	2	4	2	3	4	4	1	4	61
			21MAY90	4	3	3	3	4	4	3	3	3	3	3	3	3	4	3	3	3	4	4	3	3	3	3	3	66
9	1	US	28MAY90	3	3	3	3	2	4	2	2	3	3	3	3	3	3	3	1	4	3	3	3	3	3	3	58	
			04JUN90	3	3	3	3	2	4	2	3	3	3	3	3	3	3	3	1	4	3	3	3	3	3	3	56	
			11JUN90	2	3	2	3	3	3	3	2	2	2	2	3	3	3	3	2	1	3	2	2	2	3	3	3	50
			18JUN90	3	2	3	2	3	3	2	2	2	2	2	2	3	3	3	3	1	4	2	2	2	3	3	2	51
			25JUN90	4	3	2	3	4	3	2	2	3	3	3	2	3	3	3	3	2	3	2	2	2	3	2	3	53
			02JUL90	3	3	3	3	2	3	2	2	3	2	2	2	3	3	3	3	2	3	3	3	3	2	3	2	52
9	2	VCF	09JUL92	3	3	4	3	2	4	2	2	3	3	2	2	2	2	1	4	2	3	2	3	3	3	54		
			21MAY90	3	3	2	3	3	4	3	3	3	3	2	3	3	3	2	2	2	3	2	3	2	3	2	53	
			28MAY90	3	3	2	3	3	3	3	2	3	3	3	2	3	3	3	2	3	2	3	3	3	3	3	55	
			04JUN90	3	3	2	3	3	3	2	3	3	3	3	2	3	3	3	2	3	2	3	3	2	3	3	55	
			11JUN90	2	3	2	3	3	3	2	2	3	3	2	2	3	3	3	2	2	3	2	2	2	3	2	3	48
			18JUN90	2	2	1	2	3	3	2	2	2	2	2	2	2	2	2	1	2	1	2	2	2	2	2	1	32
9	3	SF	25JUN90	2	1	1	2	2	1	2	2	1	2	2	1	1	1	1	1	1	1	1	2	2	1	27		
			02JUL90	2	1	2	2	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	2	2	1	24	
			09JUL90	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24	
			07AUG90	3	3	3	3	2	3	3	2	3	3	3	2	3	3	3	3	3	2	3	3	3	3	3	56	
			14AUG90	3	3	3	3	2	3	3	2	3	3	2	3	3	3	3	3	3	3	3	3	3	3	3	53	
			21AUG90	2	3	2	3	3	2	3	2	3	3	2	3	3	3	3	3	2	3	3	3	3	3	3	4	55
9	4	SA	28AUG90	2	3	2	3	2	3	3	2	3	3	2	3	3	3	3	2	3	2	3	2	3	4	54		
			04SEP90	3	2	2	3	3	2	3	2	3	3	2	3	3	3	3	2	3	3	2	3	2	3	4	53	
			11SEP90	3	2	3	2	3	2	3	2	3	2	2	3	3	3	3	2	3	3	2	2	3	2	4	52	
			18SEP90	3	2	3	2	3	2	3	2	3	2	2	3	3	3	3	2	3	3	2	3	3	3	3	4	56
			25SEP90	2	3	2	3	3	2	3	2	3	3	3	2	3	3	3	2	3	3	3	3	3	3	2	4	55
			02AUG90	4	4	3	3	4	3	3	4	3	3	4	3	3	4	4	3	3	3	3	4	3	4	4	70	
09AUG90	4	4	4	4	3	4	3	4	3	4	3	4	3	4	4	3	3	4	4	3	4	3	4	69				

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.4

ZUNG SELF RATING DEPRESSION SCALE
OPEN PHASE

Centre No.	Patient No.	Initials	Date Performed	ZUNG	IT.1 IT.2 IT.3 IT.4 IT.5 IT.6 IT.7 IT.8 IT.9 IT.10 IT.11 IT.12 IT.13 IT.14 IT.15 IT.16 IT.17 IT.18 IT.19 IT.20																				Total Score (*)			
					IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20				
8	6	TL	0	21JAN91	4	4	4	2	3	4	4	4	2	4	4	2	4	4	4	4	4	4	2	4	68			
			1	28JAN91	4	4	2	3	4	4	4	4	2	4	4	2	4	4	4	4	4	4	4	2	4	62		
			2	04FEB91	2	4	1	2	4	1	1	1	1	4	4	2	4	4	4	4	4	4	4	2	4	47		
			3	11FEB91	2	3	1	2	4	1	1	1	3	3	3	2	3	3	3	3	3	3	3	1	3	43		
			4	18FEB91	2	3	1	2	1	4	1	1	2	2	2	1	2	2	2	2	2	2	2	3	1	3	37	
			5	25FEB91	2	3	1	2	1	4	1	1	1	2	2	1	2	2	2	2	2	2	2	3	1	2	35	
8	7	SZT	6	04MAR91	2	2	1	2	1	2	1	1	1	1	2	2	2	2	2	2	2	2	2	1	2	33		
			0	21MAR91	4	4	2	4	3	4	3	2	2	2	4	4	2	4	2	3	4	4	4	2	4	65		
			1	28MAR91	4	4	2	4	3	4	3	4	2	2	4	4	2	4	2	3	4	4	4	4	1	4	63	
			2	04APR91	4	4	2	4	3	4	2	2	2	4	4	2	4	2	3	4	4	4	4	4	1	4	63	
			3	11APR91	4	4	2	4	3	4	1	2	2	4	4	2	4	2	3	4	4	4	4	4	1	4	61	
			9	1	US	-1	21MAY90	4	3	3	3	4	4	3	3	3	3	3	3	4	4	3	3	3	3	3	3	3
0	28MAY90	3				3	3	3	2	4	2	3	3	3	3	3	1	4	3	3	3	3	3	3	3	3	58	
1	04JUN90	3				3	3	3	2	4	2	3	3	3	3	3	3	1	4	3	3	3	3	3	3	3	56	
2	11JUN90	2				3	2	3	3	2	4	2	3	3	3	3	2	1	3	2	2	3	3	3	3	3	3	50
3	18JUN90	3				2	3	2	3	3	2	3	2	2	2	3	3	1	4	2	2	2	3	3	3	2	2	51
4	25JUN90	4				3	2	3	2	3	2	3	2	2	2	3	3	2	3	2	2	3	3	3	2	3	2	53
9	2	VCF	5	02JUL90	3	3	3	3	2	3	2	3	2	3	2	3	3	3	3	3	3	2	3	2	3	52		
			6	09JUL92	3	3	4	3	2	4	2	3	3	2	2	1	4	2	3	3	2	3	3	2	3	3	54	
			-1	21MAY90	3	3	2	3	3	4	3	3	3	2	2	2	2	2	3	2	3	2	3	2	3	2	53	
			0	28MAY90	3	3	2	3	3	4	3	3	3	2	2	3	3	2	3	2	3	3	3	3	3	3	55	
			1	04JUN90	3	3	2	3	3	2	3	3	3	3	3	3	3	3	2	3	3	3	3	3	3	3	55	
			2	11JUN90	2	3	2	3	3	2	3	3	2	3	3	3	2	3	2	3	2	3	2	3	2	3	3	48
9	3	SF	3	18JUN90	2	2	1	2	3	3	2	2	2	2	1	2	2	1	2	2	2	2	2	2	1	32		
			4	25JUN90	2	1	1	2	2	1	2	2	1	2	2	1	2	2	1	2	2	2	2	2	2	1	33	
			5	02JUL90	2	1	2	2	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	2	2	1	27	
			6	09JUL90	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	2	1	24	
			-1	07AUG90	3	3	3	3	2	3	3	2	3	3	3	3	3	2	3	2	3	3	3	3	3	3	56	
			0	14AUG90	3	2	3	3	2	3	2	3	2	3	2	3	3	2	3	3	4	3	3	3	3	3	53	
9	4	SA	1	21AUG90	2	3	2	3	3	2	3	2	3	2	3	2	3	2	3	3	3	3	3	3	4	55		
			2	28AUG90	2	3	2	3	3	2	3	3	2	3	3	3	2	3	2	3	2	3	2	3	2	4	54	
			3	04SEP90	3	2	2	3	2	3	2	3	2	3	2	3	2	3	2	3	3	3	3	2	2	4	53	
			4	11SEP90	3	2	3	2	3	2	3	2	3	2	3	2	3	2	3	2	3	2	3	2	3	2	4	52
			5	18SEP90	3	2	3	2	3	2	3	2	3	2	3	2	3	2	3	2	3	3	3	3	3	2	4	56
			6	25SEP90	2	3	2	3	2	3	2	3	2	3	2	3	2	3	2	3	3	3	3	3	3	2	4	55
9	0		-1	26AUG90	4	4	3	3	4	3	3	4	3	3	3	3	3	4	4	4	4	4	4	4	70			
			0	31AUG90	4	4	4	3	3	4	3	4	3	3	4	3	3	3	3	4	3	3	3	3	3	69		

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit	Date Performed	ZUNG																			Total Score (*)		
					IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19		IT.20	
9	4	SA	1	07SEP90	4	4	3	3	3	3	4	3	3	3	3	3	3	3	4	4	3	3	3	67		
			2	14SEP90	3	4	4	3	3	3	3	3	3	4	4	4	4	4	4	4	4	3	3	3	68	
			3	21SEP90	3	4	4	3	3	3	3	3	3	4	4	4	4	4	4	4	4	4	4	3	3	68
			4	28SEP90	4	4	3	3	3	3	4	4	4	4	4	4	4	4	4	4	4	3	3	3	4	68
			5	05OCT90	3	3	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	3	3	4	3	68
			6	12OCT90	3	3	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	3	3	70
9	5	MF	-1	15SEP90	2	3	3	2	3	3	2	3	2	2	2	2	3	3	2	2	2	3	2	49		
			0	22SEP90	2	3	2	3	2	2	2	2	3	2	2	2	2	2	3	2	2	2	2	2	50	
			1	29SEP90	3	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	46	
			2	06OCT90	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	42	
			3	13OCT90	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	38	
			4	20OCT90	2	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25
9	6	SD	5	27OCT90	1	2	1	1	1	1	2	1	1	2	1	1	2	1	2	1	1	1	1	26		
			6	03NOV90	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23	
			-1	30OCT90	3	3	2	2	2	2	2	2	3	2	2	2	2	2	2	2	2	2	2	3	48	
			0	06NOV90	3	3	2	2	2	2	2	2	3	2	2	2	2	2	2	2	2	2	2	2	44	
			1	13NOV90	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	44	
			2	10NOV90	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	38	
9	7	PP	3	27NOV90	2	2	2	2	2	2	1	1	1	2	1	1	2	1	1	1	1	1	1	30		
			4	04DEC90	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	26	
			5	11DEC90	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25	
			6	18DEC90	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23	
			-1	01NOV90	3	2	4	3	3	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	59	
			0	08NOV90	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	59	
9	8	KTH	1	15NOV90	3	3	4	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	60		
			2	22NOV90	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	52	
			3	29NOV90	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	38	
			4	06DEC90	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	37	
			5	13DEC90	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	28	
			6	20DEC90	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22
9	8	KTH	-1	14NOV90	3	3	3	3	3	3	2	3	3	3	3	3	3	3	3	3	3	3	3	61		
			0	21NOV90	3	3	3	4	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	59	
			1	28NOV90	3	3	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	56	
			2	05DEC90	2	3	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	54	
			3	12DEC90	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	42	
			4	19DEC90	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	29
5	26DEC90	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	29			
6	02JAN91	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	27			

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 RESOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Date Performed	ZUNG	IT.1 IT.2 IT.3 IT.4 IT.5 IT.6 IT.7 IT.8 IT.9 IT.10 IT.11 IT.12 IT.13 IT.14 IT.15 IT.16 IT.17 IT.18 IT.19 IT.20																				Total Score (*)
						IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	
9	9	PL	-1	16NOV90	3	4	3	3	4	3	3	3	3	3	3	3	3	3	4	3	3	3	3	64		
			0	23NOV90	3	3	4	3	3	3	3	4	3	3	3	3	4	3	3	3	3	3	3	3	63	
			1	30NOV90	3	4	3	3	3	3	3	4	3	3	3	3	3	3	3	3	3	3	3	3	3	63
			2	07DEC90	3	4	3	3	3	3	3	3	4	3	3	3	3	3	3	3	3	3	3	3	3	62
			3	14DEC90	3	3	4	3	2	4	3	3	4	3	3	3	3	3	3	3	3	3	3	3	3	63
			4	21DEC90	3	3	4	3	3	3	3	3	3	4	3	3	3	3	3	3	3	3	3	3	3	65
9	10	BG	5	28DEC90	3	3	3	4	4	3	3	3	3	3	3	3	3	3	3	3	3	3	3	63		
			6	04JAN91	4	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	62	
			-1	03JAN91	3	4	3	3	3	3	3	3	4	3	3	2	3	3	2	3	3	3	3	3	4	62
			0	10JAN91	3	4	3	3	3	3	3	3	3	3	2	3	2	3	3	3	3	3	3	3	3	60
			1	17JAN91	3	4	3	3	3	3	3	3	3	3	2	3	3	3	3	3	3	3	3	3	3	59
			2	24JAN91	3	3	3	3	3	3	4	3	3	2	3	3	3	3	3	3	2	3	2	3	2	58
9	11	KE	3	31JAN91	3	3	2	2	3	3	4	3	2	3	3	3	3	3	3	3	3	3	3	57		
			4	07FEB91	3	4	3	3	2	2	3	3	3	3	2	3	4	2	2	3	2	3	2	3	56	
			5	14FEB91	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	60
			6	21FEB91	3	3	3	2	2	3	3	3	3	2	3	3	3	3	3	3	3	3	3	3	3	56
			-1	22JAN91	3	2	3	2	2	3	3	2	2	2	2	2	3	3	1	2	3	3	3	3	3	48
			0	29JAN91	3	3	2	3	2	2	3	3	2	2	2	2	3	2	3	2	1	3	3	2	2	48
9	12	GVT	1	05FEB91	2	2	2	3	2	1	1	1	1	2	2	2	2	2	2	2	2	2	2	42		
			2	12FEB91	2	2	2	1	1	1	1	1	2	2	1	1	1	1	1	1	1	1	1	1	28	
			3	19FEB91	1	2	1	1	1	1	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	26
			4	26FEB91	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23
			5	05MAR91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24
			6	12MAR91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22
9	13	BP	-1	27FEB91	3	3	2	3	3	2	2	2	2	2	2	2	2	3	2	2	2	2	2	48		
			0	06MAR91	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	46	
			1	13MAR91	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	45
			2	19MAR91	2	2	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	39
			3	26MAR91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	38
			4	02APR91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23
9	14	BP	5	09APR91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23		
			6	16APR91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22	
			-1	07MAR91	3	2	2	3	2	3	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	48
			0	13MAR91	2	2	2	3	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	42
			1	20MAR91	2	2	2	3	2	3	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	44
			2	27MAR91	3	3	2	3	2	3	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	51
9	15	BP	3	03APR91	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	44		
			4	10APR91	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	42	

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Date Performed	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (*)	
9	13	BP	5	17APR91	2	2	1	1	1	2	2	2	1	1	1	3	1	2	2	2	2	1	1	1	1	2	34
			6	24APR91	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25
9	14	SZF	-1	18MAR91	3	3	3	3	3	2	2	3	2	3	4	3	3	2	3	2	2	3	3	3	3	3	52
			0	24MAR91	3	3	3	3	3	3	3	3	3	3	4	3	3	2	3	3	3	3	3	3	3	3	54
			1	31MAR91	3	3	3	3	3	4	3	3	3	3	2	3	3	3	3	3	3	3	3	3	3	3	60
			2	07APR91	3	3	4	3	3	4	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	62
			3	14APR91	3	3	4	3	3	3	3	3	3	3	3	3	3	3	4	3	3	3	3	3	3	3	61
			4	21APR91	3	3	3	3	3	2	2	2	2	3	3	3	3	2	2	3	3	3	3	3	3	3	54
			5	28APR91	3	3	3	3	3	2	2	2	2	3	3	3	3	3	3	3	3	2	3	3	3	3	55
			6	05MAY91	3	3	3	3	3	3	2	3	3	3	3	3	3	3	3	3	3	3	2	3	3	3	57
9	15	BI	0	19MAY91	3	3	3	2	2	2	2	2	2	2	3	2	2	2	2	2	2	2	2	2	2	2	48
			1	26MAY91	3	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	46
			2	02JUN91	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	36
			3	09JUN91	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25
			4	16JUN91	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22
			5	23JUN91	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22
			6	30JUN91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21
9	16	UGY	0	09JUL91	3	3	2	2	2	2	2	2	2	2	2	3	2	2	2	2	2	2	2	2	2	2	48
			1	16JUL91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	38
			3	30JUL91	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	30
			4	06AUG91	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24
			5	13AUG91	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23
			6	20AUG91	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22
9	17	NL	0	04JUL91	3	3	3	2	2	2	2	2	2	2	3	3	2	2	2	2	2	2	2	2	2	2	47
			1	11FEB91	3	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	47
			2	18JUL91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	43
9	18	MBK	0	14JUL91	3	4	3	2	3	3	2	3	2	3	2	3	2	2	2	2	2	2	2	2	2	2	51
			1	21JUL91	3	4	3	2	3	3	2	3	2	3	2	3	2	2	2	2	2	2	2	2	2	2	50
			2	28JUL91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	40
			3	04AUG91	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25
			4	11AUG91	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24
			5	18AUG91	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23
			6	25AUG91	3	3	3	2	2	2	2	2	2	2	2	3	2	2	2	2	2	2	2	2	2	2	47
9	19	KF	0	13AUG90	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	45
			1	20AUG91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	42
			2	27AUG91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	38

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Patient Centre	Patient No.	Initials	Visit	Date Performed	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (*)					
9	19	KF	3	05SEP91	1	2	1	1	1	1	1	2	1	1	1	1	2	1	1	2	2	1	1	1	1	1	25				
			4	10SEP91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23		
			5	17SEP91	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22	
			6	24SEP91	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	21	
			0	23AUG91	3	3	3	2	2	2	2	2	3	3	2	2	2	3	2	2	2	2	2	2	2	2	3	3	51		
			2	06SEP91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	45	
9	20	GYE	3	13SEP91	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	39			
			4	20SEP91	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25	
			5	27SEP91	1	2	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23	
			6	04OCT91	2	1	2	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23	
			0	25OCT91	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	41	
			1	01NOV91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	40	
9	21	TA	2	08NOV91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	40			
			3	15NOV91	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	36	
			4	22NOV91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	29
			5	29NOV91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	26
			6	06DEC91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24
			0	29OCT91	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	41
9	22	RRE	1	05NOV91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	41			
			2	12NOV91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	40	
			3	19NOV91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	30
			4	26NOV91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	28
			5	03DEC91	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	27
			6	10DEC91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25
9	23	SZN	0	08NOV91	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	40			
			1	15NOV91	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	42	
			2	22NOV91	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	41
			3	29NOV91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	41
			4	06DEC91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	38
			5	13DEC91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	32
9	24	LGY	0	11NOV91	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	43			
			1	18NOV91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	42	
			2	25NOV91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	30
			3	02DEC91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	29
			4	09DEC91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	28
			0	16DEC91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	28

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXYETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Patient No.	Centre No.	Initials	Visit	Date Performed	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (Σ)				
9	24	LGY	5	16DEC91	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25			
			6	23DEC91	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23	
9	25	PM	0	19NOV91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	32			
			1	26NOV91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	30		
			2	03DEC91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	29	
			3	10DEC91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	25	
			4	17DEC91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	25	
			5	24DEC91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	24	
9	26	CP	6	31DEC91	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22			
			0	21NOV91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	32		
			1	28NOV91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	32	
			2	05DEC91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	29	
			3	12DEC91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	25	
			4	19DEC91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	25	
9	27	ZSL	5	26DEC91	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24			
			6	02JAN92	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	43		
			0	27MAR92	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	28	
			1	03APR92	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	29	
			2	10APR92	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	27	
			3	17APR92	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	25	
9	28	HI	4	24APR92	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24			
			5	01MAY92	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24		
			6	08MAY92	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23	
			0	06APR92	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	29	
			1	10APR92	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	29	
			2	20APR92	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	28	
9	29	SZF	3	27APR92	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	26		
			4	04MAY92	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	26	
			5	11MAY92	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	24
			6	18MAY92	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	24
			0	06APR92	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	31	
			1	13APR92	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	30	
9	30		2	20APR92	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	30			
			3	27APR92	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	27	
			4	04MAY92	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	25	
			5	11MAY92	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	26
9	31		6	18MAY92	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	24		
			0	06APR92	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	24	

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit	Date Performed	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (*)		
						IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20			
9	30	NF	0	06APR92	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	30		
			1	15APR92	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	34	
			2	20APR92	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	33
			3	27APR92	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	29
			4	04MAY92	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	27
			6	18MAY92	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	25
10	1	VK	0	16OCT90	3	2	3	4	2	2	2	2	2	2	2	3	3	3	4	3	3	3	3	3	3	55		
			1	23OCT90	2	2	2	3	2	2	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	50	
			2	30OCT90	2	4	3	1	2	2	2	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	49
			3	06NOV90	3	3	2	3	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	49
			4	13NOV90	2	2	2	3	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	48
			5	20NOV90	2	1	1	3	3	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	44
10	4	ZSD	0	31OCT90	4	4	3	4	4	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	62	
			1	07NOV90	4	4	3	4	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	60
			2	14NOV90	4	2	2	4	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	53
			3	21NOV90	4	2	2	4	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	53
			4	28NOV90	3	2	2	4	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	50
			5	05DEC90	3	2	2	4	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	50
10	5	AN	0	14NOV90	2	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	49	
			1	21NOV90	2	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	37
			2	28NOV90	2	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	36
			3	05DEC90	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	35
			4	12DEC90	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	33
			5	19DEC90	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	33
10	6	RS	0	16NOV90	3	4	1	3	3	1	2	1	3	3	2	2	2	2	2	2	2	2	2	2	2	2	53	
			1	23NOV90	3	3	1	4	1	3	1	4	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	47
			2	30NOV90	2	4	1	2	1	3	1	4	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	44
			3	07DEC90	2	4	1	2	1	3	1	2	1	3	2	2	2	2	2	2	2	2	2	2	2	2	2	43
			4	14DEC90	2	4	1	2	1	3	1	2	1	3	2	2	2	2	2	2	2	2	2	2	2	2	2	42
			5	19DEC90	2	4	1	4	1	4	1	4	1	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2
10	7	RK	0	20NOV90	2	2	2	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	41		
			2	04DEC90	2	1	1	3	1	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	35

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit	Date Performed	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (*)			
						IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20				
10	7	RK	3	11DEC90	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23			
			4	18DEC90	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24		
			5	27DEC90	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24	
			6	02JAN91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24	
			0	27NOV90	4	4	3	4	2	3	3	2	3	4	2	3	4	3	4	3	3	4	3	4	4	2	4	64	
			1	03DEC90	4	4	4	4	2	4	4	2	3	3	1	4	4	3	4	3	4	3	4	4	4	3	4	60	
10	8	VP	2	10DEC90	4	4	2	4	4	2	3	3	1	4	4	3	4	3	4	3	4	4	4	4	3	4	62		
			3	17DEC90	4	4	1	4	3	4	2	1	3	2	3	4	4	4	3	4	4	4	4	4	4	4	4	66	
			0	03DEC90	3	4	3	2	3	3	4	2	3	4	2	3	4	4	3	4	4	3	4	3	4	1	4	64	
			1	11DEC90	3	3	2	3	3	2	4	2	3	4	2	3	4	3	3	4	3	3	4	2	2	1	3	53	
			2	17DEC90	1	3	2	2	3	2	4	1	1	1	1	1	1	1	1	1	1	3	3	3	2	1	2	39	
			3	27DEC90	3	3	3	3	3	3	3	3	2	2	2	2	2	2	2	2	2	2	1	3	2	4	1	2	51
10	9	RT	4	02JAN91	1	2	2	2	4	3	2	4	1	1	1	1	1	2	2	4	1	2	3	4	1	2	44		
			5	07JAN91	1	2	2	2	3	2	1	1	1	1	1	1	1	1	1	1	1	4	1	2	3	3	1	37	
			6	14JAN91	1	1	1	1	1	2	1	4	1	1	1	1	1	1	1	1	2	1	2	3	3	1	2	51	
			0	03DEC90	3	4	3	2	3	3	4	2	3	4	2	3	4	4	3	4	3	4	3	4	3	4	1	4	64
			1	11DEC90	2	3	2	3	2	4	2	3	4	2	3	4	2	3	3	4	2	3	4	2	2	1	2	3	56
			2	17DEC90	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1	2	2	1	2	1	2	44
10	10	MH	3	27DEC90	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	39		
			4	02JAN91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	38	
			5	07JAN91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	33
			6	14JAN91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	32
			0	27DEC90	3	3	2	4	3	3	2	2	2	3	4	2	3	4	2	3	4	2	3	4	3	3	1	3	50
			1	02JAN91	4	4	3	4	2	3	3	3	4	4	3	3	4	4	3	4	3	4	4	4	3	4	2	4	60
10	11	TM	2	09JAN91	4	3	1	4	3	2	2	2	1	4	4	1	4	4	1	4	4	4	3	4	2	4	56		
			3	14JAN91	4	3	1	4	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	3	3	1	4	52
			0	03JAN91	3	3	2	2	1	4	1	1	2	3	4	2	3	4	1	2	3	3	3	3	2	2	1	2	46
			1	16JAN91	3	3	2	4	1	4	1	2	3	3	4	2	3	4	1	2	3	3	3	2	2	1	1	2	48
			2	22JAN91	3	3	2	4	2	4	2	2	3	2	2	3	4	1	2	3	4	2	3	4	3	3	1	3	53
			3	29JAN91	3	3	3	3	2	4	1	2	2	1	2	3	3	4	1	3	3	4	3	4	3	3	2	3	53
10	12	EP	4	04FEB91	2	3	2	3	2	4	2	2	2	2	3	3	3	1	2	2	3	3	2	3	1	3	48		
			5	12FEB91	3	2	1	2	2	3	2	3	2	4	2	3	3	3	3	3	3	3	3	3	3	2	3	50	
			6	20FEB91	3	3	2	2	2	3	2	2	2	2	2	3	3	3	1	2	2	2	3	2	3	1	3	47	
			0	12FEB91	3	4	3	4	1	4	2	4	4	4	3	3	4	4	3	4	2	4	3	4	2	4	1	4	60
			1	19FEB91	2	4	1	2	1	2	4	3	3	3	3	3	4	2	4	2	3	1	4	3	4	2	3	45	
			2	26FEB91	2	4	1	4	3	1	4	4	2	2	3	3	4	4	2	3	1	4	2	3	3	1	3	1	47

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Date Performed	ZUNG																				Total Score (*)	
					IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20		
10	13	HU	3	05MAR91	3	4	3	4	1	2	4	4	2	3	2	2	4	3	3	4	3	1	3	55		
			4	12MAR91	2	4	2	4	3	2	4	4	2	3	4	1	3	3	3	1	3	1	2	51		
			5	19MAR91	3	3	4	2	3	1	4	4	3	3	3	1	4	2	4	3	4	2	4	60		
			6	26MAR91	3	4	2	4	1	2	1	4	4	3	3	1	4	3	3	2	2	1	3	53		
			0	12FEB91	3	3	1	3	3	3	1	3	3	2	2	3	3	3	2	1	3	1	3	49		
			1	19FEB91	3	3	2	1	3	3	2	1	3	2	2	3	3	3	2	1	3	1	3	51		
10	14	AA	2	26FEB91	2	2	1	3	2	1	3	3	2	2	2	3	3	2	1	3	1	3	43			
			3	05MAR91	3	2	1	3	2	3	1	3	3	2	3	3	3	3	2	1	3	1	3	47		
			4	12MAR91	2	2	1	3	1	3	1	3	3	2	2	3	3	3	3	1	3	1	3	45		
			5	19MAR91	2	2	1	3	2	1	3	3	2	2	2	3	3	3	3	3	1	3	1	3	44	
			6	26MAR91	2	2	1	3	2	1	2	1	3	2	2	3	3	3	3	3	3	1	3	1	3	44
			0	12FEB91	3	3	2	1	2	1	2	1	3	2	2	3	2	3	3	3	2	3	1	3	43	
10	15	HT	0	21FEB91	3	3	2	4	4	1	1	1	3	3	2	4	3	2	1	4	1	3	52			
			1	27FEB91	2	1	2	2	1	2	1	1	2	4	3	3	3	3	1	3	1	2	2	59		
			2	06MAR91	2	3	2	3	2	4	1	4	3	3	3	2	3	2	3	3	3	2	3	51		
			3	13MAR91	2	3	2	4	2	2	3	2	3	2	3	4	3	2	2	3	3	2	2	47		
			4	20MAR91	2	1	1	2	2	1	2	3	3	1	1	2	2	2	2	2	1	3	4	3	38	
			5	27MAR91	3	1	3	2	1	4	1	2	2	2	4	3	3	3	3	3	4	3	3	3	55	
10	16	AJ	0	04MAR91	3	4	3	3	2	3	3	3	3	3	3	4	1	4	2	2	2	2	48			
			1	11MAR91	3	4	2	3	1	2	3	3	3	3	3	3	3	3	3	3	2	3	1	3	57	
			2	18MAR91	3	3	3	1	2	3	3	3	3	3	3	2	1	3	3	3	1	3	1	3	48	
			3	25MAR91	2	3	2	2	1	2	3	2	3	3	3	2	2	3	3	3	2	3	1	3	47	
			4	01SEP91	2	3	2	2	3	1	3	3	2	3	3	2	2	3	3	3	3	1	3	1	3	44
			5	08APR91	2	3	2	3	1	1	3	3	2	3	3	2	2	3	3	3	3	1	3	1	2	44
10	17	MH	0	13MAR91	2	3	3	2	1	4	1	3	2	3	4	2	4	3	4	1	3	2	3	54		
			1	20MAR91	2	1	3	3	1	4	1	2	2	3	3	2	2	3	2	3	2	2	3	44		
			2	27MAR91	2	4	2	3	1	4	1	2	2	4	3	4	1	3	2	3	4	3	2	3	44	
			3	03APR91	3	3	2	4	1	4	1	2	3	4	3	3	1	3	2	3	3	3	2	3	53	
			4	10APR91	2	3	2	4	1	4	2	2	3	4	3	3	1	3	2	3	3	3	2	3	53	
			5	17APR91	2	3	2	4	1	4	2	2	2	4	3	3	1	3	2	3	3	3	2	3	52	
10	18	SS	0	13MAR91	4	4	3	2	1	4	1	2	2	4	3	1	3	2	3	3	2	3	51			
			1	20MAR91	3	4	2	4	1	4	2	4	3	4	4	3	4	2	4	4	2	4	2	4	67	
			2	27MAR91	3	3	1	2	1	4	1	1	3	4	4	2	3	4	3	4	3	1	4	1	4	58
			3	03APR91	3	3	1	2	1	4	1	1	2	3	2	4	3	2	4	3	2	3	1	3	48	
			4	10APR91	2	2	1	2	1	3	2	1	2	3	2	4	3	2	3	2	3	1	3	1	3	40
			5	17APR91	4	4	3	2	1	4	1	1	3	2	4	3	4	3	4	4	3	3	2	4	60	

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD

REBOMETINE - PROTOCOL 20124/013
Listing No.: 10.4

ZUNG SELF RATING DEPRESSION SCALE
OPEN PHASE

Centre No.	Patient No.	Initials	Visit	Date Performed	ZUNG																				Total Score (*)			
					IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20				
10	18	SS	5	22APR91	4	4	3	2	1	4	2	2	3	4	4	4	4	4	4	3	3	4	2	4	65			
			6	30APR91	4	3	4	2	3	4	2	3	3	4	4	4	4	4	4	4	4	4	4	4	4	66		
10	19	TN	0	01APR91	4	4	3	3	4	1	3	1	1	3	3	4	3	3	3	3	2	2	3	1	4	56		
			1	08APR91	2	3	2	2	1	1	1	1	1	3	3	4	3	2	2	2	2	2	1	2	1	3	44	
			2	16APR91	2	2	1	2	1	1	2	1	2	2	3	2	2	2	2	2	2	2	2	1	2	1	2	35
			3	22APR91	2	2	2	1	1	1	1	1	2	2	2	2	2	2	2	2	2	2	2	2	1	2	2	36
			4	29APR91	2	2	2	1	1	1	1	1	1	1	1	1	2	2	2	2	2	2	2	1	2	1	2	32
			5	06MAY91	2	2	2	1	1	1	1	1	1	1	1	1	2	2	2	2	2	2	2	1	2	1	2	33
10	20	EJ	0	02APR91	2	2	2	1	1	1	4	2	2	3	3	2	2	1	3	3	3	3	1	2	2	39		
			1	09APR91	2	2	2	1	3	1	2	4	3	2	2	2	2	2	2	2	3	3	3	1	2	1	43	
			2	16APR91	2	2	2	1	3	1	2	4	3	2	2	2	2	2	2	2	3	3	3	1	2	1	42	
			3	23APR91	2	2	2	1	4	1	2	4	2	2	2	2	2	2	2	2	3	3	3	1	2	1	46	
			4	30APR91	2	2	1	1	2	1	1	4	2	2	2	2	2	2	2	2	3	3	3	1	2	1	48	
			5	07MAY91	2	2	1	1	3	1	2	4	2	2	2	2	2	2	2	2	3	3	3	1	2	1	42	
10	21	AK	0	03APR91	3	3	2	2	2	2	1	2	3	3	3	3	3	3	3	3	4	4	3	3	3	51		
			1	10APR91	3	4	2	3	3	1	2	2	2	3	4	2	4	3	3	3	3	4	4	2	2	3	56	
			2	17APR91	3	4	3	3	1	1	1	2	2	4	3	2	3	3	3	3	3	4	4	4	3	3	53	
			3	24APR91	3	4	4	3	4	2	1	1	2	3	3	4	1	3	3	3	3	4	4	4	1	3	53	
			4	01MAY91	3	4	4	3	4	3	2	1	1	3	4	4	1	3	2	3	3	4	4	4	1	3	55	
			5	08MAY91	3	4	4	4	4	3	2	4	3	2	4	4	4	4	4	4	4	4	4	4	1	4	65	
10	22	AA	0	16APR91	3	4	3	3	4	2	4	3	3	4	4	4	4	4	4	4	4	4	1	4	60			
			1	23APR91	3	4	2	3	3	2	1	2	3	3	3	3	3	3	3	3	3	2	2	3	1	54		
			2	30APR91	2	4	2	1	1	2	2	2	2	2	2	2	3	3	3	3	3	3	3	1	3	43		
			3	07MAY91	2	4	1	2	1	2	2	2	2	2	2	2	3	3	3	3	3	3	3	1	3	46		
			4	14MAY91	2	4	1	2	1	2	1	2	2	2	2	2	2	2	2	2	2	2	2	1	2	2	40	
			5	21MAY91	2	4	1	1	1	1	1	1	1	1	1	1	2	2	2	2	2	2	2	2	1	2	37	
10	23	LT	0	03JUN91	2	4	1	1	1	1	2	1	2	2	2	2	2	2	2	2	2	2	1	2	2	35		
			1	10JUN91	2	2	3	1	1	1	2	3	2	1	2	1	2	2	1	2	2	2	2	3	1	2	36	
			2	17JUN91	2	2	1	3	4	4	3	2	1	2	3	1	1	1	1	1	1	1	1	2	3	1	2	41
			3	24JUN91	2	3	2	3	3	2	1	1	2	1	2	1	1	1	1	1	1	1	1	2	3	1	2	40
			4	01JUL91	2	3	3	3	3	3	2	1	1	2	1	1	1	1	1	1	1	1	1	2	3	1	2	39
			5	08JUL91	2	2	2	3	3	3	3	2	1	1	2	2	1	1	1	1	1	1	1	2	3	1	2	42
10	24	TT	0	15JUL91	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	27		
			1	22JUL91	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	27	
			2	29JUL91	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	27	
			3	05AUG91	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	27	
			4	12AUG91	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	27	
			5	19AUG91	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	27	

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Date Performed	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (*)			
10	24	AL	0			2	3	1	1	2	1	2	1	3	3	4	4	2	1	3	2	2	3	1	3	1	44		
			1			1	2	1	1	1	2	2	3	3	3	3	3	3	3	2	1	2	2	2	2	1	2	37	
			2			1	2	1	1	1	1	2	3	3	3	3	3	3	3	3	2	1	2	2	2	1	2	35	
			3			1	2	1	1	1	1	2	3	3	3	3	3	3	3	3	2	1	2	2	3	1	2	35	
			4			2	2	1	1	1	1	2	3	3	3	3	3	3	3	3	2	1	2	2	2	3	1	3	37
			5			3	4	1	3	3	4	1	3	4	4	3	3	3	3	3	3	3	3	3	4	4	1	4	59
10	25	ES	0	06MAY91		2	1	4	2	3	1	1	1	2	2	1	1	1	3	2	1	1	3	1	1	1	36		
			1	20MAY91		2	1	2	3	1	1	2	2	2	1	3	3	3	3	2	1	2	3	1	1	1	38		
			2	27MAY91		4	1	3	3	1	3	1	3	3	3	3	3	3	3	3	2	1	3	1	3	1	3	51	
			0			3	3	4	1	3	3	4	3	3	3	3	3	3	3	3	3	4	1	3	1	3	54		
			1			4	4	3	4	4	4	3	3	3	3	3	3	3	3	3	3	3	3	3	2	3	1	55	
			2			4	4	3	4	4	4	4	3	3	3	3	3	3	3	3	3	3	3	3	3	2	2	62	
10	26	JIF	0			3	3	4	1	3	3	4	3	3	3	4	3	3	3	3	4	3	3	4	1	3	61		
			1			4	4	3	4	4	4	3	3	3	3	3	3	3	3	3	3	3	3	3	4	1	3	61	
			2			4	4	3	4	4	4	3	3	3	3	3	3	3	3	3	3	3	3	3	3	4	1	3	61
			3			4	4	3	4	4	4	3	3	3	3	3	3	3	3	3	3	3	3	3	3	4	1	3	61
			4			3	4	3	4	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	4	1	3	55
			5			4	4	2	4	1	2	4	3	3	2	3	2	3	3	3	3	3	3	3	3	4	1	3	55
10	27	HK	0			3	4	2	4	4	3	4	3	3	4	3	3	3	3	1	4	1	3	4	1	4	58		
			1	10JUN91		3	1	3	2	3	1	2	2	2	1	3	2	3	3	3	3	3	3	3	3	4	2	3	49
			2			1	1	1	2	1	3	1	3	2	3	1	2	3	2	2	2	2	2	2	3	1	2	35	
			3			1	1	2	2	1	3	1	2	1	1	1	1	1	1	1	1	1	1	1	2	3	1	1	29
			4			2	1	1	2	1	3	1	2	1	1	1	1	1	1	1	1	1	1	1	2	3	1	1	30
			5			1	1	4	2	1	3	1	2	1	1	1	1	1	1	1	1	1	1	1	2	2	1	1	30
10	28	LL	0			1	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	2	2	1	1	29		
			1	30MAY91		4	3	3	1	1	1	1	1	1	1	3	3	4	2	4	4	4	4	4	3	4	3	58	
			2	05JUN91		3	4	2	3	1	1	1	1	1	1	2	3	3	3	2	3	2	4	3	4	2	3	49	
			3	12JUN91		1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	1	1	1	23
			4	26JUN91		2	4	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22
			5	03JUL91		4	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	2	2	1	1	1	27
10	29	JJ	0			3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23		
			1	12AUG91		3	3	1	3	2	2	2	2	2	2	2	2	3	2	3	3	3	3	3	3	1	3	47	
			2			3	3	1	4	1	1	1	1	1	1	2	3	3	3	3	2	4	3	4	3	4	1	3	49
			3	03SEP91		3	3	1	3	1	1	1	1	1	1	2	3	3	3	3	3	2	3	3	3	3	1	3	46
			4			3	3	1	3	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	45
			5			2	3	1	2	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	42

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Date Performed	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (*)	
						Score		Score																			
10	29	JJ	6			2	3	1	3	1	2	1	2	2	2	3	4	3	4	2	4	3	4	1	4	51	
10	30	VK	0			4	3	2	4	1	4	2	4	2	4	3	3	4	4	4	4	4	4	4	4	68	
			1	23SEP91		4	3	2	4	1	4	2	4	2	3	4	3	3	4	4	3	4	4	4	4	62	
			2			4	3	3	4	1	4	2	4	2	3	3	3	2	4	4	4	4	3	4	3	63	
			3			4	2	3	4	1	4	1	4	1	3	4	4	3	2	4	4	3	4	4	3	63	
			4			3	3	2	4	1	4	1	4	2	3	4	4	2	4	4	4	3	4	4	3	61	
			5			3	3	2	4	1	4	2	4	2	3	4	4	2	4	4	3	4	4	4	3	64	
			6			3	3	2	4	2	4	2	4	2	3	4	4	2	3	4	4	4	4	4	3	61	
10	31	RK	0	16SEP91		3	3	2	3	2	3	2	1	3	4	2	4	3	3	3	3	2	3	1	3	54	
			1	23SEP91		3	3	2	3	3	3	1	2	3	2	3	3	3	2	3	3	3	3	3	1	51	
			2			2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	42	
			4			2	2	3	3	3	2	2	2	3	2	3	2	3	2	2	3	2	3	1	3	46	
			5			2	2	3	3	3	2	2	2	3	3	3	3	3	3	3	3	2	3	1	3	53	
			6			2	2	3	3	3	2	2	2	3	2	3	2	3	3	3	2	2	3	1	3	51	
10	32	LK	0	16SEP91		4	3	2	1	1	2	2	2	2	2	2	2	2	3	2	3	2	2	3	1	46	
			1	23SEP91		2	1	2	2	2	2	2	2	2	2	3	3	3	3	4	3	4	3	4	3	55	
			2			2	2	2	3	3	1	2	2	2	2	2	3	3	4	2	3	3	3	2	3	48	
			3			3	2	3	3	1	2	2	2	2	2	3	3	3	4	3	3	3	4	2	3	53	
			4			3	1	3	2	4	1	2	2	2	2	3	3	3	4	3	4	3	4	2	4	56	
			5	22OCT91		4	2	3	2	2	1	2	2	2	2	3	3	4	4	4	3	3	4	2	3	53	
			6	29OCT91		4	2	3	2	2	2	2	2	2	2	2	3	4	4	2	4	4	4	4	4	60	
10	33	EK	0	18SEP91		2	3	1	2	1	2	1	2	2	2	4	3	3	4	4	4	4	3	4	3	59	
			1			2	3	1	2	1	3	2	1	2	1	1	2	2	3	2	3	2	3	1	3	48	
			2			1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	26	
			3			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23	
			4			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21	
			5			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21	
			6			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21	
10	34	TK	0	26SEP91		4	4	1	3	3	4	1	4	2	3	3	4	3	4	3	4	3	4	2	4	63	
			1			2	3	1	4	4	1	4	2	2	2	3	3	3	3	3	4	3	3	1	3	55	
			2			3	3	1	4	4	1	4	2	2	2	3	3	3	3	2	4	3	4	1	3	53	
			3	15OCT91		3	3	1	4	4	1	4	2	2	2	3	3	3	3	3	3	4	3	4	1	4	59
			4			2	3	1	4	4	1	4	2	2	2	3	3	3	3	3	4	3	4	1	3	53	
			5			2	3	1	4	4	1	4	2	2	2	3	3	3	3	3	4	3	4	1	3	52	
			6			3	3	1	4	4	2	4	2	2	2	3	3	3	3	3	4	3	4	1	3	53	

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Date Performed	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (*)			
10	35	IM	0	23SEP91	2	1	2	2	1	1	1	1	1	1	1	1	1	2	1	4	1	3	3	3	1	2	34		
			1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	4	1	3	4	4	1	3	35	
			2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	4	1	3	4	4	1	3	35	
			3	3	2	3	2	1	1	1	1	1	1	1	1	1	1	1	3	1	4	1	3	3	3	1	3	39	
			4	3	2	3	2	2	1	2	1	2	1	1	1	1	1	1	3	1	4	1	3	4	4	1	3	43	
			5	2	2	2	1	1	2	1	2	1	2	1	1	1	1	1	3	1	4	1	3	4	3	1	4	39	
10	36	AK	0	14OCT91	4	1	4	4	4	3	1	1	1	1	1	1	1	2	3	3	4	1	3	4	1	4	55		
			1	3	1	4	4	4	1	1	1	2	1	1	1	1	1	1	3	3	4	3	4	1	3	4	49		
			2	2	1	3	2	4	3	1	1	1	1	1	1	1	1	1	4	2	3	3	3	4	1	3	49		
			3	1	1	1	1	3	2	1	1	1	1	1	1	1	1	1	4	2	3	3	3	4	1	1	51		
			4	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24	
			5	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21	
10	37	HK	0	14OCT91	4	4	4	4	4	2	3	3	3	3	3	3	3	4	3	4	3	4	3	4	2	4	69		
			1	4	2	4	4	4	2	2	3	4	4	4	4	4	4	4	4	3	4	3	4	4	1	4	66		
			2	4	2	4	1	4	3	1	3	3	3	3	3	3	3	3	4	3	4	3	4	3	4	1	4	59	
			3	4	2	2	2	2	2	1	2	2	2	2	2	2	2	2	3	2	3	2	4	1	3	1	3	48	
			4	4	2	3	3	3	4	2	1	2	2	2	2	2	2	2	3	2	3	2	4	2	4	1	4	53	
			5	3	4	2	3	3	4	3	1	2	2	2	2	2	2	2	3	3	2	3	4	1	4	1	3	53	
10	38	LL	0	26NOV91	2	4	2	3	3	4	2	1	2	2	2	2	3	2	3	2	3	4	1	3	1	3	50		
			1	2	1	2	2	4	4	2	2	3	3	3	3	3	3	4	3	4	3	4	3	2	1	2	37		
			2	1	1	1	2	4	2	1	2	3	3	3	3	3	3	3	2	1	1	3	2	1	2	1	3	40	
			3	1	1	1	2	2	1	1	1	1	1	1	1	1	1	1	2	2	1	1	2	1	1	1	1	29	
			4	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	2	2	1	1	1	1	1	1	1	24	
			5	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	1	1	1	26
10	39	VH	0	26NOV91	1	2	1	3	1	1	1	1	1	1	1	1	1	2	2	1	1	1	2	1	1	1	36		
			1	3	3	4	3	3	2	3	2	4	4	4	4	4	4	4	4	3	4	4	3	1	3	1	4	61	
			2	3	3	3	3	3	3	2	4	1	4	3	4	3	4	3	4	3	4	3	4	3	1	4	1	4	53
			3	2	3	3	3	3	2	4	1	4	3	4	3	4	3	4	3	4	3	4	3	1	3	1	3	57	
			4	2	3	3	3	3	1	2	1	5	3	4	3	3	3	3	2	3	3	3	3	1	3	1	3	46	
			5	2	3	3	3	3	1	2	2	3	3	3	2	3	3	3	2	3	3	3	3	3	1	3	1	3	50
10	40	AP	0	3	2	2	4	2	3	2	2	2	2	2	2	2	3	2	3	2	3	3	3	1	3	52			
			1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	3	2	2	2	3	3	1	2	43		

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Date Performed	ZUNG																			Total Score (*)	
					IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19		IT.20
10	40	AP	2	.	2	2	2	1	2	4	2	2	2	3	2	2	2	3	2	3	1	2	41		
			3	.	2	2	2	1	3	2	2	2	2	3	2	2	3	3	2	2	3	1	2	43	
			4	.	2	1	2	1	3	2	2	1	2	2	2	2	2	2	2	2	2	2	1	1	32
			5	.	2	1	3	2	1	3	3	1	2	2	2	2	2	2	2	2	2	2	1	2	34
			6	.	2	2	2	1	1	3	3	2	2	2	2	2	2	2	2	3	2	2	1	1	37
			0	.	2	4	2	4	1	1	1	4	1	4	1	1	2	1	2	4	1	1	1	1	39
10	41	VP	1	.	2	2	2	3	1	4	2	1	1	3	3	3	2	3	2	2	1	2	46		
			2	.	2	2	2	3	1	3	2	1	3	3	3	3	3	4	2	1	3	1	2	46	
			3	.	2	2	3	1	3	2	1	2	2	1	2	2	1	4	2	1	3	1	2	38	
			4	.	2	3	2	3	1	3	2	1	3	2	3	3	3	2	2	2	2	3	1	2	44
			5	.	2	3	2	3	1	3	2	2	1	2	3	3	2	3	2	3	1	3	1	1	42
			6	.	2	3	2	3	1	2	2	1	3	2	3	2	3	2	3	2	3	1	1	1	41
10	42	TT	0	.	3	2	2	3	1	2	2	2	2	2	2	2	3	3	1	1	1	1	39		
			1	.	3	4	3	4	3	3	1	1	1	1	4	2	4	3	4	4	4	3	4	57	
			2	.	1	4	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	32	
			3	.	4	4	3	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	46	
			4	.	1	3	2	2	1	4	1	1	1	1	1	1	1	1	1	1	1	1	1	42	
			5	18DEC91	2	3	2	3	4	1	1	1	1	1	1	1	1	1	1	1	1	1	1	4	42
10	43	IK	6	.	2	4	2	3	1	1	1	1	2	3	4	1	3	2	4	4	4	1	47		
			0	14NOV91	2	4	3	2	3	1	1	1	1	1	3	1	3	1	1	4	4	1	4	42	
			1	.	2	3	1	1	2	1	2	1	2	1	3	1	3	2	2	3	3	1	3	41	
			2	28NOV91	2	1	2	1	2	1	2	1	2	1	2	2	2	3	3	3	3	1	3	36	
			3	05DEC91	2	2	1	2	1	1	3	1	1	1	3	1	3	2	2	3	3	1	2	37	
			4	.	3	2	1	3	4	2	1	4	1	4	4	4	4	2	3	2	3	4	3	55	
10	44	AB	5	20DEC91	1	4	2	2	1	3	1	2	1	1	1	2	1	3	2	2	3	1	36		
			6	.	1	3	2	1	3	4	1	1	4	4	4	4	2	4	2	4	2	3	55		
			0	13NOV91	2	4	1	1	3	1	3	1	1	1	3	1	3	1	1	4	4	1	4	42	
			1	16NOV91	2	1	1	1	1	3	1	2	1	2	1	3	2	3	2	3	3	1	3	40	
			2	02DEC91	2	1	1	4	3	1	3	4	1	1	1	2	2	2	1	2	2	1	3	40	
			3	08DEC91	2	1	1	4	3	2	2	4	2	1	1	2	2	2	2	2	2	1	3	44	
10	45	KJ	4	18DEC91	2	4	2	1	3	3	1	2	4	2	4	4	1	4	3	3	2	4	54		
			5	23DEC91	2	4	2	1	4	1	1	4	3	3	4	4	4	1	4	3	3	2	4	55	
			6	02JAN92	2	4	1	1	4	4	1	1	2	4	4	4	4	1	4	3	3	2	4	54	
			0	21NOV91	3	4	3	1	4	3	2	3	3	3	4	4	4	1	3	2	2	1	2	55	
			1	26NOV91	3	4	2	1	4	3	1	2	1	3	4	4	4	1	3	4	2	1	3	56	
			2	05DEC91	2	4	3	3	1	3	1	2	1	3	1	4	4	3	2	4	4	3	3	50	
3	.	2	4	2	3	1	3	1	2	2	3	2	2	4	4	3	3	4	2	2	54				

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 RESOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Date Performed	ZUNG																				Total Score (*)			
					IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20				
10	45	KJ	4	19DEC91	3	3	2	1	4	4	2	3	3	2	4	4	4	3	1	4	4	4	1	1	3	56		
			5	3	4	2	3	1	2	3	2	3	2	4	3	3	3	3	3	4	2	3	4	2	3	51		
			6	3	3	2	1	3	4	2	3	3	1	3	4	4	1	3	3	3	2	1	3	2	1	3	53	
			0	02DEC91	3	3	1	2	1	3	1	1	3	4	3	4	3	4	4	3	4	3	3	3	2	4	55	
			1	3	3	1	2	3	1	2	3	4	3	3	4	3	3	2	3	3	3	3	3	3	2	3	53	
			2	16DEC91	3	3	1	1	3	1	1	2	3	4	3	3	4	3	3	4	2	4	3	4	3	4	3	50
10	46	TN	3	23DEC91	2	3	3	1	3	3	1	1	2	3	3	4	3	3	4	2	2	2	2	2	3	51		
			4	3	3	1	4	2	1	3	1	3	3	3	4	2	3	2	2	2	2	2	2	2	2	3	46	
			5	08JAN92	4	3	1	2	2	3	2	2	3	4	4	4	2	3	3	3	3	3	3	4	2	4	58	
			6	17JAN92	3	3	2	1	3	2	2	4	2	3	3	3	2	4	2	2	2	2	2	2	2	2	3	50
			0	03DEC91	3	4	3	3	1	2	1	2	2	3	3	4	2	4	3	4	3	4	3	3	3	2	3	55
			1	11DEC91	3	3	3	1	2	1	2	2	3	3	4	2	4	3	3	3	4	3	3	4	2	3	3	54
10	47	TM	2	3	4	3	4	1	2	1	1	2	3	3	4	2	3	3	3	4	3	3	2	3	3	53		
			3	3	3	2	3	1	2	1	1	2	3	3	2	3	3	3	3	3	3	3	3	3	1	3	47	
			4	02JAN92	2	3	1	2	1	1	1	1	2	1	3	2	3	2	3	2	2	3	2	2	1	2	2	37
			5	2	4	1	1	1	3	3	3	2	3	3	4	4	1	4	4	4	1	4	3	4	2	4	56	
			6	14JAN92	2	4	2	1	4	3	3	3	2	2	4	4	4	4	4	4	1	4	3	4	4	1	4	59
			10	48	IP	0	10DEC91	4	4	3	4	2	4	2	4	2	3	4	4	4	4	4	4	4	4	4	3	4
1	4	4				3	4	2	4	2	4	2	3	4	4	4	4	4	4	4	4	4	4	4	3	4	70	
2	16DEC91	4				1	4	1	4	2	3	4	1	1	3	3	4	1	1	1	4	4	3	1	4	3	4	49
3	4	4				3	4	2	4	1	4	2	4	4	4	4	4	4	4	4	4	4	4	4	4	4	71	
4	02JAN92	4				4	4	4	2	4	2	4	1	4	4	4	4	4	4	4	4	4	4	4	4	4	4	72
5	4	4				3	4	2	4	1	4	1	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	70
10	49	VM	6	14JAN92	4	4	4	4	4	3	4	1	4	4	4	4	4	4	4	4	4	4	4	4	4	73		
			0	09DEC91	3	2	4	1	3	2	3	3	2	2	3	4	2	3	4	1	3	4	1	3	2	3	49	
			1	19DEC91	4	2	3	1	4	3	3	1	3	2	3	4	2	3	3	4	3	4	2	3	2	4	54	
			2	3	3	2	1	4	2	2	2	2	3	4	4	4	4	4	4	4	4	3	4	2	2	3	61	
			3	03JAN92	4	3	3	1	4	2	2	2	4	3	4	4	4	4	4	4	4	4	4	4	4	2	4	66
			4	13JAN92	3	3	3	1	4	2	2	3	4	4	4	4	4	4	4	4	4	4	3	3	3	2	3	57
10	50	EE	6	27JAN92	4	4	3	2	1	4	2	2	3	3	3	4	3	4	4	4	4	3	4	4	4	65		
			0	16DEC91	4	3	3	1	3	1	1	3	3	4	4	3	1	3	3	1	3	3	1	3	2	3	52	
			1	23DEC91	3	3	3	2	4	2	3	1	2	3	4	4	3	2	3	3	3	3	3	4	2	3	54	
			2	02JAN92	4	3	4	2	4	2	3	4	1	3	3	4	2	3	2	4	2	3	2	4	1	1	3	56
			3	09JAN92	4	4	4	2	4	1	4	4	2	3	4	4	1	1	3	2	2	1	3	2	1	1	3	53
			4	13JAN92	4	1	4	3	4	1	3	4	1	3	4	1	3	3	4	1	3	3	4	1	2	3	3	54
5	20JAN92	4	2	4	2	4	1	4	4	1	4	4	1	4	2	2	3	2	4	4	1	1	1	1	3	54		

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Date Performed	ZUNG																				Total Score (*)	
					IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20		
10	50	EE	6	26JAN92	4	3	4	4	1	4	1	4	4	4	4	4	4	4	4	4	4	4	4	69		
			0	UL	3	2	4	1	4	3	3	1	2	3	2	4	4	4	4	4	4	4	4	4	59	
			1	UL	2	4	3	1	3	4	2	2	4	4	1	4	4	4	4	4	4	4	4	4	57	
			2	UL	3	3	2	3	4	2	3	2	2	3	2	4	4	4	4	4	4	4	4	4	58	
			3	UL	3	3	2	1	4	4	1	2	2	4	4	2	4	4	4	4	4	4	4	4	56	
			4	UL	3	3	2	1	4	4	2	2	2	4	4	2	4	4	4	4	4	4	4	4	59	
10	51	UL	5	UL	2	1	2	1	4	4	3	2	3	3	1	3	3	4	3	3	3	1	2	50		
			6	UL	2	4	2	1	2	4	1	3	2	4	4	4	4	4	4	4	4	4	4	4	56	
			0	MP	2	2	3	1	4	4	2	2	3	1	4	4	4	4	4	4	4	4	4	4	53	
			1	MP	3	1	1	1	4	4	1	2	4	1	4	4	4	4	4	4	4	4	4	4	49	
			2	MP	2	3	1	2	1	4	1	2	4	1	4	4	4	4	4	4	4	4	4	4	49	
			3	MP	2	3	1	2	1	4	1	2	4	1	4	4	4	4	4	4	4	4	4	4	50	
10	52	MP	4	MP	4	3	1	1	3	4	2	2	1	2	4	4	4	4	4	4	4	4	4	56		
			0	MA	4	3	4	3	2	1	4	2	3	2	4	4	4	4	4	4	4	4	4	4	64	
			1	MA	4	3	4	2	2	1	4	2	3	2	4	4	4	4	4	4	4	4	4	4	62	
			2	MA	4	3	4	4	1	1	4	2	2	3	4	4	4	4	4	4	4	4	4	4	63	
			3	MA	4	3	4	2	1	1	4	2	2	3	4	4	4	4	4	4	4	4	4	4	59	
			4	MA	3	3	3	2	1	1	4	2	2	3	4	4	4	4	4	4	4	4	4	4	56	
10	53	MA	5	MA	3	3	3	2	1	1	4	2	2	3	3	3	3	3	3	3	3	3	4	54		
			6	MA	2	2	2	1	3	1	1	2	3	3	4	4	4	4	4	4	4	4	4	4	48	
			0	UN	3	3	2	2	2	4	3	1	3	3	4	2	3	3	4	3	4	3	2	3	56	
			1	UN	3	3	2	2	1	4	2	1	3	3	4	2	3	3	3	3	3	3	2	3	53	
			2	UN	2	3	2	2	1	4	2	1	3	3	4	2	3	3	3	3	3	3	1	3	51	
			3	UN	2	3	2	2	1	4	2	1	3	3	4	2	3	3	3	3	3	3	1	3	50	
10	54	UN	4	UN	2	3	2	2	4	2	2	3	4	2	3	4	4	4	4	4	4	4	4	52		
			5	UN	2	3	2	2	1	4	2	2	3	3	4	2	3	3	4	3	4	3	1	3	49	
			6	UN	2	3	2	2	1	3	1	1	2	3	4	4	4	4	4	4	4	4	3	1	48	
			0	TP	4	4	3	2	2	4	3	1	3	3	4	2	3	3	4	3	4	3	2	3	56	
			1	TP	4	4	3	3	2	4	1	3	4	4	4	4	4	4	4	4	4	4	4	4	4	65
			2	TP	4	4	3	3	1	4	1	3	4	4	4	4	4	4	4	4	4	4	4	4	4	63
10	55	TP	3	TP	3	2	3	3	4	2	2	3	4	2	3	4	4	4	4	4	4	4	4	58		
			4	TP	4	2	2	1	4	1	4	3	4	4	4	4	4	4	4	4	4	4	4	4	58	
			5	TP	4	2	2	1	4	1	4	3	4	4	4	4	4	4	4	4	4	4	4	4	55	
			6	TP	3	3	2	1	4	1	2	4	3	3	4	4	4	4	4	4	4	4	4	4	53	
			0	JP	3	3	2	1	4	1	2	3	2	4	4	4	4	4	4	4	4	4	4	4	50	
			1	JP	2	1	1	3	1	1	1	2	2	2	2	3	3	3	3	3	3	3	2	3	3	40

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Date Performed	ZUNG																				Total Score (*)	
					IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20		
10	56	JP	2	28JAN92	1	2	1	1	1	1	1	2	1	1	2	2	2	3	3	3	3	2	2	37		
			3	03FEB92	1	1	1	1	1	1	1	2	1	1	2	2	2	2	3	3	3	2	2	34		
			4	10FEB92	1	1	1	1	1	1	1	2	1	1	2	1	3	2	3	3	3	2	1	2	33	
			5	18FEB92	2	2	1	3	1	1	2	2	1	1	2	3	2	3	2	3	3	3	1	3	41	
			6	26FEB92	2	2	1	3	1	1	2	2	1	1	2	2	3	2	3	3	3	3	1	3	39	
			0	16JAN92	3	4	3	2	1	2	1	1	2	3	3	3	3	3	4	2	3	1	3	1	51	
10	57	AG	1	21JAN92	2	4	2	4	1	2	1	1	2	2	2	3	3	3	2	3	1	3	47			
			2	27JAN92	2	4	2	4	1	2	1	1	3	2	4	3	2	2	3	4	3	1	3	47		
			3	03FEB92	2	2	2	2	1	3	1	1	2	1	2	2	2	2	4	3	2	1	2	37		
			4	14FEB92	2	1	2	2	1	1	1	2	2	2	2	2	2	2	3	1	2	1	2	35		
			5	18FEB92	2	1	2	3	1	2	1	1	2	2	2	2	2	2	4	1	2	1	2	2	35	
			6	25FEB92	4	2	3	3	1	2	1	2	2	2	2	4	3	3	3	3	3	1	3	1	49	
10	58	KK	0	.	3	3	3	3	4	3	2	2	3	4	3	2	4	4	3	3	3	4	57			
			1	.	3	3	3	4	4	3	2	2	2	3	3	2	4	2	4	4	4	4	2	57		
			2	.	3	3	4	4	4	3	3	2	3	4	4	4	4	4	4	4	4	4	3	4	66	
			3	.	2	2	2	3	4	3	4	2	3	4	2	4	2	3	4	4	4	4	2	4	54	
			4	10FEB92	2	1	2	3	4	2	3	1	2	3	3	1	3	3	3	3	3	3	2	3	47	
			5	.	2	2	2	3	3	2	3	1	2	3	3	1	3	2	2	3	3	3	2	4	47	
10	59	TA	6	26FEB92	2	1	2	1	3	2	3	1	1	3	3	1	3	1	2	3	3	2	2	39		
			0	20JAN91	3	4	2	1	1	1	1	2	3	4	4	3	1	4	4	3	4	1	3	49		
			1	.	3	4	3	4	4	1	1	2	3	4	4	3	1	4	4	3	3	1	1	53		
			2	04FEB91	3	3	3	2	1	1	2	3	3	3	3	3	3	4	4	4	1	4	1	3	50	
			3	.	2	2	2	4	3	2	1	4	4	3	3	2	1	4	4	2	4	1	4	1	52	
			4	18FEB91	3	3	2	2	1	2	2	4	4	4	4	2	1	4	4	4	1	3	1	3	46	
10	60	JM	6	02MAR91	2	4	2	2	2	2	1	2	4	4	3	2	1	4	4	1	4	1	4	51		
			0	.	3	4	2	2	1	3	2	4	2	1	3	4	3	4	4	4	4	2	3	57		
			1	.	3	4	2	3	2	2	2	2	2	3	3	3	3	3	3	3	4	4	1	3	55	
			2	.	3	3	2	3	1	2	1	2	2	3	3	3	2	3	3	3	3	3	1	3	47	
			4	.	3	3	2	2	1	2	1	3	2	2	3	3	2	3	3	3	3	3	2	3	49	
			5	.	3	3	2	1	3	1	1	1	1	2	2	2	2	2	2	2	3	3	3	1	2	40
10	61	JT	6	17FEB92	3	3	2	4	4	1	2	2	2	4	4	4	4	4	4	4	4	2	4	63		
			4	.	2	4	2	4	4	1	2	3	2	3	4	2	4	3	4	4	4	4	2	4	60	
			0	16JAN92	3	4	2	1	2	4	1	2	3	2	4	4	1	4	1	4	1	4	2	4	56	
			1	28JAN92	3	1	1	3	1	1	1	2	3	2	2	2	1	3	2	1	4	1	1	1	34	
			2	04FEB92	2	1	1	3	1	1	1	1	2	3	2	2	1	3	2	2	1	1	1	1	2	33
			6	.	2	3	1	1	1	1	1	2	3	2	2	2	1	3	2	1	1	1	1	1	2	33

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Date Performed	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (*)					
						IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20						
10	62	RK	3	11FEB92	2	1	1	1	1	1	1	1	1	1	2	2	2	2	2	1	2	1	1	1	1	2	31				
			4	05FEB92	1	1	1	1	1	1	1	1	1	1	1	2	2	2	2	2	1	2	1	1	1	1	1	2	32		
			5	05FEB92	1	1	1	1	1	1	1	1	1	1	1	1	2	2	2	2	2	1	2	1	1	1	1	1	1	28	
			6	02MAR92	1	1	1	1	1	1	1	1	1	1	1	1	2	2	1	1	1	2	1	1	1	1	1	1	1	26	
			0	12FEB92	2	3	1	4	1	1	1	1	2	1	2	3	3	3	3	3	3	3	2	1	1	2	1	1	1	38	
			1	12FEB92	2	4	1	1	1	1	1	1	3	2	1	4	4	4	4	4	4	4	4	3	3	1	4	2	4	53	
10	63	MS	2	25FEB92	2	2	1	1	1	1	3	4	3	2	1	4	4	4	4	4	4	3	3	1	4	2	4	55			
			3	28FEB92	2	4	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	40		
			4	28FEB92	3	4	2	1	3	4	2	2	2	2	2	3	3	3	3	3	3	4	2	4	1	3	1	1	1	53	
			5	12MAR92	1	1	1	1	1	1	1	1	1	1	1	1	2	1	2	1	2	1	1	1	1	1	1	1	1	27	
			6	19MAR92	2	4	1	1	1	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	52
			0	28JAN92	3	3	2	4	3	2	4	3	2	1	3	3	3	3	3	3	3	4	1	3	2	4	1	3	1	54	
10	64	LT	1	12FEB92	3	3	4	2	4	2	2	3	2	2	3	3	3	3	3	3	4	2	3	4	3	1	3	56			
			2	19FEB92	3	3	3	3	3	2	2	3	3	3	3	3	3	3	3	3	3	3	3	3	4	3	4	1	61		
			3	26FEB92	3	3	3	3	3	1	3	2	2	2	3	3	3	3	3	3	3	3	3	3	4	2	1	3	1	52	
			4	11MAR92	3	3	3	3	1	3	3	1	3	2	2	3	3	3	3	3	3	3	2	3	3	3	2	2	3	53	
			5	11MAR92	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	48
			6	24MAR92	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	47
10	81	JN	0	21FEB92	4	4	3	4	1	4	1	3	3	3	3	3	4	4	4	4	4	4	4	4	2	4	1	67			
			1	27FEB92	3	3	1	4	2	3	3	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	54	
			2	05MAR92	3	4	3	3	3	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	61
			3	09MAR92	3	3	1	3	2	3	3	1	2	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	50
			4	18MAR92	3	4	2	1	1	2	1	3	1	3	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	48
			5	02APR92	2	4	2	1	1	2	1	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	50
10	82	LS	0	11FEB92	2	2	3	1	3	1	3	3	2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	50			
			1	02MAR92	3	3	2	4	2	4	2	3	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	61	
			2	11MAR92	3	1	2	1	4	1	2	4	3	1	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	48
			3	14MAR92	3	3	2	2	3	3	1	3	2	4	1	3	2	4	1	2	4	4	4	4	4	4	4	4	4	4	55
			4	23MAR92	2	3	2	1	3	3	4	1	1	3	4	1	3	4	3	4	3	5	2	4	4	4	4	4	4	4	53
			5	30MAR92	3	3	1	2	3	3	1	3	3	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	57
10	83	KL	0	06APR92	2	3	1	2	2	3	1	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	52			
			1	1	4	4	1	4	1	2	1	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	60	
			2	1	4	4	3	1	4	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	52	
			3	1	4	4	3	4	1	4	1	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	63
			4	1	4	4	2	2	1	4	1	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	57
			5	30MAR92	4	4	2	4	1	4	1	4	1	4	1	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Date Performed	ZUNG																			Total Score (*)	
					IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19		IT.20
10	83	KL	5	16MAR92	2	2	2	2	1	4	1	4	1	2	2	3	2	3	3	4	1	3	47		
			6	3	4	2	4	1	4	1	4	1	3	4	3	2	4	2	4	3	4	1	4	58	
10	85	AK	0	16MAR92	2	4	2	1	1	3	1	1	3	2	2	3	2	3	2	3	2	1	3	41	
			1	2	4	2	1	3	1	1	3	2	2	3	3	2	3	2	3	2	1	3	46		
			2	2	4	2	1	3	1	1	3	2	2	3	3	2	3	2	3	2	1	2	45		
			3	2	4	1	2	1	3	1	1	2	2	3	3	3	3	3	2	3	2	1	2	44	
			4	2	4	2	1	3	1	1	2	1	2	3	3	2	2	2	2	2	2	1	2	41	
			5	2	4	1	1	3	1	1	2	1	2	1	3	3	3	2	3	2	3	1	2	38	
10	86	NP	0	16MAR92	4	3	3	3	3	4	2	1	3	4	3	4	2	4	3	4	2	4	63		
			1	3	3	3	3	4	2	1	3	4	3	4	2	4	3	4	2	4	2	4	61		
			2	3	3	2	3	3	1	1	3	4	3	4	2	4	3	4	2	3	2	4	54		
			3	3	3	2	3	3	2	2	3	4	3	4	2	4	3	4	2	3	1	4	55		
			4	15APR92	3	3	2	4	2	3	2	2	4	4	2	4	4	4	4	3	3	1	4	58	
			5	22APR92	3	3	2	4	2	3	2	2	4	4	2	4	4	2	4	2	4	3	1	4	56
10	87	AN	0	17MAR92	3	4	3	3	3	2	3	3	2	3	3	2	2	3	3	2	1	2	48		
			1	25MAR92	3	3	3	3	1	3	2	2	3	3	3	3	3	4	3	3	3	4	1	3	57
			2	3	3	3	3	1	3	3	3	2	2	3	3	3	3	3	3	3	3	2	4	55	
			3	2	2	2	2	1	3	2	2	2	3	3	3	3	3	3	1	2	3	3	2	4	53
			4	15APR92	2	2	2	2	3	1	3	2	2	2	3	2	3	3	3	3	3	3	1	3	49
			5	21APR92	2	2	2	2	2	1	3	3	2	2	2	2	2	3	3	3	3	3	3	2	4
10	88	AH	0	18MAR92	2	3	2	1	3	3	2	2	2	2	3	3	2	2	2	2	2	2	4	44	
			1	25MAR92	3	3	2	2	1	4	1	1	2	3	1	3	3	3	3	3	2	2	1	4	46
			2	2	2	2	2	1	4	1	1	2	3	2	3	2	3	3	3	2	2	1	3	46	
			3	06APR92	3	3	3	1	3	3	1	3	2	2	3	2	3	3	3	3	2	2	1	3	43
			4	15APR92	3	4	3	1	3	3	2	2	3	4	4	3	2	4	3	2	2	2	2	2	51
			5	21APR92	2	4	3	1	3	3	2	2	2	4	4	4	4	4	1	3	2	2	3	2	55
10	89	SK	0	19MAR92	3	3	2	3	1	3	2	4	2	2	3	3	2	3	3	1	2	3	52		
			1	26MAR92	3	4	3	1	4	4	3	3	4	4	1	3	1	2	4	4	4	1	1	50	
			2	2	4	2	1	4	3	3	4	3	2	3	1	3	2	3	2	3	3	1	1	50	
			3	2	4	2	1	4	3	2	3	3	2	3	1	3	2	3	2	3	4	1	3	49	
			4	16MAR92	4	3	4	3	3	2	1	2	3	4	4	3	3	3	4	4	4	2	4	2	63
			5	23APR92	3	3	3	4	4	4	4	4	4	4	4	3	3	3	3	3	4	4	1	3	59
10	90	SV	1	16MAR92	4	3	4	3	3	3	2	1	2	3	4	4	3	3	4	4	2	4	63		
			2	07APR92	2	4	3	3	3	2	3	2	3	2	3	4	4	3	3	4	4	1	3	54	

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Date Performed	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (*)				
						IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20					
10	90	SV	3	13APR92	2	3	2	4	3	1	2	2	3	3	3	3	3	3	2	3	2	3	3	3	1	3	48			
			4	22APR92	2	3	2	2	1	1	1	2	3	3	3	3	3	3	3	2	2	1	3	2	3	1	3	40		
			5	.	2	2	2	2	1	1	1	1	3	3	3	3	3	3	3	2	3	2	3	2	3	1	2	39		
			6	06MAY92	2	2	1	2	2	2	2	1	2	3	3	3	3	3	3	2	2	2	2	3	3	3	1	3	41	
			0	.	3	4	2	4	2	4	2	3	3	3	4	4	4	4	4	4	3	4	3	4	4	4	2	4	63	
			1	.	3	4	1	3	4	4	2	4	4	4	4	4	4	4	4	4	3	4	4	4	4	4	4	2	4	57
10	91	HI	2	.	3	4	2	3	3	2	3	3	4	4	4	4	4	4	3	4	4	4	4	4	4	4	57			
			3	.	3	4	2	3	3	3	2	4	4	4	4	4	4	4	4	3	4	4	4	4	4	4	4	4	57	
			4	.	3	4	2	3	3	3	2	4	4	4	4	4	4	4	4	4	3	4	4	4	4	4	4	4	60	
			5	.	2	4	2	3	4	4	3	4	4	4	4	4	4	4	4	4	3	4	4	4	4	4	4	4	55	
			6	.	2	4	1	2	4	4	2	4	4	4	4	4	4	4	4	4	3	4	4	4	4	4	4	4	51	
			0	.	2	4	1	2	4	4	3	4	4	4	4	4	4	4	4	4	2	4	4	4	4	4	4	4	54	
10	92	LA	0	30MAR92	3	2	4	4	2	3	2	1	3	3	3	3	4	4	3	3	3	4	3	4	2	4	61			
			1	.	2	2	3	1	3	1	1	2	2	3	3	3	3	3	2	3	2	3	2	3	1	3	45			
			2	13APR92	1	3	1	3	1	1	2	2	3	2	2	3	2	3	2	3	2	3	2	3	2	3	1	2	41	
			3	21APR92	1	4	1	2	1	1	2	2	3	1	2	2	3	1	2	2	3	1	3	1	3	1	2	36		
			4	30APR92	2	2	2	1	2	1	2	3	3	3	3	3	3	3	3	3	2	3	2	3	3	3	1	3	47	
			5	05MAY92	2	2	2	1	3	1	1	4	2	2	3	3	3	3	3	3	2	2	4	4	4	3	1	2	45	
10	93	AN	0	03MAR92	2	4	2	1	3	4	3	3	3	4	4	4	4	4	4	4	1	2	1	3	4	4	59			
			1	15APR92	2	2	2	1	1	2	2	3	4	3	4	3	1	2	2	2	2	2	3	2	2	1	3	41		
			2	21APR92	2	4	1	1	2	4	3	1	4	4	4	4	4	4	4	4	4	1	3	1	4	4	4	3	55	
			3	29APR92	1	2	1	1	1	1	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1	2	1	1	27	
			4	05MAY92	1	2	1	1	1	1	2	2	1	2	2	1	1	1	1	1	1	1	1	1	1	2	1	1	29	
			5	13MAY92	1	2	1	1	2	2	2	1	2	2	1	2	2	1	1	1	1	1	1	1	1	2	1	1	29	
10	94	PV	0	.	4	3	2	4	2	2	2	2	2	2	2	2	2	2	1	1	1	1	2	1	2	1	31			
			1	.	4	3	2	4	2	2	2	2	4	4	4	4	4	4	4	4	3	4	3	4	4	3	4	59		
			2	21APR92	4	4	2	2	2	2	2	2	4	4	4	4	4	4	4	4	4	3	4	3	4	3	4	4	55	
			3	.	3	3	1	2	2	2	2	2	4	4	4	4	4	4	4	4	4	3	4	3	4	3	4	4	56	
			4	04MAY92	3	3	1	2	2	2	2	2	4	4	4	4	4	4	4	4	4	4	3	4	3	4	2	4	52	
			5	13MAY92	2	3	3	4	2	1	1	3	2	3	3	2	4	4	4	4	4	3	4	4	4	4	2	3	50	
11	1	DF	0	11OCT91	3	3	4	4	3	4	1	2	2	3	3	4	4	4	4	3	4	3	1	3	1	4	59			
			1	12OCT91	2	2	4	3	4	1	1	2	3	4	3	3	3	3	3	3	3	4	1	3	1	4	52			
			2	25OCT91	3	1	3	4	1	4	2	2	3	4	1	2	1	3	3	3	3	4	1	2	1	2	1	3	48	
			3	01NOV91	3	3	1	2	2	2	2	2	3	2	3	2	3	3	3	3	3	3	3	3	3	3	1	2	49	
			4	08NOV91	2	2	1	3	2	4	2	1	1	2	2	2	2	2	2	2	2	2	3	3	3	3	4	1	3	47
			0	.	2	2	1	3	2	4	2	1	1	2	2	2	2	2	2	2	2	3	3	3	3	3	3	3	4	47

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Date Performed	ZUNG																			Total Score (*)				
					IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19		IT.20			
11	1	DF	5	15NOV91	2	1	1	3	1	4	2	2	2	3	3	3	2	3	2	3	3	3	3	1	2	43		
			6	22NOV91	2	2	1	4	1	1	1	1	1	1	3	1	3	2	4	1	4	1	3	1	2	40		
11	2	HB	0	13OCT91	3	2	3	2	2	4	1	3	2	3	3	3	1	2	3	3	4	4	4	1	2	51		
			1	20OCT91	2	2	2	4	2	4	2	4	2	4	2	4	2	4	2	4	2	1	3	4	1	2	51	
			2	27OCT91	2	2	2	4	2	4	2	4	2	4	2	3	2	2	3	2	2	2	2	2	1	2	46	
			3	03NOV91	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	39	
			4	10NOV91	1	1	1	4	1	4	1	2	1	2	1	3	2	1	1	1	1	1	1	1	1	1	30	
			5	17NOV91	1	2	2	1	1	4	1	2	1	1	1	2	1	1	1	3	1	1	1	1	1	1	1	28
11	3	RF	6	24NOV91	1	1	1	2	1	1	1	1	1	1	1	1	1	2	3	1	3	3	3	1	1	34		
			0	14OCT91	4	3	4	4	3	1	1	4	1	2	2	2	4	4	4	2	3	3	3	2	3	56		
			1	21OCT91	2	3	2	2	2	2	2	2	2	2	2	2	2	3	2	2	2	2	3	1	3	46		
			2	27OCT91	1	3	1	3	2	2	1	1	2	1	1	1	1	2	2	1	2	1	1	2	1	2	34	
			3	03NOV91	1	3	1	3	1	2	1	1	1	1	1	1	1	1	1	1	1	2	2	1	1	1	29	
			4	11NOV91	2	4	3	3	2	1	2	2	2	2	2	2	2	4	2	3	2	4	2	2	2	2	51	
11	4	BA	5	18NOV91	2	1	3	4	2	3	2	1	2	2	2	2	2	3	3	2	3	3	2	2	2	47		
			6	25NOV91	3	1	3	2	3	2	1	2	3	2	2	2	3	3	2	3	2	3	3	2	2	2	48	
			0	17OCT91	4	4	3	4	3	4	1	2	1	4	1	4	4	3	4	3	2	3	2	3	1	4	59	
			1	24OCT91	4	4	4	3	3	4	1	1	1	4	1	3	4	4	3	4	3	3	3	2	3	1	58	
			2	31OCT91	3	3	3	4	2	4	1	1	4	2	3	3	2	4	3	2	4	3	2	3	1	3	52	
			3	07NOV91	3	4	3	3	2	4	1	1	1	3	2	3	2	4	3	2	3	2	3	1	3	1	50	
11	5	ZM	4	14NOV91	2	3	2	4	2	2	1	1	1	3	2	3	2	3	2	3	2	3	2	2	2	50		
			5	21NOV91	3	4	3	2	3	4	1	1	1	3	2	3	2	3	3	2	3	1	3	1	3	1	46	
			6	28NOV91	3	4	4	2	2	4	1	1	1	3	2	3	2	3	2	3	2	3	2	3	1	3	50	
			0	17OCT91	4	4	2	3	2	3	2	1	3	4	4	4	4	4	4	4	4	4	4	4	4	4	68	
			1	24OCT91	4	4	2	3	2	3	1	2	2	4	4	4	4	4	4	4	4	4	4	4	4	4	67	
			2	31OCT91	4	4	2	4	2	4	1	1	2	4	4	4	4	4	4	4	4	4	4	4	4	4	68	
11	6	VP	3	07NOV91	4	4	2	4	1	3	2	2	2	4	4	4	4	4	4	4	4	4	4	4	4	68		
			0	15OCT91	3	4	1	4	2	3	3	4	1	3	3	4	4	4	4	4	4	4	4	4	1	4	63	
			1	22OCT91	2	2	1	3	2	3	4	1	3	3	3	3	3	3	3	3	3	2	4	1	1	45		
			2	29OCT91	2	2	1	2	2	3	1	4	1	2	1	2	2	2	2	3	3	3	3	3	1	1	45	
			3	05NOV91	2	4	1	2	1	2	1	4	1	2	4	2	2	2	3	2	3	2	3	1	2	1	43	
			4	12NOV91	2	4	1	2	1	1	1	2	1	2	3	1	3	1	3	2	3	2	2	1	2	1	3	42
11	7	KK	5	19NOV91	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	34		
			6	26NOV91	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	34	
			0	23OCT91	4	4	4	4	4	4	1	3	4	1	2	4	3	4	2	1	4	3	2	1	4	3	63	
			1	30OCT91	4	4	4	4	4	4	1	4	4	1	1	4	4	2	4	1	1	4	1	1	4	1	2	57

(*) = Total score computed

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Patient No.	Centre No.	Initials	Visit	ZUNG	Date Performed	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (*)			
11	7	KK	2	06NOV91	4	4	4	4	4	4	4	4	4	4	4	4	1	4	3	4	4	1	4	1	1	1	59		
			3	13NOV91	4	4	4	4	4	4	4	4	4	4	4	4	4	4	1	4	4	4	4	1	4	1	1	55	
			4	20NOV91	4	4	4	4	4	4	4	4	4	4	4	4	4	4	1	4	4	4	4	1	4	1	1	50	
			5	27NOV91	4	4	4	4	4	4	4	4	4	4	4	4	4	4	1	4	4	4	4	1	4	1	1	47	
			6	04DEC91	3	4	4	4	4	4	4	4	4	4	4	4	4	4	1	4	4	4	4	1	4	1	1	49	
			0	10NOV91	2	4	4	4	4	4	4	4	4	4	4	4	4	4	1	4	3	4	4	2	4	2	2	49	
11	8	KF	1	17NOV91	2	3	4	2	3	4	2	2	2	2	2	3	1	2	2	3	3	2	2	2	2	2	40		
			2	24NOV91	3	3	3	4	2	3	4	2	2	2	2	2	2	2	2	2	4	3	2	3	3	3	3	50	
			3	01DEC91	2	1	2	3	4	3	2	3	2	2	2	2	2	2	2	2	3	3	2	3	3	3	3	50	
11	9	FI	0	11NOV91	3	2	4	4	3	4	1	3	3	3	3	3	3	4	3	3	3	4	4	4	3	4	65		
			1	18NOV91	3	2	4	4	4	4	4	4	4	3	3	3	3	3	4	3	3	3	4	4	4	3	3	64	
			2	25NOV91	3	3	4	4	4	4	4	4	4	4	4	4	4	4	3	3	3	3	4	3	3	3	3	64	
			3	02DEC91	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	4	3	3	3	3	3	4	3	62	
			4	09DEC91	3	3	3	4	4	4	4	4	4	4	4	4	4	4	3	3	3	3	3	3	3	3	3	3	59
			5	16DEC91	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	59
11	10	BJ	0	25NOV91	3	2	3	3	1	3	1	4	3	3	3	3	3	4	4	3	4	4	1	3	1	3	54		
			1	02DEC91	3	2	3	2	4	3	2	4	3	3	3	3	3	4	4	4	4	4	4	4	4	4	4	54	
			2	09DEC91	2	1	3	3	2	2	2	2	2	3	3	3	3	3	3	4	3	3	3	4	4	3	1	2	51
			3	16DEC91	2	1	2	2	2	2	2	2	2	3	3	3	3	3	3	4	3	2	4	4	4	3	1	3	49
			4	23DEC91	2	2	2	2	2	2	2	2	2	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	50
			5	30DEC91	2	2	2	2	2	2	2	2	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	49
11	11	NGY	0	05DEC91	4	4	2	4	2	4	3	3	1	4	3	3	4	4	2	2	4	4	4	4	4	3	63		
			1	12DEC91	1	3	3	4	2	4	3	3	3	3	3	3	4	4	4	4	3	4	2	4	4	2	2	56	
			2	19DEC91	2	3	3	3	2	4	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1	43	
			3	26DEC91	2	2	3	4	1	4	1	1	2	2	2	2	2	2	2	2	1	2	2	2	2	2	1	39	
			4	02JAN92	1	2	2	4	1	4	1	1	2	2	2	2	2	2	2	2	1	2	2	2	1	2	1	34	
			5	09JAN92	1	1	2	4	2	4	2	4	2	1	4	4	4	4	4	4	4	4	4	4	4	4	4	4	26
11	12	PJ	0	15DEC91	3	3	3	3	2	3	3	3	3	3	3	3	3	4	3	4	2	3	3	4	3	3	56		
			1	22DEC91	4	3	3	4	4	3	2	4	4	4	4	4	4	4	2	3	3	3	3	3	2	3	2	61	
			2	29DEC91	3	4	2	3	3	4	3	3	3	3	3	3	4	2	1	1	1	1	1	1	1	1	1	52	
			3	05JAN92	3	4	2	3	4	4	4	4	3	3	3	3	4	2	1	2	3	3	4	4	4	2	1	3	55
			4	12JAN92	2	4	2	3	3	4	2	4	3	3	3	3	4	3	2	2	3	2	4	3	2	2	2	1	52
			5	19JAN92	3	4	2	3	3	4	3	3	3	3	3	3	4	2	2	2	2	2	4	2	2	2	2	2	49
11			6	26JAN92	2	4	4	3	3	4	2	1	2	2	2	2	2	2	2	2	3	2	2	2	2	2	47		

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Date Performed	ZUNG																			Total Score (*)					
					IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19		IT.20				
11	13	GK	0	14JAN92	4	4	3	2	1	1	2	4	2	4	3	4	4	4	4	4	4	4	2	4	64				
			1	21JAN92	2	2	2	3	3	1	3	4	2	2	3	3	3	3	3	3	3	3	3	1	2	46			
			2	28JAN92	2	2	2	4	2	1	2	3	2	2	3	3	2	3	3	3	3	3	3	1	2	1	44		
			3	04FEB92	4	2	4	4	3	3	3	3	4	4	4	4	4	4	4	4	4	4	4	4	4	3	69		
			4	11FEB92	4	4	4	4	2	3	1	3	2	4	4	4	4	3	3	4	4	4	4	4	4	3	66		
			5	18FEB92	4	3	4	4	4	3	3	2	3	2	4	4	4	4	4	4	4	4	4	4	4	3	70		
11	14	BJ	6	25FEB92	4	3	4	4	3	3	2	3	2	2	4	4	4	4	4	4	4	4	4	3	65				
			0	19JAN92	4	2	3	3	3	4	3	2	2	3	3	4	4	4	4	4	4	4	3	2	1	4	61		
			1	26JAN92	3	1	3	4	1	4	3	2	2	3	3	3	4	4	4	4	4	4	4	2	1	4	53		
			2	02FEB92	2	2	1	2	2	4	1	2	1	2	2	2	1	2	3	2	2	2	2	2	1	1	2	38	
			3	09FEB92	3	2	3	1	1	4	2	2	3	3	3	4	4	4	3	4	4	4	4	3	1	3	54		
			4	16FEB92	4	3	4	4	4	4	4	3	2	4	3	4	3	4	3	4	3	4	3	4	2	4	69		
11	15	NF	0	28JAN92	3	4	3	4	2	3	2	4	2	4	2	3	3	2	2	2	2	1	3	1	3	52			
			1	04FEB92	2	3	2	3	1	3	2	3	3	3	3	3	3	3	1	1	2	1	2	1	1	1	41		
			2	11FEB92	3	4	2	3	4	3	4	3	3	2	3	2	3	2	2	1	2	1	3	1	4	1	2	52	
			3	18FEB92	2	4	2	2	2	1	1	4	2	4	1	2	2	1	1	2	1	1	2	1	1	2	1	44	
			4	25FEB92	2	3	2	4	1	4	2	2	2	2	2	2	2	2	4	2	1	2	1	2	1	3	43		
			5	03MAR92	4	4	3	4	2	3	2	3	3	3	4	4	4	3	3	3	3	1	3	1	3	1	3	59	
11	16	NA	6	09MAR92	4	3	4	3	3	3	1	3	4	4	3	3	4	4	4	4	4	3	3	4	1	3	64		
			0	02FEB92	4	3	4	3	4	4	4	3	4	4	4	4	4	4	4	4	4	4	4	4	3	4	75		
			1	09FEB92	4	3	4	2	3	4	4	2	2	3	3	4	4	4	4	4	4	4	4	4	1	3	63		
			2	16FEB92	4	3	4	3	4	4	4	3	4	3	4	4	4	4	4	4	4	4	4	4	3	4	70		
			3	23FEB92	4	3	4	4	4	4	4	3	4	3	3	4	4	4	4	4	4	4	4	4	2	3	68		
			4	01MAR92	4	3	4	4	3	4	4	3	2	4	3	4	4	4	4	4	4	4	4	4	3	3	65		
11	17	UZ	5	08MAR92	4	4	4	4	4	3	4	1	3	3	2	4	4	4	4	4	4	4	4	4	3	3	68		
			6	15MAR92	3	2	3	3	3	3	4	3	2	3	3	3	3	3	4	4	4	4	3	2	3	1	3	57	
			0	04FEB92	4	3	4	3	2	4	2	3	4	4	4	4	4	4	4	4	4	4	4	3	3	4	2	4	68
			1	13FEB92	3	2	3	2	3	4	2	2	4	4	3	3	3	3	3	4	3	3	4	3	2	3	59		
			2	20FEB92	2	3	3	2	1	4	1	3	2	4	3	1	3	2	4	4	3	1	1	1	1	1	3	45	
			3	27FEB92	2	4	3	2	2	2	1	2	2	2	4	2	2	2	4	2	1	1	2	1	1	1	2	44	
11	18	EI	4	05MAR92	3	3	3	2	2	2	1	3	3	2	2	3	2	3	2	2	3	2	2	3	1	2	46		
			5	12MAR92	3	3	3	2	2	2	2	3	2	2	3	3	2	3	3	2	2	3	2	2	3	1	2	49	
			6	19MAR92	3	4	4	4	4	2	2	1	1	2	3	3	3	2	4	4	4	4	2	3	1	2	54		
			0	09FEB92	4	4	3	2	3	4	3	2	4	4	3	4	4	4	4	4	4	4	3	2	3	2	3	63	
			1	16FEB92	2	2	3	2	3	2	2	1	2	1	2	3	4	3	2	2	4	3	2	2	1	3	43		
			2	23FEB92	3	3	3	2	3	3	2	2	2	3	3	3	2	3	2	3	2	2	3	1	3	1	3	50	
11	18	EI	3	01MAR92	3	4	4	3	3	3	3	4	2	2	2	4	2	2	1	2	1	2	1	2	2	53			

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REOXYTINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Patient No.	Initials	Visit	Date Performed	ZUNG																			Total Score (*)
				IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	
11	EI	4	09MAR92	3	3	3	2	3	2	3	4	3	3	4	4	2	3	3	3	1	3	2	58
		5	15MAR92	2	3	2	2	3	2	2	2	2	2	2	3	3	3	3	3	1	2	2	44
		6	22MAR92	3	3	3	3	3	2	2	3	2	2	2	3	3	3	3	3	1	1	1	44
		0	27FEB92	4	4	3	3	2	4	2	3	4	3	3	4	3	4	3	4	2	4	1	63
		1	05MAR92	3	3	4	3	4	2	3	3	3	3	3	3	4	3	4	3	3	3	1	60
		2	12MAR92	2	2	2	3	2	4	2	3	2	2	2	2	2	2	2	2	2	2	1	42
11	FK	3	19MAR92	2	3	3	2	2	2	2	2	1	1	3	2	1	2	2	1	3	2	40	
		4	26MAR92	1	2	2	4	1	4	1	2	2	2	2	2	1	2	1	1	1	1	1	36
		5	02APR92	3	3	3	2	2	2	2	2	2	1	3	2	2	2	2	1	2	2	2	41
		6	09APR92	3	3	3	2	2	2	1	1	2	2	1	2	2	2	2	1	2	1	2	35
		0	01MAR92	4	4	4	4	4	2	4	4	4	4	3	4	4	4	4	4	3	4	3	70
		1	08MAR92	3	3	3	4	4	4	2	3	4	3	3	4	4	4	4	4	4	2	4	68
12	LJ	2	15MAR92	4	4	3	4	3	3	3	3	3	4	4	3	3	3	3	4	4	1	65	
		3	22MAR92	3	4	3	3	3	1	2	3	2	4	1	3	3	3	3	3	3	1	3	53
		4	29MAR92	3	4	3	3	3	1	2	3	3	4	2	3	4	3	4	3	2	3	1	57
		5	05JUN92	4	4	4	4	2	1	2	3	3	4	4	3	4	3	4	3	2	3	1	57
		6	12APR92	4	4	4	4	4	2	3	3	3	3	4	3	3	3	3	3	2	3	1	62
		0	30OCT91	3	4	4	1	4	4	1	2	1	3	1	2	1	3	1	3	1	4	1	44
12	IB	1	06NOV91	3	4	2	4	4	1	4	1	2	1	1	3	1	3	1	4	1	4	41	
		2	13NOV91	2	3	2	3	4	3	1	3	2	2	2	3	2	3	2	3	1	3	45	
		3	10NOV91	2	4	2	1	4	2	1	2	2	3	1	4	2	3	2	3	1	3	47	
		4	27NOV91	2	4	2	1	4	2	1	1	2	3	1	3	1	3	1	3	1	3	40	
		5	04DEC91	1	3	1	3	3	1	1	2	3	1	3	1	3	1	3	2	3	1	3	42
		6	11DEC91	2	3	1	1	4	3	2	1	3	2	4	1	3	4	1	3	4	3	1	47
12	EFC	-1	04NOV91	4	4	4	2	3	3	3	4	1	1	4	1	4	1	1	1	2	4	54	
		1	11NOV91	4	2	4	4	2	3	3	4	1	3	1	3	1	3	1	1	2	3	53	
		2	18NOV91	4	4	4	4	3	3	4	3	3	1	2	4	3	4	1	1	2	2	3	58
		3	25NOV91	4	3	4	3	3	3	4	4	4	1	2	4	3	3	2	4	1	2	3	57
		4	02DEC91	4	3	4	3	3	3	4	4	4	1	2	4	3	3	2	1	1	3	1	57
		5	13DEC91	4	4	4	4	3	3	3	4	4	1	2	4	4	4	1	1	4	3	1	60
12	IF	6	16DEC91	3	4	4	4	3	3	3	4	4	1	2	4	2	3	4	1	2	3	58	
		0	29OCT91	3	4	2	3	1	1	1	2	2	1	1	3	2	3	1	1	2	1	2	37
		1	05NOV91	2	4	2	3	1	1	1	2	3	1	3	3	2	3	2	1	2	1	2	40
		2	12NOV91	3	3	2	4	2	1	1	1	2	1	2	3	2	3	1	1	2	1	1	37
		3	19NOV91	2	3	2	3	1	1	1	2	1	2	1	2	3	2	3	1	1	2	1	35
		4	26NOV91	2	2	1	1	1	1	1	1	2	1	2	2	2	2	2	2	2	1	2	31
5	03DEC91	2	3	2	3	1	2	1	1	2	2	2	3	1	1	2	3	1	2	2	36		

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Date Performed	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (*)	
12	3	IF	6	10DEC91	2	3	1	1	1	1	1	2	1	2	1	1	1	2	1	1	1	2	1	2	1	2	23
12	4	EG	0	05NOV91	2	3	2	3	2	2	2	2	4	1	1	1	2	2	4	1	1	2	3	2	3	46	
			1	11NOV91	1	2	2	2	3	4	1	2	1	1	2	1	1	2	2	3	3	1	2	3	2	37	
			2	18NOV91	2	2	2	3	4	4	2	2	1	1	3	1	3	3	3	3	2	2	3	2	2	50	
			3	25NOV91	3	3	2	2	3	4	2	1	1	1	3	1	2	3	2	4	2	3	3	2	2	48	
			4	02DEC91	2	2	2	2	3	2	1	1	2	1	3	1	1	2	2	3	1	2	3	2	2	41	
			5	08DEC91	2	2	2	2	3	2	1	1	2	1	3	1	2	2	2	3	2	2	3	2	2	42	
			6	16DEC91	3	3	2	3	4	1	2	1	2	1	2	1	2	3	3	4	2	3	3	2	2	47	
12	5	ZSH	0	04NOV91	3	3	2	3	3	2	3	1	2	1	2	1	3	4	4	3	4	3	4	1	4	56	
			1	11NOV91	3	2	1	1	1	1	1	2	3	1	3	3	3	3	2	3	2	3	3	2	2	46	
			2	18NOV91	2	2	1	1	1	1	1	1	1	1	2	1	3	2	4	2	3	3	4	1	2	39	
			3	25NOV91	1	2	2	1	1	1	1	2	1	1	2	1	3	2	1	3	1	3	2	3	1	1	32
			4	02DEC91	1	4	1	1	1	1	1	1	1	1	1	1	3	1	3	2	2	3	3	1	1	34	
			5	09DEC91	2	4	1	1	1	1	1	1	1	1	2	1	3	2	2	2	2	3	3	1	1	36	
			6	16DEC91	1	4	1	1	1	1	1	2	1	2	2	1	2	1	2	1	2	3	2	3	1	1	32
12	6	MK	0	01NOV91	4	1	3	3	4	3	1	2	3	3	3	2	3	3	3	3	3	3	4	3	3	57	
			1	08NOV91	3	2	2	2	2	2	2	2	2	2	3	3	3	3	2	3	2	3	2	2	2	54	
			2	15NOV91	2	2	2	2	2	2	2	2	2	2	3	2	3	3	2	3	3	3	3	2	3	50	
			3	22NOV91	2	2	3	2	3	2	2	2	3	2	3	2	3	4	2	4	3	2	3	1	3	50	
			4	29NOV91	2	2	3	1	3	2	2	2	2	3	3	2	3	3	2	4	3	2	3	2	3	50	
			5	06DEC91	2	3	3	4	3	2	2	3	2	3	3	3	3	3	2	3	2	3	2	2	3	54	
			6	12DEC91	2	1	3	1	2	2	2	2	2	2	3	3	3	3	1	3	3	3	2	3	2	46	
12	7	LK	0	10FEB91	3	3	2	3	3	1	1	1	3	2	1	2	3	3	2	2	2	2	2	3	1	2	43
			1	11OCT91	2	3	1	2	1	1	1	2	2	1	2	2	1	2	3	2	2	2	2	1	2	35	
			2	18NOV91	2	3	1	2	1	1	1	2	2	1	2	1	2	3	2	2	2	1	2	1	2	34	
			3	25NOV91	3	3	2	3	1	2	1	1	3	3	3	1	2	3	2	2	2	2	2	1	1	40	
			4	02DEC91	3	3	1	2	4	1	1	1	2	3	2	1	3	1	2	1	2	1	2	1	2	37	
			5	09DEC91	2	3	1	2	1	1	1	2	3	2	3	1	2	3	1	2	1	2	2	1	2	35	
			6	16DEC91	2	3	1	2	1	1	1	1	1	1	3	1	2	3	2	2	2	2	2	2	1	2	33
12	8	FH	0	31OCT91	4	4	3	3	1	3	1	3	3	3	3	3	3	4	2	4	3	3	3	4	3	60	
			1	07NOV91	3	4	3	3	1	3	1	3	3	3	3	3	3	4	2	4	3	3	3	4	3	59	
			2	14NOV91	4	4	3	4	2	3	1	3	3	3	3	3	3	4	3	4	3	3	3	4	3	63	
			3	21NOV91	4	4	3	3	1	3	1	3	3	3	3	3	3	3	4	3	4	3	3	4	3	61	
			4	28NOV91	4	3	4	4	1	3	1	3	3	3	3	2	2	4	3	4	3	3	3	2	4	58	
			5	05DEC91	4	4	4	4	4	3	4	1	3	3	3	2	2	3	2	4	3	3	3	2	3	59	
			6	12DEC91	4	3	4	4	4	3	4	1	4	1	4	2	3	3	4	3	4	3	3	3	2	4	65

(*) = Total score computed

9550077

PHARMACIA CMS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Patient Centre No.	Initials	Visit	Date Performed	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (*)					
12	9	KBP	0	30OCT91	4	2	3	4	3	3	3	3	2	3	3	3	3	3	3	4	3	3	4	2	3	61				
			1	06NOV91	4	2	3	2	2	3	3	3	3	2	3	3	3	3	3	3	4	3	3	4	2	3	57			
			2	13NOV91	4	1	3	3	3	3	3	3	3	3	2	2	3	3	3	3	3	4	3	3	4	2	3	58		
			3	20NOV91	3	2	3	3	3	3	3	3	3	3	2	3	3	3	3	3	3	4	3	3	4	2	3	57		
			4	27NOV91	3	2	3	3	3	3	3	3	3	3	2	3	3	3	3	3	3	3	3	3	4	2	3	57		
			5	04DEC91	3	2	3	3	3	3	3	3	3	3	2	3	3	3	3	3	3	3	3	3	4	2	3	57		
12	10	IP	6	11DEC91	3	2	3	2	2	2	2	2	2	2	3	3	3	3	3	3	3	3	3	3	1	3	51			
			0	04NOV91	4	4	4	4	4	3	3	3	1	3	3	3	1	4	1	4	3	4	4	4	1	4	63			
			1	11NOV91	2	4	4	4	4	4	3	3	3	2	1	2	1	4	4	4	4	4	4	4	2	3	65			
			2	18NOV91	4	4	4	4	4	3	3	3	3	2	1	2	1	4	4	4	4	4	4	4	2	3	64			
			3	25NOV91	1	4	2	2	2	4	2	2	1	2	1	2	1	3	2	3	2	3	2	3	2	4	1	3	46	
			4	02DEC91	2	3	1	1	3	4	4	2	2	1	3	1	3	1	3	4	3	3	3	3	1	3	1	3	49	
12	11	ER	5	09DEC91	3	4	2	2	4	4	2	3	1	2	1	3	4	3	3	3	3	3	4	1	3	55				
			6	16DEC91	2	4	2	2	4	2	2	1	2	1	2	1	3	2	3	3	3	3	3	3	1	2	49			
			0	30OCT91	3	4	4	4	4	3	3	4	1	3	3	3	3	4	1	3	4	3	4	1	3	1	2	58		
			1	06NOV91	3	4	3	4	4	3	3	4	1	3	3	3	3	3	3	4	3	4	3	3	1	2	57			
			2	13NOV91	3	2	3	3	3	3	3	4	2	3	3	3	3	3	3	3	3	3	2	1	3	1	2	50		
			3	20NOV91	2	3	4	3	4	4	4	4	1	3	3	3	3	3	3	3	3	3	3	2	2	2	54			
12	12	FSZ	4	27NOV91	2	3	3	2	3	3	3	3	4	1	2	1	2	3	2	3	3	2	1	3	1	2	46			
			5	04DEC91	2	3	3	2	2	2	3	3	4	1	2	1	2	2	2	3	3	3	2	1	3	1	2	45		
			6	11DEC91	3	3	3	3	4	4	3	4	1	2	1	2	1	2	3	3	3	3	2	1	3	1	2	51		
			-1	03NOV91	4	4	3	3	2	4	2	2	3	4	2	3	4	2	3	3	4	4	2	3	4	3	3	62		
			1	11NOV91	4	4	3	3	2	4	2	2	3	3	2	3	3	3	3	4	4	4	3	3	4	3	3	62		
			2	18NOV91	4	3	4	3	2	4	2	4	3	4	3	4	4	4	4	4	4	4	4	4	4	3	3	68		
12	13	ISZ	3	25NOV91	4	3	4	3	2	4	2	3	3	3	3	3	3	3	4	3	3	4	3	3	3	3	63			
			4	02DEC91	4	3	4	3	4	2	2	3	3	3	3	3	3	3	4	4	4	4	3	4	4	3	64			
			5	09DEC91	4	4	4	4	4	2	2	3	3	3	2	4	4	4	4	4	4	4	4	4	4	4	4	69		
			6	16DEC91	4	4	4	4	4	2	4	2	1	3	2	4	4	4	4	4	4	4	4	4	4	4	4	65		
			0	03NOV91	3	4	3	3	3	3	3	3	3	3	3	3	3	1	4	4	3	3	3	3	3	2	3	60		
			2	18NOV91	3	3	4	2	3	4	2	3	3	3	2	4	2	3	3	3	3	3	3	3	1	3	2	57		
12	14	GSZ	3	25NOV91	2	3	4	3	3	2	4	3	4	1	3	4	1	3	4	1	4	3	1	3	1	2	52			
			4	01DEC91	1	2	3	4	3	3	2	4	3	4	1	3	4	1	3	4	1	4	3	2	3	4	3	55		
			5	09DEC91	2	2	3	3	2	3	3	3	1	3	4	1	3	3	1	3	3	3	3	2	3	4	1	3	52	
			6	16DEC91	3	3	3	2	3	3	2	4	3	3	1	3	3	1	3	3	1	3	3	3	2	3	4	1	3	52
			0	05NOV91	3	3	3	2	4	4	1	2	2	3	3	4	3	3	3	3	3	4	3	3	4	2	3	56		
			1	12NOV91	3	3	3	2	4	3	1	2	3	3	3	3	3	2	2	3	3	3	3	3	4	2	3	55		

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Lasting No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit	Data Performed	ZUNG																				Total Score (*)		
					IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20			
12	14	GSZ	2	19NOV91	2	1	3	2	1	3	1	2	3	3	2	2	2	3	3	3	2	3	3	1	3	44	
			3	26NOV91	3	1	3	4	2	3	3	2	2	3	3	2	2	3	3	3	2	3	3	1	3	48	
			4	03DEC91	3	3	4	3	2	2	3	3	2	2	3	3	3	4	3	2	3	2	3	2	3	55	
			5	10DEC91	3	3	3	2	2	2	2	3	2	2	2	2	2	4	2	2	2	2	2	2	2	47	
			6	17DEC91	3	3	4	2	3	3	2	2	3	2	2	3	3	4	3	2	2	3	2	3	2	3	55
			0	26NOV91	3	3	1	3	3	1	2	1	2	1	2	1	3	1	4	4	3	3	3	1	3	49	
12	15	GB	1	02DEC91	2	3	2	3	1	2	2	1	2	1	2	1	2	2	2	3	3	3	4	1	42		
			2	09DEC91	3	3	2	3	3	1	2	1	1	1	1	1	3	2	3	3	3	3	1	1	39		
			3	16DEC91	3	3	2	3	3	1	2	1	1	1	1	1	3	2	3	3	3	3	1	1	41		
			4	23DEC91	3	3	2	3	2	2	1	1	1	1	1	1	3	2	1	4	2	3	3	3	1	43	
			5	30DEC91	3	3	2	4	1	1	1	1	1	1	1	1	1	1	4	3	3	4	4	1	4	45	
			6	06JAN92	2	2	2	4	1	1	2	2	2	1	2	2	2	1	4	3	3	4	3	1	4	44	
12	16	FN	-1	10DEC91	3	4	4	2	4	4	2	2	2	2	2	3	3	4	2	3	4	4	2	4	60		
			1	17OCT91	2	3	4	2	2	1	3	2	2	1	2	2	3	3	2	2	2	2	4	1	3	46	
			2	24DEC91	1	4	2	1	4	4	2	2	1	4	3	1	4	2	2	3	4	4	4	2	4	54	
			3	31DEC91	2	4	2	1	2	2	1	2	2	1	2	2	4	2	2	2	2	3	1	2	2	43	
			4	07JAN92	2	4	1	1	2	3	1	1	1	2	2	4	2	4	2	4	3	4	2	4	2	4	50
			5	14JAN92	2	4	3	2	4	3	1	1	1	2	2	4	2	4	1	4	4	3	2	4	2	4	49
12	17	TK	2	21JAN92	2	4	4	2	4	3	1	3	2	2	2	4	2	1	4	3	4	4	1	3	53		
			0	14JAN92	4	1	4	4	3	4	2	2	4	2	4	3	4	3	4	3	3	3	4	3	61		
			1	21JAN92	3	3	3	3	3	1	2	4	3	3	3	4	4	4	3	3	4	2	3	4	2	62	
			2	28JAN92	2	3	2	2	4	3	2	3	3	3	3	3	4	3	4	3	3	3	2	3	1	53	
			3	04FEB92	2	2	2	2	4	3	3	2	4	3	2	4	3	4	3	4	3	3	2	3	2	3	56
			4	11FEB92	2	3	3	2	4	3	3	1	3	3	2	4	3	4	3	4	3	2	2	2	2	3	53
12	18	LS	5	18FEB92	2	2	3	2	2	4	2	2	1	2	3	3	3	4	3	3	3	2	3	2	3	51	
			6	25FEB92	2	2	3	2	2	4	2	2	2	3	2	3	3	4	3	4	3	3	3	2	3	53	
			0	14JAN92	3	2	2	3	4	4	3	3	2	4	1	2	4	3	3	2	1	3	2	1	3	54	
			1	21JAN92	3	3	4	4	3	3	2	4	1	2	4	3	3	3	3	2	3	1	3	1	3	55	
			2	28JAN92	3	2	3	3	3	3	2	2	3	1	2	2	2	2	2	2	1	3	1	2	3	43	
			3	04FEB92	2	3	2	3	3	2	2	3	1	1	2	2	2	3	2	2	2	2	1	3	1	2	45
12	19	SSZ	4	11FEB92	2	2	2	3	3	2	2	1	3	1	2	2	2	3	2	1	2	1	2	1	2	43	
			5	18FEB92	2	2	2	3	3	2	2	3	1	2	2	2	2	2	2	1	2	1	2	1	2	39	
			6	25FEB92	2	2	2	3	3	2	2	3	1	1	2	1	2	1	2	1	1	1	2	1	2	2	38
			0	15JAN92	3	3	2	4	3	2	2	4	2	2	4	4	4	4	2	4	4	4	4	4	4	4	61
			1	22JAN92	2	2	2	3	3	1	1	2	2	1	3	2	3	3	3	3	3	3	3	3	3	3	48
			2	29JAN92	3	2	2	2	4	3	1	1	2	2	1	3	2	4	2	4	3	3	3	3	3	3	50
12	19	SSZ	3	05FEB92	4	2	2	2	4	3	1	1	2	2	2	3	4	3	3	4	4	4	4	4	54		

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CIS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centers	Patient No.	Initials	Visit	Date Performed	ZUNG																			Total Score (*)			
					IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19		IT.20		
12	19	SSZ	4	12FEB92	2	1	2	2	1	3	4	1	2	3	1	3	3	3	4	4	2	4	54				
			5	19FEB92	3	1	2	4	1	2	2	1	3	3	4	3	3	4	4	4	2	3	51				
			6	26FEB92	2	1	2	2	2	1	1	1	3	2	4	3	3	3	3	3	4	2	3	45			
			12	20	KSZ	0	16JAN92	4	4	3	3	3	1	1	3	2	1	3	4	4	3	4	4	1	3	56	
						1	23JAN92	3	3	3	1	1	1	2	1	3	3	3	4	3	4	3	2	3	4	3	49
						2	30JAN92	3	3	3	4	1	1	1	2	1	2	3	4	4	3	4	3	2	2	4	44
12	21	FL	0	06FEB92	3	3	1	4	2	3	1	2	3	3	1	1	2	2	3	1	1	2	41				
			1	13FEB92	2	3	1	2	2	3	1	2	3	1	1	2	1	3	1	1	1	1	1	40			
			2	20FEB92	2	3	1	2	3	1	1	2	3	1	1	2	1	2	1	1	1	2	1	34			
			3	27FEB92	3	3	3	1	3	1	1	2	3	1	1	2	1	2	1	1	1	1	1	2	33		
			4	05MAR92	2	4	2	2	1	3	1	1	2	3	1	1	3	2	3	1	1	3	1	42			
			5	12MAR92	2	4	2	2	1	3	1	1	2	3	1	1	3	1	3	1	1	1	1	2	36		
12	22	MV	0	27JAN92	3	2	3	3	4	2	3	2	2	2	2	2	3	2	4	2	1	1	46				
			1	03FEB92	3	2	4	3	3	4	2	3	2	2	2	2	3	1	4	2	1	1	47				
			2	10FEB92	3	3	3	3	4	2	3	2	3	2	2	2	3	2	3	2	2	2	2	51			
			3	17FEB92	2	3	3	2	3	4	3	3	2	2	2	2	3	2	2	2	2	1	1	47			
			4	24FEB92	3	3	3	2	2	4	2	4	3	1	2	2	2	3	2	2	2	1	2	46			
			5	02MAR92	2	3	3	2	2	2	2	4	2	3	1	2	2	3	2	3	2	2	2	46			
12	23	EN	0	06FEB92	4	4	3	4	3	4	4	3	3	2	2	4	4	4	4	3	3	4	67				
			1	13FEB92	4	3	3	1	3	4	4	2	3	4	2	2	3	4	4	4	4	3	4	67			
			2	20FEB92	4	3	3	1	3	4	4	2	3	3	2	3	4	4	4	4	4	4	4	66			
			3	27FEB92	4	3	3	1	3	4	4	4	3	3	2	3	4	4	4	4	3	4	4	66			
			4	05MAR92	3	3	2	1	3	2	3	2	3	2	2	1	4	2	1	4	2	3	4	47			
			5	12MAR92	2	3	3	3	3	3	3	3	2	3	2	3	3	4	4	3	4	2	3	51			
12	24	HF	0	07FEB92	4	4	3	4	4	4	4	3	3	4	3	3	4	3	4	3	4	4	71				
			1	14FEB92	4	4	3	3	4	4	2	4	3	3	3	3	3	3	3	3	3	3	3	66			
			2	21FEB92	3	4	2	3	4	4	1	3	2	3	3	3	3	3	3	3	3	1	3	56			
			3	28FEB92	1	4	1	1	2	4	1	2	4	1	2	2	2	2	2	2	2	2	1	2	39		
			4	06MAR92	1	4	1	2	2	4	1	1	2	3	2	2	1	2	1	2	2	3	1	2	39		
			5	13MAR92	1	4	1	3	2	4	1	1	3	2	2	2	2	2	2	2	2	2	1	2	43		

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Date Performed	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (*)	
12	24	MF	6	20MAR92	2	4	3	2	2	4	1	2	4	1	2	3	1	1	2	1	4	1	2	1	1	1	40
12	25	FS	0	10FEB92	4	4	1	4	4	2	4	2	4	2	4	3	3	4	4	3	4	4	4	3	4	4	69
			1	17FEB92	4	4	2	4	3	4	2	4	2	4	3	4	3	4	4	4	4	4	4	3	3	4	71
			2	24FEB92	4	4	2	4	3	4	2	4	2	4	3	3	4	4	4	4	4	4	3	3	3	4	68
			3	02MAR92	3	4	2	4	2	3	2	3	2	3	2	3	3	3	3	3	4	3	3	3	3	3	57
			4	09MAR92	3	4	2	4	4	2	3	2	3	2	3	2	3	2	2	1	2	3	3	3	2	3	59
			5	16MAR92	3	4	2	4	4	2	2	3	2	3	3	3	4	4	3	4	3	3	3	2	3	3	54
			6	23MAR92	4	3	3	3	2	4	3	2	3	2	3	3	3	4	3	4	3	2	2	3	2	3	61
12	26	LB	0	05FEB92	4	3	3	4	3	4	3	2	4	3	4	3	4	4	4	4	4	4	4	4	4	4	72
			1	11FEB92	3	3	4	4	3	3	2	1	4	2	3	4	2	3	4	3	3	3	4	4	3	3	62
			2	18FEB92	3	3	3	3	3	3	3	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	57
			3	25FEB92	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	58
			4	03MAR92	3	4	3	3	4	2	3	2	3	2	3	3	3	3	3	4	3	3	4	3	3	3	61
			5	10MAR92	3	3	3	3	3	3	2	2	3	2	3	3	3	3	3	4	3	3	4	3	3	3	62
			6	17MAR92	4	3	3	4	2	3	2	3	3	3	4	3	3	4	3	4	3	3	4	3	3	3	64
12	27	VCS	0	07FEB92	3	3	2	2	3	4	3	3	1	1	3	2	2	2	4	3	3	3	3	3	2	2	53
			1	14FEB92	3	3	3	3	2	3	2	3	2	3	2	3	2	3	2	3	4	3	4	4	3	2	55
			2	21FEB92	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	4	3	3	4	4	3	2	56
			3	28FEB92	3	3	3	3	2	3	2	2	3	2	2	3	2	3	2	3	3	3	4	4	4	2	55
			4	06MAR92	3	3	3	2	2	4	2	3	3	2	2	3	2	3	2	4	3	3	4	4	4	2	58
			5	13MAR92	3	3	3	2	2	4	2	3	3	2	2	3	2	3	2	4	3	3	4	4	4	2	58
			6	20MAR92	3	2	3	2	2	4	2	3	3	2	2	3	2	3	3	3	3	3	3	3	3	1	52
12	28	IV	0	07FEB92	4	2	3	4	4	3	4	1	3	4	2	4	2	2	4	3	4	2	3	3	2	2	59
			1	14FEB92	2	2	3	3	3	3	4	1	3	4	2	3	4	1	1	1	1	1	1	1	1	2	45
			2	21FEB92	3	3	3	4	3	4	1	2	1	2	1	2	3	4	4	2	4	1	2	1	1	2	48
			3	28FEB92	3	3	3	4	4	3	4	1	4	4	3	4	3	4	3	1	1	2	1	2	1	2	57
			4	06MAR92	3	3	3	3	3	3	2	2	3	2	2	3	2	4	2	4	2	2	2	2	1	2	51
			5	13MAR92	3	3	3	3	4	3	3	2	3	3	3	3	3	4	3	3	3	3	3	2	1	3	55
			6	20MAR92	3	3	3	3	3	3	4	2	3	4	2	3	4	2	4	3	3	3	3	3	3	3	59
12	29	AK	0	10FEB92	4	3	4	4	3	4	2	2	4	2	3	3	3	4	4	4	3	3	4	1	3	3	63
			1	17FEB92	4	4	3	4	4	1	1	1	2	4	2	4	2	3	4	4	4	3	3	4	1	4	51
			2	24FEB92	4	3	2	3	4	2	1	3	3	2	3	3	2	2	3	2	4	3	3	4	1	3	55
			3	02MAR92	3	2	3	1	2	4	1	1	3	3	2	3	2	3	3	4	3	3	3	3	1	3	51
			4	09MAR92	2	2	2	2	4	1	1	2	2	2	2	2	2	3	3	2	2	2	2	3	1	2	42
			5	16MAR92	3	3	2	1	2	4	1	2	2	2	2	2	2	3	2	3	3	2	2	3	1	3	46
			6	23MAR92	3	2	2	1	2	4	1	1	1	1	2	2	2	3	2	2	3	2	2	3	1	3	42

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Date Performed	ZUNG																				Total Score (*)				
					IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20					
12	30	FS	0	24FEB92	4	3	4	4	2	1	4	2	2	3	3	3	4	3	4	3	1	3	1	3	1	3	58		
			1	02MAR92	4	4	4	4	2	2	3	3	3	2	2	3	3	4	3	4	3	1	3	1	3	1	3	58	
			2	09MAR92	3	3	3	3	2	2	3	2	2	2	2	3	2	3	3	3	3	1	3	1	3	1	3	47	
			3	16MAR92	4	3	4	2	2	2	3	2	2	3	4	3	3	4	3	3	3	1	3	1	3	1	3	52	
			4	23MAR92	3	3	4	2	2	2	3	2	2	3	4	3	3	3	3	3	3	1	3	1	3	1	3	51	
12	31	FM	5	30MAR92	3	3	3	2	1	2	2	3	3	2	2	3	3	3	3	3	1	3	1	3	1	3	49		
			0	26MAR92	3	3	2	4	3	1	1	3	3	3	2	1	4	3	3	3	3	3	3	3	3	2	3	53	
			1	31MAR92	3	3	2	4	3	1	3	3	3	2	1	4	1	4	3	3	3	3	3	3	3	4	3	56	
			2	07APR92	3	3	2	4	3	1	3	4	3	2	1	4	1	4	3	3	3	3	3	3	3	4	3	56	
			3	14APR92	3	3	2	4	3	1	3	4	3	2	1	4	1	4	3	3	3	3	3	3	3	4	3	57	
			4	21APR92	3	3	2	4	3	1	3	4	4	3	2	2	4	1	4	3	3	3	3	3	3	4	3	59	
12	32	LM	5	28APR92	3	3	2	4	3	1	3	4	4	3	2	2	4	3	3	3	3	3	3	4	3	61			
			6	05MAY92	4	3	2	4	3	1	3	4	4	3	2	3	4	1	4	3	3	3	3	3	4	3	62		
			0	01APR92	3	4	2	3	3	3	3	3	4	2	3	4	3	3	3	3	3	4	3	3	3	3	4	61	
			1	08APR92	3	3	1	2	3	3	1	3	2	3	1	3	1	3	1	3	1	2	2	2	1	2	1	2	59
			2	15APR92	3	3	1	2	3	3	2	3	4	3	2	3	1	3	2	3	2	2	1	2	2	1	2	2	43
			3	22APR92	3	3	1	2	3	1	3	2	2	1	2	2	3	2	3	2	2	1	3	1	3	1	1	2	48
12	33	LN	4	29APR92	3	3	1	2	3	3	1	3	2	4	2	2	2	4	1	2	1	2	1	1	1	1	43		
			5	06MAY92	3	3	1	2	3	3	2	3	2	2	2	2	4	2	2	2	2	1	2	1	1	1	1	43	
			6	13MAY92	3	3	1	2	3	3	1	3	2	1	2	2	2	4	2	2	2	1	2	1	1	1	1	41	
			0	01APR92	4	3	4	2	2	4	1	1	2	2	3	3	3	3	3	3	4	2	4	1	4	1	3	54	
			1	08APR92	3	2	4	2	2	4	1	1	1	2	3	3	4	3	4	3	4	3	2	4	1	4	1	54	
			2	15APR92	3	2	3	1	3	4	1	1	2	3	3	3	3	4	3	4	3	2	4	1	3	1	3	52	
12	34	TGB	3	22APR92	3	2	4	3	3	3	1	1	3	4	2	3	3	3	3	3	3	1	3	1	3	1	53		
			4	29APR92	3	2	4	1	3	4	1	1	3	3	3	3	3	3	3	3	3	1	3	1	3	1	51		
			5	06MAY92	2	2	4	3	2	4	1	1	2	3	3	3	3	4	3	3	3	1	4	1	3	1	3	53	
			6	13MAY92	2	2	4	2	4	1	1	3	3	3	3	3	3	3	3	3	3	1	4	2	3	1	3	52	
			0	27MAR92	3	3	3	3	4	3	3	3	2	4	1	4	3	4	3	4	4	3	3	3	3	3	3	63	
			1	03APR92	3	4	3	4	3	3	3	2	4	2	4	3	3	3	3	4	4	4	3	4	3	3	3	62	
12	35	LP	2	10APR92	2	3	4	3	3	3	3	3	3	1	4	3	3	4	4	3	3	3	3	2	3	2	55		
			3	17APR92	2	2	4	2	3	3	3	1	3	1	4	3	3	4	3	4	3	3	3	3	3	2	3	57	
			4	23APR92	2	2	1	3	3	3	2	1	3	1	4	3	2	3	3	3	3	2	3	1	3	1	3	44	
			5	01MAY92	2	2	1	4	2	3	3	2	1	3	1	3	2	2	3	3	3	2	2	1	3	2	1	3	45
			6	08MAY92	2	2	1	4	3	3	3	1	2	1	2	2	2	3	3	3	3	2	2	3	2	3	1	3	45
			0	27MAR92	2	2	3	2	1	2	1	2	3	3	3	3	4	2	3	4	2	3	2	3	2	3	2	47	
12	36	LP	1	03APR92	3	4	3	3	1	2	2	3	3	3	3	4	3	3	3	3	3	3	3	3	3	2	54		
			2	10APR92	3	3	3	3	1	2	2	2	2	3	4	3	3	3	3	3	3	3	3	3	4	2	2	53	

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Date Performed	Date Performed																				Total Score (*)				
					IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20					
12	35	LP	3	17APR92	3	3	4	3	2	1	1	2	2	3	3	2	3	1	2	3	3	3	4	2	3	50			
			4	23APR92	3	1	3	3	1	2	1	1	2	4	3	2	3	3	2	3	3	3	3	3	2	2	47		
			5	01MAY92	3	1	3	3	1	2	1	1	2	4	3	3	3	2	2	3	3	3	2	2	2	2	43		
			6	08MAY92	2	3	3	4	1	1	2	1	2	3	3	2	3	3	3	3	3	3	3	3	3	2	2	49	
			0	30MAR92	4	4	4	3	2	2	2	3	4	4	4	4	4	4	4	4	4	4	4	4	4	1	3	62	
			1	06APR92	4	3	4	3	4	2	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	1	3	62	
12	36	FB	2	13APR92	4	4	3	4	3	2	3	2	3	4	4	4	4	4	4	4	4	4	4	4	1	3	60		
			3	20APR92	3	4	3	3	2	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	3	1	3	59	
			4	27APR92	3	4	4	3	2	3	1	2	3	4	4	4	4	4	4	4	4	4	4	4	3	1	3	55	
			5	05MAY92	3	3	3	3	3	3	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	1	3	56	
			6	11MAY92	3	4	3	3	2	3	2	3	3	4	4	4	4	4	4	4	4	4	4	4	4	1	3	57	
			0	03APR92	4	2	4	3	3	4	1	3	3	1	1	4	3	4	1	1	3	4	1	1	3	1	2	51	
12	37	EK	1	10APR92	3	2	1	1	1	3	2	4	2	3	1	4	2	3	4	1	2	1	4	3	2	3	43		
			2	17APR92	2	2	3	2	1	4	1	3	3	1	1	3	1	4	1	3	3	3	1	3	3	3	1	45	
			3	24APR92	3	3	3	1	2	4	2	3	3	4	4	4	4	4	4	4	4	4	2	1	2	3	2	51	
			4	01MAY92	2	1	3	2	1	4	1	1	2	2	2	1	1	3	3	4	4	1	1	1	3	4	1	41	
			5	08MAY92	4	2	3	3	2	4	1	3	3	1	1	3	3	4	4	1	1	1	1	3	1	2	2	48	
			6	15MAY92	4	4	4	3	1	2	2	4	2	3	3	3	3	4	2	2	2	2	2	2	2	1	2	51	
12	38	FG	0	06APR92	3	2	3	3	2	3	2	2	3	3	3	3	3	3	4	4	3	3	3	4	2	44			
			1	13APR92	3	3	3	3	1	4	2	3	3	3	3	3	3	3	3	3	3	3	1	3	4	3	53		
			2	20APR92	3	4	4	4	3	3	3	3	3	2	4	4	4	4	4	4	4	4	3	3	3	3	3	61	
			3	27APR92	4	2	4	3	3	3	3	2	3	4	3	2	4	3	2	2	3	3	2	2	3	3	2	56	
			4	04MAY92	3	4	4	3	1	1	4	2	3	3	1	1	4	4	4	4	4	4	2	2	3	4	3	54	
			5	11MAY92	3	1	3	4	3	3	4	2	4	4	4	4	4	4	4	4	4	4	2	1	3	4	4	55	
13	1	PZ	0	15OCT91	4	4	3	2	4	4	4	2	3	4	2	3	4	3	4	3	1	3	2	4	3	61			
			1	22OCT91	3	3	2	3	3	3	2	1	3	1	1	3	1	1	3	1	1	1	3	1	3	1	43		
			2	29OCT91	2	4	2	1	3	3	2	1	2	2	1	4	2	1	4	2	1	1	3	1	1	1	1	40	
			3	05NOV91	2	3	2	2	3	3	1	2	2	1	2	2	1	3	2	1	3	2	1	3	1	2	2	41	
			4	12NOV91	2	3	2	2	3	3	2	2	1	1	1	1	2	1	3	2	1	3	1	2	1	2	2	41	
			5	19NOV91	2	3	2	2	3	3	2	2	1	1	1	1	2	1	2	1	1	2	1	2	1	2	1	37	
13	2	TCS	0	16OCT91	3	4	4	3	2	3	2	2	1	4	4	4	4	4	4	4	4	4	4	4	3	4	69		
			1	22OCT91	3	4	4	3	3	4	4	2	3	3	1	3	4	4	3	4	3	4	3	4	4	3	4	65	
			2	30OCT91	3	3	4	4	2	3	3	2	3	3	2	3	3	4	3	3	4	3	4	3	4	3	3	61	
			3	06NOV91	3	4	3	2	3	3	2	3	3	1	3	3	3	3	3	3	3	3	3	4	2	3	2	57	
			4	13NOV91	3	4	4	4	3	3	4	2	2	3	4	2	4	4	4	4	4	4	4	4	4	4	3	4	66
			5	20NOV91	3	4	4	3	3	3	4	2	2	3	4	2	4	4	4	4	4	4	4	4	4	4	4	4	66

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REMEXIME - PROTOCOL 2012A/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit	Date Performed	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (x)			
13	2	TCS	5	19NOV92	2	3	2	2	2	2	3	2	4	3	2	1	2	3	3	3	3	3	4	2	2	4	57		
			6	27NOV91	2	3	2	2	2	2	2	4	3	3	3	3	3	3	1	2	3	3	3	3	4	2	3	54	
13	3	AI	0	15OCT91	4	2	4	4	4	3	2	2	2	2	3	3	3	3	3	3	4	3	4	3	3	4	64		
			1	22OCT91	2	3	4	3	2	2	1	2	2	2	2	2	2	2	2	2	2	2	3	2	3	2	2	49	
			2	30OCT91	2	3	3	2	2	2	2	1	2	1	2	2	2	2	2	2	2	2	2	2	3	2	2	2	43
			3	05NOV91	2	3	2	1	1	1	1	1	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	1	37
			4	12NOV91	1	2	2	1	2	1	1	1	2	1	1	1	2	1	1	1	1	1	2	2	2	1	1	1	28
			5	19NOV91	1	1	2	1	1	1	1	1	2	1	2	1	2	1	1	2	2	2	2	4	2	1	1	1	29
13	4	SZJ	6	26NOV91	1	2	1	1	1	1	1	1	1	1	1	1	1	2	2	2	2	1	1	2	1	1	1	24	
			0	15OCT91	4	4	4	4	4	4	2	3	4	3	4	4	4	3	4	4	4	4	4	1	4	2	3	65	
			1	22OCT91	3	3	3	3	3	3	2	3	3	1	2	3	2	2	2	2	2	2	2	2	2	2	2	2	56
			2	29OCT91	2	3	3	4	4	3	1	2	3	4	1	1	4	1	1	1	4	2	4	2	4	2	2	2	53
			3	05NOV91	3	3	3	2	2	2	2	3	3	2	2	2	3	3	2	3	3	3	4	3	3	3	3	3	54
			4	12NOV91	4	4	4	4	4	4	3	2	4	3	4	1	1	4	1	1	4	4	4	1	1	4	2	3	57
13	5	NF	4	19NOV91	4	4	3	4	4	4	4	3	1	3	4	4	3	4	3	3	3	4	1	1	4	3	3	63	
			5	26NOV91	4	4	3	4	4	4	4	4	4	2	4	1	3	4	2	4	4	3	1	1	1	4	3	3	62
			0	17OCT91	4	4	3	4	4	4	4	4	4	4	4	4	3	4	4	4	4	4	4	3	1	4	1	4	67
			1	25OCT91	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	76
			0	17OCT91	3	4	2	1	2	3	2	1	4	3	2	1	4	3	2	4	3	3	4	3	2	3	1	2	52
			1	25OCT91	4	2	1	3	3	1	3	1	3	4	2	3	3	3	3	3	3	3	3	4	2	3	1	2	51
13	6	KE	2	01NOV91	4	2	1	4	4	4	4	3	4	1	3	4	1	3	3	4	3	3	1	4	1	3	55		
			3	08NOV91	3	1	1	3	2	2	4	3	3	3	3	3	3	3	3	3	3	4	3	1	4	1	3	53	
			4	15NOV91	3	1	1	3	2	2	2	1	3	2	2	2	3	3	3	3	3	3	3	2	3	1	3	48	
			5	21NOV91	2	2	2	2	2	2	2	2	2	2	2	3	2	3	3	4	4	4	4	1	4	1	1	51	
			6	28NOV91	3	1	1	3	1	1	2	2	2	3	2	2	3	2	3	4	3	3	3	1	4	1	1	44	
			0	24OCT91	4	2	4	4	4	2	4	3	1	1	3	2	2	2	3	2	3	4	2	2	3	1	2	2	52
13	7	BL	1	31OCT91	3	3	2	3	3	4	2	2	2	3	1	2	3	1	2	3	3	4	3	1	4	1	2	51	
			2	07NOV91	1	3	2	3	2	4	1	1	2	2	1	2	2	1	2	2	2	1	4	3	1	2	1	2	41
			3	14NOV91	1	2	1	2	2	4	1	1	2	2	2	2	2	2	2	2	2	2	2	2	4	2	1	2	41
			4	21NOV91	1	2	1	2	2	4	1	2	1	2	1	2	2	2	2	2	2	2	2	2	1	2	1	1	33
			5	28NOV91	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	30
			6	05DEC91	1	3	1	1	1	1	1	1	3	2	1	2	2	2	1	1	1	2	1	2	1	1	1	1	1
13	8	PK	0	21OCT91	4	4	3	4	4	4	4	3	3	4	4	4	4	4	4	4	4	4	2	4	3	4	74		
			1	28OCT91	2	3	3	4	2	4	2	3	1	1	2	2	2	2	2	2	2	2	2	2	1	2	1	1	43
			2	04NOV91	2	4	2	3	4	4	2	4	2	4	2	4	2	1	1	1	1	1	1	4	2	1	1	1	45
			3	11NOV91	2	4	2	3	4	4	2	4	2	3	1	1	2	2	2	3	3	2	2	2	1	2	1	1	52

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 2012A/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Patient Centre No.	Initials	Visit	Date Performed	ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	IT.19	IT.20	Total Score (*)				
13	8	PK	4	19NOV91	2	3	3	3	3	4	2	3	3	3	3	2	3	3	3	4	3	2	3	1	2	55			
			5	26NOV91	2	4	2	2	3	2	2	1	2	3	1	3	2	1	1	1	1	2	1	1	1	39			
			6	02DEC91	2	4	2	3	4	4	2	3	3	2	1	3	2	1	2	2	1	3	2	1	1	4	48		
			0	21OCT91	4	4	4	4	3	4	3	4	3	4	3	4	4	4	4	4	4	4	4	2	4	3	4	74	
			1	28OCT91	4	4	3	4	4	3	2	3	1	2	4	3	3	1	3	4	3	4	3	1	4	1	4	58	
			2	04NOV91	4	4	3	3	4	4	3	2	1	3	1	4	3	1	3	3	4	4	3	1	4	2	4	60	
13	9	SZE	3	11NOV91	4	4	4	4	3	3	4	4	4	4	4	1	1	3	4	4	4	4	2	4	2	4	60		
			4	19NOV91	4	3	4	4	4	4	4	1	4	1	2	4	3	4	3	4	2	2	2	3	1	4	62		
			5	26NOV91	2	3	2	4	4	4	2	4	1	2	3	4	2	1	2	3	4	2	1	4	1	3	49		
			6	02DEC91	3	2	2	3	3	4	2	4	1	2	1	3	4	1	1	3	4	4	1	4	1	3	49		
			0	17OCT91	4	2	3	3	3	4	2	1	2	4	1	4	3	1	4	3	2	4	3	1	3	1	2	52	
			-1	17OCT91	4	3	4	4	4	4	4	3	4	3	4	4	4	4	4	4	4	3	4	2	4	4	4	74	
13	11	HS	0	14NOV91	4	4	4	4	4	4	4	3	3	4	3	3	3	4	4	4	4	4	3	4	4	4	73		
			1	21NOV91	3	4	4	4	4	4	2	3	4	3	3	4	3	3	2	4	4	4	4	2	4	2	4	66	
			2	28NOV91	2	4	2	2	4	4	1	3	3	2	4	4	4	4	4	4	4	4	4	2	4	2	4	59	
			3	05DEC91	3	4	2	2	2	2	2	4	1	3	3	3	1	3	3	3	4	4	3	3	4	2	4	56	
			4	10DEC91	3	4	2	2	1	4	1	3	3	3	3	3	3	3	3	3	3	3	3	3	1	3	1	47	
			6	27DEC91	3	4	3	2	1	3	2	2	2	1	3	2	2	1	3	3	1	3	3	1	3	1	3	47	
13	12	BF	0	30OCT91	4	4	2	4	3	4	3	2	2	4	3	4	3	4	3	4	4	3	4	4	4	4	64		
			1	06NOV91	3	4	3	3	4	4	3	3	4	3	3	4	3	3	3	4	4	4	4	4	2	3	65		
			2	13NOV91	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	2	4	69	
			3	20NOV91	4	4	3	3	3	3	3	4	1	4	4	4	4	4	4	4	4	4	4	4	2	4	2	4	66
			4	27NOV91	4	4	3	4	3	3	2	2	2	2	2	2	2	2	4	3	4	4	4	2	4	2	4	66	
			5	04DEC91	4	4	3	4	3	4	3	3	4	3	3	4	3	4	4	3	4	4	4	4	3	4	3	69	
13	13	BM	0	01NOV91	3	4	1	4	4	3	4	4	3	4	3	4	1	3	4	4	4	4	2	2	1	3	62		
			1	08NOV91	3	4	1	2	2	4	3	2	1	3	1	4	4	1	4	4	4	4	4	1	3	1	1	47	
			2	14NOV91	3	4	1	4	2	4	2	3	1	3	1	4	3	1	4	3	2	4	4	1	1	1	3	51	
			3	21NOV91	4	4	1	4	2	4	2	4	2	4	1	4	3	1	1	4	4	3	1	2	1	2	1	52	
			4	28NOV91	3	4	1	4	1	3	1	4	1	3	4	4	1	3	4	4	4	4	4	2	2	1	3	56	
			5	05DEC91	3	4	1	3	1	4	1	3	1	3	2	3	3	1	3	3	1	4	3	1	1	1	4	47	
13	14	DF	6	13DEC91	3	3	1	3	1	3	1	3	4	1	3	4	1	4	4	4	4	4	1	1	1	2	45		
			-1	28OCT91	4	4	2	4	4	4	4	3	4	2	2	4	4	2	4	4	4	4	4	2	4	1	1	65	
			0	01NOV91	3	4	2	4	3	4	3	3	4	2	3	4	2	3	2	4	4	4	4	2	4	1	1	59	
			1	08NOV91	3	4	2	4	1	4	2	4	2	3	1	2	2	4	4	4	4	4	4	4	1	1	1	53	
			2	14NOV91	3	4	2	4	2	4	2	3	3	2	1	1	2	1	1	2	1	4	2	1	4	1	1	47	

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre	Patient No.	Initials	Visit	Date Performed	Date																			Total Score (*)
					ZUNG	IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17	IT.18	
13	14	DF	3	23NOV91	2	3	2	3	2	3	1	3	3	2	3	3	4	2	2	3	1	48		
			4	26NOV91	3	4	1	4	4	3	2	3	2	3	2	1	4	4	1	3	1	51		
			5	05DEC91	2	4	2	1	3	3	1	2	1	2	2	1	3	3	1	3	1	41		
			6	12DEC91	3	4	2	3	2	4	2	2	1	2	3	1	1	4	1	1	4	1	45	
			0	06NOV91	4	4	3	4	1	2	1	2	3	3	2	3	1	4	3	1	1	4	46	
			1	15NOV91	3	4	3	4	1	4	1	2	3	4	1	3	1	4	3	1	4	1	55	
13	15	KG	2	20NOV91	3	4	3	4	1	4	2	3	1	3	3	1	4	3	1	4	1	51		
			4	04DEC91	2	4	3	4	2	3	1	1	3	3	1	2	1	3	3	1	4	1	64	
			5	14DEC91	3	4	2	3	2	1	2	3	1	2	2	2	2	3	2	1	1	1	65	
			6	17DEC91	2	4	3	2	1	3	2	1	2	2	1	2	2	1	3	2	1	3	1	40
			0	19NOV91	4	4	4	4	4	3	2	3	4	2	4	3	4	3	4	3	3	4	2	69
			1	26NOV91	4	4	3	4	4	3	2	4	1	3	2	1	4	3	1	3	1	3	1	57
13	16	S2L	2	04DEC91	4	4	3	4	4	3	2	3	1	3	2	4	4	4	1	3	1	57		
			3	10DEC91	3	4	2	3	3	2	3	2	2	2	3	3	3	1	3	1	3	1	51	
			4	16DEC91	3	4	2	2	3	2	2	3	2	1	2	2	2	1	3	1	3	1	42	
			5	23DEC91	2	4	1	4	2	3	2	1	1	2	2	2	2	2	2	2	1	3	1	41
			6	02JAN92	2	4	2	3	2	3	2	2	1	2	2	1	3	2	1	3	1	3	1	41
			0	19NOV91	3	3	4	3	3	3	4	2	4	1	1	4	2	2	1	3	1	3	1	50
13	17	GSM	1	26NOV91	2	3	4	3	2	4	3	3	1	2	3	2	3	2	1	2	1	49		
			2	03DEC91	2	2	1	2	2	4	4	3	2	1	2	2	1	3	2	1	2	1	40	
			3	10DEC91	1	2	1	1	2	4	3	3	1	2	2	3	2	2	2	2	1	2	40	
			4	17DEC91	2	4	1	1	1	2	4	2	3	3	1	2	2	1	3	1	1	1	37	
			5	23DEC91	2	4	2	4	1	2	2	3	2	1	3	2	1	3	2	1	3	1	1	43
			6	28DEC91	2	2	3	2	2	3	3	3	3	2	3	3	2	2	3	2	2	1	3	49
13	18	VT	0	03DEC91	3	3	2	2	2	4	3	3	3	2	3	2	4	3	1	1	1	48		
			1	10DEC91	3	3	3	1	2	2	4	3	4	1	2	3	2	3	2	1	2	1	48	
			2	17DEC91	3	3	3	3	1	2	2	4	3	4	1	2	3	1	4	3	1	2	48	
			3	23DEC91	4	4	2	2	2	2	2	3	2	2	1	2	3	1	1	1	1	1	37	
			4	30DEC91	3	3	3	1	2	2	4	3	3	1	2	3	1	3	3	1	1	1	1	46
			5	07JAN92	3	2	4	1	2	2	4	3	3	1	2	3	1	3	3	1	1	1	2	44
13	19	KK	0	14JAN92	3	4	4	2	2	1	4	3	1	3	3	1	4	3	1	1	1	48		
			0	23JAN92	4	4	4	3	4	3	2	2	1	3	3	4	4	4	4	4	1	4	65	
			1	30JAN92	4	4	4	4	4	3	3	4	1	3	4	4	4	4	4	4	4	2	75	
			2	06FEB92	4	4	2	3	4	3	2	3	2	3	3	4	4	3	4	4	3	3	64	
			3	13FEB92	3	4	3	3	4	4	3	3	2	3	1	3	3	4	4	3	4	2	2	61
			0	28JAN92	4	4	3	3	4	3	2	3	3	3	4	3	3	3	4	3	3	3	3	63

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 OPEN PHASE

Centre No.	Patient No.	Initials	Visit	Date Performed	ZUNG																	Total Score (*)			
					IT.1	IT.2	IT.3	IT.4	IT.5	IT.6	IT.7	IT.8	IT.9	IT.10	IT.11	IT.12	IT.13	IT.14	IT.15	IT.16	IT.17		IT.18	IT.19	IT.20
13	20	NL	1	04FEB92	2	4	2	2	2	3	3	1	2	3	2	2	4	4	3	3	2	2	2	51	
			2	11FEB92	2	3	2	2	1	1	3	2	2	2	3	2	2	4	3	3	4	2	2	47	
			3	18FEB92	2	2	2	2	2	1	2	2	2	2	2	2	2	4	3	2	2	1	2	2	47
			4	25FEB92	2	3	2	1	1	2	1	3	2	2	2	2	2	4	3	2	2	2	2	2	41
			5	03MAR92	2	2	1	1	2	2	2	2	1	2	1	3	2	4	3	2	2	1	2	2	41
			6	10MAR92	2	2	1	2	1	2	2	1	1	2	1	3	2	4	3	2	2	1	2	1	36
13	21	CL	0	18FEB92	2	4	3	2	4	2	3	3	4	1	4	2	4	1	4	4	3	3	61		
			1	25FEB92	3	1	3	2	2	4	2	3	3	2	1	4	4	4	4	4	4	1	3	52	
			2	02MAR92	3	4	4	3	3	4	3	4	1	1	4	4	4	4	1	4	4	4	3	62	
			3	09MAR92	3	4	4	2	3	4	3	2	1	1	3	4	4	4	1	4	4	4	3	55	
			4	17MAR92	3	4	4	2	3	4	2	4	2	1	1	3	4	4	1	4	3	3	2	56	
			5	24MAR92	2	4	3	2	2	4	2	3	2	1	1	2	4	4	4	1	3	4	4	3	51
13	22	NYH	0	05MAY92	3	3	2	4	3	3	2	3	2	1	3	2	1	3	4	1	3	1	50		
			1	19MAY92	3	3	2	3	3	4	3	2	1	2	1	3	2	2	4	1	3	1	2	46	
			2	19MAY92	3	2	2	2	3	2	3	2	3	1	2	2	4	3	1	3	1	3	1	3	48
			3	26MAY92	3	3	3	3	3	4	3	1	2	3	1	3	2	4	3	1	3	1	3	52	
			4	01JUN92	3	2	3	3	3	3	2	3	1	3	2	3	2	3	3	2	3	2	4	53	
			5	09JUN92	3	2	3	4	3	3	3	3	2	3	1	3	2	3	3	3	3	2	3	3	55
13	23	BSB	0	16JUN92	2	2	2	3	3	3	3	2	3	1	3	2	2	3	2	3	1	3	49		
			1	06MAY92	3	3	3	4	4	2	2	3	3	1	2	3	4	4	3	1	3	2	2	56	
			2	13MAY92	3	4	4	3	4	4	4	3	1	3	3	1	3	3	4	3	3	4	4	2	63
			3	19MAY92	4	4	3	4	4	4	4	4	2	4	2	1	4	3	4	4	4	4	4	2	69
			4	27MAY92	3	4	2	3	4	4	4	4	2	4	2	1	4	4	4	4	4	2	3	1	62
			5	03JUN92	2	4	1	3	4	3	4	4	2	4	1	1	4	2	1	1	1	1	1	1	46
13	24	NYH	4	10MAR92	1	3	1	4	4	4	4	4	2	3	4	1	4	4	1	1	1	1	52		
			6	17JUN92	2	3	1	2	2	3	3	2	2	1	3	3	3	4	3	1	1	1	1	43	

(*) = Total score computed

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Patient Centre No. (a)	Initials	Visit	Date Performed	ZUNG	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	Total Score (b)
1	3/2	TA	8	11JAN91	2	1	1	2	4	1	1	2	1	2	1	1	1	2	2	1	1	2	1	1	30
			12	08FEB91	1	2	1	2	2	1	2	1	3	2	1	1	1	2	2	1	2	1	1	1	31
			16	08MAR91	1	1	2	1	2	1	1	3	2	2	1	1	1	2	1	2	1	2	1	1	32
			20	05APR91	1	1	2	2	2	1	2	1	3	2	1	1	1	2	1	2	1	1	1	1	31
			24	03MAY91	1	1	2	1	1	2	1	2	3	2	1	1	1	2	1	1	2	1	1	1	28
			28	31MAY91	1	1	1	2	2	1	1	2	1	2	1	1	1	2	1	1	2	1	1	1	27
			32	28JUN91	1	1	2	2	2	1	1	2	1	2	1	1	1	2	2	2	1	1	1	2	31
			36	26JUL91	1	1	1	2	2	1	1	2	1	2	1	1	1	2	1	1	2	1	1	2	27
			40	23AUG91	1	3	1	2	1	2	2	2	2	2	3	1	1	1	1	2	2	1	1	2	33
			44	20SEP91	1	1	2	2	1	1	2	1	1	2	1	1	1	2	1	1	2	1	1	1	26
			48	18OCT91	3	1	1	1	2	1	1	2	1	1	2	1	1	1	1	1	2	1	1	1	26
			52	14NOV91	1	1	2	1	1	2	1	1	1	2	1	1	2	1	1	2	1	1	1	2	26
1	4/3	DNC	8	16JAN91	1	1	1	2	2	2	1	1	2	1	2	1	1	2	1	1	2	2	1	1	28
			12	13FEB91	1	1	1	2	2	1	2	1	2	2	1	1	1	2	1	1	2	1	1	1	29
			16	13MAR91	1	1	2	1	1	1	1	2	1	1	1	1	1	1	1	1	1	2	1	1	24
			20	10APR91	1	2	1	2	1	1	1	3	2	1	1	2	2	1	1	1	1	2	1	1	30
			24	08MAY91	1	2	2	1	1	1	1	2	1	2	1	1	1	1	2	1	1	3	1	1	28
			28	05JUN91	1	1	2	1	1	1	1	2	1	1	2	1	1	2	1	2	1	2	1	1	28
			32	03JUL91	1	1	1	2	1	1	3	1	2	1	1	2	1	1	1	1	2	1	1	1	27
			36	31JUL91	1	1	2	1	1	2	1	2	1	2	1	1	1	1	1	1	1	1	1	1	29
			40	28AUG91	1	1	2	2	1	2	1	2	1	2	1	1	2	1	1	1	1	2	1	2	28
			44	25SEP91	1	1	2	2	1	1	1	2	1	2	1	1	1	1	1	1	1	2	1	1	26
			48	25OCT91	1	2	1	1	1	1	2	1	1	2	1	1	1	1	1	1	1	2	1	1	26
			52	20NOV91	1	1	1	1	1	1	1	2	1	1	2	1	1	1	1	1	1	2	1	1	24
1	5/4	DB	8	29JAN91	1	2	1	2	1	1	1	1	1	2	1	2	1	1	2	1	2	1	1	1	28
			12	27FEB91	1	1	1	1	1	2	1	2	2	1	2	1	1	2	1	1	3	1	1	1	28
			16	27MAR91	1	1	1	2	2	3	1	1	1	2	1	1	2	2	1	1	3	1	1	1	30
			20	24APR91	1	1	1	2	2	3	1	1	1	2	1	1	1	2	1	3	1	1	1	1	29
			24	21MAY91	1	1	1	3	2	2	1	1	1	1	1	1	2	1	1	2	1	1	1	1	27
			28	18JUN91	1	1	1	2	2	2	1	1	1	2	1	1	1	2	1	2	2	1	1	1	29
			32	16JUL91	1	1	2	2	1	1	2	1	1	2	1	1	2	1	1	1	2	1	1	1	27
			36	13AUG91	1	1	1	2	2	1	2	2	1	1	1	2	1	1	1	1	2	1	1	1	27
			40	10SEP91	1	1	1	1	2	1	1	2	1	1	2	1	1	2	1	1	1	2	1	1	26
			44	08OCT91	1	1	1	1	2	1	1	1	1	2	1	1	2	1	1	1	2	1	1	1	24
			48	05NOV91	1	1	2	1	1	1	2	1	1	2	1	1	1	1	1	1	1	1	1	1	25
			52	03DEC91	1	1	1	2	2	1	1	1	1	2	1	1	1	1	1	1	1	2	1	1	25
1	9/7	CCR	8	20FEB91	1	2	1	2	2	1	1	4	1	2	1	2	3	1	2	1	2	2	1	1	33
			16	17APR91	1	1	1	2	2	2	1	1	1	2	1	2	2	1	2	1	2	2	1	1	28

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre No. (a)	Patient No. (b)	Initials	Visit	Date Performed	ZUNG	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	Total Score (b)							
						Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score		Score	Score	Score	Score			
1	9/7	CCR	20	15MAR91	1	1	1	2	2	1	1	1	2	2	1	1	1	1	1	1	1	1	2	2	1	1	28						
			24	12JUN91	1	1	4	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	27					
			28	10JUL91	3	2	1	1	1	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	31				
			32	07AUG91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25				
			36	04SEP91	1	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	26				
			40	02OCT91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25				
			44	30OCT91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25				
			48	27NOV91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	26				
			52	26DEC91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	27				
			1	10/8	LDL	8	28MAR91	1	1	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	28		
						16	24MAY91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25		
						20	21JUN91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	28	
24	19JUL91	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	26				
28	16AUG91	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25				
32	13SEP91	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	26				
36	11OCT91	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	26				
40	08NOV91	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	26				
44	06DEC91	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	28				
48	03JAN92	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	28				
52	31JAN92	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25				
1	14/11	MLC				8	02JUL91	3	2	3	2	3	3	1	2	1	3	3	3	3	2	2	4	3	3	2	2	1	2	47			
			10	16JUL91	3	2	2	3	4	4	4	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	52					
			12	30JUL91	4	4	2	4	3	3	2	4	3	2	4	3	3	3	4	4	4	4	4	4	4	4	4	4	66				
			1	17/14	CEC	8	16JUL91	2	2	3	3	3	4	3	2	2	2	2	2	2	1	1	2	2	2	2	2	1	1	42			
						12	13AUG91	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	36		
						16	10SEP91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	26	
						20	08OCT91	2	3	3	1	3	1	2	2	3	2	2	2	2	2	2	1	1	2	1	1	1	1	1	1	36	
						24	05NOV91	1	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	1	2	1	1	1	1	1	1	29	
						28	03DEC91	1	1	2	1	1	2	1	2	1	1	2	1	2	1	2	1	1	2	1	1	1	1	1	1	29	
						32	31DEC91	1	1	2	3	1	3	1	3	1	2	1	2	1	2	1	1	2	1	1	1	1	1	1	1	29	
						1	18/15	ITM	8	17JUL91	2	2	2	3	3	4	2	4	2	2	2	2	1	1	1	2	2	2	2	3	1	1	43
									12	14AUG91	2	2	1	3	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
16	11SEP91	2							2	2	3	1	4	1	1	3	1	2	2	1	2	2	1	3	3	1	1	2	1	2	38		
1	20/17	EFC							8	26JUL91	3	2	3	3	3	3	4	3	3	3	3	3	3	1	3	2	2	3	3	2	2	3	53
									12	23AUG91	4	4	2	2	2	2	2	2	2	2	2	2	2	2	3	3	3	3	3	3	3	3	3

(a) = Open/Blind

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

9550077

Patient Centre No. (a)	Initials	Visit	Date Performed	ZUNG																				Total Score (b)						
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20							
1	22/19	SK	8	06AUG91	1	2	2	1	1	1	1	1	2	1	1	2	1	2	1	2	1	1	2	1	1	2	1	1	28	
			12	03SEP91	1	1	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	26	
			16	01OCT91	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	26
			20	29OCT91	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	26
			24	26NOV91	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25
			28	24DEC91	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25
			32	21JAN92	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	31
			36	18FEB92	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	31
			40	17MAR92	3	1	2	3	3	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	27
			44	14APR92	1	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	30
			48	12MAY92	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	30
			52	05JUN92	1	2	1	2	1	2	1	2	1	1	2	1	1	2	1	2	1	2	1	1	1	1	1	1	1	1
1	24/20	LVF	8	27AUG91	2	1	1	2	1	1	1	1	2	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	30	
			12	24SEP91	1	2	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	32	
			16	22OCT91	2	2	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	31
			20	19NOV91	2	1	2	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	33
			24	17DEC91	2	1	3	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	1	34
			28	14JAN92	1	2	1	2	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	29
			32	11FEB92	2	1	2	2	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	33
			36	09MAR92	1	1	2	2	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	32
			40	07APR92	1	2	2	2	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	1	30
			44	05MAY92	1	1	2	2	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	35
			48	02JUN92	1	1	2	2	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	28
			52	30JUN92	1	3	1	2	2	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	30
1	25/21	AMR	8	30AUG91	1	2	2	3	1	1	1	1	2	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	32	
			12	27SEP91	1	1	1	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	27	
			16	25OCT91	1	1	2	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	27
			20	22NOV91	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	26
			24	20DEC91	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	29
			28	17JAN92	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25
			32	14FEB92	1	1	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25
			36	13MAR92	1	1	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	30
			40	10APR92	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	28
			44	08MAY92	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	28
			48	05JUN92	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	32
			52	03JUL92	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	32
1	31/27	MAH	8	17SEP91	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	32		
			12	15OCT91	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	31	

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre No. (a)	Patient No. (a)	Initials	Visit	Date Performed	ZUNG																				Total Score (b)			
					It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20				
1	31/27	MMK	16	12NOV91	3	1	1	2	1	1	2	2	1	1	2	1	1	1	2	1	2	1	1	30				
			20	10DEC91	2	1	2	1	1	2	1	3	2	1	1	2	1	1	2	2	1	1	1	1	33			
			24	07JAN91	1	1	2	1	1	1	2	1	1	1	2	1	1	2	1	1	2	1	1	1	26			
			28	04FEB92	3	2	1	3	2	2	1	2	2	1	2	1	2	1	2	1	2	2	1	1	35			
			32	04MAR92	2	1	2	3	1	2	1	2	4	2	1	1	2	1	2	1	1	1	1	1	34			
			36	31MAR92	1	2	1	2	1	2	1	2	1	3	3	1	1	2	1	1	3	1	1	1	33			
			40	28APR92	1	2	1	2	1	2	1	2	1	1	1	1	2	1	2	1	1	3	1	1	29			
			44	26MAY92	1	2	1	2	1	2	1	2	4	2	1	1	1	2	1	2	1	1	1	2	35			
			48	23JUN92	2	1	1	4	2	1	2	1	2	1	1	1	2	1	1	1	1	2	1	2	31			
			52	21JUL92	1	1	2	2	1	2	1	1	2	1	1	1	2	1	1	1	2	1	1	2	28			
			1	32/28	DGN	8	16AUG91	1	1	1	2	1	1	1	1	1	1	2	1	1	1	1	1	1	1	2	26	
						12	16OCT91	2	2	1	3	2	2	1	1	1	1	2	1	1	1	1	1	1	1	1	2	35
						16	19NOV91	3	2	1	4	2	2	1	2	2	3	3	1	2	2	1	2	3	2	2	3	54
						20	11DEC91	4	3	3	4	3	3	3	3	2	4	4	2	1	2	2	2	2	2	2	3	55
						24	08JAN91	2	2	1	2	2	1	2	1	1	2	1	1	1	2	2	1	2	2	1	2	31
						28	05FEB92	3	1	1	3	2	2	1	1	1	2	2	2	1	2	1	2	2	1	2	2	34
32	04MAR92	3				2	1	2	2	2	2	2	2	3	2	1	1	2	1	2	1	1	1	1	36			
36	01APR92	1				2	3	2	3	2	2	2	4	2	1	2	1	2	3	3	4	1	1	2	43			
40	29APR92	1				2	1	2	1	2	2	2	1	2	1	2	1	2	1	2	2	1	1	1	32			
44	27MAY92	1				1	1	2	1	2	2	1	1	2	1	3	2	1	2	1	2	1	1	1	30			
48	24JUN92	1				2	1	2	1	2	1	2	1	2	1	3	3	1	2	1	2	2	1	1	29			
52	22JUL92	1				1	2	1	2	1	1	2	1	1	2	2	1	1	2	1	1	1	1	2	28			
1	34/30	GHR				8	09OCT91	2	2	2	2	1	1	3	2	1	2	2	1	1	1	3	2	2	2	36		
						12	06NOV91	2	1	2	2	1	1	1	4	2	2	1	2	2	1	2	2	3	1	2	35	
						16	06DEC91	2	2	1	2	1	2	2	2	1	1	1	2	2	3	2	2	2	1	1	32	
						20	02JAN91	2	2	2	2	2	2	1	1	2	2	3	1	2	3	1	2	3	1	2	34	
			24	29JAN92	2	2	2	3	2	2	4	1	3	2	2	3	1	3	2	2	3	2	2	3	46			
			28	26FEB92	3	2	1	2	1	2	2	4	1	2	1	2	1	4	2	2	2	2	2	2	41			
			32	25MAR92	2	1	2	1	2	1	2	2	2	3	1	2	1	2	2	2	2	1	1	1	38			
			36	22APR92	2	1	2	2	1	2	1	2	3	2	4	3	2	1	1	2	1	2	2	1	35			
			40	20MAY92	1	2	2	2	1	2	1	2	3	2	2	2	1	2	4	1	1	2	1	2	32			
			44	17JUN92	1	1	2	1	2	1	2	1	3	4	1	1	1	1	1	1	1	1	1	2	29			
			48	15JUL92	1	2	1	2	1	2	1	2	1	2	1	1	1	1	1	1	1	1	1	2	31			
			52	12AUG92	1	2	1	2	1	2	1	1	2	1	1	2	1	1	1	1	1	1	2	1	30			
			1	35/301	EMP	8	22OCT91	1	1	2	2	1	1	1	2	1	1	1	2	1	1	2	1	2	1	2	29	
						12	19NOV91	1	2	1	2	2	2	1	2	2	1	1	2	1	3	2	2	1	1	1	33	
						16	17DEC91	1	2	2	1	1	1	2	2	1	1	2	1	2	1	1	2	2	2	1	29	
			20	14JAN92	1	2	1	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	2	2	29		

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre No. (a)	Patient Initials	Date Performed	ZUNG																				Total Score (b)
			It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	
1	35/301 EMP	24 11FEB92	1	1	1	1	1	2	1	2	1	2	1	1	1	2	2	1	2	1	2	1	28
		28 10MAR92	1	2	3	2	4	2	2	2	4	2	2	1	2	1	2	2	3	1	2	1	41
		32 07APR92	2	3	3	1	2	1	2	2	2	2	2	1	1	2	1	2	1	4	3	1	40
		36 05MAY92	1	2	1	2	1	2	1	2	2	4	2	2	1	1	2	1	1	3	3	1	37
		40 02JUN92	1	2	2	2	1	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	28
		44 30JUN92	1	2	1	2	1	2	1	2	1	2	1	1	1	1	1	1	1	1	1	1	27
		48 28JUL92	1	1	2	1	2	1	2	1	2	1	2	1	2	2	3	3	1	1	1	1	30
		52 25AUG92	1	2	2	1	1	2	1	1	1	1	3	1	3	2	1	3	1	1	1	1	30
		8 29OCT91	1	1	2	2	2	1	1	1	1	1	1	1	2	1	2	1	1	2	2	1	27
		12 26NOV91	1	1	1	3	1	1	1	1	1	1	1	1	2	1	1	1	3	1	2	1	27
16 24DEC91	1	2	1	3	1	1	2	1	2	1	1	1	2	1	2	1	2	1	2	1	29		
20 21JAN92	1	1	1	2	2	2	1	2	2	1	1	1	2	2	2	1	1	1	2	1	29		
24 18FEB92	1	3	1	3	2	2	1	3	2	1	1	1	1	1	1	1	1	1	1	1	31		
28 17MAR92	1	2	1	2	2	2	2	2	2	2	1	2	1	2	2	2	2	3	1	1	33		
32 14APR92	1	1	1	2	1	3	2	1	2	2	1	1	2	2	1	4	1	2	2	1	33		
36 12MAY92	1	3	2	2	1	3	2	1	1	1	1	1	2	2	1	1	2	2	1	1	31		
40 09JUN92	1	2	2	3	1	2	2	1	2	3	1	1	1	1	2	1	2	1	2	1	32		
44 07JUL92	1	1	1	2	2	2	2	2	1	3	1	2	1	2	1	2	1	2	1	1	33		
48 04AUG92	1	2	1	2	2	2	3	1	2	3	1	2	3	1	2	1	2	1	1	1	34		
52 01SEP92	1	3	1	2	2	2	2	2	1	2	1	1	1	2	1	1	1	1	1	1	31		
8 19NOV91	2	3	1	2	1	2	2	2	1	1	2	1	1	1	2	3	1	1	2	2	33		
12 31DEC91	3	1	1	2	2	1	1	1	2	2	1	1	2	2	2	2	2	3	1	1	33		
16 14JAN92	3	1	1	2	1	3	1	2	2	3	2	2	2	1	1	3	2	1	1	1	39		
20 11FEB92	1	2	1	2	1	2	1	1	1	2	1	1	1	1	1	1	1	1	1	2	26		
24 10MAR92	1	1	2	1	2	1	2	1	1	2	1	1	2	1	1	1	1	1	2	1	26		
28 07APR92	1	1	1	2	1	1	2	1	2	2	1	2	1	2	1	2	1	1	2	1	28		
32 05MAY92	1	2	1	1	2	1	2	1	4	2	2	1	2	2	1	1	2	1	1	1	31		
36 02JUN92	1	1	2	1	2	2	1	1	4	2	2	1	2	2	1	1	1	2	1	1	29		
40 30JUN92	1	2	1	2	2	3	4	3	1	1	2	1	2	1	1	1	2	1	1	1	34		
44 28JUL92	2	1	2	2	1	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	30		
48 25AUG92	1	2	1	3	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	1	30		
52 22SEP92	1	2	2	1	2	1	2	1	2	1	2	1	2	1	2	1	1	1	2	1	30		
8 27NOV91	1	2	2	2	1	1	1	2	2	1	1	2	1	1	1	2	1	2	2	1	28		
12 26DEC91	1	2	2	1	1	1	2	2	1	1	2	1	1	2	1	1	1	1	1	1	28		
16 21JAN92	2	3	1	2	1	2	1	2	2	4	1	1	2	2	1	2	1	1	1	1	35		
20 18FEB92	1	1	1	2	1	1	2	1	2	2	1	1	2	1	1	1	1	4	1	1	30		
24 18MAR92	1	1	2	1	2	2	1	1	2	1	2	1	2	1	1	3	1	1	1	1	28		
28 15APR92	1	1	2	2	1	2	1	2	1	2	1	2	1	2	1	2	1	1	1	1	29		

(a) = Open/Blind

9550077

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Patient Centre No. (a)	Initials	Visit	Date Performed	ZUNG	It. 1 It. 2 It. 3 It. 4 It. 5 It. 6 It. 7 It. 8 It. 9 It. 10 It. 11 It. 12 It. 13 It. 14 It. 15 It. 16 It. 17 It. 18 It. 19 It. 20																				Total Score (b)			
					1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20				
1	43/309	ARN	32	13MAY92	1	2	1	2	1	2	2	1	3	1	2	1	2	2	1	2	1	2	4	1	1	1	33	
			36	10JUN92	1	1	2	1	2	1	1	2	3	1	3	1	2	1	2	1	2	1	2	1	1	1	1	31
			40	08JUL92	1	2	1	2	1	2	1	2	2	2	2	2	4	2	1	1	2	1	1	1	1	1	1	33
			44	05AUG92	2	1	1	2	1	2	1	2	1	2	1	1	2	1	1	1	1	2	1	1	1	1	1	28
			48	02SEP92	1	2	1	1	2	1	2	1	2	1	2	1	2	2	1	1	1	2	1	1	1	1	1	28
			52	30SEP92	1	2	2	1	1	1	2	1	1	2	1	3	1	1	1	1	1	1	1	2	1	1	2	29
			8	03DEC91	1	1	2	1	2	1	2	1	2	1	1	2	1	2	2	1	2	1	2	1	1	1	1	30
			12	30DEC91	1	1	1	2	1	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	26
			16	28JAN92	1	1	1	2	1	2	1	2	2	1	1	1	2	1	2	1	1	1	1	1	1	1	1	28
			20	25FEB92	1	2	1	2	1	2	1	2	1	1	2	1	1	1	1	1	1	2	1	1	1	1	1	27
24	24MAR92	1	1	1	2	3	1	2	2	1	1	2	1	1	1	1	1	1	3	1	1	1	1	1	30			
28	22APR92	1	2	1	2	2	1	2	2	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	29			
32	19MAY92	1	1	1	3	1	2	1	1	2	1	1	2	1	2	1	1	1	1	1	1	1	1	1	28			
36	16JUN92	1	1	1	2	1	2	1	1	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	28			
40	14JUL92	1	2	1	2	1	2	1	2	1	1	2	1	1	2	2	1	1	1	1	1	1	1	1	27			
44	11AUG92	1	1	2	2	1	2	1	2	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	30			
48	08SEP92	1	1	1	2	1	2	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	30			
52	06OCT92	1	1	1	2	1	2	1	1	1	1	1	1	2	1	1	1	1	1	1	2	1	1	1	27			
1	46/311	SP	8	10DEC91	3	1	1	2	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	26		
			12	07JAN92	2	1	2	1	2	1	2	1	1	2	1	1	2	1	2	1	1	1	1	1	1	1	30	
			16	04FEB92	1	1	1	2	1	2	1	2	1	2	1	1	1	2	2	1	1	1	1	1	1	1	28	
			20	04MAR92	1	2	1	2	1	2	2	1	2	1	1	2	1	1	2	2	3	1	1	1	1	1	2	30
			24	31MAR92	1	2	1	2	1	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	28
			28	28APR92	1	1	2	1	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25
			32	26MAY92	1	1	1	2	1	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	28
			36	23JUN92	1	1	2	1	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	29
			40	21JUL92	2	2	1	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	27
			44	18AUG92	1	2	1	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	28
48	15SEP92	1	2	1	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	28			
52	15OCT92	1	1	1	2	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	29			
1	48/313	SCH	8	18DEC91	2	1	2	3	1	4	1	1	3	2	2	1	2	1	3	1	1	2	1	1	1	38		
			12	15JAN92	3	3	4	3	4	2	2	3	3	3	2	1	3	3	3	4	1	2	1	1	1	1	56	
			16	12FEB92	3	1	2	3	1	3	2	2	3	4	2	2	2	3	2	1	1	1	1	1	1	1	3	43
			20	11MAR92	2	2	4	2	2	1	2	2	3	2	2	4	2	2	2	4	2	2	1	1	1	1	1	46
			24	08APR92	2	2	1	2	2	1	2	2	3	4	2	2	1	2	1	1	3	3	1	1	1	1	1	39
			28	06MAY92	2	2	2	3	1	3	2	1	2	3	1	3	2	4	2	4	1	1	1	1	1	1	1	42
			32	05JUN92	2	1	2	1	3	3	1	2	2	2	2	2	1	2	1	3	3	1	1	1	1	1	1	39
			36	01JUL92	3	2	1	3	1	3	1	2	2	4	3	4	1	2	2	3	3	1	2	1	1	1	1	44

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre No. (a)	Patient No. (a)	Initials	Visit	Date Performed	ZUNG																			Total Score (b)		
					It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19		It.20	
1	48/313	SCH	40	29JUL92	1	2	2	1	2	1	2	4	2	2	1	2	1	2	1	1	2	1	1	2	35	
			44	26AUG92	1	2	1	2	1	2	1	3	1	3	2	2	1	3	2	2	3	1	1	1	35	
			48	23SEP92	1	1	2	1	2	1	2	1	3	3	2	1	1	2	1	2	1	1	2	1	1	31
			52	21OCT92	1	2	1	2	1	2	1	2	1	2	1	2	1	1	2	1	1	2	1	2	1	29
			8	26DEC91	2	1	1	3	3	2	1	2	3	1	1	2	1	2	3	1	1	1	1	1	1	35
1	52/316	MTS	12	22JAN92	1	2	1	2	1	1	2	1	1	2	1	2	1	2	1	2	3	1	2	1	31	
			16	19FEB92	3	1	1	2	1	3	2	4	2	1	1	2	2	1	2	1	2	2	1	2	34	
			20	18MAR92	2	1	1	3	2	1	3	3	2	2	2	2	1	2	1	2	1	3	1	1	1	35
			24	15APR92	1	1	1	2	1	2	1	2	2	1	2	1	3	2	1	2	2	1	2	1	1	30
			28	13MAY92	2	1	1	2	1	2	1	1	3	1	1	2	1	2	1	2	1	3	1	1	2	32
			32	10JUN92	1	2	3	2	1	2	1	2	2	2	1	2	1	2	1	2	1	1	1	1	2	33
			36	08JUL92	1	3	2	2	1	2	1	2	1	2	1	2	1	2	1	1	1	1	1	1	2	32
			40	05AUG92	2	1	2	2	1	2	2	2	4	1	1	1	1	1	1	1	1	3	1	2	2	28
			44	02SEP92	1	1	2	1	2	1	2	1	1	2	1	2	1	1	2	1	1	1	2	1	2	29
			48	30SEP92	1	1	2	2	1	1	2	2	1	1	2	1	2	1	1	1	1	2	1	1	2	27
			52	28OCT92	1	2	2	1	1	2	1	1	2	1	2	1	1	1	1	1	1	1	1	1	1	27
			1	55/318	DMG	8	31DEC91	3	2	2	1	3	2	1	1	2	1	1	2	2	1	2	2	1	2	1
12	28JAN92	2				2	1	2	2	1	2	1	3	1	2	2	2	1	2	2	3	1	2	36		
1	56/319	IAL	8	31DEC91	2	2	3	2	4	3	1	2	3	2	2	2	2	1	2	2	1	2	43			
1	58/320	ARM	8	04FEB92	2	1	2	2	1	4	1	2	2	2	1	1	2	2	2	2	2	2	3	33		
			12	04MAR92	2	2	1	2	1	2	1	2	2	3	2	3	2	4	2	3	2	1	2	56		
			16	31MAR92	3	4	2	3	3	4	3	4	2	3	3	3	2	4	2	4	2	3	2	1	56	
1	61/323	HVC	8	16FEB92	1	1	1	3	1	2	1	2	3	1	2	2	1	2	1	3	1	1	1	32		
			12	13MAR92	1	2	1	1	3	2	1	2	3	2	1	2	1	2	1	2	4	2	1	1	36	
			16	10APR92	1	1	2	3	1	2	2	1	2	1	1	2	1	2	1	2	1	2	1	1	31	
			20	08MAY92	1	2	1	1	2	1	2	1	2	4	2	1	2	1	2	1	3	1	1	1	31	
			24	05JUN92	1	3	1	2	3	1	2	1	3	1	2	1	2	1	2	1	2	1	1	1	32	
			28	03JUL92	1	1	1	2	1	1	1	1	3	1	1	2	1	2	1	2	4	1	2	2	32	
			32	31JUL92	1	1	1	3	1	2	1	3	2	2	1	2	1	2	1	2	1	1	1	1	1	30
			36	28AUG92	1	2	1	3	1	2	1	3	2	1	2	1	2	1	2	1	1	1	1	1	2	36
			40	25SEP92	1	1	1	3	1	2	3	1	2	1	2	1	2	1	2	1	1	1	1	1	1	30
			44	23OCT92	1	1	1	4	1	2	1	1	2	1	1	2	1	1	2	1	1	1	1	1	1	27
			48	20NOV92	1	1	1	3	1	2	1	1	2	1	1	2	1	1	2	1	1	1	1	1	1	27
			52	18DEC92	1	1	1	2	1	1	1	2	1	2	1	2	2	1	2	4	2	2	1	2	1	32
1	66/326	TCG	8	17MAR92	2	1	2	2	4	2	3	1	2	2	1	2	2	1	3	2	1	1	37			

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Patient Centro No. (a)	Initials	Visit	Date Performed	ZUNG	It. 1 It. 2 It. 3 It. 4 It. 5 It. 6 It. 7 It. 8 It. 9 It. 10 It. 11 It. 12 It. 13 It. 14 It. 15 It. 16 It. 17 It. 18 It. 19 It. 20																				Total Score (b)									
					1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20										
1	66/326	TCG	12	14APR92	2	2	2	4	2	4	1	1	2	1	2	1	1	2	1	1	2	1	2	1	1	1	35							
			16	12MAY92	1	1	3	4	3	4	2	2	1	2	1	2	1	2	1	1	2	1	1	2	3	1	1	38						
			20	09JUN92	1	1	2	3	2	2	1	2	1	2	1	2	1	3	2	2	4	4	1	1	1	1	1	39						
			24	07JUL92	1	1	1	2	3	2	4	4	2	1	2	1	2	1	2	1	2	3	1	1	1	1	1	37						
			28	04AUG92	1	2	1	2	1	2	4	4	1	2	1	2	1	1	2	1	2	1	1	1	1	1	1	33						
			32	01SEP92	1	2	1	3	2	1	4	4	2	1	2	1	2	1	2	2	2	1	1	1	1	1	1	35						
			36	24SEP92	1	1	1	3	1	1	4	4	1	2	1	1	1	1	2	4	1	1	1	1	1	1	2	36						
			40	27OCT92	1	1	2	1	2	3	4	4	2	1	2	1	2	1	2	1	2	1	1	1	1	1	1	34						
			44	24NOV92	1	1	1	2	1	2	4	4	2	1	2	1	2	1	1	2	1	1	1	1	1	1	1	32						
			48	22DEC92	1	1	2	2	2	1	2	4	2	1	1	2	1	1	2	1	1	1	1	1	1	1	1	33						
			52	15JAN93	1	2	1	2	1	2	1	4	2	1	2	1	2	1	2	1	2	1	1	2	1	1	1	31						
			1	71/329	OHV	8	24MAR92	2	1	1	3	1	2	1	1	2	4	2	3	1	2	1	1	2	1	1	1	1	2	34				
12	22APR92	1				2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	1	1	1	1	1	1	29						
16	19MAY92	2				1	1	3	1	3	1	2	2	3	3	2	1	2	1	3	1	1	1	1	1	1	1	35						
20	16JUN92	1				2	1	2	1	2	1	2	2	3	1	3	1	2	1	2	2	2	1	1	1	1	1	32						
24	14JUL92	2				2	1	3	2	1	2	1	2	4	2	1	1	2	1	1	1	1	1	1	1	1	1	33						
28	11AUG92	1				2	2	3	1	1	1	2	2	3	1	2	1	1	2	1	1	1	1	1	1	1	1	31						
32	08SEP92	1				2	1	3	1	1	2	1	2	3	2	1	1	2	2	1	1	1	1	1	1	1	1	32						
36	06OCT92	1				2	1	2	1	2	1	2	1	3	2	1	2	1	2	1	2	1	1	1	1	1	1	31						
40	03NOV92	1				1	1	2	1	2	1	2	1	2	1	1	1	1	1	1	2	4	1	1	1	1	1	29						
44	01DEC92	1				1	1	2	1	1	3	2	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	28						
48	29DEC92	1				1	2	3	1	2	2	3	2	4	1	1	1	1	1	1	1	1	1	1	1	1	1	2	35					
52	26JAN93	1				1	1	2	1	3	1	3	2	3	1	1	1	2	2	1	1	1	1	1	1	1	1	2	33					
1	72/330	RLJ	8	24MAR92	2	2	1	3	1	3	2	1	3	2	3	2	2	1	2	1	2	2	1	2	1	2	38							
			12	20APR92	1	1	2	3	1	2	1	4	3	2	1	2	1	2	1	2	4	2	3	1	2	1	2	40						
			16	19MAY92	1	1	1	3	1	2	1	3	1	2	2	1	3	2	2	1	2	1	2	1	2	1	2	33						
			20	16JUN92	1	1	1	4	2	2	1	4	2	4	2	1	2	1	1	2	1	1	3	1	2	1	2	38						
			1	73/121	FMA	8	24MAR92	1	2	1	2	1	1	3	2	4	2	1	1	2	1	1	2	1	1	2	1	1	1	32				
						12	22APR92	1	1	2	2	1	2	1	4	2	2	1	2	1	2	1	1	1	1	1	1	1	1	1	30			
						16	19MAY92	1	1	1	2	1	1	4	2	1	1	2	1	1	2	1	1	2	1	1	2	1	1	2	31			
						20	16JUN92	1	2	1	2	1	2	1	3	2	1	2	1	1	2	1	1	1	2	2	1	1	1	1	33			
						24	14JUL92	3	3	1	2	1	2	1	4	2	2	1	2	1	2	1	2	3	1	2	2	1	1	2	39			
						1	75/123	ELF	8	27MAR92	1	2	1	2	1	1	2	2	1	2	1	2	1	1	2	1	1	2	1	1	1	1	1	30
									12	24APR92	1	2	2	1	2	1	1	2	1	1	2	1	2	1	1	2	1	1	1	1	1	1	1	30
									16	22MAY92	1	2	2	1	2	1	3	1	3	1	2	1	2	1	2	1	2	1	2	1	2	1	1	35
20	19JUN92	1							1	2	2	1	2	1	2	1	2	1	2	1	2	1	2	2	1	3	1	1	1	1	31			
24	17JUL92	2							2	2	3	1	1	2	1	1	2	1	1	2	1	1	1	1	1	2	1	1	1	1	31			

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Patient Centre No. (a)	Initials	Visit	Date Performed	ZUNG																	Total Score (b)								
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17		It.18	It.19	It.20					
1	75/123	ELF	28	14AUG92	1	1	1	2	2	1	2	2	1	2	2	1	1	2	1	1	2	1	1	1	1	1	1	29	
			32	11SEP92	1	2	1	1	3	2	2	1	1	2	1	2	1	1	3	1	3	3	1	1	1	1	1	34	
			36	09OCT92	1	2	1	3	1	2	2	2	1	1	2	2	1	1	1	3	1	1	1	1	1	1	1	1	33
			40	06NOV92	3	1	1	3	2	1	2	1	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	32
			44	04DEC92	3	1	1	3	2	3	1	2	4	1	1	2	1	1	2	2	4	2	1	2	2	4	2	1	39
			48	31DEC92	2	1	2	3	1	1	1	2	2	1	1	3	1	1	2	2	2	2	1	3	1	3	1	2	34
			52	29JAN93	1	1	2	1	1	1	1	2	1	2	1	1	1	1	2	1	2	1	1	1	1	1	1	1	25
			8	03APR92	1	2	1	2	2	4	2	1	2	1	2	2	1	1	2	1	2	1	1	2	1	2	1	1	34
			12	30APR92	1	2	1	5	1	2	1	2	1	2	2	1	1	1	1	1	1	3	1	1	1	2	1	2	33
			16	29MAY92	1	2	1	2	1	4	2	2	1	3	1	1	2	1	1	1	1	1	1	2	1	1	2	1	31
			20	26JUN92	1	4	1	5	2	4	1	1	1	2	1	2	1	2	1	2	1	2	2	1	1	3	1	1	32
24	24JUL92	1	2	2	2	1	4	2	1	1	2	1	2	1	2	1	1	1	1	1	1	1	3	1	1	32			
28	21AUG92	2	3	1	2	2	4	2	1	2	4	2	1	1	1	2	2	1	1	1	2	2	1	1	2	37			
32	16SEP92	2	1	2	3	1	4	2	1	2	3	1	1	2	1	1	2	1	1	1	2	1	1	1	1	35			
36	16OCT92	1	2	2	1	1	4	2	2	1	2	1	2	4	3	1	2	2	1	1	1	2	1	1	1	37			
40	15NOV92	1	2	1	1	4	4	2	2	1	2	1	2	1	1	2	1	2	1	1	2	1	1	1	1	34			
44	11DEC92	1	1	1	1	1	3	3	1	1	3	1	2	1	1	1	1	1	1	1	1	1	1	1	1	31			
48	08JAN93	1	1	1	2	1	2	1	1	1	2	1	2	1	2	1	1	1	3	1	1	1	1	1	1	27			
52	05FEB93	1	1	1	1	1	1	1	2	1	2	1	2	1	1	2	2	2	2	2	1	1	1	1	1	30			
8	03APR92	1	1	1	2	2	3	1	4	2	2	1	1	2	1	1	2	1	3	1	1	1	1	1	1	33			
12	30APR92	1	1	1	3	2	2	1	3	2	1	1	2	1	2	1	2	1	2	1	1	1	1	1	1	31			
16	29MAY92	1	1	2	2	1	2	2	3	1	2	1	1	2	1	1	2	1	1	1	1	1	1	1	1	30			
20	26JUN92	1	1	2	3	1	2	2	4	2	2	1	1	2	1	1	2	1	2	1	1	2	1	1	1	33			
24	24JUL92	2	1	2	2	2	1	2	1	3	3	1	4	1	1	1	2	1	1	1	1	1	1	1	1	33			
28	21AUG92	2	1	2	1	1	2	3	2	1	4	2	2	2	1	3	4	4	1	1	1	1	1	1	1	40			
32	16SEP92	1	2	4	2	1	1	2	1	2	1	2	1	1	1	2	1	1	1	1	1	1	1	1	1	29			
36	16OCT92	1	2	2	3	2	2	2	2	1	2	3	1	1	2	1	1	1	1	1	1	1	1	1	1	32			
40	15NOV92	1	1	1	2	2	2	2	1	3	2	2	1	1	1	3	1	1	1	3	1	1	1	1	1	32			
44	11DEC92	1	1	1	1	1	3	1	3	1	2	1	1	1	1	2	1	1	2	1	1	1	1	1	1	32			
48	08JAN93	1	1	1	3	1	3	1	3	1	2	1	1	1	1	3	1	1	2	1	2	1	1	1	1	35			
52	05FEB93	1	1	1	1	1	1	1	2	1	2	1	2	1	1	2	1	1	2	1	1	1	1	1	1	33			
8	03APR92	2	1	1	3	2	2	2	2	1	2	2	1	1	2	1	2	1	3	1	1	1	1	1	1	34			
12	30APR92	2	2	1	2	1	2	1	1	4	2	2	1	1	2	2	1	4	1	1	1	1	1	1	1	37			
16	29MAY92	3	3	1	2	2	3	2	1	1	4	2	2	3	2	3	2	3	2	3	1	1	1	1	1	44			
20	26JUN92	1	1	2	1	2	1	2	1	2	1	2	1	1	2	1	1	1	2	1	1	1	1	1	1	27			
24	24JUL92	1	2	2	1	2	1	4	2	1	4	2	1	1	3	1	1	1	1	1	1	1	1	1	1	35			
28	21AUG92	1	2	2	3	2	2	1	4	2	2	1	2	1	2	1	1	2	1	1	1	1	1	1	1	35			
32	16SEP92	1	1	2	3	2	2	2	2	1	4	2	2	1	1	2	1	1	2	1	1	1	1	1	1	34			
36	16OCT92	1	1	2	1	2	1	2	2	1	4	2	1	1	2	1	1	1	1	1	1	1	1	1	1	31			

(a) = Open/Blind
 (b) = Mean Score

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124-013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre No.	Patient (a)	Initials	Visit	ZUNG	Date Performed	It. 1	It. 2	It. 3	It. 4	It. 5	It. 6	It. 7	It. 8	It. 9	It. 10	It. 11	It. 12	It. 13	It. 14	It. 15	It. 16	It. 17	It. 18	It. 19	It. 20	Total Score (b)			
						Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score		Score	Score	Score									
1	82/129	MDS	40	13NOV92	1	1	2	2	1	1	4	1	1	1	2	2	2	1	1	1	1	2	1	1	1	1	29		
			44	11DEC92	1	2	1	1	2	4	1	2	1	1	1	2	1	1	1	1	1	1	1	3	1	1	31		
			48	06JAN93	1	1	2	2	1	4	1	1	2	1	1	1	1	2	1	1	1	1	1	1	2	1	1	30	
			52	05FEB93	1	1	1	3	2	1	4	1	2	1	1	1	1	1	2	1	1	1	1	1	1	1	1	29	
1	87/132	MDO	8	03APR92	1	1	4	2	2	1	4	2	2	1	2	2	1	2	2	2	2	3	1	2	1	2	38		
			12	30APR92	3	2	1	2	2	4	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	36	
			16	29MAY92	3	1	2	4	2	1	2	2	1	2	2	1	2	2	1	2	2	1	1	4	1	1	1	37	
			20	26JUN92	4	3	1	4	2	3	4	2	4	3	2	2	3	1	1	4	2	3	1	4	2	3	3	54	
1	89/133	MNV	8	07APR92	2	3	3	2	4	4	2	3	2	1	2	1	2	1	3	1	1	1	3	1	4	46			
			12	05MAY92	3	3	2	4	2	3	2	3	2	3	1	2	4	2	2	3	2	4	2	3	3	2	51		
1	90/134	JSS	8	07APR92	2	1	2	2	2	1	4	2	2	2	2	2	1	2	2	1	2	2	1	1	2	35			
1	95/138	GMT	8	08APR92	2	2	1	3	2	1	2	2	2	2	2	1	3	2	2	2	1	2	2	1	1	1	35		
			12	06MAY92	2	1	2	1	2	2	1	2	2	1	2	2	1	2	1	2	2	1	3	2	2	2	1	34	
			16	03JUN92	1	1	2	1	2	2	3	1	1	2	2	1	2	2	1	2	1	2	2	1	1	2	2	32	
			20	01JUL92	2	1	2	1	2	2	1	1	2	1	2	1	2	1	1	2	1	1	2	1	1	3	1	30	
			24	29JUL92	1	2	1	2	1	4	2	1	1	2	1	2	2	1	2	1	2	2	1	2	2	1	1	32	
			28	26AUG92	1	2	2	1	2	4	2	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	2	33
			32	23SEP92	1	1	2	4	2	2	4	2	2	2	1	1	1	2	1	1	1	2	1	2	3	1	1	39	
			36	21OCT92	1	1	2	2	2	3	1	1	2	2	4	2	2	1	3	2	1	3	1	1	1	2	1	34	
			40	18NOV92	1	1	1	2	2	4	1	1	2	2	3	1	1	2	1	1	2	2	1	2	2	1	1	32	
			44	16DEC92	1	1	1	2	1	3	1	1	3	1	1	2	2	3	1	1	2	1	1	2	4	1	1	31	
			48	13JAN93	1	2	2	1	2	1	2	2	1	2	1	1	1	1	1	3	1	1	1	1	1	2	1	32	
			52	10FEB93	1	1	1	3	1	1	2	1	1	1	2	1	1	1	1	1	2	1	1	1	1	1	1	1	26
1	96/139	SPW	8	08APR92	2	1	2	1	2	2	1	2	4	3	4	1	1	1	1	1	2	2	1	1	2	1	37		
			12	06MAY92	2	1	1	1	2	4	2	1	1	2	2	1	2	2	1	2	2	1	2	2	1	1	2	33	
			16	03JUN92	1	2	1	1	1	4	2	2	1	2	4	1	2	1	2	1	1	2	1	1	2	1	1	33	
			20	01JUL92	1	1	2	2	1	2	2	1	1	2	1	1	1	1	1	2	1	1	2	1	1	2	1	29	
			24	29JUL92	1	2	3	3	1	3	2	2	1	2	2	1	2	2	1	2	2	1	2	1	1	2	1	1	54
			28	26AUG92	1	2	2	4	3	2	2	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	34
			32	23SEP92	1	2	2	4	1	3	1	1	1	1	1	1	1	2	2	1	1	1	1	1	1	1	1	1	32
			36	21OCT92	1	1	1	2	1	4	2	1	1	2	1	2	1	2	1	2	1	2	1	2	3	1	1	1	32
			40	18NOV92	2	4	1	2	2	2	2	1	2	2	1	2	1	2	1	2	1	2	1	2	1	1	1	2	38
			44	16DEC92	3	2	1	3	1	4	2	2	1	3	2	2	1	1	1	1	1	1	1	1	3	1	1	2	39
			48	13JAN93	3	1	1	2	1	4	2	2	1	2	2	1	1	1	1	2	2	1	1	1	1	1	1	1	32
			52	10FEB93	1	1	2	2	1	4	1	1	1	2	2	1	2	2	2	1	1	1	1	1	1	1	1	1	32

1347

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOMETINE

Patient	Centro No. (a)	Initials	Visit	Date Performed	ZUNG	It. 1	It. 2	It. 3	It. 4	It. 5	It. 6	It. 7	It. 8	It. 9	It. 10	It. 11	It. 12	It. 13	It. 14	It. 15	It. 16	It. 17	It. 18	It. 19	It. 20	Total Score (b)						
1	98/141	YTT	8	08APR92	1	1	2	2	1	2	1	2	3	1	3	2	2	1	3	2	2	3	2	1	1	1	2	39				
			12	06MAY92	1	2	3	2	1	2	1	2	1	2	2	1	4	1	1	2	1	1	1	1	1	3	1	1	34			
			16	03JUN92	2	1	2	1	2	4	2	1	1	2	1	1	2	2	1	1	1	1	1	1	1	1	1	1	1	32		
			20	01JUL92	1	1	2	2	2	2	1	2	2	1	1	1	2	2	1	2	1	1	1	3	2	1	1	1	1	32		
			24	29JUL92	1	2	1	2	2	1	4	2	1	4	2	1	1	2	1	1	4	2	2	1	1	3	1	1	1	36		
			28	26AUG92	1	2	2	2	1	2	3	1	2	1	2	1	1	2	1	2	1	1	2	1	1	1	1	1	1	32		
			32	23SEP92	1	2	2	1	2	1	2	3	1	2	3	1	1	2	1	2	1	3	3	1	1	2	1	1	1	34		
			36	21OCT92	1	2	2	3	1	1	2	2	1	2	2	1	3	2	1	1	1	1	1	1	1	2	1	1	1	31		
			40	18NOV92	1	1	2	2	1	2	1	3	2	1	3	2	2	1	2	1	1	1	1	1	1	2	1	1	2	32		
			44	16DEC92	1	1	2	3	1	2	1	4	2	2	1	1	2	2	1	1	1	1	2	1	1	1	1	1	1	33		
			48	13JAN93	1	2	1	2	1	3	1	4	3	1	4	3	1	2	1	1	1	1	2	2	1	1	1	1	1	33		
			52	10FEB93	1	2	1	4	1	2	1	2	1	2	1	1	2	1	1	1	1	1	1	1	1	2	1	1	1	32		
			1	101/143	JLL	8	14APR92	1	2	1	2	2	3	1	2	2	2	4	2	2	2	1	2	1	1	2	2	1	1	2	36	
						12	12MAY92	1	2	1	2	2	1	2	3	2	1	1	1	1	1	1	1	1	1	3	1	1	1	1	1	32
						16	09JUN92	1	3	1	3	2	1	2	2	3	1	1	1	1	1	1	3	1	2	2	2	1	1	1	1	35
						20	07JUL92	1	2	1	2	2	1	2	2	1	1	1	1	1	1	1	1	1	1	1	2	2	1	1	1	1
24	04AUG92	1				2	2	2	2	1	4	2	4	2	4	2	1	2	3	1	1	1	1	1	4	1	1	1	2	40		
28	01SEP92	1				2	2	2	1	2	1	2	1	2	3	1	1	2	3	3	1	2	2	2	3	2	1	1	2	39		
32	29SEP92	1				2	2	2	2	1	3	2	2	1	3	2	1	1	1	1	1	1	1	1	1	1	1	1	1	34		
36	27OCT92	2				1	1	2	2	2	2	1	2	2	2	2	1	2	1	2	2	1	2	1	1	2	1	1	2	36		
40	24NOV92	1				1	1	2	3	3	1	2	2	1	2	1	2	2	1	1	1	1	1	1	2	1	1	1	2	33		
44	22DEC92	3				1	1	1	1	2	1	2	2	1	1	1	2	1	1	2	3	1	3	1	2	1	1	1	1	31		
48	19JAN93	1				2	1	1	1	3	4	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	29		
52	16FEB93	1				2	1	1	2	1	1	2	1	2	1	1	2	1	1	2	1	1	1	1	1	1	1	1	1	28		
1	107/147	LAN				8	15APR92	1	1	2	1	4	2	1	4	2	1	4	1	2	2	1	2	2	1	1	2	1	1	2	35	
						12	13MAY92	1	2	1	3	1	4	2	1	2	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	36
						16	10JUN92	1	1	1	2	1	4	2	2	1	2	2	1	2	2	1	2	1	2	2	1	1	1	1	1	31
						20	08JUL92	1	1	1	2	1	4	2	2	2	2	1	1	2	1	1	1	3	3	1	1	2	1	1	1	1
			24	06AUG92	1	1	1	2	2	1	4	2	1	2	1	1	3	1	1	1	2	1	1	1	1	1	1	1	1	32		
			28	01SEP92	1	2	1	1	2	3	1	1	2	1	2	1	1	1	1	1	2	1	1	2	1	1	1	1	1	30		
			32	29SEP92	1	1	1	2	3	1	1	2	1	2	1	1	2	1	1	1	2	1	1	3	2	1	1	1	2	33		
			36	27OCT92	1	1	1	2	2	4	1	2	3	1	2	1	2	1	2	1	2	1	2	1	1	2	1	1	1	35		
			40	24NOV92	1	2	1	2	3	1	1	2	2	1	2	2	1	2	1	2	1	2	1	2	1	3	1	1	1	33		
			44	22DEC92	1	1	1	2	3	4	1	1	2	1	1	1	2	1	2	1	1	1	1	1	1	1	1	1	1	31		
			48	19JAN93	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	27		
			52	16FEB93	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	26		
			1	109/149	IPL	8	15APR92	1	2	1	2	1	4	2	4	2	1	2	1	2	2	1	2	1	2	2	1	1	1	1	35	
						12	13MAY92	1	2	2	1	1	4	1	4	1	4	1	2	2	1	4	2	1	2	1	1	1	1	1	1	36

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre No.	(a)	Initials	Visit	Date Performed	Total Score (b)																										
					It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20							
1	109/149	IPL	16	10JUN92	1	1	2	3	1	4	2	4	2	4	1	2	1	2	1	2	1	1	2	1	1	34					
			20	06JUL92	2	1	2	3	1	4	2	4	3	2	1	1	2	1	2	1	2	1	1	1	1	1	39				
			24	05AUG92	1	2	2	1	4	2	4	2	1	1	2	1	1	2	1	1	2	1	1	1	1	1	1	38			
			28	02SEP92	1	2	2	2	2	3	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	38			
			32	30SEP92	1	2	3	2	1	3	1	4	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	38			
			36	28OCT92	1	2	3	1	3	2	3	1	2	4	2	1	1	1	1	1	1	1	1	1	1	1	1	39			
			40	25NOV92	1	1	1	1	2	4	1	4	3	2	1	1	1	1	1	1	1	1	1	1	1	1	1	34			
			44	23DEC92	1	2	1	3	1	4	1	2	2	4	2	1	1	1	1	1	1	1	1	1	1	1	1	37			
			48	19JAN93	1	1	2	1	4	1	1	2	4	1	1	1	1	1	1	1	1	1	1	1	1	1	1	34			
			52	17FEB93	1	1	1	2	1	3	1	1	3	2	1	1	1	1	1	1	1	1	1	1	1	1	1	33			
			1	110/150	IQO	8	15APR92	1	2	2	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	30		
						12	13MAY92	1	2	1	1	2	1	2	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	32	
						16	10JUN92	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	27	
						20	06JUL92	1	2	2	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	27
						24	05AUG92	2	1	2	2	1	2	2	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	33
						28	02SEP92	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	26
32	30SEP92	1				1	3	1	1	1	2	1	2	2	3	3	1	1	1	1	1	1	1	1	1	1	1	31			
36	28OCT92	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	29			
40	25NOV92	1				1	1	1	3	2	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	29			
44	23DEC92	1				2	2	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	32			
48	19JAN93	1				1	2	1	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	28			
52	17FEB93	1				2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	32			
1	116/334	MGA				8	22APR92	1	1	2	2	1	4	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	32		
						12	19MAY92	2	1	1	2	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	27	
						16	16JUN92	1	1	2	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	28	
						20	14JUL92	1	1	2	1	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	31
			24	12AUG92	1	2	1	2	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	31			
			28	05SEP92	1	2	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	33			
			32	07OCT92	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	33			
			36	04NOV92	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	28			
			40	07DEC92	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	30			
			44	29DEC92	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	32			
			48	26JAN93	1	1	1	2	2	1	1	3	4	1	1	1	1	1	1	1	1	1	1	1	1	1	1	32			
			52	24FEB93	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	30			
			1	117/335	PSL	8	22APR92	1	2	1	2	2	3	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	32		
						12	19MAY92	1	1	3	2	1	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	29	
						16	16JUN92	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	27	
						20	14JUL92	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	29	

1349

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Patient Centre No., (a)	Initials	Visit	Date Performed	ZUNG																				Total Score (b)			
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20				
1	117/335	FSL	24	12AUG92	2	2	2	1	2	1	2	1	2	2	1	3	2	1	3	3	2	1	2	40			
			28	09SEP92	2	1	2	2	1	2	2	4	2	4	2	1	1	2	2	1	3	1	1	2	41		
			32	07OCT92	1	2	1	3	1	2	1	3	3	1	4	2	1	4	1	2	1	3	1	1	38		
			36	04NOV92	1	3	1	3	2	2	1	2	4	2	1	2	1	4	1	2	4	1	1	1	42		
			40	01DEC92	1	2	1	3	1	2	2	2	1	2	1	2	1	2	1	2	2	3	1	1	42		
			44	29DEC92	1	2	2	3	1	2	2	1	1	2	1	2	1	1	4	1	1	4	1	1	33		
			48	26JAN93	2	1	3	3	1	2	2	1	2	1	2	1	1	1	3	3	2	3	1	1	38		
			52	24FEB93	2	1	3	2	1	3	2	1	2	1	2	1	2	1	1	3	1	1	1	2	34		
			1	121/336	LAC	8	22APR92	1	3	1	2	1	1	2	2	1	2	2	1	3	2	1	1	1	1	33	
						12	20MAY92	1	4	2	2	2	1	2	2	1	2	1	1	2	1	1	2	1	1	2	34
						16	17JUN92	1	1	1	3	2	1	1	2	1	4	2	2	1	1	1	1	1	1	1	33
						20	15JUL92	1	1	2	3	1	2	1	1	1	2	1	1	1	2	1	1	1	2	1	28
24	12AUG92	1				1	1	1	1	1	1	1	2	3	2	1	1	1	1	2	2	1	1	1	27		
28	09SEP92	1				2	1	1	2	1	1	2	1	2	1	1	2	1	2	1	1	1	1	1	28		
32	07OCT92	1				1	1	1	1	1	2	1	2	3	1	2	1	1	2	3	1	2	1	1	33		
36	04NOV92	1				2	1	3	1	2	2	1	2	1	2	1	1	1	2	1	1	3	1	1	30		
40	02DEC92	1				2	1	3	1	2	1	2	1	2	1	1	1	1	1	3	2	1	1	1	32		
44	30DEC92	1				3	1	1	2	2	1	2	1	4	2	2	1	1	1	1	2	4	2	2	37		
48	27JAN93	1				1	2	2	1	2	1	1	2	1	1	1	2	1	1	1	1	1	1	1	31		
52	24FEB93	1				1	2	2	1	2	1	1	2	1	1	1	2	1	1	3	1	1	3	1	31		
1	123/338	MLL	8	22APR92	1	2	2	4	1	2	2	1	2	1	1	2	1	1	1	1	2	1	31				
			12	20MAY92	1	2	1	3	1	2	1	2	2	2	1	1	1	2	1	1	1	1	1	30			
			16	17JUN92	1	1	1	2	1	1	2	1	2	2	1	1	1	2	4	2	4	1	1	33			
			20	15JUL92	1	2	1	2	2	1	1	2	1	1	1	1	1	1	1	4	1	1	1	29			
			24	12AUG92	1	1	1	2	2	1	2	1	1	2	1	1	1	2	2	2	1	1	1	1	27		
			28	09SEP92	1	1	1	1	2	4	1	1	2	1	1	1	1	1	1	1	2	1	1	1	28		
			32	07OCT92	1	1	2	3	1	4	2	3	1	1	2	1	1	4	2	2	1	2	1	1	28		
			36	04NOV92	1	1	1	3	2	1	2	1	2	1	2	1	1	2	1	2	1	1	1	1	34		
			40	02DEC92	1	2	2	2	1	2	1	2	1	2	1	1	1	2	1	1	1	3	1	1	29		
			44	30DEC92	1	1	1	4	2	1	1	1	3	2	1	1	1	2	1	3	1	1	2	1	33		
			48	27JAN93	3	1	1	4	2	1	1	1	2	3	1	1	1	1	1	2	4	1	1	2	33		
			52	24FEB93	4	1	2	3	3	4	1	1	2	1	2	1	1	1	1	1	1	1	4	1	33		
1	125/340	FDP	8	22APR92	2	3	1	4	2	2	1	2	3	4	2	1	2	4	2	1	1	2	44				
			12	20MAY92	3	2	1	4	2	2	2	1	2	1	2	1	2	1	3	3	3	2	4	42			
			16	17JUN92	3	3	2	4	2	2	1	1	4	4	2	1	1	2	1	1	2	4	2	45			
			20	15JUL92	4	4	2	4	2	2	1	1	4	2	2	1	1	4	2	3	1	3	1	49			
			24	12AUG92	3	3	1	4	1	3	1	1	2	2	1	1	2	3	3	2	3	2	3	1	40		
			28	09SEP92	3	1	1	1	3	2	1	1	2	2	1	1	2	1	1	2	1	4	3	2	44		

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOMETINE

Centre No. (a)	Patient Initials	Date Performed	ZUNG																				Total Score (b)	
			It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20		
1	125/340 FDP	07OCT92	3	2	1	1	2	1	3	2	1	2	1	2	1	1	4	4	1	1	3	1	40	
		04NOV92	2	4	1	2	1	1	1	1	2	1	2	2	1	2	1	2	1	1	4	4	2	35
		02DEC92	2	4	1	2	3	2	1	4	3	2	2	2	4	3	1	2	1	2	3	1	45	
		30DEC92	1	1	1	2	2	2	4	3	2	2	1	1	1	1	1	4	1	1	4	1	34	
		27JAN93	1	1	1	3	2	1	2	2	4	3	2	1	2	1	3	4	1	1	4	1	34	
1	127/342 VPD	24FEB93	1	2	2	1	2	2	4	1	1	2	1	2	1	3	4	1	1	3	4	1	39	
		22APR92	1	1	1	2	2	1	1	4	1	2	2	2	3	1	2	1	1	4	1	1	34	
		20MAY92	1	2	2	3	3	1	1	3	3	1	2	1	2	1	1	1	1	3	1	1	35	
		17JUN92	3	2	2	3	2	1	2	3	2	4	2	2	1	1	1	1	1	4	1	1	40	
		15JUL92	3	3	1	3	2	1	2	4	4	1	3	2	1	2	1	2	1	1	4	1	39	
1	128/343 LAM	13AUG92	2	3	1	3	1	4	2	4	2	2	1	1	1	2	1	2	1	2	2	1	38	
		07OCT92	1	1	1	2	2	2	4	2	3	2	3	1	1	1	2	1	2	2	1	1	35	
		04NOV92	1	1	1	2	1	2	1	4	1	2	1	1	1	1	1	1	1	1	4	1	27	
		02DEC92	1	1	1	3	2	1	4	4	1	2	2	1	1	1	1	1	1	1	4	1	36	
		30DEC92	1	1	1	2	2	1	4	4	1	2	1	2	1	3	4	1	1	1	1	2	35	
1	134/347 INS	27JAN93	1	2	2	1	2	2	4	4	2	1	2	1	1	1	1	1	1	4	1	2	42	
		24FEB93	1	2	1	3	1	3	2	4	1	2	1	1	4	3	1	1	1	3	1	1	39	
		22APR92	1	1	2	2	1	2	2	1	3	4	2	1	1	2	1	2	1	1	2	1	33	
		20MAY92	1	1	2	2	1	2	2	2	2	4	2	1	1	1	2	1	1	2	2	1	30	
		17JUN92	1	1	2	2	1	1	2	1	4	2	1	1	1	2	2	1	1	1	3	1	34	
1	134/347 INS	15JUL92	1	1	2	4	2	1	3	2	1	2	1	1	2	1	3	2	1	1	1	1	34	
		12AUG92	1	1	1	1	1	3	2	1	1	3	1	1	1	1	1	1	1	1	1	1	28	
		09SEP92	1	2	1	4	3	2	1	1	2	1	1	1	1	2	1	1	2	1	1	1	31	
		07OCT92	2	2	1	4	3	2	1	1	1	2	1	1	1	2	1	2	1	1	3	1	33	
		04NOV92	1	1	1	2	2	1	4	1	1	4	1	2	1	1	2	1	1	4	1	1	32	
1	134/347 INS	02DEC92	2	1	1	2	2	2	4	1	2	1	1	1	1	1	1	1	1	4	1	39		
		30DEC92	1	2	1	4	2	2	1	2	4	1	2	1	3	1	1	3	4	2	1	1	42	
		27JAN93	1	2	2	4	1	2	2	1	3	1	2	2	1	2	2	2	2	4	1	1	40	
		24FEB93	1	2	2	4	3	2	1	2	2	3	2	1	2	2	1	2	2	3	1	1	44	
		19MAY92	1	2	1	2	1	2	1	2	1	3	2	1	1	2	1	3	2	1	1	1	33	
1	134/347 INS	16JUN92	1	1	2	2	1	2	1	2	2	1	2	1	1	2	1	2	1	4	1	2	32	
		14JUL92	1	1	3	1	2	1	2	2	4	2	3	1	2	1	1	2	2	1	2	1	35	
		11AUG92	1	1	2	1	2	1	1	2	1	2	1	1	3	2	1	1	4	2	1	2	33	
		08SEP92	1	1	1	2	2	1	1	1	2	1	2	1	2	1	2	1	2	1	1	1	29	
		06OCT92	1	1	1	1	1	1	1	1	1	2	1	3	2	1	1	1	1	3	1	1	27	
1	134/347 INS	03NOV92	1	1	1	2	1	1	1	1	1	2	1	1	2	1	1	1	1	1	1	1	25	
		01DEC92	1	1	1	2	1	1	1	3	1	1	2	2	1	1	1	1	1	2	1	1	30	
		29DEC92	1	1	1	2	4	1	2	1	2	1	2	1	3	2	1	1	1	1	1	1	37	

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Patient	Centre No. (a)	Initials	Visit	Date Performed	ZUNG	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	Total Score (b)					
1	134/347	LMS	44	26JAN93	1	1	1	2	2	2	2	1	1	2	1	1	1	1	1	2	2	2	1	1	1	1	28				
			48	24FEB93	1	2	1	1	2	2	1	2	1	2	1	1	2	1	1	1	1	2	2	1	3	1	1	30			
			52	23MAR93	1	2	1	3	1	1	2	1	2	2	1	2	1	1	2	1	1	2	1	2	2	1	1	30			
1	135/348	HMS	8	19MAY92	1	1	2	2	1	4	2	1	2	3	1	1	1	1	1	2	1	2	1	2	1	1	32				
			12	16JUN92	1	1	1	2	1	4	2	2	1	2	1	2	1	1	2	1	2	1	2	1	2	1	2	31			
			16	14JUL92	1	2	2	2	1	4	1	1	1	1	2	1	1	1	1	1	2	2	2	1	1	1	1	2	33		
			20	11AUG92	1	3	1	1	2	1	4	2	1	2	2	1	1	1	2	1	2	1	2	1	1	2	1	1	32		
			24	08SEP92	1	1	1	2	2	3	2	1	2	1	2	1	2	1	3	1	2	1	2	1	1	1	1	1	31		
			28	06OCT92	1	1	1	2	2	2	3	1	1	2	2	1	1	2	1	3	1	2	1	2	1	1	1	1	31		
			32	05NOV92	2	2	1	1	2	1	3	1	1	3	2	1	2	2	1	2	1	2	2	1	1	1	1	2	34		
			36	01DEC92	1	1	1	2	2	1	1	1	1	1	1	2	1	1	2	1	1	1	1	2	1	1	1	1	36		
			40	29DEC92	1	2	1	2	1	2	1	1	1	2	1	1	3	4	1	1	1	1	1	1	1	1	1	1	35		
			44	26JAN93	1	1	1	2	1	2	1	2	1	2	1	1	2	1	1	2	2	1	1	1	1	1	1	1	31		
			48	24FEB93	1	1	1	3	2	1	2	1	2	1	1	2	1	1	2	1	1	1	1	1	1	1	1	1	28		
			52	23MAR93	1	1	1	2	2	1	1	1	1	2	1	1	2	1	1	2	1	1	1	1	1	1	1	1	29		
			1	139/351	RA	8	19MAY92	1	2	1	3	2	1	2	2	1	1	3	2	1	1	1	1	2	1	1	1	1	1	32	
						12	16JUN92	1	1	1	2	2	3	2	1	1	2	1	1	1	1	1	1	1	2	1	1	1	1	1	29
						16	14JUL92	1	1	1	2	3	2	1	1	2	2	1	1	2	1	1	1	2	2	1	1	1	1	1	30
20	11AUG92	1				1	1	3	1	2	2	1	2	2	1	1	1	1	3	2	1	2	1	2	2	1	1	1	31		
24	08SEP92	1				1	1	3	2	2	1	2	1	2	1	1	1	1	1	1	1	2	1	2	1	1	1	1	32		
28	06OCT92	1				1	1	4	1	3	2	1	2	1	2	1	1	1	1	1	1	2	1	1	1	1	1	1	33		
32	03NOV92	1				2	1	3	1	3	2	1	2	2	1	1	1	1	1	1	1	2	1	1	1	1	1	1	30		
36	01DEC92	1				2	1	4	2	3	1	3	1	1	2	1	1	2	1	1	1	2	1	1	1	1	1	1	33		
40	29DEC92	1				1	2	1	2	1	1	1	1	1	1	1	3	1	1	2	1	1	1	1	1	1	1	1	28		
44	26JAN93	1				2	1	2	2	1	2	1	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	32		
48	24FEB93	1				1	1	2	1	1	2	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	29		
52	23MAR93	1				1	1	2	2	1	1	1	1	2	1	1	2	1	1	2	1	1	1	1	1	1	1	1	27		
1	160/352	MCA				8	19MAY92	1	2	1	2	1	1	2	1	1	2	1	1	1	1	1	1	2	1	1	1	1	1	27	
						12	16JUN92	1	2	1	1	2	1	1	2	1	1	1	1	1	1	1	1	1	2	1	1	1	1	1	28
						16	14JUL92	1	1	1	2	2	1	2	1	1	2	1	1	1	1	1	1	1	2	1	1	1	1	1	1
			20	11AUG92	1	1	1	2	2	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	29		
			24	08SEP92	1	2	1	1	2	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	28		
			28	06OCT92	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	30		
			32	03NOV92	2	1	3	1	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	31		
			36	01DEC92	1	2	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	27		
			40	29DEC92	1	2	1	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	30		
			44	26JAN93	1	1	1	2	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	30		
			48	24FEB93	1	1	1	2	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	29		

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre No. (a)	Patient No. (a)	Initials	Visit	Date Performed	ZUNG	It. 1 It. 2 It. 3 It. 4 It. 5 It. 6 It. 7 It. 8 It. 9 It. 10 It. 11 It. 12 It. 13 It. 14 It. 15 It. 16 It. 17 It. 18 It. 19 It. 20																				Total Score (b)
						1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
1	140/352	HCA	52	23MAR93	1	1	1	2	1	2	2	1	1	1	2	1	1	2	1	1	3	1	1	1	28	
			8	19MAY92	1	2	1	2	2	1	2	2	1	3	2	1	1	2	1	1	2	1	1	1	1	32
			12	16JUN92	1	2	2	1	2	2	1	2	1	2	1	1	3	1	2	1	1	1	1	1	1	30
			16	14JUL92	1	2	2	1	2	2	1	1	2	1	1	2	1	1	1	1	1	2	1	1	1	29
			20	11AUG92	1	2	1	2	1	2	1	1	2	1	1	1	2	1	1	1	1	1	1	1	1	29
			24	08SEP92	1	2	1	2	1	2	1	1	2	1	1	1	2	1	1	1	1	2	1	1	1	30
			28	06OCT92	1	2	2	1	2	1	1	2	1	1	2	1	1	2	1	1	1	1	1	1	1	31
			32	03NOV92	1	2	1	2	1	1	1	1	2	1	1	1	1	2	1	1	1	1	1	1	1	30
			36	01DEC92	1	2	2	1	2	1	1	2	1	1	4	2	1	2	1	1	1	1	1	1	1	34
			40	29DEC92	1	2	2	2	1	2	1	1	2	2	3	2	2	1	2	1	1	1	1	1	1	30
			44	26JAN93	1	1	1	2	1	1	1	1	1	1	2	4	1	1	1	1	1	1	1	1	1	30
			48	24FEB93	1	1	1	2	1	1	1	1	1	1	2	1	1	1	1	1	1	1	3	1	1	28
52	23MAR93	1	1	1	2	1	1	1	1	2	1	2	1	1	1	1	1	1	2	2	1	1	34			
1	144/356	ARF	8	20MAY92	2	2	4	2	1	3	1	2	2	1	3	1	2	1	1	2	1	1	1	1	36	
			12	17JUN92	3	1	2	1	2	1	2	2	1	2	2	1	1	2	1	2	4	2	1	1	36	
			16	15JUL92	2	2	1	3	1	2	2	1	2	4	2	2	1	2	1	1	4	1	1	1	2	38
			20	12AUG92	1	3	2	2	1	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	33
			24	09SEP92	2	2	3	1	3	1	3	4	2	2	1	1	1	1	1	1	2	2	2	2	3	44
			28	07OCT92	2	1	2	3	1	3	1	2	2	1	1	1	1	1	1	1	4	4	3	3	2	43
			32	04NOV92	3	1	4	2	1	3	1	1	3	4	3	1	2	3	3	1	1	3	3	4	4	50
			36	02DEC92	3	2	3	2	1	3	1	2	1	1	1	1	1	1	1	1	3	3	1	1	1	40
			8	22MAY92	2	2	1	2	2	1	2	2	1	2	2	1	3	1	2	1	1	2	1	1	1	33
			12	19JUN92	2	1	2	1	2	1	2	1	1	2	1	1	1	1	2	1	1	1	1	1	1	30
			16	17JUL92	3	2	1	2	2	4	2	1	2	1	1	2	1	1	2	1	1	1	2	1	1	35
			20	14AUG92	1	1	2	1	2	1	2	1	2	1	1	2	1	1	1	2	2	1	1	1	1	31
24	11SEP92	2	2	1	3	1	2	1	2	1	2	1	1	1	1	1	1	1	3	1	1	1	32			
28	09OCT92	2	1	2	3	1	2	1	2	1	1	1	1	1	1	1	1	1	3	1	1	1	32			
32	06NOV92	3	1	2	1	3	2	1	2	1	1	1	1	1	1	1	1	2	3	1	1	1	33			
36	04DEC92	3	1	4	1	2	1	1	2	1	1	1	1	1	1	1	1	1	2	1	1	1	33			
40	31DEC92	2	2	1	3	2	2	1	2	1	1	1	1	1	1	1	1	1	4	2	1	1	39			
44	25JAN93	3	2	2	3	1	3	2	2	3	4	2	1	1	1	1	1	1	1	1	1	1	45			
48	26FEB93	3	3	3	3	2	2	1	2	4	1	1	1	1	1	1	1	1	1	3	1	1	48			
52	26MAR93	3	3	4	2	2	1	2	1	3	2	1	2	1	1	1	1	1	2	2	3	1	51			
1	148/359	CAS	8	22MAY92	1	2	2	1	2	4	2	1	2	3	1	1	1	1	2	2	1	1	1	33		
			12	19JUN92	1	2	1	2	1	4	2	1	1	2	1	1	1	1	1	1	1	1	1	1	29	
			16	17JUL92	1	2	1	2	1	4	2	1	2	1	1	1	1	1	1	1	1	1	1	1	32	
			20	16AUG92	1	2	1	2	1	4	2	1	2	1	1	1	1	1	1	1	1	1	1	1	31	

(a) = Open/Blind

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

9550077

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Patient Centre No. (a)	Initials	Visit	Date Performed	ZUNG	It. 1 It. 2 It. 3 It. 4 It. 5 It. 6 It. 7 It. 8 It. 9 It. 10 It. 11 It. 12 It. 13 It. 14 It. 15 It. 16 It. 17 It. 18 It. 19 It. 20																				Total Score (b)			
					Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score		Score		
1	148/359	CAS	24	11SEP92	1	2	1	2	2	3	1	2	1	2	2	2	2	2	2	2	2	1	1	35				
			28	09OCT92	1	2	1	3	1	4	1	2	2	3	1	2	1	2	1	2	1	1	1	1	34			
			32	06NOV92	1	1	1	2	1	3	2	1	1	2	1	2	1	2	1	2	1	1	1	1	29			
			36	04DEC92	1	1	1	3	1	4	2	1	1	3	1	1	3	1	1	2	1	1	3	1	32			
			40	31DEC92	1	1	2	1	1	3	1	1	2	4	1	1	2	1	2	2	2	1	1	1	31			
			44	29JAN93	1	1	1	2	2	4	1	1	2	4	1	1	2	1	1	1	1	2	1	1	31			
			48	26FEB93	1	1	1	2	1	1	2	1	1	2	1	1	2	1	1	1	1	2	1	1	27			
			52	26MAR93	1	1	1	3	1	2	2	4	1	1	2	1	2	1	2	1	1	2	1	1	31			
			3	7/71	ORI	8	05FEB91	2	2	1	4	1	4	1	3	4	3	2	3	1	3	3	2	2	2	3	48	
						16	04APR91	1	2	1	2	1	1	1	1	2	1	2	1	1	2	1	2	1	2	1	1	29
						20	02MAY91	2	2	1	2	1	3	1	1	1	2	2	1	2	2	2	2	2	2	1	2	34
						24	30MAY91	2	2	1	2	1	3	1	1	1	2	2	2	1	2	2	2	2	2	1	4	36
32	25JUL91	2				3	1	1	1	1	1	1	2	2	2	1	2	1	2	2	2	2	2	1	31			
40	19SEP91	1				1	1	2	1	1	1	1	1	2	2	2	1	2	2	2	2	1	1	1	28			
44	17OCT91	1				1	1	2	1	1	1	1	1	2	2	2	1	2	2	2	2	2	1	1	31			
48	14NOV91	1				2	1	3	1	1	1	1	2	2	1	2	1	2	2	2	2	2	1	1	31			
52	12DEC91	1				2	1	2	1	3	1	1	1	2	2	1	1	2	1	1	1	1	1	2	29			
8	3/213	JL				8	14FEB91	2	2	1	2	1	4	1	1	2	2	3	3	1	3	3	3	1	3	41		
						10	28FEB91	2	2	1	2	1	1	1	1	2	2	1	2	1	2	1	2	1	3	3	38	
						12	14MAR91	2	4	1	3	1	4	1	1	2	3	3	2	2	2	3	3	3	1	3	47	
			14	01MAR91	3	4	1	2	1	4	1	1	2	3	3	1	3	1	3	3	4	2	3	48				
			16	11APR91	3	4	1	3	1	4	1	1	2	3	3	4	2	4	3	4	4	1	4	56				
			8	6/216	TL	8	18MAR91	2	2	1	2	1	2	1	1	1	2	2	2	2	2	2	2	2	1	2	35	
						12	15APR91	2	2	1	2	1	2	1	1	1	2	2	3	2	2	2	2	2	1	2	34	
						16	13MAY91	2	3	1	2	1	3	1	1	1	2	2	1	2	2	2	2	3	2	1	2	36
						20	10JUN91	2	3	1	2	1	3	1	1	1	2	2	1	2	2	2	2	2	2	1	2	35
						24	08JUL91	2	3	1	2	1	3	1	1	1	2	2	1	2	2	2	2	2	2	1	2	34
						28	05AUG91	2	2	1	2	1	3	1	1	1	2	2	1	2	1	2	2	2	2	1	3	34
						32	02SEP91	1	1	1	2	1	3	1	1	1	1	2	2	1	2	1	2	2	1	2	1	28
36	30SEP91	1				2	1	1	1	1	1	1	1	2	2	1	1	2	2	1	1	2	1	1	29			
40	28OCT91	1				2	1	1	1	1	1	1	1	3	1	1	2	2	2	2	2	1	2	1	31			
44	28NOV91	1				2	1	2	1	4	1	1	1	1	2	1	1	1	1	1	1	1	1	1	28			
48	23DEC91	1				2	1	2	1	4	1	1	1	1	2	1	1	1	1	1	1	1	1	1	30			
52	20JAN92	1				2	1	2	1	4	1	1	1	1	2	1	2	1	2	1	1	1	1	1	29			
9	6/245	SD	8	01JAN91	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22					
			12	29JAN91	2	1	2	1	1	1	1	2	2	1	2	1	1	1	1	1	1	2	1	28				

(a) = Open/Blind
 (b) = Total Score

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Patient Centre No. (a)	Initials	Visit	Date Performed	ZUNG	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	Total Score (b)					
9	6/245	SD	16	26FEB91	1	2	1	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	22				
			20	26MAR91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25		
			24	23APR91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23	
			28	04MAY91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23	
			32	18JUN91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21	
			36	16JUL91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21	
			40	13AUG91	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21	
			44	10SEP91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	20	
			48	09OCT91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	20	
			52	05NOV91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	20	
			9	7/243	PP	8	03JAN91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22
						12	31JAN91	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
16	28FEB91	1				2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25	
20	28MAR91	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22	
24	25APR91	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21	
28	23MAY91	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	20	
32	20JUN91	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	20	
36	18JUL91	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	20	
40	15AUG91	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	20	
44		1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	20	
48	10OCT91	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	20	
52	07NOV91	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	20	
9	11/246	KE	8	26MAR91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21			
			12	23JAN91	2	2	3	2	3	2	3	2	3	2	3	2	3	2	3	2	3	2	3	2	3	2	3	49		
			16	21MAY91	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	29	
			20	18JUN91	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24	
			24	16JUL91	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22	
			28	13AUG91	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23	
			32	10SEP91	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24	
			36	08OCT91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	20	
			40	05NOV91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	20
			44	03DEC91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	20
			48	31DEC91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21
			52	28JAN92	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	20
9	15/249	BI	8	14JUL91	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23			
			12	11AUG91	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22		
			16	08SEP91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23	
			20	06OCT91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22	

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre No.	(a)	Initials	Visit	Date Performed	ZUNG	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	Total Score (b)					
						1	2	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		1	1	1	1	
9	15/249	BI	24	03NOV91	2	2	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24					
			28	01NOV91	2	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25				
			32	29DEC91	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24			
			36	26JAN92	2	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25			
			40	23FEB92	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24			
			44	22MAR92	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25			
			48	19APR92	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25			
			52	17MAY92	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25			
			9	16/250	UGX	8	03SEP91	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24		
						12	02OCT91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22	
						16	29OCT91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23
						20	26NOV91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23
24	16DEC91	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22			
28	21JAN92	2				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21			
32	18FEB92	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21			
36	17MAR92	1				2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21			
40	14APR92	2				2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	26			
44	12MAY92	2				2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25			
48	09MAY92	2				2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25			
52	07JUL92	2				2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	26			
9	20/252	GVE	8	18OCT91	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	29					
			12	15NOV91	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	30				
			16	13DEC91	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	28			
			18	27DEC91	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	46			
			9	23/256	SZN	8	03JAN92	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	27		
						12	31JAN92	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	27	
9	26/255	CP	16	28FEB92	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	26					
			20	27MAR92	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25				
			8	16JAN92	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23			
			12	13FEB92	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23			
9	29/258	S2F	16	12MAR92	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24					
			20	09APR92	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24				
			12	29JUN92	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23			
			16	27JUL92	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24			
			20	10AUG92	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23			
			24	21SEP92	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24			

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Patient Centre No. (a)	Initials	Visit	Date Performed	ZUNG	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	Total Score (b)	
9	29/258	SZF	28	19OCT92	1	1	1	1	2	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	23	
9	30/259	NF	8	01JUN92	1	1	2	2	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	23	
10	1/271	VK	8	10NOV90	2	2	1	3	1	3	1	2	2	2	2	2	2	3	2	3	3	3	1	3	42	
			12	07JAN91	2	2	1	3	3	1	2	2	2	2	2	2	2	2	3	3	3	3	1	3	46	
			16	29JAN91	2	1	1	2	1	2	1	2	2	1	2	2	2	2	2	2	2	3	1	2	34	
10	7/274	RK	8	16JAN91	1	1	2	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	23	
10	9/275	RT	8	26JAN91	1	1	1	1	1	2	1	1	1	1	1	1	4	2	1	1	1	2	1	1	26	
			9	05FEB91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21	
10	12/277	EP	8	06MAR91	2	3	2	3	3	2	2	3	3	3	3	1	2	3	2	3	2	3	2	1	3	48
			10	20MAR91	2	3	2	3	3	2	2	2	2	3	3	1	3	2	3	2	3	2	3	1	3	48
10	13/278	HU	8	08APR91	2	4	2	4	3	2	2	4	3	2	2	3	2	4	2	3	2	3	1	2	52	
10	15/280	HT	8	17APR91	1	4	1	4	2	2	2	2	1	1	1	2	4	1	1	1	1	1	1	1	32	
10	20/285	EJ	8	2	2	1	3	1	2	3	2	2	2	2	2	2	2	2	2	2	2	3	3	1	2	39
			12	2	1	1	2	1	2	4	2	2	2	2	2	2	2	2	2	2	2	2	2	1	2	38
			16	2	1	1	2	1	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	1	2	37
			20	2	1	1	1	1	2	1	3	2	1	1	1	1	1	1	1	1	1	2	2	1	1	28
			24	2	1	1	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1	1	34
10	32/286	AA	8	17JUN91	1	2	1	2	1	2	2	1	2	1	2	1	1	1	2	2	2	2	1	2	2	32
			12	2	4	1	2	1	2	2	2	2	2	2	2	1	2	1	2	2	2	2	1	2	37	
			16	2	4	1	2	1	1	2	2	2	2	2	1	2	2	2	2	2	2	2	1	2	37	
			20	3	3	2	2	3	4	2	2	2	2	2	3	3	3	3	3	3	3	3	3	2	3	54
			24	2	3	1	2	2	2	2	2	2	2	2	2	3	3	3	3	3	3	3	3	1	3	47
			28	2	4	1	1	1	1	2	1	2	2	2	2	2	2	2	2	2	2	3	3	1	2	38
			32	2	4	1	1	1	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	1	2	38
			36	2	4	1	1	2	1	3	1	2	2	2	1	2	2	2	2	2	2	2	2	1	2	38
			40	1	4	1	1	1	3	1	1	2	2	2	1	2	2	2	2	2	2	2	3	1	2	38
			44	1	4	1	1	1	3	1	1	2	2	2	2	2	2	2	2	2	2	2	3	1	2	37
			48	2	4	1	1	1	2	1	2	2	2	2	2	2	2	2	2	2	2	2	3	1	2	37
			52	2	4	1	2	1	2	1	2	2	2	2	2	2	2	2	2	2	2	3	2	3	1	41
10	23/287	LT	8	1	2	2	2	3	1	3	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	30
			12	1	2	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre No. (a)	Patient Initials	Date Performed	ZUNG	Total Score (b)																					
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20		
10	23/287	LT	16	2	2	1	2	1	2	1	1	1	1	1	1	1	1	2	1	3	1	1	29		
			20	2	2	3	2	3	2	2	1	1	1	1	1	1	1	2	2	2	1	1	33		
			24	1	2	1	1	2	2	2	1	1	1	1	1	1	1	1	1	1	2	1	1	25	
			26	1	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	2	1	1	22	
			28	1	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	2	1	1	22
			32	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	20
			40	2	3	1	3	2	2	2	1	1	1	1	1	1	1	1	1	1	1	2	1	2	30
			8	3	3	2	4	1	4	4	3	4	1	3	3	3	4	3	4	3	4	1	3	56	
10	26/290	JIF	8	1	1	1	2	1	3	1	2	1	1	1	1	1	1	1	1	1	2	1	25		
			12	1	1	2	2	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	25		
			16	1	1	1	2	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	24		
			20	1	1	2	2	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24	
			24	1	1	2	2	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25	
			28	1	1	2	2	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25	
			32	1	1	1	2	2	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	25	
			36	2	1	2	2	4	3	1	2	1	4	1	1	1	1	1	1	1	1	1	1	32	
10	27/292	MK	8	1	1	2	2	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	24		
			12	1	1	2	2	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	24		
			16	1	1	1	2	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24	
			20	1	1	2	2	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25	
			24	1	1	2	2	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25	
			28	1	1	2	2	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25	
			32	1	1	1	2	2	2	3	1	2	1	1	1	1	1	1	1	1	1	1	1	24	
			36	1	1	2	2	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24	
10	28/291	LL	8	1	1	2	2	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	24		
			12	4	4	2	3	1	1	1	2	1	3	2	2	2	2	3	3	3	1	3	45		
			16	4	4	2	1	1	1	1	1	2	2	1	2	1	2	2	2	3	1	2	4	57	
			20	4	4	4	3	4	1	1	2	2	3	4	4	4	4	4	4	4	4	4	4	35	
			24	4	4	4	4	4	2	1	2	4	3	4	4	4	4	4	4	4	4	4	4	67	
			28	4	4	4	4	4	4	4	4	4	3	4	4	4	4	4	4	4	4	4	4	60	
			32	3	3	1	1	1	1	1	1	1	2	2	2	2	2	2	2	2	2	2	2	32	
			36	4	4	4	3	1	1	1	1	1	1	2	3	4	4	4	4	4	4	4	4	55	
10	31/297	BK	8	2	2	2	4	1	3	3	4	1	3	3	4	4	4	4	4	4	4	4	63		
			12	2	2	2	2	3	3	2	2	2	3	2	2	2	2	2	2	2	2	2	61		
			16	2	3	3	2	1	3	2	2	2	2	3	2	3	2	3	3	3	3	2	3	48	
			20	2	2	2	1	1	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	42	
			24	2	2	2	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	45	
			28	3	1	3	2	1	3	2	2	2	3	2	3	2	3	3	3	3	3	3	2	47	

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXYETINE - PROTOCOL 20124/013
Listing No.: 10.4

ZUNG SELF RATING DEPRESSION SCALE
DOUBLE BLIND PHASE
TREATMENT: REBOXYETINE

Centre No.	Patient Initials	Date Performed	ZUNG																				Total Score (b)
			It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	
10	31/297 RK	32	3	3	2	2	3	3	2	2	2	2	3	3	2	3	3	3	3	3	3	51	
		36	2	2	2	3	3	2	2	2	2	2	3	3	2	3	2	3	3	3	2	3	49
		40	2	2	2	2	3	3	3	2	2	2	3	3	2	3	2	3	3	3	2	3	51
		44	2	2	2	2	3	3	2	2	2	2	3	3	2	3	2	3	3	3	2	3	51
		48	2	2	2	2	3	3	2	2	2	2	3	3	2	3	2	3	3	3	1	3	48
		52	2	2	2	2	3	3	1	2	2	2	3	3	2	3	2	3	3	3	3	1	3
10	32/299 LK	8	2	3	2	1	1	2	2	2	2	2	3	4	3	2	3	3	3	2	3	46	
		12	3	3	2	1	1	2	1	1	1	1	2	2	4	2	2	3	4	2	4	2	43
		16	3	3	4	1	1	2	2	2	2	2	3	3	4	4	4	4	4	4	4	4	59
		20	3	3	1	1	1	1	2	2	2	2	1	3	3	4	3	3	4	4	3	4	53
		24	3	3	1	1	1	1	2	2	2	2	2	3	3	4	3	4	4	4	3	4	53
		28	2	3	2	1	1	1	1	2	1	2	2	3	2	4	3	3	3	2	3	2	43
		32	2	3	2	1	1	1	1	2	2	2	2	3	2	4	3	3	3	3	2	3	43
		36	2	1	1	1	1	1	1	1	1	2	2	2	3	2	3	3	3	3	2	3	40
		40	2	2	1	1	1	1	2	2	1	1	1	1	2	1	1	2	2	2	1	1	25
		44	2	1	2	1	1	1	1	2	1	1	2	1	2	2	2	2	2	1	1	1	31
10	33/300 EK	8	2	2	2	1	1	1	1	1	1	1	2	2	2	2	2	2	1	1	1	26	
		12	2	2	1	1	1	1	1	1	1	1	2	2	2	2	2	2	1	1	1	1	28
		16	1	1	1	1	1	1	1	1	1	1	2	2	2	2	2	2	2	2	2	1	32
			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	20
10	34/31 TK	8	3	3	1	2	2	3	1	3	2	2	3	3	3	2	4	3	3	1	3	49	
		16	3	3	1	2	2	4	1	3	2	3	3	4	3	4	3	4	3	4	1	3	57
10	35/35 IM	8	3	3	3	1	2	1	1	3	3	2	3	2	4	2	3	3	3	4	1	48	
10	38/37 LL	8	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21	
		12	1	4	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24	
		16	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	20	
10	39/40 VM	8	2	3	2	2	2	3	1	2	1	2	3	2	2	3	1	3	1	3	1	42	
		12	2	3	2	2	2	3	1	2	2	2	3	3	3	2	3	2	3	1	3	45	
		16	2	2	4	1	1	2	2	2	2	2	3	2	2	3	2	2	2	1	2	2	33
		20	3	3	1	1	1	3	1	3	1	3	3	3	2	3	3	3	3	3	1	3	51
		24	2	2	2	2	3	2	2	2	2	2	3	3	2	3	3	2	3	1	3	1	45
		32	1	3	2	2	2	2	2	2	2	2	3	2	3	2	3	3	2	3	2	3	52

(a) = Open/Blind
(b) = ...

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Patient Centre No. (a)	Initials	Visit	Date Performed	ZUNG																			Total Score (b)	
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19		It.20
10	39/40	VM	36	3	3	3	3	3	4	1	3	3	3	3	3	4	3	4	3	4	2	4	62	
			40	2	3	2	2	2	3	1	3	2	3	3	2	3	3	3	1	3	2	3	49	
			44	3	3	2	2	2	3	1	3	2	3	3	2	3	3	2	3	2	3	1	3	48
			48	3	3	2	2	3	1	3	2	3	3	3	2	3	3	3	3	2	3	1	3	50
			52	3	3	2	2	2	3	1	3	2	3	3	3	2	3	3	3	2	3	1	3	50
10	41/42	VP	8	19	REC91	2	3	2	3	1	4	2	2	2	3	3	3	1	3	1	2	1	35	
			12	21	JAN92	2	4	1	1	4	4	2	2	2	1	3	4	4	3	1	2	2	4	50
			16	15	FEB92	2	1	2	1	1	4	2	1	2	2	1	4	2	3	2	1	3	1	33
			20	21	APR92	2	3	1	1	4	4	3	2	2	1	3	4	4	3	1	2	1	3	49
			24	21	APR92	2	1	2	2	1	4	3	2	2	2	3	1	2	1	2	1	3	1	32
			28	12	MAY91	2	1	2	2	1	4	2	1	2	2	1	2	1	1	1	1	3	1	29
			32	2	4	2	1	4	4	2	2	3	1	3	4	4	3	1	3	1	3	2	3	52
			36	2	1	2	2	1	4	2	1	1	3	1	1	2	1	1	1	1	1	1	1	29
			40	11	AUG91	2	4	1	1	4	3	2	2	2	4	4	4	1	1	3	2	3	2	49
			44	2	4	1	1	4	4	3	2	2	2	1	3	4	4	1	2	1	3	2	3	51
			48	2	1	2	2	2	4	3	2	2	1	3	1	1	2	1	2	3	1	1	1	31
			52	2	4	1	1	4	4	2	2	3	1	4	4	4	4	1	3	2	3	2	3	54
10	49/43	VM	8	06	FEB92	3	4	3	2	1	4	1	3	3	3	4	3	4	3	4	2	3	60	
			12	25	FEB92	3	3	1	3	3	3	3	1	3	3	3	4	3	2	3	2	3	55	
			16	07	APR92	3	4	2	2	1	4	1	3	3	3	3	4	4	3	4	3	4	61	
			20	20	APR92	3	3	2	2	1	4	1	3	3	3	3	4	3	4	3	4	2	4	59
			24	22	MAY92	3	4	3	2	1	4	2	3	4	3	3	4	3	4	3	4	2	4	63
28	3	3	3	1	3	3	3	2	3	2	3	3	3	4	3	1	3	2	3	3	56			
10	53/47	MA	8	08	MAR92	2	1	3	2	1	1	1	4	3	2	3	2	3	3	4	2	3	47	
			12	05	APR92	2	3	3	1	1	1	1	4	3	2	3	2	3	3	3	2	3	49	
			16	03	MAY92	2	2	2	1	1	1	4	2	1	2	2	2	2	3	3	1	2	40	
			20	31	MAY92	2	1	2	2	1	1	1	4	2	1	2	2	2	2	3	2	3	38	
10	54/48	UN	8	08	MAR92	2	3	2	3	1	4	2	1	3	3	2	3	2	3	3	1	3	50	
			12	04	MAR92	2	2	3	1	1	2	2	3	2	2	3	2	3	2	3	1	2	43	
			16	2	3	2	3	3	2	3	3	2	3	2	4	4	3	1	2	3	3	2	54	
			20	2	2	2	1	4	2	2	2	2	3	2	4	5	2	3	3	1	2	3	46	
24	2	2	2	1	4	2	2	2	2	2	2	3	2	3	2	3	3	1	2	3	45			
28	2	2	2	1	4	2	2	1	4	2	2	2	3	2	3	2	3	3	1	3	47			
10	56/50	JP	8	2	2	1	2	1	2	1	2	2	2	3	3	4	3	4	3	2	47			
10	57/51	AG	8	2	1	2	2	1	2	1	2	2	1	1	2	2	3	1	2	1	33			

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Patient Centre No. (a)	Initials	Visit	Date Performed	ZUNG	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	Total Score (b)	
10	57/51	AG	12	.	2	1	2	2	1	2	2	2	2	1	1	2	2	2	2	3	1	2	1	2	34	
			16	.	2	1	2	1	1	2	2	2	2	1	1	2	2	2	2	4	2	2	1	2	37	
			20	.	1	1	2	1	2	2	3	2	2	1	1	2	2	2	3	2	2	2	1	2	37	
			24	.	1	1	2	1	3	2	2	2	2	1	1	2	3	1	3	3	2	2	1	2	35	
			28	.	2	2	2	1	3	2	2	2	2	2	1	2	2	4	1	2	4	1	2	1	37	
			32	.	2	2	2	1	2	2	2	2	2	2	1	2	2	1	2	4	1	2	1	1	37	
			36	.	2	2	2	1	2	2	2	2	2	2	1	2	2	1	2	4	1	3	1	2	38	
			40	.	2	2	3	1	2	2	2	1	2	2	1	3	2	1	2	4	1	3	1	2	39	
			44	.	3	3	2	2	3	2	1	2	2	2	2	3	3	2	3	4	1	3	1	2	48	
			48	.	1	2	2	1	2	2	1	2	2	2	1	2	2	2	4	1	3	1	2	2	37	
			52	.	3	3	3	1	2	2	1	2	2	1	3	2	2	3	4	1	3	3	1	3	45	
10	59/53	TA	8	.	2	4	2	4	3	4	2	2	2	4	3	3	2	1	4	4	2	3	1	3	53	
10	63/57	MS	8	.	1	1	2	1	1	1	4	1	3	1	1	1	2	1	2	1	1	3	1	1	30	
			12	.	1	2	1	1	1	1	2	1	3	1	2	1	1	1	2	1	1	3	1	1	28	
			16	.	2	4	1	1	4	2	2	3	1	4	4	4	4	1	3	1	3	1	4	2	4	52
			20	.	1	4	1	1	1	4	2	2	3	1	4	4	4	2	3	1	4	4	3	4	53	
			24	.	1	2	1	2	1	2	2	2	1	2	1	1	2	1	1	1	1	1	1	1	27	
			28	.	1	4	2	1	1	4	2	2	3	1	4	4	4	2	3	1	4	4	3	4	54	
			32	.	1	1	1	1	1	1	1	1	1	3	1	1	2	1	2	1	1	1	1	1	21	
			36	.	1	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	26	
			40	.	1	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	21	
			44	.	2	1	1	2	1	1	2	3	1	2	1	4	4	2	3	1	1	4	3	4	53	
			48	.	2	1	1	2	1	1	2	3	1	2	1	1	2	2	1	1	1	1	1	1	29	
			52	.	2	1	1	2	1	1	1	1	1	3	1	2	1	1	2	1	1	1	1	1	26	
			52	.	2	1	1	2	1	1	1	1	1	2	1	2	1	1	2	1	1	1	1	1	25	
10	82/59	LS	8	.	3	2	1	3	1	3	3	2	1	3	3	3	1	4	1	4	3	3	3	4	50	
			12	.	2	2	1	1	1	3	1	1	4	2	4	4	2	3	3	4	3	4	2	3	51	
			32	.	1	1	1	1	1	1	2	1	1	1	1	1	2	1	1	2	1	1	1	1	23	
10	86/274	NP	8	.	2	3	2	3	4	2	3	2	4	3	4	2	3	2	4	3	2	3	1	4	54	
			12	.	2	3	1	1	2	2	2	3	2	2	2	3	3	2	3	2	3	2	3	2	46	
			16	.	2	2	2	2	3	2	2	2	2	2	2	2	2	3	2	3	2	3	1	3	42	
10	87/275	AN	8	.	15	1	2	1	3	4	2	2	3	1	4	3	4	4	2	2	1	1	2	4	51	
			12	.	25	1	2	2	3	3	2	3	3	2	3	3	2	3	2	3	3	3	1	2	50	
			16	.	30	1	3	3	3	3	4	3	3	3	3	3	2	4	3	3	3	3	3	3	60	
			20	.	03	1	4	2	1	3	2	2	3	2	3	3	4	3	1	2	2	2	2	3	50	
			24	.	2	2	2	2	1	3	4	3	2	2	2	2	2	2	2	2	2	2	2	2	42	
			28	.	29	2	2	3	1	3	2	2	3	2	3	3	2	2	2	2	1	2	2	2	4	50

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Patient Centre No. (a)	Initials	Visit	Date Performed	Total Score (b)																					
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20		
10	87/275	AN	32	2	3	2	1	3	3	2	2	2	2	2	3	4	3	2	2	2	3	1	2	43	
			36	2	3	1	3	2	2	2	2	3	3	4	2	4	1	2	2	2	2	2	2	4	50
			40	2	4	2	3	3	4	2	2	3	3	1	4	3	3	3	3	3	3	3	1	3	55
			44	2	3	2	2	1	3	3	4	2	2	2	2	3	2	2	3	2	2	3	2	3	47
			48	4	4	4	3	4	4	4	3	4	4	4	4	4	4	4	4	4	4	4	3	4	76
			52	3	4	3	3	2	3	2	4	2	3	2	1	2	3	2	3	3	3	3	2	3	53
10	89/277	SK	8	3	3	3	2	1	2	3	3	2	3	4	4	3	4	2	2	3	2	3	51		
			12	2	4	1	2	1	3	1	2	3	1	4	4	2	4	3	1	1	4	1	3	54	
10	90/70	SV	8	1	2	2	1	1	1	2	2	2	2	1	2	2	2	2	2	2	1	2	2	32	
			12	2	3	3	3	1	2	2	3	3	3	2	3	2	3	3	3	3	3	1	3	49	
			16	2	2	2	4	1	2	2	2	3	2	2	2	2	2	2	2	2	2	2	1	2	47
			20	2	1	2	1	3	1	2	2	2	2	2	2	2	2	2	2	2	2	2	1	2	36
			8	2	4	2	3	1	4	2	3	3	2	4	4	1	3	3	1	1	1	4	1	3	51
			12	2	4	1	2	1	3	1	2	3	1	4	4	2	4	3	4	4	4	4	1	4	54
10	93/285	AN	8	1	1	1	1	4	2	1	4	1	4	4	4	4	3	4	4	4	4	4	4	56	
			12	1	3	1	1	2	1	2	2	1	2	1	1	1	1	1	1	1	2	1	1	27	
			16	1	3	1	1	2	1	2	2	1	2	1	1	1	1	1	1	1	1	2	1	1	27
			20	1	3	1	1	2	1	2	1	2	1	1	1	1	1	1	1	1	1	2	1	1	25
			24	1	3	1	1	2	1	2	1	2	1	1	1	1	1	1	1	1	1	2	1	1	26
			28	1	3	1	1	2	1	2	1	2	1	2	1	1	1	1	1	1	1	2	1	1	26
11	2/373	HB	8	1	3	1	1	4	2	1	2	1	2	1	1	1	1	1	1	1	2	1	1	29	
			12	2	3	1	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	29	
			16	1	2	1	1	1	4	1	3	2	1	1	1	2	1	1	1	1	1	1	1	30	
			20	1	2	1	1	4	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	26
			24	1	1	1	1	4	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24
			28	2	2	3	2	4	1	1	1	3	2	2	3	3	3	2	2	2	2	2	1	2	41
11	3/374	RF	8	4	2	4	2	3	2	1	2	2	3	3	3	3	3	3	3	3	3	2	54		
			12	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	26	
11	6/377	VP	8	2	4	1	1	1	1	1	1	1	1	2	2	2	2	2	2	2	2	1	36		
			12	4	1	1	2	1	1	1	1	1	1	1	2	2	4	2	2	2	2	1	34		
			16	2	1	4	3	1	2	1	1	2	1	1	1	2	2	2	2	2	2	1	2	31	
			20	4	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	31	
24	3	1	1	1	1	1	1	1	1	1	1	3	3	3	3	3	3	3	2	1	1	33			

(a) = Open/Blind
 (b) = Mean Score

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REMOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REMOXETINE

Centre No. (a)	Patient Initials	Date Performed	ZUNG	It. 1 It. 2 It. 3 It. 4 It. 5 It. 6 It. 7 It. 8 It. 9 It. 10 It. 11 It. 12 It. 13 It. 14 It. 15 It. 16 It. 17 It. 18 It. 19 It. 20																				Total Score (b)		
				Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score		Score	
11	6/377	VP	28	2	3	1	2	1	1	1	1	1	1	1	2	2	2	3	2	1	2	1	1	2	32	
			32	1	1	1	1	1	1	1	1	2	1	1	2	2	2	4	2	1	1	1	1	1	1	29
			36	2	1	1	1	1	1	1	1	1	1	1	1	2	3	4	2	1	2	1	1	1	1	20
			40	1	1	1	1	1	1	1	1	2	1	1	2	2	2	4	2	1	1	1	1	1	1	30
			44	1	1	1	1	1	1	1	1	2	1	1	2	2	2	1	1	1	1	1	1	1	1	24
11	10/363	BJ	48	2	2	1	1	1	1	1	1	1	1	2	2	2	3	2	2	2	1	1	1	1	30	
			52	1	1	1	1	1	1	1	1	2	1	2	2	2	4	2	2	2	1	1	1	1	32	
			8	2	2	3	1	2	1	4	3	3	1	4	3	3	4	4	4	4	1	3	1	1	3	50
			12	4	4	3	3	3	3	3	3	4	3	4	4	4	4	4	4	4	3	4	1	1	4	68
			16	3	4	2	3	1	2	1	4	2	3	1	4	3	3	4	4	4	4	1	3	1	1	52
11	11/361	NGY	20	2	3	2	2	1	2	1	4	2	3	1	4	2	4	4	4	1	3	1	1	3	52	
			24	2	2	2	2	2	2	2	2	3	1	4	2	3	2	4	4	4	1	4	1	1	5	
			28	3	3	3	3	2	1	2	2	1	1	3	3	3	2	3	2	3	2	1	1	1	1	35
			32	3	3	2	1	2	2	2	2	2	2	2	3	3	4	3	2	2	2	2	1	1	1	48
			36	2	2	1	1	2	1	2	2	2	2	2	2	2	2	2	3	2	1	1	1	1	1	40
11	13/365	GK	40	3	3	2	2	1	1	1	1	2	3	2	2	2	3	2	2	2	2	1	1	1	39	
			44	2	2	1	1	3	2	1	1	2	2	2	2	2	3	2	2	2	2	2	1	1	37	
			48	2	2	1	1	3	2	1	1	2	2	2	2	2	3	2	2	2	1	2	1	1	39	
			52	2	2	1	1	3	2	1	1	2	2	2	2	3	2	3	2	2	2	1	2	1	1	35
			8	1	1	1	1	1	1	1	1	2	2	1	3	2	3	2	3	3	1	1	1	1	1	35
11	16/367	NA	8	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24	
			12	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24	
			16	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	40
			20	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	40
			24	4	4	4	4	3	4	1	3	2	4	3	3	4	4	4	4	4	3	3	3	2	2	4
11	17/368	UZ	8	3	2	3	4	3	3	2	3	3	3	3	3	2	3	3	2	3	1	1	1	1	54	
			12	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	40	
			16	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	45	
			20	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	34	
			24	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	45

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Patient Centre No. (a)	Initials	Visit	Date Performed ZUNG	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	Total Score (b)				
				3	4	3	3	3	3	1	3	1	3	2	2	3	3	4	4	3	4	4	2		4	3	2	58
11	17/368	UZ	24	23JUL92	3	4	3	3	3	3	1	3	1	3	2	3	4	3	4	4	2	4	3	2	58			
			28	20AUG92	3	2	3	2	4	1	2	4	1	2	3	3	4	4	3	2	2	2	3	2	49			
			32	17SEP92	3	2	2	1	4	1	1	1	1	2	1	2	1	2	3	4	2	2	2	1	1	39		
			36	15OCT92	3	4	3	2	4	1	1	1	1	2	1	2	4	4	3	4	2	2	2	1	2	44		
			40	12NOV92	3	4	3	1	2	4	1	1	1	3	2	2	3	4	3	3	3	3	3	2	1	51		
			44	10DEC92	3	2	4	1	3	4	2	1	1	4	3	4	4	4	4	4	4	2	3	3	2	56		
			48	07JAN93	3	2	3	1	1	4	2	1	1	3	1	3	3	3	3	3	4	1	3	3	1	46		
			52	04FEB93	3	2	4	1	1	3	1	1	1	3	3	3	3	3	4	2	4	3	2	3	1	47		
			11	19/370	FK	8	23APR92	3	2	3	2	3	3	1	2	2	2	2	3	3	2	2	2	2	2	1	1	45
						12	21MAY92	2	1	2	2	2	2	2	2	4	2	1	1	1	1	2	3	1	1	1	2	1
16	18JUN93	3				2	3	2	3	3	2	1	1	3	1	1	1	2	2	3	3	2	2	1	1	43		
20	16JUL92	2				1	2	1	1	1	2	1	1	1	1	1	1	2	1	1	2	1	1	1	1	27		
28	10SEP92	2				2	1	1	1	3	1	1	2	2	2	2	1	3	2	3	1	1	1	1	1	32		
32	08OCT92	2				2	1	1	1	1	1	1	1	1	1	1	1	1	3	2	2	2	1	1	1	29		
36	05NOV92	2				2	2	1	1	1	1	1	1	1	1	1	1	1	2	2	2	2	1	1	1	29		
40	03DEC92	3				2	4	3	3	3	3	1	2	1	3	1	3	4	4	3	3	3	3	1	1	54		
44	31DEC92	2				1	2	1	1	3	4	1	1	1	1	1	1	2	3	2	1	1	1	1	1	30		
48	28JAN93	2				1	2	1	1	1	1	1	1	1	1	1	1	2	3	2	4	3	2	2	1	35		
12	1/92	IB	8	25FEB93	2	2	2	1	1	3	1	1	1	1	1	1	2	1	4	2	1	1	1	31				
			12	25DEC91	2	2	1	1	3	3	1	1	1	3	2	2	3	1	3	1	1	3	3	1	3	38		
			16	21JAN92	1	4	1	1	1	1	1	1	1	3	2	4	1	1	1	1	3	3	3	1	3	40		
			20	18FEB92	3	3	3	2	4	4	2	1	2	3	3	4	3	3	4	3	2	4	3	4	1	4	59	
			24	17MAR92	3	4	1	1	4	3	5	1	2	3	3	3	2	3	2	3	2	3	2	3	1	3	50	
			28	14APR92	2	4	1	2	4	3	2	1	1	4	3	3	2	3	2	3	1	3	2	3	1	3	48	
			32	12MAY92	2	3	1	1	3	2	1	1	1	3	2	1	3	3	2	2	2	2	2	3	1	3	44	
			36	09JUN92	2	3	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	28	
			40	07JUL92	2	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	25	
			44	04AUG92	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	27	
12	3/93	IF	8	01SEP92	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	26			
			12	29SEP92	2	1	2	2	2	1	3	1	2	1	1	1	1	1	1	1	1	1	1	1	1	30		
			16	30DEC91	2	3	2	2	3	4	1	1	1	2	1	1	1	1	3	3	1	4	3	2	3	45		
			20	21JAN92	2	2	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	25		
			24	18FEB92	2	2	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	25		
			28	17MAR92	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24		
			32	16APR92	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25		
			36	12MAY92	3	3	3	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	47		
			40	09JUN92	2	3	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	35		
			44	07JUL92	2	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	25	

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Patient Centres No. (a)	Initials	Visit	Date Performed	ZUNG																			Total Score (b)						
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19		It.20					
12	4/100	EG	12	27JAN92	2	3	2	2	3	4	1	2	1	3	1	1	2	2	3	1	2	2	1	2	2	1	2	40	
			16	24FEB92	1	2	2	3	3	1	2	1	2	1	1	3	2	4	1	2	3	3	1	2	3	1	2	39	
			20	23MAR92	2	4	2	1	4	4	1	1	3	1	1	2	3	4	1	3	3	1	3	3	1	3	1	3	45
			24	21APR92	3	4	1	4	4	1	2	1	4	1	1	2	3	3	1	3	3	2	3	3	2	3	2	3	47
			26	18MAY92	3	4	2	1	4	4	1	1	3	1	2	2	3	4	1	3	3	2	3	3	2	3	2	3	48
12	7/102	LK	8	30DEC91	3	3	1	3	3	1	1	3	3	1	2	3	2	3	2	3	2	2	2	1	2	1	2	43	
			12	27JAN92	2	3	1	2	1	3	2	2	3	2	2	3	3	2	2	2	2	2	2	1	3	1	3	43	
			16	24FEB92	3	3	1	2	1	1	4	1	2	3	2	2	3	2	2	2	2	2	2	1	2	1	2	38	
			20	23MAR92	2	2	1	2	1	1	1	2	2	1	1	2	1	2	1	2	1	2	2	1	2	2	1	2	30
			24	20APR92	3	3	2	4	2	1	1	1	3	3	2	3	3	2	3	2	3	2	3	2	3	2	3	2	49
12	9/91	KBP	8	25DEC91	3	2	3	2	3	3	2	2	3	3	3	3	3	3	3	3	3	3	3	3	2	3	2	54	
			12	22JAN92	3	2	4	2	3	2	1	2	3	3	3	3	3	3	3	3	3	3	3	3	2	3	2	54	
			16	19FEB92	3	2	3	1	2	4	2	1	1	2	2	3	3	3	3	3	3	3	3	3	1	3	1	3	48
			20	18MAR92	3	1	3	1	3	3	1	1	3	3	4	3	3	3	3	4	3	3	2	3	2	3	2	3	53
			24	15APR92	2	1	3	2	2	3	2	1	2	3	3	3	2	3	3	3	3	3	1	3	1	3	1	3	48
12	15/104	GB	8	13MAY92	3	2	3	2	3	2	1	2	3	3	4	3	3	3	3	3	3	3	3	3	1	3	1	54	
			12	20JAN92	2	2	4	1	1	2	2	2	2	1	2	2	1	4	3	3	3	4	3	3	4	3	1	44	
			16	17FEB92	2	2	2	1	1	1	1	1	2	1	2	3	1	3	2	3	3	3	1	1	3	1	1	35	
			20	16MAR92	2	2	2	1	1	1	1	1	2	1	2	3	1	3	2	3	3	3	1	1	3	1	1	35	
			24	13APR92	2	2	2	1	1	1	2	1	2	1	2	3	1	4	3	3	3	3	1	1	3	1	1	35	
12	16/105	FN	8	11MAY92	2	2	2	2	2	1	2	2	1	2	1	1	3	1	4	3	3	3	3	1	1	1	39		
			12	04FEB92	2	4	3	1	2	3	2	1	2	2	2	2	4	3	3	2	3	2	3	1	2	3	1	46	
			16	03MAR92	2	4	1	1	2	3	3	2	1	2	3	1	3	3	4	3	3	4	1	2	4	1	2	48	
			20	31MAR92	3	3	2	2	3	4	3	2	3	2	3	2	3	3	3	3	3	4	3	1	2	4	1	55	
			24	28APR92	2	4	3	2	2	3	4	4	2	3	2	4	2	4	2	3	2	4	2	1	3	2	1	51	
12	19/106	SSZ	8	26MAY92	2	2	3	2	3	2	3	3	2	2	2	2	2	2	3	2	3	3	2	3	1	2	49		
			12	11MAR92	2	2	1	3	4	2	1	1	2	1	3	1	3	3	4	3	3	4	1	3	4	1	3	46	
			16	08APR92	2	2	1	2	2	3	1	1	2	1	3	2	1	3	3	3	3	3	4	1	2	4	1	42	
			20	06MAY92	2	1	2	2	3	2	1	1	2	1	2	2	1	3	3	3	3	4	1	2	4	1	2	41	
			24	26MAR92	2	4	1	2	2	3	1	2	2	3	1	1	2	1	3	3	3	4	1	2	4	1	2	41	
12	21/110	FL	8	26MAR92	2	4	1	2	2	3	1	2	2	3	1	1	2	1	1	1	2	1	1	2	1	2	36		
			12	23APR92	2	4	2	2	2	3	1	2	3	1	4	1	4	1	4	1	4	1	2	1	2	1	2	41	
			16	21MAY92	3	4	2	3	3	2	2	4	1	2	2	4	1	3	1	4	1	3	1	2	1	3	1	47	
			20	18JUN92	3	4	2	2	3	2	2	3	1	2	2	4	1	2	2	4	1	1	2	2	1	2	1	42	
			24	16JUN92	3	4	2	2	2	3	2	2	2	3	1	1	2	2	4	1	1	2	2	1	2	1	2	42	

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Patient Centre No. (a)	Initials	Visit	Date Performed	ZUNG	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	Total Score (b)
12	24/113	MF	8	17APR92	2	4	3	3	3	4	1	1	2	2	2	2	3	2	3	2	2	3	1	1	46
			12	15MAY92	3	1	3	1	1	4	1	2	3	1	1	1	3	2	4	2	2	1	1	1	38
			16	12JUN92	2	4	3	2	2	1	3	1	3	3	1	1	3	1	4	1	1	1	1	1	38
			20	10JUL92	1	4	3	2	2	4	1	1	3	3	2	2	2	2	3	2	2	2	1	2	44
			24	07AUG92	2	4	2	2	1	3	1	2	3	3	1	1	4	1	4	1	1	1	1	1	39
			28	04SEP92	2	4	2	2	1	3	1	2	3	3	1	1	2	1	4	1	1	1	1	1	37
12	25/114	FS	8	06APR92	3	1	3	4	2	4	3	4	3	4	3	3	3	3	3	3	3	2	4	3	61
			12	04MAY92	4	3	4	3	1	4	3	2	4	4	4	4	4	4	4	4	4	1	4	3	63
			16	01JUN92	3	3	3	1	1	4	2	1	2	4	3	3	4	3	4	3	3	3	2	3	56
			20	29JUN92	3	3	3	1	2	4	2	2	3	4	3	3	4	3	4	3	3	3	2	3	58
			24	27JUL92	3	4	2	1	3	3	2	2	2	3	3	3	3	3	4	3	3	3	2	3	55
			28	24AUG92	3	3	1	2	2	3	2	2	3	3	3	3	3	3	4	3	3	4	2	3	54
			32	21SEP92	3	3	1	3	2	4	2	2	3	2	3	3	3	3	3	3	3	3	4	2	55
			40	16NOV92	3	3	2	3	2	3	1	1	2	2	2	3	3	3	4	3	3	3	3	3	52
			44	14DEC92	3	3	2	3	3	4	1	1	2	3	3	3	4	3	4	3	3	3	2	3	56
			48	11JAN93	3	3	2	3	4	2	2	2	3	3	3	3	4	3	4	3	3	3	2	3	57
			52	08FEB93	3	3	2	3	2	4	1	2	2	3	3	3	3	3	4	3	3	3	3	3	56
12	27/115	VCS	8	05APR92	3	2	3	2	2	4	2	3	3	2	2	3	2	4	3	3	3	4	4	3	55
			12	01MAY92	2	2	2	3	2	4	2	3	2	2	2	3	2	4	3	3	3	3	3	4	50
			16	29MAY92	2	2	3	2	2	4	2	3	2	1	2	3	1	2	3	3	3	3	3	3	47
			20	26JUN92	2	2	3	3	4	2	3	2	1	2	3	1	3	3	3	3	3	3	3	3	49
			24	24JUL92	3	1	3	3	2	4	2	2	2	2	3	2	3	3	3	3	3	3	3	3	50
			28	21AUG92	2	2	3	2	2	4	2	2	2	3	2	3	2	3	3	3	3	3	3	2	49
			32	18SEP92	2	2	3	2	2	4	2	2	3	2	2	3	2	3	3	3	3	2	2	1	48
12	29/117	AK	8	06APR92	2	3	1	1	2	4	1	1	1	2	1	2	2	2	2	2	2	2	3	1	37
			12	04MAY92	2	3	1	1	1	4	1	1	1	2	1	2	2	2	2	2	2	2	2	1	35
			16	01JUN92	2	2	1	1	1	4	1	1	1	2	1	1	2	1	1	1	1	2	1	1	30
			20	29JUN92	1	2	1	1	1	4	1	1	1	1	1	1	1	2	1	1	1	2	1	1	27
			24	27JUL92	1	1	1	1	1	4	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21
			28	24AUG92	1	1	1	1	1	4	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21
			32	21SEP92	1	1	1	1	1	4	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21
			36	19OCT92	1	1	1	1	1	4	1	1	1	1	1	1	1	1	1	1	1	1	1	1	20
			40	16NOV92	1	1	1	1	1	4	1	1	1	1	1	1	1	1	1	1	1	1	1	1	20
			44	14DEC92	1	1	1	1	1	4	1	1	1	1	1	1	1	1	1	1	1	1	1	1	20
			48	11JAN93	1	1	1	1	1	4	1	1	1	1	1	1	1	1	1	1	1	1	1	1	20
			52	08FEB93	2	1	1	2	1	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	26
12	33/388	LN	8	27MAY92	2	1	4	2	2	4	2	1	3	3	3	3	3	4	3	4	1	4	1	3	53

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124-013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre No. (a)	Patient No. (a)	Initials	Visit	Date Performed	ZUNG	Total Score (b)																									
						It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20						
12	33/388	LN	12	24JUN92	3	1	3	2	4	1	1	1	2	3	1	3	3	3	3	3	4	1	4	1	3	48					
			16	22JUL92	3	1	3	1	2	4	1	1	2	3	1	3	3	3	3	3	3	3	1	3	1	3	45				
			20	19AUG92	3	1	3	1	2	4	1	1	2	3	1	3	3	3	3	3	3	3	1	3	1	3	45				
			8	25MAY92	3	4	3	2	3	2	3	4	4	1	4	3	2	4	4	4	4	4	1	3	1	3	57				
12	36/385	FB	12	22JUN92	4	3	4	3	2	3	4	1	4	4	3	4	4	4	4	4	4	1	3	1	3	59					
			32	09JUN92	1	2	1	2	3	2	1	3	4	1	4	3	2	4	4	4	4	2	2	3	1	3	41				
			36	07JUL92	1	1	1	1	3	2	1	1	2	2	2	2	1	2	2	2	2	2	1	2	1	1	1	29			
			40	04AUG92	1	1	1	1	1	1	1	1	1	2	2	2	1	1	1	1	1	1	2	1	2	1	1	28			
			44	07SEP92	1	2	1	2	1	1	1	1	2	2	2	2	1	2	2	2	2	2	1	2	1	1	1	26			
			48	30SEP92	1	2	1	2	1	1	1	2	2	2	2	2	1	2	2	2	2	2	2	2	2	1	2	32			
			52	28OCT92	1	2	1	2	1	1	2	1	2	2	2	2	2	2	2	2	2	2	2	2	1	2	32				
			8	10DEC92	2	3	2	1	3	2	2	2	2	2	1	2	1	2	1	2	1	2	1	3	1	2	36				
13	1/219	P2	12	07JAN92	2	3	2	2	3	2	2	2	1	1	2	1	2	1	3	1	1	3	1	3	1	2	39				
			16	04FEB92	3	4	3	2	3	3	2	3	3	1	2	3	1	3	2	1	3	2	1	3	1	3	49				
			20	03MAR92	3	3	3	2	3	2	2	2	2	1	2	2	1	3	2	1	3	2	1	3	1	2	43				
			24	31MAR92	2	3	3	2	3	2	2	2	1	1	2	1	2	1	3	2	1	3	1	3	1	2	41				
			28	26APR92	2	3	3	2	3	2	2	2	1	1	2	1	2	1	3	2	1	3	1	3	1	2	39				
			32	26MAY92	2	2	3	2	2	2	2	2	2	1	1	1	3	1	3	1	1	3	1	3	3	2	40				
			40	21JUL92	2	2	2	2	2	2	2	2	2	1	1	2	1	3	1	2	1	3	1	3	1	2	38				
			44	18AUG92	2	2	2	2	2	2	2	2	2	1	1	2	1	2	1	2	1	3	1	3	1	1	35				
			48	15SEP92	2	2	2	2	2	2	2	2	2	1	1	2	1	2	1	2	1	3	1	3	1	1	35				
			52	13OCT92	1	2	2	2	2	2	2	2	2	1	1	2	1	2	1	2	1	2	1	2	1	1	1	34			
			13	3/221	AI	8	10DEC91	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21		
						12	07JAN92	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24	
						16	04FEB92	2	1	3	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25	
						20	03MAR92	1	1	2	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	24	
						24	31MAR92	1	1	2	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24
						28	26APR92	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23
32	26MAY92	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21			
36	23JUN92	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22			
40	21JUL92	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22			
44	18AUG92	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22			
48	15SEP92	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21			
52	13OCT92	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	20			
13	6/226	RE	8	13DEC91	2	4	2	1	2	2	1	2	2	1	2	3	1	2	3	1	2	3	1	3	1	2	39				
			12	09JAN92	2	1	2	3	2	2	2	3	2	1	2	3	1	2	3	1	4	1	3	1	4	1	2	46			

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Patient Centre No. (a)	Initials	Visit	Date Performed	Total Score (b)																								
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20					
13	6/226	KE	16	06FEB92	2	1	2	2	1	1	1	3	1	3	2	2	3	2	4	3	1	3	1	2	42			
			20	05MAR92	2	3	2	3	1	1	3	2	3	2	2	2	2	4	4	2	1	3	1	2	42			
			24	02APR92	2	1	2	3	1	2	4	3	2	3	2	2	2	4	3	1	3	4	1	2	49			
			28	30JAN92	2	1	2	1	2	1	3	1	2	2	2	2	2	4	2	2	2	3	1	2	49			
			32	28MAY92	2	2	2	2	1	2	1	3	1	2	2	2	2	4	2	2	2	3	1	2	40			
			36	25JUN92	3	3	2	2	3	4	2	3	1	2	2	2	2	4	2	1	3	4	1	2	40			
			40	23JUL92	3	2	2	2	2	2	2	4	2	3	2	2	2	4	2	2	1	3	4	2	51			
			44	20AUG92	3	3	2	1	1	2	2	3	2	3	2	2	2	3	3	2	4	1	2	2	50			
			48	17SEP92	3	2	2	2	2	2	3	2	3	2	2	2	2	3	3	2	4	1	2	4	48			
			52	15OCT92	3	2	1	2	2	2	2	3	2	3	2	2	2	4	2	2	2	4	2	2	47			
			13	7/220	BL	8	19DEC91	2	2	1	1	1	1	3	1	2	1	1	1	1	1	1	1	1	1	1	25	
						12	16JAN92	1	2	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	24
						16	13FEB92	1	2	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	24
						20	12MAR92	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22
						24	08APR92	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23
						28	06MAY92	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24
32	03JUN92	1				2	1	2	1	4	1	1	1	2	1	1	1	1	1	2	1	1	1	1	28			
36	01JUL92	1				2	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	1	1	1	29			
40	29JUL92	2				1	1	1	1	1	1	2	1	1	1	1	1	1	2	1	1	1	1	1	28			
44	26AUG92	1				2	1	1	1	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	28			
48	23SEP92	1				2	1	1	1	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	29			
52	21OCT92	1				2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	30			
13	13/223	HM				8	27DEC91	3	4	1	3	1	1	3	1	4	3	4	1	4	4	1	1	1	1	4	52	
						12	23JAN92	3	2	1	2	1	1	3	1	4	1	4	1	4	1	4	1	1	1	1	3	48
						16	20FEB92	3	3	1	3	1	3	1	4	3	4	1	3	4	1	4	1	1	1	1	4	50
						20	20MAR92	3	3	1	3	1	3	1	4	3	4	1	3	4	1	4	1	1	1	1	4	50
			24	17APR92	2	1	1	2	1	3	1	4	2	3	1	4	1	4	1	4	1	1	1	4	43			
			28	15MAY92	3	1	1	2	1	3	1	4	2	3	1	4	1	4	1	4	1	1	1	4	44			
			32	12JUN92	3	1	1	2	1	3	1	4	2	3	1	4	1	4	1	4	1	1	1	4	44			
			36	10JUL92	3	1	1	2	1	3	1	4	2	3	1	4	1	4	1	4	1	1	1	4	45			
			40	07AUG92	3	1	1	2	1	3	1	4	2	3	1	4	1	4	1	4	1	1	1	3	45			
			44	04SEP92	3	1	1	2	1	3	1	4	2	3	1	4	1	4	1	4	1	1	1	3	41			
			48	02OCT92	2	1	1	2	1	3	1	3	4	2	3	1	4	1	4	1	4	1	1	3	44			
			52	30OCT92	2	1	1	2	1	3	1	3	4	2	2	1	4	1	4	1	4	1	2	1	4	47		
			13	18/227	VT	8	28JAN92	3	2	3	3	1	2	2	4	3	3	1	4	2	1	1	1	1	2	44		
						12	25FEB92	4	3	3	4	2	1	1	3	3	1	4	2	1	4	2	1	2	1	2	47	
						16	24MAR92	3	3	4	2	2	1	3	3	2	4	3	2	4	4	2	1	2	1	2	53	
						20	21APR92	3	3	4	2	2	1	4	3	2	4	2	4	4	2	4	2	3	1	2	56	

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre No. (a)	Patient No. (a)	Initials	Visit	Date Performed	ZUNG																				Total Score (b)		
					It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20			
13	18/227	VT	24	19MAY92	3	3	4	4	1	2	1	4	3	3	1	4	3	1	2	1	2	1	2	49			
			28	16JUN92	3	2	4	4	1	2	1	4	4	3	1	4	3	1	4	3	1	2	1	2	50		
			32	14JUL92	3	1	4	3	1	2	4	3	3	1	4	3	1	4	3	1	2	1	1	2	48		
			36	11AUG92	3	1	4	3	1	2	4	4	4	3	1	4	3	1	4	3	1	2	1	2	48		
			40	08SEP92	3	2	4	3	1	2	2	4	4	4	3	1	4	3	1	4	3	1	2	1	2	50	
			44	06OCT92	3	2	4	3	3	2	2	4	4	4	3	1	4	3	1	4	3	1	2	1	2	52	
			48	03NOV92	2	2	4	2	2	2	4	4	4	4	3	1	4	3	1	4	3	1	2	1	2	49	
			52	01DEC92	3	1	3	3	2	2	4	4	4	1	3	3	1	4	3	1	4	3	1	2	1	2	50
			13	20/230	NL	8	24MAR92	3	2	3	2	2	2	2	3	4	2	3	2	4	4	2	3	1	2	3	51
						12	21APR92	3	4	3	3	2	1	1	1	3	4	1	4	3	4	4	1	3	1	3	1
16	19MAY92	2				3	2	1	1	1	1	1	3	2	2	2	1	4	3	1	2	1	1	1	1	36	
20	16JUN92	2				3	2	1	1	1	1	1	2	2	2	2	1	4	3	1	2	1	1	1	1	33	
24	14JUL92	1				3	1	1	1	1	1	1	2	1	2	2	2	3	2	2	2	2	1	1	1	33	
28	11AUG92	1				2	1	1	1	1	1	1	2	2	2	2	2	3	2	2	2	1	2	1	1	31	
32	08SEP92	2				2	1	1	1	1	1	1	2	2	2	2	1	2	2	2	1	2	1	1	1	28	
36	06OCT92	2				2	1	1	1	1	1	1	3	2	2	2	2	2	2	2	1	2	1	2	1	32	
40	03NOV92	1				2	2	1	1	1	1	1	2	2	2	2	1	2	2	2	1	2	1	2	1	28	
44	01DEC92	1				1	2	1	1	1	1	1	2	2	2	1	1	2	1	1	2	1	1	2	1	26	
13	21/231	CL	8	29DEC92	1	1	1	1	1	1	1	2	2	2	2	1	3	1	1	2	1	1	1	30			
			12	26JAN93	1	2	1	1	1	1	1	2	2	2	2	1	2	1	2	1	2	1	1	2	28		
			16	14APR92	2	4	3	3	2	4	3	3	3	1	1	2	3	4	1	4	4	4	4	2	54		
			20	12MAY92	2	3	3	1	2	3	2	1	1	3	3	3	3	3	3	1	3	2	3	1	43		
			24	09JUN92	2	3	2	1	2	4	2	2	1	1	1	2	3	2	1	3	3	2	1	3	39		
			28	07JUL92	3	3	3	3	3	4	3	2	3	2	2	3	3	3	2	3	2	3	2	2	54		
			32	04AUG92	2	3	2	3	3	4	3	2	2	2	2	1	3	3	3	2	3	2	2	2	46		
			36	01SEP92	2	3	2	3	3	4	3	2	2	1	1	1	3	3	2	1	3	2	1	2	43		
			40	28SEP92	2	3	2	3	3	4	3	2	2	1	1	1	3	3	3	1	2	1	2	1	43		
			44	27OCT92	2	3	2	2	3	4	2	3	4	3	2	1	1	3	3	2	1	2	1	2	40		
13	22/232	NYK	8	24NOV92	2	3	2	2	2	4	2	4	2	1	3	2	1	3	2	1	2	2	1	40			
			12	22DEC92	2	3	2	1	3	4	2	2	1	1	1	3	2	2	1	2	2	1	2	1	37		
			16	19JAN93	2	3	2	1	2	4	2	2	1	1	1	1	3	2	1	1	3	1	1	1	32		
			20	16FEB93	2	2	2	1	1	3	1	1	1	1	1	1	2	1	1	1	1	1	1	1	27		
			24	30JUN92	3	2	3	3	3	3	3	3	2	4	3	2	4	3	2	4	3	2	3	2	54		

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Patient Centre No. (a)	Initials	Visit	Date Performed	Total Score (b)																										
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20							
1	1/1	MGA	8	11JAN91	2	2	1	3	2	2	1	2	1	1	1	1	2	2	2	2	2	1	1	1	1	33				
			10	25JAN91	2	2	2	1	2	1	1	3	3	3	3	2	1	1	2	2	2	2	1	1	1	1	37			
			12	08FEB91	3	2	1	3	3	2	1	1	2	2	2	4	2	2	2	2	2	2	1	1	1	1	2	37		
			14	22FEB91	3	2	1	3	2	2	2	3	2	2	2	3	3	2	2	2	2	3	3	1	1	1	2	40		
			16	08MAR91	4	4	3	3	4	3	4	3	4	4	4	3	1	3	1	3	3	3	3	1	1	3	1	46		
			18	22MAR91	4	3	3	3	3	4	3	2	3	4	3	3	1	3	2	4	3	3	2	2	2	4	3	59		
			8	29JAN91	2	2	1	1	3	1	1	1	2	2	3	2	2	2	1	1	1	1	1	1	1	2	32			
			12	24FEB91	2	2	2	3	3	2	3	1	4	2	1	3	2	3	3	3	3	4	3	1	2	2	2	49		
			16	26MAR91	4	3	2	3	3	4	3	3	3	3	3	4	4	3	3	3	3	3	2	2	4	4	61			
			1	8/6	NVB	8	01FEB91	2	2	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	30	
						12	01MAR91	2	2	2	3	2	1	1	1	3	1	2	2	3	2	2	3	2	2	3	1	1	1	40
						16	26MAR91	3	3	1	3	3	2	2	3	1	3	2	2	2	4	2	4	3	3	1	2	4	3	49
						20	26APR91	2	4	2	3	2	2	1	2	1	3	3	3	3	4	3	3	4	3	1	3	1	3	47
						24	24MAY91	3	3	2	3	2	3	1	2	3	3	3	3	3	4	2	3	2	2	2	3	3	3	53
						8	03MAY91	2	2	1	2	1	1	1	1	2	2	2	2	1	2	3	3	3	2	1	1	1	2	37
						10	17MAY91	3	2	2	3	4	1	3	2	4	1	3	2	4	1	1	1	1	1	1	1	1	1	41
						12	31MAY91	2	1	2	1	1	2	1	2	1	2	1	1	3	3	2	1	2	2	1	1	1	2	33
						14	14JUN91	2	1	1	2	2	3	2	1	2	2	2	2	2	1	1	1	1	1	1	1	1	2	32
16	28JUN91	2				3	2	3	2	3	3	1	2	2	2	3	3	3	2	1	1	1	1	1	1	2	42			
18	12JUL91	2				2	1	3	2	3	1	2	3	1	2	2	3	2	3	1	3	3	1	1	1	2	40			
20	26JUL91	3				1	1	1	1	1	1	2	2	1	1	2	2	1	1	2	1	1	1	1	1	2	29			
22	09AUG91	3	1	1	1	2	1	1	2	2	1	4	2	2	1	2	1	2	2	1	1	1	1	34						
24	23AUG91	2	2	1	2	1	2	1	1	1	3	2	2	1	3	2	1	3	2	2	1	1	2	32						
28	20SEP91	2	1	2	1	2	2	1	2	1	1	4	2	2	2	2	1	2	2	3	1	2	3	38						
32	18OCT91	4	3	2	3	2	3	4	1	2	2	3	2	2	2	2	2	2	2	3	3	4	4	50						
36	14NOV91	1	2	1	1	2	1	1	2	1	1	1	1	2	1	1	1	1	1	2	1	1	1	25						
1	12/10	SLT	8	14MAY91	3	2	3	1	2	1	1	2	3	2	2	3	2	1	3	2	1	1	2	1	2	40				
			12	11JUN91	2	3	1	2	2	3	1	1	4	2	2	2	2	1	1	2	2	1	2	2	1	1	36			
			16	09JUL91	2	1	1	2	3	1	1	2	2	1	1	1	2	3	1	2	3	1	1	3	2	1	34			
			20	06AUG91	1	2	1	1	1	2	2	1	2	2	1	1	1	2	3	3	1	1	1	1	1	2	31			
			24	03SEP91	2	1	3	2	2	2	3	1	4	2	3	1	2	1	2	2	1	3	3	1	1	2	42			
			28	01OCT91	3	1	2	3	1	3	1	2	2	3	2	4	1	2	2	1	2	2	1	2	3	2	3	43		
			32	29OCT91	3	2	2	3	3	2	2	2	4	1	1	2	1	1	2	2	3	3	1	2	2	3	40			
			36	26NOV91	3	2	2	3	3	2	2	2	3	1	2	2	2	2	2	2	2	3	1	2	2	2	43			
			40	24DEC91	3	2	2	3	1	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	43			
			44	21JAN92	3	1	1	3	3	2	2	1	2	2	2	2	1	1	1	1	1	2	2	2	2	2	37			
			48	18FEB92	3	2	2	3	2	2	1	2	2	2	2	1	1	1	1	1	1	3	1	1	1	2	40			

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre No. (a)	Patient Initials	Date Performed	ZUNG																				Total Score (b)		
			It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20			
1	21/18 VHC	36	11FEB92	3	2	2	3	2	2	1	3	2	2	2	2	1	2	2	2	3	1	2	2	2	42
		40	10MAR92	2	2	1	4	2	2	2	4	4	2	2	1	2	2	1	1	4	2	2	2	2	45
		44	07APR92	2	2	1	4	2	2	1	2	2	3	2	2	4	2	2	2	3	1	2	2	2	42
		48	05MAY92	2	2	1	2	2	2	1	2	2	3	1	1	2	2	2	2	3	2	1	2	2	36
		52	02JUN92	3	1	2	4	2	2	3	3	1	2	2	3	4	2	2	4	3	2	2	2	2	49
1	26/22 OC	8	05SEP91	3	3	2	1	2	1	1	2	2	3	2	1	3	1	2	3	2	1	1	2	39	
		12	01OCT91	3	2	1	3	1	2	2	2	3	1	1	2	2	2	2	3	2	2	1	2	39	
		16	29OCT91	2	2	2	3	2	2	1	2	2	2	2	2	1	2	2	1	2	3	1	2	37	
		24	24DEC91	3	3	1	3	1	2	1	2	1	2	1	1	2	1	1	1	3	2	3	1	2	37
		28	21JAN92	3	2	2	2	2	2	2	2	3	1	1	1	2	2	2	2	2	1	2	2	1	37
		32	18FEB92	3	1	1	2	3	2	1	2	2	4	2	2	2	2	1	1	3	2	1	2	2	39
		36	17MAR92	3	1	1	3	2	3	1	1	2	4	2	2	2	2	2	2	2	4	2	2	2	44
		40	14APR92	3	2	2	3	3	2	2	2	2	1	4	4	3	2	3	2	2	4	4	2	2	52
		44	12MAY92	3	3	3	3	1	2	1	2	2	4	4	2	2	3	3	2	4	4	2	2	3	53
		48	09JUN92	2	2	1	4	1	3	2	1	2	2	4	4	2	2	3	3	2	1	4	2	2	49
1	27/23 RK	8	06SEP91	2	3	2	2	2	2	2	3	1	1	1	1	2	3	2	2	1	2	2	37		
		12	04OCT91	4	3	3	4	4	2	3	3	2	2	4	3	3	3	4	3	3	3	3	4	63	
1	28/24 RHM	8	10SEP91	2	2	1	3	2	2	1	2	1	2	1	1	3	3	1	2	3	3	2	1	37	
		12	08OCT91	3	2	2	1	3	1	4	2	1	4	2	2	3	3	2	2	3	3	1	2	48	
		16	05NOV91	3	2	2	3	2	3	2	2	1	2	1	2	4	1	2	2	2	3	1	2	42	
		20	03DEC91	3	2	2	3	3	2	2	2	2	3	3	3	2	2	2	2	2	3	2	2	3	48
1	29/25 AFO	8	10SEP91	4	2	2	2	2	2	3	4	1	2	2	1	3	3	2	2	4	3	3	3	50	
		12	08OCT91	2	1	2	2	2	2	3	1	3	2	3	1	1	4	4	1	2	3	4	1	1	43
		16	05NOV91	3	2	1	2	2	1	4	2	2	3	2	2	1	1	1	1	2	1	1	2	1	38
		20	03DEC91	1	2	1	2	2	1	2	2	1	2	2	2	1	1	2	1	2	1	2	1	2	32
		24	31DEC91	2	2	1	3	1	1	2	1	2	1	1	2	1	2	1	2	1	1	2	1	1	30
		28	28JAN92	2	2	1	3	1	2	1	2	1	2	1	1	2	1	2	1	2	2	2	1	2	30
		32	25FEB92	3	1	3	3	3	2	4	2	1	2	3	3	2	2	2	1	1	2	2	1	1	41
		36	24MAR92	3	2	2	4	3	3	4	1	2	3	3	2	1	4	2	2	2	1	1	1	4	44
		40	22APR92	3	1	2	2	4	2	2	2	1	2	4	1	2	2	2	2	2	3	4	2	3	51
		44	19MAY92	2	2	1	3	2	2	2	2	3	3	2	1	2	2	2	4	1	4	2	2	2	46
1	30/26 ERV	8	16JUN92	3	1	2	3	1	2	2	2	3	2	1	2	3	2	1	4	1	2	2	2	40	
		12	14JUL92	2	2	1	3	2	2	3	2	2	1	3	2	1	2	1	2	1	4	4	2	2	42

(a) = Open/Blind

9550077

PHARMACIA CNS R&D
 REMOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre No. (a)	Patient No. (a)	Initials	Visit	Date Performed	ZUNG																				Total Score (b)
					It. 1	It. 2	It. 3	It. 4	It. 5	It. 6	It. 7	It. 8	It. 9	It. 10	It. 11	It. 12	It. 13	It. 14	It. 15	It. 16	It. 17	It. 18	It. 19	It. 20	
1	30/26	ERV	12	09OCT91	3	3	3	3	2	3	1	2	3	3	4	1	4	2	3	3	2	4	54		
			16	06NOV91	4	3	3	4	1	3	3	4	4	2	4	3	3	4	4	4	2	4	64		
			8	18SEP91	1	2	2	3	2	4	1	1	2	4	1	1	2	1	2	1	1	1	1	35	
			12	16OCT91	4	2	4	3	3	1	3	2	2	4	2	3	3	2	2	3	3	3	4	56	
			8	22OCT91	2	2	1	2	1	1	1	1	3	2	2	1	1	1	1	1	1	1	1	29	
			12	19NOV91	4	2	4	4	3	3	2	3	4	2	4	4	1	3	3	3	3	3	3	60	
	1	36/302	LM	16	17DEC91	4	4	4	4	4	3	3	4	2	4	3	2	4	4	4	3	3	65		
				8	12NOV91	1	1	1	1	1	1	1	2	2	1	1	1	1	1	1	1	1	1	25	
				12	10DEC91	1	2	1	2	1	1	1	1	1	2	2	1	2	2	1	3	2	1	1	29
				16	07JAN92	2	2	1	2	1	2	2	2	1	2	1	2	1	3	2	2	2	1	1	31
				20	04FEB92	4	3	3	1	2	2	3	1	1	2	2	1	1	1	1	3	1	2	2	38
				24	04MAR92	2	2	4	2	2	4	2	2	3	1	4	2	3	3	2	1	1	1	1	46
1		38/304	DBF	28	31MAR92	3	2	1	3	1	2	2	2	3	1	1	1	2	2	1	1	2	1	34	
				32	28APR92	2	2	1	2	2	2	2	1	1	2	2	1	1	1	2	2	2	2	2	37
				36	26MAY92	3	2	2	3	3	2	2	1	1	2	1	1	1	1	4	2	2	3	1	42
				40	23JUN92	2	3	3	2	1	3	1	2	1	1	1	2	1	1	4	4	2	1	2	43
				44	21JUL92	3	4	2	2	3	2	2	2	2	2	2	2	2	2	2	3	3	2	1	48
				48	18AUG92	1	2	1	3	2	3	1	2	3	2	1	3	2	3	3	3	3	1	1	2
	1	40/306	EM	52	15SEP92	3	3	3	4	2	3	2	1	3	2	1	2	2	1	3	2	1	1	42	
				8	19NOV91	3	3	1	1	1	1	1	2	2	1	1	1	1	2	3	1	2	1	2	35
				12	17DEC91	2	2	1	1	1	1	1	2	2	1	2	1	1	2	1	1	2	1	1	32
				16	14JAN92	1	2	2	1	3	2	2	1	1	1	2	1	1	2	1	2	1	1	1	32
				20	11FEB92	3	4	3	2	3	1	2	2	2	2	2	1	3	2	2	2	2	1	2	42
				24	10MAR92	3	1	2	4	2	3	2	3	2	2	1	1	4	1	2	4	1	2	2	42
1		41/307	SFS	28	07APR92	2	1	3	3	1	3	1	3	1	2	2	1	2	3	3	2	2	2	42	
				32	05MAY92	1	2	2	2	1	2	4	3	2	4	1	1	2	1	1	1	2	1	2	41
				36	02JUN92	2	1	2	2	2	1	2	1	2	1	2	2	2	2	2	1	3	4	1	40
				40	30JUN92	3	3	2	4	2	2	1	3	3	4	3	2	2	3	2	3	4	1	2	52
				44	28JUL92	3	2	2	1	3	3	2	2	3	3	4	2	3	3	2	2	1	2	2	46
				48	25AUG92	4	3	2	3	1	3	2	2	3	2	1	2	1	3	2	3	1	2	3	43
	1	41/307	SFS	52	22SEP92	3	4	3	2	3	2	2	1	2	2	4	3	3	4	2	2	1	2	49	
				8	19NOV91	2	2	2	3	1	2	1	2	2	1	1	2	2	2	1	2	3	1	2	34
				12	17DEC91	3	2	1	3	2	3	1	2	2	1	2	2	1	2	2	1	2	3	2	38
				16	14JAN92	2	1	2	2	1	2	3	3	1	3	2	2	1	2	2	1	2	1	2	38
				20	11FEB92	3	2	1	2	2	3	1	2	2	2	1	1	2	1	2	2	1	2	3	37
				24	10MAR92	3	1	2	2	4	2	2	2	2	1	1	3	1	1	1	3	2	2	3	41

1373

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Patient Centre No.	(a) Initials	Visit	Date Performed	It.1 It.2 It.3 It.4 It.5 It.6 It.7 It.8 It.9 It.10 It.11 It.12 It.13 It.14 It.15 It.16 It.17 It.18 It.19 It.20																				Total Score (b)						
				Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score		Score					
1	41/307	SFS	28	07APR92	2	2	2	4	2	2	4	2	2	4	4	1	2	1	2	2	1	3	4	1	2	2	47			
			32	05MAY92	4	2	2	2	4	2	2	3	3	2	2	1	1	3	2	2	2	2	1	4	2	2	2	48		
			36	02JUN92	3	1	3	2	4	2	2	4	2	1	3	1	2	1	1	1	1	1	2	1	4	2	2	2	45	
			40	30JUN92	3	1	2	3	2	4	2	4	2	4	2	2	3	2	2	3	1	2	1	2	1	2	2	2	48	
			44	28JUL92	3	2	4	2	2	4	3	2	2	3	2	2	4	2	2	2	2	2	2	4	2	2	2	2	52	
1	42/308	ICC	8	27NOV91	2	2	1	2	2	2	2	2	2	3	1	1	3	2	2	2	2	2	2	2	2	2	38			
			12	26DEC91	3	1	2	2	1	1	2	1	2	1	2	1	1	3	2	2	1	1	3	2	2	1	2	35		
			16	21JAN92	3	3	2	2	2	1	2	2	3	1	2	2	1	2	2	1	1	2	1	1	2	1	1	36		
			20	18FEB92	2	2	2	2	2	3	1	2	2	2	2	2	2	2	4	2	2	2	1	1	2	1	2	37		
			24	18MAR92	1	1	2	1	2	1	1	2	1	1	2	1	2	1	2	3	3	3	1	1	2	1	2	35		
			28	15APR92	1	1	1	2	1	1	1	2	1	2	1	2	1	2	1	2	1	1	1	1	1	1	1	27		
			32	15MAY92	1	1	1	2	1	1	1	2	1	2	4	3	2	1	1	2	2	1	2	2	1	2	1	1	33	
			36	10JUN92	1	1	1	2	2	2	1	3	1	2	3	2	2	1	1	3	1	1	3	1	1	3	1	2	36	
			40	08JUL92	2	2	1	3	2	1	2	2	3	2	1	4	2	2	2	2	2	3	2	2	2	2	2	1	40	
			44	05AUG92	2	2	1	3	2	1	2	2	3	1	1	2	1	1	2	2	2	1	1	1	1	1	1	1	33	
			48	02SEP92	1	1	2	3	2	4	2	2	1	2	3	1	1	2	2	2	1	1	1	1	1	1	1	1	35	
			52	30SEP92	1	1	1	3	1	2	2	1	1	2	2	3	1	2	1	2	1	2	1	1	1	1	1	1	30	
1	47/312	MCS	8	17DEC91	2	1	1	3	1	2	1	1	2	1	2	1	2	1	2	1	2	1	1	1	2	2	30			
			12	14JAN92	2	1	2	2	1	2	1	1	2	2	2	1	2	2	1	2	2	1	2	2	1	2	1	32		
			16	11FEB92	3	1	2	3	1	2	2	2	2	2	2	2	2	2	1	2	2	3	1	2	2	3	1	41		
			20	10MAR92	2	2	1	2	2	1	2	2	3	2	1	2	2	3	1	1	2	2	2	1	2	2	1	37		
			24	07APR92	3	2	2	2	1	3	2	4	3	3	1	1	3	3	2	1	4	2	2	1	4	2	2	46		
			28	05MAY92	2	2	2	4	2	2	3	3	2	2	1	2	2	1	3	2	2	2	2	2	2	2	2	43		
			32	02JUN92	3	1	2	2	1	2	2	1	2	2	4	2	2	2	4	2	2	2	2	2	2	2	2	46		
			36	30JUN92	2	1	2	2	1	2	2	1	3	2	2	4	3	3	2	4	3	3	1	1	2	2	2	44		
			40	28JUL92	3	3	2	4	1	2	2	2	1	2	2	4	3	3	2	2	2	2	2	3	1	1	2	44		
			44	25AUG92	4	2	2	4	2	2	1	2	2	4	4	2	2	1	2	2	2	2	3	1	3	2	2	43		
			1	50/314	NFA	8	20DEC91	2	1	1	2	1	2	1	2	2	1	2	2	2	2	2	1	1	1	1	1	2	2	32
						12	17JAN92	3	2	2	3	3	1	3	3	2	2	3	4	3	3	4	2	2	1	1	1	1	2	1
16	14FEB92	3				2	2	3	2	3	1	2	3	2	4	2	4	2	3	1	4	1	1	1	1	2	1	42		
20	13MAR92	2				1	2	4	1	2	2	1	2	2	2	1	1	3	2	2	1	3	2	1	2	2	1	40		
24	10APR92	2				1	2	1	2	1	2	1	2	1	2	1	2	2	1	2	4	2	2	1	2	2	1	34		
28	08MAY92	2				1	2	2	1	2	1	2	1	2	1	1	1	1	1	1	1	1	2	1	2	1	2	37		
32	05JUN92	2				2	1	3	2	2	2	4	4	2	3	2	2	3	2	5	1	2	1	1	1	1	1	40		
36	03JUL92	1				2	1	3	1	2	2	1	4	2	3	2	1	1	1	1	1	1	4	1	1	1	1	30		
40	31JUL92	1				2	2	1	2	2	1	1	3	1	1	2	1	1	2	1	1	2	1	1	1	1	1	30		
44	28AUG92	3				1	2	2	1	3	1	2	4	1	1	2	1	2	1	2	1	1	2	1	1	1	1	2	34	
48	25SEP92	1				2	1	2	1	3	1	2	2	4	2	2	2	1	2	2	3	1	1	1	1	1	1	1	34	

(a) = Open/Blind

9550077

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Patient Centre No. (a)	Initials	Date Performed ZUNG	Total Score (b)																				
			It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	
1	50/314	MFA	52	23OCT92	3	1	2	2	1	2	2	1	2	1	2	1	1	1	3	1	1	1	35
1	51/315	ASA	8	20DEC91	1	2	1	2	1	1	2	2	1	1	3	2	4	3	1	2	1	1	36
			12	17JAN92	2	1	2	1	2	1	2	2	1	1	1	1	1	1	2	1	1	2	32
			16	14FEB92	3	2	2	2	3	3	2	2	2	1	2	2	1	1	3	2	2	4	32
			20	13MAR92	2	2	4	2	2	1	2	2	1	1	2	2	1	3	1	3	2	4	42
			24	10APR92	3	1	2	2	3	2	2	3	1	2	2	4	2	4	2	3	1	2	39
			28	08MAY92	2	2	1	3	2	2	1	2	2	1	2	2	2	4	2	3	1	1	40
			32	05JUN92	3	1	2	3	2	2	1	2	2	1	2	2	3	1	4	3	2	2	40
			36	03JUL92	2	3	2	3	1	2	3	1	2	2	3	2	5	1	4	3	1	1	39
			40	31JUL92	3	2	2	1	2	2	1	4	2	3	3	4	2	2	4	4	1	2	51
			44	28AUG92	4	3	3	2	3	4	2	2	2	1	4	4	2	1	1	1	2	3	51
			48	25SEP92	3	4	2	1	2	2	4	2	2	2	2	1	4	2	3	2	2	2	47
			52	23OCT92	3	3	1	3	1	4	2	2	4	3	1	3	4	3	1	3	1	2	50
1	53/317	JFT	8	26DEC91	1	1	2	3	2	2	1	1	2	2	2	3	2	1	1	2	1	1	36
			12	22JAN92	2	2	3	3	2	2	2	1	3	1	4	3	2	3	2	4	4	4	48
			16	19FEB92	3	2	2	3	2	3	2	3	2	4	2	3	4	4	1	2	1	2	50
			20	18MAR92	4	3	3	2	3	1	3	3	3	4	1	3	2	3	4	3	4	4	57
1	59/321	SPF	8	11FEB92	2	4	2	2	2	2	2	3	1	1	2	2	4	2	2	3	2	2	47
			12	10MAR92	1	1	1	3	1	2	2	2	2	2	3	1	1	4	2	2	1	1	39
			16	07APR92	1	1	1	2	1	3	2	2	2	1	2	3	2	1	4	3	2	1	36
			20	05MAY92	2	1	1	1	1	2	1	2	2	2	1	2	2	2	2	1	2	1	33
			24	02JUN92	3	3	2	2	2	3	3	4	4	2	4	3	2	4	3	2	1	2	33
			28	30JUN92	3	4	1	2	2	3	3	1	1	4	2	4	3	2	1	1	1	2	50
			32	28JUL92	4	2	2	4	2	2	2	3	1	1	4	3	2	3	1	1	1	1	44
			36	25AUG92	3	2	2	2	4	2	2	1	2	2	1	2	2	4	4	2	2	2	45
			40	22SEP92	3	3	2	1	4	2	2	4	3	3	3	4	2	4	3	2	1	1	50
			44	20OCT92	4	2	2	4	2	2	1	2	2	2	2	2	2	2	1	1	1	1	44
			48	17NOV92	3	3	3	4	4	3	2	3	3	3	3	3	4	2	2	4	2	2	46
			52	15DEC92	4	2	2	2	2	1	4	3	2	1	1	2	4	2	2	3	1	2	48
1	60/322	EM	8	14FEB92	3	3	1	3	2	3	1	2	3	1	2	2	1	3	1	4	1	3	42
			12	13MAR92	3	1	1	4	3	2	1	3	4	2	4	1	2	3	2	2	1	1	42
			16	10APR92	3	1	1	4	3	2	1	2	2	2	2	1	2	2	2	1	2	2	36
			20	08MAY92	2	2	1	3	1	2	2	2	2	2	1	3	2	2	1	2	1	2	40
			24	05JUN92	2	2	1	4	2	3	1	2	2	4	3	1	1	2	2	1	2	4	43
			28	03JUL92	2	2	3	1	4	1	3	2	4	3	3	1	2	2	4	2	2	2	46
			32	31JUL92	3	1	2	2	4	2	1	4	3	1	1	2	3	1	1	2	2	2	41
			36	28AUG92	2	3	2	1	3	1	3	2	2	2	2	4	2	2	4	1	4	2	46

(a) = Open/Blind
 (b) = Total Score

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Patient Centre No. (a)	Initials	Visit	Date Performed	ZUNG	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	Total Score (b)					
					1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20						
1	60/322	EM	25SEP92	3	1	2	3	1	2	3	1	2	3	1	2	1	3	1	2	2	4	3	1	2	41					
			23OCT92	4	2	4	3	1	4	2	1	3	4	1	2	3	4	1	3	4	2	4	4	1	2	44				
			20NOV92	4	2	4	4	2	2	1	3	2	2	3	4	2	2	3	3	4	2	2	4	3	1	3	52			
			16DEC92	3	1	1	2	3	4	1	3	4	4	2	2	2	2	1	4	3	2	1	4	3	1	2	47			
			04MAR92	2	1	2	3	2	1	2	2	1	2	2	1	2	1	2	1	2	1	2	1	2	1	1	33			
1	62/324	NEA	12	3	2	2	1	2	2	1	2	2	1	4	3	1	1	1	1	2	1	3	1	1	1	34				
			16	2	1	3	2	1	2	2	2	1	2	2	1	3	2	1	2	1	2	1	2	1	1	1	33			
			20	2	1	3	1	2	2	2	1	2	1	3	2	1	3	2	1	2	1	2	1	2	1	1	34			
			24	2	1	3	2	3	2	2	1	2	2	1	2	1	2	1	2	1	1	2	4	4	1	1	40			
			28	2	1	2	4	1	2	2	1	2	2	1	2	3	3	4	3	2	2	2	2	1	1	2	43			
			32	2	1	2	3	2	4	4	2	4	4	2	2	3	3	4	4	3	4	4	4	2	2	2	54			
			36	3	3	3	4	2	3	4	2	1	1	3	3	2	2	3	3	4	2	3	3	2	1	2	50			
			40	3	3	3	4	2	1	3	1	4	2	2	2	2	2	2	1	2	1	2	2	3	3	2	41			
			44	3	3	3	4	2	1	2	1	1	4	2	2	2	2	2	1	2	1	2	2	2	2	1	2	37		
			48	2	1	4	2	2	2	2	2	2	1	1	1	2	1	2	1	1	2	1	2	2	2	1	2	40		
			52	3	3	2	2	2	2	2	2	2	3	2	2	1	4	2	3	1	2	1	3	2	3	2	2	48		
			1	64/325	EMF	13MAR92	3	2	2	1	2	2	2	2	2	1	2	2	2	2	2	1	2	2	2	1	1	35		
						12	2	1	3	2	2	1	1	2	2	2	2	2	2	2	3	2	2	4	2	2	1	1	40	
						16	2	1	2	2	1	2	2	2	1	2	2	2	2	2	2	2	2	2	2	2	3	1	1	35
						20	3	2	2	1	2	2	1	2	2	2	2	2	2	2	1	1	2	2	2	1	1	1	1	34
						24	3	3	2	3	2	3	2	3	1	2	3	2	2	2	2	1	3	2	1	3	2	2	3	45
28	4	2				2	3	2	3	2	3	4	2	4	2	4	2	4	2	2	2	1	2	2	2	2	47			
32	4	2				1	4	2	3	2	2	4	4	4	4	4	4	4	4	2	1	4	4	2	2	2	51			
36	3	2				2	3	3	1	2	4	3	4	3	4	3	4	3	4	2	3	3	4	2	4	2	54			
40	3	2				2	3	3	1	2	3	2	2	2	2	2	2	2	2	2	1	2	2	3	1	1	34			
44	1	1				1	3	2	3	2	1	2	2	2	1	2	2	1	2	1	2	2	1	2	3	1	1	32		
48	1	1				1	3	1	3	2	2	2	2	2	2	2	2	2	2	1	2	2	1	2	2	1	1	32		
52	1	1				1	3	1	2	2	2	2	2	2	2	2	2	2	2	1	2	2	1	2	2	1	1	30		
1	67/327	MAA				17MAR92	2	1	2	3	1	2	1	2	2	2	3	2	2	2	1	2	1	2	3	3	1	2	38	
						12	2	1	2	1	3	2	1	2	4	2	2	4	2	2	1	2	2	1	4	4	4	1	2	41
						16	2	1	3	3	2	1	2	2	4	2	2	2	2	2	2	3	2	2	2	2	2	1	2	40
						20	3	1	3	3	3	1	2	2	2	2	2	2	2	2	3	2	3	2	4	1	2	1	2	40
			24	3	4	4	3	2	2	2	2	2	2	2	2	2	2	2	4	4	1	1	2	1	1	2	34			
			28	3	4	4	3	2	2	3	2	3	4	4	4	4	4	3	4	4	1	1	4	2	4	3	58			
			32	3	3	3	4	3	2	3	2	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	58			
			36	3	2	2	3	3	1	2	4	3	4	3	4	3	4	3	4	2	2	2	2	3	1	1	54			
			40	2	1	1	3	2	3	1	2	2	2	2	2	2	2	2	2	2	2	2	2	3	1	1	34			
			44	1	1	1	3	2	3	2	1	2	2	2	1	2	2	1	2	1	2	2	1	2	2	1	1	32		
			48	1	1	1	3	1	3	2	2	2	2	2	2	2	2	2	2	1	2	2	1	2	2	1	1	32		
			52	1	1	1	3	1	2	2	2	2	2	2	2	2	2	2	2	1	2	2	1	2	2	1	1	30		
			1	70/328	MLM	20MAR92	3	3	1	2	2	2	1	1	2	4	2	3	2	3	2	4	1	1	4	2	1	3	44	
						12	3	3	2	4	3	4	2	3	4	2	2	3	4	2	2	2	3	1	2	3	1	2	51	
						16	3	2	4	3	4	3	4	2	2	2	1	3	4	2	2	1	3	3	1	4	4	2	2	56
						20	4	3	4	4	4	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	57
24	4	3				4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	57			

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXYTINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre No.	(a) Initials	Patient No.	Date Performed	ZUNG	Total Score (b)																							
					It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20				
1	74/122	IVL	8	24MAR92	2	1	2	2	1	2	2	4	2	2	4	1	2	2	2	2	1	2	1	3	1	1	35	
			12	22APR92	1	2	2	1	2	2	2	4	2	2	4	1	2	2	4	1	2	1	2	1	3	1	1	38
			16	19MAY92	2	1	3	2	3	1	2	3	1	2	1	2	1	2	1	1	1	3	1	2	2	1	1	35
			20	16JUN92	2	1	2	1	2	1	2	3	1	2	1	2	1	2	1	1	1	2	1	2	2	1	1	32
			24	14JUL92	2	1	3	1	2	1	2	3	1	2	3	1	2	4	3	4	3	3	1	3	3	1	3	45
			28	11MAR92	2	2	2	1	2	2	2	3	1	2	3	1	3	1	2	2	4	1	1	1	1	1	3	37
			32	08SEP92	1	2	1	2	1	2	1	2	1	1	3	2	1	4	2	2	4	2	1	3	3	1	3	40
			36	06OCT92	2	1	3	2	2	1	2	1	2	4	3	3	2	1	2	1	2	1	2	2	1	2	1	43
			40	03NOV92	2	3	1	3	2	2	2	1	3	2	4	3	2	1	2	1	1	2	2	1	2	1	2	38
			44	01DEC92	3	4	3	4	2	1	3	2	1	3	3	2	1	2	1	2	2	1	3	3	1	2	1	46
			48	29DEC92	2	2	2	4	2	1	3	2	1	3	4	2	1	2	2	1	2	2	1	4	1	1	1	42
			52	26JAN93	3	1	2	3	1	2	1	2	4	3	2	2	1	1	2	2	1	1	4	3	2	1	3	43
1	76/124	SFA	8	03APR92	1	1	1	1	1	2	2	1	1	2	1	2	1	2	2	1	1	3	1	1	1	27		
			12	30APR92	1	1	1	2	1	2	1	2	1	1	2	1	1	2	1	2	1	2	2	1	1	1	29	
			16	29MAY92	1	1	2	1	2	3	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	1	34	
			20	26JUN92	1	2	1	2	1	2	2	1	2	4	2	3	1	1	2	1	2	2	1	2	2	1	2	35
			24	24JUL92	3	3	2	2	1	2	2	1	3	4	4	4	3	3	1	1	2	2	1	2	2	1	2	46
			28	21AUG92	3	1	2	1	2	2	1	2	2	3	4	2	3	1	1	1	1	2	2	2	1	2	2	37
			32	18SEP92	2	1	2	3	2	4	2	4	3	3	4	2	1	1	2	1	1	4	2	2	1	1	1	44
			36	16OCT92	2	1	2	1	2	1	2	1	1	1	2	1	2	1	2	3	2	3	1	1	1	1	1	32
			40	13NOV92	2	2	1	3	1	2	2	1	3	2	1	1	2	1	2	2	2	4	3	2	4	3	2	39
			44	11DEC92	4	3	1	1	3	2	2	4	2	4	2	2	3	1	3	4	2	2	2	1	1	1	1	47
			48	08JAN93	3	2	1	3	2	3	3	2	1	4	2	2	1	4	2	2	1	3	3	3	2	2	1	47
			52	05FEB93	3	2	1	4	2	2	2	1	3	1	3	1	1	2	2	1	2	1	2	2	1	2	1	40
1	79/126	JCN	8	03APR92	2	1	2	3	2	2	3	1	2	1	3	2	2	4	1	2	2	1	1	1	3	42		
			12	30APR92	2	2	1	2	2	3	4	2	1	2	1	2	2	2	2	2	2	4	1	1	3	38		
			16	29MAY92	3	2	1	3	3	4	4	2	1	2	2	3	2	2	2	2	1	3	3	1	2	2	46	
			20	26JUN92	2	1	1	2	2	1	2	3	1	2	3	1	3	3	1	2	2	1	2	2	1	2	36	
			24	24JUL92	2	2	1	3	2	2	3	1	2	2	4	4	2	1	1	2	2	4	1	2	2	4	1	43
			28	21AUG92	4	2	1	3	2	3	1	2	2	3	1	1	2	2	2	2	2	4	3	2	2	3	41	
			32	18SEP92	1	2	2	2	3	4	3	2	2	3	1	1	2	2	1	2	2	3	2	2	2	2	42	
			36	16OCT92	2	3	1	3	1	2	2	4	3	2	4	2	3	1	1	2	2	4	4	2	2	3	47	
			40	13NOV92	2	3	1	2	3	2	1	4	2	2	4	2	3	1	2	2	4	4	2	2	2	3	47	
			44	11DEC92	2	4	1	4	3	2	3	1	2	1	2	1	2	1	2	1	2	1	1	3	1	2	3	37
			48	08JAN93	3	1	1	3	4	1	2	1	2	1	1	1	2	1	2	1	2	4	1	1	2	4	1	39
			52	05FEB93	1	1	2	1	2	2	1	2	1	3	1	1	3	1	1	2	1	1	1	2	1	1	1	38
1	80/127	HEL	8	03APR92	3	2	2	3	1	2	1	4	2	3	1	2	4	3	3	1	2	2	2	2	3	45		
			12	30APR92	4	3	2	3	2	3	2	3	2	4	2	3	2	2	2	3	3	4	2	2	2	2	54	

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACERO

Centre No. (a)	Patient No. (a)	Initials	Visit	Date Performed	Date																				Total Score (b)		
					It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20			
1	84/130	IN	8	03APR92	2	2	3	2	2	3	3	1	2	2	4	2	1	1	2	2	2	3	3	1	41		
			12	30APR92	2	3	2	2	2	3	2	1	2	1	4	1	1	1	1	1	1	2	2	1	2	39	
			16	29MAY92	1	1	1	3	2	2	1	3	2	1	1	4	1	2	2	1	4	1	1	2	2	37	
			20	26JUN92	3	1	2	2	2	1	1	2	1	2	2	1	3	1	1	1	3	1	1	1	2	33	
			24	24JUL92	3	2	1	2	3	2	2	1	2	1	3	1	2	1	2	1	1	1	1	1	1	37	
			28	21AUG92	2	3	2	4	2	2	1	4	3	2	1	1	2	2	2	1	1	1	1	1	2	42	
			32	16SEP92	2	2	3	2	1	1	4	2	2	2	1	4	1	1	4	1	1	1	1	1	1	37	
			36	16OCT92	1	1	1	2	2	1	4	2	1	2	2	3	1	1	4	1	1	1	1	1	1	35	
			40	13NOV92	2	1	1	2	2	1	4	2	1	2	2	1	1	1	1	1	3	1	1	1	2	34	
			44	17DEC92	2	3	2	3	3	1	4	2	2	4	1	2	2	1	1	1	2	1	1	2	1	41	
			48	08JAN93	3	2	2	4	2	2	4	2	2	1	2	1	1	2	1	1	2	1	3	2	2	41	
			52	05FEB93	3	3	2	2	2	2	1	2	2	2	1	2	1	2	1	2	1	4	2	2	2	40	
1	85/131	MLP	8	03APR92	2	1	1	1	2	1	2	1	2	1	2	1	1	1	1	1	1	1	1	1	28		
			12	30APR92	1	1	2	1	2	1	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	26	
			16	29MAY92	1	2	1	1	2	1	2	1	2	1	2	1	3	2	2	1	1	1	1	2	1	1	30
			20	26JUN92	1	1	2	1	2	1	2	1	2	2	1	2	1	2	1	1	1	4	1	1	1	1	30
			24	24JUL92	1	2	1	2	2	1	1	2	1	2	1	2	1	3	2	1	1	3	1	1	2	1	36
			28	21AUG92	2	1	2	2	3	2	1	2	1	2	4	2	2	4	2	4	2	2	2	2	2	1	47
			32	16SEP92	2	2	3	3	2	1	1	3	4	4	2	2	3	3	2	1	1	1	1	1	1	2	46
			36	16OCT92	1	3	3	2	1	3	2	1	3	4	4	2	2	3	3	4	1	1	1	1	1	2	45
			40	13NOV92	2	2	1	2	3	3	4	1	2	1	1	2	3	1	1	3	1	1	2	2	1	1	37
			44	17DEC92	4	3	1	2	2	3	1	1	2	1	1	2	1	3	2	1	2	2	2	2	2	2	38
			48	08JAN93	3	3	1	4	3	2	2	1	3	4	1	3	2	1	3	4	1	3	3	4	4	2	52
			52	05FEB93	3	3	2	3	2	2	1	2	3	3	1	2	2	1	2	2	1	3	3	4	3	3	50
1	91/135	MSC	8	07APR92	2	1	2	2	3	1	2	1	2	2	2	1	1	1	2	2	1	1	1	2	36		
			12	05MAY92	2	1	1	3	1	2	1	2	1	4	2	2	1	1	1	1	1	1	1	1	1	32	
			16	02JUN92	1	1	1	2	1	2	1	1	3	1	1	1	1	1	1	1	1	1	1	1	1	28	
			20	30JUN92	1	2	1	2	2	1	1	1	3	1	1	1	1	2	1	1	1	1	1	1	1	27	
			24	28JUL92	1	4	2	3	1	2	2	2	1	1	2	1	2	1	2	1	2	2	1	2	1	2	37
			28	25AUG92	2	1	3	3	2	1	2	1	3	2	3	3	3	2	4	3	2	1	2	1	2	40	
			32	22SEP92	3	3	3	2	1	2	2	1	2	1	3	2	4	3	2	1	2	1	2	1	2	43	
			36	20OCT92	3	4	4	3	2	2	2	2	4	2	4	2	1	1	4	3	2	1	4	1	1	2	53
			40	17NOV92	2	2	1	3	2	2	1	2	3	3	2	4	2	1	2	1	2	1	2	2	2	4	41
			44	15DEC92	3	3	1	4	3	2	2	2	4	2	1	3	3	2	1	3	2	1	3	1	3	1	47
			48	12JAN93	4	1	2	4	2	2	1	2	4	3	1	3	2	1	3	2	1	3	1	2	2	2	46
			52	09FEB93	4	1	2	4	2	2	1	2	4	4	2	1	2	3	1	2	3	1	2	3	1	2	49
1	93/136	AL	8	08APR92	2	1	2	2	1	2	1	2	1	2	1	1	2	1	1	1	1	1	1	1	30		
			12	06MAY92	2	1	2	1	2	2	1	2	2	1	2	1	2	1	1	1	2	1	1	1	1	38	

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre No.	(a)	Patient No.	Initials	Visit	Date Performed	Date																				Total Score (b)								
						It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20									
1	93/136	AL		16	03JUN92	1	2	3	1	3	1	2	4	2	1	1	1	1	1	2	2	1	3	1	1	1	1	34						
				20	01JUL92	2	1	2	1	3	4	2	1	2	1	1	1	1	1	2	1	1	2	1	1	1	1	1	36					
				24	29JUL92	1	2	2	2	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	28				
				28	26AUG92	2	2	1	3	2	1	1	2	1	2	1	1	2	1	1	1	1	1	1	1	1	1	1	1	28				
				32	23SEP92	3	3	2	2	2	1	2	1	2	2	1	1	3	3	2	1	1	1	3	3	2	1	1	2	34				
				36	21OCT92	3	2	1	2	2	1	2	1	2	1	2	1	2	2	1	2	1	2	1	2	1	1	1	1	39				
				40	18NOV92	3	2	1	4	2	3	2	4	2	4	2	2	2	2	2	2	2	2	2	2	2	2	2	2	51				
				44	16DEC92	3	3	4	2	3	4	2	4	2	4	2	4	2	4	2	2	2	2	2	2	2	2	2	2	56				
				48	13JAN93	3	4	3	4	2	2	1	2	3	4	3	2	2	2	2	2	2	2	2	2	2	2	2	2	52				
				52	10FEB93	4	2	2	2	2	3	2	1	2	4	2	1	2	1	2	1	2	1	2	2	1	2	2	2	48				
				1	94/137	RAB		8	08APR92	3	1	2	2	1	2	4	2	2	1	1	2	2	1	1	2	1	1	2	1	1	35			
								12	06MAY92	2	1	2	1	3	1	2	4	2	3	2	1	2	1	2	2	1	1	1	1	1	1	2	37	
								16	03JUN92	2	2	1	1	1	2	4	2	1	3	1	1	3	2	1	1	1	1	1	1	1	1	1	35	
								20	01JUL92	2	1	2	3	1	3	2	4	2	1	1	2	1	1	2	2	1	1	2	2	1	1	1	2	36
								24	29JUL92	2	1	2	3	2	3	2	4	2	4	2	2	2	3	2	2	2	3	4	2	4	2	1	2	53
								28	26AUG92	1	3	4	2	4	2	3	2	3	4	2	3	1	1	1	1	1	1	1	1	1	1	1	1	48
32	23SEP92	2	2					2	2	2	1	2	1	2	1	2	1	2	3	2	1	1	1	1	1	1	1	1	1	34				
36	21OCT92	2	1					2	1	3	1	2	1	2	1	4	2	1	4	2	2	1	1	1	1	1	1	1	1	41				
40	18NOV92	1	2					1	3	1	2	1	2	3	2	1	1	3	1	2	2	1	1	1	1	1	1	1	1	32				
44	16DEC92	3	3					1	4	3	1	1	1	3	2	1	4	2	2	2	2	2	2	2	2	2	2	2	2	44				
48	13JAN93	2	1					1	3	2	3	1	2	4	2	1	2	1	4	2	2	2	2	2	2	2	2	2	2	40				
52	10FEB93	3	2					1	2	3	2	2	3	2	1	2	2	1	3	2	1	2	1	2	1	2	2	1	2	43				
1	97/140	HND						8	08APR92	1	2	2	1	3	3	1	2	2	4	2	2	1	1	1	1	1	3	2	1	1	39			
								12	06MAY92	1	1	2	3	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	28	
								16	03JUN92	1	2	1	2	2	1	2	3	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	35	
								20	01JUL92	1	1	2	2	1	1	2	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	29	
				24	29JUL92	2	2	2	4	2	2	1	1	2	1	1	2	3	2	1	2	3	4	1	2	2	1	2	44					
				28	26AUG92	2	4	3	3	1	3	3	4	2	4	2	3	3	2	2	2	2	2	2	2	2	2	2	2	44				
				32	23SEP92	3	2	1	3	1	2	1	2	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	52				
				36	21OCT92	3	1	2	4	3	3	1	1	2	1	4	2	2	3	1	1	1	1	1	1	1	1	1	1	41				
				40	18NOV92	2	2	1	2	2	1	2	1	2	3	1	1	3	1	2	1	1	1	1	1	1	1	1	1	35				
				44	16DEC92	1	2	1	2	2	1	2	2	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	33				
				48	13JAN93	1	2	1	2	1	2	2	2	2	4	1	1	2	1	1	1	1	1	1	1	1	1	1	1	31				
				52	10FEB93	1	1	2	3	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	33				
				1	100/142	JWA		8	08APR92	1	2	1	2	2	1	2	2	1	1	2	1	1	1	1	1	1	1	1	1	1	31			
								12	06MAY92	1	2	2	3	1	1	2	2	3	1	1	1	1	1	1	1	1	1	1	1	1	1	35		
								16	03JUN92	1	1	2	2	1	1	2	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	32	
								20	01JUL92	1	1	3	3	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	34	

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REXOXYLINE - PROTOCOL 20124/013
 Listing No.: 10.4

ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACERO

Patient Centre No. (a)	Initials	Visit	Date Performed	ZUNG																				Total Score (b)		
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20			
1	100/142	JWA	24	29JUL92	3	4	2	1	2	2	1	1	1	1	3	2	2	3	3	2	2	2	40			
			28	26AUG92	2	3	2	1	2	2	2	1	1	2	2	4	1	1	1	4	2	2	2	41		
			32	23SEP92	2	3	2	1	2	2	2	1	1	2	1	3	1	1	1	1	2	1	1	35		
			36	21OCT92	2	1	2	1	2	1	2	4	1	1	1	1	1	1	1	1	2	1	3	35		
			40	18NOV92	2	1	2	1	2	1	2	2	4	1	3	4	2	2	1	1	1	1	3	38		
			44	16DEC92	1	2	1	2	1	2	1	1	3	2	1	4	2	2	1	1	1	1	2	38		
			48	13JAN93	1	3	1	2	1	1	1	1	3	2	1	4	2	1	1	1	1	1	1	38		
			52	10FEB93	1	2	1	1	1	1	1	1	3	4	3	1	2	1	4	2	1	1	2	42		
			1	104/144	MTF	8	14APR92	1	1	3	4	2	2	1	4	2	2	1	3	1	3	5	1	1	1	40
						12	12MAY92	1	1	3	4	3	2	4	4	1	3	2	1	3	1	1	3	2	1	2
16	09JUN92	1				1	2	3	3	1	4	4	1	4	2	2	3	2	2	2	1	1	2	44		
20	07JUL93	1				1	2	4	3	2	3	4	1	2	1	2	1	1	1	1	1	1	1	43		
24	05AUG92	3				1	3	3	1	2	2	4	1	1	2	4	1	2	1	1	3	1	1	39		
28	02SEP92	2				1	4	2	2	2	2	2	4	1	1	2	1	1	2	4	1	2	1	39		
32	30SEP92	3				1	4	2	2	1	2	2	2	1	3	2	2	1	2	2	4	1	2	41		
36	28OCT92	3				2	4	2	2	2	2	2	4	3	2	1	1	1	2	3	2	2	1	42		
40	25NOV92	2				3	1	2	2	1	2	1	1	2	1	1	1	1	2	2	4	1	2	42		
44	23DEC92	4				1	1	3	3	1	2	1	2	1	1	1	2	1	2	2	3	2	4	44		
1	105/145	ABS	8	17FEB93	3	1	2	3	1	2	1	2	2	2	1	1	2	2	1	2	4	46				
			12	12MAY92	2	2	1	4	2	2	4	2	3	2	2	3	1	1	2	2	2	1	1	41		
			16	09JUN92	3	1	3	2	2	2	2	1	3	1	2	2	3	1	2	1	1	3	1	37		
			20	07JUL92	2	1	1	4	2	4	1	2	2	1	2	3	1	2	3	1	1	2	1	41		
			24	05AUG92	4	4	1	1	4	2	4	1	2	2	1	2	3	1	2	3	1	1	1	38		
			28	02SEP92	2	1	4	2	3	1	2	1	1	1	1	2	2	1	1	2	3	1	1	39		
			32	30SEP92	3	3	1	2	4	2	3	1	2	1	2	2	1	1	3	1	1	2	2	36		
			36	28OCT92	2	3	2	3	2	4	2	4	2	1	3	2	1	2	1	3	2	2	1	39		
			40	25NOV92	1	1	2	2	4	2	1	1	2	3	1	2	2	1	2	1	3	2	1	38		
			44	23DEC92	1	1	3	3	1	4	2	1	1	1	1	1	1	1	2	1	2	3	1	38		
1	106/146	MRN	8	14APR92	1	1	2	2	1	2	1	1	1	1	1	1	1	1	1	2	1	1	29			
			12	12MAY92	1	3	2	3	2	1	2	1	2	1	1	3	2	1	2	1	1	2	2	35		
			16	09JUN92	1	2	1	2	2	1	2	2	1	2	2	2	1	2	2	2	1	1	2	33		
			20	07JUL92	1	2	2	3	1	2	2	1	2	2	1	2	1	2	1	1	1	1	1	31		
			24	04AUG92	1	1	2	2	1	2	2	1	2	2	1	1	1	1	2	1	1	2	1	31		
			28	02SEP92	2	1	3	1	2	1	2	2	2	1	2	2	1	1	2	2	1	2	2	36		

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Patient Centre No. (a)	Initials	Visit	Date Performed	ZUNG																				Total Score (b)	
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20		
1	106/146	MRN	36	27OCT92	1	2	2	2	1	3	1	2	2	4	2	1	1	1	1	3	3	1	1	37	
			40	24NOV92	2	2	1	2	2	1	1	2	1	2	4	2	1	1	1	1	4	4	1	1	36
			44	22DEC92	3	3	1	3	2	2	1	4	2	2	3	2	1	1	1	1	1	4	4	3	47
			48	19JAN93	3	2	2	2	2	1	2	1	3	1	2	4	3	4	2	2	4	1	2	2	45
			52	16FEB93	3	3	1	2	2	2	1	1	4	3	3	2	4	3	2	4	2	3	1	2	48
1	108/148	STB	8	15APR92	2	1	2	4	1	2	1	2	2	2	1	2	1	1	1	1	1	1	2	31	
			12	13MAY92	1	2	2	4	2	1	2	1	2	2	1	2	1	2	1	2	2	1	1	2	35
			16	10JUN92	2	2	1	1	1	2	2	1	1	3	4	3	3	1	1	2	2	1	1	2	38
			20	08JUL92	2	1	1	3	1	1	1	1	1	2	2	1	2	1	2	1	2	1	1	1	29
			24	05AUG92	2	3	1	2	2	1	1	2	1	4	2	2	1	2	1	2	1	1	1	1	33
			28	02SEP92	2	2	2	1	3	3	1	1	3	3	2	2	1	1	2	1	1	1	1	1	34
			32	30SEP92	1	1	1	1	3	3	1	1	2	2	2	1	1	2	1	1	2	1	1	1	30
			36	28OCT92	3	1	1	1	3	2	1	2	2	2	3	1	1	1	1	2	1	1	1	1	34
			40	25NOV92	2	1	1	1	2	1	2	1	2	4	2	2	1	3	1	1	1	4	1	1	34
			44	23DEC92	2	1	1	2	2	1	1	2	1	2	1	2	1	2	1	3	2	4	2	2	35
			48	19JAN93	3	2	3	2	3	1	4	3	1	1	2	1	1	2	1	1	2	4	3	1	41
			52	17FEB93	3	1	3	1	2	2	1	4	2	4	2	2	1	3	1	2	1	3	2	2	42
			1	111/331	JBF	8	15APR92	2	4	2	2	2	2	1	2	2	4	3	1	2	1	2	2	1	1
12	13MAY92	2				4	2	3	1	2	1	2	2	3	1	2	2	1	2	1	1	2	2	37	
16	10JUN92	1				2	1	3	2	2	1	2	2	4	2	4	2	2	1	2	2	1	1	38	
20	08JUL92	2				1	2	2	2	2	4	2	2	3	4	2	3	1	4	2	1	2	1	44	
24	05AUG92	2				2	1	2	1	2	4	2	2	3	4	2	2	1	2	2	1	2	1	2	44
28	02SEP92	3				1	1	2	1	2	1	3	2	2	3	2	1	2	1	2	1	1	1	1	37
32	30SEP92	2				1	2	1	2	1	2	1	3	2	2	2	4	1	4	2	1	2	1	2	40
36	28OCT92	2				1	2	3	2	1	3	2	2	2	2	2	1	1	2	1	1	3	2	3	36
40	25NOV92	2				1	1	2	1	3	2	1	2	2	2	2	1	1	2	2	1	3	3	4	42
44	23DEC92	3				1	2	3	1	3	1	1	3	4	2	2	1	2	1	2	1	4	1	1	33
48	19JAN93	2				2	1	3	1	3	1	1	3	4	2	4	2	2	1	2	1	2	1	1	37
52	17FEB93	3				2	2	1	2	2	1	4	2	4	2	2	1	1	2	1	2	4	1	2	35
1	114/332	CLF				8	22APR92	3	2	2	4	2	2	4	4	2	2	4	2	1	1	2	2	2	2
			12	18MAY92	4	2	2	3	4	2	2	4	3	3	1	4	2	2	1	4	4	2	2	52	
			16	16JUN92	4	2	4	2	2	3	4	2	2	2	2	3	1	1	2	3	1	2	3	49	
			20	14JUL92	4	3	1	4	3	5	4	2	2	4	3	3	3	3	3	2	2	1	3	54	
			24	12AUG92	3	3	2	3	1	2	4	2	2	2	2	4	2	3	1	2	3	1	2	1	41
			28	09SEP92	3	2	1	3	1	1	4	1	2	4	2	2	4	1	1	2	3	1	1	1	39
			32	07OCT92	2	1	1	2	1	3	1	1	1	3	1	2	3	1	1	2	2	1	2	1	33
			36	04NOV92	2	3	2	3	1	1	1	2	3	2	2	3	1	3	1	2	3	2	1	1	39
			40	02DEC92	2	3	1	2	2	1	1	2	2	1	1	2	2	2	2	2	3	2	1	1	31

(a) = Open/Blind

9550077

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

Patient Centre No.	(a) Initials	Visit	Date Performed	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	Total Score (b)
1	114/332	CLF	44	30DEC92	3	2	1	1	1	1	2	2	3	1	2	2	1	2	2	2	1	1	2	34
			48	27JAN93	2	2	1	1	1	1	2	2	1	2	1	3	1	2	3	2	1	2	2	35
			52	24FEB93	2	2	3	2	1	1	2	1	1	2	2	1	2	4	2	2	1	2	2	36
1	115/333	ELS	8	22APR92	2	1	3	2	1	2	2	3	4	2	1	2	1	2	2	1	3	1	2	40
			12	19MAY92	2	2	4	2	2	2	1	2	2	2	2	3	1	1	4	3	1	3	1	42
			16	16JUN92	3	2	4	2	2	2	1	3	2	2	4	1	3	3	2	2	4	2	4	50
			20	16JUL92	2	2	1	4	2	2	1	2	3	2	3	2	3	1	1	1	2	2	2	44
			24	12AUG92	2	1	1	2	2	3	1	2	3	2	1	1	2	3	1	2	2	1	2	35
			28	09SEP92	3	1	2	4	3	1	1	3	2	2	1	2	3	4	3	2	3	3	1	50
			32	07OCT92	1	1	1	1	1	3	2	1	1	1	2	1	2	3	1	4	2	1	1	32
			36	04NOV92	3	3	3	2	1	3	1	4	2	1	2	3	2	1	2	4	1	1	2	43
			40	02DEC92	2	2	1	2	1	2	2	1	4	2	1	4	2	1	2	1	4	1	2	35
			44	30DEC92	1	1	2	1	2	1	1	4	2	1	1	4	2	1	1	1	2	1	1	32
			48	27JAN93	1	2	2	1	1	1	1	4	2	1	2	1	1	2	1	1	1	3	1	31
			52	24FEB92	1	1	2	1	1	1	1	3	4	1	1	1	1	2	1	2	1	2	2	31
1	122/337	HSS	8	22APR92	1	2	2	4	2	1	2	2	4	2	2	1	2	2	2	1	2	1	2	40
			12	20MAY92	2	2	1	3	2	1	2	2	2	2	2	4	2	2	1	2	1	3	1	38
			16	17JUN92	2	2	1	3	2	1	2	2	2	2	2	2	2	1	2	2	2	1	2	35
			20	15JUL92	1	2	1	2	2	2	1	2	3	2	2	3	1	2	2	1	2	2	2	36
			24	12AUG92	1	2	1	2	2	2	1	1	3	2	1	1	3	1	1	1	2	1	1	30
			28	09SEP92	3	3	1	1	1	3	1	1	3	3	1	2	1	1	1	1	1	3	1	34
			32	07OCT92	1	1	1	1	1	2	1	2	2	1	1	2	1	1	1	2	2	2	1	30
			36	04NOV92	1	1	1	4	1	3	1	1	1	3	4	1	1	2	1	1	1	2	1	32
			40	02DEC92	1	1	2	1	1	1	1	1	3	1	1	1	1	2	2	1	3	3	1	28
			44	30DEC92	1	1	3	1	1	1	1	1	3	2	1	2	1	2	1	2	1	2	1	29
			48	27JAN93	1	2	1	1	1	1	1	1	3	1	1	2	4	1	1	1	2	4	1	34
			52	24FEB93	1	2	1	3	1	1	2	1	4	2	1	1	2	1	1	1	1	3	1	33
1	124/339	PPC	8	22APR92	1	2	2	3	2	4	2	4	1	1	2	3	3	1	2	2	2	1	2	42
			12	20MAY92	1	1	2	3	2	4	2	4	3	2	1	4	2	1	2	1	2	2	1	43
			16	17JUN92	1	2	2	3	2	4	1	4	1	2	2	4	2	2	1	4	1	1	1	42
			20	15JUL92	1	1	2	3	1	4	2	4	2	2	2	1	4	2	1	1	1	1	1	37
			24	12AUG92	3	2	1	4	3	1	4	2	4	1	2	2	1	3	3	1	3	1	2	40
			28	09SEP92	3	3	1	3	3	4	2	1	2	1	1	3	3	1	1	1	2	1	1	41
			32	07OCT92	2	3	3	2	2	2	1	2	1	2	1	1	3	3	2	1	1	3	1	37
			36	04NOV92	2	1	1	3	1	3	1	2	1	3	2	1	1	2	1	1	1	3	1	32
			40	02DEC92	1	1	2	2	1	3	1	1	3	1	1	2	1	2	1	1	1	4	1	32
			44	30DEC92	1	1	2	2	1	1	1	2	2	1	2	1	2	1	2	1	2	3	1	32
			48	27JAN93	3	1	1	4	1	1	2	2	4	2	1	1	2	1	2	3	1	1	2	41

(a) = Open/Blind
 (b) = Mean Score

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Patient Centre No. (a)	Initials	Visit	Date Performed	ZUNG	It.																		Total It.20 Score (b)					
					1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18		19				
1	124/339	PPC	52	24FEB93	2	1	1	2	2	2	1	2	2	1	4	2	2	1	2	1	1	3	1	1	3	1	3	36
1	126/341	SMB	8	22APR92	1	2	2	2	2	2	3	3	4	1	2	1	1	2	1	1	1	4	1	1	1	1	1	40
			12	20MAY92	1	1	1	3	2	2	2	2	3	1	2	1	1	2	1	1	2	3	1	1	1	1	1	34
			16	17JUN92	1	1	1	3	2	3	1	2	3	2	1	1	2	2	1	1	3	1	1	1	1	1	1	34
			20	15JUL92	1	1	1	3	1	2	1	2	1	1	2	1	1	2	2	1	1	2	1	1	1	1	1	28
			24	13AUG92	1	1	1	2	2	2	1	2	3	1	1	2	4	1	1	2	1	2	1	2	1	2	2	34
			28	09SEP92	1	1	1	4	2	2	3	1	2	1	1	3	1	2	1	1	2	1	2	1	2	1	2	36
			32	07OCT92	2	3	1	1	3	3	1	1	2	3	2	1	1	3	1	2	1	2	1	2	1	2	1	39
			36	04NOV92	1	2	1	2	1	2	1	3	1	1	4	2	1	1	1	1	2	1	3	1	1	2	2	34
			40	02DEC92	1	2	2	1	2	1	2	1	2	4	2	2	1	1	2	1	1	3	4	1	2	1	2	40
			44	30DEC92	1	1	2	2	1	2	1	2	1	4	3	2	2	1	2	1	4	3	1	2	2	3	1	38
			48	27JAN93	1	2	1	1	2	1	1	2	4	1	3	2	2	1	2	1	4	3	1	2	2	2	3	38
			52	24FEB93	1	1	1	2	1	2	2	1	1	2	1	1	4	3	1	2	1	2	1	2	1	2	2	34
1	129/344	MNS	8	22APR92	3	2	2	3	3	2	2	2	2	2	2	1	2	2	1	1	1	2	1	1	1	1	1	40
			12	20MAY92	2	2	1	3	1	2	2	1	2	2	2	1	2	2	1	1	2	2	2	1	1	1	1	33
			16	17JUN92	2	2	4	2	2	1	2	2	1	2	2	1	1	2	2	2	2	1	2	2	1	2	2	40
			20	15JUL92	2	1	2	2	1	3	2	1	4	2	2	1	2	2	1	1	2	2	2	1	2	1	2	37
			24	12AUG92	1	1	1	2	1	3	2	1	1	2	2	1	1	2	1	1	2	1	1	2	1	1	1	29
			28	09SEP92	3	3	2	3	1	3	1	1	2	4	2	2	3	2	1	2	1	2	2	1	1	1	1	40
			32	07OCT92	3	1	3	3	2	2	1	1	3	4	3	2	2	1	1	2	1	2	1	1	4	2	1	42
			36	04NOV92	3	3	2	4	2	2	2	1	3	4	2	2	3	2	2	2	3	1	3	2	2	2	2	49
			40	02DEC92	4	3	3	3	4	2	3	1	4	2	2	3	1	2	3	1	3	3	2	3	2	3	2	52
1	130/345	EGA	8	24APR92	2	3	4	2	2	3	2	2	4	2	2	4	3	2	2	3	2	3	2	3	3	3	55	
			12	22MAY92	3	3	4	3	4	3	2	2	3	4	2	2	1	3	3	2	3	3	2	3	3	3	56	
			16	19JUN92	3	4	2	3	3	2	3	2	2	2	2	4	3	2	4	4	2	4	4	2	3	2	55	
			20	17JUL92	3	3	2	4	3	2	2	2	2	1	1	2	4	3	1	3	1	3	4	2	2	2	50	
1	133/346	JPM	8	10MAY92	2	2	1	4	2	2	1	4	2	2	2	4	2	2	4	2	2	1	1	1	1	2	44	
			12	12JUN92	3	3	2	2	2	2	4	3	3	4	4	3	3	2	3	1	3	3	1	3	3	1	2	50
			16	10JUL92	2	3	1	3	3	4	2	2	3	4	3	4	3	3	1	4	2	4	2	2	3	2	50	
			20	07AUG92	4	2	1	4	2	2	2	4	3	3	4	2	2	2	4	4	2	3	4	2	3	2	55	
			24	04SEP92	2	1	1	2	2	2	1	3	3	2	2	2	4	3	1	2	1	2	1	2	1	1	37	
			28	02OCT92	2	2	1	2	1	2	2	1	3	3	2	2	4	3	2	4	3	2	1	2	1	2	39	
			32	30OCT92	1	1	1	2	2	1	1	2	4	3	2	3	1	1	3	2	2	1	3	2	2	1	2	35
			36	27NOV92	2	2	1	2	3	1	1	1	2	2	2	3	1	4	2	2	3	1	4	2	2	1	2	36
			40	24DEC92	2	2	1	3	1	2	2	2	2	2	1	1	1	2	1	2	1	2	2	1	2	1	2	38
			44	22JAN93	3	2	2	2	1	3	1	2	2	2	1	1	1	2	1	4	3	4	1	2	3	1	2	38
			48	19FEB93	3	1	2	2	1	2	1	1	1	1	1	3	2	4	1	2	1	1	1	1	1	1	1	43
																												36

(a) = Open/Blind
 (b) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Patient	Centre No. (a)	Initials	Visit	Date Performed	ZUNG	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	Total Score (b)	
	1	133/346	JPN	52	19MAR93	2	2	1	2	2	3	1	1	3	2	1	1	2	1	1	1	2	2	1	3	34	
	1	136/349	AVP	8	19MAY92	2	2	3	3	2	4	3	1	4	3	1	4	2	3	3	3	2	1	1	3	46	
				12	16JUN92	3	3	2	4	2	4	2	1	4	2	3	4	3	3	3	2	2	4	4	1	53	
				16	16JUL92	4	2	4	2	2	4	2	1	4	2	1	4	3	3	3	2	2	4	4	1	50	
				20	11AUG92	4	3	3	2	2	4	2	1	3	4	1	4	2	3	2	2	4	4	2	4	54	
				24	08SEP92	3	2	1	2	2	4	1	2	2	2	2	4	1	3	2	2	1	2	3	2	44	
				28	06OCT92	3	3	1	2	1	1	1	1	2	2	2	3	2	3	2	2	2	3	3	3	39	
				32	03NOV92	3	4	2	3	1	1	1	1	3	2	2	3	3	2	2	2	1	2	2	2	41	
				36	01DEC92	3	4	2	2	1	1	1	1	4	2	4	2	2	2	2	3	1	4	4	2	41	
				40	29DEC92	1	1	1	3	2	1	1	2	1	3	1	2	1	1	1	2	1	1	3	1	31	
				44	26JAN93	2	1	3	4	2	1	1	2	3	1	1	2	2	1	2	2	4	1	1	2	37	
				48	24FEB93	2	1	2	4	3	1	1	1	1	3	1	1	1	1	2	1	2	4	1	1	34	
				52	23MAR93	2	1	1	3	2	1	3	1	4	2	2	1	1	1	2	1	2	1	3	1	34	
	1	138/350	LBV	8	19MAY92	1	2	1	2	4	3	1	2	2	1	1	2	3	2	1	1	1	4	1	2	37	
				12	16JUN92	1	3	1	2	3	2	4	2	4	2	1	3	2	3	1	1	1	2	3	1	44	
				16	16JUL92	1	2	1	3	2	3	2	1	3	3	3	2	2	2	2	2	2	1	3	1	40	
				20	11AUG92	1	2	1	3	2	2	1	3	2	4	4	4	2	2	3	3	2	1	1	2	44	
				24	08SEP92	3	3	3	1	1	2	1	2	2	2	2	2	2	2	1	1	2	2	1	3	1	37
				28	06OCT92	3	4	2	3	1	1	1	2	2	2	2	2	2	2	3	3	2	4	4	1	2	43
				32	03NOV92	3	2	2	4	2	3	1	1	2	3	3	2	2	2	2	2	2	1	4	3	2	45
				36	01DEC92	4	2	3	2	3	1	1	1	3	2	2	3	3	3	2	2	2	1	4	2	47	
				40	29DEC92	3	3	2	2	1	1	1	1	2	4	2	2	4	2	4	1	1	2	4	1	42	
				44	26JAN93	1	2	4	3	4	1	1	3	1	4	3	2	3	2	4	4	2	3	2	3	55	
				48	24FEB93	3	1	2	2	2	1	2	2	2	4	2	2	4	2	2	4	2	4	2	1	40	
				52	23MAR93	2	2	1	2	3	2	1	1	2	4	2	2	1	2	2	4	2	3	2	1	40	
	1	141/353	ANG	8	19MAY92	2	2	1	3	2	3	1	2	2	4	2	2	2	1	2	3	3	1	2	1	40	
				12	16JUN92	2	1	1	2	2	2	3	3	2	2	2	1	2	2	2	2	3	4	2	2	43	
				16	16JUL92	2	1	1	2	2	1	3	4	2	2	1	2	2	1	3	1	3	2	1	2	44	
				20	11AUG92	1	1	1	2	2	1	2	2	1	2	2	1	1	2	2	1	1	3	1	2	38	
				24	08SEP92	1	1	1	3	3	2	1	2	3	1	2	2	1	1	2	2	1	1	2	1	30	
				28	06OCT92	2	3	2	1	1	2	1	3	2	2	3	1	1	1	1	1	2	1	3	1	34	
				32	03NOV92	2	3	2	4	2	2	1	1	3	2	2	4	2	4	1	2	2	1	3	1	42	
				36	01DEC92	3	3	3	4	3	2	1	2	4	2	4	2	3	1	2	2	1	2	2	1	44	
	1	143/355	JEP	8	19MAY93	1	1	1	2	2	3	4	3	2	2	1	2	2	1	3	1	1	2	2	1	37	
				12	16JUN92	2	1	2	3	3	2	2	4	3	2	3	2	4	3	1	4	3	1	4	2	47	
				16	16JUL92	3	1	1	3	3	4	2	4	2	4	2	2	4	2	4	3	3	3	1	2	52	
				20	11AUG92	4	1	2	3	3	2	4	2	4	3	2	2	2	4	4	3	2	3	3	1	56	

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Patient Centre No. (a)	Initials	Visit	Date Performed	ZUNG	It. 1 It. 2 It. 3 It. 4 It. 5 It. 6 It. 7 It. 8 It. 9 It. 10 It. 11 It. 12 It. 13 It. 14 It. 15 It. 16 It. 17 It. 18 It. 19 It. 20																			Total Score (b)							
					Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score		Score						
1	145/357	SLD	8	22MAY92	2	1	2	2	3	3	1	2	1	4	2	2	2	2	1	1	2	2	3	1	2	2	40				
			12	19JUN92	3	1	2	2	2	1	2	1	4	4	2	2	1	2	2	2	2	2	2	2	2	2	2	43			
			16	17JUL92	3	1	2	2	2	2	3	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	36			
			20	14AUG92	3	2	2	3	1	3	2	2	1	2	1	2	1	2	1	2	1	2	1	2	1	2	1	36			
			24	11SEP92	2	1	2	2	2	3	1	2	3	2	1	1	1	1	1	1	1	1	1	1	1	1	1	34			
			28	09OCT92	3	1	1	2	2	2	1	1	2	2	1	2	1	1	1	1	1	1	1	1	1	1	1	31			
			32	06NOV92	3	2	1	2	2	2	2	2	1	2	1	2	1	2	3	2	1	2	1	2	1	1	1	34			
			36	04DEC92	3	1	1	3	2	3	1	2	2	3	1	1	1	1	1	1	1	1	1	1	1	1	1	37			
			40	31DEC92	3	3	4	2	1	3	1	2	4	2	2	4	1	1	1	1	1	1	1	1	1	1	1	42			
			44	29JAN93	3	4	3	4	3	1	2	4	3	4	1	3	2	2	1	1	1	1	1	1	1	1	1	51			
			48	26FEB93	3	1	3	2	1	4	3	1	2	4	1	3	2	1	1	1	1	1	1	1	1	1	1	42			
			52	26MAR93	3	3	2	3	2	1	3	3	1	2	2	2	2	2	2	2	2	1	3	1	3	1	1	45			
1	149/360	SC	8	22MAY92	2	2	1	2	2	1	4	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	37				
			12	19JUN92	2	1	1	2	2	1	2	4	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	33			
			16	17JUL92	1	1	1	2	2	3	2	4	2	2	3	1	2	1	1	1	1	1	1	1	1	1	1	41			
			20	14AUG92	2	2	1	2	2	4	2	4	3	2	2	1	1	1	1	1	1	1	1	1	1	1	1	45			
			24	11SEP92	2	2	1	2	2	3	1	2	3	2	2	2	1	1	1	1	1	1	1	1	1	1	1	35			
			28	09OCT92	2	2	2	1	2	2	1	1	2	2	2	3	3	1	1	1	1	1	1	1	1	1	1	35			
			32	06NOV92	2	1	1	2	1	1	1	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	29			
			36	04DEC92	1	1	2	2	2	1	2	1	2	1	3	1	1	1	1	1	1	1	1	1	1	1	1	30			
			40	31DEC92	1	1	1	2	1	3	1	2	4	1	1	1	1	1	1	1	1	1	1	1	1	1	1	32			
			44	29JAN93	1	2	1	2	2	1	3	1	2	1	2	1	2	1	1	1	1	1	1	1	1	1	1	31			
			52	26MAR93	1	1	2	2	1	2	2	1	3	1	1	2	4	3	1	1	1	1	1	1	1	1	1	33			
			1	150/151	VA	8	22MAY92	1	2	2	1	3	3	4	2	2	1	3	1	2	2	2	2	2	2	2	2	2	2	38	
12	19JUN92	2				1	2	3	1	2	2	3	2	1	4	1	3	2	3	2	2	1	1	1	1	1	42				
16	17JUL92	2				3	4	2	2	1	4	3	2	1	1	3	4	1	3	4	1	3	4	4	2	1	3	48			
20	14AUG92	3				4	3	2	2	1	2	3	1	1	3	2	4	3	3	4	2	2	4	4	2	2	2	52			
24	11SEP92	1				1	1	1	1	2	1	2	3	1	1	4	2	1	1	1	1	1	1	1	1	1	1	37			
28	09OCT92	2				1	1	2	2	2	3	2	2	4	3	2	1	2	1	1	1	1	1	1	1	1	1	44			
32	06NOV92	3				3	1	3	2	2	1	1	2	4	3	3	4	1	2	1	1	1	1	1	1	1	1	44			
36	04DEC92	4				2	2	3	2	2	1	1	3	2	2	4	3	1	2	3	1	2	3	1	2	2	2	48			
3	2/61	FIL				8	11JAN91	1	4	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	3		
						12	07FEB91	2	4	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	26	
						14	21FEB91	1	1	1	1	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	34
						16	07MAR91	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25
			18	21MAR91	1	4	2	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	30			
			20	04APR91	2	4	2	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	32			
			24	02MAY91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24			

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Patient Centre No. (a)	Initials	Visit	Date Performed	ZUNG	It.																				Total Score (b)			
					1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20				
3	2/61	FIL	28	30MAY91	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25				
			40	22AUG91	1	1	2	2	2	1	2	1	1	1	1	1	1	1	1	1	1	2	2	1	28			
			42	05SEP91	1	2	2	1	1	2	1	1	1	1	1	1	1	1	1	1	1	2	3	1	27			
3	3/62	DUB	8	29MAY91	2	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	23				
			12	26JUN91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23			
			16	24APR91	1	2	4	1	1	1	1	3	1	2	1	1	1	1	1	1	1	1	1	1	32			
			20	21AUG91	1	2	1	1	3	1	1	2	1	2	1	1	1	1	1	1	1	1	1	1	31			
			8	05JUN91	2	3	2	1	1	4	1	1	3	4	3	3	3	4	2	3	3	3	2	3	51			
3	10/72	TOR	12	01JUL91	2	2	2	1	2	1	2	2	3	3	3	3	2	3	3	3	2	3	2	46				
			16	31JUL91	2	3	2	3	1	1	1	3	3	3	3	3	4	2	3	3	3	2	3	50				
			20	28AUG91	2	2	2	2	3	1	1	1	3	3	3	4	4	3	3	4	3	3	3	3	52			
			8	25JAN91	2	2	2	1	4	1	1	2	3	2	3	2	2	2	2	2	3	3	1	2	42			
8	1/211	RJ	12	25FEB91	2	2	1	2	1	1	2	2	2	2	3	2	2	2	2	2	2	3	1	59				
			16	25MAR91	2	2	1	2	1	1	1	2	2	2	2	3	2	2	2	2	2	2	2	1	58			
			20	22APR91	2	3	1	2	1	4	1	1	1	2	2	2	2	2	2	2	2	2	2	2	1	36		
			24	20MAY91	2	3	1	2	1	4	1	1	1	2	2	2	2	2	2	2	2	2	2	2	1	37		
			28	17JUN91	2	3	1	2	1	4	1	1	1	2	2	2	2	2	2	2	2	2	2	2	1	34		
			32	15JUL91	2	3	1	2	1	4	1	1	1	2	2	2	2	2	2	2	2	2	2	2	1	35		
			36	12AUG91	2	3	1	2	1	4	1	1	1	2	2	2	2	2	2	2	2	2	2	2	1	37		
			40	09SEP91	2	3	1	2	1	4	1	1	1	2	2	2	2	2	2	2	2	2	2	2	1	32		
			44	07OCT91	2	1	1	2	1	4	1	1	1	2	2	2	2	2	2	2	2	2	2	2	1	33		
			8	4/214	BA	8	07MAR91	1	1	1	1	1	2	1	1	2	2	2	2	2	2	2	2	2	2	1	34	
						10	21MAR91	1	1	1	1	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	1	34
						12	04APR91	1	1	1	1	1	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	1
16	02MAY91	1				2	1	1	1	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	1	30		
20	30MAY91	2				2	1	2	1	4	1	1	1	2	2	2	2	2	2	2	2	2	2	2	1	33		
24	27JUN91	2				3	1	2	1	4	1	1	1	2	2	2	2	2	2	2	2	2	2	2	1	36		
28	25JUL91	1				2	1	2	1	4	1	1	1	2	2	2	2	2	2	2	2	2	2	2	1	35		
32	22AUG91	1				2	1	2	1	4	1	1	1	2	2	2	2	2	2	2	2	2	2	2	1	35		
36	19SEP91	1				1	1	2	1	4	1	1	1	2	2	2	2	2	2	2	2	2	2	2	1	37		
40	27OCT91	1				1	1	2	1	4	1	1	1	2	2	2	2	2	2	2	2	2	2	2	1	31		
9	2/241	VCF	44	14NOV91	1	2	1	3	1	4	1	1	1	2	1	2	1	1	2	1	1	2	1	29				
			48	12DEC91	1	2	1	3	1	4	1	1	1	2	2	2	2	2	2	2	2	2	2	1	30			
			52	09JAN92	1	2	1	3	1	4	1	1	1	2	2	2	2	2	2	2	2	2	2	1	28			
			8	23JUL90	1	2	1	1	1	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	22			
			12	20AUG90	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21			

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RAD
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACERO

Patient	Centre No. (a)	Initials	Visit	Date Performed	ZUNG	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	Total Score (b)							
9	2/241	VCF	16	17SEP90	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21						
			20	15OCT90	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21				
			22	29OCT90	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24				
			24	12NOV90	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23				
			28	10DEC90	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22				
			32	07JAN91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23			
			36	04FEB91	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23			
			40	04MAR91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21			
			44	01APR91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21			
			48	29APR91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	20			
			52	27MAY91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	20			
			9	5/242	MF	8	17NOV90	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23		
						12	15DEC90	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23	
						16	12JAN91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22
						20	09FEB91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22
						24	09MAR91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22
28	06APR91	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	20		
32	04MAY91	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	20		
36	01JUN91	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	20		
40	25JUN91	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21		
42	15JUL91	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21		
9	8/244	KTM	8	16JAN91	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	35					
			12	18FEB91	3	3	3	3	3	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	57				
			20	10APR91	2	2	2	3	2	2	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	46			
			24	08MAY91	3	3	3	3	3	2	3	3	4	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	60			
9	12/247	GVT	8	30APR91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23					
			16	25JUN91	3	3	3	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	55				
9	13/248	BP	8	08MAY91	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23					
			12	05JUN91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21			
			16	03JUL91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21		
			20	31JUL91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22		
			24	28AUG91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24		
			28	25SEP91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24		
			32	23OCT91	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	26		
			36	20NOV91	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25		
40	18DEC91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21					

(a) = Open/Blind
 (b) = ...

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre No.	Patient No. (a)	Initials	Visit	ZUNG	Data Performed																			Total Score (b)			
					It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19				
9	13/248	BP	44	15JAN92	2	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	28			
			48	12FEB92	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22		
			52	12MAR92	2	2	2	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	30		
			8	08OCT91	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	21	
			12	05NOV91	2	2	2	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	2	34	
9	19/251	RF	16	03DEC91	2	2	2	2	2	2	1	1	2	2	2	2	2	2	2	2	2	2	2	2	34		
			18	17DEC91	3	3	3	3	3	2	2	3	3	2	2	2	2	2	2	2	2	2	2	2	46		
			8	06JAN92	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24	
			12	08FEB92	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	26	
			16	16MAR92	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	30	
9	24/253	LCY	20	30MAR92	2	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25		
			8	14JAN92	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23		
			12	11FEB92	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23	
			16	10MAR92	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23	
			20	07APR92	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25	
9	25/254	PH	24	05MAY92	1	1	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23		
			28	02JUN92	2	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25		
			32	30JUN92	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24	
			36	28JUL92	2	2	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	30	
			40	25AUG92	2	2	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	26	
9	28/257	HI	44	22SEP92	2	2	2	2	2	2	1	1	2	2	2	2	2	2	2	2	2	2	2	2	27		
			48	20OCT92	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	29		
			50	03NOV92	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	31		
			8	01JUN92	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22	
			12	29JUN92	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22	
10	4/272	ZSD	16	27JUL92	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21		
			20	26AUG92	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21		
			24	25SEP92	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22	
			28	19OCT92	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22	
			8	27DEC90	3	1	2	4	1	4	1	1	1	4	3	3	2	3	2	3	2	3	2	4	1	3	47
10	4/272	ZSD	12	22JAN91	2	2	1	4	1	1	1	1	3	3	2	4	2	4	1	4	1	4	1	3	47		
			16	19FEB91	3	1	3	4	1	4	1	1	1	3	3	2	4	2	4	1	4	1	4	1	4	50	
			21	28MAR91	3	2	3	4	1	4	1	1	1	3	3	4	4	3	4	1	4	1	4	1	3	54	
			24	16APR91	2	2	2	4	1	4	1	1	1	3	3	4	2	4	2	4	1	4	1	4	1	3	49
			28	16APR91	2	2	2	3	2	4	1	1	1	3	3	3	2	4	2	4	1	4	1	4	1	3	49

(a) = Open/Blind

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

9550077

Patient		Centre No. (a)	Date Performed																	Total Score (b)										
Initials	Visit		ZUNG	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16		It.17	It.18	It.19	It.20						
10	5/273	AN	8	09	JAN	91	2	1	1	2	2	2	2	3	1	2	1	2	1	3	2	2	2	2	1	2	33			
			8	28	JAN	91	2	1	2	2	3	2	1	2	2	2	1	2	1	2	2	1	1	1	1	1	1	34		
			10	07	FEB	91	2	1	2	2	3	2	1	2	2	1	2	1	2	1	1	1	1	1	1	1	1	28		
			8	08	APR	91	2	2	1	3	1	3	1	3	2	2	3	2	3	3	3	1	3	1	3	1	3	45		
			12	05	MAY	91	2	3	1	2	2	2	2	1	1	1	2	2	2	2	2	1	3	1	3	1	3	38		
10	14/279	AA	16	05	JUN	91	2	3	1	2	1	1	1	1	1	1	2	1	2	2	1	1	3	1	2	32				
			20	01	JUL	91	2	3	1	2	1	1	1	1	1	1	2	2	2	2	1	3	1	3	1	2	36			
			24	25	JUL	91	2	3	1	2	1	2	1	2	1	1	1	2	2	2	2	1	2	1	2	1	2	32		
			28	26	AUG	91	2	3	1	2	1	2	1	2	1	1	1	2	2	2	2	1	2	1	2	1	2	33		
			32	2			2	3	1	2	1	2	1	2	1	1	1	2	2	2	2	1	2	1	2	1	2	33		
			36	2			2	3	1	2	1	2	1	2	1	1	1	2	2	2	2	2	3	1	3	1	3	36		
			40	2			2	3	1	2	1	2	1	2	1	1	1	2	2	2	2	3	1	2	2	2	3	35		
			44	2			2	3	1	2	1	2	1	2	1	1	1	2	2	2	2	1	3	1	2	2	2	34		
			48	2			2	3	1	2	2	1	2	2	1	1	1	2	2	3	3	2	2	3	1	2	2	41		
			52	2			2	3	1	2	2	1	2	2	1	1	1	2	2	2	3	2	2	3	1	3	1	3	41	
			10	16/281	AJ	8	2			2	3	2	2	1	1	2	2	2	2	2	1	3	3	1	2	2	1	2	1	36
12	2						2	2	2	1	1	1	2	2	2	2	2	2	1	3	3	1	2	1	2	1	2	34		
16	2						2	2	2	1	1	1	2	2	2	2	2	2	1	3	3	1	1	1	1	1	1	33		
20	2						2	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24		
24	2						2	2	1	2	1	1	1	1	1	1	1	2	1	2	1	1	1	1	1	1	1	27		
28	2						2	2	1	1	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	26		
32	2						2	2	1	1	1	1	1	2	1	1	1	2	1	2	1	1	1	1	1	1	1	27		
36	2						2	2	2	1	2	2	2	1	2	2	2	1	2	1	3	3	1	1	1	1	1	35		
40	2						2	2	2	1	2	2	2	2	2	2	2	2	1	2	2	1	1	1	1	1	1	32		
44	2						2	2	2	1	2	2	2	2	2	2	2	2	2	1	2	2	1	1	1	1	1	32		
48	2						2	3	2	2	1	2	2	2	2	2	2	2	2	2	2	1	1	1	1	1	1	1	35	
52	03	MAR				92	2	2	2	1	1	1	1	1	2	2	1	2	2	2	3	1	1	1	1	1	1	1	31	
10	17/282	MH				8	2			2	2	2	1	4	1	2	2	3	3	1	3	3	3	2	3	2	3	2	3	47
						12	2			2	3	2	1	4	1	1	2	2	3	2	2	3	1	3	3	2	3	2	3	44
			16	2			2	2	2	1	4	1	1	2	2	1	2	3	2	3	3	3	3	2	3	2	3	41		
			20	1			1	1	1	1	4	1	1	2	2	1	3	2	3	3	3	3	3	2	3	2	3	40		
			24	2			2	3	1	1	4	1	1	1	1	1	1	3	1	3	1	4	1	3	2	1	1	31		
			28	2			2	1	2	4	1	4	1	2	1	1	1	1	2	3	1	3	3	2	3	2	3	41		
			32	2			2	1	1	2	4	1	2	1	1	1	1	1	1	3	1	3	1	3	2	3	2	28		
			36	2			2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21		
			40	2			2	1	1	1	1	1	1	1	1	1	1	1	1	1	2	3	3	3	3	1	1	33		
			44	2			2	1	1	1	1	1	1	1	1	1	1	1	1	1	2	3	3	3	3	1	1	24		

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Patient Centre No. (a)	Initials	Visit	Date Performed	ZUNG	Total																					
					It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	Score (b)	
10	17/282	MH	48		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21			
			52		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	21		
10	19/284	TN	8		2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	28			
			10		2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25		
			12		2	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	29		
			16		2	4	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	29		
			20		2	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	28		
			24		2	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	27		
			28		1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24		
			32		1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25		
			36		1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23		
			40		2	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24		
10	21/288	AK	48		1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24				
			52	31MAR91	1	4	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	27		
10	23/JUL91		8		3	3	2	2	2	1	1	2	2	3	4	4	4	4	4	4	4	4	47			
			12		4	3	4	3	4	2	2	3	4	3	3	4	4	4	4	4	4	4	4	61		
			16		2	3	1	2	2	2	1	2	3	2	2	2	1	2	2	3	3	3	3	38		
10	24/289	AL	8		2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	36			
			12		2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	36		
			16		2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	39		
			20		2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	30		
			24		1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	28		
			28		1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	28		
			32		1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	25		
			36		1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	27		
			40		1	4	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	50		
			44		1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	29		
			48		2	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	30		
			52		4	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	35		
			10	29/293	JJ	8	15OCT91	2	3	1	2	1	1	2	1	2	3	3	2	3	3	3	3	3	3	43
						12		3	3	1	3	1	2	1	1	2	2	3	3	4	2	3	3	3	2	4
16		3				3	1	2	2	1	2	2	2	3	4	3	3	3	3	3	3	4	2	4	52	
10	30/294	VK	8		2	3	3	3	1	4	4	4	2	3	3	2	3	3	3	3	4	4	60			
			16		3	4	1	2	2	2	1	1	1	2	3	3	4	2	3	3	3	4	2	4	50	

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 10.4

ZUNG SELF RATING DEPRESSION SCALE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Patient Centre No.	(a) Initials	Visit	Date Performed ZUNG	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	Total Score (b)
10	30/294	VK	12 09DEC91	2	3	4	3	1	4	2	4	2	3	2	3	2	3	3	3	3	3	3	3	56
			16	3	4	2	4	2	4	2	4	2	3	4	3	2	4	3	3	4	4	4	3	61
			20	2	2	4	2	4	2	4	2	4	2	3	3	2	3	3	3	3	3	3	3	55
			24	2	1	2	3	1	4	3	3	2	2	1	2	2	3	3	3	3	3	3	3	46
			28	3	2	3	1	4	1	4	2	2	2	1	1	2	2	2	2	2	2	2	2	42
			32	2	1	1	2	1	4	2	3	2	2	1	2	2	2	2	2	1	2	1	2	36
			36	3	3	3	3	1	4	2	4	3	2	2	3	3	3	2	2	2	3	2	2	43
			40	2	2	2	3	1	4	2	4	2	2	2	2	2	2	2	2	2	2	2	2	38
			44	3	3	3	3	3	4	1	3	3	3	3	3	3	3	3	3	3	3	3	3	56
			48	3	3	3	3	1	4	3	3	3	3	3	3	3	3	2	2	2	2	2	2	52
			52	2	1	2	2	1	4	2	4	2	2	2	2	2	2	2	2	2	2	2	2	42
10	37/32	BK	8	3	4	2	1	3	4	3	1	3	1	2	3	2	3	3	4	1	3	1	3	50
			12	3	4	2	4	4	4	1	3	3	3	4	4	3	3	4	4	4	4	1	4	65
			16	3	4	2	4	4	4	4	1	3	3	4	4	4	3	4	4	2	4	1	4	64
			20	3	4	2	3	4	4	4	1	2	3	3	4	3	3	4	2	4	1	4	1	61
			24	2	4	2	4	2	4	4	2	2	1	2	2	2	2	2	4	1	2	1	3	47
			28	2	4	2	3	2	4	2	1	2	2	3	3	2	3	3	4	1	3	1	3	50
10	40/33	AP	8	2	1	2	1	1	2	3	1	1	1	1	1	2	1	1	2	2	2	1	1	29
			12	2	2	2	2	1	3	3	1	1	1	1	1	1	1	1	2	1	1	1	1	28
10	42/295	TT	8	1	4	1	2	1	1	1	1	1	1	1	4	1	3	1	3	4	4	1	4	39
10	43/296	IK	8	1	1	1	1	1	1	1	2	1	1	1	2	1	1	2	1	2	2	2	1	28
			12	2	3	2	1	1	4	3	1	4	4	4	4	4	4	4	2	3	2	3	4	55
			16	2	3	1	1	1	4	2	1	4	1	4	4	4	4	4	2	4	2	3	4	55
			20	1	3	1	1	1	1	1	1	1	1	1	4	4	1	1	3	2	3	4	4	45
			24	2	2	2	2	1	2	1	1	1	1	1	2	1	2	1	2	2	2	3	1	30
10	44/298	AB	8	1	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	2	2	2	1	27
			12	1	1	1	1	1	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	22
			16	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	22
10	45/34	KJ	8	3	4	3	3	1	3	1	1	2	3	1	3	1	4	3	2	4	4	2	4	52
			12	3	4	2	4	1	3	1	1	3	2	2	2	1	4	3	1	3	4	2	3	48
10	46/38	TI	8	3	3	3	1	2	3	1	2	3	4	3	3	3	3	3	3	3	3	2	4	54
10	47/39	TH	8	2	4	2	1	4	3	3	2	3	4	4	4	2	4	1	4	3	4	1	4	58
			12	1	4	1	1	1	3	2	3	3	4	4	4	3	4	2	4	2	4	2	4	55

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre No.	(a) Initials	Visit	Date Performed	ZUNG	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	Total Score (b)				
					It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20					
10	47/39	TM	16	17MAR92	2	4	2	1	1	4	2	2	4	2	4	4	4	3	2	4	2	4	3	4	4	58			
			20	14APR92	1	4	1	1	4	2	2	4	2	4	4	4	4	4	4	4	4	4	2	4	3	4	58		
			24	12MAY92	1	4	1	1	4	3	2	4	1	4	4	4	4	4	4	4	3	4	2	4	3	4	4	60	
			28		2	4	1	1	4	2	2	3	1	4	4	4	4	4	4	4	4	4	2	4	3	4	4	57	
			32		2	4	1	1	4	3	2	3	1	4	4	4	4	4	4	4	4	4	2	4	3	4	4	57	
			36	11AUG92	2	4	1	1	4	3	2	2	2	4	4	4	4	4	4	4	4	4	2	4	3	4	4	58	
			40		2	3	2	2	1	2	1	2	2	2	1	2	2	2	2	2	2	2	2	2	3	1	2	37	
			44		2	2	2	2	1	2	1	1	2	1	2	1	2	2	2	2	2	2	2	2	2	1	2	32	
48		2	2	2	2	1	2	1	1	1	2	1	2	2	2	2	2	2	2	2	2	2	1	2	33				
52		2	2	2	2	1	1	1	1	2	1	2	1	2	1	2	1	2	2	2	2	2	1	2	31				
10	48/41	IP	8	31JAN92	4	1	4	1	4	4	1	4	2	3	4	1	3	4	1	1	4	4	4	4	4	52			
			12		4	4	3	4	2	4	1	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	71		
			16		4	4	3	3	2	4	1	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	69	
			20		3	4	3	2	4	2	4	1	4	4	4	4	4	4	4	4	4	3	4	4	4	4	4	69	
10	50/44	EE	8		3	3	4	3	4	1	4	4	1	4	2	3	4	1	3	2	4	4	1	1	3	55			
			12	10MAR92	3	3	4	4	2	4	1	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	68		
			16	07APR92	4	3	4	2	4	2	4	1	3	2	2	4	4	4	4	4	4	3	4	4	1	1	3	56	
			20	05MAY92	4	3	4	4	1	4	2	1	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	70	
			24	02JUN92	4	2	4	3	4	1	4	4	1	4	4	4	4	4	4	4	4	4	2	4	4	1	1	3	53
			28	04JUL92	4	2	3	3	4	2	4	4	1	4	4	4	4	4	4	4	4	4	4	4	4	1	1	3	54
			32	11AUG92	4	3	3	4	2	4	4	1	3	2	2	3	4	4	4	4	4	4	4	4	4	1	1	3	56
			36	08SEP92	4	2	4	3	4	1	4	4	1	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	54
			40	23SEP92	4	4	4	4	4	1	4	2	1	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	70
			44	06NOV92	4	3	4	4	3	4	2	1	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	73
			48	13NOV92	4	2	4	3	4	1	4	4	1	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	56
			52	16DEC92	4	3	4	3	4	1	4	4	1	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	53
10	51/45	UL	8		1	4	1	1	4	3	4	1	1	2	1	1	1	1	1	2	2	1	1	1	1	34			
			12		1	3	1	1	4	1	1	4	1	1	2	1	1	1	1	1	1	1	2	1	1	1	30		
			16		1	4	1	4	2	4	1	4	2	1	4	2	1	4	4	4	4	4	3	4	4	4	4	54	
			20		1	4	2	1	4	1	1	4	2	4	2	4	2	4	4	4	4	4	4	3	4	4	4	57	
			24		2	4	2	1	3	4	1	1	2	2	4	2	4	4	4	4	4	4	4	4	4	4	4	55	
			28		2	3	1	1	3	4	2	1	3	2	4	2	4	4	4	4	4	4	2	4	4	4	4	57	
			32		2	1	1	1	3	4	4	1	1	3	4	1	1	2	1	2	2	3	1	2	1	1	1	35	
			36		2	2	1	1	4	1	1	4	1	2	2	1	2	1	1	2	3	1	2	3	1	3	1	2	34
40		1	1	1	1	4	1	1	4	1	1	1	1	1	1	2	1	1	2	1	2	1	2	1	2	27			
44		1	1	1	1	4	1	1	4	1	1	1	1	1	1	1	1	1	1	2	2	1	1	1	1	29			
48		1	4	1	1	4	1	1	4	1	1	4	4	4	4	4	4	4	4	4	4	4	4	4	4	54			
52		1	4	1	1	4	1	1	4	1	1	4	4	4	4	4	4	4	4	4	4	4	4	4	4	54			

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre No.	(a) Initials	Visit	Date Performed	ZUNG																				Total Score (b)		
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20			
10	55/49	TP	8	05MAR92	3	4	2	2	1	4	1	1	3	2	3	3	1	4	3	3	3	3	1	3	50	
			12	06APR92	4	4	2	2	1	4	3	1	2	2	3	4	4	4	4	4	4	4	4	4	4	59
			16	12MAY92	3	2	1	3	3	1	2	2	1	4	4	1	4	1	4	1	4	2	3	3	4	50
			20	01JUN92	3	4	3	2	1	4	1	1	2	2	3	3	2	4	3	3	3	4	2	4	2	53
			24	04JUL92	3	2	3	1	4	4	1	2	1	3	4	4	4	4	4	4	2	4	2	4	2	55
			28	28JUL92	3	2	3	1	3	3	1	3	2	1	4	4	4	4	4	4	4	4	4	3	4	56
			32		3	4	2	1	2	4	1	1	1	2	3	3	2	4	4	3	3	4	2	3	4	52
			36		3	4	2	1	2	4	1	1	1	2	3	3	2	4	4	3	3	3	2	3	4	52
			40		3	3	2	1	2	4	1	1	1	2	3	3	3	4	4	4	3	3	2	3	3	51
			44		3	3	2	1	2	4	1	1	1	2	3	3	3	4	4	4	4	3	2	3	3	51
10	58/52	KK	8	10DEC92	3	2	3	1	3	2	3	2	2	4	4	4	4	4	4	4	3	2	4	55		
			12	16JAN93	3	4	2	2	2	4	1	1	2	2	4	3	3	3	4	3	3	3	4	2	53	
			16		1	4	2	1	3	1	1	1	1	2	2	2	2	1	2	2	2	2	1	2	37	
			20		1	2	1	2	2	1	1	1	1	1	1	3	1	1	1	2	2	1	1	2	31	
			24		1	1	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	22
			28		2	1	2	3	3	2	1	1	2	2	3	3	1	1	1	2	2	2	2	1	2	26
			32		1	1	1	3	2	1	1	1	1	1	1	1	1	1	1	2	2	2	1	1	1	37
			36		1	1	1	3	2	1	1	1	1	1	1	1	1	1	2	2	2	1	1	1	1	26
			40		1	1	1	2	2	1	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	23
			44		1	1	1	3	1	1	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	24
10	62/56	RK	8		1	1	2	3	1	1	1	1	2	1	2	1	2	1	2	2	2	1	2	27		
			12		1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	2	2	1	1	1	24	
			16		1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24	
			20		2	4	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	27	
			24		1	1	2	3	3	2	1	1	2	2	3	3	1	1	1	2	2	2	1	1	1	27
			28		1	1	1	3	2	1	1	1	1	1	1	1	1	1	1	2	2	1	1	1	1	26
			32		1	1	1	3	2	1	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	25
			36		1	1	1	2	2	1	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	23
			40		1	1	1	2	2	1	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	24
			44		1	1	1	3	1	1	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	24
10	64/58	LT	8		1	1	2	3	1	1	1	1	2	1	2	1	2	1	2	2	2	1	2	27		
			12		1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24	
			16		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24	
			20		2	4	2	1	2	2	2	3	2	4	4	4	4	4	4	4	4	4	4	4	4	54
			24		1	1	1	2	1	1	1	2	2	1	1	1	1	2	1	1	1	1	1	1	1	25
			28		1	1	1	2	1	1	1	1	2	2	1	1	1	1	1	1	1	1	1	1	1	25
			32		1	1	1	2	1	1	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	25
			8	21APR92	2	2	1	2	2	1	2	2	2	2	2	2	2	2	2	2	2	2	3	1	2	40
			12	12MAY92	2	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	38
			16	22JUN92	3	3	3	1	3	3	2	1	2	3	3	3	3	3	3	3	3	3	4	2	3	54
10	81/46	JN	8	16APR92	2	4	1	1	1	3	1	2	4	1	4	4	4	4	4	4	3	4	3	53		
			12		1	3	1	1	1	3	2	2	4	1	4	4	4	4	4	4	4	3	4	3	51	

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACERO

Patient Centre No.	(a) Initials	Visit	Date Performed	ZUNG	It. 1 to It. 20																				Total Score (b)			
					It. 1	It. 2	It. 3	It. 4	It. 5	It. 6	It. 7	It. 8	It. 9	It. 10	It. 11	It. 12	It. 13	It. 14	It. 15	It. 16	It. 17	It. 18	It. 19	It. 20				
10	81/46	JN	16	.	2	4	2	1	1	3	1	2	4	1	3	4	4	4	4	1	2	3	3	4	3	50		
			20	.	4	2	1	1	1	3	1	2	4	1	4	4	4	4	4	4	1	2	3	1	4	3	53	
			24	.	3	1	1	1	1	1	1	1	1	4	1	4	1	1	1	1	4	3	1	1	1	1	29	
			28	01SEP92	3	2	1	1	1	3	1	3	1	2	3	3	4	3	2	2	4	2	4	2	2	2	47	
			32	01OCT92	1	1	1	2	1	1	1	1	2	1	2	3	3	1	3	4	1	3	4	1	1	1	31	
			36	.	4	1	1	1	1	3	1	2	3	1	4	4	4	4	4	4	1	2	3	3	4	3	51	
			40	25NOV92	1	1	1	1	1	1	1	1	1	2	1	2	1	1	3	3	1	3	3	1	1	1	26	
			44	.	1	4	1	1	1	1	3	1	2	4	1	4	4	4	4	4	1	2	4	3	4	3	52	
			8	.	2	4	1	2	1	3	1	1	1	1	2	1	3	2	2	2	2	1	3	1	1	2	35	
			10	88/276	AH	8	28MAY92	2	4	3	1	2	3	2	2	2	2	3	4	4	4	4	2	2	2	3	2	3
12	09JUN92	1				4	1	1	4	4	1	2	1	1	4	4	4	1	4	1	3	1	3	3	4	48		
16	06JUL92	1				4	1	2	2	4	2	2	2	2	2	2	2	2	2	2	2	2	2	1	2	1	40	
20	.	1				3	1	2	2	4	2	2	2	2	2	2	2	2	2	2	2	2	1	1	1	2	38	
24	31AUG92	3				3	1	3	3	1	3	3	2	3	3	4	3	4	3	4	2	2	2	2	2	2	2	52
28	06OCT92	1				2	2	2	2	4	3	2	3	2	2	2	2	2	2	2	3	3	1	2	1	2	44	
32	.	3				3	3	4	2	3	4	2	3	2	3	4	4	4	4	3	1	2	2	3	2	3	55	
36	24NOV92	3				2	2	3	1	3	1	3	1	2	3	4	3	3	1	2	2	3	2	2	3	2	48	
40	.	2				2	2	1	4	3	2	2	2	2	2	2	3	2	3	2	2	2	2	2	1	2	43	
44	20JAN93	2				1	1	2	1	4	3	2	2	2	2	2	3	2	3	2	3	3	2	2	1	2	42	
10	92/73	IA	8	17FEB93	2	1	1	1	1	1	4	3	2	2	2	2	2	2	2	2	3	1	2	1	2	38		
			12	16MAR93	2	1	1	1	2	1	4	3	2	2	2	2	2	2	2	2	2	2	2	2	2	44		
			16	.	2	2	1	1	1	1	2	1	1	3	2	4	1	1	1	1	1	3	1	3	1	2	35	
			20	.	1	3	1	1	1	1	2	1	3	2	1	2	2	2	2	1	1	2	2	2	1	2	34	
			24	.	1	3	1	1	1	1	1	3	1	3	1	1	2	3	2	2	1	3	3	3	3	1	2	34
			28	.	1	2	1	1	1	1	2	3	1	3	1	1	1	2	2	2	2	2	2	3	1	2	38	
			32	.	2	1	2	1	1	1	1	2	1	4	1	1	2	2	2	1	2	2	2	3	1	2	34	
			36	.	2	1	2	1	1	1	2	2	1	3	1	1	2	2	2	2	1	2	2	3	1	2	34	
			40	.	2	1	2	1	1	1	2	2	1	3	1	1	2	2	2	2	1	2	2	3	1	2	34	
			44	.	2	1	2	1	1	1	3	2	1	2	1	1	2	1	1	2	1	2	2	3	1	2	32	
10	94/273	PV	8	23FEB93	2	2	1	1	1	3	2	1	2	1	3	4	2	2	1	4	2	2	3	1	2	46		
			12	.	2	2	1	2	2	1	3	1	3	1	3	4	2	2	2	2	3	3	1	3	1	5	46	
			16	.	2	2	1	1	1	1	2	3	1	3	2	2	2	2	2	2	2	2	2	2	3	1	41	
			20	.	2	3	1	1	1	1	1	3	1	2	2	4	1	1	1	1	1	3	3	3	3	3	51	
			24	.	1	3	1	1	1	1	2	1	3	1	2	2	4	1	1	1	1	2	2	1	3	3	52	
			28	.	1	3	1	1	1	1	1	2	1	3	1	1	1	1	1	1	1	2	2	1	3	3	45	
			32	.	2	1	2	1	1	1	1	2	2	1	3	1	1	2	2	2	1	2	2	3	1	2	41	
			36	.	2	1	2	1	1	1	2	2	1	3	1	1	2	2	2	2	2	2	2	3	1	2	41	
			40	.	2	1	2	1	1	1	1	3	2	1	2	1	1	1	1	1	1	2	2	3	1	2	41	
			44	.	2	1	2	1	1	1	1	3	2	1	2	1	1	1	1	1	1	4	2	2	1	3	45	
10	94/273	PV	8	20MAY92	2	3	1	1	4	3	1	1	2	2	4	4	3	4	1	3	3	3	3	3	51			
			12	02JUN92	1	3	1	1	3	4	2	2	1	2	4	4	4	4	2	3	1	3	3	4	4	52		
11	1/372	DF	8	06DEC91	3	4	1	2	4	3	2	1	1	2	2	3	2	2	3	2	1	3	1	3	45			
			8	.	4	1	2	4	3	2	1	1	2	2	2	2	2	2	2	2	2	1	3	1	3	45		

(a) = Open/Blind

1394

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Patient Centre No. (a)	Initials	Visit	Date Performed	ZUNG																				Total Score (b)				
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20					
11	1/372	DF	12	03JAN92	2	2	1	3	3	4	1	1	1	1	1	3	2	3	4	3	4	3	1	1	2	40		
			16	31JAN92	2	2	1	3	3	4	1	1	1	2	1	1	3	2	3	3	4	4	3	2	3	44		
			20	28FEB92	3	4	1	4	4	3	1	1	1	4	1	4	2	3	4	4	3	3	2	3	2	3	44	
			24	27MAR92	1	3	1	4	3	1	1	1	1	3	1	3	2	1	1	3	2	3	1	3	2	3	55	
			28	26APR92	2	3	1	4	3	3	1	1	1	2	4	3	1	3	2	3	4	3	1	3	1	3	37	
			32	22MAY92	2	2	1	3	2	3	1	1	1	2	4	3	1	3	2	3	4	3	1	3	1	3	44	
			8	12DEC91	2	1	3	2	2	4	1	1	1	3	2	3	3	2	4	3	2	4	3	2	3	2	46	
			12	05JAN92	3	4	3	2	2	4	2	2	1	3	2	3	3	2	3	3	2	3	2	3	2	3	52	
11	4/375	BA	16	06FEB92	3	4	3	2	4	1	1	1	1	1	3	2	4	3	4	3	2	3	2	3	2	52		
			18	28FEB92	3	4	3	2	4	1	1	1	1	3	2	4	3	3	4	3	2	3	1	3	2	3	54	
			20	05MAR92	4	4	3	4	3	4	2	3	3	2	3	3	4	3	4	3	2	4	1	4	1	4	52	
			22	15MAR92	4	4	3	3	3	4	1	1	1	4	2	4	3	3	3	4	3	2	4	1	4	1	4	62
			8	18DEC91	4	4	3	1	4	4	3	1	3	3	1	1	3	3	4	1	1	3	1	1	3	1	1	49
			12	15JAN92	3	4	4	2	3	4	3	1	3	3	1	1	3	3	3	3	3	3	3	3	3	2	1	49
			16	12FEB92	3	3	2	3	4	2	1	3	3	1	1	1	3	3	3	3	3	3	3	3	3	2	2	56
			20	03NOV92	3	4	3	2	2	4	2	3	3	2	3	3	4	3	4	3	3	4	2	2	2	2	2	56
11	7/376	KK	24	08APR92	3	4	3	2	2	4	1	2	3	3	3	4	3	4	3	3	3	3	3	3	3	3	57	
			28	06MAY92	2	3	2	1	1	4	3	1	3	2	1	1	2	1	1	1	1	1	1	1	1	1	1	35
			32	03JUN92	2	2	3	1	2	4	1	2	2	2	2	2	3	2	3	2	2	1	1	2	1	1	2	41
			36	01JUL92	3	2	3	2	3	4	1	2	2	2	1	1	3	1	4	1	2	2	1	2	2	1	2	42
			40	29JUL92	3	2	3	1	1	4	1	2	1	3	2	2	3	3	4	3	2	2	1	2	1	2	2	45
			44	26AUG92	3	4	3	1	1	4	3	1	3	3	1	1	3	1	3	1	1	1	2	1	1	1	1	41
			48	23SEP92	2	3	2	1	1	4	1	1	1	2	1	1	3	2	3	1	1	1	1	1	1	1	1	33
			52	21OCT92	1	2	2	1	1	4	1	1	1	1	1	1	1	3	2	3	1	1	1	1	1	1	1	30
11	9/362	FI	8	06JAN91	2	4	3	2	4	4	2	3	1	1	2	4	4	3	4	4	3	1	3	1	2	52		
			12	03FEB92	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	3	4	3	75	
			8	09FEB92	4	4	3	2	3	4	3	2	3	4	4	3	4	4	3	4	4	1	3	1	3	1	3	62
			12	08MAR92	3	3	2	3	4	1	3	4	4	4	3	3	4	3	3	3	3	2	2	1	2	1	2	56
			16	22MAR92	3	4	3	1	2	4	2	3	4	3	2	2	2	3	4	2	1	2	1	2	1	2	1	50
			20	05APR92	2	3	4	3	3	4	1	3	3	3	3	3	3	4	3	2	3	1	2	3	1	2	2	56
			24	31MAY92	3	2	3	2	4	4	3	1	1	1	1	1	1	3	1	3	1	2	1	2	1	1	1	36
			28	26JUN92	3	2	3	2	4	1	2	3	2	2	2	2	2	3	2	1	1	1	1	1	1	1	1	40
11	12/364	PJ	8	09FEB92	4	4	3	2	3	4	3	2	3	4	3	4	4	3	4	4	1	3	1	3	1	3	62	
			12	08MAR92	3	3	2	3	4	1	3	4	4	4	3	3	4	3	3	3	3	2	1	2	1	2	56	
			16	22MAR92	3	4	3	1	2	4	2	3	4	3	2	2	2	3	4	2	1	2	1	2	1	2	1	50
			20	05APR92	2	3	4	3	3	4	1	3	3	3	3	3	3	4	3	2	3	1	2	3	1	2	2	56
			24	31MAY92	3	2	3	2	4	1	2	4	3	1	1	1	1	3	1	3	1	2	1	2	1	1	1	36
			28	26JUN92	3	2	3	2	4	1	2	3	2	2	2	2	2	3	2	1	1	1	1	1	1	1	1	40
			36	23AUG92	4	3	4	2	4	1	2	3	3	2	3	3	3	3	3	3	3	3	1	3	1	2	2	47
			40	20SEP92	3	3	2	1	2	4	2	4	3	2	2	3	4	4	3	2	2	3	2	2	2	2	2	61
44	18OCT92	4	3	3	1	3	4	1	1	1	3	2	2	4	3	3	2	2	4	3	3	2	2	2	49			

(a) = Open/Blind
 (b) = Total Score

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Patient Centre No. (a)	Initials	Visit	Date Performed	ZUNG	Total Score (b)																					
					It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20		
11	12/364	PJ	48	15NOV92	3	3	3	1	2	4	1	1	3	2	2	2	3	3	3	2	1	3	3	49		
			52	13DEC92	3	3	1	4	1	1	3	3	3	3	4	2	4	2	1	3	1	3	1	2	46	
11	15/366	NF	8	24MAR92	2	4	2	2	1	1	1	1	1	1	1	2	2	3	1	2	3	1	1	35		
			12	21APR92	4	3	4	2	1	2	1	2	3	3	4	4	3	4	4	2	3	4	2	3	57	
			16	19MAY92	4	3	3	2	1	2	1	3	4	2	3	4	4	3	2	3	1	3	1	3	51	
			18	03JUN92	4	3	3	3	2	2	3	4	4	3	3	3	3	4	3	3	3	3	3	3	62	
11	18/369	EI	8	05APR92	3	2	3	1	1	3	1	2	3	2	2	2	3	2	4	2	1	1	1	42		
			12	03MAY92	3	3	4	3	2	2	2	2	3	2	3	2	3	3	3	3	2	3	1	3	54	
			16	31MAY92	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1	1	39	
			20	28JUN92	3	2	1	1	3	2	1	1	2	1	1	1	1	3	2	3	1	1	1	1	34	
			24	26JUL92	2	4	2	2	3	1	2	1	3	2	2	4	3	4	4	1	1	3	2	1	49	
			28	23AUG92	2	2	1	1	2	3	1	2	1	2	2	2	2	2	2	2	2	2	1	1	36	
			32	20SEP92	2	1	1	1	2	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	28
			36	18OCT92	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	28
			40	15NOV92	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	29
			44	13DEC92	3	2	2	1	2	3	1	1	3	2	2	2	3	1	3	2	1	1	1	1	1	36
			48	10JAN93	3	2	3	1	1	3	1	1	2	3	2	2	4	3	1	1	1	1	1	1	1	41
			52	07FEB93	3	1	3	1	2	4	1	2	2	3	3	3	2	4	1	1	1	1	1	1	1	42
11	20/371	LJ	8	26APR92	4	4	3	2	1	2	3	3	4	3	3	4	3	3	3	4	2	4	61			
			12	24MAY92	3	3	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	46		
			14	05JUN92	4	3	3	4	2	2	3	3	3	3	4	3	2	3	2	3	1	3	1	58		
12	5/95	ZSH	8	30DEC91	3	4	1	3	2	1	1	1	1	2	1	2	2	3	1	3	2	3	40			
			12	27JAN92	1	4	1	4	4	1	1	1	3	1	2	3	3	1	2	3	1	3	1	43		
			16	24FEB92	1	3	1	1	1	1	1	1	2	1	1	3	1	2	1	3	3	1	2	31		
			8	26DEC91	3	3	2	1	3	1	1	2	3	3	3	3	4	2	3	3	2	3	1	3	47	
12	6/98	MK	12	23JAN92	1	4	2	1	3	1	2	1	2	3	1	2	3	2	4	3	2	3	43			
			16	20FEB92	1	3	2	1	3	1	3	1	2	3	3	3	1	4	3	1	2	1	3	43		
			20	19MAR92	3	2	1	4	1	3	2	3	4	3	2	3	2	4	3	2	3	1	3	50		
			24	14MAY92	1	1	2	1	3	1	4	1	2	3	3	3	4	3	3	2	3	2	3	48		
12	10/96	IP	8	30DEC91	3	4	3	3	4	2	2	3	2	2	3	4	3	4	3	4	2	3	60			
			12	27JAN92	1	4	3	3	2	4	1	2	1	2	1	2	3	2	3	2	4	1	3	47		
			16	24FEB92	2	4	3	3	2	4	1	1	1	1	1	2	3	2	3	2	2	1	1	42		
			20	23MAR92	2	4	3	3	2	4	2	1	1	1	1	2	3	2	3	2	2	1	1	44		
24	20APR92	3	4	3	3	4	2	1	1	2	1	1	2	3	3	3	3	3	3	2	3	53				

(a) = Open/Blind
 (b) = Total Score

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACERO

Patient Centre No. (a)	Initials	Visit	Date Performed	ZUNG	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	Total Score (b)
12	11/94	ER	8	27DEC91	3	2	3	3	3	3	2	1	3	1	3	3	3	3	3	2	1	3	1	2	47
			12	22JAN92	3	3	3	3	3	3	4	1	3	3	3	4	4	4	4	4	2	3	1	2	57
12	12/97	FSZ	8	30DEC91	4	4	4	4	4	2	2	2	3	3	4	4	4	4	4	4	3	4	3	4	69
12	13/103	ISZ	8	30DEC91	2	2	4	2	3	2	1	3	3	1	3	3	3	1	3	3	1	2	1	2	44
			12	27JAN92	3	4	4	4	4	4	4	2	3	4	3	4	4	3	3	4	3	4	2	4	70
12	14/101	GSZ	8	31DEC91	4	3	4	3	3	3	2	1	3	3	2	2	4	3	4	3	3	3	2	3	58
12	17/108	TK	8	10MAR92	2	3	3	2	2	3	2	3	2	3	3	3	3	3	4	3	2	3	2	2	53
			12	07APR92	2	3	3	2	1	3	2	2	2	2	3	2	3	2	3	3	2	3	2	2	47
			16	05MAY92	3	3	2	2	3	1	3	1	3	3	3	3	3	3	4	3	3	3	2	3	54
			20	02JUN92	3	4	2	1	3	4	1	3	1	3	3	3	3	3	4	3	1	3	2	3	53
			24	30JUN92	3	4	3	2	3	4	1	1	1	3	3	3	3	3	4	3	2	3	1	3	53
			28	26JUL92	3	4	4	1	2	4	1	2	1	3	3	3	3	3	4	3	3	3	1	3	53
12	18/109	LS	8	10MAR92	2	2	2	3	3	2	3	3	3	1	1	2	2	2	2	1	1	2	1	1	40
			12	07APR92	2	2	3	3	3	2	2	2	3	1	1	2	1	3	2	1	3	1	2	1	41
			16	05MAY92	3	4	3	4	3	4	3	2	2	4	2	3	3	2	4	2	1	2	1	2	54
12	20/107	KSZ	8	13MAR92	2	3	2	1	1	1	1	1	1	2	2	2	3	3	3	2	2	3	2	3	42
			12	09APR92	2	3	1	1	1	1	1	1	1	2	1	1	2	2	2	2	1	1	3	2	32
			16	07MAY92	3	3	2	2	1	1	1	1	1	2	1	2	3	3	2	2	3	4	1	2	40
			20	04JUN92	2	3	2	2	1	1	1	1	1	2	1	2	3	3	2	2	2	3	1	2	37
			24	02JUL92	2	3	2	2	1	1	1	1	1	2	1	2	2	2	2	1	1	2	1	1	30
			28	30JUL92	2	3	2	3	2	2	2	1	2	3	2	3	3	3	2	2	3	2	2	3	49
12	22/111	MY	8	23MAR92	2	2	2	2	2	4	2	2	1	2	2	2	2	2	3	2	2	2	1	2	41
			12	20APR92	2	3	3	3	2	4	2	2	1	3	2	2	2	2	3	2	2	2	2	2	46
			16	18MAY92	2	3	2	2	2	2	2	1	3	2	2	2	2	2	3	2	2	2	2	2	41
			20	15JUN92	2	2	3	2	2	3	2	1	3	3	2	3	3	2	3	2	2	2	2	2	40
			24	13JUL92	2	2	3	2	2	2	2	2	1	2	2	2	3	2	2	2	2	2	2	2	39
			28	10AUG92	2	3	3	2	3	2	2	2	1	2	2	2	2	2	3	2	2	2	2	2	42
			32	07SEP92	2	2	3	2	3	4	2	2	1	2	2	2	2	2	3	2	2	2	2	2	42
			36	05OCT92	2	2	3	2	2	4	2	2	2	2	2	2	2	2	3	2	2	2	2	2	44
			40	02NOV92	2	3	3	2	3	4	2	2	2	2	2	2	2	2	2	2	2	2	2	2	45
			44	30NOV92	3	3	2	3	4	2	2	2	2	2	2	2	2	2	3	2	2	2	2	2	47
			48	28DEC92	2	3	3	2	3	4	2	2	2	2	2	2	2	2	2	2	2	2	2	2	46
			52	25JAN93	2	3	3	2	3	4	2	2	2	2	2	2	2	2	3	2	2	2	2	2	45

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre No.	(a)	Patient Initials	Date Performed	ZUNG	It.																				Total Score (b)	
					1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20		
12	23/112	EN	8	02APR92	3	3	4	2	3	2	4	1	3	4	3	3	4	4	3	3	4	3	3	63		
			12	20APR92	3	4	3	2	2	3	4	2	3	4	2	3	3	4	3	4	3	4	3	3	60	
			16	20MAY92	2	2	3	1	2	2	4	1	3	3	3	4	3	3	4	3	3	2	3	2	54	
			20	25JUN92	2	2	2	1	3	1	3	3	2	3	2	3	3	4	3	3	1	3	1	3	47	
			24	23JUL92	2	3	2	2	2	2	3	1	3	2	2	3	3	3	3	3	2	4	1	2	48	
			28	20AUG92	3	3	2	3	2	3	2	3	3	2	3	4	3	3	3	2	3	1	2	3	52	
			8	03APR92	3	3	3	4	3	3	3	1	2	3	2	3	4	3	4	1	3	1	3	1	56	
			12	01MAY92	3	3	3	4	3	3	4	2	3	4	2	2	3	4	1	1	3	1	1	1	51	
12	34/120	TGB	8	29MAY92	3	3	3	4	3	3	2	3	4	2	3	4	2	1	3	1	3	1	2	56		
			8	22MAY92	2	2	1	2	4	3	3	2	1	3	1	3	2	2	2	3	2	3	1	3	45	
			12	19JUN92	2	3	3	3	3	3	3	1	3	1	3	1	3	3	4	3	3	2	1	4	54	
			16	17JUL92	3	2	2	1	3	3	3	3	1	2	1	3	3	3	4	3	2	3	2	3	50	
			20	14AUG92	2	3	2	2	1	3	3	3	1	1	3	1	3	2	2	3	3	2	3	1	3	45
			24	11SEP92	2	2	2	2	2	3	3	2	1	2	1	2	2	2	3	3	2	3	1	3	43	
			28	03OCT92	3	3	3	2	3	3	2	3	2	3	1	3	3	3	3	3	2	3	2	3	51	
			32	06NOV92	2	3	2	3	1	3	3	2	2	2	3	1	3	2	2	3	2	3	1	3	47	
12	35/119	LP	8	04DEC92	1	3	2	1	1	3	3	2	2	1	2	2	2	3	2	2	3	1	3	41		
			12	01JAN93	2	3	2	1	1	3	3	2	1	2	1	3	2	3	3	2	3	1	3	43		
			16	29JAN93	2	2	2	2	2	2	2	2	2	2	2	2	3	3	3	2	3	2	3	49		
			20	26FEB93	3	3	2	3	2	2	2	2	2	2	1	3	3	3	3	3	4	2	3	54		
			24	26FEB93	3	3	2	3	2	3	1	3	2	2	3	1	3	3	3	3	3	4	2	3	54	
			28	26MAR93	3	3	2	3	1	4	1	3	2	2	3	1	3	3	3	3	3	4	2	3	52	
			8	22MAY92	2	2	4	2	2	3	2	2	3	2	2	3	3	4	2	4	2	3	2	2	51	
			12	19JUN92	2	2	3	2	1	1	2	2	2	2	2	3	3	3	3	3	3	3	2	2	45	
12	37/386	EK	8	17JUL92	3	3	3	3	1	1	2	2	2	3	3	2	3	3	3	3	3	3	2	51		
			16	17JUL92	3	3	3	4	1	3	2	2	3	3	2	4	3	3	3	3	3	3	3	3	57	
			18	31JUL92	3	3	3	4	1	3	2	2	3	3	2	4	3	3	3	3	3	3	3	3	57	
			8	29MAY92	2	2	2	2	2	3	1	2	3	2	2	2	1	4	2	2	1	1	1	1	39	
			12	26JUN92	2	1	2	2	3	4	1	1	3	3	1	3	1	4	1	1	1	1	1	1	37	
			16	24JUL92	4	1	3	2	3	4	3	4	3	1	3	1	4	1	4	1	1	1	1	1	53	
			8	11DEC91	3	3	4	1	2	3	1	2	3	1	3	2	4	3	4	3	3	3	3	3	55	
			12	08JAN92	3	2	2	1	2	2	1	3	3	2	1	3	3	3	3	3	3	3	3	3	49	
13	2/224	TCS	8	05FEB92	2	2	2	1	1	1	3	1	2	2	2	1	2	3	3	2	3	2	3	41		
			16	04MAR92	2	3	3	4	3	2	3	1	3	3	2	2	3	2	3	2	3	2	3	50		
			20	01APR92	3	4	3	4	3	2	4	3	3	2	2	4	4	3	4	4	3	4	3	3	62	
			24	30APR92	2	4	2	2	2	1	4	1	4	2	3	3	3	3	3	3	4	2	3	4	45	
			28	28MAY92	3	3	2	1	2	3	1	1	2	3	2	2	3	2	3	3	4	2	3	4	45	
			32	28MAY92	3	3	2	1	2	3	1	1	2	3	2	2	3	2	3	3	4	2	3	4	47	
			36	24JUN92	2	3	1	1	1	3	1	2	2	3	1	2	2	3	3	3	2	3	2	2	42	

(a) = Open/Blind

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Patient Centre No. (a)	Initials	Visit	Date Performed	Date																				Total Score (b)					
				It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20						
13	2/224	TCS	40	22JUL92	3	4	2	1	3	3	1	1	1	2	3	3	3	3	3	3	3	3	3	3	4	2	2	49	
			44	19AUG92	3	4	1	1	1	1	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	41	
			48	16SEP92	3	3	1	2	1	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	40
			52	14OCT92	3	2	1	1	1	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	37
			8	17DEC91	2	4	2	2	2	2	2	1	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	35
13	8/228	PK	12	14JAN92	2	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	45		
			16	10FEB92	2	4	1	4	1	3	1	2	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	35	
			20	09MAR92	2	2	2	2	1	4	2	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	41	
			24	06APR92	2	4	1	2	2	3	3	1	1	1	1	2	1	2	2	2	2	2	2	2	2	2	2	2	34
			28	06MAY92	3	4	2	3	4	4	4	3	2	4	2	4	3	3	4	4	4	4	4	4	4	4	4	4	63
			30	18MAY92	4	4	2	3	4	4	4	3	2	4	3	4	3	3	4	4	4	4	4	4	4	4	4	4	67
			8	30DEC91	3	4	3	3	4	3	4	4	1	3	1	1	3	4	4	4	4	4	4	4	4	4	4	4	58
13	1-9/229	S2S	12	14JAN91	3	3	3	2	3	3	4	3	1	2	3	3	4	4	4	4	4	4	4	4	4	4	48		
			16	10FEB92	4	4	3	4	3	4	3	4	1	4	1	4	4	4	4	4	4	4	4	4	4	4	4	69	
			19	28FEB92	4	4	3	4	4	4	4	3	4	1	4	4	4	4	4	4	4	4	4	4	4	4	4	71	
			8	09JAN92	2	4	2	3	1	4	2	3	3	3	1	3	3	3	3	3	3	3	3	3	3	3	3	52	
13	11/225	HS	12	06FEB92	3	3	3	3	3	2	3	2	4	4	3	3	3	3	3	3	3	3	3	3	3	3	59		
			16	05MAR92	3	2	2	3	1	4	2	4	2	4	1	4	4	4	4	4	4	4	4	4	4	4	4	55	
			20	02APR92	3	3	4	3	1	4	3	2	3	4	2	3	3	1	3	4	4	4	4	4	4	4	4	57	
			24	30APR92	3	3	3	3	1	1	4	2	3	3	1	4	3	1	3	4	4	4	4	4	4	4	4	53	
			28	28MAY92	2	1	1	1	1	1	4	2	2	3	2	1	4	3	1	3	4	4	4	4	4	4	4	4	46
			32	25JUN92	2	1	1	1	1	1	4	2	2	3	2	1	4	3	1	3	4	4	4	4	4	4	4	4	46
			36	23JUL92	2	4	2	3	1	4	2	3	3	3	3	1	3	3	3	3	3	3	3	3	3	3	3	3	52
			40	20AUG92	2	4	2	3	1	4	2	3	3	3	3	1	3	3	3	3	3	3	3	3	3	3	3	3	52
			44	17SEP92	3	4	2	3	1	4	2	3	1	4	2	3	1	4	3	1	4	4	4	4	4	4	4	4	50
			48	15OCT92	3	4	3	1	4	4	1	4	1	1	2	2	1	4	3	1	4	4	4	4	4	4	4	4	50
			52	12NOV92	3	4	3	2	2	4	2	1	2	5	1	3	3	2	4	4	4	4	4	4	4	4	4	4	56
			13	14/217	DF	8	27DEC91	2	4	1	2	1	4	2	1	2	1	1	1	2	1	3	3	3	3	3	3	3	3
12	25JAN92	2				4	1	2	1	2	1	3	1	1	1	2	3	1	2	3	3	3	3	3	3	3	3	37	
16	21FEB92	2				4	1	2	2	2	3	2	2	1	2	2	1	2	2	4	4	4	4	4	4	4	4	39	
20	20MAR92	3				4	2	3	4	4	3	5	4	2	2	4	2	4	2	4	4	4	4	4	4	4	4	4	59
24	17APR92	3				4	1	2	1	3	3	2	3	1	2	2	2	4	3	3	3	3	3	3	3	3	3	3	42
13	15MAY92	2	28	15MAY92	2	4	1	2	1	4	4	1	1	2	1	1	2	1	4	4	4	4	4	4	4	4	4	42	
			32	12JUN92	2	4	1	2	1	4	3	1	1	1	1	2	2	1	4	4	4	4	4	4	4	4	4	39	
			36	10JUL92	2	4	1	3	1	4	3	1	1	1	1	2	2	1	3	3	3	3	3	3	3	3	3	37	
13	07AUG92	2	40	07AUG92	2	1	1	3	1	4	2	1	1	1	1	2	2	1	3	3	3	3	3	3	3	3	34		
			44	03SEP92	3	3	1	3	1	4	3	3	1	2	1	2	2	1	1	2	2	2	2	2	2	2	2	41	

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 10.4
 ZUNG SELF RATING DEPRESSION SCALE
 DOUBLE BLIND PHASE
 TREATMENT: PLACERO

Centre No.	Patient No. (a)	Initials	Visit	Date Performed	ZUNG	It.1	It.2	It.3	It.4	It.5	It.6	It.7	It.8	It.9	It.10	It.11	It.12	It.13	It.14	It.15	It.16	It.17	It.18	It.19	It.20	Total Score (b)				
					Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score	Score		Score	Score	Score	
13	14/217	DF	48	02OCT92	3	4	1	3	1	4	2	3	2	3	2	2	1	2	2	1	3	4	1	1	1	1	42			
			52	20OCT92	2	4	1	3	1	4	1	3	1	3	1	1	1	1	2	2	1	4	4	1	1	2	41			
			12	28JAN92	2	3	2	1	4	1	1	3	2	1	1	3	2	1	1	2	1	3	2	1	4	1	1	38		
			16	26FEB92	2	4	3	2	1	4	1	1	3	2	1	1	3	1	1	3	1	2	1	2	4	1	1	40		
			20	25MAR92	2	4	2	3	1	4	1	1	3	2	1	1	2	1	1	2	1	2	2	1	4	1	1	39		
13	15/222	KG	24	21APR92	2	3	2	2	1	4	1	1	1	1	2	1	1	1	2	1	2	1	4	1	1	1	35			
			28	20MAY92	2	4	2	1	4	1	1	3	2	1	1	2	1	1	1	2	1	1	1	4	1	1	1	36		
			32	17JUN92	1	3	1	2	1	4	1	1	2	1	1	1	1	1	1	1	1	2	1	1	4	1	1	32		
			36	15JUL92	2	4	2	2	1	4	1	1	2	1	1	1	1	1	1	1	1	1	2	1	1	3	1	1	33	
			40	12AUG92	2	4	2	2	1	4	1	1	2	1	1	1	1	1	1	1	1	2	1	1	3	1	1	33		
			48	06OCT92	1	4	2	1	1	3	1	1	2	1	1	1	1	1	1	1	1	2	1	1	3	1	1	34		
			52	03NOV92	1	3	2	3	1	3	1	1	2	2	1	1	4	2	1	4	2	1	3	1	1	4	1	1	38	
			13	17/218	GSM	8	14JAN92	2	2	1	1	2	3	3	1	3	2	2	2	2	2	1	2	2	2	1	2	1	2	37
						12	11FEB92	1	4	2	1	3	2	3	1	1	2	1	2	1	1	2	1	2	3	2	2	1	2	38
						16	10MAR92	2	3	1	2	3	3	1	1	2	2	3	2	2	2	3	2	2	3	3	2	2	1	3
20	07APR92	2				3	1	3	3	4	3	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	42		
24	05MAY92	2				3	2	1	4	3	4	1	2	4	2	3	2	2	3	2	2	3	3	3	3	3	1	3	51	
28	02JUN92	2				3	1	2	1	4	4	1	1	3	2	2	3	2	3	2	2	3	3	3	3	3	1	3	50	
32	30JUN92	2				4	2	2	4	4	4	1	2	4	2	4	2	4	2	4	2	3	3	4	3	3	4	4	61	
36	28JUL92	1				1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	20	
48	20OCT92	1				2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	23	
52	17NOV92	1				2	1	1	1	1	1	1	1	1	1	1	2	1	1	2	1	1	1	1	1	1	1	1	23	

(a) = Open/Blind

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA DNS R&D
REBORNETIME - PROTOCOL 20124/013
Listing No.: 11.0

ADVERSE EVENTS
OPEN PHASE

Con. Pat. Init.	Start date	End date	Adverse event	Treatment	Onset date	Type record	Visit End No date	Last report visit rity	Seve rity	Hist ary	Rel ship	Rea ction	Stud y	Symp tom	Dis app.	Re cover	Out come	Open	
1	1	MBA	17/11/90	26/12/90	CONSTIPATION														
						Detail	2	1	2	1	1	NO	2	3	3				
						Detail	3	1	2	1	1	NO	2	3	3				
						Detail	4	1	2	1	1	NO	2	3	3				
						Detail	5	1	2	1	1	NO	2	3	3				
						Detail	6	1	2	1	1	NO	2	3	3				
						Summary	28/12/90(*)	6	1	2	1	NO	2	3	3				YES
						Detail	1	1	2	1	1	NO	2	3	3				
						Detail	2	1	2	1	1	NO	2	3	3				
						Detail	3	1	2	1	1	NO	2	3	3				
						Detail	4	1	2	1	1	NO	2	3	3				
						Detail	5	1	2	1	1	NO	2	3	3				
						Detail	6	1	2	1	1	NO	2	3	3				
						Summary	28/12/90(*)	6	1	2	1	NO	2	3	3				YES
						Detail	1	1	2	1	1	NO	2	3	3				
						Detail	2	1	2	1	1	NO	2	3	3				
						Detail	3	1	2	1	1	NO	2	3	3				
						Detail	4	1	2	1	1	NO	2	3	3				
						Detail	5	1	2	1	1	NO	2	3	3				
						Detail	6	1	2	1	1	NO	2	3	3				
						Summary	07/12/90(*)	3	1	2	1	NO	2	1	3				YES
						Detail	1	1	2	1	1	NO	2	3	3				
						Detail	2	1	2	1	1	NO	2	3	3				
						Detail	3	1	2	1	1	NO	2	3	3				
						Detail	4	1	2	1	1	NO	2	3	3				
						Detail	5	1	2	1	1	NO	2	3	3				
						Detail	6	1	2	1	1	NO	2	3	3				
						Summary	03/12/90	3	1	2	1	NO	2	2	1				YES
						Detail	1	1	2	1	1	NO	2	3	3				
						Detail	2	1	2	1	1	NO	2	3	3				
						Detail	3	1	2	1	1	NO	2	3	3				
						Detail	4	1	2	1	1	NO	2	3	3				
						Detail	5	1	2	1	1	NO	2	3	3				
						Detail	6	1	2	1	1	NO	2	3	3				
						Summary	03/12/90	3	1	2	1	NO	2	2	1				YES
						Detail	1	1	2	1	1	NO	2	3	3				
						Detail	2	1	2	1	1	NO	2	3	3				
						Detail	3	1	2	1	1	NO	2	3	3				
						Detail	4	1	2	1	1	NO	2	3	3				
						Detail	5	1	2	1	1	NO	2	3	3				
						Detail	6	1	2	1	1	NO	2	3	3				
						Summary	07/12/90(*)	3	1	2	1	NO	2	1	3				YES
						Detail	1	1	2	1	1	NO	2	3	3				
						Detail	2	1	2	1	1	NO	2	3	3				
						Detail	3	1	2	1	1	NO	2	3	3				
						Detail	4	1	2	1	1	NO	2	3	3				
						Detail	5	1	2	1	1	NO	2	3	3				
						Detail	6	1	2	1	1	NO	2	3	3				
						Summary	02/01/91(*)	6	1	2	1	NO	2	3	3				YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not reqd, 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date

1401

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOJETINE - PROTOCOL 20126/013
 Listing No.: 11.0

ADVERSE EVENTS
 OPEN PHASE

Cen. Pat. ID	Init.	Start date	Treatment	End date	Adverse event	Onset date	Type record	Visit No	End No date	Last			Dis app.	Re app.	Out app.	Open cca (c)			
										Report	Save	Hist					Rel Stud	Symp	
1	S DB	05/12/90	15/01/91	TREMOR		15/12/90	Detail	2		1	2	1	1	NO	2	3	3		
							Detail	3	25/12/90	1	2	2	1	NO	2	3	3	1	
							Summary		25/12/90	3	1	2	1	1	NO	2	3	3	1
							Summary			3	1	2	1	1	NO	2	3	3	1
6	CPH	05/12/90	15/01/91	MOUTH DRY		05/12/90	Detail	1		1	2	1	1	NO	2	3	3		
							Detail	2		1	2	1	1	NO	2	3	3	3	
							Detail	3		1	2	1	1	NO	2	3	3	3	
							Detail	4		1	2	1	1	NO	2	3	3	3	
							Detail	5	06/01/91	1	2	1	1	NO	2	3	3	3	
							Summary		06/01/91	5	1	2	1	1	NO	2	3	3	1
7	JSA	05/12/90	26/12/90	LIBIDO DECREASED		20/12/90	Detail	3		1	2	1	1	NO	2	3	3		
							Detail	4		1	2	1	1	NO	2	3	3	3	
							Detail	5		1	2	1	1	NO	2	3	3	3	
							Detail	6		1	2	1	1	NO	2	3	3	3	
							Summary		15/01/91(*)	6	1	2	1	1	NO	2	3	3	3
							Summary			6	1	2	1	1	NO	2	3	3	3
9	CGR	05/12/90	05/02/91	CONSTIPATION		06/12/90	Detail	1		1	2	1	1	NO	1	3	3		
							Detail	2	15/12/90	2	2	1	2	NO	2	2	1	1	
							Summary		15/12/90	2	2	1	2	NO	1	2	1	1	
							Detail	3		3	3	2	1	3	NO	2	1	3	
							Summary		26/12/90(*)	3	3	2	1	3	NO	2	1	3	
							Summary			3	3	2	1	3	NO	2	1	3	
9	CGR	27/12/90	05/02/91	CONSTIPATION		10/01/91	Detail	3		1	2	1	1	NO	2	3	3		
							Detail	4		2	2	1	1	NO	2	3	3		
							Detail	5		1	2	1	1	NO	2	3	3		
							Detail	6	31/01/91	1	2	1	1	NO	2	3	3		
							Summary		31/01/91	6	2	2	1	1	NO	2	3	3	
							Summary			6	2	2	1	1	NO	2	3	3	

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=ceef. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

1403

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
RESUBMITTAL - PROTOCOL 20124/013
Listing No.: 11.9
ADVERSE EVENTS
OPEN PHASE

Cen. Pat. No.	Incl. Start date	Treatment	End date	Adverse event	Onset date	Type record	Visit No	End No date	Last report visit	Save rty	Hist rty	Mist rty	Rat rty	Stud rty	Sym rty	Dro rty	Re rty	Out rty	Open rty	Dic rty	App. rty	App. rty	Coe rty	Coe rty	
																									12/01/91
1	9	CCR	27/12/90	06/02/91	MICTURITION DISORDER	12/01/91	3	4	21/01/91	1	2	2	1	NO	2	3	3	3							
							Summary	21/01/91	4	1	2	1	1	NO	2	3	3	3	1	YES					
11	VRT	09/03/91	19/04/91	DIZZINESS	10/03/91	1	1	2	20/03/91	1	2	1	1	NO	2	3	3	3							
							Summary	20/03/91	2	1	2	1	1	NO	2	3	3	3	1	YES					
							Detail 4	20/03/91		1	2	1	1	NO	2	3	3	3							
							Detail 5			1	2	1	1	NO	2	3	3	3							
							Detail 6			1	2	1	1	NO	2	3	3	3							
							Summary	19/04/91(*)	6	1	2	1	1	NO	2	3	3	3	3	3	YES				
12	SLT	20/03/91	30/04/91	MOUTH DRY	22/03/91	1	1	2		1	2	1	1	NO	2	3	3	3							
							Detail 2			1	2	1	1	NO	2	3	3	3							
							Detail 3			1	2	1	1	NO	2	3	3	3							
							Detail 4			1	2	1	1	NO	2	3	3	3							
							Detail 5			1	2	1	1	NO	2	3	3	3							
							Detail 6			1	2	1	1	NO	2	3	3	3							
							Summary	30/04/91(*)	6	1	2	1	1	NO	2	3	3	3	3	3	YES				
13	JR	01/05/91	14/05/91	HEADACHE	02/05/91	1	1	2	05/05/91	1	2	3	1	NO	2	3	3	3	1	YES					
							Summary	05/05/91	1	1	2	3	1	NO	2	3	3	3	1	YES					
							Detail 2			1	2	3	1	NO	2	3	3	3							
							Summary	14/05/91(*)	2	1	2	3	1	NO	2	3	3	3	3	3	YES				
							Detail 1			1	2	1	1	NO	2	3	3	3							
							Detail 2			1	2	1	1	NO	2	3	3	3							
							Summary	14/05/91(*)	2	1	2	1	1	NO	2	3	3	3	3	3	YES				
							Detail 1			1	2	1	1	NO	2	3	3	3							
							Detail 2			1	2	1	1	NO	2	3	3	3							
							Summary	14/05/91(*)	2	1	2	1	1	NO	2	3	3	3	3	3	YES				
							Detail 1			1	2	1	1	NO	2	3	3	3							
							Detail 2			1	2	1	1	NO	2	3	3	3							
							Summary	14/05/91(*)	2	1	2	1	1	NO	2	3	3	3	3	3	YES				
14	MIC	08/05/91	14/06/91	MOUTH DRY	15/05/91	2	1	2		1	2	1	1	NO	2	3	3	3							
							Detail 2			1	2	1	1	NO	2	3	3	3							
							Detail 3			1	2	1	1	NO	2	3	3	3							
							Detail 4			1	2	1	1	NO	2	3	3	3							
							Summary	14/05/91(*)	2	1	2	1	1	NO	2	3	3	3	3	3	YES				

Severity: Unknown, Mild, Moderate, Severe, -- History: Present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req, 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS TABD

REBOMETINE - PROTOCOL 20124/013
Listing No.: 11.0

ADVERSE EVENTS
OPEN PHASE

Cn. Pat.	Init.	Start date	End date	Treatment	Onset date	Type record	Visit No	Last report visit	Save Hist	Rel Stnd	Symp	Dis Hosp	Re app.	Dut app.	Open case (C)	
																visit
1	14	08/05/91	14/06/91	MOUTH DRY	15/05/91	Detail	5	1	2	1	1	NO	2	3	3	
							6	1	2	1	1	NO	2	3	3	
							Summary	6	1	2	1	1	NO	2	3	3
							Summary	6	1	2	1	1	NO	2	3	3
							Summary	6	1	2	1	1	NO	2	3	3
							Summary	6	1	2	1	1	NO	2	3	3
15	16	18/05/91	28/06/91	CONSTIPATION	25/06/91	Detail	6	1	2	1	1	NO	2	3	3	
							Summary	6	1	2	1	1	NO	2	3	3
							Summary	6	1	2	1	1	NO	2	3	3
							Summary	6	1	2	1	1	NO	2	3	3
							Summary	6	1	2	1	1	NO	2	3	3
							Summary	6	1	2	1	1	NO	2	3	3
16	17	25/05/91	03/07/91	CONSTIPATION	06/06/91	Detail	3	1	2	1	1	NO	2	3	3	
							4	1	2	1	1	NO	2	3	3	
							5	1	2	1	1	NO	2	3	3	
							6	1	2	1	1	NO	2	3	3	
							Summary	6	1	2	1	1	NO	2	3	3
							Summary	6	1	2	1	1	NO	2	3	3
17	18	03/06/91	HEADACHE	03/06/91	Detail	2	1	2	2	1	NO	2	3	3		
						3	1	2	2	1	NO	2	3	3		
						4	1	2	2	1	NO	2	3	3		
						5	1	2	2	1	NO	2	3	3		
						6	1	2	2	1	NO	2	3	3		
						Summary	6	1	2	2	1	NO	2	3	3	
18	19	21/06/91	LIPIDS DECREASED	21/06/91	Detail	5	1	2	3	1	NO	2	3	3		
						6	1	2	1	1	NO	2	3	3		
						Summary	6	1	2	1	1	NO	2	3	3	
						Summary	6	1	2	1	1	NO	2	3	3	
						Summary	6	1	2	1	1	NO	2	3	3	
						Summary	6	1	2	1	1	NO	2	3	3	
19	20	01/06/91	MOUTH DRY	01/06/91	Detail	2	1	2	1	1	NO	2	3	3		
						3	1	2	1	1	NO	2	3	3		
						4	1	2	1	1	NO	2	3	3		
						5	1	2	1	1	NO	2	3	3		
						6	1	2	1	1	NO	2	3	3		
						Summary	6	1	2	1	1	NO	2	3	3	

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl., -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./reapp.: 1=no, 2=yes, 3=not appl., -- Relationship: 1=definite, 2=probable, 3=possible, 4=suspect, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
 REBONETINE - PROTOCOL 20124/913
 Listing No.: 11.0

ADVERSE EVENTS
 OPEN PHASE

Con. Pat.	Init.	Start date	End date	Adverse event	Onset date	Type record	Visit No	End No date	Last report visit city	save	Hist	Rel	Stud	Symp	Dis Hosp	Re app.	Dis app.	Re app.	Dis app.	Open come (c)
1	18	TTM	23/05/91	03/07/91	TACHYCARDIA	25/05/91	Detail 1	1	1	2	2	1	NO	2	3	3	3	3	3	3
							Detail 2	2	1	2	1	NO	2	3	5	1				
							Summary	02/06/91	2	1	2	1	NO	2	3	3	1			YES
20	EFC	01/06/91	12/07/91	CONSTIPATION	24/06/91	Detail 4	4	1	2	1	1	NO	2	3	3	3	3	3	3	3
							Detail 5	5	1	2	1	NO	2	3	3	3	3	3	3	3
							Detail 6	6	1	2	3	1	NO	2	3	3	3	3	3	3
							Summary	12/07/91(*)	6	1	2	1	NO	2	3	3	3	3	3	YES
							Detail 2	2	1	2	1	1	NO	2	3	3	3	3	3	3
							Detail 3	3	1	2	1	1	NO	2	3	3	3	3	3	3
							Detail 4	4	1	2	1	1	NO	2	3	3	3	3	3	3
							Detail 5	5	1	2	1	1	NO	2	3	3	3	3	3	3
							Detail 6	6	1	2	1	1	NO	2	3	3	3	3	3	3
							Summary	12/07/91(*)	6	1	2	1	NO	2	3	3	3	3	3	YES
21	VHC	05/06/91	16/07/91	CONSTIPATION	20/06/91	Detail 3	3	1	2	1	1	NO	2	3	3	3	3	3	3	3
							Detail 4	4	26/06/91	1	2	1	NO	2	3	3	3	3	3	3
							Summary	26/06/91	4	1	2	1	NO	2	3	3	1			YES
							Detail 3	3	28/06/91	1	2	1	NO	2	3	3	3	3	3	3
							Detail 4	4	01/07/91	1	2	1	NO	2	3	3	3	3	3	3
							Detail 5	5	01/07/91	1	2	1	NO	2	3	3	3	3	3	3
							Summary	01/07/91	4	1	2	1	NO	2	3	3	1			YES
23	AR	22/06/91	19/07/91	VISION ABNORMAL	01/07/91	Detail 2	2	1	2	1	1	NO	2	3	3	3	3	3	3	3
							Detail 3	3	19/07/91	1	2	1	NO	2	3	3	3	3	3	3
							Detail 4	4	19/07/91	1	2	2	NO	2	2	3	1			
							Summary	19/07/91	4	1	2	1	NO	2	2	3	1			YES
29	AFO	17/07/91	27/08/91	CONSTIPATION	02/08/91	Detail 3	3	1	2	3	1	NO	2	3	3	3	3	3	3	3
							Detail 4	4	1	2	3	1	NO	2	3	3	3	3	3	3
							Detail 5	5	1	2	3	1	NO	2	3	3	3	3	3	3
							Detail 6	6	1	2	3	1	NO	2	3	3	3	3	3	3
							Summary	27/08/91(*)	6	1	2	3	1	NO	2	3	3	3	3	3

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, --- History: 1=present before, 2=not observe before, 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=covered, 2=acc. with seq., 3=still present, 4=search
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REDONETINE - PROTOCOL 20124/013
 Listing No.: 11.0
 ADVERSE EVENTS
 OPEN PHASE

Con. Pat. Init.	Start date	End date	Adverse event	Treatment	Onset date	Type	Visit	End	Last report	Severe	Hist	Rel	Stud	Symp	Dis	Re	Out	Open			
					date	record	no	date	visit city	city	dry	ship	drug	trea	hosp	app.	app.	come (c)			
1	29	AFD	17/07/91	27/08/91	MOUTH DRY		2	25/07/91	Detail	1	2	3	1	NO	2	3	3	3			
									Detail	3	1	2	3	1	NO	2	3	3	3		
									Detail	4	1	2	3	1	NO	2	3	3	3		
									Detail	5	1	2	3	1	NO	2	3	3	3		
									Detail	6	1	2	3	1	NO	2	3	3	3		
									Summary	27/08/91(*)	6	1	2	3	1	NO	2	3	3	3	3
32	D8M	25/07/91	04/05/91	CONSTIPATION		3	09/08/91	Detail	1	2	3	1	NO	2	3	3	3				
								Detail	4	1	2	3	1	NO	2	3	3	3			
								Detail	5	1	2	3	1	NO	2	3	3	3			
								Detail	6	1	2	3	1	NO	2	3	3	3			
								Summary	04/09/91(*)	6	1	2	3	1	NO	2	3	3	3	3	YES
35	DFC	25/07/91	14/09/91	CONSTIPATION		1	26/07/91	Detail	1	2	3	1	NO	2	3	3	3				
								Detail	2	1	2	3	1	NO	2	3	3	3			
								Summary	04/08/91	2	1	2	3	1	NO	2	3	3	3	1	YES
								Detail	3	1	2	3	1	NO	2	3	3	3			
								Detail	4	1	2	3	1	NO	2	3	3	3			
								Summary	23/08/91	5	1	2	3	1	NO	2	3	3	3	1	NO
36	GMH	08/08/91	18/09/91	ANOREXIA		5	24/08/91	Detail	1	2	3	1	NO	2	3	3	3				
								Detail	6	1	2	3	1	NO	2	3	3	3			
								Summary	04/09/91(*)	6	1	2	3	1	NO	2	3	3	3	3	YES
								Detail	3	1	2	3	1	NO	2	3	3	3			
								Detail	4	1	2	3	1	NO	2	3	3	3			
								Detail	5	1	2	3	1	NO	2	3	3	3			

Severely: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD
 REMOETINE - PROTOCOL 20126/013
 Listing No.: 11.0

ADVERSE EVENTS
 OPEN PHASE

Con. Pat.	Init.	Start date	End date	Adverse event	Onset date	Type record	Visit No	End No date	Last visit	save rity	Hist ory	Rel Ship	Stud ory	Simp	Dis Hosp	Re app.	Out app.	Open come (C)
1	34	08/08/91	18/09/91	ANOREXIA	23/08/91	Detail	6	13/09/91	6	1	2	3	1	NO	2	3	3	1
					Summary	13/09/91	6	1	2	3	1	NO	2	3	3	1	YES	
					25/08/91	Detail	3	1	2	3	1	NO	2	3	3	3		
					Detail	4	1	2	3	1	NO	2	3	3	3			
					Detail	5	1	2	3	1	NO	2	3	3	3			
					Detail	6	1	2	3	1	NO	2	3	3	3			
Summary	18/09/91(*)	6	1	2	3	1	NO	2	3	3	3	YES						
				CONSTIPATION	10/08/91	Detail	1	1	2	3	1	NO	2	3	3	3		
					Detail	2	1	2	3	1	NO	2	3	3	3			
					Detail	3	1	2	3	1	NO	2	3	3	3			
					Detail	4	1	2	3	1	NO	2	3	3	3			
					Detail	5	1	2	3	1	NO	2	3	3	3			
					Detail	6	1	2	3	1	NO	2	3	3	3			
Summary	18/09/91(*)	6	1	2	3	1	NO	2	3	3	3	YES						
				MOUTH DRY	29/08/91	Detail	1	1	2	3	1	NO	2	3	3	3		
					Detail	2	1	2	3	1	NO	2	3	3	3			
					Detail	3	1	2	3	1	NO	2	3	3	3			
					Detail	4	1	2	3	1	NO	2	3	3	3			
					Detail	5	1	2	3	1	NO	2	3	3	3			
					Detail	6	1	2	3	1	NO	2	3	3	3			
Summary	18/09/91(*)	6	1	2	3	1	NO	2	3	3	3	YES						
				ANOREXIA	27/08/91	Detail	1	1	2	3	1	NO	2	3	3	3		
					Detail	2	1	2	3	1	NO	2	3	3	3			
					Detail	3	1	2	3	1	NO	2	3	3	3			
					Detail	4	1	2	3	1	NO	2	3	3	3			
					Detail	5	1	2	3	1	NO	2	3	3	3			
					Detail	6	1	2	3	1	NO	2	3	3	3			
Summary	29/08/91	5	1	2	3	1	NO	2	3	3	1	YES						
				CONSTIPATION	18/08/91	Detail	3	1	2	3	1	NO	2	3	3	3		
					Detail	4	1	2	3	1	NO	2	3	3	3			
					Detail	5	1	2	3	1	NO	2	3	3	3			
					Detail	6	1	2	3	1	NO	2	3	3	3			
					Summary	25/10/91	5	1	2	3	1	NO	2	3	3	1	YES	
					Summary	25/10/91	5	1	2	3	1	NO	2	3	3	1	YES	
				DIZZINESS	10/10/91	Detail	3	1	2	3	1	NO	2	3	3	3		
					Detail	4	1	2	3	1	NO	2	3	3	3			
					Detail	5	1	2	3	1	NO	2	3	3	3			
					Detail	6	1	2	3	1	NO	2	3	3	3			
					Summary	05/11/91(*)	6	1	2	3	1	NO	2	3	3	3	YES	
					Summary	05/11/91(*)	6	1	2	3	1	NO	2	3	3	3	YES	
				MOUTH DRY	06/10/91	Detail	2	1	2	3	1	NO	2	3	3	3		
					Detail	2	1	2	3	1	NO	2	3	3	3			

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe,
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=stop. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./reapp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis

--- History: 1=present before, 2=not observe bef., 3=unknown

--- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death

--- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD

REOMETIME - PROTOCOL 20126/913
Listing No.: 11.0

ADVERSE EVENTS
OPEN PHASE

Cen. Pat. ID	Init. Start date	Treatment	End date	Adverse event	Onset date	Type record	Visit No	End No date	Last report		Dis Hosp	Re APP.	De APP.	Open come (C)				
									save rty	Hist ary								
1 49 EM	25/09/91	05/11/91	MOUTH DRY	MOUTH DRY	04/10/91	Detail	3		1	2	3	1	NO	2	3	3		
						Detail	4		1	2	3	1	NO	2	3	3		
						Detail	5		1	2	3	1	NO	2	3	3		
						Detail	6		1	2	3	1	NO	2	3	3		
						Summary	6	05/11/91(*)	6	1	2	3	1	NO	2	3	3	5
41 SFS	25/09/91	05/11/91	CONSTIPATION	CONSTIPATION	02/10/91	Detail	2		1	2	3	1	NO	2	3	3		
						Detail	3		1	2	3	1	NO	2	3	3		
						Detail	4		1	2	3	1	NO	2	3	3		
						Detail	5		1	2	3	1	NO	2	3	3		
						Detail	6		1	2	3	1	NO	2	3	3		
						Summary	6	05/11/91(*)	6	1	2	3	1	NO	2	3	3	5
43 ARN	03/10/91	13/11/91	MOUTH DRY	MOUTH DRY	26/09/91	Detail	1		1	2	3	1	NO	2	3	3		
						Detail	2		1	2	3	1	NO	2	3	3		
						Detail	3		1	2	3	1	NO	2	3	3		
						Detail	4		1	2	3	1	NO	2	3	3		
						Detail	5		1	2	3	1	NO	2	3	3		
						Summary	6	05/10/91	6	1	2	3	1	NO	2	3	3	5
43 ARN	03/10/91	13/11/91	MOUTH DRY	MOUTH DRY	26/09/91	Detail	1		1	2	3	1	NO	2	3	3		
						Detail	2		1	2	3	1	NO	2	3	3		
						Detail	3		1	2	3	1	NO	2	3	3		
						Detail	4		1	2	3	1	NO	2	3	3		
						Detail	5		1	2	3	1	NO	2	3	3		
						Summary	6	05/10/91	6	1	2	3	1	NO	2	3	3	5
43 ARN	03/10/91	13/11/91	MOUTH DRY	MOUTH DRY	05/10/91	Detail	1		1	2	3	1	NO	2	3	3		
						Detail	2		1	2	3	1	NO	2	3	3		
						Detail	3		1	2	3	1	NO	2	3	3		
						Detail	4		1	2	3	1	NO	2	3	3		
						Detail	5		1	2	3	1	NO	2	3	3		
						Summary	6	13/11/91(*)	6	1	2	3	1	NO	2	3	3	5
43 ARN	03/10/91	13/11/91	MOUTH DRY	MOUTH DRY	05/10/91	Detail	1		1	2	3	1	NO	2	3	3		
						Detail	2		1	2	3	1	NO	2	3	3		
						Detail	3		1	2	3	1	NO	2	3	3		
						Detail	4		1	2	3	1	NO	2	3	3		
						Detail	5		1	2	3	1	NO	2	3	3		
						Summary	6	05/10/91	6	1	2	3	1	NO	2	3	3	5

Severity: 1=unknown, 2=mild, 3=moderate, 4=severe, 5=critical
Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=search
Disapp./Rapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=none, 1=yes
(*) adverse event used for statistical analysis
(c) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS 182
 REMOJETINE - PROTOCOL 20126/013
 Listing No.: 11.9
 ADVERSE EVENTS
 OPEN PHASE

Con. Pat.	Inf.	Start date	End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Sev	Hist	Rel	Stud	Symp	Dis Hosp	Re app.	Out app.	Open com.	
1	49	ARN	03/10/91	15/11/91 URINARY RETENTION	05/10/91	Detail	5		1	2	3	1	NO	2	3	3	3		
						Detail	6		1	2	3	1	NO	2	3	3	3		
						Summary	13/11/91(*)		6	1	2	3	1	NO	2	3	3	3	YES
47	MCS		23/10/91	05/12/91 VISION ABNORMAL	01/11/91	Detail	2		1	2	3	1	NO	2	3	3	3		
						Detail	3		1	2	3	1	NO	2	3	3	3		
						Detail	4		1	2	3	1	NO	2	3	3	3		
						Detail	5		1	2	3	1	NO	2	3	3	3		
						Detail	6		1	2	3	1	NO	2	3	3	3		
						Summary	03/12/91(*)		6	1	2	3	1	NO	2	3	3	3	YES
48	SCH		26/10/91	06/12/91 INSOMNIA	02/11/91	Detail	2		1	2	3	1	NO	2	3	3	3		
						Detail	3		1	2	3	1	NO	2	3	3	3		
						Detail	4		1	2	3	1	NO	2	3	3	3		
						Detail	5	26/11/91	1	2	3	1	NO	2	3	3	3		
						Summary	26/11/91		5	1	2	3	1	NO	2	3	3	1	YES
						Detail	2		1	2	3	1	NO	2	3	3	3		
						Detail	3		1	2	3	1	NO	2	3	3	3		
						Detail	4	16/11/91	1	2	3	1	NO	2	3	3	3		
						Detail	5	26/11/91	1	2	3	1	NO	2	3	3	3		
						Summary	26/11/91		4	1	2	3	1	NO	2	3	3	1	YES
						Detail	2		1	2	3	1	NO	2	3	3	3		
						Detail	3		1	2	3	1	NO	2	3	3	3		
						Detail	4	16/11/91	1	2	3	1	NO	2	3	3	3		
						Detail	5	26/11/91	1	2	3	1	NO	2	3	3	3		
						Summary	26/11/91		4	1	2	3	1	NO	2	3	3	1	YES
49	DAS		26/10/91	06/11/91 TACHYCARDIA	29/10/91	Detail	1		1	2	3	1	NO	2	3	3	3		
						Detail	2	06/11/91	1	2	3	1	NO	2	2	3	3	1	YES
						Detail	3	06/11/91	2	1	2	3	NO	2	2	3	3	1	YES
						Summary	06/11/91		2	1	2	3	NO	2	2	3	3	1	YES
						Detail	2	06/11/91	3	2	1	3	NO	2	2	3	3	1	YES
						Summary	06/11/91		2	3	2	1	3	NO	2	2	3	1	YES
51	ASA		26/10/91	06/12/91 CONSTIPATION	06/11/91	Detail	2		1	2	3	1	NO	2	3	3	3		
						Detail	3		1	2	3	1	NO	2	3	3	3		
						Detail	4		1	2	3	1	NO	2	3	3	3		
						Detail	5		1	2	3	1	NO	2	3	3	3		
						Detail	6	01/12/91	1	2	3	1	NO	2	3	3	3		
						Summary	01/12/91		6	1	2	3	1	NO	2	3	3	1	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REPROBTINE - PROTOCOL 2012/013
Listing No.: 11.0

ADVERSE EVENTS
OPEN PHASE

Den. Pat. Init.	Start date	Treatment	End date	Adverse event	Onset date	Type record	Visit No	End date	Last report	Sev	Rel rity	Re ship	Stud app.	Symp app.	Dis app.	Re app.	Out app.	Open app.				
1 51 ASA	26/10/91	06/12/91 MOUTH DRY	06/11/91		2	Detail	2	06/11/91	1 2 3 1	NO	2	3	3	3	3	3	3	3				
					3	Detail	3	06/11/91	1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3		
					4	Detail	4	06/11/91	1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3	3	
					5	Detail	5	06/11/91	1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3	3	
					6	Detail	6	06/11/91	1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3	3	3
						Summary		06/12/91(*)	6	1 2 3 1	NO	2 3 3 3 3	3	3	3	3	3	3	3	3	3	3
54 JD	06/11/91	08/12/91 RASH	21/11/91		3	Detail	3	06/12/91	2 2 3 1	NO	2	3	3	3	3	3	3	3	3			
					4	Detail	4	06/12/91	2 2 3 1	NO	2	3	3	3	3	3	3	3	3	3		
						Summary		06/12/91	4	2 2 2 3	NO	2 2 2 3 1	3	3	3	3	3	3	3	3	3	
						Summary		06/12/91	4	2 2 2 3	NO	2 2 2 3 1	3	3	3	3	3	3	3	3	3	
55 IAL	06/11/91	17/12/91 LIBIDO DECREASED	08/11/91		1	Detail	1	08/11/91	1 2 3 1	NO	2	3	3	3	3	3	3	3	3			
					2	Detail	2	08/11/91	1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3		
					3	Detail	3	08/11/91	1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3		
					4	Detail	4	08/11/91	1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3	3	
					5	Detail	5	08/11/91	1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3	3	3
						Summary		17/12/91(*)	6	2 2 1 3	1	NO	2 3 3 3 3	3	3	3	3	3	3	3	3	3
57 SMC	11/12/91	31/12/91 DIARRHOEA	12/12/91		1	Detail	1	12/12/91	2 2 3 1	NO	2	3	3	3	3	3	3	3	3			
					2	Detail	2	12/12/91	2 2 3 1	NO	2	3	3	3	3	3	3	3	3	3		
					3	Detail	3	31/12/91	2 2 3 1	NO	2	3	3	3	3	3	3	3	3	3		
						Summary		31/12/91	5	2 2 2 3	NO	2 2 2 3 1	3	3	3	3	3	3	3	3	3	
58 ARM	11/12/91	21/01/92 CONSTIPATION	14/12/91		1	Detail	1	14/12/91	1 2 3 1	NO	2	3	3	3	3	3	3	3	3			
					2	Detail	2	14/12/91	1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3		
					3	Detail	3	14/12/91	1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3		
					4	Detail	4	14/12/91	1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3	3	
					5	Detail	5	14/12/91	1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3	3	
						Summary		21/01/92(*)	6	1 2 3 1	NO	2 3 3 3 3	3	3	3	3	3	3	3	3	3	
		MOUTH DRY	14/12/91		1	Detail	1	14/12/91	1 2 3 1	NO	2	3	3	3	3	3	3	3	3			
					2	Detail	2	14/12/91	1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3		
					3	Detail	3	14/12/91	1 2 3 1	NO	2 3 3 3	3	3	3	3	3	3	3	3			

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD
 REMOETINE -- PROTOCOL 2012G/913
 Listing No.: 11.0

ADVERSE EVENTS
 OPEN PHASE

Cn. Pat.	Init.	Start date	Treatment	End date	Adverse event	Onset date	Type record	Visit No	End No date	Last report visit	Save any ship	Hist any drug	Realtreat	Stud Symp	Dis Hosp	Re app.	Out app.	Open come (C)	
																			1
1	50	11/12/91	21/01/92	MOUTH DRY		14/12/91	Detail	4		1	2	3	1	NO	2	3	3		
							Detail	5		1	2	3	1	NO	2	3	3		
							Detail	6		1	2	3	1	NO	2	3	3		
							Summary	21/01/92(*)	6	1	2	3	1	NO	2	3	3	3	YES
59	SPF	18/12/91	28/01/92	SWEATING INCREASED		20/12/91	Detail	1		1	2	3	1	NO	2	3	3		
							Detail	2		1	2	3	1	NO	2	3	3		
							Detail	3	02/01/92	1	2	3	1	NO	2	3	3	1	
							Summary	02/01/92	3	1	2	3	1	NO	2	3	3	1	YES
61	PVC	21/12/91	31/01/92	VOMITING		28/12/91	Detail	1	21/12/91	1	2	4	1	NO	2	3	3	1	
							Summary	21/12/91	1	1	2	4	1	NO	2	3	3	1	YES
							Detail	4		1	2	3	1	NO	2	3	3	3	
							Summary	31/01/92(*)	6	1	2	3	1	NO	2	3	3	3	YES
62	MEA	06/01/92	18/02/92	TREMOR		24/12/91	Detail	1		1	2	3	1	NO	2	3	3		
							Detail	2		1	2	3	1	NO	2	3	3		
							Detail	3		1	2	3	1	NO	2	3	3		
							Summary	31/01/92(*)	6	1	2	3	1	NO	2	3	3	3	YES
63	JCL	09/01/92	29/01/92	CONSTIPATION		01/02/92	Detail	4		1	2	3	1	NO	2	3	3		
							Detail	5		1	2	3	1	NO	2	3	3		
							Detail	6		1	2	3	1	NO	2	3	3		
							Summary	18/02/92(*)	6	1	2	3	1	NO	2	3	3	3	YES
64	JCL	09/01/92	29/01/92	CONSTIPATION		12/01/92	Detail	1		1	2	3	1	NO	2	3	3		
							Detail	2		1	2	3	1	NO	2	3	3		
							Detail	3	29/01/92	1	2	3	1	NO	2	3	3	1	
							Summary	29/01/92	3	1	2	3	1	NO	2	3	3	1	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) DATE PRESENT STILL PRESENT; end date = visit date
 --- History: 1=present before, 2=not observe bef., 3=unknown

1411

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 11.0

ADVERSE EVENTS
 OPEN PHASE

Ch. Pat.	Init.	Start date	Treatment	End date	Adverse event	Onset date	Type record	Visit No	End No date	Last report visit	Save rity	Hist ory	Hist ship	Stud drug	Symp tress	Dis Hosp	Re app.	Out app.	Open come (C)		
1	63	JCL	09/01/92	29/01/92	LIBIDO DECREASED	12/01/92	Detail	1		1	2	3	1	NO	2	3	3	3	3	3	
							Detail	2		1	2	3	1	NO	2	3	3	3	3	3	
							Detail	3	29/01/92	1	2	3	1	NO	2	2	3	3	3	3	
							Summary	29/01/92		3	1	2	2	3	NO	2	2	3	3	1	YES
							Detail	3	29/01/92	5	2	2	3	NO	2	2	2	3	3	1	YES
							Summary	29/01/92		3	3	2	2	3	NO	2	2	3	3	1	YES
64	EMF	16/01/92	26/02/92		CONSTIPATION	20/01/92	Detail	1		1	2	3	1	NO	2	3	3	3	3	3	
							Detail	2		1	2	3	1	NO	2	3	3	3	3	3	
							Detail	3	05/02/92	1	2	4	1	NO	2	3	3	3	3	3	
							Summary	05/02/92		3	1	2	3	1	NO	2	3	3	3	1	YES
							Detail	1		1	2	3	1	NO	2	3	3	3	3	3	
							Detail	2		1	2	3	1	NO	2	3	3	3	3	3	
							Detail	3		1	2	3	1	NO	2	3	3	3	3	3	
							Detail	4		1	2	3	1	NO	2	3	3	3	3	3	
							Detail	5		1	2	3	1	NO	2	3	3	3	3	3	
							Detail	6		1	2	3	1	NO	2	3	3	3	3	3	
							Summary	26/02/92(*)		6	1	2	3	1	NO	2	3	3	3	3	YES
							Detail	1		1	2	3	1	NO	2	3	3	3	3	3	
							Detail	2		1	2	3	1	NO	2	3	3	3	3	3	
							Detail	3		1	2	3	1	NO	2	3	3	3	3	3	
							Detail	4		1	2	3	1	NO	2	3	3	3	3	3	
							Detail	5		1	2	3	1	NO	2	3	3	3	3	3	
							Detail	6		1	2	3	1	NO	2	3	3	3	3	3	
							Summary	26/02/92(*)		6	1	2	3	1	NO	2	3	3	3	3	YES
							Detail	1		1	2	3	1	NO	2	3	3	3	3	3	
							Detail	2		1	2	3	1	NO	2	3	3	3	3	3	
							Detail	3		1	2	3	1	NO	2	3	3	3	3	3	
							Detail	4		1	2	3	1	NO	2	3	3	3	3	3	
							Detail	5		1	2	3	1	NO	2	3	3	3	3	3	
							Detail	6		1	2	3	1	NO	2	3	3	3	3	3	
							Summary	26/02/92(*)		6	1	2	3	1	NO	2	3	3	3	3	YES
45	FS	22/01/92	04/02/92		CONSTIPATION	24/01/92	Detail	1		1	2	3	1	NO	2	3	3	3	3	3	
							Detail	2		1	2	3	1	NO	2	3	3	3	3	3	
							Detail	3		1	2	3	1	NO	2	3	3	3	3	3	
							Detail	4		1	2	3	1	NO	2	3	3	3	3	3	
							Detail	5		1	2	3	1	NO	2	3	3	3	3	3	
							Detail	6		1	2	3	1	NO	2	3	3	3	3	3	
							Summary	04/02/92		6	1	2	3	1	NO	2	3	3	3	3	1

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=none, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis

14113

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD

REBOXETINE - PROTOCOL 20124/013
Listing No.: 11.0

ADVERSE EVENTS
OPEN PHASE

Con. Pat. Init.	Start date	End date	Adverse event	Onset date	Type record	Visit No	End No date	Last report visit	Save	Hist	Rel	Stud	Symp	Dis	Re	Out	Open		
1	65	FS	22/01/92	06/05/92	CONSTIPATION	24/01/92	06/05/92	6	1	2	3	1	NO	2	3	3	1	YES	
	66	TCG	22/01/92	06/05/92	MOUTH DRY	22/01/92			1	2	3	1	NO	2	3	3	3		
									Detail										
									2	1	2	3	1	NO	2	3	3		
									3	1	2	3	1	NO	2	3	3		
									4	1	2	3	1	NO	2	3	3		
									5	1	2	3	1	NO	2	3	3		
									6	1	2	3	1	NO	2	3	3		
									Summary										
									06/05/92	6	1	2	3	1	NO	2	3	3	YES
	68	MS	22/01/92	06/05/92	DIZZINESS	25/01/92			1	2	3	1	NO	2	3	3	3		
									Detail										
									2	1	2	3	1	NO	2	3	3		
									3	1	2	3	1	NO	2	3	3		
									4	1	2	3	1	NO	2	3	3		
									5	1	2	3	1	NO	2	3	3		
									6	1	2	3	1	NO	2	3	3		
									Summary										
									06/05/92	6	1	2	2	1	NO	2	3	3	YES
									Detail										
									1	1	2	3	1	NO	2	3	3		
									2	1	2	3	1	NO	2	3	3		
									3	1	2	3	1	NO	2	3	3		
									4	1	2	3	1	NO	2	3	3		
									5	1	2	3	1	NO	2	3	3		
									6	1	2	3	1	NO	2	3	3		
									Summary										
									06/05/92	6	1	2	2	1	NO	2	3	3	YES
									Detail										
									2	1	2	3	1	NO	2	3	3		
									3	1	2	3	1	NO	2	3	3		
									4	1	2	3	1	NO	2	3	3		
									5	1	2	3	1	NO	2	3	3		
									6	1	2	3	1	NO	2	3	3		
									Summary										
									06/05/92	6	1	2	2	1	NO	2	3	3	YES
	69	RFA	22/01/92	06/05/92	LIBIDO DECREASED	29/01/92			1	2	3	1	NO	2	3	3	3		
									Detail										
									2	1	2	3	1	NO	2	3	3		
									3	1	2	3	1	NO	2	3	3		
									4	1	2	3	1	NO	2	3	3		
									5	1	2	3	1	NO	2	3	3		
									6	1	2	3	1	NO	2	3	3		
									Summary										
									06/05/92	6	1	2	2	1	NO	2	3	3	YES
									Detail										
									5	1	2	4	1	NO	2	3	3		
									6	1	2	3	1	NO	2	3	3		
									Summary										
									06/05/92	6	1	2	3	1	NO	2	3	3	YES

Severity: 0=unknown, 1= mild, 2= moderate, 3= severe, 4= life threatening
 Study drug: 1= none, 2= dose reduced, 3= dose withdrawn, 4= temp. inter.
 Hospital: 1= required, 2= not req., 3= not appl.
 Disapp./Reapp.: 1= no, 2= yes, 3= not appl.
 Symptomatic treatment: 0= no, 1= yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REMONETINE - PROTOCOL 20126/013
 Listing No.: 11.0
 ADVERSE EVENTS
 OPEN PHASE

Chn. Pat. Init.	Start date	Treatment	End date	Adverse event	Onset date	Type record	Visit No	Last report visit	Sev rcty	Hist ary	Rel ship	Stu Sym	Dis Hosp	Re app.	Out app.	Open com.
1	59 RFA	22/01/92	06/03/92	TACHYCARDIA	22/01/92	Detail	1	1	2	4	1	NO	2	3	3	1
					27/01/92	Summary	1	1	2	4	1	NO	2	3	3	1
70	MLH	25/01/92	06/03/92	NAUSEA	27/01/92	Detail	1	1	2	3	1	NO	2	3	3	3
						Detail	2	1	2	3	1	NO	2	3	3	3
						Detail	3	1	2	3	1	NO	2	3	3	3
						Detail	4	1	2	3	1	NO	2	3	3	3
						Detail	5	25/02/92	1	2	3	1	NO	2	3	3
						Summary	25/02/92	5	1	2	3	1	NO	2	3	3
71	OWH	29/01/92	10/03/92	TACHYCARDIA	01/02/92	Detail	1	1	2	3	1	NO	2	3	3	3
						Detail	2	1	2	3	1	NO	2	3	3	3
						Detail	3	1	2	3	1	NO	2	3	3	3
						Detail	4	20/02/92	1	2	3	1	NO	2	3	3
						Summary	20/02/92	4	1	2	3	1	NO	2	3	3
73	FMA	29/01/92	10/03/92	CONSTIPATION	01/02/92	Detail	1	1	2	3	1	NO	2	3	3	3
						Detail	2	1	2	3	1	NO	2	3	3	3
						Detail	3	1	2	3	1	NO	2	3	3	3
						Detail	4	1	2	3	1	NO	2	3	3	3
						Detail	5	1	2	3	1	NO	2	3	3	3
						Detail	6	10/03/92(*)	1	2	3	1	NO	2	3	3
						Summary	10/03/92(*)	6	1	2	3	1	NO	2	3	3
						Detail	1	1	2	3	1	NO	2	3	3	3
						Detail	2	1	2	3	1	NO	2	3	3	3
						Detail	3	1	2	3	1	NO	2	3	3	3
						Detail	4	1	2	3	1	NO	2	3	3	3
						Detail	5	1	2	3	1	NO	2	3	3	3
						Detail	6	10/03/92(*)	1	2	3	1	NO	2	3	3
						Summary	10/03/92(*)	6	1	2	3	1	NO	2	3	3
77	AGG	08/02/92	20/03/92	LIBIDO DECREASED	25/02/92	Detail	3	2	2	3	1	NO	2	3	3	3
						Detail	4	2	2	3	1	NO	2	3	3	3
						Detail	5	2	2	3	1	NO	2	3	3	3

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe,
 Study drug: 0=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=undetectable, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMONETINE - PROTOCOL 28124/013
 Listing No.: 11.0

ADVERSE EVENTS
 OPEN PHASE

Con. Pat. Id.	Init.	Start date	Treatment	End date	Adverse event	Onset date	Type record	Visit End No date	Last report visit	Sev	Hist	Rel	Stud	Symp	Dis hosp	Re app.	Out app.	Open com.							
1	77	ACG	06/02/92	20/03/92	LIBIDO DECREASED	26/02/92	6	26/02/92(*)	6	2	2	3	1	NO	2	3	3	3	3						
						Summary																			
						Detail	2	1	2	3	1	NO	2	3	3										
						Detail	3	1	2	3	1	NO	2	3	3										
						Detail	4	1	2	3	1	NO	2	3	3										
						Detail	5	1	2	3	1	NO	2	3	3										
76	SO	08/02/92	20/03/92	CONSTIPATION	20/03/92	6	20/03/92	6	1	2	2	1	NO	2	3	3	1								
					Summary																				
					Detail	3	2	2	3	1	NO	2	3	3											
					Detail	4	2	2	3	1	NO	2	3	3											
					Detail	5	2	2	3	1	NO	2	3	3											
					Detail	6	2	2	3	1	NO	2	3	3											
81	MFB	08/02/92	20/03/92	CONSTIPATION	18/02/92	5			1	2	3	1	NO	2	3	3									
					Detail	1	1	2	3	1	NO	2	3	3											
					Detail	2	1	2	3	1	NO	2	3	3											
					Detail	3	1	2	3	1	NO	2	3	3											
					Detail	4	1	2	3	1	NO	2	3	3											
					Detail	5	1	2	3	1	NO	2	3	3											

LIBIDO DECREASED

MOUTH DRY

CONSTIPATION

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=comp. inter.
 Hospital: 1=required, 2=not req, 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq, 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS R&D

REBORNETINE - PROTOCOL 20126/013
Listing No.: 11.0

ADVERSE EVENTS
OPEN PHASE

Pat. No.	Init.	Start date	Treatment	End date	Adverse event	Onset date	Type record	Visit No	End date	Last report		Rel. sev	Stud. Sympt	Dis Hosp	Re app.	Out come (C)	Open		
										visit city	dry								
01	MF8	05/02/92	20/02/92	CONSTIPATION		10/02/92	Detail	6	20/02/92(*)	1	2	3	1	NO	2	3	3	YES	
								Summary	6	1	2	3	1	NO	2	3	3	3	YES
								Detail	1	1	2	3	1	NO	2	3	3		
									2	1	2	3	1	NO	2	3	3		
									3	1	2	3	1	NO	2	3	3		
									4	1	2	3	1	NO	2	3	3		
Summary	6	1	2	3	1	NO	2	3	3										
02	MDS	06/02/92	20/02/92	SNEEZING INCREASED		10/02/92	Detail	1	20/02/92(*)	1	2	3	1	NO	2	3	3	YES	
								Summary	6	1	2	3	1	NO	2	3	3	3	YES
								Detail	1	1	2	3	1	NO	2	3	3		
									2	1	2	3	1	NO	2	3	3		
									3	1	2	3	1	NO	2	3	3		
									4	1	2	3	1	NO	2	3	3		
Summary	6	1	2	3	1	NO	2	3	3										
04	IN	08/02/92	20/02/92	MICTURITION DISORDER		09/02/92	Detail	1	20/02/92(*)	1	2	3	1	NO	2	3	3	YES	
								Summary	6	1	2	3	1	NO	2	3	3	3	YES
								Detail	1	1	2	3	1	NO	2	3	3		
									2	1	2	3	1	NO	2	3	3		
									3	1	2	3	1	NO	2	3	3		
									4	1	2	3	1	NO	2	3	3		
Summary	6	1	2	3	1	NO	2	3	3										
06	MTF	06/02/92	20/02/92	MOUTH DRY		11/02/92	Detail	1	20/02/92(*)	1	2	3	1	NO	2	3	3	YES	
								Summary	6	1	2	3	1	NO	2	3	3	3	YES
								Detail	1	1	2	3	1	NO	2	3	3		
									2	1	2	3	1	NO	2	3	3		
									3	1	2	3	1	NO	2	3	3		
									4	1	2	3	1	NO	2	3	3		
Summary	6	1	2	3	1	NO	2	3	3										

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=definitive, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: mid date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 RESOMETINE - PROTOCOL 20126/913
 Listing No.: 11.0
 ADVERSE EVENTS
 OPEN PHASE

Cen. Pat. Id.	Init.	Start date	End date	Adverse event	Onset date	Type record	Visit No	End No date	Last report visit	Save risky	Hist dry	Rel shp	Stud drug	Sypv	Dis Hosp	Re app.	Out app.	Open come (c)	
																			1
1	66	08/02/92	26/03/92	MOUTH DRY	11/02/92	Detail	3		1	2	3	1	NO	2	3	3	3		
							4	1	2	3	1	NO	2	3	3	3			
							5	1	2	3	1	NO	2	3	3	3			
							6	20/03/92	1	2	2	1	NO	2	3	3	1		
							Summary	6	1	2	2	1	NO	2	3	3	1	YES	
		10/03/92	20/03/92	PARAESTHESIA	6/20/03/92	Detail	5		1	2	4	1	NO	2	3	3	3		
							6	20/03/92	1	2	3	1	NO	2	3	3	1	YES	
							Summary	6	1	2	3	1	NO	2	3	3	1	YES	
		12/02/92		TACHYCARDIA	12/02/92	Detail	1		1	2	3	1	NO	2	3	3	3		
							2	1	2	3	1	NO	2	3	3	3			
							3	1	2	3	1	NO	2	3	3	3			
							4	02/03/92	1	2	4	1	NO	2	3	3	1		
							5	02/03/92	4	1	2	5	1	NO	2	3	3	1	YES
							Summary	4	1	2	5	1	NO	2	3	3	1	YES	
		09/02/92		CONSTIPATION	09/02/92	Detail	1		1	2	3	1	NO	2	3	3	3		
							2	1	2	3	1	NO	2	3	3	3			
							3	1	2	3	1	NO	2	3	3	3			
							4	1	2	3	1	NO	2	3	3	3			
							5	1	2	3	1	NO	2	3	3	3			
							6	20/03/92(*)	6	1	2	3	1	NO	2	3	3	3	YES
		01/03/92		DIZZINESS	01/03/92	Detail	4		1	2	3	1	NO	2	3	3	3		
							5	1	2	3	1	NO	2	3	3	3			
							6	1	2	3	1	NO	2	3	3	3			
							Summary	6	1	2	3	1	NO	2	3	3	3	YES	
		07/02/92		MOUTH DRY	07/02/92	Detail	1		1	2	3	1	NO	2	3	3	3		
							2	1	2	3	1	NO	2	3	3	3			
							3	1	2	3	1	NO	2	3	3	3			
							4	1	2	3	1	NO	2	3	3	3			
							5	1	2	3	1	NO	2	3	3	3			
							6	20/03/92(*)	6	1	2	3	1	NO	2	3	3	3	YES
		20/03/92(*)			20/03/92(*)	Detail	6		1	2	3	1	NO	2	3	3	3		
							1	1	2	3	1	NO	2	3	3	3			
							2	1	2	3	1	NO	2	3	3	3			
							3	1	2	3	1	NO	2	3	3	3			
							4	1	2	3	1	NO	2	3	3	3			
							5	1	2	3	1	NO	2	3	3	3			
Summary	6	1	2	3	1	NO	2	3	3	3	YES								

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=def. withdraw, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS 83D
 REMONETINE - PROTOCOL 20126/013
 Listing No.: 11.0

ADVERSE EVENTS
 OPEN PHASE

Con. Pat. Init.	Start date	Treatment	End date	Adverse event	Onset date	Type	Visit	End record	Last report	Seve	Hist	Rel	Stud	Symp	Dis	Re	Out	Open			
									visit	risky	ary	ship	drug	trta	Hosp	app.	app.	com.	(C)		
1	09	NMV	12/02/92	24/02/92	HEADACHE				1	17/02/92	1	2	4	1	NO	2	3	3	1		
									Summary	17/02/92	1	1	2	4	1	NO	2	3	3	1	YES
90	JSS	12/02/92	24/02/92	URINARY RETENTION					3		1	2	3	1	NO	2	3	3	3		
									Detail		1	2	3	1	NO	2	3	3	3		
									Detail		1	2	3	1	NO	2	3	3	3		
									Detail		1	2	3	1	NO	2	3	3	3		
									Detail		1	2	3	1	NO	2	3	3	3		
									Summary	24/02/92(*)	6	1	2	3	1	NO	2	3	3	3	YES
92	PSS	12/02/92	24/02/92	CONSTIPATION					1		1	2	3	1	NO	2	3	3	3		
									Detail		1	2	3	1	NO	2	3	3	3		
									Detail		1	2	3	1	NO	2	3	3	3		
									Detail		1	2	3	1	NO	2	3	3	3		
									Detail		1	2	3	1	NO	2	3	3	3		
									Summary	24/02/92	6	1	2	3	1	NO	2	3	3	1	YES
93	AL	15/02/92	25/02/92	SWEATING INCREASED					1		1	2	3	1	NO	2	3	3	3		
									Detail		1	2	3	1	NO	2	3	3	3		
									Detail		1	2	3	1	NO	2	3	3	3		
									Detail		1	2	3	1	NO	2	3	3	3		
									Detail		1	2	3	1	NO	2	3	3	3		
									Summary	24/02/92	6	1	2	2	1	NO	2	3	3	1	YES
94	AL	15/02/92	25/02/92	MOUTH DRY					1		1	2	3	1	NO	2	3	3	3		
									Detail		1	2	3	1	NO	2	3	3	3		
									Detail		1	2	3	1	NO	2	3	3	3		
									Detail		1	2	3	1	NO	2	3	3	3		
									Detail		1	2	3	1	NO	2	3	3	3		
									Summary	24/02/92	6	1	2	2	1	NO	2	3	3	1	YES
95	AL	15/02/92	25/02/92	SWEATING INCREASED					1		1	2	3	1	NO	2	3	3	3		
									Detail		1	2	3	1	NO	2	3	3	3		
									Detail		1	2	3	1	NO	2	3	3	3		
									Detail		1	2	3	1	NO	2	3	3	3		
									Detail		1	2	3	1	NO	2	3	3	3		
									Summary	25/02/92(*)	6	1	2	3	1	NO	2	3	3	3	YES
96	AL	15/02/92	25/02/92	TREMOR					1		1	2	3	1	NO	2	3	3	3		
									Detail		1	2	3	1	NO	2	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=dose withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBROXTINE - PROTOCOL 20126/013
 Listing No.: 11.5
 ADVERSE EVENTS
 OPEN PHASE

Can. Pat. No.	Init.	Start date	Treatment	End date	Adverse event	Onset date	Type record	Visit No	End date	Last report	Ses	Hist	Rel	Stud	Symp	Dis	Re	Out	Open								
																				visit	city	dry	shlp	drug	trta	Hosp	app.
1	93	15/02/92	25/05/92 TREMOR			15/02/92	Detail	3		1	2	3	1	NO	2	3	3										
								4	1	2	3	1	NO	2	3	3											
								5	1	2	3	1	NO	2	3	3											
								6	1	2	3	1	NO	2	3	3											
								Summary		25/05/92(*)	6	1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
								Summary																			
94	RAB	15/02/92	25/05/92 CONSTIPATION			17/02/92	Detail	1		1	2	3	1	NO	2	3	3										
								2	1	2	3	1	NO	2	3	3											
								3	1	2	3	1	NO	2	3	3											
								4	1	2	3	1	NO	2	3	3											
								5	1	2	3	1	NO	2	3	3											
								6	1	2	3	1	NO	2	3	3											
Summary		25/05/92(*)	6	1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3	3							
Summary																											
95	GHT	15/02/92	25/05/92 LIBIDO DECREASED			17/02/92	Detail	1		1	2	3	1	NO	2	3	3										
								2	1	2	3	1	NO	2	3	3											
								3	1	2	3	1	NO	2	3	3											
								4	1	2	3	1	NO	2	3	3											
								5	1	2	3	1	NO	2	3	3											
								6	1	2	3	1	NO	2	3	3											
Summary		25/05/92(*)	6	1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3	3							
Summary																											
96	SPW	15/02/92	25/05/92 LIBIDO DECREASED			17/02/92	Detail	1		1	2	3	1	NO	2	3	3										
								2	1	2	3	1	NO	2	3	3											
								3	1	2	3	1	NO	2	3	3											
								4	1	2	3	1	NO	2	3	3											
								5	1	2	3	1	NO	2	3	3											
								6	1	2	3	1	NO	2	3	3											
Summary		25/05/92(*)	6	1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3								
Summary																											

Severity: UNKNOWN, 1= mild, 2= moderate, 3= severe, --- History: 1= present before, 2= not observe bef., 3= unknown
 Study drug: 1= no change, 2= dose reduced, 3= def. withdrawn, 4= temp. inter.
 Hospital: 1= required, 2= not req., 3= not appl. -- Outcome: 1= recovered, 2= rec. with seq., 3= still present, 4= death
 Disapp./Kapp.: 1= no, 2= yes, 3= not appl. -- Relationship: 1= definite, 2= probable, 3= possible, 4= doubtful, 5= unknown, 6= none
 Symptomatic treatment: 0= no, 1= yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 RESUBMITTAL - PROTOCOL 20126/013
 Listing No.: 11.0
 ADVERSE EVENTS
 OPEN PHASE

Con. Pat. ID	Init. Start date	End date	Treatment	Onset date	Type record	Visit No	End No date	Last report visit	Sev rity	Hist ory	Rel ship	Stud drug	Symp Trea	Dis Hosp	Re app.	Out come	Open (C)
1	98	SPH	13/02/92	25/05/92	MICTURITION DISORDER	1	17/02/92	1	1	2	3	1	NO	2	3	3	3
						2	1	2	3	1	NO	2	3	1	3	3	
						3	1	2	3	1	NO	2	3	3	3	3	
						4	1	2	3	1	NO	2	3	3	3	3	
						5	1	2	3	1	NO	2	3	3	3	3	
						6	1	2	3	1	NO	2	3	3	3	3	
						Summary	25/03/92(*)	6	1	2	3	1	NO	2	3	3	3
98	VIT	13/02/92	25/05/92	CONSTIPATION	1	17/02/92	1	1	2	3	1	NO	2	3	3	3	3
					2	1	2	3	1	NO	2	3	3	3	3		
					3	1	2	3	1	NO	2	3	3	3	3		
					4	1	2	3	1	NO	2	3	3	3	3		
					5	1	2	3	1	NO	2	3	3	3	3		
					6	1	2	3	1	NO	2	3	3	3	3		
					Summary	25/03/92(*)	6	1	2	3	1	NO	2	3	3	3	3
99	LGD	13/02/92	25/05/92	MOUTH DRY	1	17/02/92	1	1	2	3	1	NO	2	3	3	3	3
					2	1	2	3	1	NO	2	3	3	3	3		
					3	1	2	3	1	NO	2	3	3	3	3		
					4	1	2	3	1	NO	2	3	3	3	3		
					5	1	2	3	1	NO	2	3	3	3	3		
					6	1	2	3	1	NO	2	3	3	3	3		
					Summary	25/03/92(*)	6	1	2	3	1	NO	2	3	3	3	3
99	LGD	13/02/92	25/05/92	MOUTH DRY	1	18/02/92	1	1	2	3	1	NO	2	3	3	3	3
					2	1	2	3	1	NO	2	3	3	3	3		
					3	1	2	3	1	NO	2	3	3	3	3		
					4	1	2	3	1	NO	2	3	3	3	3		
					5	1	2	3	1	NO	2	3	3	3	3		
					6	1	2	3	1	NO	2	3	3	3	3		
					Summary	25/03/92	6	1	2	3	1	NO	2	3	3	3	3
99	LGD	13/02/92	25/05/92	SWEATING INCREASED	1	18/02/92	1	1	2	3	1	NO	2	3	3	3	3
					2	1	2	3	1	NO	2	3	3	3	3		
					3	1	2	3	1	NO	2	3	3	3	3		
					4	1	2	3	1	NO	2	3	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=ref. withdraw, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not app., -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Neapp.: 1=no, 2=yes, 3=not app., -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=more
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBORNETIME - PROTOCOL 20126/013
Listing No.: 11.0

ADVERSE EVENTS
OPEN PHASE

Gen. Pat. ID	Init.	Start date	End date	Adverse event	Onset date	Type	Visit record	End No date	Last report visit	Rel. freq	Study	Drug	Trea	Hosp	Dis app.	Re app.	Det come	Dran come (C)	
1	99	LD	15/02/92	25/02/92	SWEATING INCREASED	18/02/92	Detail	5	1	2	3	1	NO	2	3	3	3		
			25/02/92	25/02/92	Summary	6	1	2	2	1	NO	2	3	3	1	YES			
			19/02/92	04/03/92	DIZZINESS	19/02/92	Detail	1	2	3	1	NO	2	3	3	3			
	103	JRA	19/02/92	04/03/92	DIZZINESS	19/02/92	Detail	2	3	2	3	NO	2	2	2	3	1	YES	
			04/03/92	04/03/92	Summary	2	3	2	3	NO	2	2	3	1	YES				
			19/02/92	04/03/92	HYPERTENSION POSTURAL	19/02/92	Detail	1	2	3	1	NO	2	3	3	3			
			19/02/92	04/03/92	HYPERTENSION POSTURAL	19/02/92	Detail	2	1	2	3	NO	2	2	3	1	YES		
			04/03/92	04/03/92	Summary	2	1	2	3	NO	2	2	3	1	YES				
			19/02/92	06/02/92	TACHYCARDIA	19/02/92	Detail	1	2	5	1	NO	2	3	3				
			19/02/92	06/02/92	TACHYCARDIA	19/02/92	Detail	2	2	2	3	NO	2	2	3	1	YES		
			06/02/92	06/02/92	Summary	2	2	2	3	NO	2	2	3	1	YES				
			19/02/92	30/02/92	CONSTIPATION	21/02/92	Detail	1	2	3	1	NO	2	3	3				
	106	WTF	19/02/92	30/02/92	CONSTIPATION	21/02/92	Detail	2	1	2	3	1	NO	2	3	3			
			30/02/92	30/02/92	Summary	2	1	2	3	1	NO	2	3	3					
			21/02/92	30/02/92	SWEATING INCREASED	21/02/92	Detail	1	2	3	1	NO	2	3	3				
			21/02/92	30/02/92	SWEATING INCREASED	21/02/92	Detail	2	1	2	3	1	NO	2	3	3			
			30/02/92	30/02/92	Summary	2	1	2	3	1	NO	2	3	3					
			21/02/92	31/03/92	LEIDO DECREASED	21/02/92	Detail	1	2	3	1	NO	2	3	3				
	105	ABS	19/02/92	31/03/92	LEIDO DECREASED	21/02/92	Detail	2	1	2	3	1	NO	2	3	3			
			31/03/92	31/03/92	Summary	2	1	2	3	1	NO	2	3	3					
			21/02/92	31/03/92	SWEATING INCREASED	21/02/92	Detail	1	2	3	1	NO	2	3	3				

Severity: 0=unknown, 1=Mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with set., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD
REBOWETINE - PROTODOL 20126/013
Listing No.: 11.0

ADVERSE EVENTS
OPEN PHASE

Cn. Pat.	Init.	Start date	End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Save rity	Hist ory	Rea. drug	Stud. Tra	Sym. Resp.	Dis. Appr.	Ra. Appr.	Out. Appr.	Open										
																			Dis. Appr.	Ra. Appr.	Out. Appr.	Open						
1	105	ABS	19/02/92	31/05/92	LIBIDO DECREASED	21/02/92	5	31/05/92(*)	6	1	2	3	1	NO	2	3	3	3	3									
																				Detail 1	1	2	3	1	NO	2	3	3
																				Detail 2	1	2	3	1	NO	2	3	3
																				Detail 3	1	2	3	1	NO	2	3	3
																				Detail 4	1	2	3	1	NO	2	3	3
																				Summary	6	1	2	3	1	NO	2	3
106	MN	19/02/92	31/05/92	MOUTH DRY	21/02/92	1	31/05/92(*)	6	1	2	3	1	NO	2	3	3	3	3	3									
																				Detail 1	1	2	3	1	NO	2	3	3
																				Detail 2	1	2	3	1	NO	2	3	3
																				Detail 3	1	2	3	1	NO	2	3	3
																				Detail 4	1	2	3	1	NO	2	3	3
																				Summary	6	1	2	3	1	NO	2	3
107	LAN	20/02/92	01/04/92	LIBIDO DECREASED	22/02/92	1	31/05/92(*)	6	2	2	3	1	NO	2	3	3	3	3	3									
																				Detail 1	2	2	3	1	NO	2	3	3
																				Detail 2	1	2	3	1	NO	2	3	3
																				Detail 3	1	2	3	1	NO	2	3	3
																				Detail 4	1	2	3	1	NO	2	3	3
																				Summary	6	2	2	3	1	NO	2	3
108	STB	20/02/92	01/04/92	INSOMNIA	20/02/92	1	31/05/92(*)	6	1	2	3	1	NO	2	3	3	3	3	3									
																				Detail 1	1	2	3	1	NO	2	3	3
																				Detail 2	1	2	3	1	NO	2	3	3
																				Detail 3	1	2	3	1	NO	2	3	3
																				Detail 4	1	2	3	1	NO	2	3	3
																				Summary	6	1	2	3	1	NO	2	3

Severity: 0=unknown, 1= mild, 2= moderate, 3= severe, 4= life threatening
 Study drug: 1= no change, 2= dose reduced, 3= dose withdrawn, 4= temp. inter.
 Hospital: 1= required, 2= not req., 3= not appl.
 Disapp./Reapp.: 1= no, 2= yes, 3= not appl.
 Symptomatic treatment: 0= no, 1= yes
 (C) adverse event used for statistical analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

RECONETINE - PROTOCOL 20126/013

Listing No.: 11.0

ADVERSE EVENTS
OPEN PHASE

Cm. Pat. Init.	Start date	Treatment	End date	Adverse event	Onset date	Type record	Visit No	End date	Last visit rity	See rity	Hist ary	Rel ship	Rep ary	Stud drug	Symp Trea	Dis Hosp	Re app.	Out app.	Open come (c)							
																				2	3	4	5	6	1	2
1 106 STB	26/02/92	01/04/92	INSOMNIA		26/02/92	Detail	2			1	2	3	1	NO	2	3	3									
							3			1	2	3	1	NO	2	3	3									
							4			1	2	3	1	NO	2	3	3									
							5			1	2	3	1	NO	2	3	3									
							6			1	2	3	1	NO	2	3	3									
							Summary		01/04/92(*)	6	1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
							109 IPL	26/02/92	01/04/92	CONSTIPATION		06/03/92	Detail	3			1	2	5	1	NO	2	5	5		
														4			1	2	5	1	NO	2	5	5		
														5			1	2	5	1	NO	2	5	5		
														6			1	2	5	1	NO	2	5	5		
Summary		01/04/92(*)	6	1	2	5								1	NO	2	5	5	5	5	5	5	5	5	5	
111 JBF	26/02/92	01/04/92	SWEATING INCREASED		01/03/92	Detail								2			1	2	3	1	NO	2	3	3		
														3			1	2	3	1	NO	2	3	3		
														4			1	2	3	1	NO	2	3	3		
														5			1	2	3	1	NO	2	3	3		
														6			1	2	3	1	NO	2	3	3		
							Summary		01/04/92(*)	6	1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	
							111 JBF	02/03/92		TREMOR		02/03/92	Detail	2			1	2	3	1	NO	2	3	3		
														3			1	2	3	1	NO	2	3	3		
														4			1	2	3	1	NO	2	3	3		
														Summary		01/04/92(*)	6	1	2	3	1	NO	2	3	3	3

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=critical
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REMEDIATION - PROTOCOL 20124/013
Listing No.: 11.0

ADVERSE EVENTS
OPEN PHASE

Cen. Pat. ID	Init. Start date	Treatment	End date	Adverse event	Onset date	Type record	Visit No	End No data	LAST		Dis app.	Re app.	Out app.	Open (C)			
									report visit	Rel Hist							
									visit	dry	trig	trig	trig				
111 JBF	20/02/92	01/04/92	TREMOR		02/03/92	Detail	5		1	2	3	1	NO	2	3	3	
							6	01/04/92(*)	6	1	2	3	1	NO	2	3	3
							Summary		6	1	2	3	1	NO	2	3	3
112 PSA	20/02/92	01/04/92	MOUTH DRY		22/02/92	Detail	1		1	2	3	1	NO	2	3	3	
							2		1	2	3	1	NO	2	3	3	
							3		1	2	3	1	NO	2	3	3	
							4		1	2	3	1	NO	2	3	3	
							5		1	2	3	1	NO	2	3	3	
							6	01/04/92	6	1	2	3	1	NO	2	3	3
Summary		6	1	2	3	1	NO	2	3	3	YES						
113 LFS	20/02/92	01/04/92	CONSTIPATION		22/02/92	Detail	1		1	2	3	1	NO	2	3	3	
							2		1	2	3	1	NO	2	3	3	
							3		1	2	3	1	NO	2	3	3	
							4		1	2	3	1	NO	2	3	3	
							5		1	2	3	1	NO	2	3	3	
							6	01/04/92	6	1	2	3	1	NO	2	3	3
Summary		6	1	2	3	1	NO	2	3	3	YES						
114 CLF	26/02/92	07/04/92	CONSTIPATION		02/03/92	Detail	1		1	2	3	1	NO	2	3	3	
							2		1	2	3	1	NO	2	3	3	
							3		1	2	3	1	NO	2	3	3	
							4		1	2	3	1	NO	2	3	3	
							5		1	2	3	1	NO	2	3	3	
							6	01/04/92	6	1	2	3	1	NO	2	3	3
Summary		6	1	2	3	1	NO	2	3	3	YES						
			MOUTH DRY		01/05/92	Detail	1		1	2	3	1	NO	2	3	3	
							2		1	2	3	1	NO	2	3	3	
							3		1	2	3	1	NO	2	3	3	
							4		1	2	3	1	NO	2	3	3	
							5		1	2	3	1	NO	2	3	3	
							6	07/04/92(*)	6	1	2	3	1	NO	2	3	3
Summary		6	1	2	3	1	NO	2	3	3	YES						

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REDBUXTIME - PROTOCOL 20126/913
Listing No.: 11.0

ADVERSE EVENTS
OPEN PHASE

Gen. Pat. No.	Init. Start date	Treatment	End date	Adverse event	Onset date	Type record	Visit No	End date	Last visit	report	Sev	Hist	Rel	Stud	Symp	Dis Hosp	Re app.	Open							
									visit	city	ory	ship	drug	tree	trrea	trrea	app.	come	(C)						
1	114	CLF	26/02/92	07/06/92 MOUTH DRY	01/05/92	Detail	2		1	2	3	1	NO	2	3	3	3	3							
						Detail	3		1	2	3	1	NO	2	3	3	3	3	3	3					
						Detail	4		1	2	3	1	NO	2	3	3	3	3	3	3	3				
						Detail	5		1	2	3	1	NO	2	3	3	3	3	3	3	3				
						Detail	6		1	2	3	1	NO	2	3	3	3	3	3	3	3				
						Summary		07/06/92(*)	6	1	2	3	1	NO	2	3	3	3	3	3	3	3	3	YES	
						Summary																			
	115	MGA	26/02/92	07/06/92 CONSTIPATION	02/05/92	Detail	1		1	2	3	1	NO	2	3	3	3	3							
						Detail	2		1	2	3	1	NO	2	3	3	3	3	3						
						Detail	3	16/03/92		1	2	3	1	NO	2	3	3	3	3	3	3				
						Summary		16/03/92	3	1	2	3	1	NO	2	3	3	3	3	3	3	3	1	YES	
						Summary																			
						Detail	2		1	2	3	1	NO	2	3	3	3	3	3	3	3				
						Summary																			
	119	HMH	26/02/92	07/06/92 PARAESTHESIA	26/02/92	Detail	1		1	2	3	1	NO	2	3	3	3	3							
						Detail	2		1	2	3	1	NO	2	3	3	3	3	3						
						Detail	3		1	2	3	1	NO	2	3	3	3	3	3						
						Detail	4	20/03/92		1	2	3	1	NO	2	3	3	3	3	3					
						Detail	5		1	2	3	1	NO	2	3	3	3	3	3						
						Detail	6		1	2	3	1	NO	2	3	3	3	3	3						
						Summary		07/06/92(*)	6	1	2	3	1	NO	2	3	3	3	3	3	3	3	3	YES	
	119	HMH	26/02/92	07/06/92 PARAESTHESIA	26/02/92	Detail	1		1	2	3	1	NO	2	3	3	3	3							
						Detail	2		1	2	3	1	NO	2	3	3	3	3							
						Detail	3		1	2	3	1	NO	2	3	3	3	3							
						Detail	4	20/03/92		1	2	3	1	NO	2	3	3	3	3						
						Detail	5		1	2	3	1	NO	2	3	3	3	3							
						Detail	6		1	2	3	1	NO	2	3	3	3	3							
						Summary		20/03/92	4	1	2	3	1	NO	2	3	3	3	3	3	3	3	1	YES	
	119	HMH	26/02/92	07/06/92 TACHYCARDIA	02/05/92	Detail	1		1	2	3	1	NO	2	3	3	3	3							
						Detail	2		1	2	3	1	NO	2	3	3	3	3							
						Detail	3	17/05/92		1	2	3	1	NO	2	3	3	3	3						
						Detail	4		1	2	3	1	NO	2	3	3	3	3							
						Detail	5		1	2	3	1	NO	2	3	3	3	3							
						Detail	6	07/06/92		1	2	3	1	NO	2	3	3	3	3						
						Summary		07/06/92	5	1	2	3	1	NO	2	3	3	3	3	3	3	3	1	YES	
	119	HMH	26/02/92	07/06/92 TREMOR	26/02/92	Detail	1		1	2	3	1	NO	2	3	3	3	3							
						Detail	2		1	2	3	1	NO	2	3	3	3	3							
						Detail	3		1	2	3	1	NO	2	3	3	3	3							
						Detail	4		1	2	3	1	NO	2	3	3	3	3							
						Detail	5		1	2	3	1	NO	2	3	3	3	3							
						Detail	6	07/06/92		1	2	3	1	NO	2	3	3	3	3						
						Summary		07/06/92	6	1	2	3	1	NO	2	3	3	3	3	3	3	3	3	1	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 11.0

ADVERSE EVENTS
 OPEN PHASE

Con. Pat.	Init.	Start date	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End No date	Last report visit	Save rity	Hist ery	Rel ship	Stu tree	Symp app.	Dis app.	Re app.	Out app.	Open case (C)
1	120	JUL 27/02/92	08/06/92		CONSTIPATION	28/02/92	Detail 1	1		1	2	3	1	NO	2	3	3	3	3
							Detail 2	2		1	2	3	1	NO	2	3	3	3	3
							Detail 3	3		1	2	3	1	NO	2	3	3	3	3
							Detail 4	4		1	2	3	1	NO	2	3	3	3	3
							Detail 5	5		1	2	3	1	NO	2	3	3	3	3
							Detail 6	08/06/92		1	2	2	1	NO	2	3	3	3	1
							Summary	08/06/92	6	1	2	2	1	NO	2	3	3	3	1
							Detail 1	1		1	2	3	1	NO	2	3	3	3	3
							Detail 2	2		1	2	3	1	NO	2	3	3	3	3
							Detail 3	3		1	2	3	1	NO	2	3	3	3	3
							Detail 4	4		1	2	3	1	NO	2	3	3	3	3
							Detail 5	5		1	2	3	1	NO	2	3	3	3	3
							Detail 6	08/06/92		1	2	2	1	NO	2	3	3	3	1
							Summary	08/06/92	6	1	2	2	1	NO	2	3	3	3	1
							Detail 1	1		1	2	3	1	NO	2	3	3	3	3
							Detail 2	2		1	2	3	1	NO	2	3	3	3	3
							Detail 3	3		1	2	3	1	NO	2	3	3	3	3
							Detail 4	4		1	2	3	1	NO	2	3	3	3	3
							Detail 5	5		1	2	3	1	NO	2	3	3	3	3
							Detail 6	08/06/92		1	2	2	1	NO	2	3	3	3	1
							Summary	08/06/92	6	1	2	2	1	NO	2	3	3	3	1
							Detail 1	1		1	2	3	1	NO	2	3	3	3	3
							Detail 2	2		1	2	3	1	NO	2	3	3	3	3
							Detail 3	3		1	2	3	1	NO	2	3	3	3	3
							Detail 4	4		1	2	3	1	NO	2	3	3	3	3
							Detail 5	5		1	2	3	1	NO	2	3	3	3	3
							Detail 6	08/06/92		1	2	2	1	NO	2	3	3	3	1
							Summary	08/06/92	6	1	2	2	1	NO	2	3	3	3	1
							Detail 2	2		1	2	3	1	NO	2	3	3	3	3
							Detail 3	3		1	2	3	1	NO	2	3	3	3	3
							Detail 4	4		1	2	3	1	NO	2	3	3	3	3
							Detail 5	5		1	2	3	1	NO	2	3	3	3	3
							Detail 6	08/06/92		1	2	3	1	NO	2	3	3	3	3
							Summary	08/06/92	6	1	2	3	1	NO	2	3	3	3	3
							Detail 1	1		1	2	3	1	NO	2	3	3	3	3
							Detail 2	2		1	2	3	1	NO	2	3	3	3	3
							Detail 3	3		1	2	3	1	NO	2	3	3	3	3
							Detail 4	4		1	2	3	1	NO	2	3	3	3	3
							Detail 5	5		1	2	3	1	NO	2	3	3	3	3
							Detail 6	25/02/92		1	2	3	1	NO	2	3	3	3	3
							Detail 2	2		1	2	3	1	NO	2	3	3	3	3
							Detail 3	3		1	2	3	1	NO	2	3	3	3	3
							Detail 4	4		1	2	3	1	NO	2	3	3	3	3
							Detail 5	5		1	2	3	1	NO	2	3	3	3	3
							Detail 6	08/06/92		1	2	3	1	NO	2	3	3	3	3
							Summary	08/06/92	6	1	2	3	1	NO	2	3	3	3	3

Severely: 5=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Rapp.: 1=nb, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RRD

RENOVETINE - PROTOCOL 2012/4/913
Listing No.: 11.0

ADVERSE EVENTS
OPEN PHASE

Cen. Pat. Id.	Init.	Start date	Treatment	End date	Adverse event	Onset date	Type record	Visit No	Last visit date	Report			Dis Hosp	Re app.	Out come	Open (C)	
										Sev	Hist	Rel					
124	PFC	27/02/92	06/04/92	MOUTH DRY	MOUTH DRY	25/02/92	Detail	6	08/04/92(*)	1	2	3	1	NO	2	3	3
							Summary	6	1	2	3	1	NO	2	3	3	3
						26/02/92	Detail	1	1	2	3	1	NO	2	3	3	3
							Detail	2	1	2	3	1	NO	2	3	3	3
							Detail	3	1	2	3	1	NO	2	3	3	3
							Detail	4	1	2	3	1	NO	2	3	3	3
							Detail	5	1	2	3	1	NO	2	3	3	3
	Summary	6	2	2	2	3	1	NO	2	3	3	3					
	Summary	08/04/92(*)	6	2	2	2	3	1	NO	2	3	3	3				
						01/03/92	Detail	1	1	2	3	1	NO	2	3	3	3
							Detail	2	1	2	3	1	NO	2	3	3	3
							Detail	3	1	2	3	1	NO	2	3	3	3
							Detail	4	1	2	3	1	NO	2	3	3	3
							Detail	5	1	2	3	1	NO	2	3	3	3
							Detail	6	1	2	3	1	NO	2	3	3	3
							Summary	6	1	2	3	1	NO	2	3	3	3
							Summary	08/04/92(*)	6	1	2	3	1	NO	2	3	3
						01/03/92	Detail	1	1	2	3	1	NO	2	3	3	3
							Detail	2	1	2	3	1	NO	2	3	3	3
							Detail	3	1	2	3	1	NO	2	3	3	3
							Detail	4	1	2	3	1	NO	2	3	3	3
							Detail	5	1	2	3	1	NO	2	3	3	3
							Detail	6	1	2	3	1	NO	2	3	3	3
							Summary	6	1	2	3	1	NO	2	3	3	3
							Summary	08/04/92(*)	6	1	2	3	1	NO	2	3	3
						01/03/92	Detail	1	1	2	3	1	NO	2	3	3	3
							Detail	2	1	2	3	1	NO	2	3	3	3
							Detail	3	1	2	3	1	NO	2	3	3	3
							Detail	4	1	2	3	1	NO	2	3	3	3
							Detail	5	1	2	3	1	NO	2	3	3	3
							Detail	6	1	2	3	1	NO	2	3	3	3
							Summary	6	1	2	3	1	NO	2	3	3	3
							Summary	08/04/92(*)	6	1	2	3	1	NO	2	3	3
						26/02/92	Detail	1	1	2	3	1	NO	2	3	3	3
							Detail	2	1	2	3	1	NO	2	3	3	3
							Detail	3	1	2	3	1	NO	2	3	3	3
							Detail	4	1	2	3	1	NO	2	3	3	3
							Detail	5	1	2	3	1	NO	2	3	3	3
							Detail	6	1	2	3	1	NO	2	3	3	3
							Summary	6	1	2	3	1	NO	2	3	3	3
							Summary	08/04/92(*)	6	1	2	3	1	NO	2	3	3
						25/02/92	Detail	1	1	2	3	1	NO	2	3	3	3
							Detail	2	1	2	3	1	NO	2	3	3	3

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=fatal
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./reapp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS 83D
 REMOETINE - PROTOCOL 20126/913
 Listing No.: 11.0
 ADVERSE EVENTS
 OPEN PHASE

Cen. Pat. Id.	Init.	Start date	Treatment	End date	Adverse event	Onset date	Type record	Visa No	Save rity	Hist ary	Rel ship	Stu drug	Syp trea	Dis Hosp	Ra app.	Dis app.	Re come	Out	Open	Last							
																				report	visit						
1	127	27/02/92	08/04/92	CONSTIPATION		29/02/92	Detail	3	1	2	3	1	NO	2	3	3	3										
							Detail	4	1	2	3	1	NO	2	3	3	3										
							Detail	5	1	2	3	1	NO	2	3	3	3										
							Detail	6	1	2	3	1	NO	2	3	3	3										
							Summary		6	1	2	1	1	NO	2	3	3	3	3	3	3	3	3	3	3	3	3
							Summary		08/04/92(*)																		
		27/02/92		MOUTH DRY		27/02/92	Detail	1	1	2	3	1	NO	2	3	3	3										
							Detail	2	1	2	3	1	NO	2	3	3	3										
							Detail	3	1	2	3	1	NO	2	3	3	3										
							Detail	4	1	2	3	1	NO	2	3	3	3										
							Detail	5	1	2	3	1	NO	2	3	3	3										
							Detail	6	1	2	3	1	NO	2	3	3	3										
Summary		08/04/92(*)																									
130	LHM	27/02/92	08/04/92	NICTURITION DISORDER		27/02/92	Detail	1	1	2	3	1	NO	2	3	3											
							Detail	2	1	2	3	1	NO	2	3	3	3										
							Detail	3	1	2	3	1	NO	2	3	3	3										
							Detail	4	1	2	3	1	NO	2	3	3	3										
							Detail	5	1	2	3	1	NO	2	3	3	3										
							Detail	6	1	2	3	1	NO	2	3	3	3										
Summary		08/04/92(*)																									
		27/02/92		PARAESTHESIA		27/02/92	Detail	1	1	2	3	1	NO	2	3	3											
							Detail	2	1	2	3	1	NO	2	3	3	3										
							Detail	3	1	2	3	1	NO	2	3	3	3										
							Detail	4	1	2	3	1	NO	2	3	3	3										
							Detail	5	1	2	3	1	NO	2	3	3	3										
							Detail	6	1	2	3	1	NO	2	3	3	3										
Summary		08/04/92(*)																									
136	EGA	29/02/92	10/04/92	CONSTIPATION		26/03/92	Detail	4	1	2	3	1	NO	2	3	3											
							Detail	5	1	2	3	1	NO	2	3	3	3										
							Detail	6	1	2	3	1	NO	2	3	3	3										
							Summary		10/04/92(*)																		
							Summary		10/04/92(*)																		
							Summary		10/04/92(*)																		
131	RHR	11/05/92	20/04/92	MOUTH DRY		11/05/92	Detail	1	1	2	3	1	NO	2	3	3											
							Detail	2	1	2	3	1	NO	2	3	3	3										

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, --- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS 183

REMOVITINE - PROTOCOL 20126/013

Listing No.: 11.9

ADVERSE EVENTS
OPEN PHASE

Cen. Pat. Id.	Init.	Start date	Treatment	End date	Adverse event	Onset date	Type record	Visit No	End No date	Last report visit	Sew	Mist rity	Hist ary	Rel ship	Rel ship	Stud drug	Symp tra	Dis Hosp	Re app.	Out app.	Open com.	(C)
1	131	RMK	11/05/92	26/06/92	MOUTH DRY	11/05/92	Detail	3			1	2	5	1	NO	2	5	3	3			
							Detail	4			1	2	5	1	NO	2	5	3	3			
							Detail	5			1	2	5	1	NO	2	5	3	3			
							Detail	6	20/06/92		1	2	2	1	NO	2	3	3	1			
							Summary	20/06/92		6	1	2	2	1	NO	2	3	3	1			YES
132	MAT	19/05/92	29/06/92		SWEATING INCREASED	20/05/92	Detail	1			1	2	3	1	NO	2	3	3	3			
							Detail	2			1	2	3	1	NO	2	3	3	3			
							Detail	3			1	2	3	1	NO	2	3	3	3			
							Detail	4			1	2	3	1	NO	2	3	3	3			
							Detail	5			1	2	3	1	NO	2	3	3	3			
							Detail	6	29/06/92		1	2	2	1	NO	2	3	3	1			
							Summary	29/06/92		6	1	2	2	1	NO	2	3	3	1			YES
135	JPH	21/05/92	30/06/92		CONSTIPATION	20/05/92	Detail	1			1	2	5	1	NO	2	5	3	3			
							Detail	2			1	2	5	1	NO	2	5	3	3			
							Detail	3			1	2	5	1	NO	2	5	3	3			
							Detail	4			1	2	5	1	NO	2	5	3	3			
							Detail	5			1	2	5	1	NO	2	5	3	3			
							Detail	6	29/06/92		1	2	2	1	NO	2	3	3	1			
							Summary	29/06/92		6	1	2	2	1	NO	2	3	3	1			YES
135	JPH	21/05/92	30/06/92		CONSTIPATION	25/05/92	Detail	1			1	2	3	1	NO	2	3	3	3			
							Detail	2			1	2	3	1	NO	2	3	3	3			
							Detail	3			1	2	3	1	NO	2	3	3	3			
							Detail	4			1	2	3	1	NO	2	3	3	3			
							Detail	5			1	2	3	1	NO	2	3	3	3			
							Detail	6			1	2	3	1	NO	2	3	3	3			
							Summary	30/06/92(*)		6	1	2	3	1	NO	2	3	3	3			YES
							Detail	2			1	2	3	1	NO	2	3	3	3			
							Detail	3			1	2	3	1	NO	2	3	3	3			
							Detail	4			1	2	3	1	NO	2	3	3	3			
							Detail	5			1	2	3	1	NO	2	3	3	3			
							Detail	6	30/06/92(*)		1	2	3	1	NO	2	3	3	3			
							Summary	30/06/92(*)		6	1	2	3	1	NO	2	3	3	3			YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=questionable, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS R&D

REMEDIATION - PROTOCOL 2012/013
Listing No.: 11.0

ADVERSE EVENTS
OPEN PHASE

Con. Pat. Init.	Start date	End date	Adverse event	Onset date	Type record	Visit No	End No date	Last report visit	Save rity	Hist ary	Rel ship	Rea Stud	Symp tra	Hosp app.	Dis app.	Re come	Out	Open
135 JPH	21/03/92	30/04/92	MOUTH DRY	25/03/92	Detail	1		1	2	5	1	NO	2	5	3	3		
					Detail	2	1	2	3	1	NO	2	5	3	3			
					Detail	3	1	2	3	1	NO	2	5	3	3			
					Detail	4	1	2	3	1	NO	2	5	3	3			
					Detail	5	1	2	3	1	NO	2	5	3	3			
					Detail	6	1	2	3	1	NO	2	5	3	3			
					Summary	30/04/92(*)	6	1	2	3	1	NO	2	5	3	3		
135 WMS	25/03/92	05/05/92	LIBIDO DECREASED	25/03/92	Detail	1		1	2	1	1	NO	2	5	3	3		
					Detail	2	1	2	3	1	NO	2	5	3	3			
					Detail	3	1	2	3	1	NO	2	5	3	3			
					Detail	4	1	2	3	1	NO	2	5	3	3			
					Detail	5	1	2	3	1	NO	2	5	3	3			
					Detail	6	1	2	3	1	NO	2	5	3	3			
					Summary	05/05/92(*)	6	1	2	3	1	NO	2	5	3	3		
136 AVP	25/03/92	05/05/92	LIBIDO DECREASED	25/03/92	Detail	1		1	2	3	1	NO	2	5	3	3		
					Detail	2	1	2	3	1	NO	2	5	3	3			
					Detail	3	1	2	3	1	NO	2	5	3	3			
					Detail	4	1	2	3	1	NO	2	5	3	3			
					Detail	5	1	2	3	1	NO	2	5	3	3			
					Detail	6	1	2	3	1	NO	2	5	3	3			
					Summary	05/05/92(*)	6	1	2	3	1	NO	2	5	3	3		
137 CHE	29/05/92	05/05/92	CONSTIPATION	26/03/92	Detail	1		1	2	3	1	NO	2	5	3	3		
					Detail	2	1	2	3	1	NO	2	5	3	3			
					Detail	3	1	2	3	1	NO	2	5	3	3			
					Detail	4	1	2	3	1	NO	2	5	3	3			
					Detail	5	1	2	3	1	NO	2	5	3	3			
					Detail	6	1	2	3	1	NO	2	5	3	3			
					Summary	05/05/92(*)	6	1	2	3	1	NO	2	5	3	3		

Serifity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with set., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBORNETINE - PROTOCOL 20126/813
 Listing No.: 11.0
 ADVERSE EVENTS
 OPEN PHASE

Con. Pat. Init.	Start date	End date	Adverse event	Treatment	Onset data	Type record	Visit No	End date	Last report	Save	Hist	Rel ship	Stud	Symp	Dis app.	Re app.	Out	Open	
									visit rity	city	ory	ship	drug	traa	Hosp	traa	app.	coms	(C)
1	137	CHE	25/03/92	05/05/92	CONSTIPATION		Summary	05/05/92	6	1	2	2	1	NO	2	3	3	1	YES
			26/03/92			Detail	1		1	2	3	1	NO	2	3	3	3		
			26/03/92		MOUTH DRY	Detail	2		1	2	3	1	NO	2	3	3	3		
						Detail	3		1	2	3	1	NO	2	3	3	3		
						Detail	4		1	2	3	1	NO	2	3	3	3		
						Detail	5		1	2	3	1	NO	2	3	3	3		
						Detail	6	05/05/92	1	2	3	1	NO	2	3	3	3		
						Summary	05/05/92		6	1	2	2	1	NO	2	3	3	1	YES
139	BA		25/03/92	05/05/92	NICTURITION DISORDER		Detail	02/04/92	2	1	2	3	1	NO	2	3	3	3	
						Detail	3		1	2	3	1	NO	2	3	3	3		
						Detail	4		1	2	3	1	NO	2	3	3	3		
						Detail	5		1	2	3	1	NO	2	3	3	3		
						Detail	6	05/05/92(*)	1	2	3	1	NO	2	3	3	3		
						Summary	05/05/92(*)		6	1	2	3	1	NO	2	3	3	3	YES
			02/04/92			Detail	2		1	2	3	1	NO	2	3	3	3		
						Detail	3		1	2	3	1	NO	2	3	3	3		
						Detail	4		1	2	3	1	NO	2	3	3	3		
						Detail	5		1	2	3	1	NO	2	3	3	3		
						Detail	6	05/05/92(*)	1	2	3	1	NO	2	3	3	3		
						Summary	05/05/92(*)		6	1	2	3	1	NO	2	3	3	3	YES
			02/04/92			Detail	2		1	2	3	1	NO	2	3	3	3		
						Detail	3		1	2	3	1	NO	2	3	3	3		
						Detail	4		1	2	3	1	NO	2	3	3	3		
						Detail	5		1	2	3	1	NO	2	3	3	3		
						Detail	6	05/05/92(*)	1	2	3	1	NO	2	3	3	3		
						Summary	05/05/92(*)		6	1	2	3	1	NO	2	3	3	3	YES
			02/04/92			Detail	2		1	2	3	1	NO	2	3	3	3		
						Detail	3		1	2	3	1	NO	2	3	3	3		
						Detail	4		1	2	3	1	NO	2	3	3	3		
						Detail	5		1	2	3	1	NO	2	3	3	3		
						Detail	6	05/05/92(*)	1	2	3	1	NO	2	3	3	3		
						Summary	05/05/92(*)		6	1	2	3	1	NO	2	3	3	3	YES
141	ANG		25/03/92	05/05/92	CONSTIPATION		Detail	27/03/92	1	2	3	1	NO	2	3	3	3		
						Detail	2		1	2	3	1	NO	2	3	3	3		
						Detail	3		1	2	3	1	NO	2	3	3	3		
						Detail	4		1	2	3	1	NO	2	3	3	3		
						Detail	5		1	2	3	1	NO	2	3	3	3		
						Detail	6	05/05/92(*)	1	2	3	1	NO	2	3	3	3		
						Summary	05/05/92(*)		6	1	2	3	1	NO	2	3	3	3	YES
			27/03/92			Detail	1		1	2	3	1	NO	2	3	3	3		
						Detail	2		1	2	3	1	NO	2	3	3	3		
						Detail	3		1	2	3	1	NO	2	3	3	3		
						Detail	4		1	2	3	1	NO	2	3	3	3		
						Detail	5		1	2	3	1	NO	2	3	3	3		
						Detail	6	05/05/92(*)	1	2	3	1	NO	2	3	3	3		
						Summary	05/05/92(*)		6	1	2	3	1	NO	2	3	3	3	YES
			27/03/92			Detail	1		1	2	3	1	NO	2	3	3	3		
						Detail	2		1	2	3	1	NO	2	3	3	3		
						Detail	3		1	2	3	1	NO	2	3	3	3		
						Detail	4		1	2	3	1	NO	2	3	3	3		
						Detail	5		1	2	3	1	NO	2	3	3	3		
						Detail	6	05/05/92(*)	1	2	3	1	NO	2	3	3	3		
						Summary	05/05/92(*)		6	1	2	3	1	NO	2	3	3	3	YES
			27/03/92			Detail	1		1	2	3	1	NO	2	3	3	3		
						Detail	2		1	2	3	1	NO	2	3	3	3		
						Detail	3		1	2	3	1	NO	2	3	3	3		
						Detail	4		1	2	3	1	NO	2	3	3	3		
						Detail	5		1	2	3	1	NO	2	3	3	3		
						Detail	6	05/05/92(*)	1	2	3	1	NO	2	3	3	3		
						Summary	05/05/92(*)		6	1	2	3	1	NO	2	3	3	3	YES

Serivito: 0=unknown, 1= mild, 2= moderate, 3= severe, --- History: 1= present before, 2= not observe bef., 3= unknown
 Study drug: 1= no change, 2= dose reduced, 3= drug withdrawn, 4= temp. inter.
 Hospital: 1= required, 2= not req., 3= not appl. -- Outcome: 1= recovered, 2= rec. with seq., 3= still present, 4= death
 Disapp./Reapp.: 1= no, 2= yes, 3= not appl. -- Relationship: 1= definite, 2= probable, 3= possible, 4= doubtful, 5= unknown, 6= none
 Symptomatic treatment: 0= no, 1= yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CVS RAD

RENORETINE - PROTOCOL 20124/013
Listing No.: 11.0

ADVERSE EVENTS
OPEN PHASE

Cen. Pat. Init.	Start date	End date	Adverse event	Onset date	Type record	Visit No	Hist No	Last report		Rel. drug	Symp. tra	Hosp app.	Dis app.	Re. app.	Out. app.	Open. app.		
								visit rity	ory ship									
1 141 AMG	25/03/92	05/05/92	TREMOR	27/03/92	Summary	6	1	2	3	1	NO	2	3	5	3	3		
						Summary	6	1	2	3	1	NO	2	3	5	3	3	
						Detail 2	1	2	3	1	NO	2	3	5	3	3	3	
						Detail 3	1	2	3	1	NO	2	3	5	3	3	3	3
						Detail 4	1	2	3	1	NO	2	3	5	3	3	3	3
						Detail 5	1	2	3	1	NO	2	3	5	3	3	3	3
143 JEP	25/03/92	05/05/92	EACULATION FAILURE	01/06/92	Summary	2	1	2	3	1	NO	2	3	5	3	3		
						Detail 3	1	2	3	1	NO	2	3	5	3	3	3	
						Detail 4	1	2	3	1	NO	2	3	5	3	3	3	
						Detail 5	1	2	3	1	NO	2	3	5	3	3	3	
						Detail 6	1	2	3	1	NO	2	3	5	3	3	3	
						Summary	6	1	2	3	1	NO	2	3	5	3	3	3
			MICTURITION DISORDER	01/06/92	Summary	2	1	2	3	1	NO	2	3	5	3	3		
						Detail 3	1	2	3	1	NO	2	3	5	3	3		
						Detail 4	1	2	3	1	NO	2	3	5	3	3		
						Detail 5	1	2	3	1	NO	2	3	5	3	3		
						Detail 6	1	2	3	1	NO	2	3	5	3	3		
						Summary	6	1	2	3	1	NO	2	3	5	3	3	
146 LRH	26/03/92	06/05/92	CONSTIPATION	29/03/92	Summary	1	1	2	3	1	NO	2	3	5	3	3		
						Detail 2	1	2	3	1	NO	2	3	5	3	3		
						Detail 3	1	2	3	1	NO	2	3	5	3	3		
						Detail 4	1	2	3	1	NO	2	3	5	3	3		
						Detail 5	1	2	3	1	NO	2	3	5	3	3		
						Summary	6	1	2	3	1	NO	2	3	5	3	3	
			MICTURITION DISORDER	29/03/92	Summary	1	1	2	3	1	NO	2	3	5	3	3		
						Detail 2	1	2	3	1	NO	2	3	5	3	3		
						Detail 3	1	2	3	1	NO	2	3	5	3	3		
						Detail 4	1	2	3	1	NO	2	3	5	3	3		
						Detail 5	1	2	3	1	NO	2	3	5	3	3		
						Summary	6	1	2	3	1	NO	2	3	5	3	3	
			SWEATING INCREASED	29/03/92	Summary	1	1	2	3	1	NO	2	3	5	3	3		
						Detail 2	1	2	3	1	NO	2	3	5	3	3		
						Detail 3	1	2	3	1	NO	2	3	5	3	3		
						Detail 4	1	2	3	1	NO	2	3	5	3	3		
						Detail 5	1	2	3	1	NO	2	3	5	3	3		
						Summary	6	1	2	3	1	NO	2	3	5	3	3	

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=resolved, 2=rec. with seq., 3=still present, 4=death
 Disapp./reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20126/913
 Listing No.: 11.0

ADVERSE EVENTS
 OPEN PHASE

Con. Pat. Init.	Start date	End date	Adverse event	Onset date	Type record	Visit No	End No data	Last report visit	Sev	Hist	Rel	Stud	Symp	Dis hosp	Re app.	Det app.	Open come		
146 LRH	28/03/92	08/05/92	SWEATING INCREASED	29/03/92	Detail	5		1	2	3	1	NO	2	3	3	3			
					Detail	6		1	2	3	1	NO	2	3	3	3			
					Summary	6	08/05/92(*)	6	1	2	3	1	NO	2	3	3	3	3	YES
147 JGH	28/03/92	10/04/92	AGITATION	28/03/92	Detail	1		2	2	3	1	NO	2	3	3	3			
					Detail	2	10/04/92	2	2	3	1	NO	2	2	3	1			
					Summary	2	10/04/92	2	2	2	3	NO	2	2	3	2	3	1	YES
	08/03/92	30/03/92	TREMOR	08/03/92	Detail	1		2	2	3	1	NO	2	3	3	3			
					Summary	1	08/06/92(*)	1	2	3	1	NO	2	3	3	3	NO		
					Detail	2	10/04/92	2	2	2	3	NO	2	2	3	2	3	1	YES
148 CAS	28/03/92	08/05/92	LIBIDO DECREASED	01/04/92	Detail	1		1	2	3	1	NO	2	3	3	3			
					Detail	2		1	2	3	1	NO	2	3	3	3			
					Detail	3		1	2	3	1	NO	2	3	3	3	3		
	08/03/92	07/04/92	NAUSEA	28/03/92	Detail	1		1	2	3	1	NO	2	3	3	3			
					Detail	2	07/04/92	2	1	2	3	1	NO	2	3	3	1	YES	
					Summary	2	07/04/92	2	1	2	3	1	NO	2	3	3	1	YES	
149 SC	28/03/92	08/05/92	CONSTIPATION	01/04/92	Detail	1		1	2	3	1	NO	2	3	3	3			
					Detail	2		1	2	3	1	NO	2	3	3	3			
					Detail	3		1	2	3	1	NO	2	3	3	3	3		
	08/03/92	07/04/92	MOUTH DRY	01/04/92	Detail	1		1	2	3	1	NO	2	3	3	3			
					Detail	2		1	2	3	1	NO	2	3	3	3			
					Detail	3		1	2	3	1	NO	2	3	3	3	3		
	08/03/92	07/04/92	MOUTH DRY	01/04/92	Detail	4		1	2	3	1	NO	2	3	3	3			
					Detail	5		1	2	3	1	NO	2	3	3	3			
					Detail	6		1	2	3	1	NO	2	3	3	3	3		
	08/03/92	07/04/92	MOUTH DRY	01/04/92	Summary	6	08/05/92(*)	6	1	2	3	1	NO	2	3	3	3	3	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

1433

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REMARKS - PROTOCOL 20124/013

Listing No.: 11.0

ADVERSE EVENTS
OPEN PHASE

Cen. Pat.	Init.	Start date	End date	Treatment	Adverse event	Onset date	Type record	Visit No	Last report visit	Sae Hist		Rel. Stud		Sympt	Disapp.	Recovery	Open		
										rft	fty	shp	tr					tr	tr
1	149	SC	26/03/92	08/05/92	MOUTH DRY	01/04/92	4	4	1	2	3	1	NO	2	3	3	3	3	
							5	5	1	2	3	1	NO	2	3	3	3	3	
							6	6	1	2	3	1	NO	2	3	3	3	3	
							Summary		6	1	2	3	1	NO	2	3	3	3	3
							Summary		6	1	2	3	1	NO	2	3	3	3	3
							Summary		6	1	2	3	1	NO	2	3	3	3	3
150	VA	26/03/92	08/05/92	CONSTIPATION	20/04/92	4	4	1	2	3	1	NO	2	3	3	3	3	3	
						5	5	1	2	3	1	NO	2	3	3	3	3		
						6	6	1	2	3	1	NO	2	3	3	3	3		
						Summary		6	1	2	3	1	NO	2	3	3	3	3	
						Summary		6	1	2	3	1	NO	2	3	3	3	3	
						Summary		6	1	2	3	1	NO	2	3	3	3	3	
2	31	IK	16/11/90	06/12/90	CONJUNCTIVITIS	28/03/92	1	1	1	2	3	1	NO	2	3	3	3	3	
							2	2	1	2	3	1	NO	2	3	3	3	3	
							3	3	1	2	3	1	NO	2	3	3	3	3	
							4	4	1	2	3	1	NO	2	3	3	3	3	
							Summary		4	1	2	3	1	NO	2	3	3	3	3
							Summary		4	1	2	3	1	NO	2	3	3	3	3
2	31	IK	16/11/90	06/12/90	CONJUNCTIVITIS	03/12/90	1	1	1	2	3	1	NO	2	3	3	3	3	
							2	2	1	2	3	1	NO	2	3	3	3	3	
							3	3	1	2	3	1	NO	2	3	3	3	3	
							4	4	1	2	3	1	NO	2	3	3	3	3	
							Summary		4	1	2	3	1	NO	2	3	3	3	3
							Summary		4	1	2	3	1	NO	2	3	3	3	3
2	31	IK	16/11/90	06/12/90	CONJUNCTIVITIS	26/11/90	3	3	1	2	3	1	NO	2	3	3	3	3	
							4	4	1	2	3	1	NO	2	3	3	3	3	
							5	5	1	2	3	1	NO	2	3	3	3	3	
							6	6	1	2	3	1	NO	2	3	3	3	3	
							Summary		6	1	2	3	1	NO	2	3	3	3	3
							Summary		6	1	2	3	1	NO	2	3	3	3	3

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=probable, 3=doubtful, 4=unknown, 5=none
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=indefinite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS 98D
 REBORETTINE - PROTOCOL 20126/013
 Listing No.: 11.0

ADVERSE EVENTS
 OPEN PHASE

Con. Pat.	Init.	Start date	End date	Adverse event	Onset date	Type record	Visit No	End No data	Last report visit	Save City	Hist	Rel	Stud	Symp	Dis app.	Re app.	Open	
2	31	10/11/90	06/12/90	VOMITING	22/11/90	Detail	2	23/11/90	2	2	2	3	1	NO	2	3	3	1
						Summary	23/11/90	2	2	2	3	1	NO	2	3	3	1	YES
3	2	17/11/90	28/12/90	INSOMNIA	07/12/90	Detail	3	10/12/90	3	1	1	5	1	YES	2	3	3	1
						Summary	10/12/90	3	1	1	5	1	YES	2	3	3	1	YES
				NEUROUSNESS	18/11/90	Detail	1	21/11/90	1	2	1	4	1	YES	3	3	3	1
						Summary	21/11/90	1	2	1	4	1	YES	3	3	3	1	NO
3	DUB	03/04/91	14/05/91	NEUROUSNESS	15/04/91	Detail	3	25/04/91	4	2	2	3	1	NO	3	3	3	3
						Summary	25/04/91	4	2	2	3	1	NO	3	3	3	1	YES
4	AUD	08/12/90	15/01/91	AGITATION	09/12/90	Detail	0	13/12/90	0	1	2	3	1	NO	2	2	2	1
						Summary	13/12/90	0	1	2	3	1	NO	2	2	2	1	YES
				TACHYCARDIA	02/01/91	Detail	4	02/01/91	4	1	2	3	2	NO	2	2	2	5
						Summary	02/01/91	4	1	2	3	2	NO	2	2	2	5	1
				TREMOR	22/12/90	Detail	3	08/01/91	4	1	2	3	1	NO	2	2	2	3
						Summary	08/01/91	4	1	2	3	2	NO	2	2	2	3	1
5	MVA	26/12/90	24/01/91	ANXIETY	28/01/91	Detail	5	25/01/91	5	3	1	3	3	NO	2	2	2	3
						Summary	25/01/91	5	3	1	3	3	NO	2	2	2	3	1
				HYPERTENSION	10/01/91	Detail	3	15/01/91	3	3	2	5	4	NO	2	2	2	1
						Summary	15/01/91	3	3	2	5	4	NO	2	2	2	1	1
				TACHYCARDIA	10/01/91	Detail	3	15/01/91	3	3	2	4	4	NO	2	2	2	1
						Summary	15/01/91	3	3	2	4	4	NO	2	2	2	1	1

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REDOPTING - PROTOCOL 20124/013

Listing No.: 11.0

ADVERSE EVENTS
OPEN PHASE

Den. Pat.	Init.	Start date	End date	Adverse event	Onset data	Type record	Visit End No date	Last report visit	Sev	Mist	Rel	Stud	Symp	Dis	Re	Out	Open	
								visit	city	ory	ship	drug	trta	hoosp	app.	come	(c)	
3	5	MMA	24/12/90	24/01/91 TACHYCARDIA	18/01/91	Detail	4	1	2	1	4	NO	2	2	2	3		
						Detail	5	1	2	3	NO	2	2	3				
						Summary	24/01/91(*)	5	1	2	1	3	NO	2	2	3	3	YES
6	AJP	20/12/90	24/12/90 FATIGUE	21/12/90	Detail	1	24/12/90	1	3	2	1	3	NO	2	2	3	1	YES
					Summary	24/12/90	1	3	2	1	3	NO	2	2	3	1	YES	
				21/12/90	Detail	1	24/12/90	3	2	3	3	NO	2	2	3	1	YES	
				Summary	24/12/90	1	3	2	3	3	NO	2	2	3	1	YES		
7	GRI	11/12/90	22/01/91 MOUTH DRY	21/12/90	Detail	1	24/12/90	1	3	2	1	3	NO	2	2	3	1	YES
					Summary	24/12/90	1	3	2	1	3	NO	2	2	3	1	YES	
				12/12/90	Detail	0	16/12/90	1	2	2	1	NO	3	3	1	YES		
				Summary	16/12/90	0	1	2	2	1	NO	3	3	1	YES			
9	DEN	19/01/91	05/02/91 DIZZINESS	05/01/91	Detail	4	15/01/91	4	1	2	3	1	NO	2	3	3	1	YES
					Summary	15/01/91	4	1	2	3	1	NO	2	3	3	1	YES	
				15/01/91	Detail	6	22/01/91	1	2	2	1	NO	2	3	3	1	YES	
				Summary	22/01/91	6	1	2	2	1	NO	2	3	3	1	YES		
9	DEN	19/01/91	05/02/91 DIZZINESS	27/12/90	Detail	3	15/01/91	4	2	2	3	1	NO	2	3	3	1	YES
					Summary	15/01/91	4	2	2	3	2	NO	2	2	3	1	YES	
				18/01/91	Detail	6	22/01/91	1	2	2	1	NO	2	3	3	1	YES	
				Summary	22/01/91	6	1	2	2	1	NO	2	3	3	1	YES		
9	DEN	19/01/91	05/02/91 DIZZINESS	17/12/90	Detail	0	17/12/90	0	1	2	3	NO	1	3	1	1	YES	
					Summary	17/12/90	0	1	2	3	NO	1	3	1	1	YES		
				18/01/91	Detail	1	25/01/91	2	2	3	1	NO	2	3	3	1	NO	
				Summary	25/01/91	1	2	2	3	1	NO	2	3	3	1	NO		

Severity: 0=unknown, 1= mild, 2= moderate, 3= severe, --- History: 1= present before, 2= not observe bef., 3= unknown
 Study drug: 1= no change, 2= dose reduced, 3= stop, 4= withdraw, 5= temp. inter.
 Hospital: 1= treated, 2= not treated, 3= not treated, 4= not treated, 5= not treated, 6= not treated, 7= not treated, 8= not treated
 Disapp./Keapp.: 1= no, 2= yes, 3= not appl. -- Relationship: 1= definite, 2= probable, 3= possible, 4= doubtful, 5= unknown, 6= none
 Symptomatic treatment: 0= no, 1= yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA DNS RED
 REDNETLINE - PROTOCOL 20124/013
 Listing No.: 11.0
 ADVERSE EVENTS
 OPEN PHASE

Can. Pat.	Int.	Start date	End date	Treatment	Onset date	Type record	Visit No	Visit End No date	Last report visit	Spa rly	Hist ory	Rel ship	Stu d	Sym p	Dis Resp app.	Re app. com	Out	Open	
3	9	DEN	19/01/91	05/02/91	DYSURIA	18/01/91	Detail	1 25/01/91	1 25/01/91	1	2	2	3	1	NO	2	3	3	1
						Summary		25/01/91		1	2	2	3	1	NO	2	3	3	1
					MUSCLE CONTRACTIONS INVOLUNTARY	22/01/91	Detail	1 25/01/91	1 25/01/91	1	2	2	3	1	NO	2	3	3	1
						Summary		25/01/91		1	2	2	3	1	NO	2	3	3	1
					TACHYCARDIA	18/01/91	Detail	2		1	1	4	1	NO	2	3	3	3	
						Detail	3		3	2	2	3	NO	2	1	3	3		
						Summary		05/02/91(*)		3	3	1	2	3	NO	2	1	3	3
10	TOR		11/04/91	22/05/91	BACK PAIN	15/04/91	Detail	1 15/05/91	1 15/05/91	1	2	3	5	1	YES	2	3	3	1
						Summary		15/05/91		1	2	3	5	1	YES	2	3	3	1
					CONSTIPATION	12/04/91	Detail	1		2	3	3	1	NO	2	3	3	3	
						Detail	2		2	3	3	1	NO	2	3	3	3		
						Detail	3		2	3	3	1	NO	2	3	3	3		
						Detail	4		2	3	3	1	NO	2	3	3	3		
						Detail	5		1	3	3	1	NO	2	3	3	3		
						Detail	6		1	3	3	1	NO	2	3	3	3		
						Summary		22/05/91(*)		6	2	3	3	1	NO	2	3	3	3
					MOUTH DRY	14/04/91	Detail	1		2	1	3	1	NO	2	3	3	3	
						Detail	2		2	1	3	1	NO	2	3	3	3		
						Detail	3		2	1	3	1	NO	2	3	3	3		
						Detail	4		2	1	3	1	NO	2	3	3	3		
						Detail	5		2	1	3	1	NO	2	3	3	3		
						Detail	6		1	1	3	1	NO	2	3	3	3		
						Summary		22/05/91(*)		6	2	1	3	1	NO	2	3	3	3
					TACHYCARDIA	04/05/91	Detail	4		2	2	3	1	NO	2	3	3	3	
						Detail	5		1	2	3	1	NO	2	3	3	3		
						Detail	6		2	2	3	1	YES	2	3	3	3		
						Summary		22/05/91(*)		6	2	2	3	1	YES	2	3	3	3
11	PIE		25/05/91	27/05/91	CONVULSIONS	27/05/91	Detail	1 27/05/91		3	2	5	3	NO	2	3	3	1	

Severity: unknown, mild, moderate, severe, --- History: present before, 2=not observe bef., 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
 Hospital: 1=requirg, 2=not req., 3=not appl. --- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. --- Relationship: 1=definite, 2=probable, 3=possible, 4= doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (*) adverse event used for statistical analysis
 (**) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CIS R&D
 REBROKETINE - PROTOCOL 20124/013
 Listing No.: 11.0

ADVERSE EVENTS
 OPEN PHASE

Cen. Pat.	Init.	Start date	End date	Adverse event	Treatment	Onset date	Type record	Visit No	End No date	Last report visit	Save rity	Hist ory	Rel drug	Stu app.	Symp app.	Dis app.	Re app.	Out app.	Open app.	
																				27/05/91
3	11	PIE	25/05/91	27/05/91	CONVULSIONS															
9	10	86	11/01/91	21/02/91	MOUTH DRY															
						12/01/91	Detail 1	1	2	2	3	1	NO	2	3	3				
						20/01/91	Detail 2	2	2	2	3	1	NO	2	3	3				
						20/01/91	Summary	2	2	2	3	1	NO	2	3	3				
10	1	VK	16/10/90	26/11/90	LACRIMAL GLAND DISORDER															
						21/10/90	Detail 1	1	3	1	6	1	NO	2	3	3				
						31/10/90	Detail 2	2	1	6	1	YES	2	3	3					
						31/10/90	Detail 3	3	1	6	1	NO	2	3	3					
						31/10/90	Summary	3	3	1	6	1	YES	2	3	2				
						16/10/90	Detail 1	1	3	1	5	1	NO	2	3	3				
						16/10/90	Detail 2	2	1	5	1	NO	2	3	3					
						16/10/90	Detail 3	3	2	1	5	1	NO	2	3	3				
						16/10/90	Detail 4	4	1	5	1	NO	2	3	3					
						16/10/90	Detail 5	5	1	5	1	NO	2	3	3					
						16/10/90	Summary	4	3	1	5	1	NO	2	3	3				
						21/10/90	Detail 1	1	1	3	1	NO	2	3	3					
						21/10/90	Detail 2	2	1	3	1	NO	2	3	3					
						21/10/90	Detail 3	3	1	3	1	NO	2	3	3					
						21/10/90	Detail 4	4	1	3	1	NO	2	3	3					
						21/10/90	Detail 5	5	1	3	1	NO	2	3	3					
						21/10/90	Summary	4	1	3	1	NO	2	3	3					
5	AN		14/11/90	26/12/90	MICTURITION DISORDER															
						92/12/90	Detail 3	3	1	3	1	NO	2	3	3					
						92/12/90	Detail 4	4	2	1	3	1	NO	2	3	3				
						92/12/90	Detail 5	5	1	3	1	NO	2	3	3					
						92/12/90	Summary	5	3	1	3	1	NO	2	3	3				
6	RS		16/11/90	15/12/90	CONSTIPATION															
						16/11/90	Detail 1	1	2	2	3	1	NO	2	3	3				
						16/11/90	Detail 2	2	1	2	3	1	NO	2	3	3				
						16/11/90	Detail 3	3	2	2	3	1	NO	2	3	3				
						16/11/90	Summary	3	2	2	3	1	NO	2	3	3				
						08/12/90	Detail 4	4	2	2	3	1	NO	2	3	3				
						08/12/90	Detail 5	5	2	2	3	1	NO	2	3	3				
						08/12/90	Summary	5	3	2	2	3	NO	2	2	3				

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=def. withdraw, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOETINE - PROTOCOL 20124/913
 Listing No.: 11.0

ADVERSE EVENTS
 OPEN PHASE

10	6	RS	16/11/90	16/12/90	MICTURITION DISORDER	Onset date	Type record	Visit No	End date	Last report visit	Sev	Hist	Rel	Stud	Symp	Dis	Rt	Out	Open			
			Treatment	Start date	End date	Adverse event	record	No	No date	city	city	city	city	city	city	city	city	city	city	city		
			16/11/90	16/11/90		16/11/90	Detail	1			1	2	3	1	NO	2	3	3	3	3		
							Detail	2	26/11/90		1	2	3	1	NO	2	3	3	3	3		
							Summary		26/11/90	2	1	2	3	1	NO	2	3	3	3	1	YES	
			15/12/90	15/12/90		15/12/90	Detail	5	17/12/90		1	2	2	3	NO	2	2	3	3	1		
							Summary		17/12/90	5	1	2	2	3	NO	2	2	3	3	1	YES	
			16/11/90	16/11/90		16/11/90	Detail	1			3	1	3	1	NO	2	3	3	3	3		
							Detail	2			2	1	3	1	NO	2	3	3	3	3		
							Detail	3			1	1	3	1	NO	2	3	3	3	3		
							Detail	4			1	1	3	1	NO	2	3	3	3	3		
							Summary		16/12/90(e)	4	3	1	3	1	NO	2	3	3	3	3	YES	
			19/11/90	19/11/90		19/11/90	Detail	5	19/12/90(e)		5	1	1	3	NO	2	1	3	3	3	YES	
							Summary		19/12/90(e)	5	1	1	3	3	NO	2	1	3	3	3	YES	
			20/11/90	20/11/90		20/11/90	Detail	1			1	2	3	1	NO	2	3	3	3	3		
							Detail	2			1	2	3	1	NO	2	3	3	3	3		
							Detail	3			1	2	3	1	NO	2	3	3	3	3		
							Detail	4	16/12/90		1	2	3	1	NO	2	3	3	3	3		
							Summary		16/12/90	4	1	2	3	1	NO	2	3	3	3	3	1	YES
			20/12/90	20/12/90		20/12/90	Detail	5			1	2	3	1	NO	2	3	3	3	3		
							Detail	6			1	2	3	1	NO	2	3	3	3	3		
							Summary		02/01/91(*)	6	1	2	3	1	NO	2	3	3	3	3	YES	
			20/11/90	20/11/90		20/11/90	Detail	1			1	1	3	1	NO	2	3	3	3	3		
							Detail	2			1	2	3	1	NO	2	3	3	3	3		
							Detail	3			1	2	3	1	NO	2	3	3	3	3		
							Detail	4	16/12/90		1	2	3	1	NO	2	3	3	3	3		
							Summary		16/12/90	4	1	2	3	1	NO	2	3	3	3	3	1	YES
			20/12/90	20/12/90		20/12/90	Detail	5			1	2	3	1	NO	2	3	3	3	3		
							Detail	6			1	2	3	1	NO	2	3	3	3	3		
							Summary		02/01/91(*)	6	1	2	3	1	NO	2	3	3	3	3	YES	
			27/11/90	27/11/90		27/11/90	Detail	1			1	1	3	1	NO	2	3	3	3	3		
							Detail	2			1	1	3	1	NO	2	3	3	3	3		
							Detail	3			1	1	3	1	NO	2	3	3	3	3		
							Detail	4	09/12/90		1	1	3	1	NO	2	3	3	3	3		
							Summary		09/12/90	3	1	1	3	1	NO	2	3	3	3	3	1	YES
			27/11/90	27/11/90		27/11/90	Detail	1			2	2	4	1	NO	2	3	3	3	3		
							Summary		30/11/90	1	2	2	4	1	NO	2	3	3	3	3	1	YES
			20/12/90	20/12/90		20/12/90	Detail	3			3	1	4	1	YES	2	3	3	3	3		
							Summary		21/12/90	3	3	1	4	1	YES	2	3	3	3	3	1	YES
			04/12/90	04/12/90		04/12/90	Detail	1			1	1	4	1	NO	2	3	3	3	3		
							Summary		04/12/90	1	1	1	4	1	NO	2	3	3	3	3	1	YES

Severities: 0=unknown, 1=mild, 2=moderate, 3=severe,
 Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (e) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CIS R&D
RESOMETIME - PROTOCOL 20124/913
Listing No.: 11.0

ADVERSE EVENTS
OPEN PHASE

Con. Pat.	Init.	Start date	End date	Adverse event	Treatment	Onset date	Type record	Visit No	End date	Last report visit	Save rity	Hist ary	Rea	Stu	Symp	Dis app.	Re app.	Out app.	Open come (c)	
10	10	04/12/90	14/01/91	VAGINITIS		11/12/90	Detail Summary	2 16	16/12/90	2 2	1 1	6 6	1 1	NO NO	2 2	3 3	3 3	1 1	YES	
11	11	27/12/90	15/01/91	CONSTIPATION		29/12/90	Detail Detail Summary	1 2 3	07/01/91	1 2 2	1 2 3	1 3 1	NO NO NO	2 2 2	3 3 3	3 3 3	1 1 1	YES		
13	13	12/02/91	25/03/91	CONSTIPATION		28/12/90	Detail Summary	1 1	01/01/91	1 1	1 1	3 3	1 1	NO NO	2 2	3 3	3 3	1 1	YES	
				SWEATING INCREASED		01/01/91	Summary	1	01/01/91	1	1	3	1	NO	2	3	3	1	YES	
				SWEATING INCREASED		13/02/91	Detail Detail Detail Detail Detail Detail Summary	1 2 3 4 5 6	25/03/91	1 1 1 1 1 6	1 1 1 1 1 1	3 3 3 3 3 3	1 1 1 1 1 1	NO NO NO NO NO NO	2 2 2 2 2 2	3 3 3 3 3 3	3 3 3 3 3 3	5 5 5 5 5 5	YES	
				OVARIAN DISORDER		21/02/91	Detail Detail Summary	2 3	04/03/91	2 2	1 1	4 4	1 1	YES YES	2 2	3 3	3 3	1 1	YES	
				RHINITIS		15/02/91	Detail Detail Detail Detail Detail Detail Summary	1 2 3 4 5 6	24/03/91	1 1 1 1 1 6	1 1 1 1 1 1	4 4 4 4 4 4	1 1 1 1 1 1	NO NO NO NO NO NO	2 2 2 2 2 2	3 3 3 3 3 3	3 3 3 3 3 3	5 5 5 5 5 5	YES	
				SWEATING INCREASED		15/02/91	Detail Detail Detail Detail	1 2 3 4	15/02/91	1 1 1 2	1 1 1 3	1 1 1 1	3 3 3 3	1 1 1 1	NO NO NO NO	2 2 2 2	3 3 3 3	3 3 3 3	5 5 5 5	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl.
Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
Symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis

-- History: 1=represent before, 2=not observe bef., 3=unknown
-- Outcome: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA DNS R0D
 REBOOTIME - PROTOCOL 20126/013
 Listing No.: 11.0

ADVERSE EVENTS
 DFEN PHASE

Con. Pat.	Init.	Start date	End date	Adverse event	Treatment	Onset date	Type record	Visit No	Last report visit	See r.f.vy	Hist opy	Rel. drug	Stud. treat	Samp. app.	Dis. app.	Re. app.	Out. app.	Open. app.	C (c)
10	L3	12/02/91	25/03/91	SWEATING INCREASED		15/02/91	Detail	5	1	1	3	1	NO	2	3	3	3		
								6	1	1	3	1	NO	2	3	3	3		
								Summary	6	2	1	3	1	NO	2	3	3	3	YES
14	AA	12/02/91	25/03/91	INSOMNIA		12/02/91	Detail	5	2	1	3	1	NO	2	3	3	1		
								6	2	1	3	1	NO	2	3	3	1		
								Summary	5	2	1	3	1	NO	2	3	3	1	YES
15	HT	21/02/91	03/04/91	MICTURITION DISORDER		03/02/91	Detail	2	1	1	3	1	NO	2	3	3	3		
								3	1	1	3	1	NO	2	3	3	3		
								4	1	1	3	1	NO	2	3	3	3		
								5	1	1	3	1	NO	2	3	3	3		
								6	1	1	3	1	NO	2	3	3	3		
								Summary	5	1	1	3	1	NO	2	3	3	1	YES
19/03/91	Detail	4	2	2	6	1	YES	2	3	3	3								
		5	2	2	6	1	YES	2	3	3	2								
		Summary	5	2	2	6	1	YES	2	3	3	2	YES						
16/03/91	Detail	6	06/06/91	2	1	3	1	YES	2	3	3	1							
		7	06/06/91	2	1	3	1	YES	2	3	3	1							
		Summary	6	2	1	3	1	YES	2	3	3	1	YES						
01/03/91	Detail	2	2	1	3	1	NO	2	3	3	3								
		3	1	1	3	1	NO	2	3	3	3								
		4	1	1	3	1	NO	2	3	3	3								
		5	1	1	3	1	NO	2	3	3	3								
		6	28/03/91	1	1	3	1	NO	2	3	3	1							
		Summary	6	2	1	3	1	NO	2	3	3	1	YES						

Severity: 1=unknown, 2=mild, 3=moderate, 4=severe, 5=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req, 3=not appl.
 Disapp./Resp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis

1 1 1 1

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA ONS RBD

REDBUXTINE - PROTOCOL 2012/013
Listing No.: 11.0

ADVERSE EVENTS
OPEN PHASE

Cen. Pat.	Init.	Start date	End date	Adverse event	Onset date	Type record	Visit No	End date	Last visit	report rfty	Save rfty	Hist rfy	Rel rfy	Stud rfy	Sympt rfy	Dis app.	Re app.	Out app.	Open app.
10	16	AJ	06/03/91	15/06/91	CONSTIPATION	Detail 1	1	15/06/91	1	1	2	3	1	NO	2	3	3	3	3
						Detail 2	2		1	2	3	1	NO	2	3	3	3	3	3
						Detail 3	3		1	1	3	1	NO	2	3	3	3	3	3
						Detail 4	4		1	1	3	1	NO	2	3	3	3	3	3
						Detail 5	5	06/06/91	1	1	3	1	NO	2	3	3	3	3	3
						Summary	5	06/06/91	5	1	1	3	1	NO	2	3	3	3	3
						Detail 6	6	06/06/91	6	1	1	3	1	NO	2	3	3	3	3
						Summary	6	16/06/91(e)	6	1	1	5	1	NO	2	3	3	3	3
						Detail 1	1	09/03/91	1	1	2	3	1	NO	2	3	3	3	3
						Detail 2	2	09/03/91	2	1	2	3	1	NO	2	3	3	3	3
						Detail 3	3	09/03/91	3	1	2	3	1	NO	2	3	3	3	3
						Detail 4	4	09/03/91	4	1	2	3	1	NO	2	3	3	3	3
						Detail 5	5	09/03/91	5	1	2	3	1	NO	2	3	3	3	3
						Detail 6	6	09/03/91	6	1	2	3	1	NO	2	3	3	3	3
						Summary	6	16/06/91(e)	6	1	2	3	1	NO	2	3	3	3	3
						Detail 1	1	05/03/91	1	1	1	3	1	NO	2	3	3	3	3
						Detail 2	2	05/03/91	2	1	1	3	1	NO	2	3	3	3	3
						Detail 3	3	05/03/91	3	1	1	3	1	NO	2	3	3	3	3
						Detail 4	4	05/03/91	4	1	1	3	1	NO	2	3	3	3	3
						Detail 5	5	05/03/91	5	1	1	3	1	NO	2	3	3	3	3
						Detail 6	6	05/03/91	6	1	1	3	1	NO	2	3	3	3	3
						Summary	6	05/03/91	6	1	1	3	1	NO	2	3	3	3	3
						Detail 1	1	18/03/91	1	1	1	3	1	NO	2	3	3	3	3
						Detail 2	2	18/03/91	2	1	1	3	1	NO	2	3	3	3	3
						Summary	3	31/03/91	3	2	1	1	3	1	NO	2	3	3	3
						Detail 3	3	08/04/91	3	1	2	4	1	YES	2	3	3	3	3
						Detail 4	4	12/04/91	4	2	2	6	1	NO	2	3	3	3	3
						Detail 5	5	12/04/91	5	4	2	4	1	YES	2	3	3	3	3
						Summary	5	12/04/91	5	4	2	4	1	YES	2	3	3	3	3
						Detail 6	6	29/04/91	6	2	4	1	YES	2	3	3	3	3	3
						Summary	6	29/04/91	6	2	4	1	YES	2	3	3	3	3	3

Severity: 0=unknown, 1= mild, 2= moderate, 3= severe, 4= life threatening, 5= death
 Study drug: 1= no change, 2= dose reduced, 3= def. withdrawn, 4= temp. inter.
 Hospital: 1= required, 2= not req., 3= not appl.
 Disapp./Reapp.: 1= no, 2= yes, 3= not appl.
 Symptomatic treatment: 0= no, 1= yes
 (c) adverse event used for statistical analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOSETINE - PROTOCOL 20124/913
 Listing No. 11.9

ADVERSE EVENTS
 OPEN PHASE

Can. Pat. Inlt.	Start date	End date	Adverse event	Treatment	Onset date	Type record	Visit No	Report	Save	Hist	Rat	Stud	Symp	Dis	Re	Out	Open	
								visit	freq	dry	ship	drug	tra	hosp	app.	app.	coms (c)	
10	18/03/91	29/04/91	RASH		22/03/91	Detail	1	25/03/91	1	1	2	4	1	NO	2	3	3	1
					Summary	25/03/91	1	1	2	4	1	NO	2	3	3	1	YES	
19	02/04/91	14/05/91	CONSTIPATION		18/03/91	Detail	1		1	2	3	1	NO	2	3	3	3	
					Detail	20/03/91	1	2	3	1	NO	2	3	3	1			
					Summary	20/03/91	2	1	2	3	1	NO	2	3	3	1	YES	
					Detail	2	19/04/91	1	1	3	1	NO	2	3	3	3		
Summary	19/04/91	3	1	1	3	1	NO	2	3	5	1	YES						
20	05/04/91		SWEATING INCREASED		05/04/91	Detail	1		1	2	3	1	NO	2	3	3	3	
					Detail	12/04/91	1	2	3	1	NO	2	3	3	1			
					Summary	12/04/91	2	1	2	3	1	NO	2	5	5	1	YES	
					Detail	2	05/05/91	3	1	3	1	NO	2	3	3	3		
Summary	05/05/91	4	1	1	3	1	NO	2	3	5	1	YES						
21	29/04/91	10/06/91	CONSTIPATION		05/05/91	Detail	2		3	1	3	1	NO	2	3	3	3	
					Detail	3	1	1	3	1	NO	1	3	3	3			
					Detail	4	18/05/91	1	1	3	1	NO	2	3	3	1		
					Summary	18/05/91	4	3	1	3	1	NO	1	3	3	1	YES	
22	23/04/91	11/06/91	CONSTIPATION		23/04/91	Detail	1	27/04/91	1	1	1	3	1	NO	2	3	3	1
					Summary	27/04/91	1	1	1	3	1	NO	2	3	3	1	YES	
					Detail	5	31/05/91	2	1	3	1	NO	2	3	3	3		
					Summary	10/06/91**	6	2	1	3	1	NO	2	3	3	3	YES	
24	01/05/91	11/06/91	FURUNCULOSIS		27/04/91	Detail	1	28/04/91	1	1	2	3	1	NO	2	3	3	1
					Summary	28/04/91	1	1	2	3	1	NO	2	3	3	1	YES	
					Detail	1	07/05/91	1	2	3	1	NO	2	3	3	1		
					Summary	07/05/91	1	1	2	3	1	NO	2	3	3	1	YES	

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (d) adverse event still present; end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA DNS R&D
 REPROMETINE - PROTOCOL 20126/013
 Listing No.: 11.0

ADVERSE EVENTS
 OPEN PHASE

Can. Pat. No.	Pat. Init.	Start date	Treatment	End date	Adverse event	Onset date	Type record	Visit No	Last report visit	Saw rcty	Hist rcty	Rel rcty	Rat rcty	Stud rcty	Syp rcty	Dis Hosp app.	Re app.	Out app.	Open come (c)	
																				report
19	24	01/05/91	11/06/91		PARAESTHESIA	15/05/91	Detail	3	21/05/91	1	1	3	1	NO	2	3	3	1		
								Summary	21/05/91	3	1	1	3	1	NO	2	3	3	1	YES
								Summary	03/06/91	5	1	1	3	1	NO	2	3	3	1	YES
25	ES	16/05/91	03/06/91	MICTURITION DISORDER	21/05/91	Detail	2		2	2	3	1	NO	2	3	3	3			
							Detail	3	03/06/91(*)	1	2	3	1	NO	1	3	3	3		
							Summary	03/06/91(*)	3	2	2	3	1	NO	1	3	3	3	YES	
26	JIF	28/05/91	08/07/91	PARAESTHESIA	29/05/91	Detail	1		1	2	3	1	NO	2	3	3	3			
							Detail	2		1	2	3	1	NO	2	3	3	3		
							Summary	11/06/91	5	1	2	5	1	NO	2	3	3	1	YES	
27	WK	03/06/91	16/07/91	INSOMNIA	10/06/91	Detail	2	17/06/91	2	2	1	4	1	YES	2	3	3	2		
							Summary	17/06/91	2	2	1	4	1	YES	2	3	3	2	YES	
							Summary	05/06/91	1	1	2	5	1	NO	2	3	3	1	YES	
28	LL	30/05/91	10/07/91	OEDEMA PERIPHERAL	05/06/91	Detail	1	05/06/91	1	2	3	1	NO	2	3	3	1			
							Summary	05/06/91	1	2	3	1	NO	2	3	3	1	YES		
							Summary	02/07/91	5	1	2	4	1	NO	2	3	3	1	YES	
29	JJ	19/08/91	29/09/91	INSOMNIA	24/06/91	Detail	4		1	2	4	1	NO	2	3	3	3			
							Detail	5	02/07/91	1	2	4	1	NO	2	3	3	1		
							Summary	02/07/91	5	1	2	4	1	NO	2	3	3	1	YES	
31	RK	16/09/91	27/10/91	CONSTIPATION	24/06/91	Detail	4		1	2	3	1	NO	2	3	3	3			
							Detail	5	28/06/91	1	2	3	1	NO	2	3	3	1		
							Summary	28/06/91	5	1	2	3	1	NO	2	3	3	1	YES	
29	JJ	19/08/91	29/09/91	INSOMNIA	24/06/91	Detail	3	06/09/91	1	1	4	1	YES	2	3	3	2			
							Summary	06/09/91	3	1	1	4	1	YES	2	3	3	2	YES	
							Summary	22/10/91	6	1	1	3	1	NO	2	3	3	3		

Specificity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req, 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS 3820
REBOMETINE - PROTOCOL 20126/913
Listing No.: 11.0
ADVERSE EVENTS
OPEN PHASE

Con. Pat.	Int.	Start date	End date	Adverse event	Treatment	Onset date	Type record	Visit No	End No date	Last report visit	Sev	Hist	Rel	Stu	Symp	Dis app.	Re app.	Out	Open			
10	51	16/09/91	27/10/91	CONSTIPATION		22/10/91	Summary		28/10/91 (*)	6	1	1	1	3	1	NO	2	5	5	5	YES	
							Detail	1														
37	HK	14/10/91	24/11/91	SWEATING INCREASED		14/10/91	Detail		25/10/91	1	2	3	1	NO	2	3	3	3	3	3	3	
							Summary		25/10/91	2	1	1	3	1	NO	2	3	3	3	3	3	1
38	LL	14/10/91	24/11/91	SWEATING INCREASED		14/10/91	Detail		16/10/91	2	2	2	2	NO	2	2	2	2	2	2	2	1
							Summary		16/10/91	1	2	2	2	NO	2	2	2	2	2	2	2	1
							Detail	5	17/11/91	1	2	4	1	NO	2	3	3	3	3	3	3	1
							Summary		17/11/91	5	1	2	4	1	NO	2	3	3	3	3	3	1
39	VH	15/10/91	25/11/91	CONSTIPATION		22/10/91	Detail		28/10/91	2	1	3	1	NO	2	3	3	3	3	3	3	1
							Summary		28/10/91	2	1	3	1	NO	2	3	3	3	3	3	3	1
							Detail	5		1	1	4	1	NO	2	3	3	3	3	3	3	1
							Summary		22/11/91	6	1	1	4	1	NO	2	3	3	3	3	3	1
							Detail	1	15/10/91	1	1	3	1	NO	2	3	3	3	3	3	3	1
							Summary		15/10/91	1	1	3	1	NO	2	3	3	3	3	3	3	1
							Detail	1	17/10/91	1	1	2	3	1	NO	2	3	3	3	3	3	1
							Summary		17/10/91	1	1	2	3	1	NO	2	3	3	3	3	3	1
40	AP	26/10/91	06/12/91	CONSTIPATION		25/10/91	Detail		10/11/91	3	1	1	3	1	NO	2	3	3	3	3	3	1
							Summary		10/11/91	3	1	1	3	1	NO	2	3	3	3	3	3	1
							Detail	1		1	1	3	1	NO	2	3	3	3	3	3	3	1
							Summary		10/11/91	3	1	1	3	1	NO	2	3	3	3	3	3	1
							Detail	1	26/10/91	1	2	3	1	NO	2	3	3	3	3	3	3	1
							Summary		15/11/91	4	1	2	3	1	NO	2	3	3	3	3	3	1

1445

Severity: 5=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=sever, withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req, 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA ONS RSD

REBOWETINE - PROTOCOL 20124/013
Listing No.: 11.0

ADVERSE EVENTS
OPEN PHASE

Con. Pat.	Init.	Start date	End date	Adverse event	Onset date	Type record	Visit No	End No date	Last report		Rel	Stud	Sym	Dis	Re	Out	Open		
									visit rity	ory ship drug tras Hosp									
10	60	26/10/91	06/12/91	RASH	22/11/91	Detail	5	1	2	3	1	NO	2	3	3	3			
							Detail	6	02/12/91	1	2	3	1	NO	2	3	3	1	
							Summary	02/12/91	6	1	2	3	1	NO	2	3	3	1	YES
41	VP	30/10/91	10/12/91	MOUTH DRY	09/11/91	Detail	3	12/11/91	1	6	1	NO	2	3	3	1			
							Summary	12/11/91	3	1	6	1	NO	2	3	3	1	YES	
							Detail	1	1	2	3	1	NO	2	3	3	3		
43	IK	15/11/91	26/12/91	ALBUMINURIA	26/12/91	Detail	6	26/12/91(4)	3	1	4	1	NO	2	3	3			
							Summary	26/12/91(4)	6	3	1	4	1	NO	2	3	3	YES	
							Detail	1	2	2	3	1	NO	2	3	3	3		
46	AB	18/11/91	25/12/91	TACHYCARDIA	17/11/91	Detail	2	2	2	3	1	NO	2	3	3	3			
							Summary	12/12/91	4	2	2	3	1	NO	2	3	3	1	YES
							Detail	1	2	3	1	NO	2	3	3	3			
48	TN	05/12/91	13/01/92	MOUTH DRY	05/12/91	Detail	1	2	2	3	1	NO	2	3	3	3			
							Summary	29/12/91(4)	6	1	2	3	1	NO	2	3	3	3	YES
							Detail	1	2	2	3	1	NO	2	3	3	3		

Severity: 0=unknown, 1= mild, 2= moderate, 3= severe, 4= life threatening
Study drug: 1= no change, 2= dose reduced, 3= def. withdrawn, 4= temp. inter.
Hospital: 1= required, 2= not req., 3= not appl.
Disapp./reapp.: 1= no, 2= yes, 3= not appl.
Symptomatic treatment: 0= no, 1= yes
(C) adverse event used for statistical analysis

-- History: 1= present before, 2= not observe bef., 3= unknown
-- Outcome: 1= recovered, 2= rec. with seq., 3= still present, 4= death
-- Relationship: 1= definite, 2= probable, 3= possible, 4= doubtful, 5= unknown, 6= none

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS 88D
 REMODETINE - PROTOCOL 20126/013
 Listing No.: 11.0

ADVERSE EVENTS
 OPEN PHASE

Can. Pac. Inlt.	Start date	Treatment	End date	Adverse event	Onset date	Type record	Visit No	Last report visit	Save Hist	Rel Ship	Rat	Stud Sym	Dis	Rt	Out	Open			
																	visit rcty	dry	ship
10	05/12/91	15/01/92	MOUTH DRY		05/12/91	Detail	5	2	2	5	1	NO	2	3	3	3			
							6	1	2	3	1	NO	2	3	3	3			
							Summary	13/01/92(*)	6	2	2	3	1	NO	1	3	3	3	YES
							Detail	1	2	3	1	NO	2	3	3	3			
							Detail	2	1	2	3	1	NO	2	3	3	3		
							Detail	3	2	3	1	NO	2	3	3	3	3		
47	05/12/91	15/01/92	MOUTH DRY		05/12/91	Detail	4	2	2	3	1	NO	2	3	3	3			
							5	1	2	3	1	NO	2	3	3	3			
							Summary	05/01/92	5	2	2	3	1	NO	2	3	3	1	
							Detail	1	2	3	1	NO	2	3	3	3			
							Detail	2	1	2	3	1	NO	2	3	3	3		
							Detail	3	2	3	1	NO	2	3	3	3	3		
48	05/12/91	15/01/92	DIZZINESS		28/12/91	Detail	4	1	2	3	1	NO	2	3	3	3			
							5	1	2	3	1	NO	2	3	3	3			
							Summary	15/01/92(*)	6	1	2	3	1	NO	2	3	3	3	YES
							Detail	1	2	3	1	NO	2	3	3	3			
							Detail	2	1	2	3	1	NO	2	3	3	3		
							Detail	3	2	3	1	NO	2	3	3	3	3		
49	05/12/91	15/01/92	DIZZINESS		06/12/91	Detail	1	2	2	3	1	NO	2	3	3	3			
							2	2	2	3	1	NO	2	3	3	3			
							Summary	30/12/91	4	2	2	3	1	NO	2	3	3	1	YES
							Detail	1	2	2	3	1	NO	2	3	3	3		
							Detail	2	1	2	3	1	NO	2	3	3	3		
							Detail	3	2	2	3	1	NO	2	3	3	3		
49	06/12/91	17/12/91	MOUTH DRY		06/12/91	Detail	1	2	2	3	1	NO	2	3	3	3			
							2	2	2	3	1	NO	2	3	3	3			
							Summary	17/12/91	2	2	2	3	1	NO	2	3	3	1	YES
							Detail	3	2	2	3	1	NO	2	3	3	3		
							Detail	4	1	2	3	1	NO	2	3	3	3		
							Detail	5	2	2	3	1	NO	2	3	3	3	1	
49	11/12/91	21/01/92	TACHYCARDIA		20/12/91	Detail	3	2	2	4	1	NO	2	3	3	3			
							4	1	2	4	1	NO	2	3	3	3			
							Summary	06/01/92	5	2	2	4	1	NO	2	3	3	1	YES
							Detail	1	2	2	3	1	NO	2	3	3	3		
							Detail	2	1	2	3	1	NO	2	3	3	3		
							Detail	3	2	2	3	1	NO	2	3	3	3		

Severity: Unkown, Mild, Moderate, Severe, -- History: Present before, 2=not observe bef., 3=unkown
 Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Kepp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unkown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) Adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

1447

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RAD

REBONETINE - PROTOCOL 20124/013
Listing No.: 11.0

ADVERSE EVENTS
OPEN PHASE

Con. Pat.	Init.	Start date	End date	Adverse event	Treatment	Onset date	Type record	Visit No	End No date	Last report visit	Sev rity	Hist ary	Hist rity	Rel ship	Stud drug	Steady state	Dis Hosp app.	Dis app. come (C)	Re app.	Dut app.	Open come (C)				
10	49	VH	11/12/91	21/01/92	HEADACHE		11/12/91	Summary	21/01/92(*)	6	2	2	2	3	1	NO	2	3	3	3	3	3	YES		
			11/12/91		MOUTH DRY		11/12/91	Detail	1			2	2	3	1	NO	2	3	3	3	3	3	3	3	
			24/12/91				24/12/91	Detail	2	2	2	2	2	3	1	NO	2	3	3	3	3	3	3	3	
			24/12/91				24/12/91	Summary	2	2	2	2	2	3	1	NO	2	3	3	3	3	3	3	1	YES
			16/01/92				16/01/92	Detail	6	2	2	2	2	4	1	NO	2	3	3	3	3	3	3	3	
			21/01/92(*)				21/01/92(*)	Summary	6	2	2	2	2	4	1	NO	2	3	3	3	3	3	3	3	YES
50	EE		19/12/91	29/01/92	MICTURITION DISORDER		01/01/92	Detail	2	2	2	2	2	3	1	NO	2	3	3	3	3	3	3	3	3
							01/01/92	Detail	3	1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
							01/01/92	Detail	4	1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
							01/01/92	Detail	5	1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
							01/01/92	Detail	6	1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
							29/01/92(*)	Summary	6	2	2	2	2	3	1	NO	2	3	3	3	3	3	3	3	3
51	UL		19/12/91	29/01/92	INSOMNIA		26/12/91	Detail	2	2	2	2	2	3	1	NO	2	3	3	3	3	3	3	3	3
							26/12/91	Detail	3	2	2	2	2	3	1	NO	2	3	3	3	3	3	3	3	3
							26/12/91	Detail	4	1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
							26/12/91	Detail	5	1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
							26/01/92	Detail	6	2	2	2	2	3	1	NO	2	3	3	3	3	3	3	3	1
							26/01/92	Summary	6	2	2	2	2	3	1	NO	2	3	3	3	3	3	3	3	1
							26/01/92	Detail	2	1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
							26/01/92	Detail	3	1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
							26/01/92	Detail	4	1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
							26/01/92	Detail	5	1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
							26/01/92	Detail	6	2	2	2	2	3	1	NO	2	3	3	3	3	3	3	3	3
							26/01/92	Summary	6	2	2	2	2	3	1	NO	2	3	3	3	3	3	3	3	3
52	MP		16/01/92	10/02/92	HEADACHE		04/02/92	Detail	4	2	2	2	2	3	1	NO	2	3	3	3	3	3	3	3	3
							10/02/92(*)	Summary	4	2	2	2	2	3	1	NO	2	3	3	3	3	3	3	3	3
53	MA		13/01/92	23/02/92	CONSTIPATION		15/01/92	Detail	1	2	2	2	2	3	1	NO	2	3	3	3	3	3	3	3	3
							15/01/92	Detail	2	2	2	2	2	3	1	NO	2	3	3	3	3	3	3	3	3
							15/01/92	Detail	3	2	2	2	2	3	1	NO	2	3	3	3	3	3	3	3	3
							15/01/92	Detail	4	1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req, 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=suspectible, 4=questionable, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOMETINE - PROTOCOL 20124/013
Listing No.: 11.0

ADVERSE EVENTS
OPEN PHASE

Cn. Pat.	Init.	Start date	End date	Adverse event	Disect date	Type record	Visit No	End No date	Last report visit	Save rity	Hist ary	Rea ship	Stud area	Symp Urea	Dis Hosp	Re app.	Out app.	Open cooa (C)	
																			Treatment
10	53	15/01/92	23/02/92	CONSTIPATION	15/01/92	Detail	5		1	2	3	1	NO	2	3	3	3	3	
							6		1	2	3	1	NO	2	3	3	3	3	
							Summary	23/02/92(*)	6	2	2	3	1	NO	2	3	3	3	3
54	UN	13/01/92	23/02/92	CONSTIPATION	13/01/92	Detail	1		2	2	3	1	NO	2	3	3	3	3	3
							2		2	2	3	1	NO	2	3	3	3	3	3
							3		1	2	3	1	NO	2	3	3	3	3	3
							4		1	2	3	1	NO	2	3	3	3	3	3
							5		2	2	3	1	NO	2	3	3	3	3	3
							6		1	2	3	1	NO	2	3	3	3	3	3
Summary	23/02/92(*)	6	2	2	3	1	NO	2	3	3	3	3	3	3	3	3	3		
55	TP	14/01/92	24/02/92	CONSTIPATION	15/01/92	Detail	1	13/01/92	1	2	3	1	NO	2	3	3	3	3	3
							2	13/01/92	1	2	3	1	NO	2	3	3	3	3	3
							Summary	13/01/92	1	2	3	1	NO	2	3	3	3	3	3
55	TP	14/01/92	24/02/92	CONSTIPATION	14/01/92	Detail	1		1	2	3	1	NO	2	3	3	3	3	3
							2		1	2	3	1	NO	2	3	3	3	3	3
							3		1	2	3	1	NO	2	3	3	3	3	3
							4		1	2	3	1	NO	2	3	3	3	3	3
							5	10/02/92	2	2	3	1	NO	2	3	3	3	3	3
							6	10/02/92	5	2	2	3	1	NO	2	3	3	3	3
Summary	10/02/92	5	2	2	3	1	NO	2	3	3	3	3	3	3	3	3			
55	TP	14/01/92	24/02/92	CONSTIPATION	14/01/92	Detail	1		1	2	3	1	NO	2	3	3	3	3	3
							2	25/01/92	1	2	4	1	NO	2	3	3	3	3	
							3	25/01/92	2	1	2	3	1	NO	2	3	3	3	3
							4	25/01/92	2	1	2	3	1	NO	2	3	3	3	3
							5	25/01/92	2	1	2	3	1	NO	2	3	3	3	3
							6	25/01/92	2	1	2	3	1	NO	2	3	3	3	3
Summary	25/01/92	2	1	2	3	1	NO	2	3	3	3	3	3	3	3	3			
55	TP	14/01/92	24/02/92	CONSTIPATION	14/01/92	Detail	1		1	2	3	1	NO	2	3	3	3	3	3
							2		1	2	3	1	NO	2	3	3	3	3	3
							3		1	2	3	1	NO	2	3	3	3	3	3
							4		1	2	3	1	NO	2	3	3	3	3	3
							5	14/02/92	1	2	3	1	NO	2	3	3	3	3	3
							6	14/02/92	5	1	2	3	1	NO	2	3	3	3	3
Summary	14/02/92	5	1	2	3	1	NO	2	3	3	3	3	3	3	3				
55	TP	14/01/92	24/02/92	CONSTIPATION	21/01/92	Detail	2		2	2	3	1	NO	2	3	3	3	3	3
							3		1	2	3	1	NO	2	3	3	3	3	
							4	05/02/92	2	2	3	1	NO	2	3	3	3	3	
							5	05/02/92	4	2	2	3	1	NO	2	3	3	3	
							6	05/02/92	4	2	2	3	1	NO	2	3	3	3	
							Summary	05/02/92	4	2	2	3	1	NO	2	3	3	3	3

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=stop. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CIS MSD
 REMOETINE - PROTOCOL 20126/913
 Listing No.: 11.0
 ADVERSE EVENTS
 OPEN PHASE

Con. Pat. ID	Init.	Start date	End date	Adverse event	Onset date	Type record	Visit No	End No date	Last report visit	Save	Hist	Rel	Stud	Symp	Dis	Re	Out	Open		
									city	ory	ship	drug	area	Mosp	app.	app.	come	(C)		
10	56	JP	14/01/92	26/02/92	MOUTH DRY	14/01/92	Detail	1		1	1	3	1	NO	2	3	3	3		
						Detail	2	22/01/92		1	1	3	1	NO	2	3	3	1		
						Summary		22/01/92		2	1	1	3	1	NO	2	3	3	1	YES
				PERINEAL PAIN MALE	14/01/92	Detail	1		1	1	3	1	NO	2	3	3	3	3		
						Detail	2	26/01/92		1	1	3	1	NO	2	3	3	1		
						Summary		26/01/92		2	1	1	3	1	NO	2	3	3	1	YES
				VISION ABNORMAL	21/01/92	Detail	2		1	1	3	1	NO	2	3	3	3	3		
						Detail	3	02/02/92		1	1	3	1	NO	2	3	3	1		
						Summary		02/02/92		3	1	1	3	1	NO	2	3	3	1	YES
57	AG	15/01/92	25/02/92	MOUTH DRY	16/01/92	Detail	1		1	1	4	1	NO	2	3	3	1			
						Summary		29/01/92		1	1	4	1	NO	2	3	3	1	YES	
					58	KK	14/01/92	24/02/92	DIZZINESS	16/01/92	Detail	1		1	1	3	1	NO	2	3
	Detail	2		1						1	3	1	NO	2	3	3	3			
	Detail	3		1						1	3	1	NO	2	3	3	3			
	Detail	4		1						1	3	1	NO	2	3	3	3			
	Detail	5	14/02/92							1	2	3	1	NO	2	3	3	1		
	Summary		14/02/92							5	1	1	3	1	NO	2	3	3	1	YES
59	TA	20/01/92	01/03/92	DIZZINESS	29/01/92	Detail	3		1	2	3	1	NO	2	3	3	1			
						Summary		01/02/92		3	1	2	3	1	NO	2	3	3	1	YES
					59	TA	20/01/92	01/03/92	DIZZINESS	21/01/92	Detail	1		1	1	3	1	NO	2	3
	Detail	2	01/02/92							1	1	3	1	NO	2	3	3	1		
	Summary		01/02/92							2	1	1	3	1	NO	2	3	3	1	YES
	Detail	4		2						1	3	1	NO	2	3	3	3			
	Detail	5		1						1	3	1	NO	2	3	3	3			
	Summary		01/03/92(*)							6	3	1	3	1	NO	2	3	3	3	3

1450

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD
 REMOBTINE - PROTOCOL 20126/013
 Listing No.: 11.0
 ADVERSE EVENTS
 OPEN PHASE

Ch. Pat.	Init.	Start date	Treatment	End date	Adverse event	Onset date	Type record	Visit No	End No date	Last report visit	Saw rity	Hist ary	Rat shlp	Stud drug	Swep tree	Hosp	Dis app.	Re app.	Dis come	Re	Out	Open
10	59	TA	20/01/92	01/03/92	VISION ABNORMAL	21/01/92	Detail	1		1	2	3	1	NO	2	3	3	3	3	3	3	3
							Detail	2	02/02/92	2	1	2	3	1	NO	2	3	3	3	3	3	3
							Summary	4	02/02/92	2	1	2	3	1	NO	2	3	3	3	3	3	3
						10/02/92	Detail	5		2	2	3	1	NO	2	3	3	3	3	3	3	3
							Detail	6		1	1	3	1	NO	2	3	3	3	3	3	3	3
							Summary	6	31/03/92(*)	6	2	1	3	1	NO	2	3	3	3	3	3	3
							Detail	1		1	2	3	1	NO	2	3	3	3	3	3	3	3
						23/01/92	Detail	2	23/01/92	1	1	3	1	NO	2	3	3	3	3	3	3	3
							Summary	2	23/01/92	2	1	1	3	1	NO	2	3	3	3	3	3	3
							Detail	0		2	1	6	1	NO	2	3	3	3	3	3	3	3
						01/11/91	Detail	1		1	1	6	1	NO	2	3	3	3	3	3	3	3
							Detail	2		2	1	4	1	NO	2	3	3	3	3	3	3	3
							Detail	3		1	1	6	1	NO	2	3	3	3	3	3	3	3
							Detail	4	18/02/92	1	1	5	1	NO	2	3	3	3	3	3	3	3
							Summary	4	18/02/92	4	2	1	4	1	NO	2	3	3	3	3	3	3
							Detail	4		2	2	3	1	NO	2	3	3	3	3	3	3	3
						17/02/92	Detail	4		2	2	3	1	NO	2	3	3	3	3	3	3	3
							Detail	5		1	2	3	1	NO	2	3	3	3	3	3	3	3
							Detail	6		1	2	3	1	NO	2	3	3	3	3	3	3	3
							Summary	6	33/03/92(*)	6	2	2	3	1	NO	2	3	3	3	3	3	3
							Detail	1		1	2	3	1	NO	2	3	3	3	3	3	3	3
						06/02/92	Detail	2		2	2	3	1	NO	2	3	3	3	3	3	3	3
							Detail	3		1	2	3	1	NO	2	3	3	3	3	3	3	3
							Detail	4	01/03/92	1	2	3	1	NO	2	3	3	3	3	3	3	3
							Summary	4	01/03/92	4	2	2	3	1	NO	2	3	3	3	3	3	3
							Detail	1		1	2	3	1	NO	2	3	3	3	3	3	3	3
						06/02/92	Detail	2		1	2	3	1	NO	2	3	3	3	3	3	3	3
							Detail	3		1	2	3	1	NO	2	3	3	3	3	3	3	3
							Summary	3	24/02/92	3	1	2	3	1	NO	2	3	3	3	3	3	3
							Detail	1		1	2	3	1	NO	2	3	3	3	3	3	3	3
						06/02/92	Detail	1		1	2	3	1	NO	2	3	3	3	3	3	3	3

Severity: Unknown, mild, moderate, severe, --- History: Present before, Not observed before, Unknown
 Study drug: Ino Ganser, 2-dose reduced, 3-def. withdrawn, 4-temp. inter.
 Hospital: Required, Not req., Not appl. -- Outcome: Recovered, 2-rec. with see., Detail Present, Death
 Disapp./Reapp.: Ino, 2-yes, 3-not appl. -- Relationship: Indefinite, Probable, Possible, Doubtful, Unknown, None
 Symptomatic treatment: gmo, lvs
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end data = visit data

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
 REMOETINE - PROTOCOL 20124/013
 Listing No.: 11.0

ADVERSE EVENTS
 OPEN PHASE

Cen. Pat.	Init.	Start date	End date	Adverse event	Onset date	Type record	Visit No	Last report visit	Save rfcy	Hist ary	Re ship	Rea drug	Rea Stud	Sypm tree	Dis Hosp	Re app.	Out app.	Open come	(C)
10	64	LT	06/02/92	16/03/92	CONSTIPATION	06/02/92	Detail 1 Summary	2 15/02/92 15/02/92	2	1 2 3 1	4 1	NO	2 3 3 1	NO	2 3 3 1	YES			
			10/02/92	16/03/92	INSOMNIA	10/02/92	Detail 1 Summary	6 14/03/92 14/03/92	6	2 1 4 1	4 1	YES	2 3 3 2	YES	2 3 3 2	YES			
			06/02/92		TACHYCARDIA	06/02/92	Detail 1 Detail 2 Detail 3 Detail 4 Detail 5 Detail 6 Summary	1 2 3 4 5 6 15/03/92(+)	6	2 2 2 3 1	3 1	NO	2 3 3 3		2 3 3 3				
			26/02/92	06/04/92	INSOMNIA	26/02/92	Detail 1 Detail 2 Detail 3 Detail 4 Detail 5 Detail 6 Summary	1 2 3 4 5 6 06/04/92 06/04/92	6	1 2 2 2 2 2 3	3 1	NO	2 3 3 3		2 3 3 3				
			20/03/92		TACHYCARDIA	20/03/92	Detail 1 Detail 2 Detail 3 Detail 4 Detail 5 Detail 6 Summary	4 5 30/03/92 30/03/92	5	1 2 4 1	4 1	NO	2 3 3 1		2 3 3 1				
			03/03/92	13/04/92	CONSTIPATION	02/03/92	Detail 1 Detail 2 Detail 3 Detail 4 Detail 5 Detail 6 Summary	1 2 3 4 5 6 13/04/92(+)	6	1 2 3 1	3 1	NO	2 3 3 3		2 3 3 3				
			19/03/92		DIZZINESS	19/03/92	Detail 1 Detail 2 Detail 3 Detail 4 Detail 5 Detail 6 Summary	2 3 4 5 6 13/04/92(+)	6	1 2 3 1	3 1	NO	2 3 3 3		2 3 3 3				

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe,
 Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (+) adverse event still present; end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD

REBONETINE - PROTOCOL 20126/913
Listing No.: 11.0

ADVERSE EVENTS
OPEN PHASE

Ch.	Pat.	Init.	Start date	End date	Adverse event	Onset date	Type record	Visit No	End No data	Last report visit	Sev	Hist	Rel	Stud	Symp	Dis app.	Re app.	Out app.	Open						
10	83	KL	05/03/92	13/06/92	DIZZINESS	10/03/92	Detail	4		1	2	3	1	NO	2	3	3	3	3	3					
							Detail	5		1	2	3	1	NO	2	3	3	3	3	3	3	3	3		
							Detail	6		1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	
							Summary	13/06/92(*)	6	1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
							Detail	6	11/06/92		2	1	3	1	YES	2	3	3	2	3	3	3	3	3	3
							Summary	11/06/92	6	2	1	3	1	YES	2	3	3	2	3	3	3	3	3	3	3
							Detail	02/02/92		1	1	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
							Detail	2		1	1	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
							Detail	3		1	1	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
							Detail	4		1	1	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
	Detail	5		1	1	3	1	NO	2	3	3	3	3	3	3	3	3	3	3						
	Detail	6		1	1	3	1	NO	2	3	3	3	3	3	3	3	3	3	3						
	Summary	13/06/92(*)	6	1	1	3	1	NO	2	3	3	3	3	3	3	3	3	3	3	3					
86	HW		11/03/92	21/06/92	CONSTIPATION	26/03/92	Detail	3		1	1	3	1	NO	2	3	3	3	3	3					
							Detail	4		1	1	3	1	NO	2	3	3	3	3	3	3	3			
							Detail	5		1	1	3	1	NO	2	3	3	3	3	3	3	3			
							Detail	6		1	1	3	1	NO	2	3	3	3	3	3	3	3			
							Summary	21/06/92(*)	6	1	1	3	1	NO	2	3	3	3	3	3	3	3	3		
							Detail	13/03/92	1	13/03/92	2	2	2	1	NO	2	3	3	1	3	3	3	3	3	
	Summary	13/03/92	1	2	2	2	1	NO	2	3	3	1	3	3	3	3	3	3							
85	AK		11/03/92	21/06/92	DIZZINESS	11/03/92	Detail	1		2	2	3	1	NO	2	3	3	3	3	3					
							Detail	2		1	2	3	1	NO	2	3	3	3	3	3	3				
							Detail	3		1	2	3	1	NO	2	3	3	3	3	3	3				
							Detail	4		1	2	3	1	NO	2	3	3	3	3	3	3				
							Detail	5	13/03/92	1	2	3	1	NO	2	3	3	1	3	3	3	3			
							Summary	13/03/92	5	2	2	3	1	NO	2	3	3	1	3	3	3	3			
			11/03/92		MOUTH DRY	11/03/92	Detail	1		2	2	3	1	NO	2	3	3	3	3	3					
							Detail	2		1	2	3	1	NO	2	3	3	3	3	3					
							Detail	3		1	2	3	1	NO	2	3	3	3	3	3					
							Detail	4		1	2	3	1	NO	2	3	3	3	3	3					

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date a visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 11.0

ADVERSE EVENTS
 OPEN PHASE

Con. Pat.	Init.	Start date	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Save rity	Hist ory	Rel shie	Stud drug	Symp trea	Dis app.	Re app.	Out come	Open some (C)	
10	85	AK	11/05/92	21/04/92	MOUTH DRY	11/05/92	Detail 5	5		1	2	3	1	NO	2	3	3	3	3	3
							Detail 6	6	21/04/92(*)	6	2	3	1	NO	2	3	3	3	3	3
							Summary													YES
66	HP		19/05/92	29/04/92	CONSTIPATION	05/06/92	Detail 3	3		2	2	3	1	NO	2	3	3	3	3	3
							Detail 4	4		1	2	3	1	NO	2	3	3	3	3	3
							Detail 5	5		1	2	3	1	NO	2	3	3	3	3	3
							Detail 6	6	29/04/92(*)	6	2	3	1	NO	2	3	3	3	3	3
							Summary													YES
							Detail 3	3		1	2	3	1	NO	2	3	3	3	3	3
							Detail 4	4		1	2	3	1	NO	2	3	3	3	3	3
							Detail 5	5	20/06/92	5	1	2	3	1	NO	2	3	3	3	3
							Detail 6	6	20/06/92	6	1	2	3	1	NO	2	3	3	3	3
							Summary													YES
87	AN		19/05/92	29/04/92	MOUTH DRY	28/05/92	Detail 1	1		1	2	3	1	NO	2	3	3	3	3	3
							Detail 2	2		1	2	3	1	NO	2	3	3	3	3	3
							Detail 3	3		1	2	3	1	NO	2	3	3	3	3	3
							Detail 4	4		1	2	3	1	NO	2	3	3	3	3	3
							Detail 5	5		1	2	3	1	NO	2	3	3	3	3	3
							Detail 6	6	29/04/92(*)	6	1	2	3	1	NO	2	3	3	3	3
							Summary													YES
88	SK		20/05/92	30/04/92	HEADACHE	20/05/92	Detail 1	1		2	2	3	1	NO	2	3	3	3	3	3
							Detail 2	2		1	2	3	1	NO	2	3	3	3	3	3
							Detail 3	3	05/06/92	3	2	3	1	NO	2	3	3	3	3	3
							Detail 4	4	05/06/92	4	2	3	1	NO	2	3	3	3	3	3
							Summary													YES
98	SV		26/05/92	04/05/92	DIZZINESS	01/06/92	Detail 1	1		1	2	3	1	NO	2	3	3	3	3	3
							Detail 2	2	12/06/92	2	3	1	NO	2	3	3	3	3	3	3
							Detail 3	3	12/06/92	3	1	2	3	1	NO	2	3	3	3	3
							Summary													YES
							Detail 1	1	25/03/92	1	2	2	3	1	NO	2	3	3	3	3
							Detail 2	2	25/03/92	2	2	3	1	NO	2	3	3	3	3	3
							Summary													YES

1454

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, --- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=def. withdraw, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. --- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./reapp.: 1=no, 2=yes, 3=not appl. --- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RAD
 RESORNETINE - PROTOCOL 20126/013
 Listing No.: 11.0

ADVERSE EVENTS
 OPEN PHASE

Con. Pat. Init.	Start date	End date	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Save rcty	Hist rcty	Rel ship	Rel ship	Stud drug	Symp treat	Dis app.	Re app.	Out app.	Open cons (c)	
10 91 HI	26/03/92	04/05/92	SWEATING INCREASED	24/03/92	Detail	1		1	2	3	1	NO	2	3	3	3	3		
					Detail	2		1	2	3	1	NO	2	3	3	3			
					Detail	3	12/04/92		1	2	3	1	NO	2	3	3	3		
					Summary	12/04/92		3	1	2	3	1	NO	2	3	3	3	1	YES
92 LA	01/04/92	12/05/92	INSOMNIA	06/04/92	Detail	1		2	1	3	1	YES	2	3	3	3	2		
					Summary	16/04/92		2	2	1	3	1	YES	2	3	3	3	2	YES
					Detail	1		1	1	3	1	NO	2	3	3	3	3		
					Detail	2		1	1	3	1	NO	2	3	3	3	3		
			MOUTH DRY	01/04/92	Detail	3		1	1	3	1	NO	2	3	3	3	3		
					Detail	4		1	1	3	1	NO	2	3	3	3	3		
					Detail	5		2	1	3	1	NO	2	3	3	3	3		
					Summary	04/05/92		1	1	3	1	NO	2	3	3	3	3	1	YES
93 AN	09/04/92	20/05/92	RICKETS	09/04/92	Detail	1		2	2	3	1	NO	2	3	3	3	3		
					Detail	2		2	2	3	1	NO	2	3	3	3	3		
					Detail	3		1	2	3	1	NO	2	3	3	3	3		
					Summary	16/05/92		1	2	3	1	NO	2	3	3	3	3		
94 PV	09/04/92	20/05/92	ACNE	01/05/92	Detail	4		2	2	3	1	NO	2	3	3	3	3		
					Detail	5		2	2	3	1	NO	2	3	3	3	3		
					Detail	6	16/05/92		1	2	4	1	NO	2	3	3	3	1	YES
					Summary	16/05/92		6	2	2	3	1	NO	2	3	3	3	1	YES
11 6 VP	16/10/91	26/11/91	INSOMNIA	17/10/91	Detail	4		2	2	3	1	NO	2	3	3	3	3		
					Detail	5		2	2	3	1	NO	2	3	3	3	3		
					Detail	6		1	2	3	1	NO	2	3	3	3	3		
					Summary	20/05/92(*)		6	2	2	3	1	NO	2	3	3	3	3	YES
11 6 VP	16/10/91	26/11/91	INSOMNIA	17/10/91	Detail	5	05/11/91	1	1	2	1	NO	2	3	3	3	3		
					Summary	05/11/91		5	1	1	2	1	NO	2	3	3	3	3	1

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=indefinite, 2=probable, 3=possible, 4=definitive, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (*) adverse event used for statistical analysis
 (c) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REMEDIATION - PROTOCOL 20124/013
Listing No.: 11.0

ADVERSE EVENTS
OPEN PHASE

Con. Pat.	Init.	Start date	Treatment	End date	Adverse event	Onset date	Type record	Visit No	End No date	Last report visit	Sae	Hist rty	Rel drug	Stud tree	Sympt app.	Dis app.	Re come	Out	Open	
																				report
12	2	EFC	05/11/91	16/12/91	MOUTH DRY	26/11/91	Detail	3	22/11/91	1	3	5	1	NO	2	3	3	1		
							Summary		22/11/91	3	1	3	5	1	NO	2	3	3	1	YES
8	PH	01/11/91	12/12/91	INSOMNIA	01/11/91	Detail	6	12/12/91	1	1	6	1	NO	2						
						Summary		12/12/91	6	1	1	6	1	NO	2				1	YES
11	ER	31/10/91	11/12/91	DIZZINESS	26/11/91	Detail	4		1	2	2	1	NO	2	3	3	3			
						Summary		04/12/91	5	1	2	2	1	NO	2	3	3	1	YES	
					FATIGUE	29/11/91	Detail	4		3	2	2	1	NO	2	1	1	3		
							Summary		11/12/91(*)	6	3	2	2	1	NO	2	1	1	3	YES
					MOUTH DRY	01/11/91	Detail	1		2	2	2	1	NO	1	1	1	3		
							Summary			4	3	2	2	1	NO	1	1	1	3	YES
12	FSZ	05/11/91	16/12/91	URINARY RETENTION	01/12/91	Detail	4	02/12/91	3	2	6	1	YES	1	3	3	1			
						Summary		02/12/91	4	3	2	6	1	YES	1	3	3	1	YES	
14	GSZ	06/11/91	17/12/91	DIZZINESS	08/11/91	Detail	1	16/11/91	1	2	6	1	NO	1	5	3	3			
						Summary		14/11/91	2	3	2	5	1	NO	1	3	3	1	YES	
					INSOMNIA	30/11/91	Detail	4	05/12/91	2	2	5	1	NO	2	3	3			
							Summary		05/12/91	5	3	2	5	1	NO	2	3	3	1	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=stop, 5=inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA DNS RBD

REBOMTINE - PROTOCOL 20126/013
Listing No.: 11.0

ADVERSE EVENTS
OPEN PHASE

Con. Pat. Init.	Start date	End date	Adverse event	Onset date	Type	Visit record	End No date	Last report visit	Save city	Hist ory	Rel drug	Stud treat	Symp	Dis hosp	Re app.	Out app.	Open some (c)	
12	14	BSZ	06/11/91	17/12/91	MOUTH DRY	06/11/91	1	2	2	4	1	NO	1	3	3	3		
						06/11/91	2	3	1	6	1	NO	1	3	3	1	YES	
						Summary												
						Detail	1	1	3	6	1	NO	1	3	3	3		
						Detail	2	1	3	6	1	NO	2	3	3	3		
						Detail	3	1	2	6	1	NO	2	3	3	3		
						Detail	4	1	2	6	1	NO	2	3	3	3		
						Detail	5	1	2	6	1	NO	2	3	3	3		
						Detail	6	1	2	6	1	NO	2	3	3	3		
						Summary	17/12/91(*)	6	1	2	6	1	NO	1	3	3	3	YES
						SWEATING INCREASED	07/11/91											
						Detail	1	1	3	6	1	NO	1	3	3	3		
						Detail	2	1	3	6	1	NO	2	3	3	3		
						Detail	3	1	2	6	1	NO	2	3	3	3		
						Detail	4	1	2	6	1	NO	2	3	3	3		
						Detail	5	1	2	6	1	NO	2	3	3	3		
						Detail	6	1	2	6	1	NO	2	3	3	3		
						Summary												
						Detail	1	1	3	6	1	NO	1	3	3	3		
						Detail	2	1	3	6	1	NO	1	3	3	3		
						Summary	16/01/92	1	1	3	4	1	NO	1	3	3	1	YES
						Detail	1	2	3	3	1	YES	1	3	3	3		
						Detail	2	2	3	3	1	YES	1	3	3	3		
						Detail	3	2	3	2	NO	1	2	2	2	1		
						Summary	25/01/92	3	2	3	2	2	YES	1	2	2	1	YES
						Detail	1	2	4	1	NO	2	1	2	1	1		
						Detail	2	2	4	1	NO	2	1	2	1	1		
						Summary	27/01/92	2	1	2	4	1	NO	2	1	1	1	YES
						Detail	1	2	3	2	1	NO	1	3	3	1		
						Detail	2	2	3	2	1	NO	1	3	3	1		
						Summary	27/01/92	2	2	3	2	1	NO	1	3	3	1	YES
						Detail	1	2	1	6	1	NO	2	1	1			
						Detail	2	2	1	6	1	NO	2	1	1			
						Summary	03/04/92	6	2	1	6	1	NO	2	1	1	1	YES
						Detail	1	3	6	3	NO	2	4	4	4	4	4	YES
						Detail	2	3	6	3	NO	2	4	4	4	4	4	YES
						Summary	03/04/92	6	3	6	3	NO	2	4	4	4	4	YES
						Detail	1	2	6	1	YES	2	1	1	1			
						Detail	2	1	2	6	1	YES	2	1	1			
						Summary	15/04/92	4	1	2	6	1	YES	2	1	1	1	YES

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe.
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawal, 4=temp. inter.
Hospital: 1=required, 2=not req, 3=not appl.
Disapp./Mapp.: 1=no, 2=yes, 3=not appl.
Symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
RESOMETINIE - PROTOCOL 20124/v13
Listing No.: 11.0

ADVERSE EVENTS
OPEN PHASE

Con. Pat.	Init.	Start date	End date	Adverse event	Treatment	Onset date	Type record	Visit No	End No date	Last report visit	Save rity	Hist ony	Rel ship	Stud drug	Symp treat	Dis hosp	Re app.	Out app.	Open coma
12	31	FW	25/03/92	05/05/92	HEADACHE		31/03/92	1	1	1	2	1	4	1	YES	2	1	3	
							Detail	2	2	2	1	6	1	YES	2	1	3		
							Detail	3	3	3	1	6	1	YES	2	1	3		
							Summary	16/06/92(4)	3	2	1	6	1	YES	2	1	3		
							Detail	6	6	6	1	6	1	NO	2	1	3		
							Summary	05/05/92	6	2	1	6	1	NO	2	1	3		
34	TGB	28/03/92	09/05/92	INSOMNIA		29/03/92	Detail	5	5	5	1	6	1	NO	2	1	3		
							Summary	02/05/92	6	1	1	6	1	NO	2	1	3		
28	FG	07/04/92	16/05/92	INSOMNIA		07/04/92	Detail	6	6	6	1	6	1	NO	2	1	3		
							Summary	16/05/92(4)	6	1	1	6	1	NO	2	1	3		
13	11	HS	15/11/91	26/12/91	HEPATIC ENZYMES INCREASED		17/10/91	Detail	6	2	1	6	1	NO	2	3	5	1	
							Summary	27/12/91	6	2	1	6	1	NO	2	3	5	1	
12	BF	31/10/91	04/12/91	MICTURITION DISORDER		16/11/91	Detail	3	3	3	1	6	1	NO	2	3	5	3	
							Detail	4	4	4	1	6	1	NO	1	3	5	3	
							Detail	5	5	5	1	6	3	NO	1	1	3	3	
							Summary	04/12/91(4)	5	1	3	6	3	NO	1	1	3	3	
14	DF	02/11/91	13/12/91	SWEATING INCREASED		26/11/91	Detail	4	4	4	2	3	3	1	NO	2	3	3	
							Detail	5	5	5	2	3	3	1	NO	2	3	3	
							Summary	05/12/91	5	2	3	3	1	NO	2	3	3	1	
							Detail	6	6	6	1	3	4	1	NO	2	3	3	
							Summary	12/12/91(4)	6	1	3	4	1	NO	2	3	3	3	
16	SZL	20/11/91	31/12/91	VISION ABNORMAL		08/12/91	Detail	3	3	3	2	3	3	1	NO	2	3	3	
							Summary	10/12/91(4)	3	2	3	3	1	NO	2	3	3	1	
							Detail	4	4	4	2	3	3	1	NO	2	3	1	
							Summary	13/12/91	4	2	3	3	1	NO	2	3	1		
17	BSH	20/11/91	31/12/91	TACHYCARDIA		15/12/91	Detail	4	4	4	1	2	3	1	NO	1	3	3	

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=def. withdraw, 5=death.
Study drug: 1=no change, 2=dose reduced, 3=def. withdraw, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REDOXETINE - PROTOCOL 20126/913
 Listing No.: 11.0

ADVERSE EVENTS
 OPEN PHASE

Cn.	Pat.	Init.	Start date	End date	Adverse event	Treatment	Onset date	Type record	Visit End No date	Last report visit	Save rity	Hist ary	Real ship	Stud drug	Symp tres	Dis Hosp	Re app.	Out app.	Open come (C)	
																				Detail
13	17	OSM	20/11/91	31/12/91	TACHYCARDIA		15/12/91	Detail	5	24/12/91	5	2	3	3	1	NO	1		1	VES
								Summary		24/12/91	5	2	2	3	1	NO	1		1	VES
18	VT		04/12/91	14/01/92	HYPOTENSION POSTURAL		08/12/91	Detail	1			2	3	3	1	NO	2		3	
								Detail	2			2	2	3	1	NO	1		3	
								Detail	3	23/12/91		2	3	3	1	NO	1		1	
								Summary		23/12/91	3	2	3	3	1	NO	1		1	VES
20	NL		23/01/92	10/03/92	SWEATING INCREASED		24/01/92	Detail	0			1	1	6	1	NO	2		2	NO
								Summary			0	1	1	6	1	NO	2		2	NO

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=fatal
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis

-- History: 1=represent before, 2=not observe bef., 3=unknown
 -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA ONS RED
 REBONETINE - PROTOCOL 20124/013
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

9550077

Con.	Patient	Init.	Start date	Start D.B.	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Save rty	Hist ory	Rel ship	Stud Sym	Dis app.	Re case	Out (C)	D.B.		
1	1/1	MCA	17/11/90	29/12/90	22/05/91	Placebo	CONSTIPATION	26/11/90	Detail	2			1	2	1	1	NO	2	3	3	3	
									Detail	3		1	2	1	1	NO	2	3	3	3	3	
									Detail	4		1	2	1	1	NO	2	3	3	3	3	
									Detail	5		1	2	1	1	NO	2	3	3	3	3	
									Detail	6		1	2	1	1	NO	2	3	3	3	3	
									Detail	8	06/01/91	1	2	1	1	NO	2	3	3	1		
									Summary		06/01/91	6	1	2	1	1	NO	2	3	3	1	
																					YES Run In Phase	
									Detail	1	20/11/90	1	2	1	1	NO	2	3	3	3	3	
							MOUTH DRY		Detail	2		1	2	1	1	NO	2	3	3	3	3	
									Detail	3		1	2	1	1	NO	2	3	3	3	3	
									Detail	4		1	2	1	1	NO	2	3	3	3	3	
									Detail	5		1	2	1	1	NO	2	3	3	3	3	
									Detail	5		1	2	1	1	NO	2	3	3	3	3	
									Detail	6	31/12/90	1	2	1	1	NO	2	3	3	3	3	
									Detail	8	31/12/90	1	2	1	1	NO	2	3	3	3	3	
									Summary		31/12/90	8	1	2	1	1	NO	2	3	3	3	1
																						YES Run In Phase
6/5	CPH		05/12/90	16/01/91	09/04/91	Placebo	MOUTH DRY	05/12/90	Detail	1		1	2	1	1	NO	2	3	3	3	3	
									Detail	2		1	2	1	1	NO	2	3	3	3	3	
									Detail	3		1	2	1	1	NO	2	3	3	3	3	
									Detail	4		1	2	1	1	NO	2	3	3	3	3	
									Detail	4		1	2	1	1	NO	2	3	3	3	3	
									Detail	5	06/01/91	1	2	1	1	NO	2	3	3	3	3	
									Detail	5	06/01/91	1	2	1	1	NO	2	3	3	3	3	
									Summary		06/01/91	5	1	2	1	1	NO	2	3	3	3	1
																						YES Run In Phase
									Detail	3	20/12/90	1	2	1	1	NO	2	3	3	3	3	
							VISION ABNORMAL		Detail	4		1	2	1	1	NO	2	3	3	3	3	
									Detail	5		1	2	1	1	NO	2	3	3	3	3	
									Detail	6		1	2	1	1	NO	2	3	3	3	3	
									Detail	6	20/01/91	1	2	1	1	NO	2	3	3	3	3	
									Detail	8	20/01/91	1	2	1	1	NO	2	3	3	3	3	
									Summary		20/01/91	6	1	2	1	1	NO	2	3	3	3	1
																						YES Run In Phase
11/9	VRT		09/05/91	20/06/91	14/11/91	Placebo	DIZZINESS	19/05/91	Detail	1		1	2	1	1	NO	2	3	3	3	3	
									Detail	2	20/05/91	1	2	1	1	NO	2	3	3	3	3	1
									Summary		20/05/91	2	1	2	1	1	NO	2	3	3	3	1
									Detail	4	01/06/91	1	2	1	1	NO	2	3	3	3	3	3
									Detail	5		1	2	1	1	NO	2	3	3	3	3	
									Detail	6		1	2	1	1	NO	2	3	3	3	3	
									Detail	6		1	2	1	1	NO	2	3	3	3	3	
									Detail	8		1	2	1	1	NO	2	3	3	3	3	

1460

Severely: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Resp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 --- History: 1=present before, 2=not observe bef., 3=unknown

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOETINE - PROTOCOL 20124/913
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Can. Patient Init.	Start date	Start D.B.	Treatment	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End No date	Last report visit	Save Hist	Rel ary	Stud drug	Symp treat	Disp Hosp	Re app.	Out. cons.	D.B. (c)	Phase	
1	11/9	VR	09/05/91	20/04/91	16/11/91	Placebo	DIZZINESS	01/06/91	Detail	10	10/05/91	1	2	1	1	MD	2	3	3	1	YES Run In Phase
								Summary			10	1	2	1	1	MD	2	3	3	1	YES Run In Phase
	12/13	SLT	20/05/91	01/05/91	17/05/92	Placebo	MOUTH DRY	22/05/91	Detail	1	1	2	1	1	MD	2	3	3	3		
								Detail			1	2	1	1	MD	2	3	3	3		
								Detail			2	1	1	1	MD	2	3	3	3		
								Detail			3	1	2	1	MD	2	3	3	3		
								Detail			4	1	2	1	MD	2	3	3	3		
								Detail			5	1	2	1	MD	2	3	3	3		
								Detail			6	1	2	1	MD	2	3	3	3		
								Detail			7	1	2	1	MD	2	3	3	3		
								Detail			8	1	2	1	MD	2	3	3	3		
								Detail			9	1	2	1	MD	2	3	3	3		
								Detail			10	1	2	1	MD	2	3	3	3		
								Summary			10	1	2	1	MD	2	3	3	3	1	YES Run In Phase
	15/12	MO	09/05/91	20/06/91	06/05/92	Placebo	LIBIDO DECREASED	21/07/91	Detail	12	1	2	3	1	MD	2	3	3	3		
								Detail			14	1	2	3	1	MD	2	3	3	3	
								Detail			16	1	2	3	1	MD	2	3	3	1	YES Double Blind
								Summary			16	1	2	3	1	MD	2	3	3	1	YES Double Blind
	14/13	MC	18/05/91	29/06/91	21/02/92	Placebo	CONSTIPATION	25/06/91	Detail	6	1	2	1	1	MD	2	3	3	3		
								Detail			8	1	2	1	MD	2	3	3	3		
								Detail			10	1	2	1	MD	2	3	3	3		
								Detail			12	1	2	3	1	MD	2	3	3	3	
								Detail			14	1	2	3	1	MD	2	3	3	3	
								Detail			16	1	2	3	1	MD	2	3	3	3	
								Detail			18	1	2	3	1	MD	2	3	3	1	YES Run In Phase
								Summary			18	1	2	3	1	MD	2	3	3	1	YES Run In Phase
	15/12	MO	09/05/91	20/06/91	06/05/92	Placebo	MOUTH DRY	20/05/91	Detail	1	1	2	1	1	MD	2	3	3	3		
								Detail			2	1	2	1	MD	2	3	3	3		
								Detail			3	1	2	1	MD	2	3	3	3		
								Detail			4	1	2	1	MD	2	3	3	3		
								Detail			5	1	2	1	MD	2	3	3	3		
								Detail			6	1	2	1	MD	2	3	3	3		
								Detail			7	1	2	1	MD	2	3	3	3		
								Detail			8	1	2	1	MD	2	3	3	3		
								Detail			9	1	2	1	MD	2	3	3	3		
								Detail			10	1	2	1	MD	2	3	3	3		
								Detail			12	1	2	3	1	MD	2	3	3	3	
								Detail			14	1	2	3	1	MD	2	3	3	3	
								Detail			16	1	2	3	1	MD	2	3	3	3	

Severity: S=unknown, F=fatal, Z=moderate, S=severe, -- History: 1=present before, 2=not observe bef., S=unknown
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present: end date a visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA INC RSD

REBOXETINE - PROTOCOL 2012Z/013
Listing No.: 11.0

ADVERSE EVENTS
DOUBLE BLIND PHASE

Can. Patient	Init.	Start date	End date	Treatment	Adverse event	Onset date	Type record	Visit No	Last report visit	Save Hist	Rel. Stud Sympt	Dis. Re	Out. D.B.	Phase	Last report visit				
															visit rity	orv ship drug treat			
1	16/13	MC	18/05/91	21/02/92	Placebo	MOUTH DRY	20/05/91	Detail 18	1	2	3	1	NO	2	3	3	3		
								Detail 20	1	2	3	1	NO	2	3	3	3		
								Summary	20	1	2	1	NO	2	3	3	1	YES Run In Phase	
21/18	VHC		05/06/91	17/07/91	02/06/92	Placebo	CONSTIPATION	Detail 3	1	2	1	1	NO	2	3	3	3		
								Detail 4	1	2	1	1	NO	2	3	3	3		
								Summary	4	1	2	1	NO	2	3	3	1	YES Run In Phase	
29/25	AFO		17/07/91	28/08/91	14/07/92	Placebo	CONSTIPATION	Detail 3	1	2	5	1	NO	2	3	3	3		
								Detail 4	1	2	3	1	NO	2	3	3	3		
								Detail 5	1	2	3	1	NO	2	3	3	3		
								Detail 6	1	2	3	1	NO	2	3	3	3		
								Detail 8	1	2	3	1	NO	2	3	3	3		
								Detail 10	1	2	3	1	NO	2	3	3	3		
								Detail 12	1	2	3	1	NO	2	3	3	3		
								Detail 14	1	2	3	1	NO	2	3	3	3		
								Summary	14	1	2	3	1	NO	2	3	3	1	YES Run In Phase
33/29	DFC		25/07/91	05/09/91	16/10/91	Placebo	CONSTIPATION	Detail 2	1	2	3	1	NO	2	3	3	3		
								Detail 3	1	2	3	1	NO	2	3	3	3		
								Detail 4	1	2	3	1	NO	2	3	3	3		
								Detail 5	1	2	3	1	NO	2	3	3	3		
								Detail 6	1	2	3	1	NO	2	3	3	3		
								Detail 8	1	2	3	1	NO	2	3	3	3		
								Detail 10	1	2	3	1	NO	2	3	3	3		
								Summary	6	1	2	3	1	NO	2	3	3	1	YES Run In Phase
33/29	DFC		25/07/91	05/09/91	16/10/91	Placebo	CONSTIPATION	Detail 2	1	2	3	1	NO	2	3	3	3		
								Detail 3	1	2	3	1	NO	2	3	3	3		
								Detail 4	1	2	3	1	NO	2	3	3	3		
								Detail 5	1	2	3	1	NO	2	3	3	3		
								Detail 6	1	2	3	1	NO	2	3	3	3		
								Detail 8	1	2	3	1	NO	2	3	3	3		
								Detail 10	1	2	3	1	NO	2	3	3	3		
								Summary	5	1	2	3	1	NO	2	3	3	1	NO Run In Phase

1462

Severity: 0=unknown, 1= mild, 2= moderate, 3= severe, 4= life threatening
 Study drug: 1= no change, 2= dose reduced, 3= def. withdrawn, 4= temp. inter.
 Hospital: 1= required, 2= not req., 3= not appl.
 Disapp./Reapp.: 1= no, 2= yes, 3= not appl.
 Symptomatic treatment: 0= no, 1= yes
 (c) adverse event used for statistical analysis

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R0D
 REFORMETINE - PROTOCOL 20124/613
 Listing No.: 11.9
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

9550077

Pat. No.	Init.	Start date	End date	Treatment	Adverse event	Onset date	Type record	Visit No	Last report visit	Mist rcty	Hist rcty	Rel Ship	Stud Sym	Dis Hosp	Re app.	Duc app.	Conc (C)	Phase		
1	33/29	07/91	05/09/91	18/10/91 Placebo	LIBIDO DECREASED	24/08/91	Detail	5	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	6	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	8	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	10	1	2	3	1	NO	2	3	3	3	3	3	
							Summary	30/09/91	10	1	2	3	1	NO	2	3	3	3	3	1 YES Run In Phase
36/302	LM	27/08/91	09/10/91	17/12/91 Placebo	AMENORRHEA	29/08/91	Detail	1	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	2	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	3	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	4	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	5	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	6	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	7	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	8	1	2	3	1	NO	2	3	3	3	3	3	
							Summary	29/09/91	5	1	2	3	1	NO	2	3	3	3	3	1 YES Run In Phase
							Summary	29/09/91	5	1	2	3	1	NO	2	3	3	3	3	1 YES Run In Phase
40/306	EM	25/09/91	06/11/91	22/09/92 Placebo	DIZZINESS	10/10/91	Detail	3	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	4	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	5	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	6	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	7	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	8	1	2	3	1	NO	2	3	3	3	3	3	
							Summary	17/11/91	6	1	2	3	1	NO	2	3	3	3	3	1 YES Run In Phase
							Summary	17/11/91	6	1	2	3	1	NO	2	3	3	3	3	1 YES Run In Phase
							Detail	2	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	3	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	4	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	5	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	6	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	7	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	8	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	9	1	2	3	1	NO	2	3	3	3	3	3	
							Summary	15/11/91	6	1	2	3	1	NO	2	3	3	3	3	1 YES Run In Phase
							Summary	15/11/91	6	1	2	3	1	NO	2	3	3	3	3	1 YES Run In Phase
41/307	SFS	25/09/91	06/11/91	26/07/92 Placebo	CONSTIPATION	02/10/91	Detail	2	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	3	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	4	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	5	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	6	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	7	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	8	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	9	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	10	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	11	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	12	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	13	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	14	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	15	1	2	3	1	NO	2	3	3	3	3	3	
							Detail	16	1	2	3	1	NO	2	3	3	3	3	3	

1462

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=fatal
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req, 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq, 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=suspect, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 11.0

ADVERSE EVENTS
DOUBLE BLIND PHASE

Con. Patient	Int.	Start date	Start D.B.	Treatment	Adverse event	Onset data	Type record	Visit End No data	Last report visit	Save rity	Hist ary	Re1 ship	Stud drug	Symp treat	Dis hosp app.	Re come (c)	Out D.B.						
																		End data	Treatment	Adverse event	Onset data	Type record	Visit End No data
1	51/315	ASA	26/11/91	07/12/91	25/10/92	Placebo	MONTH DRY	06/11/91	Detail Detail Summary	6 8 15/12/91	1 1 1	2 2 2	3 3 3	1 1 1	NO NO NO	2 2 2	3 3 3	1 1 1	YES YES YES	Run Run Run	In In In	Phase	
	59/321	SPF	18/12/91	29/01/92	15/12/92	Placebo	SWEATING INCREASED	28/12/91	Detail Detail Detail Summary	1 2 3 5	1 1 1 1	2 2 2 2	3 3 3 3	1 1 1 1	NO NO NO NO	2 2 2 2	3 3 3 3	1 1 1 1	YES YES YES YES	Run Run Run Run	In In In In	Phase	
	64/324	EMF	18/01/92	29/02/92	15/01/93	Placebo	CONSTIPATION	20/12/91	Detail Detail Detail Summary	1 2 3 5	1 1 1 1	2 2 2 2	3 3 3 3	1 1 1 1	NO NO NO NO	2 2 2 2	3 3 3 3	1 1 1 1	YES YES YES YES	Run Run Run Run	In In In In	Phase	
	64/325	EMF	18/01/92	29/02/92	15/01/93	Placebo	CONSTIPATION	20/01/92	Detail Detail Detail Detail Detail Detail Summary	1 2 3 4 5 6 11/03/92 11/03/92	1 1 1 1 1 1 10	1 1 1 1 1 1 1	2 2 2 2 2 2 2	3 3 3 3 3 3 3	1 1 1 1 1 1 1	NO NO NO NO NO NO NO	2 2 2 2 2 2 2	3 3 3 3 3 3 3	1 1 1 1 1 1 1	YES YES YES YES YES YES YES	Run Run Run Run Run Run Run	In In In In In In In	Phase

146

Serivity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with see., 3=still present, 4=search
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=dubtful, 5=unknown, 6=none
symptomatic treatment: 0=na, 1=yes
(c) adverse event used for statistical analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RAD

REBORETTINE - PROTOCOL 20124/013
Listing No.: 11.0

ADVERSE EVENTS
DOUBLE BLIND PHASE

Can. Patient Init.	Start date	End date	Treatment	Adverse event	Onset date	Type record	Visit No	Last report visit	Sev	Hist	Rel	Stud	Symp	Dis	Re	Out	D.B.						
								visit		city	ary	ship	drug	tra	Hosp	app.	come	(c) Phase					
1	64/325 EWF	18/01/92	27/02/92	15/01/93 Placebo	SWEATING INCREASED	20/01/92	1	1	2	3	1	NO	2	3	3	3							
							2	1	2	3	1	NO	2	3	3	3							
							3	1	2	3	1	NO	2	3	3	3							
							4	1	2	3	1	NO	2	3	3	3							
							5	1	2	3	1	NO	2	3	3	3							
							6	1	2	3	1	NO	2	3	3	3							
							8	1	2	3	1	NO	2	3	3	3							
							10	20/03/92	1	2	3	1	NO	2	3	3	1						
							Summary	20/03/92	10	1	2	3	1	NO	2	3	3	1	YES Run In Phase				
							70/328 HLM	25/01/92	07/03/92	26/06/92 Placebo	CONSTIPATION	18/04/92	12	1	2	3	1	NO	2	3	3	3	
14	1	2	3	1	NO	2							3	3	3								
16	1	2	3	1	NO	2							3	3	3								
18	1	2	3	1	NO	2							3	3	3								
20	1	2	3	1	NO	2							3	3	3								
22	26/06/92	1	2	3	1	NO							2	3	3	1							
Summary	26/06/92	22	1	2	3	1							NO	2	3	3	1	YES Double Blind					
76/124 SFA	08/02/92	21/03/92	05/02/93 Placebo	CONSTIPATION	30/11/92	44							1	2	3	1	NO	2	3	3	3		
						46							1	2	3	1	NO	2	3	3	3		
						48							03/01/93	1	2	3	1	NO	2	3	3	1	
						Summary	03/01/93	48	1	2	3	1	NO	2	3	3	1	YES Double Blind					
						79/126 JCH	08/02/92	21/03/92	05/02/93 Placebo	MOUTH DRY	19/02/92	1	1	2	3	1	NO	2	3	3	3		
												2	1	2	3	1	NO	2	3	3	3		
												3	1	2	3	1	NO	2	3	3	3		
												4	1	2	3	1	NO	2	3	3	3		
												5	1	2	3	1	NO	2	3	3	3		
												6	1	2	3	1	NO	2	3	3	3		
Summary	19/02/92	6	1	2	3							1	NO	2	3	3	3						

1466

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETHINE - PROTOCOL 20124/013
Listing No.: 11.0

ADVERSE EVENTS
DOUBLE BLIND PHASE

Cn.	Patient	Init.	Start date	Start	End date	Treatment	Adverse event	Onset date	Type record	Visit No	Last report visit	Save r.f.by	HIST opy	Rel Hist	Stud Sympt	Dis app.	Re com	Out. D.B.	
																			1
1	77/126	JCM	08/02/92	21/05/92	05/02/93	Placebo	MOUTH DRY	10/02/92	Detail	8	1	2	3	1	MO	2	3	3	
									Detail	10	1	2	3	1	MO	2	3	3	
									Detail	12	1	2	3	1	MO	2	3	3	
									Detail	14	1	2	3	1	MO	2	3	3	
									Detail	16	1	2	3	1	MO	2	3	3	
									Detail	18	1	2	3	1	MO	2	3	3	
									Detail	20	1	2	3	1	MO	2	3	3	
									Detail	22	1	2	3	1	MO	2	3	3	
									Detail	24	1	2	3	1	MO	2	3	3	
									Detail	26	1	2	3	1	MO	2	3	3	
									Detail	28	1	2	3	1	MO	2	3	3	
									Detail	30	1	2	3	1	MO	2	3	3	
									Summary	52	1	2	3	1	MO	2	3	3	
										12/09/92								1 YES Run In Phase	
									Detail	8	1	2	3	1	MO	2	3	3	
									Detail	10	1	2	3	1	MO	2	3	3	
									Detail	12	1	2	3	1	MO	2	3	3	
									Summary	30/04/92	12	1	2	3	3	NO	2	2	3
										30/04/92								1 YES Double Blind	
									Detail	30	1	2	3	1	MO	2	3	3	
									Detail	32	1	2	3	1	MO	2	3	3	
									Detail	34	1	2	3	1	MO	2	3	3	
									Detail	40	1	2	3	1	MO	2	3	3	
									Detail	42	1	2	3	1	MO	2	3	3	
									Summary	20/11/92	42	1	2	3	1	MO	2	3	3
										20/11/92								1 YES Double Blind	
									Detail	1	1	2	3	1	MO	2	3	3	
									Detail	2	1	2	3	1	MO	2	3	3	
									Detail	3	1	2	3	1	MO	2	3	3	
									Detail	4	1	2	3	1	MO	2	3	3	
									Detail	5	1	2	3	1	MO	2	3	3	
									Detail	6	1	2	3	1	MO	2	3	3	
									Detail	8	1	2	3	1	MO	2	3	3	
									Detail	10	1	2	3	1	MO	2	3	3	
									Detail	12	1	2	3	1	MO	2	3	3	
									Summary	20/04/92	12	1	2	3	1	MO	2	3	3
										20/04/92								1 YES Run In Phase	

1467

Severity: 0=unknown, 1= mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=def. withdraw, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Resp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 --- History: 1=present before, 2=not observe bef., 3=unknown

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOCETININE - PROTOCOL 2012/013
Listing No.: 11.6

ADVERSE EVENTS
DOUBLE BLIND PHASE

Pat. No.	Patent Init.	Start date	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End No date	Last visit rcty	Save rcty	Hist rcty	Rel. ship	Re. Stum	Symp	Dis. app.	Re. some	Out. (c)	D.B. Phase							
1	64/136	IN	05/02/92	21/05/92	05/02/95 Placebo	MOUTH DRY	09/02/92	1	1	2	3	1	NO	2	3	3	3	3	3	1						
								2	1	2	3	1	NO	2	3	3	3	3	3							
								3	1	2	3	1	NO	2	3	3	3	3	3		3	3	3	3		
								4	1	2	3	1	NO	2	3	3	3	3	3		3	3	3	3	3	
								5	1	2	3	1	NO	2	3	3	3	3	3		3	3	3	3	3	3
								6	1	2	3	1	NO	2	3	3	3	3	3		3	3	3	3	3	3
								7	1	2	3	1	NO	2	3	3	3	3	3		3	3	3	3	3	3
								8	1	2	3	1	NO	2	3	3	3	3	3		3	3	3	3	3	3
								9	1	2	3	1	NO	2	3	3	3	3	3		3	3	3	3	3	3
								10	1	2	3	1	NO	2	3	3	3	3	3		3	3	3	3	3	3
								11	1	2	3	1	NO	2	3	3	3	3	3		3	3	3	3	3	3
								12	1	2	3	1	NO	2	3	3	3	3	3		3	3	3	3	3	3
								13	1	2	3	1	NO	2	3	3	3	3	3		3	3	3	3	3	3
								14	1	2	3	1	NO	2	3	3	3	3	3		3	3	3	3	3	3
								15	1	2	3	1	NO	2	3	3	3	3	3		3	3	3	3	3	3
								16	1	2	3	1	NO	2	3	3	3	3	3		3	3	3	3	3	3
								17	1	2	3	1	NO	2	3	3	3	3	3		3	3	3	3	3	3
								18	1	2	3	1	NO	2	3	3	3	3	3		3	3	3	3	3	3
								19	1	2	3	1	NO	2	3	3	3	3	3		3	3	3	3	3	3
								20	1	2	3	1	NO	2	3	3	3	3	3		3	3	3	3	3	3
								21	1	2	3	1	NO	2	3	3	3	3	3		3	3	3	3	3	3
								22	1	2	3	1	NO	2	3	3	3	3	3		3	3	3	3	3	3
								23	1	2	3	1	NO	2	3	3	3	3	3		3	3	3	3	3	3
								24	1	2	3	1	NO	2	3	3	3	3	3		3	3	3	3	3	3
Summary	15/07/92	24	1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	1	YES Run In Phase							
85	131	MLP	05/02/92	21/05/92	05/02/95 Placebo	DIARRHOEA	17/05/92	25	1	2	4	1	NO	2	3	3	3	3	1							
								26	1	2	4	1	NO	2	3	3	3									
								30	1	2	4	1	NO	2	3	3	3	3								
Summary	01/09/92	30	1	2	4	1	NO	2	3	3	3	3	3	3	3	1	YES Double Blind									
93	136	AL	13/02/92	26/05/92	10/02/95 Placebo	SWEATING INCREASED	15/02/92	1	1	2	3	1	NO	2	3	3	3	3	1							
								2	1	2	3	1	NO	2	3	3	3	3								
								3	1	2	3	1	NO	2	3	3	3	3								
								4	1	2	3	1	NO	2	3	3	3	3								
								5	1	2	3	1	NO	2	3	3	3	3								
								6	1	2	3	1	NO	2	3	3	3	3								
								7	1	2	3	1	NO	2	3	3	3	3								
								8	1	2	3	1	NO	2	3	3	3	3								
								9	1	2	3	1	NO	2	3	3	3	3								
								10	1	2	3	1	NO	2	3	3	3	3								
								Summary	16/06/92	10	1	2	3	1	NO	2	3	3		3	3	3	3	3	1	YES Run In Phase
95	136	AL	15/02/92	TREMOR	15/02/92	1	1	2	3	1	NO	2	3	3	3	3	3	1								
						2	1	2	3	1	NO	2	3	3	3											
						3	1	2	3	1	NO	2	3	3	3											
						4	1	2	3	1	NO	2	3	3	3											

1468

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=def. withdraw, 4=temp. inter.
 Hospital: 1=recovered, 2=not recd, 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R02
 REBORENTINE - PROTOCOL 20126/013
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Con. Patient	Init.	Start date	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End date	Last visit rcty	Save Hist	Real Stud	Symp tree	Dix app.	Re app.	Out	D.B. some (C)	Phase		
1	95/136 AL	13/02/92	26/02/92	10/02/93 Placebo	TREMOR	15/02/92	Detail 5	1	2	5	1	NO	2	3	3	3				
							Detail 6	1	2	3	1	NO	2	3	3	3				
							Detail 8	1	2	3	1	NO	2	3	3	3				
							Detail 10	11/06/92	1	2	3	1	NO	2	3	3				
							Summary	11/06/92	10	1	2	3	1	NO	2	3	3	1	YES Run In Phase	
96/137 RAB	13/02/92	26/03/92	10/02/93 Placebo	CONSTIPATION	17/02/92	Detail 1	1	2	3	1	NO	2	3	3	3					
							Detail 2	1	2	3	1	NO	2	3	3	3				
							Detail 3	1	2	3	1	NO	2	3	3	3				
							Detail 4	1	2	3	1	NO	2	3	3	3				
							Detail 5	1	2	3	1	NO	2	3	3	3				
							Detail 6	1	2	3	1	NO	2	3	3	3				
							Detail 8	1	2	3	1	NO	2	3	3	3				
							Detail 9	1	2	3	1	NO	2	3	3	3				
							Detail 12	1	2	3	1	NO	2	3	3	3				
							Detail 14	1	2	3	1	NO	2	3	3	3				
							Detail 16	1	2	3	1	NO	2	3	3	3				
							Detail 18	1	2	3	1	NO	2	3	3	3				
							Detail 20	1	2	3	1	NO	2	3	3	3				
							Detail 22	1	2	3	1	NO	2	3	3	3				
							Summary	24	20/07/92	24	1	2	3	1	NO	2	3	3	1	YES Run In Phase
							Summary	20/07/92	24	1	2	3	1	NO	2	3	3	1	YES Run In Phase	
							Detail 30	01/09/92	1	2	3	1	NO	2	3	3	3			
							Detail 32	20/09/92	1	2	4	1	NO	2	3	3	1			
							Summary	20/09/92	32	1	2	3	1	NO	2	3	3	1	YES Double Blind	
							Detail 42	20/11/92	1	2	3	1	NO	2	3	3	3			
							Detail 44	12/12/92	1	2	4	1	NO	2	3	3	1			
							Summary	12/12/92	44	1	2	3	1	NO	2	3	3	1	YES Double Blind	
100/142 JWA	13/02/92	26/03/92	10/02/93 Placebo	MIGRAITION DISORDER	01/09/92	Detail 30	1	2	3	1	NO	2	3	3	3					
							Detail 32	20/09/92	1	2	4	1	NO	2	3	3	1			
							Summary	20/09/92	32	1	2	3	1	NO	2	3	3	1	YES Double Blind	
106/144 MIF	19/02/92	01/04/92	17/02/93 Placebo	CONSTIPATION	21/02/92	Detail 1	1	2	3	1	NO	2	3	3	3					
							Detail 2	1	2	3	1	NO	2	3	3	3				

1469

Severity: Unknown, mild, Moderate, Severe, --- History: Present before, 2not observe bef., 3unknown
 Study drug: 1no change, 2dose reduced, 3drug withdrawn, 4temp. inter.
 Hospital: 1required, 2not req., 3not appl. -- Outcome: 1recovered, 2ifrc. with ser., 3still present, 4death
 Disapp./Reapp.: 1no, 2yes, 3not appl. -- Relationship: 1definite, 2probable, 3possible, 4doubtful, 5unknown, 6none
 Symptomatic treatment: 0no, 1yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PARACETAMOL CNS RSD
 REMONTEME - PROTOCOL 20126/013
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Cen. Patient	Inst.	Start date	Start D.B.	17/02/93	17/02/93	Placebo	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Sev	Mist	Rel	Stud	Samp	Disapp.	Re	Out	D.B.																			
																						19/02/92	01/04/92	21/02/92	21/02/92	25/09/92	15/09/92	26	1	2	3	1	NO	2	3	3	3	3		
1	194/146	MIF				Placebo	CONSTIPATION	21/02/92	Detail	3			1	2	3	1	NO	2	3	3	3																			
									Detail	4			1	2	3	1	NO	2	3	3	3																			
									Detail	5			1	2	3	1	NO	2	3	3	3																			
									Detail	6			1	2	3	1	NO	2	3	3	3																			
									Detail	8			1	2	3	1	NO	2	3	3	3																			
									Detail	10			1	2	3	1	NO	2	3	3	3																			
									Detail	12			1	2	3	1	NO	2	3	3	3																			
									Detail	14			1	2	3	1	NO	2	3	3	3																			
									Detail	16			1	2	3	1	NO	2	3	3	3																			
									Detail	18			1	2	3	1	NO	2	3	3	3																			
									Detail	20			1	2	3	1	NO	2	3	3	3																			
									Detail	22			1	2	3	1	NO	2	3	3	3																			
									Detail	24	15/09/92		1	2	3	1	NO	2	3	3	3																			
									Detail	26	15/09/92		1	2	3	1	NO	2	3	3	3																			
									Summary				26	1	2	3	1	NO	2	3	3	3	1	YES	Run	In	Phase													
															Placebo	DIARRHOEA	22/10/92	Detail	36	27/10/92		1	2	4	1	NO	2	3	3	3	1									
																		Summary				36	1	2	4	1	NO	2	3	3	3	1	YES	Double	Blind					
																								Placebo	SWEATING INCREASED	21/02/92	Detail	1			1	2	3	1	NO	2	3	3	3	
																											Detail	2			1	2	3	1	NO	2	3	3	3	
																											Detail	3			1	2	3	1	NO	2	3	3	3	
																											Detail	4			1	2	3	1	NO	2	3	3	3	
									Detail	5			1	2	3	1	NO	2	3	3	3																			
									Detail	6			1	2	3	1	NO	2	3	3	3																			
									Detail	8			1	2	3	1	NO	2	3	3	3																			
									Detail	10			1	2	3	1	NO	2	3	3	3																			
Detail	12	05/05/92		1	2	3	1	NO	2	3	3	3																												
Summary				12	1	2	3	1	NO	2	3	3	3	1	YES	Run	In	Phase																						
						Placebo	TACHYCARDIA	01/11/92	Detail	38	08/11/92		1	2	4	1	NO	2	3	3	3																			
									Summary				38	1	2	4	1	NO	2	3	3	3	1	YES	Double	Blind														
															Placebo	LIBIDO DECREASED	21/02/92	Detail	1			1	2	3	1	NO	2	3	3											
Detail	2			1	2	3	1	NO										2	3	3	3																			
Detail	3			1	2	3	1	NO										2	3	3	3																			
Detail	4			1	2	3	1	NO										2	3	3	3																			
Detail	5			1	2	3	1	NO										2	3	3	3																			

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req, 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq, 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS MSD

REBOMETINE - PROTOCOL 20124/013
Listing No.: 11.0

ADVERSE EVENTS
DOUBLE BLIND PHASE

Cen. Patient	Init.	Start date	17/02/92	01/04/92	17/02/93	Placebo	Treatment	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End No data	Last report visit	Save rity	Hist any app.	Mist ship	Re al Hosp	Stud Drug	Sym Area	Dis app.	Re come	Dut. (c)	D.B. Phase
1	105/145	ABS	19/02/92	01/04/92	17/02/93	Placebo	LIBIDO DECREASED				21/02/92	Detail	6		1	2	3	1	NO	2	3	3	3	3	3
											Detail	8		1	2	3	1	NO	2	3	3	3	3	3	3
											Detail	10		1	2	3	1	NO	2	3	3	3	3	3	3
											Detail	12		1	2	3	1	NO	2	3	3	3	3	3	3
											Detail	14		1	2	3	1	NO	2	3	3	3	3	3	3
											Detail	16		1	2	3	1	NO	2	3	3	3	3	3	3
											Detail	18		1	2	3	1	NO	2	3	3	3	3	3	3
											Detail	20		1	2	3	1	NO	2	3	3	3	3	3	3
											Detail	22		1	2	3	1	NO	2	3	3	3	3	3	3
											Detail	24		1	2	3	1	NO	2	3	3	3	3	3	3
											Detail	26		1	2	3	1	NO	2	3	3	3	3	3	3
											Detail	28		1	2	3	1	NO	2	3	3	3	3	3	3
											Summary	34	05/19/92		54	1	2	3	1	NO	2	3	3	3	3
											Summary	35	05/11/92		56	1	2	4	1	NO	2	3	3	3	3
											Summary	36	06/11/92												
											Detail	1		1	2	3	1	NO	2	3	3	3	3	3	3
											Detail	2		1	2	3	1	NO	2	3	3	3	3	3	3
											Detail	3		1	2	3	1	NO	2	3	3	3	3	3	3
											Detail	4		1	2	3	1	NO	2	3	3	3	3	3	3
											Detail	5		1	2	3	1	NO	2	3	3	3	3	3	3
											Detail	6		1	2	3	1	NO	2	3	3	3	3	3	3
											Detail	8		1	2	3	1	NO	2	3	3	3	3	3	3
											Detail	10		1	2	3	1	NO	2	3	3	3	3	3	3
											Detail	12		1	2	3	1	NO	2	3	3	3	3	3	3
											Detail	14		1	2	3	1	NO	2	3	3	3	3	3	3
											Detail	16		1	2	3	1	NO	2	3	3	3	3	3	3
											Detail	18		1	2	3	1	NO	2	3	3	3	3	3	3
											Detail	20		1	2	3	1	NO	2	3	3	3	3	3	3
											Detail	22		1	2	3	1	NO	2	3	3	3	3	3	3
											Detail	24		1	2	3	1	NO	2	3	3	3	3	3	3
											Detail	26		1	2	3	1	NO	2	3	3	3	3	3	3
											Detail	28	25/06/92		28	1	2	3	1	NO	2	3	3	3	3
											Summary	28	25/06/92												
											Summary	28	25/06/92		28	1	2	3	1	NO	2	3	3	3	3
											Summary	28	25/06/92												

1474

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Resp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20126/013
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Can. Patient Init.	Start Date	Start D.B.	Treatment	Adverse event	Onset date	Type record	Visit No	End No date	Last report visit	Seve rity	Hst ory	Rel ship	Stud drug	Sypm trea	Hosp app.	Dis app.	Re One	Out D.B.	(c) Phase	
																				Start date
1 136/146 MRN	19/02/92	01/04/92	16/02/92 Placebo	TREMOR	20/09/92	Detail 32			1 2 3 1	MO	2	3	3	3						
						Detail 34	10/10/92		1 2 4 1	MO	2	3	3	3						
						Summary	10/10/92	34	1 2 5 1	MO	2	3	3	3						1 YES Double Blind
						Detail 1			2 2 3 1	MO	2	3	3	3						
						Detail 2			1 2 3 1	MO	2	3	3	3						
						Detail 3			1 2 3 1	NO	2	3	3	3						
						Detail 4			1 2 3 1	NO	2	3	3	3						
						Detail 5			1 2 3 1	NO	2	3	3	3						
						Detail 6			1 2 3 1	NO	2	3	3	3						
						Detail 7			1 2 3 1	NO	2	3	3	3						
						Detail 8			1 2 3 1	NO	2	3	3	3						
						Detail 9			1 2 3 1	NO	2	3	3	3						
						Detail 10			1 2 3 1	NO	2	3	3	3						
						Detail 11			1 2 3 1	NO	2	3	3	3						
						Detail 12			1 2 3 1	NO	2	3	3	3						
						Detail 13			1 2 3 1	NO	2	3	3	3						
						Detail 14			1 2 3 1	NO	2	3	3	3						
						Detail 15			1 2 3 1	NO	2	3	3	3						
						Detail 16			1 2 3 1	NO	2	3	3	3						
						Detail 17			1 2 3 1	NO	2	3	3	3						
						Detail 18			1 2 3 1	NO	2	3	3	3						
						Detail 19			1 2 3 1	NO	2	3	3	3						
						Detail 20	01/07/92		1 2 3 1	NO	2	3	3	3						
						Summary	01/07/92	20	2 2 3 1	NO	2	3	3	3						1 YES Run In Phase
186/146 STB	20/02/92	02/04/92	17/02/92 Placebo	CONSTIPATION	01/01/93	Detail 46			1 2 3 1	NO	2	3	3	3						
						Detail 48			1 2 3 1	NO	2	3	3	3						
						Detail 50			1 2 3 1	NO	2	3	3	3						
						Detail 52	17/02/93		1 2 2 1	NO	2	3	3	3						
						Summary	17/02/93	52	1 2 2 1	NO	2	3	3	3						1 YES Double Blind
						Detail 1			1 2 3 1	NO	2	3	3	3						
						Detail 2			1 2 3 1	NO	2	3	3	3						
						Detail 3			1 2 3 1	NO	2	3	3	3						
						Detail 4			1 2 3 1	NO	2	3	3	3						
						Detail 5			1 2 3 1	NO	2	3	3	3						
						Detail 6			1 2 3 1	NO	2	3	3	3						
						Detail 8			1 2 3 1	NO	2	3	3	3						
						Detail 10	21/04/92		1 2 3 1	NO	2	3	3	3						
						Detail 19	21/04/92	10	1 2 3 1	NO	2	3	3	3						1 YES Run In Phase
						Summary	21/04/92	10	1 2 3 1	NO	2	3	3	3						
						Detail 34			1 2 3 1	NO	2	3	3	3						
						Detail 36			1 2 3 1	NO	2	3	3	3						
						Detail 38			1 2 3 1	NO	2	3	3	3						

Severely: Unknown, Mild, Moderate, Severe,
 Study drug: Ino change, 2-dose reduced, 3-def, withdraw, 4-temp, inter.
 Hospital: 1-required, 2-not req, 3-not appl. -- Outcome: 1-recovered, 2-rec, with seq, 3-still present, 4-death
 Disapp./Reapp.: 1-no, 2-yes, 3-not appl. -- Relationship: 1-definite, 2-probable, 3-possible, 4-doubtful, 5-unknown, 6-none
 Symptomatic treatment: 0=none, 1=yes
 (c) adverse event used for statistical analysis
 (e) adverse event still present: end date = visit date

1472

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CHE RSD
 REDOMTINE - PROTOCOL 20124/013
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Con. Patient	Init.	Start date	End date	Treatment	Adverse event	Onset date	Type record	Visit No	Visit date	Last report	Save Hist	Rel. Stud	Symp	Dis	Re	Out	b.d.	
										visit rity	ory ship	drug	tree	Hosp	app.	some	(c) Phase	
1	108/148	STB	20/02/92	02/06/92	17/02/95 Placibo	SWEATING INCREASED	05/11/92	40	20/11/92	40	1	2	3	1	NO	2	3	3
									20/11/92						1	NO	2	3
									Summary						1	NO	2	3
									2						1	NO	2	3
									3						1	NO	2	3
									4						1	NO	2	3
									5						1	NO	2	3
									6						1	NO	2	3
									8						1	NO	2	3
									10						1	NO	2	3
									12						1	NO	2	3
									14						1	NO	2	3
									16						1	NO	2	3
									18						1	NO	2	3
									20						1	NO	2	3
									22						1	NO	2	3
									24						1	NO	2	3
									Summary						1	NO	2	3
									24						1	NO	2	3
									29/07/92						1	NO	2	3
									Summary						1	NO	2	3
									24						1	NO	2	3
									29/07/92						1	NO	2	3
									Summary						1	NO	2	3
									30						1	NO	2	3
									32						1	NO	2	3
									34						1	NO	2	3
									36						1	NO	2	3
									Summary						1	NO	2	3
									36						1	NO	2	3
									25/10/92						1	NO	2	3
									Summary						1	NO	2	3
									2						1	NO	2	3
									3						1	NO	2	3
									4						1	NO	2	3
									5						1	NO	2	3
									6						1	NO	2	3
									8						1	NO	2	3
									10						1	NO	2	3
									10						1	NO	2	3
									Summary						1	NO	2	3
									10						1	NO	2	3
									2						1	NO	2	3
									3						1	NO	2	3
									4						1	NO	2	3
									5						1	NO	2	3
									2						1	NO	2	3
									3						1	NO	2	3
									4						1	NO	2	3
									5						1	NO	2	3

1473

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe.
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis

--- History: 1=present before, 2=not observe bef., 3=unknown

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA ONS RED
 RIBONETINE - PHOTCCOL 2012/4/013
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Con.	Patient	Init.	Start date	Treatment	End date	Adverse event	Onset date	Type record	Visit No	report rcty	Hist rcty	Ship	Hist ship	Rel	Stud	Symp	Dis app.	Re app.	Out	D.B.	
1	1111/233	JBF	28/02/92	02/04/92	17/02/93	Placebo	02/03/92	Detail	6	1	2	3	1	NO	2	3	3	3	3	3	3
						TREMXO		Detail	8	1	2	3	1	NO	2	3	3	3	3	3	3
								Detail	10	1	2	3	1	NO	2	3	3	3	3	3	3
								Detail	12	1	2	3	1	NO	2	3	3	3	3	3	3
								Detail	14	1	2	3	1	NO	2	3	3	3	3	3	3
								Summary	20/05/92	14	1	2	3	1	NO	2	3	3	3	3	1
								YES Run In Phase													
114	752	CLF	25/02/92	08/04/92	24/02/93	Placebo	02/03/92	Detail	1	1	2	3	1	NO	2	3	3	3	3	3	3
						CONSTIPATION		Detail	2	1	2	3	1	NO	2	3	3	3	3	3	3
								Detail	3	1	2	3	1	NO	2	3	3	3	3	3	3
								Detail	4	1	2	3	1	NO	2	3	3	3	3	3	3
								Detail	5	1	2	3	1	NO	2	3	3	3	3	3	3
								Detail	6	1	2	3	1	NO	2	3	3	3	3	3	3
								Detail	8	1	2	3	1	NO	2	3	3	3	3	3	3
								Detail	10	1	2	3	1	NO	2	3	3	3	3	3	3
								Detail	12	1	2	3	1	NO	2	3	3	3	3	3	3
								Detail	14	1	2	3	1	NO	2	3	3	3	3	3	3
								Detail	16	1	2	3	1	NO	2	3	3	3	3	3	3
								Detail	18	1	2	3	1	NO	2	3	3	3	3	3	3
								Detail	20	1	2	3	1	NO	2	3	3	3	3	3	3
								Detail	22	1	2	3	1	NO	2	3	3	3	3	3	3
								Detail	24	1	2	3	1	NO	2	3	3	3	3	3	3
								Summary	15/08/92	26	1	2	3	1	NO	2	3	3	3	3	1
								YES Run In Phase													
01			01/03/92			MOJH DKV		Detail	1	1	2	3	1	NO	2	3	3	3	3	3	3
								Detail	2	1	2	3	1	NO	2	3	3	3	3	3	3
								Detail	3	1	2	3	1	NO	2	3	3	3	3	3	3
								Detail	4	1	2	3	1	NO	2	3	3	3	3	3	3
								Detail	5	1	2	3	1	NO	2	3	3	3	3	3	3
								Detail	6	1	2	3	1	NO	2	3	3	3	3	3	3
								Detail	8	1	2	3	1	NO	2	3	3	3	3	3	3
								Detail	10	1	2	3	1	NO	2	3	3	3	3	3	3
								Detail	12	1	2	3	1	NO	2	3	3	3	3	3	3
								Detail	14	1	2	3	1	NO	2	3	3	3	3	3	3
								Detail	16	1	2	3	1	NO	2	3	3	3	3	3	3
								Detail	18	1	2	3	1	NO	2	3	3	3	3	3	3
								Detail	20	1	2	3	1	NO	2	3	3	3	3	3	3
								Detail	22	1	2	3	1	NO	2	3	3	3	3	3	3
								Summary	15/08/92	26	1	2	3	1	NO	2	3	3	3	3	1
								YES Run In Phase													

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Raspp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=suspect, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=none, 1=yes
 (C) adverse event used for statistical analysis

1474

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOMETINE - PROTOCOL 20126/013
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Con. Patient	Init. Start date	Start date	Treatment	End date	Treatment	Adverse event	Onset data	Type record	Visit No	End date	Last report visit	Hist. drug	Hist. Hosp	Rel. app.	Dis. app.	Re. case	Out. Phase								
1	114/332	CLF	26/02/92	08/06/92	24/02/93	Placebo	MOUTH DRY		01/03/92	25	1	2	3	1	NO	2	3	3							
										Detail	26	1	2	3	1	NO	2	3	3	3					
										Detail	28	1	2	3	1	NO	2	3	3	3					
										Detail	30	1	2	3	1	NO	2	3	3	3					
										Detail	32	1	2	3	1	NO	2	3	3	3					
										Detail	34	1	2	3	1	NO	2	3	3	3					
										Detail	36	1	2	3	1	NO	2	3	3	3					
										Detail	38	1	2	3	1	NO	2	3	3	3					
										Detail	40	1	2	3	1	NO	2	3	3	3					
										Detail	42	1	2	3	1	NO	2	3	3	3					
										Summary	42	1	2	3	1	NO	2	3	3	3	1	YES	Run	In	Phase
				02/03/92	PARAMETHESIA				1	1	2	3	1	NO	2	3	3								
									Detail	2	1	2	3	1	NO	2	3	3							
									Detail	3	1	2	3	1	NO	2	3	3							
									Summary	3	1	2	3	1	NO	2	3	3	1	YES	Run	In	Phase		
122	337	HSS	27/02/92	09/06/92	24/02/93	Placebo	HICUTITION DISORDER		10/05/92	2	1	2	3	1	NO	2	3	3							
										Detail	3	1	2	3	1	NO	2	3	3						
										Detail	4	1	2	3	1	NO	2	3	3						
										Detail	5	1	2	3	1	NO	2	3	3						
										Detail	6	1	2	3	1	NO	2	3	3						
										Detail	8	1	2	3	1	NO	2	3	3						
										Detail	10	1	2	3	1	NO	2	3	3						
										Detail	12	1	2	3	1	NO	2	3	3						
										Detail	14	1	2	3	1	NO	2	3	3						
										Detail	16	1	2	3	1	NO	2	3	3						
										Detail	18	1	2	3	1	NO	2	3	3						
										Detail	20	1	2	3	1	NO	2	3	3						
										Detail	22	1	2	3	1	NO	2	3	3						
										Detail	24	1	2	3	1	NO	2	3	3						
Detail	26	1	2	3	1	NO	2	3	3																
Detail	28	1	2	3	1	NO	2	3	3																
Detail	30	1	2	3	1	NO	2	3	3																
Detail	32	1	2	3	1	NO	2	3	3																
Detail	34	1	2	3	1	NO	2	3	3																
Detail	36	1	2	3	1	NO	2	3	3																
Detail	38	1	2	3	1	NO	2	3	3																
Detail	40	1	2	3	1	NO	2	3	3																
Summary	40	1	2	3	1	NO	2	3	3	1	YES	Run	In	Phase											

1475

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CHEM RO

REBOMETINE - PROTOCOL 20124/013

Listing No.: 11.0

ADVERSE EVENTS
DOUBLE BLIND PHASE

Con. Patient	Init. Start date	Treatment	End date	Adverse event	Onset date	Type record	Visit No	Last report visit	Save rity	Hist ery	Shid drug	Stud tress	Symp	Dis Hsp	Re APP	Out some	(c) Phase	
1	122/537	MS	27/02/92	09/04/92	24/02/93	Placebo	MOUTH DRY	28/02/92	Detail 1	1	2	3	1	NO	2	3	3	3
								Detail 2	1	2	3	1	NO	2	3	3	3	3
								Detail 3	1	2	3	1	NO	2	3	3	3	3
								Detail 4	1	2	3	1	NO	2	3	3	3	3
								Detail 5	1	2	3	1	NO	2	3	3	3	3
								Detail 6	1	2	3	1	NO	2	3	3	3	3
								Detail 7	1	2	3	1	NO	2	3	3	3	3
								Detail 8	1	2	3	1	NO	2	3	3	3	3
								Detail 9	1	2	3	1	NO	2	3	3	3	3
								Detail 10	1	2	3	1	NO	2	3	3	3	3
								Detail 11	1	2	3	1	NO	2	3	3	3	3
								Detail 12	1	2	3	1	NO	2	3	3	3	3
								Detail 13	1	2	3	1	NO	2	3	3	3	3
								Detail 14	1	2	3	1	NO	2	3	3	3	3
								Detail 15	1	2	3	1	NO	2	3	3	3	3
								Detail 16	1	2	3	1	NO	2	3	3	3	3
								Detail 17	1	2	3	1	NO	2	3	3	3	3
								Detail 18	1	2	3	1	NO	2	3	3	3	3
								Detail 19	1	2	3	1	NO	2	3	3	3	3
								Detail 20	1	2	3	1	NO	2	3	3	3	3
								Detail 21	1	2	3	1	NO	2	3	3	3	3
								Detail 22	1	2	3	1	NO	2	3	3	3	3
								Detail 23	1	2	3	1	NO	2	3	3	3	3
								Detail 24	1	2	3	1	NO	2	3	3	3	3
								Detail 25	1	2	3	1	NO	2	3	3	3	3
								Detail 26	1	2	3	1	NO	2	3	3	3	3
								Detail 27	1	2	3	1	NO	2	3	3	3	3
								Detail 28	1	2	3	1	NO	2	3	3	3	3
								Detail 29	1	2	3	1	NO	2	3	3	3	3
								Detail 30	1	2	3	1	NO	2	3	3	3	3
								Detail 31	1	2	3	1	NO	2	3	3	3	3
								Detail 32	1	2	3	1	NO	2	3	3	3	3
								Detail 33	1	2	3	1	NO	2	3	3	3	3
								Detail 34	1	2	3	1	NO	2	3	3	3	3
								Detail 35	1	2	3	1	NO	2	3	3	3	3
								Detail 36	1	2	3	1	NO	2	3	3	3	3
								Detail 37	1	2	3	1	NO	2	3	3	3	3
								Detail 38	1	2	3	1	NO	2	3	3	3	3
								Detail 39	1	2	3	1	NO	2	3	3	3	3
								Detail 40	1	2	3	1	NO	2	3	3	3	3
								Detail 41	1	2	3	1	NO	2	3	3	3	3
								Detail 42	1	2	3	1	NO	2	3	3	3	3
								Detail 43	1	2	3	1	NO	2	3	3	3	3
								Detail 44	1	2	3	1	NO	2	3	3	3	3
Summary	64	21/12/92	21/12/92	44	1	2	3	1	NO	2	3	3	1	YES	Run	In	Phase	
126	538	PIC	27/02/92	09/04/92	24/02/93	Placebo	CONSTIPATION	26/02/92	Detail 1	1	2	3	1	NO	2	3	3	3
								Detail 2	1	2	3	1	NO	2	3	3	3	
								Detail 3	1	2	3	1	NO	2	3	3	3	
								Detail 4	1	2	3	1	NO	2	3	3	3	
								Detail 5	1	2	3	1	NO	2	3	3	3	
								Detail 6	1	2	3	1	NO	2	3	3	3	
								Detail 7	1	2	3	1	NO	2	3	3	3	
								Detail 8	1	2	3	1	NO	2	3	3	3	
								Detail 9	1	2	3	1	NO	2	3	3	3	
								Detail 10	1	2	3	1	NO	2	3	3	3	
								Detail 11	1	2	3	1	NO	2	3	3	3	
								Detail 12	1	2	3	1	NO	2	3	3	3	
								Detail 13	1	2	3	1	NO	2	3	3	3	
								Detail 14	1	2	3	1	NO	2	3	3	3	
								Detail 15	1	2	3	1	NO	2	3	3	3	
								Detail 16	1	2	3	1	NO	2	3	3	3	
								Detail 17	1	2	3	1	NO	2	3	3	3	
								Detail 18	1	2	3	1	NO	2	3	3	3	

Severily: 1=unknown, 1=all, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req, 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq, 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOWETINE - PROTOCOL 20124/013
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Con. Patient	Init.	Start date	Treatment	End date	Treatment	Onset date	Type record	Visit No	Visit date	Report	Save	Hist	Rel	Stud	Symp	Dis	Re	Out	D.B.	
Last																				
visit r.t.v. nry ship drue tree Hosp app. some (C) Phase																				
1	134/339	PPC	27/02/92	09/06/92	24/02/95	Placebo	CONSTITIPATION	28/02/92	Detail	20	1	2	3	1	NO	2	3	3	3	3
									Detail	22	1	2	3	1	NO	2	3	3	3	3
									Detail	24	1	2	3	1	NO	2	3	3	3	3
									Detail	26	2	2	3	1	NO	2	3	3	3	1
									Summary	20/08/92	26	2	2	3	1	NO	2	3	3	1
																				YES Run In Phase
									Detail	1	1	2	3	1	NO	2	3	3	3	3
									Detail	2	1	2	3	1	NO	2	3	3	3	3
									Detail	3	1	2	3	1	NO	2	3	3	3	3
									Detail	4	1	2	3	1	NO	2	3	3	3	3
									Detail	5	1	2	3	1	NO	2	3	3	3	3
									Detail	6	1	2	3	1	NO	2	3	3	3	3
									Detail	8	1	2	3	1	NO	2	3	3	3	3
									Detail	10	1	2	3	1	NO	2	3	3	3	3
									Detail	12	1	2	3	1	NO	2	3	3	3	3
									Detail	14	1	2	3	1	NO	2	3	3	3	3
									Detail	16	1	2	3	1	NO	2	3	3	3	3
									Detail	18	1	2	3	1	NO	2	3	3	3	3
									Detail	20	1	2	3	1	NO	2	3	3	3	3
									Detail	22	1	2	3	1	NO	2	3	3	3	3
									Detail	24	1	2	3	1	NO	2	3	3	3	3
									Detail	26	1	2	3	1	NO	2	3	3	3	3
									Detail	28	1	2	3	1	NO	2	3	3	3	3
									Detail	30	1	2	3	1	NO	2	3	3	3	3
									Detail	32	1	2	3	1	NO	2	3	3	3	3
									Detail	34	1	2	3	1	NO	2	3	3	3	3
									Detail	36	1	2	3	1	NO	2	3	3	3	3
									Detail	38	1	2	3	1	NO	2	3	3	3	3
									Detail	40	1	2	3	1	NO	2	3	3	3	3
									Detail	42	1	2	3	1	NO	2	3	3	3	3
									Summary	08/12/92	42	1	2	3	1	NO	2	3	3	1
																				YES Run In Phase
130/345	EGA	29/02/92	11/04/92	31/07/92	Placebo	CONSTITIPATION		24/03/92	Detail	4	1	2	3	1	NO	2	3	3	3	3
									Detail	5	1	2	3	1	NO	2	3	3	3	3
									Detail	6	1	2	3	1	NO	2	3	3	3	3
									Detail	8	1	2	3	1	NO	2	3	3	3	3
									Detail	10	1	2	3	1	NO	2	3	3	3	3
									Detail	12	1	2	3	1	NO	2	3	3	3	3
									Detail	14	1	2	3	1	NO	2	3	3	3	3
									Detail	16	1	2	3	1	NO	2	3	3	3	3
									Detail	18	1	2	3	1	NO	2	3	3	3	3

1477

Severity: unknown, mild, moderate, severe, --- History: present before, 2=not observe bef., 3=unknown
 Study drug: lmo change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: l=required, 2=not req., 3=not appl. --- Outcome: l=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: l=no, 2=yes, 3=not appl. --- Relationship: l=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 1=no, 2=yes
 (C) adverse event used for statistical analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Con. Patient	Init.	Start date	Start D.B.	Treatment	End date	Treatment	Adverse event	Onset data	Type record	Visit No	End No date	Last report visit	Save rity	Hist dry	Rel shld	Stud traa	Symp app.	Dis app.	Re Out	D.B. com	(C) Phase	
1	130/345	EGA	21/02/92	11/06/92	31/07/92	Placebo	CONSTIPATION	24/05/92	Detail 18	1	18	1	2	3	1	NO	2	3	3	3	3	
									Detail 20	2	20	1	2	3	1	NO	2	3	3	3	3	
									Detail 22	3	22	1	2	3	NO	2	2	2	3	1	1	
									Summary	31/07/92	22	1	2	2	3	NO	2	2	2	3	1	YES Run In Phase
1	131/346	JPM	21/05/92	01/05/92	19/05/93	Placebo	CONSTIPATION	25/05/92	Detail 1	1	1	1	2	3	1	NO	2	3	3	3	3	
									Detail 2	2	2	1	2	3	1	NO	2	3	3	3	3	
									Detail 3	3	3	1	2	3	1	NO	2	3	3	3	3	
									Detail 4	4	4	1	2	3	1	NO	2	3	3	3	3	
									Detail 5	5	5	1	2	3	1	NO	2	3	3	3	3	
									Detail 6	6	6	1	2	3	1	NO	2	3	3	3	3	
									Detail 7	7	7	1	2	3	1	NO	2	3	3	3	3	
									Detail 8	8	8	1	2	3	1	NO	2	3	3	3	3	
									Detail 9	9	9	1	2	3	1	NO	2	3	3	3	3	
									Detail 10	10	10	1	2	3	1	NO	2	3	3	3	3	
									Detail 11	11	11	1	2	3	1	NO	2	3	3	3	3	
									Detail 12	12	12	1	2	3	1	NO	2	3	3	3	3	
									Detail 13	13	13	1	2	3	1	NO	2	3	3	3	3	
									Detail 14	14	14	1	2	3	1	NO	2	3	3	3	3	
									Detail 15	15	15	1	2	3	1	NO	2	3	3	3	3	
									Detail 16	16	16	1	2	3	1	NO	2	3	3	3	3	
									Detail 17	17	17	1	2	3	1	NO	2	3	3	3	3	
									Detail 18	18	18	1	2	3	1	NO	2	3	3	3	3	
									Detail 19	19	19	1	2	3	1	NO	2	3	3	3	3	
									Detail 20	20	20	1	2	3	1	NO	2	3	3	3	3	
									Detail 21	21	21	1	2	3	1	NO	2	3	3	3	3	
									Detail 22	22	22	1	2	3	1	NO	2	3	3	3	3	
									Detail 23	23	23	1	2	3	1	NO	2	3	3	3	3	
									Detail 24	24	24	1	2	3	1	NO	2	3	3	3	3	
									Detail 25	25	25	1	2	3	1	NO	2	3	3	3	3	
									Detail 26	26	26	1	2	3	1	NO	2	3	3	3	3	
									Summary	10/09/92	26	1	2	3	1	NO	2	3	3	3	1	YES Run In Phase
									Detail 45	45	45	1	2	4	1	NO	2	3	3	3	3	
									Summary	01/02/93	46	1	2	4	1	NO	2	3	3	3	1	YES Double Blind
									Detail 2	2	2	1	2	3	1	NO	2	3	3	3	3	
									Detail 3	3	3	1	2	3	1	NO	2	3	3	3	3	
									Detail 4	4	4	1	2	3	1	NO	2	3	3	3	3	
									Detail 5	5	5	1	2	3	1	NO	2	3	3	3	3	
									Detail 6	6	6	1	2	3	1	NO	2	3	3	3	3	
									Detail 8	8	8	1	2	3	1	NO	2	3	3	3	3	
									Summary	10/05/92	6	1	2	3	1	NO	2	3	3	3	1	YES Run In Phase
									Detail 1	1	1	1	2	3	1	NO	2	3	3	3	3	
									Detail 2	2	2	1	2	3	1	NO	2	3	3	3	3	
									Detail 3	3	3	1	2	3	1	NO	2	3	3	3	3	
									Detail 4	4	4	1	2	3	1	NO	2	3	3	3	3	

Severily: unknown, 1= mild, 2= moderate, 3= severe, --- History: 1= present before, 2= not observe bef., 3= unknown
 Study drug: 1= no change, 2= dose reduced, 3= def. withdraw, 4= temp. inter.
 Hospital: 1= required, 2= not req., 3= not appl. -- Outcomes: 1= recovered, 2= rec. with seq., 3= still present, 4= death
 Disapp./Reapp.: 1= no, 2= yes, 3= not appl. -- Relationship: 1= definite, 2= probable, 3= possible, 4= doubtful, 5= unknown, 6= none
 Symptomatic treatment: 0= no, 1= yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

1478

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD
 REBONETINE - PROTOCOL 20124/R15
 Listing No.: 1110
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Cen. Patient Init.	Start date	Start date	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End date	LAST		Dis	Re	Out	D.B.									
										report	Save													
1156/349 ANP	25/05/92	06/05/92	25/05/93	Placebo	LIBIDO DECREASED	29/05/92	Detail	16		1	2	3	1	NO	2	3	3							
							Detail	20		1	2	3	1	NO	2	3	3	3						
							Detail	22		1	2	3	1	NO	2	3	3	3						
							Detail	24		1	2	3	1	NO	2	3	3	3						
							Detail	26	12/09/92	1	2	3	1	NO	2	3	3	1						
							Summary	12/09/92	26	1	2	3	1	NO	2	3	3	1	YES Run In Phase					
							Detail	30		1	2	3	1	NO	2	3	3	3						
							Detail	32		1	2	3	1	NO	2	3	3	3						
							Detail	34	10/11/92	1	2	3	1	NO	2	3	3	1	YES Double Blind					
							Summary	10/11/92	34	1	2	3	1	NO	2	3	3	1	YES Double Blind					
138/350 LBV	25/05/92	06/05/92	23/05/93	Placebo	TACHYCARDIA	26/02/93	Detail	50	05/05/93	1	2	3	1	NO	2	3	3							
							Summary	05/05/93	50	1	2	3	1	NO	2	3	3	1	YES Double Blind					
141/353 AMG	25/05/92	06/05/92	01/12/92	Placebo	CONSTIPATION	27/05/92	Detail	1		1	2	3	1	NO	2	3	3							
							Detail	2		1	2	3	1	NO	2	3	3							
							Detail	3		1	2	3	1	NO	2	3	3							
							Detail	4		1	2	3	1	NO	2	3	3							
							Detail	5		1	2	3	1	NO	2	3	3							
							Detail	6		1	2	3	1	NO	2	3	3							
							Detail	8		1	2	3	1	NO	2	3	3							
							Detail	10		1	2	3	1	NO	2	3	3							
							Detail	12		1	2	3	1	NO	2	3	3							
							Detail	14		1	2	3	1	NO	2	3	3							
							Detail	16		1	2	3	1	NO	2	3	3							
							Detail	18		1	2	3	1	NO	2	3	3							
							Detail	20		1	2	3	1	NO	2	3	3							
							Detail	22		1	2	3	1	NO	2	3	3							
							Detail	24	01/09/92	1	2	3	1	NO	2	3	3	1	YES Run In Phase					
							Summary	01/09/92	24	1	2	3	1	NO	2	3	3	1	YES Run In Phase					
							148/356 LBV	25/05/92	06/05/92	23/05/93	Placebo	TACHYCARDIA	25/05/92	Detail	28	30/09/92	1	2	4	1	NO	2	3	3
														Summary	30/09/92	28	1	2	4	1	NO	2	3	3
							141/353 AMG	25/05/92	06/05/92	01/12/92	Placebo	TREMOR	27/05/92	Detail	1		1	2	3	1	NO	2	3	3
														Detail	2		1	2	3	1	NO	2	3	3

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Repp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CHS RBD

REBOMETINE - PROTOCOL 2024/715
Listing No.: 11.0

ADVERSE EVENTS
DOUBLE BLIND PHASE

Can. Patient Infr.	Start date	Start D.B.	Treatment	End date	Treatment	Adverse event	Onset date	Type	Visit record	End No date	Last report visit rity	Save Hist	Rel. Stud Sympt	Dis app.	Re Out D.B.										
141/253 AMB	25/03/92	06/05/92	01/12/92	Placebo	TREMOB		27/03/92	Detail	3		1	2	3	1	NO	2	3	3							
							Detail	4		1	2	3	1	NO	2	3	3	3							
							Detail	5		1	2	3	1	NO	2	3	3	3							
							Detail	6		1	2	3	1	NO	2	3	3	3							
							Detail	8		1	2	3	1	NO	2	3	3	3							
							Detail	10		1	2	3	1	NO	2	3	3	3							
							Detail	12		1	2	3	1	NO	2	3	3	3							
							Detail	14	20/04/92	1	2	3	1	NO	2	3	3	3							
							Summary	20/04/92	14	1	2	3	1	NO	2	3	3	3	1	YES	Run In Phase				
							143/255 JEP	25/03/92	06/05/92	11/08/92	Placebo	EJACULATION FAILURE		01/04/92	Detail	2		1	2	3	1	NO	2	3	3
														Detail	3		1	2	3	1	NO	2	3	3	3
														Detail	4		1	2	3	1	NO	2	3	3	3
														Detail	5		1	2	3	1	NO	2	3	3	3
														Detail	6		1	2	3	1	NO	2	3	3	3
														Detail	8		1	2	3	1	NO	2	3	3	3
														Detail	10	30/05/92	1	2	3	1	NO	2	3	3	3
Detail	12	30/05/92	1	2	3	1								NO	2	3	3	3							
Summary	30/05/92	10	1	2	3	1								NO	2	3	3	3	1	YES	Run In Phase				
149/250 SC	20/03/92	09/05/92	26/03/93	Placebo	CONSTIPATION									01/04/92	Detail	1		1	2	3	1	NO	2	3	3
														Detail	2		1	2	3	1	NO	2	3	3	3
														Detail	3		1	2	3	1	NO	2	3	3	3
														Detail	4		1	2	3	1	NO	2	3	3	3
														Detail	5		1	2	3	1	NO	2	3	3	3
														Detail	6		1	2	3	1	NO	2	3	3	3
														Detail	8		1	2	3	1	NO	2	3	3	3
							Detail	10	23/05/92	1	2	3	1	NO	2	3	3	3							
							Detail	12	23/05/92	1	2	3	1	NO	2	3	3	3							
							Summary	23/05/92	10	1	2	3	1	NO	2	3	3	3	1	YES	Run In Phase				

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 5=unknown
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (*) adverse event used for statistical analysis
 (c) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA DNS RBD
 REBOMETIME - PROTOCOL 20124/013
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Con. Patient	Init.	Start date	Start D.B.	Treatment	End date	End Treatment	Adverse event	Onset date	Type record	Visit No	Visit End No date	Last report visit	Sev	Hist rity	Hist gry	Stud drug	Rel. Stud	Symp app.	Dis app.	Re. some	Out. (c)	D.B. Phase
1	169/568	SC	28/03/92	09/05/92	24/03/93	Placebo	CONSTIPATION	01/04/92	Detail	16		1	2	3	1	NO	2	3	3	3	3	3
									Detail	20		1	2	3	1	NO	2	3	3	3	3	3
									Detail	22		1	2	3	1	NO	2	3	3	3	3	3
									Detail	24	01/09/92	1	2	3	1	NO	2	3	3	3	3	3
									Summary	01/09/92	24	1	2	3	1	NO	2	3	3	3	3	1
																						YES Run In Phase
									Detail	28		1	2	3	1	NO	2	3	3	3	3	3
									Detail	30		1	2	3	1	NO	2	3	3	3	3	3
									Detail	32		1	2	3	1	NO	2	3	3	3	3	3
									Detail	34		1	2	3	1	NO	2	3	3	3	3	3
									Detail	36	01/12/92	1	2	3	1	NO	2	3	3	3	3	3
									Summary	01/12/92	36	1	2	3	1	NO	2	3	3	3	3	1
																						YES Double Blind
									Detail	1		1	2	3	1	NO	2	3	3	3	3	3
									Detail	2		1	2	3	1	NO	2	3	3	3	3	3
									Detail	3		1	2	3	1	NO	2	3	3	3	3	3
									Detail	4		1	2	3	1	NO	2	3	3	3	3	3
									Detail	5		1	2	3	1	NO	2	3	3	3	3	3
									Detail	6		1	2	3	1	NO	2	3	3	3	3	3
									Detail	8		1	2	3	1	NO	2	3	3	3	3	3
									Detail	10		1	2	3	1	NO	2	3	3	3	3	3
									Detail	12		1	2	3	1	NO	2	3	3	3	3	3
									Detail	14		1	2	3	1	NO	2	3	3	3	3	3
									Detail	16		1	2	3	1	NO	2	3	3	3	3	3
									Detail	18		1	2	3	1	NO	2	3	3	3	3	3
									Detail	20		1	2	3	1	NO	2	3	3	3	3	3
									Detail	22		1	2	3	1	NO	2	3	3	3	3	3
									Detail	24		1	2	3	1	NO	2	3	3	3	3	3
									Detail	26		1	2	3	1	NO	2	3	3	3	3	3
									Detail	28	30/09/92	1	2	3	1	NO	2	3	3	3	3	3
									Summary	30/09/92	28	1	2	3	1	NO	2	3	3	3	3	1
																						YES Run In Phase
150/151	VA		28/03/92	09/05/92	10/12/92	Placebo	CONSTIPATION	20/04/92	Detail	4		1	2	3	1	NO	2	3	3	3	3	3
									Detail	5		1	2	3	1	NO	2	3	3	3	3	3
									Detail	6		1	2	3	1	NO	2	3	3	3	3	3
									Detail	8		1	2	3	1	NO	2	3	3	3	3	3
									Detail	10		1	2	3	1	NO	2	3	3	3	3	3
									Detail	12		1	2	3	1	NO	2	3	3	3	3	3
									Detail	14		1	2	3	1	NO	2	3	3	3	3	3

1482

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, --- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMONETINE - PROTOCOL 20126/013
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Pat. No.	Pat. Name	Start date	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Save rity	Hist	Rel	Stud	Disp	Re app.	Out come	D.B.	
1	150/151 WA	20/05/92	09/05/92	16/12/92 Placebo	CONSTIPATION	20/04/92	Detail	16		1	2	3	1	NO	2	3	3	3	3
							Detail	18		1	2	3	1	NO	2	3	3	3	3
							Detail	20		1	2	3	1	NO	2	3	3	3	3
							Detail	22		1	2	3	1	NO	2	3	3	3	3
							Detail	24		1	2	3	1	NO	2	3	3	3	3
							Detail	26	20/09/92	1	2	3	1	NO	2	3	3	3	3
							Summary	20/09/92		26	1	2	3	1	NO	2	3	3	3
																			1 YES Run In Phase
							Detail	24	08/09/92	1	2	4	1	NO	2	3	3	3	3
							Summary	08/09/92		24	1	2	4	1	NO	2	3	3	3
																			1 YES Double Blind
							Detail	1		1	2	3	1	NO	2	3	3	3	3
							Detail	2		1	2	3	1	NO	2	3	3	3	3
							Detail	3		1	2	3	1	NO	2	3	3	3	3
							Detail	4		1	2	3	1	NO	2	3	3	3	3
							Detail	5		1	2	3	1	NO	2	3	3	3	3
							Detail	6	15/05/92	1	2	3	1	NO	2	3	3	3	3
							Summary	15/05/92		6	1	2	3	1	NO	2	3	3	3
																			1 YES Run In Phase
							Detail	1	01/06/92	1	2	3	1	NO	2	3	3	3	3
							Summary	01/06/92		1	1	2	3	1	NO	2	3	3	3
																			1 YES Run In Phase
3	2/61 FIL	17/11/90	29/12/90	05/09/91 Placebo	INSOMNIA	07/12/90	Detail	3	10/12/90	1	1	5	1	YES	2	3	5	1	YES Run In Phase
							Summary	10/12/90		3	1	1	5	1	YES	2	3	5	1
							Detail	1	21/11/90	2	1	6	1	YES	3	3	3	3	3
							Summary	21/11/90		1	2	1	6	1	YES	3	3	3	3
							Detail	3	15/06/91	2	2	3	1	NO	3	3	3	3	3
							Detail	4	25/06/91	1	1	2	2	NO	2	3	1	YES Run In Phase	
							Summary	25/06/91		4	2	2	2	NO	2	3	1	YES Run In Phase	
							Detail	1	15/06/91	2	3	5	1	YES	2	3	3	3	3
							Summary	15/06/91		1	2	3	5	1	YES	2	3	3	3

1483

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Keapp.: 1=no, 2=yes, 3=not appl. -- Relationshp.: 1=definite, 2=probable, 3=possible, 4=undefinite, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CHE RD
 REDOMETINE - PROTOCOL 20124/013
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Con.	Patient	Init.	Start date	Treatment	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End No date	Last report visit	Sev	Hist	Rel	Stud	Symp	Dis app.	Re come	Out	D.B.		
3	1872	TOR	11/06/91	23/05/91	11/09/91	Placebo	CONSTIPATION	12/04/91	Detail	1		2	3	3	1	NO	2	3	3	3	3	3	
									Detail	2		2	3	3	1	NO	2	3	3	3	3	3	
									Detail	3		2	3	3	1	NO	2	3	3	3	3	3	
									Detail	4		2	3	3	1	NO	2	3	3	3	3	3	
									Detail	5		1	3	3	1	NO	2	3	3	3	3	3	
									Detail	6		1	3	3	1	NO	2	3	3	3	3	3	
									Detail	8	01/06/91	1	3	3	1	NO	2	3	3	3	3	3	
									Summary	01/06/91	8	2	5	3	1	NO	2	3	3	3	3	1	
																						YES Run In Phase	
									Detail	10	17/06/91	1	1	4	1	NO	2	3	3	3	3	3	1
									Summary	17/06/91	10	1	1	4	1	NO	2	3	3	3	3	3	1
									Detail	12	22/06/91	1	1	4	1	NO	2	3	3	3	3	3	1
									Summary	22/06/91	12	1	1	4	1	NO	2	3	3	3	3	3	1
																						YES Double Blind	
									Detail	12	27/06/91	1	1	5	1	NO	2	3	3	3	3	3	1
									Summary	27/06/91	12	1	1	5	1	NO	2	3	3	3	3	3	1
																						YES Double Blind	
									Detail	16		2	1	3	1	NO	2	3	3	3	3	3	3
									Detail	18		2	1	3	1	YES	2	3	3	3	3	3	3
									Detail	20		1	1	3	1	YES	2	3	3	3	3	3	3
									Summary	28/06/91(*)	20	2	1	3	1	YES	2	3	3	3	3	3	3
																						YES Double Blind	
									Detail	1	14/06/91	2	1	3	1	NO	2	3	3	3	3	3	3
									Detail	2		2	1	3	1	NO	2	3	3	3	3	3	3
									Detail	3		2	1	3	1	NO	2	3	3	3	3	3	3
									Detail	4		2	1	3	1	NO	2	3	3	3	3	3	3
									Detail	5		1	1	3	1	NO	2	3	3	3	3	3	3
									Detail	6		1	1	3	1	NO	2	3	3	3	3	3	3
									Detail	8	01/06/91	1	1	3	1	NO	2	3	3	3	3	3	3
									Summary	01/06/91	6	2	1	3	1	NO	2	3	3	3	3	3	1
																						YES Run In Phase	
									Detail	4	06/05/91	2	2	3	1	NO	2	3	3	3	3	3	3
									Detail	5		1	2	3	1	NO	2	3	3	3	3	3	3
									Detail	6		2	2	3	1	YES	2	3	3	3	3	3	3
									Detail	8		2	2	3	1	NO	2	3	3	3	3	3	3

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=dose withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=pro. with seq., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (R) adverse event not used for statistical analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA DNS RED
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Con.	Patient	Init.	Start date	Start D.B.	Treatment	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End No date	Last report visit	Hist rity	Rel Ship	Rel Stud	Symp	Disapp.	Re Out	D.B.		
3	18/72	TOR	11/06/91	23/05/91	11/09/91	11/09/91	Placebo	TACHYCARDIA	06/05/91	Detail	10	17/06/91	10	2	2	3	1	NO	2	3	3	1
									17/06/91	Summary			10	2	2	3	1	YES	2	3	3	1
9	24/255	LEV	12/11/91	24/12/91	30/03/92	30/03/92	Placebo	INSOMNIA	06/03/92	Detail	18	15/03/92	18	2	2	4	1	NO	2			1
									15/03/92	Summary			18	2	2	4	1	NO	2			1
10	4/212	ZSD	31/10/90	12/12/90	29/05/91	29/05/91	Placebo	HEADACHE	24/12/90	Detail	6		2	1	4	1	YES	2	3	3	3	3
									24/12/90	Detail	10		2	1	4	1	NO	2	3	3	3	3
									24/12/90	Detail	12		1	1	4	1	NO	2	3	3	3	3
									24/12/90	Summary			12	2	1	4	1	YES	2	3	3	1
									23/01/91	Detail	14		2	1	4	1	NO	2	3	3	3	3
									23/01/91	Detail	16		2	1	4	1	NO	2	3	3	3	3
									23/01/91	Summary			12	2	1	4	1	YES	2	3	3	1
									16/05/91	Detail	16		2	1	4	1	NO	2	3	3	3	3
									16/05/91	Detail	18		2	1	4	1	NO	2	3	3	3	3
									16/05/91	Summary			22	2	1	4	1	NO	2	2	2	1
									16/05/91	Detail	20		2	1	4	1	NO	2	2	2	2	1
									16/05/91	Summary			22	2	1	4	1	NO	2	2	2	1
									06/01/91	Detail	10		1	1	4	1	NO	2	3	3	3	3
									06/01/91	Detail	12		2	1	4	1	NO	2	3	3	3	3
									06/01/91	Detail	14		1	1	4	1	NO	2	3	3	3	3
									06/01/91	Detail	16		2	1	4	1	YES	2	3	3	3	3
									06/01/91	Detail	18		2	1	4	1	YES	2	3	3	3	3
									06/01/91	Detail	20		1	1	4	1	YES	2	3	3	3	3
									06/01/91	Summary			24	2	1	4	1	YES	2	3	3	1
									16/05/91	Detail	22		1	1	4	1	NO	2	3	3	3	3
									16/05/91	Detail	24		1	1	4	1	NO	2	3	3	3	3
									16/05/91	Summary			30	1	1	4	1	NO	2	3	3	3
									16/05/91	Detail	26		1	1	4	1	NO	2	3	3	3	3
									16/05/91	Detail	28		1	1	4	1	NO	2	3	3	3	3
									16/05/91	Summary			30	1	1	4	1	NO	2	3	3	3
									21/12/90	Detail	6		1	3	4	1	NO	2	3	3	3	3
									21/12/90	Detail	8		1	2	4	1	NO	2	3	3	3	3
									21/12/90	Detail	10		1	2	4	1	NO	2	3	3	3	3
									21/12/90	Summary			10	1	2	4	1	NO	2	3	3	3
5/278	AN		14/11/90	27/12/90	05/02/91	05/02/91	Placebo	MICTURITION DISORDER	02/12/90	Detail	3		3	1	3	1	NO	2	3	3	3	3
									02/12/90	Detail	4		2	1	3	1	NO	2	3	3	3	3
									02/12/90	Detail	5		1	1	3	1	NO	2	3	3	3	3
									02/12/90	Summary			5	3	1	3	1	NO	2	3	3	3
10/278	WH		04/12/90	15/01/91	06/02/91	06/02/91	Placebo	CONSTIPATION	04/12/90	Detail	1	06/12/90	1	1	4	1	NO	2	3	3	3	3

-- History: 1=Present before, 2=not observe bef., 3=unknown
 Severity: 1=none, 2=moderate, 3=severe,
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=deatch
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=doubtful, 4=unknown, 5=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis

1485

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOMETINE - PROTOCOL 20124/913
Listing No.: 11.0

ADVERSE EVENTS
DOUBLE BLIND PHASE

Can. Patient Init.	Start date	Start D.B.	Treatment	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End No date	Last report visit	Save rity	Hist ory	Mist rity	Rel ated	Stud y	Sym ptom	Dis app.	Re app.	Out come	D.B. (c)		
18	10/27/98	06/12/99	15/01/91	06/02/91	Placebo	CONSTIPATION	06/12/99	Summary	06/12/99	06/12/99	1	1	1	1	4	1	NO	2	3	3	1	YES Run In Phase	
				11/12/99	Detail	VAGINITIS	11/12/99	Detail	2	16/12/99	2	1	4	1	NO	2	3	3	3	3	1	YES Run In Phase	
				12/02/91	Detail	INSOMNIA	12/02/91	Detail	5	18/02/91	2	1	3	1	NO	2	3	3	3	3	1	YES Run In Phase	
				12/02/91	Summary		18/02/91	Summary	5	2	1	3	1	NO	2	3	3	3	3	3	1	YES Run In Phase	
				12/02/91	Detail	MICTURITION DISORDER	12/02/91	Detail	1	1	1	3	1	NO	2	3	3	3	3	3	3	3	
					Detail			Detail	2	1	1	3	1	NO	2	3	3	3	3	3	3		
					Detail			Detail	3	1	1	3	1	NO	2	3	3	3	3	3	3		
					Detail			Detail	4	1	1	3	1	NO	2	3	3	3	3	3	3		
					Detail			Detail	5	15/02/91	1	1	3	1	NO	2	3	3	3	3	3		
					Summary			Summary	5	15/02/91	5	1	3	1	NO	2	3	3	3	3	3	1	YES Run In Phase
				22/03/91	Detail		22/03/91	Detail	6	1	1	3	1	NO	2	3	3	3	3	3	3		
					Detail			Detail	8	26/02/91	1	1	3	1	NO	2	3	3	3	3	3	1	YES Run In Phase
					Summary			Summary	8	26/02/91	8	1	3	1	NO	2	3	3	3	3	3	1	YES Run In Phase
				05/03/91	Detail	CONSTIPATION	05/03/91	Detail	1	1	2	3	1	NO	2	3	3	3	3	3	3		
					Detail			Detail	2	1	2	3	1	NO	2	3	3	3	3	3	3		
					Detail			Detail	3	1	1	3	1	NO	2	3	3	3	3	3	3		
					Detail			Detail	4	1	1	3	1	NO	2	3	3	3	3	3	3		
					Detail			Detail	5	06/04/91	1	1	3	1	NO	2	3	3	3	3	3		
					Summary			Summary	5	06/04/91	5	1	3	1	NO	2	3	3	3	3	3	1	YES Run In Phase
				09/06/91	Detail		09/06/91	Detail	6	1	1	3	1	NO	2	3	3	3	3	3	3		
					Detail			Detail	8	11/04/91	1	1	3	1	NO	2	3	3	3	3	3	1	YES Run In Phase
					Summary			Summary	8	11/04/91	8	1	3	1	NO	2	3	3	3	3	3	1	YES Run In Phase
				05/03/91	Detail	CONSTIPATION	05/03/91	Detail	28	1	2	3	1	NO	2	3	3	3	3	3	3		
					Detail			Detail	30	1	2	3	1	NO	2	3	3	3	3	3	3		
					Detail			Detail	32	01/10/91	1	2	3	1	NO	2	3	3	3	3	3	1	YES Double Blind
					Summary			Summary	32	01/10/91	32	1	2	3	1	NO	2	3	3	3	3	1	YES Double Blind
				09/03/91	Detail	PARAESTHESIA	09/03/91	Detail	1	1	2	3	1	NO	2	3	3	3	3	3	3		
					Detail			Detail	2	1	2	3	1	NO	2	3	3	3	3	3	3		
					Detail			Detail	3	1	2	3	1	NO	2	3	3	3	3	3	3		

Severely: Unknown, mild, moderate, severe, --- History: 1=Present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. --- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. --- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 1=no, 2=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOETINE - PROTOCOL 20124/9113
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Con.	Patient	Init.	Start date	Treatment	End date	Treatment	Adverse event	Onset date	Type record	Visit No	Last report visit	Save r	Hist r	Rel r	Stud r	Sym r	Dis app.	Re app.	Out app.	D.B.
10	14/281	AJ	04/03/91	02/03/92	16/06/91	02/03/92	Placebo	PARAESTHESIA	09/03/91	4	4	1	2	3	1	NO	2	3	3	3
									Detail	5	5	1	2	3	1	NO	2	3	3	3
									Detail	6	6	1	2	3	1	NO	2	3	3	3
									Detail	8	8	1	2	3	1	NO	2	3	3	3
									Summary	8	27/06/91	8	1	2	3	1	NO	2	3	3
									Summary	8	27/06/91	8	1	2	3	1	NO	2	3	3
									Detail	14	14	1	2	3	1	NO	2	3	3	3
									Detail	16	16	1	2	3	1	NO	2	3	3	3
									Detail	18	18	1	2	3	1	NO	2	3	3	3
									Detail	20	20	1	2	3	1	NO	2	3	3	3
									Detail	22	22	1	2	3	1	NO	2	3	3	3
									Detail	24	24	1	2	3	1	NO	2	3	3	3
									Detail	25	25	1	2	3	1	NO	2	3	3	3
									Detail	26	26	1	2	3	1	NO	2	3	3	3
									Detail	30	30	1	2	3	1	NO	2	3	3	3
									Detail	32	32	1	2	3	1	NO	2	3	3	3
									Summary	32	31/10/91	32	1	2	3	1	NO	2	3	3
									Summary	48	91/10/91	48	1	2	3	1	NO	2	3	3
									Detail	50	50	1	2	3	1	NO	2	3	3	3
									Summary	50	14/02/92	50	1	2	3	1	NO	2	3	3
									Summary	50	14/02/92	50	1	2	3	1	NO	2	3	3
									Detail	1	1	1	1	3	1	NO	2	3	3	3
									Detail	2	2	1	1	3	1	NO	2	3	3	3
									Detail	3	3	1	1	3	1	NO	2	3	3	3
									Summary	3	19/06/91	3	1	1	3	1	NO	2	3	3
									Summary	3	19/06/91	3	1	1	3	1	NO	2	3	3
									Detail	1	1	1	1	3	1	NO	2	3	3	3
									Detail	2	2	1	1	3	1	NO	2	3	3	3
									Detail	3	3	1	1	3	1	NO	2	3	3	3
									Detail	4	4	1	1	3	1	NO	2	3	3	3
									Detail	5	5	1	1	3	1	NO	2	3	3	3
									Summary	5	5	1	1	3	1	NO	2	3	3	3
									Summary	5	5	1	1	3	1	NO	2	3	3	3
									Detail	2	2	1	1	3	1	NO	2	3	3	3
									Detail	3	3	1	1	3	1	NO	2	3	3	3
									Summary	3	19/06/91	3	1	1	3	1	NO	2	3	3
									Summary	3	19/06/91	3	1	1	3	1	NO	2	3	3
									Detail	1	1	1	2	3	1	NO	2	3	3	3
									Detail	2	2	1	2	3	1	NO	2	3	3	3
									Summary	2	12/06/91	2	1	2	3	1	NO	2	3	3
									Summary	2	12/06/91	2	1	2	3	1	NO	2	3	3
									Detail	5	5	2	1	3	1	NO	2	3	3	3
									Detail	6	6	1	1	3	1	NO	2	3	3	3
									Detail	8	8	1	1	3	1	NO	2	3	3	3
									Detail	8	18/06/91	8	1	1	3	1	NO	2	3	3

-- History: 1=present before, 2=not observe bef., 3=unknown
 Severity: 0=unknown, 1=mild, 2=moderate, 3=severe.
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS 88D
 RECONNETIME - PROTOCOL 20124/013
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Can. Patient	Init.	Start date	Start D.B.	Treatment	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End No date	Last report visit	Save city	Hist ary	Rel ship	Stud drug	Symp treat	Hosp app.	Dis app.	Re app.	Out come	(C) Phase	
10	21/286	AK	29/04/91	10/06/91	29/09/91	Placebo	CONSTIPATION	31/05/91	Summary	10/06/91	6	2	1	5	1	NO	2	5	3	1	YES	Run In Phase	
	26/289	AL	01/05/91	12/06/91	28/04/92	Placebo	FURUNCULOSIS	03/05/91	Detail	1	07/05/91	1	1	2	3	1	NO	2	3	3	1	YES	Run In Phase
									Summary	07/05/91	1	1	2	3	1	NO	2	3	3	1	YES	Run In Phase	
									Detail	15/05/91	3	1	1	3	1	NO	2	3	3	1	YES	Run In Phase	
									Summary	21/05/91	3	1	1	3	1	NO	2	3	3	1	YES	Run In Phase	
									Detail	30/05/91	5	1	1	3	1	NO	2	3	3	1	YES	Run In Phase	
									Summary	03/06/91	5	1	1	3	1	NO	2	3	3	1	YES	Run In Phase	
	29/293	JJ	19/08/91	30/09/91	06/01/92	Placebo	INSOMNIA	26/08/91	Detail	3	06/09/91	3	1	1	4	1	YES	2	3	3	2	YES	Run In Phase
									Summary	06/09/91	3	1	1	4	1	YES	2	3	3	2	YES	Run In Phase	
	30/294	VK	17/09/91	29/10/91	14/09/92	Placebo	INSOMNIA	20/09/91	Detail	12	10/11/91	2	1	3	1	YES	2	3	3	2	YES	Run In Phase	
									Summary	10/11/91	12	2	1	3	1	YES	2	3	3	2	YES	Run In Phase	
	37/32	HK	14/10/91	25/11/91	26/04/92	Placebo	SWEATING INCREASED	14/10/91	Detail	1	25/10/91	1	2	3	1	NO	2	3	3	3			
									Detail	2	25/10/91	1	1	3	1	NO	2	3	3	1			
									Summary	25/10/91	2	1	1	3	1	NO	2	3	3	1	YES	Run In Phase	
	40/23	AP	24/10/91	05/12/91	28/01/92	Placebo	CONSTIPATION	25/10/91	Detail	1	10/11/91	1	1	1	5	1	NO	2	3	3	3	3	
									Detail	2	10/11/91	1	1	1	5	1	NO	2	3	3	3	3	
									Detail	3	10/11/91	1	1	1	5	1	NO	2	3	3	3	3	
									Summary	10/11/91	3	1	1	3	1	NO	2	3	3	1	YES	Run In Phase	
									Detail	24/10/91	1	1	2	3	1	NO	2	3	3	3	3	3	
									Detail	2	10/11/91	1	2	3	1	NO	2	3	3	3	3	3	
									Detail	3	10/11/91	1	2	3	1	NO	2	3	3	3	3	3	
									Detail	4	15/11/91	1	2	3	1	NO	2	3	3	3	3	3	
									Summary	15/11/91	4	1	2	3	1	NO	2	3	3	3	1	YES	Run In Phase
									Detail	22/11/91	5	1	2	3	1	NO	2	3	3	3	3	3	
									Detail	6	02/12/91	1	2	3	1	NO	2	3	3	3	3	3	
									Summary	02/12/91	6	1	2	3	1	NO	2	3	3	3	1	YES	Run In Phase

Severity: 5=unknown, 1= mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawal, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 1=no, 1=yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date
 -- History: 1=present before, 2=not observe bef., 3=unknown

1488

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RAD

REBORNTE - PROTOCOL 20124/913
Listing No.: 11.0

ADVERSE EVENTS
DOUBLE BLIND PHASE

Pat. No.	Start date	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Save Hist	Rel. Study	Symp	Dis. app.	Re. come	Out. Phase		
10 40/25 AP	24/10/91	05/12/91	28/01/92 Placebo	UPPER RESP TRACT INFECTION	09/11/91	Detail	3	12/11/91	3	1	6	1	NO	2	3	3	
						Summary		12/11/91		1	6	1	NO	2	3	3	
43/294 IK	15/11/91	27/12/91	14/05/92 Placebo	ALBUMINURIA	20/12/91	Detail	3	10/02/92	3	1	4	1	NO	2	3	3	
						Detail	10	02/01/92	3	1	4	1	NO	2	3	3	
						Summary		02/01/92	10	3	1	4	1	NO	2	3	3
						Summary		12/12/91	4	2	3	1	NO	2	3	3	
						Detail	1	17/11/91	2	2	3	1	NO	2	3	3	
						Detail	2		2	2	3	1	NO	2	3	3	
						Detail	3		1	2	3	1	NO	2	3	3	
						Detail	4		1	2	3	1	NO	2	3	3	
						Detail	5		1	2	3	1	NO	2	3	3	
						Detail	6		1	2	3	1	NO	2	3	3	
						Detail	8	10/01/92	1	2	3	1	NO	2	3	3	
						Summary		10/01/92	6	1	2	3	1	NO	2	3	3
44/298 AB	18/11/91	30/12/91	09/03/92 Placebo	TACHYCARDIA	19/11/91	Detail	1	20/01/92	10	2	1	4	1	YES	2	3	3
						Detail	2		10	2	1	4	1	YES	2	3	3
						Detail	3		10	2	1	4	1	YES	2	3	3
						Detail	4		10	2	1	4	1	YES	2	3	3
						Detail	5		10	2	1	4	1	YES	2	3	3
						Detail	6		10	2	1	4	1	YES	2	3	3
						Detail	8	10/01/92	6	1	2	3	1	NO	2	3	3
						Summary		10/01/92	6	1	2	3	1	NO	2	3	3
45/234 KJ	20/11/91	01/01/92	10/03/92 Placebo	INSOMNIA	21/11/91	Detail	10	20/01/92	10	2	1	4	1	YES	2	3	3
						Summary		20/01/92	10	2	1	4	1	YES	2	3	3
46/258 TN	03/12/91	14/01/92	27/01/92 Placebo	MOUTH DRY	03/12/91	Detail	1		2	2	3	1	NO	2	3	3	
						Detail	2		2	2	3	1	NO	2	3	3	
						Detail	3		2	2	3	1	NO	2	3	3	
						Detail	4		2	2	3	1	NO	2	3	3	
						Detail	5		2	2	3	1	NO	2	3	3	
						Detail	6		1	2	3	1	NO	2	3	3	
						Detail	8	27/01/92(*)	6	2	2	3	1	NO	2	3	3
						Summary		27/01/92(*)	6	2	2	3	1	NO	2	3	3

1489

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rac. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
REBOMETINE - PROTOCOL 20124/013
Listing No.: 11.0

ADVERSE EVENTS
DOUBLE BLIND PHASE

Con.	Patient	Init.	Start date	Treatment	End date	Treatment	Adverse event	Onset date	Type record	Visit No	Last report visit	Sev rity	Hist ory	Rel ated	Stu d Sym	Dis app.	Re com	Out	D.B.
10	47/59	TM	05/12/91	16/01/92	02/12/92	Placebo	MOUTH DR	05/12/91	Detail	1	2	3	1	NO	2	5	5	5	
									Detail	2	1	2	3	1	NO	2	5	5	
									Detail	3	2	2	3	1	NO	2	5	5	
									Detail	4	1	2	3	1	NO	2	5	5	
									Detail	5	1	2	3	1	NO	2	5	5	
									Summary	05/01/92	5	2	2	3	1	NO	2	5	
									Summary	05/01/92	5	2	2	3	1	NO	2	5	
									Detail	4	1	2	3	1	NO	2	5	5	
									Detail	5	1	2	3	1	NO	2	5	5	
									Detail	6	1	2	3	1	NO	2	5	5	
									Summary	24/01/92	6	1	2	3	1	NO	2	5	
									Detail	4	2	2	4	1	NO	2	5	5	
									Detail	5	2	2	4	1	NO	2	5	5	
									Detail	6	2	2	4	1	NO	2	5	5	
									Detail	10	2	2	4	1	NO	2	5	5	
									Detail	12	2	2	4	1	NO	2	5	5	
									Summary	25/02/92	12	2	2	4	1	NO	2	5	
									Summary	25/02/92	12	2	2	4	1	NO	2	5	
48/41	IP		05/12/91	16/01/92	22/06/92	Placebo	CONSTIPATION	22/01/92	Detail	1	2	2	3	1	NO	2	5	5	
									Detail	2	2	2	3	1	NO	2	5	5	
									Detail	3	2	2	3	1	NO	2	5	5	
									Detail	4	2	2	3	1	NO	2	5	5	
									Detail	5	1	2	3	1	NO	2	5	5	
									Detail	6	1	2	3	1	NO	2	5	5	
									Detail	7	1	2	3	1	NO	2	5	5	
									Summary	30/12/91	4	2	2	3	1	NO	2	5	
									Summary	30/12/91	4	2	2	3	1	NO	2	5	
									Detail	1	2	2	3	1	NO	2	5	5	
									Detail	2	2	2	3	1	NO	2	5	5	
									Summary	17/12/91	2	2	2	3	1	NO	2	5	
									Summary	17/12/91	2	2	2	3	1	NO	2	5	
									Detail	3	2	2	4	1	NO	2	5	5	
									Detail	4	1	2	4	1	NO	2	5	5	
									Detail	5	1	2	4	1	NO	2	5	5	
									Summary	06/01/92	5	2	2	4	1	NO	2	5	
									Summary	06/01/92	5	2	2	4	1	NO	2	5	
50/44	EE		19/12/91	30/01/92	16/12/92	Placebo	MICTURITION DISORDER	01/01/92	Detail	2	2	2	3	1	NO	2	5	5	
									Detail	3	1	2	3	1	NO	2	5	5	
									Detail	4	1	2	3	1	NO	2	5	5	
									Detail	4	1	2	3	1	NO	2	5	5	

-- History: 1=Present before, 2=not observe bef., 3=unknown
Severity: 0=unknown, 1=mild, 2=moderate, 3=severe,
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl.
Disapp./Resp.: 1=no, 2=yes, 3=not appl.
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis

9550077

1490

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA DNS R&D

REBOWETINE - PROTOCOL 20124/013

Listing No.: 11.9

ADVERSE EVENTS

DOUBLE BLIND PHASE

10	50/44	EE	19/12/91	30/01/92	16/12/92	Placebo	ADVERSE EVENT	Onset date	Type record	Visit No	Save rity	Hist ory	Rel ship	Re Stud	Dis App	Re Out	Dis. app. case (C) Phase	
		Treatment		Start date		End date		Adverse event		Last report		Save rity		Hist ory		Dis App		
		Start date		End date		Adverse event		Last report		Save rity		Hist ory		Dis App		Dis. app. case (C) Phase		
							MICTURITION DISORDER	01/01/92	Detail	5	1	2	3	1	NO	2	3	3
									Detail	6	1	2	3	1	NO	2	3	3
									Detail	8	1	2	3	1	NO	2	3	3
									Summary	6	2	2	3	1	NO	2	3	3
																	1	YES Run In Phase
							MOUTH DRY	17/05/92	Detail	22	2	2	3	1	NO	2	3	3
									Detail	24	1	2	3	1	NO	2	3	3
									Summary	24	2	2	3	1	NO	2	3	3
							INSOMNIA	26/12/91	Detail	2	2	2	3	1	NO	2	3	3
									Detail	3	2	2	3	1	NO	2	3	3
									Detail	4	1	2	3	1	NO	2	3	3
									Detail	5	1	2	3	1	NO	2	3	3
									Detail	6	1	2	3	1	NO	2	3	3
									Summary	6	2	2	3	1	NO	2	3	3
																	1	YES Run In Phase
							MOUTH DRY	24/12/91	Detail	2	1	2	3	1	NO	2	3	3
									Detail	3	1	2	3	1	NO	2	3	3
									Detail	4	1	2	3	1	NO	2	3	3
									Detail	5	1	2	3	1	NO	2	3	3
									Detail	6	1	2	3	1	NO	2	3	3
									Summary	6	1	2	3	1	NO	2	3	3
																	1	YES Run In Phase
							CONSTIPATION	14/01/92	Detail	1	1	2	3	1	NO	2	3	3
									Detail	2	1	2	3	1	NO	2	3	3
									Summary	2	1	2	3	1	NO	2	3	3
																	1	YES Run In Phase
							MOUTH DRY	14/01/92	Detail	1	1	2	3	1	NO	2	3	3
									Detail	2	1	2	3	1	NO	2	3	3
									Detail	3	1	2	3	1	NO	2	3	3
									Detail	4	1	2	3	1	NO	2	3	3
									Detail	5	1	2	3	1	NO	2	3	3
									Detail	6	1	2	3	1	NO	2	3	3
									Summary	6	1	2	3	1	NO	2	3	3
																	1	YES Run In Phase
							CONSTIPATION	14/01/92	Detail	1	1	2	3	1	NO	2	3	3
									Detail	2	1	2	3	1	NO	2	3	3
									Summary	2	1	2	3	1	NO	2	3	3
																	1	YES Run In Phase
							MOUTH DRY	14/01/92	Detail	1	1	2	3	1	NO	2	3	3
									Detail	2	1	2	3	1	NO	2	3	3
									Detail	3	1	2	3	1	NO	2	3	3
									Detail	4	1	2	3	1	NO	2	3	3
									Detail	5	1	2	3	1	NO	2	3	3
									Detail	6	1	2	3	1	NO	2	3	3
									Summary	6	1	2	3	1	NO	2	3	3
																	1	YES Run In Phase
							TACHYCARDIA	21/01/92	Detail	2	2	2	3	1	NO	2	3	3

Severity: 0=unknown, 1= mild, 2= moderate, 3= severe, 4= severe, 5= fatal
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis

1491

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

9550077

PHARMACIA CNS R&D
 REPROBETINE - PROTOCOL 20124/713
 Listing No.: 11.3

ADVERSE EVENTS
 DOUBLE BLIND PHASE

Con.	Patient Init.	Start date	Treatment	End date	Treatment	Adverse event	Onset date	Type	Visit record	End No date	Last report visit	Save Hist	Rel	Stud	Symp	Dis app.	Re Out	D.B. come	(c) Phase	
10	55/49	TP	14/01/92	25/02/92	11/01/92	Placebo	TACHYCARDIA	21/01/92	Detail	3	1	2	3	1	NO	2	3	3	3	3
									Detail	4	2	2	3	1	NO	2	3	3	3	1
									Summary		4	2	2	3	1	NO	2	3	3	1
50	52	MK	14/01/92	25/02/92	11/01/92	Placebo	DIZZINESS	16/01/92	Detail	1	1	1	3	1	NO	2	3	3	3	3
									Detail	2	1	1	3	1	NO	2	3	3	3	3
									Detail	3	1	1	3	1	NO	2	3	3	3	3
									Detail	4	1	1	3	1	NO	2	3	3	3	3
									Detail	5	1	2	3	1	NO	2	3	3	3	1
									Summary		5	1	1	3	1	NO	2	3	3	1
1499			25/01/92	01/02/92	25/01/92	Placebo	MOUTH DRY	01/02/92	Detail	3	1	2	3	1	NO	2	3	3	3	1
									Summary		3	1	2	3	1	NO	2	3	3	1
60	54	JM	20/01/92	02/03/92	14/03/92	Placebo	MICTURITION DISORDER	25/01/92	Detail	1	1	2	3	1	NO	2	3	3	3	3
									Detail	2	1	1	3	1	NO	2	3	3	3	1
									Summary		2	1	1	3	1	NO	2	3	3	1
61	55	JT	22/01/92	04/03/92	24/03/92	Placebo	TACHYCARDIA	01/11/91	Detail	0	2	1	6	1	NO	2	3	3	3	3
									Detail	1	1	1	6	1	NO	2	3	3	3	3
									Detail	2	1	1	6	1	NO	2	3	3	3	3
									Detail	3	1	1	6	1	NO	2	3	3	3	3
									Detail	4	1	1	6	1	NO	2	3	3	3	3
									Summary		4	2	1	4	1	NO	2	3	3	1
62	58	MK	22/01/92	04/03/92	01/03/92	Placebo	CONSTIPATION	17/02/92	Detail	4	2	2	3	1	NO	2	3	3	3	3
									Detail	5	1	2	3	1	NO	2	3	3	3	3
									Detail	6	1	2	3	1	NO	2	3	3	3	3
									Detail	8	1	2	3	1	NO	2	3	3	3	3
									Detail	10	1	2	3	1	NO	2	3	3	3	3
									Summary		10	2	2	3	1	NO	2	3	3	1
			25/01/92	17/02/92	25/01/92	Placebo	INSOMNIA	17/02/92	Detail	8	2	1	4	1	YES	2	3	3	3	2
									Summary		8	2	1	4	1	YES	2	3	3	2

Severity: 0=unknown, 1= mild, 2= moderate, 3= severe, --- History: 1= present before, 2= not observe bef., 3= unknown
 Study drug: 1=no change, 2= dose reduced, 3= drug withdrawn, 4= temp. inter.
 Hospital: 1= required, 2= not req., 3= not appl. -- Outcome: 1= recovered, 2= no, 3= still present, 4= death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1= definite, 2= probable, 3= possible, 4= doubtful, 5= unknown, 6= none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REPROETINE - PROTOCOL 20124/915
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Con.	Patient	Init.	Start date	Start D.B.	Treatment	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End No date	Last report visit	Save	Hist	Rel	Stud	Symp	Dis	Re	Out	D.B.	
10	64/58	LT	06/02/92	19/05/92	24/06/92	Placebo	CONSTITIPATION		06/02/92	Detail	1	1	2	3	1	NO	2	3	3	3			
										Detail	2	15/02/92	1	2	4	1	NO	2	3	3	1		
										Summary	15/02/92	2	1	2	3	1	NO	2	3	3	1	YES	Run In Phase
										Detail	6	16/03/92	2	1	4	1	YES	2	3	3	2		
										Summary	16/03/92	6	2	1	4	1	YES	2	3	3	2	YES	Run In Phase
										Detail	1	2	2	3	1	NO	2	3	3	3	3		
										Detail	2	1	2	3	1	NO	2	3	3	3	3		
										Detail	3	1	2	3	1	NO	2	3	3	3	3		
										Detail	4	1	2	3	1	NO	2	3	3	3	3		
										Detail	5	1	2	3	1	NO	2	3	3	3	3		
										Detail	6	1	2	3	1	NO	2	3	3	3	3		
										Detail	8	25/03/92	1	2	3	1	NO	2	3	3	3		
										Summary	25/03/92	6	2	2	3	1	NO	2	3	3	1	YES	Run In Phase
										Detail	1	13/03/92	2	2	2	1	NO	2	3	3	1		
										Summary	13/03/92	1	2	2	2	1	NO	2	3	3	1	YES	Run In Phase
85/272	AK		11/03/92	22/06/92	05/05/92	Placebo	DIZZINESS		11/03/92	Detail	1	2	2	2	1	NO	2	3	3	3			
										Summary	13/03/92	1	2	2	2	1	NO	2	3	3	3		
										Detail	1	2	2	3	1	NO	2	3	3	3	3		
										Detail	2	1	2	3	1	NO	2	3	3	3	3		
										Detail	3	1	2	3	1	NO	2	3	3	3	3		
										Detail	4	1	2	3	1	NO	2	3	3	3	3		
										Detail	5	13/03/92	1	2	3	1	NO	2	3	3	3		
										Summary	13/03/92	5	2	2	3	1	NO	2	3	3	1	YES	Run In Phase
										Detail	1	2	2	3	1	NO	2	3	3	3	3		
										Detail	2	1	2	3	1	NO	2	3	3	3	3		
										Detail	3	1	2	3	1	NO	2	3	3	3	3		
										Detail	4	1	2	3	1	NO	2	3	3	3	3		
										Detail	5	1	2	3	1	NO	2	3	3	3	3		
										Summary	11/03/92	6	2	2	3	1	NO	2	3	3	3	YES	Run In Phase
										Detail	1	2	2	3	1	NO	2	3	3	3	3		
										Detail	2	1	2	3	1	NO	2	3	3	3	3		
										Detail	3	1	2	3	1	NO	2	3	3	3	3		
										Detail	4	1	2	3	1	NO	2	3	3	3	3		
										Detail	5	1	2	3	1	NO	2	3	3	3	3		
										Summary	21/04/92(1)	6	2	2	3	1	NO	2	3	3	3	YES	Run In Phase
92/73	LA		01/04/92	13/05/92	30/03/92	Placebo	INSOMNIA		01/04/92	Detail	2	14/04/92	2	1	3	1	YES	2	3	3	2		
										Summary	14/04/92	2	2	1	3	1	YES	2	3	3	2	YES	Run In Phase

Severity: 1=unknown, 2=mild, 3=moderate, 4=severe, 5=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req, 3=not appl.
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis

1493

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
 REBOMETINE - PROTOCOL 20126/413
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Con.	Patient	Init.	Start date	Treatment	End date	Treatment	Adverse event	Onset date	Type record	Last visit rty	Save rty	Hist rty	Rel rty	Stud Sympt	Disapp	Reapp	Out	D.B.													
10	92/75	LA	01/06/92	30/03/92	Placebo		MOUTH DRY	01/06/92	Detail	1	1	1	1	1	NO	2	3	3	3												
									Detail	2	1	1	1	1	NO	2	3	3	3	3											
									Detail	3	1	1	1	1	1	NO	2	3	3	3	3										
									Detail	4	2	1	1	1	1	NO	2	3	3	3	3										
									Detail	5	06/05/92	1	1	1	1	1	NO	2	3	3	3	3									
									Summary	06/05/92	5	2	1	1	1	1	NO	2	3	3	3	3	3	3	3	1	YES Run In Phase				
94/223	PV	09/04/92	21/05/92	12/05/92	Placebo		ACNE	01/05/92	Detail	4	2	2	2	2	1	NO	2	3	3	3											
									Detail	5	2	2	2	2	1	NO	2	3	3	3	3										
									Detail	6	15/05/92	1	2	4	1	NO	2	3	3	3	3										
									Summary	15/05/92	6	2	2	2	2	1	NO	2	3	3	3	3	3	3	3	1	YES Run In Phase				
11	1/372	DF	12/10/91	25/11/91	05/06/92	Placebo	INSOMNIA	12/10/91	Detail	8	66/12/91	1	1	2	1	NO	2	1	1	1	YES Run In Phase										
									Summary	66/12/91	8	1	1	2	1	NO	2	1	1	1	1	1	1	1	1	1					
12	6/36	MK	02/11/91	13/12/91	28/05/92	Placebo	INSOMNIA	02/11/91	Detail	30	27/05/92	1	1	6	1	NO	2	1	1	1	YES Run In Phase										
									Summary	27/05/92	30	1	1	6	1	NO	2	1	1	1	1	1	1	1	1						
10/96	IP	05/11/91	17/12/91	20/04/92	Placebo		INSOMNIA	05/11/91	Detail	24	20/04/92	1	1	6	1	NO	2	1	1	1	1	YES Run In Phase									
									Summary	20/04/92	24	1	1	6	1	NO	2	1	1	1	1	1	1	1	1						
11/94	ER	31/10/91	12/12/91	15/01/92	Placebo		DIZZINESS	24/11/91	Detail	4	06/12/91	1	2	2	1	NO	2	3	3	3											
									Detail	5	06/12/91	1	2	2	1	NO	2	3	3	3	3										
									Summary	06/12/91	5	1	2	2	1	NO	2	3	3	3	3	3	3	3	1	YES Run In Phase					

Severities: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req, 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=unquantif., 5=unknown, 6=none
 Symptomatic treatment: 1=no, 2=yes
 (C) adverse event used for statistical analysis

1494

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBORNETINE - PROTOCOL 20124/913
Listing No.: 11.0

ADVERSE EVENTS
DOUBLE BLIND PHASE

Cap. Patient	Init.	Start date	Start D.B.	Treatment	Adverse event	Onset date	Type record	Visit No	End date	Last visit	report rity	Save	Hist	Rel	Stud	Symp	Dis	Re	Dut	D.B.					
12	11/94	ER	31/10/91	12/12/91	15/01/92	Placebo	FATIGUE	20/11/91	Detail 4	4	3	2	2	1	NO	2	1	1	1	5					
									Detail 5	5	2	2	2	1	NO	2	3	3	3						
									Detail 6	6	2	2	2	1	NO	2	1	1	3						
									Detail 8	8	2	2	2	1	NO	2	1	1	1						
									Summary	20/12/91	6	3	2	2	1	NO	2	1	1	1	YES	Run In Phase			
									Detail 12	12	1	1	1	1	NO	2	1	1	1	1	YES	Double Blind			
									Summary	15/01/92	12	1	1	1	NO	2	1	1	1	1	YES	Double Blind			
									Detail 1	1	2	2	2	1	NO	1	1	1	1	3					
									Detail 2	2	2	2	2	1	NO	2	1	1	1	3					
									Detail 3	3	2	2	2	1	NO	2	1	1	1	5					
									Detail 4	4	2	2	2	1	NO	2	1	1	1	1	YES	Run In Phase			
									Summary	24/11/91	4	2	2	2	1	NO	1	1	1	1	1	YES	Run In Phase		
12/97	FSZ	05/11/91	17/12/91	13/01/92	Placebo	INSOMNIA	07/11/91	Detail 10	10	10	1	2	6	1	NO	2	1	1	1	1	YES	Run In Phase			
									Summary	15/01/92	10	1	2	6	1	NO	2	1	1	1	1	YES	Run In Phase		
									Detail 4	4	3	2	6	1	YES	1	3	3	1	3	3	1	YES	Run In Phase	
									Summary	02/12/91	4	3	2	6	1	YES	1	3	3	1	3	3	1	YES	Run In Phase
13/103	ISZ	05/11/91	17/12/91	27/01/92	Placebo	INSOMNIA	12/11/91	Detail 12	12	12	1	2	6	1	NO	2	1	1	1	1	1	YES	Run In Phase		
									Summary	27/01/92	12	1	2	6	1	NO	2	1	1	1	1	1	YES	Run In Phase	
14/101	GSZ	05/11/91	18/12/91	14/01/92	Placebo	DIZZINESS	08/11/91	Detail 1	1	1	1	1	1	NO	1	1	1	1	1	3	3	3	1	YES	Run In Phase
									Detail 2	2	3	3	5	1	NO	1	3	3	1	3	3	1	YES	Run In Phase	
									Summary	14/11/91	2	3	2	5	1	NO	1	3	3	1	3	3	1	YES	Run In Phase
									Detail 10	10	1	2	6	1	NO	2	1	1	1	1	1	1	YES	Run In Phase	
									Summary	14/01/92	10	1	2	6	1	NO	2	1	1	1	1	1	1	YES	Run In Phase
									Detail 4	4	2	2	5	1	NO	2	3	3	3	3	3	3	1	YES	Run In Phase
									Detail 5	5	3	3	6	1	NO	2	3	3	3	3	3	3	1	YES	Run In Phase
									Summary	05/12/91	5	3	2	5	1	NO	2	3	3	3	3	3	1	YES	Run In Phase

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=code reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=search
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis

1495

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CIS R&D
 REBONETINE - PROTOCOL 20124/013
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Con. Patient	Init.	Start date	D.B.	Treatment	Adverse event	Onset date	Type record	Visit No	Visit date	Last report visit	Save rity	Hist opy	Rel ship	Reas drug	Stud app.	Sympt	Dis app.	Re com.	Out	b.b.	
																					Start date
12	14/101	GSZ	06/11/91	18/12/91	14/01/92	Placebo	MOUTH DRY		08/11/91	Detail 1	1	2	5	1	NO	1	5	5	3		
									16/11/91	Detail 2	1	6	1	NO	1	3	3	1	3	3	
									16/11/91	Summary	2	3	1	6	1	NO	1	3	3	1	YES Run In Phase
									07/11/91	Detail 1	1	3	6	1	NO	1	3	3	3	3	
									07/11/91	Detail 2	1	5	6	1	NO	2	3	3	3	3	
									07/11/91	Detail 3	1	2	6	1	NO	2	3	3	3	3	
									07/11/91	Detail 4	1	2	6	1	NO	2	3	3	3	3	
									07/11/91	Detail 5	1	2	6	1	NO	2	3	3	3	3	
									07/11/91	Detail 6	1	3	6	1	NO	2	3	3	3	3	
									24/12/91	Detail 8	1	3	2	1	NO	2	3	3	3	3	
									24/12/91	Summary	8	1	2	2	1	NO	1	3	3	1	YES Run In Phase
									15/01/92	Detail 12	1	1	6	1	NO	2	1	1	1	1	YES Run In Phase
									20/04/92	Summary	12	1	1	6	1	NO	2	1	1	1	YES Run In Phase
									15/01/92	Detail 1	1	3	4	1	NO	1	5	5	1	5	1
									20/01/92	Summary	1	1	3	4	1	NO	1	5	5	1	YES Run In Phase
									25/05/92	Detail 20	1	3	5	3	NO	1	1	1	1	3	YES Double Blind
									25/05/92	Summary	20	1	3	5	3	NO	1	1	1	1	3
									15/01/92	Detail 20	1	3	6	1	NO	1	1	1	1	1	YES Run In Phase
									23/05/92	Summary	20	1	3	6	1	NO	1	1	1	1	YES Run In Phase
									17/01/92	Detail 1	2	3	3	1	YES	1	3	3	3	3	
									29/01/92	Detail 5	2	3	2	2	NO	1	2	2	2	2	1
									29/01/92	Summary	5	2	3	2	2	YES	1	2	2	2	1
									28/01/92	Detail 8	1	1	6	1	NO	2	1	1	1	1	YES Run In Phase
									28/05/92	Summary	8	1	1	6	1	NO	2	1	1	1	YES Run In Phase

1496

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA DNS RED
 REMOETINE - PROTOCOL 20124/913
 Listing No.: 11.9
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Con. Patient	Init.	Start date	D.B.	Treatment	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Save rity	Hist ory	Rel ship	Stu dy	Sym p	Dis app.	Re com	D.B.						
																			Start date	End date	Save rity	Hist ory	Rel ship	Stu dy
12	25/112	EN	07/02/92	20/03/92	20/08/92	Placebo	INSOMNIA		10/02/92	Detail	18	28/06/92	1	1	6	1	NO	2	1	YES	Run In Phase			
									25/06/92	Summary	18	02/08/92	1	1	6	1	NO	2	1	YES	Run In Phase			
									26/07/92	Detail	24	02/08/92	24	1	6	1	NO	2	1	YES	Double Blind			
									02/08/92	Summary	24	02/08/92	24	1	6	1	NO	2	1	YES	Double Blind			
									16/05/92	Detail	16	26/05/92	1	1	6	1	NO	2	1	YES	Double Blind			
									26/05/92	Summary	16	26/05/92	16	1	6	1	NO	2	1	YES	Double Blind			
									29/03/92	Detail	6	03/05/92	1	1	6	1	NO	2	1	YES	Run In Phase			
									03/05/92	Summary	6	03/05/92	6	1	6	1	NO	2	1	YES	Run In Phase			
									05/06/92	Detail	18	30/07/92	1	1	6	1	NO	2	1	YES	Double Blind			
									30/07/92	Summary	18	30/07/92	18	1	6	1	NO	2	1	YES	Double Blind			
									12/03/93	Detail	52	26/03/93	1	1	6	1	NO	2	1	YES	Double Blind			
									26/03/93	Summary	52	26/03/93	52	1	6	1	NO	2	1	YES	Double Blind			
									29/03/92	Detail	10	05/06/92	1	1	6	1	NO	2	1	YES	Run In Phase			
									05/06/92	Summary	10	05/06/92	10	1	6	1	NO	2	1	YES	Run In Phase			
									06/06/92	Detail	16	30/07/92	1	1	6	1	NO	2	1	YES	Double Blind			
									30/07/92	Summary	16	30/07/92	16	1	6	1	NO	2	1	YES	Double Blind			
									10/02/92	Detail	16	10/02/92	2	2	6	1	NO	1	1	YES	Double Blind			
									10/02/92	Summary	16	10/02/92	16	2	6	1	NO	1	1	YES	Double Blind			
									17/10/91	Detail	6	27/12/91	2	1	6	1	NO	2	3	3	1	NO	Run In Phase	
									27/12/91	Summary	6	27/12/91	6	2	1	6	1	NO	2	3	3	1	NO	Run In Phase
									26/11/91	Detail	4	05/12/91	2	3	5	1	NO	2	3	3	3	1	YES	Run In Phase
									05/12/91	Summary	4	05/12/91	4	3	5	1	NO	2	3	3	3	1	YES	Run In Phase
									05/12/91	Detail	5	05/12/91	5	2	3	1	NO	2	3	3	3	1	YES	Run In Phase
									05/12/91	Summary	5	05/12/91	5	2	3	1	NO	2	3	3	3	1	YES	Run In Phase
									10/12/91	Detail	6	27/12/91	1	5	4	1	NO	2	3	3	3	1	YES	Run In Phase
									27/12/91	Summary	6	27/12/91	6	1	5	4	1	NO	2	3	3	1	YES	Run In Phase

149

-- History: 1=Present before, 2=not observe bef., 3=unknown
 Severity: 0=unknown, 1= mild, 2= moderate, 3= severe,
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=term. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=fre. with seq., 3=still present, 4=each
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=indefinite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA OCS R&D

REBOXETINE - PROTOCOL 2012/4/013
Listing No.: 11.0

ADVERSE EVENTS
DOUBLE BLIND PHASE

Con.	Patient	Init.	Start date	Treatment	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End No data	Last report visit	Mist report	Hist visit	Rel. Stud	Symp	Dis	Re	Out. D.B.	
				Start D.B.	End D.B.	Start D.B.	Adverse event					visit rity	ory stibp	drug tres	Hesp	app.	app.	com	(C) Phase	
13	17/210	OSM	20/11/91	01/01/92	17/11/92	Placebo	TACHYCARDIA	15/12/91	Detail	4		1	2	3	1	NO	1		3	
									Detail	5	24/12/91	2	3	3	1	NO	1		1	
									Summary	26/12/91		5	2	2	3	1	NO	1	1	
																			1	YES Run In Phase
1	4/5	DNC	21/11/90	05/01/91	20/11/91	Reboxetine	MOUTH DRY	01/12/90	Detail	2		1	2	1	1	NO	2	3	3	
									Detail	3		1	2	1	1	NO	2	3	3	
									Detail	4		1	2	1	1	NO	2	3	3	
									Detail	5		1	3	1	1	NO	2	3	3	
									Detail	6		1	2	1	1	NO	2	3	3	
									Detail	7		1	2	1	1	NO	2	3	3	
									Detail	8		1	2	1	1	NO	2	3	3	
									Detail	9		1	2	1	1	NO	2	3	3	
									Detail	10		1	2	1	1	NO	2	3	3	
									Detail	11		1	2	1	1	NO	2	3	3	
									Detail	12		1	2	1	1	NO	2	3	3	
									Detail	13		1	2	1	1	NO	2	3	3	
									Detail	14		1	2	1	1	NO	2	3	3	
									Detail	15		1	2	1	1	NO	2	3	3	
									Summary	10/02/91		12	1	2	1	1	NO	2	3	
									Summary	10/02/91		12	1	2	1	1	NO	2	3	
																			1	YES Run In Phase
1	4/4	DB	05/12/90	16/01/91	05/12/91	Reboxetine	TREMOR	15/12/90	Detail	2		1	2	1	1	NO	2	3	3	
									Detail	3	25/12/90	1	2	1	1	NO	2	3	3	
									Summary	25/12/90		3	1	2	1	1	NO	2	3	
																			1	YES Run In Phase
9/7	CCR		27/12/90	07/02/91	26/12/91	Reboxetine	CONSTIPATION	10/01/91	Detail	3		1	2	1	1	NO	2	3	3	
									Detail	4		2	2	1	1	NO	2	3	3	
									Detail	5		1	2	1	1	NO	2	3	3	
									Detail	6	31/01/91	1	2	1	1	NO	2	3	3	
									Summary	31/01/91		6	2	2	1	1	NO	2	3	
																			1	YES Run In Phase
									Detail	7		1	2	1	1	NO	2	3	3	
									Detail	8		1	2	1	1	NO	2	3	3	
									Detail	9		1	2	1	1	NO	2	3	3	
									Detail	10		1	2	1	1	NO	2	3	3	
									Detail	11		1	2	1	1	NO	2	3	3	
									Detail	12		1	2	1	1	NO	2	3	3	
									Detail	13		1	2	1	1	NO	2	3	3	
									Detail	14		1	2	1	1	NO	2	3	3	
									Detail	15		1	2	1	1	NO	2	3	3	
									Detail	16	10/04/91	1	2	3	1	NO	2	3	3	
									Summary	10/04/91		16	1	2	1	1	NO	2	3	
																			1	YES Double Blind
									Detail	17		1	2	1	1	NO	2	3	3	
									Detail	18		1	2	1	1	NO	2	3	3	
									Detail	19		1	2	1	1	NO	2	3	3	
									Detail	20		1	2	1	1	NO	2	3	3	
									Summary	02/06/91		14	1	2	1	1	NO	2	3	
									Detail	21	22/06/91	1	2	1	1	NO	2	3	3	
									Summary	22/06/91		26	1	2	1	1	NO	2	3	
																			1	YES Double Blind
									Detail	22		1	2	1	1	NO	2	3	3	
									Detail	23		1	2	1	1	NO	2	3	3	
									Detail	24		1	2	1	1	NO	2	3	3	
									Summary	12/01/91		4	1	2	1	1	NO	2	3	
									Detail	25		1	2	1	1	NO	2	3	3	
									Detail	26		1	2	1	1	NO	2	3	3	
									Summary	21/01/91		4	1	2	1	1	NO	2	3	
																			1	YES Run In Phase

Seriousness: 1= mild, 2= moderate, 3= severe, 4= life threatening
 Study drug: 1= no change, 2= dose reduced, 3= def. withdrawn, 4= temp. inter.
 Hospital: 1= required, 2= not req., 3= not appl. -- Outcome: 1= recovered, 2= ac. with set, 3= still present, 4= death
 Disapp./Reapp.: 1= no, 2= yes, 3= not appl. -- Relationship: 1= definite, 2= probable, 3= possible, 4= doubtful, 5= unknown, 6= none
 Symptomatic treatment: 0= no, 1= yes
 (C) adverse event used for statistical analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD

REBOXETINE - PROTOCOL 2024/013
Listing No.: 11.0

ADVERSE EVENTS
DOUBLE BLIND PHASE

Con.	Patient	Init.	Start date	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End No date	Last report visit	Save Hist	Hist	Rel	Stud	Symp	Dis app.	Re app.	Out	D.B.	
1	14/11	MLC	08/05/91	19/06/91	30/07/91	Reboxetine	MOUJH DKV	Detail	2		1	2	1	1	NO	2	3	3	3		
								Detail	3		1	2	1	1	NO	2	3	3	3		
								Detail	4		1	2	1	1	NO	2	3	3	3		
								Detail	5		1	2	1	1	NO	2	3	3	3		
								Detail	6		1	2	1	1	NO	2	3	3	3		
								Detail	7		1	2	1	1	NO	2	3	3	3		
								Detail	8		1	2	1	1	NO	2	3	3	3		
								Detail	9		1	2	1	1	NO	2	3	3	3		
								Detail	10		1	2	1	1	NO	2	3	3	3		
								Detail	11		1	2	1	1	NO	2	3	3	3		
								Detail	12		1	2	1	1	NO	2	3	3	3		
								Detail	13		1	2	1	1	NO	2	3	3	3		
								Detail	14		1	2	1	1	NO	2	3	3	3		
								Detail	15		1	2	1	1	NO	2	3	3	3		
								Summary	12		1	2	1	1	NO	2	3	3	3		1 YES Run In Phase
								Summary	30/07/91												
								Detail	3		1	2	1	1	NO	2	3	3	3		
								Detail	4		1	2	1	1	NO	2	3	3	3		
								Detail	5		1	2	1	1	NO	2	3	3	3		
								Detail	6		1	2	1	1	NO	2	3	3	3		
								Detail	7		1	2	1	1	NO	2	3	3	3		
								Detail	8		1	2	1	1	NO	2	3	3	3		
								Detail	9		1	2	1	1	NO	2	3	3	3		
								Detail	10		1	2	1	1	NO	2	3	3	3		
								Detail	11		1	2	1	1	NO	2	3	3	3		
								Detail	12		1	2	1	1	NO	2	3	3	3		
								Detail	13		1	2	1	1	NO	2	3	3	3		
								Detail	14		1	2	1	1	NO	2	3	3	3		
								Detail	15		1	2	1	1	NO	2	3	3	3		
								Summary	08/09/91		16	1	2	1	1	NO	2	3	3		1 YES Run In Phase
								Summary	08/09/91												
								Detail	2		1	2	2	1	NO	2	3	3	3		
								Detail	3		1	2	2	1	NO	2	3	3	3		
								Summary	05/06/91		3	1	2	2	1	NO	2	3	3		1 YES Run In Phase
								Summary	05/06/91												
								Detail	5		1	2	3	1	NO	2	3	3	3		
								Detail	6		1	2	1	1	NO	2	3	3	3		
								Detail	7		1	2	1	1	NO	2	3	3	3		
								Detail	8		1	2	1	1	NO	2	3	3	3		
								Detail	9		1	2	1	1	NO	2	3	3	3		
								Detail	10		1	2	1	1	NO	2	3	3	3		
								Detail	11		1	2	1	1	NO	2	3	3	3		
								Detail	12		1	2	1	1	NO	2	3	3	3		
								Detail	13		1	2	1	1	NO	2	3	3	3		
								Detail	14		1	2	1	1	NO	2	3	3	3		
								Detail	15		1	2	1	1	NO	2	3	3	3		
								Detail	16		1	2	1	1	NO	2	3	3	3		
								Summary	18-25/09/91		18	2	2	1	5	NO	2	2	2		1 YES Run In Phase
								Summary	25/09/91												
								Detail	2		1	2	1	1	NO	2	3	3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Resp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (e) adverse event still present: end date = white box

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/91S
Listing No.: 11.0

ADVERSE EVENTS
DOUBLE BLIND PHASE

Pat. No.	Ph. No.	DRM	Start date	End date	Treatment	Adverse event	Onset date	Typs record	Visit No	End No date	Last report visit	save city	hist ary	Rel. Stud	Symp	Dis app.	Re app.	Out. come	D.B. Phase		
1	32/28	DRM	25/07/91	05/09/91	22/07/92 Reboxetine	CONSTIPATION	07/08/91 25/08/91	Summary Detail 24	15/09/91	6	1 2 3 1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	YES Run In Phase	
							26/07/91	Detail 24	2	06/08/91	1	2 3 1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	YES Run In Phase
							09/08/91	Summary Detail 3	04/08/91	2	1 2 3 1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	YES Run In Phase	
								Detail 4			1 2 3 1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	YES Run In Phase	
								Detail 5			1 2 3 1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	YES Run In Phase	
								Detail 6			1 2 3 1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	YES Run In Phase	
								Detail 6			1 2 3 1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	YES Run In Phase	
								Summary	10/09/91	8	1 2 1 1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	YES Run In Phase	
							10/08/91	Detail 24			1 2 3 1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	YES Run In Phase	
								Detail 26			1 2 3 1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	YES Run In Phase	
								Detail 28			1 2 3 1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	YES Run In Phase	
								Detail 30	01/09/92	30	1 2 3 1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	YES Run In Phase	
								Summary	01/09/92	30	1 2 3 1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	YES Run In Phase	
35/29	09H		08/08/91	19/09/91	12/08/92 Reboxetine	ANOREXIA	23/08/91	Detail 3			1 2 3 1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	YES Run In Phase	
								Detail 4			1 2 3 1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	YES Run In Phase	
								Detail 5			1 2 3 1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	YES Run In Phase	
								Detail 6	13/09/91	6	1 2 3 1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	YES Run In Phase	
								Summary	13/09/91	6	1 2 3 1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	YES Run In Phase	
								Detail 3			1 2 3 1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	YES Run In Phase	
								Detail 4			1 2 3 1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	YES Run In Phase	
								Detail 5			1 2 3 1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	YES Run In Phase	
								Detail 8			1 2 3 1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	YES Run In Phase	
								Detail 19			1 2 3 1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	YES Run In Phase	
								Detail 12			1 2 3 1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	YES Run In Phase	
								Detail 14	11/11/91	1	2 3 1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	YES Run In Phase	
								Detail 24			1 2 3 1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	YES Run In Phase	
								Detail 25			1 2 3 1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	YES Run In Phase	
								Summary	15/02/92	20	1 2 3 1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	NO 2 3 3	1	YES Run In Phase	

1501

Severity: 0=unknown, 1= mild, 2= moderate, 3= severe, 4= life threatening, 5= fatal
 Study drug: 1= no change, 2= dose reduced, 3= stop, 4= withdrawn, 5= other
 Hospital: 1= required, 2= not req., 3= not appl.
 Disapp./Reapp.: 1= no, 2= yes, 3= not appl.
 Symptomatic treatment: 0= no, 1= yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date
 -- History: 1= present before, 2= not observe bef., 3= unknown

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA ONS REP
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Con.	Patient	Init.	Start date	Start D.B.	Treatment	End date	Treatment	Adverse event	Onset date	Type record	Visit No	Last report visit rity	Sympt ery	Rel. drug	Stud. app.	Disapp.	Re-appe.	Out. com.	(c) Phase
1	54/50	GMH	08/08/91	17/09/91	12/08/92	Reboxetine	MOUTH DRY		10/08/91	Detail	1	1	2	3	1	NO	2	3	3
										Detail	2	1	2	3	1	NO	2	3	3
										Detail	3	1	2	3	1	NO	2	3	3
										Detail	4	1	2	3	1	NO	2	3	3
										Detail	5	1	2	3	1	NO	2	3	3
										Detail	6	1	2	3	1	NO	2	3	3
										Detail	8	1	2	3	1	NO	2	3	3
										Detail	10	1	2	3	1	NO	2	3	3
										Detail	12	1	2	3	1	NO	2	3	3
										Detail	14	1	2	3	1	NO	2	3	3
										Detail	24	1	2	3	1	NO	2	3	3
										Detail	26	1	2	3	1	NO	2	3	3
										Detail	28	1	2	3	1	NO	2	3	3
										Detail	30	1	2	3	1	NO	2	3	3
										Summary	38	1	2	3	1	NO	2	3	3
										Summary	39	1	2	3	1	NO	2	3	3
34/205	ASS		25/09/91	04/11/91	22/09/92	Reboxetine	CONSTIPATION		10/10/91	Detail	3	1	2	3	1	NO	2	3	3
										Detail	4	1	2	3	1	NO	2	3	3
										Detail	5	1	2	3	1	NO	2	3	3
										Summary	25/10/91	5	1	2	3	1	NO	2	3
63/209	ARN		03/10/91	14/11/91	30/09/92	Reboxetine	MOUTH DRY		05/10/91	Detail	1	1	2	3	1	NO	2	3	3
										Detail	2	1	2	3	1	NO	2	3	3
										Detail	3	1	2	3	1	NO	2	3	3
										Detail	4	1	2	3	1	NO	2	3	3
										Detail	5	1	2	3	1	NO	2	3	3
										Detail	6	1	2	3	1	NO	2	3	3
										Detail	8	1	2	3	1	NO	2	3	3
										Detail	10	1	2	3	1	NO	2	3	3
										Detail	12	1	2	3	1	NO	2	3	3
										Detail	14	1	2	3	1	NO	2	3	3
										Detail	16	1	2	3	1	NO	2	3	3
										Detail	18	1	2	3	1	NO	2	3	3
										Detail	20	1	2	3	1	NO	2	3	3
										Detail	22	1	2	3	1	NO	2	3	3
										Detail	24	1	2	3	1	NO	2	3	3
										Detail	26	1	2	3	1	NO	2	3	3
										Detail	28	1	2	3	1	NO	2	3	3

1502

Severity: 0=unknown, 1= mild, 2= moderate, 3= severe, 4= life threatening
 Study drug: 1= no change, 2= dose reduced, 3= def. withdrawn, 4= temp. inter.
 Hospital: 1= required, 2= not req., 3= not appl. -- Outcome: 1= recovered, 2= rec. with seq., 3= still present, 4= death
 Disapp./Reapp.: 1= no, 2= yes, 3= not appl. -- Relationship: 1= definite, 2= probable, 3= possible, 4= doubtful, 5= unknown, 6= none
 Symptomatic treatment: 0= no, 1= yes
 (c) adverse event used for statistical analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA OCS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 11.0

ADVERSE EVENTS
DOUBLE BLIND PHASE

Con. Patient	Init.	Start date	Treatment	End date	Treatment	Adverse event	Onset date	Type record	Visit No	Last report visit	Save rfty	Hist ery	Misc ofy	Stud ship	Rel drug	Sev app.	Dis app.	Re Hosp	Out app.	D.B. come	Phase	
1	43/309	AN	03/10/91	14/11/91	30/09/92	Reboxetine	URINARY RETENTION	15/01/92	50	50	50/09/92	1	2	3	1	NO	2	3	3	3	3	3
								Detail	50	50/09/92	1	2	2	1	NO	2	3	3	3	3	3	3
								Summary	30/09/92	52	1	1	2	1	NO	2	3	3	3	3	3	1
																						YES Double Blind
48	218	SCN	24/10/91	05/12/91	21/10/92	Reboxetine	INSOMNIA	02/11/91	2	2	2	3	1	NO	2	3	3	3	3	3	3	3
								Detail	2	2	3	1	NO	2	3	3	3	3	3	3	3	3
								Detail	3	1	2	3	1	NO	2	3	3	3	3	3	3	3
								Detail	4	1	2	3	1	NO	2	3	3	3	3	3	3	3
								Detail	5	24/11/91	1	2	3	1	NO	2	3	3	3	3	3	3
								Summary	24/11/91	5	1	2	3	1	NO	2	3	3	3	3	3	1
																						YES Run In Phase
								Detail	2	02/11/91	1	2	4	1	NO	2	3	3	3	3	3	3
								Detail	3	1	2	4	1	NO	2	3	3	3	3	3	3	3
								Detail	4	18/11/91	1	2	4	1	NO	2	3	3	3	3	3	3
								Summary	18/11/91	4	1	2	4	1	NO	2	3	3	3	3	3	1
																						YES Run In Phase
								Detail	12	17/01/92	1	2	3	1	NO	2	3	3	3	3	3	3
								Detail	14	1	2	3	1	NO	2	3	3	3	3	3	3	3
								Detail	16	1	2	3	1	NO	2	3	3	3	3	3	3	3
								Detail	18	1	2	3	1	NO	2	3	3	3	3	3	3	3
								Detail	20	1	2	3	1	NO	2	3	3	3	3	3	3	3
								Detail	22	1	2	3	1	NO	2	3	3	3	3	3	3	3
								Detail	24	1	2	3	1	NO	2	3	3	3	3	3	3	3
								Detail	26	1	2	3	1	NO	2	3	3	3	3	3	3	3
								Detail	28	1	2	3	1	NO	2	3	3	3	3	3	3	3
								Detail	30	1	2	3	1	NO	2	3	3	3	3	3	3	3
								Detail	32	1	2	3	1	NO	2	3	3	3	3	3	3	3
								Detail	34	1	2	3	1	NO	2	3	3	3	3	3	3	3
								Detail	36	1	2	3	1	NO	2	3	3	3	3	3	3	3
								Detail	38	1	2	3	1	NO	2	3	3	3	3	3	3	3
								Detail	40	1	2	3	1	NO	2	3	3	3	3	3	3	3
								Detail	42	1	2	3	1	NO	2	3	3	3	3	3	3	3
								Detail	44	1	2	3	1	NO	2	3	3	3	3	3	3	3
								Detail	46	1	2	3	1	NO	2	3	3	3	3	3	3	3
								Detail	48	1	2	3	1	NO	2	3	3	3	3	3	3	3
								Detail	50	1	2	3	1	NO	2	3	3	3	3	3	3	3
								Detail	52	28/10/92	1	2	2	1	NO	2	3	3	3	3	3	3
								Summary	28/10/92	52	1	2	2	1	NO	2	3	3	3	3	3	1
																						YES Double Blind

1504

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA GKS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 11.0

ADVERSE EVENTS
DOUBLE BLIND PHASE

Cen. Patient	Init.	Start date	Start D.B.	Treatment	End date	End Treatment	Adverse event	Onset date	Type record	Visit No	Last visit rity	Sava Hist	Rel Stud Symp	Dis Re	Out D.B.	Last									
																report	visit rity								
1	55/318 DMG	06/11/91	18/12/91	11/02/92	Reboxetine	RASH		05/01/92	Detail	10	1	2	4	1	NO	2	3	3	3						
							Detail	12	1	2	3	1	NO	2	3	3	3								
							Detail	14	11/02/92	1	2	3	1	NO	2	2	3	1							
							Summary	31/02/92	14	1	2	2	3	NO	2	2	3	1	YES Double Blind						
							56/319 IAL	06/11/91	18/12/91	31/12/91	Reboxetine	LIBIDO DECREASED		06/11/91	Detail	1	1	2	3	1	NO	2	3	3	3
													Detail	2	1	2	3	1	NO	2	3	3	3		
													Detail	3	1	2	3	1	NO	2	3	3	3		
													Detail	4	2	1	3	1	NO	2	3	3	3		
													Detail	5	2	2	3	1	NO	2	3	3	3		
													Detail	6	2	2	3	1	NO	2	3	3	3		
													Summary	31/12/91	6	3	2	2	3	NO	2	2	3	1	YES Run In Phase
58/320 ARM	11/12/91	22/01/92	31/03/92	Reboxetine	CONSTIPATION		14/12/91	Detail	1	1	2	5	1	NO	2	3	3	3							
						Detail	2	1	2	3	1	NO	2	3	3	3									
						Detail	3	1	2	3	1	NO	2	3	3	3									
						Detail	4	1	2	3	1	NO	2	3	3	3									
						Detail	5	1	2	3	1	NO	2	3	3	3									
						Detail	6	1	2	3	1	NO	2	3	3	3									
						Detail	8	1	2	3	1	NO	2	3	3	3									
						Detail	10	1	2	3	1	NO	2	3	3	3									
						Detail	12	1	2	3	1	NO	2	3	3	3									
						Detail	14	1	2	3	1	NO	2	3	3	3									
						Detail	16	31/03/92	2	2	2	3	YES	2	2	3	1	YES Run In Phase							
						Summary	31/03/92	16	2	2	2	3	YES	2	2	3	1	YES Run In Phase							
						59/321 DRV	14/12/91	14/12/91	14/12/91	MOUTH DRY		14/12/91	Detail	1	1	2	3	1	NO	2	3	3	3		
											Detail	2	1	2	3	1	NO	2	3	3	3				
											Detail	3	1	2	3	1	NO	2	3	3	3				
											Detail	4	1	2	3	1	NO	2	3	3	3				
Detail	5	1	2	3	1						NO	2	3	3	3										
Detail	6	1	2	3	1						NO	2	3	3	3										
Detail	8	1	2	3	1						NO	2	3	3	3										
Detail	10	1	2	3	1						NO	2	3	3	3										
Detail	12	1	2	3	1						NO	2	3	3	3										
Detail	14	1	2	3	1						NO	2	3	3	3										
Detail	16	31/03/92	1	2	2						3	NO	2	2	3	1	YES Run In Phase								
Summary	31/03/92	16	1	2	2						3	NO	2	2	3	1	YES Run In Phase								

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=freq. with seq., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (R) adverse event still present: end date = visit date

1505

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CHE RD
 REBOWETINE - PROTOCOL 20124/013
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Con. Patient	Init. Start date	Treatment	End date	Treatment	Adverse event	Onset date	Type record	Visit No	Last report visit rty	See Hist	Hist	Rel	Stud	Symp	Dis	Re	Out	D.B.
1	64/326 TCG	22/01/92	05/05/92	19/01/93	Rebowetine	CONSTIPATION	12/03/92	Detail	10	1	2	3	1	NO	2	3	3	3
								Detail	12	1	2	3	1	NO	2	3	3	3
								Detail	14	1	2	3	1	NO	2	3	3	3
								Detail	16	1	2	3	1	NO	2	3	3	3
								Detail	18	1	2	3	1	NO	2	3	3	3
								Detail	20	1	2	3	1	NO	2	3	3	3
								Detail	22	1	2	3	1	NO	2	3	3	3
								Detail	24	1	2	3	1	NO	2	3	3	3
								Detail	26	1	2	3	1	NO	2	3	3	3
								Detail	28	1	2	3	1	NO	2	3	3	3
								Detail	30	1	2	3	1	NO	2	3	3	3
								Detail	32	1	2	3	1	NO	2	3	3	3
								Detail	34	1	2	3	1	NO	2	3	3	3
								Detail	36	1	2	3	1	NO	2	3	3	3
								Detail	38	1	2	3	1	NO	2	3	3	3
								Detail	40	1	2	3	1	NO	2	3	3	3
								Detail	42	1	2	3	1	NO	2	3	3	3
								Detail	44	1	2	3	1	NO	2	3	3	3
								Detail	46	1	2	3	1	NO	2	3	3	3
								Detail	48	1	2	3	1	NO	2	3	3	3
								Detail	50	1	2	3	1	NO	2	3	3	3
								Detail	52	1	2	2	1	NO	2	3	3	1
								Summary	19/01/93	52	1	2	2	1	NO	2	3	3
									19/01/93									
									22/01/92									
								Detail	1	1	2	3	1	NO	2	3	3	3
								Detail	2	1	2	3	1	NO	2	3	3	3
								Detail	3	1	2	3	1	NO	2	3	3	3
								Detail	4	1	2	3	1	NO	2	3	3	3
								Detail	5	1	2	3	1	NO	2	3	3	3
								Detail	6	1	2	3	1	NO	2	3	3	3
								Detail	8	1	2	3	1	NO	2	3	3	3
								Detail	10	1	2	3	1	NO	2	3	3	3
								Detail	12	1	2	3	1	NO	2	3	3	3
								Detail	14	1	2	3	1	NO	2	3	3	3
								Detail	16	1	2	3	1	NO	2	3	3	3
								Detail	18	1	2	3	1	NO	2	3	3	3
								Detail	20	1	2	3	1	NO	2	3	3	3
								Detail	22	1	2	3	1	NO	2	3	3	3
								Detail	24	1	2	3	1	NO	2	3	3	3
								Detail	26	1	2	3	1	NO	2	3	3	3
								Detail	28	1	2	3	1	NO	2	3	3	3

1507

Severely: 5=unknown, 1=mild, 2=moderate, 3=severe,
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS ROE
 REBOXETINE - PROTOCOL 2012/0013
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Con.	Patient	Init.	Start date	Start D.B.	End date	Treatment	Adverse event	Onset date	Type record	Last visit rfty	Report rfty	See rfty	Hist rfty	Rel. ship	Stude. app.	Symp. app.	Dis. app.	Re. app.	Out. app.	D.B.	
1	66/526	TCO	22/01/92	05/03/92	19/01/93	Reboxetine	MOUTH DRV	22/01/92	Detail 30	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 31	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 32	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 33	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 34	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 35	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 36	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 37	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 38	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 39	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 40	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 41	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 42	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 43	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 44	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 45	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 46	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 47	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 48	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 49	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 50	1	2	3	1	NO	2	3	3	3	3	3	3
									Summary	52	1	2	2	1	NO	2	3	3	3	3	3
									Summary	19/01/93											
									Detail 1	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 2	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 3	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 4	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 5	1	2	3	1	NO	2	3	3	3	3	3	3
									Summary	4	20/02/92										
									Summary	20/02/92											
									Detail 12	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 13	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 14	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 15	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 16	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 17	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 18	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 19	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 20	1	2	3	1	NO	2	3	3	3	3	3	3
									Summary	20	10/06/92										
									Summary	10/06/92											
									Detail 1	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 2	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 3	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 4	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 5	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 6	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 7	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 8	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 9	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 10	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 11	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 12	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 13	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 14	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 15	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 16	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 17	1	2	3	1	NO	2	3	3	3	3	3	3
									Detail 18	1	2	3	1	NO	2	3	3	3	3	3	3

Severity: 1=unknown, 1= mild, 2= moderate, 3= severe, --- History: 1= present before, 2= not observe bef., 3= unknown
 Study drug: 1= no change, 2= dose reduced, 3= def. withdrawn, 4= stop. inter.
 Hospital: 1= required, 2= not req., 3= not appl. -- Outcome: 1= recovered, 2= rec. with seq., 3= still present, 4= each
 Disapp./Reapp.: 1= no, 2= yes, 3= not appl. -- Relationship: 1= definite, 2= probable, 3= possible, 4= doubtful, 5= unknown, 6= none
 Symptomatic treatment: 0= no, 1= yes
 (C) adverse event used for statistical analysis
 * * * * *

1508

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 28124/915
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Con.	Patient	Init.	Start date	End date	Treatment	Adverse event	Onset date	Type	Visit	End	Last	report	Save	Hist	Re	Stud	Symp	Dis	Re	Out	D.B.	
								record	No	date	visit	city	city	city	city	city	city	city	city	city	city	
1	75/121	FMA	29/01/92	11/08/92	28/07/92	Reboxetine	CONSTIPATION	Detail	20	01/02/92	26	1	2	3	1	NO	2	3	3	3	3	
								Detail	22			1	2	3	1	NO	2	3	3	3	3	
								Detail	24			1	2	3	1	NO	2	3	3	3	3	
								Summary	26	28/07/92	26	1	2	3	NO	2	2	2	3	1	YES	Run In Phase
								Summary	26	28/07/92	26	1	2	3	NO	2	2	2	3	1	YES	Run In Phase
								Detail	1	01/02/92		1	2	3	1	NO	2	3	3	3	3	
								Detail	2			1	2	3	1	NO	2	3	3	3	3	
								Detail	3			1	2	3	1	NO	2	3	3	3	3	
								Detail	4			1	2	3	1	NO	2	3	3	3	3	
								Detail	5			1	2	3	1	NO	2	3	3	3	3	
								Detail	6			1	2	3	1	NO	2	3	3	3	3	
								Detail	7			1	2	3	1	NO	2	3	3	3	3	
								Detail	8			1	2	3	1	NO	2	3	3	3	3	
								Detail	9			1	2	3	1	NO	2	3	3	3	3	
								Detail	10			1	2	3	1	NO	2	3	3	3	3	
								Detail	11			1	2	3	1	NO	2	3	3	3	3	
								Detail	12			1	2	3	1	NO	2	3	3	3	3	
								Detail	13			1	2	3	1	NO	2	3	3	3	3	
								Detail	14			1	2	3	1	NO	2	3	3	3	3	
								Detail	15			1	2	3	1	NO	2	3	3	3	3	
								Detail	16			1	2	3	1	NO	2	3	3	3	3	
								Detail	17			1	2	3	1	NO	2	3	3	3	3	
								Detail	18			1	2	3	1	NO	2	3	3	3	3	
								Detail	19			1	2	3	1	NO	2	3	3	3	3	
								Detail	20			1	2	3	1	NO	2	3	3	3	3	
								Detail	21			1	2	3	1	NO	2	3	3	3	3	
								Detail	22			1	2	3	1	NO	2	3	3	3	3	
								Detail	23			1	2	3	1	NO	2	3	3	3	3	
								Detail	24			1	2	3	1	NO	2	3	3	3	3	
								Detail	25	28/07/92	26	1	2	3	NO	2	2	2	3	1	YES	Run In Phase
								Summary	26	28/07/92	26	1	2	3	NO	2	2	2	3	1	YES	Run In Phase
								Detail	3	28/02/92		2	2	3	1	NO	2	3	3	3	3	
								Detail	4			2	2	3	1	NO	2	3	3	3	3	
								Detail	5			2	2	3	1	NO	2	3	3	3	3	
								Detail	6			2	2	3	1	NO	2	3	3	3	3	
								Detail	7			2	2	3	1	NO	2	3	3	3	3	
								Detail	8			2	2	3	1	NO	2	3	3	3	3	
								Detail	9			2	2	3	1	NO	2	3	3	3	3	
								Detail	10			2	2	3	1	NO	2	3	3	3	3	
								Detail	11			2	2	3	1	NO	2	3	3	3	3	
								Detail	12			2	2	3	1	NO	2	3	3	3	3	
								Detail	13			2	2	3	1	NO	2	3	3	3	3	
								Detail	14			2	2	3	1	NO	2	3	3	3	3	
								Detail	15			2	2	3	1	NO	2	3	3	3	3	
								Detail	16			2	2	3	1	NO	2	3	3	3	3	
								Detail	17			2	2	3	1	NO	2	3	3	3	3	
								Detail	18			2	2	3	1	NO	2	3	3	3	3	
								Detail	19			2	2	3	1	NO	2	3	3	3	3	
								Detail	20			2	2	3	1	NO	2	3	3	3	3	
								Detail	21			2	2	3	1	NO	2	3	3	3	3	
								Detail	22			2	2	3	1	NO	2	3	3	3	3	
								Detail	23			2	2	3	1	NO	2	3	3	3	3	
								Detail	24			2	2	3	1	NO	2	3	3	3	3	
								Detail	25	14/02/92	26	1	2	3	1	NO	2	3	3	3	3	
								Summary	26	14/02/92	26	2	2	3	1	NO	2	3	3	3	3	
								Summary	26	14/02/92	26	2	2	3	1	NO	2	3	3	3	3	

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observed before, 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (*) adverse event used for statistical analysis
 (c) adverse event still present; end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CHE RED
 REBOMETINE - PROTOCOL 20126/013
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Con. Patient Init.	Start date	Start D.B.	Treatment	End date	Treatment	Adverse event	Onset date	Type record	Visit No	Visit End No date	Last report visit	See rity	Hist opy	Hist ship	Hist Hist	Rel Stud	Symp tres	Dis Hosp	Re app.	Out. come	D.B. (c)
1	77/125 ACS	08/02/92	21/05/92	05/02/93	Rebometine	LIBIDO DECREASED	15/08/92	Detail	26			1	2	3	1	NO	2	3	3	3	3
								Detail	30			1	2	3	1	NO	2	3	3	3	3
								Detail	32			1	2	3	1	NO	2	3	3	3	3
								Detail	34			1	2	3	1	NO	2	3	3	3	3
								Detail	36			1	2	3	1	NO	2	3	3	3	3
								Detail	38			1	2	3	1	NO	2	3	3	3	3
								Detail	40			1	2	3	1	NO	2	3	3	3	3
								Detail	42			1	2	3	1	NO	2	3	3	3	3
								Detail	44			1	2	3	1	NO	2	3	3	3	3
								Detail	46	15/12/92		1	2	3	1	NO	2	3	3	3	3
								Summary		15/12/92	46	1	2	3	1	NO	2	3	3	3	1
																					YES Double Blind
81/128 MB	08/02/92	21/05/92	05/02/93	Rebometine	CONSTIPATION		10/02/92	Detail	1			1	2	3	1	NO	2	3	3	3	3
								Detail	2			1	2	3	1	NO	2	3	3	3	3
								Detail	3			1	2	3	1	NO	2	3	3	3	3
								Detail	4			1	2	3	1	NO	2	3	3	3	3
								Detail	5			1	2	3	1	NO	2	3	3	3	3
								Detail	6			1	2	3	1	NO	2	3	3	3	3
								Detail	8			1	2	3	1	NO	2	3	3	3	3
								Detail	10			1	2	3	1	NO	2	3	3	3	3
								Detail	12			1	2	3	1	NO	2	3	3	3	3
								Detail	14			1	2	3	1	NO	2	3	3	3	3
								Detail	16			1	2	3	1	NO	2	3	3	3	3
								Detail	18			1	2	3	1	NO	2	3	3	3	3
								Detail	20			1	2	3	1	NO	2	3	3	3	3
								Detail	22			1	2	3	1	NO	2	3	3	3	3
								Detail	24			1	2	3	1	NO	2	3	3	3	3
								Detail	26			1	2	3	1	NO	2	3	3	3	3
								Detail	28			1	2	3	1	NO	2	3	3	3	3
								Detail	30			1	2	3	1	NO	2	3	3	3	3
								Detail	32			1	2	3	1	NO	2	3	3	3	3
								Detail	34			1	2	3	1	NO	2	3	3	3	3
								Detail	36			1	2	3	1	NO	2	3	3	3	3
								Detail	38			1	2	3	1	NO	2	3	3	3	3
								Detail	40			1	2	3	1	NO	2	3	3	3	3
								Detail	42			1	2	3	1	NO	2	3	3	3	3
								Detail	44			1	2	3	1	NO	2	3	3	3	3
								Detail	46	18/12/92		1	2	3	1	NO	2	3	3	3	3
								Summary		18/12/92	46	1	2	3	1	NO	2	3	3	3	1
																					YES Run In Phase

1510

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date
 --- History: 1=present before, 2=not observe bef., 3=unknown

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/913

Listing No.: 11.0

ADVERSE EVENTS

DOUBLE BLIND PHASE

Can. Patient	Init.	Start date	Start D.B.	End date	Treatment	Adverse event	Onset date	Type	Visit record	End No date	Last report visit	Save visit	Hist ory	Rel Ship	Re Stud	Bymp	Dis app.	Re Out	D.B. some (C) Phase		
1	81/128	MBB	05/02/92	21/05/92	05/02/92	Reboxetine	MOUTH DRY	10/02/92	Detail	1	1	2	5	1	NO	2	3	3	3	3	
									Detail	2	1	2	5	1	NO	2	3	3	3	3	
									Detail	3	1	2	5	1	NO	2	3	3	3	3	
									Detail	4	1	2	3	1	NO	2	3	3	3	3	
									Detail	5	1	2	3	1	NO	2	3	3	3	3	
									Detail	6	1	2	3	1	NO	2	3	3	3	3	
									Detail	8	1	2	3	1	NO	2	3	3	3	3	
									Detail	10	1	2	3	1	NO	2	3	3	3	3	
									Detail	12	1	2	3	1	NO	2	3	3	3	3	
									Detail	14	1	2	3	1	NO	2	3	3	3	3	
									Detail	16	1	2	3	1	NO	2	3	3	3	3	
									Detail	18	1	2	3	1	NO	2	3	3	3	3	
									Detail	20	1	2	3	1	NO	2	3	3	3	3	
									Detail	22	1	2	3	1	NO	2	3	3	3	3	
									Detail	24	1	2	3	1	NO	2	3	3	3	3	
									Detail	26	1	2	3	1	NO	2	3	3	3	3	
									Detail	28	1	2	3	1	NO	2	3	3	3	3	
									Detail	30	1	2	3	1	NO	2	3	3	3	3	
									Detail	32	1	2	3	1	NO	2	3	3	3	3	
									Detail	34	1	2	3	1	NO	2	3	3	3	3	
									Detail	36	1	2	3	1	NO	2	3	3	3	3	
									Detail	38	1	2	3	1	NO	2	3	3	3	3	
									Detail	40	1	2	3	1	NO	2	3	3	3	3	
									Detail	42	20/11/92	1	2	3	1	NO	2	3	3	3	
									Detail	42	20/11/92	1	2	3	1	NO	2	3	3	3	
									Summary	42	1	2	3	1	NO	2	3	3	3	1	
																				YES Run In Phase	
82/129	MDS		05/02/92	21/05/92	05/02/92	Reboxetine	CONSTIPATION	01/08/92	Detail	26	1	2	3	1	NO	2	3	3	3	3	
									Detail	28	1	2	3	1	NO	2	3	3	3	3	3
									Detail	30	1	2	3	1	NO	2	3	3	3	3	3
									Detail	32	1	2	3	1	NO	2	3	3	3	3	3
									Detail	34	1	2	3	1	NO	2	3	3	3	3	3
									Detail	36	1	2	3	1	NO	2	3	3	3	3	3
									Detail	38	1	2	3	1	NO	2	3	3	3	3	3
									Detail	40	1	2	3	1	NO	2	3	3	3	3	3
									Detail	42	1	2	3	1	NO	2	3	3	3	3	3
									Detail	44	1	2	3	1	NO	2	3	3	3	3	3
									Detail	46	1	2	3	1	NO	2	3	3	3	3	3
									Detail	48	1	2	3	1	NO	2	3	3	3	3	3
									Detail	50	1	2	3	1	NO	2	3	3	3	3	3
									Detail	52	05/02/95	1	2	3	1	NO	2	3	3	3	3
									Detail	52	05/02/95	1	2	3	1	NO	2	3	3	3	3
									Summary	52	1	2	3	1	NO	2	3	3	3	3	1
																				YES Double Blind	

1511

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 5=unknown
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4= doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (*) adverse event used for statistical analysis
 (**) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REROMETHINE - PROTOCOL 20124/013
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Con. Patient	Init.	Start date	Treatment	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End date	Last report visit r:by	Save Hist r:by	Hist r:by	Rel. Stud Sympt	Disapp. app.	Recovery	Out. D.B.	
1	82/129	MDS	08/02/92	21/05/92	05/02/93	Reromethine												
						SNEATING INCREASED	10/02/92	Detail	1		1	2	3	1	NO	2	3	3
								Detail	2		1	2	3	1	NO	2	3	3
								Detail	3		1	2	3	1	NO	2	3	3
								Detail	4		1	2	3	1	NO	2	3	3
								Detail	5		1	2	3	1	NO	2	3	3
								Detail	6		1	2	3	1	NO	2	3	3
								Detail	7		1	2	3	1	NO	2	3	3
								Detail	8		1	2	3	1	NO	2	3	3
								Detail	9		1	2	3	1	NO	2	3	3
								Detail	10		1	2	3	1	NO	2	3	3
								Detail	11		1	2	3	1	NO	2	3	3
								Detail	12		1	2	3	1	NO	2	3	3
								Detail	13		1	2	3	1	NO	2	3	3
								Detail	14		1	2	3	1	NO	2	3	3
								Detail	15		1	2	3	1	NO	2	3	3
								Detail	16		1	2	3	1	NO	2	3	3
								Detail	17		1	2	3	1	NO	2	3	3
								Detail	18		1	2	3	1	NO	2	3	3
								Detail	19		1	2	3	1	NO	2	3	3
								Detail	20		1	2	3	1	NO	2	3	3
								Detail	21		1	2	3	1	NO	2	3	3
								Detail	22		1	2	3	1	NO	2	3	3
								Detail	23		1	2	3	1	NO	2	3	3
								Detail	24		1	2	3	1	NO	2	3	3
								Detail	25		1	2	3	1	NO	2	3	3
								Detail	26		1	2	3	1	NO	2	3	3
								Detail	27		1	2	3	1	NO	2	3	3
								Detail	28		1	2	3	1	NO	2	3	3
								Detail	29		1	2	3	1	NO	2	3	3
								Detail	30		1	2	3	1	NO	2	3	3
								Detail	31		1	2	3	1	NO	2	3	3
								Detail	32		1	2	3	1	NO	2	3	3
								Detail	33		1	2	3	1	NO	2	3	3
								Detail	34		1	2	3	1	NO	2	3	3
								Detail	35		1	2	3	1	NO	2	3	3
								Detail	36		1	2	3	1	NO	2	3	3
								Detail	37		1	2	3	1	NO	2	3	3
								Detail	38		1	2	3	1	NO	2	3	3
								Detail	39		1	2	3	1	NO	2	3	3
								Detail	40		1	2	3	1	NO	2	3	3
								Detail	41		1	2	3	1	NO	2	3	3
								Detail	42		1	2	3	1	NO	2	3	3
								Detail	43		1	2	3	1	NO	2	3	3
								Detail	44		1	2	3	1	NO	2	3	3
								Detail	45		1	2	3	1	NO	2	3	3
								Detail	46		1	2	3	1	NO	2	3	3
								Detail	47		1	2	3	1	NO	2	3	3
								Detail	48		1	2	3	1	NO	2	3	3
								Detail	49		1	2	3	1	NO	2	3	3
								Detail	50		1	2	3	1	NO	2	3	3
								Detail	51		1	2	3	1	NO	2	3	3
								Detail	52	05/02/93	1	2	2	1	NO	2	3	3
								Summary		05/02/93	52	1	2	2	1	NO	2	3
																		1 YES Run In Phase
87/132	MDD	08/02/92	21/05/92	16/07/92	Reromethine	CONSTIPATION	09/02/92	Detail	1		1	2	3	1	NO	2	3	3
								Detail	2		1	2	3	1	NO	2	3	3
								Detail	3		1	2	3	1	NO	2	3	3
								Detail	4		1	2	3	1	NO	2	3	3
								Detail	5		1	2	3	1	NO	2	3	3
								Detail	6		1	2	3	1	NO	2	3	3
								Detail	7		1	2	3	1	NO	2	3	3
								Detail	8		1	2	3	1	NO	2	3	3
								Detail	9		1	2	3	1	NO	2	3	3
								Detail	10		1	2	3	1	NO	2	3	3

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=stop. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS 98D

REBOXETINE - PROTOCOL 20124/413
Listing No.: 11.0

ADVERSE EVENTS
DOUBLE BLIND PHASE

Cen. Patient	Init.	Start date	Start D.B.	Treatment	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End No date	Last report		Save	Mist rity	Rat dry	Ral ship	Stud drug	Samp tra	Hosp app.	Dis app.	Re come	Out (c)	D.B. Phase												
												visit	date																							
1	89/132	06/02/92	21/03/92	10/07/92	Reboxetine	CONSTITUTION		05/02/92	Detail	12			1	2	3	1	NO	2	3	3	3	3	3	3	3	3										
									Detail	14			1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3				
									Detail	16			1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3		
									Detail	18			1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
									Detail	20			1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
									Detail	22			1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
									Summary				22	1	2	2	3	NO	2	2	2	2	3	1	YES	Run	In	Phase								
									Detail	4			01/03/92				01/03/92				1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	
									Detail	5			01/03/92				01/03/92				1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
									Detail	6			01/03/92				01/03/92				1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
									Detail	8			10/06/92				10/06/92				1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
									Detail	10			10/06/92				10/06/92				1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
Summary				10/06/92				10/06/92				10	1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3									
89/133	MW	12/02/92	25/03/92	19/05/92	Reboxetine	HEADACHE		15/02/92	Detail	1			1	2	3	1	NO	2	3	3	3	3	3	3	3	3										
									Detail	2			1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3	3	3	3					
									Detail	3			1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3			
									Detail	4			1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3		
									Detail	5			1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3		
									Detail	6			1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3		
									Detail	8			1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3		
									Detail	10			1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
									Detail	12			1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
									Detail	14			16	22	05/92		22/05/92				16	1	2	3	1	NO	2	3	3	3	3	3	3	3	3	
									Summary				22/05/92				22/05/92				16	1	2	3	1	NO	2	3	3	3	3	3	3	3	3	
									89/133	MW	12/02/92	25/03/92	19/05/92	Reboxetine	HEADACHE		15/02/92	Detail	1			1	2	4	1	NO	2	3	3	3	3	3	3	3		
Summary				1	1	2	4	1										NO	2	3	3	3	3	3	3	3	3	3	3	3	3					
90/134	JSS	12/02/92	25/03/92	07/06/92	Reboxetine	CONSTIPATION		20/03/92	Detail	6			6	2	2	3	YES	2	2	3	YES	2	2	3	3											
									Summary				6	2	2	3	YES	2	2	3	YES	2	2	3	3	3	3	3	3	3	3					
90/134	JSS	12/02/92	25/03/92	07/06/92	Reboxetine	CONSTIPATION		20/02/92	Detail	3			1	2	3	1	NO	2	3	3	3	3	3	3	3											
									Detail	4			1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3	3	3	3					
									Detail	5			1	2	3	1	NO	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3			

1513

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
Study drugs: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=requires, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD
REBOXetine - PROTOCOL 20124/013
Listing No.: 11.0

ADVERSE EVENTS
DOUBLE BLIND PHASE

Cent.	Patient	Init.	Start date	End date	Treatment	Adverse event	Onset date	Type	Visit record	End No data	Last report visit rity	Save Hist ery	Re: ship	Re: Stud drug trea	Symp Hesp	Dis app.	Re come (c)	Out some (c)	D.P.	
1	95/136	GMT	13/02/92	26/02/92	10/02/93	Reboxetine	VISION ABNORMAL	17/02/92	Detail 14				1	2	3	1	NO	2	3	3
									Detail 16			1	2	3	1	NO	2	3	3	
									Detail 18			1	2	3	1	NO	2	3	3	
									Detail 20			1	2	3	1	NO	2	3	3	
									Detail 22			1	2	3	1	NO	2	3	3	
									Detail 24			1	2	3	1	NO	2	3	3	
									Detail 26			1	2	3	1	NO	2	3	3	
									Detail 28			1	2	3	1	NO	2	3	3	
									Detail 30			1	2	3	1	NO	2	3	3	
									Detail 32			1	2	3	1	NO	2	3	3	
									Detail 34			1	2	3	1	NO	2	3	3	
									Detail 36			1	2	3	1	NO	2	3	3	
									Detail 38			1	2	3	1	NO	2	3	3	
									Detail 40			1	2	3	1	NO	2	3	3	
									Detail 42			1	2	3	1	NO	2	3	3	
									Detail 44			1	2	3	1	NO	2	3	3	
									Detail 46			1	2	3	1	NO	2	3	3	
									Detail 48			1	2	3	1	NO	2	3	3	
									Detail 50			1	2	3	1	NO	2	3	3	
									Detail 52	10/02/93		1	2	3	1	NO	2	3	3	
									Summary	10/02/93	52	1	2	2	1	NO	2	3	1	

1515

96/139	SPH	13/02/92	26/03/92	10/02/93	Reboxetine	LIBIDO DECREASED	17/02/92	Detail 1				1	2	3	1	NO	2	3	3
								Detail 2				1	2	3	1	NO	2	3	3
								Detail 3				1	2	3	1	NO	2	3	3
								Detail 4				1	2	3	1	NO	2	3	3
								Detail 5				1	2	3	1	NO	2	3	3
								Detail 6				1	2	3	1	NO	2	3	3
								Detail 8				1	2	3	1	NO	2	3	3
								Detail 10				1	2	3	1	NO	2	3	3
								Detail 12				1	2	3	1	NO	2	3	3
								Detail 14				1	2	3	1	NO	2	3	3
								Detail 16				1	2	3	1	NO	2	3	3
								Detail 18				1	2	3	1	NO	2	3	3
								Detail 20				1	2	3	1	NO	2	3	3
								Detail 22				1	2	3	1	NO	2	3	3
								Detail 24				1	2	3	1	NO	2	3	3
								Detail 26				1	2	3	1	NO	2	3	3
								Detail 28				1	2	3	1	NO	2	3	3
								Detail 30				1	2	3	1	NO	2	3	3
								Detail 32				1	2	3	1	NO	2	3	3

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=critical, 5=fatal. -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=stop. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXTINE - PROTOCOL 20124/013
Listing No.: 11.0
ADVERSE EVENTS
DOUBLE BLIND PHASE

Con.	Patient's Init.	Start date	Treatment	End date	Adverse event	Onset date	Type	Visit	End	Last report	Save	Hist	Rel. Stud	Disp	Re	Out D.B.						
1	96/139 SP4	13/02/92	10/02/93	26/03/92	Reboxtine	LIBIDO DECREASED	LIBIDO DECREASED		17/02/92	34	Detail	1	2	3	1	NO	2	3	3	3		
											Detail	1	2	3	1	NO	2	3	3	3	3	
											Detail	2	1	2	3	1	NO	2	3	3	3	
											Detail	3	1	2	3	1	NO	2	3	3	3	
											Detail	4	1	2	3	1	NO	2	3	3	3	
											Detail	5	1	2	3	1	NO	2	3	3	3	
											Detail	6	1	2	3	1	NO	2	3	3	3	
											Detail	7	1	2	3	1	NO	2	3	3	3	
											Detail	8	1	2	3	1	NO	2	3	3	3	
											Detail	9	1	2	3	1	NO	2	3	3	3	
											Detail	10	1	2	3	1	NO	2	3	3	3	
											Detail	11	1	2	3	1	NO	2	3	3	3	
											Detail	12	1	2	3	1	NO	2	3	3	3	
											Detail	13	1	2	3	1	NO	2	3	3	3	
											Detail	14	1	2	3	1	NO	2	3	3	3	
											Detail	15	1	2	3	1	NO	2	3	3	3	
											Detail	16	1	2	3	1	NO	2	3	3	3	
											Detail	17	1	2	3	1	NO	2	3	3	3	
											Detail	18	1	2	3	1	NO	2	3	3	3	
											Detail	19	1	2	3	1	NO	2	3	3	3	
											Detail	20	1	2	3	1	NO	2	3	3	3	
											Detail	21	1	2	3	1	NO	2	3	3	3	
											Detail	22	1	2	3	1	NO	2	3	3	3	
											Detail	23	1	2	3	1	NO	2	3	3	3	
											Detail	24	1	2	3	1	NO	2	3	3	3	
											Detail	25	1	2	3	1	NO	2	3	3	3	
											Detail	26	1	2	3	1	NO	2	3	3	3	
											Detail	27	1	2	3	1	NO	2	3	3	3	
											Detail	28	1	2	3	1	NO	2	3	3	3	
											Detail	29	1	2	3	1	NO	2	3	3	3	
											Detail	30	1	2	3	1	NO	2	3	3	3	
											Detail	31	1	2	3	1	NO	2	3	3	3	
											Detail	32	1	2	3	1	NO	2	3	3	3	
											Detail	33	1	2	3	1	NO	2	3	3	3	
											Detail	34	1	2	3	1	NO	2	3	3	3	
											Detail	35	1	2	3	1	NO	2	3	3	3	
											Detail	36	1	2	3	1	NO	2	3	3	3	
											Detail	37	1	2	3	1	NO	2	3	3	3	
											Detail	38	1	2	3	1	NO	2	3	3	3	
											Detail	39	1	2	3	1	NO	2	3	3	3	
											Detail	40	1	2	3	1	NO	2	3	3	3	
											Detail	41	1	2	3	1	NO	2	3	3	3	
											Detail	42	1	2	3	1	NO	2	3	3	3	
											Detail	43	1	2	3	1	NO	2	3	3	3	
											Detail	44	1	2	3	1	NO	2	3	3	3	
											Detail	45	1	2	3	1	NO	2	3	3	3	
											Detail	46	1	2	3	1	NO	2	3	3	3	
											Detail	47	1	2	3	1	NO	2	3	3	3	
											Detail	48	1	2	3	1	NO	2	3	3	3	
											Detail	49	1	2	3	1	NO	2	3	3	3	
											Detail	50	1	2	3	1	NO	2	3	3	3	
											Detail	51	1	2	3	1	NO	2	3	3	3	
											Detail	52	1	2	3	1	NO	2	3	3	3	
											Summary		52	1	2	2	1	NO	2	3	3	1
											Summary		52	1	2	2	1	NO	2	3	3	1

--- History: 1=present before, 2=not observe bef., 3=unknown
Severity: 0=unknown, 1=mild, 2=moderate, 3=severe,
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl.
Disapp./Reapp.: 1=no, 2=yes, 3=not appl.
Symptomatic treatment: 1=no, 2=yes, 3=not appl.
(c) adverse event used for statistical analysis

1516

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RAD

REBOXETINE - PROTOCOL 20124/913
Listing No.: 11.0

ADVERSE EVENTS
DOUBLE BLIND PHASE

Can. Patient Init.	Start date	Start D.B.	Treatment	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Save rity	Hist ory	Mist rty	Rel ship	Stud drug	Symp tra	Dis Hosp	Re app.	Out. coma	D.B. (C)	
1	96/141	VTT	13/02/92	26/02/92	10/02/93	Reboxetine	MOUTH DRY	17/02/92	Detail 12				1	2	3	1	NO	2	5	5	5	
									Detail 14				1	2	3	1	NO	2	5	5	5	
									Detail 16				1	2	3	1	NO	2	5	5	5	
									Detail 18				1	2	3	1	NO	2	5	5	5	
									Detail 20				1	2	3	1	NO	2	5	5	5	
									Detail 22				1	2	3	1	NO	2	5	5	5	
									Detail 24				1	2	3	1	NO	2	5	5	5	
									Detail 26				1	2	3	1	NO	2	5	5	5	
									Detail 28				1	2	3	1	NO	2	5	5	5	
									Detail 30				1	2	3	1	NO	2	5	5	5	
									Detail 32				1	2	3	1	NO	2	5	5	5	
									Detail 34				1	2	3	1	NO	2	5	5	5	
									Detail 36				1	2	3	1	NO	2	5	5	5	
									Detail 38				1	2	3	1	NO	2	5	5	5	
									Detail 40				1	2	3	1	NO	2	5	5	5	
									Detail 42				1	2	3	1	NO	2	5	5	5	
									Detail 44				1	2	3	1	NO	2	5	5	5	
									Detail 46				1	2	3	1	NO	2	5	5	5	
									Detail 48				1	2	3	1	NO	2	5	5	5	
									Detail 50				1	2	3	1	NO	2	5	5	5	
									Detail 52	10/02/93		52	1	2	2	1	NO	2	3	3	1	
									Summary	10/02/93											YES Run In Phase	
181/143	JLL	19/02/92	01/04/92	16/02/93	Reboxetine	CONSTIPATION	30/02/92	Detail 24					1	2	3	1	NO	2	5	5	5	
									Detail 26				1	2	3	1	NO	2	5	5	5	
									Detail 28				1	2	3	1	NO	2	5	5	5	
									Detail 30	09/05/92			1	2	3	1	NO	2	5	5	5	
									Summary	09/05/92			30	1	2	3	1	NO	2	5	5	1 YES Double Blind
187/147	LWN	20/02/92	02/04/92	16/02/93	Reboxetine	DIZZINESS	01/10/92	Detail 34					1	2	3	1	NO	2	3	3	3	
									Detail 36	22/10/92			1	2	3	1	NO	2	3	3	3	
									Summary	22/10/92			36	1	2	3	1	NO	2	3	3	1 YES Double Blind
									Detail 1				1	2	3	1	NO	2	3	3	3	
									Detail 2				1	2	3	1	NO	2	3	3	3	
									Detail 3				1	2	3	1	NO	2	3	3	3	
									Detail 4				1	2	3	1	NO	2	3	3	3	
									Detail 5				1	2	3	1	NO	2	3	3	3	
									Detail 6				1	2	3	1	NO	2	3	3	3	

Severity: 0=unknown, 1= mild, 2= moderate, 3= severe, -- History: 1= present before, 2= not observed before, 3= unknown
Study drug: 1= no change, 2= dose reduced, 3= def. withdrawn, 4= temp. inter.
Hospital: 1= required, 2= not req., 3= not appl. -- Outcome: 1= recovered, 2= rec. with seq., 3= still present, 4= death
Disapp./Reapp.: 1= no, 2= yes, 3= not appl. -- Relationship: 1= definite, 2= probable, 3= possible, 4= doubtful, 5= unknown, 6= none
Symptomatic treatment: 0= no, 1= yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS 88D

REBOXetine - PROTOCOL 20126/913
Listing No.: 11.0

ADVERSE EVENTS
DOUBLE BLIND PHASE

Con. Patient	Init.	Start date	Start D.B.	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End No data	Last report visit	Save rity	Hist ory	Rel ship	Stud drug	Symp Trea	Hosp app.	Dis app.	Re Out	Phase	
1	107/147	LAM	20/02/92	02/04/92	15/02/93	Reboxetine	LIBIDO DECREASED	22/02/92	Detail	8		1	2	3	1	NO	2	3	3	3	3
									Detail	10		1	2	3	1	NO	2	3	3	3	3
									Detail	12		1	2	3	1	NO	2	3	3	3	3
									Detail	14		1	2	3	1	NO	2	3	3	3	3
									Detail	16		1	2	3	1	NO	2	3	3	3	3
									Detail	18		1	2	3	1	NO	2	3	3	3	3
									Detail	20		1	2	3	1	NO	2	3	3	3	3
									Detail	22		1	2	3	1	NO	2	3	3	3	3
									Detail	24		1	2	3	1	NO	2	3	3	3	3
									Detail	26		1	2	3	1	NO	2	3	3	3	3
									Detail	28		1	2	3	1	NO	2	3	3	3	3
									Detail	30		1	2	3	1	NO	2	3	3	3	3
									Detail	32		1	2	3	1	NO	2	3	3	3	3
									Summary	46	31/12/92	46	1	2	3	1	NO	2	3	3	3
									Summary	46	31/12/92	46	1	2	3	1	NO	2	3	3	3
									Summary	46	31/12/92	46	1	2	3	1	NO	2	3	3	3

1519

MOUTH DRY

22/02/92

Detail

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 1=no, 2=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA GSK RED
 REBOMETINE - PROTOCOL 20124/913
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Cen. Patient	Init.	Start date	Treatment	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Sera rft	Hist opy	Hist ship	Rel drug	Nel. Stud	Somp tras	Dis Hosp	Re app.	Out. come	D.B.								
																				Phase							
1107147	LAN	24/02/92	02/04/92	16/02/93	Reboxetine	MOUTH DRY	34	22/02/92	Detail	1	2	3	1	NO	2	3	3	3									
							35	Detail	1	2	3	1	NO	2	3	3	3										
							36	Detail	1	2	3	1	NO	2	3	3	3										
							40	Detail	1	2	3	1	NO	2	3	3	3										
							42	Detail	1	2	3	1	NO	2	3	3	3										
							44	Detail	1	2	3	1	NO	2	3	3	3										
							46	Detail	1	2	3	1	NO	2	3	3	3										
							48	Detail	1	2	3	1	NO	2	3	3	3										
							50	Detail	1	2	3	1	NO	2	3	3	3										
							52	Detail	1	2	3	1	NO	2	3	3	3										
							Summary		15/02/93	52	1	2	2	1	NO	2	3	3	1	YES	Run	In	Phase				
							109149	IPL	26/02/92	02/06/92	17/02/93	Reboxetine	CONSTIPATION	3	06/02/92	Detail	1	2	3	1	NO	2	3	3	3		
														4	Detail	1	2	3	1	NO	2	3	3	3			
														5	Detail	1	2	3	1	NO	2	3	3	3			
														6	Detail	1	2	3	1	NO	2	3	3	3			
8	Detail	1	2	3	1	NO								2	3	3	3										
10	Detail	1	2	3	1	NO								2	3	3	3										
12	Detail	1	2	3	1	NO								2	3	3	3										
14	Detail	1	2	3	1	NO								2	3	3	3										
16	Detail	1	2	3	1	NO								2	3	3	3										
18	Detail	1	2	3	1	NO								2	3	3	3										
20	Detail	1	2	3	1	NO								2	3	3	3										
22	Detail	1	2	3	1	NO								2	3	3	3										
24	Detail	1	2	3	1	NO								2	3	3	3										
26	Detail	1	2	3	1	NO								2	3	3	3										
28	Detail	1	2	3	1	NO								2	3	3	3										
30	Detail	1	2	3	1	NO	2	3	3	3																	
32	Detail	1	2	3	1	NO	2	3	3	3																	
34	Detail	1	2	3	1	NO	2	3	3	3																	
36	Detail	1	2	3	1	NO	2	3	3	3																	
38	Detail	1	2	3	1	NO	2	3	3	3																	
40	Detail	1	2	3	1	NO	2	3	3	3																	
42	Detail	1	2	3	1	NO	2	3	3	3																	
44	Detail	1	2	3	1	NO	2	3	3	3																	
Summary		10/10/92	44	1	2	3	1	NO	2	3	3	1	YES	Run	In	Phase											
						LIBIDO DECREASED	2	01/03/92	Detail	1	2	3	1	NO	2	1	1	3									
							3	Detail	1	2	3	1	NO	2	3	3	3										
							4	Detail	1	2	3	1	NO	2	3	3	3										
							Summary		10/12/92	44	1	2	3	1	NO	2	3	3	1	YES	Run	In	Phase				

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe,
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CHE R&D
 REBOXETINE - PROTOCOL 20124/913
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Con. Patient	Init.	Start date	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Save r.f.ty	Hist ery	Hist shlp	Rel. Stud Sys	Dis app.	Re app.	Out. come	(C) Phase
1	109/149	26/02/92	02/06/92	17/02/93	Reboxetine	LIBIDO DECREASED	01/05/92	Detail	5		1	2	3	1	NO	2	3	3
								Detail	6		1	2	3	1	NO	2	3	3
								Detail	8		1	2	3	1	NO	2	3	3
								Detail	10		1	2	3	1	NO	2	3	3
								Detail	12		1	2	3	1	NO	2	3	3
								Detail	14		1	2	3	1	NO	2	3	3
								Detail	16		1	2	3	1	NO	2	3	3
								Detail	18		1	2	3	1	NO	2	3	3
								Detail	20		1	2	3	1	NO	2	3	3
								Detail	22		1	2	3	1	NO	2	3	3
								Detail	24		1	2	3	1	NO	2	3	3
								Detail	26		1	2	3	1	NO	2	3	3
								Detail	28		1	2	3	1	NO	2	3	3
								Detail	30		1	2	3	1	NO	2	3	3
								Detail	32		1	2	3	1	NO	2	3	3
								Detail	34		1	2	3	1	NO	2	3	3
								Detail	36		1	2	3	1	NO	2	3	3
								Detail	38		1	2	3	1	NO	2	3	3
								Detail	40		1	2	3	1	NO	2	3	3
								Detail	42		1	2	3	1	NO	2	3	3
								Detail	44		1	2	3	1	NO	2	3	3
								Detail	46		1	2	3	1	NO	2	3	3
								Detail	48		1	2	3	1	NO	2	3	3
								Detail	50		1	2	3	1	NO	2	3	3
								Summary	52	17/02/93	1	2	2	1	NO	2	3	1
								Summary	52	17/02/93	1	2	2	1	NO	2	3	1
								Detail	2		1	2	3	1	NO	2	3	3
								Detail	3		1	2	3	1	NO	2	3	3
								Detail	4		1	2	3	1	NO	2	3	3
								Detail	5		1	2	3	1	NO	2	3	3
								Detail	8		1	2	3	1	NO	2	3	3
								Detail	9		1	2	3	1	NO	2	3	3
								Detail	10		1	2	3	1	NO	2	3	3
								Detail	12		1	2	3	1	NO	2	3	3
								Detail	14		1	2	3	1	NO	2	3	3
								Detail	16		1	2	3	1	NO	2	3	3
								Detail	18		1	2	3	1	NO	2	3	3
								Detail	20		1	2	3	1	NO	2	3	3
								Detail	22		1	2	3	1	NO	2	3	3
								Detail	24		1	2	3	1	NO	2	3	3

1521

116/334 MGA 26/02/92 08/06/92 26/02/93 Reboxetine CONSTIPATION

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD
 RESOMETINE - PROTOCOL 28124/913
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Con. Patient	Init.	Start date	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End No date	Last report visit	Save rity	Hist ary	Shp drug	Rel treat	Stud Hosp	Symp app.	Dis app.	Re Out	Phase		
1	111/334	MCA	26/02/92	05/04/92	24/02/93	Rebasetine	CONSTIPATION	26	26	06/02/92	Detail	1	2	3	1	NO	2	3	3	3	
								28			Detail	1	2	3	1	NO	2	3	3	3	
								30			Detail	1	2	3	1	NO	2	3	3	3	
								32			Detail	1	2	3	1	NO	2	3	3	3	
								34			Detail	1	2	3	1	NO	2	3	3	3	
								36			Detail	1	2	3	1	NO	2	3	3	3	
								38			Detail	1	2	3	1	NO	2	3	3	3	
								40			Detail	1	2	3	1	NO	2	3	3	3	
								42			Detail	1	2	3	1	NO	2	3	3	3	
								44			Detail	1	2	3	1	NO	2	3	3	3	
								46			Detail	1	2	3	1	NO	2	3	3	3	
								50			Detail	1	2	3	1	NO	2	3	3	3	
								52	24/02/93		Summary	52	1	2	2	1	NO	2	3	1	
																				YES Run In Phase	
								8	10/04/92		Detail	1	2	3	1	NO	2	3	3	3	
								10			Detail	1	2	3	1	NO	2	3	3	3	
								12			Detail	1	2	3	1	NO	2	3	3	3	
								14			Detail	1	2	3	1	NO	2	3	3	3	
								16			Detail	1	2	3	1	NO	2	3	3	3	
								18			Detail	1	2	3	1	NO	2	3	3	3	
								20			Detail	1	2	3	1	NO	2	3	3	3	
								22			Detail	1	2	3	1	NO	2	3	3	3	
								24			Detail	1	2	3	1	NO	2	3	3	3	
								26			Detail	1	2	3	1	NO	2	3	3	3	
								28			Detail	1	2	3	1	NO	2	3	3	3	
								30	16/09/92		Detail	1	2	3	1	NO	2	3	3	3	
									16/09/92		Summary	30	1	2	3	1	NO	2	3	3	1
																				YES Double Blind	
123/336	MIL		27/02/92	09/04/92	26/02/93	Rebasetine	CONSTIPATION	26	26/02/92		Detail	1	2	4	1	NO	2	3	3	1	
									26/02/92		Summary	26	1	2	4	1	NO	2	3	3	1
																					YES Double Blind
								32	05/10/92		Detail	1	2	4	1	NO	2	3	3	1	
									05/10/92		Summary	32	1	2	4	1	NO	2	3	3	1
																					YES Double Blind
								36	02/11/92		Detail	1	2	4	1	NO	2	3	3	1	
									02/11/92		Summary	36	1	2	4	1	NO	2	3	3	1
																					YES Double Blind

Severity: 1=unknown, 2=mild, 3=moderate, 4=severe, 5=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=stop, 5=inter.
 Hospital: 1=required, 2=not req, 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq, 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (*) adverse event used for statistical analysis
 (**) adverse event still present: end date = visit date

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS PRD
 REBOXETINE - PROTOCOL 24126/913
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Ch. Patient	Init.	Start date	24/02/93	09/06/92	27/02/92	Treatment	Adverse event	Onset date	Type record	Visit No	End date	Last report	Save	Hist	Rel	Stud	Symp	Dis	Re	Out	D.B.			
													visit	city	ery	ship	drug	trns	hosp	app.	app.	some	(C)	Phase
1	127/542	VPD						29/02/92	Detail	24			1	2	5	1	NO	2	5	5	5			
									Detail	26			1	2	5	1	NO	2	5	3	3			
									Detail	28			1	2	3	1	NO	2	3	3	3			
									Detail	30			1	2	3	1	NO	2	3	3	3			
									Detail	32			1	2	3	1	NO	2	3	3	3			
									Detail	34			1	2	3	1	NO	2	3	3	3			
									Detail	36			1	2	3	1	NO	2	3	3	3			
									Detail	38			1	2	3	1	NO	2	3	3	3			
									Detail	40			1	2	3	1	NO	2	3	3	3			
									Detail	42			1	2	3	1	NO	2	3	3	3			
									Detail	44			1	2	3	1	NO	2	3	3	3			
									Detail	46			1	2	3	1	NO	2	3	3	3			
									Detail	48			1	2	3	1	NO	2	3	3	3			
									Detail	50			1	2	3	1	NO	2	3	3	3			
								24/02/93	Detail	52			1	2	1	NO	2	3	3	3	3			
								24/02/93	Summary	52			1	2	1	NO	2	3	3	3	3			
									YES Run In Phase															
								27/02/92	Detail	1			1	2	5	1	NO	2	5	5	5			
									Detail	2			1	2	5	1	NO	2	5	5	5			
									Detail	3			1	2	3	1	NO	2	3	3	3			
									Detail	4			1	2	3	1	NO	2	3	3	3			
									Detail	5			1	2	3	1	NO	2	3	3	3			
									Detail	6			1	2	3	1	NO	2	3	3	3			
									Detail	8			1	2	3	1	NO	2	3	3	3			
									Detail	10			1	2	3	1	NO	2	3	3	3			
									Detail	12			1	2	3	1	NO	2	3	3	3			
									Detail	14			1	2	5	1	NO	2	5	5	5			
									Detail	16			1	2	5	1	NO	2	5	5	5			
									Detail	18			1	2	3	1	NO	2	3	3	3			
									Detail	20			1	2	3	1	NO	2	3	3	3			
									Detail	22			1	2	5	1	NO	2	5	5	5			
									Detail	24			1	2	3	1	NO	2	3	3	3			
									Detail	26			1	2	3	1	NO	2	3	3	3			
									Detail	28			1	2	3	1	NO	2	3	3	3			
									Detail	30			1	2	3	1	NO	2	3	3	3			
									Detail	32			1	2	3	1	NO	2	3	3	3			
									Detail	34			1	2	3	1	NO	2	3	3	3			
									Detail	36			1	2	3	1	NO	2	3	3	3			
									Detail	38			1	2	3	1	NO	2	3	3	3			
									Detail	40			1	2	3	1	NO	2	3	3	3			
									Detail	42			1	2	5	1	NO	2	5	5	5			

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=definite, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (*) adverse event used for statistical analysis
 (**) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RAD

REBOXETINE - PROTOCOL 20124/013
Listing No.: 11.0

ADVERSE EVENTS
DOUBLE BLIND PHASE

Can. Patient Init.	Start date	Start D.B.	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End No date	Last report visit	Sev	Hist	Rel	Stud	Symp	Dis app.	Re Out	Dis app.	Cona	(C) Phase	
1 127/362 WPD	27/02/92	09/06/92	26/02/93	Reboxetine	MOUTH DRY	27/02/92	Detail	44		1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3
							Detail	45		1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3
							Detail	46		1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3
							Detail	50		1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3
							Detail	52	26/02/93	1 2 2 1	NO	2	3	3	3	3	3	3	3	3	3
							Summary	26/02/93	52	1 2 2 1	NO	2	3	3	3	3	3	3	3	3	1 YES Run In Phase
							Detail	28	06/05/92	1 2 4 1	NO	2	3	3	3	3	3	3	3	3	1 YES Double Blind
							Summary	06/05/92	28	1 2 4 1	NO	2	3	3	3	3	3	3	3	3	1 YES Double Blind
128/363 LHM	27/02/92	09/06/92	26/02/93	Reboxetine	HEADACHE	15/05/92	Detail	26	21/05/92	1 2 4 1	NO	2	3	3	3	3	3	3	3	3	1 YES Double Blind
							Summary	21/05/92	26	1 2 4 1	NO	2	3	3	3	3	3	3	3	3	1 YES Double Blind
							Detail	1		1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3
							Detail	2		1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3
							Detail	3		1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3
							Detail	4		1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3
							Detail	5		1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3
							Detail	6		1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3
							Detail	8		2 1 3 1	NO	2	3	3	3	3	3	3	3	3	3
							Detail	10		1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3
							Detail	12		1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3
							Detail	14		1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3
							Detail	16		1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3
							Detail	18		1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3
							Detail	20		1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3
							Detail	22		1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3
							Detail	24		1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3
							Detail	26		1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3
							Detail	28		1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3
							Detail	30		1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3
							Detail	32		1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3
							Detail	34		1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3
							Detail	36		1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3
							Detail	38		1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3
							Detail	40		1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3
							Detail	42		1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3
							Detail	44		1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3
							Detail	46		1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3
							Detail	48		1 2 3 1	NO	2	3	3	3	3	3	3	3	3	3

Severities: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drugs: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req, 3=not appl. -- Outcome: 1=recovered, 2=rec. with set., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date

1526

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CHE RD
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Con. Patient	Init.	Start date	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End date	Last report visit rity	Save Hist	Rel. Stud	Symp	Dis. app.	Re. com	Out. (c)	In Phase						
1	126/548	LAN	27/02/92	09/06/92	24/02/95	Reboxetine	MICTURITION DISORDER	27/02/92	Detail 1 Summary 52	24/02/93	52	1	2	2	1	NO	2	3	3	1	YES	Run In Phase	
							PARAESTHESIA	27/02/92	Detail 1 Detail 2 Detail 3 Detail 4 Detail 5 Detail 6 Summary 5	05/06/92	05/06/92	5	1	2	3	1	NO	2	3	3	1	YES	Run In Phase
							TACHYCARDIA	28/03/92	Detail 1 Summary 32	05/10/92	32	1	2	4	1	NO	2	3	3	3	1	YES	Double Blind
135	548	MMS	25/03/92	06/05/92	25/05/95	Reboxetine	LIBIDO DECREASED	29/03/92	Detail 1 Detail 2 Detail 3 Detail 4 Detail 5 Detail 6 Detail 7 Detail 8 Detail 9 Detail 10 Detail 11 Detail 12 Detail 13 Detail 14 Detail 15 Detail 16 Detail 17 Detail 18 Detail 19 Detail 20 Detail 21 Detail 22 Detail 23 Detail 24 Detail 25 Detail 26 Detail 27 Detail 28 Detail 29 Detail 30 Detail 31 Detail 32 Detail 33 Summary 34	15/11/92	34	1	2	1	1	NO	2	3	3	3	1	YES	Run In Phase
							SWEATING INCREASED	28/03/92	Detail 1 Detail 2			1	2	3	1	NO	2	3	3	3	3	3	3

1527

Serivty: 0=unknown, 1= mild, 2= moderate, 3= severe, 4= life threatening
 Study drug: 1= no change, 2= dose reduced, 3= def. withdrawn, 4= temp. inter.
 Hospital: 1= required, 2= not req., 3= not appl. -- Outcome: 1= recovered, 2= rec. with seq., 3= still present, 4= death
 Disapp./Resp.: 1= no, 2= yes, 3= not appl. -- Relationship: 1= definite, 2= probable, 3= possible, 4= doubtful, 5= unknown, 6= none
 Symptomatic treatment: 0= no, 1= yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS TAB

REBOXETINE - PROTOCOL 20126/013
Listing No.: 11.0

ADVERSE EVENTS
DOUBLE BLIND PHASE

Can. Patient	Init.	Start date	End date	Treatment	Adverse event	Onset date	Type	Visit	End	Last	report	Save	Hist	Rel. Stud	Symp	Dis	Re	Out	D.B.					
							record	No	date	visit	rity	ery	shlp	drug	traa	hosp	app.	some	(C)	Phase				
1	135/348	MS	25/03/92	06/05/92	23/03/93	Reboxetine	SWEATING INCREASED	3	28/03/92	3	1	2	3	1	NO	2	3	3	3	3				
							Detail	4		4	1	2	3	1	NO	2	3	3	3	3				
							Detail	5		5	1	2	3	1	NO	2	3	3	3	3				
							Detail	6		6	1	2	3	1	NO	2	3	3	3	3				
							Detail	8		8	1	2	3	1	NO	2	3	3	3	3				
							Detail	10		10	1	2	3	1	NO	2	3	3	3	3				
							Detail	12		12	1	2	3	1	NO	2	3	3	3	3				
							Detail	14		14	1	2	3	1	NO	2	3	3	3	3				
							Detail	16		16	1	2	3	1	NO	2	3	3	3	3				
							Detail	18		18	1	2	3	1	NO	2	3	3	3	3				
							Detail	20		20	1	2	3	1	NO	2	3	3	3	3				
							Detail	22		22	1	2	3	1	NO	2	3	3	3	3				
							Detail	24		24	1	2	3	1	NO	2	3	3	3	3				
							Detail	26		26	1	2	3	1	NO	2	3	3	3	3				
							Detail	28		28	1	2	3	1	NO	2	3	3	3	3				
							Detail	30		30	1	2	3	1	NO	2	3	3	3	3				
							Detail	32		32	1	2	3	1	NO	2	3	3	3	3				
							Detail	34		34	1	2	3	1	NO	2	3	3	3	3				
							Detail	36		36	1	2	3	1	NO	2	3	3	3	3				
							Detail	38		38	1	2	3	1	NO	2	3	3	3	3				
							Detail	40		40	1	2	3	1	NO	2	3	3	3	3				
							Detail	42		42	1	2	3	1	NO	2	3	3	3	3				
							Detail	44	20/01/93	44	1	2	3	1	NO	2	3	3	3	3				
							Summary	20/01/93			44	1	2	3	1	NO	2	3	3	3				
																				1	YES	Run	In	Phase
139/351	PA	25/03/92	06/05/92	23/03/93	Reboxetine	MICTURITION DISORDER	Detail	2	02/04/92	2	1	2	3	1	NO	2	3	3	3	3				
							Detail	3		3	1	2	3	1	NO	2	3	3	3	3				
							Detail	4		4	1	2	3	1	NO	2	3	3	3	3				
							Detail	5		5	1	2	3	1	NO	2	3	3	3	3				
							Detail	6		6	1	2	3	1	NO	2	3	3	3	3				
							Detail	8		8	1	2	3	1	NO	2	3	3	3	3				
							Detail	10		10	1	2	3	1	NO	2	3	3	3	3				
							Detail	12		12	1	2	3	1	NO	2	3	3	3	3				
							Detail	14		14	1	2	3	1	NO	2	3	3	3	3				
							Detail	16		16	1	2	3	1	NO	2	3	3	3	3				
							Detail	18		18	1	2	3	1	NO	2	3	3	3	3				
							Detail	20		20	1	2	3	1	NO	2	3	3	3	3				
							Detail	22		22	1	2	3	1	NO	2	3	3	3	3				
							Detail	24		24	1	2	3	1	NO	2	3	3	3	3				
							Detail	26		26	1	2	3	1	NO	2	3	3	3	3				
							Detail	28		28	1	2	3	1	NO	2	3	3	3	3				

15:28

Severity: 0=unknown, 1= mild, 2= moderate, 3= severe, 4= life threatening, 5= fatal
 Study drug: 1= no change, 2= dose reduced, 3= def. withdrawn, 4= temp. inter.
 Hospital: 1= required, 2= not req., 3= not appl.
 Disapp./Resp.: 1= no, 2= yes, 3= not appl.
 Symptomatic treatment: 0= no, 1= yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date
 -- History: 1= present before, 2= not observe bef., 3= unknown

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
REBOMETINE - PROTOCOL 20126/013
Listing No.: 11.0
ADVERSE EVENTS
DOUBLE BLIND PHASE

Con.	Patient	Init.	Start date	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End date	Rel. drug	Stuc	Hist	Save	Report	Dis	Re	Out	In Phase	
1	139/351	RA	25/05/92	06/06/92	25/05/95 Remoxetine	MICTURITION DISORDER	02/06/92	Detail	30			1	2	3	1	NO	2	3	3	3
								Detail	32			1	2	3	1	NO	2	3	3	3
								Detail	34			1	2	3	1	NO	2	3	3	3
								Detail	36			1	2	3	1	NO	2	3	3	3
								Detail	38			1	2	3	1	NO	2	3	3	3
								Detail	40			1	2	3	1	NO	2	3	3	3
								Detail	42			1	2	3	1	NO	2	3	3	3
								Detail	44			1	2	3	1	NO	2	3	3	3
								Detail	46			1	2	3	1	NO	2	3	3	3
								Detail	48			1	2	3	1	NO	2	3	3	3
								Detail	50			1	2	3	1	NO	2	3	3	3
								Detail	52	25/05/95		1	2	3	1	NO	2	3	3	3
								Summary	23/03/93			52	1	2	1	NO	2	3	3	1
																				YES Rem In Phase

VISION ABNORMAL

02/06/92

Detail	2			1	2	3	1	NO	2	3	3
Detail	3			1	2	3	1	NO	2	3	3
Detail	4			1	2	3	1	NO	2	3	3
Detail	5			1	2	3	1	NO	2	3	3
Detail	6			1	2	3	1	NO	2	3	3
Detail	8			1	2	3	1	NO	2	3	3
Detail	10			1	2	3	1	NO	2	3	3
Detail	12			1	2	3	1	NO	2	3	3
Detail	14			1	2	3	1	NO	2	3	3
Detail	16			1	2	3	1	NO	2	3	3
Detail	18			1	2	3	1	NO	2	3	3
Detail	20			1	2	3	1	NO	2	3	3
Detail	22			1	2	3	1	NO	2	3	3
Detail	24			1	2	3	1	NO	2	3	3
Detail	26			1	2	3	1	NO	2	3	3
Detail	28			1	2	3	1	NO	2	3	3
Detail	30			1	2	3	1	NO	2	3	3
Detail	32			1	2	3	1	NO	2	3	3
Detail	34			1	2	3	1	NO	2	3	3
Detail	36			1	2	3	1	NO	2	3	3
Detail	38			1	2	3	1	NO	2	3	3
Detail	40			1	2	3	1	NO	2	3	3
Detail	42			1	2	3	1	NO	2	3	3
Detail	44			1	2	3	1	NO	2	3	3
Detail	46			1	2	3	1	NO	2	3	3
Detail	48			1	2	3	1	NO	2	3	3
Detail	50			1	2	3	1	NO	2	3	3
Detail	52			1	2	3	1	NO	2	3	3

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=amp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=frec. with ses., 3=still present, 4=death
Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date

PHARMACIA CNS RAD
 REPOMETINE - PROTOCOL 20124/013
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Cn. Patient Init.	Start date	D.B.	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End date	Last report		Dis app.	Re come	Out (c)	Phase
										visit rty	ory shlp				
1	139/251 RA	25/03/92	06/05/92	23/02/92 Reboksetine	VISION ABNORMAL	02/04/92	Detail	52	23/02/93	52	1 2 2 1 1	NO 2 3 3 1	1	YES	Run In Phase
							Summary				1 2 2 1 1	NO 2 3 3 1	1	YES	Run In Phase
146	356 LRH	28/03/92	09/06/92	26/02/92 Reboksetine	CONSTIPATION	29/03/92	Detail	1		1	2 5 1	NO 2 3 3	3		
							Detail	2		1	2 3 1	NO 2 3 3	3		
							Detail	3		1	2 3 1	NO 2 3 3	3		
							Detail	4		1	2 3 1	NO 2 3 3	3		
							Detail	5		1	2 3 1	NO 2 3 3	3		
							Detail	6		1	2 3 1	NO 2 3 3	3		
							Detail	8		1	2 3 1	NO 2 3 3	3		
							Detail	10		1	2 3 1	NO 2 3 3	3		
							Detail	12		1	2 3 1	NO 2 3 3	3		
							Detail	14		1	2 3 1	NO 2 3 3	3		
							Detail	16	10/07/92	16	1 2 5 1	NO 2 5 3 1	1	YES	Run In Phase
							Summary				1 2 5 1	NO 2 5 3 1	1	YES	Run In Phase
					DIARRHOEA	15/02/93	Detail	48	22/02/93	48	1 2 4 1	NO 2 5 3 1	1	YES	Double Blind
							Summary				1 2 4 1	NO 2 5 3 1	1	YES	Double Blind
					MICTURITION DISORDER	29/03/92	Detail	1		1	2 3 1	NO 2 3 3	3		
							Detail	2		1	2 3 1	NO 2 3 3	3		
							Detail	3		1	2 3 1	NO 2 3 3	3		
							Detail	4		1	2 3 1	NO 2 3 3	3		
							Detail	5		1	2 3 1	NO 2 3 3	3		
							Detail	6		1	2 3 1	NO 2 3 3	3		
							Detail	8		1	2 3 1	NO 2 3 3	3		
							Detail	10	01/06/92	10	1 2 3 1	NO 2 3 3 1	1	YES	Run In Phase
							Detail	24	01/06/92	10	1 2 3 1	NO 2 3 3 1	1	YES	Run In Phase
							Summary				1 2 3 1	NO 2 3 3 1	1	YES	Run In Phase
							Detail	26		1	2 3 1	NO 2 3 3	3		
							Detail	28		1	2 3 1	NO 2 3 3	3		
							Detail	30		1	2 3 1	NO 2 3 3	3		
							Detail	32		1	2 3 1	NO 2 3 3	3		
							Detail	34		1	2 3 1	NO 2 3 3	3		
							Detail	36		1	2 3 1	NO 2 3 3	3		
							Detail	38		1	2 3 1	NO 2 3 3	3		
							Detail	40		1	2 3 1	NO 2 3 3	3		
							Detail	42		1	2 3 1	NO 2 3 3	3		
							Detail	44		1	2 3 1	NO 2 3 3	3		

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req, 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=more
 symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (s) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD

REBOMETINE -- PROTOCOL 20124/013
Listing No.: 11.0

ADVERSE EVENTS
DOUBLE BLIND PHASE

Ch. Patient	Init.	Start date	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End No date	Last report visit	Save Hist	Hist	any	Ship	Drug	Trea	Mosp	app.	Dis	Re	Out	D.B.	
1	146/358	URK	26/03/92	09/05/92	26/03/93	Reboxetine	MICTURITION DISORDER	01/07/92	46	46	1	2	3	1	NO	2	3	3	3	3	3	3	3
									48		1	2	3	1	NO	2	3	3	3	3	3	3	3
									50		1	2	3	1	NO	2	3	3	3	3	3	3	3
									52	26/03/93	1	2	2	1	NO	2	3	3	3	3	3	3	3
									26/03/93	52	1	2	2	1	NO	2	3	3	3	3	3	3	3
									Summary														1 YES Double Blind
									Detail 1		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 2		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 3		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 4		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 5		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 6		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 7		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 8		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 9		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 10		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 11		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 12		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 13		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 14		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 15		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 16		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 17		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 18		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 19		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 20		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 21		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 22		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 23		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 24		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 25		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 26		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 27		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 28		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 29		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 30		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 31		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 32		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 33		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 34		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 35		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 36		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 37		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 38		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 39		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 40		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 41		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 42		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 43		1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 44	20/01/93	1	2	3	1	NO	2	3	3	3	3	3	3	3
									Detail 45		1	2	3	1	NO	2	3	3	3	3	3	3	3

Severely: 0=unknown, 1=mild, 2=moderate, 3=severe, -- History: 1=present before, 2=not observe bet., 3=unknown
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CHE RD
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Con. Patient	Init.	Start date	Start D.B.	Treatment	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End No date	Last report visit rfty	See Hist opy	Susp drug	Rel. Stud Sym	Dis app.	Re cona	Out. (C)	Phase			
1	146/359	CAS	26/05/92	09/05/92	24/05/93	Reboxetine	LIBIDO DECREASED	01/04/92	Summary	20/01/93	44	1	2	3	1	NO	2	5	3	1	YES	Run In Phase
			28/03/92				NAUSEA	28/03/92	Detail	1	1	2	3	1	NO	2	3	3				
								07/06/92	Summary	07/06/92	2	1	2	3	1	NO	2	3	3	1	YES	Run In Phase
3	7/71	GR1	11/12/90	25/01/91	06/02/91	Reboxetine	MOUTH DRY	12/12/90	Detail	0	16/12/90	0	1	2	1	NO	3					
								18/12/90	Summary	18/12/90	0	1	2	1	NO	3						
			05/01/91					15/01/91	Detail	4	15/01/91	4	1	2	1	NO	2	3	3	1	YES	Run In Phase
								22/01/91	Summary	22/01/91	6	1	2	1	NO	2	3	3	1	YES	Run In Phase	
			27/12/90				PALPITATION	27/12/90	Detail	3	2	2	3	1	NO	2	5	3				
								15/01/91	Summary	15/01/91	4	2	2	3	2	NO	2	2	3	1	YES	Run In Phase
			16/01/91				TACHYCARDIA	16/01/91	Detail	6	22/01/91	6	1	2	1	NO	2	3	3	1	YES	Run In Phase
								22/01/91	Summary	22/01/91	6	1	2	1	NO	2	3	3	1	YES	Run In Phase	
			25/01/91					05/02/91	Detail	8	05/02/91	8	2	2	2	NO	2	2	3	1	YES	Double Blind
								07/02/91	Summary	07/02/91	10	3	2	2	3	NO	2	2	3	1	YES	Double Blind
			17/12/90				VERTIGO	17/12/90	Detail	0	17/12/90	0	1	2	3	NO	1	3				
								17/12/90	Summary	17/12/90	0	1	2	3	NO	1	3					
8	2/212	TE	14/12/90	25/01/91	12/12/91	Reboxetine	HYPERTROPHIC CARDIOMYOPATHY	16/04/91	Detail	15	2	2	5	1	NO	2	5	3	3			
								20/04/91	Detail	20	2	2	5	1	NO	2	3	3				
								24/04/91	Detail	24	2	2	5	1	NO	2	3	3				
								13/06/91	Detail	26	13/06/91	2	2	5	1	NO	2	1	3	1	YES	Double Blind
								13/06/91	Summary	13/06/91	26	2	2	5	1	NO	2	1	3	1	YES	Double Blind
9	20/252	ONE	24/08/91	05/10/91	27/12/91	Reboxetine	INSOMNIA	05/10/91	Detail	8	10/10/91	2	2	4	1	YES	2					

1532

--- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=stop. inter.
 Hospital: 1=recovered, 2=not rec., 3=not appl. -- Outcomes: 1=recovered, 2=rec. with seq., 3=still present, 4=search
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (M) adverse event used for safety analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Con. Patient	Int.	Start date	Start D.B.	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End No date	Last report visit	Save rity	Hist opy ship	Hist drug tras	Rel Hosp app.	Stud app.	Symp app.	Dis app.	Re app.	Out app.	D.B. app.				
9	24/252 OVE	24/08/91	05/10/91	27/12/91	Reboxetine	INSOMNIA	05/10/91 16/11/91	Summary Detail	18/10/91 14 29/11/91	8 2	2 4	1 YES	2 2	4 1	YES 2	1 YES	2 2	4 1	YES 2	2 1	YES 2	1 1	YES 2	Double Blind	
							14/12/91	Summary	18 27/12/91	2	1	4	1	YES	2	1	YES	2	1	YES	2	1	YES	Double Blind	
							06/01/92	Detail	10 17/01/92	1	2	4	1	NO	2	1	YES	2	1	YES	2	1	YES	Double Blind	
								Summary	17/01/92	10	1	2	4	1	NO	2	1	YES	2	1	YES	2	1	YES	Double Blind
							05/10/92	Detail	26 05/10/92	1	2	5	1	NO	2	1	YES	2	1	YES	2	1	YES	Double Blind	
								Summary	05/10/92	26	1	2	5	1	NO	2	1	YES	2	1	YES	2	1	YES	Double Blind
							26/12/90	Detail	12	1	1	4	1	NO	2	3	3	3	3	3	3	3	3	3	3
								Detail	14 09/01/91	1	1	4	1	NO	2	3	3	3	3	3	3	3	3	3	3
								Summary	09/01/91	14	1	1	4	1	NO	2	3	3	3	3	3	3	3	3	3
							21/10/90	Detail	1	3	1	6	1	NO	2	3	3	3	3	3	3	3	3	3	3
								Detail	2	2	1	6	1	YES	2	3	3	3	3	3	3	3	3	3	3
								Detail	3 31/10/90	1	1	6	1	NO	2	3	3	3	3	3	3	3	3	3	3
								Summary	31/10/90	3	3	1	6	1	YES	2	3	3	3	3	3	3	3	3	3
							14/10/90	Detail	1	3	1	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
								Detail	2	2	1	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
								Detail	3	2	1	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
								Detail	4 07/11/90	1	1	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
								Summary	07/11/90	4	3	1	3	1	NO	2	3	3	3	3	3	3	3	3	3
							28/11/90	Detail	6	1	1	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
								Detail	10	1	1	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
								Detail	12	1	1	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
								Detail	14	1	1	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
								Detail	16	1	1	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
								Summary	01/02/91(*)	16	1	1	3	1	NO	2	3	3	3	3	3	3	3	3	3
							21/10/90	Detail	1	1	1	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
								Detail	2	1	1	3	1	NO	2	3	3	3	3	3	3	3	3	3	3
								Detail	4 12/11/90	1	1	3	1	NO	2	3	3	3	3	3	3	3	3	3	3

Severity: 0=unknown, 1= mild, 2= moderate, 3= severe, 4= life threatening, 5= fatal
 Study drug: 1= no change, 2= dose reduced, 3= def. withdrawn, 4= temp. inter.
 Hospital: 1= required, 2= not req., 3= not appl. -- Outcome: 1= recovered, 2= res. with seq., 3= still present, 4= death
 Disapp./Resp.: 1= no, 2= yes, 3= not appl. -- Relationship: 1= definite, 2= probable, 3= possible, 4= doubtful, 5= unknown, 6= none
 Symptomatic treatment: 0= no, 1= yes
 (*) adverse event used for statistical analysis
 (c) adverse event still present: end date = visit date

1530

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Cn. Patient	Init.	Start date	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Save Hist	Rel. Stud	Symp	Dis app.	Re come	Out (c)	Phasa						
																		dry	ship	tree	Hosp	app.	come
10	1/271	VK	16/10/98	27/11/98	01/02/99	Reboxetine	MOUTH DRY	Summary	12/11/98	4	1	1	3	1	NO	2	3	3	1	YES	Run	In Phase	
	7/274	RK	20/11/98	02/01/99	15/01/99	Reboxetine	MICTURITION DISORDER	Detail	1	1	2	3	1	NO	2	3	3	3					
								Detail	2	1	2	3	1	NO	2	3	3	3					
								Detail	3	1	2	3	1	NO	2	3	3	3					
								Detail	4	16/12/98	1	2	3	1	NO	2	3	3	1				
								Summary	15/12/98	4	1	2	3	1	NO	2	3	3	1				
								Detail	5	1	2	3	1	NO	2	3	3	3					
								Detail	6	08/01/99	1	2	3	1	NO	2	3	3	3				
								Summary	08/01/99	6	1	2	3	1	NO	2	3	3	1				
								Detail	1	20/11/98	1	1	3	1	NO	2	3	3	3				
								Detail	2	1	1	3	1	NO	2	3	3	3					
								Detail	3	09/12/98	1	1	3	1	NO	2	3	3	1				
								Summary	09/12/98	3	1	1	3	1	NO	2	3	3	1				
								Detail	1	26/12/98	3	1	4	1	YES	2	3	3	1				
								Summary	21/12/98	3	3	1	4	1	YES	2	3	3	1				
								Detail	1	15/02/99	1	1	3	1	NO	2	3	3	3				
								Detail	2	1	1	3	1	NO	2	3	3	3					
								Detail	3	1	1	3	1	NO	2	3	3	3					
								Detail	4	1	1	3	1	NO	2	3	3	3					
								Detail	5	1	1	3	1	NO	2	3	3	3					
								Detail	6	1	1	3	1	NO	2	3	3	3					
								Detail	8	08/04/99	1	1	3	1	NO	2	3	3	3				
								Summary	08/04/99	6	1	1	3	1	NO	2	3	3	3				
								Detail	1	21/02/99	2	1	4	1	YES	2	3	3	3				
								Detail	3	06/03/99	2	1	4	1	YES	2	3	3	1				
								Summary	06/03/99	3	2	1	4	1	YES	2	3	3	1				
								Detail	1	15/02/99	1	1	4	1	NO	2	3	3	3				
								Detail	2	1	1	4	1	NO	2	3	3	3					
								Detail	3	1	1	4	1	NO	2	3	3	3					
								Detail	5	1	1	4	1	NO	2	3	3	3					

Severity: 0=unknown, 1= mild, 2= moderate, 3= severe, 4= life threatening
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=probable, 3=possible, 4=definite, 5=unknown, 6=note
 Disapp./Keapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=definite, 5=unknown, 6=note
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 11.9
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Con.	Patient	Init.	Start date	End date	Treatment	Adverse event	Onset date	Type	Visit record	No date	Last report visit	Save	Hist	Rel	Stud	Symp	Dis	Re	Out	D.P.		
											visit	city	cry	shlp	drug	trea	Hosp	app.	app.	com	(c)	Phase
19	13/276	HU	12/02/91	06/04/91	Reboxetine	RHINITIS	12/02/91	Detail	4		1	1	4	1	NO	2	3	3	3			
								Detail	5	24/03/91	1	1	4	1	NO	2	3	3	3			
								Detail	6	24/03/91	1	1	4	1	NO	2	3	3	3			
								Summary	24/03/91	6	1	1	4	1	NO	2	3	3	3	1	YES	Run In Phase
								Detail	1		1	1	3	1	NO	2	3	3	3			
								Detail	2		1	1	3	1	NO	2	3	3	3			
								Detail	3		1	1	3	1	NO	2	3	3	3			
								Detail	4		2	1	3	1	NO	2	3	3	3			
								Detail	5		1	1	3	1	NO	2	3	3	3			
								Detail	6		1	1	3	1	NO	2	3	3	3			
								Detail	8	04/04/91	1	1	3	1	NO	2	3	3	3			
								Summary	04/04/91	8	2	1	3	1	NO	2	3	3	3	1	YES	Run In Phase
15/280	HT		21/02/91	06/04/91	Reboxetine	DIZZINESS	02/03/91	Detail	2		1	1	3	1	NO	2	3	3	3			
								Detail	3		1	1	3	1	NO	2	3	3	3			
								Detail	4		1	1	3	1	NO	2	3	3	3			
								Detail	5	21/03/91	1	1	3	1	NO	2	3	3	3			
								Summary	21/03/91	5	1	1	3	1	NO	2	3	3	3	1	YES	Run In Phase
								Detail	4		2	2	6	1	YES	2	3	3	3			
								Detail	5	21/03/91	2	2	6	1	YES	2	3	3	2			
								Summary	21/03/91	5	2	2	6	1	YES	2	3	3	2	2	YES	Run In Phase
								Detail	6	04/04/91	2	1	3	1	YES	2	3	3	3	1	YES	Run In Phase
								Summary	04/04/91	6	2	1	3	1	YES	2	3	3	3	1	YES	Run In Phase
								Detail	8		1	2	5	1	NO	2	3	3	3			
								Detail	10		1	2	5	1	NO	2	3	3	3			
								Summary	30/04/91(*)	10	1	2	5	1	NO	2	3	3	3	3	3	YES Double Blind
								Detail	2		2	1	3	1	NO	2	3	3	3			
								Detail	3		1	1	3	1	NO	2	3	3	3			
								Detail	4		1	1	3	1	NO	2	3	3	3			
								Detail	5		1	1	3	1	NO	2	3	3	3			
								Detail	6	28/03/91	1	1	3	1	NO	2	3	3	3			

Severity: unknown, mild, moderate, severe, --- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

1335

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
 Listing No.: 11.0

ADVERSE EVENTS
 DOUBLE BLIND PHASE

Can. Patient	Init.	Start date	Start D.B.	Treatment	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Sev	Hist	Rel	Stud	Symp	Dis app.	Re app.	Out D.B.			
10	15/280	HT	21/02/91	06/04/91	30/04/91	Reboxetine	SWEATING INCREASED	01/03/91	Summary	28/03/91	6	2	1	3	1	NO	2	3	3	1	YES	Run In Phase	
	20/285	EJ	23/04/91	06/06/91	04/11/91	Reboxetine	DIIZZINESS	05/05/91	Detail	2	3	1	3	1	NO	2	3	3	3	3			
									Detail	3	1	1	3	1	NO	1	3	3	3	3			
									Detail	4	18/05/91	4	3	1	3	1	NO	2	3	3	1	YES	Run In Phase
									Summary	18/05/91	4	3	1	3	1	NO	1	3	3	1	YES	Run In Phase	
									Detail	8	17/06/91	8	2	1	3	1	YES	2	3	3	2	YES	Run In Phase
									Summary	17/06/91	8	2	1	3	1	YES	2	3	3	2	YES	Run In Phase	
									Detail	1	27/04/91	1	1	1	3	1	NO	2	3	3	1	YES	Run In Phase
									Summary	27/04/91	1	1	1	3	1	NO	2	3	3	1	YES	Run In Phase	
22/285	AA		23/04/91	04/06/91	20/04/92	Reboxetine	CONSTIPATION	27/04/91	Detail	1	28/04/91	1	1	2	3	1	NO	2	3	3	1	YES	Run In Phase
									Summary	28/04/91	1	1	2	3	1	NO	2	3	3	1	YES	Run In Phase	
									Detail	15/08/91	36	2	1	6	1	YES	2	3	3	1	YES	Double Blind	
									Summary	29/12/91	36	2	1	6	1	YES	2	3	3	1	YES	Double Blind	
									Detail	26/08/91	22	2	1	4	1	YES	2	3	3	2	YES	Double Blind	
									Summary	23/08/91	22	2	1	4	1	YES	2	3	3	2	YES	Double Blind	
									Detail	21/11/91	32	2	2	4	1	YES	2	3	3	3			
									Detail	36	14/12/91	36	2	2	4	1	NO	2	3	3	1	YES	Double Blind
									Summary	14/12/91	36	2	2	4	1	YES	2	3	3	1	YES	Double Blind	
23/287	LT		24/04/91	05/06/91	25/02/92	Reboxetine	INSOMNIA	10/05/91	Detail	6	18/06/91	6	2	2	3	1	YES	2	3	3	2	YES	Run In Phase
									Summary	18/06/91	6	2	2	3	1	YES	2	3	3	2	YES	Run In Phase	
26/290	JIF		28/05/91	09/07/91	05/08/91	Reboxetine	ANGINA PECTORIS	09/07/91	Detail	10	05/08/91(*)	10	1	1	6	3	YES	2	1	3	3	YES	Double Blind
									Summary	05/08/91(*)	10	1	1	6	3	YES	2	1	3	3	3	YES	Double Blind

1536

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe.
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./Repp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 2012/0/013
Listing No.: 11.0

ADVERSE EVENTS
DOUBLE BLIND PHASE

Pat. No.	Start date	End date	Treatment	Adverse event	Onset date	Type	Visit record	End date	Last report visit	Save rcty	Hist opy	Hist ship	Hist drus	Hist Stud	Sym	Dis app.	Re app.	Dir. come	Phase	
10	28/05/91	09/07/91	05/08/91 Reboxetine	CHEST PAIN	25/07/91	Detail	10	05/08/91(*)	10	3	2	5	1	NO	2	3	3	3	3	YES Double Blind
						Summary														
				PARAESTHESIA	29/06/91	Detail	1			1	2	3	1	NO	2	3	3	3	3	YES Run In Phase
						Detail	2			1	2	3	1	NO	2	3	3	3	3	YES Run In Phase
					18/06/91	Detail	3			1	2	3	1	NO	2	3	3	3	3	YES Run In Phase
					18/06/91	Summary	3			3	1	2	3	1	NO	2	3	3	3	YES Run In Phase
27/292 MK	05/06/91	15/07/91	01/06/92 Reboxetine	HYPERTENSION	05/06/91	Detail	10	06/06/91	10	2	1	5	1	YES	2	3	3	3	3	YES Double Blind
						Summary				2	1	5	1	YES	2	3	3	3	3	YES Double Blind
				INSOMNIA	10/06/91	Detail	2	17/06/91	2	2	1	4	1	YES	2	3	3	3	3	2 YES Run In Phase
						Summary				2	2	1	4	1	YES	2	3	3	3	2 YES Run In Phase
				SOMNOLENCE	02/06/91	Detail	1	05/06/91	1	1	2	3	1	NO	2	3	3	3	3	1 YES Run In Phase
						Summary				1	2	3	1	NO	2	3	3	3	3	1 YES Run In Phase
28/293 LL	30/05/91	11/07/91	15/05/92 Reboxetine	EDEMA PERIPHERAL	26/06/91	Detail	4			1	2	4	1	NO	2	3	3	3	3	3
						Detail	5	02/07/91	5	1	2	4	1	NO	2	3	3	3	3	1 YES Run In Phase
						Summary				5	1	2	4	1	NO	2	3	3	3	1 YES Run In Phase
31/297 MK	16/09/91	26/10/91	14/09/92 Reboxetine	CONSTIPATION	26/06/91	Detail	4			1	2	3	1	NO	2	3	3	3	3	3
						Detail	5	26/06/91	5	1	2	3	1	NO	2	3	3	3	3	1 YES Run In Phase
						Summary				5	1	2	3	1	NO	2	3	3	3	1 YES Run In Phase
32/299 LK	16/09/91	26/10/91	14/09/92 Reboxetine	CONSTIPATION	30/10/91	Detail	6			1	1	3	1	NO	2	3	3	3	3	3
						Detail	8			1	1	3	1	NO	2	3	3	3	3	3
						Detail	10	21/11/91	10	1	1	3	1	NO	2	3	3	3	3	1 YES Run In Phase
						Summary				10	1	1	3	1	NO	2	3	3	3	1 YES Run In Phase
					16/24/11/91	Detail	6			1	1	5	1	NO	2	3	3	3	3	3
						Detail	16	24/11/91	16	1	1	5	1	NO	2	3	3	3	3	1 YES Double Blind
						Summary				19	1	1	5	1	NO	2	3	3	3	1 YES Double Blind
					26/11/91	Detail	12			1	1	5	1	NO	2	3	3	3	3	3

1537

-- History: 1=Present before, 2=not observe bef., 3=unknown
 Severity: 0=unknown, 1=mild, 2=moderate, 3=severe,
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS READ
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Ch.	Patient	Init.	Start date	End date	Treatment	Adverse event	Onset date	Type	Visit record	End No date	Last report visit rity	Save ory	Mist ship	Rel. drug	Stud. Resp	Symp. app.	Dis. app.	Re. app.	Out. app.	D.B. Phase	
10	52/299	LK	16/09/91	28/10/91	14/09/92	Reboxetine	CONSTIPATION	26/11/91	Detail	14	1	1	5	1	NO	2	5	5	5	5	3
								Detail	16	1	1	5	1	NO	2	3	3	3	3	3	3
								Detail	18/01/92	1	1	5	1	NO	2	3	3	3	3	3	3
								Summary	18/01/92	18	1	1	5	1	NO	2	3	3	3	3	1
																					YES Double Blind
38/57	LL		14/10/91	25/11/91	03/02/92	Reboxetine	SWEATING INCREASED	14/10/91	Detail	1	2	2	2	2	NO	2	2	2	2	2	1
								Summary	16/10/91	1	2	2	2	2	NO	2	2	2	2	2	1
								Detail	17/11/91	1	2	4	1	NO	2	3	3	3	3	3	1
								Summary	17/11/91	5	1	2	4	1	NO	2	3	3	3	3	1
																					YES Run In Phase
39/40	VH		15/10/91	26/11/91	13/10/92	Reboxetine	CONSTIPATION	22/10/91	Detail	2	1	3	1	NO	2	3	3	3	3	3	1
								Summary	26/10/91	2	1	3	1	NO	2	3	3	3	3	3	1
								Detail	14/11/91	5	1	4	1	NO	2	3	3	3	3	3	5
								Detail	6/22/11/91	1	1	4	1	NO	2	3	3	3	3	3	1
								Summary	22/11/91	6	1	4	1	NO	2	3	3	3	3	3	1
																					YES Run In Phase
								Detail	15/10/91	1	1	5	1	NO	2	3	3	3	3	3	1
								Summary	15/10/91	1	1	5	1	NO	2	3	3	3	3	3	1
								Detail	17/10/91	1	2	5	1	NO	2	5	5	5	5	5	1
								Summary	17/10/91	1	1	2	5	1	NO	2	5	5	5	5	1
								Detail	10/29/12/91	2	2	3	1	YES	2	3	3	3	3	2	
								Summary	29/12/91	10	2	2	3	1	YES	2	3	3	3	2	
41/42	VP		30/10/91	11/12/91	27/10/92	Reboxetine	INSOMNIA	18/11/91	Detail	1	2	5	1	NO	2	3	3	3	3	3	3
								Detail	2	1	2	5	1	NO	2	3	3	3	3	3	3
								Detail	3	1	2	5	1	NO	2	3	3	3	3	3	3
								Detail	4	1	2	5	1	NO	2	3	3	3	3	3	3
								Detail	5	1	2	5	1	NO	2	3	3	3	3	3	3
								Detail	6	1	2	5	1	NO	2	3	3	3	3	3	3
								Detail	8	1	2	5	1	NO	2	3	3	3	3	3	3
								Detail	10	1	2	5	1	NO	2	3	3	3	3	3	3
								Detail	12	1	2	5	1	NO	2	3	3	3	3	3	3
								Detail	14	1	2	5	1	NO	2	3	3	3	3	3	3
								Detail	16	1	2	5	1	NO	2	3	3	3	3	3	3

Severity: 0=unknown, 1= mild, 2= moderate, 3= severe, 4= life threatening, 5= fatal
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=probable, 3=definite, 4=doubtful, 5=unknown, 6=none
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present: end date = visit date

15300

9550077

PHARMACIA CIS RED
REBOXATINE - PROTOCOL 2012/013
Listing No.: 11.0

ADVERSE EVENTS
DOUBLE BLIND PHASE

Cen.	Patient	Init.	Start date	Treatment	End date	Treatment	Adverse event	Onset date	Type record	Last visit r.ty	Hist r.ty	Rel. drug	Stud. app.	Symp. come (C)	Dis. app.	Re. come (C)	Out. Phase			
10	41/42	UP	30/10/91	11/12/91	27/16/92	Reboxatine	MOUTH DRY	30/10/91	Detail 18	1	2	3	1	NO	2	3	3	3		
								Detail 20	1	2	3	1	NO	2	3	3	3	3		
								Detail 22	1	2	3	1	NO	2	3	3	3	3	3	
								Detail 24	1	2	3	1	NO	2	3	3	3	3	3	
								Detail 26	1	2	3	1	NO	2	3	3	3	3	3	
								Detail 28	1	2	3	1	NO	2	3	3	3	3	3	
								Detail 30	1	2	3	1	NO	2	3	3	3	3	3	
								Summary 20/05/92	30	1	2	3	1	NO	2	3	3	3	3	3
								Summary 20/05/92	30	1	2	3	1	NO	2	3	3	3	3	3
								Summary	30	1	2	3	1	NO	2	3	3	3	3	3
								Summary	30	1	2	3	1	NO	2	3	3	3	3	3
								Summary	30	1	2	3	1	NO	2	3	3	3	3	3
			44	43	UM	11/12/91	22/01/92	25/04/92	Reboxatine	CONSTIPATION	25/01/92	Detail 8	2	2	4	1	NO	2	3	3
								Detail 10	2	2	3	1	NO	2	3	3	3	3		
								Detail 12	2	2	3	1	NO	2	3	3	3	3		
								Detail 14	1	2	3	1	NO	2	3	3	3	3	3	
								Detail 16	1	2	3	1	NO	2	3	3	3	3	3	
								Detail 18	1	2	3	1	NO	2	3	3	3	3	3	
								Detail 20	2	2	3	1	NO	2	3	3	3	3	3	
								Detail 22	2	2	3	1	NO	2	3	3	3	3	3	
								Detail 24	3	2	2	1	NO	2	3	3	3	3	3	
								Detail 26	3	2	2	1	NO	2	3	3	3	3	3	
								Detail 28	3	2	2	1	NO	2	3	3	3	3	3	
					Summary 23/06/92(*)	26	3	2	2	3	NO	2	1	3	3	3	3			
			11/12/91			HEADACHE	11/12/91	Detail 1	2	2	3	1	NO	2	3	3	3	3		
								Detail 3	1	2	3	1	NO	2	3	3	3	3		
								Detail 4	1	2	3	1	NO	2	3	3	3	3		
								Detail 5	1	2	3	1	NO	2	3	3	3	3		
								Detail 6	1	2	3	1	NO	2	3	3	3	3		
								Detail 8	1	2	3	1	NO	2	3	3	3	3		
								Detail 10	2	2	3	1	NO	2	3	3	3	3		
								Detail 12	2	2	3	1	NO	2	3	3	3	3		
								Detail 14	1	2	4	1	NO	2	3	3	3	3		
								Detail 16	1	2	3	1	NO	2	3	3	3	3		
					Detail 18	1	2	4	1	NO	2	3	3	3	3					
					Summary 19/06/92	18	2	2	3	1	NO	2	3	3	3	3				
					Summary	18	2	2	3	1	NO	2	3	3	3	3				
			11/12/91			MOUTH DRY	11/12/91	Detail 1	2	2	3	1	NO	2	3	3	3	3		
								Detail 2	2	2	3	1	NO	2	3	3	3	3		
								Summary 26/12/91	2	2	3	1	NO	2	3	3	3			
					Summary 16/01/92	2	2	3	1	NO	2	3	3	3	3					
					Summary 16/01/92	2	2	4	1	NO	2	3	3	3						

1539

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
Hospital: 1=recovered, 2=not recq, 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
Disapp./Keapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
Symptomatic treatment: 0=no, 1=yes
(C) adverse event used for statistical analysis

W. ... 30.10.91 03:13:32 ...

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RAD

REBOXETINE - PROTOCOL 20126/013
Listing No.: 11.0

ADVERSE EVENTS
DOUBLE BLIND PHASE

Pat. No.	Sex	Age	Ch.	Patient Init.	Start date	Treatment	End date	Treatment	Adverse event	Onset date	Type record	Visit No.	End date	Last report visit	Save	Hist	Rel. Stud	Symp	Dis. app.	Re Out	In Phase		
19	F	49/43	VM	11/12/91	22/01/92	23/06/92	Reboxetine	MOUTH DRY	16/01/92	Detail	8			1	2	3	1	NO	2	3	3	3	
										Detail	10			1	2	3	1	NO	2	3	3	3	
										Detail	12			1	2	3	1	NO	2	3	3	3	
										Detail	14			1	2	3	1	NO	2	3	3	3	
										Detail	16			1	2	3	1	NO	2	3	3	3	
										Detail	18			1	2	3	1	NO	2	3	3	3	
										Detail	20			1	2	3	1	NO	2	3	3	3	
										Detail	22			1	2	3	1	NO	2	3	3	3	
										Summary	22	01/05/92	01/05/92	22	2	2	3	1	NO	1	3	3	1
										YES Run In Phase													
53	F	47	MA	13/01/92	24/02/92	06/09/92	Reboxetine	CONSTIPATION	15/01/92	Detail	1			2	2	3	1	NO	2	3	3	3	
										Detail	2			2	2	3	1	NO	2	3	3	3	
										Detail	3			2	2	3	1	NO	2	3	3	3	
										Detail	4			1	2	3	1	NO	2	3	3	3	
										Detail	5			1	2	3	1	NO	2	3	3	3	
										Detail	6			1	2	3	1	NO	2	3	3	3	
										Detail	8			1	2	3	1	NO	2	3	3	3	
										Detail	10			1	2	3	1	NO	2	3	3	3	
										Detail	12			1	2	3	1	NO	2	3	3	3	
										Summary	12	01/06/92	01/06/92	12	2	2	3	1	NO	2	3	3	1
										YES Run In Phase													
54	F	48	UN	13/01/92	24/02/92	06/09/92	Reboxetine	CONSTIPATION	25/03/92	Detail	12			1	1	3	1	NO	2	3	3	3	
										Detail	14	10/04/92	10/04/92	14	1	1	3	1	NO	2	3	3	1
										Summary	14	10/04/92	10/04/92	14	1	1	3	1	NO	2	3	3	1
										YES Double Blind													
56	F	48	UN	13/01/92	24/02/92	06/09/92	Reboxetine	CONSTIPATION	13/01/92	Detail	1			2	2	3	1	NO	2	3	3	3	
										Detail	2			2	2	3	1	NO	2	3	3	3	
										Detail	3			1	2	3	1	NO	2	3	3	3	
										Detail	4			1	2	3	1	NO	2	3	3	3	
										Detail	5			2	2	3	1	NO	2	3	3	3	
										Detail	6			1	2	3	1	NO	2	3	3	3	
										Detail	8			1	2	3	1	NO	2	3	3	3	
										Detail	10			1	2	3	1	NO	2	3	3	3	
										Detail	12			1	2	3	1	NO	2	3	3	3	
										Detail	14			1	2	3	1	NO	2	3	3	3	
										Detail	16			1	2	3	1	NO	2	3	3	3	
										Detail	18			1	2	3	1	NO	2	3	3	3	
										Detail	20			1	2	3	1	NO	2	3	3	3	
										Summary	20	25/05/92	25/05/92	20	2	2	3	1	NO	2	3	3	1
										YES Run In Phase													

1540

Severity: S=unknown, I=mild, Z=moderate, S=severe, -- History: I=present before, Z=not observed bef., S=unknown
Study drug: I=no change, Z=dose reduced, S=ref. withdrawn, G=temp. inter.
Hospital: I=required, Z=not req., S=not appl. -- Outcome: I=recovered, Z=rec. with seq., S=still present, G=death
Disapp./Rapp.: I=no, Z=yes, S=not appl. -- Relationship: I=definite, Z=probable, S=possible, G=doubtful, S=unknown, G=none
Symptomatic treatment: 0=no, I=yes
(c) adverse event used for statistical analysis
(*) adverse event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS MSD

REBOXETINE -- PROTOCOL 20124/015
Listing No.: 11.0

ADVERSE EVENTS
DOUBLE BLIND PHASE

Pat. No.	Sex	Age	Start date	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Save rity	Hist ory	Rea. Stud	Symp	Dis	Re	Out	D.B.	
10	56/48	UN	13/01/92	24/02/92	06/09/92 Reboxetine	MICTURITION DISORDER	15/01/92	Detail	1	19/01/92	1	1	2	5	1	NO	2	3	3	1
								Summary		19/01/92	1	1	2	3	1	NO	2	3	3	1
						TACHYCARDIA	20/01/92	Detail	2		1	2	3	1	NO	2	3	3	3	3
								Detail	3		1	2	3	1	NO	2	3	3	3	3
								Detail	4		1	2	3	1	NO	2	3	3	3	3
								Detail	5	10/02/92	2	2	3	1	NO	2	3	3	3	1
								Summary		10/02/92	5	2	3	1	NO	2	3	3	3	1
							01/03/92	Detail	6		1	2	3	1	NO	2	3	3	3	3
								Detail	19		1	2	3	1	NO	2	3	3	3	3
								Detail	12	01/06/92	1	2	3	1	NO	2	3	3	3	1
								Summary		31/06/92	12	1	2	3	1	NO	2	3	3	1
56/50	JP		14/01/92	25/02/92	23/03/92 Reboxetine	MOUTH DRY	14/01/92	Detail	1		1	1	3	1	NO	2	3	3	3	3
								Detail	2	22/01/92	1	1	3	1	NO	2	3	3	3	1
								Summary		22/01/92	2	1	1	3	1	NO	2	3	3	1
						PERINEAL PAIN MALE	14/01/92	Detail	1		1	1	3	1	NO	2	3	3	3	3
								Detail	2	28/01/92	1	1	3	1	NO	2	3	3	3	1
								Summary		28/01/92	2	1	1	3	1	NO	2	3	3	1
							25/02/92	Detail	6		2	1	1	5	1	NO	2	3	3	3
								Detail	10		3	1	5	4	NO	2	2	2	2	3
								Summary		23/02/92(*)	10	3	1	5	4	NO	2	2	2	3
						VISION ABNORMAL	21/01/92	Detail	2		1	1	3	1	NO	2	3	3	3	3
								Detail	3	02/02/92	1	1	3	1	NO	2	3	3	3	1
								Summary		02/02/92	3	1	1	3	1	NO	2	3	3	1
57/51	AG		15/01/92	26/02/92	12/01/93 Reboxetine	MOUTH DRY	16/01/92	Detail	1		1	1	4	1	NO	2	3	3	3	1
								Summary		20/01/92	1	1	1	4	1	NO	2	3	3	1
						VISION ABNORMAL	07/09/92	Detail	34		1	2	3	1	NO	2	3	3	3	3
								Detail	36	16/09/92	1	2	3	1	NO	2	3	3	3	1
								Summary		16/09/92	36	1	2	3	1	NO	2	3	3	1

1541

Severity: 1=unknown, 2=mild, 3=moderate, 4=severe, 5=critical
 Study drug: 1=no change, 2=dose reduced, 3=drug withdrawn, 4=stopped, 5=inter.
 Hospital: 1=required, 2=not req, 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq, 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 1=no, 2=yes
 (*) adverse event used for statistical analysis
 (C) adverse event used for statistical analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Can. Patient	Init.	Start date	Start D.B.	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Sev	His	Hist	Rel	Stud	Symp	Dis	Re	Out	D.B.	
10	59/55	IA	20/01/92	02/05/92	25/03/92	Reboxetine	DIZZINESS	21/01/92	Detail 1	01/02/92	1	1	1	1	1	1	1	1	1	1	1	1
									Summary	01/02/92	2	1	1	1	1	1	1	1	1	1	1	1
									Detail 4	10/02/92	4	2	1	1	1	1	1	1	1	1	1	1
									Detail 5		5	1	1	1	1	1	1	1	1	1	1	1
									Detail 6		6	1	1	1	1	1	1	1	1	1	1	1
									Summary	02/05/92	8	3	1	1	1	1	1	1	1	1	1	1
									Detail 1	21/01/92	1	1	2	1	1	1	1	1	1	1	1	1
									Summary	02/02/92	2	1	2	1	1	1	1	1	1	1	1	1
									Detail 4	10/02/92	4	1	2	1	1	1	1	1	1	1	1	1
									Detail 5		5	2	2	1	1	1	1	1	1	1	1	1
									Detail 6		6	1	1	1	1	1	1	1	1	1	1	1
									Summary	02/03/92	8	2	1	1	1	1	1	1	1	1	1	1
									Detail 1	04/02/92	1	1	2	1	1	1	1	1	1	1	1	1
									Summary	02/02/92	2	1	2	1	1	1	1	1	1	1	1	1
									Detail 3	01/03/92	3	1	2	1	1	1	1	1	1	1	1	1
									Summary	01/03/92	4	2	2	1	1	1	1	1	1	1	1	1
									Detail 1	04/02/92	1	1	2	1	1	1	1	1	1	1	1	1
									Summary	24/02/92	3	1	2	1	1	1	1	1	1	1	1	1
									Detail 1	24/02/92	1	1	2	1	1	1	1	1	1	1	1	1
									Summary	24/02/92	3	1	2	1	1	1	1	1	1	1	1	1
									Detail 1	24/02/92	1	1	2	1	1	1	1	1	1	1	1	1
									Summary	24/02/92	3	1	2	1	1	1	1	1	1	1	1	1
									Detail 1	24/02/92	1	1	2	1	1	1	1	1	1	1	1	1
									Summary	24/02/92	3	1	2	1	1	1	1	1	1	1	1	1
									Detail 1	24/02/92	1	1	2	1	1	1	1	1	1	1	1	1
									Summary	24/02/92	3	1	2	1	1	1	1	1	1	1	1	1
									Detail 1	06/06/92	1	1	2	1	1	1	1	1	1	1	1	1
									Summary	06/06/92	6	2	2	1	1	1	1	1	1	1	1	1

1542

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=pro. with sen., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (M) random event still present: end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 1119
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Con. Patient	Init.	Start date	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End date	Last report visit	Save	Hist	Rel. Stud	Symp	Disapp.	Re Out	D.B.		
										visit	city	ery	ship	drug	traa	Hesp	app.	come	{C} Phase
10	52/59	LS	25/02/92	07/06/92	25/01/93	Reboxetine	TACHYCARDIA	20/05/92	Detail 4	1	2	4	1	NO	2	3	3	3	
									Summary 5	1	2	4	1	NO	2	3	3	1	YES Run In Phase
04/63	HW	11/05/92	22/05/92	30/06/92	Reboxetine	CONSTIPATION	26/05/92	Detail 3	1	1	3	1	NO	2	3	3	3		
									Detail 4	1	1	3	1	NO	2	3	3	3	
									Detail 5	1	1	3	1	NO	2	3	3	3	
									Detail 6	1	1	3	1	NO	2	3	3	3	
									Detail 8	1	1	3	1	NO	2	3	3	3	
									Detail 10	1	1	3	1	NO	2	3	3	3	
									Detail 12	1	1	3	1	NO	2	3	3	3	
									Detail 14	1	1	3	1	NO	2	3	3	3	
									Summary 16	1	1	3	1	NO	2	3	3	3	YES Run In Phase
06/27	NP	19/03/92	30/06/92	22/07/92	Reboxetine	CONSTIPATION	05/06/92	Detail 3	2	2	3	1	NO	2	3	3	3		
									Detail 4	1	2	3	1	NO	2	3	3	3	
									Detail 5	1	2	3	1	NO	2	3	3	3	
									Detail 6	1	2	3	1	NO	2	3	3	3	
									Detail 8	1	2	3	1	NO	2	3	3	3	
									Detail 10	2	2	3	1	NO	2	3	3	1	YES Run In Phase
									Summary 10	2	2	3	1	NO	2	3	3	1	YES Run In Phase
									Detail 3	1	2	3	1	NO	2	3	3	3	
									Detail 4	1	2	3	1	NO	2	3	3	3	
									Detail 5	1	2	3	1	NO	2	3	3	1	YES Run In Phase
									Summary 5	1	2	3	1	NO	2	3	3	1	YES Run In Phase
07/275	AN	19/03/92	30/06/92	17/05/93	Reboxetine	CONSTIPATION	15/05/92	Detail 10	2	2	4	1	NO	2	3	3	3		
									Detail 12	1	2	4	1	NO	2	3	3	3	
									Detail 14	1	2	3	1	NO	2	3	3	3	
									Detail 16	1	2	3	1	NO	2	3	3	3	
									Detail 18	1	2	3	1	NO	2	3	3	3	
									Detail 20	1	2	3	1	NO	2	3	3	3	
									Detail 22	1	2	3	1	NO	2	3	3	3	
									Detail 24	1	2	3	1	NO	2	3	3	3	

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, --- History: 1=present before, 2=not observe bef., 3=unknown
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. --- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (c) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date

1543

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA DNS RED
 REDNETINE - PROTOCOL 28124/913
 Listing No.: 11.8
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Con.	Patient Init.	Start date	End date	Treatment	Adverse event	Onset date	Type record	Visit No	End No date	Last report visit	Rel ship	Hist dry	Symp drug	Stud app.	Dis app.	Re app.	Due app.	D.B.	
10	87/275 AN	19/05/92	30/06/92	17/05/93 Reboxetine	CONSTIPATION	15/05/92	Detail	24		1	2	3	1	NO	2	5	3	3	
						28/09/92	Detail	28	28/09/92	1	3	1	NO	2	3	3	1		
						20/10/92	Summary	32		28	2	2	3	1	NO	2	3	1	YES Double Blind
							Detail	34		1	2	3	1	NO	2	3	3	3	
							Detail	36		1	2	3	1	NO	2	3	3	3	
							Detail	38		1	2	3	1	NO	2	3	3	3	
							Detail	40		1	2	3	1	NO	2	3	3	3	
							Detail	42		1	2	3	1	NO	2	3	3	3	
							Detail	44		1	2	3	1	NO	2	3	3	3	
							Detail	46		1	2	3	1	NO	2	3	3	3	
							Detail	48		1	2	3	1	NO	2	3	3	3	
							Detail	50		1	2	3	1	NO	2	3	3	3	
							Detail	52	17/03/93(*)	52	1	2	3	1	NO	2	3	3	YES Double Blind
							Summary												
							Detail	1		1	2	3	1	NO	2	3	3	3	
							Detail	2		1	2	3	1	NO	2	3	3	3	
							Detail	3		1	2	3	1	NO	2	3	3	3	
							Detail	4		1	2	3	1	NO	2	3	3	3	
							Detail	5		1	2	3	1	NO	2	3	3	3	
							Detail	6		1	2	3	1	NO	2	3	3	3	
							Detail	7		1	2	3	1	NO	2	3	3	3	
							Detail	8		1	2	3	1	NO	2	3	3	3	
							Detail	9		1	2	3	1	NO	2	3	3	3	
							Detail	10		2	2	3	1	NO	2	3	3	3	
							Detail	11		1	2	3	1	NO	2	3	3	3	
							Detail	12		1	2	3	1	NO	2	3	3	3	
							Detail	13		1	2	3	1	NO	2	3	3	3	
							Detail	14		1	2	3	1	NO	2	3	3	3	
							Detail	15		1	2	3	1	NO	2	3	3	3	
							Detail	16		1	2	3	1	NO	2	3	3	3	
							Detail	17		1	2	3	1	NO	2	3	3	3	
							Detail	18		1	2	3	1	NO	2	3	3	3	
							Summary		01/08/92	28	2	2	3	1	NO	2	3	3	YES Run In Phase
87/277 SK	20/03/92	01/05/92	14/05/92	Reboxetine	HEADACHE	20/03/92	Detail	1		1	2	3	1	NO	2	3	3	3	
							Detail	2		1	2	3	1	NO	2	3	3	3	
							Detail	3	05/06/92	1	2	3	1	NO	2	3	3	3	
							Summary		05/06/92	3	2	2	3	1	NO	2	3	3	YES Run In Phase
99/76 SV	24/03/92	05/05/92	21/09/92	Reboxetine	DIZZINESS	01/04/92	Detail	2		1	2	3	1	NO	2	3	3	3	
							Detail	3	12/04/92	1	2	3	1	NO	2	3	3	3	
							Summary		12/04/92	3	1	2	3	1	NO	2	3	3	YES Run In Phase

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawal, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Rapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis

1544

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD
 REDONETINE - PROTOCOL 2016/015
 Listing No.: 11.0
 ADVERSE EVENTS
 DOUBLE BLIND PHASE

Con. Patient	Int.	Start date	Start D.B.	Treatment	End date	Treatment	Adverse event	Onset date	Type record	Visit No	Last report visit	Hist ory	Symp ory	Shi p	Str uct	Drug	Trea tment	Dis c.	Re	Out	D.B.		
10	90/70	SV	24/03/92	05/05/92	21/09/92	Reboxetine	INSOMNIA	30/03/92	Detail	6	18/05/92	2	1	3	1	YES	2	3	3	2	YES	Run In Phase	
									Summary	18/05/92	0	2	1	3	1	YES	2	3	3	2	YES	Run In Phase	
91774	HI	24/03/92	95/05/92	02/11/92	Reboxetine	SWEATING INCREASED	25/03/92	Detail	1	28/03/92	1	2	3	1	NO	2	3	3	1	YES	Run In Phase		
									Summary	28/03/92	1	2	2	3	1	NO	2	3	3	1	YES	Run In Phase	
93/285	AN	09/04/92	21/05/92	16/12/92	Reboxetine	SWEATING INCREASED	24/03/92	Detail	1		1	2	3	1	NO	2	3	3	3	3	3	3	
									Detail	2		1	2	3	1	NO	2	3	3	3	3	3	
									Detail	3	12/06/92	1	2	3	1	NO	2	3	3	3	3	3	
									Summary	12/06/92	3	1	2	3	1	NO	2	3	3	3	1	YES	Run In Phase
									Detail	1	09/06/92	1	2	3	1	NO	2	3	3	3	3	3	
									Detail	2		2	2	3	1	NO	2	3	3	3	3	3	
									Detail	3		1	2	3	1	NO	2	3	3	3	3	3	
									Detail	4		1	2	3	1	NO	2	3	3	3	3	3	
									Detail	5		1	2	3	1	NO	2	3	3	3	3	3	
									Detail	6		1	2	3	1	NO	2	3	3	3	3	3	
									Detail	8		1	2	3	1	NO	2	3	3	3	3	3	
									Detail	10		1	2	3	1	NO	2	3	3	3	3	3	
									Detail	12		1	2	3	1	NO	2	3	3	3	3	3	
									Detail	14		1	2	3	1	NO	2	3	3	3	3	3	
									Detail	15		1	2	3	1	NO	2	3	3	3	3	3	
									Detail	16	10/08/92	1	2	3	1	NO	2	3	3	3	3	3	
									Summary	10/08/92	16	2	2	3	1	NO	2	3	3	3	1	YES	Run In Phase
11	5/277	VP	18/10/91	27/11/91	13/16/92	Reboxetine	INSOMNIA	17/18/91	Detail	3	05/11/91	1	1	2	1	NO	2	2	1	YES	Run In Phase		
									Summary	05/11/91	3	1	1	2	1	NO	2	2	1	YES	Run In Phase		
12	1/92	1B	31/10/91	12/12/91	28/10/92	Reboxetine	HYPERTENSION	25/04/92	Detail	52	28/10/92(1*)	1	2	6	1	YES	2	2	3	3	YES	Double Blind	
									Summary	28/10/92(1*)	52	1	2	6	1	YES	2	2	3	3	YES	Double Blind	
2/99	EFC	05/11/91	17/12/91	27/01/92	Reboxetine	INSOMNIA	05/11/91	Detail	12	27/01/92(1)	12	1	1	5	1	NO	2	2	3	3	YES	Run In Phase	
									Summary	27/01/92(1)	12	1	1	5	1	NO	2	2	3	3	YES	Run In Phase	

Seriousness: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=Recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Reapp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/113
Listing No.: 11.0

ADVERSE EVENTS
DOUBLE BLIND PHASE

Can. Patient	Init.	Start date	Start D.B.	Treatment	End date	Treatment	Adverse event	Onset date	Type record	Visit End No date	Last report visit	Sev Hist	Rel	Stud	Symp	Dis app.	Re Out	D.B.					
											visit	city	dry	ship	drug	traz	Hosp	app.	one	(C)	Phase		
12	2/99	EFC	05/11/91	17/12/91	27/01/92	Reboxetine	MOUTH DRY	20/11/91	Detail	3	22/11/91	1	3	5	1	NO	2	3	3	1	YES	Run In Phase	
									Summary		22/11/91	3	1	3	5	1	NO	2	3	3	1	YES	Run In Phase
3/93	JF		30/10/91	11/12/91	27/10/92	Reboxetine	INSOMNIA	30/10/91	Detail	8	20/12/91	1	1	6	1	NO	2				1	YES	Run In Phase
									Summary		20/12/91	8	1	1	6	1	NO	2			1	YES	Run In Phase
4/100	EG		05/11/91	17/12/91	18/05/92	Reboxetine	INSOMNIA	05/11/91	Detail	28	18/02/92	1	1	6	1	NO	2				1	YES	Run In Phase
									Summary		18/02/92	28	1	1	6	1	NO	2			1	YES	Run In Phase
16/105	PN		11/12/91	22/01/92	25/06/92	Reboxetine	INSOMNIA	12/11/91	Detail	24	09/06/92(*)	26	1	1	6	1	NO	2			3	NO	Run In Phase
									Summary		09/06/92(*)	26	1	1	6	1	NO	2			3	NO	Run In Phase
19/106	SSZ		16/01/92	27/02/92	06/05/92	Reboxetine	INSOMNIA	16/01/92	Detail	2	27/01/92	1	2	4	1	NO	2				1	YES	Run In Phase
									Summary		27/01/92	2	1	2	4	1	NO	2			1	YES	Run In Phase
25/114	FS		11/02/92	24/03/92	08/02/93	Reboxetine	HYPERTENSION	24/01/92	Detail	2	27/01/92	2	3	2	1	NO	1	3	3	1	YES	Run In Phase	
									Summary		27/01/92	2	2	3	2	1	NO	1	5	5	1	YES	Run In Phase
31/110	FL		31/01/92	13/03/92	16/06/92	Reboxetine	INSOMNIA	01/02/92	Detail	20	16/06/92(*)	20	1	1	6	1	NO	2			3	YES	Run In Phase
									Summary		16/06/92(*)	20	1	1	6	1	NO	2			3	YES	Run In Phase
25/114	FS		11/02/92	24/03/92	08/02/93	Reboxetine	HYPERTENSION	13/07/92	Detail	22	13/07/92	1	1	6	1	YES	2				1	YES	Double Blind
									Summary		13/07/92	22	1	1	6	1	YES	2			1	YES	Double Blind
25/114	FS		11/02/92	24/03/92	08/02/93	Reboxetine	HYPERTENSION	05/10/92	Detail	34	05/10/92	0	0	1	6	1	YES				1	YES	Double Blind
									Summary		05/10/92	34	0	0	1	6	1	YES			1	YES	Double Blind
27/115	WCS		06/02/92	21/03/92	02/10/92	Reboxetine	INSOMNIA	16/11/92	Detail	52	07/02/93	1	1	6	1	NO	2				1	YES	Double Blind
									Summary		07/02/93	52	1	1	6	1	NO	2			1	YES	Double Blind
27/115	WCS		06/02/92	21/03/92	02/10/92	Reboxetine	INSOMNIA	26/02/92	Detail	22	27/06/92	1	1	6	1	NO	2				1	YES	Run In Phase
									Summary		27/06/92	22	1	1	6	1	NO	2			1	YES	Run In Phase

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death
 Study drug: 1=none, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl.
 Disapp./reapp.: 1=no, 2=yes, 3=not appl.
 Symptomatic treatment: 0=no, 1=yes
 (C) adverse event used for statistical analysis
 (*) adverse event still present; end date = visit date

1546

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing Nr.: 11.0

ADVERSE EVENTS
DOUBLE BLIND PHASE

Cen. Patient	Init.	Start date	Treatment	End date	Treatment	Adverse event	Onset date	Type record	Visit No	Last report visit	Save Hist	Rat	Stud Symp	Dis app.	Re app.	Out. com.	D.P.	Last									
																		visit rity	ery shlp	tra Hosp	app. com.	(C) Phase					
12	27/115	VCS	08/02/92	21/05/92	02/10/92	Reboxetine	INSOMNIA	24/07/92	Detail	28	20/08/92	1	1	6	1	NO	2	1	YES	Double Blind							
										Summary	28	1	1	6	1	NO	2	1	YES	Double Blind							
36/285	FB	31/03/92	12/05/92	22/06/92	Reboxetine	INSOMNIA	31/05/92	Detail	8	25/05/92	1	1	6	1	NO	2	1	YES	Run In Phase								
									Summary	8	1	1	6	1	NO	2	1	YES	Run In Phase								
13	13/223	MM	02/11/91	14/12/91	30/10/92	Reboxetine	MICTURITION DISORDER	17/06/92	Detail	42		2	3	4	1	NO	2	3									
										Detail	46	1	1	4	1	NO	2	3									
										Detail	46	1	1	4	1	NO	2	3									
										Detail	48	1	1	4	1	NO	2	3									
										Detail	50	1	1	4	1	NO	2	3									
Summary	52	2	1	4	1	NO	2	5	YES	Double Blind																	
18/227	VT	06/12/91	15/01/92	01/12/92	Reboxetine	HYPOTENSION POSTURAL	06/12/91	Detail	1		2	3	3	1	NO	2	3										
									Detail	2	2	3	3	1	NO	1	3										
									Detail	3	23/12/91	2	3	3	1	NO	1	1									
									Summary	3	23/12/91	3	2	3	3	1	NO	1	1	YES	Run In Phase						
30/250	HL	29/01/92	11/03/92	26/01/93	Reboxetine	SWEATING INCREASED	24/01/92	Detail	0		1	1	6	1	NO	2											
									Summary	0	1	1	6	1	NO	2			NO	Run In Phase							

1547

Severity: 0=unknown, 1=mild, 2=moderate, 3=severe, 4=life threatening
 Study drug: 1=no change, 2=dose reduced, 3=def. withdrawn, 4=temp. inter.
 Hospital: 1=required, 2=not req., 3=not appl. -- Outcome: 1=recovered, 2=rec. with seq., 3=still present, 4=death
 Disapp./Resp.: 1=no, 2=yes, 3=not appl. -- Relationship: 1=definite, 2=probable, 3=possible, 4=doubtful, 5=unknown, 6=none
 Symptomatic treatment: 0=no, 1=yes
 (*) adverse event used for statistical analysis
 (C) adverse event still present; end date = visit date

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXYLINE - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6			
1	1	MGA	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	09/11/90	13.30	12.90	14/12/90	12.90	28/12/90	12.70
				HTC	20/10/90	37.0	47.0	Z	13.30	40.00	12.90	42.00	39.00		
				RBC	20/10/90	3.8	5.4	10-6/MHC	4.30	4.30	4.20	4.10	4.10		
				WBC	20/10/90	4.0	11.0	10-3/MHC	8.30	8.30	10.10	10.70	10.00		
				WBC: N	20/10/90	40.0	70.0	Z	60.00	59.00	76.00	66.00	66.00		
				WBC: L	20/10/90	20.0	40.0	Z	38.00	40.00	22.00	33.00	33.00		
				WBC: E	20/10/90	1.0	5.0	Z	3.00	3.00	1.00	4.00	4.00		
				WBC: M	20/10/90	4.0	8.0	Z	2.00	2.00	1.00	2.00	1.00		
				WBC: B	20/10/90	0.0	1.0	Z	0.00	0.00	0.00	0.00	0.00		
				PLATELETS	20/10/90	150.0	550.0	10-3/MHC	140.00	142.00	141.00	138.00	329.00		
				Na+	20/10/90	138.0	155.0	M EQ/L	140.00	142.00	141.00	138.00	138.00		
				K+	20/10/90	3.5	5.5	M EQ/L	4.50	4.50	3.90	4.40	4.40		
				CL-	20/10/90	98.0	120.0	M EQ/L	103.00	103.00	101.00	102.00	102.00		
				Ca++	20/10/90	8.5	10.5	MG/DL	9.50	9.50	9.80	9.80	8.80		
				PO4-	20/10/90	3.0	4.5	MG/DL	4.00	4.00	3.50	3.60	3.60		
				SGOT	20/10/90	12.0	40.0	NU/ML	18.00	18.00	32.00	18.00	18.00		
				SGPT	20/10/90	10.0	40.0	NU/ML	14.00	14.00	14.00	19.00	19.00		
				GAMMA-GT	20/10/90	7.0	33.0	NU/ML	42.00	42.00	27.00	35.00	35.00		
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	162.00	162.00	91.00	99.00	99.00		
				ALK. PHOSPH.	20/10/90	65.0	306.0	NU/ML	24.00	24.00	152.00	153.00	153.00		
				BUN	20/10/90	10.0	50.0	MG/DL	24.00	24.00	37.00	18.00	18.00		
				CREATININE	20/10/90	0.6	1.6	MG/DL	1.10	1.10	1.10	0.80	0.80		
				URIC ACID	20/10/90	2.4	5.7	MG/DL	4.00	4.00	3.80	4.00	3.80		
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.40	0.40	0.70	1.00	0.50		
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.20	0.40	0.60	0.30		
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.30	7.30	6.90	7.20	6.20		
				ALBUMINE	20/10/90	3.5	5.0	G/DL	3.00	3.00	4.30	4.60	4.10		
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	236.00	236.00	203.00	212.00	212.00		
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	229.00	229.00	250.00	169.00	177.00		
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	Z	6.00	6.00	6.00	4.00	4.00		
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	Z	12.00	12.00	11.00	8.00	8.00		
				GLOBULINS: BETA	20/10/90	11.0	14.0	Z	14.00	14.00	12.00	9.00	9.00		
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	Z	16.00	16.00	16.00	11.00	11.00		
				T3	20/10/90	86.0	187.0	NG Z	150.00	150.00	16.00	16.00	16.00		
				T4	20/10/90	4.5	12.5	NG/DL	10.00	10.00	10.00	9.00	9.00		
2	2	RAQ	MALE	HB	20/10/90	14.0	18.0	g/100ml	09/11/90	15.60	15.60	15.60	15.60	15.60	
				HTC	20/10/90	40.0	54.0	Z	47.00	47.00	47.00	47.00	47.00		
				RBC	20/10/90	4.3	6.1	10**6/mm	5.00	5.00	5.00	5.00	5.00		
				WBC	20/10/90	4.0	11.0	10-3/MHC	9.60	9.60	9.60	9.60	9.60		
				WBC: N	20/10/90	40.0	70.0	Z	58.00	58.00	58.00	58.00	58.00		
				WBC: L	20/10/90	20.0	40.0	Z	35.00	35.00	35.00	35.00	35.00		
				WBC: E	20/10/90	1.0	5.0	Z	5.00	5.00	5.00	5.00	5.00		
				WBC: M	20/10/90	4.0	8.0	Z	7.00	7.00	7.00	7.00	7.00		
				WBC: B	20/10/90	0.0	1.0	Z	0.00	0.00	0.00	0.00	0.00		
				Na+	20/10/90	138.0	155.0	M EQ/L	143.00	143.00	143.00	143.00	143.00		
				K+	20/10/90	3.5	5.5	M EQ/L	4.30	4.30	4.30	4.30	4.30		
				CL-	20/10/90	93.0	120.0	M EQ/L	102.00	102.00	102.00	102.00	102.00		

1548

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit						
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6		
1	2	RAQ	MALE	CA++	20/10/90	8.5	10.5	MG/DL						
				PO4-	20/10/90	3.0	4.5	MG/DL	8.90					
				SGOT	20/10/90	12.0	40.0	MIU/ML	28.00					
				SGPT	20/10/90	10.0	40.0	MIU/ML	27.00					
				GAMMA-GT	20/10/90	11.0	51.0	MIU/ML	88.00					
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	93.00					
				ALK. PHOSPH.	20/10/90	65.0	306.0	MIU/ML	207.00					
				BUN	20/10/90	10.0	50.0	MG/DL	30.00					
				CREATININE	20/10/90	0.6	1.6	MG/DL	1.40					
				URIC ACID	20/10/90	3.4	7.0	MG/DL	6.50					
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	2.20					
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40					
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.10					
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.40					
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	265.00					
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	171.00					
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	g	4.00					
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	g	8.00					
				GLOBULINS: BETA	20/10/90	11.0	14.0	g	12.00					
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	g	15.00					
				T3	20/10/90	86.0	187.0	NG x	110.00					
				T4	20/10/90	4.5	12.5	NG/DL	8.80					
3	TA		FEMALE	HB	20/10/90	12.0	16.0	G/100ML	09/11/90	13.80	14/12/90	13.80	28/12/90	13.20
				HTC	20/10/90	37.0	47.0	x	42.00	30/11/90	13.10	13.80	14/12/90	13.20
				RBC	20/10/90	3.8	5.4	10 ⁶ -6/MHC	4.30	30/11/90	40.00	43.00	14/12/90	40.00
				WBC	20/10/90	4.0	11.0	10 ³ -3/MHC	5.80	30/11/90	4.50	4.70	14/12/90	4.20
				HBC: N	20/10/90	40.0	70.0	x	72.00	30/11/90	5.30	5.20	14/12/90	6.70
				HBC: L	20/10/90	20.0	40.0	x	27.00	30/11/90	63.00	66.00	14/12/90	78.00
				HBC: E	20/10/90	1.0	5.0	x	2.00	30/11/90	33.00	28.00	14/12/90	21.00
				HBC: H	20/10/90	4.0	8.0	x	1.00	30/11/90	0.00	4.00	14/12/90	4.00
				HBC: B	20/10/90	0.0	1.0	x	0.00	30/11/90	4.00	6.00	14/12/90	1.00
				NA+	20/10/90	138.0	155.0	M EQ/L	141.00	30/11/90	0.00	0.00	14/12/90	0.00
				CL-	20/10/90	98.0	120.5	M EQ/L	104.00	30/11/90	142.00	142.00	14/12/90	140.00
				CA++	20/10/90	8.5	10.5	MG/DL	8.60	30/11/90	3.90	3.90	14/12/90	4.70
				PO4-	20/10/90	3.0	4.5	MG/DL	3.60	30/11/90	104.00	104.00	14/12/90	102.00
				SGOT	20/10/90	12.0	40.0	MIU/ML	3.00	30/11/90	9.30	9.60	14/12/90	9.80
				SGPT	20/10/90	10.0	40.0	MIU/ML	42.00	30/11/90	2.90	3.10	14/12/90	2.90
				GAMMA-GT	20/10/90	7.0	33.0	MIU/ML	18.00	30/11/90	33.00	33.00	14/12/90	22.00
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	20.00	30/11/90	20.00	20.00	14/12/90	24.00
				ALK. PHOSPH.	20/10/90	65.0	306.0	MIU/ML	97.00	30/11/90	11.00	11.00	14/12/90	93.00
				BUN	20/10/90	10.0	50.0	MG/DL	134.00	30/11/90	166.00	156.00	14/12/90	146.00
				CREATININE	20/10/90	0.6	1.6	MG/DL	17.00	30/11/90	22.00	22.00	14/12/90	32.00
				URIC ACID	20/10/90	2.4	5.7	MG/DL	1.00	30/11/90	0.90	0.90	14/12/90	1.00
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	3.30	30/11/90	4.00	4.00	14/12/90	3.00
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.90	30/11/90	0.60	0.80	14/12/90	0.60
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.70	30/11/90	0.40	0.40	14/12/90	0.20
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	30/11/90	6.10	7.40	14/12/90	4.20

15/0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit								
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
1	3	TA	FEMALE	TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	175.00	138.00	179.00	166.00			
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	65.00	68.00	79.00	70.00			
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	5.00	4.00	4.00	5.00			
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	9.00	10.00	9.00	8.00			
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	11.00	13.00	14.00	13.00			
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	17.00	21.00	15.00	15.00			
				T3	20/10/90	86.0	187.0	NG %	155.00	.	.	.			
				T4	20/10/90	4.5	12.5	NG/DL	10.00	.	.	.			
				4	DNC	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	13/11/90	05/12/90	19/12/90	02/01/91
							HTC	20/10/90	37.0	47.0	%	40.00	40.00	40.00	38.00
							RBC	20/10/90	3.8	5.4	10 ⁶ -6/MMC	4.20	4.10	4.60	4.10
							HBC	20/10/90	4.0	11.0	10 ³ -3/MMC	5.90	4.80	4.50	5.30
							HBC: N	20/10/90	40.0	70.0	%	76.00	64.00	69.00	72.00
							HBC: L	20/10/90	20.0	40.0	%	20.00	31.00	24.00	25.00
HBC: E	20/10/90	1.0	5.0				%	2.00	2.00	2.00	2.00				
HBC: H	20/10/90	4.0	8.0				%	4.00	5.00	5.00	3.00				
HBC: B	20/10/90	0.0	1.0				%	0.00	0.00	0.00	0.00				
NA+	20/10/90	138.0	155.0				M EQ/L	163.00	145.00	144.00	143.00				
K+	20/10/90	3.5	5.5				M EQ/L	3.40	3.90	4.00	4.40				
CL-	20/10/90	98.0	120.0				M EQ/L	103.00	105.00	104.00	103.00				
CA++	20/10/90	8.5	10.5				MG/DL	9.90	9.90	10.10	10.50				
PO4-	20/10/90	3.0	4.5				MG/DL	2.70	3.80	3.80	3.30				
SGOT	20/10/90	12.0	40.0	U/ML	30.00	29.00	39.00	33.00							
SGPT	20/10/90	10.0	40.0	U/ML	21.00	24.00	22.00	21.00							
GAMMA-GT	20/10/90	7.0	33.0	U/ML	23.00	33.00	31.00	36.00							
GLUCOSE	20/10/90	70.0	100.0	MG/DL	104.00	96.00	91.00	83.00							
ALK. PHOSPH.	20/10/90	65.0	306.0	U/ML	253.00	268.00	288.00	346.00							
RUN	20/10/90	10.0	50.0	MG/DL	31.00	40.00	31.00	32.00							
CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	0.70	0.80	0.80							
URIC ACID	20/10/90	2.4	5.7	MG/DL	2.20	2.80	3.00	3.90							
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.90	0.80	0.90	0.70							
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.20	0.40	0.40							
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.70	6.20	7.10	6.80							
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.00	4.20	4.30							
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	199.00	176.00	204.00	187.00							
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	117.00	118.00	113.00	90.00							
GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	4.00	4.00	4.00	4.00							
GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	8.00	10.00	9.00	9.00							
GLOBULINS: BETA	20/10/90	11.0	14.0	%	12.00	13.00	11.00	15.00							
GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	16.00	15.00	16.00	13.00							
T3	20/10/90	86.0	187.0	NG %	140.00	.	.	.							
T4	20/10/90	4.5	12.5	NG/DL	7.00	.	.	.							
5	DB	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	27/11/90	18/12/90	02/01/91	15/01/91				
			HTC	20/10/90	37.0	47.0	%	44.40	43.70	43.30	42.90				
			RBC	20/10/90	3.8	5.4	10 ⁶ -6/MMC	4.90	49.00	40.00	38.00				
			HBC	20/10/90	4.0	11.0	10 ³ -3/MMC	5.4	5.10	4.50	4.30				

1550

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Unit	Screen	Visit					
					Date	Min	Max			Week 2	Week 4	Week 6			
1	5	DB	FEMALE	HBC: N	20/10/90	4.0	11.0	10-3/HMC	6.50	5.40	5.60	6.10	6.10	77.00	
				HBC: L	20/10/90	40.0	70.0	Z	68.00	56.00	56.00	56.00	56.00	56.00	
				HBC: E	20/10/90	20.0	40.0	Z	28.00	42.00	38.00	18.00	18.00	18.00	
				HBC: N	20/10/90	1.0	5.0	Z	3.00	2.00	4.00	9.00	9.00	9.00	
				HBC: B	20/10/90	4.0	8.0	Z	4.00	2.00	6.00	5.00	5.00	5.00	
				NA+	20/10/90	0.0	1.0	Z	0.00	0.00	0.00	0.00	0.00	0.00	
				CL-	20/10/90	138.0	155.0	M EQ/L	143.00	142.00	142.00	142.00	142.00	142.00	
				Ca++	20/10/90	3.5	5.5	M EQ/L	4.00	3.90	3.70	4.00	4.00	4.00	
				PO4-	20/10/90	98.0	120.0	M EQ/L	102.00	102.00	103.00	102.00	102.00	102.00	
				SGPT	20/10/90	8.5	4.5	MG/DL	9.90	10.40	9.90	8.20	8.20	8.20	
				SGPT	20/10/90	3.0	4.5	MG/DL	3.80	4.00	3.30	3.10	3.10	3.10	
				SGPT	20/10/90	12.0	40.0	MU/ML	28.00	37.00	23.00	26.00	26.00	26.00	
				SGPT	20/10/90	10.0	40.0	MU/ML	23.00	20.00	21.00	25.00	25.00	25.00	
				GAMMA-GT	20/10/90	7.0	33.0	MU/ML	47.00	42.00	47.00	49.00	49.00	49.00	
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	126.00	107.00	123.00	118.00	118.00	118.00	
				ALK. PHOSPH.	20/10/90	65.0	306.0	MU/ML	216.00	228.00	212.00	206.00	206.00	206.00	
				BUN	20/10/90	10.0	50.0	MG/DL	36.00	34.00	31.00	31.00	31.00	31.00	
				CREATININE	20/10/90	0.6	1.6	MG/DL	1.00	0.80	0.90	0.80	0.80	0.80	
				URIC ACID	20/10/90	2.4	5.7	MG/DL	4.30	3.60	5.10	4.00	4.00	4.00	
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.50	0.70	0.40	0.40	0.40	0.40	
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.30	0.20	0.20	0.20	0.20	
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.60	7.60	6.80	7.00	7.00	7.00	
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.60	4.50	4.10	4.00	4.00	4.00	
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	332.00	272.00	260.00	281.00	281.00	281.00	
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	296.00	234.00	238.00	373.00	373.00	373.00	
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	Z	4.30	6.00	4.00	3.00	3.00	3.00	
				GLOBULINS: ALPHA 2	20/10/90	7.0	14.0	Z	9.60	10.00	9.00	9.00	9.00	9.00	
				GLOBULINS: BETA	20/10/90	11.0	22.0	Z	12.80	11.00	13.00	15.00	15.00	15.00	
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	Z	15.90	16.00	15.00	17.00	17.00	17.00	
				T3	20/10/90	86.0	187.0	NG %	110.00	110.00	110.00	110.00	110.00	110.00	
				T4	20/10/90	4.5	12.5	NG/DL	7.00	7.00	7.00	7.00	7.00	7.00	
6	CPH		FEMALE	HB	20/10/90	12.0	16.0	G/100ML	13.20	18/12/90	02/01/91	15/01/91	15/01/91	15/01/91	
				HTC	20/10/90	37.0	47.0	Z	41.00	12.50	13.50	13.40	13.40	13.40	
				HBC	20/10/90	3.8	5.4	10-6/HMC	4.10	39.00	40.00	40.00	40.00	40.00	
				HBC: N	20/10/90	4.0	11.0	10-3/HMC	6.10	4.30	4.20	4.20	4.20	4.20	
				HBC: L	20/10/90	40.0	70.0	Z	59.00	5.00	7.80	5.70	5.70	5.70	
				HBC: E	20/10/90	20.0	40.0	Z	36.00	28.00	72.00	70.00	70.00	70.00	
				HBC: H	20/10/90	1.0	5.0	Z	4.00	1.00	23.00	27.00	27.00	27.00	
				HBC: B	20/10/90	4.0	8.0	Z	5.00	1.00	1.00	3.00	3.00	3.00	
				PLATELETS	20/10/90	0.0	1.0	Z	0.00	0.00	5.00	3.00	3.00	3.00	
				NA+	20/10/90	150.0	550.0	10-3/HMC	144.00	143.00	143.00	215.00	215.00	215.00	
				K+	20/10/90	138.0	155.0	M EQ/L	4.20	3.40	3.80	3.50	3.50	3.50	
				CL-	20/10/90	98.0	120.0	M EQ/L	102.00	105.00	103.00	102.00	102.00	102.00	
				Ca++	20/10/90	8.5	10.5	MG/DL	9.70	10.00	8.80	9.30	9.30	9.30	
				PO4-	20/10/90	3.0	4.5	MG/DL	3.80	3.30	3.80	3.10	3.10	3.10	
				SGPT	20/10/90	12.0	40.0	MU/ML	28.00	37.00	28.00	28.00	28.00	28.00	
				SGPT	20/10/90	4.0	12.0	MU/ML	17.00	22.00	13.00	17.00	17.00	17.00	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REXOXYTINE - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range		Visit										
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6					
1	6	CPH	FEMALE	GAMMA-GT	20/10/90	7.0	33.0	MI/ML	19.00	12.00	20.00	20.00	20.00				
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	147.00	115.00	161.00	140.00					
				ALK. PHOSPH.	20/10/90	65.0	306.0	MI/ML	210.00	197.00	223.00	207.00					
				BUN	20/10/90	10.0	50.0	MG/DL	55.00	41.00	39.00	34.00					
				CREATININE	20/10/90	0.6	1.6	MG/DL	1.00	0.90	0.90	1.00					
				URIC ACID	20/10/90	2.4	5.7	MG/DL	3.70	4.30	5.20	3.70					
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.40	1.00	0.70	0.60					
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.40	0.40	0.30					
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.70	6.80	6.80	6.60					
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.40	4.40	4.20	3.80					
				TOT. CHOLEST.	20/10/90	160.0	270.0	MG/DL	217.00	198.00	201.00	199.00					
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	127.00	92.00	108.00	118.00					
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	4.00	3.00	5.00	5.10					
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	9.00	9.00	7.00	8.20					
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	12.00	11.00	16.00	14.40					
				GLOBULINS: GAMMA	20/10/90	45.0	22.0	%	13.00	12.00	11.00	12.50					
				T3	20/10/90	86.0	187.0	NG X	100.00								
				T4	20/10/90	4.5	12.5	NG/DL	8.60								
				7	JSA		MALE	HB	20/10/90	14.0	18.0	g/100ml	30/11/90	18/12/90			
								HCT	20/10/90	40.0	54.0	%	44.00	44.00			
								RBC	20/10/90	4.3	6.1	10**6/mm	4.60	4.70			
								WBC	20/10/90	4.0	11.0	10-3/MNC	6.50	5.50			
								WBC: N	20/10/90	40.0	70.0	%	72.00	60.00			
								WBC: L	20/10/90	20.0	40.0	%	25.00	33.00			
WBC: E	20/10/90	1.0	5.0					%	1.00	2.00							
WBC: M	20/10/90	4.0	8.0					%	3.00	7.00							
WBC: B	20/10/90	0.0	1.0					%	0.00	0.00							
NA+	20/10/90	138.0	155.0					M EQ/L	141.00	143.00							
K+	20/10/90	3.5	5.5					M EQ/L	5.00	4.30							
CL-	20/10/90	98.0	120.0					M EQ/L	102.00	101.00							
CA++	20/10/90	8.5	10.5					MG/DL	10.20	10.20							
PO4-	20/10/90	3.0	4.5					MG/DL	3.70	3.10							
SGOT	20/10/90	42.0	40.0					MI/ML	33.00	30.00							
SGPT	20/10/90	10.0	40.0					MI/ML	26.00	19.00							
GAMMA-GT	20/10/90	11.0	51.0					MI/ML	29.00	19.00							
GLUCOSE	20/10/90	70.0	100.0					MG/DL	101.00	107.00							
ALK. PHOSPH.	20/10/90	65.0	306.0					MI/ML	245.00	244.00							
BUN	20/10/90	10.0	50.0					MG/DL	27.00	32.00							
CREATININE	20/10/90	0.6	1.6					MG/DL	1.00	1.00							
URIC ACID	20/10/90	3.4	7.0					MG/DL	4.30	4.60							
TOT BILIRUBIN	20/10/90	0.2	1.0					MG/DL	0.30	0.90							
DIR BILIRUBIN	20/10/90	0.0	0.4					MG/DL	0.30	0.40							
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.20	7.50											
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	4.30											
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	225.00	245.00											
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	157.00	197.00											
GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	4.00	5.00											
GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	4.00	7.00											

15/01/02

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOMETINE - PROTOCOL 20424/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
1	7	JSA	MALE	GLOBULINS: BETA	20/10/90	11.0	14.0	Z	10.00	16.00	.	.	.			
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	Z	12.00	19.00	.	.	.			
				T3	20/10/90	85.0	187.0	NG X	120.00			
				T4	20/10/90	4.5	12.5	NG/DL	7.80			
				8	MYB	MALE	HB	20/10/90	14.0	18.0	g/100ml	15.70	16.00	14.1.00	15.10	14.80
							HTC	20/10/90	40.0	54.0	Z	48.00	50.00	44.00	45.00	44.00
							RBC	20/10/90	4.3	6.1	10**6/mm	5.30	6.10	5.20	5.20	5.10
							WBC	20/10/90	4.0	11.0	10-3/MNC	5.20	5.70	5.40	5.40	5.50
							WBC: N	20/10/90	40.0	70.0	Z	72.00	68.00	73.00	73.00	66.00
							WBC: L	20/10/90	20.0	40.0	Z	26.00	28.00	23.00	23.00	25.00
							WBC: E	20/10/90	1.0	3.0	Z	0.00	2.00	4.00	4.00	5.00
							WBC: M	20/10/90	4.0	8.0	Z	2.00	4.00	4.00	4.00	8.00
							WBC: B	20/10/90	0.0	1.0	Z	0.00	0.00	0.00	0.00	0.00
							PLATELETS	20/10/90	150.0	550.0	10-3/MNC	141.00	141.00	141.00	141.00	244.00
							NA+	20/10/90	138.0	155.0	M EQ/L	3.50	3.80	4.10	4.10	159.00
							K+	20/10/90	3.5	5.5	M EQ/L	102.00	100.00	99.00	99.00	98.00
							CL-	20/10/90	98.0	120.0	M EQ/L	9.70	9.70	9.80	9.80	9.30
							CA++	20/10/90	8.5	10.5	MG/DL	9.30	9.30	9.30	9.30	9.30
PO4--	20/10/90	3.0	4.5				MG/DL	2.50	2.30	2.70	2.70	3.10				
SGPT	20/10/90	12.0	40.0				IU/ML	28.00	37.00	37.00	37.00	23.00				
SGPT	20/10/90	10.0	40.0				IU/ML	21.00	20.00	22.00	22.00	26.00				
GAMMA-GT	20/10/90	11.0	51.0				IU/ML	39.00	21.00	21.00	21.00	36.00				
GLUCOSE	20/10/90	70.0	100.0	MG/DL	75.00	69.00	69.00	69.00	94.00							
ALK. PROSPH.	20/10/90	65.0	306.0	IU/ML	233.00	245.00	285.00	285.00	303.00							
BUN	20/10/90	10.0	50.0	MG/DL	34.00	37.00	26.00	26.00	33.00							
CREATININE	20/10/90	0.6	1.6	MG/DL	1.10	1.00	1.10	1.10	1.30							
URIC ACID	20/10/90	3.4	7.0	MG/DL	5.70	7.60	5.70	5.70	6.60							
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	1.00	1.30	1.30	1.30	1.00							
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.60	0.70	0.70	0.50							
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.60	6.80	7.60	7.60	7.20							
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.50	4.40	4.70	4.70	4.60							
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	198.00	196.00	193.00	193.00	208.00							
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	109.00	87.00	99.00	99.00	160.00							
GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	Z	5.00	4.00	4.00	4.00	4.00							
GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	Z	7.00	7.00	9.00	9.00	9.00							
GLOBULINS: BETA	20/10/90	11.0	14.0	Z	13.00	12.00	12.00	12.00	12.00							
T3	20/10/90	15.0	22.0	Z	17.00	13.00	11.00	11.00	11.00							
T4	20/10/90	86.0	187.0	NG X	145.00							
	20/10/90	4.5	12.5	NG/DL	10.00							
9	CCR	MALE	HB	20/10/90	14.0	18.0	g/100ml	14.30	13.90	19.01/91	13.90	06/02/91				
			HTC	20/10/90	40.0	54.0	Z	44.00	42.00	42.00	42.00	13.20				
			RBC	20/10/90	4.3	6.1	10**6/mm	5.00	4.90	4.80	4.80	40.00				
			WBC	20/10/90	4.0	11.0	10-3/MNC	6.20	6.40	5.60	5.60	4.60				
			WBC: N	20/10/90	40.0	70.0	Z	75.00	64.00	59.00	59.00	5.70				
			WBC: L	20/10/90	20.0	40.0	Z	21.00	34.00	34.00	34.00	65.00				
				20/10/90	20.0	40.0	Z	21.00	21.00	21.00	21.00	28.00				
				20/10/90	20.0	40.0	Z	21.00	21.00	21.00	21.00	28.00				
				20/10/90	20.0	40.0	Z	21.00	21.00	21.00	21.00	28.00				
				20/10/90	20.0	40.0	Z	21.00	21.00	21.00	21.00	28.00				

1553

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBEXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6			
1	9	CCR	MALE	WBC: E	20/10/90	1.0	5.0	Z	1.00	1.00	1.00	2.00	2.00		
				WBC: M	20/10/90	4.0	8.0	Z	4.00	4.00	2.00	2.00	3.00		
				WBC: B	20/10/90	0.0	1.0	Z	0.00	0.00	0.00	0.00	0.00		
				PLATELETS	20/10/90	150.0	550.0	10-3/HMC	0.00	0.00	268.00	242.00	0.00		
				NA+	20/10/90	138.0	155.0	M EQ/L	143.00	143.00	138.00	144.00	144.00		
				K+	20/10/90	3.5	5.5	M EQ/L	4.30	4.30	4.10	4.40	3.70		
				CL-	20/10/90	98.0	120.0	M EQ/L	102.00	102.00	99.00	98.00	100.00		
				CA++	20/10/90	8.5	10.5	MG/DL	10.30	10.30	9.40	8.90	9.90		
				PO4--	20/10/90	3.0	4.5	MG/DL	3.60	3.60	3.10	3.80	3.20		
				SGPT	20/10/90	12.0	40.0	IU/ML	27.00	27.00	23.00	34.00	20.00		
				SGOT	20/10/90	10.0	40.0	IU/ML	16.00	16.00	15.00	20.00	15.00		
				GAMMA-GT	20/10/90	11.0	51.0	IU/ML	31.00	31.00	25.00	27.00	22.00		
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	109.00	109.00	92.00	88.00	103.00		
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/AL	197.00	197.00	156.00	132.00	131.00		
				BUN	20/10/90	10.0	50.0	MG/DL	36.00	36.00	36.00	32.00	28.00		
				CREATININE	20/10/90	0.6	1.6	MG/DL	1.20	1.20	1.20	1.10	1.10		
				URIC ACID	20/10/90	3.4	7.0	MG/DL	6.30	6.30	4.80	4.30	4.30		
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	0.60	1.00	1.00	0.50		
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.30	0.60	0.40	0.30		
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.60	7.60	7.50	6.70	6.70		
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.80	4.80	4.30	4.60	4.40		
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	147.00	147.00	145.00	134.00	121.00		
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	74.00	74.00	76.00	70.00	53.00		
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	Z	3.00	3.00	3.00	4.00	3.00		
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	Z	6.00	6.00	6.00	8.00	9.00		
				GLOBULINS: BETA	20/10/90	11.0	14.0	Z	12.00	12.00	14.00	14.00	12.00		
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	Z	14.00	14.00	12.00	15.00	11.00		
				T3	20/10/90	86.0	187.0	NG Z	180.00	180.00	180.00	15.00	11.00		
				T4	20/10/90	4.5	12.5	NG/DL	6.80	6.80	6.80	6.80	6.80		
				10	LDL	FEMALE	HR	20/10/90	12.0	16.0	G/100ML	25/01/91	15/02/91	01/03/91	15/03/91
							HTC	20/10/90	37.0	47.0	Z	13.60	14.20	13.50	14.40
							ERC	20/10/90	3.8	5.4	10-6/HMC	40.00	42.00	43.00	46.00
							HRC	20/10/90	4.0	11.0	10-3/HMC	4.40	4.50	4.60	4.90
							HRC: N	20/10/90	40.0	70.0	Z	6.90	10.30	6.60	8.70
HRC: L	20/10/90	20.0	40.0				Z	55.00	69.00	62.00	59.00				
HRC: E	20/10/90	1.0	5.0				Z	36.00	24.00	36.00	40.00				
HRC: H	20/10/90	4.0	8.0				Z	6.00	1.00	3.00	1.00				
HRC: B	20/10/90	0.0	1.0				Z	9.00	5.00	2.00	1.00				
PLATELETS	20/10/90	150.0	550.0				10-3/HMC	0.00	0.00	0.00	0.00				
K+	20/10/90	138.0	155.0				M EQ/L	316.00	327.00	380.00	370.00				
CL-	20/10/90	3.5	5.5				M EQ/L	144.00	145.00	146.00	142.00				
PO4--	20/10/90	98.0	120.0				M EQ/L	4.20	4.50	5.00	4.70				
CA++	20/10/90	8.5	10.5				MG/DL	102.00	104.00	104.00	104.00				
SGOT	20/10/90	12.0	40.0				IU/ML	9.00	8.80	8.00	9.10				
SGPT	20/10/90	10.0	40.0				IU/ML	23.00	3.50	3.30	3.40				
GAMMA-GT	20/10/90	10.0	40.0				IU/ML	23.00	36.00	26.00	30.00				
GLUCOSE	20/10/90	70.0	100.0				MG/DL	16.00	20.00	16.00	21.00				
ALK. PHOSPH.	20/10/90	7.0	33.0				IU/ML	26.00	21.00	33.00	32.00				
BUN	20/10/90	70.0	100.0				MG/DL	96.00	84.00	100.00	90.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
1	10	LDL	FEMALE	ALK. PHOSPH.	20/10/90	65.0	306.0	NU/ML	189.00	188.00	200.00	216.00	
				BUN	20/10/90	10.0	50.0	MG/DL	26.00	41.00	34.00	38.00	
				CREATININE	20/10/90	0.6	1.6	MG/DL	1.00	0.90	0.80	0.80	
				URIC ACID	20/10/90	2.4	5.7	MG/DL	4.90	4.50	4.40	4.10	
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.70	0.40	0.40	0.30	
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.20	0.20	0.20	
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.40	6.40	6.20	6.40	
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.80	3.90	3.80	3.90	
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	246.00	265.00	253.00	231.00	
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	247.00	197.00	206.00	161.00	
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	4.00	3.00	3.00	3.60	
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	9.00	8.00	9.00	8.90	
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	15.00	12.00	14.00	12.50	
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	14.00	15.00	13.00	18.80	
				T3	20/10/90	86.0	187.0	NG %	96.00				
				T4	20/10/90	4.5	12.5	NG/DL	6.80				
11	VRT		FEMALE	HB	20/10/90	12.0	16.0	G/100ML	13.40	15.20	13.60	19.06/91	
				HIC	20/10/90	37.0	47.0	%	41.00	41.00	42.00	41.00	
				RBC	20/10/90	3.8	5.4	10 ⁶ /MM ³	4.40	4.50	4.60	4.50	
				RBC: N	20/10/90	4.0	11.0	10 ³ /MM ³	6.70	6.80	6.90	5.50	
				RBC: L	20/10/90	40.0	70.0	%	63.00	71.00	66.00	58.00	
				RBC: E	20/10/90	20.0	40.0	%	33.00	25.00	31.00	39.00	
				RBC: H	20/10/90	1.0	5.0	%	1.00	4.00	1.00	5.00	
				RBC: B	20/10/90	4.0	8.0	%	4.00	4.00	3.00	3.00	
				PLATELETS	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	
				NA+	20/10/90	150.0	550.0	10 ³ /MM ³	351.00	290.00	373.00	310.00	
				CL-	20/10/90	138.0	155.0	M EQ/L	143.00	141.00	141.00	142.00	
				CA++	20/10/90	3.5	5.5	M EQ/L	4.40	5.20	4.50	4.80	
				PO4-	20/10/90	98.0	120.0	M EQ/L	106.00	104.00	103.00	104.00	
				SGOT	20/10/90	8.5	10.5	MG/DL	9.40	9.20	10.10	8.90	
				GAMMA-GT	20/10/90	3.0	4.5	MG/DL	3.80	5.40	3.70	3.50	
				GLUCOSE	20/10/90	12.0	40.0	MU/ML	15.00	14.00	20.00	23.00	
				ALK. PHOSPH.	20/10/90	10.0	33.0	NU/ML	12.00	19.00	20.00	14.00	
				CREATININE	20/10/90	7.0	100.0	MG/DL	20.00	19.00	23.00	23.00	
				TOT. BILIRUBIN	20/10/90	65.0	306.0	MU/ML	82.00	85.00	79.00	93.00	
				DIR BILIRUBIN	20/10/90	10.0	50.0	MG/DL	147.00	133.00	140.00	147.00	
				TOT. PROTEINS	20/10/90	0.4	1.6	MG/DL	26.00	27.00	23.00	18.00	
				ALBUMINE	20/10/90	0.4	5.7	MG/DL	0.80	0.90	0.90	0.90	
				TOT. CHOLEST.	20/10/90	2.4	11.0	%	3.90	4.20	3.80	3.50	
				TRIGLYCERIDES	20/10/90	0.2	1.0	MG/DL	0.50	0.50	0.50	0.40	
				GLOBULINS: ALPHA 1	20/10/90	0.0	0.4	MG/DL	0.20	0.30	0.20	0.20	
				GLOBULINS: ALPHA 2	20/10/90	6.0	8.0	G/DL	6.20	6.00	7.10	6.50	
				GLOBULINS: BETA	20/10/90	3.5	5.0	G/DL	3.90	3.90	4.10	3.80	
				GLOBULINS: GAMMA	20/10/90	140.0	270.0	MG/DL	169.00	159.00	184.00	161.00	
				TOT. CHOLEST.	20/10/90	35.0	175.0	MG/DL	69.00	68.00	100.00	119.00	
				TRIGLYCERIDES	20/10/90	4.0	7.0	%	3.00	4.00	3.00	4.80	
				GLOBULINS: ALPHA 1	20/10/90	7.0	11.0	%	9.00	8.00	9.00	7.90	
				GLOBULINS: ALPHA 2	20/10/90	11.0	14.0	%	12.00	13.00	13.00	12.60	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Screen			Visit		
					Date	Min	Max	Unit	Min	Max	Unit	Week 2	Week 4
1	11	VRT	FEMALE	LABORATORY TESTS	20/10/90	15.0	22.0	%	14.00	18.00	17.00	18.40	
				GLBULINS: GAMMA	20/10/90	86.0	187.0	NG %	110.00	18.00	17.00	18.40	
				T3	20/10/90	4.5	12.5	NG/DL	6.20	18.00	17.00	18.40	
				T4	20/10/90	4.5	12.5	NG/DL	6.20	18.00	17.00	18.40	
	12	SLT		FEMALE	LABORATORY TESTS	20/10/90	12.0	16.0	G/100ML	13.20	12.90	13.00	13.40
					HB	20/10/90	37.0	47.0	%	39.00	39.00	39.00	40.00
					HCT	20/10/90	3.8	5.4	10-6/HMC	4.50	4.50	4.60	4.70
					RBC	20/10/90	4.0	11.0	10-3/HMC	7.10	7.10	6.20	8.40
					HBC	20/10/90	40.0	70.0	%	78.00	77.00	76.00	66.00
					HBC: N	20/10/90	20.0	40.0	%	20.00	21.00	23.00	32.00
HBC: L					20/10/90	1.0	5.0	%	5.00	2.00	3.00	0.00	
HBC: E					20/10/90	4.0	8.0	%	2.00	2.00	1.00	2.00	
HBC: B					20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	
PLATELETS					20/10/90	150.0	550.0	10-3/HMC	206.00	242.00	236.00	249.00	
13	JR		FEMALE	LABORATORY TESTS	20/10/90	138.0	155.0	N EQ/L	145.00	141.00	142.00	144.00	
				NA+	20/10/90	3.5	5.5	N EQ/L	4.00	4.00	4.30	3.90	
				CL-	20/10/90	98.0	120.0	N EQ/L	104.00	100.00	101.00	103.00	
				CA++	20/10/90	8.5	10.5	MG/DL	9.70	9.60	9.30	9.20	
				SGOT	20/10/90	12.0	40.0	MG/DL	2.80	3.30	3.50	3.20	
				SGPT	20/10/90	10.0	40.0	MG/DL	17.00	18.00	18.00	30.00	
				GAMMA-GT	20/10/90	7.0	33.0	MG/DL	21.00	23.00	22.00	10.00	
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	77.00	77.00	90.00	87.00	
				ALK. PHOSPH.	20/10/90	65.0	306.0	MG/DL	118.00	144.00	142.00	161.00	
				BUN	20/10/90	10.0	50.0	MG/DL	27.00	21.00	23.00	21.00	
13	JR		FEMALE	LABORATORY TESTS	20/10/90	0.6	1.6	MG/DL	0.90	0.80	0.90	0.90	
				CREATININE	20/10/90	2.4	5.7	MG/DL	4.20	3.20	3.60	3.30	
				URIC ACID	20/10/90	0.2	1.0	MG/DL	0.70	0.40	0.60	0.70	
				TOT BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.20	0.30	0.30	
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.20	0.30	0.30	
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.70	7.20	7.10	7.60	
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	4.30	4.30	4.60	
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	146.00	142.00	153.00	165.00	
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	68.00	76.00	70.00	56.00	
				GLBULINS: ALPHA 1	20/10/90	4.0	7.0	%	3.50	2.80	3.90	2.70	
GLBULINS: ALPHA 2	20/10/90	7.0	11.0	%	7.90	7.60	8.80	8.20					
GLBULINS: BETA	20/10/90	11.0	14.0	%	10.50	13.40	10.80	11.80					
GLBULINS: GAMMA	20/10/90	15.0	22.0	%	20.20	19.10	19.60	20.90					
T3	20/10/90	86.0	187.0	NG %	115.00	18.00	17.00	18.40					
T4	20/10/90	4.5	12.5	NG/DL	7.60	18.00	17.00	18.40					
13	JR		FEMALE	LABORATORY TESTS	23/04/91	12.0	16.0	G/100ML	13.50	12.90	13.00	13.40	
				HB	23/04/91	37.0	47.0	%	41.00	39.00	39.00	40.00	
				HCT	23/04/91	3.8	5.4	10-6/HMC	4.40	4.50	4.60	4.70	
				RBC	23/04/91	4.0	11.0	10-3/HMC	6.70	7.10	6.20	8.40	
				HBC	23/04/91	40.0	70.0	%	60.00	77.00	76.00	66.00	
				HBC: N	23/04/91	20.0	40.0	%	20.00	21.00	23.00	32.00	
				HBC: L	23/04/91	1.0	5.0	%	5.00	2.00	3.00	0.00	
				HBC: E	23/04/91	4.0	8.0	%	2.00	2.00	1.00	2.00	
				HBC: B	23/04/91	0.0	1.0	%	0.00	0.00	0.00	0.00	
				PLATELETS	23/04/91	150.0	550.0	10-3/HMC	206.00	242.00	236.00	249.00	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Screen	Visit				
				Date	Min	Max		Unit	Week 2	Week 4	Week 6	
1	13 JR	FEMALE	WBC: N	20/10/90	4.0	8.0	X	4.00
			WBC: B	20/10/90	0.0	1.0	X	0.00
			PLATELETS	20/10/90	150.0	550.0	10-3/MNC	233.00
			NA+	20/10/90	138.0	155.0	M EQ/L	142.00
			K+	20/10/90	3.5	5.5	M EQ/L	4.20
			CL-	20/10/90	98.0	120.0	M EQ/L	104.00
			CA++	20/10/90	8.5	10.5	MG/DL	9.80
			PO4-	20/10/90	3.0	4.5	MG/DL	4.00
			SGOT	20/10/90	12.0	40.0	IU/ML	17.00
			SGPT	20/10/90	10.0	40.0	IU/ML	21.00
			GAMMA-GT	20/10/90	7.0	35.0	IU/ML	25.00
			GLUCOSE	20/10/90	70.0	100.0	MG/DL	102.00
			ALK. PHOSPH.	20/10/90	65.0	306.0	IU/HL	260.00
			BUN	20/10/90	10.0	50.0	MG/DL	29.00
			CREATININE	20/10/90	0.6	1.6	MG/DL	0.90
			URIC ACID	20/10/90	2.4	5.7	MG/DL	5.30
			TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.50
			DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30
			TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.80
			ALBUMINE	20/10/90	3.5	5.0	G/DL	4.00
			TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	252.00
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	190.00
			GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	X	4.60
			GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	X	9.10
			GLOBULINS: BETA	20/10/90	11.0	14.0	X	14.50
			GLOBULINS: GAMMA	20/10/90	15.0	22.0	X	17.30
			T3	20/10/90	86.0	187.0	NG X	135.00
			T4	20/10/90	4.5	12.5	NG/DL	9.20
14	MLC	FEMALE	HR	20/10/90	12.0	16.0	G/100ML	12.00	30/04/91	04/06/91	18/06/91	
			HTC	20/10/90	37.0	47.0	X	35.00	11.70	11.80	11.40	
			PRC	20/10/90	3.8	5.4	10-6/MNC	36.00	36.00	36.00	34.00	
			WBC	20/10/90	4.0	11.0	10-3/MNC	4.00	4.00	4.10	3.90	
			WBC: N	20/10/90	40.0	70.0	X	6.50	7.20	7.10	6.40	
			WBC: L	20/10/90	20.0	40.0	X	56.00	59.00	67.00	66.00	
			WBC: E	20/10/90	1.0	5.0	X	37.00	38.00	31.00	30.00	
			WBC: H	20/10/90	4.0	8.0	X	7.00	4.00	2.00	3.00	
			WBC: B	20/10/90	0.0	1.0	X	0.00	0.00	0.00	0.00	
			PLATELETS	20/10/90	150.0	550.0	10-3/MNC	368.00	368.00	379.00	379.00	
			NA+	20/10/90	138.0	155.0	M EQ/L	144.00	143.00	143.00	143.00	
			K+	20/10/90	3.5	5.5	M EQ/L	3.60	4.10	3.90	4.30	
			CL-	20/10/90	98.0	120.0	M EQ/L	105.00	101.00	103.00	102.00	
			CA++	20/10/90	8.5	10.5	MG/DL	10.30	11.70	12.00	10.00	
			PO4-	20/10/90	3.0	4.5	MG/DL	2.70	2.90	3.50	3.20	
			SGOT	20/10/90	12.0	40.0	IU/ML	18.00	36.00	19.00	20.00	
			SGPT	20/10/90	10.0	40.0	IU/ML	25.00	25.00	23.00	16.00	
			GAMMA-GT	20/10/90	7.0	33.0	IU/ML	28.00	27.00	26.00	26.00	
			GLUCOSE	20/10/90	70.0	100.0	MG/DL	104.00	110.00	102.00	103.00	
			ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	369.00	422.00	421.00	440.00	

1557

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit									
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6					
1	14	M/C	FEMALE	BUN	20/10/90	10.0	50.0	MG/DL	27.00	30.00	31.00	28.00				
				CREATININE	20/10/90	0.6	1.6	MG/DL	1.00	0.90	1.00	1.10				
				URIC ACID	20/10/90	2.4	5.7	MG/DL	5.00	5.00	5.60	5.30				
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.30	0.50	0.50	0.30				
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.10	0.30	0.20	0.20				
				TOT PROTEINS	20/10/90	6.0	8.0	G/DL	6.70	7.10	6.80	7.00				
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.10	4.10	4.30				
				TOT CHOLEST.	20/10/90	160.0	270.0	MG/DL	233.00	227.00	244.00	239.00				
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	175.00	215.00	260.00	209.00				
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	g	2.80	2.90	3.00	2.90				
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	g	6.50	7.73	6.00	7.80				
				GLOBULINS: BETA	20/10/90	11.0	14.0	g	14.20	16.30	16.00	13.80				
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	g	17.30	15.40	17.00	16.70				
				T3	20/10/90	86.0	187.0	NG %	135.00							
				T4	20/10/90	4.5	12.5	NG/DL	9.00							
				15	MAO		FEMALE	HB	20/10/90	12.0	16.0	G/100ML	12.90	11.20	11.70	11.50
								HTC	20/10/90	37.0	47.0	g	39.00	35.00	36.00	36.00
RBC	20/10/90	3.8	5.4					10 ⁶ /HMC	4.50	4.00	4.20	4.20				
HBC	20/10/90	4.0	11.0					10 ³ /HMC	4.70	4.40	4.10	3.80				
WBC: N	20/10/90	40.0	70.0					g	57.00	44.00	50.00	50.00				
WBC: L	20/10/90	20.0	40.0					g	42.00	52.00	46.00	45.00				
WBC: E	20/10/90	1.0	5.0					g	0.00	3.00	1.00	0.00				
WBC: M	20/10/90	4.0	8.0					g	1.00	4.00	1.00	1.00				
WBC: B	20/10/90	0.0	1.0					g	0.00	0.00	0.00	0.00				
PLATELETS	20/10/90	150.0	550.0					10 ³ /HMC	262.00	212.00	261.00	255.00				
NA+	20/10/90	138.0	155.0					M EQ/L	142.00	138.00	143.00	145.00				
K+	20/10/90	3.5	5.5					M EQ/L	4.60	4.30	4.50	4.60				
CL-	20/10/90	98.0	120.0					M EQ/L	105.00	103.00	105.00	105.00				
CA++	20/10/90	8.5	10.5					MG/DL	9.30	9.80	9.20	9.50				
PO4-	20/10/90	3.0	4.5					MG/DL	3.80	3.00	3.50	3.60				
SGOT	20/10/90	42.0	40.0					U/ML	26.00	23.00	24.00	21.00				
SGPT	20/10/90	10.0	40.0					U/ML	17.00	17.00	21.00	14.00				
GAMMA-GT	20/10/90	7.0	33.0					U/ML	39.00	28.00	35.00	42.00				
GLUCOSE	20/10/90	70.0	100.0					MG/DL	100.00	84.00	85.00	90.00				
ALK. PHOSPH.	20/10/90	65.0	306.0					U/ML	228.00	184.00	207.00	222.00				
BUN	20/10/90	10.0	50.0	MG/DL	36.00	24.00	41.00	36.00								
CREATININE	20/10/90	0.6	1.6	MG/DL	1.10	0.90	1.10	1.10								
URIC ACID	20/10/90	2.4	5.7	MG/DL	4.00	3.50	3.70	3.20								
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.70	0.60	0.60	0.50								
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.30	0.30	0.20								
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.30	7.40	7.40	7.20								
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.30	4.40	4.10	4.40								
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	314.00	287.00	324.00	340.00								
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	142.00	156.00	128.00	173.00								
GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	g	3.70	3.70	4.50	3.80								
GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	g	7.60	9.40	7.30	7.60								
GLOBULINS: BETA	20/10/90	11.0	14.0	g	15.20	16.80	15.40	15.30								
GLOBULINS: GAMMA	20/10/90	15.0	22.0	g	16.30	19.60	16.40	17.10								

1 2 3 4

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CHS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range				Visit							
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
1	15	MAD	FEMALE	T3 T4	20/10/90	86.0	187.0	NG %	115.00		
					20/10/90	4.5	12.5	NG/DL	9.00		
	16	MHC	FEMALE	HB HTC RBC WBC: N WBC: L WBC: E WBC: M PLATELETS NA+ K+ CL- CA++ PO4- SGPT GAMMA-GT GLUCOSE ALK. PHOSPH. BUN CREATININE URIC ACID TOT BILIRUBIN DIR BILIRUBIN TOT. PROTEINS ALBUMINE TOT. CHOLEST. TRIGLYCERIDES GLOBULINS: ALPHA 1 GLOBULINS: ALPHA 2 GLOBULINS: BETA GLOBULINS: GAMMA T3 T4	20/10/90	12.0	16.0	G/100ML	10/05/91	11.70	11.70	12.20	14/06/91	12.20	28/06/91	12.10
					20/10/90	37.0	47.0	%	36.00	36.00	38.00	38.00	38.00	38.00		
					20/10/90	3.8	5.4	10-6/MNC	4.20	4.20	4.40	4.40	4.50			
					20/10/90	4.0	11.0	10-3/MNC	7.00	7.50	6.40	6.40	6.30			
					20/10/90	40.0	70.0	%	74.00	69.00	63.00	63.00	79.00			
					20/10/90	20.0	40.0	%	25.00	27.00	35.00	35.00	19.00			
					20/10/90	1.0	5.0	%	0.00	1.00	1.00	1.00	0.00			
					20/10/90	4.0	8.0	%	4.00	4.00	2.00	2.00	2.00			
					20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00			
					20/10/90	150.0	550.0	10-3/MNC	298.00	251.00	309.00	309.00	281.00			
					20/10/90	136.0	155.0	M EQ/L	142.00	144.00	140.00	140.00	144.00			
					20/10/90	3.5	5.5	M EQ/L	4.90	4.60	4.70	4.70	4.60			
					20/10/90	98.0	120.0	M EQ/L	106.00	102.00	103.00	103.00	105.00			
					20/10/90	8.5	10.5	NG/DL	9.40	9.90	10.50	10.50	9.60			
					20/10/90	3.0	4.5	NG/DL	2.80	3.00	3.30	3.30	2.90			
					20/10/90	12.0	40.0	MU/HL	21.00	15.00	15.00	15.00	16.00			
					20/10/90	10.0	40.0	MU/HL	23.00	18.00	18.00	18.00	23.00			
					20/10/90	7.0	33.0	MU/HL	55.00	28.00	19.00	19.00	21.00			
					20/10/90	70.0	100.0	MG/DL	122.00	127.00	103.00	103.00	115.00			
					20/10/90	65.0	306.0	MU/ML	395.00	349.00	323.00	323.00	359.00			
					20/10/90	10.0	50.0	MG/DL	39.00	27.00	34.00	34.00	31.00			
					20/10/90	0.6	1.6	MG/DL	0.80	0.70	0.90	0.90	0.70			
					20/10/90	2.4	5.7	MG/DL	4.20	3.90	3.60	3.60	4.20			
					20/10/90	0.2	1.0	MG/DL	0.40	0.40	0.50	0.50	0.60			
					20/10/90	0.0	0.4	MG/DL	0.20	0.20	0.20	0.20	0.20			
					20/10/90	6.0	8.0	G/DL	7.60	6.50	7.30	7.30	7.00			
					20/10/90	3.5	5.0	G/DL	4.30	4.30	4.30	4.30	4.00			
					20/10/90	140.0	270.0	MG/DL	225.00	210.00	214.00	214.00	221.00			
					20/10/90	35.0	175.0	MG/DL	102.00	131.00	116.00	116.00	113.00			
					20/10/90	4.0	7.0	%	3.40	3.60	2.90	2.90	2.80			
					20/10/90	7.0	11.0	%	8.90	9.10	6.80	6.80	7.40			
					20/10/90	11.0	14.0	%	13.20	13.60	13.60	13.60	14.00			
					20/10/90	15.0	22.0	%	17.80	18.30	16.50	16.50	17.90			
					20/10/90	86.0	187.0	NG %	115.00			
					20/10/90	4.5	12.5	NG/DL	9.40			
17	CEC		FEMALE	HB HTC RBC WBC: N WBC: L WBC: E	20/10/90	12.0	16.0	G/100ML	14/05/91	11.30	11.60	18/06/91	11.60	02/07/91	11.00	
					20/10/90	37.0	47.0	%	37.00	34.00	38.00	38.00	34.00			
					20/10/90	3.8	5.4	10-6/MNC	4.40	4.70	4.40	4.40	4.70			
					20/10/90	4.0	11.0	10-3/MNC	6.80	6.00	6.20	6.20	6.80			
					20/10/90	40.0	70.0	%	76.00	58.00	63.00	63.00	68.00			
					20/10/90	20.0	40.0	%	22.00	40.00	36.00	36.00	30.00			
					20/10/90	1.0	5.0	%	3.00	1.00	1.00	1.00	1.00			
					20/10/90	4.0	8.0	%	4.00	2.00	2.00	2.00	2.00			

1350

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
1	17	CEC	FEMALE	MBC: B	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00			
				PLATELETS	20/10/90	150.0	550.0	10 ³ -3/MHC	301.00	305.00	331.00	331.00	294.00			
				NA+	20/10/90	138.0	155.0	K EQ/L	141.00	145.00	136.00	136.00	137.00			
				K+	20/10/90	3.5	5.5	K EQ/L	4.60	4.70	5.00	5.00	4.40			
				CL-	20/10/90	98.0	120.0	K EQ/L	101.00	99.00	100.00	100.00	100.00			
				CA++	20/10/90	8.5	10.5	MG/DL	9.40	9.00	8.00	8.00	9.50			
				PO4--	20/10/90	3.0	4.5	MG/DL	3.90	3.70	3.70	3.70	4.10			
				SGPT	20/10/90	12.0	40.0	IU/ML	29.00	14.00	18.00	18.00	18.00			
				SGPT	20/10/90	10.0	40.0	MIU/ML	31.00	28.00	24.00	24.00	22.00			
				GAMMA-GT	20/10/90	7.0	33.0	MIU/ML	24.00	24.00	27.00	27.00	16.00			
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	83.00	83.00	77.00	77.00	92.00			
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	234.00	205.00	229.00	229.00	220.00			
				BUN	20/10/90	10.0	50.0	MG/DL	23.00	20.00	12.00	12.00	21.00			
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.70	0.80	0.60	0.60	0.70			
				URIC ACID	20/10/90	2.4	5.7	MG/DL	3.00	3.00	2.70	2.70	1.90			
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	0.50	0.50	0.50	0.50			
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.20	0.20	0.20	0.30			
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.80	6.20	6.40	6.40	6.40			
				ALBUMINE	20/10/90	3.5	5.0	G/DL	3.70	4.10	4.10	4.10	3.90			
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	210.00	166.00	175.00	175.00	176.00			
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	62.00	102.00	82.00	82.00	62.00			
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	4.70	5.80	3.70	3.70	3.70			
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	9.30	9.60	10.10	10.10	9.20			
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	10.30	11.50	12.80	12.80	13.40			
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	16.80	18.30	18.30	18.30	15.70			
				T3	20/10/90	86.0	187.0	NG X	130.00							
				T4	20/10/90	4.5	12.5	NG/DL	10.50							
				18	TTM	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	11.30	11.60	11.60	11.60	11.60
							HTC	20/10/90	37.0	47.0	%	34.00	36.00	38.00	38.00	40.00
							RBC	20/10/90	3.8	5.4	10 ⁶ -6/MHC	4.20	4.40	4.60	4.60	4.80
							MBC: N	20/10/90	4.0	11.0	10 ³ -3/MHC	4.50	5.30	8.50	8.50	6.90
							MBC: L	20/10/90	40.0	70.0	%	59.00	64.00	67.00	67.00	67.00
							MBC: E	20/10/90	20.0	40.0	%	39.00	35.00	27.00	27.00	27.00
MBC: N	20/10/90	1.0	5.0				%	1.00	3.00	1.00	1.00	1.00				
MBC: B	20/10/90	0.0	8.0				%	2.00	1.00	6.00	6.00	5.00				
PLATELETS	20/10/90	150.0	550.0				10 ³ -3/MHC	218.00	252.00	176.00	176.00	170.00				
NA+	20/10/90	158.0	155.0				K EQ/L	140.00	143.00	136.00	136.00	138.00				
K+	20/10/90	3.5	5.5				K EQ/L	4.50	4.40	4.50	4.50	4.60				
CL-	20/10/90	98.0	120.0				K EQ/L	103.00	99.00	102.00	102.00	102.00				
PO4--	20/10/90	8.5	10.5				MG/DL	9.20	8.70	8.30	8.30	10.00				
SGPT	20/10/90	3.0	4.5				MG/DL	3.40	3.30	3.70	3.70	4.20				
GAMMA-GT	20/10/90	12.0	40.0				MIU/ML	27.00	26.00	19.00	19.00	20.00				
GLUCOSE	20/10/90	70.0	100.0				MG/DL	32.00	33.00	36.00	36.00	22.00				
ALK. PHOSPH.	20/10/90	65.0	306.0				IU/ML	146.00	138.00	152.00	152.00	82.00				
BUN	20/10/90	10.0	50.0				MG/DL	16.00	18.00	18.00	18.00	19.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
1	18	ITM	FEMALE	CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	0.90	0.80	0.90	0.90			
				URIC ACID	20/10/90	2.4	5.7	MG/DL	3.80	3.80	2.30	2.30				
				DIR BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.90	0.70	0.30	0.30				
				TOT. BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.20	0.20	0.20				
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.40	6.90	6.90	7.00				
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	3.90	4.00	4.00				
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	187.00	174.00	183.00	162.00				
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	54.00	57.00	50.00	50.00				
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	4.90	3.80	3.80	3.80				
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	10.20	8.60	11.50	11.50				
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	14.30	12.40	13.60	13.60				
				GLOBULINS: GAMMA	20/10/90	45.0	22.0	%	15.30	21.90	19.20	19.20				
				T3	20/10/90	86.0	187.0	NG %	110.00							
				T4	20/10/90	4.5	12.5	NG/DL	10.50							
				19	SR	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	13.10	21/05/91	11/06/91	25/06/91	09/07/91
							HTC	20/10/90	37.0	47.0	%	39.00	42.50	38.00	42.50	
							RBC	20/10/90	3.8	5.4	10 ⁶ /HMC	4.50	40.00	58.00	39.00	
							HBC	20/10/90	4.0	11.0	10 ³ /HMC	8.00	6.50	4.40	4.40	
							HBC: N	20/10/90	40.0	70.0	%	49.00	53.00	45.00	61.00	
							HBC: L	20/10/90	20.0	40.0	%	48.00	59.00	45.00	31.00	
HBC: E	20/10/90	1.0	5.0				%	4.00	4.00	1.00	7.00					
HBC: M	20/10/90	4.0	8.0				%	3.00	4.00	2.00	8.00					
HBC: B	20/10/90	0.0	1.0				%	0.00	0.00	0.00	1.00					
PLATELETS	20/10/90	150.0	550.0				10 ³ /HMC	226.00	230.00	230.00	226.00					
NA+	20/10/90	138.0	155.0				M EQ/L	141.00	139.00	134.00	137.00					
K+	20/10/90	3.5	5.5				M EQ/L	5.00	4.70	5.20	5.20					
CL-	20/10/90	98.0	120.0				M EQ/L	102.00	107.00	100.00	109.00					
CA++	20/10/90	8.5	10.5				MG/DL	9.50	10.00	9.70	9.50					
PO4--	20/10/90	3.0	4.5				MG/DL	3.90	3.80	3.60	3.50					
SGOT	20/10/90	12.0	40.0				NU/ML	28.00	27.00	28.00	20.00					
SGPT	20/10/90	10.0	40.0				NU/ML	21.00	18.00	20.00	15.00					
GAMMA-GT	20/10/90	7.0	33.0				NU/ML	20.00	14.00	17.00	16.00					
GLUCOSE	20/10/90	70.0	100.0				MG/DL	95.00	106.00	101.00	108.00					
ALK. PHOSPH.	20/10/90	65.0	306.0				NU/ML	218.00	222.00	219.00	206.00					
BUN	20/10/90	10.0	50.0	MG/DL	34.00	42.00	40.00	48.00								
CREATININE	20/10/90	0.6	1.6	MG/DL	1.10	1.10	1.10	1.00								
URIC ACID	20/10/90	2.4	5.7	MG/DL	5.40	4.30	4.60	4.60								
DIR BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.40	0.50	0.40	0.40								
TOT. BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.30	0.20	0.20								
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.40	7.70	7.00	6.70								
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.30	4.80	4.10	4.10								
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	289.00	182.00	215.00	200.00								
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	103.00	72.00	68.00	62.00								
GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	3.90	7.80	7.80	2.70								
GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	7.50	7.80	7.80	6.30								
GLOBULINS: BETA	20/10/90	11.0	14.0	%	14.10	13.70	13.70	12.60								
GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	17.60	19.40	16.70	16.20								
T3	20/10/90	86.0	187.0	NG %	110.00											

10:01

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMDEXYME - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
1	19	SR	FEMALE	T4	20/10/90	4.5	12.5	NG/DL	8.40				
	20	EFC	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	13.00	14/06/91	28/06/91	12/07/91	
				HTC	20/10/90	37.0	47.0	%	38.00	13.20	13.30	13.00	13.00
				RBC	20/10/90	3.8	5.4	10 ⁶ -6/MHC	4.30	39.00	39.00	39.00	39.00
				HBC: N	20/10/90	4.0	11.0	10 ³ -3/MHC	7.60	4.40	4.40	4.30	4.30
				HBC: L	20/10/90	40.0	70.0	%	74.00	6.30	7.90	7.90	7.90
				HBC: E	20/10/90	20.0	40.0	%	25.00	61.00	64.00	64.00	64.00
				HBC: M	20/10/90	1.0	5.0	%	1.00	37.00	32.00	32.00	32.00
				HBC: B	20/10/90	4.0	8.0	%	1.00	3.00	3.00	3.00	3.00
				PLATELETS	20/10/90	0.0	1.0	%	0.00	2.00	4.00	0.00	0.00
				NA+	20/10/90	150.0	550.0	10 ³ -3/MHC	211.00	199.00	220.00	250.00	250.00
				K+	20/10/90	3.5	5.5	M EQ/L	4.40	144.00	156.00	135.00	135.00
				CL-	20/10/90	98.0	120.0	M EQ/L	104.00	97.00	98.00	101.00	101.00
				CA++	20/10/90	8.5	10.5	MG/DL	8.70	8.30	8.00	8.20	8.20
				PO4-	20/10/90	3.0	4.5	MG/DL	4.50	3.50	3.30	3.30	3.30
				SGOT	20/10/90	12.0	40.0	U/L	18.00	18.00	18.00	22.00	22.00
				GAMMA-GT	20/10/90	10.0	40.0	U/L	21.00	13.00	18.00	18.00	18.00
				GLUCOSE	20/10/90	7.0	33.0	MG/DL	25.00	19.00	29.00	32.00	32.00
				ALK. PHOSPH.	20/10/90	70.0	100.0	U/L	93.00	97.00	93.00	90.00	90.00
				CREATININE	20/10/90	65.0	306.0	MG/DL	255.00	275.00	263.00	260.00	260.00
				TOT BILIRUBIN	20/10/90	0.6	1.6	MG/DL	1.10	1.00	0.80	0.90	0.90
				URIC ACID	20/10/90	2.4	5.7	MG/DL	3.10	2.50	2.60	2.50	2.50
				DIR BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.40	0.50	0.50	0.50	0.50
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	0.20	0.20	0.20	0.30	0.30
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.70	7.60	7.70	7.60	7.60
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	258.00	204.00	265.00	205.00	205.00
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	120.00	143.00	157.00	168.00	168.00
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	4.20	3.60	2.70	2.70	2.70
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	6.40	6.40	9.20	9.20	9.20
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	13.60	14.50	14.70	14.70	14.70
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	20.30	17.30	21.10	21.10	21.10
				T3	20/10/90	86.0	487.0	NG %	110.00				
				T4	20/10/90	4.5	12.5	NG/DL	8.00				
	21	VHC	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	11.10	18/06/91	02/07/91	16/07/91	
				HTC	20/10/90	37.0	47.0	%	36.00	11.40	11.40	11.30	11.30
				RBC	20/10/90	3.8	5.4	10 ⁶ -6/MHC	4.30	37.00	36.00	35.00	35.00
				HBC: N	20/10/90	4.0	11.0	10 ³ -3/MHC	6.30	4.40	4.30	4.20	4.20
				HBC: L	20/10/90	40.0	70.0	%	62.00	7.50	6.80	6.80	6.80
				HBC: E	20/10/90	20.0	40.0	%	37.00	64.00	72.00	74.00	74.00
				HBC: M	20/10/90	1.0	5.0	%	1.00	32.00	25.00	21.00	21.00
				HBC: B	20/10/90	4.0	8.0	%	1.00	1.00	3.00	1.00	1.00
				PLATELETS	20/10/90	0.0	1.0	%	0.00	4.00	3.00	4.00	4.00
				NA+	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00

1562

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 2012/4/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6			
1	21	VHC	FEMALE	PLATELETS	20/10/90	150.0	550.0	10 ³ -3/MHC	321.00	310.00	320.00	337.00			
				NA+	20/10/90	138.0	155.0	M EQ/L	137.00	136.00	134.00	136.00			
				K+	20/10/90	3.5	5.5	M EQ/L	4.60	4.30	4.50	4.10			
				CL-	20/10/90	98.0	120.0	M EQ/L	105.00	104.00	103.00	98.00			
				CA++	20/10/90	8.5	10.5	MG/DL	9.60	9.40	9.60	9.60			
				PO4-	20/10/90	3.0	4.5	MG/DL	3.50	3.90	4.30	4.10			
				SGPT	20/10/90	12.0	40.0	U/L	19.00	19.00	18.00	29.00			
				GAMMA-GT	20/10/90	10.0	40.0	U/L	18.00	15.00	13.00	26.00			
				GLUCOSE	20/10/90	70.0	330.0	MG/DL	23.00	20.00	17.00	22.00			
				ALK. PHOSPH.	20/10/90	65.0	306.0	U/L	216.00	215.00	249.00	256.00			
				BUN	20/10/90	10.0	50.0	MG/DL	17.00	20.00	22.00	23.00			
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	0.80	0.80	0.80			
				URIC ACID	20/10/90	2.4	5.7	MG/DL	3.30	3.60	4.40	3.40			
				TOT. BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.50	0.40	0.40	0.60			
				DYR. BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.20	0.20	0.30			
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.30	7.20	7.30	7.00			
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.40	4.20	4.30	4.30			
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	176.00	168.00	171.00	163.00			
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	94.00	93.00	70.00	83.00			
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	X	3.90	3.20	4.70	2.30			
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	X	7.60	7.50	9.30	9.40			
				GLOBULINS: BETA	20/10/90	11.0	14.0	X	17.60	13.80	13.10	10.10			
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	X	19.40	20.20	20.60	16.30			
				T3	20/10/90	86.0	187.0	NG X	170.00						
				T4	20/10/90	4.5	12.5	NG/DL	7.60						
				22	SK	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	10.60	10.70	10.70	9.60
							HTC	20/10/90	37.0	47.0	X	32.00	33.00	30.00	29.00
RBC	20/10/90	3.8	5.4				10 ⁶ -6/MHC	3.20	3.30	2.90	2.90				
MBC	20/10/90	4.0	11.0				10 ³ -3/MHC	6.90	5.90	8.20	6.20				
MBC: N	20/10/90	40.0	70.0				X	57.00	51.00	65.00	67.00				
MBC: L	20/10/90	20.0	40.0				X	41.00	47.00	32.00	32.00				
MBC: E	20/10/90	1.0	5.0				X	1.00	0.00	1.00	0.00				
MBC: M	20/10/90	4.0	8.0				X	2.00	2.00	3.00	1.00				
MBC: B	20/10/90	0.0	1.0				X	0.00	0.00	0.00	0.00				
PLATELETS	20/10/90	150.0	550.0				10 ³ -3/MHC	295.00	350.00	281.00	318.00				
NA+	20/10/90	138.0	155.0				M EQ/L	145.00	139.00	134.00	132.00				
K+	20/10/90	3.5	5.5				M EQ/L	4.40	5.10	4.70	4.40				
CL-	20/10/90	98.0	120.0				M EQ/L	96.00	103.00	97.00	97.00				
CA++	20/10/90	8.5	10.5				MG/DL	7.10	8.00	9.00	8.80				
PO4-	20/10/90	3.0	4.5				MG/DL	3.60	3.80	3.60	3.30				
SGPT	20/10/90	12.0	40.0				U/L	21.00	17.00	19.00	18.00				
GAMMA-GT	20/10/90	10.0	40.0				U/L	11.00	16.00	17.00	23.00				
GLUCOSE	20/10/90	70.0	330.0				MG/DL	10.00	10.00	10.00	14.00				
ALK. PHOSPH.	20/10/90	65.0	306.0				U/L	135.00	152.00	150.00	83.00				
BUN	20/10/90	10.0	50.0				MG/DL	32.00	30.00	25.00	25.00				
CREATININE	20/10/90	0.6	1.6				MG/DL	1.00	1.00	1.00	1.00				

1563

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Date	Laboratory Range			Visit						
					Min	Max	Unit	Screen	Week 2	Week 4	Week 6			
1	22 SK	FEMALE	URIC ACID	20/10/90	2.4	5.7	MG/DL	3.60	3.50	3.90	2.20			
			TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.70	0.80	0.50	0.80			
			DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.40	0.20	0.40			
			TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	9.50	9.70	8.80	9.50			
			ALBUMINE	20/10/90	3.5	5.0	G/DL	3.50	3.60	3.10	3.30			
			TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	144.00	146.00	129.00	153.00			
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	73.00	66.00	69.00	67.00			
			GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	Z	2.90	2.80	2.80	1.90			
			GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	Z	4.10	4.10	3.70	2.90			
			GLOBULINS: BETA	20/10/90	11.0	14.0	Z	9.60	10.90	8.30	8.60			
			GLOBULINS: GAMMA	20/10/90	15.0	22.0	Z	42.30	41.60	3.70	8.60			
			T3	20/10/90	86.0	187.0	NG Z	74.00	41.60	8.30	8.60			
			T4	20/10/90	4.5	12.5	NG/DL	4.50	41.60	43.90	41.30			
			23 AR	FEMALE	FEMALE	HR	20/10/90	12.0	16.0	B/100ML	14/06/91	05/07/91		
						HTC	20/10/90	37.0	47.0	Z	12.20	12.20		
						PRC	20/10/90	3.8	5.4	10-6/MNC	38.00	37.00		
						MRC	20/10/90	4.0	11.0	10-3/MNC	4.10	4.10		
						MRC: N	20/10/90	40.0	70.0	Z	6.30	7.40		
						MRC: L	20/10/90	20.0	40.0	Z	67.00	65.00		
						MRC: E	20/10/90	1.0	5.0	Z	30.00	34.00		
MRC: B	20/10/90	4.0				8.0	Z	5.00	5.00					
PLATELETS	20/10/90	0.0				1.0	Z	3.00	1.00					
NA+	20/10/90	150.0				550.0	10-3/MNC	0.00	0.00					
X+	20/10/90	138.0				155.0	M EQ/L	277.00	245.00					
CL-	20/10/90	3.5				5.5	M EQ/L	144.00	136.00					
PO4--	20/10/90	98.0				120.0	M EQ/L	4.10	3.20					
SGPT	20/10/90	8.5				10.5	MG/DL	102.00	101.00					
GAMMA-GT	20/10/90	3.0				4.5	MG/DL	8.30	9.50					
GLUCOSE	20/10/90	12.0				40.0	HU/HL	3.40	3.00					
ALK. PHOSPH.	20/10/90	10.0				40.0	HU/HL	16.00	13.00					
BUN	20/10/90	7.0				33.0	HU/HL	29.00	10.00					
CREATININE	20/10/90	70.0				100.0	MG/DL	94.00	19.00					
URIC ACID	20/10/90	65.0				306.0	HU/HL	98.00	98.00					
TOT BILIRUBIN	20/10/90	10.0	50.0	MG/DL	17.00	17.00								
DIR BILIRUBIN	20/10/90	0.6	1.6	MG/DL	0.80	0.80								
TOT. PROTEINS	20/10/90	2.4	5.7	MG/DL	3.40	3.40								
ALBUMINE	20/10/90	0.2	1.0	MG/DL	0.90	0.80								
TOT. CHOLEST.	20/10/90	0.0	0.4	MG/DL	0.60	0.60								
TRIGLYCERIDES	20/10/90	6.0	8.0	G/DL	7.00	6.60								
GLOBULINS: ALPHA 1	20/10/90	3.5	5.0	G/DL	4.20	4.00								
GLOBULINS: ALPHA 2	20/10/90	140.0	270.0	MG/DL	192.00	164.00								
GLOBULINS: BETA	20/10/90	35.0	175.0	MG/DL	72.00	53.00								
GLOBULINS: GAMMA	20/10/90	4.0	7.0	Z	2.90	3.00								
T3	20/10/90	7.0	11.0	Z	7.80	7.60								
T4	20/10/90	11.0	14.0	Z	11.80	11.90								
T3	20/10/90	15.0	22.0	Z	21.60	18.00								
T4	20/10/90	86.0	187.0	NG Z	120.00	8.60								
T4	20/10/90	4.5	12.5	NG/DL	8.60	8.60								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
1	24	LVF	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	25/06/91	16/07/91	30/07/91	13/08/91	19.00	14.30	14.30	19.00
				HTC	20/10/90	37.0	47.0	X	13.40	14.10	14.30	14.30	46.00	45.00	45.00	46.00
				RBC	20/10/90	3.8	5.4	10-6/MHC	4.80	4.90	4.90	4.90	4.90	4.90	4.90	4.90
				WBC	20/10/90	4.0	11.0	10-3/MHC	9.10	11.90	11.90	11.90	9.60	9.60	9.60	10.80
				HSC: N	20/10/90	40.0	70.0	X	46.00	71.00	71.00	71.00	56.00	56.00	56.00	82.00
				HSC: L	20/10/90	20.0	40.0	X	52.00	27.00	41.00	41.00	27.00	27.00	27.00	16.00
				HSC: E	20/10/90	1.0	5.0	X	1.00	1.00	2.00	2.00	1.00	1.00	1.00	1.00
				HSC: M	20/10/90	4.0	8.0	X	2.00	2.00	3.00	3.00	2.00	2.00	2.00	2.00
				HSC: B	20/10/90	0.0	1.0	X	0.00	0.00	1.00	1.00	0.00	0.00	0.00	0.00
				PLATELETS	20/10/90	150.0	550.0	10-3/MHC	190.00	201.00	181.00	190.00	190.00	181.00	181.00	190.00
				PL+	20/10/90	138.0	155.0	M EQ/L	138.00	137.00	139.00	139.00	139.00	139.00	139.00	139.00
				CL-	20/10/90	3.5	5.5	M EQ/L	4.00	4.20	4.20	4.40	4.40	4.20	4.20	4.40
				PO4--	20/10/90	98.0	120.0	M EQ/L	100.00	104.00	98.00	95.00	95.00	92.00	92.00	95.00
				CA++	20/10/90	8.5	10.5	MG/DL	8.10	10.40	9.30	9.20	9.20	9.30	9.30	9.20
				SGOT	20/10/90	3.0	4.5	MG/DL	3.00	4.20	4.00	4.00	3.50	4.00	4.00	3.50
				GAMMA-GT	20/10/90	12.0	40.0	MG/DL	20.00	27.00	27.00	22.00	22.00	22.00	22.00	22.00
				GLUCOSE	20/10/90	10.0	40.0	MU/HL	17.00	29.00	29.00	29.00	15.00	15.00	15.00	15.00
				ALK. PHOSPH.	20/10/90	7.0	33.0	MU/HL	31.00	29.00	113.00	123.00	123.00	113.00	113.00	123.00
				BUN	20/10/90	70.0	100.0	MG/DL	92.00	110.00	79.00	657.00	660.00	660.00	660.00	657.00
				CREATININE	20/10/90	0.6	5.0	MG/DL	21.00	21.00	20.00	19.00	20.00	20.00	19.00	19.00
				URIC ACID	20/10/90	2.4	5.7	MG/DL	3.20	2.00	2.10	2.60	2.60	2.10	2.10	2.60
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.40	0.60	0.60	0.80	0.60	0.60	0.60	0.80
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.30	0.30	0.30	0.30	0.20	0.20	0.30
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	5.90	7.20	7.20	6.90	6.90	6.60	6.60	6.90
				ALBUMINE	20/10/90	3.5	5.0	G/DL	3.90	4.00	4.00	3.80	3.80	3.90	3.90	3.80
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	259.00	330.00	299.00	299.00	299.00	299.00	299.00	299.00
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	136.00	69.00	109.00	97.00	97.00	109.00	97.00	97.00
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	X	2.80	4.80	3.10	3.80	3.80	3.10	3.10	3.80
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	X	9.10	11.50	9.70	10.60	10.60	9.70	9.70	10.60
				GLOBULINS: BETA	20/10/90	11.0	14.0	X	10.90	13.50	12.40	12.50	12.50	12.40	12.50	12.50
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	X	13.60	14.40	13.50	13.40	13.40	13.50	13.40	13.40
				T3	20/10/90	86.0	187.0	NG %	150.00	2.00	1.00	1.00	2.00	1.00	1.00	2.00
				T4	20/10/90	4.5	12.5	MG/DL	6.40	352.00	331.00	350.00	350.00	331.00	331.00	350.00
				PLATELETS	20/10/90	150.0	550.0	10-3/MHC	320.00	352.00	331.00	350.00	350.00	331.00	331.00	350.00
25	AMR		FEMALE	HB	20/10/90	12.0	16.0	G/100ML	28/06/91	19/07/91	02/08/91	16/08/91	11.30	12.60	12.60	13.10
				HTC	20/10/90	37.0	47.0	X	12.20	11.30	12.60	13.10	36.00	36.00	36.00	40.00
				RBC	20/10/90	3.8	5.4	10-6/MHC	4.20	4.00	4.20	4.40	4.20	4.20	4.20	4.40
				WBC	20/10/90	4.0	11.0	10-3/MHC	7.60	9.20	6.90	7.50	6.90	6.90	7.50	7.50
				HSC: N	20/10/90	40.0	70.0	X	66.00	62.00	69.00	54.00	69.00	69.00	54.00	54.00
				HSC: L	20/10/90	20.0	40.0	X	33.00	36.00	30.00	41.00	30.00	30.00	41.00	41.00
				HSC: E	20/10/90	1.0	5.0	X	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				HSC: M	20/10/90	4.0	8.0	X	1.00	2.00	1.00	2.00	1.00	1.00	2.00	2.00
				HSC: B	20/10/90	0.0	1.0	X	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				PLATELETS	20/10/90	150.0	550.0	10-3/MHC	320.00	352.00	331.00	350.00	350.00	331.00	331.00	350.00

1 5 6 0:

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Date	Laboratory Range			Screen	Virist			
						Min	Max	Unit		Week 2	Week 4	Week 6	
1	25	AMR	FEMALE	NA+	20/10/90	138.0	155.0	H EQ/L	138.00	135.00	141.00	140.00	
				K+	20/10/90	3.5	5.5	H EQ/L	4.30	4.40	4.50	4.70	
				CL-	20/10/90	98.0	120.0	H EQ/L	101.00	103.00	107.00	101.00	
				CA++	20/10/90	8.5	10.5	MG/DL	10.50	9.50	9.40	10.00	
				PO4-	20/10/90	3.0	4.5	MG/DL	3.50	4.00	3.90	4.40	
				SGOT	20/10/90	12.0	40.0	IU/ML	45.00	22.00	27.00	24.00	
				SGPT	20/10/90	10.0	40.0	IU/ML	59.00	38.00	32.00	32.00	
				GAMMA-GT	20/10/90	7.0	33.0	IU/ML	31.00	41.00	41.00	34.00	
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	91.00	91.00	90.00	85.00	
				BUN	20/10/90	65.0	306.0	IU/ML	253.00	215.00	263.00	235.00	
				ALK. PHOSPH.	20/10/90	10.0	50.0	MG/DL	27.00	27.00	25.00	31.00	
				CREATININE	20/10/90	0.6	1.6	MG/DL	1.70	1.00	1.00	1.00	
				URIC ACID	20/10/90	2.4	5.7	MG/DL	5.20	4.60	3.70	5.50	
				DIR BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.70	0.50	0.70	0.60	
				TOT. PROTEINS	20/10/90	6.0	8.0	MG/DL	0.20	0.20	0.20	0.30	
				ALBUMINE	20/10/90	3.5	5.0	G/DL	7.10	6.50	7.30	6.30	
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	4.10	3.80	4.10	3.80	
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	231.00	193.00	200.00	198.00	
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	X	134.00	82.00	120.00	95.00	
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	X	3.70	4.60	5.20	3.60	
				GLOBULINS: BETA	20/10/90	11.0	14.0	X	9.20	9.20	9.70	8.30	
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	X	13.80	14.80	13.20	11.90	
				T3	20/10/90	86.0	187.0	NG X	21.10	22.30	21.90	15.40	
				T4	20/10/90	4.5	12.5	NG/DL	150.00	150.00	150.00	150.00	
								8.60					
26	0C		FEMALE	HB	20/10/90	12.0	16.0	G/100ML	02/07/91	23/07/91	06/08/91	20/08/91	
				HTC	20/10/90	37.0	47.0	X	13.00	13.20	12.90	12.80	
				RBC	20/10/90	3.8	5.4	10-6/MHC	41.00	41.00	38.00	39.00	
				HBC: N	20/10/90	4.0	11.0	10-3/MHC	4.50	4.60	4.20	4.30	
				HBC: L	20/10/90	40.0	70.0	X	4.80	5.10	4.20	7.40	
				HBC: E	20/10/90	20.0	40.0	X	67.00	52.00	78.00	58.00	
				HBC: X	20/10/90	1.0	5.0	X	30.00	45.00	21.00	40.00	
				HSC: B	20/10/90	4.0	8.0	X	2.00	2.00	2.00	0.00	
				HSC: A	20/10/90	0.0	1.0	X	0.00	0.00	1.00	2.00	
				PLATELETS	20/10/90	150.0	550.0	10-3/MHC	0.00	0.00	0.00	0.00	
				Na+	20/10/90	138.0	155.0	H EQ/L	138.00	135.00	145.00	138.00	
				K+	20/10/90	3.5	5.5	H EQ/L	4.60	4.60	4.60	4.50	
				CL-	20/10/90	98.0	120.0	H EQ/L	101.00	99.00	105.00	97.00	
				CA++	20/10/90	8.5	10.5	MG/DL	10.00	10.00	9.00	9.00	
				PO4-	20/10/90	3.0	4.5	MG/DL	3.10	3.60	3.20	3.00	
				SGOT	20/10/90	12.0	40.0	IU/ML	22.00	22.00	19.00	17.00	
				SGPT	20/10/90	10.0	40.0	IU/ML	26.00	27.00	20.00	15.00	
				GAMMA-GT	20/10/90	7.0	33.0	IU/ML	20.00	21.00	21.00	27.00	
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	98.00	97.00	103.00	95.00	
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	204.00	181.00	228.00	200.00	
				BUN	20/10/90	10.0	50.0	MG/DL	31.00	25.00	36.00	31.00	
				CREATININE	20/10/90	0.6	1.6	MG/DL	1.00	1.00	0.70	0.90	
				URIC ACID	20/10/90	2.4	5.7	MG/DL	5.10	3.00	3.00	2.30	

1566

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOMETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit								
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
1	26	OC	FEMALE	TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60		0.70	0.30			
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30		0.40	0.10			
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.40	7.20	7.00	7.00			
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.40	4.00	4.00			
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	164.00	194.00	162.00	161.00			
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	54.00	62.00	58.00	66.00			
				GLORULINS: ALPHA 1	20/10/90	4.0	7.0	%	3.50	5.00	4.40	3.70			
				GLORULINS: ALPHA 2	20/10/90	7.0	11.0	%	6.20	9.00	8.90	6.50			
				GLORULINS: BETA	20/10/90	11.0	14.0	%	15.90	15.00	14.50	12.90			
				GLORULINS: GAMMA	20/10/90	15.0	22.0	%	16.80	16.00	14.60	16.70			
				T3	20/10/90	86.0	187.0	NG %	140.00						
				T4	20/10/90	4.5	12.5	NG/DL	7.40						
				27	RK	MALE	HB	20/10/90	16.0	18.0	g/100ml	13.20	05/07/91	09/08/91	23/08/91
							HTC	20/10/90	40.0	54.0	%	41.00	46.30	43.90	44.20
							RBC	20/10/90	4.3	6.1	10**6/mm	4.50	42.00	43.00	44.00
							MBC: N	20/10/90	4.0	11.0	10-3/HMC	4.80	4.60	4.50	4.60
							MBC: L	20/10/90	40.0	70.0	%	61.00	6.40	6.30	4.60
MBC: E	20/10/90	20.0	40.0				%	36.00	65.00	64.00	41.00				
MBC: M	20/10/90	1.0	5.0				%	3.00	34.00	35.00	34.00				
MBC: B	20/10/90	4.0	8.0				%	3.00	1.00	1.00	1.00				
PLATELETS	20/10/90	0.0	1.0				%	0.00	1.00	0.00	4.00				
NA+	20/10/90	150.0	550.0				10-3/HMC	299.00	0.00	0.00	0.00				
K+	20/10/90	135.0	155.0				M EQ/L	136.00	231.00	280.00	282.00				
CL-	20/10/90	98.0	120.0				M EQ/L	4.70	139.00	140.00	137.00				
CA++	20/10/90	8.5	10.5				MG/DL	100.00	4.70	4.50	4.50				
PO4-	20/10/90	3.0	4.5				MG/DL	9.80	101.00	102.00	97.00				
SGOT	20/10/90	12.0	40.0				NU/ML	3.30	9.90	10.00	8.80				
GAMMA-GT	20/10/90	11.0	51.0				NU/ML	23.00	3.20	3.30	3.90				
GLUCOSE	20/10/90	70.0	100.0				MG/DL	21.00	20.00	28.00	24.00				
ALK. PHOSP.	20/10/90	65.0	306.0				NU/ML	26.00	21.00	24.00	31.00				
CREATININE	20/10/90	10.0	50.0				MG/DL	101.00	30.00	30.00	21.00				
URIC ACID	20/10/90	0.6	1.6				MG/DL	30.00	83.00	80.00	98.00				
DIR BILIRUBIN	20/10/90	3.4	7.0				MG/DL	1.20	149.00	150.00	131.00				
TOT. PROTEINS	20/10/90	0.0	0.4				MG/DL	3.60	39.00	41.00	38.00				
ALBUMINE	20/10/90	0.0	8.0				G/DL	4.40	1.20	1.00	1.30				
TOT. CHOLEST.	20/10/90	3.5	5.0				G/DL	4.20	3.60	3.50	3.70				
TRIGLYCERIDES	20/10/90	140.0	270.0				MG/DL	4.40	0.70	0.70	0.90				
GLORULINS: ALPHA 1	20/10/90	35.0	175.0				MG/DL	0.40	0.40	0.40	0.50				
GLORULINS: ALPHA 2	20/10/90	4.0	7.0				%	6.50	6.70	6.50	6.30				
GLORULINS: BETA	20/10/90	7.0	11.0	%	4.20	4.20	4.00	4.00							
GLORULINS: GAMMA	20/10/90	11.0	14.0	%	219.00	221.00	225.00	227.00							
T3	20/10/90	15.0	22.0	%	55.00	66.00	70.00	67.00							
T4	20/10/90	4.5	12.5	NG/DL	3.70	4.60	4.60	4.10							
	20/10/90	86.0	187.0	NG %	14.70	12.80	12.80	12.30							
	20/10/90	4.5	12.5	NG/DL	22.90	16.90	16.90	13.20							
	20/10/90	86.0	187.0	NG %	100.00										
	20/10/90	4.5	12.5	NG/DL	5.80										

1 of 67

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 RENDINETINE - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Screen	Visit			
					Date	Min	Max		Unit	Week 2	Week 4	Week 6
1	28	RRM	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	09/07/91	30/07/91	13/08/91	27/08/91
				HTC	20/10/90	37.0	47.0	X	12.40	12.50	12.70	13.20
				RBC	20/10/90	3.8	5.4	10-6/MHC	38.00	38.00	37.00	39.00
				WBC	20/10/90	4.0	11.0	10-3/MHC	4.20	4.20	4.10	4.30
				MBC: N	20/10/90	40.0	70.0	X	6.30	5.90	6.40	5.80
				MBC: L	20/10/90	20.0	40.0	X	43.00	48.00	58.00	54.00
				MBC: E	20/10/90	1.0	5.0	X	52.00	48.00	41.00	40.00
				MBC: H	20/10/90	4.0	8.0	X	1.00	1.00	1.00	1.00
				MBC: B	20/10/90	0.0	1.0	X	5.00	4.00	0.00	6.00
				PLATELETS	20/10/90	150.0	550.0	10-3/MHC	323.00	296.00	300.00	285.00
				NA+	20/10/90	138.0	155.0	M EQ/L	140.00	138.00	165.00	139.00
				K+	20/10/90	3.5	5.5	M EQ/L	4.60	4.60	4.80	4.60
				CL-	20/10/90	98.0	120.0	M EQ/L	102.00	102.00	111.00	109.00
				PO4-	20/10/90	8.5	10.5	MG/DL	9.70	9.80	9.20	9.70
				SGOT	20/10/90	3.0	4.5	MG/DL	3.70	3.30	3.00	3.20
				GAMMA-GT	20/10/90	12.0	40.0	MU/ML	44.00	38.00	51.00	35.00
				GLUCOSE	20/10/90	10.0	40.0	MU/ML	72.00	49.00	58.00	54.00
				ALK. PHOSPH.	20/10/90	7.0	33.0	MU/ML	350.00	279.00	252.00	211.00
				CREATININE	20/10/90	70.0	100.0	MG/DL	100.00	103.00	105.00	86.00
				URIC ACID	20/10/90	65.0	306.0	MU/ML	423.00	375.00	368.00	362.00
				TOT. BILIRUBIN	20/10/90	10.0	50.0	MG/DL	54.00	40.00	37.00	38.00
				TOT. PROTEINS	20/10/90	0.6	1.6	MG/DL	1.40	1.30	1.20	1.20
				ALBUMINE	20/10/90	2.4	5.7	MG/DL	3.30	3.20	2.80	3.60
				TRIGLYCERIDES	20/10/90	0.0	1.0	MG/DL	0.40	0.20	0.40	0.50
				GLUCOLINS: ALPHA 1	20/10/90	0.0	0.4	MG/DL	0.20	0.20	0.20	0.20
				GLUCOLINS: ALPHA 2	20/10/90	6.0	8.0	G/DL	6.70	7.10	6.40	6.50
				GLUCOLINS: BETA	20/10/90	3.5	5.0	G/DL	4.20	4.30	4.00	4.10
				GLUCOLINS: GAMMA	20/10/90	140.0	270.0	MG/DL	233.00	206.00	193.00	217.00
				TOT. CHOLEST.	20/10/90	35.0	175.0	MG/DL	212.00	173.00	190.00	207.00
				GLUCOLINS: ALPHA 1	20/10/90	4.0	7.0	X	3.80	5.10	1.80	3.00
				GLUCOLINS: ALPHA 2	20/10/90	7.0	11.0	X	6.60	9.40	6.10	8.00
				GLUCOLINS: BETA	20/10/90	11.0	14.0	X	13.20	13.40	9.30	11.00
				GLUCOLINS: GAMMA	20/10/90	15.0	22.0	X	19.80	19.60	16.40	16.00
				TS	20/10/90	86.0	187.0	MG X	120.00			
				T4	20/10/90	4.5	12.5	MG/DL	6.80			
				HB	20/10/90	12.0	16.0	G/100ML	09/07/91	30/07/91	13/08/91	27/08/91
				HTC	20/10/90	37.0	47.0	X	12.00	12.50	13.00	12.70
				RBC	20/10/90	3.8	5.4	10-6/MHC	37.00	38.00	40.00	40.00
				WBC	20/10/90	4.0	11.0	10-3/MHC	4.20	4.40	4.50	4.40
				MBC: N	20/10/90	40.0	70.0	X	10.40	10.20	9.30	9.30
				MBC: L	20/10/90	20.0	40.0	X	69.00	74.00	71.00	71.00
				MBC: E	20/10/90	1.0	5.0	X	30.00	25.00	25.00	28.00
				MBC: H	20/10/90	4.0	8.0	X	6.00	4.00	7.00	7.00
				MBC: B	20/10/90	0.0	1.0	X	1.00	1.00	1.00	1.00
				PLATELETS	20/10/90	150.0	550.0	10-3/MHC	418.00	427.00	400.00	448.00

1568

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXEMINE - PROTOCOL 2012A/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
1	29	AFO	FEMALE	NA+	20/10/90	135.0	155.0	H EQ/L	137.00	140.00	137.00	137.00	137.00
				K+	20/10/90	3.5	5.5	H EQ/L	4.40	4.40	4.40	4.40	4.50
				CL-	20/10/90	98.0	120.0	H EQ/L	103.00	108.00	106.00	106.00	97.00
				CA++	20/10/90	8.5	10.5	MG/DL	9.70	9.80	9.70	9.70	8.80
				PO4--	20/10/90	3.0	4.5	MG/DL	2.80	3.10	3.20	3.20	3.00
				SGOT	20/10/90	12.0	40.0	HU/ML	14.00	22.00	24.00	24.00	67.00
				SGPT	20/10/90	10.0	40.0	HU/ML	11.00	21.00	14.00	14.00	92.00
				GAMMA-GT	20/10/90	7.0	33.0	HU/ML	24.00	22.00	29.00	29.00	32.00
				GLUCOSE	20/10/90	65.0	100.0	MG/DL	95.00	107.00	87.00	87.00	88.00
				ALK. PHOSPH.	20/10/90	10.0	50.0	MG/DL	213.00	239.00	262.00	262.00	264.00
				BUN	20/10/90	0.6	1.6	MG/DL	0.70	0.70	0.70	0.70	0.60
				CREATININE	20/10/90	2.4	5.7	MG/DL	4.20	1.80	1.60	1.60	2.40
				URIC ACID	20/10/90	0.2	1.0	MG/DL	0.60	0.60	0.60	0.70	0.70
				TOT. BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.20	0.20	0.20	0.30
				DIR. BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.20	0.20	0.20	0.30
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.30	7.00	7.00	7.00	6.90
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.00	4.00	3.90	3.90	3.90
				TRIGLYCERIDES	20/10/90	140.0	270.0	MG/DL	167.00	184.00	196.00	196.00	217.00
				CHOLEST.	20/10/90	35.0	175.0	MG/DL	83.00	55.00	91.00	91.00	77.00
				GLUCOLINS: ALPHA 1	20/10/90	4.0	7.0	Z	3.80	3.30	3.30	3.30	4.00
				GLUCOLINS: ALPHA 2	20/10/90	7.0	11.0	Z	9.50	8.40	8.80	8.80	10.00
				GLUCOLINS: BETA	20/10/90	11.0	14.0	Z	11.40	11.40	11.80	11.80	14.00
				GLUCOLINS: GAMMA	20/10/90	15.0	22.0	Z	12.40	19.40	19.60	19.60	21.00
				T3	20/10/90	86.0	187.0	NG X	150.00				
				T4	20/10/90	4.5	12.5	NG/DL	10.00				
30	ERV		MALE	HB	20/10/90	14.0	18.0	g/100ml	16.30	17.00	17.10	17.10	17.00
				HTC	20/10/90	40.0	54.0	Z	51.00	49.00	52.00	52.00	50.00
				RBC	20/10/90	4.3	6.1	10**6/mm	5.70	5.50	5.80	5.80	5.70
				HBC	20/10/90	4.0	11.0	10-3/HMC	6.80	6.50	6.80	6.80	6.90
				HBC: N	20/10/90	40.0	70.0	Z	63.00	56.00	61.00	61.00	60.00
				HBC: L	20/10/90	20.0	40.0	Z	35.00	40.00	35.00	35.00	36.00
				HBC: E	20/10/90	1.0	5.0	Z	5.00	0.00	1.00	1.00	1.00
				HBC: M	20/10/90	4.0	8.0	Z	2.00	4.00	4.00	4.00	4.00
				HBC: B	20/10/90	0.0	1.0	Z	0.00	0.00	0.00	0.00	0.00
				PLATELETS	20/10/90	150.0	550.0	10-3/HMC	281.00	283.00	278.00	278.00	270.00
				NA+	20/10/90	138.0	155.0	H EQ/L	140.00	139.00	138.00	138.00	140.00
				K+	20/10/90	3.5	5.5	M EQ/L	4.30	4.60	4.70	4.70	4.80
				CL-	20/10/90	98.0	120.0	H EQ/L	100.00	102.00	106.00	106.00	105.00
				CA++	20/10/90	8.5	10.5	MG/DL	9.60	9.70	9.70	9.70	9.80
				PO4--	20/10/90	3.0	4.5	MG/DL	3.60	3.50	3.20	3.20	3.20
				SGOT	20/10/90	12.0	40.0	HU/ML	35.00	43.00	33.00	33.00	30.00
				SGPT	20/10/90	10.0	40.0	HU/ML	49.00	91.00	66.00	66.00	58.00
				GAMMA-GT	20/10/90	11.0	51.0	HU/ML	58.00	64.00	75.00	75.00	70.00
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	98.00	100.00	102.00	102.00	100.00
				ALK. PHOSPH.	20/10/90	65.0	306.0	HU/ML	236.00	233.00	266.00	266.00	260.00
				BUN	20/10/90	10.0	50.0	MG/DL	21.00	36.00	25.00	25.00	25.00
				CREATININE	20/10/90	0.6	1.6	MG/DL	1.10	1.20	1.00	1.00	1.10
				URIC ACID	20/10/90	3.4	7.0	MG/DL	6.90	7.40	7.00	7.00	6.80

1-1 07 00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXYMINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range		Screen		Visit							
					Date	Min	Max	Unit	Week 2	Week 4	Week 6					
1	30	ERV	MALE	TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.50	0.80	0.80	0.70				
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.20	0.30	0.30				
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.00	7.10	7.60	7.60				
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	4.30	4.40	4.40				
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	215.00	250.00	270.00	270.00				
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	316.00	279.00	407.00	405.00				
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	2.90	2.50	4.10	4.00				
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	8.50	6.50	8.30	8.20				
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	14.10	11.70	11.50	11.40				
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	20.70	13.10	11.50	11.40				
				T3	20/10/90	86.0	187.0	NG %	160.00	160.00	16.90	16.90				
				T4	20/10/90	4.5	12.5	NG/DL	6.00	6.00						
				31	MAX		FEMALE	HB	20/10/90	12.0	16.0	G/100ML	13.00	13.00	13.10	13.50
								HTC	20/10/90	37.0	47.0	%	41.00	38.00	41.00	41.00
								RBC	20/10/90	3.8	5.4	10 ⁶ /MM ³	4.50	4.20	4.20	4.50
								HBC: N	20/10/90	4.0	11.0	10 ³ /MM ³	5.00	5.40	4.90	5.80
								HBC: L	20/10/90	40.0	70.0	%	36.00	57.00	64.00	64.00
								HBC: E	20/10/90	20.0	40.0	%	60.00	42.00	43.00	31.00
								HBC: M	20/10/90	1.0	5.0	%	2.00	1.00	2.00	1.00
								HBC: B	20/10/90	4.0	8.0	%	4.00	1.00	3.00	5.00
PLATELETS	20/10/90	0.0	1.0					%	0.00	0.00	0.00	0.00				
NA+	20/10/90	150.0	550.0					10 ³ /MM ³	294.00	247.00	286.00	294.00				
K+	20/10/90	138.0	155.0					M EQ/L	137.00	135.00	141.00	138.00				
CL-	20/10/90	98.0	120.0					M EQ/L	4.50	4.40	4.30	4.00				
PO4-	20/10/90	8.5	10.5					MG/DL	102.00	101.00	104.00	97.00				
SGPT	20/10/90	3.0	4.5					MG/DL	9.00	10.20	9.10	8.90				
GAMMA-GT	20/10/90	12.0	40.0					NU/ML	4.10	4.40	3.50	3.10				
GLUCOSE	20/10/90	7.0	33.0					NU/ML	22.00	15.00	19.00	24.00				
ALK. PHOSPH.	20/10/90	10.0	40.0					NU/ML	26.00	10.00	11.00	13.00				
CREATININE	20/10/90	70.0	100.0					MG/DL	96.00	18.00	16.00	18.00				
URIC ACID	20/10/90	65.0	306.0					NU/ML	127.00	101.00	78.00	97.00				
TOT BILIRUBIN	20/10/90	10.0	50.0					MG/DL	26.00	170.00	137.00	145.00				
DIR BILIRUBIN	20/10/90	0.6	1.6	MG/DL	1.10	1.00	1.10	1.10								
TOT. PROTEINS	20/10/90	2.4	5.7	MG/DL	2.60	2.10	2.70	2.50								
ALBUMINE	20/10/90	0.0	1.0	MG/DL	0.50	0.40	0.60	0.80								
TRIGLYCERIDES	20/10/90	6.0	6.0	G/DL	0.20	0.20	0.20	0.20								
TOT. CHOLEST.	20/10/90	3.5	5.0	G/DL	6.60	6.70	6.70	7.40								
GLOBULINS: ALPHA 1	20/10/90	440.0	270.0	MG/DL	4.10	4.00	4.10	4.00								
GLOBULINS: ALPHA 2	20/10/90	35.0	175.0	MG/DL	169.00	155.00	157.00	156.00								
GLOBULINS: BETA	20/10/90	4.0	7.0	%	109.00	92.00	103.00	106.00								
GLOBULINS: GAMMA	20/10/90	4.0	11.0	%	2.90	3.20	2.30	4.00								
T3	20/10/90	11.0	14.0	%	6.70	6.50	6.40	7.00								
T4	20/10/90	15.0	22.0	%	11.50	11.40	11.20	12.00								
	20/10/90	86.0	187.0	NG %	22.70	22.70	19.00	20.00								
	20/10/90	4.5	12.5	NG/DL	6.20	6.20										

1570

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REDOXETINE - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit				
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6
1	32	DGM	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	17/07/91	07/08/91	21/08/91	04/09/91
				HTC	20/10/90	37.0	47.0	X	12.60	14.10	13.70	12.60
				RBC	20/10/90	3.8	5.4	10-6/MHC	38.00	41.00	41.00	37.00
				WBC	20/10/90	4.0	11.0	10-3/MHC	4.50	4.90	4.90	4.50
				WBC: N	20/10/90	40.0	70.0	X	10.30	9.70	7.90	6.40
				WBC: L	20/10/90	20.0	40.0	X	61.00	74.00	64.00	69.00
				WBC: E	20/10/90	1.0	5.0	X	36.00	24.00	35.00	30.00
				WBC: M	20/10/90	4.0	8.0	X	0.00	1.00	1.00	1.00
				WBC: B	20/10/90	0.0	1.0	X	3.00	2.00	0.00	0.00
				PLATELETS	20/10/90	150.0	550.0	10-3/MHC	313.00	260.00	198.00	168.00
				Na+	20/10/90	138.0	155.0	M EQ/L	136.00	143.00	146.00	135.00
				K+	20/10/90	3.5	5.5	M EQ/L	4.10	4.50	4.10	4.00
				CL-	20/10/90	98.0	120.0	M EQ/L	98.00	107.00	107.00	97.00
				Ca++	20/10/90	8.5	10.5	MG/DL	9.60	9.60	9.70	9.90
				PO4-	20/10/90	3.0	4.5	MG/DL	4.20	4.30	4.30	3.20
				SGOT	20/10/90	12.0	40.0	IU/ML	18.00	15.00	19.00	56.00
				SGPT	20/10/90	10.0	40.0	IU/ML	21.00	13.00	17.00	91.00
				GAMMA-GT	20/10/90	7.0	33.0	IU/ML	36.00	35.00	32.00	66.00
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	84.00	88.00	106.00	85.00
				BUN	20/10/90	65.0	306.0	IU/ML	342.00	360.00	355.00	319.00
				CREATININE	20/10/90	0.6	5.0	MG/DL	10.00	12.00	16.00	15.00
				URIC ACID	20/10/90	2.4	1.6	MG/DL	0.60	0.80	0.90	0.60
				DIR BILIRUBIN	20/10/90	0.2	1.0	MG/DL	3.30	3.50	3.30	3.10
				TOT. BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.70	0.70	0.90
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	0.20	0.40	0.20	0.30
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	4.40	7.80	7.30
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	198.00	231.00	235.00	206.00
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	90.00	168.00	110.00	115.00
				GLOBALINS: ALPHA 1	20/10/90	4.0	7.0	X	4.10	3.10	4.20	4.30
				GLOBALINS: ALPHA 2	20/10/90	7.0	11.0	X	9.20	7.70	6.40	7.80
GLOBALINS: BETA	20/10/90	11.0	14.0	X	13.30	12.50	11.70	11.90				
GLOBALINS: GAMMA	20/10/90	15.0	22.0	X	23.40	18.60	19.10	20.30				
T3	20/10/90	86.0	187.0	NG %	170.00	0.00	0.00	0.00				
T4	20/10/90	4.5	12.5	NG/DL	11.50	0.00	0.00	0.00				
HB	20/10/90	14.0	18.0	g/100ml	17/07/91	07/08/91	21/08/91	04/09/91				
HTC	20/10/90	40.0	54.0	X	15.70	15.40	14.40	15.60				
RBC	20/10/90	4.3	6.1	10**6/mm	43.00	46.00	43.00	48.00				
WBC	20/10/90	4.0	11.0	10-3/MHC	4.80	5.10	4.70	5.30				
WBC: N	20/10/90	40.0	70.0	X	63.00	58.00	6.00	6.20				
WBC: L	20/10/90	20.0	40.0	X	36.00	64.00	56.00	55.00				
WBC: E	20/10/90	1.0	5.0	X	1.00	0.00	41.00	37.00				
WBC: M	20/10/90	4.0	8.0	X	1.00	4.00	2.00	2.00				
WBC: B	20/10/90	0.0	1.0	X	1.00	4.00	3.00	8.00				
PLATELETS	20/10/90	150.0	550.0	10-3/MHC	316.00	310.00	292.00	324.00				

1571

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
1	33	OFC	MALE	NA+	20/10/90	138.0	155.0	M EQ/L	136.00	135.00	141.00	136.00	
				K+	20/10/90	3.5	5.5	M EQ/L	4.80	4.20	4.20	4.30	
				CL-	20/10/90	98.0	120.0	M EQ/L	95.00	97.00	102.00	95.00	
				CA++	20/10/90	8.5	10.5	MG/DL	10.10	9.90	10.10	8.50	
				PO4-	20/10/90	3.0	4.5	MG/DL	3.20	3.60	2.70	3.70	
				SGOT	20/10/90	12.0	40.0	MIU/ML	27.00	25.00	22.00	29.00	
				SGPT	20/10/90	10.0	40.0	MIU/ML	13.00	19.00	18.00	14.00	
				GAMMA-GT	20/10/90	11.0	51.0	MIU/ML	30.00	27.00	29.00	41.00	
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	85.00	88.00	101.00	94.00	
				ALK. PHOSPH.	20/10/90	65.0	306.0	MIU/ML	175.00	180.00	169.00	165.00	
				BUN	20/10/90	10.0	50.0	MG/DL	32.00	26.00	24.00	22.00	
				CREATININE	20/10/90	0.6	1.6	MG/DL	1.00	1.00	0.90	1.10	
				URIC ACID	20/10/90	3.4	7.0	MG/DL	5.60	5.40	3.90	4.90	
				TOT. BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	0.30	0.60	0.60	
				DIR. BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.20	0.20	0.30	
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.40	7.60	7.00	6.70	
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.60	4.50	4.50	4.30	
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	186.00	163.00	164.00	168.00	
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	118.00	64.00	100.00	110.00	
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	3.80	2.70	2.70	3.00	
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	8.60	6.70	6.50	5.20	
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	13.20	12.30	12.70	9.30	
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	20.10	17.40	15.50	12.40	
				T3	20/10/90	86.0	187.0	NG %	160.00				
				T4	20/10/90	4.5	12.5	NG/DL	7.60				
34	GNH		FEMALE	HB	20/10/90	12.0	16.0	G/100HL	12.10	13.00	13.70	14.00	
				HTC	20/10/90	37.0	47.0	%	37.00	39.00	43.00	42.00	
				RBC	20/10/90	3.8	5.4	10 ⁶ /MMC	4.40	4.50	4.90	4.80	
				WBC	20/10/90	4.0	11.0	10 ³ /MMC	4.60	5.40	4.70	4.50	
				WBC: N	20/10/90	40.0	70.0	%	62.00	66.00	34.00	35.00	
				WBC: L	20/10/90	20.0	40.0	%	30.00	30.00	59.00	60.00	
				WBC: E	20/10/90	1.0	5.0	%	1.00	0.00	1.00	2.00	
				WBC: M	20/10/90	4.0	8.0	%	8.00	4.00	7.00	1.00	
				WBC: B	20/10/90	0.0	1.0	%	0.00	0.00	0.00	2.00	
				PLATELETS	20/10/90	150.0	550.0	10 ³ /MMC	222.00	221.00	266.00	260.00	
				NA+	20/10/90	138.0	155.0	M EQ/L	135.00	142.00	137.00	138.00	
				K+	20/10/90	3.5	5.5	M EQ/L	4.10	4.20	4.60	4.70	
				CL-	20/10/90	98.0	120.0	M EQ/L	98.00	105.00	100.00	101.00	
				CA++	20/10/90	8.5	10.5	MG/DL	8.60	9.30	9.30	9.40	
				PO4-	20/10/90	3.0	4.5	MG/DL	3.80	3.90	4.00	3.90	
				SGOT	20/10/90	12.0	40.0	MIU/ML	51.00	22.00	27.00	28.00	
				SGPT	20/10/90	10.0	40.0	MIU/ML	57.00	18.00	26.00	27.00	
				GAMMA-GT	20/10/90	7.0	33.0	MIU/ML	24.00	24.00	30.00	31.00	
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	81.00	81.00	94.00	90.00	
				ALK. PHOSPH.	20/10/90	65.0	306.0	MIU/ML	181.00	146.00	140.00	138.00	
				BUN	20/10/90	10.0	50.0	MG/DL	25.00	22.00	31.00	32.00	
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	1.00	0.80	0.90	
				URIC ACID	20/10/90	2.4	5.7	MG/DL	2.90	3.30	2.60	3.10	

1572

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
1	34	GRH	FEMALE	TOT BILIRUBIN	20/10/90	0.2	1.0	NG/DL	0.70	0.60	0.60	0.60	0.60			
				DIR BILIRUBIN	20/10/90	0.0	0.4	NG/DL	0.30	0.30	0.30	0.30				
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.50	7.50	7.50	7.00				
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.20	4.20	4.30				
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	347.00	271.00	268.00	270.00				
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	220.00	77.00	138.00	140.00				
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	2.90	3.00	3.00	5.50				
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	9.50	11.40	11.10	11.00				
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	14.30	13.70	13.60	13.50				
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	20.90	13.80	10.60	10.70				
				T3	20/10/90	86.0	187.0	NG %	140.00							
				T4	20/10/90	4.5	12.5	NG/DL	6.00							
				35	EMP		FEMALE	BB	20/10/90	12.0	16.0	G/100ML	12.40	12.00	12.00	12.00
								HTC	20/10/90	37.0	47.0	%	38.00	36.00	37.00	39.00
								RBC	20/10/90	3.8	5.4	10 ⁶ -6/MMC	4.40	4.40	4.40	4.60
								WBC	20/10/90	4.0	11.0	10 ³ -3/MMC	5.60	5.60	5.60	5.60
								RBC: N	20/10/90	40.0	70.0	%	43.00	60.00	54.00	50.00
RBC: L	20/10/90	20.0	40.0					%	50.00	36.00	40.00	47.00				
RBC: E	20/10/90	1.0	5.0					%	0.00	2.00	1.00	1.00				
RBC: M	20/10/90	4.0	8.0					%	7.00	4.00	6.00	2.00				
RBC: B	20/10/90	0.0	1.0					%	0.00	1.00	0.00	0.00				
PLATELETS	20/10/90	150.0	550.0					10 ³ -3/MMC	162.00	171.00	198.00	189.00				
NA+	20/10/90	138.0	155.0					M EQ/L	144.00	139.00	139.00	140.00				
K+	20/10/90	3.5	5.5					M EQ/L	4.30	4.60	4.60	4.60				
CL-	20/10/90	98.0	120.0					M EQ/L	104.00	97.00	96.00	97.00				
CA++	20/10/90	8.5	10.5					MG/DL	10.20	9.30	9.80	9.50				
PO4--	20/10/90	3.0	4.5					MG/DL	3.90	3.50	3.60	3.20				
SGPT	20/10/90	12.0	40.0					NU/ML	20.00	21.00	36.00	26.00				
GLUCOSE	20/10/90	10.0	40.0					NU/ML	15.00	15.00	18.00	15.00				
GAMMA-GT	20/10/90	7.0	33.0					NU/ML	31.00	22.00	26.00	20.00				
ALB	20/10/90	65.0	100.0					MG/DL	83.00	95.00	89.00	90.00				
ALK. PHOSPH.	20/10/90	10.0	306.0					NU/ML	137.00	119.00	152.00	90.00				
CREATININE	20/10/90	0.6	5.0					MG/DL	28.00	27.00	23.00	25.00				
URIC ACID	20/10/90	2.4	5.7					MG/DL	3.30	3.00	2.30	3.90				
TOT BILIRUBIN	20/10/90	0.2	1.0					MG/DL	0.70	0.50	0.80	0.60				
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.20	0.20	0.30								
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.80	6.40	7.00	7.20								
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.40	3.60	4.20	4.10								
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	206.00	174.00	181.00	192.00								
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	121.00	146.00	90.00	114.00								
GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	4.00	3.00	3.90	5.00								
GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	8.00	7.90	7.50	7.00								
GLOBULINS: BETA	20/10/90	11.0	14.0	%	13.00	12.20	12.90	15.90								
GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	15.00	16.80	17.90	16.80								
T3	20/10/90	86.0	187.0	NG %	120.00											
T4	20/10/90	4.5	12.5	NG/DL	11.00											

1573

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOMETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit								
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
1	36	LM	FEMALE	RB	20/10/90	12.0	16.0	G/100ML	20/08/91	10/09/91	24/09/91	08/10/91	12.60	13.10	13.30
				HTC	20/10/90	37.0	47.0	Z	12.60	13.00	13.10	13.30	40.00	40.00	42.00
				RBC	20/10/90	3.8	5.4	10-6/MHC	4.60	4.90	4.90	4.80	4.90	4.80	5.00
				MBC	20/10/90	4.0	11.0	10-3/MHC	7.50	9.70	9.70	9.60	9.70	8.20	8.20
				MBC: N	20/10/90	60.0	70.0	Z	56.00	54.00	55.00	55.00	50.00	50.00	50.00
				MBC: L	20/10/90	20.0	40.0	Z	43.00	43.00	42.00	40.00	40.00	40.00	40.00
				MBC: E	20/10/90	1.0	5.0	Z	3.00	1.00	1.00	1.00	3.00	3.00	3.00
				MBC: M	20/10/90	4.0	8.0	Z	1.00	3.00	3.00	3.00	5.00	5.00	5.00
				MBC: B	20/10/90	0.0	1.0	Z	1.00	1.00	1.00	1.00	2.00	2.00	2.00
				PLATELETS	20/10/90	150.0	550.0	10-3/MHC	355.00	348.00	320.00	300.00	300.00	300.00	300.00
				NA+	20/10/90	138.0	155.0	M EQ/L	139.00	138.00	142.00	140.00	140.00	140.00	140.00
				K+	20/10/90	3.5	5.5	M EQ/L	4.20	4.30	4.10	4.10	4.10	4.50	4.50
				CL-	20/10/90	98.0	120.0	M EQ/L	104.00	97.00	98.00	98.00	98.00	98.00	98.00
				CA++	20/10/90	8.5	10.5	MG/DL	9.80	10.10	9.80	9.80	9.80	10.00	10.00
				PO4-	20/10/90	3.0	4.5	MG/DL	3.20	2.90	3.10	3.10	3.10	3.00	3.00
				SGOT	20/10/90	12.0	40.0	NU/ML	16.00	14.00	15.00	15.00	18.00	18.00	18.00
				SGPT	20/10/90	10.0	40.0	NU/ML	20.00	16.00	16.00	16.00	20.00	20.00	20.00
				GAMMA-GT	20/10/90	7.0	33.0	NU/ML	26.00	21.00	21.00	20.00	22.00	22.00	22.00
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	98.00	110.00	100.00	100.00	110.00	110.00	110.00
				ALK. PHOSPH.	20/10/90	65.0	306.0	NU/ML	275.00	252.00	252.00	270.00	260.00	260.00	260.00
BUN	20/10/90	10.0	50.0	MG/DL	28.00	28.00	28.00	30.00	30.00	30.00	30.00				
CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	0.80	0.90	1.00	1.00	1.00	1.00				
URIC ACID	20/10/90	2.4	5.7	MG/DL	4.30	4.40	4.20	4.20	4.20	4.20	4.20				
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.30	0.70	0.60	0.60	0.60	0.60	0.60				
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.10	0.30	0.30	0.30	0.30	0.30	0.30				
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.70	6.80	6.80	6.60	6.60	6.60	6.60				
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.30	4.10	4.10	4.00	4.00	4.00	4.00				
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	191.00	183.00	173.00	190.00	190.00	190.00	190.00				
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	256.00	214.00	221.00	231.00	231.00	231.00	231.00				
GLORULINS: ALPHA 1	20/10/90	4.0	7.0	Z	3.00	1.90	1.90	2.00	2.00	2.00	2.00				
GLORULINS: ALPHA 2	20/10/90	7.0	11.0	Z	10.00	9.00	9.30	9.00	9.00	9.00	9.00				
GLORULINS: BETA	20/10/90	11.0	14.0	Z	13.00	12.10	11.80	12.50	12.50	12.50	12.50				
GLORULINS: GAMMA	20/10/90	15.0	22.0	Z	18.00	16.90	17.00	16.00	16.00	16.00	16.00				
T3	20/10/90	86.0	187.0	NG %	130.00										
T4	20/10/90	4.5	12.5	NG/DL	9.40										
37	RF	FEMALE	RB	20/10/90	12.0	16.0	G/100ML	27/08/91	17/09/91	01/10/91	15/10/91	13.20	12.60	12.60	
			HTC	20/10/90	37.0	47.0	Z	40.00	37.00	37.00	35.00	35.00	35.00	35.00	
			RBC	20/10/90	3.8	5.4	10-6/MHC	4.20	3.90	3.90	4.00	4.00	4.00	4.00	
			MBC	20/10/90	4.0	11.0	10-3/MHC	9.20	7.80	7.70	8.20	8.20	8.20	8.20	
			MBC: N	20/10/90	40.0	70.0	Z	56.00	55.00	55.00	52.00	52.00	52.00	52.00	
			MBC: L	20/10/90	20.0	40.0	Z	40.00	44.00	43.00	44.00	44.00	44.00	44.00	
			MBC: E	20/10/90	1.0	5.0	Z	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
			MBC: M	20/10/90	4.0	8.0	Z	2.00	1.00	2.00	2.00	2.00	2.00	2.00	
			MBC: B	20/10/90	0.0	1.0	Z	0.00	1.00	1.00	1.00	1.00	1.00	1.00	
			PLATELETS	20/10/90	150.0	550.0	10-3/MHC	395.00	413.00	370.00	378.00	378.00	378.00	378.00	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 RESOXETINE - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit					
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
1	37	FEMALE	NA+	20/10/90	138.0	155.0	M EQ/L	139.00	137.00	136.00	140.00	
			K+	20/10/90	3.5	5.5	M EQ/L	4.40	4.20	4.10	4.00	
			CL-	20/10/90	98.0	120.0	M EQ/L	96.00	96.00	99.00	97.00	
			CA++	20/10/90	8.5	10.5	MG/DL	8.40	8.40	8.90	9.00	
			PO4-	20/10/90	3.0	4.5	MG/DL	3.70	2.80	2.70	3.30	
			SGPT	20/10/90	12.0	40.0	IU/ML	24.00	33.00	20.00	26.00	
			GAMMA-GT	20/10/90	10.0	60.0	IU/ML	32.00	41.00	20.00	30.00	
			GLUCOSE	20/10/90	7.0	33.0	MU/ML	104.00	89.00	135.00	124.00	
			ALK. PHOSPH.	20/10/90	65.0	306.0	MU/ML	163.00	143.00	180.00	174.00	
			BUN	20/10/90	10.0	50.0	MG/DL	371.00	423.00	419.00	425.00	
			CREATININE	20/10/90	0.6	1.6	MG/DL	13.00	22.00	29.00	19.00	
			URIC ACID	20/10/90	2.4	5.7	MG/DL	4.60	5.30	5.80	6.30	
			TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.80	1.00	0.90	1.20	
			DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.40	0.20	0.30	
			TOT. PROTEINS	20/10/90	5.0	8.0	G/DL	7.20	6.70	6.80	7.30	
			ALBUMINE	20/10/90	3.5	5.0	G/DL	3.70	3.60	4.20	4.00	
			TOT. CHOLEST.	20/10/90	160.0	270.0	MG/DL	275.00	250.00	255.00	258.00	
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	190.00	184.00	163.00	230.00	
			GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	4.00	2.60	2.10	2.00	
			GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	8.00	8.30	7.00	7.00	
GLOBULINS: BETA	20/10/90	11.0	14.0	%	16.00	14.60	14.30	13.50				
GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	15.00	15.40	13.30	21.40				
T3	20/10/90	86.0	187.0	NG X	120.00							
T4	20/10/90	4.5	12.5	NG/DL	11.00							
38	DBF	MALE	HB	20/10/90	14.0	18.0	g/100ml	10/09/91	01/10/91	15/10/91	29/10/91	
			HTC	20/10/90	40.0	54.0	%	15.40	15.20	15.70	13.20	
			RBC	20/10/90	4.3	6.1	10**6/mm	44.00	45.00	45.00	39.00	
			HBC: N	20/10/90	4.0	11.0	10-3/MHC	4.90	4.90	5.00	4.30	
			HBC: L	20/10/90	40.0	70.0	%	6.60	6.40	6.40	5.70	
			HBC: E	20/10/90	20.0	40.0	%	67.00	77.00	56.00	71.00	
			HBC: M	20/10/90	1.0	5.0	%	32.00	22.00	40.00	25.00	
			HBC: B	20/10/90	4.0	8.0	%	1.00	1.00	0.00	1.00	
			PLATELETS	20/10/90	0.0	1.0	%	1.00	1.00	4.00	4.00	
			NA+	20/10/90	150.0	550.0	10-3/MHC	135.00	173.00	159.00	212.00	
			K+	20/10/90	3.5	5.5	M EQ/L	137.00	138.00	137.00	138.00	
			CL-	20/10/90	98.0	120.0	M EQ/L	4.00	4.10	4.20	4.20	
			CA++	20/10/90	8.5	10.5	MG/DL	93.00	96.00	96.00	98.00	
			PO4-	20/10/90	3.0	4.5	MG/DL	3.20	3.50	2.80	2.70	
			SGPT	20/10/90	12.0	40.0	IU/ML	179.00	177.00	242.00	162.00	
			GAMMA-GT	20/10/90	10.0	60.0	IU/ML	171.00	185.00	153.00	146.00	
			GLUCOSE	20/10/90	11.0	51.0	MU/ML	494.00	494.00	526.00	412.00	
			ALK. PHOSPH.	20/10/90	70.0	306.0	MG/DL	314.00	314.00	303.00	243.00	
			BUN	20/10/90	65.0	306.0	MU/ML	680.00	731.00	731.00	780.00	
			CREATININE	20/10/90	10.0	50.0	MG/DL	27.00	37.00	22.00	23.00	
URIC ACID	20/10/90	0.6	1.6	MG/DL	1.30	1.20	1.20	1.10				
	20/10/90	3.4	7.0	MG/DL	2.20	3.40	4.10	3.50				

15735

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Date	Laboratory Range		Unit	Screen	Visit					
					Min	Max			Week 2	Week 4	Week 6			
1	38 DBF	MALE	TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	1.30	0.40	1.30	1.10			
			DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.50	0.20	0.50	0.50			
			TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.80	7.80	8.00	7.10			
			ALBUMINE	20/10/90	3.5	5.0	G/DL	3.80	3.80	3.80	3.50			
			TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	174.00	183.00	199.00	175.00			
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	248.00	278.00	269.00	300.00			
			GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	X	3.30	2.50	2.70	2.90			
			GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	X	10.40	10.40	9.70	9.70			
			GLOBULINS: BETA	20/10/90	11.0	14.0	X	11.90	10.90	11.60	13.00			
			GLOBULINS: GAMA	20/10/90	15.0	22.0	X	26.20	22.40	27.50	25.30			
			T3	20/10/90	86.0	187.0	NG X	180.00						
			T4	20/10/90	4.5	12.5	NG/DL	11.00						
			39	ASS	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	17/09/91	08/10/91	22/10/91	05/11/91
						HTC	20/10/90	37.0	47.0	X	13.40	13.50	12.90	13.10
						RBC	20/10/90	3.8	5.4	10 ⁶ /MM ³	4.60	4.10	4.00	4.00
						HBC: N	20/10/90	4.0	11.0	10 ³ /MM ³	11.20	4.70	4.40	4.50
						HBC: L	20/10/90	40.0	70.0	X	70.00	82.00	80.00	10.50
						HBC: E	20/10/90	20.0	40.0	X	29.00	16.00	18.00	23.00
						HBC: M	20/10/90	1.0	5.0	X	1.00	3.00	2.00	2.00
						HBC: B	20/10/90	4.0	8.0	X	1.00	2.00	2.00	5.00
HBC: S	20/10/90	0.0				1.0	X	0.00	0.00	0.00	0.00			
PLATELETS	20/10/90	150.0				550.0	10 ³ /MM ³	259.00	256.00	232.00	266.00			
Na+	20/10/90	138.0				155.0	M EQ/L	137.00	138.00	137.00	136.00			
CL-	20/10/90	98.0				120.0	M EQ/L	4.00	4.00	4.10	4.60			
Ca++	20/10/90	8.5				10.5	MG/DL	95.00	95.00	97.00	97.00			
PO4--	20/10/90	3.0				4.5	MG/DL	3.60	3.60	3.60	3.50			
SGPT	20/10/90	12.0				40.0	IU/ML	18.00	16.00	24.00	20.00			
GAMMA-GT	20/10/90	7.0				33.0	IU/ML	12.00	14.00	19.00	21.00			
GLUCOSE	20/10/90	70.0				100.0	MG/DL	33.00	27.00	27.00	32.00			
ALK. PHOSPH.	20/10/90	65.0				306.0	IU/ML	100.00	105.00	84.00	82.00			
BUN	20/10/90	10.0				50.0	MG/DL	245.00	242.00	240.00	225.00			
CREATININE	20/10/90	0.6				1.6	MG/DL	1.00	0.90	1.00	1.00			
URIC ACID	20/10/90	2.4	5.7	MG/DL	2.80	3.10	2.70	2.90						
DIR BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	0.50	0.50	0.50						
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	0.20	0.20	0.30	0.30						
ALBUMINE	20/10/90	3.5	5.0	G/DL	6.70	7.10	6.80	7.10						
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	4.10	4.10	3.80	4.30						
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	229.00	258.00	224.00	220.00						
GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	X	140.00	95.00	94.00	150.00						
GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	X	3.10	3.40	3.10	3.50						
GLOBULINS: BETA	20/10/90	11.0	14.0	X	7.80	9.20	8.20	8.70						
GLOBULINS: GAMA	20/10/90	15.0	22.0	X	12.50	15.60	14.10	12.20						
T3	20/10/90	86.0	187.0	NG X	20.00	12.70	16.20	16.00						
T4	20/10/90	4.5	12.5	NG/DL	6.80									

1 5 1 6

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXYTINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit				
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6
1	40	EM	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	17/09/91	08/10/91	22/10/91	05/11/91
				HTC	20/10/90	37.0	47.0	%	17/09/91	08/10/91	22/10/91	05/11/91
				RBC	20/10/90	3.8	5.4	10 ⁶ -6/MHC	17/09/91	08/10/91	22/10/91	05/11/91
				WBC	20/10/90	4.0	11.0	10 ³ -3/MHC	17/09/91	08/10/91	22/10/91	05/11/91
				RBC: N	20/10/90	40.0	70.0	%	17/09/91	08/10/91	22/10/91	05/11/91
				RBC: L	20/10/90	20.0	40.0	%	17/09/91	08/10/91	22/10/91	05/11/91
				RBC: E	20/10/90	1.0	5.0	%	17/09/91	08/10/91	22/10/91	05/11/91
				RBC: N	20/10/90	4.0	8.0	%	17/09/91	08/10/91	22/10/91	05/11/91
				RBC: B	20/10/90	0.0	1.0	%	17/09/91	08/10/91	22/10/91	05/11/91
				PLATELETS	20/10/90	150.0	550.0	10 ³ -3/MHC	17/09/91	08/10/91	22/10/91	05/11/91
				H+	20/10/90	158.0	193.0	H EX/L	17/09/91	08/10/91	22/10/91	05/11/91
				CL-	20/10/90	98.0	120.0	H EX/L	17/09/91	08/10/91	22/10/91	05/11/91
				PO4-	20/10/90	3.0	4.5	MG/DL	17/09/91	08/10/91	22/10/91	05/11/91
				SGOT	20/10/90	12.0	40.0	IU/ML	17/09/91	08/10/91	22/10/91	05/11/91
				GAMMA-GT	20/10/90	7.0	33.0	IU/ML	17/09/91	08/10/91	22/10/91	05/11/91
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	17/09/91	08/10/91	22/10/91	05/11/91
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	17/09/91	08/10/91	22/10/91	05/11/91
				BUN	20/10/90	10.0	50.0	MG/DL	17/09/91	08/10/91	22/10/91	05/11/91
				CREATININE	20/10/90	0.6	1.6	MG/DL	17/09/91	08/10/91	22/10/91	05/11/91
				URIC ACID	20/10/90	2.4	5.7	MG/DL	17/09/91	08/10/91	22/10/91	05/11/91
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	17/09/91	08/10/91	22/10/91	05/11/91
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	17/09/91	08/10/91	22/10/91	05/11/91
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	17/09/91	08/10/91	22/10/91	05/11/91
				ALBUMINE	20/10/90	3.5	5.0	G/DL	17/09/91	08/10/91	22/10/91	05/11/91
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	17/09/91	08/10/91	22/10/91	05/11/91
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	17/09/91	08/10/91	22/10/91	05/11/91
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	17/09/91	08/10/91	22/10/91	05/11/91
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	17/09/91	08/10/91	22/10/91	05/11/91
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	17/09/91	08/10/91	22/10/91	05/11/91
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	17/09/91	08/10/91	22/10/91	05/11/91
				T3	20/10/90	86.0	187.0	NG %	17/09/91	08/10/91	22/10/91	05/11/91
				T4	20/10/90	4.5	12.5	NG/DL	17/09/91	08/10/91	22/10/91	05/11/91
				HB	20/10/90	14.0	18.0	G/100mL	17/09/91	08/10/91	22/10/91	05/11/91
				HTC	20/10/90	40.0	54.0	%	17/09/91	08/10/91	22/10/91	05/11/91
				RBC	20/10/90	4.3	6.1	10 ⁶ *6/mm	17/09/91	08/10/91	22/10/91	05/11/91
				WBC	20/10/90	4.0	11.0	10 ³ -3/MHC	17/09/91	08/10/91	22/10/91	05/11/91
				RBC: N	20/10/90	40.0	70.0	%	17/09/91	08/10/91	22/10/91	05/11/91
				RBC: L	20/10/90	20.0	40.0	%	17/09/91	08/10/91	22/10/91	05/11/91
				RBC: E	20/10/90	1.0	5.0	%	17/09/91	08/10/91	22/10/91	05/11/91
				RBC: N	20/10/90	4.0	8.0	%	17/09/91	08/10/91	22/10/91	05/11/91
				RBC: B	20/10/90	0.0	1.0	%	17/09/91	08/10/91	22/10/91	05/11/91
				PLATELETS	20/10/90	150.0	550.0	10 ³ -3/MHC	17/09/91	08/10/91	22/10/91	05/11/91
	41	SFS	MALE	HB	20/10/90	14.40	14.40		17/09/91	08/10/91	22/10/91	05/11/91
				HTC	20/10/90	43.00	43.00		17/09/91	08/10/91	22/10/91	05/11/91
				RBC	20/10/90	5.20	5.20		17/09/91	08/10/91	22/10/91	05/11/91
				WBC	20/10/90	6.60	6.60		17/09/91	08/10/91	22/10/91	05/11/91
				RBC: N	20/10/90	60.00	60.00		17/09/91	08/10/91	22/10/91	05/11/91
				RBC: L	20/10/90	26.00	26.00		17/09/91	08/10/91	22/10/91	05/11/91
				RBC: E	20/10/90	8.00	8.00		17/09/91	08/10/91	22/10/91	05/11/91
				RBC: N	20/10/90	2.00	2.00		17/09/91	08/10/91	22/10/91	05/11/91
				RBC: B	20/10/90	0.00	0.00		17/09/91	08/10/91	22/10/91	05/11/91
				PLATELETS	20/10/90	309.00	309.00		17/09/91	08/10/91	22/10/91	05/11/91

1577

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124-013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
1	41	SFS	MALE	NA+	20/10/90	138.0	155.0	M EQ/L	140.00	136.00	141.00	143.00	
				K+	20/10/90	3.5	5.5	M EQ/L	4.10	4.60	4.50	4.60	
				CL-	20/10/90	98.0	120.0	M EQ/L	98.00	96.00	96.00	98.00	
				CA++	20/10/90	8.5	10.5	MG/DL	9.40	10.30	10.20	10.10	
				PO4-	20/10/90	3.0	4.5	MG/DL	3.00	3.10	3.40	3.30	
				SGOT	20/10/90	12.0	40.0	IU/ML	25.00	12.00	26.00	36.00	
				SGPT	20/10/90	10.0	40.0	IU/ML	22.00	14.00	25.00	26.00	
				GAMMA-GT	20/10/90	11.0	51.0	IU/ML	33.00	30.00	41.00	47.00	
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	122.00	180.00	94.00	100.00	
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	262.00	255.00	307.00	300.00	
				BUN	20/10/90	10.0	50.0	MG/DL	16.00	21.00	20.00	21.00	
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.60	0.60	0.80	0.70	
				URIC ACID	20/10/90	3.4	7.0	MG/DL	6.70	6.80	5.60	6.00	
				TOT. BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.80	0.90	0.90	0.90	
				DIR. BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.20	0.20	0.40	
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.40	7.10	6.60	6.40	
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.40	4.30	4.10	4.00	
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	162.00	161.00	174.00	163.00	
				TRIGLICERIDES	20/10/90	35.0	175.0	MG/DL	131.00	116.00	159.00	162.00	
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	3.20	4.00	3.00	3.20	
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	7.90	7.60	7.50	7.60	
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	13.30	11.20	13.20	13.00	
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	16.80	16.50	13.90	13.70	
				T3	20/10/90	86.0	187.0	NG X	105.00				
				T4	20/10/90	4.5	12.5	NG/DL	7.20				
			FEMALE	HB	20/10/90	12.0	16.0	G/100ML	25.09/91	16/10/91	30/10/91	13/11/91	
				HTC	20/10/90	37.0	47.0	%	12.80	13.10	12.90	13.10	
				RBC	20/10/90	3.8	5.4	10-6/MNC	41.00	39.00	39.00	39.00	
				HBC: N	20/10/90	4.0	11.0	10-3/MNC	4.30	4.10	4.20	4.20	
				HBC: L	20/10/90	40.0	70.0	%	6.30	6.90	6.00	7.20	
				HBC: E	20/10/90	20.0	40.0	%	67.00	57.00	51.00	62.00	
				HBC: B	20/10/90	1.0	5.0	%	30.00	34.00	46.00	34.00	
				PLATELETS	20/10/90	4.0	8.0	%	20.00	21.00	9.00	15.00	
				NA+	20/10/90	0.0	1.0	%	3.00	1.00	3.00	4.00	
				K+	20/10/90	150.0	550.0	10-3/MNC	252.00	245.00	254.00	219.00	
				CL-	20/10/90	138.0	155.0	M EQ/L	141.00	141.00	140.00	141.00	
				PO4-	20/10/90	98.0	120.0	M EQ/L	96.00	97.00	97.00	99.00	
				SGOT	20/10/90	8.5	10.5	MG/DL	8.50	8.70	9.60	9.00	
				SGPT	20/10/90	3.0	4.5	MG/DL	3.20	3.80	3.60	3.50	
				GAMMA-GT	20/10/90	12.0	40.0	IU/ML	22.00	28.00	21.00	27.00	
				GLUCOSE	20/10/90	10.0	40.0	MG/DL	31.00	26.00	20.00	21.00	
				ALK. PHOSPH.	20/10/90	7.0	33.0	IU/ML	100.00	97.00	94.00	101.00	
				BUN	20/10/90	65.0	306.0	IU/ML	296.00	291.00	307.00	290.00	
				CREATININE	20/10/90	10.0	50.0	MG/DL	26.00	32.00	30.00	27.00	
				URIC ACID	20/10/90	0.6	1.6	MG/DL	0.70	0.60	0.70	0.60	
					20/10/90	2.4	5.7	MG/DL	2.10	3.20	4.00	1.60	

15 18 00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit								
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
1	42	FEMALE	TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.80	0.90	0.90	0.70				
			DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.30	0.40	0.40				
			TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.80	6.70	6.50	6.70				
			ALBUMINE	20/10/90	3.5	5.0	G/DL	4.00	3.90	4.00	4.30				
			TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	266.00	253.00	257.00	237.00				
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	136.00	127.00	130.00	105.00				
			GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	X	1.70	2.50	1.92	2.30				
			GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	X	5.30	7.00	6.00	5.20				
			GLOBULINS: BETA	20/10/90	11.0	14.0	X	12.50	13.00	13.90	10.80				
			GLOBULINS: GAMMA	20/10/90	15.0	22.0	X	19.50	19.00	19.20	16.60				
			T3	20/10/90	86.0	187.0	NG %	140.00							
			T4	20/10/90	4.5	12.5	NG/DL	8.00							
			43	ARN	MALE	HR	20/10/90	14.0	18.0	g/100ml	14.60	14.30	14.30	13/11/91	
						HCT	20/10/90	40.0	54.0	X	43.00	42.00	45.00	43.00	
						RBC	20/10/90	4.3	6.1	10 ⁶ *g/mm	4.80	4.80	4.90	4.80	
						HRC: N	20/10/90	4.0	11.0	10 ⁻³ /RMC	5.50	5.50	4.90	4.80	
						HRC: L	20/10/90	40.0	70.0	X	54.00	55.00	70.00	69.00	
						HRC: E	20/10/90	20.0	40.0	X	42.00	42.00	29.00	25.00	
						HRC: H	20/10/90	1.0	5.0	X	0.00	4.00	3.00	2.00	
						HRC: B	20/10/90	4.0	8.0	X	4.00	3.00	1.00	6.00	
PLATELETS	20/10/90	0.0				1.0	X	0.00	1.00	0.00	0.00				
NA+	20/10/90	150.0				550.0	10 ⁻³ /MHC	279.00	294.00	291.00	289.00				
CL-	20/10/90	138.0				155.0	M EQ/L	142.00	142.00	137.00	137.00				
PO4-	20/10/90	3.5				5.5	M EQ/L	4.50	4.50	4.30	4.60				
CA++	20/10/90	98.0				120.0	M EQ/L	96.00	99.00	98.00	99.00				
SGOT	20/10/90	8.5				10.5	MG/DL	10.30	9.00	9.60	9.30				
GAMMA-GT	20/10/90	3.0				4.5	MG/DL	4.70	3.80	3.50	3.00				
GLUCOSE	20/10/90	12.0				40.0	MU/HL	28.00	28.00	31.00	30.00				
ALK. PHOSPH.	20/10/90	11.0				51.0	MU/HL	58.00	40.00	62.00	54.00				
BUN	20/10/90	70.0				100.0	MG/DL	103.00	76.00	43.00	82.00				
CREATININE	20/10/90	65.0				306.0	MU/HL	141.00	103.00	98.00	109.00				
URIC ACID	20/10/90	10.0				50.0	MG/DL	37.00	38.00	30.00	33.00				
DIR BILIRUBIN	20/10/90	0.6	1.6	MG/DL	1.00	1.00	1.20	1.00							
TOT. PROTEINS	20/10/90	3.4	7.0	MG/DL	4.50	5.70	4.30	5.30							
ALBUMINE	20/10/90	0.2	1.0	MG/DL	0.50	0.60	0.70	0.80							
TOT. CHOLEST.	20/10/90	0.0	0.4	MG/DL	0.20	0.30	0.30	0.30							
TRIGLYCERIDES	20/10/90	6.0	8.0	G/DL	7.00	7.40	7.40	6.80							
GLOBULINS: ALPHA 1	20/10/90	3.5	5.0	G/DL	4.50	4.60	4.90	4.60							
GLOBULINS: ALPHA 2	20/10/90	140.0	270.0	MG/DL	290.00	253.00	250.00	257.00							
GLOBULINS: BETA	20/10/90	35.0	175.0	MG/DL	144.00	108.00	110.00	88.00							
GLOBULINS: GAMMA	20/10/90	4.0	7.0	X	2.40	2.10	2.50	2.30							
T3	20/10/90	7.0	11.0	X	7.30	7.20	6.90	6.90							
T4	20/10/90	11.0	14.0	X	12.40	12.90	13.20	12.20							
	20/10/90	15.0	22.0	X	16.10	15.90	13.70	13.70							
	20/10/90	86.0	187.0	NG %	110.00										
	20/10/90	4.5	12.5	NG/DL	8.40										

1379

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit						
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6		
1	44	MAL	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	01/10/91	22/10/91	05/11/91	19/11/91		
				HTC	20/10/90	37.0	47.0	Z	12.40	13.80	42.00	11.90		
				RBC	20/10/90	3.8	5.4	10-6/MHC	40.00	42.00	38.00	37.00		
				WBC	20/10/90	4.0	11.0	10-3/MHC	4.40	4.40	4.40	4.00		
				WBC: N	20/10/90	40.0	70.0	Z	5.80	9.60	4.80	4.80		
				WBC: L	20/10/90	20.0	40.0	Z	38.00	48.00	54.00	52.00		
				WBC: E	20/10/90	1.0	5.0	Z	58.00	64.00	40.00	36.00		
				WBC: M	20/10/90	4.0	8.0	Z	1.00	6.00	4.00	6.00		
				WBC: B	20/10/90	0.0	1.0	Z	4.00	8.00	3.00	5.00		
				PLATELETS	20/10/90	150.0	550.0	10-3/MHC	0.00	0.00	0.00	1.00		
				Na+	20/10/90	138.0	152.0	H EQ/L	395.00	343.00	355.00	350.00		
				K+	20/10/90	3.5	5.5	H EQ/L	139.00	140.00	139.00	140.00		
				Cl-	20/10/90	98.0	120.0	H EQ/L	4.10	4.60	4.30	4.20		
				Ca++	20/10/90	8.5	10.5	MG/DL	96.00	97.00	99.00	100.00		
				PO4--	20/10/90	3.0	4.5	MG/DL	3.40	4.60	4.70	4.70		
				SGOT	20/10/90	12.0	40.0	IU/ML	20.00	36.00	28.00	30.00		
				SGPT	20/10/90	10.0	40.0	IU/ML	20.00	48.00	31.00	27.00		
				GAMMA-GT	20/10/90	7.0	33.0	IU/ML	27.00	34.00	21.00	23.00		
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	89.00	100.00	94.00	91.00		
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	175.00	188.00	132.00	140.00		
				BUN	20/10/90	10.0	50.0	MG/DL	21.00	25.00	22.00	25.00		
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	0.80	1.00	0.80		
				URIC ACID	20/10/90	2.4	5.7	MG/DL	6.60	3.50	3.20	3.80		
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.70	0.70	0.50	0.80		
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.40	0.30	0.40		
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.70	6.30	6.40	6.40		
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	3.90	4.30	4.30		
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	173.00	173.00	174.00	162.00		
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	81.00	86.00	85.00	95.00		
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	Z	2.90	2.50	3.20	3.20		
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	Z	7.20	7.80	7.40	7.60		
				GLOBULINS: BETA	20/10/90	11.0	14.0	Z	10.80	10.90	10.40	10.20		
GLOBULINS: GAMMA	20/10/90	15.0	22.0	Z	17.80	16.50	14.40	14.40						
T3	20/10/90	86.0	187.0	NG Z	150.00									
T4	20/10/90	4.5	12.5	NG/DL	4.50									
45	DPS	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	01/10/91	22/10/91	05/11/91	19/11/91			
			HTC	20/10/90	37.0	47.0	Z	43.90	41.00	41.00	41.30			
			RBC	20/10/90	3.8	5.4	10-6/MHC	4.40	4.40	4.40	4.60			
			WBC	20/10/90	4.0	11.0	10-3/MHC	4.90	5.70	5.90	5.70			
			WBC: N	20/10/90	40.0	70.0	Z	71.00	71.00	62.00	61.00			
			WBC: L	20/10/90	20.0	40.0	Z	25.00	24.00	29.00	26.00			
			WBC: E	20/10/90	1.0	5.0	Z	3.00	4.00	2.00	6.00			
			WBC: M	20/10/90	4.0	8.0	Z	4.00	5.00	9.00	6.00			
			WBC: B	20/10/90	0.0	1.0	Z	0.00	0.00	0.00	1.00			
			PLATELETS	20/10/90	150.0	550.0	10-3/MHC	273.00	258.00	318.00	313.00			

1580

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range		Visit									
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
1	45	DPS	FEMALE	HA+	20/10/90	138.0	155.0	M EQ/L	140.00	142.00	138.00	136.00				
				K+	20/10/90	3.5	5.5	M EQ/L	4.70	4.60	3.60	4.10				
				CL-	20/10/90	98.0	120.0	M EQ/L	96.00	96.00	95.00	96.00				
				CA++	20/10/90	8.5	10.5	MG/DL	8.50	9.80	9.20	9.20				
				PO4-	20/10/90	3.0	4.5	MG/DL	3.50	3.40	3.90	4.20				
				SGPT	20/10/90	12.0	40.0	IU/ML	26.00	36.00	58.00	27.00				
				SGPT	20/10/90	10.0	40.0	IU/ML	18.00	28.00	28.00	37.00				
				GAMMA-GT	20/10/90	7.0	33.0	IU/ML	42.00	43.00	42.00	45.00				
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	94.00	91.00	100.00	116.00				
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	219.00	221.00	277.00	261.00				
				BUN	20/10/90	10.0	50.0	MG/DL	22.00	32.00	32.00	26.00				
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	0.80	0.90	0.80				
				URIC ACID	20/10/90	2.4	5.7	MG/DL	4.70	4.10	6.10	6.00				
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	1.00	1.10	1.00				
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.50	0.40	0.50				
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.70	6.50	7.20	7.00				
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	3.90	4.40	4.30				
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	208.00	203.00	200.00	240.00				
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	69.00	94.00	100.00	113.00				
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	3.30	3.90	2.90	2.80				
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	9.00	7.40	7.90	7.60				
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	13.60	13.20	12.70	13.10				
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	12.80	15.70	16.90	17.10				
				T3	20/10/90	86.0	187.0	NG %	110.00							
				T4	20/10/90	4.5	12.5	NG/DL	5.80							
				46	SP		FEMALE	HB	20/10/90	12.0	16.0	G/100ML	11.50	11.70	11.70	11.60
								HTC	20/10/90	37.0	47.0	%	36.00	37.00	38.00	37.00
								RRC	20/10/90	3.8	5.4	10 ⁶ -6/MHC	4.10	4.20	4.30	4.10
								NRC	20/10/90	4.0	11.0	10 ³ -3/MHC	5.90	5.00	7.40	4.90
								NRC: N	20/10/90	40.0	70.0	%	58.00	57.00	68.00	65.00
								NRC: L	20/10/90	20.0	40.0	%	40.00	41.00	30.00	31.00
								NRC: E	20/10/90	1.0	5.0	%	3.00	1.00	3.00	3.00
								NRC: H	20/10/90	4.0	8.0	%	2.00	2.00	2.00	4.00
								NRC: B	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00
								PLATELETS	20/10/90	150.0	550.0	10 ³ -3/MHC	246.00	246.00	229.00	201.00
								K+	20/10/90	138.0	155.0	M EQ/L	140.00	138.00	137.00	138.00
								CL-	20/10/90	98.0	120.0	M EQ/L	99.00	97.00	97.00	99.00
								PO4-	20/10/90	8.5	10.5	MG/DL	8.20	9.40	9.20	9.80
								SGPT	20/10/90	3.0	4.5	MG/DL	3.70	3.90	3.80	3.50
								SGPT	20/10/90	12.0	40.0	IU/ML	21.00	24.00	21.00	28.00
GAMMA-GT	20/10/90	10.0	40.0					IU/ML	10.00	20.00	19.00	29.00				
GLUCOSE	20/10/90	70.0	100.0					MG/DL	15.00	19.00	21.00	20.00				
ALK. PHOSPH.	20/10/90	65.0	306.0					IU/ML	285.00	276.00	269.00	260.00				
BUN	20/10/90	10.0	50.0					MG/DL	20.00	19.00	20.00	24.00				
CREATININE	20/10/90	0.6	1.6					MG/DL	0.80	0.60	0.70	0.70				
URIC ACID	20/10/90	2.4	5.7					MG/DL	2.90	3.00	2.80	3.70				
26			FEMALE					HB	26/11/91	12.20	11.70	G/100ML	11.60	11.70	11.60	11.60
								HTC	26/11/91	38.00	37.00	%	38.00	37.00	38.00	37.00
RRC	26/11/91	4.30	4.10					10 ⁶ -6/MHC	4.30	4.30	4.30	4.10				
NRC	26/11/91	7.40	7.40	10 ³ -3/MHC	6.80	5.00	7.40	4.90								
NRC: N	26/11/91	30.00	30.00	%	30.00	30.00	30.00	31.00								
NRC: L	26/11/91	3.00	3.00	%	3.00	3.00	3.00	3.00								
NRC: E	26/11/91	2.00	2.00	%	2.00	2.00	2.00	4.00								
NRC: H	26/11/91	0.00	0.00	%	0.00	0.00	0.00	0.00								
NRC: B	26/11/91	0.00	0.00	%	0.00	0.00	0.00	0.00								
PLATELETS	26/11/91	229.00	246.00	10 ³ -3/MHC	229.00	229.00	201.00	201.00								
K+	26/11/91	138.00	155.0	M EQ/L	137.00	138.00	138.00	138.00								
CL-	26/11/91	97.00	120.0	M EQ/L	97.00	97.00	99.00	99.00								
PO4-	26/11/91	9.20	10.5	MG/DL	9.20	9.20	9.20	9.80								
SGPT	26/11/91	3.80	4.5	MG/DL	3.80	3.90	3.80	3.50								
SGPT	26/11/91	21.00	40.0	IU/ML	21.00	24.00	21.00	28.00								
GAMMA-GT	26/11/91	19.00	40.0	IU/ML	19.00	19.00	21.00	20.00								
GLUCOSE	26/11/91	81.00	100.0	MG/DL	81.00	89.00	89.00	82.00								
ALK. PHOSPH.	26/11/91	276.00	306.0	IU/ML	269.00	276.00	269.00	260.00								
BUN	26/11/91	19.00	50.0	MG/DL	20.00	19.00	20.00	24.00								
CREATININE	26/11/91	0.60	1.6	MG/DL	0.80	0.60	0.70	0.70								
URIC ACID	26/11/91	3.00	5.7	MG/DL	2.80	3.00	2.80	3.70								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBORNEXINE - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
1	46	SP	FEMALE	TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	0.40	0.90	0.60	
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.20	0.20	0.30	
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.40	6.40	6.70	6.50	
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	4.40	4.40	4.30	
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	131.00	120.00	174.00	171.00	
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	84.00	84.00	82.00	68.00	
				GLOBALINS: ALPHA 1	20/10/90	4.0	7.0	%	3.10	3.00	3.10	2.80	
				GLOBALINS: ALPHA 2	20/10/90	7.0	11.0	%	7.10	7.10	7.60	7.10	
				GLOBALINS: BETA	20/10/90	11.0	14.0	%	11.00	10.10	13.30	10.90	
				GLOBALINS: GAMMA	20/10/90	15.0	22.0	%	13.20	9.40	9.10	13.40	
				T3	20/10/90	86.0	187.0	NG %	150.00				
				T4	20/10/90	4.5	12.5	NG/DL	7.00				
47	MCS		FEMALE	HB	20/10/90	12.0	16.0	G/100ML	13.40	14.00	13.90	13.50	
				HTC	20/10/90	37.0	47.0	%	40.00	43.00	41.00	42.00	
				RBC	20/10/90	3.8	5.4	10 ⁶ -6/MNC	4.60	4.80	4.60	4.80	
				RBC: N	20/10/90	4.0	11.0	10 ⁶ -3/MNC	8.90	7.20	7.80	8.10	
				RBC: L	20/10/90	40.0	70.0	%	65.00	57.00	56.00	51.00	
				RBC: E	20/10/90	20.0	40.0	%	32.00	41.00	42.00	47.00	
				RBC: M	20/10/90	1.0	5.0	%	1.00	0.00	2.00	0.00	
				RBC: B	20/10/90	4.0	8.0	%	3.00	2.00	2.00	2.00	
				PLATELETS	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	
				NA+	20/10/90	150.0	550.0	10 ³ -3/MNC	375.00	314.00	349.00	309.00	
				K+	20/10/90	138.0	155.0	M EQ/L	140.00	136.00	138.00	141.00	
				CL-	20/10/90	3.5	5.5	M EQ/L	4.10	4.40	4.80	3.80	
				PO4-	20/10/90	98.0	120.0	M EQ/L	96.00	95.00	96.00	95.00	
				SGPT	20/10/90	8.5	10.5	MG/DL	9.40	10.00	10.40	9.00	
				GLUCOSE	20/10/90	12.0	40.0	MG/DL	3.00	3.00	3.30	2.60	
				GAMMA-GT	20/10/90	10.0	40.0	NU/HL	19.00	20.00	26.00	26.00	
				ALK. PHOSPH.	20/10/90	7.0	33.0	NU/HL	30.00	35.00	32.00	28.00	
				BUN	20/10/90	70.0	100.0	MG/DL	109.00	100.00	93.00	107.00	
				CREATININE	20/10/90	65.0	306.0	NU/ML	190.00	196.00	183.00	178.00	
				URIC ACID	20/10/90	10.0	50.0	MG/DL	24.00	21.00	21.00	23.00	
				DIR BILIRUBIN	20/10/90	0.6	1.6	MG/DL	0.90	1.00	0.90	0.90	
				TOT. PROTEINS	20/10/90	2.4	5.7	MG/DL	4.30	4.10	3.20	4.00	
				ALBUMINE	20/10/90	0.2	1.0	MG/DL	0.50	0.40	0.60	0.40	
				TOT. CHOLEST.	20/10/90	0.0	0.4	MG/DL	0.20	0.20	0.30	0.20	
				TRIGLYCERIDES	20/10/90	6.0	8.0	G/DL	7.20	8.10	7.40	7.40	
				GLOBALINS: ALPHA 1	20/10/90	3.5	5.0	G/DL	4.00	4.60	4.50	4.40	
				GLOBALINS: ALPHA 2	20/10/90	140.0	270.0	MG/DL	248.00	234.00	190.00	181.00	
				GLOBALINS: BETA	20/10/90	35.0	175.0	MG/DL	88.00	88.00	97.00	89.00	
				GLOBALINS: GAMMA	20/10/90	4.0	7.0	%	3.20	1.90	1.90	2.90	
				T3	20/10/90	7.0	11.0	%	7.70	7.50	6.20	7.20	
				T4	20/10/90	11.0	14.0	%	12.70	13.30	12.70	11.70	
				T3	20/10/90	15.0	22.0	%	22.30	21.40	23.20	17.50	
				T4	20/10/90	86.0	187.0	NG %	120.00				
				T4	20/10/90	4.5	12.5	NG/DL	8.20				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Screen	Visit							
					Date	Min	Max		Unit	Week 2	Week 4	Week 6				
1	49	DAS	FEMALE	NA+	20/10/90	138.0	155.0	M EQ/L	141.00	141.00						
				K+	20/10/90	3.5	5.5	M EQ/L	5.00	4.20						
				CL-	20/10/90	98.0	120.0	M EQ/L	95.00	96.00						
				CA++	20/10/90	8.5	10.5	MG/DL	10.10	8.60						
				PO4--	20/10/90	3.0	4.5	MG/DL	2.60	4.00						
				SGOT	20/10/90	12.0	40.0	IU/ML	18.00	20.00						
				SGPT	20/10/90	10.0	40.0	IU/ML	20.00	24.00						
				GAMMA-GT	20/10/90	7.0	33.0	IU/ML	38.00	41.00						
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	105.00	110.00						
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	170.00	250.00						
				BUN	20/10/90	10.0	50.0	MG/DL	43.00	21.00						
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	0.80						
				URIC ACID	20/10/90	2.4	5.7	MG/DL	3.40	4.20						
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	0.80						
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.40						
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.50	6.30						
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.20						
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	232.00	224.00						
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	160.00	36.00						
				GLUCOLINS: ALPHA 1	20/10/90	4.0	7.0	%	1.90	2.70						
				GLUCOLINS: ALPHA 2	20/10/90	7.0	11.0	%	7.90	8.20						
				GLUCOLINS: BETA	20/10/90	11.0	14.0	%	12.50	11.30						
				GLUCOLINS: GAMMA	20/10/90	15.0	22.0	%	14.90	20.00						
				T3	20/10/90	86.0	187.0	NG %	115.00							
				T4	20/10/90	4.5	12.5	NG/DL	8.00							
				50	MFA	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	9.60	18/10/91	08/11/91	22/11/91	06/12/91
							HTC	20/10/90	37.0	47.0	%	31.00	10.10	10.70	9.50	
							RBC	20/10/90	3.8	5.4	10 ⁶ -6/MHC	4.20	32.00	33.00	30.00	
							MBC	20/10/90	4.0	11.0	10 ³ -3/MHC	7.70	4.40	4.50	4.10	
							MBC: N	20/10/90	40.0	70.0	%	80.00	6.10	7.50	7.60	
							MBC: L	20/10/90	20.0	40.0	%	16.00	69.00	73.00	76.00	
							MBC: E	20/10/90	1.0	5.0	%	29.00	23.00	21.00	21.00	
							MBC: M	20/10/90	4.0	8.0	%	4.00	3.00	3.00	1.00	
							MBC: B	20/10/90	0.0	1.0	%	0.00	2.00	4.00	3.00	
PLATELETS	20/10/90	150.0	550.0				10 ³ -3/MHC	247.00	277.00	297.00	271.00					
NA+	20/10/90	138.0	155.0				M EQ/L	140.00	140.00	138.00	139.00					
K+	20/10/90	3.5	5.5				M EQ/L	3.90	3.90	3.80	4.00					
CL-	20/10/90	98.0	120.0				M EQ/L	98.00	97.00	95.00	99.00					
CA++	20/10/90	8.5	10.5				MG/DL	9.40	9.70	9.70	9.20					
PO4--	20/10/90	3.0	4.5				MG/DL	2.90	4.00	3.30	3.30					
SGOT	20/10/90	12.0	40.0				IU/ML	14.00	18.00	28.00	20.00					
SGPT	20/10/90	10.0	40.0				IU/ML	12.00	22.00	34.00	15.00					
GAMMA-GT	20/10/90	7.0	33.0				IU/ML	21.00	27.00	27.00	22.00					
GLUCOSE	20/10/90	70.0	100.0				MG/DL	93.00	77.00	73.00	101.00					
ALK. PHOSPH.	20/10/90	65.0	306.0				IU/ML	127.00	177.00	163.00	145.00					
BUN	20/10/90	10.0	50.0				MG/DL	25.00	29.00	17.00	35.00					
CREATININE	20/10/90	0.6	1.6				MG/DL	1.00	0.80	0.80	0.90					
URIC ACID	20/10/90	2.4	5.7				MG/DL	3.00	3.40	2.90	3.10					

1584

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS P&D
 REMOXYLINE - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit										
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6						
1	50	MFA	FEMALE	TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.50	0.50	0.50	0.50	0.50	0.50				
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.30	0.20	0.30	0.20	0.20	0.20			
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.60	6.60	7.10	7.50	6.70	6.70	6.70			
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.40	4.40	4.50	4.50	4.50	3.70			
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	108.00	118.00	144.00	144.00	144.00	144.00	137.00			
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	72.00	66.00	66.00	66.00	66.00	66.00	77.00			
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	g	3.50	2.40	2.40	2.50	2.40	2.40	2.40			
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	g	7.70	6.70	6.70	7.40	7.10	7.10	7.10			
				GLOBULINS: BETA	20/10/90	11.0	14.0	g	10.80	11.30	11.30	11.30	11.30	11.30	10.70			
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	g	15.00	18.30	18.30	17.80	17.80	17.80	17.80			
				T3	20/10/90	86.0	187.0	NG %	90.00									
				T4	20/10/90	4.5	12.5	NG/DL	8.60									
				51	ASA	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	18/10/91	12.00	12.00	11.90	11.50	06/12/91	11.50
							HTC	20/10/90	37.0	47.0	%	36.00	36.00	36.00	36.00	36.00	36.00	34.00
RBC	20/10/90	3.8	5.4				10 ⁶ /MM ³	3.70	4.00	4.00	4.50	4.50	4.50	3.50				
WBC	20/10/90	4.0	11.0				10 ³ /MM ³	5.30	6.00	6.00	6.00	6.00	6.00	4.50				
HBC: N	20/10/90	40.0	70.0				%	67.00	55.00	55.00	59.00	59.00	59.00	56.00				
HBC: L	20/10/90	20.0	40.0				%	30.00	30.00	30.00	30.00	30.00	30.00	42.00				
HBC: E	20/10/90	1.0	5.0				%	0.00	0.00	0.00	1.00	1.00	1.00	1.00				
HBC: M	20/10/90	4.0	8.0				%	3.00	9.00	9.00	11.00	11.00	11.00	2.00				
HBC: B	20/10/90	0.0	1.0				%	0.00	1.00	1.00	0.00	0.00	0.00	0.00				
PLATELETS	20/10/90	150.0	550.0				10 ³ /MM ³	211.00	211.00	211.00	187.00	187.00	187.00	198.00				
NA+	20/10/90	138.0	155.0				M EQ/L	142.00	139.00	139.00	136.00	136.00	136.00	136.00				
CL-	20/10/90	98.0	120.0				M EQ/L	96.00	96.00	96.00	97.00	97.00	97.00	98.00				
PO4--	20/10/90	3.0	4.5				MG/DL	2.60	3.80	3.80	2.60	2.60	2.60	2.00				
SGPT	20/10/90	12.0	40.0				NU/ML	29.00	20.00	20.00	40.00	40.00	40.00	22.00				
GAMMA-GT	20/10/90	10.0	40.0	NU/ML	19.00	22.00	22.00	53.00	53.00	53.00	15.00							
GLUCOSE	20/10/90	7.0	33.0	MG/DL	21.00	26.00	26.00	52.00	52.00	52.00	30.00							
ALK. PHOSPH.	20/10/90	65.0	306.0	NU/ML	96.00	87.00	87.00	95.00	95.00	95.00	95.00							
CREATININE	20/10/90	0.6	5.0	MG/DL	232.00	186.00	186.00	272.00	272.00	272.00	208.00							
URIC ACID	20/10/90	2.4	11.6	MG/DL	2.00	2.00	2.00	16.00	16.00	16.00	16.00							
DIR BILIRUBIN	20/10/90	0.2	5.7	MG/DL	3.10	4.00	4.00	0.70	0.70	0.70	0.60							
TOT. PROTEINS	20/10/90	6.0	11.0	MG/DL	0.50	0.80	0.80	0.70	0.70	0.70	0.60							
ALBUMINE	20/10/90	3.5	5.0	G/DL	7.40	7.30	7.30	6.60	6.60	6.60	6.60							
TRIGLYCERIDES	20/10/90	140.0	270.0	MG/DL	4.30	4.30	4.30	4.50	4.50	4.50	4.20							
GLOBULINS: ALPHA 1	20/10/90	35.0	175.0	MG/DL	51.00	192.00	192.00	171.00	171.00	171.00	107.00							
GLOBULINS: ALPHA 2	20/10/90	4.0	7.0	g	2.30	96.00	96.00	2.50	2.50	2.50	60.00							
GLOBULINS: BETA	20/10/90	7.0	11.0	g	7.20	7.20	7.20	6.20	6.20	6.20	1.10							
GLOBULINS: GAMMA	20/10/90	15.0	22.0	g	11.00	11.00	11.00	18.90	18.90	18.90	5.60							
T3	20/10/90	86.0	187.0	NG %	86.00	86.00	86.00	86.00	86.00	86.00	86.00							
T4	20/10/90	4.5	12.5	NG/DL	7.60													

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Screen		Week 2		Week 4		Week 6	
					Date	Min	Max	Unit	Screen	Unit	Screen	Unit	Screen	Unit	Screen
1	52	MTS	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	23/10/91	13.20	14.20	13.80	14.20	11/12/91	12.70
				HTC	20/10/90	37.0	47.0	%	23/10/91	40.00	40.00	43.00	40.00	11/12/91	39.00
				RBC	20/10/90	3.8	5.4	10 ⁶ -6/MHC	23/10/91	4.80	4.70	5.10	4.60	11/12/91	4.60
				RBC: N	20/10/90	4.0	11.0	10 ³ -3/MHC	23/10/91	8.50	6.00	6.00	6.00	11/12/91	8.10
				RBC: L	20/10/90	40.0	70.0	%	23/10/91	54.00	58.00	65.00	54.00	11/12/91	71.00
				RBC: E	20/10/90	20.0	40.0	%	23/10/91	39.00	33.00	34.00	33.00	11/12/91	25.00
				RBC: M	20/10/90	1.0	5.0	%	23/10/91	2.00	3.00	1.00	1.00	11/12/91	2.00
				RBC: B	20/10/90	4.0	8.0	%	23/10/91	7.00	6.00	1.00	1.00	11/12/91	2.00
				PLATELETS	20/10/90	0.0	1.0	%	23/10/91	0.00	0.00	0.00	0.00	11/12/91	0.00
				HA+	20/10/90	150.0	550.0	10 ³ -3/MHC	23/10/91	252.00	310.00	283.00	310.00	11/12/91	257.00
				K+	20/10/90	138.0	155.5	M EQ/L	23/10/91	139.00	142.00	140.00	140.00	11/12/91	140.00
				CL-	20/10/90	3.5	5.5	M EQ/L	23/10/91	4.80	6.00	5.60	6.00	11/12/91	4.50
				CA++	20/10/90	98.0	120.0	M EQ/L	23/10/91	98.00	96.00	96.00	96.00	11/12/91	96.00
				PO4--	20/10/90	8.5	10.5	MG/DL	23/10/91	9.70	10.20	10.10	10.10	11/12/91	9.40
				SGPT	20/10/90	3.0	4.5	MG/DL	23/10/91	3.90	3.60	3.70	3.70	11/12/91	3.30
				GAMMA-GT	20/10/90	12.0	40.0	MG/DL	23/10/91	34.00	26.00	31.00	31.00	11/12/91	24.00
				GLUCOSE	20/10/90	70.0	33.0	MU/ML	23/10/91	25.00	28.00	32.00	32.00	11/12/91	17.00
				ALK. PHOSPH.	20/10/90	7.0	100.0	MG/DL	23/10/91	40.00	50.00	30.00	30.00	11/12/91	35.00
				BUN	20/10/90	65.0	306.0	MU/ML	23/10/91	86.00	94.00	89.00	89.00	11/12/91	83.00
				CREATININE	20/10/90	10.0	50.0	MG/DL	23/10/91	24.00	24.00	206.00	210.00	11/12/91	210.00
				URIC ACID	20/10/90	0.6	1.6	MG/DL	23/10/91	0.80	0.80	19.00	19.00	11/12/91	18.00
				TOT BILIRUBIN	20/10/90	2.4	5.7	MG/DL	23/10/91	3.10	4.80	5.90	5.90	11/12/91	3.00
				DIR BILIRUBIN	20/10/90	0.2	1.0	MG/DL	23/10/91	0.40	0.60	1.00	1.00	11/12/91	1.00
				TOT. PROTEINS	20/10/90	6.0	8.0	MG/DL	23/10/91	0.20	0.30	0.50	0.50	11/12/91	0.50
				ALBUMINE	20/10/90	3.5	5.0	G/DL	23/10/91	7.30	7.40	7.40	7.40	11/12/91	6.90
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	23/10/91	4.30	4.30	4.30	4.30	11/12/91	4.50
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	23/10/91	174.00	182.00	199.00	199.00	11/12/91	130.00
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	23/10/91	135.00	110.00	62.00	62.00	11/12/91	148.00
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	23/10/91	3.80	4.10	3.10	3.10	11/12/91	2.70
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	23/10/91	8.60	16.10	8.00	8.00	11/12/91	6.70
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	23/10/91	11.20	13.30	12.00	12.00	11/12/91	9.40
				T3	20/10/90	86.0	187.0	NG %	23/10/91	170.00	20.00	20.00	20.00	11/12/91	16.20
				T4	20/10/90	4.5	12.5	MG/DL	23/10/91	9.60	9.60	312.00	312.00	11/12/91	349.00
				PLATELETS	20/10/90	150.0	550.0	10 ³ -3/MHC	23/10/91	313.00	313.00	319.00	319.00	11/12/91	312.00
53	JFT		FEMALE	HB	20/10/90	12.0	16.0	G/100ML	25/10/91	13.30	13.40	12.50	13.40	11/12/91	12.60
				HTC	20/10/90	37.0	47.0	%	25/10/91	39.00	39.00	42.00	42.00	11/12/91	36.00
				RBC	20/10/90	3.8	5.4	10 ⁶ -6/MHC	25/10/91	4.30	4.30	4.20	4.20	11/12/91	4.20
				RBC: N	20/10/90	4.0	11.0	10 ³ -3/MHC	25/10/91	5.40	6.70	7.80	7.80	11/12/91	5.50
				RBC: L	20/10/90	40.0	70.0	%	25/10/91	43.00	51.00	58.00	58.00	11/12/91	48.00
				RBC: E	20/10/90	20.0	40.0	%	25/10/91	55.00	45.00	33.00	33.00	11/12/91	50.00
				RBC: M	20/10/90	1.0	5.0	%	25/10/91	2.00	5.00	5.00	5.00	11/12/91	5.00
				RBC: B	20/10/90	4.0	8.0	%	25/10/91	2.00	4.00	4.00	4.00	11/12/91	2.00
				PLATELETS	20/10/90	150.0	550.0	10 ³ -3/MHC	25/10/91	313.00	313.00	319.00	319.00	11/12/91	349.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Screen		Visit			
					Date	Min	Max	Unit	Week 2	Week 4	Week 6		
1	53	JFT	FEMALE	NA+	20/10/90	138.0	155.0	M EQ/L	140.00	140.00	142.00	140.00	
				K+	20/10/90	3.5	5.5	M EQ/L	4.70	4.70	3.70	3.70	5.10
				CL-	20/10/90	98.0	120.0	M EQ/L	98.00	98.00	97.00	97.00	98.00
				CA++	20/10/90	8.5	10.5	MG/DL	9.60	9.60	9.80	9.80	9.70
				PO4--	20/10/90	3.0	4.5	MG/DL	4.50	4.50	4.50	4.50	4.70
				SGPT	20/10/90	12.0	40.0	IU/ML	23.00	23.00	28.00	29.00	31.00
				SGPT	20/10/90	10.0	40.0	IU/ML	26.00	26.00	29.00	34.00	30.00
				GAMMA-GT	20/10/90	7.0	33.0	IU/ML	32.00	32.00	41.00	37.00	37.00
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	133.00	133.00	109.00	105.00	113.00
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	422.00	422.00	508.00	230.00	348.00
				BUN	20/10/90	10.0	50.0	MG/DL	30.00	30.00	23.00	32.00	31.00
				CREATININE	20/10/90	0.4	1.6	MG/DL	0.90	0.90	0.70	1.00	0.90
				URIC ACID	20/10/90	2.4	5.7	MG/DL	3.10	3.10	2.80	4.20	4.30
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.50	0.50	0.50	0.60	0.60
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.30	0.30	0.20	0.20
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.20	7.20	7.20	7.10	7.10
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.40	4.40	4.60	4.20	4.50
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	270.00	270.00	250.00	198.00	236.00
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	227.00	227.00	157.00	76.00	182.00
				GLUCOLINS: ALPHA 1	20/10/90	4.0	7.0	Z	3.20	3.20	2.20	1.40	1.40
GLUCOLINS: ALPHA 2	20/10/90	7.0	11.0	Z	7.90	7.90	6.60	4.90	5.40				
GLUCOLINS: BETA	20/10/90	11.0	14.0	Z	14.00	14.00	12.80	11.80	13.90				
GLUCOLINS: GAMMA	20/10/90	15.0	22.0	Z	16.40	16.40	15.20	18.30	16.90				
T3	20/10/90	86.0	187.0	NG X	130.00	130.00							
T4	20/10/90	4.5	12.5	NG/DL	7.20	7.20							
15887	54	JD	FEMALE	HB	20/10/91	12.0	16.0	G/100ML	29/10/91	19/11/91	03/12/91		
				HTC	20/10/90	37.0	47.0	Z	13.20	12.80	13.10		
				RBC	20/10/90	3.8	5.4	10 ⁶ /HMC	39.00	38.00	40.00		
				MBC	20/10/90	4.0	11.0	10 ³ /HMC	4.30	4.20	4.40		
				MBC: N	20/10/90	40.0	70.0	Z	7.90	7.80	8.80		
				MBC: L	20/10/90	20.0	40.0	Z	50.00	65.00	63.00		
				MBC: E	20/10/90	1.0	5.0	Z	42.00	34.00	34.00		
				MBC: M	20/10/90	4.0	8.0	Z	0.00	0.00	0.00		
				MBC: B	20/10/90	0.0	1.0	Z	8.00	1.00	3.00		
				PLATELETS	20/10/90	150.0	550.0	10 ³ /HMC	0.00	0.00	0.00		
				NA+	20/10/90	138.0	155.0	M EQ/L	359.00	368.00	406.00		
				K+	20/10/90	3.5	5.5	M EQ/L	136.00	137.00	140.00		
				CL-	20/10/90	98.0	120.0	M EQ/L	6.30	6.30	6.50		
				CA++	20/10/90	8.5	10.5	MG/DL	96.00	95.00	95.00		
				PO4--	20/10/90	3.0	4.5	MG/DL	3.20	3.20	3.50		
				SGPT	20/10/90	12.0	40.0	IU/ML	30.00	21.00	28.00		
				SGPT	20/10/90	10.0	40.0	IU/ML	19.00	16.00	20.00		
				GAMMA-GT	20/10/90	7.0	33.0	IU/ML	28.00	28.00	29.00		
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	94.00	97.00	93.00		
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	181.00	189.00	215.00		
BUN	20/10/90	10.0	50.0	MG/DL	19.00	17.00	30.00						
CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	0.70	0.80						
URIC ACID	20/10/90	2.4	5.7	MG/DL	2.30	3.00	3.60						

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOMETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
1	54	JD	FEMALE	TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	0.50	0.60	0.60	0.60
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.20	0.30	0.30	0.30
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.20	6.90	7.70	7.70	7.70
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.60	4.30	4.80	4.80	4.80
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	198.00	180.00	216.00	216.00	216.00
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	93.00	93.00	99.00	99.00	99.00
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	2.10	1.30	1.20	1.20	1.20
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	7.60	7.80	8.40	8.40	8.40
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	11.70	12.70	11.90	11.90	11.90
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	13.10	20.30	14.00	14.00	14.00
				T3	20/10/90	86.0	187.0	NG %	100.00				
				T4	20/10/90	4.5	12.5	NG/DL	7.20				
55	DMG		FEMALE	HB	20/10/90	12.0	16.0	G/100ML	11.80	12.40	12.40	12.40	12.40
				HTC	20/10/90	37.0	47.0	%	35.00	37.00	38.00	38.00	38.00
				HBC	20/10/90	3.8	5.4	10 ⁶ -6/HMC	3.80	4.00	4.10	4.10	4.10
				HBC: N	20/10/90	4.0	11.0	10 ⁶ -3/HMC	8.80	3.70	8.10	8.10	8.10
				HBC: L	20/10/90	40.0	70.0	%	43.00	67.00	52.00	52.00	52.00
				HBC: E	20/10/90	20.0	40.0	%	48.00	27.00	39.00	39.00	39.00
				HBC: M	20/10/90	1.0	5.0	%	4.00	0.00	1.00	1.00	1.00
				HBC: B	20/10/90	4.0	8.0	%	3.00	6.00	9.00	9.00	9.00
				PLATELETS	20/10/90	0.0	1.0	%	1.00	0.00	0.00	0.00	0.00
				NA+	20/10/90	150.0	550.0	10 ³ -3/HMC	228.00	223.00	232.00	232.00	246.00
				K+	20/10/90	138.0	155.0	M EQ/L	142.00	140.00	144.00	144.00	146.00
				CL-	20/10/90	3.5	5.5	M EQ/L	3.80	3.80	3.70	3.70	3.50
				PO4--	20/10/90	98.0	120.0	M EQ/L	98.00	97.00	96.00	96.00	96.00
				SGPT	20/10/90	8.5	10.5	MG/DL	8.40	8.80	8.70	8.70	9.70
				GAMMA-GT	20/10/90	3.0	4.5	MG/DL	3.80	3.90	2.80	3.20	3.20
				GLUCOSE	20/10/90	12.0	40.0	MU/HL	34.00	33.00	22.00	34.00	34.00
				ALK. PHOSPH.	20/10/90	7.0	33.0	MU/HL	23.00	26.00	20.00	23.00	23.00
				BUN	20/10/90	10.0	100.0	MG/DL	96.00	90.00	94.00	94.00	93.00
				CREATININE	20/10/90	0.6	50.0	MG/DL	233.00	205.00	237.00	233.00	233.00
				URIC ACID	20/10/90	0.6	11.6	MG/DL	36.00	30.00	27.00	46.00	46.00
				TOT BILIRUBIN	20/10/90	2.4	5.7	MG/DL	3.90	6.00	5.30	4.40	4.40
				DIR BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	0.60	0.50	0.70	0.70
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.60	6.30	6.20	6.40	6.40
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	7.10	7.20	7.30	7.30
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	134.00	249.00	222.00	207.00	207.00
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	198.00	148.00	198.00	215.00	215.00
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	2.40	2.10	2.50	2.50	2.50
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	10.20	11.00	9.50	10.70	10.70
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	15.20	15.20	11.90	13.40	13.40
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	16.70	16.70	13.80	16.10	16.10
				T3	20/10/90	86.0	187.0	NG %	100.00				
				T4	20/10/90	4.5	12.5	NG/DL	6.40				

1 5 8 8

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit												
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6								
1	56	IAL	MALE	HB	20/10/90	14.0	18.0	g/100ml	29/10/91	16.10	19/11/91	13.90	03/12/91	14.20	17/12/91	14.10				
				HTC	20/10/90	40.0	54.0	%	42.00	43.90	42.00	43.00	43.00							
				RBC	20/10/90	4.3	6.1	10**6/mm	5.20	4.80	4.80	4.80	4.80							
				WBC	20/10/90	4.0	11.0	10-3/MHC	9.60	5.70	6.10	6.10	5.70							
				NEC: N	20/10/90	40.0	70.0	%	69.00	60.00	62.00	62.00	62.00							
				NEC: L	20/10/90	20.0	40.0	%	30.00	30.00	27.00	30.00	30.00							
				NEC: E	20/10/90	1.0	5.0	%	2.00	3.00	3.00	3.00	2.00							
				NEC: M	20/10/90	4.0	8.0	%	1.00	7.00	8.00	8.00	6.00							
				NEC: B	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00							
				PLATELETS	20/10/90	150.0	550.0	10-3/MHC	258.00	264.00	266.00	211.00	211.00							
				Na+	20/10/90	138.0	155.0	M EQ/L	138.00	143.00	142.00	136.00	136.00							
				K+	20/10/90	3.5	5.5	M EQ/L	4.10	3.70	3.80	3.80	3.80							
				Cl-	20/10/90	98.0	120.0	M EQ/L	100.00	96.00	97.00	97.00	102.00							
				Ca++	20/10/90	8.5	10.5	MG/DL	8.90	9.70	9.60	9.60	9.60							
				PO4-	20/10/90	3.0	4.5	MG/DL	3.60	4.20	4.20	4.20	4.80							
				SGOT	20/10/90	12.0	40.0	U/L	22.00	20.00	22.00	22.00	28.00							
				SGPT	20/10/90	10.0	40.0	U/L	21.00	26.00	28.00	28.00	34.00							
				GAMMA-GT	20/10/90	11.0	51.0	U/L	33.00	30.00	30.00	30.00	32.00							
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	96.00	92.00	90.00	90.00	90.00							
				ALK. PHOSPH.	20/10/90	65.0	306.0	U/L	278.00	216.00	210.00	210.00	198.00							
				BUN	20/10/90	10.0	50.0	MG/DL	31.00	22.00	26.00	26.00	29.00							
				CREATININE	20/10/90	0.6	1.6	MG/DL	1.10	0.80	0.90	0.90	1.00							
				URIC ACID	20/10/90	3.4	7.0	MG/DL	5.60	4.50	4.20	4.20	4.20							
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.70	0.90	0.90	0.90	0.60							
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.30	0.30	0.30	0.30							
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.30	7.60	7.10	7.10	7.40							
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.80	4.20	4.20	4.20							
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	156.00	293.00	216.00	216.00	129.00							
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	175.00	110.00	92.00	92.00	96.00							
				GLORULINS: ALPHA 1	20/10/90	4.0	7.0	%	2.20	4.20	3.80	3.80	4.20							
				GLORULINS: ALPHA 2	20/10/90	7.0	11.0	%	8.20	8.70	9.10	9.10	8.30							
				GLORULINS: BETA	20/10/90	11.0	14.0	%	10.60	13.20	18.60	18.60	11.00							
				GLORULINS: GAMMA	20/10/90	15.0	22.0	%	12.30	19.10	20.10	20.10	19.10							
				T3	20/10/90	86.0	187.0	NG %	86.00											
				T4	20/10/90	4.5	12.5	NG/DL	4.80											
				57	SNC	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	05/12/91	12.90	24/12/91	12.90					
							HTC	20/10/90	37.0	47.0	%	36.00	40.00	40.00						
							RBC	20/10/90	3.8	5.4	10-6/MHC	4.20	4.40	4.40						
							WBC	20/10/90	4.0	11.0	10-3/MHC	5.30	5.30	5.30						
							NEC: N	20/10/90	40.0	70.0	%	71.00	70.00	70.00						
							NEC: L	20/10/90	20.0	40.0	%	28.00	24.00	24.00						
							NEC: E	20/10/90	1.0	5.0	%	1.00	3.00	3.00						
							NEC: M	20/10/90	4.0	8.0	%	1.00	3.00	3.00						
							NEC: B	20/10/90	0.0	1.0	%	0.00	0.00	0.00						
							PLATELETS	20/10/90	150.0	550.0	10-3/MHC	255.00	242.00	242.00						

1589

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXETINE - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
1	57	SNC	FEMALE	NA+	20/10/90	138.0	155.0	M EQ/L	138.00	141.00			
				K+	20/10/90	3.5	5.5	M EQ/L	4.30	4.40			
				CL-	20/10/90	98.0	120.0	M EQ/L	96.00	98.00			
				CA++	20/10/90	8.5	10.5	MG/DL	9.60	9.30			
				PO4-	20/10/90	3.0	4.5	MG/DL	3.80	4.00			
				SGOT	20/10/90	12.0	40.0	IU/ML	14.00	27.00			
				SGPT	20/10/90	10.0	40.0	IU/ML	18.00	20.00			
				GAMMA-GT	20/10/90	7.0	33.0	IU/ML	22.00	21.00			
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	91.00	97.00			
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	162.00	135.00			
				BUN	20/10/90	10.0	50.0	MG/DL	23.00	21.00			
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.70	0.80			
				URIC ACID	20/10/90	2.4	5.7	MG/DL	3.00	4.00			
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	0.80			
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.50			
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.20	7.30			
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.20			
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	200.00	171.00			
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	64.00	49.00			
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	Z	2.10	1.40			
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	Z	7.20	5.30			
				GLOBULINS: BETA	20/10/90	11.0	14.0	Z	11.10	9.10			
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	Z	17.40	21.30			
				T3	20/10/90	86.0	187.0	NG X	91.00				
				T4	20/10/90	4.5	12.5	NG/DL	2.10				
58	ARM		FEMALE	HB	20/10/90	12.0	16.0	G/100ML	13.30	12.60	07/01/92	21/01/92	
				HTC	20/10/90	37.0	47.0	Z	40.00	38.00	12.80	12.70	
				RBC	20/10/90	3.8	5.4	10 ⁶ /MNC	4.20	36.00	36.00	37.00	
				WBC: N	20/10/90	4.0	11.0	10 ³ /MNC	5.20	4.00	4.00	3.80	
				WBC: L	20/10/90	40.0	70.0	Z	52.00	5.50	4.20	4.20	
				WBC: E	20/10/90	20.0	40.0	Z	43.00	56.00	57.00	68.00	
				WBC: B	20/10/90	1.0	5.0	Z	0.00	41.00	40.00	23.00	
				WBC: M	20/10/90	4.0	8.0	Z	0.00	0.00	0.00	0.00	
				WBC: T	20/10/90	0.0	1.0	Z	0.00	3.00	3.00	9.00	
				PLATELETS	20/10/90	150.0	550.0	10 ³ /MNC	187.00	166.00	180.00	151.00	
				K+	20/10/90	138.0	195.0	M EQ/L	140.00	139.00	138.00	141.00	
				CL-	20/10/90	98.0	120.0	M EQ/L	99.00	96.00	96.00	98.00	
				CA++	20/10/90	8.5	10.5	MG/DL	10.10	9.50	9.60	8.10	
				PO4-	20/10/90	3.0	4.5	MG/DL	3.50	3.80	3.70	3.40	
				SGOT	20/10/90	12.0	40.0	IU/ML	37.00	35.00	30.00	28.00	
				SGPT	20/10/90	10.0	40.0	IU/ML	36.00	27.00	28.00	20.00	
				GAMMA-GT	20/10/90	7.0	33.0	IU/ML	42.00	28.00	32.00	25.00	
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	103.00	99.00	93.00	106.00	
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	180.00	163.00	136.00	212.00	
				BUN	20/10/90	10.0	50.0	MG/DL	23.00	18.00	20.00	26.00	
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	0.80	0.90	0.90	
				URIC ACID	20/10/90	2.4	5.7	MG/DL	2.30	2.10	3.00	3.10	

1390

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit									
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6					
1	58	ARM	FEMALE	TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.80	0.60	0.60	0.60	0.60	0.60			
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.20	0.30	0.30	0.30	0.30			
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.90	6.70	6.80	6.80	7.20	7.20			
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.00	4.00	4.00	4.00	4.30	4.30			
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	192.00	160.00	160.00	160.00	137.00	137.00			
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	76.00	87.00	80.00	80.00	66.00	66.00			
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	2.10	2.00	2.30	2.30	2.50	2.50			
				GLOBULINS: ALPHA 2	20/10/90	7.0	14.0	%	6.00	7.00	6.00	6.00	6.30	6.30			
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	12.00	11.40	11.40	11.40	9.80	9.80			
				GLOBULINS: GAMMA	20/10/90	86.0	187.0	MG %	100.00	100.00	100.00	100.00	17.40	17.40			
				T3	20/10/90	4.5	12.5	NG/DL	5.40	18.90	18.90	18.90					
				T4	20/10/90	4.5	12.5	NG/DL	5.40								
				59	SPF	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	11.80	12.30	12.30	12.40	12.40	13.30
							HTC	20/10/90	37.0	47.0	%	37.00	38.00	36.00	36.00	38.00	38.00
RBC	20/10/90	3.8	5.4				10 ⁶ /MM ³	4.10	4.30	4.00	4.00	4.00	4.30				
WBC	20/10/90	4.0	11.0				10 ³ /MM ³	4.80	5.70	5.30	5.30	5.80	5.80				
WBC: N	20/10/90	40.0	70.0				%	56.00	63.00	60.00	60.00	64.00	64.00				
WBC: L	20/10/90	20.0	40.0				%	40.00	40.00	31.00	31.00	26.00	26.00				
WBC: E	20/10/90	1.0	5.0				%	1.00	2.00	2.00	2.00	1.00	1.00				
WBC: M	20/10/90	4.0	8.0				%	4.00	4.00	4.00	4.00	9.00	9.00				
WBC: B	20/10/90	0.0	1.0				%	1.00	0.00	0.00	0.00	0.00	0.00				
PLATELETS	20/10/90	150.0	550.0				10 ³ /MM ³	206.00	218.00	202.00	202.00	189.00	189.00				
Na+	20/10/90	138.0	155.0				M EQ/L	142.00	140.00	139.00	139.00	141.00	141.00				
K+	20/10/90	3.5	5.5				M EQ/L	4.30	4.40	4.30	4.30	3.80	3.80				
CL-	20/10/90	98.0	120.0				M EQ/L	98.00	99.00	95.00	95.00	103.00	103.00				
Ca++	20/10/90	8.5	10.5				MG/DL	9.60	10.00	10.00	10.00	9.20	9.20				
PO4-	20/10/90	3.0	4.5				MG/DL	3.20	4.00	3.60	3.60	3.60	3.60				
SGPT	20/10/90	12.0	40.0				IU/ML	27.00	32.00	32.00	32.00	18.00	18.00				
SGPT	20/10/90	10.0	40.0				IU/ML	26.00	24.00	24.00	24.00	20.00	20.00				
GAMMA-GT	20/10/90	7.0	33.0				IU/ML	19.00	19.00	19.00	19.00	26.00	26.00				
GLUCOSE	20/10/90	70.0	100.0				MG/DL	95.00	85.00	85.00	85.00	94.00	94.00				
ALK. PHOSPH.	20/10/90	65.0	306.0				IU/ML	166.00	182.00	178.00	178.00	204.00	204.00				
URIC ACID	20/10/90	10.0	59.0				MG/DL	25.00	22.00	27.00	27.00	22.00	22.00				
CREATININE	20/10/90	0.6	1.6				MG/DL	0.60	0.70	0.70	0.70	0.80	0.80				
URIC ACID	20/10/90	2.4	5.7				MG/DL	2.60	3.60	3.30	3.30	4.30	4.30				
DIR BILIRUBIN	20/10/90	0.2	1.0				MG/DL	0.80	0.60	0.70	0.70	0.80	0.80				
TOT. PROTEINS	20/10/90	6.0	8.0				G/DL	6.90	7.00	6.50	6.50	7.60	7.60				
ALBUMINE	20/10/90	3.5	5.0				G/DL	4.50	4.30	4.00	4.00	3.30	3.30				
TOT. CHOLEST.	20/10/90	140.0	270.0				MG/DL	189.00	199.00	224.00	224.00	180.00	180.00				
TRIGLYCERIDES	20/10/90	35.0	175.0				MG/DL	56.00	58.00	56.00	56.00	45.00	45.00				
GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	2.00	2.10	2.10	2.10	1.80	1.80							
GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	5.40	6.50	6.50	6.50	5.60	5.60							
GLOBULINS: BETA	20/10/90	11.0	14.0	%	10.10	10.40	10.40	10.40	9.30	9.30							
GLOBULINS: GAMMA	20/10/90	86.0	187.0	MG %	110.00	117.10	117.10	117.10	21.00	21.00							
T3	20/10/90	4.5	12.5	NG/DL	8.20												
T4	20/10/90	4.5	12.5	NG/DL	8.20												

1591

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit										
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6						
1	60	EM	MALE	HB	20/10/90	14.0	18.0	g/100ml	13/12/91	03/01/92	17/01/92	31/01/92	13.50	13.50	13.50	13.50	
				HCT	20/10/90	40.0	54.0	%	14.40	42.00	40.00	40.00	40.00	40.00	40.00	40.00	40.00
				RBC	20/10/90	4.3	6.1	10**6/mm	43.00	4.50	4.20	4.30	4.20	4.30	4.20	4.30	4.30
				HBC	20/10/90	4.0	11.0	10-3/MHC	11.30	10.30	7.70	7.70	7.70	7.70	7.70	7.70	7.70
				HBC: N	20/10/90	40.0	70.0	%	61.00	67.00	58.00	58.00	58.00	58.00	58.00	58.00	58.00
				HBC: L	20/10/90	20.0	40.0	%	26.00	30.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00
				HBC: E	20/10/90	1.0	5.0	%	0.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				HBC: M	20/10/90	4.0	8.0	%	3.00	3.00	9.00	8.00	9.00	9.00	8.00	8.00	8.00
				HBC: B	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				PLATELETS	20/10/90	150.0	550.0	10-3/MHC	316.00	310.00	246.00	230.00	246.00	246.00	230.00	230.00	230.00
				NA+	20/10/90	138.0	155.0	MEQ/L	140.00	141.00	145.00	139.00	145.00	145.00	139.00	139.00	139.00
				K+	20/10/90	3.5	5.5	MEQ/L	4.40	4.60	4.70	4.00	4.70	4.70	4.00	4.00	4.00
				CL-	20/10/90	98.0	120.0	MEQ/L	99.00	97.00	101.00	100.00	101.00	101.00	100.00	100.00	100.00
				PO4--	20/10/90	8.5	10.5	MG/DL	10.30	9.80	8.80	9.70	9.80	8.80	9.70	9.70	9.70
				SGPT	20/10/90	3.0	4.5	MG/DL	3.00	2.70	3.60	3.70	3.60	3.60	3.70	3.70	3.70
				SGPT	20/10/90	12.0	40.0	MG/DL	20.00	34.00	22.00	24.00	22.00	22.00	24.00	24.00	24.00
				GAMMA-GT	20/10/90	10.0	40.0	MG/DL	17.00	32.00	20.00	26.00	20.00	20.00	26.00	26.00	26.00
				GLUCOSE	20/10/90	11.0	51.0	MG/DL	41.00	39.00	34.00	30.00	34.00	34.00	30.00	30.00	30.00
				ALK. PHOSPH.	20/10/90	70.0	100.0	MG/DL	106.00	110.00	103.00	84.00	103.00	103.00	84.00	84.00	84.00
				BUN	20/10/90	65.0	306.0	MG/DL	267.00	287.00	252.00	211.00	252.00	252.00	211.00	211.00	211.00
				CREATININE	20/10/90	10.0	50.0	MG/DL	26.00	23.00	45.00	26.00	45.00	45.00	26.00	26.00	26.00
				URIC ACID	20/10/90	0.6	1.6	MG/DL	0.80	0.80	0.90	0.90	0.80	0.90	0.90	0.90	0.90
				TOT BILIRUBIN	20/10/90	3.4	7.0	MG/DL	3.70	4.50	4.30	4.00	4.30	4.30	4.00	4.00	4.00
				DIR BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	0.90	0.60	0.70	0.60	0.60	0.70	0.70	0.70
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.10	6.60	6.70	6.40	6.60	6.60	6.40	6.40	6.40
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.60	4.70	4.30	4.20	4.70	4.70	4.20	4.20	4.20
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	238.00	205.00	180.00	166.00	180.00	180.00	166.00	166.00	166.00
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	101.00	160.00	78.00	92.00	78.00	78.00	92.00	92.00	92.00
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	2.50	3.10	3.10	3.40	3.10	3.10	3.40	3.40	3.40
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	7.80	9.60	9.60	8.60	9.60	9.60	8.60	8.60	8.60
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	11.30	12.40	15.00	12.90	12.40	15.00	12.90	12.90	12.90
GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	16.50	16.10	16.10	18.10	16.10	16.10	18.10	18.10	18.10				
T3	20/10/90	86.0	187.0	NG %	73.00	73.00	73.00	73.00	73.00	73.00	73.00	73.00	73.00				
T4	20/10/90	4.5	12.5	NG/DL	3.60	3.60	3.60	3.60	3.60	3.60	3.60	3.60	3.60				
61	FVC	FEMALE	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	15/12/91	03/01/92	17/01/92	31/01/92	13.70	13.70	13.70	13.70	
				HCT	20/10/90	37.0	47.0	%	42.00	42.00	42.00	41.00	42.00	42.00	41.00	41.00	
				RBC	20/10/90	3.8	5.4	10-6/MHC	5.00	5.00	5.10	5.10	5.10	5.10	5.10	5.10	
				HBC	20/10/90	4.0	11.0	10-3/MHC	7.30	6.10	6.00	5.20	6.00	6.00	5.20	5.20	
				HBC: N	20/10/90	40.0	70.0	%	71.00	33.00	25.00	27.00	33.00	25.00	27.00	27.00	
				HBC: L	20/10/90	20.0	40.0	%	25.00	1.00	1.00	5.00	1.00	1.00	5.00	5.00	
				HBC: E	20/10/90	1.0	5.0	%	2.00	6.00	9.00	6.00	9.00	6.00	6.00	6.00	
				HBC: M	20/10/90	4.0	8.0	%	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	
				HBC: B	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				PLATELETS	20/10/90	150.0	550.0	10-3/MHC	348.00	262.00	291.00	281.00	262.00	291.00	281.00	281.00	

1392

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
1	61	HVC	FEMALE	NA+	20/10/90	138.0	155.0	M EQ/L	139.00	140.00	140.00	140.00	140.00			
				K+	20/10/90	3.5	5.5	M EQ/L	4.20	4.10	3.60	3.70				
				CL-	20/10/90	98.0	120.0	M EQ/L	98.00	96.00	97.00	98.00				
				CA++	20/10/90	8.5	10.5	MG/DL	10.30	10.20	8.30	9.90				
				PO4--	20/10/90	3.0	4.5	MG/DL	3.80	4.40	3.50	3.40				
				SGOT	20/10/90	12.0	40.0	IU/ML	26.00	18.00	18.00	18.00				
				SGPT	20/10/90	10.0	40.0	IU/ML	20.00	19.00	15.00	16.00				
				GAMMA-GT	20/10/90	7.0	33.0	IU/ML	19.00	21.00	19.00	20.00				
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	103.00	97.00	100.00	103.00				
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	233.00	248.00	210.00	228.00				
				BUN	20/10/90	10.0	50.0	MG/DL	26.00	21.00	31.00	27.00				
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.70	0.70	0.80	0.80				
				URIC ACID	20/10/90	2.4	5.7	MG/DL	3.20	2.60	4.20	4.00				
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	1.00	1.00	0.80				
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.50	0.50	0.40				
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.00	7.00	7.10	6.90				
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.20	4.30	4.00				
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	187.00	220.00	208.00	183.00				
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	87.00	210.00	86.00	97.00				
				CHOLESTIN: ALPHA 1	20/10/90	4.0	7.0	%	2.30	2.80	2.30	3.20				
				CHOLESTIN: ALPHA 2	20/10/90	7.0	11.0	%	7.80	8.00	8.50	9.00				
				CHOLESTIN: BETA	20/10/90	11.0	14.0	%	12.40	10.10	10.10	11.00				
				CHOLESTIN: GAMMA	20/10/90	15.0	22.0	%	14.80	17.60	17.70	18.90				
				T3	20/10/90	86.0	187.0	NG %	105.00							
				T4	20/10/90	4.5	12.5	NG/DL	9.20							
				62	MEA	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	12.30	12.50	12.00	12.90	12.00
							HTC	20/10/90	37.0	47.0	%	37.00	36.00	37.00	35.00	
RBC	20/10/90	3.8	5.4				10 ⁶ /MM ³	4.10	3.90	3.90	4.00					
HBC: N	20/10/90	4.0	11.0				10 ³ /MM ³	6.00	6.40	6.10	6.60					
HBC: L	20/10/90	40.0	70.0				%	58.00	68.00	68.00	60.00					
HBC: E	20/10/90	20.0	40.0				%	39.00	25.00	24.00	28.00					
HBC: M	20/10/90	1.0	5.0				%	1.00	1.00	2.00	5.00					
HBC: B	20/10/90	4.0	8.0				%	2.00	6.00	6.00	7.00					
PLATELETS	20/10/90	150.0	550.0				10 ³ /MM ³	402.00	381.00	393.00	198.00					
NA+	20/10/90	138.0	155.0				M EQ/L	142.00	141.00	143.00	143.00					
K+	20/10/90	3.5	5.5				M EQ/L	4.30	4.30	4.50	3.80					
CL-	20/10/90	98.0	120.0				M EQ/L	97.00	96.00	97.00	95.00					
CA++	20/10/90	8.5	10.5				MG/DL	10.00	8.20	8.90	9.30					
PO4--	20/10/90	3.0	4.5				MG/DL	4.20	4.30	5.20	4.20					
SGOT	20/10/90	12.0	40.0				IU/ML	26.00	28.00	27.00	26.00					
SGPT	20/10/90	10.0	40.0				IU/ML	30.00	20.00	20.00	28.00					
GAMMA-GT	20/10/90	7.0	33.0				IU/ML	31.00	31.00	33.00	30.00					
GLUCOSE	20/10/90	70.0	100.0				MG/DL	103.00	125.00	91.00	94.00					
ALK. PHOSPH.	20/10/90	65.0	306.0				IU/ML	267.00	292.00	294.00	122.00					
BUN	20/10/90	10.0	50.0				MG/DL	29.00	31.00	28.00	26.00					
CREATININE	20/10/90	0.6	1.6				MG/DL	0.90	1.00	1.00	0.90					
URIC ACID	20/10/90	2.4	5.7				MG/DL	5.40	5.50	5.20	4.00					

1599

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20126/013
 Listing No.: 12.1

LABORATORY DATA
 OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Screen			Visit				
				Date	Min	Max	Unit	Week 2	Week 4	Week 6				
1	62	FEMALE	TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.50	0.40	0.60	0.40	0.40		
			DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.50	0.30	0.30	0.10	0.20		
			TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.80	7.40	7.20	6.80	6.80		
			ALBUMINE	20/10/90	3.5	5.0	G/DL	3.90	4.00	4.00	4.00	3.90		
			TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	240.00	242.00	264.00	193.00	193.00		
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	92.00	79.00	95.00	96.00	96.00		
			GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	2.00	2.60	3.20	4.20	4.20		
			GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	5.40	9.10	8.80	8.70	8.70		
			GLOBULINS: BETA	20/10/90	11.0	14.0	%	12.60	13.80	16.80	17.10	17.10		
			GLOBULINS: GAMA	20/10/90	15.0	22.0	%	24.80	21.90	18.00	18.10	18.10		
			T3	20/10/90	86.0	187.0	NG %	115.00						
			T4	20/10/90	4.5	12.5	NG/DL	7.00						
			63	JCL	MALE	HB	20/10/90	14.0	18.0	g/100ml	14.30	14.30	14.30	14.30
						HTC	20/10/90	40.0	54.0	%	45.00	42.00	42.00	42.00
						RBC	20/10/90	4.3	6.1	10**6/mm	4.90	4.60	4.60	4.60
						HBC	20/10/90	4.0	11.0	10-3/HMC	5.80	6.10	6.10	6.10
						HBC: N	20/10/90	40.0	70.0	%	66.00	68.00	68.00	68.00
HBC: L	20/10/90	20.0				40.0	%	29.00	22.00	22.00	22.00			
HBC: E	20/10/90	1.0				5.0	%	4.00	4.00	5.00	5.00			
HBC: M	20/10/90	4.0				8.0	%	1.00	5.00	5.00	5.00			
HBC: B	20/10/90	0.0				1.0	%	0.00	0.00	0.00	0.00			
PLATELETS	20/10/90	150.0				550.0	10-3/HMC	199.00	189.00	142.00	142.00			
Na+	20/10/90	138.0				155.0	M EQ/L	139.00	142.00	142.00	142.00			
Cl-	20/10/90	98.0				120.0	M EQ/L	98.00	98.00	98.00	98.00			
Ca++	20/10/90	8.5				10.5	MG/DL	9.60	8.80	8.80	8.80			
PO4--	20/10/90	3.0				4.5	MG/DL	3.00	3.40	3.40	3.40			
SGPT	20/10/90	12.0				40.0	NU/ML	33.00	36.00	36.00	36.00			
GAMMA-GT	20/10/90	10.0				40.0	NU/ML	34.00	47.00	47.00	47.00			
ALBUMINE	20/10/90	11.0				51.0	MG/DL	29.00	29.00	29.00	29.00			
GLUCOSE	20/10/90	70.0				100.0	MG/DL	86.00	101.00	101.00	101.00			
ALK. PHOSPH.	20/10/90	65.0				306.0	NU/ML	233.00	235.00	235.00	235.00			
URIC ACID	20/10/90	10.0				50.0	MG/DL	25.00	24.00	24.00	24.00			
CREATININE	20/10/90	0.6				1.6	MG/DL	0.90	0.90	0.90	0.90			
UREIC ACID	20/10/90	3.4				7.0	MG/DL	5.10	6.20	6.20	6.20			
TOT BILIRUBIN	20/10/90	0.2				1.0	MG/DL	0.50	0.70	0.70	0.70			
DIR BILIRUBIN	20/10/90	0.0				0.4	MG/DL	0.20	0.30	0.30	0.30			
TOT. PROTEINS	20/10/90	6.0				8.0	G/DL	7.10	7.00	7.00	7.00			
ALBUMINE	20/10/90	3.5				5.0	G/DL	4.70	4.30	4.30	4.30			
TOT. CHOLEST.	20/10/90	140.0				270.0	MG/DL	220.00	216.00	216.00	216.00			
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	135.00	110.00	110.00	110.00						
GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	1.90	1.50	1.50	1.50						
GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	5.10	5.50	5.50	5.50						
GLOBULINS: BETA	20/10/90	11.0	14.0	%	9.10	13.10	13.10	13.10						
GLOBULINS: GAMA	20/10/90	15.0	22.0	%	17.00	14.80	14.80	14.80						
T3	20/10/90	86.0	187.0	NG %	120.00									
T4	20/10/90	4.5	12.5	NG/DL	9.60									

139

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
1	64	ENF	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	10/01/92	13.50	13.80	14/02/92	13.30	28/02/92	13.00	
				HTC	20/10/90	37.0	47.0	Z	10/01/92	42.00	38.00	14/02/92	40.00	28/02/92	38.00	
				RBC	20/10/90	3.8	5.4	10-6/MNC	10/01/92	4.40	4.10	14/02/92	4.10	28/02/92	4.50	
				MBC	20/10/90	4.0	11.0	10-3/MNC	10/01/92	4.90	5.30	14/02/92	5.30	28/02/92	6.00	
				MBC: N	20/10/90	40.0	70.0	Z	10/01/92	46.00	60.00	14/02/92	63.00	28/02/92	60.00	
				MBC: L	20/10/90	20.0	40.0	Z	10/01/92	48.00	30.00	14/02/92	27.00	28/02/92	28.00	
				MBC: E	20/10/90	1.0	5.0	Z	10/01/92	0.00	1.00	14/02/92	1.00	28/02/92	6.00	
				MBC: M	20/10/90	4.0	8.0	Z	10/01/92	6.00	7.00	14/02/92	9.00	28/02/92	6.00	
				MBC: B	20/10/90	0.0	1.0	Z	10/01/92	0.00	0.00	14/02/92	0.00	28/02/92	0.00	
				PLATELETS	20/10/90	150.0	550.0	10-3/MNC	10/01/92	204.00	216.00	14/02/92	201.00	28/02/92	241.00	
				PLA+	20/10/90	138.0	153.0	M EX/L	10/01/92	141.00	141.00	14/02/92	141.00	28/02/92	138.00	
				PLA-	20/10/90	3.5	5.5	M EX/L	10/01/92	4.30	3.80	14/02/92	4.60	28/02/92	3.90	
				CL-	20/10/90	98.0	120.0	M EX/L	10/01/92	97.00	97.00	14/02/92	97.00	28/02/92	96.00	
				PO4-	20/10/90	8.5	10.5	MG/DL	10/01/92	8.40	9.90	14/02/92	10.20	28/02/92	9.70	
				SGOT	20/10/90	3.0	4.5	MG/DL	10/01/92	3.40	3.60	14/02/92	3.50	28/02/92	4.00	
				SGPT	20/10/90	12.0	40.0	MU/ML	10/01/92	28.00	20.00	14/02/92	41.00	28/02/92	21.00	
				GAMMA-GT	20/10/90	10.0	40.0	MU/ML	10/01/92	26.00	24.00	14/02/92	26.00	28/02/92	26.00	
				GLUCOSE	20/10/90	7.0	33.0	MU/ML	10/01/92	58.00	30.00	14/02/92	48.00	28/02/92	30.00	
				ALK. PHOSPH.	20/10/90	70.0	400.0	MG/DL	10/01/92	93.00	96.00	14/02/92	116.00	28/02/92	94.00	
				BUN	20/10/90	65.0	306.0	MU/ML	10/01/92	216.00	294.00	14/02/92	301.00	28/02/92	288.00	
				CREATININE	20/10/90	10.0	50.0	MG/DL	10/01/92	33.00	37.00	14/02/92	45.00	28/02/92	32.00	
				URIC ACID	20/10/90	0.6	1.6	MG/DL	10/01/92	0.90	1.00	14/02/92	0.70	28/02/92	0.90	
				TOT BILIRUBIN	20/10/90	2.4	5.7	MG/DL	10/01/92	3.70	4.20	14/02/92	3.60	28/02/92	4.00	
				DIR BILIRUBIN	20/10/90	0.2	1.0	MG/DL	10/01/92	1.00	0.60	14/02/92	0.70	28/02/92	0.70	
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	10/01/92	6.80	6.80	14/02/92	6.90	28/02/92	6.90	
				ALBUMINE	20/10/90	3.5	5.0	G/DL	10/01/92	4.40	3.90	14/02/92	4.00	28/02/92	4.00	
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	10/01/92	236.00	151.00	14/02/92	196.00	28/02/92	141.00	
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	10/01/92	90.00	95.00	14/02/92	89.00	28/02/92	89.00	
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	Z	10/01/92	2.10	3.80	14/02/92	3.20	28/02/92	3.20	
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	Z	10/01/92	8.60	10.40	14/02/92	10.30	28/02/92	8.70	
				GLOBULINS: BETA	20/10/90	11.0	14.0	Z	10/01/92	12.90	12.10	14/02/92	16.00	28/02/92	12.90	
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	Z	10/01/92	17.60	16.70	14/02/92	8.10	28/02/92	17.10	
				T3	20/10/90	86.0	187.0	NG Z	10/01/92	180.00	7.00	14/02/92	0.00	28/02/92	0.00	
				T4	20/10/90	4.5	12.5	MG/DL	10/01/92	7.00	271.00	14/02/92	271.00	28/02/92	251.00	
				65	FS	MALE	HB	20/10/90	14.0	18.0	g/100mL	14/01/92	14.80	12.90	04/02/92	13.00
HTC	20/10/90	40.0	54.0				Z	14/01/92	46.00	38.00	04/02/92	37.00	18/02/92	37.00	04/03/92	37.00
RBC	20/10/90	4.3	6.1				10x6/mm	14/01/92	4.60	4.20	04/02/92	4.20	18/02/92	4.10	04/03/92	4.20
MBC	20/10/90	4.0	11.0				10-3/MNC	14/01/92	9.40	6.30	04/02/92	6.30	18/02/92	6.60	04/03/92	6.60
MBC: N	20/10/90	40.0	70.0				Z	14/01/92	45.00	58.00	04/02/92	58.00	18/02/92	58.00	04/03/92	59.00
MBC: L	20/10/90	20.0	40.0				Z	14/01/92	48.00	32.00	04/02/92	30.00	18/02/92	29.00	04/03/92	29.00
MBC: E	20/10/90	1.0	5.0				Z	14/01/92	2.00	3.00	04/02/92	3.00	18/02/92	5.00	04/03/92	5.00
MBC: M	20/10/90	4.0	8.0				Z	14/01/92	5.00	7.00	04/02/92	7.00	18/02/92	7.00	04/03/92	7.00
MBC: B	20/10/90	0.0	1.0				Z	14/01/92	0.00	0.00	04/02/92	0.00	18/02/92	0.00	04/03/92	0.00
PLATELETS	20/10/90	150.0	550.0				10-3/MNC	14/01/92	271.00	247.00	04/02/92	247.00	18/02/92	240.00	04/03/92	251.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
1	65	FS	MALE	NA+	20/10/90	138.0	155.0	K EQ/L	138.00	145.00	140.00	196.00	
				K+	20/10/90	3.5	5.5	K EQ/L	4.40	4.20	3.80	3.80	
				CL-	20/10/90	98.0	120.0	K EQ/L	95.00	96.00	95.00	92.00	
				CA++	20/10/90	8.5	10.5	MG/DL	8.50	9.90	9.90	9.80	
				PO4--	20/10/90	3.0	4.5	MG/DL	3.50	3.80	3.80	3.60	
				SGPT	20/10/90	12.0	40.0	MIU/ML	30.00	20.00	22.00	24.00	
				SGPT	20/10/90	10.0	40.0	MIU/ML	34.00	24.00	28.00	28.00	
				GAMMA-GT	20/10/90	11.0	51.0	MIU/ML	47.00	32.00	32.00	32.00	
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	117.00	78.00	90.00	92.00	
				BUN	20/10/90	65.0	306.0	MIU/ML	270.00	208.00	192.00	244.00	
				ALK. PHOSPH.	20/10/90	10.0	50.0	MG/DL	20.00	26.00	26.00	30.00	
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	0.90	0.90	0.90	
				URIC ACID	20/10/90	3.4	7.0	MG/DL	4.30	4.00	4.10	4.10	
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.30	0.80	0.80	0.60	
				DJR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.40	0.40	0.30	
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.00	7.30	7.00	7.20	
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.30	4.20	4.30	4.30	
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	256.00	174.00	245.00	166.00	
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	69.00	88.00	108.00	95.00	
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	2.90	3.20	3.20	3.80	
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	8.30	4.90	9.10	6.90	
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	11.90	12.30	18.00	11.20	
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	20.20	21.00	21.00	19.50	
				T3	20/10/90	86.0	187.0	NG %	120.00				
				T4	20/10/90	4.5	12.5	NG/DL	10.00				
66	TCG		FEMALE	HB	20/10/90	12.0	16.0	G/100NL	14.01/92	04/02/92	18/02/92	04/03/92	
				HTC	20/10/90	37.0	47.0	%	42.80	13.10	14.20	12.60	
				RBC	20/10/90	3.8	5.4	10 ⁶ /MMC	40.00	38.00	41.00	37.00	
				WBC	20/10/90	4.0	11.0	10 ³ -6/MMC	4.20	4.30	4.40	4.80	
				WBC: N	20/10/90	40.0	70.0	%	9.90	7.00	8.20	7.30	
				WBC: L	20/10/90	20.0	40.0	%	77.00	60.00	62.00	56.00	
				WBC: E	20/10/90	1.0	5.0	%	16.00	28.00	28.00	31.00	
				WBC: K	20/10/90	4.0	8.0	%	3.00	6.00	4.00	6.00	
				WBC: B	20/10/90	0.0	1.0	%	1.00	6.00	6.00	7.00	
				PLATELETS	20/10/90	150.0	550.0	10 ³ -3/MMC	263.00	247.00	238.00	298.00	
				NA+	20/10/90	138.0	155.0	K EQ/L	141.00	137.00	138.00	138.00	
				K+	20/10/90	98.0	120.0	K EQ/L	96.00	93.00	90.00	93.00	
				CL-	20/10/90	3.0	4.5	MG/DL	3.70	3.80	3.80	3.80	
				PO4--	20/10/90	12.0	40.0	MIU/ML	20.00	23.00	28.00	20.00	
				SGPT	20/10/90	10.0	40.0	MIU/ML	19.00	26.00	16.00	26.00	
				GAMMA-GT	20/10/90	7.0	33.0	MIU/ML	25.00	32.00	31.00	31.00	
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	108.00	97.00	143.00	94.00	
				BUN	20/10/90	65.0	306.0	MIU/ML	146.00	141.00	143.00	203.00	
				ALK. PHOSPH.	20/10/90	10.0	50.0	MG/DL	30.00	30.00	41.00	38.00	
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	0.90	0.80	1.00	
				URIC ACID	20/10/90	3.4	7.0	MG/DL	4.70	4.10	6.00	4.10	

1596

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit										
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6						
1	66	TCG	FEMALE	TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.90	0.70	0.50	0.80					
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.50	0.30	0.20	0.40					
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.80	7.00	6.90	6.80					
				ALBUMINE	20/10/90	3.5	5.0	G/DL	3.90	4.20	4.00	4.10					
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	150.00	167.00	181.00	188.00					
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	49.00	87.00	85.00	97.00					
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	3.20	4.10	3.10	4.00					
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	8.30	9.70	11.60	9.30					
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	9.60	14.10	10.30	15.10					
				GLOBULINS: GAMMA	20/10/90	86.0	187.0	NG %	47.00	18.90	19.00	18.60					
				T3	20/10/90	86.0	187.0	NG %	155.00								
				T4	20/10/90	4.5	12.5	NG/DL	9.40								
				67	WAA	FEMALE	FEMALE	HR	20/10/90	12.0	16.0	G/100ML	14.00	14.10	13.50	14.10	04/03/92
								HTC	20/10/90	37.0	47.0	%	40.00	39.00	39.00	39.00	04/03/92
								PBC	20/10/90	3.8	5.4	10 ⁻⁶ /MHC	4.60	4.70	4.40	4.40	04/03/92
								MHC: N	20/10/90	4.0	11.0	10 ⁻³ /MHC	10.40	7.60	8.20	7.00	04/03/92
								MHC: L	20/10/90	40.0	70.0	%	62.00	57.00	59.00	62.00	04/03/92
MHC: E	20/10/90	1.0	5.0					%	29.00	29.00	33.00	26.00	04/03/92				
MHC: H	20/10/90	4.0	8.0					%	1.00	5.00	3.00	6.00	04/03/92				
MHC: B	20/10/90	0.0	1.0					%	8.00	9.00	5.00	6.00	04/03/92				
PLATELETS	20/10/90	150.0	550.0					10 ⁻³ /MHC	366.00	217.00	279.00	237.00	04/03/92				
NA+	20/10/90	138.0	155.0					M EQ/L	141.00	137.00	140.00	137.00	04/03/92				
K+	20/10/90	3.5	5.5					M EQ/L	3.50	3.80	4.40	4.20	04/03/92				
CL-	20/10/90	98.0	120.0					M EQ/L	92.00	102.00	95.00	104.00	04/03/92				
CA++	20/10/90	8.5	10.5					MG/DL	9.40	9.30	9.80	9.20	04/03/92				
PO4-	20/10/90	3.0	4.5					MG/DL	3.50	3.90	3.00	3.80	04/03/92				
SGPT	20/10/90	12.0	40.0					NU/ML	36.00	28.00	36.00	24.00	04/03/92				
GAMMA-GT	20/10/90	10.0	40.0					NU/ML	30.00	30.00	31.00	26.00	04/03/92				
GLUCOSE	20/10/90	70.0	33.0					NU/ML	56.00	46.00	50.00	36.00	04/03/92				
ALK. PHOSPH.	20/10/90	65.0	306.0	NU/ML	202.00	97.00	140.00	86.00	04/03/92								
BUN	20/10/90	10.0	50.0	MG/DL	23.00	30.00	25.00	210.00	04/03/92								
CREATININE	20/10/90	0.6	1.6	MG/DL	1.00	1.00	0.90	0.80	04/03/92								
URIC ACID	20/10/90	2.4	5.7	MG/DL	8.60	3.70	6.60	4.10	04/03/92								
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	1.00	0.50	0.50	0.50	04/03/92								
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.60	0.20	0.20	0.30	04/03/92								
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.80	7.50	7.50	7.40	04/03/92								
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.20	4.20	4.60	04/03/92								
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	216.00	194.00	231.00	142.00	04/03/92								
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	361.00	210.00	216.00	82.00	04/03/92								
GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	3.40	3.10	2.00	3.60	04/03/92								
GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	8.40	8.70	7.90	4.90	04/03/92								
GLOBULINS: BETA	20/10/90	11.0	14.0	%	12.90	14.10	11.90	12.70	04/03/92								
GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	20.50	20.30	22.50	19.50	04/03/92								
T3	20/10/90	86.0	187.0	NG %	200.00				04/03/92								
T4	20/10/90	4.5	12.5	NG/DL	9.00				04/03/92								

1593

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXEMINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
1	68	MGS	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	14/01/92	04/02/92	18/02/92	04/03/92	
				HTC	20/10/90	37.0	47.0	%	12.90	13.20	13.10	12.70	
				RBC	20/10/90	3.8	5.4	10 ⁶ /MNC	37.00	39.00	37.00	38.00	
				MNC	20/10/90	4.0	11.0	10 ³ /MNC	3.90	4.10	4.20	4.30	
				MNC: N	20/10/90	40.0	70.0	%	4.40	6.20	6.20	6.30	
				MNC: L	20/10/90	20.0	40.0	%	68.00	64.00	63.00	58.00	
				MNC: E	20/10/90	1.0	5.0	%	22.00	30.00	30.00	32.00	
				MNC: H	20/10/90	4.0	8.0	%	4.00	4.00	5.00	6.00	
				MNC: B	20/10/90	0.0	1.0	%	6.00	2.00	2.00	4.00	
				PLATELETS	20/10/90	150.0	550.0	10 ³ -3/MNC	142.00	371.00	363.00	334.00	
				K+	20/10/90	3.5	5.5	M EQ/L	140.00	140.00	138.00	139.00	
				CL-	20/10/90	98.0	120.0	M EQ/L	95.00	4.70	4.00	3.90	
				PO4-	20/10/90	3.0	4.5	MG/DL	7.90	10.10	10.20	9.80	
				SGPT	20/10/90	12.0	40.0	UO/HL	2.80	3.50	3.70	3.50	
				SGPT	20/10/90	10.0	40.0	UO/HL	22.00	28.00	28.00	27.00	
				GAMMA-GT	20/10/90	7.0	33.0	UO/HL	18.00	25.00	26.00	26.00	
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	97.00	96.00	103.00	101.00	
				BUN	20/10/90	65.0	306.0	UO/HL	149.00	127.00	118.00	115.00	
				CREATININE	20/10/90	0.6	50.0	MG/DL	32.00	12.00	12.00	9.90	
				URIC ACID	20/10/90	2.4	1.6	MG/DL	0.90	0.80	0.90	0.90	
				DIR BILIRUBIN	20/10/90	0.2	5.7	MG/DL	3.20	4.60	4.70	4.30	
				TOT BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.80	0.80	0.90	1.00	
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.30	6.30	6.50	6.30	
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.50	4.00	4.20	4.20	
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	200.00	166.00	166.00	152.00	
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	48.00	121.00	120.00	108.00	
				GLUCOLINS: ALPHA 1	20/10/90	4.0	7.0	%	3.00	3.90	3.80	3.60	
				GLUCOLINS: ALPHA 2	20/10/90	7.0	11.0	%	7.10	7.20	7.00	8.20	
				GLUCOLINS: BETA	20/10/90	11.0	16.0	%	10.50	11.00	11.00	10.90	
				GLUCOLINS: GAMMA	20/10/90	15.0	22.0	%	19.10	15.00	14.50	14.90	
				TS	20/10/90	86.0	187.0	MG %	150.00				
				T4	20/10/90	4.5	12.5	MG/DL	7.00				
				69	RFA	MALE	HB	20/10/90	14.0	18.0	g/100ml	14/01/92	04/02/92
HTC	20/10/90	40.0	54.0				%	12.80	13.20	13.00	13.10		
RBC	20/10/90	4.3	6.1				10 ⁶ *6/mm	36.00	40.00	41.00	38.00		
MNC	20/10/90	4.0	11.0				10 ³ -3/MNC	3.60	4.30	4.80	4.00		
MNC: N	20/10/90	40.0	70.0				%	61.00	60.00	62.00	60.00		
MNC: L	20/10/90	20.0	40.0				%	28.00	27.00	34.00	30.00		
MNC: E	20/10/90	1.0	5.0				%	7.00	4.00	2.00	2.00		
MNC: H	20/10/90	4.0	8.0				%	4.00	9.00	2.00	8.00		
MNC: B	20/10/90	0.0	1.0				%	0.00	0.00	0.00	0.00		
PLATELETS	20/10/90	150.0	550.0				10 ³ -3/MNC	239.00	250.00	220.00	245.00		

1
68
69

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 12.1
 LABORATORY DATA
 OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit					
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
1	69 RFA	MALE	NA+	20/10/90	138.0	155.0	M EQ/L	140.00	142.00	139.00	138.00	
			K+	20/10/90	3.5	5.5	M EQ/L	3.90	4.20	4.00	3.90	
			CL-	20/10/90	98.0	120.0	M EQ/L	101.00	106.00	96.00	98.00	
			CA++	20/10/90	8.5	10.5	MG/DL	9.80	9.60	9.90	9.60	
			PO4-	20/10/90	3.0	4.5	MG/DL	3.10	3.80	4.20	3.80	
			SCOT	20/10/90	12.0	40.0	MU/HL	21.00	20.00	20.00	22.00	
			SGPT	20/10/90	10.0	40.0	MU/HL	22.00	24.00	24.00	26.00	
			GAMMA-GT	20/10/90	11.0	51.0	MU/HL	26.00	32.00	29.00	30.00	
			GLUCOSE	20/10/90	70.0	100.0	MG/DL	96.00	102.00	96.00	94.00	
			ALK. PHOSPH.	20/10/90	65.0	306.0	MU/HL	196.00	192.00	208.00	166.00	
			BUN	20/10/90	10.0	50.0	MG/DL	33.00	26.00	26.00	24.00	
			CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	1.00	0.90	0.90	
			URIC ACID	20/10/90	3.4	7.0	MG/DL	3.20	4.10	4.40	4.00	
			TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	1.00	0.80	0.70	0.60	
			DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.50	0.40	0.30	0.30	
			TOT PROTEINS	20/10/90	6.0	8.0	G/DL	6.80	7.20	7.10	7.00	
			ALBUMINE	20/10/90	3.5	5.0	G/DL	4.00	3.80	4.20	4.20	
			TOT CHOLEST.	20/10/90	160.0	270.0	MG/DL	137.00	188.00	169.00	155.00	
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	81.00	96.00	92.00	90.00	
			GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	Z	4.10	2.80	3.80	3.20	
GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	Z	7.00	8.80	7.20	8.60				
GLOBULINS: BETA	20/10/90	11.0	14.0	Z	9.60	12.70	11.80	12.80				
GLOBULINS: GAMMA	20/10/90	15.0	22.0	Z	13.10	16.90	19.40	19.20				
T3	20/10/90	86.0	187.0	NG Z	96.00	.	.	.				
T4	20/10/90	4.5	12.5	NG/DL	8.70	.	.	.				
70	MLM	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	14.60	13.50	14.20	14.80	
			HTC	20/10/90	37.0	47.0	Z	44.00	38.00	41.00	41.00	
			RBC	20/10/90	3.8	5.4	10-6/MHC	4.60	4.30	4.40	4.20	
			MBC	20/10/90	4.0	11.0	10-3/MHC	5.70	6.20	7.80	6.80	
			MBC: N	20/10/90	40.0	70.0	Z	68.00	58.00	66.00	64.00	
			MBC: L	20/10/90	20.0	40.0	Z	25.00	26.00	28.00	22.00	
			MBC: E	20/10/90	1.0	5.0	Z	2.00	6.00	1.00	4.00	
			MBC: H	20/10/90	4.0	8.0	Z	5.00	10.00	5.00	9.00	
			MBC: B	20/10/90	0.0	1.0	Z	0.00	0.00	0.00	1.00	
			PLATELETS	20/10/90	150.0	550.0	10-3/MHC	252.00	248.00	266.00	253.00	
			NA+	20/10/90	138.0	155.0	M EQ/L	141.00	138.00	143.00	141.00	
			K+	20/10/90	3.5	5.5	M EQ/L	4.40	4.10	4.30	3.90	
			CL-	20/10/90	98.0	120.0	M EQ/L	97.00	100.00	99.00	98.00	
			CA++	20/10/90	8.5	10.5	MG/DL	8.40	9.30	9.80	9.60	
			PO4-	20/10/90	3.0	4.5	MG/DL	2.60	3.90	3.10	3.70	
			SCOT	20/10/90	12.0	40.0	MU/HL	37.00	20.00	29.00	23.00	
			SGPT	20/10/90	10.0	40.0	MU/HL	29.00	26.00	23.00	25.00	
			GAMMA-GT	20/10/90	7.0	33.0	MU/HL	27.00	34.00	31.00	29.00	
			GLUCOSE	20/10/90	70.0	100.0	MG/DL	98.00	98.00	116.00	87.00	
			ALK. PHOSPH.	20/10/90	65.0	306.0	MU/HL	290.00	275.00	306.00	158.00	
BUN	20/10/90	10.0	50.0	MG/DL	35.00	29.00	39.00	21.00				
CREATININE	20/10/90	0.6	1.6	MG/DL	1.00	1.10	0.90	0.80				
URIC ACID	20/10/90	2.4	5.7	MG/DL	4.20	3.60	4.00	3.40				

1399

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
1	70	MLM	FEMALE	TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.50	0.70	0.80	0.70	0.70			
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.20	0.20	0.20				
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.70	7.30	7.40	7.10				
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.00	4.30	4.60	4.30				
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	140.00	162.00	140.00	250.00				
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	59.00	59.00	53.00	63.00				
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	X	3.10	3.10	1.70	3.10				
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	X	12.50	9.00	7.80	8.10				
				GLOBULINS: BETA	20/10/90	11.0	14.0	X	9.20	12.50	12.40	14.00				
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	X	13.40	21.30	17.40	20.30				
				T3	20/10/90	86.0	187.0	NG X	105.00							
				T4	20/10/90	4.5	12.5	NG/DL	8.00							
				71	ORW	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	10.10	11/02/92	12.10	10.10	10/03/92
							HIC	20/10/90	37.0	47.0	X	31.00	35.00	51.00	40.00	
							RBC	20/10/90	3.8	5.4	10 ⁶ -6/MNC	5.30	4.00	4.00	5.00	
							REC: N	20/10/90	4.0	11.0	10 ³ -3/MNC	6.30	6.30	6.40	6.30	
							REC: L	20/10/90	40.0	70.0	X	50.00	60.00	56.00	64.00	
							REC: E	20/10/90	20.0	40.0	X	27.00	27.00	28.00	28.00	
							REC: M	20/10/90	1.0	5.0	X	4.00	5.00	2.00	2.00	
							REC: B	20/10/90	4.0	8.0	X	9.00	8.00	4.00	6.00	
PLATELETS	20/10/90	0.0	1.0				X	0.00	0.00	0.00	0.00					
NA+	20/10/90	150.0	550.0				10 ³ -3/MNC	363.00	312.00	383.00	310.00					
K+	20/10/90	138.0	155.0				M EQ/L	139.00	141.00	144.00	143.00					
CL-	20/10/90	3.5	5.5				M EQ/L	3.80	3.80	4.20	4.20					
CA++	20/10/90	98.0	120.0				M EQ/L	97.00	96.00	99.00	103.00					
PO4--	20/10/90	8.5	10.5				MG/DL	8.90	9.50	9.70	9.30					
SGPT	20/10/90	3.0	4.5				MG/DL	3.90	3.80	3.60	4.20					
GAMMA-GT	20/10/90	12.0	40.0				IU/ML	23.00	20.00	18.00	26.00					
GLUCOSE	20/10/90	10.0	40.0				IU/ML	18.00	25.00	14.00	28.00					
ALK. PHOSPH.	20/10/90	7.0	33.0				IU/ML	26.00	30.00	30.00	32.00					
CREATININE	20/10/90	70.0	100.0				MG/DL	94.00	78.00	114.00	94.00					
URIC ACID	20/10/90	65.0	306.0				IU/ML	155.00	210.00	216.00	241.00					
DIR BILIRUBIN	20/10/90	10.0	50.0	MG/DL	12.00	4.00	0.80	28.00								
TOT. PROTEINS	20/10/90	0.6	1.6	MG/DL	0.70	0.80	0.80	0.90								
ALBUMINE	20/10/90	2.4	5.7	MG/DL	3.10	4.10	3.40	4.10								
TOT. CHOLEST.	20/10/90	0.2	1.0	MG/DL	0.60	0.60	0.50	0.60								
TRIGLYCERIDES	20/10/90	0.0	0.4	MG/DL	0.30	0.20	0.10	0.30								
GLOBULINS: ALPHA 1	20/10/90	6.0	8.0	MG/DL	7.00	7.00	8.40	7.00								
GLOBULINS: ALPHA 2	20/10/90	3.5	5.0	G/DL	4.50	4.10	5.10	4.30								
GLOBULINS: BETA	20/10/90	140.0	270.0	MG/DL	244.00	160.00	255.00	160.00								
GLOBULINS: GAMMA	20/10/90	35.0	175.0	MG/DL	95.00	63.00	100.00	58.00								
T3	20/10/90	4.0	7.0	X	3.10	4.10	2.30	4.10								
T4	20/10/90	7.0	11.0	X	8.90	8.90	9.20	9.20								
T3	20/10/90	11.0	14.0	X	14.00	14.00	14.00	13.90								
T4	20/10/90	15.0	22.0	X	20.40	18.30	23.80	20.10								

1600

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
1	72	RLJ	MALE	HB	20/10/90	14.0	18.0	g/100ml	21/01/92	11/02/92	25/02/92	10/03/92				
				HTC	20/10/90	40.0	54.0	Z	43.00	38.00	38.00	13.00	14.30	13.40		
				RBC	20/10/90	4.3	6.1	10**6/mm ³	4.80	4.00	4.00	38.00	42.00	42.00	38.00	
				NBC	20/10/90	4.0	11.0	10 ³ -3/MNC	5.60	7.10	5.80	4.60	4.60	4.20	4.20	
				NBC: N	20/10/90	40.0	70.0	Z	54.00	70.00	54.00	7.10	5.80	5.80	6.50	
				NBC: L	20/10/90	20.0	40.0	Z	41.00	22.00	42.00	54.00	42.00	42.00	60.00	
				NBC: E	20/10/90	1.0	5.0	Z	3.00	3.00	3.00	42.00	25.00	25.00	25.00	
				NBC: M	20/10/90	4.0	8.0	Z	2.00	5.00	3.00	3.00	1.00	1.00	5.00	
				NBC: B	20/10/90	0.0	1.0	Z	0.00	0.00	0.00	3.00	3.00	3.00	9.00	
				PLATELETS	20/10/90	150.0	550.0	10 ³ -3/MNC	185.00	270.00	185.00	0.00	0.00	0.00	1.00	
				K+	20/10/90	138.0	155.0	M EQ/L	139.00	136.00	140.00	270.00	192.00	192.00	216.00	
				CL-	20/10/90	98.0	120.0	M EQ/L	95.00	96.00	96.00	136.00	140.00	140.00	139.00	
				PO4-	20/10/90	3.5	5.5	M EQ/L	3.90	4.10	4.10	96.00	96.00	96.00	102.00	
				SGPT	20/10/90	8.5	10.5	RG/DL	9.30	9.90	9.90	4.10	4.60	4.60	4.10	
				GAMA-GT	20/10/90	12.0	40.0	RG/DL	3.30	3.00	3.20	9.10	9.10	9.10	9.80	
				GLUCOSE	20/10/90	10.0	40.0	MU/ML	21.00	24.00	21.00	3.20	3.20	3.20	3.20	
				ALK. PHOSPH.	20/10/90	11.0	51.0	MU/ML	35.00	24.00	28.00	21.00	21.00	21.00	26.00	
				CREATININE	20/10/90	70.0	100.0	MG/DL	96.00	90.00	92.00	28.00	29.00	29.00	30.00	
				URIC ACID	20/10/90	65.0	306.0	MU/ML	140.00	240.00	240.00	90.00	96.00	96.00	90.00	
				TOT BILIRUBIN	20/10/90	10.0	50.0	MG/DL	38.00	24.00	24.00	240.00	182.00	182.00	231.00	
				DIR BILIRUBIN	20/10/90	0.6	1.6	MG/DL	1.10	1.00	1.00	27.00	27.00	27.00	27.00	
				TOT. PROTEINS	20/10/90	3.4	7.0	MG/DL	7.00	4.30	4.30	1.20	1.20	1.20	0.90	
				ALBUMINE	20/10/90	0.2	1.0	MG/DL	0.50	1.00	1.00	4.30	5.20	5.20	4.10	
				TOT. CHOLEST.	20/10/90	0.0	0.4	MG/DL	0.20	0.50	0.50	1.00	0.80	0.80	1.10	
				TRIGLYCERIDES	20/10/90	6.0	8.0	G/DL	6.60	6.90	6.90	0.20	0.20	0.20	0.50	
				GLOBULINS: ALPHA 1	20/10/90	3.5	5.0	G/DL	3.90	4.00	4.00	6.60	6.80	6.80	7.20	
				GLOBULINS: ALPHA 2	20/10/90	140.0	270.0	MG/DL	195.00	273.00	273.00	4.00	4.00	4.00	4.00	
				GLOBULINS: BETA	20/10/90	35.0	175.0	MG/DL	135.00	87.00	87.00	175.00	175.00	175.00	217.00	
				GLOBULINS: CANNA	20/10/90	4.0	7.0	Z	6.20	4.00	4.00	80.00	80.00	80.00	80.00	
				T3	20/10/90	7.0	11.0	Z	8.00	8.10	8.10	3.20	3.20	3.20	3.60	
				T4	20/10/90	11.0	14.0	Z	11.70	13.20	13.20	4.00	5.80	5.80	9.00	
					20/10/90	15.0	22.0	Z	14.10	20.10	20.10	10.20	10.20	10.20	14.10	
					20/10/90	86.0	187.0	NG Z	100.00	17.50	17.50	17.50	17.50	17.50	21.10	
					20/10/90	4.5	12.5	MG/DL	8.40	203.00	203.00	21.10	21.10	21.10	21.10	
					20/10/90	150.0	550.0	10 ³ -3/MNC								
					20/10/90	12.0	16.0	G/100ML	21/01/92	11/02/92	25/02/92	10/03/92				
				HR	20/10/90	37.0	47.0	Z	12.70	13.60	12.90	15.60	12.90	12.90	15.60	
				HTC	20/10/90	3.8	5.4	10 ³ -6/MNC	38.00	36.00	36.00	38.00	38.00	38.00	38.00	
				RBC	20/10/90	4.0	11.0	10 ³ -3/MNC	4.20	4.60	4.60	4.60	4.60	4.60	4.60	
				NBC	20/10/90	40.0	70.0	Z	59.00	50.00	50.00	5.90	5.80	5.80	5.90	
				NBC: N	20/10/90	20.0	40.0	Z	30.00	40.00	40.00	41.00	41.00	41.00	55.00	
				NBC: L	20/10/90	1.0	5.0	Z	6.00	2.00	2.00	35.00	46.00	46.00	35.00	
				NBC: E	20/10/90	4.0	8.0	Z	5.00	8.00	8.00	9.00	9.00	9.00	3.00	
				NBC: M	20/10/90	0.0	1.0	Z	0.00	0.00	0.00	7.00	4.00	4.00	7.00	
				PLATELETS	20/10/90	150.0	550.0	10 ³ -3/MNC	203.00	263.00	263.00	0.00	0.00	0.00	0.00	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6			
1	73	FMA	FEMALE	MA+	20/10/90	138.0	155.0	M EQ/L	139.00	139.00	138.00	139.00	139.00		
				K+	20/10/90	3.5	5.5	M EQ/L	4.20	4.20	4.00	4.10			
				CL-	20/10/90	98.0	120.0	M EQ/L	96.00	97.00	96.00	99.00			
				Ca++	20/10/90	8.5	10.5	MG/DL	8.70	9.50	9.30	9.70			
				PO4-	20/10/90	3.0	4.5	MG/DL	3.60	4.00	3.80	3.80			
				SGOT	20/10/90	12.0	40.0	IU/ML	23.00	23.00	28.00	22.00			
				SGPT	20/10/90	10.0	40.0	IU/ML	26.00	26.00	19.00	26.00			
				GAMMA-GT	20/10/90	7.0	33.0	IU/ML	18.00	30.00	29.00	34.00			
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	101.00	86.00	98.00	91.00			
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	234.00	210.00	254.00	273.00			
				BUN	20/10/90	10.0	50.0	MG/DL	29.00	26.00	25.00	28.00			
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	0.80	1.00	0.90			
				URIC ACID	20/10/90	2.4	5.7	MG/DL	2.90	3.60	2.70	3.80			
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.70	0.80	0.60	0.90			
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.60	0.30	0.40			
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.80	7.20	7.20	7.20			
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.20	4.30	4.30			
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	167.00	152.00	169.00	172.00			
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	50.00	89.00	42.00	89.00			
				GLUCOLINS: ALPHA 1	20/10/90	4.0	7.0	%	4.00	4.00	2.20	4.00			
				GLUCOLINS: ALPHA 2	20/10/90	7.0	11.0	%	8.70	8.70	7.10	12.10			
				GLUCOLINS: BETA	20/10/90	11.0	14.0	%	13.40	13.40	10.90	9.30			
				GLUCOLINS: GAMMA	20/10/90	15.0	22.0	%	20.80	19.50	25.40	18.20			
				T3	20/10/90	86.0	187.0	NG %	96.00						
				T4	20/10/90	4.5	12.5	NG/DL	8.70						
				74	IVL	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	11.10	11/02/92	21/01/92	10/03/92
							HTC	20/10/90	37.0	47.0	%	12.20	12.20	11.80	13.20
							RBC	20/10/90	3.8	5.4	10 ⁶ -6/HMC	34.00	37.00	35.00	38.00
							HRC: N	20/10/90	4.0	11.0	10 ⁶ -3/HMC	3.60	4.10	3.80	4.40
							HRC: L	20/10/90	40.0	70.0	%	5.70	6.30	5.30	6.00
							HRC: E	20/10/90	20.0	40.0	%	61.00	56.00	60.00	60.00
							HRC: M	20/10/90	1.0	5.0	%	30.00	30.00	29.00	25.00
							HRC: B	20/10/90	4.0	8.0	%	3.00	6.00	3.00	5.00
							PLATELETS	20/10/90	0.0	1.0	%	5.00	8.00	8.00	10.00
NA+	20/10/90	150.0	550.0				10 ³ -3/HMC	295.00	271.00	273.00	270.00				
K+	20/10/90	138.0	155.0				M EQ/L	139.00	141.00	137.00	137.00				
CL-	20/10/90	98.0	120.0				M EQ/L	98.00	98.00	96.00	98.00				
PO4-	20/10/90	3.0	4.5				MG/DL	3.50	3.50	3.40	3.40				
SGOT	20/10/90	12.0	40.0				IU/ML	33.00	20.00	21.00	22.00				
SGPT	20/10/90	10.0	40.0				IU/ML	27.00	26.00	30.00	28.00				
GAMMA-GT	20/10/90	7.0	33.0				IU/ML	58.00	52.00	31.00	31.00				
GLUCOSE	20/10/90	70.0	100.0				MG/DL	87.00	102.00	82.00	93.00				
ALK. PHOSPH.	20/10/90	65.0	306.0				IU/ML	158.00	166.00	143.00	143.00				
BUN	20/10/90	10.0	50.0				MG/DL	33.00	30.00	28.00	36.00				
CREATININE	20/10/90	0.6	1.6				MG/DL	0.80	0.80	0.80	0.90				
URIC ACID	20/10/90	2.4	5.7	MG/DL	4.10	4.00	4.00	3.60							

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOEMINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6			
1	74	IVL	FEMALE	TOT BILIRUBIN	20/10/90	0.2	1.0	NG/DL	1.30	0.60	0.50	0.70			
				DIR BILIRUBIN	20/10/90	0.0	0.4	NG/DL	0.80	0.20	0.30	0.40			
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.00	7.20	7.00	7.40			
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	4.30	4.00	4.30			
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	198.00	160.00	90.00	169.00			
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	66.00	87.00	45.00	88.00			
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	Z	3.90	3.00	2.30	4.00			
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	Z	9.00	6.00	6.70	6.30			
				GLOBULINS: BETA	20/10/90	11.0	14.0	Z	12.80	11.40	11.50	11.20			
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	Z	17.60	17.30	19.10	16.70			
				T3	20/10/90	86.0	187.0	NG %	110.00						
				T4	20/10/90	4.5	12.5	NG/DL	8.60						
				75	ELF	FEMALE	HR	20/10/90	12.0	16.0	G/100ML	12.70	14.20	14.00	13/03/92
							HTC	20/10/90	37.0	47.0	Z	38.00	40.00	39.00	41.00
							RBC	20/10/90	3.8	5.4	10 ⁶ /MHC	4.30	4.40	4.40	4.60
							HBC	20/10/90	4.0	11.0	10 ³ /MHC	4.90	5.90	5.50	5.30
							HBC: N	20/10/90	40.0	70.0	Z	52.00	59.00	62.00	58.00
							HBC: L	20/10/90	20.0	40.0	Z	39.00	32.00	24.00	26.00
							HBC: E	20/10/90	1.0	5.0	Z	4.00	3.00	4.00	5.00
							HBC: M	20/10/90	4.0	8.0	Z	5.00	6.00	10.00	10.00
HBC: B	20/10/90	0.0	1.0				Z	0.00	0.00	0.00	1.00				
PLATELETS	20/10/90	150.0	550.0				10 ³ -3/MHC	210.00	263.00	227.00	190.00				
Na+	20/10/90	138.0	155.0				M EQ/L	142.00	139.00	141.00	140.00				
K+	20/10/90	3.5	5.5				M EQ/L	4.30	4.20	4.00	3.90				
CL-	20/10/90	98.0	120.0				M EQ/L	98.00	103.00	103.00	100.00				
Ca++	20/10/90	8.5	10.5				MG/DL	9.40	9.80	9.80	9.40				
PO4--	20/10/90	3.0	4.5				MG/DL	4.20	4.20	4.00	3.80				
SGOT	20/10/90	12.0	40.0				MU/ML	27.00	34.00	38.00	36.00				
SGPT	20/10/90	10.0	40.0				MU/ML	28.00	38.00	40.00	38.00				
GAMMA-GT	20/10/90	7.0	33.0				MU/ML	34.00	26.00	28.00	27.00				
GLUCOSE	20/10/90	70.0	100.0				MG/DL	84.00	96.00	94.00	99.00				
ALK. PHOSPH.	20/10/90	65.0	306.0				MU/ML	221.00	191.00	219.00	220.00				
UREA	20/10/90	10.0	50.0	MG/DL	32.00	26.00	24.00	29.00							
CREATININE	20/10/90	0.6	1.6	MG/DL	1.00	1.00	0.90	0.80							
URIC ACID	20/10/90	2.4	5.7	MG/DL	4.60	3.60	3.80	4.10							
DIR BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	0.90	0.80	0.90							
TOT BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.40	0.40	0.40							
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.20	7.20	7.30	7.50							
ALBUMINE	20/10/90	3.5	5.0	G/DL	3.80	4.30	4.30	4.40							
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	214.00	163.00	161.00	148.00							
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	112.00	69.00	76.00	83.00							
GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	Z	3.10	4.10	4.10	3.00							
GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	Z	9.20	10.20	10.20	10.00							
GLOBULINS: BETA	20/10/90	11.0	14.0	Z	14.50	13.90	9.30	8.60							
GLOBULINS: GAMMA	20/10/90	15.0	22.0	Z	20.60	20.90	21.10	22.30							
T3	20/10/90	86.0	187.0	NG %	90.00										
T4	20/10/90	4.5	12.5	NG/DL	7.60										

1603

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6			
1	76	SFA	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	31/01/92	21/02/92	06/03/92	20/03/92	13.10	13.30	13.10
				HTC	20/10/90	37.0	47.0	Z	40.00	39.00	39.00	38.00	39.00	38.00	
				RBC	20/10/90	3.8	5.4	10 ⁶ -6/MHC	4.60	4.50	4.60	4.40	4.60	4.40	
				HBC	20/10/90	4.0	11.0	10 ³ -3/MHC	6.50	6.40	6.20	5.90	6.20	4.40	
				NBC: N	20/10/90	40.0	70.0	Z	58.00	60.00	63.00	62.00	63.00	62.00	
				NBC: L	20/10/90	20.0	40.0	Z	29.00	27.00	27.00	28.00	27.00	28.00	
				NBC: E	20/10/90	1.0	5.0	Z	5.00	5.00	5.00	4.00	5.00	4.00	
				NBC: M	20/10/90	4.0	8.0	Z	6.00	6.00	7.00	6.00	7.00	6.00	
				NBC: B	20/10/90	0.0	1.0	Z	2.00	2.00	0.00	0.00	0.00	0.00	
				PLATELETS	20/10/90	150.0	550.0	10 ³ -3/MHC	217.00	215.00	261.00	273.00	261.00	273.00	
				NA+	20/10/90	138.0	155.0	MEQ/L	183.00	137.00	138.00	142.00	138.00	142.00	
				K+	20/10/90	3.5	5.5	MEQ/L	3.90	3.80	3.90	3.90	3.80	3.90	
				CL-	20/10/90	98.0	120.0	MEQ/L	98.00	100.00	96.00	101.00	96.00	101.00	
				CA++	20/10/90	8.5	10.5	MG/DL	9.50	9.50	9.70	9.60	9.70	9.60	
				PO4-	20/10/90	3.0	4.5	MG/DL	3.40	3.30	3.30	3.30	3.30	3.30	
				SGPT	20/10/90	12.0	40.0	NU/ML	18.00	22.00	22.00	28.00	22.00	28.00	
				SGPT	20/10/90	10.0	40.0	NU/ML	20.00	26.00	24.00	30.00	24.00	30.00	
				GAMMA-GT	20/10/90	7.0	33.0	NU/ML	35.00	38.00	36.00	36.00	36.00	36.00	
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	91.00	98.00	98.00	103.00	98.00	103.00	
				ALK. PHOSPH.	20/10/90	65.0	306.0	NU/ML	193.00	163.00	182.00	176.00	182.00	176.00	
				BUN	20/10/90	10.0	50.0	MG/DL	30.00	29.00	29.00	34.00	29.00	34.00	
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	0.90	0.80	0.90	0.80	0.90	
				URIC ACID	20/10/90	2.4	5.7	MG/DL	7.10	7.00	6.30	5.70	6.30	5.70	
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	1.00	0.90	1.10	1.00	1.10	1.00	
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.50	0.40	0.50	0.50	0.50	0.50	
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.70	6.50	6.60	6.40	6.60	6.40	
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.10	4.20	4.00	4.20	4.00	
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	200.00	213.00	218.00	190.00	218.00	190.00	
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	145.00	143.00	122.00	123.00	122.00	123.00					
GLORULINS: ALPHA 1	20/10/90	4.0	7.0	Z	6.80	6.90	4.20	4.30	6.90	4.30					
GLORULINS: ALPHA 2	20/10/90	7.0	11.0	Z	7.60	7.50	8.50	9.50	7.50	9.50					
GLORULINS: BETA	20/10/90	11.0	14.0	Z	11.70	11.50	12.30	13.30	11.50	13.30					
GLORULINS: GAMMA	20/10/90	15.0	22.0	Z	14.10	14.20	13.90	14.10	13.90	14.10					
T3	20/10/90	86.0	187.0	NG Z	98.00	98.00	98.00	8.00	98.00	8.00					
T4	20/10/90	4.5	12.5	NG/DL	8.30	8.30	8.30	1.00	8.30	1.00					
PLATELETS	20/10/90	150.0	550.0	10 ³ -3/MHC	273.00	293.00	255.00	331.00	255.00	331.00					
77	ACS	MALE	HB	20/10/90	14.0	18.0	g/100ml	31/01/92	21/02/92	06/03/92	20/03/92	13.10	13.40	13.10	
			HTC	20/10/90	40.0	54.0	Z	39.00	40.00	40.00	41.00	40.00	41.00		
			RBC	20/10/90	4.3	6.1	10 ⁶ *6/mm	4.60	4.70	4.60	4.30	4.60	4.30		
			HBC	20/10/90	4.0	11.0	10 ³ -3/MHC	6.00	5.80	5.60	5.90	5.60	5.90		
			NBC: N	20/10/90	40.0	70.0	Z	62.00	56.00	52.00	53.00	52.00	53.00		
			NBC: L	20/10/90	20.0	40.0	Z	32.00	27.00	26.00	32.00	26.00	32.00		
			NBC: E	20/10/90	1.0	5.0	Z	4.00	2.00	3.00	3.00	3.00	3.00		
			NBC: M	20/10/90	4.0	8.0	Z	2.00	1.00	1.00	2.00	1.00	2.00		
			NBC: B	20/10/90	0.0	1.0	Z	0.00	0.00	0.00	0.00	0.00	0.00		
			PLATELETS	20/10/90	150.0	550.0	10 ³ -3/MHC	273.00	293.00	255.00	331.00	255.00	331.00		

1604

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Screen	Visit					
					Date	Min	Max		Unit	Week 2	Week 4	Week 6		
1	77	ACS	MALE	NA+	20/10/90	138.0	155.0	M EQ/L	141.00	142.00	140.00	142.00	142.00	142.00
				K+	20/10/90	3.5	5.5	M EQ/L	3.70	3.90	3.90	3.90	3.90	4.10
				CL-	20/10/90	98.0	120.0	M EQ/L	101.00	99.00	103.00	103.00	97.00	97.00
				CA++	20/10/90	8.5	10.5	MG/DL	9.40	9.60	9.80	9.80	9.80	9.80
				PO4--	20/10/90	3.0	4.5	MG/DL	3.60	3.40	3.20	3.20	3.60	3.60
				SGOT	20/10/90	12.0	40.0	NU/ML	22.00	25.00	28.00	28.00	28.00	28.00
				GAMMA-GT	20/10/90	10.0	40.0	NU/ML	24.00	28.00	26.00	32.00	32.00	32.00
				GLUCOSE	20/10/90	11.0	51.0	MU/ML	36.00	38.00	32.00	34.00	34.00	34.00
				ALK. PHOSPH.	20/10/90	70.0	100.0	NG/DL	96.00	86.00	92.00	92.00	92.00	92.00
				BUN	20/10/90	65.0	306.0	MU/ML	182.00	216.00	198.00	188.00	188.00	188.00
				CREATININE	20/10/90	10.0	50.0	MG/DL	25.00	26.00	28.00	29.00	29.00	29.00
				URIC ACID	20/10/90	0.6	1.6	MG/DL	0.70	0.80	0.90	0.80	0.80	0.80
				TOT BILIRUBIN	20/10/90	3.4	7.0	MG/DL	7.30	6.80	6.40	6.20	6.20	6.20
				DIR BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.90	0.90	0.80	0.80	0.80	0.80
				TOT. PROTEINS	20/10/90	0.0	0.4	MG/DL	0.50	0.50	0.50	0.50	0.50	0.50
				ALBUMINE	20/10/90	6.0	8.0	G/DL	6.20	6.20	6.20	6.20	6.20	6.20
				TOT. CHOLEST.	20/10/90	3.5	5.0	G/DL	4.10	4.20	4.00	3.90	3.90	3.90
				TRIGLYCERIDES	20/10/90	140.0	270.0	MG/DL	198.00	213.00	194.00	137.00	137.00	137.00
				GLOBULINS: ALPHA 1	20/10/90	35.0	175.0	MG/DL	136.00	110.00	103.00	88.00	88.00	88.00
				GLOBULINS: ALPHA 2	20/10/90	4.0	7.0	X	5.00	4.80	4.60	4.50	4.50	4.50
				GLOBULINS: BETA	20/10/90	7.0	11.0	X	6.70	6.60	6.30	6.40	6.40	6.40
				GLOBULINS: GAMMA	20/10/90	11.0	14.0	X	10.30	12.40	13.20	12.90	12.90	12.90
				T3	20/10/90	15.0	22.0	X	13.20	13.60	12.80	13.80	13.80	13.80
				T4	20/10/90	86.0	187.0	NG X	97.00					
					20/10/90	4.5	12.5	NG/DL	7.60					
78	SD		FEMALE	HB	20/10/90	12.0	16.0	G/100ML	31/01/92	21/02/92	06/03/92	20/03/92		
				HTC	20/10/90	37.0	47.0	X	12.50	12.80	13.20	12.40	12.40	12.40
				RBC	20/10/90	3.8	5.4	10-6/MHC	41.00	40.00	40.00	39.00	39.00	39.00
				MBC: N	20/10/90	4.0	11.0	10-3/MHC	4.00	4.10	3.90	4.10	4.10	4.10
				MBC: L	20/10/90	40.0	70.0	X	5.20	5.50	6.00	6.70	6.70	6.70
				MBC: E	20/10/90	20.0	40.0	X	58.00	56.00	59.00	61.00	61.00	61.00
				MBC: M	20/10/90	1.0	5.0	X	35.00	36.00	30.00	27.00	27.00	27.00
				MBC: B	20/10/90	4.0	8.0	X	2.00	3.00	4.00	5.00	5.00	5.00
				PLATELETS	20/10/90	0.0	1.0	X	0.00	0.00	0.00	0.00	0.00	0.00
				NA+	20/10/90	150.0	550.0	10-3/MHC	312.00	341.00	227.00	311.00	311.00	311.00
				K+	20/10/90	138.0	165.0	M EQ/L	142.00	138.00	141.00	137.00	137.00	137.00
				CL-	20/10/90	98.0	120.0	H EQ/L	102.00	104.00	104.00	98.00	98.00	98.00
				CA++	20/10/90	8.5	10.5	MG/DL	9.90	9.50	9.90	9.60	9.60	9.60
				PO4--	20/10/90	3.0	4.5	MG/DL	3.80	3.80	3.60	3.50	3.50	3.50
				SGOT	20/10/90	12.0	40.0	NU/ML	35.00	36.00	32.00	27.00	27.00	27.00
				SGPT	20/10/90	10.0	40.0	NU/ML	32.00	33.00	36.00	26.00	26.00	26.00
				GAMMA-GT	20/10/90	7.0	33.0	NU/ML	39.00	42.00	37.00	34.00	34.00	34.00
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	104.00	104.00	96.00	96.00	96.00	96.00
				ALK. PHOSPH.	20/10/90	65.0	306.0	MU/ML	210.00	178.00	223.00	191.00	191.00	191.00
				BUN	20/10/90	10.0	50.0	MG/DL	28.00	26.00	26.00	27.00	27.00	27.00
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.60	0.70	1.00	1.00	1.00	1.00
				URIC ACID	20/10/90	2.4	5.7	MG/DL	7.20	6.60	6.50	6.60	6.60	6.60

1605

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit									
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6					
1	78	SD	FEMALE	TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.80	0.90	0.70	0.90					
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.50	0.40	0.40					
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.70	6.70	6.50	6.50					
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.30	4.30	4.00	4.10					
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	171.00	173.00	230.00	133.00					
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	106.00	92.00	89.00	102.00					
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	4.60	4.10	4.80	4.20					
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	6.60	7.30	6.90	6.70					
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	13.20	14.10	16.20	13.40					
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	15.10	16.20	13.70	18.20					
				T3	20/10/90	86.0	187.0	NG %	99.00								
				T4	20/10/90	4.5	12.5	NG/DL	7.80								
				79	JCH	SD	MALE	RR	20/10/90	14.0	18.0	g/100mL	11.80	12.00	12.20	12.10	
								HTC	20/10/90	40.0	94.0	%	36.00	36.00	37.00	37.00	
								RBC	20/10/90	4.3	6.1	10 ⁶ /mm ³	4.90	4.00	4.20	3.90	
								REC	20/10/90	4.0	11.0	10 ³ -S/MHC	4.90	5.10	5.30	5.20	
								REC: N	20/10/90	40.0	70.0	%	65.00	63.00	66.00	58.00	
REC: L	20/10/90	20.0	40.0					%	27.00	28.00	29.00	26.00					
REC: E	20/10/90	1.0	5.0					%	4.00	2.00	1.00	4.00					
REC: M	20/10/90	4.0	8.0					%	4.00	7.00	4.00	8.00					
REC: B	20/10/90	0.0	1.0					%	0.00	0.00	0.00	0.00					
PLATELETS	20/10/90	150.0	550.0					10 ³ -S/MHC	239.00	247.00	261.00	279.00					
NA+	20/10/90	138.0	155.0					M EQ/L	137.00	138.00	137.00	141.00					
K+	20/10/90	3.5	5.5					M EQ/L	3.90	3.80	4.10	3.80					
CL-	20/10/90	98.0	120.0					M EQ/L	96.00	98.00	97.00	97.00					
CA++	20/10/90	8.5	10.5					MG/DL	7.90	8.80	9.20	9.00					
PO4--	20/10/90	3.0	4.5					MG/DL	2.90	3.20	3.00	3.10					
SCOT	20/10/90	12.0	40.0					MU/HL	25.00	26.00	27.00	27.00					
SGPT	20/10/90	10.0	40.0					MU/HL	28.00	28.00	36.00	29.00					
GAMMA-GT	20/10/90	11.0	51.0	MU/HL	12.00	13.00	21.00	22.00									
GLUCOSE	20/10/90	70.0	100.0	MG/DL	89.00	92.00	103.00	86.00									
ALK. PHOSPH.	20/10/90	65.0	306.0	MU/HL	139.00	141.00	193.00	141.00									
BUN	20/10/90	10.0	50.0	MG/DL	30.00	32.00	28.00	27.00									
CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	0.80	0.90	0.90									
URIC ACID	20/10/90	3.4	7.0	MG/DL	3.30	3.40	3.40	3.20									
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.70	0.80	0.90	0.80									
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.50	0.40	0.40									
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.10	6.80	6.80	6.10									
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.50	4.10	4.00	4.00									
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	183.00	192.00	191.00	162.00									
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	61.00	57.00	61.00	63.00									
GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	6.30	5.90	6.10	6.00									
GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	8.20	8.50	8.30	7.40									
GLOBULINS: BETA	20/10/90	11.0	14.0	%	11.90	12.10	12.50	12.30									
GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	17.10	18.00	18.20	19.10									
T3	20/10/90	86.0	187.0	NG %	130.00												
T4	20/10/90	4.5	12.5	NG/DL	6.90												

1606

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Unit	Screen	Visit		
					Date	Min	Max			Week 2	Week 4	Week 6
1	80	MEL	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	31/01/92	21/02/92	06/03/92	20/03/92
				HTC	20/10/90	37.0	47.0	Z	12.30	12.50	12.80	12.40
				PRC	20/10/90	3.8	5.4	10-6/HMC	38.00	38.00	38.00	38.00
				HBC: N	20/10/90	4.0	11.0	10-3/HMC	3.90	3.90	4.10	4.20
				HBC: L	20/10/90	40.0	70.0	Z	5.90	6.20	6.30	6.10
				HBC: E	20/10/90	20.0	40.0	Z	62.00	66.00	64.00	65.00
				HBC: M	20/10/90	1.0	5.0	Z	30.00	26.00	24.00	25.00
				HBC: B	20/10/90	4.0	8.0	Z	4.00	2.00	6.00	4.00
				PLATELETS	20/10/90	0.0	1.0	Z	0.00	0.00	0.00	0.00
				NA+	20/10/90	150.0	550.0	10-3/HMC	307.00	325.00	282.00	318.00
				K+	20/10/90	138.0	155.0	M EQ/L	158.00	138.00	138.00	139.00
				CL-	20/10/90	98.0	120.0	M EQ/L	98.00	99.00	96.00	96.00
				CA++	20/10/90	8.5	10.5	MG/DL	8.10	8.60	8.40	9.00
				PO4--	20/10/90	3.0	4.5	MG/DL	3.20	3.30	3.20	3.40
				SGPT	20/10/90	12.0	40.0	RU/HL	27.00	29.00	37.00	28.00
				GAMMA-GT	20/10/90	10.0	40.0	RU/HL	28.00	30.00	38.00	36.00
				GLUCOSE	20/10/90	7.0	33.0	MG/DL	18.00	17.00	28.00	18.00
				ALK. PHOSPH.	20/10/90	70.0	100.0	MG/DL	108.00	102.00	86.00	102.00
				URIC ACID	20/10/90	65.0	306.0	MG/DL	151.00	163.00	173.00	165.00
				CREATININE	20/10/90	10.0	50.0	MG/DL	27.00	28.00	28.00	28.00
				TOT BILIRUBIN	20/10/90	0.6	1.6	MG/DL	1.00	0.80	1.10	0.90
				DIR BILIRUBIN	20/10/90	2.4	5.7	MG/DL	3.70	3.50	3.80	3.80
				TOT. PROTEINS	20/10/90	0.2	1.0	MG/DL	0.80	0.70	0.90	0.60
				ALBUMINE	20/10/90	0.0	0.4	MG/DL	0.40	0.40	0.50	0.30
				TOT. CHOLEST.	20/10/90	6.0	8.0	G/DL	7.20	6.20	6.20	6.80
				TRIGLYCERIDES	20/10/90	3.5	5.0	G/DL	4.60	4.10	3.60	4.10
				GLORULINS: ALPHA 1	20/10/90	140.0	270.0	MG/DL	195.00	192.00	175.00	165.00
				GLORULINS: ALPHA 2	20/10/90	35.0	175.0	MG/DL	82.00	88.00	92.00	104.00
				GLORULINS: BETA	20/10/90	4.0	7.0	Z	6.60	4.90	3.60	6.30
				GLORULINS: GAMMA	20/10/90	11.0	14.0	Z	7.20	7.10	6.20	7.50
				T3	20/10/90	15.0	22.0	Z	10.90	8.90	14.80	10.30
T4	20/10/90	86.0	187.0	NG %	136.00	16.30	17.60	15.90				
	20/10/90	4.5	12.5	MG/DL	7.40							
81	MFB	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	31/01/92	21/02/92	06/03/92	20/03/92	
			HTC	20/10/90	37.0	47.0	Z	14.10	14.00	14.20	14.80	
			PRC	20/10/90	3.8	5.4	10-6/HMC	40.00	40.00	41.00	42.00	
			HBC: N	20/10/90	4.0	11.0	10-3/HMC	4.30	4.20	4.50	4.60	
			HBC: L	20/10/90	40.0	70.0	Z	59.00	60.00	63.00	56.00	
			HBC: E	20/10/90	20.0	40.0	Z	31.00	29.00	27.00	30.00	
			HBC: M	20/10/90	1.0	5.0	Z	5.00	4.00	2.00	4.00	
			HBC: B	20/10/90	4.0	8.0	Z	5.00	7.00	8.00	9.00	
			PLATELETS	20/10/90	0.0	1.0	Z	0.00	0.00	0.00	1.00	
				20/10/90	150.0	550.0	10-3/HMC	318.00	331.00	310.00	288.00	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Screen	Visit				
					Date	Min	Max		Unit	Week 2	Week 4	Week 6	
1	81	MFB	FEMALE	Na+	20/10/90	138.0	155.0	M EQ/L	141.00	143.00	142.00	140.00	
				K+	20/10/90	3.5	5.5	M EQ/L	3.80	3.70	3.90	4.20	
				CL-	20/10/90	98.0	120.0	M EQ/L	102.00	101.00	97.00	103.00	
				Ca++	20/10/90	8.5	10.5	MG/DL	9.20	9.00	8.90	10.20	
				PO4-	20/10/90	3.0	4.5	MG/DL	4.10	4.20	4.20	4.00	
				SGOT	20/10/90	12.0	40.0	IU/HL	30.00	38.00	28.00	33.00	
				SGPT	20/10/90	10.0	40.0	IU/HL	26.00	36.00	32.00	36.00	
				GAMMA-GT	20/10/90	7.0	33.0	IU/HL	21.00	22.00	24.00	24.00	
				GLUCOSE	20/10/90	65.0	100.0	MG/DL	110.00	103.00	96.00	105.00	
				ALK. PHOSPH.	20/10/90	10.0	306.0	IU/HL	143.00	158.00	128.00	188.00	
				BUN	20/10/90	0.6	50.0	MG/DL	32.00	34.00	29.00	34.00	
				CREATININE	20/10/90	0.6	1.6	MG/DL	1.10	1.00	1.00	1.20	
				URIC ACID	20/10/90	2.4	5.7	MG/DL	3.80	3.70	3.60	4.20	
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.90	0.90	0.80	1.00	
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.40	0.40	0.50	
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	8.00	7.80	7.60	7.80	
				ALBUMINE	20/10/90	3.5	5.0	G/DL	5.00	4.80	4.10	3.80	
				TOT. CHOLEST.	20/10/90	160.0	270.0	MG/DL	187.00	174.00	138.00	178.00	
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	93.00	98.00	107.00	103.00	
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	6.20	5.80	5.20	4.50	
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	7.10	6.10	8.00	8.20	
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	12.90	11.50	14.10	14.30	
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	16.30	18.20	18.30	17.20	
				T3	20/10/90	86.0	187.0	NG %	137.00				
				T4	20/10/90	4.5	12.5	NG/DL	8.10				
82	MDS		FEMALE	HB	20/10/90	12.0	16.0	G/100ML	14.30	31/01/92	21/02/92	06/03/92	20/03/92
				HTC	20/10/90	37.0	47.0	%	42.00	14.20	14.10	14.20	14.10
				RBC	20/10/90	3.8	5.4	10 ⁶ -6/HMC	4.40	39.00	41.00	40.00	40.00
				HBC: N	20/10/90	4.0	11.0	10 ³ -3/HMC	6.90	4.30	4.30	4.50	4.50
				HBC: L	20/10/90	40.0	70.0	%	60.00	5.80	7.40	7.20	7.20
				HBC: E	20/10/90	20.0	40.0	%	26.00	60.00	58.00	61.00	61.00
				HRC: M	20/10/90	1.0	5.0	%	4.00	36.00	28.00	31.00	31.00
				HRC: B	20/10/90	4.0	8.0	%	10.00	2.00	4.00	2.00	2.00
				PLATELETS	20/10/90	0.0	1.0	%	0.00	0.00	1.00	0.00	0.00
				Na+	20/10/90	150.0	550.0	10 ³ -3/HMC	321.00	321.00	290.00	293.00	293.00
				K+	20/10/90	3.5	5.5	M EQ/L	141.00	138.00	142.00	142.00	142.00
				CL-	20/10/90	98.0	120.0	M EQ/L	106.00	100.00	99.00	99.00	99.00
				PO4-	20/10/90	3.0	4.5	MG/DL	4.30	3.40	3.40	3.90	3.90
				SGOT	20/10/90	12.0	40.0	IU/HL	31.00	36.00	33.00	34.00	34.00
				SGPT	20/10/90	10.0	40.0	IU/HL	34.00	32.00	35.00	36.00	36.00
				GAMMA-GT	20/10/90	7.0	33.0	IU/HL	25.00	22.00	26.00	26.00	26.00
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	91.00	84.00	94.00	103.00	103.00
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/HL	118.00	216.00	122.00	210.00	210.00
				BUN	20/10/90	10.0	50.0	MG/DL	36.00	34.00	34.00	32.00	32.00
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	0.90	0.80	0.80	0.80
				URIC ACID	20/10/90	2.4	5.7	MG/DL	3.20	3.20	4.10	4.10	4.10

1608

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
1	82	MDS	FEMALE	TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.90	0.80	1.00	0.90				
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.40	0.50	0.40				
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.40	6.80	6.90	6.80				
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.80	4.20	4.20	4.10				
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	201.00	212.00	216.00	168.00				
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	94.00	118.00	87.00	92.00				
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	4.90	4.10	4.80	4.80				
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	6.80	6.30	6.90	7.00				
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	11.30	13.50	12.90	12.50				
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	15.30	16.10	16.20	15.80				
				T3	20/10/90	86.0	187.0	NG %	141.00							
				T4	20/10/90	4.5	12.5	NG/DL	7.30							
				83	LFM	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	13.00	13.20	13.40	13.40	
							HTC	20/10/90	37.0	47.0	%	41.00	40.00	41.00	40.00	
							PRC	20/10/90	3.8	5.4	10-6/HMC	4.80	4.60	4.70	5.10	
							WBC	20/10/90	4.0	11.0	10-3/HMC	6.10	6.40	5.80	5.80	
							WBC: N	20/10/90	40.0	70.0	%	63.00	65.00	60.00	58.00	
WBC: L	20/10/90	20.0	40.0				%	26.00	27.00	28.00	28.00					
WBC: E	20/10/90	1.0	5.0				%	6.00	2.00	3.00	4.00					
WBC: H	20/10/90	4.0	8.0				%	5.00	6.00	8.00	9.00					
WBC: B	20/10/90	0.0	1.0				%	0.00	0.00	0.00	1.00					
PLATELETS	20/10/90	150.0	550.0				10-3/HMC	316.00	283.00	271.00	308.00					
NA+	20/10/90	138.0	155.0				M EQ/L	142.00	141.00	141.00	136.00					
CL-	20/10/90	3.5	5.5				M EQ/L	3.70	3.80	3.80	4.10					
PO4--	20/10/90	98.0	120.0				M EQ/L	103.00	101.00	102.00	99.00					
SCOT	20/10/90	3.0	4.5				MG/DL	10.10	10.20	10.10	9.60					
SGPT	20/10/90	12.0	40.0				HU/HL	31.00	32.00	36.00	28.00					
GAMMA-GT	20/10/90	10.0	40.0				HU/HL	33.00	34.00	34.00	26.00					
GLUCOSE	20/10/90	70.0	33.0				HU/HL	26.00	26.00	28.00	24.00					
ALK. PHOSPH.	20/10/90	65.0	306.0				HU/HL	81.00	93.00	93.00	103.00					
BUN	20/10/90	10.0	50.0				MG/DL	175.00	162.00	216.00	178.00					
CREATININE	20/10/90	0.6	1.6				MG/DL	20.00	23.00	26.00	23.00					
URIC ACID	20/10/90	2.4	5.7				MG/DL	3.50	3.20	3.60	3.40					
TOT BILIRUBIN	20/10/90	0.2	1.0				MG/DL	0.60	0.60	0.60	0.70					
DIR BILIRUBIN	20/10/90	0.0	0.4				MG/DL	0.30	0.30	0.30	0.40					
TOT. PROTEINS	20/10/90	6.0	8.0				G/DL	6.90	6.70	6.70	6.70					
ALBUMINE	20/10/90	3.5	5.0				G/DL	4.00	4.00	4.20	4.00					
TOT. CHOLEST.	20/10/90	140.0	270.0				MG/DL	161.00	162.00	210.00	129.00					
TRIGLYCERIDES	20/10/90	35.0	175.0				MG/DL	78.00	82.00	87.00	93.00					
GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	7.00	2.30	3.10	3.10								
GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	7.00	10.80	5.80	5.90								
GLOBULINS: BETA	20/10/90	11.0	14.0	%	11.10	11.30	11.30	16.80								
GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	24.30	22.30	25.10	22.30								
T3	20/10/90	86.0	187.0	NG %	92.00											
T4	20/10/90	4.5	12.5	NG/DL	9.30											

1600

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 12.1
 LABORATORY DATA
 OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Unit	Visit			
					Date	Min	Max		Screen	Week 2	Week 4	Week 6
1	84	IN	MALE	HB	20/10/90	14.0	18.0	g/100ml	31/01/92	14/02/92	06/03/92	20/03/92
				HTC	20/10/90	40.0	54.0	Z	12.80	12.70	13.20	13.20
				RBC	20/10/90	4.3	6.1	10**6/mm	38.00	36.00	37.00	40.00
				NBC	20/10/90	4.0	11.0	10-3/HMC	4.80	4.60	4.70	4.80
				NBC: N	20/10/90	40.0	70.0	Z	5.30	5.50	6.20	7.00
				NBC: L	20/10/90	20.0	40.0	Z	58.00	57.00	61.00	60.00
				NBC: E	20/10/90	1.0	5.0	Z	28.00	28.00	27.00	31.00
				NBC: M	20/10/90	4.0	8.0	Z	6.00	6.00	4.00	3.00
				NBC: B	20/10/90	0.0	1.0	Z	8.00	9.00	8.00	6.00
				PLATELETS	20/10/90	150.0	550.0	10-3/HMC	188.00	210.00	220.00	285.00
				K+	20/10/90	3.5	5.5	M EQ/L	143.00	140.00	137.00	139.00
				CL-	20/10/90	98.0	120.5	M EQ/L	3.70	3.80	3.80	3.80
				PO4-	20/10/90	3.0	4.5	MG/DL	96.00	97.00	98.00	107.00
				SGPT	20/10/90	12.0	40.0	RU/ML	4.10	4.20	4.10	3.40
				GAMMA-GT	20/10/90	10.0	40.0	RU/ML	28.00	32.00	28.00	26.00
				GLUCOSE	20/10/90	11.0	51.0	MG/ML	34.00	36.00	30.00	28.00
				ALK. PHOSPH.	20/10/90	70.0	100.0	MG/DL	26.00	28.00	24.00	22.00
				BUN	20/10/90	65.0	306.0	MG/ML	81.00	86.00	98.00	88.00
				CREATININE	20/10/90	10.0	50.0	MG/DL	172.00	151.00	141.00	184.00
				URIC ACID	20/10/90	0.6	1.6	MG/DL	17.00	18.00	21.00	21.00
				TOT BILIRUBIN	20/10/90	3.4	7.0	MG/DL	1.10	1.20	0.90	0.80
				DIR BILIRUBIN	20/10/90	0.2	1.0	MG/DL	3.40	3.20	3.30	3.80
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	1.10	0.90	0.80	0.90
				ALBUMINE	20/10/90	6.0	8.0	G/DL	0.60	0.40	0.40	0.40
				TOT. CHOLEST.	20/10/90	3.5	5.0	G/DL	6.90	6.80	6.80	7.00
				TRIGLYCERIDES	20/10/90	140.0	270.0	MG/DL	3.90	3.90	4.10	4.10
				GLOBULINS: ALPHA 1	20/10/90	35.0	175.0	MG/DL	163.00	211.00	192.00	233.00
				GLOBULINS: ALPHA 2	20/10/90	4.0	7.0	Z	88.00	120.00	116.00	95.00
				GLOBULINS: BETA	20/10/90	11.0	14.0	Z	2.00	2.50	2.40	2.60
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	Z	9.00	8.30	8.70	8.40
				T3	20/10/90	86.0	187.0	NG %	11.30	12.70	14.10	10.80
T4	20/10/90	4.5	12.5	NG/DL	23.10	23.10	23.10	24.10				
					8.80							
85	MLP	MALE	HB	20/10/90	14.0	18.0	g/100ml	31/01/92	21/02/92	06/03/92	20/03/92	
			HTC	20/10/90	40.0	54.0	Z	14.00	14.20	14.20	14.30	
			RBC	20/10/90	4.3	6.1	10**6/mm	42.00	42.00	42.00	41.00	
			NBC	20/10/90	4.0	11.0	10-3/HMC	5.00	5.20	5.00	4.80	
			NBC: N	20/10/90	40.0	70.0	Z	5.70	5.80	6.20	5.80	
			NBC: L	20/10/90	20.0	40.0	Z	61.00	61.00	64.00	61.00	
			NBC: E	20/10/90	1.0	5.0	Z	32.00	32.00	32.00	30.00	
			NBC: M	20/10/90	4.0	8.0	Z	3.00	2.00	1.00	3.00	
			NBC: B	20/10/90	0.0	1.0	Z	7.00	5.00	3.00	6.00	
			PLATELETS	20/10/90	150.0	550.0	10-3/HMC	233.00	270.00	268.00	295.00	

1610

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOLVETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Date	Laboratory Range			Screen	Visit		
						Min	Max	Unit		Week 2	Week 4	Week 6
1	85	MLP	MALE		20/10/90	138.0	155.0	K EQ/L	138.00	137.00	142.00	142.00
				K+	20/10/90	3.5	5.5	K EQ/L	4.00	4.10	3.80	4.10
				CL-	20/10/90	98.0	120.0	K EQ/L	108.00	97.00	98.00	102.00
				CA++	20/10/90	8.5	10.5	MG/DL	9.90	9.60	10.30	9.60
				PO4-	20/10/90	3.0	4.5	MG/DL	3.60	3.80	4.40	4.00
				SGPT	20/10/90	12.0	40.0	UI/ML	21.00	23.00	28.00	28.00
				SGPT	20/10/90	10.0	40.0	UI/ML	23.00	25.00	32.00	32.00
				GAMMA-GT	20/10/90	11.0	51.0	UI/ML	26.00	26.00	26.00	24.00
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	79.00	83.00	97.00	96.00
				BUN	20/10/90	65.0	306.0	MG/DL	177.00	194.00	180.00	163.00
				ALK. PHOSPH.	20/10/90	10.0	50.0	MG/DL	18.00	36.00	28.00	22.00
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	0.90	0.90	0.80
				URIC ACID	20/10/90	3.4	7.0	MG/DL	3.60	4.50	4.00	3.60
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.70	0.90	0.90	0.80
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.40	0.40	0.40
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.10	7.10	7.10	6.80
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	4.00	4.20	4.00
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	172.00	186.00	163.00	188.00
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	92.00	96.00	108.00	107.00
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	2.20	3.20	3.20	3.20
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	8.70	9.10	6.40	5.40
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	12.40	12.40	12.60	12.30
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	19.00	19.00	16.20	18.70
				T3	20/10/90	86.0	187.0	NG X	103.00			
				T4	20/10/90	4.5	12.5	NG/DL	9.30			
86	HTF		FEMALE		20/10/90	12.0	16.0	G/100ML	31/01/92	21/02/92	06/03/92	20/03/92
				HR	20/10/90	37.0	47.0	%	8.50	10.40	11.40	11.20
				HTC	20/10/90	3.8	5.4	10-6/MNC	28.00	33.00	35.00	35.00
				PRC	20/10/90	4.0	11.0	10-3/MNC	4.40	4.60	4.40	4.80
				HRC: N	20/10/90	40.0	70.0	%	3.80	4.00	5.00	5.20
				HRC: L	20/10/90	20.0	40.0	%	60.00	60.00	58.00	64.00
				HRC: E	20/10/90	1.0	5.0	%	37.00	35.00	27.00	28.00
				HRC: H	20/10/90	4.0	8.0	%	1.00	3.00	3.00	2.00
				HRC: B	20/10/90	0.0	1.0	%	2.00	2.00	10.00	6.00
				FLAYELETS	20/10/90	150.0	550.0	10-3/MNC	370.00	351.00	310.00	310.00
				K+	20/10/90	138.0	155.0	M EQ/L	141.00	149.00	139.00	142.00
				CL-	20/10/90	98.0	120.0	M EQ/L	4.60	4.60	4.10	3.90
				CA++	20/10/90	3.0	4.5	MG/DL	8.80	8.80	9.20	103.00
				PO4-	20/10/90	12.0	40.0	UI/ML	3.60	3.40	4.00	3.60
				SGPT	20/10/90	10.0	40.0	UI/ML	25.00	25.00	26.00	28.00
				SGPT	20/10/90	7.0	33.0	UI/ML	17.00	18.00	24.00	30.00
				GAMMA-GT	20/10/90	70.0	100.0	MG/DL	90.00	86.00	18.00	16.00
				GLUCOSE	20/10/90	65.0	306.0	MG/DL	290.00	264.00	258.00	276.00
				BUN	20/10/90	10.0	50.0	MG/DL	15.00	16.00	16.00	20.00
				ALK. PHOSPH.	20/10/90	0.6	1.6	MG/DL	0.80	0.90	0.90	0.90
				CREATININE	20/10/90	0.6	1.6	MG/DL	3.30	3.50	3.50	3.60

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit								
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
1	86	M/F	FEMALE	TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.40	0.40	0.60	0.60			
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.20	0.30	0.30			
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.00	7.20	7.20	7.20			
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.10	4.30	4.30			
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	176.00	188.00	188.00	192.00			
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	51.00	63.00	64.00	74.00			
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	3.10	3.20	4.00	2.80			
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	6.40	6.30	8.30	4.60			
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	13.60	14.10	14.20	14.20			
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	21.70	20.60	20.00	20.80			
				T3	20/10/90	86.0	187.0	NG %	76.00						
				T4	20/10/90	4.5	12.5	NG/DL	5.80						
				87	M/D	FEMALE	HR	20/10/90	12.0	16.0	G/100ML	31/01/92	21/02/92	06/03/92	20/03/92
							HTC	20/10/90	37.0	47.0	%	44.30	43.40	43.50	43.80
							PRC	20/10/90	3.8	5.4	10-6/MHC	43.00	39.00	38.00	39.00
							HRC	20/10/90	4.0	11.0	10-3/MHC	4.60	4.20	4.00	4.10
							HRC: N	20/10/90	40.0	70.0	%	7.80	8.20	5.80	5.80
HRC: L	20/10/90	20.0	40.0				%	61.00	56.00	60.00	62.00				
HRC: E	20/10/90	1.0	5.0				%	33.00	34.00	30.00	30.00				
HRC: H	20/10/90	4.0	8.0				%	1.00	3.00	5.00	2.00				
HRC: B	20/10/90	4.0	8.0				%	5.00	7.00	5.00	6.00				
HRC: S	20/10/90	0.0	1.0				%	0.00	0.00	0.00	0.00				
PLATELETS	20/10/90	150.0	550.0				10-3/MHC	290.00	261.00	208.00	189.00				
NA+	20/10/90	138.0	155.0				M EQ/L	140.00	138.00	138.00	140.00				
CL-	20/10/90	3.5	5.5				M EQ/L	4.10	4.10	4.00	3.90				
CA++	20/10/90	98.0	120.0				MG/DL	96.00	96.00	97.00	99.00				
PO4--	20/10/90	8.5	10.5				MG/DL	10.00	9.70	9.80	9.80				
SGPT	20/10/90	3.0	4.5				MG/DL	4.50	4.00	3.90	4.00				
GAMMA-GT	20/10/90	12.0	40.0				NU/HL	29.00	26.00	28.00	24.00				
GLUCOSE	20/10/90	10.0	40.0				MG/DL	30.00	28.00	30.00	28.00				
ALK. PHOSPH.	20/10/90	7.0	33.0				NU/HL	28.00	32.00	34.00	30.00				
BUN	20/10/90	70.0	100.0				MG/DL	92.00	91.00	86.00	102.00				
CREATININE	20/10/90	65.0	306.0				NU/HL	110.00	164.00	163.00	216.00				
URIC ACID	20/10/90	10.0	50.0				MG/DL	39.00	28.00	26.00	24.00				
TOT BILIRUBIN	20/10/90	0.6	1.6				MG/DL	0.90	0.90	0.90	0.90				
DIR BILIRUBIN	20/10/90	2.4	5.7	MG/DL	3.70	4.10	4.10	3.80							
TOT. PROTEINS	20/10/90	0.2	1.0	MG/DL	0.60	0.60	0.49	0.50							
ALBUMINE	20/10/90	0.0	0.4	MG/DL	0.20	0.20	0.20	0.30							
TOT. CHOLEST.	20/10/90	6.0	8.0	G/DL	7.60	7.00	6.80	6.80							
TRIGLYCERIDES	20/10/90	3.5	5.0	G/DL	5.20	4.20	4.20	4.00							
GLOBULINS: ALPHA 1	20/10/90	148.0	270.0	MG/DL	267.00	166.00	150.00	181.00							
GLOBULINS: ALPHA 2	20/10/90	33.0	175.0	MG/DL	111.00	110.00	92.00	90.00							
GLOBULINS: BETA	20/10/90	4.0	7.0	%	2.80	3.20	4.10	4.00							
GLOBULINS: GAMMA	20/10/90	7.0	11.0	%	8.70	8.00	8.00	8.30							
T3	20/10/90	11.0	14.0	%	14.30	11.00	11.20	11.90							
T4	20/10/90	15.0	22.0	%	14.50	14.10	18.20	18.40							

1 0 1 2

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
1	88	VRL	FEMALE	BB	20/10/90	12.0	16.0	G/100ML	04/02/92	12.00	13.90	10/03/92	14.20	24/03/92	13.90	
				HTC	20/10/90	37.0	47.0	Z	12.00	37.00	10/03/92	41.00	39.00	14.20	41.00	
				RBC	20/10/90	3.8	5.4	10-6/MNC	37.00	40.00	10/03/92	4.20	3.90	4.10	4.60	
				HBC	20/10/90	4.0	11.0	10-3/MNC	4.20	6.20	10/03/92	6.30	6.00	6.00	6.30	
				HBC: N	20/10/90	40.0	70.0	Z	6.20	60.00	10/03/92	58.00	58.00	58.00	60.00	
				HBC: L	20/10/90	20.0	40.0	Z	23.00	25.00	10/03/92	28.00	28.00	28.00	28.00	
				HBC: E	20/10/90	1.0	5.0	Z	0.00	5.00	10/03/92	5.00	5.00	5.00	4.00	
				HBC: R	20/10/90	4.0	8.0	Z	5.00	8.00	10/03/92	8.00	8.00	8.00	8.00	
				HBC: B	20/10/90	0.0	1.0	Z	0.00	2.00	10/03/92	1.00	1.00	1.00	0.00	
				PLATELETS	20/10/90	150.0	550.0	10-3/MNC	282.00	210.00	10/03/92	205.00	205.00	231.00	231.00	
				K+	20/10/90	138.0	155.0	M EQ/L	139.00	139.00	10/03/92	139.00	139.00	139.00	139.00	
				Na+	20/10/90	98.0	120.0	M EQ/L	95.00	96.00	10/03/92	96.00	96.00	96.00	102.00	
				CL-	20/10/90	8.5	10.5	MG/DL	8.60	9.80	10/03/92	9.80	9.90	9.90	9.60	
				CA++	20/10/90	3.0	4.5	MG/DL	3.40	3.90	10/03/92	4.10	4.10	4.10	3.80	
				SGOT	20/10/90	12.0	40.0	IU/ML	32.00	30.00	10/03/92	30.00	30.00	30.00	16.00	
				SGPT	20/10/90	10.0	40.0	IU/ML	13.00	32.00	10/03/92	32.00	32.00	34.00	18.00	
				GAMMA-GT	20/10/90	7.0	33.0	IU/ML	28.00	28.00	10/03/92	28.00	28.00	26.00	30.00	
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	92.00	83.00	10/03/92	91.00	91.00	91.00	92.00	
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	245.00	162.00	10/03/92	162.00	162.00	172.00	172.00	
				BUN	20/10/90	10.0	50.0	MG/DL	34.00	27.00	10/03/92	30.00	27.00	30.00	27.00	
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	0.90	10/03/92	1.00	1.00	1.00	1.00	
				URIC ACID	20/10/90	2.4	5.7	MG/DL	3.30	4.10	10/03/92	4.10	4.00	4.00	4.00	
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	1.00	0.80	10/03/92	0.80	0.80	0.90	0.90	
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.50	0.50	10/03/92	0.50	0.50	0.50	0.40	
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.80	7.00	10/03/92	7.00	7.00	6.90	7.00	
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.50	4.20	10/03/92	4.20	4.20	4.20	3.90	
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	284.00	174.00	10/03/92	174.00	174.00	171.00	178.00	
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	94.00	88.00	10/03/92	97.00	97.00	104.00	104.00	
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	Z	1.90	3.90	10/03/92	3.90	3.90	3.50	4.50	
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	Z	7.80	8.70	10/03/92	8.70	8.30	10.20	10.20	
				GLOBULINS: BETA	20/10/90	11.0	14.0	Z	13.50	11.90	10/03/92	11.90	11.90	9.60	9.60	
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	Z	7.90	20.10	10/03/92	20.10	19.70	19.50	19.50	
				T3	20/10/90	86.0	187.0	NG Z	120.00	6.80	10/03/92	6.80				
T4	20/10/90	4.5	12.5	NG/DL	6.80		10/03/92									
89	NRV		FEMALE	BB	20/10/90	12.0	16.0	G/100ML	04/02/92	13.70	25/02/92	13.70	10/03/92	15.80	24/03/92	13.80
				HTC	20/10/90	37.0	47.0	Z	41.00	40.00	10/03/92	41.00	41.00	40.00	40.00	
				RBC	20/10/90	3.8	5.4	10-6/MNC	4.50	4.50	10/03/92	4.50	4.50	4.50	4.50	
				HBC	20/10/90	4.0	11.0	10-3/MNC	4.10	4.30	10/03/92	4.30	4.00	4.00	5.00	
				HBC: N	20/10/90	40.0	70.0	Z	50.00	62.00	10/03/92	62.00	60.00	60.00	58.00	
				HBC: L	20/10/90	20.0	40.0	Z	42.00	31.00	10/03/92	31.00	30.00	30.00	32.00	
				HBC: E	20/10/90	1.0	5.0	Z	0.00	2.00	10/03/92	2.00	2.00	2.00	3.00	
				HBC: R	20/10/90	4.0	8.0	Z	8.00	5.00	10/03/92	5.00	8.00	8.00	7.00	
				HBC: B	20/10/90	0.0	1.0	Z	7.00	0.00	10/03/92	0.00	0.00	0.00	0.00	
				PLATELETS	20/10/90	150.0	550.0	10-3/MNC	184.00	170.00	10/03/92	170.00	170.00	158.00	188.00	
				K+	20/10/90	138.0	155.0	M EQ/L	139.00	139.00	10/03/92	139.00	139.00	139.00	139.00	
				Na+	20/10/90	98.0	120.0	M EQ/L	95.00	96.00	10/03/92	96.00	96.00	96.00	102.00	

1610

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPER PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Screen	Visit			
				Date	Min	Max		Unit	Week 2	Week 4	Week 6
1	89 NHV	FEMALE	NA+	20/10/90	138.0	155.0	M ER/L	141.00	140.00	139.00	139.00
			K+	20/10/90	3.5	5.5	M ER/L	3.90	3.80	3.90	4.00
			CL-	20/10/90	98.0	120.0	M ER/L	98.00	96.00	96.00	98.00
			CA++	20/10/90	8.5	10.5	MG/DL	9.50	9.80	9.70	9.60
			PO4-	20/10/90	3.0	4.5	MG/DL	3.20	3.00	2.70	4.00
			SGOT	20/10/90	12.0	40.0	IU/ML	81.00	45.00	86.00	50.00
			SGPT	20/10/90	10.0	40.0	IU/ML	101.00	48.00	90.00	48.00
			GAMMA-GT	20/10/90	7.0	33.0	IU/ML	86.00	60.00	77.00	38.00
			GLUCOSE	20/10/90	70.0	100.0	MG/DL	105.00	104.00	108.00	94.00
			ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	286.00	230.00	256.00	193.00
			BUN	20/10/90	10.0	50.0	MG/DL	38.00	30.00	35.00	32.00
			CREATININE	20/10/90	0.6	1.6	MG/DL	0.70	0.80	0.80	0.90
			URIC ACID	20/10/90	2.4	5.7	MG/DL	4.60	4.30	4.10	4.10
			TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.90	0.80	0.70	0.40
			DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.30	0.30	0.20
			TOT. PROTEINS	20/10/90	5.0	8.0	G/DL	7.10	6.90	6.90	7.00
			ALBUMINE	20/10/90	3.5	5.0	G/DL	4.30	4.00	3.90	4.20
			TOT. CHOLEST.	20/10/90	160.0	270.0	MG/DL	250.00	220.00	217.00	192.00
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	174.00	166.00	183.00	130.00
			GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	3.60	3.20	3.20	3.80
GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	8.20	10.20	10.40	4.70			
GLOBULINS: BETA	20/10/90	11.0	14.0	%	16.90	11.10	13.10	12.80			
GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	8.30	18.10	18.50	19.10			
T3	20/10/90	86.0	187.0	NG %	150.00						
T4	20/10/90	4.5	12.5	NG/DL	8.40						
90 JSS	MALE		HB	20/10/90	14.0	18.0	g/100ml	04/02/92	25/02/92	10/03/92	24/03/92
			HTC	20/10/90	40.0	54.0	%	13.90	14.40	14.20	14.00
			RBC	20/10/90	4.3	6.1	10**6/mm	4.10	4.10	4.20	39.00
			HBC: N	20/10/90	4.0	11.0	10-3/MHC	4.50	4.50	4.60	4.30
			HBC: L	20/10/90	40.0	70.0	%	5.70	6.30	6.50	6.40
			HBC: E	20/10/90	20.0	40.0	%	56.00	60.00	54.00	58.00
			HBC: M	20/10/90	1.0	5.0	%	33.00	30.00	31.00	27.00
			HBC: B	20/10/90	4.0	8.0	%	3.00	2.00	6.00	5.00
			PLATELETS	20/10/90	0.0	1.0	%	8.00	8.00	9.00	9.00
			NA+	20/10/90	150.0	550.0	10-3/MHC	196.00	217.00	217.00	280.00
			K+	20/10/90	3.5	5.5	M ER/L	162.00	138.00	141.00	141.00
			CL-	20/10/90	98.0	120.0	M ER/L	98.00	96.00	96.00	102.00
			CA++	20/10/90	8.5	10.5	MG/DL	9.50	9.20	9.20	9.60
			PO4-	20/10/90	3.0	4.5	MG/DL	3.80	3.80	3.60	3.90
			SGOT	20/10/90	12.0	40.0	IU/ML	33.00	32.00	37.00	24.00
			SGPT	20/10/90	10.0	40.0	IU/ML	19.00	30.00	28.00	28.00
			GAMMA-GT	20/10/90	11.0	51.0	IU/ML	26.00	29.00	29.00	30.00
			GLUCOSE	20/10/90	70.0	100.0	MG/DL	91.00	92.00	91.00	85.00
			ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	215.00	290.00	201.00	142.00
			BUN	20/10/90	10.0	50.0	MG/DL	48.00	28.00	54.00	26.00
CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	0.90	1.10	1.00			
URIC ACID	20/10/90	3.4	7.0	MG/DL	4.50	4.10	6.00	3.90			

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Screen			Visit					
					Date	Min	Max	Unit	Week 2	Week 4	Week 6					
1	90	JSS	MALE	TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	1.00	0.80	0.80				
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.50	0.40					
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.20	7.00	6.80					
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.50	4.10	4.20					
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	199.00	192.00	218.00					
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	54.00	84.00	90.00					
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	2.50	3.20	3.80					
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	9.10	8.30	7.40					
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	13.30	11.00	10.40					
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	8.80	11.00	10.80					
				T3	20/10/90	86.0	187.0	NG %	92.00	19.50	19.00					
				T4	20/10/90	4.5	12.5	NG/DL	8.80							
				91	MSC	FERALE	HB	20/10/90	12.0	16.0	G/100ML	14.30	14.10	14.00	24/03/92	13.80
							HTC	20/10/90	37.0	47.0	%	43.00	42.00	41.00	42.00	
							HSC	20/10/90	3.8	5.4	10 ⁶ -6/MHC	4.40	4.30	4.60	4.50	
HRC: N	20/10/90	4.0	11.0				10 ³ -3/MHC	5.90	6.60	6.20	6.20					
HRC: L	20/10/90	40.0	70.0				%	65.00	68.00	64.00	62.00					
HRC: N	20/10/90	20.0	40.0				%	25.00	26.00	26.00	28.00					
HRC: E	20/10/90	1.0	5.0				%	5.00	3.00	3.00	4.00					
HRC: M	20/10/90	4.0	8.0				%	5.00	8.00	7.00	6.00					
HRC: B	20/10/90	0.0	1.0				%	0.00	0.00	0.00	0.00					
PLATELETS	20/10/90	150.0	550.0				10 ³ -3/MHC	243.00	230.00	208.00	208.00					
NA+	20/10/90	138.0	155.0				M EQ/L	140.00	142.00	138.00	138.00					
K+	20/10/90	3.5	5.5				M EQ/L	3.90	4.10	3.80	3.80					
CL-	20/10/90	98.0	120.0				M EQ/L	98.00	99.00	101.00	96.00					
CA++	20/10/90	8.5	10.5				MG/DL	8.40	8.90	9.20	9.40					
SGOT	20/10/90	3.0	4.5				MG/DL	2.80	3.00	3.60	3.10					
SGPT	20/10/90	12.0	40.0	NU/HL	32.00	32.00	34.00	26.00								
GAMMA-GT	20/10/90	10.0	40.0	NU/HL	34.00	36.00	28.00	30.00								
GLUCOSE	20/10/90	7.0	33.0	NU/HL	28.00	26.00	26.00	24.00								
ALK. PHOSPH.	20/10/90	70.0	100.0	MG/DL	92.00	97.00	90.00	102.00								
CREATININE	20/10/90	65.0	306.0	NU/HL	290.00	234.00	210.00	231.00								
URIC ACID	20/10/90	10.0	50.0	MG/DL	35.00	32.00	30.00	32.00								
TOT BILIRUBIN	20/10/90	0.6	1.6	MG/DL	0.90	0.80	0.90	0.90								
DIR BILIRUBIN	20/10/90	2.4	5.7	MG/DL	4.30	4.20	4.10	4.30								
TOT. PROTEINS	20/10/90	0.2	1.0	MG/DL	1.10	1.00	1.00	1.00								
ALBUMINE	20/10/90	0.0	0.4	MG/DL	0.50	0.40	0.50	0.60								
TOT. CHOLEST.	20/10/90	6.0	8.0	G/DL	7.10	7.10	6.80	7.00								
TRIGLYCERIDES	20/10/90	3.5	5.0	G/DL	4.40	4.40	6.00	4.20								
GLOBULINS: ALPHA 1	20/10/90	140.0	270.0	MG/DL	141.00	186.00	158.00	167.00								
GLOBULINS: ALPHA 2	20/10/90	35.0	175.0	MG/DL	64.00	72.00	87.00	108.00								
GLOBULINS: BETA	20/10/90	4.0	7.0	%	4.30	4.20	4.70	3.80								
GLOBULINS: GAMMA	20/10/90	7.0	11.0	%	12.80	12.90	10.80	11.90								
T3	20/10/90	11.0	14.0	%	9.00	8.70	8.70	8.70								
T4	20/10/90	15.0	22.0	%	13.30	13.80	14.10	12.60								

16115

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1
LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Unit	Screen	Visit			
					Date	Min	Max			Week 2	Week 4	Week 6	
1	92	PSS	FEMALE	HR	20/10/90	12.0	16.0	G/100ML	04/02/92	25/02/92	10/03/92	24/03/92	
				HTC	20/10/90	37.0	47.0	Z	14.10	14.00	13.80	13.80	
				RBC	20/10/90	3.8	5.4	10-6/MHC	40.00	40.00	39.00	39.00	
				MBC	20/10/90	4.0	11.0	10-3/MHC	4.50	4.50	4.20	4.60	
				MBC: N	20/10/90	40.0	70.0	Z	6.10	6.90	6.60	6.40	
				MBC: L	20/10/90	20.0	40.0	Z	67.00	58.00	60.00	62.00	
				MBC: E	20/10/90	1.0	5.0	Z	28.00	37.00	38.00	30.00	
				MBC: M	20/10/90	4.0	8.0	Z	3.00	2.00	1.00	4.00	
				MBC: B	20/10/90	0.0	1.0	Z	2.00	3.00	1.00	4.00	
				PLATELETS	20/10/90	150.0	550.0	10-3/MHC	360.00	361.00	335.00	345.00	
				NA+	20/10/90	138.0	155.0	M EQ/L	139.00	141.00	139.00	141.00	
				K+	20/10/90	3.5	5.5	M EQ/L	3.80	3.90	3.90	3.90	
				Ca++	20/10/90	8.5	10.5	MG/DL	98.00	99.00	101.00	100.00	
				PO4-	20/10/90	3.0	4.5	MG/DL	8.90	9.20	10.20	9.90	
				SGPT	20/10/90	12.0	40.0	RU/ML	5.00	3.20	3.60	3.80	
				GAMMA-GT	20/10/90	10.0	40.0	RU/ML	37.00	17.00	17.00	20.00	
				GLUCOSE	20/10/90	70.0	33.0	RU/ML	29.00	19.00	21.00	22.00	
				ALK. PHOSPH.	20/10/90	65.0	306.0	RU/ML	27.00	28.00	29.00	30.00	
				UREA	20/10/90	10.0	50.0	MG/DL	98.00	112.00	96.00	94.00	
				CREATININE	20/10/90	0.6	1.6	MG/DL	35.00	242.00	242.00	246.00	
				URIC ACID	20/10/90	2.4	5.7	MG/DL	1.00	20.00	21.00	21.00	
				DIR BILIRUBIN	20/10/90	0.2	1.0	MG/DL	4.20	4.00	4.10	3.80	
				TOT. PROTEINS	20/10/90	6.0	8.0	MG/DL	1.00	0.50	0.90	0.80	
				ALBUMINE	20/10/90	3.5	5.0	G/DL	0.50	0.20	0.40	0.40	
				TRIGLYCERIDES	20/10/90	140.0	270.0	MG/DL	6.80	6.90	7.40	6.90	
GLOBULINS: ALPHA 1	20/10/90	35.0	175.0	MG/DL	4.10	4.30	4.30	4.00					
GLOBULINS: ALPHA 2	20/10/90	4.0	7.0	Z	166.00	137.00	128.00	152.00					
GLOBULINS: BETA	20/10/90	7.0	11.0	Z	108.00	100.00	96.00	90.00					
GLOBULINS: GAMMA	20/10/90	11.0	14.0	Z	5.40	3.90	3.80	3.80					
T3	20/10/90	15.0	22.0	Z	11.10	11.10	10.10	6.40					
T4	20/10/90	86.0	187.0	NG X	16.10	20.00	12.00	12.20					
	20/10/90	4.5	12.5	NG/DL	106.00	20.00	16.40	18.90					
	20/10/90	150.0	550.0	10-3/MHC	8.30	273.00	263.00	288.00					
93	AL		FEMALE	HR	20/10/90	12.0	16.0	G/100ML	05/02/92	26/02/92	11/03/92	25/03/92	
				HTC	20/10/90	37.0	47.0	Z	13.80	13.50	13.40	13.40	
				RBC	20/10/90	3.8	5.4	10-6/MHC	38.00	37.00	37.00	37.00	
				MBC	20/10/90	4.0	11.0	10-3/MHC	4.30	4.10	4.10	4.00	
				MBC: N	20/10/90	40.0	70.0	Z	5.20	5.40	6.30	6.40	
				MBC: L	20/10/90	20.0	40.0	Z	58.00	60.00	61.00	61.00	
				MBC: E	20/10/90	1.0	5.0	Z	30.00	32.00	30.00	29.00	
				MBC: M	20/10/90	4.0	8.0	Z	2.00	2.00	2.00	3.00	
				MBC: B	20/10/90	0.0	1.0	Z	8.00	6.00	7.00	7.00	
				PLATELETS	20/10/90	150.0	550.0	10-3/MHC	290.00	273.00	263.00	288.00	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 RENDNETINE - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6			
1	93	AL	FEMALE	NA+	20/10/90	138.0	155.0	M EQ/L	137.00	136.00	136.00	136.00			
				K+	20/10/90	3.5	5.5	M EQ/L	3.60	4.10	3.70	4.10			
				CL-	20/10/90	98.0	120.0	M EQ/L	101.00	99.00	98.00	99.00			
				CA++	20/10/90	8.5	10.5	MG/DL	9.80	9.70	9.80	9.80			
				PO4-	20/10/90	3.0	4.5	MG/DL	3.20	3.40	3.80	3.60			
				SGOT	20/10/90	12.0	40.0	MIU/ML	36.00	26.00	16.00	18.00			
				SGPT	20/10/90	10.0	40.0	MIU/ML	31.00	24.00	18.00	24.00			
				GAMMA-GT	20/10/90	7.0	33.0	MIU/ML	30.00	28.00	28.00	30.00			
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	105.00	103.00	104.00	102.00			
				BUN	20/10/90	65.0	306.0	MIU/ML	271.00	217.00	221.00	241.00			
				ALK. PHOSPH.	20/10/90	10.0	50.0	MG/DL	33.00	23.00	28.00	28.00			
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	0.90	0.80	0.80			
				URIC ACID	20/10/90	2.4	5.7	MG/DL	4.10	4.00	3.80	3.90			
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.80	0.80	0.90	0.80			
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.40	0.50	0.40			
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.60	6.50	6.60	6.60			
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	3.80	4.00	3.90			
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	173.00	210.00	152.00	160.00			
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	88.00	78.00	103.00	92.00			
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	Z	4.10	4.00	3.90	4.20			
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	Z	12.80	13.10	12.00	13.00			
				GLOBULINS: BETA	20/10/90	11.0	14.0	Z	9.10	8.90	8.70	7.80			
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	Z	13.00	14.80	18.70	13.90			
				T3	20/10/90	86.0	187.0	NG Z	110.00						
				T4	20/10/90	4.5	12.5	NG/DL	9.10						
				94	RAB	MALE	HB	20/10/90	14.0	18.0	G/100ml	12.90	12.50	12.50	12.20
							HTC	20/10/90	40.0	54.0	Z	38.00	37.00	36.00	36.00
RBC	20/10/90	4.3	6.1				10**6/mm	4.20	4.30	4.20	3.80				
WBC	20/10/90	4.0	11.0				10-3/MNC	6.10	6.00	6.00	6.50				
WBC: N	20/10/90	40.0	70.0				Z	60.00	62.00	59.00	58.00				
WBC: L	20/10/90	20.0	40.0				Z	30.00	30.00	31.00	33.00				
WBC: E	20/10/90	1.0	5.0				Z	2.00	2.00	3.00	3.00				
WBC: M	20/10/90	4.0	8.0				Z	6.00	6.00	7.00	6.00				
WBC: B	20/10/90	0.0	1.0				Z	0.00	0.00	0.00	0.00				
PLATELETS	20/10/90	150.0	550.0				10-3/MNC	283.00	270.00	251.00	210.00				
NA+	20/10/90	136.0	195.0				M EQ/L	142.00	140.00	140.00	140.00				
K+	20/10/90	3.5	5.5				M EQ/L	3.60	3.80	3.70	3.80				
CL-	20/10/90	98.0	120.0				M EQ/L	103.00	104.00	102.00	101.00				
CA++	20/10/90	8.5	10.5				MG/DL	9.70	9.90	9.80	9.60				
PO4-	20/10/90	3.0	4.5				MG/DL	3.20	3.60	3.80	3.80				
SGOT	20/10/90	12.0	40.0				MIU/ML	24.00	20.00	24.00	27.00				
SGPT	20/10/90	10.0	40.0				MIU/ML	28.00	26.00	26.00	30.00				
GAMMA-GT	20/10/90	11.0	51.0				MIU/ML	32.00	32.00	32.00	35.00				
GLUCOSE	20/10/90	70.0	100.0				MG/DL	86.00	90.00	96.00	76.00				
ALK. PHOSPH.	20/10/90	65.0	306.0				MIU/ML	212.00	202.00	181.00	236.00				
BUN	20/10/90	10.0	50.0				MG/DL	30.00	21.00	24.00	26.00				
CREATININE	20/10/90	0.6	1.6				MG/DL	1.00	0.70	0.80	0.80				
URIC ACID	20/10/90	2.4	5.7				MG/DL	3.10	3.20	3.40	4.00				

1617

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
1	94	RAB	MALE	TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.90	0.70	0.60	0.60	0.60
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.50	0.40	0.30	0.30	0.30
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.80	7.00	7.00	7.00	7.20
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.00	4.20	4.10	4.10	4.30
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	151.00	134.00	182.00	183.00	183.00
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	88.00	104.00	96.00	98.00	98.00
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	X	4.60	4.30	3.90	4.00	4.00
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	X	13.00	13.00	15.20	14.10	14.10
				GLOBULINS: BETA	20/10/90	11.0	14.0	X	8.90	9.20	9.30	9.50	9.50
				GLOBULINS: GAMMA	20/10/90	86.0	187.0	NG %	103.00	15.80	16.80	16.80	16.80
				T3	20/10/90								
				T4	20/10/90	4.5	12.5	NG/DL	10.20				
	95	GMT	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	13.80	13.50	13.90	13.90	14.20
				HTC	20/10/90	37.0	47.0	X	41.00	40.00	40.00	40.00	41.00
				RBC	20/10/90	5.8	5.4	10 ⁶ /MHC	4.70	4.60	4.60	4.60	4.80
				HSC: N	20/10/90	4.0	11.0	10 ⁶ /MHC	7.50	7.00	8.10	8.10	6.80
				HSC: L	20/10/90	60.0	70.0	X	53.00	58.00	59.00	60.00	60.00
				HSC: E	20/10/90	20.0	40.0	X	41.00	37.00	36.00	32.00	32.00
				HSC: F	20/10/90	1.0	5.0	X	2.00	1.00	2.00	2.00	2.00
				HSC: H	20/10/90	4.0	8.0	X	4.00	4.00	3.00	6.00	6.00
				HSC: B	20/10/90	0.0	1.0	X	0.00	0.00	0.00	0.00	0.00
				PLATELETS	20/10/90	150.0	550.0	10 ³ /MHC	318.00	323.00	342.00	330.00	330.00
				NA+	20/10/90	138.0	155.0	M EQ/L	142.00	144.00	141.00	141.00	141.00
				K+	20/10/90	3.5	5.5	M EQ/L	3.90	3.80	3.90	3.80	3.80
				CL-	20/10/90	98.0	120.0	M EQ/L	98.00	96.00	100.00	96.00	96.00
				CA++	20/10/90	8.5	10.5	MG/DL	9.70	9.50	9.60	9.70	9.70
				PD4-	20/10/90	3.0	4.5	MG/DL	3.20	3.60	3.70	3.40	3.40
				SGPT	20/10/90	12.0	40.0	NU/ML	36.00	28.00	25.00	18.00	18.00
				GAMMA-GT	20/10/90	10.0	40.0	NU/ML	38.00	30.00	28.00	20.00	20.00
				GLUCOSE	20/10/90	7.0	33.0	MG/ML	29.00	26.00	26.00	26.00	26.00
				ALK. PHOSPH.	20/10/90	70.0	100.0	MG/DL	92.00	82.00	90.00	90.00	90.00
				BUN	20/10/90	65.0	306.0	MG/ML	216.00	200.00	198.00	210.00	210.00
				CREATININE	20/10/90	10.0	50.0	MG/DL	29.00	26.00	26.00	27.00	27.00
				URIC ACID	20/10/90	0.6	1.6	MG/DL	1.00	1.00	1.20	0.90	0.90
				DIR BILIRUBIN	20/10/90	2.4	5.7	MG/DL	4.20	4.40	3.60	4.00	4.00
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	1.10	0.80	0.80	0.60	0.60
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.60	0.30	0.30	0.20	0.20
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.70	7.00	7.00	7.00	7.00
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.00	4.10	4.40	4.20	4.20
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	170.00	192.00	136.00	123.00	123.00
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	78.00	80.00	92.00	93.00	93.00
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	X	4.00	3.10	2.90	3.60	3.60
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	X	12.80	12.70	13.60	12.70	12.70
				GLOBULINS: BETA	20/10/90	11.0	14.0	X	9.60	10.10	10.20	10.10	10.10
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	X	13.50	13.20	8.40	8.40	8.40
				T3	20/10/90	86.0	187.0	NG %	101.00				
				T4	20/10/90	4.5	12.5	NG/DL	8.20				

1618

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Screen		Visit					
					Date	Min	Max	Unit	Week 2	Week 4	Week 6				
1	96	SPK	MALE												
				HB	20/10/90	14.0	18.0	g/100ml	05/02/92	13.80	14.20	11/03/92	14.10	25/03/92	14.20
				HTC	20/10/90	40.0	54.0	%	13.80	37.00	39.00	38.00	39.00	39.00	
				RBC	20/10/90	4.3	6.1	10**6/mm	4.20	4.20	4.50	4.50	4.50	4.60	
				WBC	20/10/90	4.0	11.0	10-3/MNC	7.40	6.80	6.80	7.00	6.90	6.90	
				WBC: N	20/10/90	40.0	70.0	%	58.00	56.00	62.00	62.00	62.00	62.00	
				WBC: L	20/10/90	20.0	40.0	%	27.00	32.00	30.00	30.00	30.00	30.00	
				WBC: E	20/10/90	1.0	5.0	%	4.00	6.00	2.00	2.00	3.00	3.00	
				WBC: M	20/10/90	4.0	8.0	%	10.00	6.00	6.00	6.00	5.00	5.00	
				WBC: B	20/10/90	0.0	1.0	%	1.00	0.00	0.00	0.00	0.00	0.00	
				PLATELETS	20/10/90	150.0	550.0	10-3/MNC	310.00	321.00	311.00	311.00	341.00	341.00	
				NA+	20/10/90	138.0	153.0	R EQ/L	138.00	156.00	141.00	141.00	138.00	138.00	
				K+	20/10/90	3.5	5.5	R EQ/L	3.70	3.70	3.80	3.80	4.10	4.10	
				CL-	20/10/90	98.0	120.0	R EQ/L	99.00	97.00	97.00	97.00	97.00	97.00	
				CA++	20/10/90	8.5	10.5	MG/DL	9.70	9.70	9.70	9.70	9.70	9.70	
				PO4--	20/10/90	3.0	4.5	MG/DL	3.30	4.10	4.10	4.10	4.20	4.20	
				SGOT	20/10/90	12.0	40.0	IU/ML	32.00	30.00	30.00	26.00	18.00	18.00	
				GAMMA-GT	20/10/90	10.0	40.0	IU/ML	34.00	28.00	28.00	28.00	20.00	20.00	
				GLUCOSE	20/10/90	11.0	51.0	MG/DL	29.00	26.00	22.00	22.00	26.00	26.00	
				ALK. PHOSPH.	20/10/90	70.0	100.0	MG/DL	104.00	103.00	100.00	100.00	94.00	94.00	
				BUN	20/10/90	65.0	306.0	MG/DL	202.00	182.00	182.00	216.00	217.00	217.00	
				CREATININE	20/10/90	10.0	50.0	MG/DL	32.00	27.00	26.00	26.00	26.00	26.00	
				URIC ACID	20/10/90	0.6	1.6	MG/DL	0.90	0.90	0.90	0.90	1.00	1.00	
				TOT BILIRUBIN	20/10/90	3.4	7.0	MG/DL	3.90	3.80	4.00	4.00	4.10	4.10	
				DIR BILIRUBIN	20/10/90	0.2	1.0	MG/DL	1.20	0.60	0.80	0.80	0.80	0.80	
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.90	0.60	0.30	0.30	0.40	0.40	
				ALBUMINE	20/10/90	6.0	8.0	G/DL	6.90	7.20	7.20	7.40	7.20	7.20	
				TOT. CHOLEST.	20/10/90	3.5	5.0	G/DL	3.90	4.00	4.00	4.10	4.30	4.30	
				TRIGLYCERIDES	20/10/90	140.0	270.0	MG/DL	160.00	192.00	176.00	176.00	182.00	182.00	
				GLORULINS: ALPHA 1	20/10/90	35.0	175.0	MG/DL	72.00	127.00	123.00	123.00	116.00	116.00	
				GLORULINS: ALPHA 2	20/10/90	4.0	7.0	%	3.80	3.60	3.50	3.50	4.10	4.10	
				GLORULINS: BETA	20/10/90	7.0	11.0	%	12.00	12.10	8.60	8.60	8.90	8.90	
				GLORULINS: GAMMA	20/10/90	11.0	14.0	%	10.30	11.10	16.10	16.10	16.30	16.30	
				T3	20/10/90	15.0	22.0	%	14.10	16.20	15.20	15.20	18.20	18.20	
				T4	20/10/90	86.0	187.0	NG Z	106.00	106.00	106.00	106.00	106.00	106.00	
				PLATELETS	20/10/90	4.5	12.5	MG/DL	8.80	240.00	257.00	310.00	270.00	270.00	
				HB	20/10/90	14.0	18.0	g/100ml	05/02/92	13.50	13.50	11/03/92	14.20	25/03/92	14.40
				HTC	20/10/90	40.0	54.0	%	42.00	40.00	41.00	41.00	43.00	43.00	
				RBC	20/10/90	4.3	6.1	10**6/mm	4.10	4.20	4.40	4.40	5.10	5.10	
				WBC	20/10/90	4.0	11.0	10-3/MNC	6.60	6.30	6.80	6.80	6.00	6.00	
				WBC: N	20/10/90	40.0	70.0	%	59.00	63.00	62.00	62.00	65.00	65.00	
				WBC: L	20/10/90	20.0	40.0	%	30.00	31.00	30.00	30.00	25.00	25.00	
				WBC: E	20/10/90	1.0	5.0	%	4.00	2.00	2.00	2.00	3.00	3.00	
				WBC: M	20/10/90	4.0	8.0	%	6.00	4.00	6.00	6.00	7.00	7.00	
				WBC: B	20/10/90	0.0	1.0	%	1.00	0.00	0.00	0.00	0.00	0.00	
				PLATELETS	20/10/90	150.0	550.0	10-3/MNC	240.00	257.00	310.00	310.00	270.00	270.00	
	97	HND	MALE												

1619

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXYLINE - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
1	97	MND	MALE	NA+	20/10/90	138.0	155.0	K EQ/L	136.00	138.00	149.00	138.00	136.00
				K+	20/10/90	3.5	5.5	K EQ/L	4.10	4.20	4.10	3.80	4.10
				CL-	20/10/90	98.0	120.0	K EQ/L	103.00	101.00	97.00	98.00	98.00
				CA++	20/10/90	8.5	10.5	MG/DL	9.70	9.70	9.20	9.60	9.60
				PO4-	20/10/90	3.0	4.5	MG/DL	3.50	4.20	3.60	3.60	4.20
				SGOT	20/10/90	12.0	40.0	MIU/ML	28.00	18.00	12.00	18.00	19.00
				SGPT	20/10/90	10.0	40.0	MIU/ML	30.00	20.00	18.00	25.00	25.00
				GAMMA-GT	20/10/90	11.0	51.0	MIU/ML	34.00	26.00	18.00	29.00	29.00
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	106.00	91.00	110.00	102.00	102.00
				ALK. PHOSPH.	20/10/90	65.0	306.0	MIU/ML	280.00	261.00	245.00	214.00	214.00
				BUN	20/10/90	10.0	50.0	MG/DL	32.00	26.00	26.00	28.00	28.00
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	0.80	0.90	1.00	1.00
				URIC ACID	20/10/90	3.4	7.0	MG/DL	2.70	2.90	2.60	3.20	3.20
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.80	0.60	0.60	0.70	0.70
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.30	0.30	0.30	0.30
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.80	7.20	7.20	7.20	7.20
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	4.20	4.10	4.10	4.10
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	132.00	143.00	182.00	210.00	210.00
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	83.00	84.00	90.00	115.00	115.00
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	4.20	3.90	4.10	3.20	3.20
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	13.40	14.10	14.10	14.10	14.10
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	9.80	8.90	9.80	8.70	8.70
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	103.00	13.90	16.80	15.40	15.40
				T4	20/10/90	86.0	187.0	NG %	9.10				
				T4	20/10/90	4.5	12.5	NG/DL					
98	YTT		FEMALE	HB	20/10/90	12.0	16.0	G/100ML	12.70	12.80	12.40	12.80	12.40
				HTC	20/10/90	37.0	47.0	%	37.00	37.00	36.00	37.00	37.00
				RBC	20/10/90	3.8	5.4	10 ⁶ /MM ³	3.90	4.00	4.40	4.40	4.10
				WBC	20/10/90	4.0	11.0	10 ³ /MM ³	8.30	8.10	8.40	7.80	7.80
				WBC: N	20/10/90	40.0	70.0	%	60.00	67.00	62.00	62.00	62.00
				WBC: L	20/10/90	20.0	40.0	%	30.00	24.00	32.00	27.00	27.00
				WBC: E	20/10/90	1.0	5.0	%	8.00	3.00	1.00	3.00	3.00
				WBC: K	20/10/90	4.0	8.0	%	2.00	6.00	5.00	8.00	8.00
				WBC: B	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00
				PLATELETS	20/10/90	150.0	550.0	10 ³ /MM ³	290.00	285.00	271.00	311.00	311.00
				NA+	20/10/90	138.0	155.0	K EQ/L	141.00	142.00	140.00	140.00	140.00
				K+	20/10/90	3.5	5.5	K EQ/L	3.80	3.70	3.90	3.90	3.90
				CL-	20/10/90	98.0	120.0	K EQ/L	96.00	97.00	96.00	97.00	97.00
				CA++	20/10/90	8.5	10.5	MG/DL	9.40	9.50	9.40	9.50	9.50
				PO4-	20/10/90	3.0	4.5	MG/DL	3.50	3.80	3.60	3.60	4.10
				SGOT	20/10/90	12.0	40.0	MIU/ML	28.00	20.00	26.00	26.00	26.00
				SGPT	20/10/90	10.0	40.0	MIU/ML	36.00	28.00	28.00	28.00	28.00
				GAMMA-GT	20/10/90	7.0	33.0	MIU/ML	33.00	28.00	30.00	30.00	30.00
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	93.00	98.00	110.00	110.00	110.00
				ALK. PHOSPH.	20/10/90	65.0	306.0	MIU/ML	218.00	241.00	164.00	162.00	162.00
				BUN	20/10/90	10.0	50.0	MG/DL	26.00	26.00	26.00	26.00	26.00
				CREATININE	20/10/90	0.6	1.6	MG/DL	1.10	1.00	0.90	1.00	1.00
				URIC ACID	20/10/90	3.4	7.0	MG/DL	4.30	4.30	4.00	4.30	4.30

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOMEXINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
1	98	YTT	FEMALE	TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.70	0.80	0.70	1.00				
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.30	0.30	0.50				
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.50	6.80	6.80	7.00				
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.00	4.30	4.00	4.50				
				TOT. CHOLEST.	20/10/90	140.0	170.0	MG/DL	137.00	172.00	138.00	172.00				
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	88.00	106.00	96.00	120.00				
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	5.10	4.90	4.10	5.00				
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	8.30	8.40	9.20	8.30				
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	10.50	11.60	11.50	11.80				
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	23.10	22.20	22.80	21.70				
				T3	20/10/90	86.0	187.0	NG %	108.00							
				T4	20/10/90	4.5	12.5	NG/DL	9.90							
				99	LGD		FEMALE	HB	20/10/90	12.0	16.0	G/100ML	44.30	44.20	45.20	41.00
								HTC	20/10/90	37.0	47.0	%	38.00	37.00	37.00	41.00
								RBC	20/10/90	3.8	5.4	10 ⁶ /MM ³	4.30	5.00	4.80	4.80
								RBC: N	20/10/90	4.0	11.0	10 ³ /MM ³	7.00	7.10	7.40	7.30
								RBC: L	20/10/90	40.0	70.0	%	58.00	60.00	60.00	56.00
RBC: E	20/10/90	20.0	40.0					%	22.00	28.00	30.00	30.00				
RBC: M	20/10/90	1.0	5.0					%	10.00	4.00	3.00	4.00				
RBC: B	20/10/90	4.0	8.0					%	10.00	8.00	7.00	9.00				
PLATELETS	20/10/90	0.0	1.0					%	0.00	0.00	0.00	1.00				
NA+	20/10/90	150.0	550.0					10 ⁻³ /MM ³	291.00	192.00	221.00	183.00				
K+	20/10/90	138.0	155.0					M EQ/L	142.00	140.00	142.00	137.00				
CL-	20/10/90	3.5	5.5					M EQ/L	3.70	3.70	3.80	3.80				
CA++	20/10/90	98.0	120.0					M EQ/L	96.00	98.00	97.00	101.00				
PO4--	20/10/90	8.5	10.5					MG/DL	10.10	10.20	9.90	9.70				
SGPT	20/10/90	3.0	4.5					NU/ML	3.00	3.80	3.60	4.10				
GAMMA-GT	20/10/90	12.0	40.0					NU/ML	24.00	23.00	26.00	22.00				
GLUCOSE	20/10/90	7.0	33.0					NU/ML	28.00	25.00	30.00	24.00				
ALK. PHOSPH.	20/10/90	70.0	100.0	MG/DL	92.00	90.00	86.00	96.00								
CREATININE	20/10/90	65.0	306.0	NU/ML	119.00	131.00	129.00	121.00								
URIC ACID	20/10/90	10.0	50.0	MG/DL	28.00	24.00	23.00	18.00								
TOT BILIRUBIN	20/10/90	0.4	1.6	MG/DL	0.80	0.80	1.00	0.80								
DIR BILIRUBIN	20/10/90	2.4	5.7	MG/DL	3.20	3.40	4.20	4.20								
TOT. PROTEINS	20/10/90	0.2	1.0	MG/DL	0.60	0.60	0.50	0.60								
ALBUMINE	20/10/90	6.0	8.0	G/DL	6.80	6.80	7.30	6.80								
TOT. CHOLEST.	20/10/90	3.5	5.0	G/DL	3.90	4.10	4.50	4.10								
TRIGLYCERIDES	20/10/90	140.0	270.0	MG/DL	122.00	142.00	127.00	112.00								
GLOBULINS: ALPHA 1	20/10/90	35.0	175.0	MG/DL	82.00	80.00	90.00	90.00								
GLOBULINS: ALPHA 2	20/10/90	4.0	7.0	%	3.70	4.00	4.10	3.90								
GLOBULINS: BETA	20/10/90	7.0	11.0	%	9.80	10.80	10.20	10.10								
GLOBULINS: GAMMA	20/10/90	11.0	14.0	%	13.40	15.20	14.20	12.70								
T3	20/10/90	15.0	22.0	%	18.10	19.40	21.60	18.50								
T4	20/10/90	86.0	187.0	NG %	96.00											
	20/10/90	4.5	12.5	NG/DL	10.60											

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Unit	Screen	Visit							
					Date	Min	Max			Week 2	Week 4	Week 6					
1	100	JMA	MALE	HB	20/10/90	14.0	18.0	g/100ml	05/02/92	13.80	14.00	11/03/92	13.90	25/03/92	14.10		
				HTC	20/10/90	40.0	54.0	%	13.80	40.00	11/03/92	39.00	40.00	11/03/92	39.00	25/03/92	40.00
				RBC	20/10/90	4.3	6.1	10**6/mm	4.40	4.80	11/03/92	4.40	4.50	11/03/92	4.50	25/03/92	4.50
				HBC	20/10/90	4.0	11.0	10-3/HMC	6.20	6.00	11/03/92	57.00	58.00	11/03/92	60.00	25/03/92	59.00
				HBC: N	20/10/90	40.0	70.0	%	23.00	33.00	11/03/92	33.00	31.00	11/03/92	31.00	25/03/92	30.00
				HBC: L	20/10/90	20.0	40.0	%	8.00	8.00	11/03/92	8.00	3.00	11/03/92	3.00	25/03/92	5.00
				HBC: E	20/10/90	1.0	5.0	%	4.0	8.0	11/03/92	10.00	6.00	11/03/92	6.00	25/03/92	6.00
				HBC: M	20/10/90	0.0	8.0	%	0.0	2.00	11/03/92	0.00	0.00	11/03/92	0.00	25/03/92	0.00
				HBC: B	20/10/90	0.0	1.0	%	0.0	0.00	11/03/92	0.00	0.00	11/03/92	0.00	25/03/92	0.00
				PLATELETS	20/10/90	150.0	550.0	10-3/HMC	343.00	292.00	11/03/92	343.00	320.00	11/03/92	320.00	25/03/92	299.00
				NA+	20/10/90	138.0	155.0	M ER/L	138.00	141.00	11/03/92	138.00	142.00	11/03/92	142.00	25/03/92	142.00
				K+	20/10/90	3.5	5.5	M ER/L	3.80	3.90	11/03/92	3.80	3.60	11/03/92	3.60	25/03/92	3.80
				Ca++	20/10/90	98.5	120.0	M ER/L	103.00	96.00	11/03/92	103.00	98.00	11/03/92	98.00	25/03/92	97.00
				Fe6+	20/10/90	3.0	4.5	MG/DL	3.20	3.20	11/03/92	3.20	3.50	11/03/92	3.50	25/03/92	3.50
				SGOT	20/10/90	12.0	40.0	NU/ML	27.00	26.00	11/03/92	27.00	28.00	11/03/92	28.00	25/03/92	26.00
				SGPT	20/10/90	11.0	51.0	NU/ML	32.00	28.00	11/03/92	32.00	28.00	11/03/92	30.00	25/03/92	28.00
				GAMMA-GT	20/10/90	11.0	51.0	NU/ML	26.00	26.00	11/03/92	26.00	28.00	11/03/92	28.00	25/03/92	22.00
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	100.00	92.00	11/03/92	100.00	92.00	11/03/92	87.00	25/03/92	91.00
				ALK. PHOSPH.	20/10/90	65.0	306.0	NU/ML	218.00	220.00	11/03/92	218.00	220.00	11/03/92	210.00	25/03/92	216.00
				BUN	20/10/90	10.0	50.0	MG/DL	33.00	27.00	11/03/92	33.00	27.00	11/03/92	24.00	25/03/92	26.00
				CREATININE	20/10/90	0.6	1.6	MG/DL	1.00	0.80	11/03/92	1.00	0.80	11/03/92	0.80	25/03/92	0.80
				URIC ACID	20/10/90	3.4	7.0	MG/DL	3.80	3.20	11/03/92	3.80	4.10	11/03/92	4.10	25/03/92	4.10
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.80	0.60	11/03/92	0.80	0.70	11/03/92	0.70	25/03/92	0.60
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.30	11/03/92	0.30	0.30	11/03/92	0.30	25/03/92	0.30
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.40	6.60	11/03/92	6.40	6.60	11/03/92	6.90	25/03/92	7.10
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.00	4.00	11/03/92	4.00	4.00	11/03/92	4.00	25/03/92	4.20
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	193.00	171.00	11/03/92	193.00	171.00	11/03/92	163.00	25/03/92	188.00
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	117.00	103.00	11/03/92	117.00	103.00	11/03/92	96.00	25/03/92	96.00
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	4.10	3.10	11/03/92	4.10	3.20	11/03/92	3.20	25/03/92	3.20
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	11.90	12.00	11/03/92	11.90	12.00	11/03/92	6.10	25/03/92	7.40
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	13.60	13.50	11/03/92	13.60	13.50	11/03/92	12.00	25/03/92	12.10
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	12.70	18.10	11/03/92	12.70	18.10	11/03/92	15.60	25/03/92	18.20
				T3	20/10/90	86.0	187.0	NG %	110.00	110.00	11/03/92	110.00	110.00	11/03/92	110.00	25/03/92	110.00
T4	20/10/90	4.5	12.5	NG/DL	8.20	8.20	11/03/92	8.20	8.20	11/03/92	8.20	25/03/92	8.20				
101	JLL	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	11/02/92	12.90	04/03/92	15.00	17/03/92	15.10	31/03/92	13.30		
			HTC	20/10/90	37.0	47.0	%	36.00	37.00	17/03/92	37.00	38.00	17/03/92	38.00	31/03/92	38.00	
			RBC	20/10/90	3.8	5.4	10-6/HMC	4.00	4.00	17/03/92	4.00	4.20	17/03/92	4.20	31/03/92	4.20	
			HBC	20/10/90	4.0	11.0	10-3/HMC	68.00	67.00	17/03/92	68.00	65.00	17/03/92	65.00	31/03/92	61.00	
			HBC: N	20/10/90	20.0	40.0	%	29.00	24.00	17/03/92	29.00	23.00	17/03/92	23.00	31/03/92	26.00	
			HBC: L	20/10/90	1.0	5.0	%	2.00	2.00	17/03/92	2.00	3.00	17/03/92	3.00	31/03/92	6.00	
			HBC: E	20/10/90	4.0	8.0	%	1.00	5.00	17/03/92	1.00	8.00	17/03/92	8.00	31/03/92	7.00	
			HBC: M	20/10/90	0.0	1.0	%	0.00	1.00	17/03/92	0.00	1.00	17/03/92	0.00	31/03/92	0.00	
			HBC: B	20/10/90	150.0	550.0	10-3/HMC	264.00	329.00	17/03/92	264.00	329.00	17/03/92	320.00	31/03/92	211.00	
			PLATELETS	20/10/90	150.0	550.0	10-3/HMC	264.00	329.00	17/03/92	264.00	329.00	17/03/92	320.00	31/03/92	211.00	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1
LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Screen	Visit					
				Date	Min	Max		Unit	Week 2	Week 4	Week 6		
1	101 JLL	FEMALE	NA+	20/10/90	138.0	155.0	M EQ/L	138.00	139.00	138.00	138.00	138.00	
			K+	20/10/90	3.5	5.5	M EQ/L	4.30	4.50	4.30	4.30	4.10	
			CL-	20/10/90	98.0	120.0	M EQ/L	97.00	95.00	96.00	96.00	97.00	
			CA++	20/10/90	8.5	10.5	MG/DL	9.20	10.00	9.80	9.80	9.90	
			PO4-	20/10/90	3.0	4.5	MG/DL	3.80	4.10	4.10	4.10	4.00	
			SCOT	20/10/90	12.0	40.0	IU/HL	23.00	16.00	20.00	20.00	22.00	
			SGPT	20/10/90	10.0	40.0	IU/HL	20.00	18.00	26.00	26.00	26.00	
			GAMMA-GT	20/10/90	7.0	33.0	IU/HL	28.00	27.00	30.00	30.00	32.00	
			GLUCOSE	20/10/90	70.0	100.0	MG/DL	105.00	88.00	94.00	94.00	87.00	
			ALK. PHOSPH.	20/10/90	65.0	306.0	IU/HL	185.00	162.00	174.00	174.00	171.00	
			BUN	20/10/90	10.0	50.0	MG/DL	32.00	24.00	22.00	22.00	27.00	
			CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	0.70	0.80	0.80	0.80	
			URIC ACID	20/10/90	2.4	5.7	MG/DL	3.00	2.60	3.00	3.00	4.10	
			TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.30	0.40	0.40	0.40	0.60	
			DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.10	0.20	0.20	0.20	0.30	
			TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.20	6.80	6.80	6.80	7.30	
			ALBUMINE	20/10/90	3.5	5.0	G/DL	4.50	3.90	3.90	3.80	4.00	
			TOT. CHOLEST.	20/10/90	160.0	270.0	MG/DL	187.00	177.00	162.00	162.00	152.00	
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	115.00	56.00	61.00	61.00	53.00	
			GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	2.50	3.00	3.10	3.10	4.10	
			GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	8.50	8.70	8.00	8.00	7.20	
			GLOBULINS: BETA	20/10/90	11.0	14.0	%	11.20	12.60	13.20	13.20	10.80	
			GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	20.10	20.80	20.30	20.30	20.00	
			T3	20/10/90	86.0	187.0	NG %	110.00					
			T4	20/10/90	4.5	12.5	NG/DL	7.40					
102	ESF	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	9.80	11/02/92	11/02/92	11/02/92	11/02/92	11/02/92
			HTC	20/10/90	37.0	47.0	%	32.00	37.00	39.00	39.00	38.00	
			RBC	20/10/90	3.8	5.4	10 ⁶ -6/MHC	4.80	4.60	4.60	4.40	4.30	
			HBC: N	20/10/90	4.0	11.0	10 ³ -3/MHC	5.80	6.70	7.30	7.30	7.00	
			HBC: L	20/10/90	40.0	70.0	%	46.00	62.00	62.00	62.00	61.00	
			HBC: E	20/10/90	20.0	40.0	%	30.00	26.00	27.00	27.00	26.00	
			HBC: M	20/10/90	1.0	5.0	%	14.00	5.00	4.00	4.00	6.00	
			HBC: B	20/10/90	4.0	8.0	%	10.00	7.00	7.00	7.00	7.00	
			PLATELETS	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	
			NA+	20/10/90	150.0	550.0	10 ³ -3/HMC	465.00	193.00	194.00	194.00	182.00	
			K+	20/10/90	138.0	155.0	M EQ/L	139.00	138.00	138.00	138.00	138.00	
			CL-	20/10/90	98.0	120.0	M EQ/L	96.00	98.00	97.00	97.00	102.00	
			PO4-	20/10/90	3.0	4.5	MG/DL	3.90	3.50	3.50	3.50	3.70	
			SGPT	20/10/90	12.0	40.0	IU/HL	27.00	18.00	20.00	20.00	12.00	
			SCOT	20/10/90	10.0	40.0	IU/HL	24.00	22.00	24.00	24.00	18.00	
			GAMMA-GT	20/10/90	7.0	33.0	IU/HL	33.00	31.00	30.00	30.00	30.00	
			GLUCOSE	20/10/90	70.0	100.0	MG/DL	122.00	86.00	92.00	92.00	82.00	
			ALK. PHOSPH.	20/10/90	65.0	306.0	IU/HL	147.00	147.00	193.00	193.00	160.00	
			BUN	20/10/90	10.0	50.0	MG/DL	15.00	26.00	24.00	24.00	28.00	
			CREATININE	20/10/90	0.6	1.6	MG/DL	0.70	0.90	1.00	1.00	0.80	
			URIC ACID	20/10/90	2.4	5.7	MG/DL	5.20	3.80	4.20	4.20	4.10	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit									
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6					
1	102	ESF	FEMALE	TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.40	0.70	0.70	0.80				
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.30	0.30	0.40				
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.90	7.40	7.20	7.60				
				ALBUMINE	20/10/90	3.5	5.0	G/DL	3.90	4.30	4.30	4.30				
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	208.00	172.00	172.00	163.00				
				TRIGLYCERIDES	20/10/90	95.0	175.0	MG/DL	192.00	66.00	71.00	90.00				
				GLORULINS: ALPHA 1	20/10/90	4.0	7.0	%	3.00	3.90	4.00	3.80				
				GLORULINS: ALPHA 2	20/10/90	7.0	11.0	%	11.80	8.70	7.30	7.10				
				GLORULINS: BETA	20/10/90	11.0	14.0	%	13.90	12.30	12.80	13.20				
				GLORULINS: GAMMA	20/10/90	15.0	22.0	%	16.00	21.50	20.10	20.10				
				T3	20/10/90	86.0	187.0	NG Z	90.00							
				T4	20/10/90	4.5	12.5	NG/DL	7.20							
				103	JRA	MALE		HB	20/10/90	14.0	18.0	g/100ml	14.40	06/03/92	14.30	
								HTC	20/10/90	40.0	54.0	%	43.00	44.00		
								RBC	20/10/90	4.3	6.1	10**6/mm	4.70	4.80		
								WBC	20/10/90	4.0	11.0	10 ³ /HMC	6.00	6.10		
								RBC: N	20/10/90	40.0	70.0	%	60.00	62.00		
								RBC: L	20/10/90	20.0	40.0	%	32.00	31.00		
								RBC: E	20/10/90	1.0	5.0	%	3.00	3.00		
								RBC: M	20/10/90	4.0	8.0	%	5.00	4.00		
RBC: B	20/10/90	0.0	1.0					%	0.00	0.00						
PLATELETS	20/10/90	150.0	550.0					10 ³ /HMC	301.00	298.00						
NA+	20/10/90	138.0	155.0					M EQ/L	142.00	141.00						
K+	20/10/90	3.5	5.5					M EQ/L	3.80	3.80						
CL-	20/10/90	98.0	120.0					M EQ/L	96.00	97.00						
CA++	20/10/90	8.5	10.5					MG/DL	9.90	9.80						
PO4-	20/10/90	3.0	4.5					MG/DL	3.60	3.70						
SGPT	20/10/90	12.0	40.0					NU/ML	28.00	26.00						
SGOT	20/10/90	11.0	40.0					NU/ML	30.00	28.00						
GAMMA-GT	20/10/90	70.0	51.0					NU/ML	34.00	32.00						
GLUCOSE	20/10/90	65.0	100.0					MG/DL	82.00	91.00						
ALK. PHOSPH.	20/10/90	10.0	306.0					NU/ML	190.00	184.00						
BUN	20/10/90	10.0	50.0	MG/DL	20.00	22.00										
CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	0.90										
URIC ACID	20/10/90	3.4	7.0	MG/DL	4.50	4.60										
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	0.70										
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.30										
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.20	7.10										
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.50	4.50										
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	170.00	182.00										
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	113.00	118.00										
GLORULINS: ALPHA 1	20/10/90	4.0	7.0	%	3.20	3.10										
GLORULINS: ALPHA 2	20/10/90	7.0	11.0	%	6.40	5.60										
GLORULINS: BETA	20/10/90	11.0	14.0	%	11.80	12.00										
GLORULINS: GAMMA	20/10/90	15.0	22.0	%	15.00	16.20										
T3	20/10/90	86.0	187.0	NG Z	108.00											
T4	20/10/90	4.5	12.5	NG/DL	9.10											

1624

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBEXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit				
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6
1	104	MTF	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	11/02/92	04/03/92	17/03/92	31/03/92
				HTC	20/10/90	37.0	47.0	Z	12.80	12.70	12.90	12.70
				RBC	20/10/90	3.8	5.4	10-6/MHC	38.00	36.00	40.00	37.00
				WBC	20/10/90	4.0	11.0	10-3/MHC	4.30	4.40	4.60	4.20
				HBC: N	20/10/90	40.0	70.0	Z	4.80	5.50	5.20	5.30
				HBC: L	20/10/90	20.0	40.0	Z	52.00	56.00	60.00	62.00
				HBC: E	20/10/90	1.0	5.0	Z	38.00	33.00	30.00	30.00
				HBC: H	20/10/90	4.0	8.0	Z	5.00	5.00	4.00	3.00
				HBC: B	20/10/90	0.0	1.0	Z	5.00	6.00	6.00	5.00
				PLATELETS	20/10/90	150.0	550.0	10-3/MHC	208.00	210.00	221.00	205.00
				NA+	20/10/90	138.0	155.0	M EQ/L	143.00	141.00	149.00	142.00
				K+	20/10/90	3.5	5.5	M EQ/L	4.00	4.10	3.90	3.90
				CL-	20/10/90	98.0	120.0	M EQ/L	99.00	96.00	101.00	98.00
				CA++	20/10/90	8.5	10.5	MG/DL	9.50	9.70	9.60	9.60
				PO4-	20/10/90	3.0	4.5	MG/DL	3.80	4.20	4.00	4.20
				SGOT	20/10/90	12.0	40.0	MU/HL	28.00	26.00	26.00	26.00
				SGPT	20/10/90	10.0	40.0	MU/HL	29.00	30.00	29.00	30.00
				GAMMA-GT	20/10/90	7.0	33.0	MU/HL	35.00	34.00	36.00	32.00
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	91.00	86.00	92.00	94.00
				ALK. PHOSPH.	20/10/90	65.0	306.0	MU/HL	211.00	231.00	218.00	172.00
				BUN	20/10/90	0.6	50.0	MG/DL	33.00	26.00	24.00	26.00
				CREATININE	20/10/90	0.6	1.6	MG/DL	1.00	1.00	0.80	0.80
				URIC ACID	20/10/90	2.4	5.7	MG/DL	4.50	4.30	4.60	3.90
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	0.60	0.70	0.60
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.30	0.30	0.30
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.00	7.20	7.10	7.20
				ALBUMINE	20/10/90	3.5	5.0	G/DL	3.80	4.10	4.30	4.10
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	215.00	220.00	191.00	157.00				
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	110.00	96.00	107.00	116.00				
GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	Z	3.00	3.20	4.00	4.00				
GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	Z	7.40	9.30	11.20	10.30				
GLOBULINS: BETA	20/10/90	11.0	14.0	Z	14.00	14.30	8.70	16.10				
GLOBULINS: GAMMA	20/10/90	15.0	22.0	Z	20.20	21.20	19.40	18.90				
TS	20/10/90	86.0	187.0	MG X	90.00							
T4	20/10/90	4.5	12.5	MG/DL	7.60							
105	ABS		FEMALE	HB	20/10/90	12.0	16.0	G/100ML	11/02/92	04/03/92	17/03/92	31/03/92
				HTC	20/10/90	37.0	47.0	Z	13.20	13.60	13.50	13.90
				RBC	20/10/90	3.8	5.4	10-6/MHC	39.00	39.00	36.00	40.00
				WBC	20/10/90	4.0	11.0	10-3/MHC	4.30	4.50	4.10	4.60
				HBC: N	20/10/90	40.0	70.0	Z	5.80	6.10	5.50	5.80
				HBC: L	20/10/90	20.0	40.0	Z	56.00	58.00	60.00	58.00
				HBC: E	20/10/90	1.0	5.0	Z	30.00	38.00	28.00	26.00
				HBC: H	20/10/90	4.0	8.0	Z	5.00	2.00	4.00	6.00
				HBC: B	20/10/90	0.0	1.0	Z	9.00	2.00	8.00	10.00
				PLATELETS	20/10/90	150.0	550.0	10-3/MHC	782.00	236.00	263.00	263.00

1625

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
1	105	ABS	FEMALE	NA+	20/10/90	138.0	155.0	M ER/L	138.00	139.00	139.00	139.00	139.00
				K+	20/10/90	3.5	5.5	M ER/L	4.30	4.10	4.10	4.10	4.20
				CL-	20/10/90	98.0	120.0	M ER/L	96.00	97.00	97.00	101.00	98.00
				CA++	20/10/90	8.5	10.5	MG/DL	10.10	9.40	9.40	9.60	9.70
				PO4-	20/10/90	3.0	4.5	MG/DL	3.80	4.10	4.10	3.80	3.80
				SGOT	20/10/90	12.0	40.0	IU/ML	36.00	36.00	36.00	34.00	32.00
				SGPT	20/10/90	10.0	40.0	IU/ML	38.00	39.00	38.00	34.00	34.00
				GAMMA-GT	20/10/90	7.0	33.0	IU/ML	26.00	27.00	30.00	28.00	28.00
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	92.00	79.00	82.00	92.00	92.00
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	203.00	214.00	196.00	216.00	216.00
				BUN	20/10/90	10.0	50.0	MG/DL	28.00	26.00	24.00	24.00	24.00
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	0.80	0.80	0.80	0.80
				URIC ACID	20/10/90	2.4	5.7	MG/DL	3.80	3.90	3.90	3.90	3.90
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	1.00	0.80	0.80	0.60	0.60
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.50	0.60	0.60	0.30	0.30
				TOT PROTEINS	20/10/90	6.0	8.0	G/DL	6.80	6.90	7.50	7.50	7.40
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.30	4.50	4.50	4.60
				TOT CHOLEST.	20/10/90	140.0	270.0	MG/DL	192.00	176.00	176.00	176.00	176.00
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	90.00	96.00	84.00	88.00	88.00
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	4.10	4.10	3.20	2.10	2.10
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	6.20	9.60	11.00	5.60	5.60
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	13.50	13.60	9.10	11.20	11.20
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	21.60	22.50	18.90	13.40	13.40
				T3	20/10/90	86.0	187.0	NG %	96.00				
				T4	20/10/90	4.5	12.5	NG/DL	10.30				
				HB	20/10/90	14.0	18.0	g/100ml	11/02/92	11/02/92	04/03/92	17/03/92	31/03/92
				HTC	20/10/90	40.0	54.0	%	13.80	13.70	14.00	14.00	13.90
				RBC	20/10/90	4.3	6.1	10**6/mm	41.00	40.00	42.00	42.00	40.00
				HBC	20/10/90	4.0	11.0	10-3/MNC	4.20	4.40	4.50	4.50	4.50
				HBC: N	20/10/90	40.0	70.0	%	5.80	5.80	7.80	7.80	6.60
				HBC: L	20/10/90	20.0	40.0	%	54.00	56.00	60.00	60.00	59.00
				HBC: E	20/10/90	1.0	5.0	%	36.00	34.00	28.00	30.00	30.00
				HBC: M	20/10/90	4.0	8.0	%	4.00	4.00	4.00	5.00	5.00
				HBC: B	20/10/90	0.0	1.0	%	6.00	6.00	8.00	6.00	6.00
				PLATELETS	20/10/90	150.0	550.0	10-3/MNC	260.00	237.00	220.00	220.00	251.00
				NA+	20/10/90	138.0	155.0	M ER/L	142.00	141.00	141.00	141.00	140.00
				K+	20/10/90	3.5	5.5	M ER/L	3.90	3.80	3.90	3.90	3.90
				CL-	20/10/90	98.0	120.0	M ER/L	106.00	103.00	102.00	102.00	98.00
				CA++	20/10/90	8.5	10.5	MG/DL	9.30	9.70	9.30	9.30	9.50
				PO4-	20/10/90	3.0	4.5	MG/DL	3.80	4.00	4.20	4.20	3.50
				SGOT	20/10/90	12.0	40.0	IU/ML	30.00	28.00	30.00	30.00	32.00
				SGPT	20/10/90	10.0	40.0	IU/ML	32.00	34.00	34.00	34.00	34.00
				GAMMA-GT	20/10/90	11.0	51.0	IU/ML	36.00	32.00	38.00	38.00	30.00
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	98.00	96.00	92.00	88.00	88.00
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	192.00	199.00	186.00	216.00	216.00
				BUN	20/10/90	10.0	50.0	MG/DL	26.00	24.00	20.00	24.00	24.00
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	0.90	0.80	0.80	0.80
				URIC ACID	20/10/90	3.4	7.0	MG/DL	3.60	3.80	4.10	4.10	4.20

1626

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Contro	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit						
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6		
1	106	MRN	MALE	20/10/90	0.2	1.0	MG/DL	1.10	1.20	0.90	0.60		
			TOT BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.60	0.50	0.40	0.30		
			DIR BILIRUBIN	20/10/90	6.0	8.0	G/DL	6.90	7.30	7.60	7.50		
			TOT. PROTEINS	20/10/90	3.5	5.0	G/DL	4.10	3.90	4.30	4.30		
			ALBUMINE	20/10/90	140.0	270.0	MG/DL	136.00	162.00	174.00	163.00		
			TOT. CHOLEST.	20/10/90	35.0	175.0	MG/DL	92.00	80.00	98.00	84.00		
			TRIGLYCERIDES	20/10/90	4.0	7.0	X	4.60	4.30	4.50	4.00		
			GLOBULINS: ALPHA 1	20/10/90	7.0	11.0	X	5.70	9.70	6.70	6.30		
			GLOBULINS: ALPHA 2	20/10/90	11.0	14.0	X	15.50	12.50	13.20	16.70		
			GLOBULINS: BETA	20/10/90	15.0	22.0	X	19.10	21.60	20.10	22.30		
			GLOBULINS: GAMMA	20/10/90	86.0	187.0	NG %	98.00					
			T3	20/10/90	4.5	12.5	NG/DL	8.60					
			T4	20/10/90									
107	LAN	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	12.50	12.40	13.00	12.60		
			HTC	20/10/90	37.0	47.0	X	36.00	36.00	37.00	36.00		
			RBC	20/10/90	3.8	5.4	10 ⁶ -S/MHC	5.00	4.00	4.00	4.30		
			HRC: N	20/10/90	4.0	11.0	10 ⁶ -S/MHC	7.00	7.50	6.30	6.80		
			HRC: L	20/10/90	40.0	70.0	X	58.00	56.00	56.00	57.00		
			HRC: E	20/10/90	20.0	40.0	X	28.00	28.00	28.00	30.00		
			HRC: H	20/10/90	1.0	5.0	X	5.00	6.00	6.00	2.00		
			HRC: B	20/10/90	4.0	8.0	X	10.00	10.00	10.00	11.00		
			HRC: S	20/10/90	0.0	1.0	X	1.00	0.00	0.00	0.00		
			PLATELETS	20/10/90	150.0	550.0	10 ³ -S/MHC	315.00	320.00	320.00	293.00		
			NA+	20/10/90	138.0	155.0	M EQ/L	136.00	137.00	139.00	138.00		
			K+	20/10/90	3.5	5.5	M EQ/L	3.80	4.00	4.00	4.00		
			CL-	20/10/90	98.0	120.0	M EQ/L	102.00	96.00	98.00	101.00		
			CA++	20/10/90	8.5	10.5	MG/DL	9.60	9.20	9.50	9.50		
			PO4-	20/10/90	3.0	4.5	MG/DL	3.20	4.10	3.60	3.80		
			SGPT	20/10/90	12.0	40.0	NU/HL	28.00	27.00	26.00	30.00		
			GAMMA-GT	20/10/90	10.0	40.0	NU/HL	30.00	30.00	30.00	34.00		
			GLUCOSE	20/10/90	7.0	33.0	MG/DL	34.00	35.00	34.00	28.00		
			ALK. PHOSPH.	20/10/90	70.0	100.0	NG/DL	89.00	86.00	84.00	94.00		
			BUN	20/10/90	65.0	306.0	MG/DL	202.00	184.00	192.00	183.00		
			CREATININE	20/10/90	10.0	50.0	MG/DL	32.00	28.00	28.00	24.00		
			URIC ACID	20/10/90	0.6	1.6	MG/DL	0.80	0.90	0.90	0.80		
			TOT BILIRUBIN	20/10/90	2.4	5.7	MG/DL	3.40	4.00	4.30	3.60		
			DIR BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.80	0.80	0.70	0.70		
			TOT. PROTEINS	20/10/90	0.0	0.4	MG/DL	0.40	0.40	0.30	0.30		
			ALBUMINE	20/10/90	6.0	8.0	G/DL	6.10	7.00	6.80	7.00		
			TOT. CHOLEST.	20/10/90	3.5	5.0	G/DL	3.80	4.20	4.00	4.20		
			TRIGLYCERIDES	20/10/90	140.0	270.0	MG/DL	182.00	180.00	153.00	171.00		
			GLOBULINS: ALPHA 1	20/10/90	35.0	175.0	MG/DL	93.00	90.00	90.00	96.00		
			GLOBULINS: ALPHA 2	20/10/90	4.0	7.0	X	5.10	6.10	3.80	3.80		
			GLOBULINS: BETA	20/10/90	7.0	11.0	X	8.70	7.20	9.00	7.60		
			GLOBULINS: GAMMA	20/10/90	11.0	14.0	X	12.50	12.40	12.50	11.90		
			T3	20/10/90	15.0	22.0	X	18.00	18.10	18.10	19.20		
			T4	20/10/90	86.0	187.0	NG %	106.00					
				20/10/90	4.5	12.5	NG/DL	10.20					

1627

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBORNETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
1	108	STB	FEMALE	HR	20/10/90	12.0	16.0	G/100ML	12/02/92	04/03/92	18/03/92	01/04/92	
				HTC	20/10/90	37.0	47.0	Z	14.20	14.00	14.10	13.90	
				RBC	20/10/90	3.8	5.4	10 ⁶ -6/MNC	41.00	41.00	40.00	40.00	
				HBC	20/10/90	4.0	11.0	10 ⁻³ /MNC	4.20	4.40	4.50	4.30	
				HRC: N	20/10/90	40.0	70.0	Z	6.30	6.20	6.20	6.40	
				HRC: L	20/10/90	20.0	40.0	Z	56.00	58.00	58.00	60.00	
				HRC: E	20/10/90	1.0	5.0	Z	24.00	26.00	26.00	24.00	
				HRC: M	20/10/90	4.0	8.0	Z	8.00	8.00	6.00	8.00	
				HRC: B	20/10/90	0.0	1.0	Z	12.00	10.00	10.00	8.00	
				PLATELETS	20/10/90	150.0	550.0	10 ³ -3/MNC	0.00	0.00	0.00	0.00	
				Na+	20/10/90	138.0	155.0	M EQ/L	281.00	274.00	272.00	260.00	
				K+	20/10/90	3.5	5.5	M EQ/L	142.00	140.00	138.00	138.00	
				Cl-	20/10/90	98.0	120.0	M EQ/L	97.00	98.00	98.00	96.00	
				PO4--	20/10/90	3.0	4.5	MG/DL	9.70	9.60	9.60	9.40	
				SGPT	20/10/90	12.0	40.0	NU/ML	3.50	4.10	4.00	3.80	
				GAMMA-GT	20/10/90	10.0	40.0	NU/ML	26.00	22.00	24.00	24.00	
				GLUCOSE	20/10/90	7.0	33.0	MG/DL	29.00	28.00	28.00	26.00	
				ALK. PHOSPH.	20/10/90	70.0	100.0	NU/ML	41.00	30.00	30.00	36.00	
				CREATININE	20/10/90	65.0	306.0	MG/DL	76.00	78.00	78.00	78.00	
				TOT BILIRUBIN	20/10/90	10.0	50.0	MG/DL	163.00	168.00	170.00	144.00	
				DIR BILIRUBIN	20/10/90	0.6	1.6	MG/DL	26.00	20.00	22.00	28.00	
				TOT. PROTEINS	20/10/90	2.4	5.7	MG/DL	0.80	0.90	0.90	0.90	
				ALBUMINE	20/10/90	3.5	8.0	MG/DL	3.20	3.80	4.00	3.60	
				TOT. CHOLEST.	20/10/90	0.2	1.0	MG/DL	0.60	0.60	0.90	0.60	
				TRIGLYCERIDES	20/10/90	0.0	0.4	MG/DL	0.30	0.30	0.40	0.30	
				GLUCOLINS: ALPHA 1	20/10/90	6.0	8.0	G/DL	6.20	7.20	6.90	6.80	
				GLUCOLINS: ALPHA 2	20/10/90	3.5	5.0	G/DL	4.00	4.50	4.00	4.10	
				GLUCOLINS: BETA	20/10/90	35.0	175.0	MG/DL	136.00	130.00	163.00	152.00	
				GLUCOLINS: GAMMA	20/10/90	7.0	11.0	Z	69.00	92.00	94.00	94.00	
				T3	20/10/90	11.0	14.0	Z	4.00	4.00	4.10	4.00	
				T4	20/10/90	7.0	11.0	Z	6.20	6.20	9.30	9.30	
					20/10/90	15.0	22.0	Z	12.70	10.80	12.80	12.70	
					20/10/90	86.0	187.0	MG Z	16.80	19.50	21.20	20.00	
	20/10/90	4.5	12.5	MG/DL	108.00								
	20/10/90	150.0	550.0	10 ³ -3/MNC	9.60	234.00	252.00	260.00					
109	IPL	FEMALE	HR	20/10/90	12.0	16.0	G/100ML	12/02/92	04/03/92	18/03/92	01/04/92		
			HTC	20/10/90	37.0	47.0	Z	11.80	12.00	12.20	13.00		
			RBC	20/10/90	3.8	5.4	10 ⁶ -6/MNC	35.00	36.00	36.00	37.00		
			HBC	20/10/90	4.0	11.0	10 ⁻³ /MNC	3.70	3.90	3.80	4.00		
			HRC: N	20/10/90	40.0	70.0	Z	8.40	8.00	7.60	7.80		
			HRC: L	20/10/90	20.0	40.0	Z	60.00	58.00	56.00	57.00		
			HRC: E	20/10/90	1.0	5.0	Z	28.00	28.00	30.00	30.00		
			HRC: M	20/10/90	4.0	8.0	Z	6.00	6.00	6.00	3.00		
			HRC: B	20/10/90	0.0	1.0	Z	6.00	8.00	6.00	10.00		
			PLATELETS	20/10/90	150.0	550.0	10 ³ -3/MNC	0.00	0.00	0.00	0.00		

1291

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOMETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Screen	Visit						
					Date	Min	Max		Unit	Week 2	Week 4	Week 6			
1	109	IPL	FEMALE	NA+	20/10/90	138.0	155.0	M EQ/L	138.00	137.00	141.00	142.00			
				K+	20/10/90	3.5	5.5	M EQ/L	4.20	4.10	4.30	4.30			
				CL-	20/10/90	98.0	120.0	M EQ/L	102.00	102.00	94.00	96.00			
				CA++	20/10/90	8.5	10.5	MG/DL	9.60	9.70	9.50	9.00			
				PO4--	20/10/90	3.0	4.5	MG/DL	3.60	4.00	4.20	4.20			
				SGOT	20/10/90	12.0	40.0	IU/ML	28.00	28.00	28.00	25.00			
				SGPT	20/10/90	10.0	40.0	IU/ML	30.00	30.00	32.00	28.00			
				GAMMA-GT	20/10/90	7.0	33.0	IU/ML	34.00	32.00	36.00	30.00			
				GLUCOSE	20/10/90	65.0	306.0	MG/DL	86.00	91.00	90.00	92.00			
				ALK. PHOSPH.	20/10/90	10.0	50.0	MG/DL	189.00	192.00	153.00	165.00			
				BUN	20/10/90	0.6	1.6	MG/DL	32.00	30.00	30.00	24.00			
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	0.90	0.80	0.90			
				URIC ACID	20/10/90	2.4	5.7	MG/DL	3.20	3.60	4.10	3.80			
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.70	0.80	0.90	0.80			
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.60	0.60	0.60	0.60			
				TOT. PROTEINS	20/10/90	6.0	8.4	MG/DL	6.60	6.80	6.80	6.70			
				ALBUMINE	20/10/90	3.5	5.0	G/DL	3.50	4.00	4.20	4.20			
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	173.00	160.00	194.00	187.00			
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	92.00	117.00	118.00	120.00			
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	3.80	3.70	3.80	3.70			
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	6.30	6.40	7.30	8.00			
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	15.10	14.80	15.20	15.10			
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	16.50	16.50	16.70	18.70			
				T3	20/10/90	86.0	187.0	NG X	112.00	112.00	112.00	112.00			
				T4	20/10/90	4.5	12.5	NG/DL	9.30	9.30	9.30	9.30			
				110	TQO	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	12/02/92	04/03/92	18/03/92	01/04/92
							HTC	20/10/90	37.0	47.0	%	13.60	13.80	13.80	14.00
							RBC	20/10/90	3.8	5.4	10 ⁶ /HMC	38.00	39.00	39.00	40.00
							MBC	20/10/90	4.0	11.0	10 ⁶ -3/HMC	4.00	4.20	4.20	4.20
							MBC: N	20/10/90	4.0	70.0	%	5.20	5.60	6.00	5.80
							MBC: L	20/10/90	20.0	40.0	%	52.00	56.00	60.00	58.00
							MBC: E	20/10/90	1.0	5.0	%	32.00	28.00	30.00	30.00
							MBC: B	20/10/90	4.0	8.0	%	6.00	6.00	2.00	4.00
MBC: R	20/10/90	0.0	1.0				%	10.00	10.00	8.00	8.00				
PLATELETS	20/10/90	150.0	550.0				10 ³ /HMC	227.00	205.00	243.00	214.00				
NA+	20/10/90	138.0	155.0				M EQ/L	159.00	138.00	138.00	139.00				
K+	20/10/90	3.5	5.5				M EQ/L	4.10	4.20	3.90	4.10				
CL-	20/10/90	98.0	120.0				M EQ/L	92.00	93.00	101.00	102.00				
CA++	20/10/90	8.5	10.5				MG/DL	9.50	9.60	9.20	9.60				
PO4--	20/10/90	3.0	4.5				MG/DL	3.60	3.80	3.80	3.70				
SGOT	20/10/90	12.0	40.0				IU/ML	30.00	30.00	20.00	26.00				
SGPT	20/10/90	10.0	40.0				IU/ML	28.00	32.00	28.00	28.00				
GAMMA-GT	20/10/90	7.0	33.0				IU/ML	36.00	32.00	32.00	32.00				
GLUCOSE	20/10/90	65.0	306.0				MG/DL	107.00	102.00	101.00	103.00				
ALK. PHOSPH.	20/10/90	10.0	50.0				MG/DL	134.00	126.00	116.00	116.00				
BUN	20/10/90	0.6	1.6				MG/DL	31.00	26.00	26.00	28.00				
CREATININE	20/10/90	0.6	1.6	MG/DL	1.10	1.00	0.90	0.90							
URIC ACID	20/10/90	2.4	5.7	MG/DL	3.60	4.00	3.80	4.00							

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6			
1	110	TQO	FEMALE	TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	0.70	0.80	0.60	0.60		
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.30	0.40	0.30			
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.40	6.50	6.60	6.70			
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	4.10	4.20	4.10			
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	182.00	208.00	146.00	178.00			
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	96.00	100.00	94.00	80.00			
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	Z	4.10	3.80	3.20	3.80			
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	Z	6.20	8.10	6.80	7.20			
				GLOBULINS: BETA	20/10/90	11.0	14.0	Z	15.30	14.30	16.30	12.30			
				GLOBULINS: GAMA	20/10/90	15.0	22.0	Z	18.10	19.60	19.00	19.90			
				T3	20/10/90	86.0	187.0	NG Z	96.00						
				T4	20/10/90	4.5	12.5	NG/DL	11.10						
				111	JBF	MALE	HR	20/10/90	14.0	18.0	9/100ml	13.00	13.30	13.40	13.40
							HTC	20/10/90	40.0	94.0	Z	42.00	42.00	43.00	42.00
							RBC	20/10/90	4.3	6.1	10 ⁶ /mm ³	5.00	5.10	4.90	5.10
							WBC	20/10/90	4.0	11.0	10 ³ /mm ³	6.30	5.80	6.20	6.40
							NEC: N	20/10/90	40.0	70.0	Z	60.00	61.00	59.00	58.00
							NEC: L	20/10/90	20.0	40.0	Z	27.00	27.00	27.00	28.00
							NEC: E	20/10/90	1.0	5.0	Z	6.00	5.00	6.00	5.00
							NEC: M	20/10/90	4.0	8.0	Z	7.00	7.00	8.00	9.00
NEC: B	20/10/90	0.0	1.0				Z	0.00	0.00	0.00	0.00				
PLATELETS	20/10/90	150.0	550.0				10 ³ /mm ³	281.00	294.00	279.00	293.00				
NA+	20/10/90	138.0	155.0				M EQ/L	138.00	141.00	139.00	140.00				
K+	20/10/90	3.5	5.5				M EQ/L	4.10	3.80	4.00	3.80				
CL-	20/10/90	98.0	120.0				M EQ/L	103.00	102.00	102.00	96.00				
CA++	20/10/90	8.5	10.5				MG/DL	10.10	10.20	9.50	9.40				
PO4--	20/10/90	3.0	4.5				MG/DL	3.60	3.90	3.20	3.80				
SGPT	20/10/90	12.0	40.0				IU/ML	37.00	32.00	27.00	23.00				
GAMMA-GT	20/10/90	10.0	40.0				IU/ML	38.00	34.00	29.00	26.00				
GLUCOSE	20/10/90	11.0	51.0				MG/DL	31.00	30.00	30.00	32.00				
ALK. PHOSPH.	20/10/90	70.0	100.0				MG/DL	92.00	90.00	94.00	90.00				
CREATININE	20/10/90	65.0	306.0				IU/ML	182.00	176.00	116.00	190.00				
UREIC ACID	20/10/90	10.0	50.0	MG/DL	32.00	30.00	26.00	24.00							
TOT BILIRUBIN	20/10/90	0.6	1.6	MG/DL	0.90	0.80	0.90	0.90							
DIR BILIRUBIN	20/10/90	3.4	7.0	MG/DL	3.20	3.80	3.60	4.10							
TOT. PROTEINS	20/10/90	0.2	1.0	MG/DL	0.80	0.70	0.70	0.60							
ALBUMINE	20/10/90	0.0	0.4	MG/DL	0.40	0.30	0.30	0.30							
TOT. CHOLEST.	20/10/90	5.0	8.0	G/DL	6.20	6.50	7.00	7.00							
TRIGLYCERIDES	20/10/90	3.5	5.0	G/DL	4.10	4.00	3.90	4.30							
GLOBULINS: ALPHA 1	20/10/90	160.0	270.0	MG/DL	182.00	170.00	178.00	144.00							
GLOBULINS: ALPHA 2	20/10/90	35.0	175.0	MG/DL	95.00	80.00	96.00	86.00							
GLOBULINS: BETA	20/10/90	4.0	7.0	Z	3.80	2.70	3.20	3.20							
GLOBULINS: GAMA	20/10/90	7.0	11.0	Z	6.20	7.00	7.40	8.00							
T3	20/10/90	11.0	44.0	Z	16.10	19.10	14.00	12.10							
T4	20/10/90	15.0	22.0	Z	18.30	20.20	21.00	23.00							

1630

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REDOXYTINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6			
1	112	PSA	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	12/02/92	04/03/92	18/03/92	01/04/92			
				HTC	20/10/90	37.0	47.0	X	12.80	13.00	13.20	13.50			
				RBC	20/10/90	3.8	5.4	10-6/MHC	39.00	40.00	40.00	40.00			
				MHC	20/10/90	4.0	11.0	10-3/MHC	3.80	4.30	4.20	4.00			
				MBC: N	20/10/90	40.0	70.0	X	6.10	7.00	6.50	7.00			
				MBC: L	20/10/90	20.0	40.0	X	58.00	62.00	60.00	58.00			
				MBC: E	20/10/90	1.0	5.0	X	22.00	23.00	24.00	22.00			
				MBC: H	20/10/90	4.0	8.0	X	14.00	8.00	6.00	6.00			
				MBC: B	20/10/90	0.0	1.0	X	4.00	7.00	10.00	4.00			
				PLATELETS	20/10/90	150.0	550.0	10-3/MHC	2.00	215.00	232.00	214.00			
				NA+	20/10/90	138.0	155.0	M EQ/L	142.00	143.00	141.00	138.00			
				K+	20/10/90	3.5	5.5	M EQ/L	3.70	3.90	3.90	4.00			
				CL-	20/10/90	98.0	120.0	M EQ/L	105.00	98.00	104.00	104.00			
				PO4--	20/10/90	8.5	10.5	MG/DL	10.10	9.50	9.80	9.40			
				SGOT	20/10/90	12.0	40.0	MG/DL	3.80	4.00	3.90	4.00			
				SGPT	20/10/90	10.0	40.0	IU/ML	38.00	36.00	36.00	28.00			
				GAMMA-GT	20/10/90	7.0	33.0	IU/ML	36.00	38.00	40.00	32.00			
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	106.00	94.00	102.00	104.00			
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	211.00	230.00	223.00	192.00			
				BUN	20/10/90	10.0	50.0	MG/DL	34.00	30.00	30.00	28.00			
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	0.90	1.00	0.90			
				URIC ACID	20/10/90	2.4	5.7	MG/DL	3.90	3.80	4.20	4.10			
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	1.00	0.70	0.60	1.00			
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.50	0.30	0.30	0.50			
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.40	6.60	6.60	6.80			
				ALBUMINE	20/10/90	3.5	5.0	G/DL	3.80	4.30	4.00	4.00			
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	191.00	180.00	170.00	180.00			
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	76.00	82.00	82.00	63.00			
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	X	4.30	4.00	3.00	2.50			
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	X	8.10	9.00	6.10	8.00			
				GLOBULINS: BETA	20/10/90	11.0	14.0	X	13.20	12.30	14.00	12.30			
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	X	16.10	18.20	22.10	18.10			
				T3	20/10/90	86.0	187.0	NG %	108.00						
				T4	20/10/90	4.5	12.5	NG/DL	10.20						
				119	LFS	MALE	HB	20/10/90	14.0	18.0	G/100mL	12/02/92	04/03/92	18/03/92	01/04/92
							HTC	20/10/90	40.0	54.0	X	13.50	13.80	14.00	13.60
							RBC	20/10/90	4.3	6.1	10**6/mm	40.00	41.00	39.00	41.00
							MHC	20/10/90	4.0	11.0	10-3/MHC	3.80	4.20	4.10	4.50
							MBC: N	20/10/90	40.0	70.0	X	7.40	7.30	7.20	6.50
							MBC: L	20/10/90	20.0	40.0	X	60.00	62.00	59.00	59.00
							MBC: E	20/10/90	1.0	5.0	X	26.00	26.00	25.00	25.00
							MBC: H	20/10/90	4.0	8.0	X	6.00	6.00	6.00	6.00
							MBC: B	20/10/90	0.0	1.0	X	8.00	6.00	10.00	10.00
							PLATELETS	20/10/90	150.0	550.0	10-3/MHC	76.00	293.00	285.00	290.00

1631

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Date	Laboratory Range			Unit	Screen	Visit			
						Min	Max	Max			Week 2	Week 4	Week 6	
1	113	LPS	MALE	NA+	20/10/90	138.0	155.0	155.0	M EQ/L	138.00	141.00	139.00	141.00	
				K+	20/10/90	3.5	5.5	5.5	M EQ/L	3.70	4.20	4.00	3.90	
				CL-	20/10/90	98.0	120.0	120.0	M EQ/L	103.00	104.00	101.00	102.00	
				CA++	20/10/90	8.5	10.5	10.5	MG/DL	10.20	9.90	10.10	10.10	
				PO4-	20/10/90	3.0	4.5	4.5	MG/DL	4.00	4.20	3.90	4.20	
				SGPT	20/10/90	12.0	40.0	40.0	IU/ML	23.00	30.00	26.00	24.00	
				SGPT	20/10/90	10.0	40.0	40.0	IU/ML	34.00	34.00	30.00	28.00	
				GAMMA-GT	20/10/90	11.0	51.0	51.0	IU/ML	32.00	28.00	34.00	30.00	
				GLUCOSE	20/10/90	70.0	100.0	100.0	MG/DL	92.00	80.00	80.00	87.00	
				ALK. PHOSPH.	20/10/90	65.0	306.0	306.0	IU/ML	132.00	130.00	130.00	141.00	
				BUN	20/10/90	10.0	50.0	50.0	MG/DL	28.00	26.00	24.00	24.00	
				CREATININE	20/10/90	0.6	1.6	1.6	MG/DL	0.70	0.80	1.00	0.80	
				URIC ACID	20/10/90	3.4	7.0	7.0	MG/DL	3.90	4.00	3.90	3.80	
				TOT BILIRUBIN	20/10/90	0.2	1.0	1.0	MG/DL	0.80	0.70	0.60	0.60	
				DIR BILIRUBIN	20/10/90	0.0	0.4	0.4	MG/DL	0.60	0.30	0.30	0.30	
				TOT. PROTEINS	20/10/90	6.0	8.0	8.0	G/DL	6.60	7.20	6.80	7.30	
				ALBUMINE	20/10/90	3.5	5.0	5.0	G/DL	4.00	4.20	4.20	4.10	
				TOT. CHOLEST.	20/10/90	140.0	270.0	270.0	MG/DL	172.00	163.00	182.00	160.00	
				TRIGLYCERIDES	20/10/90	35.0	175.0	175.0	MG/DL	116.00	110.00	170.00	97.00	
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	7.0	g	4.20	4.00	3.00	4.00	
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	11.0	g	8.20	8.20	8.10	8.10	
				GLOBULINS: BETA	20/10/90	11.0	14.0	14.0	g	12.10	16.30	12.00	12.30	
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	22.0	g	17.00	20.40	18.20	17.00	
				T3	20/10/90	86.0	187.0	187.0	NG %	106.00				
T4	20/10/90	4.5	12.5	12.5	NG/DL	9.60								
114	CLF	FEMALE	HB	20/10/90	12.0	16.0	16.0	G/100HL	18/02/92	10/03/92	24/03/92	07/04/92		
			HTC	20/10/90	37.0	47.0	47.0	g	13.40	13.20	13.80	13.80		
			RBC	20/10/90	3.8	5.4	5.4	10 ⁶ /HMC	40.00	38.00	42.00	40.00		
			MBC: N	20/10/90	4.0	11.0	10-3/HMC	4.70	4.30	4.80	4.70			
			MBC: L	20/10/90	40.0	70.0	g	10.20	7.00	7.00	5.80			
			MBC: E	20/10/90	20.0	40.0	g	69.00	58.00	58.00	57.00			
			MBC: M	20/10/90	1.0	5.0	g	23.00	27.00	33.00	23.00			
			MBC: B	20/10/90	4.0	8.0	g	0.00	6.00	3.00	15.00			
			PLATELETS	20/10/90	0.0	1.0	g	8.00	9.00	6.00	5.00			
			NA+	20/10/90	150.0	550.0	10-3/HMC	283.00	283.00	316.00	252.00			
			K+	20/10/90	3.5	5.5	M EQ/L	142.00	139.00	138.00	142.00			
			CL-	20/10/90	98.0	120.0	M EQ/L	4.70	4.20	4.90	3.90			
			CA++	20/10/90	8.5	10.5	MG/DL	98.00	108.00	96.00	100.00			
			PO4-	20/10/90	3.0	4.5	MG/DL	3.30	3.70	10.30	9.30			
			SGPT	20/10/90	12.0	40.0	IU/ML	3.90	4.20	4.40	3.80			
			SGPT	20/10/90	10.0	40.0	IU/ML	27.00	28.00	16.00	24.00			
			GAMMA-GT	20/10/90	7.0	33.0	IU/ML	16.00	30.00	18.00	28.00			
			GLUCOSE	20/10/90	70.0	100.0	MG/DL	87.00	47.00	37.00	32.00			
			ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	231.00	202.00	208.00	192.00			
			BUN	20/10/90	10.0	50.0	MG/DL	27.00	27.00	20.00	24.00			
			CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	1.00	0.70	0.80			
			URIC ACID	20/10/90	2.4	5.7	MG/DL	4.20	4.20	3.80	3.70			

1632

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXYTINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit									
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6					
1	114	CIF	FEMALE	TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.40	0.80	0.40	0.70					
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.40	0.20	0.30					
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.80	7.20	7.00	7.30					
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.00	4.30	4.20	4.10					
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	213.00	193.00	209.00	163.00					
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	93.00	72.00	108.00	72.00					
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	g	2.70	3.20	3.30	4.10					
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	g	8.00	7.10	9.10	8.30					
				GLOBULINS: BETA	20/10/90	11.0	14.0	g	10.50	12.30	11.90	11.00					
				GLOBULINS: GAMMA	20/10/90	45.0	22.0	g	22.50	19.20	20.30	18.70					
				T3	20/10/90	86.0	187.0	NG Z	110.00								
				T4	20/10/90	4.5	12.5	NG/DL	8.00								
				145	ELS	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	14.30	14.00	13.80	13.90		
							HTC	20/10/90	37.0	47.0	z	42.00	40.00	41.00	40.00		
							RBC	20/10/90	3.8	5.4	10 ⁶ /HMC	4.90	4.50	4.80	4.80		
							HBC	20/10/90	4.0	11.0	10 ³ /HMC	9.00	10.10	11.60	8.80		
							HBC: N	20/10/90	40.0	70.0	z	61.00	61.00	68.00	59.00		
							HBC: L	20/10/90	20.0	40.0	z	30.00	28.00	28.00	30.00		
							HBC: E	20/10/90	1.0	5.0	z	4.00	4.00	1.00	5.00		
							HBC: M	20/10/90	4.0	8.0	z	5.00	7.00	5.00	6.00		
HBC: B	20/10/90	0.0	1.0				z	0.00	0.00	0.00	0.00						
PLATELETS	20/10/90	150.0	550.0				10 ³ /HMC	262.00	267.00	251.00	288.00						
NA+	20/10/90	138.0	155.0				M EQ/L	142.00	142.00	139.00	141.00						
CL-	20/10/90	98.0	120.0				M EQ/L	98.00	98.00	97.00	98.00						
CA++	20/10/90	8.5	10.5				MG/DL	9.00	9.90	9.70	9.60						
PO4--	20/10/90	3.0	4.5				MG/DL	3.60	4.20	4.20	4.10						
SGPT	20/10/90	12.0	40.0				NU/ML	24.00	28.00	23.00	26.00						
GAMMA-GT	20/10/90	10.0	40.0				NU/ML	16.00	32.00	25.00	30.00						
GLUCOSE	20/10/90	7.0	33.0				NU/ML	27.00	40.00	39.00	38.00						
ALK. PHOSPH.	20/10/90	70.0	100.0				NG/DL	99.00	86.00	101.00	94.00						
BUN	20/10/90	65.0	306.0				NU/ML	266.00	220.00	277.00	261.00						
CREATININE	20/10/90	10.0	50.0				MG/DL	20.00	28.00	30.00	28.00						
URIC ACID	20/10/90	0.6	1.6	MG/DL	0.80	1.00	0.90	0.90									
TOT BILIRUBIN	20/10/90	2.4	5.7	MG/DL	5.50	4.20	5.00	4.00									
DIR BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	0.70	0.50	0.70									
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.00	7.40	6.80	7.10									
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.30	3.90	3.70	4.00									
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	345.00	281.00	313.00	273.00									
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	260.00	152.00	197.00	141.00									
GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	g	3.20	4.00	3.80	3.70									
GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	g	9.40	10.20	12.60	9.20									
GLOBULINS: BETA	20/10/90	11.0	14.0	g	13.10	13.10	13.80	13.60									
GLOBULINS: GAMMA	20/10/90	15.0	22.0	g	18.80	19.20	14.90	20.30									
T3	20/10/90	86.0	187.0	NG Z	140.00												
T4	20/10/90	4.5	12.5	NG/DL	8.80												

1630

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Screen	Visit					
					Date	Min	Max		Unit	Week 2	Week 4	Week 6		
1	117	PSL	FEMALE	NA+	20/10/90	138.0	155.0	M ER/L	143.00	142.00	142.00	138.00		
				K+	20/10/90	3.5	5.5	M ER/L	4.60	4.10	4.10	4.00		
				CL-	20/10/90	98.0	120.0	M ER/L	97.00	102.00	99.00	96.00		
				CA++	20/10/90	8.5	10.5	MG/DL	9.40	9.60	9.10	9.50		
				PO4--	20/10/90	3.0	4.5	MG/DL	3.80	4.20	3.60	3.80		
				SGOT	20/10/90	12.0	40.0	IU/ML	21.00	24.00	29.00	26.00		
				SGPT	20/10/90	10.0	40.0	IU/ML	19.00	26.00	23.00	30.00		
				GANNA-GT	20/10/90	7.0	33.0	IU/ML	39.00	30.00	45.00	28.00		
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	132.00	172.00	104.00	87.00		
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	250.00	28.00	229.00	163.00		
				BUN	20/10/90	10.0	50.0	MG/DL	25.00	28.00	28.00	32.00		
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	1.10	1.10	1.00		
				URIC ACID	20/10/90	2.4	5.7	MG/DL	5.80	4.10	5.60	3.20		
				TOT. BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.50	0.80	0.50	0.70		
				DIR. BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.30	0.20	0.30		
				TOT. PROTEINS	20/10/90	6.1	8.0	G/DL	7.20	7.60	7.40	7.10		
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.00	4.10	4.20		
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	229.00	193.00	199.00	193.00		
				TRIGLICERIDES	20/10/90	35.0	175.0	MG/DL	67.00	103.00	62.00	88.00		
				GLOBALINS: ALPHA 1	20/10/90	4.0	7.0	Z	2.50	3.70	3.00	4.10		
				GLOBALINS: ALPHA 2	20/10/90	7.0	11.0	Z	6.60	8.20	8.00	12.30		
				GLOBALINS: BETA	20/10/90	11.0	14.0	Z	15.00	12.30	13.10	10.20		
				GLOBALINS: GAMMA	20/10/90	15.0	22.0	Z	23.70	24.10	25.00	21.30		
				T3	20/10/90	86.0	187.0	NG Z	110.00					
				T4	20/10/90	4.5	12.5	NG/DL	8.00					
				HB	20/10/90	12.0	16.0	G/100ML	11.80	18/02/92	10/03/92	24/03/92		
				HTC	20/10/90	37.0	47.0	Z	34.00	12.00	12.30	12.30		
				RBC	20/10/90	3.8	5.4	10-6/MNC	3.90	36.00	36.00	36.00		
				HBC	20/10/90	4.0	11.0	10-3/MNC	6.00	4.20	4.30	4.30		
				HBC: N	20/10/90	40.0	70.0	Z	50.00	6.30	7.10	58.00		
				HBC: L	20/10/90	20.0	40.0	Z	38.00	36.00	32.00	32.00		
				HBC: E	20/10/90	1.0	5.0	Z	7.00	3.00	3.00	3.00		
				HBC: M	20/10/90	4.0	8.0	Z	5.00	5.00	7.00	7.00		
				HBC: B	20/10/90	0.0	1.0	Z	0.00	0.00	0.00	0.00		
				PLATELETS	20/10/90	150.0	550.0	10-3/MNC	280.00	276.00	253.00	253.00		
				NA+	20/10/90	138.0	165.0	M ER/L	140.00	139.00	138.00	138.00		
				K+	20/10/90	3.5	5.5	M ER/L	3.90	4.00	4.20	4.20		
				CL-	20/10/90	98.0	120.0	M ER/L	96.00	96.00	97.00	97.00		
				PO4--	20/10/90	3.0	4.5	MG/DL	3.10	10.20	9.30	9.30		
				SGOT	20/10/90	12.0	40.0	IU/ML	20.00	18.00	20.00	20.00		
				SGPT	20/10/90	10.0	40.0	IU/ML	11.00	24.00	24.00	24.00		
				GANNA-GT	20/10/90	7.0	33.0	IU/ML	22.00	26.00	28.00	28.00		
				GLUCOSE	20/10/90	65.0	306.0	MG/DL	88.00	89.00	85.00	85.00		
				ALK. PHOSPH.	20/10/90	65.0	306.0	MG/DL	203.00	210.00	174.00	174.00		
				BUN	20/10/90	10.0	50.0	MG/DL	33.00	29.00	27.00	27.00		
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.70	0.70	1.10	1.10		
				URIC ACID	20/10/90	2.4	5.7	MG/DL	3.60	3.80	3.20	3.20		

1635

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Screen	Visit					
					Date	Min	Max		Unit	Week 2	Week 4	Week 6		
1	117	PSL	FEMALE	NA+	20/10/90	138.0	155.0	M ER/L	143.00	142.00	142.00	138.00		
				K+	20/10/90	3.5	5.5	M ER/L	4.60	4.10	4.10	4.00		
				CL-	20/10/90	98.0	120.0	M ER/L	97.00	102.00	99.00	96.00		
				CA++	20/10/90	8.5	10.5	MG/DL	9.40	9.60	9.10	9.50		
				PO4--	20/10/90	3.0	4.5	MG/DL	3.80	4.20	3.60	3.80		
				SGOT	20/10/90	12.0	40.0	IU/ML	21.00	24.00	29.00	26.00		
				SGPT	20/10/90	10.0	40.0	IU/ML	19.00	26.00	23.00	30.00		
				GANNA-GT	20/10/90	7.0	33.0	IU/ML	39.00	30.00	45.00	28.00		
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	132.00	172.00	104.00	87.00		
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	250.00	172.00	229.00	163.00		
				BUN	20/10/90	10.0	50.0	MG/DL	25.00	28.00	28.00	32.00		
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	1.10	1.10	1.00		
				URIC ACID	20/10/90	2.4	5.7	MG/DL	5.80	4.10	5.60	3.20		
				TOT. BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.50	0.80	0.50	0.70		
				DIR. BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.30	0.20	0.30		
				TOT. PROTEINS	20/10/90	6.1	8.0	G/DL	7.20	7.60	7.40	7.10		
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.00	4.10	4.20		
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	229.00	193.00	193.00	193.00		
				TRIGLICERIDES	20/10/90	35.0	175.0	MG/DL	67.00	103.00	62.00	88.00		
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	Z	2.50	3.70	3.00	4.10		
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	Z	6.60	8.20	8.00	12.30		
				GLOBULINS: BETA	20/10/90	11.0	14.0	Z	15.00	12.30	13.10	10.20		
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	Z	23.70	24.10	25.00	21.30		
				T3	20/10/90	86.0	187.0	NG X	110.00					
				T4	20/10/90	4.5	12.5	NG/DL	8.00					
				HB	20/10/90	12.0	16.0	G/100ML	11.80	18/02/92	10/03/92	24/03/92		
				HTC	20/10/90	37.0	47.0	X	34.00	12.00	12.30	12.30		
				RBC	20/10/90	3.8	5.4	10-6/MNC	3.90	36.00	36.00	36.00		
				MBC	20/10/90	4.0	11.0	10-3/MNC	6.00	4.20	4.30	4.30		
				MBC: N	20/10/90	40.0	70.0	X	50.00	6.30	7.10	58.00		
				MBC: L	20/10/90	20.0	40.0	X	38.00	36.00	32.00	32.00		
				MBC: E	20/10/90	1.0	5.0	X	7.00	3.00	3.00	3.00		
				MBC: M	20/10/90	4.0	8.0	X	5.00	5.00	7.00	7.00		
				MBC: B	20/10/90	0.0	1.0	X	0.00	0.00	0.00	0.00		
				PLATELETS	20/10/90	150.0	550.0	10-3/MNC	280.00	276.00	253.00	253.00		
				NA+	20/10/90	138.0	165.0	M ER/L	140.00	139.00	138.00	138.00		
				K+	20/10/90	3.5	5.5	M ER/L	3.90	4.00	4.20	4.20		
				CL-	20/10/90	98.0	120.0	M ER/L	96.00	96.00	97.00	97.00		
				PO4--	20/10/90	3.0	4.5	MG/DL	3.10	10.20	9.30	9.30		
				SGOT	20/10/90	12.0	40.0	IU/ML	20.00	18.00	18.00	20.00		
				SGPT	20/10/90	10.0	40.0	IU/ML	11.00	20.00	24.00	24.00		
				GANNA-GT	20/10/90	7.0	33.0	IU/ML	22.00	26.00	28.00	28.00		
				GLUCOSE	20/10/90	65.0	306.0	MG/DL	88.00	89.00	85.00	85.00		
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	203.00	210.00	174.00	174.00		
				BUN	20/10/90	10.0	50.0	MG/DL	33.00	29.00	27.00	27.00		
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.70	0.70	1.10	1.10		
				URIC ACID	20/10/90	2.4	5.7	MG/DL	3.60	3.80	3.20	3.20		

1635

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXEMINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit								
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
1	118	FEMALE	TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	1.00	1.00	0.60					
			DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.30	0.30					
			TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.30	7.10	7.00					
			ALBUMINE	20/10/90	3.5	5.0	G/DL	4.50	4.30	4.30					
			TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	179.00	162.00	188.00					
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	70.00	76.00	87.00					
			GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	2.10	3.10	3.70					
			GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	7.70	8.70	9.30					
			GLOBULINS: BETA	20/10/90	11.0	14.0	%	14.10	14.30	18.70					
			GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	21.20	23.00	21.10					
			T3	20/10/90	86.0	187.0	NG X	140.00							
			T4	20/10/90	4.5	12.5	NG/DL	7.40							
			1	119	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	14.10	13.80	14.30	07/04/92	
						HTC	20/10/90	37.0	47.0	X	38.00	39.00	38.00	14.00	14.00
						RBC	20/10/90	3.8	5.4	10 ⁶ -6/MMC	4.20	4.30	4.40	39.00	39.00
						RBC: N	20/10/90	4.0	11.0	10 ³ -3/MMC	6.50	6.60	7.00	4.40	4.20
RBC: L	20/10/90	40.0				70.0	X	58.00	60.00	56.00	7.00	7.10			
RBC: E	20/10/90	20.0				40.0	X	30.00	30.00	29.00	56.00	56.00			
RBC: M	20/10/90	1.0				5.0	X	4.00	4.00	5.00	30.00	30.00			
RBC: B	20/10/90	4.0				8.0	X	8.00	6.00	9.00	5.00	5.00			
PLATELETS	20/10/90	0.0				1.0	X	0.00	0.00	1.00	9.00	9.00			
NA+	20/10/90	150.0				550.0	10 ⁻³ /MMC	311.00	331.00	340.00	0.00	0.00			
K+	20/10/90	138.0				155.0	M EQ/L	141.00	136.00	138.00	326.00	340.00			
CL-	20/10/90	3.5				5.5	M EQ/L	3.90	4.00	4.00	138.00	138.00			
CA++	20/10/90	98.0				120.0	M EQ/L	102.00	101.00	98.00	4.00	4.00			
PO4-	20/10/90	3.0				4.5	MG/DL	9.30	9.40	9.60	9.60	9.60			
SGPT	20/10/90	12.0				40.0	IU/ML	28.00	26.00	25.00	9.60	9.60			
GAMMA-GT	20/10/90	10.0				40.0	IU/ML	30.00	30.00	24.00	4.10	4.10			
GLUCOSE	20/10/90	70.0	330.0	MG/DL	27.00	32.00	30.00	20.00	20.00						
ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	90.00	88.00	82.00	30.00	30.00						
CREATININE	20/10/90	10.0	50.0	MG/DL	42.00	26.00	32.00	84.00	84.00						
URIC ACID	20/10/90	2.4	5.7	MG/DL	4.60	4.30	4.10	241.00	241.00						
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.80	0.60	0.70	26.00	26.00						
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.60	0.30	0.50	0.90	0.90						
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.90	7.00	7.30	4.10	4.10						
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.00	4.20	4.20	0.50	0.50						
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	178.00	192.00	171.00	7.30	7.30						
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	82.00	96.00	88.00	4.20	4.20						
GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	4.00	3.90	2.80	171.00	171.00						
GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	4.00	5.40	4.00	68.00	68.00						
GLOBULINS: BETA	20/10/90	11.0	14.0	%	6.20	6.40	9.00	74.00	74.00						
GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	13.20	14.20	11.30	4.00	4.00						
T3	20/10/90	86.0	187.0	NG X	108.00	22.00	8.70	10.90	10.90						
T4	20/10/90	4.5	12.5	NG/DL	9.20		21.20	8.70	8.70						

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Screen		Visit			
					Date	Min	Max	Unit	Week 2	Week 4	Week 6		
1	120	JLB	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	19/02/92	13.80	11/03/92	14.10	08/04/92
				HTC	20/10/90	37.0	47.0	%	40.00	40.00	39.00	39.00	
				RBC	20/10/90	3.8	5.4	10 ⁶ /MNC	4.30	4.30	4.30	4.50	
				WBC	20/10/90	4.0	11.0	10 ³ /MNC	7.00	7.10	6.90	7.20	
				NEC: N	20/10/90	40.0	70.0	%	60.00	62.00	58.00	58.00	
				NEC: L	20/10/90	20.0	40.0	%	22.00	28.00	27.00	23.00	
				NEC: E	20/10/90	1.0	5.0	%	6.00	6.00	6.00	8.00	
				NEC: M	20/10/90	4.0	8.0	%	10.00	6.00	9.00	10.00	
				NEC: B	20/10/90	0.0	1.0	%	2.00	0.00	0.00	1.00	
				PLATELETS	20/10/90	150.0	550.0	10 ³ /MNC	192.00	208.00	241.00	227.00	
				UA+	20/10/90	158.0	155.0	MG/L	137.00	198.00	140.00	141.00	
				E+	20/10/90	3.5	5.5	MG/L	3.80	4.00	3.90	3.90	
				CL-	20/10/90	98.0	120.0	MG/L	96.00	92.00	97.00	97.00	
				CA++	20/10/90	3.0	4.5	MG/DL	3.20	4.10	4.00	4.20	
				PO4--	20/10/90	12.0	40.0	MG/DL	31.00	28.00	30.00	30.00	
				SGPT	20/10/90	10.0	40.0	MG/DL	33.00	32.00	28.00	34.00	
				GAMMA-GT	20/10/90	7.0	33.0	MG/DL	28.00	23.00	24.00	27.00	
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	88.00	91.00	91.00	86.00	
				ALK. PHOSPH.	20/10/90	65.0	306.0	MG/DL	185.00	172.00	163.00	172.00	
				BUN	20/10/90	10.0	50.0	MG/DL	36.00	30.00	28.00	28.00	
				CREATININE	20/10/90	0.6	1.6	MG/DL	1.00	1.00	0.80	1.00	
				URIC ACID	20/10/90	2.4	5.7	MG/DL	4.20	4.00	3.90	4.20	
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.80	0.80	0.80	0.70	
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.40	0.40	0.30	
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.80	7.10	6.90	6.90	
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.00	4.10	4.10	4.00	
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	177.00	152.00	162.00	161.00	
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	92.00	96.00	91.00	96.00	
GLORULINS: ALPHA 1	20/10/90	4.0	7.0	%	3.10	4.00	3.00	4.00					
GLORULINS: ALPHA 2	20/10/90	7.0	11.0	%	5.20	10.80	6.10	6.10					
GLORULINS: BETA	20/10/90	11.0	16.0	%	9.80	9.10	7.20	7.20					
GLORULINS: GAMMA	20/10/90	15.0	22.0	%	13.70	20.00	18.50	14.80					
T3	20/10/90	86.0	187.0	NG %	98.00								
T4	20/10/90	4.5	12.5	NG/DL	8.70								
121	LAC		FEMALE	HB	20/10/90	12.0	16.0	G/100ML	19/02/92	13.60	11/03/92	13.60	08/04/92
				HTC	20/10/90	37.0	47.0	%	39.00	38.00	40.00	40.00	
				RBC	20/10/90	3.8	5.4	10 ⁶ /MNC	4.80	4.70	4.50	4.70	
				WBC	20/10/90	4.0	11.0	10 ³ /MNC	6.30	6.20	5.80	6.00	
				NEC: N	20/10/90	40.0	70.0	%	54.00	56.00	58.00	59.00	
				NEC: L	20/10/90	20.0	40.0	%	32.00	30.00	29.00	31.00	
				NEC: E	20/10/90	1.0	5.0	%	6.00	4.00	5.00	3.00	
				NEC: M	20/10/90	4.0	8.0	%	8.00	10.00	6.00	7.00	
				NEC: B	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	
				PLATELETS	20/10/90	150.0	550.0	10 ³ /MNC	287.00	293.00	291.00	303.00	

1 6 3 7

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit				
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6
1	121	LAC	FEMALE	NA+	20/10/90	138.0	155.0	M EQ/L	137.00	136.00	138.00	138.00
				K+	20/10/90	3.5	5.5	M EQ/L	4.00	3.80	4.10	3.70
				CL-	20/10/90	98.0	120.0	M EQ/L	96.00	97.00	97.00	98.00
				CA++	20/10/90	8.5	10.5	MG/DL	8.90	9.40	9.40	9.00
				PO4-	20/10/90	3.0	4.5	MG/DL	3.90	4.20	3.80	3.80
				SGOT	20/10/90	12.0	40.0	NU/HL	26.00	24.00	26.00	24.00
				SGPT	20/10/90	10.0	40.0	NU/HL	28.00	28.00	30.00	28.00
				GAMMA-GT	20/10/90	7.0	33.0	NU/HL	24.00	30.00	26.00	30.00
				GLUCOSE	20/10/90	65.0	100.0	MG/DL	92.00	82.00	94.00	91.00
				ALK. PHOSPH.	20/10/90	10.0	306.0	NU/HL	186.00	174.00	162.00	151.00
				BUN	20/10/90	0.6	50.0	MG/DL	35.00	28.00	28.00	28.00
				CREATININE	20/10/90	0.6	1.6	MG/DL	1.00	1.00	0.90	0.90
				URIC ACID	20/10/90	2.4	5.7	MG/DL	4.80	4.50	3.80	3.90
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.90	1.00	0.80	0.70
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.50	0.40	0.40	0.40
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.20	7.10	7.00	7.10
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	4.10	3.90	4.00
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	216.00	193.00	174.00	186.00
				TRIGLICERIDES	20/10/90	35.0	175.0	MG/DL	93.00	86.00	80.00	91.00
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	g	3.40	3.50	4.10	4.10
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	g	6.80	10.80	8.30	7.00
				GLOBULINS: BETA	20/10/90	11.0	14.0	g	11.20	12.10	10.20	13.20
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	g	15.70	20.00	18.70	21.00
				T3	20/10/90	86.0	187.0	NG %	90.00			
				T4	20/10/90	4.5	12.5	NG/DL	11.20			
				HB	20/10/90	14.0	18.0	g/100ml	19/02/92	11/03/92	25/03/92	08/04/92
				HTC	20/10/90	40.0	54.0	%	14.20	14.00	14.10	14.00
				RBC	20/10/90	4.3	6.1	10 ⁶ /mm ³	42.00	41.00	42.00	40.00
				MBC	20/10/90	4.0	11.0	10 ³ /MNC	4.50	4.50	4.50	4.40
				MBC: N	20/10/90	40.0	70.0	%	62.00	60.00	58.00	61.00
				MBC: L	20/10/90	20.0	40.0	%	30.00	29.00	30.00	27.00
				MBC: E	20/10/90	1.0	5.0	%	2.00	3.00	4.00	5.00
				MBC: M	20/10/90	4.0	8.0	%	6.00	8.00	7.00	7.00
				MBC: R	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00
				PLATELETS	20/10/90	150.0	550.0	10 ³ /MNC	224.00	210.00	231.00	240.00
				NA+	20/10/90	138.0	155.0	M EQ/L	136.00	137.00	138.00	140.00
				CL-	20/10/90	3.5	5.5	M EQ/L	3.70	3.80	4.00	3.70
				CA++	20/10/90	98.0	120.0	M EQ/L	100.00	99.00	98.00	99.00
				PO4-	20/10/90	8.5	10.5	MG/DL	9.60	9.50	9.90	9.80
				SGOT	20/10/90	3.0	4.5	MG/DL	3.00	4.30	4.30	4.20
				SGPT	20/10/90	12.0	40.0	NU/HL	30.00	28.00	28.00	27.00
				GAMMA-GT	20/10/90	11.0	40.0	NU/HL	32.00	30.00	32.00	30.00
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	82.00	72.00	76.00	86.00
				ALK. PHOSPH.	20/10/90	65.0	306.0	NU/HL	165.00	172.00	151.00	170.00
				BUN	20/10/90	10.0	50.0	MG/DL	38.00	28.00	30.00	32.00
				CREATININE	20/10/90	0.6	1.6	MG/DL	1.10	1.00	0.90	1.00
				URIC ACID	20/10/90	3.4	7.0	MG/DL	4.80	4.70	4.20	4.10

1633

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6			
1	122	HSS	MALE	TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	0.70	0.80	0.90			
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.40	0.40	0.40			
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.20	7.00	7.00	7.20			
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.20	4.10	4.30			
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	138.00	162.00	177.00	174.00			
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	96.00	87.00	68.00	72.00			
				GLOBALINS: ALPHA 1	20/10/90	4.0	7.0	%	3.80	3.70	2.50	3.00			
				GLOBALINS: ALPHA 2	20/10/90	7.0	11.0	%	6.40	7.10	10.10	11.00			
				GLOBALINS: BETA	20/10/90	11.0	14.0	%	12.20	12.80	8.50	8.60			
				GLOBALINS: GAMMA	20/10/90	15.0	22.0	%	16.40	19.00	21.20	23.10			
				T3	20/10/90	86.0	187.0	NG %	108.00						
				T4	20/10/90	4.5	12.5	NG/DL	8.40						
				123	MLL	FEMALE	HR	20/10/90	12.0	16.0	G/100ML	15.60	11/03/92	13.80	08/04/92
							HTC	20/10/90	37.0	47.0	%	37.00	39.80	44.00	
							RBC	20/10/90	3.8	5.4	10 ⁶ /MHC	3.90	4.10	3.80	
							RBC: N	20/10/90	4.0	11.0	10 ³ /MHC	8.10	7.40	7.60	
							RBC: L	20/10/90	40.0	70.0	%	64.00	60.00	61.00	
							RBC: E	20/10/90	20.0	40.0	%	29.00	28.00	25.00	
							RBC: M	20/10/90	1.0	5.0	%	3.00	3.00	8.00	
							RBC: B	20/10/90	4.0	8.0	%	5.00	3.00	6.00	
PLATELETS	20/10/90	0.0	1.0				%	0.00	0.00	0.00					
NA+	20/10/90	150.0	550.0				10 ³ /MHC	247.00	262.00	253.00					
K+	20/10/90	138.0	155.0				M EQ/L	139.00	140.00	138.00					
CL-	20/10/90	3.5	5.5				M EQ/L	4.00	3.80	4.00					
CA++	20/10/90	98.0	120.0				M EQ/L	96.00	97.00	97.00					
PO4--	20/10/90	8.5	10.5				MG/DL	8.90	9.10	9.20					
SODT	20/10/90	12.0	4.5				MG/DL	3.20	4.00	4.10					
GAMMA-GT	20/10/90	10.0	40.0				NU/ML	28.00	24.00	27.00					
GLUCOSE	20/10/90	7.0	33.0				NU/ML	30.00	28.00	30.00					
ALK. PHOSPH.	20/10/90	65.0	306.0				NU/ML	26.00	30.00	34.00					
RUN	20/10/90	10.0	50.0				MG/DL	94.00	96.00	89.00					
CREATININE	20/10/90	0.6	1.6				MG/DL	231.00	204.00	230.00					
URIC ACID	20/10/90	2.4	5.7	MG/DL	1.00	24.00	28.00								
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	4.90	3.80	4.50								
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.60	0.60	0.80								
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	0.30	0.30	0.40								
ALBUMINE	20/10/90	3.5	5.0	G/DL	7.40	7.30	7.20								
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	4.10	4.10	4.00								
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	218.00	213.00	189.00								
GLOBALINS: ALPHA 1	20/10/90	4.0	7.0	%	98.00	94.00	93.00								
GLOBALINS: ALPHA 2	20/10/90	7.0	11.0	%	4.00	3.80	3.70								
GLOBALINS: BETA	20/10/90	11.0	14.0	%	5.80	6.70	5.10								
GLOBALINS: GAMMA	20/10/90	15.0	22.0	%	12.70	13.00	13.40								
T3	20/10/90	86.0	187.0	NG %	105.00	12.00	16.10								
T4	20/10/90	4.5	12.5	NG/DL	8.90										

1630

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBEXETINE - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit								
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
1	124	PPC	MALE	HS	20/10/90	14.0	18.0	g/100ml	19/02/92	13.10	13.00	11/03/92	13.00	08/04/92	13.20
				HTC	20/10/90	40.0	54.0	Z	37.00	37.00	36.00	36.00	14.30	13.00	38.00
				HB	20/10/90	4.3	6.1	10**6/mm	4.00	4.00	4.00	4.00	39.00	39.00	38.00
				HRC	20/10/90	4.0	11.0	10-3/MHC	7.90	6.20	6.20	6.20	4.60	4.60	4.30
				HRC: N	20/10/90	40.0	70.0	Z	63.00	64.00	64.00	64.00	6.20	6.20	6.50
				HRC: L	20/10/90	20.0	40.0	Z	30.00	26.00	31.00	31.00	58.00	58.00	61.00
				HRC: E	20/10/90	1.0	5.0	Z	2.00	3.00	3.00	3.00	28.00	28.00	28.00
				HRC: M	20/10/90	4.0	8.0	Z	5.00	7.00	6.00	6.00	5.00	5.00	5.00
				HRC: B	20/10/90	0.0	1.0	Z	0.00	0.00	0.00	0.00	6.00	6.00	6.00
				PLATELETS	20/10/90	150.0	550.0	10-3/MHC	284.00	293.00	293.00	293.00	0.00	0.00	0.00
				NA+	20/10/90	138.0	155.0	M EQ/L	138.00	137.00	138.00	138.00	310.00	310.00	310.00
				K+	20/10/90	98.0	120.0	M EQ/L	94.00	95.00	94.00	94.00	140.00	140.00	140.00
				CL-	20/10/90	8.5	10.5	MG/DL	9.70	9.80	9.80	9.80	3.90	3.90	3.90
				CA++	20/10/90	3.0	4.5	MG/DL	4.30	4.10	4.10	4.10	4.20	4.20	4.20
				PO4--	20/10/90	12.0	40.0	MU/ML	23.00	22.00	22.00	22.00	97.00	97.00	97.00
				SGPT	20/10/90	10.0	40.0	MU/ML	26.00	28.00	28.00	28.00	10.20	10.20	10.20
				GAMMA-GT	20/10/90	11.0	51.0	MU/ML	30.00	34.00	34.00	34.00	4.10	4.10	4.10
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	76.00	82.00	82.00	82.00	24.00	24.00	28.00
				ALK. PHOSPH.	20/10/90	65.0	306.0	MU/ML	29.00	185.00	185.00	185.00	30.00	32.00	42.00
				BUN	20/10/90	10.0	50.0	MG/DL	29.00	30.00	31.00	31.00	96.00	96.00	96.00
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	0.90	0.90	0.90	211.00	211.00	211.00
				URIC ACID	20/10/90	3.4	7.0	MG/DL	4.90	4.20	4.20	4.20	18.00	18.00	18.00
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.80	0.80	0.80	0.80	1.10	1.10	1.10
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.40	0.40	0.40	4.20	4.10	4.20
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.80	6.90	6.80	6.80	0.50	0.50	0.40
				ALBUMINE	20/10/90	3.5	5.0	G/DL	3.90	3.90	3.90	3.90	6.90	6.80	6.90
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	177.00	182.00	182.00	182.00	4.10	4.00	4.10
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	112.00	104.00	104.00	104.00	193.00	193.00	193.00
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	Z	4.30	3.80	3.80	3.80	88.00	88.00	88.00
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	Z	7.20	8.10	8.10	8.10	94.00	94.00	94.00
				GLOBULINS: BETA	20/10/90	11.0	14.0	Z	9.60	10.50	10.50	10.50	3.10	3.10	3.10
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	Z	13.80	16.30	16.30	16.30	7.00	7.00	7.00
				T3	20/10/90	86.0	187.0	NG Z	103.00	103.00	103.00	103.00	6.80	6.80	6.80
T4	20/10/90	4.5	12.5	NG/DL	9.80	9.80	9.80	9.80	17.20	17.20	18.30				
125	FDP	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	19/02/92	13.80	11/03/92	13.80	08/04/92	13.80		
			HTC	20/10/90	37.0	47.0	Z	36.00	40.00	40.00	40.00	14.20	14.00	14.00	
			HRC	20/10/90	3.8	5.4	10-6/MHC	3.80	4.70	4.70	4.70	38.00	38.00	38.00	
			HRC: N	20/10/90	40.0	70.0	Z	56.00	58.00	58.00	58.00	4.10	4.10	4.10	
			HRC: L	20/10/90	20.0	40.0	Z	32.00	30.00	30.00	30.00	6.40	6.40	6.30	
			HRC: E	20/10/90	1.0	5.0	Z	4.00	6.00	6.00	6.00	58.00	58.00	58.00	
			HRC: M	20/10/90	4.0	8.0	Z	8.00	8.00	8.00	8.00	28.00	28.00	30.00	
			HRC: B	20/10/90	0.0	1.0	Z	0.00	0.00	0.00	0.00	4.00	4.00	4.00	
			PLATELETS	20/10/90	150.0	500.0	10-3/MHC	195.00	189.00	189.00	189.00	6.00	6.00	8.00	
			NA+	20/10/90	138.0	155.0	M EQ/L	138.00	137.00	138.00	138.00	8.00	8.00	8.00	
			K+	20/10/90	98.0	120.0	M EQ/L	94.00	95.00	94.00	94.00	0.00	0.00	0.00	
			CL-	20/10/90	8.5	10.5	MG/DL	9.70	9.80	9.80	9.80	0.00	0.00	0.00	

1640

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBORENTINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
1	125	FDP	FEMALE	NA+	20/10/90	138.0	155.0	M EQ/L	136.00	137.00	135.00	138.00	
				K+	20/10/90	3.5	5.5	M EQ/L	3.70	3.80	3.80	3.90	
				CL-	20/10/90	98.0	120.0	M EQ/L	95.00	95.00	96.00	100.00	
				CA++	20/10/90	8.5	10.5	MG/DL	9.60	9.70	9.80	10.20	
				PO4-	20/10/90	3.0	4.5	MG/DL	3.90	4.00	4.00	3.90	
				SGPT	20/10/90	12.0	40.0	IU/ML	29.00	27.00	28.00	32.00	
				GAMMA-GT	20/10/90	10.0	40.0	IU/ML	32.00	30.00	30.00	34.00	
				ALB	20/10/90	7.0	33.0	IU/ML	28.00	29.00	28.00	30.00	
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	94.00	96.00	96.00	92.00	
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	171.00	152.00	151.00	153.00	
				BUN	20/10/90	10.0	50.0	MG/DL	40.00	35.00	32.00	32.00	
				CREATININE	20/10/90	0.6	1.6	MG/DL	1.00	0.90	1.00	1.00	
				URIC ACID	20/10/90	2.4	5.7	MG/DL	4.00	3.80	3.80	3.80	
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.80	0.80	0.90	0.80	
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.40	0.40	0.40	
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.70	6.80	6.80	7.00	
				ALBUMINE	20/10/90	3.5	5.0	G/DL	3.90	3.80	4.00	4.00	
				TRIGLYCERIDES	20/10/90	140.0	270.0	MG/DL	188.00	194.00	193.00	192.00	
				CHOLEST.	20/10/90	35.0	175.0	MG/DL	105.00	96.00	89.00	94.00	
				GLUCOLINS: ALPHA 1	20/10/90	4.0	7.0	Z	5.20	4.10	3.10	1.90	
				GLUCOLINS: ALPHA 2	20/10/90	7.0	11.0	Z	4.30	8.00	6.70	6.70	
				GLUCOLINS: BETA	20/10/90	11.0	14.0	Z	11.80	12.20	13.00	12.30	
				GLUCOLINS: GAMMA	20/10/90	15.0	22.0	Z	15.10	17.30	18.20	18.90	
				T3	20/10/90	86.0	187.0	NG %	98.00				
				T4	20/10/90	4.5	12.5	NG/DL	8.40				
				HB	20/10/90	12.0	16.0	G/100ML	12.90	11/03/92	11/03/92	08/04/92	
				HTC	20/10/90	37.0	47.0	Z	38.00	37.00	39.00	37.00	
				RBC	20/10/90	3.8	5.4	10 ⁶ -6/MHC	4.20	4.10	4.30	4.20	
				HBC: N	20/10/90	4.0	11.0	10 ³ -3/MHC	6.40	5.80	6.30	6.00	
				HRC: L	20/10/90	40.0	70.0	Z	60.00	62.00	58.00	59.00	
				HRC: E	20/10/90	20.0	40.0	Z	27.00	26.00	28.00	28.00	
				HRC: M	20/10/90	1.0	5.0	Z	6.00	5.00	6.00	4.00	
				HRC: B	20/10/90	4.0	8.0	Z	7.00	7.00	8.00	8.00	
				PLATELETS	20/10/90	150.0	550.0	10 ³ -3/HMC	191.00	186.00	216.00	213.00	
				NA+	20/10/90	138.0	155.0	M EQ/L	138.00	139.00	139.00	139.00	
				K+	20/10/90	3.5	5.5	M EQ/L	3.70	3.80	3.80	3.90	
				CL-	20/10/90	98.0	120.0	M EQ/L	94.00	95.00	96.00	102.00	
				CA++	20/10/90	8.5	10.5	MG/DL	9.80	9.90	9.90	9.60	
				PO4-	20/10/90	3.0	4.5	MG/DL	4.80	4.50	4.70	4.00	
				SGPT	20/10/90	12.0	40.0	IU/ML	36.00	34.00	30.00	30.00	
				GAMMA-GT	20/10/90	10.0	40.0	IU/ML	34.00	38.00	34.00	34.00	
				GLUCOSE	20/10/90	7.0	33.0	IU/ML	24.00	26.00	22.00	28.00	
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	182.00	190.00	165.00	96.00	
				BUN	20/10/90	10.0	50.0	MG/DL	38.00	32.00	32.00	30.00	
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	0.80	1.00	1.10	
				URIC ACID	20/10/90	2.4	5.7	MG/DL	4.10	4.20	4.20	3.90	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
RESOMETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
1	126	SMB	FEMALE	TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.80	0.90	0.90	0.90	1.00			
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.40	0.40	0.50				
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.80	6.90	6.90	7.00				
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.00	4.00	3.90	4.30				
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	210.00	192.00	198.00	190.00				
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	92.00	84.00	80.00	86.00				
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	4.10	3.90	3.20	3.40				
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	6.00	8.50	7.10	8.70				
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	11.80	11.80	11.20	11.20				
				GLOBULINS: GAMA	20/10/90	15.0	22.0	%	17.10	19.00	19.30	19.30				
				T3	20/10/90	86.0	187.0	NG %	102.00							
				T4	20/10/90	4.5	12.5	NG/DL	9.40							
				127	VPD	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	13.40	11/03/92	19/02/92	25/03/92	08/04/92
							HCT	20/10/90	37.0	47.0	%	38.00	36.00	37.00	39.00	
RBC	20/10/90	3.8	5.4				10 ⁶ -6/HMC	4.00	4.10	4.20	4.20					
WBC	20/10/90	4.0	11.0				10 ³ -3/HMC	4.90	5.00	5.60	6.10					
HBC: L	20/10/90	40.0	70.0				%	64.00	62.00	58.00	60.00					
HBC: E	20/10/90	20.0	40.0				%	24.00	24.00	28.00	28.00					
HBC: M	20/10/90	1.0	5.0				%	4.00	4.00	6.00	4.00					
HBC: B	20/10/90	4.0	8.0				%	10.00	10.00	8.00	8.00					
PLATELETS	20/10/90	0.0	1.0				%	2.00	0.00	0.00	0.00					
NA+	20/10/90	150.0	550.0				10 ⁻³ /HMC	253.00	241.00	210.00	240.00					
K+	20/10/90	138.0	155.0				M EQ/L	137.00	136.00	141.00	139.00					
CL-	20/10/90	3.5	5.5				M EQ/L	3.60	3.90	3.80	3.80					
CA++	20/10/90	98.0	120.0				M EQ/L	103.00	102.00	102.00	104.00					
PO4--	20/10/90	3.0	4.5				MG/DL	4.10	9.80	9.80	9.80					
SGPT	20/10/90	12.0	40.0				NU/HL	4.10	4.10	4.20	4.00					
GAMMA-GT	20/10/90	10.0	40.0				NU/HL	26.00	28.00	30.00	26.00					
GLUCOSE	20/10/90	7.0	33.0				MG/HL	28.00	30.00	32.00	30.00					
ALK. PHOSPH.	20/10/90	65.0	100.0				MG/DL	90.00	92.00	94.00	103.00					
UREA	20/10/90	50.0	306.0				MG/HL	176.00	160.00	163.00	141.00					
CREATININE	20/10/90	10.0	50.0				MG/DL	32.00	30.00	28.00	40.00					
URIC ACID	20/10/90	0.6	1.6				MG/DL	1.00	1.00	0.80	1.10					
DIR BILIRUBIN	20/10/90	2.4	5.7				MG/DL	4.20	3.80	3.80	4.00					
TOT. PROTEINS	20/10/90	0.2	1.0				MG/DL	0.80	0.90	0.80	0.90					
ALBUMINE	20/10/90	0.0	0.4				MG/DL	0.40	0.40	0.40	0.40					
TOT. CHOLEST.	20/10/90	6.0	8.0	G/DL	6.80	6.80	7.20	7.00								
TRIGLYCERIDES	20/10/90	3.5	5.0	G/DL	4.20	4.00	4.10	4.10								
GLOBULINS: ALPHA 1	20/10/90	140.0	270.0	MG/DL	186.00	190.00	196.00	180.00								
GLOBULINS: ALPHA 2	20/10/90	35.0	175.0	MG/DL	74.00	80.00	83.00	91.00								
GLOBULINS: BETA	20/10/90	4.0	7.0	%	6.20	3.50	3.10	2.10								
GLOBULINS: GAMA	20/10/90	11.0	14.0	%	6.20	6.40	9.20	5.80								
T3	20/10/90	15.0	22.0	%	11.90	13.00	12.10	11.20								
T4	20/10/90	86.0	187.0	NG %	103.00	18.20	19.50	20.30								

1642

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXYTINE - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit				
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6
1	128	LAM	MALE	HB	20/10/90	14.0	18.0	g/100ml	19/02/92	11/03/92	25/03/92	08/04/92
				HCT	20/10/90	40.0	54.0	%	13.40	13.80	14.00	14.20
				RBC	20/10/90	4.3	6.1	10 ⁶ /mm ³	38.00	39.00	41.00	41.00
				WBC	20/10/90	4.0	11.0	10 ³ /mm ³	4.60	4.70	4.40	4.60
				WBC: N	20/10/90	40.0	70.0	%	5.80	6.70	6.30	7.00
				WBC: L	20/10/90	20.0	40.0	%	64.00	58.00	61.00	58.00
				WBC: E	20/10/90	1.0	5.0	%	21.00	30.00	26.00	27.00
				WBC: H	20/10/90	4.0	8.0	%	5.00	4.00	5.00	5.00
				WBC: B	20/10/90	0.0	1.0	%	8.00	8.00	8.00	10.00
				PLATELETS	20/10/90	150.0	550.0	10 ³ /mm ³	271.00	260.00	263.00	216.00
				NA+	20/10/90	138.0	155.0	mEq/L	140.00	141.00	139.00	141.00
				K+	20/10/90	3.5	5.5	mEq/L	3.80	3.90	4.00	3.90
				Cl-	20/10/90	98.0	120.0	mEq/L	96.00	98.00	97.00	98.00
				Ca++	20/10/90	8.5	10.5	mg/dl	9.90	9.00	9.30	9.50
				P04-	20/10/90	3.0	4.5	mg/dl	4.20	4.30	4.00	3.80
				SGOT	20/10/90	12.0	40.0	mu/ml	26.00	24.00	20.00	27.00
				SGPT	20/10/90	10.0	40.0	mu/ml	24.00	28.00	26.00	30.00
				GAMMA-GT	20/10/90	11.0	51.0	mu/ml	22.00	30.00	22.00	22.00
				GLUCOSE	20/10/90	70.0	100.0	mg/dl	94.00	97.00	82.00	106.00
				ALK. PHOSPH.	20/10/90	65.0	306.0	mu/ml	216.00	174.00	210.00	170.00
				BUN	20/10/90	10.0	50.0	mg/dl	32.00	24.00	21.00	26.00
				CREATININE	20/10/90	0.6	1.6	mg/dl	0.80	0.90	0.80	0.90
				URIC ACID	20/10/90	3.4	7.0	mg/dl	4.10	3.80	4.00	3.80
				TOT BILIRUBIN	20/10/90	0.2	1.0	mg/dl	0.80	0.90	0.80	0.80
				DIR BILIRUBIN	20/10/90	0.0	0.4	mg/dl	0.40	0.40	0.40	0.40
				TOT. PROTEINS	20/10/90	6.0	8.0	g/dl	6.20	7.30	7.30	7.40
				ALBUMINE	20/10/90	3.5	5.0	g/dl	4.10	4.20	4.40	4.30
				TOT. CHOLEST.	20/10/90	140.0	270.0	mg/dl	182.00	174.00	176.00	186.00
				TRIGLYCERIDES	20/10/90	35.0	175.0	mg/dl	96.00	82.00	74.00	92.00
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	2.00	4.10	4.10	4.10
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	4.10	12.10	10.80	12.30
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	11.80	7.20	9.20	8.70
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	16.30	22.30	20.70	21.30
				T3	20/10/90	86.0	487.0	ng %	121.00			
				T4	20/10/90	4.5	12.5	ng/dl	10.80			
129	MNS		MALE	HB	20/10/90	14.0	18.0	g/100ml	19/02/92	11/03/92	25/03/92	08/04/92
				HCT	20/10/90	40.0	54.0	%	15.90	14.20	14.00	14.20
				RBC	20/10/90	4.3	6.1	10 ⁶ /mm ³	42.00	41.00	41.00	41.00
				WBC	20/10/90	4.0	11.0	10 ³ /mm ³	4.60	4.40	4.60	4.60
				WBC: N	20/10/90	40.0	70.0	%	7.90	5.80	7.80	6.10
				WBC: L	20/10/90	20.0	40.0	%	41.00	62.00	41.00	58.00
				WBC: E	20/10/90	1.0	5.0	%	31.00	38.00	38.00	30.00
				WBC: H	20/10/90	4.0	8.0	%	20.00	2.00	11.00	4.00
				WBC: B	20/10/90	0.0	1.0	%	8.00	4.00	10.00	8.00
				PLATELETS	20/10/90	150.0	550.0	10 ³ /mm ³	240.00	230.00	269.00	270.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Date	Laboratory Range			Screen	Visit		
						Min	Max	Unit		Week 2	Week 4	Week 6
1	129	MNS	MALE	NA+	20/10/90	138.0	155.0	M EQ/L	142.00	141.00	140.00	199.00
				K+	20/10/90	3.5	5.5	M EQ/L	4.50	4.00	4.50	4.20
				CL-	20/10/90	98.0	120.0	M EQ/L	100.00	98.00	99.00	99.00
				CA++	20/10/90	8.5	10.5	MG/DL	10.30	9.60	9.90	9.50
				PO4-	20/10/90	3.0	4.5	MG/DL	2.90	3.80	4.00	4.10
				SGPT	20/10/90	12.0	40.0	IU/ML	32.00	22.00	27.00	24.00
				SGPT	20/10/90	10.0	40.0	IU/ML	28.00	26.00	22.00	28.00
				GAMMA-GT	20/10/90	11.0	51.0	IU/ML	47.00	28.00	39.00	30.00
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	115.00	94.00	102.00	83.00
				BUN	20/10/90	65.0	306.0	IU/ML	230.00	152.00	198.00	171.00
				ALK. PHOSPH.	20/10/90	10.0	50.0	MG/DL	19.00	32.00	24.00	28.00
				CREATININE	20/10/90	0.6	1.6	MG/DL	1.00	0.80	0.80	0.90
				URIC ACID	20/10/90	3.4	7.0	MG/DL	8.30	4.20	5.60	4.10
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.70	0.70	1.00	0.60
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.30	0.50	0.30
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	8.00	7.00	7.30	7.60
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.60	4.20	4.20	4.20
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	231.00	162.00	197.00	133.00
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	120.00	86.00	64.00	87.00
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	5.40	4.70	5.00	3.60
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	13.40	8.00	7.20	8.70
GLOBULINS: BETA	20/10/90	11.0	14.0	%	13.50	13.50	11.50	12.30				
GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	14.80	20.10	19.60	20.20				
T4	20/10/90	86.0	187.0	NG %	120.00							
	20/10/90	4.5	12.5	NG/DL	5.20							
130	EGA	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	21/02/92	13/03/92	27/03/92	10/04/92	
			HTC	20/10/90	37.0	47.0	%	38.00	41.00	42.00	41.20	
			RBC	20/10/90	3.8	5.4	10 ⁶ /MNC	4.30	4.70	4.70	4.60	
			HBC	20/10/90	4.0	11.0	10 ³ /MNC	6.90	6.80	7.60	7.00	
			HBC: N	20/10/90	40.0	70.0	%	60.00	60.00	54.00	60.00	
			HBC: L	20/10/90	20.0	40.0	%	32.00	25.00	36.00	30.00	
			HBC: E	20/10/90	1.0	5.0	%	3.00	6.00	1.00	3.00	
			HBC: M	20/10/90	4.0	8.0	%	5.00	9.00	9.00	7.00	
			HBC: R	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	
			PLATELETS	20/10/90	150.0	550.0	10 ³ /MNC	278.00	241.00	240.00	252.00	
			NA+	20/10/90	138.0	155.0	M EQ/L	140.00	145.00	137.00	140.00	
			K+	20/10/90	3.5	5.5	M EQ/L	4.60	4.10	4.60	3.90	
			CL-	20/10/90	98.0	120.0	M EQ/L	99.00	96.00	97.00	101.00	
			CA++	20/10/90	8.5	10.5	MG/DL	9.70	8.50	9.80	9.20	
			PO4-	20/10/90	3.0	4.5	MG/DL	3.10	4.10	3.20	4.30	
			SGPT	20/10/90	12.0	40.0	IU/ML	33.00	28.00	19.00	24.00	
			SGPT	20/10/90	10.0	40.0	IU/ML	25.00	30.00	12.00	28.00	
			GAMMA-GT	20/10/90	7.0	33.0	IU/ML	39.00	22.00	34.00	26.00	
			GLUCOSE	20/10/90	70.0	100.0	MG/DL	90.00	98.00	103.00	90.00	
			ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	179.00	120.00	196.00	213.00	
			BUN	20/10/90	10.0	50.0	MG/DL	24.00	28.00	28.00	26.00	
CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	0.80	0.90	0.80				
URIC ACID	20/10/90	2.4	5.7	MG/DL	4.90	4.50	4.80	3.60				

1644

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6			
1	130	EGA	FEMALE	TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.30	0.60	0.50	0.80			
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.10	0.30	0.20	0.40			
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.30	6.90	6.80	7.40			
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.40	3.60	3.60	4.20			
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	192.00	156.00	198.00	176.00			
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	48.00	86.00	60.00	82.00			
				GLOBALINS: ALPHA 1	20/10/90	4.0	7.0	%	2.40	3.20	1.90	3.20			
				GLOBALINS: ALPHA 2	20/10/90	7.0	11.0	%	8.40	6.10	8.50	6.70			
				GLOBALINS: BETA	20/10/90	11.0	14.0	%	11.20	13.40	11.60	12.80			
				GLOBALINS: GAMMA	20/10/90	15.0	22.0	%	17.90	20.20	19.60	21.00			
				T3	20/10/90	86.0	187.0	NG %	145.00						
				T4	20/10/90	4.5	12.5	NG/DL	8.20						
				131	RMR	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	12.10	12.50	12.30	12.30
							HTC	20/10/90	37.0	47.0	%	35.00	36.00	35.00	39.00
HCC	20/10/90	3.8	5.4				10 ⁶ /MHC	3.90	4.00	3.90	4.20				
HCC: N	20/10/90	4.0	11.0				10 ³ /MHC	6.90	7.00	6.50	6.10				
HCC: L	20/10/90	40.0	70.0				%	56.00	57.00	55.00	59.00				
HCC: E	20/10/90	20.0	40.0				%	34.00	27.00	35.00	28.00				
HCC: M	20/10/90	1.0	5.0				%	6.00	6.00	3.00	6.00				
HCC: B	20/10/90	4.0	8.0				%	3.00	10.00	7.00	7.00				
PLATELETS	20/10/90	0.0	1.0				%	1.00	0.00	0.00	0.00				
NA+	20/10/90	150.0	550.0				10 ³ /MHC	275.00	231.00	260.00	238.00				
K+	20/10/90	138.0	155.0				M EQ/L	138.00	139.00	139.00	140.00				
CL-	20/10/90	3.5	5.5				M EQ/L	4.10	4.00	3.80	4.20				
CA++	20/10/90	98.0	120.0				M EQ/L	97.00	98.00	102.00	103.00				
PO4--	20/10/90	8.5	10.5				MG/DL	9.80	9.90	9.40	9.40				
SGPT	20/10/90	12.0	40.0	RU/HL	24.00	2.90	4.00	4.00							
GAMMA-GT	20/10/90	10.0	40.0	RU/HL	15.00	28.00	20.00	26.00							
GLUCOSE	20/10/90	7.0	33.0	MG/DL	25.00	38.00	33.00	28.00							
ALK. PHOSPH.	20/10/90	65.0	306.0	NU/HL	97.00	106.00	97.00	82.00							
BUN	20/10/90	10.0	50.0	MG/DL	35.00	33.00	30.00	30.00							
CREATININE	20/10/90	0.6	1.5	MG/DL	0.80	0.90	0.90	1.00							
URIC ACID	20/10/90	2.4	5.7	MG/DL	4.00	4.00	4.10	4.20							
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	0.60	0.90	0.60							
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.30	0.40	0.30							
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.10	7.10	7.20	7.20							
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.20	4.10	4.20							
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	144.00	158.00	176.00	137.00							
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	74.00	90.00	82.00	82.00							
GLOBALINS: ALPHA 1	20/10/90	4.0	7.0	%	3.20	3.00	3.00	3.10							
GLOBALINS: ALPHA 2	20/10/90	7.0	11.0	%	9.70	9.60	6.70	10.20							
GLOBALINS: BETA	20/10/90	11.0	14.0	%	18.20	12.20	12.80	8.70							
GLOBALINS: GAMMA	20/10/90	15.0	22.0	%	17.40	17.30	21.50	21.30							
T3	20/10/90	86.0	187.0	NG %	120.00										
T4	20/10/90	4.5	12.5	NG/DL	10.00										

131 391

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPER PHASE

Centre	Patient Initials	Sex	Laboratory test	Date	Laboratory Range			Screen	Visit		
					Min	Max	Unit		Week 2	Week 4	Week 6
1	132	MAT	FEMALE	20/10/90	12.0	16.0	G/100ML	11/03/92	01/04/92	08/04/92	29/04/92
				HB	37.0	47.0	Z	13.80	14.00	13.90	14.20
				HTC	3.8	5.4	10-6/MHC	4.00	40.00	42.00	42.00
				RBC	4.0	11.0	10-3/MHC	4.60	4.30	4.70	4.70
				MBC	40.0	70.0	Z	9.90	6.10	6.00	6.00
				MBC: N	20.0	40.0	Z	73.00	62.00	75.00	69.00
				MBC: L	1.0	5.0	Z	16.00	20.00	19.00	21.00
				MBC: E	4.0	8.0	Z	2.00	9.00	2.00	3.00
				MBC: M	0.0	1.0	Z	9.00	9.00	4.00	7.00
				MBC: B	0.0	1.0	Z	0.00	0.00	0.00	0.00
				PLATELETS	150.0	550.0	10-3/MNC	313.00	216.00	317.00	310.00
				NA+	138.0	155.0	M EQ/L	140.00	142.00	137.00	140.00
				K+	3.5	5.5	M EQ/L	3.80	4.00	4.10	4.20
				CL-	98.0	120.0	M EQ/L	96.00	96.00	97.00	98.00
				CA++	8.5	10.5	MG/DL	8.70	8.90	9.10	10.20
				PO4-	3.0	4.5	MG/DL	3.40	4.00	2.70	3.60
				SGOT	12.0	40.0	RU/ML	18.00	20.00	15.00	24.00
				SGPT	10.0	40.0	RU/ML	18.00	20.00	14.00	28.00
				GAMMA-GT	7.0	33.0	RU/ML	32.00	28.00	33.00	33.00
				GLUCOSE	70.0	100.0	MG/DL	93.00	98.00	105.00	101.00
				ALK. PHOSPH.	65.0	306.0	RU/ML	193.00	152.00	165.00	241.00
				BUN	10.0	50.0	MG/DL	17.00	28.00	19.00	28.00
				CREATININE	0.6	1.6	MG/DL	0.80	0.90	0.90	0.80
				URIC ACID	2.4	5.7	MG/DL	4.20	4.30	3.80	4.30
				TOT BILIRUBIN	0.2	1.0	MG/DL	0.60	0.80	0.60	0.90
				DIR BILIRUBIN	0.0	0.4	MG/DL	0.20	0.40	0.20	0.40
				TOT. PROTEINS	6.0	8.0	G/DL	6.80	7.30	6.80	7.10
				ALBUMINE	3.5	5.0	G/DL	4.10	4.10	4.00	4.00
				TOT. CHOLEST.	140.0	270.0	MG/DL	185.00	176.00	172.00	176.00
				TRIGLYCERIDES	35.0	175.0	MG/DL	82.00	63.00	63.00	102.00
				GLOBULINS: ALPHA 1	4.0	7.0	Z	3.20	3.40	3.40	4.00
				GLOBULINS: ALPHA 2	7.0	11.0	Z	11.00	8.00	11.10	6.30
				GLOBULINS: BETA	11.0	14.0	Z	8.98	12.30	9.40	12.10
				GLOBULINS: GAMA	15.0	22.0	Z	16.80	18.70	14.70	18.90
T3	86.0	187.0	NG %	125.00							
T4	4.5	12.5	NG/DL	7.60							
133	JPN	MALE		20/10/90	14.0	18.0	g/100mL	13/03/92	03/04/92	17/06/92	30/06/92
				HB	40.0	54.0	Z	13.40	13.50	13.60	13.60
				HTC	4.3	6.1	10x*6/mm	38.00	39.00	39.00	39.00
				RBC	4.0	11.0	10-3/MHC	4.10	4.50	4.50	4.60
				MBC	40.0	70.0	Z	62.00	5.80	5.70	5.80
				MBC: N	20.0	40.0	Z	27.00	28.00	28.00	28.00
				MBC: L	1.0	5.0	Z	5.00	5.00	5.00	5.00
				MBC: E	4.0	8.0	Z	6.00	7.00	7.00	8.00
				MBC: M	0.0	1.0	Z	0.00	0.00	0.00	0.00
				MBC: B	0.0	1.0	Z	0.00	0.00	0.00	0.00
				PLATELETS	150.0	550.0	10-3/MNC	237.00	230.00	251.00	241.00

1646

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
1	133	JPX	MALE	NA+	20/10/90	138.0	155.0	M EQ/L	137.00	135.00	139.00	138.00	
				K+	20/10/90	3.5	5.5	M EQ/L	4.10	3.90	4.00	4.20	
				CL-	20/10/90	98.0	120.0	M EQ/L	100.00	99.00	97.00	98.00	
				CA++	20/10/90	8.5	10.5	MG/DL	9.80	9.80	9.60	9.70	
				PO4-	20/10/90	3.0	4.5	MG/DL	3.90	4.00	4.20	4.10	
				SGOT	20/10/90	12.0	40.0	IU/ML	22.00	23.00	20.00	24.00	
				SGPT	20/10/90	10.0	40.0	IU/ML	28.00	25.00	32.00	28.00	
				GAMMA-GT	20/10/90	11.0	51.0	IU/ML	26.00	30.00	24.00	30.00	
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	82.00	84.00	86.00	88.00	
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	160.00	161.00	152.00	141.00	
				BUN	20/10/90	10.0	50.0	MG/DL	24.00	27.00	28.00	24.00	
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	1.00	0.90	0.80	
				URIC ACID	20/10/90	3.4	7.0	MG/DL	3.80	3.70	3.70	3.70	
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	0.60	0.60	0.60	
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.30	0.30	0.30	
				TOT. PROTEINS	20/10/90	5.0	8.0	G/DL	7.90	7.20	7.10	7.40	
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.20	4.20	4.10	
				TOT. CHOLEST.	20/10/90	160.0	270.0	MG/DL	131.00	138.00	143.00	152.00	
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	72.00	76.00	76.00	80.00	
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	4.00	4.00	3.80	3.80	
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	8.30	8.10	7.20	9.10	
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	16.10	15.70	15.80	16.20	
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	19.20	22.30	21.20	20.10	
				T3	20/10/90	86.0	187.0	NG %	108.00				
				T4	20/10/90	4.5	12.5	NG/DL	7.90				
				HB	20/10/90	12.0	16.0	G/100ML	12.60	12.90	13.40	13.40	
				HTC	20/10/90	37.0	47.0	%	36.00	38.00	37.00	38.00	
				RBC	20/10/90	3.8	5.4	10 ⁶ -6/MNC	4.10	4.70	4.70	4.50	
				MBC: N	20/10/90	4.0	11.0	10 ³ -3/MNC	6.60	9.00	7.90	7.30	
				MBC: L	20/10/90	40.0	70.0	%	52.00	58.00	60.00	58.00	
				MBC: E	20/10/90	20.0	40.0	%	32.00	26.00	25.00	26.00	
				MBC: M	20/10/90	1.0	5.0	%	8.00	7.00	6.00	8.00	
				MBC: B	20/10/90	4.0	8.0	%	8.00	9.00	9.00	8.00	
				PLATELETS	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	
				NA+	20/10/90	150.0	550.0	10 ³ -3/MNC	274.00	280.00	253.00	236.00	
				K+	20/10/90	138.0	155.0	M EQ/L	140.00	139.00	138.00	139.00	
				CL-	20/10/90	3.5	5.5	M EQ/L	4.10	4.20	4.00	4.10	
				CA++	20/10/90	8.5	10.5	MG/DL	9.40	9.30	9.60	9.60	
				PO4-	20/10/90	3.0	4.5	MG/DL	4.10	4.30	4.30	4.20	
				SGOT	20/10/90	12.0	40.0	IU/ML	16.00	16.00	15.00	20.00	
				SGPT	20/10/90	10.0	40.0	IU/ML	18.00	19.00	18.00	24.00	
				GAMMA-GT	20/10/90	7.0	33.0	IU/ML	26.00	24.00	24.00	28.00	
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	116.00	108.00	102.00	104.00	
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	236.00	247.00	257.00	215.00	
				BUN	20/10/90	10.0	50.0	MG/DL	26.00	21.00	29.00	28.00	
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	0.90	0.80	0.90	
				URIC ACID	20/10/90	2.4	5.7	MG/DL	4.10	3.80	4.30	4.20	

1647

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
1	134	LMS	FEMALE	TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.40	0.40	0.60	0.60	0.60			
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.20	0.30	0.30				
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.80	6.90	7.20	7.30				
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	3.90	4.00	4.10				
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	116.00	127.00	173.00	163.00				
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	68.00	70.00	91.00	86.00				
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	3.20	3.60	3.10	3.00				
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	8.10	7.40	8.00	8.70				
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	15.10	14.90	16.30	15.20				
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	23.00	22.50	21.40	21.30				
				T3	20/10/90	86.0	187.0	NG %	103.00							
				T4	20/10/90	4.5	12.5	NG/DL	8.70							
				135	MMS		FEMALE	HB	20/10/90	12.0	16.0	G/100ML	14.30	17/03/92	14.50	05/05/92
								HTC	20/10/90	37.0	47.0	%	43.00	44.00	44.00	44.00
								RBC	20/10/90	3.8	5.4	10 ⁶ /HMC	4.80	4.80	4.50	5.00
								MBC	20/10/90	4.0	11.0	10 ³ /HMC	5.70	6.30	5.80	5.80
								MBC: N	20/10/90	40.0	70.0	%	62.00	60.00	61.00	61.00
								MBC: L	20/10/90	20.0	40.0	%	26.00	28.00	28.00	28.00
								MBC: E	20/10/90	1.0	5.0	%	4.00	4.00	4.00	5.00
								MBC: M	20/10/90	4.0	8.0	%	7.00	7.00	9.00	6.00
MBC: B	20/10/90	0.0	1.0					%	1.00	1.00	0.00	0.00				
PLATELETS	20/10/90	150.0	550.0					10 ³ /HMC	314.00	336.00	323.00	345.00				
NA+	20/10/90	138.0	155.0					M EQ/L	136.00	137.00	141.00	138.00				
K+	20/10/90	3.5	5.5					M EQ/L	4.20	4.20	4.30	4.10				
CL-	20/10/90	98.0	120.0					M EQ/L	98.00	101.00	99.00	99.00				
CA++	20/10/90	8.5	10.5					MG/DL	8.90	8.90	9.20	8.90				
PO4-	20/10/90	3.0	4.5					MG/DL	4.50	4.30	4.40	4.30				
SGPT	20/10/90	12.0	40.0					NU/ML	20.00	20.00	22.00	22.00				
GAMMA-GT	20/10/90	10.0	40.0					NU/ML	26.00	24.00	26.00	28.00				
GLUCOSE	20/10/90	7.0	33.0					NU/ML	28.00	28.00	30.00	23.00				
ALK. PHOSPH.	20/10/90	70.0	100.0					NG/DL	94.00	95.00	97.00	92.00				
RUN	20/10/90	65.0	306.0					NU/ML	208.00	213.00	241.00	217.00				
CREATININE	20/10/90	10.0	50.0	MG/DL	30.00	30.00	32.00	31.00								
URIC ACID	20/10/90	0.6	1.6	MG/DL	1.00	1.00	1.00	0.90								
DIR BILIRUBIN	20/10/90	2.4	5.7	MG/DL	4.10	4.20	4.30	3.80								
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	0.60	0.70	0.80								
TOT. PROTEINS	20/10/90	6.0	0.4	MG/DL	0.30	0.30	0.30	0.40								
ALBUMINE	20/10/90	6.0	8.0	G/DL	6.50	6.50	7.20	7.30								
TOT. CHOLEST.	20/10/90	3.5	5.0	G/DL	4.10	4.10	4.20	4.10								
TRIGLYCERIDES	20/10/90	140.0	270.0	MG/DL	166.00	153.00	175.00	176.00								
GLOBULINS: ALPHA 1	20/10/90	35.0	175.0	MG/DL	94.00	87.00	92.00	94.00								
GLOBULINS: ALPHA 2	20/10/90	4.0	7.0	%	4.10	3.80	3.80	3.80								
GLOBULINS: BETA	20/10/90	7.0	11.0	%	8.20	8.20	9.10	7.50								
GLOBULINS: GAMMA	20/10/90	11.0	14.0	%	13.00	14.10	14.20	15.20								
T3	20/10/90	15.0	22.0	%	19.80	20.30	20.30	21.30								
T4	20/10/90	86.0	187.0	NG %	98.00											
	20/10/90	4.5	12.5	NG/DL	9.30											

1642

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
1	136	AVP	MALE	HB	20/10/90	14.0	18.0	g/100ml	17/03/92	07/04/92	20/04/92	05/05/92	13.00	13.40	13.20	13.20
				HTC	20/10/90	40.0	54.0	g	13.00	38.00	39.00	39.00	40.00	40.00	40.00	
				RBC	20/10/90	4.3	6.1	10 ⁶ /mm ³	4.30	4.30	4.40	4.40	4.50	4.50	4.80	
				MBC	20/10/90	4.0	11.0	10 ³ -3/MHC	7.80	7.80	7.40	7.40	7.20	7.20	6.50	
				MBC: N	20/10/90	40.0	70.0	g	60.00	58.00	58.00	58.00	58.00	58.00	57.00	
				MBC: L	20/10/90	20.0	40.0	g	32.00	32.00	30.00	30.00	30.00	30.00	23.00	
				MBC: E	20/10/90	1.0	5.0	g	2.00	2.00	4.00	4.00	4.00	4.00	6.00	
				MBC: M	20/10/90	4.0	8.0	g	6.00	6.00	6.00	6.00	8.00	8.00	14.00	
				MBC: B	20/10/90	0.0	1.0	g	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				PLATELETS	20/10/90	150.0	550.0	10 ³ -3/MHC	280.00	263.00	283.00	283.00	276.00	276.00	276.00	
				Na+	20/10/90	138.0	155.0	mmol/L	141.00	142.00	142.00	142.00	142.00	142.00	142.00	
				K+	20/10/90	3.5	5.5	mmol/L	3.80	3.80	3.80	3.80	4.10	4.10	4.20	
				Cl-	20/10/90	98.0	120.0	mmol/L	98.00	98.00	96.00	96.00	97.00	97.00	95.00	
				PO4--	20/10/90	8.5	10.5	mmol/L	9.70	9.70	9.50	9.50	9.50	9.50	9.40	
				SGOT	20/10/90	3.0	4.5	mmol/L	4.10	4.10	4.00	4.00	3.70	3.70	3.60	
				SGPT	20/10/90	12.0	40.0	mmol/L	28.00	26.00	26.00	26.00	24.00	24.00	26.00	
				GAMMA-GT	20/10/90	10.0	40.0	mmol/L	30.00	30.00	30.00	30.00	28.00	28.00	28.00	
				TOT BILIRUBIN	20/10/90	11.0	51.0	mmol/L	26.00	22.00	22.00	22.00	28.00	28.00	20.00	
				GLUCOSE	20/10/90	70.0	100.0	mmol/L	108.00	104.00	104.00	104.00	98.00	98.00	94.00	
				ALK. PHOSPH.	20/10/90	65.0	306.0	mmol/L	260.00	241.00	241.00	241.00	230.00	230.00	212.00	
				BUN	20/10/90	10.0	50.0	mmol/L	24.00	24.00	26.00	26.00	22.00	22.00	26.00	
				CREATININE	20/10/90	0.6	1.6	mmol/L	1.00	1.00	1.10	1.10	1.10	1.10	0.90	
				URIC ACID	20/10/90	3.4	7.0	mmol/L	3.60	3.60	3.70	3.70	3.70	3.70	3.80	
				TOT BILIRUBIN	20/10/90	0.2	1.0	mmol/L	0.40	0.40	0.40	0.40	0.40	0.40	0.50	
				DIR BILIRUBIN	20/10/90	0.0	0.4	mmol/L	0.20	0.20	0.10	0.10	0.20	0.20	0.20	
				TOT. PROTEINS	20/10/90	6.0	8.0	g/dl	6.60	6.60	6.70	6.70	6.90	6.90	7.10	
				ALBUMINE	20/10/90	3.5	5.0	g/dl	3.80	3.80	3.80	3.80	3.90	3.90	4.00	
				TOT. CHOLEST.	20/10/90	140.0	270.0	mg/dl	213.00	182.00	182.00	182.00	174.00	174.00	123.00	
				TRIGLYCERIDES	20/10/90	35.0	175.0	mg/dl	118.00	94.00	94.00	94.00	96.00	96.00	104.00	
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	g	4.10	4.10	3.20	3.20	3.80	3.80	3.00	
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	g	8.90	8.40	8.40	8.40	8.20	8.20	8.10	
				GLOBULINS: BETA	20/10/90	11.0	14.0	g	12.30	12.60	12.60	12.60	11.40	11.40	12.30	
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	g	19.70	20.20	20.20	20.20	18.70	18.70	18.90	
				T3	20/10/90	86.0	187.0	ng	112.00	112.00	112.00	112.00	112.00	112.00	112.00	
				T4	20/10/90	4.5	12.5	ng/dl	9.50	9.50	9.50	9.50	9.50	9.50	9.50	
137	CME		FEMALE	HB	20/10/90	12.0	16.0	g/100ml	17/03/92	07/04/92	20/04/92	05/05/92	12.50	13.40	13.50	12.80
				HTC	20/10/90	37.0	47.0	g	42.50	39.00	39.00	39.00	38.00	38.00	37.00	
				RBC	20/10/90	3.8	5.4	10 ⁶ /mm ³	4.00	4.00	4.20	4.20	4.50	4.50	4.20	
				MBC	20/10/90	4.0	11.0	10 ³ -3/MHC	7.20	6.00	6.00	6.00	6.80	6.80	6.90	
				MBC: N	20/10/90	40.0	70.0	g	59.00	28.00	28.00	28.00	28.00	28.00	27.00	
				MBC: L	20/10/90	20.0	40.0	g	29.00	28.00	28.00	28.00	28.00	28.00	27.00	
				MBC: E	20/10/90	1.0	5.0	g	5.00	4.00	4.00	4.00	5.00	5.00	6.00	
				MBC: M	20/10/90	4.0	8.0	g	7.00	7.00	7.00	7.00	9.00	9.00	9.00	
				MBC: B	20/10/90	0.0	1.0	g	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
				PLATELETS	20/10/90	150.0	550.0	10 ³ -3/MHC	210.00	186.00	186.00	186.00	232.00	232.00	241.00	

1640

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
1	137	CHE	FEMALE	NA+	20/10/90	138.0	155.0	M EQ/L	138.00	140.00	141.00	137.00	
				K+	20/10/90	3.5	5.5	M EQ/L	3.90	4.10	4.00	4.00	
				CL-	20/10/90	98.0	120.0	M EQ/L	98.00	97.00	97.00	95.00	
				CA++	20/10/90	8.5	10.5	MG/DL	9.60	9.40	9.50	9.40	
				PO4--	20/10/90	3.0	4.5	MG/DL	3.10	3.50	3.60	3.70	
				SGPT	20/10/90	12.0	40.0	IU/ML	25.00	24.00	28.00	20.00	
				SGPT	20/10/90	10.0	40.0	IU/ML	27.00	28.00	30.00	26.00	
				GAMMA-GT	20/10/90	7.0	33.0	IU/ML	32.00	22.00	22.00	34.00	
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	96.00	98.00	90.00	94.00	
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	102.00	120.00	123.00	126.00	
				BUN	20/10/90	10.0	50.0	MG/DL	21.00	24.00	26.00	26.00	
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	0.80	0.90	0.90	
				URIC ACID	20/10/90	2.4	5.7	MG/DL	3.80	3.60	3.60	4.10	
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.70	0.60	0.60	0.60	
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.20	0.10	0.20	
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.80	6.80	7.00	7.30	
				ALBUMINS	20/10/90	3.5	5.0	G/DL	3.90	3.80	3.80	4.20	
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	132.00	143.00	142.00	149.00	
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	92.00	90.00	94.00	76.00	
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	g	4.00	3.20	3.00	3.00	
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	g	8.10	7.40	8.20	7.50	
				GLOBULINS: BETA	20/10/90	11.0	14.0	g	12.80	12.90	12.50	12.10	
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	g	18.90	20.40	18.90	18.40	
				T3	20/10/90	86.0	187.0	NG %	98.00				
				T4	20/10/90	4.5	12.5	NG/DL	9.10				
				HB	20/10/90	12.0	16.0	G/100ML	17/03/92	07/04/92	20/04/92	05/05/92	
				HTC	20/10/90	37.0	47.0	%	42.30	42.50	43.20	43.80	
				RBC	20/10/90	3.8	5.4	10 ⁶ /MNC	37.00	38.00	38.00	40.00	
				MBC	20/10/90	4.0	11.0	10 ³ /MNC	4.70	4.80	4.80	4.60	
				MBC: N	20/10/90	40.0	70.0	%	62.00	61.00	63.00	62.00	
				MBC: L	20/10/90	20.0	40.0	%	30.00	29.00	28.00	30.00	
				MBC: E	20/10/90	1.0	5.0	%	2.00	4.00	3.00	4.00	
				MBC: M	20/10/90	4.0	8.0	%	6.00	7.00	5.00	8.00	
				MBC: B	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	
				PLATELETS	20/10/90	150.0	550.0	10 ³ /MNC	310.00	315.00	311.00	261.00	
				NA+	20/10/90	138.0	155.0	M EQ/L	138.00	139.00	139.00	138.00	
				K+	20/10/90	3.5	5.5	M EQ/L	4.20	4.10	4.10	4.20	
				CL-	20/10/90	98.0	120.0	M EQ/L	98.00	97.00	97.00	95.00	
				CA++	20/10/90	8.5	10.5	MG/DL	9.60	9.60	9.50	9.40	
				PO4--	20/10/90	3.0	4.5	MG/DL	3.80	4.10	3.90	3.80	
				SGPT	20/10/90	12.0	40.0	IU/ML	20.00	22.00	22.00	24.00	
				SGPT	20/10/90	10.0	40.0	IU/ML	24.00	28.00	26.00	29.00	
				GAMMA-GT	20/10/90	7.0	33.0	IU/ML	36.00	38.00	35.00	22.00	
				GLUCOSE	20/10/90	65.0	306.0	MG/DL	94.00	96.00	92.00	94.00	
				ALK. PHOSPH.	20/10/90	10.0	50.0	MG/DL	22.00	183.00	174.00	172.00	
				BUN	20/10/90	10.0	50.0	MG/DL	22.00	24.00	24.00	30.00	
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	0.80	0.90	1.00	
				URIC ACID	20/10/90	2.4	5.7	MG/DL	3.60	3.70	3.70	3.80	

1650

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit									
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6					
1	138	LEV	FEMALE	TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.70	0.40	0.40	0.70					
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.10	0.10	0.20					
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.00	7.10	7.20	7.40					
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	4.00	4.10	4.30					
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	152.00	148.00	168.00	172.00					
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	69.00	72.00	71.00	92.00					
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	4.10	3.20	3.60	3.10					
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	8.90	6.30	8.00	7.40					
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	13.10	12.80	12.30	13.80					
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	19.20	20.20	20.10	20.20					
				T3	20/10/90	86.0	187.0	NG %	98.00								
				T4	20/10/90	4.5	12.5	NG/DL	10.10								
				139	RA		MALE	HB	20/10/90	14.0	18.0	g/100ml	17.00	13.00	13.00	13.80	
								HTC	20/10/90	40.0	54.0	%	42.30	41.00	42.00	41.00	
								RBC	20/10/90	4.3	6.1	10 ⁶ /mm ³	4.60	4.70	4.80	4.80	
								WBC	20/10/90	4.0	11.0	10 ³ /mm ³	6.50	6.20	6.00	6.40	
								NEC: N	20/10/90	40.0	70.0	%	59.00	58.00	58.00	57.00	
								NEC: L	20/10/90	20.0	40.0	%	30.00	28.00	27.00	30.00	
								NEC: E	20/10/90	1.0	5.0	%	4.00	5.00	5.00	5.00	
								NEC: M	20/10/90	4.0	8.0	%	7.00	9.00	10.00	8.00	
NEC: B	20/10/90	0.0	1.0					%	0.00	0.00	0.00	0.00					
PLATELETS	20/10/90	150.0	550.0					10 ³ -3/MHC	247.00	236.00	253.00	263.00					
NA+	20/10/90	138.0	155.0					M EQ/L	136.00	139.00	139.00	139.00					
K+	20/10/90	3.5	5.5					M EQ/L	3.90	4.10	4.20	4.20					
CL-	20/10/90	98.0	120.0					M EQ/L	102.00	101.00	97.00	103.00					
CA++	20/10/90	8.5	10.5					MG/DL	9.70	9.50	9.50	9.80					
PO4--	20/10/90	3.0	4.5					MG/DL	3.80	4.00	4.10	4.10					
SGOT	20/10/90	12.0	40.0					IU/ML	23.00	24.00	24.00	32.00					
SGPT	20/10/90	10.0	40.0					IU/ML	26.00	26.00	28.00	34.00					
GAMMA-GT	20/10/90	11.0	51.0					IU/ML	28.00	27.00	32.00	26.00					
GLUCOSE	20/10/90	70.0	100.0					MG/DL	104.00	96.00	93.00	98.00					
ALK. PHOSPH.	20/10/90	65.0	306.0					IU/ML	204.00	221.00	216.00	176.00					
RUN	20/10/90	10.0	50.0	MG/DL	21.00	24.00	24.00	23.00									
CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	0.90	1.00	1.00									
URIC ACID	20/10/90	3.4	7.0	MG/DL	3.20	4.20	4.20	3.40									
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	0.50	0.60	0.70									
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.20	0.30	0.30									
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.00	7.30	7.20	7.10									
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.30	4.10	4.10	4.20									
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	128.00	136.00	135.00	134.00									
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	92.00	92.00	87.00	96.00									
GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	3.80	2.80	2.60	3.10									
GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	12.30	13.80	13.80	18.10									
GLOBULINS: BETA	20/10/90	11.0	14.0	%	8.10	9.50	9.50	9.00									
GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	19.80	20.10	21.50	20.20									
T3	20/10/90	86.0	187.0	NG %	102.00												
T4	20/10/90	4.5	12.5	NG/DL	8.90												

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Screen	Visit							
					Date	Min	Max		Unit	Week 2	Week 4	Week 6				
1	140	MCA	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	17/03/92	07/04/92	20/04/92	05/05/92	13.80	14.80	14.20	14.90
				HTC	20/10/90	37.0	47.0	X	13.80	14.80	14.20	14.90	42.00	41.00	41.00	42.00
				RBC	20/10/90	3.8	5.4	10-6/MHC	4.00	4.80	4.90	4.90	4.80	4.90	4.90	4.90
				WBC	20/10/90	4.0	11.0	10-3/MHC	6.80	6.80	6.30	6.50	6.50	6.30	6.50	6.50
				WBC: N	20/10/90	40.0	70.0	X	62.00	65.00	58.00	65.00	58.00	58.00	56.00	56.00
				WBC: L	20/10/90	20.0	40.0	X	28.00	28.00	30.00	28.00	30.00	30.00	28.00	28.00
				WBC: E	20/10/90	1.0	5.0	X	3.00	3.00	5.00	2.00	5.00	5.00	6.00	6.00
				WBC: M	20/10/90	4.0	8.0	X	7.00	7.00	10.00	5.00	10.00	10.00	10.00	10.00
				WBC: B	20/10/90	0.0	1.0	X	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				PLATELETS	20/10/90	150.0	550.0	10-3/MHC	185.00	193.00	216.00	193.00	216.00	216.00	213.00	213.00
				Na+	20/10/90	138.0	135.0	H EQ/L	136.00	137.00	138.00	137.00	138.00	138.00	139.00	139.00
				K+	20/10/90	3.5	5.5	H EQ/L	4.10	4.20	4.20	4.10	4.20	4.20	4.10	4.10
				CL-	20/10/90	98.0	120.0	H EQ/L	98.00	96.00	100.00	96.00	100.00	100.00	96.00	96.00
				Ca++	20/10/90	8.5	10.5	MG/DL	9.70	9.70	9.70	9.50	9.70	9.70	9.50	9.50
				PO4--	20/10/90	3.0	4.5	MG/DL	3.80	4.00	3.60	4.00	3.60	3.60	4.00	4.00
				SGOT	20/10/90	12.0	40.0	IU/ML	20.00	25.00	30.00	28.00	30.00	30.00	28.00	28.00
				SGPT	20/10/90	10.0	40.0	IU/ML	22.00	29.00	28.00	28.00	34.00	34.00	30.00	30.00
				GAMMA-GT	20/10/90	7.0	33.0	IU/ML	27.00	29.00	28.00	28.00	34.00	34.00	30.00	30.00
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	94.00	90.00	93.00	94.00	93.00	94.00	94.00	94.00
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	142.00	161.00	166.00	161.00	166.00	166.00	132.00	132.00
				BUN	20/10/90	10.0	50.0	MG/DL	36.00	36.00	28.00	36.00	28.00	28.00	28.00	28.00
				CREATININE	20/10/90	0.6	1.6	MG/DL	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
				URIC ACID	20/10/90	2.4	5.7	MG/DL	4.30	4.30	4.30	4.30	4.30	4.30	3.90	3.90
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.70	0.60	0.70	0.60	0.70	0.70	0.80	0.80
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.30	0.30	0.30	0.30	0.30	0.30	0.30
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.00	7.20	7.40	7.20	7.40	7.40	7.30	7.30
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	4.10	4.20	4.10	4.20	4.20	4.10	4.10
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	162.00	158.00	150.00	158.00	150.00	150.00	147.00	147.00				
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	88.00	76.00	93.00	76.00	93.00	93.00	93.00	93.00				
GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	X	3.80	3.00	2.50	3.00	2.50	2.50	2.80	2.80				
GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	X	16.10	14.20	13.20	14.20	13.20	13.20	14.80	14.80				
GLOBULINS: BETA	20/10/90	11.0	14.0	X	8.90	7.90	7.60	7.90	7.60	7.60	12.00	12.00				
GLOBULINS: GAMMA	20/10/90	15.0	22.0	X	18.70	20.10	20.30	20.10	20.30	20.30	28.30	28.30				
T3	20/10/90	86.0	187.0	NG %	103.00	103.00	103.00	103.00	103.00	103.00	103.00	103.00				
T4	20/10/90	4.5	12.5	NG/DL	9.80	9.80	9.80	9.80	9.80	9.80	9.80	9.80				
141	ANG	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	17/03/92	07/04/92	20/04/92	05/05/92	13.70	14.10	13.80	14.00	
			HTC	20/10/90	37.0	47.0	X	13.70	14.10	13.80	14.00	42.00	41.00	41.00	41.00	
			RBC	20/10/90	3.8	5.4	10-6/MHC	4.30	4.80	4.70	4.70	4.80	4.70	4.70		
			WBC	20/10/90	4.0	11.0	10-3/MHC	6.90	6.20	5.80	5.80	6.20	5.80	5.80		
			WBC: N	20/10/90	40.0	70.0	X	62.00	58.00	60.00	60.00	60.00	59.00	59.00		
			WBC: L	20/10/90	20.0	40.0	X	27.00	27.00	28.00	27.00	28.00	28.00	28.00		
			WBC: E	20/10/90	1.0	5.0	X	4.00	4.00	4.00	4.00	4.00	5.00	5.00		
			WBC: M	20/10/90	4.0	8.0	X	7.00	10.00	8.00	10.00	8.00	8.00	8.00		
			WBC: B	20/10/90	0.0	1.0	X	0.00	1.00	0.00	1.00	0.00	0.00	0.00		
			PLATELETS	20/10/90	150.0	550.0	10-3/MHC	210.00	235.00	310.00	235.00	310.00	310.00	290.00		

1653

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013

Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Unit	Screen	Visit							
				Date	Min	Max			Week 2	Week 4	Week 6					
1	141	AMG	FEMALE	NA+	20/10/90	138.0	155.0	M EQ/L	139.00	139.00	141.00	138.00				
				K+	20/10/90	3.5	5.5	M EQ/L	4.20	4.10	3.80	3.90				
				CL-	20/10/90	98.0	120.0	M EQ/L	96.00	97.00	100.00	97.00				
				CA++	20/10/90	8.5	10.5	MG/DL	9.50	9.40	9.70	9.50				
				PO4-	20/10/90	3.0	4.5	MG/DL	3.20	4.00	3.80	3.60				
				SGOT	20/10/90	12.0	40.0	IU/ML	23.00	26.00	26.00	24.00				
				SGPT	20/10/90	10.0	40.0	IU/ML	29.00	28.00	28.00	28.00				
				GAMMA-GT	20/10/90	7.0	33.0	IU/ML	26.00	24.00	34.00	34.00				
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	92.00	96.00	96.00	106.00				
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	172.00	153.00	160.00	153.00				
				BUN	20/10/90	10.0	50.0	MG/DL	24.00	26.00	28.00	28.00				
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	0.90	1.00	0.90				
				URIC ACID	20/10/90	2.4	5.7	MG/DL	4.10	4.10	4.20	4.00				
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.90	0.80	0.70	0.70				
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.60	0.30	0.30	0.30				
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.80	7.20	7.40	7.00				
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.10	4.10	4.10				
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	176.00	181.00	183.00	178.00				
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	92.00	86.00	88.00	68.00				
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	3.60	2.50	3.50	3.20				
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	12.80	13.10	13.20	11.80				
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	7.40	6.90	8.10	7.00				
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	20.20	20.40	21.00	18.10				
				T3	20/10/90	86.0	187.0	NG %	94.00	.	.	.				
				T4	20/10/90	4.5	12.5	NG/DL	8.50	.	.	.				
				16	142	SCC	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	17/03/92	13.00	13.00	05/05/92
								HTC	20/10/90	37.0	47.0	%	37.00	38.00	37.00	13.40
RBC	20/10/90	3.8	5.4					10 ⁶ /HMC	4.70	4.80	4.60	41.00				
MBC	20/10/90	4.0	11.0					10 ³ /HMC	6.60	6.40	5.70	5.00				
MBC: N	20/10/90	40.0	70.0					%	54.00	55.00	58.00	56.00				
MBC: L	20/10/90	20.0	40.0					%	36.00	30.00	32.00	22.00				
MBC: E	20/10/90	1.0	5.0					%	3.00	6.00	3.00	12.00				
MBC: M	20/10/90	4.0	8.0					%	7.00	9.00	7.00	10.00				
MBC: B	20/10/90	0.0	1.0					%	0.00	0.00	0.00	0.00				
PLATELETS	20/10/90	150.0	550.0					10 ³ /HMC	245.00	263.00	260.00	230.00				
NA+	20/10/90	138.0	155.0					M EQ/L	142.00	141.00	140.00	141.00				
K+	20/10/90	3.5	5.5					M EQ/L	3.70	3.80	4.20	4.20				
CL-	20/10/90	98.0	120.0					M EQ/L	100.00	101.00	97.00	98.00				
PO4-	20/10/90	8.5	10.5					MG/DL	9.20	9.50	9.30	9.50				
SGOT	20/10/90	3.0	4.5					MG/DL	4.10	4.20	3.60	4.30				
SGPT	20/10/90	12.0	40.0					IU/ML	20.00	24.00	24.00	26.00				
GAMMA-GT	20/10/90	7.0	33.0					IU/ML	26.00	28.00	28.00	28.00				
GLUCOSE	20/10/90	70.0	100.0					MG/DL	103.00	96.00	32.00	34.00				
ALK. PHOSPH.	20/10/90	65.0	306.0					IU/ML	223.00	211.00	208.00	88.00				
BUN	20/10/90	10.0	50.0					MG/DL	24.00	24.00	26.00	26.00				
CREATININE	20/10/90	0.6	1.6					MG/DL	1.00	1.00	1.00	1.10				
URIC ACID	20/10/90	2.4	5.7					MG/DL	4.10	4.10	4.10	3.80				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Screen	Visit								
				Date	Min	Max		Unit	Week 2	Week 4	Week 6					
1	142	SCC	FEMALE	TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.40	0.40	0.40	0.40	0.40			
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.20	0.20	0.20				
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.00	7.10	7.20	7.20				
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	4.10	4.10	4.10				
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	152.00	143.00	170.00	163.00				
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	88.00	92.00	92.00	92.00				
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	3.10	3.00	3.10	2.70				
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	8.90	9.10	8.00	9.10				
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	11.50	12.40	12.10	12.10				
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	19.20	20.20	20.20	18.60				
				T3	20/10/90	86.0	187.0	NG %	107.00							
				T4	20/10/90	4.5	12.5	NG/DL	9.30							
				143	JEP	MALE	HR	20/10/90	14.0	18.0	g/100ml	14.20	17/03/92	07/04/92	20/04/92	05/05/92
							HTC	20/10/90	40.0	54.0	%	42.00	41.00	44.80	15.10	
							RBC	20/10/90	4.3	6.1	10**6/mm	4.50	5.00	46.00	46.00	
							HBC: N	20/10/90	4.0	11.0	10-3/HMC	7.60	6.10	5.80	4.70	
							HBC: L	20/10/90	40.0	70.0	%	60.00	58.00	43.00	58.00	
							HBC: E	20/10/90	20.0	40.0	%	29.00	21.00	40.00	30.00	
							HBC: M	20/10/90	1.0	5.0	%	4.00	8.00	10.00	4.00	
							HBC: B	20/10/90	4.0	8.0	%	7.00	13.00	6.00	8.00	
PLATELETS	20/10/90	0.0	1.0				%	0.00	0.00	1.00	0.00					
NA+	20/10/90	150.0	550.0				10-3/HMC	195.00	218.00	254.00	270.00					
K+	20/10/90	138.0	155.0				M EQ/L	138.00	141.00	141.00	142.00					
CL-	20/10/90	3.5	5.5				M EQ/L	4.00	3.90	4.10	3.90					
PO4-	20/10/90	98.0	120.0				M EQ/L	98.00	102.00	96.00	96.00					
SGPT	20/10/90	8.5	10.5				MG/DL	9.70	9.70	9.80	9.60					
GLUCOSE	20/10/90	12.0	40.0				MG/DL	3.80	3.60	3.30	3.80					
GAMMA-GT	20/10/90	10.0	40.0				IU/ML	26.00	24.00	32.00	26.00					
ALK. PHOSPH.	20/10/90	11.0	51.0				IU/ML	28.00	28.00	19.00	30.00					
CREATININE	20/10/90	70.0	100.0				MG/DL	82.00	96.00	22.00	24.00					
URIC ACID	20/10/90	65.0	306.0				IU/ML	230.00	176.00	94.00	94.00					
TOT BILIRUBIN	20/10/90	10.0	50.0				MG/DL	22.00	30.00	179.00	232.00					
DIR BILIRUBIN	20/10/90	0.6	1.6	MG/DL	1.00	1.00	30.00	32.00								
TOT. PROTEINS	20/10/90	3.4	7.0	MG/DL	3.90	5.00	5.70	4.80								
ALBUMINE	20/10/90	0.2	1.0	MG/DL	0.40	0.90	0.70	0.70								
TOT. CHOLEST.	20/10/90	0.0	0.4	MG/DL	0.20	0.40	0.30	0.30								
TRIGLYCERIDES	20/10/90	6.0	8.0	G/DL	6.80	7.10	7.00	7.20								
GLOBULINS: ALPHA 1	20/10/90	3.5	5.0	G/DL	4.00	4.10	4.10	4.10								
GLOBULINS: ALPHA 2	20/10/90	140.0	270.0	MG/DL	152.00	178.00	198.00	163.00								
GLOBULINS: BETA	20/10/90	35.0	175.0	MG/DL	92.00	96.00	65.00	90.00								
GLOBULINS: GAMMA	20/10/90	4.0	7.0	%	4.10	3.80	3.60	3.70								
T3	20/10/90	7.0	11.0	%	9.20	7.10	6.70	7.20								
T4	20/10/90	11.0	14.0	%	11.20	11.30	11.30	13.00								
T3	20/10/90	15.0	22.0	%	19.70	20.10	20.50	21.20								
T4	20/10/90	86.0	187.0	NG %	103.00											
T4	20/10/90	4.5	12.5	NG/DL	9.60											

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit									
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6					
1	144	ARF	MALE	HB	20/10/90	14.0	18.0	g/100ml	18/03/92	08/04/92	22/04/92	06/05/92	14.50	14.50	14.50	14.50	
				HCT	20/10/90	40.0	54.0	%	43.00	44.00	46.00	43.00	44.00	46.00	43.00	43.00	43.00
				RBC	20/10/90	4.3	6.1	10 ⁶ /mm ³	4.50	4.80	4.80	4.70	4.80	4.80	4.70	4.70	4.70
				WBC	20/10/90	4.0	11.0	10 ³ /mm ³	8.10	5.50	6.60	6.00	6.60	6.60	6.00	6.00	6.00
				HbC: N	20/10/90	40.0	70.0	%	51.00	55.00	57.00	61.00	57.00	57.00	61.00	61.00	61.00
				HbC: L	20/10/90	20.0	40.0	%	39.00	30.00	33.00	28.00	33.00	33.00	28.00	28.00	28.00
				HbC: E	20/10/90	1.0	5.0	%	3.00	3.00	3.00	5.00	3.00	3.00	5.00	5.00	5.00
				HbC: H	20/10/90	4.0	8.0	%	7.00	7.00	7.00	6.00	7.00	7.00	6.00	6.00	6.00
				HbC: B	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				PLATELETS	20/10/90	150.0	550.0	10 ³ /mm ³	203.00	240.00	187.00	220.00	240.00	187.00	220.00	220.00	220.00
				NA+	20/10/90	138.0	155.0	M EQ/L	138.00	138.00	139.00	141.00	138.00	139.00	141.00	141.00	141.00
				K+	20/10/90	3.5	5.5	M EQ/L	4.80	4.00	4.80	3.80	4.00	4.80	3.80	3.80	3.80
				Ca++	20/10/90	98.0	120.0	M EQ/L	96.00	95.00	95.00	97.00	95.00	95.00	97.00	97.00	97.00
				PO4-	20/10/90	3.0	4.5	MG/DL	3.20	3.80	3.80	3.40	3.80	3.80	3.40	3.40	3.40
				SGOT	20/10/90	12.0	40.0	U/HL	28.00	26.00	22.00	24.00	22.00	22.00	24.00	24.00	24.00
				SGPT	20/10/90	10.0	40.0	U/HL	26.00	26.00	25.00	26.00	25.00	25.00	26.00	26.00	26.00
				GAMMA-GT	20/10/90	11.0	51.0	U/HL	33.00	30.00	41.00	20.00	30.00	41.00	20.00	20.00	20.00
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	134.00	94.00	94.00	103.00	94.00	94.00	103.00	103.00	103.00
				ALK. PHOSPH.	20/10/90	65.0	306.0	U/HL	151.00	151.00	216.00	193.00	216.00	145.00	193.00	193.00	193.00
				BUN	20/10/90	10.0	50.0	MG/DL	23.00	24.00	24.00	28.00	24.00	24.00	28.00	28.00	28.00
				CREATININE	20/10/90	0.6	1.6	MG/DL	1.00	0.80	0.80	1.00	0.80	0.80	1.00	1.00	1.00
				URIC ACID	20/10/90	3.4	7.0	MG/DL	3.80	4.30	7.00	3.90	4.30	7.00	3.90	3.90	3.90
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	0.60	0.60	0.80	0.60	0.50	0.80	0.80	0.80
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.30	0.40	0.40	0.40	0.20	0.40	0.40	0.40
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.90	7.30	7.50	7.40	7.30	7.50	7.40	7.40	7.40
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	4.20	4.00	4.30	4.20	4.00	4.30	4.30	4.30
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	186.00	271.00	219.00	163.00	271.00	219.00	163.00	163.00	163.00
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	121.00	93.00	226.00	92.00	93.00	226.00	92.00	92.00	92.00				
GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	4.80	2.50	2.00	2.50	2.50	2.00	2.50	2.50	2.50				
GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	7.30	8.40	8.40	8.70	8.40	8.40	8.70	8.70	8.70				
GLOBULINS: BETA	20/10/90	11.0	14.0	%	12.10	13.50	15.70	13.80	13.50	15.70	13.80	13.80	13.80				
GLOBULINS: GANNA	20/10/90	15.0	22.0	%	18.30	18.30	17.40	17.40	18.30	17.40	17.40	17.40	17.40				
T3	20/10/90	86.0	187.0	NG %	94.00	94.00	94.00	94.00	94.00	94.00	94.00	94.00	94.00				
T4	20/10/90	4.5	12.5	NG/DL	10.30	10.30	10.30	10.30	10.30	10.30	10.30	10.30	10.30				
145	SLD	MALE	HB	20/10/90	14.0	18.0	g/100ml	20/03/92	10/04/92	24/04/92	08/05/92	15.00	15.00	15.00	15.00		
			HCT	20/10/90	40.0	54.0	%	45.00	45.00	48.00	46.00	45.00	48.00	46.00	46.00		
			RBC	20/10/90	4.3	6.1	10 ⁶ /mm ³	7.40	5.00	5.40	5.30	5.40	5.30	5.40	5.30		
			WBC	20/10/90	4.0	11.0	10 ³ /mm ³	66.00	68.00	70.00	65.00	68.00	70.00	65.00	65.00		
			HbC: N	20/10/90	40.0	70.0	%	25.00	23.00	21.00	22.00	23.00	21.00	22.00	22.00		
			HbC: L	20/10/90	20.0	40.0	%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			HbC: E	20/10/90	1.0	5.0	%	9.00	8.00	5.00	6.00	8.00	5.00	6.00	6.00		
			HbC: H	20/10/90	4.0	8.0	%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			HbC: B	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			PLATELETS	20/10/90	150.0	550.0	10 ³ /mm ³	237.00	249.00	230.00	241.00	249.00	230.00	241.00	241.00		

1653

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
1	145	SLD	MALE	NA+	20/10/90	138.0	155.0	M EQ/L	138.00	141.00	138.00	138.00	138.00
				K+	20/10/90	3.5	5.5	M EQ/L	4.20	3.90	4.20	4.00	4.10
				CL-	20/10/90	98.0	120.0	M EQ/L	95.00	97.00	95.00	95.00	96.00
				CA++	20/10/90	8.5	10.5	MG/DL	9.80	9.60	9.80	9.30	9.80
				PO4--	20/10/90	3.0	4.5	MG/DL	4.40	4.20	4.40	4.20	4.00
				SGOT	20/10/90	12.0	40.0	IU/ML	21.00	24.00	21.00	20.00	22.00
				SGPT	20/10/90	10.0	40.0	IU/ML	23.00	28.00	26.00	26.00	26.00
				GAMMA-GT	20/10/90	11.0	51.0	IU/ML	72.00	22.00	24.00	24.00	20.00
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	103.00	96.00	94.00	94.00	94.00
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	197.00	108.00	87.00	87.00	103.00
				BUN	20/10/90	10.0	50.0	MG/DL	39.00	26.00	26.00	39.00	36.00
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	1.00	1.00	1.00	1.00
				URIC ACID	20/10/90	3.4	7.0	MG/DL	4.20	4.00	3.70	3.80	3.80
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.50	0.50	0.50	0.50	0.40
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.10	0.20	0.20	0.20
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.60	7.40	7.40	7.40	7.30
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.30	4.20	4.30	4.30	4.20
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	176.00	123.00	180.00	171.00	171.00
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	48.00	91.00	74.00	82.00	82.00
				GLUCOLINS: ALPHA 1	20/10/90	4.0	7.0	Z	3.10	3.10	2.80	2.50	2.50
				GLUCOLINS: ALPHA 2	20/10/90	7.0	11.0	Z	8.60	8.50	8.20	8.00	8.00
				GLUCOLINS: BETA	20/10/90	11.0	14.0	Z	12.60	12.30	11.90	12.30	12.30
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	Z	10.80	15.90	13.10	15.10	15.10
				T3	20/10/90	86.0	187.0	NG %	115.00				
				T4	20/10/90	4.5	12.5	NG/DL	7.60				
	146	LRH	MALE	HB	20/10/90	14.0	18.0	g/100ml	16.80	10/04/92	20/03/92	10/04/92	08/05/92
				HTC	20/10/90	40.0	54.0	Z	48.00	15.40	16.80	15.90	15.30
				RBC	20/10/90	4.3	6.1	10**6/mm	5.20	46.00	48.00	44.00	44.00
				HBC: N	20/10/90	4.0	11.0	10-3/HMC	8.90	4.90	5.10	4.70	4.70
				HBC: L	20/10/90	40.0	70.0	Z	60.00	7.00	7.30	6.50	6.50
				HBC: E	20/10/90	20.0	40.0	Z	30.00	61.00	62.00	59.00	59.00
				HBC: K	20/10/90	1.0	5.0	Z	1.00	28.00	29.00	30.00	30.00
				HBC: B	20/10/90	4.0	8.0	Z	8.00	4.00	2.00	4.00	4.00
				PLATELETS	20/10/90	0.0	1.0	Z	1.00	7.00	7.00	7.00	7.00
				NA+	20/10/90	150.0	550.0	10-3/HMC	295.00	0.00	0.00	0.00	0.00
				K+	20/10/90	138.0	155.0	M EQ/L	139.00	276.00	283.00	294.00	294.00
				CL-	20/10/90	98.0	120.0	M EQ/L	97.00	142.00	138.00	140.00	140.00
				CA++	20/10/90	8.5	10.5	MG/DL	9.60	4.10	4.00	3.90	3.90
				PO4--	20/10/90	3.0	4.5	MG/DL	3.30	9.80	9.80	9.80	103.00
				SGOT	20/10/90	12.0	40.0	IU/ML	35.00	4.00	2.50	4.20	4.20
				SGPT	20/10/90	10.0	40.0	IU/ML	39.00	26.00	26.00	26.00	26.00
				GAMMA-GT	20/10/90	11.0	51.0	IU/ML	47.00	51.00	51.00	28.00	28.00
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	127.00	42.00	49.00	36.00	36.00
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	370.00	167.00	336.00	210.00	210.00
				BUN	20/10/90	10.0	50.0	MG/DL	35.00	25.00	34.00	28.00	28.00
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	0.90	0.80	0.90	0.90
				URIC ACID	20/10/90	3.4	7.0	MG/DL	6.30	3.20	4.40	4.40	4.40

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit									
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6					
1	146	LRH	MALE	TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	0.60	0.50	0.60	0.60				
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.30	0.30	0.30	0.30				
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.10	7.40	7.30	7.30	7.30				
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	3.90	4.00	4.10	4.10				
				TOT. CHOLEST.	20/10/90	140.0	170.0	MG/DL	225.00	198.00	220.00	190.00	187.00				
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	136.00	220.00	212.00	187.00	187.00				
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	3.40	3.00	2.60	3.20	3.20				
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	8.60	6.70	8.90	8.30	8.30				
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	13.50	12.20	12.70	11.70	11.70				
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	15.30	19.10	11.80	18.60	18.60				
				T3	20/10/90	86.0	187.0	NG %	115.00								
				T4	20/10/90	4.5	12.5	NG/DL	7.20								
				1657	147	JGH	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	20/03/92	10/06/92			
								HTC	20/10/90	37.0	47.0	%	13.60	14.50			
RBC	20/10/90	3.8	5.4					10 ⁶ /MHC	40.00	36.00							
RBC: N	20/10/90	4.0	11.0					10 ⁶ -3/MHC	4.30	4.80							
RBC: L	20/10/90	40.0	70.0					%	47.00	6.50							
RBC: E	20/10/90	20.0	40.0					%	46.00	57.00							
RBC: M	20/10/90	1.0	5.0					%	2.00	28.00							
RBC: B	20/10/90	4.0	8.0					%	5.00	6.00							
PLATELETS	20/10/90	0.0	1.0					%	0.00	9.00							
NA+	20/10/90	150.0	550.0					10 ³ -3/MHC	203.00	0.00							
K+	20/10/90	138.0	155.0					M EQ/L	143.00	236.00							
CL-	20/10/90	3.5	5.5					M EQ/L	4.00	138.00							
PO4--	20/10/90	98.0	120.0					M EQ/L	99.00	4.10							
SGPT	20/10/90	8.5	10.5					MG/DL	8.60	9.00							
GAMMA-GT	20/10/90	12.0	40.0	MU/HL	30.00	4.20											
GLUCOSE	20/10/90	10.0	60.0	MU/HL	26.00	25.00											
ALK. PHOSPH.	20/10/90	7.0	33.0	MU/HL	19.00	28.00											
CREATININE	20/10/90	70.0	100.0	MG/DL	101.00	32.00											
URIC ACID	20/10/90	65.0	306.0	MU/ML	203.00	98.00											
TOT BILIRUBIN	20/10/90	10.0	50.0	MG/DL	28.00	28.00											
DIR BILIRUBIN	20/10/90	0.6	1.6	MG/DL	0.80	0.90											
TOT. PROTEINS	20/10/90	2.4	5.7	MG/DL	4.70	4.10											
ALBUMINE	20/10/90	0.2	1.0	MG/DL	0.30	0.80											
TOT. CHOLEST.	20/10/90	0.0	0.4	MG/DL	0.10	0.60											
TRIGLYCERIDES	20/10/90	8.0	8.0	G/DL	7.00	7.00											
GLOBULINS: ALPHA 1	20/10/90	3.5	5.0	G/DL	3.90	4.50											
GLOBULINS: ALPHA 2	20/10/90	140.0	270.0	MG/DL	260.00	163.00											
GLOBULINS: BETA	20/10/90	35.0	175.0	MG/DL	153.00	82.00											
GLOBULINS: GAMMA	20/10/90	4.0	7.0	%	3.10	3.60											
T3	20/10/90	7.0	11.0	%	8.00	9.30											
T4	20/10/90	11.0	14.0	%	12.60	12.20											
T3	20/10/90	15.0	22.0	%	20.80	20.30											
T4	20/10/90	86.0	187.0	NG %	96.00												
T4	20/10/90	4.5	12.5	NG/DL	7.00												

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit									
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6					
1	148	CAS	MALE	HB	20/10/90	14.0	18.0	g/100ml	20/03/92	13.30	13.50	10/04/92	13.50	24/04/92	13.80	08/05/92	13.60
				HTC	20/10/90	40.0	54.0	Z	20/03/92	37.00	38.00	10/04/92	38.00	24/04/92	39.00	08/05/92	38.00
				RBC	20/10/90	4.3	6.1	10**6/mm	20/03/92	4.80	4.80	10/04/92	4.50	24/04/92	5.00	08/05/92	4.60
				HBC	20/10/90	4.0	11.0	10-3/HMC	20/03/92	7.20	6.80	10/04/92	6.80	24/04/92	6.80	08/05/92	6.70
				HBC: N	20/10/90	40.0	70.0	Z	20/03/92	62.00	60.00	10/04/92	60.00	24/04/92	58.00	08/05/92	58.00
				HBC: L	20/10/90	20.0	40.0	Z	20/03/92	26.00	25.00	10/04/92	25.00	24/04/92	25.00	08/05/92	28.00
				HBC: E	20/10/90	1.0	5.0	Z	20/03/92	4.00	4.00	10/04/92	5.00	24/04/92	7.00	08/05/92	5.00
				HBC: M	20/10/90	4.0	8.0	Z	20/03/92	7.00	7.00	10/04/92	10.00	24/04/92	10.00	08/05/92	9.00
				HBC: B	20/10/90	0.0	1.0	Z	20/03/92	1.00	0.00	10/04/92	0.00	24/04/92	0.00	08/05/92	0.00
				PLATELETS	20/10/90	150.0	550.0	10-3/HMC	20/03/92	230.00	240.00	10/04/92	240.00	24/04/92	248.00	08/05/92	254.00
				NA+	20/10/90	138.0	155.0	M ER/L	20/03/92	136.00	137.00	10/04/92	137.00	24/04/92	138.00	08/05/92	141.00
				K+	20/10/90	98.0	120.0	M ER/L	20/03/92	97.00	96.00	10/04/92	96.00	24/04/92	98.00	08/05/92	98.00
				Ca++	20/10/90	8.5	10.5	MG/DL	20/03/92	9.20	9.30	10/04/92	9.20	24/04/92	9.40	08/05/92	9.30
				PO4-	20/10/90	3.0	4.5	MG/DL	20/03/92	3.60	3.60	10/04/92	4.10	24/04/92	3.80	08/05/92	3.80
				SGOT	20/10/90	12.0	40.0	RU/HL	20/03/92	20.00	24.00	10/04/92	24.00	24/04/92	28.00	08/05/92	28.00
				SGPT	20/10/90	10.0	40.0	RU/HL	20/03/92	24.00	24.00	10/04/92	28.00	24/04/92	34.00	08/05/92	32.00
				GAHMA-GT	20/10/90	11.0	51.0	RU/HL	20/03/92	32.00	28.00	10/04/92	28.00	24/04/92	24.00	08/05/92	26.00
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	20/03/92	82.00	88.00	10/04/92	88.00	24/04/92	97.00	08/05/92	84.00
				ALK. PHOSPH.	20/10/90	65.0	306.0	RU/HL	20/03/92	242.00	212.00	10/04/92	212.00	24/04/92	230.00	08/05/92	203.00
				BUN	20/10/90	10.0	50.0	MG/DL	20/03/92	30.00	32.00	10/04/92	32.00	24/04/92	32.00	08/05/92	28.00
				CREATININE	20/10/90	0.6	1.6	MG/DL	20/03/92	0.70	0.80	10/04/92	0.80	24/04/92	0.80	08/05/92	0.80
				URIC ACID	20/10/90	3.4	7.0	MG/DL	20/03/92	4.00	4.00	10/04/92	3.20	24/04/92	3.20	08/05/92	3.70
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	20/03/92	0.60	0.60	10/04/92	0.50	24/04/92	0.80	08/05/92	0.50
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	20/03/92	0.30	0.30	10/04/92	0.20	24/04/92	0.40	08/05/92	0.20
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	20/03/92	6.90	6.90	10/04/92	6.80	24/04/92	6.80	08/05/92	6.80
				ALBUMINE	20/10/90	3.5	5.0	G/DL	20/03/92	3.90	3.90	10/04/92	3.80	24/04/92	3.70	08/05/92	4.00
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	20/03/92	144.00	144.00	10/04/92	132.00	24/04/92	190.00	08/05/92	178.00
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	20/03/92	72.00	72.00	10/04/92	84.00	24/04/92	82.00	08/05/92	93.00
GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	Z	20/03/92	2.90	2.90	10/04/92	2.50	24/04/92	2.50	08/05/92	3.00				
GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	Z	20/03/92	11.10	11.10	10/04/92	12.10	24/04/92	9.80	08/05/92	11.30				
GLOBULINS: BETA	20/10/90	11.0	14.0	Z	20/03/92	8.20	8.20	10/04/92	7.90	24/04/92	12.00	08/05/92	9.70				
GLOBULINS: GAMMA	20/10/90	15.0	22.0	Z	20/03/92	18.60	18.60	10/04/92	18.60	24/04/92	17.10	08/05/92	18.60				
T3	20/10/90	86.0	187.0	NG Z	20/03/92	99.00	99.00	10/04/92	99.00	24/04/92	99.00	08/05/92	99.00				
T4	20/10/90	4.5	12.5	NG/DL	20/03/92	8.60	8.60	10/04/92	8.60	24/04/92	8.60	08/05/92	8.60				
149	SC	FEMALE	HB	20/10/90	12.0	16.0	G/100ML	20/03/92	13.00	13.50	10/04/92	13.50	24/04/92	13.50	08/05/92	13.60	
			HTC	20/10/90	37.0	47.0	Z	20/03/92	40.00	40.00	10/04/92	40.00	24/04/92	41.00	08/05/92	41.00	
			RBC	20/10/90	3.8	5.4	10-6/HMC	20/03/92	4.30	4.30	10/04/92	4.30	24/04/92	4.70	08/05/92	4.80	
			HBC	20/10/90	4.0	11.0	10-3/HMC	20/03/92	6.90	6.90	10/04/92	5.80	24/04/92	5.80	08/05/92	6.00	
			HBC: N	20/10/90	40.0	70.0	Z	20/03/92	63.00	63.00	10/04/92	58.00	24/04/92	57.00	08/05/92	60.00	
			HBC: L	20/10/90	20.0	40.0	Z	20/03/92	28.00	29.00	10/04/92	29.00	24/04/92	26.00	08/05/92	28.00	
			HBC: E	20/10/90	1.0	5.0	Z	20/03/92	3.00	3.00	10/04/92	5.00	24/04/92	7.00	08/05/92	5.00	
			HBC: M	20/10/90	4.0	8.0	Z	20/03/92	6.00	6.00	10/04/92	8.00	24/04/92	10.00	08/05/92	7.00	
			HBC: B	20/10/90	0.0	1.0	Z	20/03/92	0.00	0.00	10/04/92	0.00	24/04/92	0.00	08/05/92	0.00	
			PLATELETS	20/10/90	150.0	550.0	10-3/HMC	20/03/92	261.00	261.00	10/04/92	270.00	24/04/92	280.00	08/05/92	305.00	

1658

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOREXINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
1	149	SC	FEMALE	NA+	20/10/90	138.0	155.0	M EQ/L	138.00	137.00	137.00	141.00				
				K+	20/10/90	3.5	5.5	M EQ/L	3.70	4.20	4.20	4.10				
				CL-	20/10/90	98.0	120.0	M EQ/L	98.00	97.00	97.00	96.00				
				CA++	20/10/90	8.5	10.5	MG/DL	9.40	9.70	9.50	9.50				
				PO4-	20/10/90	3.0	4.5	MG/DL	3.80	4.10	4.10	4.00				
				SGPT	20/10/90	12.0	40.0	MIU/ML	20.00	24.00	22.00	22.00				
				SGPT	20/10/90	10.0	40.0	MIU/ML	22.00	28.00	26.00	28.00				
				GAMMA-GT	20/10/90	7.0	33.0	MIU/ML	30.00	32.00	29.00	34.00				
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	94.00	91.00	91.00	97.00				
				ALK. PHOSPH.	20/10/90	65.0	306.0	MIU/ML	247.00	181.00	163.00	176.00				
				BUN	20/10/90	10.0	50.0	MG/DL	30.00	33.00	28.00	32.00				
				CREATININE	20/10/90	0.6	1.6	MG/DL	1.00	1.10	1.10	1.00				
				URIC ACID	20/10/90	2.4	5.7	MG/DL	4.30	4.20	4.20	3.70				
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	0.70	0.60	0.80				
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.30	0.30	0.40				
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.20	7.30	7.30	7.30				
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	4.10	4.20	4.20				
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	151.00	151.00	161.00	156.00				
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	88.00	88.00	96.00	98.00				
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	2.50	2.30	2.70	2.30				
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	12.30	11.50	11.20	12.10				
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	6.60	6.60	8.00	7.80				
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	20.40	18.90	20.20	19.30				
				T3	20/10/90	86.0	187.0	NG %	107.00							
				T4	20/10/90	4.5	12.5	NG/DL	9.60							
				150	VA		FEMALE	HB	20/10/90	12.0	16.0	G/100ML	13.80	10/03/92	10/04/92	08/05/92
								HTC	20/10/90	37.0	47.0	%	41.00	41.00	41.00	14.20
ERC	20/10/90	3.8	5.4					10-6/MNC	4.80	4.80	4.80	40.00				
WRC	20/10/90	4.0	11.0					10-3/MNC	7.00	6.90	6.40	4.70				
HRC: N	20/10/90	40.0	70.0					%	60.00	58.00	58.00	6.50				
HRC: L	20/10/90	20.0	40.0					%	30.00	30.00	30.00	56.00				
HRC: E	20/10/90	1.0	5.0					%	4.00	4.00	4.00	28.00				
HRC: X	20/10/90	4.0	8.0					%	6.00	8.00	8.00	6.00				
HRC: B	20/10/90	0.0	1.0					%	0.00	0.00	0.00	10.00				
PLATELETS	20/10/90	150.0	550.0					10-3/MNC	183.00	220.00	196.00	231.00				
NA+	20/10/90	138.0	155.0					M EQ/L	138.00	133.00	141.00	140.00				
K+	20/10/90	3.5	5.5					M EQ/L	4.10	4.00	4.20	4.20				
CL-	20/10/90	98.0	120.0					M EQ/L	96.00	95.00	94.00	95.00				
CA++	20/10/90	8.5	10.5					MG/DL	9.80	9.70	9.90	9.60				
PO4-	20/10/90	3.0	4.5					MG/DL	4.10	3.90	4.30	4.30				
SGPT	20/10/90	12.0	40.0					MIU/ML	20.00	24.00	23.00	24.00				
SGPT	20/10/90	10.0	40.0					MIU/ML	28.00	28.00	28.00	30.00				
GAMMA-GT	20/10/90	7.0	33.0					MIU/ML	28.00	30.00	36.00	38.00				
GLUCOSE	20/10/90	70.0	100.0					MG/DL	82.00	94.00	90.00	97.00				
ALK. PHOSPH.	20/10/90	65.0	306.0					MIU/ML	241.00	260.00	223.00	232.00				
BUN	20/10/90	10.0	50.0					MG/DL	23.00	26.00	28.00	28.00				
CREATININE	20/10/90	0.6	1.6					MG/DL	0.90	0.90	1.00	1.00				
URIC ACID	20/10/90	2.4	5.7					MG/DL	3.60	3.70	3.80	3.80				

1650

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
1	150	VA	FEMALE	TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.70	0.70	0.70	0.70	0.70			
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.30	0.30	0.30	0.30			
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.20	7.30	7.40	7.40	7.40			
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.00	4.10	4.10	4.10	4.20			
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	123.00	128.00	138.00	138.00	136.00			
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	80.00	80.00	76.00	80.00	72.00			
				GLOBULINS: ALPHA 1	20/10/90	4.0	7.0	%	4.10	3.90	3.90	3.90	2.90			
				GLOBULINS: ALPHA 2	20/10/90	7.0	11.0	%	8.00	8.00	7.40	7.40	7.60			
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	12.10	12.50	13.80	13.80	13.20			
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	18.50	19.10	20.10	20.10	20.10			
				T3	20/10/90	86.0	487.0	NG %	103.00							
				T4	20/10/90	4.5	12.5	NG/DL	10.20							
				2	31	IK	FEMALE	HB	15/10/90	12.0	16.0	G/DL	14.30	13.50	14.30	14.30
								HCT	15/10/90	36.0	46.0	%	45.50	41.70	45.90	45.90
								RBC	15/10/90	4.2	5.4	10**6/UL	4.75	4.30	5.70	5.70
								RBC: N	15/10/90	4.0	10.0	10**3/UL	8.20	60.00	68.00	68.00
RBC: L	15/10/90	50.0	70.0					%	52.00	50.00	24.00	24.00				
RBC: E	15/10/90	25.0	40.0					%	42.00	0.00	1.00	1.00				
RBC: M	15/10/90	1.0	3.0					%	0.00	0.00	7.00	7.00				
RBC: H	15/10/90	3.0	7.0					%	6.00	10.00	0.00	0.00				
PLATELETS	15/10/90	0.0	0.8					%	0.00	0.00	0.00	0.00				
NA+	15/10/90	150.0	350.0					10**3/UL	231.00	217.00	202.00	202.00				
K+	15/10/90	136.0	150.0					MMOL/L	138.00	143.00	142.00	142.00				
CA++	15/10/90	3.8	5.5					MMOL/L	3.70	4.80	5.50	5.50				
SGPT	15/10/90	2.3	2.8					MMOL/L	2.40	2.50	2.15	2.15				
GAMMA-GT	15/10/90	320.0	490.0					UNOL/L	275.00	500.00	700.00	700.00				
GLUCOSE	15/10/90	410.0	550.0					UNOL/L	566.00	375.00	484.00	484.00				
BUN	15/10/90	0.0	420.0					UNOL/L	360.00	260.00	350.00	350.00				
CREATININE	15/10/90	3.4	5.6					MMOL/L	4.57	4.24	4.85	4.85				
URIC ACID	15/10/90	3.8	8.3					MMOL/L	54.00	6.80	4.90	4.90				
TOT. BILIRUBIN	15/10/90	54.0	88.3					UMOL/L	80.00	80.00	56.00	56.00				
TOT. PROTEINS	15/10/90	135.0	416.0					UMOL/L	303.00	303.00	4.00	4.00				
ALBUMINE	15/10/90	4.0	21.0					UMOL/L	16.00	13.50	68.00	68.00				
TOT. CHOLEST.	15/10/90	60.0	83.0					G/L	72.00	6.10	0.48	0.48				
TRIGLYCERIDES	15/10/90	0.6	0.7					RATIO	0.41	6.20	1.03	1.03				
GLOBULINS: ALPHA 1	15/10/90	5.5	6.6					MMOL/L	6.30	1.44	0.07	0.07				
GLOBULINS: ALPHA 2	15/10/90	0.4	1.7	MMOL/L	1.16	0.06	0.11	0.11								
GLOBULINS: BETA	15/10/90	0.0	0.1	RATIO	0.06	0.06	0.12	0.12								
GLOBULINS: GAMMA	15/10/90	0.1	0.1	RATIO	0.18	0.15	0.22	0.22								
32	GE	FEMALE	HB	05/12/90	12.0	16.0	G/DL	12.20	12.20	12.20	12.20					
			HCT	05/12/90	36.0	46.0	%	36.60	38.20	38.20	38.20					
			RBC	05/12/90	4.2	5.4	10**6/UL	3.84	4.02	4.02	4.02					
			RBC	05/12/90	4.0	10.0	10**3/UL	5.00	5.80	5.80	5.80					

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOREXINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit								
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
2	33 HS	FEMALE	TOT BILIRUBIN	20/12/90	4.0	21.0	UMOL/L	17.00							
			TOT. PROTEINS	20/12/90	60.0	83.0	G/L	70.00		14.85					
			ALBUMINE	20/12/90	0.6	0.7	RATIO	0.50		74.00					
			TOT. CHOLEST.	20/12/90	5.5	6.6	MMOL/L	7.47		0.43					
			TRIGLYCERIDES	20/12/90	0.4	1.7	MMOL/L	1.09		5.76					
			GLOBULINS: ALPHA 1	20/12/90	0.0	0.1	RATIO	0.05		1.29					
			GLOBULINS: ALPHA 2	20/12/90	0.1	0.1	RATIO	0.06		0.06					
			GLOBULINS: BETA	20/12/90	0.1	0.1	RATIO	0.15		0.15					
			GLOBULINS: GAMMA	20/12/90	0.1	0.2	RATIO	0.13		0.16					
				20/12/90	0.1	0.2	RATIO	0.17		0.20					
			34	EH	FEMALE	HR	20/12/90	12.0	16.0	G/DL	22/03/91	10/04/91	24/04/91		
HTC	20/12/90	36.0				46.0	%	35.80	15.80	15.00					
ERC	20/12/90	4.2				5.4	10**6/UL	50.20	55.30	46.90					
REC: N	20/12/90	4.0				10.0	10**9/UL	5.48	6.03	5.07					
REC: L	20/12/90	50.0				70.0	%	5.80	7.60	5.70					
REC: E	20/12/90	25.0				40.0	%	66.00	46.00	40.00					
REC: H	20/12/90	1.0				3.0	%	28.00	50.00	50.00					
REC: B	20/12/90	3.0				7.0	%	2.00	1.00	2.00					
PLATELETS	20/12/90	0.0				0.8	%	4.00	3.00	8.00					
NA+	20/12/90	150.0				350.0	10**3/UL	219.00	356.00	224.00					
K+	20/12/90	136.0				150.0	MMOL/L	143.00	142.00	142.00					
CL-	20/12/90	3.8				5.5	MMOL/L	4.55	4.78	4.67					
PO4--	20/12/90	97.0				108.0	MMOL/L	107.00	103.00	106.00					
SGPT	20/12/90	2.3				2.8	MMOL/L	2.27	2.01	2.19					
GAMMA-GT	20/12/90	0.8				1.6	MMOL/L	1.30	1.30	1.30					
GLUCOSE	20/12/90	0.0				18.0	U/L	9.00	12.00	9.00					
ALK. PHOSPH.	20/12/90	0.0				20.0	U/L	10.00	10.00	8.00					
BUN	20/12/90	0.0				28.0	U/L	16.00	11.00	6.00					
CREATININE	20/12/90	3.4				5.6	MMOL/L	4.10	4.64	3.81					
URIC ACID	20/12/90	120.0				175.0	U/L	121.00	142.00	120.00					
TOT BILIRUBIN	20/12/90	3.8				8.3	MMOL/L	4.77	5.71	3.82					
TOT. PROTEINS	20/12/90	54.0				88.3	UMOL/L	59.00	62.00	61.00					
TOT. CHOLEST.	20/12/90	135.0				416.0	UMOL/L	237.00	283.00	265.00					
TRIGLYCERIDES	20/12/90	4.0	21.0	UMOL/L	5.80	4.90	6.70								
	20/12/90	60.0	83.0	G/L	69.80	71.00	67.30								
	20/12/90	5.5	6.6	MMOL/L	8.14	8.35	7.76								
	20/12/90	0.4	1.7	MMOL/L	1.45	1.98	2.03								
3	1 AMR	FEMALE	HR	18/10/90	7.4	9.9	MMOL/L	09/11/90							
			HTC	18/10/90	0.3	0.5	%	7.90							
			REC	18/10/90	4.0	5.5	10**12/L	0.45							
			REC: N	18/10/90	4.0	10.0	10**9/L	4.62							
			REC: L	18/10/90	15.0	74.0	%	5.49							
			REC: E	18/10/90	16.0	45.0	%	61.70							
			REC: H	18/10/90	0.0	7.0	%	28.30							
			REC: B	18/10/90	4.0	10.0	%	3.40							
				18/10/90	0.0	2.0	%	5.80							
				18/10/90	0.0	2.0	%	0.40							

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Screen	Visit							
					Date	Min	Max		Unit	Week 2	Week 4	Week 6				
3	1	AHR	FEMALE	PLATELETS	18/10/90	150.0	400.0	10**9/L	314.00							
				NA+	18/10/90	135.0	145.0	MMOL/L	139.00							
				K+	18/10/90	3.5	5.0	MMOL/L	4.50							
				CL-	18/10/90	95.0	105.0	MMOL/L	107.00							
				CA++	18/10/90	2.1	2.8	MMOL/L	2.38							
				PO4-	18/10/90	0.8	1.5	MMOL/L	0.80							
				SGPT	18/10/90	5.0	53.0	UI/L	7.00							
				SEPT	18/10/90	7.0	40.0	UI/L	13.00							
				GAMMA-GT	18/10/90	5.0	20.0	UI/L	15.00							
				GLUCOSE	18/10/90	3.9	5.6	MMOL/L	4.27							
				ALK. PHOSPH.	18/10/90	2.7	6.7	MMOL/L	3.60							
				BUN	18/10/90	3.0	90.0	UMOL/L	69.00							
				CREATININE	18/10/90	150.0	475.0	UMOL/L	199.00							
				URIC ACID	18/10/90	2.0	7.0	UMOL/L	7.00							
				TOT BILIRUBIN	18/10/90	0.0	2.0	UMOL/L	0.00							
				DIR BILIRUBIN	18/10/90	60.0	75.0	G/L	67.00							
				TOT. PROTEINS	18/10/90	500.0	725.0	UMOL/L	594.00							
				ALBUMINE	18/10/90	0.9	2.0	MMOL/L	0.74							
				TRIGLYCERIDES	18/10/90	2.0	4.0	Z	3.00							
				GLOBULINS: ALPHA 1	18/10/90	6.0	10.0	Z	2.00							
				GLOBULINS: ALPHA 2	18/10/90	8.0	12.0	Z	11.00							
				GLOBULINS: BETA	18/10/90	12.0	19.0	Z	17.00							
				GLOBULINS: GAMMA	18/10/90	60.0	75.0	G/L	67.00							
				2	FIL	FEMALE	HB	18/10/90	7.4	9.9	MMOL/L	6.00	02/11/90	30/11/90	14/12/90	28/12/90
							HTC	18/10/90	0.3	0.5	MMOL/L	0.31	6.20	5.70	6.20	6.20
							RBC	18/10/90	4.0	5.5	10**12/L	4.88	0.31	0.31	0.31	0.31
							WBC	18/10/90	4.0	10.0	10**9/L	8.18	4.88	4.88	5.26	5.25
HRC: N	18/10/90	15.0	74.0				Z	58.30	8.43	8.43	7.60	9.90				
HRC: L	18/10/90	16.0	45.0				Z	32.10	51.08	51.08	52.40	60.60				
HRC: E	18/10/90	0.0	7.0				Z	0.70	23.85	23.85	36.90	28.20				
HRC: M	18/10/90	4.0	10.0				Z	1.20	0.70	0.70	1.70	0.80				
HRC: B	18/10/90	0.0	2.0				Z	6.70	6.90	7.00	8.50	8.50				
PLATELETS	18/10/90	150.0	400.0				10**9/L	438.00	438.00	438.00	612.00	612.00				
NA+	18/10/90	135.0	145.0				MMOL/L	141.00	143.00	143.00	140.00	140.00				
K+	18/10/90	3.5	5.0				MMOL/L	4.70	4.60	4.70	4.50	4.50				
CL-	18/10/90	95.0	105.0				MMOL/L	109.00	107.00	110.00	105.00	105.00				
CA++	18/10/90	2.1	2.8				MMOL/L	2.44	2.44	2.48	2.59	2.59				
PO4-	18/10/90	0.8	1.5				MMOL/L	0.86	0.86	0.90	0.83	0.83				
SGPT	18/10/90	6.0	53.0				UI/L	13.00	12.00	13.00	19.00	19.00				
SEPT	18/10/90	7.0	40.0				UI/L	16.00	16.00	15.00	25.00	25.00				
GAMMA-GT	18/10/90	3.9	5.6				MMOL/L	4.60	3.94	4.27	5.16	5.16				
GLUCOSE	18/10/90	30.0	85.0				UI/L	67.00	72.00	75.00	89.00	89.00				
ALK. PHOSPH.	18/10/90	2.7	6.7				MMOL/L	3.50	3.06	3.06	65.00	65.00				
BUN	18/10/90	2.0	90.0				UMOL/L	72.00	198.00	226.00	239.00	239.00				
CREATININE	18/10/90	150.0	475.0				UMOL/L	201.00	5.00	5.00	7.00	7.00				
URIC ACID	18/10/90	2.0	7.0				UMOL/L	7.00	2.00	2.00	2.00	2.00				
TOT BILIRUBIN	18/10/90	0.0	2.0				UMOL/L	0.00	0.00	0.00	2.00	2.00				
DIR BILIRUBIN	18/10/90	60.0	75.0				G/L	67.00	68.00	67.00	76.00	76.00				

1660

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
3	2	FIL	FEMALE	ALBUMINE	18/10/90	500.0	725.0	UMOL/L	646.00	624.00	607.00	688.00	
				TOT. CHOLEST.	18/10/90	3.9	6.3	MMOL/L		5.30		6.28	
				TRIGLYCERIDES	18/10/90	0.9	2.0	MMOL/L		0.68		1.07	
				GLOBULINS: ALPHA 1	18/10/90	2.0	4.0	%	2.80	2.00	2.00		
				GLOBULINS: ALPHA 2	18/10/90	6.0	10.0	%	7.40	6.50	7.00		
				GLOBULINS: BETA	18/10/90	8.0	12.0	%	12.90	7.00	7.00		
				GLOBULINS: GAMMA	18/10/90	12.0	19.0	%	12.80	14.00	13.00		
3	DUB		MALE	HR	18/10/90	8.0	11.0	MMOL/L	25/03/91	25/04/91	25/04/91		
				HTC	18/10/90	0.4	0.5	MMOL/L	8.50	8.80	8.80		
				RBC	18/10/90	4.2	5.7	10**12/L	0.48	0.41	0.41		
				RBC: N	18/10/90	15.0	74.0	%	4.26	4.39	4.39		
				RBC: L	18/10/90	16.0	45.0	%	4.63	6.22	6.22		
				RBC: E	18/10/90	0.0	7.0	%	35.60				
				RBC: M	18/10/90	4.0	10.0	%	48.80				
				RBC: B	18/10/90	0.0	2.0	%	6.00				
				PLATELETS	18/10/90	150.0	400.0	10**9/L	1.70				
				NA+	18/10/90	135.0	165.0	MMOL/L	259.00	351.00	351.00		
				K+	18/10/90	3.5	5.0	MMOL/L	144.00	146.00	146.00		
				CL-	18/10/90	95.0	105.0	MMOL/L	4.00	4.70	4.70		
				CA++	18/10/90	2.1	2.8	MMOL/L	106.00	108.00	108.00		
				PO4--	18/10/90	0.8	1.5	MMOL/L	2.37	2.35	2.35		
				SGPT	18/10/90	6.0	53.0	U/L	1.49	18.00	12.00		
				SGPT	18/10/90	7.0	40.0	U/L	20.00	35.00	35.00		
				GAMMA-GT	18/10/90	8.0	38.0	U/L	16.00				
				GLUCOSE	18/10/90	3.9	5.6	MMOL/L	4.77	5.50	5.11		
				ALK. PHOSPH.	18/10/90	30.0	85.0	U/L	87.00	134.00	134.00		
				BUN	18/10/90	2.7	6.7	MMOL/L	5.70	6.44	6.44		
				CREATININE	18/10/90	9.0	90.0	UMOL/L	89.00	93.00	93.00		
				URIC ACID	18/10/90	150.0	475.0	UMOL/L	239.00	251.00	251.00		
				TOT. BILIRUBIN	18/10/90	2.0	7.0	UMOL/L	12.00	5.00	5.00		
				DIR. BILIRUBIN	18/10/90	0.0	2.0	UMOL/L	2.00	2.00	2.00		
				TOT. PROTEINS	18/10/90	60.0	75.0	G/L	59.00	64.00	64.00		
				ALBUMINE	18/10/90	500.0	725.0	UMOL/L	585.00	609.00	609.00		
				TOT. CHOLEST.	18/10/90	3.9	6.3	MMOL/L	4.94				
				TRIGLYCERIDES	18/10/90	0.9	2.0	MMOL/L	0.73	0.81	0.81		
				GLOBULINS: ALPHA 1	18/10/90	2.0	4.0	%	2.00				
				GLOBULINS: ALPHA 2	18/10/90	6.0	10.0	%	6.00				
				GLOBULINS: BETA	18/10/90	8.0	12.0	%	10.00				
				GLOBULINS: GAMMA	18/10/90	12.0	19.0	%	12.00				
				T3	18/10/90	1.4	2.8	MMOL/L	2.02				
				T4	18/10/90	11.0	24.0	MMOL/L	12.00				
4	AUD		FEMALE	HR	18/10/90	7.4	9.9	MMOL/L	29/11/90	21/12/90	04/01/91		
				HTC	18/10/90	0.3	0.5	MMOL/L	7.90	9.20	8.20		
				RBC	18/10/90	4.0	5.5	10**12/L	0.41	0.46	0.43		

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOZETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
3	4	AUD	FEMALE	WBC: N	18/10/90	4.0	10.0	10**9/L	6.52	6.27	5.06					
				WBC: L	18/10/90	15.0	74.0	Z	68.00	62.50	63.00					
				WBC: E	18/10/90	16.0	45.0	Z	33.50	30.40	28.80					
				WBC: M	18/10/90	0.0	7.0	Z	1.50	1.10	0.90					
				WBC: B	18/10/90	4.0	10.0	Z	7.20	5.40	5.90					
				PLATELETS	18/10/90	0.0	2.0	Z	0.60	0.40	0.60					
				Na+	18/10/90	150.0	400.0	10**9/L	185.00	235.00	257.00					
				K+	18/10/90	3.5	14.5	MMOL/L	150.00	142.00	143.00					
				CL-	18/10/90	95.0	105.0	MMOL/L	111.00	107.00	107.00					
				CA++	18/10/90	2.1	2.8	MMOL/L	2.42	2.47	2.45					
				PO4-	18/10/90	0.8	1.5	MMOL/L	0.95	0.87	0.90					
				SGPT	18/10/90	7.0	55.0	UI/L	7.00	10.00	11.00					
				GAMMA-GT	18/10/90	7.0	40.0	UI/L	12.00	5.00	7.00					
				GLUCOSE	18/10/90	5.0	20.0	UI/L	10.00	8.00	11.00					
				ALK. PHOSPH.	18/10/90	3.9	5.6	MMOL/L	4.50	4.38	4.44					
				BUN	18/10/90	30.0	85.0	UI/L	74.00	61.00	58.00					
				CREATININE	18/10/90	2.7	6.7	MMOL/L	4.28	3.67	3.88					
				URIC ACID	18/10/90	9.0	90.0	UMOL/L	89.00	75.00	68.00					
				TOT BILIRUBIN	18/10/90	150.0	475.0	UMOL/L	319.00	266.00	282.00					
				DIR BILIRUBIN	18/10/90	0.0	7.0	UMOL/L	9.00	2.00	12.00					
				TOT. PROTEINS	18/10/90	60.0	75.0	G/L	73.00	66.00	65.00					
				ALBUMINE	18/10/90	500.0	725.0	UMOL/L	507.70	459.00	440.00					
				TOT. CHOLEST.	18/10/90	3.9	6.3	MMOL/L	4.46	4.46	4.81					
				TRIGLYCERIDES	18/10/90	0.9	2.0	MMOL/L	1.33	1.33	1.95					
				GLOBULINS: ALPHA 1	18/10/90	2.0	4.0	Z	1.46	1.98	1.95					
				GLOBULINS: ALPHA 2	18/10/90	6.0	10.0	Z	4.38	3.96	3.90					
				GLOBULINS: BETA	18/10/90	8.0	12.0	Z	6.57	5.94	5.85					
				GLOBULINS: GAMMA	18/10/90	12.0	19.0	Z	10.22	8.58	8.45					
				T3	18/10/90	1.4	2.8	MMOL/L	2.37	2.37	2.37					
				T4	18/10/90	11.0	24.0	PMOL/L	20.60	20.60	20.60					
				5	MMA		FEMALE	HR	18/10/90	7.4	9.9	MMOL/L	20/12/90			
								HTC	18/10/90	0.3	0.5	MMOL/L	7.50			
								PRC	18/10/90	4.0	5.5	10**12/L	0.38			
								WBC: N	18/10/90	4.0	10.0	10**9/L	4.21			
								WBC: L	18/10/90	15.0	74.0	Z	6.97			
								WBC: E	18/10/90	16.0	45.0	Z	64.50			
								WBC: M	18/10/90	0.0	7.0	Z	25.50			
								WBC: B	18/10/90	4.0	10.0	Z	3.10			
								PLATELETS	18/10/90	4.0	10.0	Z	6.30			
								Na+	18/10/90	150.0	400.0	10**9/L	0.40			
								K+	18/10/90	3.5	14.5	MMOL/L	268.00			
								CL-	18/10/90	95.0	105.0	MMOL/L	142.00			
								PO4-	18/10/90	2.1	2.8	MMOL/L	162.00			
								SGPT	18/10/90	0.8	1.5	MMOL/L	4.10			

1665

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
3	5	MMA	FEMALE	SGPT	18/10/90	7.0	40.0	UI/L	10.00				
				GAMMA-GT	18/10/90	5.0	20.0	UI/L	14.00				
				GLUCOSE	18/10/90	3.9	5.6	MMOL/L	4.72				
				ALK. PHOSPH.	18/10/90	30.0	85.0	UI/L	56.00				
				BUN	18/10/90	2.7	6.7	MMOL/L	5.48				
				CREATININE	18/10/90	9.0	90.0	UMOL/L	86.00				
				URIC ACID	18/10/90	150.0	475.0	UMOL/L	295.00				
				TOT BILIRUBIN	18/10/90	2.0	7.0	UMOL/L	9.00				
				DIR BILIRUBIN	18/10/90	0.0	2.0	UMOL/L	2.00				
				TOT. PROTEINS	18/10/90	60.0	75.0	G/L	68.00				
				ALBUMINE	18/10/90	500.0	725.0	UMOL/L	440.50				
				TOT. CHOLEST.	18/10/90	3.3	6.3	MMOL/L	4.20				
				TRIGLYCERIDES	18/10/90	0.3	2.0	MMOL/L	0.32				
									29/11/90				
				HB	18/10/90	8.0	11.0	MMOL/L	16.50				
				HTC	18/10/90	0.4	0.5		0.47				
				RBC	18/10/90	4.2	5.7	10**12/L	5.70				
				MBC: N	18/10/90	4.0	10.0	10**9/L	5.60				
				MBC: L	18/10/90	15.0	74.0	%	58.00				
				MBC: E	18/10/90	16.0	45.0	%	32.00				
				MBC: M	18/10/90	0.0	7.0	%	1.00				
				MBC: B	18/10/90	4.0	10.0	%	7.00				
				NA+	18/10/90	0.0	2.0	%	2.00				
				K+	18/10/90	135.0	145.0	MMOL/L	138.00				
				CL-	18/10/90	3.5	5.0	MMOL/L	4.80				
				CA++	18/10/90	95.0	105.0	MMOL/L	99.00				
				PO4--	18/10/90	2.1	2.8	MMOL/L	2.23				
				SGPT	18/10/90	0.8	1.5	MMOL/L	0.90				
				GAMMA-GT	18/10/90	7.0	40.0	UI/L	29.00				
				GLUCOSE	18/10/90	8.0	38.0	UI/L	37.00				
				ALK. PHOSPH.	18/10/90	3.9	5.6	MMOL/L	4.61				
				CREATININE	18/10/90	30.0	85.0	UMOL/L	95.00				
				URIC ACID	18/10/90	2.7	6.7	MMOL/L	5.34				
				TOT BILIRUBIN	18/10/90	9.0	90.0	UMOL/L	9.00				
				DIR BILIRUBIN	18/10/90	150.0	475.0	UMOL/L	295.00				
				TOT. PROTEINS	18/10/90	2.0	7.0	UMOL/L	3.90				
				ALBUMINE	18/10/90	0.0	2.0	UMOL/L	1.90				
				TOT. CHOLEST.	18/10/90	60.0	75.0	G/L	69.00				
				TRIGLYCERIDES	18/10/90	500.0	725.0	UMOL/L	558.00				
				GLOBULINS: ALPHA 1	18/10/90	3.9	6.3	MMOL/L	1.99				
				GLOBULINS: ALPHA 2	18/10/90	0.9	2.0	MMOL/L	0.72				
				GLOBULINS: BETA	18/10/90	6.0	10.0	%	2.50				
				GLOBULINS: GAMMA	18/10/90	8.0	12.0	%	16.50				
					18/10/90	12.0	19.0	%	14.70				
									10/12/90				
									25/12/90				
									08/01/91				
									22/01/91				

1666

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Screen	Visit			
					Date	Min	Max		Unit	Week 2	Week 4	Week 6
3	7	GRI	FEMALE	HB	18/10/90	7.4	9.9	MMOL/L	9.10	9.20	8.50	8.90
				HTC	18/10/90	0.3	0.5	MMOL/L	0.43	0.44	0.39	0.42
				RBC	18/10/90	4.0	5.5	10**12/L	4.15	4.24	3.92	4.13
				WBC	18/10/90	4.0	10.0	10**9/L	5.71	5.39	4.89	5.70
				WBC: N	18/10/90	15.0	74.0	%	49.30	49.30	54.60	56.10
				WBC: L	18/10/90	16.0	45.0	%	30.40	40.40	24.70	35.20
				WBC: E	18/10/90	0.0	7.0	%	2.20	2.20	2.40	1.90
				WBC: M	18/10/90	4.0	10.0	%	7.80	5.90	6.50	5.60
				WBC: B	18/10/90	0.0	2.0	%	0.50	1.10	0.60	0.30
				PLATELETS	18/10/90	150.0	400.0	10**9/L	301.00	343.00	326.00	361.00
				NA+	18/10/90	135.0	145.0	MMOL/L	142.00	142.00	142.00	144.00
				K+	18/10/90	3.5	5.0	MMOL/L	4.50	4.50	4.50	4.80
				CL-	18/10/90	95.0	105.0	MMOL/L	105.00	108.00	109.00	109.00
				CA++	18/10/90	2.1	2.8	MMOL/L	2.52	2.53	2.53	2.53
				PO4-	18/10/90	0.8	1.5	MMOL/L	0.87	0.78	0.81	0.87
				SGOT	18/10/90	6.0	53.0	U/L	65.00	7.00	18.00	7.00
				SGPT	18/10/90	7.0	40.0	U/L	22.00	7.00	7.00	7.00
				GAMMA-GT	18/10/90	5.0	20.0	U/L	17.00	17.00	12.00	15.00
				GLUCOSE	18/10/90	3.9	5.6	MMOL/L	4.58	5.55	4.50	4.50
				ALK. PHOSPH.	18/10/90	30.0	85.0	U/L	98.00	3.68	80.00	6.62
				CREATININE	18/10/90	9.0	90.0	UMOL/L	86.00	78.00	73.00	78.00
				URIC ACID	18/10/90	150.0	475.0	UMOL/L	332.00	281.00	316.00	281.00
				TOT BILIRUBIN	18/10/90	2.0	7.0	UMOL/L	45.00	7.00	14.00	12.00
				DIR BILIRUBIN	18/10/90	0.0	2.0	UMOL/L	2.00	2.00	2.00	2.00
				TOT. PROTEINS	18/10/90	60.0	75.0	G/L	65.00	74.00	70.00	70.00
				ALBUMINE	18/10/90	500.0	725.0	UMOL/L	393.00	477.00	458.60	429.40
				TOT. CHOLEST.	18/10/90	3.9	6.3	MMOL/L	5.55	5.62	5.30	6.07
				TRIGLYCERIDES	18/10/90	0.9	2.0	MMOL/L	1.25	1.31	1.31	1.05
				GLOBULINS: ALPHA 1	18/10/90	2.0	4.0	%	1.95	1.48	1.42	1.40
				GLOBULINS: ALPHA 2	18/10/90	6.0	10.0	%	4.55	5.18	4.26	4.20
				GLOBULINS: BETA	18/10/90	8.0	12.0	%	8.45	8.14	8.52	7.00
				GLOBULINS: GAMMA	18/10/90	12.0	19.0	%	11.05	11.84	9.94	9.80
				T3	18/10/90	1.4	2.8	MMOL/L	1.56	1.56	1.56	1.56
				T4	18/10/90	11.0	24.0	PMOL/L	13.00	13.00	13.00	13.00
				HB	18/10/91	7.4	9.9	MMOL/L	7.90	7.90	7.90	7.90
				HTC	18/10/91	0.3	0.5	MMOL/L	0.40	0.40	0.40	0.40
				RBC	18/10/91	4.0	5.5	10**12/L	4.41	4.41	4.41	4.41
				WBC	18/10/91	4.0	10.0	10**9/L	6.31	6.31	6.31	6.31
				WBC: N	18/10/91	15.0	74.0	%	44.80	44.80	44.80	44.80
				WBC: L	18/10/91	16.0	45.0	%	44.50	44.50	44.50	44.50
				WBC: E	18/10/91	0.0	7.0	%	2.80	2.80	2.80	2.80
				WBC: M	18/10/91	4.0	10.0	%	6.30	6.30	6.30	6.30
				WBC: B	18/10/91	0.0	2.0	%	0.80	0.80	0.80	0.80
				PLATELETS	18/10/91	150.0	400.0	10**9/L	332.00	332.00	332.00	332.00
				NA+	18/10/91	135.0	145.0	MMOL/L	145.00	145.00	145.00	145.00
				K+	18/10/91	3.5	5.0	MMOL/L	4.00	4.00	4.00	4.00
				CL-	18/10/91	95.0	105.0	MMOL/L	110.00	110.00	110.00	110.00
				HB	18/10/91	7.4	9.9	MMOL/L	7.90	7.90	7.90	7.90
				HTC	18/10/91	0.3	0.5	MMOL/L	0.40	0.40	0.40	0.40
				RBC	18/10/91	4.0	5.5	10**12/L	4.41	4.41	4.41	4.41
				WBC	18/10/91	4.0	10.0	10**9/L	6.31	6.31	6.31	6.31
				WBC: N	18/10/91	15.0	74.0	%	44.80	44.80	44.80	44.80
				WBC: L	18/10/91	16.0	45.0	%	44.50	44.50	44.50	44.50
				WBC: E	18/10/91	0.0	7.0	%	2.80	2.80	2.80	2.80
				WBC: M	18/10/91	4.0	10.0	%	6.30	6.30	6.30	6.30
				WBC: B	18/10/91	0.0	2.0	%	0.80	0.80	0.80	0.80
				PLATELETS	18/10/91	150.0	400.0	10**9/L	332.00	332.00	332.00	332.00
				NA+	18/10/91	135.0	145.0	MMOL/L	145.00	145.00	145.00	145.00
				K+	18/10/91	3.5	5.0	MMOL/L	4.00	4.00	4.00	4.00
				CL-	18/10/91	95.0	105.0	MMOL/L	110.00	110.00	110.00	110.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Screen		Visit						
					Date	Min	Max	Unit	Week 2	Week 4	Week 6					
3	9	DEN	FEMALE	CA++	18/10/90	2.1	2.8	MMOL/L	2.44							
				PO4-	18/10/90	0.8	1.5	MMOL/L	0.81							
				SGOT	18/10/90	6.0	53.0	UI/L	10.00							
				SGPT	18/10/90	7.0	40.0	UI/L	11.00							
				GAMMA-GT	18/10/90	5.0	20.0	UI/L	10.00							
				GLUCOSE	18/10/90	3.9	5.6	MMOL/L	4.72							
				ALK. PHOSPH.	18/10/90	30.0	85.0	UI/L	54.00							
				RUN	18/10/90	2.7	6.7	MMOL/L	5.20							
				CREATININE	18/10/90	9.0	90.0	UMOL/L	68.00							
				URIC ACID	18/10/90	150.0	475.0	UMOL/L	255.00							
				TOT BILIRUBIN	18/10/90	2.0	7.0	UMOL/L	7.00							
				DIR BILIRUBIN	18/10/90	0.0	2.0	UMOL/L	0.00							
				TOT. PROTEINS	18/10/90	60.0	75.0	G/L	63.00							
				ALBUMINE	18/10/90	500.0	725.0	UMOL/L	450.00							
				TOT. CHOLEST.	18/10/90	3.9	6.3	MMOL/L	4.93							
				TRIGLYCERIDES	18/10/90	0.9	2.0	Z	0.80							
				GLORULINS: ALPHA 1	18/10/90	2.0	4.0	Z	1.26							
				GLORULINS: ALPHA 2	18/10/90	6.0	10.0	Z	4.41							
				GLORULINS: BETA	18/10/90	8.0	12.0	Z	5.04							
				GLORULINS: GAMMA	18/10/90	12.0	19.0	Z	8.19							
				10	TOR	MALE	HB	18/10/90	8.0	11.0	MMOL/L	9.30	03/04/91	24/04/91	08/05/91	22/05/91
							HTC	18/10/90	0.4	0.5		0.45	9.80	9.90	9.90	9.80
							RBC	18/10/90	4.2	5.7	10**12/L	4.81	0.45	0.47	0.47	0.47
WBC	18/10/90	4.0	10.0				10**9/L	8.27	4.93	5.17	5.20	5.20				
MBC: N	18/10/90	15.0	74.0				Z	60.30	7.91	7.39	5.82	5.82				
MBC: L	18/10/90	16.0	45.0				Z	27.40	59.50	53.60	52.00	52.00				
MBC: E	18/10/90	0.0	7.0				Z	3.10	30.90	35.70	37.20	37.20				
MBC: M	18/10/90	4.0	10.0				Z	7.80	1.76	2.16	2.40	2.40				
MBC: B	18/10/90	0.0	2.0				Z	0.70	6.40	7.40	6.70	6.70				
PLATELETS	18/10/90	150.0	400.0				10**9/L	362.00	0.75	0.50	0.68	0.68				
NA+	18/10/90	135.0	145.0				MMOL/L	140.00	352.00	386.00	357.00	357.00				
K+	18/10/90	3.5	5.0				MMOL/L	4.20	144.00	144.00	144.00	144.00				
CL-	18/10/90	2.1	2.8				MMOL/L	100.00	4.60	4.20	4.10	4.10				
CA++	18/10/90	0.8	1.5				MMOL/L	2.40	103.00	106.00	106.00	106.00				
PO4-	18/10/90	6.0	53.0				UI/L	60.00								
SGPT	18/10/90	7.0	40.0				UI/L	68.00	48.00	83.00	61.00	61.00				
GAMMA-GT	18/10/90	8.0	38.0				UI/L	109.00								
GLUCOSE	18/10/90	3.9	5.6				MMOL/L	4.44								
ALK. PHOSPH.	18/10/90	30.0	85.0				UI/L	61.00								
RUN	18/10/90	2.7	6.7				MMOL/L	5.38								
CREATININE	18/10/90	9.0	90.0				UMOL/L	96.00	5.34	5.91	5.16	5.16				
URIC ACID	18/10/90	150.0	475.0				UMOL/L	175.00	94.00	107.00	103.00	103.00				
TOT BILIRUBIN	18/10/90	2.0	7.0				UMOL/L	9.00	170.00	199.00	220.00	220.00				
DIR BILIRUBIN	18/10/90	0.0	2.0	UMOL/L	2.00	9.00	7.00	10.00	10.00							
TOT. PROTEINS	18/10/90	60.0	75.0	G/L	61.00	2.00	0.00	2.00	2.00							
ALBUMINE	18/10/90	500.0	725.0	UMOL/L	410.20	64.00	61.00	61.00	61.00							
TOT. CHOLEST.	18/10/90	3.9	6.3	MMOL/L	5.00	405.80	405.80	435.40	435.40							

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R8D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Unit	Screen	Visit						
					Date	Min	Max			Week 2	Week 4	Week 6				
3	10	TOR	MALE	TRIGLYCERIDES	18/10/90	0.9	2.0	MMOL/L	1.01							
				GLOBULINS: ALPHA 1	18/10/90	2.0	4.0	Z	1.83	1.92	1.68	0.60				
				GLOBULINS: ALPHA 2	18/10/90	6.0	10.0	Z	5.49	5.12	5.49					
				GLOBULINS: BETA	18/10/90	8.0	12.0	Z	6.71	6.40	6.10					
				GLOBULINS: GAMMA	18/10/90	12.0	19.0	Z	7.93	8.32	7.32					
				T3	18/10/90	1.4	2.8	NMOL/L	1.60							
				T4	18/10/90	11.0	24.0	PMOL/L	10.40							
				11	PTE		FEMALE	HB	18/10/90	7.4	9.9	MMOL/L	17/05/91			
HCT	18/10/90	0.3	0.5					MMOL/L	9.10							
PRC	18/10/90	4.0	5.5					10**12/L	0.44							
NRC	18/10/90	4.0	10.0					10**9/L	4.70							
NRC: N	18/10/90	15.0	74.0					Z	7.31							
NRC: L	18/10/90	16.0	45.0					Z	48.90							
NRC: E	18/10/90	0.0	7.0					Z	42.20							
NRC: H	18/10/90	4.0	10.0					Z	2.50							
NRC: B	18/10/90	0.0	2.0					Z	5.00							
PLATELETS	18/10/90	150.0	400.0					10**9/L	238.00							
K+	18/10/90	135.0	145.0					MMOL/L	150.00							
CL-	18/10/90	3.5	5.0					MMOL/L	4.50							
CA++	18/10/90	95.0	105.0					MMOL/L	111.00							
PO4-	18/10/90	2.1	2.8					MMOL/L	2.59							
SGOT	18/10/90	0.8	1.5	MMOL/L	1.51											
SGPT	18/10/90	6.0	53.0	UI/L	10.00											
GAMMA-GT	18/10/90	7.0	40.0	UI/L	10.00											
GLUCOSE	18/10/90	5.0	20.0	UI/L	24.00											
BUN	18/10/90	3.9	5.6	MMOL/L	4.38											
ALK. PHOSPH.	18/10/90	30.0	85.0	UI/L	97.00											
CREATININE	18/10/90	2.7	6.7	MMOL/L	4.75											
TOT BILIRUBIN	18/10/90	9.0	90.0	UMOL/L	69.00											
DIR BILIRUBIN	18/10/90	150.0	475.0	UMOL/L	343.00											
TOT. PROTEINS	18/10/90	2.0	7.0	UMOL/L	7.00											
ALBUMINE	18/10/90	0.0	2.0	UMOL/L	0.00											
TOT. CHOLEST.	18/10/90	60.0	75.0	G/L	65.00											
TRIGLYCERIDES	18/10/90	500.0	725.0	UMOL/L	436.40											
GLOBULINS: ALPHA 1	18/10/90	3.9	6.3	MMOL/L	5.44											
GLOBULINS: ALPHA 2	18/10/90	0.9	2.0	MMOL/L	1.01											
GLOBULINS: BETA	18/10/90	2.0	4.0	Z	1.95											
GLOBULINS: GAMMA	18/10/90	6.0	10.0	Z	5.20											
8	1	HJ	FEMALE	HB	18/10/90	120.0	150.0	g/l	27/11/90	144.00	17/12/90	30/12/90	14/01/91			
				HCT	19/10/90	0.4	0.5	l/l	0.38	133.00	130.00	139.00				
				HBC	19/10/90	4.5	5.5	10**12/L	4.75	4.75	4.73	4.88				
				HBC: N	19/10/90	5.0	10.0	10**9/L	6.10	6.10	5.80	5.90				
				HBC: N	19/10/90	60.0	75.0	Z	59.00	66.00	62.00	67.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
8	1	HJ	FEMALE	HEC: L	19/10/90	20.0	28.0	X	32.00	29.00	30.00	29.00				
				HEC: E	19/10/90	1.0	4.0	X	2.00	2.00	2.00	2.00				
				HEC: M	19/10/90	1.0	8.0	X	7.00	3.00	5.00	3.00				
				HEC: B	19/10/90	0.0	1.0	X		1.00	1.00	1.00				
				PLATELETS	19/10/90	150.0	300.0	10**9/1	171.00	194.00	192.00	235.00				
				NA+	19/10/90	135.0	146.0	mmol/l	135.00	139.00	144.00	139.00				
				K+	19/10/90	3.8	5.2	mmol/l	3.70	4.00	4.60	4.50				
				CL-	19/10/90	95.0	108.0	mmol/l	108.00	107.00	106.00	103.00				
				CA++	19/10/90	2.1	2.6	mmol/l	2.26	2.43	2.40	2.40				
				PO4--	19/10/90	0.8	1.6	mmol/l	1.20	1.06	1.06	0.98				
				SGPT	19/10/90	7.0	21.0	U/l	9.00	13.00	12.00	10.00				
				GAMMA-GT	19/10/90	4.0	22.0	U/l	9.00	12.00	10.00	8.00				
				ALB	19/10/90	5.0	25.0	U/l	56.00	20.00	24.00	20.00				
				GLUCOSE	19/10/90	2.8	5.6	mmol/l	4.60	4.60	5.20	4.80				
				ALK. PHOSPH.	19/10/90	73.0	207.0	U/l	102.00	201.00	188.00	204.00				
				BUN	19/10/90	2.0	9.0	mmol/l	5.90	6.60	6.40	4.90				
				CREATININE	19/10/90	60.0	100.0	umol/l	71.00	99.00	88.00	82.00				
				URIC ACID	19/10/90	200.0	420.0	umol/l	326.00	276.00	298.00	257.00				
				TOT. BILIRUBIN	19/10/90	2.0	17.0	umol/l	12.00	14.00	14.00	10.00				
				DER. BILIRUBIN	19/10/90	0.0	0.0	0.00	0.00	0.00	0.00	0.00				
				TOT. PROTEINS	19/10/90	60.0	85.0	g/l	66.00	72.00	71.00	71.00				
				ALBUMINE	19/10/90	35.0	48.0	g/l	43.00	46.00	44.00	45.00				
				TOT. CHOLEST.	19/10/90	3.9	6.5	mmol/l	4.97	5.73	4.80	5.80				
				TRIGLYCERIDES	19/10/90	0.8	1.7	mmol/l	1.53	1.17	1.50	0.92				
				GLOBULINS: ALPHA 1	19/10/90	2.4	3.6	X	3.20	2.80	3.00	3.00				
				GLOBULINS: ALPHA 2	19/10/90	6.6	9.8	X	6.80	6.90	7.80	7.40				
				GLOBULINS: BETA	19/10/90	8.1	12.1	X	8.20	9.80	8.80	9.80				
				GLOBULINS: GAMMA	19/10/90	12.6	18.8	X	12.80	14.00	14.00	10.90				
				T3	19/10/90	0.9	1.2	nmol/l	0.90							
				T4	19/10/90	60.0	160.0	nmol/l	100.00							
				2	TE		FEMALE	HEC: L	19/10/90	120.0	150.0	g/l	10/12/90	27/12/90	10/01/91	24/01/91
								HEC: E	19/10/90	0.4	0.5	l/l	137.00	130.00	139.00	143.00
								HEC: M	19/10/90	4.5	5.5	10**12/1	0.42	0.43	0.44	0.44
HEC: B	19/10/90	5.0	10.0					10**9/1	4.38	4.58	4.60	5.20				
PLATELETS	19/10/90	60.0	75.0					X	5.20	5.90	5.40	6.20				
NA+	19/10/90	20.0	28.0					X	66.00	71.00	68.00	68.00				
K+	19/10/90	2.0	2.8					X	28.00	24.00	25.00	28.00				
CL-	19/10/90	1.0	4.0					X	2.00	1.00	1.00	1.00				
CA++	19/10/90	1.0	8.0					X	3.00	3.00	4.00	4.00				
PO4--	19/10/90	0.0	1.0					X	1.00	1.00	1.00	1.00				
SGPT	19/10/90	150.0	300.0					10**9/1	162.00	250.00	140.00	155.00				
GAMMA-GT	19/10/90	135.0	146.0					mmol/l	139.00	157.00	140.00	140.00				
ALB	19/10/90	3.8	5.2					mmol/l	3.80	4.30	4.00	3.90				
CL-	19/10/90	95.0	108.0					mmol/l	103.00	106.00	102.00	102.00				
CA++	19/10/90	2.1	2.6					mmol/l	2.34	2.41	2.30	2.20				
PO4--	19/10/90	0.8	1.6	mmol/l	1.06	1.00	1.10	1.20								
SGPT	19/10/90	7.0	21.0	U/l	13.00	11.00	12.00	12.00								
GAMMA-GT	19/10/90	4.0	22.0	U/l	15.00	15.00	14.00	12.00								
ALB	19/10/90	5.0	25.0	U/l	25.00	23.00	24.00	23.00								

1670

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Date	Laboratory Range			Screen	Visit			
					Min	Max	Unit		Week 2	Week 4	Week 6	
8	2	TE	FEMALE	19/10/90	2.8	5.6	mmol/l	5.20	4.10	5.10	4.80	4.80
			GLUCOSE	19/10/90	73.0	207.0	U/l	125.00	109.00	126.00	170.00	170.00
			ALK. PHOSPH.	19/10/90	2.0	9.0	mmol/l	3.20	4.30	4.00	3.80	3.80
			BUN	19/10/90	60.0	100.0	umol/l	69.00	73.00	66.00	75.00	75.00
			CREATININE	19/10/90	200.0	420.0	umol/l	289.00	218.00	280.00	330.00	330.00
			URIC ACID	19/10/90	2.0	17.0	umol/l	16.00	13.00	15.00	14.00	14.00
			TOT. BILIRUBIN	19/10/90	60.0	85.0	g/l	67.00	79.00	66.00	74.00	74.00
			TOT. PROTEINS	19/10/90	35.0	48.0	g/l	40.00	48.00	39.00	43.00	43.00
			ALBUMINE	19/10/90	3.9	6.5	mmol/l	6.40	6.35	5.80	4.70	4.70
			TOT. CHOLEST.	19/10/90	0.8	1.7	mmol/l	0.96	1.16	1.00	1.20	1.20
			TRIGLYCERIDES	19/10/90	2.4	3.6	z	3.10	3.00	3.20	3.20	3.20
			GLOBULINS: ALPHA 1	19/10/90	6.6	9.8	z	7.20	7.40	7.00	7.40	7.40
			GLOBULINS: ALPHA 2	19/10/90	8.1	12.1	z	9.20	9.60	9.40	9.60	9.60
			GLOBULINS: BETA	19/10/90	12.6	18.8	z	13.00	14.00	13.00	13.60	13.60
			GLOBULINS: GAMMA	19/10/90	0.9	1.2	mmol/l	0.90	1.00	1.00	1.00	1.00
			T3	19/10/90	60.0	160.0	nmol/l	90.00	148.00	151.00	145.00	145.00
			T4	19/10/90	140.0	170.0	g/l	144.00	148.00	151.00	145.00	145.00
3	JL	MALE	HB	19/10/90	0.4	0.5	l/l	0.44	0.46	0.47	0.46	0.46
			HTC	19/10/90	4.5	5.5	10**12/l	5.30	5.48	5.90	5.40	5.40
			RBC	19/10/90	5.0	10.0	10**9/l	5.80	5.50	8.50	5.60	5.60
			HBC: N	19/10/90	60.0	75.0	z	62.00	66.00	62.00	64.00	64.00
			HBC: L	19/10/90	20.0	28.0	z	29.00	28.00	28.00	28.00	28.00
			HBC: E	19/10/90	1.0	4.0	z	2.00	2.00	5.00	1.00	1.00
			HBC: M	19/10/90	1.0	8.0	z	6.00	4.00	2.00	6.00	6.00
			HBC: B	19/10/90	0.0	1.0	z	1.00	0.00	3.00	1.00	1.00
			PLATELETS	19/10/90	150.0	300.0	10**9/l	220.00	189.00	240.00	198.00	198.00
			Na+	19/10/90	135.0	146.0	mmol/l	138.00	142.00	140.00	140.00	140.00
			K+	19/10/90	3.8	5.2	mmol/l	4.80	4.50	4.70	4.60	4.60
			Cl-	19/10/90	95.0	108.0	mmol/l	98.00	103.00	100.00	96.00	96.00
			Ca++	19/10/90	2.1	2.6	mmol/l	2.40	2.31	2.30	2.30	2.30
			FO4+	19/10/90	0.8	1.6	mmol/l	1.20	1.20	1.10	1.10	1.10
			SGPT	19/10/90	10.0	25.0	U/l	21.00	21.00	18.00	20.00	20.00
			SGPT	19/10/90	8.0	29.0	U/l	28.00	18.00	22.00	26.00	26.00
			GAMMA-GT	19/10/90	8.0	38.0	U/l	26.00	36.00	24.00	24.00	24.00
			GLUCOSE	19/10/90	2.8	5.6	mmol/l	4.60	4.50	5.40	4.80	4.80
			ALK. PHOSPH.	19/10/90	73.0	207.0	U/l	137.00	123.00	142.00	140.00	140.00
			BUN	19/10/90	2.0	9.0	mmol/l	6.10	7.50	5.80	5.80	5.80
			CREATININE	19/10/90	60.0	100.0	umol/l	90.00	79.00	86.00	88.00	88.00
			TOT. BILIRUBIN	19/10/90	2.0	420.0	umol/l	346.00	293.00	360.00	360.00	360.00
			DIR BILIRUBIN	19/10/90	0.0	17.0	umol/l	10.00	14.00	13.00	12.00	12.00
			TOT. PROTEINS	19/10/90	0.0	0.0	z	0.00	0.00	0.00	0.00	0.00
			ALBUMINE	19/10/90	60.0	85.0	g/l	72.00	68.00	70.00	70.00	70.00
			TOT. CHOLEST.	19/10/90	35.0	48.0	g/l	44.00	43.00	46.00	42.00	42.00
			TRIGLYCERIDES	19/10/90	3.9	6.5	mmol/l	6.00	5.92	5.80	5.80	5.80
			GLOBULINS: ALPHA 1	19/10/90	0.8	1.7	mmol/l	1.50	1.12	1.40	1.40	1.40
			GLOBULINS: ALPHA 2	19/10/90	2.4	3.6	z	3.00	3.00	3.20	3.20	3.20
			TOT. CHOLEST.	19/10/90	6.6	9.8	z	7.20	7.00	7.10	7.40	7.40
			GLOBULINS: ALPHA 2	19/10/90	6.6	9.8	z	9.80	9.20	9.70	9.80	9.80

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXYTINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
8	3	JL	MALE	GLOBULINS: GAMMA	19/10/90	12.5	18.8	g/l	14.20	13.00	13.80	13.90	
				T3	19/10/90	0.9	1.2	mmol/l	0.90				
				T4	19/10/90	60.0	160.0	nmol/l	80.00				
4	BA	FEMALE	HB	19/10/90	120.0	150.0	g/l	144.00	142.00	145.00	146.00		
			HTC	19/10/90	0.4	0.5	l/l	0.47	0.46	0.48	0.48		
			RBC	19/10/90	4.5	5.5	10**12/l	5.10	5.30	5.30	5.20		
			WBC	19/10/90	5.0	10.0	10**9/l	5.20	5.40	5.60	5.40		
			HBC: N	19/10/90	60.0	75.0	g	66.00	68.00	68.00	65.00		
			HBC: L	19/10/90	20.0	28.0	g	26.00	25.00	24.00	25.00		
			HBC: E	19/10/90	1.0	4.0	g	3.00	2.00	2.00	2.00		
			HBC: H	19/10/90	1.0	8.0	g	7.00	5.00	6.00	6.00		
			HBC: B	19/10/90	0.0	1.0	g	0.00	0.00	0.00	0.00		
			PLATELETS	19/10/90	150.0	300.0	10**9/l	159.00	160.00	164.00	160.00		
			NA+	19/10/90	135.0	146.0	mmol/l	140.00	156.00	142.00	141.00		
			K+	19/10/90	3.8	5.2	mmol/l	5.00	4.80	4.40	4.40		
			CL-	19/10/90	95.0	108.0	mmol/l	100.00	98.00	102.00	98.00		
			CA++	19/10/90	2.1	2.6	mmol/l	2.30	2.20	2.20	2.10		
			PO4--	19/10/90	0.8	1.6	mmol/l	0.90	1.00	1.00	1.00		
			SGPT	19/10/90	7.0	21.0	U/l	12.00	14.00	10.00	10.00		
			GAMMA-GT	19/10/90	4.0	22.0	U/l	14.00	14.00	14.00	10.00		
			GLUCOSE	19/10/90	5.0	25.0	U/l	18.00	20.00	14.00	20.00		
			ALK. PHOSPH.	19/10/90	2.8	5.6	mmol/l	4.80	5.00	4.60	4.60		
			BUN	19/10/90	7.0	20.0	U/l	16.00	16.00	16.00	17.00		
			CREATININE	19/10/90	2.0	9.0	mmol/l	2.90	3.00	3.00	3.20		
			URIC ACID	19/10/90	60.0	420.0	umol/l	89.00	80.00	290.00	78.00		
			TOT. BILIRUBIN	19/10/90	2.0	17.0	umol/l	13.00	14.00	12.00	12.00		
			ALBUMINE	19/10/90	35.0	48.0	g/l	43.00	42.00	42.00	42.00		
			TOT. CHOLEST.	19/10/90	3.9	6.5	mmol/l	5.80	5.60	5.40	5.40		
			TRIGLYCERIDES	19/10/90	0.8	1.7	mmol/l	1.40	1.50	1.30	1.30		
			GLOBULINS: ALPHA 1	19/10/90	2.4	3.6	g	3.10	3.20	3.20	3.20		
GLOBULINS: ALPHA 2	19/10/90	6.6	9.8	g	7.40	7.60	7.40	7.60					
GLOBULINS: BETA	19/10/90	8.1	12.1	g	8.90	9.20	9.20	9.20					
GLOBULINS: GAMMA	19/10/90	12.5	18.8	g	14.20	14.00	13.80	13.80					
T3	19/10/90	0.9	1.2	mmol/l	0.90								
T4	19/10/90	60.0	160.0	nmol/l	88.00								
5	SL	MALE	HB	19/10/90	140.0	170.0	g/l	141.00	144.00	145.00	142.00		
			HTC	19/10/90	0.4	0.5	l/l	0.40	0.42	0.43	0.41		
			RBC	19/10/90	4.5	5.5	10**12/l	5.00	5.30	5.60	5.20		
			WBC	19/10/90	5.0	10.0	10**9/l	6.20	6.10	6.00	6.00		
			HBC: N	19/10/90	60.0	75.0	g	65.00	66.00	65.00	64.00		
			HBC: L	19/10/90	20.0	28.0	g	26.00	25.00	26.00	27.00		
			HBC: E	19/10/90	1.0	4.0	g	3.00	3.00	2.00	3.00		

1672

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBORENTINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit					
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
8	5 SL	MALE	HBC: B	19/10/90	0.0	1.0	%	1.00	1.00	1.00	1.00	0.00
			PLATELETS	19/10/90	150.0	300.0	10**9/1	180.00	190.00	188.00	185.00	188.00
			NA+	19/10/90	135.0	146.0	mmol/l	140.00	141.00	142.00	142.00	142.00
			K+	19/10/90	3.8	5.2	mmol/l	4.00	4.20	4.30	4.30	4.30
			CL-	19/10/90	95.0	108.0	mmol/l	103.00	102.00	101.00	102.00	102.00
			CA++	19/10/90	2.1	2.6	mmol/l	2.30	2.10	2.00	2.10	2.10
			PO4-	19/10/90	0.8	1.6	mmol/l	1.40	1.30	1.40	1.30	1.30
			SGOT	19/10/90	10.0	25.0	U/l	14.00	14.00	14.00	14.00	12.00
			SGPT	19/10/90	8.0	29.0	U/l	16.00	14.00	16.00	14.00	14.00
			GAMMA-GT	19/10/90	8.0	38.0	U/l	18.00	20.00	16.00	14.00	14.00
			GLUCOSE	19/10/90	2.8	5.6	mmol/l	5.20	5.40	4.60	5.00	5.00
			BUN	19/10/90	73.0	207.0	U/l	130.00	136.00	140.00	136.00	136.00
			ALK. PHOSPH.	19/10/90	2.0	9.0	mmol/l	6.00	8.00	6.80	7.00	7.00
			CREATININE	19/10/90	60.0	100.0	umol/l	80.00	80.00	80.00	76.00	76.00
			URIC ACID	19/10/90	200.0	420.0	umol/l	300.00	340.00	300.00	288.00	288.00
			TOT BILIRUBIN	19/10/90	2.0	17.0	umol/l	15.00	14.00	10.00	14.00	14.00
			DIR BILIRUBIN	19/10/90	0.0	0.0		0.00	0.00	0.00	0.00	0.00
			TOT. PROTEINS	19/10/90	60.0	85.0	g/l	70.00	66.00	66.00	66.00	66.00
			ALBUMINE	19/10/90	35.0	48.0	g/l	40.00	42.00	42.00	41.00	41.00
			TOT. CHOLEST.	19/10/90	3.9	6.5	mmol/l	5.00	5.10	4.90	5.10	5.10
			TRIGLYCERIDES	19/10/90	0.8	1.7	mmol/l	1.10	1.20	1.10	1.10	1.20
			GLOBULINS: ALPHA 1	19/10/90	2.4	3.6	%	3.00	3.20	3.30	4.00	4.00
			GLOBULINS: ALPHA 2	19/10/90	6.6	9.8	%	7.00	7.10	7.00	7.20	7.20
			GLOBULINS: BETA	19/10/90	8.1	12.1	%	10.00	10.00	10.00	10.60	10.60
			GLOBULINS: GAMMA	19/10/90	12.6	18.8	%	14.00	13.80	14.00	13.80	13.80
			T3	19/10/90	0.9	1.2	mmol/l	1.00	1.00	1.00	1.00	1.00
			T4	19/10/90	60.0	160.0	mmol/l	120.00	120.00	120.00	120.00	120.00
6	TL	FEMALE	HB	19/10/90	120.0	150.0	g/l	125.00	130.00	130.00	130.00	130.00
			HTC	19/10/90	0.4	0.5	l/l	0.38	0.40	0.40	0.40	0.40
			RBC	19/10/90	4.5	5.5	10**12/l	4.80	5.00	4.90	4.90	4.90
			HBC: N	19/10/90	5.0	10.0	10**9/l	7.00	6.80	6.20	6.80	6.80
			HBC: L	19/10/90	60.0	75.0	%	62.00	64.00	64.00	64.00	64.00
			HBC: E	19/10/90	20.0	28.0	%	26.00	27.00	27.00	26.00	26.00
			HBC: M	19/10/90	1.0	4.0	%	4.00	3.00	3.00	2.00	2.00
			HBC: B	19/10/90	1.0	8.0	%	7.00	6.00	5.00	6.00	6.00
			PLATELETS	19/10/90	0.0	1.0	%	1.00	1.00	1.00	2.00	2.00
			NA+	19/10/90	150.0	300.0	10**9/l	176.00	180.00	178.00	180.00	180.00
			K+	19/10/90	135.0	146.0	mmol/l	141.00	142.00	142.00	144.00	144.00
			CL-	19/10/90	3.8	5.2	mmol/l	4.30	3.00	4.40	4.40	4.40
			CA++	19/10/90	95.0	108.0	mmol/l	107.00	106.00	106.00	106.00	106.00
			PO4-	19/10/90	2.1	2.6	mmol/l	2.40	2.30	2.30	2.30	2.30
			SGOT	19/10/90	0.8	1.6	mmol/l	1.30	1.20	1.20	1.20	1.20
			SGPT	19/10/90	7.0	21.0	U/l	8.00	8.00	8.00	8.00	8.00
			GAMMA-GT	19/10/90	4.0	22.0	U/l	4.00	6.00	6.00	6.00	6.00
			GLUCOSE	19/10/90	5.0	25.0	U/l	12.00	10.00	10.00	14.00	14.00
			ALK. PHOSPH.	19/10/90	2.8	5.6	mmol/l	5.30	4.80	5.20	4.80	4.80
			BUN	19/10/90	73.0	207.0	U/l	85.00	90.00	90.00	90.00	90.00
				19/10/90	2.0	9.0	mmol/l	7.30	5.40	6.80	7.10	7.10
				04/02/91				15/01/91	04/02/91	18/02/91	04/03/91	

1673

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Screen	Visit						
					Date	Min	Max		Unit	Week 2	Week 4	Week 6			
8	6	TL	FEMALE	CREATININE	19/10/90	60.0	100.0	umol/l	57.00	60.00	55.00	58.00			
				URIC ACID	19/10/90	200.0	420.0	umol/l	284.00	290.00	262.00	265.00			
				TOT BILIRUBIN	19/10/90	2.0	17.0	umol/l	11.00	10.00	10.00	10.00			
				DIR BILIRUBIN	19/10/90	0.0	0.0	umol/l	0.00	0.00	0.00	0.00			
				TOT. PROTEINS	19/10/90	60.0	85.0	g/l	76.00	76.00	78.00	76.00			
				ALBUMINE	19/10/90	35.0	48.0	g/l	46.00	45.00	48.00	44.00			
				TOT. CHOLEST.	19/10/90	3.9	6.5	mmol/l	6.20	6.10	5.80	6.00			
				TRIGLYCERIDES	19/10/90	0.8	1.7	mmol/l	1.40	1.30	1.30	1.20			
				GLOBULINS: ALPHA 1	19/10/90	2.4	3.6	%	3.00	2.90	3.20	3.20			
				GLOBULINS: ALPHA 2	19/10/90	6.6	9.8	%	8.10	8.20	8.00	8.30			
				GLOBULINS: BETA	19/10/90	8.1	12.1	%	9.10	9.20	8.00	8.30			
				GLOBULINS: GAMMA	19/10/90	12.6	18.8	%	14.00	13.80	9.40	9.50			
				T3	19/10/90	0.9	1.2	nmol/l	14.00	13.80	14.20	14.30			
				T4	19/10/90	60.0	160.0	nmol/l	105.00						
				7	SZT	FEMALE	HB	19/10/90	120.0	150.0	g/l	15/03/91	04/06/91		
							HTC	19/10/90	0.4	0.5	l/l	141.00	131.00		
							RBC	19/10/90	4.5	5.5	10**12/l	4.90	0.59		
							RBC: N	19/10/90	5.0	10.0	10**9/l	5.40	5.74		
							RBC: L	19/10/90	60.0	75.0	%	70.00	57.00		
							RBC: E	19/10/90	20.0	28.0	%	26.00	33.00		
RBC: M	19/10/90	1.0	4.0				%	1.00	1.00						
RBC: B	19/10/90	1.0	8.0				%	3.00	8.00						
PLATELETS	19/10/90	0.0	1.0				%	1.00	1.00						
NA+	19/10/90	150.0	300.0				10**9/l	190.00	147.00						
K+	19/10/90	135.0	146.0				mmol/l	140.00	141.00						
CL-	19/10/90	3.8	5.2				mmol/l	4.40	4.30						
PO4-	19/10/90	95.0	108.0				mmol/l	102.00	105.00						
SGPT	19/10/90	2.1	2.6				mmol/l	2.30	2.50						
GAMMA-GT	19/10/90	0.8	1.6				mmol/l	1.40	1.40						
GLUCOSE	19/10/90	7.0	21.0				U/l	10.00	13.00						
ALK. PHOSPH.	19/10/90	4.0	22.0				U/l	12.00	10.00						
BUN	19/10/90	5.0	25.0				U/l	14.00	11.00						
CREATININE	19/10/90	2.8	5.6				mmol/l	4.80	4.20						
URIC ACID	19/10/90	73.0	207.0				U/l	110.00	79.00						
TOT. BILIRUBIN	19/10/90	2.0	9.0	umol/l	4.60	7.50									
DIR BILIRUBIN	19/10/90	60.0	100.0	umol/l	80.00	55.00									
TOT. PROTEINS	19/10/90	200.0	420.0	umol/l	280.00	179.00									
ALBUMINE	19/10/90	2.0	17.0	umol/l	8.00	8.00									
TOT. CHOLEST.	19/10/90	0.0	0.0	umol/l	0.00	0.80									
TRIGLYCERIDES	19/10/90	60.0	85.0	g/l	70.00	75.80									
GLOBULINS: ALPHA 1	19/10/90	35.0	48.0	g/l	40.00	47.80									
GLOBULINS: ALPHA 2	19/10/90	3.9	6.5	mmol/l	5.00	6.50									
GLOBULINS: BETA	19/10/90	0.8	1.7	mmol/l	1.00	1.40									
GLOBULINS: GAMMA	19/10/90	2.4	3.6	%	3.00	3.00									
T3	19/10/90	6.6	9.8	%	8.00	8.00									
T4	19/10/90	8.1	12.1	%	10.10	14.60									
T3	19/10/90	12.6	18.8	%	14.60	0.96									

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXYTINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit							
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6			
8	7	SZT	FEMALE	T4	19/10/90	60.0	160.0	nmol/l	110.00					
9	1	US	FEMALE	HB	20/05/90	4.0	10.0	mmol/l	21/05/90	11/06/90	25/06/90	09/07/90		
				HTC	20/05/90	36.0	53.0	Z	8.00	9.10	8.90	9.00		
				RBC	20/05/90	4.0	5.8	10**6/uL	41.00	40.00	40.00	41.00		
				MBC	20/05/90	4.0	12.0	10**3/uL	4.40	4.20	4.20	4.40		
				MBC: N	20/05/90	60.0	80.0	Z	8.00	8.00	7.00	6.80		
				MBC: L	20/05/90	15.0	40.0	Z	80.00	80.00	79.00	80.00		
				MBC: E	20/05/90	0.0	5.0	Z	15.00	15.00	17.00	18.00		
				MBC: M	20/05/90	1.0	6.0	Z	2.00	2.00	2.00	1.00		
				MBC: B	20/05/90	0.0	1.0	Z	1.00	1.00	1.00	0.00		
				PLATELETS	20/05/90	120.0	640.0	10**9/l	159.00	145.00	156.00	162.00		
				NA+	20/05/90	138.0	158.0	mmol/l	139.00	141.00	139.00	140.00		
				K+	20/05/90	3.6	5.0	mmol/l	4.00	4.00	4.10	3.90		
				CL-	20/05/90	90.0	110.0	mmol/l	98.00	101.00	102.00	99.00		
				CA++	20/05/90	1.8	2.6	mmol/l	2.20	2.00	2.20	2.00		
				PO4-	20/05/90	0.9	1.6	mmol/l	1.10	1.00	1.00	1.20		
				SGOT	20/05/90	4.0	25.0	U/l	11.00	10.00	12.00	10.00		
				SGPT	20/05/90	4.0	27.0	U/l	9.00	10.00	10.00	10.00		
				GAMMA-GT	20/05/90	4.0	28.0	U/l	12.00	28.00	28.00	29.00		
				GLUCOSE	20/05/90	3.6	5.7	mmol/l	5.00	3.90	4.20	4.00		
				ALK. PHOSPH.	20/05/90	20.0	55.0	mmol/l	21.00	49.00	45.00	48.00		
BUN	20/05/90	2.0	10.0	mmol/l	5.00	6.00	7.20	5.20						
CREATININE	20/05/90	45.0	105.0	umol/l	81.00	78.00	80.00	75.00						
TOT BILIRUBIN	20/05/90	100.0	400.0	umol/l	150.00	160.00	160.00	162.00						
URIC ACID	20/05/90	2.0	20.0	umol/l	8.00	12.00	10.00	8.00						
DIR BILIRUBIN	20/05/90	0.0	5.0	umol/l	0.00	0.00	0.00	0.00						
TOT. PROTEINS	20/05/90	66.0	97.0	g/l	79.00	76.00	72.00	70.00						
ALBUMINE	20/05/90	32.0	55.0	g/l	46.00	62.00	59.00	58.00						
TOT. CHOLEST.	20/05/90	3.0	8.7	mmol/l	6.10	5.10	5.10	5.00						
TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/l	1.10	1.20	1.10	1.20						
GLOBULINS: ALPHA 1	20/05/90	2.5	4.0	Z	2.50	4.00	4.00	3.00						
GLOBULINS: ALPHA 2	20/05/90	7.0	10.0	Z	7.40	8.00	9.00	8.00						
GLOBULINS: BETA	20/05/90	8.3	14.5	Z	10.10	10.00	10.00	9.00						
GLOBULINS: GAMMA	20/05/90	14.0	25.0	Z	16.20	16.00	18.00	18.00						
T3	20/05/90	2.0	5.0	nmol/l	1.40									
T4	20/05/90	100.0	300.0	nmol/l	69.00									
2	VCF	FEMALE	HB	20/05/90	4.0	10.0	mmol/l	21/05/90	11/06/90	25/06/90	09/07/90			
			HTC	20/05/90	36.0	53.0	Z	42.00	40.00	41.00	42.00			
			RBC	20/05/90	4.0	5.8	10**6/uL	5.10	4.30	4.30	4.40			
			MBC	20/05/90	4.0	12.0	10**3/uL	6.20	7.00	7.00	7.10			
			MBC: N	20/05/90	60.0	80.0	Z		80.00	80.00	79.00			
			MBC: L	20/05/90	15.0	40.0	Z		16.00	16.00	18.00			
			MBC: E	20/05/90	0.0	5.0	Z		1.00	1.00	1.00			
MBC: M	20/05/90	1.0	6.0	Z		1.00	1.00	1.00						

1675

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOREXINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
9	2	VCF	FEMALE	PLATELETS	20/05/90	120.0	640.0	10**9/1	264.00	160.00	150.00	159.00	
				NA+	20/05/90	138.0	158.0	mmol/l	172.00	138.00	140.00	138.00	
				K+	20/05/90	3.6	5.0	mmol/l	3.90	4.20	4.00	3.80	
				CL-	20/05/90	90.0	110.0	mmol/l	88.00	102.00	101.00	101.00	
				CA++	20/05/90	1.8	2.6	mmol/l	2.30	2.20	2.00	2.00	
				PO4--	20/05/90	0.9	1.6	mmol/l	1.00	1.40	1.00	1.30	
				SCPT	20/05/90	4.0	25.0	U/l	16.00	10.00	10.00	10.00	
				GAMMA-GT	20/05/90	4.0	27.0	U/l	12.00	10.00	11.00	12.00	
				GLUCOSE	20/05/90	4.0	28.0	U/l	14.00	21.00	28.00	22.00	
				ALK. PHOSPH.	20/05/90	3.6	5.7	mmol/l	3.90	3.90	4.40	4.10	
				BUN	20/05/90	2.0	10.0	mmol/l	34.00	5.00	4.00	6.00	
				CREATININE	20/05/90	45.0	105.0	mmol/l	80.00	5.00	4.00	6.00	
				URIC ACID	20/05/90	100.0	400.0	mmol/l	250.00	160.00	152.00	102.00	
				TOT. BILIRUBIN	20/05/90	2.0	20.0	mmol/l	12.00	0.00	8.00	8.00	
				DIR. BILIRUBIN	20/05/90	0.0	5.0	mmol/l	4.00	0.00	0.00	0.00	
				TOT. PROTEINS	20/05/90	66.0	97.0	g/l	81.00	72.00	70.00	72.00	
				ALBUMINE	20/05/90	32.0	55.0	g/l	47.00	61.00	58.00	61.00	
				TOT. CHOLEST.	20/05/90	3.0	8.7	mmol/l	5.60	5.00	4.90	5.10	
				TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/l	1.20	1.00	1.00	1.00	
				GLOBULINS: ALPHA 1	20/05/90	2.5	4.0	%	2.90	3.00	4.00	4.00	
				GLOBULINS: ALPHA 2	20/05/90	7.0	10.0	%	8.20	9.00	10.00	8.00	
				GLOBULINS: BETA	20/05/90	8.3	14.5	%	9.10	10.00	10.00	8.00	
				GLOBULINS: GAMMA	20/05/90	14.0	25.0	%	15.20	17.00	19.00	19.00	
T3	20/05/90	2.0	5.0	mmol/l	1.20	.	.	.					
T4	20/05/90	100.0	300.0	mmol/l	68.00	.	.	.					
9	3	SF	FEMALE	HB	20/05/90	4.0	10.0	mmol/l	07/08/90	28/08/90	11/09/90	25/09/90	
				HTC	20/05/90	36.0	53.0	%	7.20	8.50	8.90	8.90	
				RBC	20/05/90	4.0	5.8	10**6/u1	40.00	39.00	40.00	41.00	
				WBC	20/05/90	4.0	12.0	10**3/u1	4.90	4.00	4.60	4.00	
				HBC: N	20/05/90	60.0	80.0	%	8.60	6.10	7.80	5.90	
				HBC: L	20/05/90	15.0	40.0	%	.	78.00	78.00	80.00	
				HBC: E	20/05/90	0.0	6.0	%	.	18.00	18.00	15.00	
				HRC: M	20/05/90	1.0	5.0	%	.	1.00	1.00	1.00	
				HRC: B	20/05/90	0.0	1.0	%	.	1.00	1.00	2.00	
				PLATELETS	20/05/90	120.0	660.0	10**9/1	216.00	167.00	160.00	169.00	
				NA+	20/05/90	138.0	158.0	mmol/l	139.00	139.00	139.00	141.00	
				CL-	20/05/90	90.0	110.0	mmol/l	99.00	104.00	101.00	105.00	
				CA++	20/05/90	1.8	2.6	mmol/l	2.30	2.10	2.10	2.30	
				PO4--	20/05/90	0.9	1.6	mmol/l	1.20	1.00	1.00	1.40	
				SCPT	20/05/90	4.0	25.0	U/l	16.00	10.00	10.00	10.00	
				GAMMA-GT	20/05/90	4.0	28.0	U/l	12.00	10.00	10.00	10.00	
				GLUCOSE	20/05/90	3.6	5.7	mmol/l	5.40	4.00	3.90	3.90	
ALK. PHOSPH.	20/05/90	20.0	55.0	mmol/l	29.00	46.00	40.00	46.00					
BUN	20/05/90	2.0	10.0	mmol/l	6.00	6.10	4.00	5.00					
CREATININE	20/05/90	45.0	105.0	mmol/l	29.00	28.00	28.00	28.00					

1676

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
9	3	SF	FEMALE	URIC ACID	20/05/90	100.0	400.0	umol/l	210.00	170.00	190.00	150.00				
				TOT BILIRUBIN	20/05/90	2.0	20.0	umol/l	14.00	10.00	11.00	15.00				
				DIR BILIRUBIN	20/05/90	0.0	5.0	umol/l	0.00	0.00	0.00	0.00				
				TOT. PROTEINS	20/05/90	66.0	97.0	g/l	76.00	72.00	70.00	76.00				
				ALBUMINE	20/05/90	32.0	55.0	g/l	42.00	42.00	60.00	59.00				
				TOT. CHOLEST.	20/05/90	3.0	8.7	mmol/l	6.20	4.10	5.10	5.10				
				TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/l	1.40	1.00	1.00	1.00				
				GLOBULINS: ALPHA 1	20/05/90	2.5	4.0	g	3.00	3.00	4.00	4.00				
				GLOBULINS: ALPHA 2	20/05/90	7.0	10.0	g	7.60	8.00	8.00	10.00				
				GLOBULINS: BETA	20/05/90	8.3	14.5	g	8.90	9.00	10.00	10.00				
				GLOBULINS: GAMMA	20/05/90	14.0	25.0	g	19.10	14.00	18.00	17.00				
				T3	20/05/90	2.0	5.0	nmol/l	1.90							
				T4	20/05/90	100.0	300.0	nmol/l	86.00							
				4	SA	FEMALE	HR	20/05/90	4.0	10.0	mmol/l	24/08/90	8.60	14/09/90	28/09/90	12/10/90
							RFC	20/05/90	36.0	55.0	g	42.00	41.00	40.00	40.00	
							RBC	20/05/90	4.0	5.8	10**6/uL	4.50	4.50	4.10	4.50	
							RBC: N	20/05/90	60.0	12.0	10**3/uL	5.40	6.70	6.50	6.10	
							RBC: L	20/05/90	15.0	40.0	g		17.00	12.00	15.00	
							RBC: E	20/05/90	0.0	5.0	g		0.00	1.00	2.00	
							RBC: M	20/05/90	1.0	6.0	g		1.00	1.00	2.00	
RBC: B	20/05/90	0.0	1.0				g		0.00	1.00	1.00					
PLATELETS	20/05/90	120.0	640.0				10**9/l	252.00	156.00	168.00	160.00					
NA+	20/05/90	138.0	158.0				mmol/l	141.00	139.00	140.00	140.00					
K+	20/05/90	3.6	5.0				mmol/l	4.10	4.00	4.20	3.90					
CL-	20/05/90	90.0	110.0				mmol/l	101.00	107.00	108.00	108.00					
CA++	20/05/90	1.8	2.6				mmol/l	2.10	2.10	2.10	2.40					
PO4--	20/05/90	0.9	1.6				mmol/l	1.30	1.50	1.30	0.90					
SGPT	20/05/90	4.0	25.0				U/l	8.00	10.00	10.00	12.00					
GAMMA-GT	20/05/90	4.0	27.0				U/l	10.00	8.00	8.00	10.00					
GLUCOSE	20/05/90	4.0	28.0				U/l	11.00	30.00	31.00	28.00					
ALK. PHOSPH.	20/05/90	3.6	5.7				mmol/l	4.30	4.00	4.60	4.90					
BUN	20/05/90	2.0	5.0				mmol/l	23.00	45.00	46.00	41.00					
CREATININE	20/05/90	45.0	105.0				umol/l	75.00	86.00	85.00	104.00					
URIC ACID	20/05/90	100.0	400.0	umol/l	86.00	130.00	135.00	180.00								
TOT BILIRUBIN	20/05/90	2.0	20.0	umol/l	12.00	8.00	12.00	10.00								
DIR BILIRUBIN	20/05/90	0.0	5.0	umol/l	0.00	0.00	0.00	0.00								
TOT. PROTEINS	20/05/90	66.0	97.0	g/l	76.00	75.00	62.00	69.00								
ALBUMINE	20/05/90	32.0	55.0	g/l	48.00	60.00	65.00	70.00								
TOT. CHOLEST.	20/05/90	3.0	8.7	mmol/l	5.60	5.00	4.00	4.60								
TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/l	1.30	1.60	1.60	1.00								
GLOBULINS: ALPHA 1	20/05/90	2.5	4.0	g	2.10	3.00	3.00	2.50								
GLOBULINS: ALPHA 2	20/05/90	7.0	10.0	g	8.00	8.00	8.00	7.90								
GLOBULINS: BETA	20/05/90	8.3	14.5	g	10.10	9.00	9.00	8.90								
GLOBULINS: GAMMA	20/05/90	14.0	25.0	g	15.20	19.00	15.00	13.80								
T3	20/05/90	2.0	5.0	nmol/l	1.30											
T4	20/05/90	100.0	300.0	nmol/l	63.00											

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit				
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6
9	5 MF	FEMALE	HB	20/05/90	4.0	10.0	mmol/l	15/09/90	06/10/90	20/10/90	03/11/90
			HTC	20/05/90	36.0	53.0	g/l	8.10	9.40	8.20	8.50
			RBC	20/05/90	4.0	5.8	10**6/u1	42.00	40.00	41.00	43.00
			WBC	20/05/90	4.0	12.0	10**3/u1	4.90	5.10	4.50	4.80
			PLATELETS	20/05/90	60.0	80.0	z	8.60	7.30	4.60	5.00
			HAEMOGLOBIN	20/05/90	15.0	40.0	g/l	75.00	61.00	61.00	47.00
			HAEMATOCRIT	20/05/90	0.0	5.0	z	18.00	33.00	33.00	48.00
			HAEMATOCENTRIFUGATION	20/05/90	1.0	6.0	z	1.00	2.00	2.00	1.00
			HAEMATOCENTRIFUGATION	20/05/90	0.0	1.0	z	5.00	4.00	4.00	0.00
			HAEMATOCENTRIFUGATION	20/05/90	0.0	1.0	z	2.00	2.00	0.00	0.00
			PLATELETS	20/05/90	120.0	640.0	10**9/l	291.00	145.00	297.00	323.00
			PLATELETS	20/05/90	138.0	158.0	mmol/l	147.00	140.00	147.00	148.00
			PLATELETS	20/05/90	3.6	5.0	mmol/l	4.20	3.90	2.97.00	148.00
			PLATELETS	20/05/90	90.0	110.0	mmol/l	102.00	109.00	147.00	148.00
			PLATELETS	20/05/90	1.8	2.6	mmol/l	2.50	2.50	2.30	2.60
			PLATELETS	20/05/90	0.9	1.6	mmol/l	1.20	1.50	1.20	1.60
			PLATELETS	20/05/90	4.0	25.0	U/l	8.00	10.00	8.00	8.00
			PLATELETS	20/05/90	4.0	27.0	U/l	12.00	12.00	7.00	10.00
			PLATELETS	20/05/90	4.0	28.0	U/l	10.00	30.00	11.00	10.00
			PLATELETS	20/05/90	3.6	5.7	mmol/l	4.70	4.30	3.90	4.60
			PLATELETS	20/05/90	20.0	55.0	mmol/l	38.00	34.50	41.00	35.00
			PLATELETS	20/05/90	2.0	10.0	mmol/l	6.00	5.10	4.00	5.00
			PLATELETS	20/05/90	45.0	105.0	umol/l	56.00	70.00	80.00	85.00
			PLATELETS	20/05/90	100.0	400.0	umol/l	220.00	125.00	253.00	149.00
			PLATELETS	20/05/90	2.0	20.0	umol/l	16.00	10.00	14.00	13.00
			PLATELETS	20/05/90	66.0	97.0	g/l	0.00	0.00	0.00	0.00
			PLATELETS	20/05/90	32.0	55.0	g/l	78.00	75.00	96.00	73.00
PLATELETS	20/05/90	3.0	8.7	mmol/l	44.00	60.00	56.00	51.10			
PLATELETS	20/05/90	0.3	1.8	mmol/l	4.90	5.10	6.70	6.70			
PLATELETS	20/05/90	2.5	4.0	z	1.20	1.30	1.20	1.40			
PLATELETS	20/05/90	7.0	10.0	z	2.70	3.00	3.70	3.10			
PLATELETS	20/05/90	8.3	14.5	z	10.10	8.00	10.80	9.90			
PLATELETS	20/05/90	14.0	25.0	z	18.50	19.40	18.50	18.50			
PLATELETS	20/05/90	2.0	5.0	mmol/l	1.30	20.00	20.20	17.40			
PLATELETS	20/05/90	100.0	300.0	mmol/l	69.00	382.00	407.00	429.00			
6	SD	FEMALE	HB	20/05/90	4.0	10.0	mmol/l	30/10/90	20/11/90	04/12/90	18/12/90
			HTC	20/05/90	36.0	53.0	g/l	8.60	7.30	7.50	12.40
			RBC	20/05/90	4.0	5.8	10**6/u1	43.00	37.00	37.00	39.00
			WBC	20/05/90	4.0	12.0	10**3/u1	4.72	4.10	4.10	4.20
			PLATELETS	20/05/90	60.0	80.0	z	59.00	6.50	6.90	5.70
			HAEMOGLOBIN	20/05/90	15.0	40.0	g/l	37.00	37.00	37.00	37.00
			HAEMATOCRIT	20/05/90	0.0	5.0	z	1.00	1.00	1.00	1.00
			HAEMATOCENTRIFUGATION	20/05/90	1.0	6.0	z	3.00	3.00	3.00	3.00
			HAEMATOCENTRIFUGATION	20/05/90	0.0	1.0	z	0.00	0.00	0.00	0.00
			PLATELETS	20/05/90	120.0	640.0	10**9/l	381.00	382.00	407.00	429.00

1678

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOMETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit					
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
9	6 SD	FEMALE	NA+	20/05/90	138.0	158.0	mmol/l	149.00	147.00	147.00	145.00	
			K+	20/05/90	3.6	5.0	mmol/l	4.70	4.50	4.50	5.00	
			CA++	20/05/90	1.8	2.6	mmol/l	2.30	2.20	2.20	2.10	
			PO4--	20/05/90	0.9	1.6	mmol/l	1.50	1.30	1.30	1.30	
			SGOT	20/05/90	4.0	25.0	U/l	7.00	7.00	6.00	8.00	
			SGPT	20/05/90	4.0	27.0	U/l	10.00	10.00	8.00	10.00	
			GAMMA-GT	20/05/90	4.0	28.0	U/l	12.00	7.00	4.00	9.00	
			GLUCOSE	20/05/90	3.6	5.7	mmol/l	5.00	5.40	4.40	4.70	
			ALK. PHOSPH.	20/05/90	20.0	55.0	mmol/l	43.00	34.00	22.00	36.00	
			BUN	20/05/90	2.0	10.0	mmol/l	5.00	7.00	10.00	9.00	
			CREATININE	20/05/90	45.0	105.0	umol/l	80.00	60.00	60.00	60.00	
			URIC ACID	20/05/90	100.0	400.0	umol/l	183.00	334.00	259.00	270.00	
			TOT. BILIRUBIN	20/05/90	2.0	20.0	umol/l	7.00	11.00	13.00	8.00	
			DIR. BILIRUBIN	20/05/90	0.0	5.0	umol/l	0.00	0.00	0.00	0.00	
			TOT. PROTEINS	20/05/90	66.0	97.0	g/l	86.00	75.00	76.00	79.00	
			ALBUMINE	20/05/90	32.0	55.0	g/l	44.00	48.00	39.00	38.00	
			TOT. CHOLEST.	20/05/90	3.0	8.7	mmol/l	9.60	9.00	8.30	5.60	
			TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/l	2.50	1.70	1.30	0.80	
			GLOBULINS: ALPHA 1	20/05/90	2.5	4.0	%	3.10	2.80	2.90	2.70	
			GLOBULINS: ALPHA 2	20/05/90	7.0	10.0	%	8.30	12.80	13.10	11.30	
			GLOBULINS: BETA	20/05/90	8.3	14.5	%	11.00	16.80	18.90	17.50	
			GLOBULINS: GAMMA	20/05/90	14.0	25.0	%	18.00	15.60	18.30	15.70	
			T3	20/05/90	2.0	5.0	nmol/l	1.40				
			T4	20/05/90	100.0	300.0	nmol/l	60.00				
7	PP	MALE	HB	20/05/90	4.0	10.5	mmol/l	10.20	08/11/90	22/11/90	06/12/90	20/12/90
			HTC	20/05/90	38.0	53.0	%	50.00	48.00	48.00	50.00	47.00
			RBC	20/05/90	4.0	6.0	10**6/u1	5.68	5.50	5.50	5.60	5.40
			MBC	20/05/90	4.0	12.0	10**3/u1	7.90	6.80	6.80	6.30	5.70
			MBC: N	20/05/90	60.0	80.0	%		66.00	66.00	63.00	63.00
			MBC: L	20/05/90	15.0	40.0	%		28.00	28.00	35.00	35.00
			MBC: E	20/05/90	0.0	5.0	%		2.00	2.00	0.00	0.00
			MBC: N	20/05/90	1.0	6.0	%		4.00	4.00	2.00	2.00
			MBC: B	20/05/90	0.0	1.0	%		0.00	0.00	0.00	0.00
			PLATELETS	20/05/90	120.0	660.0	10**9/l	275.00	242.00	242.00	260.00	260.00
			NA+	20/05/90	138.0	158.0	mmol/l	146.00	146.00	146.00	149.00	149.00
			K+	20/05/90	3.6	5.0	mmol/l	3.80	4.30	4.30	4.40	4.40
			CA++	20/05/90	1.8	2.6	mmol/l	2.10	2.00	2.00	2.10	2.10
			PO4--	20/05/90	0.9	1.6	mmol/l	0.90	0.90	1.00	0.90	0.90
			SGOT	20/05/90	7.0	28.0	U/l	8.00	8.00	7.00	7.00	7.00
			SGPT	20/05/90	6.0	28.0	U/l	15.00	10.00	10.00	8.00	8.00
			GAMMA-GT	20/05/90	6.0	28.0	U/l	15.00	9.00	12.00	5.00	5.00
			GLUCOSE	20/05/90	3.6	5.7	mmol/l	4.60	4.50	4.50	4.80	4.80
			ALK. PHOSPH.	20/05/90	20.0	55.0	mmol/l	22.00	25.00	24.00	36.00	36.00
			BUN	20/05/90	2.0	9.0	mmol/l	4.00	4.00	4.00	5.00	5.00
			CREATININE	20/05/90	55.0	105.0	umol/l	60.00	90.00	90.00	95.00	95.00
			URIC ACID	20/05/90	100.0	420.0	umol/l	264.00	305.00	280.00	280.00	280.00
			TOT BILIRUBIN	20/05/90	2.0	20.0	umol/l	19.00	11.00	11.00	11.00	11.00
			DIR BILIRUBIN	20/05/90	0.0	5.0	umol/l	0.00	0.00	0.00	0.00	0.00

1679

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit							
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6			
9	7 PP	MALE	TOT. PROTEINS	20/05/90	66.0	97.0	g/l	94.00	85.00	81.00	85.00			
			ALBUMINE	20/05/90	32.0	55.0	g/l	46.00	55.00	48.00	43.00			
			TOT. CHOLEST.	20/05/90	0.3	8.7	mmol/l	6.10	6.60	6.40	6.00			
			TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/l	0.90	0.50	1.80	0.50			
			GLOBULINS: ALPHA 1	20/05/90	2.5	4.0	g	3.10	2.60	1.70	2.60			
			GLOBULINS: ALPHA 2	20/05/90	7.0	10.0	g	9.50	7.80	5.10	5.50			
			GLOBULINS: BETA	20/05/90	8.3	14.5	g	12.60	12.90	12.00	15.90			
			GLOBULINS: GAMMA	20/05/90	14.0	25.0	g	27.80	18.80	19.00	26.00			
			T3	20/05/90	1.2	4.5	nmol/l	2.00						
			T4	20/05/90	50.0	200.0	nmol/l	101.00						
			8	KTM	FEMALE	HTC	20/05/90	4.0	10.0	mmol/l	19/11/90	06/12/90	18/12/90	02/01/91
						RBC	20/05/90	36.0	53.0	x	8.60	8.60	15.20	15.50
						WBC	20/05/90	4.0	5.8	10**6/ml	43.00	44.00	45.00	46.00
						WBC: N	20/05/90	4.0	12.0	10**3/ml	4.40	4.60	4.80	4.90
WBC: L	20/05/90	60.0				80.0	x	9.40	4.50	5.90	5.50			
WBC: E	20/05/90	15.0				40.0	x	22.00						
WBC: M	20/05/90	0.0				5.0	x	1.00						
WBC: B	20/05/90	1.0				6.0	x	4.00						
PLATELETS	20/05/90	0.0				1.0	x	0.00	300.00	379.00	516.00			
NA+	20/05/90	120.0				640.0	10**9/l	403.00	145.00	146.00	141.00			
K+	20/05/90	3.6				5.0	mmol/l	4.60	5.00	4.80	4.00			
PO4-	20/05/90	0.9				1.6	mmol/l	2.00	2.30	2.20	2.20			
SGOT	20/05/90	4.0				25.0	U/l	1.10	1.20	1.00	1.00			
SGPT	20/05/90	4.0				27.0	U/l	17.00	6.00	13.00	16.00			
GAMMA-GT	20/05/90	4.0	28.0	U/l	25.00	46.00	42.00	62.00						
GLUCOSE	20/05/90	3.6	5.7	mmol/l	4.30	4.70	4.30	4.30						
ALK. PHOSPH.	20/05/90	20.0	55.0	mmol/l	43.00	31.00	32.00	34.00						
BUN	20/05/90	2.0	10.0	mmol/l	4.00	3.00	4.00	5.00						
CREATININE	20/05/90	45.0	105.0	umol/l	70.00	70.00	82.00	70.00						
URIC ACID	20/05/90	100.0	400.0	umol/l	192.00	182.00	247.00	300.00						
TOT. BILIRUBIN	20/05/90	2.0	20.0	umol/l	15.00	16.00	13.00	21.00						
DIR BILIRUBIN	20/05/90	0.0	5.0	umol/l	0.00	0.00	0.00	0.00						
TOT. PROTEINS	20/05/90	66.0	97.0	g/l	98.00	83.00	80.00	79.00						
ALBUMINE	20/05/90	32.0	55.0	g/l	51.00	47.00	42.00	53.00						
TOT. CHOLEST.	20/05/90	3.0	8.7	mmol/l	7.20	5.80	6.60	5.90						
TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/l	1.50	2.00	2.10	1.20						
GLOBULINS: ALPHA 1	20/05/90	2.5	4.0	g	3.10	3.00	2.10	2.80						
GLOBULINS: ALPHA 2	20/05/90	7.0	10.0	g	10.50	8.00	10.30	9.40						
GLOBULINS: BETA	20/05/90	8.3	14.5	g	16.80	8.40	14.70	18.90						
GLOBULINS: GAMMA	20/05/90	14.0	25.0	g	20.00	15.00	21.50	19.90						
T3	20/05/90	2.0	5.0	nmol/l	2.10									
T4	20/05/90	100.0	300.0	nmol/l	55.00									
9	PL	FEMALE	HTC	22/11/90	4.0	10.0	mmol/l	8.40	06/12/90	21/12/90	04/01/91			
			RBC	22/11/90	4.0	10.0	mmol/l	8.40	8.40	8.60	13.90			

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOMEXINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
9	9	PL	FEMALE	HTC	20/05/90	36.0	53.0	Z	43.00	42.00	40.00	43.00	
				RBC	20/05/90	4.0	5.8	10**6/uL	4.60	4.50	5.30	5.10	
				WBC	20/05/90	4.0	12.0	10**3/uL	8.00	82.00	7.60	8.30	
				HbC: N	20/05/90	60.0	80.0	Z		15.00			
				HbC: L	20/05/90	15.0	40.0	Z		1.00			
				HbC: E	20/05/90	0.0	5.0	Z		1.00			
				HbC: M	20/05/90	1.0	6.0	Z		1.00			
				HbC: B	20/05/90	0.0	1.0	Z		1.00			
				PLATELETS	20/05/90	120.0	660.0	10**9/l	344.00	378.00	214.00	314.00	
				NA+	20/05/90	138.0	158.0	mmol/l	150.00	143.00	141.00	145.00	
				K+	20/05/90	3.6	5.0	mmol/l	5.00	5.10	4.20	5.40	
				Ca++	20/05/90	1.8	2.6	mmol/l	2.60	2.10	1.10	1.00	
				PO4-	20/05/90	0.9	1.6	mmol/l	1.30	1.00	1.10	1.00	
				SGOT	20/05/90	4.0	25.0	U/l	11.00	9.00	12.00	8.00	
				SGPT	20/05/90	4.0	27.0	U/l	10.00	7.00	10.00	10.00	
				GAHMA-GT	20/05/90	4.0	28.0	U/l	8.00	10.00	21.00	24.00	
				GLUCOSE	20/05/90	3.6	5.7	mmol/l	5.00	5.20	4.20	4.20	
				ALK. PHOSPH.	20/05/90	20.0	55.0	mmol/l	27.00	27.00	32.00	32.00	
				BUN	20/05/90	2.0	10.0	mmol/l	8.00	4.00	6.00	4.00	
				CREATININE	20/05/90	45.0	105.0	umol/l	65.00	60.00	84.00	60.00	
				URIC ACID	20/05/90	2.0	400.0	umol/l	209.00	146.00	212.00	205.00	
				TOT BILIRUBIN	20/05/90	0.0	2.0	umol/l	11.00	12.00	12.00	12.00	
				DIR BILIRUBIN	20/05/90	66.0	97.0	g/l	74.00	75.00	80.00	79.00	
				TOT. PROTEINS	20/05/90	32.0	55.0	g/l	54.00	43.00	56.00	58.00	
				ALBUMINE	20/05/90	3.0	8.7	mmol/l	8.50	4.60	5.10	5.10	
				TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/l	1.50	1.90	1.20	1.20	
				GLOBULINS: ALPHA 1	20/05/90	2.5	4.0	Z	7.10	1.80	2.40	3.00	
				GLOBULINS: ALPHA 2	20/05/90	7.0	10.0	Z	11.10	10.10	8.90	9.20	
				GLOBULINS: BETA	20/05/90	8.3	14.5	Z	17.50	20.00	10.10	11.20	
				GLOBULINS: GAMMA	20/05/90	14.0	25.0	Z	12.30	12.10	15.20	14.50	
				T3	20/05/90	2.0	5.0	nmol/l	1.30				
				T4	20/05/90	100.0	300.0	nmol/l	85.00				
10	BG		FEMALE	HB	20/05/90	4.0	10.0	mmol/l	15.20	15.80	14.30	13.40	
				HTC	20/05/90	36.0	53.0	Z	46.00	49.00	43.00	41.00	
				RBC	20/05/90	4.0	5.8	10**6/uL	4.10	4.30	4.30	4.30	
				HbC: N	20/05/90	60.0	80.0	Z	10.10	9.80	8.80	8.80	
				HbC: L	20/05/90	15.0	40.0	Z		72.00			
				HbC: E	20/05/90	0.0	5.0	Z		24.00			
				HbC: M	20/05/90	1.0	6.0	Z		4.00			
				HbC: B	20/05/90	0.0	1.0	Z		0.00			
				PLATELETS	20/05/90	120.0	640.0	10**9/l	310.00	310.00	139.00	189.00	
				NA+	20/05/90	138.0	158.0	mmol/l	147.00	146.00	142.00	144.00	
				K+	20/05/90	3.6	5.0	mmol/l	4.40	4.90	4.60	4.90	
				Ca++	20/05/90	1.8	2.6	mmol/l	2.20	2.40	2.20	2.20	
				PO4-	20/05/90	0.9	1.6	mmol/l	0.90	0.90	1.00	1.40	
				SGOT	20/05/90	4.0	25.0	U/l	4.00	6.00	11.00	7.00	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit									
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6					
9	10	BG	FEMALE	SGPT	20/05/90	4.0	27.0	U/l	4.00	21.00	10.00	8.00				
				GAMMA-GT	20/05/90	4.0	28.0	U/l	3.00	8.00	2.00	4.00				
				GLUCOSE	20/05/90	3.6	5.7	mmol/l	5.10	4.70	4.70	4.60				
				ALK. PHOSPH.	20/05/90	20.0	55.0	mmol/l	24.00	29.00	24.00	39.00				
				BUN	20/05/90	2.0	10.0	mmol/l	4.00	4.00	5.00	4.00				
				CREATININE	20/05/90	45.0	105.0	umol/l	80.00	70.00	65.00	70.00				
				URIC ACID	20/05/90	100.0	400.0	umol/l	240.00	249.00	194.00	189.00				
				TOT BILIRUBIN	20/05/90	2.0	20.0	umol/l	12.00	15.00	6.00	17.00				
				DIR BILIRUBIN	20/05/90	0.0	5.0	umol/l	0.00	0.00	0.00	0.00				
				TOT. PROTEINS	20/05/90	66.0	97.0	g/l	75.00	67.00	75.00	78.00				
				ALBUMINE	20/05/90	32.0	55.0	g/l	51.00	50.00	38.00	49.00				
				TOT. CHOLEST.	20/05/90	3.0	8.7	mmol/l	5.50	6.10	5.90	6.40				
				TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/l	1.70	1.10	1.40	1.00				
				GLUCOLINS: ALPHA 1	20/05/90	2.5	4.0	%	4.30	4.30	3.30	3.90				
				GLUCOLINS: ALPHA 2	20/05/90	7.0	10.0	%	8.30	8.30	11.30	9.30				
				GLUCOLINS: BETA	20/05/90	8.3	14.5	%	10.60	8.30	13.10	14.60				
				GLUCOLINS: GAMMA	20/05/90	14.0	25.0	%	17.10	17.90	16.90	17.90				
				T3	20/05/90	2.0	5.0	nmol/l	2.10	.	.	.				
				T4	20/05/90	100.0	300.0	nmol/l	149.00	.	.	.				
				11	KE	11	FEMALE	HB	20/05/90	4.0	10.0	mmol/l	22/01/91	12/02/91	26/02/91	12/03/91
								HTC	20/05/90	36.0	53.0	%	42.60	12.10	12.50	12.40
								RBC	20/05/90	4.0	5.8	10**6/u1	39.00	37.00	39.00	38.00
								HBC	20/05/90	4.0	12.0	10**3/u1	4.12	4.00	4.20	4.00
HRC: N	20/05/90	60.0	80.0					%	7.60	6.90	8.20	7.60				
HRC: L	20/05/90	15.0	40.0					%	.	80.00	.	.				
HRC: E	20/05/90	0.0	5.0					%	.	15.00	.	.				
HRC: M	20/05/90	1.0	6.0					%	.	2.00	.	.				
HRC: B	20/05/90	0.0	1.0					%	.	3.00	.	.				
PLATELETS	20/05/90	120.0	640.0					10**9/l	315.00	334.00	362.00	341.00				
NA+	20/05/90	138.0	158.0					mmol/l	142.00	144.00	142.00	142.00				
K+	20/05/90	3.6	5.0					mmol/l	4.60	5.40	5.00	4.80				
CA++	20/05/90	1.8	2.6					mmol/l	2.10	2.20	2.10	2.20				
PO4--	20/05/90	0.9	1.6					mmol/l	0.50	1.30	0.90	0.60				
SGOT	20/05/90	4.0	25.0					U/l	12.00	5.00	5.00	9.00				
SGPT	20/05/90	4.0	27.0					U/l	24.00	6.00	5.00	7.00				
GAMMA-GT	20/05/90	4.0	28.0					U/l	6.00	4.00	4.00	8.00				
GLUCOSE	20/05/90	3.6	5.7					mmol/l	4.20	5.10	5.00	4.80				
ALK. PHOSPH.	20/05/90	20.0	55.0					mmol/l	25.00	22.00	31.00	24.00				
BUN	20/05/90	2.0	10.0					mmol/l	10.00	6.00	3.00	4.00				
CREATININE	20/05/90	45.0	105.0					umol/l	70.00	70.00	55.00	70.00				
URIC ACID	20/05/90	100.0	400.0					umol/l	192.00	197.00	170.00	162.00				
TOT BILIRUBIN	20/05/90	2.0	20.0					umol/l	18.00	14.00	12.00	13.00				
DIR BILIRUBIN	20/05/90	0.0	5.0	umol/l	0.00	0.00	0.00	0.00								
TOT. PROTEINS	20/05/90	66.0	97.0	g/l	76.00	66.80	76.00	80.00								
ALBUMINE	20/05/90	32.0	55.0	g/l	46.00	51.90	49.00	45.00								
TOT. CHOLEST.	20/05/90	3.0	8.7	mmol/l	4.30	4.70	4.40	4.40								
TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/l	1.10	0.80	1.00	0.80								
GLUCOLINS: ALPHA 1	20/05/90	2.5	4.0	%	3.60	2.80	4.50	5.50								

1688

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit							
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6			
9	11 KE	FEMALE	GLOBULINS: ALPHA 2	20/05/90	7.0	10.0	Z	8.60	9.80	10.30	7.70			
			GLOBULINS: BETA	20/05/90	8.3	14.5	Z	17.00	14.30	15.30	14.40			
			GLOBULINS: GAMMA	20/05/90	14.0	25.0	Z	15.90	21.20	19.20	17.70			
			T3	20/05/90	2.0	5.0	nmol/l	2.20	.	.	.			
			T4	20/05/90	100.0	300.0	nmol/l	128.00	.	.	.			
			12	6YT	FEMALE	HB	20/05/90	4.0	10.0	mmol/l	27/02/91	19/03/91	02/04/91	16/04/91
						HTC	20/05/90	36.0	53.0	Z	13.30	13.50	13.30	13.50
						RBC	20/05/90	4.0	5.8	10**6/uL	41.00	43.00	41.00	41.00
						HBC	20/05/90	4.0	12.0	10**3/uL	4.80	4.70	4.50	4.50
						PLATELETS	20/05/90	120.0	640.0	10**9/l	6.60	9.10	7.50	6.50
						NA+	20/05/90	138.0	158.0	mmol/l	201.00	231.00	228.00	320.00
						K+	20/05/90	3.6	5.0	mmol/l	144.00	145.00	145.00	150.00
						CA++	20/05/90	1.8	2.6	mmol/l	4.00	4.50	5.00	4.70
						PO4--	20/05/90	0.9	1.6	mmol/l	2.00	2.50	2.00	2.30
SGOT	20/05/90	4.0				25.0	U/l	11.00	8.00	7.00	1.10			
SGPT	20/05/90	4.0				27.0	U/l	6.00	9.00	10.00	10.00			
GAMMA-GT	20/05/90	4.0				28.0	U/l	4.00	9.00	12.00	13.00			
GLUCOSE	20/05/90	3.6				5.7	mmol/l	5.30	4.90	5.20	5.80			
ALK. PHOSPH.	20/05/90	2.0				10.0	mmol/l	22.00	34.00	29.00	53.00			
13	BP	FEMALE	BUN	20/05/90	45.0	105.0	mmol/l	90.00	85.00	80.00	85.00			
			CREATININE	20/05/90	100.0	400.0	umol/l	216.00	288.00	206.00	113.00			
			URIC ACID	20/05/90	2.0	20.0	umol/l	11.00	7.00	7.00	13.00			
			TOT BILIRUBIN	20/05/90	0.0	5.0	umol/l	0.00	67.00	79.00	82.00			
			DIR BILIRUBIN	20/05/90	66.0	97.0	g/l	69.00	38.00	31.00	42.00			
			TOT. PROTEINS	20/05/90	32.0	55.0	g/l	49.00	36.00	49.00	42.00			
			ALBUMINE	20/05/90	3.0	8.7	mmol/l	5.10	7.00	8.40	8.70			
			TOT. CHOLEST.	20/05/90	0.3	1.8	mmol/l	1.50	2.10	2.90	1.60			
			TRIGLYCERIDES	20/05/90	2.5	4.0	Z	3.30	3.90	2.80	2.60			
			GLOBULINS: ALPHA 1	20/05/90	7.0	10.0	Z	9.60	12.10	9.10	9.70			
			GLOBULINS: ALPHA 2	20/05/90	8.3	14.5	Z	13.30	16.40	18.50	16.70			
			GLOBULINS: BETA	20/05/90	14.0	25.0	Z	15.70	17.50	16.20	15.10			
			GLOBULINS: GAMMA	20/05/90	2.0	5.0	mmol/l	1.50	.	.	.			
			T4	20/05/90	100.0	300.0	nmol/l	113.00	.	.	.			
13	BP	FEMALE	HB	20/05/90	4.0	10.0	mmol/l	07/03/91	26/03/91	10/06/91	24/06/91			
			HTC	20/05/90	36.0	53.0	Z	11.60	12.20	11.40	10.90			
			RBC	20/05/90	4.0	5.8	10**6/uL	37.00	37.00	35.00	33.00			
			HBC	20/05/90	4.0	12.0	10**3/uL	4.10	4.10	3.90	3.70			
			NBC: N	20/05/90	60.0	80.0	Z	5.50	6.70	7.00	8.20			
			NBC: L	20/05/90	15.0	40.0	Z	70.00	.	.	.			
			NBC: E	20/05/90	0.0	5.0	Z	22.00	.	.	.			
			NBC: M	20/05/90	1.0	6.0	Z	5.00	.	.	.			
			NBC: B	20/05/90	0.0	1.0	Z	3.00	.	.	.			
			PLATELETS	20/05/90	120.0	640.0	10**9/l	229.00	220.00	298.00	256.00			
			T4	20/05/90	100.0	300.0	nmol/l	144.00	145.00	147.00	144.00			

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
9	13	BP	FEMALE	K+	20/05/90	3.6	5.0	mmol/l	5.00	5.00	5.00	4.70	
				CA++	20/05/90	1.8	2.6	mmol/l	2.20	2.20	2.60	2.30	
				PO4-	20/05/90	0.9	1.6	mmol/l	1.00	1.00	0.90	0.80	
				SGOT	20/05/90	4.0	25.0	U/l	14.00	12.00	9.00	9.00	
				SGPT	20/05/90	4.0	27.0	U/l	23.00	11.00	10.00	10.00	
				GAMMA-GT	20/05/90	4.0	28.0	U/l	21.00	14.00	15.00	5.00	
				GLUCOSE	20/05/90	3.6	8.7	mmol/l	4.60	4.30	3.90	3.90	
				ALK. PHOSPH.	20/05/90	20.0	55.0	mmol/l	28.00	25.00	33.00	27.00	
				BUN	20/05/90	2.0	10.0	mmol/l	7.00	6.00	4.00	5.00	
				CREATININE	20/05/90	45.0	105.0	umol/l	100.00	85.00	85.00	105.00	
				URIC ACID	20/05/90	100.0	400.0	umol/l	304.00	443.00	382.00	437.00	
				TOT BILIRUBIN	20/05/90	0.0	20.0	umol/l	16.00	21.00	20.00	16.00	
				DIR BILIRUBIN	20/05/90	0.0	5.0	umol/l	0.00	0.00	0.00	0.00	
				TOT. PROTEINS	20/05/90	66.0	97.0	g/l	84.00	91.00	88.00	87.00	
				ALBUMINE	20/05/90	32.0	55.0	g/l	44.00	51.00	47.00	47.00	
				TOT. CHOLEST.	20/05/90	3.0	8.7	mmol/l	6.20	5.40	5.40	4.80	
				TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/l	0.30	0.80	0.70	4.10	
				GLOBULINS: ALPHA 1	20/05/90	2.5	4.0	g	2.40	1.90	2.30	2.30	
				GLOBULINS: ALPHA 2	20/05/90	7.0	10.0	g	6.70	7.10	7.10	7.70	
				GLOBULINS: BETA	20/05/90	8.3	14.5	g	10.30	10.30	8.80	12.00	
				GLOBULINS: GAMMA	20/05/90	14.0	25.0	g	21.90	23.10	23.10	21.60	
				T3	20/05/90	2.0	5.0	nmol/l	1.70				
				T4	20/05/90	100.0	300.0	nmol/l	99.00				
14	SZF		FEMALE	HB	20/05/90	4.0	10.0	mmol/l	18/03/91	07/04/91	21/04/91	05/05/91	
				HTC	20/05/90	34.0	53.0	g	14.00	13.30	12.00	11.80	
				HPC	20/05/90	4.0	5.8	10**6/u1	44.00	40.00	38.00	38.00	
				MBC	20/05/90	4.0	12.0	10**3/u1	5.10	4.60	4.40	4.30	
				MBC: N	20/05/90	60.0	80.0	g	9.00	7.70	5.20	6.70	
				MBC: L	20/05/90	15.0	40.0	g	81.00	82.00			
				MBC: E	20/05/90	0.0	5.0	g	15.00	15.00			
				PLATELETS	20/05/90	1.0	6.0	g	1.00	1.00			
				K+	20/05/90	120.0	660.0	10**9/l	3.00	2.00			
				Na+	20/05/90	136.0	158.0	mmol/l	163.00	196.00	189.00	191.00	
				Ca++	20/05/90	3.6	5.0	mmol/l	146.00	145.00	141.00	144.00	
				PO4-	20/05/90	1.8	2.6	mmol/l	4.30	4.90	3.80	4.60	
				SGOT	20/05/90	0.9	1.6	mmol/l	2.10	2.10	2.00	1.90	
				SGPT	20/05/90	4.0	25.0	U/l	1.10	1.00	1.20	1.10	
				GAMMA-GT	20/05/90	4.0	27.0	U/l	10.00	45.00	10.00	12.00	
				GLUCOSE	20/05/90	4.0	28.0	U/l	9.00	17.00	11.00	8.00	
				ALK. PHOSPH.	20/05/90	3.6	5.7	mmol/l	8.00	54.00	8.00	10.00	
				BUN	20/05/90	20.0	55.0	mmol/l	4.40	4.40	4.40	6.00	
				CREATININE	20/05/90	2.0	10.0	mmol/l	23.00	49.00	28.00	26.00	
				URIC ACID	20/05/90	45.0	105.0	umol/l	9.00	6.00	4.00	6.00	
				TOT BILIRUBIN	20/05/90	4.0	10.0	umol/l	70.00	70.00	70.00	90.00	
				DIR BILIRUBIN	20/05/90	100.0	400.0	umol/l	105.00	167.00	192.00	169.00	
				TOT. PROTEINS	20/05/90	2.0	20.0	umol/l	12.00	17.00	11.00	10.00	
				T3	20/05/90	0.0	5.0	umol/l	0.00	0.00	0.00	0.00	
				T4	20/05/90	66.0	97.0	g/l	72.00	77.00	81.00	78.00	
					20/05/90	1.7	5.0	g/l	4.00	4.60	43.00	46.00	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit								
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
9	14	SZF	FEMALE	TOT. CHOLEST.	20/05/90	3.0	8.7	mmol/l	4.90	5.70	5.00	4.80			
				TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/l	1.40	1.70	1.20	1.00			
				GLOBULINS: ALPHA 1	20/05/90	2.5	4.0	g	1.40	2.40	2.40	2.10			
				GLOBULINS: ALPHA 2	20/05/90	7.0	10.0	g	8.30	11.10	7.90	9.30			
				GLOBULINS: BETA	20/05/90	8.3	14.5	g	12.20	15.70	16.30	15.20			
				GLOBULINS: GAMMA	20/05/90	14.0	25.0	g	13.50	21.20	14.20	15.10			
				T3	20/05/90	2.0	5.0	nmol/l	1.50						
				T4	20/05/90	100.0	300.0	nmol/l	86.00						
				15	BI	FEMALE	HB	20/05/90	4.0	10.0	mmol/l	12.90	11.80	11.40	14.00
							HTC	20/05/90	36.0	53.0	g	41.00	36.00	36.00	43.00
							RBC	20/05/90	4.0	5.8	10**6/ul	4.50	4.00	3.90	4.60
							HBC: N	20/05/90	60.0	80.0	g	87.00	9.80	7.10	9.90
							HBC: L	20/05/90	15.0	40.0	g	11.00			
							HBC: M	20/05/90	1.0	6.0	g	2.00			
PLATELETS	20/05/90	120.0	640.0				10**9/l	315.00	359.00						
NA+	20/05/90	138.0	158.0				mmol/l	145.00	151.00	149.00	150.00				
K+	20/05/90	3.6	5.0				mmol/l	4.90	4.40	2.10	4.80				
CA++	20/05/90	1.8	2.6				mmol/l	2.30	1.90	2.00	2.00				
PO4--	20/05/90	0.9	1.6				mmol/l	1.10	1.10	1.00	1.00				
SGOT	20/05/90	4.0	25.0				U/l	7.00	11.00	9.00	9.00				
SGPT	20/05/90	4.0	27.0				U/l	8.00	16.00	11.00	8.00				
GAMMA-GT	20/05/90	4.0	28.0				U/l	37.00	20.00	12.00	14.00				
GLUCOSE	20/05/90	3.6	5.7	mmol/l	4.20	5.80	4.60	4.80							
ALK. PHOSPH.	20/05/90	20.0	55.0	mmol/l	53.00	29.00	34.00	32.00							
CREATININE	20/05/90	45.0	105.0	umol/l	7.00	3.00	7.00	7.00							
TOT. BILIRUBIN	20/05/90	100.0	400.0	umol/l	208.00	145.00	100.00	80.00							
DIR. BILIRUBIN	20/05/90	2.0	20.0	umol/l	12.00	71.00	15.00	19.00							
TOT. PROTEINS	20/05/90	66.0	97.0	g/l	72.00	79.00	79.00	72.00							
ALBUMINE	20/05/90	32.0	55.0	g/l	51.00	49.00	49.00	35.00							
TOT. CHOLEST.	20/05/90	3.0	8.7	mmol/l	6.80	4.50	5.00	6.00							
TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/l	1.50	1.00	0.90	1.30							
GLOBULINS: ALPHA 1	20/05/90	2.5	4.0	g	1.70	2.80	3.00	2.00							
GLOBULINS: ALPHA 2	20/05/90	7.0	10.0	g	7.00	7.90	8.80	7.30							
GLOBULINS: BETA	20/05/90	8.3	14.5	g	11.30	12.30	11.90	11.20							
GLOBULINS: GAMMA	20/05/90	14.0	25.0	g	23.00	29.20	32.20	26.50							
16	UGY	FEMALE	HB	20/05/90	4.0	10.0	mmol/l	14.00	12.30	11.20	14.00				
			HTC	20/05/90	36.0	53.0	g	43.00	36.00	39.00	35.00				
			RBC	20/05/90	4.0	5.8	10**6/ul	5.00	4.20	3.80	4.00				
			HBC: N	20/05/90	60.0	80.0	g	6.80	5.80	6.10	6.30				
			HBC: L	20/05/90	15.0	40.0	g								
			HBC: M	20/05/90	1.0	6.0	g								
			PLATELETS	20/05/90	120.0	640.0	10**9/l								
			NA+	20/05/90	138.0	158.0	mmol/l								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOREXINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit				
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6
9	16	UGY	FEMALE	MBC: M	20/05/90	1.0	6.0	Z	352.00	3.00	306.00	386.00
				PLATELETS	20/05/90	120.0	640.0	10**9/1	347.00	3.00	306.00	386.00
				NA+	20/05/90	138.0	158.0	mmol/l	147.00	147.00	148.00	146.00
				K+	20/05/90	3.6	5.0	mmol/l	4.50	4.40	4.10	4.60
				Ca++	20/05/90	1.8	2.6	mmol/l	2.10	2.10	2.10	2.20
				PO4--	20/05/90	0.9	1.6	mmol/l	0.90	1.10	0.90	1.00
				SGPT	20/05/90	4.0	25.0	U/l	26.00	18.00	16.00	17.00
				GAMMA-GT	20/05/90	4.0	27.0	U/l	33.00	21.00	17.00	22.00
				GLUCOSE	20/05/90	4.0	28.0	U/l	10.00	8.00	6.00	7.00
				ALK. PHOSPH.	20/05/90	3.6	5.7	mmol/l	4.20	4.50	4.30	3.80
				BUN	20/05/90	2.0	10.0	mmol/l	35.00	41.00	34.00	36.00
				CREATININE	20/05/90	45.0	105.0	mmol/l	8.00	7.00	9.00	7.00
				URIC ACID	20/05/90	100.0	400.0	mmol/l	65.00	70.00	75.00	70.00
				TOT. BILIRUBIN	20/05/90	2.0	20.0	mmol/l	11.00	13.00	152.00	177.00
				DIR. BILIRUBIN	20/05/90	0.0	5.0	umol/l	0.00	0.00	0.00	0.00
				TOT. PROTEINS	20/05/90	66.0	97.0	g/l	61.00	74.00	70.00	74.00
				ALBUMINE	20/05/90	32.0	55.0	g/l	33.00	46.00	44.00	43.00
				TOT. CHOLEST.	20/05/90	3.0	8.7	mmol/l	5.20	5.40	4.00	5.80
				TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/l	1.10	0.90	1.30	1.30
				GLOBULINS: ALPHA 1	20/05/90	2.5	4.0	Z	3.50	2.50	2.60	2.26
				GLOBULINS: ALPHA 2	20/05/90	7.0	10.0	Z	8.70	8.70	8.30	9.50
				GLOBULINS: BETA	20/05/90	8.3	14.5	Z	17.30	11.60	11.51	11.80
				GLOBULINS: GAMMA	20/05/90	14.0	25.0	Z	21.80	24.10	18.50	20.40
				T3	20/05/90	2.0	5.0	nmol/l	2.20	2.20	2.20	2.20
				T4	20/05/90	100.0	300.0	nmol/l	123.00	123.00	123.00	123.00
17	NL	MALE		HB	20/05/90	4.0	10.5	mmol/l	04/07/91	14.60	14.60	14.60
				HTC	20/05/90	38.0	53.0	Z	44.00	44.00	44.00	44.00
				RBC	20/05/90	4.0	6.0	10**6/u1	4.00	4.00	4.00	4.00
				MBC	20/05/90	4.0	12.0	10**3/u1	7.70	7.70	7.70	7.70
				PLATELETS	20/05/90	120.0	640.0	10**9/1	283.00	283.00	283.00	283.00
				NA+	20/05/90	138.0	158.0	mmol/l	143.00	143.00	143.00	143.00
				K+	20/05/90	3.6	5.0	mmol/l	4.50	4.50	4.50	4.50
				Ca++	20/05/90	1.8	2.6	mmol/l	2.00	2.00	2.00	2.00
				PO4--	20/05/90	0.9	1.6	mmol/l	0.40	0.40	0.40	0.40
				SGOT	20/05/90	7.0	28.0	U/l	13.00	13.00	13.00	13.00
				SOPT	20/05/90	6.0	22.0	U/l	13.00	13.00	13.00	13.00
				GAMMA-GT	20/05/90	8.0	28.0	U/l	14.00	14.00	14.00	14.00
				GLUCOSE	20/05/90	3.6	5.7	mmol/l	4.30	4.30	4.30	4.30
				ALK. PHOSPH.	20/05/90	20.0	55.0	mmol/l	61.00	61.00	61.00	61.00
				BUN	20/05/90	2.0	9.0	mmol/l	4.00	4.00	4.00	4.00
				CREATININE	20/05/90	55.0	105.0	umol/l	90.00	90.00	90.00	90.00
				URIC ACID	20/05/90	100.0	420.0	umol/l	197.00	197.00	197.00	197.00
				TOT. BILIRUBIN	20/05/90	2.0	20.0	umol/l	15.00	15.00	15.00	15.00
				DIR. BILIRUBIN	20/05/90	0.0	5.0	umol/l	0.00	0.00	0.00	0.00
				TOT. PROTEINS	20/05/90	66.0	97.0	g/l	70.00	70.00	70.00	70.00
				ALBUMINE	20/05/90	32.0	55.0	g/l	41.00	41.00	41.00	41.00
				TOT. CHOLEST.	20/05/90	3.0	8.7	mmol/l	4.40	4.40	4.40	4.40

1686

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Screen	Visit								
				Date	Mn	Max		Week 2	Week 4	Week 6						
9	17	NL	MALE	TRIGLYCERIDES	0.3	1.8	mmol/l	0.40								
				GLOBULINS: ALPHA 1	20/05/90	2.5	4.0	%	2.10							
				GLOBULINS: ALPHA 2	20/05/90	4.0	7.0	%	4.40							
				GLOBULINS: BETA	20/05/90	8.3	14.5	%	8.20							
				GLOBULINS: GAMMA	20/05/90	14.0	25.0	%	24.80							
				T3	20/05/90	1.2	4.5	nmol/l	1.50							
				T4	20/05/90	50.0	200.0	nmol/l	75.00							
				18	MBH	FEMALE	HB	20/05/90	4.0	10.0	mmol/l	15.30	09/07/91	22/07/91	05/08/91	25/08/91
							HTC	20/05/90	36.0	53.0	%	45.00	14.80	15.00	14.70	14.70
							RBC	20/05/90	4.0	5.8	10**6/ul	4.80	43.00	43.00	43.00	43.00
							HBC	20/05/90	4.0	12.0	10**3/ul	5.10	4.80	4.90	4.90	4.80
							RBC: N	20/05/90	60.0	80.0	%	4.10	4.70	4.30	4.30	3.90
							RBC: L	20/05/90	15.0	40.0	%	72.00				60.00
							RBC: E	20/05/90	0.0	5.0	%	20.00				36.00
RBC: M	20/05/90	1.0	6.0				%	3.00				1.00				
PLATELETS	20/05/90	120.0	640.0				10**9/l	5.00	289.00	281.00	281.00	3.00				
NA+	20/05/90	138.0	158.0				mmol/l	279.00	146.00	146.00	146.00	235.00				
K+	20/05/90	3.6	5.0				mmol/l	4.10	4.00	4.00	4.00	144.00				
CA++	20/05/90	1.8	2.6				mmol/l	2.40	2.20	2.60	2.60	4.20				
PO4--	20/05/90	0.9	1.6				mmol/l	0.90	1.30	0.70	0.70	0.80				
SGPT	20/05/90	4.0	25.0				U/l	8.00	8.00	8.00	8.00	7.00				
GAMMA-GT	20/05/90	4.0	27.0	U/l	8.00	7.00	8.00	8.00	4.00							
GLUCOSE	20/05/90	4.0	28.0	U/l	15.00	10.00	5.00	5.00	4.00							
ALK. PHOSPH.	20/05/90	3.6	5.7	mmol/l	4.50	4.10	3.50	3.50	3.70							
BUN	20/05/90	2.0	5.0	mmol/l	44.00	37.00	28.00	28.00	31.00							
CREATININE	20/05/90	2.0	10.0	mmol/l	5.00	7.00	9.00	9.00	4.00							
URIC ACID	20/05/90	45.0	105.0	umol/l	85.00	85.00	100.00	100.00	80.00							
TOT. BILIRUBIN	20/05/90	100.0	400.0	umol/l	198.00	253.00	266.00	266.00	172.00							
DAR. BILIRUBIN	20/05/90	2.0	20.0	umol/l	13.00	13.00	15.00	15.00	9.00							
TOT. PROTEINS	20/05/90	66.0	97.0	g/l	72.00	74.00	72.00	72.00	73.00							
ALBUMINE	20/05/90	32.0	55.0	g/l	36.00	49.00	50.00	50.00	51.00							
TOT. CHOLEST.	20/05/90	3.0	8.7	mmol/l	8.90	8.60	8.30	8.30	6.80							
TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/l	1.00	1.20	0.80	0.80	0.70							
GLOBULINS: ALPHA 1	20/05/90	2.5	4.0	%	3.50	2.60	2.40	2.40	2.40							
GLOBULINS: ALPHA 2	20/05/90	7.0	10.0	%	11.20	9.80	10.80	10.80	8.20							
GLOBULINS: BETA	20/05/90	8.3	14.5	%	17.50	15.50	11.90	11.90	11.50							
GLOBULINS: GAMMA	20/05/90	14.0	25.0	%	14.10	12.80	14.70	14.70	11.00							
T3	20/05/90	2.0	5.0	nmol/l	1.80											
T4	20/05/90	100.0	300.0	nmol/l	9.30											
19	KF	FEMALE	HB	20/05/90	4.0	10.0	mmol/l	13.50	07/08/91	27/08/91	10/09/91	24/09/91				
			HTC	20/05/90	36.0	53.0	%	39.00	13.80	13.60	13.60	12.70				
			RBC	20/05/90	4.0	5.8	10**6/ul	4.40	41.00	41.00	41.00	39.00				
			RBC	20/05/90	4.0	12.0	10**3/ul	5.70	4.40	4.60	4.60	4.20				

1687

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REDOMETINE - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Date	Laboratory Range			Visit					
						Min	Max	Unit	Screen	Week 2	Week 4	Week 6		
9	19	MF	FEMALE	NA+	20/05/90	138.0	158.0	mmol/l	147.00	146.00	148.00	147.00		
				K+	20/05/90	3.6	5.0	mmol/l	4.20	4.40	4.70	4.80		
				PO4-	20/05/90	1.8	2.6	mmol/l	2.30	2.40	2.20	2.50		
				SGPT	20/05/90	0.9	1.6	mmol/l		0.90	1.20	0.40		
				SGPT	20/05/90	4.0	25.0	U/l	10.00	9.00	11.00	7.00		
				GAMMA-GT	20/05/90	4.0	27.0	U/l	4.00	11.00	11.00	8.00		
				GLUCOSE	20/05/90	4.0	28.0	U/l	8.00	7.00	3.00	8.00		
				ALK. PHOSPH.	20/05/90	3.6	5.7	mmol/l	4.20	3.90	4.60	3.90		
				BUN	20/05/90	2.0	55.0	mmol/l	36.00	38.00	28.00	32.00		
				CREATININE	20/05/90	2.0	10.0	mmol/l	6.00	4.00	3.00	5.00		
				URIC ACID	20/05/90	45.0	105.0	mmol/l	80.00	60.00	65.00	70.00		
				TOT BILIRUBIN	20/05/90	100.0	400.0	umol/l	164.00	106.00	190.00	170.00		
				DIR BILIRUBIN	20/05/90	2.0	20.0	umol/l	13.00	12.00	16.00	21.00		
				TOT. PROTEINS	20/05/90	0.0	5.0	umol/l	0.00	0.00	0.00	0.00		
				ALBUMINE	20/05/90	66.0	97.0	g/l	72.00	75.00	78.00	77.00		
				TOT. CHOLEST.	20/05/90	32.0	55.0	g/l	49.00	49.00	52.00	44.00		
				TRIGLYCERIDES	20/05/90	3.0	8.7	mmol/l	4.70	5.30	5.20	5.20		
				GLOBULINS: ALPHA 1	20/05/90	0.3	1.8	mmol/l	1.80	1.20	1.50	1.00		
				GLOBULINS: ALPHA 2	20/05/90	2.5	4.0	g	1.70	1.80	0.80	1.50		
				GLOBULINS: BETA	20/05/90	7.0	10.0	g	9.70	8.50	7.70	8.40		
				GLOBULINS: GAMMA	20/05/90	8.3	14.5	g	14.00	15.60	12.90	14.30		
					20/05/90	14.0	25.0	g	23.10	22.20	19.30	22.80		
1	20	GVE	FEMALE	HB	22/08/91				18.10	06/09/91	20/05/91	04/10/91		
00				HTC	20/05/90	4.0	10.0	mmol/l	15.30	14.20	14.20	13.30		
00				RBC	20/05/90	36.0	53.0	g	53.00	44.00	40.00	41.00		
00				WBC	20/05/90	4.0	5.8	10**6/u1	5.30	4.50	3.90	4.00		
				WBC: N	20/05/90	4.0	12.0	10**3/u1	14.60	12.90	8.00	5.50		
				WBC: L	20/05/90	60.0	80.0	g	85.00	73.00				
				WBC: E	20/05/90	15.0	40.0	g	11.00	22.00				
				WBC: M	20/05/90	0.0	5.0	g	1.00	1.00				
				WBC: B	20/05/90	1.0	6.0	g	3.00	4.00				
				PLATELETS	20/05/90	0.0	1.0	g	0.00	0.00				
				NA+	20/05/90	120.0	640.0	10**9/l	378.00	283.00	230.00	263.00		
				K+	20/05/90	138.0	158.0	mmol/l	147.00	149.00	146.00	147.00		
				PO4-	20/05/90	3.6	5.0	mmol/l	4.80	5.20	4.90	4.90		
				SGPT	20/05/90	1.8	2.6	mmol/l	2.10	2.00	2.10	2.20		
				GAMMA-GT	20/05/90	0.3	1.6	mmol/l	1.00	0.80	1.20	1.10		
				GLUCOSE	20/05/90	4.0	25.0	U/l	28.00	10.00	8.00	7.00		
				ALK. PHOSPH.	20/05/90	4.0	27.0	U/l	8.00	10.00	8.00	8.00		
				BUN	20/05/90	4.0	28.0	U/l	39.00	7.00	14.00	10.00		
				CREATININE	20/05/90	3.6	5.7	mmol/l	5.10	5.10	39.00	30.00		
				URIC ACID	20/05/90	2.0	10.0	mmol/l	4.00	28.00	4.00	6.00		
				TOT BILIRUBIN	20/05/90	45.0	105.0	umol/l	95.00	95.00	125.00	85.00		
				DIR BILIRUBIN	20/05/90	100.0	400.0	umol/l	565.00	370.00	420.00	375.00		
				TOT. PROTEINS	20/05/90	2.0	20.0	umol/l	14.00	7.00	10.00	20.00		
				ALBUMINE	20/05/90	0.0	5.0	umol/l	0.00	0.00	0.00	0.00		
				TOT. PROTEINS	20/05/90	66.0	97.0	g/l	93.00	70.00	74.00	80.00		
					20/05/90	80.0	55.0	g/l	54.00	46.00	42.00	48.00		

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit							
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6			
9	20 GYE	FEMALE	TOT. CHOLEST.	20/05/90	3.0	8.7	mmol/l	5.50	5.50	5.10	5.20			
			TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/l	1.10	1.40	1.90	1.10			
			GLOBULINS: ALPHA 1	20/05/90	2.5	4.0	g	2.20	2.90	2.30	1.70			
			GLOBULINS: ALPHA 2	20/05/90	7.0	10.0	g	12.30	11.40	10.10	8.80			
			GLOBULINS: BETA	20/05/90	8.3	14.5	g	16.20	15.90	14.20	15.90			
			GLOBULINS: GAMMA	20/05/90	14.0	25.0	g	13.00	19.40	13.80	20.50			
			T3	20/05/90	2.0	5.0	nmol/l	1.60	.	.	.			
			T4	20/05/90	100.0	300.0	nmol/l	118.00	.	.	.			
			21	TA	FEMALE	BB	20/05/90	4.0	10.0	mmol/l	19/10/91	08/11/91	22/11/91	06/12/91
						BTC	20/05/90	36.0	53.0	g	14.30	14.40	14.40	13.90
						RBC	20/05/90	4.0	5.8	10**6/uL	43.00	45.00	43.00	42.00
						WBC	20/05/90	4.0	12.0	10**6/uL	4.60	4.70	4.60	4.90
						HBC: N	20/05/90	60.0	80.0	g	5.00	5.00	5.00	8.10
						HBC: L	20/05/90	15.0	40.0	g	50.00	51.00	.	.
HBC: E	20/05/90	0.0				5.0	g	45.00	50.00	.	.			
HBC: M	20/05/90	1.0				6.0	g	1.00	0.00	.	.			
HBC: B	20/05/90	0.0				1.0	g	3.00	4.00	.	.			
PLATELETS	20/05/90	120.0				640.0	10**9/l	1.00	0.00	215.00	165.00			
NA+	20/05/90	138.0				158.0	mmol/l	164.00	155.00	144.00	144.00			
K+	20/05/90	3.6				5.0	mmol/l	144.00	146.00	142.00	140.00			
CA++	20/05/90	1.8				2.6	mmol/l	4.50	4.20	4.10	4.10			
PO4--	20/05/90	0.9				1.6	mmol/l	2.30	2.30	2.10	2.30			
SGPT	20/05/90	4.0	25.0	U/l	0.70	1.00	1.20	0.70						
22	REE	FEMALE	GAMMA-GT	20/05/90	4.0	28.0	U/l	8.00	14.00	10.00	12.00			
			GLUCOSE	20/05/90	3.6	5.7	mmol/l	8.00	15.00	10.00	28.00			
			ALK. PHOSPH.	20/05/90	20.0	55.0	mmol/l	4.00	4.10	8.00	11.00			
			CREATININE	20/05/90	2.0	10.0	mmol/l	19.00	43.00	31.00	26.00			
			URIC ACID	20/05/90	45.0	105.0	umol/l	4.00	5.00	6.00	2.00			
			TOT. BILIRUBIN	20/05/90	100.0	400.0	umol/l	88.00	90.00	81.00	75.00			
			DIR. BILIRUBIN	20/05/90	0.0	20.0	umol/l	165.00	327.00	218.00	322.00			
			TOT. PROTEINS	20/05/90	66.0	97.0	g/l	20.00	7.00	11.00	8.00			
			ALBUMINE	20/05/90	33.0	55.0	g/l	85.00	80.00	82.00	72.00			
			TOT. CHOLEST.	20/05/90	3.0	8.7	mmol/l	51.00	49.00	50.00	46.00			
			TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/l	7.00	7.00	4.20	5.80			
			GLOBULINS: ALPHA 1	20/05/90	2.5	4.0	g	1.00	1.40	1.20	1.60			
			GLOBULINS: ALPHA 2	20/05/90	7.0	10.0	g	3.60	2.90	2.40	1.10			
			GLOBULINS: BETA	20/05/90	8.3	14.5	g	8.50	9.70	8.60	9.40			
GLOBULINS: GAMMA	20/05/90	14.0	25.0	g	14.50	16.00	15.00	14.60						
T3	20/05/90	2.0	5.0	nmol/l	19.20	14.70	14.10	12.60						
T4	20/05/90	100.0	300.0	nmol/l	111.00	.	.	.						
22	REE	FEMALE	BB	20/05/90	4.0	10.0	mmol/l	24/10/91	05/11/91	26/11/91	10/12/91			
			BTC	20/05/90	36.0	53.0	g	14.60	12.90	12.40	13.40			
			RBC	20/05/90	4.0	5.8	10**6/uL	44.00	44.00	43.00	44.00			
			WBC	20/05/90	4.0	12.0	10**6/uL	4.90	4.50	4.80	4.30			

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
9	22	RRE	FEMALE	MBC	20/05/90	4.0	12.0	10**3/uL	6.50	5.40	7.60	8.10	
				PLATELETS	20/05/90	120.0	640.0	10**9/l	151.00	98.00	154.00	187.00	
				Na+	20/05/90	138.0	158.0	mmol/l	149.00	147.00	145.00	141.00	
				K+	20/05/90	3.6	5.0	mmol/l	4.30	4.40	4.20	3.90	
				Ca++	20/05/90	1.8	2.6	mmol/l	2.00	2.20	2.10	2.00	
				PO4--	20/05/90	0.9	1.6	mmol/l	1.00	0.90	1.00	1.10	
				SGPT	20/05/90	4.0	25.0	U/l	9.00	6.00	12.00	8.00	
				SGPT	20/05/90	4.0	27.0	U/l	9.00	6.00	9.00	9.00	
				GAMMA-GT	20/05/90	4.0	28.0	U/l	15.00	10.00	13.00	12.00	
				GLUCOSE	20/05/90	3.6	5.7	mmol/l	4.60	3.80	4.50	4.80	
				ALK. PHOSPH.	20/05/90	2.0	10.0	mmol/l	35.00	41.00	35.00	29.00	
				BUN	20/05/90	4.5	10.5	mmol/l	7.00	3.00	5.00	7.00	
				CREATININE	20/05/90	100.0	400.0	umol/l	95.00	70.00	79.00	85.00	
				URIC ACID	20/05/90	2.0	20.0	umol/l	34.60	24.00	189.00	215.00	
				TOT. BILIRUBIN	20/05/90	0.0	5.0	umol/l	5.00	0.00	8.00	13.00	
				DIR. BILIRUBIN	20/05/90	0.0	97.0	g/l	78.00	65.00	89.00	88.00	
				TOT. PROTEINS	20/05/90	32.0	55.0	g/l	51.00	48.00	50.00	53.00	
				ALBUMINE	20/05/90	3.0	8.7	mmol/l	6.20	5.80	5.10	4.90	
				TOT. CHOLEST.	20/05/90	0.3	1.8	mmol/l	1.10	1.00	1.20	0.90	
				TRIGLYCERIDES	20/05/90	2.5	4.0	z	1.30	1.00	1.20	2.10	
				GLOBULINS: ALPHA 1	20/05/90	7.0	10.0	z	10.50	11.10	9.80	8.90	
				GLOBULINS: ALPHA 2	20/05/90	8.3	14.5	z	12.20	16.20	18.10	16.90	
				GLOBULINS: BETA	20/05/90	14.0	25.0	z	11.50	19.30	15.30	14.10	
				GLOBULINS: GAMMA	20/05/90	2.0	5.0	mmol/l	1.60	2.0	1.60	1.60	
				T3	20/05/90	100.0	300.0	nmol/l	96.00				
				T4	20/05/90								
				23	S2N	FEMALE	HB	20/05/90	4.0	10.0	mmol/l	14.80	13.80
HTC	20/05/90	36.0	53.0				z	44.00	41.00	44.00	42.00		
RBC	20/05/90	4.0	5.8				10**6/uL	4.90	4.50	4.80	4.40		
MBC	20/05/90	60.0	80.0				z	6.80	7.70	6.90	7.00		
MBC: N	20/05/90	15.0	40.0				z	73.00	73.00	67.00	67.00		
MBC: L	20/05/90	0.0	5.0				z	25.00	25.00	29.00	29.00		
MBC: E	20/05/90	1.0	6.0				z	0.00	0.00	0.00	1.00		
MBC: M	20/05/90	0.0	1.0				z	0.00	0.00	0.00	3.00		
MBC: B	20/05/90	0.0	1.0				z	0.00	0.00	0.00	0.00		
PLATELETS	20/05/90	120.0	640.0				10**9/l	182.00	169.00	215.00	232.00		
Na+	20/05/90	138.0	158.0				mmol/l	146.00	146.00	145.00	144.00		
K+	20/05/90	3.6	5.0				mmol/l	4.50	4.50	4.30	4.40		
Ca++	20/05/90	1.8	2.6				mmol/l	2.00	2.00	2.70	2.60		
PO4--	20/05/90	0.9	1.6				mmol/l	1.30	1.00	0.80	0.90		
SGPT	20/05/90	4.0	25.0				U/l	8.00	6.00	9.00	6.00		
SGPT	20/05/90	4.0	27.0				U/l	6.00	6.00	9.00	9.00		
GAMMA-GT	20/05/90	4.0	28.0				U/l	13.00	6.00	5.00	11.00		
GLUCOSE	20/05/90	3.6	5.7				mmol/l	3.30	2.90	3.40	3.00		
ALK. PHOSPH.	20/05/90	2.0	10.0				mmol/l	39.00	29.00	29.00	35.00		
BUN	20/05/90	4.5	10.5				mmol/l	4.00	4.00	2.00	2.00		
CREATININE	20/05/90	100.0	400.0				umol/l	86.00	80.00	70.00	80.00		
URIC ACID	20/05/90	2.0	10.0				mmol/l	260.00	261.00	262.00	227.00		

1690

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXYTINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
9	23	SZN	FEMALE	TOT BILIRUBIN	20/05/90	2.0	20.0	umol/l	12.00	5.00	10.00	12.00				
				DIR BILIRUBIN	20/05/90	0.0	5.0	umol/l	0.00	0.00	0.00	0.00				
				TOT. PROTEINS	20/05/90	66.0	97.0	g/l	94.00	85.00	85.00	81.50				
				ALBUMINE	20/05/90	32.0	55.0	g/l	57.00	46.00	46.00	59.90				
				TOT. CHOLEST.	20/05/90	3.0	8.7	mmol/l	5.60	3.90	5.40	4.80				
				TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/l	1.60	1.60	2.70	0.90				
				GLOBULINS: ALPHA 1	20/05/90	2.5	4.0	g	2.10	1.70	1.70	1.30				
				GLOBULINS: ALPHA 2	20/05/90	7.0	10.0	g	9.10	9.00	9.00	7.70				
				GLOBULINS: BETA	20/05/90	8.3	14.5	g	13.20	15.30	15.30	14.00				
				GLOBULINS: GAMMA	20/05/90	14.0	25.0	g	20.50	22.90	22.90	17.10				
				24	LOY		MALE	HB	20/05/90	4.0	10.5	mmol/l	04/11/91	25/11/91	09/12/91	19/12/91
								HTC	20/05/90	38.0	55.0	g	15.10	16.90	16.90	14.50
								RBC	20/05/90	4.0	6.0	10 ⁶ /ul	45.00	43.00	43.00	41.00
								HBC: N	20/05/90	4.0	12.0	10 ⁶ /ul	4.90	4.70	4.80	4.60
								HBC: L	20/05/90	60.0	80.0	g	5.20	6.00	5.70	4.90
								HBC: E	20/05/90	15.0	40.0	g	69.00	53.00	53.00	69.00
HBC: M	20/05/90	0.0	5.0					g	23.00	7.00	7.00	8.00				
HBC: B	20/05/90	1.0	6.0					g	4.00	3.00	3.00	4.00				
PLATELETS	20/05/90	0.0	1.0					z	175.00	153.00	146.00	167.00				
NA+	20/05/90	138.0	158.0					mmol/l	147.00	146.00	146.00	149.00				
K+	20/05/90	3.6	5.0					mmol/l	4.80	4.20	4.50	5.10				
CA++	20/05/90	1.8	2.6					mmol/l	2.00	2.20	2.30	2.30				
PO4--	20/05/90	0.9	1.6					mmol/l	0.90	1.10	1.20	0.90				
SGPT	20/05/90	7.0	28.0					U/l	23.00	19.00	11.00	9.00				
GAMMA-GT	20/05/90	6.0	22.0					U/l	14.00	9.00	10.00	7.00				
GLUCOSE	20/05/90	6.0	28.0					U/l	6.00	3.00	9.00	4.70				
ALK. PHOSPH.	20/05/90	3.6	5.7	mmol/l	41.00	36.00	38.00	31.00								
CREATININE	20/05/90	2.0	9.0	mmol/l	6.00	3.00	2.00	4.00								
URIC ACID	20/05/90	55.0	105.0	umol/l	85.00	95.00	85.00	85.00								
DIR BILIRUBIN	20/05/90	100.0	420.0	umol/l	239.00	214.00	201.00	219.00								
TOT BILIRUBIN	20/05/90	2.0	20.0	umol/l	14.00	15.00	10.00	11.00								
TOT. PROTEINS	20/05/90	0.0	5.0	umol/l	0.00	0.00	0.00	0.00								
ALBUMINE	20/05/90	66.0	97.0	g/l	72.00	66.00	74.00	70.00								
TOT. CHOLEST.	20/05/90	32.0	55.0	g/l	47.00	52.00	43.00	54.00								
TRIGLYCERIDES	20/05/90	3.0	8.7	mmol/l	3.70	4.50	3.80	4.70								
GLOBULINS: ALPHA 1	20/05/90	0.5	1.8	mmol/l	0.60	0.50	0.50	0.50								
GLOBULINS: ALPHA 2	20/05/90	2.5	4.0	g	3.40	2.30	2.10	2.00								
GLOBULINS: BETA	20/05/90	7.0	10.0	g	8.10	5.80	5.00	6.50								
GLOBULINS: GAMMA	20/05/90	8.3	14.5	g	11.30	12.00	12.60	12.10								
T3	20/05/90	14.0	25.0	g	18.90	18.60	20.40	24.80								
T4	20/05/90	1.2	4.5	mmol/l	1.90	1.90	1.90	1.90								
25	PK		FEMALE	HB	20/05/90	4.0	10.0	mmol/l	15/11/91	03/12/91	17/12/91	31/12/91				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centro	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
9	25	PH	FEMALE	HTC	20/05/90	36.0	53.0	Z	45.00	46.00	46.00	42.00	
				RBC	20/05/90	4.0	5.8	10**6/u1	4.70	5.00	4.90	4.50	
				HBC: N	20/05/90	4.0	12.0	10**3/u1	5.70	5.70	5.80	5.00	
				HBC: L	20/05/90	60.0	80.0	Z	60.00	67.00	52.00	.	
				HBC: E	20/05/90	15.0	40.0	Z	33.00	29.00	41.00	.	
				HBC: M	20/05/90	0.0	5.0	Z	2.00	0.00	3.00	.	
				HBC: B	20/05/90	1.0	6.0	Z	5.00	4.00	4.00	.	
				PLATELETS	20/05/90	0.0	1.0	Z	.	0.00	0.00	.	
				NA+	20/05/90	120.0	640.0	10**9/l	130.00	135.00	146.00	156.00	
				K+	20/05/90	138.0	158.0	mmol/l	149.00	146.00	144.00	146.00	
				CA++	20/05/90	3.6	5.0	mmol/l	5.00	4.80	4.50	4.40	
				PO4--	20/05/90	1.8	2.6	mmol/l	2.30	2.40	2.40	2.50	
				SGOT	20/05/90	0.9	1.6	mmol/l	0.70	0.80	0.70	20.00	
				SGPT	20/05/90	4.0	25.0	U/l	13.00	16.00	19.00	20.00	
				GAMMA-GT	20/05/90	4.0	27.0	U/l	28.00	36.00	47.00	25.00	
				GLUCOSE	20/05/90	4.0	28.0	U/l	25.00	18.00	26.00	24.00	
				ALK. PHOSPH.	20/05/90	3.6	5.7	mmol/l	5.60	6.50	4.40	5.30	
				BUN	20/05/90	2.0	5.0	mmol/l	4.40	4.00	35.00	27.00	
				CREATININE	20/05/90	2.0	10.0	mmol/l	5.00	3.00	80.00	5.00	
				URIC ACID	20/05/90	45.0	105.0	mmol/l	75.00	85.00	80.00	85.00	
				TOT. BILIRUBIN	20/05/90	100.0	400.0	umol/l	282.00	266.00	281.00	288.00	
				TOT. PROTEINS	20/05/90	2.0	20.0	umol/l	17.00	8.00	17.00	13.00	
				ALBUMINE	20/05/90	66.0	97.0	g/l	78.00	82.00	78.00	76.40	
				TRIGLYCERIDES	20/05/90	32.0	55.0	g/l	53.00	47.00	52.00	41.10	
				GLOBULINS: ALPHA 1	20/05/90	3.0	8.7	mmol/l	4.50	3.90	5.60	4.40	
				GLOBULINS: ALPHA 2	20/05/90	0.3	1.8	mmol/l	1.60	1.80	2.20	1.60	
				GLOBULINS: BETA	20/05/90	2.5	4.0	Z	2.30	2.30	1.30	3.70	
				GLOBULINS: GAMMA	20/05/90	7.0	10.0	Z	9.80	9.50	7.70	12.00	
				T3	20/05/90	8.3	14.5	Z	14.80	20.30	17.70	21.30	
				T4	20/05/90	14.0	25.0	Z	16.60	15.90	18.10	21.90	
					20/05/90	100.0	300.0	mmol/l	1.80	.	.	.	
					20/05/90	100.0	300.0	mmol/l	127.00	.	.	.	
26	CP		FEMALE	HB	21/11/91	4.0	10.0	mmol/l	14.90	14.80	14.40	14.50	
				HTC	20/05/90	36.0	53.0	Z	44.00	43.00	43.00	41.00	
				RBC	20/05/90	4.0	5.8	10**6/u1	4.70	4.60	4.80	4.40	
				HBC: N	20/05/90	60.0	80.0	Z	9.60	11.50	8.30	9.00	
				HBC: L	20/05/90	15.0	40.0	Z	78.00	65.00	.	.	
				HBC: E	20/05/90	0.0	5.0	Z	17.00	31.00	.	.	
				HBC: M	20/05/90	1.0	6.0	Z	4.00	0.00	.	.	
				HBC: B	20/05/90	0.0	1.0	Z	4.00	4.00	.	.	
				PLATELETS	20/05/90	120.0	640.0	10**9/l	290.00	150.00	196.00	274.00	
				NA+	20/05/90	138.0	158.0	mmol/l	144.00	144.00	145.00	147.00	
				K+	20/05/90	3.6	5.0	mmol/l	5.00	4.90	4.20	4.60	
				CA++	20/05/90	1.8	2.6	mmol/l	2.10	2.80	2.60	2.50	
				PO4--	20/05/90	0.9	1.6	mmol/l	1.20	1.40	1.00	0.90	
				SGOT	20/05/90	4.0	25.0	U/l	7.00	9.00	11.00	7.00	

1693

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOMETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit				
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6
9	26	CP	FEMALE	SGPT	20/05/90	4.0	27.0	U/l	13.00	14.00	9.00	12.00
				GAMMA-GT	20/05/90	4.0	28.0	U/l	32.00	6.00	15.00	29.00
				GLUCOSE	20/05/90	3.6	5.7	mmol/l	4.00	3.60	5.00	5.70
				ALK. PHOSPH.	20/05/90	20.0	55.0	mmol/l	68.00	67.00	56.00	76.00
				BUN	20/05/90	2.0	10.0	mmol/l	3.00	7.00	7.00	3.00
				CREATININE	20/05/90	45.0	105.0	umol/l	75.00	75.00	80.00	70.00
				URIC ACID	20/05/90	100.0	400.0	umol/l	323.00	260.00	280.00	349.00
				TOT BILIRUBIN	20/05/90	2.0	20.0	umol/l	14.00	8.00	10.00	11.00
				DIR BILIRUBIN	20/05/90	0.0	5.0	umol/l	0.00	0.00	0.00	0.00
				TOT. PROTEINS	20/05/90	66.0	97.0	g/l	74.00	80.00	76.00	84.00
				ALBUMINE	20/05/90	32.0	55.0	g/l	46.00	46.00	49.00	52.00
				TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/l	5.60	6.00	10.80	6.30
				CHOLEST.	20/05/90	2.5	4.0	%	2.70	3.30	4.30	2.60
				GLOBULINS: ALPHA 1	20/05/90	7.0	10.5	%	2.50	1.50	2.10	1.70
				GLOBULINS: ALPHA 2	20/05/90	8.3	14.5	%	9.40	5.60	6.10	6.40
				GLOBULINS: BETA	20/05/90	14.0	25.0	%	16.60	15.90	18.80	16.70
				GLOBULINS: GAMMA	20/05/90	2.0	5.0	mmol/l	22.40	16.90	22.70	17.90
				T3	20/05/90	100.0	300.0	nmol/l	1.40			
				T4	20/05/90	100.0	300.0	nmol/l	130.00			
				27	25L	MALE	HB	20/05/90	4.0	10.5	mmol/l	13.10
HTC	20/05/90	38.0	53.0				%	41.00	42.00	39.00	42.00	
RBC	20/05/90	4.0	6.0				10**6/u1	4.50	4.60	3.90	4.60	
WBC	20/05/90	4.0	12.0				10**3/u1	4.70	7.30	5.80	7.30	
NBC: N	20/05/90	60.0	80.0				%	81.00	67.00	89.00	89.00	
NBC: L	20/05/90	15.0	40.0				%	17.00	26.00	14.00	14.00	
NBC: E	20/05/90	0.0	5.0				%	0.00	4.00	0.00	0.00	
NBC: B	20/05/90	1.0	6.0				%	2.00	3.00	3.00	3.00	
NBC: H	20/05/90	0.0	1.0				%	0.00	0.00	0.00	0.00	
PLATELETS	20/05/90	120.0	640.0				10**9/l	269.00	269.00	150.00	150.00	
NA+	20/05/90	138.0	158.0				mmol/l	140.00	144.00	144.00	144.00	
K+	20/05/90	3.6	5.0				mmol/l	4.50	4.70	4.60	4.60	
CA++	20/05/90	1.8	2.6				mmol/l	2.20	1.90	2.10	2.10	
PO4--	20/05/90	0.9	1.6				mmol/l	0.90	1.10	1.10	1.10	
SGOT	20/05/90	7.0	28.0				U/l	11.00	8.00	8.00	8.00	
SGPT	20/05/90	6.0	22.0				U/l	13.00	7.00	8.00	8.00	
GAMMA-GT	20/05/90	6.0	28.0				U/l	17.00	14.00	15.00	15.00	
GLUCOSE	20/05/90	3.6	5.7				mmol/l	3.70	3.90	5.40	5.40	
ALK. PHOSPH.	20/05/90	20.0	55.0				mmol/l	19.00	20.00	43.00	43.00	
BUN	20/05/90	2.0	10.0				mmol/l	7.00	5.00	5.00	5.00	
CREATININE	20/05/90	55.0	105.0	umol/l	95.00	95.00	140.00	140.00				
URIC ACID	20/05/90	100.0	420.0	umol/l	287.00	244.00	198.00	198.00				
TOT BILIRUBIN	20/05/90	2.0	20.0	umol/l	7.00	14.00	8.00	8.00				
TOT. PROTEINS	20/05/90	66.0	97.0	g/l	68.00	80.00	68.00	68.00				
ALBUMINE	20/05/90	32.0	55.0	g/l	41.00	50.00	45.00	45.00				
CHOLEST.	20/05/90	3.0	8.7	mmol/l	4.10	5.80	5.90	5.90				
TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/l	1.50	0.50	1.20	1.20				
GLOBULINS: ALPHA 1	20/05/90	2.5	4.0	%	1.70	1.30	1.30	1.30				
GLOBULINS: ALPHA 2	20/05/90	7.0	10.0	%	6.10	6.00	9.70	9.70				

1690

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBORELINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit									
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6					
9	27	ZSL	MALE	GLUCOLINS: BETA	20/05/90	8.3	14.5	%	13.30	15.20	15.50						
				GLUCOLINS: GAMMA	20/05/90	14.0	25.0	%	22.80	22.20	18.20						
				T3	20/05/90	1.2	4.5	nmol/l	1.20								
				T4	20/05/90	50.0	200.0	nmol/l	103.00								
				28	HI		MALE	HB	20/05/90	4.0	10.5	mmol/l	14.10	14.00	13.40	18/05/92	13.50
								HTC	20/05/90	38.0	53.0	%	43.00	43.00	41.00	04/05/92	41.00
								RBC	20/05/90	4.0	6.0	10**6/u1	4.60	4.70	4.40	04/05/92	4.40
								WBC	20/05/90	4.0	12.0	10**3/u1	6.60	9.10	7.60	04/05/92	7.30
								PLT	20/05/90	60.0	80.0	%	69.00		68.00	04/05/92	65.00
								CRP	20/05/90	15.0	40.0	%	25.00		27.00	04/05/92	31.00
								ALB	20/05/90	0.0	5.0	%	2.00		1.00	04/05/92	1.00
								GLU	20/05/90	1.0	6.0	%	4.00		4.00	04/05/92	3.00
UREA	20/05/90	0.0	1.0					%	0.00		0.00	04/05/92	0.00				
CREAT	20/05/90	120.0	640.0					10**9/l	215.00	143.00	291.00	04/05/92	298.00				
UREA	20/05/90	158.0	158.0					mmol/l	145.00	143.00	143.00	04/05/92	144.00				
UREA	20/05/90	3.6	5.0					mmol/l	4.80	4.90	5.70	04/05/92	4.60				
29	SZF		FEMALE	HB	20/05/90	4.0	10.0	mmol/l	11.70	11.10	11.30	04/05/92	11.00				
				HTC	20/05/90	36.0	53.0	%	36.00	35.00	36.00	04/05/92	33.00				
				RBC	20/05/90	4.0	5.8	10**6/u1	4.10	3.90	4.00	04/05/92	3.80				
				WBC	20/05/90	4.0	12.0	10**3/u1	4.00	4.80	4.30	04/05/92	4.20				
				PLT	20/05/90	60.0	80.0	%	62.00	71.00	45.00	04/05/92	72.00				
				CRP	20/05/90	15.0	40.0	%	31.00	27.00	23.00	04/05/92	24.00				
				ALB	20/05/90	0.0	5.0	%	2.00	0.00	0.00	04/05/92	1.00				
				GLU	20/05/90	1.0	6.0	%	4.00	2.00	2.00	04/05/92	3.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit						
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6		
9	29	SZF	FEMALE	WBC: B	20/05/90	0.0	1.0	%	1.00	0.00	0.00	0.00	0.00	0.00
				PLATELETS	20/05/90	120.0	640.0	10**9/l	248.00	263.00	269.00	221.00		
				NA+	20/05/90	138.0	158.0	mmol/l	144.00	145.00	145.00	142.00		
				K+	20/05/90	3.6	5.0	mmol/l	5.00	5.00	5.00	5.20		
				CA++	20/05/90	1.8	2.6	mmol/l	1.90	2.30	2.10	2.10		
				PO4-	20/05/90	0.9	1.6	mmol/l	1.40	1.20	1.10	1.20		
				SGOT	20/05/90	4.0	25.0	U/l	19.00	10.00	23.00	40.00		
				SGPT	20/05/90	4.0	27.0	U/l	32.00	26.00	18.00	107.00		
				GAMMA-GT	20/05/90	4.0	28.0	U/l	28.00	34.00	22.00	28.00		
				GLUCOSE	20/05/90	3.6	5.7	mmol/l	3.40	3.70	4.10	4.10		
				ALK. PHOSPH.	20/05/90	20.0	55.0	mmol/l	30.00	35.00	41.00	55.00		
				BUN	20/05/90	2.0	10.0	mmol/l	5.00	6.00	4.00	5.00		
				CREATININE	20/05/90	45.0	105.0	umol/l	75.00	75.00	65.00	75.00		
				URIC ACID	20/05/90	100.0	400.0	umol/l	158.00	203.00	271.00	261.00		
				TOT. BILIRUBIN	20/05/90	2.0	20.0	umol/l	8.00	7.00	9.00	11.00		
				TOT. PROTEINS	20/05/90	66.0	97.0	g/l	80.00	76.00	80.00	80.00		
				ALBUMINE	20/05/90	32.0	55.0	g/l	47.00	55.00	55.00	51.00		
				TOT. CHOLEST.	20/05/90	3.0	8.7	mmol/l	5.80	5.50	5.30	5.00		
				TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/l	0.80	0.50	0.40	0.50		
				GLOBULINS: ALPHA 1	20/05/90	2.5	4.0	%	1.30	0.80	0.30	2.50		
GLOBULINS: ALPHA 2	20/05/90	7.0	10.0	%	6.20	7.90	9.30	6.50						
GLOBULINS: BETA	20/05/90	8.3	14.5	%	14.80	13.40	18.50	13.70						
GLOBULINS: GAMMA	20/05/90	14.0	25.0	%	23.80	23.50	28.20	26.50						
T3	20/05/90	2.0	5.0	mmol/l	1.80	.	.	.						
T4	20/05/90	100.0	300.0	mmol/l	110.00	.	.	.						
30	NF	FEMALE	HB	20/05/90	4.0	10.0	mmol/l	13.10	07/04/92	17/04/92	04/05/92	18/05/92		
			HTC	20/05/90	36.0	53.0	%	40.00	13.50	13.50	13.30			
			PRC	20/05/90	4.0	5.8	10**6/ul	4.20	4.00	4.00	41.00			
			HRC: N	20/05/90	4.0	12.0	10**3/ul	8.70	4.20	4.30	4.20			
			HRC: L	20/05/90	60.0	80.0	%	70.00	10.80	10.80	11.30			
			HRC: E	20/05/90	15.0	40.0	%	24.00	71.00	71.00	75.00			
			HRC: H	20/05/90	0.0	5.0	%	3.00	23.00	23.00	21.00			
			HRC: B	20/05/90	1.0	6.0	%	3.00	2.00	2.00	0.00			
			PLATELETS	20/05/90	120.0	640.0	10**9/l	381.00	0.00	0.00	0.00			
			NA+	20/05/90	138.0	158.0	mmol/l	144.00	146.00	145.00	145.00			
			K+	20/05/90	3.6	5.0	mmol/l	4.60	5.30	5.30	5.60			
			CA++	20/05/90	1.8	2.6	mmol/l	2.10	2.30	2.30	2.30			
			PO4-	20/05/90	0.9	1.6	mmol/l	1.80	1.20	1.50	1.50			
			SGOT	20/05/90	4.0	25.0	U/l	7.00	6.00	7.00	10.00			
			SGPT	20/05/90	4.0	27.0	U/l	4.00	6.00	6.00	5.00			
			GAMMA-GT	20/05/90	4.0	28.0	U/l	17.00	18.00	19.00	19.00			
			GLUCOSE	20/05/90	3.6	5.7	mmol/l	4.70	4.40	4.50	3.20			
			ALK. PHOSPH.	20/05/90	20.0	55.0	mmol/l	30.00	31.00	28.00	46.00			
			BUN	20/05/90	2.0	10.0	mmol/l	4.00	4.00	4.00	4.00			
			CREATININE	20/05/90	45.0	105.0	umol/l	75.00	70.00	75.00	4.00			
URIC ACID	20/05/90	100.0	400.0	umol/l	204.00	193.00	295.00	253.00						

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
9	30	NF	FEMALE	TOT. PROTEINS	20/05/90	66.0	97.0	g/l	74.00	76.00	76.00	76.00	78.00
				ALBUMINE	20/05/90	32.0	55.0	g/l	47.00	46.00	51.00	53.00	
				TOT. CHOLEST.	20/05/90	3.0	8.7	mmol/l	5.50	4.30	4.90	5.40	
				TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/l	1.60	1.30	1.30	1.20	
				GLOBULINS: ALPHA 1	20/05/90	2.5	4.0	%	1.10	1.00	1.80	1.70	
				GLOBULINS: ALPHA 2	20/05/90	7.0	10.0	%	4.50	5.20	7.50	7.80	
				GLOBULINS: BETA	20/05/90	8.3	14.5	%	17.20	18.10	16.20	15.50	
				GLOBULINS: GAMMA	20/05/90	14.0	25.0	%	18.70	17.90	18.60	18.40	
				T3	20/05/90	2.0	5.0	nmol/l	2.20				
				T4	20/05/90	100.0	300.0	nmol/l	106.00				
10	1	VK	MALE	BB	01/10/90	129.0	150.0	g/l	03/10/90	30/10/90	13/11/90	27/11/90	
				BTC	01/10/90	0.4	0.5	l/l	135.00	138.00	140.00	136.00	
				RBC	01/10/90	4.0	5.0	10 ^{xx} 12/l	0.42	0.43	0.43	0.43	
				HBC	01/10/90	4.0	8.8	10 ^{xx} 9/l	4.15	4.20	4.30	4.25	
				HBC: N	01/10/90	51.0	77.0	%	5.10	5.80	5.30	4.20	
				HBC: L	01/10/90	18.0	38.0	%	72.00	64.00	49.00	64.00	
				HBC: E	01/10/90	1.0	5.0	%	22.00	27.00	42.00	31.00	
				HBC: M	01/10/90	2.0	10.0	%	3.00	6.00	7.00	3.00	
				HBC: B	01/10/90	0.0	1.0	%	3.00	3.00	2.00	2.00	
				PLATELETS	01/10/90	180.0	320.0	10 ^{xx} 9/l	0.00	0.00	0.00	0.00	
				NA+	01/10/90	135.0	150.0	mmol/l	225.00	220.00	237.00	215.00	
				K+	01/10/90	4.0	5.6	mmol/l	135.00	136.00	136.00	139.00	
				CL-	01/10/90	95.0	105.0	mmol/l	4.10	4.20	4.60	4.50	
				PO4-	01/10/90	0.6	1.3	mmol/l	107.80	99.50	98.90	95.90	
				SGPT	01/10/90	1.0	12.0	U/l	1.23	7.00	0.98	0.94	
				GAMMA-GT	01/10/90	1.0	9.0	U/l	6.20	7.00	4.90	7.40	
				GLUCOSE	01/10/90	15.0	106.0	U/l	8.30	6.50	9.70	6.70	
				ALK. PHOSPH.	01/10/90	3.5	5.5	nmol/l	57.00	59.00	35.00	44.00	
				CREATININE	01/10/90	135.0	360.0	nmol/l	4.60	5.00	4.20	4.40	
				UREIC ACID	01/10/90	3.3	10.0	nmol/l	344.00	252.00	292.00	320.00	
				TOT. BILIRUBIN	01/10/90	44.0	101.0	umol/l	4.80	5.20	4.40	4.40	
				DER. BILIRUBIN	01/10/90	119.0	357.0	umol/l	74.60	79.90	70.00	73.30	
TOT. BILIRUBIN	01/10/90	8.6	20.5	umol/l	361.00	329.00	382.00	512.00					
DER. BILIRUBIN	01/10/90	0.0	5.1	umol/l	14.50	13.60	17.80	18.10					
ALBUMINE	01/10/90	65.0	85.0	g/l	2.90	2.30	2.50	1.30					
TOT. PROTEINS	01/10/90	34.0	55.0	g/l	78.50	81.00	81.00	81.00					
TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/l	49.80	50.40	50.40	50.60					
TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/l	51.40	6.20	6.30	4.30					
GLOBULINS: ALPHA 1	01/10/90	1.3	6.0	g/l	1.70	1.80	1.76	1.73					
GLOBULINS: ALPHA 2	01/10/90	5.0	9.0	g/l	2.80	3.20	6.20	5.10					
GLOBULINS: BETA	01/10/90	5.0	13.0	g/l	5.90	6.90	6.40	5.30					
GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	10.10	10.10	7.70	11.30					
T3	01/10/90	1.1	2.2	nmol/l	12.80	11.00	10.30	7.10					
T4	01/10/90	60.0	140.0	nmol/l	110.00								
4	ZSD		FEMALE	BB	01/10/90	140.0	140.0	g/l	24/10/90	14/11/90	28/11/90	11/12/90	
				BTC	01/10/90	140.0	140.0	g/l	125.00	124.00	120.00	125.00	

1696

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range		Unit	Visit					
					Date	Min		Max	Screen	Week 2	Week 4	Week 6	
10	4	ZSD	FEMALE	HTC	01/10/90	0.4	0.5	L/l	0.37	0.39	0.37	0.37	0.37
				RBC	01/10/90	3.7	4.7	10**12/l	3.80	3.80	3.67	3.70	
				RBC: N	01/10/90	4.0	8.8	10**9/l	4.80	4.20	7.10	6.60	
				RBC: L	01/10/90	51.0	77.0	%	58.00	71.00	64.00	68.00	
				RBC: E	01/10/90	18.0	38.0	%	31.00	21.00	31.00	27.00	
				RBC: N	01/10/90	1.0	5.0	%	0.00	3.00	1.00	4.00	
				RBC: B	01/10/90	2.0	10.0	%	4.00	5.00	4.00	1.00	
				PLATELETS	01/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	
				Na+	01/10/90	180.0	320.0	10**9/l	225.00	187.00	205.00	200.00	
				CL-	01/10/90	135.0	150.0	mmol/l	141.00	140.00	138.00	142.00	
				PO4--	01/10/90	0.6	1.3	mmol/l	1.03	1.03	1.01	1.04	
				SGPT	01/10/90	1.0	12.0	U/l	6.00	1.80	4.50	7.50	
				GAMMA-GT	01/10/90	1.0	9.0	U/l	9.70	1.50	3.80	4.50	
				GLUCOSE	01/10/90	3.5	5.5	mmol/l	4.90	4.20	4.80	26.00	
				ALK. PHOSPH.	01/10/90	135.0	360.0	mmol/l	265.00	321.00	392.00	388.00	
				CREATININE	01/10/90	44.0	88.0	mmol/l	6.60	4.90	4.80	15.80	
				URIC ACID	01/10/90	119.0	357.0	umol/l	278.00	315.00	262.00	270.00	
				DIR. BILIRUBIN	01/10/90	8.6	20.5	umol/l	10.90	9.80	16.30	17.40	
				TOT. PROTEINS	01/10/90	65.0	85.0	g/l	2.60	1.20	1.90	1.30	
				ALBUMINE	01/10/90	34.0	55.0	g/l	56.50	53.50	45.70	53.40	
				TRIGLYCERIDES	01/10/90	3.1	6.2	mmol/l	6.40	6.60	6.90	6.70	
				GLOBULINS: ALPHA 1	01/10/90	0.5	1.9	mmol/l	1.20	1.82	1.75	1.92	
				GLOBULINS: ALPHA 2	01/10/90	1.3	6.0	g/l	2.40	2.60	4.30	3.00	
				GLOBULINS: BETA	01/10/90	5.0	13.0	g/l	6.20	6.80	11.50	8.90	
				GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	8.80	10.50	10.20	5.60	
				T3	01/10/90	1.1	2.2	nmol/l	10.10	9.60	11.90	8.50	
				T4	01/10/90	60.0	140.0	nmol/l	0.72	0.72	0.72	0.72	
5	AN	FEMALE	HB	01/10/90	112.0	140.0	g/l	07/11/90	28/11/90	11/12/90	27/12/90		
			HTC	01/10/90	3.7	4.7	10**12/l	126.00	126.00	127.00	126.00		
			RBC	01/10/90	0.4	0.5	l/l	0.41	0.41	0.41	0.40		
			RBC: N	01/10/90	4.0	8.8	10**9/l	4.05	4.00	4.00	4.00		
			RBC: L	01/10/90	51.0	77.0	%	4.70	5.60	5.60	4.70		
			RBC: E	01/10/90	18.0	38.0	%	64.00	69.00	79.00	68.00		
			RBC: B	01/10/90	1.0	5.0	%	54.00	24.00	18.00	24.00		
			RBC: N	01/10/90	2.0	10.0	%	2.00	2.00	1.00	2.00		
			RBC: B	01/10/90	0.0	1.0	%	5.00	5.00	2.00	5.00		
			PLATELETS	01/10/90	180.0	320.0	10**9/l	0.00	0.00	0.00	1.00		
			Na+	01/10/90	135.0	150.0	mmol/l	210.00	210.00	218.00	210.00		
			K+	01/10/90	4.0	5.6	mmol/l	139.00	137.00	137.00	142.00		
			CL-	01/10/90	95.0	105.0	mmol/l	99.80	100.60	96.80	96.90		
			PO4--	01/10/90	0.6	1.3	mmol/l	1.13	1.10	1.11	0.90		
SCOT	01/10/90	1.0	12.0	U/l	3.00	8.10	5.80	3.50					

1697

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
10	5	AN	FEMALE	SGPT	01/10/90	1.0	9.0	U/l	5.00	6.80	7.00	4.50	
				GAMMA-GT	01/10/90	10.0	66.0	U/l	12.00	18.00	32.00	21.00	
				GLUCOSE	01/10/90	3.5	5.5	mmol/l	4.70	4.30	5.00	4.20	
				ALK. PHOSPH.	01/10/90	135.0	360.0	mmol/l	205.00	238.00	243.00	210.00	
				BUN	01/10/90	3.3	10.0	mmol/l	4.90	6.90	4.50	10.80	
				CREATININE	01/10/90	44.0	88.0	umol/l	76.60	64.30	70.40	67.00	
				URIC ACID	01/10/90	119.0	357.0	umol/l	251.00	294.00	256.00	238.00	
				TOT BILIRUBIN	01/10/90	8.6	20.5	umol/l	15.20	15.20	15.60	14.40	
				DIR BILIRUBIN	01/10/90	0.5	4.3	umol/l	1.30	1.40	1.20	0.90	
				TOT. PROTEINS	01/10/90	65.0	85.0	g/l	70.00	72.30	71.00	76.00	
				ALBUMINE	01/10/90	34.0	55.0	g/l	43.30	43.20	43.20	39.80	
				TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/l	5.20	5.00	4.70	4.80	
				TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/l	1.65	1.58	1.70	1.53	
				GLOBULINS: ALPHA 1	01/10/90	1.3	6.0	g/l	2.00	2.20	3.00	5.20	
				GLOBULINS: ALPHA 2	01/10/90	5.0	13.0	g/l	6.50	6.80	6.50	8.40	
				GLOBULINS: BETA	01/10/90	5.0	13.0	g/l	8.40	8.20	8.40	12.00	
				GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	9.80	11.30	9.30	10.60	
				T3	01/10/90	1.1	2.2	nmol/l	0.87				
				T4	01/10/90	60.0	140.0	nmol/l	96.00				
6	RS		MALE	HB	01/10/90	129.0	150.0	g/l	148.00	147.00	148.00	144.00	08/01/91
				HTC	01/10/90	0.4	0.5	l/l	0.45	0.46	0.45	0.44	
				RBC	01/10/90	4.0	5.0	10**12/l	4.47	4.50	4.50	4.40	
				WBC	01/10/90	4.0	8.8	10**9/l	4.20	4.40	5.20	4.30	
				PLT	01/10/90	51.0	77.0	%	72.00	69.00	66.00	70.00	
				HGB: L	01/10/90	18.0	38.0	%	22.00	27.00	29.00	24.00	
				HGB: E	01/10/90	1.0	5.0	%	4.00	1.00	0.00	2.00	
				HGB: M	01/10/90	2.0	10.0	%	2.00	3.00	5.00	4.00	
				HGB: B	01/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	
				PLATELETS	01/10/90	180.0	320.0	10**9/l	235.00	237.00	230.00	220.00	
				NA+	01/10/90	135.0	150.0	mmol/l	139.00	137.00	136.00	139.00	
				K+	01/10/90	4.0	5.6	mmol/l	4.60	4.40	5.10	4.60	
				Cl-	01/10/90	95.0	105.0	mmol/l	104.30	96.80	101.60	100.20	
				PO4-	01/10/90	0.6	1.3	mmol/l	1.04	1.13	1.31	1.22	
				SCOT	01/10/90	1.0	12.0	U/l	7.50	3.50	3.00	5.00	
				GAMMA-GT	01/10/90	15.0	106.0	U/l	47.00	67.00	42.00	64.00	
				GLUCOSE	01/10/90	3.5	5.5	mmol/l	4.60	4.40	3.60	4.30	
				ALK. PHOSPH.	01/10/90	135.0	360.0	mmol/l	365.00	185.00	302.00	250.00	
				BUN	01/10/90	3.3	10.0	mmol/l	4.80	4.80	4.90	6.10	
				CREATININE	01/10/90	44.0	101.0	umol/l	69.20	69.90	71.90	74.10	
				URIC ACID	01/10/90	119.0	357.0	umol/l	328.00	21.20	301.00	311.00	
				TOT BILIRUBIN	01/10/90	8.6	20.5	umol/l	17.60	18.80	2.10	17.40	
				DIR BILIRUBIN	01/10/90	0.0	5.1	umol/l	2.20	2.30	2.10	1.10	
				TOT. PROTEINS	01/10/90	65.0	85.0	g/l	79.00	71.00	44.80	83.00	
				ALBUMINE	01/10/90	34.0	55.0	g/l	48.00	46.60	44.80	53.50	
				TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/l	4.10	4.10	1.82	5.80	
				TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/l	1.72	1.78	1.82	1.80	
				GLOBULINS: ALPHA 1	01/10/90	1.3	6.0	g/l	2.50	2.90	10.80	5.60	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6			
10	6	RS	MALE	GLOBULINS: ALPHA 2	01/10/90	5.0	9.0	g/l	4.30	7.40	7.40	7.30			
				GLOBULINS: BETA	01/10/90	5.0	13.0	g/l	10.40	8.40	11.00	9.50			
				GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	13.80	5.80	8.00	7.10			
				T3	01/10/90	1.1	2.2	nmol/l	0.82						
				T4	01/10/90	60.0	140.0	nmol/l	89.00						
7	RK		MALE	HB	01/10/90	129.0	150.0	g/l	13/11/90	04/12/90	18/12/90	03/01/91			
				HTC	01/10/90	0.4	0.5	l/l	138.00	140.00	144.00	138.00			
				RBC	01/10/90	4.0	5.0	10**12/l	4.43	0.43	0.44	0.43			
				HRC	01/10/90	4.0	8.8	10**9/l	4.27	4.30	4.44	4.30			
				HRC: N	01/10/90	51.0	77.0	%	4.60	4.60	5.60	5.60			
				HRC: L	01/10/90	18.0	38.0	%	65.00	58.00	59.00	68.00			
				HRC: E	01/10/90	1.0	5.0	%	30.00	32.00	26.00	25.00			
				HRC: K	01/10/90	2.0	10.0	%	3.00	4.00	13.00	4.00			
				HRC: B	01/10/90	0.0	1.0	%	0.00	0.00	2.00	1.00			
				PLATELETS	01/10/90	180.0	320.0	10**9/l	230.00	217.00	225.00	225.00			
				NA+	01/10/90	135.0	150.0	mmol/l	137.00	138.00	138.00	139.00			
				K+	01/10/90	4.0	5.6	mmol/l	4.90	3.90	4.20	4.30			
				CL-	01/10/90	95.0	105.0	mmol/l	103.30	98.90	94.70	95.20			
				PO4-	01/10/90	0.6	1.3	mmol/l	0.71	0.95	0.92	1.19			
				SGPT	01/10/90	1.0	12.0	U/l	3.50	2.50	3.00	6.00			
				GAMMA-GT	01/10/90	1.0	9.0	U/l	5.80	3.00	7.00	3.50			
				GLUCOSE	01/10/90	15.0	106.0	U/l	18.00	41.00	63.00	44.00			
				ALK. PHOSPH.	01/10/90	3.5	5.5	mmol/l	4.70	3.90	4.10	4.20			
				CREATININE	01/10/90	135.0	360.0	mmol/l	204.00	237.00	389.00	320.00			
				BUN	01/10/90	3.3	10.0	mmol/l	3.90	4.60	6.60	4.20			
URIC ACID	01/10/90	44.0	101.0	mmol/l	68.80	69.90	72.00	79.70							
TOT BILIRUBIN	01/10/90	119.0	357.0	umol/l	347.00	367.00	321.00	360.00							
DIR BILIRUBIN	01/10/90	8.6	20.5	umol/l	16.80	12.00	16.50	16.50							
TOT. PROTEINS	01/10/90	0.0	5.1	umol/l	2.30	2.40	1.80	1.80							
ALBUMINE	01/10/90	65.0	85.0	g/l	78.00	79.00	81.00	82.00							
TOT. CHOLEST.	01/10/90	34.0	55.0	g/l	46.80	56.30	47.00	58.40							
TRIGLYCERIDES	01/10/90	3.1	6.2	mmol/l	5.80	3.10	4.90	5.10							
GLOBULINS: ALPHA 1	01/10/90	0.5	1.9	mmol/l	0.92	1.70	1.68	1.60							
GLOBULINS: ALPHA 2	01/10/90	1.3	6.0	g/l	2.50	1.60	5.10	1.20							
GLOBULINS: BETA	01/10/90	5.0	9.0	g/l	9.00	5.10	7.70	7.70							
GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	12.80	9.40	10.20	8.50							
T3	01/10/90	1.1	2.2	nmol/l	1.05	6.60	9.30	6.20							
T4	01/10/90	60.0	140.0	nmol/l	88.00										
8	VP		FEMALE	HB	01/10/90	112.0	140.0	g/l	26/11/90	11/12/90	18/12/90				
				HTC	01/10/90	0.4	0.5	l/l	134.00	137.00	137.00				
				RBC	01/10/90	3.7	4.7	10**12/l	4.20	0.42	0.43				
				HRC	01/10/90	4.0	8.8	10**9/l	4.20	4.20	4.20				
				HRC: N	01/10/90	51.0	77.0	%	72.00	66.00	66.00				
HRC: L	01/10/90	18.0	38.0	%	23.00	40.00	28.00								

1699

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOMETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit								
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
10	S VP	FEMALE	WBC: E	01/10/90	1.0	5.0	Z	3.00	2.00	4.00	4.00				
			WBC: N	01/10/90	2.0	10.0	Z	2.00	2.00	2.00	2.00				
			WBC: B	01/10/90	0.0	1.0	Z	0.00	0.00	0.00	0.00				
			PLATELETS	01/10/90	180.0	320.0	10**9/1	175.00	180.00	195.00	195.00				
			NA+	01/10/90	135.0	150.0	mmol/l	137.00	135.00	139.00	139.00				
			K+	01/10/90	4.0	5.6	mmol/l	4.50	4.00	4.10	4.10				
			CL-	01/10/90	95.0	105.0	mmol/l	95.00	100.00	103.20	103.20				
			PO4-	01/10/90	0.6	1.3	mmol/l	1.01	1.06	0.98	0.98				
			SGPT	01/10/90	1.0	12.0	U/l	2.50	4.00	6.00	6.00				
			SGOT	01/10/90	1.0	9.0	U/l	5.50	7.00	7.00	7.00				
			GAMMA-GT	01/10/90	10.0	66.0	U/l	16.00	18.00	17.00	17.00				
			GLUCOSE	01/10/90	3.5	5.5	mmol/l	4.60	4.80	4.10	4.10				
			ALK. PHOSPH.	01/10/90	135.0	360.0	mmol/l	247.00	399.00	386.00	386.00				
			BUN	01/10/90	3.3	10.0	mmol/l	4.70	3.70	7.40	7.40				
			CREATININE	01/10/90	44.0	88.0	mmol/l	61.80	62.00	63.70	63.70				
			URIC ACID	01/10/90	119.0	357.0	mmol/l	258.00	248.00	258.00	258.00				
			TOT BILIRUBIN	01/10/90	8.6	20.5	mmol/l	14.00	15.60	15.20	15.20				
			DIR BILIRUBIN	01/10/90	0.5	4.3	mmol/l	1.90	1.00	0.90	0.90				
			TOT. PROTEINS	01/10/90	65.0	85.0	g/l	78.00	72.00	81.00	81.00				
			ALBUMINE	01/10/90	34.0	55.0	g/l	46.80	48.20	44.20	44.20				
			TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/l	3.90	3.80	3.90	3.90				
			TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/l	1.80	1.82	1.75	1.75				
			GLOBULINS: ALPHA 1	01/10/90	1.3	6.0	g/l	2.60	1.40	2.80	2.80				
			GLOBULINS: ALPHA 2	01/10/90	5.0	9.0	g/l	8.80	10.90	8.70	8.70				
			GLOBULINS: BETA	01/10/90	5.0	13.0	g/l	12.20	8.30	13.00	13.00				
			GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	7.60	6.20	12.30	12.30				
			T3	01/10/90	1.1	2.2	mmol/l	1.59							
			T4	01/10/90	60.0	140.0	mmol/l	151.00							
			9	RT	FEMALE	HB	01/10/90	112.0	140.0	g/l	134.00	130.00	134.00	132.00	157/01/91
						HTC	01/10/90	0.4	0.5	l/l	0.42	0.41	0.42	0.42	0.42
						RBC	01/10/90	3.7	4.7	10**12/l	4.17	4.10	4.15	4.15	4.20
						WBC	01/10/90	4.0	8.8	10**9/l	4.40	4.70	4.60	4.60	6.40
						WBC: N	01/10/90	51.0	77.0	Z	72.00	74.00	72.00	72.00	72.00
WBC: L	01/10/90	18.0				38.0	Z	22.00	23.00	25.00	25.00	23.00			
WBC: E	01/10/90	1.0				5.0	Z	4.00	2.00	2.00	2.00	3.00			
WBC: B	01/10/90	2.0				10.0	Z	2.00	1.00	1.00	1.00	2.00			
WBC: R	01/10/90	0.0				1.0	Z	0.00	0.00	0.00	0.00	0.00			
PLATELETS	01/10/90	180.0				320.0	10**9/l	220.00	205.00	200.00	200.00	215.00			
NA+	01/10/90	135.0				150.0	mmol/l	138.00	137.00	136.00	136.00	138.00			
K+	01/10/90	4.0				5.6	mmol/l	4.20	4.20	4.30	4.30	3.60			
CL-	01/10/90	95.0				105.0	mmol/l	95.80	104.40	102.70	102.70	101.60			
PO4-	01/10/90	0.6				1.3	mmol/l	1.32	1.22	1.37	1.37	1.29			
SGPT	01/10/90	1.0				12.0	U/l	5.20	3.00	3.00	3.00	4.50			
SGOT	01/10/90	1.0				9.0	U/l	8.50	4.40	4.70	4.70	3.80			
GAMMA-GT	01/10/90	10.0				66.0	U/l	15.00	21.00	21.00	21.00	19.00			
GLUCOSE	01/10/90	3.5				5.5	mmol/l	3.60	4.00	3.80	3.80	4.10			
BUN	01/10/90	135.0				360.0	mmol/l	189.00	312.00	193.00	193.00	230.00			
	01/10/90	3.3				10.0	mmol/l	6.20	8.30	6.80	6.80	5.80			

1700

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Date	Laboratory Range			Visit							
					Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
10	9	RT	FEMALE												
			CREATININE	01/10/90	44.0	88.0	umol/l	63.30	63.70	66.40	66.40	64.90			
			URIC ACID	01/10/90	119.0	357.0	umol/l	555.00	210.00	238.00	238.00	202.00			
			TOT BILIRUBIN	01/10/90	8.6	20.5	umol/l	18.00	18.00	15.50	15.50	18.50			
			DIR BILIRUBIN	01/10/90	0.5	4.3	umol/l	2.10	1.40	0.90	0.90	0.90			
			TOT PROTEINS	01/10/90	65.0	85.0	g/l	83.00	79.00	82.00	82.00	80.00			
			ALBUMINE	01/10/90	34.0	55.0	g/l	55.90	41.50	56.50	56.50	48.50			
			TOT CHOLEST.	01/10/90	3.1	6.2	mmol/l	4.80	5.70	5.80	5.80	5.00			
			TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/l	1.74	1.60	1.70	1.70	1.65			
			GLOBULINS: ALPHA 1	01/10/90	1.3	6.0	g/l	2.90	4.30	4.70	4.70	3.30			
			GLOBULINS: ALPHA 2	01/10/90	5.0	9.0	g/l	9.10	8.20	6.90	6.90	7.30			
			GLOBULINS: BETA	01/10/90	5.0	13.0	g/l	9.00	11.20	5.20	5.20	8.40			
			GLOBULINS: GAMMA	01/10/90	1.1	2.2	mmol/l	6.10	13.80	8.70	8.70	12.50			
			T3	01/10/90	1.1	2.2	nmol/l	1.50							
			T4	01/10/90	60.0	140.0	nmol/l	97.00							
10	10	HR	FEMALE												
			HB	01/10/90	112.0	140.0	g/l	130.00	131.00	128.00	128.00	128.00	15/01/91		
			HTC	01/10/90	0.4	0.5	l/l	0.42	0.42	0.39	0.39	0.41			
			RBC	01/10/90	3.7	4.7	10**12/l	4.20	4.17	3.82	3.82	4.00			
			HBC	01/10/90	4.0	8.8	10**9/l	4.00	5.40	7.00	7.00	6.00			
			HBC: N	01/10/90	51.0	77.0	%	67.00	58.00	76.00	76.00	77.00			
			HBC: L	01/10/90	18.0	38.0	%	26.00	38.00	20.00	20.00	22.00			
			HBC: E	01/10/90	1.0	5.0	%	3.00	2.00	2.00	2.00	0.00			
			HBC: M	01/10/90	2.0	10.0	%	4.00	2.00	2.00	2.00	1.00			
			HBC: B	01/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00			
			PLATELETS	01/10/90	180.0	320.0	10**9/l	205.00	197.00	195.00	195.00	225.00			
			NA+	01/10/90	135.0	150.0	mmol/l	136.00	136.00	136.00	136.00	136.00			
			K+	01/10/90	4.0	5.6	mmol/l	4.30	4.70	5.10	5.10	4.40			
			CL-	01/10/90	95.0	105.0	mmol/l	96.90	94.70	99.50	99.50	102.20			
			PO4-	01/10/90	0.6	1.3	mmol/l	1.04	1.23	1.08	1.08	1.16			
			SCOT	01/10/90	1.0	12.0	U/l	5.50	6.50	5.00	5.00	5.00			
			SGPT	01/10/90	1.0	9.0	U/l	6.40	8.80	3.00	3.00	3.50			
			GAMMA-GT	01/10/90	10.0	66.0	U/l	21.00	18.00	15.00	15.00	17.00			
			GLUCOSE	01/10/90	3.5	5.5	mmol/l	3.80	4.70	4.10	4.10	4.70			
			ALK. PHOSPH.	01/10/90	135.0	360.0	mmol/l	163.00	376.00	310.00	310.00	350.00			
			BUN	01/10/90	3.3	10.0	mmol/l	2.70	6.20	5.10	5.10	4.90			
			CREATININE	01/10/90	44.0	88.0	umol/l	65.30	218.00	104.30	104.30	67.70			
			TOT BILIRUBIN	01/10/90	119.0	357.0	umol/l	278.00	218.00	252.00	252.00	258.00			
			DIR BILIRUBIN	01/10/90	8.6	20.5	umol/l	14.00	15.20	12.60	12.60	9.60			
			TOT PROTEINS	01/10/90	65.0	85.0	g/l	1.50	1.30	0.80	0.80	0.60			
			ALBUMINE	01/10/90	34.0	55.0	g/l	69.00	76.00	77.00	77.00	79.00			
			TOT CHOLEST.	01/10/90	3.1	6.2	mmol/l	41.70	43.20	51.40	51.40	51.40			
			TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/l	5.00	5.90	4.70	4.70	4.90			
			GLOBULINS: ALPHA 1	01/10/90	1.3	6.0	g/l	1.20	0.92	0.90	0.90	0.70			
			GLOBULINS: ALPHA 2	01/10/90	5.0	9.0	g/l	3.50	3.50	3.50	3.50	3.80			
			GLOBULINS: BETA	01/10/90	5.0	13.0	g/l	9.20	6.80	3.30	3.30	6.20			
			GLOBULINS: GAMMA	01/10/90	1.1	2.2	mmol/l	7.50	10.90	8.40	8.40	9.70			
			T3	01/10/90	1.1	2.2	nmol/l	7.10	11.60	8.40	8.40	8.00			
			T4	01/10/90	60.0	140.0	nmol/l	118.00							

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS R&D
NEBOUTINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6			
10	11	TK	FEMALE	HB	01/10/90	112.0	140.0	g/l	19/12/90	14/01/91					
				HTC	01/10/90	0.4	0.5	l/l	128.00	127.00					
				HBC	01/10/90	3.7	4.7	10**12/l	4.16	4.05					
				HBC: N	01/10/90	4.0	8.8	10**9/l	3.90	6.20					
				HBC: L	01/10/90	51.0	77.0	z	64.00	64.00					
				HBC: E	01/10/90	18.0	38.0	z	30.00	30.00					
				HBC: M	01/10/90	1.0	5.0	z	2.00	2.00					
				HBC: B	01/10/90	2.0	10.0	z	2.00	4.00					
				PLATELETS	01/10/90	8.0	1.0	z	0.00	0.00					
				NA+	01/10/90	180.0	320.0	10**9/l	187.00	197.00					
				K+	01/10/90	135.0	150.0	mmol/l	141.00	138.00					
				CL-	01/10/90	95.0	105.0	mmol/l	5.50	5.30					
				PO4--	01/10/90	0.6	1.3	mmol/l	97.90	100.50					
				SGOT	01/10/90	1.0	12.0	U/l	8.70	3.70					
				SGPT	01/10/90	1.0	9.0	U/l	3.00	3.00					
				GAMMA-GT	01/10/90	10.0	66.0	U/l	16.00	18.00					
				GLUCOSE	01/10/90	3.5	5.5	mmol/l	4.80	4.40					
				ALK. PHOSPH.	01/10/90	135.0	360.0	mmol/l	286.00	225.00					
				BUN	01/10/90	3.3	10.0	mmol/l	5.80	6.70					
				CREATININE	01/10/90	44.0	88.0	umol/l	65.40	75.90					
				URIC ACID	01/10/90	119.0	357.0	umol/l	198.00	246.00					
				TOT BILIRUBIN	01/10/90	8.6	20.5	umol/l	13.90	12.90					
				DIR BILIRUBIN	01/10/90	0.5	4.3	umol/l	0.70	3.90					
				TOT. PROTEINS	01/10/90	65.0	85.0	g/l	74.00	77.00					
				ALBUMINE	01/10/90	34.0	55.0	g/l	43.60	49.40					
				TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/l	3.80	3.70					
				TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/l	0.64	0.90					
GLOBULINS: ALPHA 1	01/10/90	1.3	6.0	g/l	2.90	4.60									
GLOBULINS: ALPHA 2	01/10/90	5.0	9.0	g/l	6.00	5.90									
GLOBULINS: BETA	01/10/90	5.0	13.0	g/l	10.20	9.30									
GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	11.30	7.80									
TS	01/10/90	1.1	2.2	mmol/l	1.38										
T4	01/10/90	60.0	140.0	mmol/l	155.00										
12	EP	FEMALE	HB	01/10/90	112.0	140.0	g/l	08/01/91	23/01/91	06/02/91	20/02/91				
			HTC	01/10/90	0.4	0.5	l/l	134.00	135.00	138.00	138.00				
			HBC	01/10/90	3.7	4.7	10**12/l	4.20	4.41	4.30	4.27				
			HBC: N	01/10/90	4.0	8.8	10**9/l	6.40	5.40	6.00	6.00				
			HBC: L	01/10/90	51.0	77.0	z	65.00	50.00	69.00	60.00				
			HBC: E	01/10/90	18.0	38.0	z	29.00	47.00	26.00	36.00				
			HBC: M	01/10/90	1.0	5.0	z	3.00	2.00	2.00	0.00				
			HBC: B	01/10/90	2.0	10.0	z	3.00	1.00	3.00	4.00				
			PLATELETS	01/10/90	8.0	1.0	z	0.00	0.00	0.00	0.00				
			NA+	01/10/90	180.0	320.0	10**9/l	210.00	200.00	215.00	223.00				
			K+	01/10/90	135.0	150.0	mmol/l	139.00	138.00	141.00	139.00				

1702

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Date	Laboratory Range		Unit	Screen	Visit					
						Min	Max			Week 2	Week 4	Week 6			
10	12	EP	FEMALE	K+	01/10/90	4.0	5.6	mmol/l	4.40	4.00	5.20	5.10	5.10	5.10	
				CL-	01/10/90	95.0	105.0	mmol/l	99.40	97.20	100.10	100.20	100.20	100.20	
				PO4-	01/10/90	0.6	1.3	mmol/l	0.96	1.09	1.01	1.29	1.29	1.29	
				SGOT	01/10/90	1.0	12.0	U/l	5.00	7.00	5.20	4.60	4.60	4.60	
				SGPT	01/10/90	1.0	9.0	U/l	4.00	7.50	4.50	4.10	4.10	4.10	
				GAMMA-GT	01/10/90	10.0	66.0	U/l	14.00	15.00	14.00	17.00	17.00	17.00	
				GLUCOSE	01/10/90	3.5	5.5	mmol/l	4.80	4.30	5.00	4.40	4.40	4.40	
				ALK. PHOSPH.	01/10/90	135.0	360.0	mmol/l	292.00	483.00	220.00	327.00	327.00	327.00	
				BUN	01/10/90	3.3	10.0	mmol/l	5.50	6.20	5.20	4.90	4.90	4.90	
				CREATININE	01/10/90	44.0	88.0	umol/l	74.20	74.50	70.00	70.20	70.20	70.20	
				URIC ACID	01/10/90	119.0	357.0	umol/l	337.00	278.00	356.00	349.00	349.00	349.00	
				TOT BILIRUBIN	01/10/90	8.6	20.5	umol/l	12.50	14.50	18.60	17.20	17.20	17.20	
				DIR BILIRUBIN	01/10/90	0.5	4.3	umol/l	0.80	0.30	0.90	1.00	1.00	1.00	
				TOT. PROTEINS	01/10/90	65.0	85.0	g/l	81.00	79.00	84.00	82.00	82.00	82.00	
				ALBUMINE	01/10/90	34.0	55.0	g/l	47.20	46.80	52.00	44.40	44.40	44.40	
				TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/l	5.50	5.90	6.20	6.50	6.50	6.50	
				TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/l	1.30	0.96	1.10	1.90	1.90	1.90	
				GLOBULINS: ALPHA 1	01/10/90	1.3	6.0	g/l	4.40	5.80	5.20	6.20	6.20	6.20	
				GLOBULINS: ALPHA 2	01/10/90	5.0	9.0	g/l	7.80	7.50	6.60	9.80	9.80	9.80	
				GLOBULINS: BETA	01/10/90	5.0	13.0	g/l	11.70	9.90	8.20	12.00	12.00	12.00	
				GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	9.90	11.00	12.00	9.60	9.60	9.60	
				T3	01/10/90	1.1	2.2	nmol/l	1.41	1.41	1.41	1.41	1.41	1.41	
				T4	01/10/90	60.0	140.0	nmol/l	81.00	81.00	81.00	81.00	81.00	81.00	
				HB	01/10/90	112.0	140.0	g/l	116.00	122.00	121.00	125.00	125.00	125.00	
				HTC	01/10/90	0.4	0.5	l/l	0.35	0.37	0.36	0.37	0.37	0.37	
				RBC	01/10/90	3.7	4.7	10**12/l	3.50	3.67	3.60	3.80	3.80	3.80	
				WBC	01/10/90	4.0	8.8	10**9/l	4.10	4.40	4.80	6.00	6.00	6.00	
				WBC: N	01/10/90	51.0	77.0	%	56.00	58.00	70.00	60.00	60.00	60.00	
				WBC: L	01/10/90	18.0	38.0	%	40.00	35.00	21.00	38.00	38.00	38.00	
				WBC: E	01/10/90	1.0	5.0	%	2.00	2.00	2.00	0.00	0.00	0.00	
				WBC: M	01/10/90	2.0	10.0	%	2.00	4.00	6.00	2.00	2.00	2.00	
				WBC: B	01/10/90	0.0	1.0	%	0.00	1.00	1.00	0.00	0.00	0.00	
				PLATELETS	01/10/90	180.0	320.0	10**9/l	195.00	207.00	205.00	210.00	210.00	210.00	
				Na+	01/10/90	135.0	150.0	mmol/l	142.00	136.00	134.00	140.00	140.00	140.00	
				K+	01/10/90	4.0	5.6	mmol/l	5.20	4.10	4.50	4.70	4.70	4.70	
				CL-	01/10/90	95.0	105.0	mmol/l	100.10	100.20	100.00	102.00	102.00	102.00	
				SGOT	01/10/90	1.0	12.0	U/l	8.80	8.80	6.50	4.60	4.60	4.60	
				SGPT	01/10/90	1.0	9.0	U/l	7.40	7.00	6.50	1.20	1.20	1.20	
				GAMMA-GT	01/10/90	10.0	66.0	U/l	15.00	15.00	14.00	21.00	21.00	21.00	
				GLUCOSE	01/10/90	3.5	5.5	mmol/l	4.40	4.70	4.70	4.00	4.00	4.00	
				ALK. PHOSPH.	01/10/90	135.0	360.0	mmol/l	169.00	146.00	202.00	214.00	214.00	214.00	
				BUN	01/10/90	3.3	10.0	mmol/l	8.10	8.20	4.90	5.00	5.00	5.00	
				CREATININE	01/10/90	44.0	88.0	umol/l	66.80	66.50	62.50	69.40	69.40	69.40	
				URIC ACID	01/10/90	119.0	357.0	umol/l	188.00	189.00	175.00	175.00	175.00	175.00	
				TOT BILIRUBIN	01/10/90	8.6	20.5	umol/l	13.20	13.20	15.40	16.20	16.20	16.20	
				DIR BILIRUBIN	01/10/90	0.5	4.3	umol/l	3.10	1.40	1.30	1.10	1.10	1.10	
				TOT. PROTEINS	01/10/90	65.0	85.0	g/l	79.00	81.00	84.00	81.00	81.00	81.00	

1700

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOREXINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit							
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6			
10	13 HU	FEMALE	ALBUMINE	01/10/90	34.0	55.0	g/l	49.60	42.80	45.90	46.60			
			TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/l	5.20	5.00	4.20	5.00			
			TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/l	1.40	1.79	1.80	1.86			
			GLOBULINS: ALPHA 1	01/10/90	1.3	6.0	g/l	3.30	3.30	2.20	3.20			
			GLOBULINS: ALPHA 2	01/10/90	5.0	9.0	g/l	6.80	5.50	6.70	5.00			
			GLOBULINS: BETA	01/10/90	5.0	13.0	g/l	9.30	18.60	16.00	12.00			
			GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	10.00	12.50	13.20	14.20			
			T3	01/10/90	1.1	2.2	mmol/l	1.35	.	.	.			
			T4	01/10/90	60.0	140.0	nmol/l	109.00	.	.	.			
			14	AA	MALE	HB	01/10/90	129.0	150.0	g/l	141.00	142.00	141.00	144.00
						HTC	01/10/90	0.4	0.5	l/l	0.43	0.43	0.43	0.44
						RBC	01/10/90	4.0	5.0	10 ¹² /l	4.30	4.30	4.37	4.40
						HBC: N	01/10/90	4.0	8.8	10 ¹² /l	8.60	6.80	7.40	6.20
						HBC: L	01/10/90	51.0	77.0	z	68.00	70.00	73.00	66.00
HBC: E	01/10/90	18.0				38.0	z	22.00	28.00	22.00	23.00			
HBC: H	01/10/90	1.0				5.0	z	4.00	0.00	2.00	3.00			
HBC: B	01/10/90	2.0				10.0	z	6.00	0.00	3.00	2.00			
PLATELETS	01/10/90	0.0				1.0	z	0.00	0.00	0.00	0.00			
NA+	01/10/90	180.0				320.0	10 ⁹ /l	230.00	227.00	239.00	230.00			
CL-	01/10/90	135.0				150.0	mmol/l	140.00	136.00	133.00	137.00			
K+	01/10/90	4.0				5.6	mmol/l	4.90	4.00	4.30	4.30			
PO4-	01/10/90	95.0				105.0	mmol/l	99.80	99.80	98.90	99.40			
SCPT	01/10/90	0.6				1.3	mmol/l	1.02	0.96	0.96	1.14			
GAMMA-GT	01/10/90	1.0	12.0	U/l	10.50	8.80	9.50	4.90						
GLUCOSE	01/10/90	1.0	106.0	U/l	5.60	5.20	12.20	1.40						
ALK. PHOSPH.	01/10/90	15.0	106.0	U/l	41.00	18.00	28.00	42.00						
BUN	01/10/90	3.5	5.5	mmol/l	4.80	5.00	4.70	4.80						
CREATININE	01/10/90	135.0	360.0	umol/l	291.00	258.00	353.00	319.00						
URIC ACID	01/10/90	3.3	10.0	mmol/l	7.30	7.30	5.30	5.80						
TOT. BILIRUBIN	01/10/90	44.0	101.0	umol/l	73.30	73.50	68.80	76.10						
DIR BILIRUBIN	01/10/90	119.0	357.0	umol/l	381.00	364.00	466.00	420.00						
TOT. PROTEINS	01/10/90	8.6	20.5	umol/l	16.80	15.40	17.00	18.00						
ALBUMINE	01/10/90	0.0	5.1	umol/l	0.80	0.70	1.30	2.20						
TOT. CHOLEST.	01/10/90	65.0	85.0	g/l	76.00	80.00	81.00	90.00						
TRIGLYCERIDES	01/10/90	34.0	55.0	g/l	48.20	43.90	44.30	56.00						
GLOBULINS: ALPHA 1	01/10/90	3.1	6.2	mmol/l	4.30	5.00	6.90	5.80						
GLOBULINS: ALPHA 2	01/10/90	0.5	1.9	mmol/l	1.70	1.84	2.20	2.30						
GLOBULINS: BETA	01/10/90	1.3	6.0	g/l	2.60	2.40	3.40	2.90						
GLOBULINS: GAMMA	01/10/90	5.0	9.0	g/l	5.80	6.70	8.50	7.10						
T3	01/10/90	5.0	13.0	g/l	7.60	14.30	13.30	14.40						
T4	01/10/90	10.0	17.0	g/l	11.90	10.70	11.20	9.60						
15	HT	FEMALE	HB	01/10/90	112.0	140.0	g/l	136.00	136.00	138.00				

1704

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXEMINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
10	15	HT	FEMALE	RBC	01/10/90	3.7	4.7	10**12/l	4.27	4.27	4.30	4.30	4.30
				WBC	01/10/90	4.0	8.8	10**9/l	4.20	6.20	4.50	4.50	4.80
				HBC: N	01/10/90	51.0	77.0	%	74.00	77.00	70.00	70.00	68.00
				HBC: L	01/10/90	18.0	38.0	%	24.00	21.00	25.00	25.00	28.00
				HBC: E	01/10/90	1.0	5.0	%	0.00	1.00	3.00	3.00	2.00
				HBC: M	01/10/90	2.0	10.0	%	2.00	1.00	1.00	1.00	1.00
				HBC: B	01/10/90	0.0	1.0	%	0.00	0.00	1.00	1.00	1.00
				PLATELETS	01/10/90	180.0	320.0	10**9/l	227.00	215.00	208.00	210.00	210.00
				NA+	01/10/90	135.0	150.0	mmol/l	136.00	141.00	134.00	143.00	143.00
				CL-	01/10/90	95.0	105.0	mmol/l	97.10	102.00	100.10	97.00	97.00
				PO4--	01/10/90	0.6	1.3	mmol/l	1.24	1.11	0.81	1.18	1.18
				SGOT	01/10/90	1.0	12.0	U/l	7.20	4.10	1.20	1.70	1.70
				GAMMA-GT	01/10/90	10.0	66.0	U/l	18.00	22.00	7.00	12.20	12.20
				GLUCOSE	01/10/90	3.5	5.5	mmol/l	4.80	4.60	4.70	4.70	4.70
				ALK. PHOSPH.	01/10/90	33.0	360.0	mmol/l	236.00	401.00	293.00	254.00	254.00
				CREATININE	01/10/90	3.3	10.0	mmol/l	3.90	4.80	3.50	3.80	3.80
				DIR. BILIRUBIN	01/10/90	44.0	88.0	umol/l	65.30	64.40	64.40	64.20	64.20
				TOT. BILIRUBIN	01/10/90	119.0	357.0	umol/l	232.00	311.00	273.00	391.00	391.00
				TOT. PROTEINS	01/10/90	8.6	20.5	umol/l	15.60	20.60	18.20	17.60	17.60
				ALBUMINE	01/10/90	0.5	4.3	umol/l	0.80	0.66	1.20	1.00	1.00
				TOT. CHOLEST.	01/10/90	34.0	55.0	g/l	81.00	84.00	76.00	90.00	90.00
				TRIGLYCERIDES	01/10/90	3.1	6.2	mmol/l	46.40	51.70	43.80	54.70	54.70
				GLUCOLINS: ALPHA 1	01/10/90	0.5	1.9	mmol/l	1.88	2.00	1.90	2.00	2.00
				GLUCOLINS: ALPHA 2	01/10/90	1.3	6.0	g/l	2.00	2.10	2.80	4.60	4.60
				GLUCOLINS: BETA	01/10/90	5.0	13.0	g/l	8.20	6.20	5.90	8.90	8.90
				GLUCOLINS: GAMMA	01/10/90	10.0	17.0	g/l	14.10	13.30	12.50	13.30	13.30
				T3	01/10/90	1.1	2.2	mmol/l	10.30	10.70	11.00	11.00	11.00
				T4	01/10/90	60.0	140.0	mmol/l	109.00	109.00	109.00	109.00	109.00
16	AJ		FEMALE	HR	01/10/90	112.0	140.0	g/l	138.00	138.00	134.00	132.00	132.00
				HTC	01/10/90	0.4	0.5	l/l	0.52	0.53	0.42	0.42	0.42
				PRC	01/10/90	3.7	4.7	10**12/l	4.27	4.30	4.20	4.17	4.17
				HBC	01/10/90	4.0	8.8	10**9/l	5.20	4.80	5.40	4.60	4.60
				HBC: N	01/10/90	51.0	77.0	%	62.00	61.00	78.00	58.00	58.00
				HBC: L	01/10/90	18.0	38.0	%	32.00	36.00	20.00	40.00	40.00
				HBC: E	01/10/90	1.0	5.0	%	2.00	0.00	2.00	1.00	1.00
				HBC: M	01/10/90	2.0	10.0	%	4.00	3.00	0.00	1.00	1.00
				HBC: B	01/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00
				PLATELETS	01/10/90	180.0	320.0	10**9/l	187.00	215.00	217.00	220.00	220.00
				NA+	01/10/90	135.0	150.0	mmol/l	137.00	137.00	130.00	140.00	140.00
				CL-	01/10/90	95.0	105.0	mmol/l	97.60	99.60	100.50	101.50	101.50
				PO4--	01/10/90	0.6	1.3	mmol/l	0.94	0.91	0.84	0.78	0.78
				SGOT	01/10/90	1.0	12.0	U/l	5.00	6.80	11.80	2.70	2.70
				SGPT	01/10/90	1.0	9.0	U/l	2.80	4.20	5.90	4.20	4.20

1705

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOMETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Date	Laboratory Range		Unit	Screen	Visit								
					Min	Max			Week 2	Week 4	Week 6						
10	16	AJ	FEMALE	GAMMA-GT	01/10/90	10.0	66.0	U/l	21.00	18.00	18.00	18.00	12.00				
				GLUCOSE	01/10/90	3.5	5.5	mmol/l	5.30	4.60	4.60	4.00					
				ALK. PHOSPH.	01/10/90	135.0	360.0	nmol/l	199.00	171.00	205.00	230.00					
				BUN	01/10/90	3.3	10.0	mmol/l	4.10	3.50	3.40	3.00					
				CREATININE	01/10/90	44.0	88.0	umol/l	77.00	78.20	74.80	71.40					
				URIC ACID	01/10/90	119.0	357.0	umol/l	198.00	132.00	168.00	195.00					
				TOT. BILIRUBIN	01/10/90	8.6	20.5	umol/l	15.80	14.60	8.90	9.20					
				DIR. BILIRUBIN	01/10/90	0.5	4.3	umol/l	0.60	0.50	0.80	1.20					
				TOT. PROTEINS	01/10/90	65.0	85.0	g/l	83.00	78.00	80.00	80.00					
				ALBUMINE	01/10/90	34.0	55.0	g/l	52.40	45.00	46.10	51.80					
				TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/l	6.10	5.50	5.50	5.00					
				TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/l	1.80	1.70	1.52	1.40					
				GLOBULINS: ALPHA 1	01/10/90	1.3	6.0	g/l	4.80	3.90	3.40	3.00					
				GLOBULINS: ALPHA 2	01/10/90	5.0	9.0	g/l	4.30	4.20	6.80	6.80					
				GLOBULINS: BETA	01/10/90	5.0	13.0	g/l	11.30	12.30	10.20	8.20					
				GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	9.60	10.60	8.80	10.20					
				T3	01/10/90	1.1	2.2	nmol/l	1.40	1.40							
				T4	01/10/90	60.0	140.0	nmol/l	96.00								
				17	NH		FEMALE	HB	01/10/90	112.0	140.0	g/l	132.00	133.00	135.00	132.00	132.00
								HTC	01/10/90	0.4	0.5	l/l	0.42	0.42	0.41	0.41	
								RBC	01/10/90	3.7	4.7	10**12/l	4.17	4.20	4.17	4.15	
								WBC	01/10/90	4.0	8.8	10**9/l	4.90	5.40	5.50	5.70	
								WBC: N	01/10/90	51.0	77.0	%	70.00	68.00	72.00	66.00	
								WBC: L	01/10/90	18.0	38.0	%	28.00	24.00	25.00	31.00	
WBC: E	01/10/90	1.0	5.0					%	0.00	4.00	0.00	2.00					
WBC: M	01/10/90	2.0	10.0					%	2.00	4.00	2.00	1.00					
WBC: R	01/10/90	0.0	1.0					%	0.00	0.00	1.00	0.00					
PLATELETS	01/10/90	180.0	320.0					10**9/l	217.00	215.00	220.00	225.00					
Na+	01/10/90	135.0	150.0					mmol/l	140.00	139.00	136.00	139.00					
K+	01/10/90	4.0	5.6					mmol/l	4.90	4.10	3.60	4.10					
CL-	01/10/90	95.0	105.0					mmol/l	100.50	99.00	99.00	97.60					
PO4-	01/10/90	0.6	1.3					mmol/l	1.12	1.43	1.26	1.22					
SGPT	01/10/90	1.0	12.0					U/l	3.50	4.80	7.60	2.10					
GAMMA-GT	01/10/90	10.0	66.0					U/l	18.00	26.00	18.00	24.00					
GLUCOSE	01/10/90	3.5	5.5					mmol/l	6.70	6.60	4.50	4.60					
BUN	01/10/90	135.0	360.0					umol/l	365.00	307.00	245.00	380.00					
CREATININE	01/10/90	3.3	10.0					umol/l	6.10	6.30	6.80	4.80					
URIC ACID	01/10/90	44.0	88.0					umol/l	71.00	72.80	77.00	73.10					
TOT. BILIRUBIN	01/10/90	119.0	357.0					umol/l	315.00	238.00	298.00	288.00					
DIR. BILIRUBIN	01/10/90	8.6	20.5					umol/l	17.50	9.00	0.40	1.12					
TOT. PROTEINS	01/10/90	65.0	85.0					g/l	74.00	79.00	84.00	83.00					
ALBUMINE	01/10/90	34.0	55.0					g/l	48.00	47.00	50.60	49.30					
TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/l	6.50	6.20	6.20	5.30									
TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/l	1.80	1.70	1.40	1.40									
GLOBULINS: ALPHA 1	01/10/90	1.3	6.0	g/l	3.50	3.30	3.30	4.00									
GLOBULINS: ALPHA 2	01/10/90	5.0	9.0	g/l	4.40	4.40	8.80	8.20									

1706

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
10	17	MH	FEMALE	GLOBALINS: BETA	01/10/90	5.0	13.0	g/l	7.60	9.40	9.00	9.40	
				GLOBALINS: GAMMA	01/10/90	10.0	17.0	g/l	12.20	10.30	10.80	12.10	
				T3	01/10/90	1.1	2.2	nmol/l	1.00
				T4	01/10/90	60.0	140.0	nmol/l	95.00
				HB	01/10/90	112.0	140.0	g/l	14/03/91	08/04/91	16/04/91		
				HTC	01/10/90	0.4	0.5	l/l	128.00	126.00	128.00		
				RBC	01/10/90	3.7	4.7	10**12/l	0.42	0.40	0.41		
				HRC	01/10/90	4.0	8.8	10**9/l	4.14	3.95	4.05		
				HRC: N	01/10/90	51.0	77.0	z	4.40	4.40	4.70		
				HRC: L	01/10/90	18.0	38.0	z	64.00	68.00	59.00		
18	SS	SS	FEMALE	HRC: E	01/10/90	1.0	5.0	z	30.00	27.00	34.00		
				HRC: B	01/10/90	2.0	10.0	z	1.00	3.00	3.00		
				HRC: M	01/10/90	0.0	1.0	z	5.00	2.00	4.00		
				HRC: X	01/10/90	0.0	1.0	z	0.00	0.00	0.00		
				PLATELETS	01/10/90	180.0	320.0	10**9/l	218.00	205.00	205.00		
				Ma+	01/10/90	135.0	150.0	mmol/l	136.00	136.00	135.00		
				K+	01/10/90	4.0	5.6	mmol/l	5.00	4.30	4.40		
				CL-	01/10/90	95.0	105.0	mmol/l	99.50	101.00	104.00		
				PO4-	01/10/90	0.6	1.3	mmol/l	1.20	1.01	1.21		
				SGPT	01/10/90	1.0	12.0	U/l	4.70	2.70	4.40		
19	TN	TN	FEMALE	SGPT	01/10/90	1.0	9.0	U/l	4.70	9.60	5.00		
				GAMMA-GT	01/10/90	10.0	66.0	U/l	15.00	14.00	16.00		
				GLUCOSE	01/10/90	3.5	5.5	mmol/l	4.40	4.00	4.80		
				ALK. PHOSPH.	01/10/90	135.0	360.0	mmol/l	213.00	190.00	168.00		
				BUN	01/10/90	3.3	10.0	mmol/l	5.30	4.80	4.50		
				CREATININE	01/10/90	44.0	88.0	umol/l	69.50	62.00	70.70		
				TOT BILIRUBIN	01/10/90	119.0	357.0	umol/l	185.00	180.00	189.00		
				DIR BILIRUBIN	01/10/90	8.6	20.5	umol/l	14.80	10.20	10.20		
				TOT. PROTEINS	01/10/90	0.5	4.3	umol/l	0.60	1.90	1.30		
				ALBUMINE	01/10/90	65.0	85.0	g/l	79.00	82.00	78.00		
19	TN	TN	FEMALE	TOT. CHOLEST.	01/10/90	34.0	55.0	g/l	44.70	53.50	48.70		
				TRIGLYCERIDES	01/10/90	3.1	6.2	mmol/l	4.10	4.80	3.40		
				GLOBALINS: ALPHA 1	01/10/90	0.5	1.9	mmol/l	1.20	0.90	0.86		
				GLOBALINS: ALPHA 2	01/10/90	1.3	6.0	g/l	4.08	3.48	2.30		
				GLOBALINS: BETA	01/10/90	5.0	9.0	g/l	6.20	7.80	7.80		
				GLOBALINS: GAMMA	01/10/90	5.0	13.0	g/l	10.40	10.10	7.60		
				T3	01/10/90	10.0	17.0	g/l	13.70	8.80	11.60		
				T4	01/10/90	1.1	2.2	nmol/l	1.10	.	.		
				HB	01/10/90	60.0	140.0	nmol/l	95.00	.	.		
				19	TN	TN	FEMALE	HB	01/10/90	112.0	140.0	g/l	27/03/91
HTC	01/10/90	0.4	0.5					l/l	138.00	136.00	130.00	132.00	
RBC	01/10/90	3.7	4.7					10**12/l	0.40	0.41	0.41	0.42	
HRC	01/10/90	4.0	8.8					10**9/l	3.94	4.05	4.05	4.17	
HRC: N	01/10/90	4.0	8.8					10**9/l	5.10	5.70	4.50	4.80	
HRC: L	01/10/90	51.0	77.0					z	52.00	65.00	68.00	63.00	
HRC: E	01/10/90	18.0	38.0					z	44.00	30.00	27.00	31.00	
HRC: B	01/10/90	1.0	5.0					z	2.00	3.00	3.00	0.00	
HRC: M	01/10/90	0.0	1.0					z					
HRC: X	01/10/90	0.0	1.0					z					

1707

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Unit	Screen	Visit			
				Date	Kin	Max			Week 2	Week 4	Week 6	
10	19 TN	FEMALE	HBC: M	01/10/90	2.0	10.0	Z	2.00	1.00	4.00	6.00	
			HBC: B	01/10/90	0.0	1.0	Z	0.00	1.00	0.00	0.00	
			PLATELETS	01/10/90	180.0	320.0	10**9/1	240.00	214.00	203.00	213.00	
			Na+	01/10/90	135.0	150.0	mmol/l	140.00	137.00	133.00	135.00	
			K+	01/10/90	4.0	5.6	mmol/l	4.80	3.90	3.90	3.80	
			CL-	01/10/90	95.0	105.0	mmol/l	96.00	99.50	98.00	101.50	
			PO4-	01/10/90	0.6	1.3	mmol/l	1.27	1.14	1.40	1.17	
			SCPT	01/10/90	1.0	12.0	U/l	1.90	9.00	8.20	4.00	
			GAMMA-GT	01/10/90	1.0	9.0	U/l	1.80	7.60	8.80	9.30	
			GLUCOSE	01/10/90	10.0	66.0	U/l	18.00	22.00	26.00	20.00	
			ALK. PHOSPH.	01/10/90	35.0	5.5	mmol/l	4.60	4.40	4.70	4.40	
			BUN	01/10/90	3.3	10.0	mmol/l	5.10	5.00	4.70	4.40	
			CREATININE	01/10/90	44.0	88.0	umol/l	71.00	69.70	72.20	75.70	
			UIC ACID	01/10/90	119.0	357.0	umol/l	193.00	158.00	126.00	162.00	
			DTX BILIRUBIN	01/10/90	8.5	20.5	umol/l	15.20	14.80	10.40	14.20	
			DTX BILIRUBIN	01/10/90	0.5	4.5	umol/l	1.40	1.00	1.12	1.12	
			TOT. PROTEINS	01/10/90	65.0	85.0	g/l	84.00	85.00	81.00	79.00	
			ALBUMINE	01/10/90	34.0	55.0	g/l	47.60	53.70	52.00	49.60	
			TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/l	5.10	4.80	4.80	5.30	
			TRIGLUCERIDES	01/10/90	0.5	1.9	mmol/l	0.60	1.20	1.40	0.96	
			GLOBULINS: ALPHA 1	01/10/90	1.3	6.0	g/l	3.20	2.70	1.30	2.20	
			GLOBULINS: ALPHA 2	01/10/90	5.0	9.0	g/l	12.40	8.50	8.10	8.40	
			GLOBULINS: BETA	01/10/90	5.0	13.0	g/l	9.00	8.30	9.90	9.20	
			GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	11.80	9.80	9.70	9.60	
			T3	01/10/90	1.1	2.2	mmol/l	2.05	.	.	.	
			T4	01/10/90	60.0	140.0	mmol/l	177.00	.	.	.	
20	EJ	FEMALE	HB	01/10/90	112.0	140.0	g/l	17/04/91	07/05/91	22/05/91	04/06/91	
			HTC	01/10/90	0.4	0.5	l/l	135.00	132.00	136.00	134.00	
			RBC	01/10/90	3.7	4.7	10**12/l	4.47	4.10	4.42	4.42	
			HBC: N	01/10/90	4.0	8.8	10**9/l	5.40	4.00	4.15	4.15	
			HBC: L	01/10/90	51.0	77.0	Z	68.00	76.00	5.00	6.40	
			HBC: E	01/10/90	18.0	38.0	Z	26.00	20.00	29.00	60.00	
			HBC: M	01/10/90	1.0	5.0	Z	6.00	2.00	4.00	32.00	
			HBC: B	01/10/90	2.0	10.0	Z	0.00	2.00	3.00	4.00	
			PLATELETS	01/10/90	0.0	1.0	Z	0.00	0.00	0.00	0.00	
			Na+	01/10/90	180.0	320.0	10**9/1	220.00	217.00	210.00	218.00	
			K+	01/10/90	135.0	150.0	mmol/l	135.00	139.00	135.00	136.00	
			CL-	01/10/90	4.0	5.6	mmol/l	4.10	4.60	4.40	4.20	
			PO4-	01/10/90	0.6	1.3	mmol/l	0.80	0.80	1.16	1.13	
			SCPT	01/10/90	1.0	12.0	U/l	2.00	4.90	6.10	7.80	
			GAMMA-GT	01/10/90	1.0	9.0	U/l	6.80	1.50	5.20	4.20	
			GLUCOSE	01/10/90	10.0	66.0	U/l	21.00	20.00	21.00	26.00	
			ALK. PHOSPH.	01/10/90	35.0	5.5	mmol/l	3.80	4.70	4.10	4.30	
			BUN	01/10/90	3.3	10.0	mmol/l	158.00	194.00	270.00	255.00	
			CREATININE	01/10/90	44.0	88.0	umol/l	64.70	68.40	5.20	4.60	
										67.80		

1700

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOMEXINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit								
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
10	20	EJ	FEMALE	URIC ACID	01/10/90	119.0	357.0	umol/l	189.00	273.00	201.00	214.00			
				TOT BILIRUBIN	01/10/90	8.6	20.5	umol/l	14.00	18.40	16.40	13.50			
				DIR BILIRUBIN	01/10/90	0.5	4.3	umol/l	1.40	3.60	1.40	1.10			
				TOT. PROTEINS	01/10/90	65.0	85.0	g/l	80.00	78.00	80.00	76.00			
				ALBUMINE	01/10/90	34.0	55.0	g/l	49.80	48.10	44.30	47.40			
				TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/l	4.20	5.00	5.10	4.90			
				TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/l	1.70	1.65	1.40	1.30			
				GLOBULINS: ALPHA 1	01/10/90	1.3	6.0	g/l	2.90	2.10	6.50	2.40			
				GLOBULINS: ALPHA 2	01/10/90	5.0	9.0	g/l	9.00	4.30	8.40	8.40			
				GLOBULINS: BETA	01/10/90	5.0	13.0	g/l	8.60	7.90	10.20	6.30			
				GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	9.70	10.60	14.70	11.50			
				T3	01/10/90	1.1	2.2	nmol/l	1.51						
				T4	01/10/90	60.0	140.0	nmol/l	117.00						
				21	AK	FEMALE	HB	01/10/90	112.0	140.0	g/l	130.00	128.00	126.00	130.00
							HTC	01/10/90	0.4	0.5	l/l	0.40	0.40	0.39	0.42
							RBC	01/10/90	3.7	4.7	10 ¹² /l	3.90	4.05	3.87	4.17
							HBC: N	01/10/90	4.0	8.8	10 ¹² /l	6.00	4.00	7.00	5.40
							HBC: L	01/10/90	51.0	77.0	%	70.00	72.00	62.00	61.00
							HBC: E	01/10/90	18.0	38.0	%	24.00	28.00	35.00	30.00
							HBC: M	01/10/90	1.0	5.0	%	4.00	0.00	1.00	5.00
							HBC: B	01/10/90	2.0	10.0	%	2.00	0.00	2.00	4.00
							PLATELETS	01/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00
							NA+	01/10/90	180.0	320.0	10 ⁹ /l	215.00	217.00	218.00	218.00
							K+	01/10/90	4.0	5.6	mmol/l	138.00	138.00	134.00	135.00
							CL-	01/10/90	95.0	105.0	mmol/l	5.00	4.80	4.50	4.20
							PO4-	01/10/90	0.6	1.3	mmol/l	98.00	98.00	99.60	100.00
							SGPT	01/10/90	1.0	12.0	U/l	1.30	1.42	1.42	1.50
SGPT	01/10/90	1.0	9.0				U/l	6.50	4.60	1.90	1.40				
GAMMA-GT	01/10/90	10.0	66.0				U/l	2.70	1.60	1.70	4.60				
GLUCOSE	01/10/90	3.5	5.5				mmol/l	15.00	17.00	16.00	24.00				
ALK. PHOSPH.	01/10/90	360.0	440.0				U/l	4.40	4.70	4.70	4.10				
BUN	01/10/90	135.0	220.0				umol/l	220.00	322.00	349.00	279.00				
CREATININE	01/10/90	3.3	10.0				mmol/l	5.00	3.30	3.70	3.40				
URIC ACID	01/10/90	44.0	88.0				umol/l	63.10	63.40	64.80	72.20				
TOT BILIRUBIN	01/10/90	119.0	357.0				umol/l	279.00	201.00	227.00	238.00				
DIR BILIRUBIN	01/10/90	8.6	20.5				umol/l	13.50	7.90	13.50	18.00				
TOT. PROTEINS	01/10/90	65.0	85.0				g/l	85.00	80.00	78.00	80.00				
ALBUMINE	01/10/90	34.0	55.0				g/l	51.80	47.30	45.00	49.00				
TOT. CHOLEST.	01/10/90	3.1	6.2				mmol/l	3.90	3.40	4.70	3.80				
TRIGLYCERIDES	01/10/90	0.5	1.9				mmol/l	0.64	0.50	0.60	0.50				
GLOBULINS: ALPHA 1	01/10/90	1.3	6.0	g/l	3.40	1.90	3.90	2.80							
GLOBULINS: ALPHA 2	01/10/90	5.0	9.0	g/l	8.20	7.80	6.90	6.30							
GLOBULINS: BETA	01/10/90	5.0	13.0	g/l	10.50	9.00	8.60	9.40							
GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	11.10	14.00	13.60	12.50							
T3	01/10/90	1.1	2.2	nmol/l	1.86										
T4	01/10/90	60.0	140.0	nmol/l	102.00										

1700

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOMENTINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit					
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
10	22	AA	MALE	HB	01/10/90	129.0	150.0	g/l	17/04/91	07/05/91	21/05/91	04/06/91
				HTC	01/10/90	0.4	0.5	l/l	142.00	144.00	144.00	143.00
				RBC	01/10/90	4.0	5.0	10**12/l	0.43	0.44	0.44	0.44
				HBC	01/10/90	4.0	8.8	10**9/l	4.30	4.37	4.40	4.36
				HBC: N	01/10/90	51.0	77.0	%	4.80	6.20	6.70	7.60
				HBC: L	01/10/90	18.0	38.0	%	59.00	77.00	52.00	56.00
				HBC: E	01/10/90	1.0	5.0	%	20.00	30.00	30.00	30.00
				HBC: M	01/10/90	2.0	10.0	%	3.00	8.00	8.00	8.00
				HBC: B	01/10/90	0.0	1.0	%	2.00	1.00	10.00	6.00
				PLATELETS	01/10/90	180.0	320.0	10**9/l	0.00	0.00	0.00	0.00
				NA+	01/10/90	135.0	150.0	mmol/l	235.00	230.00	227.00	234.00
				K+	01/10/90	4.0	5.6	mmol/l	140.00	141.00	136.00	135.00
				CL-	01/10/90	95.0	105.0	mmol/l	99.50	100.90	95.10	103.50
				PO4-	01/10/90	0.6	1.3	mmol/l	1.22	1.51	1.50	1.30
				SGPT	01/10/90	1.0	12.0	U/l	1.50	8.50	5.60	3.20
				GAMMA-GT	01/10/90	15.0	106.0	U/l	26.00	30.00	28.00	40.00
				GLUCOSE	01/10/90	3.5	5.5	mmol/l	4.10	4.10	4.90	4.20
				ALK. PHOSPH.	01/10/90	33.0	360.0	mmol/l	356.00	621.00	403.00	429.00
				CREATININE	01/10/90	44.0	101.0	umol/l	84.00	78.20	73.90	76.00
				TOT BILIRUBIN	01/10/90	119.0	357.0	umol/l	84.00	162.00	302.00	378.00
				DIR BILIRUBIN	01/10/90	8.6	20.5	umol/l	22.50	11.20	15.20	18.00
				TOT. PROTEINS	01/10/90	65.0	85.0	g/l	2.20	3.70	3.40	2.20
				ALBUMINE	01/10/90	34.0	55.0	g/l	88.00	82.00	79.00	81.00
TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/l	54.30	52.00	49.30	49.70				
TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/l	1.80	5.40	5.40	5.30				
GLOBULINS: ALPHA 1	01/10/90	1.3	6.0	g/l	1.80	1.90	1.86	1.94				
GLOBULINS: ALPHA 2	01/10/90	5.0	9.0	g/l	4.00	3.30	2.50	1.60				
GLOBULINS: BETA	01/10/90	5.0	13.0	g/l	9.50	8.00	7.50	11.50				
GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	9.40	8.90	8.80	7.20				
T3	01/10/90	1.1	2.2	nmol/l	10.80	9.80	10.90	11.00				
T4	01/10/90	60.0	140.0	nmol/l	113.00							
23	LT	FEMALE	HB	01/10/90	112.0	140.0	g/l	23/06/91	07/05/91	22/05/91	05/06/91	
			HTC	01/10/90	0.4	0.5	l/l	127.00	130.00	130.00	130.00	
			RBC	01/10/90	3.7	4.7	10**12/l	0.41	0.41	0.41	0.41	
			HBC	01/10/90	4.0	8.8	10**9/l	3.95	4.05	4.15	4.08	
			HBC: N	01/10/90	51.0	77.0	%	3.90	5.00	4.10	6.30	
			HBC: L	01/10/90	18.0	38.0	%	65.00	64.00	64.00	62.00	
			HBC: E	01/10/90	1.0	5.0	%	34.00	29.00	32.00	36.00	
			HBC: M	01/10/90	2.0	10.0	%	2.00	5.00	1.00	1.00	
			HBC: B	01/10/90	0.0	1.0	%	1.00	1.00	3.00	1.00	
			PLATELETS	01/10/90	180.0	320.0	10**9/l	0.00	0.00	0.00	0.00	
			NA+	01/10/90	135.0	150.0	mmol/l	215.00	220.00	218.00	218.00	

1710

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 RENDOMETINE - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
10	23	LT	FEMALE	K+	01/10/90	4.0	5.6	mmol/l	4.80	4.00	4.10	4.30	
				CL-	01/10/90	95.0	105.0	mmol/l	104.60	100.50	98.00	96.50	
				PO4-	01/10/90	0.6	1.3	mmol/l	0.97	1.41	0.97	1.39	
				SGOT	01/10/90	1.0	12.0	U/l	6.50	3.60	2.70	6.10	
				SGPT	01/10/90	1.0	9.0	U/l	2.20	4.40	3.10	1.70	
				GAMMA-GT	01/10/90	10.0	66.0	U/l	22.00	16.00	18.00	20.00	
				GLUCOSE	01/10/90	3.5	5.5	mmol/l	4.40	4.70	4.70	4.60	
				ALK. PHOSPH.	01/10/90	135.0	360.0	mmol/l	210.00	212.00	303.00	228.00	
				BUN	01/10/90	3.3	10.0	mmol/l	4.80	3.70	4.80	4.00	
				CREATININE	01/10/90	44.0	88.0	umol/l	74.00	73.30	72.20	73.00	
				TOT. BILIRUBIN	01/10/90	119.0	357.0	umol/l	214.00	189.00	201.00	210.00	
				DIR. BILIRUBIN	01/10/90	8.6	20.5	umol/l	8.70	8.60	9.20	13.50	
				TOT. PROTEINS	01/10/90	65.0	85.0	g/l	82.00	80.00	72.00	75.00	
				ALBUMINE	01/10/90	34.0	55.0	g/l	50.00	48.20	45.70	51.20	
				TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/l	3.60	3.80	3.80	3.50	
				TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/l	0.60	0.90	0.96	0.80	
				GLOBULINS: ALPHA 1	01/10/90	1.3	6.0	g/l	1.30	4.10	3.40	2.00	
				GLOBULINS: ALPHA 2	01/10/90	5.0	9.0	g/l	6.70	10.40	5.60	7.30	
				GLOBULINS: BETA	01/10/90	5.0	13.0	g/l	11.80	12.40	5.30	5.70	
				GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	12.20	7.90	12.00	8.90	
				T3	01/10/90	1.1	2.2	nmol/l	1.43				
				T4	01/10/90	60.0	140.0	nmol/l	118.50				
24	AL		MALE	HB	01/10/90	129.0	150.0	g/l	163.00	142.00	143.00	144.00	
				HTC	01/10/90	0.4	0.5	l/l	0.44	0.43	0.43	0.43	
				RBC	01/10/90	4.0	5.0	10**12/l	4.35	4.29	4.30	4.32	
				WBC	01/10/90	51.0	8.8	10**9/l	4.40	4.60	4.50	4.00	
				WBC: N	01/10/90	18.0	77.0	%	61.00	60.00	58.00	67.00	
				WBC: L	01/10/90	1.0	5.0	%	33.00	34.00	40.00	27.00	
				WBC: E	01/10/90	2.0	5.0	%	2.00	2.00	2.00	2.00	
				WBC: M	01/10/90	0.0	1.0	%	4.00	4.00	2.00	4.00	
				WBC: B	01/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	
				PLATELETS	01/10/90	180.0	320.0	10**9/l	237.00	230.00	227.00	217.00	
				AP	01/10/90	135.0	150.0	mmol/l	141.00	139.00	136.00	137.00	
				K+	01/10/90	4.0	5.6	mmol/l	4.10	4.00	3.80	3.90	
				CL-	01/10/90	95.0	105.0	mmol/l	100.90	99.50	97.80	97.00	
				PO4-	01/10/90	0.6	1.3	mmol/l	0.85	1.09	1.21	1.30	
				SGOT	01/10/90	1.0	12.0	U/l	2.00	3.40	2.20	6.30	
				SGPT	01/10/90	1.0	9.0	U/l	64.00	38.00	36.00	32.00	
				GAMMA-GT	01/10/90	15.0	106.0	U/l	4.80	4.50	4.70	4.30	
				GLUCOSE	01/10/90	3.5	5.5	mmol/l	323.00	348.00	319.00	324.00	
				ALK. PHOSPH.	01/10/90	135.0	360.0	mmol/l	4.30	4.90	4.60	4.80	
				BUN	01/10/90	3.3	10.0	mmol/l	76.40	73.80	72.30	74.80	
				CREATININE	01/10/90	44.0	101.0	umol/l	278.00	273.00	294.00	311.00	
				URIC ACID	01/10/90	119.0	357.0	umol/l	14.20	14.00	15.20	11.30	
				TOT. BILIRUBIN	01/10/90	8.6	20.5	umol/l	1.40	3.38	2.20	1.70	
				DIR. BILIRUBIN	01/10/90	0.0	5.1	umol/l	81.00	80.00	78.00	79.00	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOMETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit										
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6						
10	24	AL	MALE	ALBUMINE	01/10/90	34.0	55.0	g/l	52.50	46.20	51.60	48.50						
				TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/l	3.60	3.50	3.90	4.00						
				TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/l	1.42	1.70	1.38	1.40						
				GLOBULINS: ALPHA 1	01/10/90	1.3	6.0	g/l	1.40	2.80	3.00	2.30						
				GLOBULINS: ALPHA 2	01/10/90	5.0	9.0	g/l	6.20	8.00	6.10	10.10						
				GLOBULINS: BETA	01/10/90	5.0	13.0	g/l	10.30	10.20	7.90	7.80						
				GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	10.60	12.80	9.40	10.30						
				T3	01/10/90	1.1	2.2	nmol/l	1.57									
				T4	01/10/90	60.0	140.0	nmol/l	153.00									
				25	ES		MALE	HB	01/10/90	129.0	150.0	g/l	13/05/91	28/05/91				
								HTC	01/10/90	0.4	0.5	l/l	147.00	166.00				
								ERC	01/10/90	4.0	5.0	10**12/l	0.44	0.44				
								WBC	01/10/90	4.0	8.0	10**9/l	4.40	4.35				
								WBC: N	01/10/90	51.0	77.0	%	4.30	4.30				
WBC: E	01/10/90	18.0	38.0					%	64.00	72.00								
WBC: B	01/10/90	1.0	5.0					%	53.00	25.00								
WBC: H	01/10/90	2.0	10.0					%	2.00	2.00								
PLATELETS	01/10/90	0.0	1.0					%	1.00	1.00								
Na+	01/10/90	180.0	320.0					10**9/l	237.00	235.00								
K+	01/10/90	4.0	5.6					mmol/l	139.00	135.00								
CL-	01/10/90	95.0	105.0					mmol/l	4.30	4.60								
PO4--	01/10/90	0.6	1.3					mmol/l	100.00	100.40								
SGPT	01/10/90	1.0	12.0					U/l	1.06	0.99								
GAMMA-GT	01/10/90	15.0	106.0	U/l	6.10	2.50												
GLUCOSE	01/10/90	3.5	5.5	mmol/l	42.00	46.00												
ALK. PHOSPH.	01/10/90	135.0	360.0	mmol/l	244.00	271.00												
CREATININE	01/10/90	3.3	10.0	mmol/l	4.90	5.30												
URIC ACID	01/10/90	44.0	101.0	mmol/l	77.40	78.60												
TOT BILIRUBIN	01/10/90	119.0	357.0	umol/l	336.00	372.00												
DIR BILIRUBIN	01/10/90	0.0	5.1	umol/l	20.25	26.90												
TOT. PROTEINS	01/10/90	65.0	85.0	g/l	7.88	8.00												
ALBUMINE	01/10/90	34.0	55.0	g/l	49.10	49.10												
TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/l	4.60	3.60												
TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/l	0.80	0.78												
GLOBULINS: ALPHA 1	01/10/90	1.3	6.0	g/l	3.40	2.10												
GLOBULINS: ALPHA 2	01/10/90	5.0	9.0	g/l	7.90	10.80												
GLOBULINS: BETA	01/10/90	5.0	13.0	g/l	7.90	8.40												
GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	13.70	15.60												
T3	01/10/90	1.1	2.2	nmol/l	1.51													
T4	01/10/90	60.0	140.0	nmol/l	94.00													
26	JIF		FEMALE	HB	01/10/90	112.0	140.0	g/l	27/05/91	12/06/91	26/06/91	08/07/91						
				HTC	01/10/90	0.4	0.5	l/l	140.00	144.00	140.00	138.00						
								0.43	0.44	0.42	0.40							

17112

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBORENTINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Screen	Visit			
					Date	Min	Max		Unit	Week 2	Week 4	Week 6
10	26	JIF	FEMALE	RBC	01/10/90	3.7	4.7	10**12/l	4.27	4.37	4.18	4.00
				HBC: N	01/10/90	4.0	8.8	10**9/l	5.00	3.80	8.60	7.20
				HBC: L	01/10/90	51.0	77.0	Z	64.00	67.00	56.00	63.00
				HBC: E	01/10/90	18.0	38.0	Z	32.00	25.00	34.00	33.00
				HBC: M	01/10/90	1.0	5.0	Z	0.00	4.00	4.00	2.00
				HBC: B	01/10/90	2.0	10.0	Z	4.00	4.00	2.00	2.00
				PLATELETS	01/10/90	0.0	1.0	Z	0.00	0.00	0.00	0.00
				NA+	01/10/90	180.0	320.0	10**9/l	227.00	220.00	230.00	217.00
				K+	01/10/90	135.0	150.0	mmol/l	138.00	135.00	145.00	140.00
				CL-	01/10/90	95.0	105.0	mmol/l	97.80	98.50	98.50	105.90
				PO4-	01/10/90	0.6	1.3	mmol/l	1.09	1.20	1.10	1.10
				SGPT	01/10/90	1.0	12.0	U/l	1.20	3.00	4.00	4.00
				SGPT	01/10/90	1.0	2.0	U/l	2.60	3.60	4.50	3.50
				GAMMA-GT	01/10/90	10.0	66.0	U/l	22.00	28.00	17.00	26.00
				GLUCOSE	01/10/90	3.5	5.5	mmol/l	5.40	4.70	4.80	4.60
				ALK. PHOSPH.	01/10/90	135.0	360.0	mmol/l	257.00	225.00	194.00	236.00
				RUN	01/10/90	3.3	10.0	mmol/l	5.20	5.30	5.00	7.60
				CREATININE	01/10/90	44.0	88.0	umol/l	74.00	76.60	77.60	74.30
				URIC ACID	01/10/90	119.0	357.0	umol/l	342.00	16.80	18.00	208.00
				TOT BILIRUBIN	01/10/90	8.6	20.5	umol/l	18.00	1.90	1.68	1.68
				DIR BILIRUBIN	01/10/90	0.5	4.3	umol/l	2.20	83.00	81.00	82.00
				TOT. PROTEINS	01/10/90	65.0	85.0	g/l	81.00	51.50	53.90	49.50
				ALBUMINE	01/10/90	34.0	55.0	g/l	47.30	7.50	8.40	8.10
				TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/l	7.50	1.94	1.92	2.00
				TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/l	1.90	8.10	8.40	5.20
				GLOBULINS: ALPHA 1	01/10/90	1.3	6.0	g/l	3.00	6.10	6.10	13.10
				GLOBULINS: ALPHA 2	01/10/90	5.0	9.0	g/l	14.70	6.10	6.60	6.60
				GLOBULINS: BETA	01/10/90	5.0	13.0	g/l	7.40	10.70	8.30	7.60
				GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	8.60	10.70	8.30	7.60
				T3	01/10/90	1.1	2.2	nmol/l	1.38			
				T4	01/10/90	60.0	140.0	nmol/l	94.00			
27	MK		FEMALE	HR	01/10/90	112.0	140.0	g/l	130.00	134.00	128.00	127.00
				HTC	01/10/90	0.4	0.5	l/l	0.42	0.40	0.39	0.38
				RBC	01/10/90	3.7	4.7	10**12/l	4.17	3.97	3.80	3.76
				HBC	01/10/90	4.0	8.8	10**9/l	4.30	3.80	4.30	5.60
				HBC: N	01/10/90	51.0	77.0	Z	70.00	53.00	72.00	56.00
				HBC: L	01/10/90	18.0	38.0	Z	24.00	43.00	31.00	40.00
				HBC: E	01/10/90	1.0	5.0	Z	4.00	3.00	4.00	1.00
				HBC: M	01/10/90	2.0	10.0	Z	1.00	1.00	3.00	3.00
				HBC: B	01/10/90	0.0	1.0	Z	0.00	0.00	0.00	0.00
				PLATELETS	01/10/90	180.0	320.0	10**9/l	225.00	198.00	225.00	216.00
				NA+	01/10/90	135.0	150.0	mmol/l	134.00	129.00	141.00	141.00
				K+	01/10/90	4.0	5.6	mmol/l	4.30	4.20	4.60	4.20
				CL-	01/10/90	95.0	105.0	mmol/l	97.80	98.00	97.10	99.00
				PO4-	01/10/90	0.6	1.3	mmol/l	1.08	1.08	1.00	1.09
				SGPT	01/10/90	1.0	12.0	U/l	7.20	6.00	6.00	3.80
				SGPT	01/10/90	1.0	9.0	U/l	12.80	5.30	4.00	3.00

1713

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Date	Laboratory Range			Visit					
					Min	Max	Unit	Screen	Week 2	Week 4	Week 6		
10	27	FK	FEMALE	01/10/90	10.0	66.0	U/l	24.00	68.00	78.00	53.00		
			GAMMA-GT	01/10/90	3.5	5.5	mmol/l	4.50	4.60	4.80	4.70		
			GLUCOSE	01/10/90	135.0	360.0	mmol/l	492.00	309.00	397.00	306.00		
			ALK. PHOSPH.	01/10/90	3.3	10.0	mmol/l	5.60	5.70	7.00	6.20		
			BUN	01/10/90	44.0	88.0	umol/l	70.20	74.20	72.50	57.20		
			CREATININE	01/10/90	119.0	357.0	umol/l	252.00	294.00	347.00	211.00		
			URIC ACID	01/10/90	8.6	20.5	umol/l	13.50	15.20	13.50	11.30		
			TOT. BILIRUBIN	01/10/90	0.5	4.3	umol/l	1.10	1.12	0.56	1.10		
			DIR. BILIRUBIN	01/10/90	65.0	85.0	g/l	74.00	79.00	81.00	82.00		
			TOT. PROTEINS	01/10/90	54.0	55.0	g/l	45.10	50.60	49.50	51.50		
			ALBUMINE	01/10/90	3.1	6.2	mmol/l	6.10	6.00	6.10	5.80		
			TOT. CHOLEST.	01/10/90	0.5	1.9	mmol/l	1.54	1.40	1.64	1.24		
			TRIGLYCERIDES	01/10/90	1.3	6.0	g/l	4.10	3.00	3.60	3.70		
			GLOBULINS: ALPHA 1	01/10/90	5.0	9.0	g/l	8.70	8.40	8.70	9.10		
			GLOBULINS: ALPHA 2	01/10/90	5.0	13.0	g/l	8.00	8.80	7.80	6.50		
			GLOBULINS: BETA	01/10/90	10.0	17.0	g/l	8.10	8.20	11.60	11.20		
			GLOBULINS: GAMMA	01/10/90	1.1	2.2	mmol/l	1.12	1.12				
			T3	01/10/90	60.0	140.0	nmol/l	66.00					
			T4	01/10/90									
28	LL	MALE		01/10/90	129.0	150.0	g/l	138.00	12/06/91	26/06/91	10/07/91		
			HB	01/10/90	0.4	0.5	l/l	0.46	0.43	0.43	0.43		
			HTC	01/10/90	4.0	5.0	10**12/l	4.54	4.32	4.27	4.24		
			RBC	01/10/90	4.0	8.8	10**9/l	5.20	4.80	4.40	6.00		
			WBC	01/10/90	51.0	77.0	z	64.00	68.00	66.00	72.00		
			WBC: N	01/10/90	18.0	38.0	z	35.00	27.00	30.00	16.00		
			WBC: L	01/10/90	1.0	5.0	z	0.00	1.00	3.00	6.00		
			WBC: E	01/10/90	2.0	10.0	z	1.00	4.00	3.00	8.00		
			WBC: M	01/10/90	0.0	1.0	z	0.00	0.00	0.00	0.00		
			PLATELETS	01/10/90	180.0	320.0	10**9/l	215.00	225.00	217.00	228.00		
			NA+	01/10/90	135.0	150.0	mmol/l	138.00	137.00	140.00	141.00		
			K+	01/10/90	4.0	5.6	mmol/l	4.60	4.40	4.50	4.30		
			CL-	01/10/90	95.0	105.0	mmol/l	101.80	101.50	102.00	102.00		
			PO4-	01/10/90	0.6	1.3	mmol/l	0.86	1.00	0.80	1.04		
			SGOT	01/10/90	1.0	12.0	U/l	2.90	7.50	4.80	5.20		
			SGPT	01/10/90	1.0	10.0	U/l	3.30	8.60	6.30	6.30		
			GAMMA-GT	01/10/90	15.0	106.0	U/l	56.00	30.00	21.00	21.00		
			GLUCOSE	01/10/90	3.5	5.5	mmol/l	5.20	189.00	177.00	221.00		
			BUN	01/10/90	3.3	10.0	mmol/l	4.40	4.00	4.70	4.30		
			ALK. PHOSPH.	01/10/90	3.3	10.0	mmol/l	9.60	9.80	6.70	6.70		
			CREATININE	01/10/90	44.0	101.0	umol/l	140.00	86.20	86.30	67.70		
			URIC ACID	01/10/90	119.0	357.0	umol/l	258.00	349.00	326.00	240.00		
			TOT. BILIRUBIN	01/10/90	8.6	20.5	umol/l	15.20	16.80	15.20	15.50		
			DIR. BILIRUBIN	01/10/90	0.0	5.1	umol/l	1.40	1.10	0.56	1.12		
			TOT. PROTEINS	01/10/90	65.0	85.0	g/l	77.00	80.00	78.00	79.00		
			ALBUMINE	01/10/90	34.0	55.0	g/l	47.50	50.40	47.00	47.00		
			TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/l	1.20	1.15	1.15	1.30		
			TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/l	1.40	1.20	1.20	1.30		
			GLOBULINS: ALPHA 1	01/10/90	1.3	6.0	g/l	3.10	1.00	4.00	2.90		
			GLOBULINS: ALPHA 2	01/10/90	1.5	6.0	g/l	6.90	6.90	6.80	6.30		

1714

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBORELINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Date	Laboratory Range		Screen	Visit						
					Min	Max		Unit	Week 2	Week 4	Week 6			
10	28	LL	MALE											
			GLOBULINS: BETA	01/10/90	5.0	13.0	g/l	8.80	6.90	6.40	6.10			
			T3	01/10/90	10.0	17.0	g/l	10.70	10.30	13.80	16.70			
			T4	01/10/90	1.1	2.2	nmol/l	1.22						
				01/10/90	60.0	140.0	nmol/l	66.00						
10	29	JJ	MALE											
			HB	01/10/90	129.0	150.0	g/l	138.00	142.00	139.00	141.00			
			HTC	01/10/90	0.4	0.5	l/l	0.43	0.46	0.44	0.46			
			RBC	01/10/90	4.0	5.0	10**12/l	4.24	4.40	4.30	4.30			
				01/10/90	4.0	5.0	10**9/l	6.90	6.80	6.00	5.90			
			RBC: N	01/10/90	51.0	77.0	z	68.00	69.00	73.00	76.00			
			RBC: L	01/10/90	18.0	38.0	z	24.00	25.00	24.00	21.00			
			RBC: E	01/10/90	1.0	5.0	z	4.00	2.00	1.00	1.00			
			RBC: H	01/10/90	2.0	10.0	z	4.00	4.00	2.00	2.00			
			RBC: B	01/10/90	0.0	1.0	z	0.00	0.00	0.00	0.00			
			PLATELETS	01/10/90	180.0	320.0	10**9/l	230.00	220.00	215.00	218.00			
			NA+	01/10/90	135.0	150.0	mmol/l	138.00	140.00	139.00	142.00			
			K+	01/10/90	4.0	5.6	mmol/l	4.10	4.20	4.60	4.60			
			PO4-	01/10/90	95.0	105.0	mmol/l	102.00	101.00	103.10	99.10			
			CL-	01/10/90	0.6	1.3	mmol/l	1.13	1.15	0.96	0.87			
			SGPT	01/10/90	1.0	12.0	U/l	4.00	4.10	5.10	5.00			
				01/10/90	1.0	9.0	U/l	3.50	3.90	7.90	8.20			
			GAMMA-GT	01/10/90	15.0	106.0	U/l	10.00	21.00	28.00	26.00			
			GLUCOSE	01/10/90	3.5	5.5	mmol/l	3.90	4.20	4.40	4.30			
			ALK. PHOSPH.	01/10/90	135.0	360.0	nmol/l	319.00	320.00	230.00	280.00			
			BUN	01/10/90	3.3	10.0	mmol/l	5.00	4.60	4.20	5.30			
			URIC ACID	01/10/90	44.0	101.0	umol/l	68.40	68.20	68.40	69.10			
			TOT BILLIRUBIN	01/10/90	119.0	357.0	umol/l	304.00	306.00	328.00	359.00			
			DJR BILLIRUBIN	01/10/90	8.6	20.5	umol/l	19.10	18.60	18.00	20.30			
			TOT. PROTEINS	01/10/90	0.0	5.1	umol/l	3.40	2.40	1.90	3.70			
			ALBUMINE	01/10/90	34.0	85.0	g/l	80.00	80.90	81.00	82.00			
				01/10/90	3.1	55.0	g/l	53.40	52.80	52.70	52.00			
			TRIGLICERIDES	01/10/90	3.1	6.2	mmol/l	4.20	3.90	3.50	3.40			
				01/10/90	0.5	1.9	mmol/l	1.86	1.58	0.90	0.78			
			GLOBULINS: ALPHA 1	01/10/90	1.3	6.0	g/l	3.10	3.10	4.20	2.50			
			GLOBULINS: ALPHA 2	01/10/90	5.0	9.0	g/l	6.90	5.60	6.00	7.90			
			GLOBULINS: BETA	01/10/90	3.0	13.0	g/l	4.60	9.30	8.90	9.00			
			GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	14.00	10.30	9.20	9.80			
			T3	01/10/90	1.1	2.2	nmol/l	1.60						
			T4	01/10/90	60.0	140.0	nmol/l	112.00						
10	30	VK	FEMALE											
			HB	01/10/90	112.0	140.0	g/l	129.00	130.00	130.00	132.00			
			HTC	01/10/90	0.4	0.5	l/l	0.31	0.39	0.40	0.41			
			RBC	01/10/90	3.7	4.7	10**12/l	3.84	3.95	3.91	4.10			
				01/10/90	4.0	8.8	10**9/l	3.90	4.00	3.40	4.30			
			RBC: N	01/10/90	51.0	77.0	z	51.00	74.00	57.00	66.00			
			RBC: L	01/10/90	18.0	38.0	z	46.00	20.00	36.00	26.00			
			RBC: E	01/10/90	1.0	5.0	z	2.00	2.00	4.00	4.00			
			RBC: H	01/10/90	0.0	1.0	z	0.00	0.00	0.00	0.00			

1716

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R0D

REBOREXINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Screen	Visit			
					Date	Min	Max		Unit	Week 2	Week 4	Week 6
10	30	VK	FEMALE	WBC: M	01/10/90	2.0	10.0	Z	1.00	4.00	3.00	4.00
				WBC: B	01/10/90	0.0	1.0	Z	0.00	0.00	0.00	0.00
				PLATELETS	01/10/90	180.0	320.0	10**9/L	198.00	227.00	217.00	220.00
				Na+	01/10/90	135.0	150.0	mmol/L	144.00	141.00	141.00	143.00
				K+	01/10/90	4.0	5.6	mmol/L	4.70	4.70	4.30	4.00
				CL-	01/10/90	95.0	105.0	mmol/L	99.70	98.80	100.20	97.40
				PO4--	01/10/90	0.6	1.3	mmol/L	0.96	1.00	0.94	1.06
				SGPT	01/10/90	1.0	12.0	U/l	6.20	4.20	3.50	3.50
				SGPT	01/10/90	1.0	9.0	U/l	4.10	4.00	9.80	5.00
				GAMMA-GT	01/10/90	10.0	66.0	U/l	68.00	4.70	20.00	30.00
				GLUCOSE	01/10/90	3.5	5.5	mmol/L	4.80	4.40	4.50	3.70
				ALK. PHOSPH.	01/10/90	135.0	360.0	mmol/L	405.00	349.00	258.00	299.00
				BUN	01/10/90	3.3	10.0	mmol/L	5.00	3.50	4.50	4.40
				CREATININE	01/10/90	44.0	88.0	umol/L	76.30	75.40	76.60	73.90
				URIC ACID	01/10/90	119.0	357.0	umol/L	252.00	218.00	123.00	216.00
				DIR BILIRUBIN	01/10/90	8.6	20.5	umol/L	12.40	16.80	8.20	14.90
				TOT. BILIRUBIN	01/10/90	0.5	4.3	umol/L	2.00	2.00	1.20	3.70
				TOT. PROTEINS	01/10/90	65.0	85.0	g/l	84.00	78.00	81.00	86.00
				ALBUMINE	01/10/90	34.0	55.0	g/l	52.90	52.90	51.90	55.80
				TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/L	5.60	4.60	3.80	5.30
				TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/L	1.62	1.67	2.21	0.95
				GLOBULINS: ALPHA 1	01/10/90	1.3	6.0	g/l	3.00	3.00	2.40	1.30
				GLOBULINS: ALPHA 2	01/10/90	5.0	9.0	g/l	10.00	6.70	7.00	8.70
				GLOBULINS: BETA	01/10/90	5.0	13.0	g/l	9.40	8.00	8.70	8.80
				GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	8.60	7.40	11.00	9.40
				T3	01/10/90	1.1	2.2	nmol/L	1.10			
				T4	01/10/90	60.0	140.0	nmol/L	88.00			
31	RK		FEMALE	HB	01/10/90	112.0	140.0	g/l	135.00	138.00	139.00	141.00
				HTC	01/10/90	0.4	0.5	l/l	0.31	0.42	0.43	0.43
				PRC	01/10/90	3.7	4.7	10**12/l	4.04	4.20	4.20	4.26
				HRC	01/10/90	4.0	8.8	10**9/l	4.30	5.60	5.50	5.20
				HRC: N	01/10/90	51.0	77.0	Z	58.00	68.00	67.00	59.00
				HRC: L	01/10/90	18.0	39.0	Z	30.00	30.00	29.00	28.00
				HRC: E	01/10/90	1.0	5.0	Z	4.00	1.00	2.00	9.00
				HRC: H	01/10/90	2.0	10.0	Z	8.00	1.00	2.00	4.00
				HRC: B	01/10/90	0.0	1.0	Z	0.00	0.00	0.00	0.00
				PLATELETS	01/10/90	180.0	320.0	10**9/l	215.00	220.00	218.00	217.00
				Na+	01/10/90	135.0	150.0	mmol/L	134.00	139.00	144.00	141.00
				K+	01/10/90	4.0	5.6	mmol/L	4.30	4.50	4.50	4.40
				CL-	01/10/90	95.0	105.0	mmol/L	101.80	102.00	98.20	102.60
				PO4--	01/10/90	0.6	1.3	mmol/L	1.07	1.19	1.19	1.05
				SGPT	01/10/90	1.0	12.0	U/l	8.20	4.00	6.00	5.00
				SGPT	01/10/90	1.0	9.0	U/l	24.00	27.00	23.00	37.00
				GAMMA-GT	01/10/90	10.0	66.0	U/l	4.60	3.50	3.70	3.20
				GLUCOSE	01/10/90	3.5	5.5	mmol/L	4.60	229.00	267.00	257.00
				ALK. PHOSPH.	01/10/90	135.0	360.0	mmol/L	225.00	3.00	4.50	3.30
				BUN	01/10/90	3.3	10.0	mmol/L	3.60	3.00	3.00	3.30
				CREATININE	01/10/90	44.0	88.0	umol/L	64.80	91.10	70.10	70.40

1716

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit								
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
10	31	RK	FEMALE	URIC ACID	01/10/90	119.0	357.0	umol/l	274.00	187.00	144.00	266.00			
				TOT BILIRUBIN	01/10/90	8.6	20.5	umol/l	18.00	13.50	18.00	15.80			
				DIR BILIRUBIN	01/10/90	0.5	4.3	umol/l	1.70	0.80	2.80	0.56			
				TOT. PROTEINS	01/10/90	65.0	85.0	g/l	82.00	76.00	79.00	79.00			
				ALBUMINE	01/10/90	34.0	55.0	g/l	47.50	48.00	48.10	48.50			
				TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/l	4.40	3.70	4.00	3.60			
				TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/l	1.70	1.20	1.86	0.94			
				GLOBULINS: ALPHA 1	01/10/90	1.3	6.0	g/l	2.60	1.70	1.30	1.20			
				GLOBULINS: ALPHA 2	01/10/90	5.0	9.0	g/l	10.30	7.50	7.50	8.10			
				GLOBULINS: BETA	01/10/90	5.0	13.0	g/l	10.20	7.00	8.20	8.80			
				GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	11.50	11.80	13.90	12.40			
				T3	01/10/90	1.1	2.2	mmol/l	1.05						
				T4	01/10/90	60.0	140.0	mmol/l	77.00						
				32	LK	FEMALE	HB	01/10/90	112.0	140.0	g/l	121.00	125.00	132.00	127.00
							HTC	01/10/90	0.4	0.5	l/l	0.43	0.58	0.41	0.37
							RBC	01/10/90	3.7	4.7	10**12/l	3.69	3.70	4.05	3.70
							RBC: N	01/10/90	4.0	8.8	10**9/l	4.40	4.20	3.60	5.00
RBC: L	01/10/90	51.0	77.0				%	54.00	64.00	60.00	58.00				
RBC: E	01/10/90	18.0	38.0				%	39.00	24.00	34.00	31.00				
RBC: M	01/10/90	1.0	5.0				%	7.00	4.00	4.00	6.00				
RBC: B	01/10/90	2.0	10.0				%	0.00	8.00	2.00	5.00				
PLATELETS	01/10/90	0.0	1.0				%	0.00	0.00	0.00	0.00				
NA+	01/10/90	180.0	320.0				10**9/l	220.00	215.00	210.00	225.00				
K+	01/10/90	135.0	150.0				mmol/l	140.00	147.00	142.00	141.00				
CL-	01/10/90	95.0	105.0				mmol/l	5.60	4.30	4.30	4.10				
PO4-	01/10/90	0.6	1.3				mmol/l	99.80	100.20	99.10	100.20				
SGPT	01/10/90	1.0	12.0				U/l	0.97	1.32	1.21	1.01				
GAMMA-GT	01/10/90	1.0	6.0				U/l	7.20	7.50	3.80	6.00				
GLUCOSE	01/10/90	10.0	66.0				U/l	32.00	40.00	18.00	37.00				
ALK. PHOSPH.	01/10/90	3.5	5.5				mmol/l	4.90	4.50	4.20	3.90				
CREATININE	01/10/90	135.0	360.0				umol/l	183.00	161.00	139.00	188.00				
RUN	01/10/90	3.3	10.0				mmol/l	7.00	3.50	3.10	3.80				
URIC ACID	01/10/90	44.0	88.0				umol/l	79.30	75.40	83.10	84.50				
TOT BILIRUBIN	01/10/90	119.0	357.0				umol/l	337.00	347.00	170.00	313.00				
DIR BILIRUBIN	01/10/90	8.6	20.5				umol/l	12.90	17.40	15.50	18.00				
TOT. PROTEINS	01/10/90	0.5	4.3				umol/l	1.70	0.56	2.00	2.80				
ALBUMINE	01/10/90	65.0	85.0	g/l	78.00	77.00	80.00	79.00							
TOT. CHOLEST.	01/10/90	34.0	55.0	g/l	47.20	48.50	48.60	50.00							
TRIGLYCERIDES	01/10/90	3.1	6.2	mmol/l	3.30	3.20	3.80	3.10							
GLOBULINS: ALPHA 1	01/10/90	0.5	1.9	mmol/l	0.60	1.32	2.00	1.18							
GLOBULINS: ALPHA 2	01/10/90	1.3	6.0	g/l	2.30	1.40	1.00	2.90							
GLOBULINS: BETA	01/10/90	5.0	9.0	g/l	6.00	6.40	8.20	4.20							
GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	9.00	7.50	8.60	5.70							
T3	01/10/90	1.1	2.2	mmol/l	13.50	13.20	13.60	16.20							
T4	01/10/90	60.0	140.0	mmol/l	64.00										

1717

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit									
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6					
10	33	EK	MALE	16/09/91	143.00	150.0	g/l	16/09/91	143.00	150.0	g/l	16/10/91	130.00	142.00	30/10/91	142.00
				01/10/90	129.0	150.0	g/l	02/10/91	138.00	150.0	g/l	16/10/91	130.00	142.00	30/10/91	142.00
				01/10/90	0.4	0.5	l/l	02/10/91	0.43	0.43	l/l	16/10/91	0.43	0.43	30/10/91	0.44
				01/10/90	4.0	5.0	10**12/l	02/10/91	4.29	4.29	10**12/l	16/10/91	4.17	4.17	30/10/91	4.40
				01/10/90	4.0	8.8	10**9/l	02/10/91	4.80	5.60	10**9/l	16/10/91	5.90	5.90	30/10/91	8.20
				01/10/90	51.0	77.0	z	02/10/91	58.00	69.00	z	16/10/91	62.00	62.00	30/10/91	80.00
				01/10/90	18.0	38.0	z	02/10/91	40.00	27.00	z	16/10/91	31.00	31.00	30/10/91	14.00
				01/10/90	1.0	5.0	z	02/10/91	2.00	1.00	z	16/10/91	4.00	4.00	30/10/91	0.00
				01/10/90	2.0	10.0	z	02/10/91	0.00	3.00	z	16/10/91	3.00	3.00	30/10/91	6.00
				01/10/90	0.0	1.0	z	02/10/91	0.00	0.00	z	16/10/91	0.00	0.00	30/10/91	0.00
				01/10/90	180.0	320.0	10**9/l	02/10/91	220.00	230.00	10**9/l	16/10/91	237.00	237.00	30/10/91	227.00
				01/10/90	135.0	150.0	mmol/l	02/10/91	144.00	144.00	mmol/l	16/10/91	143.00	143.00	30/10/91	145.00
				01/10/90	4.0	5.6	mmol/l	02/10/91	4.30	4.30	mmol/l	16/10/91	3.60	3.60	30/10/91	4.50
				01/10/90	95.0	105.0	mmol/l	02/10/91	101.50	101.50	mmol/l	16/10/91	97.80	97.80	30/10/91	105.30
				01/10/90	0.6	1.3	mmol/l	02/10/91	1.15	0.87	mmol/l	16/10/91	0.91	0.91	30/10/91	0.99
				01/10/90	1.0	12.0	U/l	02/10/91	9.80	3.50	U/l	16/10/91	5.00	5.00	30/10/91	3.50
				01/10/90	1.0	9.0	U/l	02/10/91	6.20	3.00	U/l	16/10/91	3.00	3.00	30/10/91	2.00
				01/10/90	15.0	106.0	U/l	02/10/91	34.00	90.00	U/l	16/10/91	44.00	44.00	30/10/91	44.00
				01/10/90	3.5	5.5	mmol/l	02/10/91	4.80	4.10	mmol/l	16/10/91	6.00	6.00	30/10/91	4.30
				01/10/90	135.0	360.0	mmol/l	02/10/91	338.00	240.00	mmol/l	16/10/91	257.00	257.00	30/10/91	262.00
				01/10/90	3.3	10.0	mmol/l	02/10/91	4.00	4.10	mmol/l	16/10/91	4.70	4.70	30/10/91	6.10
				01/10/90	44.0	101.0	umol/l	02/10/91	77.00	77.00	umol/l	16/10/91	74.90	74.90	30/10/91	91.50
				01/10/90	119.0	357.0	umol/l	02/10/91	337.00	357.00	umol/l	16/10/91	191.00	191.00	30/10/91	401.00
				01/10/90	8.6	20.5	umol/l	02/10/91	16.90	14.00	umol/l	16/10/91	16.80	16.80	30/10/91	16.10
				01/10/90	0.0	5.1	umol/l	02/10/91	3.10	1.10	umol/l	16/10/91	1.40	1.40	30/10/91	5.00
				01/10/90	65.0	85.0	g/l	02/10/91	80.00	80.00	g/l	16/10/91	82.00	82.00	30/10/91	80.00
				01/10/90	34.0	55.0	g/l	02/10/91	46.00	51.50	g/l	16/10/91	48.50	48.50	30/10/91	48.70
01/10/90	3.1	6.2	mmol/l	02/10/91	7.00	5.20	mmol/l	16/10/91	5.00	5.00	30/10/91	4.40				
01/10/90	0.5	1.9	mmol/l	02/10/91	1.20	2.00	mmol/l	16/10/91	2.17	2.17	30/10/91	3.78				
01/10/90	1.3	6.0	g/l	02/10/91	1.30	2.40	g/l	16/10/91	2.40	2.40	30/10/91	1.10				
01/10/90	5.0	9.0	g/l	02/10/91	14.20	7.40	g/l	16/10/91	10.00	10.00	30/10/91	10.80				
01/10/90	5.0	13.0	g/l	02/10/91	7.90	10.30	g/l	16/10/91	11.40	11.40	30/10/91	8.40				
01/10/90	10.0	17.0	g/l	02/10/91	10.60	8.40	g/l	16/10/91	9.70	9.70	30/10/91	11.00				
01/10/90	1.1	2.2	mmol/l	02/10/91	0.90	0.90	mmol/l	16/10/91	0.90	0.90	30/10/91	0.90				
01/10/90	60.0	140.0	mmol/l	02/10/91	70.00	70.00	mmol/l	16/10/91	70.00	70.00	30/10/91	70.00				
34	TK	MALE	16/09/91	137.00	150.0	g/l	16/09/91	137.00	150.0	g/l	16/10/91	144.00	144.00	05/11/91	144.00	
			01/10/90	129.0	150.0	g/l	08/10/91	142.00	142.00	g/l	16/10/91	144.00	144.00	05/11/91	144.00	
			01/10/90	0.4	0.5	l/l	08/10/91	0.42	0.45	l/l	16/10/91	0.43	0.43	05/11/91	0.44	
			01/10/90	4.0	5.0	10**12/l	08/10/91	4.19	4.48	10**12/l	16/10/91	4.31	4.31	05/11/91	4.37	
			01/10/90	4.0	8.8	10**9/l	08/10/91	7.80	54.00	10**9/l	16/10/91	5.20	5.20	05/11/91	4.10	
			01/10/90	51.0	77.0	z	08/10/91	59.00	38.00	z	16/10/91	66.00	66.00	05/11/91	62.00	
			01/10/90	18.0	38.0	z	08/10/91	28.00	28.00	z	16/10/91	30.00	30.00	05/11/91	32.00	
			01/10/90	1.0	5.0	z	08/10/91	2.00	2.00	z	16/10/91	2.00	2.00	05/11/91	2.00	
			01/10/90	2.0	10.0	z	08/10/91	11.00	8.00	z	16/10/91	8.00	8.00	05/11/91	4.00	
			01/10/90	0.0	1.0	z	08/10/91	0.00	0.00	z	16/10/91	0.00	0.00	05/11/91	0.00	
			01/10/90	180.0	320.0	10**9/l	08/10/91	200.00	240.00	10**9/l	16/10/91	240.00	240.00	05/11/91	227.00	
			01/10/90	135.0	150.0	mmol/l	08/10/91	136.00	141.00	mmol/l	16/10/91	140.00	140.00	05/11/91	141.00	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXYTINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit													
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6									
10	34	TK	MALE																	
			K+	01/10/90	4.0	5.6	mmol/l				4.20	4.30	4.30	4.30						
			CL-	01/10/90	95.0	105.0	mmol/l				96.00	97.90	98.90							
			PO4-	01/10/90	0.6	1.3	mmol/l				1.24	1.10	1.07							
			SGOT	01/10/90	1.0	12.0	U/l				6.80	8.80	3.00							
			SGPT	01/10/90	1.0	9.0	U/l				5.30	7.00	2.50							
			GAMMA-GT	01/10/90	15.0	106.0	U/l				42.00	16.00	66.00							
			GLUCOSE	01/10/90	3.5	5.5	mmol/l				4.50	4.00	4.70							
			ALK. PHOSPH.	01/10/90	135.0	360.0	mmol/l				245.00	283.00	345.00							
			BUN	01/10/90	3.3	10.0	mmol/l				5.00	6.50	5.40							
			CREATININE	01/10/90	44.0	101.0	mmol/l				84.70	76.40	73.30							
			URIC ACID	01/10/90	8.6	357.0	mmol/l				262.00	306.00	333.00							
			TOT BILIRUBIN	01/10/90	0.0	5.1	umol/l				3.90	80.00	2.20							
			DIR BILIRUBIN	01/10/90	65.0	85.0	g/l				75.00	81.00	81.00							
			TOT. PROTEINS	01/10/90	34.0	55.0	g/l				64.50	65.80	53.30							
			ALBUMINE	01/10/90	3.1	6.2	mmol/l				4.20	4.90	3.50							
			TOT. CHOLEST.	01/10/90	0.5	1.9	mmol/l				0.92	1.04	1.58							
			TRIGLYCERIDES	01/10/90	1.3	6.0	g/l				3.20	2.50	4.20							
			GLOBULINS: ALPHA 1	01/10/90	5.0	9.0	g/l				7.70	10.80	6.40							
			GLOBULINS: ALPHA 2	01/10/90	5.0	13.0	g/l				9.70	7.60	9.40							
			GLOBULINS: BETA	01/10/90	10.0	17.0	g/l				8.60	12.00	9.40							
			GLOBULINS: GAMMA	01/10/90	1.1	2.2	mmol/l				1.30	9.20	7.70							
			T3	01/10/90	60.0	140.0	mmol/l				79.00									
			T4	01/10/90																
35	IN		FEMALE																	
			HB	01/10/90	112.0	140.0	g/l				18/09/91	09/10/91	22/10/91	05/11/91						
			HTC	01/10/90	0.4	0.5	l/l				131.00	134.00	137.00	131.00						
			ERC	01/10/90	3.7	4.7	10**12/l				0.42	0.42	0.42	0.41						
			WBC	01/10/90	4.0	8.8	10**9/l				3.90	4.16	4.20	4.10						
			HRC: N	01/10/90	51.0	77.0	%				5.30	6.30	7.90	5.50						
			HRC: I	01/10/90	18.0	38.0	%				52.00	60.00	72.00	54.00						
			HRC: E	01/10/90	1.0	5.0	%				35.00	32.00	18.00	37.00						
			HRC: X	01/10/90	2.0	10.0	%				5.00	2.00	4.00	6.00						
			HRC: B	01/10/90	0.0	1.0	%				8.00	6.00	6.00	2.00						
			PLATELETS	01/10/90	180.0	320.0	10**9/l				200.00	217.00	217.00	210.00						
			NA+	01/10/90	155.0	150.0	mmol/l				141.00	140.00	142.00	137.00						
			K+	01/10/90	4.0	5.6	mmol/l				4.60	4.20	5.20	4.00						
			CL-	01/10/90	95.0	105.0	mmol/l				97.80	97.00	101.00	101.00						
			PO4-	01/10/90	0.6	1.3	mmol/l				1.42	1.03	1.30	0.94						
			SGOT	01/10/90	1.0	12.0	U/l				11.00	9.00	4.00	8.10						
			SGPT	01/10/90	1.0	9.0	U/l				6.20	6.00	3.00	6.30						
			GAMMA-GT	01/10/90	10.0	66.0	U/l				25.00	18.00	18.00	46.00						
			GLUCOSE	01/10/90	3.5	5.5	mmol/l				4.50	3.40	4.10	4.10						
			ALK. PHOSPH.	01/10/90	135.0	360.0	mmol/l				151.00	159.00	206.00	243.00						
			BUN	01/10/90	3.3	10.0	mmol/l				3.50	4.80	4.20	4.20						
			CREATININE	01/10/90	44.0	88.0	umol/l				76.30	78.20	72.70	64.20						
			URIC ACID	01/10/90	119.0	357.0	umol/l				198.00	198.00	240.00	179.00						
			TOT BILIRUBIN	01/10/90	8.6	20.5	umol/l				17.40	15.50	14.90	14.90						
			DIR BILIRUBIN	01/10/90	0.5	4.3	umol/l				1.40	2.50	1.10	0.56						
			TOT. CHOLEST.	01/10/90	0.5	1.9	mmol/l				75.00	80.00	80.00	85.00						

1710

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit									
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6					
10	35	IH	FEMALE	ALBUMINE	01/10/90	34.0	55.0	g/l	46.20	48.80	46.60	52.60				
				TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/l	4.60	4.80	3.70	2.70				
				TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/l	1.42	1.66	1.40	0.85				
				GLOBULINS: ALPHA 1	01/10/90	1.3	6.0	g/l	2.30	1.50	1.90	6.00				
				GLOBULINS: ALPHA 2	01/10/90	5.0	9.0	g/l	7.50	9.50	8.30	5.00				
				GLOBULINS: BETA	01/10/90	5.0	13.0	g/l	8.30	7.30	12.80	11.80				
				GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	10.70	10.90	10.40	9.60				
				T3	01/10/90	1.1	2.2	nmol/l	0.90							
				T4	01/10/90	60.0	140.0	nmol/l	78.00							
				36	AK		FEMALE	HB	08/10/91	112.0	140.0	g/l	132.00	132.00	132.00	132.00
								HTC	01/10/90	0.4	0.5	l/l	0.39	0.38	0.42	0.41
								RBC	01/10/90	3.7	4.7	10**9/l	3.80	3.80	4.17	4.08
								HBC: N	01/10/90	4.0	8.8	10**9/l	5.40	4.10	5.50	8.60
								HBC: L	01/10/90	51.0	77.0	%	62.00	64.00	60.00	54.00
HBC: E	01/10/90	18.0	38.0					%	32.00	31.00	39.00	42.00				
HBC: M	01/10/90	1.0	5.0					%	0.00	3.00	0.00	0.00				
HBC: B	01/10/90	2.0	10.0					%	6.00	2.00	6.00	3.00				
PLATELETS	01/10/90	0.0	1.0					%	0.00	0.00	0.00	1.00				
NA+	01/10/90	180.0	320.0					10**9/l	220.00	217.00	215.00	217.00				
K+	01/10/90	135.0	150.0					mmol/l	142.00	143.00	142.00	140.00				
CL-	01/10/90	4.0	5.6					mmol/l	4.80	6.10	5.00	4.30				
PO4--	01/10/90	95.0	105.0					mmol/l	98.00	106.20	97.80	100.10				
SCPT	01/10/90	0.6	1.3					mmol/l	1.27	1.41	1.43	1.74				
37	HK		FEMALE	GAMMA-GT	01/10/90	1.0	12.0	U/l	4.80	3.00	1.50	7.50				
				GLUCOSE	01/10/90	10.0	66.0	U/l	12.00	40.00	29.00	27.00				
				ALK. PHOSPH.	01/10/90	3.5	5.5	nmol/l	4.90	3.70	3.70	3.20				
				RUN	01/10/90	135.0	360.0	nmol/l	480.00	374.00	548.00	466.00				
				CREATININE	01/10/90	3.3	10.0	nmol/l	5.30	6.50	7.00	7.70				
				URIC ACID	01/10/90	44.0	88.0	umol/l	81.50	77.10	77.70	88.00				
				TOT. BILIRUBIN	01/10/90	119.0	357.0	umol/l	258.00	367.00	244.00	324.00				
				DIR. BILIRUBIN	01/10/90	8.6	20.5	umol/l	18.80	25.20	8.20	12.90				
				TOT. PROTEINS	01/10/90	0.5	4.3	umol/l	8.40	3.10	1.40	1.00				
				ALBUMINE	01/10/90	65.0	85.0	g/l	78.00	86.00	82.00	80.00				
				TRIGLYCERIDES	01/10/90	34.0	55.0	g/l	45.60	53.10	48.60	48.60				
				TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/l	6.60	6.90	5.00	6.20				
				GLOBULINS: ALPHA 1	01/10/90	0.5	1.9	mmol/l	1.49	1.60	1.52	1.74				
				GLOBULINS: ALPHA 2	01/10/90	1.3	6.0	g/l	4.49	5.40	3.60	2.50				
GLOBULINS: BETA	01/10/90	5.0	9.0	g/l	12.50	7.30	9.80	11.00								
GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	10.50	10.80	10.20	9.80								
T3	01/10/90	1.1	2.2	nmol/l	0.95	9.40	9.60	8.10								
T4	01/10/90	60.0	140.0	nmol/l	69.00											
37	HK		FEMALE	HB	08/10/91	112.0	140.0	g/l	131.00	135.00	136.00	130.00				
				HTC	01/10/90	0.4	0.5	l/l	0.41	0.40	0.42	0.41				
					01/10/90											

1720

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBONETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Screen	Visit			
				Date	Min	Max		Unit	Week 2	Week 4	Week 6
10	37	HK	FEMALE	01/10/90	3.7	4.7	10**12/l	4.08	4.11	4.17	4.15
			RBC	01/10/90	4.0	8.5	10**9/l	6.70	5.40	7.30	4.80
			RBC: N	01/10/90	51.0	77.0	X	74.00	77.00	70.00	80.00
			RBC: L	01/10/90	18.0	38.0	X	20.00	14.00	24.00	18.00
			RBC: E	01/10/90	1.0	5.0	X	4.00	4.00	4.00	1.00
			RBC: M	01/10/90	2.0	10.0	X	0.00	5.00	2.00	1.00
			RBC: B	01/10/90	0.0	1.0	X	0.00	0.00	0.00	0.00
			PLATELETS	01/10/90	180.0	320.0	10**9/l	215.00	218.00	220.00	225.00
			NA+	01/10/90	135.0	150.0	mmol/l	140.00	144.00	141.00	138.00
			K+	01/10/90	4.0	5.6	mmol/l	4.40	4.40	4.40	4.60
			CL-	01/10/90	95.0	105.0	mmol/l	97.80	97.90	97.90	102.10
			PO4-	01/10/90	0.6	1.3	mmol/l	1.08	1.22	1.37	1.03
			SGOT	01/10/90	1.0	12.0	U/l	5.20	5.00	5.50	6.50
			SGPT	01/10/90	1.0	9.0	U/l	9.00	4.00	4.50	3.00
			GAMMA-GT	01/10/90	10.0	66.0	U/l	23.00	33.00	12.00	31.00
			GLUCOSE	01/10/90	3.5	5.5	mmol/l	5.70	4.20	4.30	5.00
			ALK. PHOSPH.	01/10/90	195.0	360.0	mmol/l	188.00	136.00	205.00	164.00
			BUN	01/10/90	3.3	10.0	mmol/l	4.70	5.00	5.00	4.70
			CREATININE	01/10/90	44.0	88.0	umol/l	76.60	88.00	84.50	77.40
			URIC ACID	01/10/90	119.0	357.0	umol/l	278.00	270.00	298.00	366.00
			TOT BILIRUBIN	01/10/90	8.6	20.5	umol/l	14.00	15.80	11.80	16.50
			DIR BILIRUBIN	01/10/90	0.5	4.3	umol/l	2.20	1.70	1.10	1.40
			TOT. PROTEINS	01/10/90	65.0	85.0	g/l	80.00	79.00	84.00	83.00
			ALBUMINE	01/10/90	34.0	55.0	g/l	52.60	54.00	53.30	43.60
			TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/l	4.40	5.20	5.30	3.70
			TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/l	0.46	1.15	1.22	0.98
			GLOBULINS: ALPHA 1	01/10/90	1.3	6.0	g/l	1.40	3.10	2.90	4.30
			GLOBULINS: ALPHA 2	01/10/90	5.0	13.0	g/l	10.80	7.90	8.10	9.60
			GLOBULINS: BETA	01/10/90	5.0	17.0	g/l	8.20	6.60	10.70	15.80
			GLOBULINS: GAMMA	01/10/90	1.1	2.2	mmol/l	7.00	7.40	9.30	9.70
			T3	01/10/90	1.1	2.2	mmol/l	1.00	1.00	1.00	1.00
			T4	01/10/90	60.0	140.0	mmol/l	71.00	71.00	71.00	71.00
38	LL	FEMALE		09/10/91	112.0	140.0	g/l	135.00	137.00	135.00	136.00
			HB	01/10/90	0.4	0.5	g/l	0.41	0.42	0.41	0.41
			HTC	01/10/90	3.7	4.7	10**12/l	4.06	4.18	4.08	4.15
			RBC	01/10/90	4.0	8.8	10**9/l	6.30	4.90	5.40	4.00
			RBC: N	01/10/90	51.0	77.0	X	68.00	53.00	72.00	72.00
			RBC: L	01/10/90	18.0	38.0	X	23.00	44.00	21.00	23.00
			RBC: E	01/10/90	1.0	5.0	X	5.00	1.00	4.00	2.00
			RBC: M	01/10/90	2.0	10.0	X	0.00	4.00	3.00	3.00
			RBC: B	01/10/90	0.0	1.0	X	0.00	0.00	0.00	0.00
			PLATELETS	01/10/90	180.0	320.0	10**9/l	225.00	218.00	217.00	215.00
			NA+	01/10/90	135.0	150.0	mmol/l	143.00	142.00	140.00	138.00
			K+	01/10/90	4.0	5.6	mmol/l	4.10	4.30	4.50	4.40
			CL-	01/10/90	95.0	105.0	mmol/l	97.50	100.00	101.00	104.20
			PO4-	01/10/90	0.6	1.3	mmol/l	0.91	0.99	0.96	1.02
			SGOT	01/10/90	1.0	12.0	U/l	5.00	4.00	4.00	3.00
			SGPT	01/10/90	1.0	9.0	U/l	7.00	3.50	4.20	5.50

1721

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Date	Laboratory Range			Screen	Visit		
					Min	Max	Unit		Week 2	Week 4	Week 6
10	38 LL	FEMALE	GAMMA-GT	01/10/90	10.0	66.0	U/l	10.00	23.00	17.00	23.00
			GLUCOSE	01/10/90	3.5	5.5	mmol/l	4.80	3.80	3.60	3.90
			ALK. PHOSPH.	01/10/90	135.0	360.0	nmol/l	197.00	168.00	244.00	245.00
			BUN	01/10/90	3.3	10.0	mmol/l	3.50	4.40	4.00	5.90
			CREATININE	01/10/90	44.0	88.0	umol/l	74.90	72.90	71.50	66.90
			URIC ACID	01/10/90	119.0	357.0	umol/l	238.00	177.00	238.00	243.00
			TOT BILIRUBIN	01/10/90	8.6	20.5	umol/l	14.00	16.90	45.40	29.70
			DIR BILIRUBIN	01/10/90	0.5	4.3	umol/l	5.60	3.90	0.70	6.70
			TOT. PROTEINS	01/10/90	65.0	85.0	g/l	80.00	75.00	80.00	78.00
			ALBUMINE	01/10/90	34.0	55.0	g/l	52.60	48.00	50.30	49.30
			TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/l	3.90	3.30	3.00	3.00
			TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/l	1.32	0.43	1.52	1.88
			GLOBULINS: ALPHA 1	01/10/90	1.3	6.0	g/l	1.40	1.10	2.90	1.60
			GLOBULINS: ALPHA 2	01/10/90	5.0	9.0	g/l	10.80	8.10	7.00	7.80
			GLOBULINS: BETA	01/10/90	5.0	13.0	g/l	8.20	8.60	10.20	8.40
			GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	7.00	9.20	9.60	10.90
			T3	01/10/90	1.1	2.2	nmol/l	1.00			
			T4	01/10/90	60.0	140.0	nmol/l	74.00			
11	39 YH	FEMALE	HB	01/10/90	112.0	140.0	g/l	144.00	142.00	138.00	138.00
			HTC	01/10/90	0.4	0.5	l/l	0.43	0.42	0.42	0.42
			RBC	01/10/90	3.7	4.7	10**12/l	4.20	4.27	4.23	4.24
			WBC	01/10/90	4.0	8.8	10**9/l	5.30	4.20	4.80	5.70
			WBC: N	01/10/90	51.0	77.0	%	66.00	74.00	80.00	62.00
			WBC: L	01/10/90	18.0	38.0	%	32.00	20.00	17.00	37.00
			WBC: E	01/10/90	1.0	5.0	%	8.00	2.00	0.00	0.00
			WBC: M	01/10/90	2.0	10.0	%	2.00	4.00	3.00	1.00
			WBC: B	01/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00
			PLATELETS	01/10/90	180.0	320.0	10**9/l	230.00	228.00	227.00	225.00
			Na+	01/10/90	135.0	150.0	mmol/l	140.00	145.00	139.00	143.00
			K+	01/10/90	4.0	5.6	mmol/l	4.60	5.60	4.00	4.50
			CL-	01/10/90	95.0	105.0	mmol/l	101.80	98.40	99.00	98.90
			PO4-	01/10/90	0.6	1.3	mmol/l	0.85	0.94	0.98	0.89
			SGOT	01/10/90	1.0	12.0	U/l	5.50	6.00	2.00	4.00
			SGPT	01/10/90	1.0	9.0	U/l	5.00	5.50	5.50	9.50
			GAMMA-GT	01/10/90	10.0	66.0	U/l	47.00	20.00	22.00	25.00
			GLUCOSE	01/10/90	3.5	5.5	mmol/l	4.00	4.00	4.50	3.30
			BUN	01/10/90	135.0	360.0	nmol/l	145.00	183.00	212.00	274.00
			CREATININE	01/10/90	3.3	10.0	umol/l	5.00	5.00	5.00	4.70
			URIC ACID	01/10/90	44.0	88.0	umol/l	81.50	80.20	84.20	80.90
			TOT BILIRUBIN	01/10/90	119.0	357.0	umol/l	218.00	228.00	262.00	247.00
			DIR BILIRUBIN	01/10/90	8.6	20.5	umol/l	8.50	8.50	26.60	16.30
			TOT. PROTEINS	01/10/90	65.0	85.0	g/l	83.00	80.00	83.00	80.00
			ALBUMINE	01/10/90	34.0	55.0	g/l	52.40	52.40	55.40	48.10
			TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/l	3.50	3.60	3.30	3.20
			TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/l	1.73	0.47	0.78	0.82
			GLOBULINS: ALPHA 1	01/10/90	1.3	6.0	g/l	1.80	1.80	2.40	1.80
			GLOBULINS: ALPHA 2	01/10/90	5.0	9.0	g/l	9.80	7.50	7.40	9.90

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit					
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
10	39	VH	FEMALE	GLOBULINS: BETA	01/10/90	5.0	13.0	g/l	9.40	8.00	8.70	9.10
				GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	10.00	10.30	9.10	11.10
				T3	01/10/90	1.1	2.2	nmol/l	1.20			
				T4	01/10/90	60.0	140.0	nmol/l	105.00			
				HB	01/10/90	112.0	140.0	g/l	22/130.00	06/11/91	20/11/91	04/12/91
				HTC	01/10/90	0.4	0.5	l/l	130.00	132.00	132.00	125.00
				RBC	01/10/90	3.7	4.7	10**12/l	0.42	0.42	0.38	0.39
				RBC: N	01/10/90	4.0	8.8	10**9/l	4.17	4.17	3.85	3.85
				RBC: L	01/10/90	51.0	77.0	%	68.00	5.60	5.90	3.60
				RBC: E	01/10/90	18.0	38.0	%	72.00	6.00	80.00	76.00
40	AP	FEMALE	RBC: M	01/10/90	1.0	5.0	%	22.00	26.00	18.00	20.00	
			RBC: B	01/10/90	2.0	10.0	%	2.00	3.00	0.00	2.00	
			FLATELETS	01/10/90	0.0	1.0	%	4.00	3.00	0.00	0.00	
			NA+	01/10/90	180.0	320.0	10**9/l	0.00	0.00	0.00	0.00	
			K+	01/10/90	3.5	5.6	mmol/l	220.00	215.00	215.00	210.00	
			PO4-	01/10/90	4.0	5.6	mmol/l	142.00	144.00	139.00	142.00	
			CL-	01/10/90	95.0	105.0	mmol/l	4.10	4.40	3.90	4.80	
			SGOT	01/10/90	0.6	1.3	mmol/l	1.00	0.99	1.08	1.21	
			SGPT	01/10/90	1.0	12.0	U/l	4.50	7.30	3.00	4.00	
			GAMMA-GT	01/10/90	10.0	66.0	U/l	3.00	6.10	5.00	5.00	
41	VP	FEMALE	GLUCOSE	01/10/90	3.5	5.5	mmol/l	74.00	23.00	25.00	37.00	
			ALK. PHOSPH.	01/10/90	135.0	360.0	mmol/l	4.00	4.10	3.90	3.20	
			CREATININE	01/10/90	3.3	10.0	mmol/l	152.00	213.00	214.00	208.00	
			TOT BILIRUBIN	01/10/90	44.0	88.0	umol/l	3.80	4.80	4.70	5.10	
			DIR BILIRUBIN	01/10/90	119.0	357.0	umol/l	83.00	67.80	65.00	71.70	
			TOT PROTEINS	01/10/90	8.6	20.5	umol/l	250.00	226.00	228.00	270.00	
			ALBUMINE	01/10/90	0.5	4.3	umol/l	20.20	21.10	10.40	18.00	
			TOT CHOLEST.	01/10/90	34.0	85.0	g/l	3.40	2.00	3.70	3.10	
			TRIGLICERIDES	01/10/90	3.1	55.0	g/l	79.00	83.00	79.00	78.00	
			GLUCERIDES: ALPHA 1	01/10/90	0.5	6.2	mmol/l	51.40	54.20	50.30	41.30	
GLUCERIDES: ALPHA 2	01/10/90	1.3	1.9	mmol/l	4.60	3.20	3.50	4.90				
GLUCERIDES: BETA	01/10/90	5.0	6.0	g/l	1.84	0.58	1.04	1.16				
GLUCERIDES: GAMMA	01/10/90	5.0	13.0	g/l	1.30	3.60	2.10	4.90				
T3	01/10/90	10.0	17.0	g/l	8.50	6.00	9.60	10.20				
T4	01/10/90	1.1	2.2	nmol/l	8.20	10.10	9.60	13.90				
	01/10/90	60.0	140.0	nmol/l	87.00	9.10	7.40	7.70				
41	VP	FEMALE	HB	01/10/90	112.0	140.0	g/l	29/10/91	12/11/91	26/11/91	10/12/91	
			HTC	01/10/90	0.4	0.5	l/l	132.00	133.00	134.00	138.00	
			RBC	01/10/90	3.7	4.7	10**12/l	0.40	0.40	0.41	0.39	
			RBC: N	01/10/90	4.0	8.8	10**9/l	3.95	3.97	4.07	4.03	
			RBC: L	01/10/90	51.0	77.0	%	58.00	68.00	56.00	48.00	
			RBC: E	01/10/90	18.0	38.0	%	26.00	26.00	40.00	44.00	
			RBC: M	01/10/90	1.0	5.0	%	4.00	4.00	0.00	4.00	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXYTINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit						
				Date	Min	Max	Unit	Screen	Week 2		Week 4		Week 6
10	41	VP	FEMALE	01/10/90	2.0	10.0	%	4.00	2.00	4.00	4.00	4.00	4.00
			WBC: M	01/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00
			PLATELETS	01/10/90	180.0	320.0	10**9/L	227.00	227.00	227.00	227.00	220.00	220.00
			Na+	01/10/90	135.0	150.0	MMOL/L	145.00	139.00	140.00	140.00	148.00	148.00
			K+	01/10/90	4.0	5.6	MMOL/L	4.60	4.50	4.70	4.70	4.70	4.70
			CL-	01/10/90	95.0	105.0	MMOL/L	101.60	96.90	96.90	96.90	100.50	100.50
			PO4-	01/10/90	0.6	1.3	MMOL/L	0.99	1.10	1.09	1.09	1.12	1.12
			SGPT	01/10/90	1.0	12.0	U/L	4.20	4.00	2.00	2.00	6.50	6.50
			SGPT	01/10/90	1.0	9.0	U/L	5.80	3.50	3.50	3.50	5.00	5.00
			GAMMA-GT	10/12/91	0.2	1.1	UKAT/L	57.00	10.00	17.00	17.00	4.20	4.20
			GAMMA-GT	01/10/90	10.0	66.0	U/L	3.90	4.40	4.90	4.90	4.20	4.20
			GLUCOSE	01/10/90	3.5	5.5	MMOL/L	274.00	266.00	381.00	381.00	337.00	337.00
			ALK. PHOSPH.	01/10/90	3.3	10.0	MMOL/L	4.40	5.50	5.00	4.60	4.60	4.60
			BUN	01/10/90	44.0	88.0	MMOL/L	72.20	73.30	68.60	68.60	67.70	67.70
			CREATININE	01/10/90	119.0	357.0	UMOL/L	284.00	238.00	270.00	270.00	238.00	238.00
			URIC ACID	01/10/90	8.6	20.5	UMOL/L	16.10	10.10	18.80	18.80	8.90	8.90
			TOT BILIRUBIN	01/10/90	0.5	4.3	UMOL/L	2.00	0.56	2.50	2.50	1.70	1.70
			DIR BILIRUBIN	01/10/90	65.0	85.0	G/L	74.00	79.00	76.00	76.00	70.00	70.00
			TOT. PROTEINS	01/10/90	34.0	55.0	G/L	43.00	49.00	44.20	44.20	39.60	39.60
			ALBUMINE	01/10/90	3.1	6.2	MMOL/L	7.10	4.50	4.20	4.20	5.30	5.30
			TOT. CHOLEST.	01/10/90	0.5	1.9	MMOL/L	1.24	1.08	0.97	0.97	0.98	0.98
			TRIGLYCERIDES	01/10/90	1.3	6.0	G/L	3.70	2.30	3.40	3.40	1.60	1.60
			GLOBULINS: ALPHA 1	01/10/90	5.0	9.0	G/L	6.30	5.40	4.90	4.90	8.30	8.30
			GLOBULINS: ALPHA 2	01/10/90	5.0	13.0	G/L	6.70	9.60	12.80	12.80	12.20	12.20
			GLOBULINS: BETA	01/10/90	10.0	17.0	G/L	14.30	12.70	10.70	10.70	8.30	8.30
			GLOBULINS: GAMMA	01/10/90	1.1	2.2	mmol/l	1.55	1.55	1.55	1.55	1.55	1.55
			T3	01/10/90	60.0	140.0	nmol/l	58.00	58.00	58.00	58.00	58.00	58.00
			T4	01/10/90	60.0	140.0	nmol/l	58.00	58.00	58.00	58.00	58.00	58.00
42	TT	MALE		01/10/90	129.0	150.0	G/L	144.00	140.00	147.00	147.00	144.00	144.00
			HR	01/10/90	0.4	0.5	L/L	0.44	0.42	0.42	0.42	0.42	0.42
			HTC	01/10/90	4.0	5.0	10**12/L	4.35	4.20	4.25	4.25	4.20	4.20
			RBC	01/10/90	4.0	8.8	10**9/L	7.80	5.30	7.90	7.90	4.80	4.80
			HGB: N	01/10/90	51.0	77.0	%	72.00	62.00	54.00	54.00	66.00	66.00
			HGB: L	01/10/90	18.0	38.0	%	25.00	32.00	40.00	40.00	28.00	28.00
			HGB: E	01/10/90	1.0	5.0	%	1.00	2.00	2.00	2.00	3.00	3.00
			HGB: M	01/10/90	2.0	10.0	%	2.00	4.00	4.00	4.00	3.00	3.00
			HGB: B	01/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00
			PLATELETS	01/10/90	180.0	320.0	10**9/L	230.00	230.00	225.00	225.00	242.00	242.00
			Na+	01/10/90	135.0	150.0	MMOL/L	139.00	141.00	142.00	142.00	136.00	136.00
			K+	01/10/90	4.0	5.6	MMOL/L	4.70	4.90	4.20	4.20	4.50	4.50
			CL-	01/10/90	95.0	105.0	MMOL/L	95.90	100.00	101.60	101.60	101.60	101.60
			PO4-	01/10/90	0.6	1.3	MMOL/L	1.11	0.91	1.10	1.10	1.16	1.16
			SGPT	01/10/90	1.0	12.0	U/L	8.50	3.00	3.50	3.50	3.50	3.50
			SGPT	01/10/90	1.0	9.0	U/L	5.00	6.50	0.30	0.30	4.50	4.50
			GAMMA-GT	10/12/91	0.3	1.8	UKAT/L	24.00	24.00	3.70	3.70	4.20	4.20
			GAMMA-GT	01/10/90	15.0	106.0	U/L	409.00	548.00	330.00	330.00	364.00	364.00
			GLUCOSE	01/10/90	3.5	5.5	MMOL/L	4.60	4.60	4.60	4.60	4.60	4.60
			GLUCOSE	01/10/90	3.5	5.5	MMOL/L	4.60	4.60	4.60	4.60	4.60	4.60

1724

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOREXINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Screen		Visit					
				Date	Min	Max	Unit	Week 2	Week 4	Week 6				
10	42	TT	MALE	BUN	01/10/90	3.3	10.0	MMOL/L	5.50	7.70	7.10			
				CREATININE	01/10/90	44.0	101.0	UMOL/L	77.00	89.50	74.80			
				URIC ACID	01/10/90	119.0	357.0	UMOL/L	381.00	560.00	82.30			
				TOT BILIRUBIN	01/10/90	8.6	20.5	UMOL/L	14.90	10.40	565.00			
				DIR BILIRUBIN	10/12/91	0.5	4.3	UMOL/L		1.20	18.20			
				DIR BILIRUBIN	01/10/90	0.0	5.1	umol/l	3.70	1.40	3.70			
				TOT. PROTEINS	01/10/90	65.0	85.0	G/L	81.00	81.00	85.00			
				ALBUMINE	01/10/90	34.0	55.0	G/L	50.00	46.60	51.40			
				TOT. CHOLEST.	01/10/90	3.1	6.2	MMOL/L	4.80	3.20	4.80			
				TRIGLYCERIDES	01/10/90	0.5	1.9	MMOL/L	1.08	1.60	1.57			
				GLOBULINS: ALPHA 1	01/10/90	1.3	6.0	G/L	2.40	4.50	3.40			
				GLOBULINS: ALPHA 2	01/10/90	5.0	9.0	G/L	8.30	4.30	8.30			
				GLOBULINS: BETA	01/10/90	5.0	13.0	G/L	9.60	13.70	9.60			
				GLOBULINS: GAMMA	01/10/90	10.0	17.0	G/L	10.90	11.90	11.90			
				T3	01/10/90	1.1	2.2	mmol/l	1.16					
				T4	01/10/90	60.0	140.0	mmol/l	59.00					
				43	IK	FEMALE	HB	01/10/90	112.0	140.0	G/L	132.00	140.00	140.00
							HTC	01/10/90	0.4	0.5	L/L	0.41	0.40	0.40
							RBC	01/10/90	3.7	4.7	10**12/L	4.08	4.15	4.10
							NBC	01/10/90	4.0	8.8	10**9/L	5.10	8.30	6.80
NBC: N	01/10/90	51.0	77.0				X	58.00	51.00	48.00				
NBC: L	01/10/90	18.0	38.0				X	36.00	39.00	50.00				
NBC: E	01/10/90	1.0	5.0				X	2.00	4.00	0.00				
NBC: M	01/10/90	2.0	10.0				X	4.00	6.00	2.00				
NBC: B	01/10/90	0.0	1.0				X	0.00	0.00	0.00				
PLATELETS	01/10/90	180.0	320.0				10**9/L	215.00	200.00	203.00				
NA+	01/10/90	135.0	150.0				MMOL/L	137.00	141.00	139.00				
CL-	01/10/90	4.0	5.6				MMOL/L	7.20	4.20	4.70				
PO4-	01/10/90	0.6	1.3				MMOL/L	100.30	93.80	95.80				
SCPT	01/10/90	1.0	12.0				U/L	0.91	1.13	1.25				
GAMMA-GT	01/10/90	1.0	9.0				U/L	1.50	3.50	6.20				
GAMMA-GT	10/12/91	0.2	1.1				UKAT/L	3.00	2.50	4.50				
GLUCOSE	01/10/90	10.0	66.0				U/L	32.00	0.45	0.16				
ALK. PHOSPH.	01/10/90	3.5	5.5				MMOL/L	3.90	3.90	4.70				
BUN	01/10/90	135.0	340.0				MMOL/L	342.00	365.00	266.00				
CREATININE	01/10/90	3.3	10.0				MMOL/L	4.50	5.70	6.70				
URIC ACID	01/10/90	44.0	88.0	UMOL/L	67.80	78.60	70.80							
TOT BILIRUBIN	01/10/90	119.0	357.0	UMOL/L	292.00	270.00	343.00							
DIR BILIRUBIN	01/10/90	8.6	20.5	UMOL/L	19.50	10.70	15.50							
DIR BILIRUBIN	01/10/90	0.5	4.3	UMOL/L	3.50	0.70	1.10							
TOT. PROTEINS	01/10/90	65.0	85.0	G/L	83.00	83.00	80.00							
ALBUMINE	01/10/90	34.0	55.0	G/L	48.90	49.40	43.50							
TOT. CHOLEST.	01/10/90	3.1	6.2	MMOL/L	3.20	4.00	4.80							
TRIGLYCERIDES	01/10/90	0.5	1.9	MMOL/L	1.51	1.43	1.38							
GLOBULINS: ALPHA 1	01/10/90	1.3	6.0	G/L	2.70	4.10	3.10							
GLOBULINS: ALPHA 2	01/10/90	5.0	9.0	G/L	7.00	10.40	8.50							
GLOBULINS: BETA	01/10/90	5.0	13.0	G/L	8.50	10.90	15.20							

1725

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
10	43	IK	FEMALE	GLOBALINS: GAMMA	01/10/90	10.0	17.0	G/L	15.90	8.90	10.20	9.70	
				T3	01/10/90	1.1	2.2	nmol/L	1.42	.	.	.	
				T4	01/10/90	60.0	140.0	nmol/L	99.00	.	.	.	
	44	AB	MALE	HB	01/10/90	129.0	150.0	G/L	17/11/91	01/12/91	15/12/91	29/12/91	
				HTC	01/10/90	0.4	0.5	L/L	122.00	147.00	133.00	138.00	
				RBC	01/10/90	4.0	5.0	10**12/L	0.38	0.42	0.40	0.40	
				HBC	01/10/90	4.0	8.8	10**9/L	3.75	4.23	4.02	4.18	
				HBC: N	01/10/90	51.0	77.0	Z	7.40	4.70	4.40	4.10	
				HBC: L	01/10/90	18.0	38.0	Z	62.00	53.00	36.00	60.00	
				HBC: E	01/10/90	1.0	5.0	Z	26.00	38.00	48.00	36.00	
HBC: H				01/10/90	2.0	10.0	Z	8.00	5.00	6.00	0.00		
HBC: B				01/10/90	0.0	1.0	Z	4.00	4.00	10.00	4.00		
PLATELETS				01/10/90	180.0	320.0	10**9/L	223.00	190.00	200.00	227.00		
NA+				01/10/90	135.0	150.0	MMOL/L	138.00	141.00	141.00	137.00		
K+				01/10/90	4.0	5.6	MMOL/L	4.20	4.20	4.30	4.20		
CL-				01/10/90	95.0	105.0	MMOL/L	101.00	96.90	92.90	99.80		
PO4-				01/10/90	0.6	1.3	MMOL/L	1.02	1.36	1.04	0.81		
SGPT				01/10/90	1.0	12.0	U/L	5.50	3.00	4.00	4.50		
GAMMA-GT				01/10/90	1.0	9.0	U/L	2.50	2.00	3.50	4.50		
GAMMA-GT				10/12/91	0.3	1.8	UKAT/L	.	.	0.85	0.94		
GLUCOSE	01/10/90	15.0	106.0	U/L	16.00	25.00	5.50	3.90					
ALK. PHOSPH.	01/10/90	3.5	5.5	MMOL/L	4.10	3.10	3.64	299.00					
BUN	01/10/90	135.0	360.0	MMOL/L	298.00	339.00	4.10	5.60					
CREATININE	01/10/90	3.3	10.0	MMOL/L	6.90	5.70	4.10	60.90					
TOT BILIRUBIN	01/10/90	44.0	101.0	UMOL/L	74.60	93.10	78.40	490.00					
DIR BILIRUBIN	01/10/90	119.0	357.0	UMOL/L	397.00	386.00	452.00	490.00					
TOT PROTEINS	01/10/90	8.6	20.5	UMOL/L	19.10	21.10	9.80	12.60					
ALBUMINE	10/12/91	0.5	4.3	UMOL/L	.	.	0.80	2.20					
TRIGLYCERIDES	01/10/90	0.0	5.1	umol/L	0.80	1.90	84.00	81.00					
CHOLEST.	01/10/90	65.0	85.0	G/L	82.00	82.00	50.30	55.50					
GLUCOLINS: ALPHA 1	01/10/90	34.0	55.0	G/L	55.60	46.00	3.10	5.00					
GLUCOLINS: ALPHA 2	01/10/90	3.1	6.2	MMOL/L	3.20	4.10	3.10	0.62					
GLUCOLINS: BETA	01/10/90	0.5	1.9	MMOL/L	1.56	1.37	1.38	1.10					
GLUCOLINS: GAMMA	01/10/90	1.3	6.0	G/L	3.30	3.30	4.00	7.40					
T3	01/10/90	5.0	9.0	G/L	8.10	8.10	7.80	6.40					
T4	01/10/90	10.0	17.0	G/L	15.90	15.90	7.90	10.60					
T4	01/10/90	1.1	2.2	nmol/L	10.40	8.70	14.00	10.60					
	01/10/90	60.0	140.0	nmol/L	125.00	.	.	.					
45	KJ	FEMALE	HB	01/10/90	112.0	140.0	G/L	18/11/91	03/12/91	17/12/91	31/12/91		
			HTC	01/10/90	0.4	0.5	L/L	140.00	120.00	129.00	135.00		
			RBC	01/10/90	3.7	4.7	10**12/L	0.42	0.37	0.37	0.43		
			HBC: N	01/10/90	4.0	8.8	10**9/L	4.27	3.61	3.72	4.24		
			HBC: L	01/10/90	51.0	77.0	Z	78.00	68.00	70.00	70.00		

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOVETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit											
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6							
10	45 KJ	FEMALE	WBC: E WBC: M WBC: B PLATELETS NA+ K+ CL- PO4- SGPT SGOT GAMMA-GT GAMMA-GT GLUCOSE ALK. PHOSPH. CREATININE UREA ACID TOT. BILIRUBIN DIR. BILIRUBIN TOT. PROTEINS ALBUMINE ALBUMINE TOT. CHOLEST. TRIGLYCERIDES GLOBULINS: ALPHA 1 GLOBULINS: ALPHA 2 GLOBULINS: BETA GLOBULINS: GAMMA T3 T4	01/10/90	1.0	5.0	Z	0.00	2.00	0.00	0.00	2.00	0.00	2.00				
				01/10/90	2.0	10.0	Z	2.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00			
				01/10/90	0.0	1.0	Z	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
				01/10/90	180.0	320.0	10**9/L	230.00	225.00	230.00	230.00	230.00	230.00	230.00	230.00			
				01/10/90	135.0	150.0	MMOL/L	138.00	140.00	138.00	140.00	138.00	140.00	138.00	140.00			
				01/10/90	4.0	5.6	MMOL/L	4.80	4.10	4.00	4.70	4.00	4.00	4.00	4.70			
				01/10/90	95.0	105.0	MMOL/L	102.60	97.90	95.90	95.20	97.90	95.90	95.20	95.20			
				01/10/90	0.6	1.3	MMOL/L	1.20	1.18	1.23	1.23	1.23	1.23	1.23	1.23			
				01/10/90	1.0	12.0	U/L	6.00	3.00	3.00	7.00	3.00	3.00	7.00	3.00			
				01/10/90	1.0	9.0	U/L	6.00	3.60	3.60	2.80	3.00	2.80	3.00	3.00			
				10/12/91	0.2	1.1	UKAT/L	21.00	23.00	23.00	1.90	1.90	1.90	1.90	0.30			
				01/10/90	10.2	66.0	U/l	5.00	4.80	4.80	5.50	4.80	5.50	4.20	4.20			
				01/10/90	3.5	5.5	MMOL/L	5.00	5.00	5.00	5.50	4.80	5.50	4.20	4.20			
				01/10/90	135.0	360.0	MMOL/L	287.00	330.00	330.00	253.00	330.00	253.00	239.00	239.00			
				01/10/90	3.3	10.0	MMOL/L	5.90	5.10	5.10	4.60	5.10	4.60	5.60	5.60			
				01/10/90	44.0	88.0	MMOL/L	66.30	66.00	66.00	68.90	66.00	68.90	80.60	80.60			
				01/10/90	119.0	357.0	MMOL/L	361.00	368.00	368.00	317.00	368.00	317.00	298.00	298.00			
				01/10/90	8.6	20.5	MMOL/L	13.50	12.60	12.60	9.00	12.60	9.00	9.00	9.00			
				01/10/90	0.5	4.3	MMOL/L	5.70	3.90	3.90	1.70	3.90	1.70	1.10	1.10			
				01/10/90	65.0	85.0	G/L	78.00	80.00	80.00	78.00	80.00	78.00	76.00	76.00			
				01/10/90	34.0	55.0	G/L	48.80	42.80	42.80	49.80	42.80	49.80	46.30	46.30			
				01/10/90	3.1	6.2	MMOL/L	5.30	4.80	4.80	5.20	4.80	5.20	5.20	5.20			
				01/10/90	0.5	1.9	MMOL/L	1.68	1.80	1.80	1.76	1.80	1.76	1.70	1.70			
				01/10/90	1.3	6.0	G/L	2.30	3.30	3.30	4.80	3.30	4.80	1.40	1.40			
				01/10/90	5.0	9.0	G/L	8.90	9.50	9.50	7.70	9.50	7.70	8.50	8.50			
				01/10/90	5.0	13.0	G/L	8.30	16.50	16.50	6.20	16.50	6.20	7.20	7.20			
				01/10/90	10.0	17.0	G/L	9.70	7.90	7.90	15.40	7.90	15.40	12.60	12.60			
				01/10/90	1.1	2.2	mmol/l	1.59	1.59	1.59	1.59	1.59	1.59	1.59	1.59			
				01/10/90	60.0	140.0	mmol/l	93.00	93.00	93.00	93.00	93.00	93.00	93.00	93.00			
				46 TN	MALE		HB HTC PRC WBC WBC: N WBC: L WBC: E WBC: R WBC: K WBC: B PLATELETS NA+ K+ PO4- SGPT SGOT GAMMA-GT GAMMA-GT GLUCOSE	01/10/90	129.0	150.0	G/L	143.00	136.00	143.00	136.00	143.00	136.00	
								01/10/90	0.4	0.5	L/L	0.43	0.42	0.46	0.46	0.46	0.46	0.46
								01/10/90	4.0	5.0	10**12/L	4.25	4.23	4.24	4.30	4.23	4.24	4.30
								01/10/90	5.0	8.8	10**9/L	5.10	4.60	4.60	5.00	4.60	5.00	4.60
01/10/90	51.0	77.0	Z					72.00	68.00	68.00	70.00	68.00	70.00	70.00				
01/10/90	18.0	38.0	Z					24.00	28.00	28.00	25.00	28.00	25.00	25.00				
01/10/90	1.0	5.0	Z					2.00	7.00	7.00	2.00	7.00	2.00	2.00				
01/10/90	2.0	10.0	Z					2.00	2.00	2.00	2.00	2.00	2.00	2.00				
01/10/90	0.0	1.0	Z					0.00	0.00	0.00	0.00	0.00	0.00	0.00				
01/10/90	180.0	320.0	10**9/L					237.00	230.00	230.00	232.00	230.00	232.00	232.00				
01/10/90	135.0	150.0	MMOL/L					143.00	143.00	143.00	143.00	143.00	143.00	143.00				
01/10/90	4.0	5.6	MMOL/L					4.50	4.60	4.60	4.40	4.60	4.40	4.40				
01/10/90	95.0	105.0	MMOL/L					100.30	100.20	100.20	100.50	100.20	100.50	100.50				
01/10/90	0.6	1.3	MMOL/L					1.11	1.11	1.11	1.02	1.11	1.02	0.98				
01/10/90	1.0	12.0	U/L					6.00	4.50	4.50	4.50	4.50	4.50	4.50				
01/10/90	1.0	9.0	U/L					3.00	8.00	8.00	5.00	8.00	5.00	5.00				
10/12/91	0.3	1.8	UKAT/L					61.00	61.00	61.00	0.70	61.00	0.70	0.70				
01/10/90	15.0	106.0	U/l					4.40	5.70	5.70	5.40	5.70	5.40	5.60				
01/10/90	3.5	5.5	MMOL/L	4.40	4.40	4.40	4.40	4.40	4.40	4.40								

1727

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit					
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
10	46	TM	MALE	01/10/90	135.0	360.0	MMOL/L	286.00	230.00	240.00	230.00	
			ALK. PHOSPH.	01/10/90	3.3	10.0	MMOL/L	5.10	5.00	5.10	5.00	
			RUN	01/10/90	44.0	101.0	UNOL/L	79.50	70.90	76.20	71.20	
			CREATININE	01/10/90	119.0	357.0	UNOL/L	401.00	268.00	302.00		
			URIC ACID	01/01/92	214.0	458.0	UNOL/L				289.00	
			URIC ACID	01/10/90	8.6	20.5	UNOL/L	22.20	18.20	22.20	18.20	
			TOT BILIRUBIN	10/12/91	0.5	4.3	UNOL/L	4.30	4.30	1.70	4.30	
			DIR BILIRUBIN	01/10/90	0.0	5.1	umol/L	1.70				
			TOT. PROTEINS	01/10/90	65.0	85.0	G/L	75.00	70.00	75.00	70.00	
			ALBUMINE	01/10/90	34.0	55.0	G/L	38.20	36.50	38.20	36.50	
			TOT. CHOLEST.	01/10/90	3.1	6.2	MMOL/L	3.00	3.00	3.00	2.80	
			TRIGLYCERIDES	01/10/90	0.5	1.9	MMOL/L	1.80	1.79	1.80	1.78	
			GLOBULINS: ALPHA 1	01/10/90	1.3	6.0	G/L	3.50	3.40	3.50	3.60	
			GLOBULINS: ALPHA 2	01/10/90	5.0	9.0	G/L	9.00	8.00	9.00	8.30	
			GLOBULINS: BETA	01/10/90	5.0	13.0	G/L	14.60	7.50	14.60	7.50	
			GLOBULINS: GAMMA	01/10/90	10.0	17.0	G/L	9.90	14.20	9.90	14.20	
			T3	01/10/90	1.1	2.2	nmol/L	1.58				
			T4	01/10/90	60.0	140.0	nmol/L	109.00				
47	TM		FEMALE	01/10/90	112.0	140.0	G/L	138.00	123.00	135.00	136.00	
			HB	01/10/90	0.4	0.5	L/L	0.42	0.37	0.42	0.42	
			HTC	01/10/90	3.7	4.7	10**12/L	4.21	3.69	4.17	4.17	
			RBC	01/10/90	4.0	8.8	10**9/L	7.50	5.80	5.30	4.10	
			HBC: N	01/10/90	51.0	77.0	X	72.00	65.00	58.00	72.00	
			HBC: L	01/10/90	18.0	38.0	X	20.00	26.00	32.00	19.00	
			HBC: E	01/10/90	1.0	5.0	X	4.00	5.00	8.00	8.00	
			HBC: M	01/10/90	2.0	10.0	X	4.00	4.00	2.00	1.00	
			HBC: B	01/10/90	0.0	1.0	X	0.00	0.00	0.00	0.00	
			PLATELETS	01/10/90	180.0	320.0	10**9/L	225.00	203.00	235.00	210.00	
			NA+	01/10/90	135.0	150.0	MMOL/L	140.00	140.00	134.00	138.00	
			K+	01/10/90	4.0	5.6	MMOL/L	4.30	4.70	4.60	4.60	
			CL-	01/10/90	95.0	105.0	MMOL/L	103.60	100.40	100.90	100.00	
			PO4--	01/10/90	0.6	1.3	MMOL/L	0.84	0.83	0.99	0.93	
			SCOT	01/10/90	1.0	12.0	U/L	4.00	6.00	4.50	4.00	
			SGPT	01/10/90	1.0	9.0	U/L	6.50	7.00	3.50	5.50	
			GAMMA-GT	10/12/91	0.2	1.1	UKAT/L	0.95	0.95	0.73	0.95	
			GAMMA-GT	01/10/90	10.0	66.0	U/L	83.00	6.20	3.80	3.70	
			GLUCOSE	01/10/90	3.5	5.5	MMOL/L	3.90	5.20	3.80	3.70	
			ALK. PHOSPH.	01/10/90	135.0	360.0	MMOL/L	257.00	237.00	216.00	219.00	
			RUN	01/10/90	3.3	10.0	MMOL/L	4.10	4.10	4.90	5.00	
			CREATININE	01/10/90	44.0	88.0	UNOL/L	82.70	80.30	81.20	81.00	
			URIC ACID	01/10/90	119.0	357.0	UNOL/L	295.00	298.00			
			URIC ACID	01/01/92	149.0	405.0	UNOL/L				312.00	
			TOT BILIRUBIN	01/10/90	8.6	20.5	UNOL/L	24.90	9.20	258.00	18.20	
			DIR BILIRUBIN	01/10/90	0.5	4.3	UNOL/L	2.80	3.40	4.80	3.10	
			TOT. PROTEINS	01/10/90	65.0	85.0	G/L	77.00	79.00	79.00	79.00	
			ALBUMINE	01/10/90	34.0	55.0	G/L	47.40	49.90	47.80	42.70	
			TOT. CHOLEST.	01/10/90	3.1	6.2	MMOL/L	3.00	3.90	5.60	5.30	
			TRIGLYCERIDES	01/10/90	0.5	1.9	MMOL/L	1.76	1.25	2.40	1.25	

1728

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1
LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
10	47	TM	FEMALE	GLOBULINS: ALPHA 1	01/10/90	1.3	6.0	G/L	1.50	3.60	3.10	7.20				
				GLOBULINS: ALPHA 2	01/10/90	5.0	9.0	G/L	9.00	4.40	6.80	7.30				
				GLOBULINS: BETA	01/10/90	5.0	13.0	G/L	7.90	7.10	9.10	7.10				
				GLOBULINS: GAMMA	01/10/90	10.0	17.0	G/L	11.20	14.00	12.20	14.70				
				T3	01/10/90	1.1	2.2	nmol/L	1.40	.	.	.				
				T4	01/10/90	60.0	140.0	nmol/L	108.00	.	.	.				
				48	IP		FEMALE	HB	01/10/90	112.0	140.0	G/L	132.00	128.00	130.00	127.00
								HTC	01/10/90	0.4	0.5	L/L	0.42	0.37	0.41	0.39
								RBC	01/10/90	3.7	4.7	10**12/L	4.18	3.86	4.10	3.86
								WBC	01/10/90	4.0	8.8	10**9/L	8.50	10.20	9.10	7.80
WBC: N	01/10/90	51.0	77.0					%	76.00	58.00	70.00	52.00				
WBC: L	01/10/90	18.0	38.0					%	23.00	30.00	27.00	48.00				
WBC: E	01/10/90	1.0	5.0					%	0.00	6.00	2.00	3.00				
WBC: B	01/10/90	2.0	10.0					%	3.00	0.00	1.00	2.00				
PLATELETS	01/10/90	180.0	320.0					10**9/L	217.00	210.00	218.00	217.00				
PL	01/10/90	135.0	150.0					MMOL/L	162.00	139.00	136.00	141.00				
49	VI		FEMALE	HB	01/10/90	112.0	140.0	G/L	128.00	122.00	124.00	124.00				
				HTC	01/10/90	0.4	0.5	L/L	0.35	0.36	0.36	0.38				
				RBC	01/10/90	3.7	4.7	10**12/L	3.89	3.73	3.74	3.78				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Date	Laboratory Range			Visit					
					Min	Max	Unit	Screen	Week 2	Week 4	Week 6		
10	49	VK	FEMALE	01/10/90	4.0	8.8	10**9/L	5.70	4.50	8.40	9.30		
			KBC: N	01/10/90	51.0	77.0	X	38.00	48.00	70.00	60.00		
			KBC: L	01/10/90	18.0	38.0	X	50.00	38.00	26.00	26.00		
			KBC: E	01/10/90	1.0	5.0	X	10.00	8.00	2.00	8.00		
			KBC: M	01/10/90	2.0	10.0	X	2.00	6.00	2.00	6.00		
			KBC: B	01/10/90	0.0	1.0	X	0.00	0.00	0.00	0.00		
			PLATELETS	01/10/90	180.0	320.0	10**9/L	200.00	201.00	220.00	200.00		
			NA+	01/10/90	135.0	150.0	MMOL/L	141.00	139.00	140.00	142.00		
			K+	01/10/90	4.0	5.6	MMOL/L	4.20	4.40	4.30	4.50		
			CL-	01/10/90	95.0	105.0	MMOL/L	101.00	99.00	99.20	98.10		
			PO4-	01/10/90	0.6	1.3	MMOL/L	1.04	1.03	1.10	1.06		
			SGPT	01/10/90	1.0	9.0	U/L	4.00	5.50	5.50	4.00		
			SGOT	01/10/90	1.0	9.0	U/L	3.80	4.50	4.50	4.50		
			GAMMA-GT	01/10/90	0.2	1.1	Ukat/L	41.00	0.35	0.80	0.85		
			GLUCOSE	01/10/90	3.5	5.5	MMOL/L	4.40	4.40	4.40	4.40		
			ALK. PHOSPH.	01/10/90	135.0	360.0	MMOL/L	248.00	222.00	230.00	230.00		
			BUN	01/10/90	3.3	10.0	MMOL/L	6.80	4.60	5.00	5.30		
			CREATININE	01/10/90	44.0	88.0	UMOL/L	74.50	68.80	66.60	62.60		
			URIC ACID	01/01/92	119.0	357.0	UMOL/L	257.00	188.00	202.00	242.00		
			TOT. BILIRUBIN	01/10/90	8.6	20.5	UMOL/L	14.90	8.70	10.20	10.20		
			DIR. BILIRUBIN	01/10/90	0.5	4.3	UMOL/L	2.80	2.80	1.70	1.70		
			TOT. PROTEINS	01/10/90	65.0	85.0	G/L	78.00	70.00	72.00	79.00		
			ALBUMINE	01/10/90	34.0	55.0	G/L	43.90	35.30	37.50	50.70		
			TOT. CHOLEST.	01/10/90	3.1	6.2	MMOL/L	5.40	4.20	3.90	3.90		
			GLOBULINS: ALPHA 1	01/10/90	0.5	1.9	MMOL/L	1.57	0.79	0.98	1.08		
			GLOBULINS: ALPHA 2	01/10/90	1.3	6.0	G/L	4.80	3.90	3.80	2.20		
			GLOBULINS: BETA	01/10/90	5.0	13.0	G/L	7.40	8.80	8.70	8.20		
			GLOBULINS: GAMMA	01/10/90	5.0	17.0	G/L	12.50	11.10	11.30	9.40		
			TE	01/10/90	1.1	2.2	mmol/L	1.28	1.28	1.28	1.28		
			T4	01/10/90	60.0	140.0	nmol/L	89.00	89.00	89.00	89.00		
50	EE	MALE		18/12/91				18/12/91	01/01/92	15/01/92	29/01/92		
			HB	10/12/91	129.0	150.0	G/L	127.00	138.00	146.00	138.00		
			HTC	10/12/91	0.4	0.5	L/L	0.37	0.42	0.44	0.41		
			RBC	10/12/91	4.0	5.0	10**12/L	3.69	4.16	4.37	4.21		
			KBC: N	10/12/91	4.0	8.8	10**9/L	5.30	4.90	7.00	5.90		
			KBC: L	10/12/91	51.0	77.0	X	78.00	72.00	61.00	56.00		
			KBC: E	10/12/91	18.0	38.0	X	16.00	28.00	29.00	33.00		
			KBC: M	10/12/91	1.0	5.0	X	4.00	0.80	4.00	5.00		
			KBC: B	10/12/91	2.0	10.0	X	2.00	2.00	5.00	5.00		
			PLATELETS	10/12/91	180.0	320.0	10**9/L	202.00	227.00	237.00	203.00		
			NA+	10/12/91	135.0	150.0	MMOL/L	149.00	144.00	138.00	140.00		
			K+	10/12/91	4.0	5.6	MMOL/L	4.50	5.10	5.50	5.00		
			CL-	10/12/91	95.0	105.0	MMOL/L	96.90	103.10	100.90	100.10		
			PO4-	10/12/91	0.6	1.3	MMOL/L	1.02	0.96	0.98	0.96		
			TE	10/12/91	1.1	2.2	mmol/L	1.28	1.28	1.28	1.28		
			T4	10/12/91	60.0	140.0	nmol/L	89.00	89.00	89.00	89.00		

1730

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
10	50	EE	MALE	SGPT	10/12/91	1.0	9.0	U/L	6.00	5.00	5.50	5.00	5.00
				GAMMA-GT	10/12/91	0.3	1.8	UKAT/L	1.53	0.70	1.35	1.35	1.35
				GLUCOSE	10/12/91	3.5	5.5	MMOL/L	7.80	3.80	4.20	4.80	4.80
				ALK. PHOSPH.	10/12/91	135.0	360.0	MMOL/L	281.00	340.00	364.00	225.00	225.00
				BUN	10/12/91	3.3	10.0	MMOL/L	6.20	6.20	5.60	4.00	4.00
				CREATININE	10/12/91	44.0	101.0	UMOL/L	82.30	79.50	80.20	81.50	81.50
				URIC ACID	10/12/91	119.0	357.0	UMOL/L	430.00	390.00	434.00	389.00	389.00
				URIC ACID	01/01/92	214.0	458.0	UMOL/L	9.00	24.70	22.20	10.40	10.40
				TOT. BILIRUBIN	10/12/91	8.6	20.5	UMOL/L	1.10	3.70	1.70	0.80	0.80
				DIR. BILIRUBIN	10/12/91	0.5	4.3	UMOL/L	80.00	82.00	77.00	84.00	84.00
				TOT. PROTEINS	10/12/91	65.0	85.0	G/L	51.00	51.00	46.00	51.60	51.60
				ALBUMINE	10/12/91	34.0	55.0	G/L	6.00	6.00	5.90	4.80	4.80
				TOT. CHOLEST.	10/12/91	3.1	6.2	MMOL/L	2.06	2.27	3.28	1.56	1.56
				TRIGLYCERIDES	10/12/91	0.5	1.9	MMOL/L	1.30	1.30	3.50	1.40	1.40
				GLOBULINS: ALPHA 1	10/12/91	1.3	6.0	G/L	4.30	10.20	7.60	12.30	12.30
				GLOBULINS: ALPHA 2	10/12/91	5.0	9.0	G/L	12.60	8.40	6.60	9.70	9.70
				GLOBULINS: BETA	10/12/91	5.0	13.0	G/L	12.50	11.10	13.50	9.00	9.00
				GLOBULINS: GAMMA	10/12/91	10.0	17.0	G/L	93.50				
				T3	10/12/91	1.1	2.2	MMOL/L					
				T4	10/12/91	60.0	140.0	MMOL/L					
51	UL		FEMALE	HB	10/12/91	112.0	140.0	G/L	18/12/91	01/01/92	15/01/92	29/01/92	
				HTC	10/12/91	0.4	0.5	L/L	130.00	128.00	132.00	138.00	138.00
				RBC	10/12/91	3.7	4.7	10**12/L	0.37	0.39	0.41	0.42	0.42
				RBC: N	10/12/91	4.0	8.8	10**9/L	3.74	3.85	4.17	4.24	4.24
				RBC: L	10/12/91	51.0	77.0	Z	6.40	7.70	6.70	7.90	7.90
				RBC: E	10/12/91	18.0	38.0	Z	62.00	76.00	68.00	67.00	67.00
				RBC: M	10/12/91	1.0	5.0	Z	32.00	16.00	30.00	27.00	27.00
				RBC: B	10/12/91	2.0	10.0	Z	0.00	2.00	0.00	0.00	0.00
				PLATELETS	10/12/91	0.0	1.0	Z	6.00	6.00	2.00	3.00	3.00
				NA+	10/12/91	180.0	320.0	10**9/L	203.00	205.00	220.00	224.00	224.00
				CL-	10/12/91	135.0	150.0	MMOL/L	140.00	137.00	136.00	147.00	147.00
				PO4-	10/12/91	95.0	105.0	MMOL/L	4.10	4.40	4.00	5.10	5.10
				SGDT	10/12/91	0.6	1.3	MMOL/L	100.00	101.00	101.20	98.20	98.20
				GAMMA-GT	10/12/91	1.0	12.0	U/L	1.02	6.00	3.50	3.00	3.00
				BUN	10/12/91	0.2	1.1	UMAT/L	4.00	2.50	6.00	3.50	3.50
				GLUCOSE	10/12/91	3.5	5.5	MMOL/L	0.30	0.75	0.57	0.54	0.54
				CREATININE	10/12/91	135.0	360.0	MMOL/L	3.70	4.10	4.20	4.20	4.20
				BUN	10/12/91	3.3	10.0	MMOL/L	248.00	284.00	274.00	148.00	148.00
				URIC ACID	10/12/91	44.0	88.0	UMOL/L	4.10	4.90	4.70	4.80	4.80
				URIC ACID	01/01/92	119.0	357.0	UMOL/L	74.60	69.40	72.60	103.10	103.10
				DIR. BILIRUBIN	10/12/91	8.6	20.5	UMOL/L	301.00	278.00	349.00	187.00	187.00
				TOT. PROTEINS	10/12/91	0.5	4.3	UMOL/L	16.30	23.90	22.00	14.60	14.60
				ALBUMINE	10/12/91	65.0	85.0	G/L	2.00	2.50	2.80	2.00	2.00
				TOT. CHOLEST.	10/12/91	34.0	55.0	G/L	70.00	78.00	69.00	76.00	76.00
				TOT. PROTEINS	10/12/91	3.1	6.2	MMOL/L	34.90	49.80	44.10	49.00	49.00
				TOT. CHOLEST.	10/12/91	3.1	6.2	MMOL/L	3.30	2.70	3.10	2.70	2.70

1731

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit					
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
10	51	UL	FEMALE	TRIGLYCERIDES	10/12/91	0.5	1.9	NMOL/L	0.84	1.22	1.19	2.68
				GLOBULINS: ALPHA 1	10/12/91	1.3	6.0	G/L	3.60	2.30	1.80	2.00
				GLOBULINS: ALPHA 2	10/12/91	5.0	9.0	G/L	6.80	6.80	5.90	5.80
				GLOBULINS: BETA	10/12/91	5.0	13.0	G/L	13.90	6.60	6.90	9.70
				GLOBULINS: GAMMA	10/12/91	10.0	17.0	G/L	9.10	12.50	10.30	9.50
	T3	10/12/91	1.1	2.2	NMOL/L	1.18						
	T4	10/12/91	60.0	140.0	NMOL/L	82.50						
	52	HP	MALE	HB	01/01/92	129.0	150.0	G/L	145.00	143.00	135.00	
				HTC	01/01/92	0.4	0.5	L/L	0.43	0.40	0.41	
				RBC	01/01/92	4.0	5.0	10**12/L	4.35	4.21	4.15	
HBC: N				01/01/92	4.0	8.8	10**9/L	5.80	5.70	6.00		
HBC: L				01/01/92	51.0	77.0	%	69.00	59.00	47.00		
HBC: E				01/01/92	18.0	38.0	%	25.00	34.00	40.00		
HBC: M				01/01/92	1.0	5.0	%	6.00	6.00	9.00		
HBC: B				01/01/92	2.0	10.0	%	4.00	4.00	4.00		
PLATELETS				01/01/92	0.0	1.0	%	0.00	0.00	0.00		
NA+				01/01/92	180.0	320.0	10**9/L	235.00	230.00	220.00		
53	MA	FEMALE	HB	01/01/92	112.0	140.0	G/L	144.00	142.00	142.00		
			HTC	01/01/92	0.4	0.5	L/L	0.43	0.43	0.43		
			RBC	01/01/92	3.7	4.7	10**12/L	4.30	4.27	4.30		
			HBC: N	01/01/92	4.0	8.8	10**9/L	5.80	5.70	6.00		
			HBC: L	01/01/92	51.0	77.0	%	69.00	59.00	47.00		
			HBC: E	01/01/92	18.0	38.0	%	25.00	34.00	40.00		
			HBC: M	01/01/92	1.0	5.0	%	6.00	6.00	9.00		
			HBC: B	01/01/92	2.0	10.0	%	4.00	4.00	4.00		
			PLATELETS	01/01/92	0.0	1.0	%	0.00	0.00	0.00		
			NA+	01/01/92	135.0	150.0	NMOL/L	133.00	140.00	142.00		

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Unit	Screen	Visit							
					Date	Min	Max			Week 2	Week 4	Week 6					
10	53	MA	FEMALE	HbC: N	01/01/92	51.0	77.0	Z	62.00	58.00							
				HbC: L	01/01/92	18.0	38.0	Z	31.00	39.00							
				HbC: E	01/01/92	1.0	5.0	Z	4.00	2.00							
				HbC: H	01/01/92	2.0	10.0	Z	3.00	1.00							
				HbC: B	01/01/92	0.0	1.0	Z	0.00	0.00							
				PLATELETS	01/01/92	180.0	320.0	10**9/L	237.00	225.00							
				NA+	01/01/92	135.0	150.0	MMOL/L	140.00	141.00							
				K+	01/01/92	4.0	5.6	MMOL/L	4.80	4.50							
				PO4-	01/01/92	0.6	1.3	MMOL/L	0.98	1.02							
				SCOT	01/01/92	1.0	12.0	U/L	3.50	5.00							
				GAMMA-GT	01/01/92	1.0	9.0	U/L	2.50	7.00							
				GLUCOSE	01/01/92	0.2	1.1	UKAT/L	0.25	0.40							
				BUN	01/01/92	3.5	5.5	MMOL/L	4.60	4.60							
				ALK. PHOSPH.	01/01/92	135.0	360.0	MMOL/L	257.00	133.00							
				CREATININE	01/01/92	3.3	10.0	MMOL/L	7.30	7.30							
				URIC ACID	01/01/92	44.0	88.0	UMOL/L	53.60	67.00							
				TOT BILIRUBIN	01/01/92	149.0	405.0	UMOL/L	333.00	199.00							
				DIR BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	20.30	8.60							
				TOT PROTEINS	01/01/92	65.0	85.0	G/L	78.00	81.00							
				ALBUMINE	01/01/92	34.0	55.0	G/L	49.20	45.70							
				TOT CHOLEST.	01/01/92	3.1	6.2	MMOL/L	2.90	3.00							
				TRIGLUCERIDES	01/01/92	0.5	1.9	MMOL/L	1.22	2.34							
				GLOBULINS: ALPHA 1	01/01/92	1.3	6.0	G/L	2.00	2.80							
				GLOBULINS: ALPHA 2	01/01/92	5.0	9.0	G/L	6.70	7.30							
				GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	8.10	11.00							
				GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	12.00	14.70							
				T3	01/01/92	1.1	2.2	MMOL/L	0.99								
				T4	01/01/92	60.0	140.0	MMOL/L	83.50								
				54	UN		FEMALE	Hb	01/01/92	112.0	140.0	G/L	125.00	128.00	131.00	23/02/92	
								HtC	01/01/92	0.4	0.5	L/L	0.37	0.41	0.39	130.00	0.38
								HbC	01/01/92	3.7	4.7	10**12/L	3.68	4.05	3.92	0.38	0.38
								HbC	01/01/92	4.0	8.8	10**9/L	3.90	4.70	3.92	3.78	3.78
								HbC: N	01/01/92	51.0	77.0	Z	60.00	62.00	62.00	4.70	5.20
HbC: L	01/01/92	18.0	38.0					Z	38.00	58.00	62.00	78.00	78.00				
HbC: E	01/01/92	1.0	5.0					Z	4.00	2.00	2.00	18.00	18.00				
HbC: B	01/01/92	2.0	10.0					Z	2.00	1.00	1.00	2.00	2.00				
PLATELETS	01/01/92	0.0	1.0					Z	1.00	0.00	0.00	2.00	2.00				
NA+	01/01/92	180.0	320.0					10**9/L	205.00	197.00	221.00	0.00	0.00				
K+	01/01/92	4.0	5.6					MMOL/L	4.50	4.40	4.40	205.00	205.00				
PO4-	01/01/92	0.6	1.3					MMOL/L	1.02	0.98	1.00	144.00	144.00				
SCOT	01/01/92	1.0	12.0					U/L	4.00	6.00	102.40	4.40	4.50				
GAMMA-GT	01/01/92	0.2	1.1					UKAT/L	0.82	0.82	98.20	1.10	1.06				
GLUCOSE	01/01/92	3.5	5.5					MMOL/L	4.40	3.70	102.40	3.00	1.00				

1733

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
10	54	UN	FEMALE	ALK. PHOSPH.	01/01/92	135.0	360.0	MMOL/L	432.00	240.00	233.00	272.00	
				BUN	01/01/92	3.3	10.0	MMOL/L	6.10	6.00	3.70	7.49	
				CREATININE	01/01/92	44.0	88.0	UMOL/L	67.70	74.90	102.40	68.10	
				URIC ACID	01/01/92	149.0	405.0	UMOL/L	232.00	179.00	192.00	213.00	
				TOT BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	12.90	9.00	9.40	8.70	
				DIR BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	2.00	0.60	0.60	1.90	
				TOT. PROTEINS	01/01/92	65.0	85.0	G/L	80.00	80.00	81.00	75.00	
				ALBUMINE	01/01/92	34.0	55.0	G/L	45.80	45.80	54.30	49.50	
				TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	3.20	4.10	3.50	3.40	
				TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	1.53	1.05	0.61	0.72	
				GLOBULINS: ALPHA 1	01/01/92	1.3	6.0	G/L	1.80	2.90	2.30	1.80	
				GLOBULINS: ALPHA 2	01/01/92	5.0	9.0	G/L	8.00	7.60	8.80	7.10	
				GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	7.90	12.10	7.50	6.70	
				GLOBULINS: GANMA	01/01/92	1.1	2.2	MMOL/L	8.40	11.60	8.10	9.90	
				T3	01/01/92	60.0	140.0	MMOL/L	136.00				
				T4	01/01/92	60.0	140.0	MMOL/L	136.00				
55	TP		MALE	HB	01/01/92	129.0	150.0	G/L	132.00	138.00	145.00	24/02/92	
				HTC	01/01/92	0.4	0.5	L/L	0.41	0.43	0.43	0.43	
				RBC	01/01/92	4.0	5.0	10**12/L	4.15	4.27	4.28	4.25	
				MEC	01/01/92	4.0	8.8	10**9/L	7.00	7.60	7.20	5.20	
				MEC: N	01/01/92	51.0	77.0	X	64.00	72.00	80.00	67.00	
				MEC: L	01/01/92	18.0	38.0	X	32.00	24.00	14.00	27.00	
				MEC: E	01/01/92	1.0	5.0	X	0.00	3.00	4.00	2.00	
				MEC: M	01/01/92	2.0	10.0	X	4.00	1.00	2.00	3.00	
				MEC: B	01/01/92	0.0	1.0	X	0.00	0.00	0.00	0.00	
				PLATELETS	01/01/92	180.0	320.0	10**9/L	217.00	224.00	214.00	227.00	
				NA+	01/01/92	135.0	150.0	MMOL/L	136.00	150.00	140.00	144.00	
				CL-	01/01/92	95.0	105.0	MMOL/L	101.20	98.50	95.50	98.90	
				PO4--	01/01/92	0.6	1.3	MMOL/L	0.99	3.63	0.92	0.99	
				SGPT	01/01/92	1.0	12.0	U/L	3.50	4.50	5.00	9.00	
				SGOT	01/01/92	1.0	9.0	U/L	8.00	6.00	4.50	8.50	
				GLUCOSE	01/01/92	3.5	5.5	MMOL/L	4.20	4.60	3.80	4.10	
				ALK. PHOSPH.	01/01/92	135.0	360.0	MMOL/L	287.00	194.00	175.00	196.00	
				BUN	01/01/92	3.3	10.0	MMOL/L	4.70	4.70	5.50	6.33	
				CREATININE	01/01/92	44.0	104.0	UMOL/L	72.70	82.20	79.50	75.00	
				URIC ACID	01/01/92	244.0	458.0	UMOL/L	337.00	314.00	367.00	310.00	
				TOT BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	14.00	9.00	16.80	10.20	
				DIR BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	0.60	0.60	0.60	0.80	
				TOT. PROTEINS	01/01/92	65.0	85.0	G/L	72.00	80.00	79.00	78.00	
				ALBUMINE	01/01/92	34.0	55.0	G/L	46.20	44.50	48.10	51.90	
				TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	3.90	2.90	4.30	4.00	
				TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	1.93	2.37	2.57	0.33	
				GLOBULINS: ALPHA 1	01/01/92	1.3	6.0	G/L	2.10	4.80	3.00	1.90	
				GLOBULINS: ALPHA 2	01/01/92	5.0	9.0	G/L	6.10	7.30	7.70	6.10	
				GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	7.10	10.10	6.00	8.10	
				GLOBULINS: GANMA	01/01/92	10.0	17.0	G/L	10.50	13.30	14.20	10.00	

1734

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit						
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6		
10	55	TP	MALE	T3	01/01/92	1.1	2.2	NHOL/L	1.17					
				T4	01/01/92	60.0	140.0	NHOL/L	77.50					
	56	JP	MALE	HB	01/01/92	129.0	150.0	G/L	08/01/92	27/01/92	10/02/92	24/02/92		
				HTC	01/01/92	0.4	0.5	L/L	147.00	145.00	141.00	144.00		
				RBC	01/01/92	4.0	5.0	10**12/L	0.44	0.44	0.43	0.44		
				HBC	01/01/92	4.0	8.8	10**9/L	4.47	4.45	4.23	4.38		
				HBC: N	01/01/92	51.0	77.0	X	4.70	5.20	8.00	8.00		
				HBC: L	01/01/92	18.0	38.0	X	57.00	54.00	60.00	69.00		
				HBC: E	01/01/92	1.0	5.0	X	37.00	44.00	32.00	25.00		
				HBC: K	01/01/92	2.0	10.0	X	4.00	0.00	5.00	3.00		
				HBC: B	01/01/92	0.0	1.0	X	2.00	2.00	0.00	0.00		
				PLATELETS	01/01/92	180.0	320.0	10**9/L	0.00	0.00	200.00	237.00		
				NA+	01/01/92	135.0	150.0	NHOL/L	223.00	230.00	141.00	143.00		
				K+	01/01/92	4.0	5.6	NHOL/L	160.00	141.00	138.00	163.00		
				PO4-	01/01/92	95.0	105.0	NHOL/L	102.10	104.80	106.60	98.60		
				SGPT	01/01/92	0.6	1.3	NHOL/L	1.10	3.04	0.82	1.02		
				GLUCOSE	01/01/92	1.0	12.0	U/L	5.50	1.00	7.00	4.50		
				ALB.	01/01/92	1.0	9.0	U/L	5.50	1.50	6.50	6.50		
				GAMMA-GT	01/01/92	0.3	1.8	UKAT/L	0.65	0.97	0.40	0.30		
				ALK.	01/01/92	3.5	5.5	NHOL/L	4.90	4.90	4.60	4.90		
				CREATININE	01/01/92	135.0	360.0	NHOL/L	213.00	117.00	114.00	118.00		
				BUN	01/01/92	3.3	10.0	NHOL/L	4.90	5.20	3.50	5.20		
				URIC ACID	01/01/92	44.0	101.0	UMOL/L	70.40	67.00	69.50	84.70		
				TOT BILIRUBIN	01/01/92	214.0	458.0	UMOL/L	480.00	396.00	375.00	358.00		
				TOT ALBUMINE	01/01/92	8.6	20.5	UMOL/L	19.70	20.80	15.20	9.70		
				TOT PROTEINS	01/01/92	65.0	85.0	G/L	1.70	2.80	1.00	0.80		
				TOT CHOLEST.	01/01/92	34.0	55.0	G/L	75.00	79.00	80.00	77.00		
				TRIGLYCERIDES	01/01/92	3.1	6.2	NHOL/L	45.30	48.60	50.40	34.40		
				GLOBULINS: ALPHA 1	01/01/92	0.5	1.9	NHOL/L	4.80	4.20	3.50	3.90		
				GLOBULINS: ALPHA 2	01/01/92	1.3	6.0	G/L	3.29	2.50	2.10	1.83		
				GLOBULINS: BETA	01/01/92	5.0	9.0	G/L	8.00	2.00	2.10	5.20		
				GLOBULINS: GAMMA	01/01/92	5.0	13.0	G/L	8.40	8.40	9.00	9.00		
				T3	01/01/92	10.0	17.0	G/L	7.50	9.50	8.20	13.60		
				T4	01/01/92	1.1	2.2	NHOL/L	12.20	10.50	10.30	14.80		
					01/01/92	60.0	140.0	NHOL/L	91.50					
	57	AG	FEMALE	HB	01/01/92	112.0	140.0	G/L	13/01/92	28/01/92	11/02/92	25/02/92		
				HTC	01/01/92	0.4	0.5	L/L	130.00	132.00	128.00	139.00		
				RBC	01/01/92	3.7	4.7	10**12/L	0.41	0.41	0.37	0.40		
				HBC	01/01/92	4.0	8.8	10**9/L	4.10	4.14	3.69	4.18		
				HBC: N	01/01/92	51.0	77.0	X	56.00	62.00	64.00	68.00		
				HBC: L	01/01/92	18.0	38.0	X	38.00	34.00	32.00	26.00		
				HBC: E	01/01/92	1.0	5.0	X	4.00	2.00	4.00	2.00		
				HBC: K	01/01/92	2.0	10.0	X	2.00	2.00	0.00	0.00		
				HBC: B	01/01/92	0.0	1.0	X	0.00	0.00	0.00	0.00		

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
10	57	AG	FEMALE	PLATELETS	01/01/92	180.0	320.0	10**9/L	215.00	220.00	203.00	200.00	
				NA+	01/01/92	135.0	150.0	NNDL/L	142.00	141.00	139.00	137.00	
				K+	01/01/92	4.0	5.6	NNDL/L	4.80	4.50	4.00	4.60	
				CL-	01/01/92	95.0	105.0	NNDL/L	103.00	111.00	97.60	99.00	
				PO4-	01/01/92	0.6	1.3	NNDL/L	1.19	3.52	1.13	1.23	
				SGPT	01/01/92	1.0	12.0	U/L	5.00	4.00	2.00	4.90	
				SGPT	01/01/92	1.0	9.0	U/L	7.50	2.00	1.50	10.40	
				GAMMA-GT	01/01/92	0.2	1.1	UKAT/L	0.83	0.52	0.20	0.20	
				GLUCOSE	01/01/92	3.5	5.5	NNDL/L	4.50	5.40	6.80	4.70	
				ALK. PHOSPH.	01/01/92	135.0	360.0	NNDL/L	242.00	141.00	138.00	107.00	
				BUN	01/01/92	3.3	10.0	NNDL/L	7.60	7.60	6.70	4.50	
				CREATININE	01/01/92	44.0	88.0	UMOL/L	8.30	75.60	70.50	66.90	
				URIC ACID	01/01/92	149.0	405.0	UMOL/L	246.00	216.00	228.00	192.00	
				TOT BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	18.50	10.40	15.00	31.40	
				DIR BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	1.90	1.60	2.00	2.50	
				TOT. PROTEINS	01/01/92	65.0	85.0	G/L	80.00	78.00	74.00	83.00	
				ALBUMINE	01/01/92	34.0	55.0	G/L	45.60	47.70	46.80	50.90	
				TOT. CHOLEST.	01/01/92	3.1	6.2	NNDL/L	4.30	4.10	3.80	3.00	
				TRIGLYCERIDES	01/01/92	0.5	1.3	NNDL/L	1.66	1.66	0.51	1.02	
				GLUCOLINS: ALPHA 1	01/01/92	1.3	6.0	G/L	6.50	2.50	1.50	2.50	
				GLUCOLINS: ALPHA 2	01/01/92	5.0	9.0	G/L	6.30	7.50	5.70	8.80	
				GLUCOLINS: BETA	01/01/92	5.0	13.0	G/L	6.70	9.20	8.00	11.20	
				GLUCOLINS: GAMMA	01/01/92	10.0	17.0	G/L	14.90	11.50	12.00	9.60	
				T3	01/01/92	1.1	2.2	NNDL/L	1.27	.	.	.	
				T4	01/01/92	60.0	140.0	NNDL/L	104.50	.	.	.	
58	KK		FEMALE	HB	01/01/92	112.0	140.0	G/L	13.01/92	27/01/92	10/02/92	24/02/92	
				HTC	01/01/92	0.4	0.5	L/L	135.00	138.00	131.00	132.00	
				RBC	01/01/92	3.7	4.7	10**12/L	0.41	0.42	0.40	0.42	
				WBC	01/01/92	4.0	8.8	10**9/L	4.20	4.15	4.00	4.15	
				HBC: N	01/01/92	51.0	77.0	%	4.50	4.60	4.60	5.40	
				HBC: L	01/01/92	18.0	38.0	%	69.00	68.00	74.00	71.00	
				HBC: E	01/01/92	1.0	5.0	%	27.00	29.00	21.00	25.00	
				HBC: M	01/01/92	2.0	10.0	%	2.00	2.00	2.00	3.00	
				HBC: B	01/01/92	0.0	1.0	%	2.00	1.00	3.00	1.00	
				PLATELETS	01/01/92	180.0	320.0	10**9/L	0.00	0.00	0.00	0.00	
				NA+	01/01/92	135.0	150.0	NNDL/L	136.00	139.00	200.00	220.00	
				K+	01/01/92	4.0	5.6	NNDL/L	4.60	4.80	4.10	4.70	
				CL-	01/01/92	95.0	105.0	NNDL/L	98.20	104.10	95.30	95.60	
				PO4-	01/01/92	0.6	1.3	NNDL/L	1.33	1.26	1.08	1.48	
				SGPT	01/01/92	1.0	9.0	U/L	3.00	2.00	7.50	3.50	
				SGPT	01/01/92	1.0	1.1	UKAT/L	5.50	2.40	4.00	1.50	
				GAMMA-GT	01/01/92	0.2	1.1	UKAT/L	0.63	0.48	0.35	0.40	
				GLUCOSE	01/01/92	3.5	5.5	NNDL/L	4.30	4.70	4.50	4.50	
				ALK. PHOSPH.	01/01/92	135.0	360.0	NNDL/L	246.00	142.00	105.00	161.00	
				BUN	01/01/92	3.3	10.0	NNDL/L	4.20	4.30	3.30	8.16	
				CREATININE	01/01/92	44.0	88.0	UMOL/L	68.70	66.80	66.20	69.70	
				URIC ACID	01/01/92	149.0	405.0	UMOL/L	278.00	182.00	289.00	250.00	
				TOT BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	10.20	8.70	9.80	9.20	

1736

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 RENDRETIME - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit							
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6			
10	58 KK	FEMALE	DIR BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	1.10	0.60	0.60	0.60	1.10		
			TOT. PROTEINS	01/01/92	65.0	85.0	G/L	75.00	73.00	79.00	79.00	79.00		
			ALBUMINE	01/01/92	34.0	55.0	G/L	46.80	45.40	50.00	50.00	50.00		
			TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	4.80	4.40	4.40	4.40	4.90		
			TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	1.80	0.78	0.67	0.67	1.12		
			GLOBULINS: ALPHA 1	01/01/92	1.3	6.0	G/L	1.50	1.80	2.20	2.20	1.40		
			GLOBULINS: ALPHA 2	01/01/92	5.0	9.0	G/L	6.80	6.80	9.00	9.00	8.70		
			GLOBULINS: BETA	01/01/92	10.0	17.0	G/L	10.90	9.20	8.20	8.20	9.00		
			GLOBULINS: GAMMA	01/01/92	1.1	2.2	MMOL/L	0.76	9.80	10.50	10.50	9.90		
			T3	01/01/92	60.0	140.0	MMOL/L	70.50						
			T4	01/01/92										
			59 TA	FEMALE	FEMALE	HB	01/01/92	112.0	140.0	G/L	20/01/92	02/02/92	16/02/92	01/03/92
						HTC	01/01/92	0.4	0.5	L/L	127.00	134.00	138.00	130.00
						RBC	01/01/92	3.7	4.7	10**12/L	4.10	0.38	0.60	0.60
						WBC	01/01/92	4.0	8.8	10**9/L	4.70	3.35	4.21	4.10
						WBC: N	01/01/92	51.0	77.0	%	58.00	76.00	71.50	70.00
						WBC: L	01/01/92	18.0	38.0	%	21.00	21.00	38.00	25.00
						WBC: E	01/01/92	1.0	5.0	%	0.00	0.00	0.00	3.00
						WBC: B	01/01/92	2.0	10.0	%	0.00	3.00	4.00	2.00
						WBC: M	01/01/92	0.0	1.0	%	0.00	0.00	0.00	0.00
PLATELETS	01/01/92	180.0				320.0	10**9/L	215.00	205.00	210.00	217.00			
NA+	01/01/92	135.0				150.0	MMOL/L	134.00	142.00	138.00	142.00			
CL-	01/01/92	95.0				105.0	MMOL/L	97.50	98.60	93.50	105.80			
PO4-	01/01/92	0.6				1.3	MMOL/L	1.26	1.22	1.47	1.46			
SGPT	01/01/92	1.0				12.0	U/L	3.00	3.50	6.10	3.00			
GAMMA-GT	01/01/92	1.0				9.0	U/L	3.00	3.00	5.10	3.50			
GLUCOSE	01/01/92	0.2				1.1	UKAT/L	0.37	0.45	0.30	0.15			
BUN	01/01/92	3.5				5.5	MMOL/L	4.10	4.10	4.70	4.40			
ALK. PHOSPH.	01/01/92	135.0				360.0	MMOL/L	270.00	135.00	166.00	170.00			
CREATININE	01/01/92	3.3				10.0	MMOL/L	4.20	4.70	5.70	8.66			
URIC ACID	01/01/92	44.0				88.0	UMOL/L	80.90	64.60	68.40	65.10			
TOT. BILIRUBIN	01/01/92	149.0	405.0	UMOL/L	236.00	247.00	245.00	253.00						
DIR BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	18.20	9.80	11.30	8.60						
TOT. PROTEINS	01/01/92	0.5	4.3	G/L	2.50	0.70	1.70	0.80						
ALBUMINE	01/01/92	65.0	85.0	G/L	78.00	80.00	79.00	77.00						
TRIGLYCERIDES	01/01/92	3.1	6.2	MMOL/L	44.20	44.20	47.40	48.50						
GLOBULINS: ALPHA 1	01/01/92	0.5	1.9	MMOL/L	3.90	3.20	3.20	3.00						
GLOBULINS: ALPHA 2	01/01/92	1.3	6.0	G/L	1.27	0.71	1.22	0.98						
GLOBULINS: BETA	01/01/92	5.0	9.0	G/L	1.70	4.40	1.70	2.80						
GLOBULINS: GAMMA	01/01/92	5.0	13.0	G/L	13.40	7.50	10.50	8.90						
T3	01/01/92	10.0	17.0	G/L	11.30	7.50	12.10	8.30						
T4	01/01/92	1.1	2.2	MMOL/L	1.26	15.00	12.10	10.30						
T3	01/01/92	60.0	140.0	MMOL/L	103.50									

1737

15/01/92 02/02/92 16/02/92 03/03/92

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
10	60	JH	MALE	HB	01/01/92	129.0	150.0	G/L	137.00	152.00	141.00	138.00	
				HTC	01/01/92	0.4	0.5	L/L	0.43	0.40	0.40	0.38	
				RBC	01/01/92	4.0	5.0	10**12/L	4.25	3.97	4.28	4.20	
				HBC: N	01/01/92	4.0	8.8	10**9/L	5.60	5.40	7.50	4.50	
				HBC: L	01/01/92	51.0	77.0	Z	68.00	63.00	40.00	63.00	
				HBC: E	01/01/92	18.0	38.0	Z	26.00	36.00	50.00	33.00	
				HBC: M	01/01/92	1.0	5.0	Z	4.00	4.00	7.00	3.00	
				HBC: B	01/01/92	2.0	10.0	Z	2.00	7.00	3.00	1.00	
				PLATELETS	01/01/92	0.0	1.0	Z	0.00	0.00	0.00	0.00	
				KA+	01/01/92	180.0	320.0	10**9/L	237.00	210.00	208.00	227.00	
				CL-	01/01/92	135.0	150.0	MMOL/L	141.00	140.00	144.00	140.00	
				PO4-	01/01/92	95.0	105.0	MMOL/L	98.30	97.50	99.10	101.30	
				SGPT	01/01/92	0.6	1.3	MMOL/L	1.13	0.93	1.30	1.17	
				SGPT	01/01/92	1.0	12.0	U/L	2.00	5.50	8.50	3.00	
				GAMMA-GT	01/01/92	1.0	9.0	U/L	7.00	3.00	7.90	4.00	
				GLUCOSE	01/01/92	0.3	1.8	MMOL/L	1.52	0.55	0.40	0.25	
				ALK. PHOSPH.	01/01/92	3.5	5.5	MMOL/L	4.30	4.30	4.30	5.00	
				BUN	01/01/92	3.3	10.0	MMOL/L	249.00	148.00	169.00	183.00	
				CREATININE	01/01/92	44.0	101.0	UMOL/L	3.40	3.70	6.20	5.99	
				URIC ACID	01/01/92	214.0	458.0	UMOL/L	103.80	82.00	67.10	66.40	
				TOT BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	11.30	10.10	270.00	219.00	
				DIR BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	0.80	0.80	1.10	1.40	
				TOT. PROTEINS	01/01/92	65.0	85.0	G/L	80.00	75.00	74.00	82.00	
				ALBUMINE	01/01/92	34.0	55.0	G/L	41.60	45.30	44.40	50.20	
				TRIGLYCERIDES	01/01/92	3.1	6.2	MMOL/L	3.20	3.20	3.70	3.10	
				GLOBULINS: ALPHA 1	01/01/92	0.5	1.9	MMOL/L	0.90	0.68	0.54	0.95	
				GLOBULINS: ALPHA 2	01/01/92	1.3	6.0	G/L	2.10	1.30	2.00	1.60	
				GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	8.30	7.80	7.50	7.50	
				GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	9.60	7.40	7.20	7.10	
				T3	01/01/92	1.1	2.2	MMOL/L	18.40	13.20	12.90	15.60	
				T4	01/01/92	60.0	140.0	MMOL/L	97.00	97.00	97.00	97.00	
61	JT		MALE	HB	21/01/92	129.0	150.0	G/L	138.00	147.00	151.00	147.00	
				HTC	01/01/92	0.4	0.5	L/L	0.33	0.33	0.50	0.43	
				RBC	01/01/92	4.0	5.0	10**12/L	4.25	4.41	4.60	4.32	
				HBC: N	01/01/92	4.0	8.8	10**9/L	6.40	5.00	5.60	4.50	
				HBC: L	01/01/92	51.0	77.0	Z	64.00	49.00	68.00	58.00	
				HBC: E	01/01/92	18.0	38.0	Z	32.00	43.00	26.00	34.00	
				HBC: M	01/01/92	1.0	5.0	Z	0.00	6.00	2.00	4.00	
				HBC: B	01/01/92	2.0	10.0	Z	4.00	2.00	0.00	0.00	
				PLATELETS	01/01/92	0.0	1.0	Z	0.00	0.00	0.00	0.00	
				KA+	01/01/92	180.0	320.0	10**9/L	230.00	221.00	225.00	227.00	
				CL-	01/01/92	135.0	150.0	MMOL/L	135.00	142.00	146.00	139.00	
				PO4-	01/01/92	95.0	105.0	MMOL/L	100.20	96.20	93.80	96.00	
					01/01/92	0.6	1.3	MMOL/L	1.19	1.32	1.25	1.24	

1738

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 RENOVETINE - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit				
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6
10	61	JT	MALE	01/01/92	1.0	12.0	U/L	3.00	8.50	10.30	1.50
				01/01/92	1.0	9.0	U/L	3.50	9.00	8.20	5.50
			GAMMA-GT	01/01/92	0.3	1.8	UKAT/L	0.25	0.25	0.73	0.15
			GLUCOSE	01/01/92	3.5	5.5	MMOL/L	4.20	3.00	5.00	4.70
			ALK. PHOSPH.	01/01/92	135.0	360.0	MMOL/L	270.00	142.00	203.00	226.00
			BUN	01/01/92	3.3	10.0	MMOL/L	5.60	6.20	8.20	8.82
			CREATININE	01/01/92	44.0	101.0	UMOL/L	77.40	73.30	73.30	70.70
			URIC ACID	01/01/92	214.0	658.0	UMOL/L	411.00	276.00	340.00	347.00
			TOT. BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	16.10	12.90	13.20	10.30
			DIR. BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	2.20	1.40	2.20	1.70
			TOT. PROTEINS	01/01/92	65.0	85.0	G/L	70.00	73.00	76.00	78.00
			ALBUMINE	01/01/92	34.0	55.0	G/L	38.30	46.00	46.70	47.80
			TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	5.40	5.00	4.60	4.40
			TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	1.42	2.00	2.37	2.00
			GLOBULINS: ALPHA 1	01/01/92	1.3	6.0	G/L	2.80	3.00	1.70	1.00
			GLOBULINS: ALPHA 2	01/01/92	5.0	9.0	G/L	9.00	9.30	8.70	8.00
			GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	11.80	7.10	7.60	10.00
			GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	8.10	10.60	9.30	11.20
			T3	01/01/92	1.1	2.2	MMOL/L	1.05			
			T4	01/01/92	60.0	140.0	MMOL/L	134.50			
				1730							
	62	RK	MALE	01/01/92	129.0	150.0	G/L	144.00	145.00	140.00	147.00
			HB	01/01/92	0.4	0.5	L/L	0.44	0.43	0.41	0.44
			HTC	01/01/92	4.0	5.0	10**12/L	4.30	4.50	4.29	4.40
			RBC	01/01/92	4.0	8.8	10**9/L	8.50	6.40	7.50	6.30
			WBC	01/01/92	51.0	77.0	X	66.00	59.00	56.00	56.00
			WBC: N	01/01/92	18.0	38.0	X	31.00	37.00	38.00	36.00
			WBC: L	01/01/92	1.0	5.0	X	2.00	2.00	2.00	2.00
			WBC: E	01/01/92	2.0	10.0	X	2.00	2.00	2.00	2.00
			WBC: M	01/01/92	0.0	1.0	X	1.00	0.00	0.00	0.00
			WBC: B	01/01/92	180.0	320.0	10**9/L	235.00	228.00	232.00	234.00
			PLATELETS	01/01/92	135.0	150.0	MMOL/L	140.00	142.00	132.00	141.00
			NA+	01/01/92	4.0	5.6	MMOL/L	4.80	4.70	4.90	4.60
			CL-	01/01/92	95.0	105.0	MMOL/L	94.00	101.00	97.20	100.00
			PO4-	01/01/92	0.6	1.3	MMOL/L	0.80	1.02	0.98	1.11
			SGPT	01/01/92	1.0	12.0	U/L	6.00	6.50	11.50	9.50
			SGPT	01/01/92	1.0	9.0	U/L	2.50	5.50	7.50	5.50
			GAMMA-GT	01/01/92	0.3	1.8	UKAT/L	1.30	1.30	1.00	1.40
			GLUCOSE	01/01/92	3.5	5.5	MMOL/L	5.00	5.70	6.40	4.80
			BUN	01/01/92	135.0	360.0	MMOL/L	69.00	315.00	304.00	315.00
			ALK. PHOSPH.	01/01/92	3.3	10.0	MMOL/L	8.20	8.20	5.30	8.16
			CREATININE	01/01/92	44.0	101.0	UMOL/L	66.90	68.70	66.80	69.20
			URIC ACID	01/01/92	214.0	658.0	UMOL/L	337.00	370.00	360.00	358.00
			TOT. BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	14.70	14.70	15.20	14.60
			DIR. BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	1.40	2.30	2.50	2.20
			TOT. PROTEINS	01/01/92	65.0	85.0	G/L	83.00	80.00	75.00	80.00
			ALBUMINE	01/01/92	34.0	55.0	G/L	46.20	46.70	42.40	46.70
			TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	4.80	4.00	3.20	3.90
			TOT. CHOLEST.	01/01/92	0.5	1.9	MMOL/L	1.70	1.26	2.00	1.90

04/02/92 09/03/92
 18/02/92
 21/01/92
 04/02/92
 18/02/92
 09/03/92

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOMETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit								
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
10	62	MALE	GLOBULINS: ALPHA 1	01/01/92	1.3	6.0	G/L	3.00	2.90	1.40	2.90	1.40	2.90		
			GLOBULINS: ALPHA 2	01/01/92	5.0	9.0	G/L	9.50	6.80	7.90	6.80	7.90	6.80		
			GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	10.30	9.80	9.80	9.80	9.80	9.80		
			GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	12.00	13.80	15.20	13.80	15.20	13.80		
			T3	01/01/92	1.1	2.2	NMOL/L	0.98							
			T4	01/01/92	60.0	140.0	NMOL/L	113.00							
			63	MS	MALE	HB	01/01/92	129.0	150.0	G/L	144.00	153.00	145.00	145.00	146.00
						HTC	01/01/92	0.4	0.5	L/L	0.43	0.50	0.43	0.43	0.43
						PRC	01/01/92	4.0	5.0	10**12/L	4.30	4.42	4.35	4.30	4.30
						WBC	01/01/92	4.0	8.8	10**9/L	4.40	6.50	5.90	4.80	4.80
						WBC: N	01/01/92	51.0	77.0	%	64.00	64.00	60.00	62.00	62.00
						WBC: L	01/01/92	16.0	38.0	%	28.00	27.00	37.00	32.00	32.00
						WBC: E	01/01/92	1.0	5.0	%	2.00	3.00	2.00	2.00	2.00
						WBC: K	01/01/92	2.0	10.0	%	5.00	6.00	1.00	2.00	2.00
						WBC: B	01/01/92	0.0	1.0	%	1.00	0.00	0.00	0.00	0.00
						PLATELETS	01/01/92	180.0	320.0	10**9/L	237.00	236.00	231.00	230.00	230.00
						NA+	01/01/92	135.0	150.0	NMOL/L	140.00	135.00	139.00	140.00	140.00
						K+	01/01/92	4.0	5.6	NMOL/L	4.50	4.30	4.50	4.60	4.60
						CL-	01/01/92	95.0	105.0	NMOL/L	99.20	96.30	99.70	100.20	100.20
PO4--	01/01/92	0.6				1.3	NMOL/L	0.90	1.02	1.07	0.97	0.97			
SGPT	01/01/92	1.0				12.0	U/L	7.00	8.20	8.00	5.50	5.50			
GLUCOSE	01/01/92	1.0				9.0	U/L	8.00	5.00	6.50	3.50	3.50			
GAMMA-GT	01/01/92	0.3				1.8	UKAT/L	0.72	0.60	0.35	1.00	1.00			
ALK. PHOSPH.	01/01/92	3.5				5.5	NMOL/L	4.50	3.60	4.00	4.40	4.40			
CREATININE	01/01/92	135.0				360.0	NMOL/L	108.00	139.00	149.00	124.00	124.00			
TOT BILIRUBIN	01/01/92	3.3	10.0	NMOL/L	7.00	6.30	8.16	7.80	7.80						
URIC ACID	01/01/92	44.0	101.0	UMOL/L	68.20	66.20	66.40	73.40	73.40						
DIR BILIRUBIN	01/01/92	214.0	458.0	UMOL/L	256.00	380.00	346.00	267.00	267.00						
TOT. PROTEINS	01/01/92	8.6	20.5	UMOL/L	18.50	19.70	10.90	17.20	17.20						
ALBUMINE	01/01/92	65.0	85.0	G/L	78.00	81.00	81.00	79.00	79.00						
TOT. CHOLEST.	01/01/92	34.0	55.0	G/L	45.80	52.70	45.60	43.20	43.20						
TRIGLYCERIDES	01/01/92	3.1	6.2	NMOL/L	4.20	3.90	4.00	5.30	5.30						
GLOBULINS: ALPHA 1	01/01/92	3.5	1.9	NMOL/L	1.18	1.05	1.27	0.34	0.34						
GLOBULINS: ALPHA 2	01/01/92	1.3	6.0	G/L	1.50	1.60	1.60	1.40	1.40						
GLOBULINS: BETA	01/01/92	5.0	9.0	G/L	8.30	7.30	9.00	9.10	9.10						
GLOBULINS: GAMMA	01/01/92	5.0	13.0	G/L	10.40	7.10	10.30	11.30	11.30						
T3	01/01/92	10.0	17.0	G/L	12.00	12.00	14.50	14.00	14.00						
T4	01/01/92	1.1	2.2	NMOL/L	1.90										
	01/01/92	60.0	140.0	NMOL/L	105.00										
64	IT	FEMALE	HB	01/01/92	112.0	140.0	G/L	135.00	132.00	134.00	132.00				
			HTC	01/01/92	0.4	0.5	L/L	0.40	0.40	0.41	0.41				
			WBC	01/01/92	3.7	4.7	10**12/L	4.18	3.96	4.09	4.08				
			WBC: N	01/01/92	4.0	8.8	10**9/L	6.70	5.60	5.40	5.40				
			WBC: L	01/01/92	51.0	77.0	%	53.00	50.00	60.00	56.00				

1740

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6			
10	64	LT	FEMALE												
				WBC: L	01/01/92	18.0	38.0	Z	42.00	34.00	36.00	38.00			
				WBC: E	01/01/92	1.0	5.0	Z	5.00	2.00	2.00	4.00			
				WBC: M	01/01/92	2.0	10.0	Z	0.00	10.00	2.00	6.00			
				WBC: B	01/01/92	0.0	1.0	Z	0.00	0.00	0.00	0.00			
				PLATELETS	01/01/92	180.0	320.0	10**9/L	213.00	220.00	222.00	225.00			
				NA+	01/01/92	135.0	150.0	MMOL/L	140.00	135.00	142.00	143.00			
				K+	01/01/92	4.0	5.6	MMOL/L	4.00	4.60	4.30	4.80			
				PO4-	01/01/92	95.0	105.0	MMOL/L	95.00	100.80	100.10	102.10			
				SGPT	01/01/92	0.6	1.3	MMOL/L	1.01	1.20	1.18	1.06			
				SGPT	01/01/92	1.0	12.0	U/L	6.00	6.70	5.50	2.50			
				GAMMA-GT	01/01/92	1.0	9.0	U/L	6.50	4.70	5.00	4.50			
				GLUCOSE	01/01/92	0.2	1.1	UKAT/L	0.40	0.45	0.50	0.20			
				ALK. PHOSPH.	01/01/92	3.5	5.5	MMOL/L	3.20	4.20	4.40	5.00			
				RUN	01/01/92	135.0	360.0	MMOL/L	6.20	100.00	100.00	113.00			
				CREATININE	01/01/92	3.3	10.0	MMOL/L	5.50	6.20	6.00	6.00			
				URIC ACID	01/01/92	44.0	88.0	UMOL/L	68.20	61.90	78.00	71.00			
				DIR. BILIRUBIN	01/01/92	149.0	405.0	UMOL/L	247.00	211.00	220.00	155.00			
				TOT. BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	10.40	9.20	10.00	10.90			
				TOT. PROTEINS	01/01/92	65.0	85.0	G/L	1.10	0.70	0.90	2.80			
				ALBUMINE	01/01/92	34.0	55.0	G/L	38.60	46.40	47.00	79.00			
				TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	3.70	3.60	3.80	3.20			
				TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	0.54	1.12	1.12	1.25			
				GLOBULINS: ALPHA 1	01/01/92	1.3	6.0	G/L	4.50	1.90	4.50	2.20			
				GLOBULINS: ALPHA 2	01/01/92	5.0	9.0	G/L	3.90	7.90	8.00	7.40			
				GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	5.00	9.60	10.70	13.00			
				GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	17.00	15.20	9.80	17.40			
				T4	01/01/92	1.1	2.2	MMOL/L	1.10						
					01/01/92	60.0	140.0	MMOL/L	80.00						
81	JN		FEMALE												
				HB	01/01/92	112.0	140.0	G/L	134.00	132.00	138.00	137.00			
				HTC	01/01/92	0.4	0.5	L/L	0.40	0.41	0.42	0.41			
				RBC	01/01/92	3.7	4.7	10**12/L	4.08	4.15	4.25	4.14			
				WBC: N	01/01/92	4.0	8.8	10**9/L	6.10	4.10	4.40	4.10			
				WBC: L	01/01/92	51.0	77.0	Z	66.00	58.00	60.00	48.00			
				WBC: E	01/01/92	18.0	38.0	Z	30.00	36.00	36.00	44.00			
				WBC: M	01/01/92	1.0	5.0	Z	1.00	2.00	2.00	6.00			
				WBC: B	01/01/92	2.0	10.0	Z	3.00	4.00	2.00	2.00			
				PLATELETS	01/01/92	0.0	1.0	Z	0.00	0.00	0.00	0.00			
				NA+	01/01/92	180.0	320.0	10**9/L	220.00	220.00	225.00	220.00			
				K+	01/01/92	135.0	150.0	MMOL/L	135.00	136.00	136.00	140.00			
				CL-	01/01/92	4.0	5.6	MMOL/L	4.20	4.40	4.40	4.10			
				PO4-	01/01/92	95.0	105.0	MMOL/L	97.20	98.00	95.80	100.20			
				SGPT	01/01/92	0.6	1.3	MMOL/L	0.98	1.13	1.04	1.13			
				SGPT	01/01/92	1.0	12.0	U/L	8.40	2.00	4.50	4.00			
				GAMMA-GT	01/01/92	0.2	1.1	UKAT/L	0.45	0.30	0.30	0.32			
				GLUCOSE	01/01/92	3.5	5.5	MMOL/L	3.50	4.30	3.80	3.90			
				ALK. PHOSPH.	01/01/92	135.0	360.0	MMOL/L	108.00	125.00	110.00	116.00			

1741

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
10	81	JN	FEMALE	RUN	01/01/92	3.3	10.0	MMOL/L	6.80	5.99	9.20	5.30	
				CREATININE	01/01/92	44.0	88.0	UMOL/L	65.20	64.50	71.70	71.00	
				URIC ACID	01/01/92	149.0	405.0	UMOL/L	231.00	271.00	200.00	245.00	
				TOT BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	20.80	13.20	19.90	8.40	
				DIR BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	3.70	1.60	4.20	1.70	
				TOT. PROTEINS	01/01/92	65.0	85.0	G/L	80.00	80.00	83.00	75.00	
				ALBUMINE	01/01/92	34.0	55.0	G/L	49.90	55.70	46.70	47.80	
				TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	4.80	5.10	3.50	3.70	
				TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	1.46	1.35	1.49	0.61	
				GLOBULINS: ALPHA 1	01/01/92	1.3	5.0	G/L	2.80	1.40	3.70	1.60	
				GLOBULINS: ALPHA 2	01/01/92	5.0	9.0	G/L	8.70	7.70	7.30	8.40	
				GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	8.60	8.00	11.30	8.00	
				GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	10.00	7.20	13.40	9.20	
				T3	01/01/92	1.1	2.2	MMOL/L	1.00				
				T4	01/01/92	60.0	140.0	MMOL/L	83.00				
82	IS		MALE	HB	01/01/92	129.0	150.0	G/L	147.00	140.00	140.00	147.00	
				HCT	01/01/92	0.4	0.5	L/L	0.42	0.48	0.42	0.42	
				RBC	01/01/92	4.0	5.0	10**12/L	4.28	4.20	4.18	4.30	
				WBC	01/01/92	4.0	8.8	10**9/L	5.70	5.20	5.10	4.80	
				WBC: N	01/01/92	51.0	77.0	%	62.00	74.00	56.00	66.00	
				WBC: L	01/01/92	18.0	38.0	%	30.00	24.00	42.00	34.00	
				WBC: E	01/01/92	1.0	5.0	%	0.00	0.00	0.00	0.00	
				WBC: M	01/01/92	2.0	10.0	%	8.00	2.00	2.00	0.00	
				WBC: B	01/01/92	0.0	1.0	%	0.00	0.00	0.00	0.00	
				PLATELETS	01/01/92	180.0	320.0	10**9/L	220.00	227.00	218.00	215.00	
				NA+	01/01/92	135.0	150.0	MMOL/L	133.00	141.00	140.00	138.00	
				K+	01/01/92	4.0	5.6	MMOL/L	5.70	4.60	4.70	4.70	
				CL-	01/01/92	95.0	105.0	MMOL/L	98.00	97.50	98.80	101.50	
				PO4--	01/01/92	0.6	1.3	MMOL/L	0.65	1.09	0.73	0.99	
				SGPT	01/01/92	1.0	12.0	U/L	10.00	4.50	2.50	5.00	
				SGPT	01/01/92	1.0	9.0	U/L	3.00	3.00	5.00	6.50	
				GAMMA-GT	01/01/92	0.3	1.8	UMAT/L	0.80	1.30	0.65	0.28	
				GLUCOSE	01/01/92	3.5	5.5	MMOL/L	4.60	4.80	4.70	4.80	
				ALK. PHOSPH.	01/01/92	135.0	360.0	MMOL/L	232.00	259.00	274.00	263.00	
				BUN	01/01/92	3.3	10.0	MMOL/L	5.80	5.99	5.20	5.10	
				CREATININE	01/01/92	44.0	101.0	UMOL/L	76.60	68.40	68.30	76.10	
				URIC ACID	01/01/92	214.0	458.0	UMOL/L	355.00	286.00	264.00	349.00	
				DIR BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	8.20	13.50	8.40	14.20	
				TOT. PROTEINS	01/01/92	65.0	85.0	G/L	80.00	81.00	88.00	78.00	
				ALBUMINE	01/01/92	34.0	55.0	G/L	49.00	53.90	34.30	48.30	
				TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	3.40	5.40	4.10	4.80	
				TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	1.70	0.54	0.75	0.67	
				GLOBULINS: ALPHA 1	01/01/92	1.3	6.0	G/L	1.40	2.10	3.50	1.30	
				GLOBULINS: ALPHA 2	01/01/92	5.0	9.0	G/L	8.20	8.30	9.10	9.20	
				GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	6.80	6.80	9.10	7.00	
				GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	11.60	7.60	11.80	11.60	
				T3	01/01/92	1.1	2.2	MMOL/L	1.82				

1742

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R8D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit						
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6		
10	82	LS	MALE	T4	01/01/92	60.0	140.0	NMOL/L	98.00					
	83	KL	MALE	HB	01/01/92	129.0	150.0	G/L	02/03/92	16/03/92	30/03/92			
				HTC	01/01/92	0.4	0.5	L/L	138.00	138.00	143.00			
				RBC	01/01/92	4.0	5.0	10**12/L	0.42	0.43	0.42			
				HBC	01/01/92	4.0	8.8	10**9/L	4.25	4.25	4.24			
				HBC: N	01/01/92	51.0	77.0	Z	4.20	5.30	3.70			
				HBC: L	01/01/92	18.0	38.0	Z	68.00	50.00	68.00			
				HBC: E	01/01/92	1.0	5.0	Z	24.00	34.00	22.00			
				HBC: M	01/01/92	2.0	10.0	Z	3.00	8.00	4.00			
				HBC: B	01/01/92	0.0	1.0	Z	3.00	4.00	2.00			
				PLATELETS	01/01/92	180.0	320.0	10**9/L	0.00	0.00	0.00			
				K+	01/01/92	135.0	150.0	NMOL/L	230.00	230.00	228.00			
				Cl-	01/01/92	95.0	105.0	NMOL/L	141.00	142.00	141.00			
				PDW-	01/01/92	0.6	1.3	NMOL/L	94.80	94.80	99.50			
				SGPT	01/01/92	1.0	12.0	U/L	1.11	1.10	0.87			
				GAMMA-GT	01/01/92	0.3	9.0	U/L	6.00	4.50	5.00			
				ALX. PHOSPH.	01/01/92	3.5	5.5	NMOL/L	0.30	0.50	0.75			
				RUN	01/01/92	3.3	10.0	NMOL/L	169.00	147.00	187.00			
				CREATININE	01/01/92	44.0	101.0	UMOL/L	7.49	4.30	5.10			
				URIC ACID	01/01/92	214.0	458.0	UMOL/L	71.40	73.30	71.10			
				TOT BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	311.00	285.00	337.00			
				DIR BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	9.80	22.40	11.80			
				TOT. PROTEINS	01/01/92	65.0	85.0	G/L	1.70	1.40	3.10			
				ALBUMINE	01/01/92	34.0	55.0	G/L	80.00	80.00	69.00			
				TOT. CHOLEST.	01/01/92	3.1	6.2	NMOL/L	52.60	59.70	45.00			
				TRIGLYCERIDES	01/01/92	0.5	1.9	NMOL/L	3.50	4.10	3.70			
				GLOBULINS: ALPHA 1	01/01/92	1.3	6.0	G/L	1.54	1.02	0.89			
				GLOBULINS: ALPHA 2	01/01/92	5.0	9.0	G/L	2.20	1.10	1.10			
				GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	8.60	9.70	8.10			
				GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	8.20	8.00	7.10			
				T3	01/01/92	1.1	2.2	NMOL/L	8.40	7.50	7.70			
				T4	01/01/92	60.0	140.0	NMOL/L	0.90					
	84	HV	FEMALE	HB	01/03/92	112.0	140.0	G/L	10/03/92	24/03/92	07/06/92	21/06/92		
				HTC	01/01/92	0.4	0.5	L/L	138.00	135.00	138.00	134.00		
				RBC	01/01/92	3.7	4.7	10**12/L	0.42	0.43	0.41	0.40		
				HBC	01/01/92	4.0	8.8	10**9/L	4.25	4.17	4.12	3.98		
				HBC: N	01/01/92	51.0	77.0	Z	56.00	58.00	4.50	5.40		
				HBC: L	01/01/92	18.0	38.0	Z	38.00	34.00	22.00	44.00		
				HBC: E	01/01/92	1.0	5.0	Z	0.00	2.00	0.00	0.00		
				HBC: M	01/01/92	2.0	10.0	Z	4.00	2.00	0.00	4.00		
				HBC: B	01/01/92	0.0	1.0	Z	0.00	0.00	0.00	0.00		
				PLATELETS	01/01/92	180.0	320.0	10**9/L	228.00	220.00	218.00	220.00		

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit									
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6					
10	84	HV	FEMALE	NA+	01/01/92	135.0	150.0	NHOL/L	141.00	142.00	138.00	138.00	138.00				
				K+	01/01/92	4.0	5.6	NHOL/L	4.10	4.90	4.50	4.50	3.80				
				CL-	01/01/92	95.0	105.0	NHOL/L	101.80	100.50	98.00	98.00	96.50				
				PO4-	01/01/92	0.6	1.3	NHOL/L	1.19	1.40	1.24	1.24	1.45				
				SGOT	01/01/92	1.0	12.0	U/L	1.00	6.50	3.00	3.00	6.00				
				SGPT	01/01/92	1.0	9.0	U/L	3.50	3.50	4.00	4.00	3.00				
				GAMMA-GT	01/01/92	0.2	1.1	UKAT/L	0.65	0.70	0.31	0.31	0.58				
				GLUCOSE	01/01/92	3.5	5.5	NHOL/L	4.70	4.70	4.20	4.20	4.40				
				ALK. PHOSPH.	01/01/92	135.0	360.0	NHOL/L	147.00	136.00	173.00	173.00	125.00				
				BUN	01/01/92	3.3	10.0	NHOL/L	4.50	3.00	2.90	2.90	3.30				
				CREATININE	01/01/92	44.0	88.0	UMOL/L	65.20	72.00	67.00	67.00	69.00				
				URIC ACID	01/01/92	149.0	405.0	UMOL/L	221.00	214.00	345.00	345.00	279.00				
				DIR BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	9.50	12.60	12.20	12.20	13.10				
				TOT BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	0.80	2.80	3.40	3.40	4.20				
				TOT. PROTEINS	01/01/92	65.0	85.0	G/L	79.00	77.00	75.00	75.00	68.00				
				ALBUMINE	01/01/92	34.0	55.0	G/L	49.80	36.30	45.50	45.50	42.30				
				TOT. CHOLEST.	01/01/92	3.1	6.2	NHOL/L	3.20	3.90	4.00	4.00	3.90				
				TRIGLYCERIDES	01/01/92	0.5	1.9	NHOL/L	1.05	2.34	0.46	0.46	3.08				
				GLOBULINS: ALPHA 1	01/01/92	1.3	6.0	G/L	1.80	2.30	2.60	2.60	1.70				
				GLOBULINS: ALPHA 2	01/01/92	5.0	9.0	G/L	7.90	8.30	5.80	5.80	5.60				
				GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	9.90	14.50	8.40	8.40	6.00				
				GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	9.60	15.60	12.70	12.70	12.40				
				T3	01/01/92	1.1	2.2	NHOL/L	1.10								
				T4	01/01/92	60.0	140.0	NHOL/L	64.00								
				85	AK		MALE	HB	01/01/92	129.0	150.0	G/L	10/03/92	10/03/92	07/04/92	07/04/92	07/04/92
								HTC	01/01/92	0.4	0.5	L/L	147.00	143.00	145.00	145.00	145.00
								RBC	01/01/92	4.0	5.0	10**12/L	0.44	0.43	0.43	0.43	0.43
								HBC	01/01/92	4.0	8.8	10**9/L	4.45	4.50	4.28	4.28	4.28
HBC: N	01/01/92	51.0	77.0					X	5.20	5.30	5.00	5.00	5.00				
HBC: L	01/01/92	18.0	38.0					X	66.00	70.00	70.00	70.00	70.00				
HBC: E	01/01/92	1.0	5.0					X	26.00	22.00	22.00	22.00	22.00				
HBC: M	01/01/92	2.0	10.0					X	3.00	4.00	2.00	2.00	2.00				
HBC: B	01/01/92	0.0	1.0					Z	4.00	4.00	6.00	6.00	6.00				
PLATELETS	01/01/92	180.0	320.0					10**9/L	240.00	0.00	0.00	0.00	0.00				
Na+	01/01/92	135.0	150.0					NHOL/L	142.00	225.00	230.00	230.00	230.00				
K+	01/01/92	95.0	105.0					NHOL/L	162.00	142.00	139.00	139.00	139.00				
PO4-	01/01/92	0.6	1.3					NHOL/L	99.30	100.00	99.50	99.50	99.50				
SGOT	01/01/92	1.0	12.0					U/L	3.09	1.11	1.17	1.17	1.17				
SGPT	01/01/92	1.0	9.0					U/L	8.00	6.50	8.50	8.50	8.50				
GAMMA-GT	01/01/92	0.3	1.8					UKAT/L	5.50	4.50	0.27	0.27	0.27				
GLUCOSE	01/01/92	3.5	5.5					NHOL/L	4.00	4.50	3.60	3.60	3.60				
ALK. PHOSPH.	01/01/92	135.0	360.0					NHOL/L	124.00	132.00	153.00	153.00	153.00				
BUN	01/01/92	3.3	10.0					NHOL/L	7.16	7.20	4.80	4.80	4.80				
CREATININE	01/01/92	44.0	101.0					UMOL/L	79.80	82.10	71.70	71.70	71.70				
URIC ACID	01/01/92	214.0	458.0					UMOL/L	331.00	331.00	347.00	347.00	347.00				
TOT BILIRUBIN	01/01/92	8.6	20.5					UMOL/L	16.90	16.90	14.90	14.90	14.90				
DIR BILIRUBIN	01/01/92	0.5	4.3					UMOL/L	1.70	1.70	1.70	1.70	1.70				

1744

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit									
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6					
10	85 AK	MALE	TOT. PROTEINS	01/01/92	65.0	85.0	G/L	80.00	80.00	80.00	80.00	80.00	80.00	80.00		
			ALBUMINE	01/01/92	34.0	55.0	G/L	56.10	56.10	56.10	56.10	56.10	56.10	56.10		
			TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	3.00	3.20	3.00	3.20	3.00	3.20	3.00		
			TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	1.36	1.42	1.36	1.42	1.36	1.42	1.36		
			GLOBULINS: ALPHA 1	01/01/92	1.3	6.0	G/L	1.90	2.00	1.90	2.00	1.90	2.00	1.90		
			GLOBULINS: ALPHA 2	01/01/92	5.0	9.0	G/L	8.10	8.10	8.10	8.10	8.10	8.10	8.10		
			GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	6.30	6.50	6.30	6.50	6.30	6.50	6.30		
			GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	7.40	7.20	7.40	7.20	7.40	7.20	7.40		
			T3	01/01/92	1.1	2.2	NMOL/L	1.40	1.40	1.40	1.40	1.40	1.40	1.40		
			T4	01/01/92	60.0	140.0	NMOL/L	86.50	86.50	86.50	86.50	86.50	86.50	86.50		
			86 NP	FEMALE	HB	01/01/92	112.0	140.0	G/L	135.00	135.00	135.00	135.00	135.00	135.00	135.00
					HCT	01/01/92	0.4	0.5	L/L	0.42	0.42	0.42	0.42	0.42	0.42	0.42
					RBC	01/01/92	3.7	4.7	10**12/L	4.20	4.23	4.20	4.23	4.20	4.23	4.20
					WBC	01/01/92	4.0	8.8	10**9/L	6.90	5.70	6.90	5.70	6.90	5.70	6.90
					WBC: N	01/01/92	51.0	77.0	%	54.00	54.00	54.00	54.00	54.00	54.00	54.00
					WBC: L	01/01/92	18.0	38.0	%	42.00	42.00	42.00	42.00	42.00	42.00	42.00
					WBC: E	01/01/92	1.0	5.0	%	2.00	2.00	2.00	2.00	2.00	2.00	2.00
					WBC: B	01/01/92	2.0	10.0	%	2.00	2.00	2.00	2.00	2.00	2.00	2.00
					PLATELETS	01/01/92	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00	0.00
					Na+	01/01/92	180.0	320.0	10**9/L	215.00	215.00	215.00	215.00	215.00	215.00	215.00
K+	01/01/92	135.0			150.0	NMOL/L	139.00	139.00	139.00	139.00	139.00	139.00	139.00			
CL-	01/01/92	95.0			105.0	NMOL/L	103.00	103.00	103.00	103.00	103.00	103.00	103.00			
PO4-	01/01/92	0.6			1.3	MMOL/L	1.09	1.07	1.09	1.07	1.09	1.07	1.09			
SGPT	01/01/92	1.0			12.0	U/L	4.50	4.40	4.50	4.40	4.50	4.40	4.50			
SGOT	01/01/92	1.0			9.0	U/L	4.50	4.50	4.50	4.50	4.50	4.50	4.50			
GAMMA-GT	01/01/92	0.2			1.1	UKAT/L	0.25	0.19	0.25	0.19	0.25	0.19	0.25			
GLUCOSE	01/01/92	3.5			5.5	MMOL/L	4.30	4.30	4.30	4.30	4.30	4.30	4.30			
ALK. PHOSPH.	01/01/92	135.0			360.0	NMOL/L	121.00	121.00	121.00	121.00	121.00	121.00	121.00			
CREATININE	01/01/92	3.3			10.0	MMOL/L	4.30	4.30	4.30	4.30	4.30	4.30	4.30			
BUN	01/01/92	44.0			88.0	UMOL/L	73.10	73.10	73.10	73.10	73.10	73.10	73.10			
URIC ACID	01/01/92	149.0	405.0	UMOL/L	208.00	281.00	281.00	281.00	281.00	281.00	281.00					
TOT. BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	9.50	13.40	13.40	13.40	13.40	13.40	13.40					
DIR BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	5.30	3.70	3.70	3.70	3.70	3.70	3.70					
TOT. PROTEINS	01/01/92	65.0	85.0	G/L	72.00	80.00	80.00	80.00	80.00	80.00	80.00					
ALBUMINE	01/01/92	34.0	55.0	G/L	35.60	49.50	49.50	49.50	49.50	49.50	49.50					
TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	6.00	6.00	6.00	6.00	6.00	6.00	6.00					
TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	1.05	0.47	0.85	0.85	0.85	0.85	0.85					
GLOBULINS: ALPHA 1	01/01/92	1.3	6.0	G/L	2.50	2.50	2.50	2.50	2.50	2.50	2.50					
GLOBULINS: ALPHA 2	01/01/92	5.0	9.0	G/L	7.60	7.60	7.60	7.60	7.60	7.60	7.60					
GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	10.00	10.00	10.00	10.00	10.00	10.00	10.00					
GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	15.00	15.00	15.00	15.00	15.00	15.00	15.00					
T3	01/01/92	1.1	2.2	NMOL/L	1.30	1.30	1.30	1.30	1.30	1.30	1.30					
T4	01/01/92	60.0	140.0	NMOL/L	101.00	101.00	101.00	101.00	101.00	101.00	101.00					
87 AN	FEMALE	HB	01/01/92	112.0	140.0	G/L	141.00	141.00	141.00	141.00	141.00	141.00	141.00			
		Screen	01/04/92	18/03/92	01/04/92	15/04/92	29/04/92									

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit						
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6		
10	87	AN	FEMALE	HTC	01/01/92	0.4	0.5	L/L	0.42	0.42	0.40	0.42	0.42
				RBC	01/01/92	3.7	4.7	10**12/L	4.24	4.20	4.10	4.15	
				RBC: N	01/01/92	4.0	8.8	10**9/L	4.60	4.30	5.40	5.20	
				RBC: L	01/01/92	51.0	77.0	X	72.00	66.00	70.00	69.00	
				RBC: E	01/01/92	18.0	38.0	X	16.00	18.00	26.00	27.00	
				RBC: N	01/01/92	1.0	5.0	X	8.00	11.00	2.00	2.00	
				RBC: B	01/01/92	2.0	10.0	X	2.00	3.00	2.00	2.00	
				PLATELETS	01/01/92	0.0	1.0	X	0.00	0.00	0.00	0.00	
				Na+	01/01/92	180.0	320.0	10**9/L	223.00	220.00	214.00	217.00	
				K+	01/01/92	135.0	150.0	MMOL/L	141.00	142.00	140.00	149.00	
				PO4-	01/01/92	95.0	105.0	MMOL/L	4.90	4.80	5.00	5.30	
				SGPT	01/01/92	0.6	1.3	MMOL/L	101.80	89.70	103.00	99.50	
				SGPT	01/01/92	1.0	12.0	U/L	1.19	1.06	1.09	0.88	
				GAMMA-GT	01/01/92	1.0	9.0	U/L	2.50	9.00	7.00	2.00	
				GLUCOSE	01/01/92	0.2	1.1	MMOL/L	2.50	7.50	5.50	2.50	
				ALB	01/01/92	3.5	5.5	MMOL/L	0.70	0.63	0.42	0.66	
				CREATININE	01/01/92	135.0	360.0	MMOL/L	4.90	4.80	4.50	4.30	
				URIC ACID	01/01/92	3.3	10.0	MMOL/L	126.00	143.00	150.00	152.00	
				TOT. BILIRUBIN	01/01/92	44.0	88.0	UMOL/L	74.70	74.50	86.20	79.20	
				TOT. PROTEINS	01/01/92	149.0	405.0	UMOL/L	302.00	285.00	271.00	225.00	
DAR BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	13.50	9.00	18.70	15.90					
ALBUMINE	01/01/92	0.5	4.3	UMOL/L	1.70	1.10	0.80	3.70					
TOT. CHOLEST.	01/01/92	65.0	85.0	G/L	70.00	72.00	80.00	74.00					
TRIGLYCERIDES	01/01/92	3.1	6.2	MMOL/L	38.20	46.70	50.60	47.10					
ALBUMINS: ALPHA 1	01/01/92	0.5	1.9	MMOL/L	0.85	0.61	1.20	3.50					
ALBUMINS: ALPHA 2	01/01/92	1.3	6.0	G/L	1.70	1.70	1.70	1.08					
ALBUMINS: BETA	01/01/92	5.0	9.0	G/L	9.10	5.30	6.20	8.10					
ALBUMINS: GAMMA	01/01/92	5.0	13.0	G/L	10.60	8.00	11.40	7.60					
T3	01/01/92	1.1	2.2	MMOL/L	10.40	10.30	10.80	9.50					
T4	01/01/92	60.0	140.0	MMOL/L	1.30	1.30	1.24	1.14					
					95.00			2.00					
88	AH		FEMALE	HB	01/03/92	112.0	140.0	G/L	18/03/92	01/04/92	15/04/92	29/04/92	
				HTC	01/01/92	0.4	0.5	L/L	132.00	135.00	138.00	135.00	
				RBC	01/01/92	3.7	4.7	10**12/L	0.42	0.41	0.41	0.42	
				RBC: N	01/01/92	4.0	8.8	10**9/L	4.15	4.12	4.18	4.15	
				RBC: L	01/01/92	51.0	77.0	X	4.90	6.00	6.70	7.60	
				RBC: E	01/01/92	18.0	38.0	X	54.00	58.00	38.00	58.00	
				RBC: N	01/01/92	1.0	5.0	X	38.00	38.00	56.00	40.00	
				RBC: B	01/01/92	2.0	10.0	X	0.00	2.00	4.00	0.00	
				PLATELETS	01/01/92	0.0	1.0	X	6.00	0.00	2.00	2.00	
				Na+	01/01/92	180.0	320.0	10**9/L	0.00	0.00	0.00	0.00	
				K+	01/01/92	135.0	150.0	MMOL/L	218.00	215.00	216.00	220.00	
				PO4-	01/01/92	95.0	105.0	MMOL/L	140.00	140.00	141.00	149.00	
				SGPT	01/01/92	0.6	1.3	MMOL/L	4.20	3.90	5.10	4.40	
				SGPT	01/01/92	1.0	12.0	U/L	95.20	97.40	99.00	96.40	
					1.10	1.52	1.24	1.14					
					4.00	5.00	5.00	2.00					

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBONETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Date	Laboratory Range			Visit					
					Min	Max	Unit	Screen	Week 2	Week 4	Week 6		
10	88	AM	FEMALE	01/01/92	1.0	9.0	U/L	2.50	5.50	8.50	1.00		
			SGPT	01/01/92	0.2	1.1	UKAT/L	0.55	0.78	0.82	0.26		
			GAMMA-GT	01/01/92	3.5	5.5	MMOL/L	3.80	3.60	3.70	4.40		
			GLUCOSE	01/01/92	135.0	360.0	MMOL/L	246.00	213.00	224.00	227.00		
			ALK. PHOSPH.	01/01/92	3.3	10.0	MMOL/L	6.70	7.30	6.30	7.70		
			BUN	01/01/92	44.0	88.0	MMOL/L	67.00	67.60	78.50	82.70		
			CREATININE	01/01/92	149.0	405.0	MMOL/L	160.00	229.00	209.00	185.00		
			URIC ACID	01/01/92	8.5	20.5	MMOL/L	8.50	13.10	15.10	15.60		
			TOT BILIRUBIN	01/01/92	0.5	4.3	MMOL/L	0.60	1.70	2.20	1.70		
			DIR BILIRUBIN	01/01/92	65.0	85.0	G/L	80.00	80.00	83.00	85.00		
			TOT. PROTEINS	01/01/92	34.0	55.0	G/L	33.00	47.10	47.60	51.10		
			ALBUMINE	01/01/92	3.1	6.2	MMOL/L	3.10	3.20	4.00	3.60		
			TRIGLYCERIDES	01/01/92	0.5	1.5	MMOL/L	1.18	0.56	3.05	1.66		
			GLOBULINS: ALPHA 1	01/01/92	1.3	6.0	G/L	1.00	3.30	1.10	1.30		
			GLOBULINS: ALPHA 2	01/01/92	5.0	9.0	G/L	13.70	9.40	8.80	9.20		
			GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	11.00	8.40	7.20	9.30		
			GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	21.30	11.80	18.30	14.10		
			T3	01/01/92	1.1	2.2	MMOL/L	1.10					
			T4	01/01/92	60.0	140.0	MMOL/L	72.00					
89	SK		FEMALE	01/01/92	112.0	140.0	G/L	132.00	138.00	137.00	128.00		
			HB	01/01/92	0.4	0.5	L/L	0.42	0.42	0.41	0.41		
			HTC	01/01/92	3.7	4.7	10**12/L	4.15	4.18	4.14	4.10		
			RBC	01/01/92	4.0	8.8	10**9/L	8.00	4.90	4.90	6.40		
			WBC	01/01/92	51.0	77.0	X	78.00	62.00	58.00	71.00		
			WBC: N	01/01/92	18.0	38.0	X	15.00	32.00	38.00	28.00		
			WBC: L	01/01/92	1.0	5.0	X	3.00	2.00	2.00	0.00		
			WBC: E	01/01/92	2.0	10.0	X	2.00	4.00	2.00	1.00		
			WBC: M	01/01/92	0.0	1.0	X	0.00	0.00	0.00	0.00		
			WBC: R	01/01/92	180.0	320.0	10**9/L	220.00	218.00	215.00	217.00		
			PLATELETS	01/01/92	135.0	150.0	MMOL/L	139.00	140.00	142.00	140.00		
			Na+	01/01/92	4.0	5.6	MMOL/L	4.60	4.00	5.30	4.40		
			K+	01/01/92	95.0	105.0	MMOL/L	103.80	101.20	98.90	103.00		
			CL-	01/01/92	0.6	1.3	MMOL/L	1.43	1.31	1.50	1.19		
			FD04-	01/01/92	1.0	12.0	U/L	3.50	6.00	7.00	3.50		
			SGPT	01/01/92	1.0	9.0	U/L	3.50	4.00	6.00	3.00		
			GAMMA-GT	01/01/92	0.2	1.1	UKAT/L	0.30	0.53	0.71	0.26		
			GLUCOSE	01/01/92	3.5	5.5	MMOL/L	4.00	4.40	4.20	4.10		
			ALK. PHOSPH.	01/01/92	135.0	360.0	MMOL/L	113.00	123.00	113.00	123.00		
			BUN	01/01/92	3.3	10.0	MMOL/L	6.00	6.00	4.30	3.40		
			CREATININE	01/01/92	44.0	88.0	MMOL/L	67.70	304.00	79.20	70.70		
			URIC ACID	01/01/92	149.0	405.0	MMOL/L	284.00	308.00	251.00	265.00		
			TOT BILIRUBIN	01/01/92	8.6	20.5	MMOL/L	12.10	10.00	14.80	14.20		
			DIR BILIRUBIN	01/01/92	0.5	4.3	MMOL/L	0.70	0.60	1.00	1.70		
			TOT. PROTEINS	01/01/92	65.0	85.0	G/L	80.00	50.70	73.00	72.00		
			ALBUMINE	01/01/92	34.0	55.0	G/L	40.20	3.20	3.50	3.50		
			TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	0.54	0.64	1.22	0.95		
			TRIGLYCERIDES	01/01/92	0.5	1.5	MMOL/L	3.60	3.00	2.00	1.80		

1747

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit					
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
10	89 SK	FEMALE	GLOBULINS: ALPHA 2	01/01/92	5.0	9.0	G/L	11.70	7.70	6.60	9.70	
			GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	11.20	6.90	8.40	6.90	
			GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	13.30	10.70	8.00	9.40	
			T3	01/01/92	1.1	2.2	NMOL/L					
			T4	01/01/92	60.0	140.0	NMOL/L	83.50				
90 SV	FEMALE	HB	01/01/92	112.0	140.0	G/L	23/03/92	06/04/92	20/04/92	04/05/92		
		HTC	01/01/92	0.4	0.5	L/L	132.00	127.00	135.00	127.00		
		RBC	01/01/92	3.7	4.7	10**12/L	0.41	0.37	0.41	0.40		
		RBC: N	01/01/92	4.0	8.8	10**9/L	4.10	3.63	4.15	4.00		
		RBC: L	01/01/92	51.0	77.0	Z	4.80	4.50	4.40	5.30		
		RBC: E	01/01/92	18.0	38.0	Z	63.00	66.00	58.00	67.00		
		RBC: M	01/01/92	1.0	5.0	Z	27.00	27.00	36.00	27.00		
		RBC: B	01/01/92	2.0	10.0	Z	4.00	2.00	6.00	4.00		
		PLATELETS	01/01/92	0.0	1.0	Z	2.00	5.00	0.00	2.00		
		W*	01/01/92	180.0	320.0	10**9/L	218.00	210.00	205.00	215.00		
		CL*	01/01/92	135.0	150.0	NMOL/L	141.00	142.00				
		CL	01/01/92	4.0	5.6	NMOL/L	5.40	4.50				
		PO4	01/01/92	0.6	1.3	NMOL/L	94.50	94.30				
		SGPT	01/01/92	1.0	12.0	U/L	1.00	5.00				
		GAMMA-GT	01/01/92	1.0	9.0	U/L	4.50	4.50				
		GLUCOSE	01/01/92	0.2	1.1	UKAT/L	0.74	0.68				
		ALK. PHOSPH.	01/01/92	3.5	5.5	NMOL/L	4.00	3.80	4.60	4.20		
		CREATININE	01/01/92	135.0	360.0	NMOL/L	110.00	134.00				
		TOT. BILIRUBIN	01/01/92	3.3	10.0	NMOL/L	6.00	3.80				
		DIR. BILIRUBIN	01/01/92	44.0	88.0	UMOL/L	78.40	64.30				
		TOT. PROTEINS	01/01/92	149.0	405.0	UMOL/L	211.00	233.00				
		ALBUMINE	01/01/92	8.6	20.5	UMOL/L	14.10	14.10				
		TOT. CHOLEST.	01/01/92	0.5	4.3	UMOL/L	1.10	1.90				
TRIGLYCERIDES	01/01/92	65.0	85.0	G/L	79.00	78.00						
GLOBULINS: ALPHA 1	01/01/92	34.0	55.0	G/L	49.40	50.40						
GLOBULINS: ALPHA 2	01/01/92	3.1	6.2	NMOL/L	3.80	4.80						
GLOBULINS: BETA	01/01/92	1.3	6.0	G/L	0.95	0.55						
GLOBULINS: GAMMA	01/01/92	5.0	13.0	G/L	2.40	2.20						
T3	01/01/92	10.0	17.0	G/L	7.50	9.50						
T4	01/01/92	1.1	2.2	NMOL/L	6.40	8.30						
			T4	01/01/92	60.0	140.0	NMOL/L	76.00				
91 HI	MALE	HB	01/01/92	129.0	150.0	G/L	23/03/92	06/04/92	20/04/92	05/05/92		
		HTC	01/01/92	0.4	0.5	L/L	144.00	135.00	144.00	136.00		
		RBC	01/01/92	4.0	5.0	10**12/L	0.43	0.40	0.43	0.42		
		RBC: N	01/01/92	4.0	8.8	10**9/L	4.30	4.02	4.30	4.18		
		RBC: L	01/01/92	51.0	77.0	Z	6.60	4.80	7.10	4.90		
			RBC: E	01/01/92	18.0	38.0	Z	64.00	64.00	72.00		
			RBC: M	01/01/92	1.0	5.0	Z	32.00	28.00	26.00		

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Date	Laboratory Range			Screen	Visit						
					Min	Max	Unit		Week 2	Week 4	Week 6				
10	91	MALE	RBC: E	01/01/92	1.0	5.0	%	0.00	4.00	0.00	2.00	2.00			
			RBC: M	01/01/92	2.0	10.0	%	2.00	4.00	2.00	4.00	4.00			
			RBC: B	01/01/92	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00			
			PLATELETS	01/01/92	180.0	320.0	10**9/L	243.00	238.00	230.00	224.00	224.00			
			Na+	01/01/92	135.0	150.0	MMOL/L	142.00	136.00	141.00	140.00	140.00			
			K+	01/01/92	4.0	5.6	MMOL/L	4.60	4.00	4.30	4.10	4.10			
			CL-	01/01/92	95.0	105.0	MMOL/L	96.50	98.80	97.00	101.50	101.50			
			PO4-	01/01/92	0.6	1.3	MMOL/L	0.82	0.85	0.87	1.05	1.05			
			SGOT	01/01/92	1.0	12.0	U/L	5.00	3.00	3.50	4.50	4.50			
			SGPT	01/01/92	1.0	9.0	U/L	5.50	3.50	4.00	3.50	3.50			
			GAMMA-GT	01/01/92	1.8	1.8	UKAT/L	0.85	0.40	0.55	0.55	0.55			
			GLUCOSE	01/01/92	3.5	5.5	MMOL/L	4.30	5.00	4.50	4.70	4.70			
			ALK. PHOSPH.	01/01/92	135.0	360.0	MMOL/L	135.00	128.00	101.00	100.00	100.00			
			BUN	01/01/92	3.3	10.0	MMOL/L	7.70	4.80	5.30	6.50	6.50			
			CREATININE	01/01/92	44.0	101.0	UMOL/L	94.50	74.80	89.70	91.50	91.50			
			URIC ACID	01/01/92	214.0	458.0	UMOL/L	282.00	313.00	286.00	315.00	315.00			
			DIR BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	11.30	10.40	23.30	17.00	17.00			
			TOT BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	2.70	1.70	2.00	2.80	2.80			
			TOT. PROTEINS	01/01/92	65.0	85.0	G/L	83.00	78.00	80.00	75.00	75.00			
			ALBUMINE	01/01/92	34.0	55.0	G/L	48.20	52.30	46.90	49.30	49.30			
			TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	3.10	3.10	4.40	5.20	5.20			
			TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	0.81	0.46	0.76	0.30	0.30			
			GLOBULINS: ALPHA 1	01/01/92	1.3	6.0	G/L	1.80	1.80	3.90	1.10	1.10			
			GLOBULINS: ALPHA 2	01/01/92	5.0	9.0	G/L	8.10	7.80	8.90	8.60	8.60			
			GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	11.00	8.40	10.70	6.60	6.60			
			GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	13.90	7.70	9.60	9.50	9.50			
			T3	01/01/92	1.1	2.2	MMOL/L	2.00	2.00	2.00	2.00	2.00			
			T4	01/01/92	60.0	140.0	MMOL/L	50.00	50.00	50.00	50.00	50.00			
			92	LA	FEMALE	HR	01/01/92	112.0	140.0	G/L	160.00	148.00	138.00	135.00	138.00
						RFC	01/01/92	0.4	0.5	L/L	0.43	0.42	0.42	0.42	0.42
						RBC	01/01/92	3.7	4.7	10**12/L	4.21	4.20	4.17	4.24	4.24
RBC: N	01/01/92	4.0				8.8	10**9/L	10.20	5.00	5.40	9.50	9.50			
RBC: L	01/01/92	51.0				77.0	%	70.00	66.00	69.00	66.00	66.00			
RBC: E	01/01/92	16.0				38.0	%	20.00	28.00	23.00	32.00	32.00			
RBC: H	01/01/92	1.0				5.0	%	4.00	3.00	3.00	0.00	0.00			
RBC: B	01/01/92	2.0				10.0	%	3.00	3.00	5.00	2.00	2.00			
PLATELETS	01/01/92	0.0				1.0	%	0.00	0.00	0.00	0.00	0.00			
Na+	01/01/92	180.0				320.0	10**9/L	220.00	225.00	220.00	218.00	218.00			
K+	01/01/92	4.0				5.6	MMOL/L	4.40	4.40	4.70	4.90	4.90			
CL-	01/01/92	95.0				105.0	MMOL/L	97.20	102.60	94.50	98.20	98.20			
PO4-	01/01/92	0.6				1.3	MMOL/L	1.18	1.27	1.29	1.23	1.23			
SGOT	01/01/92	1.0				12.0	U/L	1.60	7.50	3.50	9.00	9.00			
SGPT	01/01/92	1.0				9.0	U/L	4.60	9.00	2.00	5.00	5.00			
GAMMA-GT	01/01/92	0.2				1.1	UKAT/L	0.65	0.50	0.44	0.44	0.44			
GLUCOSE	01/01/92	3.5				5.5	MMOL/L	3.20	4.40	4.20	4.20	4.20			
ALK. PHOSPH.	01/01/92	135.0				360.0	MMOL/L	183.00	152.00	183.00	179.00	179.00			
T3	01/01/92	1.1				2.2	MMOL/L	2.00	2.00	2.00	2.00	2.00			
T4	01/01/92	60.0				140.0	MMOL/L	50.00	50.00	50.00	50.00	50.00			
92	LA	FEMALE				HR	12/05/92	112.0	140.0	G/L	160.00	148.00	138.00	135.00	138.00
			RFC	12/05/92	0.4	0.5	L/L	0.43	0.42	0.42	0.42	0.42			
			RBC	12/05/92	3.7	4.7	10**12/L	4.21	4.20	4.17	4.24	4.24			
			RBC: N	12/05/92	4.0	8.8	10**9/L	10.20	5.00	5.40	9.50	9.50			
			RBC: L	12/05/92	51.0	77.0	%	70.00	66.00	69.00	66.00	66.00			
			RBC: E	12/05/92	16.0	38.0	%	20.00	28.00	23.00	32.00	32.00			
			RBC: H	12/05/92	1.0	5.0	%	4.00	3.00	3.00	0.00	0.00			
			RBC: B	12/05/92	2.0	10.0	%	3.00	3.00	5.00	2.00	2.00			
			PLATELETS	12/05/92	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00			
			Na+	12/05/92	180.0	320.0	10**9/L	220.00	225.00	220.00	218.00	218.00			
			K+	12/05/92	4.0	5.6	MMOL/L	4.40	4.40	4.70	4.90	4.90			
			CL-	12/05/92	95.0	105.0	MMOL/L	97.20	102.60	94.50	98.20	98.20			

1749

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit								
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
10	92	LA	FEMALE	CREATININE	01/01/92	44.0	88.0	UMOL/L	78.60	68.00	79.40	79.50			
				URIC ACID	01/01/92	149.0	405.0	UMOL/L	208.00	277.00	187.00	192.00			
				TOT BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	9.20	9.60	14.80	17.90			
				DIR BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	1.10	1.10	1.10	2.00			
				TOT. PROTEINS	01/01/92	65.0	85.0	G/L	69.00	72.00	75.00	73.00			
				ALBUMINE	01/01/92	34.0	55.0	G/L	45.50	47.40	50.90	46.60			
				TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	4.00	3.70	3.10	3.60			
				TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	0.81	1.00	0.64	1.12			
				GLOBULINS: ALPHA 1	01/01/92	1.3	6.0	G/L	2.60	1.70	1.90	2.10			
				GLOBULINS: ALPHA 2	01/01/92	5.0	9.0	G/L	6.60	6.70	5.60	7.10			
				GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	6.30	7.70	7.30	7.90			
				GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	8.00	9.50	9.30	9.30			
				T3	01/01/92	1.1	2.2	MMOL/L	1.20						
				T4	01/01/92	60.0	140.0	MMOL/L	75.00						
				93	AN	FEMALE	HR	01/01/92	112.0	140.0	G/L	143.00	136.00	135.00	140.00
							HTC	01/01/92	0.4	0.5	L/L	0.43	0.42	0.41	0.42
							RBC	01/01/92	3.7	4.7	10**12/L	4.24	4.18	4.05	4.16
							RBC: N	01/01/92	4.0	8.8	10**9/L	6.00	4.10	4.80	5.10
							RBC: L	01/01/92	51.0	77.0	%	62.00	50.00	58.00	68.00
							RBC: E	01/01/92	18.0	38.0	%	28.00	44.00	37.00	25.00
RBC: H	01/01/92	1.0	5.0				%	0.00	4.00	3.00	3.00				
RBC: B	01/01/92	2.0	10.0				%	4.00	2.00	2.00	4.00				
PLATELETS	01/01/92	0.0	1.0				%	0.00	0.00	0.00	0.00				
NA+	01/01/92	180.0	320.0				10**9/L	210.00	200.00	210.00	218.00				
K+	01/01/92	135.0	150.0				MMOL/L	142.00	140.00	147.00	142.00				
CL-	01/01/92	4.0	5.6				MMOL/L	4.80	5.20	4.80	4.10				
PO4--	01/01/92	95.0	105.0				MMOL/L	100.10	98.40	103.50	101.30				
SGPT	01/01/92	0.6	1.3				MMOL/L	1.04	1.28	1.19	1.21				
GAMMA-GT	01/01/92	1.0	12.0				U/L	4.00	3.80	3.00	4.50				
GLUCOSE	01/01/92	1.0	9.0				U/L	5.00	6.00	4.50	6.00				
ALK. PHOSPH.	01/01/92	0.2	1.1				UKAT/L	0.43	0.76	0.76	0.52				
BUN	01/01/92	3.5	5.5				MMOL/L	4.20	3.40	4.00	4.10				
CREATININE	01/01/92	135.0	360.0				MMOL/L	137.00	122.00	84.70	134.00				
URIC ACID	01/01/92	44.0	88.0				UMOL/L	5.30	5.20	6.30	6.30				
DIR BILIRUBIN	01/01/92	149.0	405.0	UMOL/L	72.80	82.70	66.90	71.10							
TOT. PROTEINS	01/01/92	8.6	20.5	UMOL/L	260.00	225.00	236.00	238.00							
ALBUMINE	01/01/92	65.0	85.0	G/L	9.60	18.20	9.00	9.00							
TOT. CHOLEST.	01/01/92	34.0	55.0	G/L	2.20	4.20	1.70	1.70							
TRIGLYCERIDES	01/01/92	3.1	6.2	MMOL/L	76.00	82.00	72.00	84.00							
GLOBULINS: ALPHA 1	01/01/92	0.5	1.9	MMOL/L	4.60	4.70	4.10	4.30							
GLOBULINS: ALPHA 2	01/01/92	1.3	6.0	G/L	0.47	2.14	1.36	1.05							
GLOBULINS: BETA	01/01/92	5.0	9.0	G/L	2.30	3.40	1.20	3.30							
GLOBULINS: GAMMA	01/01/92	5.0	13.0	G/L	6.90	8.90	8.00	8.60							
T3	01/01/92	10.0	17.0	G/L	10.60	13.90	11.10	13.30							
T4	01/01/92	1.1	2.2	MMOL/L	2.00			11.50							
	01/01/92	60.0	140.0	MMOL/L	123.00										

1750

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit						
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6		
10	94	PV	FEMALE	RB	01/01/92	112.0	140.0	G/L	133.00	08/04/92	22/04/92	06/05/92	20/05/92	
				HTC	01/01/92	0.4	0.5	L/L	0.40	0.40	0.40	0.40	128.00	130.00
				RBC	01/01/92	3.7	4.7	10**12/L	4.05	4.08	3.95	4.05	3.95	4.05
				WBC	01/01/92	4.0	8.8	10**9/L	4.90	4.70	6.40	5.60	6.40	5.60
				HGB: N	01/01/92	53.0	77.0	%	52.00	60.00	73.00	76.00	73.00	76.00
				HGB: L	01/01/92	18.0	38.0	%	42.00	38.00	23.00	22.00	23.00	22.00
				HGB: E	01/01/92	1.0	5.0	%	0.00	0.00	2.00	0.00	2.00	0.00
				HGB: H	01/01/92	2.0	10.0	%	6.00	6.00	2.00	2.00	2.00	0.00
				HGB: B	01/01/92	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00
				PLATELETS	01/01/92	180.0	320.0	10**9/L	200.00	200.00	210.00	218.00	210.00	218.00
				NA+	01/01/92	135.0	150.0	MMOL/L	135.00	140.00	140.00	144.00	144.00	138.00
				K+	01/01/92	4.0	5.6	MMOL/L	4.10	4.20	4.50	4.00	4.50	4.00
				CL-	01/01/92	95.0	105.0	MMOL/L	100.30	101.10	101.00	98.20	101.00	98.20
				PO4-	01/01/92	0.6	1.3	MMOL/L	1.13	1.22	1.12	1.16	1.12	1.16
				SGPT	01/01/92	1.0	12.0	U/L	4.00	4.00	2.00	3.50	2.00	3.00
				SGOT	01/01/92	1.0	9.0	U/L	2.70	6.00	3.00	3.00	3.00	3.00
				GAMMA-GT	01/01/92	0.2	1.1	UKAT/L	0.37	0.66	0.17	0.47	0.17	0.47
				GLUCOSE	01/01/92	3.5	5.5	MMOL/L	3.80	3.80	4.00	4.10	4.00	4.10
				ALK. PHOSPH.	01/01/92	135.0	360.0	MMOL/L	158.00	182.00	155.00	149.00	155.00	149.00
				BUN	01/01/92	3.3	10.0	MMOL/L	4.70	4.70	3.20	5.30	3.20	5.30
				CREATININE	01/01/92	44.0	88.0	UMOL/L	69.40	65.60	65.60	67.60	65.60	67.60
				URIC ACID	01/01/92	149.0	405.0	UMOL/L	313.00	300.00	245.00	293.00	245.00	293.00
				TOT BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	15.10	17.00	13.70	15.60	13.70	15.60
				DIR BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	2.20	2.50	1.40	1.40	1.40	1.40
				TOT. PROTEINS	01/01/92	65.0	85.0	G/L	80.00	75.00	68.00	84.00	75.00	68.00
				ALBUMINE	01/01/92	34.0	55.0	G/L	52.00	49.10	45.40	51.20	45.40	51.20
				TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	4.00	3.10	3.90	3.30	3.90	3.30
TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	0.72	1.56	0.85	1.19	0.85	1.19				
GLOBULINS: ALPHA 1	01/01/92	1.3	6.0	G/L	3.10	2.30	1.30	2.40	2.30	2.40				
GLOBULINS: ALPHA 2	01/01/92	5.0	9.0	G/L	7.30	6.70	6.00	10.40	6.00	10.40				
GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	7.40	6.20	6.90	8.90	6.90	8.90				
GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	10.20	10.70	8.40	11.20	8.40	11.20				
T3	01/01/92	1.1	2.2	MMOL/L	1.10	1.10	1.10	1.10	1.10	1.10				
T4	01/01/92	60.0	140.0	MMOL/L	60.00	60.00	60.00	60.00	60.00	60.00				
11	1	DF	MALE	RB	24/09/91	8.7	11.2	MMOL/L	9.80	07/10/91	23/10/91	08/11/91	22/11/91	
				HTC	24/09/91	0.4	0.5	L/L	0.40	0.40	0.40	0.40	9.62	9.55
				RBC	24/09/91	4.5	6.0	10-12/L	3.90	3.90	5.44	5.38	0.44	0.45
				WBC	24/09/91	5.0	10.0	10-9/L	10.28	11.80	10.30	10.00	5.08	5.38
				HGB: N	24/09/91	51.0	75.0	%	50.00	72.00	66.00	58.00	10.30	10.00
				HGB: L	24/09/91	20.0	40.0	%	36.00	18.00	24.00	32.00	66.00	58.00
				HGB: E	24/09/91	1.0	4.0	%	2.00	2.00	2.00	2.00	24.00	32.00
				HGB: H	24/09/91	2.0	8.0	%	2.00	2.00	2.00	2.00	2.00	2.00
				HGB: B	24/09/91	135.0	150.0	MMOL/L	148.00	145.00	142.00	141.00	2.00	2.00
				NA+	24/09/91	3.5	5.3	MMOL/L	4.10	5.10	4.70	4.80	142.00	141.00
K+	24/09/91	97.0	107.0	MMOL/L	99.00	94.00	103.00	104.00	4.70	4.80				
CL-	24/09/91	97.0	107.0	MMOL/L	99.00	94.00	103.00	104.00	5.10	4.80				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Screen	Visit							
					Date	Min	Max		Unit	Week 2	Week 4	Week 6				
11	1	DF	MALE	CA++	24/09/91	2.3	2.8	MMOL/L	2.28	2.36	2.50	2.28				
				PO4-	24/09/91	0.7	1.5	MMOL/L	1.14	0.75	0.72	0.74				
				SGOT	24/09/91	5.0	17.0	U/L	25.00	11.00	11.00	11.00				
				SGPT	24/09/91	5.0	23.0	U/L	85.00	41.00	43.00	10.00				
				GAMMA-GT	24/09/91	4.0	28.0	U/L	304.00	139.00	120.00					
				GLUCOSE	24/09/91	3.9	6.1	MMOL/L	4.60	4.40	4.50	4.40				
				ALK. PHOSPH.	24/09/91	40.0	200.0	U/L	102.00	94.00	87.00	97.00				
				BUN	24/09/91	2.1	9.6	MMOL/L	82.00	74.00	6.00	6.00				
				CREATININE	24/09/91	35.0	115.0	UMOL/L	82.00	74.00	80.00	92.00				
				URIC ACID	24/09/91	118.0	416.0	UMOL/L	229.00	306.00	311.00	303.00				
				TOT BILIRUBIN	24/09/91	7.0	18.0	UMOL/L		17.00	17.00					
				TOT. PROTEINS	24/09/91	0.0	64.3	UMOL/L		70.00	71.00	77.00				
				ALBUMINE	24/09/91	60.0	85.0	G/L	68.00	63.00	44.00	46.70				
				TOT. CHOLEST.	24/09/91	3.9	6.7	MMOL/L	42.00	6.80	6.20	6.60				
				TRIGLYCERIDES	24/09/91	0.5	2.3	MMOL/L	1.99	1.65	2.08	1.50				
				GLORULINS: ALPHA 1	24/09/91	1.0	4.0	g	2.20	2.30	2.10	6.70				
				GLORULINS: ALPHA 2	24/09/91	4.0	10.0	g	5.90	6.20	5.50	11.40				
				GLORULINS: BETA	24/09/91	5.0	11.0	g	9.30	10.30	9.60	11.40				
				GLORULINS: GAMMA	24/09/91	7.0	17.0	g	10.20	10.80	10.20	10.70				
				T3	24/09/91	1.2	3.2	NMOL/L	1.90							
				T4	24/09/91	50.0	155.0	NMOL/L	98.00							
				2	HB		FEMALE	HB	24/09/91	7.5	10.0	MMOL/L	8.50	8.51	8.36	8.47
								HTC	24/09/91	0.4	0.5	L/L	0.36	0.42	0.44	0.41
								RBC	24/09/91	4.1	5.4	10 ¹² /L	5.07	5.07	5.59	5.01
WBC	24/09/91	5.0	10.0					10 ⁹ /L	5.60	5.40	4.70	7.30				
WBC: N	24/09/91	51.0	75.0					%	52.00	56.00	32.00	62.00				
WBC: L	24/09/91	20.0	40.0					%	38.00	38.00	58.00	30.00				
WBC: E	24/09/91	1.0	4.0					%	8.00	6.00	6.00	4.00				
WBC: M	24/09/91	2.0	8.0					%	2.00							
WBC: B	24/09/91	0.0	1.0					%			0.00					
PLATELETS	24/09/91	150.0	350.0					10 ⁹ /L				200.00				
Na+	24/09/91	135.0	150.0					MMOL/L	146.00	142.00	142.00	141.00				
K+	24/09/91	3.5	5.3					MMOL/L	4.00	4.70	4.10	4.50				
CL-	24/09/91	97.0	107.0					MMOL/L	98.00	101.00	105.00	98.00				
CA++	24/09/91	2.3	2.8					MMOL/L	2.08	2.50	2.26	2.30				
PO4-	24/09/91	0.7	1.5					MMOL/L	1.06	0.93	0.78	1.00				
SGOT	24/09/91	5.0	15.0					U/L	16.00	21.00	10.00	9.00				
SGPT	24/09/91	5.0	19.0					U/L	15.00	14.00	11.00	12.00				
GAMMA-GT	24/09/91	4.0	18.0					U/L	30.00	49.00	27.00	12.00				
GLUCOSE	24/09/91	3.9	6.1					MMOL/L	5.30	6.40	5.60	5.00				
ALK. PHOSPH.	24/09/91	40.0	200.0					U/L	114.00	156.00	122.00	129.00				
BUN	24/09/91	2.1	9.6					MMOL/L	4.40	6.40	5.40	5.40				
CREATININE	24/09/91	36.0	115.0					UMOL/L	96.00	96.00	86.00	79.00				
URIC ACID	24/09/91	118.0	416.0					UMOL/L	152.00	339.00	194.00	174.00				
TOT. PROTEINS	24/09/91	60.0	85.0					G/L	62.00	67.00	64.00	64.00				
ALBUMINE	24/09/91	35.0	50.0	G/L	39.00	40.00	44.00	41.00								
TOT. CHOLEST.	24/09/91	3.9	6.7	MMOL/L	4.40	4.80	5.90	4.80								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
11	2	HB	FEMALE	TRIGLYCERIDES	24/09/91	0.5	2.3	MMOL/L	1.08	1.22	0.72	1.08				
				GLOBULINS: ALPHA 1	24/09/91	1.0	4.0	Z	2.70	3.60	3.00	2.40				
				GLOBULINS: ALPHA 2	24/09/91	4.0	10.0	Z	5.90	7.60	6.90	5.70				
				GLOBULINS: BETA	24/09/91	5.0	11.0	Z	8.20	11.00	10.30	7.40				
				GLOBULINS: GAMMA	24/09/91	7.0	17.0	Z	9.70	11.60	13.10	10.40				
				T3	24/09/91	1.2	3.2	NMOL/L	1.50	.	.	.				
				T4	24/09/91	50.0	155.0	NMOL/L	83.00	.	.	.				
				3	RF		FEMALE	HB	24/09/91	7.5	10.0	NMOL/L	11/10/91	24/10/91	05/11/91	19/11/91
								HTC	24/09/91	0.4	0.5	L/L	9.30	8.94	8.92	8.28
								RBC	24/09/91	4.1	5.4	10 ¹² /L	0.36	0.43	0.43	0.40
HBC	24/09/91	5.0	10.0					10 ⁹ /L	7.80	4.85	4.85	4.54				
HRC: N	24/09/91	51.0	75.0					Z	74.00	66.00	6.80	7.50				
HRC: L	24/09/91	20.0	40.0					Z	24.00	52.00	58.00	72.00				
HRC: E	24/09/91	1.0	4.0					Z	2.00	32.00	36.00	26.00				
HRC: M	24/09/91	2.0	8.0					Z	2.00	2.00	4.00	2.00				
PLATELETS	24/09/91	150.0	350.0					10 ⁹ /L	141.00	137.00	140.00	190.00				
NA+	24/09/91	155.0	190.0					NMOL/L	3.20	4.30	3.90	4.60				
4	BA		MALE	K+	24/09/91	3.5	5.3	NMOL/L	100.00	113.00	100.00	96.00				
				Cl-	24/09/91	97.0	107.0	NMOL/L	2.20	2.50	2.10	2.20				
				Ca++	24/09/91	2.3	2.8	NMOL/L	0.74	0.87	0.90	1.30				
				PO4-	24/09/91	0.7	1.5	NMOL/L	19.00	37.00	17.00	24.00				
				SGPT	24/09/91	5.0	15.0	U/L	44.00	15.00	22.00	18.00				
				SGPT	24/09/91	4.0	18.0	U/L	6.40	34.00	27.00	18.00				
				GLUCOSE	24/09/91	3.9	6.1	MMOL/L	154.00	151.00	147.00	127.00				
				BUN	24/09/91	2.1	9.6	MMOL/L	4.80	6.00	4.40	6.69				
				CREATININE	24/09/91	36.0	115.0	UMOL/L	72.00	100.00	72.00	81.00				
				URIC ACID	24/09/91	118.0	416.0	UMOL/L	205.00	189.00	267.00	259.00				
TOT. PROTEINS	24/09/91	60.0	85.0	G/L	65.00	74.00	66.00	69.00								
ALBUMINE	24/09/91	35.0	50.0	G/L	38.00	41.00	40.00	40.00								
TOT. CHOLEST.	24/09/91	3.9	6.7	MMOL/L	5.90	5.00	6.20	5.80								
TRIGLYCERIDES	24/09/91	0.5	2.3	MMOL/L	1.08	0.96	1.18	1.18								
GLOBULINS: ALPHA 1	24/09/91	1.0	4.0	Z	1.70	3.70	3.30	3.30								
GLOBULINS: ALPHA 2	24/09/91	4.0	10.0	Z	6.10	7.70	6.40	6.40								
GLOBULINS: BETA	24/09/91	5.0	11.0	Z	9.40	9.90	9.20	9.20								
GLOBULINS: GAMMA	24/09/91	7.0	17.0	Z	11.40	12.80	12.40	12.40								
T3	24/09/91	1.2	3.2	NMOL/L	1.80	.	.	.								
T4	24/09/91	50.0	155.0	NMOL/L	135.00	.	.	.								
4	BA		MALE	HB	24/09/91	8.7	11.2	NMOL/L	11/10/91	28/10/91	12/11/91	25/11/91				
				HTC	24/09/91	0.4	0.5	L/L	0.39	0.45	0.46	0.41				
				RBC	24/09/91	4.5	6.0	10 ¹² /L	7.00	4.73	5.23	4.52				
				HBC	24/09/91	5.0	10.0	10 ⁹ /L	66.00	8.00	6.80	6.40				
				HRC: N	24/09/91	51.0	75.0	Z	66.00	72.00	58.00	70.00				
				HRC: L	24/09/91	20.0	40.0	Z	30.00	22.00	26.00	26.00				

1753

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXYTINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Screen	Visit								
				Date	Min	Max		Unit	Week 2	Week 4	Week 6					
11	4	BA	MALE	WBC: E	24/09/91	1.0	4.0	X	4.00	6.00	10.00	2.00				
				WBC: M	24/09/91	2.0	8.0	X		6.00	6.00	2.00				
				PLATELETS	24/09/91	150.0	350.0	10-9/L			162.00	200.00				
				Na+	24/09/91	135.0	150.0	MMOL/L	141.00	147.00	144.00	144.00				
				K+	24/09/91	3.5	5.3	MMOL/L	4.20	4.20	4.30	4.20				
				CL-	24/09/91	97.0	107.0	MMOL/L	100.00	115.00	99.00	102.00				
				Ca++	24/09/91	2.3	2.8	MMOL/L	2.20	2.30	2.29	2.29				
				PO4-	24/09/91	0.7	1.5	MMOL/L	0.95	1.10	1.00	1.00				
				SGPT	24/09/91	5.0	17.0	U/L	20.00	11.00	14.00	11.00				
				GAMMA-GT	24/09/91	5.0	23.0	U/L	23.00	11.00	16.00	11.00				
				GLUCOSE	24/09/91	4.0	28.0	U/L	45.00	19.00	28.00	28.00				
				ALK. PHOSPH.	24/09/91	3.5	6.1	MMOL/L	5.10	5.00	5.00	4.80				
				BUN	24/09/91	40.0	200.0	U/L	73.00	119.00	114.00	117.00				
				CREATININE	24/09/91	2.1	9.6	MMOL/L	8.80	8.80	8.80	9.60				
				URIC ACID	24/09/91	36.0	115.0	MMOL/L	6.80	93.00	102.00	106.00				
				TOT. PROTEINS	24/09/91	118.0	416.0	UMOL/L	73.00	360.00	360.00	315.00				
				ALBUMINE	24/09/91	60.0	85.0	G/L	71.00	347.00	372.00	79.00				
				TOT. CHOLEST.	24/09/91	35.0	50.0	G/L	42.00	43.00	43.00	44.00				
				TRIGLYCERIDES	24/09/91	3.9	6.7	MMOL/L	8.70	6.50	7.30	7.30				
				GLUCOLINS: ALPHA 1	24/09/91	0.5	2.3	MMOL/L	3.80	2.00	2.26	1.54				
				GLUCOLINS: ALPHA 2	24/09/91	1.0	4.0	X	2.00	2.00	2.00	3.30				
				GLUCOLINS: BETA	24/09/91	4.0	10.0	X	6.50	5.60	4.50	7.50				
				GLUCOLINS: GAMMA	24/09/91	5.0	11.0	X	12.00	8.00	8.40	10.80				
				T3	24/09/91	7.0	17.0	X	12.50	11.10	10.20	13.20				
				T4	24/09/91	1.2	3.2	MMOL/L	1.40							
					24/09/91	50.0	155.0	MMOL/L	105.00							
				5	ZH	MALE	MALE	HR	24/09/91	8.7	11.2	MMOL/L	14/10/91	28/10/91	12/11/91	
								HTC	24/09/91	0.4	0.5	L/L	9.80	11.10	10.10	
ERC	24/09/91	4.5	6.0					10-12/L	0.43	0.52	0.51					
WBC: N	24/09/91	5.0	10.0					10-9/L	17.60	5.93	6.20					
WBC: L	24/09/91	51.0	75.0					X	76.00	10.30	12.40					
WBC: E	24/09/91	20.0	40.0					X	20.00	60.00	58.00					
WBC: H	24/09/91	1.0	6.0					X	2.00	34.00	34.00					
Na+	24/09/91	135.0	150.0					MMOL/L	4.00	2.00	4.00					
K+	24/09/91	3.5	5.3					MMOL/L	144.00	140.00	140.00					
CL-	24/09/91	97.0	107.0					MMOL/L	6.30	4.40	4.40					
Ca++	24/09/91	2.3	2.8					MMOL/L	102.00	107.00	101.00					
PO4-	24/09/91	0.7	1.5					MMOL/L	2.20	2.30	2.30					
SGPT	24/09/91	5.0	17.0					U/L	0.81	1.00	1.00					
GAMMA-GT	24/09/91	5.0	23.0					U/L	12.00	10.00	8.00					
GLUCOSE	24/09/91	4.0	28.0					U/L	11.00	14.00	12.00					
ALK. PHOSPH.	24/09/91	3.5	6.1					MMOL/L	23.00	33.00	32.00					
BUN	24/09/91	40.0	200.0					U/L	4.60	4.80	4.80					
CREATININE	24/09/91	2.1	9.6					MMOL/L	4.40	4.40	4.00					
URIC ACID	24/09/91	36.0	115.0					UMOL/L	89.00	71.00	79.00					
T3	24/09/91	118.0	416.0					UMOL/L	257.00	238.00	324.00					
T4	24/09/91	11.0	34.0					MMOL/L	59.00	68.00	66.00					

1754

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R8D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Date	Laboratory Range			Visit										
						Min	Max	Unit	Screen	Week 2	Week 4	Week 6							
11	5	ZK	MALE	ALBUMINE	24/09/91	35.0	50.0	G/L	38.00	43.00	42.00	42.00							
				TOT. CHOLEST.	24/09/91	3.9	6.7	MMOL/L	5.10	5.80	5.20								
				TRIGLYCERIDES	24/09/91	0.5	2.3	MMOL/L		2.00	2.62								
				GLOBULINS: ALPHA 1	24/09/91	1.0	4.0	X	2.00	3.20	2.72								
				GLOBULINS: ALPHA 2	24/09/91	4.0	10.0	X	6.40	8.00	7.92								
				GLOBULINS: BETA	24/09/91	5.0	11.0	X	8.20	9.70	8.32								
				GLOBULINS: GAMMA	24/09/91	7.0	17.0	X	6.50	6.80	6.66								
				T3	24/09/91	1.2	3.2	MMOL/L	1.70										
				T4	24/09/91	50.0	155.0	MMOL/L	115.00										
				6	VP		MALE	HB	24/09/91	8.7	11.2	MMOL/L	16/10/91	29/10/91	12/11/91	26/11/91			
								HTC	24/09/91	0.4	0.5	L/L	10.20	10.00	9.51	9.61			
								RBC	24/09/91	4.5	6.0	10 ¹² /L	0.43	4.90	0.43	0.44			
								WBC	24/09/91	5.0	10.0	10 ⁹ /L	6.80	8.00	4.59	4.92			
								WBC: N	24/09/91	51.0	75.0	X	62.00	58.00	6.60	8.60			
								WBC: L	24/09/91	20.0	40.0	X	30.00	26.00	64.00	50.00			
								WBC: E	24/09/91	1.0	4.0	X		2.00	2.00	40.00			
								WBC: M	24/09/91	2.0	8.0	X	4.00	6.00	4.00	8.00			
PLATELETS	24/09/91	150.0	350.0					10 ⁹ /L		250.00									
NA+	24/09/91	135.0	150.0					MMOL/L	144.00	148.00	142.00	147.00							
K+	24/09/91	3.5	5.3					MMOL/L	4.40	5.00	4.50	4.70							
CL-	24/09/91	97.0	107.0					MMOL/L	99.00	102.00	104.00	105.00							
CA++	24/09/91	2.3	2.8					MMOL/L	2.20	2.28	2.30	2.30							
PO4-	24/09/91	0.7	1.5					MMOL/L	0.79	1.10	0.76	0.76							
SGPT	24/09/91	5.0	17.0					U/L	19.00	11.00	13.00	12.00							
SGOT	24/09/91	5.0	23.0					U/L	35.00	19.00	20.00	27.00							
GAMMA-GT	24/09/91	4.0	28.0					U/L	33.00	16.00	25.00								
GLUCOSE	24/09/91	3.9	6.1	MMOL/L	4.20	4.60	4.30	4.60											
BUN	24/09/91	40.0	200.0	U/L	119.00	125.00	89.00	138.00											
CREATININE	24/09/91	2.1	9.6	MMOL/L	4.80	5.20	5.20	6.60											
URIC ACID	24/09/91	36.0	115.0	UMOL/L	75.00	85.00	83.00	88.00											
DIR BILIRUBIN	24/09/91	118.0	416.0	UMOL/L	413.00	442.00	398.00	321.00											
TOT BILIRUBIN	24/09/91	7.0	18.0	UMOL/L			17.00												
TOT. PROTEINS	24/09/91	0.0	4.3	UMOL/L			12.00												
ALBUMINE	24/09/91	60.0	85.0	G/L	71.00	78.00	69.00	69.00											
TOT. CHOLEST.	24/09/91	35.0	50.0	G/L	42.00	49.20	40.10	45.70											
TRIGLYCERIDES	24/09/91	3.9	6.7	MMOL/L	5.40	5.40	5.80												
GLOBULINS: ALPHA 1	24/09/91	0.5	2.3	MMOL/L	1.40	0.87	1.45	1.30											
GLOBULINS: ALPHA 2	24/09/91	1.0	4.0	X	2.20	2.70	2.10	2.30											
GLOBULINS: BETA	24/09/91	4.0	10.0	X	6.10	6.10	5.20	3.50											
GLOBULINS: GAMMA	24/09/91	5.0	11.0	X	8.80	8.80	6.90	6.60											
T3	24/09/91	7.0	17.0	X	10.10	11.10	8.70	8.60											
T4	24/09/91	1.2	3.2	MMOL/L	1.60														
7	KK		FEMALE	HB	24/09/91	7.5	10.0	MMOL/L	17/10/91	01/11/91	15/11/91	04/12/91							
				HTC	24/09/91	0.4	0.5	L/L	7.40	7.29	7.94	6.92							
									0.34	0.34	0.35								

1755

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
11	7	KK	FEMALE	RBC	24/09/91	4.1	5.4	10-12/L		4.43	4.22	4.22				
				RBC: N	24/09/91	5.0	10.0	10-9/L	3.80	4.00	3.50	4.22				
				RBC: L	24/09/91	51.0	75.0	Z	42.00	4.00	3.20	3.20				
				RBC: E	24/09/91	20.0	40.0	Z	54.00	58.00	54.00	38.00				
				RBC: H	24/09/91	1.0	4.0	Z	2.00	2.00	4.00	58.00				
				PLATELETS	24/09/91	2.0	8.0	Z	2.00	4.00	4.00	2.00				
				NA+	24/09/91	150.0	350.0	10-9/L				180.00				
				K+	24/09/91	35.0	150.0	MMOL/L	145.00	148.00	143.00	141.00				
				CL-	24/09/91	3.5	5.3	MMOL/L	4.50	5.20	5.20	4.70				
				CA++	24/09/91	97.0	107.0	MMOL/L	97.00	105.00	103.00	106.00				
				PO4--	24/09/91	2.3	2.8	MMOL/L	2.20	2.30	2.30	2.60				
				SGPT	24/09/91	5.0	15.0	U/L	24.00	12.00	0.99	0.87				
				GAMMA-GT	24/09/91	5.0	19.0	U/L	74.00	10.00	11.00	15.00				
				GLUCOSE	24/09/91	4.0	18.0	U/L	64.00	24.00	8.00	11.00				
				ALK. PHOSPH.	24/09/91	3.9	6.1	MMOL/L	4.70	4.00	6.00	4.40				
				BUN	24/09/91	40.0	200.0	U/L	191.00	126.00	92.00	102.00				
				CREATININE	24/09/91	2.1	9.6	MMOL/L	5.20	4.40	4.00	5.60				
				URIC ACID	24/09/91	36.0	115.0	UMOL/L	87.00	70.00	80.00	80.00				
				TOT. PROTEINS	24/09/91	118.0	416.0	UMOL/L	194.00	186.00	275.00	160.00				
				ALBUMINE	24/09/91	60.0	185.0	G/L	78.00	66.00	69.00	68.00				
				TOT. CHOLEST.	24/09/91	35.0	50.0	G/L	44.00	42.00	42.00	44.00				
				TRIGLYCERIDES	24/09/91	3.9	6.7	MMOL/L	7.70	8.70	8.90	7.90				
				GLUCOLINS: ALPHA 1	24/09/91	0.5	2.3	MMOL/L	1.42	1.36	1.63	0.98				
				GLUCOLINS: ALPHA 2	24/09/91	1.0	4.0	Z	2.70	2.40	2.50	2.10				
				GLUCOLINS: BETA	24/09/91	4.0	10.0	Z	9.60	6.10	6.20	5.40				
				GLUCOLINS: GAMMA	24/09/91	5.0	11.0	Z	11.60	8.80	9.00	7.90				
				T3	24/09/91	7.0	17.0	Z	14.20	12.30	12.80	12.20				
				T4	24/09/91	1.2	3.2	MMOL/L	1.50							
					24/09/91	50.0	155.0	MMOL/L	97.00							
				8	KF		FEMALE	HB	24/09/91	7.5	10.0	MMOL/L		05/11/91	02/12/91	
								HTC	24/09/91	0.4	0.5	L/L	8.70	8.70	8.66	
								RBC	24/09/91	4.1	5.4	10-12/L	0.46	0.35	0.43	
RBC: N	24/09/91	5.0	10.0					10-9/L	5.14	4.06	4.67					
RBC: L	24/09/91	51.0	75.0					Z	7.00	7.00	3.00					
RBC: E	24/09/91	20.0	40.0					Z	50.00	34.00	58.00					
RBC: H	24/09/91	2.0	8.0					Z	46.00	62.00	38.00					
PLATELETS	24/09/91	2.0	8.0					Z	4.00	4.00	4.00					
NA+	24/09/91	150.0	350.0					10-9/L	190.00	190.00	180.00					
K+	24/09/91	35.0	150.0					MMOL/L	144.00	143.00	143.00					
CL-	24/09/91	3.5	5.3					MMOL/L	4.10	4.40						
CA++	24/09/91	97.0	107.0					MMOL/L	103.00	100.00						
PO4--	24/09/91	2.3	2.8					MMOL/L	2.10	2.26						
SGPT	24/09/91	0.7	1.5					MMOL/L	1.10	0.82						
SGPT	24/09/91	5.0	15.0					U/L	12.00	13.00	12.00					
GAMMA-GT	24/09/91	5.0	19.0					U/L	39.00	18.00	22.00					
GLUCOSE	24/09/91	4.0	18.0	U/L	42.00	14.00	14.00									
ALK. PHOSPH.	24/09/91	3.9	6.1	MMOL/L	4.40	4.40	3.20									
	24/09/91	40.0	200.0	U/L	156.00	101.00	101.00									

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
11	8	KF	FEMALE	CREATININE	24/09/91	2.1	9.6	MMOL/L	4.80	7.00	6.00					
				URIC ACID	24/09/91	36.0	115.0	UMOL/L	69.00	73.00	75.00					
				TOT. PROTEINS	24/09/91	118.0	416.0	UMOL/L	171.00	157.00	211.00					
				ALBUMINE	24/09/91	60.0	85.0	G/L	66.00	67.00	65.00					
				TOT. CHOLEST.	24/09/91	35.0	50.0	G/L	40.00	40.00	39.80					
				TRIGLYCERIDES	24/09/91	3.9	6.7	MMOL/L	7.40	6.80						
				GLOBULINS: ALPHA 1	24/09/91	0.5	2.3	MMOL/L	1.18	1.36	0.76					
				GLOBULINS: ALPHA 2	24/09/91	1.0	4.0	Z	3.40	3.40	2.70					
				GLOBULINS: BETA	24/09/91	4.0	10.0	Z	5.50	5.50	4.80					
				GLOBULINS: GAMMA	24/09/91	5.0	11.0	Z	9.80	9.80	8.40					
				T3	24/09/91	7.0	17.0	Z	10.00	10.00	9.40					
				T4	24/09/91	1.2	3.2	MMOL/L	1.70							
					24/09/91	50.0	155.0	MMOL/L	132.00							
				9	FI		FEMALE	HR	24/09/91	7.5	10.0	MMOL/L	8.34	8.61	7.98	18/12/91
								RBC	24/09/91	0.4	0.5	L/L	0.41	0.41	0.36	8.16
								WBC	24/09/91	4.1	5.4	10 ⁹ /L	4.87	4.81	4.54	0.39
								MEC: N	24/09/91	5.0	10.0	10 ⁹ /L	4.70	6.50	4.30	4.52
								MEC: L	24/09/91	51.0	75.0	Z	48.00	54.00	54.00	4.60
								MEC: H	24/09/91	20.0	40.0	Z	48.00	44.00	44.00	52.00
								PLATELETS	24/09/91	2.0	8.0	Z	4.00	2.00	2.00	46.00
NA+	24/09/91	150.0	350.0					10 ⁹ /L		250.00	200.00	2.00				
K+	24/09/91	135.0	150.0					MMOL/L	147.00	143.00	143.00	145.00				
CL-	24/09/91	3.5	5.3					MMOL/L	4.60	4.10	3.90	4.00				
Ca++	24/09/91	97.0	107.0					MMOL/L	103.00	97.00	101.00	107.00				
PO4--	24/09/91	2.3	2.8					MMOL/L	2.40	2.10	2.40	2.30				
SGPT	24/09/91	0.7	1.5					MMOL/L	0.87	0.90	0.81	1.10				
GAMMA-GT	24/09/91	5.0	15.0					U/L	26.00	13.00	16.00	13.00				
GLUCOSE	24/09/91	4.0	18.0					U/L	26.00	20.00	26.00	38.00				
ALK. PHOSPH.	24/09/91	3.9	6.1					MMOL/L	14.00	20.00	10.00	7.00				
BUN	24/09/91	40.0	200.0					U/L	4.50	4.30	5.20	4.80				
CREATININE	24/09/91	2.1	9.6					MMOL/L	133.00	128.00	132.00	139.00				
URIC ACID	24/09/91	36.0	115.0					UMOL/L	3.00	6.00	4.40	4.40				
TOT. PROTEINS	24/09/91	118.0	416.0					UMOL/L	68.00	78.00	70.00	71.00				
ALBUMINE	24/09/91	60.0	85.0	G/L	317.00	317.00	248.00	201.00								
TOT. CHOLEST.	24/09/91	35.0	50.0	G/L	70.00	67.00	67.00	79.00								
TRIGLYCERIDES	24/09/91	3.9	6.7	MMOL/L	42.00	45.10	41.00	45.00								
GLOBULINS: ALPHA 1	24/09/91	0.5	2.3	MMOL/L	5.00	5.20	5.20	4.10								
GLOBULINS: ALPHA 2	24/09/91	1.0	4.0	Z	1.63	1.81	1.23	1.48								
GLOBULINS: BETA	24/09/91	4.0	10.0	Z	6.10	6.10	2.20	3.10								
GLOBULINS: GAMMA	24/09/91	5.0	11.0	Z	9.30	9.30	6.00	7.30								
T3	24/09/91	7.0	17.0	Z	11.00	11.00	7.10	11.90								
T4	24/09/91	1.2	3.2	MMOL/L	1.60	1.60	10.70	14.80								
	24/09/91	50.0	155.0	MMOL/L	129.00											
10	BJ		FEMALE	HR	24/09/91	7.5	10.0	MMOL/L	19/11/91	9.20	03/12/91	17/12/91	30/12/91			
											8.56	8.69	8.99			

1757

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit				
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6
11	10	BJ	FEMALE	HTC	24/09/91	0.4	0.5	L/L	0.40	0.41	0.41	0.42
				RBC	24/09/91	4.1	5.4	10-12/L	4.58	4.58	4.70	4.88
				HGB: N	24/09/91	5.0	10.0	10-9/L	4.00	3.00	3.90	3.90
				HGB: L	24/09/91	51.0	75.0	X	72.00	72.00	66.00	64.00
				HGB: E	24/09/91	20.0	40.0	X	22.00	28.00	22.00	32.00
				HGB: M	24/09/91	1.0	4.0	X	2.00	4.00	4.00	2.00
				PLATELETS	24/09/91	2.0	8.0	X	4.00	8.00	8.00	2.00
				NA+	24/09/91	150.0	350.0	10-9/L	150.00	170.00	160.00	170.00
				K+	24/09/91	135.0	150.0	MMOL/L	147.00	140.00	141.00	141.00
				CL-	24/09/91	3.5	5.3	MMOL/L	4.60	4.20	4.80	4.30
				CA++	24/09/91	2.3	2.8	MMOL/L	2.22	2.20	2.10	2.31
				PO4--	24/09/91	0.7	1.5	MMOL/L	0.70	0.81	0.60	0.71
				SGPT	24/09/91	5.0	15.0	U/L	9.00	6.00	10.00	8.00
				GAMMA-GT	24/09/91	5.0	19.0	U/L	9.00	7.00	10.00	9.00
				GLUCOSE	24/09/91	4.0	18.0	U/L	9.00	12.00	10.00	11.00
				ALK. PHOSPH.	24/09/91	3.9	6.1	MMOL/L	4.40	3.60	4.20	4.80
				BUN	24/09/91	40.0	200.0	U/L	101.00	58.00	91.00	58.00
				CREATININE	24/09/91	2.1	8.6	MMOL/L	4.00	4.00	5.40	5.20
				URIC ACID	24/09/91	38.0	115.0	UMOL/L	73.00	65.00	66.00	74.00
				TOT. PROTEINS	24/09/91	118.0	416.0	UNOL/L	179.00	180.00	148.00	174.00
				ALBUMINE	24/09/91	60.0	85.0	G/L	59.00	62.00	78.00	76.00
				TOT. CHOLEST.	24/09/91	35.0	50.0	G/L	39.00	37.50	47.00	42.00
				TRIGLICERIDES	24/09/91	0.5	6.7	MMOL/L	3.90	5.20	5.00	5.70
				GLOBULINS: ALPHA 1	24/09/91	0.5	2.3	MMOL/L	1.18	1.10	1.80	1.80
				GLOBULINS: ALPHA 2	24/09/91	1.0	4.0	X	2.20	2.10	3.50	3.56
				GLOBULINS: BETA	24/09/91	4.0	10.0	X	4.80	4.40	5.60	7.51
				GLOBULINS: GAMMA	24/09/91	5.0	11.0	X	7.10	7.20	9.60	9.50
				T3	24/09/91	7.0	17.0	X	10.20	10.80	14.00	17.74
				T4	24/09/91	1.2	3.2	MMOL/L	1.40	1.40	1.40	1.40
					24/09/91	50.0	155.0	MMOL/L	105.00	105.00	105.00	105.00
11	NGY		FEMALE	HB	24/09/91	7.5	10.0	MMOL/L	9.35	9.00	9.60	9.17
				HTC	24/09/91	0.4	0.5	L/L	0.44	0.44	0.45	0.45
				RBC	24/09/91	4.1	5.4	10-12/L	5.51	5.24	5.51	5.18
				HGB: N	24/09/91	5.0	10.0	10-9/L	9.70	7.80	8.90	9.40
				HGB: L	24/09/91	51.0	75.0	X	60.00	36.00	46.00	64.00
				HGB: E	24/09/91	20.0	40.0	X	36.00	56.00	44.00	32.00
				HGB: M	24/09/91	1.0	4.0	X	0.00	2.00	6.00	4.00
				PLATELETS	24/09/91	2.0	8.0	X	4.00	6.00	4.00	4.00
				NA+	24/09/91	150.0	350.0	10-9/L	220.00	180.00	260.00	280.00
				K+	24/09/91	135.0	150.0	MMOL/L	149.00	146.00	147.00	147.00
				CL-	24/09/91	3.5	5.3	MMOL/L	4.20	4.50	5.40	5.60
				CA++	24/09/91	97.0	107.0	MMOL/L	106.00	107.00	98.00	99.00
				PO4--	24/09/91	2.3	2.8	MMOL/L	2.40	2.41	2.30	2.37
				SGPT	24/09/91	0.7	1.5	MMOL/L	0.75	0.97	1.00	1.00
					24/09/91	5.0	15.0	U/L	11.00	12.00	16.00	14.00
					24/09/91	5.0	19.0	U/L	18.00	14.00	12.00	24.00

1758

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
11	11	NGY	FEMALE	GAMMA-GT	24/09/91	4.0	18.0	U/L		10.00	10.00	15.00				
				GLUCOSE	24/09/91	3.9	6.1	MMOL/L	5.00	5.00	4.20	4.80				
				ALK. PHOSPH.	24/09/91	40.0	200.0	U/L	155.00	144.00	174.00	152.00				
				BUN	24/09/91	2.1	9.6	MMOL/L	5.80	5.40	6.20	6.60				
				CREATININE	24/09/91	36.0	115.0	UMOL/L	88.00	82.00	68.00	79.00				
				URIC ACID	24/09/91	118.0	416.0	UMOL/L	245.00	267.00	319.00	294.00				
				TOT. PROTEINS	24/09/91	60.0	85.0	G/L	67.00	68.00	70.00	71.00				
				ALBUMINE	24/09/91	35.0	50.0	G/L	37.20	43.00	44.00	41.00				
				TOT. CHOLEST.	24/09/91	3.9	6.7	MMOL/L	6.00	6.20	5.70	6.60				
				TRIGLYCERIDES	24/09/91	0.5	2.3	MMOL/L	1.85	1.72	1.28	1.28				
				GLORULINS: ALPHA 1	24/09/91	1.0	4.0	Z	2.90	3.05	2.80	2.67				
				GLORULINS: ALPHA 2	24/09/91	4.0	10.0	Z	7.50	6.08	5.90	6.20				
				GLORULINS: BETA	24/09/91	5.0	11.0	Z	10.30	11.61	11.40	12.17				
				GLORULINS: GAMMA	24/09/91	7.0	17.0	Z	9.00	11.64	15.00	12.26				
				T3	24/09/91	1.2	3.2	NMOL/L	1.20							
				T4	24/09/91	50.0	155.0	NMOL/L	123.00							
				12	PJ		FEMALE	IB	24/09/91	7.5	10.0	MMOL/L	10/12/91	7.91	07/01/92	20/01/92
								HTC	24/09/91	0.4	0.5	L/L	0.38	0.39	0.40	0.38
								RBC	24/09/91	4.1	5.4	10-12/L	4.18	4.52	4.30	4.14
								RBC: N	24/09/91	5.0	10.0	10-9/L	4.30	6.90	8.80	7.30
								RBC: L	24/09/91	51.0	75.0	X	56.00	58.00	62.00	58.00
								RBC: E	24/09/91	20.0	40.0	X	40.00	20.00	34.00	36.00
								RBC: M	24/09/91	1.0	4.0	X	0.00	10.00	4.00	2.00
								RBC: B	24/09/91	2.0	8.0	X	4.00	12.00	4.00	4.00
PLATELETS	24/09/91	0.0	1.0					Z	0.00	0.00		0.00				
NA+	24/09/91	150.0	350.0					10-9/L	160.00	250.00		200.00				
K+	24/09/91	135.0	150.0					MMOL/L	149.00	145.00	146.00	140.00				
CL-	24/09/91	97.0	107.0					MMOL/L	102.00	100.00	102.00	105.00				
CA++	24/09/91	2.3	2.8					MMOL/L	2.60		2.48	2.32				
PO4--	24/09/91	0.7	1.5					MMOL/L	0.82		0.90	0.90				
SGPT	24/09/91	5.0	15.0					U/L	11.00	17.00	14.00	13.00				
GAMMA-GT	24/09/91	5.0	19.0					U/L	9.00	16.00	16.00	18.00				
GLUCOSE	24/09/91	4.0	18.0					U/L	6.00	11.00	10.00	12.00				
ALK. PHOSPH.	24/09/91	3.9	6.1					MMOL/L	4.00	6.00	4.40	4.80				
BUN	24/09/91	40.0	200.0					U/L	111.00	96.00	96.00	94.00				
CREATININE	24/09/91	2.1	9.6					MMOL/L	7.20	6.00	4.60	4.80				
URIC ACID	24/09/91	35.0	115.0					UMOL/L	83.00	77.00	92.00	75.00				
TOT. PROTEINS	24/09/91	118.0	416.0					UMOL/L	188.00	227.00	216.00	180.00				
ALBUMINE	24/09/91	60.0	85.0					G/L	65.00	70.00	71.00	75.00				
TOT. CHOLEST.	24/09/91	3.9	6.7					MMOL/L	42.00	43.00	39.00	39.00				
TRIGLYCERIDES	24/09/91	0.5	2.3	MMOL/L	5.40	5.30	6.40	5.70								
GLORULINS: ALPHA 1	24/09/91	0.5	2.3	MMOL/L	1.28		1.28	1.75								
GLORULINS: ALPHA 2	24/09/91	1.0	4.0	Z	2.20	4.40	3.06	2.76								
GLORULINS: BETA	24/09/91	4.0	10.0	Z	5.40	8.00	5.93	6.35								
GLORULINS: GAMMA	24/09/91	5.0	11.0	Z	7.10	9.00	8.43	9.93								
T3	24/09/91	7.0	17.0	X	12.50	15.00	14.36	15.78								
T4	24/09/91	1.2	3.2	NMOL/L	1.70											

1759

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Date	Laboratory Range			Screen	Visit				
					Min	Max	Unit		Week 2	Week 4	Week 6		
11	12 PJ	FEMALE	T4	24/09/91	50.0	155.0	NMOL/L	126.00					
			HB	24/09/91	7.5	10.0	NMOL/L	7.78	08/01/92	21/01/92	11/02/92	25/02/92	
		FEMALE	HTC	24/09/91	0.4	0.5	L/L	0.37	7.82	0.35	7.49	7.85	
			RBC	24/09/91	4.1	5.4	10 ¹² /L	4.63	0.36	0.36	0.36	0.39	
			MBC	24/09/91	5.0	10.0	10 ⁹ /L	4.35	4.63	4.32	4.32	4.83	
			MBC: N	24/09/91	51.0	75.0	%	5.80	5.00	4.50	4.50	6.40	
			MBC: L	24/09/91	20.0	40.0	%	58.00	58.00	46.00	46.00	68.00	
			MBC: E	24/09/91	1.0	4.0	%	32.00	32.00	46.00	22.00	22.00	
			MBC: M	24/09/91	2.0	8.0	%	10.00	4.00	8.00	8.00	8.00	
			MBC: B	24/09/91	0.0	1.0	%		0.00	0.00	0.00	0.00	
			PLATELETS	24/09/91	150.0	350.0	10 ⁹ /L	280.00	150.00	150.00	260.00	250.00	
			NA+	24/09/91	135.0	150.0	NMOL/L	143.00	140.00	140.00	140.00	142.00	
			K+	24/09/91	3.5	5.3	NMOL/L	4.10	3.50	4.70	4.40	4.40	
			CL-	24/09/91	97.0	107.0	NMOL/L	97.00	103.00	104.00	107.00	107.00	
			CA++	24/09/91	2.3	2.8	NMOL/L	2.40	2.10	2.10	2.30	2.30	
			PO4-	24/09/91	0.7	1.5	NMOL/L	1.20	1.00	1.12	1.00	1.00	
			SGOT	24/09/91	5.0	15.0	U/L	13.00	11.00	15.00	15.00	19.00	
			SGPT	24/09/91	5.0	19.0	U/L	11.00	8.00	7.00	15.00	15.00	
			GAMMA-GT	24/09/91	4.0	18.0	U/L	7.00	5.00	5.00	9.00	9.00	
			GLUCOSE	24/09/91	3.9	6.1	NMOL/L	4.40	4.20	4.20	4.40	4.40	
			ALK. PHOSPH.	24/09/91	40.0	200.0	U/L	62.00	77.00	124.00	110.00	110.00	
			BUN	24/09/91	2.1	9.6	NMOL/L	6.00	4.80	4.80	5.80	5.80	
			CREATININE	24/09/91	36.0	115.0	UMOL/L	76.00	70.00	65.00	61.00	61.00	
			URIC ACID	24/09/91	118.0	416.0	UMOL/L	199.00	154.00	194.00	206.00	206.00	
			TOT. PROTEINS	24/09/91	60.0	85.0	G/L	68.00	73.00	79.00	81.00	81.00	
			ALBUMINE	24/09/91	35.0	50.0	G/L	41.00	42.00	43.00	44.00	44.00	
			TOT. CHOLEST.	24/09/91	3.9	6.7	NMOL/L	5.10	4.00	4.00	4.90	4.90	
			TRIGLYCERIDES	24/09/91	0.5	2.3	NMOL/L	0.66	0.57	0.68	1.13	1.13	
			GLOBULINS: ALPHA 1	24/09/91	1.0	4.0	%	2.02	2.80	2.18	2.71	2.71	
			GLOBULINS: ALPHA 2	24/09/91	4.0	10.0	%	5.66	6.38	5.15	5.71	5.71	
			GLOBULINS: BETA	24/09/91	5.0	11.0	%	8.22	8.46	7.46	9.13	9.13	
			GLOBULINS: GAMMA	24/09/91	7.0	17.0	%	16.11	17.97	19.25	19.98	19.98	
			T3	24/09/91	1.2	3.2	NMOL/L	1.30					
			T4	24/09/91	50.0	155.0	NMOL/L	90.00					
			HB	24/09/91	7.5	10.0	NMOL/L	8.33	14/01/92	28/01/92	16/02/92		
		FEMALE	HTC	24/09/91	0.4	0.5	L/L	0.39	9.36	9.36	7.50	7.50	
			RBC	24/09/91	4.1	5.4	10 ¹² /L	4.61	0.43	0.43	0.36	0.36	
			MBC	24/09/91	5.0	10.0	10 ⁹ /L	6.40	5.21	5.21	4.33	4.33	
			MBC: N	24/09/91	51.0	75.0	%	70.00	68.00	67.00	70.00	70.00	
			MBC: L	24/09/91	20.0	40.0	%	24.00	28.00	26.00	26.00	26.00	
			MBC: E	24/09/91	1.0	4.0	%	2.00	2.00	2.00	2.00	2.00	
			MBC: M	24/09/91	2.0	8.0	%	4.00	2.00	2.00	2.00	2.00	
			MBC: B	24/09/91	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	
			PLATELETS	24/09/91	150.0	350.0	10 ⁹ /L	160.00	170.00	130.00	130.00	130.00	
			NA+	24/09/91	135.0	150.0	NMOL/L	146.00	141.00	140.00	140.00	140.00	

1760

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit									
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6					
11	14	BJ	FEMALE	K+	24/09/91	3.5	5.3	MMOL/L	4.60	4.60	3.80						
				CL-	24/09/91	97.0	107.0	MMOL/L	103.00	99.00	99.00						
				CA++	24/09/91	2.3	2.8	MMOL/L	2.42	2.20	2.20						
				PO4--	24/09/91	0.7	1.5	MMOL/L	1.10	1.10	1.00						
				SGPT	24/09/91	5.0	15.0	U/L	6.00	10.00	14.00						
				SGPT	24/09/91	5.0	19.0	U/L	8.00	11.00	13.00						
				GAMMA-GT	24/09/91	4.0	18.0	U/L	7.00	7.00	6.00						
				GLUCOSE	24/09/91	3.9	6.1	MMOL/L	5.90	4.50	4.20						
				ALK. PHOSPH.	24/09/91	40.0	200.0	U/L	89.00	87.00	52.00						
				BUN	24/09/91	2.1	9.6	MMOL/L	6.80	6.20	5.60						
				CREATININE	24/09/91	36.0	115.0	UMOL/L	82.00	92.00	70.00						
				URIC ACID	24/09/91	118.0	416.0	UMOL/L	167.00	198.00	229.00						
				TOT. PROTEINS	24/09/91	60.0	85.0	G/L	77.00	75.00	73.00						
				ALBUMINE	24/09/91	35.0	50.0	G/L	44.00	44.00	42.00						
				TOT. CHOLEST.	24/09/91	3.9	6.7	MMOL/L	5.20	5.40	5.40						
				TRIGLYCERIDES	24/09/91	0.5	2.3	MMOL/L	1.21	1.31	1.28						
				GLOBULINS: ALPHA 1	24/09/91	1.0	4.0	%	1.70	1.66	2.52						
				GLOBULINS: ALPHA 2	24/09/91	4.0	10.0	%	6.15	4.49	4.86						
				GLOBULINS: BETA	24/09/91	5.0	11.0	%	9.00	7.54	7.78						
				GLOBULINS: GAMMA	24/09/91	7.0	17.0	%	21.35	18.45	19.31						
				T3	24/09/91	1.2	3.2	MMOL/L	1.40								
				T4	24/09/91	50.0	155.0	MMOL/L	95.00								
				15	NF	NF	FEMALE	HB	24/09/91	7.5	10.0	MMOL/L	23.01/92	11/02/92	25/02/92	09/03/92	
								HTC	24/09/91	0.4	0.5	L/L	9.10	9.41	9.95	7.54	
RBC	24/09/91	4.1	5.4					10-12/L	0.43	0.46	0.46	0.36					
RBC	24/09/91	5.0	10.0					10-9/L	5.09	5.50	5.48	4.33					
RBC: N	24/09/91	51.0	75.0					%	6.10	6.00	7.30	6.40					
RBC: L	24/09/91	20.0	40.0					%	62.00	78.00	68.00	70.00					
RBC: E	24/09/91	1.0	4.0					%	26.00	20.00	32.00	24.00					
RBC: M	24/09/91	2.0	8.0					%	2.00	0.00	0.00	0.00					
RBC: B	24/09/91	0.0	1.0					%	10.00	2.00	0.00	0.00					
PLATELETS	24/09/91	150.0	350.0					10-9/L	200.00	270.00	260.00	240.00					
NA+	24/09/91	135.0	150.0					MMOL/L	141.00	146.00	140.00	139.00					
K+	24/09/91	3.5	5.3					MMOL/L	4.40	4.60	4.90	5.00					
CL-	24/09/91	97.0	107.0					MMOL/L	106.00	98.00	100.00	106.00					
CA++	24/09/91	2.3	2.8					MMOL/L	2.32	2.20	2.40	2.16					
PO4--	24/09/91	0.7	1.5					MMOL/L	0.80	0.85	0.84	0.86					
SGPT	24/09/91	5.0	15.0					U/L	4.00	13.00	12.00	9.00					
SGPT	24/09/91	5.0	19.0					U/L	9.00	11.00	10.00	12.00					
GAMMA-GT	24/09/91	4.0	18.0					U/L	8.00	7.00	6.00	5.00					
GLUCOSE	24/09/91	3.9	6.1					MMOL/L	4.40	5.00	3.20	5.00					
ALK. PHOSPH.	24/09/91	40.0	200.0					U/L	125.00	109.00	159.00	74.00					
BUN	24/09/91	2.1	9.6					MMOL/L	5.80	5.20	5.00	5.60					
CREATININE	24/09/91	36.0	115.0					UMOL/L	82.00	88.00	74.00	83.00					
URIC ACID	24/09/91	118.0	416.0					UMOL/L	230.00	304.00	242.00	241.00					
TOT. PROTEINS	24/09/91	60.0	85.0					G/L	62.00	62.00	73.00	73.00					
ALBUMINE	24/09/91	35.0	50.0	G/L	41.00	35.00	46.00	44.00									
TOT. CHOLEST.	24/09/91	3.9	6.7	MMOL/L	7.20	6.60	6.90	6.00									

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Screen	Visit								
				Date	Min	Max		Unit	Week 2	Week 4	Week 6					
11	15	NF	FEMALE	TRIGLYCERIDES	24/09/91	0.5	2.3	MMOL/L	0.94	1.21	1.28	0.90				
				GLOBULINS: ALPHA 1	24/09/91	1.0	4.0	Z	2.66	2.14	2.27	2.80				
				GLOBULINS: ALPHA 2	24/09/91	4.0	10.0	Z	8.37	6.89	6.64	7.91				
				GLOBULINS: BETA	24/09/91	5.0	11.0	Z	10.32	8.75	8.22	10.01				
				GLOBULINS: GAMMA	24/09/91	7.0	17.0	Z	16.70	14.85	13.67	16.54				
				T3	24/09/91	1.2	3.2	NMOL/L	1.20	.	.	.				
				T4	24/09/91	50.0	155.0	NMOL/L	106.00	.	.	.				
				16	NA		FEMALE	HB	24/09/91	7.5	10.0	MMOL/L	28/01/92	16/02/92	28/02/92	15/03/92
								HCT	24/09/91	0.4	0.5	L/L	9.38	8.37	8.26	7.35
								RBC	24/09/91	4.1	5.4	10 ¹² /L	0.45	0.41	0.40	0.34
								WBC	24/09/91	5.0	10.0	10 ⁹ /L	5.22	4.81	4.62	4.06
								WBC: N	24/09/91	51.0	75.0	Z	6.80	9.00	8.50	8.00
								WBC: L	24/09/91	20.0	40.0	Z	60.00	70.00	62.00	62.00
								WBC: E	24/09/91	1.0	4.0	Z	14.00	24.00	28.00	30.00
WBC: M	24/09/91	2.0	8.0					Z	2.00	4.00	4.00	4.00				
WBC: B	24/09/91	0.0	1.0					Z	0.00	0.00	0.00	0.00				
PLATELETS	24/09/91	150.0	350.0					10 ⁹ /L	170.00	160.00	170.00	200.00				
NA+	24/09/91	135.0	150.0					MMOL/L	143.00	144.00	143.00	143.00				
K+	24/09/91	3.5	5.3					MMOL/L	4.60	5.20	4.20	4.80				
CL-	24/09/91	97.0	107.0					MMOL/L	102.00	100.00	105.00	104.00				
CA++	24/09/91	2.3	2.8					MMOL/L	2.47	2.40	2.50	2.60				
PO4-	24/09/91	0.7	1.5	MMOL/L	0.90	1.00	0.92	0.82								
SGPT	24/09/91	5.0	15.0	U/L	7.00	18.00	11.00	15.00								
SGPT	24/09/91	5.0	19.0	U/L	7.00	12.00	10.00	5.00								
GAMMA-GT	24/09/91	4.0	18.0	U/L	6.00	5.00	7.00	8.00								
GLUCOSE	24/09/91	3.9	6.1	MMOL/L	4.80	3.80	4.60	6.20								
ALK. PHOSPH.	24/09/91	40.0	200.0	U/L	119.00	64.00	117.00	140.00								
CREATININE	24/09/91	2.1	9.6	MMOL/L	4.00	5.10	4.80	4.80								
URIC ACID	24/09/91	36.0	115.0	UMOL/L	96.00	98.00	103.00	105.00								
TOT. PROTEINS	24/09/91	118.0	416.0	UMOL/L	185.00	262.00	256.00	200.00								
ALBUMINE	24/09/91	60.0	85.0	G/L	65.00	79.00	66.00	59.00								
TOT. CHOLEST.	24/09/91	35.0	50.0	G/L	40.00	46.00	37.00	36.00								
TRIGLYCERIDES	24/09/91	3.9	6.7	MMOL/L	8.30	9.00	7.40	7.50								
GLOBULINS: ALPHA 1	24/09/91	0.5	2.3	MMOL/L	1.82	2.11	2.41	1.82								
GLOBULINS: ALPHA 2	24/09/91	1.0	4.0	Z	2.36	2.94	4.77	2.31								
GLOBULINS: BETA	24/09/91	4.0	10.0	Z	6.35	8.97	10.70	6.35								
GLOBULINS: GAMMA	24/09/91	5.0	11.0	Z	8.81	11.86	10.49	9.10								
T3	24/09/91	7.0	17.0	Z	10.36	14.11	11.39	12.74								
T4	24/09/91	1.2	3.2	MMOL/L	2.05	.	.	.								
	24/09/91	50.0	155.0	MMOL/L	132.00	.	.	.								
17	UZ		FEMALE	HB	24/09/91	7.5	10.0	MMOL/L	03/02/92	20/02/92	05/03/92	19/03/92				
				HCT	24/09/91	0.4	0.5	L/L	9.93	8.85	9.16	8.83				
				RBC	24/09/91	4.1	5.4	10 ¹² /L	0.46	0.46	0.43	0.43				
				WBC	24/09/91	5.0	10.0	10 ⁹ /L	5.59	5.29	5.10	5.19				
				WBC: N	24/09/91	51.0	75.0	Z	50.00	70.00	7.20	6.30				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Date	Laboratory Range			Screen	Visit			
					Min	Max	Unit		Week 2	Week 4	Week 6	
11	17 UZ	FEMALE	REC: L	24/09/91	20.0	40.0	X	40.00	28.00	30.00	14.00	
			REC: E	24/09/91	1.0	4.0	X	6.00	0.00	0.00	2.00	
			REC: M	24/09/91	2.0	8.0	X	4.00	2.00	2.00	6.00	
			REC: B	24/09/91	0.0	1.0	X	0.00	0.00	0.00	0.00	
			PLATELETS	24/09/91	150.0	10-9/L		260.00	200.00	200.00	260.00	
			NA+	24/09/91	135.0	150.0	MMOL/L	140.00	142.00	141.00	139.00	
			K+	24/09/91	3.5	5.3	MMOL/L	5.10	5.00	4.90	4.00	
			CL-	24/09/91	97.0	107.0	MMOL/L	104.00	97.00	99.00	101.00	
			CA++	24/09/91	2.3	2.8	MMOL/L	2.30	2.50	2.40	2.20	
			PO4-	24/09/91	0.7	1.5	MMOL/L	0.82	0.82	0.85	0.90	
			SGPT	24/09/91	5.0	15.0	I/L	12.00	11.00	22.00	21.00	
			GAMMA-GT	24/09/91	5.0	19.0	I/L	15.00	11.00	14.00	18.00	
			GLUCOSE	24/09/91	4.0	18.0	I/L	35.00	18.00	18.00	10.00	
			ALK. PHOSPH.	24/09/91	3.9	6.1	MMOL/L	8.00	4.40	5.00	4.30	
			RUN	24/09/91	40.0	200.0	I/L	136.00	85.00	113.00	86.00	
			CREATININE	24/09/91	2.1	9.6	MMOL/L	4.60	6.00	6.00	4.20	
			URIC ACID	24/09/91	36.0	115.0	UMOL/L	71.00	73.00	70.00	65.00	
			TOT. PROTEINS	24/09/91	118.0	416.0	UMOL/L	289.00	241.00	194.00	254.00	
			ALBUMINE	24/09/91	60.0	85.0	G/L	82.00	85.00	72.00	73.00	
			TOT. CHOLEST.	24/09/91	3.9	6.7	MMOL/L	50.00	42.00	41.00	42.00	
			TRIGLYCERIDES	24/09/91	0.5	2.3	MMOL/L	1.84	8.20	8.00	7.10	
			GLOBULINS: ALPHA 1	24/09/91	1.0	4.0	X	2.41	3.20	2.11	1.44	
			GLOBULINS: ALPHA 2	24/09/91	4.0	10.0	X	6.55	6.10	5.28	2.64	
			GLOBULINS: BETA	24/09/91	5.0	11.0	X	11.06	8.03	8.18	6.27	
			GLOBULINS: GAMMA	24/09/91	7.0	17.0	X	21.33	22.63	18.47	9.03	
			T3	24/09/91	1.2	3.2	MMOL/L	1.35	.	.	15.44	
			T4	24/09/91	50.0	155.0	MMOL/L	86.00	.	.	.	
			18	EI	FEMALE	HB	24/09/91	7.5	10.0	MMOL/L	04/02/92	21/02/92
HTC	24/09/91	0.4				0.5	L/L	7.92	6.98	7.37	7.16	
RBC	24/09/91	4.1				5.4	10-12/L	0.39	0.35	0.36	0.34	
NRC	24/09/91	5.0				10.0	10-9/L	4.51	4.06	4.26	4.03	
NRC: N	24/09/91	51.0				75.0	X	8.40	7.20	6.50	8.00	
NRC: L	24/09/91	20.0				40.0	X	48.00	56.00	64.00	60.00	
NRC: E	24/09/91	1.0				4.0	X	42.00	32.00	32.00	32.00	
NRC: M	24/09/91	2.0				8.0	X	4.00	6.00	2.00	4.00	
NRC: B	24/09/91	0.0				1.0	X	6.00	6.00	2.00	4.00	
PLATELETS	24/09/91	150.0				350.0	10-9/L	230.00	330.00	300.00	300.00	
NA+	24/09/91	135.0				150.0	MMOL/L	146.00	140.00	139.00	140.00	
K+	24/09/91	3.5				5.3	MMOL/L	4.50	4.80	4.70	4.80	
CL-	24/09/91	97.0				107.0	MMOL/L	102.00	100.00	102.00	96.70	
CA++	24/09/91	2.3				2.8	MMOL/L	2.30	2.50	2.10	2.20	
PO4-	24/09/91	0.7				1.5	MMOL/L	0.71	0.95	1.07	1.00	
SGPT	24/09/91	5.0				15.0	I/L	16.00	6.00	6.00	16.00	
GAMMA-GT	24/09/91	4.0				18.0	I/L	8.00	6.00	8.00	11.00	
GLUCOSE	24/09/91	3.9				6.1	MMOL/L	8.00	5.00	5.00	8.00	
ALK. PHOSPH.	24/09/91	40.0				200.0	I/L	4.60	4.70	4.90	5.00	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REDOXETINE - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
11	18	EI	FEMALE	BUN	24/09/91	2.1	9.6	MMOL/L	5.10	6.40	5.20	4.20	
				CREATININE	24/09/91	36.0	115.0	UMOL/L	69.00	79.00	70.00	75.00	
				URIC ACID	24/09/91	118.0	416.0	UMOL/L	136.00	137.00	177.00	126.00	
				TOT. PROTEINS	24/09/91	60.0	85.0	G/L	70.00	70.00	79.00	69.00	
				ALBUMINE	24/09/91	35.0	50.0	G/L	42.00	34.00	45.00	39.00	
				TOT. CHOLEST.	24/09/91	3.9	6.7	MMOL/L	6.20	4.70	6.00	5.00	
				TRIGLYCERIDES	24/09/91	0.5	2.3	MMOL/L	0.92	1.05	1.13	0.70	
				GLUCOLINS: ALPHA 1	24/09/91	1.0	4.0	Z	2.65	1.52	2.29	2.08	
				GLUCOLINS: ALPHA 2	24/09/91	4.0	10.0	Z	7.43	6.25	6.52	4.66	
				GLUCOLINS: BETA	24/09/91	5.0	11.0	Z	10.98	6.27	9.57	6.81	
				GLUCOLINS: BETA	24/09/91	7.0	17.0	Z	16.93	6.27	9.57	6.81	
				T3	24/09/91	1.2	3.2	MMOL/L	1.80	16.09	15.97	13.64	
				T4	24/09/91	50.0	155.0	MMOL/L	140.00				
				19	FK	FEMALE	HB	01/04/92	120.0	170.0	G/L	9.60	9.58
HCT	01/04/92	7.5	10.0				MMOL/L	0.45	0.45	0.39	0.38		
HTC	01/04/92	0.4	0.5				L/L	0.45	0.45	0.39	4.34		
RBC	01/04/92	3.5	5.6				10-12/L	5.20	5.07	4.56	5.60		
RBC	01/04/92	4.1	5.4				10-12/L	8.00	4.70	6.50	66.00		
MBC	01/04/92	4.0	10.0				10-9/L	70.00	56.00	58.00	32.00		
MBC: N	24/09/91	51.0	75.0				Z	30.00	38.00	40.00	0.00		
MBC: L	24/09/91	20.0	40.0				Z	0.00	0.00	0.00	0.00		
MBC: E	24/09/91	1.0	4.0				Z	0.00	0.00	0.00	0.00		
MBC: B	24/09/91	2.0	8.0				Z	0.00	0.00	0.00	0.00		
PLATELETS	24/09/91	150.0	350.0				10-9/L	250.00	220.00	160.00	220.00		
Na+	24/09/91	135.0	150.0				MMOL/L	144.00	141.00	141.00	142.00		
K+	24/09/91	3.5	5.3				MMOL/L	4.60	5.20	4.40	5.10		
Cl-	24/09/91	97.0	107.0				MMOL/L	107.00	98.00	98.00	103.00		
Ca++	24/09/91	2.3	2.8	MMOL/L	2.60	2.40	2.40	2.66					
PO4--	24/09/91	0.7	1.5	MMOL/L	0.79	0.98	0.90	0.90					
SGOT	24/09/91	5.0	15.0	U/L	12.00	10.00	12.00	18.00					
SGPT	24/09/91	5.0	19.0	U/L	16.00	8.00	7.00	13.00					
GAMMA-GT	24/09/91	4.0	18.0	U/L	22.00	9.00	8.00	13.00					
GLUCOSE	24/09/91	3.3	6.1	MMOL/L	4.80	5.20	5.00	4.60					
ALK. PHOSPH.	24/09/91	40.0	200.0	U/L	105.00	104.00	120.00	127.00					
BUN	24/09/91	2.1	9.6	MMOL/L	4.20	4.60	4.00	4.20					
CREATININE	24/09/91	36.0	115.0	UMOL/L	68.00	79.00	89.00	72.00					
URIC ACID	24/09/91	118.0	416.0	UMOL/L	89.00	180.00	117.00	155.00					
TOT. PROTEINS	24/09/91	60.0	85.0	G/L	79.00	70.00	70.00	75.00					
ALBUMINE	24/09/91	35.0	50.0	G/L	47.00	43.00	40.00	37.00					
TOT. CHOLEST.	24/09/91	3.9	6.7	MMOL/L	6.20	5.00	6.10	6.50					
TRIGLYCERIDES	24/09/91	0.5	2.3	MMOL/L	2.21	2.28	1.70	2.41					
GLUCOLINS: ALPHA 1	24/09/91	1.0	4.0	Z	2.21	2.16	1.70	2.16					
GLUCOLINS: ALPHA 2	24/09/91	4.0	10.0	Z	8.40	5.44	7.00	7.00					
GLUCOLINS: BETA	24/09/91	5.0	11.0	Z	10.94	10.08	9.42	9.42					
GLUCOLINS: BETA	24/09/91	7.0	17.0	Z	14.11	14.50	15.69	14.55					

1464

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Date	Laboratory Range		Screen	Visit				
						Min	Max		Unit	Week 2	Week 4	Week 6	
11	19	FK	FEMALE	T3	24/09/91	1.2	3.2	NHDL/L	1.60				
				T4	24/09/91	50.0	155.0	NHDL/L	106.00				
11	20	LJ	FEMALE	HB	01/04/92	120.0	170.0	G/L	24/02/92	16/03/92	30/03/92	12/04/92	
				HB	24/09/91	7.5	10.0	NHDL/L	8.35	8.30	9.04	146.00	
				HTC	01/04/92	0.4	0.5	L/L	0.42	0.39	0.43	0.41	
				HTC	24/09/91	0.4	0.5	L/L	0.42	0.39	0.43	0.41	
				RBC	01/04/92	3.5	5.6	10-12/L	4.81	4.50	5.03	4.57	
				RBC	24/09/91	4.1	5.4	10-12/L	4.81	4.50	5.03	4.57	
				RBC	01/04/92	4.0	10.0	10-9/L	4.80	6.50	4.00	7.00	
				RBC	24/09/91	5.0	10.0	10-9/L	4.80	6.50	4.00	7.00	
				HBC: N	24/09/91	51.0	73.0	%	62.00	28.00	65.00	74.00	
				HBC: L	24/09/91	20.0	40.0	%	32.00	28.00	50.00	26.00	
				HBC: E	24/09/91	1.0	4.0	%	2.00	4.00	6.00	0.00	
				HBC: R	24/09/91	2.0	8.0	%	4.00	6.00	0.00	0.00	
				HBC: B	24/09/91	0.0	1.0	%	0.00	0.00	0.00	0.00	
				PLATELETS	24/09/91	150.0	350.0	10-9/L	190.00	180.00	220.00	220.00	
				NA+	24/09/91	135.0	150.0	NHDL/L	140.00	140.00	143.00	142.00	
				K+	24/09/91	3.5	5.3	NHDL/L	4.10	4.70	4.70	4.20	
				CL-	24/09/91	97.0	107.0	NHDL/L	102.00	105.00	104.00	103.00	
				CA++	24/09/91	2.3	2.8	NHDL/L	2.40	2.50	2.40	2.46	
				PO4--	24/09/91	0.7	1.5	NHDL/L	0.87	0.96	0.87	1.31	
				SGPT	24/09/91	5.0	15.0	U/L	15.00	11.00	25.00	34.00	
GAMMA-GT	24/09/91	4.0	18.0	U/L	10.00	10.00	11.00	30.00					
GLUCOSE	24/09/91	3.9	6.1	NHDL/L	26.00	30.00	16.00	21.00					
ALK. PHOSPH.	24/09/91	40.0	200.0	U/L	5.40	4.60	3.80	5.20					
BUN	24/09/91	2.1	9.6	NHDL/L	99.00	235.00	138.00	134.00					
CREATININE	24/09/91	36.0	115.0	UMOL/L	73.00	4.00	3.60	4.50					
URIC ACID	24/09/91	118.0	416.0	UMOL/L	100.00	79.00	78.00	93.00					
TOT. PROTEINS	24/09/91	60.0	85.0	G/L	66.00	65.00	235.00	231.00					
ALBUMINE	24/09/91	35.0	50.0	G/L	45.00	39.00	66.00	70.00					
TOT. CHOLEST.	24/09/91	3.9	6.7	NHDL/L	5.30	6.30	36.00	38.00					
TRIGLYCERIDES	24/09/91	0.5	2.3	NHDL/L	1.98	1.39	7.90	8.10					
GLOBULINS: ALPHA 1	24/09/91	1.0	4.0	%	2.17	2.17	1.41	1.29					
GLOBULINS: ALPHA 2	24/09/91	4.0	10.0	%	2.14	2.17	2.21	2.47					
GLOBULINS: BETA	24/09/91	5.0	17.0	%	5.30	5.30	6.24	5.29					
GLOBULINS: GAMMA	24/09/91	7.0	17.0	%	10.47	7.91	10.96	7.26					
T3	24/09/91	1.2	3.2	NHDL/L	13.84	10.53	12.28	14.61					
T4	24/09/91	50.0	155.0	NHDL/L	111.00								
12	1	IB	MALE	HB	20/10/91	7.5	10.0	mmol/L	30/10/91	13/11/91	27/11/91	11/12/91	
				HTC	20/10/91	0.4	0.5	L/L	8.73	8.83	8.93	8.93	
				RBC	20/10/91	4.5	5.0	10**12/L	0.41	0.37	0.42	0.42	
				HBC	20/10/91	4.0	10.0	10**9/L	4.59	4.31	4.83	4.83	
				HBC: L	20/10/91	60.0	70.0	%	72.00	64.00	67.00	67.00	
HBC: N	20/10/91	20.0	45.0	%	15.00	28.00	28.00	28.00					

1 7 6 5

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
12	1	IB	MALE	WBC: E	20/10/91	1.0	5.0	Z	4.00	5.00	3.00	3.00	3.00
				WBC: M	20/10/91	1.0	6.0	Z	1.00	3.00	2.00	2.00	
				WBC: B	20/10/91	0.0	1.0	Z	1.00	2.00	2.00	2.00	
				PLATELETS	20/10/91	140.0	300.0	10**9/L	265.00	226.00	220.00	209.00	
				NA+	20/10/91	137.0	147.0	mmol/L	141.00	140.00	139.00	141.00	
				K+	20/10/91	3.7	5.3	mmol/L	3.90	4.00	4.00	4.10	
				CL-	20/10/91	97.0	107.0	mmol/L	94.00	94.00	96.00	96.00	
				CA++	20/10/91	2.3	2.7	mmol/L	2.21	2.28	2.41	2.20	
				PO4-	20/10/91	0.7	1.5	mmol/L	0.90	1.14	0.93	0.91	
				SGPT	20/10/91	5.0	30.0	U/l	16.00	4.00	13.00	20.00	
				SGOT	20/10/91	5.0	34.0	U/l	8.00	2.00	13.00	14.00	
				GAMMA-GT	20/10/91	6.0	28.0	U/l	21.00	15.00	13.00	13.00	
				GLUCOSE	20/10/91	3.3	5.5	mmol/L	5.10	3.40	4.70	4.40	
				ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	294.00	259.00	280.00	280.00	
				BUN	20/10/91	3.0	9.6	mmol/L	3.40	5.70	3.40	4.90	
				CREATININE	20/10/91	50.0	110.0	umol/L	88.00	90.00	74.00	78.00	
				URIC ACID	20/10/91	120.0	410.0	umol/L	289.00	268.00	257.00	262.00	
				TOT BILIRUBIN	20/10/91	3.4	22.0	umol/L	17.10	7.20	8.90	17.10	
				DIR BILIRUBIN	20/10/91	0.0	4.5	umol/L	67.00	4.60	5.00	68.00	
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	0.71	0.71	0.65	0.68	
ALBUMINE	20/10/91	0.5	0.7	RATIO	4.50	5.20	5.20	5.30					
TRIGLYCERIDES	20/10/91	2.6	7.0	mmol/L	1.10	2.40	1.00	1.20					
GLYCERINS: ALPHA 1	20/10/91	0.0	1.9	mmol/L	0.04	0.04	0.04	0.03					
GLYCERINS: ALPHA 2	20/10/91	0.0	0.1	RATIO	0.06	0.05	0.07	0.06					
GLYCERINS: BETA	20/10/91	0.1	0.1	RATIO	0.09	0.07	0.07	0.09					
GLYCERINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.15	0.13	0.15	0.14					
T3	20/10/91	0.9	1.1	nmol/L	1.02	1.02	1.02	1.02					
T4	20/10/91	60.0	160.0	nmol/L	74.60	74.60	74.60	74.60					
2	EFC		FEMALE	HR	20/10/91	7.5	10.0	mmol/L	7.72	8.45	8.54	8.82	
				HTC	20/10/91	0.4	0.5	l/l	0.35	0.38	0.40	0.40	
				RBC	20/10/91	4.5	5.0	10**12/L	4.26	4.60	4.88	4.84	
				HGB	20/10/91	4.0	10.0	10**9/L	5.10	4.80	6.20	4.30	
				HCT: N	20/10/91	60.0	70.0	Z	62.00	61.00	61.00	59.00	
				HCT: L	20/10/91	20.0	45.0	Z	29.00	36.00	34.00	34.00	
				HCT: E	20/10/91	1.0	5.0	Z	1.00	3.00	1.00	1.00	
				PLATELETS	20/10/91	140.0	300.0	10**9/L	8.00	249.00	199.00	6.00	
				NA+	20/10/91	137.0	147.0	mmol/L	144.00	147.00	145.00	142.00	
				K+	20/10/91	3.7	5.3	mmol/L	4.20	4.30	4.80	3.80	
				CL-	20/10/91	97.0	107.0	mmol/L	96.00	96.00	96.00	96.00	
				CA++	20/10/91	2.3	2.7	mmol/L	2.15	2.39	2.29	2.29	
				PO4-	20/10/91	0.7	1.5	mmol/L	0.96	0.96	1.05	1.05	
				SGPT	20/10/91	5.0	30.0	U/l	20.00	20.00	19.00	23.00	
				SGOT	20/10/91	5.0	34.0	U/l	37.00	17.00	26.00	23.00	
				GAMMA-GT	20/10/91	6.0	28.0	U/l	176.00	65.00	72.00	51.00	
				GLUCOSE	20/10/91	3.3	5.5	mmol/L	4.60	4.60	4.20	4.10	
				ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	391.00	266.00	328.00	279.00	

1766

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOMETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Screen			Visit		
					Date	Min	Max	Unit	Week 2	Week 4	Week 6		
12	2	EFC	FEMALE	BUN	20/10/91	3.0	9.6	mmol/l	78.00	4.40	5.00	64.00	
				CREATININE	20/10/91	50.0	110.0	umol/l	228.00	84.00	69.00	258.00	
				URIC ACID	20/10/91	120.0	410.0	umol/l	17.10	242.00	257.00	9.70	
				TOT BILIRUBIN	20/10/91	3.4	22.0	umol/l	65.00	4.30	7.50	4.60	
				DIR BILIRUBIN	20/10/91	0.0	4.5	umol/l	65.00	65.00	68.00	67.00	
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	0.61	0.62	0.61	0.63	
				ALBUMINE	20/10/91	0.5	0.7	RATIO	7.10	7.10	7.20	7.50	
				TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	1.20	1.30	1.50	1.60	
				TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	0.04	0.04	0.05	0.04	
				GLUCURINS: ALPHA 1	20/10/91	0.0	0.1	RATIO	0.12	0.12	0.11	0.10	
				GLUCURINS: ALPHA 2	20/10/91	0.1	0.1	RATIO	0.13	0.12	0.12	0.11	
				GLUCURINS: BETA	20/10/91	0.1	0.1	RATIO	104.90	0.12	0.13	0.12	
				GLUCURINS: GAMMA	20/10/91	0.1	0.2	RATIO					
				T4	20/10/91	60.0	160.0	nmol/l					
3	IF		FEMALE	HB	20/10/91	7.5	10.0	mmol/l	8.63	8.63	8.87	8.41	
				HTC	20/10/91	0.4	0.5	l/l	0.44	0.36	0.35	0.39	
				RBC	20/10/91	4.5	5.0	10**9/l	4.59	4.10	5.33	4.41	
				MBC	20/10/91	4.0	10.0	10**9/l	7.60	12.80	7.30	6.50	
				RBC: N	20/10/91	60.0	70.0	%	57.00	63.00	68.00	59.00	
				RBC: L	20/10/91	30.0	45.0	%	40.00	35.00	29.00	34.00	
				RBC: E	20/10/91	1.0	5.0	%	1.00	2.00	1.00	2.00	
				RBC: M	20/10/91	1.0	6.0	%	1.00	2.00	1.00	5.00	
				RBC: B	20/10/91	0.0	1.0	%	1.00	1.00	1.00	2.00	
				PLATELETS	20/10/91	140.0	300.0	10**9/l	235.00	301.00	460.00	264.00	
				NA+	20/10/91	137.0	147.0	mmol/l	145.00	139.00	144.00	139.00	
				K+	20/10/91	3.7	5.3	mmol/l	3.90	4.40	4.20	4.00	
				CL-	20/10/91	97.0	107.0	mmol/l	100.00	100.00	96.00	96.00	
				CA++	20/10/91	2.3	2.7	mmol/l	2.21	2.40	2.40	2.24	
				PO4--	20/10/91	0.7	1.5	mmol/l	1.20	1.28	0.92	1.22	
				SGPT	20/10/91	5.0	30.0	U/l	15.00	2.00	12.00	17.00	
				GAMMA-GT	20/10/91	5.0	34.0	U/l	16.00	4.00	23.00	21.00	
				GLUCOSE	20/10/91	6.0	28.0	U/l	27.00	46.00	23.00	16.00	
				ALK. PHOSPH.	20/10/91	3.3	5.5	mmol/l	4.10	3.70	4.40	4.20	
				BUN	20/10/91	100.0	280.0	U/l	102.00	141.00	134.00	118.00	
				CREATININE	20/10/91	3.0	9.6	mmol/l	4.60	4.60	4.90	7.00	
				URIC ACID	20/10/91	50.0	110.0	umol/l	81.00	77.00	71.00	59.00	
				TOT BILIRUBIN	20/10/91	120.0	410.0	umol/l	221.00	202.00	245.00	225.00	
				DIR BILIRUBIN	20/10/91	3.4	22.0	umol/l	17.10	10.00	10.80	9.50	
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	69.00	63.00	71.00	74.00	
				ALBUMINE	20/10/91	0.5	0.7	RATIO	0.61	0.71	0.60	0.66	
				TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	5.60	4.60	5.80	5.80	
				TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	2.20	2.40	1.90	2.40	
				GLUCURINS: ALPHA 1	20/10/91	0.0	0.1	RATIO	0.07	0.04	0.05	0.05	
				GLUCURINS: ALPHA 2	20/10/91	0.1	0.1	RATIO	0.08	0.08	0.10	0.08	
				GLUCURINS: BETA	20/10/91	0.1	0.1	RATIO	0.11	0.07	0.10	0.09	
				GLUCURINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.13	0.10	0.14	0.12	
				T3	20/10/91	0.9	1.1	nmol/l	2.90				

1767

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centro	Patient	Initials	Sex	Laboratory test	Laboratory Range			Screen	Visit				
					Date	Min	Max		Unit	Week 2	Week 4	Week 6	
12	3	IF	FEMALE	T ₄	20/10/91	60.0	160.0	mmol/L	180.80				
			FEMALE	HB	20/10/91	7.5	10.0	mmol/L	31/10/91	18/11/91	02/12/91	16/12/91	
				HTC	20/10/91	0.4	0.5	L/L	8.71	8.73	8.41	8.64	
				RBC	20/10/91	4.5	5.0	10 ^{xx} 12/1	0.38	0.40	0.39	0.41	
				HBC	20/10/91	4.0	10.0	10 ^{xx} 9/1	5.12	5.09	4.89	5.11	
				HBC: N	20/10/91	60.0	70.0	Z	7.40	8.50	7.20	8.30	
				HBC: L	20/10/91	20.0	45.0	Z	65.00	39.00	69.00	75.00	
				HBC: E	20/10/91	1.0	5.0	Z	28.00	59.00	29.00	20.00	
				HBC: M	20/10/91	1.0	6.0	Z	1.00	1.00	2.00	3.00	
				HBC: R	20/10/91	0.0	1.0	Z	4.00	1.00	2.00	2.00	
				PLATELETS	20/10/91	140.0	300.0	10 ^{xx} 9/1	203.00	201.00	238.00	325.00	
				NA+	20/10/91	137.0	147.0	mmol/L	146.00	143.00	143.00	144.00	
				K+	20/10/91	3.7	5.3	mmol/L	4.20	4.30	4.20	3.90	
				CA++	20/10/91	2.3	2.7	mmol/L	2.36	2.23	2.26	2.51	
				PO4-	20/10/91	0.7	1.5	mmol/L	1.35	1.11	1.15	1.29	
				SGPT	20/10/91	5.0	30.0	U/l	47.00	16.00	11.00	20.00	
				GAMMA-GT	20/10/91	5.0	34.0	U/l	115.00	17.00	13.00	23.00	
				GLUCOSE	20/10/91	6.0	28.0	U/l	81.00	31.00	28.00	18.00	
				ALK. PHOSPH.	20/10/91	3.3	5.5	mmol/L	4.00	5.70	3.60	4.60	
				BUN	20/10/91	100.0	280.0	U/l	4.00	201.00	181.00	214.00	
				CREATININE	20/10/91	3.0	9.6	mmol/L	4.20	4.40	4.70	5.60	
				URIC ACID	20/10/91	50.0	110.0	umol/L	82.00	81.00	65.00	56.00	
				TOT BILIRUBIN	20/10/91	120.0	410.0	umol/L	220.00	303.00	201.00	187.00	
				DIR BILIRUBIN	20/10/91	3.4	22.0	umol/L	13.50	15.30	10.70	9.40	
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	10.00	8.10	10.10	7.60	
				ALBUMINE	20/10/91	0.5	0.7	RATIO	73.00	74.00	71.00	76.00	
				TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/L	0.41	0.61	0.63	0.62	
				TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/L	6.60	6.10	5.70	5.60	
				GLOBULINS: ALPHA 1	20/10/91	0.0	0.1	RATIO	1.80	1.60	2.10	1.30	
				GLOBULINS: ALPHA 2	20/10/91	0.1	0.1	RATIO	0.06	0.04	0.04	0.04	
				GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.16	0.09	0.08	0.09	
				GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.15	0.09	0.10	0.10	
				T ₃	20/10/91	0.9	1.1	mmol/L	1.06	0.17	0.15	0.16	
				T ₄	20/10/91	60.0	160.0	mmol/L	108.40				
			MALE	HB	20/10/91	7.5	10.0	mmol/L	26/10/91	18/11/91	02/12/91	16/12/91	
				HTC	20/10/91	0.4	0.5	L/L	7.91	8.76	9.26	9.54	
				RBC	20/10/91	4.5	5.0	10 ^{xx} 12/1	0.42	0.38	0.43	0.43	
				HBC	20/10/91	4.0	10.0	10 ^{xx} 9/1	3.77	4.23	4.70	4.79	
				HBC: N	20/10/91	60.0	70.0	Z	49.00	6.00	6.90	6.90	
				HBC: L	20/10/91	20.0	45.0	Z	39.00	45.00	42.00	36.00	
				HBC: E	20/10/91	1.0	5.0	Z	9.00	47.00	49.00	52.00	
				HBC: M	20/10/91	1.0	6.0	Z	0.00	7.00	9.00	6.00	
				HBC: R	20/10/91	0.0	1.0	Z	0.00	1.00	0.00	0.00	

1768

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
12	5	ZSH	MALE	PLATELETS	20/10/91	140.0	300.0	10**9/1	223.00	199.00			340.00
				NA+	20/10/91	137.0	147.0	mmol/l	145.00	143.00	142.00	142.00	142.00
				K+	20/10/91	3.7	5.3	mmol/l	4.20	4.50	3.80	3.70	3.70
				CA++	20/10/91	2.3	2.7	mmol/l	2.10	2.21	2.37	2.37	2.37
				PO4-	20/10/91	0.7	1.5	mmol/l	1.51	1.75	1.71	1.55	1.55
				SGPT	20/10/91	5.0	30.0	U/l	33.00	25.00	15.00	15.00	26.00
				SGPT	20/10/91	5.0	34.0	U/l	43.00	15.00	11.00	17.00	17.00
				GAMMA-GT	20/10/91	6.0	28.0	U/l	101.00	27.00	22.00	24.00	24.00
				GLUCOSE	20/10/91	3.3	5.5	mmol/l	4.30	4.00	3.70	3.20	3.20
				ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	145.00	269.00	262.00	262.00	262.00
				RUN	20/10/91	3.0	9.6	mmol/l	5.50	6.30	5.70	7.70	7.70
				CREATININE	20/10/91	50.0	110.0	umol/l	111.00	111.00	93.00	82.00	82.00
				URIC ACID	20/10/91	120.0	410.0	umol/l	272.00	280.00	280.00	302.00	302.00
				TOT BILIRUBIN	20/10/91	3.4	22.0	umol/l	17.10	17.10	17.10	17.10	17.10
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	67.00	66.00	67.00	71.00	71.00
				ALBUMINE	20/10/91	0.5	0.7	RATIO	0.60	0.60	0.64	0.64	0.64
				TOT. CHOLEST.	20/10/91	2.5	7.0	mmol/l	7.10	6.00	5.60	5.80	5.80
				TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	2.80	1.20	1.30	1.50	1.50
				GLUCOLINS: ALPHA 1	20/10/91	0.0	0.1	RATIO	0.06	0.04	0.04	0.04	0.04
				GLUCOLINS: ALPHA 2	20/10/91	0.1	0.1	RATIO	0.09	0.04	0.04	0.04	0.04
GLUCOLINS: BETA	20/10/91	0.1	0.1	RATIO	0.11	0.04	0.04	0.10	0.10				
GLUCOLINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.14	0.04	0.15	0.14	0.14				
I3	20/10/91	0.9	1.1	mmol/l	1.40	1.40	1.40	1.40	1.40				
I4	20/10/91	60.0	160.0	mmol/l	59.40	59.40	59.40	59.40	59.40				
17	6	HK	FEMALE	HB	20/10/91	7.5	10.0	mmol/l	9.22	7.89	8.37	8.26	
				HTC	20/10/91	0.4	0.5	l/l	0.46	0.36	0.43	0.36	
				RBC	20/10/91	4.5	5.0	10**12/l	4.42	3.90	5.22	3.66	
				HBC	20/10/91	4.0	10.0	10**9/l	6.70	5.70	6.90	6.90	
				HBC: N	20/10/91	60.0	70.0	%	65.00	69.00	71.00	62.00	
				HBC: L	20/10/91	20.0	45.0	%	34.00	25.00	26.00	34.00	
				HBC: E	20/10/91	1.0	5.0	%	0.00	6.00	1.00	2.00	
				HBC: N	20/10/91	1.0	6.0	%	1.00	0.00	2.00	2.00	
				HBC: B	20/10/91	0.0	1.0	%	0.00	0.00	0.00	0.00	
				PLATELETS	20/10/91	140.0	300.0	10**9/l	265.00	320.00	294.00	208.00	
				NA+	20/10/91	137.0	147.0	mmol/l	140.00	146.00	143.00	142.00	
				K+	20/10/91	3.7	5.3	mmol/l	4.80	4.80	4.60	4.50	
				CA++	20/10/91	2.3	2.7	mmol/l	2.24	2.32	2.18	2.18	
				PO4-	20/10/91	0.7	1.5	mmol/l	1.00	1.30	1.30	1.30	
				SGPT	20/10/91	5.0	30.0	U/l	18.00	21.00	8.00	19.00	
				SGPT	20/10/91	5.0	34.0	U/l	10.00	30.00	32.00	23.00	
				GAMMA-GT	20/10/91	6.0	28.0	U/l	32.00	28.00	25.00	50.00	
				GLUCOSE	20/10/91	3.3	5.5	mmol/l	3.70	3.90	3.10	3.10	
				ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	246.00	208.00	211.00	206.00	
				RUN	20/10/91	3.0	9.6	mmol/l	4.60	5.80	4.10	4.70	
CREATININE	20/10/91	50.0	110.0	umol/l	90.00	82.00	75.00	75.00					
URIC ACID	20/10/91	120.0	410.0	umol/l	297.00	267.00	345.00	267.00					
TOT BILIRUBIN	20/10/91	3.4	22.0	umol/l	17.10	17.10	17.10	17.10					

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6			
12	6	MK	FEMALE	DIR BILIRUBIN	20/10/91	0.0	4.5	umol/l		7.40	9.90	7.40	7.40		
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	83.00	68.00	76.00	67.00			
				ALBUMINE	20/10/91	0.5	0.7	RATIO	0.58	0.64	0.64	0.62			
				TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	5.80	4.60	5.50	4.70			
				TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	2.00	2.90	2.00	2.20			
				GLOBULINS: ALPHA 1	20/10/91	0.0	0.1	RATIO	0.06	0.04	0.04	0.05			
				GLOBULINS: ALPHA 2	20/10/91	0.1	0.1	RATIO	0.04	0.07	0.08	0.09			
				GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.10	0.09	0.08	0.04			
				GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.16	0.16	0.17	0.15			
				T3	20/10/91	0.9	1.1	nmol/l							
				T4	20/10/91	60.0	160.0	nmol/l	147.10						
				7	LK	MALE	HB	20/10/91	7.5	10.0	mmol/l	31/10/91	15/11/91	02/12/91	16/12/91
							HTC	20/10/91	0.4	0.5	l/l	10.80	10.10	9.89	10.50
							PRC	20/10/91	4.5	5.0	10**12/l	0.45	0.46	0.45	0.46
							WBC	20/10/91	4.0	10.0	10**9/l	5.53	5.32	5.11	5.26
							WBC: N	20/10/91	60.0	70.0	%	8.50	6.20	9.00	5.70
WBC: L	20/10/91	20.0	45.0				%	62.00	66.00	63.00	60.00				
WBC: E	20/10/91	1.0	5.0				%	32.00	28.00	31.00	30.00				
WBC: M	20/10/91	1.0	6.0				%	0.00	4.00	5.00	5.00				
WBC: B	20/10/91	0.0	1.0				%	3.00	2.00	0.00	0.00				
PLATELETS	20/10/91	140.0	300.0				10**9/l	295.00	284.00	175.00	137.00				
NA+	20/10/91	137.0	147.0				mmol/l	140.00	144.00	140.00					
K+	20/10/91	3.7	5.3				mmol/l	3.80	4.50	4.20	3.90				
CL-	20/10/91	97.0	107.0				mmol/l			79.00	96.00				
CA++	20/10/91	2.3	2.7				mmol/l	2.34	0.72	2.40	2.38				
PO4--	20/10/91	0.7	1.5				mmol/l	0.74	0.78	0.78	0.73				
SGPT	20/10/91	5.0	30.0				U/l	15.00	13.00	10.00	19.00				
GAMMA-GT	20/10/91	5.0	34.0	U/l	15.00	15.00	13.00	19.00							
GLUCOSE	20/10/91	6.0	28.0	U/l	21.00	14.00	12.00	13.00							
ALK. PHOSPH.	20/10/91	3.3	5.5	mmol/l	4.30	4.80	4.00	3.90							
BUN	20/10/91	100.0	280.0	U/l	244.00	224.00	268.00	275.00							
CREATININE	20/10/91	3.0	9.6	mmol/l		3.90	5.10								
URIC ACID	20/10/91	50.0	110.0	umol/l	86.00	86.00	64.00	70.00							
TOT BILIRUBIN	20/10/91	120.0	410.0	umol/l	303.00	259.00	306.00	311.00							
DIR BILIRUBIN	20/10/91	3.4	22.0	umol/l	25.70	9.90	7.60	7.90							
TOT. PROTEINS	20/10/91	0.0	4.5	umol/l	11.90	4.60	7.50	5.20							
ALBUMINE	20/10/91	60.0	80.0	g/l	75.00	70.00	70.00	71.00							
TOT. CHOLEST.	20/10/91	0.5	0.7	RATIO	0.52	0.64	0.64	0.64							
TRIGLYCERIDES	20/10/91	2.5	7.0	mmol/l	4.50	4.30	4.30	4.60							
GLOBULINS: ALPHA 1	20/10/91	0.5	1.9	mmol/l	2.20	1.30	1.00	1.90							
GLOBULINS: ALPHA 2	20/10/91	0.0	0.1	RATIO	0.04	0.05	0.04	0.04							
GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.13	0.08	0.08	0.07							
GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.12	0.10	0.10	0.10							
T3	20/10/91	0.9	1.1	nmol/l	1.00	0.11	0.14	0.13							
T4	20/10/91	60.0	160.0	nmol/l	98.60										

1770

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013

Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit									
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6					
12	8	FH	FEMALE	HB	20/10/91	7.5	10.0	mmol/l	25/10/91	7.19	21/11/91	8.36	28/11/91	7.85	12/12/91	8.57
				HTC	20/10/91	0.4	0.5	l/l	0.36	0.36	0.36	0.38	0.40			
				RBC	20/10/91	4.5	5.0	10**12/l	4.33	4.68	4.54	4.82	4.82			
				WBC	20/10/91	4.0	10.0	10**9/l	4.80	6.60	6.60	5.60	5.60			
				HBC: N	20/10/91	60.0	70.0	%	72.00	62.00	63.00	62.00	62.00			
				HBC: L	20/10/91	20.0	45.0	%	26.00	33.00	30.00	32.00	32.00			
				HBC: E	20/10/91	1.0	5.0	%	2.00	5.00	6.00	2.00	2.00			
				HBC: M	20/10/91	1.0	6.0	%	0.00	0.00	1.00	4.00	4.00			
				HBC: B	20/10/91	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00			
				PLATELETS	20/10/91	140.0	300.0	10**9/l	145.00	220.00	268.00	251.00	251.00			
				NA+	20/10/91	137.0	147.0	mmol/l	145.00	136.00	142.00	144.00	144.00			
				K+	20/10/91	3.7	5.3	mmol/l	3.90	3.30	3.80	3.70	3.70			
				Cl-	20/10/91	97.0	107.0	mmol/l	2.62	2.36	2.30	2.14	2.14			
				Ca++	20/10/91	2.3	2.7	mmol/l	1.04	1.33	1.24	1.24	1.24			
				PO4-	20/10/91	0.7	1.5	mmol/l	21.00	30.00	13.00	26.00	26.00			
				SGPT	20/10/91	5.0	30.0	U/l	36.00	71.00	45.00	45.00	45.00			
				SGPT	20/10/91	5.0	34.0	U/l	39.00	36.00	28.00	28.00	28.00			
				GAMMA-GT	20/10/91	6.0	28.0	U/l	3.90	4.70	4.50	4.20	4.20			
				GLUCOSE	20/10/91	3.3	5.5	mmol/l	280.00	320.00	316.00	291.00	291.00			
				ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	7.40	6.70	6.00	7.10	7.10			
				UREA	20/10/91	3.0	9.6	mmol/l	92.00	93.00	87.00	95.00	95.00			
				CREATININE	20/10/91	50.0	110.0	umol/l	326.00	308.00	224.00	321.00	321.00			
				URIC ACID	20/10/91	120.0	410.0	umol/l	17.10	17.10	17.10	9.60	9.60			
				TOT BILIRUBIN	20/10/91	3.4	22.0	umol/l	68.00	79.00	84.00	5.00	5.00			
				DIR BILIRUBIN	20/10/91	0.0	4.5	umol/l	0.64	0.59	0.56	0.56	0.56			
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	6.20	6.00	6.90	6.70	6.70			
				ALBUMINE	20/10/91	0.5	0.7	RATIO	2.10	1.40	2.60	1.80	1.80			
				TRIGLYCERIDES	20/10/91	2.6	7.0	mmol/l	0.02	0.04	0.04	0.04	0.04			
				GLOBULINS: ALPHA 1	20/10/91	0.3	1.9	RATIO	0.07	0.08	0.09	0.09	0.09			
				GLOBULINS: ALPHA 2	20/10/91	0.0	0.1	RATIO	0.09	0.11	0.11	0.11	0.11			
				GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.17	0.18	0.18	0.18	0.18			
				GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	79.10	79.10	79.10	79.10	79.10			
				T3	20/10/91	0.9	1.1	mmol/l	8.94	8.94	8.19	8.47	8.47			
T4	20/10/91	60.0	160.0	mmol/l	0.35	0.35	0.38	0.40	0.40							
9	KBP		FEMALE	HB	20/10/91	7.5	10.0	mmol/l	25/10/91	7.92	13/11/91	8.94	28/11/91	8.94	11/12/91	8.47
				HTC	20/10/91	0.4	0.5	l/l	0.35	0.35	0.38	0.40	0.40			
				RBC	20/10/91	4.5	5.0	10**12/l	7.50	4.22	4.17	4.40	4.40			
				WBC	20/10/91	4.0	10.0	10**9/l	3.88	10.20	12.20	8.10	8.10			
				HBC: N	20/10/91	60.0	70.0	%	56.00	65.00	65.00	54.00	54.00			
				HBC: L	20/10/91	20.0	45.0	%	38.00	30.00	27.00	38.00	38.00			
				HBC: E	20/10/91	1.0	5.0	%	2.00	5.00	5.00	2.00	2.00			
				HBC: M	20/10/91	1.0	6.0	%	4.00	1.00	0.00	6.00	6.00			
				HBC: B	20/10/91	0.0	1.0	%	0.00	1.00	2.00	0.00	0.00			
				PLATELETS	20/10/91	140.0	300.0	10**9/l	145.00	190.00	260.00	180.00	180.00			
				NA+	20/10/91	137.0	147.0	mmol/l	202.00	137.00	144.00	144.00	144.00			
				K+	20/10/91	3.7	5.3	mmol/l	4.60	5.10	4.60	4.60	4.60			

1771

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Date	Laboratory Range		Screen	Visit							
						Min	Max		Unit	Week 2	Week 4	Week 6				
12	10	IP	FEMALE	TOT. PROTEINS	20/10/91	60.0	80.0	g/l	65.00	59.00	63.00	67.00				
				ALBUMINE	20/10/91	0.5	0.7	RATIO	0.67		0.67	0.68				
				TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	5.10	4.50	5.00	5.30				
				TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	0.90	0.50	0.90	1.20				
				GLOBULINS: ALPHA 1	20/10/91	0.0	0.1	RATIO	0.07		0.04	0.05				
				GLOBULINS: ALPHA 2	20/10/91	0.1	0.1	RATIO	0.07		0.08	0.07				
				GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.04		0.08	0.04				
				GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.15		0.13	0.13				
				T3	20/10/91	0.9	1.1	nmol/l	1.01							
				T4	20/10/91	60.0	160.0	nmol/l	79.60							
				11	ER		FEMALE	HB	20/10/91	7.5	10.0	mmol/l	31/10/91	13/11/91	27/11/91	12/12/91
								HTC	20/10/91	0.4	0.5	l/l	8.49	8.06	7.92	8.12
								RBC	20/10/91	4.5	5.0	10 ¹² /l	0.36	0.36	0.37	0.36
								WBC	20/10/91	4.0	10.0	10 ⁹ /l	4.62	4.47	4.50	4.22
NBC: N	20/10/91	60.0	70.0					%	7.00	6.70	6.50	7.00				
NBC: L	20/10/91	20.0	45.0					%	59.00	58.00	54.00	72.00				
NBC: E	20/10/91	1.0	5.0					%	35.00	38.00	45.00	23.00				
NBC: M	20/10/91	1.0	6.0					%	0.00	4.00	1.00	4.00				
NBC: B	20/10/91	0.0	1.0					%	0.00	0.00	0.00	1.00				
PLATELETS	20/10/91	140.0	300.0					10 ⁹ /l	0.00	0.00	0.00	0.00				
K+	20/10/91	137.0	147.0					mmol/l	237.00	290.00	285.00	411.00				
Cl-	20/10/91	97.0	107.0					mmol/l	141.00	142.00	145.00	140.00				
Ca++	20/10/91	3.7	5.3					mmol/l	4.50	4.60	4.70	4.50				
PO4-	20/10/91	2.3	2.7					mmol/l	2.44	2.44	2.22	2.28				
SGPT	20/10/91	0.7	1.5	mmol/l	1.44	1.32	1.07	1.08								
GAMMA-GT	20/10/91	5.0	30.0	U/l	22.00	27.00	6.00	24.00								
GLUCOSE	20/10/91	6.0	34.0	U/l	21.00	26.00	26.00	29.00								
BUN	20/10/91	3.3	5.5	mmol/l	41.00	19.00	19.00	20.00								
CREATININE	20/10/91	100.0	280.0	U/l	3.60	159.00	190.00	217.00								
TOT BILIRUBIN	20/10/91	3.0	9.6	mmol/l	5.40	4.30	4.30	4.50								
DIR BILIRUBIN	20/10/91	50.0	110.0	mmol/l	104.00	91.00	81.00	88.00								
TOT. PROTEINS	20/10/91	120.0	410.0	mmol/l	273.00	333.00	296.00	326.00								
ALBUMINE	20/10/91	3.4	22.0	mmol/l	18.20	8.10	9.50	9.50								
TRIGLYCERIDES	20/10/91	0.0	4.5	mmol/l	13.60	7.40	3.90	7.40								
TOT. CHOLEST.	20/10/91	60.0	80.0	g/l	73.00	73.00	67.00	75.00								
GLOBULINS: ALPHA 1	20/10/91	0.5	0.7	RATIO	0.55	0.71	0.60	0.62								
GLOBULINS: ALPHA 2	20/10/91	2.6	7.0	mmol/l	9.70	8.10	7.20	6.40								
GLOBULINS: BETA	20/10/91	0.3	1.9	mmol/l	2.20	2.10	2.10	1.30								
GLOBULINS: GAMMA	20/10/91	0.0	0.1	RATIO	0.03	0.05	0.03	0.05								
T3	20/10/91	0.1	0.1	RATIO	0.12	0.06	0.07	0.08								
T4	20/10/91	0.1	0.2	RATIO	0.21	0.12	0.21	0.16								
12	FSZ		FEMALE	HB	20/10/91	60.0	160.0	mmol/l	101.40							
				HTC	20/10/91	0.9	1.1	mmol/l	0.92							
				RBC	20/10/91	60.0	160.0	mmol/l	101.40							
				WBC	20/10/91	60.0	160.0	mmol/l	101.40							
				NBC: N	20/10/91	60.0	160.0	mmol/l	101.40							
				NBC: L	20/10/91	60.0	160.0	mmol/l	101.40							
				NBC: E	20/10/91	60.0	160.0	mmol/l	101.40							
				NBC: M	20/10/91	60.0	160.0	mmol/l	101.40							
				NBC: B	20/10/91	60.0	160.0	mmol/l	101.40							
				PLATELETS	20/10/91	60.0	160.0	mmol/l	101.40							
				K+	20/10/91	60.0	160.0	mmol/l	101.40							
				Cl-	20/10/91	60.0	160.0	mmol/l	101.40							
				PO4-	20/10/91	60.0	160.0	mmol/l	101.40							
				SGPT	20/10/91	60.0	160.0	mmol/l	101.40							
GAMMA-GT	20/10/91	60.0	160.0	mmol/l	101.40											
GLUCOSE	20/10/91	60.0	160.0	mmol/l	101.40											
BUN	20/10/91	60.0	160.0	mmol/l	101.40											
CREATININE	20/10/91	60.0	160.0	mmol/l	101.40											
TOT BILIRUBIN	20/10/91	60.0	160.0	mmol/l	101.40											
DIR BILIRUBIN	20/10/91	60.0	160.0	mmol/l	101.40											
TOT. PROTEINS	20/10/91	60.0	160.0	mmol/l	101.40											
ALBUMINE	20/10/91	60.0	160.0	mmol/l	101.40											
TRIGLYCERIDES	20/10/91	60.0	160.0	mmol/l	101.40											
TOT. CHOLEST.	20/10/91	60.0	160.0	mmol/l	101.40											
GLOBULINS: ALPHA 1	20/10/91	60.0	160.0	mmol/l	101.40											
GLOBULINS: ALPHA 2	20/10/91	60.0	160.0	mmol/l	101.40											
GLOBULINS: BETA	20/10/91	60.0	160.0	mmol/l	101.40											
GLOBULINS: GAMMA	20/10/91	60.0	160.0	mmol/l	101.40											
T3	20/10/91	60.0	160.0	mmol/l	101.40											
T4	20/10/91	60.0	160.0	mmol/l	101.40											

1773

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Date	Laboratory Range		Unit	Screen	Visit					
						Min	Max			Week 2	Week 4	Week 6	Week 8	Week 10	Week 12
12	12	FSZ	FEMALE	HB	20/10/91	7.5	10.0	mmol/l	8.99	8.61	9.48	8.60			
				HTC	20/10/91	0.4	0.5	l/l	0.42	0.38	0.44	0.40			
				RBC	20/10/91	4.5	5.0	10**12/l	5.08	4.68	5.34	4.89			
				HBC	20/10/91	4.0	10.0	10**9/l	7.70	9.80	7.90	6.50			
				HBC: N	20/10/91	60.0	70.0	Z	64.00	59.00	68.00	70.00			
				HBC: L	20/10/91	20.0	45.0	Z	30.00	31.00	28.00	28.00			
				HBC: E	20/10/91	1.0	5.0	Z	2.00	5.00	3.00	0.00			
				HBC: M	20/10/91	1.0	6.0	Z	3.00	4.00	1.00	2.00			
				HBC: B	20/10/91	0.0	1.0	Z	1.00	1.00	0.00	0.00			
				PLATELETS	20/10/91	140.0	300.0	10**9/l	140.00	305.00	324.00	315.00			
				NA+	20/10/91	137.0	147.0	mmol/l	140.00	147.00	142.00	140.00			
				K+	20/10/91	3.7	5.3	mmol/l	4.10	4.80	4.50	4.10			
				CL-	20/10/91	97.0	107.0	mmol/l	4.10	4.80	73.00	96.00			
				CA++	20/10/91	2.3	2.7	mmol/l	2.16	2.11	2.39	2.28			
				PO4--	20/10/91	0.7	1.5	mmol/l	1.07	1.08	1.11	1.07			
				SGOT	20/10/91	5.0	30.0	U/l	18.00	27.00	15.00	21.00			
				SGPT	20/10/91	5.0	34.0	U/l	20.00	35.00	17.00	22.00			
				GAMMA-GT	20/10/91	6.0	28.0	U/l	19.00	23.00	23.00	20.00			
				GLUCOSE	20/10/91	3.3	5.5	mmol/l	3.40	3.50	3.90	3.30			
				ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	169.00	199.00	220.00	208.00			
				UREA	20/10/91	3.0	9.6	mmol/l	6.20	7.90	6.30	6.20			
				CREATININE	20/10/91	50.0	110.0	umol/l	87.00	76.00	69.00	62.00			
				URIC ACID	20/10/91	120.0	410.0	umol/l	205.00	226.00	219.00	272.00			
				TOT BILIRUBIN	20/10/91	3.4	22.0	umol/l	17.10	8.90	7.90	5.30			
				DIR BILIRUBIN	20/10/91	0.0	4.5	umol/l	17.10	8.90	7.90	5.30			
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	63.00	76.00	76.00	67.00			
				ALBUMINE	20/10/91	0.5	0.7	RATIO	0.53	0.66	0.67	0.67			
				TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	4.30	5.50	5.70	5.00			
				TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	2.90	1.90	2.10	1.40			
				GLOBULINS: ALPHA 1	20/10/91	0.0	0.1	RATIO	0.07	0.05	0.04	0.04			
				GLOBULINS: ALPHA 2	20/10/91	0.1	0.1	RATIO	0.11	0.07	0.07	0.07			
				GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.11	0.09	0.09	0.08			
				GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.20	0.14	0.13	0.14			
T3	20/10/91	0.9	1.1	mmol/l	1.10	1.10	1.10	1.10							
T4	20/10/91	60.0	160.0	mmol/l	71.30	71.30	71.30	71.30							
13	ISZ	FEMALE	HB	20/10/91	7.5	10.0	mmol/l	8.73	8.36	8.87	8.53				
			HTC	20/10/91	0.4	0.5	l/l	0.43	0.36	0.43	0.38				
			RBC	20/10/91	4.5	5.0	10**12/l	4.25	3.85	4.21	4.60				
			HBC	20/10/91	4.0	10.0	10**9/l	6.50	6.50	6.00	6.90				
			HBC: N	20/10/91	60.0	70.0	Z	65.00	78.00	68.00	69.00				
			HBC: L	20/10/91	20.0	45.0	Z	29.00	18.00	31.00	26.00				
			HBC: E	20/10/91	1.0	5.0	Z	3.00	0.00	0.00	2.00				
			HBC: M	20/10/91	1.0	6.0	Z	3.00	0.00	1.00	5.00				
			HBC: B	20/10/91	0.0	1.0	Z	0.00	0.00	0.00	0.00				
			PLATELETS	20/10/91	140.0	300.0	10**9/l	316.00	356.00	149.00	374.00				
			NA+	20/10/91	137.0	147.0	mmol/l	141.00	146.00	141.00	141.00				
			K+	20/10/91	3.7	5.3	mmol/l	4.50	4.50	4.40	4.20				
			CL-	20/10/91	97.0	107.0	mmol/l	3.70	4.50	4.40	4.20				

1774

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit				
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6
12	13	ISZ	FEMALE	CA++	20/10/91	2.3	2.7	mmol/L	2.24	2.04	2.27	2.42
				PO4-	20/10/91	0.7	1.5	mmol/L	1.19	1.21	1.32	1.16
				SGPT	20/10/91	5.0	30.0	U/l	39.00	25.00	10.00	23.00
				SGPT	20/10/91	5.0	34.0	U/l	65.00	42.00	12.00	19.00
				GAMMA-GT	20/10/91	6.0	28.0	U/l	59.00	32.00	19.00	14.00
				GLUCOSE	20/10/91	3.3	5.5	mmol/L	4.30	4.10	4.20	4.90
				ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	162.00	138.00	135.00	141.00
				BUN	20/10/91	3.0	9.6	mmol/L	6.90	6.50	8.40	8.40
				CREATININE	20/10/91	50.0	110.0	umol/L	88.00	75.00	60.00	57.00
				URIC ACID	20/10/91	120.0	410.0	umol/L	251.00	215.00	214.00	193.00
				TOT BILIRUBIN	20/10/91	3.4	22.0	umol/L	17.10	10.10	12.90	7.60
				DIR BILIRUBIN	20/10/91	0.0	4.5	umol/L	72.00	71.00	66.00	70.00
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	0.64	0.63	0.63	0.68
				ALBUMINE	20/10/91	0.5	0.7	RATIO	5.70	4.90	5.30	5.10
				TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/L	2.10	0.90	0.90	0.80
				TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/L	0.04	0.03	0.04	0.03
				GLOBULINS: ALPHA 1	20/10/91	0.0	0.1	RATIO	0.06	0.07	0.07	0.06
				GLOBULINS: ALPHA 2	20/10/91	0.1	0.1	RATIO	0.09	0.09	0.09	0.07
				GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.16	0.17	0.17	0.15
				GLOBULINS: GAMMA	20/10/91	0.9	1.1	mmol/L	1.01	1.01	1.01	1.01
T3	20/10/91	60.0	160.0	mmol/L	62.70							
T4	20/10/91											
14	GSZ	FEMALE	HB	20/10/91	7.5	10.0	mmol/L	31/10/91	19/11/91	03/12/91	17/12/91	
			HTC	20/10/91	0.4	0.5	l/l	8.96	9.16	9.10	9.10	
			RBC	20/10/91	4.5	5.0	10**12/l	0.39	0.41	0.44	0.44	
			RBC	20/10/91	4.0	10.0	10**9/l	4.81	4.88	4.88	4.88	
			WBC: N	20/10/91	60.0	70.0	%	6.90	7.80	63.00	70.00	
			WBC: L	20/10/91	20.0	45.0	%	31.00	59.00	35.00	25.00	
			WBC: E	20/10/91	1.0	5.0	%	3.00	4.10	0.00	1.00	
			WBC: M	20/10/91	1.0	6.0	%	3.00	0.00	2.00	4.00	
			WBC: B	20/10/91	0.0	1.0	%	0.00	0.00	0.00	0.00	
			PLATELETS	20/10/91	160.0	300.0	10**9/l	305.00	297.00	219.00	258.00	
			HA+	20/10/91	137.0	147.0	mmol/l	136.00	141.00	146.00	136.00	
			K+	20/10/91	3.7	5.3	mmol/l	4.00	4.80	4.40	3.90	
			CL-	20/10/91	97.0	107.0	mmol/l	2.31	98.00	2.41	2.26	
			CA++	20/10/91	2.3	2.7	mmol/l	1.52	2.26	1.17	1.01	
			PO4-	20/10/91	0.7	1.5	mmol/l	21.00	16.00	14.00	22.00	
			SGPT	20/10/91	5.0	30.0	U/l	37.00	21.00	24.00	26.00	
			SGPT	20/10/91	5.0	34.0	U/l	28.00	22.00	18.00	31.00	
			GAMMA-GT	20/10/91	6.0	28.0	U/l	5.40	4.40	4.30	6.10	
			GLUCOSE	20/10/91	3.3	5.5	mmol/L	198.00	176.00	181.00	160.00	
			ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	4.60	4.30	4.70	5.00	
BUN	20/10/91	3.0	9.6	mmol/L	86.00	53.00	58.00	273.00				
CREATININE	20/10/91	50.0	110.0	umol/l	194.00	333.00	426.00	50.00				
URIC ACID	20/10/91	120.0	410.0	umol/l	7.90	13.50	8.30	8.30				
TOT BILIRUBIN	20/10/91	3.4	22.0	umol/l	4.10	6.30	3.80	3.50				
DIR BILIRUBIN	20/10/91	0.0	4.5	umol/l	67.00	67.00	67.00	67.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit									
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6					
12	14	GS2	FEMALE	ALBUMINE	20/10/91	0.5	0.7	RATIO	0.37	0.63	0.64	0.65				
				TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	6.80	6.70	6.50	7.30				
				TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	1.60	1.70	1.00	1.70				
				GLOBULINS: ALPHA 1	20/10/91	0.0	0.1	RATIO	0.04	0.04	0.04	0.05				
				GLOBULINS: ALPHA 2	20/10/91	0.1	0.1	RATIO	0.07	0.09	0.08	0.08				
				GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.25	0.10	0.10	0.08				
				GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.27	0.14	0.14	0.14				
				T3	20/10/91	0.9	1.1	nmol/l	0.87	.	.	.				
				T4	20/10/91	60.0	160.0	nmol/l	111.60	.	.	.				
				15	GB		MALE	ALBUMINE	20/10/91	7.5	10.0	mmol/l	8.97	9.16	8.83	9.06
								HB	20/10/91	0.4	0.5	l/l	0.38	0.44	0.43	0.42
								HRC	20/10/91	4.5	5.0	10**12/l	4.56	5.07	4.80	4.66
								HRC: N	20/10/91	4.0	10.0	10**9/l	5.90	6.70	8.20	7.10
								HRC: L	20/10/91	60.0	70.0	z	58.00	69.00	56.00	61.00
HRC: E	20/10/91	1.0	45.0					z	32.00	27.00	30.00	35.00				
HRC: R	20/10/91	1.0	5.0					z	4.00	1.00	4.00	2.00				
HRC: B	20/10/91	1.0	6.0					z	5.00	2.00	8.00	1.00				
PLATELETS	20/10/91	0.0	1.0					z	1.00	2.00	2.00	0.00				
Na+	20/10/91	140.0	300.0					10**9/l	166.00	259.00	186.00	181.00				
K+	20/10/91	137.0	147.0					mmol/l	144.00	143.00	141.00	145.00				
Ca++	20/10/91	3.7	5.3					mmol/l	4.50	4.50	4.10	3.80				
PO4--	20/10/91	2.3	2.7					mmol/l	2.25	2.34	2.40	2.29				
SOPT	20/10/91	0.7	1.5					mmol/l	1.10	1.34	0.99	1.03				
SOPT	20/10/91	5.0	30.0	U/l	33.00	40.00	31.00	35.00								
GAMMA-GT	20/10/91	5.0	34.0	U/l	55.00	65.00	49.00	67.00								
GLUCOSE	20/10/91	6.0	28.0	U/l	43.00	34.00	25.00	32.00								
ALK. PHOSPH.	20/10/91	3.3	5.5	mmol/l	3.90	3.70	3.20	4.90								
BUN	20/10/91	100.0	280.0	U/l	236.00	296.00	326.00	270.00								
CREATININE	20/10/91	3.0	9.6	mmol/l	7.30	6.10	6.10	6.00								
URIC ACID	20/10/91	50.0	140.0	umol/l	103.00	90.00	59.00	93.00								
TOT BILIRUBIN	20/10/91	120.0	410.0	umol/l	259.00	349.00	355.00	368.00								
TOT. PROTEINS	20/10/91	3.4	22.0	umol/l	17.10	17.10	17.10	17.30								
ALBUMINE	20/10/91	60.0	80.0	g/l	69.00	73.00	65.00	73.00								
TOT. CHOLEST.	20/10/91	0.5	0.7	RATIO	0.64	0.64	0.61	0.63								
TRIGLYCERIDES	20/10/91	2.6	7.0	mmol/l	4.30	4.30	3.30	4.50								
GLOBULINS: ALPHA 1	20/10/91	0.3	1.9	mmol/l	1.50	0.90	0.04	0.70								
GLOBULINS: ALPHA 2	20/10/91	0.0	0.1	RATIO	0.02	0.02	0.04	0.04								
GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.07	0.07	0.09	0.08								
GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.09	0.09	0.09	0.10								
T3	20/10/91	0.9	1.1	nmol/l	2.10	.	.	.								
T4	20/10/91	60.0	160.0	nmol/l	50.50	.	.	.								
16	FN		FEMALE	ALBUMINE	20/10/91	7.5	10.0	mmol/l	7.72	7.06	8.03	7.62				
				HB	20/10/91	0.4	0.5	l/l	0.36	0.34	0.34	0.35				
				HRC	20/10/91	4.5	5.0	10**12/l	4.22	3.77	3.86	4.11				
				REC	20/10/91	4.5	5.0	10**12/l	4.22	3.77	3.86	4.11				

1776

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Date	Laboratory Range		Unit	Screen	Visit																								
				Min	Max			Week 2	Week 4	Week 6																						
12	16 FN	FEMALE																														
			Laboratory test																													
						20/10/91	4.0	10.0	10**9/l	5.30	5.30																					
						20/10/91	60.0	70.0	z	49.00	44.00																					
						20/10/91	20.0	45.0	z	42.00	56.00																					
						20/10/91	1.0	5.0	z	6.00	0.00																					
						20/10/91	1.0	6.0	z	3.00	0.00																					
						20/10/91	0.0	1.0	z	0.00	0.00																					
						20/10/91	140.0	300.0	10**9/l	226.00	151.00																					
						20/10/91	137.0	147.0	mmol/l	147.00	141.00																					
						20/10/91	3.7	5.3	mmol/l	3.80	4.10																					
						20/10/91	97.0	107.0	mmol/l	91.00																						
						20/10/91	2.3	2.7	mmol/l	1.90	1.95																					
						20/10/91	0.7	1.5	mmol/l	1.48	1.34																					
						20/10/91	5.0	30.0	U/l	8.00	22.00																					
						20/10/91	5.0	34.0	U/l	20.00	23.00																					
						20/10/91	6.0	28.0	U/l	14.00	13.00																					
						20/10/91	3.5	5.5	mmol/l	3.60	4.60																					
						20/10/91	100.0	280.0	U/l	155.00	165.00																					
						20/10/91	3.0	9.6	mmol/l	4.00	4.90																					
						20/10/91	50.0	110.0	mmol/l	67.00	58.00																					
						20/10/91	120.0	410.0	mmol/l	134.00	235.00																					
						20/10/91	3.4	22.0	mmol/l	6.20	6.20																					
						20/10/91	0.0	4.5	mmol/l	3.30	5.90																					
						20/10/91	60.0	80.0	g/l	64.00	72.00																					
						20/10/91	0.5	0.7	RATIO	0.65	0.67																					
			20/10/91	2.6	7.0	mmol/l	4.80	4.50																								
			20/10/91	0.3	1.9	mmol/l	0.90	2.80																								
			20/10/91	0.0	0.1	RATIO	0.03	0.03																								
			20/10/91	0.1	0.1	RATIO	0.07	0.07																								
			20/10/91	0.1	0.1	RATIO	0.07	0.07																								
			20/10/91	0.1	0.2	RATIO	0.17	0.16																								
			20/10/91	0.9	1.1	mmol/l	1.02	1.02																								
			20/10/91	60.0	160.0	mmol/l	88.30																									
17	TK	MALE																														
			Laboratory test																													
						09/01/92																										
						20/10/91	7.5	10.0	mmol/l	9.45	9.27																					
						20/10/91	0.4	0.5	l/l	0.49	0.43																					
						20/10/91	4.5	5.0	10**12/l	5.71	4.86																					
						20/10/91	4.0	10.0	10**9/l	6.00	5.60																					
						20/10/91	60.0	70.0	z	56.00	57.00																					
						20/10/91	20.0	45.0	z	40.00	38.00																					
						20/10/91	1.0	5.0	z	1.00	0.80																					
						20/10/91	1.0	6.0	z	3.00	4.00																					
						20/10/91	0.0	1.0	z	0.00	0.00																					
						20/10/91	140.0	300.0	10**9/l	245.00	208.00																					
						20/10/91	137.0	147.0	mmol/l	140.00	139.00																					
						20/10/91	3.7	5.3	mmol/l	3.60	4.50																					
						20/10/91	2.3	2.7	mmol/l	2.25	2.65																					
						20/10/91	0.7	1.5	mmol/l	1.01	1.01																					
						20/10/91	5.0	30.0	U/l	18.00	16.00																					
			20/10/91	5.0	34.0	U/l	24.00	22.00																								

1777

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6			
12	17	TK	MALE	GAMMA-GT	20/10/91	6.0	28.0	U/l	41.00	23.00	16.00	17.00			
				GLUCOSE	20/10/91	3.3	5.5	mmol/l	3.40	3.50	3.00	2.90			
				ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	200.00	181.00	169.00	155.00			
				BUN	20/10/91	3.0	9.6	mmol/l	5.60	4.70	4.20	4.10			
				CREATININE	20/10/91	50.0	110.0	umol/l	90.00	91.00	75.00	83.00			
				URIC ACID	20/10/91	120.0	410.0	umol/l	269.00	366.00	325.00	303.00			
				TOT BILIRUBIN	20/10/91	3.4	22.0	umol/l	14.80	17.10	9.80	11.80			
				DIR BILIRUBIN	20/10/91	0.0	4.5	umol/l	6.00	6.00	6.50	7.10			
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	70.00	71.00	76.00	79.00			
				ALBUMINE	20/10/91	0.5	0.7	RATIO	0.72	0.61	0.63	0.56			
				TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	5.10	5.00	4.80	5.30			
				TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	2.60	1.20	2.00	2.00			
				GLOBULINS: ALPHA 1	20/10/91	0.0	0.1	RATIO	0.02	0.08	0.05	0.07			
				GLOBULINS: ALPHA 2	20/10/91	0.1	0.1	RATIO	0.07	0.08	0.05	0.06			
				GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.06	0.08	0.06	0.09			
				GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.13	0.15	0.21	0.21			
				T3	20/10/91	0.9	1.1	mmol/l	1.08						
				T4	20/10/91	60.0	160.0	nmol/l	92.50						
				18	LS	MALE	HB	20/10/91	7.5	10.0	mmol/l	9.72	9.64	9.54	10.30
							HTC	20/10/91	0.4	0.5	l/l	0.51	0.45	0.45	0.44
RBC	20/10/91	4.5	5.0				10**12/l	5.62	4.76	4.71	4.84				
WBC	20/10/91	4.0	10.0				10**9/l	8.70	5.90	8.90	7.70				
WBC: N	20/10/91	60.0	70.0				%	60.00	61.00	65.00	40.00				
WBC: L	20/10/91	20.0	45.0				%	32.00	34.00	32.00	51.00				
WBC: E	20/10/91	1.0	5.0				%	4.00	4.00	1.00	5.00				
WBC: M	20/10/91	1.0	6.0				%	3.00	1.00	2.00	3.00				
WBC: B	20/10/91	0.0	1.0				%	1.00	0.00	0.00	0.00				
PLATELETS	20/10/91	140.0	300.0				10**9/l	225.00	188.00	237.00	251.00				
Na+	20/10/91	137.0	147.0				mmol/l	146.00	143.00	140.00	137.00				
K+	20/10/91	3.7	5.3				mmol/l	3.60	4.40	4.00	4.00				
Ca++	20/10/91	2.3	2.7				mmol/l	2.18	2.45	1.99	2.52				
PO4--	20/10/91	0.7	1.5				mmol/l	1.32	1.46	1.13	1.50				
SGOT	20/10/91	5.0	30.0				U/l	19.00	25.00	41.00	22.00				
SGPT	20/10/91	5.0	34.0				U/l	22.00	30.00	48.00	53.00				
GAMMA-GT	20/10/91	6.0	28.0				U/l	38.00	25.00	41.00	36.00				
GLUCOSE	20/10/91	3.3	5.5				mmol/l	3.30	3.40	2.70	3.40				
ALK. PHOSPH.	20/10/91	100.0	280.0				U/l	262.00	277.00	254.00	227.00				
BUN	20/10/91	3.0	9.6				mmol/l	3.70		4.00	5.90				
CREATININE	20/10/91	50.0	110.0	umol/l	78.00		74.00	95.00							
URIC ACID	20/10/91	120.0	410.0	umol/l	224.00		326.00	280.00							
TOT BILIRUBIN	20/10/91	3.4	22.0	umol/l	9.00		5.90	9.90							
DIR BILIRUBIN	20/10/91	0.0	4.5	umol/l	3.50		3.30	5.80							
TOT. PROTEINS	20/10/91	60.0	80.0	g/l	68.00		72.00	79.00							
ALBUMINE	20/10/91	0.5	0.7	RATIO	0.73		0.53	0.55							
TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	4.50		4.80	6.30							
TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	1.10		1.80	2.50							
GLOBULINS: ALPHA 1	20/10/91	0.0	0.1	RATIO	0.03		0.11	0.05							
GLOBULINS: ALPHA 2	20/10/91	0.1	0.1	RATIO	0.07		0.08	0.07							

1778

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit				
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6
12	18 LS	MALE	GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.07	0.09	0.11	0.11
			GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.10	0.18	0.17	0.21
			T3	20/10/91	0.9	1.1	nmol/l	1.04	.	.	.
			T4	20/10/91	60.0	160.0	nmol/l	101.40	.	.	.
			HB	20/10/91	7.5	10.0	mmol/l	10/01/92	29/01/92	12/02/92	26/02/92
			HTC	20/10/91	0.4	0.5	l/l	9.01	8.38	7.66	7.64
			RBC	20/10/91	4.5	5.0	10**12/l	0.41	0.38	0.36	0.37
			HBC: N	20/10/91	60.0	70.0	10**9/l	4.52	4.22	4.22	4.68
			HBC: L	20/10/91	20.0	45.0	z	8.70	8.00	7.30	8.40
HBC: E	20/10/91	1.0	5.0	z	66.00	36.00	54.00	58.00			
HBC: M	20/10/91	1.0	6.0	z	30.00	58.00	40.00	31.00			
HBC: B	20/10/91	0.0	1.0	z	0.00	3.00	3.00	2.00			
HBC: R	20/10/91	0.0	1.0	z	4.00	3.00	0.00	0.00			
PLATELETS	20/10/91	140.0	300.0	10**9/l	0.00	164.00	401.00	277.00			
Na+	20/10/91	137.0	147.0	mmol/l	339.00	141.00	140.00	136.00			
K+	20/10/91	3.7	5.5	mmol/l	4.10	4.50	4.60	4.10			
Ca++	20/10/91	2.3	2.7	mmol/l	2.25	2.20	2.22	2.62			
PO4+	20/10/91	0.7	1.5	mmol/l	1.18	1.40	0.93	1.22			
SGPT	20/10/91	5.0	30.0	U/l	22.00	14.00	19.00	21.00			
SGOT	20/10/91	5.0	34.0	U/l	23.00	10.00	9.00	26.00			
GAMMA-GT	20/10/91	6.0	28.0	U/l	22.00	18.00	16.00	23.00			
GLUCOSE	20/10/91	3.3	5.5	mmol/l	3.20	3.90	3.80	3.40			
ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	165.00	165.00	108.00	171.00			
BUN	20/10/91	3.0	9.6	mmol/l	5.50	5.30	5.60	6.30			
CREATININE	20/10/91	50.0	110.0	umol/l	86.00	86.00	86.00	78.00			
TOT BILIRUBIN	20/10/91	120.0	410.0	umol/l	238.00	222.00	186.00	260.00			
DIR BILIRUBIN	20/10/91	3.4	22.0	umol/l	10.80	17.10	6.50	8.00			
TOT. PROTEINS	20/10/91	60.0	80.0	g/l	10.40	3.60	3.60	4.00			
ALBUMINE	20/10/91	0.5	0.7	RATIO	73.00	69.00	69.00	76.00			
TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	0.72	0.65	0.56	0.53			
TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	6.40	6.00	4.90	5.70			
GLOBULINS: ALPHA 1	20/10/91	0.0	0.1	RATIO	2.40	1.00	1.20	2.00			
GLOBULINS: ALPHA 2	20/10/91	0.1	0.1	RATIO	0.01	0.02	0.04	0.06			
GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.06	0.04	0.07	0.08			
GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.07	0.06	0.11	0.12			
T3	20/10/91	0.9	1.1	nmol/l	1.40	0.22	0.23	0.21			
T4	20/10/91	60.0	160.0	nmol/l	69.90	.	.	.			
20	KSZ	MALE	HB	20/10/91	7.5	10.0	mmol/l	10/01/92	30/01/92	13/02/92	27/02/92
			HTC	20/10/91	0.4	0.5	l/l	8.72	8.65	8.39	7.64
			RBC	20/10/91	4.5	5.0	10**12/l	0.39	0.39	0.40	0.37
			HBC: N	20/10/91	4.0	10.0	10**9/l	4.14	4.33	4.19	4.62
			HBC: L	20/10/91	60.0	70.0	z	37.00	6.70	4.60	4.50
			HBC: E	20/10/91	20.0	45.0	z	55.00	55.00	64.00	44.00
			HBC: M	20/10/91	20.0	45.0	z	32.00	32.00	33.00	46.00
			HBC: B	20/10/91	1.0	5.0	z	7.00	6.00	1.00	8.00
			HBC: R	20/10/91	1.0	5.0	z	7.00	6.00	1.00	8.00

1779

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOMEXINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit							
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6			
12	20 K52	MALE	HBC: M	20/10/91	1.0	6.0	Z	3.00	7.00	2.00	2.00	2.00		
			HBC: B	20/10/91	0.0	1.0	Z	0.00	0.00	0.00	0.00	0.00		
			PLATELETS	20/10/91	140.0	300.0	10**9/1	255.00	223.00	168.00	168.00	289.00		
			NA+	20/10/91	137.0	147.0	mmol/l	141.00	141.00	140.00	140.00	140.00		
			K+	20/10/91	3.7	5.3	mmol/l	4.30	4.90	4.80	4.80	4.40		
			CL-	20/10/91	97.0	107.0	mmol/l			105.00	105.00	105.00		
			CA++	20/10/91	2.3	2.7	mmol/l	2.21	2.27	2.38	2.47	2.47		
			PO4-	20/10/91	0.7	1.5	mmol/l	0.82	1.04	1.01	1.16	1.16		
			SGPT	20/10/91	5.0	30.0	U/l	21.00	20.00	20.00	20.00	20.00		
			SGPT	20/10/91	5.0	34.0	U/l	25.00	21.00	24.00	24.00	36.00		
			GAMMA-GT	20/10/91	6.0	28.0	U/l	70.00	42.00	32.00	32.00	25.00		
			GLUCOSE	20/10/91	3.3	5.5	mmol/l	3.00	3.50	3.40	3.40	3.30		
			ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	202.00	218.00	162.00	162.00	168.00		
			BUN	20/10/91	3.0	9.6	mmol/l	3.90	3.80	4.50	4.50	3.70		
			CREATININE	20/10/91	50.0	110.0	umol/l	111.00	78.00	88.00	88.00	68.00		
			URIC ACID	20/10/91	120.0	410.0	umol/l	306.00	307.00	326.00	326.00	307.00		
			TOT BILIRUBIN	20/10/91	3.4	22.0	umol/l	9.70	5.90	10.20	10.20	9.30		
			DIR BILIRUBIN	20/10/91	0.0	4.5	umol/l	7.00	3.10	4.50	4.50	3.00		
			TOT. PROTEINS	20/10/91	60.0	80.0	g/l	64.00	80.00	61.00	61.00	63.00		
			ALBUMINE	20/10/91	0.5	0.7	RATIO	0.71	0.63	0.59	0.59	0.54		
			TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	4.10	4.70	4.20	4.20	4.20		
			TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	0.80	0.70	0.60	0.60	0.70		
			GLOBULINS: ALPHA 1	20/10/91	0.0	0.1	RATIO	0.02	0.05	0.05	0.05	0.08		
			GLOBULINS: ALPHA 2	20/10/91	0.1	0.1	RATIO	0.06	0.07	0.06	0.06	0.08		
			GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.06	0.09	0.06	0.06	0.11		
			GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.10	0.16	0.10	0.10	0.19		
			T3	20/10/91	0.9	1.1	mmol/l	1.09						
			T4	20/10/91	60.0	160.0	mmol/l	77.80						
			21	FL	FEMALE	HB	20/10/91	7.5	10.0	mmol/l	30/01/92	13/02/92	27/02/92	12/03/92
						HTC	20/10/91	0.4	0.5	l/l	8.88	9.59	8.02	8.74
RBC	20/10/91	4.5				5.0	10**12/l	0.41	0.48	0.41	0.41			
NBC	20/10/91	4.0				10.0	10**9/1	6.50	5.15	5.12	5.25			
WBC: N	20/10/91	60.0				70.0	Z	58.00	64.00	63.00	5.60			
WBC: L	20/10/91	20.0				45.0	Z	38.00	35.00	33.00	62.00			
WBC: E	20/10/91	1.0				5.0	Z	0.00	0.00	0.00	36.00			
WBC: M	20/10/91	1.0				6.0	Z	0.00	0.00	0.00	0.00			
HRC: B	20/10/91	0.0				1.0	Z	0.00	1.00	0.00	2.00			
PLATELETS	20/10/91	140.0				300.0	10**9/1	321.00	198.00	275.00	164.00			
NA+	20/10/91	137.0				147.0	mmol/l	143.00	143.00	140.00	140.00			
K+	20/10/91	3.7				5.3	mmol/l	4.30	4.50	4.80	5.00			
CL-	20/10/91	97.0				107.0	mmol/l			100.00	100.00			
CA++	20/10/91	2.3				2.7	mmol/l	2.23	2.39	2.44	2.43			
PO4-	20/10/91	0.7				1.5	mmol/l	1.03	0.88	1.74	1.00			
SGPT	20/10/91	5.0				30.0	U/l	21.00	18.00	10.00	15.00			
SGPT	20/10/91	5.0				34.0	U/l	34.00	10.00	23.00	20.00			
GAMMA-GT	20/10/91	6.0				28.0	U/l	19.00	18.00	20.00	24.00			
GLUCOSE	20/10/91	3.3				5.5	mmol/l	4.00	3.50	2.60	2.80			
ALK. PHOSPH.	20/10/91	100.0				280.0	U/l	195.00	175.00	146.00	152.00			

1780

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
12	21	FL	FEMALE	BUN	20/10/91	3.0	9.6	mmol/L	.	3.30	5.30	5.30				
				CREATININE	20/10/91	50.0	110.0	umol/L	.	87.00	69.00	95.00				
				URIC ACID	20/10/91	120.0	410.0	umol/L	271.00	299.00	178.00	484.00				
				TOT BILIRUBIN	20/10/91	3.4	22.0	umol/L	17.10	9.30	6.80	7.30				
				DIR BILIRUBIN	20/10/91	0.0	4.5	umol/L		3.60	3.50	4.80				
				TOT. PROTEINS	20/10/91	60.0	80.0	g/L	74.00	68.00	60.00	61.00				
				ALBUMINE	20/10/91	0.5	0.7	RATIO	0.64	0.61	0.60	0.59				
				TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/L	7.70	5.10	6.00	6.50				
				TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/L	1.50	1.80	1.70	2.20				
				GLUCOSYL: ALPHA 1	20/10/91	0.0	0.1	RATIO	0.06	0.04	0.05	0.07				
				GLUCOSYL: ALPHA 2	20/10/91	0.1	0.1	RATIO	0.08	0.08	0.07	0.08				
				GLUCOSYL: BETA	20/10/91	0.1	0.1	RATIO	0.08	0.06	0.09	0.11				
				GLUCOSYL: GAMMA	20/10/91	0.1	0.2	RATIO	0.15	0.21	0.18	0.15				
				T3	20/10/91	0.9	1.1	mmol/L	0.93	.	.	.				
				T4	20/10/91	60.0	160.0	mmol/L	143.70	.	.	.				
				22	NV	FEMALE	HB	20/10/91	7.5	10.0	mmol/L	8.77	8.19	7.90	8.60	
							HTC	20/10/91	0.4	0.5	L/L	0.41	0.39	0.32	0.40	
							RBC	20/10/91	4.5	5.0	10**12/L	5.09	4.58	4.01	5.23	
							HBC: N	20/10/91	4.0	10.0	10**9/L	6.20	4.80	4.60	4.50	
							HBC: L	20/10/91	60.0	70.0	z	57.00	64.00	66.00	68.00	
HBC: E	20/10/91	20.0	45.0				z	36.00	31.00	28.00	30.00					
HBC: H	20/10/91	1.0	5.0				z	0.00	0.00	5.00	2.00					
HBC: B	20/10/91	1.0	6.0				z	6.00	5.00	1.00	0.00					
PLATELETS	20/10/91	140.0	300.0				10**9/L	288.00	257.00	191.00	251.00					
NA+	20/10/91	137.0	147.0				mmol/L	162.00	138.00	145.00	139.00					
K+	20/10/91	3.7	5.3				mmol/L	4.90	4.40	4.50	3.90					
CL-	20/10/91	97.0	107.0				mmol/L	.	.	.	100.00					
CA++	20/10/91	2.3	2.7				mmol/L	2.43	2.10	2.56	2.11					
PO4--	20/10/91	0.7	1.5				mmol/L	1.53	1.42	1.31	1.14					
SGPT	20/10/91	5.0	30.0				U/L	19.00	19.00	99.00	32.00					
SGPT	20/10/91	5.0	34.0				U/L	16.00	14.00	148.00	47.00					
GAMMA-GT	20/10/91	6.0	28.0				U/L	36.00	34.00	51.00	35.00					
GLUCOSE	20/10/91	3.3	5.5				mmol/L	3.80	3.80	4.60	4.70					
ALK. PHOSPH.	20/10/91	100.0	280.0				U/L	298.00	225.00	284.00	263.00					
BUN	20/10/91	3.0	9.6				mmol/L	6.70	6.70	8.00	7.20					
CREATININE	20/10/91	50.0	110.0	umol/L	68.00	66.00	73.00	70.00								
URIC ACID	20/10/91	120.0	410.0	umol/L	203.00	196.00	171.00	171.00								
TOT BILIRUBIN	20/10/91	3.4	22.0	umol/L	21.30	11.80	11.70	11.70								
DIR BILIRUBIN	20/10/91	0.0	4.5	umol/L	7.40	5.50	10.60	10.60								
TOT. PROTEINS	20/10/91	60.0	80.0	g/L	75.00	71.00	79.00	70.00								
ALBUMINE	20/10/91	0.5	0.7	RATIO	0.62	0.60	0.57	0.57								
TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/L	9.30	7.40	8.10	8.10								
TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/L	2.40	1.90	2.70	2.70								
GLUCOSYL: ALPHA 1	20/10/91	0.0	0.1	RATIO	0.04	0.06	0.05	0.06								
GLUCOSYL: ALPHA 2	20/10/91	0.1	0.1	RATIO	0.08	0.07	0.08	0.08								
GLUCOSYL: BETA	20/10/91	0.1	0.1	RATIO	0.11	0.11	0.10	0.14								
GLUCOSYL: GAMMA	20/10/91	0.1	0.2	RATIO	0.15	0.15	0.17	0.15								

9550077

PHARMACIA CNS R&D
REBOMETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit					
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
12	22	MF	T3 T4	20/10/91 20/10/91	0.9 60.0	1.1 160.0	mmol/L mmol/L	0.91 122.60				
	23	EN	FEMALE									
			HB	20/10/91	7.5	10.0	mmol/L	8.55	9.56	7.76	8.06	
			HTC	20/10/91	0.4	0.5	L/l	0.38	0.44	0.35	0.40	
			RBC	20/10/91	4.5	5.0	10**12/l	4.09	4.60	4.59	4.52	
			WBC	20/10/91	4.0	10.0	10**9/l	9.30	12.00	7.90	8.80	
			NBC: N	20/10/91	60.0	70.0	%	53.00	63.00	54.00	62.00	
			NBC: L	20/10/91	20.0	45.0	%	31.00	32.00	32.00	36.00	
			NBC: E	20/10/91	1.0	5.0	%	9.00	6.00	8.00	2.00	
			NBC: M	20/10/91	1.0	6.0	%	2.00	0.00	5.00	0.00	
			NBC: B	20/10/91	0.0	1.0	%	0.00	0.00	1.00	0.00	
			PLATELETS	20/10/91	140.0	300.0	10**9/l	245.00	276.00	190.00	160.00	
			Na+	20/10/91	137.0	147.0	mmol/L	145.00	156.00	139.00	143.00	
			K+	20/10/91	3.7	5.3	mmol/L	4.50	4.60	4.20	4.70	
			Cl-	20/10/91	97.0	107.0	mmol/L	2.10	2.52	2.16	2.38	
			Ca++	20/10/91	2.3	2.7	mmol/L	1.11	1.11	0.90	1.29	
			PO4-	20/10/91	0.7	1.5	mmol/L	1.24	20.00	21.00	22.00	
			SGOT	20/10/91	5.0	30.0	U/l	15.00	19.00	16.00	21.00	
			SGPT	20/10/91	5.0	34.0	U/l	17.00	14.00	13.00	13.00	
			GAMMA-GT	20/10/91	6.0	28.0	U/l	3.90	202.00	2.50	3.40	
			GLUCOSE	20/10/91	3.3	5.5	mmol/L	179.00	202.00	142.00	138.00	
			BUN	20/10/91	100.0	280.0	U/l	6.70	7.20	6.20	8.40	
			CREATININE	20/10/91	3.0	9.6	mmol/L	63.00	83.00	83.00	91.00	
			URIC ACID	20/10/91	50.0	110.0	umol/L	164.00	241.00	268.00	252.00	
			TOT BILIRUBIN	20/10/91	120.0	410.0	umol/L	10.00	8.90	8.60	9.40	
			DIR BILIRUBIN	20/10/91	3.4	22.0	umol/L	3.00	6.50	3.80	6.10	
			TOT. PROTEINS	20/10/91	60.0	80.0	g/l	79.00	75.00	62.00	74.00	
			ALBUMINE	20/10/91	0.5	0.7	RATIO	0.61	0.56	0.53	0.57	
			TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/L	6.20	5.80	6.60	7.40	
			TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/L	1.00	1.80	1.50	1.70	
			GLOBULINS: ALPHA 1	20/10/91	0.0	0.1	RATIO	0.05	0.05	0.05	0.08	
			GLOBULINS: ALPHA 2	20/10/91	0.1	0.1	RATIO	0.08	0.08	0.08	0.07	
			GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.16	0.10	0.11	0.10	
			GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.18	0.20	0.23	0.18	
			T3	20/10/91	0.9	1.1	mmol/L	0.88				
			T4	20/10/91	60.0	160.0	mmol/L	94.00				
	24	MF	FEMALE									
			HB	20/10/91	7.5	10.0	mmol/L		21/02/92	06/03/92	20/03/92	
			HTC	20/10/91	0.4	0.5	L/l				7.91	
			RBC	20/10/91	4.5	5.0	10**12/l				0.44	
			WBC	20/10/91	4.0	10.0	10**9/l				5.85	
			NBC: N	20/10/91	60.0	70.0	%	54.00	55.00		6.90	
			NBC: L	20/10/91	20.0	45.0	%	42.00	40.00		46.00	
			NBC: E	20/10/91	1.0	5.0	%	3.00	3.00		44.00	
			NBC: M	20/10/91	1.0	6.0	%	3.00	2.00		10.00	
			NBC: B	20/10/91	1.0	6.0	%	3.00	2.00		0.00	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Date	Laboratory Range			Screen	Visit		
						Min	Max	Unit		Week 2	Week 4	Week 6
12	24	HF	FEMALE	HRC: B	20/10/91	0.0	1.0	%	0.00	0.00	0.00	0.00
				PLATELETS	20/10/91	140.0	300.0	10**9/1	0.00	324.00	297.00	
				NA+	20/10/91	137.0	147.0	mmol/l	248.00	140.00	149.00	
				K+	20/10/91	3.7	5.3	mmol/l	4.60	4.00	4.50	
				CL-	20/10/91	97.0	107.0	mmol/l	102.00	101.00	94.00	
				CA++	20/10/91	2.3	2.7	mmol/l	1.92	2.00	2.27	
				PO4--	20/10/91	0.7	1.5	mmol/l	1.25	1.20	1.11	
				SGOT	20/10/91	5.0	30.0	U/l	18.00	14.00	19.00	
				SGPT	20/10/91	5.0	34.0	U/l	22.00	15.00	21.00	
				GAMMA-GT	20/10/91	6.0	28.0	U/l	28.00	18.00	17.00	
				GLUCOSE	20/10/91	3.3	5.5	mmol/l	4.10	4.00	4.00	
				BUN	20/10/91	100.0	280.0	U/l	273.00	185.00	214.00	
				ALK. PHOSPH.	20/10/91	3.0	9.6	mmol/l	4.40	5.30	6.00	
				CREATININE	20/10/91	50.0	110.0	umol/l	70.00	65.00	58.00	
				URIC ACID	20/10/91	120.0	410.0	umol/l	207.00	266.00	256.00	
				TOT. BILIRUBIN	20/10/91	3.4	22.0	umol/l	4.60	5.90	7.80	
				DIR. BILIRUBIN	20/10/91	0.0	4.5	umol/l	3.10	4.60	6.00	
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	59.00	73.00	66.00	
				ALBUMINE	20/10/91	0.5	0.7	RATIO	0.54	0.56	0.59	
				TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	5.90	6.60	7.90	
TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	1.30	0.80	1.40					
GLOBULINS: ALPHA 1	20/10/91	0.0	0.1	RATIO	0.05	0.07	0.11					
GLOBULINS: ALPHA 2	20/10/91	0.1	0.1	RATIO	0.08	0.09	0.08					
GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.13	0.11	0.12					
GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.20	0.18	0.15					
T3	20/10/91	0.9	1.1	mmol/l	1.04	1.04	1.04					
T4	20/10/91	60.0	160.0	mmol/l	114.80	114.80	114.80					
25	FS	FEMALE	HB	20/10/91	7.5	10.0	mmol/l	9.96	8.84	8.59	8.59	
			HTC	20/10/91	0.4	0.5	L/l	0.46	0.39	0.42		
			RBC	20/10/91	4.5	5.0	10**12/l	4.78	4.58	5.12		
			HGB: N	20/10/91	4.0	10.0	10**9/l	4.50	4.00	5.00		
			HGB: L	20/10/91	60.0	70.0	%	62.00	56.00	60.00		
			HGB: E	20/10/91	20.0	45.0	%	35.00	37.00	40.00		
			HRC: M	20/10/91	1.0	5.0	%	1.00	3.00	2.00		
			HRC: B	20/10/91	1.0	6.0	%	2.00	4.00	1.00		
			HRC: A	20/10/91	0.0	1.0	%	0.00	0.00	0.00		
			PLATELETS	20/10/91	160.0	300.0	10**9/l	196.00	173.00	314.00		
			NA+	20/10/91	137.0	147.0	mmol/l	138.00	139.00	145.00		
			K+	20/10/91	3.7	5.3	mmol/l	3.60	3.80	3.90		
			CL-	20/10/91	97.0	107.0	mmol/l	102.00	98.00	100.00		
			CA++	20/10/91	2.3	2.7	mmol/l	2.37	2.42	2.35		
			PO4--	20/10/91	0.7	1.5	mmol/l	1.00	0.95	0.94		
			SGOT	20/10/91	5.0	30.0	U/l	14.00	9.00	17.00		
			SGPT	20/10/91	5.0	34.0	U/l	9.00	14.00	12.00		
			GAMMA-GT	20/10/91	6.0	28.0	U/l	31.00	15.00	15.00		
			GLUCOSE	20/10/91	3.3	5.5	mmol/l	4.60	4.00	3.10		
			BUN	20/10/91	100.0	280.0	U/l	181.00	134.00	189.00		
ALK. PHOSPH.	20/10/91	3.0	9.6	mmol/l	6.00	6.00	6.30					

17803

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REROXETINE - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Date	Laboratory Range		Unit	Screen	Visit					
						Min	Max			Week 2	Week 4	Week 6			
12	25	FS	FEMALE	CREATININE	20/10/91	50.0	110.0	umol/l	58.00	55.00	73.00	63.00			
				URIC ACID	20/10/91	120.0	410.0	umol/l	291.00	290.00	307.00	288.00			
				TOT BILIRUBIN	20/10/91	3.4	22.0	umol/l	9.50	9.50	17.10	9.40			
				DIR BILIRUBIN	20/10/91	0.0	4.5	umol/l	3.10	4.00	9.10	8.40			
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	82.00	70.00	60.00	75.00			
				ALBUMINE	20/10/91	0.5	0.7	RATIO	0.58	0.55	0.55	0.53			
				TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	5.50	6.80	8.50	8.80			
				TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	1.20	2.00	4.00	2.00			
				GLOBULINS: ALPHA 1	20/10/91	0.0	0.1	RATIO	0.05	0.07	0.09	0.08			
				GLOBULINS: ALPHA 2	20/10/91	0.1	0.1	RATIO	0.08	0.08	0.07	0.07			
				GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.13	0.12	0.13	0.13			
				GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.16	0.19	0.16	0.19			
				T3	20/10/91	0.9	1.1	nmol/l	1.90						
				T4	20/10/91	60.0	160.0	nmol/l	152.90						
26	LB		MALE	HB	20/10/91	7.5	10.0	mmol/l	10.20	19/02/92	05/02/92	03/03/92	17/03/92		
				HTC	20/10/91	0.4	0.5	l/l	0.47	0.56	0.86	0.86	9.95		
				PRC	20/10/91	4.5	5.0	10**12/l	4.53	4.44	0.41	0.41	0.48		
				WBC	20/10/91	4.0	10.0	10**9/l	5.60	6.30	5.64	5.72	5.30		
				WBC: N	20/10/91	60.0	70.0	%	46.00	56.00	45.00	45.00	56.00		
				WBC: L	20/10/91	20.0	45.0	%	50.00	41.00	48.00	44.00	44.00		
				WBC: E	20/10/91	1.0	5.0	%	2.00	1.00	3.00	0.00	0.00		
				WBC: R	20/10/91	1.0	6.0	%	2.00	2.00	4.00	0.00	0.00		
				WBC: B	20/10/91	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00		
				PLATELETS	20/10/91	140.0	300.0	10**9/l	203.00	274.00	179.00	156.00	156.00		
				K+	20/10/91	3.7	5.3	mmol/l	142.00	145.00	145.00	145.00	148.00		
				CL-	20/10/91	97.0	107.0	mmol/l	4.00	4.10	4.10	4.30	4.30		
				Ca++	20/10/91	2.3	2.7	mmol/l	2.41	2.65	2.27	2.40	2.40		
				PO4--	20/10/91	0.7	1.5	mmol/l	1.21	1.21	1.11	0.85	0.85		
				SGOT	20/10/91	5.0	30.0	U/l	17.00	18.00	26.00	28.00	28.00		
				SGPT	20/10/91	5.0	34.0	U/l	22.00	27.00	52.00	53.00	53.00		
				GAMMA-GT	20/10/91	6.0	28.0	U/l	61.00	54.00	61.00	51.00	51.00		
				GLUCOSE	20/10/91	3.3	5.5	mmol/l	3.30	4.20	4.20	4.20	4.20		
				ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	226.00	254.00	239.00	229.00	229.00		
				BUN	20/10/91	3.0	9.6	mmol/l	3.30	6.30	3.80	4.10	4.10		
				CREATININE	20/10/91	50.0	110.0	umol/l	88.00	102.00	107.00	74.00	74.00		
				URIC ACID	20/10/91	120.0	410.0	umol/l	396.00	435.00	499.00	452.00	452.00		
				TOT BILIRUBIN	20/10/91	3.4	22.0	umol/l	13.50	17.10	15.60	14.80	14.80		
				DIR BILIRUBIN	20/10/91	0.0	4.5	umol/l	3.10	4.00	9.10	8.40	8.40		
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	81.00	68.00	78.00	74.00	74.00		
				ALBUMINE	20/10/91	0.5	0.7	RATIO	0.60	0.62	0.55	0.60	0.60		
				TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	3.80	4.10	4.80	4.80	4.80		
				TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	0.90	1.20	1.10	1.10	1.10		
				GLOBULINS: ALPHA 1	20/10/91	0.0	0.1	RATIO	0.06	0.04	0.06	0.07	0.07		
				GLOBULINS: ALPHA 2	20/10/91	0.1	0.1	RATIO	0.10	0.05	0.08	0.08	0.08		
				GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.12	0.09	0.12	0.10	0.10		
				GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.12	0.20	0.21	0.15	0.15		
				T3	20/10/91	0.9	1.1	nmol/l	0.99						

1784

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
12	26	LB	MALE	T4	20/10/91	60.0	160.0	nmol/L	129.90				
	27	VCS	FEMALE	HB	20/10/91	7.5	10.0	mmol/L	5.98	07/02/92	21/02/92	06/03/92	20/03/92
				HTC	20/10/91	0.4	0.5	L/l	0.29				
				RBC	20/10/91	4.5	5.0	10 ^{xx} 12/l	3.07				
				RBC	20/10/91	4.0	10.0	10 ^{xx} 9/l	4.70				
				RBC: N	20/10/91	60.0	70.0	%	59.00				
				RBC: L	20/10/91	20.0	45.0	%	35.00				
				RBC: E	20/10/91	1.0	5.0	%	4.00				
				RBC: H	20/10/91	1.0	6.0	%	2.00				
				RBC: B	20/10/91	0.0	1.0	%	0.00				
				PLATELETS	20/10/91	140.0	300.0	10 ^{xx} 9/l	204.00				
				NA+	20/10/91	137.0	147.0	mmol/l	140.00				
				K+	20/10/91	3.7	5.3	mmol/l	4.00				
				CL-	20/10/91	97.0	107.0	mmol/l					
				CA++	20/10/91	2.3	2.7	mmol/l	2.31				
				PO4--	20/10/91	0.7	1.5	mmol/l	1.11				
				SGOT	20/10/91	5.0	30.0	U/l	9.00				
				SGPT	20/10/91	5.0	34.0	U/l	8.00				
				GAMMA-GT	20/10/91	6.0	28.0	U/l	27.00				
				GLUCOSE	20/10/91	3.3	5.5	mmol/l	3.70				
				ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	133.00				
				BUN	20/10/91	3.0	9.6	mmol/l	3.20				
				CREATININE	20/10/91	50.0	110.0	umol/l	66.00				
				URIC ACID	20/10/91	120.0	410.0	umol/l	289.00				
				TOT BILIRUBIN	20/10/91	3.4	22.0	umol/l	5.10				
				DIR BILIRUBIN	20/10/91	0.0	4.5	umol/l	2.80				
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	53.00				
				ALBUMINE	20/10/91	0.5	0.7	RATIO					
				TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	2.90				
				TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	1.50				
				GLOBULINS: ALPHA 1	20/10/91	0.0	0.1	RATIO					
				GLOBULINS: ALPHA 2	20/10/91	0.1	0.1	RATIO					
				GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO					
				GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO					
				T3	20/10/91	0.5	1.1	nmol/l	1.00				
				T4	20/10/91	60.0	160.0	nmol/l	59.90				
	28	IV	FEMALE	HB	20/10/91	7.5	10.0	mmol/l	7.76	04/02/92	21/02/92	06/03/92	20/03/92
				HTC	20/10/91	0.4	0.5	L/l	0.32				
				RBC	20/10/91	4.5	5.0	10 ^{xx} 12/l	3.69				
				RBC	20/10/91	4.0	10.0	10 ^{xx} 9/l	5.20				
				RBC: N	20/10/91	60.0	70.0	%	55.00				
				RBC: L	20/10/91	20.0	45.0	%	41.00				
				RBC: E	20/10/91	1.0	5.0	%	2.00				
				RBC: H	20/10/91	1.0	6.0	%	2.00				
				RBC: B	20/10/91	0.0	1.0	%	0.00				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Rangs			Visit					
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
12	28	IV	FEMALE	PLATELETS	20/10/91	140.0	300.0	10**9/1	197.00	319.00	101.00	251.00
				NA+	20/10/91	137.0	147.0	mmol/l	139.00	145.00	142.00	143.00
				K+	20/10/91	3.7	5.3	mmol/l	4.00	4.10	3.80	3.70
				CL-	20/10/91	97.0	107.0	mmol/l	2.34	2.10	2.00	2.23
				CA++	20/10/91	2.3	2.7	mmol/l	1.43	1.08	1.00	1.12
				PO4--	20/10/91	0.7	1.5	mmol/l	90.00	26.00	12.00	20.00
				SGPT	20/10/91	5.0	30.0	U/l	166.00	41.00	37.00	35.00
				GAMMA-GT	20/10/91	6.0	28.0	U/l	61.00	65.00	36.00	23.00
				GLUCOSE	20/10/91	3.3	5.5	mmol/l	3.90	3.60	3.70	3.90
				ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	282.00	290.00	211.00	180.00
				BUN	20/10/91	3.0	9.6	mmol/l	6.50	6.50	4.70	5.60
				CREATININE	20/10/91	50.0	110.0	umol/l	74.00	74.00	77.00	61.00
				URIC ACID	20/10/91	120.0	410.0	umol/l	180.00	164.00	228.00	212.00
				TOT BILIRUBIN	20/10/91	3.4	22.0	umol/l	17.10	5.80	6.70	10.20
				DIR BILIRUBIN	20/10/91	0.0	4.5	umol/l	84.00	3.50	4.90	4.80
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	81.00	81.00	65.00	71.00
				ALBUMINE	20/10/91	0.5	0.7	RATIO	0.58	0.58	0.56	0.64
				TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	4.70	5.00	4.50	5.20
				TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	0.80	2.60	1.90	2.00
				GLUCOLINS: ALPHA 1	20/10/91	0.0	0.1	RATIO	0.05	0.05	0.11	0.03
GLUCOLINS: ALPHA 2	20/10/91	0.1	0.1	RATIO	0.07	0.07	0.09	0.06				
GLUCOLINS: BETA	20/10/91	0.1	0.1	RATIO	0.11	0.11	0.11	0.10				
GLUCOLINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.20	0.20	0.13	0.19				
T3	20/10/91	0.9	1.1	nmol/l	2.30	2.30	0.00	0.00				
T4	20/10/91	60.0	160.0	nmol/l	111.00	111.00	0.00	0.00				
29	AK	FEMALE	HB	20/10/91	7.5	10.0	mmol/l	07/02/92	24/02/92	09/03/92	23/03/92	
			HTC	20/10/91	0.4	0.5	l/l	8.70	8.70	8.28	8.70	
			RBC	20/10/91	4.5	5.0	10**12/l	0.37	0.37	0.37	0.42	
			HBC	20/10/91	4.0	10.0	10**9/l	4.23	4.23	4.72	5.20	
			HBC: N	20/10/91	60.0	70.0	%	6.70	6.70	8.40	8.50	
			HBC: L	20/10/91	20.0	45.0	%	68.00	64.00	76.00	66.00	
			HBC: E	20/10/91	1.0	5.0	%	31.00	24.00	30.00	30.00	
			HBC: M	20/10/91	1.0	6.0	%	4.00	2.00	0.00	1.00	
			HBC: B	20/10/91	0.0	1.0	%	1.00	2.00	0.00	3.00	
			PLATELETS	20/10/91	140.0	300.0	10**9/l	0.00	0.00	0.00	0.00	
			NA+	20/10/91	137.0	147.0	mmol/l	339.00	253.00	103.00	275.00	
			K+	20/10/91	3.7	5.3	mmol/l	139.00	138.00	141.00	133.00	
			CL-	20/10/91	97.0	107.0	mmol/l	4.20	4.20	4.10	3.90	
			CA++	20/10/91	2.3	2.7	mmol/l	2.20	2.52	2.18	2.40	
			PO4--	20/10/91	0.7	1.5	mmol/l	1.31	1.25	1.20	1.15	
			SGPT	20/10/91	5.0	30.0	U/l	19.00	15.00	14.00	21.00	
			GAMMA-GT	20/10/91	6.0	28.0	U/l	22.00	21.00	17.00	22.00	
			GLUCOSE	20/10/91	3.3	5.5	mmol/l	20.00	16.00	14.00	28.00	
			ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	4.30	3.80	3.90	4.10	
			BUN	20/10/91	3.0	9.6	mmol/l	180.00	187.00	135.00	134.00	
CREATININE	20/10/91	50.0	110.0	umol/l	81.00	82.00	5.00	4.00				

1 2 0 6

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOMETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit					
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
12	29	AK	FEMALE	20/10/91	120.0	410.0	umol/l	367.00	419.00	370.00	261.00	
			URIC ACID	20/10/91	3.4	22.0	umol/l	6.70	7.00	6.90	5.40	
			TOT BILIRUBIN	20/10/91	0.0	4.5	umol/l	3.10	5.80	5.00	4.40	
			DIR BILIRUBIN	20/10/91	60.0	80.0	g/l	77.00	76.00	73.00	77.00	
			TOT. PROTEINS	20/10/91	0.5	0.7	RATIO		0.63	0.61	0.56	
			ALBUMINE	20/10/91	2.6	7.0	mmol/l	4.10	6.30	5.00	5.20	
			TOT. CHOLEST.	20/10/91	0.3	1.9	mmol/l	1.10	1.60	1.00	1.00	
			TRIGLYCERIDES	20/10/91	0.0	0.1	RATIO		0.05	0.11	0.09	
			GLOBULINS: ALPHA 1	20/10/91	0.1	0.1	RATIO		0.07	0.08	0.08	
			GLOBULINS: ALPHA 2	20/10/91	0.1	0.1	RATIO		0.09	0.11	0.10	
			GLOBULINS: BETA	20/10/91	0.1	0.2	RATIO		0.17	0.08	0.16	
			GLOBULINS: GAMMA	20/10/91	0.9	1.1	mmol/l	1.00				
			T3	20/10/91	60.0	160.0	nmol/l	112.80				
			T4	20/10/91								
30	FS	FEMALE	20/10/91	7.5	10.0	mmol/l	8.10	8.26	8.80	8.80		
			HB	20/10/91	0.4	0.5	l/l	0.38	0.43	0.43		
			HCT	20/10/91	4.5	5.0	10**12/l	4.43	5.66	5.74		
			RBC	20/10/91	4.0	10.0	10**9/l	4.70	6.80	6.60		
			WBC: N	20/10/91	60.0	70.0	%	48.00	70.00	68.00		
			WBC: L	20/10/91	20.0	45.0	%	43.00	26.00	26.00		
			WBC: E	20/10/91	1.0	5.0	%	4.00	2.00	3.00		
			WBC: M	20/10/91	1.0	6.0	%	5.00	2.00	3.00		
			PLATELETS	20/10/91	140.0	300.0	10**9/l	180.00	193.00	326.00		
			NA+	20/10/91	137.0	147.0	mmol/l	136.00	148.00	140.00		
			K+	20/10/91	3.7	5.3	mmol/l	4.10	4.70	4.80		
			CL-	20/10/91	97.0	107.0	mmol/l	2.51	2.17	2.32		
			CA++	20/10/91	2.3	2.7	mmol/l	2.51	2.17	2.32		
			PO4--	20/10/91	0.7	1.5	mmol/l	0.82	1.27	1.22		
			SGOT	20/10/91	5.0	30.0	U/l	41.00	20.00	23.00		
			SGPT	20/10/91	5.0	34.0	U/l	65.00	21.00	37.00		
			GAMMA-GT	20/10/91	6.0	28.0	U/l	28.00	18.00	15.00		
			GLUCOSE	20/10/91	3.3	5.5	mmol/l	2.90	3.60	3.60		
			ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	212.00	169.00	165.00		
			RUN	20/10/91	3.0	9.6	mmol/l	4.60	4.10	4.10		
			CREATININE	20/10/91	50.0	110.0	umol/l	90.00	71.00	69.00		
			URIC ACID	20/10/91	120.0	410.0	umol/l	212.00	155.00	195.00		
			TOT BILIRUBIN	20/10/91	3.4	22.0	umol/l	8.50	8.50	8.50		
			DIR BILIRUBIN	20/10/91	0.0	4.5	umol/l	5.60	4.60	4.60		
			TOT. PROTEINS	20/10/91	60.0	80.0	g/l	68.00	80.00	65.00		
			ALBUMINE	20/10/91	0.5	0.7	RATIO	0.55	0.56	0.55		
			TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	4.70	6.40	6.00		
			TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	1.60	1.60	1.50		
			GLOBULINS: ALPHA 1	20/10/91	0.0	0.1	RATIO	0.05	0.05	0.11		
			GLOBULINS: ALPHA 2	20/10/91	0.1	0.1	RATIO	0.08	0.07	0.09		
			GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.13	0.11	0.10		
			GLOBULINS: GAMMA	20/10/91	0.9	1.1	mmol/l	0.20	0.21	0.15		
			T3	20/10/91	60.0	160.0	nmol/l	0.89				
			T4	20/10/91				67.80				

1787

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R8D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Date	Laboratory Range		Screen	Visit			
						Min	Max		Unit	Week 2	Week 4	Week 6
12	31	FX	MALE	HB	20/10/91	7.5	10.0	mmol/l	24/03/92	08/04/92	21/04/92	07/05/92
				HTC	20/10/91	0.4	0.5	l/l	9.02	9.35	8.84	
				RBC	20/10/91	4.5	5.0	10**12/l	0.42	0.45	0.40	
				MBC	20/10/91	4.0	10.0	10**9/l	5.33	5.65	5.25	
				MBC: N	20/10/91	60.0	70.0	%	4.00	5.00	5.00	
				MBC: L	20/10/91	20.0	45.0	%	67.00	55.00	74.00	
				MBC: E	20/10/91	1.0	5.0	%	30.00	43.00	22.00	
				MBC: B	20/10/91	1.0	6.0	%	2.00	0.00	0.00	
				PLATELETS	20/10/91	0.0	1.0	%	1.00	2.00	4.00	
				NA+	20/10/91	140.0	300.0	10**9/l	0.00	0.00	0.00	
				K+	20/10/91	3.7	5.3	mmol/l	147.00	146.00	142.00	144.00
				CA++	20/10/91	2.3	2.7	mmol/l	3.90	3.80	3.80	3.90
				PO4-	20/10/91	0.7	1.5	mmol/l	0.92	0.92	0.96	1.00
				SGPT	20/10/91	5.0	30.0	U/l	15.00	15.00	15.00	17.00
				SGOT	20/10/91	6.0	28.0	U/l	16.00	16.00	16.00	18.00
				GLUCOSE	20/10/91	3.3	5.5	mmol/l	3.80	3.80	4.80	4.80
				ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	185.00	201.00	181.00	226.00
				UREA	20/10/91	3.0	9.6	mmol/l	5.80	6.00	8.40	8.00
				CREATININE	20/10/91	50.0	170.0	umol/l	87.00	90.00	109.00	100.00
				URIC ACID	20/10/91	120.0	440.0	umol/l	299.00	323.00	316.00	354.00
				DIR BILIRUBIN	20/10/91	3.4	22.0	umol/l	9.00	5.30	5.20	12.90
				TOT BILIRUBIN	20/10/91	0.0	4.5	umol/l	5.30	4.30	2.60	5.10
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	63.00	65.00	67.00	70.00
				ALBUMINE	20/10/91	0.5	0.7	RATIO	0.59	0.62	0.60	0.56
				TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	6.30	6.30	6.80	6.80
				TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	1.60	1.10	0.60	0.90
				GLOBULINS: ALPHA 1	20/10/91	0.0	0.1	RATIO	0.10	0.05	0.07	0.07
GLOBULINS: ALPHA 2	20/10/91	0.1	0.1	RATIO	0.08	0.08	0.08	0.07				
GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.10	0.11	0.11	0.13				
GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.14	0.14	0.13	0.17				
T3	20/10/91	0.9	1.1	mmol/l	0.98							
T4	20/10/91	60.0	160.0	mmol/l	74.60							
32	LN	MALE	HB	20/10/91	7.5	10.0	mmol/l	31/03/92	15/04/92	29/04/92	13/05/92	
			HTC	20/10/91	0.4	0.5	l/l	8.70	8.63	8.65	8.60	
			RBC	20/10/91	4.5	5.0	10**12/l	0.42	0.41	0.41	0.38	
			MBC	20/10/91	4.0	10.0	10**9/l	5.46	5.21	5.60	5.23	
			MBC: N	20/10/91	60.0	70.0	%	7.40	7.00	6.60	6.20	
			MBC: L	20/10/91	20.0	45.0	%	51.00	59.00	58.00	58.00	
			MBC: E	20/10/91	1.0	5.0	%	40.00	33.00	32.00	40.00	
			MBC: B	20/10/91	1.0	6.0	%	7.00	6.00	8.00	2.00	
			PLATELETS	20/10/91	0.0	1.0	%	2.00	2.00	2.00	0.00	
				20/10/91	140.0	300.0	10**9/l	172.00	265.00	213.00	138.00	

1788

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1
LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
12	32	LM	MALE	NA+	20/10/91	137.0	147.0	mmol/L	147.00	137.00	140.00	140.00	140.00
				K+	20/10/91	3.7	5.3	mmol/L	4.40	4.30	4.60	4.20	
				CL-	20/10/91	97.0	107.0	mmol/L	97.00	109.00	99.00	95.00	
				CA++	20/10/91	2.3	2.7	mmol/L	2.46	2.36	2.43	2.45	
				PO4-	20/10/91	0.7	1.5	mmol/L	1.05	1.08	1.31	1.13	
				SGOT	20/10/91	5.0	30.0	U/l	18.00	12.00	15.00	15.00	
				SGPT	20/10/91	5.0	34.0	U/l	26.00	19.00	23.00	20.00	
				GAMMA-GT	20/10/91	6.0	28.0	U/l	39.00	28.00	34.00	49.00	
				GLUCOSE	20/10/91	3.3	5.5	mmol/L	4.10	3.70	3.30	4.10	
				ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	280.00	224.00	215.00	220.00	
				BUN	20/10/91	3.0	9.6	mmol/L	6.80	6.90	8.80	5.70	
				CREATININE	20/10/91	50.0	110.0	umol/L	100.00	131.00	143.00	113.00	
				URIC ACID	20/10/91	120.0	410.0	umol/L	268.00	295.00	290.00	281.00	
				TOT. BILIRUBIN	20/10/91	3.4	22.0	umol/L	8.00	14.20	11.40	12.20	
				DIR. BILIRUBIN	20/10/91	0.0	4.5	umol/L	6.30	3.10	8.80	6.20	
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	67.00	65.00	63.00	66.00	
				ALBUMINE	20/10/91	0.5	0.7	RATIO	0.58	0.62	0.54	0.59	
				TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/L	7.00	6.50	6.80	6.20	
				TRIGLICERIDES	20/10/91	0.3	1.9	mmol/L	1.60	1.40	1.20	1.20	
				GLOBULINS: ALPHA 1	20/10/91	0.0	0.1	RATIO	0.08	0.05	0.11	0.05	
GLOBULINS: ALPHA 2	20/10/91	0.1	0.1	RATIO	0.07	0.07	0.08	0.10					
GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.12	0.13	0.13	0.13					
GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.14	0.12	0.13	0.12					
T3	20/10/91	0.9	1.1	nmol/L	0.89								
T4	20/10/91	60.0	160.0	nmol/L	75.00								
33	LN	FEMALE	HB	20/10/91	7.5	10.0	mmol/L	8.14	15/04/92	23/03/92	29/04/92	13/05/92	
			HTC	20/10/91	0.4	0.5	L/l	0.39	7.96	8.17	8.27		
			RBC	20/10/91	4.5	5.0	10**12/l	5.04	4.59	4.96	4.73		
			HBC: N	20/10/91	4.0	10.0	10**9/l	4.40	4.50	5.90	4.20		
			HBC: L	20/10/91	60.0	70.0	%		52.00	46.00	52.00		
			HBC: E	20/10/91	20.0	45.0	%		32.00	44.00	40.00		
			HBC: B	20/10/91	1.0	5.0	%		10.00	1.00	8.00		
			HBC: M	20/10/91	1.0	6.0	%		6.00	9.00	0.00		
			HBC: B	20/10/91	0.0	1.0	%		0.00	0.00	0.00		
			PLATELETS	20/10/91	160.0	300.0	10**9/l	253.00	242.00	227.00	132.00		
			NA+	20/10/91	137.0	147.0	mmol/L	136.00	137.00	139.00	140.00		
			K+	20/10/91	3.7	5.3	mmol/L	3.50	4.10	3.90	4.10		
			CL-	20/10/91	97.0	107.0	mmol/L	106.00	97.00	97.00	95.00		
			PO4-	20/10/91	2.3	2.7	mmol/L	2.27	2.40	2.30	2.30		
			SGOT	20/10/91	0.7	1.5	mmol/L	1.22	1.10	1.06	1.06		
			SGPT	20/10/91	5.0	30.0	U/l	34.00	25.00	21.00	20.00		
			GAMMA-GT	20/10/91	5.0	34.0	U/l	43.00	42.00	34.00	29.00		
			GLUCOSE	20/10/91	6.0	28.0	U/l	63.00	68.00	76.00	74.00		
			ALK. PHOSPH.	20/10/91	3.3	5.5	mmol/L	7.30	6.80	7.60	7.20		
			BUN	20/10/91	100.0	280.0	U/l	180.00	227.00	180.00	198.00		
CREATININE	20/10/91	3.0	9.6	mmol/L	8.00	8.00	7.20	6.20					
URIC ACID	20/10/91	50.0	110.0	umol/L	96.00	89.00	96.00	101.00					
URIC ACID	20/10/91	120.0	410.0	umol/L	3.80	257.00	255.00	263.00					

1789

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6			
12	33	LN	FEMALE	TOT BILIRUBIN	20/10/91	3.4	22.0	umol/l	17.10	8.40	15.40	12.60			
				DIR BILIRUBIN	20/10/91	0.0	4.5	umol/l	3.40	3.40	10.50	9.70			
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	77.00	77.00	69.00	67.00			
				ALBUMINE	20/10/91	0.5	0.7	RATIO	0.56	0.56	0.54	0.55			
				TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	7.30	7.30	7.50	7.50			
				TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	4.40	4.40	2.70	3.70			
				GLOBULINS: ALPHA 1	20/10/91	0.0	0.1	RATIO	0.06	0.06	0.11	0.06			
				GLOBULINS: ALPHA 2	20/10/91	0.1	0.1	RATIO	0.08	0.08	0.07	0.09			
				GLOBULINS: BETA	20/10/91	0.1	0.2	RATIO	0.15	0.15	0.13	0.13			
				GLOBULINS: GAMMA	20/10/91	0.9	1.1	mmol/l	0.15	0.15	0.16	0.16			
				T3	20/10/91	60.0	160.0	nmol/l	1.12						
				T4	20/10/91			nmol/l	122.00						
				34	TGB	FEMALE	HR	20/10/91	7.5	10.0	mmol/l	8.68	8.68	9.96	8.61
							HTC	20/10/91	0.4	0.5	l/l	0.42	0.42	0.50	0.41
							RBC	20/10/91	4.5	5.0	10**12/l	5.22	5.08	5.27	5.06
							RBC: N	20/10/91	4.0	10.0	10**9/l	5.30	7.00	6.40	5.80
							RBC: L	20/10/91	60.0	70.0	%	45.00	60.00	63.00	55.00
							RBC: E	20/10/91	1.0	45.0	%	49.00	34.00	35.00	40.00
							RBC: H	20/10/91	1.0	5.0	%	4.00	3.00	0.00	1.00
							RBC: B	20/10/91	1.0	6.0	%	2.00	3.00	2.00	4.00
PLATELETS	20/10/91	0.0	1.0				%	0.00	0.00	0.00	0.00				
NA+	20/10/91	140.0	300.0				10**9/l	248.00	248.00	219.00	319.00				
K+	20/10/91	137.0	147.0				mmol/l	144.00	144.00	143.00	141.00				
CL-	20/10/91	3.7	5.3				mmol/l	4.70	5.40	4.20	4.20				
CA++	20/10/91	97.0	107.0				mmol/l	100.00	89.00	95.00	89.00				
PO4--	20/10/91	2.3	2.7				mmol/l	2.40	2.41	2.44	2.65				
SGPT	20/10/91	0.7	1.5				mmol/l	1.10	1.07	1.22	1.11				
GAMMA-GT	20/10/91	5.0	30.0				U/l	23.00	13.00	13.00	14.00				
GLUCOSE	20/10/91	6.0	23.0				U/l	24.00	14.00	10.00	18.00				
ALK. PHOSPH.	20/10/91	3.3	5.5				mmol/l	15.00	14.00	25.00	21.00				
RUN	20/10/91	100.0	280.0				U/l	3.60	3.70	3.60	4.10				
CREATININE	20/10/91	3.0	9.6				mmol/l	201.00	169.00	175.00	188.00				
URIC ACID	20/10/91	50.0	110.0	umol/l	6.30	6.30	4.10	6.10							
TOT BILIRUBIN	20/10/91	120.0	410.0	umol/l	82.00	93.00	87.00	98.00							
DIR BILIRUBIN	20/10/91	3.4	22.0	umol/l	237.00	238.00	235.00	249.00							
TOT. PROTEINS	20/10/91	0.0	4.5	umol/l	12.60	8.50	7.60	9.50							
ALBUMINE	20/10/91	60.0	80.0	g/l	57.00	4.60	4.50	6.10							
TRIGLYCERIDES	20/10/91	0.5	9.7	RATIO	0.55	0.55	0.63	0.63							
TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	8.10	7.30	6.40	6.70							
GLOBULINS: ALPHA 1	20/10/91	0.3	1.9	mmol/l	1.40	1.60	1.90	1.40							
GLOBULINS: ALPHA 2	20/10/91	0.0	0.1	RATIO	0.13	0.07	0.18	0.09							
GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.09	0.08	0.09	0.08							
GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.10	0.10	0.11	0.10							
T3	20/10/91	0.9	1.1	nmol/l	1.04	0.10	0.12	0.10							
T4	20/10/91	60.0	160.0	nmol/l	131.60										

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 RESOXETINE - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
12	35	LP	FEMALE	HB	20/10/91	7.5	10.0	mmol/l	8.77	8.14	8.79	8.68	
				HTC	20/10/91	0.4	0.5	l/l	0.45	0.41	0.46	0.40	
				RBC	20/10/91	4.5	5.0	10**12/l	5.72	4.93	5.26	5.03	
				WBC	20/10/91	4.0	10.0	10**9/l	8.40	8.40	8.40	7.50	
				WBC: N	20/10/91	60.0	70.0	%	64.00	65.00	70.00	66.00	
				WBC: L	20/10/91	20.0	45.0	%	31.00	32.00	28.00	32.00	
				WBC: E	20/10/91	1.0	5.0	%	2.00	3.00	2.00	1.00	
				WBC: M	20/10/91	1.0	6.0	%	2.00	0.00	0.00	1.00	
				WBC: B	20/10/91	0.0	1.0	%	1.00	0.00	0.00	0.00	
				PLATELETS	20/10/91	140.0	300.0	10**9/l	249.00	349.00	253.00	361.00	
				NA+	20/10/91	137.0	147.0	mmol/l	137.00	142.00	141.00	133.00	
				K+	20/10/91	3.7	5.3	mmol/l	4.20	4.30	4.40	3.50	
				CL-	20/10/91	2.3	2.7	mmol/l	2.43	2.38	2.47	2.83	
				PO4--	20/10/91	0.7	1.5	mmol/l	1.48	1.16	1.30	1.03	
				SGOT	20/10/91	5.0	30.0	U/l	30.00	32.00	28.00	29.00	
				GAMMA-GT	20/10/91	5.0	34.0	U/l	74.00	68.00	96.00	55.00	
				GLUCOSE	20/10/91	6.0	28.0	U/l	145.00	107.00	96.00	116.00	
				ALK. PHOSPH.	20/10/91	3.3	5.5	mmol/l	4.60	3.60	3.40	3.40	
				BUN	20/10/91	100.0	280.0	U/l	233.00	214.00	208.00	216.00	
				CREATININE	20/10/91	3.0	9.6	mmol/l	7.90	5.40	5.40	4.70	
				URIC ACID	20/10/91	50.0	110.0	umol/l	70.00	70.00	84.00	90.00	
				TOT BILIRUBIN	20/10/91	120.0	410.0	umol/l	270.00	270.00	341.00	352.00	
				DIR BILIRUBIN	20/10/91	3.4	22.0	umol/l	9.60	9.60	15.40	16.00	
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	5.80	5.80	8.50	7.50	
				ALBUMINE	20/10/91	0.5	0.7	RATIO	70.00	70.00	68.00	72.00	
				TRIGLYCERIDES	20/10/91	2.6	7.0	mmol/l	0.54	0.57	0.54	0.62	
				GLORULINS: ALPHA 1	20/10/91	0.3	1.9	mmol/l	7.30	5.60	6.10	7.30	
				GLORULINS: ALPHA 2	20/10/91	0.0	0.1	RATIO	2.10	2.10	2.70	1.50	
				GLORULINS: BETA	20/10/91	0.1	0.1	RATIO	0.14	0.10	0.08	0.06	
				GLORULINS: GAMMA	20/10/91	0.1	0.1	RATIO	0.10	0.07	0.09	0.08	
				T3	20/10/91	0.1	0.2	RATIO	0.12	0.12	0.13	0.11	
				T4	20/10/91	0.9	1.1	mmol/l	0.94	0.14	0.16	0.13	
					20/10/91	60.0	160.0	mmol/l	94.10				
36	FB	FEMALE	HB	20/10/91	7.5	10.0	mmol/l	7.55	7.36	7.40	7.58		
			HTC	20/10/91	0.4	0.5	l/l	0.38	0.37	0.35	0.37		
			RBC	20/10/91	4.5	5.0	10**12/l	4.85	4.57	4.53	4.50		
			WBC	20/10/91	4.0	10.0	10**9/l	6.60	6.00	7.10	6.70		
			WBC: N	20/10/91	60.0	70.0	%	52.00	60.00	60.00	48.00		
			WBC: L	20/10/91	20.0	45.0	%	42.00	37.00	40.00	44.00		
			WBC: E	20/10/91	1.0	5.0	%	6.00	1.00	0.00	2.00		
			WBC: M	20/10/91	1.0	6.0	%	0.00	2.00	0.00	6.00		
			WBC: B	20/10/91	0.0	1.0	%	0.00	0.00	0.00	0.00		
			PLATELETS	20/10/91	140.0	300.0	10**9/l	241.00	241.00	305.00	199.00		
				20/10/91									

1791

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
12	36	FB	FEMALE	NA+	20/10/91	137.0	147.0	mmol/l	141.00	139.00	140.00	139.00	139.00
				K+	20/10/91	3.7	5.3	mmol/l	4.10	3.90	4.10	3.90	3.90
				CL-	20/10/91	97.0	107.0	mmol/l	98.00	100.00	98.00	96.00	96.00
				CA++	20/10/91	2.3	2.7	mmol/l	2.43	2.40	2.21	2.72	2.72
				PO4--	20/10/91	0.7	1.5	mmol/l	1.18	0.88	1.13	0.99	0.99
				SGPT	20/10/91	5.0	30.0	U/l	9.00	9.00	20.00	25.00	25.00
				SGPT	20/10/91	5.0	34.0	U/l	15.00	11.00	13.00	19.00	19.00
				GAMMA-GT	20/10/91	6.0	28.0	U/l	16.00	12.00	16.00	34.00	34.00
				GLUCOSE	20/10/91	3.3	5.5	mmol/l	3.90	4.50	3.80	4.00	4.00
				ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	173.00	187.00	176.00	213.00	213.00
				BUN	20/10/91	3.0	9.6	mmol/l	3.30	4.60	5.80	3.20	3.20
				CREATININE	20/10/91	50.0	110.0	umol/l	62.00	77.00	63.00	75.00	75.00
				URIC ACID	20/10/91	120.0	410.0	umol/l	305.00	320.00	274.00	301.00	301.00
				TOT BILIRUBIN	20/10/91	3.4	22.0	umol/l	17.00	13.60	16.40	18.00	18.00
				DIR BILIRUBIN	20/10/91	0.0	4.5	umol/l	5.00	3.80	4.70	8.60	8.60
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	56.00	71.00	78.00	78.00	78.00
				ALBUMINE	20/10/91	0.5	0.7	RATIO	0.55	0.65	0.61	0.63	0.63
				TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	5.10	4.30	5.30	5.80	5.80
				TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	1.10	0.80	0.80	0.70	0.70
				GLUCOLINS: ALPHA 1	20/10/91	0.0	0.1	RATIO	0.11	0.06	0.05	0.06	0.06
GLUCOLINS: ALPHA 2	20/10/91	0.1	0.1	RATIO	0.09	0.05	0.08	0.06	0.06				
GLUCOLINS: BETA	20/10/91	0.1	0.1	RATIO	0.10	0.11	0.09	0.11	0.11				
GLUCOLINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.14	0.15	0.16	0.14	0.14				
T3	20/10/91	0.9	1.1	nmol/l	1.02								
T4	20/10/91	60.0	160.0	nmol/l	113.60								
37	EK	FEMALE	HB	20/10/91	7.5	10.0	mmol/l	8.85	8.99	8.32	8.99	8.57	
			HTC	20/10/91	0.4	0.5	l/l	0.42	0.39	0.41	0.38	0.41	
			RBC	20/10/91	4.5	5.0	10**12/l	5.10	5.08	5.43	4.75	4.75	
			HBC	20/10/91	4.0	10.0	10**9/l	7.00	5.50	5.30	5.10	5.10	
			HBC: N	20/10/91	60.0	70.0	%	54.00	61.00	61.00	60.00	60.00	
			HBC: L	20/10/91	20.0	45.0	%	44.00	32.00	33.00	37.00	37.00	
			HBC: E	20/10/91	1.0	5.0	%	0.00	1.00	2.00	3.00	3.00	
			HBC: M	20/10/91	1.0	6.0	%	2.00	5.00	4.00	1.00	1.00	
			HBC: B	20/10/91	0.0	1.0	%	0.00	1.00	0.00	0.00	0.00	
			PLATELETS	20/10/91	140.0	300.0	10**9/l	240.00	139.00	321.00	241.00	241.00	
			NA+	20/10/91	137.0	147.0	mmol/l	142.00	143.00	143.00	136.00	136.00	
			K+	20/10/91	3.7	5.3	mmol/l	4.20	4.10	3.60	3.90	3.90	
			CL-	20/10/91	2.3	2.7	mmol/l	2.77	2.56	2.62	2.82	2.82	
			PO4--	20/10/91	0.7	1.5	mmol/l	1.53	1.04	1.21	1.09	1.09	
			SGPT	20/10/91	5.0	30.0	U/l	36.00	17.00	14.00	15.00	15.00	
			SGPT	20/10/91	5.0	34.0	U/l	31.00	17.00	20.00	24.00	24.00	
			GAMMA-GT	20/10/91	6.0	28.0	U/l	4.40	4.30	4.80	4.30	4.30	
			GLUCOSE	20/10/91	3.3	5.5	mmol/l	4.30	202.00	173.00	198.00	198.00	
			ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	433.00	266.00	173.00	198.00	198.00	
			BUN	20/10/91	3.0	9.6	mmol/l	7.20	7.60	7.50	7.00	7.00	
CREATININE	20/10/91	50.0	110.0	umol/l	83.00	101.00	101.00	95.00	95.00				
URIC ACID	20/10/91	120.0	410.0	umol/l	272.00	266.00	211.00	194.00	194.00				

1792

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6			
12	37	EK	FEMALE	TOT. BILIRUBIN	20/10/91	3.4	22.0	umol/l	7.60	12.10	6.80	10.70			
				DIR. BILIRUBIN	20/10/91	0.0	4.5	umol/l	5.80	3.60	5.20	5.50			
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	72.00	76.00	71.00	75.00			
				ALBUMINE	20/10/91	0.5	0.7	RATIO	0.59	0.59	0.67	0.68			
				TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	8.20	7.70	6.30	7.70			
				TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	2.70	1.40	1.40	1.50			
				GLOBULINS: ALPHA 1	20/10/91	0.0	0.1	RATIO	0.15	0.15	0.05	0.05			
				GLOBULINS: ALPHA 2	20/10/91	0.1	0.1	RATIO	0.05	0.05	0.07	0.05			
				GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.08	0.08	0.09	0.10			
				GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.14	0.14	0.13	0.12			
				T3	20/10/91	0.3	1.1	nmol/l	0.94	0.94	0.94	0.94			
				T4	20/10/91	60.0	160.0	nmol/l	78.70	78.70	78.70	78.70			
				38	FC	FEMALE	HB	20/10/91	7.5	10.0	mmol/l	8.45	8.91	8.34	8.75
							HTC	20/10/91	0.4	0.5	l/l	0.42	0.39	0.37	0.41
RBC	20/10/91	4.5	5.0				10**12/l	4.88	5.14	4.86	5.10				
WBC	20/10/91	4.0	10.0				10**9/l	10.10	12.60	8.50	12.00				
RBC: N	20/10/91	60.0	70.0				%	70.00	64.00	64.00	60.00				
RBC: L	20/10/91	20.0	45.0				%	26.00	33.00	33.00	40.00				
RBC: E	20/10/91	1.0	5.0				%	1.00	0.00	0.00	0.00				
RBC: M	20/10/91	1.0	6.0				%	3.00	3.00	3.00	0.00				
RBC: B	20/10/91	0.0	1.0				%	0.00	0.00	0.00	0.00				
PLATELETS	20/10/91	140.0	300.0				10**9/l	198.00	216.00	142.00	233.00				
NA+	20/10/91	137.0	147.0				mmol/l	138.00	140.00	142.00	140.00				
K+	20/10/91	3.7	5.3				mmol/l	3.90	4.40	4.60	4.00				
CL-	20/10/91	97.0	107.0				mmol/l	100.00	94.00	98.00	98.00				
CA++	20/10/91	2.3	2.7				mmol/l	2.47	2.50	2.49	2.37				
SGPT	20/10/91	0.7	1.5	mmol/l	1.12	1.24	1.24	1.03							
GAMMA-GT	20/10/91	5.0	30.0	U/l	14.00	14.00	17.00	14.00							
GLUCOSE	20/10/91	6.0	28.0	U/l	7.00	11.00	20.00	17.00							
ALK. PHOSPH.	20/10/91	3.3	5.5	mmol/l	34.00	15.00	35.00	20.00							
BUN	20/10/91	100.0	280.0	U/l	3.50	4.00	4.00	2.37							
CREATININE	20/10/91	3.0	9.6	mmol/l	160.00	148.00	141.00	134.00							
URIC ACID	20/10/91	50.0	110.0	umol/l	6.40	7.00	6.50	5.00							
DIR. BILIRUBIN	20/10/91	120.0	410.0	umol/l	86.00	103.00	94.00	90.00							
TOT. BILIRUBIN	20/10/91	3.4	22.0	umol/l	255.00	275.00	293.00	253.00							
TOT. PROTEINS	20/10/91	60.0	80.0	g/l	8.10	6.70	8.30	9.40							
ALBUMINE	20/10/91	0.5	0.7	RATIO	5.10	3.20	6.40	7.00							
TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	72.00	0.63	67.00	71.00							
TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	5.60	0.66	0.66	0.65							
GLOBULINS: ALPHA 1	20/10/91	0.0	0.1	RATIO	0.90	0.70	5.40	5.10							
GLOBULINS: ALPHA 2	20/10/91	0.1	0.1	RATIO	0.05	0.06	0.06	0.07							
GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.08	0.06	0.06	0.06							
GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.17	0.08	0.08	0.08							
T3	20/10/91	0.9	1.1	nmol/l	0.94	0.94	0.14	0.15							
T4	20/10/91	60.0	160.0	nmol/l	88.00	88.00	88.00	88.00							

1793

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Screen	Visit					
					Date	Min	Max		Unit	Week 2	Week 4	Week 6		
13	1	P2	FEMALE	HB	02/10/91	120.0	140.0	g/l	08/10/91	29/10/91	12/11/91	26/11/91		
				HCT	02/10/91	38.0	47.0	%	146.00	143.00	150.00	164.00		
				RBC	02/10/91	4.0	5.5	10**12/l	43.00	43.00	44.00	47.00		
				WBC	02/10/91	4.5	8.0	10**9/l	4.70	4.70	4.90	4.90		
				NEC: N	02/10/91	60.0	70.0	%	6.00	7.70	6.00	6.40		
				NEC: L	02/10/91	20.0	30.0	%	66.00	58.00	56.00	62.00		
				NEC: E	02/10/91	1.0	5.0	%	31.00	37.00	39.00	34.00		
				NEC: M	02/10/91	2.0	6.0	%	2.00	3.00	4.00	4.00		
				NEC: B	02/10/91	0.0	1.0	%	1.00	2.00	0.00	0.00		
				PLATELETS	02/10/91	150.0	400.0	10**9/l	172.00	232.00	193.00	315.00		
				PLATELETS	02/10/91	135.0	145.0	mmol/l	138.00	137.00	135.00	141.00		
				PLATELETS	02/10/91	3.5	5.0	mmol/l	4.20	4.10	4.00	4.00		
				PLATELETS	02/10/91	95.0	108.0	mmol/l	104.00	98.00	101.00	104.00		
				PLATELETS	02/10/91	2.5	2.7	mmol/l	2.55	2.64	2.54	2.54		
				PLATELETS	02/10/91	1.0	1.5	mmol/l	0.75	0.87	0.90	1.02		
				PLATELETS	02/10/91	10.0	40.0	u/l	31.00	50.00	29.00	26.00		
				PLATELETS	02/10/91	10.0	40.0	u/l	18.00	50.00	35.00	63.00		
				PLATELETS	02/10/91	10.0	40.0	u/l	48.00	23.00	29.00	24.00		
				PLATELETS	02/10/91	4.0	6.0	mmol/l	5.40	6.50	5.30	6.70		
				PLATELETS	02/10/91	100.0	300.0	u/l	119.00	153.00	144.00	142.00		
				PLATELETS	02/10/91	2.0	10.0	mmol/l	6.20	4.70	5.10	5.70		
				PLATELETS	02/10/91	50.0	100.0	mmol/l	59.00	77.00	57.00	68.00		
				PLATELETS	02/10/91	150.0	400.0	mmol/l	193.00	228.00	192.00	239.00		
				PLATELETS	02/10/91	2.0	17.0	mmol/l	10.00	11.00	6.00	16.00		
				PLATELETS	02/10/91	0.0	5.0	mmol/l	4.00	4.00	4.00	6.00		
				PLATELETS	02/10/91	35.0	50.0	g/l	40.00	45.00	48.00	42.00		
PLATELETS	02/10/91	4.0	7.0	mmol/l	4.50	4.30	6.50	3.90						
PLATELETS	02/10/91	0.5	2.0	mmol/l	0.90	1.20	1.30	1.10						
PLATELETS	02/10/91	2.0	6.0	%	8.00	5.00	5.00	7.00						
PLATELETS	02/10/91	7.0	14.0	%	9.00	12.00	10.00	11.00						
PLATELETS	02/10/91	8.0	14.0	%	11.00	12.00	10.00	11.00						
PLATELETS	02/10/91	12.0	22.0	%	21.00	14.00	18.00	16.00						
PLATELETS	02/10/91	3.3	8.2	u/l	3.50	3.50	1.00	0.00						
PLATELETS	02/10/91	9.4	25.0	u/l	12.42	369.00	400.00	410.00						
2	TCS	2	FEMALE	HB	02/10/91	120.0	140.0	g/l	08/10/91	24/10/91	13/11/91	27/11/91		
				HCT	02/10/91	38.0	47.0	%	143.00	145.00	149.00	163.00		
				RBC	02/10/91	4.0	5.5	10**12/l	41.00	41.00	42.00	40.00		
				WBC	02/10/91	4.5	8.0	10**9/l	4.50	4.50	4.60	4.60		
				NEC: N	02/10/91	60.0	70.0	%	10.90	9.30	8.40	9.40		
				NEC: L	02/10/91	20.0	30.0	%	74.00	62.00	62.00	70.00		
				NEC: E	02/10/91	1.0	5.0	%	24.00	29.00	35.00	29.00		
				NEC: M	02/10/91	2.0	6.0	%	0.00	0.00	1.00	1.00		
				NEC: B	02/10/91	0.0	1.0	%	0.00	0.00	1.00	0.00		
				PLATELETS	02/10/91	150.0	400.0	10**9/l	383.00	369.00	400.00	410.00		

1794

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Date	Laboratory Range			Screen	Visit			
						Min	Max	Unit		Week 2	Week 4	Week 6	
13	2	TCS	FEMALE		02/10/91	135.0	145.0	mmol/l	139.00	140.00	139.00	159.00	
				NA+	02/10/91	3.5	5.0	mmol/l	4.30	4.50	4.30	4.30	
				K+	02/10/91	95.0	108.0	mmol/l	103.00	97.00	106.00	102.00	
				CL-	02/10/91	2.3	2.7	mmol/l	2.52	2.53	2.43	2.48	
				CA++	02/10/91	1.0	1.5	mmol/l	1.03	1.70	1.18	1.21	
				PO4-	02/10/91	10.0	40.0	u/l	28.00	19.00	23.00	58.00	
				SGOT	02/10/91	10.0	40.0	u/l	17.00	33.00	12.00	49.00	
				SGPT	02/10/91	10.0	40.0	u/l	34.00	32.00	30.00	28.00	
				GAMMA-GT	02/10/91	6.0	6.0	mmol/l	5.40	3.70	5.00	5.70	
				GLUCOSE	02/10/91	100.0	300.0	u/l	103.00	115.00	119.00	110.00	
				ALK. PHOSPH.	02/10/91	2.0	10.0	mmol/l	4.30	4.20	4.00	5.70	
				BUN	02/10/91	50.0	100.0	umol/l	62.00	60.00	71.00	251.00	
				CREATININE	02/10/91	150.0	400.0	umol/l	254.00	256.00	300.00	4.00	
				URIC ACID	02/10/91	2.0	17.0	umol/l	8.00	4.00	10.00	4.00	
				TOT BILIRUBIN	02/10/91	0.0	5.0	umol/l	4.00	82.00	82.00	81.00	
				DIR BILIRUBIN	02/10/91	0.0	80.0	g/l	80.00	46.00	46.00	66.00	
				TOT. PROTEINS	02/10/91	55.0	50.0	g/l	45.00	47.00	47.00	48.00	
				ALBUMINE	02/10/91	4.0	7.0	mmol/l	4.70	4.80	4.80	4.80	
				TOT. CHOLEST.	02/10/91	0.5	2.0	mmol/l	1.10	1.20	1.20	1.20	
				TRIGLYCERIDES	02/10/91	2.0	6.0	z	9.00	5.00	7.00	9.00	
				GLOBULINS: ALPHA 1	02/10/91	7.0	12.0	z	8.00	10.00	8.00	10.00	
				GLOBULINS: ALPHA 2	02/10/91	8.0	14.0	z	11.00	13.00	9.00	11.00	
				GLOBULINS: BETA	02/10/91	12.0	22.0	z	15.00	17.00	24.00	17.00	
				GLOBULINS: GAMMA	02/10/91	3.3	8.2	u/l	2.40				
				T3	02/10/91	9.4	25.0	u/l	11.08				
				T4	02/10/91								
3	AI		FEMALE		08/10/91	120.0	140.0	g/l	156.00	165.00	153.00	26/11/91	
				HB	02/10/91	38.0	47.0	z	44.00	46.00	43.00	159.00	
				HTC	02/10/91	4.0	5.5	10**12/l	4.90	4.90	4.90	45.00	
				RBC	02/10/91	4.5	8.0	10**9/l	5.70	8.40	4.90	5.10	
				HBC: N	02/10/91	60.0	70.0	z	55.00	54.00	7.10	9.00	
				HBC: L	02/10/91	20.0	30.0	z	37.00	40.00	58.00	53.00	
				HBC: E	02/10/91	1.0	5.0	z	6.00	43.00	40.00	43.00	
				HBC: H	02/10/91	2.0	6.0	z	1.00	3.00	3.00	2.00	
				HBC: B	02/10/91	0.0	1.0	z	1.00	3.00	2.00	1.00	
				PLATELETS	02/10/91	150.0	400.0	10**9/l	241.00	0.00	0.00	0.00	
				NA+	02/10/91	135.0	145.0	mmol/l	141.00	135.00	238.00	247.00	
				K+	02/10/91	95.0	108.0	mmol/l	105.00	97.00	106.00	140.00	
				CL-	02/10/91	2.3	2.7	mmol/l	2.38	2.49	2.35	103.00	
				CA++	02/10/91	1.0	1.5	mmol/l	0.92	1.00	1.08	2.50	
				PO4-	02/10/91	10.0	40.0	u/l	32.00	21.00	26.00	1.00	
				SGOT	02/10/91	10.0	40.0	u/l	22.00	29.00	25.00	22.00	
				SGPT	02/10/91	10.0	40.0	u/l	53.00	27.00	40.00	36.00	
				GAMMA-GT	02/10/91	4.0	6.0	mmol/l	5.30	4.20	5.30	53.00	
				GLUCOSE	02/10/91	100.0	300.0	u/l	97.00	138.00	128.00	4.50	
				ALK. PHOSPH.	02/10/91	2.0	10.0	mmol/l	4.70	3.80	3.60	127.00	
				BUN	02/10/91	50.0	100.0	umol/l	72.00	56.00	72.00	3.40	
				CREATININE	02/10/91	150.0	400.0	umol/l	162.00	208.00	177.00	54.00	
					02/10/91							180.00	

1795

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
 REROMETINE - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6			
13	3	AI	FEMALE	TOT BILIRUBIN	02/10/91	2.0	17.0	umol/l	4.00	5.00	12.00	10.00			
				DIR BILIRUBIN	02/10/91	0.0	5.0	umol/l	4.00	4.00	4.00	8.00			
				TOT. PROTEINS	02/10/91	60.0	80.0	g/l	67.00	70.00	77.00	77.00			
				ALBUMINE	02/10/91	35.0	50.0	g/l	40.00	41.00	45.00	41.00			
				TOT. CHOLEST.	02/10/91	4.0	7.0	mmol/l	6.00	5.40	7.90	5.00			
				TRIGLYCERIDES	02/10/91	0.5	2.0	mmol/l	2.60	2.10	2.10	1.40			
				GLOBULINS: ALPHA 1	02/10/91	2.0	6.0	g	6.00	8.00	6.00	9.00			
				GLOBULINS: ALPHA 2	02/10/91	7.0	12.0	g	8.00	9.00	9.00	10.00			
				GLOBULINS: BETA	02/10/91	8.0	14.0	g	11.00	12.00	11.00	12.00			
				GLOBULINS: GAMMA	02/10/91	12.0	22.0	g	15.00	16.00	16.00	15.00			
				T3	02/10/91	3.3	8.2	u/l	2.70						
				T4	02/10/91	9.4	25.0	u/l	12.92						
				4	SZJ	MALE	HR	02/10/91	140.0	160.0	g/l	150.00	149.00	150.00	158.00
							HTC	02/10/91	40.0	54.0	g	42.00	42.00	42.00	45.00
							HRC	02/10/91	4.0	5.5	10**9/l	4.30	4.60	4.40	4.60
							HRC: N	02/10/91	4.5	8.0	10**12/l	10.70	10.90	8.70	8.60
							HRC: L	02/10/91	60.0	70.0	g	75.00	69.00	64.00	65.00
HRC: E	02/10/91	20.0	30.0				g	19.00	20.00	27.00	27.00				
HRC: R	02/10/91	1.0	5.0				g	4.00	9.00	7.00	7.00				
HRC: B	02/10/91	2.0	6.0				g	2.00	1.00	1.00	0.00				
PLATELETS	02/10/91	0.0	1.0				g	0.00	1.00	1.00	1.00				
NA+	02/10/91	150.0	400.0				10**9/l	206.00	170.00	214.00	198.00				
CL-	02/10/91	135.0	145.0				mmol/l	141.00	140.00	136.00	139.00				
PO4--	02/10/91	3.5	5.0				mmol/l	4.50	4.10	3.80	3.70				
SGPT	02/10/91	95.0	108.0				mmol/l	108.00	106.00	98.00	101.00				
GAMMA-GT	02/10/91	2.3	2.7				mmol/l	2.32	2.40	2.38	2.44				
GLUCOSE	02/10/91	1.0	1.5				mmol/l	1.09	1.00	0.83	0.90				
ALK. PHOSPH.	02/10/91	10.0	40.0				u/l	14.00	32.00	23.00	28.00				
BUN	02/10/91	10.0	40.0				u/l	25.00	18.00	33.00	48.00				
CREATININE	02/10/91	10.0	40.0	u/l	50.00	19.00	30.00	38.00							
URIC ACID	02/10/91	4.0	6.0	mmol/l	5.20	5.30	6.60	4.40							
DIR BILIRUBIN	02/10/91	100.0	300.0	u/l	117.00	98.00	95.00	113.00							
TOT. PROTEINS	02/10/91	2.0	10.0	mmol/l	5.80	7.10	8.90	6.10							
ALBUMINE	02/10/91	50.0	100.0	umol/l	76.00	80.00	72.00	85.00							
TOT. CHOLEST.	02/10/91	150.0	400.0	umol/l	281.00	219.00	226.00	263.00							
TRIGLYCERIDES	02/10/91	2.0	17.0	umol/l	8.00	8.00	8.00	5.00							
GLOBULINS: ALPHA 1	02/10/91	0.0	5.0	umol/l	4.00	4.00	4.00	4.00							
GLOBULINS: ALPHA 2	02/10/91	60.0	80.0	g/l	72.00	74.00	78.00	78.00							
GLOBULINS: BETA	02/10/91	35.0	50.0	g/l	40.00	45.00	45.00	41.00							
GLOBULINS: GAMMA	02/10/91	4.0	7.0	mmol/l	4.60	4.70	5.60	3.80							
T3	02/10/91	0.5	2.0	mmol/l	1.70	0.60	0.60	0.60							
T4	02/10/91	2.0	6.0	g	5.00	9.00	7.00	7.00							
T3	02/10/91	7.0	12.0	g	11.00	11.00	12.00	9.00							
T4	02/10/91	8.0	14.0	g	9.00	11.00	15.00	12.00							
T3	02/10/91	12.0	22.0	g	16.00	16.00	14.00	15.00							
T4	02/10/91	3.3	8.2	u/l	3.30										
T4	02/10/91	9.4	25.0	u/l	9.00										

1796

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Screen	Visit					
					Date	Min	Max		Unit	Week 2	Week 4	Week 6		
13	5	MF	FEMALE	HB	02/10/91	120.0	140.0	g/l	10/10/91	25/10/91	10/10/91	140.00	140.00	
				HTC	02/10/91	38.0	47.0	z	145.00	145.00	145.00	41.00	41.00	
				RBC	02/10/91	4.0	5.5	10**12/l	43.00	43.00	43.00	4.00	4.00	
				WBC	02/10/91	4.5	8.0	10**9/l	4.30	4.30	4.30	7.90	7.90	
				RBC: N	02/10/91	60.0	70.0	z	10.10	10.10	10.10	76.00	76.00	
				RBC: L	02/10/91	20.0	30.0	z	76.00	76.00	76.00	23.00	23.00	
				RBC: E	02/10/91	1.0	5.0	z	22.00	22.00	22.00	1.00	1.00	
				RBC: M	02/10/91	2.0	6.0	z	2.00	2.00	2.00	3.00	3.00	
				RBC: B	02/10/91	0.0	1.0	z	0.00	0.00	0.00	0.00	0.00	
				PLATELETS	02/10/91	150.0	400.0	10**9/l	237.00	237.00	237.00	230.00	230.00	
				Na+	02/10/91	133.0	145.0	mmol/l	141.00	141.00	141.00	140.00	140.00	
				K+	02/10/91	3.5	5.0	mmol/l	5.40	5.40	5.40	4.90	4.90	
				Cl-	02/10/91	95.0	108.0	mmol/l	108.00	108.00	108.00	108.00	108.00	
				PO4--	02/10/91	2.3	2.7	mmol/l	2.58	2.58	2.58	2.42	2.42	
				SGOT	02/10/91	1.0	1.5	mmol/l	1.05	1.05	1.05	1.00	1.00	
				SGPT	02/10/91	10.0	40.0	u/l	44.00	44.00	44.00	39.00	39.00	
				GAMMA-GT	02/10/91	10.0	40.0	u/l	29.00	29.00	29.00	39.00	39.00	
				GLUCOSE	02/10/91	4.0	6.0	mmol/l	93.00	93.00	93.00	95.00	95.00	
				ALK. PHOSPH.	02/10/91	100.0	300.0	u/l	5.10	5.10	5.10	5.40	5.40	
				BUN	02/10/91	2.0	10.0	mmol/l	110.00	110.00	110.00	91.00	91.00	
				CREATININE	02/10/91	50.0	100.0	umol/l	2.80	2.80	2.80	4.70	4.70	
				URIC ACID	02/10/91	150.0	400.0	umol/l	66.00	66.00	66.00	87.00	87.00	
				TOT BILIRUBIN	02/10/91	2.0	17.0	umol/l	112.00	112.00	112.00	88.00	88.00	
				DIR BILIRUBIN	02/10/91	0.0	5.0	umol/l	5.00	5.00	5.00	10.00	10.00	
				TOT. PROTEINS	02/10/91	60.0	80.0	g/l	72.00	72.00	72.00	2.00	2.00	
				ALBUMINE	02/10/91	35.0	50.0	g/l	40.00	40.00	40.00	67.00	67.00	
				TOT. CHOLEST.	02/10/91	4.0	7.0	mmol/l	5.70	5.70	5.70	91.00	91.00	
				TRIGLYCERIDES	02/10/91	0.5	2.0	mmol/l	1.10	1.10	1.10	0.90	0.90	
				GLOBULINS: ALPHA 1	02/10/91	2.0	6.0	z	5.00	5.00	5.00	4.00	4.00	
				GLOBULINS: ALPHA 2	02/10/91	7.0	12.0	z	6.00	6.00	6.00	6.00	6.00	
				GLOBULINS: BETA	02/10/91	8.0	14.0	z	9.00	9.00	9.00	10.00	10.00	
				GLOBULINS: GAMMA	02/10/91	12.0	22.0	z	25.00	25.00	25.00	20.00	20.00	
				T3	02/10/91	3.3	8.2	u/l	5.40	5.40	5.40	5.40	5.40	
				T4	02/10/91	9.4	25.0	u/l	19.00	19.00	19.00	19.00	19.00	
6	KE		FEMALE	HB	02/10/91	120.0	140.0	g/l	11/10/91	28/10/91	13/11/91	155.00	155.00	155.00
				HTC	02/10/91	38.0	47.0	z	154.00	154.00	154.00	44.00	44.00	
				RBC	02/10/91	4.0	5.5	10**12/l	45.00	45.00	45.00	5.20	5.20	
				WBC	02/10/91	4.5	8.0	10**9/l	7.80	7.80	7.80	8.10	8.10	
				RBC: N	02/10/91	60.0	70.0	z	77.00	77.00	77.00	81.00	81.00	
				RBC: L	02/10/91	20.0	30.0	z	16.00	16.00	16.00	19.00	19.00	
				RBC: E	02/10/91	1.0	5.0	z	2.00	2.00	2.00	1.00	1.00	
				RBC: M	02/10/91	2.0	6.0	z	4.00	4.00	4.00	0.00	0.00	
				RBC: B	02/10/91	0.0	1.0	z	1.00	1.00	1.00	0.00	0.00	
				PLATELETS	02/10/91	150.0	400.0	10**9/l	185.00	185.00	185.00	205.00	205.00	

1797

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
13	6	KE	FEMALE	NA+	02/10/91	135.0	145.0	mmol/l	136.00	137.00	137.00	137.00	199.00
				K+	02/10/91	3.5	5.0	mmol/l	4.50	4.10	4.10	3.80	3.50
				CL-	02/10/91	95.0	108.0	mmol/l	103.00	100.00	102.00	102.00	103.00
				CA++	02/10/91	2.3	2.7	mmol/l	2.48	2.53	2.41	2.41	2.45
				PO4-	02/10/91	1.0	1.5	mmol/l	0.90	0.87	0.89	0.89	0.80
				SGOT	02/10/91	10.0	40.0	U/l	34.00	46.00	21.00	21.00	19.00
				SGPT	02/10/91	10.0	40.0	U/l	22.00	29.00	54.00	54.00	50.00
				GAMMA-GT	02/10/91	10.0	40.0	U/l	68.00	55.00	57.00	57.00	52.00
				GLUCOSE	02/10/91	4.0	6.0	mmol/l	5.20	6.40	5.20	5.20	3.10
				ALK. PHOSPH.	02/10/91	100.0	300.0	U/l	127.00	130.00	129.00	129.00	126.00
				BUN	02/10/91	2.0	10.0	mmol/l	3.80	3.60	4.30	4.30	4.00
				CREATININE	02/10/91	50.0	100.0	umol/l	67.00	59.00	44.00	44.00	54.00
				URIC ACID	02/10/91	150.0	400.0	umol/l	240.00	216.00	213.00	213.00	223.00
				TOT BILIRUBIN	02/10/91	0.0	17.0	umol/l	7.00	9.00	12.00	12.00	13.00
				DIR BILIRUBIN	02/10/91	0.0	5.0	umol/l	4.00	4.00	5.00	5.00	5.00
				TOT. PROTEINS	02/10/91	60.0	80.0	g/l	77.00	79.00	75.00	75.00	78.00
				ALBUMINE	02/10/91	35.0	50.0	g/l	45.00	44.00	44.00	44.00	45.00
				TOT. CHOLEST.	02/10/91	4.0	7.0	mmol/l	4.80	5.90	4.60	4.60	5.60
				TRIGLYCERIDES	02/10/91	0.5	2.0	mmol/l	0.80	0.80	0.60	0.60	0.50
				GLOBULINS: ALPHA 1	02/10/91	2.0	6.0	g	4.00	7.00	8.00	8.00	7.00
				GLOBULINS: ALPHA 2	02/10/91	7.0	12.0	g	4.00	4.00	9.00	9.00	9.00
				GLOBULINS: BETA	02/10/91	8.0	14.0	g	11.00	10.00	10.00	10.00	10.00
				GLOBULINS: GAMMA	02/10/91	12.0	22.0	g	16.00	17.00	16.00	16.00	16.00
				T3	02/10/91	3.3	8.2	U/l	3.43				
				T4	02/10/91	9.4	25.0	U/l	30.85				
	7	BL	FEMALE	HB	11/10/91	120.0	140.0	g/l	128.00	130.00	125.00	125.00	124.00
				HTC	02/10/91	38.0	47.0	g	38.00	39.00	38.00	38.00	38.00
				RBC	02/10/91	4.0	5.5	10**12/l	4.50	4.50	4.40	4.40	4.40
				MBC	02/10/91	4.5	8.0	10**9/l	6.40	6.80	6.60	6.60	6.10
				MBC: N	02/10/91	60.0	70.0	g	66.00	74.00	72.00	72.00	75.00
				MBC: L	02/10/91	20.0	30.0	g	30.00	22.00	25.00	25.00	24.00
				MBC: E	02/10/91	1.0	5.0	g	4.00	4.00	3.00	3.00	1.00
				MBC: M	02/10/91	2.0	6.0	g	0.00	0.00	0.00	0.00	0.00
				MBC: B	02/10/91	0.0	1.0	g	0.00	0.00	0.00	0.00	0.00
				PLATELETS	02/10/91	150.0	400.0	10**9/l	256.00	261.00	266.00	266.00	306.00
				NA+	02/10/91	135.0	165.0	mmol/l	135.00	135.00	136.00	136.00	136.00
				K+	02/10/91	3.5	5.0	mmol/l	4.00	3.70	3.70	3.70	3.90
				CL-	02/10/91	95.0	108.0	mmol/l	100.00	95.00	98.00	98.00	102.00
				PO4-	02/10/91	2.3	2.7	mmol/l	2.42	2.33	2.28	2.28	2.29
				SGOT	02/10/91	1.0	1.5	mmol/l	1.17	1.10	0.78	0.78	1.12
				SGPT	02/10/91	10.0	40.0	U/l	27.00	48.00	27.00	27.00	26.00
				GAMMA-GT	02/10/91	10.0	40.0	U/l	21.00	36.00	45.00	45.00	35.00
				GLUCOSE	02/10/91	10.0	40.0	U/l	31.00	16.00	41.00	41.00	39.00
				ALK. PHOSPH.	02/10/91	4.0	6.0	mmol/l	4.90	5.50	5.40	5.40	5.50
				GLUCOSE	02/10/91	100.0	300.0	U/l	99.00	107.00	104.00	104.00	108.00
				BUN	02/10/91	2.0	10.0	mmol/l	5.70	5.70	5.70	5.70	5.30
				CREATININE	02/10/91	50.0	100.0	umol/l	59.00	57.00	51.00	51.00	48.00
				URIC ACID	02/10/91	150.0	400.0	umol/l	222.00	156.00	171.00	171.00	203.00

1798

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20126/013
 Listing No.: 12.1
 LABORATORY DATA
 OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit								
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
13	7	BL	FEMALE	TOT BILIRUBIN	02/10/91	2.0	17.0	umol/l	11.00	11.00	9.00	10.00			
				DIR BILIRUBIN	02/10/91	0.0	5.0	umol/l	4.00	4.00	4.00	4.00			
				TOT. PROTEINS	02/10/91	60.0	80.0	g/l	74.00	76.00	75.00	71.00			
				ALBUMINE	02/10/91	35.0	50.0	g/l	39.00	38.00	38.00	38.00			
				TOT. CHOLEST.	02/10/91	4.0	7.0	mmol/l	3.70	4.60	3.90	4.40			
				TRIGLYCERIDES	02/10/91	0.5	2.0	mmol/l	0.80	0.80	0.80	0.50			
				GLOBULINS: ALPHA 1	02/10/91	2.0	6.0	g	7.00	8.00	6.00	6.00			
				GLOBULINS: ALPHA 2	02/10/91	7.0	12.0	g	11.00	11.00	10.00	10.00			
				GLOBULINS: BETA	02/10/91	8.0	14.0	g	10.00	12.00	14.00	12.00			
				GLOBULINS: GAMMA	02/10/91	12.0	22.0	g	24.00	16.00	20.00	19.00			
				T3	02/10/91	3.3	8.2	u/l	10.50						
				T4	02/10/91	9.4	25.0	u/l	13.86						
				8	PK	FEMALE	HB	02/10/91	120.0	160.0	g/l	15/10/91	16/10/91	19/11/91	03/12/91
							HTC	02/10/91	38.0	47.0	g/l	192.00	141.00	131.00	130.00
							RBC	02/10/91	4.0	5.5	10**12/l	39.00	40.00	37.00	38.00
							HBC	02/10/91	4.5	8.0	10**9/l	4.70	4.90	4.60	4.60
							HBC: N	02/10/91	60.0	70.0	g	6.00	4.90	4.70	4.70
HBC: L	02/10/91	20.0	30.0				g	54.00	53.00	68.00	45.00				
HBC: E	02/10/91	1.0	5.0				g	37.00	38.00	29.00	52.00				
HBC: H	02/10/91	2.0	6.0				g	7.00	5.00	1.00	3.00				
HBC: B	02/10/91	0.0	1.0				g	1.00	3.00	1.00	0.00				
PLATELETS	02/10/91	150.0	400.0				10**9/l	1.00	1.00	1.00	0.00				
Na+	02/10/91	135.0	145.0				mmol/l	264.00	236.00	256.00	245.00				
Cl-	02/10/91	3.5	5.0				mmol/l	137.00	142.00	136.00	138.00				
PO4--	02/10/91	95.0	108.0				mmol/l	4.60	4.70	4.30	4.30				
SGOT	02/10/91	2.3	2.7				mmol/l	106.00	98.00	102.00	100.00				
GAMMA-GT	02/10/91	1.0	1.5				mmol/l	2.45	2.44	2.39	2.40				
GLUCOSE	02/10/91	10.0	40.0				u/l	1.01	0.90	1.03	1.05				
ALK. PHOSPH.	02/10/91	4.0	6.0				mmol/l	27.00	27.00	23.00	20.00				
BUN	02/10/91	10.0	40.0				u/l	28.00	43.00	34.00	33.00				
CREATININE	02/10/91	10.0	40.0				u/l	32.00	24.00	24.00	21.00				
URIC ACID	02/10/91	100.0	300.0				u/l	4.70	4.50	5.00	5.50				
TOT BILIRUBIN	02/10/91	2.0	10.0				mmol/l	182.00	169.00	107.00	89.00				
DIR BILIRUBIN	02/10/91	50.0	100.0				umol/l	6.30	7.20	7.20	6.60				
TOT. PROTEINS	02/10/91	150.0	400.0				umol/l	72.00	55.00	119.00	68.00				
ALBUMINE	02/10/91	2.0	17.0	umol/l	180.00	194.00	198.00	178.00							
TRIGLYCERIDES	02/10/91	0.0	5.0	mmol/l	6.00	6.00	6.00	4.00							
GLOBULINS: ALPHA 1	02/10/91	35.0	50.0	g/l	73.00	76.00	75.00	72.00							
GLOBULINS: ALPHA 2	02/10/91	4.0	7.0	mmol/l	41.00	32.00	46.00	42.00							
GLOBULINS: BETA	02/10/91	0.5	2.0	mmol/l	5.20	5.40	5.30	6.10							
GLOBULINS: GAMMA	02/10/91	2.0	6.0	g	0.40	0.70	0.90	0.70							
T3	02/10/91	7.0	12.0	g	9.00	10.00	9.00	8.00							
T4	02/10/91	8.0	14.0	g	11.00	13.00	11.00	12.00							
T3	02/10/91	12.0	22.0	g	17.00	17.00	15.00	16.00							
T4	02/10/91	3.3	8.2	u/l	3.14										
T4	02/10/91	9.4	25.0	u/l	21.30										

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit									
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6					
13	9	S23	MALE	HB	02/10/91	140.0	160.0	g/l	15/10/91	141.00	04/11/91	157.00	03/11/91	132.00		
				HTC	02/10/91	40.0	54.0	%	15/10/91	40.00	04/11/91	43.00	19/11/91	45.00	03/11/91	38.00
				RBC	02/10/91	4.0	5.5	10**12/l	15/10/91	4.50	04/11/91	4.50	19/11/91	5.10	03/11/91	4.30
				HBC: N	02/10/91	4.5	8.0	10**9/l	15/10/91	5.80	04/11/91	5.80	19/11/91	6.30	03/11/91	4.70
				HBC: L	02/10/91	60.0	70.0	%	15/10/91	58.00	04/11/91	58.00	19/11/91	61.00	03/11/91	60.00
				HBC: E	02/10/91	20.0	30.0	%	15/10/91	49.00	04/11/91	49.00	19/11/91	35.00	03/11/91	35.00
				HBC: H	02/10/91	1.0	5.0	%	15/10/91	3.00	04/11/91	3.00	19/11/91	2.00	03/11/91	2.00
				HBC: B	02/10/91	2.0	6.0	%	15/10/91	0.00	04/11/91	0.00	19/11/91	2.00	03/11/91	1.00
				PLATELETS	02/10/91	0.0	1.0	%	15/10/91	0.00	04/11/91	0.00	19/11/91	0.00	03/11/91	0.00
				NA+	02/10/91	150.0	400.0	10**9/l	15/10/91	260.00	04/11/91	290.00	19/11/91	277.00	03/11/91	214.00
				K+	02/10/91	135.0	165.0	mmol/l	15/10/91	137.00	04/11/91	144.00	19/11/91	135.00	03/11/91	137.00
				Ca++	02/10/91	3.5	5.0	mmol/l	15/10/91	4.30	04/11/91	5.00	19/11/91	4.40	03/11/91	4.10
				Cl-	02/10/91	95.0	108.0	mmol/l	15/10/91	108.00	04/11/91	102.00	19/11/91	102.00	03/11/91	104.00
				PO4--	02/10/91	2.3	2.7	mmol/l	15/10/91	2.41	04/11/91	2.38	19/11/91	2.38	03/11/91	2.27
				SGPT	02/10/91	1.0	1.5	mmol/l	15/10/91	37.00	04/11/91	22.00	19/11/91	25.00	03/11/91	34.00
				SGOT	02/10/91	10.0	40.0	u/l	15/10/91	46.00	04/11/91	35.00	19/11/91	24.00	03/11/91	40.00
				GGMA-GT	02/10/91	10.0	40.0	u/l	15/10/91	138.00	04/11/91	66.00	19/11/91	59.00	03/11/91	36.00
				GLUCOSE	02/10/91	4.0	6.0	mmol/l	15/10/91	6.00	04/11/91	6.10	19/11/91	6.40	03/11/91	6.10
				ALK. PHOSPH.	02/10/91	100.0	300.0	u/l	15/10/91	100.00	04/11/91	145.00	19/11/91	80.00	03/11/91	85.00
				UREA	02/10/91	2.0	10.0	mmol/l	15/10/91	8.90	04/11/91	10.10	19/11/91	13.80	03/11/91	9.30
				CREATININE	02/10/91	50.0	100.0	umol/l	15/10/91	86.00	04/11/91	82.00	19/11/91	177.00	03/11/91	83.00
				URIC ACID	02/10/91	150.0	400.0	umol/l	15/10/91	266.00	04/11/91	253.00	19/11/91	285.00	03/11/91	298.00
				TOT BILIRUBIN	02/10/91	2.0	17.0	umol/l	15/10/91	12.00	04/11/91	19.00	19/11/91	15.00	03/11/91	24.00
				DIR BILIRUBIN	02/10/91	0.0	5.0	umol/l	15/10/91	3.00	04/11/91	3.00	19/11/91	4.00	03/11/91	7.00
				TOT. PROTEINS	02/10/91	60.0	80.0	g/l	15/10/91	78.00	04/11/91	80.00	19/11/91	78.00	03/11/91	74.00
				ALBUMINE	02/10/91	35.0	50.0	g/l	15/10/91	42.00	04/11/91	43.00	19/11/91	46.00	03/11/91	43.00
				TOT. CHOLEST.	02/10/91	4.0	7.0	mmol/l	15/10/91	8.60	04/11/91	6.80	19/11/91	7.80	03/11/91	7.20
				TRIGLYCERIDES	02/10/91	0.5	2.0	mmol/l	15/10/91	1.10	04/11/91	0.70	19/11/91	1.20	03/11/91	0.50
				GLOBULINS: ALPHA 1	02/10/91	2.0	6.0	%	15/10/91	8.00	04/11/91	6.00	19/11/91	7.00	03/11/91	6.00
				GLOBULINS: ALPHA 2	02/10/91	7.0	12.0	%	15/10/91	9.00	04/11/91	8.00	19/11/91	8.00	03/11/91	7.00
				GLOBULINS: BETA	02/10/91	8.0	14.0	%	15/10/91	9.00	04/11/91	10.00	19/11/91	10.00	03/11/91	10.00
				GLOBULINS: GAMA	02/10/91	12.0	22.0	%	15/10/91	21.00	04/11/91	21.00	19/11/91	17.00	03/11/91	16.00
				T3	02/10/91	3.3	8.2	u/l	15/10/91	3.49	04/11/91	3.49	19/11/91	3.49	03/11/91	3.49
T4	02/10/91	9.4	25.0	u/l	15/10/91	7.41	04/11/91	7.41	19/11/91	7.41	03/11/91	7.41				
10	BM	FEMALE	HR	02/10/91	120.0	160.0	g/l	15/10/91	138.00	30/10/91	135.00	03/11/91	132.00			
			HTC	02/10/91	38.0	47.0	%	15/10/91	39.00	30/10/91	39.00	03/11/91	38.00			
			RBC	02/10/91	4.0	5.5	10**12/l	15/10/91	4.40	30/10/91	4.40	03/11/91	4.30			
			HBC: N	02/10/91	60.0	70.0	%	15/10/91	59.00	30/10/91	65.00	03/11/91	60.00			
			HBC: L	02/10/91	20.0	30.0	%	15/10/91	35.00	30/10/91	29.00	03/11/91	29.00			
			HBC: E	02/10/91	1.0	5.0	%	15/10/91	4.00	30/10/91	3.00	03/11/91	3.00			
			HBC: H	02/10/91	2.0	6.0	%	15/10/91	2.00	30/10/91	1.00	03/11/91	1.00			
			HBC: B	02/10/91	0.0	1.0	%	15/10/91	0.00	30/10/91	2.00	03/11/91	2.00			
			PLATELETS	02/10/91	150.0	400.0	10**9/l	15/10/91	387.00	30/10/91	371.00	03/11/91	371.00			

10031

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOMETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Screen	Visit				
					Date	Min	Max		Unit	Week 2	Week 4	Week 6	
13	10	BH	FEMALE	NA+	02/10/91	135.0	145.0	mmol/l	141.00	159.00			
				K+	02/10/91	3.5	5.0	mmol/l	3.80	3.70			
				CL-	02/10/91	95.0	108.0	mmol/l	108.00	102.00			
				CA++	02/10/91	2.3	2.7	mmol/l	2.48	2.56			
				PO4--	02/10/91	1.0	1.5	mmol/l	1.42	1.10			
				SGOT	02/10/91	10.0	40.0	u/l	37.00	48.00			
				SGPT	02/10/91	10.0	40.0	u/l	56.00	49.00			
				GAMMA-GT	02/10/91	10.0	40.0	u/l	37.00	25.00			
				GLUCOSE	02/10/91	4.0	6.0	mmol/l	5.10	5.50			
				ALK. PHOSPH.	02/10/91	100.0	300.0	u/l	111.00	158.00			
				RUN	02/10/91	2.0	10.0	mmol/l	7.70	6.70			
				CREATININE	02/10/91	50.0	100.0	umol/l	69.00	58.00			
				URIC ACID	02/10/91	150.0	400.0	umol/l	370.00	298.00			
				TOT BILIRUBIN	02/10/91	2.0	17.0	umol/l	4.00	8.00			
				DIR BILIRUBIN	02/10/91	0.0	5.0	umol/l	2.00	4.00			
				TOT. PROTEINS	02/10/91	60.0	80.0	g/l	75.00	78.00			
				ALBUMINE	02/10/91	35.0	50.0	g/l	45.00	48.00			
				TOT. CHOLEST.	02/10/91	4.0	7.0	mmol/l	7.20	5.10			
				TRIGLYCERIDES	02/10/91	0.5	2.0	mmol/l	0.90	2.00			
				GLOBULINS: ALPHA 1	02/10/91	2.0	6.0	%	7.00	6.00			
				GLOBULINS: ALPHA 2	02/10/91	7.0	12.0	%	11.00	9.00			
				GLOBULINS: BETA	02/10/91	8.0	14.0	%	10.00	11.00			
				GLOBULINS: GAMMA	02/10/91	12.0	22.0	%	17.00	15.00			
				T3	02/10/91	3.3	8.2	u/l	3.60				
				T4	02/10/91	9.4	25.0	u/l	17.73				
11	HS		FEMALE	HB	02/10/91	120.0	140.0	g/l	17/10/91	17/10/91	28/11/91	09/12/91	27/12/91
				HTC	02/10/91	38.0	47.0	%	154.00	148.00	148.00	151.00	151.00
				RBC	02/10/91	4.0	5.5	10**12/l	45.00	43.00	43.00	44.00	45.00
				MBC	02/10/91	4.5	8.0	10**9/l	5.00	5.00	5.00	5.00	5.00
				MBC: N	02/10/91	60.0	70.0	%	8.10	8.10	5.80	6.00	5.60
				MBC: L	02/10/91	20.0	30.0	%	58.00	58.00	62.00	75.00	63.00
				MBC: E	02/10/91	1.0	5.0	%	35.00	37.00	37.00	25.00	34.00
				MBC: M	02/10/91	2.0	6.0	%	5.00	0.00	0.00	0.00	2.00
				MBC: B	02/10/91	0.0	1.0	%	1.00	1.00	1.00	0.00	1.00
				PLATELETS	02/10/91	150.0	400.0	10**9/l	261.00	265.00	265.00	246.00	262.00
				NA+	02/10/91	135.0	145.0	mmol/l	137.00	139.00	137.00	139.00	136.00
				K+	02/10/91	3.5	5.0	mmol/l	4.20	3.60	3.60	4.20	4.00
				CL-	02/10/91	95.0	108.0	mmol/l	105.00	101.00	106.00	106.00	105.00
				CA++	02/10/91	2.3	2.7	mmol/l	2.48	2.63	2.63	2.32	2.33
				PO4--	02/10/91	1.0	1.5	mmol/l	1.00	0.82	0.82	0.97	1.07
				SGOT	02/10/91	10.0	40.0	u/l	55.00	25.00	25.00	46.00	27.00
				SGPT	02/10/91	10.0	40.0	u/l	127.00	71.00	71.00	74.00	30.00
				GAMMA-GT	02/10/91	10.0	40.0	u/l	195.00	76.00	76.00	72.00	65.00
				GLUCOSE	02/10/91	4.0	6.0	mmol/l	5.20	5.80	5.80	6.00	5.70
				ALK. PHOSPH.	02/10/91	100.0	300.0	u/l	162.00	93.00	93.00	107.00	68.00
				RUN	02/10/91	2.0	10.0	mmol/l	7.30	4.90	4.90	5.10	8.60
				CREATININE	02/10/91	50.0	100.0	umol/l	89.00	76.00	76.00	75.00	72.00
				URIC ACID	02/10/91	150.0	400.0	umol/l	327.00	300.00	300.00	262.00	255.00

1801

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXEMINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6				
13	11	HS	FEMALE	TOT BILIRUBIN	02/10/91	2.0	17.0	umol/l	22.00	9.00	4.00	4.00				
				DIR BILIRUBIN	02/10/91	0.0	5.0	umol/l	4.00	4.00	4.00	4.00				
				TOT. PROTEINS	02/10/91	60.0	80.0	g/l	79.00	80.00	72.00	78.00				
				ALBUMINE	02/10/91	35.0	50.0	g/l	41.00	41.00	39.00	40.00				
				TOT. CHOLEST.	02/10/91	4.0	7.0	mmol/l	6.60	6.60	5.40	4.70				
				TRIGLYCERIDES	02/10/91	0.5	2.0	mmol/l	1.40	0.80	0.80	1.10				
				GLOBULINS: ALPHA 1	02/10/91	2.0	6.0	%	6.00	8.00	6.00	8.00				
				GLOBULINS: ALPHA 2	02/10/91	7.0	12.0	%	9.00	11.00	8.00	8.00				
				GLOBULINS: BETA	02/10/91	8.0	14.0	%	13.00	12.00	10.00	12.00				
				GLOBULINS: GAMMA	02/10/91	12.0	22.0	%	17.00	15.00	10.00	12.00				
				T3	02/10/91	3.3	8.2	u/l	4.30							
				T4	02/10/91	9.4	25.0	u/l	13.23							
				12	BF		MALE	HB	02/10/91	140.0	160.0	g/l	164.00	164.00	167.00	167.00
								HTC	02/10/91	40.0	54.0	%	48.00	47.00	50.00	50.00
RBC	02/10/91	4.0	5.5					10**9/l	5.20	5.10	5.40	5.40				
RBC: N	02/10/91	4.5	8.0					10**9/l	9.50	10.50	10.50	10.50				
RBC: L	02/10/91	60.0	70.0					%	61.00	67.00	67.00	67.00				
RBC: E	02/10/91	20.0	30.0					%	33.00	29.00	29.00	29.00				
RBC: N	02/10/91	1.0	5.0					%	4.00	2.00	1.00	1.00				
RBC: E	02/10/91	2.0	6.0					%	1.00	1.00	3.00	3.00				
RBC: B	02/10/91	0.0	1.0					%	1.00	1.00	0.00	0.00				
PLATELETS	02/10/91	150.0	400.0					10**9/l	231.00	257.00	302.00	302.00				
Na+	02/10/91	135.0	145.0					mmol/l	139.00	140.00	139.00	139.00				
K+	02/10/91	3.5	5.0					mmol/l	4.00	4.40	4.60	4.60				
Cl-	02/10/91	95.0	108.0					mmol/l	109.00	100.00	102.00	102.00				
Ca++	02/10/91	2.3	2.7					mmol/l	2.40	2.47	2.54	2.54				
PO4--	02/10/91	1.0	1.5	mmol/l	1.11	1.05	1.01	1.01								
SGPT	02/10/91	10.0	40.0	u/l	27.00	49.00	43.00	43.00								
GAMMA-GT	02/10/91	10.0	40.0	u/l	31.00	73.00	82.00	82.00								
GLUCOSE	02/10/91	10.0	40.0	u/l	56.00	41.00	24.00	24.00								
ALK. PHOSPH.	02/10/91	4.0	6.0	mmol/l	6.00	5.20	6.00	6.00								
BUN	02/10/91	100.0	300.0	u/l	164.00	126.00	154.00	154.00								
CREATININE	02/10/91	2.0	10.0	mmol/l	4.00	4.20	2.80	2.80								
URIC ACID	02/10/91	50.0	100.0	umol/l	75.00	74.00	95.00	95.00								
TOT BILIRUBIN	02/10/91	150.0	400.0	umol/l	198.00	230.00	203.00	203.00								
DIR BILIRUBIN	02/10/91	0.0	17.0	umol/l	16.00	9.00	7.00	7.00								
TOT. PROTEINS	02/10/91	60.0	80.0	g/l	71.00	73.00	75.00	75.00								
ALBUMINE	02/10/91	35.0	50.0	g/l	38.00	43.00	40.00	40.00								
TOT. CHOLEST.	02/10/91	4.0	7.0	mmol/l	7.00	5.50	1.70	1.70								
TRIGLYCERIDES	02/10/91	0.5	2.0	mmol/l	1.80	1.10	4.00	4.00								
GLOBULINS: ALPHA 1	02/10/91	2.0	6.0	%	8.00	7.00	11.00	11.00								
GLOBULINS: ALPHA 2	02/10/91	7.0	12.0	%	9.00	10.00	14.00	14.00								
GLOBULINS: BETA	02/10/91	8.0	14.0	%	12.00	11.00	14.00	14.00								
GLOBULINS: GAMMA	02/10/91	12.0	22.0	%	16.00	14.00	16.00	16.00								
T3	02/10/91	3.3	8.2	u/l	2.90											
T4	02/10/91	9.4	25.0	u/l	10.72											

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOMETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit					
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
13	HM	MALE	HB	02/10/91	140.0	160.0	g/l	28/10/91	14/11/91	28/11/91	13/12/91	
			HTC	02/10/91	40.0	54.0	Z	162.00	160.00	168.00	156.00	
			RBC	02/10/91	4.0	5.5	10**12/l	47.00	46.00	48.00	45.00	
			HBC: N	02/10/91	4.5	8.0	10**9/l	4.60	4.60	5.10	4.50	
			HBC: L	02/10/91	60.0	70.0	Z	15.60	12.80	10.50	13.10	
			HBC: E	02/10/91	20.0	30.0	Z	73.00	68.00	65.00	70.00	
			HRC: M	02/10/91	1.0	5.0	Z	15.00	28.00	34.00	27.00	
			HRC: B	02/10/91	2.0	6.0	Z	9.00	3.00	1.00	3.00	
			PLATELETS	02/10/91	0.0	1.0	Z	2.00	1.00	0.00	0.00	
			PLATELETS	02/10/91	150.0	400.0	10**9/l	335.00	253.00	296.00	275.00	
			PLATELETS	02/10/91	135.0	145.0	mmol/l	141.00	138.00	139.00	138.00	
			Ca++	02/10/91	3.5	5.0	mmol/l	4.20	4.20	4.00	4.10	
			Ca++	02/10/91	95.0	103.0	mmol/l	99.00	106.00	105.00	110.00	
			Ca++	02/10/91	2.3	2.7	mmol/l	2.49	2.43	2.38	2.42	
			SGOT	02/10/91	1.0	1.5	mmol/l	1.04	1.04	1.28	1.10	
			SGPT	02/10/91	10.0	40.0	u/l	40.00	47.00	29.00	19.00	
			GAMMA-GT	02/10/91	10.0	40.0	u/l	34.00	92.00	49.00	42.00	
			GLUCOSE	02/10/91	10.0	40.0	u/l	61.00	51.00	68.00	109.00	
			ALK. PHOSPH.	02/10/91	4.0	6.0	mmol/l	6.80	7.20	6.50	7.90	
			BUN	02/10/91	100.0	300.0	u/l	153.00	131.00	104.00	98.00	
			CREATININE	02/10/91	2.0	10.0	mmol/l	3.20	3.10	4.30	3.70	
			TOT BILIRUBIN	02/10/91	50.0	100.0	umol/l	81.00	62.00	72.00	82.00	
			DIR BILIRUBIN	02/10/91	150.0	400.0	umol/l	288.00	361.00	305.00	336.00	
			TOT. PROTEINS	02/10/91	2.0	17.0	umol/l	4.00	4.00	7.00	12.00	
			ALBUMINE	02/10/91	60.0	80.0	g/l	4.00	4.00	6.00	4.00	
			TOT. CHOLEST.	02/10/91	35.0	50.0	g/l	42.00	46.00	42.00	44.00	
			TRIGLYCERIDES	02/10/91	4.0	7.0	mmol/l	6.00	4.80	5.50	6.30	
			GLOBULINS: ALPHA 1	02/10/91	0.5	2.0	mmol/l	0.90	0.70	0.90	1.70	
GLOBULINS: ALPHA 2	02/10/91	2.0	6.0	Z	5.00	5.00	4.00	6.00				
GLOBULINS: BETA	02/10/91	8.0	14.0	Z	11.00	8.00	8.00	10.00				
GLOBULINS: GAMMA	02/10/91	12.0	22.0	Z	18.00	15.00	17.00	17.00				
T3	02/10/91	3.3	8.2	u/l	4.30							
T4	02/10/91	9.4	25.0	u/l	14.11							
14	DF	FEMALE	HB	02/10/91	120.0	140.0	g/l	28/10/91	14/11/91	28/11/91	12/12/91	
			HTC	02/10/91	38.0	47.0	Z	137.00	130.00	123.00	130.00	
			RBC	02/10/91	4.0	5.5	10**12/l	42.00	40.00	37.00	40.00	
			HBC: N	02/10/91	4.5	8.0	10**9/l	4.50	4.10	4.10	4.30	
			HBC: L	02/10/91	60.0	70.0	Z	72.00	65.00	6.20	6.60	
			HBC: E	02/10/91	20.0	30.0	Z	27.00	32.00	26.00	31.00	
			HRC: M	02/10/91	1.0	5.0	Z	1.00	0.00	1.00	0.00	
			HRC: B	02/10/91	2.0	6.0	Z	0.00	3.00	2.00	0.00	
			PLATELETS	02/10/91	0.0	1.0	Z	0.00	0.00	0.00	0.00	
			PLATELETS	02/10/91	150.0	400.0	10**9/l	168.00	189.00	184.00	285.00	

1000

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range		Unit	Screen	Visit				
				Min	Max			Week 2	Week 4	Week 6		
13	14	DF	FEMALE	02/10/91	135.0	145.0	mmol/L	142.00	139.00	140.00		
			K+	02/10/91	3.5	5.0	mmol/L	4.40	4.10	4.00		
			CL-	02/10/91	95.0	108.0	mmol/L	104.00	105.00	110.00		
			CA++	02/10/91	2.3	2.7	mmol/L	2.56	2.44	2.46		
			PO4--	02/10/91	1.0	1.5	mmol/L	0.90	0.96	0.92		
			SGPT	02/10/91	10.0	40.0	u/l	22.00	23.00	18.00		
			SGPT	02/10/91	10.0	40.0	u/l	21.00	23.00	23.00		
			GAMMA-GT	02/10/91	10.0	40.0	u/l	35.00	24.00	16.00		
			GLUCOSE	02/10/91	4.0	6.0	mmol/L	5.10	4.70	6.40		
			BUN	02/10/91	100.0	300.0	u/l	152.00	127.00	131.00		
			ALB.	02/10/91	2.0	10.0	mmol/L	4.40	5.20	4.70		
			CREATININE	02/10/91	50.0	100.0	umol/L	87.00	64.00	81.00		
			URIC ACID	02/10/91	150.0	400.0	umol/L	229.00	223.00	209.00		
			TOT. BILIRUBIN	02/10/91	2.0	17.0	umol/L	4.00	9.00	7.00		
			DIR. BILIRUBIN	02/10/91	0.0	5.0	umol/L	4.00	4.00	4.00		
			TOT. PROTEINS	02/10/91	60.0	80.0	g/l	79.00	72.00	80.00		
			ALBUMINE	02/10/91	35.0	50.0	g/l	43.00	44.00	44.00		
			TOT. CHOLEST.	02/10/91	4.0	7.0	mmol/L	5.50	4.64	5.30		
			TRIGLYCERIDES	02/10/91	0.5	2.0	mmol/L	0.50	0.60	0.70		
			GLUCOLINS: ALPHA 1	02/10/91	2.0	8.0	%	4.00	6.00	6.00		
			GLUCOLINS: ALPHA 2	02/10/91	7.0	12.0	%	8.00	9.00	9.00		
			GLUCOLINS: BETA	02/10/91	8.0	14.0	%	10.00	8.00	12.00		
			GLUCOLINS: GAMMA	02/10/91	12.0	22.0	%	18.00	13.00	14.00		
			T3	02/10/91	3.3	8.2	u/l	2.10				
			T4	02/10/91	9.4	25.0	u/l	7.71				
15	KG		FEMALE	02/10/91	120.0	140.0	g/l	144.00	148.00	133.00		
			HR	02/10/91	38.0	47.0	z	42.00	40.00	38.00		
			RBC	02/10/91	4.0	5.5	10**12/l	4.60	4.80	4.20		
			RBC: N	02/10/91	4.5	8.0	10**9/l	9.60	6.80	5.40		
			RBC: L	02/10/91	60.0	70.0	z	78.00	61.00	58.00		
			RBC: E	02/10/91	20.0	30.0	z	21.00	37.00	37.00		
			RBC: M	02/10/91	1.0	5.0	z	0.00	1.00	3.00		
			RBC: B	02/10/91	2.0	6.0	z	1.00	2.00	1.00		
			PLATELETS	02/10/91	400.0	10**9/l	z	0.00	0.00	1.00		
			NA+	02/10/91	135.0	145.0	mmol/L	140.00	276.00	308.00		
			K+	02/10/91	3.5	5.0	mmol/L	4.40	4.50	4.50		
			CL-	02/10/91	95.0	108.0	mmol/L	98.00	101.00	110.00		
			PO4--	02/10/91	2.3	2.7	mmol/L	2.51	2.53	2.32		
			SGPT	02/10/91	1.0	1.5	mmol/L	1.13	1.43	1.00		
			SGPT	02/10/91	10.0	40.0	u/l	39.00	18.00	21.00		
			GAMMA-GT	02/10/91	10.0	40.0	u/l	44.00	47.00	44.00		
			GLUCOSE	02/10/91	4.0	6.0	mmol/L	105.00	36.00	65.00		
			ALB. PHOSPH.	02/10/91	100.0	300.0	u/l	187.00	171.00	150.00		
			BUN	02/10/91	2.0	10.0	mmol/L	3.80	3.80	6.10		
			CREATININE	02/10/91	50.0	100.0	umol/L	97.00	71.00	71.00		
			URIC ACID	02/10/91	150.0	400.0	umol/L	205.00	260.00	222.00		

1804

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOMETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range		Screen	Visit							
					Date	Date		Week 2	Week 4	Week 6					
13	15	KG	FEMALE	TOT BILIRUBIN	2.0	17.0	umol/l	8.00	10.00	9.00	9.00	9.00			
				DIR BILIRUBIN	0.0	5.0	umol/l	4.00	4.00	4.00	4.00	4.00			
				TOT. PROTEINS	60.0	80.0	g/l	82.00	81.00	77.00	76.00	76.00			
				ALBUMINE	35.0	50.0	g/l	41.00	41.00	40.00	45.00	45.00			
				TOT. CHOLEST.	4.0	7.0	mmol/l	6.20	4.90	4.80	4.80	4.80			
				TRIGLYCERIDES	0.5	2.0	mmol/l	0.80	0.70	0.50	0.40	0.40			
				GLOBULINS: ALPHA 1	2.0	6.0	g	7.00	8.00	7.00	5.00	5.00			
				GLOBULINS: ALPHA 2	7.0	12.0	g	9.00	10.00	10.00	7.00	7.00			
				GLOBULINS: BETA	8.0	14.0	g	13.00	11.00	11.00	10.00	10.00			
				GLOBULINS: GAMMA	12.0	22.0	g	17.00	10.00	17.00	10.00	17.00			
				T3	3.3	8.2	u/l	4.60							
				T4	9.4	25.0	u/l	16.86							
				16	SZL		FEMALE	TOT BILIRUBIN	120.0	140.0	g/l	130.00	142.00	142.00	138.00
								DIR BILIRUBIN	38.0	47.0	g/l	38.00	41.00	40.00	40.00
RBC	4.0	5.5	10**12/l					4.40	4.80	4.50	4.70				
WBC	4.5	8.0	10**9/l					4.30	3.90	6.10	5.60				
HBC: N	60.0	70.0	g					64.00	56.00	66.00	68.00				
HBC: L	20.0	30.0	g					34.00	41.00	32.00	31.00				
HBC: E	1.0	5.0	g					2.00	1.00	1.00	1.00				
HBC: M	2.0	6.0	g					0.00	1.00	0.00	0.00				
HBC: B	0.0	1.0	g					0.00	1.00	1.00	0.00				
PLATELETS	150.0	400.0	10**9/l					176.00	195.00	220.00	209.00				
NA+	135.0	145.0	mmol/l					138.00	142.00	143.00	141.00				
K+	3.5	5.0	mmol/l					3.90	4.70	3.70	4.20				
CL-	95.0	108.0	mmol/l					102.00	106.00	112.00	101.00				
CA++	2.3	2.7	mmol/l					2.36	2.48	2.34	2.40				
PO4-	1.0	1.5	mmol/l					0.80	0.80	0.88	1.10				
SGPT	10.0	40.0	u/l					22.00	23.00	23.00	24.00				
SGOT	10.0	40.0	u/l					30.00	17.00	37.00	20.00				
GAMMA-GT	10.0	40.0	u/l					23.00	25.00	59.00	42.00				
GLUCOSE	4.0	6.0	mmol/l					5.50	5.50	4.80	5.60				
ALK. PHOSPH.	100.0	300.0	u/l					156.00	137.00	135.00	121.00				
BUN	2.0	10.0	mmol/l					4.90	6.30	6.60	5.60				
CREATININE	50.0	100.0	umol/l					62.00	59.00	48.00	58.00				
URIC ACID	150.0	400.0	umol/l					200.00	259.00	235.00	266.00				
DIR BILIRUBIN	2.0	17.0	umol/l					4.00	4.00	4.00	4.00				
TOT BILIRUBIN	60.0	80.0	g/l	72.00	79.00	74.00	76.00								
TOT. PROTEINS	35.0	50.0	g/l	50.00	41.00	45.00	46.00								
ALBUMINE	4.0	7.0	mmol/l	4.30	5.40	5.30	5.40								
TOT. CHOLEST.	0.5	2.0	mmol/l	0.70	1.40	1.30	0.90								
TRIGLYCERIDES	2.0	6.0	g	5.00	8.00	6.00	7.00								
GLOBULINS: ALPHA 1	7.0	12.0	g	8.00	8.00	8.00	10.00								
GLOBULINS: ALPHA 2	8.0	14.0	g	10.00	10.00	11.00	10.00								
GLOBULINS: BETA	12.0	22.0	g	15.00	16.00	15.00	13.00								
GLOBULINS: GAMMA	3.3	8.2	u/l	3.58											
T3	9.4	25.0	u/l	13.10											
T4															

1805

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXENTINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient Initials	Sex	Laboratory test	Laboratory Range			Visit					
				Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
13	17	GSM	FEMALE	HB	02/10/91	120.0	140.0	g/l	15/11/91	03/12/91	17/12/91	28/12/91
				HTC	02/10/91	38.0	47.0	g/l	15/11/91	03/12/91	17/12/91	28/12/91
				RBC	02/10/91	4.0	5.5	10 ¹² /l	15/11/91	03/12/91	17/12/91	28/12/91
				WBC	02/10/91	4.5	8.0	10 ⁹ /l	15/11/91	03/12/91	17/12/91	28/12/91
				HbC: N	02/10/91	60.0	70.0	%	15/11/91	03/12/91	17/12/91	28/12/91
				HbC: L	02/10/91	20.0	30.0	%	15/11/91	03/12/91	17/12/91	28/12/91
				HbC: E	02/10/91	1.0	5.0	%	15/11/91	03/12/91	17/12/91	28/12/91
				HbC: M	02/10/91	2.0	6.0	%	15/11/91	03/12/91	17/12/91	28/12/91
				HbC: B	02/10/91	0.0	1.0	%	15/11/91	03/12/91	17/12/91	28/12/91
				PLATELETS	02/10/91	150.0	400.0	10 ⁹ /l	15/11/91	03/12/91	17/12/91	28/12/91
				Na+	02/10/91	135.0	145.0	mmol/l	15/11/91	03/12/91	17/12/91	28/12/91
				K+	02/10/91	3.5	5.0	mmol/l	15/11/91	03/12/91	17/12/91	28/12/91
				Cl-	02/10/91	95.0	108.0	mmol/l	15/11/91	03/12/91	17/12/91	28/12/91
				Ca++	02/10/91	2.3	2.7	mmol/l	15/11/91	03/12/91	17/12/91	28/12/91
				PO4--	02/10/91	1.0	1.5	mmol/l	15/11/91	03/12/91	17/12/91	28/12/91
				SGPT	02/10/91	10.0	40.0	u/l	15/11/91	03/12/91	17/12/91	28/12/91
				GAMMA-GT	02/10/91	10.0	40.0	u/l	15/11/91	03/12/91	17/12/91	28/12/91
				GLUCOSE	02/10/91	4.0	6.0	mmol/l	15/11/91	03/12/91	17/12/91	28/12/91
				ALK. PHOSPH.	02/10/91	100.0	300.0	u/l	15/11/91	03/12/91	17/12/91	28/12/91
				BUN	02/10/91	2.0	10.0	mmol/l	15/11/91	03/12/91	17/12/91	28/12/91
				CREATININE	02/10/91	50.0	100.0	umol/l	15/11/91	03/12/91	17/12/91	28/12/91
				URIC ACID	02/10/91	150.0	400.0	umol/l	15/11/91	03/12/91	17/12/91	28/12/91
				TOT BILIRUBIN	02/10/91	2.0	17.0	umol/l	15/11/91	03/12/91	17/12/91	28/12/91
				DIR BILIRUBIN	02/10/91	0.0	5.0	umol/l	15/11/91	03/12/91	17/12/91	28/12/91
				TOT. PROTEINS	02/10/91	35.0	80.0	g/l	15/11/91	03/12/91	17/12/91	28/12/91
				ALBUMINE	02/10/91	4.0	7.0	mmol/l	15/11/91	03/12/91	17/12/91	28/12/91
				TOT. CHOLEST.	02/10/91	0.5	2.0	mmol/l	15/11/91	03/12/91	17/12/91	28/12/91
				TRIGLYCERIDES	02/10/91	2.0	6.0	mmol/l	15/11/91	03/12/91	17/12/91	28/12/91
GLOBULINS: ALPHA 1	02/10/91	7.0	12.0	%	15/11/91	03/12/91	17/12/91	28/12/91				
GLOBULINS: ALPHA 2	02/10/91	8.0	14.0	%	15/11/91	03/12/91	17/12/91	28/12/91				
GLOBULINS: BETA	02/10/91	12.0	22.0	%	15/11/91	03/12/91	17/12/91	28/12/91				
GLOBULINS: GAMMA	02/10/91	3.3	8.2	%	15/11/91	03/12/91	17/12/91	28/12/91				
T3	02/10/91	9.4	25.0	u/l	15/11/91	03/12/91	17/12/91	28/12/91				
T4	02/10/91	9.4	25.0	u/l	15/11/91	03/12/91	17/12/91	28/12/91				
18	VT	FEMALE	HB	02/10/91	120.0	140.0	g/l	26/11/91	17/12/91	30/12/91	14/01/92	
			HTC	02/10/91	38.0	47.0	g/l	26/11/91	17/12/91	30/12/91	14/01/92	
			RBC	02/10/91	4.0	5.5	10 ¹² /l	26/11/91	17/12/91	30/12/91	14/01/92	
			WBC	02/10/91	4.5	8.0	10 ⁹ /l	26/11/91	17/12/91	30/12/91	14/01/92	
			HbC: N	02/10/91	60.0	70.0	%	26/11/91	17/12/91	30/12/91	14/01/92	
			HbC: L	02/10/91	20.0	30.0	%	26/11/91	17/12/91	30/12/91	14/01/92	
			HbC: E	02/10/91	1.0	5.0	%	26/11/91	17/12/91	30/12/91	14/01/92	
			HbC: M	02/10/91	2.0	6.0	%	26/11/91	17/12/91	30/12/91	14/01/92	
			HbC: B	02/10/91	0.0	1.0	%	26/11/91	17/12/91	30/12/91	14/01/92	
			PLATELETS	02/10/91	150.0	400.0	10 ⁹ /l	26/11/91	17/12/91	30/12/91	14/01/92	

1806

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Unit	Screen	Visit		
					Date	Min	Max			Week 2	Week 4	Week 6
13	48	VT	FEMALE	NA+	02/10/91	135.0	145.0	mmol/l	138.00	135.00	138.00	140.00
				K+	02/10/91	3.5	5.0	mmol/l	4.40	4.10	4.60	4.80
				CL-	02/10/91	95.0	108.0	mmol/l	100.00	108.00	105.00	104.00
				CA++	02/10/91	2.3	2.7	mmol/l	2.51	2.35	2.56	2.53
				PO4-	02/10/91	1.0	1.5	mmol/l	1.02	1.12	1.30	1.10
				SGOT	02/10/91	10.0	40.0	u/l	25.00	22.00	18.00	18.00
				SGPT	02/10/91	10.0	40.0	u/l	44.00	39.00	36.00	61.00
				GAMMA-GT	02/10/91	10.0	40.0	u/l	37.00	94.00	43.00	75.00
				GLUCOSE	02/10/91	4.0	6.0	mmol/l	5.20	4.80	5.80	4.50
				ALK. PHOSPH.	02/10/91	100.0	300.0	u/l	93.00	82.00	68.00	95.00
				BUN	02/10/91	2.0	10.0	mmol/l	5.80	4.30	4.90	3.40
				CREATININE	02/10/91	50.0	100.0	umol/l	71.00	56.00	71.00	74.00
				URIC ACID	02/10/91	150.0	400.0	umol/l	164.00	203.00	258.00	135.00
				TOT BILIRUBIN	02/10/91	2.0	17.0	umol/l	8.00	8.00	4.00	4.00
				DIR BILIRUBIN	02/10/91	0.0	5.0	umol/l	4.00	4.00	4.00	4.00
				TOT. PROTEINS	02/10/91	60.0	80.0	g/l	77.00	73.00	77.00	80.00
				ALBUMINE	02/10/91	35.0	50.0	g/l	40.00	43.00	38.00	47.00
				TRIGL. CHOLEST.	02/10/91	4.0	7.0	mmol/l	5.40	5.10	6.30	6.70
				GLUCOLINS: ALPHA 1	02/10/91	0.5	2.0	mmol/l	0.80	0.80	0.80	0.80
				GLUCOLINS: ALPHA 2	02/10/91	2.0	6.0	z	7.00	5.00	8.00	9.00
				GLUCOLINS: BETA	02/10/91	7.0	12.0	z	8.00	8.00	10.00	9.00
				GLUCOLINS: GAMMA	02/10/91	8.0	14.0	z	13.00	12.00	11.00	11.00
				T3	02/10/91	12.0	22.0	z	16.00	15.00	16.00	12.00
				T4	02/10/91	3.3	8.2	u/l	2.20	2.20	2.20	2.20
					02/10/91	9.4	25.0	u/l	9.17	9.17	9.17	9.17
19	KK		FEMALE	HB	02/10/91	120.0	140.0	g/l	122.00	136.00	118.00	118.00
				HTC	02/10/91	38.0	47.0	z	36.00	39.00	35.00	35.00
				RBC	02/10/91	4.0	5.5	10**12/l	4.00	4.40	3.90	3.90
				MBC	02/10/91	4.5	8.0	10**9/l	5.30	6.40	6.80	6.80
				HBC: N	02/10/91	60.0	70.0	z	53.00	58.00	61.00	61.00
				HBC: L	02/10/91	20.0	30.0	z	45.00	40.00	37.00	40.00
				HBC: E	02/10/91	1.0	5.0	z	1.00	1.00	0.00	0.00
				HBC: M	02/10/91	2.0	6.0	z	1.00	1.00	1.00	1.00
				HBC: B	02/10/91	0.0	1.0	z	0.00	0.00	0.00	0.00
				PLATELETS	02/10/91	130.0	400.0	10**9/l	205.00	278.00	230.00	230.00
				NA+	02/10/91	135.0	145.0	mmol/l	140.00	134.00	140.00	140.00
				K+	02/10/91	3.5	5.0	mmol/l	4.80	4.50	4.70	4.70
				CL-	02/10/91	95.0	108.0	mmol/l	104.00	100.00	111.00	111.00
				CA++	02/10/91	2.3	2.7	mmol/l	2.40	2.67	2.42	2.42
				PO4-	02/10/91	1.0	1.5	mmol/l	1.04	1.07	0.91	0.91
				SGOT	02/10/91	10.0	40.0	u/l	19.00	27.00	40.00	40.00
				SGPT	02/10/91	10.0	40.0	u/l	28.00	23.00	42.00	42.00
				GAMMA-GT	02/10/91	10.0	40.0	u/l	79.00	35.00	15.00	15.00
				GLUCOSE	02/10/91	4.0	6.0	mmol/l	4.70	4.40	4.40	4.40
				ALK. PHOSPH.	02/10/91	100.0	300.0	u/l	87.00	119.00	88.00	88.00
				BUN	02/10/91	2.0	10.0	mmol/l	3.10	4.90	4.60	4.60
				CREATININE	02/10/91	50.0	100.0	umol/l	75.00	78.00	60.00	60.00
				URIC ACID	02/10/91	150.0	400.0	umol/l	199.00	302.00	244.00	244.00

1807

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit									
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6					
13	19	KK	FEMALE	TOT BILIRUBIN	02/10/91	2.0	17.0	umol/l	4.00	5.00	6.00						
				DIR BILIRUBIN	02/10/91	0.0	5.0	umol/l	4.00	4.00	5.00						
				TOT. PROTEINS	02/10/91	60.0	80.0	g/l	74.00	74.00	72.00						
				ALBUMINE	02/10/91	35.0	50.0	g/l	43.00	45.00	42.00						
				TOT. CHOLEST.	02/10/91	4.0	7.0	mmol/l	7.20	8.90	6.50						
				TRIGLYCERIDES	02/10/91	0.5	2.0	mmol/l	2.50	1.20	1.70						
				GLOBULINS: ALPHA 1	02/10/91	2.0	6.0	g	8.00	7.00	6.00						
				GLOBULINS: ALPHA 2	02/10/91	7.0	12.0	g	8.00	7.00	7.00						
				GLOBULINS: BETA	02/10/91	8.0	14.0	g	7.00	9.00	12.00						
				GLOBULINS: GAMMA	02/10/91	12.0	22.0	g	15.00	9.00	16.00						
				T3	02/10/91	3.3	8.2	u/l	2.24								
				T4	02/10/91	9.4	25.0	u/l	20.50								
				20	NL		FEMALE	HB	02/10/91	120.0	160.0	g/l	147.00	111.00	139.00	103.00	160.00
								HTC	02/10/91	38.0	47.0	g	45.00	42.00	41.00	42.00	42.00
RBC	02/10/91	4.0	5.5					10 ¹² /l	4.80	6.60	4.50	4.50	4.50				
HRC: N	02/10/91	4.5	8.0					10 ⁹ /l	7.00	6.00	4.80	4.60	4.60				
HRC: L	02/10/91	60.0	70.0					g	77.00	73.00	73.00	69.00	69.00				
HRC: E	02/10/91	20.0	30.0					g	21.00	24.00	22.00	26.00	26.00				
HRC: M	02/10/91	1.0	5.0					g	0.00	2.00	3.00	4.00	4.00				
HRC: B	02/10/91	2.0	6.0					g	2.00	1.00	1.00	1.00	1.00				
PLATELETS	02/10/91	0.0	1.0					g	0.00	0.00	1.00	1.00	0.00				
Na+	02/10/91	150.0	400.0					10 ⁹ /l	243.00	227.00	214.00	227.00	227.00				
K+	02/10/91	135.0	145.0					mmol/l	139.00	137.00	136.00	139.00	139.00				
Cl-	02/10/91	95.0	108.0					mmol/l	4.40	4.50	4.10	4.40	4.40				
Ca++	02/10/91	2.3	2.7					mmol/l	106.00	105.00	110.00	108.00	108.00				
PO4--	02/10/91	1.0	1.5					mmol/l	2.40	2.34	2.50	2.36	2.36				
SGPT	02/10/91	10.0	40.0	u/l	1.00	1.08	0.98	1.18	1.18								
GAMMA-GT	02/10/91	10.0	40.0	u/l	31.00	31.00	23.00	18.00	18.00								
GLUCOSE	02/10/91	10.0	40.0	u/l	33.00	35.00	45.00	18.00	18.00								
ALK. PHOSPH.	02/10/91	4.0	6.0	mmol/l	4.90	5.20	4.70	4.50	4.50								
BUN	02/10/91	100.0	300.0	u/l	92.00	94.00	110.00	93.00	93.00								
CREATININE	02/10/91	2.0	10.0	mmol/l	6.20	4.20	3.30	3.70	3.70								
URIC ACID	02/10/91	50.0	100.0	umol/l	70.00	76.00	80.00	72.00	72.00								
TOT BILIRUBIN	02/10/91	150.0	400.0	umol/l	147.00	286.00	211.00	211.00	211.00								
DIR BILIRUBIN	02/10/91	0.0	5.0	umol/l	4.00	4.00	4.00	4.00	4.00								
TOT. PROTEINS	02/10/91	60.0	80.0	g/l	78.00	73.00	76.00	74.00	74.00								
ALBUMINE	02/10/91	35.0	50.0	g/l	44.00	42.00	46.00	46.00	46.00								
TOT. CHOLEST.	02/10/91	4.0	7.0	mmol/l	6.90	6.00	5.80	6.80	6.80								
TRIGLYCERIDES	02/10/91	0.5	2.0	mmol/l	1.10	1.20	1.00	0.70	0.70								
GLOBULINS: ALPHA 1	02/10/91	2.0	6.0	g	7.00	16.00	7.00	6.00	6.00								
GLOBULINS: ALPHA 2	02/10/91	7.0	12.0	g	9.00	9.00	10.00	11.00	11.00								
GLOBULINS: BETA	02/10/91	8.0	14.0	g	11.00	10.00	13.00	13.00	13.00								
GLOBULINS: GAMMA	02/10/91	12.0	22.0	g	17.00	10.00	15.00	13.00	13.00								
T3	02/10/91	3.3	8.2	u/l	22.29												
T4	02/10/91	9.4	25.0	u/l	6.27												

1 00 08

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1
LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit						
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6		
13	21	CL	FEMALE	HB	02/10/91	120.0	140.0	g/l	132.00	132.00	137.00	136.00	144.00	144.00
				HTC	02/10/91	38.0	47.0	Z	37.00	37.00	39.00	38.00	40.50	40.50
				RBC	02/10/91	4.0	5.5	10**12/l	4.40	4.40	4.70	4.60	4.86	4.86
				RBC: N	02/10/91	4.5	8.0	10**9/l	6.30	6.30	5.50	4.70	7.10	7.10
				RBC: L	02/10/91	60.0	70.0	Z	62.00	62.00	57.00	66.00	64.00	64.00
				RBC: E	02/10/91	20.0	30.0	Z	37.00	37.00	42.00	29.00	35.00	35.00
				RBC: N	02/10/91	1.0	5.0	Z	1.00	1.00	1.00	4.00	0.00	0.00
				RBC: E	02/10/91	2.0	6.0	Z	0.00	0.00	0.00	0.00	0.00	0.00
				RBC: B	02/10/91	0.0	1.0	Z	0.00	0.00	0.00	1.00	0.00	1.00
				PLATELETS	02/10/91	150.0	400.0	10**9/l	261.00	261.00	240.00	250.00	282.00	282.00
				NA+	02/10/91	135.0	145.0	mmol/l	137.00	137.00	137.00	137.00	140.00	140.00
				K+	02/10/91	3.5	5.0	mmol/l	4.10	4.10	3.80	4.20	3.80	3.80
				CL-	02/10/91	95.0	108.0	mmol/l	104.00	104.00	102.00	105.00	98.00	98.00
				PO4--	02/10/91	2.3	2.7	mmol/l	2.36	2.36	2.60	2.35	2.50	2.50
				SGPT	02/10/91	1.0	1.5	u/l	1.04	1.04	0.92	0.95	0.95	0.95
				SGPT	02/10/91	10.0	40.0	u/l	23.00	23.00	18.00	30.00	19.00	19.00
				GAMMA-GT	02/10/91	10.0	40.0	u/l	21.00	21.00	19.00	30.00	19.00	19.00
				GLUCOSE	02/10/91	10.0	40.0	u/l	36.00	36.00	16.00	14.00	27.00	27.00
				ALK. PHOSPH.	02/10/91	4.0	6.0	mmol/l	4.90	4.90	5.40	4.90	4.60	4.60
				UN	02/10/91	100.0	300.0	u/l	87.00	87.00	86.00	104.00	61.00	61.00
				CREATININE	02/10/91	2.0	10.0	mmol/l	4.60	4.60	3.20	5.20	3.10	3.10
				URIC ACID	02/10/91	50.0	100.0	umol/l	68.00	68.00	74.00	65.00	66.00	66.00
				TOT. BILIRUBIN	02/10/91	150.0	400.0	umol/l	222.00	222.00	235.00	184.00	188.00	188.00
DIR. BILIRUBIN	02/10/91	2.0	17.0	umol/l	6.00	6.00	12.00	10.00	8.00	8.00				
TOT. PROTEINS	02/10/91	60.0	80.0	g/l	4.00	4.00	4.00	4.00	4.00	4.00				
ALBUMINE	02/10/91	35.0	50.0	g/l	71.00	71.00	75.00	69.00	77.00	77.00				
TOT. CHOLEST.	02/10/91	4.0	7.0	mmol/l	45.00	45.00	48.00	47.00	34.00	34.00				
TRIGLYCERIDES	02/10/91	0.5	2.0	mmol/l	5.20	5.20	5.20	5.80	6.00	6.00				
GLOBULINS: ALPHA 1	02/10/91	2.0	6.0	Z	1.00	1.00	0.90	0.60	0.90	0.90				
GLOBULINS: ALPHA 2	02/10/91	7.0	12.0	Z	11.00	11.00	3.00	5.00	9.00	9.00				
GLOBULINS: BETA	02/10/91	8.0	14.0	Z	10.00	10.00	8.00	8.00	8.00	8.00				
GLOBULINS: GAMMA	02/10/91	12.0	22.0	Z	14.00	14.00	14.00	10.00	11.00	11.00				
T3	02/10/91	3.3	8.2	u/l	5.39	5.39		10.00	25.00	25.00				
T4	02/10/91	9.4	25.0	u/l	12.09	12.09								
22	NYH		FEMALE	HB	02/10/91	120.0	140.0	g/l	168.00	168.00	151.00	150.00	145.00	145.00
				HTC	02/10/91	38.0	47.0	Z	43.60	43.60	44.30	43.70	43.00	43.00
				RBC	02/10/91	4.0	5.5	10**12/l	4.71	4.71	4.85	4.75	4.63	4.63
				RBC: N	02/10/91	4.5	8.0	10**9/l	6.70	6.70	5.60	4.20	5.80	5.80
				RBC: L	02/10/91	60.0	70.0	Z	82.00	82.00	59.00	60.00	69.00	69.00
				RBC: E	02/10/91	20.0	30.0	Z	17.00	17.00	39.00	36.00	30.00	30.00
				RBC: N	02/10/91	1.0	5.0	Z	1.00	1.00	1.00	3.00	1.00	1.00
				RBC: E	02/10/91	2.0	6.0	Z	0.00	0.00	0.00	0.00	0.00	0.00
				RBC: B	02/10/91	0.0	1.0	Z	0.00	0.00	1.00	1.00	0.00	0.00
				PLATELETS	02/10/91	150.0	400.0	10**9/l	183.00	183.00	176.00	188.00	207.00	207.00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Screen	Week 2	Week 4	Week 6	
13	22	NYA	FEMALE	NA+	02/10/91	135.0	145.0	mmol/l	137.00	136.00	137.00	138.00	
				K+	02/10/91	3.5	5.0	mmol/l	3.90	3.80	4.00	4.10	
				CL-	02/10/91	95.0	108.0	mmol/l	102.00	92.00	108.00	98.00	
				CA++	02/10/91	2.3	2.7	mmol/l	2.30	2.28	2.40	2.40	
				PO4--	02/10/91	1.0	1.5	mmol/l	0.92	0.81	1.28	1.15	
				SGOT	02/10/91	10.0	40.0	u/l	38.00	33.00	34.00	38.00	
				SGPT	02/10/91	10.0	40.0	u/l	44.00	42.00	29.00	45.00	
				GAMMA-GT	02/10/91	10.0	40.0	u/l	103.00	49.00	32.00	25.00	
				GLUCOSE	02/10/91	4.0	6.0	mmol/l	6.30	5.20	5.10	5.20	
				ALK. PHOSPH.	02/10/91	100.0	300.0	u/l	92.00	185.00	89.00	82.00	
				BUN	02/10/91	2.0	10.0	mmol/l	8.10	5.10	4.70	6.20	
				CREATININE	02/10/91	50.0	100.0	umol/l	93.00	78.00	73.00	62.00	
				URIC ACID	02/10/91	150.0	400.0	umol/l	208.00	270.00	268.00	259.00	
				TOT. BILIRUBIN	02/10/91	2.0	17.0	umol/l	4.00	7.00	7.00	4.00	
				DIR. BILIRUBIN	02/10/91	0.0	5.0	umol/l	4.00	4.00	4.00	4.00	
				TOT. PROTEINS	02/10/91	60.0	80.0	g/l	77.00	73.00	70.00	72.00	
				ALBUMINE	02/10/91	35.0	50.0	g/l	47.00	43.00	44.00	40.00	
				TOT. CHOLEST.	02/10/91	4.0	7.0	mmol/l	6.10	6.50	6.50	6.20	
				TRIGLYCERIDES	02/10/91	0.5	2.0	mmol/l	0.60	0.70	0.90	1.10	
				GLUCOLINS: ALPHA 1	02/10/91	2.0	6.0	z	3.00	6.00	7.00	9.00	
				GLUCOLINS: ALPHA 2	02/10/91	7.0	12.0	z	4.00	7.00	7.00	9.00	
				GLUCOLINS: BETA	02/10/91	8.0	14.0	z	14.00	14.00	12.00	14.00	
				GLUCOLINS: GAMMA	02/10/91	12.0	22.0	z	15.00	16.00	16.00	11.00	
				T3	02/10/91	3.3	8.2	u/l	2.89				
				T4	02/10/91	9.4	25.0	u/l	19.34				
23	B8B		FEMALE	HB	02/10/91	120.0	140.0	g/l	127.00	147.00	141.00	136.00	17/06/92
				HTC	02/10/91	38.0	47.0	z	39.60	43.60	42.00	40.80	
				RBC	02/10/91	4.0	5.5	10**12/l	3.92	4.48	4.29	4.13	
				HBC: N	02/10/91	4.5	8.0	10**9/l	6.60	6.90	8.60	8.20	
				HBC: L	02/10/91	60.0	70.0	z	57.00	60.00	52.00	59.00	
				HBC: E	02/10/91	20.0	30.0	z	40.00	36.00	47.00	39.00	
				HBC: N	02/10/91	1.0	5.0	z	3.00	2.00	1.00	2.00	
				HBC: B	02/10/91	2.0	6.0	z	0.00	1.00	0.00	0.00	
				PLATELETS	02/10/91	0.0	1.0	z	0.00	1.00	0.00	0.00	
				NA+	02/10/91	150.0	400.0	10**9/l	168.00	187.00	198.00	162.00	
				K+	02/10/91	135.0	145.0	mmol/l	135.00	132.00	138.00	137.00	
				CL-	02/10/91	3.5	5.0	mmol/l	3.60	4.40	3.90	3.90	
				PO4--	02/10/91	95.0	108.0	mmol/l	102.00	102.00	106.00	100.00	
				CA++	02/10/91	2.3	2.7	mmol/l	2.30	2.41	2.54	2.48	
				SGOT	02/10/91	1.0	1.5	mmol/l	1.02	0.93	1.20	1.22	
				SGPT	02/10/91	10.0	40.0	u/l	37.00	26.00	28.00	34.00	
				GAMMA-GT	02/10/91	10.0	40.0	u/l	44.00	62.00	35.00	20.00	
				GLUCOSE	02/10/91	4.0	6.0	mmol/l	4.60	4.90	4.40	4.80	
				ALK. PHOSPH.	02/10/91	100.0	300.0	u/l	86.00	83.00	100.00	123.00	
				BUN	02/10/91	2.0	10.0	mmol/l	3.50	4.30	5.40	4.00	
				CREATININE	02/10/91	50.0	100.0	umol/l	68.00	79.00	53.00	53.00	
				URIC ACID	02/10/91	150.0	400.0	umol/l	226.00	193.00	385.00	236.00	

1810

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
OPEN PHASE

Centre	Patient	Initials	Sex	Laboratory test	Date	Laboratory Range			Unit	Screen	Visit			
						Min	Max	Max			Week 2	Week 4	Week 6	
13	23	BSB	FEMALE	TOT BILIRUBIN	02/10/91	2.0	17.0		umol/l	4.00	8.00	4.00	4.00	
				DIR BILIRUBIN	02/10/91	0.0	5.0		umol/l	4.00	4.00	4.00	4.00	
				TOT. PROTEINS	02/10/91	60.0	80.0		g/l	72.00	92.00	81.00	78.00	
				ALBUMINE	02/10/91	35.0	50.0		g/l	43.00	50.00	45.00	44.00	
				TOT. CHOLEST.	02/10/91	4.0	7.0		mmol/l	5.60	7.60	5.50	5.60	
				TRIGLYCERIDES	02/10/91	0.5	2.0		mmol/l	1.20	0.80	1.80	0.90	
				GLOBULINS: ALPHA 1	02/10/91	2.0	6.0		%	4.00	7.00	4.00	6.00	
				GLOBULINS: ALPHA 2	02/10/91	7.0	12.0		%	8.00	8.00	8.00	8.00	
				GLOBULINS: BETA	02/10/91	8.0	14.0		%	8.00	10.00	10.00	8.00	
				GLOBULINS: GAMMA	02/10/91	12.0	22.0		%	17.00	18.00	18.00	19.00	
				T3	02/10/91	3.3	8.2		u/l	2.56	.	.	.	
				T4	02/10/91	9.4	25.0		u/l	13.00	.	.	.	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit						
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
1	3-2	F	HB	20/10/90	12.0	16.0	G/100ML	25/01/91	22/03/91	17/05/91	12/07/91	06/09/91	14/11/91
			HTC	20/10/90	37.0	47.0	%	12.80	12.50	12.80	12.10	13.20	12.80
			RBC	20/10/90	3.8	5.4	10 ⁶ -6/HMC	38.00	37.00	37.00	38.00	40.00	39.00
			WBC	20/10/90	4.0	11.0	10 ³ -3/HMC	4.00	3.90	4.00	4.00	4.30	4.10
			WBC: N	20/10/90	40.0	70.0	%	66.00	69.00	58.00	62.00	64.00	62.00
			WBC: L	20/10/90	20.0	40.0	%	31.00	29.00	35.00	37.00	32.00	31.00
			WBC: E	20/10/90	1.0	5.0	%	7.00	1.00	3.00	3.00	3.00	3.00
			WBC: M	20/10/90	4.0	8.0	%	3.00	2.00	7.00	1.00	4.00	7.00
			WBC: B	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00
			PLATELETS	20/10/90	150.0	550.0	10 ³ -3/HMC	218.00	216.00	217.00	231.00	244.00	224.00
			NA+	20/10/90	138.0	155.0	M ER/L	141.00	140.00	139.00	136.00	139.00	138.00
			CL-	20/10/90	98.0	120.0	M ER/L	99.00	104.00	102.00	99.00	96.00	100.00
			CA++	20/10/90	8.5	10.5	MG/DL	9.00	7.90	8.50	9.60	9.40	9.10
			FD4-	20/10/90	3.0	4.5	MG/DL	3.40	3.10	3.10	3.40	3.20	3.10
			SGPT	20/10/90	12.0	40.0	RU/RL	27.00	23.00	30.00	19.00	18.00	24.00
			GAMMA-GT	20/10/90	10.0	40.0	RU/RL	16.00	11.00	15.00	18.00	16.00	23.00
			GLUCOSE	20/10/90	70.0	33.0	RU/RL	24.00	17.00	19.00	17.00	22.00	22.00
			ALK. PHOSPH.	20/10/90	65.0	100.0	MG/DL	79.00	86.00	96.00	99.00	92.00	93.00
			CREATININE	20/10/90	10.0	50.0	MG/DL	139.00	139.00	137.00	148.00	148.00	164.00
			URIC ACID	20/10/90	0.6	1.6	MG/DL	1.00	0.90	1.00	1.00	0.90	0.80
			TOT BILIRUBIN	20/10/90	2.4	5.7	MG/DL	3.60	3.30	3.10	2.60	2.00	2.30
			DIR BILIRUBIN	20/10/90	0.2	1.0	MG/DL	1.10	0.60	0.70	0.50	0.70	0.50
			TOT. PROTEINS	20/10/90	6.0	0.4	MG/DL	6.80	0.20	0.40	0.20	0.20	0.20
			ALBUMINE	20/10/90	3.5	8.0	G/DL	6.80	5.80	7.10	6.30	6.70	6.60
			TOT. CHOLEST.	20/10/90	140.0	5.0	G/DL	4.00	3.70	4.00	3.60	3.80	4.10
			TRIGLYCERIDES	20/10/90	35.0	270.0	MG/DL	163.00	160.00	157.00	154.00	171.00	168.00
			GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	3.00	57.00	49.00	47.00	73.00	54.00
			GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	8.00	3.50	3.00	2.90	2.00	1.90
			GLOBULINS: BETA	20/10/90	11.0	14.0	%	11.00	7.00	8.00	14.60	9.80	9.30
			GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	21.00	21.50	26.00	24.30	20.70	20.00
4-3		F	HR	20/10/90	12.0	16.0	G/100ML	30/01/91	27/03/91	22/05/91	17/07/91	11/09/91	20/11/91
			HTC	20/10/90	37.0	47.0	%	12.50	12.50	12.50	12.10	14.00	13.30
			RBC	20/10/90	3.8	5.4	10 ⁶ -6/HMC	37.00	39.00	39.00	38.00	43.00	39.00
			WBC	20/10/90	4.0	11.0	10 ³ -3/HMC	4.20	4.30	4.40	4.20	4.80	4.40
			WBC: N	20/10/90	40.0	70.0	%	4.70	4.80	5.00	6.90	6.40	6.00
			WBC: L	20/10/90	20.0	40.0	%	57.00	65.00	72.00	60.00	64.00	59.00
			WBC: E	20/10/90	1.0	5.0	%	38.00	28.00	25.00	38.00	30.00	38.00
			WBC: M	20/10/90	4.0	8.0	%	0.00	3.00	6.00	1.00	1.00	1.00

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range		Visit									
				Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52			
1	4-3	F	HRC: M	4.0	8.0	Z	5.00	7.00	3.00	2.00	6.00	3.00			
			HRC: B	0.0	1.0	Z	1.00	0.00	0.00	0.00	2.00	1.00			
			PLATELETS	150.0	550.0	10-3/MNC	295.00	331.00	332.00	462.00	421.00	312.00			
			NA+	138.0	155.0	M EQ/L	141.00	142.00	144.00	137.00	144.00	138.00			
			K+	3.5	5.5	M EQ/L	4.10	4.40	3.80	4.90	4.40	4.40			
			CL-	98.0	120.0	M EQ/L	102.00	103.00	103.00	101.00	100.00	98.00			
			CA++	8.5	10.5	MG/DL	8.60	9.30	8.90	9.40	9.90	9.70			
			PO4--	3.0	4.5	MG/DL	3.60	3.50	3.60	3.50	3.80	3.80			
			SGOT	12.0	40.0	IU/ML	20.00	31.00	33.00	38.00	32.00	29.00			
			SGPT	10.0	40.0	IU/ML	14.00	28.00	32.00	31.00	28.00	28.00			
			GAMMA-GT	7.0	33.0	IU/ML	29.00	31.00	30.00	64.00	37.00	31.00			
			GLUCOSE	70.0	100.0	MG/DL	79.00	87.00	96.00	85.00	94.00	90.00			
			ALK. PHOSPH.	65.0	306.0	IU/ML	339.00	331.00	336.00	370.00	300.00	309.00			
			BUN	10.0	50.0	MG/DL	34.00	29.00	35.00	32.00	30.00	36.00			
			CREATININE	0.6	1.6	MG/DL	0.80	0.90	0.90	0.80	0.80	0.80			
			URIC ACID	2.4	5.7	MG/DL	3.00	2.70	2.40	2.60	2.60	2.50			
			TOT BILIRUBIN	0.2	1.0	MG/DL	1.30	1.00	0.90	0.50	0.60	0.70			
			DIR BILIRUBIN	0.0	0.4	MG/DL	0.60	0.30	0.30	0.20	0.20	0.40			
			TOT. PROTEINS	6.0	8.0	G/DL	6.30	6.90	6.60	7.00	7.10	6.70			
			ALBUMINE	3.5	5.0	G/DL	4.30	4.40	4.30	4.30	4.00	4.30			
			TOT. CHOLEST.	140.0	270.0	MG/DL	174.00	200.00	188.00	191.00	222.00	192.00			
			TRIGLYCERIDES	35.0	175.0	MG/DL	82.00	80.00	98.00	76.00	77.00	72.00			
			GLOBULINS: ALPHA1	4.0	7.0	Z	4.00	4.60	2.90	2.80	4.00	2.00			
			GLOBULINS: ALPHA2	7.0	11.0	Z	8.00	8.90	8.90	8.50	9.00	8.20			
			GLOBULINS: BETA	11.0	14.0	Z	11.00	13.10	13.70	11.30	13.00	13.40			
			GLOBULINS: GAMMA	15.0	22.0	Z	10.00	15.60	16.70	12.30	15.00	17.60			
5-4		F	HR	12.0	16.0	G/100ML	14.00	12.80	12.60	13.00	13.50	13.40			
			HTC	37.0	47.0	Z	42.00	39.00	39.00	38.00	42.00	41.00			
			RBC	3.8	5.4	10-6/MNC	4.80	4.30	4.40	4.30	4.70	4.60			
			HBC: N	4.0	11.0	10-3/MNC	5.90	5.60	5.00	5.70	5.60	6.00			
			HBC: L	40.0	70.0	Z	68.00	58.00	55.00	53.00	69.00	53.00			
			HBC: E	20.0	40.0	Z	36.00	34.00	39.00	43.00	28.00	45.00			
			HBC: H	1.0	5.0	Z	4.00	1.00	6.00	3.00	2.00	5.00			
			HBC: B	4.0	8.0	Z	2.00	8.00	6.00	4.00	3.00	2.00			
			PLATELETS	0.0	1.0	Z	0.00	0.00	0.00	0.00	0.00	0.00			
			NA+	150.0	550.0	10-3/MNC	214.00	190.00	201.00	219.00	259.00	275.00			
			K+	138.0	155.0	M EQ/L	141.00	143.00	143.00	137.00	142.00	142.00			
			CL-	3.5	5.5	M EQ/L	4.00	3.90	4.10	4.20	4.00	4.40			
			CA++	98.0	120.0	M EQ/L	102.00	103.00	103.00	101.00	96.00	96.00			
			PO4--	8.5	10.5	MG/DL	9.90	9.90	9.70	10.10	9.20	8.20			
				3.0	4.5	MG/DL	4.20	4.40	4.40	4.60	3.60	3.10			

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit												
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52						
1 5-4	F			SGPT	20/10/90	12.0	40.0	MU/ML	26.00	25.00	31.00	26.00	31.00	25.00						
				SGPT	20/10/90	10.0	40.0	MU/ML	31.00	20.00	28.00	35.00	23.00	23.00						
				GAMMA-GT	20/10/90	7.0	33.0	MU/ML	51.00	43.00	42.00	63.00	57.00	44.00						
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	118.00	117.00	127.00	120.00	107.00	122.00						
				ALK. PHOSPH.	20/10/90	65.0	306.0	MU/ML	206.00	226.00	256.00	220.00	284.00	275.00						
				BUN	20/10/90	10.0	50.0	MG/DL	37.00	52.00	41.00	52.00	34.00	51.00						
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	1.00	1.30	1.00	0.80	0.90						
				URIC ACID	20/10/90	2.4	5.7	MG/DL	4.30	4.80	4.80	3.20	2.60	3.90						
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.40	0.60	0.40	0.50	0.60	0.40						
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.20	0.20	0.30	0.20	0.10						
				TOT. PROTEINS	20/10/90	6.0	8.0	MG/DL	6.70	7.10	7.20	7.00	7.10	6.90						
				ALBUMINE	20/10/90	3.5	5.0	G/DL	3.90	4.10	4.40	4.20	4.00	3.90						
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	318.00	285.00	275.00	357.00	349.00	262.00						
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	458.00	257.00	294.00	464.00	641.00	305.00						
				GLOBALINS: ALPHA1	20/10/90	4.0	7.0	X	4.00	2.90	2.80	2.70	2.20	2.70						
				GLOBALINS: ALPHA2	20/10/90	7.0	11.0	X	9.00	8.60	8.90	10.30	9.60	9.60						
				GLOBALINS: BETA	20/10/90	11.0	14.0	X	13.00	13.60	15.20	14.80	14.80	12.90						
				GLOBALINS: GAMMA	20/10/90	15.0	22.0	X	16.00	17.50	14.30	16.10	15.90	15.90						
				9-7	M			HB	20/10/90	14.0	16.0	g/100ml	14.00	14.70	14.70	13.50	16/10/91	15.10	26/12/91	13.40
								HTC	20/10/90	40.0	54.0	X	42.00	45.00	41.00	41.00	45.00	42.00	16/10/91	45.00
RBC	20/10/90	4.3	6.1					10**6/mm	4.80	5.20	4.90	4.90	4.70	4.80	16/10/91	5.30	26/12/91	4.80		
MBC	20/10/90	4.0	11.0					10-3/MHC	5.80	6.60	5.90	5.90	4.80	5.90	16/10/91	6.60	26/12/91	5.90		
MBC: N	20/10/90	40.0	70.0					X	59.00	71.00	71.00	69.00	69.00	61.00	16/10/91	69.00	26/12/91	61.00		
MBC: L	20/10/90	20.0	40.0					X	37.00	28.00	25.00	31.00	29.00	35.00	16/10/91	31.00	26/12/91	35.00		
MBC: E	20/10/90	1.0	5.0					X	2.00	0.00	0.00	0.00	3.00	1.00	16/10/91	3.00	26/12/91	1.00		
MBC: M	20/10/90	4.0	8.0					X	4.00	1.00	4.00	6.00	2.00	4.00	16/10/91	2.00	26/12/91	4.00		
MBC: B	20/10/90	0.0	1.0					X	0.00	0.00	0.00	0.00	0.00	0.00	16/10/91	0.00	26/12/91	0.00		
PLATELETS	20/10/90	150.0	550.0					10-3/MHC	273.00	304.00	270.00	272.00	307.00	256.00	16/10/91	307.00	26/12/91	256.00		
NA+	20/10/90	138.0	155.0					M EQ/L	144.00	142.00	140.00	137.00	139.00	138.00	16/10/91	139.00	26/12/91	138.00		
K+	20/10/90	3.5	5.5					M EQ/L	3.80	4.70	4.50	4.20	4.60	4.00	16/10/91	4.60	26/12/91	4.00		
CL-	20/10/90	98.0	120.0					M EQ/L	100.00	97.00	94.00	103.00	97.00	95.00	16/10/91	97.00	26/12/91	95.00		
Ca++	20/10/90	8.5	10.5					MG/DL	10.00	10.00	8.80	9.10	9.50	8.70	16/10/91	9.50	26/12/91	8.70		
PO4--	20/10/90	3.0	4.5					MG/DL	3.40	3.90	3.10	3.40	3.60	3.70	16/10/91	3.60	26/12/91	3.70		
SGPT	20/10/90	12.0	40.0					MU/ML	25.00	23.00	23.00	20.00	29.00	22.00	16/10/91	29.00	26/12/91	22.00		
GAMMA-GT	20/10/90	10.0	40.0					MU/ML	24.00	23.00	25.00	15.00	28.00	18.00	16/10/91	28.00	26/12/91	18.00		
GLUCOSE	20/10/90	70.0	100.0					MG/DL	109.00	109.00	97.00	104.00	102.00	98.00	16/10/91	102.00	26/12/91	98.00		
ALK. PHOSPH.	20/10/90	65.0	306.0					MU/ML	135.00	166.00	168.00	154.00	164.00	129.00	16/10/91	164.00	26/12/91	129.00		
BUN	20/10/90	10.0	50.0					MG/DL	32.00	30.00	34.00	30.00	35.00	25.00	16/10/91	35.00	26/12/91	25.00		
CREATININE	20/10/90	0.6	1.6	MG/DL	1.20	0.90	1.20	1.20	1.10	1.10	16/10/91	1.10	26/12/91	1.10						
URIC ACID	20/10/90	3.4	7.0	MG/DL	4.20	4.90	4.60	3.90	4.10	5.50	16/10/91	4.10	26/12/91	5.50						

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

1814

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOMETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOMETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit											
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52					
1 9-7	M			TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.80	0.90	0.70	0.60	0.70	1.00					
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.50	0.30	0.30	0.40	0.30	0.30				
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.10	7.30	7.20	7.30	7.40	7.30	6.80				
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.50	4.40	4.40	4.30	4.70	4.40	4.10				
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	143.00	138.00	155.00	144.00	153.00	130.00	130.00				
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	62.00	63.00	65.00	84.00	84.00	69.00	69.00				
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	g %	3.00	3.50	2.70	2.80	1.80	2.90	2.90				
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	g %	8.00	7.10	7.20	7.40	6.40	7.60	7.60				
				GLOBULINS: BETA	20/10/90	11.0	14.0	g %	15.00	13.10	15.30	13.50	13.20	13.20	13.20				
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	g %	12.00	15.80	16.20	14.50	15.20	15.90	15.90				
				10-8	F			HB	20/10/90	12.0	16.0	G/100ML	14.00	14.00	14.00	12.70	12.70	13.90	
								HTC	20/10/90	37.0	47.0	%	42.00	43.00	41.00	41.00	41.00	42.00	42.00
								RBC	20/10/90	3.8	5.4	10 ⁶ /MM ³	4.20	4.80	4.50	4.40	4.50	4.50	4.50
								HBC	20/10/90	4.0	11.0	10 ³ /MM ³	7.20	9.00	7.90	7.00	8.00	10.00	10.00
HBC: N	20/10/90	40.0	70.0					%	60.00	65.00	53.00	67.00	62.00	69.00	69.00				
HBC: L	20/10/90	20.0	40.0					%	36.00	38.00	44.00	26.00	36.00	17.00	17.00				
HBC: E	20/10/90	1.0	5.0					%	4.00	2.00	1.00	3.00	1.00	9.00	9.00				
HBC: M	20/10/90	4.0	8.0					%	4.00	5.00	3.00	7.00	2.00	5.00	5.00				
HBC: B	20/10/90	0.0	1.0					%	0.00	0.00	0.00	0.00	1.00	0.00	0.00				
PLATELETS	20/10/90	150.0	550.0					10 ³ /MM ³	359.00	378.00	359.00	344.00	329.00	358.00	358.00				
NA*	20/10/90	138.0	155.0					MM ³ /L	143.00	139.00	140.00	140.00	142.00	142.00	142.00				
K*	20/10/90	3.5	5.5					MM ³ /L	4.70	4.80	4.70	4.70	4.50	4.80	4.80				
Cl-	20/10/90	98.0	120.0					MM ³ /L	101.00	100.00	102.00	100.00	99.00	97.00	97.00				
CA**	20/10/90	8.5	10.5					MG/DL	9.60	8.00	9.10	9.50	8.60	9.40	9.40				
PO4-	20/10/90	3.0	4.5					MG/DL	3.80	3.80	3.20	3.20	3.20	3.40	3.40				
SGPT	20/10/90	12.0	40.0					MM ³ /L	36.00	29.00	21.00	20.00	28.00	34.00	34.00				
SGPT	20/10/90	10.0	40.0					MM ³ /L	25.00	22.00	19.00	23.00	25.00	36.00	36.00				
GAMMA-GT	20/10/90	7.0	33.0					MM ³ /L	32.00	23.00	29.00	36.00	27.00	37.00	37.00				
GLUCOSE	20/10/90	70.0	100.0					MG/DL	97.00	103.00	109.00	99.00	94.00	110.00	110.00				
ALK. PHOSPH.	20/10/90	65.0	306.0					MM ³ /L	242.00	249.00	218.00	243.00	214.00	301.00	301.00				
BUN	20/10/90	10.0	50.0	MG/DL	31.00	32.00	37.00	39.00	30.00	32.00	32.00								
CREATININE	20/10/90	0.6	1.6	MG/DL	1.10	1.00	1.00	0.80	0.80	0.90	0.90								
URIC ACID	20/10/90	2.4	5.7	MG/DL	4.30	4.50	3.10	3.40	3.90	4.60	4.60								
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.80	0.40	0.40	0.40	0.50	0.80	0.80								
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.20	0.20	0.20	0.30	0.40	0.40								
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.90	7.40	6.60	6.60	6.10	7.40	7.40								
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.40	4.00	4.00	3.90	4.30	4.30								
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	215.00	216.00	231.00	272.00	195.00	280.00	280.00								
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	134.00	121.00	201.00	210.00	128.00	157.00	157.00								
GLOBULINS: ALPHA1	20/10/90	4.0	7.0	g %	2.90	3.80	2.30	2.10	3.20	3.20	3.20								
GLOBULINS: ALPHA2	20/10/90	7.0	11.0	g %	8.70	9.50	10.00	9.00	8.60	10.70	10.70								

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

18115

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit						
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
1	10-8	F		GLOBALINS: BETA	20/10/90	11.0	14.0	%	14.60	14.30	12.60	12.60	11.00	13.50
				GLOBALINS: GAMMA	20/10/90	15.0	22.0	%	15.60	16.20	15.50	14.50	14.60	8.30
17-14		F		HB	20/10/90	12.0	16.0	G/100ML	30/07/91	24/09/91	19/11/91			
				HTC	20/10/90	37.0	47.0	%	12.50	12.20	10.00			
				RBC	20/10/90	3.8	5.4	10 ⁶ /MM ³	38.00	39.00	31.00			
				HBC	20/10/90	4.0	11.0	10 ³ /MM ³	4.50	4.70	3.50			
				HBC: N	20/10/90	40.0	70.0	%	66.00	6.40	6.70			
				HBC: L	20/10/90	20.0	40.0	%	29.00	74.00	65.00			
				HBC: E	20/10/90	1.0	5.0	%	2.00	21.00	29.00			
				HBC: M	20/10/90	4.0	8.0	%	5.00	0.00	0.00			
				HBC: B	20/10/90	0.0	1.0	%	0.00	5.00	6.00			
				PLATELETS	20/10/90	150.0	550.0	10 ³ /MM ³	280.00	283.00	228.00			
				NA+	20/10/90	138.0	155.0	M EQ/L	143.00	142.00	135.00			
				K+	20/10/90	3.5	5.5	M EQ/L	5.00	4.50	4.20			
				CL-	20/10/90	98.0	120.0	M EQ/L	110.00	98.00	96.00			
				CA++	20/10/90	8.5	10.5	MG/DL	9.10	8.40	8.90			
				PO4-	20/10/90	3.0	4.5	MG/DL	4.10	4.20	4.10			
				SGOT	20/10/90	12.0	40.0	U/L	19.00	21.00	30.00			
				SGPT	20/10/90	10.0	40.0	U/L	22.00	20.00	23.00			
				GAMMA-GT	20/10/90	7.0	35.0	U/L	18.00	20.00	20.00			
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	91.00	87.00	81.00			
				ALK. PHOSPH.	20/10/90	65.0	306.0	U/L	218.00	214.00	179.00			
				UREA	20/10/90	10.0	50.0	MG/DL	19.00	19.00	19.00			
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	0.60	0.70			
				URIC ACID	20/10/90	2.4	5.7	MG/DL	2.00	2.20	1.50			
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	0.50	0.40			
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.20	0.20			
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.70	6.50	6.30			
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.00	3.90	4.20			
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	185.00	171.00	147.00			
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	78.00	84.00	101.00							
GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	3.90	3.70	2.40							
GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	6.40	8.40	8.00							
GLOBULINS: BETA	20/10/90	11.0	14.0	%	10.40	9.80	11.30							
GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	19.70	17.10	11.60							
18-15	F		HB	20/10/90	12.0	16.0	G/100ML	31/07/91						
			HTC	20/10/90	37.0	47.0	%	12.00						
			RBC	20/10/90	3.8	5.4	10 ⁶ /MM ³	39.00						

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit									
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52			
1	18-15	F	HBC: N	20/10/90	4.0	11.0	10-3/HMC	5.70								
			HBC: L	20/10/90	40.0	70.0	X	57.00								
			HBC: E	20/10/90	20.0	40.0	X	36.00								
			HBC: H	20/10/90	1.0	5.0	X	2.00								
			HBC: B	20/10/90	4.0	8.0	X	4.00								
			PLATELETS	20/10/90	0.0	1.0	X	1.00								
			NA+	20/10/90	150.0	550.0	10-3/HMC	171.00								
			K+	20/10/90	138.0	155.0	M EQ/L	140.00								
			CL-	20/10/90	98.0	120.0	M EQ/L	97.00								
			CA++	20/10/90	8.5	10.5	MG/DL	9.30								
			PO4-	20/10/90	3.0	4.5	MG/DL	3.60								
			SGOT	20/10/90	12.0	40.0	MU/ML	20.00								
			SGPT	20/10/90	10.0	40.0	MU/ML	16.00								
			GAMMA-GT	20/10/90	7.0	33.0	MU/ML	23.00								
			GLUCOSE	20/10/90	70.0	100.0	MG/DL	95.00								
			ALK. PHOSPH.	20/10/90	65.0	306.0	MU/ML	119.00								
			BUN	20/10/90	10.0	50.0	MG/DL	27.00								
			CREATININE	20/10/90	0.6	1.6	MG/DL	0.80								
			URIC ACID	20/10/90	2.4	5.7	MG/DL	3.10								
			TOT. BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60								
			DIR. BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30								
			TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.50								
			ALBUMINE	20/10/90	3.5	5.0	G/DL	3.70								
			TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	174.00								
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	146.00								
			GLOBULINS: ALPHA1	20/10/90	4.0	7.0	X	3.00								
			GLOBULINS: ALPHA2	20/10/90	7.0	11.0	X	7.90								
			GLOBULINS: BETA	20/10/90	11.0	14.0	X	12.20								
			GLOBULINS: GAMMA	20/10/90	15.0	22.0	X	16.80								
22-19		F	HB	20/10/90	12.0	16.0	G/100ML	20/08/91	15/10/91	10/12/91	04/02/92	31/03/92	09/06/92			
			HCT	20/10/90	37.0	47.0	X	10.60	10.80	10.60	10.60	11.00	11.40	10.00		
			RBC	20/10/90	3.8	5.4	10-6/HMC	31.00	33.00	32.00	36.00	34.00	31.00	10.00		
			HBC: N	20/10/90	4.0	11.0	10-3/HMC	3.10	3.20	3.10	4.10	4.50	3.10			
			HBC: L	20/10/90	40.0	70.0	X	51.00	5.60	5.40	5.50	6.00	6.60			
			HBC: E	20/10/90	20.0	40.0	X	47.00	50.00	51.00	60.00	62.00	67.00			
			HBC: B	20/10/90	1.0	5.0	X	0.00	0.00	0.00	3.00	3.00	2.00			
			HBC: H	20/10/90	4.0	8.0	X	2.00	5.00	2.00	7.00	6.00	6.00			
			HBC: B	20/10/90	0.0	1.0	X	0.00	0.00	0.00	0.00	0.00	0.00			
			PLATELETS	20/10/90	150.0	550.0	10-3/HMC	291.00	292.00	309.00	310.00	310.00	350.00			
			NA+	20/10/90	138.0	155.0	M EQ/L	144.00	139.00	139.00	158.00	158.00	139.00			

(*-) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1817

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
1	22-19	F		K+	20/10/90	3.5	5.5	M	EQ/L	5.00	4.70	4.60	4.30	4.20	4.50
				CL-	20/10/90	98.0	120.0	M	ER/L	102.00	96.00	96.00	96.00	96.00	96.00
24-20	F			CL+	20/10/90	8.5	10.5	MG/DL	9.00	9.30	8.80	9.00	9.00	9.30	
				PO4-	20/10/90	3.0	4.5	MG/DL	3.80	3.20	3.30	3.50	4.00	3.60	
				SGOT	20/10/90	12.0	40.0	MIU/ML	20.00	27.00	24.00	24.00	18.00	20.00	
				SGPT	20/10/90	10.0	40.0	MIU/ML	21.00	20.00	23.00	23.00	20.00	16.00	
				GAMMA-GT	20/10/90	7.0	33.0	MIU/ML	17.00	16.00	17.00	18.00	22.00	11.00	
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	86.00	101.00	91.00	96.00	93.00	107.00	
				ALK. PHOSPH.	20/10/90	65.0	306.0	MIU/ML	125.00	119.00	119.00	120.00	117.00	131.00	
				BUN	20/10/90	10.0	50.0	MG/DL	31.00	26.00	30.00	28.00	30.00	32.00	
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	0.90	1.00	1.00	0.90	1.10	
				URIC ACID	20/10/90	2.4	5.7	MG/DL	2.00	2.70	3.10	3.30	3.80	3.30	
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.90	0.70	0.60	0.60	0.40	0.40	
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.20	0.20	0.20	0.20	0.20	
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	9.30	9.50	9.30	8.00	9.00	10.00	
				ALBUMINE	20/10/90	3.5	5.0	G/DL	3.80	3.50	3.80	4.00	4.50	3.00	
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	137.00	145.00	155.00	166.00	176.00	138.00	
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	74.00	106.00	94.00	98.00	104.00	94.00	
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	2.70	2.00	1.80	2.00	4.50	1.60	
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	4.30	4.20	3.40	8.00	12.20	4.00	
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	8.60	8.90	9.40	10.40	7.80	8.00	
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	43.30	43.40	45.00	30.40	25.50	56.20	
24-20	F			HB	10/09/91	12.0	16.0	G/100ML	14.10	16.60	13.10	12.80	13.00	12.90	
				HTC	20/10/90	37.0	47.0	%	44.00	45.00	40.00	36.00	36.00	36.00	
				EBC	20/10/90	3.8	5.4	10 ⁶ /HMC	4.80	5.00	4.40	4.30	4.10	4.00	
				WBC	20/10/90	4.0	11.0	10 ³ /HMC	9.10	8.90	6.10	5.20	6.00	5.80	
				WBC: N	20/10/90	40.0	70.0	%	71.00	31.00	57.00	60.00	60.00	58.00	
				WBC: L	20/10/90	20.0	40.0	%	25.00	60.00	36.00	27.00	32.00	34.00	
				WBC: E	20/10/90	1.0	5.0	%	1.00	2.00	2.00	2.00	2.00	3.00	
				WBC: K	20/10/90	4.0	8.0	%	4.00	9.00	7.00	6.00	6.00	5.00	
				WBC: B	20/10/90	0.0	1.0	%	0.00	0.00	2.00	1.00	0.00	0.00	
				PLATELETS	20/10/90	150.0	550.0	10 ³ /HMC	110.00	200.00	108.00	157.00	191.00	216.00	
				NA+	20/10/90	138.0	155.0	M EQ/L	138.00	137.00	142.00	142.00	139.00	138.00	
				K+	20/10/90	3.5	5.5	M EQ/L	4.20	4.00	3.80	3.70	4.00	4.20	
				CL-	20/10/90	98.0	120.0	M EQ/L	94.00	96.00	97.00	96.00	99.00	101.00	
				CA++	20/10/90	8.5	10.5	MG/DL	8.00	9.50	10.20	9.60	9.00	9.20	
				PO4-	20/10/90	3.0	4.5	MG/DL	4.20	4.20	3.80	4.00	4.10	3.70	
				SGOT	20/10/90	12.0	40.0	MIU/ML	25.00	34.00	23.00	18.00	32.00	36.00	
				SGPT	20/10/90	10.0	40.0	MIU/ML	18.00	24.00	19.00	20.00	26.00	34.00	
				GAMMA-GT	20/10/90	7.0	33.0	MIU/ML	26.00	24.00	23.00	22.00	27.00	27.00	
GLUCOSE	20/10/90	70.0	100.0	MG/DL	90.00	117.00	90.00	91.00	116.00	121.00					

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range		Visit									
				Min	Max Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52				
1	24-20	F	ALK. PHOSPH.	20/10/90	65.0	306.0	NIU/ML	264.00	1076.00	957.00	142.00	140.00	138.00		
			BUN	20/10/90	10.0	50.0	MG/DL	27.00	24.00	28.00	26.00	30.00	32.00		
			CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	0.80	0.90	0.80	1.10	1.00		
			URIC ACID	20/10/90	2.4	5.7	MG/DL	2.80	3.30	2.40	3.80	3.30	3.80		
			TOT. BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.50	0.60	0.50	0.60	1.00	0.90		
			DIR. BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.20	0.20	0.30	0.50	0.40		
			TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.20	7.40	6.50	7.10	6.70	6.80		
			ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	4.70	4.30	4.30	3.70	3.90		
			TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	270.00	300.00	258.00	193.00	108.00	171.00		
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	70.00	96.00	82.00	66.00	93.00	97.00		
			GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	2.70	2.40	3.30	4.10	3.60	3.20		
			GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	9.60	10.70	9.70	8.70	11.10	12.10		
			GLOBULINS: BETA	20/10/90	11.0	14.0	%	11.70	14.80	11.30	14.10	12.30	13.90		
			GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	11.00	10.20	8.90	16.20	21.00	21.70		
			25-21	F	HB	20/10/90	12.0	16.0	G/100ML	12.60	12.30	13.40	13.80	13.80	15.90
					HCT	20/10/90	37.0	47.0	%	37.00	36.00	41.00	39.00	41.00	41.00
					RBC	20/10/90	3.8	5.4	10 ⁶ -6/MNC	4.20	4.10	4.60	4.60	4.80	4.70
					MBC	20/10/90	4.0	11.0	10 ³ -3/MNC	6.20	6.50	6.60	7.10	6.90	6.50
					MBC: N	20/10/90	40.0	70.0	%	62.00	65.00	63.00	61.00	63.00	62.00
					MBC: L	20/10/90	20.0	40.0	%	37.00	33.00	52.00	28.00	31.00	30.00
MBC: E	20/10/90	1.0			5.0	%	1.00	2.00	2.00	6.00	2.00	2.00			
MBC: M	20/10/90	4.0			8.0	%	1.00	2.00	3.00	5.00	4.00	6.00			
MBC: B	20/10/90	0.0			1.0	%	1.00	0.00	0.00	0.00	0.00	0.00			
PLATELETS	20/10/90	150.0			550.0	10 ³ -3/MNC	283.00	295.00	334.00	205.00	276.00	261.00			
NA+	20/10/90	138.0			155.0	M EQ/L	140.00	139.00	139.00	137.00	142.00	142.00			
CL-	20/10/90	98.0			120.0	H EQ/L	99.00	99.00	97.00	95.00	96.00	98.00			
CA++	20/10/90	8.5			10.5	MG/DL	9.50	9.80	8.40	9.00	9.50	9.50			
PO4--	20/10/90	3.0			4.5	MG/DL	4.20	4.10	4.30	4.20	4.10	4.00			
SGOT	20/10/90	12.0			40.0	IU/ML	30.00	31.00	24.00	26.00	26.00	26.00			
GAMMA-GT	20/10/90	10.0			40.0	IU/ML	56.00	33.00	29.00	28.00	28.00	28.00			
GLUCOSE	20/10/90	70.0			33.0	MG/ML	47.00	45.00	30.00	34.00	34.00	32.00			
ALK. PHOSPH.	20/10/90	65.0			100.0	MG/DL	95.00	88.00	90.00	88.00	97.00	97.00			
BUN	20/10/90	10.0			30.0	MG/DL	215.00	268.00	281.00	213.00	216.00	181.00			
CREATININE	20/10/90	0.6			5.0	MG/DL	0.80	0.80	0.90	0.90	1.00	0.90			
URIC ACID	20/10/90	2.4	5.7	MG/DL	4.70	4.40	5.50	4.20	4.20	3.80					
TOT. BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	0.40	0.80	0.70	0.60	0.60					
DIR. BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.20	0.40	0.30	0.30	0.40					
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.70	6.90	7.20	7.00	7.40	7.30					
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.00	4.10	4.10	4.10	4.30	4.20					

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 12.1
 LABORATORY DATA
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit										
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52				
1 25-21	F			TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	174.00	185.00	193.00	172.00	160.00	176.00				
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	128.00	103.00	97.00	81.00	81.00	93.00				
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	2.40	2.30	3.00	4.20	3.20	3.00				
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	8.60	7.80	8.70	7.00	12.60	13.10				
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	12.10	11.70	11.30	12.30	8.00	7.20				
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	19.40	18.10	19.30	18.40	19.50	18.90				
				31-27	F			HR	20/10/90	12.0	16.0	G/100ML	13.50	13.50	13.50	17.03/92	12/05/92	21/07/92
								RBC	20/10/90	37.0	47.0	%	41.00	43.00	41.00	40.00	40.00	41.00
								WBC	20/10/90	3.8	5.4	10 ⁶ /MNC	4.40	4.60	4.50	6.90	4.70	4.50
								REC: N	20/10/90	4.0	11.0	10 ³ /MNC	6.70	4.50	4.60	6.90	4.70	4.10
REC: L	20/10/90	40.0	70.0					%	56.00	47.00	57.00	60.00	57.00	47.00				
REC: E	20/10/90	20.0	40.0					%	42.00	49.00	33.00	30.00	30.00	35.00				
REC: H	20/10/90	1.0	5.0					%	1.00	2.00	3.00	4.00	4.00	16.00				
REC: B	20/10/90	4.0	8.0					%	2.00	7.00	6.00	6.00	6.00	0.00				
PLATELETS	20/10/90	150.0	550.0					10 ³ /MNC	315.00	312.00	307.00	310.00	350.00	270.00				
NA+	20/10/90	138.0	155.0					M EQ/L	139.00	138.00	140.00	142.00	139.00	138.00				
				K+	20/10/90	3.5	5.5	M EQ/L	4.10	4.20	4.20	3.90	4.20	4.60				
				CL-	20/10/90	98.0	120.0	M EQ/L	98.00	98.00	98.00	96.00	93.00	97.00				
				CA++	20/10/90	8.5	10.5	MG/DL	9.30	9.20	9.50	9.80	9.90	8.80				
				PO4--	20/10/90	3.0	4.5	MG/DL	3.00	4.20	4.00	4.20	3.00	4.20				
				SGPT	20/10/90	12.0	40.0	RU/ML	17.00	24.00	23.00	22.00	28.00	23.00				
				GAMMA-GT	20/10/90	10.0	40.0	RU/ML	11.00	18.00	18.00	28.00	30.00	22.00				
				GLUCOSE	20/10/90	7.0	33.0	MU/ML	19.00	22.00	25.00	33.00	18.00	15.00				
				ALK. PHOSPH.	20/10/90	70.0	100.0	MG/DL	95.00	94.00	89.00	94.00	94.00	93.00				
				BUN	20/10/90	65.0	306.0	MU/ML	171.00	140.00	123.00	162.00	159.00	176.00				
				CREATININE	20/10/90	10.0	50.0	MG/DL	29.00	25.00	24.00	28.00	30.00	33.00				
				URIC ACID	20/10/90	0.6	1.6	MG/DL	1.00	1.00	1.00	0.90	0.80	0.80				
				TOT BILIRUBIN	20/10/90	2.4	5.7	MG/DL	3.00	2.50	3.50	4.30	3.60	2.90				
				DIR BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.40	0.60	0.70	0.60	0.60	0.40				
				TOT PROTEINS	20/10/90	0.0	0.4	MG/DL	0.20	0.30	0.30	0.30	0.30	0.20				
				ALBUMINE	20/10/90	6.0	8.0	G/DL	6.90	6.70	7.10	7.40	7.20	7.30				
				TOT. CHOLEST.	20/10/90	3.5	5.0	G/DL	4.10	4.00	4.30	4.30	3.90	4.05				
				TRIGLYCERIDES	20/10/90	140.0	270.0	MG/DL	156.00	164.00	184.00	182.00	190.00	158.00				
				GLOBULINS: ALPHA1	20/10/90	35.0	175.0	MG/DL	85.00	117.00	81.00	94.00	82.00	96.00				
				GLOBULINS: ALPHA2	20/10/90	4.0	7.0	%	2.90	3.20	2.80	3.20	4.10	2.30				
				GLOBULINS: BETA	20/10/90	7.0	11.0	%	6.30	6.50	5.60	6.50	8.60	6.30				
GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	10.30	10.30	10.20	9.00	14.20	11.90								
					20/10/90	15.0	22.0	%	21.50	20.00	19.70	18.20	19.50	24.00				

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre Open-Blind Sex	Laboratory test	Laboratory Range			Visit						
			Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
1 32-28	F	HB	20/10/90	12.0	16.0	G/100ML	02/10/91	27/11/91	22/01/92	18/03/92	13/05/92	22/07/92
		HTC	20/10/90	37.0	47.0	X	43.70	14.00	12.80	13.10	12.90	12.40
		RBC	20/10/90	3.8	5.4	10-6/MNC	43.00	42.00	40.00	40.00	40.00	40.00
		RBC	20/10/90	4.0	11.0	10-3/MNC	5.00	4.80	4.70	4.60	4.60	4.50
		MBC: N	20/10/90	40.0	70.0	X	72.00	70.00	8.20	8.20	6.30	7.80
		MBC: L	20/10/90	20.0	40.0	X	23.00	28.00	25.00	24.00	58.00	57.00
		MBC: E	20/10/90	1.0	5.0	X	0.00	0.00	0.00	1.00	3.00	1.00
		MBC: H	20/10/90	0.0	4.0	X	5.00	2.00	4.00	4.00	9.00	4.00
		MBC: B	20/10/90	0.0	1.0	X	0.00	0.00	0.00	0.00	0.00	0.00
		PLATELETS	20/10/90	150.0	550.0	10-3/MNC	138.00	183.00	317.00	320.00	252.00	308.00
		NA+	20/10/90	138.0	155.0	M EQ/L	139.00	138.00	140.00	141.00	141.00	141.00
		K+	20/10/90	3.5	5.5	M EQ/L	4.40	4.20	4.50	4.30	4.20	5.00
		CL-	20/10/90	98.0	120.0	M EQ/L	99.00	98.00	100.00	101.00	97.00	96.00
		CA++	20/10/90	8.5	10.5	MG/DL	8.80	8.80	8.80	9.10	9.50	9.50
		PO4-	20/10/90	3.0	4.5	MG/DL	3.90	3.60	3.60	4.00	3.60	4.20
		SGOT	20/10/90	12.0	40.0	NU/ML	25.00	26.00	27.00	26.00	20.00	25.00
		SGPT	20/10/90	10.0	40.0	NU/ML	17.00	18.00	25.00	30.00	26.00	22.00
		GAMMA-GT	20/10/90	7.0	35.0	NU/ML	29.00	30.00	31.00	22.00	18.00	36.00
		GLUCOSE	20/10/90	70.0	100.0	MG/DL	108.00	100.00	96.00	96.00	98.00	102.00
		ALK. PHOSPH.	20/10/90	65.0	306.0	NU/ML	301.00	312.00	307.00	301.00	260.00	354.00
BUN	20/10/90	10.0	50.0	MG/DL	17.00	18.00	10.00	12.00	31.00	14.00		
CREATININE	20/10/90	0.6	1.6	MG/DL	0.70	0.70	0.80	0.80	0.90	0.80		
URIC ACID	20/10/90	2.4	5.7	MG/DL	3.40	3.60	3.40	3.20	4.00	4.00		
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.70	0.60	0.70	0.60	0.40	0.20		
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.30	0.30	0.20	0.20	0.10		
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.80	7.50	7.00	7.00	7.30	8.10		
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.70	4.60	3.90	4.00	4.10	4.40		
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	210.00	200.00	190.00	182.00	174.00	226.00		
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	96.00	106.00	102.00	93.00	106.00	91.00		
GLOBULINS: ALPHA1	20/10/90	4.0	7.0	X	2.60	2.80	4.10	3.90	2.60	2.50		
GLOBULINS: ALPHA2	20/10/90	7.0	11.0	X	7.40	7.50	9.20	8.90	8.00	7.40		
GLOBULINS: BETA	20/10/90	11.0	14.0	X	11.80	11.00	13.10	13.40	12.30	14.10		
GLOBULINS: GAMMA	20/10/90	15.0	22.0	X	18.80	19.20	19.40	20.20	19.00	21.40		
34-30	F	HB	20/10/90	12.0	16.0	G/100ML	23/10/91	18/12/91	12/02/92	08/04/92	03/06/92	12/08/92
		HTC	20/10/90	37.0	47.0	X	15.40	13.20	13.40	14.00	13.60	13.30
		RBC	20/10/90	3.8	5.4	10-6/MNC	42.00	41.00	39.00	41.00	41.00	40.00
		RBC	20/10/90	4.0	11.0	10-3/MNC	4.70	4.80	4.60	4.50	4.60	4.60
		MBC: N	20/10/90	40.0	70.0	X	64.00	64.00	60.00	58.00	50.00	47.00
		MBC: L	20/10/90	20.0	40.0	X	28.00	27.00	29.00	30.00	37.00	52.00
		MBC: E	20/10/90	1.0	5.0	X	3.00	4.00	3.00	5.00	37.00	40.00
		MBC: H	20/10/90	0.0	4.0	X	0.00	0.00	0.00	0.00	1.00	1.00
		MBC: B	20/10/90	0.0	1.0	X	0.00	0.00	0.00	0.00	0.00	0.00
		MBC: I	20/10/90	0.0	1.0	X	0.00	0.00	0.00	0.00	0.00	0.00

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1821

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REXOXYLINE - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 DOUBLE BLIND PHASE
 TREATMENT: REXOXYLINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit											
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52					
1 34-30	F			HBC: M	20/10/90	4.0	8.0	X	5.00	5.00	8.00	9.00	2.00	7.00					
				HBC: B	20/10/90	0.0	1.0	X	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
				PLATELETS	20/10/90	150.0	550.0	10-3/MHC	244.00	216.00	271.00	268.00	210.00	192.00	0.00				
				NA+	20/10/90	138.0	155.0	M EQ/L	140.00	141.00	138.00	142.00	138.00	137.00	0.00				
				K+	20/10/90	3.5	5.5	M EQ/L	4.40	4.30	4.00	4.30	4.50	5.70	0.00				
				CL-	20/10/90	98.0	120.0	M EQ/L	94.00	95.00	97.00	95.00	97.00	96.00	0.00				
				CA++	20/10/90	8.5	10.5	MG/DL	8.70	9.10	9.50	9.30	9.20	9.10	0.00				
				PO4--	20/10/90	3.0	4.5	MG/DL	4.20	4.10	4.10	4.20	3.60	4.10	0.00				
				SGPT	20/10/90	12.0	40.0	NU/ML	17.00	18.00	34.00	36.00	25.00	26.00	0.00				
				GAMMA-GT	20/10/90	10.0	40.0	NU/ML	16.00	16.00	38.00	40.00	32.00	21.00	0.00				
				GLUCOSE	20/10/90	70.0	33.0	MU/ML	26.00	28.00	29.00	28.00	19.00	19.00	0.00				
				ALK. PHOSPH.	20/10/90	65.0	100.0	MG/DL	86.00	92.00	106.00	97.00	97.00	92.00	0.00				
				URIN	20/10/90	10.0	306.0	MU/ML	133.00	131.00	150.00	168.00	167.00	169.00	0.00				
				CREATININE	20/10/90	0.6	50.0	MG/DL	24.00	24.00	32.00	31.00	28.00	27.00	0.00				
				URIC ACID	20/10/90	2.4	1.6	MG/DL	1.00	0.80	0.90	1.00	0.90	0.70	0.00				
				TOT. BILIRUBIN	20/10/90	0.2	5.7	MG/DL	3.70	4.00	4.10	4.30	2.90	4.10	0.00				
				DIR. BILIRUBIN	20/10/90	0.0	1.0	MG/DL	0.40	0.40	0.80	0.80	0.40	0.40	0.00				
				TOT. PROTEINS	20/10/90	6.0	0.4	MG/DL	0.20	0.20	0.50	0.40	0.20	0.20	0.00				
				ALBUMINE	20/10/90	3.5	8.0	G/DL	7.80	7.60	7.40	7.30	7.00	7.00	0.00				
				TOT. CHOLEST.	20/10/90	140.0	5.0	MG/DL	4.30	4.20	4.20	4.10	4.00	3.90	0.00				
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	260.00	242.00	171.00	156.00	259.00	323.00	0.00				
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	X	2.20	3.20	3.80	4.00	2.50	2.70	0.00				
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	X	9.70	8.20	12.50	11.50	6.30	8.90	0.00				
				GLOBULINS: BETA	20/10/90	11.0	14.0	X	14.00	14.50	9.60	8.70	14.10	13.60	0.00				
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	X	16.10	18.90	21.50	22.30	19.00	19.00	0.00				
				35-301	F			HB	20/10/90	12.0	16.0	G/100ML	11.80	11.80	11.70	12.80	12.50	12.40	
								HTC	20/10/90	37.0	47.0	X	36.00	36.00	35.00	36.00	37.00	37.00	0.00
								RBC	20/10/90	3.8	5.4	10-6/MHC	4.30	4.30	4.20	4.20	4.20	4.60	0.00
MBC: N	20/10/90	4.0	11.0					10-3/MHC	5.20	5.20	6.00	5.80	5.80	5.90	0.00				
MBC: L	20/10/90	20.0	70.0					X	62.00	62.00	63.00	62.00	59.00	58.00	0.00				
MBC: E	20/10/90	1.0	40.0					X	35.00	35.00	29.00	28.00	34.00	35.00	0.00				
MBC: M	20/10/90	4.0	5.0					X	2.00	2.00	2.00	2.00	2.00	1.00	0.00				
MBC: B	20/10/90	0.0	8.0					X	3.00	3.00	6.00	9.00	5.00	6.00	0.00				
PLATELETS	20/10/90	150.0	550.0					10-3/MHC	157.00	157.00	168.00	215.00	240.00	232.00	0.00				
NA+	20/10/90	138.0	155.0					M EQ/L	139.00	139.00	140.00	141.00	143.00	143.00	0.00				
K+	20/10/90	3.5	5.5					M EQ/L	4.70	4.70	3.90	3.80	4.60	4.60	0.00				
CL-	20/10/90	98.0	120.0					M EQ/L	96.00	96.00	97.00	96.00	94.00	95.00	0.00				
CA++	20/10/90	8.5	10.5					MG/DL	9.50	9.50	8.90	9.00	9.30	9.30	0.00				
PO4--	20/10/90	3.0	4.5					MG/DL	3.90	3.90	3.80	3.70	3.50	3.90	0.00				

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Open-Blind Sex	Laboratory test	Laboratory Range			Visit								
			Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52		
1 35-301	F	SGPT	20/10/90	12.0	40.0	U/ML	33.00	33.00	24.00	26.00	20.00	20.00		
		SQPT	20/10/90	10.0	40.0	U/ML	20.00	20.00	16.00	18.00	14.00	12.00		
		GAMMA-GT	20/10/90	7.0	33.0	U/ML	28.00	28.00	30.00	32.00	25.00	28.00		
		GLUCOSE	20/10/90	70.0	100.0	MG/DL	93.00	103.00	103.00	95.00	96.00	102.00		
		ALK. PHOSPH.	20/10/90	65.0	306.0	U/ML	147.00	147.00	140.00	136.00	146.00	157.00		
		BUN	20/10/90	10.0	50.0	MG/DL	26.00	26.00	28.00	30.00	28.00	27.00		
		CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	0.90	0.90	0.90	0.90	0.90		
		URIC ACID	20/10/90	2.4	5.7	MG/DL	3.30	3.30	4.10	3.90	3.50	3.70		
		TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.30	0.30	0.50	0.30	0.60	0.40		
		DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.10	0.10	0.30	0.30	0.20	0.20		
		TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.90	6.90	7.10	7.10	7.00	6.90		
		ALBUMINE	20/10/90	3.5	5.0	G/DL	3.80	3.80	4.10	4.00	3.90	3.90		
		TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	182.00	182.00	175.00	179.00	176.00	175.00		
		TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	60.00	60.00	69.00	81.00	87.00	103.00		
		GLORULINS: ALPHA1	20/10/90	4.0	7.0	%	2.80	2.80	2.40	2.60	3.20	3.30		
		GLORULINS: ALPHA2	20/10/90	7.0	11.0	%	7.50	7.50	8.40	8.20	8.40	8.00		
		GLORULINS: BETA	20/10/90	11.0	14.0	%	10.90	10.90	13.00	13.60	12.90	12.90		
		GLORULINS: GAMMA	20/10/90	15.0	22.0	%	16.30	16.30	18.60	17.90	19.60	19.40		
		37-303	F	HB	20/10/90	12.0	16.0	G/100ML	14.60	14.10	12.40	12.60	23/06/92	01/09/92
				HTC	20/10/90	37.0	47.0	%	43.00	41.00	37.00	37.00	37.00	12.50
				RBC	20/10/90	3.8	5.4	10 ⁶ /MNC	4.50	4.40	4.00	4.40	4.20	4.00
				HBC	20/10/90	4.0	11.0	10 ³ /MNC	9.00	8.00	8.40	7.20	8.00	9.20
				HBC: N	20/10/90	40.0	70.0	%	57.00	60.00	64.00	60.00	64.00	65.00
				HBC: L	20/10/90	20.0	40.0	%	39.00	35.00	33.00	30.00	28.00	30.00
				HBC: E	20/10/90	1.0	5.0	%	0.00	1.00	0.00	1.00	2.00	1.00
				HBC: M	20/10/90	4.0	8.0	%	4.00	4.00	3.00	6.00	6.00	6.00
				HBC: B	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00
PLATELETS	20/10/90			150.0	550.0	10 ³ /MNC	420.00	364.00	392.00	366.00	416.00	422.00		
NA+	20/10/90			138.0	155.0	M EQ/L	138.00	140.00	141.00	142.00	144.00	134.00		
CL-	20/10/90			3.5	5.5	M EQ/L	4.20	3.20	4.30	4.10	4.30	3.20		
CA++	20/10/90			8.5	10.5	MG/DL	9.40	9.40	9.80	9.90	9.70	10.60		
PO4-	20/10/90			3.0	4.5	MG/DL	3.50	3.00	3.30	3.50	3.70	3.80		
SGPT	20/10/90			12.0	40.0	U/ML	45.00	65.00	38.00	32.00	28.00	25.00		
GAMMA-GT	20/10/90			10.0	40.0	U/ML	56.00	67.00	31.00	30.00	15.00	15.00		
GLUCOSE	20/10/90			7.0	33.0	MG/DL	109.00	85.00	70.00	56.00	63.00	74.00		
ALK. PHOSPH.	20/10/90			65.0	306.0	U/ML	182.00	160.00	106.00	102.00	136.00	157.00		
BUN	20/10/90			10.0	50.0	MG/DL	22.00	348.00	302.00	276.00	287.00	287.00		
CREATININE	20/10/90			0.6	1.6	MG/DL	0.90	0.80	0.80	0.80	1.00	1.10		
URIC ACID	20/10/90			2.4	5.7	MG/DL	7.00	7.10	5.40	4.80	7.20	8.70		

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit											
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52					
1 37-303	F			TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.80	0.70	0.50	0.60	0.60	0.60	0.40				
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.30	0.20	0.30	0.30	0.30	0.30	0.20			
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.80	7.70	7.20	7.30	7.30	7.30	7.20	7.20			
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.30	4.20	4.10	4.10	4.00	4.00	4.10	4.10			
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	274.00	288.00	253.00	261.00	247.00	263.00	263.00	263.00			
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	270.00	188.00	94.00	86.00	158.00	194.00	194.00	194.00			
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	3.30	2.50	3.60	3.70	3.60	2.40	2.40	2.40			
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	9.00	9.30	11.20	11.90	10.00	9.50	9.50	9.50			
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	13.70	13.50	11.50	10.50	12.60	14.20	14.20	14.20			
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	14.10	14.50	17.30	19.20	18.20	16.40	16.40	16.40			
				39-305	F				03/12/91										
								HR	20/10/90	12.0	16.0	6/100ML	12.70	14.40	13.20	13.50	14.00	14.00	13.70
								HTC	20/10/90	37.0	47.0	%	40.00	41.00	40.00	40.00	41.00	41.00	42.00
								HBC	20/10/90	3.8	5.4	10 ⁶ -6/MHC	4.40	4.90	4.40	4.50	4.60	4.70	4.70
								RBC	20/10/90	4.0	11.0	10 ³ -3/MHC	10.70	5.30	12.30	9.10	8.80	13.70	13.70
								RBC: N	20/10/90	40.0	70.0	%	64.00	60.00	73.00	62.00	65.00	78.00	78.00
								RBC: L	20/10/90	20.0	40.0	%	40.00	27.00	20.00	29.00	20.00	15.00	15.00
RBC: E	20/10/90	1.0	5.0					%	0.00	5.00	2.00	2.00	2.00	2.00	2.00				
RBC: M	20/10/90	4.0	8.0					%	1.00	8.00	5.00	7.00	9.00	5.00	5.00				
RBC: B	20/10/90	0.0	1.0					%	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
PLATELETS	20/10/90	150.0	550.0					10 ³ -3/MHC	280.00	311.00	238.00	245.00	342.00	394.00	394.00				
NA+	20/10/90	138.0	155.0					M EQ/L	138.00	141.00	138.00	138.00	142.00	141.00	141.00				
K+	20/10/90	3.5	5.5					M EQ/L	4.00	3.80	4.40	4.20	4.00	4.70	4.70				
CL-	20/10/90	98.0	120.0					M EQ/L	97.00	94.00	98.00	99.00	98.00	100.00	100.00				
CA++	20/10/90	8.5	10.5					MG/DL	10.00	8.90	9.80	9.60	9.70	9.90	9.90				
PO4--	20/10/90	3.0	4.5					MG/DL	4.20	4.20	3.30	3.50	3.70	3.50	3.50				
SGOT	20/10/90	12.0	40.0					U/HL	25.00	26.00	22.00	24.00	22.00	20.00	20.00				
SGPT	20/10/90	10.0	40.0					U/HL	17.00	30.00	28.00	28.00	15.00	13.00	13.00				
GAMMA-GT	20/10/90	7.0	33.0					U/HL	29.00	32.00	27.00	22.00	20.00	21.00	21.00				
GLUCOSE	20/10/90	70.0	100.0					MG/DL	80.00	94.00	97.00	93.00	97.00	101.00	101.00				
ALK. PHOSPH.	20/10/90	65.0	306.0					U/HL	274.00	152.00	242.00	201.00	198.00	255.00	255.00				
BUN	20/10/90	10.0	50.0					MG/DL	41.00	28.00	37.00	32.00	32.00	34.00	34.00				
CREATININE	20/10/90	0.6	1.6					MG/DL	1.00	0.90	0.90	0.90	1.00	0.90	0.90				
URIC ACID	20/10/90	2.4	5.7	MG/DL	4.20	4.10	3.30	3.50	3.70	3.90	3.90								
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.70	0.90	0.40	0.50	0.40	0.20	0.20								
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.40	0.20	0.20	0.20	0.10	0.10								
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.70	6.90	6.80	6.90	6.90	6.80	6.80								
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.00	4.00	3.73	3.80	3.50	3.50	3.50								
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	200.00	165.00	222.00	193.00	265.00	248.00	248.00								
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	117.00	28.00	163.00	134.00	120.00	113.00	113.00								
GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	2.90	3.90	4.00	3.50	2.30	2.10	2.10								
GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	7.80	9.10	9.50	9.70	10.40	10.60	10.60								

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1 0 2 4

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit								
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52		
1	45-310	F	MBC: N	20/10/90	4.0	11.0	10-3/MHC	4.70	6.10	4.60	4.60	4.60	4.60	5.80	5.20
			MBC: L	20/10/90	40.0	70.0	X	52.00	60.00	76.00	65.00	71.00			
			MBC: E	20/10/90	20.0	40.0	X	38.00	27.00	18.00	30.00	22.00			
			MBC: M	20/10/90	1.0	5.0	X	3.00	6.00	2.00	5.00	3.00	5.00		
			MBC: B	20/10/90	4.0	8.0	X	7.00	7.00	4.00	10.00	6.00	6.00		
			PLATELETS	20/10/90	0.0	1.0	X	0.00	0.00	0.00	0.00	0.00	1.00		
			NA+	20/10/90	150.0	550.0	10-3/MHC	245.00	283.00	204.00	326.00	260.00	256.00		
			K+	20/10/90	138.0	155.0	M EQ/L	141.00	140.00	141.00	136.00	143.00	142.00		
			CL-	20/10/90	3.5	5.5	M EQ/L	4.70	4.20	4.50	4.60	4.20	4.90		
			CA++	20/10/90	98.0	120.0	M EQ/L	97.00	98.00	98.00	94.00	97.00	95.00		
			PO4-	20/10/90	3.0	4.5	MG/DL	3.40	3.40	3.50	3.40	3.70	3.60		
			SGPT	20/10/90	12.0	40.0	UO/ML	33.00	24.00	24.00	29.00	28.00	30.00		
			GAMMA-GT	20/10/90	10.0	40.0	UO/ML	23.00	24.00	25.00	28.00	20.00	17.00		
			GLUCOSE	20/10/90	7.0	33.0	MU/ML	43.00	32.00	42.00	40.00	30.00	35.00		
			ALK. PHOSPH.	20/10/90	70.0	100.0	MG/DL	94.00	98.00	100.00	91.00	92.00	96.00		
			UREIC ACID	20/10/90	65.0	306.0	MU/ML	222.00	214.00	182.00	251.00	215.00	235.00		
			TOT. BILIRUBIN	20/10/90	10.0	50.0	MG/DL	35.00	28.00	29.00	31.00	30.00	31.00		
			DIR. BILIRUBIN	20/10/90	0.6	1.6	MG/DL	0.90	1.00	0.60	1.10	0.60	0.70		
			TOT. PROTEINS	20/10/90	2.4	5.7	MG/DL	5.80	4.30	5.60	5.90	5.60	5.90		
			ALBUMINE	20/10/90	0.2	1.0	MG/DL	0.90	1.00	1.40	0.80	0.70	0.80		
			TOT. CHOLEST.	20/10/90	0.0	0.4	MG/DL	0.40	0.40	0.30	0.30	0.30	0.30		
			TRIGLYCERIDES	20/10/90	6.0	8.0	G/DL	7.20	7.20	6.80	7.00	7.20	7.20		
			GLOBULINS: ALPHA1	20/10/90	3.5	5.0	G/DL	4.10	4.00	3.85	3.91	4.00	4.00		
			GLOBULINS: ALPHA2	20/10/90	140.0	270.0	MG/DL	195.00	203.00	215.00	196.00	196.00	210.00		
			GLOBULINS: BETA	20/10/90	35.0	175.0	MG/DL	91.00	97.00	88.00	103.00	82.00	79.00		
			GLOBULINS: GAMMA	20/10/90	4.0	7.0	X	3.60	4.10	2.30	3.70	3.10	3.30		
			PLATELETS	20/10/90	7.0	11.0	X	8.90	11.20	7.20	8.60	9.50	9.10		
			NA+	20/10/90	11.0	14.0	X	13.50	9.00	14.90	14.40	14.80	15.10		
				20/10/90	15.0	22.0	X	17.40	19.40	18.60	17.40	16.20	16.30		
			46-311	F	HR	20/10/90	12.0	16.0	G/100ML	24/12/91	18/02/92	14/04/92	09/06/92	04/08/92	13/10/92
					HTC	20/10/90	37.0	47.0	X	11.90	12.30	14.00	13.80	13.50	13.30
					RBC	20/10/90	3.8	5.4	10-6/MHC	36.00	37.00	41.00	41.00	38.00	37.00
					MBC: N	20/10/90	4.0	11.0	10-3/MHC	4.10	4.20	4.80	4.70	4.30	4.20
MBC: L	20/10/90	20.0			70.0	X	5.30	5.00	6.00	5.20	6.10	6.00			
MBC: E	20/10/90	40.0			40.0	X	58.00	58.00	62.00	61.00	62.00	62.00			
MBC: M	20/10/90	1.0			5.0	X	3.00	3.00	3.00	2.90	3.00	2.70			
MBC: B	20/10/90	4.0			8.0	X	2.00	3.00	3.00	3.00	3.00	3.00			
PLATELETS	20/10/90	0.0			1.0	X	0.00	0.00	0.00	0.00	0.00	0.00			
NA+	20/10/90	150.0			550.0	10-3/MHC	261.00	257.00	216.00	269.00	264.00	266.00			
	20/10/90	138.0			155.0	M EQ/L	138.00	138.00	142.00	142.00	142.00	141.00			

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Open-Blind Sex	Laboratory test	Laboratory Range			Visit									
			Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52			
1 46-311	F	K+	20/10/90	3.5	5.5	M	EQ/L	4.60	4.30	3.90	4.00	4.10	4.20		
		CL-	20/10/90	98.0	120.0	M	EQ/L	96.00	97.00	96.00	98.00	96.00	90.00		
		CA++	20/10/90	8.5	10.5	MG/DL	9.70	9.50	9.90	9.90	8.90	9.70	9.70		
		PO4-	20/10/90	3.0	4.5	MG/DL	3.70	3.80	4.00	4.00	4.00	3.60	3.40		
		SCOT	20/10/90	12.0	40.0	HU/ML	22.00	23.00	24.00	28.00	24.00	24.00	26.00		
		SGPT	20/10/90	10.0	40.0	HU/ML	19.00	20.00	28.00	32.00	30.00	30.00	32.00		
		GAMMA-GT	20/10/90	7.0	33.0	HU/ML	20.00	22.00	20.00	22.00	22.00	22.00	28.00		
		GLUCOSE	20/10/90	70.0	100.0	MG/DL	91.00	92.00	102.00	122.00	91.00	97.00	93.00		
		ALK. PHOSPH.	20/10/90	65.0	306.0	HU/ML	277.00	214.00	120.00	122.00	122.00	122.00	128.00		
		BUN	20/10/90	10.0	50.0	MG/DL	20.00	28.00	29.00	30.00	32.00	30.00	30.00		
		CREATININE	20/10/90	0.6	1.6	MG/DL	0.70	0.90	0.80	0.90	0.80	1.10	0.90		
		URIC ACID	20/10/90	2.4	5.7	MG/DL	3.30	4.10	3.40	4.10	3.60	3.60	3.60		
		TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.70	0.80	0.60	0.70	0.70	0.60	0.60		
		DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.30	0.30	0.30	0.30	0.30	0.30		
		TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.80	7.20	7.20	7.30	7.20	7.40	7.40		
		ALBUMINE	20/10/90	3.5	5.0	G/DL	4.50	4.00	3.90	4.00	3.90	3.90	4.00		
		TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	195.00	210.00	141.00	156.00	156.00	162.00	162.00		
		TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	84.00	97.00	90.00	88.00	88.00	90.00	90.00		
		GLORULINS: ALPHA1	20/10/90	4.0	7.0	%	3.90	3.00	3.50	3.00	3.00	3.60	4.30		
		GLORULINS: ALPHA2	20/10/90	7.0	11.0	%	8.80	8.40	8.20	5.90	5.90	8.20	8.80		
		GLORULINS: BETA	20/10/90	11.0	14.0	%	11.90	12.00	13.50	13.60	13.60	14.20	14.20		
		GLORULINS: GAMMA	20/10/90	15.0	22.0	%	10.10	18.30	20.10	22.70	22.70	21.20	18.70		
		48-313	F	HB	20/10/90	12.0	16.0	G/100ML	12.50	14.00	12.10	12.30	12.00	11.10	
				HTC	20/10/90	37.0	47.0	%	39.00	41.00	38.00	40.00	36.00	34.00	
				RBC	20/10/90	3.8	5.4	10 ⁶ /MNC	4.70	4.60	4.70	4.90	4.60	4.50	
				MBC	20/10/90	4.0	11.0	10 ³ /MNC	9.10	6.40	9.70	9.00	9.00	11.70	
				HBC: N	20/10/90	40.0	70.0	%	60.00	58.00	63.00	63.00	63.00	65.00	
				HBC: L	20/10/90	20.0	40.0	%	33.00	31.00	32.00	30.00	28.00	26.00	
				HBC: E	20/10/90	1.0	5.0	%	2.00	4.00	1.00	2.00	1.00	2.00	
				HBC: M	20/10/90	4.0	8.0	%	5.00	7.00	4.00	5.00	8.00	7.00	
				HBC: B	20/10/90	0.0	1.0	%	2.00	0.00	0.00	0.00	0.00	0.00	
				PLATELETS	20/10/90	150.0	550.0	10 ³ /MNC	377.00	310.00	373.00	358.00	314.00	330.00	
				NA+	20/10/90	138.0	155.0	M EQ/L	136.00	139.00	140.00	142.00	142.00	141.00	
K+	20/10/90			3.5	5.5	M EQ/L	4.30	4.20	4.10	4.20	4.10	4.30			
CL-	20/10/90			98.0	120.0	M EQ/L	95.00	102.00	97.00	99.00	101.00	99.00			
CA++	20/10/90			8.5	10.5	MG/DL	9.60	9.40	9.90	9.30	8.90	8.40			
PO4-	20/10/90			3.0	4.5	MG/DL	4.10	4.00	3.50	3.60	3.00	2.80			
SCOT	20/10/90			12.0	40.0	HU/ML	25.00	28.00	20.00	22.00	28.00	25.00			
SGPT	20/10/90			10.0	40.0	HU/ML	39.00	30.00	26.00	26.00	32.00	16.00			
GAMMA-GT	20/10/90			7.0	33.0	HU/ML	34.00	22.00	30.00	30.00	16.00	27.00			
GLUCOSE	20/10/90	70.0	100.0	MG/DL	91.00	99.00	106.00	97.00	92.00	86.00					

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit										
					Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52					
1 48-313	F			ALK. PHOSPH.	20/10/90	65.0	306.0	NU/WL	213.00	247.00	204.00	163.00	214.00	235.00				
				BUN	20/10/90	10.0	50.0	MG/DL	30.00	28.00	24.00	26.00	20.00	18.00				
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.70	0.90	0.80	0.90	0.90	0.80				
				URIC ACID	20/10/90	2.4	5.7	MG/DL	4.30	4.20	3.90	3.90	3.00	2.90				
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.50	0.60	0.50	0.40	0.40	0.30				
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.30	0.20	0.20	0.20	0.20				
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.30	7.20	7.40	7.50	7.20	7.20				
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.00	4.31	4.20	4.00	3.70				
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	187.00	183.00	200.00	193.00	182.00	164.00				
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	89.00	97.00	98.00	95.00	96.00	113.00				
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	g	2.10	3.00	1.90	3.50	1.60	2.00				
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	g	6.30	6.60	5.40	6.20	8.00	8.10				
				GLOBULINS: BETA	20/10/90	11.0	14.0	g	11.40	11.00	12.40	13.60	12.50	14.20				
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	g	23.50	22.50	22.10	22.50	21.40	24.70				
				52-316	F			HB	20/10/90	12.0	16.0	G/100ML	12.80	13.00	13.10	14.20	13.50	14.00
								HTC	20/10/90	37.0	47.0	g	40.00	40.00	41.00	42.00	40.00	41.00
								RBC	20/10/90	3.8	5.4	10 ⁶ -c/MNC	4.80	4.70	4.90	4.80	4.50	5.00
								HBC	20/10/90	4.0	11.0	10 ³ -MNC	6.40	6.10	6.60	6.00	6.00	6.00
								HBC: N	20/10/90	40.0	70.0	g	58.00	57.00	60.00	62.00	59.00	61.00
								HBC: L	20/10/90	20.0	40.0	g	38.00	30.00	33.00	31.00	30.00	28.00
HBC: E	20/10/90	1.0	5.0					g	1.00	6.00	1.00	1.00	3.00	3.00				
HBC: M	20/10/90	4.0	8.0					g	3.00	7.00	6.00	6.00	8.00	8.00				
HBC: B	20/10/90	0.0	1.0					g	0.00	0.00	0.00	0.00	0.00	0.00				
PLATELETS	20/10/90	150.0	550.0					10 ³ -MNC	336.00	310.00	272.00	281.00	215.00	264.00				
NA+	20/10/90	138.0	155.0					M EQ/L	139.00	138.00	138.00	139.00	142.00	141.00				
K+	20/10/90	3.5	5.5					M EQ/L	4.70	4.60	4.70	4.40	4.10	4.20				
CL-	20/10/90	8.5	10.5					MG/DL	9.80	9.60	9.60	9.20	9.90	95.00				
CA++	20/10/90	3.0	4.5					MG/DL	3.70	3.50	3.50	3.60	4.00	4.20				
PD4-	20/10/90	12.0	40.0					NU/ML	24.00	26.00	20.00	18.00	18.00	20.00				
SGPT	20/10/90	10.0	40.0					NU/ML	28.00	28.00	18.00	20.00	22.00	24.00				
SGPT	20/10/90	7.0	33.0					NU/ML	51.00	40.00	38.00	36.00	26.00	32.00				
GAMMA-GT	20/10/90	70.0	100.0					MG/DL	91.00	82.00	85.00	90.00	91.00	93.00				
GLUCOSE	20/10/90	65.0	306.0					MG/DL	207.00	262.00	209.00	210.00	163.00	115.00				
ALK. PHOSPH.	20/10/90	10.0	50.0					MG/DL	29.00	25.00	26.00	28.00	30.00	31.00				
BUN	20/10/90	0.6	1.6	MG/DL	1.00	0.90	0.80	0.90	0.90	0.90								
CREATININE	20/10/90	2.4	5.7	MG/DL	4.30	4.40	3.80	3.80	4.10	4.20								
URIC ACID	20/10/90	0.2	1.0	MG/DL	0.60	0.70	0.60	0.40	0.80	0.70								
TOT BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.30	0.20	0.20	0.40	0.30								
DIR BILIRUBIN	20/10/90	6.0	8.0	G/DL	7.30	7.40	7.00	7.00	6.90	7.00								
TOT. PROTEINS	20/10/90	3.5	5.0	G/DL	4.40	4.30	4.42	4.50	3.90	3.90								
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.40	4.30	4.42	4.50	3.90	3.90								

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1 8 8 3

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit							
				Date	Min	Max Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52		
1	52-316	F	TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	184.00	169.00	187.00	188.00	212.00	260.00	
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	71.00	66.00	90.00	63.00	65.00	93.00	
			GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	1.50	1.80	2.40	2.40	3.20	4.00	
			GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	6.20	6.00	7.30	8.00	8.10	6.30	
			GLOBULINS: BETA	20/10/90	11.0	14.0	%	8.60	9.10	11.30	12.10	12.00	12.90	
			GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	18.00	18.30	15.90	15.20	17.90	21.20	
			HB	14/01/92			14.0 G/100ML							
			HTC	20/10/90	12.0	47.0	%	37.00						
			RBC	20/10/90	3.8	5.4	10 ⁶ -6/MIC	4.20						
			MBC	20/10/90	4.0	11.0	10 ³ -3/MIC	6.10						
MBC: N	20/10/90	40.0	70.0	%	60.00									
MBC: L	20/10/90	20.0	40.0	%	30.00									
MBC: E	20/10/90	1.0	5.0	%	3.00									
MBC: M	20/10/90	4.0	8.0	%	7.00									
MBC: B	20/10/90	0.0	1.0	%	0.00									
PLATELETS	20/10/90	150.0	550.0	10 ³ -3/MIC	221.00									
NA+	20/10/90	138.0	155.0	M EQ/L	136.00									
K+	20/10/90	3.5	5.5	M EQ/L	4.10									
CL-	20/10/90	98.0	120.0	M EQ/L	97.00									
CA++	20/10/90	8.5	10.5	MG/DL	10.30									
PO4-	20/10/90	3.0	4.5	MG/DL	3.20									
SGOT	20/10/90	12.0	40.0	IU/ML	42.00									
SGPT	20/10/90	10.0	40.0	IU/ML	44.00									
GAMMA-GT	20/10/90	7.0	33.0	IU/ML	29.00									
GLUCOSE	20/10/90	70.0	100.0	MG/DL	143.00									
ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	292.00									
RUN	20/10/90	10.0	50.0	MG/DL	32.00									
CREATININE	20/10/90	0.6	1.6	MG/DL	1.10									
URIC ACID	20/10/90	2.4	5.7	MG/DL	4.80									
TOT. BILIRUBIN	20/10/90	0.2	1.0	MG/DL	1.10									
DIR. BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.50									
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.30									
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.00									
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	278.00									
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	164.00									
GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	3.00									
GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	10.20									
GLOBULINS: BETA	20/10/90	11.0	14.0	%	8.10									
GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	23.10									

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1822

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

9550077

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range		Visit												
					Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52						
1	58-320		F																
				HB	20/10/90	12.0	16.0	G/100ML	18/02/92										
				HTC	20/10/90	37.0	47.0	%	12.30										
				RBC	20/10/90	3.8	5.4	10 ⁶ -6/MNC	37.00										
				WBC	20/10/90	4.0	11.0	10 ³ -3/MNC	3.80										
				HBC: N	20/10/90	40.0	70.0	%	5.30										
				HBC: L	20/10/90	20.0	40.0	%	61.00										
				HBC: E	20/10/90	1.0	5.0	%	0.00										
				HBC: M	20/10/90	4.0	8.0	%	9.00										
				HBC: R	20/10/90	0.0	1.0	%	0.00										
				PLATELETS	20/10/90	150.0	550.0	10 ³ -3/MNC	164.00										
				NA+	20/10/90	138.0	155.0	M EQ/L	139.00										
				K+	20/10/90	3.5	5.5	M EQ/L	3.80										
				Cl-	20/10/90	98.0	120.0	M EQ/L	97.00										
				Ca++	20/10/90	8.5	10.5	MG/DL	8.40										
				PO4-	20/10/90	3.0	4.5	MG/DL	3.50										
				SGPT	20/10/90	12.0	40.0	MG/DL	45.00										
				SGPT	20/10/90	10.0	40.0	MG/DL	32.00										
				GAMMA-GT	20/10/90	7.0	33.0	MG/DL	25.00										
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	112.00										
				ALK. PHOSPH.	20/10/90	65.0	306.0	MG/DL	158.00										
				BUN	20/10/90	10.0	50.0	MG/DL	27.00										
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.80										
				URIC ACID	20/10/90	2.4	5.7	MG/DL	3.40										
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.40										
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20										
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.30										
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20										
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	138.00										
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	98.00										
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	2.70										
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	9.10										
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	10.30										
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	14.80										
61-323			F	HB	20/10/90	12.0	16.0	G/100ML	18/02/92	24/04/92	19/06/92	14/08/92	09/10/92	18/12/92					
				HTC	20/10/90	37.0	47.0	%	14.20	14.30	14.70	14.40	15.00	14.90					
				RBC	20/10/90	3.8	5.4	10 ⁶ -6/MNC	44.00	43.00	45.00	44.00	46.00	45.00					
				WBC	20/10/90	4.0	11.0	10 ³ -3/MNC	5.40	5.20	5.60	5.50	5.50	5.60					
				HBC: N	20/10/90	4.0	11.0	10 ³ -3/MNC	5.90	5.00	5.50	4.90	6.10	6.00					
				HBC: L	20/10/90	40.0	70.0	%	58.00	60.00	59.00	61.00	60.00	62.00					
				HBC: E	20/10/90	20.0	40.0	%	27.00	27.00	26.00	27.00	27.00	27.00					
				HBC: M	20/10/90	1.0	5.0	%	4.00	5.00	5.00	5.00	3.00	7.00					

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1830

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit						
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
1	61-323	F		WBC: M	20/10/90	4.0	8.0	Z	11.00	8.00	7.00	8.00	10.00	8.00
				WBC: B	20/10/90	0.0	1.0	Z	0.00	0.00	0.00	0.00	0.00	0.00
				PLATELETS	20/10/90	150.0	550.0	10-3/MNC	295.00	286.00	312.00	320.00	310.00	346.00
				NA+	20/10/90	138.0	155.0	M EQ/L	139.00	141.00	138.00	139.00	142.00	141.00
				K+	20/10/90	3.5	5.5	M EQ/L	4.10	4.20	4.60	4.40	4.30	4.40
				CL-	20/10/90	98.0	120.0	M EQ/L	97.00	96.00	97.00	98.00	96.00	95.00
				CA++	20/10/90	8.5	10.5	MG/DL	10.30	10.20	9.80	9.40	8.60	8.40
				PO4--	20/10/90	3.0	4.5	MG/DL	3.90	4.00	4.20	4.30	3.20	3.10
				SCOT	20/10/90	12.0	60.0	MU/ML	17.00	16.00	30.00	20.00	22.00	21.00
				SEPT	20/10/90	10.0	40.0	MU/ML	20.00	22.00	19.00	19.00	18.00	17.00
				GAMMA-GT	20/10/90	7.0	33.0	MU/ML	25.00	17.00	17.00	18.00	18.00	16.00
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	94.00	55.00	108.00	93.00	93.00	99.00
				ALK. PHOSPH.	20/10/90	65.0	306.0	MU/AL	239.00	270.00	289.00	274.00	245.00	289.00
				BUN	20/10/90	10.0	30.0	MG/DL	35.00	31.00	32.00	34.00	23.00	21.00
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.70	0.80	0.80	0.80	0.80	0.70
				URIC ACID	20/10/90	2.4	5.7	MG/DL	4.00	3.70	3.70	3.60	2.80	2.90
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.50	0.50	0.40	0.50	0.60	0.50
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.20	0.20	0.20	0.30	0.30
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.40	7.40	7.30	7.20	6.40	6.30
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.30	4.20	4.40	4.60	3.50	3.40
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	241.00	233.00	268.00	254.00	194.00	200.00
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	122.00	126.00	142.00	124.00	142.00	157.00
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	Z	3.40	3.20	1.30	1.30	3.00	2.90
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	Z	12.00	12.00	7.00	6.50	7.40	8.20
				GLOBULINS: BETA	20/10/90	11.0	14.0	Z	9.30	9.40	12.00	11.80	14.10	13.80
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	Z	21.40	20.60	19.40	19.80	20.80	21.20
66-336		F		HB	20/10/90	12.0	16.0	G/100ML	13.90	14.20	12.60	12.80	13.70	12.30
				HTC	20/10/90	37.0	47.0	Z	41.00	41.00	36.00	37.00	37.00	36.00
				ERC	20/10/90	3.8	5.4	10-6/MNC	4.70	4.70	3.90	4.00	4.10	3.80
				WBC	20/10/90	4.0	11.0	10-3/MNC	5.40	5.80	7.00	6.30	5.20	10.20
				WBC: N	20/10/90	40.0	70.0	Z	60.00	58.00	69.00	67.00	62.00	69.00
				WBC: L	20/10/90	20.0	40.0	Z	27.00	30.00	24.00	26.00	30.00	24.00
				WBC: E	20/10/90	1.0	5.0	Z	5.00	3.00	2.00	2.00	2.00	2.00
				WBC: M	20/10/90	4.0	8.0	Z	8.00	9.00	5.00	5.00	6.00	5.00
				WBC: B	20/10/90	0.0	1.0	Z	0.00	0.00	0.00	0.00	0.00	0.00
				PLATELETS	20/10/90	150.0	550.0	10-3/MNC	253.00	266.00	305.00	274.00	245.00	226.00
				NA+	20/10/90	138.0	155.0	M EQ/L	137.00	139.00	140.00	142.00	142.00	138.00
				K+	20/10/90	3.5	5.5	M EQ/L	4.30	4.10	3.90	4.30	4.30	4.60
				CL-	20/10/90	98.0	120.0	M EQ/L	97.00	96.00	97.00	98.00	96.00	96.00
				CA++	20/10/90	8.5	10.5	MG/DL	9.00	9.10	9.70	9.50	8.00	8.50
				PO4--	20/10/90	3.0	4.5	MG/DL	3.90	3.20	3.70	3.60	3.90	2.90

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit						
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
1	66-326	F		SGOT	20/10/90	12.0	40.0	IU/ML	13.00	20.00	23.00	25.00	16.00	15.00
				SGPT	20/10/90	10.0	40.0	IU/ML	12.00	18.00	12.00	18.00	18.00	18.00
100	326	F		GAMMA-GT	20/10/90	7.0	33.0	IU/ML	16.00	31.00	17.00	15.00	15.00	13.00
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	104.00	97.00	95.00	92.00	97.00	77.00
20	326	F		ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	122.00	131.00	178.00	153.00	196.00	156.00
				BUN	20/10/90	10.0	50.0	MG/DL	36.00	34.00	30.00	28.00	34.00	26.00
20	326	F		CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	0.90	1.00	1.00	1.00	0.60
				URIC ACID	20/10/90	2.4	5.7	MG/DL	5.30	4.60	2.90	2.70	4.30	2.70
20	326	F		TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.40	0.40	0.30	0.40	0.60	0.40
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.20	0.10	0.20	0.30	0.20
20	326	F		TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.50	7.60	7.30	7.30	7.00	6.50
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.30	4.00	3.90	3.80	3.60
20	326	F		TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	138.00	130.00	138.00	152.00	145.00	137.00
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	60.00	67.00	58.00	63.00	61.00	56.00
20	326	F		GLUCURILINS: ALPHA1	20/10/90	4.0	7.0	X	2.20	2.30	3.30	3.10	2.50	
				GLUCURILINS: BETA	20/10/90	7.0	11.0	X	8.10	9.50	8.10	8.50	8.60	8.40
20	326	F		GLUCURILINS: GAMMA	20/10/90	11.0	14.0	X	10.40	11.20	12.80	12.60	12.70	12.50
				GLUCURILINS: BETA	20/10/90	15.0	22.0	X	17.00	18.00	21.10	22.00	21.50	21.30
71-329	F			HB	20/10/90	12.0	16.0	G/100ML	9.40	10.50	11.40	12.50	14.00	14.10
				HTC	20/10/90	37.0	47.0	X	30.00	33.00	33.00	36.00	41.00	41.00
100	329	F		RBC	20/10/90	3.8	5.4	10 ⁶ /MHC	3.80	4.10	4.10	4.20	4.70	4.80
				RBC: N	20/10/90	4.0	11.0	10 ⁶ /MHC	5.50	5.40	5.00	4.90	5.00	4.30
20	329	F		RBC: L	20/10/90	40.0	70.0	X	51.00	58.00	56.00	57.00	60.00	61.00
				RBC: E	20/10/90	20.0	40.0	X	34.00	32.00	34.00	30.00	28.00	30.00
20	329	F		RBC: B	20/10/90	1.0	5.0	X	5.00	3.00	4.00	4.00	3.00	2.00
				RBC: M	20/10/90	4.0	8.0	X	10.00	7.00	6.00	9.00	9.00	7.00
20	329	F		RBC: B	20/10/90	0.0	1.0	X	0.00	0.00	0.00	0.00	0.00	0.00
				RBC: M	20/10/90	150.0	550.0	10 ³ /MHC	352.00	249.00	315.00	323.00	283.00	280.00
20	329	F		PLATELETS	20/10/90	138.0	155.0	M EQ/L	140.00	141.00	138.00	139.00	144.00	142.00
				NA+	20/10/90	3.5	5.5	M EQ/L	4.00	4.20	4.50	4.60	4.30	4.30
20	329	F		CL-	20/10/90	98.0	120.0	M EQ/L	99.00	98.00	96.00	97.00	96.00	95.00
				CA++	20/10/90	8.5	10.5	MG/DL	8.40	8.30	9.90	10.50	9.50	9.60
20	329	F		PO4--	20/10/90	3.0	4.5	MG/DL	3.30	3.60	2.90	2.70	4.00	3.80
				SGPT	20/10/90	12.0	40.0	IU/ML	19.00	22.00	16.00	18.00	28.00	20.00
20	329	F		GAMMA-GT	20/10/90	10.0	40.0	IU/ML	21.00	25.00	20.00	20.00	22.00	24.00
				GLUCOSE	20/10/90	70.0	33.0	MG/ML	25.00	36.00	30.00	26.00	30.00	18.00
20	329	F		ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	152.00	161.00	103.00	96.00	102.00	94.00
				BUN	20/10/90	10.0	50.0	MG/DL	12.00	15.00	10.00	183.00	140.00	141.00
20	329	F		CREATININE	20/10/90	0.6	1.6	MG/DL	0.60	0.70	0.60	0.70	1.00	0.60
				URIC ACID	20/10/90	2.4	5.7	MG/DL	3.20	3.50	2.90	3.10	3.90	3.70

(*): MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXETINE - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 DOUBLE BLIND PHASE
 TREATMENT: REMOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Ranges			Visit										
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52				
1 71-329	F			TOT BILIRUBIN	20/10/90	0.2	1.0	NG/DL	0.50	0.50	0.40	0.30	0.90	0.80				
				DIR BILIRUBIN	20/10/90	0.0	0.4	NG/DL	0.20	0.20	0.20	0.10	0.50	0.40				
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.30	7.40	7.40	7.50	7.00	7.10				
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.07	4.10	4.10	4.20	3.80	3.90				
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	225.00	225.00	260.00	237.00	194.00	210.00				
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	108.00	99.00	114.00	128.00	91.00	86.00				
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	2.50	2.30	2.60	1.90	3.60	3.40				
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	7.50	7.00	8.20	8.40	8.20	7.50				
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	15.00	15.00	14.60	14.50	14.00	13.10				
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	19.30	18.30	19.10	19.00	19.90	21.10				
				72-330	M			HR	20/10/90	14.0	18.0	g/100ml	07/06/92	02/06/92				
								HTC	20/10/90	40.0	54.0	%	13.50	13.80				
								RBC	20/10/90	4.3	6.1	10 ⁶ *6/mm	4.60	4.60				
								RBC: N	20/10/90	4.0	11.0	10 ³ -S/MNC	5.80	5.80				
RBC: L	20/10/90	40.0	70.0					%	59.00	59.00								
RBC: E	20/10/90	20.0	40.0					%	30.00	30.00								
RBC: M	20/10/90	1.0	5.0					%	3.00	4.00								
RBC: B	20/10/90	4.0	8.0					%	8.00	8.00								
PLATELETS	20/10/90	0.0	1.0					%	0.00	0.00								
NA+	20/10/90	150.0	550.0					10 ³ -S/MNC	297.00	269.00								
K+	20/10/90	3.5	5.5					M EQ/L	141.00	138.00								
CL-	20/10/90	98.0	120.0					M EQ/L	96.00	97.00								
CA++	20/10/90	8.5	10.5					MG/DL	9.50	9.50								
PO4--	20/10/90	3.0	4.5					MG/DL	4.20	4.20								
SGPT	20/10/90	12.0	40.0	NU/HL	28.00	26.00												
GAMMA-GT	20/10/90	10.0	40.0	NU/HL	34.00	30.00												
GLUCOSE	20/10/90	70.0	51.0	MG/DL	22.00	22.00												
ALK. PROSPH.	20/10/90	65.0	306.0	NU/HL	161.00	143.00												
UREA	20/10/90	10.0	50.0	MG/DL	25.00	32.00												
CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	0.80												
URIC ACID	20/10/90	3.4	7.0	MG/DL	4.10	4.00												
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.80	0.60												
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.30												
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.30	7.40												
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	4.20												
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	179.00	156.00												
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	87.00	98.00												
GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	4.10	3.60												
GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	12.00	10.20												

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
1	72-330	M		GLOBALINS: BETA	20/10/90	11.0	14.0	%	9.70	8.60					
				GLOBALINS: GAMMA	20/10/90	15.0	22.0	%	20.10	19.50					
	73-121	F		HB	20/10/90	12.0	16.0	G/100ML	07/04/92	02/06/92	28/07/92				
				HTC	20/10/90	37.0	47.0	%	13.80	13.40	13.50				
				RBC	20/10/90	3.8	5.4	10 ⁶ -6/MNC	40.00	39.00	39.00				
				HBC: N	20/10/90	4.0	11.0	10 ⁶ -3/MNC	4.60	4.60	4.30				
				HBC: L	20/10/90	40.0	70.0	%	5.40	5.10	6.20				
				HBC: E	20/10/90	20.0	40.0	%	62.00	59.00	62.00				
				HBC: M	20/10/90	1.0	5.0	%	30.00	30.00	30.00				
				HBC: B	20/10/90	4.0	8.0	%	3.00	4.00	2.00				
				PLATELETS	20/10/90	0.0	1.0	%	5.00	7.00	6.00				
				NA+	20/10/90	150.0	550.0	10 ³ -3/MNC	265.00	243.00	282.00				
				CL-	20/10/90	138.0	155.0	M EQ/L	142.00	142.00	142.00				
				CA++	20/10/90	3.5	5.5	M EQ/L	4.10	3.90	4.10				
				PO4-	20/10/90	8.5	10.5	MG/DL	9.50	9.20	9.40				
				SGPT	20/10/90	12.0	40.0	RU/HL	4.00	4.00	3.50				
				GAMMA-GT	20/10/90	10.0	40.0	RU/HL	24.00	28.00	28.00				
				GLUCOSE	20/10/90	7.0	33.0	MG/DL	22.00	24.00	34.00				
				ALK. PHOSPH.	20/10/90	65.0	100.0	MG/DL	90.00	88.00	92.00				
				CREATININE	20/10/90	0.6	50.0	MG/DL	151.00	165.00	136.00				
				TOT BILIRUBIN	20/10/90	0.2	1.6	MG/DL	0.90	0.80	0.90				
				TOT. PROTEINS	20/10/90	6.0	5.7	MG/DL	4.10	3.50	3.30				
				TOT. CHOLEST.	20/10/90	3.5	1.0	MG/DL	0.70	0.80	0.50				
				TRIGLYCERIDES	20/10/90	140.0	4.0	MG/DL	0.30	0.40	0.20				
				GLOBULINS: ALPHA1	20/10/90	35.0	175.0	MG/DL	7.00	7.20	7.30				
				GLOBULINS: ALPHA2	20/10/90	7.0	7.0	%	3.90	4.00	4.10				
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	143.00	143.00	149.00				
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	90.00	84.00	99.00				
									2.60	2.60					
									8.10	8.10					
									13.40	13.40					
									19.60	19.60					
	75-123	F		HB	20/10/90	12.0	16.0	G/100ML	10/04/92	05/06/92	31/07/92	25/09/92	20/11/92	29/01/93	
				HTC	20/10/90	37.0	47.0	%	13.80	13.40	13.30	13.50	14.20	14.20	
				RBC	20/10/90	3.8	5.4	10 ⁶ -6/MNC	40.00	39.00	39.00	40.00	39.00	41.00	

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Date	Laboratory Range			Visit								
						Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52			
1	75-123	F		MBC	20/10/90	4.0	11.0	10 ⁻³ /HMC	4.40	5.00	5.70	6.00	5.50	5.90			
				MBC: N	20/10/90	40.0	70.0	Z	61.00	60.00	53.00	58.00	62.00	61.00			
				MBC: L	20/10/90	20.0	40.0	Z	32.00	31.00	39.00	40.00	30.00	28.00			
				MBC: E	20/10/90	1.0	5.0	Z	2.00	2.00	0.00	0.00	2.00	2.00			
				MBC: M	20/10/90	4.0	8.0	Z	5.00	7.00	8.00	2.00	6.00	9.00			
				MBC: B	20/10/90	0.0	1.0	Z	0.00	0.00	0.00	0.00	0.00	0.00			
				PLATELETS	20/10/90	150.0	550.0	10 ⁻³ /HMC	274.00	294.00	281.00	272.00	275.00	265.00			
				NA+	20/10/90	138.0	155.0	N EQ/L	141.00	141.00	141.00	142.00	142.00	141.00			
				CA+	20/10/90	98.0	120.0	N EQ/L	96.00	96.00	101.00	98.00	97.00	94.00			
				PO4+	20/10/90	3.0	4.5	MG/DL	4.10	4.20	4.40	4.10	4.20	4.30			
				SGPT	20/10/90	12.0	40.0	IU/ML	22.00	24.00	26.00	24.00	20.00	22.00			
				GAMMA-GT	20/10/90	10.0	40.0	IU/ML	28.00	30.00	27.00	28.00	26.00	18.00			
				GLUCOSE	20/10/90	70.0	33.0	IU/ML	28.00	40.00	40.00	43.00	18.00	26.00			
				ALK. PHOSPH.	20/10/90	65.0	400.0	IU/ML	103.00	96.00	96.00	92.00	94.00	97.00			
				CREATININE	20/10/90	10.0	50.0	MG/DL	30.00	30.00	23.00	27.00	30.00	32.00			
				TOT BILIRUBIN	20/10/90	0.6	1.6	MG/DL	0.90	1.00	0.90	0.80	0.90	1.00			
				DIR BILIRUBIN	20/10/90	2.4	5.7	MG/DL	4.10	3.60	3.70	3.80	4.60	4.30			
				TOT. PROTEINS	20/10/90	0.2	1.0	MG/DL	0.80	0.80	0.40	0.50	0.40	0.60			
				ALBUMINE	20/10/90	6.0	8.0	G/DL	7.30	7.40	6.90	7.00	7.20	7.10			
				TOT. CHOLEST.	20/10/90	3.5	5.0	G/DL	4.10	4.30	3.60	3.60	4.00	3.90			
				TRIGLYCERIDES	20/10/90	140.0	270.0	MG/DL	152.00	161.00	221.00	236.00	163.00	181.00			
				GLOBULINS: ALPHA1	20/10/90	35.0	175.0	MG/DL	86.00	89.00	142.00	121.00	49.00	63.00			
				GLOBULINS: ALPHA2	20/10/90	4.0	7.0	Z	2.30	2.50	0.70	1.00	2.80	3.00			
				GLOBULINS: BETA	20/10/90	7.0	11.0	Z	6.40	7.30	7.70	8.50	5.60	6.10			
				GLOBULINS: GAMMA	20/10/90	11.0	14.0	Z	12.30	13.20	15.10	16.50	11.80	12.30			
					20/10/90	15.0	22.0	Z	20.10	21.00	23.70	24.00	24.20	23.70			
				77-125	M		HB	20/10/90	14.0	18.0	g/100ml	13.50	14.10	14.20	13.80	13.60	
							HTC	20/10/90	40.0	54.0	Z	40.00	41.00	41.00	40.00	39.00	40.00
							PRC	20/10/90	4.3	6.1	10 ³ x6/mm	4.40	4.80	5.70	4.50	4.70	4.80
							MBC: N	20/10/90	4.0	11.0	10 ⁻³ /HMC	6.80	6.20	5.30	5.20	6.00	7.00
							MBC: L	20/10/90	40.0	70.0	Z	57.00	60.00	58.00	58.00	66.00	64.00
							MBC: E	20/10/90	20.0	40.0	Z	31.00	28.00	27.00	30.00	27.00	30.00
							MBC: M	20/10/90	1.0	5.0	Z	6.00	6.00	5.00	4.00	2.00	1.00
							MBC: B	20/10/90	4.0	8.0	Z	6.00	6.00	10.00	8.00	5.00	5.00
							PLATELETS	20/10/90	0.0	1.0	Z	0.00	0.00	0.00	0.00	0.00	0.00
NA+	20/10/90	150.0	550.0				10 ⁻³ /HMC	252.00	247.00	295.00	308.00	310.00	280.00				
	20/10/90	138.0	155.0				N EQ/L	141.00	139.00	142.00	143.00	142.00	142.00				

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1835

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD

REBOMETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOMETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
1	77-	125	M	K+	20/10/90	3.5	5.5	M	EQ/L	4.20	4.20	4.50	4.10	4.30	4.30
				CL-	20/10/90	98.0	120.0	M	EQ/L	98.00	97.00	99.00	97.00	97.00	98.00
1	83	67	F	CA++	20/10/90	8.5	10.5	MG/DL	9.50	9.60	9.30	9.20	9.50	9.00	
				PO4-	20/10/90	3.0	4.5	MG/DL	4.10	4.00	3.60	3.80	3.80	3.60	
1	83	67	F	SGOT	20/10/90	12.0	40.0	IU/ML	28.00	26.00	26.00	24.00	26.00	24.00	
				SGPT	20/10/90	10.0	40.0	IU/ML	32.00	28.00	28.00	28.00	30.00	30.00	
1	83	67	F	GAMMA-GT	20/10/90	11.0	51.0	IU/ML	38.00	22.00	18.00	30.00	28.00	26.00	
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	94.00	94.00	96.00	94.00	99.00	106.00	
1	83	67	F	ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	171.00	181.00	170.00	132.00	147.00	152.00	
				BUN	20/10/90	10.0	50.0	MG/DL	24.00	32.00	32.00	27.00	32.00	30.00	
1	83	67	F	CREATININE	20/10/90	0.6	1.6	MG/DL	1.00	1.00	0.80	0.70	0.90	0.90	
				URIC ACID	20/10/90	3.4	7.0	MG/DL	4.20	4.20	4.00	3.60	3.60	4.30	
1	83	67	F	TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	0.80	0.60	0.50	0.40	0.70	
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.40	0.20	0.20	0.20	0.30	
1	83	67	F	TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.20	7.00	7.30	7.20	7.00	7.20	
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	3.90	4.00	4.10	3.90	3.90	
1	83	67	F	TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	178.00	163.00	186.00	160.00	176.00	156.00	
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	96.00	102.00	83.00	72.00	96.00	94.00	
1	83	67	F	GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	3.20	3.00	4.10	3.40	3.00	3.00	
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	8.30	8.10	12.30	11.60	7.50	10.80	
1	83	67	F	GLOBULINS: BETA	20/10/90	11.0	14.0	%	13.00	11.90	9.70	9.50	12.80	11.40	
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	18.20	18.20	21.60	20.30	21.00	20.60	
1	81-	123	F	HB	20/10/90	12.0	16.0	G/100ML	13.10	13.20	13.20	14.10	14.20	14.20	
				HTC	20/10/90	37.0	47.0	%	38.00	40.00	39.00	42.00	41.00	41.00	
1	81-	123	F	RBC	20/10/90	3.8	5.4	10 ⁶ -MNC	4.40	4.80	4.60	4.90	4.80	4.80	
				WBC	20/10/90	4.0	11.0	10 ³ -MNC	6.10	5.50	5.20	5.20	5.50	6.00	
1	81-	123	F	WBC: N	20/10/90	40.0	70.0	%	59.00	59.00	61.00	62.00	63.00	62.00	
				WBC: L	20/10/90	20.0	40.0	%	30.00	30.00	28.00	30.00	26.00	30.00	
1	81-	123	F	WBC: E	20/10/90	1.0	5.0	%	3.00	3.00	3.00	2.00	3.00	2.00	
				WBC: M	20/10/90	4.0	8.0	%	8.00	8.00	8.00	6.00	8.00	6.00	
1	81-	123	F	WBC: B	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00	
				PLATELETS	20/10/90	150.0	550.0	10 ³ -MNC	210.00	250.00	310.00	316.00	265.00	259.00	
1	81-	123	F	NA+	20/10/90	138.0	155.0	M EQ/L	141.00	141.00	143.00	143.00	142.00	142.00	
				K+	20/10/90	3.5	5.5	M EQ/L	4.20	4.20	4.20	4.10	4.40	4.40	
1	81-	123	F	CL-	20/10/90	98.0	120.0	M EQ/L	93.00	96.00	97.00	99.00	97.00	98.00	
				CA++	20/10/90	8.5	10.5	MG/DL	9.40	9.70	9.40	9.30	9.00	9.20	
1	81-	123	F	PO4-	20/10/90	3.0	4.5	MG/DL	3.80	3.80	4.10	3.20	3.70	3.60	
				SGOT	20/10/90	12.0	40.0	IU/ML	24.00	28.00	26.00	24.00	24.00	28.00	
1	81-	123	F	SGPT	20/10/90	10.0	40.0	IU/ML	28.00	28.00	30.00	28.00	28.00	32.00	
				GAMMA-GT	20/10/90	10.0	40.0	IU/ML	28.00	28.00	30.00	28.00	28.00	24.00	
1	81-	123	F	GLUCOSE	20/10/90	70.0	100.0	MG/DL	94.00	94.00	96.00	94.00	99.00	106.00	
					20/10/90	7.0	33.0	IU/ML	32.00	30.00	22.00	18.00	20.00	24.00	
1	81-	123	F		20/10/90	70.0	100.0	MG/DL	86.00	92.00	91.00	94.00	105.00	90.00	

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre Open-Blind Sex	Laboratory test	Date	Laboratory Range		Visit												
				Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52						
1	81-128	F	ALK. PHOSPH.	20/10/90	65.0	306.0	MD/ML	140.00	143.00	124.00	143.00	136.00	143.00	143.00				
			BUN	20/10/90	10.0	50.0	MG/DL	28.00	26.00	26.00	26.00	26.00	32.00	32.00	32.00			
			CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	0.90	1.10	1.10	1.10	1.00	1.00	1.10			
			URIC ACID	20/10/90	2.4	5.7	MG/DL	4.10	4.00	3.80	4.10	3.70	3.70	4.10	5.00			
			TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.70	0.80	0.80	0.70	1.00	0.90	1.00	1.00			
			DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.40	0.40	0.40	0.40	0.40	0.50	0.50			
			TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.00	7.10	7.20	7.20	7.20	7.20	7.00	7.00			
			ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	4.00	4.00	4.10	3.90	3.90	3.80	3.80			
			TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	169.00	192.00	193.00	174.00	162.00	162.00	159.00	159.00			
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	107.00	88.00	90.00	61.00	86.00	86.00	73.00	73.00			
			GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	3.40	2.80	3.20	3.20	2.50	2.50	1.90	1.90			
			GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	3.60	10.40	6.10	6.90	12.00	12.00	13.10	13.10			
			GLOBULINS: BETA	20/10/90	11.0	14.0	%	11.70	12.10	13.00	13.50	9.00	9.00	7.50	7.50			
			GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	17.90	18.90	20.20	20.30	22.30	22.30	23.20	23.20			
			82-129	F	F	HB	20/10/90	12.0	16.0	G/100ML	13.80	13.40	14.20	13.60	14.30	14.00	14.00	
						HTC	20/10/90	37.0	47.0	%	40.00	39.00	41.00	40.00	41.00	41.00	40.00	40.00
						RBC	20/10/90	3.8	5.4	10 ⁶ -6/MNC	4.70	4.40	4.80	4.40	4.80	4.80	4.70	4.70
						HBC	20/10/90	4.0	11.0	10 ³ -3/MNC	4.90	4.40	5.50	4.70	6.60	6.60	6.20	6.20
						HBC: N	20/10/90	40.0	70.0	%	61.00	62.00	61.00	58.00	64.00	64.00	65.00	65.00
						HBC: L	20/10/90	20.0	40.0	%	32.00	31.00	28.00	30.00	24.00	24.00	27.00	27.00
HBC: E	20/10/90	1.0				5.0	%	2.00	2.00	3.00	2.00	3.00	3.00	2.00	2.00			
HBC: M	20/10/90	4.0				8.0	%	5.00	5.00	8.00	9.00	9.00	8.00	8.00	8.00			
HBC: B	20/10/90	0.0				1.0	%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
PLATELETS	20/10/90	150.0				550.0	10 ³ -3/MNC	217.00	228.00	318.00	301.00	270.00	270.00	300.00	300.00			
NA+	20/10/90	138.0				155.0	M EQ/L	143.00	142.00	142.00	142.00	142.00	142.00	140.00	140.00			
K+	20/10/90	3.5				5.5	M EQ/L	4.10	4.00	4.60	4.60	4.40	4.40	4.30	4.30			
CL-	20/10/90	98.0				120.0	M EQ/L	92.00	97.00	99.00	98.00	97.00	97.00	98.00	98.00			
CA++	20/10/90	8.5				10.5	MG/DL	9.60	9.00	9.20	10.10	9.50	9.50	9.50	9.50			
PO4-	20/10/90	3.0				4.5	MG/DL	4.10	3.60	3.50	3.40	4.10	4.10	4.80	4.80			
SODT	20/10/90	12.0				40.0	MU/ML	26.00	29.00	26.00	26.00	28.00	28.00	26.00	26.00			
SGPT	20/10/90	10.0				40.0	MU/ML	30.00	33.00	30.00	32.00	32.00	32.00	30.00	30.00			
GAMMA-GT	20/10/90	7.0				33.0	MU/ML	34.00	25.00	22.00	18.00	24.00	24.00	22.00	22.00			
GLUCOSE	20/10/90	70.0				100.0	MG/DL	92.00	91.00	91.00	86.00	90.00	90.00	93.00	93.00			
ALK. PHOSPH.	20/10/90	65.0				306.0	MD/ML	131.00	114.00	153.00	120.00	136.00	136.00	152.00	152.00			
BUN	20/10/90	10.0	50.0	MG/DL	27.00	28.00	32.00	30.00	34.00	34.00	32.00	32.00						
CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	0.90	0.80	0.90	0.80	0.80	0.80	0.80						
URIC ACID	20/10/90	2.4	5.7	MG/DL	3.20	3.80	3.60	3.60	4.30	4.30	4.30	4.30						
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.40	0.40	0.80	0.80	0.80	0.80	0.70	0.70						
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.20	0.40	0.40	0.40	0.40	0.40	0.40						
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.30	7.00	7.30	7.20	7.10	7.10	7.00	7.00						
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.10	4.00	4.00	4.00	4.00	3.80	3.80						

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit									
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52			
1 82-129	F		TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	143.00	152.00	166.00	163.00	129.00	155.00			
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	91.00	95.00	88.00	92.00	104.00	91.00			
			GLUCOLINS: ALPHA1	20/10/90	4.0	7.0	%	3.00	2.00	2.90	3.40	3.10	3.20			
			GLUCOLINS: ALPHA2	20/10/90	7.0	11.0	%	12.10	8.70	6.70	11.20	11.20	12.10			
			GLUCOLINS: BETA	20/10/90	11.0	16.0	%	8.70	9.50	15.10	14.20	7.00	8.00			
			GLUCOLINS: GAMMA	20/10/90	15.0	22.0	%	19.60	16.30	20.60	17.30	22.40	22.40			
			87-132	F		HB	28/10/90	12.0	16.0	G/100ML	17/06/92	12/06/92				
						HTC	28/10/90	37.0	47.0	%	33.00	37.00				
						RBC	28/10/90	3.8	5.4	10 ⁶ /M ³	4.50	4.40				
						WBC	28/10/90	4.0	11.0	10 ³ /M ³	5.40	6.10				
						MBC: N	20/10/90	40.0	70.0	%	58.00	63.00				
						MBC: L	20/10/90	20.0	40.0	%	30.00	28.00				
						MBC: E	20/10/90	1.0	5.0	%	5.00	3.00				
						MBC: M	20/10/90	4.0	8.0	%	7.00	6.00				
MBC: B	20/10/90	0.0				1.0	%	0.00	0.00							
PLATELETS	20/10/90	150.0				550.0	10 ³ /M ³	280.00	295.00							
NA+	20/10/90	138.0				155.0	M EQ/L	139.00	139.00							
K+	20/10/90	3.5				5.5	M EQ/L	4.00	4.10							
CL-	20/10/90	98.0				120.0	M EQ/L	98.00	97.00							
CA++	20/10/90	8.5				10.5	MG/DL	9.50	9.50							
PO4--	20/10/90	3.0	4.5	MG/DL	3.80	4.30										
SGOT	20/10/90	12.0	40.0	NU/ML	32.00	24.00										
SGPT	20/10/90	10.0	40.0	NU/ML	36.00	30.00										
GAMMA-GT	20/10/90	7.0	33.0	NU/ML	28.00	22.00										
GLUCOSE	20/10/90	70.0	100.0	MG/DL	84.00	97.00										
ALK. PHOSPH.	20/10/90	65.0	306.0	NU/ML	172.00	183.00										
SUN.	20/10/90	10.0	50.0	MG/DL	32.00	31.00										
CREATININE	20/10/90	0.6	1.6	MG/DL	1.00	0.90										
URIC ACID	20/10/90	2.4	5.7	MG/DL	4.30	3.80										
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.80	0.70										
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.30										
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.40	7.30										
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.30	4.20										
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	190.00	194.00										
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	88.00	66.00										
GLUCOLINS: ALPHA1	20/10/90	4.0	7.0	%	3.80	2.90										
GLUCOLINS: ALPHA2	20/10/90	7.0	11.0	%	10.20	12.10										
GLUCOLINS: BETA	20/10/90	11.0	14.0	%	14.10	9.30										
GLUCOLINS: GAMMA	20/10/90	15.0	22.0	%	17.80	19.60										

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Date	Laboratory Range			Visit											
						Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52						
1 89-133			F																	
				HB	20/10/90	12.0	16.0	G/100ML	20/04/92											
				HTC	20/10/90	37.0	47.0	X	13.50											
				RBC	20/10/90	3.8	5.4	10 ⁶ -6/MMC	40.00											
				HBC	20/10/90	4.0	11.0	10 ³ -3/MHC	4.50											
				HBC: N	20/10/90	40.0	70.0	X	61.00											
				HBC: L	20/10/90	20.0	40.0	X	30.00											
				HBC: E	20/10/90	1.0	5.0	X	2.00											
				HBC: M	20/10/90	4.0	8.0	X	7.00											
				HBC: B	20/10/90	0.0	1.0	X	0.00											
				PLATELETS	20/10/90	150.0	550.0	10 ³ -3/MHC	241.00											
				Na+	20/10/90	138.0	165.0	M EQ/L	139.00											
				K+	20/10/90	3.5	5.5	M EQ/L	4.70											
				Cl-	20/10/90	98.0	120.0	M EQ/L	98.00											
				Ca++	20/10/90	8.5	10.5	MG/DL	9.50											
				PO4--	20/10/90	3.0	4.5	MG/DL	4.00											
				SOD	20/10/90	12.0	40.0	RU/RL	26.00											
				GAMMA-GT	20/10/90	10.0	40.0	RU/RL	30.00											
				GLUCOSE	20/10/90	7.0	33.0	MG/DL	24.00											
				ALK. PHOSPH.	20/10/90	65.0	306.0	RU/ML	98.00											
				BUN	20/10/90	10.0	50.0	MG/DL	216.00											
				CREATININE	20/10/90	0.6	1.6	MG/DL	1.10											
				URIC ACID	20/10/90	2.4	5.7	MG/DL	4.50											
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	1.20											
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.60											
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.40											
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.60											
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	271.00											
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	147.00											
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	X	4.20											
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	X	8.30											
				GLOBULINS: BETA	20/10/90	11.0	14.0	X	12.70											
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	X	19.10											
95-138			F																	
				HB	20/10/90	12.0	16.0	G/100ML	22/06/92	17/06/92	12/08/92	07/10/92	02/12/92	10/02/93						
				HTC	20/10/90	37.0	47.0	X	14.20	13.90	12.90	12.90	13.80	13.80						
				RBC	20/10/90	3.8	5.4	10 ⁶ -6/MHC	42.00	41.00	37.00	37.00	39.00	40.00						
				HBC	20/10/90	4.0	11.0	10 ³ -3/MHC	4.70	4.20	4.50	4.40	4.60	4.80						
				HBC: N	20/10/90	40.0	70.0	X	6.00	5.80	8.30	8.30	7.20	6.40						
				HBC: L	20/10/90	20.0	40.0	X	61.00	60.00	65.00	62.00	63.00	61.00						
				HBC: E	20/10/90	1.0	5.0	X	32.00	32.00	28.00	28.00	27.00	29.00						
				HBC: M	20/10/90	4.0	8.0	X	2.00	3.00	3.00	2.00	1.00	2.00						

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
1	95-138	F		HBC: M	20/10/90	4.0	8.0	%	5.00	5.00	6.00	8.00	9.00	8.00	8.00
				HBC: B	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				PLATELETS	20/10/90	150.0	550.0	10 ³ /HMC	270.00	311.00	266.00	309.00	284.00	266.00	266.00
				Na+	20/10/90	138.0	155.0	M EQ/L	138.00	138.00	142.00	143.00	142.00	142.00	142.00
				K+	20/10/90	3.5	5.5	M EQ/L	4.00	4.20	4.20	4.30	4.30	4.20	4.40
				CL-	20/10/90	98.0	120.0	M EQ/L	90.00	102.00	101.00	99.00	97.00	97.00	97.00
				CA++	20/10/90	8.5	10.5	MG/DL	9.50	9.50	9.60	9.60	9.50	9.40	9.40
				PO4--	20/10/90	3.0	4.5	MG/DL	3.80	4.20	4.20	4.00	4.00	3.70	3.70
				SGOT	20/10/90	12.0	40.0	NIU/ML	20.00	20.00	28.00	28.00	32.00	28.00	28.00
				SGPT	20/10/90	10.0	40.0	NIU/ML	28.00	26.00	36.00	34.00	36.00	34.00	34.00
				GAMMA-GT	20/10/90	7.0	33.0	NIU/ML	34.00	33.00	22.00	22.00	24.00	26.00	26.00
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	82.00	90.00	106.00	94.00	89.00	90.00	90.00
				ALK. PHOSPH.	20/10/90	65.0	306.0	NIU/ML	178.00	146.00	137.00	176.00	153.00	143.00	143.00
				BUN	20/10/90	10.0	50.0	MG/DL	28.00	27.00	32.00	31.00	28.00	30.00	30.00
				CREATININE	20/10/90	0.6	1.6	MG/DL	1.00	0.80	0.80	0.80	1.00	0.80	0.80
				URIC ACID	20/10/90	2.4	5.7	MG/DL	4.10	3.70	3.60	3.60	3.90	4.10	4.10
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.90	0.60	0.40	0.60	0.80	0.70	0.70
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.30	0.20	0.30	0.40	0.30	0.30
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.40	7.00	7.00	7.10	7.30	7.00	7.00
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.10	3.90	4.00	4.00	3.90	3.90
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	123.00	160.00	176.00	193.00	186.00	175.00	175.00
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	92.00	102.00	80.00	86.00	93.00	88.00	88.00
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	3.00	3.00	3.60	3.60	2.80	3.10	3.10
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	12.10	10.20	8.10	7.60	7.50	8.40	8.40
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	9.10	9.10	12.60	13.70	11.50	12.20	12.20
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	21.20	21.50	20.30	20.20	23.40	20.60	20.60

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
96-139		F		HB	20/10/90	14.0	18.0	g/100ml	13.00	13.50	13.90	13.90	13.50	13.60	13.60
				HCT	20/10/90	40.0	54.0	%	37.00	38.00	40.00	41.00	38.00	39.00	39.00
				RBC	20/10/90	4.3	6.1	10 ⁶ /mm ³	4.40	4.60	4.70	5.00	4.70	4.80	4.80
				WBC	20/10/90	4.0	11.0	10 ³ /HMC	5.50	6.00	4.90	6.20	6.00	6.00	6.00
				NRC: N	20/10/90	40.0	70.0	%	62.00	59.00	62.00	60.00	62.00	61.00	61.00
				NRC: L	20/10/90	20.0	40.0	%	32.00	30.00	26.00	28.00	27.00	28.00	28.00
				NRC: E	20/10/90	1.0	5.0	%	2.60	4.00	3.00	2.00	3.00	2.00	2.00
				NRC: M	20/10/90	4.0	8.0	%	4.00	7.00	9.00	10.00	8.00	9.00	9.00
				NRC: B	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				PLATELETS	20/10/90	150.0	550.0	10 ³ /HMC	193.00	253.00	310.00	308.00	280.00	282.00	282.00
				Na+	20/10/90	138.0	155.0	M EQ/L	138.00	142.00	142.00	143.00	143.00	143.00	142.00
				K+	20/10/90	3.5	5.5	M EQ/L	4.20	4.00	4.30	4.10	4.40	4.30	4.30
				CL-	20/10/90	98.0	120.0	M EQ/L	98.00	102.00	97.00	90.00	96.00	97.00	97.00
				CA++	20/10/90	8.5	10.5	MG/DL	9.00	9.30	9.50	9.30	9.80	9.40	9.40
				PO4--	20/10/90	3.0	4.5	MG/DL	3.90	4.00	3.80	3.80	3.80	3.80	3.80

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1840

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit									
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52			
1 96-139	M			SGOT	20/10/90	12.0	40.0	U/ML	26.00	28.00	20.00	24.00	27.00	26.00			
				SGPT	20/10/90	10.0	40.0	U/ML	30.00	30.00	24.00	28.00	33.00	30.00			
				GAMMA-GT	20/10/90	11.0	51.0	U/ML	42.00	22.00	19.00	21.00	24.00	22.00			
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	99.00	94.00	94.00	94.00	90.00	90.00			
				ALK. PHOSPH.	20/10/90	65.0	306.0	U/ML	152.00	161.00	138.00	147.00	162.00	141.00			
				BUN	20/10/90	10.0	50.0	MG/DL	30.00	26.00	30.00	26.00	33.00	29.00			
				CREATININE	20/10/90	0.6	1.5	MG/DL	0.80	0.80	0.90	0.90	1.00	1.00			
				URIC ACID	20/10/90	3.4	7.0	MG/DL	4.30	3.50	4.20	4.20	4.20	4.00			
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	1.00	0.80	0.60	0.50	0.60	0.70			
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.50	0.40	0.30	0.20	0.30	0.30			
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.10	7.40	7.20	7.20	7.00	7.00			
				ALBUMINE	20/10/90	3.5	5.0	G/DL	3.90	4.20	4.00	3.90	4.00	4.10			
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	151.00	142.00	186.00	176.00	172.00	190.00			
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	107.00	92.00	102.00	82.00	90.00	91.00			
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	4.10	3.20	4.00	4.00	3.10	3.00			
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	8.10	10.40	8.10	9.20	7.40	7.50			
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	13.10	13.10	12.00	13.10	12.50	13.10			
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	19.30	20.10	22.50	20.60	19.90	17.80			
				98-141	F			HB	20/10/90	12.0	16.0	G/100ML	13.50	14.00	14.10	13.80	13.40
								HCT	20/10/90	37.0	47.0	%	37.00	41.00	41.00	39.00	37.00
RBC	20/10/90	3.8	5.4					10 ⁶ /MHC	4.60	4.60	4.80	4.40	4.50	4.40			
WBC	20/10/90	4.0	11.0					10 ³ /MHC	6.90	5.70	6.20	5.80	6.10	5.80			
WBC: N	20/10/90	40.0	70.0					%	63.00	60.00	74.00	63.00	60.00	61.00			
WBC: L	20/10/90	20.0	40.0					%	26.00	28.00	20.00	28.00	28.00	32.00			
WBC: E	20/10/90	1.0	5.0					%	4.00	4.00	1.00	2.00	2.00	2.00			
WBC: M	20/10/90	4.0	8.0					%	7.00	8.00	5.00	7.00	10.00	5.00			
WBC: B	20/10/90	0.0	1.0					%	0.00	0.00	0.00	0.00	0.00	0.00			
PLATELETS	20/10/90	150.0	550.0					10 ³ /MHC	318.00	316.00	280.00	254.00	245.00	286.00			
NA+	20/10/90	138.0	155.0					M EQ/L	142.00	141.00	142.00	142.00	140.00	144.00			
K+	20/10/90	3.5	5.5					M EQ/L	3.90	3.90	4.50	4.30	4.20	4.30			
Ca++	20/10/90	98.0	120.0					M EQ/L	101.00	97.00	97.00	99.00	95.00	96.00			
CL-	20/10/90	8.5	10.5					MG/DL	9.50	9.50	9.50	10.20	9.30	9.70			
PO4--	20/10/90	3.0	4.5					MG/DL	4.20	4.10	4.10	3.70	4.00	4.10			
SGOT	20/10/90	12.0	40.0					U/ML	28.00	26.00	22.00	28.00	20.00	26.00			
SGPT	20/10/90	10.0	40.0					U/ML	36.00	30.00	26.00	32.00	24.00	30.00			
GAMMA-GT	20/10/90	7.0	33.0					U/ML	42.00	22.00	20.00	20.00	18.00	24.00			
GLUCOSE	20/10/90	70.0	100.0					MG/DL	98.00	104.00	102.00	104.00	95.00	97.00			
ALK. PHOSPH.	20/10/90	65.0	306.0					U/ML	161.00	120.00	131.00	145.00	161.00	141.00			
BUN	20/10/90	10.0	50.0	MG/DL	28.00	31.00	29.00	31.00	28.00	28.00							
CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	0.90	0.80	0.90	0.80	0.90							
URIC ACID	20/10/90	2.4	5.7	MG/DL	3.70	3.70	5.10	4.50	3.60	4.10							

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

1041

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit									
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52			
1 98-141	F		TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.90	0.80	0.70	0.80	0.40	0.60			
			DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.40	0.30	0.40	0.20	0.30			
			TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.30	7.20	7.00	7.30	7.00	7.10			
			ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	4.10	3.90	4.00	3.80	4.00			
			TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	157.00	160.00	214.00	251.00	144.00	152.00			
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	41.00	62.00	93.00	90.00	96.00	97.00			
			GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	3.10	3.10	3.10	2.90	1.90	2.00			
			GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	7.30	9.50	8.60	9.10	6.30	7.30			
			GLOBULINS: BETA	20/10/90	11.0	14.0	%	12.80	12.30	13.40	13.50	13.80	14.10			
			GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	18.90	17.50	22.00	21.20	23.70	20.30			
			101-143	F		HTC	20/10/90	12.0	16.0	G/100ML	12.60	23/06/92	18/08/92	13/10/92	08/12/92	16/02/93
						HTC	20/10/90	37.0	47.0	%	38.00	38.00	37.00	37.00	41.00	40.00
						RBC	20/10/90	3.8	5.4	10 ⁶ /MM ³	3.90	4.10	4.30	4.30	4.30	4.20
						WBC	20/10/90	4.0	11.0	10 ³ /MM ³	7.70	7.20	5.80	6.80	7.00	7.30
						WBC: N	20/10/90	40.0	70.0	%	61.00	62.00	63.00	63.00	60.00	59.00
						WBC: L	20/10/90	20.0	40.0	%	30.00	29.00	28.00	27.00	30.00	32.00
						WBC: E	20/10/90	1.0	5.0	%	2.00	2.00	1.00	1.00	2.00	3.00
WBC: M	20/10/90	4.0				8.0	%	7.00	7.00	8.00	9.00	8.00	6.00			
WBC: B	20/10/90	0.0				1.0	%	0.00	0.00	0.00	0.00	0.00	0.00			
PLATELETS	20/10/90	150.0				550.0	10 ³ /MM ³	288.00	271.00	216.00	225.00	275.00	320.00			
Na+	20/10/90	138.0				155.0	MM EQ/L	139.00	138.00	142.00	143.00	141.00	140.00			
K+	20/10/90	3.5				5.5	MM EQ/L	3.70	3.80	4.30	4.20	4.30	4.00			
Cl-	20/10/90	98.0				120.0	MM EQ/L	95.00	96.00	97.00	98.00	96.00	96.00			
Ca++	20/10/90	8.5				10.5	MG/DL	9.20	9.30	9.30	9.30	9.40	9.20			
PO4--	20/10/90	3.0				4.5	MG/DL	4.00	4.20	4.00	4.00	4.00	3.50			
SGPT	20/10/90	12.0				40.0	NU/ML	24.00	26.00	26.00	26.00	18.00	19.00			
SGPT	20/10/90	10.0				40.0	NU/ML	15.00	28.00	30.00	30.00	12.00	13.00			
GAMMA-GT	20/10/90	7.0				33.0	NU/ML	19.00	32.00	27.00	22.00	20.00	17.00			
GLUCOSE	20/10/90	70.0				100.0	MG/DL	100.00	98.00	94.00	104.00	96.00	89.00			
ALK. PHOSPH.	20/10/90	65.0				306.0	NU/ML	150.00	152.00	126.00	136.00	161.00	161.00			
BUN	20/10/90	10.0				50.0	MG/DL	25.00	26.00	27.00	28.00	23.00	24.00			
CREATININE	20/10/90	0.6	1.6	MG/DL	0.70	0.80	0.80	0.90	1.00	1.00						
URIC ACID	20/10/90	2.4	5.7	MG/DL	3.30	4.00	3.40	3.40	2.80	2.20						
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.40	0.50	0.50	0.60	0.70	0.60						
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.20	0.30	0.30	0.30	0.30						
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	8.10	8.00	6.90	7.00	7.40	7.40						
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.99	4.90	3.80	3.90	4.20	3.70						
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	173.00	162.00	172.00	162.00	180.00	177.00						
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	74.00	83.00	102.00	93.00	91.00	80.00						
GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	1.90	2.00	3.90	4.00	3.10	3.10						
GLOBULINS: BETA	20/10/90	7.0	11.0	%	6.50	5.90	10.40	9.10	7.50	8.70						

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBONETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBONETINE

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range		Visit									
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52		
1	101-143	F	GLOBALINS: BETA	20/10/90	11.0	14.0	X	11.00	11.00	12.60	14.20	14.20	12.60	14.40	
			GLOBALINS: GAMMA	20/10/90	15.0	22.0	X	19.30	19.30	13.90	20.10	20.10	13.90	23.50	
107	147	F	HB	20/10/90	12.0	16.0	G/100ML	29/04/92	24/06/92	18/08/92	13/10/92	08/12/92	16/02/93	14.00	
			HTC	20/10/90	37.0	47.0	X	33.30	33.20	14.20	13.80	13.20	14.00	41.00	
			RBC	20/10/90	3.8	5.4	10-6/MHC	37.00	39.00	40.00	41.00	37.00	41.00	41.00	4.90
			WBC	20/10/90	4.0	11.0	10-3/MHC	4.00	4.60	4.60	4.50	4.50	4.50	5.00	5.00
			WBC: N	20/10/90	40.0	70.0	X	59.00	58.00	62.00	61.00	60.00	61.00	62.00	62.00
			WBC: L	20/10/90	20.0	40.0	X	29.00	30.00	27.00	30.00	28.00	30.00	27.00	27.00
			WBC: E	20/10/90	1.0	5.0	X	4.00	4.00	2.00	2.00	4.00	2.00	2.00	2.00
			WBC: M	20/10/90	4.0	8.0	X	8.00	8.00	9.00	7.00	8.00	8.00	9.00	9.00
			WBC: B	20/10/90	0.0	1.0	X	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
			PLATELETS	20/10/90	150.0	550.0	10-3/MHC	305.00	295.00	216.00	276.00	263.00	243.00	270.00	270.00
			NA+	20/10/90	138.0	155.0	M EQ/L	140.00	162.00	144.00	142.00	142.00	142.00	142.00	142.00
			K+	20/10/90	3.5	5.5	M EQ/L	4.10	4.10	4.30	4.30	4.30	4.50	4.30	4.30
			CL-	20/10/90	98.0	120.0	M EQ/L	101.00	102.00	98.00	97.00	98.00	98.00	95.00	95.00
			CA++	20/10/90	8.5	10.5	MG/DL	9.50	9.30	9.40	9.50	9.40	9.50	9.00	9.00
			PO4-	20/10/90	3.0	4.5	MG/DL	4.10	4.10	3.80	4.00	4.00	4.00	3.80	3.80
			SGOT	20/10/90	12.0	40.0	IU/ML	30.00	29.00	20.00	26.00	20.00	24.00	26.00	26.00
			SGPT	20/10/90	10.0	40.0	IU/ML	34.00	36.00	26.00	30.00	30.00	24.00	30.00	30.00
			GAMMA-GT	20/10/90	7.0	35.0	IU/ML	22.00	25.00	16.00	22.00	18.00	22.00	18.00	22.00
			GLUCOSE	20/10/90	70.0	100.0	MG/DL	91.00	86.00	94.00	102.00	90.00	90.00	90.00	90.00
			ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	134.00	116.00	138.00	154.00	102.00	155.00	127.00	127.00
RUN	20/10/90	10.0	50.0	MG/DL	26.00	29.00	32.00	32.00	32.00	32.00	28.00	28.00			
CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	0.90	0.90	0.90	0.90	0.90	0.90	0.90			
URIC ACID	20/10/90	2.4	5.7	MG/DL	4.10	3.50	4.10	3.40	3.40	3.80	4.10	4.10			
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.70	0.80	0.60	0.60	0.60	0.60	0.70	0.70			
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.40	0.30	0.30	0.30	0.30	0.30	0.30			
TOT PROTEINS	20/10/90	6.0	8.0	G/DL	7.00	7.00	7.40	7.20	7.20	7.00	7.20	7.20			
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	3.80	4.00	3.90	3.80	3.80	4.00	4.00			
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	150.00	159.00	176.00	195.00	175.00	175.00	194.00	194.00			
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	90.00	53.00	81.00	108.00	82.00	82.00	82.00	82.00			
GLOBULINS: ALPHA1	20/10/90	4.0	7.0	X	2.50	2.50	2.50	2.50	2.50	2.50	2.50	2.50			
GLOBULINS: ALPHA2	20/10/90	7.0	11.0	X	7.60	10.10	5.90	8.90	8.90	8.90	9.00	9.00			
GLOBULINS: BETA	20/10/90	11.0	14.0	X	14.80	14.70	12.60	14.60	14.60	13.80	13.60	13.60			
GLOBULINS: GAMMA	20/10/90	15.0	22.0	X	22.00	21.30	24.20	18.00	18.00	18.50	17.70	17.70			
109	149	F	HB	20/10/90	12.0	16.0	G/100ML	29/04/92	24/06/92	19/08/92	14/10/92	09/12/92	17/02/93	13.70	
			HTC	20/10/90	37.0	47.0	X	14.00	13.90	13.00	14.10	13.50	13.50	38.00	
			RBC	20/10/90	3.8	5.4	10-6/MHC	4.60	4.50	4.40	4.50	4.50	4.80	4.80	

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1843

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Date	Laboratory Range		Visit							
						Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
1	109-149	F		MBC	20/10/90	4.0	11.0	10-3/HMC	5.00	4.70	8.20	7.60	6.20	6.00	
				MBC: N	20/10/90	40.0	70.0	%	61.00	60.00	64.00	65.00	60.00	60.00	62.00
				MBC: L	20/10/90	20.0	40.0	%	26.00	31.00	27.00	25.00	27.00	25.00	28.00
				MBC: E	20/10/90	1.0	5.0	%	4.00	2.00	2.00	2.00	4.00	2.00	2.00
				MBC: H	20/10/90	4.0	8.0	%	9.00	7.00	7.00	8.00	9.00	8.00	8.00
				MBC: B	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				PLATELETS	20/10/90	150.0	550.0	10-3/HMC	310.00	305.00	265.00	314.00	285.00	275.00	275.00
				NA+	20/10/90	138.0	155.0	M EQ/L	142.00	142.00	143.00	144.00	142.00	141.00	141.00
				CL-	20/10/90	3.5	5.5	M EQ/L	4.10	4.20	4.50	4.30	4.00	4.40	4.40
				CA++	20/10/90	98.0	120.0	M EQ/L	103.00	103.00	98.00	95.00	95.00	97.00	97.00
				PO4-	20/10/90	3.0	4.5	MG/DL	4.10	4.40	4.30	4.10	4.20	4.00	4.00
				SCOT	20/10/90	12.0	40.0	HU/ML	26.00	28.00	26.00	32.00	16.00	24.00	24.00
				SEPT	20/10/90	10.0	40.0	HU/ML	30.00	36.00	30.00	34.00	18.00	28.00	28.00
				GAMMA-GT	20/10/90	7.0	39.0	HU/ML	22.00	24.00	22.00	28.00	14.00	20.00	20.00
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	82.00	100.00	102.00	104.00	101.00	90.00	90.00
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	143.00	156.00	150.00	137.00	180.00	160.00	160.00
				UREA	20/10/90	10.0	50.0	MG/DL	26.00	26.00	32.00	28.00	28.00	27.00	27.00
				CREATININE	20/10/90	0.6	1.6	MG/DL	1.00	1.00	0.90	0.80	0.90	0.80	0.80
				URIC ACID	20/10/90	2.4	5.7	MG/DL	3.30	4.20	3.30	4.30	3.50	3.90	3.90
				TOT BILLIRUBIN	20/10/90	0.2	1.0	MG/DL	0.70	0.80	0.60	0.60	0.90	0.80	0.80
				DIR BILLIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.40	0.30	0.40	0.50	0.40	0.40
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.30	7.00	7.60	7.50	6.90	6.90	6.90
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	3.90	4.20	3.90	3.80	3.80	3.80
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	144.00	183.00	162.00	252.00	161.00	151.00	151.00
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	92.00	76.00	74.00	65.00	85.00	75.00	75.00
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	2.30	2.80	4.00	4.10	3.20	3.60	3.60
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	7.10	11.50	13.20	8.80	6.00	9.00	9.00
GLOBULINS: BETA	20/10/90	11.0	14.0	%	10.20	9.00	8.90	15.00	13.50	14.10	14.10				
GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	19.50	20.20	18.60	20.10	22.20	18.20	18.20				
110-150	F		FB	20/10/90	12.0	16.0	G/100ML	13.00	13.00	13.60	13.60	13.80	13.90		
			HTC	20/10/90	37.0	47.0	%	38.00	37.00	38.00	38.00	40.00	41.00		
			RBC	20/10/90	3.8	5.4	10-6/HMC	4.30	4.30	4.30	4.50	4.60	4.70		
			MBC: N	20/10/90	4.0	11.0	10-3/HMC	5.10	4.90	5.00	6.40	5.80	5.00		
			MBC: L	20/10/90	40.0	70.0	%	60.00	61.00	61.00	62.00	61.00	62.00		
			MBC: E	20/10/90	20.0	40.0	%	27.00	31.00	28.00	28.00	27.00	30.00		
			MBC: B	20/10/90	1.0	5.0	%	6.00	3.00	2.00	2.00	3.00	3.00		
			MBC: H	20/10/90	4.0	8.0	%	7.00	6.00	9.00	8.00	9.00	6.00		
			MBC: B	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00		
			PLATELETS	20/10/90	150.0	550.0	10-3/HMC	286.00	316.00	343.00	279.00	257.00	250.00		
			NA+	20/10/90	138.0	155.0	M EQ/L	141.00	142.00	142.00	142.00	142.00	142.00		

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1844

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Sex	Lab. test	Laboratory Ranges			Visit									
			Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52			
1 110-150	F	K+	20/10/90	3.5	5.5	M EQ/L	3.90	4.20	4.30	4.50	4.30	4.30	4.40		
		CL-	20/10/90	98.0	120.0	M EQ/L	90.00	93.00	98.00	92.00	96.00	96.00	98.00		
		CA++	20/10/90	8.5	10.5	MG/DL	10.20	9.00	10.10	10.30	10.30	9.00	9.30		
		PO4-	20/10/90	3.0	4.5	MG/DL	3.70	4.00	4.20	4.20	3.20	4.20	4.10		
		SGOT	20/10/90	12.0	40.0	U/L	26.00	27.00	29.00	28.00	20.00	20.00	28.00		
		SGPT	20/10/90	10.0	40.0	U/L	28.00	32.00	34.00	34.00	24.00	24.00	26.00		
		GAMMA-GT	20/10/90	7.0	33.0	U/L	20.00	24.00	26.00	24.00	18.00	18.00	20.00		
		GLUCOSE	20/10/90	70.0	100.0	MG/DL	94.00	89.00	88.00	94.00	97.00	95.00	95.00		
		ALK. PHOSPH.	20/10/90	65.0	306.0	U/L	172.00	157.00	122.00	143.00	141.00	141.00	127.00		
		BUN	20/10/90	10.0	50.0	MG/DL	29.00	29.00	28.00	34.00	28.00	29.00	29.00		
		CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	0.80	0.90	0.90	1.20	1.00	1.00		
		URIC ACID	20/10/90	2.4	5.7	MG/DL	3.70	3.60	3.90	4.30	4.50	4.20	4.20		
		TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	0.60	0.80	0.60	0.70	0.60	0.60		
		DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.30	0.40	0.30	0.30	0.30	0.30		
		TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.00	7.10	7.30	7.60	7.00	7.10	7.10		
		ALBUMINE	20/10/90	3.5	5.0	G/DL	3.90	4.00	4.00	4.00	4.00	4.00	4.00		
		TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	132.00	191.00	181.00	225.00	166.00	166.00	184.00		
		TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	57.00	62.00	74.00	106.00	80.00	80.00	90.00		
		GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	2.00	2.30	2.80	4.20	3.00	3.20	3.20		
		GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	11.10	10.40	10.10	9.30	8.50	8.50	7.60		
		GLOBULINS: BETA	20/10/90	11.0	14.0	%	9.00	8.70	13.50	13.80	12.70	12.70	12.50		
		GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	21.30	20.30	18.80	20.10	18.70	18.70	20.40		
		116-334	F	HB	20/10/90	12.0	16.0	G/100ML	12.40	12.50	12.90	12.90	15/12/92	12.90	
				HTC	20/10/90	37.0	47.0	%	37.00	37.00	38.00	40.00	13.00	40.00	
				RBC	20/10/90	3.8	5.4	10 ⁶ /MNC	4.10	4.20	4.20	4.80	4.50	4.50	
				WBC	20/10/90	4.0	11.0	10 ³ /MNC	7.90	7.00	10.90	6.20	7.00	9.90	
				WBC: N	20/10/90	40.0	70.0	%	61.00	61.00	65.00	61.00	62.00	65.00	
WBC: L	20/10/90			20.0	40.0	%	21.00	23.00	17.00	29.00	26.00	18.00			
WBC: E	20/10/90			1.0	5.0	%	9.00	5.00	8.00	5.00	6.00	7.00			
WBC: K	20/10/90			4.0	8.0	%	9.00	10.00	10.00	5.00	6.00	10.00			
WBC: B	20/10/90			0.0	1.0	%	0.00	1.00	0.00	0.00	0.00	0.00			
PLATELETS	20/10/90			150.0	550.0	10 ³ /MNC	265.00	288.00	199.00	310.00	270.00	286.00			
HA+	20/10/90			138.0	155.0	M EQ/L	139.00	139.00	140.00	145.00	140.00	138.00			
K+	20/10/90			3.5	5.5	M EQ/L	3.60	3.90	4.00	4.20	4.30	4.40			
CL-	20/10/90			98.0	120.0	M EQ/L	95.00	96.00	104.00	98.00	97.00	96.00			
CA++	20/10/90			8.5	10.5	MG/DL	8.80	9.00	8.20	9.30	9.50	9.60			
PO4-	20/10/90			3.0	4.5	MG/DL	3.20	3.20	3.40	3.40	3.40	3.30			
SGOT	20/10/90	12.0	40.0	U/L	15.00	17.00	19.00	22.00	21.00	20.00					
SGPT	20/10/90	10.0	40.0	U/L	13.00	19.00	18.00	28.00	15.00	13.00					
GAMMA-GT	20/10/90	7.0	33.0	U/L	14.00	15.00	11.00	40.00	16.00	18.00					
GLUCOSE	20/10/90	70.0	100.0	MG/DL	91.00	94.00	102.00	94.00	80.00	75.00					

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit											
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52					
1116-334	F	1		ALK. PHOSPH.	20/10/90	65.0	306.0	KU/HL	191.00	163.00	181.00	143.00	154.00	162.00					
				BUN	20/10/90	10.0	50.0	MG/DL	19.00	20.00	17.00	31.00	16.00	15.00	15.00				
				CREATININE	20/10/90	0.6	1.6	MG/DL	1.10	1.00	0.70	1.10	0.80	0.70	0.70				
				URIC ACID	20/10/90	2.4	5.7	MG/DL	4.40	4.20	3.00	5.00	4.00	3.50	3.50				
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.30	0.40	0.30	0.30	0.40	0.40	0.40				
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.10	0.20	0.10	0.30	0.40	0.20	0.20				
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.80	6.90	6.90	7.00	7.20	7.10	7.10				
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.53	4.50	3.50	4.10	4.00	4.10	4.10				
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	186.00	190.00	158.00	250.00	175.00	184.00	184.00				
				TRIGLYCERIDES	20/10/90	38.0	175.0	MG/DL	56.00	72.00	39.00	90.00	40.00	41.00	41.00				
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	2.30	2.30	2.70	3.50	2.00	2.50	2.50				
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	6.50	6.00	9.10	8.00	6.50	7.40	7.40				
				GLOBULINS: BETA	20/10/90	11.0	44.0	%	8.50	8.40	13.10	12.80	12.80	12.50	12.50				
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	17.00	16.50	24.50	20.40	23.10	19.70	19.70				
				117-335	F			HB	20/10/90	12.0	16.0	G/100ML	13.80	30/06/92	26/08/92	21/10/92	15/12/92	24/02/93	
								HTC	20/10/90	37.0	47.0	%	41.00	40.00	43.00	41.00	41.00	43.00	43.00
								RBC	20/10/90	3.8	5.4	10 ⁶ /MM ³	4.90	4.80	5.00	4.90	4.80	5.20	5.10
								HBC	20/10/90	4.0	11.0	10 ³ /MM ³	6.00	6.20	6.50	6.30	6.00	6.10	6.10
								HBC: N	20/10/90	40.0	70.0	%	58.00	60.00	55.00	58.00	61.00	57.00	57.00
HBC: L	20/10/90	20.0	40.0					%	34.00	33.00	37.00	36.00	30.00	37.00	37.00				
HBC: E	20/10/90	1.0	5.0					%	2.00	2.00	2.00	2.00	2.00	1.00	1.00				
HBC: M	20/10/90	4.0	8.0					%	6.00	5.00	6.00	4.00	7.00	5.00	5.00				
HBC: B	20/10/90	0.0	1.0					%	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
PLATELETS	20/10/90	150.0	550.0					10 ³ /MM ³	268.00	290.00	318.00	324.00	256.00	285.00	285.00				
NA+	20/10/90	138.0	155.0					M EQ/L	139.00	139.00	141.00	142.00	142.00	140.00	140.00				
K+	20/10/90	3.5	5.5					M EQ/L	4.40	4.30	4.60	4.40	4.30	4.50	4.50				
CL-	20/10/90	98.0	120.0					M EQ/L	97.00	98.00	98.00	99.00	99.00	97.00	97.00				
CA++	20/10/90	8.5	10.5					MG/DL	9.60	9.50	9.90	9.70	9.90	10.00	10.00				
PO4--	20/10/90	3.0	4.5					MG/DL	3.40	4.10	3.90	4.00	4.00	3.80	3.80				
SGOT	20/10/90	12.0	40.0					U/ML	19.00	21.00	20.00	22.00	20.00	20.00	20.00				
SGPT	20/10/90	10.0	40.0					U/ML	17.00	18.00	15.00	16.00	16.00	15.00	15.00				
GAMMA-GT	20/10/90	7.0	33.0					U/ML	34.00	32.00	33.00	34.00	27.00	31.00	31.00				
GLUCOSE	20/10/90	70.0	100.0					MG/DL	110.00	106.00	127.00	114.00	112.00	110.00	110.00				
ALK. PHOSPH.	20/10/90	65.0	306.0					KU/HL	240.00	246.00	252.00	267.00	205.00	248.00	248.00				
BUN	20/10/90	10.0	50.0					MG/DL	28.00	28.00	29.00	30.00	40.00	42.00	42.00				
CREATININE	20/10/90	0.6	1.6	MG/DL	0.30	0.30	0.80	0.90	1.00	0.90	0.90								
URIC ACID	20/10/90	2.4	5.7	MG/DL	5.60	4.30	4.80	4.50	4.90	4.90	4.90								
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.50	0.40	0.30	0.30	0.60	0.60	0.60								
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.20	0.20	0.10	0.30	0.30	0.30								
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.40	7.50	7.00	7.00	7.90	8.00	8.00								
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.08	4.10	3.50	3.70	4.00	3.90	3.90								

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9481

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit									
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52			
1 117-335	F		TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	196.00	185.00	198.00	174.00	216.00	227.00			
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	68.00	70.00	90.00	85.00	90.00	87.00			
			GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	1.70	1.80	2.90	2.50	4.00	3.10			
			GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	5.40	5.60	7.50	7.20	8.20	7.40			
			GLOBULINS: BETA	20/10/90	11.0	14.0	%	13.20	12.40	14.60	13.00	14.50	15.60			
			GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	24.60	23.80	25.00	23.80	22.70	24.90			
			121-336	F		HB	20/10/90	12.0	16.0	G/100ML	14.10	13.90	13.00	13.20	15.00	14.80
						HTC	20/10/90	37.0	47.0	%	41.00	40.00	38.00	40.00	44.00	42.00
						RBC	20/10/90	3.8	5.4	10 ⁶ /MNC	4.50	4.60	4.30	4.50	4.90	4.70
						HBC	20/10/90	4.0	11.0	10 ³ /MNC	6.10	5.80	6.10	5.20	4.50	4.80
						HBC: N	20/10/90	40.0	70.0	%	59.00	60.00	63.00	60.00	62.00	60.00
						HBC: L	20/10/90	20.0	40.0	%	32.00	31.00	28.00	27.00	27.00	27.00
HBC: E	20/10/90	1.0				5.0	%	2.00	2.00	2.00	3.00	3.00	3.00			
HBC: M	20/10/90	4.0				8.0	%	7.00	7.00	7.00	10.00	8.00	9.00			
HBC: B	20/10/90	0.0				1.0	%	0.00	0.00	0.00	0.00	0.00	1.00			
PLATELETS	20/10/90	150.0				550.0	10 ³ /MNC	249.00	303.00	263.00	242.00	290.00	275.00			
NA+	20/10/90	138.0				155.0	M ER/L	139.00	140.00	144.00	144.00	140.00	142.00			
E+	20/10/90	3.5				5.5	M ER/L	4.20	4.00	3.90	4.30	4.20	4.30			
CL-	20/10/90	98.0	120.0	M ER/L	99.00	97.00	97.00	95.00	95.00	96.00						
CA++	20/10/90	8.5	10.5	MG/DL	9.20	9.20	9.30	9.80	9.00	9.50						
PO4--	20/10/90	3.0	4.5	MG/DL	3.80	3.50	4.00	3.70	3.70	3.80						
SGPT	20/10/90	12.0	40.0	RU/HL	20.00	22.00	25.00	30.00	22.00	26.00						
GAMMA-GT	20/10/90	10.0	40.0	RU/HL	28.00	28.00	27.00	36.00	28.00	28.00						
GLUCOSE	20/10/90	7.0	33.0	MG/DL	34.00	33.00	22.00	24.00	18.00	22.00						
ALK. PHOSPH.	20/10/90	65.0	100.0	RU/HL	89.00	94.00	98.00	98.00	92.00	96.00						
BUN	20/10/90	10.0	50.0	MG/DL	132.00	141.00	136.00	147.00	138.00	170.00						
CREATININE	20/10/90	0.6	1.6	MG/DL	1.00	0.90	0.90	0.90	0.90	0.80						
URIC ACID	20/10/90	2.4	5.7	MG/DL	3.20	3.60	4.20	3.60	4.20	3.60						
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	0.80	0.70	0.40	0.90	0.40						
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.40	0.30	0.20	0.40	0.20						
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.20	7.30	7.40	7.20	6.90	7.00						
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	4.00	4.20	3.90	3.90	3.90						
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	116.00	132.00	163.00	243.00	190.00	152.00						
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	70.00	77.00	108.00	89.00	76.00	86.00						
GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	1.80	1.70	2.90	3.00	3.20	3.00						
GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	7.90	8.60	7.50	6.60	7.50	7.60						
GLOBULINS: BETA	20/10/90	11.0	14.0	%	12.10	13.30	14.20	15.10	13.00	12.90						
GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	19.00	20.20	18.70	19.10	19.80	20.80						

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1847

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No. 1 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit						
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
1 123-338	F			HB	20/10/90	12.0	16.0	G/100ML	06/05/92	01/07/92	26/08/92	21/10/92	16/12/92	24/02/93
				HCT	20/10/90	37.0	47.0	%	13.40	13.60	13.50	14.00	13.80	14.20
				RBC	20/10/90	3.8	5.4	10 ⁶ /MM ³	39.00	40.00	39.00	40.00	40.00	41.00
				HBC	20/10/90	4.0	11.0	10 ⁶ /MM ³	4.40	4.50	4.60	4.70	4.60	4.80
				HSC: N	20/10/90	40.0	70.0	%	4.80	4.80	5.80	8.00	7.50	6.00
				HSC: L	20/10/90	20.0	40.0	%	62.00	61.00	63.00	62.00	61.00	62.00
				HSC: E	20/10/90	1.0	5.0	%	30.00	28.00	25.00	31.00	30.00	30.00
				HSC: K	20/10/90	4.0	8.0	%	2.00	4.00	3.00	1.00	2.00	2.00
				HSC: B	20/10/90	0.0	1.0	%	6.00	7.00	9.00	6.00	7.00	6.00
				PLATELETS	20/10/90	150.0	550.0	10 ³ /MM ³	0.00	0.00	0.00	0.00	0.00	0.00
				Na+	20/10/90	138.0	155.0	M EQ/L	290.00	305.00	286.00	351.00	320.00	214.00
				CL-	20/10/90	3.5	5.5	M EQ/L	141.00	141.00	143.00	142.00	142.00	141.00
				K+	20/10/90	3.5	5.5	M EQ/L	3.90	3.90	4.50	4.30	4.30	4.30
				Ca++	20/10/90	8.5	10.5	MG/DL	98.00	102.00	98.00	98.00	97.00	98.00
				PO4--	20/10/90	3.0	4.5	MG/DL	10.40	3.50	9.50	9.50	9.50	9.50
				SGPT	20/10/90	12.0	40.0	IU/ML	4.10	4.00	4.00	3.60	4.00	4.10
				GAMMA-GT	20/10/90	10.0	40.0	IU/ML	30.00	28.00	26.00	24.00	26.00	26.00
				GLUCOSE	20/10/90	7.0	33.0	MG/DL	34.00	34.00	30.00	28.00	30.00	30.00
				ALK. PHOSPH.	20/10/90	70.0	100.0	MG/DL	24.00	22.00	22.00	36.00	22.00	22.00
				BUN	20/10/90	65.0	306.0	MG/DL	99.00	94.00	95.00	104.00	92.00	108.00
				CREATININE	20/10/90	0.6	50.0	MG/DL	121.00	121.00	172.00	146.00	144.00	156.00
				TOT BILIRUBIN	20/10/90	0.2	1.6	MG/DL	0.80	0.90	0.80	0.70	0.80	1.00
				DIR BILIRUBIN	20/10/90	0.0	5.7	MG/DL	3.60	3.30	4.30	4.30	4.40	4.50
				TOT. PROTEINS	20/10/90	6.0	1.0	MG/DL	0.80	0.70	0.60	0.60	0.60	0.70
				ALBUMINE	20/10/90	3.5	8.0	MG/DL	0.40	0.30	0.30	0.30	0.40	0.30
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	7.00	7.00	7.20	7.50	7.00	7.00
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	3.90	3.90	4.00	4.00	3.90	4.00
				GLORULINS: ALPHA1	20/10/90	4.0	7.0	%	143.00	140.00	238.00	316.00	184.00	175.00
				GLORULINS: ALPHA2	20/10/90	7.0	11.0	%	94.00	95.00	97.00	99.00	90.00	91.00
				GLORULINS: BETA	20/10/90	11.0	14.0	%	2.10	2.00	3.90	3.00	3.50	3.20
				GLORULINS: GAMMA	20/10/90	15.0	22.0	%	8.30	7.90	9.10	8.60	8.00	7.50
				HB	20/10/90	12.0	16.0	G/100ML	14.10	14.00	13.60	14.00	13.50	14.00
				HCT	20/10/90	37.0	47.0	%	40.00	39.00	40.00	39.00	38.00	38.00
RBC	20/10/90	3.8	5.4	10 ⁶ /MM ³	4.20	4.50	4.50	4.40	4.30	4.30				
HBC: N	20/10/90	4.0	11.0	10 ⁶ /MM ³	5.30	5.20	8.60	8.70	8.00	6.50				
HBC: L	20/10/90	20.0	40.0	%	62.00	60.00	65.00	63.00	60.00	60.00				
HBC: E	20/10/90	1.0	5.0	%	31.00	31.00	24.00	30.00	28.00	27.00				
HBC: K	20/10/90	4.0	8.0	%	2.00	2.00	3.00	1.00	2.00	2.00				

(**) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit						
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
1	125-340	F		HBC: M	20/10/90	4.0	8.0	%	6.00	7.00	8.00	5.00	10.00	10.00
				HBC: B	20/10/90	0.0	1.0	%	0.00	0.00	0.00	1.00	0.00	0.00
				PLATELETS	20/10/90	150.0	550.0	10 ³ /NMC	315.00	321.00	256.00	260.00	275.00	280.00
				NA+	20/10/90	138.0	155.0	M EQ/L	142.00	140.00	140.00	142.00	142.00	140.00
				K+	20/10/90	3.5	5.5	M EQ/L	4.00	3.90	4.50	4.30	4.30	4.30
				CL-	20/10/90	98.0	120.0	M EQ/L	99.00	98.00	97.00	96.00	95.00	98.00
				CA++	20/10/90	8.5	10.5	MG/DL	10.20	9.50	9.00	9.20	9.00	9.50
				PO4--	20/10/90	3.0	4.5	MG/DL	3.60	3.80	4.10	4.10	3.60	4.20
				SCOT	20/10/90	12.0	40.0	MG/ML	30.00	28.00	27.00	27.00	25.00	28.00
				SGPT	20/10/90	10.0	40.0	MG/ML	34.00	32.00	30.00	32.00	28.00	32.00
				GAMMA-GT	20/10/90	7.0	33.0	MG/ML	28.00	24.00	24.00	25.00	20.00	24.00
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	91.00	86.00	112.00	118.00	93.00	88.00
				ALK. PHOSPH.	20/10/90	65.0	306.0	MG/DL	131.00	146.00	154.00	164.00	147.00	156.00
				EUR	20/10/90	10.0	50.0	MG/DL	26.00	31.00	35.00	34.00	29.00	29.00
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	0.80	1.00	0.90	0.80	0.80
				URIC ACID	20/10/90	2.4	5.7	MG/DL	3.70	3.20	4.80	4.80	4.30	5.00
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	1.00	0.80	0.90	0.80	0.70	0.70
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.50	0.40	0.40	0.40	0.30	0.30
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.80	7.10	7.10	7.30	7.00	7.10
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.20	4.30	4.10	3.90	4.00
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	122.00	123.00	199.00	215.00	151.00	178.00
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	76.00	88.00	72.00	76.00	92.00	90.00
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	1.70	1.80	3.10	3.00	3.50	3.50
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	6.50	9.00	7.50	8.10	7.50	8.00
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	12.10	12.30	14.30	13.60	13.80	13.80
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	17.90	17.60	14.50	19.10	20.00	18.40
127-342		F		HB	20/10/90	12.0	16.0	G/100ML	13.20	13.60	13.50	13.40	13.30	13.30
				HTC	20/10/90	37.0	47.0	%	38.00	39.00	38.00	37.00	38.00	40.00
				RBC	20/10/90	3.8	5.4	10 ⁶ /NMC	4.50	4.40	4.50	4.40	4.20	4.60
				WBC	20/10/90	4.0	11.0	10 ³ /NMC	6.40	6.00	7.20	7.50	4.80	5.00
				PLT	20/10/90	40.0	70.0	%	64.00	60.00	60.00	62.00	58.00	57.00
				HRC: L	20/10/90	20.0	40.0	%	28.00	30.00	31.00	27.00	30.00	29.00
				HRC: E	20/10/90	1.0	5.0	%	3.00	2.00	2.00	3.00	3.00	5.00
				HRC: M	20/10/90	4.0	8.0	%	8.00	7.00	7.00	8.00	9.00	9.00
				HRC: B	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00
				PLATELETS	20/10/90	150.0	550.0	10 ³ /NMC	295.00	306.00	282.00	316.00	286.00	253.00
				NA+	20/10/90	138.0	155.0	M EQ/L	142.00	140.00	143.00	142.00	140.00	140.00
				K+	20/10/90	3.5	5.5	M EQ/L	4.10	3.90	4.40	4.30	4.30	3.90
				CL-	20/10/90	98.0	120.0	M EQ/L	99.00	90.00	101.00	95.00	99.00	95.00
				CA++	20/10/90	8.5	10.5	MG/DL	10.20	10.10	9.80	9.80	9.20	9.00
				PO4--	20/10/90	3.0	4.5	MG/DL	3.80	3.60	3.70	4.20	3.70	3.80

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1849

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit											
					Date	Min	Max	Unit	Week 10	Week 1B	Week 18	Week 26	Week 34	Week 42	Week 52				
1 127-342	F			SCOT	20/10/90	12.0	40.0	MU/ML	26.00	24.00	34.00	32.00	34.00	24.00	20.00				
				SCPT	20/10/90	10.0	40.0	MU/ML	30.00	28.00	38.00	36.00	38.00	24.00	20.00				
				GAMMA-GT	20/10/90	7.0	33.0	MU/ML	20.00	20.00	27.00	28.00	27.00	20.00	24.00				
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	94.00	101.00	92.00	90.00	92.00	20.00	25.00				
				ALK. PHOSPH.	20/10/90	65.0	306.0	MU/ML	143.00	135.00	125.00	132.00	133.00	102.00	146.00				
				BUN	20/10/90	10.0	50.0	MG/DL	31.00	29.00	32.00	32.00	32.00	26.00	26.00				
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	0.90	0.80	0.90	0.80	0.90	0.90				
				URIC ACID	20/10/90	2.4	5.7	MG/DL	3.60	3.70	4.50	4.50	4.00	3.70	3.70				
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.70	0.80	0.70	0.70	0.70	0.90	0.90				
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.40	0.30	0.30	0.30	0.40	0.40				
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.10	7.20	7.30	7.20	7.30	7.00	7.30				
				ALBUMINE	20/10/90	3.5	5.0	G/DL	3.90	3.90	4.00	3.90	4.00	3.90	4.00				
				TOT. CHOLEST.	20/10/90	160.0	270.0	MG/DL	169.00	154.00	195.00	225.00	195.00	176.00	193.00				
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	82.00	80.00	72.00	90.00	72.00	90.00	116.00				
				GLORULINS: ALPHA1	20/10/90	4.0	7.0	%	2.10	1.90	3.00	3.00	3.20	3.10	3.80				
				GLORULINS: ALPHA2	20/10/90	7.0	11.0	%	7.30	8.50	8.60	8.60	8.60	7.50	4.30				
				GLORULINS: BETA	20/10/90	11.0	14.0	%	12.80	13.20	14.10	12.90	14.10	12.60	12.60				
				GLORULINS: GAMMA	20/10/90	15.0	22.0	%	23.50	23.60	19.90	21.30	19.90	20.90	23.90				
				128-343	M			HB	20/10/90	14.0	18.0	g/100ml	14.00	14.00	14.00	14.00	14.00	13.10	
								HIC	20/10/90	40.0	54.0	%	41.00	39.00	41.00	41.00	41.00	37.00	36.00
								RBC	20/10/90	4.3	6.1	10 ⁶ /mm	4.60	4.40	4.70	4.70	4.50	4.30	4.00
								RBC: N	20/10/90	4.0	11.0	10 ⁻³ /RMC	6.00	6.60	6.00	6.00	4.30	8.10	5.90
								RBC: L	20/10/90	40.0	70.0	%	62.00	60.00	62.00	62.00	60.00	60.00	62.00
RBC: E	20/10/90	20.0	40.0					%	31.00	31.00	28.00	30.00	28.00	27.00	28.00				
RBC: M	20/10/90	1.0	5.0					%	2.00	2.00	2.00	2.00	4.00	3.00	3.00				
RBC: B	20/10/90	4.0	8.0					%	5.00	7.00	8.00	6.00	8.00	10.00	7.00				
PLATELETS	20/10/90	0.0	1.0					%	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
NA+	20/10/90	150.0	550.0					10 ⁻³ /RMC	318.00	320.00	274.00	304.00	274.00	256.00	260.00				
K+	20/10/90	3.5	5.5					M EQ/L	3.80	3.80	4.20	4.20	4.40	4.10	4.10				
CL-	20/10/90	98.0	120.0					M EQ/L	94.00	93.00	98.00	98.00	98.00	90.00	92.00				
PO4--	20/10/90	3.0	4.5					MG/DL	3.80	3.60	4.50	4.50	4.00	4.40	4.40				
SGPT	20/10/90	12.0	40.0					MU/ML	26.00	25.00	27.00	27.00	36.00	25.00	26.00				
GAMMA-GT	20/10/90	10.0	40.0					MU/ML	30.00	28.00	30.00	30.00	40.00	30.00	28.00				
GLUCOSE	20/10/90	11.0	51.0					MU/ML	22.00	22.00	22.00	22.00	28.00	18.00	20.00				
ALK. PHOSPH.	20/10/90	70.0	100.0					MG/DL	93.00	90.00	97.00	97.00	92.00	90.00	95.00				
BUN	20/10/90	65.0	306.0					MU/ML	161.00	115.00	150.00	150.00	155.00	132.00	142.00				
CREATININE	20/10/90	10.0	50.0					MG/DL	32.00	28.00	29.00	32.00	29.00	28.00	30.00				
URIC ACID	20/10/90	0.6	1.6					MG/DL	0.90	0.90	1.00	1.00	0.80	0.80	0.90				
	20/10/90	3.4	7.0					MG/DL	3.40	3.60	4.50	3.80	4.50	4.30	4.20				

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit										
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52				
1 128-343	K			TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.50	0.40	0.90	0.70	0.60	0.70				
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.20	0.40	0.30	0.30	0.30				
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.30	7.10	7.30	7.30	7.30	7.10				
				ALBUMINE	20/10/90	3.5	5.0	G/DL	3.90	3.90	4.10	4.20	3.90	4.00				
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	193.00	169.00	176.00	161.00	148.00	175.00				
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	89.00	91.00	84.00	72.00	97.00	93.00				
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	2.00	2.50	4.10	3.00	3.20	3.20				
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	8.80	9.00	6.60	9.20	8.50	8.00				
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	12.60	15.20	15.00	16.40	14.10	13.90				
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	21.50	21.40	18.10	13.90	17.70	18.60				
				134-347	F			HB	20/10/90	12.0	16.0	G/100ML	14.00	13.80	13.50	17.11/92	12/01/93	23/03/93
								HTC	20/10/90	37.0	47.0	%	41.00	41.00	38.00	39.00	40.00	40.00
								RBC	20/10/90	3.8	5.4	10 ⁶ /MNC	4.60	4.60	4.50	6.10	4.80	4.80
								MBC: N	20/10/90	4.0	11.0	10 ³ /MNC	6.10	4.90	6.10	7.40	5.90	6.60
								MBC: L	20/10/90	40.0	70.0	%	58.00	61.00	66.00	61.00	61.00	61.00
								MBC: E	20/10/90	20.0	40.0	%	30.00	28.00	25.00	20.00	28.00	29.00
								MBC: M	20/10/90	1.0	5.0	%	4.00	3.00	2.00	10.00	3.00	2.00
								MBC: B	20/10/90	4.0	8.0	%	8.00	8.00	7.00	9.00	8.00	8.00
								PLATELETS	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00
								NA+	20/10/90	150.0	550.0	10 ³ /MNC	286.00	239.00	290.00	274.00	284.00	290.00
CL-	20/10/90	138.0	155.0					M EQ/L	139.00	141.00	143.00	145.00	144.00	142.00				
CA++	20/10/90	3.5	5.5					M EQ/L	4.20	4.00	4.50	4.10	4.00	4.10				
PO4--	20/10/90	8.5	10.5					MG/DL	9.60	9.30	9.50	9.80	9.70	9.60				
SGPT	20/10/90	3.0	4.5					MG/DL	4.00	3.70	4.20	4.00	3.60	4.10				
GAMMA-GT	20/10/90	12.0	40.0					NU/HL	24.00	28.00	24.00	25.00	23.00	20.00				
GLUCOSE	20/10/90	10.0	40.0					MG/DL	30.00	32.00	28.00	28.00	26.00	26.00				
ALK. PHOSPR.	20/10/90	7.0	33.0					NU/HL	22.00	20.00	18.00	27.00	18.00	17.00				
CREATININE	20/10/90	70.0	100.0					MG/DL	95.00	93.00	96.00	94.00	91.00	89.00				
URIC ACID	20/10/90	65.0	306.0					MG/DL	110.00	122.00	127.00	132.00	136.00	121.00				
DIR BILIRUBIN	20/10/90	10.0	50.0					MG/DL	28.00	30.00	30.00	33.00	32.00	32.00				
TOT. PROTEINS	20/10/90	0.6	1.6	MG/DL	1.00	0.90	0.80	0.90	0.90	0.80								
ALBUMINE	20/10/90	2.4	5.7	MG/DL	3.60	3.60	4.30	4.20	4.10	4.30								
TOT. CHOLEST.	20/10/90	0.2	1.0	MG/DL	0.70	0.60	0.70	0.70	0.70	0.90								
TRIGLYCERIDES	20/10/90	0.0	0.4	MG/DL	0.30	0.20	0.30	0.30	0.30	0.40								
GLOBULINS: ALPHA1	20/10/90	6.0	8.0	G/DL	7.00	7.10	7.40	7.00	7.00	7.00								
GLOBULINS: ALPHA2	20/10/90	3.5	5.0	G/DL	3.90	3.90	4.00	3.90	3.90	3.90								
GLOBULINS: BETA	20/10/90	140.0	270.0	MG/DL	156.00	142.00	152.00	175.00	161.00	165.00								
GLOBULINS: GAMMA	20/10/90	35.0	175.0	MG/DL	88.00	71.00	65.00	80.00	88.00	98.00								
TOT. CHOLEST.	20/10/90	4.0	7.0	%	2.00	3.10	3.80	2.10	3.20	3.10								
GLOBULINS: ALPHA1	20/10/90	7.0	11.0	%	6.10	8.30	7.60	8.70	7.50	7.40								

(**) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit										
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52				
1 134-347	F			GLOBULINS: BETA	20/10/90	11.0	14.0	%	11.40	12.60	12.90	12.50	14.10	12.60				
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	18.30	20.10	21.60	22.40	19.70	21.20				
				135-348	F			HB	20/10/90	12.0	16.0	g/100ML	13.40	13.50	13.20	13.60	13.30	13.80
								HTC	20/10/90	37.0	47.0	%	38.00	38.00	37.00	40.00	40.00	39.00
								RBC	20/10/90	3.8	5.4	10 ⁶ /MMC	4.20	4.30	4.40	4.60	4.50	4.40
								RBC: N	20/10/90	4.0	11.0	10 ³ -3/MMC	5.10	4.80	6.20	7.20	7.30	7.50
								RBC: I	20/10/90	40.0	70.0	%	62.00	61.00	59.00	65.00	65.00	64.00
								RBC: E	20/10/90	20.0	40.0	%	29.00	28.00	31.00	28.00	25.00	25.00
								RBC: K	20/10/90	1.0	5.0	%	2.00	3.00	2.00	4.00	2.00	3.00
								RBC: B	20/10/90	0.0	8.0	%	7.00	8.00	8.00	10.00	8.00	8.00
								RBC: A	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00
								PLATELETS	20/10/90	150.0	550.0	10 ³ -3/MMC	280.00	295.00	251.00	260.00	285.00	266.00
								NA+	20/10/90	158.0	155.0	MMEN/L	141.00	142.00	143.00	142.00	142.00	142.00
								K+	20/10/90	3.5	5.5	MMEN/L	3.90	3.70	98.00	95.00	99.00	96.00
CL-	20/10/90	98.0	120.0					MMEN/L	103.00	99.00	10.10	9.00	9.70	9.30				
CA++	20/10/90	8.5	10.5	MG/DL	9.20	10.10	4.00	4.10	4.00	4.80								
SGPT	20/10/90	12.0	40.0	MMEN/L	4.10	4.00	26.00	26.00	26.00	27.00								
SGOT	20/10/90	10.0	40.0	MMEN/L	22.00	29.00	28.00	32.00	30.00	30.00								
GAMMA-GT	20/10/90	7.0	33.0	MMEN/L	18.00	20.00	24.00	18.00	22.00	22.00								
GLUCOSE	20/10/90	70.0	100.0	MG/DL	94.00	92.00	97.00	91.00	88.00	105.00								
ALK. PHOSPH.	20/10/90	65.0	306.0	MMEN/L	193.00	130.00	150.00	143.00	143.00	143.00								
BUN	20/10/90	10.0	50.0	MG/DL	32.00	28.00	31.00	32.00	31.00	32.00								
CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	0.80	0.80	1.00	0.90	0.80								
URIC ACID	20/10/90	2.4	5.7	MG/DL	3.60	3.90	4.30	4.50	3.80	5.10								
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.90	0.90	0.60	0.70	1.00	1.00								
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.40	0.30	0.30	0.30	0.50								
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.00	7.10	7.40	7.20	7.10	7.10								
ALBUMINE	20/10/90	3.5	5.0	G/DL	3.90	4.00	4.10	3.90	3.90	3.80								
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	148.00	156.00	176.00	162.00	186.00	193.00								
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	97.00	81.00	82.00	97.00	101.00	96.00								
GLOBULINS: ALPHA1	20/10/90	0.0	7.0	%	3.00	2.90	3.50	2.80	3.20	3.10								
GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	7.10	6.30	9.00	9.10	7.00	7.60								
GLOBULINS: BETA	20/10/90	11.0	14.0	%	15.40	12.50	12.20	10.90	14.40	14.10								
GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	20.60	17.90	19.90	23.00	20.50	21.70								
139-351	M			HB	20/10/90	14.0	18.0	g/100ml	14.20	13.80	13.70	13.80	14.10	13.80				
				HTC	20/10/90	40.0	54.0	%	40.00	40.00	42.00	43.00	40.00	40.00				
				REC	20/10/90	4.3	6.1	10 ³ *6/mm	4.50	4.50	4.80	4.90	4.60	4.60				

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1852

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52		
1	139-351	M														
				WBC	20/10/90	4.0	11.0	10 ³ /HMC	4.90	5.10	6.30	5.70	5.20	5.00		
				WBC: N	20/10/90	40.0	70.0	X	62.00	64.00	61.00	60.00	60.00	60.00		
				WBC: L	20/10/90	20.0	40.0	X	28.00	29.00	27.00	27.00	27.00	27.00		
				WBC: E	20/10/90	1.0	5.0	X	3.00	2.00	3.00	4.00	3.00	4.00		
				WBC: H	20/10/90	4.0	8.0	X	7.00	5.00	8.00	9.00	10.00	9.00		
				WBC: B	20/10/90	0.0	1.0	X	0.00	0.00	1.00	0.00	0.00	0.00		
				PLATELETS	20/10/90	150.0	550.0	10 ³ /HMC	293.00	258.00	275.00	310.00	295.00	293.00		
				Na+	20/10/90	138.0	155.0	M EQ/L	140.00	141.00	143.00	142.00	142.00	142.00		
				CL-	20/10/90	3.5	5.5	M EQ/L	3.90	3.90	4.50	4.40	4.30	4.10		
				Ca++	20/10/90	98.0	120.0	M EQ/L	94.00	96.00	99.00	97.00	97.00	94.00		
				PO4--	20/10/90	8.5	10.5	MG/DL	9.00	9.40	9.30	9.80	9.60	9.80		
				SGPT	20/10/90	3.0	4.5	MG/DL	3.70	3.80	4.10	4.30	4.50	4.30		
				SGOT	20/10/90	12.0	40.0	MIU/ML	32.00	36.00	27.00	27.00	28.00	26.00		
				GAMMA-GT	20/10/90	10.0	40.0	MIU/ML	36.00	38.00	30.00	30.00	32.00	30.00		
				GLUCOSE	20/10/90	11.0	51.0	MG/ML	24.00	27.00	22.00	23.00	24.00	20.00		
				ALK. PHOSPH.	20/10/90	70.0	100.0	MG/DL	89.00	98.00	95.00	90.00	103.00	87.00		
				BUN	20/10/90	65.0	306.0	MG/ML	136.00	141.00	163.00	172.00	136.00	152.00		
				CREATININE	20/10/90	0.6	30.0	MG/DL	26.00	32.00	30.00	32.00	32.00	32.00		
				URIC ACID	20/10/90	3.4	7.0	MG/DL	3.80	3.50	4.20	4.50	4.50	4.10		
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.40	0.40	0.40	0.70	0.60	0.60		
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.20	0.20	0.30	0.30	0.30		
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.30	7.40	7.20	7.50	7.00	7.00		
				ALBUMINE	20/10/90	3.5	5.0	G/DL	3.90	4.10	3.90	4.20	4.20	4.10		
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	141.00	160.00	152.00	159.00	156.00	194.00		
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	72.00	83.00	71.00	62.00	93.00	91.00		
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	X	2.00	3.00	3.00	3.00	3.10	3.10		
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	X	8.30	7.80	8.50	7.40	7.60	8.50		
				GLOBULINS: BETA	20/10/90	11.0	14.0	X	14.70	16.50	11.40	13.00	12.70	12.70		
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	X	20.20	19.90	22.90	20.00	16.60	17.10		
				HB	20/10/90	12.0	16.0	G/100ML	12.50	12.40	13.60	14.20	14.20	14.10		
				HCT	20/10/90	37.0	47.0	X	36.00	36.00	41.00	41.00	42.00	42.00		
				RBC	20/10/90	3.8	5.4	10 ⁶ /HMC	4.10	4.10	4.60	4.70	4.90	4.90		
				WBC: N	20/10/90	4.0	11.0	10 ³ /HMC	8.00	7.80	4.90	5.30	5.20	5.10		
				WBC: L	20/10/90	40.0	70.0	X	57.00	61.00	62.00	61.00	61.00	62.00		
				WBC: E	20/10/90	20.0	40.0	X	32.00	32.00	30.00	28.00	28.00	27.00		
				WBC: B	20/10/90	1.0	5.0	X	3.00	2.00	2.00	3.00	3.00	3.00		
				WBC: H	20/10/90	4.0	8.0	X	8.00	5.00	6.00	8.00	8.00	8.00		
				WBC: B	20/10/90	0.0	1.0	X	0.00	0.00	0.00	0.00	0.00	0.00		
				PLATELETS	20/10/90	150.0	550.0	10 ³ /HMC	321.00	315.00	301.00	264.00	263.00	275.00		
				Na+	20/10/90	136.0	155.0	M EQ/L	141.00	143.00	142.00	140.00	141.00	141.00		

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXEMINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXEMINE

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Date	Laboratory Range			Visit							
					Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52		
1	140-352	F	K+	20/10/90	3.5	5.5	M EQ/L	4.30	4.10	4.40	4.30	4.20	4.30		
			CL-	20/10/90	98.0	120.0	M EQ/L	102.00	102.00	97.00	100.00	94.00	95.00		
			CA++	20/10/90	8.5	10.5	MG/DL	10.30	9.90	9.00	9.30	9.30	9.20		
			PO4-	20/10/90	3.0	4.5	MG/DL	3.30	3.40	3.60	4.20	4.00	4.30		
			SGPT	20/10/90	12.0	40.0	U/L	32.00	24.00	28.00	27.00	28.00	28.00		
			SGPT	20/10/90	10.0	40.0	U/L	36.00	28.00	32.00	32.00	30.00	30.00		
			GAMMA-GT	20/10/90	7.0	33.0	U/L	27.00	18.00	24.00	24.00	20.00	22.00		
			GLUCOSE	20/10/90	70.0	100.0	MG/DL	112.00	115.00	88.00	96.00	95.00	97.00		
			ALK. PHOSPH.	20/10/90	65.0	306.0	U/L	159.00	172.00	163.00	138.00	128.00	141.00		
			BUN	20/10/90	10.0	30.0	MG/DL	32.00	33.00	32.00	32.00	28.00	32.00		
			CREATININE	20/10/90	0.6	1.6	MG/DL	1.10	1.00	1.10	1.00	0.70	1.00		
			URIC ACID	20/10/90	2.4	5.7	MG/DL	4.30	3.80	4.30	4.00	4.10	5.20		
			TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	1.10	1.10	0.50	0.70	0.60	0.70		
			DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.50	0.50	0.30	0.30	0.30	0.30		
			TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.90	7.00	7.20	7.40	7.00	7.10		
			ALBUMINE	20/10/90	3.5	5.0	G/DL	3.90	3.90	4.30	4.20	4.00	4.00		
			TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	197.00	168.00	144.00	160.00	188.00	210.00		
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	104.00	113.00	80.00	81.00	69.00	86.00		
			GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	2.60	2.80	2.00	4.10	2.50	2.90		
			GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	4.70	5.00	7.40	8.00	7.30	7.60		
			GLOBULINS: BETA	20/10/90	11.0	14.0	%	13.60	14.10	11.20	12.30	12.70	13.50		
			GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	19.30	20.40	19.70	18.80	20.40	19.70		
			142-354	F	HB	20/10/90	12.0	16.0	G/100ML	12.90	12.70	15.00	17.10	14.20	23/03/93
					HTC	20/10/90	37.0	47.0	%	39.00	38.00	45.00	42.00	42.00	14.10
					RBC	20/10/90	3.8	5.4	10 ⁶ /MM ³	4.30	4.20	4.90	4.80	4.80	42.00
					WBC	20/10/90	4.0	11.0	10 ³ /MM ³	6.20	6.00	5.30	4.80	4.80	4.90
					WBC: N	20/10/90	40.0	70.0	%	64.00	63.00	60.00	61.00	5.50	6.10
					WBC: L	20/10/90	20.0	40.0	%	27.00	26.00	28.00	29.00	60.00	64.00
					WBC: E	20/10/90	1.0	5.0	%	3.00	3.00	4.00	2.00	25.00	32.00
					WBC: M	20/10/90	4.0	8.0	%	6.00	8.00	8.00	8.00	5.00	1.00
					WBC: X	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	10.00	3.00
					PLATELETS	20/10/90	150.0	550.0	10 ³ /MM ³	284.00	286.00	275.00	280.00	0.00	0.00
					HA+	20/10/90	138.0	155.0	M EQ/L	142.00	141.00	142.00	143.00	263.00	256.00
K+	20/10/90	3.5			5.5	M EQ/L	4.30	3.90	4.30	4.30	162.00	141.00			
CL-	20/10/90	98.0			120.0	M EQ/L	95.00	101.00	98.00	95.00	4.30	4.00			
CA++	20/10/90	8.5			10.5	MG/DL	9.60	9.60	9.30	9.00	97.00	99.00			
PO4-	20/10/90	3.0			4.5	MG/DL	3.70	3.70	4.10	4.50	4.20	4.30			
SGPT	20/10/90	12.0			40.0	U/L	30.00	28.00	24.00	28.00	28.00	25.00			
SGPT	20/10/90	10.0			40.0	U/L	34.00	34.00	26.00	34.00	30.00	32.00			
GAMMA-GT	20/10/90	7.0			33.0	U/L	26.00	21.00	20.00	24.00	24.00	20.00			
GLUCOSE	20/10/90	70.0	100.0	MG/DL	86.00	88.00	87.00	82.00	88.00	100.00					

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Oper-Blind	Sex	Laboratory test	Date	Laboratory Range			Visit					
						Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
1	142-354	F		ALK: PHOSPH.	20/10/90	65.0	306.0	μU/ML	124.00	129.00	142.00	153.00	120.00	132.00
				BUN	20/10/90	10.0	50.0	MG/DL	40.00	36.00	33.00	34.00	31.00	32.00
				CREATININE	20/10/90	0.6	1.6	MG/DL	1.00	0.90	0.80	1.20	0.90	0.90
				URIC ACID	20/10/90	2.4	5.7	MG/DL	3.20	4.00	4.30	4.30	4.20	4.40
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	0.70	0.80	0.90	0.60	0.80
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.30	0.40	0.40	0.30	0.40
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.30	7.20	7.00	7.00	7.10	7.00
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	4.00	3.90	4.00	4.20	4.10
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	163.00	170.00	128.00	138.00	143.00	195.00
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	92.00	95.00	73.00	90.00	98.00	76.00
				GLORULINS: ALPHA1	20/10/90	4.0	7.0	%	3.00	2.50	1.80	1.90	3.10	3.00
				GLORULINS: ALPHA2	20/10/90	7.0	11.0	%	4.50	4.60	8.50	8.10	4.90	8.50
				GLORULINS: BETA	20/10/90	11.0	14.0	%	12.50	13.20	14.00	13.50	13.50	13.10
				GLORULINS: GAMMA	20/10/90	15.0	22.0	%	18.50	19.20	20.00	19.40	19.30	16.80
144-356		M		HB	03/06/92	14.0	18.0	g/100ml	15.00	15.10	15.40	15.00	15.00	
				HTC	20/10/90	40.0	54.0	%	45.00	45.00	47.00	46.00	46.00	
				RBC	20/10/90	4.3	6.1	10 ³ *6/mm	4.90	4.80	5.10	4.90	4.90	
				MBC	20/10/90	4.0	11.0	10 ³ -3/MHC	7.40	7.10	8.60	8.00	8.00	
				MBC: N	20/10/90	40.0	70.0	%	61.00	60.00	66.00	67.00	67.00	
				MBC: L	20/10/90	20.0	40.0	%	30.00	29.00	25.00	25.00	25.00	
				MBC: E	20/10/90	1.0	5.0	%	2.00	3.00	3.00	2.00	2.00	
				MBC: M	20/10/90	4.0	8.0	%	7.00	8.00	6.00	6.00	6.00	
				MBC: B	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	
				PLATELETS	20/10/90	150.0	550.0	10 ³ -3/MHC	245.00	250.00	299.00	285.00	285.00	
				NA+	20/10/90	138.0	155.0	M EQ/L	141.00	140.00	140.00	140.00	140.00	
				K+	20/10/90	3.5	5.5	M EQ/L	5.00	4.20	4.60	4.70	4.70	
				CL-	20/10/90	98.0	120.0	M EQ/L	93.00	95.00	91.00	92.00	92.00	
				CA++	20/10/90	8.5	10.5	MG/DL	9.70	10.10	9.00	9.30	9.30	
				PO4--	20/10/90	3.0	4.5	MG/DL	3.60	4.00	3.30	3.50	3.50	
				SGOT	20/10/90	12.0	40.0	NU/ML	29.00	30.00	21.00	26.00	26.00	
				SGPT	20/10/90	10.0	40.0	NU/ML	40.00	38.00	29.00	30.00	30.00	
				GAMMA-GT	20/10/90	11.0	51.0	NU/ML	53.00	46.00	44.00	47.00	47.00	
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	128.00	96.00	132.00	143.00	143.00	
				ALK. PHOSPH.	20/10/90	65.0	306.0	NU/ML	187.00	153.00	198.00	205.00	205.00	
				BUN	20/10/90	10.0	50.0	MG/DL	34.00	32.00	35.00	32.00	32.00	
				CREATININE	20/10/90	0.6	1.6	MG/DL	1.10	1.00	0.90	1.00	1.00	
				URIC ACID	20/10/90	3.4	7.0	MG/DL	5.90	4.50	6.80	6.10	6.10	
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.50	0.40	0.30	0.40	0.40	
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.20	0.20	0.20	0.20	
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.10	7.00	7.20	7.20	7.20	
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.04	4.00	3.70	3.70	3.70	

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1855

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 12.1
 LABORATORY DATA
 DOUBLE BLIND PHASE
 TREATMENT: REBOMETINE

Pat. No.	Centre	Oper-Blind	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52		
1	144	356	M	TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	210.00	216.00	203.00	213.00	215.00	213.00	213.00	26/03/93
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	331.00	257.00	224.00	184.00	184.00	184.00	184.00	15.90
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	1.80	2.00	3.60	4.00	4.00	4.00	4.00	46.00
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	7.60	5.40	9.90	10.00	10.00	10.00	10.00	5.20
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	14.20	13.80	17.20	18.20	18.20	18.20	18.20	7.50
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	19.50	18.10	18.50	20.10	20.10	20.10	20.10	10.80
																22.00
																6.00
																0.00
																285.00
																145.00
																4.30
																98.00
																8.60
																2.60
																25.00
																48.00
																132.00
																456.00
																34.00
																1.00
																5.00
																4.80
																0.50
																0.30
																6.70
																4.00
																209.00
																173.00
																2.80
																8.60
																14.90
																14.70
																15.00
																16.80
																17.00

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit										
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52				
1	148-359	M	HB	20/10/90	14.0	18.0	g/100ml	05/06/92	31/07/92	25/09/92	20/11/92	15/01/93	26/03/93				
			HCT	20/10/90	40.0	54.0	%	13.50	13.80	14.00	14.20	14.00	14.00	13.60			
			RBC	20/10/90	4.3	6.1	10 ⁶ *6/mm ³	37.00	40.00	41.00	41.00	40.00	40.00	40.00			
			WBC	20/10/90	4.0	11.0	10 ³ -3/MNC	4.30	4.50	4.70	4.80	4.50	4.50	4.30			
			HBC: N	20/10/90	40.0	70.0	%	5.20	5.20	5.50	6.00	5.80	5.00	5.00			
			HBC: L	20/10/90	20.0	40.0	%	62.00	60.00	61.00	60.00	60.00	60.00	58.00			
			HBC: E	20/10/90	1.0	5.0	%	27.00	32.00	28.00	30.00	28.00	28.00	30.00			
			HBC: M	20/10/90	4.0	8.0	%	3.00	2.00	3.00	2.00	4.00	4.00	1.00			
			HBC: B	20/10/90	0.0	1.0	%	8.00	6.00	8.00	6.00	7.00	7.00	10.00			
			PLATELETS	20/10/90	150.0	550.0	10 ³ -3/MNC	263.00	304.00	300.00	281.00	283.00	283.00	280.00			
			NA+	20/10/90	158.0	158.0	M EQ/L	143.00	142.00	143.00	143.00	144.00	144.00	142.00			
			CL-	20/10/90	3.5	5.5	M EQ/L	94.00	91.00	98.00	9.60	9.00	9.00	9.30			
			CA++	20/10/90	8.5	10.5	MG/DL	9.70	10.10	9.60	9.20	9.00	9.00	9.30			
			PO4-	20/10/90	3.0	4.5	MG/DL	4.00	4.00	5.00	4.20	4.10	4.10	4.50			
			SGPT	20/10/90	12.0	40.0	IU/ML	32.00	28.00	25.00	27.00	28.00	28.00	25.00			
			GAMMA-GT	20/10/90	11.0	51.0	IU/ML	36.00	34.00	31.00	30.00	32.00	32.00	30.00			
			GLUCOSE	20/10/90	70.0	100.0	MG/DL	103.00	93.00	15.00	16.00	16.00	16.00	22.00			
			ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	136.00	141.00	89.00	90.00	91.00	91.00	108.00			
			UREA	20/10/90	10.0	50.0	MG/DL	26.00	27.00	30.00	31.00	32.00	32.00	141.00			
			CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	0.90	0.80	0.80	0.90	0.90	0.70			
			URIC ACID	20/10/90	3.4	7.0	MG/DL	3.40	3.60	3.60	4.20	4.10	4.10	4.60			
			TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	0.60	0.40	0.60	0.60	0.60	0.90			
			DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.30	0.20	0.30	0.40	0.40	0.40			
			TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.20	7.10	7.60	7.00	7.30	7.00	7.00			
			ALBUMINE	20/10/90	3.5	5.0	G/DL	4.00	4.00	3.90	3.90	4.10	4.10	3.90			
			TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	151.00	163.00	172.00	216.00	186.00	186.00	186.00			
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	99.00	92.00	86.00	94.00	95.00	95.00	87.00			
			GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	2.10	1.90	4.30	3.60	3.00	3.00	2.50			
			GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	4.80	4.70	8.60	8.00	8.20	8.20	8.60			
			GLOBULINS: BETA	20/10/90	11.0	14.0	%	12.60	12.50	13.50	13.10	12.70	12.70	13.00			
			GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	17.90	18.00	22.30	19.60	19.90	19.90	20.20			
			8	2-212	F	HB	19/10/90	120.0	150.0	g/l	21/02/91	18/04/91	30/05/91	08/08/91	05/01/91	12/12/91	
						HCT	19/10/90	0.4	0.5	l/l	138.00	140.00	137.00	142.00	139.00	139.00	125.00
						RBC	19/10/90	4.5	5.5	10 ⁶ *12/l	4.46	4.83	4.85	4.21	4.86	4.42	4.42
						WBC	19/10/90	5.0	10.0	10 ³ *9/l	6.10	6.70	6.30	5.20	7.70	7.00	10.00
HBC: N	19/10/90	60.0				75.0	%	67.00	67.00	77.00	66.00	72.00	70.00	70.00			
HBC: L	19/10/90	20.0				28.0	%	27.00	27.00	18.00	27.00	17.00	20.00	20.00			
HBC: E	19/10/90	1.0				4.0	%	3.00	3.00	2.00	2.00	1.00	1.00	1.00			

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit											
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52					
8	2-212	F		WBC: M	19/10/90	1.0	8.0	%	2.00		6.00	6.00	6.00	10.00	7.00				
				WBC: B	19/10/90	0.0	1.0	%	1.00		2.00	2.00	2.00	2.00	2.00	2.00			
				PLATELETS	19/10/90	150.0	300.0	10**9/L	178.00	151.00	194.00	247.00	218.00	194.00	164.00	140.00			
				NA+	19/10/90	135.0	146.0	mmol/L	140.00	141.00	138.00	140.00	138.00	140.00	140.00	140.00			
				K+	19/10/90	3.8	5.2	mmol/L	4.00	4.80	5.10	4.10	4.60	4.80	4.80	4.80			
				Cl-	19/10/90	95.0	108.0	mmol/L	102.00	108.00	103.00	105.00	100.00	107.00	107.00	107.00			
				CA++	19/10/90	2.1	2.6	mmol/L	2.30	2.30	2.40	2.30	2.30	2.50	2.50	2.50			
				PO4--	19/10/90	0.8	1.6	mmol/L	1.10	1.20	1.30	1.10	1.10	0.90	0.90	0.90			
				SGOT	19/10/90	7.0	21.0	U/L	12.00	11.00	13.00	19.00	20.00	20.00	20.00	20.00			
				SGPT	19/10/90	4.0	22.0	U/L	14.00	20.00	25.00	14.00	22.00	23.00	23.00	23.00			
				GAMMA-GT	19/10/90	5.0	25.0	U/L	18.00	8.00	64.00	16.00	48.00	48.00	48.00	48.00			
				GLUCOSE	19/10/90	2.8	5.6	mmol/L	4.80	5.20	6.40	4.70	4.90	4.60	4.60	4.60			
				ALK. PHOSPH.	19/10/90	73.0	207.0	U/L	128.00	120.00	164.00	131.00	212.00	207.00	207.00	207.00			
				CREATININE	19/10/90	2.0	9.0	mmol/L	4.00	6.10	8.00	5.00	5.00	2.40	2.40	2.40			
				URIC ACID	19/10/90	60.0	420.0	umol/L	70.00	73.00	83.00	60.00	76.00	76.00	76.00	76.00			
				TOT BILIRUBIN	19/10/90	2.0	17.0	umol/L	12.00	8.00	158.00	224.00	162.00	196.00	196.00	196.00			
				TOT. PROTEINS	19/10/90	60.0	85.0	g/L	66.00	70.00	74.00	68.00	80.00	80.00	80.00	80.00			
				ALBUMINE	19/10/90	35.0	48.0	g/L	38.00	45.00	48.00	46.00	46.00	45.00	45.00	45.00			
				TOT. CHOLEST.	19/10/90	3.9	6.5	mmol/L	6.30	6.30	9.10	5.90	6.00	7.90	7.90	7.90			
				TRIGLYCERIDES	19/10/90	0.8	1.7	mmol/L	1.00	4.40	6.30	1.60	1.60	1.60	1.60	1.60			
				LOBULINS: ALPHA1	19/10/90	2.4	3.6	%	3.20	4.00	4.40	3.20	3.20	3.20	3.20	3.20			
				LOBULINS: ALPHA2	19/10/90	6.6	9.8	%	7.10	8.00	8.00	8.00	8.00	8.00	8.00	8.00			
				LOBULINS: BETA	19/10/90	8.1	12.1	%	9.30	10.00	10.00	10.00	10.00	10.00	10.00	10.00			
				LOBULINS: GAMMA	19/10/90	12.6	18.8	%	13.10	15.00	15.00	15.00	15.00	15.00	15.00	15.00			
				3	2-213	M		HB	19/10/90	140.0	170.0	g/L	146.00		146.00				
								HCT	19/10/90	0.4	0.5	L/L	0.46						
								ERC	19/10/90	4.5	5.5	10**12/L	5.40						
								WBC	19/10/90	5.0	10.0	10**9/L	5.80						
WBC: N	19/10/90	60.0	75.0					%	64.00										
WBC: L	19/10/90	20.0	28.0					%	28.00										
WBC: E	19/10/90	1.0	4.0					%	4.00										
WBC: M	19/10/90	1.0	8.0					%	4.00										
WBC: B	19/10/90	0.0	1.0					%	0.00										
PLATELETS	19/10/90	150.0	300.0					10**9/L	230.00										
NA+	19/10/90	135.0	146.0					mmol/L	142.00										
K+	19/10/90	3.8	5.2					mmol/L	4.40										
Cl-	19/10/90	95.0	108.0	mmol/L	102.00														
CA++	19/10/90	2.1	2.6	mmol/L	2.00														
PO4--	19/10/90	0.8	1.6	mmol/L	1.00														

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R8D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre Oper-Blind Sex	Laboratory test	Laboratory Range			Visit																	
			Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52											
8 3-213	M	SGOT	19/10/90	10.0	25.0	U/l	14.00																
		SGPT	19/10/90	8.0	29.0	U/l	18.00																
		GAMMA-GT	19/10/90	8.0	38.0	U/l	20.00																
		GLUCOSE	19/10/90	2.8	5.6	mmol/l	4.60																
		ALK. PHOSPH.	19/10/90	73.0	207.0	U/l	140.00																
		BUN	19/10/90	2.0	9.0	mmol/l	7.00																
		CREATININE	19/10/90	60.0	100.0	umol/l	86.00																
		URIC ACID	19/10/90	200.0	420.0	umol/l	340.00																
		TOT BILIRUBIN	19/10/90	2.0	17.0	umol/l	12.00																
		TOT. PROTEINS	19/10/90	65.0	85.0	g/l	74.00																
		ALBUMINE	19/10/90	35.0	48.0	g/l	46.00																
		TOT. CHOLEST.	19/10/90	3.9	6.5	mmol/l	5.80																
		TRIGLYCERIDES	19/10/90	0.8	1.7	mmol/l	1.40																
		GLOBULINS: ALPHA1	19/10/90	2.4	3.6	g/l	3.00																
		GLOBULINS: ALPHA2	19/10/90	6.4	9.8	g/l	7.00																
		GLOBULINS: BETA	19/10/90	8.1	12.1	g/l	9.60																
		GLOBULINS: GAMMA	19/10/90	12.6	18.8	g/l	14.60																
		6-216	F	HB	19/10/90	120.0	150.0	g/l	117.00	02/04/91	117.00	27/05/91	131.00	22/07/91	16/09/91	11/11/91	20/01/92						
				HCT	19/10/90	0.4	0.5	l/l	0.34		0.34	0.44	0.41	0.39	0.34	0.34	0.38						
				RBC	19/10/90	4.5	5.5	10**12/l	4.53		4.53	5.45	5.17	4.82	4.45	4.45	4.53						
HBC	19/10/90			5.0	10.0	10**9/l	7.00		7.00	6.10	6.20	7.80	7.80	7.80	7.10								
HBC: N	19/10/90			60.0	75.0	g	64.00		64.00	53.00	51.00	61.00	60.00	60.00	52.00								
HBC: L	19/10/90			20.0	28.0	g	28.00		28.00	40.00	38.00	30.00	30.00	30.00	39.00								
HBC: E	19/10/90			1.0	4.0	g	4.00		4.00	3.00	2.00	2.00	2.00	2.00	3.00								
HBC: M	19/10/90			1.0	8.0	g	4.00		4.00	4.00	7.00	5.00	6.00	6.00	6.00								
HBC: B	19/10/90			0.0	1.0	g	0.00		0.00	0.00	2.00	2.00	2.00	2.00	0.00								
PLATELETS	19/10/90			150.0	300.0	10**9/l	157.00		157.00	269.00	228.00	219.00	200.00	180.00	154.00								
NA+	19/10/90			135.0	146.0	mmol/l	139.00		139.00	142.00	136.00	139.00	141.00	141.00	140.00								
K+	19/10/90			95.0	108.0	mmol/l	111.00		111.00	106.00	106.00	103.00	103.00	103.00	103.00								
CL-	19/10/90			2.1	2.6	mmol/l	2.30		2.30	2.60	2.50	2.50	2.30	2.30	2.30								
CA++	19/10/90			0.8	1.6	mmol/l	1.10		1.10	1.10	0.90	1.10	1.10	1.10	1.10								
PO4-	19/10/90			7.0	21.0	U/l	8.00		8.00	7.00	16.00	14.00	17.00	17.00	12.00								
SSGT	19/10/90			4.0	22.0	U/l	5.00		5.00	5.00	15.00	10.00	12.00	12.00	8.00								
GAMMA-GT	19/10/90			5.0	25.0	U/l	7.00		7.00	9.00	14.00	12.00	11.00	11.00	16.00								
GLUCOSE	19/10/90			2.8	5.6	mmol/l	4.50		4.50	5.20	5.20	6.10	5.50	5.50	5.70								
ALK. PHOSPH.	19/10/90			73.0	207.0	U/l	73.00		73.00	95.00	150.00	124.00	110.00	110.00	124.00								
BUN	19/10/90			2.0	9.0	mmol/l	7.00		7.00	6.90	7.70	6.70	5.60	5.60	6.70								
CREATININE	19/10/90	60.0	100.0	umol/l	60.00		60.00	77.00	74.00	69.00	69.00	69.00	72.00										
URIC ACID	19/10/90	200.0	420.0	umol/l	205.00		205.00	266.00	142.00	252.00	209.00	209.00	221.00										
TOT BILIRUBIN	19/10/90	2.0	17.0	umol/l	8.00		8.00	8.00	8.00	8.00	8.00	8.00	8.00										

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Contra	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit														
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52								
8 6-216	F			DIR BILIRUBIN	19/10/90	0.0	0.0	0.0	0.00													
				TOT. PROTEINS	19/10/90	60.0	85.0	g/l	75.00	74.00		67.00	77.00									
				ALBUMINE	19/10/90	35.0	48.0	g/l	46.00	48.00		49.00	49.00									
				TOT. CHOLEST.	19/10/90	3.9	6.5	mmol/l	6.30	5.50		4.20	5.90									
9 6-245	F			TRIGLYCERIDES	19/10/90	0.8	1.7	mmol/l	2.30	2.10		1.30	1.60									
				HB	20/05/90	4.0	10.0	mmol/l	11.90	12.70		12.00	12.40									
				HTC	20/05/90	36.0	53.0	%	38.00	40.00		38.00	39.00									
				RBC	20/05/90	4.0	5.8	10**6/ul	4.20	4.40		4.20	4.30									
				HRC	20/05/90	4.0	12.0	10**3/ul	6.20	6.90		7.90	7.00									
				HRC: N	20/05/90	60.0	80.0	%														
				HRC: L	20/05/90	15.0	40.0	%														
				HRC: E	20/05/90	0.0	5.0	%														
				HRC: H	20/05/90	1.0	6.0	%														
				HRC: B	20/05/90	0.0	1.0	%														
				PLATELETS	20/05/90	120.0	640.0	10**9/l	431.00	371.00		361.00	290.00									
				PL*	20/05/90	138.0	158.0	mmol/l	144.00	146.00		148.00	144.00									
				K*	20/05/90	3.6	5.0	mmol/l	5.30	5.30		4.80	5.00									
				Ca++	20/05/90	1.8	2.6	mmol/l	1.20			1.80	2.00									
				PO4--	20/05/90	0.9	1.6	mmol/l	1.20			1.30	0.70									
				SGPT	20/05/90	4.0	25.0	U/l	7.00	9.00		10.00	10.00									
GAMMA-GT	20/05/90	4.0	27.0	U/l	9.00	7.00		12.00	14.00													
GLUCOSE	20/05/90	3.6	5.7	mmol/l	11.00	6.00		12.00	7.00													
ALK. PHOSPH.	20/05/90	2.0	55.0	mmol/l	33.00	4.70		16.00	5.40													
CREATININE	20/05/90	45.0	105.0	umol/l	70.00	6.00		70.00	10.00													
TOT BILIRUBIN	20/05/90	100.0	400.0	umol/l	259.00	80.00		292.00	284.00													
DIR BILIRUBIN	20/05/90	2.0	20.0	umol/l	12.00	14.00		13.00	13.00													
TOT. PROTEINS	20/05/90	66.0	97.0	g/l	70.00	80.00		70.00	70.00													
ALBUMINE	20/05/90	32.0	55.0	g/l	47.00	45.00		45.00	41.00													
TRIGLYCERIDES	20/05/90	3.0	8.8	mmol/l	5.90	5.40		8.90	8.30													
GLORULINS: ALPHA1	20/05/90	0.3	1.8	mmol/l	0.90	1.80		1.40	1.80													
GLORULINS: ALPHA2	20/05/90	2.5	4.0	%	1.70	3.60		1.70	2.40													
GLORULINS: BETA	20/05/90	7.0	10.0	%	10.50	12.00		10.00	12.50													
GLORULINS: GAMMA	20/05/90	8.3	14.5	%	18.80	19.00		18.40	18.60													
HB	20/05/90	4.0	10.5	mmol/l	14.30	15.40		15.10	16.30													

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1860

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBEXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBEXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit									
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52			
9	7-243	M		HTC	20/05/90	38.0	53.0	%	44.00	46.00	50.00	51.00	50.00	51.00	51.00		
				RBC	20/05/90	4.0	6.0	10**6/uL	5.00	5.30	5.60	5.80	5.50	5.50	5.50	5.50	
				WBC	20/05/90	4.0	12.0	10**3/uL	5.60	5.80	7.00	6.60	7.40	6.50	7.40	6.50	
				WBC: N	20/05/90	60.0	80.0	%	78.00	.	78.00	18.00
				WBC: L	20/05/90	15.0	40.0	%	1.00	.	1.00	1.00
				WBC: E	20/05/90	0.0	5.0	%	3.00	.	3.00	3.00
				WBC: M	20/05/90	1.0	6.0	%	0.00	.	0.00	0.00
				WBC: B	20/05/90	0.0	1.0	%	167.00	.	167.00	167.00
				PLATELETS	20/05/90	120.0	640.0	10**9/L	227.00	336.00	252.00	228.00	281.00	167.00	228.00	281.00	167.00
				NA+	20/05/90	138.0	158.0	mmol/L	146.00	145.00	144.00	144.00	144.00	145.00	144.00	144.00	145.00
				K+	20/05/90	3.6	5.0	mmol/L	4.70	3.90	4.10	4.20	4.50	4.40	4.20	4.50	4.40
				CR++	20/05/90	1.8	2.6	mmol/L	2.70	.	2.80	2.10	2.10	2.40	2.10	2.40	2.40
				PO4-	20/05/90	0.5	1.6	mmol/L	0.70	.	0.70	0.70	1.00	0.90	0.70	1.00	0.90
				SGPT	20/05/90	6.0	28.0	U/L	8.00	12.00	10.00	8.00	10.00	10.00	8.00	10.00	9.00
				GAMMA-GT	20/05/90	6.0	28.0	U/L	13.00	21.00	18.00	11.00	13.00	9.00	11.00	13.00	9.00
				GLUCOSE	20/05/90	3.6	5.7	mmol/L	4.00	4.00	4.00	4.00	3.80	5.00	4.00	3.80	5.00
				BUN	20/05/90	2.0	9.0	mmol/L	30.00	23.00	4.60	3.90	3.00	36.00	2.00	3.00	36.00
				UREIC ACID	20/05/90	2.0	9.0	mmol/L	4.00	2.00	5.00	5.00	3.00	3.00	5.00	3.00	3.00
				TOT BILIRUBIN	20/05/90	100.0	420.0	umol/L	110.00	95.00	90.00	100.00	85.00	103.00	100.00	85.00	103.00
				DIR BILIRUBIN	20/05/90	2.0	20.0	umol/L	134.00	22.00	21.00	20.00	15.00	358.00	20.00	15.00	358.00
				TOT. PROTEINS	20/05/90	66.0	97.0	g/L	78.00	78.00	83.00	80.00	87.00	85.00	80.00	87.00	85.00
				ALBUMINE	20/05/90	32.0	55.0	g/L	46.00	46.00	47.00	42.00	60.00	58.00	42.00	60.00	58.00
				TOT. CHOLEST.	20/05/90	3.0	8.7	mmol/L	5.80	5.60	5.40	5.10	6.40	6.40	5.10	6.40	6.40
				TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/L	0.80	0.30	0.70	0.80	0.90	1.10	0.80	0.90	1.10
				GLOBULINS: ALPHA1	20/05/90	2.5	4.0	%	2.80	.	2.20	1.00	1.50	1.50	1.00	1.50	1.50
				GLOBULINS: ALPHA2	20/05/90	7.0	10.0	%	7.90	.	5.30	5.00	8.30	5.50	5.00	8.30	5.50
				GLOBULINS: BETA	20/05/90	8.3	14.5	%	12.00	.	13.50	11.90	13.40	16.40	11.90	13.40	16.40
				GLOBULINS: GAMMA	20/05/90	14.0	25.0	%	22.60	.	22.20	20.20	23.30	22.90	20.20	23.30	22.90
11-246	F			HTC	20/05/90	4.0	10.0	mmol/L	10/04/91	04/06/91	30/07/91	24/09/91	19/11/91	28/01/92			
				RBC	20/05/90	36.0	53.0	%	13.70	13.00	14.50	13.30	13.30	12.20	13.30		
				WBC	20/05/90	4.0	5.8	10**6/uL	4.40	39.00	42.00	38.00	39.00	37.00	39.00		
				WBC: N	20/05/90	4.0	12.0	10**3/uL	6.10	4.20	6.90	3.90	4.20	4.00	4.00		
				WBC: L	20/05/90	60.0	80.0	%	.	7.00	.	5.80	8.40	4.50	8.40		
				WBC: E	20/05/90	15.0	40.0	%	15.00	20.00	15.00		
				WBC: M	20/05/90	0.0	5.0	%	1.00	3.00	1.00		
				WBC: B	20/05/90	1.0	6.0	%	4.00	3.00	4.00		
				PLATELETS	20/05/90	120.0	640.0	10**9/L	373.00	410.00	370.00	297.00	321.00	230.00	321.00		

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
9	11-246	F		NA+	20/05/90	138.0	158.0	mmol/l	147.00	141.00	142.00	142.00	142.00	144.00	140.00
				K+	20/05/90	3.6	5.0	mmol/l	5.30	4.80	5.00	5.00	5.00	5.00	5.20
				CA++	20/05/90	1.8	2.6	mmol/l	2.00	2.30	2.10	2.10	2.10	2.10	2.10
				PO4-	20/05/90	0.9	1.6	mmol/l	1.00	0.70	0.60	0.60	0.50	0.70	0.70
				SGOT	20/05/90	4.0	25.0	U/l	9.00	7.00	8.00	8.00	8.00	10.00	14.00
				SGPT	20/05/90	4.0	27.0	U/l	7.00	5.00	6.00	6.00	7.00	6.00	20.00
				GAMMA-GT	20/05/90	4.0	28.0	U/l	6.00	7.00	5.00	5.00	7.00	3.00	11.00
				GLUCOSE	20/05/90	3.6	5.7	mmol/l	5.00	4.90	5.00	5.00	4.90	5.20	4.10
				ALK. PHOSPH.	20/05/90	20.0	55.0	mmol/l	26.00	35.00	31.00	31.00	33.00	32.00	27.00
				UREA	20/05/90	2.0	10.0	mmol/l	5.00	8.00	4.00	4.00	4.00	4.00	5.00
				CREATININE	20/05/90	45.0	105.0	umol/l	70.00	80.00	70.00	70.00	70.00	70.00	65.00
				TOT. BILIRUBIN	20/05/90	100.0	400.0	umol/l	206.00	87.00	174.00	174.00	140.00	151.00	206.00
				DIR. BILIRUBIN	20/05/90	0.0	20.0	umol/l	10.00	16.00	13.00	13.00	9.00	13.00	13.00
				TOT. PROTEINS	20/05/90	66.0	97.0	g/l	69.10	76.00	78.00	78.00	75.00	78.00	75.00
				ALBUMINE	20/05/90	32.0	55.0	g/l	59.10	59.10	49.00	49.00	47.00	53.00	39.00
				TRIGLYCERIDES	20/05/90	3.0	8.7	mmol/l	5.00	4.60	5.10	5.10	5.90	4.60	4.40
				CHOLESTEROL	20/05/90	0.3	1.8	mmol/l	0.50	1.00	1.20	1.20	0.90	1.10	0.80
				ALPHA1	20/05/90	2.5	4.0	x	2.50	3.00	2.00	2.00	2.90	3.60	3.40
				ALPHA2	20/05/90	7.0	10.0	x	6.80	9.70	9.20	9.20	5.70	5.80	9.40
				BETA	20/05/90	8.3	14.5	x	16.70	18.30	17.10	17.10	21.50	18.20	18.20
				GAMMA	20/05/90	14.0	25.0	x	14.90	18.70	20.80	20.80	19.90	20.60	18.80
10015-249	F			HB	20/05/90	4.0	10.0	mmol/l	13.80	22/09/91	18/11/91	17/01/92	10/03/92	20/05/92	13.00
				HCT	20/05/90	36.0	53.0	x	40.00	41.00	36.00	36.00	41.00	41.00	41.00
				RBC	20/05/90	4.0	5.8	10**6/u1	4.40	4.30	4.30	4.30	4.30	4.30	4.30
				HBC	20/05/90	4.0	12.0	10**3/u1	5.50	4.40	4.40	4.40	4.80	4.80	6.30
				WBC: N	20/05/90	60.0	80.0	x	5.50	5.50	5.50	5.50	5.50	61.00	76.00
				WBC: L	20/05/90	15.0	40.0	x	5.50	5.50	5.50	5.50	5.50	33.00	20.00
				WBC: E	20/05/90	0.0	5.0	x	5.50	5.50	5.50	5.50	5.50	4.00	0.00
				WBC: M	20/05/90	1.0	6.0	x	5.50	5.50	5.50	5.50	5.50	4.00	0.00
				WBC: B	20/05/90	0.0	1.0	x	5.50	5.50	5.50	5.50	5.50	4.00	0.00
				PLATELETS	20/05/90	120.0	640.0	10**9/l	339.00	224.00	179.00	179.00	179.00	285.00	302.00
				NA+	20/05/90	138.0	158.0	mmol/l	143.00	148.00	146.00	146.00	146.00	148.00	137.00
				K+	20/05/90	3.6	5.0	mmol/l	4.60	4.00	4.70	4.70	4.60	4.60	4.90
				CA++	20/05/90	1.8	2.6	mmol/l	2.20	2.10	2.10	2.10	2.10	2.10	2.30
				PO4-	20/05/90	0.9	1.6	mmol/l	1.00	0.70	0.60	0.60	0.50	0.70	0.70
				SGPT	20/05/90	4.0	25.0	U/l	8.00	7.00	8.00	8.00	8.00	8.00	8.00
				SGOT	20/05/90	4.0	27.0	U/l	7.00	5.00	6.00	6.00	7.00	6.00	11.00
				GAMMA-GT	20/05/90	4.0	28.0	U/l	6.00	7.00	5.00	5.00	7.00	3.00	4.10
				GLUCOSE	20/05/90	3.6	5.7	mmol/l	5.00	4.90	5.00	5.00	4.90	5.20	4.10
				ALK. PHOSPH.	20/05/90	20.0	55.0	mmol/l	26.00	35.00	31.00	31.00	33.00	32.00	27.00
				UREA	20/05/90	45.0	105.0	umol/l	70.00	80.00	70.00	70.00	70.00	70.00	65.00
				TOT. BILIRUBIN	20/05/90	100.0	400.0	umol/l	206.00	87.00	174.00	174.00	140.00	151.00	206.00
				DIR. BILIRUBIN	20/05/90	0.0	20.0	umol/l	10.00	16.00	13.00	13.00	9.00	13.00	13.00
				TOT. PROTEINS	20/05/90	66.0	97.0	g/l	69.10	76.00	78.00	78.00	75.00	78.00	75.00
				ALBUMINE	20/05/90	32.0	55.0	g/l	59.10	59.10	49.00	49.00	47.00	53.00	39.00
				TRIGLYCERIDES	20/05/90	3.0	8.7	mmol/l	5.00	4.60	5.10	5.10	5.90	4.60	4.40
				CHOLESTEROL	20/05/90	0.3	1.8	mmol/l	0.50	1.00	1.20	1.20	0.90	1.10	0.80
				ALPHA1	20/05/90	2.5	4.0	x	2.50	3.00	2.00	2.00	2.90	3.60	3.40
				ALPHA2	20/05/90	7.0	10.0	x	6.80	9.70	9.20	9.20	5.70	5.80	9.40
				BETA	20/05/90	8.3	14.5	x	16.70	18.30	17.10	17.10	21.50	18.20	18.20
				GAMMA	20/05/90	14.0	25.0	x	14.90	18.70	20.80	20.80	19.90	20.60	18.80

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Oper-Blind	Sex	Laboratory test	Laboratory Ranges			Visit											
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52					
9 15-249	F			RUN	20/05/90	2.0	10.0	mmol/l	5.00	6.00	5.00	11.00	6.00	6.00					
				CREATININE	20/05/90	45.0	105.0	umol/l	75.00	80.00	80.00	80.00	80.00	80.00	70.00				
				URIC ACID	20/05/90	100.0	400.0	umol/l	216.00	270.00	126.00	216.00	179.00	179.00	247.00				
				TOT BILIRUBIN	20/05/90	2.0	20.0	umol/l	14.00	18.00	14.00	14.00	12.00	12.00	6.00				
				DIR BILIRUBIN	20/05/90	0.0	5.0	umol/l	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
				TOT. PROTEINS	20/05/90	66.0	97.0	g/l	76.00	70.00	68.00	67.00	73.00	73.00	72.00				
				ALBUMINE	20/05/90	32.0	55.0	g/l	48.00	46.00	48.00	41.00	39.00	41.00	46.00				
				TOT. CHOLEST.	20/05/90	3.0	8.7	mmol/l	7.00	7.70	6.50	7.00	6.00	6.00	6.80				
				TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/l	1.80	1.40	1.30	2.20	1.00	1.00	1.40				
				GLORULINS: ALPHA1	20/05/90	2.5	4.0	%	2.00	2.00	2.10	2.50	1.60	1.60	1.90				
				GLORULINS: ALPHA2	20/05/90	7.0	10.0	%	6.80	9.60	9.30	10.60	5.90	5.90	7.10				
				GLORULINS: BETA	20/05/90	8.3	14.5	%	12.20	13.60	15.70	17.10	17.70	17.70	12.30				
				GLORULINS: GAMMA	20/05/90	14.0	25.0	%	24.00	22.70	22.60	22.10	20.70	20.70	21.60				
				16-250	F			HB	20/05/90	4.0	10.0	mmol/l	17/09/91	12/11/91	14/01/92	23/03/92	28/04/92	06/07/92	
								HTC	20/05/90	36.0	53.0	%	12.40	13.00	11.30	11.20	11.70	11.70	11.50
								RBC	20/05/90	4.0	5.8	10**6/u1	38.00	38.00	34.00	34.00	34.00	34.00	35.00
								RBC: N	20/05/90	4.0	12.0	10**3/u1	4.30	4.50	4.00	4.00	4.10	4.10	4.20
								RBC: L	20/05/90	60.0	80.0	%	8.60	6.60	10.50	8.60	10.00	10.00	6.20
RBC: E	20/05/90	15.0	40.0					%	.	.	77.00	80.00	79.00	79.00	63.00				
RBC: H	20/05/90	0.0	5.0					%	.	.	20.00	16.00	17.00	17.00	31.00				
RBC: B	20/05/90	1.0	6.0					%	.	.	0.00	1.00	1.00	1.00	1.00				
PLATELETS	20/05/90	0.0	1.0					%	.	.	3.00	3.00	3.00	3.00	5.00				
NA+	20/05/90	120.0	640.0					10**9/l	310.00	260.00	590.00	402.00	624.00	624.00	345.00				
K+	20/05/90	138.0	158.0					mmol/l	142.00	146.00	148.00	146.00	147.00	147.00	141.00				
CA++	20/05/90	1.8	2.6					mmol/l	4.60	4.20	4.40	4.70	4.50	4.50	4.20				
PO4--	20/05/90	0.9	1.6					mmol/l	2.30	2.30	1.90	1.90	2.10	2.10	1.80				
SGPT	20/05/90	4.0	25.0					U/l	15.00	21.00	9.00	16.00	13.00	13.00	18.00				
GAMMA-GT	20/05/90	4.0	27.0					U/l	19.00	20.00	9.00	23.00	16.00	16.00	26.00				
GLUCOSE	20/05/90	3.6	5.7					mmol/l	13.00	6.00	12.00	4.00	4.00	4.00	11.00				
ALK. PHOSPH.	20/05/90	20.0	55.0					mmol/l	39.00	51.00	38.00	31.00	35.00	35.00	42.00				
RUN	20/05/90	2.0	10.0					mmol/l	5.00	5.00	3.00	6.00	5.00	5.00	5.00				
CREATININE	20/05/90	45.0	105.0					umol/l	80.00	80.00	65.00	70.00	75.00	75.00	80.00				
URIC ACID	20/05/90	100.0	400.0					umol/l	143.00	189.00	221.00	150.00	203.00	203.00	209.00				
TOT BILIRUBIN	20/05/90	2.0	20.0					umol/l	6.00	15.00	8.00	10.00	8.00	8.00	19.00				
DIR BILIRUBIN	20/05/90	0.0	5.0	umol/l	0.00	0.00	0.00	0.00	0.00	0.00	73.00								
TOT. PROTEINS	20/05/90	66.0	97.0	g/l	74.00	74.00	64.00	74.00	68.00	68.00	73.00								
ALBUMINE	20/05/90	32.0	55.0	g/l	45.00	46.00	38.00	41.00	50.00	50.00	48.00								
TOT. CHOLEST.	20/05/90	3.0	8.7	mmol/l	5.70	6.00	4.00	5.00	4.30	4.30	4.60								
TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/l	0.90	0.90	0.50	1.50	0.50	0.50	0.80								

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1860

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit					
					Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
9	16-250	F		GLOBALINS: ALPHA1	2.5	4.0	%	2.80	1.90	2.70	1.00	1.50	1.80
				GLOBALINS: ALPHA2	7.0	10.0	%	10.10	9.70	10.00	10.70	9.30	6.60
				GLOBALINS: BETA	8.3	14.5	%	14.60	11.50	16.30	10.70	14.60	13.60
				GLOBALINS: GAMMA	14.0	25.0	%	22.60	19.70	23.80	20.30	24.40	27.40
20-252	F			HB	4.0	10.0	mmol/l	07/11/91	27/12/91				
				HTC	36.0	53.0	%	59.00	41.00				
				RBC	4.0	5.8	10 ⁶ /ul	6.00	4.30				
				MBC	4.0	12.0	10 ³ /ul	4.20	6.40				
				PLATELETS	120.0	640.0	10 ³ /ul	105.00	169.00				
				NA+	138.0	158.0	mmol/l	146.00	145.00				
				K+	3.6	5.0	mmol/l	5.30	4.70				
				CA++	1.8	2.6	mmol/l	2.00	2.60				
				PO4--	0.9	1.6	mmol/l	0.90	0.60				
				SGOT	4.0	25.0	U/l	7.00	9.00				
				SGPT	4.0	27.0	U/l	7.00	12.00				
				GAMMA-GT	4.0	28.0	U/l	3.00	7.00				
				GLUCOSE	3.6	5.7	mmol/l	4.70	3.80				
				ALK. PHOSPH.	20.0	55.0	mmol/l	33.00	38.00				
				BUN	2.0	10.0	mmol/l	4.00	2.00				
				CREATININE	45.0	105.0	umol/l	145.00	95.00				
				URIC ACID	100.0	400.0	umol/l	431.00	318.00				
				TOT. BILIRUBIN	2.0	20.0	umol/l	10.00	4.00				
				DIR. BILIRUBIN	0.0	5.0	umol/l	0.00	0.00				
				TOT. PROTEINS	66.0	97.0	g/l	76.00	71.00				
				ALBUMINE	32.0	55.0	g/l	65.00	44.00				
				TOT. CHOLEST.	3.0	8.7	mmol/l	4.70	3.90				
				TRIGLYCERIDES	0.3	1.8	mmol/l	1.00	1.50				
				GLOBALINS: ALPHA1	2.5	4.0	%	2.30	2.40				
				GLOBALINS: ALPHA2	7.0	10.0	%	8.80	10.10				
				GLOBALINS: BETA	8.3	14.5	%	13.80	17.20				
				GLOBALINS: GAMMA	14.0	25.0	%	16.90	20.40				
23-256	F			HB	4.0	10.0	mmol/l	23/01/92	01/06/92				
				HTC	36.0	53.0	%	12.20					
				RBC	4.0	5.8	10 ⁶ /ul	36.00					
				MBC	4.0	12.0	10 ³ /ul	4.40					
				HBC: N	60.0	80.0	%	7.80					
				HBC: L	15.0	40.0	%	72.00					
				MBC: E	0.0	5.0	%	23.00					

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1864

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range		Visit																							
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52																
9 23-256	F			WBC: M	20/05/90	1.0	6.0	%	5.00				
				WBC: B	20/05/90	0.0	1.0	%	0.00		
				PLATELETS	20/05/90	120.0	640.0	10**9/l	229.00	
				NA+	20/05/90	138.0	158.0	mmol/l	143.00	
				K+	20/05/90	3.6	5.0	mmol/l	4.50	
				CA++	20/05/90	1.8	2.6	mmol/l	2.40	
				PO4-	20/05/90	0.9	1.6	mmol/l	1.10	
				SCOT	20/05/90	4.0	25.0	U/l	7.00	
				SGPT	20/05/90	4.0	27.0	U/l	5.00	
				GAMMA-GT	20/05/90	4.0	28.0	U/l	19.00	
				GLUCOSE	20/05/90	3.6	5.7	mmol/l	4.30	
				ALK. PROSPH.	20/05/90	20.0	55.0	mmol/l	35.00	
				BUN	20/05/90	2.0	10.0	mmol/l	10.00	
				CREATININE	20/05/90	45.0	105.0	umol/l	95.00	
				URIC ACID	20/05/90	100.0	400.0	umol/l	321.00	
				TOT BILIRUBIN	20/05/90	2.0	20.0	umol/l	12.00	
				TOT. PROTEINS	20/05/90	66.0	97.0	g/l	80.00	
				ALBUMINE	20/05/90	32.0	55.0	g/l	42.00	
				TOT. CHOLEST.	20/05/90	3.0	8.7	mmol/l	7.40	
				TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/l	1.20	
				GLOBULINS: ALPHA1	20/05/90	2.5	4.0	%	1.50	
				GLOBULINS: ALPHA2	20/05/90	7.0	10.0	%	8.20	
				GLOBULINS: BETA	20/05/90	8.3	14.5	%	16.80	
				GLOBULINS: GAMMA	20/05/90	14.0	25.0	%	22.20	
				1-00026-255	F			HB	20/05/90	4.0	10.0	mmol/l	14.60	24/03/92	15.00
								HTC	20/05/90	36.0	53.0	%	42.00	30/01/92	45.00
ERC	20/05/90	4.0	5.8					10**6/ul	4.50	30/01/92	4.90		
WBC	20/05/90	4.0	12.0					10**3/ul	10.10	30/01/92	8.20	
WBC: N	20/05/90	60.0	80.0					%	72.00	30/01/92	68.00	
WBC: L	20/05/90	15.0	40.0					%	23.00	30/01/92	26.00	
WBC: E	20/05/90	0.0	5.0					%	0.00	30/01/92	1.00	
WBC: M	20/05/90	1.0	6.0					%	5.00	30/01/92	5.00	
WBC: B	20/05/90	0.0	1.0					%	0.00	30/01/92	0.00	
PLATELETS	20/05/90	120.0	640.0					10**9/l	253.00	30/01/92	335.00	
NA+	20/05/90	138.0	158.0					mmol/l	145.00	30/01/92	149.00	
K+	20/05/90	3.6	5.0					mmol/l	4.30	30/01/92	4.60	
CA++	20/05/90	1.8	2.6					mmol/l	2.10	30/01/92	2.10	
PO4-	20/05/90	0.9	1.6					mmol/l	1.10	30/01/92	1.00	
SCOT	20/05/90	4.0	25.0					U/l	11.00	30/01/92	7.00	
SGPT	20/05/90	4.0	27.0					U/l	14.00	30/01/92	8.00	
GAMMA-GT	20/05/90	4.0	28.0	U/l	30.00	30/01/92	24.00					

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXYETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXYETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Date	Laboratory Range			Visit										
						Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52					
9 26-255	F			GLUCOSE	20/05/90	3.6	5.7	mmol/l	5.40	4.30									
				ALK. PHOSPH.	20/05/90	20.0	55.0	mmol/l	66.00	47.00									
				BUN	20/05/90	2.0	10.0	mmol/l	7.00	5.00									
				CREATININE	20/05/90	45.0	105.0	umol/l	80.00	65.00									
				URIC ACID	20/05/90	100.0	400.0	umol/l	303.00	256.00									
				TOT. BILIRUBIN	20/05/90	2.0	20.0	umol/l	16.00	7.00									
				TOT. PROTEINS	20/05/90	65.0	97.0	g/l	81.00	74.00									
				ALBUMINE	20/05/90	32.0	55.0	g/l	48.00	55.00									
				TOT. CHOLEST.	20/05/90	3.0	8.7	mmol/l	6.50	7.00									
				TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/l	3.20	2.10									
				GLOBULINS: ALPHA1	20/05/90	2.5	4.0	%	1.00	1.50									
				GLOBULINS: ALPHA2	20/05/90	7.0	10.0	%	6.70	4.60									
				GLOBULINS: BETA	20/05/90	8.3	14.5	%	17.90	16.30									
				GLOBULINS: GAMMA	20/05/90	14.0	25.0	%	20.60	18.50									
				29-258	F			HB	20/05/90	4.0	10.0	mmol/l	10.90	11/08/92	10.40				
								HTC	20/05/90	36.0	53.0	%	33.00	33.00					
								RBC	20/05/90	4.0	5.8	10**6/u1	3.80	4.00					
								WBC	20/05/90	4.0	12.0	10**3/u1	4.50	5.70					
								PLT	20/05/90	60.0	80.0	%	57.00	70.00					
NEUT	20/05/90	15.0	40.0					%	39.00	23.00									
L	20/05/90	0.0	5.0					%	1.00	2.00									
E	20/05/90	1.0	6.0					%	3.00	5.00									
M	20/05/90	1.0	6.0					%	3.00	5.00									
B	20/05/90	0.0	1.0					%	0.00	0.00									
PLATELETS	20/05/90	120.0	640.0					10**9/l	225.00	276.00									
NA+	20/05/90	138.0	158.0					mmol/l	142.00	144.00									
K+	20/05/90	3.6	5.0					mmol/l	5.20	5.50									
CA++	20/05/90	1.8	2.6					mmol/l	2.20	2.00									
PO4--	20/05/90	0.9	1.6					mmol/l	0.81	1.00									
SGOT	20/05/90	4.0	25.0					U/l	21.00	12.00									
SGPT	20/05/90	4.0	27.0					U/l	45.00	32.00									
GAMMA-GT	20/05/90	4.0	28.0					U/l	22.00	4.10									
GLUCOSE	20/05/90	3.6	5.7					mmol/l	4.60	33.00									
ALK. PHOSPH.	20/05/90	20.0	55.0					mmol/l	33.00	33.00									
BUN	20/05/90	2.0	10.0					mmol/l	4.00	7.00									
CREATININE	20/05/90	45.0	105.0	umol/l	70.00	110.00													
URIC ACID	20/05/90	100.0	400.0	umol/l	137.00	239.00													
TOT. BILIRUBIN	20/05/90	2.0	20.0	umol/l	14.00	26.00													
TOT. PROTEINS	20/05/90	65.0	97.0	g/l	80.00	7.00													
ALBUMINE	20/05/90	32.0	55.0	g/l	41.00	53.00													
TOT. CHOLEST.	20/05/90	3.0	8.7	mmol/l	6.50	6.70													

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1866

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit						
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
9 29-258	F			TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/l	0.80	0.80				
				GLOBULINS: ALPHA1	20/05/90	2.5	4.0	%	2.10	3.20				
				GLOBULINS: ALPHA2	20/05/90	7.0	10.0	%	6.20	10.10				
				GLOBULINS: BETA	20/05/90	8.3	14.5	%	13.80	14.60				
				GLOBULINS: GAMMA	20/05/90	14.0	25.0	%	26.50	29.20				
				HB	01/10/90	129.0	150.0	g/l	140.00	146.00				
				HTC	01/10/90	0.4	0.5	l/l	0.45	0.44				
				RBC	01/10/90	4.0	5.0	10**12/l	4.27	6.38				
				HBC	01/10/90	4.0	8.8	10**9/l	7.20	5.60				
				HBC: N	01/10/90	51.0	77.0	%	54.00	64.00				
HBC: L	01/10/90	18.0	38.0	%	35.00	28.00								
HBC: E	01/10/90	1.0	5.0	%	8.00	2.00								
HBC: M	01/10/90	2.0	10.0	%	2.00	1.00								
HBC: B	01/10/90	0.0	1.0	%	1.00	0.00								
PLATELETS	01/10/90	180.0	320.0	10**9/l	225.00	237.00								
NA+	01/10/90	135.0	150.0	mmol/l	139.00	135.00								
K+	01/10/90	4.0	5.6	mmol/l	4.50	4.90								
CL-	01/10/90	95.0	105.0	mmol/l	92.60	94.60								
PO4-	01/10/90	0.6	1.3	mmol/l	0.80	0.71								
SGPT	01/10/90	1.0	12.0	U/l	3.00	4.00								
SGPT	01/10/90	1.0	9.0	U/l	5.00	7.50								
GAMMA-GT	01/10/90	15.0	106.0	U/l	62.00	5.40								
GLUCOSE	01/10/90	3.5	5.5	mmol/l	4.80	4.70								
ALK. PHOSPH.	01/10/90	135.0	360.0	nmol/l	385.00	283.00								
ALK. PHOSPH.	01/10/90	3.3	10.0	mmol/l	10.80	6.70								
BUN	01/10/90	44.0	101.0	umol/l	71.40	71.80								
CREATININE	01/10/90	119.0	357.0	umol/l	361.00	366.00								
URIC ACID	01/10/90	8.6	20.5	umol/l	17.40	19.00								
TOT. BILIRUBIN	01/10/90	0.0	5.1	umol/l	2.00	1.20								
DIR. BILIRUBIN	01/10/90	65.0	85.0	g/l	85.00	81.00								
TOT. PROTEINS	01/10/90	34.0	55.0	g/l	49.80	54.60								
ALBUMINE	01/10/90	3.1	6.2	mmol/l	6.20	4.80								
TOT. CHOLEST.	01/10/90	0.5	1.3	mmol/l	1.60	1.80								
TRIGLYCERIDES	01/10/90	1.3	6.0	g/l	5.90	3.60								
GLOBULINS: ALPHA1	01/10/90	5.0	9.0	g/l	6.00	4.90								
GLOBULINS: ALPHA2	01/10/90	5.0	13.0	g/l	6.80	8.90								
GLOBULINS: BETA	01/10/90	5.0	17.0	g/l	16.50	9.20								
GLOBULINS: GAMMA	01/10/90	10.0												
9-275	F		HB		01/10/90	112.0	140.0	g/l						

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1 0 0 7

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Pat. No.	Open-Blind Sex	Laboratory test	Laboratory Range			Visit						
				Date	Min	Max Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
10	9-275	F	HTC	01/10/90	0.4	0.5 l/l							
		RBC	01/10/90	3.7	4.7 10**12/l								
		HGB	01/10/90	4.0	8.8 10**g/l								
		HBC: N	01/10/90	51.0	77.0 %								
		HBC: L	01/10/90	18.0	38.0 %								
		HBC: E	01/10/90	1.0	5.0 %								
		HBC: M	01/10/90	2.0	10.0 %								
		HBC: B	01/10/90	0.0	1.0 %								
		PLATELETS	01/10/90	180.0	320.0 10**9/l								
		NA+	01/10/90	135.0	150.0 mmol/l								
		K+	01/10/90	4.0	5.6 mmol/l								
		PO4-	01/10/90	0.6	1.3 mmol/l								
		SGPT	01/10/90	1.0	12.0 U/l								
		SGOT	01/10/90	1.0	9.0 U/l								
		GAMMA-GT	01/10/90	10.0	66.0 U/l								
		GLUCOSE	01/10/90	3.5	5.5 mmol/l								
		ALK. PHOSPH.	01/10/90	135.0	360.0 mmol/l								
		BUN	01/10/90	3.3	10.0 mmol/l								
		UREIC ACID	01/10/90	44.0	88.0 umol/l								
		CREATININE	01/10/90	119.0	357.0 umol/l								
		TOT. BILIRUBIN	01/10/90	8.6	20.5 umol/l								
		TOT. BILIRUBIN	01/10/90	0.5	4.3 umol/l								
		TOT. PROTEINS	01/10/90	65.0	85.0 g/l								
		ALBUMINE	01/10/90	34.0	55.0 g/l								
		TOT. CHOLEST.	01/10/90	3.1	6.2 mmol/l								
		TRIGLYCERIDES	01/10/90	0.5	1.9 mmol/l								
		GLOBULINS: ALPHA1	01/10/90	1.3	6.0 g/l								
GLOBULINS: ALPHA2	01/10/90	5.0	9.0 g/l										
GLOBULINS: BETA	01/10/90	5.0	13.0 g/l										
GLOBULINS: GAMMA	01/10/90	10.0	17.0 g/l										
				20/03/91									
12-277		F	HTC	01/10/90	112.0	140.0 g/l							
		RBC	01/10/90	0.4	0.5 l/l								
		HBC	01/10/90	3.7	4.7 10**12/l								
		HBC: N	01/10/90	4.0	8.8 10**g/l								
		HBC: L	01/10/90	18.0	38.0 %								
		HBC: E	01/10/90	1.0	5.0 %								
		HBC: M	01/10/90	2.0	10.0 %								
		HBC: B	01/10/90	0.0	1.0 %								
		PLATELETS	01/10/90	180.0	320.0 10**9/l								
				136.00									

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1868

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
10 12-277	F			NA+	01/10/90	135.0	150.0	mmol/l	145.00
				K+	01/10/90	4.0	5.6	mmol/l	4.10
10 12-277	F			CL-	01/10/90	95.0	105.0	mmol/l	98.40
				PO4-	01/10/90	0.6	1.3	mmol/l	0.88
10 12-277	F			SGOT	01/10/90	1.0	12.0	U/l	1.30
				SGPT	01/10/90	1.0	9.0	U/l	5.20
10 12-277	F			GAMMA-GT	01/10/90	10.0	66.0	U/l	20.00
				GLUCOSE	01/10/90	3.5	5.5	mmol/l	4.30
10 12-277	F			ALK. PHOSPH.	01/10/90	135.0	360.0	mmol/l	299.00
				BUN	01/10/90	3.3	10.0	mmol/l	6.40
10 12-277	F			CREATININE	01/10/90	44.0	88.0	mmol/l	68.80
				URIC ACID	01/10/90	119.0	357.0	mmol/l	252.00
10 12-277	F			TOT BILIRUBIN	01/10/90	8.6	20.5	umol/l	15.30
				DIR BILIRUBIN	01/10/90	0.5	4.3	umol/l	0.80
10 12-277	F			TOT. PROTEINS	01/10/90	65.0	85.0	g/l	87.00
				ALBUMINE	01/10/90	34.0	55.0	g/l	53.50
10 12-277	F			TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/l	6.90
				TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/l	2.00
10 12-277	F			GLOBULINS: ALPHA1	01/10/90	1.3	6.0	g/l	2.70
				GLOBULINS: ALPHA2	01/10/90	5.0	9.0	g/l	7.00
10 12-277	F			GLOBULINS: BETA	01/10/90	5.0	13.0	g/l	13.60
				GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	10.20
15-280	F			HB	01/10/90	112.0	140.0	g/l	136.00	30/04/91
				HCT	01/10/90	0.4	0.5	l/l	0.43
15-280	F			RBC	01/10/90	3.7	4.7	10**12/l	4.27
				WBC	01/10/90	4.0	8.8	10**9/l	5.00
15-280	F			WBC: N	01/10/90	51.0	77.0	%	60.00
				WBC: L	01/10/90	18.0	38.0	%	37.00
15-280	F			WBC: E	01/10/90	1.0	5.0	%	2.00
				WBC: M	01/10/90	2.0	10.0	%	1.00
15-280	F			WBC: B	01/10/90	0.0	1.0	%	0.00
				PLATELETS	01/10/90	180.0	320.0	10**9/l	218.00
15-280	F			NA+	01/10/90	135.0	150.0	mmol/l	137.00
				K+	01/10/90	4.0	5.6	mmol/l	4.20
15-280	F			CL-	01/10/90	95.0	105.0	mmol/l	97.00
				PO4-	01/10/90	0.6	1.3	mmol/l	1.32
15-280	F			SGOT	01/10/90	1.0	12.0	U/l	6.20
				SGPT	01/10/90	1.0	9.0	U/l	9.60
15-280	F			GAMMA-GT	01/10/90	10.0	66.0	U/l	30.00
				GLUCOSE	01/10/90	3.5	5.5	mmol/l	4.60
15-280	F			ALK. PHOSPH.	01/10/90	135.0	360.0	mmol/l	312.00

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXYETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXYETINE

Pat. No.	Open-Blind Sex	Laboratory test	Laboratory Range			Visit									
			Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52			
10	F	BUN	01/10/90	3.3	10.0	mmol/l	6.90								
		CREATININE	01/10/90	44.0	88.0	umol/l	73.90								
		URIC ACID	01/10/90	119.0	357.0	umol/l	317.00								
		TOT BILIRUBIN	01/10/90	8.6	20.5	umol/l	15.00								
		DIR BILIRUBIN	01/10/90	0.5	4.3	umol/l	2.80								
		TOT. PROTEINS	01/10/90	65.0	85.0	g/l	80.00								
		ALBUMINE	01/10/90	34.0	55.0	g/l	46.80								
		TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/l	4.90								
		TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/l	1.80								
		GLORULINS: ALPHA1	01/10/90	1.3	6.0	g/l	2.90								
		GLORULINS: ALPHA2	01/10/90	5.0	9.0	g/l	9.90								
		GLORULINS: BETA	01/10/90	5.0	13.0	g/l	11.40								
		GLORULINS: GAMMA	01/10/90	10.0	17.0	g/l	9.00								
		20-285	F	HB	01/10/90	112.0	140.0	g/l	132.00	26/08/91	21/10/91				
				HCT	01/10/90	0.4	0.5	l/l	0.42	134.00	130.00				
				HRC	01/10/90	3.7	4.7	10 ⁹ *12/l	4.15	0.41	0.42				
				REC	01/10/90	4.0	8.8	10 ⁹ *9/l	6.30	4.15	4.18				
REC: N	01/10/90			51.0	77.0	x	54.00	3.90	7.70						
REC: L	01/10/90			18.0	38.0	x	42.00	64.00	64.00						
REC: E	01/10/90			1.0	5.0	x	2.00	26.00	32.00						
REC: H	01/10/90			2.0	10.0	x	2.00	6.00	2.00						
REC: B	01/10/90			0.0	1.0	x	0.00	4.00	2.00						
PLATELETS	01/10/90			180.0	320.0	10 ⁹ *9/l	227.00	0.00	0.00						
K+	01/10/90			135.0	150.0	mmol/l	141.00	225.00	225.00						
CL-	01/10/90			95.0	105.0	mmol/l	101.00	145.00	142.00						
PO4-	01/10/90			0.6	1.3	mmol/l	1.00	99.80	104.20						
SGPT	01/10/90			1.0	12.0	U/l	4.50	1.21	1.11						
GAMMA-GT	01/10/90			10.0	66.0	U/l	21.00	7.00	2.70						
GLUCOSE	01/10/90			3.5	5.5	mmol/l	4.20	4.50	2.00						
BUN	01/10/90			3.3	360.0	mmol/l	205.00	24.00	53.00						
ALK. PHOSPH.	01/10/90			44.0	10.0	mmol/l	7.50	185.00	237.00						
CREATININE	01/10/90			119.0	88.0	umol/l	69.00	4.20	5.40						
URIC ACID	01/10/90			8.6	357.0	umol/l	229.00	91.30	91.70						
TOT BILIRUBIN	01/10/90			0.5	20.5	umol/l	16.80	232.00	198.00						
DIR BILIRUBIN	01/10/90			0.5	4.3	umol/l	1.40	17.60	16.10						
TOT. PROTEINS	01/10/90			65.0	85.0	g/l	79.00	1.90	0.56						
ALBUMINE	01/10/90	34.0	55.0	g/l	48.50	80.00	80.00								
TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/l	4.60	51.00	49.50								
TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/l	1.40	3.90	2.70								

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit						
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
10 20-285	F			GLIUBULINS: ALPHA1	01/10/90	1.3	6.0	g/l	1.90	1.60	5.00			
				GLIUBULINS: ALPHA2	01/10/90	5.0	9.0	g/l	7.30	5.70	5.20			
				GLIUBULINS: BETA	01/10/90	5.0	13.0	g/l	9.60	9.10	10.30			
				GLIUBULINS: GAMMA	01/10/90	10.0	17.0	g/l	11.30	12.60	9.60			
				HB	01/10/90	129.0	150.0	g/L	142.00	144.00	136.00	16/12/91	10/02/92	
				HCT	01/10/90	0.4	0.5	L/L	0.41	0.43	0.40	0.43	141.00	
				RBC	01/10/90	4.0	5.0	10 ¹² /L	4.02	4.27	3.98	4.27	4.30	
				WBC	01/10/90	4.0	8.8	10 ⁹ /L	6.40	6.00	6.10	6.80	5.70	
				WBC: N	01/10/90	51.0	77.0	%	64.00	76.00	62.00	56.00	59.00	
				WBC: L	01/10/90	18.0	38.0	%	28.00	22.00	34.00	38.00	35.00	
WBC: E	01/10/90	1.0	5.0	%	6.00	0.00	2.00	2.00	3.00					
WBC: M	01/10/90	2.0	10.0	%	2.00	2.00	2.00	4.00	3.00					
WBC: B	01/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00					
PLATELETS	01/10/90	180.0	320.0	10 ⁹ /L	218.00	249.00	227.00	218.00	220.00					
NA+	01/10/90	135.0	150.0	MMOL/L	142.00	146.00	142.00	135.00	137.00					
K+	01/10/90	4.0	5.6	MMOL/L	4.60	4.80	4.30	4.70	4.80					
CL-	01/10/90	95.0	105.0	MMOL/L	99.50	100.10	95.40	99.30	99.40					
PO4--	01/10/90	0.6	1.3	MMOL/L	1.40	1.04	1.70	1.20	1.22					
SGPT	01/10/90	1.0	12.0	U/L	4.00	5.00	6.00	3.50	3.00					
SGPT	01/10/90	1.0	9.0	U/L	7.50	9.00	8.00	8.50	4.80					
GAMMA-GT	01/10/90	15.0	106.0	U/L	38.00	40.00	56.00							
GLUCOSE	10/12/91	0.3	1.8	UKAT/L				1.45	1.40					
ALK. PHOSPH.	01/10/90	3.5	5.5	MMOL/L	4.70	4.30	2.60	4.20	4.40					
BUN	01/10/90	135.0	360.0	MMOL/L	284.00	328.00	483.00	438.00	422.00					
CREATININE	01/10/90	3.3	10.0	MMOL/L	4.50	4.00	3.80	4.00	4.40					
URIC ACID	01/01/92	214.0	458.0	UMOL/L	96.60	76.40	105.40	80.20	78.40					
TOT BILIRUBIN	01/10/90	119.0	357.0	UMOL/L	359.00	347.00	316.00	333.00	327.00					
DIR BILIRUBIN	01/10/90	8.6	20.5	UMOL/L	13.50	15.20	17.40	10.10	14.30					
TOT. PROTEINS	01/10/90	65.0	85.0	g/L	80.00	82.00	80.00	80.00	84.00					
ALBUMINE	01/10/90	34.0	55.0	g/L	49.70	52.60	43.30	52.20	54.20					
TOT. CHOLEST.	01/10/90	3.1	6.2	MMOL/L	6.10	4.60	4.00	4.40	4.10					
TRIGLYCERIDES	01/10/90	0.5	1.9	MMOL/L	1.82	1.65	1.30	1.90	1.84					
GLIUBULINS: ALPHA1	01/10/90	1.3	6.0	g/L	3.00	1.90	1.90	1.30	1.40					
GLIUBULINS: ALPHA2	01/10/90	5.0	9.0	g/L	6.00	8.90	9.40	8.50	8.70					
GLIUBULINS: BETA	01/10/90	5.0	13.0	g/L	6.80	9.00	11.40	7.80	8.60					
GLIUBULINS: GAMMA	01/10/90	10.0	17.0	g/L	14.50	9.60	14.00	10.20	11.30					

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit						
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
10 23-287	F			HB	01/10/90	112.0	140.0	G/L	02/07/91	26/08/91	22/10/91	17/12/91	11/02/92	
				HCT	01/10/90	0.4	0.5	L/L	127.00	130.00	132.00	122.00	138.00	
				RBC	01/10/90	3.7	4.7	10**12/L	0.37	0.42	0.35	0.37	0.41	
				HGB	01/10/90	4.0	8.8	10**9/L	3.68	4.15	3.85	3.85	4.21	
				HBC: N	01/10/90	51.0	77.0	X	7.50	4.20	4.30	4.40	6.60	
				HBC: L	01/10/90	18.0	38.0	X	24.00	58.00	76.00	54.00	66.00	
				HBC: E	01/10/90	1.0	5.0	X	5.00	40.00	18.00	44.00	28.00	
				HBC: M	01/10/90	2.0	10.0	X	1.00	2.00	4.00	2.00	6.00	
				HBC: B	01/10/90	0.0	1.0	X	0.00	0.00	0.00	0.00	0.00	
				PLATELETS	01/10/90	180.0	320.0	10**9/L	225.00	210.00	210.00	200.00	200.00	
				K+	01/10/90	135.0	150.0	MMOL/L	144.00	130.00	143.00	142.00	138.00	
				CL-	01/10/90	4.0	5.6	MMOL/L	4.00	4.90	5.10	4.80	5.30	
				PO4-	01/10/90	95.0	105.0	MMOL/L	99.50	100.30	95.40	103.10	98.10	
				SGOT	01/10/90	0.6	1.3	MMOL/L	0.78	0.81	1.10	0.88	1.18	
				SGPT	01/10/90	1.0	12.0	U/L	6.00	6.00	2.50	5.50	4.00	
				GAMMA-GT	01/10/90	10.0	66.0	U/L	25.00	30.00	41.00	5.00	2.50	
				GLUCOSE	10/12/91	0.2	1.1	UKAT/L	4.30	4.10	3.50	0.17	0.20	
				ALK. PHOSPH.	01/10/90	135.0	360.0	MMOL/L	228.00	298.00	148.00	225.00	100.00	
				BUN	01/10/90	3.3	10.0	MMOL/L	7.20	4.60	4.00	4.60	5.70	
				CREATININE	01/10/90	44.0	88.0	UMOL/L	69.00	83.20	83.60	73.80	69.80	
				URIC ACID	01/01/92	149.0	405.0	UMOL/L	231.00	224.00	222.00	218.00	165.00	
				TOT BILIRUBIN	01/10/90	119.0	357.0	UMOL/L	14.00	11.30	14.00	8.20	9.60	
				DIR BILIRUBIN	01/10/90	0.5	4.3	UMOL/L	0.56	1.40	1.70	0.56	0.80	
				TOT. PROTEINS	01/10/90	65.0	85.0	G/L	78.00	80.00	80.00	69.00	77.00	
				ALBUMINE	01/10/90	34.0	55.0	G/L	50.20	53.30	46.20	35.80	53.50	
				TOT. CHOLEST.	01/10/90	3.1	6.2	MMOL/L	3.70	4.00	4.20	3.70	3.90	
				TRIGLYCERIDES	01/10/90	0.5	1.9	MMOL/L	0.96	1.16	1.32	0.57	0.46	
				GLOBULINS: ALPHA1	01/10/90	1.3	6.0	G/L	1.90	1.90	2.60	3.80	2.20	
				GLOBULINS: ALPHA2	01/10/90	5.0	9.0	G/L	8.90	6.90	8.00	8.90	5.80	
				GLOBULINS: BETA	01/10/90	5.0	13.0	G/L	8.60	8.60	10.50	12.70	7.70	
				GLOBULINS: GAMMA	01/10/90	10.0	17.0	G/L	8.40	9.30	12.70	7.80	7.80	

26-290 F 05/08/91 138.00
 HB 01/10/90 112.0 140.0 G/L
 HCT 01/10/90 0.4 0.5 L/L
 RBC 01/10/90 3.7 4.7 10**12/L
 HGB 01/10/90 4.0 8.8 10**9/L
 HBC: N 01/10/90 51.0 77.0 X
 HBC: L 01/10/90 18.0 38.0 X
 HBC: E 01/10/90 1.0 5.0 X
 HBC: M 01/10/90 2.0 10.0 X
 HBC: B 01/10/90 0.0 1.0 X
 PLATELETS 01/10/90 180.0 320.0 10**9/L
 K+ 01/10/90 135.0 150.0 MMOL/L
 CL- 01/10/90 4.0 5.6 MMOL/L
 PO4- 01/10/90 95.0 105.0 MMOL/L
 SGOT 01/10/90 0.6 1.3 MMOL/L
 SGPT 01/10/90 1.0 12.0 U/L
 GAMMA-GT 01/10/90 10.0 66.0 U/L
 GLUCOSE 10/12/91 0.2 1.1 UKAT/L
 ALK. PHOSPH. 01/10/90 135.0 360.0 MMOL/L
 BUN 01/10/90 3.3 10.0 MMOL/L
 CREATININE 01/10/90 44.0 88.0 UMOL/L
 URIC ACID 01/01/92 149.0 405.0 UMOL/L
 TOT BILIRUBIN 01/10/90 119.0 357.0 UMOL/L
 DIR BILIRUBIN 01/10/90 0.5 4.3 UMOL/L
 TOT. PROTEINS 01/10/90 65.0 85.0 G/L
 ALBUMINE 01/10/90 34.0 55.0 G/L
 TOT. CHOLEST. 01/10/90 3.1 6.2 MMOL/L
 TRIGLYCERIDES 01/10/90 0.5 1.9 MMOL/L
 GLOBULINS: ALPHA1 01/10/90 1.3 6.0 G/L
 GLOBULINS: ALPHA2 01/10/90 5.0 9.0 G/L
 GLOBULINS: BETA 01/10/90 5.0 13.0 G/L
 GLOBULINS: GAMMA 01/10/90 10.0 17.0 G/L

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centro	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit																														
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52																								
10	26	290	F	HBC: E	01/10/90	1.0	5.0	Z	0.00																													
				HBC: M	01/10/90	2.0	10.0	X	4.00																													
				HBC: B	01/10/90	0.0	1.0	X	0.00																													
				PLATELETS	01/10/90	180.0	320.0	10**9/L	230.00																													
				NA+	01/10/90	135.0	150.0	mmol/L	149.00																													
				K+	01/10/90	4.0	5.6	mmol/L	4.40																													
				CL-	01/10/90	95.0	105.0	mmol/L	97.00																													
				PO4-	01/10/90	0.6	1.3	mmol/L	1.18																													
				SGPT	01/10/90	1.0	12.0	U/L	8.70																													
				SGPT	01/10/90	1.0	9.0	U/L	9.20																													
				GAMMA-GT	01/10/90	10.0	66.0	U/L	19.00																													
				GLUCOSE	01/10/90	3.5	5.5	mmol/L	4.80																													
				ALK. PHOSPH.	01/10/90	135.0	360.0	mmol/L	211.00																													
				BUN	01/10/90	3.3	10.0	mmol/L	6.20																													
				CREATININE	01/10/90	44.0	88.0	umol/L	91.10																													
				TOT. BILIRUBIN	01/10/90	119.0	357.0	umol/L	355.00																													
				DIR. BILIRUBIN	01/10/90	8.6	20.5	umol/L	19.00																													
				TOT. PROTEINS	01/10/90	65.0	85.0	g/L	72.40																													
				ALBUMINE	01/10/90	34.0	55.0	g/L	53.10																													
				TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/L	6.80																													
				TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/L	1.90																													
				GLOBULINS: ALPHA1	01/10/90	1.3	6.0	g/L	1.60																													
				GLOBULINS: ALPHA2	01/10/90	5.0	9.0	g/L	11.20																													
				GLOBULINS: BETA	01/10/90	5.0	13.0	g/L	6.70																													
				GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/L	9.40																													
				27	292	F	HB	01/10/90	112.0	140.0	G/L	132.00																										
							HTC	01/10/90	0.4	0.5	L/L	0.40																										
RBC	01/10/90	3.7	4.7				10**12/L	3.96																														
HBC: N	01/10/90	4.0	8.8				10**9/L	3.30																														
HBC: L	01/10/90	51.0	77.0				X	64.00																														
HBC: E	01/10/90	18.0	38.0				X	32.00																														
HBC: M	01/10/90	1.0	5.0				X	2.00																														
HBC: B	01/10/90	2.0	10.0				X	2.00																														
PLATELETS	01/10/90	180.0	320.0				10**9/L	224.00																														
NA+	01/10/90	135.0	150.0				mmol/L	138.00																														
K+	01/10/90	4.0	5.6				mmol/L	4.80																														
CL-	01/10/90	95.0	105.0				mmol/L	95.10																														
PO4-	01/10/90	0.6	1.3				mmol/L	1.04																														
SGOT	01/10/90	1.0	12.0				U/L	8.00																														

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1873

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range		Visit								
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
10 27-292	F			SGPT	01/10/90	1.0	9.0	U/L	3.00	7.00	4.50	4.50	7.00	4.50	4.50
				GAMMA-GT	01/01/92	0.2	1.1	UKAT/L	25.00	27.00	1.60	0.71	0.40	0.71	1.51
				GLUCOSE	01/10/90	10.0	66.0	U/L	25.00	27.00	1.60	0.71	0.40	0.71	1.51
				ALK. PHOSPH.	01/10/90	3.5	5.5	MMOL/L	4.40	5.50	5.80	3.60	4.70	3.60	5.00
				BUN	01/10/90	135.0	360.0	MMOL/L	382.00	485.00	527.00	254.00	245.00	254.00	221.00
				CREATININE	01/10/90	3.3	10.0	MMOL/L	6.90	7.10	6.20	8.10	6.00	8.10	9.20
				URIC ACID	01/01/92	44.0	88.0	MMOL/L	72.30	71.70	66.90	67.20	76.60	67.20	67.10
				TOT BILIRUBIN	01/10/90	119.0	405.0	MMOL/L	317.00	381.00	337.00	245.00	254.00	254.00	300.00
				DIR BILIRUBIN	01/10/90	8.6	20.5	MMOL/L	13.50	15.80	7.90	8.20	9.80	8.20	14.90
				TOT. PROTEINS	01/10/90	65.0	85.0	G/L	81.00	85.00	69.00	77.00	82.00	77.00	80.00
				ALBUMINE	01/10/90	34.0	55.0	G/L	50.50	52.40	36.10	49.50	47.30	49.50	42.40
				TOT. CHOLEST.	01/10/90	3.1	6.2	MMOL/L	3.90	5.40	5.50	6.20	5.60	6.20	6.50
				TRIGLYCERIDES	01/10/90	0.5	1.9	MMOL/L	2.00	3.40	1.25	4.44	1.66	4.44	2.30
				GLOBULINS: ALPHA1	01/10/90	1.3	6.0	G/L	3.90	3.10	3.90	3.10	4.00	3.10	2.80
				GLOBULINS: ALPHA2	01/10/90	5.0	9.0	G/L	7.30	10.20	7.30	7.50	10.70	7.50	10.20
				GLOBULINS: BETA	01/10/90	5.0	13.0	G/L	7.00	8.40	13.30	8.90	6.60	8.90	8.70
				GLOBULINS: GAMMA	01/10/90	10.0	17.0	G/L	12.10	10.90	8.40	8.40	13.40	8.40	13.90
28-291	M			HB	01/10/90	129.0	150.0	G/L	141.00	141.00	142.00	136.00	132.00	136.00	132.00
				HTC	01/10/90	0.4	0.5	L/L	0.43	0.44	0.43	0.43	0.42	0.43	0.42
				RBC	01/10/90	4.0	5.0	10**12/L	4.27	4.20	4.27	4.27	4.18	4.27	4.18
				WBC	01/10/90	4.0	8.8	10**9/L	8.30	5.00	9.30	4.60	5.80	4.60	5.80
				WBC: N	01/10/90	51.0	77.0	%	66.00	52.00	70.00	64.00	68.00	64.00	68.00
				WBC: L	01/10/90	18.0	38.0	%	28.00	34.00	20.00	30.00	30.00	30.00	30.00
				WBC: E	01/10/90	1.0	5.0	%	0.00	6.00	5.00	4.00	0.00	4.00	0.00
				WBC: M	01/10/90	2.0	10.0	%	0.00	8.00	4.00	2.00	2.00	2.00	2.00
				WBC: B	01/10/90	0.0	1.0	%	0.00	0.00	1.00	0.00	0.00	0.00	0.00
				PLATELETS	01/10/90	180.0	320.0	10**9/L	217.00	230.00	230.00	227.00	225.00	227.00	225.00
				PA*	01/10/90	135.0	150.0	MMOL/L	147.00	144.00	140.00	140.00	145.00	140.00	145.00
				CL*	01/10/90	4.0	5.6	MMOL/L	5.10	5.10	4.80	5.10	5.10	5.10	5.10
				PO4*	01/10/90	95.0	105.0	MMOL/L	98.00	95.80	101.40	101.80	98.00	101.80	98.00
				SGPT	01/10/90	1.0	12.0	U/L	6.00	0.93	5.50	5.00	4.00	5.00	4.00
				GAMMA-GT	01/01/92	0.3	1.8	UKAT/L	4.50	3.80	6.50	1.16	0.85	1.16	0.85
				GLUCOSE	01/10/90	15.0	106.0	U/L	25.00	53.00	57.00	4.20	4.20	4.20	4.20
				ALK. PHOSPH.	01/10/90	3.5	5.5	MMOL/L	4.30	3.50	3.60	270.00	152.00	270.00	152.00
				BUN	01/10/90	135.0	360.0	MMOL/L	300.00	243.00	296.00	7.80	6.80	7.80	6.80
				CREATININE	01/10/90	3.3	10.0	MMOL/L	8.30	8.60	89.60	85.20	99.10	85.20	99.10

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

1874

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit									
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52			
10 28-291	M		URIC ACID	01/01/92	214.0	458.0	UMOL/L									
			TOT BILIRUBIN	01/10/90	119.0	357.0	UMOL/L	270.00	343.00	367.00	312.00	179.00				
			DIR BILIRUBIN	01/10/90	8.6	20.5	UMOL/L	17.40	18.50	20.50	8.40	9.40				
				01/01/92	0.5	4.3	UMOL/L				0.70	0.50				
			TOT. PROTEINS	01/10/90	0.0	5.1	UMOL/L	2.80	3.10	2.00						
			ALBUMINE	01/10/90	65.0	85.0	G/L	82.00	80.00	75.00	72.00	78.00				
			TOT. CHOLEST.	01/10/90	34.0	55.0	G/L	50.90	49.00	48.00	36.00	48.60				
			TRIGLYCERIDES	01/10/90	3.1	6.2	MMOL/L	3.90	4.00	3.10	3.80	4.20				
			GLOBULINS: ALPHA1	01/10/90	0.5	1.9	MMOL/L	1.42	2.15	1.89	0.92	0.31				
			GLOBULINS: ALPHA2	01/10/90	1.3	6.0	G/L	1.70	2.70	1.70	2.10	1.00				
			GLOBULINS: BETA	01/10/90	5.0	9.0	G/L	9.20	8.30	7.00	9.20	7.20				
			GLOBULINS: GAMMA	01/10/90	5.0	13.0	G/L	8.90	8.30	8.00	14.60	10.40				
				01/10/90	10.0	17.0	G/L	11.30	11.70	10.30	10.30	10.80				
31-297	F		HR	01/10/90	112.0	140.0	G/L		26/11/91	135.00	131.00	151.00	12/05/92	17/03/92	21/01/92	07/07/92
			HTC	01/10/90	0.4	0.5	L/L	0.42	135.00	0.43	0.41	0.41	0.41	0.41	0.41	0.41
			RBC	01/10/90	3.7	4.7	10**12/L	4.23	4.23	4.18	4.10	4.10	4.10	4.10	4.10	4.10
			HBC: N	01/10/90	4.0	8.8	10**9/L	4.30	4.30	4.30	4.30	4.30	4.30	4.30	4.30	4.30
			HBC: L	01/10/90	51.0	77.0	%	61.00	61.00	76.00	74.00	76.00	76.00	76.00	76.00	76.00
			HBC: E	01/10/90	18.0	38.0	%	34.00	34.00	18.00	22.00	22.00	22.00	22.00	22.00	22.00
			HBC: M	01/10/90	1.0	5.0	%	4.00	4.00	0.00	2.00	2.00	2.00	2.00	2.00	2.00
			HBC: B	01/10/90	2.0	10.0	%	1.00	1.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00
			PLATELETS	01/10/90	180.0	320.0	10**9/L	235.00	225.00	217.00	217.00	217.00	217.00	217.00	217.00	217.00
			Na+	01/10/90	135.0	150.0	MMOL/L	136.00	139.00	140.00	141.00	141.00	141.00	141.00	141.00	141.00
			K+	01/10/90	4.0	5.6	MMOL/L	4.10	4.70	4.60	4.60	4.70	4.90	4.90	4.90	4.90
			CL-	01/10/90	95.0	105.0	MMOL/L	102.40	102.40	100.30	103.10	101.00	101.00	101.00	101.00	101.00
			PO4-	01/10/90	0.6	1.3	MMOL/L	1.11	1.08	1.33	1.22	1.26	1.26	1.26	1.26	1.26
			SGPT	01/10/90	1.0	12.0	U/L	4.50	1.50	2.50	7.50	3.50	3.50	3.50	3.50	3.50
			SGPT	01/10/90	1.0	9.0	U/L	7.00	1.70	5.00	3.00	3.00	3.00	3.00	3.00	3.00
			GAMMA-GT	01/01/92	0.2	1.1	UMAT/L		1.00	0.65	0.60	0.50	0.50	0.50	0.50	0.50
			GLUCOSE	01/10/90	10.0	66.0	U/L	25.00								
			ALK. PHOSPH.	01/10/90	3.5	5.5	MMOL/L	4.20	4.30	4.50	4.10	4.40	4.40	4.40	4.40	4.40
			RUN	01/10/90	135.0	360.0	MMOL/L	265.00	227.00	132.00	120.00	124.00	124.00	124.00	124.00	124.00
			CREATININE	01/10/90	3.3	10.0	MMOL/L	4.70	4.50	5.80	3.40	5.70	5.70	5.70	5.70	5.70
			URIC ACID	01/01/92	169.0	405.0	UMOL/L	61.60	73.90	69.70	64.00	72.10	211.00	211.00	211.00	211.00
				01/10/90	119.0	357.0	UMOL/L	282.00	246.00	202.00	202.00	202.00	202.00	202.00	202.00	202.00
			TOT BILIRUBIN	01/10/90	8.6	20.5	UMOL/L	15.50	15.10	8.40	14.50	16.80	16.80	16.80	16.80	16.80
			DIR BILIRUBIN	01/10/90	0.5	4.3	UMOL/L	1.70	1.90	0.70	2.00	2.30	2.30	2.30	2.30	2.30
			TOT. PROTEINS	01/10/90	65.0	85.0	G/L	80.00	71.00	75.00	79.00	79.00	79.00	79.00	79.00	79.00
			ALBUMINE	01/10/90	34.0	55.0	G/L	40.40	34.90	48.20	47.40	47.40	47.40	47.40	47.40	47.40

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1875

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit						
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
10 31-297	F		TOT. CHOLEST.	01/10/90	3.1	6.2	MMOL/L	3.10	3.00	4.60	3.40	4.20	
			TRIGLYCERIDES	01/10/90	0.5	1.9	MMOL/L	1.12	1.59	0.68	1.59	1.15	
			GLUCOLINS: ALPHA1	01/10/90	1.3	6.0	G/L	4.70	1.40	1.20	2.30	3.30	
			GLUCOLINS: ALPHA2	01/10/90	5.0	9.0	G/L	6.10	8.30	7.00	5.40	6.00	
			GLUCOLINS: BETA	01/10/90	5.0	13.0	G/L	14.70	14.80	8.10	7.40	6.70	
			GLUCOLINS: GAMMA	01/10/90	10.0	17.0	G/L	14.10	11.60	10.50	16.50	12.00	
			HB	01/10/90	112.0	140.0	G/L	126.00	132.00	130.00	128.00	130.00	132.00
			HTC	01/10/90	0.4	0.5	L/L	0.37	0.38	0.38	0.40	0.41	0.40
			RBC	01/10/90	3.7	4.7	10**12/L	3.75	3.83	3.83	4.05	4.08	3.97
			MBC: N	01/10/90	4.0	8.8	10**9/L	4.20	3.30	3.60	3.60	4.20	4.70
			MBC: L	01/10/90	51.0	77.0	%	64.00	50.00	60.00	57.00	70.00	70.00
			MBC: E	01/10/90	18.0	38.0	%	28.00	40.00	27.00	37.00	26.00	22.00
			MBC: M	01/10/90	1.0	5.0	%	6.00	4.00	4.00	2.00	2.00	6.00
MBC: B	01/10/90	2.0	10.0	%	2.00	6.00	7.00	4.00	2.00	2.00			
PLATELETS	01/10/90	180.0	320.0	10**9/L	218.00	210.00	203.00	205.00	220.00	241.00			
NA+	01/10/90	135.0	150.0	MMOL/L	138.00	141.00	140.00	146.00	145.00	141.00			
K+	01/10/90	4.0	5.6	MMOL/L	4.20	4.20	5.10	4.40	5.30	5.10			
CL-	01/10/90	95.0	105.0	MMOL/L	98.90	94.10	104.00	101.00	105.00	99.80			
PO4-	01/10/90	0.6	1.3	MMOL/L	0.89	1.42	1.33	1.09	1.12	1.19			
SCOT	01/10/90	1.0	12.0	U/L	2.00	8.00	6.00	5.00	2.50	5.50			
SGPT	01/10/90	1.0	9.0	U/L	2.50	4.50	7.50	4.00	2.00	4.60			
GAMMA-GT	01/01/92	0.2	1.1	UKAT/L	0.55	0.55	0.73	0.44	0.92	0.71			
GLUCOSE	01/10/90	10.0	66.0	U/L	27.00	4.20	3.70	3.90	4.70	3.70			
ALK. PHOSPH.	01/10/90	3.5	5.5	MMOL/L	4.60	86.00	107.00	98.00	104.00	87.00			
RUN	01/10/90	3.3	10.0	MMOL/L	151.00	6.20	5.50	4.20	5.00	4.30			
CREATININE	01/10/90	44.0	88.0	UMOL/L	4.70	73.60	73.40	97.40	75.10	81.20			
URIC ACID	01/01/92	149.0	405.0	UMOL/L	82.00	247.00	260.00	270.00	273.00	306.00			
TOT. BILIRUBIN	01/10/90	119.0	357.0	UMOL/L	318.00	13.70	15.60	16.30	15.50	15.50			
DIR. BILIRUBIN	01/10/90	6.6	20.5	UMOL/L	20.80	0.80	1.40	1.40	1.40	1.40			
TOT. PROTEINS	01/10/90	65.0	85.0	G/L	80.00	82.00	76.00	74.00	65.00	72.00			
ALBUMINE	01/10/90	34.0	55.0	G/L	40.20	48.40	46.60	42.20	37.10	46.60			
TOT. CHOLEST.	01/10/90	3.1	6.2	MMOL/L	3.00	3.40	0.43	3.80	3.10	3.10			
TRIGLYCERIDES	01/10/90	0.5	1.9	MMOL/L	1.34	0.41	0.88	0.88	0.84	1.97			
GLUCOLINS: ALPHA1	01/10/90	1.3	6.0	G/L	1.00	2.60	2.60	2.50	2.60	1.00			
GLUCOLINS: ALPHA2	01/10/90	5.0	9.0	G/L	5.20	8.00	6.40	7.20	6.40	6.40			
GLUCOLINS: BETA	01/10/90	5.0	13.0	G/L	13.60	7.60	8.40	8.60	6.10	5.40			
GLUCOLINS: GAMMA	01/10/90	10.0	17.0	G/L	16.00	17.00	12.00	13.50	13.00	12.60			

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit										
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52				
10-33-300	M			HB	01/10/90	129.0	150.0	G/L	26/11/91	138.00	21/01/92							
				HTC	01/10/90	0.4	0.5	L/L	0.42	0.43								
				RBC	01/10/90	4.0	5.0	10**12/L	4.23	4.27								
				HBC	01/10/90	4.0	8.8	10**9/L	8.60	5.10								
				HBC: N	01/10/90	51.0	77.0	%	62.00	64.00								
				HBC: L	01/10/90	18.0	38.0	%	35.00	32.00								
				HBC: E	01/10/90	1.0	5.0	%	2.00	2.00								
				HBC: H	01/10/90	2.0	10.0	%	1.00	1.00								
				HBC: B	01/10/90	0.0	1.0	%	0.00	1.00								
				PLATELETS	01/10/90	180.0	320.0	10**9/L	237.00	230.00								
				MA+	01/10/90	135.0	50.0	MMOL/L	141.00	148.00								
				K+	01/10/90	4.0	5.6	MMOL/L	4.60	5.50								
				CL-	01/10/90	95.0	105.0	MMOL/L	101.20	100.50								
				PO4-	01/10/90	0.6	1.3	MMOL/L	0.91	0.92								
				SGOT	01/10/90	1.0	12.0	U/L	3.50	7.00								
				SGPT	01/10/90	1.0	9.0	U/L	6.00	6.00								
				GAMMA-GT	01/01/92	0.3	1.8	UKAT/L	6.00	1.24								
				GLUCOSE	01/10/90	15.0	106.0	U/l	66.00	66.00								
				ALK. PHOSPH.	01/10/90	135.0	360.0	MMOL/L	3.30	4.70								
				BUN	01/10/90	3.3	10.0	MMOL/L	406.00	364.00								
				CREATININE	01/10/90	44.0	101.0	UMOL/L	73.90	6.50								
				URIC ACID	01/01/92	214.0	458.0	UMOL/L	357.00	82.00								
				TOT BILIRUBIN	01/10/90	119.0	357.0	umol/L	347.00	357.00								
				DIR BILIRUBIN	01/10/90	8.6	20.5	UMOL/L	22.50	9.20								
				TOT. PROTEINS	01/10/90	0.5	4.3	UMOL/L	3.40	0.80								
				ALBUMINE	01/10/90	65.0	85.0	G/L	79.00	73.00								
				TOT. CHOLEST.	01/10/90	34.0	55.0	G/L	49.90	44.40								
				TRIGLYCERIDES	01/10/90	3.1	6.2	MMOL/L	3.20	6.90								
				GLOBULINS: ALPHA1	01/10/90	0.5	1.9	MMOL/L	1.90	3.73								
				GLOBULINS: ALPHA2	01/10/90	1.3	6.0	G/L	2.90	2.90								
				GLOBULINS: BETA	01/10/90	5.0	13.0	G/L	9.80	7.30								
				GLOBULINS: GAMMA	01/10/90	10.0	17.0	G/L	8.40	9.20								
				HB	01/10/90	129.0	150.0	g/l	05/12/91	138.00								
HTC	01/10/90	0.4	0.5	l/l		0.40												
RBC	01/10/90	4.0	5.0	10**12/l		4.05												

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1877

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Date	Laboratory Range			Visit							
						Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52		
10 34-31			M	HRC: N	01/10/90	4.0	8.8	10**g/l	4.90							
				HRC: L	01/10/90	51.0	77.0	%	60.00							
				HRC: E	01/10/90	18.0	38.0	%	34.00							
				HBC: N	01/10/90	1.0	5.0	%	0.00							
				HBC: L	01/10/90	2.0	10.0	%	6.00							
				HBC: E	01/10/90	0.0	1.0	%	0.00							
				PLATELETS	01/10/90	180.0	320.0	10**g/l	210.00							
				NA+	01/10/90	135.0	150.0	mmol/l	145.00							
				CL-	01/10/90	95.0	105.0	mmol/l	102.10							
				PO4-	01/10/90	0.6	1.3	mmol/l	1.12							
				SGOT	01/10/90	1.0	12.0	U/l	5.00							
				SGPT	01/10/90	1.0	9.0	U/l	3.00							
				GAMMA-GT	01/10/90	15.0	106.0	U/l	58.00							
				GLUCOSE	01/10/90	3.5	5.5	mmol/l	4.10							
				ALK. PHOSPH.	01/10/90	135.0	360.0	mmol/l	359.00							
				BUN	01/10/90	3.3	10.0	mmol/l	6.20							
				CREATININE	01/10/90	44.0	101.0	umol/l	77.80							
				URIC ACID	01/10/90	119.0	357.0	umol/l	313.00							
				DIR BILIRUBIN	01/10/90	8.6	20.5	umol/l	24.60							
				TOT BILIRUBIN	01/10/90	0.0	5.1	umol/l	2.80							
				TOT. PROTEINS	01/10/90	65.0	85.0	g/l	83.00							
				ALBUMINE	01/10/90	34.0	55.0	g/l	44.10							
				TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/l	4.60							
				TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/l	1.77							
				GLOBULINS: ALPHA1	01/10/90	1.3	6.0	g/l	3.60							
				GLOBULINS: ALPHA2	01/10/90	5.0	9.0	g/l	8.80							
				GLOBULINS: BETA	01/10/90	5.0	13.0	g/l	16.00							
				GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	10.50							
35-35			F	IB	01/10/90	112.0	140.0	g/l	130.00							
				IBC	01/10/90	8.4	0.5	l/l	0.39							
				HBC	01/10/90	3.7	4.7	10**12/l	3.91							
				HBC	01/10/90	4.0	8.8	10**g/l	6.70							
				HBC: N	01/10/90	51.0	77.0	%	68.00							
				HBC: L	01/10/90	18.0	38.0	%	30.00							
				HBC: E	01/10/90	1.0	5.0	%	1.00							
				HBC: N	01/10/90	2.0	10.0	%	1.00							
				HBC: L	01/10/90	0.0	1.0	%	0.00							
				PLATELETS	01/10/90	180.0	320.0	10**g/l	200.00							
				NA+	01/10/90	135.0	150.0	mmol/l	143.00							
				K+	01/10/90	4.0	5.6	mmol/l	4.40							

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

9550077

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Date	Laboratory Range			Visit						
						Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
10	35-35	F		CL-	01/10/90	95.0	105.0	mmol/L	101.40						
				PO4-	01/10/90	0.6	1.3	mmol/L	1.24						
				SGOT	01/10/90	1.0	12.0	U/l	3.50						
				SGPT	01/10/90	1.0	9.0	U/l	3.00						
				GAMMA-GT	01/10/90	10.0	66.0	U/l	40.00						
				GLUCOSE	01/10/90	3.5	5.5	mmol/L	3.80						
				ALK. PHOSPH.	01/10/90	135.0	360.0	mmol/L	223.00						
				BUN	01/10/90	3.3	10.0	mmol/L	5.10						
				CREATININE	01/10/90	44.0	88.0	umol/L	72.80						
				URIC ACID	01/10/90	119.0	357.0	umol/L	251.00						
				TOT BILIRUBIN	01/10/90	8.5	20.5	umol/L	20.20						
				DIR BILIRUBIN	01/10/90	0.5	4.3	umol/L	2.50						
				TOT. PROTEINS	01/10/90	65.0	85.0	g/l	80.00						
				ALBUMINE	01/10/90	34.0	55.0	g/l	42.00						
				TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/L	4.00						
				TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/L	1.12						
				GLOBULINS: ALPHA1	01/10/90	1.3	6.0	g/l	4.00						
				GLOBULINS: ALPHA2	01/10/90	5.0	9.0	g/l	7.80						
				GLOBULINS: BETA	01/10/90	5.0	13.0	g/l	16.90						
				GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	9.30						
38-37		F		HB	10/12/91	112.0	140.0	g/L	115.00						
				HTC	10/12/91	0.4	0.5	L/L	0.35						
				RBC	10/12/91	3.7	4.7	10**12/L	3.55						
				WBC	10/12/91	4.0	8.8	10**9/L	3.40						
				WBC: N	10/12/91	51.0	77.0	%	63.00						
				WBC: L	10/12/91	18.0	38.0	%	31.00						
				WBC: E	10/12/91	1.0	5.0	%	2.00						
				WBC: M	10/12/91	2.0	10.0	%	4.00						
				WBC: B	10/12/91	0.0	1.0	%	0.00						
				PLATELETS	10/12/91	180.0	320.0	10**9/L	210.00						
				NA+	10/12/91	135.0	150.0	MMOL/L	139.00						
				K+	10/12/91	4.0	5.6	MMOL/L	4.30						
				CL-	10/12/91	95.0	105.0	MMOL/L	106.10						
				PO4-	10/12/91	0.6	1.3	MMOL/L	1.00						
				SGOT	10/12/91	1.0	12.0	U/l	6.50						
				SGPT	10/12/91	1.0	9.0	U/l	5.00						
				GAMMA-GT	10/12/91	0.2	1.1	UKAT/L	0.20						
				GLUCOSE	10/12/91	3.5	5.5	MMOL/L	5.40						
				ALK. PHOSPH.	10/12/91	135.0	360.0	MMOL/L	177.00						
				BUN	10/12/91	3.3	10.0	MMOL/L	4.60						
				CREATININE	10/12/91	44.0	88.0	UMOL/L	67.00						

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1879

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range		Visit																						
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52															
10 38-37	F			URIC ACID	10/12/91	119.0	357.0	UMOL/L	171.00																				
				TOT BILIRUBIN	10/12/91	8.6	20.5	UMOL/L	10.40																				
				DIR BILIRUBIN	10/12/91	0.5	4.3	UMOL/L	2.80																				
				TOT. PROTEINS	10/12/91	65.0	85.0	G/L	77.00																				
				ALBUMINE	10/12/91	34.0	55.0	G/L	46.60																				
				TOT. CHOLEST.	10/12/91	3.1	6.2	MMOL/L	3.80																				
				TRIGLYCERIDES	10/12/91	0.5	1.9	MMOL/L	1.32																				
				GLOBULINS: ALPHA1	10/12/91	1.3	6.0	G/L	4.90																				
				GLOBULINS: ALPHA2	10/12/91	5.0	9.0	G/L	5.50																				
				GLOBULINS: BETA	10/12/91	5.0	13.0	G/L	6.40																				
				GLOBULINS: GAMMA	10/12/91	10.0	17.0	G/L	13.60																				
				39-40	F			HR	10/12/91	112.0	140.0	G/L	138.00	18/02/92	147.00	13/06/92	195.00	06/08/92	198.00	13/10/92	141.00								
								HTC	10/12/91	0.4	0.5	L/L	0.42																
								ERC	10/12/91	3.7	4.7	10**12/L	4.25																
								HRC	10/12/91	4.0	8.8	10**9/L	10.10																
								HRC: N	10/12/91	51.0	77.0	Z	58.00																
								HRC: L	10/12/91	18.0	38.0	Z	25.00																
								HRC: E	10/12/91	1.0	5.0	Z	2.00																
								HRC: M	10/12/91	2.0	10.0	Z	4.00																
								HRC: B	10/12/91	0.0	1.0	Z	0.00																
PLATELETS	10/12/91	180.0	320.0					10**9/L	220.00																				
Na+	10/12/91	135.0	150.0					MMOL/L	137.00																				
K+	10/12/91	4.0	5.6					MMOL/L	4.40																				
Cl-	10/12/91	95.0	105.0					MMOL/L	97.50																				
PO4-	10/12/91	0.6	1.3					MMOL/L	1.01																				
SGPT	10/12/91	1.0	12.0					U/L	6.50																				
GAMMA-GT	10/12/91	0.2	1.1					UKAT/L	0.40																				
GLUCOSE	10/12/91	3.5	5.5					MMOL/L	4.30																				
ALK. PHOSPH.	10/12/91	135.0	360.0					MMOL/L	190.00																				
BUN	10/12/91	3.3	10.0					MMOL/L	5.40																				
CREATININE	10/12/91	44.0	88.0					UMOL/L	62.60																				
URIC ACID	01/01/92	169.0	405.0	UMOL/L	203.00																								
TOT BILIRUBIN	10/12/91	119.0	357.0	UMOL/L	218.00																								
DIR BILIRUBIN	10/12/91	8.6	20.5	UMOL/L	17.40																								
TOT. PROTEINS	10/12/91	0.5	4.3	UMOL/L	2.80																								
ALBUMINE	10/12/91	65.0	85.0	G/L	76.00																								
TOT. CHOLEST.	10/12/91	34.0	55.0	G/L	46.60																								
TRIGLYCERIDES	10/12/91	3.1	6.2	MMOL/L	3.50																								
GLOBULINS: ALPHA1	10/12/91	0.5	1.9	MMOL/L	1.56																								
GLOBULINS: ALPHA2	10/12/91	1.3	6.0	G/L	4.50																								
GLOBULINS: BETA	10/12/91	5.0	9.0	G/L	5.50																								
GLOBULINS: GAMMA	10/12/91	10.0	17.0	G/L	13.60																								

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1880

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit							
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
10 39-40	F		GLOBULINS: ALPHA2	10/12/91	5.0	9.0	G/L	7.10	6.30	8.00	8.40	7.70	8.00	
			GLOBULINS: BETA	10/12/91	5.0	13.0	G/L	6.70	5.50	6.50	8.50	4.30	5.60	
			GLOBULINS: GAMMA	10/12/91	10.0	17.0	G/L	12.10	10.10	9.40	10.60	17.70	11.70	
41-42	F		HB	01/01/92	112.0	140.0	G/L	138.00	124.00	133.00	137.00	135.00	130.00	
			HTC	01/01/92	0.4	0.5	L/L	0.38	0.38	0.40	0.41	0.42	0.40	
			ERC	01/01/92	3.7	4.7	10**12/L	4.03	3.85	4.08	4.10	4.80	4.80	3.97
			WBC	01/01/92	4.0	8.8	10**9/L	5.20	5.80	6.60	5.30	6.30	6.00	4.00
			WBC: N	01/01/92	51.0	77.0	%	48.00	66.00	66.00	76.00	64.00	64.00	69.00
			WBC: L	01/01/92	18.0	38.0	%	44.00	24.00	32.00	19.00	28.00	26.00	26.00
			WBC: E	01/01/92	1.0	5.0	%	4.00	2.00	2.00	2.00	6.00	3.00	3.00
			WBC: H	01/01/92	2.0	10.0	%	4.00	8.00	0.00	3.00	2.00	2.00	2.00
			WBC: B	01/01/92	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00	0.00
			PLATELETS	01/01/92	180.0	320.0	10**9/L	220.00	220.00	203.00	217.00	210.00	217.00	217.00
			HA+	01/01/92	135.0	150.0	MMOL/L	148.00	139.00	141.00	139.00	145.00	145.00	145.00
			K+	01/01/92	4.0	5.6	MMOL/L	4.70	5.10	5.00	4.80	4.80	5.80	5.80
			CL-	01/01/92	95.0	105.0	MMOL/L	100.50	97.30	101.00	98.10	101.30	107.70	107.70
			PO4--	01/01/92	0.6	1.3	MMOL/L	1.12	1.54	1.23	1.21	1.16	1.63	1.63
			SGOT	01/01/92	1.0	12.0	U/L	6.50	4.50	5.00	3.00	5.00	11.50	11.50
			SGPT	01/01/92	1.0	9.0	U/L	5.00	4.00	5.00	3.70	3.70	6.20	6.20
			GAMMA-GT	01/01/92	0.2	1.1	UKAT/L	0.28	0.60	0.52	0.52	1.02	1.30	1.30
			GLUCOSE	01/01/92	3.5	5.5	MMOL/L	4.20	4.30	3.80	4.40	3.80	4.70	4.70
			ALK. PHOSPH.	01/01/92	135.0	360.0	MMOL/L	337.00	177.00	148.00	158.00	263.00	137.00	137.00
			BUN	01/01/92	3.3	10.0	MMOL/L	4.40	9.99	7.20	8.20	5.83	6.30	6.30
			CREATININE	01/01/92	44.0	88.0	UMOL/L	67.70	69.70	75.70	82.90	79.20	75.70	75.70
			TOT BILIRUBIN	01/01/92	149.0	405.0	UMOL/L	238.00	206.00	240.00	248.00	243.00	300.00	300.00
			URIC ACID	01/01/92	8.6	20.5	UMOL/L	8.90	8.20	17.90	11.30	16.00	16.20	16.20
			DIR BILIRUBIN	01/01/92	0.5	6.2	MMOL/L	1.70	0.70	3.10	0.90	2.50	3.60	3.60
			TOT. PROTEINS	01/01/92	65.0	85.0	G/L	70.00	79.00	77.00	80.00	80.00	82.00	82.00
			ALBUMINE	01/01/92	34.0	55.0	G/L	39.40	50.00	48.00	49.10	47.10	52.60	52.60
			TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	5.30	4.50	5.00	5.20	5.40	3.40	3.40
TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	0.98	1.43	1.36	2.64	2.03	1.76	1.76			
GLOBULINS: ALPHA1	01/01/92	1.3	6.0	G/L	1.80	1.00	2.70	3.10	4.80	1.90	1.90			
GLOBULINS: ALPHA2	01/01/92	5.0	9.0	G/L	8.30	5.20	5.10	8.00	7.30	6.30	6.30			
GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	12.20	7.60	10.80	7.60	5.40	8.80	8.80			
GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	8.30	15.20	10.40	12.20	15.40	11.50	11.50			
49-43	F		HB	01/01/92	112.0	140.0	G/L	124.00	153.00	128.00	128.00	128.00	128.00	
			HTC	01/01/92	0.4	0.5	L/L	0.38	0.40	0.40	0.40	0.40	0.40	
			REC	01/01/92	3.7	4.7	10**12/L	3.74	4.01	3.85	3.85	3.85	3.85	

(**) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBORETTINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBORETTINE

Pat. No.	Open-Blind Sex	Laboratory test	Laboratory Range			Visit						
			Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
10 49-43	F	WBC	01/01/92	4.0	8.8	10**9/L	8.40	5.30	5.60			
			01/01/92	51.0	77.0	%	64.00	66.00	70.00			
		WBC: L	01/01/92	18.0	38.0	%	26.00	26.00	22.00			
		WBC: E	01/01/92	1.0	5.0	%	2.00	2.00	6.00			
		WBC: M	01/01/92	2.0	10.0	%	2.00	2.00	2.00			
		WBC: B	01/01/92	0.0	1.0	%	0.00	0.00	0.00			
		PLATELETS	01/01/92	180.0	320.0	10**9/L	220.00	195.00	210.00			
		Na+	01/01/92	135.0	150.0	MMOL/L	140.00	143.00	140.00			
		CL-	01/01/92	95.0	105.0	MMOL/L	99.20	106.80	100.30			
		PO4-	01/01/92	0.6	1.3	MMOL/L	1.10	1.16				
		SGOT	01/01/92	1.0	42.0	U/L	5.50	3.05	7.20			
		SGPT	01/01/92	1.0	9.0	U/L	4.50	6.05	4.50			
		GAMMA-GT	01/01/92	0.2	1.1	UKAT/L	0.80	0.42	0.42			
		GLUCOSE	01/01/92	3.5	5.5	MMOL/L	4.30	3.90	4.30			
		ALK. PHOSPH.	01/01/92	135.0	360.0	MMOL/L	230.00	172.00	164.00			
		BUN	01/01/92	3.3	10.0	MMOL/L	5.10	6.70	3.50			
		CREATININE	01/01/92	44.0	88.0	UMOL/L	66.50	74.80	62.60			
		URIC ACID	01/01/92	149.0	405.0	UMOL/L	204.00	189.00	217.00			
		TOT BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	10.20	13.40	16.20			
		DIR BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	1.70	3.90	2.50			
		TOT. PROTEINS	01/01/92	65.0	85.0	G/L	70.00	73.00	82.00			
		ALBUMINE	01/01/92	34.0	55.0	G/L	37.30	47.30	49.90			
		TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	3.80	3.70	3.80			
TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	0.99	0.44	1.53					
GLOBULINS: ALPHA1	01/01/92	1.3	6.0	G/L	3.80	2.30	1.10					
GLOBULINS: ALPHA2	01/01/92	5.0	9.0	G/L	8.70	7.70	10.60					
GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	10.30	8.10	8.50					
GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	9.90	7.60	11.90					
53-47	F	HB	01/01/92	112.0	140.0	G/L	135.00	170.00	138.00			
		HTC	01/01/92	0.4	0.5	L/L	0.40	0.40	0.42			
		ERC	01/01/92	3.7	4.7	10**12/L	4.05	4.10	4.18			
		WBC	01/01/92	4.0	8.8	10**9/L	4.60	4.80	7.20			
		WBC: N	01/01/92	51.0	77.0	%	59.00	62.00	70.00			
		WBC: L	01/01/92	18.0	38.0	%	35.00	34.00	27.00			
		WBC: E	01/01/92	1.0	5.0	%	3.00	2.00	2.00			
		WBC: M	01/01/92	2.0	10.0	%	3.00	2.00	1.00			
		WBC: B	01/01/92	0.0	1.0	%	0.00	0.00	0.00			
		PLATELETS	01/01/92	180.0	320.0	10**9/L	225.00	225.00	225.00			
		Na+	01/01/92	135.0	150.0	MMOL/L	134.00	135.00	140.00			
		K+	01/01/92	4.0	5.6	MMOL/L	4.30	4.50	4.70			

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Date	Laboratory Range			Visit					
						Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
10	53-47	F		CL-	01/01/92	95.0	105.0	MMOL/L	95.80	96.30	99.00			
				PO4--	01/01/92	0.6	1.3	MMOL/L	1.12	1.20	1.10			
				SGOT	01/01/92	1.0	12.0	U/L	3.50	3.50	3.50			
				SGPT	01/01/92	1.0	9.0	U/L	1.50	2.00	2.50			
				GAMMA-GT	01/01/92	0.2	1.1	UKAT/L	0.82	0.85	0.25			
				GLUCOSE	01/01/92	3.5	5.5	MMOL/L	4.60	5.00	4.00			
				ALK. PHOSPH.	01/01/92	135.0	360.0	MMOL/L	127.00	130.00	240.00			
				BUN	01/01/92	3.3	10.0	MMOL/L	6.30	5.50	5.60			
				CREATININE	01/01/92	44.0	88.0	UMOL/L	62.80	63.20	64.50			
				URIC ACID	01/01/92	149.0	405.0	UMOL/L	308.00	305.00	345.00			
				TOT BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	18.60	18.50	20.30			
				DIR BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	2.90	2.80	3.70			
				TOT. PROTEINS	01/01/92	65.0	85.0	G/L	73.00	75.00	78.00			
				ALBUMINE	01/01/92	34.0	55.0	G/L	47.30	48.20	49.20			
				TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	3.10	3.20	3.10			
				TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	1.35	1.30	1.30			
				GLOBULINS: ALPHA1	01/01/92	1.3	6.0	G/L	1.10	1.30	2.00			
				GLOBULINS: ALPHA2	01/01/92	5.0	9.0	G/L	5.20	6.20	6.80			
				GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	6.60	6.60	8.00			
				GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	12.80	12.70	12.00			
54-48		F		HB	01/01/92	112.0	140.0	G/L	145.00	143.00	145.00			
				HTC	01/01/92	0.4	0.5	L/L	0.43	0.43	0.44			
				RBC	01/01/92	3.7	4.7	10**12/L	4.23	4.22	4.30			
				RBC: N	01/01/92	4.0	8.8	10**9/L	5.90	4.90	5.10			
				RBC: L	01/01/92	51.0	77.0	%	70.00	68.00	70.00			
				RBC: E	01/01/92	18.0	38.0	%	22.00	24.00	22.00			
				RBC: M	01/01/92	1.0	5.0	%	4.00	3.00	4.00			
				RBC: B	01/01/92	2.0	10.0	%	4.00	5.00	4.00			
				PLATELETS	01/01/92	180.0	320.0	10**9/L	220.00	225.00	222.00			
				NA+	01/01/92	135.0	150.0	MMOL/L	141.00	145.00	140.00			
				K+	01/01/92	4.0	5.6	MMOL/L	5.60	5.00	5.00			
				CL-	01/01/92	95.0	105.0	MMOL/L	99.80	102.00	101.20			
				PO4--	01/01/92	0.6	1.3	MMOL/L	1.06	1.10	1.30			
				SGOT	01/01/92	1.0	12.0	U/L	1.80	2.50	2.00			
				SGPT	01/01/92	1.0	9.0	U/L	7.50	5.50	6.00			
				GAMMA-GT	01/01/92	0.2	1.1	UKAT/L	0.25	0.32	0.51			
				GLUCOSE	01/01/92	3.5	5.5	MMOL/L	3.70	4.10	4.40			
				ALK. PHOSPH.	01/01/92	135.0	360.0	MMOL/L	260.00	270.00	276.00			
				BUN	01/01/92	3.3	10.0	MMOL/L	6.80	6.50	6.20			
				CREATININE	01/01/92	44.0	88.0	UMOL/L	69.40	70.20	68.90			

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

100000

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBONETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBONETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit													
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52							
10 54-48	F			URIC ACID	01/01/92	149.0	405.0	UMOL/L	206.00	220.00	204.00										
				TOT BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	8.60	9.80	10.80										
				DIR BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	0.60	1.30	2.70										
				TOT. PROTEINS	01/01/92	65.0	85.0	G/L	79.00	80.00	78.20										
				ALBUMINE	01/01/92	34.0	55.0	G/L	50.60	49.50	49.40										
				TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	4.00	4.80	4.70										
				TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	0.75	0.80	0.80										
				GLOBULINS: ALPHA1	01/01/92	1.3	6.0	G/L	1.80	2.80	3.00										
				GLOBULINS: ALPHA2	01/01/92	5.0	9.0	G/L	8.00	7.90	7.90										
				GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	6.60	6.50	7.00										
				GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	12.00	12.10	11.90										
				57-51	F			HR	01/01/92	112.0	140.0	G/L	135.00	132.00	138.00	08/05/92	131.00	03/11/92	135.00	12/01/92	138.00
								HTC	01/01/92	0.4	0.5	L/L	0.42	0.42	0.40				0.41	0.41	0.42
								RBC	01/01/92	3.7	4.7	10 ¹² /L	4.15	4.18	4.12				4.05	4.05	4.10
								HRC	01/01/92	4.0	8.8	10 ⁹ /L	3.40	4.20	3.00				4.50	4.50	7.50
								RBC: N	01/01/92	51.0	77.0	%	70.00	60.00	64.00				66.00	60.00	69.00
								RBC: L	01/01/92	18.0	38.0	%	26.00	38.00	32.00				52.00	60.00	27.00
								RBC: E	01/01/92	1.0	5.0	%	3.00	0.00	4.00				0.00	2.00	2.00
								RBC: H	01/01/92	2.0	10.0	%	1.00	2.00	0.00				2.00	3.00	2.00
								RBC: B	01/01/92	0.0	1.0	%	0.00	0.00	0.00				0.00	0.00	0.00
PLATELETS	01/01/92	180.0	320.0					10 ⁹ /L	220.00	217.00	215.00				218.00	217.00	225.00				
NA+	01/01/92	135.0	150.0					MMOL/L	140.00	140.00	140.00				139.00	142.00	136.00				
CL-	01/01/92	95.0	105.0					MMOL/L	98.20	103.00	90.50				100.30	97.60	98.30				
PO4--	01/01/92	0.6	1.3					MMOL/L	1.13	1.23	1.41				1.07	1.22	1.22				
SGPT	01/01/92	1.0	12.0					U/L	1.00	3.00	9.00				3.00	5.70	6.50				
GAMMA-GT	01/01/92	0.2	1.1					UKAT/L	0.45	0.52	0.50				0.40	0.66	0.60				
GLUCOSE	01/01/92	3.5	5.5					MMOL/L	4.20	4.70	4.90				4.90	4.60	4.90				
ALK. PHOSPH.	01/01/92	135.0	360.0					MMOL/L	142.00	139.00	121.00				159.00	171.00	133.00				
BUN	01/01/92	3.3	10.0					MMOL/L	3.00	5.80	4.50				5.50	3.90	7.00				
CREATININE	01/01/92	44.0	88.0					UMOL/L	70.10	72.80	84.20				75.70	81.20	74.60				
URIC ACID	01/01/92	149.0	405.0					UMOL/L	157.00	204.00	279.00				294.00	300.00	279.00				
DIR BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	8.60	8.20	15.60				15.50	17.70	18.00								
TOT. PROTEINS	01/01/92	65.0	85.0	G/L	77.00	79.00	69.00				80.00	80.00	71.00								
ALBUMINE	01/01/92	34.0	55.0	G/L	39.20	45.30	37.90				47.00	44.60	41.50								
TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	2.90	3.50	2.60				3.10	3.60	3.70								
TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	1.59	1.36	2.34				1.99	1.83	3.49								
GLOBULINS: ALPHA1	01/01/92	1.3	6.0	G/L	2.20	3.70	4.10				3.10	4.10	1.80								
GLOBULINS: ALPHA2	01/01/92	5.0	9.0	G/L	8.50	8.20	7.20				8.50	8.40	6.60								

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

10004

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit						
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
10	57-51	F		GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	15.70	9.90	13.20	8.10	9.20	7.20
				GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	11.40	11.90	8.30	13.30	13.90	13.90
59-53	F			HB	01/01/92	112.0	140.0	G/L	30/03/92					
				HTC	01/01/92	0.4	0.5	L/L	131.00					
				RBC	01/01/92	3.7	4.7	10**12/L	0.39					
				HBC	01/01/92	4.0	8.8	10**9/L	3.87					
				HBC: N	01/01/92	51.0	77.0	%	6.00					
				HBC: L	01/01/92	18.0	38.0	%	62.00					
				HBC: E	01/01/92	1.0	5.0	%	32.00					
				HBC: H	01/01/92	2.0	10.0	%	2.00					
				HBC: B	01/01/92	0.0	1.0	%	4.00					
				PLATELETS	01/01/92	180.0	320.0	10**9/L	0.00					
				NA+	01/01/92	135.0	150.0	MMOL/L	215.00					
				K+	01/01/92	4.0	5.6	MMOL/L	150.00					
				CL-	01/01/92	95.0	105.0	MMOL/L	4.90					
				PO4-	01/01/92	0.6	1.3	MMOL/L	99.80					
				SGPT	01/01/92	1.0	12.0	U/L	1.16					
				GAMMA-GT	01/01/92	1.0	9.0	U/L	3.00					
				GLUCOSE	01/01/92	3.5	5.5	MMOL/L	3.50					
				ALK. PHOSPH.	01/01/92	33.0	360.0	MMOL/L	6.10					
				CREATININE	01/01/92	44.0	88.0	UMOL/L	160.00					
				TOT. BILIRUBIN	01/01/92	169.0	405.0	UMOL/L	77.80					
				DIR. BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	232.00					
				TOT. PROTEINS	01/01/92	0.5	4.3	UMOL/L	10.40					
				ALBUMINE	01/01/92	65.0	85.0	G/L	2.80					
				TRIGLYCERIDES	01/01/92	34.0	55.0	G/L	82.00					
				GLOBULINS: ALPHA1	01/01/92	0.5	1.9	MMOL/L	52.30					
				GLOBULINS: ALPHA2	01/01/92	1.3	6.0	G/L	3.00					
				GLOBULINS: BETA	01/01/92	5.0	9.0	G/L	0.54					
				GLOBULINS: GAMMA	01/01/92	5.0	13.0	G/L	1.50					
					01/01/92	10.0	17.0	G/L	6.40					
63-57	M			HB	01/01/92	129.0	150.0	G/L	13/04/92	08/06/92	03/08/92	28/09/92	23/11/92	01/02/93
				HTC	01/01/92	0.4	0.5	L/L	132.00	145.00	141.00	146.00	145.00	141.00
				RBC	01/01/92	4.0	5.0	10**12/L	0.42	0.44	0.42	0.43	0.43	0.42
				HBC	01/01/92	4.0	8.8	10**9/L	4.18	4.40	4.24	4.27	4.40	4.27
					01/01/92	4.0	8.8	10**9/L	6.40	6.90	7.60	5.80	5.60	5.30

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1885

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42
10	63-57	M		WBC: N	51.0	77.0	%	72.00	68.00	78.00	74.00	80.00	80.00
				HBC: L	18.0	38.0	%	23.00	24.00	17.00	24.00	18.00	16.00
				HBC: E	1.0	5.0	%	2.00	4.00	3.00	3.00	0.00	0.00
				HBC: M	2.0	10.0	%	2.00	4.00	1.00	2.00	2.00	4.00
				HBC: B	0.0	1.0	%	1.00	0.00	1.00	0.00	0.00	0.00
				PLATELETS	180.0	320.0	10**9/L	218.00	203.00	220.00	225.00	237.00	235.00
				Na+	135.0	150.0	MMOL/L	136.00	140.00	140.00	146.00	150.00	148.00
				K+	4.0	5.6	MMOL/L	3.90	4.60	4.10	4.90	5.30	4.60
				CL-	95.0	105.0	MMOL/L	100.50	104.50	101.80	104.30	93.70	102.30
				PO4-	0.6	1.3	MMOL/L	1.02	1.16	1.06	0.96	1.14	1.17
				SGOT	1.0	12.0	U/L	6.50	5.00	6.00	12.80	8.80	7.80
				SGPT	1.0	9.0	U/L	7.80	6.00	3.50	6.00	5.20	4.00
				GAMMA-GT	0.3	1.8	U/L	0.79	0.66	0.60	1.25	1.55	0.87
				GLUCOSE	3.5	5.5	MMOL/L	5.00	4.90	6.10	4.70	5.00	4.70
				ALK. PHOSPH.	135.0	360.0	MMOL/L	153.00	135.00	129.00	132.00	151.00	152.00
				BUN	3.3	10.0	MMOL/L	6.30	7.20	86.20	82.70	85.10	79.60
				UREIC ACID	44.0	101.0	UMOL/L	72.40	72.20	236.00	232.00	208.00	310.00
				TOT. BILIRUBIN	214.0	458.0	UMOL/L	281.00	229.00	15.80	12.10	11.80	15.80
				TOT. BILIRUBIN	8.6	20.5	UMOL/L	17.40	19.30	1.70	3.40	2.20	1.10
				TOT. BILIRUBIN	0.5	4.3	UMOL/L	1.40	1.00	78.00	67.00	66.00	67.00
				TOT. PROTEINS	65.0	85.0	G/L	80.00	71.00	47.70	46.70	44.10	42.20
				ALBUMINE	34.0	55.0	G/L	51.20	45.50	3.50	3.00	3.60	3.00
				TOT. CHOLEST.	3.1	6.2	MMOL/L	4.20	4.60	0.75	1.66	1.72	0.71
				TRIGLYCERIDES	0.5	1.9	MMOL/L	0.92	0.64	3.50	3.00	1.20	2.00
				GLOBULINS: ALPHA1	1.3	6.0	G/L	2.20	3.60	5.40	1.10	1.20	2.00
				GLOBULINS: ALPHA2	5.0	9.0	G/L	8.30	6.40	5.40	6.40	5.50	6.00
				GLOBULINS: BETA	5.0	13.0	G/L	7.90	7.80	5.80	6.80	8.90	7.10
				GLOBULINS: GAMMA	10.0	17.0	G/L	10.40	7.70	15.60	8.20	6.30	9.70
82-59		M		HB	129.0	150.0	G/L	145.00	140.00	143.00	144.00	140.00	140.00
				HTC	0.4	0.5	L/L	0.45	0.41	0.43	0.43	0.40	0.40
				RBC	4.0	5.0	10**12/L	4.45	4.18	4.29	4.28	4.30	4.30
				HRC	4.0	8.8	10**9/L	6.60	11.20	6.60	8.90	8.70	8.70
				HRC: N	51.0	77.0	%	69.00	76.00	59.00	62.00	70.00	70.00
				HRC: L	18.0	38.0	%	25.00	22.00	39.00	32.00	28.00	28.00
				HRC: E	1.0	5.0	%	3.00	2.00	2.00	2.00	1.00	1.00
				HRC: M	2.0	10.0	%	3.00	0.00	0.00	4.00	3.00	3.00
				HRC: B	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00
				HRC: E	180.0	320.0	10**9/L	237.00	205.00	232.00	230.00	225.00	225.00
				PLATELETS	135.0	150.0	MMOL/L	142.00	149.00	140.00	141.00	145.00	145.00
				Na+	4.0	5.6	MMOL/L	5.10	5.10	4.00	5.10	5.10	5.10
				K+	95.0	105.0	MMOL/L	104.40	97.60	96.10	99.20	100.50	100.50

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit					
					Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
10	82-59	M		PO4-	0.6	1.3	MMOL/L	1.38	1.10	1.16	0.88	0.92	
				SGOT	1.0	12.0	U/L	5.00	6.50	2.50	11.20	10.50	
				SGPT	1.0	9.0	U/L	3.50	4.50	3.00	8.00	6.50	
				GAMMA-GT	0.3	1.8	UKAT/L	0.60	0.40	0.63	0.66	0.69	
				GLUCOSE	3.5	5.5	MMOL/L	4.80	3.90	4.50	5.10	5.00	
				ALK. PHOSPH.	135.0	360.0	MMOL/L	247.00	258.00	197.00	271.00	272.00	
				BUN	3.3	10.0	MMOL/L	5.00	5.30	3.30	4.80	5.10	
				CREATININE	44.0	101.0	UMOL/L	86.60	71.10	74.40	70.40	69.90	
				URIC ACID	214.0	458.0	UMOL/L	364.00	346.00	16.70	376.00	374.00	
				TOT. BILIRUBIN	8.6	20.5	UMOL/L	18.50	9.50	3.90	15.20	15.30	
				DIR. BILIRUBIN	0.5	4.3	UMOL/L	2.50	0.60	3.90	1.80	1.80	
				TOT. PROTEINS	65.0	85.0	G/L	90.00	76.00	72.00	90.00	85.00	
				ALBUMINE	34.0	55.0	G/L	58.80	46.60	43.30	57.60	56.10	
				TOT. CHOLEST.	3.1	6.2	MMOL/L	3.50	3.70	4.60	4.00	3.90	
				TRIGLYCERIDES	0.5	1.9	MMOL/L	1.58	1.62	2.37	0.83	0.91	
				GLOBULINS: ALPHA1	1.3	6.0	G/L	1.90	1.90	1.40	3.20	3.00	
				GLOBULINS: ALPHA2	5.0	9.0	G/L	7.40	9.10	6.60	8.20	6.50	
				GLOBULINS: BETA	5.0	13.0	G/L	7.90	7.50	11.10	7.40	6.80	
				GLOBULINS: GAMMA	10.0	17.0	G/L	13.60	10.90	9.60	13.60	12.60	

9550077

84-63	F			HB	112.0	140.0	G/L	138.00					
				HCT	0.4	0.5	L/L	0.42					
				RBC	3.7	4.7	10**12/L	4.25					
				HBC	4.0	8.8	10**9/L	4.20					
				MBC: N	51.0	77.0	%	74.00					
				MBC: L	18.0	38.0	%	24.00					
				MBC: E	1.0	5.0	%	0.00					
				MBC: M	2.0	10.0	%	0.00					
				MBC: B	0.0	1.0	%	0.00					
				PLATELETS	180.0	320.0	10**9/L	240.00					
				NA+	135.0	150.0	MMOL/L	139.00					
				K+	4.0	5.6	MMOL/L	4.40					
				CL-	95.0	105.0	MMOL/L	100.20					
				PO4-	0.6	1.3	MMOL/L	1.49					
				SGOT	1.0	12.0	U/L	3.50					
				SGPT	1.0	9.0	U/L	3.00					
				GAMMA-GT	0.2	1.1	UKAT/L	0.47					
				GLUCOSE	3.5	5.5	MMOL/L	4.10					
				ALK. PHOSPH.	135.0	360.0	MMOL/L	117.00					
				BUN	3.3	10.0	MMOL/L	4.20					
				CREATININE	44.0	88.0	UMOL/L	79.50					
				URIC ACID	149.0	405.0	UMOL/L	199.00					

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

10007

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit									
					Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52				
10 84-63	F			TOT BILIRUBIN	8.6	20.5	UMOL/L	9.00									
				DIR BILIRUBIN	0.5	4.3	UMOL/L	1.40									
				TOT. PROTEINS	65.0	85.0	G/L	78.00									
				ALBUMINE	34.0	55.0	G/L	47.30									
				TOT. CHOLEST.	3.1	6.2	MMOL/L	5.00									
				TRIGLYCERIDES	0.5	1.9	MMOL/L	2.61									
				GLUCOLINS: ALPHA1	1.3	6.0	G/L	1.40									
				GLUCOLINS: ALPHA2	5.0	9.0	G/L	6.60									
				GLUCOLINS: BETA	5.0	13.0	G/L	11.90									
				GLUCOLINS: GAMMA	10.0	17.0	G/L	10.80									
				27/05/92													
				112.0	140.0	G/L	132.00										
				0.4	0.5	L/L	0.42										
				3.7	4.7	10**x12/L	4.17										
4.0	8.8	10**x9/L	6.80														
51.0	77.0	x	58.00														
18.0	36.0	x	32.00														
1.0	5.0	x	2.00														
2.0	10.0	x	8.00														
0.0	1.0	x	0.00														
180.0	320.0	10**x9/L	218.00														
135.0	150.0	MMOL/L	142.00														
4.0	5.6	MMOL/L	4.20														
95.0	105.0	MMOL/L	100.80														
0.6	1.3	MMOL/L	1.24														
1.0	12.0	U/L	5.00														
1.0	9.0	U/L	3.50														
0.2	1.1	UKAT/L	0.55														
3.5	5.5	MMOL/L	4.40														
135.0	360.0	MMOL/L	118.00														
3.3	10.0	MMOL/L	5.70														
44.0	88.0	UMOL/L	77.00														
149.0	405.0	UMOL/L	293.00														
8.6	20.5	UMOL/L	13.40														
0.5	4.3	UMOL/L	0.80														
63.0	85.0	G/L	75.00														
34.0	55.0	G/L	44.00														
3.1	6.2	MMOL/L	5.70														
0.5	1.9	MMOL/L	1.42														
1.3	6.0	G/L	2.00														
5.0	9.0	G/L	9.70														
5.0	13.0	G/L	8.10														

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range		Visit												
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52					
10 86-274	F			GLUCULINS: GAMMA	01/01/92	10.0	17.0	G/L	11.20										
87-275	F			HB	01/01/92	112.0	140.0	G/L	134.00	22/07/92	134.00	16/09/92	131.00	11/11/92	135.00	06/01/93	129.00	17/03/93	136.00
				HTC	01/01/92	0.4	0.5	L/L	0.42		0.41		0.40		0.42		0.41		0.42
				RBC	01/01/92	3.7	4.7	10**12/L	4.17		4.13		3.93		4.15		4.10		4.25
				MBC	01/01/92	4.0	8.8	10**9/L	5.80		6.70		6.60		72.00		80.00		76.00
				MBC: N	01/01/92	51.0	77.0	%	62.00		32.00		31.00		22.00		18.00		14.00
				MBC: L	01/01/92	18.0	38.0	%	4.00		4.00		2.00		5.00		2.00		3.00
				MBC: E	01/01/92	2.0	10.0	%	2.00		4.00		2.00		1.00		0.00		7.00
				MBC: N	01/01/92	0.0	1.0	%	0.00		0.00		0.00		0.00		0.00		0.00
				MBC: B	01/01/92	180.0	320.0	10**9/L	220.00		230.00		217.00		225.00		237.00		217.00
				PLATELETS	01/01/92	135.0	150.0	MMOL/L	142.00		141.00		146.00		142.00		141.00		139.00
				NA+	01/01/92	95.0	105.0	MMOL/L	104.00		101.90		102.00		101.50		101.50		100.30
				CL-	01/01/92	0.6	1.3	MMOL/L	1.16		1.07		1.11		1.15		1.22		1.11
				PO4-	01/01/92	1.0	12.0	U/L	5.80		4.50		6.80		3.50		5.50		5.70
				SGOT	01/01/92	1.0	9.0	U/L	3.50		2.50		3.30		4.00		2.50		2.20
				SGPT	01/01/92	0.2	1.1	UKAT/L	0.31		0.29		0.71		0.44		0.29		0.65
				GAMMA-GT	01/01/92	3.5	5.5	MMOL/L	4.30		4.40		3.90		4.00		4.70		4.90
				GLUCOSE	01/01/92	135.0	360.0	MMOL/L	137.00		107.00		150.00		164.00		145.00		275.00
				ALK. PHOSPH.	01/01/92	3.3	10.0	MMOL/L	3.30		4.70		4.30		4.00		5.80		4.60
				CREATININE	01/01/92	44.0	88.0	UMOL/L	78.60		72.80		81.20		80.70		73.90		83.10
				URIC ACID	01/01/92	149.0	405.0	UMOL/L	265.00		240.00		299.00		358.00		295.00		363.00
				TOT. BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	10.90		13.50		9.50		16.20		11.80		11.30
				DIR. BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	1.40		0.80		0.80		1.40		1.00		3.40
				TOT. PROTEINS	01/01/92	65.0	85.0	G/L	75.00		77.00		76.00		78.00		77.00		71.00
				ALBUMINE	01/01/92	34.0	55.0	G/L	47.10		45.80		52.10		48.20		45.10		34.70
				TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	3.70		4.40		5.00		4.20		3.90		3.90
				TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	1.02		2.14		1.20		1.60		1.85		1.02
				GLOBULINS: ALPHA1	01/01/92	1.3	6.0	G/L	1.80		2.50		2.50		2.20		1.50		1.20
				GLOBULINS: ALPHA2	01/01/92	5.0	9.0	G/L	8.60		8.90		8.00		5.30		6.90		7.30
				GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	8.00		8.30		8.20		4.90		6.10		6.70
				GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	9.50		11.30		6.50		17.40		9.40		21.10
90-70	F			HB	01/01/92	112.0	140.0	G/L	130.00	28/07/92	132.00	21/09/92	130.00		130.00		130.00		
				HTC	01/01/92	0.4	0.5	L/L	0.39		0.41		0.39		0.41		0.39		
				RBC	01/01/92	3.7	4.7	10**12/L	3.92		4.05		4.05		3.91		3.91		
				MBC	01/01/92	4.0	8.8	10**9/L	6.40		5.80		9.00		9.00		9.00		
				MBC: N	01/01/92	51.0	77.0	%	58.00		68.00		60.00		60.00		60.00		

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
10	90-70	F		HBC: L	01/01/92	18.0	38.0	Z	37.00	26.00	36.00				
				HBC: E	01/01/92	1.0	5.0	Z	5.00	4.00	4.00				
				HBC: M	01/01/92	2.0	10.0	Z	0.00	2.00	0.00				
				HBC: B	01/01/92	0.0	1.0	Z	0.00	0.00	0.00				
				PLATELETS	01/01/92	180.0	320.0	10**9/L	213.00	220.00	223.00				
				NA+	01/01/92	135.0	150.0	MMOL/L	142.00	140.00	143.00				
				K+	01/01/92	4.0	5.6	MMOL/L	4.60	4.30	4.80				
				CL-	01/01/92	95.0	105.0	MMOL/L	93.30		102.00				
				PO4--	01/01/92	0.6	1.3	MMOL/L	0.90	1.10	1.45				
				SGPT	01/01/92	1.0	12.0	U/L	3.50	3.00	9.00				
				SGPT	01/01/92	1.0	9.0	U/L	4.00	3.50	5.00				
				GAMMA-GT	01/01/92	0.2	1.1	UWAT/L	0.85	0.50	0.50				
				GLUCOSE	01/01/92	3.5	5.5	MMOL/L	4.30	4.30	3.70				
				ALK. PHOSPH.	01/01/92	133.0	360.0	MMOL/L	147.00	140.00	139.00				
				BUN	01/01/92	3.3	10.0	MMOL/L	3.20	3.66	5.50				
				CREATININE	01/01/92	44.0	88.0	UMOL/L	83.00	72.00	73.20				
				URIC ACID	01/01/92	149.0	405.0	UMOL/L	213.00	193.00	261.00				
				TOT. BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	10.90	13.10	15.60				
				DIR. BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	1.00	0.60	2.50				
				TOT. PROTEINS	01/01/92	65.0	85.0	G/L	80.00	84.00	67.00				
				ALBUMINE	01/01/92	34.0	55.0	G/L	49.30	47.80	43.60				
				TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	4.60	4.40	6.20				
				TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	1.45	1.87	1.46				
				GLOBULINS: ALPHA1	01/01/92	1.3	6.0	G/L	1.50	2.40	4.00				
				GLOBULINS: ALPHA2	01/01/92	5.0	9.0	G/L	10.80	9.40	3.80				
				GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	7.60	6.10	7.70				
				GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	10.80	18.30	7.90				
91-74		M		HB	02/06/92	129.0	150.0	G/L	150.00						
				HTC	01/01/92	0.4	0.5	L/L	0.43						
				RBC	01/01/92	4.0	5.0	10**12/L	4.33						
				HBC	01/01/92	4.0	8.8	10**9/L	11.30						
				HBC: N	01/01/92	51.0	77.0	Z	74.00						
				HBC: L	01/01/92	18.0	38.0	Z	20.00						
				HBC: E	01/01/92	1.0	5.0	Z	2.00						
				HBC: M	01/01/92	2.0	10.0	Z	4.00						
				HBC: B	01/01/92	0.0	1.0	Z	0.00						
				PLATELETS	01/01/92	189.0	320.0	10**9/L	215.00						
				NA+	01/01/92	135.0	150.0	MMOL/L	142.00						
				K+	01/01/92	4.0	5.6	MMOL/L	4.40						
				CL-	01/01/92	95.0	105.0	MMOL/L	98.10						
				PO4--	01/01/92	0.6	1.3	MMOL/L	1.27						

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

10000

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit																			
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52													
10	91-74	M		SGOT	01/01/92	1.0	12.0	U/L	5.00																		
				GAMMA-GT	01/01/92	1.0	9.0	U/L	3.00																		
				GLUCOSE	01/01/92	0.3	1.8	UKAT/L	0.87																		
				ALK. PHOSPH.	01/01/92	3.5	5.5	MMOL/L	5.10																		
				BUN	01/01/92	135.0	360.0	MMOL/L	107.00																		
				CREATININE	01/01/92	3.3	10.0	MMOL/L	5.00																		
				URIC ACID	01/01/92	44.0	101.0	UMOL/L	74.60																		
				TOT BILIRUBIN	01/01/92	214.0	458.0	UMOL/L	261.00																		
				DIR BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	13.30																		
				TOT. PROTEINS	01/01/92	65.0	85.0	G/L	82.00																		
				ALBUMINE	01/01/92	34.0	55.0	G/L	47.80																		
				TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	3.50																		
				TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	0.68																		
				GLOBULINS: ALPHA1	01/01/92	1.3	6.0	G/L	4.90																		
				GLOBULINS: ALPHA2	01/01/92	5.0	9.0	G/L	4.70																		
				GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	8.00																		
				GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	16.80																		
				93-285	F			FB	01/01/92	112.0	140.0	G/L	143.00	17/06/92	12/08/92	07/10/92	02/12/92										
								HCT	01/01/92	0.4	0.5	L/L	0.42	140.00	140.00	135.00	140.00	140.00	140.00	140.00	140.00	140.00	140.00	140.00	140.00	140.00	140.00
								RBC	01/01/92	3.7	4.7	10**12/L	4.25	4.25	4.25	4.85	4.85	4.85	4.85	4.85	4.85	4.85	4.85	4.85	4.85	4.85	4.85
WBC	01/01/92	4.0	8.8					10**9/L	11.20	11.20	11.20	5.70	5.70	5.70	5.70	5.70	5.70	5.70	5.70	5.70	5.70	5.70	5.70				
WBC: N	01/01/92	51.0	77.0					%	53.00	53.00	53.00	34.00	34.00	34.00	34.00	34.00	34.00	34.00	34.00	34.00	34.00	34.00	34.00				
WBC: L	01/01/92	18.0	38.0					%	38.00	38.00	38.00	46.00	46.00	46.00	46.00	46.00	46.00	46.00	46.00	46.00	46.00	46.00	46.00				
WBC: E	01/01/92	1.0	5.0					%	5.00	5.00	5.00	20.00	20.00	20.00	20.00	20.00	20.00	20.00	20.00	20.00	20.00	20.00	20.00				
WBC: M	01/01/92	2.0	10.0					%	4.00	4.00	4.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
WBC: B	01/01/92	0.0	1.0					%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
PLATELETS	01/01/92	180.0	320.0					10**9/L	203.00	203.00	203.00	234.00	234.00	234.00	234.00	234.00	234.00	234.00	234.00	234.00	234.00	234.00	234.00				
NA+	01/01/92	135.0	150.0					MMOL/L	138.00	138.00	138.00	140.00	140.00	140.00	140.00	140.00	140.00	140.00	140.00	140.00	140.00	140.00	140.00				
K+	01/01/92	4.0	5.6					MMOL/L	4.70	4.70	4.70	5.10	5.10	5.10	5.10	5.10	5.10	5.10	5.10	5.10	5.10	5.10	5.10				
CL-	01/01/92	95.0	105.0					MMOL/L	99.50	99.50	99.50	102.50	102.50	102.50	102.50	102.50	102.50	102.50	102.50	102.50	102.50	102.50	102.50				
PO4-	01/01/92	0.6	1.3					MMOL/L	1.30	1.30	1.30	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50				
SGPT	01/01/92	1.0	9.0					U/L	4.50	4.50	4.50	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00				
GAMMA-GT	01/01/92	0.2	1.1					UKAT/L	0.17	0.17	0.17	1.94	1.94	1.94	1.94	1.94	1.94	1.94	1.94	1.94	1.94	1.94	1.94				
GLUCOSE	01/01/92	3.5	5.5					MMOL/L	3.30	3.30	3.30	4.30	4.30	4.30	4.30	4.30	4.30	4.30	4.30	4.30	4.30	4.30	4.30				
ALK. PHOSPH.	01/01/92	135.0	360.0					MMOL/L	101.00	101.00	101.00	106.00	106.00	106.00	106.00	106.00	106.00	106.00	106.00	106.00	106.00	106.00	106.00				
BUN	01/01/92	3.3	10.0					MMOL/L	5.80	5.80	5.80	3.35	3.35	3.35	3.35	3.35	3.35	3.35	3.35	3.35	3.35	3.35	3.35				
CREATININE	01/01/92	44.0	88.0					UMOL/L	78.00	78.00	78.00	80.70	80.70	80.70	80.70	80.70	80.70	80.70	80.70	80.70	80.70	80.70	80.70				
URIC ACID	01/01/92	149.0	405.0	UMOL/L	22.90	22.90	22.90	293.00	293.00	293.00	293.00	293.00	293.00	293.00	293.00	293.00	293.00	293.00	293.00								
TOT BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	14.90	14.90	14.90	16.40	16.40	16.40	16.40	16.40	16.40	16.40	16.40	16.40	16.40	16.40	16.40								

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

1800

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit						
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
10 93-285	F		DIR BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	0.80	2.80	0.80	1.70		
			TOT. PROTEINS	01/01/92	65.0	85.0	G/L	85.00	70.00	71.00	73.00		
			ALBUMINE	01/01/92	34.0	55.0	G/L	44.00	37.30	41.20	40.40		
			TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	4.20	3.90	4.20	3.90		
			TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	1.53	1.87	2.44	1.70		
			GLOBULINS: ALPHA1	01/01/92	1.3	6.0	G/L	2.90	2.70	3.10	2.80		
			GLOBULINS: ALPHA2	01/01/92	5.0	9.0	G/L	9.30	8.60	4.30	7.40		
			GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	10.70	8.90	9.00	13.80		
			GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	18.10	12.50	12.40	8.60		
			HB	01/06/92	120.0	170.0	G/L	09/12/91	16/02/92	13/04/92	28/05/92		
			HTC	01/06/92	7.5	10.0	MMOL/L	7.91	8.74	146.00	149.00		
			RBC	24/09/91	0.4	0.5	L/L	0.40	0.43	0.39	0.41		
			MBC	24/09/91	3.3	5.6	10-12/L	4.69	5.15	4.89	6.30		
			MBC: N	24/09/91	4.0	10.0	10-9/L	6.30	5.30	5.80	5.40		
MBC: L	24/09/91	51.0	75.0	X	62.00	66.00	50.00	44.00					
MBC: E	24/09/91	20.0	40.0	X	30.00	30.00	48.00	52.00					
MBC: M	24/09/91	1.0	4.0	X	4.00	2.00	0.00	2.00					
MBC: B	24/09/91	2.0	8.0	X	4.00	2.00	2.00	2.00					
PLATELETS	24/09/91	150.0	350.0	10-9/L	140.00	160.00	210.00	184.00					
NA+	24/09/91	135.0	150.0	MMOL/L	145.00	143.00	139.00	143.00					
K+	24/09/91	3.5	5.3	MMOL/L	100.00	102.00	101.00	103.00					
CA++	24/09/91	2.3	2.8	MMOL/L	2.50	2.40	2.35	2.30					
PO4--	24/09/91	0.7	1.5	MMOL/L	0.82	0.88	1.06	1.06					
SGPT	24/09/91	5.0	15.0	U/L	9.00	6.00	22.00	16.00					
GAMMA-GT	24/09/91	4.0	18.0	U/L	13.00	10.00	25.00	16.00					
GLUCOSE	24/09/91	3.9	6.1	MMOL/L	4.30	5.20	5.60	4.40					
ALK. PHOSPH.	24/09/91	40.0	200.0	U/L	108.00	153.00	107.00	74.00					
UREA	24/09/91	2.1	9.6	MMOL/L	5.80	5.20	5.20	5.20					
CREATININE	24/09/91	35.0	115.0	UMOL/L	72.00	78.00	99.00	73.00					
URIC ACID	24/09/91	118.0	416.0	UMOL/L	174.00	186.00	212.00	154.00					
DIR BILIRUBIN	01/06/92	0.0	18.0	UMOL/L			10.00						
TOT. PROTEINS	24/09/91	60.0	85.0	G/L	74.00	71.00	66.00	74.00					
ALBUMINE	24/09/91	35.0	50.0	G/L	44.00	45.00	57.00	40.00					
TOT. CHOLEST.	24/09/91	3.9	6.7	MMOL/L	4.60	5.70	4.30	5.00					

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
11 2-373	F			TRIGLYCERIDES	24/09/91	0.5	2.3	MMOL/L	0.85	0.82	0.72	0.73			
				GLOBULINS: ALPHA1	24/09/91	1.0	4.0	%	2.70	2.15	2.45	2.81			
				GLOBULINS: ALPHA2	24/09/91	4.0	10.0	%	7.10	6.67	5.83	7.88			
				GLOBULINS: BETA	24/09/91	5.0	11.0	%	9.90	10.80	9.26	12.04			
				GLOBULINS: GAMMA	24/09/91	7.0	17.0	%	12.20	14.30	12.66	11.11			
				HB	24/09/91	7.5	10.0	MMOL/L	10/12/91	8.09					
				HTC	24/09/91	0.4	0.5	L/L		0.39					
				RBC	24/09/91	4.1	5.4	10 ¹² /L		4.43					
				HBC: N	24/09/91	5.0	10.0	10 ⁹ /L		6.30					
				HBC: L	24/09/91	51.0	75.0	%		68.00					
3-374	F			HBC: I	24/09/91	20.0	40.0	%		26.00					
				HBC: K	24/09/91	2.0	8.0	%		6.00					
				PLATELETS	24/09/91	150.0	350.0	10 ⁹ /L		190.00					
				NA+	24/09/91	135.0	150.0	MMOL/L		143.00					
				K+	24/09/91	3.5	5.3	MMOL/L		4.50					
				CL-	24/09/91	97.0	107.0	MMOL/L		104.00					
				CA++	24/09/91	2.3	2.8	MMOL/L		2.50					
				PO4--	24/09/91	0.7	1.5	MMOL/L		0.77					
				SGOT	24/09/91	5.0	15.0	U/L		15.00					
				GAMMA-GT	24/09/91	4.0	18.0	U/L		11.00					
6-377	M			GLUCOSE	24/09/91	3.9	6.1	MMOL/L		5.00					
				ALK. PHOSPH.	24/09/91	40.0	200.0	U/L		114.00					
				BUN	24/09/91	2.1	9.6	MMOL/L		5.00					
				CREATININE	24/09/91	36.0	115.0	UMOL/L		66.00					
				URIC ACID	24/09/91	118.0	416.0	UMOL/L		150.00					
				TOT. PROTEINS	24/09/91	60.0	85.0	G/L		68.00					
				ALBUMINE	24/09/91	35.0	50.0	G/L		42.00					
				TOT. CHOLEST.	24/09/91	3.9	6.7	MMOL/L		5.30					
				TRIGLYCERIDES	24/09/91	0.5	2.3	MMOL/L		0.71					
				GLOBULINS: ALPHA1	24/09/91	1.0	4.0	%		3.00					
GLOBULINS: ALPHA2	24/09/91	4.0	10.0	%		6.10									
GLOBULINS: BETA	24/09/91	5.0	11.0	%		8.20									
GLOBULINS: GAMMA	24/09/91	7.0	17.0	%		12.70									
6-377	M			HB	01/04/92	120.0	170.0	G/L	27/12/91	18/02/92	14/04/92	09/06/92	04/08/92	13/10/92	
				HTC	24/09/91	8.7	11.2	MMOL/L		9.86	10.00	172.00	169.00	170.00	161.00
				RBC	01/04/92	0.4	0.5	L/L		0.45	0.48	0.46	0.45	0.45	0.46
				RBC	01/04/92	3.5	5.6	10 ¹² /L		0.45	0.48	0.46	0.45	0.45	0.46

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1899

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Ranges			Visit						
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
11 6-377	M			RBC	24/09/91	4.5	6.0	10-12/L	5.01	5.40	7.20	8.80	10.10	7.70
				RBC	01/04/92	4.0	10.0	10-9/L	9.10	7.70	68.00	72.00	74.00	78.00
				HBC: N	24/09/91	5.0	10.0	10-9/L	66.00	74.00	30.00	16.00	22.00	14.00
				HBC: L	24/09/91	51.0	75.0	X	32.00	20.00	2.00	2.00	4.00	2.00
				HBC: E	24/09/91	1.0	4.0	X	0.00	4.00	2.00	2.00	4.00	6.00
				HBC: M	24/09/91	2.0	8.0	X	0.00	4.00	2.00	2.00	4.00	6.00
				HBC: B	24/09/91	0.0	1.0	X	0.00	0.00	243.00	193.00	266.00	220.00
				PLATELETS	24/09/91	150.0	350.0	10-9/L	190.00	160.00	144.00	145.00	140.00	
				NA+	24/09/91	135.0	150.0	MMOL/L	138.00	143.00	144.60	137.00	3.90	
				K+	24/09/91	3.5	5.3	MMOL/L	102.00	98.00	105.00	97.00	106.00	
				CL-	24/09/91	97.0	107.0	MMOL/L	2.20	2.40	2.44	2.30	2.34	
				CA++	24/09/91	2.3	2.8	MMOL/L	0.80	1.40	0.98	0.72	1.10	
				PO4-	24/09/91	0.7	1.5	MMOL/L	15.00	20.00	17.00	28.00	40.00	
				SGPT	24/09/91	5.0	23.0	U/L	45.00	59.00	35.00	24.00	41.00	
				SEPT	24/09/91	5.0	23.0	U/L	17.00	45.00	36.00	53.00	54.00	
				GAMMA-GT	24/09/91	4.0	28.0	U/L	4.30	4.40	4.80	5.60	4.70	
				GLUCOSE	24/09/91	3.3	6.1	MMOL/L	181.00	141.00	125.00	114.00	110.00	
				ALK. PHOSPH.	24/09/91	40.0	200.0	U/L	4.60	4.80	4.40	6.20	5.10	
				CREATININE	24/09/91	2.1	9.6	MMOL/L	78.00	83.00	88.00	73.00	89.00	
				URIC ACID	24/09/91	36.0	115.0	UMOL/L	335.00	344.00	364.00	399.00	441.00	
TOT BILIRUBIN	24/09/91	118.0	416.0	UMOL/L										
TOT. PROTEINS	01/04/92	7.0	18.0	UMOL/L										
ALBUMINE	24/09/91	60.0	85.0	G/L	66.00	69.00	77.00	67.00	81.00					
TOT. CHOLEST.	24/09/91	35.0	50.0	G/L	47.00	36.00	41.00	38.00	41.00					
TRIGLYCERIDES	24/09/91	3.9	6.7	MMOL/L	4.60	4.30	5.50	4.70	3.60					
GLOBULINS: ALPHA1	24/09/91	0.5	2.3	MMOL/L	2.86	2.86	2.86	2.33						
GLOBULINS: ALPHA2	24/09/91	1.0	4.0	X	2.60	2.83	2.55	1.78	2.29					
GLOBULINS: BETA	24/09/91	4.0	10.0	X	6.60	6.98	6.55	5.85	6.74					
GLOBULINS: GAMMA	24/09/91	5.0	11.0	X	8.50	8.93	9.77	8.05	8.72					
	24/09/91	7.0	17.0	X	13.40	12.76	10.06	9.92	11.53					

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

10-363 F

1888

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit									
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52			
11	10-363	F		HBC: L	24/09/91	20.0	40.0	%	30.00	34.00	40.00	30.00	24.00	22.00			
				HBC: E	24/09/91	1.0	4.0	%	0.00	2.00	2.00	14.00	0.00	4.00			
				HBC: M	24/09/91	2.0	8.0	%	4.00	2.00	8.00	6.00	2.00	0.00			
				HBC: R	24/09/91	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00			
				PLATELETS	24/09/91	150.0	350.0	10 ⁹ /L	170.00	180.00	212.00	215.00	235.00	227.00			
				NA*	24/09/91	135.0	150.0	MMOL/L	144.00	141.00	141.00	142.00	141.00	141.00			
				CL-	24/09/91	3.5	5.3	MMOL/L	4.20	4.70	6.50	4.40	4.40	4.30			
				CA++	24/09/91	97.0	107.0	MMOL/L	104.00	96.80	98.00	101.00	107.00	104.00			
				PO4--	24/09/91	2.3	2.9	MMOL/L	2.25	2.20	2.20	2.30	2.01	2.42			
				SGPT	24/09/91	0.7	1.5	MMOL/L	0.75	0.72	0.90	0.90	1.49	0.72			
				SGOT	24/09/91	5.0	15.0	U/L	13.00	14.00	15.00	14.00	16.00	12.00			
				GAMMA-GT	24/09/91	5.0	19.0	U/L	10.00	11.00	15.00	17.00	14.00	16.00			
				GLUCOSE	24/09/91	4.0	18.0	U/L	10.00	14.00	13.00	14.00	14.00	13.00			
				ALK. PHOSPH.	24/09/91	3.9	6.1	MMOL/L	4.60	4.60	3.20	4.00	4.40	4.40			
				BUN	24/09/91	40.0	200.0	U/L	107.00	91.00	141.00	4.00	78.00	97.00			
				CREATININE	24/09/91	2.1	9.6	MMOL/L	4.60	3.00	4.00	3.60	4.70	4.10			
				URIC ACID	24/09/91	36.0	115.0	UMOL/L	67.00	59.00	62.00	65.00	57.00	59.00			
				TOT. PROTEINS	24/09/91	60.0	85.0	G/L	77.00	80.00	70.00	134.00	125.00	103.00			
				ALBUMINE	24/09/91	35.0	50.0	G/L	45.00	43.00	41.00	36.00	40.00	40.00			
				TOT. CHOLEST.	24/09/91	3.9	6.7	MMOL/L	4.60	4.90	4.30	4.30	1.06	0.99			
				TRIGLYCERIDES	24/09/91	0.5	2.3	MMOL/L	1.20	0.71	0.80	1.06	2.91	1.53			
				GLOBULINS: ALPHA1	24/09/91	1.0	4.0	%	2.91	2.28	2.27	2.22	2.91	1.53			
				GLOBULINS: ALPHA2	24/09/91	4.0	10.0	%	6.62	6.61	5.14	5.32	6.62	7.10			
				GLOBULINS: BETA	24/09/91	5.0	11.0	%	10.06	8.29	7.86	8.55	11.80	11.80			
				GLOBULINS: GAMMA	24/09/91	7.0	17.0	%	14.15	16.41	14.46	13.92	14.15	14.23			
11-361	F			HB	01/04/92	120.0	170.0	G/L	30/01/92	13/04/92	19/05/92	161.00	161.00				
				HTC	24/09/91	7.5	10.0	MMOL/L	9.61	0.45	0.45						
				RBC	24/09/91	0.4	0.5	L/L	0.47	5.29	5.33						
				RBC	01/04/92	3.5	5.6	10 ¹² /L	5.43	10.00	9.80						
				RBC	01/04/92	4.0	10.0	10 ⁹ /L	9.50	60.00	70.00						
				RBC: N	24/09/91	5.0	10.0	10 ⁹ /L	76.00	36.00	26.00						
				RBC: L	24/09/91	51.0	75.0	%	18.00	4.00	4.00						
				RBC: E	24/09/91	20.0	40.0	%	2.00	4.00	4.00						
				RBC: M	24/09/91	2.0	8.0	%	4.00	0.00	0.00						
				RBC: B	24/09/91	0.0	1.0	%	0.00	0.00	0.00						
				PLATELETS	24/09/91	150.0	350.0	10 ⁹ /L	230.00	210.00	292.00						
				NA*	24/09/91	135.0	150.0	MMOL/L	145.00	146.00	144.00						

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit									
				Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52				
11	11-361	F	K+	3.5	5.3	MMOL/L	3.70	4.70	3.70							
			CL-	97.0	107.0	MMOL/L	105.00	106.00	99.00							
			CA++	2.3	2.8	MMOL/L	2.69	2.45	2.00							
			PO4-	0.7	1.5	MMOL/L	1.40	0.82	0.80							
			SGPT	5.0	15.0	U/L	15.00	22.00	28.00							
			SGPT	5.0	19.0	U/L	43.00	35.00	31.00							
			GAMMA-GT	4.0	18.0	U/L	11.00	33.00	21.00							
			GLUCOSE	3.9	6.1	MMOL/L	4.80	6.30	5.00							
			ALK. PHOSPH.	40.0	200.0	U/L	199.00	169.00	136.00							
			BUN	2.1	9.6	MMOL/L	8.00	6.00	6.00							
			CREATININE	36.0	115.0	UMOL/L	91.00	84.00	63.00							
			URIC ACID	118.0	416.0	UMOL/L	219.00	212.00	316.00							
			TOT. PROTEINS	60.0	85.0	G/L	75.00	86.00	62.00							
			ALBUMINE	35.0	50.0	G/L	42.00	38.00	35.00							
			TOT. CHOLEST.	3.9	6.7	MMOL/L	7.00	7.60	6.90							
			TRIGLYCERIDES	0.5	2.3	MMOL/L	2.77	1.34								
			GLOBULINS: ALPHA1	1.0	4.0	%	2.88	2.79	3.16							
			GLOBULINS: ALPHA2	4.0	10.0	%	5.73	5.79	6.06							
			GLOBULINS: BETA	5.0	11.0	%	12.33	10.07	8.82							
			GLOBULINS: GAMMA	7.0	17.0	%	11.66	11.70	15.71							
13-365		F	HB	120.0	170.0	G/L	122.00	127.00	119.00							
			HTC	0.4	0.5	L/L	0.33	0.35	0.34							
			RBC	3.5	5.6	10 ¹² /L	3.85	4.22	4.06							
			WBC	4.0	10.0	10 ⁹ /L	6.10	8.90	7.00							
			WBC: N	51.0	75.0	%	52.00	80.00	60.00							
			WBC: L	20.0	40.0	%	46.00	14.00	24.00							
			WBC: E	1.0	4.0	%	2.00	2.00	12.00							
			WBC: M	2.0	8.0	%	0.00	4.00	4.00							
			WBC: B	0.0	1.0	%	0.00	0.00	0.00							
			PLATELETS	150.0	350.0	10 ⁹ /L	180.00	364.00	374.00							
			K+	135.0	150.0	MMOL/L	137.00	137.00	140.00							
			Na+	3.5	5.3	MMOL/L	4.30	6.30	3.90							
			CL-	97.0	107.0	MMOL/L	106.00	107.00	99.00							
			Ca++	2.3	2.8	MMOL/L	2.30	2.10	1.90							
			PO4-	0.7	1.5	MMOL/L	1.20	1.06	0.77							
			SGPT	5.0	15.0	U/L	24.00	9.00	16.00							
			SGPT	5.0	19.0	U/L	21.00	6.00	15.00							
			GAMMA-GT	4.0	18.0	U/L	8.00	7.00	9.00							
			GLUCOSE	3.9	6.1	MMOL/L	4.40	4.30	4.00							
			ALK. PHOSPH.	40.0	200.0	U/L	102.00	75.00	81.00							
			BUN	2.1	9.6	MMOL/L	4.20	4.80	4.80							

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Date	Laboratory Range			Visit										
						Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52					
11 13-365	F			CREATININE	01/04/92	36.0	115.0	UMOL/L	66.00	67.00	60.00								
				URIC ACID	01/04/92	118.0	416.0	UMOL/L	156.00	172.00	186.00								
				TOT. PROTEINS	01/04/92	60.0	85.0	G/L	82.00	80.00	70.00								
				ALBUMINE	01/04/92	35.0	50.0	G/L	38.00	41.00	39.00								
				TOT. CHOLEST.	01/04/92	3.9	6.7	MMOL/L	5.20	5.10	5.10								
				TRIGLYCERIDES	01/04/92	0.5	2.3	MMOL/L	0.73	0.83	1.02								
				GLUCOLINS: ALPHA1	01/04/92	1.0	4.0	%		2.00	2.21								
				GLUCOLINS: ALPHA2	01/04/92	4.0	10.0	%		5.60	5.62								
				GLUCOLINS: BETA	01/04/92	5.0	11.0	%		8.20	8.26								
				GLUCOLINS: GAMMA	01/04/92	7.0	17.0	%		16.10	16.13								
				16-367	F			HB	01/04/92	120.0	170.0	G/L	131.00	129.00					
								HTC	01/04/92	0.4	0.5	L/L	0.36	0.38					
								RBC	01/04/92	3.5	5.6	10 ¹² /L	4.15	4.20					
								HBC: N	01/04/92	4.0	10.0	10 ⁹ /L	6.10	7.40					
								HBC: L	01/04/92	51.0	75.0	%	76.00	70.00					
HBC: E	01/04/92	20.0	40.0					%	22.00	28.00									
HBC: H	01/04/92	1.0	4.0					%	0.00	0.00									
HBC: B	01/04/92	2.0	8.0					%	2.00	2.00									
PLATELETS	01/04/92	0.0	1.0					%	0.00	0.00									
Na+	01/04/92	150.0	350.0					10 ⁻⁹ /L	210.00	243.00									
K+	01/04/92	135.0	150.0					MMOL/L	141.00	143.00									
CL-	01/04/92	3.5	5.3					MMOL/L	5.00	4.50									
PO4--	01/04/92	97.0	107.0					MMOL/L	106.00	103.00									
SGPT	01/04/92	0.7	2.8					MMOL/L	2.46	2.40									
GAMMA-GT	01/04/92	5.0	15.0					U/L	15.00	20.00									
GLUCOSE	01/04/92	4.0	18.0	U/L	9.00	14.00													
ALK. PHOSPH.	01/04/92	3.9	6.1	MMOL/L	5.40	3.40													
RUN	01/04/92	40.0	200.0	U/L	116.00	89.00													
CREATININE	01/04/92	2.1	9.6	MMOL/L	5.20	5.60													
URIC ACID	01/04/92	36.0	115.0	UMOL/L	92.00	88.00													
TOT. PROTEINS	01/04/92	118.0	416.0	UMOL/L	229.00	202.00													
ALBUMINE	01/04/92	60.0	85.0	G/L	66.00	72.00													
TOT. CHOLEST.	01/04/92	3.9	6.7	MMOL/L	37.00	40.00													
TRIGLYCERIDES	01/04/92	0.5	2.3	MMOL/L	9.30	8.00													
GLUCOLINS: ALPHA1	01/04/92	1.0	4.0	%	2.70	3.44													
GLUCOLINS: ALPHA2	01/04/92	4.0	10.0	%	6.08	7.66													
GLUCOLINS: BETA	01/04/92	5.0	11.0	%	8.19	9.51													
GLUCOLINS: GAMMA	01/04/92	7.0	17.0	%	12.16	11.40													

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

10097

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Date	Laboratory Range		Visit		Week 10	Week 18	Week 26	Week 34	Week 42	Week 52			
						Min	Max	Unit	Unit									
11 17-368	F			RB	01/04/92	120.0	170.0	G/L	151.00	16/04/92	11/06/92	06/08/92	01/10/92	24/11/92	04/02/93			
				HTC	01/04/92	0.4	0.5	L/L	0.42	0.40	0.42	149.00	146.00	145.00	146.00	149.00	161.00	
				RBC	01/04/92	3.5	5.6	10-12/L	4.80	4.81	4.80	4.70	4.72	4.72	4.86	4.70	4.72	4.95
				WBC	01/04/92	4.0	10.0	10-9/L	7.60	7.90	7.90	7.30	7.90	7.90	5.80	7.30	6.10	6.10
				WBC: N	01/04/92	51.0	75.0	%	52.00	70.00	70.00	68.00	68.00	68.00	62.00	66.00	66.00	66.00
				WBC: L	01/04/92	20.0	40.0	%	34.00	18.00	18.00	28.00	28.00	28.00	32.00	30.00	30.00	30.00
				WBC: E	01/04/92	1.0	4.0	%	4.00	4.00	4.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
				WBC: M	01/04/92	2.0	8.0	%	10.00	8.00	8.00	2.00	2.00	2.00	4.00	4.00	4.00	2.00
				WBC: B	01/04/92	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				PLATELETS	01/04/92	150.0	350.0	10-9/L	200.00	364.00	367.00	326.00	326.00	326.00	311.00	347.00	311.00	319.00
				NA+	01/04/92	135.0	150.0	MMOL/L	136.00	141.00	140.00	140.00	140.00	140.00	141.00	140.00	141.00	142.00
				K+	01/04/92	3.5	5.3	MMOL/L	4.20	4.40	4.40	4.40	4.40	4.40	4.40	4.50	4.60	4.90
				CL-	01/04/92	97.0	107.0	MMOL/L	104.00	106.00	102.00	102.00	102.00	102.00	102.00	102.00	104.00	104.00
				CA++	01/04/92	2.3	2.8	MMOL/L	2.54	2.40	2.53	2.52	2.45	2.45	2.52	2.52	2.45	2.39
				PO4-	01/04/92	0.7	1.5	MMOL/L	0.95	0.98	0.98	0.86	0.65	0.65	0.86	0.86	0.65	0.86
				SGOT	01/04/92	5.0	15.0	U/L	25.00	24.00	11.00	11.00	13.00	13.00	16.00	14.00	13.00	24.00
				SGPT	01/04/92	5.0	19.0	U/L	32.00	28.00	16.00	16.00	23.00	23.00	21.00	19.00	21.00	23.00
				GAMMA-GT	01/04/92	4.0	18.0	U/L	19.00	30.00	21.00	21.00	21.00	21.00	21.00	19.00	21.00	16.00
				GLUCOSE	01/04/92	3.9	6.1	MMOL/L	3.90	4.60	6.30	5.70	4.80	4.80	6.30	5.70	4.80	6.00
				ALK. PHOSPH.	01/04/92	40.0	200.0	U/L	101.00	97.00	70.00	69.00	95.00	95.00	70.00	69.00	95.00	96.00
				CREATININE	01/04/92	2.1	9.6	MMOL/L	4.00	6.00	4.10	3.60	4.10	4.10	4.10	3.60	4.10	3.60
				URIC ACID	01/04/92	36.0	115.0	UMOL/L	68.00	54.00	77.00	67.00	68.00	68.00	77.00	67.00	68.00	66.00
				TOT. PROTEINS	01/04/92	118.0	416.0	UMOL/L	214.00	254.00	271.00	309.00	243.00	243.00	271.00	309.00	243.00	259.00
				ALBUMINE	01/04/92	35.0	50.0	G/L	41.00	39.00	36.00	68.00	85.00	85.00	68.00	68.00	85.00	77.00
				TOT. CHOLEST.	01/04/92	3.9	6.7	MMOL/L	6.30	5.60	5.40	5.40	6.20	6.20	5.40	5.40	6.20	6.20
				TRIGLYCERIDES	01/04/92	0.5	2.3	MMOL/L	1.54	1.16	1.97	1.44	1.46	1.46	1.97	1.44	1.46	1.72
GLOBULINS: ALPHA1	01/04/92	1.0	4.0	%	2.52	1.88	2.51	2.21	2.96	2.96	2.51	2.21	2.96	1.93				
GLOBULINS: ALPHA2	01/04/92	4.0	10.0	%	5.51	4.50	7.24	4.80	6.59	6.59	4.80	4.80	6.59	5.32				
GLOBULINS: BETA	01/04/92	5.0	11.0	%	8.93	8.11	7.87	6.83	10.42	10.42	6.83	6.83	10.42	8.21				
GLOBULINS: GAMMA	01/04/92	7.0	17.0	%	18.33	15.17	22.31	15.31	17.48	17.48	15.31	15.31	17.48	17.07				
19-370	F			RB	01/04/92	120.0	170.0	G/L	143.00	07/05/92	02/07/92	24/08/92	26/10/92	17/12/92	25/02/93			
				HTC	01/04/92	0.4	0.5	L/L	0.39	0.38	0.37	0.42	0.38	0.38	0.42	0.39	0.43	
				RBC	01/04/92	3.5	5.6	10-12/L	4.42	4.44	4.11	4.68	4.19	4.19	4.68	4.19	4.43	
				WBC	01/04/92	4.0	10.0	10-9/L	66.00	5.60	7.10	7.10	6.30	6.30	7.10	6.30	6.40	
				WBC: N	01/04/92	51.0	75.0	%	34.00	26.00	22.00	28.00	28.00	28.00	28.00	28.00	48.00	
				WBC: L	01/04/92	20.0	40.0	%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	48.00	

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit											
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52					
11	19-370	F		HBC: M	01/04/92	2.0	8.0	%	0.00	2.00	4.00	2.00	2.00	2.00	2.00	4.00	4.00		
				HBC: B	01/04/92	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				PLATELETS	01/04/92	150.0	350.0	10-9/L	264.00	252.00	284.00	259.00	259.00	284.00	259.00	259.00	259.00	272.00	272.00
				Na+	01/04/92	135.0	150.0	MMOL/L	142.00	142.00	142.00	139.00	139.00	142.00	139.00	139.00	139.00	142.00	142.00
				K+	01/04/92	3.5	5.3	MMOL/L	4.90	4.70	4.80	4.90	4.70	4.80	4.90	4.70	4.80	4.60	4.60
				CL-	01/04/92	97.0	107.0	MMOL/L	110.00	97.00	100.00	96.00	96.00	100.00	96.00	96.00	96.00	104.00	104.00
				Ca++	01/04/92	2.3	2.8	MMOL/L	2.78	2.30	2.20	2.41	2.30	2.20	2.41	2.30	2.34	2.48	2.48
				PO4-	01/04/92	0.7	1.5	MMOL/L	1.39	1.30	1.08	1.03	1.30	1.08	1.03	1.03	1.15	1.05	1.05
				SGOT	01/04/92	5.0	15.0	U/L	12.00	14.00	11.00	13.00	13.00	11.00	13.00	13.00	13.00	15.00	15.00
				SGPT	01/04/92	5.0	19.0	U/L	12.00	20.00	13.00	11.00	13.00	11.00	13.00	11.00	16.00	13.00	13.00
				GAMMA-GT	01/04/92	4.0	18.0	U/L	9.00	9.00	15.00	10.00	10.00	15.00	10.00	10.00	13.00	7.00	7.00
				GLUCOSE	01/04/92	3.9	6.1	MMOL/L	5.60	5.00	5.00	5.00	5.00	5.00	5.00	5.00	4.70	5.20	5.20
				ALK. PHOSPH.	01/04/92	40.0	200.0	U/L	111.00	140.00	98.00	93.00	93.00	98.00	93.00	93.00	83.00	105.00	105.00
				BUN	01/04/92	2.1	9.6	MMOL/L	4.60	4.60	6.00	6.00	6.00	6.00	6.00	6.00	4.50	3.60	3.60
				CREATININE	01/04/92	36.0	115.0	UMOL/L	69.00	66.00	73.00	76.00	76.00	73.00	76.00	76.00	68.00	70.00	70.00
				URIC ACID	01/04/92	118.0	416.0	UMOL/L	148.00	105.00	129.00	144.00	144.00	129.00	144.00	144.00	97.00	112.00	112.00
				TOT. PROTEINS	01/04/92	60.0	85.0	G/L	78.00	68.00	70.00	80.00	80.00	70.00	80.00	80.00	72.00	65.00	65.00
				ALBUMINE	01/04/92	35.0	50.0	G/L	40.00	39.00	37.00	46.00	46.00	37.00	46.00	46.00	36.00	38.00	38.00
				TOT. CHOLEST.	01/04/92	3.9	6.7	MMOL/L	6.10	5.80	4.00	5.20	5.20	4.00	5.20	5.20	7.10	5.30	5.30
				TRIGLYCERIDES	01/04/92	0.5	2.3	MMOL/L	1.28	2.33	1.73	1.31	1.31	1.73	1.31	1.31	2.05	1.51	1.51
GLORULINS: ALPHA1	01/04/92	1.0	4.0	%	2.96	2.96	2.28	2.05	2.05	2.28	2.05	2.05	1.53	6.73	6.73				
GLORULINS: ALPHA2	01/04/92	4.0	10.0	%	6.94	6.94	8.40	9.18	9.18	8.40	9.18	9.18	6.59	8.79	8.79				
GLORULINS: BETA	01/04/92	5.0	11.0	%	9.37	9.37	10.08	11.35	11.35	10.08	11.35	11.35	10.05	14.23	14.23				
GLORULINS: GAMMA	01/04/92	7.0	17.0	%	16.34	16.34	14.50	16.76	16.76	14.50	16.76	16.76	12.12	12.12	12.12				
12	1-92	M		HB	20/10/91	7.5	10.0	mmol/L	8.61	8.31	8.51	8.78	8.53	8.53	9.47	9.47			
				HTC	20/10/91	0.4	0.5	L/l	0.41	0.38	0.42	0.41	0.38	0.42	0.41	0.47	0.47		
				RBC	20/10/91	4.5	5.0	10**12/l	4.64	5.15	5.67	5.23	5.23	5.67	5.23	5.00	5.25	5.25	
				HBC: N	20/10/91	4.0	10.0	10**9/l	6.00	5.40	8.60	6.00	5.40	8.60	6.00	7.50	8.20	8.20	
				HBC: L	20/10/91	60.0	70.0	%	77.00	67.00	66.00	66.00	66.00	66.00	66.00	66.00	62.00	62.00	
				HBC: E	20/10/91	20.0	45.0	%	22.00	29.00	29.00	29.00	29.00	29.00	29.00	29.00	28.00	28.00	
				HBC: M	20/10/91	1.0	5.0	%	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	
				HBC: B	20/10/91	1.0	6.0	%	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	
				PLATELETS	20/10/91	140.0	300.0	10**9/l	170.00	200.00	137.00	197.00	197.00	137.00	197.00	197.00	305.00	305.00	
				Na+	20/10/91	137.0	147.0	mmol/l	141.00	144.00	144.00	144.00	144.00	144.00	144.00	144.00	142.00	142.00	
				K+	20/10/91	3.7	5.3	mmol/l	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	3.80	3.80	
				CL-	20/10/91	97.0	107.0	mmol/l	88.00	88.00	88.00	88.00	88.00	88.00	88.00	88.00	89.00	89.00	
				Ca++	20/10/91	2.3	2.7	mmol/l	2.64	2.33	2.36	2.36	2.33	2.36	2.36	2.18	2.25	2.25	
				PO4-	20/10/91	0.7	1.5	mmol/l	0.58	0.83	0.97	0.87	0.83	0.97	0.87	0.77	0.90	0.90	
SGOT	20/10/91	5.0	30.0	U/l	15.00	18.00	21.00	12.00	12.00	21.00	12.00	13.00	22.00	22.00					
SGPT	20/10/91	5.0	34.0	U/l	11.00	12.00	21.00	18.00	18.00	21.00	18.00	22.00	24.00	24.00					

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit										
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52				
12	1-92	M		GAMMA-GT	20/10/91	6.0	28.0	U/l	13.00	15.00	15.00	27.00	17.00	18.00				
				GLUCOSE	20/10/91	3.3	5.5	mmol/l	4.70	4.90	6.00	4.50	4.60	6.60				
				ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	295.00	286.00	310.00	261.00	286.00	300.00				
				BUN	20/10/91	3.0	9.5	mmol/l	3.90	4.70	5.00	4.10	8.20	4.80				
				CREATININE	20/10/91	50.0	110.0	umol/l	85.00	96.00	120.00	110.00	89.00	74.00				
				URIC ACID	20/10/91	120.0	410.0	umol/l	262.00	303.00	225.00	257.00	271.00	277.00				
				TOT BILIRUBIN	20/10/91	3.4	22.0	umol/l	7.90	9.70	15.30	17.10	14.00	12.00				
				DIR BILIRUBIN	20/10/91	0.0	4.5	umol/l	4.30	2.90	8.80	.	5.70	5.70				
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	73.00	67.00	66.00	62.00	67.00	69.00				
				ALBUMIN	20/10/91	0.5	0.7	RATIO	0.64	0.58	0.61	0.66	0.63	0.54				
				TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	4.80	5.80	5.50	4.30	4.80	5.50				
				TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	1.70	0.80	1.20	0.90	1.20	0.80				
				GLOBULINS: ALPHA1	20/10/91	0.0	0.1	RATIO	0.04	0.05	0.06	0.05	0.05	0.05				
				GLOBULINS: ALPHA2	20/10/91	0.1	0.1	RATIO	0.04	0.07	0.06	0.02	0.06	0.07				
				GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.10	0.09	0.12	0.10	0.10	0.09				
				GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.19	0.20	0.14	0.16	0.14	0.14				
				2-99	F			HB	20/10/91	7.5	10.0	mmol/l	13/01/92
								HTC	20/10/91	0.4	0.5	l/l	8.26
								RBC	20/10/91	4.5	5.0	10**12/l	4.86
								WBC	20/10/91	4.0	10.0	10**9/l	4.20
NBC: N	20/10/91	60.0	70.0					%	66.00				
NBC: L	20/10/91	20.0	45.0					%	34.00				
PLATELETS	20/10/91	140.0	300.0					10**9/l	268.00				
NA+	20/10/91	137.0	147.0					mmol/l	137.00				
K+	20/10/91	3.7	5.3					mmol/l	4.40				
CA++	20/10/91	2.3	2.7					mmol/l	1.97				
PO4-	20/10/91	0.7	1.5					mmol/l	0.96				
SCOT	20/10/91	5.0	30.0					U/l	23.00				
SGPT	20/10/91	5.0	34.0					U/l	41.00				
GAMMA-GT	20/10/91	6.0	28.0					U/l	96.00				
GLUCOSE	20/10/91	3.3	5.5					mmol/l	3.90				
ALK. PHOSPH.	20/10/91	100.0	280.0					U/l	299.00				
BUN	20/10/91	3.0	9.6					mmol/l	5.20				
CREATININE	20/10/91	50.0	110.0					umol/l	77.00				
URIC ACID	20/10/91	120.0	410.0	umol/l	186.00								
TOT BILIRUBIN	20/10/91	3.4	22.0	umol/l	7.90								
DIR BILIRUBIN	20/10/91	0.0	4.5	umol/l	4.40								
3-93	F			HB	20/10/91	7.5	10.0	mmol/l	17/01/92	13/03/92	23/06/92	18/08/92	06/12/92					
							7.96	8.20	7.89	7.95	8.36	8.97						

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1900

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range		Visit							
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
12 3-93	F			HTC	20/10/91	0.4	0.5	L/l	0.35	0.40	0.39	0.37	0.41	0.41
				RBC	20/10/91	4.5	5.0	10**12/l	4.14	4.70	4.74	4.47	4.84	4.78
				WBC	20/10/91	4.0	10.0	10**9/l	7.00	7.50	5.80	6.90	8.40	7.00
				WBC: N	20/10/91	60.0	70.0	%	55.00	58.00	55.00	63.00	74.00	
				WBC: L	20/10/91	20.0	45.0	%	41.00	38.00	41.00	36.00	26.00	
				WBC: E	20/10/91	1.0	5.0	%	3.00	4.00	1.00	1.00	0.00	
				WBC: B	20/10/91	1.0	6.0	%	1.00	0.00	2.00	0.00	0.00	
				PLATELETS	20/10/91	140.0	300.0	10**9/l	374.00	288.00	227.00	189.00	335.00	350.00
				NA+	20/10/91	137.0	147.0	mmol/l		142.00	146.00	140.00	145.00	141.00
				CL-	20/10/91	97.0	107.0	mmol/l		76.00	6.00	93.00	102.00	4.00
				CA++	20/10/91	2.5	2.7	mmol/l	2.36	2.27	2.54	2.44	2.45	
				PO4-	20/10/91	0.7	1.5	mmol/l	0.96	1.00	0.97	0.96	0.87	
				SGOT	20/10/91	5.0	30.0	U/l	22.00	23.00	15.00	13.00	20.00	
				SGPT	20/10/91	5.0	34.0	U/l	22.00	23.00	29.00	27.00	20.00	
				GAMMA-GT	20/10/91	6.0	28.0	U/l	30.00	26.00	28.00	26.00	17.00	
				GLUCOSE	20/10/91	3.3	5.5	mmol/l	1.60	3.30	4.20	4.70	4.70	4.50
				ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	121.00	113.00	111.00	122.00	126.00	
				CREATININE	20/10/91	3.0	9.6	mmol/l	3.90	5.40	5.50	4.70	5.60	5.70
				URIC ACID	20/10/91	50.0	110.0	umol/l	55.00	69.00	76.00	90.00	76.00	62.00
				TOT BILIRUBIN	20/10/91	120.0	410.0	umol/l	207.00	215.00	229.00	279.00	292.00	
				TOT. PROTEINS	20/10/91	3.4	22.0	umol/l	17.10	11.70	8.70	17.10	17.10	17.10
				ALBUMINE	20/10/91	60.0	80.0	g/l	69.00	9.80	6.80	56.00	74.00	69.00
				TOT. CHOLEST.	20/10/91	0.5	0.7	RATIO	0.64	0.54	0.54	0.69	0.66	
				TRIGLYCERIDES	20/10/91	2.6	7.0	mmol/l	5.70	6.30	6.60	5.80	6.10	
				GLOBULINS: ALPHA1	20/10/91	0.3	1.9	mmol/l	3.00	3.90	2.50	1.70	2.80	
				GLOBULINS: ALPHA2	20/10/91	0.0	0.1	RATIO	0.05	0.10	0.07	0.08	0.06	
				GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.07	0.09	0.08	0.05	0.07	
				GLOBULINS: GAMMA	20/10/91	0.1	0.1	RATIO	0.12	0.12	0.13	0.09	0.09	
					20/10/91	0.1	0.2	RATIO	0.12	0.15	0.13	0.09	0.12	
4-100	F			HTC	20/10/91	7.5	10.0	mmol/l		8.24	04/05/92			
				RBC	20/10/91	0.4	0.5	l/l	8.37	8.28				
				WBC	20/10/91	4.5	5.0	10**12/l	5.25	5.31	0.38			
				WBC: N	20/10/91	60.0	70.0	%	6.40	10.00	8.20			
				WBC: L	20/10/91	20.0	45.0	%	72.00	72.00	65.00			
				WBC: E	20/10/91	1.0	5.0	%	28.00	28.00	31.00			
				WBC: B	20/10/91	1.0	6.0	%	0.00	0.00	1.00			
					20/10/91	0.0	1.0	%	0.00	0.00	0.00			

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1901

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Pat. No.	Open-Blind Sex	Laboratory test	Date	Laboratory Range		Visit							
					Min	Max Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52		
12	4-100	F	PLATELETS	20/10/91	140.0	300.0	10**9/1	198.00	284.00	296.00				
			NA+	20/10/91	137.0	147.0	mmol/L	145.00	137.00	142.00				
			K+	20/10/91	3.7	5.3	mmol/L	4.00	3.70	4.40				
			CL-	20/10/91	97.0	107.0	mmol/L		97.00					
			CA++	20/10/91	2.3	2.7	mmol/L	2.00	2.10	2.35				
			PO4--	20/10/91	0.7	1.5	mmol/L	1.05	1.10	1.02				
			SGOT	20/10/91	5.0	30.0	U/l	22.00	15.00	34.00				
			SGPT	20/10/91	5.0	34.0	U/l	51.00	21.00	48.00				
			GAMMA-GT	20/10/91	6.0	28.0	U/l	18.00	19.00	57.00				
			GLUCOSE	20/10/91	3.3	5.5	mmol/L	4.30	4.90	4.80				
			ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	188.00	132.00	218.00				
			BUN	20/10/91	3.0	9.6	mmol/L	5.60	4.50	7.60				
			CREATININE	20/10/91	50.0	110.0	umol/L	71.00	215.00	261.00				
			URIC ACID	20/10/91	120.0	410.0	umol/L		7.00	6.70				
			TOT BILIRUBIN	20/10/91	3.4	22.0	umol/L	8.60	4.60	6.40				
			DIR BILIRUBIN	20/10/91	0.0	4.5	umol/L	6.60	4.60	7.00				
			TOT. PROTEINS	20/10/91	60.0	80.0	g/l	80.00	80.00	74.00				
			ALBUMINE	20/10/91	0.5	0.7	RATIO	0.70	0.56	0.58				
			TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/L		6.80	6.90				
			TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/L		1.90	1.70				
			GLOBULINS: ALPHA1	20/10/91	0.0	0.1	RATIO	0.03	0.07	0.08				
			GLOBULINS: ALPHA2	20/10/91	0.1	0.1	RATIO	0.07	0.09	0.08				
			GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.08	0.13	0.12				
			GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.11	0.14	0.13				
			HR	20/10/91	7.5	10.0	mmol/L	9.45	10.30	9.51				
			HTC	20/10/91	0.4	0.5	1/l	0.49	0.46	0.44				
			RBC	20/10/91	4.5	5.0	10**12/l	5.29	5.95	5.76				
			HRC	20/10/91	4.0	10.0	10**9/l	5.60	7.00	6.80				
			HRC: W	20/10/91	60.0	70.0	%	54.00	74.00	63.00				
			HRC: L	20/10/91	20.0	45.0	%	38.00	24.00	33.00				
			HRC: E	20/10/91	1.0	5.0	%	4.00	2.00	3.00				
			HRC: H	20/10/91	1.0	6.0	%	3.00	0.00	1.00				
			HRC: B	20/10/91	0.0	1.0	%	1.00	0.00	0.00				
			PLATELETS	20/10/91	140.0	300.0	10**9/l	236.00	151.00	202.00				
			NA+	20/10/91	137.0	147.0	mmol/L	137.00	140.00	142.00				
			K+	20/10/91	3.7	5.3	mmol/L	4.20	4.60	4.10				
			CL-	20/10/91	97.0	107.0	mmol/L		98.00					
			CA++	20/10/91	2.3	2.7	mmol/L	2.30	2.28	2.38				
			PO4--	20/10/91	0.7	1.5	mmol/L	0.58	0.58	1.07				
			SGOT	20/10/91	5.0	30.0	U/l	14.00	15.00	11.00				
			SGPT	20/10/91	5.0	34.0	U/l	22.00	21.00	24.00				

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1902

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit									
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52			
12 7-102	M		GAMMA-GT	20/10/91	6.0	28.0	U/l	10.00	17.00	13.00						
			GLUCOSE	20/10/91	3.3	5.5	mmol/l	8.70	7.40	4.40						
			ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	213.00	235.00	254.00						
			BUN	20/10/91	3.0	9.6	mmol/l		4.00	7.20						
			CREATININE	20/10/91	50.0	110.0	umol/l	71.00	95.00	93.00						
			URIC ACID	20/10/91	120.0	410.0	umol/l	240.00	314.00	266.00						
			TOT. BILIRUBIN	20/10/91	3.4	22.0	umol/l	8.50	9.60	16.60						
			DIR. BILIRUBIN	20/10/91	0.0	4.5	umol/l	8.40	4.90	4.20						
			TOT. PROTEINS	20/10/91	60.0	80.0	g/l	69.00	70.00	71.00						
			ALBUMINE	20/10/91	0.5	0.7	RATIO	0.78	0.53	0.65						
			TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	4.10	6.10	6.30						
			TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	2.20	1.20	5.80						
			GLOBULINS: ALPHA1	20/10/91	0.0	0.1	RATIO	0.02	0.08	0.05						
			GLOBULINS: ALPHA2	20/10/91	0.1	0.1	RATIO	0.04	0.09	0.06						
			GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.06	0.13	0.11						
			GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.10	0.16	0.13						
			9-91	F		HB	20/10/91	7.5	10.0	mmol/l	08/01/92	04/03/92	29/04/92			
						HIC	20/10/91	0.4	0.5	l/l	7.82	7.17	7.31			
						RBC	20/10/91	4.5	5.0	10**12/l	4.05	4.34	4.28			
						WBC	20/10/91	4.0	10.0	10**9/l	8.50	11.70	10.50			
RBC: N	20/10/91	60.0				70.0	%	55.00	65.00	66.00						
RBC: L	20/10/91	20.0				45.0	%	34.00	27.00	32.00						
RBC: E	20/10/91	1.0				5.0	%	1.00	3.00	1.00						
RBC: M	20/10/91	1.0				6.0	%	10.00	4.00	1.00						
RBC: B	20/10/91	0.0				1.0	%	0.00	1.00	0.00						
PLATELETS	20/10/91	140.0				300.0	10**9/l	259.00	169.00	249.00						
NA+	20/10/91	137.0				147.0	mmol/l	139.00	138.00	139.00						
K+	20/10/91	3.7				5.3	mmol/l	4.10	4.20	4.10						
CL-	20/10/91	97.0				107.0	mmol/l		103.00							
CA++	20/10/91	2.3				2.7	mmol/l	2.49	2.30	2.37						
PO4--	20/10/91	0.7				1.5	mmol/l	1.47	1.40	1.35						
SGOT	20/10/91	5.0				30.0	U/l	19.00	18.00	22.00						
SGPT	20/10/91	5.0				34.0	U/l	16.00	15.00	19.00						
GAMMA-GT	20/10/91	6.0				28.0	U/l	17.00	22.00	15.00						
GLUCOSE	20/10/91	3.3				5.5	mmol/l	4.00	3.50	3.80						
ALK. PHOSPH.	20/10/91	100.0				280.0	U/l	158.00	131.00	121.00						
BUN	20/10/91	3.0	9.6	mmol/l	5.00	4.30	5.20									
CREATININE	20/10/91	50.0	110.0	umol/l	60.00	84.00	116.00									
URIC ACID	20/10/91	120.0	410.0	umol/l	269.00	313.00	323.00									
TOT. BILIRUBIN	20/10/91	3.4	22.0	umol/l	6.60	6.90	11.20									
DIR. BILIRUBIN	20/10/91	0.0	4.5	umol/l	3.50	5.50	6.10									

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1900

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre Open-Blind Sex	Laboratory test	Date	Laboratory Range		Visit					
				Min	Max Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
12 9-91	F	TOT. PROTEINS	20/10/91	60.0	80.0 g/l	75.00	84.00	67.00			
		ALBUMINE	20/10/91	0.5	0.7 RATIO	0.63	0.54	0.53			
		TOT. CHOLEST.	20/10/91	2.6	7.0 mmol/l	4.40	4.50	4.80			
		TRIGLYCERIDES	20/10/91	0.3	1.9 mmol/l	1.10	1.00	0.90			
		GLOBULINS: ALPHA1	20/10/91	0.0	0.1 RATIO	0.06	0.06	0.17			
		GLOBULINS: ALPHA2	20/10/91	0.1	0.1 RATIO	0.08	0.10	0.09			
		GLOBULINS: BETA	20/10/91	0.1	0.1 RATIO	0.07	0.10	0.09			
		GLOBULINS: GAMMA	20/10/91	0.1	0.2 RATIO	0.15	0.21	0.12			
		HB	20/10/91	7.5	10.0 mmol/l	9.14	8.62	9.43			
		HTC	20/10/91	0.4	0.5 l/l	0.43	0.41	0.44			
		RBC	20/10/91	4.5	5.0 10 ¹² /l	5.03	5.23	5.67			
		WBC	20/10/91	4.0	10.0 10 ⁹ /l	5.70	6.70	7.00			
		MBC: N	20/10/91	60.0	70.0 %	48.00	60.00	66.00			
MBC: L	20/10/91	20.0	45.0 %	46.00	33.00	34.00					
MBC: E	20/10/91	1.0	5.0 %	3.00	4.00	0.00					
MBC: B	20/10/91	1.0	6.0 %	2.00	3.00	0.00					
MBC: T	20/10/91	0.0	1.0 %	1.00	0.00	0.00					
PLATELETS	20/10/91	140.0	300.0 10 ⁹ /l	298.00	231.00	187.00					
NA+	20/10/91	137.0	147.0 mmol/l	140.00	140.00	146.00					
K+	20/10/91	3.7	5.3 mmol/l	4.40	4.00	4.30					
CL-	20/10/91	97.0	107.0 mmol/l	105.00	96.00	92.00					
CA++	20/10/91	2.3	2.7 mmol/l	2.24	2.43	2.33					
PO4--	20/10/91	0.7	1.5 mmol/l	1.05	1.18	0.98					
SGOT	20/10/91	5.0	30.0 U/l	32.00	35.00	35.00					
SGPT	20/10/91	5.0	34.0 U/l	53.00	37.00	37.00					
GAMMA-GT	20/10/91	6.0	28.0 U/l	53.00	38.00	66.00					
GLUCOSE	20/10/91	3.3	5.5 mmol/l	3.00	3.70	5.30					
ALK. PHOSPH.	20/10/91	100.0	280.0 U/l	319.00	323.00	277.00					
BUN	20/10/91	3.0	9.6 mmol/l	6.80	6.30	7.70					
CREATININE	20/10/91	50.0	110.0 umol/l	108.00	92.00	99.00					
URIC ACID	20/10/91	120.0	410.0 umol/l	323.00	379.00	364.00					
TOT. BILIRUBIN	20/10/91	3.4	22.0 umol/l	7.50	6.40	11.20					
DIR. BILIRUBIN	20/10/91	0.0	4.5 umol/l	3.30	5.20	6.20					
TOT. PROTEINS	20/10/91	60.0	80.0 g/l	75.00	67.00	76.00					
ALBUMINE	20/10/91	0.5	0.7 RATIO	0.63	0.59	0.59					
TOT. CHOLEST.	20/10/91	2.6	7.0 mmol/l	4.40	4.60	6.90					
TRIGLYCERIDES	20/10/91	0.3	1.9 mmol/l	0.90	1.40	0.80					
GLOBULINS: ALPHA1	20/10/91	0.0	0.1 RATIO	0.05	0.05	0.05					
GLOBULINS: ALPHA2	20/10/91	0.1	0.1 RATIO	0.07	0.08	0.08					
GLOBULINS: BETA	20/10/91	0.1	0.1 RATIO	0.09	0.10	0.10					
GLOBULINS: GAMMA	20/10/91	0.1	0.2 RATIO	0.16	0.17	0.17					

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1905

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sox	Laboratory test	Date	Laboratory Range			Visit					
						Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
12 16-105	F			HB	20/10/91	7.5	10.0	mmol/l	18/02/92	14/04/92	09/06/92			
				HTC	20/10/91	0.4	0.5	l/l	8.23	7.30	7.68			
				RBC	20/10/91	4.5	5.0	10**12/l	0.36	0.36	0.38			
				MBC	20/10/91	4.0	10.0	10**9/l	4.06	4.21	4.70			
				MBC: N	20/10/91	60.0	70.0	%	5.50	4.40	4.70			
				MBC: L	20/10/91	20.0	45.0	%	64.00	68.00	56.00			
				MBC: E	20/10/91	1.0	5.0	%	32.00	28.00	39.00			
				MBC: M	20/10/91	1.0	6.0	%	3.00	2.00	2.00			
				MBC: R	20/10/91	0.0	1.0	%	1.00	2.00	2.00			
				PLATELETS	20/10/91	140.0	300.0	10**9/l	0.00	0.00	1.00			
				NA*	20/10/91	137.0	147.0	mmol/l	218.00	215.00	217.00			
				CL-	20/10/91	3.7	5.5	mmol/l	137.00	143.00	136.00			
				CA**	20/10/91	97.0	107.0	mmol/l	4.30	4.70	3.40			
				PO4-	20/10/91	2.3	2.7	mmol/l	1.92	2.60	2.41			
				SOD	20/10/91	0.7	1.5	mmol/l	1.19	1.15	1.49			
				GAMMA-GT	20/10/91	5.0	30.0	U/l	31.00	19.00	21.00			
				GLUCOSE	20/10/91	5.0	34.0	U/l	27.00	20.00	20.00			
				ALK. PHOSPH.	20/10/91	6.0	28.0	U/l	16.00	16.00	30.00			
				CREATININE	20/10/91	3.3	5.5	mmol/l	3.90	4.60	4.30			
				TOT BILIRUBIN	20/10/91	100.0	280.0	U/l	174.00	146.00	153.00			
DIR BILIRUBIN	20/10/91	3.0	9.6	mmol/l	4.80	4.40	4.70							
TOT. PROTEINS	20/10/91	50.0	110.0	mmol/l	64.00	69.00	82.00							
ALBUMINE	20/10/91	120.0	410.0	mmol/l	226.00	177.00	238.00							
TOT. CHOLEST.	20/10/91	3.4	22.0	mmol/l	10.00	10.00	22.40							
TRIGLYCERIDES	20/10/91	0.0	4.5	mmol/l	3.20	6.80	14.70							
GLOBULINS: ALPHA1	20/10/91	60.0	80.0	g/l	76.00	67.00	77.00							
GLOBULINS: ALPHA2	20/10/91	0.5	0.7	RATIO	0.60	0.59	0.59							
GLOBULINS: BETA	20/10/91	2.6	7.0	mmol/l	4.60	4.90	5.20							
GLOBULINS: GAMMA	20/10/91	0.3	1.9	mmol/l	1.10	1.10	1.10							
GLOBULINS: RATIO	20/10/91	0.0	0.1	RATIO	0.05	0.05	0.05							
GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.06	0.06	0.06							
GLOBULINS: GAMMA	20/10/91	0.1	0.1	RATIO	0.13	0.11	0.11							
GLOBULINS: RATIO	20/10/91	0.1	0.2	RATIO	0.15	0.18	0.18							
19-106	F			HB	20/10/91	7.5	10.0	mmol/l	25/03/92					
				HTC	20/10/91	0.4	0.5	l/l	8.08					
				RBC	20/10/91	4.5	5.0	10**12/l	0.41					
				MBC	20/10/91	4.0	10.0	10**9/l	5.26					
				MBC: N	20/10/91	60.0	70.0	%	51.00					

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1905

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sox	Laboratory test	Laboratory Range			Visit												
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52						
12	19-	106	F	HBC: L	20/10/91	20.0	45.0	Z	36.00											
				HBC: E	20/10/91	1.0	5.0	Z	2.00											
				HBC: K	20/10/91	1.0	6.0	Z	0.00											
				HBC: B	20/10/91	0.0	1.0	Z	1.00											
				PLATELETS	20/10/91	140.0	300.0	10**9/L	391.00											
				NA+	20/10/91	137.0	147.0	mmol/L	140.00											
				K+	20/10/91	3.7	5.3	mmol/L	4.20											
				CL-	20/10/91	97.0	107.0	mmol/L	94.00											
				CA++	20/10/91	2.3	2.7	mmol/L	2.45											
				PO4--	20/10/91	0.7	1.5	mmol/L	1.22											
				SSGT	20/10/91	5.0	30.0	U/L	17.00											
				SGPT	20/10/91	5.0	34.0	U/L	27.00											
				GAMMA-GT	20/10/91	6.0	28.0	U/L	59.00											
				GLUCOSE	20/10/91	3.3	5.5	mmol/L	4.40											
				ALK. PHOSPH.	20/10/91	100.0	280.0	U/L	157.00											
				BUN	20/10/91	3.0	9.6	mmol/L	4.30											
				CREATININE	20/10/91	50.0	110.0	umol/L	62.00											
				URIC ACID	20/10/91	120.0	410.0	umol/L	195.00											
				TOT BILIRUBIN	20/10/91	3.4	22.0	umol/L	10.10											
				DIR BILIRUBIN	20/10/91	0.0	4.5	umol/L	7.40											
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	62.00											
				ALBUMINE	20/10/91	0.5	0.7	RATIO	0.55											
				TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/L	5.90											
				TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/L	1.80											
				GLOBULINS: ALPHA1	20/10/91	0.0	0.1	RATIO	0.12											
				GLOBULINS: ALPHA2	20/10/91	0.1	0.1	RATIO	0.08											
				GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.10											
				GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.15											
				21-	110	F	HB	20/10/91	7.5	10.0	mmol/L	8.96	06/04/92	04/06/92	9.42					
							HCT	20/10/91	0.4	0.5	l/l	0.43								
							RBC	20/10/91	4.5	5.0	10**12/L	5.42								
							HRC	20/10/91	4.0	10.0	10**9/L	8.40								
HRC: N	20/10/91	60.0	70.0				Z	73.00												
HRC: L	20/10/91	20.0	45.0				Z	26.00												
HRC: E	20/10/91	1.0	5.0				Z	0.00												
HRC: B	20/10/91	1.0	6.0				Z	1.00												
HRC: M	20/10/91	0.0	1.0				Z	0.00												
PLATELETS	20/10/91	140.0	300.0				10**9/L	291.00												
Na+	20/10/91	137.0	147.0				mmol/L	144.00												
K+	20/10/91	3.7	5.3				mmol/L	4.70												
CL-	20/10/91	97.0	107.0	mmol/L	89.00															

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1906

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range		Visit								
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
12-21-110	F			CA++	2.3	2.7	mmol/l	2.39	2.45						
				PO4-	0.7	1.5	mmol/l	1.04	1.03						
				SGOT	5.0	30.0	U/l	19.00	19.00						
				SGPT	5.0	34.0	U/l	33.00	29.00						
				GAMMA-GT	6.0	28.0	U/l	50.00	35.00						
				GLUCOSE	3.3	5.5	mmol/l	4.10	3.70						
				ALK. PHOSPH.	100.0	280.0	U/l	154.00	168.00						
				BUN	3.0	9.6	mmol/l	4.70	5.60						
				CREATININE	50.0	110.0	umol/l	73.00	76.00						
				URIC ACID	120.0	410.0	umol/l	231.00	253.00						
				TOT BILIRUBIN	3.4	22.0	umol/l	10.40	6.20						
				DIR BILIRUBIN	0.0	4.5	umol/l	5.60	5.70						
				TOT. PROTEINS	60.0	80.0	g/l	59.00	67.00						
				ALBUMINE	0.5	0.7	RATIO	0.61	0.67						
				TOT. CHOLEST.	2.6	7.0	mmol/l	7.30	7.90						
				TRIGLYCERIDES	0.3	1.9	mmol/l	1.70	1.70						
				GLOBULINS: ALPHA1	0.0	0.1	RATIO	0.10	0.06						
				GLOBULINS: ALPHA2	0.1	0.1	RATIO	0.08	0.08						
				GLOBULINS: BETA	0.1	0.1	RATIO	0.09	0.08						
				GLOBULINS: GAMMA	0.1	0.2	RATIO	0.12	0.11						
24-113	F			HB	7.5	10.0	mmol/l	8.18	8.03	21/08/92	8.74				
				HCT	0.4	0.5	l/l	0.39	0.42						
				RBC	4.5	5.0	10**12/l	5.49	5.57						
				WBC	4.0	10.0	10**9/l	5.40	6.10						
				WBC: N	60.0	70.0	%	54.00	56.00						
				WBC: L	20.0	45.0	%	39.00	40.00						
				WBC: E	1.0	5.0	%	1.00	4.00						
				WBC: M	1.0	6.0	%	5.00	0.00						
				WBC: B	0.0	1.0	%	1.00	0.00						
				PLATELETS	140.0	300.0	10**9/l	297.00	171.00						
				PL+	137.0	147.0	mmol/l	141.00	140.00						
				K+	3.7	5.3	mmol/l	4.40	4.30						
				CL-	97.0	107.0	mmol/l	102.00	94.00						
				CA++	2.3	2.7	mmol/l	2.35	1.94						
				PO4-	0.7	1.5	mmol/l	1.01	0.87						
				SGOT	5.0	30.0	U/l	17.00	20.00						
				SGPT	5.0	34.0	U/l	18.00	24.00						
				GAMMA-GT	6.0	28.0	U/l	17.00	55.00						
				GLUCOSE	3.3	5.5	mmol/l	4.40	4.50						
				ALK. PHOSPH.	100.0	280.0	U/l	198.00	203.00						
BUN	3.0	9.6	mmol/l	6.10	8.60										

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Open-Blind Sex	Laboratory test	Laboratory Range			Visit														
			Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52								
12 24-113	F	CREATININE	20/10/91	50.0	110.0	umol/l	73.00	76.00												
		URIC ACID	20/10/91	120.0	410.0	umol/l	253.00	242.00	262.00											
		TOT BILIRUBIN	20/10/91	3.4	22.0	umol/l	6.60	17.10	9.60											
		DIR BILIRUBIN	20/10/91	0.0	4.5	umol/l	2.50													
		TOT. PROTEINS	20/10/91	60.0	80.0	g/l	72.00	71.00	81.00											
		ALBUMINE	20/10/91	0.5	0.7	RATIO	0.56		0.63											
		TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	7.30	6.60	7.50											
		TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	1.00	0.90	1.70											
		GLOBULINS: ALPHA1	20/10/91	0.0	0.1	RATIO	0.11		0.05											
		GLOBULINS: ALPHA2	20/10/91	0.1	0.1	RATIO	0.08		0.07											
		GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.12		0.11											
		GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.13		0.13											
		25-114	F	HB	20/10/91	7.5	10.0	mmol/l	8.74	8.62	8.62									
				HTC	20/10/91	0.4	0.5	l/l	0.39	0.38	0.39									
				RBC	20/10/91	4.5	5.0	10**12/l	5.14	5.13	5.26									
				RBC: N	20/10/91	4.0	10.0	10**9/l	4.20	4.10	4.30									
				RBC: L	20/10/91	60.0	70.0	%	66.00	59.00	64.00									
RBC: E	20/10/91			20.0	45.0	%	26.00	35.00	36.00											
RBC: M	20/10/91			1.0	5.0	%	3.00	2.00	0.00											
RBC: B	20/10/91			1.0	6.0	%	3.00	0.00	0.00											
PLATELETS	20/10/91			140.0	300.0	10**9/l	243.00	249.00	132.00											
NA+	20/10/91			137.0	147.0	mmol/l	138.00	143.00	141.00											
K+	20/10/91			3.7	5.3	mmol/l	3.90	4.00	4.20											
CL-	20/10/91			97.0	107.0	mmol/l	95.00		96.00											
CA++	20/10/91			2.3	2.7	mmol/l	2.33	2.44	2.38											
PO4--	20/10/91			0.7	1.5	mmol/l	1.07	1.29	1.22											
SGOT	20/10/91			5.0	30.0	U/l	18.00	21.00	17.00											
SGPT	20/10/91			5.0	34.0	U/l	19.00	25.00	20.00											
GAMMA-GT	20/10/91			6.0	28.0	U/l	21.00	40.00	17.00											
GLUCOSE	20/10/91			3.3	5.5	mmol/l	4.90	4.20	4.10											
ALK. PHOSPH.	20/10/91			100.0	280.0	U/l	183.00	169.00	172.00											
SUN	20/10/91			3.0	9.6	mmol/l	6.90	5.00	8.80											
CREATININE	20/10/91	50.0	110.0	umol/l	73.00	84.00	81.00													
URIC ACID	20/10/91	120.0	410.0	umol/l	248.00	272.00	116.00													
TOT BILIRUBIN	20/10/91	3.4	22.0	umol/l	4.20	10.20														
DIR BILIRUBIN	20/10/91	0.0	4.5	umol/l	1.30	3.60														
TOT. PROTEINS	20/10/91	60.0	80.0	g/l	75.00	62.00	60.00													
ALBUMINE	20/10/91	0.5	0.7	RATIO	0.64	0.61	0.64													
TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	7.40	7.40	7.00													
TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	1.40	1.60	1.20													

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Open-Blind Sex	Laboratory test	Laboratory Range			Date	Visit									
			Min	Max	Unit		Week 10	Week 18	Week 26	Week 34	Week 42	Week 52				
12 25-114	F	GLOBULINS: ALPHA1	0.0	0.1	RATIO	17/04/92	0.06	0.06	0.06	0.06	0.06	0.06	0.06	0.06	0.07	
		GLOBULINS: ALPHA2	0.1	0.1	RATIO	17/04/92	0.06	0.06	0.06	0.06	0.06	0.06	0.06	0.06	0.07	
		GLOBULINS: BETA	0.1	0.1	RATIO	17/04/92	0.10	0.12	0.09	0.12	0.09	0.11	0.11	0.09	0.09	
		GLOBULINS: GAMMA	0.1	0.2	RATIO	17/04/92	0.14	0.15	0.15	0.15	0.15	0.14	0.14	0.17	0.17	
		HB	7.5	10.0	mmol/l	12/06/92	7.65	7.78	7.53	7.80	7.53	7.80	7.53	7.80	7.53	7.80
		HCT	0.4	0.5	l/l	12/06/92	0.40	0.39	0.37	0.38	0.37	0.38	0.37	0.38	0.37	0.38
		RBC	4.5	5.0	10**12/l	12/06/92	5.58	4.91	4.61	4.90	4.61	4.90	4.61	4.90	4.61	4.90
		WBC	4.0	10.0	10**9/l	12/06/92	4.40	4.90	4.90	4.90	4.90	4.90	4.90	4.90	4.90	4.90
		WBC: N	60.0	70.0	%	12/06/92	67.00	55.00	58.00	60.00	58.00	60.00	58.00	60.00	58.00	60.00
		WBC: L	20.0	45.0	%	12/06/92	31.00	40.00	34.00	32.00	34.00	32.00	34.00	32.00	34.00	32.00
		WBC: E	1.0	5.0	%	12/06/92	2.00	5.00	8.00	5.00	8.00	5.00	8.00	5.00	8.00	5.00
		WBC: M	1.0	6.0	%	12/06/92	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
WBC: B	0.0	1.0	%	12/06/92	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
PLATELETS	140.0	300.0	10**9/l	17/04/92	219.00	298.00	157.00	257.00	157.00	257.00	157.00	257.00	157.00	257.00		
Na+	137.0	147.0	mmol/l	17/04/92	141.00	139.00	138.00	144.00	138.00	144.00	138.00	144.00	138.00	144.00		
K+	3.7	5.3	mmol/l	17/04/92	4.30	4.30	4.00	4.50	4.00	4.50	4.00	4.50	4.00	4.50		
Cl-	97.0	107.0	mmol/l	17/04/92	116.00	101.00	95.00	110.00	95.00	110.00	95.00	110.00	95.00	110.00		
Ca++	2.3	2.7	mmol/l	17/04/92	2.21	2.39	2.46	2.34	2.46	2.34	2.46	2.34	2.46	2.34		
PD4-	0.7	1.5	mmol/l	17/04/92	1.31	1.02	1.25	1.44	1.25	1.44	1.25	1.44	1.25	1.44		
SGPT	5.0	30.0	U/l	17/04/92	16.00	17.00	12.00	17.00	12.00	17.00	12.00	17.00	12.00	17.00		
SGPT	5.0	34.0	U/l	17/04/92	17.00	17.00	15.00	24.00	15.00	24.00	15.00	24.00	15.00	24.00		
GAMMA-GT	6.0	28.0	U/l	17/04/92	10.00	35.00	16.00	9.00	16.00	9.00	16.00	9.00	16.00	9.00		
GLUCOSE	3.3	5.5	mmol/l	17/04/92	3.40	4.50	5.00	5.20	5.00	5.20	5.00	5.20	5.00	5.20		
ALK. PHOSPH.	100.0	280.0	U/l	17/04/92	125.00	136.00	130.00	119.00	130.00	119.00	130.00	119.00	130.00	119.00		
BUN	3.0	9.6	mmol/l	17/04/92	4.20	4.30	7.00	4.50	7.00	4.50	7.00	4.50	7.00	4.50		
CREATININE	50.0	110.0	umol/l	17/04/92	85.00	74.00	52.00	73.00	52.00	73.00	52.00	73.00	52.00	73.00		
URIC ACID	120.0	410.0	umol/l	17/04/92	243.00	189.00	322.00	232.00	322.00	232.00	322.00	232.00	322.00	232.00		
TOT BILIRUBIN	3.4	22.0	umol/l	17/04/92	10.00	8.40	17.10	8.40	17.10	8.40	17.10	8.40	17.10	8.40		
DIR BILIRUBIN	0.0	4.5	umol/l	17/04/92	8.40	68.00	75.00	6.50	75.00	6.50	75.00	6.50	75.00	6.50		
TOT. PROTEINS	60.0	80.0	g/l	17/04/92	69.00	0.61	0.68	0.69	0.68	0.69	0.68	0.69	0.68	0.69		
ALBUMINE	0.5	0.7	RATIO	17/04/92	0.61	0.61	0.69	0.61	0.69	0.61	0.69	0.61	0.69	0.61		
TOT. CHOLEST.	2.6	7.0	mmol/l	17/04/92	4.20	3.90	4.80	4.30	4.80	4.30	4.80	4.30	4.80	4.30		
TRIGLYCERIDES	0.3	1.9	mmol/l	17/04/92	2.00	1.10	1.70	1.70	1.70	1.70	1.70	1.70	1.70	1.70		
GLOBULINS: ALPHA1	0.0	0.1	RATIO	17/04/92	0.10	0.08	0.05	0.03	0.05	0.03	0.05	0.03	0.05	0.03		
GLOBULINS: ALPHA2	0.1	0.1	RATIO	17/04/92	0.06	0.07	0.06	0.05	0.06	0.05	0.06	0.05	0.06	0.05		
GLOBULINS: BETA	0.1	0.1	RATIO	17/04/92	0.09	0.09	0.09	0.09	0.09	0.09	0.09	0.09	0.09	0.09		
GLOBULINS: GAMMA	0.1	0.2	RATIO	17/04/92	0.13	0.14	0.12	0.14	0.12	0.14	0.12	0.14	0.12	0.14		
29-117	F	HB	7.5	10.0	mmol/l	20/04/92	8.51	9.03	7.78	8.70	8.97	8.70	8.97	8.70	8.97	
		HB	7.5	10.0	mmol/l	20/04/92	8.51	9.03	7.78	8.70	8.97	8.70	8.97	8.70	8.97	

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1900

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
12 29-117	F			HTC	20/10/91	0.4	0.5	L/L	0.38	0.40	0.39	0.42	0.40	0.49	
				RBC	20/10/91	4.5	5.0	10**12/L	4.88	5.25	4.67	4.74	5.17	4.48	
				WBC	20/10/91	4.0	10.0	10**9/L	7.70	9.20	10.70	9.30	10.00	10.10	
				WBC: N	20/10/91	60.0	70.0	Z	66.00	63.00		56.00	50.00		
				WBC: L	20/10/91	20.0	45.0	Z	34.00	26.00		42.00	46.00		
				WBC: E	20/10/91	1.0	5.0	Z	6.00	6.00		2.00	2.00		
				WBC: M	20/10/91	1.0	6.0	Z	0.00	4.00		0.00	0.00		
				WBC: B	20/10/91	0.0	1.0	Z	0.00	1.00		0.00	2.00		
				PLATELETS	20/10/91	140.0	300.0	10**9/L	287.00	213.00	247.00	238.00	139.00	135.00	
				NA+	20/10/91	157.0	147.0	mmol/L	159.00	147.00	146.00	146.00	3.90	3.70	
				K+	20/10/91	3.7	5.3	mmol/L	3.70	4.10	3.80	3.80	90.00	93.00	
				CL-	20/10/91	97.0	107.0	mmol/L	94.00		94.00	105.00	2.44		
				CA++	20/10/91	2.3	2.7	mmol/L	2.35		2.41	2.16	1.08		
				PO4-	20/10/91	0.7	1.5	mmol/L	1.02	1.14	1.00	1.02	16.00		
				SGOT	20/10/91	5.0	30.0	U/L	15.00	19.00	35.00	16.00	13.00		
				SGPT	20/10/91	5.0	34.0	U/L	22.00	22.00	30.00	14.00	11.00		
				GAMMA-GT	20/10/91	6.0	28.0	U/L	51.00	50.00	18.00	10.00	2.90	4.30	
				GLUCOSE	20/10/91	3.3	5.5	mmol/L	4.30	3.80	3.80	5.70			
				ALK. PHOSPH.	20/10/91	100.0	280.0	U/L	128.00	138.00	154.00	120.00	3.90	3.60	
				CREATININE	20/10/91	3.0	9.6	mmol/L	1.50	4.00	3.50	4.40	99.00	65.00	
URIC ACID	20/10/91	50.0	110.0	umol/L	98.00	97.00	84.00	76.00	227.00						
TOT BILIRUBIN	20/10/91	120.0	410.0	umol/L	275.00	270.00	273.00	243.00	17.10	17.10					
DIR BILIRUBIN	20/10/91	3.4	22.0	umol/L	6.70	17.10	17.10	17.10	60.00	67.00					
TOT. PROTEINS	20/10/91	60.0	80.0	g/L	70.00		66.00	70.00	0.69						
ALBUMINE	20/10/91	0.5	0.7	RATIO	0.59		0.63	0.67	5.00						
TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/L	4.50		4.70	4.90							
TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/L	0.80		1.30	0.90							
GLOBULINS: ALPHA1	20/10/91	0.0	0.1	RATIO	0.09		0.06	0.06		0.04					
GLOBULINS: ALPHA2	20/10/91	0.1	0.1	RATIO	0.08		0.08	0.07		0.06					
GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.11		0.10	0.10		0.07					
GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.13		0.14	0.10		0.13					
33-388	F			HB	28/05/92	7.5	10.0	mmol/L							
				RBC	20/10/91	0.4	0.5	L/L	7.96						
				WBC	20/10/91	4.5	5.0	10**12/L	4.80						
				WBC: N	20/10/91	60.0	70.0	Z	4.60						
				WBC: L	20/10/91	20.0	45.0	Z		50.00					
				WBC: E	20/10/91	1.0	5.0	Z		46.00					
				WBC: B	20/10/91	1.0	6.0	Z		4.00					

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit									
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52			
12	33-368	F		PLATELETS	20/10/91	140.0	300.0	10**9/L									
				NA+	20/10/91	137.0	147.0	mmol/L	135.00	223.00							
				K+	20/10/91	3.7	5.3	mmol/L	4.10	140.00							
				CL-	20/10/91	97.0	107.0	mmol/L	96.00	87.00							
				CA++	20/10/91	2.3	2.7	mmol/L	2.26	2.25							
				PO4-	20/10/91	0.7	1.5	mmol/L	1.28	1.10							
				SGOT	20/10/91	5.0	30.0	U/l		31.00							
				SGPT	20/10/91	5.0	34.0	U/l		28.00							
				GAMMA-GT	20/10/91	6.0	28.0	U/l	68.00	74.00							
				GLUCOSE	20/10/91	3.3	5.5	mmol/L	8.30	8.10							
				ALK. PROSPH.	20/10/91	100.0	280.0	U/l	158.00	197.00							
				BUN	20/10/91	3.0	9.6	mmol/L	5.90	7.10							
				CREATININE	20/10/91	50.0	110.0	umol/L	83.00	102.00							
				URIC ACID	20/10/91	120.0	410.0	umol/L	245.00	220.00							
				TOT. BILIRUBIN	20/10/91	3.4	22.0	umol/L	17.10	17.10							
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	70.00	67.00							
				ALBUMINE	20/10/91	0.5	0.7	RATIO	0.49	0.58							
				TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/L	7.00	7.20							
				TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/L	2.80	3.60							
				GLOBULINS: ALPHA1	20/10/91	0.0	0.1	RATIO	0.13	0.04							
				GLOBULINS: ALPHA2	20/10/91	0.1	0.1	RATIO	0.12	0.09							
				GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.11	0.11							
				GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.15	0.18							
36-385		F		HB	20/10/91	7.5	10.0	mmol/L			08/06/92						
				HTC	20/10/91	0.4	0.5	l/l	7.83								
				RBC.	20/10/91	4.5	5.0	10**12/l	4.84								
				WBC	20/10/91	4.0	10.0	10**9/l	8.70								
				WBC: N	20/10/91	60.0	70.0	%	52.00								
				WBC: L	20/10/91	20.0	45.0	%	39.00								
				WBC: E	20/10/91	1.0	5.0	%	0.00								
				WBC: M	20/10/91	1.0	6.0	%	9.00								
				WBC: B	20/10/91	0.0	1.0	%	0.00								
				PLATELETS	20/10/91	140.0	300.0	10**9/l	187.00								
				NA+	20/10/91	137.0	147.0	mmol/L	140.00								
				K+	20/10/91	3.7	5.3	mmol/L	3.80								
				CL-	20/10/91	97.0	107.0	mmol/L	88.00								
				CA++	20/10/91	2.3	2.7	mmol/L	2.27								
				PO4-	20/10/91	0.7	1.5	mmol/L	0.83								
				SGOT	20/10/91	5.0	30.0	U/l	23.00								
				SGPT	20/10/91	5.0	34.0	U/l	20.00								
				GAMMA-GT	20/10/91	6.0	28.0	U/l	29.00								

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range				Visit													
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52								
12	36-385	F		GLUCOSE	20/10/91	3.3	5.5	mmol/l	4.10													
				ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	189.00													
				CREATININE	20/10/91	3.0	9.6	mmol/l	4.60													
				URIC ACID	20/10/91	50.0	110.0	umol/l	90.00													
				TOT. BILIRUBIN	20/10/91	120.0	410.0	umol/l	257.00													
				TOT. PROTEINS	20/10/91	3.4	22.0	umol/l	17.10													
				ALBUMINE	20/10/91	60.0	80.0	g/l	74.00													
				TOT. CHOLEST.	20/10/91	0.5	0.7	RATIO	0.62													
				TRIGLYCERIDES	20/10/91	2.6	7.0	mmol/l	4.70													
				GLOBALINS: ALPHA1	20/10/91	0.3	1.9	mmol/l	1.20													
				GLOBALINS: ALPHA2	20/10/91	0.0	0.1	RATIO	0.05													
				GLOBALINS: BETA	20/10/91	0.1	0.1	RATIO	0.07													
				GLOBALINS: GAMMA	20/10/91	0.1	0.1	RATIO	0.09													
				GLOBALINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.17													
				13	1-219	F		HR	02/10/91	120.0	140.0	g/l	23/12/91	158.00	18/02/92	158.00	09/06/92	153.00	04/08/92	158.00	13/10/92	
								HTC	02/10/91	38.0	47.0	z	39.00	39.00	39.00	38.50	40.10	43.00	43.00	43.00	43.00	43.00
								RBC	02/10/91	4.0	5.5	10 ¹² /l	4.30	4.30	4.30	4.22	4.11	4.44	4.11	4.11	4.44	4.44
RBC: N	02/10/91	4.5	8.0					10 ¹² /l	5.80	5.80	5.80	4.90	6.50	6.50	6.50	6.50	6.50					
RBC: L	02/10/91	60.0	70.0					z	72.00	72.00	72.00	57.00	61.00	68.00	59.00	68.00	68.00					
RBC: E	02/10/91	20.0	30.0					z	28.00	28.00	28.00	36.00	36.00	40.00	40.00	40.00	40.00					
RBC: H	02/10/91	1.0	5.0					z	0.00	0.00	0.00	1.00	1.00	2.00	1.00	2.00	2.00					
RBC: B	02/10/91	2.0	6.0					z	0.00	0.00	0.00	1.00	1.00	0.00	0.00	0.00	0.00					
PLATELETS	02/10/91	0.0	1.0					z	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00					
NA+	02/10/91	150.0	400.0					10 ⁹ /l	175.00	200.00	200.00	191.00	182.00	174.00	182.00	174.00	182.00					
K+	02/10/91	3.5	145.0					mmol/l	139.00	141.00	141.00	141.00	143.00	137.00	143.00	137.00	143.00					
CL-	02/10/91	95.0	108.0					mmol/l	109.00	110.00	110.00	106.00	109.00	104.00	109.00	104.00	112.00					
PO4--	02/10/91	2.3	2.7					mmol/l	2.37	2.41	2.41	2.40	2.40	2.42	2.40	2.42	2.34					
SGOT	02/10/91	1.0	1.5					mmol/l	1.00	1.02	1.02	1.01	1.05	1.28	1.01	1.05	1.18					
SGPT	02/10/91	10.0	40.0					U/l	23.00	21.00	21.00	39.00	42.00	38.00	42.00	40.00	38.00					
GAMMA-GT	02/10/91	10.0	40.0					U/l	62.00	26.00	26.00	20.00	18.00	28.00	20.00	18.00	28.00					
GLUCOSE	02/10/91	4.0	40.0					U/l	46.00	14.00	14.00	19.00	19.00	16.00	19.00	16.00	17.00					
ALK. PHOSPH.	02/10/91	100.0	300.0					U/l	5.30	5.10	5.10	4.90	4.70	5.60	4.70	5.60	4.40					
BUN	02/10/91	2.0	10.0					mmol/l	5.20	4.00	4.00	5.70	5.10	4.70	5.10	4.70	5.70					
CREATININE	02/10/91	50.0	100.0					umol/l	53.00	64.00	64.00	71.00	53.00	72.00	53.00	72.00	58.00					
URIC ACID	02/10/91	150.0	400.0	umol/l	235.00	195.00	195.00	250.00	171.00	280.00	171.00	280.00	216.00									
TOT. BILIRUBIN	02/10/91	2.0	17.0	umol/l	9.00	9.00	9.00	7.00	13.00	24.00	13.00	24.00	11.00									
DIR. BILIRUBIN	02/10/91	0.0	5.0	umol/l	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00									
TOT. PROTEINS	02/10/91	60.0	80.0	g/l	72.00	75.00	75.00	72.00	77.00	76.00	77.00	76.00	95.00									
ALBUMINE	02/10/91	35.0	50.0	g/l	42.00	50.00	50.00	42.00	42.00	44.00	42.00	44.00	51.00									

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit									
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52			
13 1-219	F		TOT. CHOLEST.	02/10/91	4.0	7.0	mmol/l	3.60	4.00	3.60	3.80	4.00	4.10			
			TRIGLYCERIDES	02/10/91	0.5	2.0	mmol/l	0.60	0.60	0.60	0.60	0.80	0.70			
			GLOBULINS: ALPHA1	02/10/91	2.0	6.0	%	7.00	6.00	6.00	6.00	8.00	4.00			
			GLOBULINS: ALPHA2	02/10/91	7.0	12.0	%	9.00	9.00	8.00	9.00	6.00	8.00			
			GLOBULINS: BETA	02/10/91	8.0	14.0	%	9.00	12.00	8.00	9.00	8.00	12.00			
			GLOBULINS: GAMMA	02/10/91	12.0	22.0	%	14.00	19.00	18.00	18.00	17.00	19.00			
			3-221	F		HB	02/10/91	120.0	140.0	g/l	155.00	145.00	150.00	157.00	154.00	155.00
						HCT	02/10/91	38.0	47.0	%	43.00	41.00	41.10	46.30	47.00	46.40
						ERC	02/10/91	4.0	5.5	10 ⁹ /l	4.90	4.70	4.66	4.32	5.00	5.02
						HRC	02/10/91	4.5	8.0	10 ⁹ /l	8.50	6.00	8.50	7.30	9.00	7.80
						HRC: N	02/10/91	60.0	70.0	%	56.00	53.00	66.00	62.00	64.00	64.00
						HRC: L	02/10/91	20.0	30.0	%	40.00	46.00	32.00	37.00	32.00	32.00
						HRC: E	02/10/91	1.0	5.0	%	4.00	1.00	1.00	1.00	2.00	2.00
HRC: M	02/10/91	2.0				6.0	%	0.00	0.00	0.00	0.00	0.00	0.00			
HRC: B	02/10/91	0.0				1.0	%	0.00	0.00	0.00	0.00	0.00	0.00			
PLATELETS	02/10/91	150.0				400.0	10 ⁹ /l	252.00	211.00	274.00	241.00	245.00	249.00			
Na+	02/10/91	135.0				145.0	mmol/l	141.00	142.00	162.00	144.00	157.00	158.00			
K+	02/10/91	3.5				5.0	mmol/l	4.10	3.80	4.60	4.30	3.90	4.60			
Cl-	02/10/91	95.0				108.0	mmol/l	104.00	110.00	98.00	101.00	100.00	98.00			
Ca++	02/10/91	2.3	2.7	mmol/l	2.35	2.33	2.40	2.50	2.42	2.53						
PO4--	02/10/91	1.0	1.5	mmol/l	1.18	0.97	0.86	1.02	0.93	0.86						
SGPT	02/10/91	10.0	40.0	u/l	22.00	21.00	42.00	37.00	32.00	64.00						
GAMMA-GT	02/10/91	10.0	40.0	u/l	36.00	29.00	34.00	27.00	30.00	67.00						
GLUCOSE	02/10/91	4.0	40.0	u/l	55.00	21.00	26.00	30.00	25.00	65.00						
ALK. PHOSPH.	02/10/91	100.0	300.0	u/l	117.00	102.00	148.00	112.00	61.00	158.00						
CREATININE	02/10/91	2.0	10.0	mmol/l	5.40	3.80	2.80	4.00	3.30	3.40						
TOT BILIRUBIN	02/10/91	50.0	100.0	umol/l	61.00	88.00	68.00	60.00	77.00	53.00						
DIR BILIRUBIN	02/10/91	150.0	400.0	umol/l	210.00	177.00	202.00	256.00	252.00	243.00						
TOT. PROTEINS	02/10/91	0.0	17.0	mmol/l	11.00	11.00	4.00	16.00	17.00	12.00						
ALBUMINE	02/10/91	60.0	80.0	g/l	78.00	79.00	76.00	80.00	74.00	79.00						
TOT. CHOLEST.	02/10/91	35.0	50.0	mmol/l	48.00	29.00	43.00	47.00	44.00	43.00						
TRIGLYCERIDES	02/10/91	0.5	7.0	mmol/l	1.00	1.60	1.50	5.20	6.10	5.20						
GLOBULINS: ALPHA1	02/10/91	2.0	6.0	%	4.00	6.00	5.00	6.00	5.00	6.00						
GLOBULINS: ALPHA2	02/10/91	7.0	12.0	%	8.00	8.00	8.00	6.00	8.00	8.00						
GLOBULINS: BETA	02/10/91	8.0	14.0	%	12.00	10.00	10.00	11.00	10.00	10.00						
GLOBULINS: GAMMA	02/10/91	12.0	22.0	%	16.00	13.00	17.00	15.00	18.00	20.00						

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit						
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
13	6-226	F		HB	02/10/91	120.0	140.0	g/l	27/12/91	20/02/92	16/04/92	11/06/92	06/08/92	15/10/92
				HTC	02/10/91	38.0	47.0	g/l	164.00	148.00	141.00	153.00	144.00	153.00
				RBC	02/10/91	4.0	5.5	10**12/l	47.00	41.00	38.70	46.00	43.30	46.30
				WBC	02/10/91	4.5	8.0	10**9/l	5.50	4.90	4.51	5.01	4.72	5.13
				WBC: N	02/10/91	20.0	70.0	%	10.80	7.40	6.90	10.10	9.50	8.70
				WBC: L	02/10/91	60.0	30.0	%	90.00	69.00	74.00	83.00	81.00	73.00
				WBC: E	02/10/91	1.0	5.0	%	10.00	25.00	21.00	16.00	17.00	23.00
				WBC: M	02/10/91	2.0	6.0	%	0.00	1.00	3.00	1.00	1.00	3.00
				WBC: B	02/10/91	0.0	1.0	%	0.00	3.00	1.00	0.00	0.00	1.00
				PLATELETS	02/10/91	150.0	400.0	10**9/l	190.00	189.00	174.00	187.00	170.00	211.00
				Na+	02/10/91	135.0	145.0	mmol/l	140.00	137.00	139.00	139.00	137.00	137.00
				K+	02/10/91	3.5	5.0	mmol/l	4.40	4.40	3.70	3.80	4.00	4.00
				Cl-	02/10/91	95.0	108.0	mmol/l	110.00	105.00	99.00	104.00	106.00	107.00
				PO4--	02/10/91	2.3	2.7	mmol/l	2.64	2.45	2.35	2.33	2.47	2.38
				SGOT	02/10/91	1.0	1.5	mmol/l	0.74	0.87	1.00	0.90	0.81	0.89
				SGPT	02/10/91	10.0	40.0	u/l	28.00	22.00	35.00	30.00	36.00	33.00
				GAMMA-GT	02/10/91	10.0	40.0	u/l	52.00	42.00	24.00	45.00	21.00	26.00
				GLUCOSE	02/10/91	10.0	40.0	g/l	91.00	43.00	37.00	35.00	34.00	36.00
				ALK. PHOSPH.	02/10/91	4.0	6.0	mmol/l	4.00	3.90	4.30	4.30	4.10	4.90
				UREA	02/10/91	100.0	300.0	u/l	122.00	130.00	116.00	114.00	112.00	124.00
				CREATININE	02/10/91	2.0	10.0	mmol/l	3.70	3.90	4.60	5.00	4.40	3.20
				URIC ACID	02/10/91	50.0	100.0	umol/l	54.00	57.00	66.00	42.00	61.00	52.00
				TOT BILIRUBIN	02/10/91	150.0	400.0	umol/l	280.00	221.00	236.00	215.00	252.00	221.00
				DIR BILIRUBIN	02/10/91	2.0	17.0	umol/l	4.00	10.00	15.00	4.00	11.00	8.00
				TOT. PROTEINS	02/10/91	60.0	80.0	g/l	78.00	84.00	72.00	73.00	78.00	80.00
				ALBUMINE	02/10/91	35.0	50.0	g/l	43.00	53.00	44.00	42.00	46.00	45.00
				TOT. CHOLEST.	02/10/91	4.0	7.0	mmol/l	4.10	4.00	4.20	4.20	4.40	4.40
				TRIGLYCERIDES	02/10/91	0.5	2.0	mmol/l	1.20	0.70	0.50	0.50	0.50	0.90
				GLOBULINS: ALPHA1	02/10/91	2.0	6.0	%	5.00	6.00	6.00	5.00	8.00	5.00
				GLOBULINS: ALPHA2	02/10/91	7.0	12.0	%	12.00	8.00	7.00	7.00	9.00	8.00
				GLOBULINS: BETA	02/10/91	8.0	14.0	%	14.00	10.00	10.00	7.00	10.00	9.00
				GLOBULINS: GAMMA	02/10/91	12.0	22.0	%	16.00	14.00	17.00	22.00	13.00	20.00
7-220		F		HB	02/10/91	120.0	140.0	g/l	02/01/92	27/02/92	23/04/92	16/06/92	11/08/92	21/10/92
				HTC	02/10/91	38.0	47.0	g/l	122.00	119.00	122.00	111.00	120.00	124.00
				RBC	02/10/91	4.0	5.5	10**12/l	37.00	35.00	37.00	34.60	38.00	39.10
				WBC	02/10/91	4.5	8.0	10**9/l	6.00	4.30	4.50	4.02	4.34	4.56
				WBC: N	02/10/91	60.0	30.0	%	72.00	72.00	66.00	63.00	60.00	5.90
				WBC: L	02/10/91	20.0	30.0	%	28.00	24.00	30.00	34.00	35.00	60.00
				WBC: E	02/10/91	1.0	5.0	%	0.00	4.00	2.00	3.00	3.00	34.00

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit										
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52				
13-223	M	F	HRC: H	02/10/91	2.0	6.0	%	0.00	0.00	2.00	0.00	0.00	2.00	0.00	2.00	2.00	
			HRC: B	02/10/91	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
			PLATELETS	02/10/91	150.0	400.0	10 ⁹ xg/l	262.00	265.00	220.00	277.00	230.00	262.00	230.00	277.00	230.00	262.00
			NA+	02/10/91	135.0	145.0	mmol/l	137.00	138.00	137.00	141.00	140.00	136.00	140.00	141.00	136.00	136.00
			K+	02/10/91	3.5	5.0	mmol/l	3.90	3.70	4.00	4.00	4.00	3.90	4.00	4.00	3.90	4.30
			CL-	02/10/91	95.0	108.0	mmol/l	104.00	104.00	102.00	102.00	102.00	100.00	102.00	102.00	100.00	100.00
			CA++	02/10/91	2.3	2.7	mmol/l	2.35	2.13	2.13	2.13	2.13	2.38	2.10	2.26	2.10	2.38
			PO4--	02/10/91	1.0	1.5	mmol/l	1.34	1.00	0.90	1.00	1.00	1.24	1.00	1.00	1.00	1.24
			SGOT	02/10/91	10.0	40.0	U/l	23.00	19.00	37.00	30.00	30.00	32.00	36.00	30.00	32.00	32.00
			SGPT	02/10/91	10.0	40.0	U/l	39.00	31.00	18.00	19.00	19.00	18.00	19.00	19.00	18.00	18.00
			GAMMA-GT	02/10/91	10.0	40.0	U/l	44.00	20.00	23.00	18.00	18.00	17.00	15.00	17.00	17.00	17.00
			GLUCOSE	02/10/91	4.0	6.0	mmol/l	5.30	5.30	5.30	5.30	5.20	5.70	5.00	5.20	5.00	5.70
			ALK. PHOSPH.	02/10/91	100.0	300.0	U/l	86.00	89.00	87.00	95.00	95.00	86.00	99.00	95.00	86.00	86.00
			CREATININE	02/10/91	2.0	10.0	mmol/l	5.60	5.00	6.00	5.40	5.40	6.00	5.00	5.40	5.00	6.00
			URIC ACID	02/10/91	50.0	100.0	umol/l	53.00	65.00	66.00	50.00	50.00	77.00	65.00	50.00	77.00	77.00
			TOT. BILIRUBIN	02/10/91	150.0	400.0	umol/l	232.00	199.00	162.00	165.00	165.00	197.00	177.00	165.00	197.00	197.00
			DIR. BILIRUBIN	02/10/91	2.0	17.0	umol/l	8.00	7.00	6.00	6.00	6.00	17.00	12.00	6.00	17.00	17.00
			ALBUMINE	02/10/91	60.0	80.0	g/l	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
			TOT. PROTEINS	02/10/91	35.0	50.0	g/l	77.00	76.00	72.00	76.00	76.00	79.00	76.00	76.00	79.00	79.00
			TOT. CHOLEST.	02/10/91	4.0	7.0	mmol/l	4.20	4.00	3.80	3.60	3.60	4.00	3.60	3.60	4.00	4.00
TRIGLYCERIDES	02/10/91	0.5	2.0	mmol/l	0.50	0.60	0.50	0.50	0.50	0.70	0.60	0.50	0.70	0.70			
GLOBULINS: ALPHA1	02/10/91	2.0	6.0	%	5.00	9.00	3.00	8.00	8.00	6.00	3.00	8.00	6.00	6.00			
GLOBULINS: ALPHA2	02/10/91	7.0	12.0	%	9.00	9.00	5.00	9.00	9.00	6.00	6.00	9.00	6.00	6.00			
GLOBULINS: BETA	02/10/91	8.0	14.0	%	10.00	7.00	11.00	13.00	13.00	8.00	13.00	13.00	8.00	8.00			
GLOBULINS: GAMMA	02/10/91	12.0	22.0	%	22.00	22.00	19.00	17.00	17.00	20.00	20.00	17.00	20.00	20.00			
13-223	M	F	HB	02/10/91	140.0	160.0	g/l	155.00	147.00	167.00	150.00	150.00	167.00	150.00	167.00	167.00	
			HTC	02/10/91	40.0	54.0	%	45.00	42.00	47.20	45.00	45.00	44.90	42.70	45.00	44.90	
			RBC	02/10/91	4.0	5.5	10 ¹² /l	4.60	4.30	4.42	4.40	4.40	4.26	4.42	4.40	4.26	
			HRC: N	02/10/91	4.5	8.0	10 ¹² xg/l	13.40	12.30	10.00	10.70	10.70	11.90	10.90	10.70	11.90	
			HRC: E	02/10/91	20.0	70.0	%	73.00	68.00	71.00	73.00	73.00	64.00	72.00	73.00	64.00	
			HRC: L	02/10/91	20.0	30.0	%	24.00	30.00	27.00	30.00	30.00	25.00	25.00	30.00	25.00	
			HRC: B	02/10/91	1.0	5.0	%	3.00	2.00	1.00	3.00	3.00	3.00	2.00	3.00	3.00	
			HRC: M	02/10/91	2.0	6.0	%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			HRC: S	02/10/91	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
			PLATELETS	02/10/91	150.0	400.0	10 ⁹ xg/l	316.00	337.00	278.00	270.00	270.00	350.00	279.00	270.00	350.00	
			NA+	02/10/91	135.0	145.0	mmol/l	138.00	139.00	137.00	137.00	137.00	140.00	140.00	137.00	140.00	
			K+	02/10/91	3.5	5.0	mmol/l	4.40	4.20	5.20	4.30	4.30	5.60	4.30	4.30	5.60	
CL-	02/10/91	95.0	108.0	mmol/l	108.00	102.00	103.00	105.00	105.00	97.00	105.00	105.00	97.00				
CA++	02/10/91	2.3	2.7	mmol/l	2.44	2.35	2.37	2.23	2.23	2.52	2.28	2.23	2.52				
PO4--	02/10/91	1.0	1.5	mmol/l	1.19	1.09	1.18	1.22	1.22	1.16	1.28	1.22	1.16				

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre Open-Blind Sex	Laboratory test	Laboratory Range			Visit		Week 26	Week 34	Week 42	Week 52	
			Date	Min	Max	Unit						
13 13-223	M	SGOT	02/10/91	10.0	40.0	w/l	25.00	27.00	24.00	30.00	24.00	32.00
		SGPT	02/10/91	10.0	40.0	w/l	43.00	32.00	20.00	23.00	18.00	19.00
		GAMMA-GT	02/10/91	10.0	40.0	w/l	90.00	52.00	25.00	31.00	32.00	32.00
		GLUCOSE	02/10/91	4.0	6.0	mmol/l	7.60	7.60	7.30	6.90	7.20	6.30
		ALK. PHOSPH.	02/10/91	100.0	300.0	w/l	139.00	108.00	84.00	85.00	83.00	90.00
		URIC ACID	02/10/91	2.0	10.0	mmol/l	3.70	8.20	6.80	6.00	7.10	7.80
		CREATININE	02/10/91	50.0	100.0	umol/l	87.00	92.00	80.00	69.00	95.00	95.00
		URIC ACID	02/10/91	150.0	400.0	umol/l	368.00	309.00	273.00	234.00	264.00	295.00
		TOT BILIRUBIN	02/10/91	0.0	5.0	umol/l	7.00	4.00	4.00	4.00	4.00	4.00
		DIR BILIRUBIN	02/10/91	60.0	80.0	g/l	79.00	72.00	74.00	66.00	74.00	75.00
		TOT. PROTEINS	02/10/91	35.0	50.0	g/l	42.00	47.00	41.00	40.00	44.00	41.00
		ALBUMINE	02/10/91	4.0	7.0	mmol/l	5.50	5.80	4.90	4.20	5.10	4.60
		TRIGLYCERIDES	02/10/91	0.5	2.0	mmol/l	1.10	0.80	0.50	0.60	0.60	0.60
		GLOBULINS: ALPHA1	02/10/91	2.0	6.0	%	6.00	4.00	6.00	6.00	4.00	7.00
		GLOBULINS: ALPHA2	02/10/91	7.0	12.0	%	8.00	5.00	5.00	8.00	5.00	9.00
		GLOBULINS: BETA	02/10/91	8.0	14.0	%	12.00	7.00	7.00	9.00	12.00	10.00
		GLOBULINS: GAMMA	02/10/91	12.0	22.0	%	18.00	13.00	29.00	15.00	18.00	15.00
18-227	F	HB	02/10/91	120.0	140.0	g/l	144.00	147.00	159.00	151.00	137.00	148.00
		HTC	02/10/91	38.0	47.0	%	41.00	41.80	47.10	45.10	48.20	44.70
		RBC	02/10/91	4.0	5.5	10**12/l	4.30	4.35	4.64	4.50	4.77	4.43
		HBC	02/10/91	4.5	8.0	10**9/l	4.90	7.50	7.50	5.50	7.20	8.40
		HBC: N	02/10/91	60.0	70.0	%	65.00	70.00	77.00	77.00	65.00	85.00
		HBC: L	02/10/91	20.0	30.0	%	34.00	25.00	22.00	22.00	33.00	14.00
		HBC: E	02/10/91	1.0	5.0	%	1.00	0.00	0.00	1.00	0.00	0.00
		HBC: M	02/10/91	2.0	6.0	%	0.00	5.00	1.00	0.00	2.00	1.00
		HBC: B	02/10/91	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00
		PLATELETS	02/10/91	150.0	400.0	10**9/l	304.00	289.00	361.00	309.00	350.00	358.00
		NA+	02/10/91	135.0	145.0	mmol/l	138.00	136.00	140.00	137.00	142.00	136.00
		K+	02/10/91	3.5	5.0	mmol/l	4.80	4.00	5.10	4.90	4.80	4.00
		CL-	02/10/91	95.0	108.0	mmol/l	103.00	106.00	106.00	109.00	110.00	102.00
		CA++	02/10/91	2.3	2.7	mmol/l	2.38	2.62	2.49	2.32	2.30	2.41
		PO4--	02/10/91	1.0	1.5	mmol/l	1.10	0.80	0.90	0.90	0.78	1.13
		SGOT	02/10/91	10.0	40.0	w/l	40.00	47.00	40.00	41.00	48.00	20.00
		SGPT	02/10/91	10.0	40.0	w/l	25.00	66.00	37.00	25.00	24.00	17.00
GAMMA-GT	02/10/91	10.0	40.0	w/l	48.00	108.00	64.00	36.00	37.00	36.00		
GLUCOSE	02/10/91	4.0	6.0	mmol/l	4.70	4.90	4.90	5.20	5.70	4.20		
URIC ACID	02/10/91	2.0	10.0	mmol/l	73.00	89.00	90.00	66.00	76.00	70.00		
CREATININE	02/10/91	50.0	100.0	umol/l	4.40	3.00	3.90	2.10	3.70	4.10		
URIC ACID	02/10/91	150.0	400.0	umol/l	157.00	210.00	222.00	262.00	58.00	188.00		

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

1 0 1 6

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Date	Laboratory Range		Visit										
						Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52				
13	18-227	F		TOT. BILIRUBIN	02/10/91	2.0	17.0	umol/l	12.00	5.00	9.00	6.00	7.00	4.00				
				DIR. BILIRUBIN	02/10/91	0.0	5.0	umol/l	4.00	4.00	4.00	4.00	4.00	4.00	4.00			
				TOT. PROTEINS	02/10/91	60.0	80.0	g/l	72.00	74.00	80.00	75.00	76.00	70.00	70.00			
				ALBUMINE	02/10/91	35.0	50.0	g/l	46.00	44.00	48.00	43.00	45.00	42.00	42.00			
				TOT. CHOLEST.	02/10/91	4.0	7.0	mmol/l	5.90	6.90	7.20	6.20	6.20	5.10	5.10			
				TRIGLYCERIDES	02/10/91	0.5	2.0	mmol/l	1.00	0.80	0.80	0.80	0.80	0.60	0.60			
				GLOBULINS: ALPHA1	02/10/91	2.0	6.0	g/l	8.00	4.00	6.00	7.00	9.00	4.00	4.00			
				GLOBULINS: ALPHA2	02/10/91	7.0	12.0	g/l	8.00	8.00	6.00	8.00	12.00	5.00	5.00			
				GLOBULINS: BETA	02/10/91	8.0	14.0	g/l	7.00	9.00	9.00	10.00	11.00	12.00	12.00			
				GLOBULINS: GAMMA	02/10/91	12.0	22.0	g/l	11.00	17.00	16.00	15.00	10.00	10.00	21.00			
				20-230	F			TOT. BILIRUBIN	02/10/91	120.0	140.0	g/l	140.00	147.00	145.00	149.00	147.00	140.00
								DIR. BILIRUBIN	02/10/91	38.0	47.0	g/l	41.90	44.50	44.60	46.80	46.50	43.80
								RBC	02/10/91	4.0	5.5	10**12/l	4.49	4.55	4.52	4.80	4.85	4.68
								HBC	02/10/91	4.5	8.0	10**9/l	5.60	6.80	6.50	7.50	7.50	5.00
HBC: N	02/10/91	60.0	70.0					g/l	68.00	68.00	65.00	72.00	57.00	57.00				
HBC: L	02/10/91	20.0	30.0					g/l	28.00	28.00	32.00	24.00	41.00	36.00				
HBC: E	02/10/91	1.0	5.0					g/l	2.00	3.00	2.00	2.00	1.00	4.00				
HBC: M	02/10/91	2.0	6.0					g/l	1.00	1.00	1.00	1.00	1.00	3.00				
HBC: B	02/10/91	0.0	1.0					g/l	0.00	0.00	0.00	0.00	0.00	0.00				
PLATELETS	02/10/91	150.0	400.0					10**9/l	226.00	232.00	244.00	259.00	278.00	264.00				
NA+	02/10/91	135.0	145.0					mmol/l	139.00	139.00	140.00	141.00	138.00	138.00				
K+	02/10/91	95.0	108.0					mmol/l	4.70	4.30	5.00	4.30	3.90	4.40				
CL-	02/10/91	2.3	2.7					mmol/l	2.32	2.37	2.33	2.29	2.35	2.31				
CA++	02/10/91	1.0	1.5					mmol/l	1.83	1.25	0.76	1.01	0.90	1.27				
SGOT	02/10/91	10.0	40.0					u/l	31.00	28.00	34.00	23.00	15.00	25.00				
SGPT	02/10/91	10.0	40.0					u/l	20.00	28.00	20.00	18.00	36.00	15.00				
GAMMA-GT	02/10/91	10.0	40.0					u/l	16.00	19.00	14.00	20.00	48.00	28.00				
GLUCOSE	02/10/91	4.0	6.0					mmol/l	4.80	4.40	4.90	4.70	5.30	5.40				
ALK. PHOSPH.	02/10/91	100.0	300.0					u/l	82.00	96.00	82.00	92.00	92.00	112.00				
UREA	02/10/91	2.0	10.0					mmol/l	4.10	4.10	4.40	3.90	4.30	4.10				
CREATININE	02/10/91	50.0	100.0					umol/l	63.00	57.00	72.00	55.00	68.00	72.00				
URIC ACID	02/10/91	150.0	400.0					umol/l	295.00	177.00	193.00	182.00	222.00	224.00				
TOT. BILIRUBIN	02/10/91	0.0	17.0	umol/l	9.00	6.00	6.00	5.00	4.00	11.00								
DIR. BILIRUBIN	02/10/91	0.0	5.0	umol/l	4.00	4.00	4.00	4.00	4.00	4.00								
TOT. PROTEINS	02/10/91	60.0	80.0	g/l	72.00	72.00	73.00	70.00	75.00	75.00								
ALBUMINE	02/10/91	35.0	50.0	g/l	43.00	45.00	45.00	41.00	50.00	41.00								
TOT. CHOLEST.	02/10/91	4.0	7.0	mmol/l	6.00	5.40	5.70	5.80	5.70	0.70								
TRIGLYCERIDES	02/10/91	0.5	2.0	mmol/l	0.80	0.40	0.50	0.50	0.80	0.70								
GLOBULINS: ALPHA1	02/10/91	2.0	6.0	g/l	4.00	5.00	5.00	5.00	4.00	5.00								
GLOBULINS: ALPHA2	02/10/91	7.0	12.0	g/l	11.00	8.00	9.00	7.00	9.00	7.00								

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No. Centre Open-Blind Sex	Laboratory test	Date	Laboratory Range		Week 10		Week 18		Week 26		Week 34		Week 42		Week 52	
			Min	Max	Unit	Value	Unit	Value	Unit	Value	Unit	Value	Unit	Value	Unit	Value
13 20-230	F	02/10/91	8.0	14.0	X	18.00	9.00	9.00	10.00	9.00	10.00	9.00	10.00	9.00	12.00	
		02/10/91	12.0	22.0	X	15.00	14.00	17.00	14.00	14.00	14.00	14.00	14.00	14.00	15.00	
21-231	F	02/10/91	120.0	140.0	g/l	141.00	160.00	141.00	139.00	139.00	141.00	138.00	141.00	136.00	16/02/93	
		02/10/91	38.0	47.0	X	42.10	41.40	41.40	41.80	42.10	42.40	42.10	42.10	40.50		
		02/10/91	4.0	5.5	10**12/1	4.72	4.64	4.64	4.64	4.72	4.86	4.72	4.72	4.72		
		02/10/91	4.5	8.0	10**9/1	5.60	6.40	6.40	6.40	6.30	7.10	7.10	7.90	6.50		
		02/10/91	60.0	70.0	X	58.00	56.00	56.00	56.00	55.00	55.00	62.00	62.00	38.00		
		02/10/91	20.0	30.0	X	38.00	41.00	42.00	42.00	42.00	42.00	34.00	34.00	54.00		
		02/10/91	1.0	5.0	X	2.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	7.00		
		02/10/91	2.0	6.0	X	1.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00		
		02/10/91	0.0	1.0	X	1.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	0.00		
		02/10/91	150.0	400.0	10**9/1	252.00	257.00	257.00	268.00	365.00	365.00	299.00	299.00	291.00		
		02/10/91	135.0	145.0	mmol/l	137.00	141.00	141.00	140.00	141.00	137.00	139.00	139.00	141.00		
		02/10/91	3.5	5.0	mmol/l	3.20	3.70	3.70	3.80	3.80	3.80	3.70	3.70	3.50		
		02/10/91	95.0	108.0	mmol/l	102.00	105.00	105.00	100.00	104.00	104.00	102.00	102.00	105.00		
		02/10/91	2.3	2.7	mmol/l	2.20	2.20	2.20	2.22	2.46	2.46	2.36	2.36	2.33		
		02/10/91	1.0	1.5	mmol/l	2.30	1.00	1.00	0.83	0.94	0.94	1.57	1.57	1.33		
		02/10/91	10.0	40.0	u/l	32.00	37.00	37.00	27.00	28.00	28.00	46.00	46.00	34.00		
		02/10/91	10.0	40.0	u/l	16.00	21.00	21.00	15.00	15.00	19.00	20.00	20.00	19.00		
		02/10/91	10.0	40.0	u/l	15.00	19.00	19.00	15.00	15.00	33.00	29.00	29.00	21.00		
		02/10/91	4.0	6.0	mmol/l	5.50	5.00	5.00	4.60	4.60	4.30	5.70	5.70	5.70		
		02/10/91	100.0	300.0	u/l	83.00	93.00	93.00	77.00	85.00	85.00	106.00	106.00	87.00		
		02/10/91	2.0	10.0	mmol/l	3.40	3.60	3.60	3.00	3.40	3.40	3.50	3.50	3.70		
		02/10/91	50.0	100.0	umol/l	67.00	63.00	63.00	74.00	74.00	74.00	65.00	65.00	76.00		
		02/10/91	17.0	17.0	umol/l	162.00	218.00	218.00	165.00	230.00	230.00	166.00	166.00	156.00		
		02/10/91	0.0	5.0	umol/l	6.00	10.00	10.00	4.00	4.00	4.00	11.00	11.00	8.00		
		02/10/91	0.0	80.0	g/l	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00		
		02/10/91	60.0	50.0	g/l	72.00	68.00	68.00	68.00	68.00	82.00	71.00	71.00	75.00		
		02/10/91	35.0	50.0	g/l	45.00	43.00	43.00	44.00	44.00	44.00	42.00	42.00	49.00		
		02/10/91	4.0	7.0	mmol/l	5.20	5.30	5.30	4.90	5.30	5.70	4.90	4.90	5.40		
		02/10/91	0.5	2.0	mmol/l	0.60	1.40	1.40	1.30	1.30	1.10	0.90	0.90	0.90		
		02/10/91	2.0	6.0	X	3.00	7.00	7.00	4.00	4.00	7.00	5.00	5.00	6.00		
		02/10/91	7.0	12.0	X	6.00	9.00	9.00	9.00	9.00	12.00	11.00	11.00	9.00		
		02/10/91	8.0	14.0	X	13.00	9.00	9.00	9.00	9.00	15.00	11.00	11.00	10.00		
		02/10/91	12.0	22.0	X	15.00	16.00	16.00	12.00	14.00	14.00	16.00	16.00	16.00		
22-232	F	02/10/91	120.0	140.0	g/l	140.00	140.00	140.00	140.00	140.00	140.00	140.00	140.00	140.00		
		02/10/91	38.0	47.0	X	42.00	42.00	42.00	42.00	42.00	42.00	42.00	42.00	42.00		
		02/10/91	4.0	5.5	10**12/1	4.52	4.52	4.52	4.52	4.52	4.52	4.52	4.52	4.52		

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1913

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52		
13	22-232	F		RBC	02/10/91	4.5	8.0	10**9/l	6.30							
				RBC: N	02/10/91	60.0	70.0	X	76.00							
				RBC: L	02/10/91	20.0	30.0	X	23.00							
				RBC: E	02/10/91	1.0	5.0	X	1.00							
				RBC: M	02/10/91	2.0	6.0	X	0.00							
				RBC: B	02/10/91	0.0	1.0	X	0.00							
				PLATELETS	02/10/91	150.0	400.0	10**9/l	182.00							
				NA+	02/10/91	135.0	145.0	mmol/l	135.00							
				K+	02/10/91	3.5	5.0	mmol/l	3.90							
				CL-	02/10/91	95.0	108.0	mmol/l	105.00							
				PO4--	02/10/91	2.3	2.7	mmol/l	2.30							
				SGOT	02/10/91	1.0	1.5	mmol/l	1.17							
				SGPT	02/10/91	10.0	40.0	u/l	41.00							
				GAMMA-GT	02/10/91	10.0	40.0	u/l	37.00							
				GLUCOSE	02/10/91	4.0	6.0	mmol/l	5.60							
				ALK. PHOSPH.	02/10/91	100.0	300.0	u/l	73.00							
				BUN	02/10/91	2.0	10.0	mmol/l	5.40							
				CREATININE	02/10/91	50.0	100.0	umol/l	74.00							
				URIC ACID	02/10/91	150.0	400.0	umol/l	255.00							
				TOT. BILIRUBIN	02/10/91	2.0	17.0	umol/l	8.00							
				DIR. BILIRUBIN	02/10/91	0.0	5.0	umol/l	4.00							
				ALBUMINE	02/10/91	60.0	80.0	g/l	70.00							
				TOT. PROTEINS	02/10/91	35.0	50.0	g/l	37.00							
				TOT. CHOLEST.	02/10/91	4.0	7.0	mmol/l	5.80							
				TRIGLYCERIDES	02/10/91	0.5	2.0	mmol/l	1.10							
				GLORULINS: ALPHA1	02/10/91	2.0	6.0	X	5.00							
				GLORULINS: ALPHA2	02/10/91	7.0	12.0	X	9.00							
				GLORULINS: BETA	02/10/91	8.0	14.0	X	8.00							
				GLORULINS: GAMMA	02/10/91	12.0	22.0	X	18.00							

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1919

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
1	1-1	F		HB	20/10/90	12.0	16.0	G/100ML	25/01/91	22/03/91					
				HTC	20/10/90	37.0	47.0	%	13.80	13.20					
				RBC	20/10/90	3.8	5.4	10 ⁶ /MM ³	39.00	48.00					
				WBC	20/10/90	4.0	11.0	10 ³ /MM ³	4.30	4.50					
				WBC: N	20/10/90	40.0	70.0	%	7.50	11.60					
				WBC: L	20/10/90	20.0	40.0	%	56.00	64.00					
				WBC: E	20/10/90	1.0	5.0	%	38.00	35.00					
				WBC: K	20/10/90	4.0	8.0	%	4.00	0.00					
				WBC: B	20/10/90	0.0	1.0	%	6.00	1.00					
				PLATELETS	20/10/90	150.0	550.0	10 ³ /MM ³	304.00	305.00					
				NA+	20/10/90	138.0	155.0	M EQ/L	141.00	141.00					
				K+	20/10/90	3.5	5.5	M EQ/L	4.50	4.50					
				CL-	20/10/90	98.0	120.0	M EQ/L	101.00	104.00					
				PO4--	20/10/90	8.5	10.5	MG/DL	9.20	9.60					
				SGOT	20/10/90	3.0	4.5	MG/DL	3.90	4.00					
				GAMMA-GT	20/10/90	12.0	40.0	RU/ML	27.00	34.00					
				GLUCOSE	20/10/90	7.0	33.0	MG/DL	23.00	18.00					
				ALK. PHOSPH.	20/10/90	70.0	100.0	MG/DL	39.00	41.00					
				BUN	20/10/90	65.0	306.0	MG/DL	91.00	88.00					
				CREATININE	20/10/90	10.0	50.0	MG/DL	200.00	132.00					
				URIC ACID	20/10/90	0.6	1.6	MG/DL	17.00	36.00					
				TOT BILIRUBIN	20/10/90	2.4	5.7	MG/DL	0.90	1.00					
				DIR BILIRUBIN	20/10/90	0.2	1.0	MG/DL	4.20	4.00					
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	0.50	0.30					
				ALBUMINE	20/10/90	3.5	5.0	G/DL	0.20	0.20					
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	6.20	6.70					
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	4.00	4.80					
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	227.00	232.00					
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	3.00	3.10					
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	8.00	6.20					
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	18.00	13.80					
				HB	20/10/90	12.0	16.0	G/100ML	13/02/91	09/04/91					
				HTC	20/10/90	37.0	47.0	%	15.60	12.90					
				RBC	20/10/90	3.8	5.4	10 ⁶ /MM ³	41.00	40.00					
				WBC	20/10/90	4.0	11.0	10 ³ /MM ³	4.20	4.20					
				WBC: N	20/10/90	40.0	70.0	%	4.80	4.60					
				WBC: L	20/10/90	20.0	40.0	%	59.00	61.00					
				WBC: E	20/10/90	1.0	5.0	%	49.00	37.00					
				WBC: K	20/10/90	4.0	8.0	%	1.00	1.00					

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1920

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit																
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52										
1	6-5	F		HBC: M	20/10/90	4.0	8.0	%	1.00															
				HBC: B	20/10/90	0.0	1.0	%	0.00															
				PLATELETS	20/10/90	150.0	550.0	10 ³ -3/HMC	192.00															
				Na+	20/10/90	138.0	155.0	M EQ/L	147.00															
				K+	20/10/90	3.5	5.5	M EQ/L	3.80															
				CL-	20/10/90	98.0	120.0	M EQ/L	105.00															
				Ca++	20/10/90	8.5	10.5	MG/DL	10.10															
				PO4--	20/10/90	3.0	4.5	MG/DL	4.30															
				SGOT	20/10/90	12.0	40.0	IU/ML	25.00															
				SGPT	20/10/90	10.0	40.0	IU/ML	18.00															
				GAMMA-GT	20/10/90	7.0	33.0	IU/ML	23.00															
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	133.00															
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	219.00															
				UUN	20/10/90	10.0	50.0	MG/DL	36.00															
				CREATININE	20/10/90	0.6	1.5	MG/DL	1.50															
				URIC ACID	20/10/90	2.4	5.7	MG/DL	4.50															
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.40															
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20															
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.20															
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10															
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	230.00																			
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	110.00																			
GLOBALINS: ALPHA1	20/10/90	4.0	7.0	%	3.00																			
GLOBALINS: ALPHA2	20/10/90	7.0	11.0	%	9.00																			
GLOBALINS: BETA	20/10/90	11.0	14.0	%	15.00																			
GLOBALINS: GAMMA	20/10/90	15.0	22.0	%	14.00																			
8-6	M		HB	20/10/90	14.0	18.0	g/100ml	15/02/91	12/04/91	07/06/91														
			HTC	20/10/90	40.0	54.0	%	44.00																
			RBC	20/10/90	4.3	6.1	10 ⁶ /mm	5.10																
			HBC: N	20/10/90	4.0	11.0	10 ³ -3/HMC	4.90																
			HBC: L	20/10/90	40.0	70.0	%	72.00																
			HBC: E	20/10/90	20.0	40.0	%	20.00																
			HBC: M	20/10/90	1.0	5.0	%	3.00																
			HBC: B	20/10/90	4.0	8.0	%	8.00																
			PLATELETS	20/10/90	150.0	550.0	10 ³ -3/HMC	221.00																
			Na+	20/10/90	138.0	155.0	M EQ/L	136.00																
			K+	20/10/90	3.5	5.5	M EQ/L	4.40																
			CL-	20/10/90	98.0	120.0	M EQ/L	108.00																
			Ca++	20/10/90	8.5	10.5	MG/DL	9.20																
			PO4--	20/10/90	3.0	4.5	MG/DL	2.70																

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REDUXETINE - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit												
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52						
11-9	F	1	8-6	M	SGOT	20/10/90	12.0	40.0	NU/HL	28.00	27.00	24.00							
					SGPT	20/10/90	10.0	40.0	NU/HL	39.00	22.00	31.00							
					GAMMA-GT	20/10/90	11.0	51.0	NU/HL	28.00	26.00	37.00							
					GLUCOSE	20/10/90	70.0	100.0	MG/DL	85.00	89.00	93.00							
					ALK. PHOSPH.	20/10/90	65.0	306.0	NU/HL	266.00	257.00	273.00							
					BUN	20/10/90	10.0	50.0	MG/DL	32.00	32.00	31.00							
					CREATININE	20/10/90	0.6	1.6	MG/DL	1.00	1.00	1.20							
					URIC ACID	20/10/90	3.4	7.0	MG/DL	6.90	6.90	6.00							
					TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.80	1.00	1.20							
					DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.40	0.40							
					TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.60	6.80	7.00							
					ALBUMINE	20/10/90	3.5	5.0	G/DL	4.30	4.30	4.20							
					TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	217.00	195.00	191.00							
					TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	106.00	96.00	107.00							
					GLOBULINS: ALPHA1	20/10/90	4.0	7.0	g	3.00	2.80	3.90							
					GLOBULINS: ALPHA2	20/10/90	7.0	11.0	g	9.00	7.50	11.60							
					GLOBULINS: BETA	20/10/90	11.0	14.0	g	12.00	14.10	12.60							
					GLOBULINS: GAMMA	20/10/90	15.0	22.0	g	11.00	15.20	17.50							
					11-9	F	11-9	F	M	HB	20/10/90	12.0	16.0	G/100ML	17/05/91	12/07/91	06/09/91	01/11/91	
										HTC	20/10/90	37.0	47.0	g	12.90	13.60	15.10	14.40	
										RBC	20/10/90	3.8	5.4	10 ⁶ /MCL	40.00	41.00	44.00	43.00	
										RBC: M	20/10/90	4.0	11.0	10 ⁻³ /MCL	6.90	4.60	4.90	4.70	
										RBC: L	20/10/90	40.0	70.0	g	55.00	7.30	7.50	8.50	
										RBC: E	20/10/90	20.0	40.0	g	32.00	65.00	59.00	64.00	
										RBC: M	20/10/90	1.0	5.0	g	41.00	4.00	39.00	34.00	
										RBC: B	20/10/90	4.0	8.0	g	3.00	4.00	1.00	3.00	
										RBC: B	20/10/90	0.0	1.0	g	4.00	3.00	2.00	2.00	
										PLATELETS	20/10/90	150.0	550.0	10 ⁻³ /MCL	340.00	337.00	328.00	384.00	
										Na+	20/10/90	138.0	155.0	M EQ/L	140.00	130.00	134.00	142.00	
										Cl-	20/10/90	98.0	120.0	M EQ/L	105.00	102.00	99.00	97.00	
Ca++	20/10/90	8.5	10.5	MG/DL						9.70	4.50	4.50	4.90						
PO4--	20/10/90	3.0	4.5	MG/DL						4.00	3.50	3.40	3.20						
SGOT	20/10/90	12.0	40.0	NU/ML						16.00	20.00	15.00	25.00						
SGPT	20/10/90	10.0	40.0	NU/ML						13.00	22.00	17.00	17.00						
GAMMA-GT	20/10/90	7.0	33.0	NU/ML						17.00	21.00	22.00	22.00						
GLUCOSE	20/10/90	70.0	100.0	MG/DL						95.00	92.00	100.00	72.00						
ALK. PHOSPH.	20/10/90	65.0	306.0	NU/ML						122.00	139.00	129.00	147.00						
BUN	20/10/90	10.0	50.0	MG/DL						50.00	29.00	21.00	27.00						
CREATININE	20/10/90	0.6	1.6	MG/DL	1.00	0.90	0.70	0.90											
URIC ACID	20/10/90	2.4	5.7	MG/DL	4.20	3.70	2.80	3.90											

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

1920

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range		Date		Week 10		Week 18		Week 26		Week 34		Week 42		Week 52								
					Min	Max	Unit	Unit	Unit	Unit	Unit	Unit	Unit	Unit	Unit	Unit	Unit	Unit	Unit	Unit	Unit	Unit	Unit				
1	11-9	F		TOT. BILIRUBIN	0.2	1.0	MG/DL	20/10/90	0.60	0.60	0.60	0.60	0.80	0.80	0.40	0.40											
				DIR. BILIRUBIN	0.0	0.4	MG/DL	20/10/90	0.30	0.30	0.30	0.30	0.30	0.30	0.30	0.30	0.20	0.20									
				TOT. PROTEINS	6.0	8.0	G/DL	20/10/90	6.50	6.50	6.50	6.50	6.50	6.50	6.50	6.50	6.50	6.50									
				ALBUMINE	3.5	5.0	G/DL	20/10/90	4.10	4.10	4.10	4.10	4.10	4.10	4.10	4.10	4.30	4.30									
				TOT. CHOLEST.	140.0	270.0	MG/DL	20/10/90	208.00	208.00	208.00	208.00	208.00	208.00	172.00	172.00	189.00	189.00									
				TRIGLYCERIDES	35.0	175.0	MG/DL	20/10/90	74.00	74.00	74.00	74.00	95.00	95.00	95.00	95.00	64.00	64.00									
				GLOBULINS: ALPHA1	4.0	7.0	g	20/10/90	3.70	3.70	3.70	3.70	1.20	1.20	1.20	1.20	4.50	4.50									
				GLOBULINS: ALPHA2	7.0	11.0	g	20/10/90	7.60	7.60	7.60	7.60	7.60	7.60	7.60	7.60	7.50	7.50									
				GLOBULINS: BETA	11.0	14.0	g	20/10/90	11.20	11.20	11.20	11.20	13.20	13.20	13.20	13.20	11.70	11.70									
				GLOBULINS: GAMMA	15.0	22.0	g	20/10/90	17.50	17.50	17.50	17.50	20.70	20.70	20.70	20.70	11.90	11.90									
				12-10	F			BB	12.0	16.0	G/100ML	20/10/90	11.70	11.70	11.70	11.70	13.20	13.20	12.00	12.00							
								HTC	37.0	47.0	g	20/10/90	35.00	35.00	35.00	35.00	40.00	40.00	39.00	39.00	38.00	38.00					
								RBC	3.8	5.4	10 ⁶ /MHC	20/10/90	4.10	4.10	4.10	4.10	4.70	4.70	4.60	4.60	4.30	4.30					
								HBC	4.0	11.0	10 ³ /MHC	20/10/90	4.80	4.80	4.80	4.80	4.70	4.70	6.30	6.30	6.80	6.80					
								HBC: M	40.0	70.0	g	20/10/90	62.00	62.00	62.00	62.00	58.00	58.00	65.00	65.00	62.00	62.00					
HBC: L	20.0	40.0	g					20/10/90	32.00	32.00	32.00	32.00	36.00	36.00	34.00	34.00	27.00	27.00									
HBC: E	1.0	5.0	g					20/10/90	1.00	1.00	1.00	1.00	0.00	0.00	3.00	3.00	5.00	5.00									
HBC: M	4.0	8.0	g					20/10/90	6.00	6.00	6.00	6.00	6.00	6.00	1.00	1.00	6.00	6.00									
HBC: B	150.0	550.0	10 ³ /MHC					20/10/90	216.00	216.00	216.00	216.00	206.00	206.00	215.00	215.00	280.00	280.00									
PLATELETS	138.0	155.0	M EQ/L					20/10/90	142.00	142.00	142.00	142.00	145.00	145.00	138.00	138.00	140.00	140.00									
NA+	3.5	5.5	M EQ/L					20/10/90	4.20	4.20	4.20	4.20	4.20	4.20	4.30	4.30	3.80	3.80									
K+	8.5	10.5	M EQ/L					20/10/90	103.00	103.00	103.00	103.00	106.00	106.00	95.00	95.00	100.00	100.00									
CA++	3.0	4.5	MG/DL					20/10/90	9.10	9.10	9.10	9.10	9.70	9.70	9.20	9.20	9.30	9.30									
PO4--	12.0	40.0	MU/ML					20/10/90	21.00	21.00	21.00	21.00	17.00	17.00	3.30	3.30	3.80	3.80									
SGPT	10.0	40.0	MU/ML					20/10/90	18.00	18.00	18.00	18.00	11.00	11.00	11.00	11.00	20.00	20.00									
GAMMA-GT	7.0	33.0	MU/ML					20/10/90	19.00	19.00	19.00	19.00	16.00	16.00	20.00	20.00	18.00	18.00									
GLUCOSE	65.0	306.0	MU/ML					20/10/90	82.00	82.00	82.00	82.00	92.00	92.00	79.00	79.00	82.00	82.00									
ALK. PHOSPH.	10.0	50.0	MG/DL					20/10/90	177.00	177.00	177.00	177.00	151.00	151.00	155.00	155.00	240.00	240.00									
UREA	0.6	1.6	MG/DL					20/10/90	0.90	0.90	0.90	0.90	32.00	32.00	31.00	31.00	28.00	28.00									
CREATININE	2.4	5.7	MG/DL					20/10/90	3.90	3.90	3.90	3.90	0.90	0.90	0.70	0.70	0.80	0.80									
URIC ACID	0.2	1.0	MG/DL					20/10/90	0.40	0.40	0.40	0.40	0.70	0.70	0.90	0.90	0.60	0.60									
TOT. BILIRUBIN	0.0	0.4	MG/DL					20/10/90	0.40	0.40	0.40	0.40	0.40	0.40	0.30	0.30	0.30	0.30									
DIR. BILIRUBIN	0.0	0.4	MG/DL					20/10/90	0.40	0.40	0.40	0.40	0.40	0.40	0.30	0.30	0.30	0.30									
TOT. PROTEINS	6.0	8.0	G/DL					20/10/90	6.70	6.70	6.70	6.70	7.30	7.30	7.10	7.10	6.80	6.80									
ALBUMINE	3.5	5.0	G/DL					20/10/90	4.30	4.30	4.30	4.30	4.30	4.30	4.60	4.60	4.50	4.50									
TOT. CHOLEST.	140.0	270.0	MG/DL	20/10/90	140.00	140.00	140.00	140.00	164.00	164.00	156.00	156.00	163.00	163.00													
TRIGLYCERIDES	35.0	175.0	MG/DL	20/10/90	69.00	69.00	69.00	69.00	73.00	73.00	55.00	55.00	101.00	101.00													
GLOBULINS: ALPHA1	4.0	7.0	g	20/10/90	3.80	3.80	3.80	3.80	3.00	3.00	2.60	2.60	3.00	3.00													
GLOBULINS: ALPHA2	7.0	11.0	g	20/10/90	5.80	5.80	5.80	5.80	4.70	4.70	7.10	7.10	8.20	8.20													

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range				Visit					
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
1	12-10	F		GLOBALINS: BETA	20/10/90	11.0	14.0	X	12.50	11.30	10.60	10.10	11.20	13.00
				GLOBALINS: GAMMA	20/10/90	15.0	22.0	X	17.30	14.50	14.70	14.60	16.70	10.80
				HB	20/10/90	12.0	16.0	G/100ML	11.00	11/09/91	06/11/91	02/01/92	26/02/92	06/05/92
				HTC	20/10/90	37.0	47.0	X	34.00	37.00	37.00	36.00	37.00	37.00
				RBC	20/10/90	3.8	5.4	10 ⁶ -6/MNC	3.90	4.10	4.20	4.20	4.20	4.20
				WBC	20/10/90	4.0	11.0	10 ³ -3/MNC	2.90	4.80	5.10	3.20	6.80	3.50
				WBC: N	20/10/90	40.0	70.0	X	49.00	47.00	44.00	38.00	60.00	43.00
				WBC: L	20/10/90	20.0	40.0	X	4.00	5.00	1.00	0.00	30.00	49.00
				WBC: E	20/10/90	1.0	5.0	X	4.00	2.00	2.00	0.00	2.00	1.00
				WBC: M	20/10/90	0.0	8.0	X	0.00	0.00	0.00	0.00	8.00	7.00
15-12	F			PLATELETS	20/10/90	150.0	550.0	10 ³ -3/MNC	229.00	261.00	260.00	227.00	237.00	211.00
				NA+	20/10/90	138.0	155.0	M EQ/L	139.00	162.00	139.00	162.00	141.00	142.00
				CL-	20/10/90	98.0	120.0	M EQ/L	102.00	99.00	100.00	98.00	98.00	98.00
				CA++	20/10/90	8.5	10.5	MG/DL	9.30	9.50	9.50	9.50	9.50	8.20
				PO4-	20/10/90	3.0	4.5	MG/DL	3.70	3.50	2.00	2.00	4.10	3.00
				SGPT	20/10/90	12.0	40.0	IU/ML	21.00	26.00	25.00	34.00	28.00	18.00
				GAMMA-GT	20/10/90	7.0	33.0	IU/ML	28.00	38.00	23.00	35.00	24.00	19.00
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	95.00	85.00	88.00	86.00	108.00	87.00
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	218.00	204.00	194.00	185.00	118.00	185.00
				CREATININE	20/10/90	0.6	1.6	MG/DL	1.10	1.10	21.00	39.00	30.00	31.00
16-13	F			URIC ACID	20/10/90	2.4	5.7	MG/DL	6.50	3.20	3.10	4.00	3.80	4.80
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.40	0.60	0.60	0.80	0.70	0.60
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.30	0.30	0.40	0.30	0.30
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.80	7.20	7.10	7.00	7.10	7.10
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.00	4.10	4.20	4.20	4.20	4.10
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	294.00	299.00	317.00	286.00	170.00	291.00
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	133.00	180.00	224.00	149.00	94.00	198.00
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	X	2.90	3.20	2.80	3.10	3.10	2.90
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	X	7.80	8.00	8.00	4.00	10.20	7.00
				GLOBULINS: BETA	20/10/90	11.0	14.0	X	14.60	13.80	14.40	16.20	8.70	13.80
GLOBULINS: GAMMA	20/10/90	15.0	22.0	X	19.40	15.90	13.30	17.30	22.00	12.60				
16-13	F			HB	20/10/90	12.0	16.0	G/100ML	11.80	20/09/91	14/11/91	10/01/92	13.60	
				HTC	20/10/90	37.0	47.0	X	37.00	40.00	38.00	38.00	38.00	
				RBC	20/10/90	5.8	5.4	10 ⁶ -6/MNC	4.50	4.60	4.50	4.60	4.60	

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXYETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range		Visit						
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42
1	16-13	F		HBC	4.0	11.0	10-3/MHC	6.30	4.80	5.00	6.10		
				HBC: N	40.0	70.0	z	70.00	56.00	62.00	60.00		
				HBC: L	20.0	40.0	z	29.00	39.00	28.00	30.00		
				HBC: E	1.0	5.0	z	1.00	1.00	3.00	3.00		
				HBC: M	4.0	8.0	z	1.00	5.00	7.00	7.00		
				HBC: B	0.0	1.0	z	0.00	0.00	0.00	0.00		
				PLATELETS	150.0	550.0	10-3/MHC	265.00	252.00	197.00	211.00		
				NA+	138.0	155.0	M EQ/L	137.00	142.00	137.00	139.00		
				K+	3.5	5.5	M EQ/L	4.90	5.00	3.70	4.20		
				CL-	98.0	120.0	M EQ/L	103.00	95.00	100.00	103.00		
				CA++	8.5	10.5	MG/DL	10.90	11.40	9.80	9.60		
				PO4--	3.0	4.5	MG/DL	3.20	3.10	3.60	3.80		
				SGOT	12.0	40.0	KU/ML	17.00	26.00	24.00	20.00		
				SGPT	10.0	40.0	KU/ML	13.00	15.00	26.00	24.00		
				GAMMA-GT	7.0	33.0	KU/ML	21.00	21.00	30.00	28.00		
				GLUCOSE	70.0	100.0	MG/DL	114.00	108.00	94.00	92.00		
				ALK. PHOSPH.	65.0	306.0	RU/PL	343.00	331.00	217.00	162.00		
				BUN	10.0	50.0	MG/DL	44.00	27.00	24.00	26.00		
				CREATININE	0.6	1.6	MG/DL	0.80	0.70	0.90	0.90		
				URIC ACID	2.4	5.7	MG/DL	2.90	3.20	4.50	4.20		
				TOT BILIRUBIN	0.2	1.0	MG/DL	0.30	0.80	0.80	0.60		
				DIR BILIRUBIN	0.0	0.4	MG/DL	0.10	0.30	0.40	0.30		
				TOT. PROTEINS	6.0	8.0	G/DL	6.60	6.60	7.10	7.00		
				ALBUMINE	3.5	5.0	G/DL	4.10	4.20	4.30	4.30		
				TOT. CHOLEST.	140.0	270.0	MG/DL	239.00	288.00	160.00	177.00		
				TRIGLYCERIDES	35.0	175.0	MG/DL	162.00	100.00	86.00	94.00		
				GLOBULINS: ALPHA1	4.0	7.0	z	3.20	2.70	3.80	3.20		
				GLOBULINS: ALPHA2	7.0	11.0	z	8.30	7.90	8.70	7.40		
				GLOBULINS: BETA	11.0	14.0	z	14.60	11.10	11.40	16.10		
				GLOBULINS: GAMMA	15.0	22.0	z	11.40	14.20	17.00	18.00		
19-16	F			HB	12.0	16.0	G/100ML	12.30	12.50	12.00	12.20		
				HTC	37.0	47.0	z	36.00	38.00	38.00	38.00		
				RBC	3.8	5.4	10-6/MHC	4.10	4.30	4.30	4.40		
				HBC	4.0	11.0	10-3/MHC	5.60	6.00	5.20	5.80		
				HBC: N	40.0	70.0	z	48.00	48.00	48.00	62.00		
				HBC: L	20.0	40.0	z	51.00	51.00	30.00	30.00		
				HBC: E	1.0	5.0	z	3.00	3.00	3.00	3.00		
				HBC: M	4.0	8.0	z	7.00	9.00	2.00	5.00		
				HBC: B	0.0	1.0	z	0.00	0.00	0.00	0.00		
				PLATELETS	150.0	550.0	10-3/MHC	199.00	219.00	196.00	230.00		
				NA+	138.0	155.0	M EQ/L	140.00	139.00	140.00	140.00		

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit										
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52				
1	19-16	F		K+	20/10/90	3.5	5.5	M	ER/L	5.20	5.00	4.20	4.10	4.20				
				CL-	20/10/90	98.0	120.0	M	ER/L	104.00	97.00	97.00	96.00					
				CA++	20/10/90	8.5	10.5	MG/DL		9.30	9.30	8.30	8.60					
				PO4-	20/10/90	3.0	4.5	MG/DL		3.10	3.40	2.70	3.20					
				SGOT	20/10/90	12.0	40.0	IU/ML		34.00	23.00	31.00	26.00					
				SGPT	20/10/90	10.0	40.0	IU/ML		19.00	18.00	18.00	28.00					
				GAMMA-GT	20/10/90	7.0	33.0	IU/ML		15.00	17.00	16.00	15.00					
				GLUCOSE	20/10/90	70.0	100.0	MG/DL		102.00	96.00	95.00	96.00					
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML		191.00	228.00	191.00	220.00					
				UREA	20/10/90	10.0	50.0	MG/DL		41.00	46.00	37.00	32.00					
				CREATININE	20/10/90	0.6	1.6	MG/DL		1.00	0.80	0.90	1.00					
				URIC ACID	20/10/90	2.4	5.7	MG/DL		2.80	4.10	4.00	4.20					
				TOT. BILIRUBIN	20/10/90	0.2	1.0	MG/DL		0.40	0.50	0.40	0.60					
				DIR. BILIRUBIN	20/10/90	0.0	0.4	MG/DL		0.20	0.20	0.10	0.20					
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL		6.50	6.30	6.30	6.50					
				ALBUMINE	20/10/90	3.5	5.0	G/DL		3.90	4.30	4.00	4.20					
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL		194.00	210.00	180.00	171.00					
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL		75.00	67.00	60.00	72.00					
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%		2.40	2.10	3.00	3.20					
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%		8.20	7.50	7.40	7.50					
				GLOBULINS: BETA	20/10/90	11.0	14.0	%		12.90	11.00	12.00	11.80					
GLOBULINS: GAMMA	20/10/90	15.0	22.0	%		13.30	15.70	14.80	14.40									
21-18	1926	F		HB	20/10/90	12.0	16.0	G/100ML		13/08/91	08/10/91	03/12/91	28/01/92	24/03/92	02/06/92			
				HTC	20/10/90	37.0	47.0	%		11.50	11.00	11.00	11.00	12.10	13.00	13.60		
				RBC	20/10/90	3.8	5.4	10 ⁶ /MM ³		37.00	35.00	36.00	36.00	36.00	37.00	38.00		
				WBC	20/10/90	4.0	11.0	10 ³ /MM ³		4.40	4.30	4.40	4.40	4.50	4.40	4.50		
				PLATELETS	20/10/90	40.0	70.0	%		6.30	4.90	4.90	4.90	5.00	6.50	6.10		
				WBC: N	20/10/90	20.0	40.0	%		24.00	54.00	57.00	58.00	62.00	64.00	64.00		
				WBC: L	20/10/90	1.0	5.0	%		1.00	42.00	34.00	35.00	29.00	30.00	30.00		
				WBC: E	20/10/90	4.0	8.0	%		6.00	4.00	8.00	2.00	2.00	2.00	2.00		
				WBC: M	20/10/90	0.0	1.0	%		0.00	4.00	8.00	5.00	7.00	4.00	4.00		
				WBC: B	20/10/90	0.0	1.0	%		0.00	309.00	359.00	280.00	208.00	243.00	243.00		
				PLATELETS	20/10/90	150.0	550.0	10 ³ /MM ³		346.00	138.00	160.00	140.00	142.00	142.00	142.00		
				WBC: N	20/10/90	138.0	155.0	M	ER/L	135.00	138.00	140.00	140.00	140.00	142.00	142.00		
				CL-	20/10/90	3.5	5.5	M	ER/L	4.50	4.80	4.30	4.40	4.10	3.90	3.90		
				CA++	20/10/90	98.0	120.0	M	ER/L	9.60	98.00	98.00	98.00	97.00	99.00	99.00		
				PO4-	20/10/90	8.5	10.5	MG/DL		9.60	8.50	8.80	8.60	9.50	10.10	10.10		
				SGOT	20/10/90	3.0	4.5	MG/DL		3.60	4.20	3.80	3.80	3.80	3.60	3.60		
				SGPT	20/10/90	12.0	40.0	IU/ML		21.00	31.00	15.00	16.00	34.00	34.00	34.00		
				GAMMA-GT	20/10/90	7.0	40.0	IU/ML		16.00	21.00	12.00	18.00	38.00	38.00	38.00		
				GLUCOSE	20/10/90	70.0	33.0	IU/ML		22.00	22.00	28.00	28.00	26.00	26.00	26.00		
				GLUCOSE	20/10/90	70.0	100.0	MG/DL		85.00	86.00	89.00	92.00	86.00	86.00	86.00		

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit									
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52			
1 21-18	F		ALK. PHOSPH.	20/10/90	65.0	306.0	NU/HL	232.00	242.00	209.00	202.00	134.00	152.00			
			RUN	20/10/90	10.0	50.0	MG/DL	26.00	15.00	16.00	18.00	30.00	28.00			
			CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	0.70	0.90	0.90	1.00	1.00			
			URIC ACID	20/10/90	2.4	5.7	MG/DL	4.00	3.00	4.20	4.00	3.90	3.70			
			TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.30	0.60	0.80	0.70	0.80	0.90			
			DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.10	0.20	0.40	0.30	0.40	0.40			
			TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.40	6.60	6.90	7.00	6.90	7.00			
			ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	3.80	4.20	4.20	3.80	3.90			
			TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	191.00	166.00	152.00	166.00	192.00	187.00			
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	131.00	79.00	88.00	94.00	89.00	94.00			
			GLOBULINS: ALPHA1	20/10/90	4.0	7.0	X	4.00	2.50	2.70	2.80	2.50	3.00			
			GLOBULINS: ALPHA2	20/10/90	7.0	11.0	X	8.00	8.70	8.90	8.80	10.90	11.80			
			GLOBULINS: BETA	20/10/90	11.0	14.0	X	14.00	13.60	16.40	16.50	7.60	9.70			
			GLOBULINS: GAMMA	20/10/90	15.0	22.0	X	16.00	17.90	12.00	12.30	18.90	20.20			
			26-22	F		HB	20/10/90	12.0	16.0	G/100ML	17/09/91	12/11/91	07/01/92	04/03/92	22/04/92	07/07/92
						HTC	20/10/90	37.0	47.0	Z	36.00	38.00	37.00	38.00	40.00	39.00
						RBC	20/10/90	3.8	5.4	10 ⁶ /MHC	4.10	4.20	4.10	4.30	4.40	4.20
						MBC	20/10/90	4.0	11.0	10 ³ /MHC	5.10	5.00	5.00	5.20	5.20	4.30
						MBC: N	20/10/90	40.0	70.0	X	59.00	52.00	46.00	51.00	58.00	56.00
						MBC: L	20/10/90	20.0	40.0	X	33.00	39.00	45.00	40.00	50.00	37.00
MBC: E	20/10/90	1.0				5.0	X	1.00	12.00	2.00	2.00	4.00	0.00			
MBC: M	20/10/90	4.0				8.0	X	8.00	9.00	7.00	7.00	8.00	7.00			
MBC: B	20/10/90	0.0				1.0	X	1.00	0.00	0.00	0.00	0.00	0.00			
PLATELETS	20/10/90	150.0				550.0	10 ³ /MHC	283.00	294.00	282.00	314.00	312.00	308.00			
NA+	20/10/90	138.0				155.0	M EQ/L	137.00	137.00	138.00	139.00	141.00	141.00			
K+	20/10/90	3.5				5.5	M EQ/L	4.50	4.60	4.70	4.20	3.90	5.00			
CL-	20/10/90	98.0				120.0	M EQ/L	95.00	98.00	95.00	96.00	101.00	94.00			
CA++	20/10/90	8.5				10.5	MG/DL	9.50	9.50	9.10	9.80	9.20	8.90			
PO4--	20/10/90	3.0				4.5	MG/DL	3.10	3.40	4.00	4.10	3.60	3.70			
SGOT	20/10/90	12.0				40.0	NU/ML	24.00	27.00	26.00	24.00	28.00	22.00			
SGPT	20/10/90	10.0				40.0	NU/ML	19.00	32.00	17.00	18.00	34.00	17.00			
GAMMA-GT	20/10/90	7.0				33.0	NU/ML	15.00	17.00	21.00	22.00	14.00	14.00			
GLUCOSE	20/10/90	70.0				100.0	MG/DL	91.00	101.00	98.00	103.00	96.00	96.00			
ALK. PHOSPH.	20/10/90	65.0				306.0	NU/ML	171.00	188.00	201.00	182.00	176.00	210.00			
RUN	20/10/90	10.0	50.0	MG/DL	24.00	24.00	24.00	26.00	28.00	17.00						
CREATININE	20/10/90	0.6	1.6	MG/DL	0.50	1.00	0.80	0.80	0.90	1.00						
URIC ACID	20/10/90	2.4	5.7	MG/DL	1.60	3.60	3.90	4.10	3.70	4.40						
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.90	0.60	0.60	0.50	0.70	0.80						
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.20	0.20	0.20	0.30	0.30						
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.50	7.10	7.20	7.30	7.20	7.40						
ALBUMINE	20/10/90	3.5	5.0	G/DL	3.90	4.40	3.90	4.00	4.60	4.60						

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOMETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Date	Laboratory Range			Visit							
					Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52		
1	26-22	F	TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	153.00	151.00	180.00	163.00	163.00	180.00		
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	40.00	48.00	87.00	94.00	94.00	94.00	180.00	
			GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	3.70	3.60	4.00	3.50	2.20	2.80	42.00	
			GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	8.00	6.00	8.60	8.30	7.60	6.20	6.20	
			GLOBULINS: BETA	20/10/90	11.0	16.0	%	13.50	11.30	14.50	15.00	15.50	12.70	12.70	
			GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	15.40	13.30	17.10	18.60	19.30	15.60	15.60	
			HB	20/09/91			g/100ml	14.20							
			HTC	20/10/90	40.0	54.0	%	44.00							
			RBC	20/10/90	4.3	6.1	10**6/mm	4.70							
			MBC	20/10/90	4.0	11.0	10-3/HMC	4.30							
27-23	M		MBC: N	20/10/90	40.0	70.0	%	44.00							
			MBC: L	20/10/90	20.0	40.0	%	46.00							
			MBC: E	20/10/90	1.0	5.0	%	1.00							
			MBC: M	20/10/90	4.0	8.0	%	10.00							
			MBC: B	20/10/90	0.0	1.0	%	0.00							
			PLATELETS	20/10/90	150.0	550.0	10-3/HMC	277.00							
			NA+	20/10/90	138.0	155.0	M EQ/L	137.00							
			K+	20/10/90	3.5	5.5	M EQ/L	4.30							
			CL-	20/10/90	98.0	120.0	M EQ/L	97.00							
			CA++	20/10/90	8.5	10.5	MG/DL	8.70							
			PO4--	20/10/90	3.0	4.5	MG/DL	3.10							
			SGPT	20/10/90	12.0	40.0	IU/ML	32.00							
			GGT	20/10/90	10.0	40.0	IU/ML	27.00							
			GAMMA-GT	20/10/90	11.0	51.0	IU/ML	33.00							
			GLUCOSE	20/10/90	70.0	100.0	MG/DL	93.00							
			ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	139.00							
			UREA	20/10/90	10.0	50.0	MG/DL	29.00							
			CREATININE	20/10/90	0.6	1.6	MG/DL	0.90							
			URIC ACID	20/10/90	3.4	7.0	MG/DL	3.20							
			TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	1.00							
			DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40							
			TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.20							
			ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20							
			TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	232.00							
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	72.00							
			GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	3.70							
			GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	5.70							
			GLOBULINS: BETA	20/10/90	11.0	14.0	%	13.60							
			GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	17.60							

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Week 10		Week 18		Week 26		Week 34		Week 42		Week 52			
				Date	Min	Max	Unit	Min	Max	Unit	Min	Max	Unit	Min	Max	Unit	Min	Max	Unit	
1	28-24	F	HB	20/10/90	12.0	16.0	G/100ML	24/09/91	13.10	14.20	19/11/91	14.20								
			HTC	20/10/90	37.0	47.0	%	24/09/91	40.00	41.00	19/11/91	41.00								
			RBC	20/10/90	3.8	5.4	10 ⁶ -6/MNC	24/09/91	4.20	4.50	19/11/91	4.50								
			HBC	20/10/90	4.0	11.0	10 ³ -3/MNC	24/09/91	5.20	5.80	19/11/91	5.80								
			HBC: N	20/10/90	40.0	70.0	%	24/09/91	63.00	44.00	19/11/91	44.00								
			HBC: L	20/10/90	20.0	40.0	%	24/09/91	35.00	54.00	19/11/91	54.00								
			HBC: E	20/10/90	1.0	5.0	%	24/09/91	0.00	0.00	19/11/91	0.00								
			HBC: H	20/10/90	4.0	8.0	%	24/09/91	2.00	2.00	19/11/91	2.00								
			HBC: B	20/10/90	0.0	1.0	%	24/09/91	0.00	0.00	19/11/91	0.00								
			PLATELETS	20/10/90	150.0	550.0	10 ³ -3/MNC	24/09/91	298.00	269.00	19/11/91	269.00								
			NA+	20/10/90	138.0	155.0	M EQ/L	24/09/91	141.00	140.00	19/11/91	140.00								
			K+	20/10/90	3.5	5.5	M EQ/L	24/09/91	3.70	4.30	19/11/91	4.30								
			CL-	20/10/90	98.0	120.0	M EQ/L	24/09/91	97.00	98.00	19/11/91	98.00								
			CA++	20/10/90	8.5	10.5	MG/DL	24/09/91	8.90	9.50	19/11/91	9.50								
			PO4-	20/10/90	3.0	4.5	MG/DL	24/09/91	3.00	2.80	19/11/91	2.80								
			SGOT	20/10/90	12.0	40.0	IU/ML	24/09/91	30.00	34.00	19/11/91	34.00								
			SGPT	20/10/90	10.0	40.0	IU/ML	24/09/91	29.00	43.00	19/11/91	43.00								
			GAMMA-GT	20/10/90	7.0	33.0	IU/ML	24/09/91	174.00	182.00	19/11/91	182.00								
			GLUCOSE	20/10/90	70.0	100.0	MG/DL	24/09/91	90.00	102.00	19/11/91	102.00								
			ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	24/09/91	357.00	348.00	19/11/91	348.00								
			BUN	20/10/90	10.0	50.0	MG/DL	24/09/91	45.00	35.00	19/11/91	35.00								
			CREATININE	20/10/90	0.6	1.6	MG/DL	24/09/91	1.10	1.20	19/11/91	1.20								
			URIC ACID	20/10/90	2.4	5.7	MG/DL	24/09/91	3.00	2.70	19/11/91	2.70								
			TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	24/09/91	0.60	0.40	19/11/91	0.40								
			DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	24/09/91	0.30	0.10	19/11/91	0.10								
			TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	24/09/91	6.30	7.00	19/11/91	7.00								
			ALBUMINE	20/10/90	3.5	5.0	G/DL	24/09/91	4.20	4.30	19/11/91	4.30								
			TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	24/09/91	183.00	200.00	19/11/91	200.00								
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	24/09/91	220.00	213.00	19/11/91	213.00								
GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	24/09/91	2.80	2.60	19/11/91	2.60											
GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	24/09/91	7.10	7.20	19/11/91	7.20											
GLOBULINS: BETA	20/10/90	11.0	14.0	%	24/09/91	10.50	10.30	19/11/91	10.30											
GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	24/09/91	16.00	18.00	19/11/91	18.00											
29-25	F	HB	20/10/90	12.0	16.0	G/100ML	24/09/91	15.00	19/11/91	12.70	14/01/92	12.20	10/03/92	12.90	05/05/92	12.50	14/07/92	12.20		
		HTC	20/10/90	37.0	47.0	%	24/09/91	39.00	19/11/91	38.00	14/01/92	37.00	10/03/92	38.00	05/05/92	38.00	14/07/92	38.00		
		RBC	20/10/90	3.8	5.4	10 ⁶ -6/MNC	24/09/91	4.40	19/11/91	4.30	14/01/92	4.20	10/03/92	4.60	05/05/92	4.40	14/07/92	4.20		
		HBC	20/10/90	4.0	11.0	10 ³ -3/MNC	24/09/91	7.00	19/11/91	6.60	14/01/92	6.70	10/03/92	6.80	05/05/92	7.00	14/07/92	6.80		
		HBC: N	20/10/90	40.0	70.0	%	24/09/91	56.00	19/11/91	58.00	14/01/92	61.00	10/03/92	61.00	05/05/92	60.00	14/07/92	68.00		
		HBC: L	20/10/90	20.0	40.0	%	24/09/91	30.00	19/11/91	30.00	14/01/92	34.00	10/03/92	34.00	05/05/92	31.00	14/07/92	23.00		
HBC: E	20/10/90	20.0	40.0	%	24/09/91	6.00	19/11/91	6.00	14/01/92	2.00	10/03/92	2.00	05/05/92	4.00	14/07/92	3.00				
HBC: H	20/10/90	1.0	5.0	%	24/09/91	6.00	19/11/91	6.00	14/01/92	2.00	10/03/92	2.00	05/05/92	4.00	14/07/92	3.00				

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit						
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
1	29-25	F		HBC: M	20/10/90	4.0	8.0	X	14.00	2.00	3.00	5.00	6.00	6.00
				HBC: B	20/10/90	0.0	1.0	X	0.00	0.00	0.00	0.00	0.00	0.00
				PLATELETS	20/10/90	150.0	550.0	10-3/MHC	385.00	386.00	413.00	420.00	410.00	426.00
				NA+	20/10/90	138.0	155.0	M EQ/L	141.00	137.00	139.00	139.00	141.00	138.00
				K+	20/10/90	3.5	5.5	M EQ/L	4.70	4.60	4.20	4.10	4.20	4.60
				CL-	20/10/90	98.0	120.0	M EQ/L	98.00	96.00	97.00	95.00	96.00	97.00
				CA++	20/10/90	8.5	10.5	MG/DL	9.80	8.80	8.30	9.30	10.10	8.70
				PO4--	20/10/90	3.0	4.5	MG/DL	3.20	2.90	2.60	4.00	3.70	3.30
				SGOT	20/10/90	12.0	40.0	MU/ML	19.00	25.00	26.00	28.00	22.00	21.00
				SGPT	20/10/90	10.0	40.0	MU/ML	28.00	27.00	23.00	34.00	16.00	15.00
				GAMMA-GT	20/10/90	7.0	33.0	MU/ML	27.00	28.00	18.00	26.00	17.00	17.00
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	100.00	94.00	100.00	94.00	81.00	88.00
				ALK. PHOSPH.	20/10/90	65.0	306.0	MU/ML	240.00	203.00	202.00	204.00	214.00	232.00
				BUN	20/10/90	10.0	50.0	MG/DL	25.00	30.00	20.00	28.00	21.00	20.00
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.60	0.70	0.70	0.80	0.70	0.70
				URIC ACID	20/10/90	2.4	5.7	MG/DL	3.50	2.40	3.50	3.60	3.60	2.50
				TOT. BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.70	0.60	0.70	0.70	0.70	0.50
				DIR. BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.20	0.30	0.50	0.30	0.20
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.20	6.90	6.70	7.20	7.30	6.90
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.00	4.10	3.90	4.00	4.10	4.05
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	184.00	209.00	188.00	166.00	160.00	165.00
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	66.00	109.00	44.00	90.00	86.00	46.00
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	X	3.80	2.60	3.10	3.00	2.50	
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	X	8.80	7.40	7.50	11.10	7.00	
				GLOBULINS: BETA	20/10/90	11.0	14.0	X	11.60	11.30	11.00	9.10	11.60	
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	X	19.40	22.50	20.50	18.70	20.30	
				HB	25/09/91	14.0	18.0	g/100ml	16.70					
				HTC	20/10/90	40.0	54.0	X	52.00					
				RBC	20/10/90	4.3	6.1	10**6/mm	5.60					
				MBC: N	20/10/90	4.0	11.0	10-3/MHC	6.90					
				MBC: L	20/10/90	40.0	70.0	X	56.00					
				MBC: E	20/10/90	20.0	40.0	X	40.00					
				MBC: B	20/10/90	1.0	5.0	X	3.00					
				PLATELETS	20/10/90	0.0	1.0	X	4.00					
				NA+	20/10/90	150.0	550.0	10-3/MHC	281.00					
				K+	20/10/90	138.0	155.0	M EQ/L	144.00					
				CL-	20/10/90	98.0	120.0	M EQ/L	98.00					
				CA++	20/10/90	8.5	10.5	MG/DL	9.80					
				PO4--	20/10/90	3.0	4.5	MG/DL	4.10					

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1930

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1
LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

9550077

Pat. No.	Open-Blind Sex	Laboratory test	Laboratory Range			Visit									
			Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52			
1 30-26	M	SCOT	20/10/90	12.0	40.0	MU/ML									
		SQPT	20/10/90	10.0	40.0	MU/ML	39.00								
		GAMMA-GT	20/10/90	11.0	51.0	MU/ML	50.00								
		GLUCOSE	20/10/90	70.0	100.0	MG/DL	73.00								
		ALK. PHOSPH.	20/10/90	65.0	306.0	MU/ML	102.00								
		BUN	20/10/90	10.0	50.0	MG/DL	249.00								
		CREATININE	20/10/90	0.6	1.6	MG/DL	31.00								
		URIC ACID	20/10/90	3.4	7.0	MG/DL	1.00								
		TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	7.40								
		DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.60								
		TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	0.20								
		ALBUMINE	20/10/90	3.5	5.0	G/DL	7.30								
		TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	6.40								
		TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	257.00								
		GLOBALINS: ALPHA1	20/10/90	4.0	7.0	%	4177.00								
		GLOBALINS: ALPHA2	20/10/90	7.0	11.0	%	2.70								
		GLOBALINS: BETA	20/10/90	11.0	14.0	%	7.50								
		GLOBALINS: GAMMA	20/10/90	15.0	22.0	%	11.60								
							16.70								
		33-29	M	HB	20/10/90	14.0	18.0	g/100ml							
				HCT	20/10/90	40.0	54.0	%	16.50						
				RBC	20/10/90	4.3	6.1	10**6/mm	42.00						
				HBC	20/10/90	4.0	11.0	10-3/HMC	4.60						
				HBC: N	20/10/90	40.0	70.0	%	5.00						
				HBC: L	20/10/90	20.0	40.0	%	65.00						
				HBC: E	20/10/90	1.0	5.0	%	34.00						
				HBC: H	20/10/90	4.0	8.0	%	1.00						
				HBC: B	20/10/90	0.0	1.0	%	1.00						
				PLATELETS	20/10/90	150.0	550.0	10-3/HMC	299.00						
				NA+	20/10/90	138.0	155.0	M EQ/L	136.00						
K+	20/10/90			3.5	5.5	M EQ/L	4.30								
CL-	20/10/90			98.0	120.0	M EQ/L	96.00								
CA++	20/10/90			8.5	10.5	MG/DL	9.00								
PO4-	20/10/90			3.0	4.5	MG/DL	3.00								
SQPT	20/10/90			12.0	40.0	MU/ML	24.00								
GAMMA-GT	20/10/90			11.0	51.0	MU/ML	18.00								
GLUCOSE	20/10/90			70.0	100.0	MG/DL	93.00								
ALK. PHOSPH.	20/10/90			65.0	306.0	MU/ML	170.00								
BUN	20/10/90			10.0	50.0	MG/DL	22.00								
CREATININE	20/10/90	0.6	1.6	MG/DL	0.90										
URIC ACID	20/10/90	3.4	7.0	MG/DL	4.90										

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Date	Laboratory Range			Visit												
						Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52							
1	33-29	M		TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL							0.70						
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL									0.40				
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL									7.00				
				ALBUMINE	20/10/90	3.5	5.0	G/DL									4.40				
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL									157.00				
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL									73.00				
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%									2.70				
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%									5.20				
				GLOBULINS: BETA	20/10/90	11.0	14.0	%									9.20				
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%									16.20				
				36-302	F			HB	20/10/90	12.0	16.0	G/100ML							13.00		
								HTC	20/10/90	37.0	47.0	%									40.00
								RBC	20/10/90	3.8	5.4	10 ⁶ /MHC									4.80
								HBC	20/10/90	4.0	11.0	10 ³ /MHC									8.50
								HBC: N	20/10/90	40.0	70.0	%									51.00
HBC: L	20/10/90	20.0	40.0					%									38.00				
HBC: E	20/10/90	1.0	5.0					%									4.00				
HBC: M	20/10/90	4.0	8.0					%									5.00				
HBC: B	20/10/90	0.0	1.0					%									2.00				
PLATELETS	20/10/90	150.0	550.0					10 ³ /MHC									275.00				
NA+	20/10/90	138.0	155.0					M EQ/L									142.00				
K+	20/10/90	3.5	5.5					M EQ/L									4.60				
CL-	20/10/90	98.0	120.0					M EQ/L									99.00				
CA++	20/10/90	8.5	10.5					MG/DL									10.00				
PO4--	20/10/90	3.0	4.5					MG/DL									3.10				
SGPT	20/10/90	12.0	40.0	U/L									16.00								
SGPT	20/10/90	10.0	40.0	U/L									18.00								
GAMMA-GT	20/10/90	7.0	33.0	U/L									24.00								
GLUCOSE	20/10/90	70.0	100.0	MG/DL									100.00								
ALK. PHOSPH.	20/10/90	65.0	306.0	U/L									245.00								
UR	20/10/90	10.0	50.0	MG/DL									32.00								
CREATININE	20/10/90	0.6	1.6	MG/DL									0.90								
URIC ACID	20/10/90	2.4	5.7	MG/DL									4.30								
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL									0.70								
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL									0.40								
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL									6.80								
ALBUMINE	20/10/90	3.5	5.0	G/DL									4.50								
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL									191.00								
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL									232.00								
GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%									2.00								
GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%									10.00								

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 12.1
 LABORATORY DATA
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Pat. No.	Centre	Open	Blind	Sex	Laboratory test	Laboratory Range			Visit								
						Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52		
1	36-302	F			GLOBULINS: BETA GLOBULINS: GAMMA	20/10/90	11.0	14.0	%	13.40							
						20/10/90	15.0	22.0	%	16.10							
38-304	M				HB	20/10/90	14.0	18.0	g/100ml	26/11/91	15.70	17/03/92	12/05/92	07/07/92	15/09/92		
					HTC	20/10/90	40.0	54.0	%	45.00	15.00	15.00	14.70	15.00	15.00		
					RBC	20/10/90	4.3	6.1	10 ^{xx6} /mm	44.00	44.00	44.00	43.00	44.00	47.00		
					HBC	20/10/90	4.0	11.0	10 ⁻³ /MMC	5.00	5.00	4.80	4.80	5.40	5.30		
					HBC: N	20/10/90	40.0	70.0	%	7.20	7.90	5.50	5.20	6.10	6.30		
					HBC: L	20/10/90	20.0	40.0	%	58.00	68.00	63.00	62.00	71.00	70.00		
					HBC: E	20/10/90	1.0	5.0	%	29.00	23.00	29.00	31.00	25.00	22.00		
					HBC: K	20/10/90	4.0	8.0	%	6.00	0.00	3.00	2.00	1.00	1.00		
					HBC: R	20/10/90	0.0	1.0	%	7.00	0.00	5.00	5.00	3.00	7.00		
					PLATELETS	20/10/90	150.0	550.0	10 ³ /MMC	411.00	186.00	139.00	204.00	184.00	175.00		
					Na+	20/10/90	138.0	158.0	mmol/L	142.00	149.00	141.00	141.00	141.00	140.00		
					K+	20/10/90	3.5	5.5	mmol/L	3.80	4.00	3.30	4.20	4.20	4.20		
					Cl-	20/10/90	98.0	120.0	mmol/L	96.00	96.00	96.00	97.00	98.00	100.00		
					PO4--	20/10/90	3.0	4.5	mmol/L	3.40	3.40	4.00	4.10	4.00	3.90		
					SGOT	20/10/90	12.0	40.0	mmol/L	104.00	142.00	119.00	86.00	140.00	197.00		
					SGPT	20/10/90	10.0	40.0	mmol/L	116.00	178.00	156.00	91.00	256.00	276.00		
					GAMMA-GT	20/10/90	11.0	51.0	mmol/L	245.00	328.00	290.00	114.00	316.00	471.00		
					GLUCOSE	20/10/90	70.0	100.0	mmol/L	99.00	188.00	136.00	118.00	134.00	151.00		
					ALK. PHOSPH.	20/10/90	65.0	306.0	mmol/L	246.00	660.00	512.00	426.00	418.00	558.00		
					BUN	20/10/90	10.0	50.0	mmol/L	30.00	47.00	41.00	34.00	43.00	47.00		
					CREATININE	20/10/90	0.6	1.6	mmol/L	1.00	1.60	1.10	1.00	1.20	1.20		
					URIC ACID	20/10/90	3.4	7.0	mmol/L	4.30	6.70	5.80	5.30	4.60	4.80		
					TOT BILIRUBIN	20/10/90	0.2	1.0	mmol/L	0.80	0.90	0.60	0.60	0.40	0.50		
					DIR BILIRUBIN	20/10/90	0.0	0.4	mmol/L	0.40	0.40	0.40	0.30	0.10	0.30		
					TOT. PROTEINS	20/10/90	6.0	8.0	g/dl	7.00	7.20	7.80	7.80	7.90	8.00		
					ALBUMINE	20/10/90	3.5	5.0	g/dl	4.10	4.10	4.13	4.20	4.10	4.10		
					TOT. CHOLEST.	20/10/90	140.0	270.0	mmol/L	167.00	160.00	169.00	151.00	163.00	180.00		
					TRIGLYCERIDES	20/10/90	35.0	175.0	mmol/L	72.00	150.00	153.00	138.00	208.00	202.00		
					GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	4.00	2.70	3.10	3.00	2.40	2.30		
					GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	11.30	8.60	9.00	8.70	10.00	10.00		
					GLOBULINS: BETA	20/10/90	11.0	14.0	%	23.10	11.50	12.10	11.90	13.80	12.90		
					GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	12.00	25.30	22.80	21.30	24.10	23.30		
40-306	F				HB	20/10/90	12.0	16.0	g/100ML	03/12/91	12.70	24/03/92	19/05/92	14/07/92	22/09/92		
					HTC	20/10/90	37.0	47.0	%	40.00	39.00	40.00	40.00	40.00	43.00		
					RBC	20/10/90	3.8	5.4	10 ⁶ /MMC	4.30	4.10	4.20	4.40	4.90	4.30		

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOMETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit										
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52				
1	40-306	F		NBC	20/10/90	4.0	11.0	10-3/MHC	7.40	7.50	9.70	6.30	8.00	9.10				
				NBC: N	20/10/90	40.0	70.0	X	66.00	68.00	56.00	61.00	61.00	60.00				
				NBC: L	20/10/90	20.0	40.0	X	31.00	26.00	30.00	30.00	27.00	24.00				
				NBC: E	20/10/90	1.0	5.0	X	7.00	3.00	0.00	4.00	3.00	11.00				
				NBC: M	20/10/90	4.0	8.0	X	3.00	3.00	7.00	5.00	9.00	5.00				
				NBC: B	20/10/90	0.0	1.0	X	0.00	0.00	0.00	0.00	0.00	0.00				
				PLATELETS	20/10/90	150.0	550.0	10-3/MHC	345.00	325.00	293.00	270.00	363.00	389.00				
				NA+	20/10/90	138.0	155.0	M EQ/L	143.00	143.00	141.00	142.00	142.00	136.00				
				CL-	20/10/90	98.0	120.0	M EQ/L	4.80	4.70	4.40	4.20	4.30	4.60				
				CA++	20/10/90	8.5	10.5	MG/DL	9.60	100.00	100.00	99.00	96.00	99.00				
				PO4-	20/10/90	3.0	4.5	MG/DL	3.70	9.60	9.50	9.70	9.80	10.50				
				SGOT	20/10/90	12.0	40.0	IU/ML	4.10	4.10	3.70	4.00	3.70	4.10				
				SGPT	20/10/90	10.0	40.0	IU/ML	24.00	16.00	23.00	24.00	20.00	15.00				
				GAMMA-GT	20/10/90	7.0	33.0	IU/ML	25.00	16.00	19.00	28.00	24.00	14.00				
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	96.00	95.00	94.00	94.00	18.00	28.00				
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	263.00	252.00	250.00	174.00	95.00	96.00				
				CREATININE	20/10/90	0.6	1.6	MG/DL	17.00	22.00	21.00	20.00	30.00	254.00				
				URIC ACID	20/10/90	2.4	5.7	MG/DL	0.80	0.80	0.80	0.80	0.80	0.80				
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	4.00	4.00	3.80	3.60	3.20	3.70				
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.70	0.50	0.60	0.60	0.20				
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.40	6.40	6.50	6.60	7.20	6.80				
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.20	4.26	4.10	4.00	3.80				
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	185.00	170.00	204.00	214.00	149.00	180.00				
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	98.00	94.00	111.00	87.00	126.00	123.00				
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	3.50	4.50	3.00	3.00	3.60	3.80				
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	9.80	11.80	10.30	10.20	8.40	12.00				
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	11.60	13.00	12.40	11.00	13.50	14.00				
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	9.20	5.80	8.80	12.50	16.90	14.40				
				41-307	M			HB	20/10/90	14.0	18.0	g/100ml	03/12/91	28/01/92	24/03/92	19/05/92	14/07/92	
								HTC	20/10/90	40.0	54.0	%	14.00	13.40	13.30	13.60	13.80	13.60
								RBC	20/10/90	4.3	6.1	10 ⁶ /mm ³	43.00	41.00	38.00	38.00	39.00	39.00
								NBC: N	20/10/90	4.0	11.0	10-3/MHC	6.30	6.30	6.20	6.10	5.10	4.60
								NBC: L	20/10/90	20.0	70.0	X	60.00	58.00	61.00	63.00	60.00	60.00
								NBC: E	20/10/90	40.0	40.0	X	36.00	28.00	30.00	30.00	32.00	30.00
								NBC: M	20/10/90	1.0	5.0	X	6.00	8.00	3.00	2.00	3.00	3.00
								NBC: B	20/10/90	4.0	8.0	X	4.00	8.00	0.00	0.00	0.00	0.00
								PLATELETS	20/10/90	150.0	550.0	10-3/MHC	309.00	279.00	261.00	275.00	249.00	249.00
								NA+	20/10/90	138.0	155.0	M EQ/L	143.00	141.00	143.00	141.00	156.00	156.00

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Date	Laboratory Range			Visit					
						Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
1	41-307	M		K+	20/10/90	3.5	5.5	M EQ/L	4.40	3.80	4.20	4.00	4.20	
				CL-	20/10/90	98.0	120.0	M EQ/L	99.00	99.00	97.00	97.00	96.00	
				CA++	20/10/90	8.5	10.5	MG/DL	9.00	8.40	9.40	9.40	9.70	
				PO4-	20/10/90	3.0	4.5	MG/DL	2.50	2.70	4.20	3.80	4.10	
				SGOT	20/10/90	12.0	40.0	IU/ML	18.00	21.00	28.00	24.00	25.00	
				SGPT	20/10/90	10.0	40.0	IU/ML	23.00	29.00	32.00	28.00	29.00	
				GAMMA-GT	20/10/90	11.0	51.0	IU/ML	37.00	37.00	41.00	30.00	37.00	
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	156.00	153.00	107.00	91.00	99.00	
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	272.00	226.00	115.00	125.00	143.00	
				BUN	20/10/90	10.0	50.0	MG/DL	23.00	19.00	35.00	30.00	29.00	
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	0.80	1.10	0.80	0.80	
				URIC ACID	20/10/90	3.4	7.0	MG/DL	6.20	7.20	3.60	4.10	3.90	
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.30	0.90	0.90	0.90	0.90	
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.10	0.20	0.40	0.60	0.40	
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.40	6.40	7.60	7.60	7.40	
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.00	4.10	4.50	4.10	4.00	
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	190.00	166.00	196.00	165.00	176.00	
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	126.00	130.00	108.00	103.00	82.00	
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	2.40	2.60	3.50	3.20	3.40	
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	6.60	7.20	12.80	12.10	10.20	
GLOBULINS: BETA	20/10/90	11.0	14.0	%	12.40	12.60	7.60	9.40	9.10					
GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	16.80	15.60	30.10	21.20	18.70					
42-308	F		HB	20/10/90	12.0	16.0	G/100ML	11/12/91	04/02/92	01/04/92	27/05/92	22/07/92	30/09/92	
			HTC	20/10/90	37.0	47.0	%	12.80	12.60	13.50	13.60	14.20	12.90	
			RBC	20/10/90	3.8	5.4	10 ⁶ /MNC	4.20	38.00	41.00	41.00	41.00	38.00	
			HBC	20/10/90	4.0	11.0	10 ³ /MNC	5.90	4.40	4.20	4.30	4.60	4.00	
			HRC: N	20/10/90	40.0	70.0	%	54.00	7.00	6.60	5.20	6.00	6.30	
			HRC: L	20/10/90	20.0	40.0	%	31.00	56.00	52.00	56.00	62.00	49.00	
			HRC: E	20/10/90	1.0	5.0	%	10.00	30.00	30.00	32.00	30.00	27.00	
			HRC: M	20/10/90	4.0	8.0	%	5.00	4.00	12.00	6.00	2.00	18.00	
			HRC: B	20/10/90	0.0	1.0	%	0.00	10.00	6.00	6.00	6.00	6.00	
			PLATELETS	20/10/90	150.0	550.0	10 ³ /MNC	234.00	219.00	211.00	251.00	318.00	259.00	
			NA+	20/10/90	138.0	155.0	M EQ/L	140.00	138.00	142.00	141.00	142.00	139.00	
			K+	20/10/90	3.5	5.5	M EQ/L	4.30	5.10	4.20	4.10	4.30	4.40	
			CL-	20/10/90	98.0	120.0	M EQ/L	99.00	98.00	97.00	101.00	98.00	98.00	
			CA++	20/10/90	8.5	10.5	MG/DL	9.00	9.30	9.00	9.80	9.70	9.10	
			PO4-	20/10/90	3.0	4.5	MG/DL	3.50	3.00	3.40	3.90	4.10	2.90	
			SGOT	20/10/90	12.0	40.0	IU/ML	24.00	28.00	27.00	27.00	20.00	20.00	
SGPT	20/10/90	10.0	40.0	IU/ML	16.00	34.00	26.00	29.00	24.00	13.00				
GAMMA-GT	20/10/90	7.0	33.0	IU/ML	22.00	26.00	23.00	23.00	23.00	12.00				
GLUCOSE	20/10/90	70.0	100.0	MG/DL	97.00	99.00	100.00	96.00	96.00	91.00				

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit										
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52				
1 42-308	F			ALK. PHOSPH.	20/10/90	65.0	306.0	U/ML	229.00	208.00	218.00	194.00	196.00	255.00				
				BUN	20/10/90	10.0	50.0	MG/DL	24.00	23.00	32.00	28.00	30.00	31.00	31.00			
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	0.80	0.70	0.70	0.70	0.60	0.60			
				URIC ACID	20/10/90	2.4	5.7	MG/DL	2.40	2.50	3.20	3.30	4.80	2.20	2.20			
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.70	0.80	0.50	0.50	0.80	0.50	0.50			
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.40	0.20	0.20	0.40	0.20	0.20			
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.50	6.50	6.90	7.00	6.50	6.70	6.70			
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.00	4.00	3.91	3.90	4.00	3.40	3.40			
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	215.00	220.00	259.00	210.00	290.00	233.00	233.00			
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	134.00	122.00	132.00	113.00	143.00	166.00	166.00			
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	Z	1.90	2.00	3.00	2.90	3.00	2.70	2.70			
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	Z	5.60	5.70	7.40	8.50	8.20	9.50	9.50			
				GLOBULINS: BETA	20/10/90	11.0	14.0	Z	13.00	12.60	12.70	12.70	12.50	16.30	16.30			
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	Z	17.20	18.00	20.20	21.60	20.20	20.80	20.80			
				47-512	F			HB	20/10/90	12.0	16.0	G/100ML	13.70	14.30	12.90	16/06/92	11/08/92	
								HTC	20/10/90	37.0	47.0	Z	40.00	42.00	40.00	40.00	39.00	39.00
								RBC	20/10/90	3.8	5.4	10 ⁶ /MCC	4.40	4.80	4.50	4.40	4.50	4.50
								MBC	20/10/90	4.0	11.0	10 ³ /MCC	8.20	7.00	5.80	5.60	4.50	4.50
								MBC: N	20/10/90	40.0	70.0	Z	47.00	58.00	49.00	60.00	63.00	63.00
								MBC: L	20/10/90	20.0	40.0	Z	50.00	30.00	37.00	31.00	28.00	28.00
MBC: E	20/10/90	1.0	5.0					Z	4.00	6.00	3.00	2.00	2.00	2.00				
MBC: M	20/10/90	4.0	8.0					Z	3.00	6.00	11.00	7.00	7.00	7.00				
MBC: B	20/10/90	0.0	1.0					Z	0.00	0.00	0.00	0.00	0.00	0.00				
PLATELETS	20/10/90	150.0	550.0					10 ³ /MCC	260.00	241.00	352.00	316.00	256.00	256.00				
NA+	20/10/90	138.0	155.0					M EQ/L	138.00	139.00	138.00	139.00	143.00	143.00				
K+	20/10/90	3.5	5.5					M EQ/L	3.80	4.00	4.10	4.20	4.20	4.20				
CL-	20/10/90	98.0	120.0					M EQ/L	96.00	102.00	97.00	98.00	94.00	94.00				
CA++	20/10/90	8.5	10.5					MG/DL	9.80	9.50	8.80	8.90	9.30	9.30				
PO4-	20/10/90	3.0	4.5					MG/DL	2.90	4.00	3.30	3.50	2.80	2.80				
SGOT	20/10/90	12.0	40.0					U/ML	28.00	24.00	31.00	32.00	26.00	26.00				
SGPT	20/10/90	10.0	40.0					U/ML	31.00	28.00	26.00	28.00	20.00	20.00				
GAMMA-GT	20/10/90	7.0	33.0					U/ML	32.00	30.00	39.00	42.00	31.00	31.00				
GLUCOSE	20/10/90	70.0	100.0					MG/DL	103.00	94.00	99.00	94.00	88.00	88.00				
ALK. PHOSPH.	20/10/90	65.0	306.0					U/ML	223.00	210.00	182.00	176.00	127.00	127.00				
BUN	20/10/90	10.0	50.0	MG/DL	25.00	28.00	17.00	19.00	30.00	30.00								
CREATININE	20/10/90	0.6	1.6	MG/DL	1.10	1.30	0.90	0.90	1.00	1.00								
URIC ACID	20/10/90	2.4	5.7	MG/DL	3.70	3.60	4.30	4.20	3.60	3.60								
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.40	0.40	0.30	0.30	0.30	0.30								
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.20	0.20	0.10	0.30	0.30								
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.60	7.50	7.10	7.20	7.00	7.00								
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.00	4.00	3.88	3.90	3.90	3.90								

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1936

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXYTINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit						
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
1 47-312	F			TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	208.00	212.00	214.00	206.00	158.00	
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	117.00	110.00	240.00	143.00	80.00	
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	3.40	3.30	3.30	4.00	3.10	
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	7.40	7.60	8.40	8.60	8.60	
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	11.50	11.80	12.30	12.40	11.70	
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	20.40	21.20	21.40	20.80	20.20	
				HB	20/10/90	12.0	16.0	G/100ML	10.30	12.10	11.10	12.00	12.70	23/10/92
				HTC	20/10/90	37.0	47.0	%	32.00	35.00	35.00	36.00	37.00	37.00
				RBC	20/10/90	3.8	5.4	10 ⁶ /MM ³	4.40	4.40	4.80	4.80	4.30	4.00
				WBC	20/10/90	4.0	11.0	10 ³ /MM ³	7.00	6.30	6.30	6.30	5.80	5.00
50-314	F			HRC: N	20/10/90	40.0	70.0	%	71.00	64.00	78.00	62.00	61.00	58.00
				HRC: L	20/10/90	20.0	40.0	%	25.00	25.00	17.00	23.00	27.00	30.00
				HRC: E	20/10/90	1.0	5.0	%	0.00	7.00	0.00	5.00	4.00	5.00
				HRC: K	20/10/90	4.0	8.0	%	4.00	7.00	5.00	10.00	8.00	7.00
				HRC: B	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00
				PLATELETS	20/10/90	150.0	550.0	10 ³ /MM ³	272.00	259.00	311.00	320.00	198.00	230.00
				Na+	20/10/90	138.0	155.0	MEQ/L	140.00	141.00	137.00	138.00	145.00	146.00
				K+	20/10/90	3.5	5.5	MEQ/L	3.80	3.80	4.10	4.50	3.90	4.10
				CL-	20/10/90	98.0	120.0	MEQ/L	96.00	95.00	87.00	98.00	102.00	99.00
				Ca++	20/10/90	8.5	10.5	MG/DL	8.30	9.00	8.70	8.90	9.50	9.00
PO4--	20/10/90	3.0	4.5	MG/DL	4.00	4.20	3.50	3.60	3.90	4.20				
SGPT	20/10/90	12.0	40.0	MG/ML	27.00	26.00	17.00	20.00	30.00	34.00				
GAMMA-GT	20/10/90	7.0	33.0	MG/ML	15.00	28.00	12.00	24.00	32.00	36.00				
GLUCOSE	20/10/90	70.0	100.0	MG/DL	87.00	89.00	108.00	106.00	104.00	104.00				
BUN	20/10/90	65.0	306.0	MG/ML	162.00	172.00	137.00	141.00	114.00	136.00				
CREATININE	20/10/90	0.6	1.6	MG/DL	1.00	1.00	0.80	0.90	0.90	0.80				
URIC ACID	20/10/90	2.4	5.7	MG/DL	3.80	3.70	4.30	4.20	3.50	4.10				
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.40	0.40	0.40	0.30	0.60	0.70				
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.10	0.20	0.20	0.10	0.30	0.30				
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.80	6.90	7.70	7.80	7.00	7.10				
ALBUMINE	20/10/90	3.5	5.0	G/DL	3.80	3.80	4.77	4.80	3.80	3.80				
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	133.00	142.00	149.00	136.00	188.00	163.00				
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	68.00	66.00	46.00	52.00	96.00	85.00				
GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	3.60	3.80	1.90	2.20	4.10	4.10				
GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	7.80	8.40	6.70	7.00	8.30	8.30				
GLOBULINS: BETA	20/10/90	11.0	14.0	%	14.30	16.20	11.60	11.50	12.80	12.50				
GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	12.30	19.70	17.90	18.20	18.70	20.20				

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Open-Blind Sex	Laboratory test	Laboratory Range			Visit						
			Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
1 51-315	F	RB	20/10/90	12.0	16.0	G/100ML	03/01/92	28/02/92	24/04/92	12/06/92	14/08/92	23/10/92
		HTC	20/10/90	37.0	47.0	Z	12.10	12.50	12.20	14.00	12.20	11.90
		RBC	20/10/90	3.8	5.4	10 ⁶ /MM ³	35.00	36.00	36.00	41.00	36.00	35.00
		WBC	20/10/90	4.0	11.0	10 ³ /MM ³	3.60	4.00	3.70	4.30	3.80	3.40
		PLT	20/10/90	40.0	70.0	Z	4.90	5.10	4.00	6.00	5.00	3.60
		HGB: L	20/10/90	20.0	40.0	Z	72.00	69.00	60.00	60.00	62.00	61.00
		HGB: E	20/10/90	1.0	5.0	Z	24.00	22.00	31.00	31.00	28.00	30.00
		HGB: M	20/10/90	4.0	8.0	Z	0.00	3.00	0.00	2.00	2.00	0.00
		HGB: B	20/10/90	0.0	1.0	Z	0.00	6.00	9.00	7.00	8.00	9.00
		PLATELETS	20/10/90	150.0	550.0	10 ³ /MM ³	184.00	193.00	194.00	280.00	210.00	186.00
		NA+	20/10/90	138.0	155.0	M EQ/L	139.00	138.00	136.00	142.00	138.00	136.00
		CL-	20/10/90	98.0	120.0	M EQ/L	96.00	97.00	96.00	97.00	96.00	98.00
		CA++	20/10/90	8.5	10.5	MG/DL	9.30	9.40	9.00	9.50	9.70	9.30
		PO4-	20/10/90	3.0	4.5	MG/DL	2.80	3.00	2.30	3.80	2.50	2.20
		SODT	20/10/90	12.0	40.0	UO/ML	17.00	18.00	18.00	28.00	28.00	30.00
		SGPT	20/10/90	10.0	40.0	UO/ML	18.00	20.00	15.00	24.00	31.00	29.00
		GAMMA-GT	20/10/90	7.0	33.0	UO/ML	22.00	24.00	25.00	22.00	38.00	43.00
		GLUCOSE	20/10/90	70.0	100.0	MG/DL	93.00	96.00	97.00	96.00	96.00	96.00
		ALK. PHOSPH.	20/10/90	65.0	306.0	UO/ML	201.00	209.00	224.00	197.00	263.00	254.00
		BUN	20/10/90	10.0	50.0	MG/DL	16.00	12.00	22.00	30.00	23.00	21.00
		CREATININE	20/10/90	0.6	1.6	MG/DL	0.70	0.80	0.90	1.00	0.90	0.90
		URIC ACID	20/10/90	2.4	5.7	MG/DL	3.80	3.90	3.90	4.30	4.10	4.20
		TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.90	0.80	0.70	0.60	0.50	0.60
		DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.30	0.20	0.30	0.20	0.30
		TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.30	7.20	7.10	7.20	7.20	7.10
		ALBUMINE	20/10/90	3.5	5.0	G/DL	4.00	4.00	4.51	4.00	4.00	4.00
		TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	120.00	116.00	151.00	153.00	138.00	159.00
		TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	70.00	84.00	63.00	96.00	96.00	89.00
		GLOBULINS: ALPHA1	20/10/90	4.0	7.0	Z	0.70	1.20	1.30	2.20	2.30	2.30
		GLOBULINS: ALPHA2	20/10/90	7.0	11.0	Z	2.10	2.30	5.70	5.80	8.00	7.80
		GLOBULINS: BETA	20/10/90	11.0	14.0	Z	10.40	11.40	10.80	11.90	13.20	13.00
		GLOBULINS: GAMMA	20/10/90	15.0	22.0	Z	29.00	23.60	18.70	24.50	21.00	20.00
53-317	F	RB	20/10/90	12.0	16.0	G/100ML	08/01/92	04/03/92				
		HTC	20/10/90	37.0	47.0	Z	12.40	12.70				
		RBC	20/10/90	3.8	5.4	10 ⁶ /MM ³	36.00	37.00				
		WBC	20/10/90	4.0	11.0	10 ³ /MM ³	4.00	4.20				
		PLT	20/10/90	40.0	70.0	Z	6.20	6.30				
		HGB: L	20/10/90	20.0	40.0	Z	58.00	60.00				
		HGB: E	20/10/90	1.0	5.0	Z	32.00	28.00				
		HGB: M	20/10/90	4.0	8.0	Z	6.00	6.00				

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Date	Laboratory Range		Visit							
						Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
1	53-317	F		WBC: M	20/10/90	4.0	8.0	%	4.00	6.00					
				WBC: B	20/10/90	0.0	1.0	%	0.00	0.00					
				PLATELETS	20/10/90	150.0	550.0	10 ³ -3/MHC	325.00	315.00					
				NA+	20/10/90	138.0	155.0	M EQ/L	141.00	141.00					
				K+	20/10/90	3.5	5.5	M EQ/L	4.70	3.90					
				CL-	20/10/90	98.0	120.0	M EQ/L	96.00	95.00					
				CA++	20/10/90	8.5	10.5	MG/DL	9.30	9.80					
				PO4--	20/10/90	3.0	4.5	MG/DL	4.40	4.30					
				SOD	20/10/90	12.0	40.0	MU/ML	32.00	26.00					
				SGPT	20/10/90	10.0	40.0	MU/ML	29.00	28.00					
				GAMMA-GT	20/10/90	7.0	55.0	MU/ML	41.00	40.00					
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	114.00	101.00					
				ALK. PHOSPH.	20/10/90	65.0	306.0	MU/AL	398.00	325.00					
				BUN	20/10/90	10.0	50.0	MG/DL	22.00	24.00					
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	0.90					
				URIC ACID	20/10/90	2.4	5.7	MG/DL	4.20	4.10					
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60	0.70					
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.40					
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.50	7.40					
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.10					
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	244.00	236.00					
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	496.00	216.00					
				1.0	20/10/90	4.0	7.0	%	1.70	2.10					
				2.0	20/10/90	4.0	7.0	%	1.70	2.10					
				3.0	20/10/90	7.0	11.0	%	3.80	4.00					
				4.0	20/10/90	11.0	14.0	%	12.30	11.70					
				5.0	20/10/90	15.0	22.0	%	25.20	23.20					
59-321	F			HR	20/10/90	12.0	16.0	G/100ML	25/02/92	20/04/92	16/06/92	11/08/92	06/10/92	15/12/92	
				WTC	20/10/90	37.0	47.0	%	12.50	12.80	13.20	13.40	13.40	13.40	14.00
				PRC	20/10/90	3.8	5.4	10 ⁻⁶ /MHC	37.00	37.00	40.00	40.00	40.00	40.00	42.00
				WRC	20/10/90	4.0	11.0	10 ⁻³ /MHC	4.20	4.20	4.50	4.70	4.70	4.70	4.70
				RBC: N	20/10/90	40.0	70.0	%	5.80	5.60	5.90	5.00	5.00	6.10	6.30
				RBC: L	20/10/90	20.0	40.0	%	53.00	55.00	68.00	66.00	63.00	61.00	61.00
				RBC: E	20/10/90	1.0	5.0	%	43.00	36.00	25.00	26.00	20.00	25.00	25.00
				RBC: M	20/10/90	4.0	8.0	%	1.00	3.00	1.00	1.00	7.00	2.00	2.00
				RBC: B	20/10/90	0.0	1.0	%	3.00	6.00	6.00	7.00	10.00	9.00	9.00
				PLATELETS	20/10/90	150.0	550.0	10 ³ -3/MHC	0.00	0.00	0.00	0.00	0.00	0.00	0.00
				NA+	20/10/90	138.0	155.0	M EQ/L	225.00	219.00	197.00	210.00	216.00	309.00	309.00
				K+	20/10/90	3.5	5.5	M EQ/L	139.00	139.00	136.00	143.00	143.00	142.00	142.00
				CL-	20/10/90	98.0	120.0	M EQ/L	4.60	4.20	4.10	4.10	4.30	4.30	4.30
				CA++	20/10/90	8.5	10.5	MG/DL	96.00	99.00	101.00	103.00	98.00	98.00	98.00
				PO4--	20/10/90	3.0	4.5	MG/DL	10.40	9.50	10.50	10.10	10.10	10.10	10.10
					20/10/90	3.0	4.5	MG/DL	3.40	4.10	2.70	3.10	3.10	4.00	4.30

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit										
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52				
1	59-321	F		SGPT	20/10/90	12.0	40.0	40.0	30.00	22.00	17.00	19.00	27.00	28.00				
				GAMMA-GT	20/10/90	10.0	40.0	40.0	30.00	22.00	13.00	15.00	32.00	29.00				
60-322	M			GAMMA-GT	20/10/90	7.0	33.0	33.0	21.00	20.00	14.00	21.00	20.00	24.00				
				GLUCOSE	20/10/90	70.0	100.0	100.0	78.00	93.00	100.00	93.00	94.00	92.00				
				ALK. PHOSPH.	20/10/90	65.0	306.0	306.0	151.00	166.00	177.00	144.00	132.00	127.00				
				BUN	20/10/90	10.0	50.0	50.0	24.00	26.00	24.00	24.00	31.00	32.00				
				CREATININE	20/10/90	0.6	1.6	1.6	0.80	0.80	0.80	0.90	1.00	0.80				
				URIC ACID	20/10/90	2.4	5.7	5.7	3.00	3.20	3.40	3.60	4.70	4.30				
				TOT. BILIRUBIN	20/10/90	0.2	1.0	1.0	0.40	0.40	0.50	0.60	0.80	0.90				
				DIR. BILIRUBIN	20/10/90	0.0	0.4	0.4	0.20	0.10	0.20	0.30	0.40	0.40				
				TOT. PROTEINS	20/10/90	6.0	8.0	8.0	7.70	7.70	7.40	7.40	7.30	7.30				
				ALBUMINE	20/10/90	3.5	5.0	5.0	4.20	4.40	4.05	4.00	3.90	4.00				
				TOT. CHOLEST.	20/10/90	140.0	270.0	270.0	208.00	192.00	198.00	190.00	293.00	236.00				
				TRIGLYCERIDES	20/10/90	35.0	175.0	175.0	62.00	74.00	46.00	72.00	72.00	89.00				
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	7.0	1.90	2.00	2.10	2.10	3.50	3.00				
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	11.0	10.20	11.0	8.10	8.20	7.40	8.10				
				GLOBULINS: BETA	20/10/90	11.0	14.0	14.0	8.20	8.00	13.40	13.30	10.80	12.50				
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	22.0	19.80	18.90	21.80	21.50	16.60	19.00				
				60-322	M			HB	20/10/90	14.0	18.0	18.0	13.20	13.60	13.40	13.20	13.50	13.30
								HCT	20/10/90	40.0	54.0	54.0	40.00	41.00	40.00	41.00	42.00	41.00
								RBC	20/10/90	4.3	6.1	6.1	4.30	4.40	4.30	4.50	4.60	4.40
								RBC: N	20/10/90	4.0	11.0	10-3/MHC	7.50	7.00	7.20	7.00	7.50	8.00
RBC: L	20/10/90	40.0	70.0					70.0	62.00	61.00	54.00	58.00	56.00	50.00				
RBC: E	20/10/90	20.0	40.0					40.0	30.00	29.00	34.00	31.00	32.00	35.00				
RBC: M	20/10/90	1.0	5.0					5.0	4.00	3.00	3.00	3.00	4.00	5.00				
RBC: B	20/10/90	4.0	8.0					8.0	4.00	7.00	8.00	8.00	10.00	10.00				
PLATELETS	20/10/90	0.0	1.0					1.0	0.00	0.00	0.00	0.00	0.00	0.00				
NA+	20/10/90	150.0	550.0					10-3/MHC	256.00	274.00	251.00	263.00	294.00	300.00				
K+	20/10/90	3.5	5.5					5.5	4.00	4.20	4.10	4.20	4.20	4.30				
CL-	20/10/90	98.0	120.0					120.0	99.00	99.00	98.00	99.00	98.00	98.00				
CA++	20/10/90	8.5	10.5					10.5	9.00	8.60	9.70	9.60	9.40	9.50				
PO4-	20/10/90	3.0	4.5					4.5	3.40	3.50	3.60	3.00	3.10	3.10				
SGPT	20/10/90	12.0	40.0					40.0	31.00	30.00	28.00	28.00	25.00	24.00				
GAMMA-GT	20/10/90	10.0	40.0					40.0	33.00	34.00	24.00	24.00	23.00	23.00				
GLUCOSE	20/10/90	11.0	51.0					51.0	29.00	26.00	21.00	22.00	31.00	29.00				
ALK. PHOSPH.	20/10/90	70.0	306.0					306.0	179.00	163.00	96.00	97.00	108.00	129.00				
BUN	20/10/90	65.0	100.0					100.0	24.00	23.00	212.00	212.00	174.00	211.00				
CREATININE	20/10/90	10.0	50.0					50.0	0.80	0.90	42.00	43.00	37.00	45.00				
URIC ACID	20/10/90	0.6	1.6	1.6	0.80	0.80	0.90	0.90	0.90	0.80								
	20/10/90	3.4	7.0	7.0	3.30	3.20	3.50	3.60	3.80	3.60								

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

1940

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
RESOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit									
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52			
1 60-322	M		TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.30	0.30	0.60	0.40	0.60	0.50			
			DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.10	0.10	0.30	0.20	0.30	0.20			
			TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.30	6.50	6.80	6.90	6.90	6.90			
			ALBUMINE	20/10/90	3.5	5.0	G/DL	4.00	3.70	4.03	4.00	3.60	3.70			
			TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	186.00	190.00	188.00	180.00	218.00	208.00			
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	47.00	61.00	82.00	76.00	160.00	164.00			
			GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	2.40	2.30	2.20	2.50	2.20	2.20			
			GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	8.10	7.70	7.10	8.00	8.60	8.60			
			GLOBULINS: BETA	20/10/90	11.0	14.0	%	12.80	12.70	12.80	11.30	15.50	15.40			
			GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	18.80	19.40	18.60	18.20	20.10	20.20			
			62-324	F		HB	20/10/90	12.0	16.0	G/100ML	12.90	12.80	12.20	12.50	12.00	05/01/93
						HIC	20/10/90	37.0	47.0	%	40.00	40.00	38.00	38.00	39.00	12.00
						RBC	20/10/90	3.8	5.4	10 ⁶ /MHC	4.50	4.50	4.10	4.00	4.50	38.00
						RBC: N	20/10/90	4.0	11.0	10 ³ /MHC	6.00	5.90	4.70	4.80	4.70	4.10
						RBC: L	20/10/90	40.0	70.0	%	60.00	61.00	62.00	61.00	69.00	66.00
						RBC: E	20/10/90	20.0	40.0	%	32.00	29.00	30.00	28.00	22.00	26.00
						RBC: M	20/10/90	1.0	5.0	%	2.00	3.00	2.00	3.00	2.00	2.00
RBC: B	20/10/90	4.0				8.0	%	6.00	7.00	6.00	8.00	7.00	6.00			
PLATELETS	20/10/90	150.0				550.0	10 ³ /MHC	0.00	0.00	0.00	0.00	0.00	0.00			
NA+	20/10/90	138.0				155.0	M EQ/L	141.00	140.00	142.00	141.00	141.00	139.00			
K+	20/10/90	3.5				5.5	M EQ/L	4.00	4.10	5.10	4.30	4.30	4.50			
CL-	20/10/90	98.0				120.0	M EQ/L	94.00	94.00	96.00	95.00	96.00	98.00			
CA++	20/10/90	8.5				10.5	MG/DL	9.80	9.60	10.10	9.30	9.00	8.60			
PO4--	20/10/90	3.0				4.5	MG/DL	3.80	3.70	4.30	4.00	4.10	2.10			
SGOT	20/10/90	12.0				40.0	NU/HL	24.00	24.00	29.00	26.00	16.00	15.00			
SGPT	20/10/90	10.0				40.0	NU/HL	28.00	28.00	20.00	24.00	18.00	14.00			
GAMMA-GT	20/10/90	7.0				33.0	NU/HL	42.00	36.00	19.00	19.00	24.00	22.00			
GLUCOSE	20/10/90	70.0				100.0	MG/DL	108.00	95.00	110.00	103.00	88.00	101.00			
ALK. PHOSPH.	20/10/90	65.0				306.0	NU/HL	161.00	148.00	246.00	216.00	184.00	170.00			
RUN	20/10/90	10.0				50.0	MG/DL	26.00	32.00	34.00	32.00	31.00	30.00			
CREATININE	20/10/90	0.6				1.6	MG/DL	0.90	0.90	1.20	1.10	0.90	0.70			
URIC ACID	20/10/90	2.4				5.7	MG/DL	4.00	4.10	5.00	4.30	4.20	4.20			
TOT BILIRUBIN	20/10/90	0.2				1.0	MG/DL	0.50	0.60	0.30	0.30	0.30	0.20			
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.30	0.20	0.10	0.10	0.10						
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.10	7.30	7.50	7.50	7.00	6.10						
ALBUMINE	20/10/90	6.0	8.0	G/DL	3.90	3.90	4.33	4.20	4.00	2.90						
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	127.00	171.00	261.00	234.00	158.00	178.00						
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	106.00	110.00	120.00	116.00	104.00	108.00						
GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	4.00	4.00	2.20	4.10	3.20	3.30						
GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	10.90	9.80	7.10	8.30	8.80	9.50						

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBONETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit						
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
1	62-324	F	GLORULINS: BETA	20/10/90	11.0	14.0	Z	12.50	12.30	13.20	13.20	14.00	16.40
			GLORULINS: GAMMA	20/10/90	15.0	22.0	Z	20.10	20.20	19.80	20.10	21.50	22.80
64-325	F	HB	20/10/90	12.0	16.0	G/100ML	13.90	14.10	12.90	12.90	13.10	13.00	
		HCT	20/10/90	37.0	47.0	Z	41.00	40.00	41.00	41.00	40.00	39.00	
		RBC	20/10/90	3.8	5.4	10 ⁶ /MNC	4.30	4.40	4.20	4.30	4.50	4.10	
		WBC	20/10/90	4.0	11.0	10 ³ /MNC	5.20	6.10	6.90	6.10	6.00	4.60	
		WBC: N	20/10/90	40.0	70.0	Z	66.00	68.00	65.00	62.00	62.00	51.00	
		WBC: L	20/10/90	20.0	40.0	Z	30.00	30.00	26.00	28.00	27.00	36.00	
		WBC: E	20/10/90	1.0	5.0	Z	0.00	0.00	1.00	1.00	3.00	1.00	
		WBC: M	20/10/90	4.0	8.0	Z	4.00	2.00	8.00	6.00	8.00	12.00	
		WBC: R	20/10/90	0.0	1.0	Z	0.00	0.00	0.00	0.00	0.00	0.00	
		PLATELETS	20/10/90	150.0	550.0	10 ³ /MNC	247.00	250.00	194.00	315.00	430.00	442.00	
		HA+	20/10/90	138.0	155.0	M ER/L	140.00	141.00	139.00	138.00	142.00	140.00	
		PA+	20/10/90	3.5	3.5	M ER/L	3.40	4.50	4.80	4.70	4.30	4.60	
		CA++	20/10/90	98.0	120.0	M ER/L	96.00	10.50	100.00	97.00	97.00	98.00	
		FM+	20/10/90	8.5	10.5	MG/DL	9.00	3.60	4.00	2.60	3.10	2.80	
		SGPT	20/10/90	12.0	40.0	MU/ML	39.00	34.00	50.00	42.00	24.00	23.00	
		SGOT	20/10/90	10.0	40.0	MU/ML	26.00	34.00	37.00	48.00	30.00	29.00	
		GAMMA-GT	20/10/90	7.0	33.0	MU/ML	91.00	75.00	63.00	68.00	46.00	47.00	
		GLUCOSE	20/10/90	70.0	100.0	MG/DL	91.00	85.00	103.00	94.00	90.00	89.00	
		ALK. PHOSPH.	20/10/90	65.0	306.0	MU/ML	233.00	210.00	301.00	263.00	283.00	263.00	
		BUN	20/10/90	10.0	50.0	MG/DL	25.00	26.00	34.00	32.00	32.00	34.00	
		CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	0.80	0.80	0.90	0.90	0.80	
		URIC ACID	20/10/90	2.4	5.7	MG/DL	3.40	3.60	3.10	3.40	2.80	2.20	
		TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.40	0.40	0.30	0.40	0.80	0.90	
		DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.20	0.10	0.20	0.40	0.40	
		TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.30	7.40	7.40	7.40	6.90	6.40	
		ALBUMINE	20/10/90	3.5	5.0	G/DL	3.90	4.00	4.20	4.10	3.90	3.80	
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	217.00	180.00	208.00	186.00	218.00	207.00			
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	144.00	136.00	146.00	120.00	120.00	113.00			
GLORULINS: ALPHA1	20/10/90	4.0	7.0	Z	2.90	3.00	2.20	2.50	2.20	2.40			
GLORULINS: ALPHA2	20/10/90	7.0	11.0	Z	10.60	11.50	8.00	7.90	7.80	7.30			
GLORULINS: BETA	20/10/90	11.0	14.0	Z	14.00	13.60	13.30	14.30	13.00	12.10			
GLORULINS: GAMMA	20/10/90	15.0	22.0	Z	20.50	20.60	19.70	18.80	20.50	19.30			
67-327	F	HB	20/10/90	12.0	16.0	G/100ML	13.60	14.00	13.80	14.00	14.00	16.40	
		HCT	20/10/90	37.0	47.0	Z	41.00	42.00	41.00	41.00	41.00	41.00	
		RBC	20/10/90	3.8	5.4	10 ⁶ /MNC	4.50	4.60	4.60	4.60	4.60	4.60	

(*): MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1943

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit										
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52				
1	67-327	F	HBC	20/10/90	4.0	11.0	10-3/HMC	9.20	8.00	5.10							
			HBC: N	20/10/90	40.0	70.0	X	68.00	61.00	61.00							
			HBC: L	20/10/90	20.0	40.0	X	25.00	27.00	28.00							
			HBC: E	20/10/90	1.0	5.0	X	1.00	2.00	3.00							
			HBC: M	20/10/90	4.0	8.0	X	6.00	10.00	8.00							
			HBC: B	20/10/90	0.0	1.0	X	0.00	0.00	0.00							
			PLATELETS	20/10/90	150.0	550.0	10-3/HMC	305.00	310.00	286.00							
			NA+	20/10/90	138.0	155.0	M EQ/L	140.00	141.00	142.00							
			CL-	20/10/90	3.5	5.5	M EQ/L	3.30	3.80	4.20							
			CA++	20/10/90	8.5	12.0	M EQ/L	93.00	95.00	97.00							
			PO4-	20/10/90	3.0	4.5	MG/DL	3.50	4.10	4.70							
			SCOT	20/10/90	12.0	40.0	MU/HL	36.00	38.00	34.00							
			SGPT	20/10/90	10.0	40.0	MU/HL	39.00	34.00	38.00							
			GAMMA-GT	20/10/90	7.0	33.0	MU/HL	53.00	48.00	40.00							
			GLUCOSE	20/10/90	70.0	100.0	MG/DL	146.00	140.00	124.00							
			ALK. PHOSPH.	20/10/90	65.0	306.0	MU/HL	160.00	156.00	201.00							
			BUN	20/10/90	10.0	50.0	MG/DL	34.00	31.00	36.00							
			CREATININE	20/10/90	0.6	1.6	MG/DL	0.60	0.70	1.10							
			URIC ACID	20/10/90	2.4	5.7	MG/DL	7.90	6.00	4.00							
			TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.70	0.70	1.10							
			DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.30	0.50							
			TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.90	7.90	7.30							
			ALBUMINE	20/10/90	3.5	5.0	G/DL	3.90	3.90	4.00							
			TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	211.00	188.00	258.00							
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	280.00	209.00	143.00							
			GLOBULINS: ALPHA1	20/10/90	4.0	7.0	X	3.40	3.50	3.00							
			GLOBULINS: ALPHA2	20/10/90	7.0	11.0	X	9.10	10.20	7.20							
			GLOBULINS: BETA	20/10/90	11.0	14.0	X	12.90	13.00	14.00							
			GLOBULINS: GAMMA	20/10/90	15.0	22.0	X	22.50	21.40	18.60							
			70-328	F	HB	03/04/92	12.0	16.0	G/100ML	13.80	14.10	14.10					
					HCT	20/10/90	37.0	47.0	X	40.00	43.00	43.00					
					RBC	20/10/90	3.8	5.4	10 ⁶ /HMC	4.80	4.60	4.60					
					HBC	20/10/90	4.0	11.0	10-3/HMC	5.70	4.90	4.90					
					HBC: N	20/10/90	40.0	70.0	X	61.00	58.00	58.00					
					HBC: L	20/10/90	20.0	40.0	X	30.00	26.00	26.00					
HBC: E	20/10/90	1.0			5.0	X	2.00	6.00	6.00								
HBC: B	20/10/90	4.0			8.0	X	7.00	10.00	10.00								
PLATELETS	20/10/90	150.0			550.0	10-3/HMC	280.00	281.00	281.00								
NA+	20/10/90	138.0			155.0	M EQ/L	141.00	142.00	142.00								

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1942

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit									
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52			
1 74-122	F		ALK: PHOSPH.	20/10/90	65.0	306.0	µU/ML	156.00	142.00	147.00	151.00	135.00	144.00			
			BUN	20/10/90	10.0	50.0	MG/DL	40.00	35.00	29.00	30.00	34.00	27.00			
			CREATININE	20/10/90	0.6	1.6	MG/DL	1.10	1.00	0.90	1.00	0.90	0.80			
			URIC ACID	20/10/90	2.4	5.7	MG/DL	4.00	3.90	3.60	3.80	4.20	3.40			
			TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.40	0.50	0.70	0.60	0.70	1.00			
			DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.20	0.30	0.20	0.30	0.50			
			TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.20	7.20	7.20	7.00	7.00	7.10			
			ALBUMINE	20/10/90	3.5	5.0	G/DL	4.36	4.30	4.00	3.90	3.90	3.60			
			TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	181.00	164.00	159.00	163.00	167.00	186.00			
			TRIGLICERIDES	20/10/90	35.0	175.0	MG/DL	193.00	116.00	82.00	94.00	82.00	58.00			
			GLUCOSYL: ALPHA1	20/10/90	4.0	7.0	%	3.10	3.00	3.50	3.50	3.00	3.00			
			GLUCOSYL: ALPHA2	20/10/90	7.0	11.0	%	6.50	8.50	7.60	8.20	7.50	9.00			
			GLUCOSYL: BETA	20/10/90	11.0	14.0	%	11.70	12.30	14.10	13.90	12.80	14.70			
			GLUCOSYL: GAMMA	20/10/90	15.0	22.0	%	16.20	17.00	19.50	20.00	21.00	22.10			
			76-124	F		HB	20/10/90	12.0	16.0	G/100ML	13.80	13.70	13.80	13.60	13.60	14.20
						HTC	20/10/90	37.0	47.0	%	39.00	38.00	38.00	40.00	40.00	41.00
						RBC	20/10/90	3.8	5.4	10 ⁶ /MNC	4.30	4.30	4.50	4.40	4.60	4.80
						MBC	20/10/90	4.0	11.0	10 ³ /MNC	6.10	6.60	6.00	5.70	8.50	7.20
						MBC: N	20/10/90	40.0	70.0	%	58.00	58.00	58.00	62.00	68.00	68.00
						MBC: L	20/10/90	20.0	40.0	%	27.00	28.00	30.00	30.00	26.00	26.00
MBC: E	20/10/90	1.0				5.0	%	6.00	5.00	3.00	2.00	2.00	1.00			
MBC: M	20/10/90	4.0				8.0	%	9.00	9.00	9.00	6.00	4.00	5.00			
MBC: B	20/10/90	0.0				1.0	%	0.00	0.00	0.00	0.00	0.00	0.00			
PLATELETS	20/10/90	150.0				550.0	10 ³ /MNC	237.00	302.00	320.00	309.00	314.00	310.00			
NA+	20/10/90	138.0				155.0	M ER/L	139.00	141.00	142.00	148.00	144.00	143.00			
K+	20/10/90	3.5				5.5	M ER/L	4.20	4.10	4.30	4.20	3.90	4.10			
CL-	20/10/90	98.0				120.0	M ER/L	97.00	96.00	99.00	99.00	97.00	96.00			
CA++	20/10/90	8.5				10.5	MG/DL	9.80	9.50	9.00	9.30	9.40	9.50			
PO4--	20/10/90	3.0				4.5	MG/DL	4.30	3.80	3.60	4.10	4.10	3.80			
SGOT	20/10/90	12.0				40.0	µU/ML	24.00	22.00	24.00	26.00	28.00	26.00			
SGPT	20/10/90	10.0				40.0	µU/ML	28.00	30.00	26.00	30.00	32.00	30.00			
GAMMA-GT	20/10/90	7.0				33.0	µU/ML	32.00	28.00	37.00	41.00	24.00	22.00			
GLUCOSE	20/10/90	70.0				100.0	MG/DL	85.00	87.00	92.00	92.00	104.00	104.00			
ALK. PHOSPH.	20/10/90	65.0				506.0	µU/ML	172.00	238.00	123.00	137.00	146.00	161.00			
BUN	20/10/90	10.0	50.0	MG/DL	27.00	24.00	26.00	28.00	34.00	33.00						
CREATININE	20/10/90	0.6	1.6	MG/DL	1.00	1.10	0.90	0.90	0.90	0.80						
URIC ACID	20/10/90	2.4	5.7	MG/DL	3.80	4.30	4.10	3.60	4.90	4.30						
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.80	0.90	0.70	0.40	0.60	0.70						
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.40	0.50	0.30	0.30	0.30						
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.60	7.30	7.20	7.30	7.40	7.30						
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.00	4.00	4.00	4.20	3.90						

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1945

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit									
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52			
1	76-124	F	TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	170.00	142.00	138.00	134.00	163.00	188.00			
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	95.00	90.00	97.00	88.00	94.00	79.00			
			GLOBULINS: ALPHA1	20/10/90	4.0	7.0	X	4.30	2.80	3.60	3.60	3.20	2.70			
			GLOBULINS: ALPHA2	20/10/90	7.0	11.0	X	10.80	8.30	11.00	10.50	10.00	11.00			
			GLOBULINS: BETA	20/10/90	11.0	16.0	X	6.70	15.70	6.90	12.70	8.90	8.10			
			GLOBULINS: GAMMA	20/10/90	15.0	22.0	X	22.10	21.00	18.80	19.10	21.10	24.80			
			79-126	M	H	HB	20/10/90	14.0	18.0	g/100ml	14.00	13.80	12.80	13.00	13.50	13.80
						HTC	20/10/90	40.0	54.0	X	40.00	40.00	38.00	39.00	38.00	39.00
						RBC	20/10/90	4.3	6.1	10**6/mm	4.50	4.60	4.60	4.60	4.60	4.60
						WBC	20/10/90	4.0	11.0	10-3/MNC	6.30	5.30	5.10	5.00	7.30	5.80
						MBC: N	20/10/90	40.0	70.0	X	57.00	61.00	58.00	61.00	74.00	65.00
						MBC: L	20/10/90	20.0	40.0	X	30.00	28.00	30.00	27.00	22.00	27.00
MBC: E	20/10/90	1.0				5.0	X	5.00	4.00	4.00	3.00	4.00	2.00			
MBC: M	20/10/90	4.0				8.0	X	8.00	7.00	8.00	7.00	10.00	6.00			
MBC: B	20/10/90	0.0				1.0	X	0.00	0.00	0.00	0.00	0.00	0.00			
PLATELETS	20/10/90	150.0				550.0	10-3/MNC	210.00	236.00	316.00	312.00	291.00	275.00			
Na+	20/10/90	138.0				155.0	M EQ/L	141.00	138.00	143.00	142.00	143.00	143.00			
K+	20/10/90	3.5				5.5	M EQ/L	3.90	4.20	4.20	4.30	4.60	4.50			
CL-	20/10/90	98.0	120.0	M EQ/L	95.00	97.00	98.00	99.00	95.00	96.00						
Ca++	20/10/90	8.5	10.5	MG/DL	9.20	9.40	9.40	9.50	9.80	9.20						
PO4-	20/10/90	3.0	4.5	MG/DL	4.30	4.10	3.80	3.80	3.30	4.00						
SGPT	20/10/90	12.0	40.0	IU/ML	29.00	26.00	24.00	26.00	30.00	28.00						
SGOT	20/10/90	10.0	40.0	IU/ML	34.00	28.00	30.00	28.00	34.00	28.00						
GAMMA-GT	20/10/90	11.0	51.0	IU/ML	26.00	31.00	20.00	24.00	26.00	36.00						
GLUCOSE	20/10/90	70.0	100.0	MG/DL	89.00	88.00	102.00	96.00	104.00	89.00						
ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	144.00	216.00	136.00	134.00	137.00	137.00						
BUN	20/10/90	10.0	50.0	MG/DL	31.00	28.00	31.00	32.00	32.00	32.00						
CREATININE	20/10/90	0.6	1.6	MG/DL	1.10	0.90	0.90	0.90	0.80	1.10						
URIC ACID	20/10/90	3.4	7.0	MG/DL	4.30	3.90	3.90	4.10	4.10	4.30						
TOT. BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.40	0.90	0.80	0.70	0.70	0.80						
DIR. BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.40	0.40	0.30	0.40	0.40						
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.00	7.20	7.60	7.40	7.00	7.10						
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	4.10	4.00	4.10	3.80	3.90						
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	163.00	170.00	156.00	172.00	159.00	176.00						
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	84.00	81.00	81.00	91.00	80.00	90.00						
GLOBULINS: ALPHA1	20/10/90	4.0	7.0	X	3.20	3.00	4.40	3.60	2.40	2.50						
GLOBULINS: ALPHA2	20/10/90	7.0	11.0	X	11.40	9.30	8.30	8.10	8.10	10.40						
GLOBULINS: BETA	20/10/90	11.0	14.0	X	9.60	10.40	13.50	13.60	11.00	8.20						
GLOBULINS: GAMMA	20/10/90	15.0	22.0	X	18.90	19.60	22.20	19.50	23.20	24.00						

1046

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

PHARMACIA CNS R&D
 REBONETINE - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Pat. No.	Open-Blind Sex	Laboratory Test	Laboratory Range			Visit							
			Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
180-127	F												
		HB	20/10/90	12.0	16.0	G/100ML	17/04/92						
		HTC	20/10/90	37.0	47.0	%	13.00						
		RBC	20/10/90	3.8	5.4	10 ⁶ /MM ³	4.30						
		RBC: N	20/10/90	4.0	11.0	10 ³ -3/MM ³	5.80						
		RBC: L	20/10/90	40.0	70.0	%	52.00						
		RBC: E	20/10/90	1.0	5.0	%	34.00						
		RBC: M	20/10/90	4.0	8.0	%	6.00						
		RBC: B	20/10/90	0.0	1.0	%	8.00						
		PLATELETS	20/10/90	150.0	550.0	10 ³ -3/MM ³	194.00						
		NA+	20/10/90	138.0	155.0	M EQ/L	139.00						
		K+	20/10/90	3.5	5.5	M EQ/L	3.80						
		CL-	20/10/90	98.0	120.0	M EQ/L	97.00						
		CA++	20/10/90	8.5	10.5	MG/DL	9.70						
		PO4-	20/10/90	3.0	4.5	MG/DL	4.10						
		SGPT	20/10/90	12.0	60.0	IU/ML	22.00						
		SEPT	20/10/90	10.0	60.0	IU/ML	28.00						
		GAMMA-GT	20/10/90	7.0	35.0	IU/ML	36.00						
		GLUCOSE	20/10/90	70.0	100.0	MG/DL	110.00						
		ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	127.00						
		URIC ACID	20/10/90	0.6	1.6	MG/DL	1.00						
		TOT BILIRUBIN	20/10/90	2.4	5.7	MG/DL	3.80						
		DIR BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.80						
		TOT. ALBUMINE	20/10/90	6.0	0.4	MG/DL	0.40						
		TOT. CHOLEST.	20/10/90	3.5	8.0	G/DL	7.30						
		TRIGLYCERIDES	20/10/90	140.0	270.0	MG/DL	176.00						
		GLOBULINS: ALPHA1	20/10/90	35.0	175.0	MG/DL	82.00						
		GLOBULINS: ALPHA2	20/10/90	4.0	7.0	%	3.10						
		GLOBULINS: BETA	20/10/90	11.0	14.0	%	8.20						
		GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	12.10						
			20/10/90	14.0	18.0	G/100ml	14.10		12/06/92		02/10/92	27/11/92	05/02/93
		HB	20/10/90	14.0	18.0	G/100ml	14.10	14.00	14.20	14.00	14.00	13.70	13.80
		HTC	20/10/90	40.0	54.0	%	39.00	38.00	41.00	41.00	41.00	39.00	39.00
		RBC	20/10/90	4.3	6.1	10 ⁶ /mm ³	4.40	4.20	4.50	4.60	4.60	4.70	4.70
		RBC: N	20/10/90	4.0	11.0	10 ³ -3/MM ³	7.00	5.20	5.30	5.20	5.80	6.00	6.00
		RBC: L	20/10/90	40.0	70.0	%	62.00	63.00	61.00	60.00	62.00	63.00	63.00
		RBC: E	20/10/90	20.0	40.0	%	29.00	29.00	28.00	27.00	27.00	26.00	26.00
		RBC: M	20/10/90	1.0	5.0	%	4.00	2.00	3.00	3.00	3.00	2.00	2.00

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOMETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range		Week 10		Week 18		Week 26		Week 34		Week 42		Week 52				
					Date	Min	Max	Unit	Date	Min	Max	Unit	Date	Min	Max	Unit	Date	Min	Max	Unit	Date
1	84-130	M		HBC: M	20/10/90	4.0	8.0	%	5.00	6.00	7.00	9.00	9.00	9.00	9.00	7.00	7.00				
				WBC: B	20/10/90	0.0	1.0	%	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00		
				PLATELETS	20/10/90	150.0	550.0	10 ³ /MM ³	237.00	195.00	305.00	310.00	310.00	305.00	275.00	275.00	275.00	264.00	264.00		
				NA+	20/10/90	138.0	155.0	M EQ/L	139.00	138.00	142.00	141.00	141.00	142.00	142.00	141.00	142.00	141.00	141.00		
				K+	20/10/90	3.5	5.5	M EQ/L	4.10	4.20	4.30	4.30	4.30	4.20	4.30	4.30	4.30	4.30	4.30		
				CL-	20/10/90	98.0	120.0	M EQ/L	96.00	92.00	95.00	98.00	98.00	95.00	97.00	97.00	97.00	97.00	97.00		
				CA++	20/10/90	3.5	10.5	MG/DL	9.40	9.70	9.80	9.50	9.50	9.80	9.40	9.40	9.40	9.00	9.00		
				PO4--	20/10/90	3.0	4.5	MG/DL	4.10	3.60	3.00	3.20	3.00	3.00	3.20	3.20	3.60	3.60	3.60		
				SGPT	20/10/90	12.0	40.0	IU/ML	29.00	26.00	26.00	26.00	26.00	26.00	26.00	26.00	26.00	26.00	28.00	28.00	
				GAMMA-GT	20/10/90	10.0	40.0	IU/ML	32.00	29.00	30.00	34.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	
				GLUCOSE	20/10/90	70.0	51.0	MG/DL	27.00	34.00	18.00	19.00	18.00	18.00	19.00	19.00	19.00	22.00	22.00		
				ALK. PHOSPH.	20/10/90	65.0	100.0	MG/DL	84.00	88.00	98.00	96.00	94.00	94.00	94.00	94.00	94.00	94.00	94.00		
				UREA	20/10/90	10.0	30.0	MG/DL	123.00	161.00	141.00	137.00	137.00	141.00	143.00	143.00	143.00	137.00	137.00		
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	1.00	0.80	0.90	0.80	0.80	0.90	0.90	0.90	0.90	0.90		
				URIC ACID	20/10/90	3.4	7.0	MG/DL	3.70	3.20	3.20	3.20	3.20	3.20	3.20	3.20	3.20	3.20	3.20		
				TOT. BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.80	0.70	0.60	0.60	0.60	0.60	0.60	0.60	0.60	0.60	0.60		
				DIR. BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.40	0.30	0.30	0.30	0.30	0.30	0.30	0.30	0.30	0.30		
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.90	7.30	7.40	7.20	7.20	7.40	7.20	7.20	7.20	7.20	7.20		
				ALBUMINE	20/10/90	3.5	5.0	G/DL	3.80	4.10	3.90	4.00	3.90	4.00	4.00	4.00	4.00	4.00	4.00		
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	170.00	179.00	162.00	153.00	153.00	162.00	162.00	153.00	153.00	153.00	156.00		
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	116.00	108.00	94.00	91.00	91.00	94.00	94.00	88.00	88.00	88.00	98.00		
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	2.00	2.60	2.60	3.00	3.00	2.60	3.00	3.00	3.00	3.00	3.00		
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	10.40	12.10	10.20	11.20	11.20	10.20	11.20	11.20	11.20	11.20	10.50		
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	9.50	9.70	8.70	9.30	9.30	8.70	9.30	9.30	9.30	9.30	8.20		
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	20.30	21.20	16.50	16.50	16.50	16.50	16.50	16.50	16.50	16.50	22.70		
				85-131	M		Hb	20/10/90	14.0	18.0	g/100ml	13.90	13.50	13.00	13.00	13.00	13.00	13.00	13.00	13.80	13.80
							HTC	20/10/90	40.0	54.0	%	40.00	38.00	39.00	39.00	39.00	39.00	40.00	40.00	39.00	39.00
							RBC	20/10/90	4.3	6.1	10 ⁶ /mm ³	4.50	4.70	4.40	4.50	4.50	4.40	4.50	4.50	4.60	4.60
							HBC: N	20/10/90	4.0	11.0	10 ³ /MM ³	7.30	5.30	4.90	6.10	6.10	4.90	6.30	6.30	6.00	6.00
							HBC: L	20/10/90	40.0	70.0	%	58.00	60.00	58.00	61.00	61.00	58.00	61.00	61.00	66.00	66.00
							HBC: E	20/10/90	20.0	40.0	%	27.00	28.00	30.00	28.00	28.00	30.00	28.00	28.00	25.00	25.00
							HBC: M	20/10/90	1.0	5.0	%	7.00	5.00	9.00	2.00	2.00	9.00	2.00	2.00	2.00	2.00
							HBC: H	20/10/90	4.0	8.0	%	8.00	7.00	9.00	10.00	10.00	9.00	9.00	9.00	7.00	7.00
HBC: B	20/10/90	0.0	1.0				%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
PLATELETS	20/10/90	150.0	550.0				10 ³ /MM ³	294.00	241.00	280.00	275.00	275.00	280.00	275.00	275.00	275.00	290.00				
NA+	20/10/90	138.0	155.0				M EQ/L	140.00	142.00	142.00	142.00	142.00	142.00	142.00	142.00	141.00	140.00				
K+	20/10/90	3.5	5.5				M EQ/L	3.90	3.70	4.20	4.20	4.20	4.20	4.20	4.20	4.20	4.30				
CL-	20/10/90	98.0	120.0				M EQ/L	99.00	90.00	97.00	100.00	100.00	97.00	96.00	96.00	98.00	98.00				
CA++	20/10/90	8.5	10.5				MG/DL	10.20	9.50	9.50	9.50	9.50	9.50	9.50	9.50	9.50	9.60				
PO4--	20/10/90	3.0	4.5				MG/DL	3.70	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00				

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
1	85-131	M		SGPT	20/10/99	12.0	40.0	NU/HL	30.00	32.00	32.00	30.00	32.00	32.00	32.00
				SGPT	20/10/99	10.0	40.0	NU/HL	34.00	36.00	36.00	32.00	32.00	36.00	36.00
1	85-131	M		GAMMA-GT	20/10/99	11.0	51.0	NU/HL	26.00	24.00	20.00	22.00	22.00	27.00	27.00
				GLUCOSE	20/10/99	70.0	100.0	MG/DL	102.00	94.00	106.00	90.00	106.00	108.00	108.00
1	85-131	M		ALK. PHOSPH.	20/10/99	65.0	306.0	NU/HL	137.00	116.00	132.00	129.00	137.00	141.00	141.00
				BUN	20/10/99	10.0	50.0	MG/DL	28.00	30.00	28.00	32.00	30.00	30.00	30.00
1	85-131	M		CREATININE	20/10/99	0.6	1.6	MG/DL	0.90	0.90	0.90	1.00	1.00	0.80	0.80
				URIC ACID	20/10/99	3.4	7.0	MG/DL	3.70	3.50	3.60	3.40	3.40	4.30	4.30
1	85-131	M		TOT. BILIRUBIN	20/10/99	0.2	1.0	MG/DL	0.80	0.40	0.40	0.60	0.60	0.90	0.90
				DIR. BILIRUBIN	20/10/99	0.0	0.4	MG/DL	0.40	0.30	0.20	0.30	0.40	0.40	0.40
1	85-131	M		TOT. PROTEINS	20/10/99	6.0	8.0	G/DL	7.00	6.80	7.30	7.50	7.10	7.00	7.00
				ALBUMINE	20/10/99	3.5	5.0	G/DL	3.90	3.90	4.00	4.00	4.00	3.90	3.90
1	85-131	M		TOT. CHOLEST.	20/10/99	140.0	270.0	MG/DL	191.00	141.00	170.00	183.00	183.00	174.00	174.00
				TRIGLYCERIDES	20/10/99	35.0	175.0	MG/DL	102.00	92.00	88.00	72.00	96.00	90.00	90.00
1	85-131	M		GLOBULINS: ALPHA1	20/10/99	4.0	7.0	%	4.00	3.20	3.60	3.50	2.80	2.80	2.80
				GLOBULINS: ALPHA2	20/10/99	7.0	11.0	%	8.20	8.20	8.20	10.20	12.30	13.20	13.20
1	85-131	M		GLOBULINS: BETA	20/10/99	11.0	14.0	%	12.60	8.70	12.50	11.80	7.50	7.50	7.50
				GLOBULINS: GAMMA	20/10/99	15.0	22.0	%	19.90	21.50	18.60	18.50	21.10	20.80	20.80
1	91-135	F		HR	20/10/99	12.0	16.0	G/100ML	22/04/92	16/06/92	11/08/92	06/10/92	01/12/92	09/02/93	
				HTC	20/10/99	37.0	47.0	%	40.00	40.00	37.00	38.00	41.00	41.00	38.00
1	91-135	F		RBC	20/10/99	3.8	5.4	10 ⁶ -6/MHC	4.80	4.60	4.30	4.50	4.70	4.60	4.60
				MBC: N	20/10/99	4.0	11.0	10 ³ -3/MHC	5.70	5.80	6.20	6.70	5.60	6.60	6.60
1	91-135	F		MBC: L	20/10/99	40.0	70.0	%	60.00	61.00	64.00	61.00	62.00	59.00	59.00
				MBC: E	20/10/99	20.0	40.0	%	31.00	32.00	25.00	28.00	28.00	30.00	30.00
1	91-135	F		MBC: M	20/10/99	1.0	5.0	%	3.00	2.00	3.00	3.00	2.00	2.00	2.00
				MBC: B	20/10/99	4.0	8.0	%	6.00	5.00	8.00	8.00	8.00	9.00	9.00
1	91-135	F		PLATELETS	20/10/99	150.0	550.0	10 ³ -3/MHC	260.00	210.00	304.00	315.00	290.00	286.00	286.00
				K+	20/10/99	138.0	155.0	M EQ/L	141.00	139.00	143.00	140.00	143.00	143.00	143.00
1	91-135	F		CL-	20/10/99	3.5	5.5	M EQ/L	3.70	4.10	4.20	4.30	4.80	4.20	4.20
				PO4-	20/10/99	3.0	4.5	MG/DL	3.60	3.80	3.20	3.50	3.50	3.50	3.50
1	91-135	F		SGPT	20/10/99	12.0	40.0	NU/HL	28.00	28.00	28.00	28.00	28.00	28.00	28.00
				GAMMA-GT	20/10/99	10.0	40.0	NU/HL	32.00	34.00	32.00	34.00	34.00	32.00	32.00
1	91-135	F		GLUCOSE	20/10/99	7.0	33.0	NU/HL	40.00	38.00	39.00	24.00	25.00	26.00	26.00
				ALK. PHOSPH.	20/10/99	65.0	306.0	NU/HL	163.00	161.00	125.00	150.00	100.00	100.00	100.00
1	91-135	F		BUN	20/10/99	10.0	50.0	MG/DL	28.00	28.00	31.00	32.00	30.00	32.00	32.00
				CREATININE	20/10/99	0.6	1.6	MG/DL	1.10	1.00	0.80	0.90	0.90	1.10	1.10
1	91-135	F		URIC ACID	20/10/99	2.4	5.7	MG/DL	3.70	3.70	3.50	3.50	3.70	3.70	3.70

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit										
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52				
1	91-135	F		TOT BILIRUBIN	20/10/90	0.2	1.0	NG/DL	0.90	0.90	0.60	0.70	0.90	0.80				
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.40	0.20	0.30	0.40	0.40				
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.30	7.00	7.00	7.10	6.90	7.20				
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.10	3.90	3.90	3.80	3.90				
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	177.00	149.00	186.00	167.00	182.00	186.00				
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	108.00	108.00	105.00	113.00	99.00	84.00				
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	3.60	3.00	2.60	3.50	2.50	3.10				
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	8.30	10.20	10.40	9.80	8.70	8.00				
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	12.50	9.50	11.20	13.10	11.00	16.00				
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	23.00	17.90	17.90	19.60	22.70	18.70				
				93-136	F			HB	20/10/90	12.0	16.0	G/100ML	13.80	13.20	13.00	13.20	14.20	14.20
								HTC	20/10/90	37.0	47.0	%	39.00	38.00	39.00	39.00	41.00	40.00
								RBC	20/10/90	3.8	5.4	10 ⁶ /MNC	4.40	4.40	4.40	4.60	4.80	4.70
								MBC: N	20/10/90	4.0	11.0	10 ³ /MNC	6.10	6.10	5.20	6.10	5.00	5.80
MBC: L	20/10/90	40.0	70.0					%	59.00	58.00	59.00	58.00	62.00	62.00				
MBC: E	20/10/90	20.0	40.0					%	32.00	33.00	27.00	29.00	28.00	29.00				
MBC: B	20/10/90	1.0	5.0					%	3.00	3.00	4.00	5.00	2.00	2.00				
MBC: B	20/10/90	4.0	8.0					%	6.00	6.00	9.00	8.00	8.00	7.00				
PLATELETS	20/10/90	150.0	550.0					10 ³ /MNC	199.00	187.00	187.00	285.00	260.00	300.00				
NA+	20/10/90	138.0	155.0					M EQ/L	138.00	138.00	143.00	140.00	141.00	143.00				
K+	20/10/90	3.5	5.5					M EQ/L	4.20	4.20	4.20	4.20	4.20	4.50				
CL-	20/10/90	98.0	120.0					M EQ/L	103.00	95.00	97.00	99.00	92.00	95.00				
CA++	20/10/90	8.5	10.5					MG/DL	9.60	10.10	9.00	9.30	9.60	9.20				
PO4--	20/10/90	3.0	4.5					MG/DL	3.80	4.00	3.60	4.10	3.60	4.00				
SGPT	20/10/90	12.0	40.0	U/L	26.00	24.00	28.00	28.00	28.00	27.00								
GAMMA-GT	20/10/90	7.0	33.0	U/L	22.00	28.00	34.00	36.00	34.00	32.00								
GLUCOSE	20/10/90	70.0	100.0	MG/DL	88.00	90.00	25.00	22.00	40.00	42.00								
ALK. PHOSPH.	20/10/90	65.0	306.0	U/L	161.00	121.00	174.00	102.00	92.00	107.00								
UREA	20/10/90	10.0	50.0	MG/DL	28.00	29.00	32.00	26.00	32.00	28.00								
CREATININE	20/10/90	0.6	1.5	MG/DL	0.80	0.80	0.90	0.90	1.00	0.90								
URIC ACID	20/10/90	2.4	5.7	MG/DL	3.60	3.70	3.50	3.60	4.60	4.10								
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	1.00	0.60	0.70	0.40	0.90	0.60								
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.50	0.70	0.30	0.20	0.40	0.30								
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.00	7.00	7.00	7.20	7.00	7.10								
ALBUMINE	20/10/90	3.5	5.0	G/DL	3.90	3.90	3.90	4.60	3.90	3.90								
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	160.00	152.00	160.00	198.00	172.00	170.00								
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	101.00	89.00	93.00	90.00	82.00	82.00								
GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	3.00	2.70	3.50	4.20	2.90	2.70								
GLOBULINS: BETA	20/10/90	7.0	11.0	%	10.20	8.90	8.90	8.70	8.50	9.40								

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1950

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBORETTINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range		Week 10		Week 18		Week 26		Week 34		Week 42		Week 52		
					Date	Min	Max	Unit	Date	Min	Max	Unit	Date	Min	Max	Unit	Date	Min	Max
1	93-136	F		GLORULINS: BETA	20/10/90	11.0	14.0	X	8.10	9.50	14.10	14.70	14.70	12.70	11.00	11.00			
				GLORULINS: GAMMA	20/10/90	15.0	22.0	X	24.00	22.30	20.00	20.20	20.20	20.20	20.20	20.20	20.20	20.20	20.20
94-137	M			HB	20/10/90	14.0	18.0	g/100ml	13.60	13.60	13.20	13.30	13.30	13.60	13.60	13.60	13.90	13.90	
				HTC	20/10/90	40.0	54.0	X	40.00	39.00	39.00	39.00	39.00	38.00	38.00	40.00	40.00	40.00	40.00
				RBC	20/10/90	4.3	6.1	10**6/mm	4.80	4.80	4.40	4.50	4.50	4.70	4.80	4.80	4.80	4.80	4.80
				MBC: N	20/10/90	4.0	11.0	10-3/MNC	6.90	6.10	5.00	6.20	6.20	8.40	8.40	9.00	9.00	9.00	9.00
				MBC: L	20/10/90	40.0	70.0	X	55.00	60.00	61.00	66.00	66.00	60.00	60.00	64.00	64.00	64.00	64.00
				MBC: E	20/10/90	20.0	40.0	X	32.00	32.00	29.00	29.00	29.00	28.00	28.00	28.00	28.00	28.00	28.00
				MBC: H	20/10/90	4.0	5.0	X	5.00	5.00	1.00	2.00	2.00	3.00	3.00	1.00	1.00	1.00	1.00
				MBC: B	20/10/90	0.0	1.0	X	8.00	5.00	9.00	4.00	4.00	8.00	8.00	7.00	7.00	7.00	7.00
				PLATELETS	20/10/90	150.0	550.0	10-3/MNC	293.00	291.00	305.00	257.00	257.00	264.00	264.00	266.00	266.00	266.00	266.00
				NA+	20/10/90	138.0	155.0	H EQ/L	142.00	137.00	142.00	159.00	159.00	141.00	141.00	143.00	143.00	143.00	143.00
				K+	20/10/90	3.5	5.5	H EQ/L	9.50	9.60	4.30	4.20	4.20	95.00	95.00	98.00	98.00	98.00	
				CL-	20/10/90	98.0	120.0	H EQ/L	103.00	103.00	97.00	97.00	97.00	9.50	9.50	9.50	9.50	9.50	9.50
				PO4-	20/10/90	3.0	4.5	MG/DL	4.00	4.20	4.00	4.00	4.00	3.60	3.60	3.60	3.60	3.60	3.60
				SGOT	20/10/90	12.0	40.0	NU/ML	28.00	28.00	26.00	26.00	26.00	28.00	28.00	28.00	28.00	28.00	28.00
				GAMMA-GT	20/10/90	11.0	51.0	NU/ML	32.00	32.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	86.00	86.00	97.00	97.00	97.00	22.00	22.00	22.00	24.00	24.00	24.00
				ALK. PHOSPH.	20/10/90	65.0	306.0	NU/ML	179.00	179.00	140.00	140.00	140.00	156.00	156.00	156.00	156.00	156.00	156.00
				BUN	20/10/90	10.0	50.0	MG/DL	28.00	28.00	31.00	31.00	31.00	28.00	28.00	28.00	29.00	29.00	29.00
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	0.90	0.90	0.90	0.90	1.10	1.10	1.10	1.10	1.10	1.10
				URIC ACID	20/10/90	3.4	7.0	MG/DL	4.10	3.70	3.60	3.60	3.60	3.60	3.60	3.60	3.60	3.60	3.60
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.70	0.80	0.40	0.40	0.40	0.70	0.70	0.60	0.60	0.60	0.60
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.40	0.20	0.20	0.20	0.30	0.30	0.30	0.30	0.30	0.30
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.20	7.20	6.90	7.10	7.10	7.00	7.00	7.00	7.00	7.00	7.00
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	4.00	3.80	3.80	3.80	4.00	4.00	3.90	3.90	3.90	3.90
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	155.00	142.00	156.00	139.00	139.00	156.00	156.00	143.00	143.00	143.00	143.00
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	86.00	95.00	82.00	82.00	82.00	88.00	88.00	72.00	72.00	72.00	72.00
				GLORULINS: ALPHA1	20/10/90	4.0	7.0	X	3.20	3.00	3.00	3.50	3.50	3.00	3.00	4.10	4.10	4.10	
				GLORULINS: ALPHA2	20/10/90	7.0	11.0	X	7.60	8.60	4.90	8.60	8.60	8.20	8.00	8.00	8.00	8.00	8.00
				GLORULINS: BETA	20/10/90	11.0	14.0	X	9.80	9.10	12.60	14.10	14.10	11.50	11.50	11.00	11.00	11.00	
				GLORULINS: GAMMA	20/10/90	15.0	22.0	X	22.50	23.00	17.70	22.00	22.00	21.60	21.60	22.00	22.00	22.00	22.00
97-140	M			HB	20/10/90	14.0	18.0	g/100ml	13.10	13.80	13.50	13.00	13.00	14.50	14.50	14.60	14.60	14.60	
				HTC	20/10/90	40.0	54.0	X	37.00	40.00	42.00	41.00	41.00	42.00	42.00	42.00	42.00	42.00	42.00
				RBC	20/10/90	4.3	6.1	10**6/mm	4.40	4.70	4.60	4.60	4.60	4.90	4.90	4.90	4.90	4.90	

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit									
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52			
1	97-140	M	HBC	20/10/90	4.0	11.0	10-3/HMC	5.60	5.80	6.30	6.40	5.40	5.60			
			HBC: N	20/10/90	40.0	70.0	Z	62.00	60.00	58.00	57.00	63.00	66.00			
			HBC: L	20/10/90	20.0	40.0	Z	27.00	32.00	30.00	30.00	29.00	25.00			
			HBC: E	20/10/90	1.0	5.0	Z	6.00	4.00	3.00	3.00	2.00	3.00			
			HBC: H	20/10/90	4.0	8.0	Z	5.00	4.00	8.00	10.00	7.00	6.00			
			HBC: B	20/10/90	0.0	1.0	Z	0.00	0.00	0.00	1.00	0.00	0.00			
			PLATELETS	20/10/90	150.0	550.0	10-3/HMC	310.00	320.00	295.00	274.00	280.00	266.00			
			NA+	20/10/90	138.0	155.0	M ER/L	141.00	142.00	141.00	140.00	143.00	143.00			
			CA++	20/10/90	98.0	120.0	M ER/L	98.00	98.00	97.00	96.00	97.00	98.00			
			PO4--	20/10/90	3.0	4.5	MG/DL	3.90	4.10	3.90	3.40	3.80	4.80			
			SGPT	20/10/90	12.0	40.0	U/L	26.00	28.00	28.00	20.00	29.00	26.00			
			GAMMA-GT	20/10/90	11.0	40.0	U/L	28.00	32.00	36.00	25.00	32.00	30.00			
			GLUCOSE	20/10/90	70.0	51.0	MG/DL	23.00	27.00	22.00	15.00	25.00	24.00			
			ALK. PHOSPH.	20/10/90	65.0	306.0	RU/AL	121.00	89.00	89.00	94.00	106.00	100.00			
			CREATININE	20/10/90	10.0	50.0	MG/DL	27.00	23.00	31.00	28.00	29.00	28.00			
			TOT BILIRUBIN	20/10/90	0.6	1.6	MG/DL	1.00	0.80	0.90	0.90	0.90	1.00			
			DIR BILIRUBIN	20/10/90	0.2	1.0	MG/DL	3.80	4.00	3.80	3.40	3.60	4.30			
			TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	0.40	0.70	0.50	0.50	0.40	0.70			
			ALBUMINE	20/10/90	3.5	5.0	G/DL	7.30	7.20	7.20	7.20	7.30	7.10			
			TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	4.00	4.00	194.00	186.00	192.00	169.00			
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	66.00	71.00	86.00	74.00	69.00	86.00			
			GLOBULINS: ALPHA1	20/10/90	4.0	7.0	Z	2.80	2.70	4.20	4.10	4.00	4.00			
			GLOBULINS: ALPHA2	20/10/90	7.0	11.0	Z	10.40	7.80	9.20	9.00	8.60	7.50			
			GLOBULINS: BETA	20/10/90	11.0	14.0	Z	11.90	11.90	14.10	12.60	12.30	13.10			
			GLOBULINS: GAMMA	20/10/90	15.0	22.0	Z	17.60	19.20	20.80	21.30	20.30	20.50			
			100-142	M	HB	20/10/90	14.0	18.0	g/100ml	13.00	14.10	13.80	14.20	13.60	14.20	
					HCT	20/10/90	40.0	54.0	Z	39.00	40.00	39.00	41.00	38.00	41.00	
					RBC	20/10/90	4.3	6.1	10**6/mm	4.50	4.60	4.40	4.60	4.70	4.80	
					HBC	20/10/90	4.0	11.0	10-3/HMC	6.50	4.90	7.20	6.80	4.90	4.90	
					HBC: N	20/10/90	40.0	70.0	Z	61.00	58.00	60.00	61.00	60.00	62.00	
HBC: L	20/10/90	20.0			40.0	Z	30.00	30.00	28.00	28.00	30.00	30.00				
HBC: E	20/10/90	1.0			5.0	Z	4.00	4.00	3.00	2.00	3.00	2.00				
HBC: H	20/10/90	4.0			8.0	Z	7.00	8.00	9.00	9.00	9.00	6.00				
HBC: B	20/10/90	0.0			1.0	Z	0.00	0.00	0.00	0.00	0.00	0.00				
PLATELETS	20/10/90	150.0			550.0	10-3/HMC	266.00	244.00	310.00	284.00	294.00	290.00				
NA+	20/10/90	138.0			155.0	M ER/L	142.00	139.00	143.00	143.00	141.00	142.00				

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit								
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52		
1	100-142	M	K+	20/10/90	3.5	5.5	M	EQ/L	4.00	4.20	4.40	4.40	4.40	4.20	4.40
			CL-	20/10/90	98.0	120.0	M	EQ/L	96.00	93.00	97.00	100.00	98.00	98.00	96.00
			CA++	20/10/90	8.5	10.5	MG/DL	9.20	9.70	9.50	9.70	9.50	9.70	9.50	9.30
			PO4--	20/10/90	3.0	4.5	MG/DL	4.00	4.10	4.00	4.00	4.00	4.30	4.30	3.80
			SGOT	20/10/90	12.0	40.0	MG/DL	20.00	24.00	20.00	30.00	29.00	29.00	29.00	26.00
			SGPT	20/10/90	10.0	40.0	MG/DL	22.00	28.00	28.00	34.00	34.00	34.00	34.00	30.00
			GAMMA-GT	20/10/90	11.0	51.0	MG/DL	30.00	25.00	19.00	24.00	24.00	24.00	24.00	24.00
			GLUCOSE	20/10/90	70.0	100.0	MG/DL	90.00	89.00	95.00	108.00	101.00	101.00	102.00	
			ALK. PHOSPH.	20/10/90	65.0	306.0	MG/DL	141.00	117.00	126.00	151.00	151.00	151.00	151.00	
			BUN	20/10/90	10.0	50.0	MG/DL	24.00	28.00	31.00	32.00	29.00	30.00	30.00	
			CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	0.80	1.00	0.80	1.00	0.90	0.90	
			URIC ACID	20/10/90	3.4	7.0	MG/DL	3.80	3.60	5.20	5.10	4.10	4.10	3.90	
			TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.70	0.50	0.60	0.60	0.70	0.70	1.00	
			DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.20	0.30	0.30	0.30	0.30	0.50	
			TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.40	7.30	7.20	7.30	7.20	7.20	7.20	
			ALBUMINE	20/10/90	3.5	5.0	G/DL	4.00	4.00	3.90	3.90	4.00	4.00	4.20	
			TOT. CHOLEST.	20/10/90	160.0	270.0	MG/DL	242.00	198.00	180.00	216.00	193.00	193.00	156.00	
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	52.00	61.00	76.00	84.00	76.00	76.00	77.00	
			GLOBULINS: ALPHA1	20/10/90	7.0	17.0	%	3.00	3.00	3.00	4.10	3.00	3.00	2.10	
			GLOBULINS: ALPHA2	20/10/90	1.0	11.0	%	8.60	7.60	5.40	9.50	8.50	9.00	8.50	
			GLOBULINS: BETA	20/10/90	11.0	14.0	%	18.50	15.30	14.10	12.80	13.10	13.10	12.20	
			GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	22.10	19.10	19.70	19.90	18.50	18.50	18.50	
19	51	F	HB	20/10/90	12.0	16.0	G/100ML	13.20	23/06/92	19/08/92	14/10/92	09/12/92	17/02/93		
			HTC	20/10/90	37.0	47.0	%	40.00	13.30	13.00	14.20	13.60	13.80		
			RBC	20/10/90	3.8	5.4	10 ⁶ /MM ³	4.60	4.00	38.00	42.00	36.00	37.00		
			HBC	20/10/90	4.0	11.0	10 ³ /MM ³	4.60	4.60	4.30	4.90	4.30	4.10		
			HBC: N	20/10/90	40.0	70.0	%	59.00	63.00	62.00	61.00	61.00	61.00		
			HBC: L	20/10/90	20.0	40.0	%	30.00	28.00	30.00	29.00	26.00	26.00		
			HBC: E	20/10/90	1.0	5.0	%	4.00	2.00	2.00	2.00	3.00	4.00		
			HBC: B	20/10/90	4.0	8.0	%	7.00	7.00	6.00	8.00	10.00	9.00		
			PLATELETS	20/10/90	150.0	550.0	10 ³ /MM ³	231.00	246.00	314.00	324.00	264.00	271.00		
			NA+	20/10/90	138.0	155.0	M	EQ/L	139.00	142.00	143.00	143.00	141.00		
			CL-	20/10/90	3.5	5.5	M	EQ/L	4.20	4.20	4.50	4.40	4.40		
			CA++	20/10/90	8.5	10.5	MG/DL	9.50	103.00	98.00	97.00	96.00	93.00		
			PO4--	20/10/90	3.0	4.5	MG/DL	4.10	4.00	4.10	5.00	4.40	5.20		
			SGOT	20/10/90	12.0	40.0	MG/DL	23.00	26.00	26.00	32.00	26.00	24.00		
			SGPT	20/10/90	10.0	40.0	MG/DL	28.00	30.00	32.00	36.00	30.00	30.00		
			GAMMA-GT	20/10/90	7.0	33.0	MG/DL	18.00	18.00	18.00	28.00	20.00	22.00		
			GLUCOSE	20/10/90	70.0	100.0	MG/DL	87.00	93.00	95.00	87.00	89.00	91.00		

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit									
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52			
1 104-144	F		ALK. PHOSPH.	20/10/90	65.0	306.0	NU/HL	123.00	210.00	155.00	126.00	152.00	143.00			
			BUN	20/10/90	10.0	50.0	MG/DL	26.00	27.00	31.00	30.00	32.00	30.00			
			CREATININE	20/10/90	0.6	1.6	MG/DL	1.00	0.90	1.00	1.00	0.80	1.10			
			URIC ACID	20/10/90	2.4	5.7	MG/DL	3.60	4.20	4.20	5.20	4.40	5.00			
			TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.90	0.80	0.70	0.90	0.60	0.70			
			DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.40	0.30	0.40	0.30	0.30			
			TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.90	7.20	7.20	7.00	7.00	7.00			
			ALBUMINE	20/10/90	3.5	5.0	G/DL	3.80	4.10	4.00	3.80	4.00	3.90			
			TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	139.00	135.00	178.00	236.00	180.00	185.00			
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	91.00	92.00	66.00	94.00	65.00	79.00			
			GLORULINS: ALPHA1	20/10/90	4.0	7.0	%	2.80	3.00	4.10	4.10	3.50	3.20			
			GLORULINS: ALPHA2	20/10/90	7.0	11.0	%	8.30	8.40	12.00	9.30	7.90	7.50			
			GLORULINS: BETA	20/10/90	11.0	14.0	%	15.10	12.50	9.30	14.20	13.20	14.00			
			GLORULINS: GAMMA	20/10/90	15.0	22.0	%	20.40	21.00	17.50	20.00	18.30	19.60			
			105-145	F		HB	20/10/90	12.0	16.0	G/100ML	15.60	23.06/92	19/08/92	14/10/92	09/12/92	17/02/93
						HIC	20/10/90	37.0	47.0	%	40.00	38.00	42.00	39.00	33.60	38.60
						RBC	20/10/90	3.8	5.4	10 ⁶ /MNC	4.40	4.40	4.90	4.50	4.20	5.50
						MBC	20/10/90	4.0	11.0	10 ³ /MNC	6.10	5.50	6.10	6.30	6.00	6.00
						MBC: N	20/10/90	40.0	70.0	%	62.00	61.00	62.00	64.00	62.00	62.00
						MBC: L	20/10/90	20.0	40.0	%	27.00	27.00	29.00	28.00	25.00	28.00
MBC: E	20/10/90	1.0				5.0	%	3.00	4.00	2.00	2.00	5.00	2.00			
MBC: M	20/10/90	4.0				8.0	%	6.00	8.00	7.00	6.00	8.00	8.00			
MBC: B	20/10/90	0.0				1.0	%	0.00	0.00	0.00	0.00	0.00	0.00			
PLATELETS	20/10/90	150.0				550.0	10 ³ /MNC	263.00	212.00	315.00	304.00	280.00	295.00			
NA+	20/10/90	138.0				155.0	M EQ/L	141.00	139.00	143.00	145.00	140.00	142.00			
CL-	20/10/90	3.5				5.5	M EQ/L	4.20	4.20	4.40	4.30	4.30	4.30			
CA++	20/10/90	8.5				10.5	MG/DL	9.10	9.50	9.70	9.70	9.50	9.50			
PO4-	20/10/90	3.0				4.5	MG/DL	4.20	4.10	4.10	4.10	4.20	3.70			
SCPT	20/10/90	12.0				40.0	NU/HL	24.00	26.00	26.00	26.00	24.00	20.00			
GAMMA-GT	20/10/90	10.0				40.0	NU/HL	30.00	28.00	30.00	30.00	28.00	24.00			
GLUCOSE	20/10/90	7.0				33.0	MG/DL	28.00	19.00	22.00	20.00	20.00	18.00			
ALK. PHOSPH.	20/10/90	65.0				306.0	NU/HL	136.00	210.00	105.00	95.00	97.00	90.00			
BUN	20/10/90	10.0				50.0	MG/DL	26.00	27.00	30.00	28.00	32.00	29.00			
CREATININE	20/10/90	0.6				1.6	MG/DL	0.90	0.90	0.90	0.90	0.80	1.10			
URIC ACID	20/10/90	2.4	5.7	MG/DL	4.20	4.20	4.20	4.20	4.40	3.60						
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.80	0.80	0.60	0.50	1.00	0.90						
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.40	0.30	0.50	0.40	0.40						
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.50	7.50	7.50	7.50	6.90	6.90						
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.20	4.00	4.20	3.90	3.80						

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOMETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range		Visit										
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52			
1 105-145	F		TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	173.00	135.00	161.00	184.00	166.00	169.00			
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	62.00	60.00	86.00	80.00	74.00	83.00			
			GLOBULINS: ALPHA1	20/10/90	4.0	7.0	X	2.50	2.30	3.80	4.10	2.70	3.00			
			GLOBULINS: ALPHA2	20/10/90	7.0	11.0	X	8.10	8.50	9.40	7.50	9.00	7.40			
			GLOBULINS: BETA	20/10/90	11.0	14.0	X	13.00	13.60	13.10	14.20	11.50	12.80			
			GLOBULINS: GAMMA	20/10/90	15.0	22.0	X	22.10	22.00	20.50	19.80	20.30	21.70			
			106-146	M		HB	20/10/90	14.0	18.0	g/100ml	12.90	12.50	13.00	13.20	13.90	14.10
						HTC	20/10/90	40.0	54.0	X	36.00	36.00	38.00	38.00	41.00	40.00
						RBC	20/10/90	4.3	6.1	10**6/mm	4.30	4.40	4.30	4.50	4.80	4.80
						HBC	20/10/90	4.0	11.0	10-3/MNC	4.90	4.80	7.40	7.00	8.40	6.50
						HBC: N	20/10/90	40.0	70.0	X	60.00	58.00	63.00	63.00	64.00	61.00
						HBC: L	20/10/90	20.0	40.0	X	29.00	30.00	28.00	25.00	26.00	30.00
						HBC: E	20/10/90	1.0	5.0	X	5.00	5.00	3.00	4.00	2.00	2.00
						HBC: M	20/10/90	4.0	8.0	X	6.00	7.00	6.00	6.00	6.00	7.00
HBC: B	20/10/90	0.0				1.0	X	0.00	0.00	0.00	0.00	0.00	0.00			
PLATELETS	20/10/90	150.0				550.0	10-3/MNC	237.00	195.00	285.00	290.00	279.00	290.00			
NA+	20/10/90	138.0				155.0	M EQ/L	140.00	142.00	145.00	143.00	142.00	142.00			
K+	20/10/90	3.5				5.5	M EQ/L	4.30	4.00	4.40	4.10	4.30	4.30			
CL-	20/10/90	98.0				120.0	M EQ/L	96.00	102.00	98.00	98.00	97.00	97.00			
CA++	20/10/90	8.5				10.5	MG/DL	9.10	10.10	9.70	9.50	9.00	9.50			
PO4--	20/10/90	3.0	4.5	MG/DL	4.00	3.50	4.10	4.10	4.20	4.10						
SGOT	20/10/90	12.0	40.0	NU/ML	32.00	22.00	22.00	28.00	20.00	18.00						
SGPT	20/10/90	10.0	40.0	NU/ML	38.00	28.00	20.00	34.00	26.00	24.00						
GAMMA-GT	20/10/90	11.0	51.0	NU/ML	26.00	30.00	16.00	24.00	18.00	16.00						
GLUCOSE	20/10/90	70.0	400.0	MG/DL	107.00	99.00	96.00	90.00	109.00	88.00						
ALK. PHOSPH.	20/10/90	65.0	306.0	NU/ML	166.00	211.00	123.00	142.00	136.00	130.00						
BUN	20/10/90	10.0	50.0	MG/DL	26.00	29.00	32.00	31.00	32.00	28.00						
CREATININE	20/10/90	0.6	1.6	MG/DL	1.00	0.80	0.80	0.80	0.90	0.90						
URIC ACID	20/10/90	3.4	7.0	MG/DL	4.30	4.20	4.30	4.30	3.60	4.20						
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.70	0.80	0.70	0.80	0.90	0.70						
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.40	0.30	0.40	0.40	0.30						
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.80	6.80	7.20	7.30	6.90	6.90						
ALBUMINE	20/10/90	3.5	5.0	G/DL	3.90	3.90	3.90	4.00	3.90	4.00						
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	231.00	240.00	188.00	216.00	180.00	193.00						
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	126.00	75.00	66.00	90.00	76.00	84.00						
GLOBULINS: ALPHA1	20/10/90	4.0	7.0	X	1.90	1.80	2.50	2.50	2.90	2.40						
GLOBULINS: ALPHA2	20/10/90	7.0	11.0	X	12.30	10.40	9.30	8.60	7.60	5.00						
GLOBULINS: BETA	20/10/90	11.0	14.0	X	8.70	8.70	14.00	13.90	13.50	12.80						
GLOBULINS: GAMMA	20/10/90	15.0	22.0	X	21.30	21.20	21.60	18.70	19.50	17.80						

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXETINE - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42
1 108-148			F					29/04/92	24/06/92	19/08/92	14/10/92	09/12/92	17/02/93
				HB	12.0	16.0	G/100ML	14.10	13.90	12.80	12.80	13.60	14.00
				HTC	37.0	47.0	Z	42.00	42.00	37.00	37.00	39.00	39.00
				RBC	3.8	5.4	10 ⁶ /MHC	4.60	4.60	4.30	4.30	4.50	4.60
				HBC: N	4.0	11.0	10 ⁻³ /MHC	5.20	5.20	6.50	6.00	5.80	5.20
				HBC: L	20.0	70.0	Z	57.00	59.00	62.00	63.00	62.00	60.00
				HBC: E	40.0	40.0	Z	32.00	30.00	30.00	26.00	30.00	27.00
				HBC: M	1.0	5.0	Z	4.00	3.00	2.00	4.00	2.00	4.00
				HBC: B	4.0	8.0	Z	7.00	8.00	6.00	7.00	6.00	9.00
				HBC: A	0.0	1.0	Z	0.00	0.00	0.00	0.00	0.00	0.00
				PLATELETS	150.0	550.0	10 ³ /MHC	220.00	215.00	318.00	310.00	280.00	280.00
				NA+	138.0	155.0	M EQ/L	141.00	142.00	142.00	144.00	141.00	141.00
				K+	3.5	5.5	M EQ/L	3.90	4.30	4.50	4.30	4.20	4.20
				CL-	98.0	120.0	M EQ/L	98.00	96.00	99.00	98.00	97.00	99.00
				CA++	8.5	10.5	MG/DL	10.10	9.70	9.70	9.90	9.30	9.00
				PO4--	3.0	4.5	MG/DL	3.80	4.10	4.10	4.10	4.00	4.10
				SGPT	12.0	40.0	U/L	28.00	28.00	28.00	28.00	26.00	26.00
				GAMMA-GT	10.0	60.0	U/L	34.00	34.00	32.00	32.00	30.00	30.00
				ALBUMINE	7.0	33.0	MG/DL	22.00	22.00	26.00	24.00	22.00	24.00
				GLUCOSE	70.0	100.0	MG/DL	88.00	91.00	93.00	97.00	100.00	90.00
				ALK. PHOSPH.	65.0	306.0	U/L	132.00	130.00	152.00	143.00	131.00	141.00
				UREIC ACID	0.6	1.6	MG/DL	0.80	0.90	0.80	0.90	1.00	0.80
				TOT. BILIRUBIN	2.4	5.7	MG/DL	3.60	3.70	4.30	5.10	5.20	4.70
				DIR. BILIRUBIN	0.2	1.0	MG/DL	1.00	0.70	0.70	0.50	0.40	0.90
				TOT. PROTEINS	6.0	8.0	G/DL	7.00	7.00	7.50	7.30	7.00	6.90
				ALBUMINE	3.5	5.0	G/DL	3.80	3.80	4.10	4.10	3.90	3.80
				TOT. CHOLEST.	140.0	270.0	MG/DL	141.00	145.00	225.00	163.00	181.00	150.00
				TRIGLYCERIDES	35.0	175.0	MG/DL	72.00	66.00	93.00	104.00	93.00	81.00
				GLOBULINS: ALPHA1	4.0	7.0	Z	2.70	2.50	3.70	3.80	2.00	3.00
				GLOBULINS: ALPHA2	7.0	11.0	Z	8.50	7.60	9.20	8.50	8.30	7.50
				GLOBULINS: BETA	11.0	14.0	Z	16.20	15.30	13.50	13.60	12.50	12.40
				GLOBULINS: GAMMA	15.0	22.0	Z	20.30	21.50	18.90	17.90	21.50	22.00
111-331			M					29/04/92	24/06/92	19/08/92	14/10/92	09/12/92	17/02/93
				HB	14.0	18.0	G/100ML	14.10	13.90	14.30	13.00	14.10	13.90
				HTC	40.0	54.0	Z	43.00	42.00	41.00	37.00	41.00	41.00
				RBC	4.3	6.1	10 ⁶ /mm	5.00	4.80	4.60	4.20	4.80	4.90
				HBC: N	4.0	11.0	10 ⁻³ /MHC	6.00	5.60	5.20	6.30	6.50	5.30
				HBC: L	40.0	70.0	Z	57.00	60.00	63.00	61.00	61.00	60.00
				HBC: M	20.0	40.0	Z	29.00	29.00	30.00	30.00	30.00	28.00
				HBC: E	1.0	5.0	Z	6.00	4.00	2.00	2.00	2.00	3.00

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Oper-Blind	Sex	Laboratory test	Laboratory Range			Visit						
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
1	1111-331	M	HBC: M	20/10/90	4.0	8.0	X	8.00	7.00	5.00	7.00	7.00	9.00
			HBC: B	20/10/90	0.0	1.0	X	0.00	0.00	0.00	0.00	0.00	0.00
			PLATELETS	20/10/90	150.0	550.0	10-3/MNC	233.00	249.00	258.00	260.00	260.00	263.00
			NA+	20/10/90	138.0	155.0	M EQ/L	141.00	140.00	142.00	144.00	141.00	142.00
			K+	20/10/90	3.5	5.5	M EQ/L	4.20	4.10	4.40	4.50	4.30	4.00
			CL-	20/10/90	98.0	120.0	M EQ/L	95.00	94.00	97.00	97.00	97.00	98.00
			CA++	20/10/90	8.5	10.5	MG/DL	9.00	9.00	9.80	9.80	9.50	9.60
			PO4-	20/10/90	3.0	4.5	MG/DL	4.20	3.80	4.50	4.20	3.20	3.60
			SGPT	20/10/90	12.0	40.0	NU/ML	32.00	30.00	28.00	28.00	24.00	24.00
			SGFT	20/10/90	11.0	40.0	NU/ML	38.00	34.00	32.00	34.00	28.00	28.00
			GAMMA-GT	20/10/90	11.0	51.0	NU/ML	28.00	26.00	27.00	26.00	22.00	18.00
			GLUCOSE	20/10/90	70.0	100.0	MG/DL	103.00	94.00	105.00	104.00	92.00	92.00
			ALK. PHOSPH.	20/10/90	65.0	306.0	NU/ML	163.00	141.00	133.00	142.00	137.00	142.00
			UREA	20/10/90	10.0	50.0	MG/DL	32.00	29.00	32.00	28.00	29.00	29.00
			CREATININE	20/10/90	0.6	1.6	MG/DL	0.70	0.80	0.90	0.90	0.80	0.70
			URIC ACID	20/10/90	3.4	7.0	MG/DL	3.90	3.90	4.30	3.70	3.90	4.30
			TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	1.10	0.90	0.70	0.90	0.70	0.70
			DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.50	0.40	0.30	0.40	0.30	0.30
			TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.30	7.30	7.20	7.40	5.90	7.00
			ALBUMINE	20/10/90	3.5	5.0	G/DL	4.20	4.10	4.00	3.90	3.90	4.00
			TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	182.00	159.00	191.00	203.00	165.00	175.00
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	74.00	66.00	66.00	74.00	80.00	79.00
			GLOBULINS: ALPHA1	20/10/90	4.0	7.0	X	2.60	2.40	2.50	3.90	3.00	3.50
			GLOBULINS: ALPHA2	20/10/90	7.0	11.0	X	7.40	8.20	8.30	8.80	8.50	9.00
			GLOBULINS: BETA	20/10/90	11.0	14.0	X	13.10	12.30	14.00	12.90	13.90	12.60
			GLOBULINS: GAMMA	20/10/90	15.0	22.0	X	19.50	19.50	19.70	21.70	18.10	17.80

Pat. No.	Oper-Blind	Sex	Laboratory test	Laboratory Range			Visit						
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
114-332	F		HB	20/10/90	12.0	16.0	G/100ML	12.90	12.70	14.30	14.00	14.00	13.90
			HTC	20/10/90	37.0	47.0	X	39.00	38.00	42.00	41.00	42.00	41.00
			RBC	20/10/90	3.8	5.4	10-6/MNC	4.50	4.50	4.60	4.60	4.70	4.60
			HBC	20/10/90	4.0	11.0	10-3/MNC	7.20	6.80	6.30	7.00	5.50	4.30
			HBC: N	20/10/90	40.0	70.0	X	70.00	64.00	60.00	63.00	62.00	61.00
			HBC: L	20/10/90	20.0	40.0	X	20.00	26.00	27.00	28.00	27.00	29.00
			HBC: E	20/10/90	1.0	5.0	X	3.00	3.00	4.00	2.00	2.00	2.00
			HBC: M	20/10/90	4.0	8.0	X	7.00	7.00	9.00	7.00	9.00	8.00
			HBC: R	20/10/90	0.0	1.0	X	0.00	0.00	0.00	0.00	0.00	0.00
			PLATELETS	20/10/90	150.0	550.0	10-3/MNC	279.00	285.00	341.00	216.00	250.00	250.00
			NA+	20/10/90	138.0	155.0	M EQ/L	139.00	141.00	143.00	143.00	142.00	144.00
			K+	20/10/90	3.5	5.5	M EQ/L	3.90	4.20	4.60	4.50	4.00	4.20
			CL-	20/10/90	98.0	120.0	M EQ/L	97.00	94.00	99.00	97.00	98.00	96.00
			CA++	20/10/90	8.5	10.5	MG/DL	8.90	9.30	10.20	9.60	9.50	9.10
			PO4-	20/10/90	3.0	4.5	MG/DL	3.80	3.70	4.50	5.10	4.00	3.60

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit									
				Date	Min	Max Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52				
1 114-332	F		SGOT	20/10/90	12.0	40.0	MU/ML	21.00	20.00	28.00	28.00	27.00	32.00			
			SGPT	20/10/90	10.0	40.0	MU/ML	17.00	28.00	32.00	34.00	32.00	34.00			
			GAMMA-GT	20/10/90	7.0	33.0	MU/ML	45.00	18.00	24.00	26.00	29.00	29.00			
			GLUCOSE	20/10/90	70.0	100.0	MG/DL	93.00	91.00	103.00	90.00	98.00	100.00			
			ALK. PHOSPH.	20/10/90	65.0	306.0	MU/ML	202.00	205.00	191.00	216.00	145.00	151.00			
			BUN	20/10/90	10.0	50.0	MG/DL	19.00	20.00	28.00	36.00	32.00	31.00			
			CREATININE	20/10/90	0.5	1.6	MG/DL	0.78	0.80	1.00	0.90	0.90	0.90			
			URIC ACID	20/10/90	2.4	5.7	MG/DL	4.00	3.80	4.30	3.90	4.00	4.40			
			TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.40	0.40	0.70	0.80	1.00	0.90			
			DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.20	0.20	0.30	0.40	0.50	0.40			
			TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.80	6.90	7.50	7.30	6.80	6.80			
			ALBUMINE	20/10/90	3.5	5.0	G/DL	4.64	4.50	3.90	4.10	3.80	3.90			
			TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	200.00	183.00	192.00	225.00	149.00	166.00			
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	151.00	140.00	80.00	80.00	118.00	93.00			
			GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	1.90	2.00	3.80	2.60	3.00	3.60			
			GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	4.80	5.10	9.40	7.70	7.00	8.20			
			GLOBULINS: BETA	20/10/90	11.0	44.0	%	7.90	8.50	13.00	13.00	11.50	11.20			
			GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	17.20	17.60	25.50	20.50	22.60	19.50			
			115-333	F		HB	20/10/90	12.0	16.0	G/100ML	13.60	13.80	13.80	14.50	15/12/92	24/02/93
						HTC	20/10/90	37.0	47.0	%	42.00	41.00	39.00	41.00	38.00	36.00
RBC	20/10/90	3.8				5.4	10 ⁶ /MMC	4.90	4.70	4.70	4.50	4.60	4.50			
HBC	20/10/90	4.0				11.0	10 ³ /MMC	7.60	7.40	5.30	9.30	8.20	6.00			
HBC: N	20/10/90	40.0				70.0	%	62.00	61.00	61.00	64.00	64.00	65.00			
HBC: L	20/10/90	20.0				40.0	%	30.00	30.00	31.00	26.00	27.00	25.00			
HBC: E	20/10/90	1.0				5.0	%	1.00	2.00	2.00	2.00	2.00	2.00			
HBC: B	20/10/90	4.0				8.0	%	7.00	7.00	6.00	8.00	7.00	8.00			
HBC: M	20/10/90	0.0				1.0	%	0.00	0.00	0.00	0.00	0.00	0.00			
PLATELETS	20/10/90	150.0				550.0	10 ³ /MMC	280.00	275.00	342.00	223.00	290.00	314.00			
NA+	20/10/90	138.0				155.0	M EQ/L	143.00	142.00	144.00	144.00	142.00	140.00			
K+	20/10/90	3.5				5.5	M EQ/L	4.60	4.10	4.30	4.30	4.00	4.20			
CL-	20/10/90	98.0				120.0	M EQ/L	99.00	100.00	99.00	98.00	97.00	97.00			
CA++	20/10/90	8.5				10.5	MG/DL	9.90	9.80	9.80	9.70	9.40	9.50			
PO4-	20/10/90	3.0				4.5	MG/DL	2.90	3.00	4.50	4.50	3.60	3.20			
SGOT	20/10/90	12.0				40.0	MU/ML	24.00	26.00	32.00	29.00	27.00	26.00			
GAMMA-GT	20/10/90	7.0				40.0	MU/ML	32.00	28.00	36.00	33.00	30.00	28.00			
GLUCOSE	20/10/90	70.0				35.0	MU/ML	31.00	30.00	24.00	42.00	22.00	24.00			
ALK. PHOSPH.	20/10/90	65.0				306.0	MU/ML	161.00	88.00	104.00	98.00	116.00	110.00			
BUN	20/10/90	10.0				50.0	MG/DL	320.00	270.00	138.00	149.00	182.00	180.00			
CREATININE	20/10/90	0.6	1.6	MG/DL	25.00	28.00	34.00	30.00	30.00	26.00						
URIC ACID	20/10/90	2.4	5.7	MG/DL	5.70	1.00	0.80	0.70	0.80	0.80						

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit										
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52				
1 115-333	F			TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	1.00	1.00	0.90	0.40	0.60	0.70				
				DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.30	0.40	0.20	0.30	0.30				
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.40	6.60	7.40	7.50	7.20	6.90				
				ALBUMINE	20/10/90	3.5	5.0	G/DL	3.77	3.70	3.80	4.30	4.10	3.90				
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	308.00	282.00	193.00	186.00	225.00	168.00				
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	209.00	177.00	65.00	94.00	143.00	72.00				
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	3.00	3.20	4.40	3.20	4.10	3.20				
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	8.90	9.10	8.50	9.10	7.00	5.90				
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	12.10	12.60	14.20	12.60	13.20	13.50				
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	17.10	18.00	21.60	17.80	18.80	20.90				
				122-337	M			HB	20/10/90	14.0	18.0	g/100ml	12.90	13.00	14.20	14.50	16.12/92	14.40
								HTC	20/10/90	40.0	54.0	%	37.00	38.00	42.00	42.00	44.00	44.00
								RBC	20/10/90	4.3	6.1	10**6/mm	4.30	4.20	4.70	4.90	4.90	5.00
								WBC	20/10/90	4.0	11.0	10-3/MNC	5.50	5.10	9.10	6.10	5.20	6.20
								WBC: N	20/10/90	40.0	70.0	%	61.00	62.00	62.00	63.00	62.00	60.00
WBC: L	20/10/90	20.0	40.0					%	28.00	28.00	27.00	30.00	27.00	27.00				
WBC: E	20/10/90	1.0	5.0					%	6.00	7.00	3.00	1.00	3.00	3.00				
WBC: M	20/10/90	4.0	8.0					%	7.00	0.00	8.00	6.00	8.00	10.00				
WBC: B	20/10/90	0.0	1.0					%	0.00	0.00	0.00	0.00	0.00	0.00				
PLATELETS	20/10/90	150.0	550.0					10-3/MNC	310.00	316.00	314.00	328.00	237.00	245.00				
Na+	20/10/90	138.0	155.0					mEq/L	141.00	141.00	143.00	142.00	140.00	142.00				
K+	20/10/90	3.5	5.5					mEq/L	4.20	4.20	4.50	4.30	4.30	4.10				
Cl-	20/10/90	98.0	120.0					mEq/L	102.00	97.00	100.00	99.00	98.00	97.00				
Ca++	20/10/90	8.5	10.5					MG/DL	9.70	10.10	9.30	9.00	9.00	9.50				
PO4--	20/10/90	3.0	4.5					MG/DL	3.40	3.40	4.10	4.20	3.80	4.20				
SGOT	20/10/90	12.0	40.0					RU/HL	28.00	26.00	36.00	32.00	25.00	26.00				
SGPT	20/10/90	10.0	40.0					RU/HL	30.00	29.00	38.00	38.00	28.00	28.00				
GAMMA-GT	20/10/90	11.0	51.0					RU/HL	24.00	23.00	44.00	41.00	23.00	22.00				
GLUCOSE	20/10/90	70.0	100.0					MG/DL	91.00	94.00	88.00	93.00	94.00	105.00				
ALK. PHOSPH.	20/10/90	65.0	306.0					RU/HL	116.00	107.00	156.00	164.00	138.00	152.00				
SUN	20/10/90	10.0	50.0					MG/DL	30.00	29.00	30.00	31.00	30.00	30.00				
CREATININE	20/10/90	0.6	1.6					MG/DL	1.10	1.10	0.80	0.90	0.90	0.90				
URIC ACID	20/10/90	3.4	7.0					MG/DL	3.40	3.60	4.10	4.30	4.10	4.80				
TOT BILIRUBIN	20/10/90	0.2	1.0					MG/DL	0.70	0.70	0.50	0.60	0.60	0.90				
DIR BILIRUBIN	20/10/90	0.0	0.4					MG/DL	0.30	0.30	0.20	0.30	0.30	0.40				
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.90	6.80	7.40	7.50	7.00	7.00								
ALBUMINE	20/10/90	3.5	5.0	G/DL	3.90	3.90	4.10	4.00	3.80	4.00								
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	194.00	210.00	216.00	193.00	165.00	186.00								
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	116.00	113.00	74.00	75.00	76.00	90.00								
GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	2.00	2.40	3.90	2.50	4.00	3.00								
GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	8.60	9.00	7.40	7.80	8.20	9.20								

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit						
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
1 122-337	M			GLOBALINS: BETA	20/10/90	11.0	14.0	%	14.10	14.30	14.50	15.00	13.50	12.80
				GLOBALINS: GAMMA	20/10/90	15.0	22.0	%	20.20	19.70	18.80	19.40	20.00	18.00
124-339	M			HB	20/10/90	14.0	18.0	g/100ml	06/05/92	01/07/92	26/08/92	21/10/92	16/12/92	24/02/93
				HTC	20/10/90	40.0	54.0	%	43.70	41.00	38.20	43.60	44.20	44.50
				RBC	20/10/90	4.3	6.1	10**6/mm	4.30	4.80	4.60	4.50	4.50	4.50
				WBC	20/10/90	4.0	11.0	10-3/HMC	4.30	5.00	8.40	6.00	6.00	5.10
				WBC: N	20/10/90	40.0	70.0	%	61.00	60.00	63.00	62.00	62.00	63.00
				WBC: L	20/10/90	20.0	40.0	%	30.00	28.00	29.00	30.00	30.00	28.00
				WBC: E	20/10/90	1.0	5.0	%	4.00	4.00	1.00	2.00	3.00	3.00
				WBC: M	20/10/90	0.0	8.0	%	5.00	8.00	7.00	6.00	7.00	8.00
				WBC: B	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	1.00
				PLATELETS	20/10/90	150.0	550.0	10-3/HMC	284.00	279.00	241.00	320.00	255.00	288.00
				Na+	20/10/90	138.0	155.0	m EQ/L	142.00	142.00	143.00	143.00	141.00	144.00
				K+	20/10/90	3.5	5.5	m EQ/L	4.10	4.10	4.50	4.60	4.20	4.30
				Cl-	20/10/90	98.0	120.0	m EQ/L	99.00	103.00	97.00	99.00	98.00	98.00
				Ca++	20/10/90	8.5	10.5	MG/DL	9.50	9.20	9.40	9.40	9.30	9.60
				SGOT	20/10/90	3.0	4.5	MG/DL	3.80	4.10	3.80	4.10	4.00	4.00
				SGPT	20/10/90	12.0	40.0	MG/DL	20.00	24.00	28.00	29.00	28.00	26.00
				GAMMA-GT	20/10/90	10.0	40.0	MG/DL	28.00	28.00	34.00	34.00	30.00	30.00
GLUCOSE	20/10/90	70.0	100.0	MG/DL	183.00	20.00	66.00	58.00	24.00	24.00				
ALK. PHOSPH.	20/10/90	65.0	306.0	MG/DL	215.00	143.00	141.00	132.00	114.00	102.00				
BUN	20/10/90	10.0	50.0	MG/DL	32.00	31.00	32.00	27.00	32.00	32.00				
CREATININE	20/10/90	0.6	1.6	MG/DL	0.80	1.00	1.00	1.00	1.10	1.20				
URIC ACID	20/10/90	3.4	7.0	MG/DL	4.20	4.10	4.30	4.80	4.50	4.40				
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.80	0.80	0.70	0.70	0.80	0.70				
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.40	0.30	0.30	0.40	0.40				
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.90	7.00	7.00	7.00	6.90	7.00				
ALBUMINE	20/10/90	3.5	5.0	G/DL	3.90	4.10	3.90	4.00	4.00	3.90				
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	153.00	142.00	223.00	218.00	148.00	158.00				
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	90.00	84.00	70.00	90.00	93.00	84.00				
GLORULINS: ALPHA1	20/10/90	4.0	7.0	%	2.10	1.70	3.60	4.00	4.10	3.50				
GLORULINS: ALPHA2	20/10/90	7.0	11.0	%	8.00	5.60	9.00	9.00	9.00	9.10				
GLORULINS: BETA	20/10/90	11.0	14.0	%	12.40	12.50	14.50	14.00	12.30	12.80				
GLORULINS: GAMMA	20/10/90	15.0	22.0	%	18.30	17.00	17.20	16.40	16.60	18.90				
126-341	F			HB	20/10/90	12.0	16.0	g/100ML	06/05/92	01/07/92	26/08/92	21/10/92	16/12/92	24/02/93
				HTC	20/10/90	37.0	47.0	%	40.00	37.00	40.00	37.00	37.00	37.00
				RBC	20/10/90	3.8	5.4	10-6/HMC	4.40	4.30	4.60	4.60	4.20	4.20

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

14660

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit						
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
1	126-341	F	HBC	20/10/90	4.0	11.0	10-3/HMC	5.50	6.00	6.50	6.20	4.90	4.70
			HBC: N	20/10/90	40.0	70.0	%	58.00	62.00	65.00	64.00	60.00	56.00
			HBC: L	20/10/90	20.0	40.0	%	30.00	29.00	28.00	30.00	28.00	28.00
			HBC: E	20/10/90	1.0	5.0	%	4.00	3.00	2.00	2.00	3.00	6.00
			HBC: M	20/10/90	4.0	8.0	%	8.00	6.00	5.00	4.00	9.00	9.00
			HBC: B	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	1.00
			PLATELETS	20/10/90	150.0	550.0	10-3/HMC	310.00	284.00	310.00	321.00	295.00	310.00
			NA+	20/10/90	138.0	155.0	M EQ/L	141.00	142.00	142.00	143.00	142.00	141.00
			K+	20/10/90	3.5	5.5	M EQ/L	4.00	4.10	4.30	4.50	4.10	4.30
			CL-	20/10/90	98.0	120.0	M EQ/L	98.00	99.00	98.00	99.00	100.00	96.00
			CA++	20/10/90	8.5	10.5	MG/DL	10.20	9.50	9.50	9.20	9.30	9.00
			PO4-	20/10/90	3.0	4.5	MG/DL	4.00	3.80	4.10	4.10	4.20	3.70
			SGOT	20/10/90	12.0	40.0	U/L	28.00	28.00	28.00	28.00	20.00	26.00
			SGPT	20/10/90	10.0	40.0	U/L	32.00	34.00	32.00	32.00	24.00	30.00
			GAMMA-GT	20/10/90	7.0	33.0	U/L	28.00	24.00	21.00	24.00	16.00	20.00
			GLUCOSE	20/10/90	70.0	100.0	MG/DL	100.00	94.00	97.00	108.00	89.00	104.00
			ALK. PHOSPH.	20/10/90	65.0	306.0	RU/M/L	143.00	161.00	143.00	156.00	137.00	136.00
			BUN	20/10/90	10.0	50.0	MG/DL	28.00	32.00	29.00	32.00	28.00	27.00
			CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	1.00	0.90	1.00	1.10	0.80
			URIC ACID	20/10/90	2.4	5.7	MG/DL	3.60	3.70	4.50	4.30	4.50	4.30
			TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.90	0.70	0.70	0.60	0.70	0.90
			DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.30	0.30	0.30	0.30	0.40
			TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.20	7.20	7.10	7.20	6.90	7.00
			ALBUMINE	20/10/90	3.5	5.0	G/DL	4.00	4.00	3.90	4.00	3.80	4.10
			TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	186.00	162.00	205.00	205.00	159.00	193.00
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	91.00	88.00	90.00	108.00	88.00	92.00
			GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	2.00	1.90	2.00	3.20	3.00	2.70
			GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	5.40	5.40	7.40	7.00	7.50	9.00
			GLOBULINS: BETA	20/10/90	11.0	14.0	%	12.30	11.80	13.20	14.10	12.80	13.10
			GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	20.10	18.30	21.90	20.20	21.60	16.60
129-344	M		HB	20/10/90	14.0	18.0	g/100ml	14.20	14.30	14.50	14.30	14.20	14.30
			HCT	20/10/90	40.0	54.0	%	43.00	43.00	43.00	43.00	42.00	42.00
			RBC	20/10/90	4.3	6.1	10**6/mm	4.80	4.80	4.90	5.00	4.80	4.80
			WBC	20/10/90	4.0	11.0	10-3/HMC	9.60	10.10	9.70	8.10	6.50	6.50
			WBC: N	20/10/90	40.0	70.0	%	52.00	53.00	53.00	60.00	62.00	62.00
			WBC: L	20/10/90	20.0	40.0	%	18.00	29.00	24.00	25.00	30.00	30.00
			WBC: E	20/10/90	1.0	5.0	%	21.00	10.00	16.00	8.00	2.00	2.00
			WBC: M	20/10/90	4.0	8.0	%	9.00	8.00	7.00	6.00	6.00	6.00
			WBC: B	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00
			PLATELETS	20/10/90	150.0	550.0	10-3/HMC	254.00	280.00	319.00	315.00	316.00	316.00
			NA+	20/10/90	138.0	155.0	M EQ/L	138.00	139.00	135.00	155.00	142.00	142.00

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit										
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52				
1	129-344	M	K+	20/10/90	3.5	5.5	M EQ/L	4.90	4.10	4.90	4.30	4.40					
			CL-	20/10/90	98.0	120.0	M EQ/L	97.00	96.00	96.00	96.00	97.00					
			CA++	20/10/90	8.5	10.5	MG/DL	9.90	9.40	9.40	9.30	9.30					
			PO4-	20/10/90	3.0	4.5	MG/DL	3.30	3.80	4.00	4.20	4.10					
			SCOT	20/10/90	12.0	40.0	MU/ML	19.00	16.00	15.00	15.00	28.00					
			SGPT	20/10/90	10.0	40.0	MU/ML	18.00	17.00	13.00	16.00	30.00					
			GAMMA-GT	20/10/90	11.0	51.0	MU/ML	46.00	19.00	43.00	44.00	24.00					
			GLUCOSE	20/10/90	70.0	100.0	MG/DL	110.00	102.00	98.00	93.00	96.00					
			ALK. PHOSPH.	20/10/90	65.0	306.0	MU/ML	210.00	114.00	225.00	198.00	152.00					
			BUN	20/10/90	10.0	50.0	MG/DL	30.00	28.00	24.00	26.00	32.00					
			CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	1.00	1.00	1.00	0.80					
			URIC ACID	20/10/90	3.4	7.0	MG/DL	3.60	3.40	6.20	6.10	4.30					
			TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	1.00	1.00	0.50	0.60	0.60					
			DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.40	0.20	0.30	0.30					
			TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.00	7.00	7.40	7.40	7.40					
			ALBUMINE	20/10/90	3.5	5.0	G/DL	3.56	3.40	4.10	4.00	4.10					
			TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	204.00	187.00	195.00	175.00	181.00					
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	89.00	82.00	2.70	98.00	97.00					
			GLOBULINS: ALPHA1	20/10/90	4.0	17.0	%	2.50	2.70	2.40	2.60	3.00					
			GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	6.30	6.60	7.10	7.00	8.20					
			GLOBULINS: BETA	20/10/90	11.0	14.0	%	11.60	12.10	11.40	11.80	13.50					
			GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	26.70	26.30	23.90	24.60	19.90					
			130-345	F	HB	20/10/90	12.0	16.0	G/100ML	13.50	13.20	13.20					
					HTC	20/10/90	37.0	47.0	%	38.00	39.00						
					RBC	20/10/90	3.8	5.4	10 ⁶ /MHC	4.30	4.50						
					WBC	20/10/90	4.0	11.0	10 ³ /MHC	5.00	4.30						
					NEC: N	20/10/90	40.0	70.0	%	59.00	60.00						
					NEC: L	20/10/90	20.0	40.0	%	32.00	30.00						
					NEC: E	20/10/90	1.0	5.0	%	3.00	3.00						
					NEC: M	20/10/90	4.0	8.0	%	6.00	7.00						
					NEC: B	20/10/90	0.0	1.0	%	0.00	0.00						
					PLATELETS	20/10/90	150.0	550.0	10 ³ /MHC	248.00	225.00						
					MA+	20/10/90	138.0	155.0	M EQ/L	161.00	137.00						
K+	20/10/90	3.5			5.5	M EQ/L	4.30	4.00									
CL-	20/10/90	98.0			120.0	M EQ/L	96.00	97.00									
PO4-	20/10/90	3.0			4.5	MG/DL	3.30	3.80									
SGPT	20/10/90	10.0			40.0	MU/ML	32.00	30.00									
GAMMA-GT	20/10/90	7.0			33.0	MU/ML	26.00	26.00									
GLUCOSE	20/10/90	70.0			100.0	MG/DL	94.00	82.00									

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 2012A/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit																			
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52													
1 130-345	F		ALK. PHOSPH.	20/10/90	65.0	306.0	MU/ML	183.00																		
			BUN	20/10/90	10.0	50.0	MG/DL	25.00																		
			CREATININE	20/10/90	0.6	1.6	MG/DL	1.00																		
			URIC ACID	20/10/90	2.4	5.7	MG/DL	3.70																		
			TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.60																		
			DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30																		
			TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.00																		
			ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10																		
			TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	112.00																		
			TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	51.00																		
			GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	2.30																		
			GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	8.70																		
			GLOBULINS: BETA	20/10/90	11.0	14.0	%	10.30																		
			GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	19.60																		
			135-346	M		HB	20/10/90	14.0	18.0	g/100ml	14.00															
						HTC	20/10/90	40.0	54.0	%	41.00															
						RBC	20/10/90	4.3	6.1	10**6/mm	4.60															
						WBC	20/10/90	4.0	11.0	10 ³ /MNC	5.10															
						WBC: N	20/10/90	40.0	70.0	%	62.00															
						WBC: L	20/10/90	20.0	40.0	%	30.00															
WBC: E	20/10/90	1.0				5.0	%	2.00																		
WBC: M	20/10/90	4.0				8.0	%	6.00																		
WBC: B	20/10/90	0.0				1.0	%	0.00																		
PLATELETS	20/10/90	150.0				550.0	10 ³ /MNC	263.00																		
NA+	20/10/90	138.0				155.0	M EQ/L	142.00																		
K+	20/10/90	3.5				5.5	M EQ/L	4.00																		
CL-	20/10/90	98.0				120.0	M EQ/L	99.00																		
CA++	20/10/90	8.5				10.5	MG/DL	9.50																		
PO4--	20/10/90	3.0				4.5	MG/DL	3.60																		
SGOT	20/10/90	12.0				40.0	MU/ML	28.00																		
SGPT	20/10/90	10.0				40.0	MU/ML	32.00																		
GAMMA-GT	20/10/90	11.0				51.0	MU/ML	22.00																		
GLUCOSE	20/10/90	70.0				100.0	MG/DL	91.00																		
ALK. PHOSPH.	20/10/90	65.0				306.0	MU/ML	163.00																		
BUN	20/10/90	10.0	50.0	MG/DL	31.00																					
CREATININE	20/10/90	0.6	1.6	MG/DL	0.90																					
URIC ACID	20/10/90	3.4	7.0	MG/DL	3.60																					
TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.80																					
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30																					
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.30																					
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.00																					

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOMETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit										
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52				
1	133-346	M		TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	135.00	158.00	160.00	176.00	151.00	166.00				
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	90.00	86.00	93.00	94.00	95.00	105.00				
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	X	2.50	2.60	3.80	3.20	2.20	2.70				
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	X	8.30	7.40	6.10	4.90	5.60	7.40				
				GLOBULINS: BETA	20/10/90	11.0	14.0	X	16.50	12.30	12.80	12.60	13.40	12.90				
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	X	19.00	20.10	22.50	24.00	23.70	22.70				
				136-349	M			HB	20/10/90	14.0	18.0	g/100ml	12.50	13.00	13.00	13.60	14.40	13.90
								HTC	20/10/90	40.0	54.0	X	37.00	40.00	38.00	38.00	42.00	40.00
								RBC	20/10/90	4.3	6.1	10**6/mm	4.40	4.40	4.30	4.50	4.70	4.50
								WBC	20/10/90	4.0	11.0	10-3/HMC	4.30	4.30	6.40	7.40	5.00	4.50
WBC: N	20/10/90	40.0	70.0					X	5.00	63.00	62.00	62.00	61.00	60.00				
WBC: L	20/10/90	20.0	40.0					X	28.00	29.00	28.00	30.00	30.00	28.00				
WBC: E	20/10/90	1.0	5.0					X	3.00	2.00	1.00	2.00	2.00	3.00				
WBC: M	20/10/90	4.0	8.0					X	6.00	6.00	9.00	6.00	7.00	9.00				
WBC: B	20/10/90	0.0	1.0					X	0.80	0.00	0.00	0.00	0.00	0.00				
PLATELETS	20/10/90	150.0	550.0					10-3/HMC	316.00	295.00	310.00	312.00	272.00	265.00				
136-349	M			NA+	20/10/90	138.0	155.0	M EQ/L	142.00	141.00	143.00	143.00	143.00	140.00				
				K+	20/10/90	3.5	5.5	M EQ/L	4.00	3.90	4.50	4.40	4.00	4.30				
				CL-	20/10/90	98.0	120.0	M EQ/L	96.00	102.00	99.00	99.00	98.00	97.00				
				CA++	20/10/90	8.5	10.5	MG/DL	9.40	9.70	9.70	9.20	9.50	9.50				
				PO4--	20/10/90	3.0	4.5	MG/DL	3.70	4.00	4.00	4.10	4.10	4.10				
				SGOT	20/10/90	12.0	40.0	IU/ML	24.00	26.00	26.00	26.00	24.00	26.00				
				SGPT	20/10/90	10.0	40.0	IU/ML	24.00	30.00	30.00	30.00	28.00	29.00				
				GAMMA-GT	20/10/90	11.0	51.0	IU/ML	20.00	22.00	24.00	22.00	18.00	23.00				
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	86.00	90.00	105.00	88.00	92.00	94.00				
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	142.00	138.00	138.00	141.00	153.00	115.00				
136-349	M			RUN	20/10/90	10.0	50.0	MG/DL	30.00	27.00	29.00	29.00	31.00	30.00				
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	0.80	0.80	0.90	0.90	0.80				
				UREIC ACID	20/10/90	3.4	7.0	MG/DL	3.20	3.90	3.60	4.20	4.30	4.20				
				TOT. BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.80	0.60	0.40	0.60	0.60	0.90				
				DIR. BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.40	0.30	0.20	0.30	0.30	0.40				
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.20	7.20	7.10	7.50	7.20	7.10				
				ALBUMINE	20/10/90	3.5	5.0	G/DL	3.90	4.10	3.80	4.00	4.00	3.90				
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	143.00	160.00	156.00	163.00	172.00	186.00				
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	80.00	82.00	93.00	80.00	99.00	70.00				
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	X	2.50	4.00	4.00	3.00	2.20	3.20				
GLOBULINS: ALPHA2	20/10/90	7.0	11.0	X	3.90	8.60	8.60	8.40	8.70	7.50								
GLOBULINS: BETA	20/10/90	11.0	14.0	X	15.10	12.80	13.50	13.90	13.10	14.10								
GLOBULINS: GAMMA	20/10/90	15.0	22.0	X	22.30	20.30	20.40	21.40	20.40	20.30								

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit						
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
1 138-350	F			HB	20/10/90	12.0	16.0	G/100ML	02/06/92	28/07/92	22/09/92	17/11/92	12/01/93	23/03/93
				HTC	20/10/90	37.0	47.0	%	13.90	13.70	13.00	13.10	13.70	13.80
				RBC	20/10/90	3.8	5.4	10 ⁶ -6/MMC	42.00	41.00	38.00	38.00	39.00	40.00
				WBC	20/10/90	4.0	11.0	10 ³ -3/MMC	4.50	4.40	4.40	4.50	4.50	4.60
				WBC: N	20/10/90	40.0	70.0	%	4.80	5.00	6.00	6.60	4.90	6.50
				WBC: L	20/10/90	20.0	40.0	%	63.00	60.00	61.00	62.00	59.00	62.00
				WBC: E	20/10/90	1.0	5.0	%	28.00	31.00	28.00	28.00	30.00	30.00
				WBC: M	20/10/90	4.0	8.0	%	2.00	2.00	3.00	2.00	3.00	2.00
				WBC: B	20/10/90	0.0	1.0	%	7.00	7.00	8.00	8.00	8.00	6.00
				PLATELETS	20/10/90	150.0	550.0	10 ³ -3/MMC	286.00	311.00	311.00	245.00	270.00	290.00
				Na+	20/10/90	138.0	155.0	MEQ/L	142.00	143.00	144.00	142.00	142.00	142.00
				K+	20/10/90	3.5	5.5	MEQ/L	3.90	4.20	4.30	4.30	4.00	4.10
				CL-	20/10/90	98.0	120.0	MEQ/L	98.00	98.00	98.00	97.00	98.00	96.00
				Ca++	20/10/90	8.5	10.5	MG/DL	10.10	9.50	9.60	9.50	9.50	9.80
				PO4--	20/10/90	3.0	4.5	MG/DL	3.70	4.10	4.00	4.00	4.30	4.10
				SGPT	20/10/90	12.0	40.0	IU/ML	28.00	26.00	20.00	26.00	28.00	28.00
				GAMMA-GT	20/10/90	7.0	33.0	IU/ML	34.00	32.00	22.00	28.00	28.00	30.00
				GLUCOSE	20/10/90	70.0	100.0	MG/DL	26.00	20.00	16.00	20.00	24.00	18.00
				ALK. PHOSPH.	20/10/90	65.0	306.0	IU/ML	106.00	93.00	98.00	90.00	91.00	95.00
				BUN	20/10/90	10.0	50.0	MG/DL	125.00	137.00	161.00	136.00	155.00	140.00
				CREATININE	20/10/90	0.6	1.6	MG/DL	0.90	0.80	0.90	0.70	1.00	0.90
				URIC ACID	20/10/90	2.4	5.7	MG/DL	3.90	3.50	4.30	4.30	4.50	4.30
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.30	0.30	0.30	0.80	0.80	0.60
DIR BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.10	0.10	0.30	0.40	0.40	0.30				
TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.30	7.40	7.00	7.00	7.10	7.00				
ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	4.10	3.80	3.90	4.10	4.10				
TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	212.00	196.00	143.00	150.00	216.00	190.00				
TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	88.00	94.00	81.00	93.00	85.00	85.00				
GLORULINS: ALPHA1	20/10/90	4.0	7.0	%	3.10	3.50	2.00	2.20	3.10	3.30				
GLORULINS: ALPHA2	20/10/90	7.0	11.0	%	8.20	9.20	6.90	8.00	7.20	7.80				
GLORULINS: BETA	20/10/90	11.0	14.0	%	16.10	16.50	11.50	12.10	14.00	13.10				
GLORULINS: GAMMA	20/10/90	15.0	22.0	%	21.30	22.80	25.30	22.00	17.90	17.20				
141-353	F			HB	20/10/90	12.0	16.0	G/100ML	02/06/92	28/07/92	22/09/92	17/11/92		
				HTC	20/10/90	37.0	47.0	%	13.50	13.60	13.60	13.60		
				RBC	20/10/90	3.8	5.4	10 ⁶ -6/MMC	38.00	38.00	40.00	38.00		
				WBC	20/10/90	4.0	11.0	10 ³ -3/MMC	4.40	4.50	4.80	4.90		
				WBC: N	20/10/90	40.0	70.0	%	7.50	7.10	6.10	6.30		
				WBC: L	20/10/90	20.0	40.0	%	60.00	62.00	63.00	61.00		
				WBC: E	20/10/90	20.0	40.0	%	28.00	29.00	28.00	29.00		
				WBC: M	20/10/90	1.0	5.0	%	4.00	3.00	2.00	2.00		
				WBC: B	20/10/90	0.0	1.0	%						
				PLATELETS	20/10/90	150.0	550.0	10 ³ -3/MMC						

1965

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBORNETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
1	141-353	F		WBC: M	20/10/90	4.0	8.0	%	8.00	6.00	7.00	8.00			
				WBC: B	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00			
				PLATELETS	20/10/90	150.0	550.0	10-3/HMC	245.00	311.00	256.00	265.00			
				NA+	20/10/90	138.0	155.0	M EQ/L	141.00	142.00	142.00	142.00			
				CL-	20/10/90	3.5	5.5	M EQ/L	3.90	4.30	4.30	4.50			
				CA++	20/10/90	98.0	120.0	M EQ/L	98.00	94.00	97.00	99.00			
				PO4--	20/10/90	8.5	10.5	MG/DL	9.00	9.70	9.50	10.10			
				SCOT	20/10/90	3.0	4.5	MG/DL	3.60	3.80	4.20	4.30			
				SGPT	20/10/90	12.0	40.0	U/L	24.00	21.00	30.00	26.00			
				GAMMA-GT	20/10/90	10.0	40.0	U/L	30.00	23.00	34.00	28.00			
				GLUCOSE	20/10/90	7.0	33.0	MG/DL	20.00	18.00	25.00	20.00			
				ALK. PHOSPH.	20/10/90	65.0	306.0	RU/ML	98.00	93.00	98.00	95.00			
				CREATININE	20/10/90	0.6	1.6	MG/DL	31.00	160.00	30.00	30.00			
				URIC ACID	20/10/90	2.4	5.7	MG/DL	0.80	0.90	0.90	1.10			
				TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	3.70	3.70	4.50	4.20			
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	0.40	0.40	0.50	0.60			
				ALBUMINE	20/10/90	3.5	5.0	G/DL	7.30	7.30	7.30	7.20			
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	149.00	161.00	160.00	147.00			
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	88.00	93.00	72.00	62.00			
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	2.20	2.70	2.80	3.10			
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	6.10	5.50	6.90	7.00			
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	11.00	13.00	12.50	12.60			
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	18.30	20.30	23.00	23.10			
143-355		M		HB	20/10/90	14.0	18.0	g/100ml	13.60	13.80					
				HTC	20/10/90	40.0	54.0	%	41.00	41.00					
				HRC	20/10/90	4.3	6.1	10**6/mm	4.60	4.60					
				HRC: N	20/10/90	4.0	11.0	10-3/HMC	6.30	5.40					
				HRC: L	20/10/90	40.0	70.0	%	59.00	61.00					
				HRC: E	20/10/90	20.0	40.0	%	27.00	30.00					
				HRC: H	20/10/90	1.0	5.0	%	5.00	3.00					
				HRC: B	20/10/90	4.0	8.0	%	9.00	6.00					
				PLATELETS	20/10/90	150.0	550.0	10-3/HMC	274.00	251.00					
				NA+	20/10/90	138.0	155.0	M EQ/L	139.00	142.00					
				K+	20/10/90	3.5	5.5	M EQ/L	4.00	4.10					
				CL-	20/10/90	98.0	120.0	M EQ/L	96.00	96.00					
				CA++	20/10/90	8.5	10.5	MG/DL	9.50	9.50					
				PO4--	20/10/90	3.0	4.5	MG/DL	4.20	3.60					

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1966

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range		Visit																				
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52													
1	143-355	M		SGOT	20/10/90	12.0	40.0	MU/ML	25.00																		
				GAMMA-GT	20/10/90	10.0	40.0	MU/ML	32.00	29.00																	
				GLUCOSE	20/10/90	11.0	51.0	MU/ML	24.00	22.00																	
				ALK. PHOSPH.	20/10/90	70.0	100.0	MG/DL	95.00	90.00																	
				BUN	20/10/90	65.0	306.0	MU/ML	133.00	137.00																	
				CREATININE	20/10/90	10.0	50.0	MG/DL	24.00	23.00																	
				URIC ACID	20/10/90	0.6	1.6	MG/DL	0.80	0.90																	
				TOT BILIRUBIN	20/10/90	3.4	7.0	MG/DL	3.60	3.50																	
				DIR BILIRUBIN	20/10/90	0.2	1.0	MG/DL	1.00	0.80																	
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	7.20	7.10																	
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.10	4.10																	
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	161.00	126.00																	
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	63.00	66.00																	
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	2.70	2.40																	
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	9.40	7.90																	
				GLOBULINS: BETA	20/10/90	11.0	14.0	%	12.30	13.20																	
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	18.60	19.50																	
				145-357	M			HB	20/10/90	14.0	18.0	g/100ml	14.70	31/07/92	16.00	25/09/92	20/11/92	15/01/93	26/03/93								
								HTC	20/10/90	40.0	54.0	%	46.00	45.00	48.00	47.00	45.00	39.00	40.00	40.00	40.00						
								RBC	20/10/90	4.3	6.1	10**6/mm	5.20	4.90	5.60	5.40	5.60	5.80	6.00	6.00	6.00						
WBC	20/10/90	4.0	11.0					10-3/MNC	5.40	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00										
WBC: N	20/10/90	40.0	70.0					%	70.00	63.00	63.00	64.00	63.00	61.00	60.00	60.00	60.00										
WBC: L	20/10/90	20.0	40.0					%	22.00	28.00	27.00	25.00	25.00	25.00	28.00	28.00	28.00										
WBC: E	20/10/90	1.0	5.0					%	2.00	3.00	4.00	5.00	5.00	5.00	5.00	5.00	5.00										
WBC: M	20/10/90	4.0	8.0					%	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00										
WBC: B	20/10/90	0.0	1.0					%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00										
PLATELETS	20/10/90	150.0	550.0					10-3/MNC	239.00	318.00	323.00	310.00	310.00	265.00	280.00	280.00	280.00										
NA*	20/10/90	138.0	155.0					M ES/L	138.00	142.00	138.00	139.00	142.00	142.00	141.00	141.00	141.00										
CL*	20/10/90	3.5	5.5					M ES/L	4.10	3.90	4.60	4.40	4.40	4.10	4.10	4.10	4.10										
CA*	20/10/90	98.0	120.0					M ES/L	96.00	102.00	97.00	98.00	98.00	99.00	96.00	96.00	96.00										
CA**	20/10/90	8.5	10.5					MG/DL	9.10	9.30	9.60	9.70	9.70	9.30	9.40	9.40	9.40										
PO4*	20/10/90	3.0	4.5					MG/DL	3.80	4.30	4.30	4.40	4.40	4.10	4.10	4.10	4.10										
SGPT	20/10/90	12.0	40.0					MU/ML	20.00	26.00	26.00	28.00	28.00	28.00	25.00	25.00	25.00										
GAMMA-GT	20/10/90	11.0	40.0					MU/ML	28.00	26.00	30.00	30.00	30.00	36.00	32.00	32.00	32.00										
GLUCOSE	20/10/90	70.0	51.0					MU/ML	23.00	18.00	23.00	24.00	24.00	24.00	22.00	22.00	22.00										
ALK. PHOSPH.	20/10/90	65.0	306.0					MU/ML	95.00	98.00	98.00	95.00	95.00	95.00	98.00	98.00	98.00										
BUN	20/10/90	10.0	50.0					MG/DL	41.00	36.00	28.00	29.00	29.00	28.00	28.00	28.00	28.00										
CREATININE	20/10/90	0.6	1.6	MG/DL	1.20	1.00	1.10	1.00	1.00	0.90	0.80	0.80	0.80														
URIC ACID	20/10/90	3.4	7.0	MG/DL	2.70	2.90	4.10	4.20	4.20	4.10	4.30	4.30	4.30														

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Date	Laboratory Range		Week 10		Week 18		Week 26		Week 34		Week 42		Week 52							
						Min	Max	Unit	Unit	Unit	Unit	Unit	Unit	Unit	Unit	Unit	Unit	Unit	Unit	Unit	Unit	Unit	Unit		
1	145-357	M		TOT BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.70	0.80	0.60	0.60	0.60	0.60	0.60	0.80	0.60	0.60	0.60	0.60					
				DIP BILIRUBIN	20/10/90	0.0	0.4	MG/DL	0.30	0.40	0.30	0.30	0.30	0.30	0.30	0.30	0.40	0.30	0.30	0.30	0.30				
				TOT. PROTEINS	20/10/90	6.0	8.0	G/DL	6.40	6.60	6.40	6.40	6.40	6.40	6.40	6.40	7.00	6.40	6.40	7.00	6.40				
				ALBUMINE	20/10/90	3.5	5.0	G/DL	4.07	4.00	4.10	4.10	4.10	4.10	4.10	4.10	4.00	4.10	4.00	4.10	4.00	4.10			
				TOT. CHOLEST.	20/10/90	140.0	270.0	MG/DL	180.00	172.00	180.00	180.00	180.00	180.00	180.00	180.00	192.00	185.00	192.00	185.00	195.00				
				TRIGLICERIDES	20/10/90	35.0	175.0	MG/DL	86.00	82.00	86.00	86.00	86.00	86.00	86.00	86.00	65.00	70.00	65.00	88.00	88.00				
				GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	3.20	3.00	3.20	3.20	3.20	3.20	3.20	3.20	1.70	2.00	3.60	3.20	3.20				
				GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	7.40	8.10	7.40	7.40	7.40	7.40	7.40	7.40	6.70	8.10	7.40	7.40	7.40				
				GLOBULINS: BETA	20/10/90	11.0	44.0	%	11.20	12.50	11.20	11.20	11.20	11.20	11.20	11.20	12.30	13.00	12.00	13.00	12.60				
				GLOBULINS: GAMMA	20/10/90	15.0	22.0	%	14.60	16.00	14.60	14.60	14.60	14.60	14.60	14.60	17.10	18.20	17.10	18.20	18.20				
				149-360	F			HB	20/10/90	12.0	16.0	G/100ML	14.20	14.00	13.60	13.60	13.60	13.60	13.60	13.60	13.60	13.60	13.60		
								HTC	20/10/90	37.0	47.0	%	41.00	41.00	38.00	38.00	38.00	38.00	38.00	38.00	41.00	41.00	41.00	41.00	
								RBC	20/10/90	3.8	5.4	10 ⁶ /HMC	4.60	4.60	4.60	4.60	4.60	4.60	4.60	4.60	4.60	4.60	4.60	4.60	4.60
								WBC	20/10/90	4.0	11.0	10 ³ /HMC	5.80	5.10	6.00	6.00	6.00	6.00	6.00	6.00	6.00	5.30	6.00	5.30	6.00
WBC: N	20/10/90	40.0	70.0					%	60.00	62.00	60.00	60.00	60.00	60.00	60.00	60.00	60.00	62.00	60.00	62.00	60.00				
WBC: L	20/10/90	20.0	40.0					%	31.00	29.00	28.00	28.00	28.00	28.00	28.00	28.00	28.00	25.00	28.00	25.00	27.00				
WBC: E	20/10/90	1.0	5.0					%	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	3.00	3.00	3.00					
WBC: M	20/10/90	4.0	8.0					%	6.00	7.00	6.00	6.00	6.00	6.00	6.00	6.00	9.00	9.00	10.00	10.00					
WBC: B	20/10/90	0.0	1.0					%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
PLATELETS	20/10/90	150.0	550.0					10 ³ /HMC	310.00	292.00	260.00	260.00	260.00	260.00	260.00	260.00	258.00	260.00	258.00	260.00	260.00				
NA+	20/10/90	138.0	155.0					M EQ/L	142.00	141.00	143.00	143.00	143.00	143.00	143.00	143.00	143.00	141.00	143.00	143.00	143.00				
K+	20/10/90	3.5	5.5					M EQ/L	4.00	4.30	4.30	4.30	4.30	4.30	4.30	4.30	4.30	4.30	4.30	4.30	4.30				
CL-	20/10/90	98.0	120.0					M EQ/L	92.00	97.00	92.00	92.00	92.00	92.00	92.00	92.00	99.00	96.00	96.00	96.00					
CA++	20/10/90	8.5	10.5					MG/DL	9.50	9.50	9.50	9.50	9.50	9.50	9.50	9.50	9.50	9.50	9.50	9.50	9.50				
PO4-	20/10/90	3.0	4.5					MG/DL	3.00	3.20	3.00	3.00	3.00	3.00	3.00	3.00	4.00	4.10	4.00	4.00					
SGOT	20/10/90	12.0	40.0					NU/ML	26.00	28.00	28.00	28.00	28.00	28.00	28.00	28.00	28.00	24.00	27.00	24.00	26.00				
SGPT	20/10/90	10.0	40.0					NU/ML	28.00	32.00	34.00	34.00	34.00	34.00	34.00	34.00	28.00	29.00	28.00	30.00					
GAMMA-GT	20/10/90	7.0	33.0					NU/ML	20.00	27.00	28.00	28.00	28.00	28.00	28.00	28.00	20.00	18.00	20.00	20.00					
GLUCOSE	20/10/90	70.0	100.0					MG/DL	82.00	94.00	96.00	96.00	96.00	96.00	96.00	96.00	94.00	94.00	94.00	92.00					
ALK. PHOSPH.	20/10/90	65.0	306.0					NU/ML	154.00	168.00	168.00	168.00	168.00	168.00	168.00	168.00	153.00	143.00	138.00	123.00					
BUN	20/10/90	10.0	50.0					MG/DL	30.00	32.00	32.00	32.00	32.00	32.00	32.00	32.00	32.00	31.00	28.00	31.00					
CREATININE	20/10/90	0.6	1.6					MG/DL	0.90	0.90	0.90	0.90	0.90	0.90	0.90	0.90	0.90	0.80	0.80	0.80					
URIC ACID	20/10/90	2.4	5.7					MG/DL	3.60	3.60	3.60	3.60	3.60	3.60	3.60	3.60	3.60	3.60	3.60	3.60					
TOT BILIRUBIN	20/10/90	0.2	1.0					MG/DL	0.50	0.60	0.60	0.60	0.60	0.60	0.60	0.60	0.60	0.70	0.70	0.70					
DIP BILIRUBIN	20/10/90	0.0	0.4					MG/DL	0.20	0.30	0.30	0.30	0.30	0.30	0.30	0.30	0.30	0.40	0.40	0.40					
TOT. PROTEINS	20/10/90	6.0	8.0					G/DL	7.30	7.30	7.30	7.30	7.30	7.30	7.30	7.30	7.30	7.10	7.20	7.20					
ALBUMINE	20/10/90	3.5	5.0					G/DL	4.10	4.00	4.00	4.00	4.00	4.00	4.00	4.00	3.90	4.00	4.00						
TOT. CHOLEST.	20/10/90	140.0	270.0					MG/DL	178.00	197.00	197.00	197.00	197.00	197.00	197.00	197.00	169.00	169.00	163.00						
TRIGLICERIDES	20/10/90	35.0	175.0	MG/DL	74.00	94.00	96.00	96.00	96.00	96.00	96.00	96.00	80.00	80.00	90.00										
GLOBULINS: ALPHA1	20/10/90	4.0	7.0	%	3.00	2.50	2.50	2.50	2.50	2.50	2.50	2.50	3.20	3.60											
GLOBULINS: ALPHA2	20/10/90	7.0	11.0	%	8.10	9.00	7.60	7.60	7.60	7.60	7.60	7.60	8.50	7.90											

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit											
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52					
1	149-360	F		GLOBALINS: BETA	20/10/90	11.0	14.0	%	13.30	12.60	14.00	12.80	19.00	14.00	19.00	12.50			
				GLOBALINS: GAMMA	20/10/90	15.0	22.0	%	19.50	19.70	20.00	23.50	19.00	20.40					
150-151	F			HB	20/10/90	12.0	16.0	G/100ML	13.50	14.00	14.00	14.20	14.30	14.00	14.20				
				HCT	20/10/90	37.0	47.0	%	38.00	39.00	41.00	41.00	41.00	41.00	41.00	41.00			
				RBC	20/10/90	3.8	5.4	10 ⁶ /MM ³	4.50	4.30	4.80	4.80	4.80	4.80	4.80	4.80	4.80		
				MBC: N	20/10/90	4.0	11.0	10 ³ /MM ³	5.80	4.80	5.20	6.00	6.00	6.00	6.00	6.00	6.00		
				MBC: I	20/10/90	40.0	70.0	%	60.00	60.00	60.00	62.00	62.00	62.00	62.00	62.00	62.00		
				MBC: E	20/10/90	20.0	40.0	%	28.00	27.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00		
				MBC: M	20/10/90	1.0	5.0	%	3.00	6.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00		
				MBC: B	20/10/90	4.0	8.0	%	9.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00		
				PLATELETS	20/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
				NA+	20/10/90	150.0	550.0	10 ³ /MM ³	304.00	316.00	320.00	300.00	300.00	320.00	300.00	300.00	300.00		
				K+	20/10/90	138.0	155.0	M EQ/L	142.00	140.00	143.00	142.00	143.00	143.00	143.00	143.00	143.00		
				CL-	20/10/90	3.5	5.5	M EQ/L	4.10	4.20	4.50	4.50	4.50	4.50	4.50	4.50	4.50		
				CA++	20/10/90	96.0	120.0	M EQ/L	96.00	94.00	98.00	98.00	98.00	98.00	98.00	98.00	98.00		
				PO4-	20/10/90	8.5	10.5	MG/DL	9.50	9.20	9.60	9.60	9.60	9.60	9.60	9.60	9.60		
				SGOT	20/10/90	3.0	4.5	MG/DL	4.10	3.00	4.30	4.30	4.30	4.30	4.30	4.30	4.30		
				SGPT	20/10/90	12.0	40.0	MG/DL	28.00	30.00	25.00	26.00	26.00	26.00	26.00	26.00	26.00		
				GAMMA-GT	20/10/90	10.0	40.0	MG/DL	34.00	36.00	28.00	28.00	28.00	28.00	28.00	28.00	28.00		
				GLUCOSE	20/10/90	7.0	33.0	MG/DL	20.00	26.00	23.00	23.00	23.00	23.00	23.00	23.00	23.00		
				ALK. PHOSPH.	20/10/90	65.0	305.0	MG/DL	98.00	97.00	91.00	91.00	91.00	91.00	91.00	91.00	91.00		
				UREIC ACID	20/10/90	10.0	50.0	MG/DL	210.00	130.00	135.00	135.00	135.00	135.00	135.00	135.00	135.00		
				TOT BILIRUBIN	20/10/90	0.6	1.6	MG/DL	0.80	0.90	0.80	0.80	0.80	0.80	0.80	0.80	0.80		
				DIR BILIRUBIN	20/10/90	0.2	1.0	MG/DL	0.30	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50		
				TOT PROTEINS	20/10/90	6.0	8.0	G/DL	7.20	7.20	7.40	7.40	7.40	7.40	7.40	7.40	7.40		
				ALBUMINS	20/10/90	3.5	5.0	G/DL	4.00	3.90	4.20	4.20	4.20	4.20	4.20	4.20	4.20		
				TOT CHOLEST.	20/10/90	140.0	270.0	MG/DL	174.00	193.00	158.00	158.00	158.00	158.00	158.00	158.00	158.00		
				TRIGLYCERIDES	20/10/90	35.0	175.0	MG/DL	86.00	90.00	67.00	67.00	67.00	67.00	67.00	67.00	67.00		
GLOBALINS: ALPHA1	20/10/90	4.0	7.0	%	3.00	3.10	3.10	3.10	3.10	3.10	3.10	3.10	3.10						
GLOBALINS: ALPHA2	20/10/90	7.0	11.0	%	7.20	8.60	8.20	8.20	8.20	8.20	8.20	8.20	8.20						
GLOBALINS: BETA	20/10/90	11.0	14.0	%	12.50	13.00	11.90	11.90	11.90	11.90	11.90	11.90	11.90						
GLOBALINS: GAMMA	20/10/90	15.0	22.0	%	19.60	20.20	19.10	19.10	19.10	19.10	19.10	19.10	19.10						
3	2-61	F		HB	18/10/90	7.4	9.9	MMOL/L	4.98	5.70	6.00	6.00	6.00	6.00	6.00	6.00	6.00		
				HCT	18/10/90	0.3	0.5		0.31	0.32	0.31	0.32	0.32	0.32	0.32	0.32	0.32	0.32	
				RBC	18/10/90	4.0	5.5	10 ¹² /L	5.13	5.13	5.13	5.13	5.13	5.13	5.13	5.13	5.13	5.13	

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOMETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit						
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
3	2-61	F		HRC	18/10/90	4.0	10.0	10**g/L	7.46	8.40	8.37			
				HRC: L	18/10/90	15.0	74.0	X		54.10	51.90			
				HRC: E	18/10/90	16.0	45.0	X		35.80	24.10			
				HRC: H	18/10/90	4.0	7.0	X		0.50	0.60			
				HRC: B	18/10/90	4.0	10.0	X		7.20	6.20			
				PLATELETS	18/10/90	0.0	2.0	X		0.70	0.40			
				NA+	18/10/90	150.0	400.0	10**g/L	474.00	586.00	645.00			
				CL-	18/10/90	3.5	145.0	MMOL/L	135.00	142.00	140.00			
				Ca++	18/10/90	95.0	105.0	MMOL/L	107.00	103.00	111.00			
				PO4--	18/10/90	2.1	2.8	MMOL/L		2.45	2.43			
				SGOT	18/10/90	0.8	1.5	MMOL/L	0.83	1.25	0.98			
				SGPT	18/10/90	6.0	53.0	UI/L	15.00	13.00	16.00			
				GAMMA-GT	18/10/90	7.0	40.0	UI/L	16.00	14.00	20.00			
				GLUCOSE	18/10/90	5.0	20.0	UI/L	7.00	13.00	13.00			
				ALK. PHOSPH.	18/10/90	3.9	5.6	MMOL/L		4.60	4.22			
				BUN	18/10/90	30.0	85.0	UI/L		67.00	72.00			
				CREATININE	18/10/90	2.7	6.7	MMOL/L	3.99	3.70	3.92			
				URIC ACID	18/10/90	9.0	90.0	UMOL/L	58.00	68.00	60.00			
				DIR BILIRUBIN	18/10/90	150.0	475.0	UMOL/L		243.00	218.00			
				TOT BILIRUBIN	18/10/90	2.0	7.0	UMOL/L		5.00	5.00			
				ALBUMINE	18/10/90	60.0	2.0	UMOL/L	69.00	0.00	0.00			
				TOT. PROTEINS	18/10/90	60.0	75.0	G/L		74.00	69.00			
				TOT. CHOLEST.	18/10/90	500.0	725.0	UMOL/L		649.00	459.00			
				TRIGLYCELIDES	18/10/90	3.3	6.3	MMOL/L		4.70	4.69			
				GLOBULINS: ALPHA1	18/10/90	0.9	2.0	MMOL/L		0.66	1.16			
				GLOBULINS: ALPHA2	18/10/90	2.0	4.0	X		3.00	2.07			
				GLOBULINS: BETA	18/10/90	6.0	10.0	X		7.00	4.83			
				GLOBULINS: GAMMA	18/10/90	8.0	12.0	X		13.00	8.28			
				PLATELETS	18/10/90	150.0	400.0	10**g/L						
				NA+	18/10/90	135.0	145.0	MMOL/L						
10-72		H		HB	18/10/90	8.0	11.0	MMOL/L	19/06/91	14/08/91				
				HTC	18/10/90	0.4	0.5		10.50	9.70				
				RBC	18/10/90	4.2	5.7	10**12/L	5.55	0.47				
				HBC: N	18/10/90	4.0	10.0	10**g/L	6.31	5.29				
				HBC: L	18/10/90	15.0	74.0	X	59.70	8.38				
				HBC: E	18/10/90	16.0	45.0	X	31.70	57.20				
				HBC: K	18/10/90	0.0	7.0	X	2.00	2.00				
				HBC: B	18/10/90	4.0	10.0	X	5.70	4.60				
				PLATELETS	18/10/90	150.0	400.0	10**g/L	342.00	322.00				
				NA+	18/10/90	135.0	145.0	MMOL/L	142.00	144.00				

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1970

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52		
3	10-72	M		K+	18/10/90	3.5	5.0	MMOL/L	4.30	4.30						
				CL-	18/10/90	95.0	105.0	MMOL/L	109.00	109.00						
				CA++	18/10/90	2.1	2.8	MMOL/L	2.43	2.46						
				PO4-	18/10/90	0.8	1.5	MMOL/L	1.17	1.55						
				SGOT	18/10/90	6.0	53.0	U/L	23.00	20.00						
				SGPT	18/10/90	7.0	40.0	U/L	37.00	31.00						
				GLUCOSE	18/10/90	3.9	5.6	MMOL/L	5.66							
				ALK. PHOSPH.	18/10/90	30.0	85.0	U/L	59.00	50.00						
				BUN	18/10/90	2.7	6.7	MMOL/L	4.94							
				CREATININE	18/10/90	9.0	90.0	UMOL/L	105.00	111.00						
				URIC ACID	18/10/90	150.0	475.0	UMOL/L	259.00	255.00						
				TOT BILIRUBIN	18/10/90	2.0	7.0	UMOL/L	10.00	12.00						
				DIR BILIRUBIN	18/10/90	0.0	2.0	UMOL/L	2.00	2.00						
				TOT. PROTEINS	18/10/90	60.0	75.0	G/L	67.00	67.00						
				ALBUMINE	18/10/90	500.0	725.0	UMOL/L	451.50	451.50						
				TRIGLYCERIDES	18/10/90	0.9	2.0	MMOL/L	0.73							
				GLOBULINS: ALPHA1	18/10/90	2.0	4.0	X	1.54							
				GLOBULINS: ALPHA2	18/10/90	6.0	10.0	X	5.56							
				GLOBULINS: BETA	18/10/90	8.0	12.0	X	6.70							
				GLOBULINS: GAMMA	18/10/90	12.0	19.0	X	8.71							
8	1-211	F		HB	19/10/90	120.0	150.0	g/l	140.00	143.00	08/04/91	03/06/91	29/07/91	23/09/91		
19				HTC	19/10/90	0.4	0.5	l/l	0.40	0.42				137.00		
19				RBC	19/10/90	4.5	5.5	10**12/l	4.90	4.97				0.47		
19				RBC: N	19/10/90	5.0	10.0	10**9/l	6.00	5.80				4.82		
19				RBC: L	19/10/90	60.0	75.0	X	65.00	69.00				5.60		
19				RBC: E	19/10/90	20.0	28.0	X	29.00	26.00				75.00		
19				RBC: M	19/10/90	1.0	4.0	X	2.00	2.00				21.00		
19				RBC: B	19/10/90	0.0	1.0	X	4.00	5.00				2.00		
19				PLATELETS	19/10/90	150.0	300.0	10**9/l	213.00	188.00				0.00		
19				NA+	19/10/90	135.0	146.0	mmol/l	140.00	142.00				211.00		
19				K+	19/10/90	3.8	5.2	mmol/l	4.60	4.10	08/04/91	03/06/91	29/07/91	175.00		
19				CL-	19/10/90	95.0	108.0	mmol/l	104.00	107.00				144.00		
19				CA++	19/10/90	2.1	2.6	mmol/l	2.30	2.50				4.20		
19				PO4-	19/10/90	0.8	1.6	mmol/l	0.96	1.60				101.00		
19				SGOT	19/10/90	7.0	21.0	U/l	12.00	12.00				2.30		
19				SGPT	19/10/90	4.0	22.0	U/l	10.00	10.00				1.20		
19				GAMMA-GT	19/10/90	5.0	25.0	U/l	18.00	20.00				18.00		
19				GLUCOSE	19/10/90	2.8	5.6	mmol/l	4.60	4.50				22.00		
19				ALK. PHOSPH.	19/10/90	73.0	207.0	U/l	206.00	149.00				18.00		
19				BUN	19/10/90	2.0	9.0	mmol/l	5.00	4.70				5.00		

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit															
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52									
8	1-211	F	CREATININE	19/10/90	60.0	100.0	umol/L	80.00	78.00	78.00	71.00	70.00										
			URIC ACID	19/10/90	200.0	420.0	umol/L	260.00	247.00	252.00	203.00	203.00	320.00									
			TOT BILIRUBIN	19/10/90	2.0	17.0	umol/L	8.00	8.00	8.00	8.00	8.00	8.00									
			DIR BILIRUBIN	19/10/90	0.0	0.0		0.00	0.00	0.00	0.00	0.00	0.00									
			TOT. PROTEINS	19/10/90	60.0	85.0	g/l	70.00	70.00	64.00	68.00	70.00	70.00									
			ALBUMINE	19/10/90	35.0	48.0	g/l	44.00	45.00	41.00	44.00	42.00	44.00									
			TOT. CHOLEST.	19/10/90	3.9	6.5	mmol/L	5.60	5.40	5.50	7.20	4.60	4.60									
			TRIGLYCERIDES	19/10/90	0.8	1.7	mmol/L	1.00	1.20	1.40	3.00	1.40	1.40									
			GLOBULINS: ALPHA1	19/10/90	2.4	3.6	%	3.20														
			GLOBULINS: ALPHA2	19/10/90	6.6	9.8	%	7.80														
			GLOBULINS: BETA	19/10/90	8.1	12.1	%	9.60														
			GLOBULINS: GAMMA	19/10/90	12.6	18.3	%	10.80														
			4	214	F	HB	19/10/90	120.0	150.0	g/l	148.00	152.00	122.00	125.00	129.00	138.00						
						HTC	19/10/90	0.4	0.5	L/L	0.42	0.46	0.36	0.39	0.37	0.40						
						RBC	19/10/90	4.5	5.5	10**12/L	4.80	5.04	4.52	4.84	3.91	4.16						
						HBC	19/10/90	5.0	10.0	10**9/L	5.80	4.80	4.40	7.10	6.20	6.90						
						HBC: N	19/10/90	60.0	75.0	%	70.00	67.00		62.00	61.00	59.00						
HBC: L	19/10/90	20.0				28.0	%	26.00	26.00		27.00	31.00	32.00									
HBC: E	19/10/90	1.0				4.0	%	2.00	5.00		1.00	2.00	1.00									
HBC: M	19/10/90	1.0				8.0	%	2.00	4.00		1.00	5.00	9.00									
HBC: B	19/10/90	0.0				1.0	%	0.00	4.00		1.00	1.00	0.00									
PLATELETS	19/10/90	150.0				300.0	10**9/L	180.00	126.00		212.00	148.00	155.00									
NA+	19/10/90	135.0				146.0	mmol/L	141.00	141.00		139.00	144.00	145.00									
K+	19/10/90	3.8				5.2	mmol/L	4.80	4.40		4.00	4.80	4.30									
CL-	19/10/90	95.0				108.0	mmol/L	102.00	4.40		104.00	105.00	102.00									
CA++	19/10/90	2.1				2.6	mmol/L	2.40	2.50		2.40	2.70	2.40									
PO4--	19/10/90	0.8				1.6	mmol/L	1.40			1.10	1.00	0.90									
SGOT	19/10/90	7.0				21.0	U/l	14.00	17.00		9.00	15.00	16.00									
SGPT	19/10/90	4.0				22.0	U/l	14.00	14.00		6.00	10.00	12.00									
GAMMA-GT	19/10/90	5.0				25.0	U/l	20.00	11.00		18.00	13.00	11.00									
GLUCOSE	19/10/90	2.8				5.6	mmol/L	5.00	4.60		6.20	5.40	5.40									
ALK. PHOSPH.	19/10/90	73.0				207.0	U/l	170.00	6.80		134.00	121.00	125.00									
BUN	19/10/90	2.0				3.0	mmol/L	4.00	6.80		4.20	5.10	4.00									
CREATININE	19/10/90	60.0				100.0	umol/L	90.00	84.00		84.00	66.00	62.00									
URIC ACID	19/10/90	200.0				420.0	umol/L	260.00	253.00		169.00	243.00	152.00									
TOT BILIRUBIN	19/10/90	2.0	17.0	umol/L	10.00	8.00		8.00	8.00	8.00												
DIR BILIRUBIN	19/10/90	0.0	0.0		0.00	0.00		0.00	0.00	0.00												
TOT. PROTEINS	19/10/90	60.0	85.0	g/l	72.00	78.00		59.00	76.00	69.00												
ALBUMINE	19/10/90	35.0	48.0	g/l	42.00	42.00		48.00	50.00	47.00												
TOT. CHOLEST.	19/10/90	3.9	6.5	mmol/L	5.60	6.90		5.40	6.20	6.20												
TRIGLYCERIDES	19/10/90	0.8	1.7	mmol/L	1.20	2.10		1.00	1.50	0.50												

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1972

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Date	Laboratory Range		Visit												
					Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52						
8 4-214	F		GLOBALINS: ALPHA1	19/10/90	2.4	3.6	%	3.00											
			GLOBALINS: ALPHA2	19/10/90	6.6	9.8	%	8.00											
			GLOBALINS: BETA	19/10/90	8.1	12.1	%	9.60											
			GLOBALINS: GAMMA	19/10/90	12.6	18.8	%	15.00											
			HB	20/05/90	4.0	10.0	mmol/L	8.90	8.90										
			HTC	20/05/90	36.0	53.0	%	42.00	42.00										
			RBC	20/05/90	4.0	5.8	10 ¹² /L	4.90	4.90										
9 2-241	F		WBC: N	20/05/90	6.0	12.0	10 ⁹ /L	7.10	7.10										
			WBC: L	20/05/90	15.0	40.0	%	20.00	20.00										
			WBC: E	20/05/90	0.0	5.0	%	1.00	2.00										
			WBC: M	20/05/90	1.0	6.0	%	1.00	2.00										
			WBC: B	20/05/90	0.0	1.0	%	0.00	3.00										
			PLATELETS	20/05/90	120.0	640.0	10 ⁹ /L	168.00	154.00										
			NA+	20/05/90	138.0	158.0	mmol/L	139.00	141.00										
			K+	20/05/90	3.6	5.0	mmol/L	3.90	4.00										
			CL-	20/05/90	90.0	110.0	mmol/L	109.00	108.00										
			CA++	20/05/90	1.8	2.6	mmol/L	2.10	2.10										
			PO4-	20/05/90	0.9	1.6	mmol/L	1.20	1.60										
			SGOT	20/05/90	4.0	25.0	U/L	8.00	10.00										
			SGPT	20/05/90	4.0	27.0	U/L	7.00	8.00										
			GAMMA-GT	20/05/90	4.0	28.0	U/L	32.00	25.00										
GLUCOSE	20/05/90	3.6	5.7	mmol/L	4.90	4.60													
ALK. PHOSPH.	20/05/90	20.0	55.0	mmol/L	40.00	47.00													
CREATININE	20/05/90	2.0	10.0	mmol/L	5.60	8.00													
UREIC ACID	20/05/90	45.0	105.0	umol/L	76.00	82.00													
TOT. BILIRUBIN	20/05/90	100.0	400.0	umol/L	125.00	125.00													
TOT. BILIRUBIN	20/05/90	0.0	20.0	umol/L	8.00	8.00													
TOT. PROTEINS	20/05/90	66.0	97.0	g/L	79.00	75.00													
ALBUMINE	20/05/90	32.0	58.0	g/L	65.00	65.00													
TOT. CHOLEST.	20/05/90	3.0	8.7	mmol/L	5.10	5.60													
TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/L	1.40	1.00													
GLOBALINS: ALPHA1	20/05/90	2.5	4.0	%	3.00	2.00													
GLOBALINS: ALPHA2	20/05/90	7.0	10.0	%	8.00	8.00													
GLOBALINS: BETA	20/05/90	8.3	14.5	%	9.00	9.70													
GLOBALINS: GAMMA	20/05/90	14.0	25.0	%	15.00	16.00													
5-242	F		HB	20/05/90	4.0	10.0	mmol/L	8.20	12.80										
			HB	26/01/91	12.80	12.80													

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOMETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Date	Laboratory Range		Visit									
					Min	Max Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52				
9 5-242	F		HTC	20/05/90	36.0	53.0 %	41.00	40.00	41.00	39.00						
			RBC	20/05/90	4.0	5.8 10**6/u1	4.60	5.80	4.60	4.40						
			HRC	20/05/90	4.0	12.0 10**9/l	5.30	5.60	4.50	5.20						
			PLATELETS	20/05/90	120.0	640.0 10**9/l	328.00	216.00	264.00	329.00						
			NA+	20/05/90	138.0	158.0 mmol/l	149.00	146.00	148.00	143.00						
			K+	20/05/90	3.6	5.0 mmol/l	4.70	3.90	4.70	5.20						
			CA++	20/05/90	1.8	2.6 mmol/l	2.20	2.40	2.00	1.90						
			PO4-	20/05/90	0.9	1.6 mmol/l	1.30	0.70	0.80	0.80						
			SGOT	20/05/90	4.0	27.0 U/l	7.00	7.00	6.00	9.00						
			SGPT	20/05/90	4.0	27.0 U/l	7.00	6.00	6.00	8.00						
			GAMMA-GT	20/05/90	3.6	5.7 mmol/l	8.00	5.00	12.00	30.00						
			GLUCOSE	20/05/90	20.0	55.0 mmol/l	42.00	42.00	42.00	38.00						
			ALK. PHOSPH.	20/05/90	2.0	10.0 mmol/l	8.00	4.00	4.00	7.00						
			CREATININE	20/05/90	45.0	105.0 umol/l	85.00	75.00	80.00	90.00						
			TOT BILIRUBIN	20/05/90	2.0	20.0 umol/l	260.00	253.00	274.00	205.00						
			DIR BILIRUBIN	20/05/90	0.0	20.0 umol/l	9.00	16.00	17.00	14.00						
			TOT. PROTEINS	20/05/90	66.0	97.0 g/l	73.00	79.00	91.00	75.00						
			ALBUMINE	20/05/90	32.0	55.0 g/l	44.00	48.00	51.00	43.00						
			TOT. CHOLEST.	20/05/90	3.0	8.7 mmol/l	6.00	7.20	6.60	5.50						
			TRIGLYCERIDES	20/05/90	0.3	1.8 mmol/l	1.70	1.30	1.40	1.40						
			GLOBULINS: ALPHA1	20/05/90	2.5	4.0 %	3.10	1.20	1.60	3.30						
			GLOBULINS: ALPHA2	20/05/90	7.0	10.0 %	8.00	7.40	7.80	9.50						
			GLOBULINS: BETA	20/05/90	8.3	14.5 %	10.10	14.90	18.90	17.30						
			GLOBULINS: GAMMA	20/05/90	14.0	25.0 %	15.20	16.70	13.30	17.40						
			8-244	F		HB	20/05/90	4.0	10.0 mmol/l	14.60	15.50	14.60	14.40			
						HTC	20/05/90	36.0	53.0 %	45.00	44.00	44.00	44.00			
						RBC	20/05/90	4.0	5.8 10**6/u1	5.10	5.50	4.60	4.40			
						HRC	20/05/90	4.0	12.0 10**9/l	5.40	6.50	5.50	5.50			
						RBC: N	20/05/90	60.0	80.0 %		77.00					
						RBC: L	20/05/90	15.0	40.0 %		18.00					
RBC: E	20/05/90	0.0				2.0 %		3.00								
RBC: H	20/05/90	1.0				6.0 %		2.00								
PLATELETS	20/05/90	120.0				640.0 10**9/l	563.00	359.00	319.00	319.00						
NA+	20/05/90	138.0				158.0 mmol/l	143.00	144.00	143.00	143.00						
K+	20/05/90	3.6				5.0 mmol/l	4.40	4.40	4.80	4.80						
CA++	20/05/90	1.8				2.6 mmol/l	2.70	2.20	1.40	1.40						
PO4-	20/05/90	0.9				1.6 mmol/l	1.00	0.90	0.50	0.50						
SGOT	20/05/90	4.0				25.0 U/l	11.00	11.00	15.00	15.00						
SGPT	20/05/90	4.0				27.0 U/l	13.00	10.00	20.00	20.00						

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Pat. No.	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit									
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52			
9	8-244	F		GAMMA-GT	20/05/90	4.0	28.0	U/l	33.00	43.00	7.00						
				GLUCOSE	20/05/90	3.6	5.7	mmol/l	4.90	4.80	4.30						
				ALK. PHOSPH.	20/05/90	20.0	55.0	mmol/l	43.00	32.00	55.00						
				EUR.	20/05/90	2.0	10.0	mmol/l	4.00	5.00	3.00						
				CREATININE	20/05/90	45.0	105.0	umol/l	75.00	80.00	70.00						
				URIC ACID	20/05/90	100.0	400.0	umol/l	307.00	328.00	240.00						
				TOT. BILIRUBIN	20/05/90	2.0	20.0	umol/l	13.00	17.00	12.00						
				DIR. BILIRUBIN	20/05/90	0.0	5.0	umol/l	0.00	0.00	0.00						
				TOT. PROTEINS	20/05/90	66.0	97.0	g/l	95.00	76.00	82.00						
				ALBUMINE	20/05/90	32.0	55.0	g/l	58.00	45.00	67.00						
				TOT. CHOLEST.	20/05/90	3.0	8.7	mmol/l	7.50	6.30	7.10						
				TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/l	1.90	0.90	1.20						
				GLOBULINS: ALPHA1	20/05/90	2.5	4.0	g	1.60	1.60	1.80						
				GLOBULINS: ALPHA2	20/05/90	7.0	10.0	g	8.30	7.80	8.10						
				GLOBULINS: BETA	20/05/90	8.3	14.5	g	17.50	12.30	16.70						
				GLOBULINS: GAMMA	20/05/90	14.0	25.0	g	18.40	16.20	21.30						
				12-247	F			HB	20/05/90	4.0	10.0	mmol/l	13.00	13.70			
								HTC	20/05/90	36.0	53.0	%	41.00	42.00			
								RBC	20/05/90	4.0	5.8	10**6/ul	4.40	4.70			
								WBC	20/05/90	4.0	12.0	10**3/ul	6.60	8.40			
PLATELETS	20/05/90	120.0	640.0					10**9/l	226.00	218.00							
NA+	20/05/90	138.0	158.0					mmol/l	148.00	144.00							
K+	20/05/90	3.6	5.0					mmol/l	4.70	4.30							
CA++	20/05/90	1.8	2.6					mmol/l	2.10	1.70							
PO4--	20/05/90	0.9	1.6					mmol/l	0.70	1.10							
SGPT	20/05/90	4.0	25.0					U/l	9.00	7.00							
SGOT	20/05/90	4.0	27.0					U/l	8.00	8.00							
GAMMA-GT	20/05/90	4.0	28.0					U/l	18.00	11.00							
GLUCOSE	20/05/90	3.6	5.7					mmol/l	5.20	5.20							
ALK. PHOSPH.	20/05/90	20.0	55.0					mmol/l	98.00	29.00							
URON	20/05/90	2.0	10.0					mmol/l	5.00	32.00							
CREATININE	20/05/90	45.0	105.0					umol/l	80.00	90.00							
URIC ACID	20/05/90	100.0	400.0					umol/l	195.00	174.00							
TOT. BILIRUBIN	20/05/90	2.0	20.0					umol/l	10.00	7.00							
DIR. BILIRUBIN	20/05/90	0.0	5.0					umol/l	0.00	0.00							
TOT. PROTEINS	20/05/90	66.0	97.0					g/l	80.00	70.00							
ALBUMINE	20/05/90	32.0	55.0	g/l	59.00	48.00											
TOT. CHOLEST.	20/05/90	3.0	8.7	mmol/l	7.30	7.10											
TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/l	0.90	1.70											
GLOBULINS: ALPHA1	20/05/90	2.5	4.0	g	1.90	3.20											
GLOBULINS: ALPHA2	20/05/90	7.0	10.0	g	7.70	9.80											

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

1975

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit								
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52		
9	12-247	F	GLOBULINS: BETA GLOBULINS: GAMMA	20/05/90 20/05/90	8.3 14.0	14.5 % 25.0 %	11.10 14.40	18.50 14.30							
13-248	F		HB	20/05/90	4.0	10.0	mmol/l	11.60	11.50	11.80	10.60	137.00	107.00	107.00	107.00
			HCT	20/05/90	36.0	53.0	%	36.00	34.00	34.00	32.00	144.00	144.00	144.00	144.00
			RBC	20/05/90	4.0	5.8	10**6/uL	4.10	4.00	3.90	3.80	2.20	4.80	5.00	4.50
			WBC	20/05/90	4.0	12.0	10**3/uL	6.30	7.90	8.00	4.50	1.00	2.30	0.80	1.00
			WBC: N	20/05/90	60.0	80.0	%		69.00			12.00	15.00	15.00	10.00
			WBC: L	20/05/90	15.0	40.0	%		20.00				7.00	7.00	6.00
			WBC: E	20/05/90	0.0	5.0	%		7.00						1.00
			WBC: M	20/05/90	1.0	6.0	%		4.00						4.00
			WBC: B	20/05/90	0.0	1.0	%								0.00
			PLATELETS	20/05/90	120.0	640.0	10**9/l	246.00	204.00	180.00	143.00	143.00	146.00	146.00	146.00
			Na+	20/05/90	138.0	158.0	mmol/l	143.00	144.00	143.00	142.00	142.00	144.00	144.00	145.00
			K+	20/05/90	3.6	5.0	mmol/l	4.70	4.90	5.00	4.80	5.00	5.00	5.00	4.50
			Ca++	20/05/90	1.8	2.6	mmol/l	2.00	2.00	2.20	2.20	2.20	2.30	2.30	2.10
			PO4--	20/05/90	0.3	1.6	mmol/l	0.70	1.20	0.70	1.00	1.00	0.80	0.80	1.00
			SGOT	20/05/90	4.0	25.0	U/l	11.00	13.00	10.00	12.00	12.00	15.00	15.00	10.00
			SGPT	20/05/90	4.0	27.0	U/l	7.00	15.00	5.00	7.00	7.00	7.00	7.00	10.00
			GAMMA-GT	20/05/90	4.0	28.0	U/l	8.00	11.00	6.00	8.00	8.00	7.00	7.00	6.00
			GLUCOSE	20/05/90	3.6	5.7	mmol/l	4.30	5.00	4.10	9.30	5.40	5.40	5.40	4.50
			ALK. PHOSPH.	20/05/90	20.0	55.0	mmol/l	22.00	34.00	22.00	36.00	36.00	39.00	39.00	12.00
			BUN	20/05/90	2.0	10.0	mmol/l	6.00	7.00	5.00	5.00	5.00	8.00	8.00	5.00
			CREATININE	20/05/90	45.0	105.0	umol/l	95.00	105.00	90.00	105.00	105.00	90.00	90.00	85.00
			URIC ACID	20/05/90	100.0	400.0	umol/l	322.00	332.00	290.00	420.00	420.00	368.00	368.00	391.00
			TOT BILIRUBIN	20/05/90	2.0	20.0	umol/l	16.00	18.00	11.00	11.00	11.00	20.00	20.00	13.00
			DIR BILIRUBIN	20/05/90	0.0	5.0	umol/l	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
			TOT. PROTEINS	20/05/90	66.0	97.0	g/l	73.00	70.00	83.00	81.00	81.00	86.50	86.50	77.00
			ALBUMINE	20/05/90	32.0	55.0	g/l	51.00	49.00	48.00	48.00	48.00	45.00	45.00	40.00
			TRIGLYCERIDES	20/05/90	3.0	8.7	mmol/l	5.00	3.90	5.00	4.00	4.00	4.00	4.00	4.80
			GLOBULINS: ALPHA1	20/05/90	0.3	1.8	mmol/l	0.70	1.10	1.10	0.50	0.50	0.30	0.30	0.50
			GLOBULINS: ALPHA2	20/05/90	2.5	4.0	%	2.30	2.10	1.20	1.30	1.30	2.00	2.00	1.40
			GLOBULINS: BETA	20/05/90	7.0	10.0	%	7.20	7.70	5.90	6.30	6.30	7.90	7.90	6.50
			GLOBULINS: GAMMA	20/05/90	8.3	14.5	%	13.30	13.70	9.70	10.10	10.10	14.60	14.60	15.60
				20/05/90	14.0	25.0	%	28.50	26.40	21.00	22.20	22.20	30.60	30.60	29.90
19-251	F			22/10/91											
			HB	20/05/90	4.0	10.0	mmol/l	15.20	13.30						
			HCT	20/05/90	36.0	53.0	%	45.00	39.00						
			RBC	20/05/90	4.0	5.8	10**6/uL	5.10	4.50						
			WBC	20/05/90	4.0	12.0	10**3/uL	12.20	4.20						

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1976

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit														
					Data	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52								
9	19-251	F		HBC: N	20/05/90	60.0	80.0	%	53.00	63.00												
				HBC: L	20/05/90	15.0	40.0	%	41.00	32.00												
				HBC: E	20/05/90	0.0	5.0	%	1.00	0.00												
				HBC: H	20/05/90	1.0	6.0	%	5.00	5.00												
				HBC: B	20/05/90	0.0	1.0	%	0.00	0.00												
				PLATELETS	20/05/90	120.0	640.0	10 ⁹ /l	164.00	151.00												
				NA+	20/05/90	158.0	158.0	mmol/l	150.00	145.00												
				K+	20/05/90	3.6	5.0	mmol/l	4.10	4.40												
				CA++	20/05/90	1.8	2.6	mmol/l	2.20	2.40												
				PO4-	20/05/90	0.9	1.6	mmol/l	0.90	1.20												
				SGPT	20/05/90	4.0	25.0	U/l	7.00	19.00												
				SGOT	20/05/90	4.0	27.0	U/l	6.00	28.00												
				GAMMA-GT	20/05/90	4.0	28.0	U/l	5.00	7.00												
				GLUCOSE	20/05/90	3.6	5.7	mmol/l	5.10	3.20												
				ALK. PHOSPH.	20/05/90	20.0	55.0	mmol/l	26.00	34.00												
				CREATININE	20/05/90	2.0	10.0	mmol/l	4.00	5.00												
				URIC ACID	20/05/90	45.0	105.0	umol/l	75.00	95.00												
				TOT BILIRUBIN	20/05/90	100.0	400.0	umol/l	180.00	239.00												
				DIR BILIRUBIN	20/05/90	2.0	20.0	umol/l	14.00	6.00												
				TOT. PROTEINS	20/05/90	66.0	97.0	g/l	83.00	74.00												
				ALBUMINE	20/05/90	32.0	55.0	g/l	55.00	48.00												
				TOT. CHOLEST.	20/05/90	3.0	8.7	mmol/l	5.80	5.20												
				TRIGLYCERIDES	20/05/90	0.3	1.8	mmol/l	1.00	1.50												
				GLOBULINS: ALPHA1	20/05/90	2.5	4.0	%	1.90	6.80												
				GLOBULINS: ALPHA2	20/05/90	7.0	10.0	%	9.40	6.80												
				GLOBULINS: BETA	20/05/90	8.3	14.5	%	15.80	14.90												
				GLOBULINS: GAMMA	20/05/90	14.0	25.0	%	22.30	21.40												
				24-253	M			HB	20/05/90	4.0	10.5	mmol/l	14.70	01/04/92								
								HCT	20/05/90	38.0	53.0	%	42.00									
								HBC	20/05/90	4.0	6.0	10 ⁹ /l	4.70									
								HBC: N	20/05/90	60.0	80.0	%	5.50									
								HBC: L	20/05/90	15.0	40.0	%	27.00									
								HBC: E	20/05/90	0.0	5.0	%	3.00									
HBC: H	20/05/90	1.0	6.0					%	4.00													
HBC: B	20/05/90	0.0	1.0					%	0.00													
PLATELETS	20/05/90	120.0	640.0					10 ⁹ /l	173.00													
NA+	20/05/90	158.0	158.0					mmol/l	145.00													
K+	20/05/90	3.6	5.0					mmol/l	4.70													
CA++	20/05/90	1.8	2.6					mmol/l	2.30													

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1977

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXYTINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range		Visit		Week 10	Week 18	Week 26	Week 34	Week 42	Week 52				
					Min	Max	Unit	Unit										
9	24-253	M		PO4-	0.9	1.6	mmol/l	1.30	1.30									
				SCOT	7.0	28.0	U/l	12.00	39.00									
				SCPT	6.0	22.0	U/l	15.00	13.00									
				GAMMA-GT	6.0	28.0	U/l	12.00	43.00									
				GLUCOSE	3.6	5.7	mmol/l	3.30	4.10									
				ALK. PHOSPH.	20.0	55.0	mmol/l	44.00	44.00									
				BUN	2.0	9.0	mmol/l	4.00	6.00									
				CREATININE	55.0	105.0	umol/l	95.00	90.00									
				URIC ACID	100.0	420.0	umol/l	237.00	400.00									
				TOT. BILIRUBIN	2.0	20.0	umol/l	21.00	14.00									
				TOT. PROTEINS	66.0	97.0	g/l	67.00	68.00									
				ALBUMINE	32.0	55.0	g/l	40.00	42.00									
				TOT. CHOLEST.	3.0	8.7	mmol/l	4.00	3.70									
				TRIGLYCERIDES	0.3	1.8	mmol/l	0.90	1.10									
				GLOBULINS: ALPHA1	2.5	4.0	g	1.90	2.00									
				GLOBULINS: ALPHA2	7.0	10.0	g	6.80	11.40									
				GLOBULINS: BETA	8.3	14.5	g	15.70	17.40									
				GLOBULINS: GAMMA	14.0	25.0	g	24.40	18.80									
				25-254	F			HB	4.0	10.0	mmol/l	28/01/92	24/03/92	14/05/92	14/07/92	08/09/92		
								HTC	36.0	53.0	g	20.70	45.00	44.00	46.00	44.00	44.00	
RBC	4.0	5.8	10**6/u1					6.40	5.10	4.90	5.10	4.90	4.90					
WBC	6.0	12.0	10**3/u1					3.70	5.30	5.80	4.60	5.10	4.90					
WBC: N	80.0	80.0	%					57.00	76.00	69.00	68.00	68.00	81.00					
WBC: L	15.0	40.0	%					40.00	21.00	26.00	27.00	17.00	17.00					
WBC: E	0.0	5.0	%					0.00	0.00	1.00	1.00	2.00	2.00					
WBC: M	1.0	6.0	%					3.00	3.00	3.00	4.00	4.00	0.00					
WBC: B	0.0	1.0	%					0.00	0.00	0.00	0.00	0.00	0.00					
PLATELETS	120.0	640.0	10**9/l					78.00	152.00	159.00	140.00	140.00	260.00					
NA+	138.0	158.0	mmol/l					145.00	145.00	148.00	148.00	148.00	148.00					
K+	3.6	5.0	mmol/l					4.70	5.30	4.60	4.90	4.90	4.90					
CA++	1.8	2.6	mmol/l					2.40	2.10	2.30	1.90	2.30	2.30					
PO4-	0.9	1.6	mmol/l					0.80	1.40	0.90	1.30	0.80	0.80					
SCOT	4.0	25.0	U/l					20.00	19.00	23.00	14.00	13.00	13.00					
SCPT	4.0	27.0	U/l					31.00	26.00	37.00	21.00	21.00	21.00					
GAMMA-GT	4.0	28.0	U/l					24.00	22.00	21.00	19.00	19.00	66.00					
GLUCOSE	3.6	5.7	mmol/l					5.00	4.40	3.60	3.60	5.50	5.50					
ALK. PHOSPH.	20.0	55.0	mmol/l					35.00	22.00	28.00	28.00	41.00	41.00					
BUN	2.0	10.0	mmol/l					4.00	6.00	6.00	4.00	2.00	2.00					
CREATININE	45.0	105.0	umol/l	100.00	85.00	95.00	100.00	85.00	85.00									
URIC ACID	100.0	400.0	umol/l	351.00	279.00	278.00	264.00	374.00	374.00									
TOT. BILIRUBIN	2.0	20.0	umol/l	27.00	8.00	17.00	26.00	10.00	10.00									

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Pat. No.	Centre	Open-Blind	Sex	Laboratory Range	Date	Lab test	Range		Visit											
							Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52					
9 25-254	F				20/05/90	DIR BILIRUBIN	0.0	5.0	umol/l	6.00	80.00	78.00	7.00	72.00						
					20/05/90	TOT. PROTEINS	66.0	97.0	g/l	88.00	57.00	55.00	51.00	50.00						
					20/05/90	ALBUMINE	32.0	55.0	g/l	47.00	5.20	5.80	4.90	6.40						
					20/05/90	TOT. CHOLEST.	3.0	8.7	mmol/l	4.50	1.70	1.00	1.60	1.30						
					20/05/90	TRIGLYCERIDES	0.3	1.8	mmol/l	1.70	1.10	1.00	1.60	1.30						
					20/05/90	GLOBULINS: ALPHA1	2.5	4.0	%	1.50	2.30	2.30	1.30	6.40						
					20/05/90	GLOBULINS: ALPHA2	7.0	10.0	%	8.00	7.80	8.90	6.30	18.20						
					20/05/90	GLOBULINS: BETA	8.3	14.5	%	22.10	20.30	17.20	22.50	17.10						
					20/05/90	GLOBULINS: GAMMA	14.0	25.0	%	20.40	17.40	19.50	23.00	10.10						
					28-257	M				15/06/92	HB	4.0	10.5	mmol/l	13.40	43.40				
										20/05/90	HTC	38.0	53.0	%	42.00	42.00				
										20/05/90	PRC	4.0	6.0	10 ⁹ x6 ⁹ /ul	4.60	4.60				
										20/05/90	HRC	4.0	12.0	10 ⁹ x3 ⁹ /ul	7.50	7.70				
										20/05/90	HRC: N	60.0	80.0	%	68.00	69.00				
20/05/90	HRC: L	15.0	40.0	%						25.00	25.00									
20/05/90	HRC: E	0.0	5.0	%						4.00	2.00									
20/05/90	HRC: H	1.0	6.0	%						5.00	4.00									
20/05/90	HRC: B	0.0	1.0	%						0.00	0.00									
20/05/90	PLATELETS	120.0	640.0	10 ⁹ x9 ⁹ /l						270.00	297.00									
20/05/90	NA+	138.0	158.0	mmol/l						145.00	146.00									
20/05/90	K+	3.6	5.0	mmol/l						5.10	5.10									
20/05/90	CA++	1.8	2.6	mmol/l						2.00	2.80									
20/05/90	PO4--	0.9	1.6	mmol/l						1.08	0.80									
20/05/90	SGPT	7.0	28.0	U/l	5.00	9.00														
20/05/90	GAMMA-GT	6.0	22.0	U/l	8.00	17.00														
20/05/90	GLUCOSE	3.6	5.7	mmol/l	35.00	45.00														
20/05/90	ALK. PHOSPH.	2.0	9.0	mmol/l	29.00	42.00														
20/05/90	CREATININE	55.0	105.0	umol/l	80.00	90.00														
20/05/90	URIC ACID	100.0	420.0	umol/l	334.00	310.00														
20/05/90	TOT. BILIRUBIN	2.0	20.0	umol/l	9.00	10.00														
20/05/90	TOT. PROTEINS	66.0	97.0	g/l	93.00	75.00														
20/05/90	ALBUMINE	32.0	55.0	g/l	50.00	54.00														
20/05/90	TOT. CHOLEST.	3.0	8.7	mmol/l	9.90	6.90														
20/05/90	TRIGLYCERIDES	0.3	1.8	mmol/l	1.60	1.90														
20/05/90	GLOBULINS: ALPHA1	2.5	4.0	%	2.10	2.70														
20/05/90	GLOBULINS: ALPHA2	7.0	10.0	%	6.60	6.10														
20/05/90	GLOBULINS: BETA	8.3	14.5	%	16.10	17.50														
20/05/90	GLOBULINS: GAMMA	14.0	25.0	%	19.50	22.10														

(*): MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1979

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
RESOMETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Date	Laboratory Range			Visit						
						Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
10 4-272	F			HB	01/10/90	112.0	140.0	g/l	08/01/91	02/04/91	29/04/91				
				HCT	01/10/90	0.4	0.5	l/l	116.00	128.00	130.00				
				RBC	01/10/90	3.7	4.7	10 ¹² /l	3.57	3.95	4.15				
				WBC	01/10/90	4.0	8.8	10 ⁹ /l	4.60	5.20	6.00				
				WBC: N	01/10/90	51.0	77.0	%	57.00	68.00	63.00				
				WBC: L	01/10/90	18.0	38.0	%	35.00	25.00	34.00				
				WBC: E	01/10/90	1.0	5.0	%	4.00	4.00	2.00				
				WBC: M	01/10/90	2.0	10.0	%	3.00	3.00	1.00				
				WBC: B	01/10/90	0.0	1.0	%	1.00	0.00	0.00				
				PLATELETS	01/10/90	180.0	320.0	10 ⁹ /l	218.00	205.00	218.00				
				PL ⁺	01/10/90	135.0	150.0	mmol/l	142.00	144.00	140.00				
				CL ⁻	01/10/90	4.0	5.6	mmol/l	4.70	4.30	4.80				
				PO4 ⁻	01/10/90	0.6	1.3	mmol/l	1.15	0.89	1.57				
				SGPT	01/10/90	1.0	12.0	U/l	4.50	2.80	7.50				
				GAMMA-GT	01/10/90	1.0	9.0	U/l	5.00	11.00	5.60				
				GLUCOSE	01/10/90	10.0	66.0	U/l	22.00	18.00	28.00				
				ALK. PHOSPH.	01/10/90	3.5	5.5	mmol/l	4.60	4.80	4.10				
				CREATININE	01/10/90	3.3	360.0	mmol/l	342.00	245.00	321.00				
				URIC ACID	01/10/90	44.0	10.0	mmol/l	6.60	66.00	6.90				
				TOT BILIRUBIN	01/10/90	119.0	88.0	umol/l	72.50	66.00	76.70				
				DIR BILIRUBIN	01/10/90	8.6	20.5	umol/l	264.00	292.00	317.00				
				TOT. PROTEINS	01/10/90	65.0	4.3	umol/l	18.50	17.00	8.80				
				ALBUMINE	01/10/90	34.0	85.0	g/l	79.00	1.20	1.12				
				TOT. CHOLEST.	01/10/90	3.1	55.0	g/l	49.80	49.00	45.80				
				TRIGLYCERIDES	01/10/90	0.5	6.2	mmol/l	5.00	5.70	6.90				
				GLOBULINS: ALPHA1	01/10/90	1.3	1.9	mmol/l	1.70	1.50	1.50				
				GLOBULINS: ALPHA2	01/10/90	5.0	6.0	g/l	6.00	2.80	3.10				
GLOBULINS: BETA	01/10/90	5.0	9.0	g/l	5.80	6.70	10.30								
GLOBULINS: GAMMA	01/10/90	10.0	13.0	g/l	8.70	11.00	10.80								
							10.40								
5-273	F			HB	01/10/90	112.0	140.0	g/l	23/01/91	06/02/91					
				HCT	01/10/90	0.4	0.5	l/l	127.00	127.00					
				RBC	01/10/90	3.7	4.7	10 ¹² /l	4.00	0.40					
				WBC	01/10/90	4.0	8.8	10 ⁹ /l	5.20	3.95					
				WBC: N	01/10/90	51.0	77.0	%	76.00	5.40					
WBC: L	01/10/90	18.0	38.0	%	22.00	68.00									
WBC: E	01/10/90	1.0	5.0	%		25.00									
WBC: M	01/10/90	2.0	10.0	%											

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1988

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Date	Laboratory Range			Visit						
						Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
10 5-273	F			HRC: E	01/10/90	1.0	5.0	%	0.00	2.00					
				HRC: M	01/10/90	2.0	10.0	%	2.00	4.00					
				HRC: B	01/10/90	0.0	1.0	%	0.00	1.00					
				PLATELETS	01/10/90	180.0	320.0	10**9/l	197.00	205.00					
				KA+	01/10/90	135.0	150.0	mmol/l	140.00	150.00					
				K+	01/10/90	4.0	5.6	mmol/l	4.30	4.70					
				CL-	01/10/90	95.0	105.0	mmol/l	100.30	99.50					
				PO4-	01/10/90	0.6	1.3	mmol/l	1.59	1.25					
				SGPT	01/10/90	1.0	12.0	U/l	5.00	3.00					
				SGT	01/10/90	1.0	9.0	U/l	4.80	3.60					
				GAMMA-GT	01/10/90	10.0	66.0	U/l	20.00	21.00					
				GLUCOSE	01/10/90	3.5	5.5	mmol/l	4.10	4.50					
				ALK. PHOSPH.	01/10/90	135.0	360.0	mmol/l	264.00	163.00					
				BUN	01/10/90	3.3	10.0	mmol/l	7.60	6.40					
				CREATININE	01/10/90	44.0	88.0	umol/l	72.80	68.20					
				URIC ACID	01/10/90	119.0	357.0	umol/l	206.00	208.00					
				TOT BILIRUBIN	01/10/90	8.6	20.5	umol/l	15.50	17.40					
				DIR BILIRUBIN	01/10/90	0.5	4.3	umol/l	0.70	0.90					
				TOT. PROTEINS	01/10/90	65.0	85.0	g/l	78.00	79.00					
				ALBUMINE	01/10/90	34.0	55.0	g/l	47.00	51.40					
				TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/l	5.10	5.40					
				TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/l	1.30	1.40					
				GLOBULINS: ALPHA1	01/10/90	1.3	6.0	g/l	4.20	3.80					
				GLOBULINS: ALPHA2	01/10/90	5.0	9.0	g/l	6.10	4.90					
				GLOBULINS: BETA	01/10/90	5.0	13.0	g/l	9.80	8.20					
				GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	11.50	10.70					
10-276	F			HR	01/10/90	112.0	140.0	g/l	130.00						
				HTC	01/10/90	0.4	0.5	l/l	0.41						
				RBC	01/10/90	3.7	4.7	10**12/l	4.15						
				RBC	01/10/90	4.0	8.8	10**9/l	5.70						
				HRC: N	01/10/90	51.0	77.0	%	70.00						
				HRC: L	01/10/90	18.0	38.0	%	25.00						
				HRC: E	01/10/90	1.0	5.0	%	2.00						
				HRC: M	01/10/90	2.0	10.0	%	2.00						
				HRC: B	01/10/90	0.0	1.0	%	1.00						
				PLATELETS	01/10/90	180.0	320.0	10**9/l	220.00						
				NA+	01/10/90	135.0	150.0	mmol/l	137.00						
				K+	01/10/90	4.0	5.6	mmol/l	4.50						
				CL-	01/10/90	95.0	105.0	mmol/l	102.90						
				PO4-	01/10/90	0.6	1.3	mmol/l	1.02						
				SCOT	01/10/90	1.0	12.0	U/l	3.00						

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit																		
				Data	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52												
10 10-276	F		SGPT	01/10/90	1.0	9.0	U/l																		
			GAMMA-GT	01/10/90	10.0	66.0	U/l	8.70																	
			GLUCOSE	01/10/90	3.5	5.5	mmol/l	4.60																	
			ALK. PHOSPH.	01/10/90	135.0	360.0	nmol/l	308.00																	
			BUN	01/10/90	3.3	10.0	mmol/l	5.20																	
			CREATININE	01/10/90	44.0	88.0	umol/l	63.50																	
			URIC ACID	01/10/90	119.0	357.0	umol/l	257.00																	
			TOT BILIRUBIN	01/10/90	8.6	20.5	umol/l	12.60																	
			DIR BILIRUBIN	01/10/90	0.5	4.5	umol/l	0.60																	
			TOT. PROTEINS	01/10/90	65.0	85.0	g/l	77.00																	
			ALBUMINE	01/10/90	34.0	55.0	g/l	44.00																	
			TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/l	5.50																	
			TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/l	0.90																	
			GLOBULINS: ALPHA1	01/10/90	1.3	6.0	g/l	3.40																	
			GLOBULINS: ALPHA2	01/10/90	5.0	9.0	g/l	7.00																	
			GLOBULINS: BETA	01/10/90	5.0	13.0	g/l	6.70																	
			GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	13.90																	
			14-279	M		HB	01/10/90	129.0	150.0	g/l	144.00	17/06/91	138.00	12/08/91	148.00	07/10/91	136.00	17/12/91	146.00	10/02/92					
						HTC	01/10/90	0.4	0.5	L/L	0.44														
						RBC	01/10/90	4.0	5.0	10 ¹² /L	4.40														
WBC	01/10/90	4.0				8.8	10 ⁹ /L	5.80																	
WBC: N	01/10/90	51.0				77.0	%	67.00																	
WBC: L	01/10/90	18.0				38.0	%	28.00																	
WBC: E	01/10/90	1.0				5.0	%	2.00																	
WBC: M	01/10/90	2.0				10.0	%	3.00																	
WBC: B	01/10/90	0.0				1.0	%	0.00																	
PLATELETS	01/10/90	180.0				320.0	10 ⁹ /L	238.00	24/04/91	230.00	17/06/91	230.00	12/08/91	217.00	07/10/91	210.00	17/12/91	205.00	10/02/92						
NA+	01/10/90	135.0				150.0	mmol/L	137.00																	
CL-	01/10/90	4.0				5.6	mmol/L	4.00																	
Ca+	01/10/90	95.0				105.0	mmol/L	100.10																	
PO4-	01/10/90	0.6				1.3	mmol/L	1.17																	
SGOT	01/10/90	1.0				12.0	U/L	3.70																	
SGPT	01/10/90	1.0				9.0	U/L	1.40																	
GAMMA-GT	10/12/91	0.3				1.8	Ukat/L																		
GAMMA-GT	01/10/90	15.0				106.0	U/l	50.00																	
GLUCOSE	01/10/90	3.5				5.5	mmol/L	5.00																	
ALK. PHOSPH.	01/10/90	135.0				360.0	nmol/L	311.00																	
BUN	01/10/90	3.3	10.0	mmol/L	4.30																				
CREATININE	01/10/90	44.0	101.0	umol/L	78.00																				
URIC ACID	01/10/90	119.0	357.0	umol/L	403.00																				
URIC ACID	01/01/92	214.0	458.0	umol/L																					

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 2012A/013
Listing No.: 12.1
LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Open-Blind	Sex	Pat. No.	Laboratory test	Laboratory Range		Visit							
					Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
10	14-279	M		TOT BILIRUBIN	01/10/90	8.6	20.5	UMOL/L	16.60	14.00	18.50	16.80	16.80	25.20
				DIR BILIRUBIN	10/12/91	0.5	4.3	UMOL/L	3.40	1.12	1.90	2.80	1.90	2.80
				TOT. PROTEINS	01/10/90	65.0	85.0	G/L	81.00	81.00	83.00	78.00	80.00	75.00
				ALBUMINE	01/10/90	34.0	55.0	G/L	45.70	51.40	51.90	44.50	41.30	48.40
				TOT. CHOLEST.	01/10/90	9.1	6.2	MMOL/L	5.30	4.00	4.80	5.00	5.90	3.90
				TRIGLYCERIDES	01/10/90	0.5	1.9	MMOL/L	2.00	1.58	1.74	1.82	1.82	1.25
				GLOBULINS: ALPHA1	01/10/90	1.3	6.0	G/L	1.40	3.60	2.40	1.40	4.70	2.20
				GLOBULINS: ALPHA2	01/10/90	5.0	9.0	G/L	11.90	4.90	7.80	9.10	7.80	6.60
				GLOBULINS: BETA	01/10/90	5.0	13.0	G/L	10.00	8.30	12.30	11.50	10.30	8.80
				GLOBULINS: GAMMA	01/10/90	10.0	17.0	G/L	12.00	12.80	8.60	11.50	15.90	9.00
16-281		F		HB	01/10/90	112.0	140.0	G/L	156.00	126.00	137.00	136.00	114.00	131.00
				HTC	01/10/90	0.4	0.5	L/L	0.43	0.58	0.42	0.39	0.34	0.42
				RBC	01/10/90	3.7	4.7	10**12/L	4.27	3.78	4.15	3.97	3.59	4.15
				WBC	01/10/90	4.0	8.8	10**9/L	3.80	4.80	5.30	6.90	3.60	4.90
				WBC: N	01/10/90	51.0	77.0	%	70.00	66.00	66.00	72.00	60.00	66.00
				WBC: L	01/10/90	18.0	38.0	%	26.00	26.00	28.00	18.00	36.00	28.00
				WBC: E	01/10/90	1.0	5.0	%	2.00	2.00	2.00	2.00	0.00	3.00
				WBC: M	01/10/90	2.0	10.0	%	2.00	4.00	4.00	8.00	4.00	3.00
				WBC: B	01/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00
				PLATELETS	01/10/90	180.0	320.0	10**9/L	225.00	218.00	220.00	225.00	200.00	205.00
				NA+	01/10/90	135.0	150.0	MMOL/L	137.00	140.00	145.00	143.00	141.00	138.00
				K+	01/10/90	4.0	5.6	MMOL/L	4.10	4.10	4.40	4.40	5.10	5.30
				CL-	01/10/90	95.0	105.0	MMOL/L	97.50	101.00	104.20	103.10	102.00	97.50
				PO4-	01/10/90	0.6	1.3	MMOL/L	0.95	1.08	1.02	0.89	0.93	1.24
				SGOT	01/10/90	1.0	12.0	U/L	3.80	4.60	3.50	3.50	6.00	1.00
				SGPT	01/10/90	1.0	9.0	U/L	3.40	8.00	7.50	3.00	8.00	1.00
				GAMMA-GT	10/12/91	0.2	1.1	UKAT/L	14.00	15.00	23.00	27.00	1.95	0.15
				GAMMA-GT	01/10/90	10.0	66.0	U/L	4.20	4.80	4.00	3.50	5.80	4.10
				GLUCOSE	01/10/90	3.5	5.5	MMOL/L	4.60	4.80	4.00	3.50	5.80	4.10
				ALK. PHOSPH.	01/10/90	135.0	360.0	MMOL/L	167.00	168.00	166.00	149.00	324.00	127.00
				BUN	01/10/90	3.3	10.0	MMOL/L	4.40	3.60	5.80	3.30	4.60	5.83
				CREATININE	01/10/90	44.0	88.0	UMOL/L	73.90	60.20	84.70	80.90	77.70	63.10
				URIC ACID	01/10/90	119.0	357.0	UMOL/L	168.00	209.00	258.00	212.00	301.00	162.00
				URIC ACID	01/01/92	149.0	405.0	UMOL/L	18.00	17.60	16.90	20.30	10.40	8.40
				TOT BILIRUBIN	01/10/90	8.6	20.5	UMOL/L	3.40	1.12	1.90	2.80	1.90	2.80
				DIR BILIRUBIN	01/10/90	0.5	4.3	UMOL/L	3.40	1.12	1.90	2.80	1.90	2.80
				TOT. PROTEINS	01/10/90	65.0	85.0	G/L	81.00	81.00	83.00	78.00	80.00	75.00
				ALBUMINE	01/10/90	34.0	55.0	G/L	45.70	51.40	51.90	44.50	41.30	48.40
				TOT. CHOLEST.	01/10/90	9.1	6.2	MMOL/L	5.30	4.00	4.80	5.00	5.90	3.90
				TRIGLYCERIDES	01/10/90	0.5	1.9	MMOL/L	2.00	1.58	1.74	1.82	1.82	1.25
				GLOBULINS: ALPHA1	01/10/90	1.3	6.0	G/L	1.40	3.60	2.40	1.40	4.70	2.20
				GLOBULINS: ALPHA2	01/10/90	5.0	9.0	G/L	11.90	4.90	7.80	9.10	7.80	6.60
				GLOBULINS: BETA	01/10/90	5.0	13.0	G/L	10.00	8.30	12.30	11.50	10.30	8.80
				GLOBULINS: GAMMA	01/10/90	10.0	17.0	G/L	12.00	12.80	8.60	11.50	15.90	9.00

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1
LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit						
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
10 16-281	F			GLOBULINS: ALPHA1	01/10/90	1.3	6.0	G/L	2.70	3.10	4.30	3.10	4.00	1.30
				GLOBULINS: ALPHA2	01/10/90	5.0	9.0	G/L	8.20	7.50	7.00	7.50	7.60	7.00
				GLOBULINS: BETA	01/10/90	5.0	13.0	G/L	8.40	4.40	8.80	8.60	13.00	6.70
				GLOBULINS: GAMMA	01/10/90	10.0	17.0	G/L	9.40	15.00	9.70	7.80	8.30	10.00
				HB	01/10/90	112.0	140.0	G/L	134.00	135.00	131.00	136.00	132.00	141.00
				HCT	01/10/90	0.4	0.5	L/L	0.42	0.42	0.39	0.42	0.42	0.42
				RBC	01/10/90	3.7	4.7	10**12/L	4.20	4.18	3.90	4.17	4.20	4.25
				WBC	01/10/90	4.0	8.8	10**9/L	4.30	4.40	6.60	5.70	5.90	9.80
				WBC: N	01/10/90	51.0	77.0	%	62.00	72.00	60.00	61.00	72.00	64.00
				WBC: L	01/10/90	18.0	38.0	%	31.00	24.00	36.00	33.00	22.00	34.00
17-282	F			WBC: E	01/10/90	1.0	5.0	%	3.00	2.00	0.00	3.00	2.00	0.00
				WBC: M	01/10/90	2.0	10.0	%	4.00	2.00	4.00	3.00	4.00	2.00
				WBC: B	01/10/90	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00
				PLATELETS	01/10/90	180.0	320.0	10**9/L	225.00	220.00	183.00	220.00	227.00	227.00
				NA+	01/10/90	135.0	150.0	MMOL/L	140.00	140.00	142.00	142.00	136.00	141.00
				K+	01/10/90	4.0	5.6	MMOL/L	4.00	4.40	4.70	4.50	4.60	5.20
				CL-	01/10/90	95.0	105.0	MMOL/L	97.10	96.00	100.90	104.10	97.00	100.30
				PO4--	01/10/90	0.6	1.3	MMOL/L	1.08	1.28	0.99	1.22	1.13	1.07
				SGPT	01/10/90	1.0	12.0	U/L	3.40	4.00	8.40	7.50	1.50	4.50
				SGPT	01/01/92	1.0	9.0	U/L	3.80	8.30	6.20	6.80	4.50	3.50
19-284	F			GAMMA-GT	01/01/92	0.2	1.1	UKAT/L	18.00	15.00	20.00	33.00	4.00	4.50
				GAMMA-GT	01/10/90	10.0	66.0	U/L	18.00	4.90	3.10	5.50	4.00	4.50
				GLUCOSE	01/10/90	3.5	5.5	MMOL/L	4.50	3.99.00	4.11.00	4.38.00	352.00	352.00
				ALK. PHOSPH.	01/10/90	3.3	10.0	MMOL/L	7.10	6.60	5.40	5.90	6.10	9.49
				BUN	01/10/90	44.0	88.0	UMOL/L	70.40	67.70	69.30	66.00	72.80	69.40
				CREATININE	01/10/90	119.0	357.0	UMOL/L	344.00	304.00	401.00	278.00	278.00	292.00
				URIC ACID	01/01/92	149.0	405.0	UMOL/L	18.00	18.50	16.10	14.60	349.00	292.00
				TOT BILIRUBIN	01/10/90	8.6	20.5	UMOL/L	18.00	18.50	16.10	14.60	13.50	10.40
				DIR BILIRUBIN	01/10/90	0.5	4.3	UMOL/L	2.20	1.90	2.50	2.50	2.00	1.00
				TOT. PROTEINS	01/10/90	65.0	85.0	G/L	80.00	82.00	80.00	82.00	79.00	75.00
19-284	F			ALBUMINE	01/10/90	34.0	55.0	G/L	46.20	49.00	50.30	48.20	47.10	47.10
				TOT. CHOLEST.	01/10/90	3.1	6.2	MMOL/L	6.90	5.90	6.90	5.10	6.50	5.20
				TRIGLYCERIDES	01/10/90	0.5	1.9	MMOL/L	1.24	1.88	1.90	1.08	0.95	0.58
				GLOBULINS: ALPHA1	01/10/90	1.3	6.0	G/L	5.10	2.00	3.00	4.10	3.00	3.20
				GLOBULINS: ALPHA2	01/10/90	5.0	9.0	G/L	7.90	8.80	8.20	9.10	8.50	7.30
				GLOBULINS: BETA	01/10/90	5.0	13.0	G/L	8.60	10.80	8.20	10.80	9.20	8.60
				GLOBULINS: GAMMA	01/10/90	10.0	17.0	G/L	12.20	9.90	9.70	9.80	11.10	8.80
				GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	12.20	9.90	9.70	9.80	11.10	8.80
				GLOBULINS: GAMMA	05/08/91	10.0	17.0	G/L	12.20	9.90	9.70	9.80	11.10	8.80
				GLOBULINS: GAMMA	25/11/91	10.0	17.0	G/L	12.20	9.90	9.70	9.80	11.10	8.80

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit						
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
10 19-284	F			HB	01/10/90	112.0	140.0	G/L	140.00	131.00	138.00	138.00	138.00	138.00
				HCT	01/10/90	0.4	0.5	L/L	0.40	0.41	0.42	0.43	0.43	0.42
				RBC	01/10/90	3.7	4.7	10**12/L	3.95	4.10	4.17	4.08	4.27	4.12
				HBC	01/10/90	4.0	8.8	10**9/L	5.80	4.90	5.40	5.50	3.90	7.70
				HBC: N	01/10/90	51.0	77.0	%	65.00	72.00	69.00	64.00	58.00	58.00
				HBC: L	01/10/90	18.0	38.0	%	30.00	24.00	24.00	32.00	36.00	36.00
				HBC: E	01/10/90	1.0	5.0	%	1.00	0.00	4.00	0.00	2.00	0.00
				HBC: M	01/10/90	2.0	10.0	%	3.00	4.00	3.00	4.00	4.00	6.00
				HBC: B	01/10/90	0.0	1.0	%	1.00	0.00	0.00	0.00	0.00	0.00
				PLATELETS	01/10/90	180.0	320.0	10**9/L	217.00	227.00	225.00	210.00	218.00	215.00
				NA+	01/10/90	135.0	150.0	MMOL/L	133.00	144.00	139.00	141.00	144.00	136.00
				K+	01/10/90	4.0	5.6	MMOL/L	3.90	4.40	4.40	4.20	4.60	4.60
				CL-	01/10/90	95.0	105.0	MMOL/L	98.00	99.50	103.70	108.00	104.80	100.30
				PO4-	01/10/90	0.6	1.3	MMOL/L	1.40	1.07	1.05	1.16	1.26	1.16
				SGOT	01/10/90	1.0	12.0	U/L	4.80	6.00	5.00	3.00	5.50	6.00
				SGPT	01/10/90	1.0	9.0	U/L	11.90	4.00	4.00	2.50	7.00	6.60
				GAMMA-GT	01/01/92	0.2	1.1	UKAT/L	26.00	30.00	44.00	0.20	0.57	0.30
				GAMMA-GT	01/10/90	10.0	66.0	U/L	4.30	4.50	4.80	4.50	4.50	4.50
				GLUCOSE	01/10/90	3.5	5.5	MMOL/L	153.00	265.00	234.00	281.00	234.00	144.00
				ALK. PHOSPH.	01/10/90	3.3	10.0	MMOL/L	4.80	5.20	3.50	4.40	4.60	5.80
				UREA	01/10/90	4.0	88.0	UMOL/L	71.30	69.70	59.70	69.40	63.40	74.50
				CREATININE	01/10/90	44.0	88.0	UMOL/L	147.00	179.00	154.00	165.00	165.00	139.00
				URIC ACID	01/01/92	149.0	405.0	UMOL/L	15.20	11.30	15.50	13.50	92.00	8.40
				TOT. BILIRUBIN	01/10/90	8.6	20.5	UMOL/L	0.56	1.40	1.70	1.40	10.60	8.40
				DIR. BILIRUBIN	01/10/90	0.5	4.3	UMOL/L	81.00	83.00	84.00	74.00	1.10	1.10
				TOT. PROTEINS	01/10/90	65.0	85.0	G/L	51.50	54.30	55.30	43.30	76.00	73.00
				ALBUMINE	01/10/90	34.0	55.0	G/L	5.40	4.10	4.60	4.00	46.80	46.80
				TOT. CHOLEST.	01/10/90	3.1	6.2	MMOL/L	1.20	1.09	1.09	1.22	3.20	3.20
				TRIGLYCERIDES	01/10/90	0.5	1.9	MMOL/L	1.90	3.20	1.90	2.90	1.42	1.25
				GLOBULINS: ALPHA1	01/10/90	1.3	6.0	G/L	9.00	7.60	7.50	8.50	1.50	1.50
				GLOBULINS: ALPHA2	01/10/90	5.0	9.0	G/L	9.20	7.80	9.40	10.30	6.60	6.60
				GLOBULINS: BETA	01/10/90	5.0	13.0	G/L	9.40	7.80	9.40	10.30	7.80	7.30
				GLOBULINS: GAMMA	01/10/90	10.0	17.0	G/L	9.40	10.10	9.90	9.00	9.00	10.80

21-288	F			HB	08/07/91	112.0	140.0	G/L	123.00	124.00	124.00	124.00	124.00	
				HCT	01/10/90	0.4	0.5	L/L	0.39	0.38	0.38	0.38	0.38	0.38
				RBC	01/10/90	3.7	4.7	10**12/L	3.84	3.72	3.84	3.72	3.72	3.72
				HBC	01/10/90	4.0	8.8	10**9/L	6.20	4.40	4.40	4.40	4.40	4.40
				HBC: N	01/10/90	51.0	77.0	%	72.00	66.00	66.00	66.00	66.00	66.00
				HBC: L	01/10/90	18.0	38.0	%	24.00	29.00	29.00	29.00	29.00	29.00
HBC: E	01/10/90	1.0	5.0	%	0.00	2.00	2.00	2.00	2.00	2.00				

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOMETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit										
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52				
10 21-288	F			RBC: M	01/10/90	2.0	10.0	%	4.00									
				RBC: B	01/10/90	0.0	1.0	%	0.00									
				PLATELETS	01/10/90	180.0	320.0	10**9/L	218.00									
				NA+	01/10/90	135.0	150.0	mmol/L	138.00									
				K+	01/10/90	4.0	5.6	mmol/L	4.60									
				Cl-	01/10/90	95.0	105.0	mmol/L	98.00									
				PO4-	01/10/90	0.5	1.3	mmol/L	1.60									
				SGOT	01/10/90	1.0	12.0	U/l	5.80									
				SGPT	01/10/90	1.0	9.0	U/l	4.40									
				GARRA-GT	01/10/90	10.0	65.0	U/l	17.00									
				GLUCOSE	01/10/90	3.5	5.5	mmol/L	4.60									
				ALK. PHOSPH.	01/10/90	135.0	360.0	mmol/L	246.00									
				UREA	01/10/90	3.3	10.0	mmol/L	6.50									
				CREATININE	01/10/90	44.0	88.0	umol/L	61.60									
				URIC ACID	01/10/90	119.0	357.0	umol/L	276.00									
				DIR. BILIRUBIN	01/10/90	8.6	20.5	umol/L	16.80									
				TOT. BILIRUBIN	01/10/90	0.5	4.3	umol/L	1.12									
				TOT. PROTEINS	01/10/90	65.0	85.0	g/l	81.00									
				ALBUMINE	01/10/90	34.0	55.0	g/l	48.00									
				TOT. CHOLEST.	01/10/90	3.1	6.2	mmol/L	5.00									
				TRIGLYCERIDES	01/10/90	0.5	1.9	mmol/L	0.68									
				GLOBULINS: ALPHA1	01/10/90	1.3	6.0	g/l	3.10									
				GLOBULINS: ALPHA2	01/10/90	5.0	9.0	g/l	6.60									
				GLOBULINS: BETA	01/10/90	5.0	13.0	g/l	6.40									
				GLOBULINS: GAMMA	01/10/90	10.0	17.0	g/l	16.90									
24-289	M			HB	01/10/90	129.0	150.0	g/L	135.00		08/07/91	17/12/91	29/10/91	02/09/91	18/02/92	28/04/92		
				HTC	01/10/90	0.4	0.5	L/L	0.42		145.00	130.00	139.00	145.00	161.00	153.00		
				ERC	01/10/90	4.0	5.0	10**12/L	4.17		0.44	0.43	0.43	0.44	0.43	0.43		
				WBC	01/10/90	4.0	8.8	10**9/L	6.70		4.37	3.79	4.25	4.37	4.28	4.30		
				WBC: N	01/10/90	51.0	77.0	%	6.80		6.80	5.80	5.80	6.80	3.20	6.00		
				WBC: L	01/10/90	18.0	38.0	%	80.00		70.00	62.00	62.00	70.00	64.00	58.00		
				WBC: E	01/10/90	1.0	5.0	%	27.00		23.00	36.00	36.00	30.00	30.00	38.00		
				WBC: M	01/10/90	2.0	10.0	%	0.00		4.00	0.00	0.00	2.00	0.00	2.00		
				RBC: B	01/10/90	0.0	1.0	%	1.00		3.00	0.00	0.00	0.00	0.00	0.00		
				PLATELETS	01/10/90	180.0	320.0	10**9/L	220.00		234.00	193.00	230.00	234.00	198.00	225.00		
				HA+	01/10/90	135.0	150.0	mmol/L	140.00		144.00	143.00	143.00	144.00	140.00	142.00		
				K+	01/10/90	4.0	5.6	mmol/L	4.40		4.50	4.50	4.50	4.70	4.70	4.10		
				Cl-	01/10/90	95.0	105.0	mmol/L	94.10		98.00	100.50	100.50	104.20	104.20	101.00		
				PO4-	01/10/90	0.6	1.3	mmol/L	1.10		1.09	0.85	0.85	0.98	0.98	0.94		
				SGOT	01/10/90	1.0	12.0	U/l	6.00		6.00	6.00	6.00	6.00	10.60	3.00		
				SGPT	01/10/90	1.0	9.0	U/l	3.70		5.00	3.00	3.00	6.90	6.90	2.50		

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1
LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

9550077

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range		Visit																																				
					Date	Min	Max	Unit	Week 10	Week 13	Week 26	Week 34	Week 42	Week 52																													
10 24-289	M			GAMMA-GT	10/12/91	0.3	1.8	UKAT/L										0.15				0.57												0.42									
				GAMMA-GT	01/10/90	15.0	106.0	U/L	16.00			63.00													4.70											3.70							
				GLUCOSE	01/10/90	3.5	5.5	MMOL/L	4.70			4.30													203.00												171.00						
				ALK. PHOSPH.	01/10/90	135.0	360.0	MMOL/L	290.00			531.00													7.50												4.80						
				RUN.	01/10/90	3.3	10.0	MMOL/L	7.90			7.50													72.90													65.60					
				CREATININE	01/10/90	44.0	101.0	UMOL/L	72.50			71.70													347.00																		
				URIC ACID	01/10/90	119.0	357.0	UMOL/L	274.00			328.00																															
				TOT BILIRUBIN	01/10/90	8.6	20.5	UMOL/L	8.40			11.30													8.70													287.00					
				DIR BILIRUBIN	10/12/91	0.5	4.3	UMOL/L				1.10																										12.60					
				DIR BILIRUBIN	01/10/90	0.0	5.1	umol/L	0.56			1.10																										1.40					
				TOT. PROTEINS	01/10/90	65.0	85.0	G/L	80.00			82.00													78.00													80.00					
				ALBUMINE	01/10/90	34.0	55.0	G/L	48.00			50.10													53.00													43.50					
				TOT. CHOLEST.	01/10/90	3.1	6.2	MMOL/L	5.60			3.20													2.90													3.20					
				TRIGLYCERIDES	01/10/90	0.5	1.9	MMOL/L	1.50			1.62													1.36													0.85					
				GLOBULINS: ALPHA1	01/10/90	1.3	6.0	G/L	2.90			2.00													1.40													2.10					
				GLOBULINS: ALPHA2	01/10/90	5.0	9.0	G/L	6.40			7.50													6.20													9.50					
				GLOBULINS: BETA	01/10/90	5.0	13.0	G/L	6.70			9.50													7.30													10.00					
				GLOBULINS: GAMMA	01/10/90	10.0	17.0	G/L	16.00			12.90													10.10													14.90					
				29-293	M			HB	01/10/90	129.0	150.0	G/L													29/10/91													23/12/91					
								HTC	01/10/90	0.4	0.5	L/L	138.00			144.00																											
								RBC	01/10/90	4.0	5.0	10**12/L	0.42			0.43																											
								WBC	01/10/90	4.0	8.8	10**9/L	6.70			7.20																											
								WBC: N	01/10/90	51.0	77.0	%	64.00			66.00																											
WBC: L	01/10/90	18.0	38.0					%	26.00			26.00																															
WBC: E	01/10/90	1.0	5.0					%	4.00			4.00																															
WBC: M	01/10/90	2.0	10.0					%	6.00			6.00																															
WBC: B	01/10/90	0.0	1.0					%	0.00			0.00																															
PLATELETS	01/10/90	180.0	320.0					10**9/L	228.00			230.00																															
HA+	01/10/90	135.0	150.0					MMOL/L	142.00			135.00																															
K+	01/10/90	4.0	5.6					MMOL/L	4.50			4.60																															
CL-	01/10/90	95.0	105.0					MMOL/L	106.30			99.00																															
PO4-	01/10/90	0.6	1.3					MMOL/L	0.97			0.95																															
SGPT	01/10/90	1.0	12.0					U/L	3.00			2.50																															
SGPT	01/10/90	1.0	9.0					U/L	2.00			4.50																															
GAMMA-GT	10/12/91	0.3	1.8					UKAT/L				0.86																															
GAMMA-GT	01/10/90	15.0	106.0					U/L	66.00			4.30																															
GLUCOSE	01/10/90	3.5	5.5					MMOL/L	4.20			4.30																															
ALK. PHOSPH.	01/10/90	135.0	360.0					MMOL/L	225.00			343.00																															
RUN	01/10/90	3.3	10.0					MMOL/L	3.80			5.60																															
CREATININE	01/10/90	44.0	101.0					UMOL/L	91.30			71.10																															

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit												
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52						
10 29-293	M			URIC ACID	01/10/90	119.0	357.0	UMOL/L	392.00	428.00										
				TOT BILIRUBIN	10/12/91	8.6	20.5	UMOL/L	19.00	17.70										
				DIR BILIRUBIN	01/10/90	0.5	4.3	UMOL/L		2.50										
				TOT. PROTEINS	01/10/90	0.0	5.1	UMOL/L	3.70											
				ALBUMINE	01/10/90	65.0	85.0	G/L	81.00											
				TOT. CHOLEST.	01/10/90	34.0	55.0	G/L	51.40											
				TRIGLYCERIDES	01/10/90	3.1	6.2	MMOL/L	4.00											
				GLOBULINS: ALPHA1	01/10/90	0.5	1.9	MMOL/L	0.56											
				GLOBULINS: ALPHA2	01/10/90	1.3	6.0	G/L	2.10											
				GLOBULINS: BETA	01/10/90	5.0	9.0	G/L	8.50											
				GLOBULINS: GAMMA	01/10/90	5.0	13.0	G/L	7.10											
					01/10/90	10.0	17.0	G/L	11.90											
				30-294	F			HB	01/10/90	112.0	140.0	G/L	127.00	130.00	16/03/92	11/05/92	06/07/92	29/09/92		
								HCT	01/10/90	0.4	0.5	L/L	0.39	0.41	135.00	124.00	126.00	112.00		
								RBC	01/10/90	3.7	4.7	10**12/L	3.91	4.15	0.42	0.38	0.38	0.37		
								WBC	01/10/90	4.0	8.8	10**9/L	4.10	5.40	4.17	3.75	3.80	3.36		
								WBC: N	01/10/90	51.0	77.0	%	62.00	70.00	5.70	6.60	6.60	4.30		
WBC: L	01/10/90	18.0	38.0					%	33.00	25.00	28.00	82.00	69.00	68.00						
WBC: E	01/10/90	1.0	5.0					%	3.00	3.00	4.00	14.00	24.00	30.00						
WBC: M	01/10/90	2.0	10.0					%	2.00	2.00	3.00	2.00	4.00	0.00						
WBC: B	01/10/90	0.0	1.0					%	0.00	0.00	0.00	0.00	0.00	0.00						
PLATELETS	01/10/90	180.0	320.0					10**9/L	219.00	215.00	217.00	205.00	220.00	205.00						
NA+	01/10/90	135.0	150.0					MMOL/L	138.00	147.00	143.00	141.00	138.00	140.00						
K+	01/10/90	4.0	5.6					MMOL/L	4.10	4.70	4.40	4.00	4.80	4.60						
CL-	01/10/90	95.0	105.0					MMOL/L	102.40	104.20	100.60	99.00	101.20	102.40						
PO4--	01/10/90	0.6	1.3					MMOL/L	0.90	0.74	1.18	1.47	1.04	1.04						
SGOT	01/10/90	1.0	12.0					U/L	4.00	4.50	4.50	6.00	2.50	7.00						
SGPT	01/10/90	1.0	9.0					U/L	5.50	3.50	7.00	4.50	4.00	3.60						
GAMMA-GT	01/01/92	0.2	1.1					UKAT/L		0.63	0.50	0.58	1.03	0.98						
GAMMA-GT	01/10/90	10.0	66.0					U/l	27.00				4.20	3.50						
GLUCOSE	01/10/90	3.5	5.5					MMOL/L	3.80	3.90	4.30	3.90	4.20	3.50						
ALE. PHOSPH.	01/10/90	135.0	360.0					MMOL/L	428.00	300.00	114.00	145.00	143.00	120.00						
BUN	01/10/90	3.3	10.0					MMOL/L	4.10	4.30	5.30	3.30	3.00	5.00						
CREATININE	01/10/90	44.0	88.0					UMOL/L	70.40	67.90	78.20	88.00	73.80	75.80						
URIC ACID	01/01/92	149.0	405.0					UMOL/L	289.00											
TOT BILIRUBIN	01/10/90	8.6	20.5					UMOL/L	13.70	12.60	226.00	246.00	247.00	231.00						
DIR BILIRUBIN	01/10/90	0.5	4.3					UMOL/L	2.80	1.10	9.80	9.80	12.10	12.90						
TOT. PROTEINS	01/10/90	65.0	85.0					G/L	79.00	82.00	80.00	73.00	69.00	73.00						
ALBUMINE	01/10/90	34.0	55.0					G/L	53.00	49.00	44.50	46.50	43.60	51.60						
TOT. CHOLEST.	01/10/90	3.1	6.2	MMOL/L	3.50	4.30	3.60	5.40	4.10	5.00										

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1 9 8 8

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Date	Laboratory Range			Visit						
					Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
10 30-294	F		TRIGLYCERIDES	01/10/90	0.5	1.9	MMOL/L	0.89	1.40	2.41	2.68	2.32	1.76	
			GLOBULINS: ALPHA1	01/10/90	1.3	6.0	G/L	1.80	2.40	2.20	1.80	2.40	2.70	
			GLOBULINS: ALPHA2	01/10/90	5.0	9.0	G/L	7.60	8.40	11.20	6.90	6.50	4.80	
			GLOBULINS: BETA	01/10/90	5.0	13.0	G/L	8.40	11.80	13.00	7.70	7.30	7.50	
			GLOBULINS: GAMMA	01/10/90	10.0	17.0	G/L	8.20	10.40	9.10	10.10	9.20	6.40	
			HB	10/12/91	112.0	140.0	G/L	118.00	140.00	134.00				
			HTC	10/12/91	0.4	0.5	L/L	0.36	0.39	0.42				
			RBC	10/12/91	3.7	4.7	10**12/L	3.63	4.20	4.15				
			WBC	10/12/91	4.0	8.8	10**9/L	7.30	6.30	6.20				
			MBC: N	10/12/91	51.0	77.0	%	78.00	74.00	67.00				
MBC: L	10/12/91	18.0	38.0	%	20.00	20.00	21.00							
MBC: E	10/12/91	1.0	5.0	%	2.00	4.00	0.00							
MBC: M	10/12/91	2.0	10.0	%	0.00	2.00	0.00							
MBC: B	10/12/91	0.0	1.0	%	0.00	0.00	0.00							
PLATELETS	10/12/91	180.0	320.0	10**9/L	195.00	205.00	217.00							
NA+	10/12/91	135.0	150.0	MMOL/L	145.00	130.00	140.00							
K+	10/12/91	95.0	105.0	MMOL/L	101.00	105.00	106.50							
PO4-	10/12/91	0.6	1.3	MMOL/L	1.37	1.41	1.23							
SGPT	10/12/91	1.0	12.0	U/L	7.00	8.00	3.00							
SGOT	10/12/91	1.0	9.0	U/L	5.00	7.00	4.00							
GAMMA-GT	10/12/91	0.2	1.1	UKATY/L	0.50	1.15	0.90							
GLUCOSE	10/12/91	3.5	5.5	MMOL/L	5.30	4.40	4.20							
ALK. PHOSPH.	10/12/91	135.0	360.0	MMOL/L	141.00	128.00	99.00							
CREATININE	10/12/91	3.3	10.0	MMOL/L	4.10	5.70	4.30							
URIC ACID	10/12/91	119.0	357.0	UMOL/L	68.10	84.70	71.40							
URIC ACID	01/01/92	149.0	405.0	UMOL/L	363.00									
TOT BILIRUBIN	10/12/91	8.6	20.5	UMOL/L	8.90	370.00	242.00							
DIR BILIRUBIN	10/12/91	0.5	4.3	UMOL/L	1.70	8.20	15.10							
TOT. PROTEINS	10/12/91	65.0	85.0	G/L	82.00	79.00	81.00							
ALBUMINE	10/12/91	34.0	58.0	G/L	44.80	53.40	53.00							
TOT. CHOLEST.	10/12/91	3.1	6.2	MMOL/L	6.00	6.40	4.10							
TRIGLYCERIDES	10/12/91	0.5	1.9	MMOL/L	1.74	1.66	0.84							
GLOBULINS: ALPHA1	10/12/91	1.3	6.0	G/L	3.80	1.50	2.90							
GLOBULINS: ALPHA2	10/12/91	5.0	9.0	G/L	8.60	9.50	9.00							
GLOBULINS: BETA	10/12/91	5.0	13.0	G/L	11.80	7.60	7.80							
GLOBULINS: GAMMA	10/12/91	10.0	17.0	G/L	13.00	7.00	8.30							

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

19000

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXEMINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range		Visit									
					Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52			
10 40-33	F			HB	112.0	140.0	G/L	130.00								
				HTC	0.4	0.5	L/L	0.40								
				RBC	3.7	4.7	10**12/L	4.05								
				WBC	4.0	8.6	10**9/L	5.60								
				HBC: N	51.0	77.0	X	70.00								
				HBC: L	18.0	38.0	X	24.00								
				HBC: E	1.0	5.0	X	3.00								
				HBC: H	2.0	10.0	X	3.00								
				HBC: B	0.0	1.0	X	0.00								
				PLATELETS	180.0	320.0	10**9/L	227.00								
				NA+	135.0	150.0	MMOL/L	158.00								
				K+	4.0	5.6	MMOL/L	4.70								
				CL-	95.0	105.0	MMOL/L	100.00								
				PO4-	0.6	1.3	MMOL/L	0.82								
				SGOT	1.0	12.0	U/L	2.50								
				SGPT	1.0	9.0	U/L	1.50								
				GAMMA-GT	0.2	1.1	UKATY/L	0.31								
				GLUCOSE	3.5	5.5	MMOL/L	4.30								
				ALK. PHOSPH.	135.0	360.0	MMOL/L	229.00								
				BUN	3.3	10.0	MMOL/L	5.60								
				CREATININE	44.0	405.0	UMOL/L	74.50								
				URIC ACID	149.0	405.0	UMOL/L	224.00								
				TOT BILIRUBIN	8.6	20.5	UMOL/L	11.30								
				DIR BILIRUBIN	0.5	4.3	UMOL/L	1.70								
				TOT. PROTEINS	65.0	85.0	G/L	80.00								
				ALBUMINE	34.0	55.0	G/L	52.60								
				TOT. CHOLEST.	3.1	6.2	MMOL/L	5.20								
				TRIGLYCERIDES	0.5	1.9	MMOL/L	0.88								
				GLOBULINS: ALPHA1	1.3	6.0	G/L	2.80								
				GLOBULINS: ALPHA2	5.0	9.0	G/L	7.30								
				GLOBULINS: BETA	5.0	13.0	G/L	7.70								
				GLOBULINS: GAMMA	10.0	17.0	G/L	9.60								
42-295	M			HB	129.0	150.0	G/L	136.00								
				HTC	0.4	0.5	L/L	0.42								
				RBC	4.0	5.0	10**12/L	4.20								
				WBC	4.0	8.8	10**9/L	5.20								
				HBC: N	51.0	77.0	X	62.00								
				HBC: L	18.0	38.0	X	34.00								
				HBC: E	1.0	5.0	X	2.00								
				HBC: H	2.0	10.0	X	2.00								
				HBC: B	0.0	1.0	X	0.00								

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

1990

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52		
10	42-295	M		PLATELETS	01/01/92	180.0	320.0	10**9/L	223.00							
				NA+	01/01/92	135.0	150.0	MMOL/L	137.00							
				K+	01/01/92	4.0	5.6	MMOL/L	3.80							
				CL-	01/01/92	95.0	105.0	MMOL/L	99.00							
				PO4--	01/01/92	0.6	1.3	MMOL/L	1.30							
				SGOT	01/01/92	1.0	12.0	U/L	1.00							
				SGPT	01/01/92	1.0	9.0	U/L	1.50							
				GAMMA-GT	01/01/92	0.3	1.8	UKAT/L	1.60							
				GLUCOSE	01/01/92	3.5	5.5	MMOL/L	4.60							
				ALK. PHOSPH.	01/01/92	35.0	360.0	MMOL/L	260.00							
				BUN	01/01/92	3.3	10.0	MMOL/L	7.40							
				CREATININE	01/01/92	44.0	101.0	UMOL/L	84.50							
				URIC ACID	01/01/92	214.0	458.0	UMOL/L	535.00							
				TOT BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	8.70							
				DIR BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	0.60							
				TOT. PROTEINS	01/01/92	65.0	85.0	G/L	82.00							
				ALBUMINE	01/01/92	34.0	55.0	G/L	46.10							
				TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	5.00							
				TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	2.00							
				GLOBULINS: ALPHA1	01/01/92	1.3	6.0	G/L	2.80							
				GLOBULINS: ALPHA2	01/01/92	5.0	9.0	G/L	9.20							
				GLOBULINS: BETA	01/01/92	5.0	15.0	G/L	9.30							
				GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	14.60							
43-296		F		HB	23/01/92	112.0	140.0	G/L	132.00	19/03/92	136.00					
				HTC	01/01/92	0.4	0.5	L/L	0.42							
				RBC	01/01/92	3.7	4.7	10**12/L	4.21							
				RBC: N	01/01/92	4.0	8.8	10**9/L	5.60							
				RBC: L	01/01/92	51.0	77.0	%	72.00							
				RBC: E	01/01/92	18.0	38.0	%	22.00							
				RBC: H	01/01/92	1.0	5.0	%	5.00							
				RBC: B	01/01/92	2.0	10.0	%	1.00							
				PLATELETS	01/01/92	180.0	320.0	10**9/L	225.00							
				NA+	01/01/92	135.0	150.0	MMOL/L	138.00							
				K+	01/01/92	4.0	5.6	MMOL/L	4.70							
				CL-	01/01/92	95.0	105.0	MMOL/L	95.90							
				PO4--	01/01/92	0.6	1.3	MMOL/L	1.26							
				SGOT	01/01/92	1.0	12.0	U/L	6.00							
				SGPT	01/01/92	1.0	9.0	U/L	5.50							
				GAMMA-GT	01/01/92	0.2	1.1	UKAT/L	0.16							
				GLUCOSE	01/01/92	3.5	5.5	MMOL/L	4.30							

(*-) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit						
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
10	43-296	F		ALK. PHOSPH.	01/01/92	135.0	360.0	MMOL/L	268.00	124.00				
				BUN	01/01/92	3.3	10.0	MMOL/L	6.50	3.00				
				CREATININE	01/01/92	44.0	88.0	UMOL/L	71.10	66.80				
				URIC ACID	01/01/92	149.0	405.0	UMOL/L	344.00	251.00				
				TOT BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	15.50	8.70				
				DIR BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	1.20	0.60				
				TOT. PROTEINS	01/01/92	65.0	85.0	G/L	80.00	74.00				
				ALBUMINE	01/01/92	34.0	55.0	G/L	43.50	33.20				
				TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	4.80	3.20				
				TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	1.38	1.73				
				GLUCOLINS: ALPHA1	01/01/92	1.3	6.0	G/L	3.10	1.60				
				GLUCOLINS: ALPHA2	01/01/92	5.0	9.0	G/L	8.50	8.80				
				GLUCOLINS: BETA	01/01/92	5.0	13.0	G/L	15.20	12.90				
				GLUCOLINS: GAMMA	01/01/92	10.0	17.0	G/L	9.70	17.50				
44-298		M		HB	01/01/92	123.0	150.0	G/L	267.01/92					
				HTC	01/01/92	0.4	0.5	L/L	138.00					
				RBC	01/01/92	4.0	5.0	10**12/L	0.40					
				RBC: N	01/01/92	4.0	8.8	10**9/L	4.60					
				RBC: L	01/01/92	51.0	77.0	%	71.00					
				RBC: E	01/01/92	18.0	38.0	%	26.00					
				RBC: H	01/01/92	1.0	5.0	%	0.00					
				RBC: B	01/01/92	2.0	10.0	%	3.00					
				PLATELETS	01/01/92	0.0	1.0	%	0.00					
				NA+	01/01/92	180.0	320.0	10**9/L	223.00					
				K+	01/01/92	135.0	150.0	MMOL/L	141.00					
				CL-	01/01/92	95.0	105.0	MMOL/L	98.60					
				PO4-	01/01/92	0.6	1.3	MMOL/L	0.82					
				SGPT	01/01/92	1.0	12.0	U/L	5.50					
				GAMMA-GT	01/01/92	0.3	1.8	UKAT/L	4.00					
				GLUCOSE	01/01/92	3.5	5.5	MMOL/L	0.50					
				ALK. PHOSPH.	01/01/92	135.0	360.0	MMOL/L	160.00					
				BUN	01/01/92	3.3	10.0	MMOL/L	3.70					
				CREATININE	01/01/92	44.0	101.0	UMOL/L	77.10					
				URIC ACID	01/01/92	214.0	458.0	UMOL/L	310.00					
				TOT BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	16.40					
				DIR BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	2.80					
				TOT. PROTEINS	01/01/92	65.0	85.0	G/L	73.00					
				ALBUMINE	01/01/92	34.0	55.0	G/L	50.00					
				TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	3.70					

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
10 44-298	M			TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	0.56						
				GLOBULINS: ALPHA1	01/01/92	1.3	6.0	G/L	2.60						
				GLOBULINS: ALPHA2	01/01/92	5.0	9.0	G/L	6.00						
				GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	6.40						
				GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	8.00						
				HB	01/01/92	112.0	140.0	G/L	129.00						
				HCT	01/01/92	0.4	0.5	L/L	0.37						
				RBC	01/01/92	3.7	4.7	10**12/L	3.72						
				WBC	01/01/92	4.0	8.8	10**9/L	3.90						
				HBC: N	01/01/92	51.0	77.0	X	68.00						
HBC: L	01/01/92	18.0	38.0	X	26.00										
HBC: E	01/01/92	1.0	5.0	X	2.00										
HBC: M	01/01/92	2.0	10.0	X	4.00										
HBC: B	01/01/92	0.0	1.0	X	0.00										
PLATELETS	01/01/92	180.0	320.0	10**9/L	200.00										
NA+	01/01/92	135.0	150.0	MMOL/L	138.00										
K+	01/01/92	4.0	5.6	MMOL/L	4.20										
CL-	01/01/92	95.0	105.0	MMOL/L	95.00										
PD4-	01/01/92	0.6	1.3	MMOL/L	1.16										
SGOT	01/01/92	1.0	12.0	U/L	7.00										
SGPT	01/01/92	1.0	9.0	U/L	5.80										
GAMMA-GT	01/01/92	0.2	1.1	UKAT/L	0.50										
GLUCOSE	01/01/92	3.5	5.5	MMOL/L	5.50										
ALK. PHOSPH.	01/01/92	135.0	360.0	MMOL/L	117.00										
BUN	01/01/92	3.3	10.0	MMOL/L	3.40										
CREATININE	01/01/92	44.0	88.0	UMOL/L	72.10										
URIC ACID	01/01/92	169.0	405.0	UMOL/L	309.00										
TOT. BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	9.80										
DIR. BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	1.10										
TOT. PROTEINS	01/01/92	65.0	85.0	G/L	80.00										
ALBUMINE	01/01/92	34.0	52.0	G/L	51.50										
TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	3.90										
TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	1.15										
GLOBULINS: ALPHA1	01/01/92	1.3	6.0	G/L	1.20										
GLOBULINS: ALPHA2	01/01/92	5.0	9.0	G/L	9.50										
GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	8.70										
GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	8.40										
45-34	F			HB	01/01/92	112.0	140.0	G/L	129.00						
				HCT	01/01/92	0.4	0.5	L/L	0.37						
				RBC	01/01/92	3.7	4.7	10**12/L	3.72						
47-39	F			HB	01/01/92	112.0	140.0	G/L	139.00						
				HCT	01/01/92	0.4	0.5	L/L	0.37						
				RBC	01/01/92	3.7	4.7	10**12/L	3.72						

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOMETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit						
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
10 47-39	F			HTC	01/01/92	0.4	0.5	L/L	0.40	0.41	0.42	0.42	0.43	0.42
				RBC	01/01/92	3.7	4.7	10 ^{xx} 12/L	4.24	4.05	4.23	4.25	4.25	4.11
				HGB	01/01/92	4.0	8.8	10 ^{xx} 9/L	5.60	5.60	6.10	6.20	7.30	4.80
				HCT	01/01/92	51.0	77.0	%	88.00	75.00	80.00	84.00	77.00	74.00
				WBC	01/01/92	18.0	38.0	x	10.00	22.00	16.00	16.00	18.00	22.00
				PLT	01/01/92	1.0	5.0	x	0.00	1.00	4.00	2.00	3.00	0.00
				HAEMOGLOBIN	01/01/92	2.0	10.0	g/L	2.00	2.00	0.00	0.00	2.00	4.00
				HAEMATOCRIT	01/01/92	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00
				PLATELETS	01/01/92	180.0	320.0	10 ^{xx} 9/L	223.00	212.00	230.00	217.00	220.00	210.00
				HAEMOGLOBIN A1C	01/01/92	135.0	150.0	MMOL/L	134.00	142.00	141.00	144.00	146.00	148.00
				HAEMOGLOBIN A1B	01/01/92	4.0	5.6	MMOL/L	3.80	5.60	5.00	4.60	5.10	5.70
				HAEMOGLOBIN A2	01/01/92	95.0	105.0	MMOL/L	97.80	104.30	100.30	103.70	107.60	101.80
				HAEMOGLOBIN F	01/01/92	0.6	1.3	MMOL/L	0.91	0.94	1.18	0.91	0.96	0.84
				HAEMOGLOBIN G	01/01/92	1.0	12.0	U/L	6.00	3.00	5.00	3.50	5.50	5.00
				HAEMOGLOBIN H	01/01/92	1.0	9.0	U/L	8.10	4.00	6.50	2.70	5.80	4.50
				HAEMOGLOBIN I	01/01/92	0.2	1.1	UKATY/L	1.57	0.76	1.27	0.92	0.95	0.90
				HAEMOGLOBIN J	01/01/92	3.5	5.5	MMOL/L	4.40	3.90	3.40	4.50	5.00	5.80
				HAEMOGLOBIN K	01/01/92	135.0	360.0	MMOL/L	157.00	127.00	157.00	126.00	120.00	141.00
				HAEMOGLOBIN L	01/01/92	3.3	10.0	MMOL/L	7.80	4.30	5.20	4.16	4.50	5.80
				HAEMOGLOBIN M	01/01/92	44.0	86.0	MMOL/L	67.80	69.70	79.50	73.90	89.00	67.70
				HAEMOGLOBIN N	01/01/92	149.0	405.0	MMOL/L	130.00	229.00	300.00	270.00	331.00	290.00
				HAEMOGLOBIN O	01/01/92	8.6	20.5	MMOL/L	8.90	11.60	9.20	22.70	19.70	17.20
				HAEMOGLOBIN P	01/01/92	0.5	4.3	MMOL/L	0.80	1.70	0.70	2.00	1.00	3.60
				HAEMOGLOBIN Q	01/01/92	65.0	85.0	MMOL/L	80.00	77.00	82.00	89.00	76.00	71.00
				HAEMOGLOBIN R	01/01/92	34.0	55.0	MMOL/L	50.30	45.80	47.80	53.70	47.00	43.00
				HAEMOGLOBIN S	01/01/92	3.1	6.2	MMOL/L	4.10	5.60	5.40	4.60	3.10	5.20
				HAEMOGLOBIN T	01/01/92	0.5	1.9	MMOL/L	2.44	1.24	1.86	1.73	2.98	1.82
				HAEMOGLOBIN U	01/01/92	1.3	6.0	MMOL/L	1.00	3.40	4.00	2.80	1.00	2.20
				HAEMOGLOBIN V	01/01/92	5.0	9.0	MMOL/L	9.10	8.90	8.60	6.30	9.00	8.70
				HAEMOGLOBIN W	01/01/92	5.0	13.0	MMOL/L	8.60	9.00	9.30	10.60	9.30	9.50
				HAEMOGLOBIN X	01/01/92	10.0	17.0	MMOL/L	11.00	9.90	12.30	15.69	9.70	7.60
				HAEMOGLOBIN Y	01/01/92	112.0	140.0	MMOL/L	134.00	136.00	134.00	134.00	134.00	134.00
				HAEMOGLOBIN Z	01/01/92	0.4	0.5	MMOL/L	0.40	0.40	0.40	0.40	0.40	0.40
				HAEMOGLOBIN AA	01/01/92	3.7	4.7	10 ^{xx} 12/L	4.03	4.03	4.03	4.03	4.03	4.03
				HAEMOGLOBIN AB	01/01/92	4.0	8.8	10 ^{xx} 9/L	7.00	7.00	7.00	7.00	7.00	7.00
				HAEMOGLOBIN AC	01/01/92	51.0	77.0	%	72.00	72.00	72.00	72.00	72.00	72.00
				HAEMOGLOBIN AD	01/01/92	18.0	38.0	x	28.00	28.00	28.00	28.00	28.00	28.00
				HAEMOGLOBIN AE	01/01/92	1.0	5.0	x	0.00	0.00	0.00	0.00	0.00	0.00
				HAEMOGLOBIN AF	01/01/92	2.0	10.0	x	0.00	0.00	0.00	0.00	0.00	0.00
				HAEMOGLOBIN AG	01/01/92	0.0	1.0	x	0.00	0.00	0.00	0.00	0.00	0.00
				HAEMOGLOBIN AH	01/01/92	180.0	320.0	10 ^{xx} 9/L	230.00	230.00	230.00	230.00	230.00	230.00

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52		
10	48-41	F		NA+	01/01/92	135.0	150.0	MMOL/L	141.00							
				K+	01/01/92	4.0	5.6	MMOL/L	4.70							
				CL-	01/01/92	95.0	105.0	MMOL/L	98.40							
				PO4-	01/01/92	0.6	1.3	MMOL/L	1.07							
				SGOT	01/01/92	1.0	12.0	U/L	7.00							
				SGPT	01/01/92	1.0	9.0	U/L	4.00							
				GAMMA-GT	01/01/92	0.2	1.1	UKAT/L	0.20							
				GLUCOSE	01/01/92	3.5	5.5	MMOL/L	5.30							
				ALK. PHOSPH.	01/01/92	135.0	360.0	MMOL/L	200.00							
				BUN	01/01/92	3.3	10.0	MMOL/L	3.60							
				CREATININE	01/01/92	44.0	88.0	UMOL/L	82.70							
				URIC ACID	01/01/92	149.0	405.0	UMOL/L	218.00							
				TOT BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	14.50							
				DIR BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	1.40							
				TOT. PROTEINS	01/01/92	65.0	85.0	G/L	68.00							
				ALBUMINE	01/01/92	34.0	55.0	G/L	46.60							
				TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	4.80							
				TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	0.54							
				GLOBULINS: ALPHA1	01/01/92	1.3	6.0	G/L	1.40							
				GLOBULINS: ALPHA2	01/01/92	5.0	9.0	G/L	7.30							
				GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	5.70							
				GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	7.00							
50-44		M		HB	01/01/92	129.0	150.0	G/L	147.00	26/02/92	22/04/92	17/06/92	12/08/92	07/10/92	16/12/92	
				HTC	01/01/92	0.4	0.5	L/L	0.42	145.00	145.00	150.00	141.00	147.00	155.00	
				RBC	01/01/92	4.0	5.0	10**12/L	4.28	0.42	0.42	0.44	0.43	0.43	0.43	
				WBC	01/01/92	4.0	8.8	10**9/L	4.28	4.25	4.28	4.48	4.28	4.27	4.33	
				WBC: N	01/01/92	51.0	77.0	%	58.00	4.00	4.00	11.80	5.40	5.90	4.80	
				WBC: L	01/01/92	18.0	38.0	%	32.00	52.00	52.00	66.00	66.00	71.00	64.00	
				WBC: E	01/01/92	1.0	5.0	%	4.00	36.00	36.00	28.00	24.00	19.00	30.00	
				WBC: M	01/01/92	2.0	10.0	%	6.00	8.00	8.00	6.00	2.00	6.00	6.00	
				WBC: B	01/01/92	0.0	1.0	%	0.00	4.00	4.00	0.00	0.00	3.00	0.00	
				PLATELETS	01/01/92	180.0	320.0	10**9/L	200.00	240.00	240.00	223.00	225.00	237.00	230.00	
				NA+	01/01/92	135.0	150.0	MMOL/L	144.00	139.00	142.00	143.00	143.00	148.00	145.00	
				K+	01/01/92	4.0	5.6	MMOL/L	4.60	4.60	4.60	4.60	5.30	4.90	5.60	
				CL-	01/01/92	95.0	105.0	MMOL/L	100.30	99.40	104.90	104.90	105.10	98.50	103.50	
				PO4-	01/01/92	0.6	1.3	MMOL/L	0.95	0.95	1.09	1.09	1.20	0.94	1.16	
				SGOT	01/01/92	1.0	12.0	U/L	4.60	8.00	4.00	4.00	3.00	5.50	8.00	
				SGPT	01/01/92	1.0	9.0	U/L	7.70	9.00	6.00	4.00	6.00	6.00	2.50	
				GAMMA-GT	01/01/92	0.3	1.8	UKAT/L	0.95	0.82	0.68	0.68	0.60	0.63	0.74	
				GLUCOSE	01/01/92	3.5	5.5	MMOL/L	5.30	4.20	5.00	4.40	4.40	4.40	5.50	
				ALK. PHOSPH.	01/01/92	135.0	360.0	MMOL/L	191.00	215.00	203.00	203.00	190.00	202.00	168.00	

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit										
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52				
10 50-44	M			BUN	01/01/92	3.3	10.0	MMOL/L	5.00	7.80	5.50	5.50	5.50	5.50	4.70			
				CREATININE	01/01/92	44.0	101.0	UMOL/L	75.70	81.70	80.50	80.90	86.60	82.30				
				URIC ACID	01/01/92	214.0	458.0	UMOL/L	426.00	391.00	337.00	387.00	421.00	306.00				
				TOT BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	16.10	11.50	18.00	9.20	14.90	18.70				
				DIR BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	1.40	4.20	2.20	1.30	3.00	10.80				
				TOT. PROTEINS	01/01/92	65.0	80.0	G/L	80.00	81.00	85.00	80.00	77.00	75.00				
				ALBUMINE	01/01/92	34.0	55.0	G/L	49.00	49.40	44.30	48.80	41.40	47.60				
				TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	6.60	5.80	5.10	4.40	4.20	4.90				
				TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	4.37	1.05	3.53	2.41	1.80	1.63				
				GLUCOLINS: ALPHA1	01/01/92	1.3	6.0	G/L	1.80	2.40	3.50	2.60	5.40	3.80				
				GLUCOLINS: ALPHA2	01/01/92	5.0	9.0	G/L	10.50	10.00	8.20	5.10	7.30	2.90				
				GLUCOLINS: BETA	01/01/92	5.0	13.0	G/L	9.70	10.80	11.40	5.70	8.20	9.90				
				GLUCOLINS: GAMMA	01/01/92	10.0	17.0	G/L	9.00	8.40	17.60	17.80	14.70	10.80				
				51-45	F			HB	01/01/92	112.0	140.0	G/L	130.00	121.00	124.00	136.00	137.00	16/12/92
								HCT	01/01/92	0.4	0.5	L/L	0.39	0.37	0.38	0.41	0.42	0.38
								RBC	01/01/92	3.7	4.7	10**12/L	3.88	3.75	3.85	4.12	4.15	4.11
								WBC	01/01/92	4.0	8.8	10**9/L	5.20	4.40	6.50	6.50	7.40	7.00
WBC: N	01/01/92	51.0	77.0					%	72.00	71.00	64.00	68.00	68.00	80.00				
WBC: L	01/01/92	18.0	38.0					%	20.00	23.00	28.00	28.00	27.00	16.00				
WBC: E	01/01/92	1.0	5.0					%	2.00	2.00	4.00	4.00	2.00	2.00				
WBC: M	01/01/92	2.0	10.0					%	4.00	4.00	4.00	4.00	3.00	2.00				
WBC: B	01/01/92	0.0	1.0					%	0.00	0.00	0.00	0.00	0.00	0.00				
PLATELETS	01/01/92	180.0	320.0					10**9/L	210.00	205.00	205.00	248.00	217.00	225.00				
NA+	01/01/92	135.0	150.0					MMOL/L	138.00	141.00	140.00	141.00	144.00	134.00				
K+	01/01/92	4.0	5.6					MMOL/L	4.20	4.30	4.70	4.80	4.40	4.20				
CL-	01/01/92	95.0	105.0					MMOL/L	98.20	104.20	102.50	102.50	96.10	101.80				
PO4-	01/01/92	0.6	1.3					MMOL/L	0.99	1.06	1.10	1.27	1.24	1.13				
SCOT	01/01/92	1.0	12.0					U/L	6.60	6.00	4.00	5.00	11.00	6.20				
SGPT	01/01/92	1.0	9.0					U/L	6.40	3.50	2.50	6.00	6.00	3.50				
GAMMA-GT	01/01/92	0.2	1.1					UKAT/L	0.15	0.42	0.40	0.66	0.23	0.50				
GLUCOSE	01/01/92	3.5	5.5					MMOL/L	5.30	3.80	3.80	3.70	5.50	4.50				
BUN	01/01/92	135.0	360.0					MMOL/L	90.00	124.00	100.00	138.00	114.00	114.00				
CREATININE	01/01/92	3.3	10.0					MMOL/L	3.66	4.30	4.30	4.70	9.30	5.50				
URIC ACID	01/01/92	44.0	88.0					UMOL/L	72.20	67.70	81.00	84.30	78.10	82.80				
TOT BILIRUBIN	01/01/92	149.0	405.0					UMOL/L	247.00	219.00	279.00	329.00	406.00	333.00				
DIR BILIRUBIN	01/01/92	8.6	20.5					UMOL/L	15.50	8.70	16.00	13.70	23.80	25.40				
TOT. PROTEINS	01/01/92	65.0	85.0	G/L	79.00	82.00	82.00	71.00	80.00	77.00								
ALBUMINE	01/01/92	34.0	55.0	G/L	50.80	48.40	50.70	43.60	48.80	50.80								
TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	3.30	3.30	3.70	3.30	3.00	3.50								
TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	3.36	0.64	0.95	1.18	1.72	1.46								

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOMETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range		Visit							
					Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
10 51-45	F			GLOBALINS: ALPHA1	01/01/92	1.3	6.0	G/L	1.70	3.60	3.40	3.60	1.90	1.50
				GLOBALINS: ALPHA2	01/01/92	5.0	9.0	G/L	8.90	8.60	8.10	4.80	8.60	6.50
				GLOBALINS: BETA	01/01/92	5.0	13.0	G/L	9.00	8.60	8.20	6.80	6.90	6.50
				GLOBALINS: GAMMA	01/01/92	10.0	17.0	G/L	8.60	12.80	11.60	12.20	13.80	11.70
				HB	01/01/92	129.0	150.0	G/L	144.00	138.00	142.00	140.00	141.00	135.00
				HTC	01/01/92	0.4	0.5	L/L	0.42	0.42	0.42	0.42	0.44	0.42
				RBC	01/01/92	4.0	5.0	10**12/L	4.28	4.18	4.27	4.20	4.18	4.30
				WBC	01/01/92	4.0	8.8	10**9/L	7.20	9.00	4.30	6.60	9.00	7.50
				PLATELETS	01/01/92	51.0	77.0	X	80.00	72.00	78.00	59.00	75.00	74.00
				GLUCOSE	01/01/92	18.0	38.0	X	14.00	22.00	12.00	32.00	18.00	18.00
55-49	M			GLOBALINS: ALPHA1	01/01/92	1.0	5.0	X	4.00	4.00	8.00	7.00	1.00	8.00
				GLOBALINS: ALPHA2	01/01/92	2.0	10.0	X	2.00	2.00	2.00	2.00	6.00	8.00
				GLOBALINS: BETA	01/01/92	0.0	1.0	X	0.00	0.00	0.00	0.00	0.00	0.00
				GLOBALINS: GAMMA	01/01/92	0.0	1.0	X	0.00	0.00	0.00	0.00	0.00	0.00
				HB	01/01/92	180.0	320.0	10**9/L	213.00	203.00	230.00	205.00	250.00	232.00
				HTC	01/01/92	135.0	150.0	NHOL/L	140.00	145.00	139.00	142.00	140.00	146.00
				RBC	01/01/92	4.0	5.6	NHOL/L	4.20	4.30	4.30	4.50	5.10	4.60
				WBC	01/01/92	95.0	105.0	NHOL/L	94.50	100.30	102.30	106.30	103.20	103.00
				PLATELETS	01/01/92	0.6	1.3	NHOL/L	0.92	1.09	0.90	1.00	0.95	0.95
				GLUCOSE	01/01/92	1.0	12.0	U/L	5.00	6.00	5.50	6.50	9.00	9.50
58-52	F			GLOBALINS: ALPHA1	01/01/92	1.0	9.0	U/L	4.50	5.00	4.50	4.80	5.50	4.00
				GLOBALINS: ALPHA2	01/01/92	0.3	1.8	UKAT/L	1.46	0.98	0.98	0.34	5.00	4.00
				GLOBALINS: BETA	01/01/92	3.5	5.5	NHOL/L	3.70	6.50	4.30	4.40	5.00	4.90
				GLOBALINS: GAMMA	01/01/92	135.0	360.0	NHOL/L	175.00	178.00	150.00	167.00	158.00	236.00
				HB	01/01/92	112.0	140.0	G/L	130.00	130.00	128.00	135.00	138.00	130.00
				HTC	01/01/92	0.4	0.5	L/L	0.41	0.41	0.40	0.41	0.38	0.40

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Open-Blind	Sex	Pet. No.	Laboratory test	Laboratory Range			Visit					
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42
10	58	F		RBC	3.7	4.7	10**12/L	4.10	4.05	4.10	4.10	4.06	4.12
				HBC: N	4.0	8.8	10**9/L	7.60	4.80	4.10	4.50	5.40	8.00
				HBC: L	51.0	77.0	%	72.00	64.00	58.00	58.00	74.00	66.00
				HBC: E	18.0	38.0	%	25.00	32.00	28.00	32.00	19.00	28.00
				HBC: H	1.0	5.0	%	0.00	0.00	2.00	6.00	1.00	4.00
				HBC: B	2.0	10.0	%	3.00	4.00	2.00	0.00	6.00	2.00
				PLATELETS	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00
				NA+	180.0	320.0	10**9/L	218.00	220.00	213.00	213.00	270.00	218.00
				K+	135.0	150.0	MMOL/L	139.00	141.00	145.00	141.00	141.00	140.00
				CL-	95.0	105.0	MMOL/L	97.00	101.00	103.00	102.50	96.50	98.50
				PO4-	0.6	1.3	MMOL/L	1.27	1.23	1.13	1.30	1.31	1.50
				SGOT	1.0	12.0	U/L	5.50	3.00	2.00	6.00	5.00	5.50
				SGPT	1.0	9.0	U/L	5.50	2.50	7.00	1.20	1.00	3.00
				GAMMA-GT	0.2	1.1	UKAT/L	0.60	0.71	0.71	0.71	0.76	0.60
				GLUCOSE	3.5	5.5	MMOL/L	4.20	4.40	4.10	4.30	4.70	4.30
				ALK. PHOSPH.	135.0	360.0	MMOL/L	114.00	113.00	134.00	116.00	124.00	144.00
				CREATININE	3.3	10.0	MMOL/L	2.50	4.50	3.80	2.80	5.60	7.70
				URIC ACID	44.0	88.0	UMOL/L	65.20	67.60	82.20	76.50	71.10	88.00
				TOT. BILIRUBIN	8.6	20.5	UMOL/L	165.00	197.00	239.00	190.00	406.00	376.00
				TOT. PROTEINS	65.0	85.0	G/L	9.80	14.20	14.90	14.50	20.00	27.70
				ALBUMINE	34.0	55.0	G/L	72.00	71.00	65.00	69.00	93.00	68.00
				TRIGLYCERIDES	3.1	6.2	MMOL/L	3.90	3.70	3.90	3.40	3.90	3.80
				GLOBULINS: ALPHA1	0.5	1.9	MMOL/L	1.42	1.15	1.53	1.59	1.20	1.05
				GLOBULINS: ALPHA2	1.3	6.0	G/L	4.20	1.90	1.90	3.60	3.90	1.60
				GLOBULINS: BETA	5.0	13.0	G/L	9.00	7.50	6.00	7.30	8.60	6.20
				GLOBULINS: GAMMA	5.0	17.0	G/L	14.50	8.90	6.60	10.90	11.20	3.90
				NA+	10.0	150.0	MMOL/L	145.00	136.00	9.40	6.40	11.50	9.70
61-55		M		HB	129.0	150.0	G/L	145.00	142.00				
				HCT	0.4	0.5	L/L	0.45	0.43				
				RBC	4.0	5.0	10**12/L	4.43	4.25				
				HBC: N	4.0	8.8	10**9/L	4.50	6.80				
				HBC: L	51.0	77.0	%	60.00	66.00				
				HBC: E	18.0	38.0	%	32.00	29.00				
				HBC: H	1.0	5.0	%	2.00	4.00				
				HBC: B	2.0	10.0	%	2.00	1.00				
				PLATELETS	180.0	320.0	10**9/L	225.00	237.00				
				NA+	135.0	150.0	MMOL/L	145.00	136.00				

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXYLINE - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Date	Laboratory Range		Visit							
						Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
10	61-55	M		K+	01/01/92	4.0	5.6	MMOL/L	4.50	4.30					
				CL-	01/01/92	95.0	105.0	MMOL/L	97.00	99.50					
				PO4-	01/01/92	0.6	1.3	MMOL/L	1.20	1.10					
				SGOT	01/01/92	1.0	12.0	U/L	2.50	4.50					
				SGPT	01/01/92	1.0	9.0	U/L	5.50	5.50					
				GAMMA-GT	01/01/92	0.3	1.8	UKAT/L	0.20	0.70					
				GLUCOSE	01/01/92	3.5	5.5	MMOL/L	4.50	4.10					
				ALK. PHOSPH.	01/01/92	135.0	360.0	MMOL/L	236.00	272.00					
				BUN	01/01/92	3.3	10.0	MMOL/L	7.80	5.70					
				CREATININE	01/01/92	44.0	101.0	UMOL/L	74.20	78.20					
				URIC ACID	01/01/92	274.0	458.0	UMOL/L	358.00	382.00					
				TOT BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	10.30	4.30					
				DIR BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	1.70	4.30					
				TOT. PROTEINS	01/01/92	65.0	85.0	G/L	80.00	78.00					
				ALBUMINE	01/01/92	34.0	55.0	G/L	49.50	47.50					
				TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	4.50	3.70					
				TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	1.80	1.78					
				GLOBULINS: ALPHA1	01/01/92	1.3	6.0	G/L	2.00	2.20					
				GLOBULINS: ALPHA2	01/01/92	5.0	9.0	G/L	8.20	7.90					
				GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	12.00	12.10					
				GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	8.30	8.30					
62-56		M		HB	01/01/92	129.0	150.0	G/L	143.00						
				HTC	01/01/92	0.4	0.5	L/L	0.43						
				RBC	01/01/92	4.0	5.0	10**12/L	4.22						
				WBC	01/01/92	4.0	8.8	10**9/L	7.10						
				HGC: N	01/01/92	51.0	77.0	%	66.00						
				HGC: L	01/01/92	18.0	38.0	%	26.00						
				HGC: E	01/01/92	1.0	5.0	%	4.00						
				HGC: M	01/01/92	2.0	10.0	%	2.00						
				HGC: B	01/01/92	0.0	1.0	%	0.00						
				PLATELETS	01/01/92	180.0	320.0	10**9/L	232.00						
				NA+	01/01/92	135.0	150.0	MMOL/L	141.00						
				K+	01/01/92	4.0	5.6	MMOL/L	5.20						
				CL-	01/01/92	95.0	105.0	MMOL/L	100.10						
				PO4-	01/01/92	0.6	1.3	MMOL/L	1.09						
				SGOT	01/01/92	1.0	12.0	U/L	5.00						
				SGPT	01/01/92	1.0	9.0	U/L	4.00						
				GAMMA-GT	01/01/92	0.3	1.8	UKAT/L	0.80						
				GLUCOSE	01/01/92	3.5	5.5	MMOL/L	4.10						
				ALK. PHOSPH.	01/01/92	135.0	360.0	MMOL/L	351.00						
				BUN	01/01/92	3.3	10.0	MMOL/L	7.50						

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit																
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52										
10 62-56		M		CREATININE	01/01/92	44.0	101.0	UMOL/L	73.80															
				URIC ACID	01/01/92	214.0	458.0	UMOL/L	364.00															
				TOT BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	16.20															
				DIR BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	2.20															
				TOT. PROTEINS	01/01/92	65.0	85.0	G/L	69.00															
				ALBUMINE	01/01/92	34.0	55.0	G/L	40.20															
				TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	5.00															
				TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	0.83															
				GLOBULINS: ALPHA1	01/01/92	1.3	6.0	G/L	3.30															
				GLOBULINS: ALPHA2	01/01/92	5.0	9.0	G/L	7.80															
				GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	8.10															
				GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	9.60															
				64-58		F		HB	15/04/92	112.0	140.0	G/L	135.00											
								HCT	01/01/92	0.4	0.5	L/L	0.41											
								RBC	01/01/92	3.7	4.7	10**12/L	4.18											
								HBC	01/01/92	4.0	8.8	10**9/L	5.50											
								HBC: M	01/01/92	51.0	77.0	%	64.00											
HBC: L	01/01/92	18.0	38.0					%	30.00															
HBC: E	01/01/92	1.0	5.0					%	6.00															
HBC: M	01/01/92	2.0	10.0					%	0.00															
HBC: B	01/01/92	0.0	1.0					%	0.00															
PLATELETS	01/01/92	180.0	320.0					10**9/L	220.00															
NA+	01/01/92	135.0	150.0					MMOL/L	141.00															
K+	01/01/92	4.0	5.6					MMOL/L	4.20															
CL-	01/01/92	95.0	105.0					MMOL/L	99.50															
PO4-	01/01/92	0.6	1.3					MMOL/L	1.15															
SGOT	01/01/92	1.0	12.0					U/L	5.00															
GAMMA-GT	01/01/92	0.2	1.1					UKAT/L	6.40															
GLUCOSE	01/01/92	3.5	5.5					MMOL/L	0.55															
ALK. PHOSPH.	01/01/92	135.0	360.0					MMOL/L	100.00															
CREATININE	01/01/92	3.3	10.0					MMOL/L	4.50															
BUN	01/01/92	44.0	88.0					UMOL/L	80.30															
URIC ACID	01/01/92	149.0	405.0	UMOL/L	228.00																			
TOT BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	15.60																			
DIR BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	2.20																			
TOT. PROTEINS	01/01/92	65.0	85.0	G/L	78.00																			
ALBUMINE	01/01/92	34.0	55.0	G/L	47.00																			
TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	4.10																			
TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	0.42																			
GLOBULINS: ALPHA1	01/01/92	1.3	6.0	G/L	3.40																			

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Date	Laboratory Range			Visit						
					Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
10 64-58	F		GLOBULINS: ALPHA2	01/01/92	5.0	9.0	G/L	8.00						
			GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	9.80						
			GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	9.80						
81-46	F		HB	01/01/92	112.0	140.0	G/L	132.00	25/06/92	20/08/92	15/10/92			
			HCT	01/01/92	0.4	0.5	L/L	0.41	0.42	0.42	0.40			
			RBC	01/01/92	3.7	4.7	10**12/L	4.10	4.16	4.18	4.04			
			WBC	01/01/92	4.0	8.8	10**9/L	5.70	6.00	5.10	5.90			
			PLATELETS	01/01/92	51.0	77.0	X	66.00	66.00	60.00	62.00			
			ALB	01/01/92	18.0	38.0	X	33.00	34.00	37.00	38.00			
			GLUCOSE	01/01/92	1.0	5.0	X	0.00	0.00	2.00	0.00			
			CHOLEST.	01/01/92	2.0	10.0	X	1.00	0.00	1.00	0.00			
			TRIGL.	01/01/92	0.0	1.0	X	0.00	0.00	0.00	0.00			
			UREA	01/01/92	180.0	320.0	10**9/L	218.00	203.00	220.00	213.00			
			CREATININE	01/01/92	135.0	150.0	UMOL/L	141.00	145.00	140.00	141.00			
			UREIC ACID	01/01/92	4.0	5.6	MMOL/L	4.10	4.80	4.50	4.10			
			GLUCOSE	01/01/92	95.0	105.0	MMOL/L	104.10	100.80	100.50	99.00			
			CHOLEST.	01/01/92	1.0	12.0	U/L	1.11	1.13	1.20	1.02			
			TRIGL.	01/01/92	1.0	9.0	U/L	5.50	3.00	5.50	7.00			
			UREA	01/01/92	0.2	1.1	UMOL/L	0.23	0.34	0.63	0.34			
			CREATININE	01/01/92	3.5	5.5	MMOL/L	4.30	6.10	4.10	4.90			
			GLUCOSE	01/01/92	135.0	360.0	UMOL/L	110.00	131.00	96.00	186.20			
			UREIC ACID	01/01/92	3.3	10.0	UMOL/L	75.70	66.90	88.00	71.70			
			TOT. BILIRUBIN	01/01/92	149.0	405.0	UMOL/L	210.00	207.00	211.00	203.00			
			TOT. PROTEINS	01/01/92	6.6	20.5	UMOL/L	15.90	13.70	11.00	10.90			
			ALBUMIN	01/01/92	65.0	85.0	G/L	74.00	78.00	77.00	68.00			
			CHOLEST.	01/01/92	34.0	55.0	G/L	48.20	52.30	50.30	40.10			
			TRIGL.	01/01/92	3.1	6.2	MMOL/L	3.50	3.70	3.00	3.70			
			GLOBULINS: ALPHA1	01/01/92	0.5	6.0	G/L	1.05	0.92	1.30	1.36			
			GLOBULINS: ALPHA2	01/01/92	1.3	6.0	G/L	0.90	1.00	3.30	2.30			
			GLOBULINS: BETA	01/01/92	5.0	9.0	G/L	8.90	9.10	7.40	5.60			
GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	8.70	8.70	7.70	4.60						
88-276	F		HB	01/01/92	112.0	140.0	G/L	128.00	27/05/92	16/09/92	11/11/92	06/01/93	17/03/93	
			HCT	01/01/92	0.4	0.5	L/L	0.38	0.42	0.40	0.40	0.40	0.42	
			RBC	01/01/92	3.7	4.7	10**12/L	3.75	4.17	4.00	3.57	4.25	4.17	

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit									
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52			
10 88-276	F		HBC	01/01/92	4.0	8.8	10**g/L	5.00	5.70	7.00	6.30	6.00	4.90			
			HBC: N	01/01/92	51.0	77.0	X	64.00	62.00	64.00	58.00	72.00	64.00	64.00		
			HBC: L	01/01/92	18.0	38.0	X	30.00	30.00	33.00	34.00	30.00	25.00	33.00		
			HBC: E	01/01/92	1.0	5.0	X	4.00	3.00	2.00	2.00	0.00	0.00	1.00		
			HBC: M	01/01/92	2.0	10.0	X	2.00	4.00	1.00	6.00	3.00	0.00	2.00		
			HBC: B	01/01/92	0.0	1.0	X	0.00	1.00	0.00	0.00	0.00	0.00	0.00		
			PLATELETS	01/01/92	180.0	320.0	10**g/L	225.00	217.00	210.00	195.00	225.00	225.00	225.00		
			NA+	01/01/92	135.0	150.0	MMOL/L	141.00	138.00	142.00	143.00	145.00	140.00	140.00		
			K+	01/01/92	4.0	5.6	MMOL/L	4.40	4.00	4.30	4.80	5.20	4.40	4.40		
			PO4--	01/01/92	0.6	1.3	MMOL/L	1.27	1.16	1.30	1.44	1.24	1.23	1.23		
			SGOT	01/01/92	1.0	12.0	U/L	6.00	5.00	3.80	7.00	5.00	6.00	6.00		
			SGPT	01/01/92	1.0	9.0	U/L	4.70	1.50	3.80	2.00	6.20	4.40	4.40		
			GAMMA-GT	01/01/92	0.2	1.1	UMAT/L	0.63	0.95	0.60	0.87	0.85	0.51	0.51		
			GLUCOSE	01/01/92	3.5	5.5	MMOL/L	4.30	4.90	4.10	5.30	4.20	4.50	4.50		
			ALK. PHOSPH.	01/01/92	3.3	10.0	MMOL/L	240.00	259.00	258.00	218.00	296.00	352.00	352.00		
			BUN	01/01/92	3.3	10.0	MMOL/L	6.30	7.00	3.00	8.00	7.20	5.30	5.30		
			CREATININE	01/01/92	44.0	88.0	UMOL/L	70.00	71.10	71.10	75.60	68.60	65.20	65.20		
			URIC ACID	01/01/92	149.0	485.0	UMOL/L	145.00	184.00	192.00	249.00	213.00	204.00	204.00		
			DIP. BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	14.20	11.30	15.60	12.40	10.10	15.20	15.20		
			TOT. BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	0.80	1.00	1.40	1.00	1.40	1.70	1.70		
			TOT. PROTEINS	01/01/92	65.0	85.0	G/L	82.00	90.00	82.00	82.00	78.00	79.00	79.00		
			ALBUMINE	01/01/92	34.0	55.0	G/L	44.10	49.30	47.70	51.70	43.70	39.70	39.70		
			TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	3.90	3.20	3.90	3.30	4.20	3.20	3.20		
			TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	1.42	1.37	2.03	2.44	2.71	1.32	1.32		
			GLOBULINS: ALPHA1	01/01/92	1.3	6.0	G/L	2.80	2.60	3.60	3.70	2.70	2.90	2.90		
			GLOBULINS: ALPHA2	01/01/92	5.0	9.0	G/L	11.30	11.90	8.20	15.40	7.80	7.90	7.90		
GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	8.40	8.00	13.40	1.00	7.60	7.70	7.70					
GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	15.40	18.20	9.10	10.20	16.20	20.80	20.80					
92-73	F		HB	01/01/92	112.0	140.0	G/L	165.00	135.00	135.00	144.00	136.00	141.00			
			HTC	01/01/92	0.4	0.5	L/L	0.43	0.42	0.42	0.42	0.42	0.44	0.44		
			RBC	01/01/92	3.7	4.7	10**12/L	4.35	4.17	4.17	4.27	4.17	4.20	4.20		
			HBC	01/01/92	4.0	8.8	10**g/L	10.00	6.40	8.10	8.10	11.80	6.30	6.30		
			HBC: N	01/01/92	51.0	77.0	X	64.00	70.00	70.00	65.00	70.00	65.00	65.00		
			HBC: L	01/01/92	18.0	38.0	X	32.00	28.00	30.00	30.00	24.00	31.00	31.00		
			HBC: E	01/01/92	1.0	5.0	X	2.00	0.00	0.00	0.00	0.00	2.00	2.00		
			HBC: M	01/01/92	2.0	10.0	X	2.00	2.00	0.00	2.00	0.00	0.00	0.00		
			HBC: B	01/01/92	0.0	1.0	X	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
			PLATELETS	01/01/92	180.0	320.0	10**g/L	205.00	217.00	217.00	225.00	205.00	240.00	240.00		
			NA+	01/01/92	135.0	150.0	MMOL/L	144.00	142.00	142.00	153.00	146.00	140.00	140.00		
			K+	01/01/92	4.0	5.6	MMOL/L	5.10	4.70	6.00	6.00	4.20	4.50	4.50		

(*-) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Sex	Laboratory test	Date	Laboratory Range		Visit						
				Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
10 92-73	F	CL-	01/01/92	95.0	105.0	MMOL/L	106.50	103.50		102.10	101.80	101.00
		PO4-	01/01/92	0.6	1.3	MMOL/L	1.34	1.10		1.25	1.37	1.30
		SGOT	01/01/92	1.0	12.0	U/L	3.00	2.50		7.00	8.00	3.70
		SGPT	01/01/92	1.0	9.0	U/L	6.00	3.00		3.80	1.00	7.50
		GAMMA-GT	01/01/92	0.2	1.1	UKAT/L	0.36	0.74		0.90	0.58	0.55
		GLUCOSE	01/01/92	3.5	5.5	MMOL/L	5.50	4.10		4.20	4.30	5.00
		ALK. PHOSPH.	01/01/92	153.0	360.0	MMOL/L	161.00	173.70		200.00	192.00	242.00
		BUN	01/01/92	3.3	10.0	MMOL/L	6.80	4.66		4.90	4.66	5.30
		CREATININE	01/01/92	44.0	88.0	UMOL/L	63.40	73.30		71.90	78.50	67.20
		URIC ACID	01/01/92	149.0	405.0	UMOL/L	195.00	186.00		197.00	295.00	308.00
		TOT BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	16.10	15.00		15.60	14.90	10.90
		DIR BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	1.40	0.60		1.80	0.56	1.40
		TOT. PROTEINS	01/01/92	34.0	85.0	G/L	67.00	74.00		60.00	90.00	67.00
		ALBUMINE	01/01/92	34.0	55.0	G/L	43.60	39.40		41.80	62.20	45.50
		TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	3.50	3.90		3.20	3.30	5.70
		TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	1.19	0.65		1.46	0.68	1.64
		GLOBULINS: ALPHA1	01/01/92	1.3	6.0	G/L	1.10	0.90		1.50	1.30	1.30
		GLOBULINS: ALPHA2	01/01/92	5.0	9.0	G/L	8.00	7.90		5.80	9.20	6.00
		GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	6.80	9.10		6.70	8.20	6.70
		GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	7.50	12.70		4.70	8.90	7.50
94-273	F	HB	17/06/92	112.0	140.0	G/L	127.00					
		HCT	01/01/92	0.4	0.5	L/L	0.39					
		RBC	01/01/92	3.7	4.7	10**12/L	3.87					
		HBC	01/01/92	4.0	8.8	10**9/L	5.30					
		HBC: N	01/01/92	51.0	77.0	%	60.00					
		HBC: L	01/01/92	18.0	38.0	%	36.00					
		HBC: E	01/01/92	1.0	5.0	%	1.00					
		HBC: H	01/01/92	2.0	10.0	%	3.00					
		HBC: B	01/01/92	0.0	1.0	%	0.00					
		PLATELETS	01/01/92	180.0	320.0	10**9/L	205.00					
		NA+	01/01/92	135.0	150.0	MMOL/L	137.00					
		K+	01/01/92	4.0	5.6	MMOL/L	4.30					
		CL-	01/01/92	95.0	105.0	MMOL/L	102.40					
		PO4-	01/01/92	0.6	1.3	MMOL/L	1.06					
		SGOT	01/01/92	1.0	12.0	U/L	2.00					
		SGPT	01/01/92	1.0	9.0	U/L	4.50					
		GAMMA-GT	01/01/92	0.2	1.1	UKAT/L	0.34					
		GLUCOSE	01/01/92	3.5	5.5	MMOL/L	5.30					
		ALK. PHOSPH.	01/01/92	135.0	360.0	MMOL/L	99.00					
		BUN	01/01/92	3.3	10.0	MMOL/L	3.70					
		CREATININE	01/01/92	44.0	88.0	UMOL/L	69.40					

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOMETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit												
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52						
10 94-273	F			URIC ACID	01/01/92	149.0	405.0	UMOL/L	314.00											
				TOT BILIRUBIN	01/01/92	8.6	20.5	UMOL/L	10.40											
				DIR BILIRUBIN	01/01/92	0.5	4.3	UMOL/L	1.40											
				TOT. PROTEINS	01/01/92	65.0	85.0	G/L	78.00											
				ALBUMIN	01/01/92	34.0	55.0	G/L	50.90											
				TOT. CHOLEST.	01/01/92	3.1	6.2	MMOL/L	3.70											
				TRIGLYCERIDES	01/01/92	0.5	1.9	MMOL/L	0.92											
				GLOBULINS: ALPHA1	01/01/92	1.5	6.0	G/L	2.10											
				GLOBULINS: ALPHA2	01/01/92	5.0	9.0	G/L	7.80											
				GLOBULINS: BETA	01/01/92	5.0	13.0	G/L	7.50											
				GLOBULINS: GAMMA	01/01/92	10.0	17.0	G/L	9.90											
				11 1-372	M			HB	01/04/92	120.0	170.0	G/L		20/12/91	17/02/92	10/04/92	05/06/92			
								HB	24/09/91	8.7	11.2	MMOL/L	9.31	9.90	155.00	166.00				
								HTC	01/04/92	0.4	0.5	L/L		0.43	0.46					
								HTC	24/09/91	0.4	0.5	L/L	0.45	0.48	4.90	5.26				
								RBC	01/04/92	3.5	5.6	10 ¹² /L		5.07	7.90	10.50				
								RBC	24/09/91	4.5	6.0	10 ¹² /L	5.07	5.57	7.90	10.50				
WBC	01/04/92	4.0	10.0					10 ⁹ /L		8.70	8.70	68.00								
WBC	24/09/91	5.0	10.0					10 ⁹ /L	8.70	8.70	68.00	68.00								
WBC: N	24/09/91	51.0	75.0					%	76.00	72.00	26.00	20.00								
WBC: L	24/09/91	20.0	40.0					%	22.00	22.00	2.00	2.00								
WBC: E	24/09/91	1.0	4.0					%	0.00	0.00	4.00	10.00								
WBC: M	24/09/91	2.0	8.0					%	2.00	6.00	0.00	0.00								
WBC: B	24/09/91	0.0	1.0					%	0.00	0.00	0.00	0.00								
PLATELETS	24/09/91	150.0	350.0					10 ⁹ /L	200.00	170.00	229.00	255.00								
Na+	24/09/91	135.0	150.0					MMOL/L	143.00	140.00	142.00	141.00								
K+	24/09/91	3.5	5.3					MMOL/L	4.40	4.40	4.40	4.50								
Cl-	24/09/91	97.0	107.0					MMOL/L	96.00	98.00	103.00	95.00								
Ca++	24/09/91	2.3	2.8					MMOL/L	2.63	2.40	2.73	2.20								
PO4--	24/09/91	0.7	1.5					MMOL/L	0.85	0.75	0.87	0.80								
SGPT	24/09/91	5.0	17.0					U/L	17.00	7.00	22.00	19.00								
SGPT	24/09/91	5.0	23.0					U/L	14.00	8.00	16.00	18.00								
GAMMA-GT	24/09/91	4.0	28.0	U/L	14.00	9.00	13.00	21.00												
GLUCOSE	24/09/91	3.9	6.1	MMOL/L	5.50	5.00	4.80	5.00												
ALK. PHOSPH.	24/09/91	40.0	200.0	U/L	82.00	76.00	104.00	74.00												
BUN	24/09/91	2.1	9.6	MMOL/L	7.20	6.00	6.00	6.00												
CREATININE	24/09/91	36.0	115.0	UMOL/L	81.00	106.00	72.00	83.00												
URIC ACID	24/09/91	188.0	416.0	UMOL/L	205.00	288.00	229.00	167.00												
TOT. PROTEINS	24/09/91	60.0	85.0	G/L	75.00	85.00	75.00	71.00												
ALBUMINE	24/09/91	35.0	50.0	G/L	43.00	40.00	38.00	36.00												
TOT. CHOLEST.	24/09/91	3.9	6.7	MMOL/L	5.90	5.40	7.80	6.20												

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2004

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 RENOXETINE - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit						
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
11	1-372	H		TRIGLYCERIDES	24/09/91	0.5	2.3	MMOL/L	2.12	1.58	0.92			
				GLOBULINS: ALPHA1	24/09/91	1.0	4.0	%	2.60	2.51	2.13	2.07		
				GLOBULINS: ALPHA2	24/09/91	4.0	10.0	%	7.80	7.78	7.24	6.77		
				GLOBULINS: BETA	24/09/91	5.0	11.0	%	11.60	12.72	12.45	11.05		
				GLOBULINS: GAMMA	24/09/91	7.0	17.0	%	10.00	16.22	13.02	14.83		
				HB	24/09/91	8.7	11.2	MMOL/L	9.74	9.31	10.30			
				HTC	24/09/91	0.4	0.5	L/L	0.47	0.46	0.49			
				RBC	24/09/91	4.5	6.0	10 ¹² /L	4.96	4.96	5.53			
				WBC	24/09/91	5.0	10.0	10 ⁹ /L	6.70	6.40	6.20			
				NRC: N	24/09/91	51.0	75.0	%	60.00	72.00	62.00			
NRC: L	24/09/91	20.0	40.0	%	34.00	22.00	32.00							
NRC: E	24/09/91	1.0	4.0	%	2.00	6.00	2.00							
NRC: M	24/09/91	2.0	8.0	%	4.00	6.00	4.00							
NRC: B	24/09/91	0.0	1.0	%	0.00	0.00	0.00							
PLATELETS	24/09/91	150.0	350.0	10 ⁹ /L	210.00	200.00	180.00							
Na+	24/09/91	135.0	150.0	MMOL/L	142.00	141.00	145.00							
K+	24/09/91	3.5	5.3	MMOL/L	4.10	4.10	4.80							
Cl-	24/09/91	97.0	107.0	MMOL/L	100.00	98.00	96.00							
Ca++	24/09/91	2.3	2.8	MMOL/L	2.45	2.50	2.50							
PO4--	24/09/91	0.7	1.5	MMOL/L	1.02	1.02	1.40							
SGPT	24/09/91	5.0	17.0	U/L	16.00	13.00	13.00							
GAMMA-GT	24/09/91	4.0	23.0	U/L	11.00	9.00	10.00							
GLUCOSE	24/09/91	3.9	6.1	MMOL/L	5.50	4.90	4.60							
ALK. PHOSPH.	24/09/91	40.0	200.0	U/L	117.00	94.00	134.00							
BUN	24/09/91	2.1	9.6	MMOL/L	8.40	8.00	8.00							
CREATININE	24/09/91	36.0	115.0	UMOL/L	111.00	110.00	115.00							
URIC ACID	24/09/91	118.0	416.0	UMOL/L	292.00	288.00	275.00							
TOT. PROTEINS	24/09/91	60.0	85.0	G/L	71.00	83.00	70.00							
ALBUMINE	24/09/91	35.0	50.0	G/L	45.00	42.00	43.00							
TOT. CHOLEST.	24/09/91	3.9	6.7	MMOL/L	8.50	7.90	7.40							
TRIGLYCERIDES	24/09/91	0.5	2.3	MMOL/L	2.42	2.86	2.62							
GLOBULINS: ALPHA1	24/09/91	1.0	4.0	%	2.60	1.98	2.28							
GLOBULINS: ALPHA2	24/09/91	4.0	10.0	%	6.00	7.77	5.53							
GLOBULINS: BETA	24/09/91	5.0	11.0	%	10.30	12.63	8.08							
GLOBULINS: GAMMA	24/09/91	7.0	17.0	%	10.20	14.51	11.93							
7-376	F		HB	01/04/92	120.0	170.0	G/L	19/12/91	28/02/92	23/04/92	18/06/92	12/08/92	26/10/92	
			HB	24/09/91	7.5	10.0	MMOL/L	7.77	7.91	131.00	125.00	155.00	133.00	

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2005

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBORENTINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52		
11 7-376	F			HTC	01/04/92	0.4	0.5	L/L			0.37	0.37	0.38	0.39		
				RBC	24/09/91	0.4	0.5	L/L		0.39						
				RBC	01/04/92	3.5	5.6	10-12/L			4.50			4.47	4.57	4.59
				RBC	24/09/91	4.1	5.4	10-12/L		4.83						
				RBC	01/04/92	4.0	10.0	10-9/L				3.90			3.50	3.90
				RBC	24/09/91	5.0	10.0	10-9/L		3.10						
				RBC: N	24/09/91	51.0	75.0	%		54.00				56.00	66.00	50.00
				RBC: L	24/09/91	20.0	40.0	%		44.00				40.00	30.00	42.00
				RBC: E	24/09/91	1.0	4.0	%		2.00				2.00	2.00	2.00
				RBC: M	24/09/91	2.0	8.0	%		2.00				6.00	2.00	6.00
				RBC: B	24/09/91	0.0	1.0	%		0.00				0.00	0.00	0.00
				PLATELETS	24/09/91	150.0	350.0	10-9/L		160.00				192.00	200.00	232.00
				NA+	24/09/91	135.0	150.0	MMOL/L		143.00				144.00	139.00	143.00
				K+	24/09/91	3.5	5.3	MMOL/L		4.70				4.70	4.70	4.80
				CL-	24/09/91	97.0	107.0	MMOL/L		104.00				103.00	103.00	98.00
				Ca++	24/09/91	2.3	2.8	MMOL/L		2.45				2.54	2.40	2.39
				PO4-	24/09/91	0.7	1.5	MMOL/L		1.04				1.36	1.03	1.09
				SGPT	24/09/91	5.0	15.0	U/L		12.00				26.00	17.00	9.00
				GAMMA-GT	24/09/91	4.0	18.0	U/L		14.00				41.00	11.00	14.00
				TOT. PROTEINS	24/09/91	60.0	85.0	G/L		6.00				57.00	10.00	16.00
				ALBUMINE	24/09/91	35.0	50.0	G/L		4.00				4.80	4.10	4.60
				TOT. CHOLEST.	24/09/91	3.9	6.1	MMOL/L		5.60				4.80	4.80	4.80
				TRIGLYCERIDES	24/09/91	40.0	200.0	U/L		96.00				100.00	145.00	74.00
				BUN	24/09/91	2.1	9.6	MMOL/L		4.40				4.80	5.30	4.00
				CREATININE	24/09/91	36.0	115.0	UMOL/L		70.00				62.00	68.00	72.00
				URIC ACID	24/09/91	118.0	416.0	UMOL/L		132.00				131.00	204.00	214.00
TOT. PROTEINS	24/09/91	60.0	85.0	G/L		74.00				70.00	67.00	82.00				
ALBUMINE	24/09/91	35.0	50.0	G/L		44.00				40.00	36.00	47.00				
TOT. CHOLEST.	24/09/91	3.9	6.7	MMOL/L		7.60				10.30	7.00	8.40				
TRIGLYCERIDES	24/09/91	0.5	2.3	MMOL/L		1.32				2.89	1.99	2.62				
GLOBULINS: ALPHA1	24/09/91	1.0	4.0	%		2.30				2.20	1.71	2.62				
GLOBULINS: ALPHA2	24/09/91	4.0	10.0	%		5.90				6.20	4.34	7.39				
GLOBULINS: BETA	24/09/91	5.0	11.0	%		9.20				8.11	5.67	11.95				
GLOBULINS: GAMMA	24/09/91	7.0	17.0	%		13.20				15.02	7.74	13.15				
9-362	F				06/01/92											
				HR	24/09/91	7.5	10.0	MMOL/L		7.97						
				HTC	24/09/91	0.4	0.5	L/L		0.38						
				RBC	24/09/91	4.1	5.4	10-12/L		4.38						
				RBC: N	24/09/91	5.0	10.0	10-9/L		4.40						
				RBC: L	24/09/91	20.0	40.0	%		52.00						
				RBC: E	24/09/91	1.0	4.0	%		2.00						
				RBC: M	24/09/91	2.0	8.0	%		2.00						

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2006

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R6D

REBORETYNE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit													
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52							
11 9-362	F		NA+	24/09/91	135.0	150.0	MMOL/L	145.00												
			K+	24/09/91	3.5	5.3	MMOL/L	3.70												
			CL-	24/09/91	97.0	107.0	MMOL/L	104.00												
			CA++	24/09/91	2.3	2.8	MMOL/L	2.23												
			PO4-	24/09/91	0.7	1.5	MMOL/L	1.00												
			SGOT	24/09/91	5.0	15.0	U/L	18.00												
			SGPT	24/09/91	5.0	19.0	U/L	38.00												
			GAMMA-GT	24/09/91	4.0	18.0	U/L	9.00												
			GLUCOSE	24/09/91	3.9	6.1	MMOL/L	5.00												
			ALK. PHOSPH.	24/09/91	40.0	200.0	U/L	90.00												
			BUN	24/09/91	2.1	9.6	MMOL/L	5.20												
			CREATININE	24/09/91	36.0	115.0	UMOL/L	74.00												
			URIC ACID	24/09/91	118.0	416.0	UMOL/L	227.00												
			TOT. PROTEINS	24/09/91	60.0	85.0	G/L	68.00												
			ALBUMINE	24/09/91	35.0	50.0	G/L	42.00												
			TOT. CHOLEST.	24/09/91	3.9	6.7	MMOL/L	4.30												
			TRIGLYCERIDES	24/09/91	0.5	2.3	MMOL/L	1.28												
			GLOBULINS: ALPHA1	24/09/91	1.0	4.0	%	2.20												
			GLOBULINS: ALPHA2	24/09/91	4.0	10.0	%	6.48												
			GLOBULINS: BETA	24/09/91	5.0	11.0	%	9.53												
			GLOBULINS: GAMMA	24/09/91	7.0	17.0	%	11.35												
12-364	F		HB	01/04/92	120.0	170.0	G/L	8.40	21/04/92	137.00	16/06/92	157.00	09/08/92	133.00	13/10/92	135.00	13/12/92	118.00		
			HTC	24/09/91	7.5	10.0	MMOL/L	8.40												
			HTC	01/04/92	0.4	0.5	L/L	0.39	21/04/92	0.38	16/06/92	0.44	09/08/92	0.37	13/10/92	0.37	13/12/92	0.35		
			ERC	24/09/91	3.5	5.6	10 ⁻¹² /L	4.36												
			ERC	01/04/92	4.1	5.4	10 ⁻¹² /L	4.36	21/04/92	4.24	16/06/92	4.92	09/08/92	3.99	13/10/92	3.97	13/12/92	3.51		
			WBC	24/09/91	4.0	10.0	10 ⁹ /L	6.40												
			WBC	01/04/92	5.0	10.0	10 ⁹ /L	6.40	21/04/92	7.30	16/06/92	10.20	09/08/92	4.10	13/10/92	5.30	13/12/92	4.70		
			HRC: N	24/09/91	51.0	75.0	%	52.00												
			HRC: L	24/09/91	20.0	40.0	%	46.00												
			HRC: E	24/09/91	1.0	4.0	%	0.00												
			HRC: R	24/09/91	2.0	6.0	%	2.00												
			HRC: B	24/09/91	0.0	1.0	%	0.00												
			PLATELETS	24/09/91	150.0	350.0	10 ⁹ /L	190.00												
			NA+	24/09/91	135.0	150.0	MMOL/L	144.00												
			K+	24/09/91	3.5	5.3	MMOL/L	4.60												
			CL-	24/09/91	97.0	107.0	MMOL/L	104.00												
			CA++	24/09/91	2.3	2.8	MMOL/L	2.70												
			PO4-	24/09/91	0.7	1.5	MMOL/L	0.90												
			SGOT	24/09/91	5.0	15.0	U/L	55.00												

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit									
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52			
11 12-364	F		SGPT	24/09/91	5.0	19.0	U/L	81.00	27.00	23.00	16.00	16.00	13.00			
			GAMMA-GT	24/09/91	4.0	18.0	U/L	13.00	15.00	11.00	15.00	8.00	16.00			
			GLUCOSE	24/09/91	3.9	6.1	MMOL/L	4.20	4.60	6.00	4.20	3.50	4.50			
			ALK. PHOSPH.	24/09/91	40.0	200.0	U/L	139.00	146.00	124.00	107.00	101.00	93.00			
			BUN	24/09/91	2.1	9.6	MMOL/L	4.40	6.00	4.60	6.70	4.60	5.80			
			CREATININE	24/09/91	36.0	115.0	UMOL/L	75.00	82.00	86.00	84.00	78.00	103.00			
			URIC ACID	24/09/91	118.0	416.0	UMOL/L	225.00	209.00	353.00	274.00	256.00	237.00			
			TOT. PROTEINS	24/09/91	60.0	85.0	G/L	67.00	81.00	69.00	63.00	59.00	62.00			
			ALBUMINE	24/09/91	35.0	50.0	G/L	45.00	40.00	38.00	38.00	36.00	38.00			
			TOT. CHOLEST.	24/09/91	3.9	6.7	MMOL/L	6.10	6.40	7.10	6.00	4.80	5.40			
			TRIGLYCERIDES	24/09/91	0.5	2.3	MMOL/L	2.34	1.28	1.63	1.60	1.16	1.31			
			GLOBULINS: ALPHA1	24/09/91	1.0	4.0	Z	1.98	2.76	2.16	1.89	2.25	2.04			
			GLOBULINS: ALPHA2	24/09/91	4.0	10.0	Z	5.71	6.30	5.73	4.59	3.03	5.31			
			GLOBULINS: BETA	24/09/91	5.0	11.0	Z	7.88	9.90	7.78	6.21	6.79	8.27			
			GLOBULINS: GAMMA	24/09/91	7.0	17.0	Z	12.10	15.80	13.67	10.13	23.05	12.17			
			15-366	F		HB	01/04/92	120.0	170.0	G/L	143.00	03/06/92	156.00			
						HCT	01/04/92	0.4	0.5	L/L	0.39	0.43				
						HRC	01/04/92	3.5	5.6	10-12/L	4.56	5.07				
						RBC	01/04/92	4.0	10.0	10-9/L	8.30	7.80				
						RBC: N	01/04/92	51.0	75.0	Z	62.00	72.00				
RBC: L	01/04/92	20.0				40.0	Z	36.00	28.00							
RBC: E	01/04/92	1.0				4.0	Z	0.00	0.00							
RBC: H	01/04/92	2.0				8.0	Z	1.00	4.00							
RBC: B	01/04/92	0.0				1.0	Z	0.00	0.00							
PLATELETS	01/04/92	150.0				350.0	10-9/L	220.00	227.00							
Na+	01/04/92	135.0				150.0	MMOL/L	139.00	140.00							
K+	01/04/92	3.5				5.3	MMOL/L	4.40	4.60							
CL-	01/04/92	97.0				107.0	MMOL/L	106.00	99.00							
Ca++	01/04/92	2.3				2.8	MMOL/L	2.50	2.20							
PO4-	01/04/92	0.7				1.5	MMOL/L	0.74	1.00							
SGOT	01/04/92	5.0				15.0	U/L	26.00	19.00							
SGPT	01/04/92	5.0				19.0	U/L	19.00	19.00							
GAMMA-GT	01/04/92	4.0				18.0	U/L	10.00	8.00							
GLUCOSE	01/04/92	3.9				6.1	MMOL/L	4.40	4.00							
ALK. PHOSPH.	01/04/92	40.0				200.0	U/L	73.00	102.00							
BUN	01/04/92	2.1	9.6	MMOL/L	5.20	4.80										
CREATININE	01/04/92	36.0	115.0	UMOL/L	69.00	72.00										
URIC ACID	01/04/92	118.0	416.0	UMOL/L	277.00	266.00										
TOT. PROTEINS	01/04/92	60.0	85.0	G/L	78.00	75.00										
ALBUMINE	01/04/92	35.0	50.0	G/L	39.00	37.00										
TOT. CHOLEST.	01/04/92	3.9	6.7	MMOL/L	7.50	6.40										

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2000

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit											
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52					
11 15-366	F			TRIGLYCERIDES	0.5	2.3	MMOL/L	1.28	1.46										
				GLOBULINS: ALPHA1	1.0	4.0	X	2.91	2.01										
				GLOBULINS: ALPHA2	4.0	10.0	X	7.65	7.26										
				GLOBULINS: BETA	5.0	11.0	X	9.10	9.24										
				GLOBULINS: GAMMA	7.0	17.0	X	16.68	14.44										
				HB	120.0	170.0	G/L	118.00	115.00	117.00	116.00	115.00	122.00	125.00	126.00	126.00	126.00	126.00	126.00
				HTC	0.4	0.5	L/L	0.35	0.33	0.35	0.33	0.35	0.38	0.37	0.38	0.38	0.38	0.39	0.39
				WBC	3.5	5.6	10 ⁹ /L	2.84	3.73	3.98	3.73	3.98	3.98	4.09	4.06	4.06	4.06	4.05	4.05
				HGB: N	4.0	10.0	10 ⁹ /L	6.90	6.50	6.70	6.50	6.70	6.70	6.70	6.50	6.50	6.50	7.30	7.30
				HGB: L	51.0	75.0	X	50.00	66.00	66.00	66.00	66.00	54.00	50.00	68.00	68.00	68.00	62.00	62.00
HGB: E	20.0	40.0	X	42.00	28.00	28.00	28.00	28.00	32.00	32.00	26.00	26.00	26.00	38.00	38.00				
HGB: M	1.0	4.0	X	4.00	2.00	2.00	2.00	2.00	6.00	6.00	0.00	0.00	0.00	0.00	0.00				
HGB: B	2.0	8.0	X	4.00	4.00	4.00	4.00	4.00	8.00	6.00	6.00	6.00	6.00	0.00	0.00				
HGB: PLATELETS	0.0	1.0	X	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00				
PLATELETS	150.0	350.0	10 ⁹ /L	200.00	250.00	250.00	250.00	250.00	259.00	292.00	275.00	275.00	275.00	274.00	274.00				
NA+	135.0	150.0	MMOL/L	139.00	140.00	143.00	140.00	143.00	143.00	142.00	141.00	141.00	141.00	141.00	141.00				
K+	3.5	5.3	MMOL/L	4.30	4.30	4.30	4.30	4.30	4.20	4.80	4.60	4.60	4.60	4.60	4.60				
CL-	97.0	107.0	MMOL/L	106.00	99.00	99.00	99.00	99.00	102.00	106.00	107.00	107.00	107.00	105.00	105.00				
CA++	2.3	2.8	MMOL/L	2.47	2.40	2.40	2.40	2.40	2.31	2.30	2.43	2.43	2.43	2.35	2.35				
PO4-	0.7	1.5	MMOL/L	1.03	0.83	0.83	0.83	0.83	0.98	0.85	1.00	1.00	1.00	0.99	0.99				
SGOT	5.0	15.0	U/L	26.00	18.00	18.00	18.00	18.00	13.00	12.00	10.00	10.00	10.00	28.00	28.00				
SGPT	5.0	19.0	U/L	20.00	20.00	20.00	20.00	20.00	9.00	9.00	12.00	12.00	12.00	25.00	25.00				
GAMMA-GT	4.0	18.0	U/L	12.00	21.00	21.00	21.00	21.00	5.00	9.00	6.00	6.00	6.00	5.00	5.00				
GLUCOSE	3.9	6.1	MMOL/L	5.00	4.40	4.40	4.40	4.40	5.00	5.30	4.90	4.90	4.90	5.40	5.40				
ALK. PHOSPH.	40.0	200.0	U/L	100.00	73.00	73.00	73.00	73.00	71.00	89.00	94.00	94.00	94.00	93.00	93.00				
BUN	2.1	9.6	MMOL/L	3.60	5.60	5.60	5.60	5.60	3.60	4.30	4.30	4.30	4.30	3.50	3.50				
CREATININE	36.0	115.0	UMOL/L	77.00	76.00	76.00	76.00	76.00	74.00	62.00	64.00	64.00	64.00	82.00	82.00				
URIC ACID	118.0	416.0	UMOL/L	120.00	187.00	187.00	187.00	187.00	207.00	135.00	198.00	198.00	198.00	167.00	167.00				
TOT. PROTEINS	60.0	85.0	G/L	78.00	65.00	65.00	65.00	65.00	78.00	66.00	72.00	72.00	72.00	68.00	68.00				
ALBUMINE	35.0	50.0	G/L	39.00	37.00	37.00	37.00	37.00	39.00	39.00	40.00	40.00	40.00	39.00	39.00				
TOT. CHOLEST.	3.9	6.7	MMOL/L	6.40	4.90	4.90	4.90	4.90	3.80	5.80	5.10	5.10	5.10	5.40	5.40				
TRIGLYCERIDES	0.5	2.5	MMOL/L	0.97	0.73	0.73	0.73	0.73	0.87	0.78	0.67	0.67	0.67	0.67	0.67				
GLOBULINS: ALPHA1	1.0	4.0	X	2.26	1.83	1.83	1.83	1.83	2.30	1.64	1.96	1.96	1.96	2.00	2.00				
GLOBULINS: ALPHA2	4.0	10.0	X	6.56	4.88	4.88	4.88	4.88	7.01	5.46	6.53	6.53	6.53	5.44	5.44				
GLOBULINS: BETA	5.0	11.0	X	9.10	7.54	7.54	7.54	7.54	9.61	7.62	10.06	10.06	10.06	7.81	7.81				
GLOBULINS: GAMMA	7.0	17.0	X	16.34	11.95	11.95	11.95	11.95	15.13	12.43	14.25	14.25	14.25	12.62	12.62				
20-371	F			HB	120.0	170.0	G/L	144.00	140.00	140.00	140.00	140.00	140.00	140.00	140.00	140.00			
				HTC	0.4	0.5	L/L	0.39	0.39	0.39	0.39	0.39	0.39	0.39	0.39	0.39	0.39		

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2000

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Date	Laboratory Range			Visit							
						Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52		
11	20-371	F		RBC	01/04/92	3.5	5.6	10-12/L	4.48	4.35						
				HBC: N	01/04/92	4.0	10.0	10-9/L	7.10	7.90						
				HBC: L	01/04/92	51.0	75.0	%	62.00	64.00						
				HBC: E	01/04/92	20.0	40.0	%	30.00	30.00						
				HBC: H	01/04/92	1.0	4.0	%	4.00	4.00						
				HBC: B	01/04/92	2.0	8.0	%	4.00	2.00						
				HBC: K	01/04/92	0.0	1.0	%	0.00	0.00						
				PLATELETS	01/04/92	150.0	350.0	10-9/L	228.00	318.00						
				NA+	01/04/92	135.0	150.0	MMOL/L	141.00	145.00						
				K+	01/04/92	3.5	5.3	MMOL/L	4.60	4.20						
				CL-	01/04/92	97.0	107.0	MMOL/L	103.00	102.00						
				CA++	01/04/92	2.3	2.8	MMOL/L	2.70	2.00						
				PO4--	01/04/92	0.7	1.5	MMOL/L	0.87	0.70						
				SGOT	01/04/92	5.0	15.0	U/L	27.00	31.00						
				GAMMA-GT	01/04/92	5.0	19.0	U/L	20.00	12.00						
				GLUCOSE	01/04/92	4.0	18.0	U/L	33.00	15.00						
				ALK. PHOSPH.	01/04/92	3.9	6.1	MMOL/L	4.60	4.70						
				BUN	01/04/92	4.0	20.0	U/L	190.00	144.00						
				CREATININE	01/04/92	2.1	9.6	MMOL/L	8.00	5.40						
				URIC ACID	01/04/92	36.0	115.0	UMOL/L	85.00	86.00						
TOT. PROTEINS	01/04/92	118.0	416.0	UMOL/L	239.00	212.00										
ALBUMINE	01/04/92	60.0	85.0	G/L	67.00	69.00										
TOT. CHOLEST.	01/04/92	35.0	50.0	G/L	38.00	39.00										
TRIGLYCERIDES	01/04/92	3.9	6.7	MMOL/L	8.50	6.20										
GLORULINS: ALPHA1	01/04/92	0.5	2.3	MMOL/L	1.98	1.38										
GLORULINS: ALPHA2	01/04/92	1.0	4.0	%	2.57	2.22										
GLORULINS: BETA	01/04/92	4.0	10.0	%	6.48	5.19										
GLORULINS: GAMMA	01/04/92	5.0	11.0	%	10.61	8.52										
PLATELETS	01/04/92	7.0	17.0	%	13.86	12.31										
NA+	20/10/91	137.0	147.0	mmol/L	139.00	143.00										
K+	20/10/91	3.7	5.3	mmol/L	4.40	4.10										
12	5-95	M		HB	09/03/92	7.5	10.0	mmol/L	9.65	9.65						
				HTC	20/10/91	0.4	0.5	L/L	0.46	0.41						
				RBC	20/10/91	4.5	5.0	10**12/L	4.65	4.80						
				HBC: N	20/10/91	4.0	10.0	10**9/L	4.60	11.80						
				HBC: L	20/10/91	60.0	70.0	%	65.00	70.00						
				HBC: E	20/10/91	20.0	45.0	%	30.00	28.00						
				HBC: H	20/10/91	1.0	5.0	%	5.00	2.00						
				HBC: B	20/10/91	1.0	6.0	%	0.00	0.00						
				HBC: K	20/10/91	0.0	1.0	%	0.00	0.00						
				PLATELETS	20/10/91	140.0	300.0	10**9/L	243.00	135.00						
				NA+	20/10/91	137.0	147.0	mmol/L	139.00	143.00						
				K+	20/10/91	3.7	5.3	mmol/L	4.40	4.10						

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Date	Laboratory Range			Visit					
						Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
12 5-95	H			CL-	20/10/91	97.0	107.0	mmol/L		94.00				
				CA++	20/10/91	2.3	2.7	mmol/L	2.58					
				PO4-	20/10/91	0.7	1.5	mmol/L	1.03	1.07				
				SGOT	20/10/91	5.0	30.0	U/l	104.00	46.00				
				SGPT	20/10/91	5.0	34.0	U/l	75.00	29.00				
				GAMMA-GT	20/10/91	6.0	28.0	U/l	64.00	59.00				
				GLUCOSE	20/10/91	3.3	5.5	mmol/L	5.00	4.00				
				ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	320.00	362.00				
				BUN	20/10/91	3.0	9.6	mmol/L	8.50	4.70				
				CREATININE	20/10/91	50.0	110.0	umol/L	86.00	95.00				
				URIC ACID	20/10/91	120.0	410.0	umol/L	508.00	389.00				
				TOT BILIRUBIN	20/10/91	3.4	22.0	umol/L	22.70	7.80				
				DIR BILIRUBIN	20/10/91	0.0	4.5	umol/L	11.70	3.60				
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	88.00	65.00				
				ALBUMINE	20/10/91	0.5	0.7	RATIO	0.77	0.54				
				TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/L	7.60	6.10				
				TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/L	1.40	1.20				
				GLOBULINS: ALPHA1	20/10/91	0.0	0.1	RATIO	0.03	0.08				
				GLOBULINS: ALPHA2	20/10/91	0.1	0.1	RATIO	0.05	0.09				
				GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.05	0.12				
				GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.10	0.16				
6-98	F			HB	20/10/91	7.5	10.0	mmol/L			09/01/92	30/04/92		
				HTC	20/10/91	0.4	0.5	l/l	7.83	7.37	8.28			
				RBC	20/10/91	4.5	5.0	10**12/l	0.38	0.34	0.43			
				HBC: N	20/10/91	4.0	10.0	10**9/l	3.61	4.24	5.32			
				HBC: L	20/10/91	60.0	70.0	z	6.40	6.70	6.10			
				HBC: E	20/10/91	20.0	45.0	z	61.00	69.00	63.00			
				HBC: M	20/10/91	1.0	5.0	z	33.00	26.00	34.00			
				HBC: B	20/10/91	1.0	6.0	z	0.00	2.00	2.00			
				PLATELETS	20/10/91	140.0	300.0	10**9/l	6.00	3.00	1.00			
				NA+	20/10/91	137.0	147.0	mmol/l	217.00	0.00	204.00			
				K+	20/10/91	3.7	5.3	mmol/L	141.00	4.70	145.00			
				CL-	20/10/91	97.0	107.0	mmol/L	4.00	4.20	4.20			
				CA++	20/10/91	2.3	2.7	mmol/L	2.31	2.41	2.61			
				PO4-	20/10/91	0.7	1.5	mmol/L	1.41	0.68	1.57			
				SGOT	20/10/91	5.0	30.0	U/l	21.00	18.00	27.00			
				SGPT	20/10/91	5.0	34.0	U/l	22.00	15.00	29.00			
				GAMMA-GT	20/10/91	6.0	28.0	U/l	42.00	27.00	59.00			
				GLUCOSE	20/10/91	3.3	5.5	mmol/L	3.20	3.80	3.80			
				ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	222.00	251.00	259.00			

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Open-Blind Sex	Laboratory test	Laboratory Range			Visit									
			Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52			
12 6-98	F	BUN	20/10/91	3.0	9.6	mmol/L	4.70	3.40	4.30						
		CREATININE	20/10/91	50.0	110.0	umol/L	85.00	103.00	95.00						
		URIC ACID	20/10/91	120.0	410.0	umol/L	235.00	222.00	221.00						
		TOT BILIRUBIN	20/10/91	3.4	22.0	umol/L	12.50	8.20	10.60						
		DIR BILIRUBIN	20/10/91	0.0	4.5	umol/L	3.50	4.10	7.10						
		TOT. PROTEINS	20/10/91	60.0	80.0	g/l	69.00	73.00	75.00						
		ALBUMINE	20/10/91	0.5	0.7	RATIO	0.71	0.55	0.64						
		TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/L	4.50	6.30	6.60						
		TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/L	1.80	1.10	2.10						
		GLOBULINS: ALPHA1	20/10/91	0.0	0.1	RATIO	0.03	0.07	0.04						
		GLOBULINS: ALPHA2	20/10/91	0.1	0.1	RATIO	0.06	0.07	0.08						
		GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.08	0.14	0.11						
		GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.11	0.17	0.13						
		10-96	F	HR	20/10/91	7.5	10.0	mmol/L	13/01/92	09/03/92					
				HTC	20/10/91	0.4	0.5	l/l	7.65	7.37					
				PRC	20/10/91	4.5	5.0	10 ⁹ x12/l	0.38	0.31					
				WBC	20/10/91	4.0	10.0	10 ⁹ x9/l	4.14	3.94					
WBC: N	20/10/91			60.0	70.0	%	6.90	7.90							
WBC: L	20/10/91			20.0	45.0	%	76.00	82.00							
WBC: E	20/10/91			1.0	5.0	%	22.00	18.00							
WBC: H	20/10/91			1.0	6.0	%	2.00	0.00							
WBC: B	20/10/91			0.0	1.0	%	0.00	0.00							
PLATELETS	20/10/91			140.0	300.0	10 ⁹ x9/l	278.00	138.00							
K+	20/10/91			137.0	147.0	mmol/L	140.00	144.00							
CL-	20/10/91			97.0	107.0	mmol/L	4.60	4.60							
Ca++	20/10/91			2.3	2.7	mmol/L	2.56	2.00							
PO4-	20/10/91			0.7	1.5	mmol/L	0.90	1.00							
SGPT	20/10/91			5.0	30.0	U/l	16.00	15.00							
GAMMA-GT	20/10/91			5.0	34.0	U/l	16.00	12.00							
GLUCOSE	20/10/91			6.0	28.0	U/l	15.00	13.00							
ALK. PHOSPH.	20/10/91			3.3	5.5	mmol/L	5.90	4.00							
BUN	20/10/91			100.0	280.0	U/l	185.00	83.00							
CREATININE	20/10/91			3.0	9.6	mmol/L	4.80	4.50							
URIC ACID	20/10/91			50.0	110.0	umol/L	81.00	103.00							
TOT BILIRUBIN	20/10/91			120.0	410.0	umol/L	158.00	158.00							
DIR BILIRUBIN	20/10/91			3.4	22.0	umol/L	17.10	9.00							
TOT. PROTEINS	20/10/91	0.0	4.5	umol/L	5.50	5.50									
ALBUMINE	20/10/91	60.0	80.0	g/l	78.00	61.00									
TOT. CHOLEST.	20/10/91	0.5	0.7	RATIO	0.82	0.59									
TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/L	5.90	5.50									

(*-) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2012

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No	Centre	Open-Blind Sex	Laboratory test	Laboratory Range			Visit							
				Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
12	10-96	F	TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/L	1.00	0.80					
			GLOBULINS: ALPHA1	20/10/91	0.0	0.1	RATIO	0.02	0.08					
			GLOBULINS: ALPHA2	20/10/91	0.1	0.1	RATIO	0.05	0.09					
			GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.05	0.11					
			GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.06	0.13					
11-94		F	HB	20/10/91	7.5	10.0	mmol/L			08/01/92				
			HTC	20/10/91	0.4	0.5	L/L	7.75						
			RBC	20/10/91	4.5	5.0	10**12/L	4.22						
			HBC: N	20/10/91	4.0	10.0	10**9/L	7.50						
			HBC: L	20/10/91	60.0	70.0	%	66.00						
			HBC: E	20/10/91	20.0	45.0	%	27.00						
			HBC: M	20/10/91	1.0	5.0	%	7.00						
			HBC: B	20/10/91	0.0	1.0	%	0.00						
			PLATELETS	20/10/91	160.0	300.0	10**9/L	207.00						
			NA+	20/10/91	137.0	147.0	mmol/L	142.00						
			Ca++	20/10/91	3.7	5.5	mmol/L	4.40						
			PO4-	20/10/91	2.5	2.7	mmol/L	2.48						
			SGOT	20/10/91	0.7	1.5	mmol/L	1.50						
			SGPT	20/10/91	5.0	30.0	U/l	30.00						
			GAMMA-GT	20/10/91	5.0	34.0	U/l	27.00						
			GLUCOSE	20/10/91	6.0	28.0	U/l	16.00						
			ALK. PHOSPH.	20/10/91	3.3	5.5	mmol/L	4.10						
			BUN	20/10/91	100.0	280.0	U/l	172.00						
			CREATININE	20/10/91	3.0	9.6	mmol/L	5.50						
			URIC ACID	20/10/91	50.0	110.0	umol/L	70.00						
			TOT BILIRUBIN	20/10/91	120.0	410.0	umol/L	279.00						
			DIR BILIRUBIN	20/10/91	3.4	22.0	umol/L	5.30						
			TOT. PROTEINS	20/10/91	60.0	80.0	g/l	73.00						
			ALBUMINE	20/10/91	0.5	0.7	RATIO	0.64						
			TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/L	8.00						
			TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/L	2.00						
			GLOBULINS: ALPHA1	20/10/91	0.0	0.1	RATIO	0.04						
			GLOBULINS: ALPHA2	20/10/91	0.1	0.1	RATIO	0.09						
			GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.09						
			GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.14						
12-97		F	HB	20/10/91	7.5	10.0	mmol/L			13/01/92				

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2010

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range		Date	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
					Min	Max Unit							
12	12-97	F		HTC	0.4	0.5 l/l	20/10/91						
				RBC	4.5	5.0 10**12/l	20/10/91	0.48					
				WBC: N	4.0	10.0 10**9/l	20/10/91	5.37					
				WBC: L	60.0	70.0 x	20/10/91	7.60					
				WBC: E	20.0	45.0 x	20/10/91	24.00					
				WBC: B	1.0	5.0 x	20/10/91	4.00					
				PLATELETS	140.0	300.0 10**9/l	20/10/91	2.00					
				K+	3.7	5.3 mmol/l	20/10/91	396.00					
				Ca++	2.3	2.7 mmol/l	20/10/91	146.00					
				PO4--	0.7	1.5 mmol/l	20/10/91	2.07					
				SGPT	5.0	30.0 U/l	20/10/91	1.06					
				GAMMA-GT	6.0	84.0 U/l	20/10/91	13.00					
				GLUCOSE	3.3	5.5 mmol/l	20/10/91	19.00					
				ALK. PHOSPH.	100.0	280.0 U/l	20/10/91	22.00					
				BUN	3.0	9.6 mmol/l	20/10/91	3.70					
				CREATININE	50.0	140.0 umol/l	20/10/91	188.00					
				URIC ACID	120.0	410.0 umol/l	20/10/91	8.20					
				TOT BILIRUBIN	3.4	22.0 umol/l	20/10/91	69.00					
				DIR BILIRUBIN	0.0	4.5 umol/l	20/10/91	170.00					
				TOT. PROTEINS	60.0	80.0 g/l	20/10/91	7.40					
				ALBUMINE	0.5	0.7 RATIO	20/10/91	5.10					
				TOT. CHOLEST.	2.6	7.0 mmol/l	20/10/91	0.78					
				TRIGLYCERIDES	0.3	1.9 mmol/l	20/10/91	5.20					
				GLOBULINS: ALPHA1	0.0	0.1 RATIO	20/10/91	3.50					
				GLOBULINS: ALPHA2	0.1	0.1 RATIO	20/10/91	0.02					
				GLOBULINS: BETA	0.1	0.1 RATIO	20/10/91	0.06					
				GLOBULINS: GAMMA	0.1	0.2 RATIO	20/10/91	0.05					
								0.10					
13-103		F		HS	7.5	10.0 mmol/l	13/01/92						
				HTC	0.4	0.5 l/l	20/10/91	8.60					
				RBC	4.5	5.0 10**12/l	20/10/91	0.44					
				WBC	4.0	10.0 10**9/l	20/10/91	4.34					
				WBC: N	60.0	70.0 x	20/10/91	6.20					
				WBC: L	20.0	45.0 x	20/10/91	70.00					
				WBC: E	1.0	5.0 x	20/10/91	30.00					
				WBC: B	1.0	6.0 x	20/10/91	0.00					
				PLATELETS	140.0	300.0 10**9/l	20/10/91	0.00					

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2014

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Date	Laboratory Range			Visit									
						Min	Max	Unit	Week 10	Week 16	Week 26	Week 34	Week 42	Week 52				
12	13-103	F	NA+	20/10/91	137.0	147.0	mmol/l	138.00										
			K+	20/10/91	3.7	5.3	mmol/l	4.00										
			CA++	20/10/91	2.3	2.7	mmol/l	2.13										
			PO4-	20/10/91	0.7	1.5	mmol/l	0.81										
			SGOT	20/10/91	5.0	30.0	U/l	16.00										
			SGPT	20/10/91	5.0	34.0	U/l	17.00										
			GAMMA-GT	20/10/91	6.0	28.0	U/l	10.00										
			GLUCOSE	20/10/91	3.3	5.5	mmol/l	5.50										
			ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	133.00										
			BUN	20/10/91	3.0	9.6	mmol/l	3.90										
			CREATININE	20/10/91	50.0	110.0	umol/l	70.00										
			URIC ACID	20/10/91	120.0	410.0	umol/l	194.00										
			TOT. BILIRUBIN	20/10/91	3.4	22.0	umol/l	5.00										
			DIR. BILIRUBIN	20/10/91	0.0	4.5	umol/l	3.40										
			TOT. PROTEINS	20/10/91	60.0	80.0	g/l	73.00										
			ALBUMINE	20/10/91	0.5	0.7	RATIO	0.75										
			TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	4.70										
			TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	0.50										
			GLOBULINS: ALPHA 1	20/10/91	0.0	0.1	RATIO	0.03										
			GLOBULINS: ALPHA 2	20/10/91	0.1	0.1	RATIO	0.05										
			GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.06										
			GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.13										
			14-101	F	HB	20/10/91	7.5	10.0	mmol/l	8.93								
HTC	20/10/91	0.4			0.5	l/l	0.43											
RBC	20/10/91	4.5			5.0	10 ¹² /l	4.73											
HRC	20/10/91	4.0			10.0	10 ⁹ /l	8.40											
HRC: N	20/10/91	60.0			70.0	%	67.00											
HRC: L	20/10/91	20.0			45.0	%	28.00											
HRC: E	20/10/91	1.0			5.0	%	1.00											
HRC: M	20/10/91	1.0			6.0	%	4.00											
HRC: B	20/10/91	0.0			1.0	%	0.00											
PLATELETS	20/10/91	140.0			300.0	10 ⁹ /l	290.00											
NA+	20/10/91	137.0			147.0	mmol/l	140.00											
K+	20/10/91	3.7			5.3	mmol/l	4.30											
CA++	20/10/91	2.3			2.7	mmol/l	2.13											
PO4-	20/10/91	0.7			1.5	mmol/l	0.84											
SGOT	20/10/91	5.0			30.0	U/l	22.00											
SGPT	20/10/91	5.0			34.0	U/l	38.00											
GAMMA-GT	20/10/91	6.0			28.0	U/l	26.00											
GLUCOSE	20/10/91	3.3	5.5	mmol/l	5.50													
ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	148.00													

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit															
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52									
12	14-101	F		BUN	20/10/91	3.0	9.6	mmol/L															
				CREATININE	20/10/91	50.0	110.0	umol/L	4.50														
				URIC ACID	20/10/91	120.0	410.0	umol/L	67.00														
				TOT BILIRUBIN	20/10/91	3.4	22.0	umol/L	214.00														
				DIR BILIRUBIN	20/10/91	0.0	4.5	umol/L	8.10														
				TOT. PROTEINS	20/10/91	60.0	80.0	g/L	59.00														
				ALBUMINE	20/10/91	0.5	0.7	RATIO	0.74														
				TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/L	5.70														
				TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/L	1.00														
				GLOBULINS: ALPHA1	20/10/91	0.0	0.1	RATIO	0.03														
				GLOBULINS: ALPHA2	20/10/91	0.1	0.1	RATIO	0.06														
				GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.07														
				GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.09														
				17-108	M		HB	20/10/91	7.5	10.0	mmol/L		24/03/92	8.52	19/05/92	9.59	14/07/92	9.36					
							HCT	20/10/91	0.4	0.5	L/I	0.44		0.40		0.44		0.43					
							RBC	20/10/91	4.5	5.0	10**12/L	5.06		5.69		5.69		5.54					
							HBC	20/10/91	4.0	10.0	10**9/L	5.50		6.20		6.20		5.60					
HBC: N	20/10/91	60.0	70.0				X	62.00		62.00		62.00		54.00									
HBC: L	20/10/91	20.0	45.0				X	36.00		36.00		36.00		38.00									
HBC: E	20/10/91	1.0	5.0				X	2.00		2.00		2.00		4.00									
HBC: M	20/10/91	1.0	6.0				X	0.00		0.00		0.00		0.00									
HBC: B	20/10/91	140.0	300.0				10**9/L	0.00		0.00		0.00		0.00									
PLATELETS	20/10/91	137.0	147.0				mmol/L	287.00		287.00		117.00		77.00									
NA+	20/10/91	3.7	5.3				mmol/L	4.80		4.80		144.00		148.00									
K+	20/10/91	97.0	107.0				mmol/L	107.00		107.00		4.40		4.70									
CL-	20/10/91	2.3	2.7				mmol/L	2.28		2.28		2.41		2.05									
CA++	20/10/91	0.7	1.5				mmol/L	1.06		1.06		1.14		0.72									
SDOT	20/10/91	5.0	30.0				U/I	12.00		12.00		15.00		15.00									
SEPT	20/10/91	5.0	34.0				U/I	21.00		21.00		28.00		17.00									
GAMMA-GT	20/10/91	6.0	28.0				U/I	13.00		13.00		32.00		27.00									
GLUCOSE	20/10/91	3.3	5.5				mmol/L	3.10		3.10		4.00		4.00									
ALK. PHOSPH.	20/10/91	100.0	280.0				U/I	119.00		119.00		163.00		162.00									
BUN	20/10/91	3.0	9.6				mmol/L	5.00		5.00		5.90		7.40									
CREATININE	20/10/91	50.0	110.0				umol/L	64.00		64.00		87.00		87.00									
URIC ACID	20/10/91	120.0	410.0				umol/L	305.00		305.00		362.00		194.00									
TOT BILIRUBIN	20/10/91	3.4	22.0				umol/L	13.70		13.70		18.60		17.20									
DIR BILIRUBIN	20/10/91	0.0	4.5	umol/L	8.60		8.60		5.70		7.10												
TOT. PROTEINS	20/10/91	60.0	80.0	g/L	61.00		61.00		61.00		79.00												
ALBUMINE	20/10/91	0.5	0.7	RATIO	0.63		0.63		0.64		0.65												
TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/L	5.30		5.30		5.00		4.50												

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2016

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Date	Laboratory Range			Visit					
						Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
12	17-108	M		TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	3.10	2.30	2.00			
				GLOBULINS: ALPHA1	20/10/91	0.0	0.1	RATIO	0.08	0.07	0.04			
				GLOBULINS: ALPHA2	20/10/91	0.1	0.1	RATIO	0.08	0.07	0.08			
				GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.09	0.09	0.08			
				GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.12	0.13	0.15			
18-109	M			HB	20/10/91	7.5	10.0	mmol/l	9.48	9.48				
				HTC	20/10/91	0.4	0.5	l/l	0.43	0.46				
				RBC	20/10/91	4.5	5.0	10**12/l	4.90	5.75				
				WBC	20/10/91	4.0	10.0	10**9/l	7.00	6.80				
				MBC: N	20/10/91	60.0	70.0	%	60.00	60.00				
				MBC: L	20/10/91	20.0	45.0	%	32.00	32.00				
				MBC: E	20/10/91	1.0	5.0	%	4.00	6.00				
				MBC: M	20/10/91	1.0	6.0	%	4.00	2.00				
				MBC: B	20/10/91	0.0	1.0	%	0.00	0.00				
				PLATELETS	20/10/91	140.0	300.0	10**9/l	264.00	162.00				
				NA+	20/10/91	137.0	147.0	mmol/l	147.00	163.00				
				K+	20/10/91	3.7	5.3	mmol/l	4.60	4.90				
				CL-	20/10/91	97.0	107.0	mmol/l	106.00					
				CA++	20/10/91	2.3	2.7	mmol/l	2.41	2.43				
				PO4-	20/10/91	0.7	1.5	mmol/l	1.30	1.45				
				SGOT	20/10/91	5.0	30.0	U/l	40.00	22.00				
				SGPT	20/10/91	5.0	34.0	U/l	53.00	29.00				
				GAMMA-GT	20/10/91	6.0	28.0	U/l	61.00	29.00				
				GLUCOSE	20/10/91	3.3	5.5	mmol/l	4.70	5.00				
				ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	206.00	150.00				
				BUN	20/10/91	3.0	9.6	mmol/l	3.00	3.50				
				CREATININE	20/10/91	50.0	110.0	umol/l	86.00	95.00				
				URIC ACID	20/10/91	120.0	410.0	umol/l	356.00	296.00				
				TOT BILIRUBIN	20/10/91	3.4	22.0	umol/l	7.70	6.80				
				DIR BILIRUBIN	20/10/91	0.0	4.5	umol/l	3.80	4.60				
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	77.00	69.00				
ALBUMINE	20/10/91	0.5	0.7	RATIO	0.56	0.63								
TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	6.20	6.20								
TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	1.40	1.50								
GLOBULINS: ALPHA1	20/10/91	0.0	0.1	RATIO	0.12	0.07								
GLOBULINS: ALPHA2	20/10/91	0.1	0.1	RATIO	0.09	0.07								
GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.09	0.10								
GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.14	0.13								
20-107	M				26/03/92				2.00					
					19/05/92									
					26/03/92									

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1
LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Ranges			Visit							
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
12	20-107	M		HB	20/10/91	7.5	10.0	mmol/l	8.26	8.31	10.10				
				HCT	20/10/91	0.4	0.5	l/l	0.37	0.38	0.46				
				RBC	20/10/91	4.5	5.0	10 ¹² /l	4.44	5.11	5.91				
				HBC	20/10/91	4.0	10.0	10 ⁹ /l	4.70	5.80	5.50				
				HBC: N	20/10/91	60.0	70.0	%	65.00	72.00	76.00				
				HBC: L	20/10/91	20.0	45.0	%	30.00	26.00	22.00				
				HBC: E	20/10/91	1.0	5.0	%	4.00	2.00	0.00				
				HBC: M	20/10/91	1.0	6.0	%	1.00	0.00	2.00				
				HBC: B	20/10/91	0.0	1.0	%	0.00	0.00	0.00				
				PLATELETS	20/10/91	140.0	300.0	10 ⁹ /l	236.00	197.00	165.00				
				NA+	20/10/91	137.0	147.0	mmol/l	148.00	140.00	143.00				
				K+	20/10/91	3.7	5.3	mmol/l	4.10	4.20	3.80				
				CL-	20/10/91	97.0	107.0	mmol/l	98.00	90.00	90.00				
				CA++	20/10/91	2.3	2.7	mmol/l	2.40	2.08	2.08				
				PO4-	20/10/91	0.7	1.5	mmol/l	1.06	0.52	0.66				
				SGPT	20/10/91	5.0	30.0	U/l	32.00	24.00	113.00				
				SGOT	20/10/91	5.0	34.0	U/l	74.00	48.00	167.00				
				GAMMA-GT	20/10/91	6.0	28.0	U/l	26.00	23.00	91.00				
				GLUCOSE	20/10/91	3.3	5.5	mmol/l	3.80	4.20	7.60				
				ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	165.00	162.00	173.00				
				BUN	20/10/91	3.0	9.6	mmol/l	3.20	4.00	4.80				
				CREATININE	20/10/91	50.0	110.0	umol/l	77.00	112.00	84.00				
				URIC ACID	20/10/91	120.0	410.0	umol/l	394.00	406.00	265.00				
				TOT BILIRUBIN	20/10/91	3.4	22.0	umol/l	7.20	17.10	22.40				
				DIR BILIRUBIN	20/10/91	0.0	4.5	umol/l	3.80	6.30	6.30				
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	74.00	76.00	79.00				
				ALBUMINE	20/10/91	0.5	0.7	RATIO	0.59	0.66	0.64				
				TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	4.20	4.80	4.50				
				TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	0.80	0.70	0.70				
				GLOBULINS: ALPHA1	20/10/91	0.0	0.1	RATIO	0.10	0.05	0.06				
				GLOBULINS: ALPHA2	20/10/91	0.1	0.1	RATIO	0.08	0.07	0.06				
				GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.09	0.09	0.07				
GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.14	0.13	0.15								
22-111	F			HB	20/10/91	7.5	10.0	mmol/l	7.59	7.86	7.89	21/09/92	10/11/92	02/02/93	
				HCT	20/10/91	0.4	0.5	l/l	0.37	0.38	0.38	7.89	8.03	8.03	
				RBC	20/10/91	4.5	5.0	10 ¹² /l	4.67	4.81	4.83	0.37	0.40	0.40	
				HBC	20/10/91	4.0	10.0	10 ⁹ /l	4.67	5.60	4.87	4.87	4.73	4.73	
				HBC: N	20/10/91	60.0	70.0	%	62.00	61.00	68.00	56.00	59.00	60.00	
				HBC: L	20/10/91	20.0	45.0	%	31.00	31.00	28.00	40.00	37.00	34.00	
				HBC: E	20/10/91	1.0	5.0	%	2.00	5.00	4.00	2.00	3.00	4.00	
				HBC: M	20/10/91	1.0	6.0	%	5.00	3.00	0.00	2.00	1.00	2.00	
				HBC: B	20/10/91	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00	
					06/04/92										

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

3012

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Date	Laboratory Range			Visit									
						Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52				
12	22-111	F		MBC: B	20/10/91	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
				PLATELETS	20/10/91	140.0	300.0	10**9/1	225.00	226.00	207.00	207.00	183.00	207.00	183.00	236.00		
				NA+	20/10/91	137.0	147.0	mmol/l	137.00	130.00	147.00	144.00	140.00	144.00	140.00	148.00		
				K+	20/10/91	3.7	5.3	mmol/l	4.30	4.10	4.70	4.20	4.00	4.20	4.00	4.60		
				CL-	20/10/91	97.0	107.0	mmol/l	88.00	97.00	107.00	102.00	102.00	102.00	102.00	97.00		
				CA++	20/10/91	2.3	2.7	mmol/l	2.29	2.23	2.14	2.31	2.14	2.31	2.14	2.31		
				PO4--	20/10/91	0.7	1.5	mmol/l	1.08	1.21	1.30	1.07	1.06	1.07	1.06	1.35		
				SGOT	20/10/91	5.0	30.0	U/l	26.00	14.00	17.00	25.00	154.00	14.00	27.00	14.00		
				SGPT	20/10/91	5.0	34.0	U/l	24.00	17.00	17.00	33.00	213.00	27.00	27.00	16.00		
				GAMMA-GT	20/10/91	5.0	28.0	U/l	24.00	17.00	17.00	30.00	27.00	30.00	27.00	12.00		
				GLUCOSE	20/10/91	3.3	5.5	mmol/l	4.50	34.00	4.20	4.40	4.60	4.40	4.60	4.80		
				ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	263.00	271.00	278.00	251.00	267.00	251.00	267.00	267.00		
				BUN	20/10/91	3.0	9.6	mmol/l	7.50	11.00	7.20	7.00	8.90	7.00	8.90	8.90		
				CREATININE	20/10/91	50.0	170.0	umol/l	60.00	183.00	84.00	58.00	66.00	58.00	66.00	80.00		
				URIC ACID	20/10/91	120.0	410.0	umol/l	184.00	14.00	135.00	147.00	157.00	147.00	157.00	157.00		
				TOT BILIRUBIN	20/10/91	3.4	22.0	umol/l	12.70	14.00	17.10	17.10	17.10	17.10	17.10	17.10		
				DIR BILIRUBIN	20/10/91	0.0	4.5	umol/l	6.90	5.20	73.00	70.00	73.00	70.00	73.00	73.00		
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	67.00	70.00	67.00	70.00	67.00	70.00	67.00	67.00		
				ALBUMINE	20/10/91	0.5	0.7	RATIO	0.60	0.60	0.61	0.63	0.68	0.61	0.63	0.65		
				TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	7.30	7.60	6.80	6.30	6.50	6.80	6.30	6.50		
				TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	3.30	2.00	2.20	2.10	2.20	2.10	2.20	2.10		
				GLOBULINS: ALPHA1	20/10/91	0.0	0.1	RATIO	0.08	0.06	0.09	0.04	0.04	0.09	0.04	0.05		
				GLOBULINS: ALPHA2	20/10/91	0.1	0.1	RATIO	0.08	0.08	0.07	0.08	0.06	0.07	0.08	0.06		
				GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.12	0.12	0.11	0.12	0.10	0.11	0.12	0.08		
				GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.13	0.14	0.12	0.13	0.11	0.12	0.13	0.16		
				23-112	F		HB	20/10/91	7.5	10.0	mmol/l	8.31	8.87	8.17	8.17	8.17	8.17	
							HTC	20/10/91	0.4	0.5	l/l	0.40	0.43	0.37	0.37	0.37	0.37	0.37
							RBC	20/10/91	4.5	5.0	10**12/l	4.55	5.00	4.53	4.53	4.53	4.53	4.53
							WBC	20/10/91	4.0	10.0	10**9/l	8.70	12.80	9.50	9.50	9.50	9.50	9.50
							MBC: N	20/10/91	60.0	70.0	%	57.00	76.00	70.00	70.00	70.00	70.00	70.00
							MBC: L	20/10/91	20.0	45.0	%	24.00	21.00	22.00	22.00	22.00	22.00	22.00
							MBC: E	20/10/91	1.0	5.0	%	1.00	3.00	3.00	3.00	3.00	3.00	3.00
							MBC: H	20/10/91	1.0	6.0	%	1.00	3.00	3.00	3.00	3.00	3.00	3.00
MBC: B	20/10/91	0.0	1.0				%	1.00	0.00	0.00	0.00	0.00	0.00	0.00				
PLATELETS	20/10/91	140.0	300.0				10**9/l	116.00	287.00	151.00	151.00	151.00	151.00	151.00				
NA+	20/10/91	137.0	147.0				mmol/l	143.00	156.00	135.00	135.00	135.00	135.00	135.00				
K+	20/10/91	3.7	5.3				mmol/l	4.30	5.80	5.50	5.50	5.50	5.50	5.50				
CL-	20/10/91	97.0	107.0				mmol/l	97.00	97.00	89.00	89.00	89.00	89.00	89.00				
CA++	20/10/91	2.3	2.7				mmol/l	2.44	2.51	2.22	2.22	2.22	2.22	2.22				
PO4--	20/10/91	0.7	1.5				mmol/l	1.14	1.42	1.13	1.13	1.13	1.13	1.13				
SGOT	20/10/91	5.0	30.0	U/l	25.00	35.00	24.00	24.00	24.00	24.00	24.00							

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXYLINE - PROTOCOL 20124/013
 Listing No.: 12.1

LABORATORY DATA
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

9550077

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Date	Laboratory Range			Visit					
						Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
12	23-112	F		SGPT	20/10/91	5.0	34.0	U/l	47.00	30.00	25.00			
				GAMMA-GT	20/10/91	6.0	28.0	U/l	14.00	22.00	14.00			
				GLUCOSE	20/10/91	3.3	5.5	mmol/l	4.40	4.00	3.90			
				ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	139.00	145.00	130.00			
				BUN	20/10/91	3.0	9.6	mmol/l	7.50	6.40	6.90			
				CREATININE	20/10/91	50.0	110.0	umol/l	100.00	94.00	123.00			
				URIC ACID	20/10/91	120.0	410.0	umol/l		280.00	184.00			
				TOT BILIRUBIN	20/10/91	3.4	22.0	umol/l	13.50		17.10			
				DIR BILIRUBIN	20/10/91	0.0	4.5	umol/l	4.60					
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	68.00	80.00	68.00			
				ALBUMINE	20/10/91	0.5	0.7	RATIO	0.52	0.60	0.62			
				TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	6.10	7.70	5.80			
				TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	1.40	1.70	1.70			
				GLOBULINS: ALPHA1	20/10/91	0.0	0.1	RATIO	0.15	0.87	0.05			
				GLOBULINS: ALPHA2	20/10/91	0.1	0.1	RATIO	0.12	0.08	0.06			
				GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.10	0.08	0.08			
				GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.13	0.18	0.18			
28-116		F		HB	20/10/91	7.5	10.0	mmol/l	17/04/92					
				HTC	20/10/91	0.4	0.5	l/l	8.57					
				RBC	20/10/91	4.5	5.0	10**12/l	0.41					
				MBC	20/10/91	4.0	10.0	10**9/l	5.36					
				MBC: N	20/10/91	60.0	70.0	%	6.70					
				MBC: L	20/10/91	20.0	45.0	%	54.00					
				MBC: E	20/10/91	1.0	5.0	%	39.00					
				MBC: M	20/10/91	1.0	6.0	%	5.00					
				MBC: B	20/10/91	0.0	1.0	%	2.00					
				PLATELETS	20/10/91	140.0	300.0	10**9/l	0.00					
				NA+	20/10/91	137.0	147.0	mmol/l	237.00					
				K+	20/10/91	3.7	5.3	mmol/l	139.00					
				CL-	20/10/91	97.0	107.0	mmol/l	3.30					
				CA++	20/10/91	2.3	2.7	mmol/l	107.00					
				PO4-	20/10/91	0.7	1.5	mmol/l	2.27					
				SGOT	20/10/91	5.0	30.0	U/l	0.94					
				SGPT	20/10/91	5.0	34.0	U/l	27.00					
				GAMMA-GT	20/10/91	6.0	28.0	U/l	17.00					
				GLUCOSE	20/10/91	3.3	5.5	mmol/l	32.00					
				ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	3.60					
				BUN	20/10/91	3.0	9.6	mmol/l	175.00					
				CREATININE	20/10/91	50.0	110.0	umol/l	9.10					
				URIC ACID	20/10/91	120.0	410.0	umol/l	83.00					
				TOT BILIRUBIN	20/10/91	3.4	22.0	umol/l	232.00					
									5.70					

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1
LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52		
12 28-116	F			DIR BILIRUBIN	20/10/91	0.0	4.5	umol/l	2.90							
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	73.00							
				ALBUMINE	20/10/91	0.5	0.7	RATIO	0.55							
				TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	4.00							
				TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	1.20							
				GLOBULINS: ALPHA1	20/10/91	0.0	0.1	RATIO	0.09							
				GLOBULINS: ALPHA2	20/10/91	0.1	0.1	RATIO	0.08							
				GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.10							
				GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.17							
				HR	20/10/91	7.5	10.0	mmol/l	9.42	05/06/92	31/07/92	25/09/92	12/11/92	15/01/93	26/03/93	
				HTC	20/10/91	0.4	0.5	l/l	0.44	9.68	9.11	9.12	9.12	9.75	9.60	
				RBC	20/10/91	4.5	5.0	10**12/l	5.44	0.44	0.41	0.45	0.45	0.51	0.46	
				RBC: N	20/10/91	4.0	10.0	10**9/l	5.60	5.47	5.70	5.80	5.80	5.42	5.21	
				RBC: L	20/10/91	20.0	45.0	x	37.00	74.00	48.00	55.00	55.00	4.90	11.10	
RBC: E	20/10/91	1.0	5.0	x	2.00	26.00	50.00	42.00	42.00	57.00	66.00					
RBC: H	20/10/91	1.0	6.0	x	4.00	0.00	2.00	1.00	1.00	41.00	24.00					
RBC: B	20/10/91	0.0	1.0	x	0.00	0.00	0.00	0.00	0.00	1.00	5.00					
PLATELETS	20/10/91	140.0	300.0	10**9/l	343.00	176.00	221.00	233.00	233.00	257.00	197.00					
NA+	20/10/91	137.0	147.0	mmol/l	140.00	163.00	143.00	143.00	143.00	142.00	142.00					
K+	20/10/91	3.7	5.3	mmol/l	4.00	4.20	4.70	4.70	4.20	4.00	4.20					
CL-	20/10/91	97.0	107.0	mmol/l	92.00	94.00	83.00	83.00	83.00	89.00	89.00					
PO4--	20/10/91	2.3	2.7	mmol/l	2.44	2.21	2.31	2.21	2.43	2.20	2.18					
SGPT	20/10/91	0.7	1.5	mmol/l	1.00	0.91	1.05	1.00	1.00	1.15	1.00					
GAMMA-GT	20/10/91	5.0	34.0	U/l	18.00	19.00	15.00	15.00	15.00	16.00	15.00					
GLUCOSE	20/10/91	5.0	34.0	U/l	24.00	18.00	13.00	12.00	12.00	12.00	12.00					
ALK. PHOSPH.	20/10/91	6.0	28.0	U/l	31.00	3.60	9.00	9.00	11.00	14.00	22.00					
BUN	20/10/91	3.3	5.5	mmol/l	4.70	3.60	4.80	4.80	4.10	4.60	3.80					
CREATININE	20/10/91	100.0	280.0	U/l	204.00	186.00	198.00	198.00	198.00	199.00	159.00					
URIC ACID	20/10/91	3.0	9.6	mmol/l	6.50	4.80	5.40	5.40	4.70	6.40	6.00					
DIR BILIRUBIN	20/10/91	50.0	110.0	umol/l	100.00	83.00	227.00	227.00	75.00	77.00	60.00					
TOT. PROTEINS	20/10/91	120.0	410.0	umol/l	246.00	217.00	17.10	17.10	17.10	219.00	181.00					
ALBUMINE	20/10/91	3.4	22.0	umol/l	7.50	17.10	17.10	17.10	17.10	17.10	17.10					
TOT. CHOLEST.	20/10/91	0.0	4.5	mmol/l	1.30	63.00	65.00	61.00	61.00	66.00	66.00					
TRIGLYCERIDES	20/10/91	0.5	0.7	RATIO	8.00	6.00	7.60	6.00	6.00	7.90	7.20					
GLOBULINS: ALPHA1	20/10/91	2.6	7.0	mmol/l	1.90	1.80	1.70	1.70	1.70	1.70	1.90					
GLOBULINS: ALPHA2	20/10/91	0.0	0.1	RATIO	0.06	0.06	0.06	0.06	0.06	0.06	0.06					
GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.07	0.07	0.07	0.07	0.07	0.08	0.08					
GLOBULINS: GAMMA	20/10/91	0.1	0.1	RATIO	0.09	0.09	0.09	0.09	0.09	0.08	0.08					

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Date	Laboratory Range			Visit					
						Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
12	34-120	F		GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO			0.11	0.11	0.17	
35-119	F			HB	20/10/91	7.5	10.0	mmol/L	04/06/92	31/07/92				
				HTC	20/10/91	0.4	0.5	l/l	7.73	9.24				
				RBC	20/10/91	4.5	5.0	10 ¹² /l	0.37	0.42				
				WBC	20/10/91	4.0	10.0	10 ⁹ /l	4.55	5.47				
				WBC: N	20/10/91	60.0	70.0	%	7.90	7.10				
				WBC: L	20/10/91	20.0	45.0	%	58.00	58.00				
				WBC: E	20/10/91	1.0	5.0	%	33.00	34.00				
				WBC: M	20/10/91	1.0	6.0	%	6.00	8.00				
				WBC: B	20/10/91	0.0	1.0	%	3.00	0.00				
				PLATELETS	20/10/91	140.0	300.0	10 ⁹ /l	0.00	244.00				
				NA+	20/10/91	137.0	147.0	mmol/l	146.00	141.00				
				K+	20/10/91	3.7	5.3	mmol/l	3.90	4.40				
				CL-	20/10/91	97.0	107.0	mmol/l	99.00	96.00				
				CA++	20/10/91	2.3	2.7	mmol/l	2.26	2.28				
				PO4--	20/10/91	0.7	1.5	mmol/l	1.30	1.06				
				SGOT	20/10/91	5.0	30.0	U/l	23.00	20.00				
				SGPT	20/10/91	5.0	34.0	U/l	35.00	34.00				
				GAMMA-GT	20/10/91	6.0	28.0	U/l	99.00					
				GLUCOSE	20/10/91	3.3	5.5	mmol/l	3.60	3.90				
				ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	176.00	203.00				
				BUN	20/10/91	3.0	9.6	mmol/l	5.70	4.80				
				CREATININE	20/10/91	50.0	110.0	umol/l	80.00	91.00				
				URIC ACID	20/10/91	120.0	410.0	umol/l	241.00	209.00				
				TOT BILIRUBIN	20/10/91	3.4	22.0	umol/l	15.00	17.10				
				DIR BILIRUBIN	20/10/91	0.0	4.5	umol/l	7.40					
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	67.00	71.00				
				TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/l	7.20	6.90				
				TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/l	5.10	3.10				
37-386	F			HB	20/10/91	7.5	10.0	mmol/l	16/06/92	07/08/92				
				HTC	20/10/91	0.4	0.5	l/l	8.39	8.12				
				RBC	20/10/91	4.5	5.0	10 ¹² /l	0.36	0.36				
				WBC	20/10/91	4.0	10.0	10 ⁹ /l	4.72	4.50				
				WBC: N	20/10/91	60.0	70.0	%	5.00	5.00				
				WBC: L	20/10/91	20.0	45.0	%	43.00	48.00				
				WBC: E	20/10/91	1.0	5.0	%	3.00	2.00				
				WBC: M	20/10/91	1.0	6.0	%	2.00	0.00				
				WBC: B	20/10/91	0.0	1.0	%	0.00	0.00				

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit								
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52		
12 37-386	F			PLATELETS	20/10/91	140.0	300.0	10**9/L	181.00	198.00						
				NA+	20/10/91	137.0	147.0	mmol/L	147.00	141.00						
				K+	20/10/91	3.7	5.3	mmol/L	4.20	3.60						
				CL-	20/10/91	97.0	107.0	mmol/L		109.00						
				CA++	20/10/91	2.3	2.7	mmol/L	2.33	2.38						
				PO4-	20/10/91	0.7	1.5	mmol/L	1.47	1.27						
				SGOT	20/10/91	5.0	30.0	U/l	17.00	16.00						
				SGPT	20/10/91	5.0	34.0	U/l	24.00	24.00						
				GAMMA-GT	20/10/91	6.0	28.0	U/l	37.00	17.00						
				GLUCOSE	20/10/91	3.3	5.5	mmol/L	5.20	5.20						
				ALK. PHOSPH.	20/10/91	100.0	280.0	U/l	172.00	163.00						
				BUN	20/10/91	3.0	9.6	mmol/L	5.50	4.50						
				CREATININE	20/10/91	50.0	110.0	umol/L	105.00	113.00						
				URIC ACID	20/10/91	120.0	410.0	umol/L	226.00	313.00						
				TOT BILIRUBIN	20/10/91	3.4	22.0	umol/L	7.10	17.10						
				DIR BILIRUBIN	20/10/91	0.0	4.5	umol/L	1.95	3.70						
				TOT. PROTEINS	20/10/91	60.0	80.0	g/l	63.00	77.00						
				ALBUMINE	20/10/91	0.5	0.7	RATIO	0.62	0.66						
				TOT. CHOLEST.	20/10/91	2.6	7.0	mmol/L	7.10	5.80						
				TRIGLYCERIDES	20/10/91	0.3	1.9	mmol/L	1.80	1.20						
				GLOBULINS: ALPHA1	20/10/91	0.0	0.1	RATIO	0.06	0.05						
				GLOBULINS: ALPHA2	20/10/91	0.1	0.1	RATIO	0.06	0.06						
				GLOBULINS: BETA	20/10/91	0.1	0.1	RATIO	0.12	0.09						
GLOBULINS: GAMMA	20/10/91	0.1	0.2	RATIO	0.14	0.14										
13 2-224	F			HB	02/10/91	120.0	140.0	g/l	23/12/91	19/02/92	15/04/92	10/06/92	31/07/92	14/07/92		
				HTC	02/10/91	38.0	47.0	%	147.00	125.00	130.00	139.00	137.00	140.00		
				RBC	02/10/91	4.0	5.5	10**12/L	41.00	34.00	34.50	39.30	41.00	40.40		
				MBC	02/10/91	4.5	8.0	10**9/L	4.60	3.90	3.94	4.27	4.33	4.41		
				HBC: N	02/10/91	60.0	70.0	%	10.30	11.80	7.10	7.40	9.20	8.10		
				HBC: L	02/10/91	20.0	30.0	%	69.00	75.00	54.00	59.00	45.00	35.00		
				HBC: E	02/10/91	1.0	5.0	%	30.00	21.00	43.00	38.00	47.00	64.00		
				HBC: K	02/10/91	2.0	6.0	%	1.00	3.00	2.00	1.00	6.00	1.00		
				HBC: B	02/10/91	0.0	1.0	%	0.00	0.00	1.00	1.00	2.00	0.00		
				PLATELETS	02/10/91	150.0	400.0	10**9/L	337.00	332.00	386.00	355.00	363.00	331.00		
				NA+	02/10/91	135.0	145.0	mmol/L	139.00	136.00	139.00	139.00	141.00	137.00		
				K+	02/10/91	3.5	5.0	mmol/L	4.00	4.00	4.20	4.20	4.90	4.10		
				CL-	02/10/91	95.0	108.0	mmol/L	105.00	100.00	94.00	102.00	105.00	102.00		
				CA++	02/10/91	1.0	2.7	mmol/L	2.41	2.65	2.34	2.40	2.41	2.56		
				PO4-	02/10/91	1.0	1.5	mmol/L	1.19	1.23	1.26	1.43	1.52	1.09		
				SGOT	02/10/91	10.0	40.0	U/l	21.00	20.00	45.00	29.00	27.00	37.00		
SGPT	02/10/91	10.0	40.0	U/l	47.00	27.00	27.00	22.00	20.00	24.00						

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit						
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
13	2-224	F		GAMMA-GT	02/10/91	10.0	40.0	u/l	64.00	20.00	25.00	28.00	18.00	25.00
				GLUCOSE	02/10/91	4.0	6.0	mmol/l	4.80	5.00	7.60	4.80	4.40	4.90
				ALK. PHOSPH.	02/10/91	100.0	300.0	u/l	123.00	113.00	110.00	89.00	80.00	91.00
				BUN	02/10/91	2.0	10.0	mmol/l	2.80	3.80	3.00	4.70	4.00	4.40
				CREATININE	02/10/91	50.0	100.0	umol/l	55.00	55.00	77.00	51.00	64.00	61.00
				URIC ACID	02/10/91	150.0	400.0	umol/l	253.00	320.00	220.00	238.00	294.00	280.00
				TOT. BILIRUBIN	02/10/91	2.0	17.0	umol/l	8.00	9.00	4.00	12.00	11.00	4.00
				DIR. BILIRUBIN	02/10/91	0.0	5.0	umol/l	4.00	4.00	4.00	4.00	4.00	4.00
				TOT. PROTEINS	02/10/91	60.0	80.0	g/l	80.00	77.00	75.00	84.00	74.00	79.00
				ALBUMINE	02/10/91	35.0	50.0	g/l	46.00	55.00	44.00	51.00	44.00	44.00
				TOT. CHOLEST.	02/10/91	4.0	7.0	mmol/l	4.40	5.40	4.40	4.80	5.00	4.60
				TRIGLYCERIDES	02/10/91	0.5	2.0	mmol/l	1.40	0.80	0.80	0.50	3.70	0.80
				GLORULINS: ALPHA1	02/10/91	2.0	6.0	%	6.00	7.00	6.00	5.00	7.00	5.00
				GLORULINS: ALPHA2	02/10/91	7.0	12.0	%	9.00	8.00	9.00	7.00	7.00	9.00
				GLORULINS: BETA	02/10/91	8.0	14.0	%	11.00	9.00	9.00	8.00	9.00	12.00
				GLORULINS: GAMMA	02/10/91	12.0	22.0	%	14.00	14.00	15.00	16.00	17.00	14.00
8-228		F		HB	02/10/91	120.0	140.0	g/l	126.00	116.00	127.00	132.00	127.00	132.00
				HTC	02/10/91	38.0	47.0	%	36.30	34.00	34.90	39.00	34.00	39.00
				RBC	02/10/91	4.0	5.5	10**12/l	4.30	4.00	4.20	4.36	4.00	4.36
				HBC: N	02/10/91	4.5	8.0	10**9/l	4.10	3.60	4.90	6.40	4.90	6.40
				HBC: L	02/10/91	60.0	70.0	%	48.00	40.00	68.00	66.00	40.00	66.00
				HBC: E	02/10/91	20.0	30.0	%	47.00	54.00	30.00	30.00	30.00	30.00
				HBC: M	02/10/91	1.0	5.0	%	3.00	4.00	2.00	2.00	2.00	2.00
				HBC: B	02/10/91	2.0	6.0	%	0.00	1.00	0.00	1.00	1.00	1.00
				PLATELETS	02/10/91	150.0	400.0	10**9/l	290.00	208.00	227.00	261.00	261.00	261.00
				NA+	02/10/91	135.0	145.0	mmol/l	140.00	136.00	141.00	137.00	137.00	137.00
				K+	02/10/91	3.5	5.0	mmol/l	4.30	4.90	3.90	4.10	4.10	4.10
				CL-	02/10/91	95.0	108.0	mmol/l	104.00	105.00	101.00	100.00	100.00	100.00
				PO4--	02/10/91	2.3	2.7	mmol/l	2.46	2.39	2.41	2.45	2.45	2.45
				SGOT	02/10/91	1.0	1.5	mmol/l	1.00	1.03	1.00	0.99	1.00	0.99
				SGPT	02/10/91	10.0	40.0	u/l	19.00	19.00	34.00	33.00	33.00	33.00
				GAMMA-GT	02/10/91	10.0	40.0	u/l	40.00	25.00	22.00	22.00	22.00	22.00
				GLUCOSE	02/10/91	10.0	40.0	u/l	27.00	26.00	22.00	21.00	21.00	21.00
				ALK. PHOSPH.	02/10/91	4.0	6.0	mmol/l	4.80	4.70	5.50	9.20	9.20	9.20
				BUN	02/10/91	100.0	300.0	u/l	112.00	122.00	97.00	105.00	105.00	105.00
				CREATININE	02/10/91	2.0	10.0	mmol/l	6.40	5.70	5.20	6.80	6.80	6.80
				URIC ACID	02/10/91	50.0	100.0	umol/l	66.00	67.00	77.00	68.00	68.00	68.00
				TOT. BILIRUBIN	02/10/91	150.0	400.0	umol/l	273.00	219.00	236.00	168.00	168.00	168.00
				DIR. BILIRUBIN	02/10/91	2.0	17.0	umol/l	11.00	6.00	4.00	5.00	5.00	5.00
					02/10/91	0.0	5.0	umol/l	4.00	5.00	4.00	4.00	4.00	4.00

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Date	Laboratory Range		Visit						
						Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
13 8-228	F			TOT. PROTEINS	02/10/91	60.0	80.0	g/l	75.00	80.00	70.00	75.00		
				ALBUMINE	02/10/91	35.0	50.0	g/l	40.00	49.00	44.00	43.00		
				TOT. CHOLEST.	02/10/91	4.0	7.0	mmol/l	6.80	6.20	5.30	4.40		
				TRIGLYCERIDES	02/10/91	0.5	2.0	mmol/l	0.40	0.50	0.50	0.50		
				GLOBULINS: ALPHA1	02/10/91	2.0	6.0	%	8.00	8.00	4.00	5.00		
				GLOBULINS: ALPHA2	02/10/91	7.0	12.0	%	10.00	11.00	8.00	9.00		
				GLOBULINS: BETA	02/10/91	8.0	14.0	%	12.00	12.00	11.00	9.00		
				GLOBULINS: GAMMA	02/10/91	12.0	22.0	%	14.00	15.00	16.00	16.00		
				HB	02/10/91	140.0	160.0	g/l	130.00	145.00				
				HTC	02/10/91	40.0	54.0	%	39.00	41.00				
				RBC	02/10/91	4.0	5.5	10**12/l	4.40	4.70				
				HBC: N	02/10/91	4.5	6.0	10**9/l	6.40	8.70				
				HBC: L	02/10/91	60.0	70.0	%	57.00	66.00				
HBC: E	02/10/91	20.0	30.0	%	40.00	34.00								
HBC: H	02/10/91	1.0	5.0	%	3.00	0.00								
HBC: B	02/10/91	2.0	6.0	%	0.00	0.00								
PLATELETS	02/10/91	0.0	1.0	%	0.00	0.00								
NA+	02/10/91	150.0	400.0	10**9/l	266.00	245.00								
K+	02/10/91	135.0	145.0	mmol/l	142.00	136.00								
CL-	02/10/91	95.0	5.0	mmol/l	3.90	4.70								
PO4-	02/10/91	2.3	2.7	mmol/l	2.29	2.38								
SGPT	02/10/91	1.0	1.5	mmol/l	1.00	1.25								
SGOT	02/10/91	10.0	40.0	u/l	31.00	25.00								
GAMMA-GT	02/10/91	10.0	40.0	u/l	48.00	46.00								
GLUCOSE	02/10/91	4.0	6.0	mmol/l	39.00	40.00								
ALK. PHOSPH.	02/10/91	100.0	300.0	u/l	88.00	100.00								
BUN	02/10/91	2.0	10.0	mmol/l	8.80	9.90								
CREATININE	02/10/91	50.0	100.0	umol/l	76.00	92.00								
URIC ACID	02/10/91	150.0	400.0	umol/l	293.00	301.00								
TOT BILIRUBIN	02/10/91	2.0	17.0	umol/l	15.00	4.00								
DIR BILIRUBIN	02/10/91	0.0	5.0	umol/l	4.00	4.00								
TOT. PROTEINS	02/10/91	60.0	80.0	g/l	72.00	83.00								
ALBUMINE	02/10/91	35.0	50.0	g/l	54.00	54.00								
TOT. CHOLEST.	02/10/91	4.0	7.0	mmol/l	7.60	7.90								
TRIGLYCERIDES	02/10/91	0.5	2.0	mmol/l	1.00	1.00								
GLOBULINS: ALPHA1	02/10/91	2.0	6.0	%	4.00	6.00								
GLOBULINS: ALPHA2	02/10/91	7.0	12.0	%	10.00	7.00								
GLOBULINS: BETA	02/10/91	8.0	14.0	%	13.00	10.00								
GLOBULINS: GAMMA	02/10/91	12.0	22.0	%	16.00	17.00								

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2025

9550077

090177e1803f2135Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1
LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit							
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52	
13	11-225	F		HB	02/10/91	120.0	140.0	g/l	23/01/92	19/03/92	14/05/92	09/07/92	03/09/92	12/11/92	
				HTC	02/10/91	38.0	47.0	%	160.00	140.00	144.00	146.00	138.00	146.00	146.00
				RBC	02/10/91	4.0	5.5	10**12/l	46.00	39.30	42.80	43.20	44.00	44.00	44.20
				WBC	02/10/91	4.5	8.0	10**9/l	6.80	4.52	4.51	4.59	4.60	4.60	4.83
				HBC: N	02/10/91	20.0	70.0	%	56.00	81.00	65.00	63.00	52.00	52.00	57.00
				HBC: L	02/10/91	60.0	30.0	%	41.00	17.00	31.00	33.00	44.00	44.00	35.00
				HBC: E	02/10/91	1.0	5.0	%	2.00	0.00	3.00	4.00	2.00	2.00	7.00
				HBC: M	02/10/91	2.0	6.0	%	1.00	0.00	1.00	0.00	2.00	2.00	0.00
				HBC: B	02/10/91	0.0	1.0	%	0.00	0.00	0.00	0.00	0.00	0.00	1.00
				PLATELETS	02/10/91	150.0	400.0	10**9/l	270.00	256.00	251.00	236.00	200.00	200.00	220.00
				Na+	02/10/91	135.0	145.0	mmol/l	136.00	134.00	139.00	137.00	139.00	138.00	138.00
				Cl-	02/10/91	95.0	106.0	mmol/l	107.00	100.00	108.00	106.00	110.00	108.00	108.00
				Ca++	02/10/91	2.3	2.7	mmol/l	2.23	2.20	2.30	2.30	2.20	2.20	2.28
				PO4-	02/10/91	1.0	1.5	mmol/l	1.45	1.30	1.48	1.45	1.40	1.40	1.41
				SGOT	02/10/91	10.0	40.0	u/l	24.00	25.00	44.00	42.00	41.00	41.00	31.00
				SGPT	02/10/91	10.0	40.0	u/l	53.00	54.00	40.00	35.00	30.00	30.00	26.00
				GAMMA-GT	02/10/91	10.0	40.0	u/l	75.00	50.00	33.00	42.00	47.00	47.00	52.00
				GLUCOSE	02/10/91	4.0	6.0	mmol/l	5.70	5.70	5.60	5.00	6.20	6.20	5.20
				ALK. PHOSPH.	02/10/91	100.0	300.0	u/l	102.00	90.00	86.00	74.00	87.00	87.00	117.00
				BUN	02/10/91	2.0	10.0	mmol/l	4.30	5.30	7.30	4.50	4.40	4.40	6.70
				CREATININE	02/10/91	50.0	100.0	umol/l	92.00	92.00	55.50	74.00	70.00	70.00	77.00
				URIC ACID	02/10/91	150.0	400.0	umol/l	318.00	309.00	239.00	302.00	261.00	261.00	308.00
				TOT. BILIRUBIN	02/10/91	2.0	17.0	umol/l	4.00	6.00	7.00	4.00	4.00	4.00	4.00
TOT. PROTEINS	02/10/91	60.0	80.0	g/l	69.00	76.00	76.00	74.00	70.00	70.00	76.00				
ALBUMINE	02/10/91	35.0	50.0	g/l	41.00	41.00	41.00	40.00	36.00	36.00	43.00				
TOT. CHOLEST.	02/10/91	4.0	7.0	mmol/l	6.30	6.30	4.70	4.80	5.50	5.50	6.10				
TRIGLYCERIDES	02/10/91	0.5	2.0	mmol/l	1.30	1.30	0.90	0.90	1.20	1.20	1.50				
GLOBULINS: ALPHA1	02/10/91	2.0	6.0	%	5.00	6.00	3.00	3.00	4.00	4.00	5.00				
GLOBULINS: ALPHA2	02/10/91	7.0	12.0	%	7.00	8.00	4.00	4.00	7.00	7.00	8.00				
GLOBULINS: BETA	02/10/91	8.0	14.0	%	8.00	10.00	8.00	8.00	8.00	8.00	12.00				
GLOBULINS: GAMMA	02/10/91	12.0	22.0	%	15.00	17.00	17.00	19.00	20.00	20.00	22.00				
14-	217	F		HB	02/10/91	120.0	140.0	g/l	09/01/92	06/03/92	30/06/92	25/06/92	18/08/92	29/10/92	
				HTC	02/10/91	38.0	47.0	%	137.00	121.00	129.00	124.00	126.00	129.00	
				RBC	02/10/91	4.0	5.5	10**12/l	42.00	36.00	40.90	37.60	39.60	39.60	
				WBC	02/10/91	4.5	8.0	10**9/l	5.90	4.00	4.19	3.97	4.09	4.27	
				HBC: N	02/10/91	60.0	70.0	%	68.00	79.00	65.00	65.00	5.70	5.80	

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2026

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Laboratory Range			Visit						
					Date	Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
13	14-217	F		HBC: L	02/10/91	20.0	30.0	Z	31.00	20.00	27.00	33.00	23.00	44.00
				HBC: E	02/10/91	1.0	5.0	Z	0.00	0.00	1.00	1.00	0.00	3.00
				HBC: H	02/10/91	2.0	6.0	Z	1.00	1.00	3.00	2.00	0.00	3.00
				HBC: B	02/10/91	0.0	1.0	Z	0.00	0.00	1.00	1.00	0.00	0.00
				PLATELETS	02/10/91	150.0	400.0	10**9/1	200.00	147.00	165.00	182.00	166.00	220.00
				NA+	02/10/91	135.0	145.0	mmol/L	140.00	141.00	141.00	143.00	142.00	135.00
				K+	02/10/91	3.5	5.0	mmol/L	4.50	3.70	4.40	4.10	4.20	4.00
				CL-	02/10/91	95.0	108.0	mmol/L	110.00	110.00	105.00	108.00	110.00	102.00
				CA++	02/10/91	2.3	2.7	mmol/L	2.56	2.30	2.35	2.22	2.37	2.35
				PO4-	02/10/91	1.0	1.5	mmol/L	0.99	0.99	0.86	1.00	1.23	0.88
				SGOT	02/10/91	10.0	40.0	U/L	21.00	18.00	34.00	36.00	43.00	19.00
				SGPT	02/10/91	10.0	40.0	U/L	29.00	25.00	29.00	18.00	20.00	20.00
				GAMMA-GT	02/10/91	10.0	40.0	U/L	42.00	13.00	12.00	14.00	15.00	11.00
				GLUCOSE	02/10/91	4.0	6.0	mmol/L	5.50	4.80	4.80	4.50	5.20	5.50
				ALK. PHOSPH.	02/10/91	100.0	300.0	U/L	152.00	103.00	104.00	113.00	115.00	115.00
				UREA	02/10/91	2.0	10.0	mmol/L	4.30	4.30	4.50	5.00	5.10	5.30
				CREATININE	02/10/91	50.0	100.0	umol/L	93.00	70.00	76.00	64.00	83.00	99.00
				TOT BILIRUBIN	02/10/91	150.0	400.0	umol/L	311.00	262.00	227.00	232.00	219.00	257.00
				DIR BILIRUBIN	02/10/91	2.0	17.0	umol/L	8.00	5.00	6.00	4.00	9.00	8.00
				TOT. PROTEINS	02/10/91	60.0	80.0	g/l	81.00	74.00	77.00	72.00	72.00	76.00
				ALBUMINE	02/10/91	35.0	50.0	g/l	44.00	45.00	42.00	41.00	45.00	43.00
				TOT. CHOLEST.	02/10/91	4.0	7.0	mmol/L	5.50	4.80	4.40	4.50	4.80	5.00
				TRIGLYCERIDES	02/10/91	0.5	2.0	mmol/L	0.70	0.80	0.30	0.80	0.60	0.70
				GLOBULINS: ALPHA1	02/10/91	2.0	6.0	Z	6.00	3.00	5.00	5.00	5.00	8.00
				GLOBULINS: ALPHA2	02/10/91	7.0	12.0	Z	9.00	5.00	9.00	9.00	6.00	7.00
				GLOBULINS: BETA	02/10/91	8.0	14.0	Z	12.00	7.00	8.00	8.00	9.00	11.00
				GLOBULINS: GAMMA	02/10/91	12.0	22.0	Z	15.00	16.00	19.00	19.00	14.00	23.00
15-222	F			HB	02/10/91	120.0	140.0	g/l	138.00	131.00	127.00	133.00	128.00	134.00
				HCT	02/10/91	38.0	47.0	Z	39.00	37.40	39.00	39.20	37.50	39.30
				RBC	02/10/91	4.0	5.5	10**12/L	4.40	4.30	4.04	4.14	3.98	4.29
				WBC	02/10/91	4.5	8.0	10**9/L	5.90	6.70	4.60	5.80	4.60	6.10
				PLATELETS	02/10/91	60.0	70.0	Z	64.00	66.00	50.00	67.00	49.00	63.00
				NA+	02/10/91	20.0	30.0	Z	32.00	33.00	47.00	30.00	49.00	36.00
				K+	02/10/91	1.0	5.0	Z	3.00	1.00	2.00	2.00	2.00	1.00
				CL-	02/10/91	2.0	6.0	Z	0.00	0.00	0.00	1.00	0.00	0.00
				CA++	02/10/91	0.0	1.0	Z	0.00	0.00	0.00	0.00	0.00	0.00
				SGOT	02/10/91	150.0	400.0	10**9/1	265.00	248.00	247.00	247.00	185.00	261.00
				SGPT	02/10/91	135.0	145.0	mmol/L	137.00	137.00	135.00	139.00	140.00	137.00
				PLATELETS	02/10/91	3.5	5.0	mmol/L	4.70	4.70	4.20	4.60	4.50	4.20
				K+	02/10/91	95.0	108.0	mmol/L	102.00	108.00	100.00	109.00	103.00	104.00
				CL-	02/10/91	12.0	22.0	Z	15.00	16.00	19.00	19.00	14.00	23.00

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centre	Open-Blind	Sex	Laboratory test	Date	Laboratory Range		Visit										
						Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52				
13 15-222	F			CA++	02/10/91	2.3	2.7	mmol/l	2.43	2.41	2.37	2.40	2.37	2.37				
				PO4-	02/10/91	1.0	1.5	mmol/l	1.10	1.44	0.88	1.35	1.15	1.07				
				SGOT	02/10/91	10.0	40.0	u/l	20.00	24.00	30.00	41.00	40.00	31.00				
				SGPT	02/10/91	10.0	40.0	u/l	39.00	28.00	27.00	40.00	20.00	23.00				
				GAMMA-GT	02/10/91	10.0	40.0	u/l	45.00	30.00	35.00	37.00	17.00	25.00				
				GLUCOSE	02/10/91	4.0	6.0	mmol/l	4.70	4.70	4.90	4.80	4.50	5.00				
				ALK. PHOSPH.	02/10/91	100.0	300.0	u/l	157.00	151.00	148.00	128.00	121.00	136.00				
				BUN	02/10/91	2.0	10.0	mmol/l	4.60	6.00	6.70	5.00	4.40	4.20				
				CREATININE	02/10/91	50.0	100.0	mmol/l	78.00	83.00	63.00	64.00	64.00	69.00				
				URIC ACID	02/10/91	150.0	400.0	mmol/l	179.00	264.00	208.00	244.00	181.00	208.00				
				TOT BILIRUBIN	02/10/91	0.0	17.0	mmol/l	11.00	8.00	10.00	6.00	10.00	10.00				
				DIR BILIRUBIN	02/10/91	0.0	5.0	mmol/l	4.00	4.00	4.00	4.00	4.00	4.00				
				TOT. PROTEINS	02/10/91	60.0	80.0	g/l	78.00	78.00	78.00	79.00	68.00	79.00				
				ALBUMINE	02/10/91	35.0	50.0	g/l	43.00	47.00	40.00	44.00	40.00	45.00				
				TOT. CHOLEST.	02/10/91	4.0	7.0	mmol/l	5.90	5.20	4.70	5.30	5.30	4.00				
				TRIGLYCERIDES	02/10/91	0.5	2.0	mmol/l	0.80	0.50	0.50	1.10	0.90	0.50				
				GLOBULINS: ALPHA1	02/10/91	2.0	6.0	%	5.00	7.00	6.00	7.00	6.00	5.00				
				GLOBULINS: ALPHA2	02/10/91	7.0	12.0	%	8.00	7.00	10.00	9.00	7.00	7.00				
				GLOBULINS: BETA	02/10/91	8.0	14.0	%	10.00	8.00	14.00	10.00	6.00	9.00				
				GLOBULINS: GAMMA	02/10/91	12.0	22.0	%	17.00	16.00	24.00	17.00	19.00	18.00				
				17-218	F			HB	02/10/91	120.0	140.0	g/l	133.00	128.00	126.00	128.00	127.00	
								HCT	02/10/91	38.0	47.0	%	38.00	37.40	38.10	39.10	37.30	41.00
								RBC	02/10/91	4.0	5.5	10**12/l	4.80	4.36	4.20	4.28	4.26	4.71
WBC	02/10/91	4.5	8.0					10**9/l	6.20	5.70	5.60	6.70	5.70	7.40				
NBC: N	02/10/91	60.0	70.0					%	64.00	56.00	45.00	60.00	67.00	66.00				
NBC: L	02/10/91	20.0	30.0					%	29.00	41.00	50.00	39.00	28.00	34.00				
NBC: E	02/10/91	1.0	5.0					%	4.00	3.00	4.00	0.00	4.00	0.00				
NBC: M	02/10/91	2.0	6.0					%	2.00	0.00	0.00	0.00	0.00	0.00				
NBC: B	02/10/91	0.0	1.0					%	1.00	0.00	1.00	0.00	1.00	0.00				
PLATELETS	02/10/91	150.0	400.0					10**9/l	338.00	172.00	180.00	176.00	191.00	203.00				
MP+	02/10/91	135.0	145.0					mmol/l	137.00	140.00	139.00	140.00	136.00	142.00				
K+	02/10/91	3.5	5.0					mmol/l	3.80	4.10	3.70	4.20	4.10	3.90				
CL-	02/10/91	95.0	108.0					mmol/l	111.00	98.00	102.00	108.00	112.00	104.00				
CA++	02/10/91	2.3	2.7					mmol/l	2.30	1.07	2.35	2.50	2.46	2.51				
PO4-	02/10/91	1.0	1.5					mmol/l	1.39	1.20	1.37	1.24	1.03	1.07				
SGOT	02/10/91	10.0	40.0					u/l	19.00	56.00	31.00	42.00	39.00	16.00				
SGPT	02/10/91	10.0	40.0					u/l	74.00	19.00	23.00	27.00	25.00	28.00				
GAMMA-GT	02/10/91	10.0	40.0					u/l	35.00	19.00	18.00	15.00	16.00	34.00				
GLUCOSE	02/10/91	4.0	6.0					mmol/l	6.40	4.90	5.60	4.70	5.80	5.70				
ALK. PHOSPH.	02/10/91	100.0	300.0					u/l	121.00	105.00	128.00	120.00	130.00	120.00				
BUN	02/10/91	2.0	10.0					mmol/l	5.50	6.50	6.80	4.70	4.30	5.30				

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.1

LABORATORY DATA
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Pat. No.	Centro	Open-Blind	Sex	Laboratory test	Date	Laboratory Range		Visit						
						Min	Max	Unit	Week 10	Week 18	Week 26	Week 34	Week 42	Week 52
13	17-218	F		CREATININE	02/10/91	50.0	100.0	umol/l	73.00	90.00	64.00	64.00	62.00	74.00
				URIC ACID	02/10/91	150.0	400.0	umol/l	151.00	130.00	163.00	190.00	184.00	175.00
				TOT BILIRUBIN	02/10/91	2.0	17.0	umol/l	5.00	4.00	8.00	5.00	9.00	11.00
				DIP BILIRUBIN	02/10/91	0.0	5.0	umol/l	4.00	4.00	4.00	4.00	4.00	4.00
				TOT PROTEINS	02/10/91	60.0	80.0	g/l	67.00	69.00	73.00	68.00	74.00	70.00
				ALBUMINE	02/10/91	35.0	50.0	g/l	40.00	42.00	43.00	39.00	42.00	47.00
				TOT. CHOLEST.	02/10/91	4.0	7.0	mmol/l	5.80	5.70	5.20	5.40	5.40	4.90
				TRIGLYCERIDES	02/10/91	0.5	2.0	mmol/l	0.80	0.90	0.70	0.60	0.50	0.90
				GLOBULINS: ALPHA1	02/10/91	2.0	6.0	%	9.00	9.00	5.00	3.00	6.00	3.00
				GLOBULINS: ALPHA2	02/10/91	7.0	12.0	%	10.00	10.00	7.00	7.00	11.00	9.00
				GLOBULINS: BETA	02/10/91	8.0	14.0	%	12.00	13.00	10.00	9.00	9.00	7.00
				GLOBULINS: GAMMA	02/10/91	12.0	22.0	%	15.00	15.00	14.00	16.00	14.00	13.00

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2020

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOMETINE - PROTOCOL 20124/013
Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
OPEN PHASE

CENTRE	PATIENT	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	% VARIATION TO CONSIDER CLIN. RELEVANCE
1	1	MGA	F	6	GLOBULINS: GAMMA	9.0	15.0	22.0	+-
1	1	MGA	F	-1	TRIGLYCERIDES	229.0	35.0	175.0	+
1	1	MGA	F	2	TRIGLYCERIDES	250.0	35.0	175.0	+
1	2	RAQ	H	-1	TOT BILIRUBIN	2.2	0.2	1.0	+
1	5	DB	F	-1	TRIGLYCERIDES	296.0	35.0	175.0	+
1	5	DB	F	2	TRIGLYCERIDES	234.0	35.0	175.0	+
1	5	DB	F	4	TRIGLYCERIDES	238.0	35.0	175.0	+
1	5	DB	F	6	TRIGLYCERIDES	373.0	35.0	175.0	+
1	6	CPM	F	-1	GLUCOSE	147.0	70.0	100.0	+-
1	6	CPM	F	4	GLUCOSE	161.0	70.0	100.0	+-
1	6	CPM	F	6	GLUCOSE	140.0	70.0	100.0	+-
1	8	MVB	H	-1	PO4--	2.5	3.0	4.5	+-
1	8	MVB	H	2	PO4--	2.3	3.0	4.5	+-
1	10	LDL	F	-1	TRIGLYCERIDES	247.0	35.0	175.0	+
1	11	VRT	F	2	PO4--	5.4	3.0	4.5	+-
1	12	SLT	F	2	GLOBULINS: ALPHA 1	2.8	4.0	7.0	+-
1	12	SLT	F	6	GLOBULINS: ALPHA 1	2.7	4.0	7.0	+-
1	14	MLC	F	-1	GLOBULINS: ALPHA 1	2.6	4.0	7.0	+-
1	14	MLC	F	4	TRIGLYCERIDES	240.0	35.0	175.0	+
1	16	MHC	F	4	GLOBULINS: ALPHA 1	2.8	4.0	7.0	+-
1	19	SR	F	6	GLOBULINS: ALPHA 1	2.7	4.0	7.0	+-
1	20	EFC	F	4	GLOBULINS: ALPHA 1	2.7	4.0	7.0	+-
1	20	EFC	F	6	GLOBULINS: ALPHA 1	2.7	4.0	7.0	+-
1	21	VMC	F	6	GLOBULINS: ALPHA 1	2.5	4.0	7.0	+-
1	21	SK	F	4	HB	9.7	12.0	16.0	-
1	22	SK	F	6	HB	9.6	12.0	16.0	-
1	22	SK	F	4	HTC	30.0	37.0	47.0	-
1	22	SK	F	6	HTC	29.0	37.0	47.0	-
1	22	SK	F	-1	RBC	3.2	3.8	5.4	-
1	22	SK	F	4	RBC	2.9	3.8	5.4	-
1	22	SK	F	6	RBC	2.9	3.8	5.4	-
1	22	SK	F	2	GLOBULINS: ALPHA 1	2.8	4.0	7.0	+-
1	22	SK	F	4	GLOBULINS: ALPHA 1	2.8	4.0	7.0	+-
1	22	SK	F	6	GLOBULINS: ALPHA 1	1.9	4.0	7.0	+-
1	22	SK	F	-1	GLOBULINS: ALPHA 2	4.8	7.0	11.0	+-
1	22	SK	F	2	GLOBULINS: ALPHA 2	4.1	7.0	11.0	+-
1	22	SK	F	4	GLOBULINS: ALPHA 2	3.7	7.0	11.0	+-
1	22	SK	F	6	GLOBULINS: ALPHA 2	2.9	7.0	11.0	+-
1	22	SK	F	-1	GLOBULINS: GAMMA	42.3	15.0	22.0	+-
1	22	SK	F	2	GLOBULINS: GAMMA	41.6	15.0	22.0	+-
1	22	SK	F	4	GLOBULINS: GAMMA	43.9	15.0	22.0	+-
1	22	SK	F	6	GLOBULINS: GAMMA	41.3	15.0	22.0	+-
1	22	SK	F	-1	CA++	7.1	8.5	10.5	+-
1	24	LVF	F	2	ALK. PHOSPH.	719.0	65.0	306.0	+
1	24	LVF	F	4	ALK. PHOSPH.	660.0	65.0	306.0	+
1	24	LVF	F	6	ALK. PHOSPH.	657.0	65.0	306.0	+

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

0000

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOVETINE - PROTOCOL 20124/013
Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
OPEN PHASE

CENTRE	PATIENT	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	% VARIATION TO CONSIDER CLIN. RELEVANCE
1	24	LVF	F	-1	GLOBULINS: ALPHA 1	2.8	4	7	30
1	27	RK	M	4	GLOBULINS: ALPHA 2	4.6	7	11	30
1	27	RK	M	4	GLOBULINS: ALPHA 2	4.6	7	11	30
1	28	RHM	F	-1	GAMMA-GT	350.0	7	33	100
1	28	RHM	F	2	GAMMA-GT	279.0	7	33	100
1	28	RHM	F	4	GAMMA-GT	252.0	7	33	100
1	28	RHM	F	6	GAMMA-GT	211.0	7	33	100
1	28	RHM	F	4	GLOBULINS: ALPHA 1	1.8	4	7	30
1	29	AFO	F	6	SGPT	92.0	10	40	100
1	30	ERV	M	2	SGPT	91.0	10	40	100
1	30	ERV	M	2	GLOBULINS: ALPHA 1	2.5	4	7	30
1	30	ERV	M	-1	TRIGLYCERIDES	316.0	35	175	30
1	30	ERV	M	2	TRIGLYCERIDES	279.0	35	175	30
1	30	ERV	M	4	TRIGLYCERIDES	407.0	35	175	30
1	30	ERV	M	6	TRIGLYCERIDES	405.0	35	175	30
1	31	KAM	F	4	GLOBULINS: ALPHA 1	2.3	4	7	30
1	32	DCR	F	6	SGPT	91.0	10	40	100
1	32	DCR	F	6	GAMMA-GT	66.0	7	33	100
1	33	OPC	H	2	GLOBULINS: ALPHA 1	2.7	4	7	30
1	33	OPC	H	4	GLOBULINS: ALPHA 1	2.7	4	7	30
1	36	LH	F	2	GLOBULINS: ALPHA 1	1.9	4	7	30
1	36	LH	F	4	GLOBULINS: ALPHA 1	1.9	4	7	30
1	36	LH	F	6	GLOBULINS: ALPHA 1	2.0	4	7	30
1	36	LH	F	-1	TRIGLYCERIDES	256.0	35	175	30
1	36	LH	F	6	TRIGLYCERIDES	231.0	35	175	30
1	37	RF	F	-1	GAMMA-GT	104.0	7	33	100
1	37	RF	F	2	GAMMA-GT	89.0	7	33	100
1	37	RF	F	4	GAMMA-GT	135.0	7	33	100
1	37	RF	F	6	GAMMA-GT	124.0	7	33	100
1	37	RF	F	2	GLOBULINS: ALPHA 1	2.6	4	7	30
1	37	RF	F	4	GLOBULINS: ALPHA 1	2.1	4	7	30
1	37	RF	F	6	GLOBULINS: ALPHA 1	2.0	4	7	30
1	37	RF	F	-1	TRIGLYCERIDES	230.0	35	175	30
1	37	RF	F	2	TRIGLYCERIDES	163.0	70	100	30
1	37	RF	F	4	TRIGLYCERIDES	143.0	70	100	30
1	37	RF	F	6	TRIGLYCERIDES	180.0	70	100	30
1	37	RF	F	4	GLUCOSE	174.0	70	100	30
1	37	RF	F	-1	GLUCOSE	179.0	12	40	100
1	38	DBF	M	2	SGPT	177.0	12	40	100
1	38	DBF	M	4	SGPT	177.0	12	40	100
1	38	DBF	M	6	SGPT	242.0	12	40	100
1	38	DBF	M	4	SGPT	162.0	12	40	100
1	38	DBF	M	-1	SGPT	171.0	10	40	100
1	38	DBF	M	2	SGPT	185.0	10	40	100
1	38	DBF	M	4	SGPT	153.0	10	40	100
1	38	DBF	M	6	SGPT	146.0	10	40	100
1	38	DBF	M	-1	GAMMA-GT	491.0	11	51	100

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

0001

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
OPEN PHASE

CENTRE	PATIENT	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	% VARIATION TO CONSIDER CLIN. RELEVANCE
1	38	DBF	M	2	GAMMA-GT	494.00	11	51	+
1	38	DBF	M	4	GAMMA-GT	526.00	11	51	+
1	38	DBF	M	6	GAMMA-GT	412.00	11	51	+
1	38	DBF	M	-1	ALK. PHOSPH.	680.00	65	306	+
1	38	DBF	M	2	ALK. PHOSPH.	731.00	65	306	+
1	38	DBF	M	4	ALK. PHOSPH.	731.00	65	306	+
1	38	DBF	M	6	ALK. PHOSPH.	780.00	65	306	+
1	38	DBF	M	2	GLOBULINS: ALPHA 1	2.50	4	7	+-
1	38	DBF	M	4	GLOBULINS: ALPHA 1	2.70	4	7	+-
1	38	DBF	M	-1	TRIGLYCERIDES	248.00	35	175	+
1	38	DBF	M	2	TRIGLYCERIDES	278.00	35	175	+
1	38	DBF	M	4	TRIGLYCERIDES	269.00	35	175	+
1	38	DBF	M	6	TRIGLYCERIDES	301.00	35	175	+
1	38	DBF	M	-1	GLUCOSE	344.00	70	100	+-
1	38	DBF	M	2	GLUCOSE	344.00	70	100	+-
1	38	DBF	M	4	GLUCOSE	303.00	70	100	+-
1	38	DBF	M	6	GLUCOSE	243.00	70	100	+-
1	40	EN	F	-1	GLOBULINS: ALPHA 1	2.80	4	7	+-
1	40	EN	F	2	GLOBULINS: GAMMA	9.80	15	22	+-
1	40	EN	F	4	GLOBULINS: GAMMA	9.00	15	22	+-
1	40	EN	F	6	GLOBULINS: GAMMA	9.60	15	22	+-
1	41	SFS	M	2	GLUCOSE	180.00	70	100	+-
1	42	ICC	F	-1	GLOBULINS: ALPHA 1	1.70	4	7	+-
1	42	ICC	F	2	GLOBULINS: ALPHA 1	2.50	4	7	+-
1	42	ICC	F	4	GLOBULINS: ALPHA 1	1.92	4	7	+-
1	42	ICC	F	6	GLOBULINS: ALPHA 1	2.30	4	7	+-
1	43	ARN	M	-1	GLOBULINS: ALPHA 1	2.40	4	7	+-
1	43	ARN	M	2	GLOBULINS: ALPHA 1	2.10	4	7	+-
1	43	ARN	M	4	GLOBULINS: ALPHA 1	2.50	4	7	+-
1	43	ARN	M	6	GLOBULINS: ALPHA 1	2.30	4	7	+-
1	44	MAL	F	2	GLOBULINS: ALPHA 1	2.50	4	7	+-
1	45	DPS	F	6	GLOBULINS: ALPHA 1	2.80	4	7	+-
1	46	SP	F	2	GLOBULINS: ALPHA 1	2.80	4	7	+-
1	46	SP	F	4	GLOBULINS: GAMMA	9.40	15	22	+-
1	47	MCS	F	-1	GLOBULINS: ALPHA 1	2.20	4	7	+-
1	47	MCS	F	4	GLOBULINS: ALPHA 1	1.90	4	7	+-
1	47	MCS	F	-1	TRIGLYCERIDES	286.00	35	175	+-
1	48	SCN	F	-1	GLOBULINS: ALPHA 1	1.60	4	7	+-
1	48	SCN	F	2	GLOBULINS: ALPHA 1	2.00	4	7	+-
1	48	SCN	F	4	GLOBULINS: ALPHA 1	1.80	4	7	+-
1	48	SCN	F	6	GLOBULINS: ALPHA 1	2.00	4	7	+-
1	48	SCR	F	-1	GLOBULINS: ALPHA 2	4.90	7	11	+-
1	49	DAS	F	-1	GLOBULINS: ALPHA 1	1.90	4	7	+-
1	49	DAS	F	2	GLOBULINS: ALPHA 1	2.70	4	7	+-
1	50	HFA	F	-1	HB	9.60	12	16	-

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013

Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
OPEN PHASE

CENTRE	PATIENT	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	% VARIATION TO CONSIDER CLIN. RELEVANCE
1	50	MFA	F	2	HB	10.1	12	16.0	-15
1	50	MFA	F	6	HB	9.5	12	16.0	-15
1	50	MFA	F	-1	HTC	31.0	37	47.0	-15
1	50	MFA	F	6	HTC	30.0	37	47.0	-15
1	50	MFA	F	2	GLOBULINS: ALPHA 1	2.4	4	7.0	++
1	50	MFA	F	4	GLOBULINS: ALPHA 1	2.5	4	7.0	++
1	50	MFA	F	6	GLOBULINS: ALPHA 1	2.4	4	7.0	++
1	51	ASA	F	-1	GLOBULINS: ALPHA 1	2.3	4	7.0	++
1	51	ASA	F	2	GLOBULINS: ALPHA 1	2.3	4	7.0	++
1	51	ASA	F	4	GLOBULINS: ALPHA 1	2.5	4	7.0	++
1	51	ASA	F	6	GLOBULINS: ALPHA 1	1.1	4	7.0	++
1	51	ASA	F	2	GLOBULINS: BETA	18.9	11	14.0	++
1	51	ASA	F	6	PO4-	2.0	3	4.5	++
1	52	MTS	F	6	GLOBULINS: ALPHA 1	2.7	4	7.0	++
1	52	MTS	F	2	GLOBULINS: ALPHA 2	16.1	7	11.0	++
1	53	JFT	F	2	GLOBULINS: ALPHA 1	2.2	4	7.0	++
1	53	JFT	F	4	GLOBULINS: ALPHA 1	2.3	4	7.0	++
1	53	JFT	F	6	GLOBULINS: ALPHA 1	1.4	4	7.0	++
1	53	JFT	F	4	GLOBULINS: ALPHA 2	4.9	7	11.0	++
1	53	JFT	F	-1	GLUCOSE	193.0	70	100.0	++
1	54	JD	F	-1	GLOBULINS: ALPHA 1	2.1	4	7.0	++
1	54	JD	F	2	GLOBULINS: ALPHA 1	1.5	4	7.0	++
1	54	JD	F	4	GLOBULINS: ALPHA 1	1.2	4	7.0	++
1	55	DMG	F	-1	GLOBULINS: ALPHA 1	2.4	4	7.0	++
1	55	DMG	F	2	GLOBULINS: ALPHA 1	2.2	4	7.0	++
1	55	DMG	F	4	GLOBULINS: ALPHA 1	2.1	4	7.0	++
1	56	IAL	F	6	GLOBULINS: ALPHA 1	2.5	4	7.0	++
1	56	IAL	M	-1	GLOBULINS: ALPHA 1	2.2	4	7.0	++
1	57	SNC	F	-1	GLOBULINS: BETA	18.6	11	14.0	++
1	57	SNC	F	2	GLOBULINS: ALPHA 1	2.1	4	7.0	++
1	58	ARM	F	-1	GLOBULINS: ALPHA 1	1.4	4	7.0	++
1	58	ARM	F	2	GLOBULINS: ALPHA 1	2.1	4	7.0	++
1	58	ARM	F	4	GLOBULINS: ALPHA 1	2.2	4	7.0	++
1	58	ARM	F	6	GLOBULINS: ALPHA 1	2.3	4	7.0	++
1	58	ARM	F	6	GLOBULINS: ALPHA 1	2.5	4	7.0	++
1	59	SPF	F	-1	GLOBULINS: ALPHA 1	2.0	4	7.0	++
1	59	SPF	F	2	GLOBULINS: ALPHA 1	2.1	4	7.0	++
1	59	SPF	F	4	GLOBULINS: ALPHA 1	22.0	4	7.0	++
1	60	EM	M	-1	GLOBULINS: ALPHA 1	2.5	4	7.0	++
1	61	HVC	F	-1	GLOBULINS: ALPHA 1	2.3	4	7.0	++
1	61	HVC	F	2	GLOBULINS: ALPHA 1	2.8	4	7.0	++
1	61	HVC	F	4	GLOBULINS: ALPHA 1	2.3	4	7.0	++
1	62	MEA	F	-1	GLOBULINS: ALPHA 1	2.0	4	7.0	++
1	62	MEA	F	2	GLOBULINS: ALPHA 1	2.4	4	7.0	++
1	62	MEA	F	4	PO4-	5.2	3	4.5	++
1	63	JCL	M	-1	GLOBULINS: ALPHA 1	1.9	4	7.0	++

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

0000

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REOMETINE - PROTOCOL 20124/013

Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
OPEN PHASE

CENTRE	PATIENT	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	% VARIATION TO CONSIDER CLIN. RELEVANCE
1	63	JEL	M	2	GLOBULINS: ALPHA 1	1.5	4.0	7.0	++
1	64	ERF	F	-1	GLOBULINS: ALPHA 1	2.1	4.0	7.0	++
1	64	ERF	F	4	GLOBULINS: GAMMA	8.1	15.0	22.0	++
1	65	FS	M	2	GLOBULINS: ALPHA 2	4.9	7.0	11.0	++
1	67	MAA	F	-1	URIC ACID	8.6	2.4	5.7	+
1	67	MAA	F	4	GLOBULINS: ALPHA 1	2.0	4.0	7.0	++
1	67	MAA	F	6	GLOBULINS: ALPHA 2	4.9	7.0	11.0	++
1	67	MAA	F	-1	TRIGLYCERIDES	361.0	35.0	175.0	+
1	67	MAA	F	-1	GLUCOSE	146.0	70.0	100.0	++
1	67	MAA	F	4	GLUCOSE	140.0	70.0	100.0	++
1	69	REA	M	-1	RBC	3.6	4.3	6.1	-
1	69	REA	M	2	GLOBULINS: ALPHA 1	2.8	4.0	7.0	++
1	70	MLM	F	4	GLOBULINS: ALPHA 1	1.7	4.0	7.0	++
1	71	ONV	F	-1	HB	10.1	12.0	16.0	-
1	71	ONV	F	4	HB	10.1	12.0	16.0	-
1	71	ONV	F	-1	HTC	31.0	37.0	47.0	-
1	71	ONV	F	4	HTC	31.0	37.0	47.0	-
1	71	ONV	F	4	GLOBULINS: ALPHA 1	2.3	4.0	7.0	++
1	73	FMA	F	4	GLOBULINS: ALPHA 1	2.2	4.0	7.0	++
1	74	IVL	F	-1	DTP BILIRUBIN	0.8	0.0	0.4	+
1	74	IVL	F	4	DTP BILIRUBIN	0.8	0.0	0.4	+
1	79	JCM	M	-1	GLOBULINS: ALPHA 1	11.8	14.0	18.0	-
1	83	LEK	F	-1	HE	11.8	14.0	18.0	-
1	83	LEK	F	2	GLOBULINS: ALPHA 1	1.8	4.0	7.0	++
1	84	IN	M	-1	GLOBULINS: ALPHA 1	2.3	4.0	7.0	++
1	84	IN	M	2	GLOBULINS: ALPHA 1	2.0	4.0	7.0	++
1	84	IN	M	-1	GLOBULINS: ALPHA 1	2.5	4.0	7.0	++
1	84	IN	M	4	GLOBULINS: ALPHA 1	2.4	4.0	7.0	++
1	84	IN	M	6	GLOBULINS: ALPHA 1	2.6	4.0	7.0	++
1	85	ALP	M	-1	GLOBULINS: ALPHA 1	2.2	4.0	7.0	++
1	86	MTF	F	-1	HB	8.5	12.0	16.0	-
1	86	MTF	F	6	HTC	28.0	37.0	47.0	-
1	86	MTF	F	6	GLOBULINS: ALPHA 1	2.8	4.0	7.0	++
1	87	MDO	F	-1	GLOBULINS: ALPHA 2	4.6	7.0	11.0	++
1	88	VEL	F	-1	GLOBULINS: ALPHA 1	2.8	4.0	7.0	++
1	88	VEL	F	-1	GLOBULINS: ALPHA 1	1.9	4.0	7.0	++
1	88	VEL	F	-1	GLOBULINS: GAMMA	7.9	15.0	22.0	++
1	89	NHV	F	-1	SGOT	81.0	12.0	40.0	+
1	89	NHV	F	4	SGOT	86.0	12.0	40.0	+
1	89	NHV	F	-1	SGPT	101.0	10.0	40.0	+
1	89	NHV	F	4	SGPT	90.0	10.0	40.0	+
1	89	NHV	F	-1	GAMMA-GT	86.0	7.0	33.0	+
1	89	NHV	F	4	GAMMA-GT	77.0	7.0	33.0	+
1	89	NHV	F	6	GLOBULINS: ALPHA 2	4.7	7.0	11.0	++
1	89	NHV	F	-1	GLOBULINS: GAMMA	8.3	15.0	22.0	++
1	90	JSS	M	-1	GLOBULINS: ALPHA 1	2.3	4.0	7.0	++
1	90	JSS	M	4	GLOBULINS: ALPHA 1	2.1	4.0	7.0	++

(*-) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2004

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOMETINE - PROTOCOL 20124/013
Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
OPEN PHASE

CENTRE	PATIENT	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	% VARIATION TO CONSIDER CLIN. RELEVANCE
1	90	JSS	M	-1	GLOBULINS: GAMMA	8.8	15	22.0	++
1	94	RAB	H	4	GLOBULINS: ALPHA 2	15.2	7	11.0	++
1	95	GNT	F	4	GLOBULINS: GAMMA	8.4	15	22.0	++
1	101	JLL	F	-1	GLOBULINS: ALPHA 1	2.5	4	7.0	++
1	102	ESF	F	-1	HB	9.8	12	16.0	-
1	105	ABS	F	6	GLOBULINS: ALPHA 1	2.1	4	7.0	++
1	111	JBF	M	2	GLOBULINS: ALPHA 1	2.7	4	7.0	++
1	111	JBF	M	2	GLOBULINS: BETA	19.1	11	14.0	++
1	112	PSA	F	6	GLOBULINS: ALPHA 1	2.5	4	7.0	++
1	113	LPS	M	4	GLOBULINS: ALPHA 2	4.6	7	11.0	++
1	114	CLF	F	-1	GLOBULINS: ALPHA 1	2.7	4	7.0	++
1	115	ELS	F	-1	TRIGLYCERIDES	260.0	35	175.0	+
1	116	HGA	F	-1	GLOBULINS: ALPHA 1	2.4	4	7.0	++
1	117	PSL	F	-1	GLOBULINS: ALPHA 1	2.5	4	7.0	++
1	117	PSL	F	-1	GLUCOSE	132.0	70	100.0	++
1	118	MVM	F	-1	GLOBULINS: ALPHA 1	2.1	4	7.0	++
1	118	MVM	F	4	GLOBULINS: BETA	18.7	11	14.0	++
1	119	MVB	F	4	GLOBULINS: ALPHA 1	2.8	4	7.0	++
1	120	JLB	F	6	GLOBULINS: BETA	7.2	11	14.0	++
1	122	HSS	M	4	GLOBULINS: ALPHA 1	2.5	4	7.0	++
1	124	PPC	M	4	GLOBULINS: BETA	6.8	11	14.0	++
1	125	FDP	F	6	GLOBULINS: ALPHA 1	1.9	4	7.0	++
1	125	FDP	F	-1	GLOBULINS: ALPHA 2	4.3	7	11.0	++
1	127	VPD	F	6	GLOBULINS: ALPHA 1	2.1	4	7.0	++
1	128	LAK	M	-1	GLOBULINS: ALPHA 1	2.0	4	7.0	++
1	128	LAK	M	-1	GLOBULINS: ALPHA 2	4.1	7	11.0	++
1	128	LAK	M	2	GLOBULINS: BETA	7.2	11	14.0	++
1	130	EGA	F	-1	GLOBULINS: ALPHA 1	2.4	4	7.0	++
1	130	EGA	F	4	GLOBULINS: ALPHA 1	1.9	4	7.0	++
1	131	RMR	F	-1	PO4-	2.4	3	4.5	++
1	139	RA	M	2	GLOBULINS: ALPHA 1	2.8	4	7.0	++
1	139	RA	M	4	GLOBULINS: ALPHA 1	2.6	4	7.0	++
1	139	RA	M	6	GLOBULINS: ALPHA 2	18.1	7	11.0	++
1	140	MCA	F	4	GLOBULINS: ALPHA 1	2.5	4	7.0	++
1	140	MCA	F	6	GLOBULINS: ALPHA 1	2.8	4	7.0	++
1	140	MCA	F	-1	GLOBULINS: ALPHA 2	16.1	7	11.0	++
1	140	MCA	F	6	GLOBULINS: ALPHA 2	14.8	7	11.0	++
1	140	MCA	F	4	GLOBULINS: BETA	7.6	11	14.0	++
1	141	ANG	F	2	GLOBULINS: ALPHA 1	2.5	4	7.0	++
1	141	ANG	F	-1	GLOBULINS: BETA	7.4	11	14.0	++
1	141	ANG	F	2	GLOBULINS: BETA	6.9	11	14.0	++
1	141	ANG	F	6	GLOBULINS: BETA	7.0	11	14.0	++
1	142	SCC	F	6	GLOBULINS: ALPHA 1	2.7	4	7.0	++
1	144	ARF	M	2	GLOBULINS: ALPHA 1	2.5	4	7.0	++
1	144	ARF	M	4	GLOBULINS: ALPHA 1	2.0	4	7.0	++
1	144	ARF	M	6	GLOBULINS: ALPHA 1	2.5	4	7.0	++

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
OPEN PHASE

CENTRE	PATIENT	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	% VARIATION TO CONSIDER CLIN. RELEVANCE
1	144	ARF	M	-1	GLUCOSE	134.00	70.00	100.0	30
1	144	ARF	M	4	GLUCOSE	131.00	70.00	100.0	30
1	145	SLD	M	4	GLOBULINS: ALPHA 1	2.80	4.00	7.0	30
1	145	SLD	M	6	GLOBULINS: ALPHA 1	2.50	4.00	7.0	30
1	146	LRM	M	4	GLOBULINS: ALPHA 1	2.60	4.00	7.0	30
1	146	LRM	M	4	PO4--	2.50	3.00	4.5	15
1	148	CAS	M	2	GLOBULINS: ALPHA 1	2.50	4.00	7.0	30
1	148	CAS	M	4	GLOBULINS: ALPHA 1	2.50	4.00	7.0	30
1	149	SC	F	-1	GLOBULINS: ALPHA 1	2.50	4.00	7.0	30
1	149	SC	F	2	GLOBULINS: ALPHA 1	2.30	4.00	7.0	30
1	149	SC	F	4	GLOBULINS: ALPHA 1	2.70	4.00	7.0	30
1	149	SC	F	6	GLOBULINS: ALPHA 1	2.30	4.00	7.0	30
1	149	SC	F	-1	GLOBULINS: BETA	7.60	11.00	14.0	30
1	149	SC	F	2	GLOBULINS: BETA	6.60	11.00	14.0	30
2	31	IK	F	-1	GLOBULINS: ALPHA 2	0.13	0.05	0.1	30
2	32	GE	F	-1	GLOBULINS: ALPHA 2	0.13	0.05	0.1	30
2	32	GE	F	2	TOT. CHOLEST.	11.30	5.50	6.6	30
2	32	GE	F	2	TOT. CHOLEST.	8.82	5.50	6.6	30
2	32	GE	F	-1	TRIGLYCERIDES	2.23	0.35	1.7	30
2	33	HS	F	-1	GLOBULINS: ALPHA 2	0.13	0.05	0.1	30
2	33	HS	F	2	GLOBULINS: ALPHA 2	0.15	0.05	0.1	30
3	1	AMR	F	-1	GLOBULINS: ALPHA 2	2.00	6.00	10.0	30
3	2	FIL	F	-1	HS	6.00	7.40	9.9	-15
3	2	FIL	F	2	HS	5.70	7.40	9.9	-15
3	2	FIL	F	4	HS	6.20	7.40	9.9	-15
3	2	FIL	F	6	HS	6.20	7.40	9.9	-15
3	4	AUD	F	2	GLOBULINS: ALPHA 2	3.96	6.00	10.0	30
3	4	AUD	F	4	GLOBULINS: ALPHA 2	3.90	6.00	10.0	30
3	6	AJP	M	-1	GLOBULINS: BETA	16.50	8.00	12.0	30
3	7	GRI	F	-1	TOT BILIRUBIN	15.00	2.00	7.0	100
3	7	GRI	F	4	TOT BILIRUBIN	14.00	2.00	7.0	100
3	7	GRI	F	6	GLOBULINS: ALPHA 1	1.40	2.00	4.0	30
3	7	GRI	F	6	GLOBULINS: ALPHA 2	4.20	6.00	10.0	30
3	9	DEN	F	-1	GLOBULINS: ALPHA 1	1.26	2.00	4.0	30
3	9	DEN	F	-1	GLOBULINS: BETA	5.04	8.00	12.0	30
3	9	DEN	F	-1	GLOBULINS: GAMMA	8.19	12.00	19.0	30
3	10	TOR	M	-1	GAMMA-GT	109.00	8.00	38.0	100
3	10	TOR	M	4	GAMMA-GT	83.00	8.00	38.0	100
3	10	TOR	M	-1	GLOBULINS: GAMMA	7.93	12.00	19.0	30
3	10	TOR	M	2	GLOBULINS: GAMMA	6.32	12.00	19.0	30
3	10	TOR	M	4	GLOBULINS: GAMMA	7.32	12.00	19.0	30
3	11	PIE	F	-1	GLOBULINS: GAMMA	7.80	12.00	19.0	30
8	1	HJ	F	-1	GAMMA-GT	56.00	5.00	25.0	100
9	5	MF	F	4	GLOBULINS: BETA	19.40	8.30	14.5	30
9	6	SD	F	4	GLOBULINS: ALPHA 2	13.10	7.00	10.0	30
9	6	SD	F	4	GLOBULINS: BETA	18.90	8.30	14.5	30

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2036

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
OPEN PHASE

CENTRE	PATIENT	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	% VARIATION TO CONSIDER CLIN. RELEVANCE
9	6	SD	F	-1	TRIGLYCERIDES	2.5	0.3	1.8	30
9	7	PP	M	4	GLOBULINS: ALPHA 1	1.7	2.5	4.0	+
9	8	KTH	F	6	GAMMA-GT	62.0	4.0	28.0	+
9	8	KTH	F	6	GLOBULINS: BETA	18.9	8.3	14.5	+
9	9	PL	F	-1	GLOBULINS: ALPHA 1	7.1	2.5	4.0	+
9	9	PL	F	2	GLOBULINS: BETA	20.0	8.3	14.5	+
9	11	KE	F	6	GLOBULINS: ALPHA 1	5.5	2.5	4.0	+
9	11	KE	F	-1	P04-	0.5	0.9	1.6	+
9	11	KE	F	6	P04-	0.6	0.9	1.6	+
9	12	GVT	F	-1	GLOBULINS: BETA	19.3	8.3	14.5	+
9	12	GVT	F	4	TRIGLYCERIDES	2.9	0.3	1.8	+
9	13	RP	F	6	TRIGLYCERIDES	4.1	0.3	1.8	+
9	14	SZF	F	-1	GLOBULINS: ALPHA 1	1.4	2.5	4.0	+
9	15	BI	F	2	TOT BILLIRUBIN	71.0	2.0	20.0	+
9	15	BI	F	-1	GLOBULINS: ALPHA 1	1.7	2.5	4.0	+
9	17	NL	M	4	GLOBULINS: ALPHA 2	4.4	7.0	10.0	+
9	17	NL	M	-1	P04-	0.4	0.9	1.6	+
9	18	NBM	F	4	P04-	0.7	0.9	1.6	+
9	19	KF	F	-1	GLOBULINS: ALPHA 1	1.7	2.5	4.0	+
9	19	KF	F	4	GLOBULINS: ALPHA 1	0.8	2.5	4.0	+
9	19	KF	F	6	GLOBULINS: ALPHA 1	1.5	2.5	4.0	+
9	19	KF	F	6	P04-	0.4	0.9	1.6	+
9	20	GYE	F	-1	URIC ACID	565.0	100.0	400.0	+
9	20	GYE	F	6	GLOBULINS: ALPHA 1	1.7	2.5	4.0	+
9	21	TA	F	6	GLOBULINS: ALPHA 1	1.1	2.5	4.0	+
9	21	TA	F	-1	P04-	0.7	0.9	1.6	+
9	21	TA	F	6	P04-	0.7	0.9	1.6	+
9	22	RKE	F	-1	GLOBULINS: ALPHA 1	1.3	2.5	4.0	+
9	22	RKE	F	2	GLOBULINS: ALPHA 1	1.0	2.5	4.0	+
9	23	SZN	F	4	GLOBULINS: ALPHA 1	1.7	2.5	4.0	+
9	23	SZN	F	6	GLOBULINS: ALPHA 1	1.3	2.5	4.0	+
9	23	SZN	F	4	TRIGLYCERIDES	2.7	0.3	1.8	+
9	25	PM	F	4	GLOBULINS: ALPHA 1	1.3	2.5	4.0	+
9	25	PM	F	2	GLOBULINS: BETA	20.3	8.3	14.5	+
9	25	PM	F	6	GLOBULINS: BETA	21.3	8.3	14.5	+
9	25	PM	F	-1	P04-	0.7	0.9	1.6	+
9	25	PM	F	4	P04-	0.7	0.9	1.6	+
9	25	CP	F	2	GLOBULINS: ALPHA 1	1.5	2.5	4.0	+
9	25	CP	F	6	GLOBULINS: ALPHA 1	1.7	2.5	4.0	+
9	26	CP	F	-1	TRIGLYCERIDES	2.7	0.3	1.8	+
9	26	CP	F	2	TRIGLYCERIDES	3.3	0.3	1.8	+
9	26	CP	F	4	TRIGLYCERIDES	4.3	0.3	1.8	+
9	26	CP	F	6	TRIGLYCERIDES	2.6	0.3	1.8	+
9	27	ZSL	M	-1	GLOBULINS: ALPHA 1	1.7	2.5	4.0	+
9	27	ZSL	M	2	GLOBULINS: ALPHA 1	1.2	2.5	4.0	+
9	27	ZSL	M	4	GLOBULINS: ALPHA 1	1.3	2.5	4.0	+

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RRD

REBOXYMINE - PROTOCOL 20124/013
Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
OPEN PHASE

CENTRE	PATIENT	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	% VARIATION TO CONSIDER CLIN. RELEVANCE	
9	27	ZSL	M	4	TRIGLYCERIDES	3.50	0.30	1.80	+	30
9	9	HI	M	-1	GLOBULINS: ALPHA 1	1.00	2.50	4.00	+	30
9	28	HI	M	2	GLOBULINS: ALPHA 1	0.90	2.50	4.00	+	30
9	9	HI	M	6	GLOBULINS: ALPHA 1	0.80	2.50	4.00	+	30
9	29	SZF	F	6	SGPT	107.00	4.00	27.00	+	100
9	29	SZF	F	-1	GLOBULINS: ALPHA 1	1.30	2.50	4.00	+	30
9	9	SZF	F	2	GLOBULINS: ALPHA 1	0.80	2.50	4.00	+	30
9	29	SZF	F	4	GLOBULINS: ALPHA 1	1.30	2.50	4.00	+	30
9	9	NF	F	-1	GLOBULINS: ALPHA 1	1.10	2.50	4.00	+	30
9	30	NF	F	2	GLOBULINS: ALPHA 1	1.00	2.50	4.00	+	30
9	30	NF	F	6	GLOBULINS: ALPHA 1	1.70	2.50	4.00	+	30
9	30	NF	F	-1	GLOBULINS: ALPHA 2	4.50	7.00	10.00	+	30
10	1	VK	M	6	BUN	19.80	3.30	10.00	+	50
10	1	VK	M	6	URIC ACID	512.00	119.00	357.00	+	30
10	4	ZSD	F	6	BUN	15.80	3.30	10.00	+	50
10	6	RS	H	4	GLOBULINS: ALPHA 1	10.80	1.30	6.00	+	30
10	6	RS	H	2	GLOBULINS: GAMMA	5.80	10.00	17.00	+	30
10	7	RK	M	2	GLOBULINS: GAMMA	6.60	10.00	17.00	+	30
10	7	RK	M	6	GLOBULINS: GAMMA	6.20	10.00	17.00	+	30
10	8	VP	F	2	GLOBULINS: GAMMA	6.20	10.00	17.00	+	30
10	9	RT	F	-1	URIC ACID	555.00	119.00	357.00	+	30
10	9	RT	F	-1	GLOBULINS: GAMMA	6.10	10.00	17.00	+	30
10	10	HR	F	4	GLOBULINS: ALPHA 2	3.30	5.00	9.00	+	30
10	13	HU	F	2	GLOBULINS: BETA	18.60	5.00	13.00	+	30
10	14	AA	M	4	URIC ACID	466.00	119.00	357.00	+	30
10	19	TN	F	-1	GLOBULINS: ALPHA 2	12.40	5.00	9.00	+	30
10	20	EJ	F	2	PD4-	1.52	0.60	1.30	+	15
10	21	AK	F	6	PD4-	1.50	0.60	1.30	+	15
10	22	AA	M	4	PD4-	1.50	0.60	1.30	+	15
10	24	AL	M	2	SGPT	21.00	1.00	9.00	+	100
10	26	JIF	F	2	GLOBULINS: ALPHA 1	8.10	1.30	6.00	+	30
10	26	JIF	F	-1	GLOBULINS: ALPHA 2	14.70	5.00	9.00	+	30
10	26	JIF	F	6	GLOBULINS: ALPHA 2	13.10	5.00	9.00	+	30
10	26	JIF	F	4	TOT. CHOLEST.	8.40	3.10	6.20	+	30
10	26	JIF	F	6	TOT. CHOLEST.	8.10	3.10	6.20	+	30
10	30	VK	F	-1	HTC	0.31	0.37	0.47	-	-15
10	31	RK	M	-1	HTC	0.31	0.37	0.47	-	-15
10	33	EK	M	-1	GLOBULINS: ALPHA 2	14.20	5.00	9.00	+	30
10	33	EK	M	6	TRIGLYCERIDES	3.78	0.45	1.86	+	30
10	36	AK	F	-1	GLOBULINS: ALPHA 2	12.50	5.00	9.00	+	30
10	36	AK	F	-1	TRIGLYCERIDES	4.49	0.45	1.86	+	30
10	36	LL	F	4	TOT. BILIRUBIN	45.60	8.60	20.50	+	100
10	42	TT	H	2	URIC ACID	560.00	119.00	357.00	+	30
10	42	TT	H	4	URIC ACID	565.00	119.00	357.00	+	30
10	42	TT	H	6	URIC ACID	563.00	119.00	357.00	+	30
10	43	IK	F	-1	K+	7.20	4.00	5.60	+	15

(*-) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2038

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
OPEN PHASE

CENTRE	PATIENT	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	% VARIATION TO CONSIDER CLIN. RELEVANCE	
10	44	AB	M	6	URIC ACID	490.00	119.00	357.00	+	30
10	48	IP	F	6	GLOBULINS: ALPHA 1	8.00	1.30	6.00	++	30
10	50	EE	M	6	GLOBULINS: ALPHA 2	12.30	5.00	9.00	++	30
10	50	EE	M	4	TRIGLYCERIDES	3.28	0.45	1.86	+	30
10	50	EE	M	-1	GLUCOSE	7.80	3.50	5.50	++	30
10	51	UL	F	6	TRIGLYCERIDES	2.68	0.45	1.86	+	30
10	51	UL	F	6	PO4--	3.00	0.60	1.30	++	15
10	53	MA	F	2	PO4--	4.07	0.60	1.30	++	15
10	54	UN	F	2	PO4--	4.30	0.60	1.30	++	15
10	55	TP	M	2	PO4--	3.63	0.60	1.30	++	15
10	56	JP	M	-1	TRIGLYCERIDES	3.29	0.45	1.86	+	30
10	56	JP	M	2	TRIGLYCERIDES	2.50	0.45	1.86	+	30
10	56	JP	M	2	TRIGLYCERIDES	3.04	0.60	1.30	++	15
10	57	AG	F	2	PO4--	3.52	0.60	1.30	++	15
10	59	TA	F	-1	K+	2.80	4.00	5.60	++	15
10	84	HV	F	6	TRIGLYCERIDES	3.08	0.45	1.86	+	30
10	88	AH	F	-1	GLOBULINS: ALPHA 2	13.70	5.00	9.00	++	30
10	88	AH	F	4	TRIGLYCERIDES	3.05	0.45	1.86	+	30
10	88	AK	F	-2	PO4--	1.52	0.60	1.30	++	15
10	89	SK	F	4	DIR BILIRUBIN	10.00	0.00	4.30	++	100
11	1	DF	M	4	SGPT	85.00	5.00	23.00	+	100
11	1	DF	M	-1	GAMMA-GT	304.00	4.00	28.00	+	100
11	1	DF	M	2	GAMMA-GT	139.00	4.00	28.00	+	100
11	1	DF	M	4	GAMMA-GT	120.00	4.00	28.00	+	100
11	2	HB	F	4	GAMMA-GT	139.00	4.00	28.00	+	100
11	2	HB	F	2	MBC: N	32.00	51.00	75.00	-	-30
11	3	RF	F	2	GAMMA-GT	49.00	4.00	18.00	+	100
11	3	RF	F	2	SGOT	37.00	5.00	15.00	+	100
11	3	RF	F	-1	GAMMA-GT	44.00	4.00	18.00	+	100
11	3	RF	F	2	GLUCOSE	10.00	3.89	6.10	++	30
11	3	RF	F	4	GLUCOSE	8.80	3.89	6.10	++	30
11	4	BA	M	-1	TRIGLYCERIDES	3.80	0.47	2.29	+	30
11	6	VP	M	4	DIR BILIRUBIN	12.00	0.00	4.30	+	100
11	7	KK	F	6	MBC	3.20	5.00	10.00	-	-30
11	7	KK	F	-1	SGPT	74.00	5.00	19.00	+	100
11	7	KK	F	-1	GAMMA-GT	64.00	4.00	18.00	+	100
11	7	KK	F	4	TOT. CHOLEST.	8.90	3.90	6.70	+	30
11	8	XF	F	4	MBC	3.00	5.00	10.00	-	-30
11	8	XF	F	2	MBC: N	34.00	51.00	75.00	-	-30
11	8	XF	F	-1	SGPT	39.00	5.00	19.00	+	100
11	8	XF	F	-1	GAMMA-GT	42.00	4.00	18.00	+	100
11	9	ET	F	6	SGPT	38.00	5.00	19.00	+	100
11	10	BJ	F	2	MBC	3.00	5.00	10.00	-	-30
11	10	BJ	F	4	PO4--	0.60	0.71	1.50	++	15
11	16	NA	F	2	TOT. CHOLEST.	9.60	3.90	6.70	+	30
11	17	UZ	F	2	GLOBULINS: GAMMA	22.63	7.00	17.00	++	30

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2030

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013

Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
OPEN PHASE

CENTRE	PATIENT	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	Z VARIATION TO CONSIDER CLIN. RELEVANCE
11	17	UZ	F	2	TRIGLYCERIDES	3.200	0.470	2.29	+
11	17	UZ	F	-1	GLUCOSE	8.000	3.890	6.10	+-
11	17	UZ	F	-1	PO4--	0.600	0.710	1.50	+-
11	20	LJ	F	6	SGPT	34.000	5.000	15.00	+
12	2	EFC	F	-1	GAMMA-GT	176.000	6.000	28.00	+
12	2	EFC	F	2	GAMMA-GT	65.000	6.000	28.00	+
12	2	EFC	F	4	GAMMA-GT	72.000	6.000	28.00	+
12	2	EFC	F	2	GLOBULINS: ALPHA 2	0.035	0.070	0.13	+-
12	2	EFC	F	4	CL-	76.000	97.000	107.00	+
12	3	IF	F	-1	GLOBULINS: ALPHA 1	0.069	0.025	0.05	+-
12	4	EG	F	2	WBC: N	39.000	60.000	70.00	-
12	4	EG	F	-1	DIR BILIRUBIN	10.000	0.000	4.50	+
12	4	EG	F	4	DIR BILIRUBIN	10.000	0.000	4.50	+
12	4	EG	F	-1	SGPT	115.000	5.000	34.00	+
12	4	EG	F	-1	GAMMA-GT	81.000	6.000	28.00	+
12	4	EG	F	4	CL-	81.000	97.000	107.00	+-
12	5	ZSH	M	-1	RBC	3.770	4.500	5.00	-
12	5	ZSH	M	6	WBC: N	36.000	60.000	70.00	-
12	5	ZSH	M	-1	GAMMA-GT	101.000	6.000	28.00	+
12	5	ZSH	M	4	GLOBULINS: ALPHA 2	0.035	0.070	0.13	+-
12	5	ZSH	M	4	GLOBULINS: BETA	0.038	0.060	0.14	+-
12	5	ZSH	M	-1	TRIGLYCERIDES	2.800	0.300	1.86	+
12	5	ZSH	M	2	PO4--	1.750	0.700	1.50	+-
12	6	MK	F	6	RBC	3.660	4.500	5.00	-
12	6	MK	F	4	DIR BILIRUBIN	9.900	0.000	4.50	+
12	6	MK	F	-1	GLOBULINS: ALPHA 2	0.038	0.070	0.13	+-
12	6	MK	F	6	GLOBULINS: BETA	0.035	0.060	0.14	+-
12	6	MK	F	2	TRIGLYCERIDES	2.900	0.300	1.86	+
12	7	LK	M	-1	DIR BILIRUBIN	11.900	0.000	4.50	+
12	7	LK	M	-1	TRIGLYCERIDES	2.600	0.300	1.86	+
12	7	LK	M	4	CL-	79.000	97.000	107.00	+-
12	8	FM	F	2	SGPT	71.000	5.000	34.00	+
12	8	FM	F	4	TRIGLYCERIDES	2.600	0.300	1.86	+
12	9	KBP	F	2	TRIGLYCERIDES	2.500	0.300	1.86	+
12	9	KBP	F	4	CA++	1.900	2.250	2.70	+-
12	10	IP	F	2	HTC	0.314	0.380	0.46	-
12	10	IP	F	-1	RBC	3.550	4.500	5.00	-
12	10	IP	F	2	RBC	3.650	4.500	5.00	-
12	10	IP	F	-1	GLOBULINS: ALPHA 1	0.070	0.025	0.05	+-
12	10	IP	F	-1	GLOBULINS: BETA	0.041	0.080	0.14	+-
12	10	IP	F	6	GLOBULINS: BETA	0.035	0.060	0.14	+-
12	11	ER	F	-1	DIR BILIRUBIN	19.600	0.000	4.50	+
12	11	ER	F	-1	TOT. CHOLEST.	9.700	2.600	7.02	+
12	11	ER	F	-1	TRIGLYCERIDES	2.800	0.300	1.86	+
12	11	ER	F	6	CL-	68.000	97.000	107.00	+-
12	12	FSZ	F	-1	GLOBULINS: ALPHA 1	0.070	0.025	0.05	+-

(*-) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

0702

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
OPEN PHASE

CENTRE	PATIENT	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	Z VARIATION TO CONSIDER CLIN. RELEVANCE	
12	12	FS2	F	-1	TRIGLYCERIDES	2.900	0.300	1.86	+	30
12	12	FS2	F	4	CL-	73.000	97.000	107.00	++	10
12	13	IS2	F	4	DIR BILIRUBIN	12.000	0.000	4.50	+	100
12	13	IS2	F	4	GAMMA-GT	59.000	6.000	28.00	+	100
12	14	GS2	F	-1	GLOBULINS: BETA	0.248	0.080	0.74	++	30
12	16	FN	F	2	RBC	3.770	4.500	5.00	-	-15
12	16	FN	F	4	DIR BILIRUBIN	13.100	0.000	4.50	+	100
12	16	FN	F	6	GLOBULINS: ALPHA 2	0.045	0.070	0.13	++	30
12	16	FN	F	2	TRIGLYCERIDES	2.800	0.300	1.86	+	30
12	16	FN	F	-1	CA++	1.900	2.250	2.70	++	15
12	17	TK	M	2	GLOBULINS: ALPHA 1	0.084	0.025	0.05	++	30
12	17	TK	M	6	GLOBULINS: ALPHA 1	0.067	0.025	0.05	++	30
12	17	TK	M	-1	TRIGLYCERIDES	2.600	0.300	1.86	+	30
12	18	LS	M	2	RBC: N	40.000	60.000	70.00	-	-30
12	18	LS	M	6	GLOBULINS: ALPHA 1	0.069	0.025	0.05	++	30
12	18	LS	M	4	GLOBULINS: ALPHA 1	0.130	0.025	0.05	++	30
12	18	LS	M	6	TRIGLYCERIDES	2.500	0.300	1.86	+	30
12	19	SS2	F	2	RBC: N	36.000	60.000	70.00	-	-30
12	19	SS2	F	-1	DIR BILIRUBIN	10.400	0.000	4.50	+	100
12	19	SS2	F	-1	GLOBULINS: ALPHA 1	0.074	0.025	0.05	++	30
12	19	SS2	F	2	GLOBULINS: ALPHA 2	0.041	0.070	0.15	++	30
12	20	KS2	M	-1	RBC: N	37.000	60.000	70.00	-	-30
12	20	KS2	M	-1	GAMMA-GT	70.000	6.000	28.00	+	100
12	20	KS2	M	6	GLOBULINS: ALPHA 1	0.082	0.025	0.05	++	30
12	20	KS2	M	-1	GLOBULINS: BETA	0.055	0.080	0.14	++	30
12	21	FL	F	6	GLOBULINS: ALPHA 1	0.070	0.025	0.05	++	30
12	22	HV	F	6	DIR BILIRUBIN	10.800	0.000	4.50	+	100
12	22	HV	F	4	SGPT	99.000	5.000	30.00	+	100
12	22	HV	F	4	TOT. CHOLEST.	148.000	5.000	34.00	+	100
12	22	HV	F	-1	TRIGLYCERIDES	9.300	2.600	7.02	+	30
12	22	HV	F	4	TRIGLYCERIDES	4.600	0.300	1.86	+	30
12	22	HV	F	6	TRIGLYCERIDES	2.700	0.300	1.86	+	30
12	23	EN	F	6	GLOBULINS: ALPHA 1	0.079	0.025	0.05	++	30
12	23	EN	F	6	CL-	83.000	97.000	107.00	++	10
12	24	MF	F	2	GLOBULINS: ALPHA 1	0.066	0.025	0.05	++	30
12	24	MF	F	4	GLOBULINS: ALPHA 1	0.111	0.025	0.05	++	30
12	25	FS	F	4	DIR BILIRUBIN	9.100	0.000	4.50	+	100
12	25	FS	F	2	GLOBULINS: ALPHA 1	0.070	0.025	0.05	++	30
12	25	FS	F	4	GLOBULINS: ALPHA 1	0.087	0.025	0.05	++	30
12	25	FS	F	6	GLOBULINS: ALPHA 1	0.080	0.025	0.05	++	30
12	26	LB	M	-1	TRIGLYCERIDES	4.000	0.300	1.86	+	30
12	26	LB	M	4	GAMMA-GT	61.000	6.000	28.00	+	100
12	26	LB	M	4	GAMMA-GT	61.000	6.000	28.00	+	100
12	27	VCS	F	-1	RBC	0.066	0.025	0.05	++	30
12	27	VCS	F	-1	HTC	5.360	7.500	10.00	-	-15
12	27	VCS	F	-1	HTC	0.288	0.380	0.46	-	-15

(*-) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2041

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
OPEN PHASE

CENTRE	PATIENT	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	Z VARIATION TO CONSIDER CLIN. RELEVANCE
12	27	VCS	F	-1	RBC	3.070	4.500	5.00	-15
12	27	VCS	F	2	RBC	3.730	4.500	5.00	-15
12	27	VCS	F	2	GLOBULINS: ALPHA 1	0.074	0.025	0.05	30
12	27	VCS	F	4	GLOBULINS: ALPHA 1	0.077	0.025	0.05	30
12	27	VCS	F	2	TRIGLYCERIDES	2.900	0.300	1.86	30
12	28	IV	F	-1	RBC	3.690	4.500	5.00	-15
12	28	IV	F	-1	SGPT	90.000	5.000	34.00	100
12	28	IV	F	-1	GAMMA-GT	166.000	5.000	34.00	100
12	28	IV	F	2	GAMMA-GT	61.000	6.000	28.00	100
12	28	IV	F	4	GAMMA-GT	65.000	6.000	28.00	100
12	28	IV	F	2	GLOBULINS: ALPHA 1	0.108	0.025	0.05	30
12	28	IV	F	4	TRIGLYCERIDES	2.600	0.300	1.86	30
12	29	AK	F	4	GLOBULINS: ALPHA 1	0.134	0.025	0.05	30
12	29	AK	F	6	GLOBULINS: ALPHA 1	0.094	0.025	0.05	30
12	30	FS	F	4	GLOBULINS: ALPHA 1	0.107	0.025	0.05	30
12	31	PH	M	4	GAMMA-GT	58.000	6.000	28.00	100
12	31	PH	M	-1	GLOBULINS: ALPHA 1	0.096	0.025	0.05	30
12	31	PH	M	4	GLOBULINS: ALPHA 1	0.076	0.025	0.05	30
12	31	PH	M	6	GLOBULINS: ALPHA 1	0.070	0.025	0.05	30
12	32	LH	M	-1	GLOBULINS: ALPHA 1	0.085	0.025	0.05	30
12	32	LH	M	4	GLOBULINS: ALPHA 1	0.106	0.025	0.05	30
12	33	LN	F	4	DIR BILIRUBIN	10.500	0.000	4.50	100
12	33	LN	F	6	DIR BILIRUBIN	9.700	0.000	4.50	100
12	33	LN	F	-1	GAMMA-GT	64.000	6.000	28.00	100
12	33	LN	F	2	GAMMA-GT	83.000	6.000	28.00	100
12	33	LN	F	4	GAMMA-GT	76.000	6.000	28.00	100
12	33	LN	F	6	GAMMA-GT	74.000	6.000	28.00	100
12	33	LN	F	4	GLOBULINS: ALPHA 1	0.110	0.025	0.05	30
12	33	LN	F	2	TRIGLYCERIDES	4.400	0.300	1.86	30
12	33	LN	F	4	TRIGLYCERIDES	2.700	0.300	1.86	30
12	33	LN	F	6	TRIGLYCERIDES	3.700	0.300	1.86	30
12	33	LN	F	-1	GLUCOSE	7.300	3.300	5.50	30
12	33	LN	F	4	GLUCOSE	7.600	3.300	5.50	30
12	33	LN	F	6	GLUCOSE	7.200	3.300	5.50	30
12	34	TGS	F	-1	GLOBULINS: ALPHA 1	0.131	0.025	0.05	30
12	34	TGS	F	2	GLOBULINS: ALPHA 1	0.069	0.025	0.05	30
12	34	TGS	F	4	GLOBULINS: ALPHA 1	0.182	0.025	0.05	30
12	34	TGS	F	6	GLOBULINS: ALPHA 1	0.094	0.025	0.05	30
12	35	LP	F	4	SGPT	89.000	5.000	34.00	100
12	35	LP	F	-1	SGPT	76.000	5.000	34.00	100
12	35	LP	F	2	SGPT	66.000	5.000	34.00	100
12	35	LP	F	4	SGPT	139.000	5.000	34.00	100
12	35	LP	F	-1	GAMMA-GT	145.000	6.000	28.00	100
12	35	LP	F	2	GAMMA-GT	107.000	6.000	28.00	100
12	35	LP	F	4	GAMMA-GT	96.000	6.000	28.00	100
12	35	LP	F	6	GAMMA-GT	116.000	6.000	28.00	100

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2042

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
OPEN PHASE

CENTRE	PATIENT	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	% VARIATION TO CONSIDER CLIN. RELEVANCE
12	35	LP	F	-1	GLOBULINS: ALPHA 1	0.139	0.025	0.05	30
12	35	LP	F	2	GLOBULINS: ALPHA 1	0.104	0.025	0.05	30
12	35	LP	F	4	GLOBULINS: ALPHA 1	0.077	0.025	0.05	30
12	36	LP	F	4	TRIGLYCERIDES	2.700	0.300	1.86	30
12	37	FK	F	-1	GLOBULINS: ALPHA 1	0.114	0.025	0.05	30
12	37	FK	F	-1	GLOBULINS: ALPHA 1	0.146	0.025	0.05	30
12	38	FG	F	6	TRIGLYCERIDES	2.700	0.300	1.86	30
13	1	P2	F	-1	GLOBULINS: ALPHA 1	0.066	0.025	0.05	30
13	1	P2	F	-1	GLOBULINS: ALPHA 1	8.000	2.000	6.00	30
13	2	TCS	F	-1	PO4--	0.750	1.000	1.50	15
13	2	TCS	F	-1	GLOBULINS: ALPHA 1	9.000	2.000	6.00	30
13	3	AI	F	2	GLOBULINS: ALPHA 1	9.000	2.000	6.00	30
13	3	AI	F	6	GLOBULINS: ALPHA 1	8.000	2.000	6.00	30
13	4	AI	F	6	GLOBULINS: ALPHA 1	9.000	2.000	6.00	30
13	4	SZJ	M	2	GLOBULINS: ALPHA 1	9.000	2.000	6.00	30
13	4	SZJ	M	4	PO4--	0.830	1.000	1.50	15
13	5	NF	F	1	ALBUMINE	91.000	35.000	50.00	30
13	5	NF	F	-1	GAMMA-GT	93.000	10.000	40.00	100
13	5	NF	F	1	GAMMA-GT	95.000	10.000	40.00	100
13	6	KE	F	2	HRC: L	12.000	20.000	30.00	-30
13	6	KE	F	4	GLOBULINS: ALPHA 1	8.000	2.000	6.00	30
13	6	KE	F	6	PO4--	0.800	1.000	1.50	15
13	7	BL	F	2	GLOBULINS: ALPHA 1	8.000	2.000	6.00	30
13	7	BL	F	4	PO4--	0.780	1.000	1.50	15
13	8	PK	F	4	GLOBULINS: ALPHA 1	8.000	2.000	6.00	30
13	9	SZS	M	-1	CREATININE	177.000	50.000	100.00	50
13	9	SZS	M	-1	GAMMA-GT	138.000	10.000	40.00	100
13	9	SZS	M	-1	GLOBULINS: ALPHA 1	8.000	2.000	6.00	30
13	11	HS	F	-1	SGPT	127.000	10.000	40.00	100
13	11	HS	F	-1	GAMMA-GT	195.000	10.000	40.00	100
13	11	HS	F	2	GLOBULINS: ALPHA 1	8.000	2.000	6.00	30
13	11	HS	F	6	GLOBULINS: ALPHA 1	8.000	2.000	6.00	30
13	11	HS	F	2	PO4--	0.820	1.000	1.50	15
13	12	BF	M	4	SGPT	82.000	10.000	40.00	100
13	12	BF	M	-1	GLOBULINS: ALPHA 1	8.000	2.000	6.00	30
13	13	HM	M	2	SGPT	92.000	10.000	40.00	100
13	13	HM	M	6	GLUCOSE	109.000	10.000	40.00	100
13	13	HM	M	6	GAMMA-GT	7.900	4.000	6.00	30
13	14	DF	F	4	GLOBULINS: ALPHA 1	8.000	2.000	6.00	30
13	15	KG	F	-1	GAMMA-GT	105.000	10.000	40.00	100
13	15	KG	F	2	GLOBULINS: ALPHA 1	8.000	2.000	6.00	30
13	15	KG	F	4	PO4--	0.800	1.000	1.50	15
13	16	SZL	F	-1	PO4--	0.800	1.000	1.50	15
13	16	SZL	F	2	PO4--	0.800	1.000	1.50	15
13	17	GSM	F	4	SGPT	104.000	10.000	40.00	100
13	17	GSM	F	-1	GAMMA-GT	87.000	10.000	40.00	100

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2042

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
OPEN PHASE

CENTRE	PATIENT	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MTN	MAX	Z VARIATION TO CONSIDER CLIN. RELEVANCE
13	17	GSM	F	6	GLOBULINS: ALPHA 1	8.00	2	6.0	+-
13	18	VT	F	2	GAMMA-GT	94.00	10	40.0	+
13	18	VT	F	4	GLOBULINS: ALPHA 1	8.00	2	6.0	+-
13	18	VT	F	6	GLOBULINS: ALPHA 1	9.00	2	6.0	+-
13	19	KK	F	-1	GLOBULINS: ALPHA 1	8.00	2	6.0	+-
13	20	NL	F	2	GLOBULINS: ALPHA 1	16.00	2	6.0	+-
13	21	CL	F	6	GLOBULINS: ALPHA 1	9.00	2	6.0	+-
13	22	NXH	F	-1	GAMMA-GT	103.00	10	40.0	+
13	22	NXH	F	4	GLOBULINS: ALPHA 1	11.00	2	6.0	+-
13	22	NXH	F	-1	GLOBULINS: ALPHA 2	4.00	7	12.0	+-
13	22	NXH	F	2	PO4-	0.81	1	1.5	+-

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, AND PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2044

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 12.2
 LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
 DOUBLE BLIND PHASE

TREATMENT	CENTRE	PATIENT NO. OPEN/BLIND	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	X VARIATION TO CONSIDER CLIN. REL. (%)
REBOXETINE	1	3/2	TA	F	42	GLOBULINS: ALPHA 1	2.00	4.000	7.00	30
		3/2	TA	F	52	GLOBULINS: ALPHA 1	1.90	4.000	7.00	30
		4/3	DNC	F	34	GLOBULINS: ALPHA 1	2.80	4.000	7.00	30
		4/3	DNC	F	52	GLOBULINS: ALPHA 1	2.00	4.000	7.00	30
		5/4	DNC	F	10	GLOBULINS: GAMMA	10.00	15.000	22.00	30
		5/4	DB	F	26	GLOBULINS: ALPHA 1	2.80	4.000	7.00	30
		5/4	DB	F	34	GLOBULINS: ALPHA 1	2.70	4.000	7.00	30
		5/4	DB	F	42	GLOBULINS: ALPHA 1	2.20	4.000	7.00	30
		5/4	DB	F	52	GLOBULINS: ALPHA 1	2.70	4.000	7.00	30
		5/4	DB	F	34	TOT. CHOLEST.	357.00	140.000	270.00	30
		5/4	DB	F	-1	TRIGLYCERIDES	296.00	35.000	175.00	30
		5/4	DB	F	2	TRIGLYCERIDES	234.00	35.000	175.00	30
		5/4	DB	F	4	TRIGLYCERIDES	238.00	35.000	175.00	30
		5/4	DB	F	6	TRIGLYCERIDES	373.00	35.000	175.00	30
		5/4	DB	F	10	TRIGLYCERIDES	438.00	35.000	175.00	30
		5/4	DB	F	18	TRIGLYCERIDES	257.00	35.000	175.00	30
		5/4	DB	F	26	TRIGLYCERIDES	294.00	35.000	175.00	30
		5/4	DB	F	34	TRIGLYCERIDES	464.00	35.000	175.00	30
		5/4	DB	F	42	TRIGLYCERIDES	641.00	35.000	175.00	30
		5/4	DB	F	52	TRIGLYCERIDES	305.00	35.000	175.00	30
		9/7	CCR	M	26	GLOBULINS: ALPHA 1	2.70	4.000	7.00	30
		9/7	CCR	M	34	GLOBULINS: ALPHA 1	2.80	4.000	7.00	30
		10/8	LDL	M	42	GLOBULINS: ALPHA 1	1.80	4.000	7.00	30
		10/8	LDL	F	26	GLOBULINS: ALPHA 1	2.30	4.000	7.00	30
		10/8	LDL	F	34	GLOBULINS: ALPHA 1	2.10	4.000	7.00	30
		10/8	LDL	F	42	GLOBULINS: ALPHA 1	2.10	4.000	7.00	30
		10/8	LDL	F	52	GLOBULINS: GAMMA	8.30	15.000	22.00	30
		14/11	MLC	F	-1	TRIGLYCERIDES	247.00	35.000	175.00	30
		14/11	MLC	F	-1	GLOBULINS: ALPHA 1	2.80	4.000	7.00	30
		17/14	CEC	F	4	TRIGLYCERIDES	260.00	35.000	175.00	30
		17/14	CEC	F	26	HB	10.00	12.000	16.00	30
		17/14	CEC	F	26	HTC	31.00	37.000	47.00	30
		17/14	CEC	F	26	GLOBULINS: ALPHA 1	2.40	4.000	7.00	30
		20/17	EFC	F	4	GLOBULINS: ALPHA 1	2.70	4.000	7.00	30
		20/17	EFC	F	6	GLOBULINS: ALPHA 1	2.70	4.000	7.00	30
		22/19	SK	F	4	HB	9.70	12.000	16.00	30
		22/19	SK	F	6	HB	9.60	12.000	16.00	30
		22/19	SK	F	52	HB	10.00	12.000	16.00	30
		22/19	SK	F	4	HTC	30.00	37.000	47.00	30
		22/19	SK	F	6	HTC	29.00	37.000	47.00	30
		22/19	SK	F	10	HTC	31.00	37.000	47.00	30
		22/19	SK	F	52	HTC	31.00	37.000	47.00	30
		22/19	SK	F	-1	RBC	3.20	3.800	5.40	30
		22/19	SK	F	4	RBC	2.90	3.800	5.40	30

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2045

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 12.2
 LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
 DOUBLE BLIND PHASE

TREATMENT	CENTRE	PATIENT NO. OPEN/BLIND	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	% VARIATION TO CONSIDER CLIN. REL. (*)
REBOXETINE	1	22/19	SK	F	6	RBC	2.90	3.800	5.40	-15
		22/19	SK	F	10	RBC	3.10	3.800	5.40	-15
		22/19	SK	F	18	RBC	3.20	3.800	5.40	-15
		22/19	SK	F	26	RBC	3.10	3.800	5.40	-15
		22/19	SK	F	52	RBC	3.10	3.800	5.40	-15
		22/19	SK	F	2	GLOBULINS: ALPHA 1	2.80	4.000	7.00	30
		22/19	SK	F	4	GLOBULINS: ALPHA 1	2.80	4.000	7.00	30
		22/19	SK	F	6	GLOBULINS: ALPHA 1	1.90	4.000	7.00	30
		22/19	SK	F	10	GLOBULINS: ALPHA 1	2.70	4.000	7.00	30
		22/19	SK	F	18	GLOBULINS: ALPHA 1	2.00	4.000	7.00	30
		22/19	SK	F	26	GLOBULINS: ALPHA 1	2.00	4.000	7.00	30
		22/19	SK	F	34	GLOBULINS: ALPHA 1	1.80	4.000	7.00	30
		22/19	SK	F	52	GLOBULINS: ALPHA 1	2.00	4.000	7.00	30
		22/19	SK	F	-1	GLOBULINS: ALPHA 2	1.40	4.000	7.00	30
		22/19	SK	F	2	GLOBULINS: ALPHA 2	4.80	7.000	11.00	30
		22/19	SK	F	4	GLOBULINS: ALPHA 2	4.10	7.000	11.00	30
		22/19	SK	F	6	GLOBULINS: ALPHA 2	3.70	7.000	11.00	30
		22/19	SK	F	10	GLOBULINS: ALPHA 2	2.90	7.000	11.00	30
		22/19	SK	F	18	GLOBULINS: ALPHA 2	4.20	7.000	11.00	30
		22/19	SK	F	26	GLOBULINS: ALPHA 2	3.40	7.000	11.00	30
		22/19	SK	F	52	GLOBULINS: ALPHA 2	4.00	7.000	11.00	30
		22/19	SK	F	1	GLOBULINS: GAMMA	42.30	45.000	22.00	30
		22/19	SK	F	2	GLOBULINS: GAMMA	41.60	45.000	22.00	30
		22/19	SK	F	4	GLOBULINS: GAMMA	43.90	45.000	22.00	30
		22/19	SK	F	6	GLOBULINS: GAMMA	41.30	45.000	22.00	30
		22/19	SK	F	10	GLOBULINS: GAMMA	43.30	45.000	22.00	30
		22/19	SK	F	18	GLOBULINS: GAMMA	43.40	45.000	22.00	30
		22/19	SK	F	26	GLOBULINS: GAMMA	45.00	45.000	22.00	30
		22/19	SK	F	34	GLOBULINS: GAMMA	30.10	15.000	22.00	30
		22/19	SK	F	52	GLOBULINS: GAMMA	56.20	15.000	22.00	30
		24/20	SK	F	-1	CA++	7.10	8.500	10.50	15
		24/20	LVF	F	2	ALK. PHOSPH.	719.00	65.000	306.00	100
		24/20	LVF	F	4	ALK. PHOSPH.	660.00	65.000	306.00	100
		24/20	LVF	F	6	ALK. PHOSPH.	657.00	65.000	306.00	100
		24/20	LVF	F	18	ALK. PHOSPH.	1076.00	65.000	306.00	100
		24/20	LVF	F	26	ALK. PHOSPH.	957.00	65.000	306.00	100
		24/20	LVF	F	-1	GLOBULINS: ALPHA 1	2.80	4.000	7.00	30
		24/20	LVF	F	10	GLOBULINS: ALPHA 1	2.70	4.000	7.00	30
		24/20	LVF	F	18	GLOBULINS: ALPHA 1	2.40	4.000	7.00	30
		24/20	LVF	F	26	GLOBULINS: ALPHA 1	10.20	15.000	22.00	30
		24/20	LVF	F	18	GLOBULINS: GAMMA	8.90	15.000	22.00	30
		24/20	LVF	F	26	GLOBULINS: GAMMA	2.40	4.000	7.00	30
		25/21	AMR	F	10	GLOBULINS: ALPHA 1	2.40	4.000	7.00	30
		25/21	AMR	F	18	GLOBULINS: ALPHA 1	2.30	4.000	7.00	30
		25/21	AMR	F	52	GLOBULINS: BETA	7.20	11.000	14.00	30

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXYTINE - PROTOCOL 20124/013
Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
DOUBLE BLIND PHASE

TREATMENT	CENTRE	PATIENT NO. OPEN/BLIND	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	% VARIATION TO CONSIDER CLIN. REL. (*)
REBOXYTINE	1	31/27	MAH	F	4	GLOBULINS: ALPHA 1	2.30	4.000	7.00	+ - 30
		31/27	MAH	F	26	GLOBULINS: ALPHA 1	2.80	4.000	7.00	+ - 30
		31/27	MAH	F	52	GLOBULINS: ALPHA 1	2.30	4.000	7.00	+ - 30
		32/28	DGM	F	6	SGPT	91.00	10.000	40.00	+ 100
		32/28	DGM	F	6	GAMMA-GT	66.00	7.000	33.00	+ 100
		32/28	DGM	F	10	GLOBULINS: ALPHA 1	2.60	4.000	7.00	+ - 30
		32/28	DGM	F	18	GLOBULINS: ALPHA 1	2.80	4.000	7.00	+ - 30
		32/28	DGM	F	42	GLOBULINS: ALPHA 1	2.60	4.000	7.00	+ - 30
		32/28	DGM	F	52	GLOBULINS: ALPHA 1	2.50	4.000	7.00	+ - 30
		34/30	GHI	F	10	GLOBULINS: ALPHA 1	2.20	4.000	7.00	+ - 30
		34/30	GHI	F	42	GLOBULINS: ALPHA 1	2.50	4.000	7.00	+ - 30
		34/30	GHI	F	52	GLOBULINS: ALPHA 1	2.70	4.000	7.00	+ - 30
		35/301	EMP	F	10	GLOBULINS: ALPHA 1	2.80	4.000	7.00	+ - 30
		35/301	EMP	F	18	GLOBULINS: ALPHA 1	2.80	4.000	7.00	+ - 30
		35/301	EMP	F	26	GLOBULINS: ALPHA 1	2.40	4.000	7.00	+ - 30
		35/301	EMP	F	34	GLOBULINS: ALPHA 1	2.60	4.000	7.00	+ - 30
		37/303	RF	F	52	URIC ACID	8.70	2.400	5.70	+ 30
		37/303	RF	F	-1	GAMMA-GT	104.00	7.000	35.00	+ 100
		37/303	RF	F	2	GAMMA-GT	89.00	7.000	35.00	+ 100
		37/303	RF	F	4	GAMMA-GT	135.00	7.000	35.00	+ 100
		37/303	RF	F	6	GAMMA-GT	124.00	7.000	35.00	+ 100
		37/303	RF	F	10	GAMMA-GT	109.00	7.000	35.00	+ 100
		37/303	RF	F	18	GAMMA-GT	85.00	7.000	35.00	+ 100
		37/303	RF	F	26	GAMMA-GT	70.00	7.000	35.00	+ 100
		37/303	RF	F	52	GAMMA-GT	74.00	7.000	35.00	+ 100
		37/303	RF	F	2	GLOBULINS: ALPHA 1	2.60	4.000	7.00	+ - 30
		37/303	RF	F	4	GLOBULINS: ALPHA 1	2.10	4.000	7.00	+ - 30
		37/303	RF	F	6	GLOBULINS: ALPHA 1	2.00	4.000	7.00	+ - 30
		37/303	RF	F	18	GLOBULINS: ALPHA 1	2.50	4.000	7.00	+ - 30
		37/303	RF	F	52	GLOBULINS: ALPHA 1	2.40	4.000	7.00	+ - 30
		37/303	RF	F	6	TRIGLYCERIDES	230.00	35.000	175.00	+ 30
		37/303	RF	F	10	TRIGLYCERIDES	270.00	35.000	175.00	+ 30
		37/303	RF	F	-1	GLUCOSE	163.00	70.000	100.00	+ 30
		37/303	RF	F	2	GLUCOSE	163.00	70.000	100.00	+ 30
		37/303	RF	F	4	GLUCOSE	180.00	70.000	100.00	+ 30
		37/303	RF	F	6	GLUCOSE	174.00	70.000	100.00	+ 30
		37/303	RF	F	10	GLUCOSE	182.00	70.000	100.00	+ 30
		37/303	RF	F	18	GLUCOSE	160.00	70.000	100.00	+ 30
		37/303	RF	F	42	GLUCOSE	136.00	70.000	100.00	+ 30
		37/303	RF	F	52	GLUCOSE	157.00	70.000	100.00	+ 30
		39/305	ASS	F	42	GLOBULINS: ALPHA 1	2.30	4.000	7.00	+ - 30
		39/305	ASS	F	52	GLOBULINS: ALPHA 1	2.10	4.000	7.00	+ - 30
		43/309	ARN	H	-1	GLOBULINS: ALPHA 1	2.40	4.000	7.00	+ - 30
		43/309	ARN	H	2	GLOBULINS: ALPHA 1	2.10	4.000	7.00	+ - 30

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
DOUBLE BLIND PHASE

TREATMENT	CENTRE	PATIENT NO. OPEN/BLIND	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	% VARIATION TO CONSIDER CLIN. REL. (%)
REBOXETINE	1	43/309	ARN	M	4	GLOBULINS: ALPHA 1	2.50	4.000	7.00	30
		43/309	ARN	M	6	GLOBULINS: ALPHA 1	2.30	4.000	7.00	30
		43/309	ARN	M	10	GLOBULINS: ALPHA 1	2.50	4.000	7.00	30
		43/309	ARN	M	18	GLOBULINS: ALPHA 1	2.60	4.000	7.00	30
		43/309	ARN	M	26	GLOBULINS: ALPHA 1	2.00	4.000	7.00	30
		43/309	ARN	M	34	GLOBULINS: ALPHA 1	1.90	4.000	7.00	30
		43/309	ARN	M	26	GLOBULINS: ALPHA 2	3.60	7.000	11.00	30
		43/309	ARN	M	34	GLOBULINS: ALPHA 2	3.80	7.000	11.00	30
		45/310	DPS	F	6	GLOBULINS: ALPHA 1	2.80	4.000	7.00	30
		45/310	DPS	F	26	GLOBULINS: ALPHA 1	2.30	4.000	7.00	30
		46/311	SP	F	6	GLOBULINS: ALPHA 1	2.80	4.000	7.00	30
		46/311	SP	F	2	GLOBULINS: GAMMA	9.40	15.000	22.00	30
		46/311	SP	F	4	GLOBULINS: GAMMA	9.10	15.000	22.00	30
		46/311	SP	F	10	GLOBULINS: GAMMA	10.10	15.000	22.00	30
		48/313	SCM	F	-1	GLOBULINS: ALPHA 1	1.40	4.000	7.00	30
		48/313	SCM	F	2	GLOBULINS: ALPHA 1	2.00	4.000	7.00	30
		48/313	SCM	F	4	GLOBULINS: ALPHA 1	1.80	4.000	7.00	30
		48/313	SCM	F	6	GLOBULINS: ALPHA 1	2.00	4.000	7.00	30
		48/313	SCM	F	10	GLOBULINS: ALPHA 1	2.10	4.000	7.00	30
		48/313	SCM	F	26	GLOBULINS: ALPHA 1	1.90	4.000	7.00	30
		48/313	SCM	F	42	GLOBULINS: ALPHA 1	1.60	4.000	7.00	30
		48/313	SCM	F	52	GLOBULINS: ALPHA 1	2.00	4.000	7.00	30
		48/313	SCM	F	-1	GLOBULINS: ALPHA 2	4.90	7.000	11.00	30
		52/316	MTS	F	6	GLOBULINS: ALPHA 1	2.70	4.000	7.00	30
		52/316	MTS	F	10	GLOBULINS: ALPHA 1	1.50	4.000	7.00	30
		52/316	MTS	F	18	GLOBULINS: ALPHA 1	1.80	4.000	7.00	30
		52/316	MTS	F	26	GLOBULINS: ALPHA 1	2.40	4.000	7.00	30
		52/316	MTS	F	34	GLOBULINS: ALPHA 1	2.40	4.000	7.00	30
		52/316	MTS	F	2	GLOBULINS: ALPHA 2	16.10	7.000	11.00	30
		55/318	DNG	F	-1	GLOBULINS: ALPHA 1	2.40	4.000	7.00	30
		55/318	DNG	F	2	GLOBULINS: ALPHA 1	2.20	4.000	7.00	30
		55/318	DNG	F	4	GLOBULINS: ALPHA 1	2.10	4.000	7.00	30
		55/318	DNG	F	6	GLOBULINS: ALPHA 1	2.50	4.000	7.00	30
		55/318	DNG	F	10	GLUCOSE	143.00	70.000	100.00	30
		56/319	IAL	M	-1	GLOBULINS: ALPHA 1	2.20	4.000	7.00	30
		56/319	IAL	M	4	GLOBULINS: BETA	18.60	11.000	14.00	30
		58/320	ARM	F	-1	GLOBULINS: ALPHA 1	2.10	4.000	7.00	30
		58/320	ARM	F	2	GLOBULINS: ALPHA 1	2.20	4.000	7.00	30
		58/320	ARM	F	4	GLOBULINS: ALPHA 1	2.30	4.000	7.00	30
		58/320	ARM	F	6	GLOBULINS: ALPHA 1	2.50	4.000	7.00	30
		58/320	ARM	F	10	GLOBULINS: ALPHA 1	2.70	4.000	7.00	30
		61/323	HVC	F	-1	GLOBULINS: ALPHA 1	2.30	4.000	7.00	30
		61/323	HVC	F	2	GLOBULINS: ALPHA 1	2.80	4.000	7.00	30
		61/323	HVC	F	4	GLOBULINS: ALPHA 1	2.30	4.000	7.00	30

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2040

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXYLINE - PROTOCOL 20124/013
 Listing No.: 12.2
 LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
 DOUBLE BLIND PHASE

TREATMENT	CENTRE	PATIENT NO. OF/BLIND	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	Z VARIATION TO CONSIDER CLIN. REL. (*)
REMOXYLINE	1	61/323	HVC	F	26	GLOBULINS: ALPHA 1	1.30	4.000	7.00	++
		61/323	HVC	F	34	GLOBULINS: ALPHA 1	1.30	4.000	7.00	++
		66/326	TCG	F	10	GLOBULINS: ALPHA 1	2.20	4.000	7.00	++
		66/326	TCG	F	18	GLOBULINS: ALPHA 1	2.30	4.000	7.00	++
		66/326	TCG	F	52	GLOBULINS: ALPHA 1	2.50	4.000	7.00	++
		71/329	OHV	F	-1	HB	10.10	12.000	16.00	-
		71/329	OHV	F	4	HB	10.10	12.000	16.00	-
		71/329	OHV	F	10	HB	9.40	12.000	16.00	-
		71/329	OHV	F	-1	HTC	31.00	37.000	47.00	-
		71/329	OHV	F	4	HTC	31.00	37.000	47.00	-
		71/329	OHV	F	10	HTC	30.00	37.000	47.00	-
		71/329	OHV	F	4	GLOBULINS: ALPHA 1	2.30	4.000	7.00	++
		71/329	OHV	F	10	GLOBULINS: ALPHA 1	2.50	4.000	7.00	++
		71/329	OHV	F	18	GLOBULINS: ALPHA 1	2.30	4.000	7.00	++
		71/329	OHV	F	26	GLOBULINS: ALPHA 1	2.60	4.000	7.00	++
		71/329	OHV	F	34	GLOBULINS: ALPHA 1	1.90	4.000	7.00	++
		71/329	OHV	F	26	P04-	2.50	3.000	4.50	++
		73/121	FHA	F	4	GLOBULINS: ALPHA 1	2.20	4.000	7.00	++
		73/121	FHA	F	18	GLOBULINS: ALPHA 1	2.20	4.000	7.00	++
		73/121	FHA	F	26	GLOBULINS: ALPHA 1	2.20	4.000	7.00	++
		75/123	ELF	F	10	GLOBULINS: ALPHA 1	2.60	4.000	7.00	++
		75/123	ELF	F	18	GLOBULINS: ALPHA 1	2.30	4.000	7.00	++
		75/123	ELF	F	26	GLOBULINS: ALPHA 1	2.50	4.000	7.00	++
		75/123	ELF	F	34	GLOBULINS: ALPHA 1	0.70	4.000	7.00	++
		75/123	ELF	F	42	GLOBULINS: ALPHA 1	1.00	4.000	7.00	++
		81/128	MFB	F	18	GLOBULINS: ALPHA 1	2.80	4.000	7.00	++
		81/128	MFB	F	42	GLOBULINS: ALPHA 1	2.80	4.000	7.00	++
		81/128	MFB	F	52	GLOBULINS: ALPHA 1	2.50	4.000	7.00	++
		82/129	HDS	F	18	GLOBULINS: BETA	7.50	11.000	14.00	++
		82/129	HDS	F	42	GLOBULINS: BETA	7.00	11.000	14.00	++
		87/132	HDO	F	-1	GLOBULINS: ALPHA 1	7.00	11.000	14.00	++
		89/133	NMV	F	-1	SGOT	81.00	12.000	40.00	+
		89/133	NMV	F	4	SGOT	101.00	10.000	40.00	+
		89/133	NMV	F	-1	SGPT	101.00	10.000	40.00	+
		89/133	NMV	F	4	SGPT	101.00	10.000	40.00	+
		89/133	NMV	F	-1	GAMMA-GT	86.00	7.000	33.00	+
		89/133	NMV	F	4	GAMMA-GT	86.00	7.000	33.00	+
		89/133	NMV	F	6	GLOBULINS: ALPHA 2	77.00	7.000	33.00	+
		89/133	NMV	F	-1	GLOBULINS: GAMMA	4.70	7.000	11.00	++
		90/134	JSS	M	-1	GLOBULINS: ALPHA 1	8.50	15.000	22.00	++
		90/134	JSS	M	4	GLOBULINS: ALPHA 1	2.50	4.000	7.00	++
		90/134	JSS	M	-1	GLOBULINS: ALPHA 1	2.10	4.000	7.00	++
		95/138	OMT	F	42	GLOBULINS: GAMMA	8.80	15.000	22.00	++
		95/138	OMT	F	42	GLOBULINS: ALPHA 1	2.80	4.000	7.00	++

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REDOXETINE - PROTOCOL 20124/013
 Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
 DOUBLE BLIND PHASE

TREATMENT	CENTRE	PATIENT NO. OPEN/BLIND	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	% VARIATION TO CONSIDER CLIN. REL. (*)
REDOXETINE	1	95/138	GMT	F	4	GLOBULINS: GAMMA	8.40	15.000	22.00	++
		98/141	YTT	F	10	GLOBULINS: ALPHA 1	2.00	4.000	7.00	++
		98/141	YTT	F	42	GLOBULINS: ALPHA 1	1.90	4.000	7.00	++
		101/143	JLL	F	52	GLOBULINS: ALPHA 1	2.00	4.000	7.00	++
		101/143	JLL	F	-1	GLOBULINS: ALPHA 1	2.50	4.000	7.00	++
		101/143	JLL	F	10	GLOBULINS: ALPHA 1	1.90	4.000	7.00	++
		107/147	LAN	F	18	GLOBULINS: ALPHA 1	2.00	4.000	7.00	++
		107/147	LAN	F	10	GLOBULINS: ALPHA 1	2.50	4.000	7.00	++
		109/149	IPL	F	18	GLOBULINS: ALPHA 1	2.30	4.000	7.00	++
		110/150	TQO	F	10	GLOBULINS: ALPHA 1	2.80	4.000	7.00	++
		110/150	TQO	F	18	GLOBULINS: ALPHA 1	2.00	4.000	7.00	++
		116/334	TQO	F	18	GLOBULINS: ALPHA 1	2.30	4.000	7.00	++
		116/334	TQO	F	26	GLOBULINS: ALPHA 1	2.40	4.000	7.00	++
		116/334	NSA	F	10	GLOBULINS: ALPHA 1	2.50	4.000	7.00	++
		116/334	NSA	F	18	GLOBULINS: ALPHA 1	2.30	4.000	7.00	++
		116/334	NSA	F	26	GLOBULINS: ALPHA 1	2.70	4.000	7.00	++
		117/335	NSA	F	42	GLOBULINS: ALPHA 1	2.00	4.000	7.00	++
		117/335	NSA	F	52	GLOBULINS: ALPHA 1	2.50	4.000	7.00	++
		117/335	PSL	F	-1	GLOBULINS: ALPHA 1	2.50	4.000	7.00	++
		117/335	PSL	F	18	GLOBULINS: ALPHA 1	1.70	4.000	7.00	++
		117/335	PSL	F	18	GLOBULINS: ALPHA 1	1.80	4.000	7.00	++
		117/335	PSL	F	34	GLOBULINS: ALPHA 1	2.50	4.000	7.00	++
		117/335	PSL	F	-1	GLUCOSE	132.00	70.000	100.00	++
		121/336	LAC	F	10	GLOBULINS: ALPHA 1	1.80	4.000	7.00	++
		121/336	LAC	F	18	GLOBULINS: ALPHA 1	1.70	4.000	7.00	++
		121/336	LAC	F	18	GLOBULINS: ALPHA 2	4.90	7.000	11.00	++
		123/338	MLL	F	10	GLOBULINS: ALPHA 1	2.10	4.000	7.00	++
		123/338	MLL	F	18	GLOBULINS: ALPHA 1	2.00	4.000	7.00	++
		125/340	FDP	F	6	GLOBULINS: ALPHA 1	1.90	4.000	7.00	++
		125/340	FDP	F	10	GLOBULINS: ALPHA 1	1.70	4.000	7.00	++
		125/340	FDP	F	18	GLOBULINS: ALPHA 1	1.80	4.000	7.00	++
		127/342	VPD	F	-1	GLOBULINS: ALPHA 2	4.30	7.000	11.00	++
		127/342	VPD	F	6	GLOBULINS: ALPHA 1	2.10	4.000	7.00	++
		127/342	VPD	F	10	GLOBULINS: ALPHA 1	2.40	4.000	7.00	++
		127/342	VPD	F	18	GLOBULINS: ALPHA 1	1.50	4.000	7.00	++
		128/343	LAN	M	-1	GLOBULINS: ALPHA 2	4.90	7.000	11.00	++
		128/343	LAN	M	10	GLOBULINS: ALPHA 1	2.00	4.000	7.00	++
		128/343	LAN	M	18	GLOBULINS: ALPHA 1	2.50	4.000	7.00	++
		128/343	LAN	M	-1	GLOBULINS: ALPHA 2	4.10	7.000	11.00	++
		128/343	LAN	M	2	GLOBULINS: BETA	7.20	11.000	14.00	++
		129/347	LMS	F	10	GLOBULINS: ALPHA 1	2.00	4.000	7.00	++

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2000

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXYTINE - PROTOCOL 20124/013
Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
DOUBLE BLIND PHASE

TREATMENT	CENTRE	PATIENT NO. OPEN/BLIND	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	Z VARIATION TO CONSIDER CLIN. REL. (*)
REBOXYTINE	1	134/347	LMS	F	34	GLOBULINS: ALPHA 1	2.10	4.000	7.00	+
		135/348	MNS	F	34	GLOBULINS: ALPHA 1	2.80	4.000	7.00	+
		139/351	RA	M	2	GLOBULINS: ALPHA 1	2.60	4.000	7.00	+
		139/351	RA	M	4	GLOBULINS: ALPHA 1	2.60	4.000	7.00	+
		139/351	RA	M	10	GLOBULINS: ALPHA 1	2.00	4.000	7.00	+
		139/351	RA	M	6	GLOBULINS: ALPHA 2	16.10	7.000	11.00	+
		140/352	MCA	F	4	GLOBULINS: ALPHA 1	2.50	4.000	7.00	+
		140/352	MCA	F	6	GLOBULINS: ALPHA 1	2.80	4.000	7.00	+
		140/352	MCA	F	10	GLOBULINS: ALPHA 1	2.60	4.000	7.00	+
		140/352	MCA	F	18	GLOBULINS: ALPHA 1	2.80	4.000	7.00	+
		140/352	MCA	F	26	GLOBULINS: ALPHA 1	2.00	4.000	7.00	+
		140/352	MCA	F	42	GLOBULINS: ALPHA 1	2.50	4.000	7.00	+
		140/352	MCA	F	-1	GLOBULINS: ALPHA 2	16.10	7.000	11.00	+
		140/352	MCA	F	6	GLOBULINS: ALPHA 2	14.80	7.000	11.00	+
		140/352	MCA	F	10	GLOBULINS: ALPHA 2	4.70	7.000	11.00	+
		142/354	MCA	F	4	GLOBULINS: BETA	7.60	11.000	14.00	+
		142/354	SCC	F	6	GLOBULINS: ALPHA 1	2.70	4.000	7.00	+
		142/354	SCC	F	18	GLOBULINS: ALPHA 1	2.50	4.000	7.00	+
		142/354	SCC	F	26	GLOBULINS: ALPHA 1	1.80	4.000	7.00	+
		142/354	SCC	F	34	GLOBULINS: ALPHA 1	1.90	4.000	7.00	+
		142/354	SCC	F	10	GLOBULINS: ALPHA 2	4.50	7.000	11.00	+
		142/354	SCC	F	18	GLOBULINS: ALPHA 2	4.60	7.000	11.00	+
		142/354	SCC	F	42	GLOBULINS: ALPHA 2	4.90	7.000	11.00	+
		144/356	ARF	M	2	GLOBULINS: ALPHA 1	2.50	4.000	7.00	+
		144/356	ARF	M	4	GLOBULINS: ALPHA 1	2.00	4.000	7.00	+
		144/356	ARF	M	6	GLOBULINS: ALPHA 1	2.50	4.000	7.00	+
		144/356	ARF	M	10	GLOBULINS: ALPHA 1	2.50	4.000	7.00	+
		144/356	ARF	M	18	GLOBULINS: ALPHA 1	1.80	4.000	7.00	+
		144/356	ARF	M	10	GLOBULINS: ALPHA 1	2.00	4.000	7.00	+
		144/356	ARF	M	10	TRIGLYCERIDES	331.00	35.000	175.00	+
		144/356	ARF	M	18	TRIGLYCERIDES	257.00	35.000	175.00	+
		144/356	ARF	M	-1	GLUCOSE	134.00	70.000	100.00	+
		144/356	ARF	M	4	GLUCOSE	131.00	70.000	100.00	+
		144/356	ARF	M	26	GLUCOSE	132.00	70.000	100.00	+
		144/356	ARF	M	34	GLUCOSE	143.00	70.000	100.00	+
		146/358	LRM	M	4	GLOBULINS: ALPHA 1	2.60	4.000	7.00	+
		146/358	LRM	M	26	GLOBULINS: ALPHA 1	2.70	4.000	7.00	+
		146/358	LRM	M	42	GLOBULINS: ALPHA 1	2.80	4.000	7.00	+
		146/358	LRM	M	10	TRIGLYCERIDES	250.00	35.000	175.00	+
		146/358	LRM	M	26	GLUCOSE	152.00	70.000	100.00	+
		146/358	LRM	M	34	GLUCOSE	134.00	70.000	100.00	+
		146/358	LRM	M	52	GLUCOSE	132.00	70.000	100.00	+
		146/358	LRM	M	4	PO4-	2.50	3.000	4.50	+
		148/359	CAS	H	2	GLOBULINS: ALPHA 1	2.50	4.000	7.00	+

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2051

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013

Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
DOUBLE BLIND PHASE

TREATMENT	CENTRE	PATIENT NO. OPEN/BLIND	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	Z VARIATION TO CONSIDER CLIN. REL. (*)
REBOXETINE	1	148/359	CAS	M	4	GLOBALINS: ALPHA 1	2.50	4.000	7.00	++
		148/359	CAS	M	10	GLOBALINS: ALPHA 1	2.10	4.000	7.00	++
		148/359	CAS	M	18	GLOBALINS: ALPHA 1	1.90	4.000	7.00	++
		148/359	CAS	M	52	GLOBALINS: ALPHA 1	2.50	4.000	7.00	++
REBOXETINE	3	148/359	CAS	M	10	GLOBALINS: ALPHA 2	4.80	7.000	11.00	++
		148/359	CAS	M	18	GLOBALINS: ALPHA 2	4.70	7.000	11.00	++
		7/71	GRI	F	-1	TOT BILIRUBIN	15.00	2.000	7.00	+
		7/71	GRI	F	4	TOT BILIRUBIN	14.00	2.000	7.00	+
REBOXETINE	8	7/71	GRI	F	6	GLOBALINS: ALPHA 1	1.40	2.000	4.00	++
		7/71	GRI	F	6	GLOBALINS: ALPHA 2	4.20	6.000	10.00	++
		2/212	TE	F	26	GANMA-GT	64.00	5.000	25.00	+
		2/212	TE	F	26	TOT. CHOLEST.	9.10	3.900	6.50	+
REBOXETINE	9	2/212	TE	F	48	TRIGLYCERIDES	4.40	0.800	1.70	+
		2/212	TE	F	42	CA++	1.20	2.100	2.60	++
		2/212	TE	F	42	P04-	2.12	0.800	1.60	++
		6/216	TL	F	10	TRIGLYCERIDES	2.30	0.800	1.70	+
REBOXETINE	9	6/245	SD	F	10	GLOBALINS: ALPHA 1	1.70	2.500	4.00	++
		6/245	SD	F	26	GLOBALINS: ALPHA 1	1.70	2.500	4.00	++
		6/245	SD	F	42	GLOBALINS: ALPHA 1	1.50	2.500	4.00	++
		6/245	SD	F	4	GLOBALINS: ALPHA 2	13.10	7.000	10.00	++
		6/245	SD	F	4	GLOBALINS: BETA	18.90	6.300	14.50	++
		6/245	SD	F	18	GLOBALINS: BETA	19.00	8.300	14.50	++
		6/245	SD	F	-1	TRIGLYCERIDES	2.50	0.300	1.80	+
		6/245	SD	F	34	P04-	0.70	0.900	1.60	++
		6/245	SD	F	42	P04-	0.70	0.900	1.60	++
		7/243	PP	M	4	GLOBALINS: ALPHA 1	1.70	2.500	4.00	++
		7/243	PP	M	34	GLOBALINS: ALPHA 1	1.00	2.500	4.00	++
		7/243	PP	M	52	GLOBALINS: ALPHA 1	1.50	2.500	4.00	++
		7/243	PP	M	10	P04-	0.70	0.900	1.60	++
		7/243	PP	M	26	P04-	0.70	0.900	1.60	++
		7/243	PP	M	34	P04-	0.70	0.900	1.60	++
		11/246	KE	F	6	GLOBALINS: ALPHA 1	5.50	2.500	4.00	++
11/246	KE	F	42	GLOBALINS: BETA	21.50	8.300	14.50	++		
11/246	KE	F	-1	P04-	5.80	3.600	5.00	++		
11/246	KE	F	6	P04-	0.60	0.900	1.60	++		
11/246	KE	F	18	P04-	0.70	0.900	1.60	++		
11/246	KE	F	26	P04-	0.60	0.900	1.60	++		
11/246	KE	F	34	P04-	0.50	0.900	1.60	++		

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
DOUBLE BLIND PHASE

TREATMENT	CENTRE	PATIENT NO. OPEN/BLIND	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	% VARIATION TO CONSIDER CLIN. REL. (%)
REBOXETINE	9	11/246	KE	F	42	P04-	0.70	0.900	1.60	15
		11/246	KE	F	52	P04-	0.70	0.900	1.60	15
		15/249	BI	F	2	TOT BILIRUBIN	71.00	2.000	20.00	100
		15/249	BI	F	-1	GLOBULINS: ALPHA 1	1.70	2.500	4.00	30
		15/249	BI	F	42	GLOBULINS: ALPHA 1	1.60	2.500	4.00	30
		16/250	UGV	F	34	GLOBULINS: ALPHA 1	1.00	2.500	4.00	30
		16/250	UGV	F	42	GLOBULINS: ALPHA 1	1.50	2.500	4.00	30
		20/252	GVE	F	-1	URIC ACID	565.00	100.000	400.00	30
		20/252	GVE	F	6	GLOBULINS: ALPHA 1	1.70	2.500	4.00	30
		20/252	GVE	F	18	P04-	0.60	0.900	1.60	15
		23/256	SZN	F	4	GLOBULINS: ALPHA 1	1.70	2.500	4.00	30
		23/256	SZN	F	6	GLOBULINS: ALPHA 1	1.30	2.500	4.00	30
		23/256	SZN	F	10	GLOBULINS: ALPHA 1	1.50	2.500	4.00	30
		23/256	SZN	F	18	GLOBULINS: ALPHA 1	1.60	2.500	4.00	30
		23/256	SZN	F	4	TRIGLYCERIDES	2.70	0.300	1.80	30
		26/255	CP	F	2	GLOBULINS: ALPHA 1	1.50	2.500	4.00	30
		26/255	CP	F	6	GLOBULINS: ALPHA 1	1.70	2.500	4.00	30
		26/255	CP	F	10	GLOBULINS: ALPHA 1	1.00	2.500	4.00	30
		26/255	CP	F	18	GLOBULINS: ALPHA 1	1.50	2.500	4.00	30
		26/255	CP	F	18	GLOBULINS: ALPHA 2	4.60	7.000	10.00	30
		26/255	CP	F	-1	TRIGLYCERIDES	2.70	0.300	1.80	30
		26/255	CP	F	2	TRIGLYCERIDES	3.30	0.300	1.80	30
		26/255	CP	F	6	TRIGLYCERIDES	4.30	0.300	1.80	30
		26/255	CP	F	6	TRIGLYCERIDES	2.60	0.300	1.80	30
		26/255	CP	F	10	TRIGLYCERIDES	3.20	0.300	1.80	30
		26/255	CP	F	6	SGPT	107.00	4.000	27.00	100
		29/258	SZF	F	6	GLOBULINS: ALPHA 1	1.30	2.500	4.00	30
		29/258	SZF	F	2	GLOBULINS: ALPHA 1	0.80	2.500	4.00	30
		29/258	SZF	F	4	GLOBULINS: ALPHA 1	1.30	2.500	4.00	30
		30/259	NF	F	-1	GLOBULINS: ALPHA 1	1.10	2.500	4.00	30
		30/259	NF	F	2	GLOBULINS: ALPHA 1	1.00	2.500	4.00	30
		30/259	NF	F	6	GLOBULINS: ALPHA 1	1.70	2.500	4.00	30
		30/259	NF	F	-1	GLOBULINS: ALPHA 2	4.50	7.000	10.00	30
REBOXETINE	10	1/271	VK	M	6	RUN	19.80	3.300	10.00	50
		1/271	VK	M	6	URIC ACID	512.00	119.000	357.00	30
		7/274	RK	M	2	GLOBULINS: GAMMA	6.20	10.000	17.00	30
		7/274	RK	M	6	GLOBULINS: GAMMA	6.20	10.000	17.00	30
		9/275	RT	F	-1	URIC ACID	555.00	119.000	357.00	30
		9/275	RT	F	-1	GLOBULINS: GAMMA	6.10	10.000	17.00	30
		13/278	RU	F	2	GLOBULINS: BETA	18.60	5.000	13.00	30
		20/285	EJ	F	2	P04-	1.52	0.600	1.50	15

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
DOUBLE BLIND PHASE

TREATMENT	CENTRE	PATIENT NO. OPEN/BLIND	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	% VARIATION TO CONSIDER CLIN. REL. (*)
REBOXETINE	10	22/286	AA	M	4	PO4-	1.50	0.600	1.30	+
		22/286	AA	M	26	PO4-	1.70	0.600	1.30	+
		26/290	JIF	F	2	PO4-	8.10	1.300	6.00	+
		26/290	JIF	F	-1	PO4-	8.10	1.300	6.00	+
		26/290	JIF	F	6	PO4-	13.10	5.000	9.00	+
		26/290	JIF	F	4	PO4-	13.10	5.000	9.00	+
		26/290	JIF	F	4	PO4-	8.40	3.100	6.20	+
		26/290	JIF	F	6	PO4-	8.40	3.100	6.20	+
		27/292	MK	F	18	PO4-	3.40	0.450	1.86	+
		27/292	MK	F	34	PO4-	4.44	0.450	1.86	+
		27/292	MK	F	34	PO4-	3.74	0.600	1.30	+
		27/292	MK	F	52	PO4-	1.51	0.600	1.30	+
		31/297	RK	F	-1	PO4-	0.31	0.370	0.47	-
		33/300	EK	M	-1	PO4-	14.20	5.000	9.00	+
		33/300	EK	M	6	PO4-	3.78	0.450	1.86	+
		33/300	EK	M	18	PO4-	3.73	0.450	1.86	+
		36/36	AK	F	-1	PO4-	12.50	5.000	9.00	+
		36/36	AK	F	-1	PO4-	4.49	0.450	1.86	+
		39/37	LL	F	4	PO4-	45.40	8.600	20.50	+
		41/42	VP	F	34	PO4-	2.64	0.450	1.86	+
		41/42	VP	F	18	PO4-	1.54	0.600	1.30	+
		53/47	HA	F	2	PO4-	4.07	0.600	1.30	+
		54/48	UN	F	2	PO4-	4.30	0.600	1.30	+
		56/50	JP	M	-1	PO4-	3.29	0.450	1.86	+
		56/50	JP	M	2	PO4-	2.50	0.450	1.86	+
		56/50	JP	M	2	PO4-	3.04	0.600	1.30	+
		57/51	AG	F	52	PO4-	3.49	0.450	1.86	+
		57/51	AG	F	2	PO4-	3.52	0.600	1.30	+
		59/53	TA	F	-1	PO4-	2.80	4.000	5.60	+
		63/57	MS	F	42	PO4-	6.30	10.000	17.00	+
		84/63	HV	F	6	PO4-	3.08	0.450	1.86	+
		84/63	HV	F	10	PO4-	2.61	0.450	1.86	+
		87/275	AN	F	26	PO4-	6.50	10.000	17.00	+
89/277	SK	F	4	PO4-	1.50	0.600	1.30	+		
93/285	AN	F	26	PO4-	34.00	51.000	77.00	+		
93/285	AN	F	26	PO4-	2.44	0.450	1.86	+		
REBOXETINE	11	2/373	HB	F	4	WBC: N	32.00	51.000	75.00	-
		2/373	HB	F	26	WBC: N	10.00	0.000	4.30	+
		2/373	HB	F	2	WBC: N	49.00	4.000	18.00	+
		3/374	RF	F	2	WBC: N	37.00	5.000	15.00	+
		3/374	RF	F	-1	WBC: N	44.00	4.000	18.00	+
		3/374	RF	F	2	WBC: N	10.00	3.890	6.10	+
		3/374	RF	F	2	WBC: N	10.00	3.890	6.10	+
		3/374	RF	F	2	WBC: N	10.00	3.890	6.10	+

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2054

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
DOUBLE BLIND PHASE

TREATMENT	CENTRE	PATIENT NO. OPEN/BLIND	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	% VARIATION TO CONSIDER CLIN. REL. (*)		
REBOXETINE	11	3/374	RF	F	4	GLUCOSE	8.80	3.890	6.10	30		
		6/377	VP	M	4	DIR BILIRUBIN	12.00	0.000	4.30	100		
		6/377	VP	M	42	SCOT	40.00	5.000	17.00	100		
		10/363	BJ	F	2	GAMMA-GT	63.00	4.000	28.00	100		
		10/363	BJ	F	26	WBC	3.00	5.000	10.00	-30		
		10/363	BJ	F	4	K+	6.50	3.500	5.30	15		
		11/361	NGY	F	10	PO4-	0.60	0.710	1.50	15		
		13/365	GK	F	20	SGPT	43.00	5.000	19.00	100		
		16/367	NA	F	2	CA++	1.90	2.250	2.75	15		
		16/367	NA	F	2	TOT. CHOLEST.	9.00	3.900	6.70	30		
		17/368	UZ	F	10	TOT. CHOLEST.	9.30	3.900	6.70	30		
		17/368	UZ	F	2	GLUCOLINS: GAMMA	22.65	7.000	17.00	30		
		17/368	UZ	F	2	GLUCOLINS: GAMMA	22.51	7.000	17.00	30		
		17/368	UZ	F	2	TRIGLYCERIDES	3.20	0.470	2.29	30		
		17/368	UZ	F	-1	GLUCOSE	8.00	3.890	6.10	30		
		17/368	UZ	F	-1	PO4-	0.60	0.710	1.50	15		
		REBOXETINE	12	1/92	IB	M	10	GLUCOLINS: ALPHA 2	0.04	0.070	0.13	30
				1/92	IB	M	34	GLUCOLINS: ALPHA 2	0.02	0.070	0.13	30
				1/92	IB	M	10	PO4-	0.58	0.700	1.50	15
				2/99	EFC	F	-1	GAMMA-GT	176.00	6.000	28.00	100
2/99	EFC			F	2	GAMMA-GT	65.00	6.000	28.00	100		
2/99	EFC			F	4	GAMMA-GT	72.00	6.000	28.00	100		
2/99	EFC			F	10	GAMMA-GT	96.00	6.000	28.00	100		
2/99	EFC			F	2	GLUCOLINS: ALPHA 2	0.04	0.070	0.13	30		
2/99	EFC			F	4	CL-	76.00	97.000	107.00	10		
3/93	IF			F	18	DIR BILIRUBIN	9.80	0.000	4.50	100		
3/93	IF			F	-1	GLUCOLINS: ALPHA 1	0.07	0.025	0.05	30		
3/93	IF			F	18	GLUCOLINS: ALPHA 1	0.10	0.025	0.05	30		
3/93	IF			F	26	GLUCOLINS: ALPHA 1	0.07	0.025	0.05	30		
3/93	IF			F	34	GLUCOLINS: ALPHA 1	0.08	0.025	0.05	30		
3/93	IF			F	10	TRIGLYCERIDES	3.00	0.300	1.86	30		
3/93	IF			F	18	TRIGLYCERIDES	3.90	0.300	1.86	30		
3/93	IF			F	26	TRIGLYCERIDES	2.50	0.300	1.86	30		
3/93	IF			F	42	TRIGLYCERIDES	2.80	0.300	1.86	30		
3/93	IF			F	10	GLUCOSE	1.60	3.300	5.50	30		
4/100	EG			F	18	CL-	76.00	97.000	107.00	10		
4/100	EG	F	2	WBC: N	39.00	60.000	70.00	-30				
4/100	EG	F	-1	DIR BILIRUBIN	10.00	0.000	4.50	100				
4/100	EG	F	4	DIR BILIRUBIN	10.10	0.000	4.50	100				
4/100	EG	F	-1	SGPT	115.00	5.000	94.00	100				
4/100	EG	F	-1	GAMMA-GT	81.00	6.000	28.00	100				

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
DOUBLE BLIND PHASE

TREATMENT	CENTRE	PATIENT NO. OPEN/BLIND	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	Z VARIATION TO CONSIDER CLIN. REL. (%)
REBOXETINE	12	4/100	EG	F	26	GAMMA-GT	57.00	6.000	28.00	+
		4/100	EG	F	18	LOBULINS: ALPHA 1	0.07	0.025	0.05	+
		4/100	EG	F	26	LOBULINS: ALPHA 1	0.08	0.025	0.05	+
		4/100	EG	F	4	CL-	81.00	97.000	107.00	+
		7/102	LK	M	-1	DIR BILIRUBIN	11.90	0.000	4.50	+
		7/102	LK	M	18	LOBULINS: ALPHA 1	0.08	0.025	0.05	+
		7/102	LK	M	10	LOBULINS: ALPHA 2	0.04	0.070	0.13	+
		7/102	LK	M	10	LOBULINS: BETA	0.06	0.080	0.14	+
		7/102	LK	M	-1	TRIGLYCERIDES	2.60	0.300	1.86	+
		7/102	LK	M	26	TRIGLYCERIDES	8.70	0.300	1.86	+
		7/102	LK	M	10	GLUCOSE	8.70	3.300	5.50	+
		7/102	LK	M	18	GLUCOSE	7.40	3.300	5.50	+
		7/102	LK	M	4	CL-	79.00	97.000	107.00	+
		7/102	LK	M	10	FO4-	0.58	0.700	1.50	+
		7/102	LK	M	18	FO4-	0.58	0.700	1.50	+
		9/91	KBP	F	26	LOBULINS: ALPHA 1	0.17	0.025	0.05	+
		9/91	KBP	F	2	TRIGLYCERIDES	2.50	0.300	1.86	+
		9/91	KBP	F	4	CA++	1.30	2.250	2.70	+
		15/104	GB	M	26	SGPT	112.00	5.000	34.00	+
		16/105	FN	F	2	RBC	3.77	4.500	5.00	-
		16/105	FN	F	4	DIR BILIRUBIN	13.10	0.000	4.50	+
		16/105	FN	F	26	DIR BILIRUBIN	14.70	0.000	4.50	+
		16/105	FN	F	6	LOBULINS: ALPHA 2	0.05	0.070	0.13	+
		16/105	FN	F	2	TRIGLYCERIDES	2.80	0.300	1.86	+
		16/105	FN	F	-1	CA++	1.90	2.250	2.70	+
		19/106	SS2	F	2	HBC: N	36.00	60.000	70.00	-
		19/106	SS2	F	-1	DIR BILIRUBIN	10.40	0.000	4.50	+
		19/106	SS2	F	10	GAMMA-GT	59.00	6.000	28.00	+
		19/106	SS2	F	-1	LOBULINS: ALPHA 1	0.01	0.025	0.05	+
		19/106	SS2	F	10	LOBULINS: ALPHA 2	0.12	0.025	0.05	+
		19/106	SS2	F	2	LOBULINS: ALPHA 1	0.04	0.070	0.13	+
		21/110	FL	F	6	LOBULINS: ALPHA 1	0.07	0.025	0.05	+
		21/110	FL	F	10	LOBULINS: ALPHA 1	0.10	0.025	0.05	+
		24/113	MF	F	2	LOBULINS: ALPHA 1	0.07	0.025	0.05	+
		24/113	MF	F	4	LOBULINS: ALPHA 1	0.11	0.025	0.05	+
		24/113	MF	F	4	LOBULINS: ALPHA 1	0.11	0.025	0.05	+
		25/114	FS	F	42	HBC: N	39.00	60.000	70.00	-
		25/114	FS	F	4	DIR BILIRUBIN	9.10	0.000	4.50	+
		25/114	FS	F	2	LOBULINS: ALPHA 1	0.07	0.025	0.05	+
		25/114	FS	F	4	LOBULINS: ALPHA 1	0.09	0.025	0.05	+
		25/114	FS	F	6	LOBULINS: ALPHA 1	0.08	0.025	0.05	+

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2056

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
DOUBLE BLIND PHASE

TREATMENT	CENTRE	PATIENT NO. OPEN/BLIND	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	% VARIATION TO CONSIDER CLIN. REL. (*)
REBOXETINE	12	25/114	FS	F	52	GLOBULINS: ALPHA 1	0.07	0.025	0.05	+
		25/114	FS	F	4	TRIGLYCERIDES	4.00	0.300	1.86	+
		27/115	VCS	F	-1	HB	5.98	7.500	10.00	-
		27/115	VCS	F	-1	HTC	0.29	0.380	0.46	-
		27/115	VCS	F	-1	RBC	3.07	4.500	5.00	-
		27/115	VCS	F	2	RBC	3.73	4.500	5.00	-
		27/115	VCS	F	2	GLOBULINS: ALPHA 1	0.07	0.025	0.05	+
		27/115	VCS	F	4	GLOBULINS: ALPHA 1	0.08	0.025	0.05	+
		27/115	VCS	F	10	GLOBULINS: ALPHA 1	0.10	0.025	0.05	+
		27/115	VCS	F	18	GLOBULINS: ALPHA 1	0.10	0.025	0.05	+
		27/115	VCS	F	36	GLOBULINS: ALPHA 1	0.07	0.025	0.05	+
		27/115	VCS	F	36	GLOBULINS: ALPHA 2	0.05	0.070	0.13	+
		27/115	VCS	F	36	GLOBULINS: BETA	0.03	0.080	0.14	+
		27/115	VCS	F	2	TRIGLYCERIDES	2.90	0.300	1.86	+
		29/117	AK	F	4	GLOBULINS: ALPHA 1	0.11	0.025	0.05	+
		29/117	AK	F	6	GLOBULINS: ALPHA 1	0.09	0.025	0.05	+
		29/117	AK	F	10	GLOBULINS: ALPHA 1	0.09	0.025	0.05	+
		33/388	LN	F	4	DIR BILIRUBIN	10.50	0.000	4.50	+
		33/388	LN	F	6	DIR BILIRUBIN	9.70	0.000	4.50	+
		33/388	LN	F	-1	GAMMA-GT	64.00	6.000	28.00	+
		33/388	LN	F	2	GAMMA-GT	83.00	6.000	28.00	+
		33/388	LN	F	4	GAMMA-GT	76.00	6.000	28.00	+
		33/388	LN	F	6	GAMMA-GT	74.00	6.000	28.00	+
		33/388	LN	F	10	GAMMA-GT	68.00	6.000	28.00	+
		33/388	LN	F	18	GAMMA-GT	74.00	6.000	28.00	+
		33/388	LN	F	4	GLOBULINS: ALPHA 1	0.11	0.025	0.05	+
		33/388	LN	F	2	GLOBULINS: ALPHA 1	0.13	0.025	0.05	+
		33/388	LN	F	4	TRIGLYCERIDES	4.40	0.300	1.86	+
		33/388	LN	F	6	TRIGLYCERIDES	2.70	0.300	1.86	+
		33/388	LN	F	10	TRIGLYCERIDES	2.80	0.300	1.86	+
		33/388	LN	F	18	TRIGLYCERIDES	3.60	0.300	1.86	+
		33/388	LN	F	-1	GLUCOSE	7.30	3.300	5.50	+
		33/388	LN	F	4	GLUCOSE	7.20	3.300	5.50	+
		33/388	LN	F	6	GLUCOSE	7.20	3.300	5.50	+
		33/388	LN	F	10	GLUCOSE	8.30	3.300	5.50	+
		33/388	LN	F	18	GLUCOSE	8.10	3.300	5.50	+
33/388	LN	F	18	CT-	87.00	97.000	107.00	+		
36/385	FB	F	-1	GLOBULINS: ALPHA 1	0.11	0.025	0.05	+		
REBOXETINE	13	1/219	PZ	F	-1	GLOBULINS: ALPHA 1	8.00	2.000	6.00	+
		1/219	PZ	F	42	GLOBULINS: ALPHA 1	8.00	2.000	6.00	+
		1/219	PZ	F	-1	P04-	0.75	1.000	1.50	+

2057

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
DOUBLE BLIND PHASE

TREATMENT	CENTRE	PATIENT NO. OPEN/BLIND	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	% VARIATION TO CONSIDER CLIN. REL. (%)
REBOXETINE	13	3/221	AI	F	2	GLOBALINS: ALPHA 1	8.00	2.000	6.00	+ - 30
		3/221	AI	F	6	GLOBALINS: ALPHA 1	9.00	2.000	6.00	+ - 30
		6/226	KE	F	2	HBC: L	12.00	20.000	30.00	- - 30
		6/226	KE	F	10	HBC: L	10.00	20.000	30.00	- - 30
		6/226	KE	F	10	GAMMA-GT	91.00	10.000	40.00	+ 100
		6/226	KE	F	4	GLOBALINS: ALPHA 1	8.00	2.000	6.00	+ - 30
		6/226	KE	F	42	GLOBALINS: ALPHA 1	8.00	2.000	6.00	+ - 30
		6/226	KE	F	6	P04-	0.80	1.000	1.50	+ - 15
		6/226	KE	F	10	P04-	0.74	1.000	1.50	+ - 15
		6/226	KE	F	42	P04-	0.81	1.000	1.50	+ - 15
		7/220	BL	F	2	GLOBALINS: ALPHA 1	8.00	2.000	6.00	+ - 30
		7/220	BL	F	18	GLOBALINS: ALPHA 1	9.00	2.000	6.00	+ - 30
		7/220	BL	F	34	GLOBALINS: ALPHA 1	8.00	2.000	6.00	+ - 30
		7/220	BL	F	52	GLOBALINS: GAMMA	8.00	12.000	22.00	+ - 30
		7/220	BL	F	4	P04-	0.78	1.000	1.50	+ - 15
		13/223	HH	H	2	SPT	92.00	10.000	40.00	+ 100
		13/223	HH	H	6	GAMMA-GT	109.00	10.000	40.00	+ 100
		13/223	HH	H	10	GAMMA-GT	90.00	10.000	40.00	+ 100
		13/223	HH	H	26	GLOBALINS: GAMMA	29.00	12.000	22.00	+ - 30
		13/223	HH	H	6	GLUCOSE	7.90	4.000	6.00	+ - 30
		18/227	VT	F	2	GAMMA-GT	94.00	10.000	40.00	+ 100
		18/227	VT	F	18	GAMMA-GT	108.00	10.000	40.00	+ 100
		18/227	VT	F	4	GLOBALINS: ALPHA 1	8.00	2.000	6.00	+ - 30
		18/227	VT	F	6	GLOBALINS: ALPHA 1	9.00	2.000	6.00	+ - 30
		18/227	VT	F	10	GLOBALINS: ALPHA 1	8.00	2.000	6.00	+ - 30
		18/227	VT	F	42	GLOBALINS: ALPHA 1	9.00	2.000	6.00	+ - 30
		18/227	VT	F	18	P04-	0.80	1.000	1.50	+ - 15
		18/227	VT	F	42	P04-	0.78	1.000	1.50	+ - 15
		20/230	NL	F	2	GLOBALINS: ALPHA 1	16.00	2.000	6.00	+ - 30
		20/230	NL	F	10	P04-	1.83	1.000	1.50	+ - 15
		20/230	NL	F	26	P04-	0.76	1.000	1.50	+ - 15
		21/231	CL	F	52	HBC: N	38.00	60.000	70.00	- - 30
21/231	CL	F	6	GLOBALINS: ALPHA 1	9.00	2.000	6.00	+ - 30		
21/231	CL	F	10	P04-	2.30	1.000	1.50	+ - 15		
21/231	CL	F	26	P04-	0.83	1.000	1.50	+ - 15		
22/232	NVM	F	-1	GAMMA-GT	103.00	10.000	40.00	+ 100		
22/232	NVM	F	4	GLOBALINS: ALPHA 1	11.00	2.000	6.00	+ - 30		
22/232	NVM	F	-1	GLOBALINS: ALPHA 2	4.00	7.000	12.00	+ - 30		
22/232	NVM	F	2	P04-	0.81	1.000	1.50	+ - 15		
PLACEBO	1	1/1	HGA	F	6	GLOBALINS: GAMMA	9.00	15.000	22.00	+ - 30
		1/1	HGA	F	10	GLOBALINS: GAMMA	10.00	15.000	22.00	+ - 30

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2058

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
DOUBLE BLIND PHASE

TREATMENT	CENTRE	PATIENT NO. OPEN/BLIND	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	% VARIATION TO CONSIDER CLIN. REL. (*)
PLACERO	1	1/1	MGA	F	-1	TRIGLYCERIDES	229.00	35.000	175.00	+ 30
		1/1	MGA	F	2	TRIGLYCERIDES	250.00	35.000	175.00	+ 30
		1/1	MGA	F	10	TRIGLYCERIDES	272.00	35.000	175.00	+ 30
		6/5	CPM	F	-1	GLUCOSE	147.00	70.000	100.00	+ 30
		6/5	CPM	F	4	GLUCOSE	161.00	70.000	100.00	+ 30
		6/5	CPM	F	6	GLUCOSE	140.00	70.000	100.00	+ 30
		6/5	CPM	F	10	GLUCOSE	133.00	70.000	100.00	+ 30
		8/6	MVB	M	18	GLUCOSE	2.80	4.000	7.00	+ 30
		8/6	MVB	M	-1	PO4-	2.50	3.000	4.50	+ 30
		8/6	MVB	M	2	PO4-	2.50	3.000	4.50	+ 30
		11/9	VRT	F	26	GLOBULINS: ALPHA 1	1.20	4.000	7.00	+ 30
		11/9	VRT	F	2	GLOBULINS: ALPHA 1	1.20	4.000	7.00	+ 30
		12/10	VRT	F	2	GLOBULINS: ALPHA 1	2.80	4.000	7.00	+ 30
		12/10	SLI	F	2	GLOBULINS: ALPHA 1	2.70	4.000	7.00	+ 30
		12/10	SLI	F	6	GLOBULINS: ALPHA 1	2.60	4.000	7.00	+ 30
		12/10	SLI	F	26	GLOBULINS: ALPHA 2	4.70	7.000	11.00	+ 30
		12/10	SLI	F	18	GLOBULINS: ALPHA 2	2.80	4.000	7.00	+ 30
		15/12	MAO	F	26	GLOBULINS: ALPHA 1	2.80	4.000	7.00	+ 30
		15/12	MAO	F	34	GLOBULINS: ALPHA 1	1.30	4.000	7.00	+ 30
		15/12	MAO	F	34	GLOBULINS: ALPHA 2	4.00	7.000	11.00	+ 30
		15/12	MAO	F	26	PO4-	2.00	3.000	4.50	+ 30
		16/13	MHC	F	6	GLOBULINS: ALPHA 1	2.80	4.000	7.00	+ 30
		16/13	MHC	F	18	GLOBULINS: ALPHA 1	2.70	4.000	7.00	+ 30
		19/16	SR	F	6	GLOBULINS: ALPHA 1	2.70	4.000	7.00	+ 30
		19/16	SR	F	10	GLOBULINS: ALPHA 1	2.40	4.000	7.00	+ 30
		19/16	SR	F	18	GLOBULINS: ALPHA 1	2.10	4.000	7.00	+ 30
		21/18	VNC	F	6	GLOBULINS: ALPHA 1	2.30	4.000	7.00	+ 30
		21/18	VNC	F	18	GLOBULINS: ALPHA 1	2.50	4.000	7.00	+ 30
		21/18	VNC	F	26	GLOBULINS: ALPHA 1	2.70	4.000	7.00	+ 30
		21/18	VNC	F	34	GLOBULINS: ALPHA 1	2.50	4.000	7.00	+ 30
		21/18	VNC	F	42	GLOBULINS: ALPHA 1	2.50	4.000	7.00	+ 30
		21/18	VNC	F	42	GLOBULINS: BETA	7.60	11.000	14.00	+ 30
		26/22	OC	F	42	GLOBULINS: ALPHA 1	2.20	4.000	7.00	+ 30
		26/22	OC	F	52	GLOBULINS: ALPHA 1	2.80	4.000	7.00	+ 30
27/23	RK	M	4	GLOBULINS: ALPHA 1	4.60	7.000	11.00	+ 30		
27/23	RK	M	4	GLOBULINS: ALPHA 2	4.60	7.000	11.00	+ 30		
28/24	RHM	F	-1	GAMMA-GT	950.00	7.000	53.00	+ 30		
28/24	RHM	F	2	GAMMA-GT	279.00	7.000	53.00	+ 100		
28/24	RHM	F	4	GAMMA-GT	252.00	7.000	53.00	+ 100		
28/24	RHM	F	6	GAMMA-GT	211.00	7.000	53.00	+ 100		
28/24	RHM	F	10	GAMMA-GT	174.00	7.000	53.00	+ 100		
28/24	RHM	F	18	GAMMA-GT	182.00	7.000	53.00	+ 100		
28/24	RHM	F	4	GLOBULINS: ALPHA 1	1.80	4.000	7.00	+ 30		

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2059

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 12.2
 LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
 DOUBLE BLIND PHASE

TREATMENT	CENTRE	PATIENT NO. OPEN/BLIND	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	Z VARIATION TO CONSIDER CLIN. REL. (*)
PLACEBO	1	28/24	RMH	F	10	GLOBULINS: ALPHA 1	2.80	4.000	7.00	30
		28/24	RMH	F	18	GLOBULINS: ALPHA 1	2.60	4.000	7.00	30
		29/25	AFO	F	6	SGPT	92.00	10.000	40.00	100
		29/25	AFO	F	18	GLOBULINS: ALPHA 1	2.60	4.000	7.00	30
		29/25	AFO	F	42	GLOBULINS: ALPHA 1	2.50	4.000	7.00	30
		29/25	AFO	F	52	GLOBULINS: ALPHA 1	2.50	4.000	7.00	30
		30/26	ERV	M	2	SGPT	91.00	10.000	40.00	100
		30/26	ERV	M	2	GLOBULINS: ALPHA 1	2.50	4.000	7.00	30
		30/26	ERV	M	10	GLOBULINS: ALPHA 1	2.70	4.000	7.00	30
		30/26	ERV	M	-1	TRIGLYCERIDES	316.00	35.000	175.00	30
		30/26	ERV	M	2	TRIGLYCERIDES	279.00	35.000	175.00	30
		30/26	ERV	M	4	TRIGLYCERIDES	407.00	35.000	175.00	30
		30/26	ERV	M	6	TRIGLYCERIDES	405.00	35.000	175.00	30
		30/26	ERV	M	10	TRIGLYCERIDES	417.00	35.000	175.00	30
		33/29	OFC	M	2	GLOBULINS: ALPHA 1	2.70	4.000	7.00	30
		33/29	OFC	M	4	GLOBULINS: ALPHA 1	2.70	4.000	7.00	30
		33/29	OFC	M	10	GLOBULINS: ALPHA 1	2.70	4.000	7.00	30
		36/302	LN	F	2	GLOBULINS: ALPHA 1	1.90	4.000	7.00	30
		36/302	LN	F	4	GLOBULINS: ALPHA 1	1.90	4.000	7.00	30
		36/302	LN	F	6	GLOBULINS: ALPHA 1	2.00	4.000	7.00	30
		36/302	LN	F	10	GLOBULINS: ALPHA 1	2.00	4.000	7.00	30
		36/302	LN	F	-1	TRIGLYCERIDES	256.00	35.000	175.00	30
		36/302	LN	F	6	TRIGLYCERIDES	231.00	35.000	175.00	30
		36/304	DBF	F	10	TRIGLYCERIDES	232.00	35.000	175.00	30
		36/304	DBF	M	-1	SGPT	179.00	12.000	40.00	100
		36/304	DBF	M	2	SGPT	177.00	12.000	40.00	100
		36/304	DBF	M	4	SGPT	242.00	12.000	40.00	100
		36/304	DBF	M	6	SGPT	162.00	12.000	40.00	100
		36/304	DBF	M	10	SGPT	104.00	12.000	40.00	100
		36/304	DBF	M	18	SGPT	142.00	12.000	40.00	100
		36/304	DBF	M	26	SGPT	119.00	12.000	40.00	100
		36/304	DBF	M	34	SGPT	86.00	12.000	40.00	100
		36/304	DBF	M	42	SGPT	140.00	12.000	40.00	100
		36/304	DBF	M	52	SGPT	197.00	12.000	40.00	100
		36/304	DBF	M	-1	SGPT	171.00	10.000	40.00	100
		36/304	DBF	M	2	SGPT	185.00	10.000	40.00	100
		36/304	DBF	M	4	SGPT	153.00	10.000	40.00	100
		36/304	DBF	M	6	SGPT	146.00	10.000	40.00	100
		36/304	DBF	M	10	SGPT	116.00	10.000	40.00	100
		36/304	DBF	M	18	SGPT	178.00	10.000	40.00	100
		36/304	DBF	M	26	SGPT	156.00	10.000	40.00	100
		36/304	DBF	M	34	SGPT	91.00	10.000	40.00	100
		36/304	DBF	M	42	SGPT	256.00	10.000	40.00	100
		36/304	DBF	M	52	SGPT	276.00	10.000	40.00	100

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOETINE - PROTOCOL 20124/013
Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
DOUBLE BLIND PHASE

TREATMENT	CENTRE	PATIENT NO. OPEN/BLIND	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	% VARIATION TO CONSIDER CLIN. REL. (*)
PLACEBO	1	38/304	DBF	M	-1	GAMMA-GT	491.00	11.000	51.00	+
		38/304	DBF	M	2	GAMMA-GT	494.00	11.000	51.00	+
		38/304	DBF	M	4	GAMMA-GT	526.00	11.000	51.00	+
		38/304	DBF	M	6	GAMMA-GT	412.00	11.000	51.00	+
		38/304	DBF	M	10	GAMMA-GT	245.00	11.000	51.00	+
		38/304	DBF	M	18	GAMMA-GT	328.00	11.000	51.00	+
		38/304	DBF	M	26	GAMMA-GT	299.00	11.000	51.00	+
		38/304	DBF	M	34	GAMMA-GT	114.00	11.000	51.00	+
		38/304	DBF	M	42	GAMMA-GT	316.00	11.000	51.00	+
		38/304	DBF	M	52	GAMMA-GT	471.00	11.000	51.00	+
		38/304	DBF	M	-1	ALK. PHOSPH.	680.00	65.000	306.00	+
		38/304	DBF	M	2	ALK. PHOSPH.	731.00	65.000	306.00	+
		38/304	DBF	M	4	ALK. PHOSPH.	731.00	65.000	306.00	+
		38/304	DBF	M	6	ALK. PHOSPH.	780.00	65.000	306.00	+
		38/304	DBF	M	18	ALK. PHOSPH.	660.00	65.000	306.00	+
		38/304	DBF	M	2	ALB. PHOSPH.	2.50	4.000	7.00	+
		38/304	DBF	M	4	ALB. PHOSPH.	2.70	4.000	7.00	+
		38/304	DBF	M	18	ALB. PHOSPH.	2.70	4.000	7.00	+
		38/304	DBF	M	42	ALB. PHOSPH.	2.40	4.000	7.00	+
		38/304	DBF	M	52	ALB. PHOSPH.	2.30	4.000	7.00	+
		38/304	DBF	M	10	TRIGLYCERIDES	23.10	11.000	14.00	+
		38/304	DBF	M	-1	TRIGLYCERIDES	248.00	35.000	175.00	+
		38/304	DBF	M	2	TRIGLYCERIDES	278.00	35.000	175.00	+
		38/304	DBF	M	4	TRIGLYCERIDES	269.00	35.000	175.00	+
		38/304	DBF	M	6	TRIGLYCERIDES	300.00	35.000	175.00	+
		38/304	DBF	M	-1	GLUCOSE	314.00	70.000	100.00	+
		38/304	DBF	M	2	GLUCOSE	314.00	70.000	100.00	+
		38/304	DBF	M	4	GLUCOSE	303.00	70.000	100.00	+
		38/304	DBF	M	6	GLUCOSE	243.00	70.000	100.00	+
		38/304	DBF	M	18	GLUCOSE	188.00	70.000	100.00	+
		38/304	DBF	M	26	GLUCOSE	136.00	70.000	100.00	+
		38/304	DBF	M	42	GLUCOSE	134.00	70.000	100.00	+
		38/304	DBF	M	52	GLUCOSE	151.00	70.000	100.00	+
		40/306	EM	F	-1	GLOBULINS: ALPHA 1	2.80	4.000	7.00	+
		40/306	EM	F	2	GLOBULINS: ALPHA 1	9.80	15.000	22.00	+
		40/306	EM	F	4	GLOBULINS: GAMMA	9.00	15.000	22.00	+
		40/306	EM	F	6	GLOBULINS: GAMMA	9.60	15.000	22.00	+
		40/306	EM	F	10	GLOBULINS: GAMMA	9.20	15.000	22.00	+
		40/306	EM	F	18	GLOBULINS: GAMMA	5.80	15.000	22.00	+
		40/306	EM	F	26	GLOBULINS: GAMMA	8.80	15.000	22.00	+
		41/307	SFS	M	10	GLOBULINS: ALPHA 1	2.40	4.000	7.00	+
		41/307	SFS	M	18	GLOBULINS: ALPHA 1	2.60	4.000	7.00	+
		41/307	SFS	M	26	GLOBULINS: ALPHA 1	7.60	11.000	14.00	+
		41/307	SFS	M	26	GLOBULINS: BETA	30.10	15.000	22.00	+

(*): MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
DOUBLE BLIND PHASE

TREATMENT	CENTRE	PATIENT NO. OPEN/BLIND	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	Z VARIATION TO CONSIDER CLIN. REL. (%)
PLACEBO	1	41/307	SFS	M	2	GLUCOSE	180.00	70.000	100.00	+*
		41/307	SFS	M	10	GLUCOSE	156.00	70.000	100.00	+*
		41/307	SFS	M	18	GLUCOSE	153.00	70.000	100.00	+*
		41/307	SFS	M	10	P04-	2.50	3.000	4.50	+*
		42/308	ICC	F	-1	GLORULINS: ALPHA 1	1.70	4.000	7.00	+*
		42/308	ICC	F	2	GLORULINS: ALPHA 1	2.50	4.000	7.00	+*
		42/308	ICC	F	4	GLORULINS: ALPHA 1	1.92	4.000	7.00	+*
		42/308	ICC	F	6	GLORULINS: ALPHA 1	2.30	4.000	7.00	+*
		42/308	ICC	F	10	GLORULINS: ALPHA 1	1.90	4.000	7.00	+*
		42/308	ICC	F	18	GLORULINS: ALPHA 1	2.00	4.000	7.00	+*
		42/308	ICC	F	52	GLORULINS: ALPHA 1	2.70	4.000	7.00	+*
		47/312	HCS	F	-1	GLORULINS: ALPHA 1	2.20	4.000	7.00	+*
		47/312	HCS	F	4	GLORULINS: ALPHA 1	1.90	4.000	7.00	+*
		47/312	HCS	F	-1	TRIGLYCERIDES	284.00	85.000	175.00	+*
		47/312	HCS	F	26	TRIGLYCERIDES	240.00	85.000	175.00	+*
		50/314	MFA	F	-1	HB	9.60	12.000	16.00	-
		50/314	MFA	F	6	HB	10.10	12.000	16.00	-
		50/314	MFA	F	6	HB	9.50	12.000	16.00	-
		50/314	MFA	F	-1	HTC	31.00	37.000	47.00	-
		50/314	MFA	F	6	HTC	30.00	37.000	47.00	-
		50/314	MFA	F	2	GLORULINS: ALPHA 1	2.40	4.000	7.00	+*
		50/314	MFA	F	4	GLORULINS: ALPHA 1	2.50	4.000	7.00	+*
		50/314	MFA	F	6	GLORULINS: ALPHA 1	2.40	4.000	7.00	+*
		50/314	MFA	F	26	GLORULINS: ALPHA 1	1.90	4.000	7.00	+*
		50/314	MFA	F	34	GLORULINS: ALPHA 1	2.20	4.000	7.00	+*
		51/315	ASA	F	-1	GLORULINS: ALPHA 1	2.30	4.000	7.00	+*
		51/315	ASA	F	2	GLORULINS: ALPHA 1	2.30	4.000	7.00	+*
		51/315	ASA	F	4	GLORULINS: ALPHA 1	2.50	4.000	7.00	+*
		51/315	ASA	F	6	GLORULINS: ALPHA 1	1.10	4.000	7.00	+*
		51/315	ASA	F	10	GLORULINS: ALPHA 1	0.70	4.000	7.00	+*
		51/315	ASA	F	18	GLORULINS: ALPHA 1	1.20	4.000	7.00	+*
		51/315	ASA	F	26	GLORULINS: ALPHA 1	1.30	4.000	7.00	+*
		51/315	ASA	F	34	GLORULINS: ALPHA 1	2.30	4.000	7.00	+*
		51/315	ASA	F	42	GLORULINS: ALPHA 1	2.30	4.000	7.00	+*
		51/315	ASA	F	52	GLORULINS: ALPHA 1	2.30	4.000	7.00	+*
		51/315	ASA	F	10	GLORULINS: ALPHA 2	2.10	7.000	11.00	+*
		51/315	ASA	F	18	GLORULINS: ALPHA 2	18.30	11.000	14.00	+*
		51/315	ASA	F	2	GLORULINS: BETA	18.90	11.000	14.00	+*
		51/315	ASA	F	10	GLORULINS: GAMMA	29.00	15.000	22.00	+*
		51/315	ASA	F	6	P04-	2.00	3.000	4.50	+*
		51/315	ASA	F	26	P04-	2.30	3.000	4.50	+*
		51/315	ASA	F	42	P04-	2.50	3.000	4.50	+*
		51/315	ASA	F	52	P04-	2.20	3.000	4.50	+*
		53/317	JFT	F	2	GLORULINS: ALPHA 1	2.20	4.000	7.00	+*

(**) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
DOUBLE BLIND PHASE

TREATMENT	CENTRE	PATIENT NO. OPEN/BLIND	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	% VARIATION TO CONSIDER CLIN. REL. (*)
PLACERO	1	53/317	JFT	F	4	GLOBULINS: ALPHA 1	2.30	4.000	7.00	+- 30
		53/317	JFT	F	6	GLOBULINS: ALPHA 1	1.40	4.000	7.00	+- 30
		53/317	JFT	F	10	GLOBULINS: ALPHA 1	1.70	4.000	7.00	+- 30
		53/317	JFT	F	18	GLOBULINS: ALPHA 1	2.10	4.000	7.00	+- 30
		53/317	JFT	F	4	GLOBULINS: ALPHA 2	4.90	7.000	11.00	+- 30
		53/317	JFT	F	10	GLOBULINS: ALPHA 2	3.80	7.000	11.00	+- 30
		53/317	JFT	F	18	GLOBULINS: ALPHA 2	4.00	7.000	11.00	+- 30
		53/317	JFT	F	10	TRIGLYCERIDES	496.00	35.000	175.00	+- 30
		53/317	JFT	F	-1	GLUCOSE	133.00	70.000	100.00	+- 30
		53/317	SFF	F	-1	GLOBULINS: ALPHA 1	2.00	4.000	7.00	+- 30
		59/321	SFF	F	2	GLOBULINS: ALPHA 1	2.10	4.000	7.00	+- 30
		59/321	SFF	F	4	GLOBULINS: ALPHA 1	22.00	4.000	7.00	+- 30
		59/321	SFF	F	10	GLOBULINS: ALPHA 1	1.90	4.000	7.00	+- 30
		59/321	SFF	F	18	GLOBULINS: ALPHA 1	2.00	4.000	7.00	+- 30
		59/321	SFF	F	26	GLOBULINS: ALPHA 1	2.00	4.000	7.00	+- 30
		59/321	SFF	F	34	GLOBULINS: ALPHA 1	2.10	4.000	7.00	+- 30
		60/322	EM	M	-1	GLOBULINS: ALPHA 1	2.50	4.000	7.00	+- 30
		60/322	EM	M	10	GLOBULINS: ALPHA 1	2.40	4.000	7.00	+- 30
		60/322	EM	M	18	GLOBULINS: ALPHA 1	2.30	4.000	7.00	+- 30
		60/322	EM	M	26	GLOBULINS: ALPHA 1	2.20	4.000	7.00	+- 30
		60/322	EM	M	34	GLOBULINS: ALPHA 1	2.50	4.000	7.00	+- 30
		60/322	EM	M	42	GLOBULINS: ALPHA 1	2.20	4.000	7.00	+- 30
		62/324	MEA	F	-1	GLOBULINS: ALPHA 1	2.20	4.000	7.00	+- 30
		62/324	MEA	F	2	GLOBULINS: ALPHA 1	2.60	4.000	7.00	+- 30
		62/324	MEA	F	26	GLOBULINS: ALPHA 1	2.20	4.000	7.00	+- 30
		62/324	MEA	F	4	PO4--	5.20	3.000	4.50	+- 15
		62/324	MEA	F	52	PO4--	2.10	3.000	4.50	+- 15
		64/325	EMF	F	10	GAMMA-GT	91.00	7.000	33.00	+- 100
		64/325	EMF	F	18	GAMMA-GT	75.00	7.000	33.00	+- 100
		64/325	EMF	F	34	GAMMA-GT	68.00	7.000	33.00	+- 100
		64/325	EMF	F	-1	GLOBULINS: ALPHA 1	2.10	4.000	7.00	+- 30
		64/325	EMF	F	26	GLOBULINS: ALPHA 1	2.20	4.000	7.00	+- 30
		64/325	EMF	F	34	GLOBULINS: ALPHA 1	2.50	4.000	7.00	+- 30
		64/325	EMF	F	42	GLOBULINS: ALPHA 1	2.40	4.000	7.00	+- 30
		64/325	EMF	F	52	GLOBULINS: ALPHA 1	2.40	4.000	7.00	+- 30
		64/325	EMF	F	4	GLOBULINS: GAMMA	8.10	15.000	22.00	+- 30
		64/325	EMF	F	-1	URIC ACID	8.60	2.600	5.70	+- 30
		67/327	MAA	F	10	URIC ACID	7.90	2.600	5.70	+- 30
		67/327	MAA	F	4	GLOBULINS: ALPHA 1	2.00	4.000	7.00	+- 30
		67/327	MAA	F	4	GLOBULINS: ALPHA 2	4.90	7.000	11.00	+- 30
		67/327	MAA	F	-1	GLOBULINS: ALPHA 2	361.00	35.000	175.00	+- 30
		67/327	MAA	F	-1	TRIGLYCERIDES	280.00	35.000	175.00	+- 30
		67/327	MAA	F	10	TRIGLYCERIDES	146.00	70.000	100.00	+- 30
		67/327	MAA	F	-1	GLUCOSE	146.00	70.000	100.00	+- 30

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2063

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOZETINE - PROTOCOL 20124/013
 Listing No.: 12.2
 LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
 DOUBLE BLIND PHASE

TREATMENT	CENTRE	PATIENT NO. OPEN/BLIND	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	% VARIATION TO CONSIDER CLIN. REL. (*)
PLACEBO	1	67/327	MAA	F	4	GLUCOSE	140.00	70.000	100.00	30
		67/327	MAA	F	10	GLUCOSE	146.00	70.000	100.00	30
		67/327	MAA	F	18	GLUCOSE	140.00	70.000	100.00	30
		70/328	MLM	F	4	GLUCOSE	1.70	0.000	7.00	30
		74/122	IVL	F	-1	DIR. BILIRUBIN	0.80	0.000	0.40	100
		74/122	IVL	F	4	GLUCOLINS: ALPHA 1	2.30	4.000	7.00	30
		76/124	SFA	F	18	GLUCOLINS: ALPHA 1	2.80	4.000	7.00	30
		76/124	SFA	F	52	GLUCOLINS: ALPHA 1	2.70	4.000	7.00	30
		76/124	SFA	F	10	GLUCOLINS: BETA	6.70	11.000	14.00	30
		76/124	SFA	F	26	GLUCOLINS: BETA	6.90	11.000	14.00	30
		79/126	JCM	M	-1	HP	11.80	14.000	16.00	-15
		79/126	JCM	M	42	GLUCOLINS: ALPHA 1	2.40	4.000	7.00	30
		79/126	JCM	M	52	GLUCOLINS: ALPHA 1	2.50	4.000	7.00	30
		84/130	IN	M	-1	GLUCOLINS: ALPHA 1	2.00	4.000	7.00	30
		84/130	IN	M	2	GLUCOLINS: ALPHA 1	2.50	4.000	7.00	30
		84/130	IN	M	4	GLUCOLINS: ALPHA 1	2.40	4.000	7.00	30
		84/130	IN	M	6	GLUCOLINS: ALPHA 1	2.60	4.000	7.00	30
		84/130	IN	M	10	GLUCOLINS: ALPHA 1	2.00	4.000	7.00	30
		84/130	IN	M	18	GLUCOLINS: ALPHA 1	2.60	4.000	7.00	30
		84/130	IN	M	26	GLUCOLINS: ALPHA 1	2.60	4.000	7.00	30
		85/131	MFP	M	-1	GLUCOLINS: ALPHA 1	1.90	4.000	7.00	30
		85/131	MFP	M	42	GLUCOLINS: ALPHA 1	2.20	4.000	7.00	30
		85/131	MFP	M	52	GLUCOLINS: ALPHA 1	2.80	4.000	7.00	30
		85/131	MFP	M	42	GLUCOLINS: BETA	7.50	11.000	14.00	30
		85/131	MFP	M	52	GLUCOLINS: BETA	7.50	11.000	14.00	30
		91/135	MSC	F	26	PD4-	5.20	3.000	4.50	15
		91/135	MSC	F	42	GLUCOLINS: ALPHA 1	2.60	4.000	7.00	30
		93/136	AL	F	18	GLUCOLINS: ALPHA 1	2.50	4.000	7.00	30
		93/136	AL	F	52	GLUCOLINS: ALPHA 1	2.70	4.000	7.00	30
		94/137	RAB	M	4	GLUCOLINS: ALPHA 1	15.20	7.000	11.00	30
		94/137	RAB	M	26	GLUCOLINS: ALPHA 2	4.90	7.000	11.00	30
		97/140	MND	M	10	GLUCOLINS: ALPHA 1	2.80	4.000	7.00	30
		97/140	MND	M	18	GLUCOLINS: ALPHA 1	2.70	4.000	7.00	30
		100/142	JWA	M	52	GLUCOLINS: ALPHA 1	2.40	4.000	7.00	30
		104/144	WTF	F	10	GLUCOLINS: BETA	18.50	11.000	16.00	30
		104/144	WTF	F	52	GLUCOLINS: ALPHA 1	2.80	4.000	7.00	30
		105/145	ABS	F	6	PD4-	5.20	3.000	4.50	15
		105/145	ABS	F	10	GLUCOLINS: ALPHA 1	2.10	4.000	7.00	30
		105/145	ABS	F	18	GLUCOLINS: ALPHA 1	2.50	4.000	7.00	30
		105/145	ABS	F	42	GLUCOLINS: ALPHA 1	2.30	4.000	7.00	30
		106/146	HRN	M	40	GLUCOLINS: ALPHA 1	2.70	4.000	7.00	30
		106/146	HRN	M	48	GLUCOLINS: ALPHA 1	1.90	4.000	7.00	30
		106/146	HRN	M	18	GLUCOLINS: ALPHA 1	1.80	4.000	7.00	30

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2064

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXTINE - PROTOCOL 20124/013
 Listing No.: 12.2
 LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
 DOUBLE BLIND PHASE

TREATMENT	CENTRE	PATIENT NO. OPEN/BLIND	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	Z VARIATION TO CONSIDER CLIN. REL. (*)
PLACEBO	1	106/146	MRN	M	26	GLOBULINS: ALPHA 1	2.50	4.000	7.00	++
		106/146	MRN	M	52	GLOBULINS: ALPHA 1	2.40	4.000	7.00	++
		108/148	STB	F	10	GLOBULINS: ALPHA 1	2.70	4.000	7.00	++
		108/148	STB	F	18	GLOBULINS: ALPHA 1	2.50	4.000	7.00	++
		108/148	STB	F	42	GLOBULINS: ALPHA 1	2.00	4.000	7.00	++
		111/331	JBF	M	2	GLOBULINS: ALPHA 1	2.70	4.000	7.00	++
		111/331	JBF	M	10	GLOBULINS: ALPHA 1	2.60	4.000	7.00	++
		111/331	JBF	M	18	GLOBULINS: ALPHA 1	2.40	4.000	7.00	++
		111/331	JBF	M	26	GLOBULINS: ALPHA 1	2.50	4.000	7.00	++
		111/331	JBF	M	2	GLOBULINS: BETA 1	19.10	11.000	14.00	++
		114/332	CLF	F	-1	GLOBULINS: ALPHA 1	2.70	4.000	7.00	++
		114/332	CLF	F	10	GLOBULINS: ALPHA 1	1.90	4.000	7.00	++
		114/332	CLF	F	18	GLOBULINS: ALPHA 1	2.00	4.000	7.00	++
		114/332	CLF	F	34	GLOBULINS: ALPHA 1	2.60	4.000	7.00	++
		114/332	CLF	F	40	GLOBULINS: ALPHA 2	4.80	4.000	11.00	++
		115/333	ELS	F	-1	TRIGLYCERIDES	260.00	35.000	175.00	+
		122/337	HSS	M	4	GLOBULINS: ALPHA 1	2.50	4.000	7.00	++
		122/337	HSS	M	10	GLOBULINS: ALPHA 1	2.90	4.000	7.00	++
		122/337	HSS	M	18	GLOBULINS: ALPHA 1	2.10	4.000	7.00	++
		122/337	HSS	M	34	GLOBULINS: ALPHA 1	2.50	4.000	7.00	++
		124/339	PPC	M	10	GLOBULINS: ALPHA 1	2.10	4.000	7.00	++
		124/339	PPC	M	18	GLOBULINS: ALPHA 1	1.70	4.000	7.00	++
		124/339	PPC	M	4	GLOBULINS: BETA 1	6.80	11.000	14.00	++
		126/341	SNB	F	10	GLOBULINS: ALPHA 1	2.00	4.000	7.00	++
		126/341	SNB	F	18	GLOBULINS: ALPHA 1	1.90	4.000	7.00	++
		126/341	SNB	F	26	GLOBULINS: ALPHA 1	2.60	4.000	7.00	++
		126/341	SNB	F	52	GLOBULINS: ALPHA 1	2.70	4.000	7.00	++
		129/344	MNS	M	10	GLOBULINS: ALPHA 1	2.50	4.000	7.00	++
		129/344	MNS	M	18	GLOBULINS: ALPHA 1	2.40	4.000	7.00	++
		129/344	MNS	M	26	GLOBULINS: ALPHA 1	2.60	4.000	7.00	++
		129/344	MNS	M	34	GLOBULINS: ALPHA 1	2.40	4.000	7.00	++
		130/345	EGA	F	-1	GLOBULINS: ALPHA 1	1.90	4.000	7.00	++
		130/345	EGA	F	4	GLOBULINS: ALPHA 1	2.40	4.000	7.00	++
		130/345	EGA	F	10	GLOBULINS: ALPHA 1	2.30	4.000	7.00	++
		130/345	EGA	F	18	GLOBULINS: ALPHA 1	2.00	4.000	7.00	++
		130/345	EGA	F	4	GLOBULINS: ALPHA 1	2.50	4.000	7.00	++
		133/346	JPM	M	10	GLOBULINS: ALPHA 1	2.60	4.000	7.00	++
		133/346	JPM	M	18	GLOBULINS: ALPHA 1	2.60	4.000	7.00	++
		133/346	JPM	M	42	GLOBULINS: ALPHA 1	2.20	4.000	7.00	++
		133/346	JPM	M	52	GLOBULINS: ALPHA 1	2.70	4.000	7.00	++
		133/346	JPM	M	34	GLOBULINS: ALPHA 2	4.90	7.000	11.00	++
		136/349	AVP	M	10	GLOBULINS: ALPHA 1	2.50	4.000	7.00	++
		136/349	AVP	M	18	GLOBULINS: ALPHA 1	2.50	4.000	7.00	++
		136/349	AVP	M	42	GLOBULINS: ALPHA 1	2.20	4.000	7.00	++
		136/349	AVP	M	10	GLOBULINS: ALPHA 2	3.90	7.000	11.00	++

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2065

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
DOUBLE BLIND PHASE

TREATMENT	CENTRE	PATIENT NO. OPEN/BLIND	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	Z VARIATION TO CONSIDER CLIN. REL. (*)		
PLACEBO	1	138/350	LBV	F	26	GLOBULINS: ALPHA 1	2.00	4.000	7.00	+ - 30		
		138/350	LBV	F	34	GLOBULINS: ALPHA 1	2.20	4.000	7.00	+ - 30		
		141/353	ANG	F	2	GLOBULINS: ALPHA 1	2.50	4.000	7.00	+ - 30		
		141/353	ANG	F	10	GLOBULINS: ALPHA 1	2.20	4.000	7.00	+ - 30		
		141/353	ANG	F	18	GLOBULINS: ALPHA 1	2.70	4.000	7.00	+ - 30		
		141/353	ANG	F	26	GLOBULINS: ALPHA 1	2.80	4.000	7.00	+ - 30		
		141/353	ANG	F	-1	GLOBULINS: BETA	7.40	11.000	14.00	+ - 30		
		141/353	ANG	F	2	GLOBULINS: BETA	6.90	11.000	14.00	+ - 30		
		141/353	ANG	F	6	GLOBULINS: BETA	7.00	11.000	14.00	+ - 30		
		141/353	ANG	F	10	GLOBULINS: ALPHA 1	2.70	4.000	7.00	+ - 30		
		141/353	JEP	H	18	GLOBULINS: ALPHA 1	2.40	4.000	7.00	+ - 30		
		149/357	JEP	H	4	GLOBULINS: ALPHA 1	2.80	4.000	7.00	+ - 30		
		149/357	SJD	H	4	GLOBULINS: ALPHA 1	2.50	4.000	7.00	+ - 30		
		149/357	SJD	H	6	GLOBULINS: ALPHA 1	1.70	4.000	7.00	+ - 30		
		149/357	SJD	H	26	GLOBULINS: ALPHA 1	2.50	4.000	7.00	+ - 30		
		149/360	SC	F	-1	GLOBULINS: ALPHA 1	2.50	4.000	7.00	+ - 30		
		149/360	SC	F	2	GLOBULINS: ALPHA 1	2.30	4.000	7.00	+ - 30		
		149/360	SC	F	4	GLOBULINS: ALPHA 1	2.70	4.000	7.00	+ - 30		
		149/360	SC	F	6	GLOBULINS: ALPHA 1	2.30	4.000	7.00	+ - 30		
		149/360	SC	F	18	GLOBULINS: ALPHA 1	2.50	4.000	7.00	+ - 30		
		149/360	SC	F	26	GLOBULINS: ALPHA 1	2.80	4.000	7.00	+ - 30		
		149/360	SC	F	-1	GLOBULINS: BETA	7.60	11.000	14.00	+ - 30		
		149/360	SC	F	2	GLOBULINS: BETA	6.60	11.000	14.00	+ - 30		
		PLACEBO	3	2/61	FIL	F	-1	HB	6.00	7.400	9.90	- 15
				2/61	FIL	F	2	HB	5.70	7.400	9.90	- 15
				2/61	FIL	F	4	HB	6.20	7.400	9.90	- 15
2/61	FIL			F	6	HB	6.20	7.400	9.90	- 15		
2/61	FIL			F	10	HB	6.20	7.400	9.90	- 15		
2/61	FIL			F	18	HB	4.98	7.400	9.90	- 15		
2/61	FIL			F	26	HB	5.70	7.400	9.90	- 15		
2/61	FIL			F	26	HB	6.00	7.400	9.90	- 15		
2/61	FIL			F	26	GLOBULINS: GAMMA	8.28	12.000	19.00	+ - 30		
10/72	TOR			H	-1	GAMMA-GT	109.00	8.000	38.00	+ 100		
10/72	TOR			H	4	GAMMA-GT	83.00	8.000	38.00	+ 100		
10/72	TOR			H	10	GLOBULINS: ALPHA 1	1.34	2.000	4.00	+ - 30		
10/72	TOR			H	-1	GLOBULINS: GAMMA	7.93	12.000	19.00	+ - 30		
10/72	TOR			H	2	GLOBULINS: GAMMA	8.32	12.000	19.00	+ - 30		
10/72	TOR	H	4	GLOBULINS: GAMMA	7.32	12.000	19.00	+ - 30				
PLACEBO	8	1/211	HJ	F	-1	GAMMA-GT	56.00	5.000	25.00	+ 100		
		1/211	HJ	F	26	GAMMA-GT	54.00	5.000	25.00	+ 100		
		1/211	HJ	F	34	TRIGLYCERIDES	3.00	0.800	1.70	+ 30		

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
DOUBLE BLIND PHASE

TREATMENT	CENTRE	PATIENT NO. OPEN/BLIND	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	% VARIATION TO CONSIDER CLIN. REL. (*)
PLACEBO	9	2/241	VCF	F	26	GLOBULINS: ALPHA 1	1.40	2.500	4.00	30
		2/241	VCF	F	42	PO4-	0.70	0.900	1.60	15
		5/242	MF	F	18	GLOBULINS: ALPHA 1	1.20	2.500	4.00	30
		5/242	MF	F	26	GLOBULINS: ALPHA 1	1.60	2.500	4.00	30
		5/242	MF	F	4	GLOBULINS: BETA	19.40	8.300	14.50	30
		5/242	MF	F	26	GLOBULINS: BETA	18.90	8.300	14.50	30
		5/242	MF	F	18	PO4-	0.70	0.900	1.60	15
		8/244	KTH	F	6	GAMMA-GT	62.00	4.000	28.00	100
		8/244	KTH	F	10	GLOBULINS: ALPHA 1	1.60	2.500	4.00	30
		8/244	KTH	F	18	GLOBULINS: ALPHA 1	1.60	2.500	4.00	30
		8/244	KTH	F	6	GLOBULINS: BETA	18.90	8.300	14.50	30
		8/244	KTH	F	24	CA++	1.40	1.800	2.60	15
		8/244	KTH	F	16	PO4-	0.50	0.900	1.60	15
		12/247	GYT	F	16	RUN	32.00	2.000	10.00	50
		12/247	GYT	F	-1	GLOBULINS: BETA	19.30	8.300	14.50	30
		12/247	GYT	F	4	TRIGLYCERIDES	2.80	0.300	1.80	30
		13/248	BP	F	10	PO4-	0.70	0.900	1.60	15
		13/248	BP	F	26	GLOBULINS: ALPHA 1	1.20	2.500	4.00	30
		13/248	BP	F	34	GLOBULINS: ALPHA 1	1.50	2.500	4.00	30
		13/248	BP	F	52	GLOBULINS: ALPHA 1	1.40	2.500	4.00	30
		13/248	BP	F	6	TRIGLYCERIDES	4.10	0.300	1.80	30
		13/248	BP	F	34	GLUCOSE	9.30	3.600	5.70	30
		13/248	BP	F	10	PO4-	0.70	0.900	1.60	15
		13/248	BP	F	26	PO4-	0.70	0.900	1.60	15
		19/251	KF	F	-1	GLOBULINS: ALPHA 1	1.70	2.500	4.00	30
		19/251	KF	F	4	GLOBULINS: ALPHA 1	0.80	2.500	4.00	30
		19/251	KF	F	6	GLOBULINS: ALPHA 1	1.50	2.500	4.00	30
		19/251	KF	F	18	GLOBULINS: ALPHA 1	1.50	2.500	4.00	30
		19/251	KF	F	6	PO4-	0.40	0.900	1.60	15
		25/254	PH	F	10	PLATELETS	78.00	120.000	640.00	-30
		25/254	PH	F	42	GAMMA-GT	66.00	4.000	28.00	100
		25/254	PH	F	4	GLOBULINS: ALPHA 1	1.30	2.500	4.00	30
		25/254	PH	F	10	GLOBULINS: ALPHA 1	1.50	2.500	4.00	30
		25/254	PH	F	18	GLOBULINS: ALPHA 1	1.30	2.500	4.00	30
		25/254	PH	F	34	GLOBULINS: ALPHA 1	1.30	2.500	4.00	30
		25/254	PH	F	42	GLOBULINS: ALPHA 1	6.40	2.500	4.00	30
		25/254	PH	F	42	GLOBULINS: ALPHA 2	18.20	7.000	10.00	30
		25/254	PH	F	2	GLOBULINS: BETA	20.30	8.300	14.50	30
		25/254	PH	F	6	GLOBULINS: BETA	21.30	8.300	14.50	30
		25/254	PH	F	10	GLOBULINS: BETA	22.10	8.300	14.50	30
		25/254	PH	F	18	GLOBULINS: BETA	20.30	8.300	14.50	30
		25/254	PH	F	34	GLOBULINS: BETA	22.50	8.300	14.50	30
		25/254	PH	F	-1	PO4-	0.70	0.900	1.60	15
		25/254	PH	F	4	PO4-	0.70	0.900	1.60	15

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2067

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013

Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
DOUBLE BLIND PHASE

TREATMENT	CENTRE	PATIENT NO. OPEN/BLIND	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	Z VARIATION TO CONSIDER CLIN. REL. (*)
PLACEBO	9	28/257	HI	M	-1	GLOBULINS: ALPHA 1	1.00	2.500	4.00	++
		28/257	HI	M	2	GLOBULINS: ALPHA 1	0.90	2.500	4.00	++
		28/257	HI	M	6	GLOBULINS: ALPHA 1	0.80	2.500	4.00	++
		4/272	ZSD	F	6	BUN	15.80	3.300	10.00	+
		5/273	AN	F	10	P04-	1.59	0.600	1.30	++
		10/276	MH	F	4	GLOBULINS: ALPHA 2	3.30	5.000	9.00	++
PLACEBO	10	14/279	AA	M	4	URIC ACID	466.00	119.000	357.00	+
		14/279	AA	M	10	GLOBULINS: ALPHA 2	11.90	5.000	9.00	++
		19/284	TN	F	-1	GLOBULINS: ALPHA 2	12.40	5.000	9.00	++
		21/288	AK	F	6	P04-	1.50	0.600	1.30	++
		21/288	AK	F	10	P04-	1.60	0.600	1.30	++
		24/289	AL	M	34	HBC	2.80	4.000	8.80	+
		24/289	AL	M	2	SEPT	21.00	1.000	9.00	+
		30/294	VK	F	-1	HIC	0.31	0.370	0.47	-
		30/294	VK	F	52	GLOBULINS: GAMMA	6.40	10.000	17.00	++
		42/295	TT	F	34	TRIGLYCERIDES	2.68	0.450	1.86	+
		42/295	TT	M	2	URIC ACID	560.00	119.000	357.00	+
		42/295	TT	M	4	URIC ACID	585.00	119.000	357.00	+
		43/296	IK	F	6	URIC ACID	563.00	119.000	357.00	+
		44/296	IK	F	-1	K+	7.20	4.000	5.60	++
		47/29	AB	M	6	URIC ACID	490.00	119.000	357.00	+
		47/29	TH	F	10	HBC: L	10.00	18.000	38.00	+
		47/29	TH	F	10	TRIGLYCERIDES	2.44	0.450	1.86	+
		47/29	TH	F	42	TRIGLYCERIDES	2.98	0.450	1.86	+
		48/41	IP	F	6	GLOBULINS: ALPHA 1	8.00	1.300	6.00	++
		50/44	EE	M	52	DIR BILIRUBIN	10.80	0.500	4.30	++
		50/44	EE	M	6	GLOBULINS: ALPHA 2	12.30	5.000	9.00	++
		50/44	EE	M	52	GLOBULINS: ALPHA 2	2.90	5.000	9.00	++
		50/44	EE	M	4	TRIGLYCERIDES	3.28	0.450	1.86	+
		50/44	EE	M	10	TRIGLYCERIDES	4.17	0.450	1.86	+
		50/44	EE	M	26	TRIGLYCERIDES	3.53	0.450	1.86	+
		50/44	EE	M	-1	GLUCOSE	7.80	3.500	5.50	++
51/45	UL	F	6	TRIGLYCERIDES	2.68	0.450	1.86	+		
51/45	UL	F	10	TRIGLYCERIDES	3.96	0.450	1.86	+		
51/45	UL	F	6	P04-	3.00	0.600	1.30	++		
55/49	TP	M	26	HBC: L	12.00	18.000	38.00	+		
55/49	TP	M	2	P04-	3.63	0.600	1.30	++		
58/52	KK	F	34	GLOBULINS: GAMMA	6.40	10.000	17.00	++		
58/52	KK	F	52	P04	1.50	0.600	1.30	++		
81/46	JN	F	10	GLOBULINS: ALPHA 1	0.90	1.300	6.00	++		
88/276	AH	F	-1	GLOBULINS: ALPHA 2	13.70	5.000	9.00	++		

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
DOUBLE BLIND PHASE

TREATMENT	CENTRE	PATIENT NO. OPEN/BLIND	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	% VARIATION TO CONSIDER CLIN. REL. (%)		
PLACEBO	10	88/276	AH	F	18	GLOBULINS: ALPHA 2	11.90	5.000	9.00	+ - 30		
		88/276	AH	F	34	GLOBULINS: ALPHA 2	15.40	5.000	9.00	+ - 30		
		88/276	AH	F	34	GLOBULINS: BETA	1.00	5.000	13.00	+ - 30		
		88/276	AH	F	4	TRIGLYCERIDES	3.05	0.450	1.86	+ 30		
		88/276	AH	F	34	TRIGLYCERIDES	2.44	0.450	1.86	+ 30		
		88/276	AH	F	42	TRIGLYCERIDES	2.71	0.450	1.86	+ 30		
		88/276	AH	F	2	PO4-	1.52	0.600	1.30	+ - 15		
		92/75	LA	F	34	GLOBULINS: GAMMA	4.70	10.000	17.00	+ - 30		
		PLACEBO	11	1/372	DF	M	4	DIP BILIRUBIN	10.00	0.000	4.30	+ 100
				1/372	DF	M	-1	SGPT	85.00	5.000	23.00	+ 100
				1/372	DF	M	-1	GAMMA-GT	304.00	4.000	28.00	+ 100
				1/372	DF	M	2	GAMMA-GT	139.00	4.000	28.00	+ 100
				1/372	DF	M	4	GAMMA-GT	120.00	4.000	28.00	+ 100
				4/375	BA	M	-1	TRIGLYCERIDES	3.80	0.670	2.29	+ 30
				7/376	KK	F	6	RBC	3.20	5.000	10.00	- 30
				7/376	KK	F	10	RBC	3.10	5.000	10.00	- 30
7/376	KK			F	-1	SGPT	74.00	5.000	19.00	+ 100		
7/376	KK			F	26	SGPT	41.00	5.000	19.00	+ 100		
7/376	KK			F	-1	GAMMA-GT	64.00	4.000	18.00	+ 100		
7/376	KK			F	26	GAMMA-GT	57.00	4.000	18.00	+ 100		
7/376	KK			F	4	TOT. CHOLEST.	8.90	3.900	6.70	+ 30		
7/376	KK			F	18	TOT. CHOLEST.	10.40	3.900	6.70	+ 30		
7/376	KK			F	26	TOT. CHOLEST.	10.30	3.900	6.70	+ 30		
PLACEBO	12			5/95	ZSH	M	-1	RBC	3.77	4.500	5.00	- 15
		5/95	ZSH	M	6	RBC: N	36.00	60.000	70.00	- 30		
		5/95	ZSH	M	10	DIP BILIRUBIN	11.70	0.000	4.50	+ 100		
		5/95	ZSH	M	10	SGPT	104.00	5.000	30.00	+ 100		
		5/95	ZSH	M	10	SGPT	75.00	5.000	34.00	+ 100		
		5/95	ZSH	M	-1	GAMMA-GT	101.00	6.000	28.00	+ 100		
		5/95	ZSH	M	10	GAMMA-GT	64.00	6.000	28.00	+ 100		
		5/95	ZSH	M	16	GAMMA-GT	59.00	6.000	28.00	+ 100		
		12/364	PJ	F	10	SGPT	38.00	5.000	19.00	+ 100		
		12/364	PJ	F	26	SGPT	55.00	5.000	15.00	+ 100		
		12/364	PJ	F	10	SGPT	33.00	5.000	15.00	+ 100		
		12/364	PJ	F	42	SGPT	81.00	5.000	19.00	+ 100		
		12/364	PJ	F	42	GLOBULINS: GAMMA	23.05	7.000	17.00	+ 30		
		20/371	LJ	F	6	CL-	118.00	97.000	107.00	+ - 10		
		20/371	LJ	F	6	SGOT	34.00	5.000	15.00	+ 100		
		20/371	LJ	F	14	SGOT	31.00	5.000	15.00	+ 100		

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBORELINE - PROTOCOL 20124/013
 Listing No.: 12.2

LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
 DOUBLE BLIND PHASE

TREATMENT	CENTRE	PATIENT NO. OPEN/BLIND	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	% VARIATION TO CONSIDER CLIN. REL. (*)
PLACEBO	12	5/95	ZSH	M	18	GLOBULINS: ALPHA 1	0.08	0.025	0.05	+
		5/95	ZSH	M	4	GLOBULINS: ALPHA 2	0.04	0.070	0.13	+
		5/95	ZSH	M	4	GLOBULINS: BETA	0.04	0.080	0.14	+
		5/95	ZSH	M	10	GLOBULINS: BETA	0.05	0.080	0.14	+
		5/95	ZSH	M	-1	TRIGLYCERIDES	2.80	0.300	1.86	+
		5/95	ZSH	M	2	P04-	1.75	0.700	1.50	+
		6/98	MK	F	6	RBC	3.66	4.500	5.00	-
		6/98	MK	F	10	RBC	3.61	4.500	5.00	-
		6/98	MK	F	4	DIR BILIRUBIN	9.90	4.500	4.50	+
		6/98	MK	F	26	GAMMA-GT	59.00	6.000	28.00	+
		6/98	MK	F	26	GLOBULINS: ALPHA 1	0.07	0.025	0.05	+
		6/98	MK	F	18	GLOBULINS: ALPHA 2	0.04	0.070	0.13	+
		6/98	MK	F	6	GLOBULINS: BETA	0.04	0.080	0.14	+
		6/98	MK	F	2	TRIGLYCERIDES	2.90	0.300	1.86	+
		10/96	MK	F	2	HTC	0.31	0.380	0.46	-
		10/96	IP	F	18	HTC	0.31	0.380	0.46	-
		10/96	IP	F	-1	RBC	3.55	4.500	5.00	-
		10/96	IP	F	2	RBC	3.65	4.500	5.00	-
		10/96	IP	F	-1	GLOBULINS: ALPHA 1	0.07	0.025	0.05	+
		10/96	IP	F	10	GLOBULINS: ALPHA 1	0.02	0.025	0.05	+
		10/96	IP	F	18	GLOBULINS: ALPHA 1	0.08	0.025	0.05	+
		10/96	IP	F	-1	GLOBULINS: BETA	0.04	0.080	0.14	+
		10/96	IP	F	6	GLOBULINS: BETA	0.04	0.080	0.14	+
		10/96	IP	F	10	GLOBULINS: BETA	0.05	0.080	0.14	+
		10/96	IP	F	10	GLOBULINS: GAMMA	0.06	0.120	0.22	+
		11/94	ER	F	-1	DIR BILIRUBIN	13.60	0.000	4.50	+
		11/94	ER	F	-1	TOT. CHOLEST.	9.70	2.600	7.02	+
		11/94	ER	F	-1	TRIGLYCERIDES	2.80	0.300	1.86	+
		11/94	ER	F	6	CL-	68.00	97.000	107.00	+
		12/97	FSZ	F	-1	GLOBULINS: ALPHA 1	0.07	0.025	0.05	+
		12/97	FSZ	F	10	GLOBULINS: ALPHA 1	0.02	0.025	0.05	+
		12/97	FSZ	F	10	GLOBULINS: BETA	0.05	0.080	0.14	+
		12/97	FSZ	F	-1	TRIGLYCERIDES	2.90	0.300	1.86	+
		12/97	FSZ	F	10	TRIGLYCERIDES	3.50	0.300	1.86	+
		13/103	ISZ	F	4	CL-	73.00	97.000	107.00	+
		13/103	ISZ	F	4	DIR BILIRUBIN	12.00	0.000	4.50	+
		13/103	ISZ	F	-1	GAMMA-GT	59.00	6.000	28.00	+
		14/101	GSZ	F	10	GLOBULINS: ALPHA 2	0.05	0.070	0.13	+
		17/108	TK	K	26	PLATELETS	77.00	140.000	300.00	+
		17/108	TK	K	2	GLOBULINS: ALPHA 1	0.08	0.025	0.05	+
		17/108	TK	K	6	GLOBULINS: ALPHA 1	0.07	0.025	0.05	+

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2070

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 12.2
 LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
 DOUBLE BLIND PHASE

TREATMENT	CENTRE	PATIENT NO. OPEN/BLIND	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	% VARIATION TO CONSIDER CLIN. REL. (*)
PLACEBO	12	17/108	TK	M	10	GLOBULINS: ALPHA 1	0.08	0.025	0.05	30
		17/108	TK	M	18	GLOBULINS: ALPHA 1	0.07	0.025	0.05	30
		17/108	TK	M	-1	TRIGLYCERIDES	2.60	0.300	1.86	30
		17/108	TK	M	10	TRIGLYCERIDES	3.10	0.300	1.86	30
		18/109	LS	M	6	MBC: N	40.00	60.000	70.00	-30
		18/109	LS	M	10	GAMMA-GT	61.00	6.000	28.00	100
		18/109	LS	M	2	GLOBULINS: ALPHA 1	0.07	0.025	0.05	30
		18/109	LS	M	4	GLOBULINS: ALPHA 1	0.11	0.025	0.05	30
		18/109	LS	M	10	GLOBULINS: ALPHA 1	0.12	0.025	0.05	30
		18/109	LS	M	18	GLOBULINS: ALPHA 1	0.07	0.025	0.05	30
		18/109	LS	M	6	TRIGLYCERIDES	2.50	0.300	1.86	30
		20/107	KSZ	M	-1	MBC: N	37.00	60.000	70.00	-30
		20/107	KSZ	M	26	SGPT	113.00	5.000	30.00	100
		20/107	KSZ	M	10	SGPT	74.00	5.000	34.00	100
		20/107	KSZ	M	26	SGPT	157.00	5.000	34.00	100
		20/107	KSZ	M	-1	GAMMA-GT	70.00	6.000	28.00	100
		20/107	KSZ	M	26	GAMMA-GT	91.00	6.000	28.00	100
		20/107	KSZ	M	6	GLOBULINS: ALPHA 1	0.08	0.025	0.05	30
		20/107	KSZ	M	10	GLOBULINS: ALPHA 1	0.10	0.025	0.05	30
		20/107	KSZ	M	-1	GLOBULINS: BETA	0.06	0.060	0.14	30
		20/107	KSZ	M	26	GLUCOSE	7.60	3.300	5.90	30
		20/107	KSZ	M	18	FO4-	0.52	0.700	1.30	15
		22/111	HV	F	6	DIR BILIRUBIN	10.80	0.000	4.50	100
		22/111	HV	F	4	SGOT	99.00	5.000	30.00	100
		22/111	HV	F	42	SGPT	154.00	5.000	30.00	100
		22/111	HV	F	4	SGPT	148.00	5.000	34.00	100
		22/111	HV	F	42	SGPT	213.00	5.000	34.00	100
		22/111	HV	F	10	GLOBULINS: ALPHA 1	0.08	0.025	0.05	30
		22/111	HV	F	26	GLOBULINS: ALPHA 1	0.09	0.025	0.05	30
		22/111	HV	F	-1	TOT. CHOLEST.	9.30	2.600	7.02	30
		22/111	HV	F	4	TRIGLYCERIDES	4.60	0.300	1.86	30
		22/111	HV	F	6	TRIGLYCERIDES	2.70	0.300	1.86	30
		22/111	HV	F	10	TRIGLYCERIDES	3.30	0.300	1.86	30
		22/111	HV	F	42	TRIGLYCERIDES	4.20	0.300	1.86	30
		23/112	EN	F	6	GLOBULINS: ALPHA 1	0.08	0.025	0.05	30
		23/112	EN	F	10	GLOBULINS: ALPHA 1	0.13	0.025	0.05	30
		23/112	EN	F	18	GLOBULINS: ALPHA 1	0.07	0.025	0.05	30
		23/112	EN	F	6	CI-	83.00	97.000	107.00	10
		28/116	IV	F	-1	PRC	3.69	5.500	5.00	-15
		28/116	IV	F	-1	SGOT	90.00	5.000	30.00	100
		28/116	IV	F	-1	SGPT	166.00	5.000	34.00	100
		28/116	IV	F	-1	GAMMA-GT	61.00	6.000	28.00	100
		28/116	IV	F	2	GAMMA-GT	65.00	6.000	28.00	100
		28/116	IV	F	4	GLOBULINS: ALPHA 1	0.11	0.025	0.05	30

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

2074

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 12.2
 LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
 DOUBLE BLIND PHASE

TREATMENT	CENTRE	PATIENT NO. OPEN/BLIND	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	Z VARIATION TO CONSIDER CLIN. REL. (*S)		
PLACEBO	12	28/116	IV	F	10	GLOBULINS: ALPHA 1	0.09	0.025	0.05	++		
		28/116	IV	F	2	TRIGLYCERIDES	2.60	0.300	1.86	+		
		34/120	TGB	F	-1	GLOBULINS: ALPHA 1	0.13	0.025	0.05	++		
		34/120	TGB	F	2	GLOBULINS: ALPHA 1	0.07	0.025	0.05	++		
		34/120	TGB	F	4	GLOBULINS: ALPHA 1	0.18	0.025	0.05	++		
		34/120	TGB	F	6	GLOBULINS: ALPHA 1	0.09	0.025	0.05	++		
		34/120	TGB	F	26	CL-	83.00	97.000	107.00	++		
		35/119	LP	F	4	SGPT	89.00	5.000	30.00	+		
		35/119	LP	F	-1	SGPT	74.00	5.000	34.00	+		
		35/119	LP	F	2	SGPT	68.00	5.000	34.00	+		
		35/119	LP	F	4	SGPT	159.00	5.000	34.00	+		
		35/119	LP	F	-1	GAMMA-GT	145.00	6.000	28.00	+		
		35/119	LP	F	2	GAMMA-GT	107.00	6.000	28.00	+		
		35/119	LP	F	4	GAMMA-GT	96.00	6.000	28.00	+		
		35/119	LP	F	6	GAMMA-GT	116.00	6.000	28.00	+		
		35/119	LP	F	10	GAMMA-GT	99.00	6.000	28.00	+		
		35/119	LP	F	-1	GLOBULINS: ALPHA 1	0.14	0.025	0.05	++		
		35/119	LP	F	2	GLOBULINS: ALPHA 1	0.10	0.025	0.05	++		
		35/119	LP	F	4	GLOBULINS: ALPHA 1	0.08	0.025	0.05	++		
		35/119	LP	F	4	TRIGLYCERIDES	2.70	0.300	1.86	+		
		35/119	LP	F	10	TRIGLYCERIDES	5.10	0.300	1.86	+		
		35/119	LP	F	16	TRIGLYCERIDES	3.10	0.300	1.86	+		
		37/386	EK	F	-1	GLOBULINS: ALPHA 1	0.15	0.025	0.05	++		
		37/386	EK	F	-1	TRIGLYCERIDES	2.70	0.300	1.86	+		
		PLACEBO	13	2/224	TCS	F	52	WBC: N	35.00	60.000	70.00	-
				2/224	TCS	F	-1	GLOBULINS: ALPHA 1	9.00	2.000	6.00	++
				2/224	TCS	F	6	GLOBULINS: ALPHA 1	9.00	2.000	6.00	++
				2/224	TCS	F	42	TRIGLYCERIDES	3.70	0.500	2.00	+
				8/228	PK	F	18	WBC: N	40.00	60.000	70.00	-
				8/228	PK	F	-1	GLOBULINS: ALPHA 1	8.00	2.000	6.00	++
				8/228	PK	F	10	GLOBULINS: ALPHA 1	8.00	2.000	6.00	++
				8/228	PK	F	18	GLOBULINS: ALPHA 1	8.00	2.000	6.00	++
				8/228	PK	F	30	GLUCOSE	9.20	4.000	6.00	++
				9/229	SZS	M	4	CREATININE	177.00	50.000	100.00	+
9/229	SZS			M	-1	GAMMA-GT	138.00	10.000	40.00	+		
9/229	SZS			M	-1	GLOBULINS: ALPHA 1	8.00	2.000	6.00	++		
11/225	HS			F	-1	SGPT	127.00	10.000	40.00	+		
11/225	HS			F	-1	GAMMA-GT	195.00	10.000	40.00	+		
11/225	HS			F	2	GLOBULINS: ALPHA 1	8.00	2.000	6.00	++		
11/225	HS			F	6	GLOBULINS: ALPHA 1	8.00	2.000	6.00	++		
11/225	HS			F	34	GLOBULINS: ALPHA 1	8.00	2.000	6.00	++		

(*S) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBONETINE - PROTOCOL 20124/013
 Listing No.: 12.2
 LABORATORY DATA: CLINICALLY RELEVANT ABNORMALITIES
 DOUBLE BLIND PHASE

TREATMENT	CENTRE	PATIENT NO. OPEN/BLIND	INITIALS	SEX	VISIT	LABORATORY TEST	VALUE	MIN	MAX	Z VARIATION TO CONSIDER CLIN. REL. (%)
PLACEBO	13	11/225	HS	F	26	GLOBULINS: ALPHA 2	4.00	7.000	12.00	+-
		11/225	HS	F	2	P04-	0.82	1.000	1.50	+-
		11/225	HS	F	34	P04-	0.85	1.000	1.50	+-
		11/225	HS	F	52	P04-	0.81	1.000	1.50	+-
		14/217	DF	F	4	GLOBULINS: ALPHA 1	8.00	2.000	6.00	+-
		15/222	KG	F	-1	GAMMA-GT	105.00	10.000	40.00	+
		15/222	KG	F	2	GLOBULINS: ALPHA 1	8.00	2.000	6.00	+-
		15/222	KG	F	4	P04-	0.80	1.000	1.50	+-
		17/218	GSM	F	4	SGPT	104.00	10.000	40.00	+
		17/218	GSM	F	-1	GAMMA-GT	87.00	10.000	40.00	+
		17/218	GSM	F	6	GLOBULINS: ALPHA 1	8.00	2.000	6.00	+-
		17/218	GSM	F	10	GLOBULINS: ALPHA 1	9.00	2.000	6.00	+-
		17/218	GSM	F	18	GLOBULINS: ALPHA 1	9.00	2.000	6.00	+-

21
013

(*) MINUS INDICATES BELOW THE LOWER LIMIT OF NORMAL RANGE, PLUS ABOVE THE UPPER LIMIT OF NORMAL RANGE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No. : 12.5

URINALYSIS
 OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	WBC	RBC	Specific Gravity	Albumin	Glucose
1	1	MGA	-1	09NOV90	N	N	N	N	N
			2	30NOV90	N	N	N	N	N
			4	14DEC90	N	N	N	N	N
1	2	RAQ	6	28DEC90	N	N	N	N	N
			-1	09NOV90	N	N	N	N	N
			2	30NOV90	ND	ND	ND	ND	ND
1	3	TA	-1	09NOV90	N	N	N	N	N
			2	30NOV90	N	N	N	N	N
			4	14DEC90	N	N	N	N	N
1	4	DNC	6	28DEC90	N	N	N	N	N
			-1	13NOV90	N	N	N	N	N
			2	05DEC90	N	N	N	N	N
1	5	DB	4	19DEC90	N	N	N	N	N
			6	02JAN91	N	N	N	N	N
			-1	27NOV90	N	N	N	N	N
1	6	CPH	2	18DEC90	N	N	N	N	N
			4	02JAN91	N	N	N	N	N
			6	15JAN91	N	N	N	N	N
1	7	JSA	-1	30NOV90	N	N	N	N	N
			2	18DEC90	N	N	N	N	N
			-1	30NOV90	N	N	N	N	N
1	8	MYB	2	21DEC90	N	N	N	N	N
			4	04JAN91	N	N	N	N	N
			6	18JAN91	N	N	N	N	N
1	9	CCR	-1	19DEC90	N	N	N	N	N
			2	09JAN91	N	N	N	N	N
			4	23JAN91	N	N	N	N	N
1	10	LDL	6	06FEB91	N	N	N	N	N
			-1	25JAN91	N	N	N	N	N
			2	15FEB91	N	N	N	N	N
1	10	LDL	4	01MAR91	N	N	N	N	N
			6	15MAR91	N	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

2074

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No. : 12.3

URINALYSIS
 OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	RBC	WBC	Specific Gravity	Albumin	Glucose
1	11	VRT	-1	01MAR91	N	N	N	N	N
			2	22MAR91	N	N	N	N	N
			4	05APR91	N	N	N	N	N
1	12	SLT	6	19APR91	N	N	N	N	N
			-1	12MAR91	N	N	N	N	N
			2	02APR91	N	N	N	N	N
1	13	JR	4	16APR91	N	N	N	N	N
			6	30APR91	N	N	N	N	N
			-1	23APR91	N	N	N	N	N
1	14	MLC	2	14MAY91	ND	ND	ND	ND	ND
			-1	30APR91	N	N	N	N	N
			2	21MAY91	N	N	N	N	N
1	15	MAD	4	04JUN91	N	N	N	N	N
			6	18JUN91	N	N	N	N	N
			-1	30APR91	N	N	N	N	N
1	16	HBC	2	22MAY91	N	N	N	N	N
			4	05JUN91	N	N	N	N	N
			6	19JUN91	N	N	N	N	N
1	17	CEC	-1	10MAY91	N	N	N	N	N
			2	31MAY91	N	N	N	N	N
			4	14JUN91	N	N	N	N	N
1	18	TTH	6	28JUN91	N	N	N	N	N
			-1	14MAY91	N	N	N	N	N
			2	04JUN91	N	N	N	N	N
1	19	SR	4	18JUN91	N	N	N	N	N
			6	02JUL91	N	N	N	N	N
			-1	15MAY91	N	N	N	N	N
1	20	EFC	2	05JUN91	N	N	N	N	N
			4	19JUN91	N	N	N	N	N
			6	03JUL91	N	N	N	N	N
1	20	EFC	-1	21MAY91	N	N	N	N	N
			2	11JUN91	N	N	N	N	N
			4	25JUN91	N	N	N	N	N
1	20	EFC	6	09JUL91	N	N	N	N	N
			-1	24MAY91	N	N	N	N	N
			2	14JUN91	N	N	N	N	N
1	20	EFC	4	28JUN91	N	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

1075

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 RESOMETINE - PROTOCOL 20124/013
 Listing No. : 12.3
 URINALYSIS
 OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	WBC	RBC	Specific Gravity	Albumin	Glucose
1	20	EFC	6	12JUL91	N	N	N	N	N
1	21	VHC	-1	28MAY91	N	N	N	N	N
			2	18JUN91	N	N	N	N	N
			4	02JUL91	N	N	N	N	N
			6	16JUL91	N	N	N	N	N
1	22	SK	-1	04JUN91	N	N	N	N	N
			2	25JUN91	N	N	N	N	N
			4	09JUL91	N	N	N	N	N
			6	23JUL91	N	N	N	N	N
1	23	AR	-1	14JUN91	N	N	N	N	N
			2	05JUL91	N	N	N	N	N
1	24	LVF	-1	26JUN91	N	N	N	N	N
			2	16JUL91	N	N	N	N	N
			4	30JUL91	N	N	N	N	N
			6	13AUG91	N	N	N	N	N
1	25	AMR	-1	28JUN91	N	N	N	N	N
			2	19JUL91	N	N	N	N	N
			4	02AUG91	N	N	N	N	N
			6	16AUG91	N	N	N	N	N
1	26	OC	-1	02JUL91	N	N	N	N	N
			2	23JUL91	N	N	N	N	N
			4	06AUG91	N	N	N	N	N
			6	20AUG91	N	N	N	N	N
1	27	RK	-1	05JUL91	N	N	N	N	N
			2	26JUL91	N	N	N	N	N
			4	09AUG91	N	N	N	N	N
			6	23AUG91	N	N	N	N	N
1	28	RHK	-1	09JUL91	N	N	N	N	N
			2	30JUL91	N	N	N	N	N
			4	13AUG91	N	N	N	N	N
			6	27AUG91	N	N	N	N	N
1	29	AFO	-1	09JUL91	N	N	N	N	N
			2	30JUL91	N	N	N	N	N
			4	13AUG91	N	N	N	N	N
			6	27AUG91	N	N	N	N	N
1	30	ERV	-1	10JUL91	N	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

2076

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No. : 12.3

URINALYSIS
OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	MBC	RBC	Specific Gravity	Albumin	Glucose
1	30	ERV	2	31JUL91	N	N	N	N	N
			4	14AUG91	N	N	N	N	N
			6	28AUG91	N	N	N	N	N
1	31	MAH	-1	16JUL91	N	N	N	N	N
			2	06AUG91	N	N	N	N	N
			4	20AUG91	N	N	N	N	N
1	32	DEH	6	03SEP91	N	N	N	N	N
			-1	17JUL91	N	N	N	N	N
			2	07AUG91	N	N	N	N	N
1	33	OFC	4	21AUG91	N	N	N	N	N
			6	04SEP91	N	N	N	N	N
			-1	17JUL91	N	N	N	N	N
1	34	GMR	2	07AUG91	N	N	N	N	N
			4	21AUG91	N	N	N	N	N
			6	04SEP91	N	N	N	N	N
1	35	EMP	-1	31JUL91	N	N	N	N	N
			2	21AUG91	N	ND	ND	ND	ND
			4	04SEP91	N	ND	ND	ND	ND
1	36	LH	6	18SEP91	N	ND	N	ND	ND
			-1	20AUG91	N	N	N	N	N
			2	10SEP91	N	N	N	N	N
1	37	RF	4	24SEP91	N	N	N	N	N
			6	08OCT91	N	N	N	N	N
			-1	27AUG91	N	N	N	N	N
1	38	DBF	2	17SEP91	N	N	N	N	N
			4	01OCT91	N	N	N	N	N
			6	15OCT91	N	N	N	N	N
1	39	ASS	-1	10SEP91	N	N	N	N	A
			2	01OCT91	N	N	N	N	N
			4	15OCT91	N	N	N	N	N
1	39	ASS	6	29OCT91	N	N	N	N	N
			-1	17SEP91	N	N	N	N	N
			2	08OCT91	N	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

2077

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 RESOMETINE - PROTOCOL 20124/013
 Listing No. : 12.3

URINALYSIS
 OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	WBC	RBC	Specific Gravity	Albumin	Glucose
1	39	ASS	4	22OCT91	N	N	N	N	N
			6	05NOV91	N	N	N	N	N
1	40	EH	-1	17SEP91	N	N	N	N	N
			2	08OCT91	N	N	N	N	N
			4	22OCT91	N	N	N	N	N
			6	05NOV91	N	N	N	N	N
1	41	SFS	-1	17SEP91	N	N	N	N	N
			2	08OCT91	N	N	N	N	N
			4	22OCT91	N	N	N	N	N
			6	05NOV91	N	N	N	N	N
1	42	ICC	-1	25SEP91	N	N	N	N	N
			2	16OCT91	N	N	N	N	N
			4	30OCT91	N	N	N	N	N
			6	13NOV91	N	N	N	N	N
1	43	ARN	-1	25SEP91	N	N	N	N	N
			2	16OCT91	N	N	N	N	N
			4	30OCT91	N	N	N	N	N
			6	13NOV91	N	N	N	N	N
1	44	HAL	-1	01OCT91	N	N	N	N	N
			2	22OCT91	N	N	N	N	N
			4	05NOV91	N	N	N	N	N
			6	19NOV91	N	N	N	N	N
1	45	DFS	-1	01OCT91	N	N	N	N	N
			2	22OCT91	N	N	N	N	N
			4	05NOV91	N	N	N	N	N
			6	19NOV91	N	N	N	N	N
1	46	SP	-1	08OCT91	N	N	N	N	N
			2	29OCT91	N	N	N	N	N
			4	12NOV91	N	N	N	N	N
			6	26NOV91	N	N	N	N	N
1	47	MCS	-1	15OCT91	N	N	N	N	N
			2	05NOV91	N	N	N	N	N
			4	19NOV91	N	N	N	N	N
			6	03DEC91	N	N	N	N	N
1	48	SCH	-1	16OCT91	N	N	N	N	N
			2	06NOV91	N	N	N	N	N
			4	20NOV91	N	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

2078

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R6D
REBORETTINE - PROTOCOL 2012A/013
Listing No. : 12.3

URINALYSIS
OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	RBC	WBC	RBC	Specific Gravity	Albumin	Glucose
1	48	SCH	6	04DEC91	N	N	N	N	N	N
1	49	DAS	-1 2	18OCT91 08NOV91	N N	N N	N N	N N	N N	N N
1	50	MFA	-1 2 4 6	18OCT91 08NOV91 22NOV91 06DEC91	N N N N	N N N N	N N N N	N N N N	N N N N	N N N N
1	51	ASA	-1 2 4 6	18OCT91 08NOV91 22NOV91 06DEC91	N N N N	N N N N	N N N N	N N N N	N N N N	N N N N
1	52	MTS	-1 2 4 6	23OCT91 15NOV91 27NOV91 11DEC91	N N N N	N N N N	N N N N	N N N N	N N N N	N N N N
1	53	JFT	-1 2 4 6	23OCT91 15NOV91 27NOV91 11DEC91	N N N N	N N N N	N N N N	N N N N	N N N N	N N N N
1	54	JD	-1 2 4	29OCT91 19NOV91 03DEC91	N N N	N N N	N N N	N N N	N N N	N N N
1	55	DNG	-1 2 4 6	29OCT91 19NOV91 03DEC91 17DEC91	N N N N	N N N N	N N N N	N N N N	N N N N	N N N N
1	56	IAL	-1 2 4 6	29OCT91 19NOV91 03DEC91 17DEC91	N N N N	N N N N	N N N N	N N N N	N N N N	N N N N
1	57	SMC	-1 2	03DEC91 24DEC91	N N	N N	N N	N N	N N	N N
1	58	ARM	-1 2 4 6	03DEC91 24DEC91 07JAN92 21JAN92	N N N N	N N N N	N N N N	N N N N	N N N N	N N N N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

2079

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No. : 12.3

URINALYSIS
OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	RBC	RBC	Specific Gravity	Albumin	Glucose
1	59	SPF	-1	10DEC91	N	N	N	N	N
			2	31DEC91	N	N	N	N	N
			4	14JAN92	N	N	N	N	N
1	60	EM	6	28JAN92	N	N	N	N	N
			-1	13DEC91	N	N	N	N	N
			2	03JAN92	N	N	N	N	N
1	61	HVC	4	17JAN92	N	N	N	N	N
			6	31JAN92	N	N	N	N	N
			-1	13DEC91	N	N	N	N	N
1	62	WEA	2	03JAN92	N	N	N	N	N
			4	17JAN92	N	N	N	N	N
			6	31JAN92	N	N	N	N	N
1	63	JCL	-1	31DEC91	N	N	N	N	N
			2	21JAN92	N	N	N	N	N
			4	04FEB92	N	N	N	N	N
1	64	ENF	6	18FEB92	N	N	N	N	N
			-1	31DEC91	N	N	N	N	N
			2	22JAN92	N	N	N	N	N
1	65	FS	-1	10JAN92	N	N	N	N	N
			2	31JAN92	N	N	N	N	N
			4	14FEB92	N	N	N	N	N
1	66	TCG	6	28FEB92	N	N	N	N	N
			-1	14JAN92	N	N	N	N	N
			2	04FEB92	N	N	N	N	N
1	67	MAA	4	18FEB92	N	N	N	N	N
			6	04MAR92	N	N	N	N	N
			-1	14JAN92	N	N	N	N	N
1	68	HGS	2	04FEB92	N	N	N	N	N
			4	18FEB92	N	N	N	N	N
			-1	14JAN92	N	N	N	N	N

**** N = NOT DONE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 RENOXETINE - PROTOCOL 20124/013
 Listing No. : 12.3

URINALYSIS
 OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	MBC	RBC	Specific Gravity	Albumin	Glucose
1	68	MGS	6	04MAR92	N	N	N	N	N
1	69	RFA	-1	14JAN92	N	N	N	N	N
			2	04FEB92	N	N	N	N	N
			4	18FEB92	N	N	N	N	N
			6	04MAR92	N	N	N	N	N
1	70	MLM	-1	17JAN92	N	N	N	N	N
			2	07FEB92	N	N	N	N	N
			4	21FEB92	N	N	N	N	N
			6	06MAR92	N	N	N	N	N
1	71	ORV	-1	21JAN92	N	N	N	N	N
			2	11FEB92	N	N	N	N	N
			4	25FEB92	N	N	N	N	N
			6	10MAR92	N	N	N	N	N
1	72	RLJ	-1	21JAN92	N	N	N	N	N
			2	11FEB92	N	N	N	N	N
			4	25FEB92	N	N	N	N	N
			6	10MAR92	N	N	N	N	N
1	73	FHA	-1	21JAN92	N	N	N	N	N
			2	11FEB92	N	N	N	N	N
			4	25FEB92	N	N	N	N	N
			6	10MAR92	N	N	N	N	N
1	74	IVL	-1	21JAN92	N	N	N	N	N
			2	11FEB92	N	N	N	N	N
			4	25FEB92	N	N	N	N	N
			6	10MAR92	N	N	N	N	N
1	75	ELF	-1	24JAN92	N	N	N	N	N
			2	14FEB92	N	N	N	N	N
			4	28FEB92	N	N	N	N	N
			6	13MAR92	N	N	N	N	N
1	76	SFA	-1	31JAN92	N	N	N	N	N
			2	21FEB92	N	N	N	N	N
			4	06MAR92	N	N	N	N	N
			6	20MAR92	N	N	N	N	N
1	77	ACG	-1	31JAN92	N	N	N	N	N
			2	21FEB92	N	N	N	N	N
			4	06MAR92	N	N	N	N	N
			6	20MAR92	N	N	N	N	N

NONE = NO RESULT A = ABNORMAL ND = NOT DONE

2081

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D									
REBOXETINE - PROTOCOL 20124/013									
Listing No. : 12.3									
URINALYSIS									
OPEN PHASE									
Centre	Patient	Initials	Visit	Laboratory Date	RBC	RBC	Specific Gravity	Albumin	Glucose
1	78	SD	-1	31JAN92	N	N	N	N	N
			2	21FEB92	N	N	N	N	N
			4	06MAR92	N	N	N	N	N
1	79	JCK	6	20MAR92	N	N	N	N	N
			-1	31JAN92	N	N	N	N	N
			2	21FEB92	N	N	N	N	N
1	80	MEL	4	06MAR92	N	N	N	N	N
			6	20MAR92	N	N	N	N	N
			-1	31JAN92	N	N	N	N	N
1	81	HEB	2	21FEB92	N	N	N	N	N
			4	06MAR92	N	N	N	N	N
			6	20MAR92	N	N	N	N	N
1	82	RDS	-1	31JAN92	N	N	N	N	N
			2	21FEB92	N	N	N	N	N
			4	06MAR92	N	N	N	N	N
1	83	LFH	6	20MAR92	N	N	N	N	N
			-1	31JAN92	N	N	N	N	N
			2	21FEB92	N	N	N	N	N
1	84	IN	4	06MAR92	N	N	N	N	N
			6	20MAR92	N	N	N	N	N
			-1	31JAN92	N	N	N	N	N
1	85	MLP	2	21FEB92	N	N	N	N	N
			4	06MAR92	N	N	N	N	N
			6	20MAR92	N	N	N	N	N
1	86	MTF	-1	31JAN92	N	N	N	N	N
			2	21FEB92	N	N	N	N	N
			4	06MAR92	N	N	N	N	N
1	87	RDO	6	20MAR92	N	N	N	N	N
			-1	31JAN92	N	N	N	N	N
			2	21FEB92	N	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

2082

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMÁCIA CNS R8D
 RESOMETINE - PROTOCOL 20124/013
 Listing No. 1 12.3

URINALYSIS
 OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	WBC	RBC	Specific Gravity	Albumin	Glucose
1	87	MDO	2	24FEB92	N	N	N	N	N
			4	06MAR92	N	N	N	N	N
			6	20MAR92	N	N	N	N	N
1	88	YRL	-1	04FEB92	N	N	N	N	N
			2	25FEB92	N	N	N	N	N
			4	10MAR92	N	N	N	N	N
1	89	NHV	6	24MAR92	N	N	N	N	N
			-1	04FEB92	N	N	N	N	N
			2	25FEB92	N	N	N	N	N
1	90	JSS	4	10MAR92	N	N	N	N	N
			6	24MAR92	N	N	N	N	N
			-1	04FEB92	N	N	N	N	N
1	91	MSC	2	25FEB92	N	N	N	N	N
			4	10MAR92	N	N	N	N	N
			6	24MAR92	N	N	N	N	N
1	92	PSS	-1	04FEB92	N	N	N	N	N
			2	25FEB92	N	N	N	N	N
			4	10MAR92	N	N	N	N	N
1	93	AL	6	24MAR92	N	N	N	N	N
			-1	05FEB92	N	N	N	N	N
			2	26FEB92	N	N	N	N	N
1	94	RAB	4	11MAR92	N	N	N	N	N
			6	25MAR92	N	N	N	N	N
			-1	05FEB92	N	N	N	N	N
1	95	GNT	2	26FEB92	N	N	N	N	N
			4	11MAR92	N	N	N	N	N
			6	25MAR92	N	N	N	N	N
1	96	SPH	-1	05FEB92	N	N	N	N	N
			2	26FEB92	N	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

2083

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No. : 12.3

URINALYSIS
OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	WBC	RBC	Specific Gravity	Albumin	Glucose
1	96	SPK	4	11MAR92	N	N	N	N	N
			6	25MAR92	N	N	N	N	N
1	97	MND	-1	05FEB92	N	N	N	N	N
			2	26FEB92	N	N	N	N	N
			4	11MAR92	N	N	N	N	N
			6	25MAR92	N	N	N	N	N
1	98	YTT	-1	05FEB92	N	N	N	N	N
			2	26FEB92	N	N	N	N	N
			4	11MAR92	N	N	N	N	N
			6	25MAR92	N	N	N	N	N
1	99	LCD	-1	05FEB92	N	N	N	N	N
			2	26FEB92	N	N	N	N	N
			4	11MAR92	N	N	N	N	N
			6	25MAR92	N	N	N	N	N
1	100	JWA	-1	05FEB92	N	N	N	N	N
			2	26FEB92	N	N	N	N	N
			4	11MAR92	N	N	N	N	N
			6	25MAR92	N	N	N	N	N
1	101	JLL	-1	11FEB92	N	N	N	N	N
			2	04MAR92	N	N	N	N	N
			4	17MAR92	N	N	N	N	N
			6	31MAR92	N	N	N	N	N
1	102	ESF	-1	11FEB92	N	N	N	N	N
			2	04MAR92	N	N	N	N	N
			4	17MAR92	N	N	N	N	N
			6	31MAR92	N	N	N	N	N
1	103	JRA	-1	11FEB92	N	N	N	N	N
			2	04MAR92	N	N	N	N	N
1	104	MTF	-1	11FEB92	N	N	N	N	N
			2	04MAR92	N	N	N	N	N
			4	17MAR92	N	N	N	N	N
			6	31MAR92	N	N	N	N	N
1	105	ABS	-1	11FEB92	N	N	N	N	N
			2	04MAR92	N	N	N	N	N
			4	17MAR92	N	N	N	N	N
			6	31MAR92	N	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No. : 12.3

URINALYSIS
OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	WBC	RBC	Specific Gravity	Albumin	Glucose
1	106	MRN	-1	11FEB92	N	N	N	N	N
			2	04MAR92	N	N	N	N	N
			4	17MAR92	N	N	N	N	N
1	107	LAN	6	31MAR92	N	N	N	N	N
			-1	12FEB92	N	N	N	N	N
			2	06MAR92	N	N	N	N	N
1	108	STB	4	18MAR92	N	N	N	N	N
			6	01APR92	N	N	N	N	N
			-1	12FEB92	N	N	N	N	N
1	109	IPL	2	06MAR92	N	N	N	N	N
			4	18MAR92	N	N	N	N	N
			6	01APR92	N	N	N	N	N
1	110	TQO	-1	12FEB92	N	N	N	N	N
			2	04MAR92	N	N	N	N	N
			4	18MAR92	N	N	N	N	N
1	111	JBF	6	01APR92	N	N	N	N	N
			-1	12FEB92	N	N	N	N	N
			2	04MAR92	N	N	N	N	N
1	112	PSA	4	18MAR92	N	N	N	N	N
			6	01APR92	N	N	N	N	N
			-1	12FEB92	N	N	N	N	N
1	113	LPS	2	04MAR92	N	N	N	N	N
			4	18MAR92	N	N	N	N	N
			6	01APR92	N	N	N	N	N
1	114	CLF	-1	18FEB92	N	N	N	N	N
			2	10MAR92	N	N	N	N	N
			4	24MAR92	N	N	N	N	N
1	115	ELS	6	07APR92	N	N	N	N	N
			-1	18FEB92	N	N	N	N	N

N = NORMAL A = ABNORMAL ND = NOT DONE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBONETINE - PROTOCOL 20124/013
 Listing No. : 12.3

URINALYSIS
 OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	WBC	RBC	Specific Gravity	Albumin	Glucose
1	115	ELS	2	10MAR92	N	N	N	N	N
			4	24MAR92	N	N	N	N	N
			6	07APR92	N	N	N	N	N
1	116	NGA	-1	18FEB92	N	N	N	N	N
			2	10MAR92	N	N	N	N	N
			4	24MAR92	N	N	N	N	N
1	117	PSL	6	07APR92	N	N	N	N	N
			-1	18FEB92	N	N	N	N	N
			2	04MAR92	N	N	N	N	N
1	118	NVH	4	24MAR92	N	N	N	N	N
			6	07APR92	N	N	N	N	N
			-1	18FEB92	N	N	N	N	N
1	119	NVH	2	10MAR92	N	N	N	N	N
			4	24MAR92	N	N	N	N	N
			-1	18FEB92	N	N	N	N	N
1	120	JLB	2	10MAR92	N	N	N	N	N
			4	24MAR92	N	N	N	N	N
			6	07APR92	N	N	N	N	N
1	121	LAC	-1	19FEB92	N	N	N	N	N
			2	11MAR92	N	N	N	N	N
			4	25MAR92	N	N	N	N	N
1	122	HSS	6	08APR92	N	N	N	N	N
			-1	19FEB92	N	N	N	N	N
			2	11MAR92	N	N	N	N	N
1	123	MLL	4	25MAR92	N	N	N	N	N
			6	08APR92	N	N	N	N	N
			-1	19FEB92	N	N	N	N	N
1	124	PPC	2	11MAR92	N	N	N	N	N
			4	25MAR92	N	N	N	N	N
			-1	19FEB92	N	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

2086

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/013
 Listing No. : 12.3

URINALYSIS
 OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Data	RBC	RBC	Specific Gravity	Albumin	Glucose
1	124	PPC	6	08APR92	N	N	N	N	N
1	125	FDP	-1	19FEB92	N	N	N	N	N
			2	11MAR92	N	N	N	N	N
			4	25MAR92	N	N	N	N	N
			6	08APR92	N	N	N	N	N
1	126	SHB	-1	19FEB92	N	N	N	N	N
			2	11MAR92	N	N	N	N	N
			4	25MAR92	N	N	N	N	N
			6	08APR92	N	N	N	N	N
1	127	VPD	-1	19FEB92	N	N	N	N	N
			2	11MAR92	N	N	N	N	N
			4	25MAR92	N	N	N	N	N
			6	08APR92	N	N	N	N	N
1	128	LAM	-1	19FEB92	N	N	N	N	N
			2	11MAR92	N	N	N	N	N
			4	25MAR92	N	N	N	N	N
			6	08APR92	N	N	N	N	N
1	129	WNS	-1	19FEB92	N	N	N	N	N
			2	11MAR92	N	N	N	N	N
			4	25MAR92	N	N	N	N	N
			6	08APR92	N	N	N	N	N
1	130	EGA	-1	21FEB92	N	N	N	N	N
			2	13MAR92	N	N	N	N	N
			4	27MAR92	N	N	N	N	N
			6	10APR92	N	N	N	N	N
1	131	RHR	-1	06MAR92	N	N	N	N	N
			2	26MAR92	N	N	N	N	N
			4	07APR92	N	N	N	N	N
			6	20APR92	N	N	N	N	N
1	132	MAT	-1	11MAR92	N	N	N	N	N
			2	07APR92	N	N	N	N	N
			4	08APR92	N	N	N	N	N
			6	29APR92	N	N	N	N	N
1	133	JPM	-1	13MAR92	N	N	N	N	N
			2	03APR92	N	N	N	N	N
			4	17APR92	N	N	N	N	N
			6	30APR92	N	N	N	N	N

***. W = WASH. I = IRRITANT. N = NOT DONE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REROXETINE - PROTOCOL 20124/013
 Listing No. : 12.3

Centre	Patient	Initials	Visit	Laboratory Date	MBC	RBC	Specific Gravity	Albumin	Glucose	URINALYSIS OPEN PHASE				
1	134	LMS	-1	17MAR92	N	N	N	N	N					
			2	07APR92	N	N	N	N	N	N				
			4	20APR92	N	N	N	N	N	N	N			
1	135	MHS	6	05MAY92	N	N	N	N	N	N				
			-1	17MAR92	N	N	N	N	N	N	N			
			2	07APR92	N	N	N	N	N	N	N			
1	136	AVP	4	20APR92	N	N	N	N	N	N				
			6	05MAY92	N	N	N	N	N	N	N			
			-1	17MAR92	N	N	N	N	N	N	N	N		
1	137	CME	2	07APR92	N	N	N	N	N	N				
			4	20APR92	N	N	N	N	N	N	N			
			6	05MAY92	N	N	N	N	N	N	N	N		
1	138	LBV	-1	17MAR92	N	N	N	N	N	N				
			2	07APR92	N	N	N	N	N	N	N			
			4	20APR92	N	N	N	N	N	N	N	N		
1	139	RA	6	05MAY92	N	N	N	N	N	N				
			-1	17MAR92	N	N	N	N	N	N	N	N		
			2	07APR92	N	N	N	N	N	N	N	N		
1	140	MCA	4	20APR92	N	N	N	N	N	N				
			6	05MAY92	N	N	N	N	N	N	N	N		
			-1	17MAR92	N	N	N	N	N	N	N	N		
1	141	ANG	2	07APR92	N	N	N	N	N	N				
			4	20APR92	N	N	N	N	N	N	N	N		
			6	05MAY92	N	N	N	N	N	N	N	N		
1	142	SCC	-1	17MAR92	N	N	N	N	N	N				
			2	07APR92	N	N	N	N	N	N	N	N		
			4	20APR92	N	N	N	N	N	N	N	N		
1	143	JEP	6	05MAY92	N	N	N	N	N	N				
			-1	17MAR92	N	N	N	N	N	N	N	N		

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REDUXTINE - PROTOCOL 20124/013
 Listing No. : 12.3

URINALYSIS
 OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	WBC	RBC	Specific Gravity	Albumin	Glucose
1	143	JEP	2	07APR92	N	N	N	N	N
			4	20APR92	N	N	N	N	N
			6	05MAY92	N	N	N	N	N
1	144	ARF	-1	18MAR92	N	N	N	N	N
			2	08APR92	N	N	N	N	N
			4	22APR92	N	N	N	N	N
1	145	SLD	6	06MAY92	N	N	N	N	N
			-1	20MAR92	N	N	N	N	N
			2	10APR92	N	N	N	N	N
1	146	LRH	4	24APR92	N	N	N	N	N
			6	08MAY92	N	N	N	N	N
			-1	20MAR92	N	N	N	N	N
1	147	JGM	2	10APR92	N	N	N	N	N
			4	24APR92	N	N	N	N	N
			6	08MAY92	N	N	N	N	N
1	148	CAS	-1	20MAR92	N	N	N	N	N
			2	10APR92	N	N	N	N	N
			4	24APR92	N	N	N	N	N
1	149	SC	6	08MAY92	N	N	N	N	N
			-1	20MAR92	N	N	N	N	N
			2	10APR92	N	N	N	N	N
1	150	VA	4	24APR92	N	N	N	N	N
			6	08MAY92	N	N	N	N	N
			-1	20MAR92	N	N	N	N	N
2	31	IK	2	03NOV90	N	N	ND	N	N
			4	07DEC90	N	N	ND	N	N
			2	23NOV90	N	N	ND	N	N
2	32	GE	-1	05DEC90	N	N	ND	N	N
			2	24DEC90	N	N	ND	N	N
2	33	RS	-1	06JAN91	N	N	ND	N	N
			2	28JAN91	N	N	ND	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

2089

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No. : 12.3

URINALYSIS
OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	MBC	RBC	Specific Gravity	Albumin	Glucose
2	34	EH	-1	22MAR91	N	N	ND	N	N
			2	10APR91	N	N	ND	N	N
			4	24APR91	N	N	ND	N	N
3	1	AMR	-1	09NOV90	N	N	ND	N	N
			-1	02NOV90	N	N	N	N	N
3	2	FIL	2	30NOV90	N	N	N	N	N
			4	14DEC90	N	N	N	N	N
			6	28DEC90	N	N	N	N	N
			-1	25MAR91	ND	ND	ND	ND	ND
3	3	DUB	2	25APR91	N	N	ND	N	N
			4	25APR91	ND	ND	ND	ND	ND
3	4	AUD	-1	29NOV90	N	N	N	N	N
			2	21DEC90	N	N	N	N	N
3	5	MMA	4	04JAN91	N	N	N	N	N
			-1	20DEC90	N	N	ND	N	N
3	6	AJP	-1	29NOV90	N	N	ND	N	N
			-1	10DEC90	N	N	N	N	N
3	7	GRI	2	25DEC90	N	N	ND	N	N
			4	08JAN91	N	N	ND	N	N
			6	22JAN91	N	N	ND	N	N
			-1	10JAN91	N	N	N	N	N
3	9	DEN	-1	03APR91	N	N	ND	N	N
			2	24APR91	ND	ND	ND	ND	ND
3	10	TOR	4	08MAY91	N	N	ND	N	N
			6	22MAY91	N	N	ND	N	N
			-1	17MAY91	N	N	ND	N	N
			-1	27NOV90	N	N	N	N	N
8	1	HJ	2	17DEC90	N	N	N	N	N
			4	30DEC90	N	N	N	N	N
			6	14JAN91	N	N	N	N	N
			-1	10DEC90	N	N	N	N	N
8	2	TE	2	27DEC90	N	N	N	N	N
			4	10JAN91	N	N	N	N	N
			6	24JAN91	N	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No. : 12.3

URINALYSIS
OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	MBC	RBC	Specific Gravity	Albumin	Glucose
8	3	JL	-1	14DEC90	N	N	N	N	N
			2	03JAN91	N	N	N	N	N
			4	17JAN91	N	N	N	N	N
8	4	BA	6	31JAN91	N	N	N	N	N
			-1	04JAN91	N	N	N	N	N
			2	24JAN91	N	N	N	N	N
8	5	SL	4	07FEB91	N	N	N	N	N
			6	21FEB91	N	N	N	N	N
			-1	08JAN91	N	N	N	N	N
8	6	TL	2	28JAN91	N	N	N	N	N
			4	14FEB91	N	N	N	N	N
			6	25FEB91	N	N	N	N	N
8	7	SZT	-1	15JAN91	N	N	N	N	N
			2	04FEB91	N	N	N	N	N
			4	18FEB91	N	N	N	N	N
9	1	US	6	04MAR91	N	N	N	N	N
			-1	15MAR91	N	N	N	N	N
			2	04APE91	N	N	N	N	N
9	2	VCF	-1	21MAY90	N	N	N	N	N
			2	11JUN90	N	N	N	N	N
			4	25JUN90	N	N	N	N	N
9	3	SF	6	09JUL90	N	N	N	N	N
			-1	21MAY90	N	N	N	N	N
			2	11JUN90	N	N	N	N	N
9	4	SA	4	25JUN90	N	N	N	N	N
			6	09JUL90	N	N	N	N	N
			-1	07AUG90	N	N	N	N	N
9	5	MF	2	28AUG90	N	N	N	N	N
			4	11SEP90	N	N	N	N	N
			6	25SEP90	ND	N	N	N	N
9	6	MF	-1	24AUG90	N	N	N	N	N
			2	14SEP90	N	N	N	N	N
			4	28SEP90	N	N	N	N	N
9	7	MF	6	12OCT90	N	N	N	N	N
			-1	15SEP90	N	N	N	N	N
			2	06OCT90	N	N	N	N	N
9	8	MF	4	20OCT90	N	N	N	N	N

N = NORMAL A = ABNORMAL ND = NOT DONE

9550077

2091

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

Centre	Patient	Initials	Visit	Laboratory Date	RBC	Specific Gravity	Albumin	Glucose
9	5	HF	6	03NOV90	N	N	N	N
9	6	SD	-1	30OCT90	N	N	N	N
			2	20NOV90	N	N	N	N
			4	04DEC90	N	N	N	N
			6	18DEC90	N	N	N	N
9	7	PP	-1	08NOV90	N	N	N	N
			2	22NOV90	N	N	N	N
			4	06DEC90	N	N	N	N
			6	20DEC90	N	N	N	N
9	8	KTH	-1	19NOV90	N	N	N	N
			2	06DEC90	N	N	N	N
			4	18DEC90	N	N	N	N
			6	02JAN91	N	N	N	N
9	9	PL	-1	22NOV90	N	N	N	N
			2	06DEC90	N	N	N	N
			4	21DEC90	N	N	N	N
			6	04JAN91	N	N	N	N
9	10	BC	-1	03JAN91	N	N	N	N
			2	24JAN91	N	N	N	N
			4	07FEB91	N	N	N	N
			6	21FEB91	N	N	N	N
9	11	KE	-1	22JAN91	N	N	N	N
			2	12FEB91	N	N	N	N
			4	26FEB91	N	N	N	N
			6	12MAR91	N	N	N	N
9	12	GXT	-1	27FEB91	N	N	N	N
			2	19MAR91	N	N	N	N
			4	02APR91	N	N	N	N
			6	16APR91	N	N	N	N
9	13	BP	-1	07MAR91	N	N	N	N
			2	26MAR91	N	N	N	N
			4	10APR91	N	N	N	N
			6	24APR91	N	N	N	N
9	14	SZF	-1	18MAR91	N	N	N	N
			2	07APR91	N	N	N	N
			4	21APR91	N	N	N	N
			6	05MAY91	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD
 REBOXTINE - PROTOCOL 20124/013
 Listing No. : 12.3

URINALYSIS
 OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	HBC	RBC	Specific Gravity	Albumin	Glucose
9	15	BI	-1	12MAY91	N	N	ND	N	N
			2	03JUN91	N	N	N	N	N
			4	17JUN91	N	N	N	N	N
9	16	UGY	6	01JUL91	N	N	N	N	N
			-1	03JUL91	N	N	N	N	N
			2	30JUL91	N	N	ND	N	N
9	17	NL	4	06AUG91	N	N	N	N	N
			6	20AUG91	N	N	N	N	N
			-1	04JUL91	N	N	ND	N	N
9	18	MBH	-1	09JUL91	N	N	N	N	N
			2	22JUL91	N	N	N	N	N
			4	05AUG91	ND	RD	ND	ND	ND
9	19	KF	6	25AUG91	N	N	ND	N	N
			-1	07AUG91	N	N	ND	N	N
			2	27AUG91	N	N	ND	N	N
9	20	GYE	4	16SEP91	N	N	ND	N	N
			6	24SEP91	N	N	N	N	N
			-1	22AUG91	N	N	N	N	N
9	21	TA	2	06SEP91	N	N	N	N	N
			4	20SEP91	N	N	N	N	N
			6	04OCT91	N	N	N	N	N
9	22	RKE	-1	19OCT91	N	N	N	N	N
			2	08NOV91	N	N	N	N	N
			4	22NOV91	N	N	N	N	N
9	23	SZN	6	06DEC91	N	N	N	N	N
			-1	24OCT91	N	N	N	N	N
			2	01NOV91	N	N	N	N	N
9	24	LCY	4	22NOV91	ND	ND	RD	ND	ND
			6	06DEC91	N	N	N	N	N
			-1	04NOV91	N	N	N	N	N
9	24	LCY	2	25NOV91	N	N	RD	K	K
			4	09DEC91	N	N	N	K	K
			6	19DEC91	N	N	ND	N	N

**** V = VISIT ; D = DROPOUT ; N = NOT DONE

2093

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D									
REBOXETINE - PROTOCOL 20124/013									
Listing No. : 12.3									
URINALYSIS									
OPEN PHASE									
Centre	Patient	Initials	Visit	Laboratory Date	RBC	RBC	Specific Gravity	Albumin	Glucose
9	25	PH	-1	15NOV91	N	N	ND	N	N
			2	03DEC91	N	N	ND	N	N
			4	17DEC91	N	N	N	N	N
9	26	CP	6	31DEC91	ND	ND	ND	ND	ND
			-1	21NOV91	N	N	N	N	N
			2	05DEC91	N	N	ND	N	N
9	27	ZSL	4	19DEC91	N	N	N	N	N
			6	31DEC91	N	N	ND	N	N
			-1	26MAR92	N	N	N	N	N
9	28	HI	2	10APR92	N	N	ND	N	N
			4	24APR92	N	N	ND	N	N
			-1	07APR92	N	N	N	N	N
9	29	SZF	2	17APR92	N	N	N	N	N
			4	04MAY92	N	N	N	N	N
			6	15MAY92	N	N	N	N	N
9	30	NF	-1	07APR92	N	N	N	N	N
			2	17APR92	N	N	ND	N	N
			4	04MAY92	N	N	ND	N	N
10	1	VK	6	18MAY92	N	N	N	N	N
			-1	03OCT90	N	N	N	N	N
			2	30OCT90	N	N	N	N	N
10	4	ZSD	4	13NOV90	N	N	N	N	N
			6	27NOV90	N	N	N	N	N
			-1	24OCT90	N	N	N	N	N
10	5	AN	2	14NOV90	N	N	N	N	N
			4	28NOV90	N	N	N	N	N
			6	11DEC90	N	N	N	N	N
10	6	RS	-1	07NOV90	N	N	N	N	N
			2	28NOV90	N	N	N	N	N
			4	11DEC90	N	N	N	N	N
10	6	RS	6	27DEC90	N	N	N	N	N
			-1	12NOV90	N	N	N	N	N
			2	29NOV90	N	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

2094

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REDOXETINE - PROTOCOL 20124/013
 Listing No. : 12.3

URINALYSIS
 OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	RBC	Specific Gravity	Albumin	Glucose
10	6	RS	4	11DEC90	N	N	N	N
			5	08JAN91	N	N	N	N
10	7	RK	-1	13NOV90	N	N	N	N
			2	04DEC90	N	N	N	N
			4	18DEC90	N	N	N	N
			6	03JAN91	N	N	N	N
10	8	VP	-1	26NOV90	N	N	N	N
			2	11DEC90	N	N	N	N
			3	18DEC90	N	N	N	N
10	9	RT	-1	04DEC90	N	N	N	N
			2	18DEC90	N	N	N	N
			4	03JAN91	N	N	N	N
			6	15JAN91	N	N	N	N
10	10	MR	-1	30NOV90	N	N	N	N
			2	18DEC90	N	N	N	N
			4	03JAN91	N	N	N	N
			6	15JAN91	N	N	N	N
10	11	TM	-1	19DEC90	N	N	N	N
			2	14JAN91	N	N	N	N
10	12	EP	-1	08JAN91	N	N	N	N
			2	23JAN91	N	N	N	N
			4	06FEB91	N	N	N	N
			6	20FEB91	N	N	N	N
10	13	HU	-1	06FEB91	N	N	N	N
			2	26FEB91	N	N	N	N
			4	19MAR91	N	N	N	N
			6	27MAR91	N	N	N	N
10	14	AA	-1	06FEB91	N	N	N	N
			2	26FEB91	N	N	N	N
			4	12MAR91	N	N	N	N
			6	27MAR91	N	N	N	N
10	15	HT	-1	19FEB91	N	N	N	N
			2	06MAR91	N	N	N	N
			4	20MAR91	N	N	N	N
			6	03APE91	N	N	N	N
10	16	AJ	-1	26FEB91	N	N	N	N

0095

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No. : 12.3

URINALYSIS
OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	WBC	RBC	Specific Gravity	Albumin	Glucose
10	16	AJ	2	19MAR91	N	N	N	N	N
			4	02APR91	N	N	N	N	N
			6	17APR91	N	N	N	N	N
10	17	MH	-1	07MAR91	N	N	N	N	N
			2	27MAR91	N	N	N	N	N
			4	10APR91	N	N	N	N	N
			6	24APR91	N	N	N	N	N
10	18	SS	-1	14MAR91	N	N	N	N	N
			2	08APR91	N	N	N	N	N
			4	16APR91	N	N	N	N	N
			-1	27MAR91	N	N	N	N	N
10	19	TN	2	17APR91	N	N	N	N	N
			4	29APR91	N	N	N	N	N
			6	15MAY91	N	N	N	N	N
			-1	17APR91	N	N	N	N	N
10	20	EJ	2	07MAY91	N	N	N	N	N
			4	22MAY91	N	N	N	N	N
			6	04JUN91	N	N	N	N	N
			-1	17APR91	N	N	N	N	N
10	21	AK	2	16MAY91	N	N	N	N	N
			4	27MAY91	N	N	N	N	N
			6	10JUN91	N	N	N	N	N
			-1	17APR91	N	N	N	N	N
10	22	AA	2	07MAY91	N	N	N	N	N
			4	21MAY91	N	N	N	N	N
			6	04JUN91	N	N	N	N	N
			-1	23APR91	N	N	N	N	N
10	23	LT	2	07MAY91	N	N	N	N	N
			4	22MAY91	N	N	N	N	N
			6	05JUN91	N	N	N	N	N
			-1	24APR91	N	N	N	N	N
10	24	AL	2	16MAY91	N	N	N	N	N
			4	29MAY91	N	N	N	N	N
			6	12JUN91	N	N	N	N	N
			-1	13MAY91	N	N	N	N	N
10	25	ES	2	28MAY91	N	N	N	N	N
			-1	13MAY91	N	N	N	N	N

URINALYSIS = NORMAL A = ABNORMAL ND = NOT DONE

2096

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No. : 12.3

URINALYSIS
OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	MBC	RBC	Specific Gravity	Albumin	Glucose
10	26	JIF	-1	27MAY91	N	N	N	N	N
			2	12JUN91	N	N	N	N	N
			4	26JUN91	N	N	N	N	N
10	27	MK	6	08JUL91	N	N	N	N	N
			-1	29MAY91	N	N	N	N	N
			2	20JUN91	N	N	N	N	N
10	28	LL	4	01JUL91	N	N	N	N	N
			6	15JUL91	N	N	N	N	N
			-1	28MAY91	N	N	N	N	N
10	29	JJ	2	12JUN91	N	N	N	N	N
			4	26JUN91	N	N	N	N	N
			6	10JUL91	N	N	N	N	N
10	30	VK	-1	14AUG91	N	N	N	N	N
			2	02SEP91	N	N	N	N	N
			4	17SEP91	N	N	N	N	N
10	31	RK	6	30SEP91	N	N	N	N	N
			-1	12SEP91	N	N	N	N	N
			2	30SEP91	N	N	N	N	N
10	32	LK	4	16OCT91	N	N	N	N	N
			6	29OCT91	N	N	N	N	N
			-1	12SEP91	N	N	N	N	N
10	33	EK	2	30SEP91	N	N	N	N	N
			4	15OCT91	N	N	N	N	N
			6	28OCT91	N	N	N	N	N
10	34	TK	-1	16SEP91	N	N	N	N	N
			2	02OCT91	N	N	N	N	N
			4	16OCT91	N	N	N	N	N
10	35	ZH	6	30OCT91	N	N	N	N	N
			-1	18SEP91	N	N	N	N	N
			2	08OCT91	N	N	N	N	N
10	35	ZH	4	22OCT91	N	N	N	N	N
			6	05NOV91	N	N	N	N	N
			-1	18SEP91	N	N	N	N	N

*** N = NORMAL I = UNNORMAL ND = NOT DONE

2097

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No. : 12.3

URINALYSIS
OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	RBC	RBC	Specific Gravity	Albumin	Glucose
10	35	IM	2	09OCT91	N	N	N	N	N
			4	22OCT91	N	N	N	N	N
			6	05NOV91	N	N	N	N	N
10	36	AK	-1	08OCT91	N	N	N	N	N
			2	29OCT91	N	N	N	N	N
			4	12NOV91	N	N	N	N	N
10	37	HK	2	26NOV91	N	N	N	N	N
			4	08OCT91	N	N	N	N	N
			6	30OCT91	N	N	N	N	N
10	38	LL	2	12NOV91	N	N	N	N	N
			4	26NOV91	N	N	N	N	N
			6	09OCT91	N	N	N	N	N
10	39	VH	-1	29OCT91	N	N	N	N	N
			2	14OCT91	N	N	N	N	N
			4	29OCT91	N	N	N	N	N
10	40	AP	2	11NOV91	N	N	N	N	N
			4	26NOV91	N	N	N	N	N
			6	06NOV91	N	N	N	N	N
10	41	VP	-1	22OCT91	N	N	N	N	N
			2	06NOV91	N	N	N	N	N
			4	20NOV91	N	N	N	N	N
10	42	TT	2	04DEC91	N	N	N	N	N
			4	29OCT91	N	N	N	N	N
			6	12NOV91	N	N	N	N	N
10	43	IK	-1	27NOV91	N	N	N	N	N
			2	11DEC91	N	N	N	N	N
			4	25DEC91	N	N	N	N	N
10	44	AB	2	14NOV91	N	N	N	N	N
			4	28NOV91	N	N	N	N	N
			6	12DEC91	N	N	N	N	N
10	44	AB	-1	26DEC91	A	N	N	A	N
			2	17NOV91	N	N	N	N	N
				01DEC91	N	N	N	N	N

Legend: N = Normal ND = NOT DONE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No. : 12.3

URINALYSIS
 OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	WBC	RBC	Specific Gravity	Albumin	Glucose
10	44	AB	4	15DEC91	N	N	N	N	N
			6	29DEC91	N	N	N	N	N
10	45	KJ	-1	18NOV91	N	N	N	N	N
			2	03DEC91	N	N	N	N	N
			4	17DEC91	N	N	N	N	N
10	46	TN	6	31DEC91	N	N	N	N	N
			-1	28NOV91	N	N	N	N	N
			2	16DEC91	N	N	N	N	N
10	47	TH	4	30DEC91	N	N	N	N	N
			6	13JAN92	N	N	N	N	N
			-1	26NOV91	N	N	N	N	N
10	48	IP	2	18DEC91	N	N	N	N	N
			4	07JAN92	N	N	N	N	N
			6	15JAN92	N	N	N	N	N
10	49	VH	-1	04DEC91	N	N	N	N	N
			2	24DEC91	N	N	N	N	N
			4	07JAN92	N	N	N	N	N
10	50	EE	6	21JAN92	N	N	N	N	N
			-1	18DEC91	N	N	N	N	N
			2	01JAN92	N	N	N	N	N
10	51	UL	4	15JAN92	N	N	N	N	N
			6	29JAN92	N	N	N	N	N
			-1	18DEC91	N	N	N	N	N
10	52	MP	2	01JAN92	N	N	N	N	N
			4	15JAN92	N	N	N	N	N
			6	29JAN92	N	N	N	N	N
10	53	MA	-1	13JAN92	N	N	N	N	N
			2	27JAN92	N	N	N	N	N
			4	10FEB92	N	N	N	N	N
10	54	UN	-1	12JAN92	N	N	N	N	N
			2	26JAN92	N	N	N	N	N
			-1	12JAN92	N	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

2099

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXYETINE - PROTOCOL 20124/013
 Listing No. : 12.3

URINALYSIS
 OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	WBC	REC	Specific Gravity	Albumin	Glucose	
10	54	UN	2	26JAN92	N	N	N	N	N	
			4	09FEB92	N	N	N	N	N	
			6	23FEB92	N	N	N	N	N	N
10	55	TP	-1	13JAN92	N	N	N	N	N	
			2	27JAN92	N	N	N	N	N	
			4	10FEB92	N	N	N	N	N	N
10	56	JP	6	24FEB92	N	N	N	N	N	
			-1	08JAN92	N	N	N	N	N	N
			2	27JAN92	N	N	N	N	N	N
10	57	AG	4	10FEB92	N	N	N	N	N	
			6	24FEB92	N	N	N	N	N	N
			-1	13JAN92	N	N	N	N	N	N
10	58	KK	2	26JAN92	N	N	N	N	N	
			4	11FEB92	N	N	N	N	N	N
			6	25FEB92	N	N	N	N	N	N
10	59	TA	-1	15JAN92	N	N	N	N	N	
			2	27JAN92	N	N	N	N	N	N
			4	10FEB92	N	N	N	N	N	N
10	60	JM	6	24FEB92	N	N	N	N	N	
			-1	20JAN92	N	N	N	N	N	N
			2	02FEB92	N	N	N	N	N	N
10	61	JT	4	16FEB92	N	N	N	N	N	
			6	01MAR92	N	N	N	N	N	N
			-1	15JAN92	N	N	N	N	N	N
10	62	RK	2	04FEB92	N	N	N	N	N	
			4	18FEB92	N	N	N	N	N	N
			6	03MAR92	N	N	N	N	N	N
10	63	MS	-1	21JAN92	N	N	N	N	N	
			2	04FEB92	N	N	N	N	N	N
			4	18FEB92	N	N	N	N	N	N
10	63	MS	6	05MAR92	N	N	N	N	N	
			-1	03FEB92	N	N	N	N	N	
			2	17FEB92	N	N	N	N	N	

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No. : 12.3

URINALYSIS
 OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	WBC	RBC	Specific Gravity	Albumin	Glucose
10	63	MS	4	02MAR92	N	N	N	N	N
			6	16MAR92	N	N	N	N	N
10	64	LT	-1	05FEB92	N	N	N	N	N
			2	19FEB92	N	N	N	N	N
			4	04MAR92	N	N	N	N	N
			6	18MAR92	N	N	N	N	N
10	81	JN	-1	20FEB92	N	N	N	N	N
			2	05MAR92	N	N	N	N	N
			4	19MAR92	N	N	N	N	N
			6	02APR92	N	N	N	N	N
10	82	LS	-1	20FEB92	N	N	N	N	N
			2	09MAR92	N	N	N	N	N
			4	23MAR92	N	N	N	N	N
			6	06APR92	N	N	N	N	N
10	83	KL	-1	02MAR92	N	N	N	N	N
			2	16MAR92	N	N	N	N	N
			4	30MAR92	N	N	N	N	N
10	84	HV	-1	10MAR92	N	N	N	N	N
			2	24MAR92	N	N	N	N	N
			4	07APR92	N	N	N	N	N
			6	21APR92	N	N	N	N	N
10	85	AK	-1	10MAR92	N	N	N	N	N
			2	24MAR92	N	N	N	N	N
10	86	NP	-1	16MAR92	N	N	N	N	N
			2	01APR92	N	N	N	N	N
			4	15APR92	N	N	N	N	N
			6	29APR92	N	N	N	N	N
10	87	AN	-1	18MAR92	N	N	N	N	N
			2	01APR92	N	N	N	N	N
			4	15APR92	N	N	N	N	N
			6	29APR92	N	N	N	N	N
10	88	AK	-1	18MAR92	N	N	N	N	N
			2	01APR92	N	N	N	N	N
			4	15APR92	N	N	N	N	N
			6	29APR92	N	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No. : 12.3

URINALYSIS
 OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	WBC	RBC	Specific Gravity	Albumin	Glucose
10	89	SK	-1	19MAR92	N	N	N	N	N
			2	02APR92	N	N	N	N	N
			4	16APR92	N	N	N	N	N
10	90	SV	6	30APR92	N	N	N	N	N
			-1	23MAR92	N	N	N	N	N
			2	06APR92	N	N	N	N	N
10	91	HI	4	20APR92	N	N	N	N	N
			6	04MAY92	N	N	N	N	N
			-1	23MAR92	N	N	N	N	N
10	92	LA	2	06APR92	N	N	N	N	N
			4	20APR92	N	N	N	N	N
			6	05MAY92	N	N	N	N	N
10	93	AN	-1	31MAR92	N	N	N	N	N
			2	14APR92	N	N	N	N	N
			4	28APR92	N	N	N	N	N
10	94	PV	6	12MAY92	N	N	N	N	N
			-1	01APR92	N	N	N	N	N
			2	22APR92	N	N	N	N	N
11	1	DF	4	06MAY92	N	N	N	N	N
			6	20MAY92	N	N	N	N	N
			-1	08APR92	N	N	N	N	N
11	2	HB	2	22APR92	N	N	N	N	N
			4	06MAY92	N	N	N	N	N
			6	20MAY92	N	N	N	N	N
11	3	RF	-1	07OCT91	N	N	ND	N	N
			2	23OCT91	N	N	N	N	N
			4	08NOV91	N	N	N	N	N
11	4	BA	6	22NOV91	N	N	N	N	N
			-1	08OCT91	N	N	ND	N	N
			2	24OCT91	N	N	N	N	N
11	4	BA	4	04NOV91	N	N	ND	N	N
			6	18NOV91	N	N	ND	N	N
			-1	11OCT91	N	N	N	N	N
11	4	BA	2	24OCT91	N	N	RD	N	N
			4	05NOV91	N	N	RD	N	N
			6	19NOV91	N	N	RD	N	N
11	4	BA	-1	11OCT91	N	N	N	N	

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No. : 12.3

URINALYSIS
 OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	NBC	RBC	Specific Gravity	Albumin	Glucose
11	4	BA	2	28OCT91	N	N	ND	N	N
			4	12NOV91	N	N	ND	N	N
			6	25NOV91	N	N	ND	N	N
11	5	ZH	-1	14OCT91	N	N	N	N	N
			2	28OCT91	N	N	ND	N	N
			4	12NOV91	N	N	N	N	N
11	6	VP	-1	16OCT91	N	N	N	N	N
			2	29OCT91	N	N	N	N	N
			4	12NOV91	N	N	N	N	N
11	7	KK	-1	17OCT91	N	N	N	N	N
			2	01NOV91	ND	N	N	N	N
			4	15NOV91	N	N	N	N	N
11	8	RF	6	04DEC91	N	N	N	N	N
			-1	05NOV91	N	N	ND	N	N
			2	21NOV91	N	N	N	N	N
11	9	FI	4	02DEC91	N	N	ND	N	N
			-1	05NOV91	N	N	N	N	N
			2	22NOV91	N	N	N	N	N
11	10	BJ	4	04DEC91	N	N	N	N	N
			6	18DEC91	N	N	N	N	N
			-1	19NOV91	N	N	ND	N	N
11	11	NGY	2	03DEC91	N	N	ND	N	N
			4	17DEC91	N	N	N	N	N
			6	30DEC91	N	N	N	N	N
11	12	PJ	-1	25NOV91	N	N	N	N	N
			2	17DEC91	N	N	N	N	N
			4	27DEC91	N	N	N	N	N
11	13	CK	6	10JAN92	N	N	N	N	N
			-1	10DEC91	N	N	N	N	N
			2	27DEC91	N	N	ND	N	N
11	13	CK	4	07JAN92	N	N	R	N	N
			6	20JAN92	N	N	N	N	N
			-1	08JAN92	N	N	ND	N	N
11	13	CK	2	21JAN92	N	N	N	N	N
			4	11FEB92	N	N	N	N	N
			6	25FEB92	N	N	ND	N	N

Legend: N = Normal, R = Renal, ND = Not Done

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No. : 12.3
URINALYSIS
OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	RBC	RBC	Specific Gravity	Albumin	Glucose
11	14	BJ	-1	14JAN92	N	N	ND	N	N
			2	28JAN92	N	N	ND	N	N
	15	NF	4	16FEB92	N	N	N	N	N
			-1	23JAN92	N	N	N	N	N
			2	11FEB92	N	N	ND	N	N
			4	25FEB92	N	N	N	N	N
11	16	NA	6	09MAR92	N	N	N	N	N
			-1	28JAN92	N	N	ND	N	N
			2	16FEB92	N	N	N	N	N
			4	28FEB92	N	N	N	N	N
			6	15MAR92	N	N	N	N	N
			6	03FEB92	N	N	ND	N	N
11	17	UZ	-1	03FEB92	N	N	ND	N	N
			2	20FEB92	N	N	N	N	N
			4	05MAR92	N	N	N	N	N
			6	19MAR92	N	N	ND	N	N
			6	04FEB92	N	N	ND	N	N
			6	21FEB92	N	N	N	N	N
11	18	EI	4	09MAR92	N	N	N	N	N
			6	23MAR92	N	N	N	N	N
			-1	24FEB92	N	N	N	N	N
			2	12MAR92	N	N	N	N	N
			4	26MAR92	N	N	ND	N	N
			6	10APR92	N	N	N	N	N
11	20	LJ	-1	24FEB92	N	N	N	N	N
			2	16MAR92	N	N	N	N	N
			4	30MAR92	N	N	N	N	N
			6	12APR92	N	N	N	N	N
			-1	30OCT91	N	N	N	N	N
			2	13NOV91	N	N	N	N	N
12	1	IB	4	27NOV91	N	N	N	N	N
			6	11DEC91	N	N	N	N	N
			-1	29OCT91	N	N	N	N	N
			2	18NOV91	N	N	N	N	N
			4	02DEC91	N	N	N	N	N
			6	16DEC91	N	N	N	N	N
12	3	IF	-1	29OCT91	N	N	N	N	N
			2	14NOV91	N	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/013
 Listing No. : 12.3

URINALYSIS
 OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	WBC	RBC	Specific Gravity	Albumin	Glucose
12	3	IF	4	26NOV91	N	N	N	N	N
			6	11DEC91	N	N	N	N	N
12	4	EG	-1	31OCT91	N	N	N	N	N
			2	18NOV91	N	N	N	N	N
			4	02DEC91	N	N	N	N	N
			6	16DEC91	N	N	N	N	N
12	5	ZSH	-1	26OCT91	N	N	N	N	N
			2	18NOV91	N	N	N	N	N
			4	02DEC91	N	N	N	N	N
			6	16DEC91	N	N	N	N	N
12	6	MK	-1	29OCT91	N	N	N	N	N
			2	15NOV91	N	N	N	N	N
			4	29NOV91	N	N	N	N	N
			6	12DEC91	N	N	N	N	N
12	7	LK	-1	31OCT91	N	N	N	N	N
			2	15NOV91	N	N	N	N	N
			4	02DEC91	N	N	N	N	N
			6	16DEC91	N	N	N	N	N
12	8	FN	-1	25OCT91	N	N	N	N	N
			2	21NOV91	N	N	N	N	N
			4	28NOV91	N	N	N	N	N
			6	12DEC91	N	N	N	N	N
12	9	KBP	-1	25OCT91	N	N	N	N	N
			2	13NOV91	N	N	N	N	N
			4	28NOV91	N	N	N	N	N
			6	11DEC91	N	N	N	N	N
12	10	IP	-1	01NOV91	N	N	N	N	N
			2	19NOV91	N	N	N	N	N
			4	02DEC91	N	N	N	N	N
			6	16DEC91	N	N	N	N	N
12	11	ER	-1	31OCT91	N	N	N	N	N
			2	13NOV91	N	N	N	N	N
			4	27NOV91	N	N	N	N	N
			6	12DEC91	N	N	N	N	N
12	12	FSZ	-1	30OCT91	N	N	N	N	N
			2	18NOV91	N	N	N	N	N
			4	02DEC91	N	N	N	N	N
			6	12DEC91	N	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

2105

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REDUXETINE - PROTOCOL 20124/013
 Listing No. : 12.3

URINALYSIS
 OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	HBC	RBC	Specific Gravity	Albumin	Glucose
12	12	FSZ	6	16DEC91	N	N	N	N	N
12	13	ISZ	-1	29OCT91	N	N	N	N	N
			2	18NOV91	N	N	N	N	N
			4	02DEC91	N	N	N	N	N
			6	16DEC91	N	N	N	N	N
12	14	GSZ	-1	31OCT91	N	N	N	N	N
			2	19NOV91	N	N	N	N	N
			4	03DEC91	N	N	N	N	N
			6	17DEC91	N	N	N	N	N
12	15	GB	-1	14NOV91	N	N	N	N	N
			2	09DEC91	N	N	N	N	N
			4	23DEC91	N	N	N	N	N
			6	06JAN92	N	N	N	N	N
12	16	FN	-1	28NOV91	N	N	N	N	N
			2	27DEC91	N	N	N	N	N
			4	27JAN92	N	N	N	N	N
			6	21JAN92	N	N	N	N	N
12	17	TK	-1	09JAN92	N	N	N	N	N
			2	28JAN92	N	N	N	N	N
			4	11FEB92	N	N	N	N	N
			6	25FEB92	N	N	N	N	N
12	18	LS	-1	09JAN92	N	N	N	N	N
			2	28JAN92	N	N	N	N	N
			4	11FEB92	N	N	N	N	N
			6	25FEB92	N	N	N	N	N
12	19	SSZ	-1	10JAN92	N	N	N	N	N
			2	29JAN92	N	N	N	N	N
			4	12FEB92	N	N	N	N	N
			6	26FEB92	N	N	N	N	N
12	20	KSZ	-1	10JAN92	N	N	N	N	N
			2	30JAN92	N	N	N	N	N
			4	13FEB92	N	N	N	N	N
			6	27FEB92	N	N	N	N	N
12	21	FL	-1	30JAN92	N	N	N	N	N
			2	13FEB92	N	N	N	N	N
			4	27FEB92	N	N	N	N	N
			6	12MAR92	N	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No. : 12.3

URINALYSIS
OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	HBC	RBC	Specific Gravity	Albumin	Glucose
12	22	HV	-1	24-JAN92	N	N	N	N	N
			2	10-FEB92	N	N	N	N	N
			4	24-FEB92	N	N	N	N	N
12	23	EN	6	09-MAR92	N	N	N	N	N
			-1	31-JAN92	N	N	N	N	N
			2	20-FEB92	N	N	N	N	N
12	24	MF	4	05-MAR92	N	N	N	N	N
			6	18-MAR92	N	N	N	N	N
			-1	04-FEB92	N	N	N	N	N
12	25	FS	2	21-FEB92	N	N	N	N	N
			4	06-MAR92	N	N	N	N	N
			6	20-MAR92	N	N	N	N	N
12	26	LB	-1	05-FEB92	N	N	N	N	N
			2	24-FEB92	N	N	N	N	N
			4	09-MAR92	N	N	N	N	N
12	27	VCS	6	23-MAR92	N	N	N	N	N
			-1	05-FEB92	N	N	N	N	N
			2	19-FEB92	N	N	N	N	N
12	28	IV	4	03-MAR92	N	N	N	N	N
			6	17-MAR92	N	N	N	N	N
			-1	07-FEB92	N	N	N	N	N
12	29	AK	2	21-FEB92	N	N	N	N	N
			4	06-MAR92	N	N	N	N	N
			6	20-MAR92	N	N	N	N	N
12	30	FS	-1	07-FEB92	N	N	N	N	N
			2	24-FEB92	N	N	N	N	N
			4	09-MAR92	N	N	N	N	N
12	31	FH	6	23-MAR92	N	N	N	N	N
			-1	20-FEB92	N	N	N	N	N
			2	09-MAR92	N	N	N	N	N
12	31	FH	4	23-MAR92	N	N	N	N	N
			-1	24-MAR92	N	N	N	N	N
			2	06-APR92	N	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

2107

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No. : 12.3

URINALYSIS
OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	MBC	RBC	Specific Gravity	Albumin	Glucose
12	31	FH	4	21APR92	N	N	N	N	N
			6	07MAY92	N	N	N	N	N
12	32	LM	-1	31MAR92	N	N	N	N	N
			2	15APR92	N	N	N	N	N
			4	29APR92	N	N	N	N	N
			6	13MAY92	N	N	N	N	N
12	33	LN	-1	23MAR92	N	N	N	N	N
			2	15APR92	N	N	N	N	N
			4	29APR92	N	N	N	N	N
			6	13MAY92	N	N	N	N	N
12	34	TGB	-1	26MAR92	N	N	N	N	N
			2	10APR92	N	N	N	N	N
			4	24APR92	N	N	N	N	N
			6	08MAY92	N	N	N	N	N
12	35	LP	-1	24MAR92	N	N	N	N	N
			2	10APR92	N	N	N	N	N
			4	24APR92	N	N	N	N	N
			6	08MAY92	N	N	N	N	N
12	36	FB	-1	25MAR92	N	N	N	N	N
			2	13APR92	N	N	N	N	N
			4	27APR92	N	N	N	N	N
			6	11MAY92	N	N	N	N	N
12	37	EK	-1	31MAR92	N	N	N	N	N
			2	17APR92	N	N	N	N	N
			4	30APR92	N	N	N	N	N
			6	09MAY92	N	N	N	N	N
12	38	FG	-1	31MAR92	N	N	N	N	N
			2	21APR92	N	N	N	N	N
			4	04MAY92	N	N	N	N	N
			6	18MAY92	N	N	N	N	N
13	1	PZ	-1	08OCT91	N	N	N	N	N
			2	29OCT91	N	N	N	N	N
			4	12NOV91	N	N	N	N	N
			6	26NOV91	N	N	N	N	N
13	2	TCS	-1	08OCT91	N	N	N	N	N
			2	24OCT91	N	N	N	N	N
			4	13NOV91	N	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL MD = NOT DONE

2108

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

Centro	Patient	Initials	Visit	Laboratory Date	WBC	RBC	Specific Gravity	Albumin	Glucose
13	2	TCS	6	27NOV91	N	N	N	N	N
13	3	AI	-1	08OCT91	N	N	N	N	N
			2	24OCT91	N	N	N	N	N
			4	12NOV91	N	N	N	N	N
			6	26NOV91	N	N	N	N	N
13	4	SZJ	-1	10OCT91	N	N	N	N	N
			2	22OCT91	N	N	N	N	N
			4	12NOV91	N	N	N	N	N
			6	26NOV91	N	N	N	N	N
13	5	MF	-1	10OCT91	N	N	N	N	N
			1	25OCT91	N	N	N	N	N
13	6	KE	-1	11OCT91	N	N	N	N	N
			2	28OCT91	N	N	N	N	N
			4	15NOV91	N	N	N	N	N
			6	28NOV91	N	N	N	N	N
13	7	BL	-1	11OCT91	N	N	N	N	N
			2	07NOV91	N	N	N	N	N
			4	21NOV91	N	N	N	N	N
			6	05DEC91	N	N	N	N	N
13	8	PK	-1	15OCT91	N	N	N	N	N
			2	04NOV91	N	N	N	N	N
			4	19NOV91	N	N	N	N	N
			6	03DEC91	N	N	N	N	N
13	9	SZS	-1	15OCT91	N	N	N	N	N
			2	04NOV91	N	N	N	N	N
			4	19NOV91	N	N	N	N	N
			6	03DEC91	N	N	N	N	N
13	10	BM	-1	15OCT91	N	N	N	N	N
			1	30OCT91	N	N	N	N	N
13	11	HS	-1	17OCT91	N	N	N	N	N
			2	28NOV91	N	N	N	N	N
			4	09DEC91	N	N	N	N	N
			6	27DEC91	N	N	N	N	N
13	12	BF	-1	21OCT91	N	N	N	N	N
			2	13NOV91	N	N	ND	N	N
			4	26NOV91	N	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
REBOXETINE - PROTOCOL 20124/013
Listing No. : 12.3

URINALYSIS
OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	RBC	RBC	Specific Gravity	Albumin	Glucose			
13	13	RH	-1	28OCT91	N	N	N	N	N			
			2	14NOV91	N	N	N	N	N			
			4	28NOV91	N	N	N	N	N			
			6	13DEC91	N	N	N	N	N			
			13	14	DF	-1	28OCT91	N	N	N	N	N
						2	14NOV91	N	N	N	N	N
4	28NOV91	N				N	N	N	N			
6	12DEC91	N				N	N	N	N			
13	15	KG				-1	28OCT91	N	N	N	N	N
						2	20NOV91	N	N	N	N	N
			4	04DEC91	N	N	N	N	N			
			6	17DEC91	N	N	N	N	N			
			13	16	SZL	-1	14NOV91	N	N	N	N	N
						2	04DEC91	N	N	N	N	N
4	17DEC91	N				N	N	N	N			
6	02JAN92	N				N	N	N	N			
13	17	GSH				-1	15NOV91	N	N	N	N	N
						2	03DEC91	N	N	N	N	N
			4	17DEC91	N	N	N	N	N			
			6	28DEC91	N	N	N	N	N			
			13	18	VT	-1	26NOV91	N	N	N	N	N
						2	17DEC91	N	N	N	N	N
4	30DEC91	N				N	N	N	N			
6	14JAN92	N				N	N	N	N			
13	19	KK				-1	22JAN92	N	N	N	N	N
						2	06FEB92	N	N	N	N	N
			3	17FEB92	N	N	N	N	N			
			13	20	NL	-1	24JAN92	N	N	N	N	N
						2	11FEB92	N	N	N	N	N
						4	25FEB92	N	N	N	N	N
6	10MAR92	N				N	N	N	N			
13	21	CL				-1	13FEB92	N	N	N	N	N
						2	02MAR92	N	N	N	N	N
			4	17MAR92	N	N	N	N	N			
			6	31MAR92	N	N	N	N	N			
			13	22	NYH	-1	28APR92	N	N	N	N	
						2	19MAY92	N	N	N	N	

2110

APP: V = NOT DONE I = UNKNOWN NO = NOT DONE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No. : 12.3

URINALYSIS
 OPEN PHASE

Centre	Patient	Initials	Visit	Laboratory Date	WBC	RBC	Specific Gravity	Albumin	Glucose
13	22	NYM	4	01JUN92	N	N	N	N	N
			6	16JUN92	N	N	N	N	N
13	23	BSB	-1	05MAY92	N	N	ND	N	N
			2	20MAY92	N	N	N	N	N
			4	04JUN92	N	N	N	N	N
			6	17JUN92	N	N	ND	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

2111

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No. : 12.3

URINALYSIS
DOUBLE BLIND PHASE
TREATMENT : REBOXETINE

Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	WBC	REC	Specific Gravity	Albumin	Glucose	
1	10/8	LDL	10	12APR91	N	N	N	N	N	
			18	07JUN91	N	N	N	N	N	
			26	02AUG91	N	ND	N	ND	ND	ND
			34	27SEP91	N	ND	N	N	N	N
			42	22NOV91	N	N	N	N	N	N
1	101/143	JLL	10	28APR92	N	N	N	N	N	
			18	23JUN92	N	N	N	N	N	
			26	18AUG92	N	N	N	N	N	
			34	13OCT92	N	N	N	N	N	
			42	08DEC92	N	N	N	N	N	
1	107/147	LAN	10	29APR92	N	N	N	N	N	
			18	24JUN92	N	N	N	N	N	
			26	18AUG92	N	N	N	N	N	
			34	13OCT92	N	N	N	N	N	
			42	08DEC92	N	N	N	N	N	
1	109/149	IPL	10	29APR92	N	N	N	N	N	
			18	24JUN92	N	N	N	N	N	
			26	19AUG92	N	N	N	N	N	
			34	14OCT92	N	N	N	N	N	
			42	09DEC92	N	N	N	N	N	
1	110/150	TQO	10	29APR92	N	N	N	N	N	
			18	24JUN92	N	N	N	N	N	
			26	19AUG92	N	N	N	N	N	
			34	14OCT92	N	N	N	N	N	
			42	09DEC92	N	N	N	N	N	
1	116/334	MGA	10	05MAY92	N	N	N	N	N	
			18	30JUN92	N	N	N	N	N	
			26	26AUG92	N	N	N	N	N	
			34	21OCT92	N	N	N	N	N	
			42	15DEC92	N	N	N	N	N	
1	117/335	PSL	10	05MAY92	N	N	N	N	N	
			18	30JUN92	N	N	N	N	N	
			26	26AUG92	N	N	N	N	N	

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D		REBOXETINE - PROTOCOL 20124/013		Listing No. : 12.3		URINALYSIS		DOUBLE BLIND PHASE		TREATMENT : REBOXETINE				
Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	RBC	RBC	Specific Gravity	Albumin	Glucose					
1	117/335	PSL	34	21OCT92	N	N	N	N	N					
			42	15DEC92	N	N	N	N	N	N				
			52	24FEB93	N	N	N	N	N	N				
1	121/336	LAC	10	06MAY92	N	N	N	N	N					
			18	01JUL92	N	N	N	N	N	N				
			26	26AUG92	N	N	N	N	N	N				
			34	21OCT92	N	N	N	N	N	N				
			42	16DEC92	N	N	N	N	N	N				
1	123/338	MIL	52	24FEB93	N	N	N	N	N					
			10	06MAY92	N	N	N	N	N	N				
			18	01JUL92	N	N	N	N	N	N				
			26	26AUG92	N	N	N	N	N	N				
			34	21OCT92	N	N	N	N	N	N				
1	125/340	FDP	42	16DEC92	N	N	N	N	N					
			52	24FEB93	N	N	N	N	N	N				
			10	06MAY92	N	N	N	N	N	N				
			18	01JUL92	N	N	N	N	N	N				
			26	26AUG92	N	N	N	N	N	N				
1	127/342	VPD	34	21OCT92	N	N	N	N	N					
			42	16DEC92	N	N	N	N	N	N				
			52	24FEB93	N	N	N	N	N	N				
			10	06MAY92	N	N	N	N	N	N				
			18	01JUL92	N	N	N	N	N	N				
1	128/343	LAM	26	26AUG92	N	N	N	N	N					
			34	21OCT92	N	N	N	N	N	N				
			42	16DEC92	N	N	N	N	N	N				
			52	24FEB93	N	N	N	N	N	N				
			10	06MAY92	N	N	N	N	N	N				
1	134/347	LMS	18	01JUL92	N	N	N	N	N					
			26	26AUG92	N	N	N	N	N	N				
			34	21OCT92	N	N	N	N	N	N				
			42	16DEC92	N	N	N	N	N	N				
			52	24FEB93	N	N	N	N	N	N				
1	134/347	LMS	10	02JUN92	N	N	N	N	N					
			18	28JUL92	N	N	N	N	N	N				
			26	22SEP92	N	N	N	N	N	N				
			34	17NOV92	N	N	N	N	N	N				
			42	12JAN93	N	N	N	N	N	N				
1	134/347	LMS	52	23MAR93	N	N	N	N	N					

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

2113

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	MBC	RBC	Specific Gravity	Albumin	Glucose	
1	135/348	MHS	10	02JUN92	N	N	N	N	N	
			18	28JUL92	N	N	N	N	N	
			26	22SEP92	N	N	N	N	N	N
			34	17NOV92	N	N	N	N	N	N
			42	12JAN93	N	N	N	N	N	N
			52	23MAR93	N	N	N	N	N	N
1	139/351	RA	10	02JUN92	N	N	N	N	N	
			18	28JUL92	N	N	N	N	N	
			26	22SEP92	N	N	N	N	N	
			34	17NOV92	N	N	N	N	N	
			42	12JAN93	N	N	N	N	N	
			52	23MAR93	N	N	N	N	N	
1	14/11	MLC	10	16JUL91	ND	ND	ND	ND	ND	
			10	02JUN92	N	N	N	N	N	
1	140/352	HCA	10	02JUN92	N	N	N	N	N	
			18	28JUL92	N	N	N	N	N	
			26	22SEP92	N	N	N	N	N	
			34	17NOV92	N	N	N	N	N	
			42	12JAN93	N	N	N	N	N	
			52	23MAR93	N	N	N	N	N	
1	142/354	SCC	10	02JUN92	N	N	N	N	N	
			18	28JUL92	N	N	N	N	N	
			26	22SEP92	N	N	N	N	N	
			34	17NOV92	N	N	N	N	N	
			42	12JAN93	N	N	N	N	N	
			52	23MAR93	N	N	N	N	N	
1	144/356	ARF	10	03JUN92	N	N	N	N	N	
			18	29JUL92	N	N	N	N	N	
			26	23SEP92	N	N	N	N	N	
			34	18NOV92	N	N	N	N	N	
			42	05JUN92	N	N	N	N	N	
			52	26MAR93	N	N	N	N	N	
1	146/358	LRH	10	31JUL92	N	N	N	N	N	
			18	25SEP92	N	N	N	N	N	
			26	20NOV92	N	N	N	N	N	
			34	15JAN93	N	N	N	N	N	
			42	26MAR93	N	N	N	N	N	
			52	05JUN92	N	N	N	N	N	
1	148/359	CAS	10	05JUN92	N	N	N	N	N	
			18	31JUL92	N	N	N	N	N	
			26	25SEP92	N	N	N	N	N	

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

2114

9550077

PHARMACIA CNS RED
 RENOMETINE - PROTOCOL 20124/013
 Listing No. : 12.3

URINALYSIS
 DOUBLE BLIND PHASE
 TREATMENT : RENOMETINE

Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	RBC	Specific Gravity	Albumin	Glucose
1	31/27	MAN	52	21JUL92	N	N	N	N
1	32/28	DGN	10	02OCT91	N	N	N	N
			18	27NOV91	N	N	N	N
			26	24MAR92	N	N	N	N
			52	10MAY92	N	N	N	N
			62	13MAY92	N	N	N	N
			52	22JUL92	N	N	N	N
1	34/30	GNH	10	28OCT91	N	N	N	N
			18	18DEC91	N	N	N	N
			26	12FEB92	N	N	N	N
			34	08APR92	N	N	N	N
			62	03JUN92	N	N	N	N
			52	12AUG92	N	N	N	N
1	35/301	EHP	10	05NOV91	N	N	N	N
			18	31DEC91	N	N	N	N
			26	25FEB92	N	N	N	N
			52	22MAY92	N	N	N	N
			62	16JUN92	N	N	N	N
			52	25AUG92	N	N	N	N
1	37/303	RF	10	19NOV91	N	N	N	N
			18	07JAN92	N	N	N	N
			26	04MAR92	N	N	N	N
			34	28APR92	N	N	N	N
			62	23JUN92	N	N	N	N
			52	01SEP92	N	N	N	N
1	39/305	ASS	10	03DEC91	N	N	N	N
			18	28JAN92	N	N	N	N
			26	24MAR92	N	N	N	N
			52	20MAY92	N	N	N	N
			62	14JUL92	N	N	N	N
			52	22SEP92	N	N	N	N
1	4/3	DNC	10	30JAN91	N	N	N	N
			18	22MAR91	N	N	N	N
			26	22MAY91	N	N	N	N
			34	17JUL91	N	N	N	N
			62	18SEP91	N	N	N	N
			52	20NOV91	N	N	N	N
1	43/309	ARN	10	11DEC91	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOMETINE - PROTOCOL 20124/013
 Listing No. : 12.3

URINALYSIS
 DOUBLE BLIND PHASE
 TREATMENT : REBOMETINE

Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	MBC	RBC	Specific Gravity	Albumin	Glucose
1	31/27	MAN	52	21JUL92	N	N	N	N	N
1	32/28	DGH	10	02OCT91	N	N	N	N	N
			18	27NOV91	N	N	N	N	N
			26	22JAN92	N	N	N	N	N
			34	18MAR92	N	N	N	N	N
			42	13MAY92	N	N	N	N	N
			52	22JUL92	N	N	N	N	N
1	34/30	GHR	10	23OCT91	N	N	N	N	N
			18	18DEC91	N	N	N	N	N
			26	12FEB92	N	N	N	N	N
			34	08APR92	N	N	N	N	N
			42	03JUN92	N	N	N	N	N
			52	12AUG92	N	N	N	N	N
1	35/301	EMP	10	05NOV91	N	N	N	N	N
			18	31DEC91	N	N	N	N	N
			26	25FEB92	N	N	N	N	N
			34	22APR92	N	N	N	N	N
			42	16JUN92	N	N	N	N	N
			52	29AUG92	N	N	N	N	N
1	37/303	RF	10	12NOV91	N	N	N	N	N
			18	07JAN92	N	N	N	N	N
			26	04MAR92	N	N	N	N	N
			34	28APR92	N	N	N	N	N
			42	23JUN92	N	N	N	N	N
			52	01SEP92	N	N	N	N	N
1	39/305	ASS	10	03DEC91	N	N	N	N	N
			18	28JAN92	N	N	N	N	N
			26	24MAR92	N	N	N	N	N
			34	19MAY92	N	N	N	N	N
			42	14JUL92	N	N	N	N	N
			52	22SEP92	N	N	N	N	N
1	4/3	DRC	10	30JAN91	N	N	N	N	N
			18	27MAR91	N	N	N	N	N
			26	22MAY91	N	N	N	N	N
			34	17JUL91	N	N	N	N	N
			42	14SEP91	N	N	N	N	N
			52	20NOV91	N	N	N	N	N
1	43/309	ARN	10	11DEC91	N	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	RBC	Specific Gravity	Albumin	Glucose	
1	43/309	ARN	18	04FEB92	N	N	N	N	
			26	01APR92	N	N	N	N	
			34	27MAY92	N	N	N	N	N
			42	22JUL92	N	N	N	N	N
			52	30SEP92	N	N	N	N	N
			10	17DEC91	N	N	N	N	N
1	45/310	DPS	18	11FEB92	N	N	N	N	
			26	07APR92	N	N	N	N	
			34	02JUN92	N	N	N	N	
			42	28JUL92	N	N	N	N	
			52	06OCT92	N	N	N	N	
			10	26DEC91	N	N	N	N	
1	46/311	SP	18	18FEB92	N	N	N	N	
			26	14APR92	N	N	N	N	
			34	09JUN92	N	N	N	N	
			42	04AUG92	N	N	N	N	
			52	19OCT92	N	N	N	N	
			10	02JAN92	N	N	N	N	
1	48/313	SCH	18	26FEB92	N	N	N	N	
			26	22APR92	N	N	N	N	
			34	17JUN92	N	N	N	N	
			42	12AUG92	N	N	N	N	
			52	21OCT92	N	N	N	N	
			10	13FEB91	N	N	N	N	
1	5/4	DB	18	10APR91	N	N	N	N	
			26	04JUN91	N	N	N	N	
			34	30JUL91	N	N	N	N	
			42	24SEP91	N	N	N	N	
			52	03DEC91	N	N	N	N	
			10	08JAN92	N	N	N	N	
1	52/316	HTS	18	04MAR92	N	N	N	N	
			26	29APR92	N	N	N	N	
			34	24JUN92	N	N	N	N	
			42	19AUG92	N	N	N	N	
			52	28OCT92	N	N	N	N	
			10	14JAN92	N	N	N	N	
1	55/318	DMG	10	14JAN92	N	N	N	N	
1	58/320	ARM	10	18FEB92	N	N	N	N	

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

2117

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No. : 12.3

URINALYSIS
DOUBLE BLIND PHASE
TREATMENT : REBOXETINE

Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	MBC	REC	Specific Gravity	Albumin	Glucose	
1	61/323	HVC	10	28FEB92	N	N	N	N	N	
			18	24APR92	N	N	N	N	N	
			26	15JUN92	N	N	N	N	N	N
			34	14AUG92	N	N	N	N	N	N
			42	09OCT92	N	N	N	N	N	N
1	66/326	TCG	52	18DEC92	N	N	N	N	N	
			10	31MAR92	N	N	N	N	N	
			18	26MAY92	N	N	N	N	N	N
			26	21JUL92	N	N	N	N	N	N
			34	15SEP92	N	N	N	N	N	N
1	71/329	OMV	42	10NOV92	N	N	N	N	N	
			52	19JAN93	N	N	N	N	N	
			10	07APR92	N	N	N	N	N	N
			18	02JUN92	N	N	N	N	N	N
			26	28JUL92	N	N	N	N	N	N
1	72/330	RLJ	34	22SEP92	N	N	N	N	N	
			42	17NOV92	N	N	N	N	N	
			52	26JAN93	N	N	N	N	N	
			10	07APR92	N	N	N	N	N	N
			18	02JUN92	N	N	N	N	N	N
1	73/121	FHA	26	28JUL92	N	N	N	N	N	
			10	07APR92	N	N	N	N	N	
			18	02JUN92	N	N	N	N	N	
			26	28JUL92	N	N	N	N	N	
			10	10APR92	N	N	N	N	N	N
1	75/123	ELF	18	05JUN92	N	N	N	N	N	
			26	31JUL92	N	N	N	N	N	
			34	25SEP92	N	N	N	N	N	
			42	20NOV92	N	N	N	N	N	
			52	29JAN93	N	N	N	N	N	
1	77/125	ACG	10	17APR92	N	N	N	N	N	
			18	12JUN92	N	N	N	N	N	
			26	07AUG92	N	N	N	N	N	
			34	02OCT92	N	N	N	N	N	
			42	27NOV92	N	N	N	N	N	
1	81/128	HFB	52	05FEB93	N	N	N	N	N	
			10	17APR92	N	N	N	N	N	
			18	12JUN92	N	N	N	N	N	
			26	07AUG92	N	N	N	N	N	
			34	02OCT92	N	N	N	N	N	

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	MBC	RBC	Specific Gravity	Albumin	Glucose	
1	81/128	MFB	34	02OCT92	N	N	N	N	N	
			42	27NOV92	N	N	N	N	N	
			52	05FEB93	N	N	N	N	N	N
1	82/129	MDS	10	17APR92	N	N	N	N	N	
			18	12JUN92	N	N	N	N	N	
			26	07AUG92	N	N	N	N	N	N
			34	02OCT92	N	N	N	N	N	N
			42	27NOV92	N	N	N	N	N	N
			52	05FEB93	N	N	N	N	N	N
1	87/132	HDO	10	17APR92	N	N	N	N	N	
			18	12JUN92	N	N	N	N	N	
1	89/133	NHY	10	20APR92	N	N	N	N	N	
1	9/7	CCR	10	06MAR91	N	N	N	N	N	
			18	30APR91	N	N	N	N	N	
			26	26JUN91	N	N	N	N	N	N
			34	21AUG91	N	N	N	N	N	N
			42	16OCT91	N	N	N	N	N	N
			52	26DEC91	N	N	N	N	N	N
1	95/138	GMT	10	22APR92	N	N	N	N	N	
			18	17JUN92	N	N	N	N	N	
			26	12AUG92	N	N	N	N	N	N
			34	07OCT92	N	N	N	N	N	N
			42	02DEC92	N	N	N	N	N	N
			52	10FEB93	N	N	N	N	N	N
1	96/139	SPH	10	22APR92	N	N	N	N	N	
			18	17JUN92	N	N	N	N	N	
			26	12AUG92	N	N	N	N	N	N
			34	07OCT92	N	N	N	N	N	N
			42	02DEC92	N	N	N	N	N	N
			52	10FEB93	N	N	N	N	N	N
1	98/141	YTT	10	22APR92	N	N	N	N	N	
			18	17JUN92	N	N	N	N	N	
			26	12AUG92	N	N	N	N	N	N
			34	07OCT92	N	N	N	N	N	N
			42	02DEC92	N	N	N	N	N	N
			52	10FEB93	N	N	N	N	N	N
8	2/212	TE	10	21FEB91	N	N	N	N	N	

Legend: N = Normal, U = Urinary, B = Blood, C = Chemistry, H = Hematology, V = Vitals, E = ECG, X = X-ray, S = Specimen, O = Other, M = Missing, A = Not Done

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No. : 12.3

URINALYSIS
DOUBLE BLIND PHASE
TREATMENT : REBOXETINE

Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	WBC	RBC	Specific Gravity	Albumin	Glucose	
8	2/212	TE	18	18APR91	N	N	N	N	N	
			26	30MAY91	N	N	N	N	N	
			34	08AUG91	N	N	N	N	N	N
			42	03OCT91	N	N	N	N	N	N
			52	12DEC91	N	N	N	N	N	N
8	3/213	JL	10	28FEB91	N	N	N	N	N	
			10	02APR91	N	N	N	N	N	
8	6/216	TL	18	27MAY91	N	N	N	N	N	
			26	22JUL91	N	N	N	N	N	
			34	16SEP91	N	N	N	N	N	
			42	11NOV91	N	N	N	N	N	
			52	20JAN92	N	N	N	N	N	
9	11/246	KE	10	10APR91	N	N	N	N	N	
			18	04JUN91	N	N	ND	N	N	
			26	30JUL91	N	N	ND	N	N	
			34	24SEP91	N	N	ND	N	N	
			42	19NOV91	N	N	ND	N	N	
			52	28JAN92	N	N	ND	N	N	
9	15/249	BI	10	28JUL91	N	N	N	N	N	
			18	22SEP91	N	N	ND	N	N	
			26	18NOV91	N	N	ND	N	N	
			34	17JAN92	N	N	ND	N	N	
			42	10MAR92	N	N	N	N	N	
			52	20MAY92	N	N	N	N	N	
9	16/250	UGY	10	17SEP91	N	N	N	N	N	
			18	12NOV91	ND	ND	ND	ND	ND	
			26	14JAN92	N	N	ND	N	N	
			34	23MAR92	N	N	ND	N	N	
			42	28APR92	N	N	N	N	N	
			52	06JUL92	N	N	N	N	N	
9	20/252	GYE	10	07NOV91	N	N	N	N	N	
			18	27DEC91	N	N	N	N	N	
9	23/256	SZN	10	23JAN92	N	N	ND	N	N	
			18	07APR92	N	N	N	N	N	
9	26/255	CF	10	30JAN92	N	N	ND	N	N	
			18	24MAR92	N	N	N	N	N	

ND = NOT DONE
ABNORMAL

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No. : 42.3
 URINALYSIS
 DOUBLE BLIND PHASE
 TREATMENT : REBOXETINE

Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	WBC	RBC	Specific Gravity	Albumin	Glucose
9	29/258	SZF	10	15JUN92	N	N	N	N	N
			18	11AUG92	N	N	N	N	N
9	30/259	NF	10	15JUN92					
			10	15JAN91	N	N	N	N	N
			18	12MAR91	N	N	N	N	N
			26	09MAY91	N	N	N	ND	N
			34	02JUL91	N	N	N	ND	N
9	7/243	PP	42	27AUG91	N	N	N	N	N
			52	05NOV91	N	N	N	N	N
			10	17JAN91	N	N	N	N	N
			18	16MAR91	N	N	N	N	N
10	1/271	VK	26	07MAY91	N	N	N	N	N
			34	04JUL91	ND	ND	ND	ND	ND
			42	29AUG91	N	N	N	N	N
			52	07NOV91	N	N	N	N	N
			10	27DEC90	N	N	N	N	N
			16	30JAN91	N	N	N	N	N
10	12/277	EP	10	20MAR91	N	N	N	N	N
			10	30APR91	N	N	N	N	N
10	15/280	HT	10	01JUL91	N	N	N	N	N
			18	26AUG91	N	N	N	N	N
10	20/285	EJ	26	21OCT91	N	N	N	N	N
			34	16DEC91	N	N	N	N	N
			42	10FEB92	N	N	N	N	N
			10	01JUL91	N	N	N	N	N
10	22/286	AA	18	26AUG91	N	N	N	N	N
			26	21OCT91	N	N	N	N	N
			34	16DEC91	N	N	N	N	N
			42	10FEB92	N	N	N	N	N
			10	02JUL91	N	N	N	N	N
			18	26AUG91	N	N	N	N	N
10	23/287	LT	26	22OCT91	N	N	N	N	N
			34	17DEC91	N	N	N	N	N
			42	11FEB92	N	N	N	N	N
			10	05AUG91	N	N	N	N	N
10	26/290	JIF	10	05AUG91	N	N	N	N	N
			10	12AUG91	N	N	N	N	N
10	27/292	HK	10	12AUG91	N	N	N	N	N
			10	12AUG91	N	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No. : 12.5

URINALYSIS
DOUBLE BLIND PHASE
TREATMENT : REBOXETINE

Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	WBC	REC	Specific Gravity	Albumin	Glucose	
10	27/292	MK	18	07OCT91	N	N	N	N	N	
			26	02DEC91	N	N	N	N	N	
			34	28JAN92	N	N	N	N	N	N
			42	24MAR92	N	N	N	N	N	N
			52	02JUN92	N	N	N	N	N	N
10	28/291	LL	10	07AUG91	N	N	N	N	N	
			18	02OCT91	N	N	N	N	N	
			26	27NOV91	N	N	N	N	N	N
			34	22JAN92	N	N	N	N	N	N
			42	18MAR92	N	N	N	N	N	N
10	31/297	RK	10	26NOV91	N	N	N	N	N	
			18	21JAN92	N	N	N	N	N	
			26	17MAR92	N	N	N	N	N	N
			34	12MAY92	N	N	N	N	N	N
			42	07JUL92	N	N	N	N	N	N
10	32/299	LK	10	26NOV91	N	N	N	N	N	
			18	20JAN92	N	N	N	N	N	
			26	15MAR92	N	N	N	N	N	N
			34	10MAY92	N	N	N	N	N	N
			42	07JUL92	N	N	N	N	N	N
10	33/300	EK	10	26NOV91	N	N	N	N	N	
			18	21JAN92	N	N	N	N	N	
			26	03DEC91	N	N	N	N	N	N
			34	03DEC91	N	N	N	N	N	N
			42	23DEC91	N	N	N	N	N	N
10	34/40	VK	10	23DEC91	N	N	N	N	N	
			18	18FEB92	N	N	N	N	N	
			26	13APR92	N	N	N	N	N	N
			34	08JUN92	N	N	N	N	N	N
			42	04AUG92	N	N	N	N	N	N
10	41/42	VP	10	07JAN92	N	N	N	N	N	
			18	03MAR92	N	N	N	N	N	
			26	28APR92	N	N	N	N	N	
			34	23JUN92	N	N	N	N	N	
			42	15OCT92	N	N	N	N	N	

2120

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	WBC	RBC	Specific Gravity	Albumin	Glucose
10	41/42	VP	42	18AUG92	N	N	N	N	N
			52	27OCT92	N	N	N	N	N
10	49/43	VH	10	18FEB92	N	N	N	N	N
			18	14APR92	N	N	N	N	N
			26	09JUN92	N	N	N	N	N
10	53/47	MA	10	22MAR92	N	N	N	N	N
			18	17MAY92	N	N	N	N	N
			26	12JUL92	N	N	N	N	N
10	54/46	UN	10	22MAR92	N	N	N	N	N
			18	17MAY92	N	N	N	N	N
			26	12JUL92	N	N	N	N	N
10	57/51	AG	10	26MAR92	N	N	N	N	N
			18	19MAY92	N	N	N	N	N
			26	14JUL92	N	N	N	N	N
			34	08SEP92	N	N	N	N	N
			42	03NOV92	N	N	N	N	N
			52	12JAN93	N	N	N	N	N
			10	30MAR92	N	N	N	N	N
10	63/57	MS	10	13APR92	N	N	N	N	N
			18	08JUN92	N	N	N	N	N
			26	03AUG92	N	N	N	N	N
			34	28SEP92	N	N	N	N	N
			42	23NOV92	N	N	N	N	N
			52	01FEB93	N	N	N	N	N
10	82/59	LS	10	04MAY92	N	N	N	N	N
			18	29JUN92	N	N	N	N	N
			26	24AUG92	N	N	N	N	N
			34	19OCT92	N	N	N	N	N
10	84/63	HV	42	14DEC92	N	N	N	N	N
			10	19MAY92	N	N	N	N	N
10	86/274	NP	10	27MAY92	N	N	N	N	N
10	87/275	AN	10	27MAY92	N	N	N	N	N
			18	22JUL92	N	N	N	N	N
			26	16SEP92	N	N	N	N	N
			34	11NOV92	N	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

2122

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	MBC	RBC	Specific Gravity	Albumin	Glucose
10	87/275	AN	42	06JAN93	N	N	N	N	N
			52	17MAR93	N	N	N	N	N
10	9/275	RT	9	05FEB91	N	N	N	N	N
			10	01JUN92	N	N	N	N	N
			18	28JUL92	N	N	N	N	N
10	90/70	SV	26	21SEP92	N	N	N	N	N
			10	02JUN92	N	N	N	N	N
10	91/74	HI	10	02JUN92	N	N	N	N	N
			18	17JUN92	N	N	N	N	N
10	93/285	AN	18	12AUG92	N	N	N	N	N
			26	07OCT92	N	N	N	N	N
			34	02DEC92	N	N	N	N	N
			10	21JAN92	N	N	N	N	N
			18	31MAR92	N	N	N	N	N
11	10/363	BJ	26	26MAY92	N	N	N	N	N
			34	21JUL92	N	N	N	N	N
			42	15SEP92	N	N	N	N	N
			52	24NOV92	N	N	N	N	N
			10	30JAN92	N	N	N	N	N
11	11/361	NGY	18	13APR92	N	N	N	N	N
			24	19MAY92	N	N	N	N	N
			10	03APR92	N	N	N	N	N
11	13/365	GK	20	02JUN92	N	N	N	N	N
			10	13APR92	N	N	N	N	N
11	16/367	NA	18	09JUN92	N	N	N	N	N
			10	16APR92	N	N	N	N	N
11	17/368	UZ	18	11JUN92	N	N	N	N	N
			26	06AUG92	N	N	N	N	N
			34	01OCT92	N	N	N	N	N
			42	24NOV92	N	N	N	N	N
			52	04FEB93	N	N	N	N	N
11	19/370	FK	10	07MAY92	N	N	N	N	N
			18	02JUL92	N	N	N	N	N
			26	24AUG92	N	N	N	N	N
			34	26OCT92	N	N	N	N	N

URINALYSIS
DOUBLE BLIND PHASE
TREATMENT : REBOXETINE

N = NOT DONE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D									
REBOXETINE - PROTOCOL 20124/013									
Listing No. : 12.3									
URINALYSIS									
DOUBLE BLIND PHASE									
TREATMENT : REBOXETINE									
Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	MBC	RBC	Specific Gravity	Albumin	Glucose
11	19/370	FK	42	17DEC92	N	N	N	N	N
			52	25FEB93	N	N	N	N	N
11	2/373	HB	10	09DEC91	N	N	N	N	N
			18	16FEB92	N	N	ND	N	N
			26	13APR92	N	N	ND	N	N
			30	28MAY92	N	N	ND	N	N
11	3/374	RF	10	10DEC91	N	N	ND	N	N
			10	27DEC91	N	N	ND	N	N
11	6/377	VP	18	18FEB92	N	N	N	N	N
			26	14APR92	N	N	N	N	N
			34	09JUN92	N	N	N	N	N
			42	04AUG92	N	N	RD	N	N
			52	13OCT92	N	N	N	N	N
			52	13OCT92	N	N	N	N	N
12	1/92	IB	10	21JAN92	N	N	N	N	N
			18	03MAR92	N	N	N	N	N
			26	29FEB92	N	N	N	N	N
			34	23JUN92	N	N	N	N	N
			42	19AUG92	N	N	N	N	N
12	15/104	GB	10	03FEB92	N	N	N	N	N
			18	30MAR92	N	N	N	N	N
12	16/105	FN	26	25MAY92	N	N	N	N	N
			26	09JUN92	N	N	N	N	N
12	19/106	SS2	10	18FEB92	N	N	N	N	N
			18	14APR92	N	N	N	N	N
12	2/99	EFC	26	09JUN92	N	N	N	N	N
			26	09JUN92	N	N	N	N	N
12	21/110	FL	10	13JAN92	N	N	N	N	N
			18	06APR92	N	N	N	N	N
12	26/113	MF	10	17APR92	N	N	N	N	N
			18	26JUN92	N	N	N	N	N
			26	21AUG92	N	N	N	N	N
12	25/114	FS	10	20APR92	N	N	N	N	N
			18	16JUN92	N	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D.
REBOXETINE - PROTOCOL 20124/013
Listing No. : 12.3

URINALYSIS
DOUBLE BLIND PHASE
TREATMENT : REBOXETINE

Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	WBC	RBC	Specific Gravity	Albumin	Glucose
12	25/114	FS	26	10AUG92	N	N	N	N	N
			34	05OCT92	N	N	N	N	N
			42	30NOV92	N	N	N	N	N
12	27/115	VCS	52	08FEB93	ND	ND	ND	ND	ND
			10	17APR92	N	N	N	N	N
			18	12JUN92	N	N	N	N	N
12	29/117	AK	26	07AUG92	N	N	N	N	N
			34	02OCT92	N	N	N	N	N
			10	20APR92	N	N	N	N	N
12	3/93	IF	18	15JUN92	N	N	N	N	N
			26	10AUG92	N	N	N	N	N
			34	06OCT92	N	N	N	N	N
12	36/385	FB	42	30NOV92	N	N	N	N	N
			52	09FEB93	N	N	N	N	N
			10	17JAN92	N	N	N	N	N
12	4/100	EG	18	03MAR92	N	N	N	N	N
			26	13APR92	N	N	N	N	N
			34	23JUN92	N	N	N	N	N
12	7/102	LK	42	18AUG92	N	N	N	N	N
			52	04DEC92	N	N	N	N	N
			10	28MAY92	ND	ND	ND	ND	ND
12	9/91	KBP	18	06AUG92	N	N	N	N	N
			26	08JUN92	N	N	N	N	N
			10	13JAN92	N	N	N	N	N
13	1/219	P2	18	09MAR92	N	N	N	N	N
			26	04MAR92	N	N	N	N	N
			10	23DEC91	N	N	N	N	N
13	1/219	P2	18	18FEB92	N	N	N	N	N
			26	14APR92	N	N	N	N	N
			34	09JUN92	N	N	N	N	N

2126

***** = APPROVED = REJECTED = NOT APPROVED

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No. : 12.3

URINALYSIS
DOUBLE BLIND PHASE
TREATMENT : REBOXETINE

Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	MEC	RBC	Specific Gravity	Albumin	Glucose
13	1/219	PZ	42	04AUG92	N	N	N	N	N
			52	13OCT92	N	N	N	N	N
13	13/223	HM	10	09JAN92	N	N	N	N	N
			18	05KAR92	N	N	N	N	N
			26	30APR92	N	N	N	N	N
			34	25JUN92	N	N	N	N	N
			42	26AUG92	N	N	N	N	N
52	29OCT92	N	N	N	N	N	N		
13	18/227	VT	10	11FEB92	N	N	N	N	N
			18	07APR92	N	N	N	N	N
			26	02JUN92	N	N	N	N	N
			34	28JUL92	N	N	N	N	N
			42	22SEP92	N	N	N	N	N
			52	01DEC92	N	N	N	N	N
13	20/230	NL	10	06APR92	N	N	N	N	N
			18	02JUN92	N	N	N	N	N
			26	28JUL92	N	N	N	N	N
			34	22SEP92	N	N	N	N	N
			42	17NOV92	N	N	N	N	N
			52	27JAN93	N	N	N	N	N
13	21/231	CL	10	28APR92	N	N	N	N	N
			18	23JUN92	N	N	N	N	N
			26	14AUG92	N	N	N	N	N
			34	13OCT92	N	N	N	N	N
			42	07DEC92	N	N	ND	N	N
			52	16FEB93	N	N	N	N	N
13	22/232	NVN	10	14JUL92	N	N	N	N	
13	3/221	AI	10	23DEC91	N	N	N	N	N
			18	18FEB92	N	N	N	N	N
			26	14APR92	N	N	N	N	N
			34	09JUN92	N	N	N	N	N
			42	04AUG92	N	N	RD	N	N
52	14OCT92	N	N	N	N	N			
13	6/226	KE	10	27DEC91	N	N	N	N	N
			18	20FEB92	N	N	N	N	N
			26	16APR92	N	N	N	N	N
			34	11JUN92	N	N	N	N	N
42	06AUG92	N	N	N	N	N			

*** N = NOT DONE **

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No. : 12.3

URINALYSIS
 DOUBLE BLIND PHASE
 TREATMENT : REBOXETINE

Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	RBC	RBC	Specific Gravity	Albumin	Glucose
13	6/226	KE	52	15OCT92	N	N	N	N	N
13	7/220	BL	10	02JAN92	N	N	N	N	N
			18	27FEB92	N	N	N	N	N
			26	23APR92	N	N	N	N	N
			34	16JUN92	N	N	N	N	N
			42	11AUG92	N	N	N	N	N
			52	21OCT92	N	N	N	N	N

21 22 23

PHARMACIA - 1 - 15/01/92 - 10/10/92

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

Contro	Patient No. Open/Blind	Initials	Visit	Laboratory Date	RBC	Specific Gravity	Albumin	Glucose
1	1/1	MGA	10	25JAN91	N	N	N	N
			18	22MAR91	N	N	N	N
1	100/142	JHA	10	22APR92	N	N	N	N
			18	17JUN92	N	N	N	N
			26	12AUG92	N	N	N	N
			34	07OCT92	N	N	N	N
			42	02DEC92	N	N	N	N
			52	10FEB93	N	N	N	N
1	104/144	MTF	10	28APR92	N	N	N	N
			18	23JUN92	N	N	N	N
			26	19AUG92	N	N	N	N
			34	14OCT92	N	N	N	N
			42	09DEC92	N	N	N	N
			52	17FEB93	N	N	N	N
1	105/145	ABS	10	28APR92	N	N	N	N
			18	23JUN92	N	N	N	N
			26	19AUG92	N	N	N	N
			34	14OCT92	N	N	N	N
			42	09DEC92	N	N	N	N
			52	17FEB93	N	N	N	N
1	106/146	HRN	10	28APR92	N	N	N	N
			18	23JUN92	N	N	N	N
			26	18AUG92	N	N	N	N
			34	13OCT92	N	N	N	N
			42	08DEC92	N	N	N	N
			52	16FEB93	N	N	N	N
1	108/148	STB	10	29APR92	N	N	N	N
			18	24JUN92	N	N	N	N
			26	19AUG92	N	N	N	N
			34	14OCT92	N	N	N	N
			42	09DEC92	N	N	N	N
			52	17FEB93	N	N	N	N
1	11/9	VRT	10	17MAY91	N	N	N	N
			18	12JUL91	N	N	N	N
			26	06SEP91	N	N	N	N
			34	01NOV91	N	N	N	N
1	111/331	JBF	10	29APR92	N	N	N	N
			18	24JUN92	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/015
Listing No. : 12.3

URINALYSIS
DOUBLE BLIND PHASE
TREATMENT : PLACEBO

Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	HBC	RBC	Specific Gravity	Albumin	Glucose	
1	111/331	JBF	26	19AUG92	N	N	N	N	N	
			34	14OCT92	N	N	N	N	N	
			42	09DEC92	N	N	N	N	N	N
1	114/332	CLF	52	17FEB93	N	N	N	N	N	
			10	05MAY92	N	N	N	N	N	
			18	30JUN92	N	N	N	N	N	N
1	115/333	ELS	26	26AUG92	N	N	N	N	N	
			34	21OCT92	N	N	N	N	N	
			42	15DEC92	N	N	N	N	N	N
			52	24FEB93	N	N	N	N	N	N
			10	05MAY92	N	N	N	N	N	N
1	12/10	SLT	18	30JUN92	N	N	N	N	N	
			26	26AUG92	N	N	N	N	N	
			34	21OCT92	N	N	N	N	N	N
			42	15DEC92	N	N	N	N	N	N
			52	24FEB93	N	N	N	N	N	N
1	122/337	HSS	10	28MAY91	N	N	N	N	N	
			18	23JUL91	N	N	N	N	N	
			26	17SEP91	N	N	N	N	N	N
			34	12NOV91	N	N	N	N	N	N
			42	07JAN92	N	N	N	N	N	N
1	124/339	PPC	52	17MAR92	N	N	N	N	N	
			10	06MAY92	N	N	N	N	N	N
			18	01JUL92	N	N	N	N	N	N
			26	26AUG92	N	N	N	N	N	N
			34	21OCT92	N	N	N	N	N	N
1	126/341	SMB	42	16DEC92	N	N	N	N	N	
			52	24FEB93	N	N	N	N	N	N
			10	06MAY92	N	N	N	N	N	N
			18	01JUL92	N	N	N	N	N	N
			26	26AUG92	N	N	N	N	N	N
1	126/341	SMB	34	21OCT92	N	N	N	N	N	
			42	16DEC92	N	N	N	N	N	
			52	24FEB93	N	N	N	N	N	

2130

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	WBC	RBC	Specific Gravity	Albumin	Glucose
PHARMACIA CNS RED REROXETINE - PROTOCOL 20124/013 Listing No. : 12.3 URINALYSIS DOUBLE BLIND PHASE TREATMENT : PLACEBO									
1	126/341	SMB	52	24FEB93	N	N	N	N	N
1	129/344	MNS	10	06MAY92	N	N	N	N	N
			18	01JUL92	N	N	N	N	N
			26	26AUG92	N	N	N	N	N
			34	21OCT92	N	N	N	N	N
			42	16DEC92	N	N	N	N	N
1	130/345	EGA	10	08MAY92	N	N	N	N	N
			18	03JUL92	N	N	N	N	N
1	133/346	JPH	10	29MAY92	N	N	N	N	N
			18	24JUL92	N	N	N	N	N
			26	18SEP92	N	N	N	N	N
			34	13NOV92	N	N	N	N	N
			42	08JAN93	N	N	N	N	N
			52	19MAR93	N	N	N	N	N
1	136/349	AVP	10	02JUN92	N	N	N	N	N
			18	28JUL92	N	N	N	N	N
			26	22SEP92	N	N	N	N	N
			34	17NOV92	N	N	N	N	N
			42	12JAN93	N	N	N	N	N
			52	23MAR93	N	N	N	N	N
1	138/350	LBV	10	02JUN92	N	N	N	N	N
			18	28JUL92	N	N	N	N	N
			26	22SEP92	N	N	N	N	N
			34	17NOV92	N	N	N	N	N
			42	12JAN93	N	N	N	N	N
			52	23MAR93	N	N	N	N	N
1	141/353	AMG	10	02JUN92	N	N	N	N	N
			18	28JUL92	N	N	N	N	N
			26	22SEP92	N	N	N	N	N
			34	17NOV92	N	N	N	N	N
1	143/355	JEP	10	02JUN92	N	N	N	N	N
			18	28JUL92	N	N	N	N	N
1	145/357	SLD	10	05JUN92	N	N	N	N	N
			18	31JUL92	N	N	N	N	N
			26	25SEP92	N	N	N	N	N
			34	20NOV92	N	N	N	N	N
			42	15JAN93	N	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

2131

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No. : 12.5

URINALYSIS
DOUBLE BLIND PHASE
TREATMENT : PLACEBO

Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	MBC	REC	Specific Gravity	Albumin	Glucose
1	145/357	SLD	52	26MAR93	N	N	N	N	N
1	149/360	SC	10	05JUN92	N	N	N	N	N
			18	31JUL92	N	N	N	N	N
			26	25SEP92	N	N	N	N	N
			34	20NOV92	N	N	N	N	N
			42	15JAN93	N	N	N	N	N
			52	26MAR93	N	N	N	N	N
1	15/12	MAO	10	17JUL91	N	N	N	N	N
			18	11SEP91	N	N	N	N	N
			26	06NOV91	N	N	N	N	N
			34	02JAN92	N	N	N	N	N
			42	26FEB92	N	N	N	N	N
			52	06MAY92	N	N	N	N	N
1	150/151	VA	10	05JUN92	N	N	N	N	N
			18	31JUL92	N	N	N	N	N
			26	25SEP92	N	N	N	N	N
			34	20NOV92	N	N	N	N	N
1	16/13	HHC	10	26JUL91	N	ND	N	ND	ND
			18	20SEP91	N	ND	N	ND	ND
			26	14NOV91	N	N	N	N	N
			34	10JAN92	N	N	N	N	N
1	19/16	SR	10	06AUG91	N	ND	N	ND	ND
			18	01OCT91	N	N	N	ND	ND
			26	26NOV91	N	N	N	N	N
			34	21JAN92	N	N	N	N	N
1	21/18	VNC	10	13AUG91	N	ND	N	ND	ND
			18	08OCT91	N	N	N	ND	ND
			26	03DEC91	N	N	N	N	N
			34	28JAN92	N	N	N	N	N
			42	26MAR92	N	N	N	N	N
			52	02JUN92	N	N	N	N	N
1	26/22	OC	10	17SEP91	N	N	N	N	N
			18	12NOV91	N	N	N	N	N
			26	07JAN92	N	N	N	N	N
			34	04MAR92	N	N	N	N	N
			42	22APR92	N	N	N	N	N
			52	07JUL92	N	N	N	N	N

N = NORMAL A = ABNORMAL ND = NOT DONE

2132

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	MBC	RBC	Specific Gravity	Albumin	Glucose
1	27/23	RK	10	20SEP91	N	N	N	ND	ND
1	28/24	RHM	10	24SEP91	N	N	N	N	N
			18	19NOV91	N	N	N	N	N
1	29/25	AFO	10	24SEP91	N	N	N	N	N
			18	19NOV91	N	N	N	N	N
			26	14JAN92	N	N	N	N	N
			34	10MAR92	N	N	N	N	N
			42	05MAY92	N	N	N	N	N
			52	14JUL92	N	N	N	N	N
1	30/26	ERV	10	25SEP91	N	N	N	N	N
1	33/29	OFC	10	02OCT91	N	N	N	N	ND
1	36/302	LM	10	05NOV91	N	N	N	N	N
1	38/304	DBF	10	26NOV91	N	N	N	N	N
			18	21JAN92	N	N	N	N	N
			26	17MAR92	N	N	N	N	N
			34	12MAY92	N	N	N	N	N
			42	07JUL92	N	N	N	N	N
			52	15SEP92	N	N	N	N	N
1	40/306	EX	10	03DEC91	N	N	N	N	N
			18	28JAN92	N	N	N	N	N
			26	24MAR92	N	N	N	N	N
			34	19MAY92	N	N	N	N	N
			42	14JUL92	N	N	N	N	N
			52	22SEP92	N	N	N	N	N
1	41/307	SFS	10	03DEC91	N	N	N	N	ND
			18	28JAN92	N	N	N	N	N
			26	24MAR92	N	N	N	N	N
			34	19MAY92	N	N	N	N	N
			42	14JUL92	N	N	N	N	N
1	42/308	ICC	10	11DEC91	N	N	N	N	N
			18	04FEB92	N	N	N	N	N
			26	01APR92	N	N	N	N	N
			34	27MAY92	N	N	N	N	N
			42	22JUL92	N	N	N	N	N
			52	30SEP92	N	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No. : 12.3

URINALYSIS
DOUBLE BLIND PHASE
TREATMENT : PLACEBO

Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	WBC	RBC	Specific Gravity	Albumin	Glucose	
1	47/312	MCS	10	31DEC91	N	N	N	N	N	
			18	25FEB92	N	N	N	N	N	
			26	22APR92	N	N	N	N	N	N
			34	16JUN92	N	N	N	N	N	N
			42	11AUG92	N	N	N	N	N	N
1	50/314	MFA	10	03JAN92	N	N	N	N	N	
			18	28FEB92	N	N	N	N	N	
			26	24APR92	N	N	N	N	N	N
			34	19JUN92	N	N	N	N	N	N
			42	14AUG92	N	N	N	N	N	N
1	51/315	ASA	52	23OCT92	N	N	N	N	N	
			10	09JAN92	N	N	N	N	N	
			18	28FEB92	N	N	N	N	N	N
			26	24APR92	N	N	N	N	N	N
			34	12JUN92	N	N	N	N	N	N
1	53/317	JFT	42	14AUG92	N	N	N	N	N	
			52	23OCT92	N	N	N	N	N	
			10	08JAN92	N	N	N	N	N	N
			18	04MAR92	N	N	N	N	N	N
			10	25FEB92	N	N	N	N	N	N
1	59/321	SPF	18	20APR92	N	N	N	N	N	
			26	16JUN92	N	N	N	N	N	
			34	11AUG92	N	N	N	N	N	
			42	06OCT92	N	N	N	N	N	
			52	15DEC92	N	N	N	N	N	
1	6/5	CPM	10	13FEB91	N	N	N	N	N	
			18	09APR91	N	N	N	N	N	
			10	28FEB92	N	N	N	N	N	
			18	24APR92	N	N	N	N	N	
			26	19JUN92	N	N	N	N	N	
1	60/322	EM	34	14AUG92	N	N	N	N	N	
			42	09OCT92	N	N	N	N	N	
			52	18DEC92	N	N	N	N	N	
			10	17MAR92	N	N	N	N	N	
			18	12MAR92	N	N	N	N	N	
1	62/324	MEA	26	07JUL92	N	N	N	N	N	
			34	01SEP92	N	N	N	N	N	
			42	27OCT92	N	N	N	N	N	
			10	17MAR92	N	N	N	N	N	
			18	12MAR92	N	N	N	N	N	

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	WBC	RBC	Specific Gravity	Albumin	Glucose
1	62/324	MEA	52	05JAN93	N	N	N	N	N
1	64/325	EMF	10	27MAR92	N	N	N	N	N
			18	22MAY92	N	N	N	N	N
			26	17JUL92	N	N	N	N	N
			34	11SEP92	N	N	N	N	N
			42	06NOV92	N	N	N	N	N
			52	15JAN93	N	N	N	N	N
1	67/327	MAA	10	31MAR92	N	N	N	N	N
			18	26MAY92	N	N	N	N	N
			26	21JUL92	N	N	N	N	N
1	70/328	MLM	10	03APR92	N	N	N	N	N
			18	29MAY92	N	N	N	N	N
1	74/122	IVL	10	07APR92	N	N	N	N	N
			18	03JUN92	N	N	N	N	N
			26	28JUL92	N	N	N	N	N
			34	22SEP92	N	N	N	N	N
			42	17NOV92	N	N	N	N	N
			52	26JAN93	N	N	N	N	N
1	76/124	SFA	10	17APR92	N	N	N	N	N
			18	12JUN92	N	N	N	N	N
			26	07AUG92	N	N	N	N	N
			34	02OCT92	N	N	N	N	N
			42	27NOV92	N	N	N	N	N
			52	05FEB93	N	N	N	N	N
1	79/126	JCM	10	17APR92	N	N	N	N	N
			18	12JUN92	N	N	N	N	N
			26	07AUG92	N	N	N	N	N
			34	02OCT92	N	N	N	N	N
			42	27NOV92	N	N	N	N	N
			52	05FEB93	N	N	N	N	N
1	8/6	KVB	10	15FEB91	N	N	N	N	N
			18	12APR91	N	N	N	N	N
			26	07JUN91	N	N	N	N	N
1	80/127	HEL	10	17APR92	N	N	N	N	N
1	84/130	IN	10	17APR92	N	N	N	N	N
			18	12JUN92	N	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

2135

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No. : 12.3
 URINALYSIS
 DOUBLE BLIND PHASE
 TREATMENT : PLACEBO

Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	MBC	REC	Specific Gravity	Albumin	Glucose
1	84/130	IN	26	07AUG92	N	N	N	N	N
			34	02OCT92	N	N	N	N	N
			42	27NOV92	N	N	N	N	N
1	85/131	MLP	52	05FEB93	N	N	N	N	N
			10	17APR92	N	N	N	N	N
			18	12JUN92	N	N	N	N	N
1	91/135	MSC	26	07AUG92	N	N	N	N	N
			34	02OCT92	N	N	N	N	N
			42	27NOV92	N	N	N	N	N
1	93/136	AL	52	05FEB93	N	N	N	N	N
			10	22APR92	N	N	N	N	N
			18	16JUN92	N	N	N	N	N
1	94/137	RAB	26	06OCT92	N	N	N	N	N
			34	07OCT92	N	N	N	N	N
			42	02DEC92	N	N	N	N	N
1	97/140	HND	52	10FEB93	N	N	N	N	N
			10	22APR92	N	N	N	N	N
			18	17JUN92	N	N	N	N	N
3	10/72	TOR	26	12AUG92	N	N	N	N	N
			34	07OCT92	N	N	N	N	N
			42	02DEC92	N	N	N	N	N
3	2/61	FIL	52	10FEB93	N	N	N	N	N
			10	19JUN91	N	N	N	N	N
3	2/61	FIL	18	14AUG91	N	N	N	N	N
			10	09FEB91	ND	ND	ND	ND	ND
3	2/61	FIL	18	21MAR91	N	N	N	N	N
			10	09FEB91	ND	ND	ND	ND	ND

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	WBC	RBC	Specific Gravity	Albumin	Glucose
3	2/61	FIL	26	16MAY91	N	M	ND	N	N
8	1/211	HJ	10	11FEB91	N	N	N	N	N
			18	08APR91	N	N	N	N	N
			26	03JUN91	N	N	N	N	N
			34	29JUL91	N	N	N	N	N
			42	23SEP91	N	N	N	N	N
8	4/214	BA	10	21MAR91	N	N	N	N	N
			18	16MAY91	N	N	N	N	N
			26	11JUL91	N	N	N	N	N
			34	05SEP91	N	N	N	N	N
			42	31OCT91	N	N	N	N	N
			52	09JAN92	N	N	N	N	N
9	12/247	GYT	10	14MAY91	N	N	ND	N	N
			16	25JUN91	N	N	N	N	N
9	13/248	BP	10	28MAY91	ND	ND	ND	ND	ND
			18	17JUL91	N	N	N	N	N
			26	11SEP91	N	N	ND	N	N
			34	12NOV91	N	N	N	N	N
			42	01JAN92	N	N	N	N	N
			52	10MAR92	N	N	N	N	N
9	19/251	KF	10	22OCT91	N	N	ND	N	N
			18	17DEC91	N	N	N	N	N
9	2/241	VCF	10	06AUG90	N	N	N	N	N
			18	01OCT90	N	N	N	N	N
			26	26NOV90	N	N	N	N	N
			34	21JAN91	N	N	N	N	N
			42	21MAR91	ND	ND	ND	ND	ND
			52	27MAY91	ND	ND	ND	ND	ND
9	24/253	LCY	10	20JAN92	N	N	N	N	N
			18	01APR92	N	N	N	N	N
9	25/254	PH	10	28JAN92	N	N	ND	N	N
			18	24MAY92	N	N	N	N	N
			26	14MAY92	N	N	N	N	N
			34	14JUL92	N	N	ND	N	N
			42	08SEP92	N	N	N	N	N
9	28/257	HI	10	15JUN92	N	N	ND	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD

REBOXETINE - PROTOCOL 20124/013
Listing No. : 12.5

URINALYSIS
DOUBLE BLIND PHASE
TREATMENT : PLACEBO

Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	RBC	RBC	Specific Gravity	Albumin	Glucose
9	28/257	HI	18	11JUL92	N	N	N	N	N
9	5/242	MF	10	01DEC90	N	N	N	N	N
			18	26JAN91	N	N	N	N	N
			26	09APR91	N	N	ND	N	N
			34	20MAY91	N	N	ND	N	N
9	8/244	KTH	10	30JAN91	N	N	N	N	N
			18	26MAR91	N	N	N	N	N
			24	08MAY91	N	N	N	N	N
10	10/276	MH	10	07FEB91	N	N	N	N	N
10	14/279	AA	10	24APR91	N	N	N	N	N
			18	17JUN91	N	N	N	N	N
			26	12AUG91	N	N	N	N	N
			34	07OCT91	N	N	N	N	N
			42	17DEC91	N	N	N	N	N
			52	10FEB92	N	N	N	N	N
10	16/281	AJ	10	14MAY91	N	N	N	N	N
			18	08JUL91	N	N	N	N	N
			26	02SEP91	N	N	N	N	N
			34	29OCT91	N	N	N	N	N
			42	17DEC91	N	N	N	N	N
			52	03MAR92	N	N	N	N	N
10	17/282	HM	10	22MAY91	N	N	N	N	N
			18	15JUL91	N	N	N	N	N
			26	10SEP91	N	N	N	N	N
			34	05NOV91	N	N	N	N	N
			42	02JAN92	N	N	N	N	N
			52	10MAR92	N	N	N	N	N
10	19/284	TN	10	11JUN91	N	N	N	N	N
			18	05AUG91	N	N	N	N	N
			26	30SEP91	N	N	N	N	N
			34	28NOV91	N	N	N	N	N
			42	21JAN92	N	N	N	N	N
			52	31MAR92	N	N	N	N	N
10	21/288	AK	10	08JUL91	N	N	N	N	N
			18	02SEP91	N	N	N	N	N
10	24/289	AL	10	08JUL91	N	N	N	N	N

*** A = APPROVED *** NOT DONE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No. : 12.3

URINALYSIS
DOUBLE BLIND PHASE
TREATMENT : PLACEBO

Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	MRC	REC	Specific Gravity	Albumin	Glucose	
10	24/289	AL	18	02SEP91	N	N	N	N	N	
			26	29OCT91	N	N	N	N	N	
			34	17DEC91	N	N	N	N	N	N
			42	18FEB92	N	N	N	N	N	N
			52	28APR92	N	N	N	N	N	N
10	29/293	JJ	10	29OCT91	N	N	N	N	N	
			18	23DEC91	N	N	N	N	N	
10	30/294	VK	10	26NOV91	N	N	N	N	N	
			18	21JAN92	N	N	N	N	N	
			26	16MAR92	N	N	N	N	N	
			34	11MAY92	N	N	N	N	N	
			42	06JUL92	N	N	N	N	N	
			52	29SEP92	N	N	N	N	N	
10	37/32	HK	10	23DEC91	N	N	N	N	N	
			18	18FEB92	N	N	N	N	N	
			26	15APR92	N	N	N	N	N	
10	4/272	ZSD	10	08JAN91	N	N	N	N	N	
			22	02APR91	N	N	N	N	N	
			26	29APR91	N	N	N	N	N	
10	40/33	AP	10	07JAN92	N	N	N	N		
10	42/295	TT	10	22JAN92	N	N	N	N		
10	43/296	IK	10	23JAN92	N	N	N	N	N	
			18	19MAR92	N	N	N	N	N	
10	44/298	AB	10	26JAN92	N	N	N	N		
10	45/34	KJ	10	28JAN92	N	N	N	N		
10	47/39	TH	10	12FEB92	N	N	N	N	N	
			18	08APR92	N	N	N	N	N	
			26	05JUN92	N	N	N	N	N	
			34	29JUL92	N	N	N	N	N	
10	48/41	IP	42	23SEP92	N	N	N	N		
			52	02DEC92	N	N	N	N		
10	5/273	AN	10	12FEB92	N	N	N	N		
10			10	23JAN91	N	N	N	N		

N = NOT DONE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No. : 12.3

URINALYSIS
DOUBLE BLIND PHASE
TREATMENT : PLACEBO

Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	RBC	RBC	Specific Gravity	Albumin	Glucose
10	5/273	AN	12	06FEB91	N	N	N	N	N
10	50/44	EE	10	26FEB92	N	N	N	N	N
			18	22APR92	N	N	N	N	N
			26	17JUN92	N	N	N	N	N
			34	12AUG92	N	N	N	N	N
			42	07OCT92	N	N	N	N	N
			52	16DEC92	N	N	N	N	N
10	51/45	UL	10	26FEB92	N	N	N	N	N
			18	22APR92	N	N	N	N	N
			26	17JUN92	N	N	N	N	N
			34	12AUG92	N	N	N	N	N
			42	07OCT92	N	N	N	N	N
			52	16DEC92	N	N	N	N	N
10	55/49	TP	10	23MAR92	N	N	N	N	N
			18	18MAY92	N	N	N	N	N
			26	13JUL92	N	N	N	N	N
			34	07SEP92	N	N	N	N	N
			42	02NOV92	N	N	N	N	N
			52	11JAN93	N	N	N	N	N
10	58/52	KK	10	23MAR92	N	N	N	N	N
			18	19MAY92	N	N	N	N	N
			26	13JUL92	N	N	N	N	N
			34	08SEP92	N	N	N	N	N
			42	02NOV92	N	N	N	N	N
			52	12JAN93	N	N	N	N	N
10	61/55	JT	10	31MAR92	N	N	N	N	N
			18	26MAY92	N	N	N	N	N
10	62/56	RK	10	31MAR92	N	N	N	N	N
10	64/58	LT	10	15APR92	N	N	N	N	N
10	81/46	JN	10	30APR92	N	N	N	N	N
			18	25JUN92	N	N	N	N	N
			26	20AUG92	N	N	N	N	N
			34	15OCT92	N	N	N	N	N
10	88/276	AH	10	27MAY92	N	N	N	N	N
			18	22JUL92	N	N	N	N	N
			26	16SEP92	N	N	N	N	N

Legend: N = Normal, U = Urinary, B = Blood, G = Glucose, P = Protein, S = Specific Gravity, A = Albumin, C = Creatinine, F = Fasting, N = Not Done

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	MSC	RBC	Specific Gravity	Albumin	Glucose	
10	88/276	AH	34	11NOV92	N	N	N	N	N	
			42	06JAN93	N	N	N	N	N	
			52	17MAR93	N	N	N	N	N	N
10	92/73	LA	10	09JUN92	N	N	N	N	N	
			18	04AUG92	N	N	N	N	N	
			34	24NOV92	N	N	N	N	N	N
			42	19JAN93	N	N	N	N	N	N
10	94/273	PV	52	13APR93	N	N	N	N	N	
			10	17JUN92	N	N	N	N	N	N
11	1/372	DF	10	20DEC91	N	N	N	N	N	
			18	17FEB92	N	N	N	N	N	
			26	10APR92	N	N	N	N	N	N
			34	05JUN92	N	N	N	N	N	N
11	12/364	FJ	10	24FEB92	N	N	N	N	N	
			18	21APR92	N	N	ND	N	N	
			26	16JUN92	N	N	N	N	N	N
			34	09AUG92	N	N	N	N	N	N
			42	13OCT92	N	N	N	N	N	N
			52	13DEC92	N	N	N	ND	N	N
11	15/366	NF	10	06APR92	N	N	N	N	N	
			18	03JUN92	N	N	N	N	N	N
11	18/369	EI	10	19APR92	N	N	N	N	N	
			18	11JUN92	N	N	ND	N	N	
			26	06AUG92	N	N	N	N	N	N
			34	01OCT92	N	N	N	N	N	N
			42	26NOV92	N	N	N	N	N	N
11	20/371	LJ	52	07FEB93	N	N	N	N	N	
			10	11MAY92	N	N	N	N	N	N
11	4/375	BA	14	08JUN92	N	N	N	N	N	
			10	16DEC91	N	N	N	ND	N	
			18	20FEB92	N	N	N	ND	N	
11	7/376	KK	22	17MAR92	N	N	N	N	N	
			10	19DEC91	N	N	N	N	N	
			18	28FEB92	N	N	N	N	N	
			26	23APR92	N	N	N	N	N	
11			34	18JUN92	N	N	N	N	N	

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No. : 12.3

URINALYSIS
DOUBLE BLIND PHASE
TREATMENT : PLACEBO

Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	RBC	Specific Gravity	Albumin	Glucose
11	7/376	KK	42	12AUG92	N	N	N	N
			52	26OCT92	N	N	N	N
11	9/362	FI	10	06JAN92	N	N	N	N
12	10/96	IP	10	13JAN92	N	N	N	N
			18	09MAR92	N	N	N	N
12	11/94	ER	10	08JAN92	N	N	N	N
12	12/97	FSZ	10	13JAN92	N	N	N	N
12	13/103	ISZ	10	13JAN92	N	N	N	N
12	14/101	GSZ	10	14JAN92	N	N	N	N
12	17/108	TK	10	24MAR92	N	N	N	N
			18	19MAY92	N	N	N	N
			26	14JUL92	N	N	N	N
12	18/109	LS	10	26MAR92	N	N	N	N
			18	19MAY92	N	N	N	N
12	20/107	KSZ	10	26MAR92	N	N	N	N
			18	21MAY92	N	N	N	N
			26	16JUL92	N	N	N	N
12	22/111	HV	10	06APR92	N	N	N	N
			18	01JUN92	N	N	N	N
			26	27JUL92	N	N	N	N
			34	21SEP92	N	N	N	N
			42	10NOV92	N	N	N	N
			52	02FEB93	N	N	N	N
12	23/112	EN	10	16APR92	N	N	N	N
			18	11JUN92	N	N	N	N
			26	06AUG92	N	N	N	N
12	28/116	IV	10	17APR92	N	N	N	N
12	34/120	TGB	10	05JUN92	N	N	N	N
			18	31JUL92	N	N	N	N
			26	25SEP92	N	N	N	N
			34	12NOV92	N	N	N	N
			42	15JAN93	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No. : 12.3

URINALYSIS
DOUBLE BLIND PHASE
TREATMENT : PLACEBO

Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	WBC	RBC	Specific Gravity	Albumin	Glucose
12	34/120	TGB	52	26MAR93	N	N	N	N	N
12	35/119	LP	10	04JUN92	N	N	N	N	N
			18	31JUL92	N	N	N	N	N
12	37/386	EK	10	16JUN92	N	N	N	N	N
			18	07AUG92	N	N	ND	N	N
12	5/95	ZSH	10	13JAN92	N	N	N	N	N
			18	09MAR92	N	N	N	N	N
12	6/98	MK	10	09JAN92	N	N	N	N	N
			18	05MAR92	N	N	N	N	N
			26	30APR92	N	N	N	N	N
13	11/225	RS	10	23JAN92	N	N	N	N	N
			18	19MAR92	N	N	N	N	N
			26	14MAY92	N	N	N	N	N
			34	09JUL92	N	N	N	N	N
			42	03SEP92	N	N	N	N	N
			52	12NOV92	N	N	N	N	N
13	14/217	DF	10	09JAN92	N	N	N	N	N
			18	06MAR92	N	N	N	N	N
			26	30APR92	N	N	N	N	N
			34	25JUN92	N	N	N	N	N
			42	18AUG92	N	N	N	N	N
			52	29OCT92	N	N	N	N	N
13	15/222	KG	10	14JAN92	N	N	N	N	N
			18	10MAR92	N	N	N	N	N
			26	06MAY92	N	N	N	N	N
			34	30JUN92	N	N	N	N	N
			42	25AUG92	N	N	ND	N	N
			52	03NOV92	N	N	N	N	N
13	17/218	GSM	10	28JAN92	N	N	N	N	N
			18	24MAR92	N	N	N	N	N
			26	19MAY92	N	N	N	N	N
			34	16JUL92	N	N	N	N	N
			42	08SEP92	N	N	N	N	N
			52	17NOV92	N	N	N	N	N
13	2/224	TCS	10	23DEC91	N	N	N	N	N
			18	19FEB92	N	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

2143

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED										
REBOXETINE - PROTOCOL 20124/013										
Listing No. : 12.3										
URINALYSIS										
DOUBLE BLIND PHASE										
TREATMENT : PLACEBO										
Centre	Patient No. Open/Blind	Initials	Visit	Laboratory Date	WBC	RBC	Specific Gravity	Albumin	Glucose	
13	2/224	TCS	26	15APR92	N	N	N	N	N	N
			34	10JUN92	N	N	N	N	N	N
			42	31JUL92	N	N	N	N	N	N
13	8/228	PK	52	14OCT92	N	N	N	N	N	N
			10	30DEC91	N	N	N	N	N	N
			18	20FEB92	N	N	N	N	N	N
13	9/229	SZS	26	16APR92	N	N	N	N	N	N
			30	20MAY92	N	N	N	N	N	N
			10	30DEC91	N	N	N	N	N	N
			18	20FEB92	N	N	N	N	N	N

NOTE: N = NORMAL A = ABNORMAL ND = NOT DONE

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Fat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
1	1	MGA	-1	36.0	16	120	75	74	115	70	76	58
			0	36.1	.	115	80	68	110	80	70	59
			1	36.1	.	110	75	82	110	70	82	59
			2	36.0	.	115	80	74	110	75	72	59
			3	36.1	.	120	75	84	115	70	86	60
			4	36.1	.	120	80	74	115	75	76	60
1	2	RAQ	5	36.3	.	125	80	79	125	80	81	60
			6	36.1	.	125	80	70	120	70	70	60
			-1	36.0	15	130	90	74	130	85	75	75
			0	36.1	.	130	80	80	125	82	85	76
			1	36.1	.	120	85	78	125	76	76	76
			2	36.4	.	120	85	76	120	85	79	76
1	3	TA	3	36.2	.	130	85	84	125	80	88	78
			-1	36.0	18	110	70	64	110	65	66	63
			0	36.4	.	110	70	62	105	70	63	63
			1	36.0	.	110	70	76	105	70	78	62
			2	36.0	.	110	70	74	105	70	72	62
			3	36.3	.	115	75	68	110	71	71	62
1	4	DNC	4	35.9	.	120	70	78	115	65	72	63
			5	36.3	.	115	70	78	115	65	73	63
			6	36.1	.	115	70	82	110	65	84	64
			-1	36.0	17	130	80	74	125	80	76	53
			0	36.1	.	130	80	70	125	75	70	52
			1	36.4	.	130	80	74	125	80	71	52
1	5	DB	2	36.2	.	130	80	74	125	80	76	52
			3	36.2	.	125	85	84	120	85	86	53
			4	36.5	.	125	85	86	125	80	84	53
			5	36.4	.	130	80	82	125	85	84	54
			6	36.4	.	125	80	76	130	80	77	55
			-1	36.0	15	110	60	70	110	60	74	61
1	6	CPH	0	36.3	.	125	65	77	120	60	80	60
			1	36.2	.	125	65	76	125	60	78	61
			2	36.1	.	125	65	72	125	70	73	61
			3	36.1	.	125	75	68	130	70	71	62
			4	36.2	.	100	70	70	100	70	78	62
			5	36.0	.	100	60	80	100	70	85	63
1	6	CPH	6	36.1	.	120	80	76	120	80	80	63
			-1	36.0	14	130	90	72	125	80	75	60
			0	36.1	.	130	90	68	125	85	68	60
			1	36.3	.	135	85	72	140	85	74	60
1	6	CPH	2	36.2	.	140	80	76	135	80	78	60
			2	36.2	.	140	80	76	135	80	78	60

2145

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

RESOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	
1	6	CPH	3	36.4	.	140	85	72	135	80	74	60	
			4	36.2	.	130	80	80	130	80	85	60	
			5	36.3	.	140	80	88	140	80	100	60	
			6	35.9	.	135	90	74	140	90	82	60	
			1	36.0	14	130	85	90	130	90	85	74	60
			2	36.0	.	135	85	76	130	80	79	74	60
1	7	JSA	1	36.0	.	130	90	78	130	80	76	74	
			2	36.3	.	130	80	74	125	80	76	74	
			3	36.5	.	135	80	82	130	75	84	73	
			1	36.0	16	120	80	76	120	75	78	78	
			2	36.1	.	120	85	80	125	80	100	67	
			3	36.2	.	120	80	120	120	75	132	67	
1	8	MYB	3	36.3	.	100	70	116	120	80	128	67	
			4	36.1	.	100	70	120	100	70	132	68	
			5	36.2	.	110	80	110	115	75	116	68	
			6	36.1	.	110	75	110	110	75	116	68	
			1	36.3	14	120	80	62	120	70	64	64	
			2	36.1	.	115	75	60	115	70	61	68	
1	9	CCR	3	36.2	.	100	70	78	110	70	80	68	
			4	35.8	.	110	70	80	110	70	85	69	
			5	36.3	.	120	70	80	120	70	85	68	
			6	.	.	110	70	112	110	80	88	69	
			1	35.0	14	120	80	80	120	75	88	69	
			2	36.0	.	110	70	68	110	60	75	60	
1	10	LDL	1	36.0	.	110	75	80	110	70	75	60	
			2	36.2	.	115	75	104	100	70	112	60	
			3	36.6	.	110	80	100	100	75	112	61	
			4	36.9	.	120	90	92	120	90	112	62	
			5	36.4	.	110	85	96	100	80	116	63	
			6	36.0	.	90	70	90	95	70	100	63	
1	11	VRT	1	36.7	14	90	60	90	100	70	110	52	
			2	36.7	.	90	60	95	90	60	100	52	
			3	35.3	.	90	65	76	80	60	96	52	
			4	35.7	.	90	60	74	90	65	100	52	
			5	36.1	.	90	60	104	80	60	124	52	
			6	36.7	.	95	60	88	90	60	112	52	
6	36.2	.	90	60	85	90	60	88	52				

2146

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)		
1	12	SLT	-1	36.2	18	80	60	80	85	60	100	42		
			0	36.0	.	80	60	80	85	60	100	100	42	
			1	36.2	.	120	60	70	100	85	60	120	100	42
			2	35.7	.	85	60	96	85	85	60	106	106	42
			3	35.7	.	85	60	85	60	85	60	106	106	43
			4	35.4	.	90	60	106	60	90	90	114	114	43
1	13	JR	5	35.4	.	90	65	108	90	85	116	43		
			6	36.2	.	100	65	100	95	60	108	108	43	
			-1	36.4	14	100	70	82	70	82	105	70	98	50
			0	36.4	.	100	70	82	70	82	105	70	98	50
			1	36.4	.	100	70	82	70	82	105	70	98	50
			2	36.4	.	100	70	82	70	82	105	70	98	50
1	14	MLC	-1	36.2	16	130	85	92	140	90	80	80	57	
			0	36.2	.	130	85	92	140	90	80	80	57	
			1	36.1	.	125	85	92	115	85	85	100	57	
			2	36.0	.	120	80	86	125	85	92	85	100	57
			3	36.0	.	120	80	86	125	85	92	85	100	57
			4	36.2	.	110	75	104	115	80	85	72	85	56
1	15	MAO	5	36.6	.	130	85	96	125	85	100	57		
			6	35.7	.	130	85	104	130	85	85	96	58	
			-1	36	16	130	85	60	130	80	60	60	65	
			0	36.0	.	130	85	60	130	80	60	60	65	
			1	36.0	.	110	70	84	110	75	94	94	65	
			2	35.7	.	120	80	84	110	80	96	96	65	
1	16	MHC	3	35.7	.	120	80	84	110	80	96	65		
			4	36.2	.	110	70	80	110	70	80	96	65	
			5	36.2	.	120	80	84	110	80	96	96	65	
			6	36.2	.	110	70	80	110	70	80	96	65	
			-1	35.4	15	115	65	72	110	65	84	84	65	
			0	35.4	.	115	65	72	110	65	84	84	65	
1	17	CEC	1	36.0	.	100	60	86	100	60	96	65		
			2	36.0	.	100	60	90	95	70	100	100	65	
			3	36.3	.	90	60	80	90	65	65	96	65	
			4	35.0	.	100	60	88	110	70	92	92	65	
			5	36.3	.	110	70	88	105	70	105	92	65	
			6	36.0	.	100	70	88	100	65	96	96	65	
1	17	CEC	-1	36.8	12	90	60	84	90	60	104	51		
			0	36.8	.	90	60	84	90	60	104	51		
			1	36.7	.	105	60	100	100	55	112	51		
1	17	CEC	2	36.5	.	90	60	68	90	60	86	51		
			3	37.1	.	100	65	104	100	60	86	50		

2147

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	
1	17	CEC	4	37.0	.	95	60	100	100	65	120	50	
			5	37.2	.	90	65	100	100	70	100	51	
			6	36.8	.	85	65	80	90	65	100	50	
			-1	36.2	16	110	70	68	110	80	80	74	.
			1	36.8	.	110	70	68	110	80	70	100	51
			2	37.3	.	120	65	92	110	70	70	112	50
1	18	TTH	3	36.8	.	115	80	72	90	50	88	50	
			4	36.6	.	110	75	96	110	80	96	50	
			5	36.6	.	110	75	96	110	80	96	50	
			6	36.1	.	120	75	92	110	70	96	51	
			-1	35.9	18	90	65	80	90	65	65	96	.
			0	35.9	.	90	65	80	90	60	60	96	50
1	19	SR	1	35.3	.	95	65	80	75	60	60	59	
			2	35.6	.	90	60	98	80	65	100	58	
			3	35.4	.	90	70	80	90	70	100	55	
			4	35.4	.	90	70	100	85	65	100	57	
			5	35.2	.	100	70	92	90	65	106	57	
			6	36.2	.	100	70	100	90	70	106	57	
1	20	EPC	-1	37.0	14	120	75	96	120	85	102	.	
			0	37.0	.	120	75	96	120	85	102	52	
			1	37.2	.	120	70	112	120	80	110	52	
			2	36.4	.	120	90	128	120	95	136	51	
			3	36.4	.	120	90	120	130	90	128	53	
			4	37.1	.	130	90	108	130	90	116	53	
1	21	VHC	5	36.5	.	140	90	100	130	90	120	53	
			6	36.5	.	140	90	100	130	90	120	53	
			-1	36.3	14	110	80	64	115	90	72	.	
			0	36.3	.	110	80	64	115	90	72	60	
			1	36.4	.	115	90	88	110	90	96	60	
			2	35.8	.	110	90	50	115	90	58	59	
1	22	SK	3	36.7	.	120	90	80	120	90	84	58	
			4	36.0	.	110	85	52	115	95	52	58	
			5	36.5	.	125	90	84	120	90	88	57	
			6	36.8	.	125	85	50	120	80	54	58	
			-1	36.0	20	110	75	80	120	70	88	.	
			0	36.0	.	110	75	80	120	70	88	52	
1	23	SK	1	35.6	.	100	80	80	100	80	92	52	
			2	36.2	.	100	70	84	95	70	104	51	
			3	36.0	.	105	75	80	100	80	92	52	
			4	36.2	.	110	80	84	105	80	104	52	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	
1	22	SK	5	36.1	.	120	85	64	105	75	84	52	
			6	36.0	.	110	75	84	100	70	100	52	
	23	AR	-1	35.9	20	110	60	88	110	60	60	80	48
			0	35.9	.	110	60	88	110	60	70	80	48
			1	36.3	.	110	65	88	100	100	60	80	48
			2	35.8	.	115	65	72	110	110	60	80	48
24	LVF	3	35.7	.	115	70	76	110	110	60	82	48	
		4	35.9	.	115	70	62	110	110	70	76	48	
		-1	35.7	16	115	80	92	110	110	95	104	46	
		0	35.7	.	115	90	92	110	110	95	104	46	
		1	36.5	.	110	80	124	110	110	80	120	46	
		2	35.9	.	125	90	108	110	110	90	90	120	46
25	AMR	3	36.9	.	125	90	108	110	110	90	120	46	
		4	36.8	.	120	90	100	125	90	90	120	46	
		5	36.8	.	120	90	100	125	90	120	120	46	
		6	36.8	.	110	80	120	110	110	80	120	46	
		-1	36.0	18	120	80	84	110	110	80	80	90	71
		0	36.0	.	120	80	64	110	110	80	80	66	71
26	OC	1	36.1	.	125	80	76	120	120	70	82	71	
		2	36.1	.	130	80	72	120	120	80	78	71	
		3	36.2	.	120	70	72	115	115	70	70	70	
		4	36.0	.	120	80	76	120	120	80	82	69	
		5	36.0	.	125	85	72	120	120	85	80	82	68
		6	36.1	.	120	80	68	110	110	80	80	76	69
27	RK	-1	36.2	16	100	70	68	100	100	70	76	55	
		0	36.2	.	100	70	68	100	100	70	76	55	
		1	36.4	.	100	65	88	90	90	60	106	56	
		2	36.2	.	85	60	88	85	85	65	90	56	
		3	36.5	.	105	70	80	110	110	75	88	56	
		4	36.3	.	100	65	88	100	100	70	96	56	
1	RK	5	36.5	.	105	70	80	100	100	75	88	56	
		6	36.3	.	100	65	88	100	100	70	96	56	
		-1	36.5	20	120	80	72	110	110	70	82	78	
		0	36.2	.	125	80	70	120	120	80	76	78	
		1	36.2	.	125	85	82	120	120	70	72	78	
		2	36.2	.	120	80	66	110	110	75	78	78	
1	RK	3	36.1	.	120	80	74	115	115	75	78	78	
		4	36.1	.	125	80	68	125	125	75	76	78	
		5	36.1	.	130	80	66	120	120	80	72	78	
		6	36.2	.	120	80	84	115	115	80	90	79	

2149

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REDOMETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	Sm. Lying Sys BP (mmHg)	Sm. Lying Dias BP (mmHg)	Sm. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)	
1	28	RMH	-1	35.6	15	130	80	76	140	90	80	73	
			0	35.6	.	130	80	76	140	90	80	73	
			1	36.0	.	125	80	100	120	90	92	88	73
			2	36.1	.	130	90	80	120	95	130	100	73
			3	36.0	.	130	85	92	130	100	130	84	73
			4	36.5	.	130	85	80	130	105	130	88	75
1	29	AFO	6	36.3	.	125	85	80	125	90	88	75	
			-1	35.7	17	120	80	68	120	80	70	70	
			0	36.7	.	120	90	80	115	80	115	76	56
			1	36.2	.	120	90	92	120	95	116	108	57
			2	36.3	.	110	85	88	95	108	110	108	57
			3	37.0	.	120	85	60	110	80	120	64	57
1	30	ERV	4	37.3	.	120	70	64	120	80	64	58	
			5	36.8	.	115	90	100	120	90	100	100	58
			6	36.8	.	130	100	88	130	90	98	98	58
			-1	35.4	14	130	90	76	125	80	80	80	65
			0	36.2	.	120	80	80	120	80	120	84	65
			1	36.4	.	110	80	88	105	75	110	84	65
1	31	MAH	2	35.8	.	110	70	108	110	80	108	65	
			3	36.2	.	120	80	88	100	65	96	65	
			4	36.3	.	130	85	120	130	80	120	120	65
			5	36.2	.	110	75	64	110	80	60	60	65
			6	36.6	.	110	80	84	100	80	100	100	65
			-1	35.8	12	100	78	76	105	60	88	88	41
1	32	DGR	0	36.4	.	105	65	100	105	65	112	41	
			1	36.3	.	100	60	120	100	60	120	41	
			2	36.5	.	105	65	120	105	65	120	65	
			3	37.1	.	100	60	100	100	70	124	65	
			4	35.7	.	100	75	120	100	60	120	63	
			5	36.8	.	110	70	100	100	70	112	67	
1	33	OFC	6	36.9	.	105	75	100	95	70	110	63	
			-1	35.6	16	110	80	68	110	80	78	76	
			0	36.3	.	105	85	100	105	85	88	88	
			1	36.0	.	100	75	112	110	75	120	65	
			2	36.5	.	95	70	100	100	75	120	65	
			3	35.8	.	105	80	120	95	75	120	63	

2150

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 2012/4/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
1	33	OFC	0	36.5	.	115	60	100	115	65	108	62
			1	37.2	.	100	55	100	110	60	112	62
			2	37.0	.	110	65	120	105	65	120	62
			3	36.8	.	105	65	108	95	55	116	61
			4	37.0	.	110	65	120	105	65	120	62
			5	37.0	.	110	70	100	120	70	105	62
			6	37.1	.	110	60	120	115	65	128	62
1	34	GNH	-1	36.0	14	120	80	120	120	75	84	.
			0	35.4	.	120	90	80	110	80	92	56
			1	35.7	.	100	70	92	100	75	100	57
			2	35.7	.	100	70	72	100	75	80	57
			3	35.9	.	120	80	88	110	70	80	57
			4	35.9	.	120	80	88	110	70	80	57
			5	35.9	.	120	80	88	110	70	80	57
			6	35.9	.	120	80	88	110	70	80	57
1	35	EMF	-1	36.4	16	90	65	76	95	70	88	.
			0	35.9	.	120	80	78	120	80	94	58
			1	35.8	.	130	80	66	120	70	70	58
			2	36.0	.	125	85	64	120	80	78	58
			3	35.8	.	130	80	72	120	75	78	59
			4	35.8	.	130	80	70	120	80	82	59
			5	35.8	.	130	80	66	120	70	72	60
			6	36.1	.	125	85	64	120	75	72	60
1	36	LM	-1	36.6	14	150	100	68	150	100	88	.
			0	36.6	.	150	100	68	150	100	88	78
			1	36.6	.	130	85	108	120	100	116	78
			2	36.7	.	115	80	92	115	85	100	76
			3	36.1	.	135	95	84	125	90	80	74
			4	36.1	.	135	95	84	125	90	80	74
			5	36.4	.	100	80	92	120	80	88	74
			6	36.4	.	100	80	92	120	80	88	74
1	37	RF	-1	35.8	16	120	86	80	120	90	80	.
			0	36.0	.	150	100	80	160	100	100	76
			1	36.3	.	160	95	100	170	100	104	76
			2	36.8	.	155	100	92	155	100	92	76
			3	36.7	.	145	90	100	150	100	88	76
			4	36.0	.	140	100	100	150	100	96	76
			5	36.4	.	160	100	108	155	105	112	76
			6	37.0	.	165	100	96	160	100	100	77
1	38	DBF	-1	36.0	14	120	70	88	120	90	100	.
			0	36.0	.	120	70	88	120	90	100	65

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)		
1	38	DBF	1	35.4	.	120	90	120	120	90	120	65		
			2	36.7	.	125	90	120	120	90	116	65		
			3	35.8	.	120	90	120	90	108	90	108	65	
			4	36.3	.	140	90	116	90	120	150	90	120	65
			5	35.5	.	115	80	120	85	132	105	85	132	65
1	39	ASS	6	35.5	.	150	90	120	140	90	120	65		
			-1	35.9	16	120	80	80	120	80	80	84	.	
			0	35.7	.	120	70	76	70	80	70	80	60	
			1	36.3	.	90	58	96	80	85	50	100	60	
			2	36.0	.	120	80	88	70	95	70	95	61	
			3	35.2	.	100	80	84	80	88	105	80	88	61
1	40	EM	4	36.3	.	95	65	100	100	70	106	61		
			5	36.2	.	100	70	90	100	100	70	95	61	
			6	36.5	.	110	70	90	70	100	110	100	61	
			-1	35.8	12	130	80	60	80	125	80	60	.	
			0	36.0	.	100	70	80	70	100	100	70	84	53
			1	36.6	.	100	60	80	60	105	65	65	92	53
1	41	SFS	2	36.3	.	105	65	76	90	60	80	53		
			3	36.7	.	95	60	92	90	60	60	108	54	
			4	36.3	.	90	60	88	70	100	70	88	54	
			5	36.5	.	110	70	90	94	110	110	94	53	
			6	36.2	.	100	60	76	60	100	70	82	53	
			-1	35.7	18	130	90	76	90	125	90	80	80	.
1	42	ICC	0	35.9	.	130	80	88	130	85	70	70		
			1	35.5	.	120	80	80	100	70	92	92	70	
			2	35.5	.	110	65	88	80	120	80	92	70	
			3	35.7	.	120	70	104	90	130	90	100	70	
			4	35.7	.	120	70	104	90	130	90	100	70	
			5	35.7	.	110	70	96	80	120	80	100	70	
1	43	ARN	6	36.0	.	120	70	92	120	80	92	70		
			-1	35.0	16	130	80	76	80	120	70	84	.	
			0	35.8	.	130	90	80	90	92	90	92	51	
			1	36.4	.	120	90	92	110	110	95	104	51	
			2	36.6	.	120	90	104	85	110	85	100	51	
			3	36.9	.	120	85	96	100	110	80	100	51	
1	43	ARN	4	36.9	.	130	85	100	110	70	118	51		
			5	36.3	.	120	90	98	120	90	105	51		
			6	35.7	.	125	85	88	110	110	80	100	51	
			-1	36.0	14	120	80	80	80	120	80	90	.	
			0	36.8	.	110	80	96	85	110	85	100	92	
			1	35.7	.	120	85	92	80	110	80	88	92	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REDOXETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)
1	43	ARN	2	36.8	115	75	60	110	75	100	925	
			3	36.5	110	70	84	105	60	66	92	
			4	36.7	110	80	100	100	75	104	90	
			5	36.6	100	75	102	100	75	104	89	
			6	36.6	115	85	116	130	90	120	89	
			-1	36.0	105	65	112	110	85	120	65	
1	44	MAL	0	36.0	105	65	112	110	85	120	65	
			1	36.0	105	65	112	110	85	120	66	
			2	36.1	120	75	100	130	96	67	67	
			3	36.0	120	75	100	130	96	66	66	
			4	36.4	105	65	112	110	85	120	65	
			5	36.4	120	75	100	130	96	64	64	
6	36.4	120	75	100	130	96	64	64				
1	45	DPS	-1	36.0	130	80	90	120	76	80	80	65
			0	36.2	180	110	60	160	105	72	62	65
			1	35.7	145	90	76	130	90	72	66	65
			2	36.3	120	80	88	115	80	88	67	65
			3	36.3	150	90	84	130	90	88	67	65
			4	35.5	140	90	84	140	90	100	67	65
5	36.0	140	90	90	140	90	100	67	65			
6	35.3	120	75	88	120	85	98	68	68			
1	46	SP	-1	37.2	110	70	80	105	65	96	51	
			0	35.7	125	80	76	120	80	74	51	
			1	35.7	110	80	74	110	70	76	51	
			2	36.1	125	85	76	120	80	74	51	
			3	36.2	130	80	68	115	70	72	51	
			4	36.2	120	80	68	110	70	74	51	
5	35.8	120	70	72	110	70	80	51				
6	35.9	110	80	70	110	70	78	51				
1	47	MCS	-1	36.4	130	90	92	125	85	88	65	
			0	36.4	130	90	92	125	85	88	65	
			1	36.5	130	90	80	130	90	90	65	
			2	36.2	125	85	108	105	70	108	65	
			3	36.6	110	90	90	120	95	100	65	
			4	36.2	115	80	100	105	75	108	64	
5	36.4	100	80	100	100	80	100	64				
6	36.1	130	85	108	120	85	108	64				
1	48	SCH	-1	37.1	95	65	80	100	70	80	66	
			0	36.2	130	80	96	120	80	100	66	
			1	36.3	140	90	74	130	80	86	66	
2	36.2	150	80	74	125	70	82	66				

2152

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
REBOMETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)		
1	48	SCH	3	36.4	.	125	85	74	120	80	82	66		
			4	36.1	.	125	85	78	120	80	88	67		
			5	36.2	.	120	80	84	120	80	70	86	67	
			6	36.1	.	125	85	76	120	85	78	85	67	
			1	49	DAS	-1	36.3	16	120	70	96	110	100	.
			1	49	DAS	0	36.3	.	120	70	96	110	100	62
1	50	MFA	1	36.3	.	120	70	96	110	80	100	62		
			2	35.7	.	120	70	84	110	75	88	62		
			1	51	ASA	-1	37.0	14	110	60	100	104	.	
			1	51	ASA	0	37.0	.	110	60	100	104	54	
			2	36.0	.	110	70	100	110	105	70	105	54	
			3	36.1	.	110	65	116	60	132	60	132	54	
1	51	ASA	4	36.2	.	135	70	96	115	65	108	56		
			5	35.6	.	110	80	80	110	80	104	55		
			6	36.0	.	115	80	84	110	80	100	55		
			1	52	MTS	-1	36.0	14	90	70	95	70	54	
			1	52	MTS	0	36.0	.	120	70	72	120	70	.
			1	52	MTS	1	36.0	.	100	60	80	75	70	49
1	52	MTS	2	36.0	.	120	80	90	110	80	95	49		
			3	36.0	.	120	80	106	120	80	100	49		
			4	36.8	.	120	80	108	120	80	102	49		
			5	35.3	.	120	80	108	120	80	108	49		
			6	35.2	.	115	75	92	120	75	92	75	49	
			1	52	MTS	6	35.2	.	115	90	112	110	112	49
1	53	JFT	1	36.7	14	130	90	88	140	90	90	90	.	
			0	36.7	.	130	90	86	140	90	90	90	52	
			1	36.5	.	130	90	69	130	79	90	79	52	
			2	36.5	.	130	85	100	130	95	108	108	53	
			3	36.1	.	130	100	80	130	100	82	130	53	
			4	37.0	.	160	105	108	165	120	116	116	53	
1	53	JFT	5	37.0	.	130	100	80	140	100	80	53		
			6	36.3	.	130	100	80	140	110	80	54		
			1	53	JFT	-1	36.4	18	140	85	76	85	76	.
			0	36.4	.	140	85	76	135	85	76	85	68	
			1	35.8	.	110	80	84	110	75	88	75	71	
			2	35.8	.	105	70	70	115	75	70	70	71	
1	54	JFT	3	36.0	.	110	70	96	110	75	100	71		
			4	36.4	.	110	72	96	110	75	100	71		
			5	36.0	.	110	75	96	100	80	100	68		
			6	36.0	.	110	75	96	105	75	104	75	68	
			1	54	JFT	6	36.0	.	100	70	92	100	104	70
			1	54	JFT	6	36.0	.	100	70	92	100	104	70

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD

REBONEXTINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	
1	54	JD	-1	36.5	14	140	90	74	130	90	74	72	
			0	36.5	.	140	90	74	130	90	74	72	
			1	36.5	.	120	80	70	70	110	80	70	72
			2	36.5	.	110	85	84	84	110	80	72	72
			3	35.8	.	120	90	84	84	120	90	100	70
			4	35.5	.	110	80	88	88	110	85	96	70
1	55	DHG	-1	36.3	13	130	70	68	130	70	76	64	
			0	36.3	.	130	70	68	130	70	76	64	
			1	36.0	.	120	90	80	80	120	90	90	64
			2	36.2	.	120	70	90	90	125	80	100	64
			3	36.7	.	140	75	84	84	130	80	96	64
			4	36.8	.	140	80	88	88	135	85	96	64
1	56	IAL	5	36.8	.	130	85	84	130	80	84	64	
			6	36.0	.	105	65	92	95	70	104	62	
			-1	36.7	12	115	80	80	80	105	80	88	75
			0	36.0	.	115	80	80	80	105	80	88	75
			1	35.9	.	110	70	72	72	110	80	82	75
			2	36.1	.	110	70	72	72	115	80	80	75
1	57	SNC	3	35.8	.	115	80	72	110	80	82	74	
			4	35.7	.	110	70	72	115	80	80	74	
			5	36.0	.	110	70	80	80	110	70	75	
			6	35.7	.	115	80	82	82	115	80	82	75
			-1	36.1	18	90	60	68	68	80	55	76	42
			0	35.4	.	90	60	68	68	80	55	76	42
1	58	ARM	1	35.4	.	90	70	80	95	70	90	42	
			2	35.4	.	90	65	84	95	70	90	42	
			3	36.0	.	90	65	84	95	70	90	42	
			-1	36.0	18	90	60	76	76	100	70	80	53
			0	36.2	.	90	60	76	76	100	70	80	53
			1	36.2	.	110	85	88	88	100	80	100	53
1	59	SFF	2	36.2	.	115	80	88	120	80	88	48	
			3	36.2	.	120	80	80	120	80	88	48	
			4	36.2	.	115	85	68	68	100	80	88	48
			5	36.3	.	105	75	72	72	110	85	88	48
			6	36.3	.	100	75	76	76	100	80	80	48
			-1	35.7	14	100	60	80	80	105	60	88	48
1	59	SFF	0	36.7	.	100	60	80	105	60	88	48	
			1	36.7	.	80	60	100	85	65	116	48	
			2	36.7	.	100	60	74	74	100	82	48	
			3	36.6	.	100	70	108	108	95	70	48	
1	59	SFF	4	36.2	.	115	75	116	105	75	108	48	
			4	36.2	.	115	75	116	105	75	108	48	

2155

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REDUXETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	
1	59	SPF	5	36.5	.	100	60	100	100	70	108	48	
			6	36.5	.	90	65	100	110	80	100	45	
1	60	EM	-1	36.0	18	120	80	116	120	80	120	120	.
			0	36.0	.	120	80	116	120	80	120	120	62
			1	36.5	.	130	80	110	130	120	85	120	62
			2	36.5	.	120	80	116	120	120	85	120	62
			3	36.5	.	120	80	112	120	115	80	120	62
			4	36.5	.	120	80	112	120	115	80	120	62
1	61	RVC	5	36.3	.	120	80	100	115	85	116	62	
			6	36.4	.	120	80	116	120	80	116	62	
			-1	35.6	16	110	65	72	115	115	80	76	.
			0	35.6	.	110	65	72	115	115	80	76	62
			1	35.7	.	115	80	104	80	100	80	108	62
			2	35.7	.	105	70	88	90	96	65	96	62
1	62	MEA	3	35.7	.	120	80	80	105	75	100	62	
			4	36.4	.	120	75	88	95	65	96	62	
			5	36.3	.	110	75	84	100	70	100	60	
			6	36.0	.	110	80	88	95	70	100	60	
			-1	36.0	14	130	80	80	130	88	80	88	.
			0	35.9	.	130	80	80	130	88	80	88	53
1	63	JCL	1	35.9	.	120	80	92	120	80	100	53	
			2	35.5	.	140	80	88	130	90	100	53	
			3	35.7	.	140	90	92	140	95	95	100	53
			4	36.6	.	150	90	95	150	90	100	100	54
			5	36.0	.	140	90	95	140	95	90	100	54
			6	36.5	.	110	80	88	110	95	70	100	52
1	64	EMF	-1	35.8	16	120	75	104	95	65	116	.	
			0	35.8	.	120	75	104	95	65	116	60	
			1	36.5	.	130	98	92	130	120	90	120	60
			2	37.2	.	120	80	124	120	124	75	124	59
			3	35.7	.	130	80	116	130	120	90	120	59
			4	36.0	.	110	80	64	110	110	80	104	60
1	65	FS	5	36.0	.	110	90	94	110	90	96	60	
			6	36.6	.	110	70	116	100	65	128	60	
			-1	35.8	14	120	75	76	110	110	70	80	.

2156

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REMOXYLINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
1	65	FS	0	36.1	.	130	80	64	120	70	72	62
			1	36.3	.	125	80	64	115	70	72	62
			2	36.2	.	120	80	65	110	70	72	62
			3	36.0	.	125	85	76	115	80	82	62
			4	36.3	.	120	80	62	110	70	72	62
			5	36.3	.	110	70	58	105	70	66	62
1	66	TCC	6	36.1	.	125	85	56	115	80	66	62
			-1	36.0	18	120	90	80	130	90	88	.
			0	36.0	.	120	90	80	130	90	88	68
			1	36.4	.	110	90	100	100	80	110	67
			2	36.3	.	110	80	100	110	80	100	66
			3	36.4	.	120	80	92	110	104	104	65
1	67	MMA	4	35.4	.	100	75	100	100	75	100	64
			5	36.3	.	110	90	112	120	120	128	64
			6	36.5	.	100	80	92	100	80	92	63
			-1	36.5	16	150	90	98	150	90	110	85
			0	36.5	.	150	90	98	150	90	110	85
			1	36.5	.	150	90	100	150	90	104	85
1	68	MGS	2	36.5	.	140	100	108	140	104	104	87
			3	36.3	.	140	100	96	160	100	104	87
			4	36.5	.	160	120	96	160	120	102	87
			5	36.5	.	190	120	112	190	130	112	87
			6	36.7	.	150	100	95	150	100	105	87
			-1	36.7	18	100	70	80	100	70	88	.
1	69	RFA	0	36.1	.	130	80	68	120	70	78	52
			1	36.0	.	125	85	76	120	80	82	52
			2	36.2	.	130	85	72	120	80	82	52
			3	36.3	.	125	80	72	120	80	82	51
			4	36.3	.	125	85	86	120	80	90	50
			5	36.1	.	130	80	76	120	80	82	50
1	70	MLM	6	36.0	.	130	80	68	120	75	80	50
			-1	36.0	15	115	80	104	115	85	112	.
			0	36.0	.	110	70	82	105	65	88	52
			1	36.3	.	105	70	84	100	70	90	52
			2	36.4	.	110	70	80	100	65	88	52
			3	36.2	.	100	70	80	100	65	86	52
1	70	MLM	4	36.2	.	105	75	78	100	70	86	52
			5	36.2	.	105	75	76	100	70	84	52
			6	36.0	.	100	70	80	90	60	90	52
			-1	36.2	14	130	80	72	120	80	80	72
			0	36.0	.	110	75	72	115	80	84	72
			1	36.0	.	110	75	72	115	80	84	72

2157

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	
1	70	MLM	1	36.5	.	110	80	84	105	80	96	72	
			2	36.0	.	120	75	84	100	80	100	72	
			3	36.0	.	115	80	96	100	80	112	80	72
			4	35.5	.	120	90	92	120	80	96	80	72
			5	36.2	.	130	80	80	120	85	80	80	72
			6	36.5	.	110	90	88	125	90	100	100	72
1	71	OMV	-1	36.8	16	105	70	88	100	70	96	.	
			0	36.8	.	105	70	88	100	70	96	52	
			1	36.1	.	92	60	88	100	75	92	51	
			2	35.6	.	90	65	96	100	70	96	53	
			3	36.8	.	110	70	120	110	80	120	53	
			4	36.3	.	100	80	88	70	80	80	54	
1	72	RLJ	5	36.5	.	100	80	96	100	80	104	54	
			6	36.5	.	100	80	96	100	80	104	54	
			-1	36.5	12	130	80	60	120	70	64	.	
			0	36.1	.	130	80	84	125	75	86	68	
			1	36.3	.	120	80	80	115	75	86	68	
			2	36.4	.	110	70	88	110	65	74	68	
1	73	PMA	3	36.1	.	110	70	68	105	70	68	68	
			4	36.0	.	105	75	62	100	75	68	68	
			5	36.2	.	110	70	68	105	70	72	68	
			6	36.2	.	140	70	72	130	70	76	68	
			-1	36.0	14	130	100	76	130	100	60	.	
			0	36.0	.	130	100	76	130	100	60	60	
1	74	IVL	1	36.8	.	130	90	88	130	100	88	60	
			2	36.9	.	130	90	94	130	90	88	60	
			3	36.0	.	130	90	76	140	110	76	59	
			4	36.7	.	130	100	88	130	105	100	59	
			5	36.5	.	140	95	88	135	95	92	59	
			6	36.5	.	140	90	88	135	95	92	59	
1	75	ELF	-1	36.2	12	120	80	88	115	75	100	.	
			0	37.0	.	90	60	88	95	70	88	62	
			1	36.6	.	105	70	76	95	75	92	62	
			2	36.2	.	90	65	80	80	60	100	61	
			3	36.8	.	90	70	80	90	70	90	60	
			4	36.6	.	95	65	96	75	108	95	60	
1	75	ELF	5	36.6	.	95	65	96	95	75	108	60	
			6	36.6	.	95	65	96	95	75	108	60	
			-1	36.7	12	90	60	66	100	70	80	57	
			0	36.7	.	90	60	60	100	70	80	57	
			1	35.8	.	95	65	92	80	60	100	57	
			2	35.8	.	95	65	92	80	60	100	57	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	
1	75	ELF	2	36.5	.	100	80	80	100	80	96	57	
			3	35.7	.	100	70	80	95	75	80	57	
			4	35.7	.	100	80	96	100	80	100	104	57
			5	35.6	.	95	70	100	70	90	70	104	57
			6	35.6	.	95	70	100	70	90	70	104	57
1	76	SFA	-1	35.8	16	130	80	84	120	75	90	.	
			0	36.4	.	130	80	84	115	75	90	70	
			1	36.3	.	125	80	82	120	80	88	70	
			2	36.3	.	135	80	76	125	80	82	70	
			3	35.9	.	125	85	72	120	80	82	71	
			4	36.2	.	130	80	92	125	75	85	71	
1	77	ACG	5	36.4	.	130	90	78	120	85	86	71	
			6	36.3	.	130	85	76	125	80	82	71	
			-1	36.2	14	125	75	90	115	70	75	84	70
			0	36.1	.	125	80	76	115	70	82	80	69
			1	36.2	.	120	70	76	115	70	80	80	68
1	78	SD	2	36.3	.	130	80	84	120	75	90	69	
			3	36.4	.	120	75	72	110	70	82	69	
			4	36.6	.	130	80	68	120	80	74	70	
			5	36.2	.	120	80	76	115	80	84	70	
			6	36.2	.	125	85	76	115	80	78	78	
1	79	JCK	-1	36.0	18	135	85	74	120	80	76	.	
			0	36.7	.	125	70	72	120	70	80	80	
			1	36.1	.	120	70	68	110	65	76	79	
			2	36.2	.	115	70	66	105	70	72	78	
			3	36.2	.	120	70	76	115	70	84	78	
			4	36.0	.	115	75	66	110	70	72	78	
1	80	MEL	5	36.2	.	130	80	74	125	80	82	77	
			6	36.1	.	120	80	82	110	70	90	77	
			-1	36.3	20	120	90	82	130	80	90	90	.
			0	36.3	.	130	80	60	120	70	74	74	70
			1	36.4	.	135	85	72	120	70	84	84	70
1	80	MEL	2	36.4	.	130	85	76	120	75	82	70	
			3	36.1	.	135	80	84	120	80	90	70	
			4	36.3	.	130	80	80	120	75	82	70	
			5	36.3	.	130	75	76	120	70	82	70	
			6	36.2	.	130	80	68	120	75	78	70	
1	80	MEL	-1	36.3	18	130	90	92	120	80	96	.	
			0	36.4	.	120	80	92	115	80	94	62	
			1	36.3	.	125	85	84	120	80	88	63	
1	80	MEL	2	36.3	.	120	85	82	115	88	63		

2159

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 2012A/013
Listing No.: 15.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)			
1	80	MEL	3	36.2	.	120	80	72	110	70	80	63			
			4	36.4	.	120	75	76	125	75	82	64			
			5	36.2	.	130	80	76	120	86	75	65			
			6	36.4	.	130	80	82	120	75	90	65			
			1	81	MFB	-1	36.4	16	110	70	92	110	60	100	.
						0	36.2	.	115	70	84	110	60	98	66
1	36.3	.				110	70	80	100	65	84	65			
2	36.1	.				110	75	84	105	70	70	52			
3	36.1	.				110	70	68	100	78	70	88			
4	36.3	.				110	75	82	105	70	90	66			
1	82	MDS	5	36.0	.	115	80	74	110	70	78	66			
			6	36.1	.	115	80	82	110	70	78	66			
			-1	36.3	16	125	85	78	120	70	88	.			
			0	36.2	.	125	80	75	120	75	.	65			
			1	36.1	.	120	85	74	115	80	78	64			
			2	36.2	.	120	84	84	115	70	90	64			
1	83	LPH	3	36.2	.	125	80	76	120	70	82	63			
			4	36.2	.	120	80	76	120	80	86	63			
			5	36.5	.	130	80	78	115	80	86	63			
			6	36.4	.	125	85	76	120	75	80	64			
			-1	36.1	18	120	80	84	115	80	82	64			
			0	36.0	.	120	80	76	115	75	88	.			
1	84	IN	1	36.2	.	125	80	72	120	70	82	69			
			2	36.2	.	120	75	82	120	75	86	69			
			3	36.2	.	125	85	76	115	75	84	68			
			4	36.3	.	125	80	76	120	80	82	68			
			5	36.6	.	120	80	74	120	80	76	67			
			6	36.3	.	120	80	76	120	75	80	67			
1	85	MLP	-1	36.1	18	125	85	76	120	80	80	.			
			0	36.0	.	130	80	64	125	80	86	75			
			1	36.1	.	130	80	76	120	80	82	75			
			2	36.3	.	125	85	78	120	80	84	75			
			3	36.1	.	120	85	86	115	80	92	75			
			4	36.2	.	135	85	78	130	80	84	75			
1	85	MLP	5	36.2	.	125	85	78	120	80	88	75			
			6	36.2	.	130	80	86	120	70	92	75			
			-1	36.4	13	130	70	88	120	70	92	.			
1	85	MLP	0	36.2	.	130	70	82	120	70	86	71			
			1	36.3	.	125	70	76	120	70	80	71			
			2	36.3	.	125	85	76	120	80	80	70			
1	85	MLP	3	36.2	.	125	80	76	120	80	82	70			
			4	36.2	.	125	80	76	120	80	82	70			
			5	36.2	.	125	80	76	120	80	82	70			

2160

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXYETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)	
1	85	MLP	4	36.2	.	125	70	84	120	65	88	71	
			5	36.4	.	120	75	68	110	70	84	71	
			6	36.4	.	130	70	76	120	65	82	72	
			-1	36.3	17	120	90	104	130	90	120	100	73
			0	36.3	.	125	80	100	120	65	100	100	73
			1	36.2	.	130	80	86	120	80	120	98	73
1	86	MTF	2	36.2	.	130	90	88	120	80	100	73	
			3	36.2	.	130	85	76	120	80	92	73	
			4	36.1	.	130	80	68	125	80	98	72	
			5	36.4	.	120	90	88	120	80	90	90	71
			6	36.1	.	130	90	76	120	85	120	84	71
			1	87	MDO	-1	37.3	15	110	70	96	110	75
1	88	VRL	0	36.8	.	120	80	78	110	70	86	75	
			1	36.1	.	125	85	84	120	80	92	75	
			2	36.1	.	130	80	72	120	80	82	75	
			3	36.1	.	130	80	68	120	80	82	75	
			4	36.2	.	120	70	80	110	70	82	75	
			5	36.2	.	130	80	74	120	70	82	75	
1	89	NHV	6	36.0	.	120	80	70	110	70	76	75	
			-1	36.2	20	120	80	85	120	80	92	80	
			0	36.8	.	120	80	76	110	80	82	80	
			1	36.3	.	130	80	74	120	75	80	80	
			2	36.1	.	130	80	84	125	85	88	80	
			3	36.5	.	125	85	78	120	80	82	80	
1	90	JSS	4	36.2	.	130	85	76	125	80	88	60	
			5	36.2	.	130	80	82	120	70	86	60	
			6	36.4	.	120	80	76	110	70	82	60	
			-1	36.0	16	95	75	88	90	70	104	68	
			0	36.1	.	130	80	64	120	80	82	70	
			1	36.4	.	120	80	76	110	70	82	68	
1	90	JSS	2	36.4	.	120	80	78	115	75	86	68	
			3	36.3	.	120	70	84	120	75	86	68	
			4	36.0	.	120	80	78	110	75	82	68	
			5	36.2	.	120	80	78	115	80	82	68	
			6	36.2	.	130	80	78	120	80	84	68	
			-1	36.8	14	105	70	76	105	70	76	76	
1	90	JSS	0	36.8	.	105	70	76	105	70	76	65	
			1	36.5	.	100	70	100	95	75	92	65	
			2	36.0	.	110	90	80	120	90	86	65	
			3	36.5	.	115	80	92	100	75	112	65	
1	90	JSS	4	36.4	.	115	80	84	100	75	100	65	

216

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
1	90	JSS	5	36.4	.	105	80	84	95	70	104	65
			6	36.8	.	105	80	84	95	70	104	65
1	91	MSC	-1	36.1	14	125	85	82	120	80	86	.
			0	36.0	.	115	70	82	110	75	88	66
			1	36.2	.	120	75	76	110	75	84	65
			2	36.1	.	125	80	76	120	75	84	65
			3	36.1	.	120	80	82	110	75	88	65
			4	36.2	.	125	80	72	120	70	80	65
			5	35.9	.	125	85	76	115	75	84	66
			6	36.1	.	120	80	76	110	70	76	66
1	92	PSS	-1	36.2	16	130	85	80	125	80	90	.
			0	36.0	.	135	85	86	130	80	92	65
			1	36.1	.	130	85	82	120	75	88	63
			2	36.1	.	125	80	86	120	80	94	63
			3	36.3	.	130	80	82	120	80	92	64
			4	36.2	.	130	85	76	125	80	86	64
			5	36.0	.	125	80	82	115	70	86	63
			6	36.1	.	125	80	64	120	75	75	62
1	93	AL	-1	36.3	18	110	80	78	110	70	88	.
			0	36.2	.	110	80	76	110	70	88	88
			1	36.1	.	110	80	76	105	70	82	88
			2	36.2	.	105	70	70	100	60	82	89
			3	36.2	.	100	70	72	100	70	80	89
			4	36.2	.	100	70	74	90	70	82	89
			5	36.0	.	110	70	78	100	65	84	90
			6	36.2	.	110	70	76	105	65	82	90
1	94	RAB	-1	36.0	14	130	80	72	120	70	80	.
			0	36.8	.	120	70	84	125	75	90	70
			1	36.1	.	120	75	84	115	70	90	70
			2	36.2	.	120	80	80	115	75	82	70
			3	36.0	.	120	80	82	115	75	86	70
			4	36.1	.	120	80	74	115	75	76	70
			5	36.2	.	110	70	72	110	70	80	70
			6	36.1	.	115	75	78	110	70	84	70
1	95	GMT	-1	35.8	16	135	90	76	130	85	80	.
			0	36.1	.	130	90	84	120	90	92	66
			1	36.1	.	125	85	76	115	80	92	66
			2	36.2	.	130	80	74	120	80	82	66
			3	36.0	.	135	85	82	130	80	90	66
			4	36.0	.	130	90	74	125	80	82	66
			5	36.1	.	120	80	82	110	70	90	66

2162

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	Sm. Lying Sys BP (mmHg)	Sm. Lying Dias BP (mmHg)	Sm. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)
1	95	GHT	6	36.2	.	130	80	82	120	80	92	66
1	96	SPH	-1	36.4	18	140	90	80	135	85	86	.
			0	36.0	.	140	90	80	135	85	88	68
			1	36.2	.	140	90	76	140	85	80	68
			2	36.2	.	140	90	78	135	80	86	68
			3	36.5	.	140	80	76	140	85	86	68
			4	36.3	.	150	90	86	140	85	80	69
			5	36.0	.	120	85	84	130	85	69	69
			6	36.2	.	150	90	86	150	80	92	70
1	97	HND	-1	36.5	18	135	80	82	125	70	90	.
			0	36.1	.	120	80	78	120	80	86	60
			1	36.4	.	125	80	78	130	75	84	60
			2	36.3	.	130	90	82	120	80	86	60
			3	36.4	.	130	85	76	125	80	82	60
			4	36.0	.	130	80	86	130	85	92	60
			5	36.2	.	125	85	88	120	85	90	60
			6	36.1	.	130	80	78	125	80	82	60
1	98	YTT	-1	36.5	18	130	80	68	120	70	74	.
			0	36.2	.	130	80	78	120	75	78	72
			1	36.4	.	125	80	72	120	80	82	72
			2	36.2	.	120	80	68	110	75	74	72
			3	36.1	.	130	80	76	120	80	80	72
			4	36.0	.	130	75	84	120	70	92	72
			5	36.4	.	120	80	64	110	70	72	72
			6	36.2	.	125	85	84	120	80	92	72
1	99	LGD	-1	36.0	19	115	80	76	120	80	86	.
			0	36.1	.	115	75	64	110	70	72	60
			1	36.1	.	110	70	64	100	60	72	60
			2	36.2	.	110	75	66	105	70	72	60
			3	36.1	.	110	80	66	110	70	74	58
			4	36.3	.	120	80	68	110	70	72	58
			5	36.2	.	110	70	60	100	60	70	56
			6	36.2	.	110	70	72	115	75	80	56
1	100	JNA	-1	36.2	16	130	80	74	125	70	90	.
			0	36.2	.	125	80	76	120	80	82	83
			1	36.4	.	125	85	76	120	80	78	84
			2	36.2	.	130	80	88	120	75	92	84
			3	36.4	.	125	85	86	120	80	92	84
			4	36.2	.	125	85	72	120	80	82	84
			5	36.2	.	125	80	76	120	80	86	84
			6	36.3	.	120	80	86	110	70	92	84

2160

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	
1	101	JLL	-1	35.7	16	90	50	84	100	60	92	53	
			0	35.7	16	90	50	84	100	60	92	53	
			1	36.0	16	100	50	88	105	45	100	100	53
			2	36.3	16	95	55	120	85	140	50	140	50
			3	36.3	16	95	55	120	85	140	50	140	50
			4	36.3	16	110	70	98	110	105	70	105	50
1	102	ESF	5	36.3	16	110	70	98	110	70	105	50	
			6	36.0	16	110	70	98	110	70	105	50	
			-1	36.1	15	110	90	72	110	90	90	92	69
			0	36.3	15	120	80	74	110	76	110	76	68
			1	36.7	15	125	80	70	125	85	85	76	68
			2	36.4	15	120	80	68	110	74	80	74	67
1	103	JRA	3	36.2	15	120	75	76	120	70	76	67	
			4	36.4	15	130	80	68	120	75	78	67	
			5	36.1	15	125	80	74	120	75	75	67	
			6	36.2	15	130	80	76	120	70	84	67	
			-1	36.3	13	120	80	76	115	84	75	84	79
			0	36.2	13	120	80	74	120	82	70	82	78
1	104	MTF	1	36.2	16	110	70	72	100	60	82	71	
			2	36.4	16	100	60	108	80	50	116	77	
			3	36.1	16	110	70	72	100	60	82	72	
			4	36.2	16	105	75	76	100	70	80	71	
			5	36.2	16	110	70	74	90	65	78	78	
			6	36.3	16	115	75	78	100	70	78	74	
1	105	ABS	5	36.2	16	120	80	72	110	70	78	72	
			6	36.4	16	110	70	76	105	70	82	73	
			-1	36.1	16	120	85	84	115	75	75	90	
			0	36.2	16	115	75	80	110	70	84	84	
			1	36.2	16	120	70	66	125	80	74	62	
			2	36.3	16	125	80	76	115	70	84	62	
1	106	HRN	3	36.3	16	120	80	66	110	70	72	62	
			4	36.5	16	115	80	76	110	80	84	62	
			5	36.2	16	110	80	68	105	70	76	76	
			6	36.2	16	110	70	76	100	65	84	62	
			-1	35.9	18	125	90	84	120	80	90	92	65
			0	36.1	18	130	90	82	125	90	90	82	65
1	106	HRN	1	36.2	18	135	85	76	130	90	82	65	
			2	36.0	18	130	80	70	120	80	70	82	65
			3	36.2	18	120	80	66	110	70	74	66	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXYETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	
1	106	NRN	4	35.9	.	125	80	69	130	80	76	66	
			5	36.1	.	130	90	78	130	90	86	67	
			6	36.2	.	125	85	76	130	90	82	67	
			-1	36.3	14	120	70	84	100	70	90	70	70
			1	36.4	.	110	70	76	100	70	82	70	70
			2	36.2	.	125	85	72	115	75	76	76	70
1	107	LAN	3	36.2	.	110	80	74	110	70	78	68	
			4	36.2	.	120	70	68	110	70	74	69	
			5	36.3	.	110	70	70	105	65	74	70	
			6	36.2	.	115	80	74	110	70	76	69	
			-1	36.4	14	110	65	68	115	70	74	70	
			0	36.2	.	130	80	82	120	75	90	75	59
1	108	STB	1	36.3	.	120	80	70	120	70	78	58	
			2	36.4	.	123	80	74	120	80	82	58	
			3	36.0	.	123	80	68	120	70	74	58	
			4	36.2	.	120	80	67	120	75	74	58	
			5	36.1	.	125	75	72	120	80	84	59	
			6	36.4	.	110	70	74	115	70	82	60	
1	109	IPL	-1	36.2	16	115	80	68	120	80	74	60	
			0	36.3	.	120	80	82	110	70	86	71	
			1	36.2	.	120	80	76	110	70	82	71	
			2	36.1	.	125	80	74	115	70	78	71	
			3	36.1	.	110	70	68	110	75	76	71	
			4	36.2	.	110	80	68	110	70	76	72	
1	110	TQO	5	36.3	.	110	70	72	110	75	78	72	
			6	36.4	.	110	80	74	105	70	76	72	
			-1	36.0	13	125	75	76	125	75	84	66	
			0	36.4	.	130	75	72	125	70	80	66	
			1	36.0	.	130	80	72	120	70	78	66	
			2	36.0	.	120	80	68	110	70	76	66	
1	111	JBF	3	36.5	.	130	80	74	125	75	78	67	
			4	36.5	.	120	80	76	110	70	82	68	
			5	36.1	.	120	80	76	110	70	80	68	
			6	36.2	.	125	80	66	115	70	72	68	
			-1	36.2	16	120	70	74	115	70	80	70	
			0	36.4	.	110	80	72	110	70	84	70	
1	111	JBF	1	36.2	.	115	75	68	110	70	74	70	
			2	36.2	.	110	75	70	105	70	82	70	
			3	36.2	.	110	75	72	105	70	74	70	
			4	36.3	.	100	70	74	105	75	78	70	

2165

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBONETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)			
1	111	JBF	5	36.2	.	115	75	76	110	70	86	70			
			6	36.2	.	120	80	76	110	75	80	71			
			-1	36.3	16	130	80	88	120	70	94	94	.		
			0	36.4	.	130	80	88	125	80	94	94	70		
			1	36.4	.	125	85	82	115	75	88	88	70		
			2	36.2	.	125	80	76	120	70	82	82	70		
1	112	PSA	3	36.5	.	125	85	74	120	80	86	70			
			4	36.2	.	120	80	76	115	70	82	70			
			5	36.1	.	120	80	74	120	70	80	70			
			6	36.2	.	125	80	76	120	80	86	80	70		
			1	113	LPS	-1	35.9	17	125	80	74	120	80	80	75
			0	36.4	.	125	85	76	120	80	82	80	82	75	
1	114	CLF	1	36.2	.	180	80	72	170	90	96	74			
			2	36.2	.	130	80	74	125	80	88	73			
			3	36.4	.	130	80	76	120	80	80	73			
			4	36.4	.	130	85	76	125	80	82	73			
			5	36.1	.	130	80	76	125	80	82	73			
			6	36.1	.	130	85	76	125	80	82	73			
1	114	CLF	-1	36.7	14	80	55	92	80	50	104	45			
			0	36.7	.	80	55	92	80	50	104	45			
			1	36.1	.	90	55	92	85	50	96	45			
			2	36.7	.	90	55	92	85	50	96	45			
			3	36.4	.	90	70	80	90	70	88	45			
			4	35.8	.	90	70	80	90	70	88	45			
1	115	ELS	5	36.7	.	90	70	80	90	70	88	45			
			6	36.6	.	80	50	112	80	50	112	45			
			-1	35.6	16	120	80	96	125	90	96	65			
			0	35.6	.	120	80	96	125	90	96	65			
			1	35.8	.	120	80	100	120	80	104	63			
			2	36.7	.	120	80	100	120	80	104	63			
1	116	MGA	3	37.0	.	120	80	100	120	80	104	63			
			4	35.5	.	130	70	80	130	80	86	63			
			5	36.7	.	130	70	80	130	80	86	63			
			6	35.0	.	100	70	80	120	80	86	63			
			-1	36.5	14	100	65	84	95	60	96	56			
			0	36.5	.	100	65	84	95	60	96	56			
1	116	MGA	1	36.7	.	100	75	100	95	60	108	56			
			2	36.4	.	90	65	72	95	65	60	55			
			3	36.4	.	90	65	112	95	65	120	55			
			4	35.3	.	110	70	70	110	70	78	55			
			5	36.0	.	110	70	70	110	70	78	55			

2166

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD

RESOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
1	116	HGA	6	36.2	.	90	75	70	90	75	76	55
1	117	PSL	-1	36.0	12	150	110	96	150	110	100	.
			0	36.0	.	150	110	96	150	110	100	120
			1	36.8	.	115	80	108	100	80	116	120
			2	37.0	.	130	100	108	100	100	82	125
			3	37.0	.	130	100	104	100	100	116	123
			4	36.8	.	130	100	104	100	100	116	122
			5	36.7	.	130	115	100	120	100	116	121
			6	36.7	.	130	115	100	120	100	116	121
1	118	HVN	-1	36.3	18	80	60	72	100	70	88	.
			0	36.2	.	120	80	76	115	80	82	47
			1	36.1	.	125	80	72	150	70	86	47
			2	36.3	.	110	60	60	110	70	68	47
			3	36.4	.	115	75	64	110	70	68	46
			4	36.4	.	110	70	62	110	65	68	46
			5	36.2	.	110	70	68	105	70	72	47
1	119	HVN	-1	36.4	12	130	80	84	125	80	90	.
			0	36.3	.	130	80	82	120	80	86	68
			1	36.2	.	130	80	82	125	75	84	68
			2	36.1	.	125	85	76	120	80	82	68
			3	36.2	.	125	80	82	130	80	82	68
			4	36.2	.	130	80	76	120	80	80	68
			5	36.0	.	135	85	70	125	75	74	68
			6	36.2	.	120	70	76	110	70	80	68
1	120	JLB	-1	36.0	16	135	85	98	130	80	100	.
			0	36.5	.	140	90	92	135	90	94	80
			1	36.4	.	130	80	90	125	85	90	81
			2	36.4	.	135	85	94	135	85	98	81
			3	36.3	.	140	90	76	130	85	82	80
			4	36.2	.	140	80	88	130	85	92	80
			5	36.3	.	125	85	88	130	90	92	81
			6	36.4	.	130	80	76	135	90	78	79
1	121	LAC	-1	36.2	14	125	70	84	120	65	92	.
			0	36.2	.	130	80	76	120	70	82	74
			1	36.0	.	140	85	82	135	80	88	75
			2	36.4	.	125	80	72	120	80	78	75
			3	36.1	.	130	80	74	120	75	78	75
			4	36.2	.	130	80	70	120	75	74	76
			5	36.0	.	130	80	76	125	75	82	75
			6	36.4	.	130	85	74	125	80	78	76

2167

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	
1	122	HSS	-1	36.1	16	130	80	86	120	75	96		
			0	36.2		125	85	82	120	80	92	82	
			1	36.1		130	80	76	120	75	78	81	
			2	36.2		130	80	82	120	75	88	81	
			3	36.2		125	75	82	120	86	86	82	
			4	36.0		120	80	82	110	90	75	90	
1	123	MLL	5	36.3		125	85	74	120	80	84	82	
			6	36.2		120	75	70	115	75	78	82	
			-1	36.4	16	140	60	86	135	60	86	86	
			0	36.5		140	70	88	140	65	92	82	
			1	36.1		135	65	70	78	135	70	78	60
			2	36.2		140	70	74	140	60	82	82	60
1	124	PPC	3	36.1		135	75	76	130	70	82	60	
			4	36.4		130	80	82	135	75	88	60	
			5	36.2		130	80	84	140	90	86	60	
			6	36.2		130	80	86	130	85	92	60	
			-1	36.5	14	125	85	76	120	80	86	86	
			0	36.0		120	80	74	120	70	78	65	
1	125	FDP	1	36.3		125	80	86	120	80	90	65	
			2	36.2		130	85	86	120	75	88	65	
			3	36.3		135	85	76	140	90	82	66	
			4	36.3		130	80	80	135	85	84	66	
			5	36.2		130	80	76	125	75	86	66	
			6	36.1		135	85	76	140	90	82	67	
1	126	SHB	-1	36.4	18	130	70	86	120	70	92	76	
			0	36.2		120	70	84	115	70	88	88	
			1	36.1		110	70	74	105	70	82	75	
			2	36.2		110	80	82	110	70	82	76	
			3	36.0		110	70	82	105	70	84	76	
			4	36.5		110	80	82	105	75	84	76	
1	127	VPD	5	36.2		110	80	76	105	80	84	76	
			6	36.2		115	75	78	110	70	78	76	
			-1	36.4	14	110	70	92	105	70	94	65	
			0	36.0		110	70	94	110	60	98	65	
			1	36.3		120	70	84	110	65	92	65	
			2	36.2		115	70	82	110	60	90	65	
1	128	VPD	3	36.2		115	75	82	105	65	82	63	
			4	36.1		110	70	82	100	60	84	62	
			5	36.4		110	75	84	100	65	84	63	
			6	36.4		125	85	76	115	65	86	64	
			-1	36.5	14	125	75	86	120	70	92	64	
			0	36.5		125	75	86	120	70	92	64	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)		
1	127	VPD	0	36.2	.	130	80	92	120	70	100	80		
			1	36.2	.	135	80	84	130	75	88	80		
			2	36.3	.	130	80	82	130	120	80	92	80	
			3	36.4	.	135	80	82	130	88	130	70	88	81
			4	36.1	.	130	80	76	130	82	120	75	82	81
			5	36.0	.	135	80	74	130	80	130	80	78	81
1	128	LAM	0	35.8	14	120	80	94	120	75	102	.		
			1	36.1	.	120	80	94	120	75	96	72	72	
			2	36.1	.	115	75	90	70	94	110	94	70	
			3	36.2	.	120	70	82	70	86	110	86	72	
			4	36.3	.	125	80	96	80	100	120	80	100	72
			5	36.1	.	120	80	98	70	102	110	70	102	72
1	129	MNS	0	36.2	14	130	80	86	120	80	96	80		
			1	37.1	.	140	90	86	130	110	100	100	85	
			2	36.3	.	125	90	104	150	150	90	120	84	
			3	37.0	.	125	90	104	150	150	90	120	85	
			4	37.0	.	120	80	108	130	130	90	120	84	
			5	37.0	.	120	80	108	130	130	90	120	83	
1	130	EGA	0	36.3	16	120	70	86	115	65	90	.		
			1	36.6	.	100	70	116	95	65	136	42		
			2	37.0	.	95	70	116	100	70	140	140	42	
			3	37.1	.	95	70	116	100	70	140	140	42	
			4	36.2	.	100	60	104	100	60	104	104	42	
			5	36.9	.	100	60	100	100	60	88	88	42	
1	131	RMR	0	36.3	18	120	65	84	110	60	88	.		
			1	36.2	.	110	70	86	110	70	90	90	62	
			2	36.1	.	115	75	68	110	70	76	62	62	
			3	36.2	.	115	70	68	110	70	88	88	62	
			4	36.4	.	120	70	68	110	70	78	78	62	
			5	36.1	.	115	75	60	110	70	82	82	62	
1	132	MAT	0	36.0	.	120	70	78	110	70	84	60		
			1	36.3	.	120	70	84	120	70	86	60		
			2	37.3	.	110	80	100	110	80	116	70		
			3	37.3	.	110	80	100	110	80	116	70		
			4	37.3	.	110	80	100	110	80	116	70		
			5	37.3	.	110	80	100	110	80	116	70		

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXYETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	
1	132	MAT	1	37.0	.	110	80	95	100	70	105	54	
			2	37.1	.	110	80	100	110	80	105	55	
			3	37.1	.	100	65	96	95	128	80	128	55
			4	37.2	.	110	75	96	100	108	80	108	55
			5	37.2	.	110	75	96	100	108	80	108	55
			6	37.2	.	105	70	108	100	140	75	140	55
1	133	JPM	-1	36.2	16	125	85	82	120	80	90	.	
			0	36.3	.	130	80	82	120	75	84	70	
			1	36.1	.	120	80	78	110	70	82	82	
			2	36.2	.	120	80	76	115	75	82	69	
			3	36.1	.	115	75	78	105	75	84	70	
			4	36.1	.	115	80	76	110	70	80	70	
1	134	LMS	5	36.2	.	115	75	78	110	75	82	70	
			6	36.2	.	120	70	74	115	65	78	70	
			-1	36.1	15	130	80	74	120	75	86	.	
			0	36.2	.	130	70	80	125	70	84	80	
			1	36.3	.	125	75	86	125	75	92	80	
			2	36.4	.	125	85	76	115	85	88	81	
1	135	HMS	3	36.2	.	130	80	86	120	75	90	81	
			4	36.1	.	125	85	78	120	80	84	81	
			5	36.4	.	120	75	72	110	70	82	82	
			6	36.3	.	125	80	84	120	75	88	82	
			-1	36.4	18	110	60	88	105	60	100	.	
			0	36.2	.	120	80	78	110	70	88	65	
1	136	AVP	1	36.2	.	125	80	82	115	70	86	65	
			2	36.2	.	115	75	82	110	70	86	65	
			3	36.0	.	120	70	78	110	70	80	65	
			4	36.3	.	125	80	78	115	80	84	65	
			5	36.3	.	120	75	84	110	70	86	65	
			6	36.2	.	110	70	84	105	70	86	65	
1	137	CHE	-1	36.3	18	130	80	74	120	70	84	.	
			0	36.4	.	120	80	76	110	70	84	60	
			1	36.0	.	125	80	74	115	80	78	58	
			2	36.4	.	120	75	82	110	70	82	59	
			3	36.2	.	125	85	78	115	80	82	60	
			4	36.3	.	120	80	76	110	70	82	60	
1	137	CHE	5	36.3	.	125	85	78	120	80	82	60	
			6	36.4	.	120	75	78	110	70	86	61	
1	137	CHE	-1	36.1	14	125	85	78	120	80	82	.	
			0	36.5	.	120	80	74	110	75	78	63	
			1	36.4	.	125	80	74	115	70	78	63	

2170

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXYETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	
1	137	CME	2	36.2	.	130	80	76	120	70	84	63	
			3	36.2	.	125	80	78	120	70	84	62	
			4	36.1	.	125	80	84	115	70	88	62	
			5	36.1	.	125	80	80	120	70	82	62	
			6	36.2	.	130	80	76	120	70	82	61	
			1	138	LBV	-1	36.4	16	130	80	82	120	75
1	139	RA	0	36.2	.	120	80	62	115	75	66	60	
			1	36.4	.	125	80	64	115	70	66	60	
			2	36.1	.	120	70	74	110	70	76	60	
			3	36.0	.	115	75	64	110	66	66	60	
			4	36.3	.	125	85	66	120	80	70	70	
			5	35.9	.	120	78	74	115	60	78	60	
1	140	MCA	0	36.1	16	130	80	92	120	70	104	.	
			1	36.1	.	120	70	72	110	70	80	70	
			2	36.0	.	125	85	76	115	70	78	70	
			3	36.2	.	120	70	72	110	70	76	70	
			4	36.1	.	130	80	74	120	70	76	69	
			5	35.9	.	140	80	78	125	75	80	80	
1	140	MCA	6	36.2	.	120	80	76	110	75	78	69	
			-1	36.0	18	130	90	96	135	90	102	84	70
			0	36.3	.	140	90	94	135	90	100	102	.
			1	36.2	.	135	85	96	140	90	102	102	65
			2	36.2	.	135	85	98	130	80	108	108	65
			3	36.1	.	145	90	90	140	90	96	96	64
1	141	AMG	4	36.3	.	145	85	94	140	80	104	64	
			5	36.2	.	135	80	94	140	85	96	65	
			6	36.4	.	140	90	94	135	85	98	65	
			-1	36.3	17	125	85	86	120	80	90	90	.
			0	36.0	.	120	80	64	125	70	66	66	68
			1	36.2	.	120	80	62	110	66	66	68	
1	142	SCC	2	36.3	.	120	70	80	110	70	64	67	
			3	36.2	.	115	75	68	110	70	74	67	
			4	36.1	.	120	70	66	110	75	70	68	
			5	36.5	.	115	75	60	110	70	64	68	
			6	36.1	.	110	70	58	110	65	64	68	
			1	142	SCC	-1	36.1	16	130	80	86	120	80
1	142	SCC	0	36.2	.	130	80	68	120	75	70	62	
			1	36.0	.	125	80	64	120	70	68	68	
1	142	SCC	2	36.4	.	120	75	60	125	75	68	61	

2171

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
REBOXETINE - PROTOCOL 2012A/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)			
1	142	SCC	3	36.2	.	125	85	66	120	80	72	62			
			4	36.0	.	125	80	68	115	75	68	62			
			5	36.3	.	120	80	64	115	70	72	63			
			6	36.4	.	125	80	60	115	70	68	63			
			1	143	JEP	-1	36.2	18	120	70	90	110	70	92	.
						0	36.8	.	120	80	75	120	80	80	58
1	37.0	.				120	80	70	120	80	75	58			
2	37.0	.				100	70	90	110	80	94	58			
3	37.1	.				100	60	96	100	80	96	59			
4	37.0	.				110	80	96	105	80	108	59			
1	144	ARF	5	37.0	.	120	85	84	110	80	88	59			
			6	37.1	.	95	60	100	95	70	108	59			
			-1	36.3	13	145	90	104	145	90	106	.			
			0	37.1	.	120	80	96	120	85	100	87			
			1	36.0	.	120	80	96	120	85	100	87			
			2	36.5	.	120	80	96	120	85	100	87			
1	145	SLD	3	36.3	.	113	85	116	120	80	116	87			
			4	35.9	.	110	80	80	120	80	88	87			
			5	36.1	.	100	100	100	110	104	104	87			
			6	36.0	.	150	100	100	130	95	100	100			
			-1	36.4	14	110	70	84	110	80	88	88			
			0	35.8	.	130	80	88	120	70	94	.			
1	146	LRM	1	35.8	.	90	65	64	90	70	70	51			
			2	36.8	.	90	60	64	90	70	70	51			
			3	36.8	.	110	80	84	90	60	84	52			
			4	36.8	.	110	80	84	100	80	100	52			
			5	36.2	.	100	80	84	100	80	100	52			
			6	36.5	.	110	70	96	100	75	104	52			
1	147	JGN	-1	36.0	14	125	85	82	120	80	90	.			
			0	35.8	.	120	80	88	130	80	88	75			
			1	36.0	.	120	80	88	130	80	88	75			
			2	35.7	.	110	90	100	120	85	116	75			
			3	36.2	.	130	85	116	130	85	116	75			
			4	35.5	.	120	100	120	130	100	120	74			
1	147	JGN	5	35.8	.	120	90	100	120	100	100	74			
			6	35.6	.	115	90	104	130	100	112	74			
			-1	36.3	18	135	70	76	130	70	80	80			
			0	36.2	.	110	70	60	105	65	66	59			
			1	36.2	.	105	75	62	100	68	68	57			
			2	36.2	.	100	70	58	95	64	64	56			

2172

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2h. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
1	148	CAS	-1	36.3	16	130	70	82	120	65	90	72
			0	36.3	.	125	80	60	120	75	68	72
			1	36.2	.	120	75	62	115	70	66	72
			2	36.1	.	110	70	64	105	70	66	72
			3	36.0	.	120	80	66	125	90	70	72
			4	36.6	.	125	90	68	120	80	72	72
1	149	SC	5	36.2	.	130	80	74	120	75	78	72
			6	36.1	.	120	70	62	110	70	64	72
			-1	36.4	17	120	70	76	110	110	80	80
			0	36.4	.	120	70	68	110	68	110	75
			1	36.2	.	125	75	64	120	68	120	70
			2	36.2	.	115	75	72	110	74	70	69
1	150	VA	3	36.1	.	120	80	62	110	75	74	69
			4	36.2	.	115	70	60	110	70	68	70
			5	36.1	.	130	80	64	120	72	71	71
			6	36.2	.	115	70	60	105	64	64	71
			-1	36.4	15	130	70	88	120	92	70	80
			0	36.2	.	125	75	74	120	76	70	65
2	31	IK	1	36.3	.	120	85	68	110	75	76	65
			2	36.2	.	125	75	70	120	65	76	63
			3	36.1	.	120	70	64	110	74	78	64
			4	36.2	.	115	75	66	110	70	74	65
			5	36.2	.	130	70	76	115	70	72	66
			6	36.4	.	115	70	70	110	80	70	80
2	32	OE	-1	37.0	20	130	100	80	180	120	100	66
			0	36.2	.	160	100	96	170	90	120	56
			1	36.8	.	165	100	96	180	100	116	58
			2	36.2	.	160	100	96	180	110	112	55
			3	36.0	.	150	100	84	170	120	112	55
			4	36.7	.	150	95	96	180	105	112	55
2	33	HS	-1	36.7	25	150	100	76	130	90	88	71
			0	36.1	.	150	95	84	130	90	92	71
			1	36.3	.	130	80	92	120	90	116	71
			2	36.4	.	125	85	84	140	85	92	71
			3	36.5	.	130	90	84	140	90	92	71
			4	36.7	.	140	90	72	140	100	112	71
2	33	HS	0	36.9	16	140	100	76	140	100	100	94
			1	35.8	.	120	100	92	100	90	108	93
			2	36.8	.	130	80	80	120	80	108	93
2	33	HS	3	36.6	.	110	90	80	120	90	108	93
			4	36.6	.	110	90	80	120	90	108	93
			5	36.6	.	110	90	80	120	90	108	93

2173

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 RESOXETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)	
2	34	EH	-1	36.3	26	140	95	84	125	90	124	.	
			0	36.5	.	140	95	84	120	85	128	126	
			1	36.9	.	140	100	76	120	80	120	92	126
			2	37.0	.	130	90	88	130	90	100	120	120
3	1	AMR	3	36.7	.	150	90	80	130	100	88	119	
			4	36.5	.	120	80	88	130	80	100	118	
			-1	37.0	.	110	60	70	110	60	72	72	
			0	36.0	.	120	70	72	120	60	72	72	
3	2	FIL	1	37.0	.	105	70	70	100	70	.	56	
			2	36.9	.	100	70	.	100	70	70	50	
			3	37.1	.	105	70	70	105	70	70	55	
			4	37.0	.	105	70	72	109	70	72	55	
3	3	DUB	-1	37.0	.	120	70	78	120	70	80	.	
			0	36.8	.	120	70	80	120	70	80	71	
			1	37.0	.	130	70	78	130	70	78	78	
			2	37.0	.	140	70	72	130	70	72	72	
			3	37.0	.	130	70	76	130	70	76	76	
			4	37.0	.	130	70	.	130	70	.	.	
3	4	AUD	5	37.0	.	140	70	.	130	70	.	.	
			6	37.0	.	125	70	.	120	70	.	.	
			-1	37.0	18	110	70	82	110	70	70	82	68
			0	36.5	.	120	70	82	120	70	70	82	68
			1	37.0	.	130	70	.	130	70	70	70	68
			2	36.8	.	120	60	72	120	60	60	60	61
3	5	NMA	3	37.0	.	110	60	78	110	60	78	61	
			4	37.0	.	130	60	72	130	60	60	61	
			5	37.0	.	120	70	80	120	70	70	80	
			6	37.0	.	120	70	80	120	70	70	80	
			-1	37.6	30	160	90	64	160	90	90	68	
			0	37.0	.	130	100	60	140	60	80	60	58
3	5	NMA	1	37.8	.	150	80	88	130	100	76	56	
			2	36.8	.	150	80	82	130	80	88	55	
			3	36.8	.	130	80	77	130	78	78	57	
			4	37.0	.	160	100	100	170	100	100	104	
			5	36.8	.	140	80	80	140	80	82	55	
			6	55
3	5	NMA	-1	37.0	15	120	80	70	120	80	73	.	
			0	37.0	.	120	80	88	120	80	82	60	
			1	37.0	.	120	80	80	120	80	80	60	
3	5	NMA	2	37.0	.	120	80	70	120	80	80	60	
			3	37.0	.	120	70	80	120	80	80	60	
			3	37.0	.	120	70	80	120	80	80	60	

2174

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBEXETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 OPEN PHASE

Centre	Pt. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)
3	5	NMA	4	37.0	.	120	80	76	120	80	80	60
			5	37.0	.	120	80	70	120	80	72	60
3	6	AJP	-1	37.0	16	130	70	80	130	70	80	.
			0	37.1	.	130	50	70	130	80	75	69
3	7	GRI	1	37.0	.	130	70	80	130	70	82	69
			-1	36.5	25	120	60	88	125	70	89	.
3	9	DEN	0	36.7	.	110	80	64	110	80	88	57
			1	37.2	.	110	60	65	100	70	65	57
3	10	TOR	2	36.7	.	135	70	82	120	60	64	57
			3	36.8	.	110	70	65	120	70	66	56
3	11	PIE	4	36.8	.	110	70	72	110	80	80	55
			5	36.3	.	120	80	88	100	70	72	54
3	11	PIE	6	36.8	.	150	80	100	100	80	100	55
			-1	37.2	.	100	60	96	100	60	96	.
3	11	PIE	0	37.0	.	90	60	100	90	60	100	43
			1	37.0	.	100	60	96	100	60	96	44
3	11	PIE	2	36.6	.	120	80	72	100	80	80	44
			3	36.8	.	110	70	90	100	75	95	44
3	11	PIE	-1	36.5	24	120	60	80	120	60	86	.
			0	37.0	.	120	90	62	100	60	72	71
3	11	PIE	1	37.0	.	120	80	65	100	70	70	72
			2	37.0	.	120	70	65	100	70	70	72
3	11	PIE	3	37.0	.	110	70	68	100	70	72	71
			4	37.0	.	110	80	66	100	70	70	70
3	11	PIE	5	37.0	.	160	80	106	110	80	105	70
			6	37.5	.	110	60	87	90	60	106	69
3	11	PIE	-1	37.0	.	110	70	70	110	70	70	71
			0	37.0	.	130	50	80	130	50	80	66
3	11	PIE	1	37.2	.	140	80	80	140	80	80	66
			-1	36.4	16	160	90	88	140	90	90	73
3	11	PIE	0	36.5	.	130	80	82	125	80	84	73
			1	36.4	.	130	80	80	130	80	82	77
3	11	PIE	2	36.4	.	140	80	80	135	80	80	73
			3	36.5	.	135	80	78	130	80	80	73
3	11	PIE	4	36.3	.	130	80	82	135	80	84	73
			5	36.6	.	130	90	84	130	80	86	74
3	11	PIE	6	36.4	.	135	80	84	130	80	86	75
			-1	36.7	18	120	80	80	120	80	80	63
3	11	PIE	0	36.6	.	120	80	80	120	80	80	63
			1	36.6	.	120	80	80	120	80	80	63

2175

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)		
8	2	TE	1	36.7	.	110	80	68	110	80	70	66		
			2	36.7	.	120	80	72	125	80	74	66		
			3	36.5	.	130	80	74	130	80	76	67		
			4	36.4	.	135	85	76	130	80	76	67		
			5	36.7	.	120	80	76	120	80	78	67		
			6	36.7	.	120	80	88	120	80	88	67		
8	3	JL	-1	36.5	18	140	90	92	140	90	94	.		
			0	36.6	.	140	80	90	140	90	90	77	.	
			1	36.7	.	130	80	84	130	80	84	78	.	
			2	36.4	.	130	90	80	130	80	82	78	.	
			3	36.7	.	130	90	88	130	90	90	77	.	
			4	36.6	.	135	80	88	130	88	130	88	77	.
8	4	BA	5	36.5	.	130	85	86	130	85	86	78	.	
			6	36.6	.	140	80	82	140	80	84	78	.	
			-1	36.5	18	140	90	96	135	90	94	94	.	
			0	36.4	.	140	90	88	140	88	88	88	65	.
			1	36.6	.	140	80	86	140	80	88	88	65	.
			2	36.6	.	145	80	84	140	80	86	86	65	.
8	5	SL	3	36.7	.	145	90	82	140	90	82	65	.	
			4	36.4	.	140	80	88	140	80	88	66	.	
			5	36.6	.	140	80	82	140	80	82	82	66	.
			6	36.4	.	140	80	84	140	80	80	84	66	.
			-1	36.4	17	135	80	84	135	80	80	86	77	.
			0	36.6	.	140	90	86	140	90	90	86	77	.
8	6	TL	1	36.4	.	135	90	84	135	90	84	77	.	
			2	36.3	.	130	80	86	130	80	86	77	.	
			3	36.6	.	130	80	82	130	80	84	77	.	
			4	36.6	.	120	80	86	115	80	80	77	.	
			5	36.6	.	140	90	86	140	90	88	88	78	.
			6	36.4	.	130	80	82	130	80	82	82	78	.
8	7	SZT	-1	36.5	18	120	80	78	120	80	80	80	.	
			0	36.6	.	125	80	84	120	80	86	86	45	.
			1	36.4	.	130	85	82	130	85	84	84	45	.
			2	36.4	.	130	80	84	135	80	84	84	46	.
			3	36.4	.	130	80	78	130	80	78	78	46	.
			4	36.4	.	130	80	82	130	80	82	82	46	.
8	7	SZT	5	36.5	.	120	80	82	120	80	82	46	.	
			6	36.6	.	130	80	74	130	80	76	47	.	
8	7	SZT	-1	36.3	16	110	60	80	110	60	82	80	.	
			0	36.5	.	110	80	78	110	80	80	80	48	.
8	7	SZT	1	36.4	.	120	80	78	120	80	78	48	.	
			1	36.4	.	120	80	78	120	80	78	48	.	

2176

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REDNETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
8	7	SZT	3	36.4	.	120	80	76	120	80	78	48
			3	36.6	.	120	80	76	120	80	78	49
9	1	US	-1	36.5	19	135	80	82	130	80	84	.
			0	36.6	.	140	80	79	130	80	82	73
			1	36.5	.	135	90	80	120	90	82	73
			2	36.5	.	140	80	78	135	90	79	73
			3	36.3	.	140	80	78	135	80	80	73
			4	36.7	.	135	85	81	130	80	82	73
			5	36.5	.	135	85	82	130	80	80	73
			6	36.6	.	130	80	78	130	75	80	72
9	2	VCF	-1	36	20	125	85	80	120	80	87	.
			0	36.2	.	120	80	76	120	75	80	73
			1	36.6	.	120	80	80	115	75	79	72
			2	36.6	.	120	75	80	120	70	82	73
			3	36.7	.	120	80	79	120	80	82	73
			4	36.2	.	125	80	76	120	80	79	73
			5	37.7	.	125	80	76	120	80	80	73
			6	36.6	.	120	80	80	115	75	82	73
9	3	SF	-1	36.6	19	140	90	80	135	85	82	.
			0	36.6	.	150	90	80	145	90	84	55
			1	36.6	.	145	80	84	150	80	86	55
			2	36.7	.	150	90	80	140	85	80	55
			3	36.6	.	140	80	78	140	90	80	55
			4	36.6	.	130	80	78	140	80	76	54
			5	36.6	.	140	90	78	130	80	80	55
			6	36.7	.	140	90	80	130	80	82	55
9	4	SA	-1	36.5	19	140	80	82	140	85	84	.
			0	36.6	.	130	80	82	125	80	84	57
			1	36.7	.	140	80	86	140	80	86	56
			2	36.6	.	135	90	78	140	80	80	57
			3	36.4	.	130	80	76	135	80	78	57
			4	36.4	.	130	80	80	140	80	80	57
			5	36.6	.	130	80	80	120	75	80	57
			6	36.4	.	130	80	80	125	80	82	56
9	5	MF	-1	36.5	19	145	90	80	150	90	80	.
			0	36.3	.	140	80	76	135	80	80	68
			1	36.6	.	140	90	76	130	80	76	68
			2	36.7	.	140	80	78	140	90	76	68
			3	36.7	.	140	80	76	140	90	80	67
			4	36.5	.	145	90	80	140	90	78	67
			5	36.7	.	140	80	76	140	90	78	68

2177

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)	
9	5	MF	6	36.6	.	150	90	76	145	90	80	68	
	6	SD	-1	36.7	19	140	90	82	135	85	80	80	.
			0	36.6	.	150	90	80	150	90	82	80	65
			1	36.7	.	150	90	80	150	90	82	80	65
			2	36.6	.	140	85	80	140	80	82	80	65
			3	36.6	.	145	90	78	140	85	80	80	65
4	SD	4	36.4	.	150	90	76	150	85	80	80	65	
		5	36.7	.	155	90	78	160	90	80	80	65	
		6	36.6	.	150	90	75	145	85	76	80	67	
		7	36.5	18	120	80	78	120	80	80	80	80	
9	PP	0	36.5	.	120	80	86	115	75	85	88	85	
		1	36.2	.	120	80	82	100	65	90	90	84	
		2	36.6	.	120	80	78	110	70	82	80	85	
		3	36.4	.	115	70	80	105	65	85	84	85	
		4	36.6	.	110	70	82	105	65	84	80	85	
		5	36.5	.	120	80	80	110	75	85	80	85	
9	KTM	6	36.5	.	120	80	81	110	75	80	80	86	
		-1	36.5	19	100	70	82	100	70	87	80	87	
		0	36.3	.	120	80	84	115	75	86	84	86	
		1	36.3	.	130	80	82	120	80	84	80	73	
		2	36.6	.	120	80	80	120	75	80	84	73	
		3	36.5	.	120	80	80	120	70	78	80	73	
9	PL	4	36.3	.	120	80	79	120	75	80	80	73	
		5	36.5	.	120	80	78	115	75	80	80	73	
		6	36.6	.	120	70	80	115	70	80	80	74	
		-1	36.5	19	130	90	80	125	84	85	84	84	
		0	36.4	.	120	80	82	115	75	84	80	45	
		1	36.5	.	120	80	78	115	75	82	80	45	
9	BG	2	36.2	.	130	80	81	125	80	80	83	45	
		3	36.5	.	120	80	78	120	80	80	79	44	
		4	36.7	.	130	80	78	120	80	80	80	44	
		5	36.8	.	130	80	80	120	80	80	80	43	
		6	36.4	.	125	80	81	120	80	80	80	42	
		9	10	BG	-1	36.5	20	110	70	85	105	87	80
9	BG	0	36.3	.	110	70	78	110	70	80	80	54	
		1	36.7	.	110	80	78	110	70	80	80	54	
		2	36.2	.	110	70	80	110	70	80	82	54	
		3	36.5	.	120	80	76	120	80	80	80	54	
		4	36.5	.	120	80	75	120	80	80	77	54	
		5	36.4	.	120	80	76	120	80	80	80	54	
6	36.5	.	110	70	76	110	75	110	75	80			

2178

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	
9	11	NE	-1	36.5	19	120	80	72	115	75	74	54	
			0	36.6	.	120	80	74	115	75	76	54	
			1	36.5	.	120	80	78	120	80	80	54	
			2	36.6	.	120	80	76	120	80	80	54	
			3	36.1	.	120	80	75	115	80	75	80	54
			4	36.5	.	120	80	76	120	80	80	80	54
9	12	GVT	5	36.6	.	120	80	72	120	80	74	54	
			6	36.3	.	125	80	72	120	80	74	55	
			-1	36.7	19	150	90	83	145	90	86	86	64
			0	36.3	.	140	80	78	140	80	80	80	64
			1	36.3	.	140	90	76	140	80	80	80	64
			2	36.4	.	140	90	72	140	80	80	74	64
9	13	BP	3	36.4	.	130	90	70	130	85	73	64	
			4	36.6	.	130	90	70	130	85	73	64	
			5	36.5	.	130	90	70	130	80	72	64	
			6	36.5	.	130	90	70	125	80	73	64	
			5	36.6	.	120	80	71	120	80	76	65	
			6	36.6	.	120	80	71	130	90	73	65	
9	14	SZF	-1	36.4	19	125	80	78	120	80	79	65	
			0	36.3	.	125	80	76	120	80	77	65	
			1	36.3	.	120	80	72	120	75	74	65	
			2	36.3	.	120	80	70	120	70	73	65	
			3	36.7	.	120	80	72	120	80	73	65	
			4	36.5	.	120	70	70	110	70	73	65	
9	15	BI	5	36.6	.	120	80	71	120	80	76	65	
			6	36.6	.	120	70	72	110	70	75	65	
			-1	36.6	19	140	90	76	140	80	78	80	
			0	36.5	.	130	90	72	130	85	73	80	
			1	36.6	.	135	90	74	130	90	77	80	
			2	36.4	.	130	80	73	130	70	75	80	
9	16	UCY	3	36.6	.	140	90	76	130	80	78	60	
			4	36.5	.	135	90	74	130	80	78	60	
			5	36.7	.	130	80	72	120	80	80	60	
			6	36.4	.	120	80	74	120	70	76	60	
			5	36.5	.	135	80	74	130	90	76	60	
			6	36.5	.	135	80	74	130	90	76	65	
9	15	BI	-1	36.5	19	130	80	81	125	70	83	60	
			0	36.6	.	130	90	76	120	80	78	60	
			1	36.4	.	130	80	76	125	70	78	60	
			2	36.3	.	125	80	78	120	70	80	60	
			3	36.7	.	130	80	78	120	70	80	60	
			4	36.7	.	130	80	76	120	70	78	60	
9	16	UCY	5	36.4	.	130	80	74	120	70	76	60	
			6	36.5	.	135	80	74	130	70	76	60	
			-1	36.5	20	140	90	76	130	80	77	65	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REDOXYLINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	
9	16	UCY	0	36.6	.	140	80	74	130	80	75	41	
			1	36.6	.	130	90	72	120	80	76	41	
			2	36.1	.	125	80	72	120	70	120	75	40
			3	36.1	.	130	85	72	120	80	120	75	41
			4	36.4	.	130	80	70	120	70	120	72	41
			5	37.0	.	120	80	70	115	80	120	73	41
9	17	NL	6	36.5	.	130	80	70	120	75	71	41	
			-1	36.6	19	120	80	85	115	80	86	86	.
			0	36.6	.	120	80	78	115	80	120	82	78
			1	36.6	.	120	80	77	120	75	120	79	78
			2	36.8	.	120	80	72	110	70	110	70	78
			2	36.5	20	120	80	77	115	78	120	78	78
9	18	MBM	0	36.4	.	120	80	72	115	75	76	62	
			1	36.1	.	120	80	72	120	80	76	62	
			2	36.6	.	120	80	72	110	70	120	76	
			3	36.6	.	120	80	71	110	70	120	70	
			4	36.6	.	110	70	70	110	70	120	73	
			5	36.6	.	120	80	72	110	71	120	71	
9	19	KF	6	36.6	.	120	80	72	119	80	73	62	
			-1	36.6	20	140	90	74	130	90	77	61	
			0	36.4	.	130	80	72	120	80	120	74	
			1	36.5	.	120	80	70	120	80	120	72	
			2	36.4	.	120	80	71	115	80	120	72	
			3	36.4	.	130	80	70	125	80	120	72	
9	20	CYE	4	36.5	.	120	80	72	120	80	73	61	
			5	36.5	.	130	90	72	120	80	73	62	
			6	36.5	.	120	80	72	120	80	120	75	
			-1	36.6	19	130	90	78	125	80	120	75	
			0	36.5	.	130	90	76	125	80	120	80	
			1	36.5	.	130	80	71	120	80	120	73	
9	21	TA	2	36.5	.	130	80	74	120	80	74	76	
			3	36.4	.	130	90	72	125	80	74	76	
			4	36.4	.	130	80	73	130	75	120	75	
			5	36.4	.	130	80	70	130	80	120	76	
			6	36.5	.	120	80	71	110	80	120	76	
			2	36.5	20	120	80	76	110	80	120	73	
9	21	TA	0	36.5	20	120	80	76	110	80	80	78	
			1	36.7	.	120	80	76	110	80	78	67	
			2	36.6	.	120	80	76	110	80	79	67	
			3	36.6	.	110	80	72	110	80	76	67	
9	21	TA	4	36.4	.	120	80	72	110	70	78	67	
			4	36.7	.	110	80	70	110	70	78	67	
			4	36.7	.	110	80	72	110	70	78	67	
			4	36.7	.	110	80	70	110	70	73	67	

2180

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)		
9	21	TA	5	36.4	.	120	80	70	110	70	74	67		
			6	36.6	.	120	80	72	110	60	74	68		
	22	RXE	-1	36.8	20	120	80	78	120	80	80	80	.	
			0	36.8	.	120	80	75	120	70	78	61	.	
			1	36.4	.	120	80	72	110	110	80	74	61	61
			2	36.5	.	120	80	70	110	110	70	72	61	61
9	23	SZN	3	36.6	.	120	70	71	110	70	73	61	61	
			4	36.4	.	130	80	71	120	70	73	61	61	
			5	36.6	.	120	70	71	110	110	70	75	62	62
			6	36.3	.	120	80	70	110	110	60	72	62	62
			-1	36.5	20	120	70	79	100	70	70	83	51	51
			0	36.6	.	120	80	72	110	76	110	70	76	51
9	24	LGY	1	36.6	.	110	80	71	110	70	75	51	51	
			2	36.4	.	120	80	70	110	80	73	51	51	
			3	36.7	.	120	80	70	110	70	100	71	51	51
			4	36.6	.	120	70	72	110	75	110	80	52	52
			5	36.5	.	110	80	72	110	70	110	80	70	52
			6	36.5	.	120	70	71	110	70	110	80	70	52
9	25	PH	-1	36.7	20	130	80	90	120	80	91	.	.	
			0	36.4	.	120	80	79	120	80	80	80	57	57
			1	36.8	.	120	90	78	110	80	110	80	58	58
			2	36.4	.	120	80	72	110	76	110	70	58	58
			3	36.7	.	120	80	71	110	70	110	73	58	58
			4	36.8	.	120	80	70	110	70	110	70	72	58
9	26	CP	5	36.6	.	120	80	72	120	80	73	57	57	
			6	36.7	.	125	80	72	120	70	75	57	57	
			-1	36.6	20	150	90	78	140	80	140	90	56	56
			0	36.4	.	150	90	74	140	77	140	80	56	56
			1	36.4	.	140	80	72	130	71	130	70	56	56
			2	36.8	.	130	80	72	130	70	130	70	57	57
9	26	CP	3	36.3	.	150	90	72	140	80	74	58	58	
			4	36.8	.	140	90	70	130	80	72	58	58	
			5	36.5	.	140	80	73	130	80	130	80	58	58
			6	36.6	.	130	80	70	130	72	130	80	58	58
			-1	36.8	20	150	90	76	140	76	140	80	56	56
			0	36.6	.	140	90	79	140	76	140	80	56	56
9	26	CP	1	36.2	.	150	90	76	140	80	72	51	51	
			2	36.8	.	140	90	76	140	76	140	80	51	51
			3	36.5	.	140	90	74	140	76	140	80	51	51
			4	36.6	.	130	90	74	140	75	140	80	52	52
			5	36.6	.	140	90	81	120	82	120	80	52	52
			6	36.3	.	140	90	76	130	74	130	80	53	53

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
9	26	CP	6	36.5	.	130	90	70	120	80	72	53
9	27	ZSL	-1	36.5	19	140	90	76	140	85	77	.
			0	36.5	.	140	80	74	130	80	76	71
			1	36.8	.	130	80	75	130	70	72	71
			2	36.4	.	130	90	72	130	80	74	71
			3	36.6	.	140	90	71	130	80	73	71
			4	36.6	.	130	90	72	120	80	75	71
			5	36.3	.	140	90	70	130	80	73	72
			6	36.7	.	130	80	73	120	70	76	72
9	28	HI	-1	36.6	20	120	80	76	120	75	78	.
			0	36.5	.	120	80	74	120	70	75	65
			1	36.7	.	130	80	71	120	70	73	65
			2	36.7	.	120	80	70	120	70	73	65
			3	36.8	.	130	80	72	120	70	73	65
			4	36.5	.	120	80	72	110	70	73	66
			5	36.7	.	130	80	70	120	70	72	66
			6	36.4	.	120	80	73	120	80	73	66
9	29	SZF	-1	36.3	20	120	80	78	120	70	80	.
			0	36.7	.	130	80	73	120	80	75	54
			1	36.8	.	130	90	71	120	80	72	54
			2	36.4	.	130	80	71	120	70	73	54
			3	36.8	.	120	70	70	110	60	72	55
			4	36.8	.	120	80	73	110	70	72	55
			5	36.5	.	130	90	71	120	70	76	55
			6	36.7	.	140	90	74	120	80	76	55
9	30	NF	-1	36.5	20	140	90	72	140	80	76	.
			0	36.6	.	130	90	71	130	80	73	56
			1	36.6	.	140	80	73	130	80	74	56
			2	36.4	.	140	90	71	130	80	75	56
			3	36.7	.	130	80	75	120	70	80	56
			4	36.7	.	140	90	71	130	80	73	57
			5	36.8	.	120	80	73	110	70	76	57
			6	36.4	.	140	70	73	130	70	75	57
10	1	VK	-1	36.0	14	120	65	82	110	60	80	.
			0	36.4	.	125	70	83	110	65	81	84
			1	36.8	.	120	66	64	120	90	60	84
			2	36.6	.	130	86	84	120	90	60	84
			3	36.1	.	132	84	64	112	90	70	84
			4	36.3	.	150	100	73	130	90	78	83
			5	36.4	.	130	86	63	120	84	68	84
			6	35.9	.	140	90	68	140	90	68	84

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 RESOXETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)		
10	4	2SD	-1	36.4	15	110	80	57	110	85	60	62		
			0	36.5	140	80	58	140	90	60	62	62		
			1	36.5	160	95	72	160	90	72	165	90	72	
			2	36.5	130	80	65	130	80	65	145	85	71	
			3	36.2	135	80	68	135	80	68	145	90	74	
			4	36.4	130	86	66	130	80	66	130	90	66	
10	5	AN	5	36.4	136	70	72	136	156	90	80	80	63	
			6	36.6	136	70	72	136	156	90	90	80	80	63
			-1	36.6	14	90	70	58	110	59	65	59	59	89
			0	36.6	86	70	55	108	60	53	80	52	52	89
			1	36.3	80	66	51	110	60	52	110	60	52	90
			2	36.4	96	68	66	90	66	96	90	66	96	89
10	6	RS	3	36.6	110	70	66	116	70	72	72	72	89	
			4	36.7	110	70	56	110	100	70	66	66	88	
			5	36.6	105	75	56	105	80	60	80	80	60	88
			6	36.5	90	70	56	96	76	56	90	76	56	89
			-1	36.6	110	80	64	100	67	67	100	65	67	86
			0	36.4	105	75	65	86	60	63	86	60	63	86
10	7	RK	1	36.4	100	70	82	87	87	65	69	69	86	
			2	36.6	105	70	82	90	86	86	60	86	86	86
			3	36.8	100	60	100	100	100	102	100	60	102	86
			4	36.3	105	60	92	105	98	98	105	60	98	86
			5	36.8	120	90	80	115	82	82	90	90	82	85
			6	36.6	120	100	80	120	80	80	100	100	80	88
10	8	VP	0	36.7	180	80	70	180	110	76	76	76	88	
			1	36.6	135	80	83	130	80	88	100	88	88	88
			2	36.4	120	80	77	120	80	105	105	80	105	87
			3	36.6	150	90	78	140	80	88	100	80	88	88
			4	36.4	120	60	65	120	68	68	80	68	68	87
			5	36.5	120	65	65	120	85	85	85	85	80	87
10	9	RT	6	36.6	130	85	73	130	85	85	80	80	89	
			-1	36.5	15	145	85	83	145	90	90	90	65	
			0	36.3	132	80	84	130	80	90	80	80	90	65
			1	36.3	145	92	76	120	80	80	120	80	80	65
			2	36.4	138	70	100	140	90	120	140	90	120	65
			3	36.5	140	80	108	145	90	120	145	90	120	65
10	9	RT	-1	36.4	12	110	78	62	120	80	68	68	54	
			0	36.4	110	78	62	110	80	68	120	80	68	54
			1	36.2	120	80	63	125	80	67	125	80	67	53
			2	36.3	110	80	72	120	85	76	120	85	76	54
			3	36.4	115	75	68	120	80	72	120	80	72	53
			6	36.4	115	75	68	120	80	72	120	80	72	53

2180

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXYMINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	
10	9	RT	4	36.3	.	110	75	80	115	75	82	54	
			5	36.3	.	120	80	72	120	85	76	55	
			6	36.5	.	120	80	70	130	80	72	54	
	10	10	MH	-1	36.2	14	110	70	70	110	50	72	.
				1	36.3	.	110	70	70	110	50	70	67
				2	36.4	.	120	80	70	115	84	72	65
3				36.4	.	120	80	64	100	80	96	63	
4				36.4	.	120	70	88	124	78	80	80	63
5				36.3	.	116	80	84	116	70	120	88	61
10	11	TH	6	36.4	.	120	70	85	125	80	80	63	
			-1	36.7	14	110	70	70	110	55	74	63	
			0	36.7	.	130	85	90	85	80	80	96	.
			1	36.7	.	130	85	90	85	125	80	96	73
			2	36.3	.	130	80	83	80	125	80	90	73
			3	36.5	.	125	85	72	120	80	120	80	73
10	12	EP	-1	36.3	14	130	80	72	125	80	78	73	
			0	36.3	.	90	60	72	90	80	76	.	
			1	36.5	.	90	60	72	90	80	76	73	
			2	36.5	.	120	80	74	125	90	79	73	
			3	36.6	.	140	100	72	140	100	84	84	
			4	36.5	.	140	85	64	110	80	66	71	
10	13	RU	5	36.5	.	110	80	62	130	100	65	71	
			6	36.3	.	110	80	68	110	80	68	71	
			-1	36.4	14	110	80	72	115	80	78	.	
			0	36.4	.	110	80	72	115	80	78	62	
			1	36.7	.	120	80	64	110	80	68	59	
			2	36.7	.	110	78	66	96	60	68	59	
10	14	AA	3	36.6	.	120	80	64	110	90	72	59	
			4	36.4	.	120	80	98	104	90	105	59	
			5	36.6	.	120	80	80	110	90	86	58	
			6	36.5	.	110	80	76	105	90	79	58	
			-1	36.6	15	130	90	62	150	105	68	.	
			0	36.6	.	120	80	61	140	100	68	85	
10	14	AA	1	36.7	.	120	70	64	100	70	68	84	
			2	36.7	.	130	80	68	180	110	71	84	
			3	36.5	.	120	80	61	110	98	69	85	
			4	36.7	.	120	90	92	130	90	96	85	
			5	36.6	.	120	70	69	110	70	73	84	
			6	36.7	.	110	76	92	140	100	120	84	

2184

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	
10	15	RT	-1	36.1	13	120	70	68	132	80	60	100	
			0	36.1	.	120	70	68	132	80	60	100	
			1	36.8	.	120	80	70	70	140	90	82	99
			2	36.9	.	120	80	70	155	100	80	80	98
			3	36.3	.	110	80	68	130	61	80	61	97
			4	36.0	.	120	70	68	138	80	80	60	97
10	16	AJ	5	36.4	.	120	80	65	140	90	74	96	
			6	36.3	.	130	80	64	145	90	72	96	
			-1	36.1	15	120	70	75	130	82	80	82	63
			0	36.6	.	122	70	72	140	92	84	92	63
			1	36.6	.	102	70	66	110	76	80	76	63
			2	36.8	.	120	80	72	120	88	75	88	64
10	17	MM	3	36.7	.	110	78	68	118	80	88	65	
			4	36.9	.	110	70	96	120	70	100	67	
			5	36.8	.	100	60	69	100	72	84	68	
			6	36.8	.	105	65	78	100	102	75	68	
			-1	36.8	16	130	90	62	140	66	100	66	77
			0	36.8	.	130	90	62	140	68	100	68	77
10	18	SS	1	36.4	.	130	90	60	160	110	64	77	
			2	36.5	.	125	85	54	150	68	64	77	
			3	36.7	.	130	80	88	100	94	100	77	
			4	36.5	.	160	90	69	160	64	90	76	
			5	36.6	.	130	80	88	110	90	80	75	
			6	36.7	.	110	80	92	130	92	110	92	
10	19	TN	-1	36.5	14	95	60	66	105	70	71	45	
			0	36.3	.	95	60	66	105	70	71	46	
			1	36.2	.	100	65	69	110	78	70	45	
			2	36.4	.	108	65	92	108	84	65	45	
			3	37.3	.	105	65	56	105	83	70	46	
			4	36.7	.	110	70	72	105	90	75	46	
10	20	EJ	5	36.4	.	105	65	84	95	80	98	45	
			6	36.5	.	105	70	78	100	85	94	45	
			-1	36.5	14	130	90	82	130	77	100	67	
			0	36.6	.	130	90	70	128	96	95	67	
			1	36.6	.	130	85	77	120	98	85	67	
			2	36.3	.	115	80	88	110	98	80	69	
10	20	EJ	3	36.5	.	114	84	76	108	84	112	69	
			4	36.9	.	120	80	80	110	100	70	69	
			5	36.9	.	110	90	72	130	74	80	70	
			6	36.5	.	160	70	92	120	120	90	69	
			-1	36.5	13	115	55	72	115	78	70	69	
			0	36.5	.	115	55	72	115	78	70	69	

2185

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13-1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	
10	20	EJ	0	36.8	.	120	60	70	120	80	78	60	
			1	36.2	.	105	70	74	95	75	95	59	
			2	36.2	.	100	72	72	92	70	92	102	59
			3	36.3	.	125	80	90	120	70	125	100	59
			4	36.4	.	140	85	78	145	80	145	80	60
			6	36.4	.	130	80	79	120	75	120	85	60
10	21	AK	-1	36.7	13	105	70	72	115	80	80	.	
			0	36.7	.	105	70	72	115	80	80	45	
			1	36.7	.	90	70	64	100	70	98	44	
			2	36.9	.	100	80	76	120	80	92	44	
			3	36.5	.	90	80	86	96	60	98	44	
			4	36.8	.	90	60	84	100	60	96	43	
10	22	AA	5	36.5	.	100	65	84	105	70	98	44	
			6	36.5	.	120	80	78	125	80	84	44	
			-1	36.5	15	145	98	72	140	95	140	84	
			0	36.5	.	145	98	72	140	84	95	84	
			1	36.8	.	135	90	72	155	100	100	80	
			2	36.3	.	140	94	100	130	100	140	81	
10	23	IT	3	36.6	.	146	80	72	140	100	126	81	
			4	36.7	.	140	80	68	125	85	88	82	
			5	36.6	.	140	75	74	140	85	130	82	
			6	36.6	.	150	100	76	130	96	85	82	
			-1	36.4	13	105	70	62	100	80	73	73	
			0	36.5	.	105	70	54	95	80	72	58	
10	24	AL	1	36.9	.	105	60	78	98	60	100	57	
			2	36.8	.	100	60	68	96	60	92	56	
			3	36.8	.	100	60	76	110	80	122	56	
			4	36.7	.	100	70	72	100	70	100	56	
			5	36.5	.	108	65	74	105	70	92	56	
			6	36.8	.	104	66	76	100	70	100	56	
10	25	ES	-1	36.4	15	120	80	90	130	90	98	.	
			0	36.3	.	125	80	84	150	100	90	67	
			1	36.7	.	130	84	72	124	80	98	66	
			2	36.2	.	140	100	84	120	80	84	66	
			3	36.6	.	124	70	96	120	70	96	67	
			4	36.4	.	123	75	92	120	75	92	67	
10	25	ES	5	36.5	.	150	80	98	130	80	100	67	
			6	36.6	.	130	80	84	130	80	120	67	
10	25	ES	-1	36.6	13	105	80	68	120	90	78	.	
			0	36.8	.	90	60	64	130	78	72	79	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	
10	25	ES	1	36.5	.	120	90	68	120	100	122	77	
			2	36.4	.	120	90	76	120	95	98	77	
			3	36.1	.	130	60	76	114	64	64	92	76
10	26	JIF	-1	36.8	16	160	100	64	150	84	110	.	
			1	36.6	.	160	100	64	150	84	110	93	
			2	36.4	.	160	90	92	155	90	90	94	91
			3	36.4	.	160	90	83	160	88	160	88	91
			4	36.5	.	130	80	66	125	80	125	78	91
			5	36.4	.	130	85	76	130	84	130	80	84
10	27	MK	6	36.1	.	135	85	76	130	87	80	89	
			-1	36.6	15	145	90	71	120	75	80	88	
			0	36.5	.	148	98	65	148	80	100	80	
			1	36.4	.	130	75	68	140	80	108	76	
			2	36.3	.	125	80	72	130	80	90	78	
			3	36.4	.	120	85	68	125	90	90	74	
10	28	LL	4	36.2	.	125	80	76	130	95	72	71	
			5	36.3	.	130	85	78	140	90	80	71	
			6	36.3	.	130	85	78	140	90	90	78	
			-1	36.3	15	120	80	89	130	90	90	70	
			0	36.6	.	125	80	72	125	90	90	90	
			1	36.4	.	140	90	72	115	90	90	84	
10	29	JJ	2	36.5	.	115	85	78	105	95	84	82	
			3	36.3	.	135	90	78	125	105	84	83	
			4	36.3	.	145	95	70	140	105	84	83	
			5	36.4	.	125	85	68	130	100	76	82	
			6	36.5	.	145	105	69	140	105	95	81	
			-1	36.7	15	105	70	78	115	75	75	96	
10	30	VK	0	36.5	.	110	75	80	120	75	92	63	
			1	36.4	.	80	80	68	100	78	120	63	
			2	36.7	.	115	80	74	105	80	96	63	
			3	36.4	.	115	80	74	110	80	90	63	
			4	36.3	.	115	80	70	115	70	98	63	
			5	36.4	.	110	80	84	110	70	96	63	
10	30	VK	-1	36.6	13	100	50	60	90	50	68	51	
			0	36.6	.	100	50	60	90	50	68	51	
			1	36.6	.	110	60	60	120	60	66	51	
			2	36.7	.	110	60	60	130	70	64	51	
10	30	VK	3	36.3	.	120	55	64	120	60	72	51	
			4	36.7	.	100	60	78	100	50	80	51	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
10	30	VK	5	36.7	.	100	80	80	110	80	82	50
			6	36.7	.	120	60	76	120	65	80	50
10	31	RK	-1	36.3	13	110	65	66	120	75	78	.
			0	35.8	.	140	80	70	135	100	92	72
			1	36.1	.	125	70	66	140	75	78	71
			2	36.0	.	120	65	62	130	70	68	70
			3	35.9	.	110	70	76	100	65	83	69
			4	35.7	.	110	80	70	90	75	98	69
			5	36.1	.	110	85	78	100	80	96	70
			6	36.3	.	100	80	84	100	85	120	71
10	32	LK	-1	36.6	15	115	70	60	125	75	66	.
			0	36.5	.	110	75	84	105	90	92	63
			1	36.4	.	110	80	64	110	80	96	63
			2	36.5	.	110	60	68	120	65	80	62
			3	36.1	.	130	60	82	125	70	96	61
			4	36.3	.	130	65	78	120	75	92	60
			5	36.5	.	110	80	64	110	80	96	60
			6	36.4	.	110	60	68	120	65	80	61
10	33	EK	-1	36.3	15	100	75	82	105	70	66	.
			0	36.4	.	110	60	70	105	85	87	82
			1	36.7	.	100	60	60	110	60	78	81
			2	36.9	.	90	65	75	100	70	96	81
			3	36.5	.	100	80	88	110	80	92	81
			4	36.7	.	105	80	86	115	80	98	81
			5	36.4	.	120	80	87	115	80	96	82
			6	36.7	.	115	85	80	110	85	98	82
10	34	TK	-1	36.5	12	120	80	70	110	80	84	.
			0	36.6	.	115	70	60	110	60	84	78
			1	36.6	.	105	60	64	110	70	78	78
			2	36.4	.	110	60	68	115	70	80	79
			3	36.6	.	110	60	60	115	70	76	78
			4	36.6	.	125	60	82	120	60	96	79
			5	36.4	.	110	80	84	120	98	79	79
			6	36.6	.	110	80	92	130	100	100	79
10	35	IH	-1	36.7	13	105	80	84	110	85	98	.
			0	36.6	.	100	75	75	110	70	86	51
			1	36.7	.	108	70	74	105	70	88	51
			2	36.6	.	98	65	72	100	65	84	50
			3	36.9	.	104	66	72	106	66	80	51
			4	37.0	.	110	80	70	110	80	72	50
			5	36.8	.	105	80	68	120	60	88	50

2188

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
10	35	IX	6	37.0	.	105	70	75	105	70	80	50
10	36	AK	-1	36.3	12	105	80	66	110	85	58	.
			0	36.5	.	110	70	54	120	70	60	73
			1	36.5	.	115	65	66	120	70	72	72
			2	36.7	.	120	65	60	125	70	68	69
			3	36.5	.	120	80	52	106	90	80	69
			4	35.9	.	105	75	54	95	80	98	68
			5	36.1	.	120	70	60	110	65	82	68
			6	36.2	.	105	70	60	110	75	74	68
10	37	HK	-1	36.2	14	100	70	70	105	75	78	.
			0	36.7	.	120	80	80	135	70	84	58
			1	36.3	.	110	80	90	95	60	100	58
			2	36.3	.	110	60	80	110	60	80	55
			3	36.4	.	140	70	88	130	70	88	54
			4	36.2	.	140	80	88	125	70	96	54
			5	36.3	.	140	85	84	150	75	92	54
			6	36.5	.	140	70	98	150	80	98	53
10	38	LL	-1	36.7	13	110	65	72	120	70	80	.
			0	36.4	.	110	60	74	120	60	80	53
			1	36.4	.	120	60	68	125	65	98	51
			2	36.3	.	125	75	66	115	86	86	53
			3	36.4	.	120	80	60	110	70	92	53
			4	36.3	.	110	70	74	110	70	90	53
			5	36.4	.	100	70	78	100	70	104	53
			6	36.5	.	100	80	84	110	90	86	53
10	39	VH	-1	36.7	15	120	90	72	110	85	74	.
			0	36.7	.	120	90	72	110	85	74	53
			1	36.5	.	115	90	82	108	80	88	52
			2	36.7	.	125	90	84	115	85	90	52
			3	36.5	.	120	95	80	110	80	80	52
			4	36.6	.	115	80	78	120	85	84	52
			5	36.6	.	120	80	84	120	90	88	51
			6	36.4	.	110	70	68	120	80	78	51
10	40	AP	-1	36.5	14	110	70	76	115	75	76	.
			0	36.5	.	110	70	74	115	75	76	67
			1	36.5	.	105	65	84	100	70	96	66
			2	36.8	.	150	70	80	100	80	110	65
			3	36.7	.	110	78	92	115	80	88	65
			4	36.6	.	100	70	88	110	75	98	65
			5	36.4	.	100	75	78	110	80	92	65
			6	36.5	.	110	70	100	105	80	80	65

102189

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXYETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)
10	41	VP	-1	36.5	15	150	90	68	120	80	84	72
			0	36.5	.	150	90	68	120	80	84	72
			1	36.4	.	150	90	68	120	80	84	72
			2	36.5	.	145	90	70	120	80	86	72
			3	36.6	.	150	90	70	125	85	81	72
			4	36.7	.	145	85	72	120	80	88	74
10	42	TT	5	36.5	.	140	80	74	125	75	80	74
			6	36.7	.	140	80	80	120	70	84	75
			-1	36.5	14	110	80	84	120	70	70	92
			0	36.5	.	110	80	84	120	70	70	92
			1	36.7	.	120	84	64	106	84	84	92
			2	36.5	.	120	60	114	130	65	120	120
10	43	IK	3	36.4	.	123	70	72	125	70	92	69
			4	36.7	.	140	70	72	140	70	96	70
			5	36.8	.	130	90	84	110	80	80	70
			6	36.3	.	140	90	84	130	80	80	90
			-1	36.7	14	105	70	72	105	70	70	75
			0	36.7	.	105	70	72	105	70	70	75
10	44	AB	1	36.7	.	105	70	70	100	65	72	65
			2	36.7	.	100	65	68	95	65	70	65
			3	36.6	.	118	80	76	110	76	88	65
			4	35.7	.	115	75	76	110	70	84	65
			5	36.7	.	105	65	76	110	70	88	65
			6	36.6	.	105	65	72	110	70	82	65
10	45	KJ	-1	36.7	14	115	65	64	110	65	72	64
			0	36.7	.	115	65	64	110	65	72	64
			1	36.5	.	120	65	88	110	70	88	63
			2	36.7	.	125	60	96	100	60	108	62
			3	36.7	.	125	60	96	100	60	108	62
			4	36.7	.	120	70	74	90	90	92	82
10	46	TN	5	36.6	.	125	65	74	125	70	88	61
			6	36.7	.	120	65	72	125	70	88	61
			-1	36.4	14	115	70	66	120	75	72	71
			0	36.4	.	115	70	66	120	75	72	71
			1	36.4	.	120	70	66	122	76	68	71
			2	36.5	.	90	60	66	120	60	86	71
10	46	TN	3	36.5	.	118	70	70	122	75	80	70
			4	36.8	.	160	100	86	150	90	100	70
			5	36.8	.	180	80	80	130	75	88	70
			6	36.9	.	130	80	80	130	80	88	70
			-1	36.6	14	135	80	60	145	80	66	66

2190

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)	
10	46	TN	0	36.6	.	135	80	60	145	95	66	95	
			1	36.4	.	150	100	60	145	80	86	95	
			2	36.7	.	145	80	60	140	80	140	80	95
			3	36.6	.	140	80	72	145	80	145	85	80
			4	36.4	.	150	90	72	140	80	140	95	95
			5	36.6	.	160	80	72	140	80	140	80	84
10	47	TK	6	36.2	.	145	80	78	150	80	80	96	
			-1	36.4	14	120	70	70	110	80	78	78	.
			0	36.4	.	120	77	70	110	80	110	78	62
			1	36.5	.	130	65	84	130	70	130	68	62
			2	36.4	.	118	64	80	124	84	124	84	62
			3	36.5	.	120	70	84	125	80	125	68	62
10	48	IP	4	36.6	.	130	65	72	130	70	80	62	
			5	36.5	.	120	60	72	125	60	80	62	
			6	36.5	.	115	65	60	115	70	115	96	62
			-1	36.8	15	120	75	64	110	70	110	74	.
			0	36.8	.	120	75	64	110	70	110	74	53
			1	36.8	.	135	65	72	140	70	140	96	53
10	49	VH	2	36.9	.	120	70	80	120	68	96	53	
			3	36.4	.	130	70	92	100	60	120	53	
			4	36.7	.	120	65	104	110	60	120	53	
			5	36.9	.	120	70	80	108	60	102	92	
			6	36.7	.	110	70	80	118	70	96	96	53
			-1	36.2	15	110	75	64	100	70	100	80	.
10	50	EE	0	36.7	14	120	80	80	120	74	92	80	
			1	36.2	.	110	75	64	100	70	100	74	.
			2	36.3	.	110	70	80	120	80	120	100	69
			3	36.5	.	110	75	64	100	70	100	80	69
			4	36.7	.	115	80	86	120	80	120	80	69
			5	37.2	.	140	95	96	135	85	120	120	69
10	51	UL	6	36.5	.	104	60	68	120	58	72	70	
			-1	36.7	14	110	70	80	115	70	89	89	70
			0	36.7	.	120	80	80	120	80	120	92	.
			1	36.6	.	130	65	80	120	75	120	74	86
			2	36.5	.	120	70	80	135	84	135	74	86
			3	36.6	.	120	70	82	130	86	130	86	86
10	51	UL	4	36.8	.	125	80	100	150	75	96	87	
			5	36.8	.	120	80	104	150	75	112	87	
			6	36.7	.	120	80	100	125	80	100	100	87
			-1	36.6	15	140	90	68	130	80	130	128	89
			0	36.6	.	140	90	68	130	80	130	76	.
			1	36.6	.	140	90	68	130	80	130	76	65

2191

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Contre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sps BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sps BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	
10	51	UL	1	36.6	.	135	90	76	125	85	80	64	
			2	36.5	.	130	85	78	130	90	84	63	
			3	36.5	.	135	80	80	100	108	100	108	62
			4	36.9	.	120	86	64	120	86	90	88	61
			5	37.0	.	118	65	76	120	70	80	80	60
			6	36.8	.	130	80	74	125	80	80	80	60
10	52	MP	-1	36.5	14	120	90	82	110	90	90	.	
			0	36.5	.	110	90	76	120	90	84	65	
			1	36.7	.	115	80	74	110	110	75	86	65
			2	36.5	.	120	70	72	110	80	65	80	65
			3	36.7	.	105	75	74	110	80	82	80	65
			4	36.5	.	115	80	74	120	86	80	86	65
10	53	MA	-1	36.5	14	110	60	66	118	78	80	56	
			0	36.5	.	110	60	66	118	78	80	56	
			1	36.8	.	95	60	60	95	60	60	68	56
			2	36.5	.	100	70	72	100	60	60	68	56
			3	36.6	.	116	58	72	120	58	58	72	56
			4	36.6	.	110	60	70	120	60	60	72	56
10	54	UX	0	36.5	.	105	60	68	110	60	72	56	
			1	36.7	.	100	60	68	110	60	72	56	
			2	36.7	14	110	70	74	105	65	65	86	.
			3	36.3	.	115	70	74	105	65	65	86	52
			4	36.2	.	120	60	82	115	70	70	80	52
			5	36.9	.	115	60	78	110	110	60	96	52
10	55	TP	0	36.8	.	120	58	72	125	60	100	52	
			1	36.4	.	110	58	84	118	62	88	52	
			2	36.4	.	120	80	84	110	100	80	100	52
			3	36.3	13	115	70	60	110	80	80	80	.
			4	36.4	.	115	70	60	110	80	80	80	85
			5	36.6	.	120	70	64	110	75	65	75	85
10	56	JP	0	36.6	.	120	60	80	125	64	88	82	
			1	36.5	.	98	58	68	104	60	76	82	
			2	36.8	.	90	60	80	90	60	88	82	
			3	36.4	.	110	60	60	110	90	60	88	
			4	36.4	.	110	60	60	110	90	60	88	
			5	36.8	.	115	70	62	110	70	65	70	86

2192

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXYETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	
10	56	JP	4	36.6	.	115	60	76	115	60	84	82	
			5	36.7	.	115	60	66	120	65	78	82	
			6	36.6	.	115	65	66	110	60	78	82	
	10	57	AG	-1	36.8	13	110	60	74	110	65	80	.
				0	36.8	.	110	60	74	110	65	80	95
				1	36.6	.	100	70	78	110	65	90	95
2				36.6	.	100	60	64	124	60	84	94	
3				36.5	.	120	65	.	120	65	.	95	
4				36.6	.	124	60	80	124	60	96	93	
10	58	KK	5	36.7	.	125	70	80	130	76	88	93	
			6	36.6	.	130	80	88	110	80	92	93	
			-1	36.9	14	90	60	60	100	60	64	.	
			0	36.3	.	90	60	60	100	60	64	68	
			1	36.4	.	120	60	88	120	60	100	67	
			2	36.3	.	120	70	88	100	70	100	67	
10	59	TA	3	36.3	.	110	60	84	112	60	88	67	
			4	36.5	.	108	60	84	104	58	88	67	
			5	36.6	.	105	75	60	105	80	78	67	
			6	36.8	.	180	75	78	110	80	78	67	
			-1	36.5	14	98	60	66	100	60	66	.	
			0	35.8	.	104	76	62	110	80	62	47	
10	60	JM	1	36.2	.	105	75	72	110	80	90	46	
			2	36.4	.	100	70	72	110	75	96	46	
			3	36.5	.	100	80	84	110	80	96	46	
			4	36.8	.	104	90	86	110	90	120	45	
			5	36.6	.	110	60	84	110	50	90	44	
			6	36.4	.	120	80	90	122	84	92	43	
10	61	JT	-1	36.7	13	150	60	60	130	72	60	64	
			0	36.4	.	160	70	72	150	70	92	64	
			1	36.9	.	138	68	76	140	68	80	63	
			2	36.5	.	135	68	70	145	70	82	63	
			3	36.4	.	140	80	76	150	90	76	63	
			4	36.3	.	130	80	68	130	90	76	63	
10	61	JT	5	36.4	.	140	85	66	145	85	80	64	
			6	36.4	.	140	90	58	140	90	62	64	
			-1	36.9	14	130	60	60	110	80	112	.	
			0	36.3	.	130	60	60	110	80	112	80	
			1	36.3	.	130	80	78	110	80	100	100	
			2	36.7	.	130	68	84	110	64	100	80	
10	61	JT	3	36.3	.	130	80	80	132	80	88	80	
			4	36.7	.	124	65	96	124	68	112	80	

2193

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REROXETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	
10	61	JT	5	36.5	.	140	100	82	130	90	90	80	
			6	36.4	.	130	80	74	110	70	96	80	
10	62	RK	-1	36.7	14	140	90	72	140	100	96	.	
			0	36.7	.	140	90	72	140	100	96	105	
			1	36.8	.	140	96	72	140	100	96	105	
			2	36.7	.	140	70	72	145	80	75	80	105
			3	36.2	.	118	60	72	128	84	72	84	106
			4	36.5	.	116	60	80	116	80	65	88	105
10	63	MS	5	36.7	.	120	70	82	130	75	90	102	
			6	36.7	.	110	80	90	130	80	92	106	
			-1	36.8	13	110	60	78	120	78	120	70	86
			0	36.8	.	110	60	78	120	78	120	70	86
			1	36.5	.	105	60	80	110	80	65	86	67
			2	36.7	.	108	64	80	122	70	70	80	67
10	64	LT	3	36.5	.	110	65	78	128	70	84	67	
			4	36.5	.	105	60	70	110	60	74	67	
			5	36.5	.	100	60	68	110	60	74	67	
			6	36.7	.	90	60	88	110	70	96	67	
			-1	36.8	14	90	55	68	100	60	72	72	48
			0	36.8	.	90	55	68	100	60	72	72	48
10	81	JN	1	36.8	.	170	54	80	120	58	52	47	
			2	36.8	.	98	54	80	100	60	84	46	
			3	36.7	.	100	60	80	100	65	86	44	
			4	36.6	.	100	65	84	110	65	92	44	
			5	36.8	.	100	60	80	105	60	84	44	
			6	36.5	.	100	60	78	100	60	84	45	
10	82	LS	-1	36.5	14	105	80	78	105	75	82	.	
			0	36.5	.	105	80	78	105	75	82	67	
			1	36.6	.	110	70	74	105	70	82	67	
			2	36.7	.	115	80	70	110	80	76	66	
			3	36.8	.	120	80	74	114	80	94	66	
			4	36.7	.	120	80	74	120	80	80	66	
10	82	LS	5	36.7	.	120	80	72	120	80	78	65	
			6	36.5	.	120	80	76	115	80	84	63	
			-1	36.6	13	130	65	80	130	65	92	67	
			0	36.6	.	130	65	80	130	65	92	67	
			1	36.6	.	120	90	70	130	90	86	68	
10	82	LS	2	36.8	.	120	80	70	110	70	72	68	
			3	36.9	.	120	90	76	110	70	108	68	
			4	36.5	.	100	70	84	100	80	100	68	
10	82	LS	5	36.7	.	110	70	80	100	84	84		
			6	36.7	.	110	70	80	100	84	84		

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXYETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
10	82	LS	6	36.5	.	100	70	72	110	80	88	68
10	83	KL	-1	36.4	15	119	80	54	120	80	60	.
			0	36.4	.	119	80	54	120	80	60	83
			1	36.0	.	110	85	72	120	90	90	83
			2	36.3	.	115	80	84	112	80	96	81
			3	36.5	.	120	90	76	110	90	88	79
			4	36.8	.	120	80	64	110	80	86	80
			5	36.7	.	120	80	72	120	70	76	80
			6	36.6	.	120	80	72	120	80	78	80
10	84	RY	-1	36.8	14	120	80	72	130	90	80	.
			0	36.9	.	110	80	68	130	90	70	68
			1	36.7	.	135	100	100	140	100	100	68
			2	36.8	.	140	100	100	160	100	108	68
			3	36.7	.	146	84	76	124	80	80	67
			4	36.8	.	140	85	78	130	80	86	67
			5	36.6	.	135	95	100	132	100	104	65
			6	36.7	.	140	90	96	142	95	106	65
10	85	AK	-1	36.5	14	120	70	72	110	70	80	.
			0	36.5	.	120	70	72	110	70	80	65
			1	36.4	.	120	70	74	120	70	78	65
			2	36.3	.	120	70	72	110	65	80	65
			3	36.6	.	110	70	68	105	70	74	65
			4	36.4	.	120	65	70	110	60	74	65
			5	36.3	.	125	80	72	110	70	74	65
			6	36.5	.	120	70	70	115	70	74	65
10	86	NP	-1	36.6	14	110	60	68	110	65	72	.
			0	36.6	.	100	60	64	105	60	72	74
			1	36.7	.	95	50	64	110	60	64	73
			2	36.2	.	100	70	88	120	60	88	73
			3	36.5	.	106	78	80	110	80	120	73
			4	36.7	.	120	70	80	100	70	116	72
			5	36.6	.	110	70	78	100	70	86	71
			6	36.4	.	120	80	80	105	70	92	71
10	87	AN	-1	36.5	15	145	70	64	150	90	80	.
			0	36.5	.	145	70	64	150	90	80	68
			1	36.2	.	150	80	70	150	90	74	68
			2	36.8	.	150	90	60	154	90	60	68
			3	36.8	.	150	90	64	150	95	74	68
			4	36.6	.	145	90	68	150	95	74	68
			5	36.8	.	145	90	72	150	90	78	87
			6	36.3	.	145	95	74	145	90	80	68

2195

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
10	88	AH	-1	36.2	15	140	75	78	130	60	80	68
			0	36.2	.	140	75	78	130	60	80	68
			1	36.9	.	130	80	80	130	60	80	68
			2	36.6	.	134	70	80	134	70	68	68
			3	36.5	.	120	70	78	134	75	88	68
			4	36.5	.	120	75	78	134	75	88	68
10	89	SK	5	36.5	.	130	80	80	130	60	88	68
			6	36.4	.	124	64	84	140	70	84	68
			-1	36.6	14	100	60	76	100	55	80	68
			0	36.6	.	100	60	76	100	55	80	68
			1	36.8	.	100	60	88	95	80	80	68
			2	36.9	.	100	70	80	110	120	100	68
10	90	SV	3	36.9	.	110	60	92	100	50	100	68
			4	36.5	.	100	70	72	122	70	92	67
			5	37.2	.	100	60	72	110	70	86	67
			6	36.8	.	110	60	74	105	60	90	67
			-1	36.5	14	110	70	72	120	80	84	56
			0	36.7	.	110	70	72	120	80	84	56
10	91	HI	1	36.6	.	105	75	72	110	85	90	56
			2	36.8	.	110	60	88	115	70	92	56
			3	36.4	.	100	60	88	96	60	96	55
			4	36.7	.	105	60	78	110	65	90	55
			5	36.5	.	105	70	78	115	65	84	56
			6	36.3	.	100	56	100	110	50	96	56
10	92	LA	-1	36.7	14	110	80	58	110	80	60	74
			0	36.7	.	110	80	58	110	80	60	74
			1	36.6	.	130	90	64	120	76	76	72
			2	36.6	.	120	85	66	120	85	84	71
			3	36.6	.	130	80	66	120	85	90	70
			4	36.7	.	130	85	72	120	80	88	71
10	93	AN	5	36.4	.	125	90	78	125	90	96	70
			6	36.6	.	125	85	72	115	85	84	71
			-1	36.7	13	100	70	60	100	70	84	64
			0	36.7	.	100	70	60	100	70	84	64
			1	36.5	.	120	90	60	100	70	80	63
			2	36.8	.	100	60	90	100	70	108	63
10	93	AN	3	36.6	.	110	70	78	100	65	90	64
			4	36.4	.	105	75	78	105	75	96	64
			5	36.5	.	105	75	72	105	75	96	63
			6	36.7	.	115	80	78	105	65	90	63
			-1	36.5	13	120	70	68	115	65	74	74
			0	36.5	.	120	70	68	115	65	74	74

2100

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXYTINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
10	93	AN	0	36.5	.	120	70	68	115	65	74	85
			1	36.9	.	120	70	60	120	70	80	85
			2	36.6	.	120	70	68	115	70	74	85
			3	36.7	.	120	65	70	120	70	82	85
			4	36.4	.	120	70	72	120	65	74	85
			5	36.6	.	120	70	72	110	65	78	85
10	94	PV	6	36.3	.	120	70	67	120	70	75	85
			-1	36.6	14	105	60	88	118	60	84	.
			0	36.6	.	105	60	88	118	60	81	60
			1	36.8	.	105	60	82	110	60	88	60
			2	36.9	.	120	60	88	130	70	92	60
			3	36.5	.	123	70	88	130	70	94	60
11	1	DF	4	36.5	.	123	70	100	138	70	100	60
			5	36.9	.	110	70	100	120	70	110	60
			6	36.8	.	100	60	116	104	60	120	60
			-1	36.5	18	120	80	63	120	70	68	91
			0	36.6	.	120	80	68	120	80	72	91
			1	36.4	.	130	80	87	120	80	87	91
11	2	HB	2	36.6	.	140	90	88	130	90	90	91
			3	36.7	.	140	90	86	120	80	90	87
			4	36.6	.	150	90	90	155	90	96	88
			5	36.5	.	170	110	88	150	100	92	89
			6	37.0	.	130	90	94	130	80	94	87
			-1	36.7	22	130	70	78	115	90	90	90
11	3	RF	0	36.8	.	110	70	76	120	60	92	116
			1	37.0	.	130	70	70	150	80	76	116
			2	36.4	.	135	95	80	100	100	90	115
			3	36.8	.	140	100	94	150	100	94	115
			4	36.5	.	160	90	88	160	90	100	115
			5	36.1	.	150	90	88	150	90	90	115
11	4	BA	6	36.4	.	160	100	72	140	50	88	114
			-1	36.7	21	150	90	100	130	80	102	.
			0	36.7	.	160	90	102	130	70	104	83
			1	36.5	.	120	70	96	80	80	100	83
			2	36.7	.	150	90	88	155	90	90	82
			3	36.4	.	140	90	88	150	100	90	82
11	4	BA	4	36.6	.	150	90	92	140	90	100	81
			5	36.3	.	140	80	84	140	80	120	81
			6	36.2	.	140	70	82	130	70	86	81
			-1	36.3	18	150	100	80	140	90	86	.
			0	36.7	.	160	100	78	150	90	100	71
			1	36.7	.	160	100	80	160	90	86	71

2197

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)	
11	4	BA	1	36.3	.	150	100	90	130	90	96	71	
			2	36.5	.	130	90	100	130	90	102	72	
			3	36.2	.	160	100	96	100	92	150	92	72
			4	36.4	.	150	100	92	100	98	150	98	72
			5	36.2	.	150	90	92	140	98	140	98	73
			6	36.0	.	150	100	88	100	92	130	100	92
11	5	ZH	-1	36.4	23	110	80	72	110	70	94	.	
			0	36.5	.	110	70	70	110	65	82	77	.
			1	36.4	.	120	90	70	120	90	78	77	77
			2	37.0	.	120	80	78	120	80	102	102	76
11	6	VP	3	36.8	.	130	90	86	130	90	88	78	
			4	35.2	.	140	100	90	140	100	102	77	
			-1	37.4	15	110	60	78	100	50	82	.	
			0	37.7	.	100	50	80	90	50	87	80	
11	7	KK	1	37.3	.	130	80	64	120	60	68	80	
			2	37.2	.	130	70	66	130	70	70	79	
			3	36.7	.	145	90	82	145	88	100	88	
			4	37.0	.	140	80	80	140	80	90	81	
			5	36.4	.	130	90	92	130	90	90	86	
			6	37.0	.	120	80	80	120	80	80	82	
11	8	KF	-1	36.5	16	120	70	84	100	60	84	.	
			0	36.7	.	150	100	84	120	80	110	55	
			1	36.2	.	140	100	84	120	80	100	55	
			2	36.4	.	130	100	86	120	90	94	54	
			3	36.2	.	130	90	84	120	90	92	54	
			4	36.1	.	150	100	100	130	100	100	54	
11	9	FI	5	36.2	.	160	100	86	150	100	86	55	
			6	36.2	.	140	80	86	130	90	86	53	
			-1	36.1	14	120	90	100	120	90	96	.	
			0	35.9	.	120	80	84	110	80	90	59	
11	9	FI	1	36.2	.	120	80	82	115	80	94	58	
			2	35.6	.	130	80	80	110	96	96	59	
			3	36.8	.	110	80	72	90	68	68	59	
			4	36.9	.	110	80	76	100	70	84	59	
			-1	36.3	18	120	80	92	130	80	96	.	
11	9	FI	0	36.5	.	130	80	94	100	80	100	106	
			1	36.3	.	120	70	84	120	90	102	106	
			2	36.3	.	160	100	79	150	84	72	106	
			3	37.0	.	160	100	79	150	84	100	105	
			4	36.8	.	130	80	102	130	80	100	105	
5	36.7	.	140	100	88	140	84	110	84				

2198

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
11	9	FI	6	36.6	.	130	80	102	140	80	102	102
11	10	BJ	-1	36.3	18	130	80	76	120	90	80	.
	0			36.4	.	120	80	74	120	80	78	79
	1			36.2	.	120	90	76	110	90	82	78
	2			36.4	.	130	90	72	130	90	73	78
	3			36.7	.	160	90	84	140	90	86	78
	4			36.4	.	140	90	88	140	90	88	77
	5			36.2	.	120	90	86	110	80	88	77
	6			36.5	.	140	90	80	140	90	86	77
11	11	NGV	-1	37.1	18	120	80	84	130	80	88	.
	0			37.0	.	150	90	76	150	90	77	72
	1			36.6	.	130	80	76	140	80	80	71
	2			36.2	.	130	80	88	110	70	100	72
	3			36.2	.	140	90	108	130	90	112	73
	4			36.6	.	140	90	90	130	90	92	73
	5			36.6	.	130	70	84	130	70	88	74
	6			36.2	.	120	90	80	130	90	90	74
11	12	PJ	-1	36.5	20	150	100	76	150	90	80	.
	0			36.4	.	150	90	104	130	80	115	57
	1			38.0	.	140	90	98	130	90	104	57
	2			36.3	.	130	90	86	130	90	90	58
	3			36.8	.	120	80	90	130	90	96	56
	4			36.2	.	120	80	90	120	80	96	56
	5			36.5	.	110	90	76	120	90	82	56
	6			36.8	.	120	80	80	130	90	86	56
11	13	GK	-1	36.3	16	140	100	76	130	90	78	.
	0			36.6	.	120	80	70	130	80	78	48
	1			36.8	.	120	80	70	120	80	80	49
	2			36.6	.	120	80	76	130	80	82	50
	3			36.8	.	130	80	90	140	90	96	49
	4			36.3	.	130	80	82	130	90	86	47
	5			36.1	.	130	80	80	130	80	92	45
	6			36.5	.	130	80	80	120	80	78	45
11	14	BJ	-1	36.0	18	120	80	86	130	80	90	.
	0			36.5	.	130	90	80	140	80	86	67
	1			36.5	.	120	80	80	130	80	86	68
	2			36.7	.	110	90	76	130	90	80	69
	3			36.5	.	110	80	88	120	90	88	70
	4			36.8	.	120	80	76	120	80	80	68
11	15	NF	-1	36.6	20	120	80	80	130	80	88	.

2199

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
11	15	NF	0	36.5	.	130	90	80	140	90	90	82
			1	36.8	.	120	80	80	140	90	90	81
			2	36.1	.	110	80	80	130	86	90	86
			3	36.2	.	120	80	80	130	86	90	79
			4	36.5	.	120	80	80	110	86	70	86
			5	36.1	.	120	80	82	120	83	80	81
11	16	NA	6	36.5	.	120	80	82	130	80	76	81
			-1	36.8	18	120	90	80	130	90	92	82
			0	36.5	.	120	90	88	120	90	92	51
			1	36.8	.	120	90	76	120	80	80	50
			2	36.9	.	110	80	78	120	84	80	48
			3	36.4	.	130	90	86	130	90	90	47
11	17	UZ	4	36.9	.	100	70	80	110	80	90	47
			5	36.1	.	100	70	80	120	86	90	50
			6	36.8	.	110	70	90	110	80	94	50
			-1	36.6	20	130	90	80	140	100	86	86
			0	36.2	.	130	90	76	140	90	82	75
			1	36.5	.	110	70	80	110	80	82	77
11	18	EI	2	36.3	.	120	80	80	110	80	92	74
			3	36.2	.	110	70	80	120	80	86	74
			4	36.5	.	120	80	86	130	80	88	75
			5	36.9	.	120	70	80	120	80	72	74
			6	36.5	.	110	90	80	110	80	86	74
			-1	36.8	18	130	90	80	140	100	86	86
11	19	FK	0	36.3	.	120	80	80	130	90	92	60
			1	36.8	.	130	90	76	130	90	78	60
			2	36.6	.	110	80	76	120	80	80	60
			3	36.3	.	110	80	80	120	80	86	61
			4	36.7	.	120	80	80	120	80	82	61
			5	36.5	.	120	80	80	120	80	86	62
11	20	LJ	6	36.2	.	130	80	86	140	90	92	62
			-1	36.5	18	120	80	80	110	70	82	63
			0	36.4	.	120	80	72	120	80	80	63
			1	36.3	.	110	70	76	120	80	80	63
			2	36.5	.	120	80	90	130	90	92	63
			3	36.2	.	120	80	76	120	80	74	63
11	20	LJ	4	36.8	.	130	80	88	140	90	94	63
			5	36.2	.	120	80	80	120	80	86	63
			6	36.6	.	120	80	78	120	80	86	62
			-1	36.5	18	120	80	80	130	80	86	80
			0	36.4	.	120	80	88	130	80	86	80
			1	36.5	.	120	80	88	130	80	86	80

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXYETINE - PROTOCOL 20124/013
Listing No.: 13..1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)		
11	20	LJ	1	36.3	.	120	70	86	130	80	92	70		
			2	36.2	.	130	90	86	120	80	88	88	71	
			3	36.8	.	130	80	90	80	90	140	80	86	70
			4	36.2	.	120	80	76	80	70	130	80	82	70
			5	36.3	.	130	80	72	80	70	140	90	86	70
			6	36.5	.	130	90	82	90	82	140	100	86	70
12	1	IB	-1	36.9	17	140	90	75	140	90	85	.		
			0	36.9	.	140	90	75	140	90	90	85	72	
			1	36.7	.	120	90	104	100	110	90	110	72	
			2	36.5	.	140	100	80	140	86	140	90	86	71
			3	36.5	.	150	100	80	140	80	140	90	90	71
			4	36.5	.	150	110	100	110	100	115	115	110	71
12	2	EFC	5	36.6	.	150	90	92	160	95	94	94	72	
			6	36.2	.	150	90	92	160	120	106	106	74	
			-1	36.6	22	120	80	84	80	84	80	84	.	
			0	36.5	.	130	90	76	90	79	135	90	85	79
			1	36.3	.	130	80	74	80	80	130	90	80	78
			2	36.6	.	130	90	76	80	79	135	90	80	79
12	3	IF	3	36.8	.	130	90	80	135	90	86	75		
			4	36.6	.	130	90	76	135	90	82	82	75	
			5	36.6	.	130	85	90	85	70	130	85	110	
			6	36.3	.	120	80	88	80	77	110	70	100	
			-1	36.4	22	115	80	78	80	78	115	90	95	.
			0	36.4	.	115	80	78	80	78	115	90	95	66
12	4	EG	1	36.8	.	110	70	80	115	80	100	66		
			2	36.3	.	130	80	91	100	70	116	100	66	
			3	36.7	.	120	80	88	80	96	125	80	66	
			4	36.2	.	130	90	80	80	88	120	80	66	
			5	36.7	.	120	80	82	80	86	130	80	66	
			6	36.7	.	140	100	54	100	72	130	90	72	66
12	5	ZSH	-1	36.5	24	110	90	84	120	90	86	.		
			0	36.7	.	110	90	82	120	90	80	80	73	
			1	36.3	.	140	90	80	110	76	110	90	72	
			2	36.7	.	140	90	80	110	78	110	90	71	
			3	36.4	.	110	80	80	70	80	110	70	80	
			4	37.2	.	110	70	93	130	100	100	100	72	
12	5	ZSH	5	36.5	.	115	70	68	130	80	74	73		
			6	36.5	.	125	90	68	130	110	74	74		
12	5	ZSH	-1	36.6	16	110	80	88	100	80	96	.		
			0	35.6	.	110	80	80	80	80	80	88	66	
			1	36.5	.	120	80	80	100	60	82	67		

2201

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXYETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)
12	5	ZSH	2	36.5	130	80	88	120	80	88	66	
			3	36.6	120	90	88	90	80	82	67	
			4	36.5	130	80	88	120	80	96	67	
			5	36.6	140	90	88	120	90	80	67	
			6	35.5	110	90	80	110	90	80	67	
			-1	37.1	130	80	90	120	80	110	51	
12	6	HK	0	36.5	110	80	100	100	80	110	51	
			1	36.8	130	90	78	120	90	92	50	
			2	36.5	90	70	92	90	70	110	51	
			3	36.5	90	70	100	90	60	120	51	
			4	36.7	120	70	88	120	70	92	51	
			5	36.6	105	70	84	90	70	88	51	
12	7	LK	6	36.5	100	70	80	100	70	86	51	
			-1	36.3	140	100	90	140	100	100	84	
			0	35.8	140	90	90	140	98	98	84	
			1	35.5	130	80	90	110	80	98	85	
			2	36.4	130	90	90	140	90	98	85	
			3	36.8	130	85	88	140	75	96	86	
12	8	FK	4	36.2	140	90	96	135	90	100	84	
			5	36.4	135	85	88	145	90	94	84	
			6	36.4	125	85	90	140	95	100	85	
			-1	36.4	110	80	66	110	90	88	88	
			0	36.4	110	80	66	110	90	88	88	
			1	36.4	140	80	86	130	80	100	88	
12	9	KBP	2	36.4	120	80	86	130	80	95	88	
			3	36.5	115	70	94	140	90	112	88	
			4	36.6	120	80	80	120	80	88	88	
			5	36.6	120	90	96	130	100	116	88	
			6	36.5	120	80	70	110	70	68	87	
			-1	36.8	100	60	100	100	60	100	48	
12	10	IP	0	36.5	100	70	96	100	70	104	48	
			1	36.8	100	70	88	100	70	95	50	
			2	36.6	100	60	98	100	60	98	51	
			3	36.7	110	70	76	110	70	76	48	
			4	36.6	100	70	80	100	70	80	50	
			5	36.7	100	70	86	100	70	86	51	
12	10	IP	6	36.8	100	70	84	110	70	120	53	
			-1	36.5	120	80	88	110	80	88	88	
			0	36.5	120	80	80	110	80	88	64	
12	10	IP	1	36.3	110	80	80	100	80	63	80	
			2	36.5	130	90	88	140	90	88	61	

220

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)			
12	10	IP	3	36.6	.	110	80	80	100	80	78	61			
			4	36.4	.	100	80	80	90	80	80	61			
			5	36.6	.	130	90	80	110	80	80	80	63		
			6	36.5	.	120	90	80	120	80	80	92	62		
			12	11	ER	-1	36.6	20	110	80	80	110	80	88	.
						0	36.6	.	110	80	80	110	80	88	62
1	36.8	.				110	80	74	110	80	85	60			
2	37.0	.				110	80	92	110	70	82	59			
3	36.7	.				130	80	80	120	80	80	74			
4	36.7	.				110	70	88	120	80	84	60			
12	12	FSZ	5	36.7	.	120	80	82	120	80	85	59			
			6	36.6	.	110	70	92	120	80	100	59			
			-1	36.6	18	120	80	86	130	90	90	90			
			0	36.7	.	110	80	97	130	80	110	110	56		
			1	36.7	.	120	80	95	140	80	124	124	56		
			2	36.4	.	120	80	102	130	80	125	125	57		
12	13	ISZ	3	37.0	.	120	80	100	130	90	120	57			
			4	36.5	.	120	80	82	130	80	86	56			
			5	36.5	.	140	90	88	140	80	120	57			
			6	36.4	.	120	80	80	130	80	120	57			
			-1	36.4	16	110	70	74	100	60	90	90	56		
			0	36.5	.	110	70	74	100	60	85	85	54		
12	14	GSZ	1	36.5	.	120	80	75	120	70	82	54			
			2	36.4	.	120	80	78	110	60	86	54			
			3	36.5	.	120	80	74	120	75	80	54			
			4	36.7	.	130	85	76	120	80	100	54			
			5	36.7	.	120	80	84	110	75	90	54			
			6	36.5	.	120	80	88	120	80	96	56			
12	15	GB	-1	36.7	20	150	105	120	150	105	130	.			
			0	36.8	.	150	100	104	140	90	110	85			
			1	36.8	.	120	80	92	120	80	85	83			
			2	36.8	.	130	90	102	120	80	82	83			
			3	36.7	.	100	70	102	120	95	92	85			
			4	36.8	.	130	95	120	120	90	106	85			
12	15	GB	5	36.7	.	130	100	88	120	90	100	85			
			6	36.8	.	145	100	88	130	100	92	85			
			-1	36.8	18	140	100	88	130	100	88	88			
			0	36.7	.	140	80	88	130	90	88	88			
			1	36.6	.	150	100	80	150	100	80	75			
			2	36.5	.	150	90	88	150	90	80	75			
12	15	GB	3	35.5	.	130	90	96	140	90	96	74			
			3	35.5	.	130	90	96	140	90	96	74			

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)	
12	15	GB	4	36.5	.	140	100	100	140	100	88	76	
			5	35.2	.	140	90	72	80	80	80	80	
			6	35.0	.	150	90	100	90	100	90	100	79
	12	16	FN	-1	36.5	22	110	70	96	120	80	108	.
				0	36.7	.	110	80	100	80	80	112	54
				1	36.5	.	120	70	80	80	92	80	92
2				36.3	.	110	80	100	80	98	80	98	54
3				36.7	.	130	90	74	80	72	130	72	53
4				36.7	.	130	70	80	80	84	80	84	53
12	17	TK	5	36.6	.	130	70	88	120	80	92	53	
			6	36.8	.	140	90	96	120	80	108	53	
			-1	36.7	16	120	80	72	80	84	80	84	.
			0	36.8	.	120	80	72	80	88	130	88	88
			1	36.5	.	140	90	78	80	88	90	88	89
			2	36.6	.	120	80	72	80	88	130	88	88
12	18	LS	3	36.0	.	120	70	78	120	90	88	84	
			4	36.5	.	120	80	80	120	90	100	84	
			5	36.5	.	100	80	88	110	80	90	83	
			6	36.4	.	130	90	88	120	70	80	96	85
			-1	36.5	16	120	80	60	80	72	80	72	.
			0	36.5	.	120	80	58	80	82	80	82	53
12	19	SSZ	1	36.7	.	130	90	66	120	90	84	54	
			2	36.5	.	130	90	64	120	90	84	54	
			3	36.9	.	110	90	60	110	62	80	62	55
			4	36.5	.	110	70	62	70	80	90	80	54
			5	36.4	.	130	100	76	120	80	120	80	54
			6	36.2	.	110	70	67	110	82	70	82	54
12	20	KSZ	-1	36.3	21	130	90	84	120	80	108	.	
			0	36.7	.	130	90	82	120	80	84	68	
			1	36.5	.	130	90	60	120	66	80	66	
			2	36.5	.	130	90	68	120	88	80	88	68
			3	36.5	.	120	80	80	120	88	80	88	67
			4	36.7	.	125	90	78	120	92	92	92	67
12	20	KSZ	5	36.5	.	120	80	78	120	90	92	67	
			6	36.6	.	120	85	88	125	90	94	66	
			-1	36.5	21	130	80	84	140	80	80	98	.
			0	36.4	.	120	80	76	120	84	80	84	70
			1	36.3	.	120	80	84	130	96	80	96	70
			2	36.8	.	120	80	86	120	80	80	90	70
12	20	KSZ	3	36.5	.	120	80	80	120	80	82	70	
			4	36.5	.	120	70	88	125	90	100	70	

220/4

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PRARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)		
12	20	MSZ	5	36.3	.	120	80	80	130	80	88	70		
			6	36.3	.	120	80	80	125	80	88	70		
	12	21	FL	-1	36.2	20	120	80	82	125	90	94	.	
				0	36.7	.	120	80	90	130	88	88	82	
				1	36.3	.	120	80	80	120	120	80	92	81
				2	36.4	.	120	80	92	110	80	80	90	80
12	22	HV	3	36.6	.	110	70	72	110	80	98	78		
			4	36.7	.	120	80	86	120	80	100	80		
			5	36.2	.	120	80	78	120	120	80	88		
			6	36.2	.	120	80	100	110	110	70	92	77	
12	23	EN	-1	36.5	24	130	90	90	140	80	92	.		
			0	36.2	.	130	90	86	140	90	96	60		
			1	36.0	.	140	90	80	140	140	90	88	60	
			2	37.0	.	145	90	88	145	145	90	96	59	
			3	36.0	.	125	70	80	140	140	90	88	56	
			4	36.8	.	130	90	80	140	120	80	84	55	
12	24	MF	5	36.5	.	130	90	84	140	90	96	56		
			6	36.7	.	130	80	80	140	140	90	88	56	
			-1	36.3	21	140	80	76	140	140	85	82	.	
			0	36.6	.	140	80	82	140	140	80	84	53	
			1	36.4	.	140	80	78	145	145	80	92	53	
			2	36.8	.	130	80	82	130	130	90	96	53	
12	25	FS	3	37.0	.	120	80	100	130	80	98	52		
			4	37.1	.	120	80	78	130	80	96	52		
			5	36.5	.	120	80	100	110	110	70	100	52	
			6	36.4	.	110	70	98	140	140	70	109	52	
			-1	36.2	22	140	90	80	130	130	90	92	.	
			0	36.8	.	140	90	78	130	130	90	86	80	
12	25	FS	1	36.7	.	130	90	80	110	80	80	81		
			2	36.6	.	140	90	80	125	80	80	81		
			3	36.7	.	120	80	90	110	100	80	81		
			4	36.6	.	130	80	78	120	80	80	86		
			5	36.6	.	130	80	84	125	80	80	80		
12	25	FS	6	36.3	.	130	90	68	130	90	64	82		
			-1	36.2	24	110	60	100	100	60	105	.		
			0	36.4	.	130	90	84	100	100	90	77		
			1	36.8	.	150	90	84	140	140	101	78		
			2	36.2	.	170	120	84	150	110	120	78		
12	25	FS	3	36.2	.	140	90	82	120	85	90	80		
			4	36.4	.	140	80	82	120	85	82	80		
			5	36.6	.	120	80	90	120	120	85	81		

2205

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBONETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)
12	25	FS	6	36.5	.	130	90	80	120	90	84	80
12	26	LB	-1	36.8	20	110	70	74	100	60	86	.
			0	36.5	.	110	70	72	110	70	96	105
			1	36.4	.	105	60	84	100	60	102	105
			2	36.6	.	110	70	82	110	70	84	107
			3	37.0	.	120	80	84	115	70	90	108
			4	37.0	.	110	70	84	120	80	88	108
			5	36.0	.	110	70	82	120	70	90	110
			6	36.5	.	110	80	78	120	80	86	110
12	27	VCS	-1	36.6	20	110	80	80	110	80	88	.
			0	36.7	.	100	70	88	110	80	94	55
			1	36.6	.	100	70	88	100	70	100	55
			2	36.0	.	100	70	110	110	70	110	55
			3	36.0	.	110	80	80	110	80	92	58
			4	36.3	.	100	70	88	110	70	94	58
			5	36.8	.	100	70	88	120	80	100	57
			6	36.4	.	120	60	104	110	70	100	56
12	28	IV	-1	36.3	24	110	70	72	110	70	80	.
			0	36.3	.	90	70	88	100	70	96	50
			1	36.5	.	90	70	100	90	70	110	49
			2	36.0	.	90	70	100	100	80	110	49
			3	36.2	.	100	70	102	100	70	105	51
			4	36.3	.	100	70	88	100	70	100	51
			5	36.3	.	90	70	84	100	70	96	51
			6	36.3	.	110	70	97	100	70	104	51
12	29	AK	-1	36.5	22	120	80	88	120	80	96	.
			0	36.6	.	110	80	80	120	80	88	71
			1	36.5	.	130	80	92	130	90	96	71
			2	36.6	.	110	70	84	110	70	92	71
			3	36.4	.	100	60	76	110	70	82	71
			4	36.4	.	120	80	100	120	80	100	73
			5	36.2	.	120	80	98	120	80	100	73
			6	36.5	.	110	80	88	120	70	96	73
12	30	FS	-1	36.7	22	110	80	85	120	80	87	.
			0	36.1	.	120	80	85	110	80	91	57
			1	36.4	.	100	70	92	120	80	96	54
			2	36.5	.	110	70	94	120	80	97	54
			3	36.7	.	120	80	92	110	80	88	53
			4	36.6	.	110	70	100	110	70	90	53
			5	36.4	.	120	80	86	110	80	100	54
			6		.							

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 15.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	Sm. Lying Sys BP (mmHg)	Sm. Lying Dias BP (mmHg)	Sm. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	
12	31	FH	-1	36.4	18	140	90	82	130	90	94	82	
			0	36.0	.	140	90	76	120	80	80	80	
			1	36.2	.	130	90	80	110	88	70	88	80
			2	36.3	.	120	80	86	80	100	70	92	80
			3	35.9	.	120	80	86	80	100	80	86	80
			4	35.6	.	120	80	88	80	100	70	92	80
12	32	LM	5	36.0	.	150	100	82	130	80	92	80	
			6	36.4	.	110	70	92	100	70	102	80	
			-1	36.6	18	140	90	87	140	90	89	89	85
			0	36.6	.	140	90	87	140	90	89	81	84
			1	36.4	.	130	80	84	130	80	88	80	86
			2	36.0	.	110	80	84	120	80	88	80	88
12	33	LN	3	36.7	.	120	80	74	120	80	84	86	
			4	36.0	.	120	80	76	110	70	78	86	
			5	36.3	.	170	70	80	120	80	80	88	
			6	36.0	.	120	80	72	130	80	80	84	
			-1	36.0	20	180	110	68	160	110	64	64	78
			0	36.8	.	140	90	87	140	90	85	80	80
12	34	TOB	1	36.6	.	140	80	64	140	80	84	80	
			2	36.1	.	149	90	80	150	100	84	79	
			3	36.5	.	120	80	84	140	100	76	80	
			4	36.4	.	130	80	82	120	80	78	77	
			5	36.2	.	140	90	80	150	90	88	80	
			6	36.4	.	130	90	76	130	80	100	78	
12	35	LP	-1	36.4	24	130	90	84	140	90	96	80	
			0	36.3	.	140	80	90	140	90	100	59	
			1	36.2	.	120	80	88	130	90	94	59	
			2	36.7	.	110	70	68	120	70	80	59	
			3	37.0	.	130	90	72	130	90	84	59	
			4	36.2	.	120	80	76	130	80	78	59	
12	36	FB	5	36.3	.	110	70	76	120	80	88	59	
			6	36.5	.	100	60	78	120	80	72	59	
			-1	36.2	24	130	80	80	140	80	94	80	
			0	36.7	.	130	90	78	130	90	92	68	
			1	36.2	.	140	80	92	140	90	100	69	
			2	36.4	.	120	70	86	130	80	110	69	
12	36	FB	3	36.7	.	130	80	90	140	80	96	69	
			4	36.2	.	120	80	86	130	80	96	69	
			5	36.4	.	130	80	84	130	80	90	69	
			6	36.6	.	120	80	88	120	80	76	69	
			-1	36.2	20	130	80	78	130	80	92	80	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	
12	36	FB	0	36.8	.	140	80	84	140	80	90	85	
			1	36.2	.	130	80	90	140	80	98	84	
			2	36.4	.	130	80	92	130	86	120	80	84
			3	36.5	.	120	80	80	130	85	130	80	85
			4	36.3	.	120	80	86	130	85	130	90	85
			5	36.8	.	140	90	92	140	90	140	90	90
12	37	EK	6	36.7	.	120	80	90	120	80	87	85	
			-1	36.4	20	150	100	104	140	100	128	128	.
			0	36.2	.	140	100	96	150	110	100	110	76
			1	36.8	.	130	80	82	140	80	90	90	76
			2	36.0	.	130	90	93	130	90	110	90	75
			3	36.2	.	145	90	90	165	90	112	90	75
12	38	FG	4	36.2	.	110	90	116	120	100	116	74	
			5	36.5	.	120	80	80	130	90	98	74	
			6	36.4	.	140	100	80	150	150	110	96	74
			-1	37.1	24	100	80	116	120	120	90	120	.
			0	36.4	.	100	60	88	110	104	60	104	57
			1	36.7	.	100	80	100	110	100	90	100	57
13	1	P2	2	36.6	.	100	70	100	100	80	120	55	
			3	36.4	.	140	90	92	130	88	88	55	
			4	36.8	.	120	80	82	110	80	80	55	
			5	36.7	.	110	80	92	105	110	70	54	
			6	37.0	.	110	70	88	120	80	80	55	
			-1	36.2	14	115	80	80	120	120	90	85	.
13	2	TCS	0	35.9	.	120	70	99	110	70	101	56	
			1	36.1	.	115	70	88	110	80	100	58	
			2	36.8	.	110	80	90	110	110	80	58	
			3	36.8	.	115	70	102	100	120	65	57	
			4	36.8	.	130	90	100	120	128	80	128	58
			5	36.7	.	110	70	103	110	110	70	110	57
13	3	AI	6	36.6	.	110	70	72	110	70	100	56	
			-1	36.6	15	120	80	98	120	75	102	54	
			0	36.6	.	120	85	98	130	105	75	105	54
			1	37.0	.	130	80	110	130	90	90	100	55
			2	37.3	.	115	65	106	95	60	60	116	55
			3	36.7	.	120	70	88	115	70	70	98	55
13	3	AI	4	36.2	.	120	80	112	110	70	126	55	
			5	36.8	.	120	70	106	100	70	116	54	
			6	36.2	.	115	70	110	100	80	70	100	54
			-1	36.2	18	125	80	80	120	75	75	88	.
			0	36.4	.	120	80	76	115	120	70	82	69

2208

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	
13	3	AI	1	35.7	.	100	70	86	110	70	101	68	
			2	36.5	.	100	70	92	100	70	98	69	
			3	36.3	.	110	70	104	110	102	110	102	69
			4	36.5	.	120	80	104	110	102	110	102	68
			5	36.1	.	110	70	103	100	105	110	105	67
			6	36.6	.	100	70	70	110	104	110	104	66
13	4	SZJ	-1	36.2	16	140	80	74	150	85	80	.	
			0	36.8	.	120	80	80	115	75	86	65	
			1	36.8	.	110	75	76	120	80	78	65	
			2	36.6	.	140	90	80	130	80	86	65	
			3	36.3	.	130	80	66	120	70	78	62	
			4	36.2	.	100	80	64	115	85	85	78	
13	5	MF	5	36.0	.	130	90	74	120	90	78	62	
			6	36.0	.	140	90	80	120	80	100	65	
			-1	36.0	24	185	80	78	130	80	60	.	
			0	36.8	.	160	110	80	100	82	100	52	
			1	36.9	.	155	85	78	150	80	60	51	
			6	36.4	14	120	90	88	130	80	97	.	
13	6	ME	0	36.4	.	120	75	90	100	70	104	44	
			1	37.1	.	120	75	90	100	70	104	42	
			2	36.1	.	120	80	101	120	80	103	42	
			3	36.4	.	110	70	110	110	120	120	43	
			4	36.6	.	115	80	88	105	106	106	42	
			5	36.3	.	120	80	80	120	60	70	42	
13	7	BL	6	36.5	.	120	70	112	115	70	118	43	
			-1	36.6	18	110	70	92	120	80	100	.	
			0	35.7	.	130	90	88	135	90	101	69	
			1	36.4	.	110	80	88	120	80	92	69	
			2	36.4	.	115	70	80	115	70	100	69	
			3	36.6	.	120	80	103	110	80	124	71	
13	8	PK	4	36.8	.	130	90	90	140	100	100	71	
			5	36.9	.	120	80	90	110	80	95	80	
			6	36.8	.	120	80	100	120	90	105	72	
			-1	36.6	17	140	80	92	145	90	96	.	
			0	36.5	.	135	90	80	145	100	115	63	
			1	36.3	.	130	80	78	110	70	96	63	
13	9		2	36.5	.	120	70	100	130	90	108	60	
			3	35.9	.	120	80	80	120	90	90	61	
			4	36.0	.	140	80	80	140	80	100	59	
			5	36.1	.	130	80	90	115	80	100	58	
			6	36.2	.	120	80	80	115	80	110	57	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	
13	9	SZS	-1	36.2	12	130	90	82	135	90	88	80	
			0	36.5	.	120	80	84	135	90	96	80	
			1	36.0	.	120	80	80	110	80	110	104	79
			2	36.0	.	120	80	80	110	80	110	104	76
			3	36.3	.	120	80	84	110	80	110	106	76
			4	36.4	.	120	80	84	110	80	110	106	74
13	10	BH	5	36.4	.	120	80	76	100	70	100	76	
			6	35.8	.	120	80	76	115	70	88	74	
			-1	36.5	16	120	80	78	130	84	130	84	81
			0	36.2	.	130	80	92	130	98	130	85	82
			1	36.7	.	120	80	80	130	80	130	85	80
			13	11	HS	-1	36.8	19	120	80	90	120	80
0	36.7	.				120	80	66	130	90	70	82	
1	37.2	.				120	80	75	120	80	120	80	
2	36.3	.				120	80	70	130	80	130	83	
3	36.5	.				115	80	60	115	80	115	80	
4	36.1	.				145	70	68	120	80	120	80	
13	12	BF	5	36.5	.	115	80	64	110	70	80	84	
			6	36.3	.	120	80	64	110	70	80	83	
			-1	35.8	16	120	80	100	130	105	130	90	
			0	36.3	.	130	80	94	130	106	130	75	
			1	36.6	.	115	70	110	130	124	130	124	78
			2	36.2	.	120	80	90	115	102	115	102	77
13	13	HM	3	36.7	.	120	80	86	120	140	112	77	
			4	36.8	.	120	80	86	140	140	104	75	
			5	36.7	.	120	80	84	125	125	90	74	
			-1	36.3	18	140	70	73	120	74	74	74	
			0	36.0	.	130	80	62	140	72	140	80	
			1	36.5	.	130	80	60	100	60	100	80	
13	14	DF	2	36.6	.	120	80	60	115	80	75	79	
			3	36.2	.	115	80	60	100	70	79	79	
			4	36.0	.	115	70	70	105	80	80	80	
			5	36.0	.	100	80	70	95	65	80	80	
			6	36.0	.	115	75	80	100	65	90	79	
			-1	36.0	18	140	70	80	130	76	130	80	
13			0	35.8	.	120	70	78	115	80	76	66	
			1	35.8	.	120	80	82	115	80	106	67	
			2	36.5	.	120	70	75	120	60	100	66	
			3	36.2	.	120	80	80	120	60	90	67	
			4	36.0	.	125	80	84	115	80	106	66	
5	36.5	.	120	80	75	120	80	115	80				

2210

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 2012A/013
Listing No.: 13.1

VITAL SIGNS
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
13	14	DF	6	35.7	.	120	70	84	120	90	108	64
13	15	KG	-1	36.5	16	120	80	92	120	90	92	.
			0	36.4	.	140	90	74	130	80	92	80
			1	36.7	.	120	80	80	120	90	98	79
			2	36.4	.	110	70	76	120	80	88	80
			3	36.5	.	100	70	92	110	70	112	79
			4	36.0	.	115	70	70	110	70	92	78
			5	36.6	.	115	80	86	115	80	90	78
			6	36.1	.	115	70	.	110	80	.	79
13	16	SZL	-1	36.2	20	140	70	62	120	70	68	76
			0	36.2	.	140	70	62	120	70	68	76
			1	36.0	.	120	70	80	100	60	112	75
			2	36.2	.	140	70	72	100	70	104	75
			3	35.7	.	120	70	82	120	80	96	76
			4	36.2	.	140	90	80	120	80	100	76
			5	36.0	.	130	80	80	130	90	95	77
			6	35.9	.	130	70	86	130	80	90	75
13	17	GSM	-1	36.2	15	140	90	100	130	90	100	.
			0	36.2	.	140	90	100	130	90	100	46
			1	36.3	.	110	70	86	120	70	100	46
			2	36.3	.	120	80	86	130	80	96	46
			3	36.5	.	120	80	86	130	80	96	46
			4	36.1	.	115	70	104	100	70	120	47
			5	36.5	.	130	80	120	130	70	128	48
			6	35.8	.	115	80	84	110	70	100	47
13	18	VT	-1	36.2	17	120	80	66	110	70	78	.
			0	36.0	.	120	80	64	120	70	80	59
			1	36.2	.	90	60	80	90	60	100	60
			2	36.6	.	95	70	55	90	60	60	60
			3	36.0	.	115	80	65	110	80	70	60
			4	36.7	.	100	90	80	90	80	80	60
			5	36.6	.	100	70	92	85	70	112	61
			6	35.6	.	130	80	100	100	80	102	60
13	19	KK	-1	36.2	16	140	80	76	130	90	82	64
			0	36.4	.	140	80	76	130	90	82	64
			1	36.6	.	115	80	92	120	90	95	63
			2	36.2	.	145	80	92	120	80	88	62
			3	36.3	.	115	70	100	110	70	120	62
13	20	NL	-1	36.3	18	140	90	88	120	90	100	65
			0	36.3	.	140	90	88	120	90	100	65

2211

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
13	20	NL	1	36.0	.	140	70	88	120	90	100	66
			2	36.1	.	115	80	95	120	80	110	67
			3	36.2	.	120	80	88	115	80	100	69
			4	36.7	.	115	70	80	110	70	80	68
			5	36.7	.	110	70	84	110	70	92	69
			6	36.9	.	120	70	84	120	70	88	69
13	21	CL	-1	36.2	17	110	80	65	120	90	70	.
			0	36.2	.	120	80	102	120	80	112	57
			1	36.2	.	120	80	84	120	70	108	55
			2	36.5	.	100	70	88	110	70	102	54
			3	36.5	.	110	70	92	100	60	120	55
			4	36.3	.	115	70	76	100	70	100	53
13	22	NJK	5	36.3	.	120	80	80	120	80	92	54
			6	36.3	.	115	80	72	115	80	120	53
			-1	36.5	16	110	70	72	100	70	92	.
			0	36.2	.	110	60	76	100	60	100	80
			1	36.1	.	115	60	84	110	70	100	80
			2	36.1	.	115	70	80	110	70	100	79
22	23	BSB	3	36.3	.	100	80	90	115	80	95	79
			4	36.1	.	115	70	76	120	80	92	79
			5	36.4	.	100	70	86	115	80	105	79
			6	36.1	.	100	60	72	100	60	92	78
			-1	36.1	18	110	60	76	100	60	80	80
			0	36.3	.	100	60	72	100	60	84	57
13	23	BSB	1	36.4	.	100	60	84	90	60	120	56
			2	36.3	.	115	70	80	105	70	110	57
			3	36.4	.	120	70	80	105	70	110	58
			4	36.2	.	100	70	80	90	70	104	55
			5	36.3	.	120	80	75	90	70	65	55
			6	36.1	.	110	80	78	100	70	86	55

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXYETINE - PROTOCOL 2012A/013
 Listing No.: 15.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: REBOXYETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2h. Stand Sys BP (mmHg)	2h. Stand Dias BP (mmHg)	2h. Stand Heart Rate (beats/min)	Body Weight (kg)
1	3	2	TA	8	36.0	110	70	90	110	80	95	64.0
				10	35.9	110	70	98	110	80	100	64.0
				12	36.2	110	80	66	105	80	88	64.0
				14	36.0	110	70	85	120	80	92	65.0
				16	36.2	110	70	85	120	80	92	65.0
				18	35.7	110	80	66	105	80	80	65.0
				20	36.8	100	70	96	105	80	96	65.0
				22	36.2	110	70	95	110	80	100	65.0
				24	36.2	110	70	92	110	70	98	65.0
				26	36.2	120	70	80	120	80	88	65.0
				28	36.9	130	90	96	130	90	104	65.0
				30	36.4	130	95	100	130	90	104	62.0
				32	36.2	140	90	100	130	100	104	62.0
				34	36.4	105	75	88	100	75	100	62.0
				36	37.1	110	70	88	110	80	96	60.0
				38	36.9	110	70	84	100	80	100	61.0
				40	36.7	110	85	88	110	70	92	61.0
				42	36.8	120	70	88	120	70	88	62.0
				44	36.5	120	90	80	120	90	80	62.0
				46	36.4	120	85	96	120	85	100	62.0
				48	36.8	120	85	92	120	90	100	62.0
				50	36.7	95	65	92	90	65	112	62.0
				52	36.5	120	85	88	100	80	100	62.0
1	4	3	DNC	8	36.1	100	60	110	110	70	106	55.0
				10	36.4	100	70	108	110	80	114	55.0
				12	36.2	110	75	98	110	80	100	55.0
				14	36.8	120	70	95	120	70	100	55.0
				16	36.3	110	75	110	110	80	110	55.0
				18	36.2	110	70	90	110	80	110	55.0
				20	36.0	110	70	95	120	80	95	55.0
				22	36.0	110	70	95	120	80	100	55.0
				24	35.7	100	65	106	110	75	108	55.0
				26	35.7	100	65	106	110	75	108	55.0
				28	36.4	115	80	96	110	85	100	55.0
				30	35.5	120	75	108	120	75	100	55.0
				32	36.3	110	70	108	115	75	120	53.0
				34	36.2	95	65	104	95	60	112	53.0
				36	36.2	95	65	104	95	60	112	53.0
				38	36.0	100	65	92	95	60	100	53.0
				40	36.0	120	85	100	120	90	100	53.0
				42	36.2	100	70	100	100	70	104	53.0
				44	36.3	110	70	104	115	75	112	53.0
				46	36.4	110	80	96	110	85	100	53.0
				48	36.3	110	80	100	110	85	100	53.0

2210

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 ROBOXYTINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: ROBOXYTINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
1	4	3	DNC	50	36.2	110	75	96	110	80	100	53.0
				52	36.2	100	70	104	100	80	108	53.0
1	5	4	DB	8	36.1	130	85	88	110	80	92	63.0
				10	36.1	130	80	88	130	90	92	64.0
				12	36.3	120	90	80	125	95	88	64.0
				14	36.1	120	90	70	125	95	84	64.0
				16	36.1	130	90	80	130	90	90	64.0
				18	35.9	120	85	94	125	90	88	64.0
				20	36.0	140	95	78	140	90	84	64.0
				22	36.0	160	95	78	140	90	84	64.0
				24	35.8	135	90	80	130	90	84	64.0
				26	36.0	140	90	80	150	100	84	64.0
				28	36.5	140	90	78	150	100	82	64.0
				30	36.3	150	90	76	150	90	82	63.0
				32	36.7	145	95	76	150	100	76	65.0
				34	36.4	130	100	80	145	90	84	65.0
				36	36.3	140	90	60	140	100	80	65.0
				38	36.0	120	80	84	140	100	84	65.0
				40	35.8	120	90	84	110	80	88	65.0
				42	36.9	135	90	88	120	90	96	66.0
				44	36.0	130	90	80	110	90	92	67.0
				46	36.3	120	85	96	130	90	100	66.0
				48	36.3	130	90	84	120	90	100	66.0
				50	36.0	130	90	80	120	90	84	66.0
				52	36.0	120	90	76	125	95	84	66.0
											88	64.0
1	9	7	CCR	8	36.6	110	70	112	110	80	112	68.0
				10	36.6	95	65	112	90	65	116	67.0
				12	37.0	110	80	104	95	75	116	67.0
				14	36.6	110	80	80	120	80	87	67.0
				16	36.8	130	90	104	115	80	120	68.0
				18	37.1	120	80	112	105	75	128	68.0
				20	36.6	120	65	108	105	75	120	68.0
				22	36.2	115	75	104	105	80	112	68.0
				24	36.4	115	70	112	105	75	116	68.0
				26	36.8	123	70	114	110	70	120	67.0
				28	36.7	115	65	108	110	65	116	68.0
				30	36.8	100	70	100	105	50	116	69.0
				32	36.7	115	80	96	100	80	120	67.0
				34	36.3	115	80	92	100	80	116	67.0
				36	36.0	120	80	92	110	80	98	67.0
				38	36.0	125	80	94	110	70	98	67.0
				40	36.9	105	80	104	110	80	124	69.0
				42	37.0	130	90	104	120	85	120	69.0

2214

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED		REBOXETINE - PROTOCOL 20124/013		Listing No.: 13.1		VITAL SIGNS										Body Weight (kg)						
		DOUBLE BLIND PHASE										TREATMENT: REBOXETINE										
Contra	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	2m. Stand Weight (kg)										
1	9	7	CCR	44	36.8	120	80	100	120	90	105	68.0										
				46	36.8	120	80	96	115	80	112	68.0										
				48	36.3	100	65	80	100	65	92	68.0										
				50	36.7	110	70	80	120	75	96	68.0										
				52	36.7	105	65	88	110	70	88	68.0										
1	10	8	LDL	8	36.2	100	70	90	100	75	95	68.0										
				10	35.9	100	70	104	100	75	120	68.0										
				12	36.4	110	70	100	100	70	112	68.0										
				14	36.3	110	70	98	110	75	112	68.0										
				16	36.2	110	80	88	120	85	118	68.0										
				18	36.1	130	75	104	120	85	116	68.0										
				20	36.1	130	75	104	120	85	116	68.0										
				22	35.9	100	75	96	105	75	104	68.0										
				24	36.5	120	60	100	110	80	112	67.0										
				26	36.2	125	75	108	105	75	116	68.0										
				28	36.0	125	80	100	105	75	108	68.0										
				30	36.4	115	80	88	120	85	100	67.0										
				32	36.2	120	85	100	110	80	100	66.0										
				34	36.2	120	85	100	110	80	100	66.0										
				36	35.9	120	80	92	110	80	94	66.0										
				38	36.0	120	80	82	110	80	84	67.0										
				40	36.4	120	75	92	110	80	112	68.0										
				42	36.4	120	75	92	110	80	112	68.0										
				44	36.0	105	80	108	110	80	108	66.0										
				46	36.2	100	60	100	100	80	108	66.0										
				48	36.2	100	60	100	110	80	108	67.0										
				50	35.8	125	90	104	100	80	116	66.0										
				52	35.8	125	90	104	100	80	116	66.0										
1	14	11	MLC	8	35.7	130	85	104	130	85	96	58.0										
				10	35.7	130	85	104	130	85	96	58.0										
				12	35.7	130	85	104	130	85	96	58.0										
1	17	14	CEC	8	36.4	95	65	120	90	60	120	50.0										
				10	37.1	95	60	120	100	65	120	50.0										
				12	37.1	90	65	108	85	60	116	51.0										
				14	36.6	90	55	80	90	65	88	50.0										
				16	36.4	90	55	80	90	65	88	50.0										
				18	36.8	100	60	100	100	60	100	51.0										
				20	36.0	95	70	100	100	65	104	51.0										
				22	36.5	90	55	100	110	65	116	52.0										
				24	35.9	95	55	92	95	50	96	53.0										
				26	35.9	95	55	92	95	50	96	53.0										
				28	35.9	95	55	92	95	50	96	53.0										

2215

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
1	17	14	CEC	30	35.9	95	55	92	95	50	96	53.0
				32	35.9	95	55	92	95	50	96	53.0
1	18	15	ITM	8	36.0	120	80	76	110	80	78	51.0
				10	35.9	110	70	68	110	70	72	51.0
				12	35.8	115	75	62	110	70	72	51.0
				14	35.8	110	70	74	110	65	60	51.0
				16	35.7	120	70	58	110	70	64	51.0
				18	35.7	110	70	66	110	70	72	51.0
1	20	17	EFC	8	35.7	120	80	64	110	80	72	53.0
				10	35.7	115	75	68	110	75	74	53.0
				12
1	22	19	SK	8	36.4	120	80	76	105	80	84	52.0
				10	36.5	105	80	84	95	75	96	52.0
				12	35.7	105	80	76	105	80	88	52.0
				14	36.8	115	80	88	100	75	100	52.0
				16	36.0	105	75	88	100	70	84	52.0
				18	36.0	110	80	80	110	70	95	53.0
				20	36.3	105	75	84	95	70	100	52.0
				22	35.9	130	90	88	110	90	100	53.0
				24	35.8	110	80	76	110	75	96	52.0
				26	35.8	110	70	76	110	75	116	51.0
				28	36.3	100	70	80	100	70	80	51.0
				30	36.9	110	70	84	100	80	100	51.0
				32	36.5	100	70	96	110	80	100	51.0
				34	36.4	110	80	88	100	80	88	51.0
				36	36.4	110	80	88	100	80	88	51.0
				38	36.4	110	80	88	100	80	88	51.0
				40	36.7	110	80	80	105	80	100	51.0
				42	36.7	110	80	80	100	80	100	52.0
				44	36.6	105	80	84	105	85	96	54.0
				46	36.5	110	90	96	100	80	96	53.0
				48	36.1	135	100	88	120	90	96	52.0
				50	36.1	135	100	88	120	90	96	52.0
				52	36.2	130	90	84	120	85	90	53.0
1	24	20	LVF	8	36.0	120	80	76	110	80	78	46.0
				10	36.4	125	85	86	120	80	92	46.0
				12	36.1	125	80	78	120	70	84	46.0
				14	36.4	120	80	78	110	70	88	46.0
				16	36.4	120	75	78	110	70	84	46.0
				18	36.2	120	70	64	110	70	72	46.0
				20	36.2	115	75	64	110	70	72	46.0

2216

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
1	24	20	LVF	22	36.2	120	80	78	110	70	82	46.0
				24	36.2	130	80	66	115	70	74	47.0
				26	36.2	120	75	68	115	70	74	48.0
				28	36.2	130	80	78	115	75	84	48.0
				30	36.3	120	70	72	110	75	86	48.0
				32	36.2	125	85	76	120	75	82	48.0
				34	36.3	115	75	80	110	70	86	48.0
				36	36.2	110	70	68	100	70	72	48.0
				38	36.4	110	70	74	105	60	78	48.0
				40	36.1	110	70	72	110	60	80	48.0
				42	36.2	115	75	68	110	70	74	47.0
				44	36.1	115	70	64	105	70	78	48.0
				46	36.3	110	70	72	105	65	80	48.0
				48	36.4	115	80	76	120	70	84	49.0
				50	36.5	115	70	84	110	75	92	49.0
				52	36.2	120	80	76	110	75	84	50.0
1	25	21	AMR	8	36.0	120	80	84	110	80	88	69.0
				10	35.8	125	80	82	120	75	88	69.0
				12	35.7	120	80	70	110	80	72	69.0
				14	35.8	120	85	76	110	80	86	69.0
				16	35.7	125	85	78	120	80	84	69.0
				18	35.9	125	80	78	115	80	86	69.0
				20	36.0	120	80	74	110	75	80	70.0
				22	36.1	120	80	70	110	70	70	70.0
				24	36.2	130	80	72	120	80	76	70.0
				26	36.2	125	80	70	120	70	80	70.0
				28	35.9	120	80	84	125	75	86	68.0
				30	36.0	135	80	78	120	80	84	68.0
				32	36.2	120	80	76	120	80	82	68.0
				34	36.1	120	80	82	110	75	84	69.0
				36	36.1	110	70	78	115	75	84	69.0
				38	36.1	128	75	76	115	80	84	70.0
				40	36.0	120	70	84	110	75	86	70.0
				42	36.1	125	80	80	115	75	86	71.0
				44	36.1	120	80	84	115	75	86	72.0
				46	36.2	120	75	82	115	75	88	72.0
				48	36.2	125	85	84	120	80	86	72.0
				50	36.1	125	80	84	120	80	90	73.0
				52	36.1	130	80	74	115	70	86	72.0
1	31	27	MAN	8	36.5	110	70	90	110	70	95	42.0
				10	36.0	120	70	70	120	80	70	41.0
				12	36.0	100	60	80	100	60	88	41.0
				14	36.7	120	70	120	100	75	120	41.0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)					
1	31	27	MAN	16	36.3	110	70	104	105	60	108	41.0					
				18	36.8	100	70	120	100	75	120	100	41.0				
				20	36.8	100	60	112	100	60	120	100	41.0				
				22	36.5	110	80	112	120	90	112	120	41.0				
				24	37.1	110	70	100	110	80	115	110	41.0				
				26	37.1	110	70	100	110	80	115	110	42.0				
				28	36.7	100	70	116	95	75	124	100	42.0				
				30	36.8	100	70	116	95	75	124	100	42.0				
				32	36.4	110	80	110	110	80	90	110	41.0				
				34	36.4	110	80	75	110	80	90	110	41.0				
				36	36.0	90	70	114	90	65	110	110	41.0				
				38	36.2	90	70	114	90	65	110	110	41.0				
				40	36.0	90	70	114	90	65	110	110	41.0				
				42	36.0	90	70	114	90	65	110	110	41.0				
				44	36.0	100	70	116	110	95	128	110	41.0				
				46	36.0	110	75	116	110	95	128	110	42.0				
				48	36.0	110	75	80	100	70	88	100	42.0				
				50	36.0	110	75	72	100	70	78	100	42.0				
				52	36.0	110	75	80	100	70	86	100	42.0				
				1	32	28	DGH	8	36.7	100	70	60	100	80	64	67.0	
								10	36.7	120	85	116	120	90	116	120	69.0
								12	36.7	120	85	116	120	90	116	120	69.0
								14	36.7	105	65	104	110	80	104	94	68.0
								16	36.7	105	65	104	110	80	104	94	68.0
								18	36.7	105	65	104	110	80	104	94	68.0
								20	36.3	100	60	60	100	70	66	66	68.0
								22	36.3	110	90	60	100	60	66	66	68.0
				24	37.0	100	65	116	100	80	120	100	65.0				
				26	36.2	105	75	116	110	85	124	120	64.0				
				28	36.2	105	75	90	110	85	124	120	64.0				
				30	36.2	105	75	116	110	85	124	120	64.0				
				32	36.2	105	75	116	110	85	124	120	64.0				
				34	36.2	105	75	86	110	85	124	120	64.0				
				36	36.2	105	75	90	110	85	124	120	64.0				
				38	36.2	105	75	88	110	85	124	120	64.0				
				40	36.2	110	70	62	120	70	68	120	64.0				
				42	36.2	105	70	60	110	70	68	110	64.0				
				44	36.1	115	75	62	120	70	68	120	64.0				
				46	36.4	130	70	74	120	80	78	120	64.0				
				48	36.2	125	85	64	120	80	66	120	64.0				
				50	36.6	130	70	70	110	70	72	110	64.0				
				52	36.4	110	80	58	115	75	62	115	64.0				
				1	34	30	GKH	8	36.2	120	80	84	110	70	90	56.0	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 ROXOXYLINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: ROXOXYLINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
1	34	30	CHH	10	36.2	125	85	64	120	80	68	56.0
				12	36.5	130	80	62	120	70	68	56.0
				14	36.4	110	70	64	110	70	72	56.0
				16	36.1	115	75	72	110	70	76	56.0
				18	36.3	120	80	74	110	70	76	56.0
				20	36.2	110	70	64	100	70	68	56.0
				22	36.1	115	80	60	120	75	72	56.0
				24	36.5	105	75	80	95	70	92	57.0
				26	35.5	100	75	96	100	80	96	57.0
				28	35.3	100	70	80	100	70	80	56.0
				30	35.7	100	70	80	100	70	80	56.0
				32	35.7	100	70	80	100	70	80	56.0
				34	35.6	90	70	88	100	80	92	57.0
				36	35.6	90	70	88	100	80	92	57.0
				38	35.6	90	70	88	100	80	92	57.0
				40	35.6	90	70	88	100	80	92	57.0
				42	35.6	90	70	78	100	80	82	57.0
				44	35.6	90	70	88	100	80	92	57.0
				46	35.6	110	80	80	105	75	84	57.0
				48	35.6	110	80	76	105	75	82	57.0
				50	35.6	110	80	80	105	75	84	57.0
				52	35.6	110	80	80	105	75	84	57.0
				8	35.9	90	70	80	90	70	80	56.0
		301	ENP	10	36.5	110	75	92	95	65	112	57.0
				12	36.3	110	80	88	95	75	104	57.0
				14	36.3	115	70	88	100	75	104	56.0
				16	36.2	100	70	100	100	75	104	55.0
				18	36.0	110	75	104	90	75	116	55.0
				20	36.0	110	75	104	90	75	116	55.0
				22	36.1	105	75	92	90	75	108	55.0
				24	36.2	100	70	92	100	80	94	54.0
				26	36.0	100	70	92	100	80	94	53.0
				28	36.0	110	75	100	110	80	104	53.0
				30	36.5	110	75	100	110	80	104	53.0
				32	36.5	110	75	100	110	80	104	53.0
				34	36.5	105	75	100	100	80	112	53.0
				36	36.9	110	80	96	105	75	104	53.0
				38	36.9	110	80	96	105	75	104	53.0
				40	36.4	120	80	82	110	70	95	52.0
				42	36.4	120	80	82	110	70	95	52.0
				44	35.8	110	80	80	110	70	95	52.0
				46	35.8	110	80	80	110	70	95	52.0
				48	36.3	110	75	92	100	70	112	53.0
				50	36.3	110	75	92	95	75	112	54.0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	D.R. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys Bp (mmHg)	5m. Lying Dias Bp (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys Bp (mmHg)	2m. Stand Dias Bp (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)
1	35	301	ERP	52	36.3	110	75	72	95	75	80	54.0
1	37	303	RF	8	36.5	140	95	96	150	95	96	76.0
				10	36.4	140	95	104	135	95	112	76.0
				12	36.5	145	100	100	145	100	100	76.0
				14	37.0	140	95	100	150	100	108	75.0
				16	36.5	135	100	92	160	110	92	73.0
				18	36.1	140	110	100	150	110	100	73.0
				22	35.8	130	100	88	130	100	96	73.0
				24	36.2	110	80	88	130	100	96	73.0
				26	36.2	110	80	80	110	80	84	73.0
				28	36.0	110	80	80	110	80	84	73.0
				30	37.0	130	90	80	130	90	80	72.0
				32	36.7	130	90	88	130	100	88	71.0
				34	39.0	160	100	90	160	100	94	74.0
				36	36.0	155	110	80	150	100	92	76.0
				38	36.8	160	100	92	145	105	90	79.0
				40	36.8	160	100	92	145	105	90	79.0
				42	36.5	130	95	98	140	100	100	79.0
				44	36.2	140	100	100	140	100	100	78.0
				46	35.3	115	80	100	105	85	100	76.0
				48	36.0	110	85	102	130	95	104	76.0
				50	36.2	125	100	96	135	105	104	76.0
				52	36.5	130	90	92	129	95	100	75.0
1	39	305	ASS	8	36.0	100	70	90	105	70	100	60.0
				10	35.2	105	85	102	110	90	102	60.0
				12	35.2	110	70	96	100	70	100	60.0
				14	36.6	115	85	108	110	75	108	62.0
				16	35.4	100	70	96	90	60	96	62.0
				18	36.5	120	80	104	125	85	108	62.0
				20	36.0	130	90	92	130	90	92	62.0
				22	36.0	130	90	92	130	90	92	62.0
				24	35.6	95	70	96	110	80	96	62.0
				26	35.3	95	70	96	110	80	96	62.0
				28	36.1	120	80	96	120	80	96	62.0
				30	35.7	105	80	106	110	90	110	65.0
				32	35.7	105	80	106	110	90	110	65.0
				34	35.7	105	80	106	110	90	110	62.0
				36	35.7	105	80	106	110	90	110	61.0
				38	36.0	105	75	96	105	75	108	60.0
				40	36.0	105	75	96	105	75	108	60.0
				42	36.0	105	75	96	105	75	108	60.0
				44	36.0	125	90	96	125	90	96	59.0

2220

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 ROXOMETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: ROXOMETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)				
1	39	305	ASS	46	36.0	125	90	96	125	90	96	59.0				
				48	36.0	140	85	96	130	90	100	60.0				
				50	36.0	140	85	96	130	90	100	60.0				
				52	35.5	120	85	92	100	92	92	61.0				
1	43	309	ARN	8	36.4	110	80	92	110	80	100	89.0				
				10	36.5	110	80	96	110	85	100	88.0				
				12	36.5	120	90	120	120	90	128	88.0				
				14	36.6	120	80	100	110	80	106	88.0				
				16	37.0	120	80	120	105	80	124	89.0				
				18	37.0	120	80	120	105	80	124	89.0				
				20	36.5	98	75	104	100	80	124	88.0				
				22	36.5	95	96	100	100	80	106	89.0				
				24	36.6	110	80	120	110	80	116	88.0				
				26	36.2	105	80	120	110	80	120	89.0				
				28	36.2	105	80	120	110	80	120	89.0				
				30	36.2	105	80	120	110	80	120	89.0				
				32	36.2	105	80	120	110	80	120	89.0				
				34	36.2	105	80	120	110	80	120	89.0				
				36	36.9	140	100	104	100	95	104	104	89.0			
				38	36.9	140	100	104	100	95	104	104	89.0			
				40	36.9	140	100	104	100	95	104	104	89.0			
				42	36.9	140	100	104	100	95	104	104	89.0			
				44	36.2	120	75	108	100	95	104	104	89.0			
				46	36.0	105	80	116	80	90	120	120	89.0			
				48	36.0	105	80	116	80	90	120	120	89.0			
				50	36.0	105	80	94	80	90	98	120	91.0			
				52	36.0	105	80	90	80	90	98	130	91.0			
				1	45	310	DPS	8	36.3	130	90	84	110	85	92	68.0
								10	36.3	160	110	80	150	80	88	71.0
								12	36.0	150	100	84	170	84	84	73.0
								14	36.1	140	90	80	160	80	88	70.0
								16	36.1	140	90	80	160	80	88	70.0
								18	36.7	140	90	80	160	80	88	70.0
								20	36.1	140	90	80	140	80	88	70.0
								22	36.1	140	90	80	140	80	88	70.0
								24	36.1	140	90	80	140	80	88	70.0
								26	36.8	150	95	82	145	90	88	70.0
								28	36.8	150	95	88	145	90	88	70.0
								30	36.0	125	90	88	110	85	92	68.0
								32	36.0	125	90	88	110	85	92	68.0
								34	35.6	110	80	88	100	80	92	68.0
								36	36.4	140	90	84	125	90	84	70.0
38	36.4	140	90					84	125	90	84	70.0				

2221

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
1	45	310	DPS	40	36.3	140	100	88	130	100	94	71.0
				42	36.3	140	100	88	130	100	94	71.0
				44	36.8	140	100	70	130	100	84	71.0
				46	36.0	140	90	80	140	90	88	71.0
				48	36.0	140	90	80	140	90	88	71.0
				50	35.9	140	70	100	140	90	78	71.0
				52	36.3	140	100	88	130	85	84	72.0
				8	36.3	110	70	96	110	75	100	47.0
				10	36.3	110	70	96	110	75	100	47.0
				12	36.3	95	65	96	95	65	112	47.0
2	46	311	SP	14	36.3	95	70	88	100	70	104	47.0
				16	36.3	95	70	88	100	70	104	47.0
				18	36.0	105	65	104	105	70	120	46.0
				20	36.8	105	65	100	105	70	100	49.0
				22	36.8	105	65	100	105	70	100	49.0
				24	36.0	105	70	88	100	75	88	49.0
				26	36.0	105	70	88	100	75	88	49.0
				28	36.2	105	70	88	100	75	88	49.0
				30	36.2	110	75	88	105	70	88	49.0
				32	36.2	110	75	96	100	70	88	49.0
2	48	313	SCM	34	36.2	110	75	96	100	70	100	49.0
				36	36.2	110	75	96	100	70	100	49.0
				38	36.2	110	75	96	100	70	100	49.0
				40	36.1	120	80	96	100	70	100	49.0
				42	36.2	110	80	96	115	75	92	50.0
				44	36.2	120	80	102	115	70	104	50.0
				46	36.2	125	85	84	120	80	88	51.0
				48	36.2	125	89	80	120	80	88	51.0
				50	36.2	125	102	70	115	70	102	51.0
				52	36.0	115	75	100	110	70	100	51.0
1	48	313	SCM	8	37.0	110	70	88	100	70	104	72.0
				10	37.0	125	90	96	115	90	100	72.0
				12	36.9	115	75	100	105	75	108	72.0
				14	36.8	120	80	104	110	80	108	73.0
				16	36.8	110	80	88	100	80	96	73.0
				18	36.9	120	80	92	105	70	100	74.0
				20	36.8	100	75	84	90	65	104	73.0
				22	36.8	120	80	88	120	80	100	74.0
				24	36.8	120	80	88	120	85	100	74.0
				26	37.2	120	50	100	120	85	100	75.0
28	36.8	105	80	76	110	85	92	74.0				
30	37.0	120	80	72	120	80	72	74.0				
32	36.8	100	80	88	100	80	108	75.0				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)			
1	48	313	SCH	34	36.8	100	80	88	100	80	108	75.0			
				36	37.0	120	80	72	120	80	74.0				
				38	37.2	140	85	86	130	80	88				
				40	37.2	140	85	86	135	80	88				
				42	37.0	125	80	86	120	80	94				
				44	37.0	125	80	86	120	80	94				
				46	37.0	125	80	86	120	80	94				
				48	37.2	110	88	110	80	98	75.0				
				50	37.2	115	100	88	100	88	72.0				
				52	37.0	115	75	80	100	88	72.0				
				1	52	316	MTS	8	36.3	130	90	100	100	104	54.0
								10	36.4	130	70	78	140	90	54.0
				12	36.4	160	100	84	160	100	54.0				
				14	36.0	140	100	85	140	95	54.0				
				16	36.0	140	110	80	110	100	54.0				
				18	37.1	140	110	76	140	80	51.0				
				20	36.9	155	120	104	155	100	52.0				
				22	36.5	160	120	104	150	108	52.0				
				24	36.5	160	120	104	150	115	52.0				
				26	36.5	160	120	64	150	115	52.0				
				28	36.3	150	110	80	140	110	50.0				
				30	36.3	150	110	80	140	110	50.0				
				32	36.7	130	100	100	140	100	52.0				
				34	36.7	130	100	60	140	100	52.0				
				36	36.7	130	100	100	140	100	52.0				
				38	36.7	130	100	100	140	100	52.0				
				40	36.8	100	70	74	105	70	52.0				
				42	36.5	115	85	74	110	75	52.0				
				44	36.6	115	70	70	105	65	52.0				
				46	36.2	120	80	76	110	70	52.0				
				48	36.2	115	75	80	120	70	52.0				
				50	36.8	125	70	74	115	70	52.0				
				52	36.2	120	80	74	110	70	52.0				
1	55	318	DNG	8	36.0	130	90	80	160	100	88	62.0			
				10	36.0	130	90	80	160	100	88	62.0			
				12	36.0	130	90	80	160	100	88	62.0			
				14	36.0	130	90	80	160	100	88	62.0			
1	56	319	IAL	8	35.9	125	85	84	125	80	90	75.0			
1	58	320	ARH	8	36.2	110	70	64	105	75	70	58.0			
				10	36.1	115	75	66	110	70	72	58.0			
				12	36.2	115	70	66	105	60	72	56.0			

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
1	58	320	ARM	14	36.1	110	75	70	105	65	74	56.0
				16	36.2	115	75	76	110	70	78	54.0
1	61	323	HVC	8	35.5	110	80	88	110	90	88	60.0
				10	35.7	105	75	76	110	75	84	60.0
				12	35.6	115	75	88	100	70	100	60.0
				14	36.1	115	75	88	100	70	100	60.0
				16	36.3	95	70	96	95	70	108	60.0
				18	36.0	130	80	96	110	75	104	60.0
				20	36.0	115	75	88	90	70	96	60.0
				22	36.0	115	80	86	110	75	94	60.0
				24	36.6	110	75	92	110	85	104	60.0
				26	36.6	110	75	92	110	85	104	60.0
				28	36.1	125	85	84	135	85	96	62.0
				30	36.1	125	85	84	135	85	96	62.0
				32	36.7	125	85	72	135	85	86	62.0
				34	36.5	125	85	88	130	85	96	61.0
				36	35.7	130	90	100	135	85	104	62.0
				38	35.8	130	80	96	80	55	96	61.0
				40	35.8	120	80	84	100	60	92	60.0
				42	36.1	115	70	92	110	70	100	61.0
				44	36.1	130	90	80	110	70	100	61.0
				46	36.5	130	75	88	132	90	84	61.0
				48	35.6	105	75	88	110	80	104	62.0
				50	35.6	105	75	88	110	80	104	62.0
				52	36.3	105	80	92	100	70	92	61.0
1	66	326	TCC	8	36.2	130	100	82	120	100	86	63.0
				10	36.7	130	100	80	120	100	84	60.0
				12	36.7	120	90	88	110	80	84	60.0
				14	36.3	135	100	76	125	100	100	60.0
				16	37.0	130	95	88	115	85	92	59.0
				18	37.0	130	95	88	115	85	112	59.0
				20	37.0	130	95	88	115	85	112	59.0
				22	37.0	130	95	88	115	85	112	59.0
				24	36.5	110	90	120	110	90	124	58.0
				26	36.5	135	90	84	115	90	108	59.0
				28	36.3	115	85	84	110	80	86	58.0
				30	36.4	125	90	96	110	80	104	58.0
				32	35.9	130	95	104	120	95	104	58.0
				34	36.2	115	90	92	125	100	96	59.0
				36	36.8	120	100	96	135	90	100	59.0
				38	36.2	110	90	100	130	90	100	59.0
				40	36.2	120	85	96	130	100	106	58.0
				42	36.0	130	80	92	130	85	92	55.0

222/1

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D. R. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
1	66	326	TCG	44	35.0	115	85	116	135	100	108	56.0
				46	35.0	120	80	88	110	80	88	57.0
				48	35.5	120	90	84	110	90	100	57.0
				50	35.7	115	90	68	110	80	88	58.0
				52	35.4	130	90	78	125	95	80	58.0
1	71	329	ORV	8	36.9	100	80	96	100	80	104	53.0
				10	36.3	100	70	90	110	70	98	54.0
				12	37.0	110	75	108	95	75	120	53.0
				14	36.8	100	80	100	100	80	100	53.0
				16	36.8	100	80	100	100	75	100	53.0
				18	36.0	105	75	108	105	80	112	53.0
				20	36.0	105	75	108	105	75	112	53.0
				22	36.0	105	75	108	105	75	112	53.0
				24	36.8	110	70	104	100	80	112	53.0
				26	36.8	110	70	104	100	80	112	53.0
				28	36.5	95	70	100	100	80	106	53.0
				30	36.5	100	80	112	110	70	104	53.0
				32	36.5	95	70	100	100	80	106	53.0
				34	36.5	95	70	100	100	80	106	53.0
				36	36.5	120	80	104	120	80	112	53.0
				38	36.5	120	80	104	120	80	112	53.0
				40	36.3	110	75	102	105	80	112	53.0
				42	36.6	100	70	100	110	80	112	52.0
				44	36.6	100	70	100	110	80	112	52.0
				46	36.4	105	70	96	110	75	110	52.0
				48	36.3	110	70	92	110	75	108	52.0
				50	36.4	110	70	92	110	75	108	52.0
52	36.5	110	70	92	110	75	100	52.0				
1	72	330	RLJ	8	36.0	125	85	66	130	80	78	68.0
				10	36.2	120	70	60	115	70	68	68.0
				12	36.2	125	80	64	115	70	68	68.0
				14	36.0	120	70	66	110	70	76	69.0
				16	36.1	115	75	68	110	70	74	69.0
1	73	121	FMA	18	36.3	115	75	60	110	70	70	69.0
				20	36.2	110	70	72	105	70	76	69.0
				22	36.2	130	80	74	115	70	76	69.0
				8	36.5	140	95	88	135	95	92	60.0
				10	36.5	140	95	88	135	95	92	59.0
12	36.5	140	95	88	135	95	92	59.0				
14	36.5	140	95	88	135	95	92	59.0				
16	36.5	140	95	88	135	95	92	59.0				
18	36.5	140	95	88	135	95	92	59.0				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)				
1	73	121	FMA	20	36.5	140	95	88	135	95	92	59.0				
				22	36.5	140	95	88	135	95	92	59.0				
				24	36.4	125	85	74	120	80	86	59.0				
				26	36.1	120	80	62	115	70	72	58.0				
1	75	123	ELF	8	36.0	100	75	100	100	75	108	57.0				
				10	36.2	100	75	100	100	75	108	57.0				
				12	35.7	95	72	96	90	70	104	57.0				
				14	36.4	100	75	108	90	70	112	57.0				
				16	36.5	85	60	96	95	70	104	57.0				
				18	36.5	85	60	96	95	70	104	57.0				
				20	36.7	85	60	104	100	80	104	58.0				
				22	36.7	95	75	104	100	80	104	58.0				
				24	36.7	95	75	104	100	80	104	58.0				
				26	36.7	95	75	104	100	80	104	58.0				
				28	36.3	90	75	88	100	80	96	56.0				
				30	35.3	105	70	92	100	80	100	56.0				
				32	35.3	105	70	92	100	80	100	56.0				
				34	36.4	100	80	100	100	80	108	56.0				
				36	36.4	100	80	100	100	80	108	56.0				
				38	35.8	120	80	96	110	90	100	58.0				
				40	35.8	120	80	96	110	90	100	58.0				
				42	35.8	115	80	88	105	80	92	58.0				
				44	36.2	105	80	88	105	80	88	59.0				
				46	35.5	105	80	92	100	80	96	59.0				
				48	35.7	105	80	92	100	80	96	59.0				
				50	35.9	115	80	92	110	90	100	59.0				
				52	36.0	115	80	92	110	90	100	59.0				
				1	77	125	ACG	8	36.1	120	80	84	115	75	82	71.0
								10	36.2	125	70	78	120	70	86	71.0
								12	36.0	120	75	80	115	70	86	71.0
								14	36.4	130	80	68	115	70	84	71.0
								16	36.2	125	80	82	115	70	78	71.0
								18	36.1	120	80	76	110	70	82	71.0
								20	36.2	125	80	78	115	70	80	71.0
								22	36.4	115	75	78	110	70	86	71.0
								24	36.2	110	70	82	110	60	80	71.0
26	36.2	130	80					72	115	70	86	71.0				
28	36.3	120	70					72	110	70	86	71.0				
30	36.2	115	75					62	110	70	80	71.0				
32	36.2	110	70	60	110	65	68	71.0								
34	36.0	110	70	58	100	60	64	71.0								
36	36.1	110	70	60	100	60	64	71.0								
38	35.8	105	70	64	100	65	68	71.0								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
1	77	125	ACG	40	36.6	125	80	72	115	70	80	71.0
				42	36.0	125	85	84	115	75	86	71.0
				44	36.2	130	80	74	120	80	82	70.0
				46	36.0	130	80	72	115	75	74	70.0
				48	36.0	115	70	74	120	80	74	71.0
				50	36.2	120	80	84	110	75	88	71.0
				52	36.1	120	80	74	110	70	82	70.0
1	81	128	HFB	8	36.2	115	70	62	110	70	66	67.0
				10	36.1	115	70	64	105	70	60	67.0
				12	36.3	110	70	60	105	75	64	67.0
				14	36.4	110	70	56	105	60	62	67.0
				16	36.0	110	70	54	105	60	62	67.0
				18	36.2	100	70	54	100	60	58	67.0
				20	36.0	100	70	56	95	65	66	67.0
				22	36.1	105	70	56	100	65	62	67.0
				24	36.4	110	80	74	100	70	78	67.0
				26	36.5	120	70	72	110	70	82	68.0
				28	36.1	110	70	82	110	65	88	67.0
				30	36.5	115	75	72	110	70	78	67.0
				32	36.6	125	85	72	115	75	78	68.0
				34	36.7	120	70	82	110	75	86	68.0
				36	36.7	120	80	76	110	70	82	68.0
				38	36.5	130	80	72	115	70	82	68.0
				40	36.1	110	70	80	110	60	82	67.0
				42	36.0	120	70	72	110	70	74	67.0
				44	35.9	120	80	64	110	70	68	67.0
				46	36.2	125	85	66	120	80	70	68.0
				48	36.3	125	85	66	120	70	70	68.0
				50	36.1	110	70	70	105	65	72	68.0
				52	36.4	110	80	68	110	70	72	68.0
1	82	129	HDS	8	36.4	120	80	70	110	70	82	63.0
				10	36.3	115	75	72	110	75	78	63.0
				12	36.4	120	70	74	110	70	78	63.0
				14	36.3	130	70	74	115	65	82	64.0
				16	36.2	115	75	76	110	70	86	64.0
				18	36.1	120	70	78	110	65	84	63.0
				20	36.1	115	75	68	105	70	76	64.0
				22	36.2	110	70	76	105	65	82	65.0
				24	36.2	120	80	74	115	75	78	65.0
				26	36.3	130	80	74	115	75	80	65.0
				28	36.3	130	75	72	120	75	80	65.0
				30	36.3	110	70	78	115	70	88	63.0
				32	36.2	135	85	82	125	80	86	64.0

2227

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
1	82	129	MDS	34	36.1	125	85	74	120	75	82	64.0
				36	36.6	120	80	76	110	70	82	64.0
				38	36.7	120	80	78	115	80	82	64.0
				40	36.2	120	80	74	110	70	80	64.0
				42	36.3	110	70	78	110	60	84	65.0
				44	36.2	130	70	68	120	70	74	64.0
				46	36.6	120	80	72	110	70	86	64.0
				48	36.1	110	70	74	120	80	76	64.0
				50	35.8	120	70	76	115	70	78	64.0
				52	36.2	110	70	74	115	65	78	64.0
1	87	132	MDO	8	36.1	130	80	76	120	70	82	74.0
				10	36.2	125	80	78	120	80	84	74.0
				12	36.2	125	75	74	120	80	88	74.0
				14	36.3	115	75	78	110	70	86	74.0
				16	36.3	125	80	78	115	70	84	74.0
				18	36.4	130	75	84	120	75	84	73.0
				20	36.4	120	75	84	115	70	88	73.0
				22	36.5	115	70	78	110	70	84	72.0
1	89	133	MMV	8	36.1	130	80	72	120	70	82	67.0
				10	36.2	130	80	84	125	75	86	66.0
				12	36.2	130	75	84	120	70	88	66.0
				14	36.2	130	80	76	120	75	82	65.0
1	90	134	JSS	8	36.2	120	80	76	115	80	82	66.0
1	95	138	GHT	8	36.1	120	80	78	115	75	84	67.0
				10	36.0	120	80	82	115	75	86	67.0
				12	36.0	125	80	76	125	75	78	67.0
				14	36.1	125	70	68	120	70	74	67.0
				16	36.4	120	80	78	115	80	84	67.0
				18	36.0	115	75	82	120	70	86	67.0
				20	36.0	125	80	76	120	70	82	67.0
				22	36.1	120	80	74	110	70	78	68.0
				24	35.9	135	80	78	115	70	84	67.0
				26	36.2	115	80	66	110	70	74	67.0
				28	36.1	120	80	76	110	70	82	67.0
				30	36.3	115	75	64	120	70	72	66.0
				32	36.4	110	70	76	100	60	82	66.0
				34	36.1	100	70	76	110	70	80	66.0
				36	36.5	115	70	72	110	75	74	66.0
				38	36.4	120	70	74	110	70	78	66.0
				40	36.3	120	70	82	110	70	86	66.0
				42	36.1	120	80	84	115	70	86	66.0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2h. Stand Sys BP (mmHg)	2h. Stand Dias BP (mmHg)	2h. Stand Heart Rate (beats/min)	Body Weight (kg)								
1	95	138	GHT	44	36.3	125	80	74	115	70	78	66.0								
				46	36.1	130	70	84	120	70	90	66.0								
				48	36.3	120	80	78	115	70	84	66.0								
				50	36.3	110	70	84	115	70	88	66.0								
				52	36.0	125	85	82	120	70	86	66.0								
1	96	139	SPH	8	36.2	120	85	100	125	80	104	69.0								
				10	36.2	120	80	94	110	70	98	69.0								
				12	36.4	115	80	88	110	80	98	69.0								
				14	36.4	130	80	104	110	70	104	69.0								
				16	36.2	110	80	100	120	75	104	69.0								
				18	36.0	130	80	96	125	85	98	69.0								
				20	36.3	125	80	96	120	85	104	69.0								
				22	36.2	130	80	90	120	80	96	69.0								
				24	36.7	130	80	74	120	75	80	69.0								
				26	36.4	120	80	70	110	75	72	69.0								
				28	36.8	115	70	76	110	70	84	69.0								
				30	36.2	120	80	84	110	70	86	69.0								
				32	36.0	115	80	84	110	70	88	69.0								
				34	36.0	130	70	68	120	75	74	69.0								
				36	36.4	115	70	80	105	70	86	69.0								
				2	97	139	SPH	38	36.5	120	80	84	110	70	86	70.0				
								40	36.0	115	70	84	120	70	86	70.0				
								42	36.5	120	70	64	110	60	68	70.0				
								44	36.1	120	80	66	115	70	72	70.0				
								46	36.1	120	70	64	110	70	68	70.0				
								48	36.4	120	80	76	110	75	78	70.0				
								50	36.6	115	70	64	130	70	72	70.0				
								52	36.3	115	75	68	120	70	72	71.0				
								1	98	141	YTT	8	36.3	125	80	82	120	80	86	72.0
												10	36.4	120	70	78	110	65	86	72.0
												12	36.0	115	75	76	110	75	82	72.0
												14	36.2	115	75	80	110	75	86	72.0
				16	36.3	120	80					78	125	85	84	72.0				
				18	36.6	125	75					68	120	70	76	72.0				
				20	36.5	120	80					84	120	75	90	72.0				
				22	36.4	125	80					78	120	75	86	72.0				
				24	36.4	120	70					76	110	60	78	72.0				
				26	36.3	130	80					60	110	70	68	72.0				
				28	36.0	130	70					80	120	70	82	72.0				
				30	36.3	125	70					82	115	70	86	72.0				
				32	36.4	120	78	78	115	70	84	71.0								
34	36.1	125	85	60	120	80	64	71.0												
36	36.0	115	75	82	110	70	80	71.0												

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)
1	98	141	YTT	38	36.1	115	75	76	110	70	78	71.0
				40	36.5	125	80	76	115	70	78	72.0
				42	36.0	125	80	74	115	70	78	72.0
				44	36.2	115	70	80	120	70	82	72.0
				46	36.4	125	80	80	115	75	84	72.0
				48	36.5	125	80	82	115	75	84	72.0
				50	36.2	120	70	80	125	75	86	72.0
				52	36.6	120	80	84	110	70	86	73.0
				8	35.6	100	60	120	105	60	120	50.0
				10	36.3	95	65	104	95	65	112	50.0
				12	35.9	100	60	100	105	65	100	50.0
				14	36.0	100	60	120	105	60	120	50.0
16	36.0	95	65	104	95	65	112	50.0				
18	36.0	95	65	104	95	65	112	50.0				
20	36.0	100	65	100	105	65	100	50.0				
22	36.0	100	65	100	105	65	100	50.0				
24	36.1	105	60	96	115	50	96	50.0				
26	36.5	100	65	100	105	65	100	50.0				
28	36.1	100	65	88	100	65	108	52.0				
30	36.1	100	65	88	100	65	108	49.0				
32	35.4	105	70	84	100	65	92	49.0				
34	36.1	105	60	68	120	70	68	49.0				
36	35.8	115	60	108	115	60	120	48.0				
38	35.5	100	60	104	110	70	108	48.0				
40	35.0	100	70	84	105	70	108	48.0				
42	35.8	105	60	100	115	70	104	48.0				
44	36.0	110	70	116	105	70	96	48.0				
46	35.7	100	60	104	105	65	108	48.0				
48	35.5	90	65	92	110	70	100	48.0				
50	35.6	110	70	104	105	60	132	48.0				
52	35.6	105	60	96	110	80	96	48.0				
1	107	147	LAN	8	36.1	110	70	84	110	65	90	70.0
				10	36.4	115	75	60	110	70	74	71.0
				12	36.0	120	75	84	110	70	86	71.0
				14	36.3	125	85	74	115	80	78	72.0
				16	36.6	125	90	82	130	85	90	72.0
				18	36.4	130	80	68	120	85	74	72.0
				20	36.5	120	75	86	115	70	90	72.0
				22	36.3	125	80	84	120	80	92	72.0
				24	36.1	120	80	88	110	75	94	72.0
				26	36.6	125	85	90	120	80	92	72.0
				28	36.0	115	70	84	120	70	86	72.0
				30	36.3	125	85	78	120	80	82	71.0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)						
1	107	147	LAN	32	36.1	125	80	90	130	70	92	71.0						
				34	36.2	120	70	90	70	96	70	96	72.0					
				36	36.2	130	80	90	70	86	110	70	86	72.0				
				38	36.5	120	70	78	70	78	125	65	84	72.0				
				40	36.0	120	80	66	80	66	115	80	80	72.0				
				42	36.3	115	60	60	72	60	110	70	64	72.0				
				44	36.6	115	75	74	70	74	110	70	80	72.0				
				46	35.9	110	60	64	100	60	100	60	66	72.0				
				48	35.8	110	68	58	100	60	100	60	62	72.0				
				50	35.9	120	80	82	100	75	82	100	64	72.0				
				52	36.0	110	70	76	105	65	80	65	80	72.0				
				1	109	149	IPL	8	36.1	125	80	76	120	70	86	72.0		
								10	36.4	120	70	92	70	92	70	98	72.0	
								12	36.4	120	80	82	110	82	110	70	88	72.0
								14	36.2	130	76	76	120	75	76	75	88	73.0
								16	36.2	130	80	84	135	85	85	85	86	73.0
								18	36.3	120	80	88	110	70	96	70	96	73.0
								20	36.4	120	70	80	110	75	84	70	84	73.0
								22	36.1	125	75	78	120	70	86	70	86	73.0
								24	36.4	125	85	66	115	80	70	80	70	73.0
								26	36.1	125	85	62	115	80	64	65	64	73.0
								28	36.4	130	70	60	115	70	60	65	64	73.0
								30	36.1	125	80	72	115	70	72	70	72	73.0
								32	36.2	115	75	76	110	70	78	70	78	73.0
34	36.4	125	70					74	115	70	72	60	72	73.0				
36	36.2	110	70					74	120	80	76	80	76	73.0				
38	36.0	120	80					62	110	70	70	65	70	73.0				
40	36.3	120	70					72	115	70	72	70	72	73.0				
42	36.5	120	70					76	110	70	76	65	70	73.0				
44	36.4	115	80					70	110	70	70	70	72	73.0				
46	36.0	115	75					70	110	70	70	65	70	73.0				
48	36.0	115	60					72	110	70	72	65	70	73.0				
50	36.4	125	70					82	110	65	82	65	86	74.0				
52	36.2	120	80					84	115	70	88	110	70	88	74.0			
1	110	150	TQO					8	36.0	120	80	76	115	75	82	68.0		
				10	36.2	115	75	84	70	88	70	88	68.0					
				12	35.9	120	70	72	75	75	75	75	68.0					
				14	36.5	130	80	74	120	70	82	70	82	68.0				
				16	36.3	115	80	78	120	75	84	70	84	68.0				
				18	36.4	120	75	64	115	70	72	70	72	68.0				
				20	36.1	130	82	82	120	75	92	70	92	68.0				
				22	36.4	120	80	78	115	75	84	70	84	68.0				
				24	35.7	125	70	64	120	60	68	60	68	69.0				

22
23
24

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)				
1	110	150	T00	26	36.2	120	80	62	110	70	64	69.0				
				28	36.5	120	70	66	110	65	70	69.0				
				30	36.2	110	70	64	115	70	72	69.0				
				32	36.1	125	80	72	115	70	76	69.0				
				34	36.6	110	70	74	115	70	76	69.0				
				36	36.1	115	75	64	110	70	68	69.0				
				38	36.3	110	80	64	115	70	68	69.0				
				40	36.4	120	70	76	110	70	82	69.0				
				42	36.4	115	80	66	110	70	86	69.0				
				44	36.1	120	70	82	110	70	86	69.0				
				46	36.4	110	70	84	110	60	88	69.0				
				48	36.4	110	70	84	115	75	78	69.0				
				50	36.0	115	70	74	110	70	78	69.0				
				52	36.2	110	70	84	105	60	92	69.0				
				1	116	334	MGA	8	35.4	110	80	112	95	75	120	55.0
								10	36.7	115	80	108	105	75	112	55.0
								12	36.7	100	75	100	100	80	104	54.0
								14	36.5	105	75	96	100	70	100	56.0
								16	35.8	100	75	104	105	85	108	56.0
								18	35.8	100	75	104	105	85	108	56.0
								20	35.3	110	80	100	105	80	120	56.0
								22	35.3	110	80	116	105	80	120	56.0
								24	36.5	90	65	104	95	70	112	57.0
								26	36.5	90	65	104	95	70	112	57.0
								28	35.6	110	80	100	110	80	108	57.0
								30	35.6	110	80	100	110	80	108	57.0
								32	35.9	110	85	100	110	80	108	57.0
								34	35.9	110	85	100	100	65	100	58.0
								36	35.9	110	85	100	100	65	100	58.0
								38	35.7	100	70	92	100	65	94	58.0
								40	35.7	110	70	92	115	80	92	58.0
								42	35.4	95	65	88	115	80	92	58.0
				44	35.4	95	65	88	90	70	100	58.0				
				46	36.6	85	55	106	90	60	100	56.0				
				48	36.6	85	55	106	90	60	100	57.0				
				50	36.3	110	80	104	100	70	100	58.0				
				52	36.3	110	80	104	100	70	100	58.0				
				1	117	335	PSL	8	36.6	170	115	96	155	110	100	119.0
								10	36.2	130	95	108	110	95	120	120.0
								12	36.7	130	90	90	130	90	95	123.0
								14	36.3	140	110	100	140	105	100	119.0
								16	36.6	140	115	92	130	110	100	120.0
								18	36.9	145	110	112	130	105	112	119.0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)				
1	117	335	PSL	20	36.2	130	95	100	135	105	104	119.0				
				22	36.2	130	95	100	135	105	104	119.0				
				24	36.4	140	110	98	140	105	104	105	119.0			
				26	35.9	140	100	92	130	100	96	100	119.0			
				28	36.0	125	90	112	110	90	120	90	119.0			
				30	36.1	135	100	95	130	100	108	100	119.0			
				32	36.2	150	110	88	150	115	96	150	119.0			
				34	36.3	135	100	94	140	105	104	105	119.0			
				36	36.3	120	90	100	100	100	112	100	119.0			
				38	36.6	130	100	100	130	110	100	100	119.0			
				40	36.6	130	100	100	130	110	100	100	119.0			
				42	36.4	140	105	92	145	110	100	100	119.0			
				44	36.1	140	105	92	145	110	100	100	119.0			
				46	36.5	145	105	94	140	110	104	104	119.0			
				48	36.7	150	110	98	140	110	108	108	118.0			
				50	36.7	150	110	98	140	110	108	108	118.0			
				52	35.9	125	100	96	140	115	104	104	118.0			
				1	121	336	LAC	8	36.0	115	75	74	110	70	78	76.0
								10	36.4	120	80	72	115	75	80	76.0
								12	36.3	125	80	72	115	70	76	76.0
14	36.1	120	80					68	110	75	76	76.0				
16	36.1	115	75					76	110	80	82	76.0				
18	36.2	115	75					66	110	70	72	76.0				
20	36.4	110	75					70	115	80	76	76.0				
22	36.4	120	80					68	115	70	74	76.0				
24	36.1	125	80					96	120	70	104	76.0				
26	36.3	120	80					96	125	85	102	76.0				
28	36.2	120	70					82	110	70	86	76.0				
30	36.0	125	80					80	115	70	84	76.0				
32	36.0	125	80					74	115	70	76	77.0				
34	36.1	130	80					94	130	80	102	77.0				
36	36.1	125	70					80	120	80	86	77.0				
38	36.2	120	78					64	115	70	84	77.0				
40	36.0	125	85					76	120	80	82	77.0				
42	36.1	125	80					64	115	70	84	77.0				
44	36.1	120	80					82	110	75	86	76.0				
46	36.2	130	80					82	120	70	86	77.0				
48	36.2	125	80	82	115	70	88	76.0								
50	36.5	130	80	88	120	70	92	77.0								
52	36.5	120	80	100	110	70	104	77.0								
1	123	338	MLL	8	36.1	120	70	56	110	70	64	61.0				
				10	36.5	110	70	56	115	65	62	61.0				
				12	36.0	115	75	54	110	75	62	61.0				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)				
1	123	338	MLL	14	35.9	115	70	62	110	75	68	61.0				
				16	36.0	110	70	64	105	70	68	61.0				
				18	36.4	115	75	56	110	70	60	61.0				
				20	36.0	110	58	100	60	66	61.0					
				22	35.9	105	65	100	60	66	61.0					
				24	36.5	120	80	115	75	82	61.0					
				26	36.1	120	70	74	70	82	61.0					
				28	36.8	125	70	64	70	72	61.0					
				30	36.0	120	80	68	70	72	61.0					
				32	36.6	125	80	72	70	74	60.0					
				34	36.1	130	80	80	80	86	60.0					
				36	35.8	130	80	74	70	76	60.0					
				38	36.2	130	70	72	70	74	60.0					
				40	36.6	110	70	72	70	74	60.0					
				42	35.9	130	80	58	70	62	60.0					
				44	36.4	120	80	58	80	62	60.0					
				46	36.6	120	80	74	70	78	60.0					
				48	35.9	120	70	64	70	68	60.0					
				50	36.2	120	70	76	70	82	60.0					
				52	35.8	125	85	76	70	72	60.0					
										80	59.0					
				1	125	360	FDP	8	36.1	120	80	66	115	75	72	77.0
								10	36.1	120	80	60	120	80	72	77.0
								12	36.0	125	85	60	120	80	72	77.0
								14	36.0	120	80	58	120	80	68	77.0
								16	36.1	130	80	72	120	80	74	77.0
								18	36.2	125	80	74	120	85	78	77.0
								20	36.2	125	80	64	130	75	68	77.0
								22	36.6	130	80	68	120	80	74	77.0
								24	36.1	120	80	84	130	75	74	77.0
								26	36.1	120	85	88	120	80	80	78.0
								28	36.1	130	70	84	70	80	80	78.0
								30	36.4	125	80	76	120	80	86	77.0
								32	36.0	125	80	84	120	70	82	78.0
								34	36.4	125	80	80	130	80	86	77.0
								36	36.1	125	85	84	120	80	88	78.0
								38	36.2	125	85	76	120	80	84	78.0
								40	36.1	120	75	76	115	70	80	78.0
								42	36.2	120	80	74	115	70	76	77.0
								44	36.4	130	80	84	120	80	88	77.0
								46	36.3	130	80	82	120	75	85	77.0
								48	36.0	130	80	78	120	70	82	77.0
								50	36.3	130	70	82	120	70	82	77.0
								52	35.9	130	80	86	120	80	90	77.0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)				
1	127	342	VPD	8	36.1	120	85	94	120	80	100	81.0				
				10	36.5	120	75	92	110	70	104	81.0				
				12	36.2	125	85	94	120	75	108	80.0				
				14	36.2	120	75	90	120	70	96	80.0				
				16	36.0	120	75	102	115	70	106	80.0				
				18	36.2	125	88	88	120	70	96	80.0				
				20	36.6	125	85	98	115	80	102	80.0				
				22	36.1	120	80	98	115	75	104	80.0				
				24	36.0	125	80	82	115	70	90	80.0				
				26	36.2	128	70	86	125	75	88	80.0				
				28	36.2	130	75	84	120	70	90	80.0				
				30	36.2	125	80	94	115	70	100	80.0				
				32	36.6	130	80	76	120	70	78	80.0				
				34	36.0	125	75	92	120	80	84	80.0				
				36	36.7	125	80	78	125	80	80	80.0				
				38	36.5	115	75	82	120	70	84	80.0				
				40	36.1	120	70	76	115	70	80	80.0				
				42	36.2	100	70	90	120	60	78	80.0				
				44	35.8	125	70	72	115	70	82	80.0				
				46	36.4	110	74	74	110	60	82	80.0				
				48	36.3	115	75	80	110	70	84	80.0				
				50	36.0	120	70	78	110	70	84	80.0				
				52	36.2	120	80	76	110	70	82	80.0				
				1	128	343	LAM	8	36.1	130	80	72	120	75	78	71.0
								10	36.0	125	85	68	120	80	74	71.0
								12	36.4	120	80	82	110	70	86	70.0
								14	36.5	125	80	76	120	70	78	70.0
								16	36.2	125	75	72	120	70	82	70.0
								18	36.0	120	75	70	120	70	82	70.0
								20	36.0	120	70	72	110	70	78	70.0
								22	36.1	120	80	74	110	70	82	70.0
								24	36.2	125	80	68	120	70	74	70.0
								26	35.8	120	80	72	125	65	76	70.0
								28	36.4	120	70	72	115	70	76	70.0
								30	36.1	125	80	72	120	80	70	70.0
								32	36.0	120	80	72	110	70	78	70.0
								34	36.0	120	75	72	125	80	76	70.0
								36	36.3	130	70	80	120	70	84	70.0
								38	36.4	120	70	68	110	75	84	70.0
				40	36.2	120	80	86	125	80	86	70.0				
				42	35.9	110	80	76	120	80	82	70.0				
				44	36.0	120	76	76	110	75	82	70.0				
				46	36.1	115	75	66	115	65	76	69.0				
				48	36.3	115	70	68	110	60	76	70.0				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 ROXETHYLINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: ROXETHYLINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
1	128	343	LAM	50	36.5	125	85	76	120	80	82	69.0
				52	36.0	125	80	72	120	70	76	70.0
1	134	347	LMS	8	36.1	120	75	56	110	70	62	83.0
				10	36.3	115	75	66	110	70	64	83.0
				12	36.1	115	75	82	110	80	84	83.0
				14	36.0	110	70	58	115	65	64	83.0
				16	36.4	120	80	70	110	70	72	83.0
				18	36.0	110	70	62	110	65	64	83.0
				20	36.3	115	80	54	120	75	62	83.0
				22	36.0	120	80	60	115	75	62	83.0
				24	36.4	130	80	84	120	70	86	83.0
				26	36.2	120	80	84	110	75	88	83.0
				28	36.1	115	75	78	110	75	82	83.0
				30	36.3	120	70	76	110	70	82	83.0
				32	36.0	110	80	84	120	80	90	83.0
				34	36.2	125	80	80	115	70	84	83.0
				36	35.9	125	80	74	115	70	76	83.0
				38	36.2	125	80	84	115	70	86	83.0
				40	36.2	130	80	88	120	75	90	82.0
				42	36.2	115	75	64	110	70	66	84.0
				44	36.0	130	70	68	110	72	74	83.0
				46	36.4	130	70	82	120	75	86	83.0
				48	36.2	120	70	64	125	70	68	83.0
				50	36.0	125	85	74	120	80	76	83.0
				52	36.4	125	80	70	115	70	74	84.0
1	135	348	MNS	8	36.0	125	85	78	120	80	76	65.0
				10	36.4	130	80	60	115	70	66	65.0
				12	36.1	120	80	66	115	80	72	64.0
				14	36.0	115	70	62	110	70	68	65.0
				16	36.3	125	80	64	120	80	70	65.0
				18	36.0	118	70	60	115	75	70	65.0
				20	36.2	120	80	64	110	75	68	65.0
				22	36.0	120	80	64	115	75	68	65.0
				24	36.2	120	70	64	115	70	88	64.0
				26	36.4	115	80	82	120	80	90	64.0
				28	36.4	125	85	80	120	80	84	64.0
				30	36.6	115	75	78	110	70	84	65.0
				32	36.2	125	80	78	115	75	84	65.0
				34	36.6	120	70	94	115	70	98	65.0
				36	36.3	120	80	76	110	70	82	65.0
				38	36.3	130	70	76	120	70	80	65.0
				40	35.8	118	60	80	110	65	84	66.0
				42	36.2	120	70	96	110	70	100	65.0

2236

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 ROXETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: ROXETINE

Centre	Patient No.	D.B. Patient Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)					
1	135	348	MMS	44	36.1	115	65	88	110	60	92	66.0				
				46	36.0	120	70	84	115	65	90	66.0				
				48	36.3	125	85	76	120	80	82	66.0				
				50	36.2	110	88	92	65	88	66.0					
				52	35.8	100	60	96	105	60	102	66.0				
				1	139	351	RA	8	36.1	130	80	74	120	70	82	70.0
								10	36.4	120	85	78	115	80	86	69.0
								12	36.0	125	85	78	120	80	84	69.0
								14	35.8	115	75	78	110	70	84	68.0
								16	36.3	120	80	84	120	80	92	69.0
18	36.1	125	85					76	115	80	84	69.0				
20	36.1	125	80					82	120	70	90	69.0				
22	36.4	115	75					78	120	80	88	68.0				
24	36.1	125	80					72	115	70	74	69.0				
26	36.1	125	80					72	115	70	76	69.0				
1	140	352	MCA	30	36.2	130	70	82	110	70	85	69.0				
				32	36.2	120	80	82	110	70	82	69.0				
				34	36.2	120	80	82	115	75	84	68.0				
				36	36.3	125	80	80	115	80	84	69.0				
				38	36.3	120	70	78	110	70	80	69.0				
				40	36.0	120	70	76	110	75	80	69.0				
				42	36.0	115	75	70	110	70	74	69.0				
				44	36.2	125	70	64	115	70	72	69.0				
				46	36.4	115	75	74	110	70	78	69.0				
				48	35.9	115	70	84	110	60	88	69.0				
1	140	352	MCA	50	36.3	120	80	76	110	70	80	69.0				
				52	36.0	110	70	68	100	65	70	68.0				
				8	36.3	130	80	84	115	75	86	65.0				
				10	36.1	125	85	76	120	75	84	65.0				
				12	36.1	115	75	78	110	70	86	65.0				
				14	36.3	115	75	68	110	65	76	64.0				
				16	36.3	120	80	86	110	70	88	64.0				
				18	36.3	125	70	84	115	70	86	64.0				
				20	36.0	115	70	78	110	70	86	64.0				
				22	36.1	115	70	84	105	60	88	64.0				
1	140	352	MCA	24	36.2	125	70	84	115	70	86	64.0				
				26	36.4	125	85	72	115	70	86	64.0				
				28	36.1	110	80	78	115	70	82	64.0				
				30	36.0	130	70	80	100	70	80	64.0				
				32	36.4	120	70	76	110	75	80	64.0				
				34	36.4	120	80	72	115	70	82	64.0				
				36	36.3	125	70	84	115	70	86	64.0				

2237

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)				
1	140	352	MCA	38	36.6	130	70	84	110	70	84	64.0				
				40	35.9	110	60	70	100	60	70	64.0				
				42	36.3	120	80	68	115	75	72	65.0				
				44	36.2	130	70	70	115	60	80	65.0				
				46	36.4	120	70	68	105	65	76	65.0				
				48	36.2	115	75	82	120	70	86	65.0				
				50	36.3	125	75	78	115	70	84	65.0				
				52	36.2	110	70	74	115	60	78	65.0				
				1	142	354	SCC	8	36.0	115	75	78	110	75	84	64.0
								10	36.2	120	70	62	110	70	68	64.0
								12	36.3	130	70	68	130	65	74	64.0
								14	36.0	115	70	72	110	70	76	65.0
16	36.2	120	80					72	120	75	74	64.0				
18	36.1	120	75					64	115	70	68	64.0				
20	36.4	80	80					72	120	70	84	64.0				
22	36.0	125	75					74	120	70	76	64.0				
24	36.2	125	80					76	115	70	82	65.0				
26	36.4	125	80					68	115	70	72	65.0				
28	36.2	120	80					74	115	75	78	65.0				
30	36.2	125	80					74	115	70	78	65.0				
32	36.3	120	70	64	115	75	68	65.0								
34	37.0	125	80	60	115	70	66	65.0								
36	36.2	130	70	82	115	70	84	64.0								
38	36.0	120	80	82	110	70	84	65.0								
40	36.0	125	70	72	115	70	74	65.0								
42	36.1	120	80	72	110	70	78	65.0								
44	36.3	125	75	78	115	70	84	65.0								
46	36.2	130	70	82	110	65	84	65.0								
48	36.1	130	70	84	120	75	88	64.0								
50	36.0	115	80	82	120	75	84	65.0								
52	36.3	125	80	72	115	70	74	65.0								
1	144	356	ARF	8	36.5	130	100	96	130	100	96	88.0				
				10	36.0	130	80	98	120	90	104	88.0				
				12	35.4	120	80	100	120	80	100	88.0				
				14	36.4	120	80	100	120	80	100	88.0				
				16	36.3	130	90	104	145	95	108	88.0				
				18	36.3	130	90	104	145	95	108	88.0				
				20	36.2	140	95	104	160	100	116	88.0				
				22	36.5	130	95	112	130	100	120	87.0				
				24	35.9	146	100	96	164	100	96	86.0				
				26	36.0	135	90	88	150	90	92	87.0				
				28	35.7	130	90	106	106	100	104	87.0				
				30	36.2	135	90	100	135	90	106	87.0				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5p. Lying Sps BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sps BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
1	144	356	ARF	32	36.7	140	90	96	145	90	108	87.0
				34	35.9	140	90	100	130	90	100	87.0
				36	36.0	120	80	100	120	85	120	88.0
1	146	358	LRM	38	36.0	130	80	104	140	85	104	88.0
				8	35.7	130	90	100	140	90	100	73.0
				10	35.7	120	80	92	140	90	102	74.0
1	148	359	CAS	12	37.8	130	90	112	145	95	112	73.0
				14	35.3	120	80	100	130	90	100	70.0
				16	36.2	120	85	100	120	90	100	70.0
1	148	359	CAS	18	35.4	120	85	100	120	112	112	68.0
				20	36.4	125	95	96	135	110	100	68.0
				22	35.7	130	80	80	120	95	92	71.0
1	148	359	CAS	24	36.0	120	80	80	120	90	92	71.0
				26	36.1	120	80	76	120	90	80	69.0
				28	36.0	120	80	76	150	100	80	69.0
1	148	359	CAS	30	36.0	120	80	76	150	100	80	69.0
				32	35.8	120	90	100	120	95	106	68.0
				34	35.7	110	80	100	130	100	104	68.0
1	148	359	CAS	36	36.0	115	80	96	115	100	68.0	
				38	35.7	110	80	96	130	105	104	68.0
				40	36.0	120	90	92	120	90	112	68.0
1	148	359	CAS	42	36.2	120	90	92	120	90	112	68.0
				44	36.0	120	90	92	120	95	96	68.0
				46	36.0	125	90	90	130	100	112	68.0
1	148	359	CAS	48	36.0	135	95	100	130	100	112	68.0
				50	35.8	135	95	100	130	100	112	68.0
				52	36.2	135	100	98	140	105	108	68.0
1	148	359	CAS	8	36.1	110	70	82	115	80	86	72.0
				10	36.0	110	70	76	115	70	82	72.0
				12	36.1	120	80	74	115	70	78	70.0
1	148	359	CAS	14	36.1	125	85	88	120	80	78	70.0
				16	36.2	120	75	80	110	70	84	70.0
				18	36.2	120	70	74	110	70	78	70.0
1	148	359	CAS	20	36.1	120	70	68	110	70	70.0	
				22	36.0	120	80	78	120	60	82	70.0
				24	36.3	130	70	80	110	60	74	70.0
1	148	359	CAS	26	36.2	135	75	70	115	70	76	69.0
				28	36.0	115	85	70	110	70	76	70.0
				30	36.1	120	82	74	110	60	78	70.0
1	148	359	CAS	32	36.4	120	70	62	115	85	70.0	
				34	36.4	130	70	72	120	70	76	70.0
				36	36.1	120	80	72	110	70	76	70.0
1	148	359	CAS	38	36.5	130	70	72	120	70	70.0	
				40	36.1	120	80	72	110	70	76	70.0
				42	36.2	125	80	80	115	82	82	70.0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 2012A/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)
1	148	359	CAS	40	36.4	110	70	72	105	65	76	71.0
				42	36.4	120	70	80	110	65	84	71.0
				44	36.1	110	75	76	120	70	84	71.0
				46	36.1	110	70	84	105	65	86	71.0
				48	36.2	125	85	80	115	70	82	71.0
				50	36.3	115	84	84	105	70	86	71.0
				52	36.0	110	70	74	115	65	78	71.0
				8	36.8	160	90	72	120	80	104	56.0
				10	36.9	150	80	76	125	70	108	56.0
				3	7	71	GRI	8	36.4	130	80	78
10	36.4	130	80					80	130	80	82	64.0
12	36.6	120	80					74	120	80	82	67.0
14	36.4	120	80					78	120	80	76	66.0
16	36.5	125	80					76	125	80	78	66.0
18	36.5	120	75					76	120	75	76	65.0
20	36.4	130	80					78	130	80	80	65.0
22	36.5	120	80					78	120	80	78	65.0
24	36.4	120	80					78	120	80	78	65.0
28	36.5	130	80					88	130	80	88	65.0
8	2	212	TE	8	36.4	130	80	78	130	80	80	64.0
				10	36.4	130	80	80	130	80	82	64.0
				12	36.6	120	80	74	120	80	76	67.0
				14	36.4	120	80	78	120	80	78	66.0
				16	36.5	125	80	76	125	80	78	66.0
				18	36.5	120	75	76	120	75	76	65.0
				20	36.4	130	80	78	130	80	80	65.0
				22	36.5	120	80	78	120	80	78	65.0
				24	36.4	120	80	78	120	80	78	65.0
				28	36.5	130	80	88	130	80	88	65.0
8	3	213	JL	8	36.5	140	80	82	135	80	82	78.0
				10	36.4	140	80	80	130	80	82	76.0
				12	36.4	130	80	78	130	80	78	78.0
				14	36.5	130	80	80	130	80	80	78.0
				16	36.4	125	80	78	120	80	78	74.0
				8	36.6	120	80	78	120	80	80	48.0
				10	36.4	130	80	76	125	80	76	48.0
				12	36.4	120	80	76	120	80	76	47.0
				14	36.5	130	80	78	130	80	78	47.0

7240

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)				
8	6	216	TL	16	36.5	135	80	78	130	80	78	46.0				
				18	36.5	120	80	80	120	80	80	46.0				
				20	36.4	120	80	82	120	80	82	80	46.0			
				22	36.5	130	80	78	130	80	78	80	47.0			
				24	36.5	130	80	80	130	80	80	80	47.0			
				26	36.6	125	80	80	130	80	80	80	46.0			
				28	36.6	130	80	76	130	80	76	80	46.0			
				30	36.5	120	80	80	120	80	80	80	46.0			
				32	36.6	120	80	82	120	80	82	80	46.0			
				34	36.5	120	80	80	120	80	80	80	46.0			
				36	36.5	115	80	80	115	80	80	80	46.0			
				38	36.4	120	80	76	120	80	76	80	46.0			
				40	36.5	120	80	76	120	80	76	80	47.0			
				42	36.4	120	80	84	115	80	84	80	46.0			
				44	36.5	120	80	78	120	80	78	80	46.0			
				46	36.4	120	80	80	120	80	80	80	47.0			
				48	36.5	125	80	76	125	80	76	80	47.0			
				50	36.6	120	70	78	120	70	78	80	47.0			
				52	36.6	125	70	78	120	70	78	80	47.0			
				9	6	245	SD	8	36.6	150	90	78	145	85	80	67.0
								10	36.6	150	90	75	150	90	78	67.0
								12	36.8	140	90	76	140	90	80	67.0
14	36.3	145	90					76	140	90	78	67.0				
16	36.4	140	90					74	135	85	75	67.0				
18	36.6	130	80					76	130	80	78	67.0				
20	36.4	130	90					75	130	80	76	67.0				
22	36.3	135	90					71	130	85	74	67.0				
24	36.6	130	90					76	130	90	78	67.0				
26	36.5	130	80					71	130	80	74	68.0				
28	36.6	130	80					68	130	80	74	67.0				
30	36.3	140	90					86	140	80	79	68.0				
32	36.4	140	90					72	130	90	73	68.0				
34	36.6	150	90					72	140	90	74	68.0				
36	36.4	140	90					70	130	80	71	68.0				
38	36.6	140	80					70	140	80	73	69.0				
40	36.5	140	90					73	130	80	71	67.0				
42	36.4	130	80					71	125	80	70	66.0				
44	36.5	130	80					70	130	80	71	68.0				
46	36.4	130	80					72	130	80	72	68.0				
48	36.7	120	80					72	120	80	71	69.0				
50	36.6	120	80					72	120	80	72	70.0				
52	36.6	120	80	70	120	80	70	70.0								
9	7	243	PP	8	36.5	120	80	80	115	80	86.0					

224

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBORENTINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: REBORENTINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)				
9	7	243	PP	10	36.5	110	70	76	110	70	80	85.0				
				12	36.6	120	80	76	115	75	80	86.0				
				14	36.4	120	80	72	120	80	76	80	86.0			
				16	36.5	120	80	76	120	80	80	80	86.0			
				18	36.6	120	80	76	120	80	77	80	86.0			
				20	37.0	120	80	70	120	80	73	80	87.0			
				22	36.5	125	80	70	120	80	80	80	86.0			
				24	37.0	120	80	72	120	80	75	70	86.0			
				26	36.5	120	80	72	120	80	73	80	86.0			
				28	36.4	120	80	70	120	80	73	80	87.0			
				30	36.6	120	80	72	120	80	73	80	87.0			
				32	36.6	140	80	76	130	80	73	80	86.0			
				34	36.6	140	80	76	130	80	73	80	87.0			
				36	36.6	120	80	72	120	80	75	80	87.0			
				38	36.4	120	80	74	115	80	72	80	88.0			
				40	36.6	120	80	74	110	80	75	80	88.0			
				42	36.6	120	80	70	120	80	73	80	86.0			
				44	36.5	120	80	70	115	80	71	80	86.0			
				46	36.6	120	80	72	120	80	72	80	87.0			
				48	36.7	120	80	72	120	80	73	80	87.0			
				50	36.3	125	80	70	120	80	72	80	87.0			
				52	36.6	120	80	70	115	80	73	80	87.0			
				9	11	246	KE	8	36.5	120	80	72	120	75	74	54.0
								10	36.4	120	80	70	120	70	70	54.0
								12	36.4	120	80	71	120	71	74	54.0
								14	36.4	120	80	72	120	74	74	54.0
								16	36.5	120	80	72	120	75	75	54.0
								18	36.1	120	80	72	120	73	73	54.0
								20	36.6	120	80	70	120	68	68	54.0
								22	36.5	120	80	74	120	72	72	55.0
				24	36.6	110	80	72	110	75	75	55.0				
				26	36.3	120	80	72	110	70	74	55.0				
				28	36.6	110	80	71	110	72	72	55.0				
				30	36.6	120	80	73	120	75	75	56.0				
				32	36.6	120	80	70	120	74	74	56.0				
				34	36.6	110	80	72	110	71	71	55.0				
				36	36.3	110	80	73	110	75	75	56.0				
				38	36.5	120	80	70	120	70	75	56.0				
				40	36.7	120	80	71	110	70	73	56.0				
				42	36.5	120	80	72	120	69	69	56.0				
				44	36.7	110	80	70	110	70	76	57.0				
				46	36.5	120	80	71	110	70	76	57.0				
				48	36.6	110	80	70	110	70	72	56.0				
				50	36.6	120	80	72	110	70	74	57.0				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
9	11	246	KE	52	36.7	120	80	74	120	70	73	57.0
9	15	249	BI	8	36.5	120	80	70	110	70	75	60.0
				10	36.5	110	70	74	110	70	75	60.0
				12	36.6	120	80	70	120	80	70	60.0
				14	36.4	130	80	72	130	80	75	61.0
				16	36.5	130	85	70	120	80	72	61.0
				18	36.4	120	80	74	120	80	77	61.0
				20	36.8	120	80	72	120	80	75	61.0
				22	36.4	130	80	71	120	80	74	61.0
				24	36.4	130	80	71	120	70	74	61.0
				26	36.5	120	80	69	110	70	72	62.0
				28	36.2	110	70	71	100	70	72	62.0
				30	36.3	130	90	73	120	80	75	62.0
				32	36.5	120	70	71	110	70	70	62.0
				34	36.4	120	80	74	120	70	76	62.0
				36	36.5	120	80	74	110	70	75	62.0
				38	36.6	110	70	70	110	60	75	62.0
				40	36.8	120	80	76	110	70	78	62.0
				42	36.7	120	70	74	110	60	74	63.0
				44	36.7	130	80	72	120	70	76	63.0
				46	36.6	120	80	76	120	70	74	63.0
				48	36.6	120	90	71	120	80	74	63.0
				50	36.6	130	90	70	120	80	75	63.0
				52	36.5	140	90	71	130	80	72	63.0
9	16	250	UGY	8	36.4	130	80	71	120	80	73	42.0
				10	36.6	120	80	72	120	80	76	42.0
				12	36.5	130	90	73	120	80	75	43.0
				14	36.1	130	90	71	130	80	72	42.0
				16	36.5	130	80	72	130	80	73	43.0
				18	36.7	140	90	74	130	80	73	43.0
				20	36.3	130	90	76	130	80	74	43.0
				22	36.4	140	90	76	130	80	74	43.0
				24	36.5	140	80	68	130	80	74	43.0
				26	36.4	120	80	74	120	70	72	44.0
				28	36.5	130	80	76	120	70	72	44.0
				30	36.7	140	90	74	130	80	78	44.0
				32	36.6	130	90	70	130	80	75	44.0
				34	36.5	140	90	76	130	80	74	44.0
				36	36.8	120	80	76	120	70	74	45.0
				38	36.4	130	80	71	120	70	79	45.0
				40	36.6	140	80	73	130	80	74	45.0
				42	36.9	140	90	70	130	80	75	46.0
				44	37.0	130	80	74	120	90	73	46.0

2243

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXYLINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXYLINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
9	16	250	UGY	46	36.6	150	80	72	130	80	74	46.0
				48	36.5	140	80	71	130	80	74	46.0
				50	36.6	130	90	75	130	90	76	46.0
				52	36.5	140	90	73	130	90	76	46.0
				54	36.6	140	90	73	130	90	76	46.0
9	20	252	GYE	8	36.6	130	90	72	130	80	76	77.0
				10	36.2	140	90	70	140	80	73	77.0
				12	36.6	140	90	71	130	80	75	77.0
				14	36.7	130	90	71	125	80	72	77.0
				16	36.5	140	90	70	130	80	73	76.0
9	23	256	SZN	18	36.4	140	90	71	140	80	72	76.0
				8	36.4	110	80	71	110	70	73	52.0
				10	36.5	120	80	72	110	70	75	52.0
				12	36.4	110	80	74	110	70	78	52.0
				14	36.4	120	80	75	110	70	79	52.0
9	26	255	CP	16	36.3	110	80	72	110	60	77	52.0
				18	36.7	100	70	76	100	60	79	53.0
				20	36.6	110	70	78	100	60	82	53.0
				8	36.6	140	80	72	130	70	74	53.0
				10	36.5	130	80	72	130	70	75	53.0
9	29	258	SZF	12	36.8	140	90	76	130	80	80	54.0
				14	36.7	140	80	71	130	70	75	54.0
				16	36.4	130	80	75	120	70	80	54.0
				18	36.6	130	90	74	120	80	76	54.0
				20	36.6	130	90	75	120	80	76	54.0
9	30	259	NF	22	36.8	140	90	71	140	80	76	54.0
				8	36.6	140	80	74	130	70	78	53.0
				10	36.7	140	90	72	140	80	76	54.0
				12	36.8	130	90	74	130	80	77	54.0
				14	36.5	150	90	72	140	90	75	54.0
10	1	271	VK	16	36.6	140	80	81	130	70	85	54.0
				18	36.4	140	80	76	130	70	85	54.0
				20	36.7	140	80	76	130	70	85	54.0
				22	36.6	120	80	70	130	70	73	54.0
				24	36.7	130	90	71	125	80	74	55.0
10	1	271	VK	26	37.0	140	90	72	130	80	74	54.0
				28	36.5	120	80	82	130	80	80	54.0
				8	36.6	140	90	72	130	80	74	56.0
				10	36.7	130	80	76	120	80	78	56.0
				8	36.3	120	70	80	130	80	80	86.0

2244

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D												
REBOXETINE - PROTOCOL 20124/013												
Listing No.: 13.1												
VITAL SIGNS												
DOUBLE BLIND PHASE												
TREATMENT: REBOXETINE												
Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)
10	1	271	VK	10	36.4	120	70	80	125	80	82	87.0
				12	36.1	140	90	66	145	90	90	87.0
				14	36.2	120	75	71	130	80	78	89.0
				16	36.2	120	80	63	130	80	68	90.0
10	7	274	RK	8	36.5	140	90	76	142	92	80	89.8
10	9	275	RT	8	36.2	130	85	80	125	90	82	53.9
				9	36.5	132	74	90	126	90	90	54.0
10	12	277	EP	8	36.7	120	98	59	108	100	62	71.0
				10	36.8	138	90	86	130	98	88	70.0
10	13	278	HU	8	36.4	120	80	74	105	90	80	59.0
10	15	280	HT	8	36.4	130	80	66	140	85	72	95.0
				10	36.2	120	80	68	125	85	73	94.0
10	20	285	EJ	8	36.4	140	85	84	110	70	80	58.0
				10	36.5	110	65	68	115	75	80	58.0
				12	36.5	110	70	84	100	90	92	85.0
				14	36.6	120	70	88	110	75	88	58.0
				16	36.6	105	75	87	120	85	90	58.0
				18	36.4	90	50	90	105	95	98	58.0
				20	36.4	110	65	90	130	80	96	58.0
				22	36.1	110	60	72	120	80	86	58.0
				24	36.0	95	60	78	105	75	96	58.0
				26	36.1	100	70	80	110	80	92	58.0
				28	36.3	95	65	74	105	80	88	58.0
10	22	286	AA	8	36.5	165	110	76	140	100	100	84.0
				10	36.4	135	95	84	135	95	110	84.0
				12	36.5	125	90	72	125	105	85	79.0
				14	36.2	125	90	79	120	100	87	79.0
				16	36.7	130	105	84	125	105	108	79.0
				18	36.6	160	110	90	160	110	95	77.0
				20	36.5	150	100	90	140	105	98	78.0
				22	36.4	160	110	90	150	105	98	78.0
				24	36.9	140	95	86	140	100	98	76.0
				26	36.6	135	90	74	140	95	96	76.0
				28	36.8	135	95	72	155	95	90	78.0
				30	36.6	140	90	78	150	95	100	78.0
				32	36.9	160	105	76	150	110	98	78.0
				34	36.8	145	85	78	130	90	96	78.0
				36	36.6	150	105	60	135	100	78	79.0

2245

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)	
10	22	286	AA	38	36.4	130	90	70	120	80	96	79.0	
				40	36.4	130	85	66	130	85	78	79.0	
				42	36.5	125	90	72	120	85	90	78.0	
				44	36.4	130	90	78	130	90	90	77.0	
				46	36.8	125	90	78	125	90	96	75.0	
				48	36.6	125	90	84	120	90	90	75.0	
	23	287	LT	50	36.7	130	120	78	125	90	85	90	75.0
				52	36.7	120	85	88	120	85	96	76.0	
				8	36.7	109	68	76	90	60	120	57.0	
				10	36.8	135	75	88	120	70	96	56.0	
				12	36.7	105	65	64	95	85	90	57.0	
				14	36.6	105	65	72	80	85	88	58.0	
10	26	290	JIF	16	36.6	110	70	65	110	85	96	54.0	
				18	36.6	120	85	80	100	80	97	54.0	
				20	36.5	110	80	74	110	85	96	54.0	
				22	36.3	110	80	78	110	80	90	54.0	
				24	36.8	105	65	66	105	65	80	54.0	
				26	36.7	105	65	66	135	70	64	54.0	
				28	36.8	95	60	66	100	60	66	54.0	
				30	36.6	100	65	68	110	70	68	54.0	
				32	36.6	90	55	58	100	60	64	56.0	
				34	36.5	90	60	68	95	70	78	56.0	
				36	36.6	90	60	72	100	70	84	56.0	
				38	36.3	90	65	66	100	70	84	56.0	
40	36.3	95	70	72	90	65	84	56.0					
42	36.2	105	90	66	90	60	84	55.0					
44	36.4	98	70	78	95	65	90	54.0					
10	27	292	MK	8	36.3	125	80	72	115	78	76	88.0	
				10	36.3	130	80	80	115	75	96	85.0	
10	27	292	MK	8	36.5	130	80	80	150	100	84	67.0	
				10	36.6	130	80	84	145	100	88	65.0	
				12	36.7	130	80	76	140	90	84	65.0	
				14	36.5	125	80	76	140	90	84	65.0	
				16	36.4	140	90	78	130	95	90	65.0	
				18	36.5	145	100	72	140	105	84	65.0	
				20	36.7	140	105	78	130	105	90	65.0	
				22	36.4	135	95	82	132	98	84	65.0	
				24	36.5	145	95	78	140	105	78	67.0	
				26	36.4	155	95	66	150	105	84	67.0	
				28	36.3	145	90	78	140	100	84	68.0	
				30	36.3	150	95	72	145	100	84	67.0	
32	36.8	140	95	72	130	95	78	67.0					

2246

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)				
10	27	292	MK	34	36.4	145	105	72	140	100	90	67.0				
				36	36.5	140	100	78	130	95	84	67.0				
				38	36.4	140	100	72	135	95	90	68.0				
				40	36.6	135	100	78	135	100	96	68.0				
				42	36.6	140	95	72	130	95	84	68.0				
				44	36.6	135	95	78	135	95	90	67.0				
				46	36.2	130	85	90	140	105	96	67.0				
				48	36.5	125	85	84	135	95	90	67.0				
				50	36.4	100	84	78	135	100	84	67.0				
				52	36.7	135	95	78	130	100	84	67.0				
				10	28	291	LL	8	36.3	135	95	74	140	105	90	80.0
								10	36.7	140	95	68	135	100	81	80.0
								12	36.6	120	85	89	108	95	104	79.0
								14	36.4	120	85	81	110	92	104	79.0
								16	36.5	150	115	72	150	115	90	80.0
								18	36.1	130	95	76	115	100	90	79.0
								20	36.6	108	80	80	105	85	98	79.0
								22	36.4	145	105	72	125	100	84	79.0
								24	36.7	140	95	78	140	105	84	78.0
								26	36.7	140	105	78	140	100	98	79.0
28	36.6	120	80					80	120	100	100	79.0				
30	36.3	120	80					85	110	85	96	79.0				
32	36.5	130	85					78	120	85	96	79.0				
34	36.2	130	72					72	125	78	84	79.0				
36	36.4	140	90					66	130	85	90	80.0				
38	36.5	130	80					72	125	80	96	80.0				
40	36.2	110	60	60	120	90	84	79.0								
42	36.4	110	75	78	120	80	84	79.0								
44	36.3	140	90	78	130	85	84	77.0								
46	36.5	125	85	72	115	90	90	76.0								
48	36.3	115	85	66	110	90	90	75.0								
50	36.3	125	90	72	130	90	96	76.0								
10	31	297	RR	8	36.2	120	75	90	125	100	120	71.0				
				10	36.2	115	85	90	95	85	120	72.0				
				12	36.3	120	85	72	105	90	120	72.0				
				14	36.4	120	80	78	110	90	116	71.0				
				16	36.6	115	85	72	115	85	102	72.0				
				18	36.2	120	80	66	110	90	96	72.0				
				20	36.4	115	80	60	110	90	90	72.0				
				22	36.5	120	90	72	120	90	96	72.0				
24	36.2	115	90	66	125	95	90	72.0								
26	36.4	115	90	66	120	95	102	72.0								
28	36.2	110	95	78	115	95	120	72.0								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
10	31	297	RK	30	36.3	115	100	80	125	100	140	72.0
				32	36.5	120	90	78	125	95	96	72.0
				34	36.2	120	90	66	125	100	90	71.0
				36	36.4	130	85	78	130	110	96	71.0
				38	36.6	125	95	72	120	90	90	69.0
				40	36.4	120	90	78	120	90	102	67.0
				42	36.3	120	90	66	120	95	96	66.0
				44	36.3	115	85	72	125	90	96	66.0
				46	36.7	120	90	78	140	100	90	66.0
				48	36.3	125	90	66	125	84	84	66.0
				50	36.4	120	85	78	125	95	90	68.0
				52	36.8	120	80	66	130	90	78	68.0
10	32	299	LK	8	36.9	106	72	80	100	70	120	61.0
				10	36.7	110	60	72	100	60	82	61.0
				12	36.8	105	70	72	100	70	84	60.0
				14	36.6	110	75	78	105	70	90	61.0
				16	36.7	100	65	78	103	85	96	60.0
				18	36.6	102	70	72	105	80	90	60.0
				20	36.6	103	65	84	105	70	120	59.0
				22	36.3	105	70	84	105	70	98	60.0
				24	36.2	110	70	84	105	70	90	60.0
				26	36.3	115	75	78	110	75	96	60.0
				28	36.4	105	75	78	105	80	90	60.0
				30	36.3	110	75	66	110	80	90	60.0
				32	36.5	107	75	72	105	85	96	60.0
				34	36.2	90	65	84	100	80	96	60.0
				36	36.6	103	63	90	103	78	108	60.0
				38	36.5	103	75	84	105	80	96	60.0
				40	36.2	95	75	86	100	85	90	60.0
				42	36.4	90	70	84	105	80	96	60.0
				44	36.8	95	65	90	110	85	108	60.0
				46	36.7	95	70	84	105	80	90	60.0
				48	36.5	100	65	84	110	80	102	60.0
				50	36.5	100	70	78	100	75	90	61.0
				52	36.4	100	70	84	110	75	90	66.0
10	33	300	EK	8	36.3	115	85	84	105	85	110	82.0
				10	36.6	95	75	84	100	85	90	82.0
				12	36.5	115	70	78	120	95	86	83.0
				14	36.3	115	70	72	120	85	84	82.0
				16	36.4	120	80	78	125	85	90	82.0
				18	36.5	120	85	66	125	85	90	83.0
10	34	31	TK	8	36.4	115	80	74	110	80	98	79.0

2248

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
10	34	31	YX	10	35.8	110	80	66	110	70	74	80.0
				12	36.5	130	75	80	120	85	110	79.0
				14	36.4	125	70	78	115	80	96	80.0
				16	36.3	120	75	66	115	85	98	79.0
10	35	35	IH	8	36.9	110	80	94	110	80	98	51.0
				10	36.8	105	75	74	105	75	90	50.0
				12	36.9	115	85	90	120	105	98	51.0
				14	36.7	110	100	86	115	100	98	50.0
10	38	37	LL	16	36.8	105	85	90	130	95	98	50.0
				8	36.4	105	70	78	115	70	98	53.0
				10	36.5	105	75	66	120	75	98	53.0
				12	36.6	110	65	68	100	75	90	54.0
10	39	40	VH	14	36.7	110	75	70	105	75	98	53.0
				16	36.5	110	80	72	105	70	90	53.0
				8	36.6	125	70	72	120	65	80	51.0
				10	36.5	135	80	80	140	80	84	51.0
10	41	42	VF	12	36.4	120	70	88	118	74	92	51.0
				14	36.4	120	75	90	105	85	120	50.0
				16	36.5	120	80	78	110	90	98	52.0
				18	36.6	115	75	84	110	80	96	53.0
				20	36.3	115	80	78	120	85	96	52.0
				22	36.4	115	75	84	120	80	90	52.0
				24	36.6	115	85	84	120	85	102	50.0
				26	36.7	110	70	72	130	90	84	51.0
				28	36.4	120	90	78	115	90	102	51.0
				30	36.5	125	95	78	128	102	96	51.0
				32	36.6	120	80	84	105	90	96	51.0
				34	36.4	130	85	78	135	98	90	51.0
				36	36.7	135	100	84	135	100	90	51.0
				38	36.5	165	105	84	140	100	96	50.0
				40	36.3	150	85	96	145	100	108	51.0
				42	36.8	160	98	84	145	100	96	50.0
				44	36.5	150	98	84	145	100	96	50.0
				46	36.7	165	80	78	140	95	96	50.0
				48	36.6	165	85	78	130	90	96	50.0
				50	36.7	150	85	66	135	90	90	50.0
52	36.6	140	90	78	140	100	96	50.0				
10	41	42	VF	8	36.6	145	80	72	130	75	82	79.0
				10	36.5	130	80	88	120	80	88	79.0
				12	36.4	130	70	80	134	70	72	79.0
				14	36.4	130	75	72	135	75	72	79.0

2249

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)				
10	41	42	VP	16	36.5	130	70	74	130	70	80	79.0				
				18	36.6	130	70	74	130	70	80	79.0				
				20	36.2	145	85	78	140	80	86	140	86	79.0		
				22	36.2	140	90	72	130	85	72	130	85	80	79.0	
				24	36.4	140	80	72	140	80	72	130	80	80	79.0	
				26	36.5	135	85	74	130	80	74	130	80	82	81.0	
				28	36.4	140	85	78	135	85	82	135	85	90	82.0	
				30	36.9	145	80	86	140	80	86	140	80	86	82.0	
				32	36.6	130	80	82	130	80	82	130	75	90	82.0	
				34	36.7	140	80	76	140	80	76	135	75	82	82.0	
				36	36.5	145	75	76	140	75	76	140	75	84	82.0	
				38	36.6	145	80	74	140	80	74	140	75	86	82.0	
				40	36.4	140	80	76	145	80	76	135	80	86	82.0	
				42	36.8	145	80	76	140	80	76	140	75	82	82.0	
				44	36.3	140	80	76	140	80	76	140	80	86	82.0	
				46	36.4	145	85	76	145	85	76	140	80	86	82.0	
				48	36.4	140	80	74	140	80	74	135	75	80	82.0	
				50	36.2	145	80	72	145	80	72	135	70	80	82.0	
				52	36.3	140	80	74	140	80	74	135	70	82	82.0	
				10	53	47	MA	8	36.8	120	64	84	125	60	80	70.0
								10	36.5	118	64	84	114	60	100	70.0
								12	36.6	120	65	80	115	60	88	115
14	36.2	115	65					82	115	60	90	110	60	70.0		
16	36.8	110	60					72	110	60	80	110	60	80		
18	36.8	110	60					68	105	60	80	105	60	80		
20	36.7	120	70					78	110	70	88	110	65	88		
22	36.5	120	70					82	115	70	92	115	65	92		
24	36.6	110	70					78	110	70	86	115	65	86		
26	36.6	120	70					72	120	70	72	115	65	80		
28	36.4	110	70	78	110	70	78	100	60	82						
10	49	43	YM	8	36.8	95	60	70	95	60	72	56.0				
				10	36.6	95	58	68	100	60	74	56.0				
				12	36.8	100	60	74	105	60	78	56.0				
				14	36.3	110	70	72	115	70	72	56.0				
				16	36.6	110	60	70	110	60	74	56.0				
				18	36.7	110	70	68	105	70	76	56.0				
				20	36.4	100	60	70	100	60	76	56.0				
				22	36.5	105	60	68	110	60	76	56.0				
				24	36.4	95	60	72	100	65	80	56.0				
				26	36.4	100	65	66	105	65	78	56.0				
28	36.6	100	60	67	100	65	76	56.0								
30	36.4	105	60	68	110	65	74	56.0								
32	36.2	100	60	68	105	60	74	56.0								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D. R. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)
10	53	47	MA	34	36.6	100	60	68	105	65	76	56.0
10	54	48	UN	8	36.1	120	80	84	110	80	100	52.0
				10	36.4	120	80	88	115	75	102	52.0
				12	36.6	120	80	80	110	80	86	52.0
				14	36.4	120	80	78	110	75	89	52.0
				16	36.7	120	80	80	110	80	92	52.0
				18	36.4	140	80	78	135	80	90	51.0
				20	36.3	130	80	76	125	75	86	50.0
				22	36.6	135	80	74	130	70	86	50.0
				24	36.2	130	80	78	120	70	86	50.0
				26	36.2	130	82	82	125	70	94	50.0
				28	36.2	125	75	88	125	70	98	50.0
				30	36.2	130	75	96	125	70	100	50.0
				32	36.5	130	80	92	125	70	100	51.0
				34
10	56	50	JP	8	36.4	110	60	66	110	60	78	82.0
				10	36.5	110	60	72	115	65	84	83.0
10	57	51	AG	8	36.6	115	70	78	125	80	90	92.0
				10	36.8	120	80	78	130	85	96	90.0
				12	36.5	115	95	78	125	85	90	89.0
				14	36.7	120	75	84	115	95	96	87.0
				16	36.6	110	70	78	120	80	90	87.0
				18	36.8	110	70	84	110	90	96	85.0
				20	36.4	105	75	72	100	90	90	83.0
				22	36.5	110	75	72	105	85	84	80.0
				24	36.6	110	70	78	110	80	84	78.0
				26	36.4	105	70	84	105	80	96	80.0
				28	36.3	100	70	72	100	80	84	80.0
				30	36.5	95	75	78	105	85	90	87.0
				32	36.3	110	80	78	115	85	84	87.0
				34	36.7	110	85	66	120	90	78	88.0
				36	36.4	105	80	66	115	90	84	87.0
				38	36.6	100	75	66	115	85	78	86.0
				40	36.3	110	80	84	125	90	90	85.0
				42	36.2	95	65	84	105	70	90	84.0
				44	36.4	105	70	78	115	65	96	84.0
				46	36.5	105	70	72	110	80	84	84.0
				48	36.5	110	60	78	115	80	90	85.0
				50	36.8	115	70	72	120	85	84	85.0
				52	36.4	115	75	78	125	90	96	85.0
10	59	53	TA	8	36.6	115	75	78	115	75	90	43.0

7203

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXYETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXYETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
10	59	53	TA	10	36.8	110	78	80	110	76	92	43.0
10	63	57	MS	8	36.4	100	60	74	105	65	80	67.0
				10	36.4	100	60	74	110	65	84	67.0
				12	36.5	95	60	76	110	65	82	67.0
				14	36.7	100	60	78	110	70	84	67.0
				16	36.3	100	60	74	105	65	82	67.0
				18	36.5	105	60	72	110	60	78	67.0
				20	36.5	100	60	72	100	60	80	67.0
				22	36.5	100	60	74	105	65	82	67.0
				24	36.5	100	60	76	105	65	84	67.0
				26	36.7	100	65	74	105	65	82	67.0
				28	36.2	105	60	72	110	65	82	67.0
				30	36.5	100	60	68	105	65	76	67.0
				32	36.6	105	60	74	105	65	82	67.0
				34	36.5	110	70	76	105	60	84	67.0
				36	36.2	100	60	74	105	65	80	67.0
				38	36.5	105	60	70	110	65	80	67.0
				40	36.3	105	60	72	110	65	82	67.0
				42	36.4	110	65	72	105	60	80	67.0
				44	36.5	105	60	74	105	65	80	67.0
				46	36.6	105	65	70	110	70	78	67.0
				48	36.3	100	60	72	105	65	80	67.0
				50	36.4	110	65	74	105	60	78	67.0
				52	36.5	100	60	70	110	65	76	67.0
10	82	59	LS	8	36.6	115	70	72	110	70	78	68.0
				10	36.4	110	70	74	105	70	80	68.0
				12	36.5	120	70	72	115	65	76	68.0
				14	36.7	115	70	72	110	65	78	68.0
				16	36.5	120	70	70	115	70	76	68.0
				18	36.4	115	70	72	110	65	76	68.0
				20	36.6	120	70	68	115	65	76	68.0
				22	36.5	120	70	68	115	70	74	68.0
				24	36.4	115	70	72	110	60	78	68.0
				26	36.6	115	70	68	115	65	76	68.0
				28	36.6	120	70	70	115	65	76	68.0
				30	36.5	120	70	72	115	65	78	68.0
				32	36.4	115	70	70	110	65	76	68.0
				34	36.3	120	70	72	110	60	80	69.0
				36	36.2	115	65	68	115	60	75	69.0
				38	36.3	120	70	70	115	65	76	69.0
				40	36.7	115	70	72	110	65	80	69.0
				42	36.5	120	70	74	110	60	80	70.0
				44	36.8	115	65	72	105	60	82	70.0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
10	82	59	LS	46	36.6	120	70	74	110	60	80	70.0
				48
10	84	63	HV	8	36.6	140	100	80	165	120	93	65.0
				10	36.6	140	95	90	145	100	96	62.0
				12	36.7	145	95	84	160	105	90	62.0
				14	36.9	135	90	92	130	100	100	61.0
				16	36.5	140	100	90	130	105	96	60.0
10	86	274	NP	8	36.7	140	80	68	120	80	76	68.0
				10	36.5	130	70	72	120	70	78	68.0
				12	36.5	120	70	74	110	70	82	66.0
				14	36.5	130	80	68	125	75	76	65.0
				16	36.3	130	80	72	120	70	84	65.0
				18
10	87	275	AN	8	36.5	140	95	72	140	90	76	68.0
				10	36.2	140	95	72	140	90	76	68.0
				12	36.2	140	80	68	145	85	74	68.0
				14	36.6	145	85	72	150	85	76	67.0
				16	36.5	135	80	70	145	80	82	65.0
				18	36.2	140	75	72	145	80	80	65.0
				20	36.5	140	80	70	145	85	80	65.0
				22	36.1	140	90	72	140	80	78	65.0
				24	36.4	140	80	68	145	80	76	65.0
				26	36.2	140	80	70	145	85	78	65.0
				28	36.2	140	80	68	145	85	76	65.0
				30	36.5	140	80	70	150	90	78	62.0
				32	36.3	140	80	72	145	85	78	62.0
				34	36.3	145	80	70	150	85	78	62.0
				36	36.3	140	75	68	145	85	75	62.0
				38	36.4	135	75	68	145	85	74	62.0
				40	36.4	140	70	70	145	80	74	62.0
				42	36.6	140	75	68	145	80	76	62.0
				44	36.5	135	70	70	145	75	76	62.0
				46	36.6	140	75	72	140	80	78	62.0
				48	36.5	160	90	68	145	75	78	63.0
				50	36.4	145	75	70	170	100	74	63.0
				52	36.3	140	70	78	150	75	76	63.0
10	89	277	SK	8	36.8	110	60	72	100	55	86	67.0
10	90	70	SY	8	36.7	110	75	78	110	75	90	55.0
				10	36.4	110	75	66	105	80	84	55.0
				12	36.5	110	85	78	110	85	90	56.0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Contro	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys Bp (mmHg)	5m. Lying Dias Bp (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys Bp (mmHg)	2m. Stand Dias Bp (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
10	90	70	SV	14	36.8	115	83	89	105	85	96	56.0
				16	36.6	115	83	84	105	85	96	56.0
				18	36.5	110	80	84	105	85	90	56.0
				20	36.6	110	80	78	100	80	90	55.0
				22	36.2	115	80	72	100	85	84	55.0
				24	36.4	115	80	72	105	85	96	55.0
				26	36.6	115	85	78	108	85	90	56.0
10	91	74	HI	8	36.8	105	65	78	110	75	96	71.0
				10	36.6	95	70	78	95	70	96	71.0
				12	36.8	95	75	78	100	75	90	71.0
				14	36.7	100	60	78	110	75	84	71.0
				16	36.7	95	70	84	105	80	96	72.0
				18	36.5	100	60	72	110	70	90	71.0
				20	36.4	100	70	66	105	75	84	71.0
				22	36.5	95	60	66	100	70	78	72.0
				24	36.4	105	60	72	110	75	96	71.0
				26	36.3	100	70	78	110	80	84	71.0
				28	36.2	105	70	72	115	80	90	71.0
				30	36.4	100	60	66	110	80	78	70.0
10	93	285	AN	8	36.5	120	70	74	115	65	80	85.0
				10	36.4	110	70	70	110	65	78	85.0
				12	36.6	120	65	68	110	60	74	85.0
				14	36.2	120	70	68	115	65	76	85.0
				16	36.8	115	70	72	110	70	76	85.0
				18	36.2	110	65	72	110	60	78	85.0
				20	36.2	120	70	68	110	60	78	86.0
				22	36.6	110	65	68	105	60	76	86.0
				24	36.4	120	70	70	110	60	78	86.0
				26	36.4	115	65	72	110	60	78	86.0
				28	36.4	120	70	68	110	60	75	87.0
				30	36.3	110	65	70	110	60	76	87.0
				32	36.3	115	70	68	110	65	72	87.0
				34	36.5	120	70	66	110	60	70	87.0
				36	36.4	110	65	64	105	60	70	87.0
11	2	373	HB	8	36.5	140	90	83	150	90	78	117.0
				10	36.2	160	100	88	150	100	86	119.0
				12	36.6	150	100	80	165	100	82	119.0
				14	36.2	130	80	76	140	90	82	119.0
				16	36.2	140	90	76	150	100	86	119.0
				18	36.8	140	90	80	140	90	86	119.0
				20	36.8	150	90	85	150	90	86	119.0
				22	36.3	160	100	90	160	100	75	119.0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	D.R. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
11	2	373	HB	8	36.4	150	90	78	160	100	80	120.0
				24	36.7	150	100	84	150	100	94	120.0
				26	36.2	150	100	82	140	100	85	116.0
	3	374	RF	30	36.2	150	100	70	150	100	76	117.0
				8	36.4	150	80	84	140	70	82	81.0
				10	36.8	140	90	80	140	90	82	80.0
11	6	377	VP	8	37.1	130	90	82	130	90	86	83.0
				10	36.7	130	90	80	120	80	82	83.0
				12	37.1	130	80	100	130	80	102	87.0
				14	37.1	130	80	82	120	70	90	84.0
				16	37.0	130	90	76	120	90	96	83.0
				18	37.4	140	80	100	140	90	97	83.0
				20	36.8	125	90	96	115	80	84	84.0
				22	36.5	130	90	68	120	80	70	81.0
				24	36.7	140	80	79	140	80	80	82.0
	10	363	BJ	26	36.8	130	80	70	120	80	72	81.0
				28	37.1	130	90	72	120	80	84	81.0
				30	36.7	140	90	92	120	80	90	83.0
				32	35.6	140	90	92	130	90	94	83.0
				34	36.5	130	90	77	140	90	82	83.0
				36	37.2	130	90	92	130	90	90	83.0
				38	37.4	130	80	89	130	90	87	83.0
				40	37.2	130	70	88	130	70	90	83.0
				42	36.9	140	90	85	130	100	84	80.0
11	10	363	BJ	44	37.1	130	80	76	120	80	76	82.0
				46	36.7	140	80	82	130	80	84	83.0
				48	36.7	120	70	87	130	70	87	84.0
				50	36.2	110	70	88	120	70	84	84.0
				52	36.5	120	80	92	130	90	80	81.0
				8	36.6	120	90	70	110	80	72	77.0
11	10	363	BJ	10	36.5	120	80	78	110	80	72	77.0
				12	36.6	110	70	78	120	80	86	78.0
				14	36.7	120	80	78	130	80	82	77.0
				16	36.8	130	90	78	130	80	82	78.0
				18	36.5	120	80	78	130	90	76	77.0
				20	36.6	120	80	78	130	90	84	77.0
				22	36.4	130	80	76	130	80	86	77.0
				24	36.3	140	90	76	140	80	82	77.0
				26	36.5	130	80	80	140	90	86	77.0
				28	36.4	140	80	83	130	80	80	76.0
				30	36.5	130	80	76	120	80	84	75.0
				32	36.9	120	70	76	120	80	82	75.0

22 55

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED												
REBOXETINE - PROTOCOL 20124/013												
Listing No.: 13.1												
VITAL SIGNS												
DOUBLE BLIND PHASE												
TREATMENT: REBOXETINE												
Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys Bp (mmHg)	5m. Lying Dias Bp (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys Bp (mmHg)	2m. Stand Dias Bp (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)
11	10	363	BJ	34	36.4	120	70	72	110	70	70	75.0
				36	36.8	120	80	78	120	80	80	76.0
				38	36.4	130	80	70	120	70	80	75.0
				40	36.4	120	80	72	120	80	80	76.0
				42	36.8	130	90	80	130	80	86	75.0
				44	36.2	120	80	78	110	70	88	75.0
				46	36.6	120	80	68	120	80	80	76.0
				48	36.4	130	80	70	120	80	80	77.0
				50	36.8	120	80	68	130	80	76	76.0
				52	36.2	120	70	76	120	80	88	76.0
11	11	361	NGY	8	36.3	120	80	80	130	90	86	75.0
				10	36.8	110	80	80	120	80	86	77.0
				12	36.3	140	90	80	130	90	82	78.0
				14	36.3	140	90	90	150	100	86	78.0
				16	36.8	120	80	82	130	80	90	73.0
				18	36.8	140	90	88	140	100	96	78.0
				20	36.5	140	90	72	140	90	82	80.0
				22	36.4	150	90	86	150	100	90	78.0
				24	36.9	140	90	92	140	90	98	77.0
				11	13	365	GK	8	36.4	120	80	88
10	36.5	120	80					82	130	80	90	47.0
12	36.8	100	70					70	120	80	78	48.0
14	36.3	110	70					66	100	70	74	47.0
16	36.0	140	80					76	130	80	75	49.0
18	36.5	130	80					78	130	80	82	50.0
20	36.9	130	80					80	120	80	82	52.0
8	36.2	110	80					80	120	80	90	48.0
10	36.8	130	80					86	140	90	90	47.0
12	36.4	130	80					76	120	80	88	47.0
14	36.6	140	100	92	120	90	90	49.0				
16	36.0	140	100	90	140	100	94	49.0				
18	36.6	130	80	92	140	80	98	48.0				
11	17	368	UZ	8	36.2	120	80	76	130	80	88	74.0
				10	36.6	130	80	70	130	80	75	73.0
				12	36.3	140	90	78	130	90	88	76.0
				14	36.8	110	90	80	90	80	78	73.0
				16	36.1	140	90	68	130	80	70	72.0
				18	36.5	130	80	64	130	80	72	71.0
				20	36.4	130	80	62	150	80	66	73.0
				22	36.3	130	80	66	110	70	70	72.0
				24	36.6	120	80	68	120	80	74	72.0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)				
11	17	368	UZ	26	36.2	120	80	70	120	80	74	72.0				
				28	36.8	130	80	68	130	80	76	80	72.0			
				30	36.3	120	80	66	120	80	80	80	72.0			
				32	36.6	120	80	70	120	80	74	80	71.0			
				34	36.9	110	70	70	110	80	80	70	70.0			
				36	36.5	120	80	72	110	80	84	70	71.0			
				38	36.8	130	80	66	120	70	78	70	70.0			
				40	36.6	120	70	70	120	80	80	80	69.0			
				42	36.5	130	80	76	120	80	86	80	69.0			
				44	36.3	130	80	76	120	80	86	80	68.0			
				46	36.2	120	70	68	110	70	89	70	68.0			
				48	36.7	130	80	68	120	80	76	80	68.0			
				50	36.3	120	80	80	140	50	86	80	68.0			
				52	36.4	120	80	78	130	80	78	80	67.0			
				52	36.4	120	80	78	110	70	86	70	67.0			
				11	19	370	FK	8	36.6	130	80	80	120	80	86	62.0
								10	36.3	130	80	86	130	80	86	63.0
12	36.1	130	90					70	130	90	76	63.0				
14	36.6	140	90					70	130	80	72	63.0				
16	36.5	130	80					80	130	80	76	61.0				
18	36.8	130	80					80	120	80	78	62.0				
20	36.2	120	70					72	120	80	82	62.0				
22	36.6	120	80					76	110	70	76	62.0				
24	36.9	120	80					72	130	90	86	62.0				
26	36.5	120	70					86	120	80	88	62.0				
28	36.2	130	80					74	120	80	78	63.0				
30	36.4	120	80					68	120	80	76	64.0				
32	36.7	110	70					68	120	80	80	64.0				
34	36.3	120	80					78	120	80	84	64.0				
36	36.8	110	70					66	120	80	80	63.0				
38	36.2	120	80					66	130	80	80	63.0				
40	36.8	130	80					66	120	80	74	59.0				
42	36.4	130	80	66	120	70	68	62.0								
44	36.1	120	80	72	130	80	86	63.0								
46	36.5	110	70	78	130	80	84	63.0								
48	36.8	120	70	78	130	80	82	64.0								
50	37.0	140	90	66	120	70	72	63.0								
52	36.4	130	80	62	130	80	70	63.0								
12	1	92	IB	8	36.2	130	80	78	140	90	88	74.0				
				10	37.0	120	90	80	140	80	92	74.0				
				12	35.2	150	100	96	150	100	126	74.0				
				14	36.5	150	100	114	140	100	100	74.0				
				16	36.7	170	110	100	170	100	104	72.0				
				18	36.2	140	90	88	165	130	92	71.0				
				18	36.2	140	90	88	165	130	92	71.0				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D. B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)				
12	1	92	IB	20	36.7	160	120	92	160	120	120	71.0				
				22	36.7	170	120	100	160	120	120	74.0				
				24	36.5	140	90	90	150	90	96	73.0				
				26	36.4	130	80	86	140	90	92	70.0				
				28	36.5	145	80	88	145	100	110	70.0				
				30	36.4	160	100	80	160	100	88	71.0				
				32	36.2	130	80	82	140	90	78	70.0				
				34	36.0	170	100	88	180	110	90	70.0				
				36	36.3	140	90	90	150	90	94	70.0				
				38	36.4	130	90	82	140	90	85	70.0				
				40	36.2	150	80	92	140	80	94	70.0				
				42	36.4	190	100	88	170	100	98	69.0				
				44	36.3	160	100	114	140	100	124	67.0				
				46	36.2	160	100	84	160	100	88	67.0				
				48	36.5	160	110	80	160	100	88	67.0				
				50	36.2	150	90	93	140	100	97	68.0				
				52	36.5	140	90	86	140	90	90	68.0				
				12	2	99	EFC	8	36.8	120	80	86	120	80	90	78.0
								10	36.7	130	90	84	120	80	96	78.0
								12	36.6	130	80	92	120	80	104	75.0
12	3	93	IF	8	36.5	120	80	60	130	80	78	66.0				
				10	36.7	120	80	66	130	80	84	66.0				
				12	36.5	140	100	72	130	90	86	66.0				
				14	36.5	120	80	66	130	80	78	66.0				
				16	36.7	120	80	84	120	80	92	65.0				
				18	36.4	130	80	64	130	80	72	65.0				
				20	36.8	130	80	90	140	90	88	65.0				
				22	36.2	120	80	78	130	80	90	65.0				
				24	36.5	125	70	80	130	80	88	65.0				
				26	36.7	135	90	78	140	90	84	66.0				
				28	36.5	140	100	80	140	90	80	66.0				
				30	36.2	130	80	78	140	90	94	66.0				
32	36.8	125	82	82	135	80	96	66.0								
34	36.6	110	70	88	120	70	74	66.0								
36	36.2	110	70	74	120	70	74	63.0								
38	36.4	120	80	78	120	80	80	63.0								
40	36.5	130	90	68	120	80	74	62.0								
42	36.3	130	80	80	120	80	86	61.0								
44	36.4	120	80	76	130	80	86	61.0								
46	36.2	110	70	74	110	70	80	61.0								
48	36.8	120	80	76	120	80	86	61.0								
50	36.2	120	80	82	120	80	90	61.0								
52	36.9	125	80	74	135	90	88	62.0								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)				
12	4	100	EG	8	36.5	115	80	78	110	80	76	73.0				
				10	36.8	120	90	100	130	110	104	74.0				
				12	36.7	140	100	64	130	80	66	76.0				
				14	36.6	130	90	80	140	110	96	78.0				
	7	102	LK	16	36.6	120	80	78	125	80	88	78.0				
				18	36.9	110	70	74	120	80	80	79.0				
				20	36.8	115	80	76	120	80	110	79.0				
				22	36.4	120	90	82	130	90	90	80.0				
				24	36.9	120	90	88	120	90	100	80.0				
				26	36.5	140	90	95	140	90	90	80.0				
				28	36.4	150	100	86	140	80	94	83.0				
				12	7	102	LK	8	36.5	150	100	82	140	100	96	84.0
								10	36.2	125	75	72	140	90	80	84.0
								12	36.2	130	80	88	140	90	94	85.0
								14	36.4	120	80	88	120	80	100	82.0
								16	36.5	130	90	90	145	95	94	84.0
								18	36.3	120	84	84	130	90	88	84.0
								20	36.5	110	80	110	80	88	85.0	
								22	36.4	140	90	92	150	95	98	80.0
				9	91	RBP	24	36.3	160	100	101	130	90	98	80.0	
	26	36.2	130				90	92	140	95	98	82.0				
	28	36.3	130				100	90	140	100	96	81.0				
	8	36.6	100				80	86	100	70	86	50.0				
	10	36.6	100				60	80	60	60	80	51.0				
	12	36.6	100				60	80	60	60	96	51.0				
	14	36.5	100				70	76	70	70	80	51.0				
	16	36.6	110				70	80	100	70	80	52.0				
	12	15	104	GB	18	36.4	110	75	80	100	85	80	47.0			
20					36.5	110	70	75	100	70	80	47.0				
22					36.6	100	70	72	110	70	78	48.0				
24					36.7	110	70	72	100	70	80	48.0				
26					36.4	120	70	80	100	70	90	49.0				
28					36.4	110	70	72	110	70	86	48.0				
8					35.2	160	100	100	150	100	96	75.0				
10					36.6	150	100	100	150	100	88	75.0				
12	36.2	170	110	100	170	110	100	78.0								
14	36.4	140	100	100	130	100	100	78.0								
16	36.4	120	90	96	110	90	110	78.0								
18	36.5	120	80	80	120	80	80	78.0								
20	36.2	140	100	84	140	100	84	79.0								
22	36.2	130	90	88	130	90	88	80.0								
24	36.7	130	80	84	140	80	88	79.0								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RAD
 ROXETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: ROXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
12	15	104	GB	26	36.2	150	90	96	160	90	100	79.0
12	16	105	FN	8	36.0	110	70	98	110	90	120	54.0
				10	36.2	120	90	88	110	70	94	54.0
				12	36.3	120	80	76	115	80	92	52.0
				14	36.5	110	80	98	100	60	120	53.0
				16	36.2	110	70	88	110	70	94	54.0
				18	36.5	120	70	84	120	75	88	53.0
				20	36.2	110	90	90	100	70	88	52.0
				22	36.6	120	80	84	110	80	104	53.0
				24	36.8	120	70	84	110	70	92	53.0
				26	36.3	110	70	82	120	70	96	53.0
12	19	106	SSZ	8	36.2	120	80	78	125	90	84	67.0
				10	36.5	130	90	84	140	90	96	66.0
				12	36.3	120	80	80	130	80	82	65.0
				14	36.7	120	80	78	130	80	90	66.0
				16	36.3	120	80	82	130	80	92	66.0
12	21	110	FL	8	36.2	120	80	82	130	90	94	76.0
				10	36.5	130	90	82	130	90	90	76.0
				12	37.4	140	90	88	130	90	90	76.0
				14	36.5	110	80	88	120	90	100	76.0
				16	36.4	130	80	84	125	70	88	72.0
				18	36.4	100	70	92	100	70	86	70.0
				20	37.0	120	80	94	100	80	93	70.0
12	24	113	HF	8	36.4	110	80	72	130	90	84	82.0
				10	36.6	120	80	76	130	80	86	82.0
				12	36.7	140	90	84	130	80	86	80.0
				14	36.6	140	90	86	130	80	86	80.0
				16	36.6	140	90	82	130	80	90	79.0
				18	36.7	130	90	80	130	80	88	79.0
				20	36.5	140	90	84	130	80	86	79.0
				22	36.4	140	90	80	130	80	90	80.0
				24	36.6	130	80	82	130	80	88	79.0
				26	36.4	140	90	86	125	80	88	79.0
				28	36.2	130	80	82	140	90	86	80.0
12	25	114	FS	8	36.8	130	90	78	140	90	96	82.0
				10	37.0	120	80	82	120	80	94	82.0
				12	36.2	130	90	84	120	80	88	83.0
				14	36.0	130	90	78	140	90	82	81.0
				16	36.3	140	90	82	130	80	88	81.0
				18	36.4	130	90	74	140	90	82	82.0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)				
12	25	114	FS	20	36.2	140	90	88	140	90	100	84.0				
				22	36.5	180	130	80	140	100	96	85.0				
				24	36.8	140	100	92	130	90	100	84.0				
				26	36.2	130	100	84	140	90	96	85.0				
				28	36.6	130	90	82	140	100	88	84.0				
				30	36.3	130	90	78	140	95	84	84.0				
				32	36.3	130	90	72	140	100	86	84.0				
				34	36.2	170	110	96	150	100	92	84.0				
				36	36.4	150	100	84	130	110	98	84.0				
				38	36.2	140	100	86	130	90	106	82.0				
				40	36.5	140	100	82	150	110	90	82.0				
				42	36.2	150	100	88	130	100	68	83.0				
				44	36.4	140	90	72	150	100	84	83.0				
				46	36.6	150	90	86	140	90	84	82.0				
				48	36.0	140	80	150	150	94	94	82.0				
				50	36.2	140	85	78	155	95	102	82.0				
				52	36.5	150	100	80	160	100	82	82.0				
				12	27	115	VCS	8	36.2	110	70	100	110	70	100	56.0
								10	36.2	100	60	88	100	70	92	56.0
								12	36.5	100	60	88	100	70	90	57.0
								14	36.0	120	80	90	120	80	100	55.0
								16	36.0	110	70	92	110	80	100	56.0
								18	36.2	120	70	88	120	80	90	55.0
								20	36.5	100	60	80	100	70	88	55.0
								22	36.3	120	80	84	110	80	92	55.0
								24	36.4	110	70	74	120	80	80	56.0
								26	36.3	120	80	108	120	80	110	56.0
								28	36.5	120	80	76	120	80	82	57.0
								30	36.8	120	80	102	120	80	106	57.0
								32	36.2	130	80	92	130	90	102	59.0
								34	36.6	130	90	100	120	90	120	59.0
								12	29	117	AR	8	36.5	110	80	84
10	36.0	140	80									82	130	80	94	72.0
12	36.0	125	70	88	125	90	90					72.0				
14	36.3	110	70	82	130	80	90					72.0				
16	36.2	110	70	84	130	80	88					73.0				
18	36.2	110	74	88	120	80	78					72.0				
20	36.8	120	80	86	110	70	84					71.0				
22	36.5	110	68	68	120	80	76					71.0				
24	36.3	110	80	80	120	80	82					71.0				
26	36.3	140	80	88	140	90	92					69.0				
28	36.0	120	80	80	125	80	80					69.0				
30	36.4	130	80	82	140	90	95					69.0				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D. R. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
12	29	117	AK	32	36.2	115	80	80	120	85	92	69.0
				34	36.3	110	70	96	120	95	96	70.0
				36	36.4	120	80	82	125	85	90	70.0
				38	37.0	120	80	92	130	90	100	70.0
				40	36.2	120	80	84	130	80	92	70.0
				42	36.2	120	80	70	140	80	72	70.0
				44	36.4	120	80	74	130	80	78	70.0
				46	36.9	120	70	68	130	80	78	70.0
				48	36.0	120	80	86	100	70	100	70.0
				50	36.4	120	70	64	130	80	78	70.0
				52	36.3	120	80	88	140	80	94	71.0
12	33	388	LN	8	37.0	140	90	88	130	80	80	78.0
				10	36.8	120	80	81	130	90	85	78.0
				12	36.5	120	80	80	120	90	78	78.0
				14	36.7	120	80	85	120	90	85	78.0
				16	36.4	150	100	85	130	90	83	78.0
				18	36.7	130	90	85	130	95	85	78.0
				20	36.5	120	80	80	125	90	85	78.0
12	36	385	FB	8	36.5	130	80	100	130	100	104	85.0
22				10	36.4	110	80	86	120	80	92	85.0
22				12	36.2	125	90	102	125	80	100	85.0
23				8	36.5	100	75	78	95	75	92	57.0
23				10	36.3	100	70	100	100	70	95	58.0
23				12	36.6	120	70	120	120	80	130	58.0
23				14	36.8	115	70	110	115	80	120	59.0
23				16	36.4	115	70	88	90	60	126	57.0
23				18	36.8	110	70	120	115	80	130	57.0
23				20	36.5	110	70	120	100	70	132	59.0
23				22	36.4	120	80	120	110	70	125	57.0
23				24	36.7	115	70	104	110	60	120	56.0
23				26	36.0	115	70	85	100	80	90	58.0
23				28	36.4	110	70	80	100	70	85	58.0
23				30	36.4	120	60	96	115	70	108	60.0
23				32	36.7	100	70	80	100	70	100	59.0
23				34	36.1	100	70	76	90	70	107	60.0
23				36	36.9	110	70	85	120	80	105	60.0
23				38	36.6	100	60	84	115	70	112	60.0
23				40	36.3	110	70	82	100	60	110	60.0
23				42	36.2	100	60	80	100	60	68	60.0
23				44	36.4	100	70	70	100	70	75	61.0
23				46	36.8	110	70	80	100	70	98	62.0
23				48	36.9	110	80	80	100	70	85	61.0

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	
13	1	219	P2	50	36.4	120	60	84	110	60	92	62.0	
				52	36.5	100	60	80	100	70	90	61.0	
13	3	221	AI	8	36.2	115	80	74	100	80	80	66.0	
				10	36.0	115	70	120	105	70	124	68.0	
				12	36.7	110	80	100	105	70	120	67.0	
				14	36.4	100	70	120	90	70	148	69.0	
				16	36.3	100	70	134	90	60	140	68.0	
				18	36.7	115	80	110	120	80	130	65.0	
				20	36.7	110	70	112	110	80	135	65.0	
				22	36.7	120	80	100	100	70	110	65.0	
				24	36.2	100	90	120	80	60	125	65.0	
				26	36.0	115	80	98	115	80	110	66.0	
				28	36.4	110	70	100	110	70	110	68.0	
				30	36.5	115	60	76	100	70	100	67.0	
				32	36.1	110	80	120	80	80	90	69.0	
				34	36.2	105	70	86	110	70	120	69.0	
				36	36.6	100	80	110	110	90	125	71.0	
				38	36.4	115	80	100	115	80	100	121	71.0
				40	36.0	110	70	88	100	80	100	100	70.0
				42	36.5	110	80	84	100	70	116	116	70.0
				44	36.3	115	80	100	100	80	100	110	71.0
				46	36.3	100	70	92	100	70	100	100	70.0
48	36.2	115	70	84	100	60	96	96	71.0				
50	36.2	120	80	92	130	80	104	104	72.0				
52	36.0	100	70	94	90	80	106	106	70.0				
13	6	226	KE	8	36.6	115	90	120	120	90	110	43.0	
				10	36.0	120	70	108	95	70	112	48.0	
				12	36.0	120	80	110	120	80	126	43.0	
				14	36.5	120	80	110	120	80	120	43.0	
				16	36.2	120	80	100	100	70	128	44.0	
				18	36.5	100	70	100	120	80	105	44.0	
				20	36.2	110	70	100	100	60	112	44.0	
				22	36.0	120	70	92	115	70	120	44.0	
				24	36.1	120	60	86	120	90	126	44.0	
				26	36.4	110	70	108	100	70	116	44.0	
				28	36.2	120	70	80	110	70	85	44.0	
				30	36.5	110	80	110	100	70	116	44.0	
32	36.2	120	70	120	100	70	120	43.0					
34	36.2	110	70	120	110	80	115	44.0					
36	36.3	110	70	110	110	70	100	43.0					
38	36.3	120	70	100	110	70	100	43.0					
40	36.5	120	110	110	120	80	100	43.0					
42	36.3	110	80	96	100	75	116	43.0					

2263

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXYLINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXYLINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)				
13	6	226	KE	44	36.6	115	80	105	115	80	110	45.0				
				46	36.4	115	70	76	115	80	104	44.0				
				48	36.1	120	90	100	100	110	110	44.0				
				50	36.2	120	80	112	110	80	114	44.0				
				52	36.4	120	80	72	120	80	100	44.0				
13	7	220	BL	8	36.8	115	80	96	110	80	104	72.0				
				10	36.3	115	80	92	120	80	110	73.0				
				12	36.4	120	70	76	115	70	92	75.0				
				14	36.2	115	80	94	120	80	108	75.0				
				16	36.3	120	80	78	115	80	96	75.0				
				18	36.4	120	82	76	115	70	104	78.0				
				20	36.4	120	80	76	115	70	98	78.0				
				22	36.4	120	70	92	115	70	106	78.0				
				24	36.1	115	80	76	110	80	100	78.0				
				26	36.7	130	80	84	120	80	85	79.0				
				28	36.4	120	80	84	115	75	100	79.0				
				30	36.5	135	85	68	120	90	84	79.0				
				32	36.1	120	72	72	120	90	92	79.0				
				34	36.0	120	80	88	130	90	104	80.0				
				36	36.4	120	78	78	125	85	96	79.0				
				38	36.2	110	80	90	120	100	100	79.0				
				40	36.3	120	70	76	120	70	84	79.0				
				42	36.4	120	90	90	120	70	104	79.0				
				44	36.1	110	70	96	110	60	108	79.0				
				46	36.2	120	90	90	110	70	100	81.0				
				48	36.6	110	80	90	120	80	98	81.0				
				50	36.4	110	70	86	110	80	98	81.0				
				52	36.3	120	80	80	120	80	72	79.0				
				13	13	223	HM	8	36.0	100	70	76	100	80	92	82.0
								10	36.5	100	70	80	95	70	85	81.0
								12	36.3	110	70	80	100	70	100	81.0
14	36.3	120	80					90	115	70	100	82.0				
16	36.1	100	60					80	110	70	85	82.0				
18	36.1	110	80					84	100	70	88	81.0				
20	36.0	115	80					82	110	70	92	81.0				
22	36.4	120	80					84	110	80	100	78.0				
24	36.2	110	70					77	110	70	92	76.0				
26	36.1	110	70					60	90	60	75	76.0				
28	35.9	105	60					76	100	60	84	76.0				
30	35.9	120	70					112	100	70	104	76.0				
32	36.0	100	70					80	100	70	80	76.0				
34	36.0	115	80	65	115	80	70	75.0								
36	36.2	115	80	64	100	60	84	75.0								

2264

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient No.	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
13	13	223	RH	38	36.0	115	70	60	90	70	80	73.0
				40	36.5	110	70	76	100	70	88	73.0
				42	36.4	100	60	76	90	60	84	72.0
				44	36.0	115	70	60	70	80	73.0	
				46	36.3	115	70	60	80	84	75.0	
13	18	227	VT	48	36.4	100	70	68	90	60	84	74.0
				50	35.8	90	60	76	90	60	84	75.0
				52	36.1	100	60	80	90	70	80	75.0
				8	36.4	100	70	80	95	70	100	61.0
				10	36.1	90	60	68	100	70	110	62.0
				12	36.4	115	80	100	115	90	110	62.0
				14	36.0	110	70	92	100	60	112	62.0
				16	36.3	110	70	108	100	70	112	64.0
				18	36.2	100	80	100	100	70	112	63.0
				20	36.3	100	80	96	100	70	106	66.0
				22	36.0	120	90	135	80	70	85	65.0
				24	36.2	100	80	92	95	70	98	65.0
13	20	230	NL	26	36.1	100	70	90	100	60	100	64.0
				28	36.0	115	70	86	100	70	107	64.0
				30	37.0	115	70	86	120	80	107	64.0
				32	36.7	90	70	95	100	80	100	63.0
				34	36.7	90	70	95	100	80	120	61.0
				36	36.8	115	80	110	115	80	115	60.0
				38	36.4	100	70	72	100	70	100	59.0
				40	36.0	120	80	90	110	80	100	59.0
				42	36.3	115	70	76	115	70	100	59.0
				44	36.6	120	80	96	120	90	120	57.0
				46	36.2	115	80	80	120	80	90	57.0
				48	36.8	120	80	80	120	80	110	57.0
50	36.2	120	80	84	100	80	100	58.0				
52	36.7	110	80	90	100	80	100	58.0				
13	20	230	NL	8	37.2	115	70	80	120	80	100	69.0
				10	36.1	120	80	92	120	90	103	70.0
				12	36.7	120	80	80	120	80	100	70.0
				14	36.2	120	80	80	115	70	85	70.0
				16	36.2	115	70	82	120	90	86	72.0
				18	36.2	120	80	80	120	70	88	71.0
				20	36.1	120	80	80	115	70	92	72.0
				22	36.5	115	80	85	120	80	90	71.0
				24	36.2	120	80	88	120	90	92	73.0
				26	36.4	115	75	76	120	80	92	72.0
				28	36.2	120	80	80	100	80	90	72.0
				30	36.3	120	80	88	120	80	90	73.0

22 65

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXYLINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: REBOXYLINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)				
13	20	230	NL	32	36.3	120	80	88	120	80	88	73.0				
				34	36.3	120	70	92	120	70	100	88	73.0			
				36	36.4	120	90	84	115	90	88	90	110	73.0		
				38	36.9	120	80	90	115	80	115	80	92	73.0		
				40	36.2	120	70	84	120	70	115	80	96	73.0		
				42	36.4	120	80	88	120	80	115	80	90	74.0		
				44	36.4	115	70	82	120	70	115	70	88	75.0		
				46	36.5	120	80	80	120	80	100	90	88	75.0		
				48	36.3	120	80	80	120	80	100	90	88	75.0		
				50	36.2	120	80	80	120	80	100	90	88	75.0		
				52	36.5	130	70	84	120	70	92	120	70	92	75.0	
				13	21	231	CL	8	36.2	120	80	84	120	80	108	52.0
								10	36.2	120	80	84	120	80	116	53.0
12	36.3	120	80					76	120	90	104	53.0				
14	36.4	115	80					78	120	80	100	52.0				
16	36.2	120	70					80	120	80	108	52.0				
18	36.5	120	80					100	120	80	105	52.0				
20	36.6	120	90					92	120	90	104	50.0				
22	36.5	120	80					90	120	90	108	51.0				
24	36.3	100	70					96	110	80	104	50.0				
26	36.0	115	80					80	110	70	100	51.0				
28	36.3	120	80					84	100	70	95	51.0				
30	36.4	140	80					80	140	80	88	52.0				
32	36.6	115	80					84	120	90	92	50.0				
34	36.2	120	80	80	120	70	84	50.0								
36	36.6	140	80	88	130	100	92	51.0								
38	36.2	130	86	86	120	80	88	51.0								
40	36.3	115	80	78	120	80	88	51.0								
42	36.4	120	80	80	120	80	90	51.0								
44	36.3	150	100	92	150	110	100	53.0								
46	36.1	140	90	88	140	90	98	52.0								
48	36.4	110	80	80	100	80	84	53.0								
50	36.4	130	76	76	130	90	92	52.0								
52	36.5	115	80	78	115	90	80	52.0								
13	22	232	NYX	8	36.2	110	70	80	100	70	85	79.0				
				10	36.1	120	80	100	80	104	77.0					

2266

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 RESOXETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: PLACERO

Contro	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)
1	1	1	MGA	8	36.5	120	80	70	120	80	70	60
				10	36.0	100	70	116	100	90	116	60
				12	36.2	110	65	96	110	80	104	60
				14	36.8	110	70	95	110	80	100	60
				16	36.5	110	60	95	110	60	98	58
				18	36.1	110	75	96	110	70	100	58
1	6	5	CPM	8	36.3	130	80	88	135	90	100	60
				10	36.2	160	95	94	130	100	102	60
				12	35.9	130	85	90	130	90	104	60
				14	36.8	150	100	100	150	95	100	59
				16	36.0	140	86	86	140	80	90	59
				18
1	8	6	MYB	8	36.0	120	80	86	110	80	100	68
				10	36.6	110	65	102	105	80	112	68
				12	36.9	100	70	84	105	65	110	67
				14	36.4	100	70	84	105	70	82	67
				16	37.1	120	70	100	120	60	100	67
				18	36.9	110	80	88	105	75	100	67
				20	36.2	105	80	88	105	70	90	67
				22	36.9	105	88	88	105	70	104	67
				24	36.4	110	75	90	110	70	98	67
				26	37.3	110	70	100	110	75	102	65
1	11	9	VRT	8	36.3	90	60	80	90	70	88	52
				10	36.5	100	60	80	100	60	100	52
				12	36.5	90	55	80	90	60	92	52
				14	36.2	100	60	80	95	65	84	55
				16	36.4	85	55	80	95	60	92	55
				18	36.4	85	55	80	95	60	92	55
				20	36.4	85	44	80	95	60	92	55
				22	36.4	85	55	80	95	60	92	55
				24	36.8	100	65	72	95	65	84	55
				26	36.8	100	60	72	95	65	84	55
				28	36.2	90	50	70	95	65	90	55
				30	36.4	100	65	70	100	65	80	55
				32	36.5	100	65	72	95	65	80	55
				34	36.3	100	60	80	100	60	90	55
				36	36.3	100	60	80	100	60	90	55
1	12	10	SLT	8	36.2	100	60	100	110	65	108	43
				10	35.9	90	55	80	85	50	88	43
				12	35.4	160	60	96	100	65	100	41
				14	35.4	90	60	88	90	65	88	41

2267

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REDOXETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
1	12	10	SLI	16	35.4	90	60	88	90	65	88	41
				18	35.4	90	60	88	90	65	88	41
				20	35.4	90	60	88	90	65	88	41
				22	35.7	100	60	88	90	60	92	41
				24	35.9	90	60	80	90	60	80	41
				26	35.9	90	60	80	90	60	80	41
				28	36.2	90	60	84	90	60	84	40
				30	35.8	100	70	84	90	55	108	40
				32	35.8	100	60	85	110	70	95	41
				34	35.9	85	55	88	80	50	84	41
				36	35.5	85	55	88	80	55	80	40
				38	36.0	100	60	75	110	60	82	40
				40	36.0	100	60	75	110	60	82	40
				42	36.0	100	60	75	110	60	82	40
				44	35.8	90	60	76	90	60	80	40
				46	35.8	90	60	76	90	60	80	40
				48	35.8	90	60	76	90	60	80	40
				50	35.9	90	60	92	85	60	100	41
				52	35.9	90	60	92	85	60	100	41
1	15	12	MAO	8	36.0	140	90	80	140	90	87	65
				10	36.0	120	85	88	120	80	92	68
				12	36.5	130	90	80	130	85	88	66
				14	36.5	130	90	80	130	85	88	65
				16	35.4	110	75	80	120	80	92	65
				18	35.7	120	80	68	110	85	68	65
				20	36.2	130	80	60	130	85	74	65
				22	35.6	110	80	84	115	85	92	66
				24	35.6	110	65	80	110	70	88	66
				26	35.6	120	80	69	120	80	80	66
				28	35.6	120	80	64	120	80	80	66
				30	35.6	120	80	64	120	85	64	63
				32	35.6	120	80	64	120	85	64	63
				34	35.6	120	80	64	120	85	64	63
				36	35.6	120	80	64	120	85	64	63
				38	35.6	120	80	64	120	85	64	63
				40	35.6	120	80	64	120	85	64	63
				42	35.6	120	80	64	120	85	64	63
				44	35.6	120	80	64	120	85	64	63
				46	35.6	105	75	68	110	80	76	65
				48	35.6	105	75	68	110	80	76	65
				50	35.6	105	75	68	110	80	76	65
				52	35.7	115	80	68	120	85	80	67
1	16	13	MHC	8	35.9	120	80	68	110	80	80	64

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 2012A/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.P. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys Bp (mmHg)	5m. Lying Dias Bp (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys Bp (mmHg)	2m. Stand Dias Bp (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)								
1	16	13	MHC	10	36.1	95	70	88	100	70	104	63								
				12	36.1	115	75	84	100	104	65									
				14	36.3	120	80	125	85	88	65									
				16	35.6	120	70	120	70	92	67									
				18	35.9	120	80	115	75	92	66									
				20	36.9	140	90	140	90	100	66									
				22	36.5	140	90	88	84	92	66									
				24	35.7	125	70	78	75	80	63									
				26	35.9	100	80	72	80	84	63									
				28	35.7	110	70	76	80	80	63									
				30	35.7	110	70	76	80	80	64									
				32	35.7	110	70	76	80	80	64									
				34	35.7	110	70	76	80	80	65									
				36	35.5	115	70	84	80	88	65									
				38	35.5	115	70	84	80	88	66									
				40	35.5	115	70	84	80	88	66									
				1	19	16	SR	8	35.8	100	65	88	100	70	100	57				
								10	36.9	120	70	100	60	120	56					
								12	35.1	100	60	88	70	92	57					
								14	35.4	100	60	80	70	88	57					
								16	35.4	130	70	80	70	90	57					
								18	36.7	90	70	108	50	104	57					
								20	35.7	95	65	96	65	104	57					
								22	36.0	120	70	90	70	100	57					
								24	35.5	110	88	88	70	100	59					
								26	35.5	105	70	88	65	92	59					
								28	35.5	80	80	80	65	92	59					
								30	36.8	80	60	80	65	92	59					
								32	36.8	80	60	80	65	92	59					
								34	36.5	90	60	90	60	95	59					
								36	35.7	110	60	88	70	88	59					
								38	35.7	110	60	88	70	88	59					
								1	21	18	VMC	8	36.2	125	85	72	130	90	80	58
												10	37.2	130	90	80	100	92	59	
												12	36.5	90	70	80	70	80	60	
												14	36.7	100	80	72	85	68	60	
												16	36.8	130	90	80	88	60	60	
												18	35.6	120	90	76	90	60	60	
												20	36.1	110	80	68	80	60	60	
												22	36.4	130	90	68	95	72	60	
24	36.0	115	80									68	90	76	61					
26	36.0	115	80									68	90	76	61					
28	36.0	115	80									68	90	76	61					

2269

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)				
1	21	18	VHC	30	36.2	120	85	72	115	90	84	60				
				32	36.2	120	85	72	115	90	84	60				
				34	36.2	120	85	72	115	90	84	60				
				36	35.4	100	80	88	120	85	112	60				
				38	35.4	100	80	88	120	85	112	60				
				40	36.4	115	75	78	110	70	76	61				
				42	36.1	125	80	52	120	80	60	61				
				44	36.2	125	75	54	120	80	58	61				
				46	36.0	120	75	58	125	80	64	61				
				48	36.2	120	80	56	110	80	60	61				
				50	36.2	125	80	60	120	75	64	61				
				52	36.4	120	80	54	115	75	58	61				
				1	26	22	OC	8	36.5	100	60	80	100	70	80	55
								10	36.2	100	65	72	95	60	80	58
								12	36.8	85	60	68	100	65	84	56
								14	36.8	105	60	92	90	60	116	57
								16	36.8	100	65	84	105	65	92	57
								18	36.3	105	65	80	95	70	96	59
								20	37.0	105	65	96	105	65	108	59
								22	36.6	100	60	84	100	60	88	57
								24	37.0	100	60	92	110	70	92	57
								26	37.0	100	60	62	110	70	62	57
								28	36.7	100	65	72	110	70	72	58
								30	36.6	100	60	72	100	65	92	59
								32	36.6	90	60	72	90	60	88	57
								34	36.3	100	70	68	100	75	84	59
								36	36.5	100	70	68	100	75	84	59
								38	36.0	90	70	112	100	80	116	57
								40	36.1	100	60	76	105	75	92	57
								42	36.0	90	60	92	90	65	108	56
								44	36.0	90	60	92	90	65	108	56
								46	35.7	110	70	80	100	70	88	57
								48	35.7	110	70	80	100	70	88	57
								50	35.7	110	70	80	100	70	88	57
				52	36.6	110	70	72	100	75	72	56				
				1	27	23	BK	8	35.8	120	80	72	110	80	82	80
								10	35.7	125	80	74	120	80	76	80
								12	35.7	120	80	84	110	75	90	78
				1	28	24	RMN	8	36.0	150	100	84	150	100	84	75
								10	36.5	160	100	84	160	100	88	75
								12	36.0	140	100	92	150	100	92	78
								14	36.8	130	90	100	145	100	100	79

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	D.R. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)
1	28	24	RMX	16	36.5	120	80	100	130	90	100	80
				18	36.3	140	90	80	150	100	84	80
				20	36.6	130	90	96	100	100	78	100
				22	35.2	120	90	120	130	100	112	76
1	29	25	AFO	24	36.0	120	80	84	120	80	92	70
				8	37.0	120	80	90	130	90	95	61
				10	36.5	130	90	88	130	100	88	63
				12	36.1	130	90	88	120	90	80	64
1	30	26	ERV	14	36.9	110	80	70	100	70	84	64
				16	36.7	130	90	85	135	95	84	64
				18	36.3	130	100	90	120	85	94	66
				20	36.2	130	100	108	120	90	108	67
1	33	29	DFC	22	36.8	125	95	100	125	90	104	66
				24	36.4	130	80	100	130	90	110	67
				26	36.7	130	90	88	120	95	104	65
				28	36.7	110	80	88	120	90	110	62
1	36	302	LX	30	36.3	140	90	88	110	88	60	60
				32	36.0	140	90	96	120	90	100	60
				34	36.6	110	80	60	110	80	68	59
				36	36.6	110	80	60	110	80	68	59
1	36	302	LX	38	36.7	120	80	88	120	80	100	60
				40	36.7	120	80	88	120	90	100	60
				42	36.7	120	80	88	120	90	100	60
				44	36.7	120	80	88	120	90	100	60
1	33	29	DFC	46	36.2	120	95	88	140	90	96	59
				48	36.2	120	95	88	140	90	96	59
				50	36.2	120	95	88	140	90	96	58
				52	36.2	120	95	88	140	90	96	58
1	36	302	LX	8	36.5	110	70	70	110	80	85	65
				10	36.5	110	75	80	105	80	90	65
				12	36.6	110	80	84	100	80	100	65
				14	36.5	110	70	70	110	80	84	65
1	33	29	DFC	16	36.5	110	80	84	105	75	92	65
				8	36.8	120	70	68	120	70	75	62
				10	36.2	120	70	75	120	80	80	62
				12	36.2	120	70	75	120	80	80	62
1	36	302	LX	8	35.8	120	60	72	110	80	80	74
				10	35.8	125	85	74	120	80	80	74
				12	35.7	130	80	72	120	70	74	74
				14	35.8	120	75	74	120	80	74	74
1	36	302	LX	16	35.8	120	70	72	110	76	74	
				16	35.8	120	70	72	110	76	74	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXYETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Contre	Patient No.	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
1	38	304	DBF	8	35.5	110	80	88	120	85	92	65
	10			10	36.5	140	90	110	140	90	110	65
	12			12	36.7	130	90	116	130	90	120	62
	14			14	36.7	145	85	120	160	100	120	62
	16			16	36.7	150	90	92	140	100	100	62
	18			18	36.7	120	80	136	105	80	140	61
	20			20	36.3	140	90	116	150	100	100	61
	22			22	36.4	160	100	100	110	100	100	61
	24			24	36.3	160	100	104	155	100	120	60
	26			26	36.2	160	100	104	155	100	120	60
	28			28	36.2	160	100	112	125	85	120	62
	30			30	36.6	150	100	104	150	100	104	62
	32			32	35.2	140	100	88	135	90	88	62
	34			34	36.1	140	85	100	140	85	100	62
	36			36	35.3	125	95	88	115	85	92	62
	38			38	36.2	165	110	100	150	105	104	62
	40			40	35.5	130	95	88	130	90	96	62
	42			42	36.8	140	90	112	150	100	120	63
	44			44	36.4	160	95	104	170	110	120	62
	46			46	35.8	150	80	88	150	85	92	62
	48			48	35.5	150	90	76	140	80	84	62
	50			50	36.0	155	95	88	145	90	96	62
	52			52	36.0	160	105	100	145	105	108	62
1	40	306	EM	8	36.4	110	70	100	120	80	100	53
	10			10	36.7	100	60	88	105	60	108	53
	12			12	36.7	100	60	88	100	65	108	53
	14			14	36.4	110	70	100	110	70	100	53
	16			16	36.2	90	60	88	95	65	92	53
	18			18	37.0	100	75	118	100	80	120	51
	20			20	36.2	90	60	88	95	60	92	51
	22			22	36.0	90	60	92	90	60	92	51
	24			24	36.3	95	60	84	80	65	96	53
	26			26	36.8	110	65	92	110	70	100	51
	28			28	36.3	110	65	92	110	70	100	51
	30			30	36.3	110	65	92	110	70	100	51
	32			32	36.5	110	70	100	100	70	100	51
	34			34	36.5	110	70	100	100	70	100	51
	36			36	36.7	100	65	88	100	75	100	50
	38			38	36.7	110	85	88	120	75	88	50
	40			40	36.7	110	85	88	120	75	88	50
	42			42	36.7	110	85	88	120	75	88	50
	44			44	36.2	110	85	88	120	75	88	50
	46			46	36.4	115	75	76	100	75	84	50
	48			48	36.4	115	75	76	100	75	84	50

2209

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD
 REBORNETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: PLACERO

Centro	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
1	40	306	EM	50	36.4	115	75	82	100	75	90	50
				52	36.4	115	75	82	100	75	86	50
1	41	307	SFS	8	35.5	130	80	92	140	90	100	69
				10	35.7	150	90	84	130	80	96	70
				12	35.7	150	90	84	130	80	96	70
				14	36.0	150	90	84	130	80	96	70
				16	35.9	145	85	80	130	85	80	70
				18	36.0	150	90	80	140	80	84	70
				20	36.2	120	65	76	140	80	84	70
				22	36.0	120	65	76	140	80	84	70
				24	36.2	120	80	76	115	75	82	70
				26	36.3	125	85	76	120	80	82	70
				28	36.2	130	85	72	125	85	78	70
				30	36.3	135	85	78	130	90	82	70
				32	36.3	130	90	70	125	90	82	70
				34	36.3	125	80	72	120	70	82	70
				36	36.1	130	80	74	130	75	84	70
				38	36.4	135	85	82	130	85	84	70
				40	36.5	135	85	78	130	90	84	69
				42	36.4	130	90	74	135	95	78	68
				44	36.1	140	90	74	135	90	82	67
2	42	308	ICC	8	35.9	130	90	76	130	90	92	51
2				10	36.4	115	80	84	100	70	100	51
2				12	36.4	115	80	80	100	70	84	51
2				14	36.5	105	80	80	110	85	84	51
2				16	36.5	105	80	80	110	85	84	51
2				18	36.5	105	70	76	105	75	88	50
2				20	35.9	105	70	76	100	70	88	50
2				22	36.4	130	90	82	115	85	90	49
2				24	36.8	130	90	82	115	85	90	50
2				26	36.0	140	90	80	120	90	80	50
2				28	36.0	140	90	80	120	90	80	50
2				30	36.0	110	80	68	100	70	92	50
2				32	36.0	110	80	68	100	70	92	50
2				34	37.0	110	70	68	110	80	92	50
2				36	37.0	110	70	68	110	80	92	50
2				38	37.0	110	70	68	110	80	92	50
2				40	37.0	110	80	84	120	80	84	50
2				42	36.0	120	80	84	120	80	84	50
2				44	36.0	120	80	84	120	80	84	50
2				46	36.2	120	80	76	100	80	88	48
2				48	36.2	120	80	76	100	80	88	48
2				50	36.2	120	80	76	100	80	88	48

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
1	42	308	ICC	52	35.9	105	65	76	95	60	76	49
1	47	312	MCS	8	36.7	130	90	100	120	95	100	64
				10	36.6	100	75	92	110	80	96	65
				12	36.8	120	85	96	130	90	84	66
				14	36.2	110	90	96	110	90	88	64
				16	36.0	110	90	96	110	80	88	65
				18	36.3	125	85	88	120	85	96	66
				20	36.3	125	85	88	120	85	96	66
				22	36.4	105	80	80	105	80	84	65
				24	36.1	135	95	80	130	90	84	65
				26	36.5	135	95	80	130	90	84	65
				28	36.5	135	95	80	130	95	84	65
				30	36.0	115	80	84	115	80	80	66
				32	36.0	115	80	84	115	80	80	66
				34	36.0	115	80	84	115	80	80	66
				36	36.0	115	80	84	115	80	80	66
				38	35.7	115	85	80	120	80	80	66
				40	35.7	115	85	80	120	80	80	66
				42	36.0	115	80	80	120	80	82	66
				44	36.0	120	80	80	120	80	84	66
				46	36.0	120	80	80	120	80	84	66
1	50	314	MFA	8	36.2	100	60	90	100	60	95	52
				10	37.1	120	75	88	115	70	92	52
				12	36.0	100	80	114	100	80	120	56
				14	36.3	110	70	100	100	80	120	56
				16	36.5	100	60	100	100	70	110	57
				18	36.5	100	60	100	110	70	110	55
				20	36.9	130	80	92	115	80	108	55
				22	36.1	130	80	92	115	80	108	57
				24	36.8	110	75	100	110	70	108	56
				26	36.5	120	75	96	115	80	104	55
				28	36.5	115	75	98	115	75	106	54
				30	36.5	110	70	96	115	75	106	55
				32	36.5	110	70	96	115	75	100	56
				34	36.9	105	70	96	105	65	108	57
				36	36.7	105	70	96	105	65	108	58
				38	36.7	105	70	96	105	65	108	58
				40	36.1	120	70	76	110	60	82	58
				42	36.5	120	80	72	120	75	78	56
				44	36.3	130	70	82	125	80	84	56
				46	36.4	125	85	80	115	80	84	56
				48	36.7	125	80	68	115	80	74	56
				50	36.4	130	80	84	115	75	86	56

2274

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D. R. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys Bp (mmHg)	5m. Lying Dias Bp (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys Bp (mmHg)	2m. Stand Dias Bp (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)
1	50	314	NFA	52	36.8	120	80	72	110	75	76	56
1	51	315	ASA	8	35.2	125	80	80	125	85	92	48
				10	35.2	100	70	80	110	80	84	47
				12	36.6	115	65	108	120	75	112	46
				14	36.3	130	80	100	120	90	108	46
				16	36.7	110	70	120	110	70	116	46
				18	36.8	110	70	110	110	70	120	46
				20	36.6	130	80	65	130	80	72	46
				22	36.5	130	80	68	120	85	75	46
				24	35.6	120	75	104	110	108	108	47
				26	36.5	105	65	108	110	65	116	47
				28	36.5	105	65	108	110	65	116	47
				30	36.5	105	65	108	110	65	116	47
				32	36.0	115	70	100	125	80	104	47
				34	36.0	115	70	100	125	80	104	47
				36	36.0	115	70	100	125	80	104	47
				38	36.4	135	85	100	125	80	104	47
				40	36.0	130	85	108	140	85	104	48
				42	36.2	120	80	108	130	90	114	48
				44	36.2	120	80	108	110	75	108	49
				46	36.3	124	76	96	110	74	96	49
				48	36.3	120	75	100	115	80	100	49
				50	36.2	120	80	102	120	85	102	49
				52	36.0	120	85	104	130	90	104	48
1	53	317	JFT	8	36.3	120	80	68	110	70	74	68
				10	36.0	115	75	68	110	70	74	68
				12	36.0	125	80	64	120	80	74	68
				14	36.3	120	80	84	115	75	88	68
				16	36.3	115	70	68	110	70	74	68
				18	36.4	125	80	66	120	80	70	68
				20	36.4	130	80	78	120	80	82	68
				22	36.1	150	80	68	125	75	76	66
1	59	321	SPF	8	36.9	100	60	100	100	70	92	44
				10	36.9	100	60	100	100	70	92	44
				12	36.9	100	60	100	100	70	92	44
				14	36.8	95	70	80	90	70	92	43
				16	36.8	95	70	80	90	70	92	43
				18	36.8	95	70	80	90	70	92	43
				20	36.7	110	65	72	105	70	72	43
				22	36.7	110	65	72	105	70	72	43
				24	36.2	115	75	74	105	70	72	43
				26	36.2	120	70	78	110	80	84	44

0275

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.R. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)				
1	59	321	SFF	28	36.0	125	85	76	115	80	82	44				
				30	36.4	125	85	76	120	70	86	44				
				32	36.1	115	75	82	110	70	86	44				
				34	36.3	120	80	66	125	70	74	44				
				36	36.2	115	75	75	120	80	82	44				
				38	36.1	125	80	74	120	70	80	44				
				40	36.1	120	80	76	110	70	80	44				
				42	36.2	110	70	62	120	60	72	44				
				44	36.2	110	80	84	110	70	68	44				
				46	36.2	110	70	84	100	70	68	44				
				48	36.0	120	70	66	110	70	72	45				
				50	36.3	110	70	68	120	70	72	45				
				52	36.1	120	80	60	110	70	68	45				
				1	60	322	EK	8	37.1	100	80	98	120	90	100	65
								10	37.1	100	80	98	120	90	100	65
								12	37.1	100	80	98	120	90	100	65
								14	37.1	100	80	98	120	90	100	65
								16	37.1	100	80	98	120	90	100	65
								18	37.1	100	80	98	120	90	100	65
								20	37.0	120	90	98	135	95	98	63
22	37.0	120	90					98	135	95	98	63				
24	37.0	115	80					102	85	85	114	65				
26	37.0	115	80					102	85	85	114	65				
28	36.9	110	70					108	110	120	114	68				
30	36.5	120	75					94	115	70	110	68				
32	36.5	120	75					94	115	70	110	68				
34	36.2	130	88					88	120	75	100	68				
36	36.8	120	80					100	126	76	108	68				
38	36.8	120	80					100	126	76	108	68				
40	36.8	120	80					100	126	76	108	68				
42	36.0	120	78					110	126	80	115	67				
44	36.9	120	78					110	120	80	115	66				
46	36.3	120	85					104	110	80	106	65				
48	36.3	120	85	104	110	80	106	64								
50	35.8	100	70	92	106	60	96	63								
52	35.8	100	70	92	106	60	96	62								
1	62	324	MEA	8	35.3	145	80	80	145	85	88	52				
				10	35.5	145	80	80	145	85	88	52				
				12	36.0	150	100	80	150	90	88	52				
				14	36.0	150	80	80	145	90	80	53				
				16	36.0	150	80	80	145	90	80	53				
				18	36.0	150	80	80	145	90	80	53				
				20	35.3	125	80	80	145	90	80	54				
									140	100	84	55				

276

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.R. Patient	Initials	Visit No.	Body Temp.	Sm. Lying Sys BP (mmHg)	Sm. Lying Dias BP (mmHg)	Sm. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)				
1	62	324	MEA	22	35.3	125	80	84	140	100	84	55				
				24	36.0	130	80	76	120	70	80	55				
				26	36.2	130	70	60	120	70	66	55				
				28	36.1	115	75	64	110	70	68	55				
				30	36.6	130	80	66	120	75	72	55				
				32	36.0	135	85	76	130	80	82	55				
				34	36.3	130	90	62	135	90	82	55				
				36	35.8	130	80	82	120	70	84	55				
				38	35.9	125	85	76	130	80	84	55				
				40	35.8	140	80	84	150	80	80	53				
				42	35.8	140	80	84	150	80	80	53				
				44	35.8	140	70	78	130	70	76	53				
				46	35.7	135	85	82	140	90	82	53				
				48	35.7	135	85	82	140	90	82	53				
				50	35.6	140	75	84	130	70	88	53				
				52	35.5	130	90	80	135	100	84	53				
				1	64	325	EMF	8	37.3	130	75	120	120	70	120	62
								10	37.1	100	60	110	100	116	60	
								12	36.6	100	70	112	90	124	60	
								14	36.7	100	70	124	90	128	59	
								16	36.5	110	85	112	105	124	60	
								18	36.8	120	70	132	140	136	60	
20	36.8	120	70					132	140	136	60					
22	36.2	120	80					120	110	136	60					
24	36.2	120	80					120	120	120	60					
26	37.0	120	75					112	120	120	60					
28	36.4	130	80					100	110	104	61					
30	36.4	130	80					100	110	104	61					
32	36.8	130	80					128	130	124	61					
34	36.6	120	75					120	110	124	61					
36	36.7	135	80	116	120	116	61									
38	36.7	140	90	112	130	132	61									
40	36.7	130	75	114	120	126	61									
42	36.4	120	75	114	115	126	61									
44	36.0	110	44	100	65	120	61									
46	36.0	130	80	128	125	132	61									
48	36.5	140	130	124	124	124	61									
50	35.7	120	90	120	110	128	61									
52	36.7	130	80	124	140	128	61									
1	67	327	MAA	8	36.7	150	100	95	100	100	105	87				
				10	36.7	150	100	95	100	105	87					
				12	36.5	165	110	100	120	116	87					
				14	36.3	140	95	100	140	88	86					

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
1	67	327	MAA	16	36.3	140	95	88	140	95	88	86
				18	36.0	140	110	80	140	100	80	85
				20	36.0	140	90	88	140	100	88	84
				22	36.0	140	90	88	140	100	88	84
				24	36.3	140	90	76	135	90	82	83
				26	36.1	145	85	66	140	90	72	82
1	70	323	MLM	8	36.1	125	85	76	120	85	78	72
				10	36.8	130	90	60	130	90	68	71
				12	36.2	130	70	80	120	70	82	71
				14	36.2	130	80	72	125	85	74	70
				16	36.2	135	80	70	135	70	78	69
				18	36.0	135	75	68	130	70	70	70
1	74	122	IVL	20	36.2	130	80	64	130	80	72	70
				22	36.4	135	75	74	130	70	78	68
				8	36.6	95	65	96	75	108	59	
				10	36.8	90	70	100	70	108	62	
				12	36.8	90	70	100	70	108	62	
				14	36.8	90	70	100	70	108	62	
1	76	124	SFA	16	36.1	90	60	68	90	60	80	62
				18	36.7	100	65	72	100	70	84	62
				20	36.7	105	65	72	100	70	84	62
				22	36.8	100	75	76	100	70	84	62
				24	36.3	100	70	84	95	96	84	62
				26	36.1	110	80	78	90	65	84	62
				28	36.3	100	88	88	95	70	92	61
				30	36.3	100	70	88	95	70	92	61
				32	36.3	115	80	64	105	80	68	63
				34	36.3	115	80	64	105	80	68	63
				36	36.3	95	55	84	95	70	92	62
				38	36.3	95	55	84	95	70	92	62
				40	36.3	105	70	80	105	85	74	62
				42	36.3	105	70	80	105	85	74	62
				44	36.8	110	80	72	100	70	76	62
				46	36.1	110	80	80	110	70	84	64
				48	36.0	105	65	82	110	70	84	64
				50	36.1	105	70	80	110	70	84	64
52	36.0	105	75	84	100	70	88	64				
1	76	124	SFA	8	36.2	110	70	76	110	70	84	71
				10	36.1	115	75	78	115	70	86	71
				12	36.2	120	75	84	115	75	86	71
				14	36.1	130	80	82	125	70	88	71
16	36.2	130	80	82	125	70	88	71				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOMETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)						
1	76	124	SFA	18	36.1	115	80	84	110	80	88	69						
				20	36.1	120	70	76	110	70	82	69						
				22	36.2	120	115	70	115	70	92	115	70	82	69			
				24	36.2	130	80	24	130	80	78	125	70	84	69			
				26	36.3	130	75	26	130	75	84	120	70	86	69			
				28	36.3	135	84	28	135	84	84	130	80	88	69			
				30	36.3	130	80	30	130	80	88	120	75	90	69			
				32	36.3	135	76	32	135	76	82	120	80	82	69			
				34	36.1	120	74	34	120	74	74	115	70	82	68			
				36	36.1	120	74	36	120	74	74	110	70	76	68			
				38	36.6	130	68	38	130	68	76	120	70	78	69			
				40	36.3	120	68	40	120	68	76	110	70	76	69			
				42	36.1	125	66	42	125	66	66	110	70	76	69			
				44	36.4	130	72	44	130	72	72	120	70	78	69			
				46	36.0	120	74	46	120	74	74	125	75	80	68			
				48	36.4	115	82	48	115	82	82	110	70	80	68			
				50	36.4	130	76	50	130	76	76	120	70	78	68			
				52	36.6	125	80	52	125	80	70	115	70	76	68			
				1	79	126	JCM	8	35.8	130	80	60	125	75	62	70		
								10	35.7	120	70	54	110	65	60	70	69	
								12	36.0	110	70	56	105	75	64	105	60	69
								14	36.2	110	70	54	110	70	58	105	60	69
16	36.1	105	75					60	105	70	64	105	60	69				
18	36.0	110	70					54	100	60	60	100	60	68				
20	36.2	110	70					62	105	64	64	105	60	68				
22	36.2	105	58					22	105	58	64	105	60	68				
24	36.0	115	72					24	115	72	72	115	75	80	68			
26	36.3	110	70					26	110	70	70	120	70	74	68			
28	36.3	115	84	28	115	84	78	110	70	76	68							
30	36.3	120	82	30	120	82	84	110	70	84	68							
32	36.3	120	82	32	120	82	84	120	70	84	68							
34	36.3	125	85	34	125	85	86	120	85	86	68							
36	36.1	130	80	36	130	80	78	125	70	84	68							
38	36.1	125	80	38	125	80	88	120	80	82	68							
40	36.1	115	70	40	115	70	88	110	70	88	68							
42	36.2	120	90	42	120	90	82	110	70	92	69							
44	36.0	130	84	44	130	84	86	115	70	86	68							
46	36.3	115	70	46	115	70	78	110	70	80	68							
48	36.0	120	88	48	120	88	88	115	75	94	68							
50	36.4	120	92	50	120	92	92	110	70	96	69							
52	36.1	130	70	52	130	70	94	120	70	96	69							
1	80	127	MEL	8	36.5	120	80	82	115	75	90	65						
				10	36.1	125	85	76	120	82	82	63						

2270

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 RESOXETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
1	80	127	MEL	12	36.0	125	80	72	120	80	78	63
1	84	130	IN	8	36.5	110	70	76	110	65	88	75
				10	36.4	130	80	64	115	75	76	75
				12	36.2	120	80	60	115	85	72	74
				14	36.3	125	85	72	120	75	78	74
				16	36.1	130	80	74	115	80	76	75
				18	36.0	120	70	76	110	70	82	75
				20	36.1	120	70	78	110	65	84	74
				22	36.5	125	80	74	110	70	78	74
				24	36.3	120	70	62	110	70	68	74
				26	36.3	115	70	58	120	75	64	73
				28	36.0	120	80	70	115	85	72	73
				30	36.2	130	80	62	120	80	68	73
				32	36.2	125	85	70	120	80	72	73
				34	36.8	120	70	58	110	70	64	74
				36	36.1	120	80	74	110	70	76	74
				38	36.4	130	80	74	120	76	76	74
				40	36.2	120	70	80	110	70	76	73
				42	36.2	120	70	84	115	65	88	73
				44	36.1	120	70	80	110	70	72	72
				46	36.3	125	80	76	120	70	78	70
				48	36.0	125	70	72	115	70	78	71
				50	36.1	120	80	82	110	80	86	71
				52	36.0	130	70	80	115	70	84	70
1	85	131	MLP	8	36.1	130	70	82	110	75	84	72
				10	36.4	130	70	62	110	65	68	73
				12	36.1	120	70	72	110	65	76	73
				14	36.3	130	70	68	115	60	74	73
				16	36.3	115	70	64	105	65	72	73
				18	36.1	115	75	70	110	65	72	73
				20	36.1	115	70	74	110	75	78	73
				22	36.4	120	80	76	110	75	78	73
				24	36.1	130	80	72	120	75	80	73
				26	36.1	120	80	76	110	70	78	73
				28	36.2	115	80	76	110	70	82	73
				30	36.2	120	70	78	110	70	84	72
				32	36.2	110	80	74	110	70	76	72
				34	36.5	130	80	76	120	70	88	73
				36	36.1	125	75	78	120	70	82	72
				38	36.4	120	70	74	115	60	78	75
				40	36.3	125	85	80	120	80	84	73
				42	36.2	115	75	84	110	80	88	72
				44	36.2	120	70	76	110	70	82	72

2280

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	D.R. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)				
1	85	131	MLP	46	36.7	125	80	84	115	70	88	71				
				48	36.1	120	70	72	110	60	74	71				
				50	36.0	130	70	68	115	70	72	115				
				52	36.2	125	75	80	120	70	82	120				
				8	37.4	120	80	76	110	80	78	110				
1	91	135	MSC	10	36.0	120	80	76	115	75	80	66				
				12	36.2	115	75	78	110	70	84	110				
				14	36.0	120	80	84	110	80	88	110				
				16	36.3	120	80	76	115	75	82	120				
				18	36.1	125	75	70	120	80	80	120				
				20	36.1	115	80	78	110	70	82	110				
				22	36.2	120	80	74	115	75	82	120				
				24	36.8	120	80	74	115	70	78	115				
				26	36.4	115	80	78	120	70	82	120				
				28	36.1	115	80	82	110	70	84	110				
				30	36.1	120	70	82	110	70	82	110				
				32	36.4	130	70	76	120	70	82	120				
				34	36.2	125	70	76	115	70	82	115				
				36	36.6	115	75	78	120	80	84	120				
				38	36.3	120	70	76	110	70	82	110				
				40	36.1	120	74	74	115	70	76	115				
				42	36.4	115	75	76	110	70	82	110				
				44	36.3	115	75	78	110	70	82	110				
				46	36.2	115	75	64	110	70	70	110				
				48	36.5	120	80	70	110	70	74	110				
				50	36.1	125	85	76	120	75	80	120				
				52	36.3	115	75	82	110	70	86	110				
				1	93	136	AL	8	36.5	120	80	72	115	85	82	89
								10	36.1	130	80	74	125	78	89	
								12	36.2	120	70	72	120	75	78	
								14	36.2	115	75	76	110	82	89	
								16	36.0	125	85	76	120	80	88	
								18	36.2	125	85	78	120	80	88	
20	36.3	125	80					76	120	70	76					
22	36.2	120	80					82	115	75	88					
24	36.7	130	70					82	120	70	88					
26	36.7	120	70					74	115	60	78					
28	36.4	120	70					72	110	70	82					
30	36.8	130	80					84	120	75	88					
32	36.6	135	80	84	130	80	88									
34	36.8	125	80	74	130	70	76									
36	36.2	130	80	80	120	65	88									
38	36.8	115	80	76	120	70	82									

2281

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 18.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)				
1	93	136	AL	40	36.2	125	80	64	120	70	68	88				
				42	36.4	110	70	72	105	65	74	88				
				44	36.2	120	80	70	125	80	74	87				
				46	36.2	125	80	72	115	70	74	86				
				48	36.0	115	75	72	110	70	74	86				
				50	36.2	110	70	66	115	70	70	86				
				52	36.0	125	80	64	115	70	68	86				
				1	94	137	RAB	8	36.2	120	80	62	110	70	68	71
								10	36.3	110	70	58	120	70	66	71
								12	36.0	120	70	64	110	70	68	71
								14	36.2	120	80	62	115	75	72	71
								16	36.2	125	80	76	115	80	78	71
18	36.5	115	80					60	110	70	66	71				
20	36.2	120	70					64	110	70	78	71				
22	36.2	110	70					60	115	75	72	71				
24	36.2	120	80					76	110	75	82	71				
26	36.0	110	70					82	120	70	84	70				
28	36.2	125	85					74	120	70	78	70				
30	36.2	110	70					76	120	80	80	70				
32	36.5	130	80	76	110	75	80	69								
34	36.0	120	80	74	110	70	86	70								
36	36.1	120	70	82	120	70	82	70								
38	36.6	130	70	74	120	65	76	70								
40	36.3	120	80	82	125	70	86	70								
42	36.0	120	70	84	125	75	84	70								
44	36.4	130	70	88	120	75	94	70								
46	36.4	125	80	86	120	70	88	70								
48	36.2	120	70	88	110	75	92	69								
50	36.2	125	84	84	120	75	90	70								
52	35.8	115	70	74	125	60	82	70								
1	97	140	RND	8	36.1	120	70	86	115	65	92	61				
				10	36.3	115	70	80	115	65	84	61				
				12	36.2	115	70	86	110	70	88	61				
				14	36.3	120	80	86	115	75	90	61				
				16	36.2	115	75	88	110	70	96	61				
				18	36.2	105	70	78	100	60	84	62				
				20	36.5	110	70	82	110	65	82	62				
				22	36.3	120	80	64	115	70	92	62				
				24	36.8	115	75	84	110	70	82	62				
				26	36.0	130	80	74	125	75	92	62				
				28	36.5	110	70	76	110	65	82	62				
				30	36.0	130	70	74	110	70	82	62				
32	36.2	120	70	68	115	60	80	60								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 RESOMETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
1	97	140	MND	34	36.2	110	70	74	105	60	80	60
				36	36.6	120	80	82	110	70	84	60
				38	36.5	115	80	84	110	70	88	60
				40	36.0	125	80	82	115	70	84	60
				42	36.2	130	80	76	120	70	84	60
				44	36.4	130	80	78	120	70	82	59
				46	36.1	125	80	82	115	70	88	58
				48	36.6	125	80	84	115	70	86	59
				50	36.8	125	80	74	115	70	78	60
				52	36.3	130	70	64	115	70	72	59
1	100	142	JMA	8	36.3	120	70	64	115	70	72	84
				10	36.1	125	80	72	115	75	76	84
				12	36.0	115	75	68	110	70	76	84
				14	36.2	125	85	72	120	80	82	84
				16	35.9	120	75	74	110	70	80	84
				18	36.3	115	75	66	110	80	78	84
				20	36.0	125	85	76	120	80	82	84
				22	36.4	125	80	76	120	75	78	84
				24	36.0	110	70	62	110	60	66	84
				26	36.1	110	70	72	110	60	74	84
				28	36.2	115	75	78	110	70	80	84
				30	36.1	120	70	72	110	70	76	84
				32	36.0	120	70	72	120	70	76	84
				34	36.0	110	70	72	120	70	74	83
				36	36.2	110	70	60	120	60	66	83
				38	36.1	110	70	66	115	65	70	83
				40	36.4	120	70	72	125	75	74	83
				42	36.4	110	70	64	115	65	70	83
				44	36.3	120	75	78	125	70	82	83
				46	36.1	115	75	74	120	80	80	83
				48	36.0	125	85	78	120	70	84	83
				50	36.4	125	80	76	115	70	82	83
				52	36.1	110	70	78	115	75	80	84
1	104	144	MTF	8	36.0	120	75	102	115	70	104	73
				10	36.4	130	80	88	120	75	98	73
				12	36.1	120	80	74	115	70	84	73
				14	36.1	125	85	90	130	90	102	71
				16	36.2	120	80	92	120	85	98	71
				18	36.1	125	85	84	120	80	92	71
				20	36.4	130	90	96	125	85	104	71
				22	36.5	130	80	92	120	85	104	71
				24	36.0	120	70	74	125	75	78	70
				26	36.1	120	70	70	125	80	72	70

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)				
1	104	144	MTF	28	36.3	120	70	70	110	70	76	70				
				30	36.2	120	80	80	110	70	78	70				
				32	36.2	125	70	70	115	70	72	70				
				34	36.5	110	60	60	100	70	64	70				
				36	36.2	125	80	80	110	70	72	70				
				38	36.0	125	80	72	120	75	76	70				
				40	36.2	125	80	68	120	70	72	70				
				42	36.0	120	70	66	110	65	72	70				
				44	35.8	115	75	66	110	70	74	69				
				46	36.1	120	70	66	115	70	74	70				
				48	36.3	130	70	64	115	75	70	69				
				50	36.2	120	70	64	115	70	68	70				
				52	36.4	120	75	74	115	70	80	70				
				1	105	145	ABS	8	36.2	130	80	76	125	75	84	63
								10	36.3	130	85	82	135	80	88	63
								12	36.4	130	80	82	115	75	90	63
								14	36.2	125	85	76	120	85	84	63
								16	36.2	130	80	82	135	80	88	63
								18	36.6	125	85	76	120	80	82	63
								20	36.4	120	70	84	110	70	88	63
								22	36.4	125	85	82	120	80	88	63
								24	36.6	130	80	74	120	80	82	63
								26	36.1	125	85	86	120	80	92	63
								28	37.0	130	80	62	120	80	92	63
								30	36.1	135	85	72	130	75	66	63
								32	36.2	120	80	82	125	85	84	63
								34	36.3	125	90	82	120	80	84	63
								36	36.4	120	80	82	120	70	92	63
								38	36.0	130	70	74	120	70	78	63
								40	36.2	125	85	60	120	80	62	64
								42	36.0	110	70	58	115	60	60	64
								44	36.1	125	80	68	115	70	72	64
								46	36.6	125	85	64	120	80	68	64
				48	36.3	110	70	60	100	60	62	64				
				50	36.4	120	70	58	100	60	62	64				
				52	36.5	115	70	56	100	60	64	64				
				1	106	146	MRN	8	36.1	130	80	68	120	75	72	67
								10	36.2	125	85	70	120	80	78	66
								12	36.5	130	90	90	125	90	92	66
								14	36.2	120	80	84	115	75	86	67
								16	36.4	120	75	76	130	80	82	67
								18	36.2	120	80	78	125	75	86	67
								20	36.6	120	75	84	125	80	85	67
								22	36.4	120	75	84	125	80	85	67

2284

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXYLINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	D.R. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)								
1	106	146	MRN	22	36.6	130	80	84	120	75	88	68								
				24	36.5	120	70	74	110	70	78	68								
				26	36.3	120	80	58	125	70	64	67								
				28	36.2	125	80	64	115	70	68	67								
				30	36.2	125	80	82	115	70	84	67								
				32	36.2	120	80	74	115	70	84	67								
				34	36.4	130	80	58	115	70	66	66								
				36	36.0	130	80	74	120	70	76	67								
				38	36.3	125	80	74	120	70	78	67								
				40	36.2	110	70	60	115	70	64	67								
				42	36.4	110	75	56	115	75	60	66								
				44	36.6	110	70	60	100	60	62	66								
				46	36.2	120	80	64	110	70	66	66								
				48	36.4	120	70	68	105	70	72	67								
				50	36.2	125	74	74	120	60	76	67								
				52	36.1	110	70	56	100	70	58	66								
				1	108	148	STB	8	36.2	120	85	84	115	80	94	61				
								10	36.3	125	85	84	120	80	94	61				
								12	36.0	120	70	84	120	75	94	61				
								14	36.3	120	75	84	115	70	94	61				
								16	36.7	125	75	72	120	70	86	61				
								18	36.3	115	75	82	120	80	86	60				
								20	36.4	115	80	72	120	70	86	60				
								22	36.3	130	70	72	120	75	85	60				
								24	36.1	120	70	74	110	70	78	60				
								26	36.2	120	80	60	125	70	66	60				
								28	36.2	120	75	74	115	70	72	60				
								30	36.1	120	70	64	110	60	64	60				
								32	36.1	125	70	68	115	70	72	60				
								34	36.1	130	80	62	110	70	72	60				
								36	36.2	120	70	72	110	70	74	59				
								38	36.6	125	70	68	115	65	74	59				
								40	36.4	110	70	82	120	80	84	59				
								42	36.1	125	80	74	115	80	78	58				
								44	36.3	120	70	72	110	70	74	58				
								46	36.2	115	75	72	110	70	76	58				
								48	36.0	110	70	68	105	65	74	58				
								50	36.0	125	70	76	115	60	78	58				
								52	36.3	120	70	74	110	70	78	58				
								1	111	331	JBF	8	36.1	125	85	64	120	75	68	71
												10	36.4	120	75	60	110	75	68	71
												12	36.5	125	85	60	120	80	78	71
												14	36.6	120	75	62	110	70	64	69

2285

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REROMETINE - PROTOCOL 2012A/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)				
1	111	331	JBF	16	36.3	115	75	60	110	70	68	69				
				18	36.2	120	80	64	110	75	68	70				
				20	36.4	115	70	70	120	70	76	70				
				22	36.3	125	75	70	120	80	76	70				
				24	36.1	120	70	72	110	70	74	70				
				26	36.4	110	70	56	100	70	62	70				
				28	36.0	120	74	56	110	70	76	71				
				30	36.0	125	80	56	110	70	60	71				
				32	36.3	110	58	105	65	62	71					
				34	36.4	110	70	54	100	60	71					
				36	36.1	110	70	68	115	70	71					
				38	36.2	110	70	60	110	70	71					
				40	36.2	130	70	60	110	70	71					
				42	36.2	120	80	82	125	80	71					
				44	36.3	115	75	78	110	75	71					
				46	36.3	125	80	86	110	70	72					
				48	36.1	125	70	82	115	70	72					
				50	36.5	130	80	94	115	70	72					
				52	36.0	120	80	94	115	70	72					
				1	114	332	CLF	8	35.7	90	60	91	85	60	112	45
								10	36.5	85	55	88	80	60	104	45
								12	36.5	90	50	72	90	40	84	44
								14	36.6	90	60	100	60	60	112	44
								16	36.6	90	60	100	90	60	112	44
								18	36.6	90	60	100	90	60	112	44
								20	36.6	90	60	100	90	60	112	44
								22	36.6	90	60	100	90	60	112	44
								24	36.1	120	80	76	110	80	82	44
								26	36.3	120	80	80	110	70	86	44
								28	36.1	120	80	72	115	70	84	45
								30	36.2	125	80	74	110	70	84	44
								32	36.0	120	70	82	110	70	84	44
34	36.3	120	70					82	125	75	84	44				
36	36.3	125	80					76	115	70	84	44				
38	36.0	130	80					82	115	70	84	45				
40	36.1	120	80	82	110	70	84	44								
42	36.3	130	70	84	110	70	86	44								
44	36.1	125	85	76	120	70	86	45								
46	36.5	130	70	86	115	65	88	45								
48	36.2	120	70	72	125	80	88	45								
50	36.3	120	70	72	110	80	82	45								
52	36.3	120	80	82	125	75	86	45								
1	115	333	ELS	8	35.0	120	90	100	120	80	100	63				
				8	35.0	120	90	100	120	80	100	63				

2280

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXYETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: PLACERO

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)				
1	115	333	ELS	10	35.0	120	90	100	120	80	100	63				
				12	35.3	110	75	88	90	60	92	60	63			
				14	36.7	105	70	92	90	50	96	50	63			
				16	36.7	105	70	92	90	50	96	50	63			
				18	36.7	105	70	92	90	50	96	50	63			
				20	35.5	100	70	90	105	60	92	60	63			
				22	35.5	100	70	90	105	60	92	60	63			
				24	36.2	120	70	84	110	70	76	70	63			
				26	36.1	125	75	72	120	70	76	70	63			
				28	36.0	125	75	84	115	60	86	60	63			
				30	36.1	120	80	84	115	70	86	70	63			
				32	36.0	120	78	84	110	70	82	70	63			
				34	36.2	120	80	76	110	70	82	70	62			
				36	36.3	120	80	76	115	80	80	75	63			
				38	36.0	130	70	72	115	70	74	70	63			
				40	36.0	120	80	68	115	70	74	70	64			
				42	36.2	125	80	78	115	75	84	75	64			
				44	36.3	120	70	82	110	70	84	70	64			
				46	36.2	130	70	86	120	70	90	70	64			
				48	35.9	120	70	84	110	60	86	60	64			
				50	36.2	120	80	82	130	75	86	75	64			
				52	36.2	130	80	84	120	70	86	70	64			
				1	122	337	HSS	8	36.5	100	70	52	95	65	58	82
								10	36.4	100	70	54	90	60	56	82
								12	36.3	100	65	48	90	60	58	82
								14	36.1	95	60	58	100	60	62	82
								16	36.3	105	60	50	95	65	56	82
								18	36.3	90	60	48	90	60	58	82
								20	36.0	115	75	56	100	70	58	82
								22	36.2	100	70	54	90	70	58	82
								24	36.2	130	80	84	120	70	86	82
								26	36.2	120	80	64	110	70	68	82
								28	36.2	120	70	68	110	75	74	83
								30	36.1	125	80	70	115	80	74	83
								32	36.2	125	80	64	115	70	68	83
								34	36.1	125	85	66	130	70	72	83
								36	36.1	120	80	70	115	70	74	83
								38	36.0	120	80	82	125	70	84	83
								40	36.2	120	70	74	110	70	76	83
								42	36.1	125	85	72	120	80	80	83
								44	36.0	115	70	72	110	70	76	84
								46	36.0	110	70	82	115	75	80	84
								48	36.5	110	70	82	110	75	84	84
								50	36.2	120	70	82	110	75	84	84
								52	36.4	130	70	72	120	75	76	84

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBONETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centro	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)
1	122	337	HSS	52	36.4	120	70	96	125	75	100	84
1	124	339	PPC	8	36.2	105	75	88	100	70	94	67
				10	36.1	110	70	94	110	75	98	67
				12	36.2	115	75	84	120	80	92	67
				14	36.1	110	80	76	115	80	84	67
				16	36.2	120	80	92	115	80	98	66
				18	36.1	115	75	86	110	70	94	66
				20	36.0	120	75	92	115	75	96	66
				22	36.2	115	80	74	120	80	78	66
				24	36.4	120	80	82	130	80	86	66
				26	36.5	125	85	82	120	80	84	66
				28	36.0	125	85	82	120	80	84	65
				30	36.2	120	70	82	110	70	80	65
				32	35.9	115	70	84	120	75	86	66
				34	36.2	125	70	94	130	75	102	66
				36	36.2	110	70	86	120	75	88	65
				38	36.1	120	80	84	110	75	90	66
				40	36.0	110	70	62	105	65	66	66
				42	35.9	115	75	62	110	70	68	66
				44	36.1	130	70	62	120	70	68	66
				46	36.2	120	75	80	115	75	86	66
				48	36.2	120	80	84	115	75	80	66
				50	35.9	120	70	78	110	75	82	66
				52	36.0	120	80	68	110	70	70	66
1	126	341	SMB	8	36.1	125	80	64	120	80	68	64
				10	36.1	105	75	60	100	75	68	64
				12	36.0	120	80	66	110	75	72	63
				14	36.2	115	75	68	110	70	74	63
				16	36.2	120	75	74	120	80	76	63
				18	36.2	120	75	68	115	70	76	63
				20	36.0	115	75	64	120	80	82	63
				22	36.1	125	85	66	120	80	68	63
				24	36.2	120	70	64	110	70	66	63
				26	36.4	125	80	60	115	70	66	63
				28	36.0	125	85	60	120	80	64	63
				30	36.2	125	80	62	120	80	66	62
				32	36.4	130	80	72	115	70	74	62
				34	36.1	125	80	64	120	70	68	62
				36	36.2	125	85	60	115	70	66	63
				38	36.4	125	75	62	120	80	66	63
				40	36.0	110	70	74	120	80	76	63
				42	35.9	120	70	80	115	70	84	64
				44	36.1	120	70	86	125	72	94	64

2288

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)				
1	126	341	SMB	46	36.2	125	85	86	120	80	90	64				
				48	36.3	130	80	76	120	70	82	64				
				50	36.0	130	80	76	120	70	82	64				
				52	36.1	120	80	90	110	92	92	64				
1	129	344	HNS	8	36.9	120	90	116	125	100	132	83				
				10	36.9	120	90	116	125	100	132	83				
				12	35.2	120	85	100	125	85	108	83				
				14	35.2	120	85	92	125	85	100	83				
				16	35.2	120	85	100	125	85	108	83				
				18	35.2	120	85	100	125	85	108	83				
				20	35.2	120	85	90	125	85	98	83				
				22	35.2	120	85	100	125	85	108	83				
				24	36.3	120	85	66	125	75	72	83				
				26	36.1	130	70	72	110	70	74	83				
				28	36.5	120	80	74	125	70	76	83				
				30	36.3	125	80	115	70	70	74	82				
				32	34.5	125	80	72	115	70	74	82				
				34	36.5	120	70	64	110	70	70	83				
				36	36.7	120	80	72	100	70	80	82				
				38	36.4	120	80	70	115	70	74	82				
				40	36.0	125	85	74	130	80	78	82				
				42	36.3	120	80	70	125	80	78	81				
				1	130	345	EGA	8	36.1	120	60	64	110	65	68	42
								10	36.1	115	75	58	105	70	64	42
								12	36.4	110	70	64	100	70	64	42
								14	36.0	110	75	66	100	70	72	42
								16	36.2	110	70	72	100	65	78	42
								18	36.3	105	70	56	100	65	64	42
								20	36.3	105	75	82	100	70	82	42
								22	36.4	110	70	72	100	65	82	42
								24	36.2	120	75	80	110	70	86	69
								26	36.0	120	80	78	115	75	88	69
				1	133	346	JPH	10	36.0	120	80	78	120	70	84	69
								12	36.2	125	80	78	120	70	88	69
14	36.3	120	70					84	110	70	78	69				
16	36.5	125	85					74	120	80	78	69				
18	36.1	125	80					82	115	70	86	68				
20	36.0	120	85					84	115	80	90	68				
22	36.3	130	84					84	120	80	86	68				
24	36.2	125	80					76	115	70	82	68				
26	36.7	120	80					82	110	70	84	68				
28	36.7	120	86					82	110	65	90	67				
30	36.1	125	80					74	115	70	74	67				

2289

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centro	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)				
1	133	346	JPH	32	36.2	120	70	68	105	70	74	67				
				34	36.1	125	80	80	120	70	68					
				36	36.4	120	70	66	110	70	72					
				38	36.0	120	80	68	110	60	72					
				40	36.1	120	80	74	115	70	76					
				42	36.2	110	70	64	115	65	67					
				44	36.3	125	70	64	115	70	66					
				46	36.1	125	85	72	120	80	67					
				48	36.1	120	80	78	110	70	67					
				50	36.3	130	72	80	120	75	67					
				52	36.1	120	70	60	125	65	67					
				1	136	349	AVP	8	36.0	135	80	82	120	80	86	61
								10	36.1	125	70	84	115	65	61	
								12	36.5	120	85	78	115	80	60	
								14	35.9	115	75	86	110	70	60	
								16	36.2	120	80	88	115	75	60	
								18	36.2	115	75	84	110	84	60	
								20	36.3	120	70	84	110	70	60	
								22	36.1	125	80	86	115	70	60	
								24	36.0	120	70	82	110	70	60	
								26	36.2	120	80	84	115	70	60	
								28	36.1	120	70	82	110	70	60	
								30	36.6	130	80	72	110	70	60	
								32	36.5	125	80	84	115	70	60	
								34	36.6	125	80	82	115	70	60	
								36	36.2	125	70	80	120	80	60	
								38	36.0	120	80	78	115	70	60	
								40	36.1	115	75	76	110	70	60	
								42	35.8	110	70	74	100	60	59	
								44	36.0	120	70	90	110	75	60	
								46	36.3	120	70	86	125	65	59	
								48	36.2	125	85	88	115	75	60	
								50	36.4	125	75	88	120	70	60	
								52	36.0	100	70	74	90	70	59	
								1	138	350	LBY	8	36.1	115	75	64
				10	36.1	100	70					56	100	60	57	
				12	36.1	115	75					60	110	64	58	
				14	36.1	120	70					52	110	58	58	
				16	36.4	120	70					58	115	75	59	
				18	36.0	115	75					52	115	70	58	
				20	36.0	125	80					58	120	75	59	
				22	36.1	115	75					62	110	66	58	
				24	36.1	125	80	74	120	70	58					

2290

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXYMINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
1	138	350	LEV	26	36.7	130	80	92	125	85	94	58
				28	36.4	120	80	84	125	70	90	58
				30	36.3	125	80	76	115	70	80	58
				32	36.4	130	70	76	135	60	82	58
				34	36.3	120	80	80	125	70	92	58
				36	36.0	120	70	82	125	65	86	58
				38	36.3	120	70	84	125	70	86	58
				40	36.1	125	80	84	115	70	76	58
				42	36.4	105	65	68	100	60	72	58
				44	36.1	115	70	70	105	60	76	58
				46	36.3	120	70	86	105	60	90	58
				48	36.3	120	70	80	100	60	82	58
				50	36.2	130	70	72	115	70	78	58
				52	36.4	110	70	72	100	70	78	59
1	141	353	AMG	8	36.6	115	75	74	110	75	76	68
				10	36.2	130	80	76	120	70	78	68
				12	36.1	120	80	72	110	70	76	66
				14	36.2	120	80	76	110	70	76	66
				16	36.1	110	70	74	105	60	78	66
				18	36.0	120	70	70	105	65	74	66
				20	36.0	125	85	74	115	75	76	66
				22	36.0	125	85	76	120	80	82	66
				24	36.4	115	75	62	110	70	66	66
				26	36.1	110	70	60	110	65	64	66
				28	36.2	120	70	64	115	60	70	66
				30	36.0	110	70	62	100	65	64	66
				32	36.3	120	80	56	110	70	58	65
				34	36.1	125	80	58	110	70	62	66
				36	36.4	120	80	62	105	70	64	66
1	143	355	JEP	8	36.6	120	75	80	110	70	92	59
				10	36.5	120	80	78	115	60	86	58
				12	36.2	120	75	84	115	75	90	57
				14	36.4	115	75	74	120	80	82	57
				16	36.3	115	75	78	110	70	86	56
				18	36.4	130	80	74	120	75	78	56
				20	36.2	125	85	76	120	80	84	55
1	145	357	SJD	8	36.0	115	70	64	90	70	76	51
				10	36.0	115	70	64	90	70	76	51
				12	36.4	90	55	72	85	60	88	51
				14	36.4	90	55	72	85	60	88	51
				16	36.4	90	65	82	100	70	96	50
				18	36.4	90	65	82	100	70	96	50

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBEXETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)				
1	145	357	SLD	20	36.4	100	65	78	95	60	92	51				
				22	36.1	100	70	84	90	60	88	51				
				24	36.2	105	60	80	90	60	84	51				
				26	36.2	110	60	80	90	60	84	51				
				28	36.1	80	50	68	90	55	76	52				
				30	36.2	100	70	80	100	65	84	51				
				32	36.2	100	70	80	100	65	84	51				
				34	36.0	100	70	80	100	65	84	51				
				36	36.0	100	70	80	100	65	84	51				
				38	36.0	100	70	80	100	65	84	51				
				40	36.2	110	80	88	100	88	88	51				
				42	36.2	110	80	88	100	88	88	51				
				44	36.1	105	75	84	105	75	88	51				
				46	36.0	100	70	80	100	70	84	51				
				48	36.0	110	75	82	90	60	80	51				
				50	36.1	120	80	82	110	70	80	51				
				52	36.3	110	80	64	100	70	66	51				
				1	149	360	SC	8	36.1	120	75	76	115	75	82	71
								10	36.1	125	80	78	120	70	82	71
								12	36.1	120	80	78	115	70	84	70
								14	35.9	115	75	68	115	75	78	70
								16	36.4	120	80	75	115	75	88	69
								18	36.1	120	80	84	115	75	88	70
								20	36.5	130	80	74	125	70	78	70
								22	36.6	130	80	78	120	80	84	70
								24	36.0	125	80	72	115	70	76	70
								26	36.6	120	70	64	110	70	68	70
								28	36.1	120	70	68	110	70	72	70
								30	36.2	110	70	70	105	70	74	70
								32	36.2	130	80	82	110	65	84	70
								34	36.0	115	80	56	100	65	64	70
								36	36.0	125	80	74	115	70	76	70
								38	36.4	125	70	64	115	75	68	70
								40	36.1	120	80	76	125	75	82	70
								42	36.1	120	70	82	110	70	86	71
								44	36.2	120	70	74	110	65	80	70
								46	36.5	125	80	84	110	70	84	70
				48	36.5	125	75	74	115	70	76	70				
				50	36.0	125	80	78	115	70	84	70				
				52	36.1	125	70	82	120	70	84	70				
				1	150	151	VA	8	36.1	115	75	78	115	70	82	66
								10	36.1	130	80	74	115	70	78	66
								12	36.0	120	80	84	120	70	86	67

2299

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXYTINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2h. Stand Sys BP (mmHg)	2h. Stand Dias BP (mmHg)	2h. Stand Heart Rate (beats/min)	Body Weight (kg)							
1	150	151	VA	14	36.3	115	75	76	120	70	80	67							
				16	36.0	110	80	74	120	80	82	70	68						
				18	36.0	115	75	78	120	80	86	120	80	68					
				20	35.9	142	80	78	120	80	84	120	70	84	68				
				22	36.1	120	70	78	125	65	88	125	65	88	68				
				24	36.5	120	80	60	110	70	66	110	70	66	68				
				26	36.2	125	70	64	115	70	67	115	70	68	67				
				28	36.6	120	70	64	120	70	68	120	70	68	67				
				30	36.2	115	70	60	110	70	62	110	70	62	67				
				32	36.4	115	70	68	110	70	74	110	70	74	67				
				34	36.0	120	80	68	110	70	67	110	70	68	67				
				36	36.5	120	80	66	125	80	72	125	70	72	67				
				38	36.3	110	70	66	110	70	74	110	70	74	67				
				3	2	61	FIL	8	37.0	125	70	78	120	70	78	71			
								10	37.0	145	70	70	130	70	70	70	71		
								12	37.2	145	70	70	140	70	70	140	70	71	
								14	37.0	100	70	72	110	70	72	110	70	71	
								16	37.0	115	70	76	110	70	75	110	70	75	70
								18	37.0	110	70	78	110	70	78	110	70	78	70
								20	36.8	115	70	80	110	70	80	110	70	80	71
								22	37.0	120	70	70	120	70	70	120	70	70	71
								24	37.0	130	70	70	130	70	70	130	70	70	72
								26	37.0	110	70	70	110	70	70	110	70	70	72
								28	37.0	140	70	70	120	70	70	120	70	70	71
								30	36.8	120	70	70	120	70	70	120	70	70	72
								32	36.5	110	70	80	110	70	80	110	70	80	72
								34	37.0	105	70	80	110	70	80	105	60	80	72
								36	36.5	110	70	78	110	70	78	110	70	78	73
								38	38.0	120	70	78	120	70	78	120	70	78	73
								40	37.0	110	70	72	110	70	72	110	70	72	73
								42	37.0	120	70	78	120	70	78	120	70	78	73
				3	3	62	DUB	8	37.0	110	70	70	110	70	70	68			
								10	37.0	120	70	76	120	70	80	120	68		
								12	36.7	110	70	80	110	70	80	110	70	65	
								14	37.0	115	70	76	115	70	76	115	70	66	
								16	37.0	120	70	70	120	70	70	120	70	66	
								18	37.0	120	70	78	120	70	78	120	70	66	
								20	37.0	110	70	76	110	70	76	110	70	66	
22	37.0	110	70					76	110	70	76	110	70	66					
24	37.0	110	70					80	110	70	80	110	70	66					
8	37.1	120	90					92	110	80	94	110	80	94	70				
10	37.1	100	70					88	100	80	90	100	80	90	70				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)				
3	10	72	TOR	12	37.5	90	60	64	110	70	66	72				
				14	36.6	110	40	76	100	50	88	71				
				16	36.8	110	60	60	100	50	80	100	71			
				18	36.9	105	50	60	95	60	82	60	71			
				20	36.8	110	60	65	100	55	70	100	72			
				22	
				8	1	211	HJ	8	36.5	140	90	82	140	90	82	76
								10	36.5	140	90	88	140	90	90	76
								12	36.5	140	90	80	140	90	80	76
								14	36.4	130	85	84	130	80	86	76
								16	36.6	140	80	78	130	80	75	75
								18	36.5	145	80	78	140	80	78	74
								20	36.4	140	80	80	140	80	80	74
								22	36.5	145	80	78	140	80	80	74
								24	36.4	140	80	78	140	80	78	73
								26	36.5	130	80	76	140	80	78	72
								28	36.4	140	80	80	130	80	82	72
								30	36.6	130	80	78	140	80	82	73
								32	36.6	140	80	80	130	80	82	73
								34	36.4	140	80	80	140	80	80	70
								36	36.6	145	80	78	145	80	78	71
								38	36.5	140	80	82	140	80	82	71
40	36.5	140	85					80	140	85	80	71				
42	36.6	140	80					82	140	80	82	70				
44	36.6	130	80					80	135	80	82	70				
46	
8	4	214	BA					8	36.7	145	90	76	145	90	78	65
								10	36.5	140	80	82	135	80	82	66
				12	36.4	130	80	76	130	80	80	65				
				14	36.5	140	80	78	140	80	78	64				
				16	36.5	140	80	78	140	80	80	64				
				18	36.5	140	80	80	140	80	82	63				
				20	36.6	140	80	78	135	80	80	63				
				22	36.5	140	80	80	140	80	80	62				
				24	36.5	130	80	78	130	80	78	62				
				26	36.5	140	80	80	140	80	80	62				
				28	36.5	140	80	82	140	80	82	62				
				30	36.6	140	90	82	140	90	84	62				
				32	36.6	145	80	80	140	80	82	63				
				34	36.4	140	80	88	135	80	88	62				
				36	36.4	140	80	78	135	80	78	62				
				38	36.5	140	80	80	135	80	80	62				
				40	36.5	130	80	82	130	80	82	62				

2294

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centro	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)					
8	4	214	BA	42	36.5	140	80	72	135	80	72	61					
				44	36.4	140	80	80	140	80	80	80	62				
				46	36.5	135	80	80	130	80	80	80	62				
				48	36.6	130	80	78	130	80	80	80	63				
				50	36.5	130	80	76	130	80	80	80	62				
				52	36.6	130	80	84	130	80	84	80	62				
				8	5	215	SL	8	36.6	120	80	78	120	80	78	78	78
								8	36.7	120	80	76	120	80	77	80	73
								10	36.2	120	80	76	115	73	75	78	73
								12	36.7	120	80	78	115	73	75	75	73
								14	36.6	120	80	80	120	80	80	80	78
								16	36.4	120	80	76	120	80	80	80	78
18	36.3	120	80					80	120	80	82	80	82				
20	36.3	120	80					78	120	80	80	80	80				
22	36.6	120	80					76	120	80	76	80	80				
24	36.6	120	80					76	120	80	78	80	80				
26	36.7	125	80					76	120	80	75	80	73				
28	36.6	130	80					76	130	80	76	80	73				
30	36.5	120	80	78	120	80	78	80	80								
32	36.5	120	80	78	120	80	78	80	80								
34	36.6	120	80	76	120	80	76	80	80								
36	36.6	120	80	76	120	80	76	80	80								
38	36.6	120	80	74	120	80	74	80	80								
40	36.4	125	80	72	120	80	72	80	80								
42	36.3	120	80	70	120	80	70	80	80								
44	36.6	120	80	70	120	80	70	80	80								
46	36.5	120	80	72	120	80	72	80	80								
48	36.4	120	80	72	120	80	72	80	80								
50	36.6	120	80	70	120	80	70	80	80								
52	36.5	120	80	72	120	80	72	80	80								
9	5	242	MF	8	36.6	140	90	80	135	85	78	68					
				10	36.5	140	90	78	140	90	80	80					
				12	36.7	140	90	80	140	90	80	80					
				14	36.3	140	80	80	140	80	82	80					
				16	36.6	140	80	76	140	80	78	80					
				18	36.5	130	90	76	130	80	78	80					
				20	36.5	140	90	75	140	90	75	80					
				22	36.6	140	90	72	135	85	78	80					
				24	36.4	130	90	76	130	90	78	80					
				26	36.5	140	90	70	140	80	73	80					
				28	36.3	140	90	72	130	80	73	80					
				30	36.8	130	80	72	130	80	74	80					

22 22 22 22 22

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
REBOXYETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
9	5	242	MF	32	36.5	130	90	70	130	80	73	68
				34	36.6	140	90	72	140	80	73	69
				36	36.4	140	90	.	140	80	.	69
				38	36.6	140	90	.	140	85	.	69
				40	36.4	150	90	72	140	90	72	69
9	8	244	KTM	42	36.6	130	90	70	130	90	69	69
				8	36.7	120	80	78	120	80	80	74
				10	36.6	120	80	76	120	80	78	74
				12	36.4	120	80	76	120	80	80	74
				14	36.5	120	80	76	120	80	80	73
9	12	247	GYT	16	36.4	120	80	76	120	80	78	74
				18	36.4	120	80	76	120	80	76	74
				20	36.5	110	80	70	110	70	74	74
				22	36.8	120	80	71	120	70	73	74
				24	36.6	120	80	72	120	80	74	74
9	13	248	BP	8	36.5	120	80	70	120	80	72	65
				10	36.6	120	80	72	110	70	75	65
				12	36.4	120	80	74	110	80	76	65
				14	36.7	130	80	72	120	70	74	66
				16	36.4	120	80	70	110	70	74	66
9	13	248	BP	18	36.5	120	80	74	110	70	76	66
				20	36.3	120	80	70	120	70	73	66
				22	36.6	125	80	74	120	70	76	66
				24	36.6	120	80	72	110	80	73	65
				26	36.6	120	80	71	115	80	72	65
9	13	248	BP	28	36.1	120	80	70	120	80	71	65
				30	36.5	120	80	70	120	80	71	65
				32	36.3	130	80	70	120	80	72	65
				34	36.3	120	80	70	120	70	74	66
				36	36.3	130	80	71	120	70	78	66
9	13	248	BP	38	36.1	120	80	68	120	69	71	66
				40	36.7	130	80	71	120	70	72	66
				42	36.8	120	80	71	110	70	72	66
				44	36.5	120	80	76	110	70	75	66
				46	36.6	130	80	75	120	70	76	66
9	13	248	BP	48	36.7	120	80	72	120	70	74	66
				50	36.5	120	80	72	110	70	75	67

2296

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
REBOXYETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)
9	13	248	BP	52	36.4	120	80	71	120	70	73	67
9	19	251	MF	8	36.3	120	80	72	120	80	75	61
				10	36.5	130	90	71	120	80	74	61
				12	36.4	120	80	68	120	70	71	61
				14	36.4	125	90	71	120	80	74	61
				16	36.4	130	90	73	120	80	75	61
				18	36.2	120	80	71	110	70	76	61
9	24	253	LGV	8	36.6	120	80	71	120	70	72	57
				10	36.7	120	80	73	110	70	75	57
				12	36.5	130	80	72	120	70	74	57
				14	36.7	120	60	76	110	60	80	56
				16	36.8	120	80	71	120	80	75	57
				18	36.5	120	70	72	100	60	73	57
				20	36.6	120	80	73	110	70	75	57
9	25	254	PH	8	36.6	140	80	72	150	80	76	56
				10	36.7	150	90	74	140	80	77	57
				12	36.5	130	80	72	130	70	75	57
				14	36.6	140	80	73	130	70	74	58
				16	36.5	150	90	70	140	80	72	58
				18	36.7	140	90	73	130	80	76	58
				20	36.6	150	90	78	140	80	79	59
				22	36.8	140	90	72	120	80	74	59
				24	36.7	130	80	73	120	70	74	59
				26	36.5	140	80	76	130	70	81	59
				28	36.6	130	80	72	130	70	75	59
				30	36.7	120	80	76	120	70	79	59
				32	36.8	140	90	76	140	80	77	59
				34	36.5	140	90	72	130	80	79	59
				36	36.7	150	90	71	140	80	75	58
				38	36.6	150	80	86	140	70	75	59
				40	36.8	150	80	86	140	70	87	59
				42	36.7	140	80	72	130	70	76	59
				44	36.4	150	80	78	140	80	79	60
				46	36.6	140	90	76	140	80	80	60
				48	36.7	150	90	76	140	80	78	60
				50	36.6	160	90	80	140	80	92	60
9	28	257	HI	8	36.7	120	80	72	120	70	73	66
				10	36.8	120	80	76	120	70	78	67
				12	36.6	120	80	70	110	70	76	67
				14	36.6	130	80	80	120	70	74	67
				16	36.7	120	80	80	110	70	81	67

2297

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)				
9	28	257	HI	18	36.8	130	70	74	120	70	75	67				
				20	36.9	120	80	71	110	70	76	68				
				22	36.6	120	90	70	120	80	73	68				
				24	36.3	120	80	76	120	70	78	68				
				26	37.0	110	70	78	110	60	80	68				
				28	36.7	120	80	82	120	70	84	68				
				10	4	272	ZSD	8	36.6	125	85	60	140	88	60	62
								10	36.7	170	90	60	168	100	68	62
12	36.6	180	105					60	180	105	60	62				
14	36.3	160	95					58	175	90	58	63				
16	36.4	185	105					62	200	105	66	62				
18			
20			
22	36.4	130	95					52	160	110	60	62				
24	36.4	130	95					52	160	110	60	62				
26	36.4	130	100					60	140	90	66	62				
10	5	273	AN	8	36.4	90	60	60	86	60	86	89				
				10	36.6	120	70	66	108	70	78	89				
				12	36.8	100	70	65	120	80	68	89				
				8	36.4	122	85	68	177	95	80	63				
				10	36.4	140	90	72	120	85	72	64				
				10	36.8	120	80	60	130	90	74	85				
10	14	279	AA	10	36.7	130	100	64	100	80	88	85				
				12	36.7	125	85	68	140	95	68	85				
				14	36.5	120	70	62	130	90	74	85				
				16	36.6	120	80	65	132	95	74	85				
				18	36.3	130	85	52	110	95	65	86				
				20	36.5	135	90	49	105	95	62	85				
				22	36.6	130	80	70	120	90	77	85				
				24	36.2	130	85	62	125	95	72	86				
				26	36.7	125	90	58	125	95	71	85				
				28	36.6	120	75	51	130	84	78	84				
				30	36.4	105	70	58	115	80	78	84				
				32	36.5	100	65	60	110	80	78	84				
				34	36.8	110	70	66	120	80	72	85				
				36	36.4	105	70	60	115	80	72	85				
38	36.4	110	65	66	125	80	68	84								
40	36.6	115	70	60	130	84	68	84								
42	36.3	115	78	66	120	85	78	84								

2268

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys Bp (mmHg)	5m. Lying Dias Bp (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys Bp (mmHg)	2m. Stand Dias Bp (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)			
10	14	279	AA	44	36.2	125	85	60	125	85	78	85			
				46	36.4	115	75	60	120	80	72	85			
				48	36.3	95	65	66	100	85	72	84			
				50	36.4	100	70	66	105	75	78	84			
				52	36.3	100	70	60	110	80	68	84			
				16	281	AJ	8	36.6	100	70	76	108	80	98	69
							10	36.4	90	55	80	103	60	88	68
	12	36.7	110				70	60	105	85	70	68			
	14	36.6	105				60	59	110	80	70	68			
	16	36.3	105				60	67	115	75	78	68			
	18	36.6	85				40	58	95	85	88	68			
	20	36.2	108				70	66	105	75	90	68			
	10	17	282	MH	22	36.3	105	65	61	110	80	78	68		
					24	36.5	115	80	70	110	85	89	67		
26					36.5	110	80	73	110	90	90	66			
28					36.2	110	75	66	110	70	98	67			
30					36.6	108	70	66	105	85	98	66			
32					36.9	105	65	82	105	70	88	64			
34					36.7	90	65	60	100	75	96	64			
36					36.4	95	65	66	100	70	90	64			
38					36.2	90	65	66	100	65	96	64			
40					36.6	100	65	64	105	75	84	64			
42					36.6	105	70	66	110	75	78	64			
44					36.7	105	60	60	110	80	68	64			
46					36.5	100	75	60	105	80	72	64			
48					36.6	100	65	66	110	75	78	64			
50	36.5	100	70	72	105	75	84	64							
52	36.7	110	75	54	102	75	78	64							
10	17	282	MH	8	36.5	140	94	76	140	100	88	75			
				10	36.4	130	80	68	140	90	79	75			
				12	36.4	140	90	62	150	95	90	75			
				14	36.3	170	100	62	165	100	72	75			
				16	36.4	145	95	66	140	105	82	75			
				18	36.4	160	100	64	150	115	90	76			
				20	36.4	140	90	63	150	105	86	75			
				22	36.5	140	95	65	145	110	90	74			
				24	36.5	160	60	60	135	105	80	75			
				26	36.6	145	105	64	165	105	76	75			
				28	36.1	140	85	55	140	100	66	74			
				30	36.5	135	80	58	150	95	72	71			
				32	36.5	130	85	60	125	105	90	71			
				34	36.5	125	75	72	140	95	90	70			
36	36.4	140	95	60	140	100	72	70							

0342

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2h. Stand Sys BP (mmHg)	2h. Stand Dias BP (mmHg)	2h. Stand Heart Rate (beats/min)	Body Weight (kg)				
10	17	282	MK	38	36.2	130	85	62	108	95	70	70				
				40	36.6	130	95	60	120	90	72	70				
				42	36.4	150	95	72	140	100	78	71				
				44	36.5	150	90	66	135	95	78	70				
				46	36.1	130	90	60	125	95	78	71				
				48	36.3	135	90	66	125	95	84	71				
				50	36.5	155	90	60	140	100	84	71				
				52	36.4	150	80	60	135	95	66	71				
				10	19	284	TN	8	36.5	115	80	70	125	80	76	70
								10	36.5	120	80	72	120	80	74	70
								12	36.4	125	70	55	125	95	95	70
								14	36.6	120	80	75	135	85	81	70
								16	36.3	120	75	60	110	70	70	70
								18	36.4	115	80	64	125	85	73	70
								20	36.4	110	90	74	115	90	90	70
								22	36.4	115	80	81	105	75	90	71
								24	36.6	120	80	68	100	75	68	71
26	35.7	125	85					78	105	80	84	70				
28	36.2	100	65					68	105	70	76	70				
30	36.3	105	75					72	110	80	82	71				
32	36.1	105	75					84	105	75	84	72				
34	36.2	120	80					68	115	80	84	72				
36	36.0	110	80					70	110	80	84	72				
38	36.3	120	80					66	115	75	76	72				
40	36.5	120	80					66	120	80	78	73				
42	36.6	120	80	68	110	70	84	72								
44	36.3	130	85	68	120	80	84	72								
46	36.4	115	85	66	125	90	84	73								
48	36.7	120	80	72	110	75	78	73								
50	36.5	115	80	78	110	85	84	74								
52	36.5	120	80	78	110	85	86	74								
10	21	288	AK	8	36.7	95	70	80	110	75	92	44				
				10	37.0	105	65	76	95	65	84	44				
				12	36.3	180	60	68	100	65	76	44				
				14	36.5	100	60	76	100	55	84	43				
				16	36.6	100	80	76	100	76	96	43				
				18	36.7	100	60	84	100	60	92	42				
				20	36.6	110	70	70	120	80	74	42				
				22	36.8	105	75	78	120	80	78	41				
				10	24	289	AL	8	36.4	135	80	90	125	80	98	68
								10	36.6	120	75	84	120	80	74	67
								12	36.2	130	70	72	124	70	72	67

2000

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)				
10	24	289	AL	14	36.5	130	70	72	120	70	78	67				
				16	36.4	135	80	76	130	80	80	68				
				18	36.4	115	80	72	110	90	92	68				
				20	36.6	130	80	78	130	95	84	68				
				22	36.4	110	75	78	130	95	84	67				
				24	36.7	125	85	74	125	85	90	68				
				26	36.6	115	85	78	115	85	96	68				
				28	36.1	110	75	72	115	85	84	68				
				30	36.3	120	80	76	115	90	78	69				
				32	36.5	125	80	72	120	85	78	69				
				34	36.5	120	80	66	115	85	74	68				
				36	36.3	125	90	68	125	90	98	69				
				38	36.4	110	70	72	110	85	90	68				
				40	36.6	105	75	72	115	95	96	69				
				42	36.4	125	80	78	125	95	85	68				
				44	36.6	110	70	72	110	75	84	69				
				46	36.4	115	75	66	115	75	78	68				
				48	36.5	120	80	72	115	75	78	68				
				50	36.4	125	85	78	125	95	90	68				
				52	36.7	115	80	60	115	80	72	69				
				8	29	293	JJ	8	36.6	90	65	82	100	70	98	63
				10	29	293	JJ	10	36.5	110	85	96	110	85	104	63
				12	36.4	118	70	80	110	70	80	100	70	84	63	
				14	36.5	110	60	60	120	60	60	120	60	72	64	
				16	36.6	110	65	66	110	65	66	120	70	78	63	
				18	36.6	115	75	72	115	75	72	105	70	84	63	
				20	36.4	115	80	78	115	80	78	110	70	90	63	
				22	36.3	110	65	66	110	65	66	120	75	80	48	
				24	36.4	110	70	72	110	70	72	115	70	84	48	
				26	36.3	115	75	66	110	75	66	115	75	84	48	
				28	36.5	120	80	72	115	80	72	115	75	84	48	
				30	36.3	110	70	72	110	70	72	115	75	84	48	
32	36.3	115	70	66	115	70	66	115	75	78	48					
34	36.5	110	70	54	110	70	54	115	75	66	48					
36	36.4	100	70	66	100	70	66	110	70	78	47					
38	36.6	95	50	60	95	50	60	110	75	72	47					

2301

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 2012A/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
10	30	294	VK	40	36.2	105	60	66	110	70	84	47
				42	36.2	110	60	72	120	80	78	47
				44	36.4	95	55	72	115	75	84	48
				46	36.8	100	60	72	110	75	78	47
				48	36.4	110	70	66	120	80	78	47
				50	36.2	100	70	72	110	75	84	47
				52	36.4	110	70	75	120	80	78	47
				8	36.5	110	70	92	115	80	98	53
				10	36.9	150	70	78	165	80	98	52
				12	36.8	140	70	84	150	80	96	52
10	37	32	HK	14	36.7	145	80	72	85	85	90	52
				16	36.5	140	75	72	150	94	96	53
				18	36.4	130	80	84	140	95	96	53
				20	36.5	125	85	78	145	95	96	53
				22	36.2	120	85	78	140	95	96	52
				24	36.1	130	80	78	140	90	90	52
				26	36.4	130	85	66	130	85	90	52
				28	36.5	100	70	72	100	70	96	54
				8	36.9	115	75	78	105	92	98	64
				10	36.8	110	75	72	110	75	90	65
10	40	33	AP	12	36.9	115	80	78	110	75	90	64
				14	36.6	120	75	78	105	80	90	64
				8	36.3	130	80	76	135	80	80	71
				10	36.4	130	80	72	130	80	80	71
				12
				8	36.6	115	75	72	110	70	80	65
				10	36.6	105	65	72	110	65	80	65
				12	36.7	110	65	68	105	65	74	65
				14	36.5	105	65	70	110	65	78	66
				16	36.5	105	65	68	105	65	76	65
10	43	296	IK	18	36.6	100	60	68	105	65	72	66
				20	36.4	105	60	70	105	60	76	66
				22	36.2	100	60	70	105	60	76	66
				24	36.4	105	65	72	110	65	76	66
				26	36.6	105	65	72	115	70	80	66
				8	36.7	120	65	72	125	65	80	61
				10	36.6	120	70	72	120	65	86	61
				12	36.6	120	70	70	115	60	80	62
				14	36.7	115	65	70	115	65	78	62
				16	36.6	120	70	72	115	65	80	62
10	44	298	AB	8	36.7	120	65	72	125	65	80	61
				10	36.6	120	70	72	120	65	86	61
				12	36.6	120	70	70	115	60	80	62
				14	36.7	115	65	70	115	65	78	62
				16	36.6	120	70	72	115	65	80	62

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOMETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)
10	45	34	KJ	8	36.7	120	60	70	126	70	78	70
				10	36.7	120	65	72	125	75	86	70
				12	36.6	115	120	65	70	80	120	70
				14	36.5	120	65	70	78	120	70	70
				16
10	46	38	TN	8	36.4	140	80	66	135	75	74	96
				10	36.5	120	80	88	100	70	120	62
				12	36.5	115	70	74	110	65	82	62
				14	36.4	115	65	72	115	65	80	62
				16	36.2	120	70	74	115	62	82	62
10	47	39	TM	18	36.5	110	75	78	100	70	88	62
				20	36.4	120	70	74	110	65	84	62
				22	36.7	115	70	72	110	65	82	62
				24	36.4	120	70	72	115	65	78	62
				26	36.1	130	70	74	120	60	80	62
				28	36.5	115	65	72	110	60	82	62
				30	36.3	110	60	74	110	60	78	62
				32	36.5	115	60	72	110	60	80	62
				34	36.8	120	65	68	115	60	74	62
				36	36.6	120	70	70	110	60	78	62
				38	36.5	115	65	68	110	60	78	62
				40	36.3	115	70	72	110	60	78	62
				42	36.7	120	65	68	110	60	76	62
44	36.4	120	75	70	115	60	78	62				
46	36.2	115	65	68	110	60	76	62				
48	36.5	120	70	72	115	60	80	62				
50	36.3	115	70	70	110	65	78	62				
52	36.4	120	70	72	110	65	78	62				
10	48	41	IP	8	36.8	110	60	80	140	90	96	53
				10	36.7	125	80	72	125	80	80	53
				12	36.8	115	65	78	115	65	82	53
				14	36.7	120	65	76	115	65	86	53
				16	36.7	125	70	72	120	70	80	53
18	36.7	120	70	78	120	70	86	53				
20	36.5	120	70	76	110	65	86	53				
10	50	44	EE	8	36.8	130	80	84	135	80	94	91
				10	36.4	135	80	84	140	80	96	91
				12	36.6	130	80	82	135	80	86	91
				14	36.4	135	80	80	135	85	92	92
				16	36.4	125	70	78	135	80	82	92

2302

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REROXETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys Bp (mmHg)	5m. Lying Dias Bp (mmHg)	5m. Lying Heart Rate (beats/min)	2n. Stand Sys Bp (mmHg)	2n. Stand Dias Bp (mmHg)	2n. Stand Heart Rate (beats/min)	Body Weight (kg)				
10	50	44	EE	18	36.5	115	70	68	115	75	70	90				
				20	36.7	120	70	72	125	75	80	88*				
				22	36.8	120	70	74	120	75	80	86				
				24	36.8	125	70	72	130	75	80	86				
				26	36.8	130	75	74	135	80	82	86				
				28	36.9	130	70	74	140	80	86	86				
				30	36.7	130	70	72	135	70	84	86				
				32	36.5	130	70	74	140	80	80	85				
				34	36.4	125	70	70	135	75	82	84				
				36	36.5	125	70	70	135	75	82	83				
				38	36.3	135	75	72	140	80	82	83				
				40	36.7	130	75	72	140	80	82	83				
				42	36.6	130	80	70	125	85	78	83				
				44	36.3	135	80	72	135	80	80	83				
				46	36.7	130	75	70	135	80	76	83				
				48	36.3	135	75	66	140	80	72	83				
				50	36.4	130	75	66	135	80	78	83				
				52	36.5	135	75	70	140	80	78	83				
				10	51	45	UL	8	36.6	120	75	72	120	70	78	60
								10	36.8	130	80	72	120	70	84	61
12	36.7	125	80					72	120	80	82	62				
14	36.6	120	80					76	115	80	82	62				
16	36.8	130	80					74	120	80	80	62				
18	36.6	120	80					72	120	80	80	62				
20	36.5	115	70					74	120	70	84	62				
22	36.6	120	80					72	120	75	78	62				
24	36.4	125	75					68	115	80	80	62				
26	36.2	125	75					68	120	75	78	62				
28	36.4	120	70					72	115	70	78	62				
30	36.2	125	75					72	120	70	78	62				
32	36.5	120	75					70	115	70	78	62				
34	36.2	120	75					70	120	70	78	62				
36	36.1	120	70					70	115	65	74	62				
38	36.3	120	70					68	120	70	74	62				
40	36.3	120	70					68	115	65	76	62				
42	36.3	120	75					72	110	62	78	62				
44	36.6	115	70					68	110	65	74	62				
46	36.4	120	70					72	110	60	74	62				
48	36.5	120	70	70	115	60	75	62								
50	36.3	120	70	66	110	60	72	62								
52	36.5	115	70	68	110	65	74	62								
10	55	49	TP	8	36.7	115	70	66	110	65	72	86				
				10	36.8	115	65	66	110	65	72	86				

2304

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CRS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)				
10	55	49	TP	12	36.6	115	70	70	115	65	80	87				
				14	36.4	110	65	68	105	60	78	88				
				16	36.4	115	70	115	65	78	88					
				18	36.5	120	70	110	65	78	88					
				20	36.7	120	70	115	65	78	88					
				22	36.6	110	70	110	65	78	88					
				24	36.5	120	70	110	65	78	88					
				26	36.4	115	65	72	110	65	78	88				
				28	36.7	120	70	115	70	78	88	88				
				30	36.2	115	70	110	65	78	88	88				
				32	36.7	120	70	110	65	78	88	88				
				34	36.4	115	70	110	65	78	88	88				
				36	36.8	120	70	110	65	78	88	88				
				38	36.7	115	70	110	65	78	88	88				
				40	36.4	120	70	115	60	72	88	88				
				42	36.5	110	60	68	105	60	72	88				
				44	36.7	120	65	72	110	60	74	88				
				46	36.7	120	70	68	115	65	74	88				
				48	36.6	120	70	70	110	60	74	88				
				50	36.8	115	65	68	105	60	72	88				
				52	36.7	120	70	60	110	65	68	88				
				10	58	52	KK	8	36.5	100	68	48	105	80	78	67
								10	36.7	100	65	48	100	80	84	66
								12	36.6	100	70	60	110	75	78	66
								14	36.4	100	65	54	105	75	72	66
								16	36.6	95	60	60	100	70	78	66
								18	36.7	85	55	54	95	65	72	66
								20	35.9	85	55	58	90	60	67	66
								22	36.2	100	65	60	110	80	84	67
								24	36.3	100	60	54	100	75	84	65
								26	36.2	95	60	54	100	70	78	66
								28	36.8	90	50	60	95	70	84	66
								30	36.4	90	60	54	100	70	84	66
								32	36.4	90	55	54	100	70	84	66
								34	36.7	100	60	60	110	75	84	67
								36	36.8	100	65	60	105	80	84	67
								38	36.8	90	65	60	105	75	84	66
								40	36.2	100	60	60	110	80	84	66
								42	36.3	95	60	60	110	70	84	66
								44	36.2	100	60	60	105	70	84	66
								46	36.8	100	60	60	105	70	84	66
								48	36.8	95	60	54	105	70	84	67
								50	36.2	95	65	60	100	70	84	67
								52	36.6	100	70	60	105	75	84	67

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: PLACERO

Centre	Patient	D.R. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)
10	60	54	JH	8	36.5	130	85	66	130	90	72	64
10	61	55	JT	8	36.2	130	80	75	120	70	92	80
				10	36.4	130	80	78	120	75	90	80
				12	36.8	130	70	74	125	70	89	80
				14	36.6	130	80	72	120	70	84	80
				16	36.5	125	80	72	120	75	82	80
				18	36.4	120	75	58	115	70	60	81
10	62	56	RR	8	36.5	130	80	74	120	80	86	106
				10	36.4	125	75	72	118	65	84	105
				12	36.3	130	80	74	130	75	80	105
				14	36.5	135	75	76	125	75	88	105
				16	36.5	130	80	76	125	80	88	105
				18	36.3	135	80	74	130	75	82	105
				20	36.7	120	75	72	115	75	80	105
				22	36.6	130	80	76	125	80	80	105
				24	36.6	130	75	74	125	75	84	105
				26	36.2	130	80	74	125	75	86	105
				28	36.3	130	80	76	130	75	82	105
				30	36.7	125	75	74	125	75	86	105
				32	36.2	135	75	76	130	70	88	105
10	64	58	LT	8	36.5	95	60	76	100	60	84	45
				10	36.4	100	60	72	110	65	74	46
				12	36.5	100	60	70	105	65	74	45
				14	36.6	105	60	68	110	65	74	45
				16	36.4	100	60	72	105	60	78	44
				18	36.5	105	60	68	105	65	78	44
				20	36.3	100	60	72	105	70	76	44
10	81	46	JN	8	36.5	120	80	74	115	75	80	63
				10	36.3	115	80	72	110	75	78	63
				12	36.8	110	80	72	110	80	80	65
				14	36.7	110	70	72	105	70	78	65
				16	36.5	120	74	72	110	65	80	65
				18	36.7	110	65	72	110	65	76	66
				20	36.4	105	60	68	100	60	76	66
				22	36.5	110	65	72	105	60	78	66
				24	36.8	120	70	72	110	65	78	66
				26	36.5	115	70	72	110	65	78	66
				28	36.5	110	65	72	110	60	78	66
				30	36.6	110	65	68	110	60	74	66
				32	36.1	120	70	70	110	60	76	66
				34	36.3	115	70	67	110	65	74	66

1300

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Contro	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
10	81	46	JN	36	36.3	120	70	70	110	60	76	66
				38	36.5	110	65	68	105	60	76	66
				40	36.5	110	60	68	105	60	78	66
				42	36.6	115	65	70	110	60	78	66
				44	36.6	120	70	72	110	60	80	66
				46	36.7	115	70	70	110	65	78	66
10	85	272	AK	8	36.8	110	70	72	105	70	76	65
10	88	276	AH	8	36.8	150	100	72	135	80	78	68
				10	36.7	145	70	72	135	70	80	68
				12	36.5	135	80	70	140	80	78	67
				14	36.8	140	80	72	140	80	78	67
				16	36.7	140	80	72	145	80	80	65
				18	36.2	145	80	68	140	75	74	63
				20	36.5	140	75	66	140	75	74	63
				22	36.2	140	80	68	145	80	76	63
				24	36.2	145	80	68	135	70	76	63
				26	36.1	145	80	66	140	75	76	63
				28	36.7	140	80	68	135	70	76	63
				30	36.3	145	80	68	135	75	75	63
				32	36.4	145	80	70	140	70	78	63
				34	36.5	140	80	74	140	75	80	62
				36	36.3	145	75	72	135	75	80	61
				40	36.2	140	75	72	140	70	78	61
				42	36.3	145	75	68	135	70	74	61
				44	36.5	140	75	66	135	70	74	61
				46	36.3	145	80	68	140	70	74	61
				48	36.4	150	80	70	145	75	76	61
				50	36.5	145	75	67	140	70	70	61
				52	36.3	140	75	60	140	70	66	62
10	92	73	LA	8	36.4	100	70	66	90	65	84	64
				10	36.6	100	70	72	90	60	84	64
				12	36.4	110	50	66	115	65	84	63
				14	36.5	95	50	78	90	60	96	64
				16	36.2	95	60	60	105	70	78	63
				18	36.4	100	60	54	110	80	80	64
				20	36.4	100	60	60	105	80	78	63
				22	36.8	100	65	72	110	75	84	64
				24	36.6	110	70	66	110	70	78	64
				26	36.4	95	60	60	105	70	78	64
				28	36.3	95	55	66	100	70	72	63
				30	36.4	100	70	72	115	80	84	64

2307

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REMOXYLINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: PLACERO

Contro	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys Bp (mmHg)	5m. Lying Dias Bp (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys Bp (mmHg)	2m. Stand Dias Bp (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
10	92	73	LA	8	36.5	90	55	60	110	70	84	62
				9	36.2	110	75	66	105	80	84	62
				10	36.8	95	60	66	105	70	90	62
				11	36.5	105	80	66	110	75	78	64
				12	36.2	105	70	66	105	80	84	63
				13	36.7	105	75	60	110	85	78	64
				14	36.4	95	65	66	105	75	72	63
				15	36.4	105	70	66	110	80	78	60
				16	36.6	120	80	58	105	75	75	57
				17	36.2	120	80	60	110	70	72	57
				18	36.7	95	55	60	110	75	78	58
10	94	273	PV	8	36.5	110	60	96	120	70	104	60
				9	36.9	110	65	98	115	70	110	60
				10	36.8	115	65	92	125	70	100	61
				11	36.7	100	60	94	105	60	102	60
				12	36.3	105	60	92	110	65	100	60
11	1	372	DF	8	36.2	120	80	76	120	90	82	88
				9	36.4	130	90	82	140	100	84	86
				10	36.4	120	90	83	120	80	82	88
				11	36.2	120	90	80	120	80	82	85
				12	35.8	130	80	72	130	90	80	87
				13	36.2	130	90	76	130	100	78	87
				14	36.8	110	90	76	110	70	80	87
				15	36.4	120	90	84	130	90	100	84
				16	37.0	130	90	72	130	80	90	83
				17	36.8	130	80	72	120	80	78	83
				18	36.8	130	90	73	130	90	73	80
				19	37.6	115	90	76	110	90	76	80
				20	37.1	130	80	84	120	80	88	78
				21	37.0	140	90	72	140	90	76	80
11	4	375	BA	8	36.4	170	110	100	160	100	102	73
				9	36.5	160	100	84	160	90	105	73
				10	36.6	150	90	80	160	100	86	73
				11	36.6	150	80	72	160	90	80	73
				12	36.2	140	90	80	165	90	86	74
				13	36.1	140	90	80	130	90	86	75
				14	36.7	140	90	72	130	90	78	74
				15	36.7	140	90	80	150	100	74	74
				16	36.8	150	90	75	150	100	82	74
11	7	376	KK	8	36.4	170	110	86	160	100	90	53
				9	36.6	160	100	86	160	100	90	54

2308

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
11	7	376	KX	12	36.8	160	100	90	150	100	96	55
				14	36.7	160	100	86	160	100	90	55
				16	36.8	150	90	84	150	100	90	54
				18	36.5	130	70	80	120	70	76	54
				20	36.8	120	70	80	130	70	85	55
				22	36.9	140	90	78	150	100	86	54
				24	36.4	140	110	80	110	100	90	54
				26	36.2	140	90	78	140	80	90	55
				28	36.6	150	100	72	150	100	86	55
				30	36.4	150	100	76	150	100	86	56
				32	36.5	150	100	74	140	100	80	55
				34	36.3	140	78	80	140	100	80	56
11	9	362	FI	8	36.5	140	100	80	130	100	88	105
				10	36.6	130	90	80	140	90	90	105
				12	36.6	140	90	86	150	90	92	106
				10	36.5	120	80	90	130	90	96	54
				12	36.7	140	100	84	140	100	90	54
				14	36.9	130	80	76	120	80	80	55
				16	36.6	110	80	92	100	80	100	54
				18	36.5	110	80	94	120	80	100	55
				20	36.4	130	80	90	120	80	96	54
				22	36.3	140	100	82	150	90	90	57
				24	36.8	140	90	86	140	100	92	57
				26	36.3	145	90	86	130	90	90	56
28	36.1	140	80	92	120	80	92	55				
30	36.5	140	90	86	130	70	88	55				
32	36.2	130	80	86	140	80	88	55				
34	36.1	140	90	90	120	80	78	54				
36	36.9	140	80	90	120	80	94	53				
38	36.7	140	80	86	130	90	94	54				
40	36.9	140	80	86	120	80	86	55				
42	36.5	130	70	78	110	80	76	54				
44	36.2	110	70	66	120	80	70	53				

2309

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.R. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
11	12	364	PJ	46	36.5	120	80	88	110	80	90	52
				48	36.4	110	70	70	110	80	76	51
				50	36.8	120	80	86	130	80	90	50
				52	36.2	130	80	78	120	80	88	50
				8	36.8	120	80	80	120	80	84	81
11	15	366	NF	10	36.6	130	90	80	130	90	87	80
				12	36.8	140	90	76	130	90	84	80
				14	36.5	130	80	83	130	80	85	79
				16	36.4	130	80	76	120	80	88	78
				18	36.7	140	90	70	120	80	82	77
				8	36.5	110	70	78	120	80	88	63
				10	36.5	110	80	82	120	80	86	63
				12	36.2	120	80	72	120	80	74	62
				14	36.3	140	100	80	140	95	78	63
				16	36.2	140	100	80	140	100	76	63
				18	36.4	130	90	78	140	100	86	63
				20	36.0	130	70	78	130	80	76	63
				22	36.6	130	80	82	110	80	86	63
				24	36.5	130	80	74	120	80	86	62
				26	36.7	120	80	72	110	70	80	61
				28	36.2	120	80	86	130	80	88	62
				30	36.5	130	80	76	130	80	82	63
				32	36.4	140	80	80	130	80	84	63
34	36.6	120	70	70	120	80	80	63				
36	36.3	130	80	72	110	70	84	62				
38	36.6	130	78	78	140	90	86	62				
40	36.2	130	80	66	120	80	78	61				
42	36.4	130	80	62	130	80	74	61				
44	36.9	130	80	66	140	80	72	60				
46	36.5	130	80	62	130	90	68	59				
48	36.2	140	80	60	130	80	70	59				
50	36.6	130	80	68	130	80	76	58				
52	36.6	140	95	80	130	90	88	58				
11	20	371	LJ	8	36.2	110	70	72	100	70	77	71
				10	36.9	130	90	82	110	80	86	71
				12	36.2	130	80	68	120	80	76	71
				14	36.6	130	80	72	110	70	68	70
12	5	95	26H	8	36.8	140	100	74	130	90	72	67
				10	36.7	130	90	100	100	100	67	
				12	36.4	150	100	100	140	100	66	
				14	36.5	130	70	72	100	70	66	

2310

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED												
REBOXETINE - PROTOCOL 20124/013												
Listing No.: 13.1												
VITAL SIGNS												
DOUBLE BLIND PHASE												
TREATMENT: PLACEBO												
Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys Bp (mmHg)	5m. Lying Dias Bp (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys Bp (mmHg)	2m. Stand Dias Bp (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
12	5	95	ZSH	16	36.5	120	80	80	120	80	88	66
				18	36.3	120	80	88	110	80	80	66
12	6	98	MK	8	36.5	110	80	72	120	80	66	51
				10	36.5	110	60	100	110	70	90	51
				12	36.3	120	90	82	110	70	90	49
				14	36.9	100	70	64	100	70	72	48
				16	36.5	120	80	90	130	100	100	47
				18	36.4	100	70	90	110	70	96	45
				20	36.6	110	70	92	100	70	90	44
				22	36.6	110	70	100	110	80	100	45
				24	36.5	100	70	80	100	70	88	46
				26	36.5	110	70	86	110	70	100	46
12	10	96	IP	8	36.7	130	90	78	160	100	120	62
				10	36.5	120	80	80	130	80	80	63
				12	35.9	130	90	88	130	90	88	63
				14	36.8	120	70	80	110	70	80	63
				16	36.2	130	90	92	120	90	96	63
				18	36.2	120	80	72	120	80	72	63
12	11	94	ER	20	36.2	120	80	80	140	80	80	63
				22	36.5	130	100	100	130	100	100	58
				24	36.2	130	90	88	130	90	100	57
				8	36.4	130	80	80	130	80	86	59
12	12	97	FSZ	10	36.6	120	90	78	120	80	58	
				12	36.8	120	80	70	120	70	80	59
12	13	103	ISZ	8	36.5	130	80	82	140	100	54	
				10	37.2	130	90	66	130	90	56	
12	14	101	GSZ	12	36.9	140	90	60	130	85	54	
				8	36.5	150	100	74	160	110	80	
12	17	108	TK	10	36.7	150	100	86	140	92	85	
				8	36.2	120	70	78	125	80	84	
12	16	108	TK	10	36.0	130	80	72	130	80	84	
				12	36.4	120	70	66	130	80	84	
12	16	108	TK	14	36.7	120	80	86	130	90	84	
				16	36.0	120	80	60	125	90	84	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 RENOXETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	
12	17	108	TK	18	36.3	120	70	74	120	85	86	84	
				20	36.2	110	80	62	125	80	88	84	
				22	36.4	120	80	72	120	90	84	84	
				24	36.1	120	70	64	120	80	76	84	
	18	109	LS	26	36.2	120	60	60	120	70	80	80	85
				28	36.3	120	70	58	125	80	78	85	
				8	36.4	120	70	72	110	70	80	53	
				10	36.2	120	80	74	120	80	82	54	
12	20	107	KSZ	12	36.3	130	90	82	130	90	86	54	
				14	36.0	120	70	72	130	80	80	54	
				16	36.4	120	80	64	120	80	70	54	
				18	36.2	120	80	64	120	80	86	54	
	22	111	MV	20	36.4	120	80	72	130	100	94	67	
				22	36.4	120	80	74	130	80	82	69	
				24	36.4	130	80	78	140	80	82	64	
				26	36.8	140	80	88	160	100	98	68	
12	22	111	MV	28	36.4	120	80	90	140	90	94	67	
				8	36.4	130	90	86	130	80	82	56	
				10	36.1	140	90	85	140	80	88	57	
				12	36.2	130	80	92	130	90	96	60	
				14	37.2	140	80	90	140	90	94	60	
				16	36.5	140	80	96	140	80	90	60	
				18	36.2	150	90	95	160	100	98	59	
				20	36.0	140	90	94	120	90	90	59	
				22	36.4	130	90	76	120	90	92	58	
				24	36.3	110	70	78	110	70	80	58	
				26	36.2	130	90	88	120	80	90	58	
				28	36.0	140	80	68	120	80	68	55	
30	36.3	130	80	76	140	90	88	55					
32	36.3	140	90	76	130	90	78	55					
34	36.2	140	100	66	160	90	60	55					
36	36.0	140	85	78	120	90	96	56					
38	36.3	130	74	74	140	120	92	57					
40	36.4	135	86	80	130	95	84	57					
42	36.2	140	90	68	150	100	82	57					

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
12	22	111	MY	44	36.8	150	90	64	145	90	64	57
				46	36.3	135	85	66	140	90	70	57
				48	36.6	140	90	68	160	95	62	56
				50	36.2	140	85	68	150	95	88	57
				52	36.4	140	90	72	160	95	70	57
12	23	112	EN	8	36.8	120	80	84	120	90	102	52
				10	36.8	130	80	86	130	80	98	52
				12	36.2	120	70	74	130	80	90	52
				14	36.8	130	80	82	140	80	110	52
				16	36.4	120	80	80	130	90	92	53
				18	36.7	125	70	96	110	70	104	54
				20	36.5	120	92	92	110	70	98	54
				22	36.2	110	84	92	120	80	86	54
				24	37.0	140	70	84	120	80	92	55
				26	36.6	130	80	86	110	70	88	53
				28	36.2	125	80	90	125	80	94	53
				12	28	116	IV	8	36.2	100	70	84
10	36.3	90	60					80	100	60	82	51
12	36.3	100	60					87	90	60	86	51
14	36.2	105	70					96	105	80	100	51
16	36.3	120	80					88	130	80	96	51
12	34	120	TOB	8	36.4	140	100	84	140	90	92	56
				10	36.3	110	80	80	120	80	88	56
				12	36.3	130	80	90	130	80	100	56
				14	36.4	120	80	80	110	70	96	56
				16	36.4	120	80	80	110	70	96	56
				18	36.3	120	80	76	110	80	90	55
				20	36.4	120	80	88	120	70	100	55
				22	36.4	120	80	88	120	80	88	55
				24	36.2	120	80	72	110	80	84	56
				26	36.2	115	80	80	125	95	95	57
				28	36.4	120	80	76	130	80	84	56
				30	36.3	130	80	86	120	80	98	57
32	36.1	140	90	74	120	95	92	58				
34	36.7	140	80	82	130	80	86	58				
36	36.3	140	80	72	130	85	70	60				
38	36.4	130	80	76	140	85	84	60				
40	36.7	140	90	86	130	80	86	60				
42	36.4	140	90	96	150	100	100	60				
44	36.5	140	100	80	150	100	92	60				
46	36.8	120	80	78	130	80	80	60				
48	35.5	140	100	84	140	100	110	61				

2313

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE-BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D. R. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
12	34	120	TGB	50	36.2	140	100	82	150	110	96	60
				52	36.0	140	90	78	140	100	84	64
12	35	119	LP	8	36.4	110	80	80	110	80	84	71
				10	36.8	120	80	78	110	80	82	70
				12	36.5	110	80	80	110	80	88	67
				14	36.6	110	70	72	110	70	80	66
				16	36.5	120	80	86	130	80	92	67
				18	36.4	120	80	80	110	80	86	67
12	37	386	EK	8	36.8	140	90	84	140	90	92	74
				10	36.8	130	90	80	140	100	92	70
				12	36.2	125	80	88	125	90	90	66
				14	36.4	140	100	88	130	90	100	67
				16	36.2	140	90	84	140	92	100	67
				18	36.2	130	80	82	130	90	88	67
13	2	224	TCS	8	36.6	120	70	80	100	70	90	55
				10	36.3	130	80	104	100	80	120	55
				12	36.2	115	70	100	115	70	112	55
				14	36.4	120	80	98	115	70	104	55
				16	36.4	115	70	92	115	70	100	56
				18	36.4	115	70	80	120	70	108	56
				20	36.5	120	80	92	115	70	112	56
				22	36.8	120	70	108	115	70	116	54
				24	36.8	100	70	119	100	70	124	55
				26	36.4	120	80	104	115	70	120	54
				28	36.2	100	60	72	100	70	80	54
				30	36.4	115	70	80	100	70	92	55
				32	36.2	100	70	68	100	60	75	55
				34	36.0	100	60	76	100	60	84	55
36	36.2	100	80	90	110	70	80	54				
38	35.7	100	60	72	90	60	72	54				
40	36.5	115	70	76	115	70	80	54				
42	36.3	110	70	72	110	70	78	54				
44	36.5	100	80	69	100	70	65	55				
46	36.1	100	80	60	90	70	75	55				
48	36.3	105	60	72	100	60	88	56				
50	36.2	120	70	80	110	70	92	56				
52	36.7	110	80	70	100	70	78	56				
13	8	228	PK	8	36.0	130	90	80	130	90	90	57
				10	36.2	120	80	76	115	90	104	57
				12	36.0	130	70	68	120	90	80	60
				14	36.2	110	70	78	100	70	89	60

2314

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

Centre	Patient	D.R. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
PHARMACIA CNS R&D REBOXETINE - PROTOCOL 2012A/013 Listing No.: 13.1 VITAL SIGNS DOUBLE BLIND PHASE TREATMENT: PLACEBO												
13	8	228	PK	16	36.1	110	90	70	115	90	75	61
	18			18	36.1	110	80	65	120	90	80	61
	20			20	36.0	110	70	72	120	90	100	63
	22			22	36.2	100	70	95	115	80	110	63
	24			24	36.7	130	80	88	120	90	96	62
	26			26	36.6	115	70	80	115	70	104	61
	28			28	36.3	120	80	96	120	90	104	60
	30			30	36.6	140	80	80	115	70	98	57
13	9	229	SZS	8	36.0	130	90	80	140	90	100	73
	10			10	36.2	120	90	72	140	90	80	74
	12			12	35.6	140	90	76	145	100	80	75
	14			14	35.7	120	60	66	120	60	84	76
	16			16	36.1	160	100	80	180	100	100	75
	18			18	36.1	140	80	84	140	90	96	72
	20			20	36.0	130	90	80	120	80	100	70
13	11	225	HS	8	36.8	120	80	62	120	70	70	84
	10			10	36.5	115	80	60	120	90	65	83
	12			12	36.5	115	80	60	110	70	65	84
	14			14	36.0	120	80	84	120	90	88	84
	16			16	36.2	120	70	88	120	80	100	84
	18			18	36.3	130	90	68	120	80	92	84
	20			20	36.8	110	70	61	120	90	76	85
	22			22	36.4	120	80	68	130	90	92	84
	24			24	36.4	120	80	70	115	70	80	84
	26			26	36.4	115	80	60	100	70	84	83
	28			28	36.3	140	70	68	130	70	76	84
	30			30	36.3	120	80	60	120	90	84	84
	32			32	36.4	110	70	75	110	80	80	84
	34			34	36.2	120	80	72	110	70	88	84
	36			36	36.6	100	80	66	110	80	72	84
	38			38	36.1	105	80	64	115	80	88	84
	40			40	36.7	115	80	60	115	80	75	84
	42			42	36.0	100	80	60	100	80	65	85
	44			44	36.2	115	70	68	115	80	80	84
	46			46	36.4	120	70	60	120	70	72	84
	48			48	36.4	120	80	64	120	90	72	84
	50			50	36.1	120	80	68	115	70	92	84
	52			52	36.2	115	80	68	115	70	80	83
13	14	217	DF	8	35.8	130	70	80	130	90	108	66
	10			10	36.8	115	90	80	120	90	100	65
	12			12	36.2	120	80	60	115	70	80	66
	14			14	36.4	130	80	80	120	80	85	65

23 15

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.1

VITAL SIGNS
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	D.S. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys Bp (mmHg)	5m. Lying Dias Bp (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys Bp (mmHg)	2m. Stand Dias Bp (mmHg)	2m. Stand Heart Rate (beats/min)	Body Height (kg)				
13	14	217	DF	16	36.0	120	90	80	130	80	90	65				
				18	36.0	130	70	64	110	70	72	65				
				20	36.2	110	60	76	110	70	84	64				
				22	36.1	120	80	95	120	80	100	66				
				24	36.2	120	70	110	115	70	116	67				
				26	36.3	115	80	76	120	80	80	67				
				28	36.3	100	70	84	100	70	120	67				
				30	36.4	100	60	80	115	70	90	68				
				32	36.3	100	80	80	115	80	95	68				
				34	36.0	120	80	80	120	80	90	68				
				36	36.1	120	70	84	110	70	84	69				
				38	36.0	120	80	80	100	70	100	68				
				40	36.4	120	70	64	135	70	92	68				
				42	36.0	115	80	70	100	70	75	69				
				44	36.0	120	80	80	110	70	110	69				
				46	36.0	120	80	83	90	80	100	69				
				48	36.1	110	70	84	110	80	88	70				
				50	36.4	120	70	86	110	70	90	70				
				52	36.4	110	60	68	100	60	76	70				
				13	15	222	KG	8	37.0	130	90	76	120	80	92	80
								10	36.3	130	70	76	120	70	76	80
								12	36.9	120	70	72	110	60	68	78
								14	36.7	130	90	70	110	80	80	77
								16	36.2	120	70	72	120	80	80	77
								18	36.2	120	70	72	110	70	80	75
								20	36.7	130	90	70	110	80	80	77
								22	36.4	120	80	76	115	70	84	76
				24	36.5	110	70	64	100	60	80	76				
				26	36.2	105	60	88	100	60	80	76				
				28	36.1	115	70	60	115	70	68	76				
				30	36.3	100	60	60	100	60	60	77				
				32	36.1	90	60	64	90	60	68	78				
				34	36.0	110	70	60	100	70	75	79				
				36	36.4	100	60	60	100	60	80	81				
				38	36.2	100	60	60	100	60	80	81				
				40	36.5	100	80	60	100	80	70	80				
				42	36.4	100	70	64	100	60	72	80				
				44	36.1	120	80	60	100	70	65	81				
				46	36.5	115	80	60	110	80	70	80				
				48	36.3	120	80	96	115	80	100	81				
				50	36.1	110	80	84	110	70	92	80				
				52	36.3	120	80	74	110	70	92	81				
				13	17	218	GSM	8	36.5	140	80	84	120	80	89	48

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXYETINE - PROTOCOL 20124/013
 Listing No.: 13.1

VITAL SIGNS
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)
13	17	218	GSM	10	36.3	110	60	80	95	60	100	48
				12	36.1	120	80	100	120	80	100	48
				14	36.3	110	70	98	100	70	104	49
				16	36.2	100	70	84	110	80	88	48
				18	36.2	110	80	84	90	60	100	47
				20	36.0	120	70	88	110	70	96	48
				22	36.1	120	70	96	90	60	120	47
				24	36.1	115	70	104	100	70	112	47
				26	35.9	100	70	76	100	60	80	48
				28	36.1	115	80	100	120	80	120	48
				30	36.0	110	70	68	100	70	80	47
				32	36.0	130	90	80	130	70	85	47
				34	36.2	130	80	84	120	80	92	49
				36	36.4	120	80	76	120	80	76	50
				38	36.2	130	80	90	115	80	95	50
				40	36.2	120	80	84	115	70	88	50
				42	36.0	140	80	88	130	80	96	51
				44	36.2	120	80	120	130	90	125	51
				46	36.8	140	90	80	150	90	85	51
				48	36.6	150	80	88	150	90	100	53
				50	36.1	120	80	84	120	90	88	51
				52	36.6	120	80	80	100	60	88	51

2317

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.2

ORTHOSTATIC HYPOTENSION
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min.)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2n. Stand Sys BP (mmHg)	2n. Stand Dias BP (mmHg)	2n. Stand Heart Rate (beats/min)	Body Weight (kg)	orthostatic hypotension		
1	129	WNS	-1	36.2	14	130	80	86	120	80	96	.	.		
			0	37.1	.	140	90	80	130	110	100	100	85.0	.	
			1	36.3	.	125	90	104	150	90	120	120	100	.	**
			2	37.0	.	125	90	104	150	90	120	120	100	.	**
			3	37.0	.	125	90	104	150	90	120	120	100	.	**
			4	37.0	.	120	80	108	130	90	120	120	100	.	.
2	31	IK	5	37.0	.	120	80	108	130	90	120	.	.	.	
			6	37.0	.	120	80	108	130	90	120	120	.	.	
			-1	37.0	20	130	100	80	180	100	120	120	100	.	**
			0	36.2	.	160	100	96	170	90	120	120	100	56.0	.
			1	36.8	.	165	100	96	180	100	116	116	100	.	.
			2	36.2	.	160	100	96	180	110	110	112	112	.	.
10	5	AN	3	36.0	.	150	100	84	170	120	112	.	.	**	
			4	36.7	.	150	95	96	180	105	112	112	.	.	
			-1	36.6	14	90	70	58	110	65	110	65	59	.	**
			0	36.6	.	86	70	23	108	60	108	60	53	89.0	**
			1	36.3	.	80	66	51	110	60	110	60	52	.	**
			2	36.4	.	96	66	66	90	66	66	66	96	.	.
10	14	AA	3	36.6	.	110	70	66	116	70	72	.	.	.	
			4	36.7	.	110	70	66	116	70	72	72	.	.	
			5	36.6	.	105	75	56	100	70	66	66	.	.	
			6	36.5	.	90	70	56	105	80	60	60	.	.	
			-1	36.6	15	130	90	62	150	105	105	68	68	.	.
			0	36.6	.	120	80	61	140	100	100	68	68	85.3	.
10	15	HT	1	36.6	.	120	70	64	100	70	71	.	.	.	
			2	36.7	.	130	80	68	180	110	70	71	.	.	
			3	36.5	.	120	80	61	110	98	110	69	69	.	**
			4	36.7	.	120	90	92	130	90	90	96	.	.	
			5	36.6	.	120	70	69	110	70	73	73	.	.	
			6	36.7	.	110	76	92	140	100	100	120	120	.	**
10	17	HR	-1	36.1	13	120	70	68	132	80	60	.	.	.	
			0	36.1	.	120	70	68	132	80	60	60	100.0	.	
			1	36.8	.	120	80	70	140	90	82	82	.	.	
			2	36.9	.	120	80	70	155	100	80	80	.	**	
			3	36.3	.	110	80	68	130	80	61	61	.	.	
			4	36.0	.	120	70	68	138	80	80	61	.	.	
10	17	HR	5	36.4	.	120	80	65	140	90	74	.	.		
			6	36.3	.	130	80	64	145	90	72	72	.	.	
			-1	36.8	16	130	90	62	140	100	66	66	77.0	**	
0	36.8	.	130	90	62	140	100	68	68	.	.				
1	36.4	.	150	90	60	160	110	64	64	.	.				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.2

ORTHOSTATIC HYPOTENSION
OPEN PHASE

Centro	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sps BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sps BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	orthostatic hypotension		
10	17	MH	2	36.5	.	125	85	54	150	100	68	.	**		
			3	36.7	.	130	80	88	100	80	94	.	.		
			4	36.5	.	160	90	69	160	90	90	64	.	.	
			5	36.6	.	130	80	88	110	80	110	90	.	.	
			6	36.7	.	110	80	92	130	92	110	92	.	.	
10	24	AL	-1	36.4	15	120	80	90	130	90	98	.	.		
			0	36.3	.	125	80	84	150	80	100	90	66.0	**	
			1	36.7	.	130	84	72	130	124	80	98	.	.	
			2	36.2	.	140	100	84	120	84	80	84	.	.	
			3	36.6	.	124	70	96	120	70	70	96	.	.	
			4	36.4	.	125	75	92	120	92	75	92	.	.	
10	25	ES	5	36.5	.	130	80	88	130	80	100	.	.		
			6	36.6	.	130	80	84	130	80	120	.	.		
			-1	36.6	13	105	80	68	120	90	90	78	.	**	
			0	36.8	.	90	60	64	130	78	78	72	79.0	.	
			1	36.5	.	120	90	68	120	98	100	122	.	.	
10	45	EJ	2	36.4	.	130	90	76	120	95	98	.	.		
			3	36.1	.	130	60	76	114	64	64	92	.	.	
			-1	36.4	14	115	70	66	120	75	75	72	71.0	.	
			0	36.4	.	115	70	66	120	75	75	72	.	.	
			1	36.4	.	120	70	66	122	76	68	68	.	.	
10	57	AG	2	36.5	.	90	60	66	120	60	86	.	**		
			3	36.5	.	118	70	70	122	75	80	.	.		
			4	36.8	.	160	100	86	150	90	100	100	.	.	
			5	36.8	.	130	80	80	130	75	88	88	.	.	
			6	36.9	.	130	80	80	130	80	80	88	.	.	
10	89	SK	-1	36.8	13	110	60	74	110	65	80	.	.		
			0	36.8	.	110	60	74	110	65	80	80	95.0	.	
			1	36.6	.	100	70	78	110	78	110	90	.	.	
			2	36.6	.	100	60	64	124	60	60	84	.	**	
			3	36.5	.	120	65	.	120	65	65	.	.	.	
			4	36.6	.	124	60	80	124	60	60	96	.	.	
10	89	SK	5	36.7	.	125	70	80	130	76	88	.	.		
			6	36.6	.	130	80	88	110	80	92	.	.		
			-1	36.6	14	100	60	76	100	76	100	80	68.0	.	
			0	36.6	.	100	60	76	100	76	100	80	.	.	
			1	36.8	.	100	60	68	95	50	50	80	.	.	
10	89	SK	2	36.9	.	100	70	80	110	60	120	.	.		
			3	36.2	.	110	60	80	100	50	100	100	.		
			4	36.2	.	100	70	80	100	50	50	100	.		
			5	37.2	.	100	60	72	122	70	92	86	.		

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.2

ORTHOSTATIC HYPOTENSION
OPEN PHASE

Centre	Pat. No.	Initials	Visit No.	Body Temp.	Respiratory Rate (breaths/min)	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	orthostatic hypotension
10	89	SK	6	36.8	.	110	60	74	105	60	90	.	.
12	8	FH	-1	36.4	20	110	80	66	110	90	88	.	.
			0	36.4	.	110	80	66	110	90	88	90.0	.
			1	36.4	.	140	80	86	130	80	100	.	.
			2	36.4	.	120	80	86	130	80	95	.	.
			3	36.5	.	115	70	94	140	90	112	.	**
			4	36.6	.	120	80	80	120	90	88	.	.
			5	36.6	.	120	90	96	130	100	116	.	.
			6	36.5	.	120	80	70	110	70	68	.	.
12	23	EN	-1	36.3	21	140	80	76	140	85	82	.	.
			0	36.6	.	140	80	82	140	80	84	53.0	.
			1	36.4	.	140	80	78	145	80	92	.	.
			2	36.8	.	130	80	82	130	90	96	.	.
			3	37.0	.	120	80	100	130	80	98	.	.
			4	37.1	.	120	80	78	130	80	96	.	.
			5	36.5	.	120	80	100	110	70	100	.	**
			6	36.4	.	110	70	96	140	70	109	.	**

2320

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013

Listing No.: 13.2

ORTHOSTATIC HYPOTENSION
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient No.	D.B. Patient Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	orthostatic hypotension				
1	37	RF	8	36.5	140	95	96	150	95	96	76					
			10	36.4	140	95	104	135	95	112	100	76				
			12	36.5	145	100	100	145	100	100	100	108	75			
			14	37.0	140	95	100	92	160	110	110	100	73	**		
			16	36.5	135	100	110	100	150	110	100	100	73			
			18	36.1	140	110	100	88	130	100	100	96	73			
			20	36.1	140	110	100	88	130	100	100	96	73			
			22	35.8	130	100	88	80	110	85	84	84	73			
			24	36.2	130	100	80	80	110	80	80	84	73			
			26	36.2	110	80	80	80	110	80	80	84	73			
			28	36.0	110	80	80	80	110	80	80	84	73			
			30	37.0	130	90	80	80	110	80	80	84	73			
			32	36.7	130	90	88	80	110	80	80	84	73			
			34	39.0	160	100	80	80	110	80	80	84	73			
			36	36.0	155	110	80	80	110	80	80	84	73			
			38	36.8	160	100	80	80	110	80	80	84	73			
			40	36.8	160	100	80	80	110	80	80	84	73			
			42	36.5	130	95	80	80	110	80	80	84	73			
			44	36.2	140	100	80	80	110	80	80	84	73			
			46	35.3	115	80	100	100	100	100	100	100	78			
			48	36.0	110	85	100	100	100	100	100	100	76			
			50	36.2	125	100	96	96	102	130	105	104	76			
			52	36.5	130	90	92	92	129	129	95	100	75			
			1	43	ARN	8	36.4	110	80	92	110	80	100	89		
						10	36.5	110	80	96	110	85	100	88	88	
						12	36.5	120	90	120	120	90	128	85	128	
						14	36.6	120	80	100	110	80	106	88	88	
						16	37.0	120	80	120	105	80	124	89	124	
						18	37.0	120	80	120	105	80	124	89	124	
						20	36.5	95	75	104	100	80	124	88	124	
						22	36.5	95	75	96	100	80	106	89	106	
						24	36.6	110	80	120	110	80	116	88	116	
26	36.2	105				80	120	110	80	120	89	120				
28	36.2	105				80	120	110	80	120	89	120				
30	36.2	105				80	120	110	80	120	89	120				
32	36.2	105				80	120	110	80	120	89	120				
34	36.2	105				80	120	110	80	120	89	120				
36	36.9	140				100	104	130	95	104	89	104				
38	36.9	140				100	104	130	95	104	89	104				
40	36.9	140	100	104	130	95	104	89	104							
42	36.9	140	100	104	130	95	104	89	104							
44	36.2	120	75	108	130	95	104	89	104							
46	36.0	105	80	116	130	90	120	89	120	**						
48	36.0	105	80	116	130	90	120	89	120	**						

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.2

ORTHOSTATIC HYPOTENSION
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	orthostatic hypotension			
1	43	309	ARN	50	36.0	105	80	94	130	90	98	91	**			
				52	36.0	105	80	90	130	90	98	91	**			
1	55	318	DMG	8	36.0	130	90	80	160	100	88	62	**			
				10	36.0	130	90	80	160	100	88	62	**			
				12	36.0	130	90	80	160	100	88	62	**			
				14	36.0	130	90	80	160	100	88	62	**			
				16	36.2	120	85	100	100	68	100	112	68	**		
				18	35.4	120	85	100	100	68	100	112	68	**		
1	146	358	LRN	8	35.7	130	90	100	140	90	100	73				
				10	35.7	120	80	92	120	90	102	74				
				12	37.8	130	90	112	95	112	95	112	73			
				14	35.3	120	80	100	100	70	100	100	70			
				16	36.2	120	85	100	90	68	100	100	68			
				18	35.4	120	85	100	100	68	100	100	68			
				20	36.4	125	95	96	135	110	100	100	68			
				22	35.7	130	90	80	150	95	92	120	92	71		
				24	36.0	120	80	80	120	90	92	120	90	92	71	
				26	36.0	120	80	80	120	80	80	120	90	92	71	**
				28	36.1	120	80	76	150	80	80	100	100	80	69	**
				30	36.0	120	80	76	150	80	80	100	100	80	69	**
				32	35.8	120	80	100	120	95	106	120	95	106	68	
				34	35.7	110	80	100	130	105	104	100	105	104	68	
				36	36.0	115	80	96	115	85	100	100	85	100	68	
				38	35.7	110	80	100	130	105	104	100	105	104	68	
				40	36.0	120	90	92	120	90	112	120	90	112	68	
				42	36.2	120	90	92	120	90	112	120	90	112	68	
				44	36.0	120	90	92	120	90	112	120	90	112	68	
				46	36.0	125	90	90	125	95	96	125	95	96	68	
48	36.0	135	95	100	130	100	112	130	100	112	68					
50	35.8	135	95	100	130	100	112	130	100	112	68					
52	36.2	135	100	98	140	105	108	140	105	108	68					
10	35	35	IN	8	36.9	110	80	94	110	80	98	51				
				10	36.8	105	75	74	105	75	90	50				
				12	36.9	115	85	90	120	105	98	50				
				14	36.7	110	80	86	115	100	98	50				
16	36.8	105	85	90	130	95	98	50	**							
10	84	63	HV	8	36.6	140	100	80	165	93	65	**				
				10	36.6	140	95	90	145	96	62	**				
				12	36.7	145	95	84	160	90	62	**				
				14	36.9	135	90	92	100	100	61	**				
16	36.5	140	100	90	130	96	60	**								
12	1	92	IB	8	36.2	130	80	78	90	88	74					

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.2

ORTHOSTATIC HYPOTENSION
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	D.B. Patient	Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	orthostatic hypotension
12	1	92	IB	10	37.0	120	90	80	140	80	92	74	
				12	35.2	150	100	96	150	100	126	74	
				14	36.5	150	100	114	140	100	100	74	
				16	36.7	170	110	100	170	110	104	72	
				18	36.2	140	90	88	165	130	92	71	**
				20	36.7	160	120	92	160	120	120	71	
				22	36.7	170	120	100	160	120	120	74	
				24	36.5	140	90	90	150	90	96	73	
				26	36.4	130	80	86	140	90	92	70	
				28	36.5	145	80	88	145	100	110	70	
				30	36.4	160	100	80	160	100	88	71	
				32	36.2	130	80	82	140	90	78	70	
				34	36.0	170	100	88	180	110	90	70	
				36	36.3	140	90	90	150	90	94	70	
				38	36.4	130	80	92	140	90	85	70	
				40	36.2	140	80	92	150	80	94	70	
				42	36.4	190	100	88	170	100	98	69	
				44	36.3	160	100	116	140	100	124	67	
				46	36.2	160	100	84	160	100	88	67	
				48	36.5	160	110	80	160	100	88	67	
				50	36.2	150	90	93	140	100	97	68	
				52	36.5	140	90	86	140	90	90	68	

11 02 02

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.2
 ORTHOSTATIC HYPOTENSION
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient No.	D.B. Patient Initials	Visit No.	Body Temp.	5m. Lying Sys BP (mmHg)	5m. Lying Dias BP (mmHg)	5m. Lying Heart Rate (beats/min)	2m. Stand Sys BP (mmHg)	2m. Stand Dias BP (mmHg)	2m. Stand Heart Rate (beats/min)	Body Weight (kg)	orthostatic hypotension
10	4	272	8	36.6	125	85	60	140	88	60	62	
			10	36.7	170	90	60	168	100	68	62	
			12	36.6	180	105	60	180	105	60	62	
			14	36.3	160	95	58	175	90	58	63	
			16	36.4	185	105	62	200	105	66	62	
			18	
			20	
			22	36.4	130	95	52	160	110	60	62	**
			24	36.4	130	95	52	160	110	60	62	**
			26	36.4	130	100	60	140	90	66	62	**
			28	36.5	160	100	60	190	105	66	63	**
			30	36.6	160	95	60	180	105	66	63	**
10	10	276	8	36.4	122	85	68	177	95	80	63	**
			10	36.4	140	90	72	120	85	72	64	
10	48	41	8	36.8	110	60	80	140	60	96	53	**
			10	36.7	125	80	72	125	90	80	53	
			12	36.8	115	65	78	115	65	82	53	
			14	36.7	120	65	76	115	65	86	53	
			16	36.7	125	70	72	120	70	80	53	
			18	36.7	120	70	78	120	70	86	53	
			20	36.5	120	70	76	110	65	86	53	

2324

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
OPEN PHASE

Centre	Patient	Initial Visit	LYING			STANDING			
			S.B.P.	D.B.P.	H.R.	S.B.P.	D.B.P.	H.R.	
			% diff	% diff	% diff	% diff	% diff	% diff	
1	6	CPH	-1	130.0	0.0	72.0	125.0	90.0	75.0
			0	130.0	0.0	68.0	125.0	85.0	75.0
			1	135.0	3.8	-5.6	140.0	85.0	-5.6
			2	140.0	7.7	0.0	140.0	85.0	-5.6
			3	140.0	7.7	0.0	135.0	80.0	-11.1
			4	130.0	0.0	0.0	135.0	80.0	-11.1
8	HVB	-1	120.0	0.0	76.0	120.0	75.0	78.0	
		0	120.0	0.0	80.0	125.0	80.0	6.7	
		1	120.0	0.0	120.0	120.0	75.0	0.0	
		2	120.0	0.0	116.0	120.0	80.0	6.7	
		3	100.0	-16.7	70.0	100.0	70.0	-6.7	
		4	120.0	0.0	110.0	115.0	80.0	6.7	
9	CCR	-1	120.0	0.0	62.0	120.0	70.0	64.0	
		0	115.0	-4.2	60.0	115.0	70.0	61.0	
		1	110.0	-8.3	70.0	120.0	70.0	80.0	
		2	100.0	-16.7	78.0	110.0	70.0	85.0	
		3	110.0	0.0	80.0	110.0	70.0	89.0	
		4	120.0	0.0	80.0	120.0	70.0	85.0	
10	LDL	-1	110.0	-8.3	80.0	120.0	85.0	88.0	
		0	110.0	-8.3	112.0	110.0	80.0	112.0	
		1	120.0	0.0	80.0	120.0	75.0	88.0	
		2	110.0	-8.3	68.0	110.0	60.0	75.0	
		3	115.0	0.0	80.0	110.0	70.0	90.0	
		4	120.0	0.0	100.0	100.0	75.0	112.0	
12	SIT	-1	80.0	0.0	80.0	85.0	70.0	100.0	
		0	80.0	0.0	80.0	85.0	60.0	100.0	
		1	120.0	50.0	70.0	100.0	60.0	120.0	
		2	85.0	6.3	95.0	85.0	60.0	106.0	
		3	85.0	6.3	95.0	85.0	60.0	106.0	
		4	90.0	12.5	106.0	90.0	60.0	114.0	

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 50 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REMOXYLINE - PROTOCOL 20124/013
 Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 OPEN PHASE

Centre	Patient	Initial	Visit	LYING			STANDING						
				S.B.P. x diff	D.B.P. x diff	H.R. x diff	S.B.P. x diff	D.B.P. x diff	H.R. x diff				
1	12	SLT	6	100.0	25.0	8.3	100.0	25.0	11.8	60.0	0.0	108.0	8.0
			-1	130.0	0.0	0.0	92.0	0.0	0.0	140.0	0.0	80.0	0.0
	14	MLC	0	130.0	0.0	0.0	92.0	0.0	0.0	140.0	0.0	80.0	0.0
			1	125.0	-3.8	0.0	92.0	0.0	0.0	115.0	0.0	100.0	25.0
			2	120.0	-7.7	80.0	86.0	-5.9	85.0	85.0	-10.7	85.0	0.0
			3	120.0	-7.7	85.0	86.0	-5.9	85.0	85.0	-14.3	85.0	0.0
16	MHC	4	110.0	-15.4	104.0	104.0	13.0	115.0	0.0	115.0	-11.1	104.0	30.0
		5	130.0	0.0	85.0	96.0	4.3	85.0	0.0	125.0	-10.7	100.0	25.0
		6	130.0	0.0	85.0	104.0	13.0	85.0	0.0	130.0	-5.6	96.0	20.0
		-1	115.0	0.0	65.0	72.0	0.0	65.0	0.0	110.0	0.0	84.0	0.0
		0	115.0	0.0	65.0	72.0	0.0	65.0	0.0	110.0	0.0	84.0	0.0
		1	100.0	-13.0	60.0	85.0	19.4	60.0	0.0	100.0	-9.1	84.0	0.0
17	CEC	2	100.0	-13.0	60.0	80.0	25.0	95.0	-13.6	70.0	7.7	100.0	14.3
		3	90.0	-11.7	60.0	80.0	14.1	60.0	0.0	80.0	0.0	96.0	14.3
		4	100.0	-13.0	60.0	88.0	22.2	60.0	0.0	110.0	0.0	92.0	9.5
		5	110.0	-4.3	70.0	88.0	11.1	70.0	0.0	105.0	-4.5	92.0	9.5
		6	100.0	-13.0	70.0	88.0	22.2	70.0	0.0	100.0	-4.5	92.0	9.5
		-1	90.0	0.0	60.0	84.0	0.0	60.0	0.0	90.0	0.0	104.0	14.3
18	TTH	0	90.0	0.0	60.0	84.0	0.0	60.0	0.0	60.0	0.0	104.0	0.0
		1	105.0	16.7	60.0	84.0	0.0	60.0	0.0	90.0	0.0	104.0	0.0
		2	90.0	0.0	60.0	84.0	0.0	60.0	0.0	100.0	0.0	112.0	7.7
		3	100.0	11.1	65.0	83.0	8.3	65.0	0.0	100.0	0.0	80.0	-23.1
		4	95.0	5.6	60.0	80.0	0.0	60.0	0.0	100.0	0.0	86.0	0.0
		5	90.0	0.0	65.0	83.0	8.3	65.0	0.0	100.0	0.0	120.0	15.4
19	SR	6	85.0	-5.6	80.0	80.0	-4.8	80.0	0.0	90.0	8.3	100.0	-3.8
		-1	110.0	0.0	70.0	68.0	0.0	70.0	0.0	110.0	0.0	74.0	0.0
		0	110.0	0.0	70.0	68.0	0.0	70.0	0.0	110.0	0.0	74.0	0.0
		1	120.0	9.1	65.0	92.0	35.3	65.0	0.0	120.0	0.0	100.0	35.1
		2	120.0	9.1	70.0	104.0	52.9	70.0	0.0	120.0	9.1	112.0	51.4
		3	115.0	4.5	80.0	72.0	5.9	80.0	0.0	90.0	-18.2	88.0	18.9
20	SR	4	110.0	0.0	75.0	96.0	41.2	75.0	0.0	110.0	0.0	96.0	29.7
		5	110.0	0.0	75.0	96.0	41.2	75.0	0.0	110.0	0.0	96.0	29.7
		6	120.0	9.1	75.0	92.0	35.3	75.0	0.0	110.0	0.0	96.0	29.7
		-1	90.0	0.0	65.0	80.0	0.0	65.0	0.0	90.0	0.0	96.0	0.0
		0	90.0	0.0	65.0	80.0	0.0	65.0	0.0	90.0	0.0	96.0	0.0
		1	95.0	5.6	60.0	80.0	0.0	60.0	0.0	75.0	-7.7	96.0	0.0

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 beats/min
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 OPEN PHASE

Centre	Patient	Initial	Visit	LIVING			STANDING									
				S.B.P. % diff	H.R. % diff	D.B.P. % diff	S.B.P. % diff	H.R. % diff	D.B.P. % diff							
1	19	SR	4	90.0	0.0	70.0	7.7	100.0	25.0 **	85.0	-5.6	65.0	0.0	100.0	4.2	
			5	100.0	11.1	70.0	7.7	92.0	15.0	90.0	0.0	65.0	0.0	108.0	12.5	
			6	100.0	11.1	70.0	7.7	100.0	25.0 **	100.0	11.1	70.0	7.7	100.0	4.2	
	20	EFC	-1	120.0	0.0	75.0	0.0	96.0	0.0	120.0	0.0	85.0	0.0	102.0	0.0	
			1	120.0	0.0	70.0	-6.7	112.0	16.7	120.0	0.0	80.0	-5.9	110.0	7.8	
			2	120.0	0.0	90.0	20.0	128.0	33.3 **	120.0	0.0	95.0	11.8	136.0	33.3 **	
3			120.0	0.0	90.0	20.0	120.0	25.0 **	130.0	8.3	90.0	5.9	128.0	25.5 **		
4			130.0	8.3	90.0	20.0	108.0	12.5	130.0	8.3	90.0	5.9	116.0	13.7		
5			140.0	16.7	90.0	20.0	100.0	4.2	130.0	8.3	90.0	5.9	120.0	17.6		
6	140.0	16.7	90.0	20.0	100.0	4.2	130.0	8.3	90.0	5.9	120.0	17.6				
21	VNC	-1	110.0	0.0	80.0	0.0	64.0	0.0	115.0	0.0	80.0	0.0	72.0	0.0		
		0	110.0	0.0	80.0	0.0	64.0	0.0	115.0	0.0	80.0	0.0	72.0	0.0		
		1	115.0	4.5	90.0	12.5	88.0	37.5	110.0	-4.3	90.0	0.0	96.0	33.3		
		2	110.0	0.0	90.0	12.5	80.0	-21.9 *	115.0	0.0	90.0	0.0	96.0	33.3		
		3	120.0	9.1	90.0	12.5	80.0	25.0	120.0	4.3	90.0	0.0	84.0	-19.4		
		4	110.0	0.0	85.0	6.3	80.0	-18.8	115.0	0.0	95.0	5.6	84.0	-16.7		
		5	125.0	13.6	90.0	12.5	84.0	31.3	120.0	4.3	90.0	0.0	88.0	-27.8		
		6	125.0	13.6	85.0	6.3	85.0	-21.9 *	120.0	4.3	80.0	-11.1	88.0	-25.0		
		24	LVF	-1	110.0	0.0	75.0	0.0	80.0	0.0	120.0	0.0	70.0	0.0	88.0	0.0
				0	110.0	0.0	75.0	0.0	80.0	0.0	120.0	0.0	70.0	0.0	88.0	0.0
				1	100.0	-9.1	80.0	6.7	80.0	0.0	100.0	-16.7	80.0	14.3	92.0	4.5
				2	100.0	-9.1	70.0	-6.7	84.0	5.0	95.0	-20.8 *	70.0	0.0	104.0	18.2
3	105.0			-4.5	75.0	0.0	80.0	0.0	100.0	-16.7	80.0	14.3	92.0	4.5		
4	110.0			0.0	80.0	6.7	84.0	5.0	105.0	-12.5	75.0	7.1	104.0	18.2		
5	120.0	9.1	85.0	13.3	84.0	-20.0	105.0	-12.5	75.0	7.1	84.0	-4.5				
6	110.0	0.0	75.0	0.0	84.0	5.0	100.0	-16.7	70.0	0.0	100.0	13.6				
26	OC	-1	115.0	0.0	90.0	0.0	92.0	0.0	110.0	0.0	95.0	0.0	104.0	0.0		
		0	115.0	0.0	90.0	0.0	92.0	0.0	110.0	0.0	95.0	0.0	104.0	0.0		
		1	110.0	-4.3	80.0	-11.1	124.0	34.8 **	110.0	0.0	80.0	-15.8	120.0	15.4		
		2	125.0	8.7	90.0	0.0	108.0	17.4	110.0	0.0	90.0	-5.3	120.0	15.4		
		3	125.0	8.7	90.0	0.0	108.0	17.4	110.0	0.0	90.0	-5.3	120.0	15.4		
		4	120.0	4.3	90.0	0.0	108.0	8.7	125.0	13.6	90.0	-5.3	120.0	15.4		
5	120.0	4.3	90.0	0.0	100.0	8.7	125.0	13.6	90.0	-5.3	120.0	15.4				
6	110.0	-4.3	80.0	-11.1	120.0	30.4 **	110.0	0.0	80.0	-15.8	120.0	15.4				
26	OC	-1	100.0	0.0	70.0	0.0	68.0	0.0	100.0	0.0	70.0	0.0	76.0	0.0		
		1	100.0	0.0	65.0	-7.1	88.0	29.4	90.0	-10.0	60.0	-14.3	104.0	36.8 **		

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 100 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
OPEN PHASE

Centre	Patient	Initial Visit	LIVING			STANDING									
			S.B.P. % diff	H.R. % diff	D.B.P. % diff	S.B.P. % diff	H.R. % diff	D.B.P. % diff							
1	26	OC	2	85.0	-15.0	60.0	-14.3	88.0	29.4	85.0	-15.0	65.0	-7.1	90.0	18.4
			3	105.0	5.0	70.0	0.0	80.0	17.6	110.0	10.0	75.0	7.1	88.0	15.8
			4	100.0	0.0	65.0	-7.1	88.0	29.4	100.0	0.0	70.0	0.0	96.0	26.3
			5	105.0	5.0	70.0	0.0	80.0	17.6	100.0	0.0	75.0	7.1	88.0	15.8
			6	100.0	0.0	65.0	-7.1	88.0	29.4	100.0	0.0	70.0	0.0	96.0	26.3
			28	RHM	-1	130.0	0.0	80.0	0.0	76.0	0.0	140.0	0.0	90.0	0.0
0	130.0	0.0	80.0		0.0	76.0	0.0	140.0	0.0	90.0	0.0	80.0	0.0		
1	125.0	-3.8	80.0		0.0	100.0	31.6	**	120.0	-14.3	90.0	0.0	92.0	15.0	
2	130.0	0.0	80.0		12.5	80.0	5.3	**	130.0	-7.1	95.0	5.6	88.0	10.0	
3	130.0	0.0	85.0		6.3	92.0	21.1	**	130.0	0.0	90.0	0.0	100.0	25.0	
4	130.0	0.0	85.0		6.3	80.0	5.3	**	140.0	0.0	105.0	16.7	84.0	5.0	
29	AFO	-1	130.0	-3.8	80.0	6.3	88.0	15.8	130.0	-7.1	90.0	0.0	88.0	10.0	
		0	120.0	0.0	80.0	0.0	68.0	5.3	**	125.0	-10.7	90.0	0.0	88.0	10.0
		1	120.0	0.0	90.0	12.5	80.0	17.6	**	120.0	-4.2	80.0	0.0	70.0	8.6
		2	120.0	0.0	90.0	12.5	80.0	17.6	**	115.0	-4.2	80.0	0.0	76.0	8.6
		3	110.0	-8.3	85.0	6.3	88.0	29.4	**	120.0	-20.8	90.0	12.5	116.0	65.7
		4	120.0	0.0	85.0	6.3	60.0	-11.8	**	95.0	-8.3	75.0	-6.3	108.0	54.3
30	ERV	-1	130.0	-4.2	90.0	12.5	100.0	47.1	**	120.0	0.0	80.0	0.0	64.0	-14.3
		0	130.0	8.3	100.0	25.0	88.0	29.4	**	130.0	8.3	90.0	12.5	100.0	42.9
		1	130.0	-7.7	90.0	-11.1	76.0	5.3	**	125.0	-4.0	80.0	0.0	80.0	0.0
		2	110.0	-15.4	80.0	-11.1	80.0	15.8	**	105.0	-4.0	75.0	-6.3	84.0	5.0
		3	120.0	-7.7	70.0	-22.2	108.0	42.1	**	110.0	-12.0	80.0	0.0	108.0	35.0
		4	130.0	0.0	85.0	-5.6	88.0	15.8	**	100.0	-20.0	65.0	-18.8	96.0	20.0
31	MAX	-1	110.0	-15.4	75.0	-16.7	64.0	-15.8	**	110.0	-12.0	80.0	0.0	120.0	50.0
		0	130.0	-15.4	80.0	-11.1	84.0	10.5	**	100.0	-20.0	80.0	0.0	60.0	-25.0
		1	100.0	5.0	78.0	-16.7	100.0	31.6	**	105.0	0.0	60.0	8.3	88.0	27.3
		2	105.0	0.0	60.0	-23.1	120.0	57.9	**	100.0	-4.8	60.0	0.0	120.0	36.4
		3	100.0	0.0	60.0	-16.7	120.0	57.9	**	105.0	0.0	65.0	8.3	120.0	36.4
		4	100.0	0.0	60.0	-23.1	120.0	57.9	**	100.0	-4.8	70.0	16.7	124.0	40.9
32	DGM	-1	110.0	20.0	70.0	-10.3	100.0	31.6	**	100.0	-4.8	70.0	16.7	112.0	27.3
		0	120.0	20.0	70.0	-10.3	100.0	31.6	**	120.0	14.3	70.0	16.7	100.0	13.6
		1	110.0	0.0	80.0	68.0	110.0	68.0	**	110.0	80.0	80.0	78.0	78.0	

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
R.R. values >= 100 beats/min
* S.B.P. values <= 100 mm Hg
D.B.P. values <= 70 mm Hg
R.R. values <= 60 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R2D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
OPEN PHASE

Centre	Patient	Initial	Visit	LYING			STANDING										
				S.B.P. % diff	H.R. % diff	D.B.P. % diff	S.B.P. % diff	H.R. % diff	D.B.P. % diff								
1	32	DCH	0	105.0	-4.5	85.0	6.3	100.0	47.1 **	105.0	-4.5	85.0	6.3	88.0	12.8		
			1	100.0	-9.1	75.0	-6.3	112.0	66.7 **	110.0	0.0	110.0	0.0	75.0	-6.3	120.0	53.8 **
			2	95.0	-13.6	70.0	-12.5	100.0	47.1 **	100.0	-9.1	100.0	-9.1	75.0	-6.3	120.0	53.8 **
			3	105.0	-4.5	80.0	0.0	120.0	76.5 **	95.0	0.0	95.0	-13.6	75.0	0.0	120.0	53.8 **
			4	105.0	-4.5	70.0	-12.5	68.0	0.0	110.0	0.0	110.0	0.0	85.0	6.3	88.0	12.8
			5	100.0	-9.1	70.0	-12.5	100.0	47.1 **	100.0	-9.1	100.0	-9.1	80.0	0.0	110.0	41.0 **
33	OFC		6	105.0	-4.5	75.0	-6.3	100.0	47.1 **	95.0	-13.6	70.0	-12.5	100.0	28.2 **		
			-1	110.0	4.5	60.0	-14.3	100.0	38.9 **	115.0	4.5	65.0	0.0	76.0	42.1 **		
			0	115.0	9.1	60.0	-14.3	100.0	38.9 **	115.0	4.5	65.0	0.0	108.0	42.1 **		
			1	100.0	-9.1	55.0	-21.4 *	100.0	38.9 **	110.0	0.0	60.0	-7.7	112.0	47.4 **		
			2	110.0	0.0	65.0	-7.1	120.0	66.7 **	105.0	-4.5	65.0	0.0	120.0	57.9 **		
			3	105.0	-4.5	65.0	-7.1	108.0	50.0 **	95.0	-13.6	55.0	-15.4	116.0	52.6 **		
36	LM		4	110.0	0.0	65.0	-7.1	120.0	66.7 **	105.0	-4.5	65.0	0.0	120.0	57.9 **		
			5	110.0	0.0	70.0	0.0	100.0	38.9 **	120.0	9.1	70.0	7.7	105.0	38.2 **		
			6	110.0	0.0	60.0	-14.3	120.0	66.7 **	115.0	4.5	65.0	0.0	128.0	68.4 **		
			-1	150.0	0.0	100.0	0.0	68.0	0.0	150.0	0.0	100.0	0.0	88.0	0.0		
			0	150.0	0.0	100.0	0.0	68.0	0.0	150.0	0.0	100.0	0.0	88.0	0.0		
			1	130.0	-13.3	85.0	-15.0	108.0	58.8 **	120.0	-26.0	90.0	-10.0	116.0	31.8 **		
37	RF		2	115.0	-10.0	80.0	-20.0	92.0	35.3	113.0	-23.5	85.0	-15.0	100.0	15.0		
			3	135.0	-10.0	95.0	-5.0	84.0	23.5	125.0	-16.7	90.0	-10.0	80.0	-9.1		
			4	135.0	-10.0	95.0	-5.0	84.0	23.5	125.0	-16.7	90.0	-10.0	80.0	-9.1		
			5	100.0	-33.3 *	80.0	-20.0	92.0	35.3	120.0	-20.0	80.0	-20.0	88.0	0.0		
			6	100.0	-33.3 *	80.0	-20.0	92.0	35.3	120.0	-20.0	80.0	-20.0	88.0	0.0		
			-1	120.0	25.0	86.0	16.3	80.0	0.0	120.0	33.3 **	90.0	11.1	80.0	25.0 **		
38	DBF		0	150.0	33.3 **	95.0	10.5	100.0	25.0 **	170.0	41.7 **	100.0	11.1	104.0	30.0 **		
			1	160.0	29.2	100.0	16.3	92.0	15.0	155.0	29.2	100.0	11.1	92.0	15.0		
			2	155.0	20.8	90.0	4.7	100.0	25.0 **	150.0	25.0	100.0	11.1	88.0	10.0		
			3	145.0	16.7	100.0	16.3	100.0	25.0 **	150.0	25.0	100.0	11.1	96.0	20.0		
			4	160.0	33.3 **	100.0	16.3	108.0	35.0 **	155.0	29.2	105.0	16.7	112.0	40.0 **		
			5	165.0	37.5 **	100.0	16.3	96.0	20.0	160.0	33.3 **	100.0	11.1	100.0	25.0 **		
39	DBF		-1	120.0	0.0	70.0	0.0	88.0	0.0	120.0	0.0	90.0	0.0	100.0	0.0		
			0	120.0	0.0	70.0	0.0	88.0	0.0	120.0	0.0	90.0	0.0	100.0	0.0		
			1	120.0	0.0	90.0	28.6	120.0	36.4 **	120.0	0.0	90.0	0.0	120.0	20.0		
			2	125.0	4.2	90.0	28.6	120.0	36.4 **	120.0	0.0	90.0	0.0	116.0	16.0		
			3	120.0	0.0	90.0	28.6	120.0	36.4 **	120.0	0.0	90.0	0.0	108.0	8.0		
			4	140.0	16.7	90.0	28.6	116.0	31.8 **	150.0	25.0	90.0	0.0	120.0	20.0		
40	DBF		5	115.0	-4.2	80.0	14.3	120.0	36.4 **	105.0	-12.5	85.0	-5.6	132.0	32.0 **		
			6	150.0	25.0	90.0	28.6	120.0	36.4 **	140.0	16.7	90.0	0.0	120.0	20.0		

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 50 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3
VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
OPEN PHASE

Centre	Patient	Initial Visit	LYING				STANDING				
			S.B.P. Z diff	D.B.P. Z diff	H.R. Z diff	S.B.P. Z diff	D.B.P. Z diff	H.R. Z diff			
1	39	ASS	-1	120.0	80.0	80.0	120.0	-8.3	80.0	-12.5	84.0
			0	120.0	0.0	76.0	110.0	-29.2	70.0	0.0	80.0
			1	96.0	-25.0	96.0	85.0	10.0	50.0	-37.5	100.0
			2	120.0	0.0	88.0	120.0	0.0	70.0	-12.5	95.0
			3	100.0	-16.7	84.0	105.0	5.0	80.0	0.0	88.0
			4	95.0	-20.8	100.0	100.0	25.0	70.0	-12.5	104.0
40	EM		5	100.0	-16.7	90.0	100.0	-16.7	70.0	-12.5	95.0
			6	110.0	-8.3	90.0	110.0	-8.3	70.0	-12.5	100.0
			-1	130.0	80.0	60.0	125.0	-20.0	80.0	0.0	60.0
			0	106.0	-23.1	80.0	100.0	16.0	70.0	-12.5	86.0
			1	100.0	-23.1	80.0	105.0	26.7	65.0	-18.8	92.0
			2	105.0	-19.2	76.0	90.0	28.0	60.0	-25.0	80.0
41	SFS		3	95.0	-26.9	92.0	90.0	-28.0	60.0	-32.0	80.0
			4	90.0	-30.8	88.0	100.0	10.0	70.0	-32.5	88.0
			5	110.0	-15.4	90.0	110.0	-12.5	70.0	-12.5	94.0
			6	100.0	-23.1	76.0	100.0	-20.0	70.0	-12.5	82.0
			-1	130.0	0.0	76.0	125.0	4.0	90.0	-5.6	80.0
			0	130.0	-7.7	80.0	130.0	-20.0	85.0	-22.2	90.0
42	ICC		1	120.0	-15.4	85.0	120.0	-4.0	80.0	-11.1	92.0
			2	120.0	-7.7	70.0	130.0	4.0	90.0	0.0	100.0
			3	120.0	-7.7	104.0	130.0	4.0	90.0	0.0	100.0
			4	120.0	-7.7	104.0	130.0	4.0	90.0	0.0	100.0
			5	110.0	-15.4	96.0	120.0	-4.0	80.0	-11.1	100.0
			6	120.0	-7.7	92.0	120.0	-4.0	80.0	-11.1	92.0
43	ARN		-1	130.0	80.0	76.0	120.0	8.3	70.0	28.6	84.0
			0	130.0	0.0	80.0	130.0	8.3	90.0	28.6	92.0
			1	120.0	-7.7	92.0	110.0	-8.3	95.0	95.7	104.0
			2	120.0	-7.7	104.0	110.0	-8.3	85.0	21.4	104.0
			3	120.0	-7.7	96.0	110.0	-8.3	80.0	14.3	100.0
			4	130.0	0.0	100.0	110.0	-8.3	70.0	0.0	118.0
44	ARN		5	120.0	-7.7	98.0	120.0	0.0	90.0	28.6	105.0
			6	125.0	-3.8	88.0	110.0	-8.3	80.0	14.3	100.0
			-1	120.0	80.0	80.0	120.0	-8.3	80.0	0.0	90.0
			0	110.0	-8.3	80.0	110.0	-8.3	85.0	6.3	100.0
			1	120.0	0.0	92.0	110.0	-8.3	80.0	0.0	88.0
			2	115.0	-4.2	60.0	105.0	-25.0	75.0	-4.3	100.0
45	ARN		3	110.0	-8.3	84.0	105.0	-8.3	60.0	-26.7	66.0
			4	110.0	-8.3	100.0	100.0	-16.7	75.0	-6.3	104.0
			5	100.0	-16.7	75.0	100.0	-16.7	75.0	-6.3	104.0

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 50 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
OPEN PHASE

Centre	Patient	Initial Visit	LYING				STANDING								
			S.B.P. % diff	H.R. % diff	D.B.P. % diff	H.R. % diff	S.B.P. % diff	D.B.P. % diff	H.R. % diff	H.R. % diff					
1	43	ARN	6	115.0	-4.2	85.0	6.3	116.0	45.0 **	130.0	8.3	90.0	12.5	120.0	33.3 **
	45	DPS	-1	130.0	38.5 **	80.0	37.5 **	90.0	-33.3	120.0	33.3 **	76.0	38.2 **	80.0	-10.0
			1	145.0	11.5	90.0	12.5	75.0	-15.6	130.0	8.3	90.0	18.4	72.0	-10.0
			2	120.0	-7.7	90.0	0.0	88.0	-2.2	115.0	-4.2	80.0	5.3	85.0	10.0
			3	150.0	15.4	90.0	12.5	84.0	-6.7	130.0	8.3	90.0	18.4	88.0	10.0
			4	140.0	7.7	90.0	12.5	84.0	-6.7	140.0	16.7	95.0	25.0 **	100.0	25.0 **
			5	140.0	7.7	90.0	12.5	84.0	-6.7	140.0	16.7	90.0	18.4	100.0	25.0 **
			6	120.0	-7.7	75.0	-6.3	88.0	-2.2	120.0	0.0	85.0	11.8	98.0	22.5
	47	MCS	-1	130.0	0.0	90.0	0.0	92.0	0.0	125.0	0.0	85.0	0.0	88.0	0.0
			1	130.0	0.0	90.0	0.0	80.0	-13.0	130.0	4.0	90.0	5.9	90.0	2.3
			2	125.0	-3.8	85.0	-5.6	108.0	17.4	105.0	-16.0	70.0	-17.6	108.0	22.7 **
			3	110.0	-15.4	90.0	0.0	90.0	-2.2	120.0	-4.0	95.0	11.8	100.0	13.6
			4	115.0	-11.5	80.0	-11.1	100.0	8.7	105.0	-16.0	75.0	-11.8	108.0	22.7 **
			5	100.0	-23.1 *	80.0	-11.1	100.0	8.7	100.0	-20.0	80.0	-5.9	100.0	13.6
			6	130.0	0.0	85.0	-5.6	108.0	17.4	120.0	-4.0	85.0	0.0	108.0	22.7 **
	48	SCM	-1	95.0	36.8	65.0	23.1	80.0	20.0	100.0	20.0	70.0	14.3	80.0	25.0 **
			1	140.0	47.4	90.0	38.5	74.0	-7.5	130.0	30.0	80.0	14.3	86.0	7.5
			2	130.0	36.8	80.0	23.1	74.0	-7.5	125.0	25.0	70.0	0.0	82.0	2.5
			3	125.0	31.6	85.0	30.8	74.0	-7.5	120.0	20.0	80.0	14.3	82.0	2.5
			4	125.0	31.6	85.0	30.8	78.0	-2.5	120.0	20.0	80.0	14.3	88.0	10.0
			5	120.0	26.3	80.0	23.1	84.0	5.0	120.0	20.0	70.0	0.0	86.0	7.5
			6	125.0	31.6	85.0	30.8	76.0	-5.0	120.0	20.0	85.0	21.4	78.0	-2.5
	30	MFA	-1	110.0	0.0	60.0	0.0	100.0	0.0	100.0	0.0	60.0	0.0	104.0	0.0
			1	110.0	0.0	70.0	16.7	100.0	0.0	110.0	10.0	70.0	16.7	105.0	1.0
			2	110.0	0.0	65.0	8.3	116.0	16.0	105.0	5.0	60.0	0.0	132.0	26.9 **
			3	115.0	4.5	70.0	16.7	96.0	-4.0	115.0	15.0	65.0	8.3	108.0	3.8
			4	110.0	0.0	80.0	33.3	80.0	-20.0	110.0	10.0	80.0	33.3	104.0	0.0
			5	115.0	4.5	80.0	33.3	84.0	-16.0	110.0	10.0	80.0	33.3	100.0	-3.8
			6	90.0	-18.2	70.0	16.7	116.0	16.0	95.0	-5.0	70.0	16.7	120.0	15.4
	51	ASA	-1	120.0	0.0	70.0	0.0	72.0	0.0	120.0	0.0	75.0	0.0	70.0	0.0
			1	100.0	-16.7	60.0	-14.3	80.0	11.1	110.0	-8.3	70.0	-6.7	95.0	35.7 **
			2	120.0	0.0	80.0	14.3	90.0	25.0	120.0	0.0	80.0	6.7	100.0	42.9 **
			3	120.0	0.0	80.0	14.3	106.0	47.2 **	120.0	0.0	80.0	6.7	102.0	45.7 **

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 100 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 OPEN PHASE

Centre	Patient	Initial	Visit	LYING				STANDING										
				S.B.P.	Z diff	D.B.P.	Z diff	H.R.	Z diff	S.B.P.	Z diff	D.B.P.	Z diff	H.R.	Z diff			
1	51	ASA	4	120.0	0.0	80.0	14.3	108.0	50.0	**	120.0	0.0	80.0	6.7	108.0	54.3	**	
			5	115.0	-4.2	75.0	7.1	92.0	27.8		120.0	0.0	75.0	0.0	92.0	31.4		
			6	115.0	-4.2	90.0	28.6	112.0	55.6	**	110.0	-8.3	90.0	20.0	112.0	60.0	**	
	52	RTS	-1	130.0	0.0	90.0	0.0	88.0	-2.3		140.0	0.0	90.0	0.0	90.0	0.0		
			1	130.0	0.0	90.0	0.0	86.0	0.0	140.0	0.0	90.0	0.0	90.0	0.0			
			2	130.0	0.0	85.0	-5.6	100.0	13.6		130.0	-7.1	95.0	5.6	108.0	20.0		
3			130.0	0.0	100.0	11.1	80.0	-9.1		100.0	-7.1	100.0	11.1	82.0	-8.9	**		
4			160.0	23.1	**	105.0	16.7	108.0	22.7	**	165.0	17.9	120.0	33.3	**	116.0	28.9	**
5			130.0	0.0	100.0	11.1	80.0	-9.1		140.0	0.0	100.0	11.1	82.0	-8.9	**		
53	JFT	6	130.0	0.0	100.0	11.1	80.0	-9.1		140.0	0.0	110.0	22.2	**	80.0	-11.1		
		-1	140.0	0.0	85.0	0.0	76.0	0.0	135.0	0.0	85.0	0.0	76.0	0.0				
		0	140.0	0.0	85.0	0.0	76.0	0.0	135.0	0.0	85.0	0.0	76.0	0.0				
		1	110.0	-21.4	80.0	-5.9	84.0	10.5		110.0	-18.5	75.0	-11.8	88.0	15.8			
		2	105.0	-25.0	70.0	-17.6	70.0	-7.9		115.0	-14.8	75.0	-11.8	70.0	-7.9			
		3	110.0	-21.4	70.0	-17.6	96.0	26.3	*	100.0	-18.5	70.0	-11.8	100.0	31.6	**		
54	JD	4	110.0	-21.4	75.0	-11.8	96.0	26.3	*	100.0	-17.6	70.0	-11.8	80.0	5.3	**		
		5	110.0	-21.4	75.0	-11.8	96.0	26.3	*	105.0	-22.2	75.0	-17.6	104.0	36.8	**		
		6	100.0	-28.6	*	70.0	-17.6	92.0	21.1		100.0	-25.9	*	70.0	-17.6	92.0	21.1	
		-1	140.0	0.0	90.0	0.0	74.0	0.0	130.0	0.0	90.0	0.0	74.0	0.0				
		0	140.0	0.0	90.0	0.0	74.0	0.0	130.0	0.0	90.0	0.0	74.0	0.0				
		1	120.0	-14.3	80.0	-11.1	70.0	-5.4		110.0	-15.4	80.0	-11.1	70.0	-5.4			
55	DMG	2	110.0	-21.4	85.0	-5.6	84.0	13.5		120.0	-15.4	80.0	-11.1	72.0	-2.7	**		
		3	120.0	-14.3	90.0	0.0	84.0	13.5		120.0	-7.7	90.0	0.0	100.0	35.1	**		
		4	110.0	-21.4	80.0	-11.1	88.0	18.9		110.0	-15.4	85.0	-5.6	96.0	29.7	**		
		-1	130.0	0.0	70.0	0.0	68.0	0.0	130.0	0.0	70.0	0.0	76.0	0.0				
		0	130.0	0.0	70.0	0.0	68.0	0.0	130.0	0.0	70.0	0.0	76.0	0.0				
		1	120.0	-7.7	90.0	28.6	80.0	17.6		120.0	-7.7	90.0	28.6	90.0	18.4	**		
58	ARM	2	120.0	0.0	70.0	0.0	90.0	32.4		125.0	-3.8	80.0	14.3	100.0	31.6	**		
		3	140.0	7.7	75.0	7.1	84.0	23.5		130.0	0.0	80.0	14.3	96.0	26.3	**		
		4	140.0	7.7	80.0	14.3	88.0	29.4		155.0	19.2	85.0	21.4	96.0	26.3	**		
		5	150.0	15.4	85.0	21.4	84.0	23.5		130.0	0.0	80.0	14.3	92.0	21.1	**		
		6	105.0	-19.2	65.0	-7.1	92.0	35.3		95.0	-26.9	*	70.0	0.0	104.0	36.8	**	
		-1	90.0	0.0	60.0	0.0	76.0	0.0	100.0	0.0	70.0	0.0	80.0	0.0				
0	90.0	0.0	60.0	0.0	76.0	0.0	100.0	0.0	70.0	0.0	80.0	0.0						
1	110.0	22.2	85.0	41.7	88.0	15.8		100.0	0.0	70.0	0.0	100.0	25.0	**				
2	115.0	27.8	80.0	33.3	88.0	15.8		120.0	20.0	80.0	14.3	88.0	10.0					
3	120.0	33.3	80.0	33.3	80.0	5.3		120.0	20.0	80.0	14.3	88.0	10.0					

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 100 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
OPEN PHASE

Centre	Patient	Initial Visit	LIVING			STANDING											
			S.B.P. % diff	D.B.P. % diff	H.R. % diff	S.B.P. % diff	D.B.P. % diff	H.R. % diff									
1	58	ARM	4	115.0	27.8	85.0	41.7	68.0	0.0	100.0	0.0	80.0	14.3	80.0	0.0		
		5	105.0	16.7	75.0	25.0	72.0	-5.3	110.0	10.0	85.0	21.4	80.0	0.0	88.0	10.0	
		6	100.0	11.1	75.0	25.0	76.0	0.0	100.0	0.0	80.0	14.3	80.0	0.0	80.0	0.0	
	59	SFF	-1	100.0	0.0	60.0	0.0	80.0	0.0	105.0	0.0	60.0	0.0	60.0	0.0	88.0	0.0
			0	100.0	-20.0	60.0	0.0	100.0	25.0	85.0	-19.0	65.0	8.3	60.0	0.0	116.0	31.8
			1	80.0	0.0	60.0	0.0	76.0	-7.5	100.0	-4.8	60.0	0.0	60.0	0.0	116.0	-6.8
2		100.0	0.0	60.0	0.0	70.0	16.7	108.0	35.0	95.0	0.0	70.0	16.7	100.0	13.6		
3		100.0	0.0	60.0	0.0	75.0	25.0	116.0	48.0	105.0	0.0	75.0	25.0	108.0	22.7		
4		115.0	15.0	60.0	0.0	100.0	0.0	100.0	-4.8	100.0	0.0	70.0	16.7	108.0	22.7		
61	HVC	5	100.0	0.0	60.0	0.0	100.0	25.0	110.0	4.8	80.0	33.3	80.0	0.0	100.0	13.6	
		6	90.0	-10.0	65.0	8.3	100.0	25.0	115.0	0.0	80.0	0.0	80.0	0.0	76.0	0.0	
		-1	110.0	0.0	65.0	0.0	72.0	0.0	115.0	0.0	80.0	0.0	80.0	0.0	76.0	0.0	
	1	115.0	4.5	80.0	23.1	104.0	44.4	100.0	-13.0	80.0	0.0	80.0	0.0	108.0	42.1		
	2	105.0	-4.5	70.0	7.7	88.0	22.2	90.0	-21.7	90.0	-18.5	80.0	0.0	96.0	26.3		
	3	120.0	9.1	80.0	23.1	80.0	11.1	105.0	-8.7	75.0	-6.3	100.0	0.0	96.0	26.3		
62	MEA	4	120.0	9.1	75.0	15.4	88.0	22.2	95.0	-17.4	65.0	-18.8	65.0	-18.8	96.0	26.3	
		5	110.0	0.0	75.0	15.4	84.0	16.7	100.0	-13.0	70.0	-12.5	100.0	0.0	100.0	31.6	
		6	110.0	0.0	80.0	23.1	88.0	22.2	95.0	-17.4	70.0	-12.5	100.0	0.0	100.0	31.6	
	0	130.0	0.0	80.0	0.0	80.0	0.0	130.0	0.0	80.0	0.0	80.0	0.0	88.0	0.0		
	1	120.0	-7.7	80.0	0.0	92.0	15.0	120.0	-7.7	80.0	0.0	80.0	0.0	100.0	13.6		
	2	140.0	7.7	80.0	0.0	88.0	10.0	130.0	0.0	90.0	12.5	100.0	18.8	100.0	13.6		
66	TCG	3	140.0	7.7	90.0	12.5	92.0	15.0	140.0	7.7	95.0	18.8	90.0	12.5	100.0	13.6	
		4	150.0	15.4	90.0	12.5	95.0	18.8	150.0	15.4	90.0	12.5	100.0	13.6	100.0	13.6	
		5	140.0	7.7	90.0	12.5	95.0	18.8	140.0	7.7	90.0	12.5	100.0	13.6	100.0	13.6	
	6	110.0	-15.4	80.0	0.0	88.0	10.0	95.0	-26.9	70.0	-12.5	100.0	0.0	100.0	13.6		
	-1	120.0	0.0	90.0	0.0	80.0	0.0	130.0	0.0	90.0	0.0	90.0	0.0	88.0	0.0		
	0	120.0	-8.3	90.0	0.0	100.0	25.0	100.0	-23.1	80.0	-11.1	80.0	0.0	110.0	25.0		
67	MAA	1	110.0	-8.3	80.0	-11.1	100.0	15.0	110.0	-15.4	75.0	-16.7	100.0	13.6	100.0	13.6	
		2	110.0	-8.3	80.0	-11.1	92.0	15.0	100.0	-15.4	75.0	-16.7	100.0	13.6	100.0	13.6	
		3	120.0	0.0	80.0	-16.7	100.0	25.0	100.0	-23.1	80.0	0.0	90.0	0.0	128.0	45.5	
	4	100.0	-16.7	75.0	-16.7	100.0	40.0	120.0	-7.7	80.0	-11.1	80.0	0.0	92.0	4.5		
	5	110.0	-8.3	90.0	0.0	112.0	40.0	120.0	-23.1	80.0	-11.1	80.0	0.0	110.0	0.0		
	6	100.0	-16.7	80.0	-11.1	92.0	15.0	100.0	-23.1	80.0	0.0	90.0	0.0	110.0	0.0		

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 90 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
OPEN PHASE

Centre	Patient	Initial	Visit	LYING			STANDING			H.R. % diff							
				S.B.P.	D.B.P.	H.R.	S.B.P.	D.B.P.	H.R.								
				% diff	% diff	% diff	% diff	% diff	% diff	% diff							
1	67	MAA	2	140.0	-6.7	100.0	11.1	108.0	10.2	140.0	-6.7	104.0	15.6	104.0	-5.5		
			3	140.0	-6.7	100.0	11.1	96.0	-2.0	160.0	11.1	100.0	6.7	100.0	11.1	104.0	-5.5
			4	160.0	6.7	120.0	33.3	96.0	-2.0	160.0	6.7	120.0	6.7	120.0	33.3	102.0	-7.3
			5	190.0	26.7	120.0	33.3	112.0	14.3	190.0	26.7	120.0	26.7	130.0	44.4	112.0	1.8
			6	150.0	0.0	100.0	11.1	95.0	-3.1	150.0	0.0	100.0	0.0	100.0	11.1	105.0	-4.5
						-1	115.0	-4.3	80.0	-12.5	104.0	-21.2	115.0	-8.7	85.0	-23.5	112.0
69	RFA	1	105.0	-8.7	70.0	-12.5	84.0	-19.2	100.0	-13.0	70.0	-17.6	90.0	-19.6	90.0	-21.4	
		2	110.0	-4.3	70.0	-12.5	80.0	-23.1	100.0	-13.0	70.0	-17.6	88.0	-21.4	88.0	-21.4	
		3	100.0	-13.0	70.0	-12.5	82.0	-21.2	100.0	-13.0	70.0	-17.6	85.0	-23.5	85.0	-23.2	
		4	105.0	-8.7	75.0	-6.3	78.0	-25.0	100.0	-13.0	70.0	-17.6	86.0	-23.2	86.0	-23.2	
		5	105.0	-8.7	75.0	-6.3	76.0	-26.9	100.0	-13.0	70.0	-17.6	84.0	-25.0	84.0	-25.0	
		6	100.0	-13.0	70.0	-12.5	80.0	-23.1	90.0	-21.7	90.0	-21.7	70.0	-29.4	90.0	-19.6	
70	MLH	-1	130.0	-15.4	80.0	-6.3	72.0	0.0	120.0	-4.2	80.0	0.0	80.0	0.0	80.0	5.0	
		1	110.0	-15.4	75.0	0.0	72.0	0.0	115.0	-4.2	80.0	0.0	80.0	0.0	84.0	5.0	
		2	120.0	-7.7	75.0	-6.3	84.0	16.7	100.0	-16.7	80.0	0.0	100.0	0.0	96.0	20.0	
		3	115.0	-11.5	80.0	0.0	96.0	33.3	100.0	-16.7	80.0	0.0	100.0	0.0	100.0	25.0	
		4	120.0	-7.7	90.0	12.5	92.0	27.8	120.0	0.0	80.0	0.0	80.0	0.0	96.0	20.0	
		5	130.0	0.0	80.0	0.0	80.0	11.1	120.0	0.0	85.0	6.3	80.0	0.0	80.0	0.0	
71	ONV	1	105.0	0.0	70.0	0.0	88.0	0.0	100.0	0.0	70.0	0.0	96.0	0.0	96.0	0.0	
		1	105.0	0.0	70.0	0.0	88.0	0.0	100.0	0.0	70.0	0.0	96.0	0.0	96.0	0.0	
		2	92.0	-12.4	60.0	-14.3	88.0	0.0	100.0	0.0	75.0	7.1	92.0	7.1	92.0	-4.2	
		3	110.0	4.8	70.0	0.0	120.0	36.4	110.0	10.0	70.0	0.0	100.0	0.0	96.0	0.0	
		4	100.0	-4.8	70.0	0.0	88.0	0.0	100.0	0.0	80.0	0.0	80.0	0.0	120.0	25.0	
		5	100.0	-4.8	80.0	14.3	96.0	9.1	100.0	0.0	80.0	0.0	80.0	0.0	104.0	8.3	
73	FMA	1	130.0	0.0	100.0	0.0	76.0	0.0	130.0	0.0	100.0	0.0	60.0	0.0	60.0	0.0	
		1	130.0	0.0	90.0	-10.0	88.0	15.8	130.0	0.0	90.0	0.0	88.0	0.0	88.0	46.7	
		2	130.0	0.0	90.0	-10.0	94.0	23.7	130.0	0.0	90.0	0.0	90.0	-10.0	76.0	26.7	
		3	130.0	0.0	90.0	-10.0	76.0	0.0	140.0	7.7	110.0	10.0	100.0	10.0	76.0	26.7	
		4	130.0	0.0	100.0	0.0	88.0	15.8	130.0	0.0	105.0	5.0	100.0	0.0	100.0	66.7	
		5	140.0	7.7	95.0	-5.0	88.0	15.8	135.0	3.8	95.0	-5.0	92.0	5.0	92.0	53.3	
74	IVL	-1	120.0	0.0	80.0	0.0	88.0	0.0	115.0	3.8	75.0	0.0	95.0	-5.0	92.0	53.3	
		1	120.0	0.0	80.0	0.0	88.0	0.0	115.0	3.8	75.0	0.0	95.0	-5.0	92.0	53.3	

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 50 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
OPEN PHASE

Centre	Patient	Initial	Visit	LIVING				STANDING											
				S.B.P. % diff	D.B.P. % diff	H.R. % diff	S.B.P. % diff	D.B.P. % diff	H.R. % diff										
1	74	IVL	0	90.0	-25.0	*	60.0	-25.0	*	88.0	0.0	95.0	-17.4	70.0	-6.7	88.0	-12.0		
			1	105.0	-12.5		70.0	-13.6		76.0	-17.4		95.0	-17.4	70.0	0.0	92.0	-8.0	
			2	90.0	-25.0	*	65.0	-18.8		80.0	-9.1		80.0	-30.4	*	60.0	-20.0	100.0	0.0
			3	90.0	-25.0	*	70.0	-12.5		80.0	-9.1		90.0	-21.7	*	70.0	0.0	90.0	-10.0
			4	95.0	-20.8	*	65.0	-18.8		96.0	9.1		95.0	-17.4		75.0	0.0	108.0	8.0
			5	95.0	-20.8	*	65.0	-18.8		96.0	9.1		95.0	-17.4		75.0	0.0	108.0	8.0
75	ELF		-1	90.0	0.0		60.0	0.0		66.0	-9.1	100.0	0.0	70.0	0.0	80.0	0.0		
			1	95.0	5.6		65.0	8.3		92.0	39.4	80.0	-20.0	60.0	0.0	80.0	0.0		
			2	100.0	11.1		80.0	33.3		80.0	21.2	100.0	0.0	80.0	0.0	96.0	20.0		
			3	100.0	11.1		70.0	16.7		80.0	21.2	95.0	-5.0	70.0	7.1	80.0	0.0		
			4	100.0	11.1		80.0	33.3		96.0	45.5	100.0	0.0	80.0	0.0	100.0	25.0		
			5	95.0	5.6		70.0	16.7		100.0	51.5	**	90.0	-10.0	70.0	0.0	104.0	30.0	
90	JSS		-1	105.0	0.0		70.0	0.0		76.0	0.0	105.0	0.0	70.0	0.0	76.0	0.0		
			1	100.0	-4.8		70.0	0.0		100.0	31.6	**	95.0	-9.5	75.0	0.0	92.0	21.1	
			2	110.0	4.8		90.0	28.6		80.0	5.3	120.0	14.3	90.0	28.6	86.0	13.2		
			3	115.0	9.5		80.0	14.3		92.0	21.1	100.0	-4.8	75.0	7.1	112.0	47.4		
			4	115.0	9.5		80.0	14.3		84.0	10.5	100.0	-4.8	75.0	7.1	100.0	31.6		
			5	105.0	0.0		80.0	14.3		84.0	10.5	95.0	-9.5	70.0	0.0	104.0	36.8		
99	LGD		-1	115.0	0.0		80.0	0.0		84.0	10.5	95.0	-9.5	70.0	0.0	104.0	36.8		
			1	115.0	0.0		75.0	-6.3		76.0	-15.8	120.0	-8.3	80.0	-16.3	86.0	-16.3		
			2	110.0	-4.3		70.0	-12.5		64.0	-15.8	100.0	-16.7	60.0	-25.0	72.0	-16.3		
			3	110.0	-4.3		75.0	-6.3		66.0	-13.2	105.0	-12.5	70.0	-12.5	72.0	-16.3		
			4	120.0	4.3		80.0	0.0		68.0	-10.5	110.0	-8.3	70.0	-12.5	74.0	-14.0		
			5	110.0	-4.3		70.0	-12.5		60.0	-21.1	100.0	-16.7	60.0	-25.0	70.0	-16.3		
101	JLL		-1	90.0	0.0		50.0	0.0		84.0	0.0	100.0	0.0	60.0	0.0	92.0	0.0		
			1	100.0	11.1		50.0	0.0		88.0	4.8	105.0	5.0	45.0	-25.0	100.0	8.7		
			2	95.0	5.6		55.0	10.0		120.0	42.9	**	85.0	-15.0	50.0	-16.7	140.0	52.2	
			3	95.0	5.6		55.0	10.0		120.0	42.9	**	85.0	-15.0	50.0	-16.7	140.0	52.2	
			4	110.0	22.2		70.0	40.0		98.0	16.7	**	110.0	10.0	70.0	16.7	105.0	14.1	
			5	110.0	22.2		70.0	40.0		98.0	16.7	**	110.0	10.0	70.0	16.7	105.0	14.1	

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 100 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 60 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 2012A/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
OPEN PHASE

Centre	Patient	Initial	Visit	LYING				STANDING						
				S.B.P.	% diff	H.R.	% diff	S.B.P.	% diff	H.R.	% diff			
1	102	ESF	-1	110.0	9.1	72.0	2.8	110.0	0.0	90.0	-11.1	92.0	-17.4	
			0	120.0	13.6	74.0	-2.8	110.0	0.0	80.0	-5.6	76.0	-17.4	
			1	125.0	9.1	70.0	-5.6	125.0	13.6	85.0	0.0	70.0	74.0	-19.6
			2	120.0	9.1	68.0	-11.1	110.0	0.0	70.0	-22.2	70.0	79.0	-14.1
			3	120.0	9.1	76.0	-5.6	120.0	9.1	80.0	-11.1	70.0	76.0	-17.4
			4	130.0	18.2	68.0	-11.1	120.0	9.1	70.0	-22.2	70.0	78.0	-15.2
103	JRA		5	125.0	13.6	74.0	2.8	120.0	9.1	75.0	-16.7	84.0	-8.7	
			6	130.0	18.2	76.0	5.6	120.0	9.1	70.0	-22.2	84.0	-8.7	
			-1	120.0	0.0	76.0	-2.6	115.0	0.0	75.0	0.0	84.0	0.0	
			0	120.0	0.0	74.0	-2.6	120.0	0.0	70.0	-6.7	82.0	-2.4	
			1	110.0	-8.3	104.0	36.8	90.0	-21.7	55.0	-26.7	116.0	38.1	
			2	100.0	-16.7	108.0	42.1	80.0	-30.4	50.0	-33.3	116.0	38.1	
113	LPS		-1	125.0	0.0	74.0	2.7	120.0	0.0	80.0	0.0	80.0	0.0	
			0	125.0	0.0	76.0	2.7	120.0	0.0	80.0	0.0	82.0	2.5	
			1	180.0	44.0	72.0	-2.7	170.0	0.0	90.0	12.5	86.0	7.5	
			2	130.0	4.0	74.0	0.0	125.0	4.2	80.0	0.0	88.0	10.0	
			3	130.0	4.0	76.0	2.7	120.0	0.0	80.0	0.0	80.0	0.0	
			4	130.0	4.0	76.0	2.7	125.0	4.2	80.0	0.0	82.0	2.5	
114	CLF		5	130.0	4.0	76.0	2.7	125.0	4.2	80.0	0.0	82.0	2.5	
			6	130.0	4.0	76.0	2.7	125.0	4.2	80.0	0.0	82.0	2.5	
			-1	80.0	0.0	92.0	0.0	80.0	0.0	50.0	0.0	104.0	0.0	
			0	80.0	0.0	92.0	0.0	80.0	0.0	50.0	0.0	104.0	0.0	
			1	90.0	12.5	92.0	0.0	85.0	6.3	50.0	0.0	96.0	-7.7	
			2	90.0	12.5	92.0	0.0	85.0	6.3	50.0	0.0	96.0	-7.7	
116	RGA		3	90.0	12.5	80.0	-13.0	90.0	12.5	70.0	40.0	88.0	-15.4	
			4	90.0	12.5	80.0	-13.0	90.0	12.5	70.0	40.0	88.0	-15.4	
			5	90.0	12.5	70.0	27.3	80.0	-13.0	70.0	40.0	88.0	-15.4	
			6	80.0	0.0	112.0	21.7	80.0	0.0	50.0	0.0	112.0	7.7	
			-1	100.0	0.0	84.0	0.0	95.0	0.0	60.0	0.0	96.0	0.0	
			0	100.0	0.0	84.0	0.0	95.0	0.0	60.0	0.0	96.0	0.0	
117	PSL		1	100.0	0.0	100.0	19.0	95.0	0.0	60.0	0.0	108.0	12.5	
			2	90.0	-10.0	72.0	-14.3	95.0	0.0	65.0	8.3	60.0	-37.5	
			3	90.0	-10.0	112.0	33.3	95.0	0.0	65.0	8.3	120.0	25.0	
			4	110.0	10.0	70.0	-16.7	110.0	15.8	70.0	16.7	78.0	-18.8	
			5	110.0	10.0	70.0	-16.7	110.0	15.8	70.0	16.7	78.0	-18.8	
			6	90.0	-10.0	70.0	-16.7	90.0	-5.3	75.0	25.0	76.0	-20.8	
117	PSL		-1	150.0	0.0	96.0	0.0	150.0	0.0	110.0	0.0	100.0	0.0	
			0	150.0	0.0	96.0	0.0	150.0	0.0	110.0	0.0	100.0	0.0	

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
* H.R. values >= 100 beats/min
S.B.P. values <= 70 mm Hg
D.B.P. values <= 50 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXTINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 OPEN PHASE

Centre	Patient	Initial	Visit	LYING				STANDING					
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff
1	117	PSL	1	115.0	-23.3	108.0	12.5	100.0	-53.3 *	80.0	-27.3	116.0	16.0
			2	130.0	-13.3	82.0	-14.6	120.0	-20.0	100.0	-9.1	82.0	-18.0
			3	130.0	-13.3	100.0	8.3	120.0	-20.0	100.0	-9.1	116.0	16.0
			4	130.0	-13.3	104.0	8.3	120.0	-20.0	100.0	-9.1	116.0	16.0
			5	130.0	-13.3	115.0	4.5	100.0	4.2	100.0	-20.0	116.0	16.0
			6	130.0	-13.3	100.0	4.2	120.0	-20.0	100.0	-9.1	116.0	16.0
129	MNS	-1	130.0	7.7	86.0	-7.0	120.0	8.3	80.0	37.5 **	96.0	4.2	
		0	140.0	-3.8	104.0	20.9 **	150.0	25.0	90.0	12.5	120.0	25.0 **	
		1	125.0	-3.8	104.0	20.9 **	150.0	25.0	90.0	12.5	120.0	25.0 **	
		2	125.0	-3.8	104.0	20.9 **	150.0	25.0	90.0	12.5	120.0	25.0 **	
		3	125.0	-3.8	104.0	20.9 **	150.0	25.0	90.0	12.5	120.0	25.0 **	
		4	120.0	-7.7	80.0	0.0	108.0	25.6 **	130.0	8.3	90.0	12.5 **	
130	EGA	5	120.0	-7.7	80.0	0.0	108.0	25.6 **	130.0	8.3	90.0	12.5 **	
		6	120.0	-7.7	80.0	0.0	108.0	25.6 **	130.0	8.3	90.0	12.5 **	
		-1	120.0	-16.7	70.0	0.0	116.0	34.9 **	65.0	0.0	90.0	51.1 **	
		0	100.0	-20.8 *	70.0	0.0	116.0	34.9 **	65.0	0.0	136.0	55.6 **	
		1	95.0	-20.8 *	70.0	0.0	116.0	34.9 **	70.0	7.7	140.0	55.6 **	
		2	95.0	-20.8 *	70.0	0.0	116.0	34.9 **	70.0	7.7	140.0	55.6 **	
132	MAT	3	100.0	-16.7	60.0	-14.3	100.0	-13.0	60.0	-7.7	104.0	15.6	
		4	100.0	-16.7	60.0	-14.3	100.0	-13.0	60.0	-7.7	104.0	15.6	
		5	100.0	-16.7	60.0	-14.3	100.0	-13.0	60.0	-7.7	104.0	15.6	
		6	90.0	-25.0 *	70.0	0.0	116.0	34.9 **	60.0	-7.7	88.0	-2.2	
		-1	120.0	-8.3	80.0	19.0	120.0	-8.3	70.0	0.0	116.0	28.9 **	
		0	110.0	-8.3	80.0	13.1	100.0	-16.7	80.0	14.3	90.0	28.9 **	
143	JEP	1	110.0	-8.3	80.0	13.1	100.0	-16.7	80.0	0.0	116.0	28.9 **	
		2	110.0	-8.3	80.0	13.1	100.0	-16.7	80.0	0.0	105.0	16.7	
		3	100.0	-16.7	65.0	-7.1	95.0	-20.8 *	75.0	7.1	128.0	42.2 **	
		4	110.0	-8.3	75.0	7.1	96.0	14.3	80.0	14.3	108.0	20.0	
		5	110.0	-8.3	75.0	7.1	96.0	14.3	80.0	14.3	108.0	20.0	
		6	105.0	-12.5	70.0	0.0	108.0	28.6 **	75.0	7.1	140.0	55.6 **	
143	JEP	-1	120.0	0.0	90.0	-16.7	110.0	9.1	70.0	14.3	92.0	-13.0	
		0	120.0	0.0	80.0	-22.2	120.0	0.0	80.0	14.3	75.0	-18.5	
		1	120.0	0.0	70.0	0.0	100.0	0.0	80.0	14.3	94.0	2.2	
		2	100.0	-16.7	60.0	6.7	100.0	-9.1	80.0	14.3	96.0	4.3	
		3	100.0	-16.7	60.0	6.7	100.0	-9.1	80.0	14.3	108.0	17.4	
		4	110.0	-8.3	80.0	6.7	105.0	0.0	80.0	14.3	108.0	17.4	
5	120.0	0.0	85.0	-6.7	110.0	0.0	80.0	14.3	108.0	17.4			
6	95.0	-20.8 *	60.0	11.1	95.0	-13.6	70.0	0.0	108.0	17.4			

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
OPEN PHASE

Centre	Patient	Initial Visit	LIVING				STANDING								
			S.B.P.	% diff	H.R.	% diff	S.B.P.	% diff	H.R.	% diff					
1	144	ARF	-1	145.0	-17.2	90.0	-11.1	104.0	-7.7	145.0	-17.2	90.0	-5.6	106.0	-5.7
			0	120.0	-17.2	80.0	-11.1	96.0	-7.7	120.0	-17.2	85.0	-5.6	100.0	-5.7
			1	120.0	-17.2	80.0	-11.1	96.0	-7.7	120.0	-17.2	85.0	-5.6	100.0	-5.7
			2	120.0	-17.2	85.0	-5.6	116.0	11.5	120.0	-17.2	80.0	-11.1	116.0	9.4
			3	115.0	-20.7	85.0	-5.6	80.0	-23.1	120.0	-17.2	80.0	-11.1	104.0	-1.9
			4	110.0	-24.1	80.0	-11.1	100.0	-3.8	110.0	-24.1	80.0	-11.1	100.0	-5.7
145	SLD		5	150.0	3.4	100.0	11.1	100.0	-3.8	130.0	-10.3	95.0	5.6	100.0	-5.7
			6	110.0	-24.1	70.0	-22.2	84.0	-19.2	110.0	-24.1	80.0	-11.1	88.0	-17.0
			-1	130.0	-30.8	80.0	-18.8	88.0	-7.3	120.0	-25.0	70.0	0.0	94.0	-25.5
			0	90.0	-30.8	65.0	-18.8	64.0	-27.3	90.0	-25.0	70.0	0.0	70.0	-25.5
			1	90.0	-30.8	65.0	-18.8	64.0	-27.3	90.0	-25.0	70.0	0.0	70.0	-25.5
			2	90.0	-30.8	60.0	-25.0	84.0	-4.5	90.0	-25.0	60.0	-14.3	84.0	6.4
146	LRM		3	110.0	-15.4	80.0	0.0	84.0	-4.5	100.0	-16.7	80.0	14.3	100.0	6.4
			4	110.0	-15.4	80.0	0.0	84.0	-4.5	100.0	-16.7	80.0	14.3	100.0	6.4
			5	100.0	-23.1	75.0	-6.3	96.0	9.1	100.0	-16.7	75.0	7.1	104.0	10.6
			6	110.0	-15.4	70.0	-12.5	96.0	9.1	100.0	-16.7	70.0	0.0	108.0	14.9
			-1	125.0	-4.0	85.0	-5.9	82.0	-7.3	120.0	8.3	80.0	25.0	88.0	-2.2
			1	120.0	-4.0	80.0	-5.9	88.0	7.3	130.0	8.3	100.0	25.0	88.0	-2.2
31	IK		0	110.0	-12.0	90.0	5.9	100.0	22.0	120.0	0.0	95.0	18.8	116.0	28.9
			1	165.0	26.9	100.0	0.0	116.0	41.5	130.0	8.3	85.0	6.3	116.0	28.9
			2	160.0	23.1	100.0	0.0	120.0	46.3	130.0	8.3	100.0	25.0	120.0	33.3
			3	150.0	15.4	100.0	0.0	100.0	22.0	120.0	0.0	90.0	12.5	100.0	11.1
			4	150.0	15.4	95.0	-5.0	96.0	20.0	180.0	0.0	100.0	25.0	112.0	12.0
			-1	130.0	-23.1	100.0	0.0	80.0	-20.0	170.0	-5.6	120.0	0.0	100.0	20.0
32	GE		0	150.0	0.0	100.0	-5.0	76.0	10.5	130.0	0.0	90.0	0.0	88.0	4.5
			1	150.0	-13.3	95.0	-5.0	84.0	10.5	130.0	0.0	90.0	0.0	92.0	4.5
			2	125.0	-16.7	85.0	-15.0	84.0	10.5	140.0	7.7	85.0	-5.6	92.0	4.5
			-1	135.0	-18.5	70.0	0.0	60.0	-21.1	105.0	-19.2	70.0	-7.1	66.0	-17.5
			0	105.0	-22.2	75.0	7.1	62.0	-18.4	100.0	-23.1	70.0	0.0	68.0	-15.0
			2	100.0	-25.9	70.0	0.0	58.0	-23.7	95.0	-26.9	65.0	-7.1	64.0	-20.0

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 100 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REDOXETINE - PROTOCOL 20124/013
 Listing No.: 15.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 OPEN PHASE

Centre	Patient	Initial	Visit	LYING			STANDING								
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	H.R.	% diff				
2	32	GE	3	130.0	-13.3	90.0	-10.0	84.0	10.5	140.0	7.7	90.0	0.0	92.0	4.5
			-1	140.0	0.0	90.0	11.1	72.0	5.6	130.0	100.0	100.0	-10.0	100.0	0.0
			0	140.0	-14.3	100.0	11.1	92.0	27.8	100.0	-23.1	80.0	-20.0	80.0	8.0
			1	130.0	-7.1	80.0	-11.1	80.0	11.1	120.0	-7.7	90.0	-10.0	108.0	8.0
			2	110.0	-21.4	90.0	0.0	80.0	11.1	120.0	-7.7	90.0	-10.0	108.0	8.0
3	4	AUD	-1	150.0	-18.8	90.0	11.1	64.0	-6.3	160.0	-12.5	80.0	-11.1	68.0	-11.8
			0	130.0	-6.3	100.0	0.0	68.0	6.3	130.0	-48.8	100.0	11.1	76.0	11.8
			1	150.0	-6.3	90.0	0.0	68.0	6.3	130.0	-25.0	80.0	-11.1	68.0	29.4
			2	150.0	-6.3	80.0	-11.1	92.0	28.1	120.0	-18.8	70.0	-22.2	78.0	14.7
			3	130.0	-18.8	80.0	-11.1	77.0	20.3	130.0	-18.8	70.0	-22.2	78.0	14.7
			4	160.0	0.0	100.0	11.1	100.0	56.3	170.0	6.3	100.0	11.1	104.0	52.9
10	TOR	-1	120.0	-12.5	80.0	-11.1	80.0	25.0	140.0	-12.5	80.0	-11.1	82.0	20.6	
		0	120.0	0.0	60.0	0.0	80.0	0.0	120.0	-16.7	60.0	0.0	86.0	-16.3	
		1	120.0	0.0	80.0	50.0	62.0	-22.5	100.0	-16.7	70.0	16.7	70.0	-18.6	
		2	120.0	0.0	80.0	33.3	65.0	-18.8	100.0	0.0	70.0	16.7	60.0	-30.2	
		3	110.0	-8.3	70.0	16.7	68.0	-15.0	100.0	-16.7	70.0	16.7	72.0	-16.3	
		4	110.0	-8.3	80.0	33.3	66.0	-17.5	90.0	-25.0	70.0	16.7	70.0	-18.6	
9	RRE	-1	120.0	-8.3	80.0	0.0	87.0	8.8	110.0	-8.3	80.0	0.0	106.0	22.1	
		0	120.0	0.0	80.0	0.0	78.0	0.0	120.0	-25.0	60.0	0.0	106.0	23.3	
		1	120.0	0.0	80.0	0.0	75.0	-3.8	120.0	0.0	80.0	-12.5	80.0	-2.5	
		2	120.0	0.0	80.0	0.0	72.0	-7.7	110.0	-8.3	80.0	0.0	74.0	-7.5	
		3	120.0	0.0	80.0	0.0	70.0	-10.3	110.0	-8.3	70.0	-12.5	72.0	-10.0	
		4	130.0	8.3	80.0	0.0	71.0	-9.0	120.0	-8.3	70.0	-12.5	73.0	-8.8	
25	PH	-1	150.0	0.0	90.0	0.0	70.0	-10.3	110.0	-8.3	60.0	-25.0	72.0	-10.0	
		0	150.0	0.0	90.0	0.0	78.0	0.0	160.0	0.0	90.0	-11.1	80.0	-3.8	
		1	140.0	-6.7	80.0	-11.1	72.0	-7.7	130.0	-7.1	70.0	-22.2	71.0	-11.3	
		2	130.0	-19.3	80.0	-11.1	72.0	-7.7	130.0	-7.1	70.0	-22.2	70.0	-12.5	
		3	150.0	0.0	90.0	0.0	72.0	-7.7	140.0	0.0	80.0	-11.1	74.0	-7.5	
		4	140.0	-6.7	90.0	0.0	70.0	-10.3	130.0	-7.1	80.0	-11.1	72.0	-10.0	

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
OPEN PHASE

Centre	Patient	Initial Visit	LYING			STANDING					
			S.B.P. % diff	H.R. % diff	D.B.P. % diff	S.B.P. % diff	H.R. % diff	D.B.P. % diff			
9	30	NF	-1	140.0	-7.1	90.0	72.0	140.0	-7.1	80.0	76.0
			0	130.0	0.0	90.0	71.0	130.0	0.0	80.0	73.0
			1	140.0	0.0	80.0	73.0	130.0	0.0	80.0	74.0
			2	140.0	0.0	90.0	71.0	130.0	0.0	80.0	75.0
			3	130.0	-7.1	80.0	75.0	120.0	-14.3	70.0	80.0
			4	140.0	0.0	90.0	71.0	130.0	0.0	80.0	73.0
10	1	VK	5	120.0	-14.3	80.0	73.0	110.0	-21.4	70.0	76.0
			6	140.0	0.0	70.0	73.0	130.0	0.0	80.0	75.0
			-1	120.0	4.2	65.0	82.0	110.0	0.0	60.0	80.0
			0	125.0	0.0	70.0	83.0	110.0	0.0	65.0	81.0
			1	120.0	0.0	86.0	84.0	120.0	9.1	90.0	60.0
			2	130.0	8.3	86.0	84.0	120.0	9.1	90.0	60.0
4	4	ZSD	3	132.0	10.0	84.0	84.0	112.0	1.8	90.0	70.0
			4	150.0	25.0	100.0	73.0	130.0	18.2	90.0	78.0
			5	130.0	8.3	86.0	83.0	120.0	9.1	90.0	68.0
			6	140.0	16.7	90.0	68.0	140.0	27.3	90.0	68.0
			-1	110.0	27.3	80.0	57.0	110.0	0.0	85.0	60.0
			0	140.0	45.5	80.0	58.0	140.0	27.3	90.0	60.0
6	6	RS	1	100.0	-9.1	70.0	72.0	100.0	0.0	85.0	60.0
			2	105.0	-4.5	70.0	72.0	105.0	5.0	90.0	60.0
			3	135.0	22.7	80.0	68.0	145.0	31.8	90.0	71.0
			4	130.0	18.2	86.0	66.0	130.0	18.2	90.0	74.0
			5	136.0	23.6	70.0	72.0	156.0	41.8	90.0	66.0
			6	136.0	23.6	70.0	72.0	156.0	41.8	90.0	66.0
7	7	RK	-1	110.0	-4.5	80.0	64.0	100.0	-14.0	65.0	67.0
			0	105.0	-9.1	75.0	65.0	86.0	-13.0	60.0	63.0
			1	100.0	-9.1	70.0	72.0	87.0	0.0	60.0	69.0
			2	105.0	-4.5	70.0	82.0	90.0	0.0	60.0	69.0
			3	100.0	-9.1	60.0	100.0	100.0	0.0	60.0	86.0
			4	105.0	-4.5	60.0	92.0	105.0	5.0	60.0	102.0
7	7	RK	5	120.0	9.1	90.0	80.0	115.0	15.0	90.0	82.0
			-1	120.0	50.0	100.0	80.0	120.0	50.0	100.0	80.0
			0	160.0	12.5	100.0	70.0	180.0	8.3	80.0	100.0
			1	135.0	0.0	80.0	83.0	130.0	0.0	80.0	25.0
			2	120.0	0.0	80.0	77.0	120.0	0.0	80.0	31.3
			3	150.0	25.0	90.0	78.0	140.0	16.7	100.0	0.0
7	7	RK	4	120.0	0.0	60.0	66.0	120.0	0.0	80.0	68.0
			5	120.0	0.0	65.0	65.0	120.0	0.0	80.0	68.0
			6	130.0	8.3	85.0	73.0	130.0	8.3	85.0	0.0
			-1	120.0	50.0	100.0	80.0	120.0	50.0	100.0	80.0
			0	160.0	12.5	100.0	70.0	180.0	8.3	80.0	25.0
			1	135.0	0.0	80.0	83.0	130.0	0.0	80.0	31.3

** S.B.P. values => 160 mm Hg
D.B.P. values => 100 mm Hg
H.R. values => 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 70 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
OPEN PHASE

Centre	Patient	Initial	Visit	LYING			STANDING								
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	H.R.	% diff				
10	B	VP	-1	145.0	-9.0	85.0	83.0	145.0	-10.3	90.0	90.0	90.0	0.0		
			0	132.0	0.0	80.0	84.0	130.0	1.2	80.0	-11.1	80.0	80.0	0.0	
			1	145.0	0.0	92.0	8.2	120.0	-8.4	120.0	-17.2	80.0	80.0	-11.1	
	12	EP	2	138.0	-4.8	70.0	100.0	140.0	20.5 **	90.0	-3.4	90.0	0.0	120.0	33.3 **
			3	140.0	-3.4	80.0	108.0	145.0	30.1 **	145.0	0.0	90.0	0.0	120.0	33.3 **
			-1	90.0	0.0	60.0	72.0	90.0	0.0	90.0	0.0	80.0	0.0	76.0	0.0
13	HV	1	110.0	0.0	80.0	80.0	125.0	38.9	90.0	0.0	80.0	0.0	76.0	0.0	
		0	110.0	0.0	80.0	74.0	140.0	2.8	125.0	38.9	90.0	0.0	79.0	3.9	
		1	120.0	9.1	80.0	66.7 **	140.0	0.0	140.0	55.6	100.0	25.0 **	84.0	10.5	
		2	140.0	55.6	100.0	72.0 **	110.0	0.0	110.0	22.2	80.0	0.0	66.0	-13.2	
		3	140.0	55.6	85.0	41.7	130.0	-11.1	130.0	44.4	100.0	25.0 **	65.0	-14.5	
		4	140.0	55.6	100.0	66.7 **	110.0	0.0	110.0	22.2	80.0	0.0	68.0	-10.5	
14	AA	5	110.0	22.2	80.0	33.3	125.0	13.9	110.0	22.2	80.0	0.0	71.0	-6.6	
		6	120.0	33.3	80.0	68.0	115.0	-5.6	115.0	0.0	80.0	0.0	78.0	0.0	
		-1	110.0	0.0	80.0	72.0	115.0	0.0	115.0	0.0	80.0	0.0	78.0	0.0	
		0	120.0	9.1	80.0	64.0	110.0	-11.1	110.0	-4.3	80.0	0.0	68.0	-12.8	
		1	120.0	0.0	80.0	78.0	96.0	8.3	96.0	-16.3	60.0	-25.0 *	69.0	-11.5	
		2	110.0	0.0	80.0	68.0	110.0	-11.1	110.0	-4.3	90.0	0.0	72.0	-7.7	
15	HT	3	120.0	0.0	80.0	80.0	140.0	9.7	180.0	20.0	110.0	0.0	71.0	4.4	
		4	120.0	-7.7	80.0	68.0	180.0	-1.6	180.0	-26.7	98.0	-6.7	69.0	1.5	
		5	120.0	-7.7	90.0	92.0	130.0	48.4	130.0	-13.3	90.0	-14.3	96.0	41.2	
		6	110.0	-15.4	76.0	69.0	110.0	11.3	110.0	-26.7	70.0	-33.3 *	73.0	7.4	
		-1	130.0	-7.7	90.0	62.0	150.0	0.0	150.0	-6.7	105.0	-4.8	68.0	0.0	
		0	120.0	-7.7	80.0	61.0	140.0	-1.6	140.0	-6.7	100.0	-4.8	68.0	0.0	
16	AJ	1	120.0	0.0	70.0	68.0	132.0	0.0	132.0	0.0	80.0	0.0	60.0	0.0	
		2	120.0	0.0	80.0	14.3	140.0	2.9	140.0	6.1	90.0	0.0	82.0	36.7	
		3	110.0	-8.3	80.0	14.3	155.0	17.4	155.0	17.4	100.0	25.0 **	80.0	33.3	
		4	120.0	0.0	70.0	68.0	130.0	0.0	130.0	0.0	80.0	0.0	61.0	1.7	
		5	120.0	0.0	80.0	68.0	138.0	0.0	138.0	4.5	80.0	0.0	60.0	0.0	
		6	130.0	8.3	80.0	64.0	145.0	-4.4	145.0	6.1	90.0	12.5	74.0	23.3	
-1	120.0	0.0	70.0	75.0	130.0	-5.9	130.0	9.8	80.0	12.5	72.0	20.0			

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
* H.R. values >= 100 beats/min
S.B.P. values <= 70 mm Hg
D.B.P. values <= 50 beats/min
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
OPEN PHASE

Centre	Patient	Initial Visit	LYING			STANDING									
			S.B.P. % diff	H.R. % diff	D.B.P. % diff	S.B.P. % diff	H.R. % diff	D.B.P. % diff							
10	AJ	0	122.0	1.7	70.0	0.0	72.0	-4.0	140.0	7.7	84.0	5.0	92.0	12.2	
		1	102.0	-15.0	70.0	0.0	66.0	-12.0	110.0	-15.4	-7.7	80.0	0.0	76.0	-7.3
		2	120.0	0.0	80.0	14.3	72.0	-4.0	120.0	-7.7	-7.7	75.0	-6.3	88.0	7.3
		3	110.0	-8.3	78.0	11.4	68.0	-9.3	118.0	-9.2	-9.2	80.0	0.0	88.0	7.3
		4	110.0	-8.3	70.0	0.0	96.0	28.0	120.0	-7.7	-7.7	70.0	-12.5	100.0	22.0
		5	100.0	-16.7	60.0	-14.3	69.0	-8.0	100.0	-23.1	*	72.0	-10.0	84.0	2.4
17	MH	6	105.0	-12.5	65.0	-7.1	78.0	4.0	100.0	-23.1	*	75.0	-6.3	102.0	24.4
		-1	130.0	0.0	90.0	0.0	62.0	0.0	140.0	0.0	0.0	100.0	0.0	66.0	3.0
		1	130.0	0.0	90.0	0.0	60.0	-3.2	160.0	14.3	10.0	110.0	10.0	64.0	-3.0
		2	125.0	-3.8	85.0	-5.6	54.0	-12.9	150.0	7.1	0.0	100.0	0.0	68.0	3.0
		3	130.0	0.0	80.0	-11.1	88.0	41.9	100.0	-28.6	*	80.0	-20.0	94.0	42.4
		4	160.0	23.1	90.0	0.0	69.0	11.3	160.0	14.3	0.0	90.0	-10.0	64.0	-3.0
19	TN	5	130.0	0.0	80.0	-11.1	88.0	41.9	110.0	-21.4	0.0	-20.0	90.0	36.4	
		6	110.0	-15.4	80.0	-11.1	92.0	48.4	130.0	-7.1	10.0	110.0	10.0	92.0	39.4
		-1	130.0	0.0	90.0	0.0	82.0	0.0	130.0	-1.5	0.0	100.0	-5.0	77.0	24.7
		1	130.0	0.0	85.0	-3.6	77.0	-6.1	120.0	-7.7	0.0	95.0	-15.0	96.0	27.3
		2	115.0	-11.5	80.0	-11.1	86.0	7.3	110.0	-15.4	0.0	80.0	-20.0	98.0	27.3
		3	114.0	-12.3	84.0	-6.7	76.0	-7.3	108.0	-16.9	0.0	84.0	-16.0	112.0	45.5
20	EJ	4	120.0	-7.7	80.0	-11.1	80.0	-2.4	110.0	-15.4	0.0	70.0	-30.0	100.0	29.9
		5	110.0	-15.4	90.0	0.0	72.0	-12.2	130.0	0.0	0.0	80.0	-20.0	74.0	-3.9
		6	160.0	23.1	70.0	-22.2	92.0	12.2	120.0	-7.7	0.0	90.0	-10.0	120.0	55.8
		-1	115.0	4.3	55.0	9.1	72.0	-2.8	115.0	4.3	0.0	70.0	14.3	78.0	0.0
		0	120.0	-8.7	60.0	27.3	74.0	2.8	120.0	-17.4	0.0	80.0	7.1	95.0	21.8
		1	105.0	-13.0	70.0	30.9	72.0	0.0	92.0	-20.0	0.0	75.0	0.0	102.0	30.8
21	AK	2	125.0	8.7	80.0	45.5	90.0	25.0	120.0	4.3	0.0	70.0	0.0	95.0	21.8
		3	120.0	4.3	80.0	45.5	80.0	11.1	125.0	8.7	0.0	70.0	0.0	100.0	28.2
		4	140.0	21.7	85.0	54.5	78.0	8.3	115.0	0.0	0.0	85.0	21.4	100.0	2.6
		5	130.0	13.0	80.0	45.5	79.0	9.7	120.0	4.3	0.0	75.0	7.1	83.0	6.4
		-1	105.0	0.0	70.0	0.0	72.0	0.0	115.0	0.0	0.0	80.0	0.0	80.0	0.0
		1	90.0	-14.3	70.0	0.0	64.0	-11.1	100.0	-13.0	0.0	70.0	-12.5	98.0	22.5
22	AK	2	100.0	-14.3	80.0	14.3	76.0	5.6	120.0	4.3	0.0	80.0	0.0	92.0	15.0
		3	90.0	-14.3	60.0	-14.3	86.0	19.4	96.0	-16.5	0.0	60.0	-25.0	98.0	22.5
		4	90.0	-14.3	60.0	-14.3	84.0	16.7	100.0	-13.0	0.0	60.0	-25.0	96.0	20.0
		5	100.0	-4.8	65.0	-7.1	84.0	16.7	105.0	-8.7	0.0	70.0	-12.5	98.0	22.5
		6	120.0	14.3	80.0	14.3	78.0	8.3	125.0	8.7	0.0	80.0	0.0	84.0	5.0

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 100 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
OPEN PHASE

Centre	Patient	Initial	Visit	LYING			STANDING							
				S.B.P.	H.R.	D.B.P.	S.B.P.	H.R.	D.B.P.					
				% diff	% diff	% diff	% diff	% diff	% diff					
10	AA		-1	145.0	0.0	98.0	72.0	140.0	140.0	0.0	95.0	84.0	13.1	
			0	145.0	0.0	98.0	72.0	140.0	140.0	0.0	84.0	84.0	95.0	
			1	135.0	-6.9	90.0	-8.2	90.0	72.0	155.0	10.7	100.0	100.0	5.3
			2	140.0	-3.4	94.0	-4.1	100.0	100.0	130.0	-7.1	100.0	100.0	5.3
			3	146.0	0.7	98.0	0.0	140.0	0.0	140.0	0.0	100.0	100.0	5.3
			4	140.0	-3.4	80.0	-18.4	80.0	68.0	125.0	-10.7	85.0	85.0	4.8
23	LT		5	140.0	-3.4	75.0	74.0	130.0	-7.1	85.0	-10.5	92.0	9.5	
			6	150.0	3.4	100.0	2.0	130.0	5.6	130.0	-7.1	96.0	1.1	
			-1	105.0	0.0	70.0	62.0	100.0	100.0	100.0	0.0	80.0	80.0	73.0
			0	105.0	0.0	70.0	0.0	95.0	-12.9	95.0	-5.0	80.0	80.0	-1.4
			1	105.0	0.0	60.0	-14.3	78.0	25.8	98.0	0.0	60.0	60.0	37.0
			2	100.0	-4.8	60.0	-14.3	68.0	9.7	96.0	-4.0	60.0	60.0	26.0
24	AL		3	100.0	-4.8	60.0	-14.3	110.0	10.0	110.0	0.0	80.0	80.0	67.1
			4	100.0	-4.8	70.0	0.0	100.0	0.0	100.0	0.0	70.0	70.0	37.0
			5	108.0	2.9	65.0	-7.1	74.0	19.4	103.0	5.0	70.0	70.0	92.0
			6	104.0	-1.0	66.0	-5.7	76.0	22.6	100.0	0.0	70.0	70.0	26.0
			-1	120.0	4.2	80.0	90.0	130.0	0.0	130.0	15.4	90.0	90.0	37.0
			0	125.0	8.3	84.0	5.0	150.0	-6.7	150.0	15.4	100.0	100.0	37.0
25	ES		1	130.0	16.7	100.0	25.0	120.0	-7.7	80.0	-11.1	80.0	98.0	-8.2
			2	140.0	3.3	70.0	-12.5	96.0	6.7	120.0	-7.7	70.0	70.0	98.0
			3	124.0	3.3	70.0	-12.5	96.0	6.7	120.0	-7.7	70.0	70.0	98.0
			4	125.0	4.2	75.0	-6.3	92.0	2.2	120.0	-7.7	75.0	75.0	92.0
			5	130.0	8.3	80.0	0.0	98.0	8.9	130.0	0.0	80.0	80.0	92.0
			6	130.0	8.3	80.0	0.0	84.0	-6.7	130.0	0.0	80.0	80.0	92.0
28	LL		-1	105.0	-14.3	80.0	68.0	120.0	8.3	90.0	-13.3	78.0	72.0	-7.7
			0	90.0	14.3	60.0	25.0	130.0	0.0	130.0	0.0	100.0	100.0	56.4
			1	120.0	14.3	90.0	12.5	120.0	11.8	120.0	0.0	95.0	95.0	25.6
			2	120.0	14.3	90.0	12.5	76.0	11.8	114.0	-5.0	64.0	64.0	17.9
			3	130.0	23.8	60.0	-25.0	76.0	11.8	114.0	-5.0	64.0	64.0	17.9
			-1	120.0	4.2	80.0	0.0	89.0	-19.1	130.0	-3.8	90.0	90.0	28.6
29	JJ		0	125.0	16.7	90.0	12.5	115.0	0.0	90.0	0.0	90.0	90.0	28.6
			1	140.0	16.7	85.0	6.3	115.0	-11.5	115.0	-11.5	95.0	95.0	20.0
			2	115.0	-4.2	85.0	6.3	115.0	-11.5	115.0	-11.5	95.0	95.0	20.0
			3	135.0	12.5	90.0	12.5	125.0	-12.4	125.0	-3.8	105.0	105.0	20.0
			4	145.0	20.8	85.0	18.8	140.0	-21.3	140.0	7.7	105.0	105.0	20.0
			5	125.0	4.2	85.0	6.3	88.0	-23.6	130.0	0.0	100.0	100.0	8.6
29	JJ		6	145.0	20.8	105.0	31.3	140.0	-22.5	140.0	16.7	105.0	105.0	35.7
			-1	105.0	0.0	70.0	78.0	115.0	0.0	115.0	7.7	75.0	75.0	96.0

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 50 beats/min
H.R. values <= 50 beats/min

2343

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 OPEN PHASE

Centre	Patient	Initial	Visit	LYING			STANDING			H.R. % diff				
				S.B.P.	D.B.P.	H.R.	S.B.P.	D.B.P.	H.R.					
10	JJ	0	110.0	4.8	7.1	80.0	2.6	120.0	4.3	75.0	0.0	92.0	-4.2	
		1	120.0	14.3	14.3	68.0	-12.8	100.0	4.0	-13.0	78.0	4.0	120.0	25.0 **
		2	115.0	9.5	14.3	74.0	-5.1	105.0	6.7	-8.7	80.0	6.7	96.0	0.0
		3	115.0	9.5	14.3	74.0	-5.1	110.0	6.7	-4.3	80.0	6.7	90.0	-6.3
		4	110.0	4.8	14.3	80.0	7.7	115.0	6.7	0.0	70.0	-6.7	98.0	2.1
		5	110.0	4.8	14.3	84.0	7.7	110.0	6.7	-4.3	70.0	-6.7	96.0	0.0
31	RK	0	100.0	-4.8	-14.3	60.0	-23.1	120.0	4.3	65.0	-13.3	72.0	-25.0	
		-1	110.0	27.3	23.1	66.0	6.1	120.0	12.5	12.5	75.0	33.3 **	78.0	17.9
		1	140.0	13.6	7.7	66.0	0.0	140.0	16.7	8.3	70.0	-6.7	78.0	0.0
		2	120.0	9.1	0.0	62.0	-6.1	130.0	8.3	10.0	70.0	-6.7	68.0	-12.8
		3	110.0	0.0	7.7	76.0	15.2	100.0	-16.7	65.0	65.0	13.3	88.0	12.8
		4	110.0	0.0	23.1	70.0	6.1	90.0	0.0	-25.0 *	75.0	0.0	98.0	23.9
34	TK	0	110.0	0.0	30.8	78.0	18.2	100.0	-16.7	60.0	6.7	96.0	23.1	
		5	110.0	-9.1	23.1	84.0	27.3	100.0	-16.7	85.0	13.3	120.0	55.8 **	
		-1	120.0	-4.2	-12.5	70.0	-14.3	110.0	0.0	0.0	80.0	-25.0 *	84.0	0.0
		0	115.0	-12.5	60.0	60.0	-8.6	110.0	0.0	0.0	70.0	-12.5	78.0	-7.1
		1	105.0	-8.3	25.0 *	64.0	-2.9	115.0	4.5	4.5	70.0	-12.5	80.0	-4.8
		2	110.0	-8.3	60.0	60.0	-14.3	115.0	4.5	4.5	70.0	-12.5	76.0	-9.5
35	IN	0	125.0	4.2	17.1	82.0	17.1	120.0	9.1	60.0	-25.0 *	96.0	14.3	
		4	110.0	-8.3	0.0	84.0	20.0	120.0	9.1	85.0	6.3	98.0	16.7	
		5	110.0	-8.3	0.0	84.0	20.0	130.0	18.2	100.0	25.0 **	100.0	19.0	
		-1	105.0	-4.8	-6.3	84.0	-10.7	110.0	0.0	0.0	85.0	-17.6	98.0	-12.2
		0	100.0	2.9	-12.5	75.0	-11.9	105.0	-4.5	-4.5	70.0	-17.6	88.0	-10.2
		1	108.0	-6.7	-18.8	72.0	-14.3	100.0	-9.1	-9.1	65.0	-23.5 *	84.0	-14.3
36	AK	0	110.0	4.8	0.0	70.0	-16.7	110.0	0.0	80.0	-5.9	72.0	-26.5	
		1	105.0	0.0	0.0	88.0	4.8	120.0	9.1	80.0	-29.4 *	88.0	-10.2	
		2	105.0	0.0	-12.5	75.0	-10.7	105.0	-4.5	-4.5	70.0	-17.6	80.0	-18.4
		-1	105.0	4.8	66.0	66.0	-18.2	110.0	9.1	9.1	70.0	-17.6	58.0	3.4
		0	110.0	9.5	18.8	60.0	0.0	120.0	13.6	13.6	70.0	-17.6	60.0	72.0
		1	115.0	14.3	14.3	60.0	-9.1	125.0	9.5	9.5	70.0	-17.6	68.0	17.2
37	AK	0	120.0	14.3	0.0	52.0	-21.2	106.0	-3.6	80.0	5.9	80.0	37.3	
		1	120.0	14.3	0.0	54.0	-18.2	95.0	-13.6	80.0	-5.9	80.0	69.0	
		2	105.0	0.0	-6.3	60.0	-9.1	110.0	0.0	0.0	65.0	-23.5 *	82.0	41.4
		3	120.0	14.3	12.5	60.0	-9.1	110.0	0.0	0.0	75.0	-11.8	74.0	27.6
		4	105.0	0.0	-12.5	60.0	-9.1	110.0	0.0	0.0	75.0	-11.8	74.0	27.6
		5	120.0	14.3	12.5	60.0	-9.1	110.0	0.0	0.0	75.0	-11.8	74.0	27.6

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 mm Hg
 H.R. values <= 50 beats/min

2344

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
OPEN PHASE

Centre	Patient	Initial	Visit	LIVING				STANDING				
				S.B.P.	D.B.P.	H.R.	% diff	S.B.P.	D.B.P.	H.R.	% diff	
10	37	HK	-1	100.0	70.0	0.0	70.0	105.0	75.0	78.0	7.7	84.0
			0	120.0	80.0	0.0	80.0	135.0	80.0	100.0	28.2	100.0
			1	110.0	80.0	14.3	90.0	95.0	60.0	60.0	2.6	80.0
			2	110.0	80.0	14.3	80.0	110.0	60.0	20.0	12.8	88.0
			3	140.0	40.0	0.0	88.0	25.7	70.0	6.7	23.1	96.0
			4	140.0	40.0	14.3	88.0	25.7	70.0	6.7	17.9	92.0
38	LL	-1	110.0	65.0	0.0	72.0	120.0	70.0	80.0	0.0	80.0	
		0	110.0	60.0	-7.7	74.0	120.0	70.0	-14.3	0.0	80.0	
		1	120.0	9.1	-7.7	68.0	125.0	65.0	-7.1	22.5	98.0	
		2	125.0	13.6	15.4	66.0	115.0	70.0	0.0	15.0	86.0	
		3	120.0	9.1	23.1	60.0	110.0	70.0	0.0	12.5	90.0	
		4	110.0	0.0	7.7	74.0	110.0	70.0	0.0	104.0	104.0	
39	VR	-1	120.0	90.0	0.0	72.0	110.0	85.0	74.0	0.0	74.0	
		0	120.0	80.0	0.0	72.0	110.0	85.0	0.0	74.0	0.0	
		1	135.0	-4.2	0.0	82.0	108.0	80.0	-5.9	18.9	88.0	
		2	125.0	0.0	5.6	84.0	115.0	80.0	0.0	21.6	90.0	
		3	115.0	-4.2	-11.1	80.0	120.0	85.0	0.0	13.5	84.0	
		4	120.0	0.0	-11.1	84.0	120.0	90.0	5.9	18.9	88.0	
40	AP	-1	110.0	70.0	-22.2	68.0	120.0	80.0	78.0	5.4	78.0	
		0	110.0	0.0	0.0	76.0	115.0	75.0	0.0	76.0	0.0	
		1	105.0	-4.5	-7.1	84.0	100.0	70.0	-6.7	28.9	98.0	
		2	150.0	36.4	0.0	90.0	100.0	80.0	6.7	44.7	110.0	
		3	110.0	0.0	7.1	82.0	115.0	80.0	6.7	15.8	88.0	
		4	100.0	-9.1	0.0	88.0	110.0	75.0	0.0	28.9	98.0	
42	TT	-1	110.0	80.0	0.0	100.0	105.0	70.0	80.0	5.3	80.0	
		0	110.0	0.0	0.0	84.0	120.0	70.0	0.0	92.0	92.0	
		1	120.0	9.1	5.0	64.0	106.0	64.0	20.0	30.4	120.0	
		2	120.0	9.1	-25.0	114.0	130.0	65.0	-7.1	30.4	120.0	
		3	125.0	13.6	-12.5	72.0	125.0	70.0	0.0	96.0	96.0	

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 50 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 OPEN PHASE

Centre	Patient	Initial Visit	LYING			STANDING									
			S.B.P. % diff	D.B.P. % diff	H.R. % diff	S.B.P. % diff	D.B.P. % diff	H.R. % diff							
10	42	TT	6	140.0	27.3	90.0	12.5	84.0	0.0	130.0	8.3	80.0	14.3	90.0	-2.2
	44	AB	-1	115.0	0.0	65.0	0.0	64.0	0.0	110.0	0.0	65.0	0.0	72.0	0.0
			1	120.0	4.3	65.0	0.0	88.0	37.5	110.0	0.0	70.0	7.7	88.0	22.2
			2	125.0	8.7	60.0	-7.7	96.0	50.0	120.0	9.1	60.0	-7.7	108.0	50.0
			3	125.0	8.7	60.0	-7.7	96.0	50.0	120.0	9.1	60.0	-7.7	108.0	50.0
			4	120.0	4.3	70.0	7.7	60.0	-6.3	120.0	9.1	90.0	38.5	92.0	27.8
			5	125.0	8.7	65.0	0.0	74.0	15.6	125.0	13.6	70.0	7.7	88.0	22.2
			6	120.0	4.3	65.0	0.0	72.0	12.5	125.0	13.6	70.0	7.7	88.0	22.2
45	KJ		-1	115.0	0.0	70.0	0.0	66.0	0.0	120.0	0.0	75.0	0.0	72.0	0.0
			1	120.0	4.3	70.0	0.0	66.0	0.0	122.0	1.7	75.0	0.0	72.0	0.0
			2	90.0	-21.7	60.0	-14.3	66.0	0.0	120.0	0.0	60.0	-20.0	68.0	-5.6
			3	118.0	2.6	70.0	0.0	70.0	6.1	122.0	1.7	75.0	0.0	86.0	19.4
			4	160.0	39.1	80.0	42.9	86.0	30.3	150.0	25.0	90.0	20.0	100.0	11.1
			5	130.0	13.0	80.0	14.3	80.0	21.2	130.0	8.3	75.0	0.0	88.0	22.2
			6	130.0	13.0	80.0	14.3	80.0	21.2	130.0	8.3	80.0	6.7	88.0	22.2
46	TH		-1	135.0	0.0	80.0	0.0	60.0	0.0	145.0	0.0	80.0	0.0	66.0	0.0
			0	150.0	11.1	100.0	25.0	60.0	0.0	145.0	0.0	95.0	18.8	86.0	30.3
			1	145.0	7.4	80.0	0.0	60.0	0.0	140.0	-3.4	80.0	0.0	72.0	9.1
			2	140.0	3.7	80.0	0.0	72.0	20.0	145.0	0.0	85.0	6.3	80.0	21.2
			3	150.0	11.1	90.0	12.5	72.0	20.0	140.0	-3.4	95.0	18.8	78.0	18.2
			4	140.0	3.7	80.0	0.0	72.0	20.0	140.0	-3.4	80.0	0.0	84.0	27.3
			5	145.0	7.4	80.0	0.0	78.0	30.0	150.0	3.4	80.0	0.0	80.0	21.2
47	TH		-1	120.0	0.0	70.0	0.0	70.0	0.0	110.0	0.0	80.0	0.0	78.0	0.0
			0	130.0	8.3	65.0	-7.1	84.0	20.0	130.0	18.2	70.0	0.0	78.0	0.0
			1	118.0	-1.7	64.0	-8.6	80.0	14.3	124.0	12.7	60.0	-25.0	84.0	-12.8
			2	120.0	0.0	70.0	0.0	84.0	20.0	125.0	13.6	80.0	0.0	84.0	7.7
			3	130.0	8.3	65.0	-7.1	72.0	2.9	130.0	18.2	70.0	-12.5	68.0	-12.8
			4	120.0	0.0	60.0	-14.3	72.0	2.9	125.0	13.6	80.0	-25.0	80.0	2.6
			5	115.0	-4.2	65.0	-7.1	60.0	-14.3	115.0	4.5	70.0	-12.5	96.0	23.1
48	IP		-1	120.0	0.0	75.0	0.0	64.0	0.0	110.0	0.0	70.0	0.0	74.0	0.0
			0	135.0	12.5	65.0	-13.3	72.0	12.5	140.0	0.0	70.0	0.0	74.0	0.0
			1	120.0	0.0	70.0	-6.7	60.0	25.0	120.0	9.1	66.0	-2.9	96.0	29.7
			2	120.0	0.0	70.0	-6.7	60.0	25.0	120.0	9.1	66.0	-2.9	96.0	29.7
			3	130.0	8.3	70.0	-6.7	92.0	43.8	100.0	-9.1	60.0	-14.3	120.0	62.2

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 100 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 RENEXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 OPEN PHASE

Centre	Patient	Initial	Visit	LYING				STANDING								
				S.B.P.	% diff	D.B.P.	% diff	H.R.	% diff	S.B.P.	% diff	D.B.P.	% diff	H.R.	% diff	
10	48	IP	4	120.0	0.0	65.0	-13.3	104.0	62.5	110.0	0.0	60.0	-14.3	102.0	37.8	**
			5	120.0	0.0	70.0	-6.7	80.0	25.0	108.0	-1.8	60.0	-14.3	92.0	24.3	
			6	110.0	-8.3	70.0	-6.7	80.0	25.0	118.0	7.3	70.0	0.0	96.0	29.7	
	49	VM	-1	110.0	0.0	75.0	0.0	64.0	0.0	100.0	0.0	70.0	0.0	80.0	0.0	
			1	110.0	0.0	70.0	-6.7	80.0	25.0	120.0	20.0	80.0	14.3	100.0	25.0	**
			2	110.0	0.0	75.0	0.0	64.0	0.0	100.0	0.0	70.0	0.0	80.0	0.0	
3			115.0	4.5	80.0	6.7	86.0	34.4	120.0	20.0	80.0	14.3	100.0	0.0		
4			140.0	27.3	95.0	26.7	96.0	50.0	135.0	35.0	85.0	21.4	120.0	50.0	**	
5			104.0	-5.5	60.0	-20.0	68.0	6.3	120.0	20.0	58.0	-17.1	72.0	-10.0	**	
50	EE	6	110.0	0.0	70.0	-6.7	80.0	25.0	115.0	15.0	70.0	0.0	89.0	11.3		
		-1	120.0	0.0	80.0	0.0	80.0	0.0	120.0	0.0	76.0	24.3	92.0	-19.6		
		0	120.0	0.0	80.0	0.0	80.0	0.0	135.0	12.5	75.0	1.4	84.0	-8.7		
		1	130.0	8.3	85.0	0.0	80.0	0.0	130.0	8.3	80.0	8.1	86.0	-6.5		
		2	120.0	0.0	70.0	-12.5	82.0	2.5	130.0	8.3	75.0	1.4	96.0	4.5		
		3	125.0	4.2	80.0	0.0	100.0	25.0	130.0	8.3	75.0	1.4	112.0	21.7	**	
51	UL	4	120.0	0.0	80.0	0.0	104.0	30.0	130.0	4.2	80.0	8.1	100.0	8.7	**	
		5	120.0	0.0	80.0	0.0	100.0	25.0	130.0	8.3	80.0	8.1	128.0	59.1	**	
		6	120.0	0.0	80.0	0.0	100.0	25.0	130.0	8.3	80.0	8.1	128.0	59.1	**	
		-1	140.0	0.0	90.0	0.0	68.0	0.0	130.0	0.0	90.0	0.0	76.0	0.0		
		0	140.0	0.0	90.0	0.0	68.0	0.0	130.0	0.0	90.0	0.0	76.0	0.0		
		1	135.0	-3.6	90.0	0.0	76.0	11.8	125.0	-3.8	85.0	-5.6	80.0	5.3		
52	NP	2	130.0	-7.1	85.0	-5.6	78.0	14.7	130.0	0.0	90.0	0.0	84.0	10.5		
		3	135.0	-3.6	80.0	-11.1	80.0	17.6	130.0	0.0	100.0	11.1	108.0	42.1	**	
		4	120.0	-14.3	86.0	-4.4	64.0	-5.9	120.0	-7.7	90.0	0.0	88.0	15.8		
		5	118.0	-15.7	65.0	-27.8	76.0	11.8	120.0	-7.7	70.0	-22.2	80.0	5.3		
		6	130.0	-7.1	80.0	-11.1	74.0	8.8	125.0	-3.8	80.0	-11.1	80.0	5.3		
		-1	120.0	-8.3	90.0	0.0	82.0	-7.3	110.0	9.1	90.0	0.0	90.0	-6.7		
53	MA	0	110.0	-4.2	80.0	-11.1	74.0	-9.8	110.0	0.0	75.0	-16.7	86.0	-4.4		
		1	115.0	0.0	70.0	-22.2	72.0	-12.2	110.0	0.0	65.0	-27.8	80.0	-11.1		
		2	120.0	0.0	70.0	-16.7	74.0	-9.8	110.0	0.0	80.0	-11.1	82.0	-8.9		
		3	105.0	-12.5	75.0	-16.7	74.0	-9.8	110.0	0.0	80.0	-11.1	86.0	-4.4		
		4	115.0	-4.2	80.0	-11.1	74.0	-9.8	120.0	9.1	80.0	-11.1	86.0	-4.4		
		-1	110.0	0.0	60.0	0.0	66.0	0.0	118.0	0.0	78.0	0.0	80.0	0.0		
54	NA	0	110.0	0.0	60.0	0.0	66.0	0.0	118.0	0.0	78.0	0.0	80.0	0.0		
		1	95.0	-13.6	60.0	0.0	60.0	-9.1	95.0	-19.5	60.0	-23.1	68.0	-15.0		
		2	100.0	-9.1	70.0	16.7	72.0	9.1	100.0	-19.5	60.0	-23.1	88.0	10.0		
3	116.0	5.5	58.0	-3.3	72.0	9.1	120.0	1.7	58.0	-25.6	72.0	-10.0				

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 100 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
OPEN PHASE

Centre	Patient	Initial	Visit	LYING			STANDING									
				S.B.P.	Z diff	H.R.	Z diff	D.B.P.	Z diff	H.R.	Z diff					
10	53	MA	4	110.0	0.0	70.0	6.1	120.0	1.7	60.0	-23.1	*	72.0	-10.0		
			5	105.0	-4.5	68.0	3.0	110.0	-6.8	60.0	-23.1	*	72.0	-10.0		
			6	100.0	-9.1	68.0	3.0	100.0	-15.3	60.0	-23.1	*	72.0	-10.0		
			56	JP	-1	120.0	0.0	80.0	-20.0	125.0	0.0	64.0	-6.3		88.0	-9.1
					1	98.0	-18.3	58.0	-15.0	104.0	-16.8	60.0	-6.3		76.0	-13.6
					2	90.0	-25.0	60.0	0.0	90.0	-28.0	60.0	-6.3	*	88.0	0.0
	3	110.0			-8.3	60.0	-25.0	110.0	-12.0	60.0	-6.3		60.0	-51.8		
	4	115.0			-4.2	76.0	-5.0	135.0	-8.0	60.0	-6.3		80.0	-4.5		
	5	115.0			-4.2	66.0	-17.5	120.0	-4.0	65.0	1.6		78.0	-11.4		
	6	115.0	-4.2	66.0	-17.5	110.0	-12.0	60.0	-6.3		78.0	-11.4				
	58	RK	-1	90.0	0.0	60.0	0.0	100.0	0.0	60.0	0.0		64.0	0.0		
			0	90.0	0.0	60.0	0.0	100.0	0.0	60.0	0.0		64.0	0.0		
1			120.0	33.3	70.0	16.7	120.0	20.0	60.0	0.0		100.0	56.3			
2			120.0	33.3	70.0	16.7	100.0	0.0	60.0	0.0		100.0	56.3			
3			110.0	22.2	80.0	33.3	112.0	12.0	60.0	0.0		88.0	37.5			
4			108.0	20.0	84.0	40.0	104.0	4.0	58.0	-3.3		88.0	37.5			
5		105.0	16.7	79.0	25.0	110.0	10.0	60.0	0.0		78.0	21.9				
6		100.0	11.1	75.0	25.0	110.0	10.0	80.0	33.3		88.0	37.5				
59		TA	-1	98.0	6.1	66.0	-6.1	100.0	10.0	60.0	0.0		66.0	-6.1		
			0	104.0	7.1	72.0	9.1	110.0	10.0	80.0	33.3		62.0	-6.1		
			1	103.0	7.1	72.0	9.1	110.0	10.0	80.0	33.3		62.0	-6.1		
			2	100.0	2.0	70.0	16.7	110.0	10.0	75.0	25.0		90.0	36.4		
	3		100.0	2.0	80.0	33.3	110.0	10.0	80.0	33.3		96.0	45.5			
	4		104.0	6.1	90.0	50.0	110.0	10.0	90.0	50.0		120.0	81.8			
5	110.0	12.2	84.0	27.3	110.0	10.0	90.0	50.0		120.0	81.8					
6	120.0	22.4	80.0	33.3	122.0	22.0	84.0	40.0		92.0	39.4					
61	JT	-1	130.0	0.0	60.0	0.0	110.0	0.0	80.0	0.0		112.0	0.0			
		0	130.0	0.0	60.0	0.0	110.0	0.0	80.0	0.0		112.0	0.0			
		1	130.0	0.0	80.0	33.3	110.0	0.0	80.0	0.0		100.0	-10.7			
		2	130.0	0.0	68.0	13.3	110.0	0.0	64.0	-20.0		100.0	-10.7			
		3	130.0	0.0	80.0	33.3	132.0	20.0	80.0	0.0		88.0	-21.4			
		4	124.0	-4.6	65.0	8.3	124.0	12.7	68.0	-15.0		112.0	0.0			
5	140.0	7.7	100.0	66.7	130.0	16.2	90.0	12.5		90.0	-19.6					
6	130.0	0.0	80.0	33.3	110.0	0.0	70.0	-12.5		96.0	-14.3					
62	RK	-1	140.0	0.0	72.0	0.0	140.0	0.0	100.0	0.0		96.0	0.0			
		0	140.0	0.0	72.0	0.0	140.0	0.0	100.0	0.0		96.0	0.0			
		1	140.0	0.0	72.0	0.0	140.0	0.0	100.0	0.0		96.0	0.0			

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 100 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 BEROXETINE - PROTOCOL 20124/013
 Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 OPEN PHASE

Centre	Patient	Initial	Visit	LYING			STANDING					
				S.B.P. % diff	D.B.P. % diff	H.R. % diff	S.B.P. % diff	D.B.P. % diff	H.R. % diff			
10	62	RK	2	140.0	0.0	72.0	145.0	3.6	75.0	-25.0	80.0	-16.7
			3	118.0	-15.7	* 72.0	128.0	-8.6	72.0	-28.0	84.0	-12.5
			4	116.0	-17.1	* 80.0	120.0	-14.3	65.0	-35.0	88.0	-8.3
			5	120.0	-14.3	* 82.0	130.0	-7.1	75.0	-25.0	90.0	-6.3
			6	110.0	-21.4	* 90.0	130.0	-7.1	80.0	-20.0	92.0	-4.2
			-1	130.0	0.0	80.0	130.0	0.0	65.0	0.0	92.0	0.0
82	LS	1	120.0	-7.7	70.0	130.0	0.0	90.0	38.5	88.0	-4.3	
		2	120.0	-7.7	70.0	130.0	-12.5	70.0	7.7	72.0	-21.7	
		3	120.0	-7.7	76.0	110.0	-5.0	70.0	-15.4	108.0	17.4	
		4	100.0	-23.1	* 84.0	110.0	5.0	80.0	23.1	100.0	8.7	
		5	110.0	-15.4	* 80.0	100.0	-23.1	70.0	7.7	84.0	-8.7	
		6	100.0	-23.1	* 72.0	110.0	-15.4	80.0	23.1	88.0	-4.3	
84	HV	-1	120.0	-8.3	72.0	130.0	0.0	90.0	0.0	80.0	-12.5	
		1	135.0	12.5	** 68.0	130.0	0.0	90.0	0.0	70.0	-25.0	
		2	140.0	16.7	** 100.0	140.0	0.0	100.0	11.1	108.0	35.0	
		3	146.0	21.7	** 76.0	124.0	-4.6	80.0	-11.1	80.0	0.0	
		4	140.0	16.7	84.0	130.0	0.0	80.0	-11.1	86.0	7.5	
		5	135.0	12.5	95.0	132.0	1.5	100.0	11.1	104.0	30.0	
6	140.0	16.7	96.0	142.0	9.2	95.0	5.6	106.0	32.5			
86	NP	-1	110.0	-9.1	68.0	110.0	0.0	65.0	0.0	72.0	0.0	
		1	100.0	-13.6	60.0	105.0	-4.5	65.0	0.0	72.0	0.0	
		2	95.0	-16.7	64.0	110.0	0.0	60.0	-7.7	64.0	-11.1	
		3	100.0	-9.1	70.0	120.0	9.1	60.0	-7.7	88.0	22.2	
		4	106.0	-3.6	78.0	110.0	0.0	80.0	23.1	120.0	66.7	
		5	110.0	0.0	70.0	100.0	-9.1	70.0	7.7	116.0	61.1	
6	120.0	9.1	70.0	105.0	-4.5	70.0	7.7	92.0	27.8			
89	SK	-1	100.0	0.0	76.0	100.0	0.0	55.0	0.0	80.0	0.0	
		1	100.0	0.0	80.0	95.0	-5.0	50.0	-9.1	80.0	0.0	
		2	100.0	0.0	70.0	110.0	10.0	60.0	9.1	120.0	50.0	
		3	110.0	10.0	80.0	100.0	0.0	50.0	-9.1	100.0	25.0	
		4	100.0	0.0	72.0	122.0	22.0	70.0	27.3	92.0	15.0	
		5	100.0	0.0	72.0	110.0	0.0	70.0	27.3	86.0	7.5	
6	110.0	10.0	74.0	105.0	5.0	60.0	9.1	90.0	12.5			
90	SV	-1	110.0	0.0	72.0	120.0	0.0	80.0	0.0	84.0	0.0	

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 100 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

234

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
OPEN PHASE

Centre	Patient	Initial	Visit	LYING			STANDING			H.R. % diff			
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff		H.R.	% diff	
10	90	SV	0	110.0	0.0	70.0	0.0	120.0	0.0	80.0	0.0	84.0	0.0
			1	105.0	-4.5	75.0	7.1	110.0	0.0	85.0	6.3	90.0	7.1
			2	110.0	0.0	80.0	-14.3	115.0	-4.2	70.0	-12.5	92.0	9.5
			3	100.0	-9.1	60.0	-14.3	95.0	-20.8	60.0	-25.0	96.0	14.3
			4	105.0	-4.5	60.0	-14.3	80.0	8.3	110.0	-8.3	90.0	7.1
			5	105.0	-4.5	70.0	0.0	75.0	8.3	115.0	-4.2	84.0	0.0
92	LA	0	100.0	-9.1	56.0	-20.0	100.0	38.9	-8.3	50.0	-37.5	96.0	14.3
		-1	100.0	0.0	70.0	0.0	100.0	0.0	70.0	0.0	84.0	0.0	
		1	120.0	20.0	60.0	0.0	100.0	0.0	70.0	0.0	80.0	-4.8	
		2	100.0	0.0	60.0	0.0	100.0	0.0	70.0	0.0	108.0	28.6	
		3	110.0	10.0	70.0	-14.3	100.0	0.0	65.0	-7.1	90.0	7.1	
		4	105.0	5.0	75.0	7.1	105.0	5.0	75.0	7.1	96.0	14.3	
94	PV	0	105.0	5.0	75.0	7.1	100.0	0.0	65.0	-7.1	80.0	7.1	
		1	115.0	15.0	80.0	14.3	105.0	5.0	70.0	0.0	84.0	0.0	
		-1	105.0	0.0	60.0	0.0	118.0	0.0	60.0	0.0	84.0	0.0	
		1	105.0	0.0	60.0	0.0	110.0	-6.8	60.0	0.0	88.0	4.8	
		2	120.0	14.3	60.0	0.0	130.0	10.2	70.0	16.7	94.0	11.9	
		3	125.0	19.0	70.0	16.7	138.0	16.9	70.0	16.7	100.0	19.0	
110	DF	0	110.0	4.8	70.0	16.7	100.0	13.6	1.7	110.0	31.0	110.0	31.0
		1	100.0	-4.8	60.0	0.0	104.0	-11.9	60.0	0.0	120.0	42.9	
		-1	120.0	0.0	80.0	0.0	120.0	0.0	70.0	0.0	68.0	5.9	
		1	130.0	8.3	80.0	0.0	120.0	0.0	80.0	14.3	87.0	27.9	
		2	140.0	16.7	90.0	12.5	130.0	8.3	90.0	28.6	90.0	32.4	
		3	140.0	16.7	90.0	12.5	120.0	0.0	80.0	14.3	90.0	32.4	
2	BB	0	150.0	25.0	90.0	42.9	155.0	29.2	90.0	28.6	96.0	41.2	
		1	170.0	41.7	110.0	37.5	150.0	25.0	100.0	42.9	92.0	35.3	
		2	130.0	8.3	90.0	12.5	130.0	8.3	80.0	14.3	94.0	38.2	
		-1	130.0	-15.4	70.0	0.0	115.0	-4.3	90.0	-33.3	90.0	2.2	
		1	130.0	0.0	70.0	0.0	120.0	4.3	80.0	-11.1	76.0	-15.6	
		3	135.0	3.8	95.0	35.7	150.0	30.4	100.0	11.1	90.0	0.0	
2	BB	0	140.0	7.7	100.0	42.9	150.0	30.4	100.0	11.1	94.0	4.4	
		1	160.0	23.1	90.0	28.6	160.0	39.1	90.0	0.0	100.0	11.1	
		4	150.0	15.4	88.0	12.8	150.0	30.4	90.0	0.0	90.0	0.0	
		5	150.0	15.4	90.0	28.6	160.0	39.1	90.0	0.0	90.0	0.0	
		6	160.0	23.1	100.0	42.9	140.0	21.7	50.0	-44.4	88.0	-2.2	

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 40 mm Hg
H.R. values <= 50

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3
VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
OPEN PHASE

Centre	Patient	Initial Visit	LYING			STANDING							
			S.B.P. % diff	D.B.P. % diff	H.R. % diff	S.B.P. % diff	D.B.P. % diff	H.R. % diff					
11	3	RF	-1	150.0	6.7	90.0	100.0	130.0	0.0	80.0	102.0	2.0	
			0	160.0	-20.0	90.0	102.0	130.0	0.0	70.0	104.0	0.0	
			1	120.0	0.0	70.0	-22.2	96.0	-4.0	140.0	7.7	80.0	0.0
			2	150.0	0.0	90.0	0.0	88.0	-12.0	155.0	19.2	100.0	25.0
			3	140.0	-6.7	90.0	0.0	88.0	-12.0	150.0	15.4	100.0	25.0
			4	150.0	0.0	90.0	0.0	92.0	-8.0	140.0	7.7	90.0	12.5
4	BA		5	140.0	-6.7	80.0	84.0	120.0	-7.7	80.0	0.0	90.0	-11.8
			6	140.0	-6.7	70.0	-22.2	82.0	-18.0	130.0	0.0	70.0	-12.5
			-1	150.0	6.7	100.0	80.0	140.0	0.0	140.0	7.1	90.0	0.0
			0	160.0	6.7	100.0	0.0	78.0	-2.5	150.0	0.0	90.0	0.0
			1	150.0	0.0	100.0	0.0	90.0	12.5	130.0	-7.1	90.0	0.0
			2	130.0	-13.3	90.0	-10.0	100.0	25.0	130.0	-7.1	80.0	0.0
5	ZM		3	160.0	6.7	100.0	96.0	150.0	0.0	100.0	11.1	92.0	7.0
			4	150.0	0.0	100.0	0.0	92.0	15.0	150.0	7.1	100.0	11.1
			5	150.0	0.0	90.0	-10.0	92.0	15.0	140.0	0.0	90.0	0.0
			6	150.0	0.0	100.0	0.0	88.0	10.0	130.0	-7.1	100.0	11.1
			-1	110.0	0.0	80.0	72.0	110.0	0.0	110.0	0.0	70.0	94.0
			0	140.0	0.0	70.0	-12.5	70.0	-2.8	110.0	0.0	65.0	82.0
6	VP		1	120.0	9.1	80.0	78.0	120.0	9.1	80.0	28.6	78.0	-17.0
			2	120.0	9.1	80.0	0.0	78.0	8.3	120.0	9.1	80.0	14.3
			3	130.0	18.2	90.0	12.5	86.0	19.4	130.0	18.2	90.0	28.6
			4	140.0	27.3	100.0	25.0	90.0	25.0	140.0	27.3	100.0	42.9
			-1	110.0	-9.1	60.0	-16.7	80.0	2.6	100.0	-10.0	50.0	82.0
			0	100.0	18.2	60.0	0.0	64.0	-17.9	120.0	20.0	60.0	20.0
7	KK		1	130.0	18.2	70.0	66.0	130.0	30.0	70.0	40.0	68.0	-17.1
			2	145.0	31.8	90.0	50.0	145.0	45.0	100.0	100.0	70.0	-14.6
			3	140.0	27.3	80.0	33.3	140.0	5.1	145.0	45.0	100.0	100.0
			4	130.0	18.2	90.0	50.0	130.0	2.6	140.0	40.0	90.0	82.0
			5	130.0	18.2	90.0	50.0	130.0	17.9	130.0	30.0	90.0	80.0
			6	120.0	9.1	80.0	33.3	80.0	2.6	120.0	20.0	80.0	60.0
8	KK		-1	120.0	25.0	70.0	84.0	100.0	0.0	60.0	33.3	84.0	31.0
			0	150.0	16.7	100.0	42.9	120.0	0.0	120.0	20.0	80.0	110.0
			1	140.0	8.3	100.0	42.9	120.0	0.0	120.0	20.0	90.0	100.0
			2	130.0	8.3	90.0	28.6	120.0	2.4	120.0	20.0	90.0	94.0
			3	130.0	8.3	90.0	28.6	120.0	0.0	120.0	20.0	90.0	50.0
			4	150.0	25.0	100.0	42.9	130.0	19.0	130.0	50.0	100.0	66.7
9	KK		5	160.0	33.3	100.0	42.9	130.0	50.0	100.0	66.7	100.0	
			6	140.0	16.7	80.0	14.3	130.0	2.4	130.0	50.0	86.0	86.0

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 50 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 OPEN PHASE

Centre	Patient	Initial Visit	LYING			STANDING		
			S.B.P.	H.R.	D.B.P.	S.B.P.	H.R.	D.B.P.
			% diff	% diff	% diff	% diff	% diff	% diff
11	KF	-1	120.0	100.0	90.0	120.0	96.0	90.0
		0	120.0	84.0	80.0	110.0	90.0	80.0
		1	120.0	82.0	80.0	115.0	94.0	80.0
		2	130.0	80.0	80.0	110.0	96.0	96.0
		3	110.0	72.0	80.0	90.0	68.0	68.0
		4	110.0	76.0	80.0	100.0	84.0	84.0
9	FI	-1	120.0	92.0	80.0	130.0	96.0	80.0
		0	120.0	94.0	80.0	130.0	100.0	80.0
		1	130.0	94.0	90.0	120.0	102.0	80.0
		2	120.0	70.0	70.0	120.0	72.0	80.0
		3	160.0	79.0	100.0	150.0	84.0	100.0
		4	130.0	80.0	80.0	130.0	100.0	80.0
10	BJ	-1	130.0	102.0	80.0	140.0	84.0	80.0
		0	130.0	102.0	80.0	140.0	84.0	80.0
		1	120.0	76.0	80.0	120.0	80.0	80.0
		2	120.0	74.0	80.0	120.0	78.0	80.0
		3	160.0	72.0	90.0	130.0	82.0	80.0
		4	140.0	88.0	90.0	140.0	86.0	80.0
11	NGY	-1	120.0	84.0	80.0	130.0	88.0	80.0
		0	150.0	76.0	90.0	150.0	77.0	80.0
		1	130.0	76.0	90.0	140.0	80.0	80.0
		2	130.0	88.0	80.0	110.0	100.0	80.0
		3	140.0	108.0	90.0	130.0	112.0	90.0
		4	140.0	90.0	70.0	130.0	92.0	80.0
12	PJ	-1	150.0	76.0	100.0	150.0	80.0	90.0
		0	150.0	104.0	90.0	130.0	115.0	80.0
		1	140.0	98.0	90.0	130.0	104.0	80.0
		2	130.0	86.0	80.0	130.0	90.0	80.0
		3	120.0	90.0	80.0	130.0	96.0	80.0
		4	120.0	90.0	80.0	120.0	96.0	80.0

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 beats/min
 H.R. values <= 50 beats/min

2352

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
OPEN PHASE

Centre	Patient	Initial	Visit	LYING			STANDING			
				S.B.P. % diff	D.B.P. % diff	H.R. % diff	S.B.P. % diff	D.B.P. % diff	H.R. % diff	
11	16	NA	-1	120.0	0.0	80.0	130.0	-7.7	90.0	82.0
			0	120.0	0.0	88.0	120.0	0.0	90.0	92.0
			1	120.0	0.0	76.0	130.0	0.0	90.0	80.0
			2	110.0	-8.3	78.0	120.0	-7.7	80.0	84.0
			3	130.0	8.3	86.0	130.0	0.0	90.0	90.0
			4	100.0	-16.7	80.0	110.0	-15.4	80.0	90.0
17	UZ		5	100.0	-16.7	80.0	120.0	-7.7	80.0	86.0
			6	110.0	-8.3	90.0	110.0	-15.4	80.0	94.0
			-1	130.0	0.0	80.0	140.0	0.0	100.0	86.0
			0	130.0	0.0	76.0	140.0	0.0	90.0	82.0
			1	110.0	-15.4	80.0	110.0	-21.4	70.0	82.0
			2	120.0	-7.7	80.0	120.0	-21.4	80.0	92.0
20	LJ		3	110.0	-15.4	80.0	120.0	-14.3	80.0	86.0
			4	120.0	-7.7	86.0	130.0	-7.1	80.0	88.0
			5	120.0	-7.7	80.0	120.0	-14.3	80.0	72.0
			6	110.0	-15.4	80.0	110.0	-21.4	80.0	86.0
			-1	120.0	0.0	80.0	130.0	0.0	80.0	86.0
			0	120.0	0.0	88.0	130.0	0.0	80.0	90.0
12	1	IB	1	140.0	0.0	75.0	140.0	0.0	90.0	85.0
			2	140.0	0.0	75.0	140.0	0.0	90.0	85.0
			3	150.0	7.1	80.0	140.0	0.0	90.0	86.0
			4	150.0	7.1	100.0	160.0	14.3	115.0	110.0
			5	150.0	7.1	90.0	160.0	14.3	95.0	94.0
			6	150.0	7.1	92.0	160.0	14.3	120.0	106.0
2	2	EFC	-1	120.0	0.0	84.0	120.0	0.0	80.0	84.0
			0	130.0	8.3	76.0	135.0	12.5	90.0	85.0
			1	130.0	8.3	74.0	130.0	8.3	90.0	80.0
			2	130.0	8.3	76.0	135.0	12.5	90.0	80.0
			3	130.0	8.3	80.0	125.0	4.2	90.0	86.0
			4	130.0	8.3	76.0	135.0	12.5	90.0	82.0

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
* H.R. values >= 100 beats/min
S.B.P. values <= 70 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 OPEN PHASE

Centre	Patient	Initial	Visit	LYING			STANDING						
				S.B.P. % diff	D.B.P. % diff	H.R. % diff	S.B.P. % diff	D.B.P. % diff	H.R. % diff				
12	EFC	IF	6	120.0	0.0	88.0	4.8	110.0	-8.3	70.0	-12.5	100.0	19.0
			-1	115.0	0.0	78.0	0.0	115.0	0.0	90.0	0.0	95.0	0.0
			1	110.0	-4.3	80.0	2.6	115.0	0.0	80.0	0.0	90.0	0.0
			2	130.0	13.0	80.0	16.7	100.0	-13.0	70.0	-22.2	116.0	5.3
			3	120.0	4.3	80.0	12.8	125.0	8.7	80.0	-11.1	86.0	1.1
			4	130.0	13.0	80.0	2.6	120.0	4.3	80.0	-11.1	88.0	-7.4
	EG		5	120.0	4.3	82.0	5.1	130.0	13.0	80.0	-11.1	86.0	-9.5
			6	140.0	21.7	100.0	-30.8	130.0	13.0	90.0	0.0	72.0	-24.2
			-1	110.0	0.0	84.0	0.0	120.0	0.0	90.0	0.0	86.0	0.0
			0	110.0	0.0	82.0	-2.4	120.0	0.0	90.0	0.0	80.0	-7.0
			1	110.0	0.0	80.0	-4.8	110.0	-8.3	90.0	0.0	76.0	-11.6
			2	110.0	0.0	80.0	-4.8	110.0	-8.3	90.0	0.0	78.0	-9.5
ZSH	4	3	110.0	0.0	80.0	4.9	110.0	-8.3	70.0	-22.2	80.0	-7.0	
		4	110.0	0.0	80.0	10.7	130.0	8.3	100.0	11.1	100.0	16.3	
		5	115.0	4.5	70.0	-22.2	130.0	8.3	80.0	-11.1	74.0	-14.0	
		6	125.0	13.6	90.0	-19.0	130.0	8.3	110.0	22.2	74.0	-14.0	
		-1	110.0	0.0	88.0	-9.1	100.0	0.0	80.0	0.0	96.0	0.0	
		0	110.0	0.0	80.0	-9.1	100.0	0.0	80.0	0.0	88.0	-8.3	
HK	4	1	120.0	9.1	80.0	-9.1	90.0	-10.0	60.0	-25.0	82.0	-14.6	
		2	130.0	18.2	80.0	0.0	120.0	20.0	80.0	0.0	88.0	-8.3	
		3	120.0	9.1	90.0	0.0	90.0	-10.0	60.0	-25.0	82.0	-14.6	
		4	130.0	18.2	80.0	0.0	120.0	20.0	80.0	0.0	96.0	0.0	
		5	140.0	27.3	90.0	0.0	120.0	20.0	90.0	12.5	80.0	-16.7	
		6	110.0	0.0	90.0	-9.1	110.0	10.0	90.0	12.5	80.0	-16.7	
FM	4	-1	130.0	-15.4	80.0	0.0	120.0	-16.7	80.0	0.0	110.0	0.0	
		0	110.0	0.0	100.0	11.1	100.0	0.0	80.0	0.0	110.0	0.0	
		1	130.0	0.0	78.0	-13.3	120.0	0.0	90.0	-12.5	92.0	-16.4	
		2	90.0	-30.8	92.0	2.2	90.0	-25.0	70.0	-12.5	110.0	0.0	
		3	90.0	-30.8	100.0	11.1	90.0	-25.0	60.0	-25.0	120.0	9.1	
		4	120.0	-7.7	88.0	-2.2	120.0	0.0	70.0	-12.5	92.0	-16.4	
8	4	5	105.0	-19.2	84.0	-6.7	90.0	-25.0	70.0	-12.5	88.0	-20.0	
		6	100.0	-23.1	80.0	-11.1	100.0	-16.7	70.0	-12.5	86.0	-21.8	
		-1	110.0	0.0	66.0	0.0	110.0	0.0	90.0	0.0	88.0	0.0	
8	4	1	110.0	0.0	86.0	30.3	110.0	0.0	90.0	0.0	88.0	0.0	
		2	120.0	9.1	86.0	30.3	130.0	18.2	80.0	-11.1	100.0	13.6	
		3	115.0	4.5	94.0	42.4	140.0	27.3	90.0	0.0	112.0	27.3	

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 100 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3
VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
OPEN PHASE

Centre	Patient	Initial Visit	LYING			STANDING									
			S.B.P. z diff	D.B.P. z diff	H.R. z diff	S.B.P. z diff	D.B.P. z diff	H.R. z diff							
12	8	FM	4	120.0	9.1	80.0	0.0	21.2	120.0	9.1	80.0	0.0	88.0	0.0	
			5	120.0	9.1	96.0	12.5	45.5	130.0	18.2	100.0	11.1	116.0	31.8	**
			6	120.0	9.1	80.0	0.0	70.0	6.1	110.0	0.0	70.0	-22.2	68.0	-22.7
	10	IP	-1	120.0	0.0	80.0	0.0	88.0	110.0	0.0	80.0	88.0	88.0	0.0	
			1	110.0	-8.3	80.0	0.0	80.0	-9.1	100.0	0.0	80.0	0.0	80.0	0.0
			2	130.0	8.3	80.0	12.5	88.0	0.0	140.0	27.3	80.0	12.5	88.0	0.0
11	ER	3	110.0	-8.3	80.0	0.0	80.0	9.1	100.0	0.0	80.0	0.0	78.0	-11.4	
		4	100.0	-16.7	80.0	0.0	80.0	-9.1	80.0	-18.2	60.0	-25.0	80.0	-9.1	
		5	130.0	8.3	80.0	12.5	80.0	-9.1	110.0	0.0	80.0	0.0	80.0	-9.1	
		6	120.0	0.0	80.0	12.5	80.0	-9.1	120.0	9.1	80.0	0.0	92.0	4.5	
		-1	110.0	0.0	80.0	0.0	80.0	0.0	110.0	0.0	80.0	0.0	88.0	0.0	
		1	110.0	0.0	80.0	0.0	74.0	-7.5	110.0	0.0	80.0	0.0	88.0	0.0	
12	FSZ	0	110.0	0.0	80.0	0.0	74.0	110.0	0.0	80.0	0.0	85.0	-3.4		
		1	110.0	0.0	80.0	-25.0	92.0	15.0	110.0	0.0	70.0	-12.5	82.0	-6.8	
		2	130.0	18.2	80.0	0.0	80.0	0.0	120.0	9.1	80.0	0.0	74.0	-15.9	
		3	170.0	0.0	70.0	-12.5	88.0	10.0	120.0	9.1	80.0	0.0	84.0	-4.5	
		4	120.0	9.1	80.0	0.0	82.0	2.5	120.0	9.1	80.0	0.0	85.0	-3.4	
		6	110.0	0.0	70.0	-12.5	92.0	15.0	120.0	9.1	80.0	0.0	100.0	13.6	
14	GSZ	-1	120.0	-8.3	80.0	0.0	86.0	130.0	0.0	90.0	90.0	90.0	22.2	**	
		0	170.0	0.0	80.0	0.0	97.0	12.8	150.0	0.0	80.0	-11.1	110.0	37.8	
		1	120.0	0.0	80.0	0.0	95.0	10.5	140.0	7.7	80.0	-11.1	124.0	37.8	
		2	120.0	0.0	80.0	0.0	102.0	18.6	130.0	0.0	80.0	-11.1	125.0	38.9	
		3	120.0	0.0	80.0	0.0	100.0	16.3	130.0	0.0	90.0	0.0	120.0	33.3	
		4	120.0	0.0	80.0	0.0	82.0	-4.7	130.0	0.0	80.0	-11.1	86.0	-4.4	
14	GSZ	5	140.0	16.7	90.0	12.5	88.0	2.3	130.0	0.0	80.0	-11.1	120.0	33.9	
		6	120.0	0.0	80.0	0.0	80.0	-7.0	130.0	0.0	90.0	0.0	92.0	2.2	
		-1	150.0	0.0	105.0	-4.8	120.0	-13.3	150.0	-6.7	105.0	-14.3	130.0	-15.4	
		0	150.0	0.0	100.0	-23.8	92.0	-23.3	120.0	-20.0	90.0	-14.3	85.0	-36.6	
		1	120.0	-13.3	90.0	-14.3	80.0	-33.3	120.0	-20.0	80.0	-23.8	82.0	-36.6	
		3	130.0	-33.3	70.0	-33.3	102.0	-15.0	120.0	-20.0	95.0	-9.5	92.0	-23.2	
15	GS	4	130.0	-13.3	95.0	-9.5	92.0	-23.3	120.0	-20.0	90.0	-14.3	106.0	-18.5	
		5	130.0	-13.3	100.0	-4.8	88.0	-26.7	120.0	-20.0	90.0	-14.3	100.0	-23.1	
		6	145.0	-0.7	100.0	-4.8	88.0	-26.7	130.0	-13.3	100.0	-4.8	92.0	-29.2	
		-1	140.0	0.0	100.0	-20.0	88.0	0.0	130.0	0.0	100.0	-10.0	88.0	0.0	
		0	140.0	7.1	80.0	0.0	80.0	-9.1	150.0	15.4	100.0	0.0	88.0	0.0	
		1	150.0	0.0	100.0	0.0	80.0	-9.1	150.0	15.4	100.0	0.0	80.0	-9.1	

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 100 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
OPEN PHASE

Centre	Patient	Initial	Visit	LYING			STANDING							
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	H.R.	% diff			
12	GB	2	150.0	7.1	90.0	-10.0	88.0	0.0	120.0	-7.7	90.0	-10.0	80.0	-9.1
		3	130.0	-7.1	90.0	-10.0	96.0	9.1	140.0	7.7	90.0	-10.0	96.0	9.1
		4	140.0	0.0	100.0	0.0	100.0	13.6	140.0	7.7	100.0	0.0	88.0	0.0
		5	140.0	0.0	90.0	-10.0	72.0	-18.2	125.0	-3.8	80.0	-20.0	80.0	-9.1
		6	150.0	7.1	90.0	-10.0	100.0	13.6	160.0	23.1	90.0	-10.0	100.0	13.6
		-1	120.0	0.0	80.0	0.0	60.0	-3.3	120.0	0.0	80.0	0.0	72.0	13.9
18	LS	1	130.0	8.3	90.0	12.5	66.0	10.0	90.0	0.0	90.0	12.5	84.0	16.7
		2	120.0	0.0	80.0	0.0	64.0	6.7	120.0	0.0	90.0	12.5	84.0	16.7
		3	110.0	-8.3	90.0	12.5	60.0	0.0	110.0	0.0	80.0	0.0	62.0	-13.9
		4	110.0	-8.3	70.0	-12.5	62.0	3.3	110.0	-8.3	70.0	-12.5	80.0	11.1
		5	130.0	8.3	100.0	25.0	76.0	26.7	120.0	0.0	90.0	12.5	80.0	11.1
		6	110.0	-8.3	70.0	-12.5	67.0	11.7	110.0	-8.3	70.0	-12.5	82.0	13.9
21	FL	-1	120.0	0.0	80.0	0.0	82.0	9.8	125.0	4.0	90.0	0.0	94.0	-6.4
		0	120.0	0.0	80.0	0.0	80.0	0.0	130.0	-4.0	90.0	0.0	88.0	-2.1
		1	120.0	0.0	80.0	0.0	80.0	-2.4	120.0	-4.0	80.0	-11.1	92.0	-2.1
		2	120.0	0.0	80.0	0.0	82.0	12.2	110.0	-12.0	80.0	-11.1	90.0	-4.3
		3	110.0	-8.3	70.0	-12.5	72.0	-12.2	110.0	-12.0	80.0	-11.1	98.0	4.3
		4	120.0	0.0	80.0	0.0	86.0	4.9	120.0	-4.0	80.0	-11.1	100.0	6.4
22	NV	5	120.0	0.0	80.0	0.0	78.0	-4.9	120.0	-4.0	80.0	-11.1	88.0	-6.4
		6	120.0	0.0	80.0	0.0	100.0	22.0	110.0	-12.0	70.0	-22.2	92.0	-2.1
		-1	130.0	0.0	90.0	0.0	90.0	-6.7	140.0	0.0	80.0	0.0	92.0	4.3
		0	140.0	7.7	90.0	0.0	84.0	-11.1	140.0	0.0	90.0	12.5	96.0	-4.3
		1	140.0	7.7	90.0	0.0	80.0	-2.2	145.0	3.6	90.0	12.5	96.0	-4.3
		2	145.0	11.5	90.0	0.0	88.0	-2.2	140.0	0.0	90.0	12.5	88.0	-4.3
23	EN	3	125.0	-3.8	70.0	-22.2	80.0	-11.1	140.0	0.0	80.0	0.0	84.0	-8.7
		4	130.0	0.0	90.0	0.0	80.0	-11.1	120.0	-14.3	80.0	0.0	96.0	4.3
		5	130.0	0.0	90.0	0.0	84.0	-6.7	140.0	0.0	90.0	12.5	96.0	4.3
		6	130.0	0.0	80.0	-11.1	80.0	-11.1	140.0	0.0	90.0	12.5	88.0	-4.3
		-1	140.0	0.0	80.0	0.0	76.0	7.9	140.0	0.0	85.0	-5.9	82.0	2.4
		0	140.0	0.0	80.0	0.0	78.0	2.6	145.0	3.6	80.0	-5.9	92.0	12.2
25	FS	1	140.0	0.0	80.0	0.0	82.0	7.9	130.0	-7.1	90.0	5.9	96.0	17.1
		2	140.0	0.0	80.0	0.0	80.0	7.9	130.0	-7.1	80.0	-5.9	98.0	19.5
		3	120.0	-14.3	80.0	0.0	100.0	31.6	130.0	-7.1	80.0	-5.9	96.0	17.1
		4	120.0	-14.3	80.0	0.0	78.0	2.6	130.0	-7.1	80.0	-5.9	96.0	17.1
		5	120.0	-14.3	80.0	0.0	100.0	31.6	110.0	-21.4	70.0	-17.6	100.0	22.0
		6	110.0	-21.4	70.0	-12.5	98.0	28.9	140.0	0.0	70.0	-17.6	109.0	52.9
-1	110.0	-21.4	60.0	-10.0	100.0	28.9	100.0	0.0	60.0	-10.0	105.0	52.9		

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 50 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 RESOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 OPEN PHASE

Centre	Patient	Initial	Visit	LYING			STANDING					
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	H.R.	% diff	
12	FS	0	130.0	18.2	90.0	50.0	100.0	0.0	90.0	50.0	112.0	6.7
		1	150.0	36.4	90.0	50.0	140.0	40.0	80.0	33.3	101.0	-3.8
		2	170.0	54.5	120.0	100.0	150.0	50.0	110.0	83.3	120.0	14.3
		3	140.0	27.3	90.0	50.0	120.0	20.0	85.0	41.7	90.0	-14.3
		4	140.0	27.3	90.0	50.0	80.0	-20.0	85.0	41.7	82.0	-21.9
		5	120.0	9.1	80.0	33.3	120.0	20.0	75.0	25.0	94.0	-10.5
27	VCS	6	130.0	18.2	90.0	50.0	120.0	20.0	90.0	50.0	84.0	-20.0
		-1	110.0	0.0	80.0	0.0	110.0	0.0	80.0	0.0	88.0	6.8
		0	100.0	-9.1	70.0	-12.5	110.0	0.0	70.0	-12.5	100.0	13.6
		1	100.0	-9.1	70.0	-12.5	110.0	0.0	70.0	-12.5	110.0	25.0
		2	100.0	-9.1	70.0	-12.5	110.0	0.0	80.0	0.0	92.0	4.5
		3	110.0	0.0	80.0	0.0	90.0	12.5	80.0	0.0	94.0	6.8
28	IV	4	100.0	-9.1	70.0	-12.5	88.0	10.0	70.0	-12.5	94.0	13.6
		5	100.0	-9.1	70.0	-12.5	95.0	18.8	120.0	9.1	100.0	0.0
		6	120.0	9.1	60.0	-25.0	104.0	30.0	110.0	0.0	100.0	13.6
		-1	110.0	0.0	70.0	0.0	110.0	0.0	70.0	0.0	80.0	0.0
		0	90.0	-18.2	70.0	0.0	100.0	22.2	100.0	-9.1	96.0	20.0
		1	90.0	-18.2	70.0	0.0	100.0	38.9	90.0	-18.2	110.0	37.5
29	AK	2	90.0	-18.2	70.0	0.0	100.0	38.9	90.0	-18.2	110.0	37.5
		3	100.0	-9.1	70.0	0.0	102.0	41.7	100.0	-9.1	105.0	31.3
		4	100.0	-9.1	70.0	0.0	88.0	22.2	100.0	-9.1	100.0	25.0
		5	90.0	-18.2	70.0	0.0	84.0	16.7	100.0	-9.1	96.0	20.0
		6	110.0	0.0	70.0	0.0	97.0	34.7	100.0	-9.1	104.0	30.0
		-1	120.0	-8.3	80.0	0.0	88.0	-9.1	120.0	0.0	96.0	-8.3
31	FN	0	110.0	8.3	80.0	0.0	80.0	-9.1	80.0	0.0	88.0	0.0
		1	130.0	8.3	80.0	0.0	92.0	4.5	130.0	8.3	96.0	0.0
		2	110.0	-8.3	70.0	-12.5	84.0	-4.5	110.0	-8.3	92.0	-4.2
		3	100.0	-16.7	60.0	-25.0	76.0	-13.6	110.0	-8.3	70.0	-14.6
		4	120.0	0.0	80.0	0.0	100.0	13.6	120.0	0.0	80.0	0.0
		5	120.0	0.0	80.0	0.0	98.0	11.4	120.0	0.0	100.0	4.2
31	FN	6	110.0	-8.3	80.0	0.0	88.0	0.0	70.0	-12.5	96.0	0.0
		-1	160.0	0.0	90.0	0.0	82.0	-7.7	130.0	-11.1	94.0	-14.9
		0	140.0	-7.1	90.0	0.0	76.0	-7.3	120.0	-22.2	80.0	-6.4
		1	130.0	-14.3	80.0	-11.1	80.0	-2.4	110.0	-15.4	70.0	-22.2
		2	120.0	-14.3	80.0	-11.1	86.0	4.3	100.0	-23.1	80.0	-2.1
		3	120.0	-14.3	80.0	-11.1	86.0	4.3	100.0	-23.1	86.0	-8.5
31	FN	4	120.0	-14.3	80.0	-11.1	88.0	7.3	100.0	-23.1	92.0	-2.1
		5	150.0	7.1	100.0	11.1	82.0	0.0	130.0	-11.1	80.0	-2.1
		6	110.0	-21.4	70.0	-22.2	92.0	12.2	100.0	-23.1	70.0	-22.2
		-1	160.0	0.0	90.0	0.0	82.0	-7.7	130.0	-11.1	94.0	-14.9
		0	140.0	-7.1	90.0	0.0	76.0	-7.3	120.0	-22.2	80.0	-6.4
		1	130.0	-14.3	80.0	-11.1	80.0	-2.4	110.0	-15.4	70.0	-22.2

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 OPEN PHASE

Centre	Patient	Initial	Visit	LYING			STANDING							
				S.B.P.	% diff	D.B.P.	% diff	S.B.P.	% diff	D.B.P.	% diff	H.R.	% diff	
12	LM	-1	140.0	0.0	90.0	0.0	87.0	0.0	140.0	0.0	90.0	0.0	89.0	0.0
		0	140.0	-7.1	80.0	-11.1	87.0	0.0	140.0	-7.1	80.0	-11.1	89.0	-9.0
		1	130.0	-21.4	80.0	-11.1	74.0	-14.9	130.0	-14.3	80.0	-11.1	81.0	-11.1
		2	110.0	-3.4	80.0	-11.1	84.0	-3.4	120.0	-14.3	80.0	-11.1	88.0	-1.1
		3	120.0	-14.3	80.0	-11.1	74.0	-14.9	120.0	-14.3	80.0	-11.1	84.0	-5.6
		4	120.0	-14.3	80.0	-11.1	76.0	-12.6	110.0	-21.4	70.0	-22.2	78.0	-12.4
33	LN	5	110.0	-21.4	70.0	-22.2	80.0	-8.0	130.0	-14.3	80.0	-11.1	88.0	-1.1
		6	120.0	-14.3	80.0	-11.1	72.0	-17.2	130.0	-7.1	80.0	-11.1	84.0	-5.6
		-1	180.0	-22.2	110.0	-18.2	68.0	27.9	160.0	-12.5	110.0	-18.2	64.0	32.8
		0	140.0	-22.2	80.0	-27.3	64.0	-5.9	140.0	-12.5	80.0	-27.3	84.0	31.3
		1	140.0	-17.2	80.0	-18.2	80.0	17.6	150.0	-6.3	100.0	-9.1	84.0	31.3
		2	149.0	-33.3	80.0	-27.3	84.0	23.5	140.0	-12.5	100.0	-9.1	76.0	18.8
34	TGB	3	120.0	-27.8	80.0	-27.3	82.0	20.6	120.0	-25.0	80.0	-27.3	78.0	21.9
		4	130.0	-22.2	80.0	-18.2	80.0	17.6	150.0	-6.3	90.0	-18.2	88.0	37.5
		5	140.0	-27.8	80.0	-18.2	76.0	11.8	130.0	-18.8	80.0	-27.3	100.0	56.3
		6	130.0	-27.8	80.0	-18.2	76.0	11.8	130.0	-18.8	80.0	-27.3	100.0	56.3
		-1	130.0	7.7	80.0	-11.1	84.0	7.1	140.0	0.0	90.0	0.0	96.0	4.2
		0	140.0	-7.7	80.0	-11.1	86.0	4.8	140.0	-7.1	90.0	0.0	94.0	-2.1
38	FG	1	320.0	-15.4	70.0	-22.2	68.0	-19.0	320.0	-14.3	70.0	-22.2	80.0	-16.7
		2	410.0	0.0	90.0	0.0	72.0	-14.3	330.0	-7.1	90.0	0.0	84.0	-12.5
		3	420.0	-7.7	80.0	-11.1	76.0	-9.5	330.0	-7.1	80.0	-11.1	78.0	-18.8
		4	420.0	-15.4	70.0	-22.2	76.0	-9.5	330.0	-7.1	80.0	-11.1	88.0	-8.3
		5	410.0	-23.1	60.0	-33.3	78.0	-7.1	320.0	-14.3	80.0	-11.1	88.0	-8.3
		6	400.0	-23.1	60.0	-33.3	78.0	-7.1	320.0	-14.3	80.0	-11.1	72.0	-25.0
13	PZ	-1	110.0	-9.1	60.0	-25.0	116.0	-24.1	120.0	-8.3	60.0	-33.3	120.0	-13.3
		0	100.0	-9.1	80.0	0.0	100.0	-13.8	110.0	-8.3	90.0	0.0	100.0	-16.7
		1	100.0	0.0	70.0	-12.5	100.0	-13.8	100.0	-16.7	80.0	-11.1	120.0	0.0
		2	110.0	27.3	90.0	12.5	92.0	-20.7	130.0	8.3	80.0	-11.1	88.0	-26.7
		3	140.0	9.1	80.0	0.0	82.0	-29.3	110.0	-8.3	80.0	-11.1	92.0	-23.3
		4	120.0	0.0	92.0	0.0	92.0	-20.7	105.0	-12.5	70.0	-22.2	100.0	-16.7
13	PZ	5	110.0	0.0	70.0	-12.5	88.0	-24.1	120.0	0.0	80.0	-11.1	88.0	-26.7
		-1	115.0	4.3	80.0	-12.5	99.0	23.7	120.0	-8.3	90.0	-22.2	85.0	18.8
		0	120.0	0.0	70.0	-12.5	88.0	10.0	110.0	-8.3	80.0	-11.1	101.0	17.6
		1	115.0	-4.3	80.0	0.0	90.0	12.5	100.0	-16.7	70.0	-22.2	110.0	29.4
		2	110.0	0.0	70.0	-12.5	102.0	27.5	100.0	-16.7	65.0	-27.5	120.0	41.2
		3	115.0	13.0	90.0	12.5	100.0	25.0	120.0	0.0	80.0	-11.1	128.0	50.6

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R8D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
OPEN PHASE

Centre	Patient	Initial	Visit	LYING				STANDING								
				S.B.P. % diff	H.R. % diff	D.B.P. % diff	S.B.P. % diff	H.R. % diff	D.B.P. % diff	S.B.P. % diff	H.R. % diff					
13	PZ	1	6	110.0	-4.3	70.0	-12.5	72.0	-10.0	110.0	-8.3	70.0	-22.2	100.0	17.6	
		2	-1	120.0	0.0	80.0	6.3	98.0	0.0	120.0	0.0	75.0	0.0	102.0	2.9	
	TCS	1	130.0	8.3	80.0	0.0	110.0	12.2	98.0	0.0	130.0	8.3	90.0	20.0	100.0	0.0
		2	115.0	-4.2	80.0	-18.8	106.0	8.2	95.0	-20.8	115.0	-4.2	70.0	-6.7	116.0	13.7
		3	120.0	0.0	70.0	-12.5	88.0	-10.2	115.0	-4.2	115.0	-4.2	70.0	-6.7	98.0	-3.9
		4	120.0	0.0	80.0	0.0	112.0	14.3	110.0	-8.3	110.0	-8.3	70.0	-6.7	125.0	23.5 **
5	120.0	0.0	70.0	-12.5	106.0	8.2	100.0	-16.7	100.0	-16.7	70.0	-6.7	116.0	13.7		
6	115.0	-4.2	70.0	-12.5	110.0	12.2	100.0	0.0	100.0	0.0	80.0	6.7	100.0	-2.0		
3	AI	-1	125.0	-4.0	80.0	0.0	80.0	-5.0	115.0	-4.2	75.0	-6.7	75.0	88.0	-6.8	
		0	120.0	-4.0	70.0	-12.5	86.0	7.5	110.0	-8.3	70.0	-6.7	70.0	101.0	14.8	
	1	100.0	-20.0	70.0	-12.5	92.0	15.0	100.0	-16.7	70.0	-6.7	70.0	98.0	11.4		
	2	110.0	-12.0	70.0	-12.5	104.0	30.0 **	110.0	-8.3	70.0	-6.7	70.0	102.0	15.9		
	3	120.0	-4.0	80.0	0.0	104.0	30.0 **	110.0	-8.3	70.0	-6.7	70.0	102.0	15.9		
	4	110.0	-12.0	70.0	-12.5	103.0	28.7 **	100.0	-16.7	70.0	-6.7	70.0	105.0	19.3		
5	100.0	-20.0	70.0	-12.5	70.0	-12.5	110.0	-8.3	70.0	-6.7	70.0	104.0	18.2			
4	SZJ	-1	140.0	-14.3	80.0	0.0	74.0	8.1	150.0	-23.3	85.0	-11.8	80.0	80.0	7.5	
		0	120.0	-14.3	80.0	-6.3	76.0	2.7	120.0	-20.0	80.0	-5.9	78.0	-2.5		
	1	110.0	-21.4	75.0	12.5	80.0	8.1	130.0	-13.3	80.0	-5.9	86.0	7.5			
	2	140.0	0.0	80.0	0.0	66.0	-10.8	120.0	-20.0	70.0	-17.6	78.0	-2.5			
	3	130.0	-7.1	80.0	0.0	64.0	-13.5	115.0	-23.3	85.0	0.0	78.0	-2.5			
	4	100.0	-28.6	80.0	0.0	74.0	0.0	120.0	-20.0	90.0	5.9	78.0	-2.5			
5	130.0	-7.1	90.0	12.5	74.0	0.0	120.0	-20.0	80.0	-5.9	80.0	25.0 **				
6	140.0	0.0	90.0	12.5	80.0	8.1	120.0	-20.0	80.0	-5.9	80.0	25.0 **				
6	RE	-1	120.0	0.0	90.0	-16.7	88.0	2.3	130.0	-23.1 *	80.0	-12.5	97.0	7.2		
		0	120.0	0.0	75.0	-16.7	90.0	2.3	100.0	-23.1 *	70.0	-12.5	104.0	7.2		
	1	120.0	0.0	80.0	-11.1	101.0	14.8	120.0	-7.7	80.0	0.0	103.0	6.2			
	2	120.0	0.0	80.0	-11.1	110.0	25.0 **	110.0	-15.4	75.0	-6.3	120.0	23.7 **			
	3	110.0	-8.3	70.0	-22.2 *	88.0	0.0	105.0	-19.2	70.0	-12.5	106.0	9.3			
	4	115.0	-4.2	80.0	-11.1	80.0	-9.1	80.0	-7.7	60.0	-25.0 *	70.0	-27.8 **			
5	120.0	0.0	70.0	-22.2 *	112.0	27.3 **	115.0	-11.5	70.0	-12.5	118.0	21.6 **				
6	120.0	0.0	70.0	-22.2 *	92.0	0.0	120.0	0.0	80.0	0.0	100.0	1.0				
7	BL	-1	110.0	18.2	90.0	28.6	88.0	-4.3	135.0	12.5	80.0	12.5	101.0	1.0		
		0	130.0	0.0	80.0	0.0	88.0	-4.3	120.0	0.0	80.0	0.0	92.0	-8.0		
		1	110.0	4.5	70.0	0.0	80.0	-13.0	115.0	-4.2	70.0	-12.5	100.0	0.0		
2	115.0	4.5	80.0	0.0	103.0	12.0	110.0	-8.3	80.0	0.0	124.0	24.0 **				
3	120.0	9.1	80.0	14.3	103.0	12.0	110.0	-8.3	80.0	0.0	124.0	24.0 **				

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 100 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 RESOMETINE - PROTOCOL 20124/013
 Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 OPEN PHASE

Centre	Patient	Initial Visit	LYING			STANDING								
			S.B.P. % diff	H.R. % diff	D.B.P. % diff	S.B.P. % diff	H.R. % diff	D.B.P. % diff						
13	BL	4	130.0	18.2	90.0	-2.2	140.0	16.7	100.0	25.0	**	100.0	0.0	
		5	120.0	9.1	90.0	-2.2	110.0	-8.3	80.0	0.0	0.0	95.0	-5.0	
		6	120.0	9.1	100.0	8.7	120.0	0.0	90.0	12.5	105.0	5.0	105.0	5.0
	PK	-1	140.0	-3.6	92.0	-13.0	145.0	0.0	100.0	11.1	115.0	19.8	96.0	0.0
		1	130.0	-7.1	80.0	-15.2	110.0	-24.1	70.0	-22.2	96.0	0.0	115.0	19.8
		2	120.0	-14.3	70.0	8.7	130.0	-10.3	90.0	0.0	108.0	12.5	96.0	0.0
3		120.0	-14.3	80.0	-13.0	120.0	-17.2	90.0	0.0	90.0	-6.3	100.0	4.2	
4		140.0	0.0	80.0	-13.0	140.0	-3.4	90.0	0.0	100.0	4.2	100.0	4.2	
5		130.0	-7.1	90.0	-2.2	115.0	-20.7	80.0	-11.1	100.0	4.2	100.0	4.2	
6	120.0	-14.3	80.0	-13.0	115.0	-20.7	90.0	0.0	110.0	14.6	110.0	14.6		
9	SZS	-1	130.0	-7.7	80.0	2.4	135.0	0.0	90.0	0.0	88.0	9.1	96.0	9.1
		0	120.0	-7.7	80.0	-2.4	110.0	-18.5	70.0	-22.2	104.0	18.2	104.0	18.2
		1	120.0	-7.7	80.0	-2.4	110.0	-18.5	70.0	-22.2	104.0	18.2	104.0	18.2
		2	120.0	-7.7	80.0	2.4	110.0	-18.5	70.0	-22.2	106.0	20.5	106.0	20.5
		3	120.0	-7.7	80.0	2.4	110.0	-18.5	70.0	-22.2	106.0	20.5	106.0	20.5
		4	120.0	-7.7	80.0	-2.4	100.0	-25.9	*	70.0	-22.2	106.0	13.6	106.0
14	HN	-1	140.0	-7.1	70.0	-7.3	115.0	-14.8	70.0	-22.2	88.0	0.0	74.0	0.0
		0	130.0	-7.1	62.0	-15.1	140.0	16.7	70.0	0.0	74.0	0.0	74.0	0.0
		1	130.0	-7.1	80.0	-17.8	140.0	-16.7	60.0	14.3	72.0	-2.7	72.0	-2.7
		2	120.0	-14.3	80.0	-17.8	115.0	-4.2	80.0	14.3	80.0	8.1	80.0	8.1
		3	115.0	-17.9	80.0	9.6	100.0	-16.7	70.0	0.0	75.0	1.4	75.0	1.4
		4	115.0	-17.9	70.0	-4.1	105.0	-12.5	70.0	0.0	80.0	-5.4	80.0	-5.4
5	100.0	-23.6	*	70.0	-4.1	95.0	-20.8	*	70.0	0.0	80.0	8.1		
6	115.0	-17.9	75.0	9.6	100.0	-16.7	80.0	14.3	90.0	-12.2	90.0	-12.2		
14	DF	-1	140.0	-14.3	80.0	-2.5	130.0	-11.5	70.0	14.3	90.0	-15.6	90.0	-15.6
		0	120.0	-14.3	70.0	2.5	115.0	-11.5	80.0	14.3	106.0	17.8	106.0	17.8
		1	120.0	-14.3	80.0	0.0	115.0	-11.5	80.0	14.3	106.0	17.8	106.0	17.8
		2	120.0	-14.3	70.0	-6.3	100.0	-23.1	*	60.0	-14.3	-33.3	60.0	-33.3
		3	120.0	-14.3	80.0	0.0	120.0	-7.7	80.0	14.3	90.0	0.0	90.0	0.0
		4	125.0	-10.7	80.0	5.0	115.0	-11.5	80.0	14.3	106.0	17.8	106.0	17.8
5	120.0	-14.3	75.0	-6.3	120.0	-7.7	80.0	14.3	90.0	0.0	90.0	0.0		
6	120.0	-14.3	80.0	5.0	120.0	-7.7	90.0	28.6	108.0	20.0	108.0	20.0		
15	KG	-1	120.0	16.7	80.0	-19.6	130.0	8.3	90.0	-11.1	92.0	0.0	92.0	0.0
		0	140.0	0.0	80.0	-13.0	120.0	0.0	90.0	0.0	92.0	0.0	92.0	0.0
		1	120.0	0.0	80.0	-13.0	120.0	0.0	90.0	0.0	98.0	6.5	98.0	6.5

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 100 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R8D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
OPEN PHASE

Centre	Patient	Initial	Visit	LYING			STANDING										
				S.B.P. % diff	D.B.P. % diff	H.R. % diff	S.B.P. % diff	D.B.P. % diff	H.R. % diff								
13	15	KG	2	110.0	-8.3	70.0	-12.5	76.0	-17.4	120.0	0.0	80.0	-11.1	88.0	-4.3		
			3	100.0	-16.7	70.0	-12.5	92.0	0.0	110.0	-8.3	70.0	-22.2	112.0	21.7		
			4	115.0	-4.2	70.0	-12.5	70.0	-23.9	70.0	-8.3	70.0	-22.2	92.0	0.0		
			5	115.0	-4.2	80.0	0.0	86.0	-6.5	86.0	-4.2	115.0	-4.2	80.0	-11.1	90.0	-2.2
			6	115.0	-4.2	70.0	-12.5	70.0	-12.5	70.0	-8.3	110.0	-8.3	80.0	-11.1	90.0	-2.2
			-1	140.0	0.0	70.0	0.0	62.0	0.0	62.0	0.0	120.0	0.0	70.0	0.0	68.0	0.0
17	16	SZL	1	120.0	-14.3	70.0	0.0	80.0	29.0	100.0	-14.3	70.0	0.0	104.0	64.7		
			2	140.0	0.0	70.0	0.0	72.0	16.1	100.0	-16.7	70.0	0.0	96.0	52.9		
			3	120.0	-14.3	70.0	0.0	92.0	48.4	120.0	0.0	80.0	14.3	100.0	41.2		
			4	140.0	0.0	90.0	28.6	80.0	29.0	120.0	0.0	80.0	14.3	100.0	47.1		
			5	130.0	-7.1	80.0	14.3	80.0	29.0	130.0	8.3	90.0	28.6	95.0	39.7		
			6	130.0	-7.1	70.0	0.0	86.0	38.7	130.0	8.3	80.0	14.3	90.0	32.4		
18	17	GSM	-1	140.0	0.0	90.0	0.0	100.0	0.0	130.0	0.0	90.0	0.0	100.0	0.0		
			0	140.0	0.0	90.0	0.0	100.0	0.0	130.0	0.0	90.0	0.0	100.0	0.0		
			1	110.0	-21.4	70.0	-22.2	86.0	-4.0	120.0	-7.7	70.0	-22.2	100.0	0.0		
			2	120.0	-14.3	80.0	-11.1	86.0	-4.0	130.0	0.0	80.0	-11.1	96.0	-4.0		
			3	120.0	-14.3	80.0	-11.1	86.0	-4.0	130.0	0.0	80.0	-11.1	96.0	-4.0		
			4	115.0	-17.9	70.0	-22.2	104.0	4.0	100.0	-23.1	70.0	-22.2	120.0	20.0		
19	18	VT	5	130.0	-7.1	80.0	-11.1	120.0	20.0	130.0	0.0	70.0	-22.2	128.0	28.0		
			6	115.0	-17.9	80.0	-11.1	84.0	-16.0	110.0	-15.4	70.0	-22.2	100.0	0.0		
			-1	120.0	0.0	80.0	0.0	66.0	0.0	110.0	0.0	70.0	0.0	78.0	0.0		
			0	120.0	0.0	80.0	0.0	64.0	-3.0	120.0	9.1	70.0	0.0	80.0	2.6		
			1	90.0	-25.0	60.0	-25.0	80.0	21.2	90.0	-18.2	60.0	-14.3	100.0	28.2		
			2	95.0	-20.8	70.0	-12.5	55.0	-16.7	90.0	-18.2	60.0	-14.3	60.0	-23.1		
20	19	KK	3	115.0	-4.2	80.0	0.0	65.0	-1.5	110.0	0.0	80.0	0.0	70.0	-10.3		
			4	100.0	-16.7	90.0	12.5	80.0	21.2	90.0	-18.2	80.0	14.3	80.0	2.6		
			5	100.0	-16.7	70.0	-12.5	92.0	39.4	85.0	-22.7	70.0	0.0	112.0	43.6		
			6	130.0	8.3	80.0	0.0	100.0	51.5	100.0	-9.1	80.0	14.3	102.0	30.8		
			-1	140.0	0.0	80.0	0.0	76.0	0.0	130.0	0.0	90.0	0.0	82.0	0.0		
			0	140.0	0.0	80.0	0.0	92.0	21.1	120.0	-7.7	80.0	0.0	95.0	15.9		
20	19	NL	1	115.0	-17.9	80.0	0.0	92.0	21.1	120.0	-7.7	80.0	-11.1	88.0	7.3		
			2	115.0	-17.9	70.0	-12.5	100.0	31.6	110.0	-15.4	70.0	-22.2	120.0	46.3		
			3	115.0	-17.9	70.0	-12.5	100.0	31.6	110.0	-15.4	70.0	-22.2	120.0	46.3		
20	19	NL	-1	140.0	0.0	90.0	0.0	88.0	0.0	120.0	0.0	90.0	0.0	100.0	0.0		
			0	140.0	0.0	70.0	-22.2	88.0	0.0	120.0	0.0	80.0	-11.1	100.0	0.0		
20	19	NL	1	140.0	0.0	80.0	-11.1	95.0	8.0	120.0	0.0	90.0	0.0	100.0	0.0		
			2	115.0	-17.9	80.0	-11.1	95.0	8.0	120.0	0.0	90.0	0.0	100.0	0.0		

** S.B.P. values => 160 mm Hg
D.B.P. values => 100 mm Hg
R.R. values => 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 70 mm Hg
R.R. values <= 50 beats/min

23 C1

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013

Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
OPEN PHASE

Centre	Patient	Initial	Visit	LYING			STANDING								
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	H.R.	% diff				
13	20	NL	3	120.0	-14.3	88.0	0.0	115.0	-4.2	80.0	-11.1	100.0	0.0		
			4	115.0	-17.9	80.0	-9.1	110.0	-8.3	80.0	-11.1	100.0	0.0		
			5	110.0	-21.4	70.0	-22.2	84.0	-4.5	110.0	-8.3	70.0	-22.2	92.0	-8.0
			6	120.0	-14.3	70.0	-22.2	84.0	-4.5	120.0	0.0	70.0	-22.2	88.0	-12.0
			21	110.0	9.1	80.0	0.0	65.0	56.9	120.0	0.0	90.0	-11.1	70.0	60.0
			1	120.0	9.1	80.0	0.0	102.0	29.2	120.0	0.0	80.0	-22.2	112.0	54.3
23	BSB		2	100.0	-9.1	70.0	-12.5	110.0	-8.3	70.0	-22.2	108.0	54.3		
			3	110.0	0.0	70.0	-12.5	92.0	41.5	100.0	-33.3	120.0	71.4		
			4	115.0	4.5	70.0	-12.5	76.0	16.9	100.0	-16.7	70.0	-22.2	100.0	42.9
			5	120.0	9.1	80.0	0.0	80.0	23.1	120.0	0.0	80.0	-11.1	92.0	31.4
			6	115.0	4.5	80.0	0.0	72.0	10.6	115.0	-4.2	80.0	-11.1	120.0	71.4
			23	BSB	-1	110.0	-9.1	60.0	0.0	100.0	0.0	60.0	0.0	80.0	80.0
		1	100.0	-9.1	60.0	0.0	100.0	0.0	60.0	0.0	84.0	5.0			
		2	115.0	4.5	70.0	16.7	90.0	-10.0	70.0	0.0	120.0	50.0			
		3	120.0	9.1	70.0	16.7	80.0	5.0	70.0	16.7	110.0	37.5			
		4	100.0	-9.1	70.0	16.7	80.0	5.0	70.0	16.7	110.0	37.5			
		5	120.0	9.1	80.0	33.3	75.0	-1.3	90.0	-10.0	104.0	30.0			
		6	110.0	0.0	80.0	33.3	78.0	2.6	100.0	0.0	86.0	7.5			

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

2302

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD
 ROXOMETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: ROXOMETINE

Centre	Patient	Initial Visit	LYING			STANDING							
			S.B.P.	H.R.	D.B.P.	S.B.P.	H.R.	D.B.P.					
1	2	TA	-1	110.0	0.0	70.0	64.0	-3.1	110.0	-4.5	65.0	66.0	-4.5
			0	110.0	0.0	70.0	62.0	18.8	105.0	-4.5	70.0	63.0	18.2
			1	110.0	0.0	70.0	76.0	15.6	105.0	-4.5	70.0	78.0	7.7
			2	110.0	0.0	70.0	74.0	6.3	110.0	0.0	70.0	72.0	7.6
			3	115.0	9.1	75.0	68.0	9.4	115.0	4.5	65.0	72.0	9.1
			4	120.0	9.1	70.0	70.0	21.9	115.0	4.5	65.0	75.0	13.6
			5	115.0	4.5	70.0	82.0	28.1	110.0	0.0	65.0	84.0	27.3
			6	115.0	4.5	70.0	80.0	40.6	110.0	0.0	65.0	95.0	43.9
			8	110.0	0.0	70.0	88.0	53.1	110.0	0.0	80.0	100.0	51.5
			10	110.0	0.0	80.0	86.0	32.8	105.0	-4.5	80.0	88.0	33.3
			12	110.0	0.0	80.0	85.0	32.8	120.0	9.1	80.0	92.0	39.4
			14	110.0	0.0	80.0	85.0	32.8	120.0	9.1	80.0	92.0	39.4
			16	110.0	0.0	80.0	86.0	3.1	105.0	-4.5	80.0	80.0	21.2
			18	110.0	0.0	80.0	96.0	50.0	105.0	-4.5	80.0	96.0	45.5
			20	100.0	-9.1	70.0	95.0	48.4	110.0	0.0	80.0	100.0	51.5
			22	110.0	0.0	70.0	92.0	43.8	110.0	0.0	80.0	98.0	48.5
			24	110.0	0.0	70.0	80.0	25.0	120.0	9.1	80.0	88.0	33.3
			26	120.0	9.1	70.0	80.0	53.1	130.0	18.2	90.0	104.0	57.6
			28	130.0	18.2	95.0	100.0	56.3	130.0	18.2	90.0	104.0	57.6
			30	130.0	18.2	95.0	100.0	56.3	130.0	18.2	90.0	104.0	57.6
			32	140.0	27.3	90.0	88.0	37.5	100.0	-9.1	75.0	88.0	39.4
			34	105.0	-4.5	75.0	88.0	37.5	100.0	-9.1	75.0	88.0	39.4
			36	110.0	0.0	70.0	88.0	31.3	110.0	0.0	80.0	92.0	39.4
			38	105.0	-4.5	85.0	88.0	37.5	110.0	0.0	80.0	92.0	39.4
			40	110.0	0.0	85.0	88.0	37.5	120.0	9.1	70.0	77.0	7.7
			42	120.0	9.1	90.0	80.0	25.0	120.0	9.1	90.0	88.0	33.3
			44	120.0	9.1	90.0	80.0	25.0	120.0	9.1	90.0	88.0	33.3
			46	120.0	9.1	85.0	96.0	50.0	120.0	9.1	85.0	100.0	51.5
			48	120.0	9.1	85.0	92.0	43.8	120.0	9.1	90.0	100.0	51.5
			50	95.0	-13.6	65.0	92.0	43.8	90.0	-18.2	65.0	112.0	69.7
			52	120.0	9.1	85.0	88.0	37.5	100.0	-9.1	80.0	100.0	51.5
3	DNC		-1	130.0	0.0	80.0	74.0	-5.4	125.0	0.0	80.0	76.0	-7.9
			0	130.0	0.0	80.0	74.0	0.0	125.0	0.0	80.0	70.0	-6.6
			1	130.0	0.0	80.0	74.0	0.0	125.0	0.0	80.0	71.0	-6.6
			2	130.0	0.0	80.0	74.0	0.0	125.0	0.0	80.0	76.0	0.0
			3	125.0	-3.8	85.0	84.0	13.5	120.0	-4.0	85.0	86.0	13.2
			4	125.0	-3.8	85.0	86.0	16.2	125.0	0.0	80.0	84.0	10.5
			5	130.0	0.0	80.0	82.0	10.8	125.0	0.0	85.0	84.0	10.5
			6	125.0	-3.8	80.0	76.0	2.7	130.0	4.0	80.0	77.0	1.3

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	Initial Visit	LYING				STANDING					
			S.B.P. % diff	H.R. % diff	D.B.P. % diff	S.B.P. % diff	H.R. % diff	D.B.P. % diff	H.R. % diff			
1	3	DNC	108.0	-23.1	60.0	-25.0	110.0	-12.0	70.0	-12.5	106.0	39.5
	10		108.0	-23.1	70.0	-12.5	110.0	-12.0	80.0	0.0	114.0	50.0
	12		110.0	-15.4	75.0	-6.3	110.0	-12.0	80.0	0.0	100.0	31.6
	14		120.0	-7.7	70.0	-12.5	120.0	-4.0	70.0	-12.5	100.0	31.6
	16		110.0	-15.4	75.0	-6.3	110.0	-12.0	80.0	0.0	110.0	44.7
	18		110.0	-15.4	70.0	-12.5	110.0	-12.0	80.0	0.0	95.0	25.0
	20		110.0	-15.4	70.0	-12.5	120.0	-4.0	80.0	0.0	100.0	31.6
	22		110.0	-15.4	70.0	-12.5	120.0	-4.0	80.0	0.0	100.0	31.6
	24		100.0	-23.1	65.0	-18.8	110.0	-12.0	75.0	-6.3	108.0	42.1
	26		100.0	-23.1	65.0	-18.8	110.0	-12.0	75.0	-6.3	108.0	42.1
	28		115.0	-11.5	80.0	0.0	96.0	-6.3	85.0	6.3	100.0	31.6
	30		120.0	-7.7	75.0	-6.3	100.0	-4.0	75.0	-6.3	100.0	31.6
	32		110.0	-15.4	70.0	-12.5	108.0	-8.0	75.0	-6.3	120.0	57.9
	34		95.0	-26.9	65.0	-18.8	104.0	-24.0	60.0	-25.0	112.0	47.4
	36		95.0	-26.9	65.0	-18.8	104.0	-24.0	60.0	-25.0	112.0	47.4
	38		100.0	-23.1	65.0	-18.8	92.0	-24.0	60.0	-25.0	100.0	31.6
	40		120.0	-7.7	85.0	6.3	100.0	-4.0	90.0	-12.5	100.0	31.6
	42		100.0	-23.1	70.0	-12.5	100.0	-20.0	70.0	-12.5	104.0	36.8
	44		110.0	-15.4	80.0	0.0	104.0	-8.0	75.0	-6.3	112.0	47.4
	46		110.0	-15.4	80.0	0.0	96.0	-8.0	85.0	6.3	100.0	31.6
	48		110.0	-15.4	80.0	0.0	100.0	-12.0	85.0	6.3	100.0	31.6
	50		110.0	-15.4	75.0	-6.3	96.0	-12.0	80.0	0.0	100.0	31.6
	52		100.0	-23.1	70.0	-12.5	104.0	-20.0	80.0	0.0	108.0	42.1
1	4	DB	110.0	13.6	60.0	8.3	110.0	9.1	60.0	0.0	74.0	8.1
	0		125.0	13.6	65.0	8.3	120.0	13.6	60.0	0.0	80.0	8.1
	1		125.0	13.6	65.0	8.3	125.0	13.6	60.0	0.0	78.0	5.4
	2		125.0	13.6	65.0	8.3	125.0	13.6	70.0	16.7	73.0	-1.4
	3		100.0	-9.1	70.0	16.7	130.0	18.2	70.0	16.7	71.0	-4.1
	4		100.0	-9.1	70.0	16.7	100.0	-9.1	70.0	16.7	78.0	5.4
	5		100.0	-9.1	60.0	0.0	100.0	-9.1	70.0	16.7	85.0	14.9
	6		120.0	9.1	80.0	35.3	120.0	9.1	80.0	35.3	80.0	8.1
	8		130.0	18.2	85.0	41.7	110.0	0.0	80.0	33.3	92.0	24.3
	10		130.0	18.2	80.0	35.3	130.0	18.2	90.0	50.0	92.0	24.3
	12		120.0	9.1	90.0	50.0	125.0	13.6	95.0	58.3	88.0	18.9
	14		120.0	9.1	90.0	50.0	125.0	13.6	95.0	58.3	84.0	13.5
	16		130.0	18.2	80.0	35.3	130.0	18.2	90.0	50.0	90.0	21.6
	18		120.0	9.1	85.0	41.7	125.0	13.6	90.0	50.0	88.0	18.9
	20		140.0	27.3	95.0	58.3	140.0	27.3	90.0	50.0	84.0	13.5
	22		140.0	27.3	95.0	58.3	140.0	27.3	90.0	50.0	84.0	13.5

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 mm Hg
 H.R. values <= 50 beats/min

2364

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	Initial	Visit	LYING				STANDING								
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff			
1	4	DB	24	135.0	22.7	90.0	50.0	80.0	14.3	130.0	18.2	100.0	66.7	**	84.0	13.5
			26	140.0	27.3	90.0	50.0	78.0	11.4	150.0	36.4	90.0	66.7	**	82.0	10.8
			28	140.0	27.3	90.0	50.0	78.0	11.4	150.0	36.4	90.0	66.7	**	82.0	10.8
			30	150.0	36.4	95.0	58.3	76.0	8.6	150.0	36.4	90.0	66.7	**	76.0	2.7
			32	145.0	31.8	90.0	50.0	80.0	14.3	145.0	31.8	90.0	66.7	**	84.0	13.5
			34	130.0	18.2	100.0	66.7	60.0	-14.3	140.0	27.3	100.0	66.7	**	80.0	8.1
			36	140.0	27.3	90.0	50.0	80.0	14.3	140.0	27.3	100.0	66.7	**	84.0	13.5
			38	120.0	9.1	80.0	33.3	84.0	20.0	110.0	0.0	80.0	33.3	**	88.0	18.9
			40	120.0	9.1	90.0	50.0	84.0	20.0	120.0	9.1	90.0	50.0	**	96.0	29.7
			42	135.0	22.7	90.0	50.0	88.0	25.7	110.0	0.0	90.0	50.0	**	92.0	24.3
			44	130.0	18.2	90.0	50.0	80.0	14.3	130.0	18.2	90.0	50.0	**	90.0	21.6
			46	120.0	9.1	85.0	41.7	96.0	37.1	120.0	9.1	90.0	50.0	**	100.0	35.1
			48	130.0	18.2	90.0	50.0	84.0	20.0	120.0	9.1	90.0	50.0	**	84.0	13.5
			50	130.0	18.2	90.0	50.0	80.0	14.3	125.0	13.6	95.0	58.3	**	84.0	13.5
			52	120.0	9.1	90.0	50.0	76.0	8.6	120.0	9.1	90.0	50.0	**	88.0	18.9
	7	CCR	-1	120.0	-4.2	80.0	-6.3	62.0	-3.2	120.0	-4.2	70.0	0.0	**	64.0	-4.7
			0	115.0	-8.3	75.0	-12.5	70.0	12.5	115.0	-4.2	70.0	0.0	**	61.0	-25.0
			1	110.0	-16.7	70.0	-12.5	78.0	25.8	110.0	-8.3	70.0	0.0	**	80.0	25.0
			2	100.0	-36.4	70.0	-12.5	80.0	29.0	110.0	-8.3	70.0	0.0	**	85.0	32.8
			3	110.0	-8.3	70.0	-12.5	80.0	29.0	110.0	-8.3	70.0	0.0	**	89.0	39.1
			4	120.0	0.0	80.0	0.0	80.0	29.0	120.0	0.0	85.0	21.4	**	85.0	32.8
			5	110.0	-8.3	80.0	0.0	80.0	29.0	120.0	0.0	85.0	21.4	**	88.0	37.5
			6	110.0	-8.3	70.0	-12.5	112.0	80.6	110.0	-8.3	80.0	14.3	**	112.0	75.0
			8	110.0	-8.3	70.0	-12.5	112.0	80.6	110.0	-8.3	80.0	14.3	**	112.0	75.0
			10	95.0	-20.8	65.0	-18.8	112.0	80.6	90.0	-25.0	65.0	-7.1	**	116.0	81.3
			12	110.0	-8.3	80.0	0.0	104.0	67.7	95.0	-20.8	75.0	7.1	**	116.0	81.3
			14	110.0	-8.3	80.0	0.0	104.0	67.7	95.0	-20.8	75.0	7.1	**	116.0	81.3
			16	130.0	8.3	90.0	12.5	104.0	67.7	115.0	0.0	80.0	14.3	**	87.0	35.9
			18	120.0	0.0	80.0	0.0	112.0	80.6	115.0	-4.2	80.0	14.3	**	120.0	87.5
			20	120.0	0.0	65.0	-18.8	108.0	74.2	105.0	-12.5	75.0	7.1	**	128.0	100.0
			22	115.0	-4.2	75.0	-6.3	104.0	67.7	105.0	-12.5	75.0	7.1	**	120.0	87.5
			24	115.0	-4.2	70.0	-12.5	112.0	80.6	105.0	-12.5	80.0	14.3	**	120.0	87.5
			26	125.0	4.2	70.0	-12.5	114.0	83.9	105.0	-12.5	75.0	7.1	**	116.0	81.3
			28	125.0	4.2	80.0	0.0	108.0	74.2	110.0	-8.3	70.0	0.0	**	120.0	87.5
			30	115.0	-4.2	65.0	-18.8	104.0	67.7	110.0	-8.3	65.0	-28.6	*	116.0	81.3
			32	100.0	-16.7	70.0	-12.5	100.0	61.3	105.0	-12.5	80.0	14.3	**	120.0	87.5
			34	115.0	-4.2	80.0	0.0	96.0	54.8	100.0	-8.3	80.0	14.3	**	116.0	81.3
			36	120.0	0.0	80.0	0.0	92.0	48.4	110.0	-8.3	80.0	14.3	**	98.0	53.1
			38	125.0	4.2	80.0	0.0	94.0	51.6	110.0	-8.3	70.0	0.0	**	98.0	53.1

** S.B.P. values => 160 mm Hg
 D.B.P. values => 100 mm Hg
 H.R. values => 100 beats/min
 * S.B.P. values <= 100 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

23 3 6 5

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	Initial	Visit	LYING				STANDING												
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff							
1	7	CCR	40	105.0	-12.5	80.0	0.0	104.0	67.7	**	110.0	-8.3	80.0	14.3	124.0	93.8	**			
			42	130.0	8.3	90.0	12.5	104.0	67.7	**	120.0	0.0	0.0	85.0	21.4	120.0	87.5	**		
			44	120.0	0.0	80.0	0.0	100.0	61.3	**	120.0	0.0	0.0	90.0	28.6	105.0	64.1	**		
			46	120.0	0.0	80.0	0.0	96.0	54.8	**	115.0	-4.2	0.0	80.0	14.3	112.0	75.0	**		
			48	100.0	-16.7	80.0	-18.8	80.0	29.0	**	100.0	-16.7	0.0	65.0	-7.1	92.0	43.8	**		
			50	110.0	-8.3	70.0	-12.5	80.0	29.0	**	120.0	0.0	0.0	75.0	7.1	96.0	50.0	**		
			52	105.0	-12.5	65.0	-18.8	88.0	41.9	**	110.0	-8.3	0.0	70.0	0.0	88.0	37.5	**		
			8	LDL	-1	120.0	-8.3	80.0	-15.0	80.0	68.0	**	120.0	-8.3	75.0	-20.0	88.0	75.0	-14.8	**
					1	110.0	-8.3	75.0	-6.3	80.0	0.0	80.0	0.0	110.0	-8.3	70.0	-6.7	90.0	2.3	**
					2	115.0	-4.2	75.0	-6.3	104.0	30.0	**	100.0	-16.7	0.0	75.0	0.0	112.0	27.3	**
					3	110.0	-8.3	80.0	0.0	100.0	25.0	**	100.0	-16.7	0.0	75.0	0.0	112.0	27.3	**
					4	120.0	0.0	90.0	12.5	92.0	15.0	**	120.0	0.0	0.0	90.0	20.0	112.0	27.3	**
					5	110.0	-8.3	85.0	6.3	96.0	20.0	**	100.0	-16.7	0.0	80.0	6.7	116.0	31.8	**
					6	90.0	-25.0	70.0	-12.5	90.0	12.5	**	95.0	-20.8	*	70.0	-6.7	100.0	15.6	**
					8	100.0	-16.7	70.0	-12.5	104.0	30.0	**	100.0	-16.7	0.0	75.0	0.0	95.0	8.0	**
					10	100.0	-16.7	70.0	-12.5	100.0	25.0	**	100.0	-16.7	0.0	70.0	-6.7	112.0	27.3	**
					12	110.0	-8.3	70.0	-12.5	100.0	22.5	**	110.0	-8.3	0.0	75.0	0.0	112.0	27.3	**
23	33	66	16	110.0	-8.3	80.0	0.0	98.0	22.5	**	120.0	0.0	85.0	13.3	118.0	34.1	**			
			18	130.0	8.3	75.0	-6.3	104.0	30.0	**	120.0	0.0	85.0	13.3	116.0	31.8	**			
			20	130.0	8.3	75.0	-6.3	104.0	30.0	**	120.0	0.0	85.0	13.3	116.0	31.8	**			
			22	100.0	-16.7	75.0	-6.3	96.0	20.0	**	105.0	-12.5	0.0	75.0	0.0	104.0	18.2	**		
			24	120.0	0.0	80.0	0.0	100.0	25.0	**	110.0	-8.3	0.0	80.0	6.7	116.0	27.3	**		
			26	125.0	4.2	75.0	-6.3	108.0	35.0	**	105.0	-12.5	0.0	75.0	0.0	116.0	31.8	**		
			28	125.0	4.2	80.0	0.0	100.0	25.0	**	105.0	-12.5	0.0	85.0	13.3	108.0	22.7	**		
			30	115.0	-4.2	80.0	0.0	100.0	25.0	**	110.0	-12.5	0.0	85.0	13.3	100.0	13.6	**		
			32	120.0	0.0	85.0	6.3	100.0	25.0	**	110.0	-8.3	0.0	80.0	6.7	100.0	13.6	**		
			34	120.0	0.0	80.0	0.0	100.0	25.0	**	110.0	-8.3	0.0	80.0	6.7	100.0	13.6	**		
66	66	66	36	120.0	0.0	80.0	0.0	92.0	15.0	**	110.0	-8.3	80.0	6.7	94.0	6.8	**			
			38	120.0	0.0	80.0	0.0	82.0	2.5	**	110.0	-8.3	80.0	6.7	94.0	6.8	**			
			40	120.0	0.0	75.0	-6.3	92.0	15.0	**	110.0	-8.3	80.0	6.7	112.0	27.3	**			
			42	120.0	0.0	75.0	-6.3	92.0	15.0	**	110.0	-8.3	80.0	6.7	112.0	27.3	**			
			44	105.0	-12.5	80.0	0.0	108.0	35.0	**	110.0	-8.3	0.0	80.0	6.7	108.0	22.7	**		
			46	100.0	-16.7	60.0	-25.0	100.0	25.0	**	110.0	-8.3	0.0	80.0	6.7	108.0	22.7	**		
			48	100.0	-16.7	60.0	-25.0	100.0	25.0	**	110.0	-8.3	0.0	80.0	6.7	108.0	22.7	**		
			50	125.0	4.2	90.0	12.5	104.0	30.0	**	100.0	-16.7	0.0	80.0	6.7	116.0	31.8	**		
			52	125.0	4.2	90.0	12.5	104.0	30.0	**	100.0	-16.7	0.0	80.0	6.7	116.0	31.8	**		

** S.B.P. values => 160 mm Hg
D.B.P. values => 100 mm Hg
H.R. values => 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 50 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: REMOXETINE

Centre	Patient	Initial	Visit	LYING				STANDING								
				S.B.P.	% diff	H.R.	% diff	S.B.P.	% diff	H.R.	% diff					
1	11	MLC	-1	130.0	0.0	85.0	0.0	92.0	0.0	140.0	0.0	90.0	0.0	80.0	0.0	
			0	125.0	-3.8	85.0	0.0	92.0	0.0	140.0	-17.9	85.0	-5.6	100.0	25.0	**
			1	120.0	-7.7	80.0	-5.9	86.0	-6.5	125.0	-10.7	85.0	-5.6	92.0	15.0	
			2	120.0	-7.7	85.0	0.0	76.0	-17.4	120.0	-14.3	85.0	-5.6	72.0	-10.0	
			3	110.0	-15.4	75.0	-11.8	104.0	13.0	115.0	-10.7	80.0	-11.1	104.0	30.0	**
			4	130.0	0.0	85.0	0.0	96.0	4.3	125.0	-10.7	85.0	-5.6	100.0	25.0	**
			5	130.0	0.0	85.0	0.0	104.0	13.0	130.0	-7.1	85.0	-5.6	96.0	20.0	**
			6	130.0	0.0	85.0	0.0	104.0	13.0	130.0	-7.1	85.0	-5.6	96.0	20.0	**
			8	130.0	0.0	85.0	0.0	104.0	13.0	130.0	-7.1	85.0	-5.6	96.0	20.0	**
			10	130.0	0.0	85.0	0.0	104.0	13.0	130.0	-7.1	85.0	-5.6	96.0	20.0	**
			12	130.0	0.0	85.0	0.0	104.0	13.0	130.0	-7.1	85.0	-5.6	96.0	20.0	**
			14	CEC	-1	90.0	0.0	60.0	0.0	84.0	0.0	90.0	0.0	60.0	0.0	104.0
0	90.0	0.0			60.0	0.0	84.0	0.0	90.0	0.0	60.0	0.0	104.0	0.0		
1	105.0	16.7			60.0	0.0	100.0	19.0	100.0	11.1	55.0	-8.3	112.0	7.7		
2	90.0	0.0			60.0	0.0	68.0	-19.0	90.0	0.0	60.0	0.0	80.0	-23.1		
3	100.0	11.1			65.0	8.3	104.0	23.8	100.0	11.1	60.0	0.0	86.0	-17.3		
4	95.0	5.6			60.0	0.0	100.0	19.0	100.0	11.1	65.0	8.3	120.0	15.4		
5	90.0	0.0			65.0	8.3	100.0	19.0	100.0	11.1	70.0	16.7	100.0	-3.8		
6	85.0	-5.6			65.0	8.3	80.0	-4.8	90.0	0.0	65.0	8.3	100.0	-3.8		
8	95.0	5.6			65.0	8.3	120.0	42.9	100.0	11.1	65.0	8.3	120.0	15.4		
10	90.0	0.0			60.0	0.0	108.0	28.6	85.0	-5.6	60.0	0.0	116.0	11.5		
12	90.0	0.0			55.0	-8.3	80.0	-4.8	90.0	0.0	65.0	8.3	88.0	-15.4		
14	90.0	0.0			55.0	-8.3	80.0	-4.8	90.0	0.0	60.0	0.0	88.0	-15.4		
15	TTH	-1	110.0	0.0	70.0	0.0	68.0	0.0	110.0	0.0	80.0	0.0	74.0	0.0		
		0	110.0	0.0	70.0	0.0	68.0	0.0	110.0	0.0	80.0	0.0	74.0	0.0		
		1	120.0	9.1	65.0	-7.1	92.0	35.3	110.0	0.0	70.0	-12.5	100.0	35.1	**	
		2	120.0	9.1	70.0	0.0	104.0	52.9	120.0	9.1	70.0	-12.5	132.0	51.4	**	
		3	115.0	4.5	80.0	14.3	72.0	5.9	90.0	-18.2	50.0	-37.5	88.0	18.9		
		4	110.0	0.0	75.0	7.1	96.0	41.2	110.0	0.0	80.0	0.0	96.0	29.7		

** S.B.P. values => 160 mm Hg
 D.B.P. values => 100 mm Hg
 H.R. values => 100 beats/min
 * S.B.P. values <= 100 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 ROXOXYLINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: ROXOXYLINE

Centre	Patient	Initial	Visit	LIVING				STANDING							
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff		
1	15	TTH	5	110.0	0.0	75.0	7.1	96.0	41.2	110.0	0.0	80.0	0.0	96.0	29.7
			6	120.0	9.1	75.0	14.3	92.0	35.3	110.0	0.0	70.0	-12.5	96.0	29.7
			8	120.0	9.1	80.0	11.8	76.0	11.8	110.0	0.0	80.0	0.0	78.0	5.4
			10	110.0	0.0	70.0	0.0	68.0	0.0	110.0	0.0	70.0	-12.5	72.0	-2.7
			12	115.0	4.5	75.0	7.1	62.0	-8.8	110.0	0.0	70.0	-12.5	72.0	-2.7
			14	110.0	0.0	70.0	0.0	74.0	8.8	110.0	0.0	74.0	0.0	65.0	8.1
			16	120.0	9.1	70.0	0.0	58.0	-14.7	110.0	0.0	70.0	-12.5	64.0	-13.5
			18	110.0	0.0	70.0	0.0	66.0	-2.9	110.0	0.0	70.0	-12.5	72.0	-2.7
			-1	120.0	0.0	75.0	0.0	96.0	0.0	120.0	0.0	85.0	0.0	102.0	0.0
			1	120.0	0.0	70.0	-6.7	112.0	16.7	120.0	0.0	80.0	-5.9	102.0	0.0
			2	120.0	0.0	90.0	20.0	128.0	33.3	120.0	0.0	95.0	41.8	136.0	33.3
			3	120.0	0.0	90.0	20.0	120.0	25.0	130.0	8.3	90.0	5.9	128.0	33.3
			4	130.0	8.3	90.0	20.0	108.0	12.5	130.0	8.3	90.0	5.9	116.0	13.7
			5	140.0	16.7	90.0	20.0	100.0	4.2	130.0	8.3	90.0	5.9	120.0	17.6
			6	140.0	16.7	90.0	20.0	100.0	4.2	130.0	8.3	90.0	5.9	120.0	17.6
			8	120.0	0.0	80.0	6.7	64.0	-33.3	110.0	-8.3	80.0	-5.9	72.0	-29.4
			10	115.0	-4.2	75.0	0.0	68.0	-29.2	110.0	-8.3	75.0	-11.8	74.0	-27.5
			19	SK		-1	110.0	0.0	75.0	0.0	80.0	0.0	120.0	0.0	70.0
1	100.0	-9.1				80.0	6.7	80.0	0.0	100.0	-16.7	80.0	0.0	88.0	0.0
2	100.0	-9.1				70.0	-6.7	84.0	5.0	95.0	-20.8	70.0	0.0	104.0	18.2
3	105.0	-4.5				75.0	0.0	80.0	0.0	100.0	-16.7	80.0	0.0	104.0	18.2
4	110.0	0.0				80.0	6.7	84.0	5.0	105.0	-12.5	75.0	7.1	104.0	18.2
5	120.0	9.1				85.0	13.3	64.0	-20.0	105.0	-12.5	75.0	7.1	84.0	-4.5
6	110.0	0.0				75.0	0.0	84.0	5.0	100.0	-16.7	70.0	0.0	100.0	13.6
8	120.0	9.1				80.0	6.7	76.0	-5.0	105.0	-12.5	80.0	14.3	84.0	-4.5
10	105.0	-4.5				80.0	6.7	84.0	5.0	95.0	-20.8	75.0	7.1	96.0	9.1
12	105.0	-4.5				80.0	6.7	76.0	-5.0	105.0	-12.5	80.0	14.3	88.0	0.0
14	115.0	4.5				80.0	6.7	88.0	10.0	100.0	-16.7	75.0	7.1	100.0	13.6
16	105.0	-4.5				75.0	0.0	88.0	10.0	100.0	-16.7	70.0	0.0	84.0	-4.5
18	110.0	0.0				70.0	-6.7	80.0	0.0	110.0	-8.3	70.0	0.0	95.0	8.0
20	105.0	-4.5				75.0	0.0	84.0	5.0	95.0	-20.8	70.0	0.0	100.0	13.6
22	130.0	18.2				90.0	20.0	88.0	10.0	110.0	-8.3	90.0	28.6	100.0	13.6
24	110.0	0.0				80.0	6.7	76.0	-5.0	110.0	-8.3	75.0	7.1	96.0	9.1
25	110.0	0.0				70.0	-6.7	100.0	25.0	105.0	-12.5	75.0	7.1	116.0	31.8
28	100.0	-9.1				70.0	-6.7	80.0	0.0	100.0	-16.7	70.0	0.0	80.0	-9.1

** S.B.P. values => 160 mm Hg
 D.B.P. values => 100 mm Hg
 H.R. values => 100 beats/min
 * S.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

200608

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXYETINE - PROTOCOL 20124/013
 Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXYETINE

Centre	Patient	Initial	Visit	LYING			STANDING			
				S.B.P.	H.R.	D.B.P.	S.B.P.	H.R.	D.B.P.	
				% diff	% diff	% diff	% diff	% diff	% diff	
1	19	SK	50	110.0	84.0	70.0	100.0	104.0	80.0	100.0
			52	100.0	88.0	80.0	110.0	104.0	80.0	100.0
			34	110.0	96.0	80.0	100.0	104.3	80.0	100.0
			36	110.0	88.0	80.0	100.0	104.3	80.0	100.0
			38	110.0	88.0	80.0	100.0	104.3	80.0	100.0
			40	110.0	88.0	80.0	100.0	104.3	80.0	100.0
			42	110.0	88.0	80.0	100.0	104.3	80.0	100.0
			44	105.0	80.0	80.0	105.0	104.3	80.0	100.0
			46	110.0	84.0	80.0	105.0	104.3	80.0	100.0
			48	135.0	96.0	90.0	100.0	104.3	80.0	100.0
			50	135.0	88.0	100.0	120.0	104.3	80.0	100.0
			52	130.0	88.0	90.0	120.0	104.3	80.0	100.0
			-1	115.0	84.0	90.0	110.0	104.0	85.0	104.0
			1	110.0	82.0	90.0	110.0	104.0	85.0	104.0
			2	125.0	82.0	80.0	110.0	104.0	85.0	104.0
			3	125.0	84.8	80.0	110.0	104.0	85.0	104.0
			4	120.0	88.0	80.0	110.0	104.0	85.0	104.0
			5	120.0	88.0	80.0	110.0	104.0	85.0	104.0
			6	110.0	88.0	80.0	110.0	104.0	85.0	104.0
			8	120.0	88.0	80.0	110.0	104.0	85.0	104.0
			10	125.0	86.0	80.0	110.0	104.0	85.0	104.0
			12	120.0	86.0	80.0	110.0	104.0	85.0	104.0
			14	120.0	86.0	80.0	110.0	104.0	85.0	104.0
			16	120.0	86.0	80.0	110.0	104.0	85.0	104.0
			18	120.0	86.0	80.0	110.0	104.0	85.0	104.0
			20	115.0	86.0	80.0	110.0	104.0	85.0	104.0
			22	120.0	86.0	80.0	110.0	104.0	85.0	104.0
			24	130.0	86.0	80.0	110.0	104.0	85.0	104.0
			26	120.0	86.0	80.0	110.0	104.0	85.0	104.0
			28	130.0	86.0	80.0	110.0	104.0	85.0	104.0
			30	120.0	86.0	80.0	110.0	104.0	85.0	104.0
			32	125.0	86.0	80.0	110.0	104.0	85.0	104.0
			34	115.0	86.0	80.0	110.0	104.0	85.0	104.0
			36	110.0	86.0	80.0	110.0	104.0	85.0	104.0
			38	110.0	86.0	80.0	110.0	104.0	85.0	104.0
			40	110.0	86.0	80.0	110.0	104.0	85.0	104.0
			42	115.0	86.0	80.0	110.0	104.0	85.0	104.0
			44	115.0	86.0	80.0	110.0	104.0	85.0	104.0

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 100 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: REBOMETINE

Centre	Patient	Initial	Visit	LYING			STANDING													
				S.B.P.	D.B.P.	H.R.	S.B.P.	D.B.P.	H.R.											
1	LVF	20	46	110.0	-4.3	70.0	-22.2	*	72.0	-21.7	105.0	-4.5	65.0	-31.6	*	80.0	-23.1			
			48	115.0	0.0	80.0	-11.1	*	76.0	-17.4	120.0	9.1	70.0	9.1	70.0	-26.3	*	84.0	-19.2	
			50	115.0	0.0	70.0	-22.2	*	84.0	-8.7	110.0	0.0	75.0	0.0	75.0	-21.1	*	92.0	-11.5	
			52	120.0	4.3	80.0	-11.1	*	76.0	-17.4	110.0	0.0	75.0	0.0	75.0	-21.1	*	84.0	-19.2	
			-1	100.0	5.0	78.0	-16.7	*	76.0	31.6	105.0	0.0	60.0	0.0	60.0	8.3	*	88.0	27.3	
			0	105.0	0.0	65.0	-23.1	*	100.0	57.9	100.0	0.0	65.0	0.0	65.0	0.0	*	112.0	56.4	
			1	100.0	0.0	60.0	-16.7	*	120.0	57.9	100.0	0.0	60.0	0.0	60.0	8.3	*	120.0	56.4	
			2	105.0	5.0	65.0	-23.1	*	120.0	57.9	100.0	0.0	65.0	0.0	65.0	8.3	*	120.0	56.4	
			3	100.0	0.0	60.0	-16.7	*	120.0	57.9	100.0	0.0	60.0	0.0	60.0	8.3	*	120.0	56.4	
			4	100.0	0.0	75.0	-3.8	*	120.0	57.9	100.0	0.0	75.0	0.0	75.0	16.7	*	120.0	56.4	
			5	110.0	10.0	70.0	-10.3	*	100.0	31.6	100.0	0.0	70.0	0.0	70.0	16.7	*	112.0	27.3	
			6	120.0	20.0	70.0	-10.3	*	100.0	31.6	100.0	0.0	70.0	0.0	70.0	16.7	*	100.0	13.6	
			8	110.0	10.0	70.0	-10.3	*	90.0	18.4	110.0	0.0	70.0	0.0	70.0	16.7	*	95.0	8.0	
			10	120.0	20.0	70.0	-10.3	*	70.0	7.9	120.0	0.0	70.0	0.0	70.0	16.7	*	95.0	12.5	
			12	100.0	0.0	60.0	-23.1	*	80.0	5.3	100.0	0.0	60.0	0.0	60.0	0.0	*	88.0	0.0	
			14	120.0	20.0	70.0	-10.3	*	120.0	57.9	100.0	0.0	70.0	0.0	70.0	25.0	*	120.0	36.4	
			16	110.0	10.0	70.0	-10.3	*	104.0	36.8	100.0	0.0	70.0	0.0	70.0	25.0	*	108.0	22.7	
			18	100.0	0.0	70.0	-10.3	*	120.0	57.9	100.0	0.0	70.0	0.0	70.0	25.0	*	120.0	36.4	
			20	100.0	0.0	60.0	-10.3	*	112.0	47.4	100.0	0.0	60.0	0.0	60.0	0.0	*	120.0	36.4	
			22	110.0	10.0	80.0	2.6	*	112.0	47.4	100.0	0.0	80.0	0.0	80.0	50.0	*	112.0	27.3	
			24	110.0	10.0	70.0	-10.3	*	100.0	31.6	100.0	0.0	70.0	0.0	70.0	33.3	*	115.0	30.7	
			26	100.0	0.0	70.0	-10.3	*	100.0	31.6	100.0	0.0	70.0	0.0	70.0	33.3	*	115.0	30.7	
			28	100.0	0.0	70.0	-10.3	*	116.0	52.6	95.0	0.0	75.0	0.0	75.0	25.0	*	124.0	40.9	
			30	100.0	0.0	70.0	-10.3	*	116.0	52.6	95.0	0.0	75.0	0.0	75.0	25.0	*	124.0	40.9	
			32	110.0	10.0	80.0	2.6	*	75.0	-1.3	110.0	0.0	80.0	0.0	80.0	33.3	*	90.0	2.3	
			34	110.0	10.0	80.0	2.6	*	75.0	-1.3	110.0	0.0	80.0	0.0	80.0	33.3	*	90.0	2.3	
			36	90.0	-10.0	70.0	-10.3	*	114.0	50.0	90.0	0.0	65.0	0.0	65.0	8.3	*	110.0	25.0	
			38	90.0	-10.0	70.0	-10.3	*	114.0	50.0	90.0	0.0	65.0	0.0	65.0	8.3	*	110.0	25.0	
			40	90.0	-10.0	70.0	-10.3	*	114.0	50.0	90.0	0.0	65.0	0.0	65.0	8.3	*	110.0	25.0	
			42	90.0	-10.0	70.0	-10.3	*	74.0	-2.6	90.0	0.0	65.0	0.0	65.0	8.3	*	80.0	-9.1	
			44	100.0	0.0	70.0	-10.3	*	110.0	44.7	95.0	0.0	70.0	0.0	70.0	16.7	*	110.0	25.0	
			46	110.0	10.0	75.0	-3.8	*	116.0	52.6	95.0	0.0	70.0	0.0	70.0	16.7	*	128.0	45.5	
			48	110.0	10.0	75.0	-3.8	*	80.0	5.3	100.0	0.0	70.0	0.0	70.0	16.7	*	88.0	0.0	
			50	110.0	10.0	75.0	-3.8	*	72.0	-5.3	100.0	0.0	70.0	0.0	70.0	16.7	*	78.0	-11.4	
			52	110.0	10.0	75.0	-3.8	*	80.0	5.3	100.0	0.0	70.0	0.0	70.0	16.7	*	86.0	-2.3	
			28	DEK	28	-1	110.0	-4.5	80.0	6.3	110.0	68.0	110.0	0.0	80.0	-4.5	80.0	6.3	88.0	12.8
						0	105.0	-9.1	85.0	-6.3	100.0	47.1	105.0	0.0	85.0	-4.5	88.0	6.3	120.0	53.8
						1	100.0	-9.1	75.0	-6.3	112.0	64.7	110.0	0.0	75.0	-6.3	86.0	-2.3	86.0	-2.3

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 100 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

2370

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

ROBEXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: ROBEXETINE

Centre	Patient	Initial Visit	LYING					STANDING											
			S.B.P.	D.B.P.	H.R.	% diff	S.B.P.	D.B.P.	H.R.	% diff									
1	28	DGM	2	95.0	-13.6	70.0	-12.5	100.0	47.1	**	100.0	-9.1	75.0	-6.3	120.0	53.8	**		
			3	105.0	-4.5	80.0	0.0	120.0	76.5	**	95.0	-13.6	75.0	-6.3	120.0	53.8	**		
			4	105.0	-4.5	70.0	-12.5	68.0	0.0	110.0	0.0	110.0	0.0	85.0	6.3	88.0	12.8	**	
			5	100.0	-9.1	70.0	-12.5	100.0	47.1	**	100.0	-9.1	80.0	0.0	110.0	41.0	**		
			6	105.0	-4.5	75.0	-6.3	100.0	47.1	**	95.0	-13.6	70.0	0.0	100.0	28.2	**		
			7	100.0	-9.1	70.0	-12.5	60.0	-11.8	**	100.0	0.0	80.0	0.0	80.0	-17.9	**		
			8	120.0	9.1	85.0	6.3	116.0	70.6	**	120.0	9.1	90.0	12.5	90.0	48.7	**		
			9	120.0	9.1	85.0	6.3	116.0	70.6	**	120.0	9.1	90.0	12.5	116.0	48.7	**		
			10	105.0	-4.5	65.0	-18.8	104.0	52.9	**	110.0	0.0	80.0	0.0	94.0	20.5	**		
			11	105.0	-4.5	65.0	-18.8	104.0	52.9	**	110.0	0.0	80.0	0.0	94.0	20.5	**		
			12	105.0	-4.5	65.0	-18.8	104.0	52.9	**	110.0	0.0	80.0	0.0	94.0	20.5	**		
			13	105.0	-4.5	65.0	-18.8	104.0	52.9	**	110.0	0.0	80.0	0.0	94.0	20.5	**		
			14	105.0	-4.5	65.0	-18.8	104.0	52.9	**	110.0	0.0	80.0	0.0	94.0	20.5	**		
			15	105.0	-4.5	65.0	-18.8	104.0	52.9	**	110.0	0.0	80.0	0.0	94.0	20.5	**		
			16	105.0	-4.5	65.0	-18.8	104.0	52.9	**	110.0	0.0	80.0	0.0	94.0	20.5	**		
			17	105.0	-4.5	65.0	-18.8	104.0	52.9	**	110.0	0.0	80.0	0.0	94.0	20.5	**		
			18	105.0	-4.5	65.0	-18.8	104.0	52.9	**	110.0	0.0	80.0	0.0	94.0	20.5	**		
			19	105.0	-4.5	65.0	-18.8	104.0	52.9	**	110.0	0.0	80.0	0.0	94.0	20.5	**		
			20	100.0	-9.1	60.0	-25.0	60.0	-11.8	*	100.0	-9.1	70.0	-25.0	70.0	-15.4	**		
			21	110.0	0.0	90.0	12.5	60.0	-11.8	**	100.0	0.0	60.0	0.0	60.0	0.0	120.0	53.8	**
			22	110.0	0.0	90.0	12.5	60.0	-11.8	**	100.0	0.0	60.0	0.0	60.0	0.0	120.0	53.8	**
			23	100.0	-9.1	65.0	-18.8	116.0	70.6	**	100.0	-9.1	80.0	0.0	80.0	0.0	124.0	59.0	**
			24	100.0	-9.1	65.0	-18.8	116.0	70.6	**	100.0	-9.1	80.0	0.0	80.0	0.0	124.0	59.0	**
			25	105.0	-4.5	75.0	-6.3	116.0	70.6	**	110.0	0.0	85.0	6.3	85.0	0.0	124.0	59.0	**
			26	105.0	-4.5	75.0	-6.3	116.0	70.6	**	110.0	0.0	85.0	6.3	85.0	0.0	124.0	59.0	**
			27	105.0	-4.5	75.0	-6.3	116.0	70.6	**	110.0	0.0	85.0	6.3	85.0	0.0	124.0	59.0	**
			28	105.0	-4.5	75.0	-6.3	116.0	70.6	**	110.0	0.0	85.0	6.3	85.0	0.0	124.0	59.0	**
			29	105.0	-4.5	75.0	-6.3	116.0	70.6	**	110.0	0.0	85.0	6.3	85.0	0.0	124.0	59.0	**
			30	105.0	-4.5	75.0	-6.3	116.0	70.6	**	110.0	0.0	85.0	6.3	85.0	0.0	124.0	59.0	**
			31	105.0	-4.5	75.0	-6.3	116.0	70.6	**	110.0	0.0	85.0	6.3	85.0	0.0	124.0	59.0	**
			32	105.0	-4.5	75.0	-6.3	116.0	70.6	**	110.0	0.0	85.0	6.3	85.0	0.0	124.0	59.0	**
			33	105.0	-4.5	75.0	-6.3	116.0	70.6	**	110.0	0.0	85.0	6.3	85.0	0.0	124.0	59.0	**
			34	105.0	-4.5	75.0	-6.3	116.0	70.6	**	110.0	0.0	85.0	6.3	85.0	0.0	124.0	59.0	**
			35	105.0	-4.5	75.0	-6.3	116.0	70.6	**	110.0	0.0	85.0	6.3	85.0	0.0	124.0	59.0	**
			36	105.0	-4.5	75.0	-6.3	116.0	70.6	**	110.0	0.0	85.0	6.3	85.0	0.0	124.0	59.0	**
			37	105.0	-4.5	75.0	-6.3	116.0	70.6	**	110.0	0.0	85.0	6.3	85.0	0.0	124.0	59.0	**
			38	105.0	-4.5	75.0	-6.3	116.0	70.6	**	110.0	0.0	85.0	6.3	85.0	0.0	124.0	59.0	**
			39	110.0	0.0	70.0	-12.5	88.0	29.4		110.0	0.0	85.0	6.3	84.0	7.7	94.0	20.5	**
			40	110.0	0.0	70.0	-12.5	88.0	29.4		110.0	0.0	85.0	6.3	84.0	7.7	94.0	20.5	**
			41	110.0	0.0	70.0	-12.5	88.0	29.4		110.0	0.0	85.0	6.3	84.0	7.7	94.0	20.5	**
			42	110.0	0.0	70.0	-12.5	88.0	29.4		110.0	0.0	85.0	6.3	84.0	7.7	94.0	20.5	**
			43	115.0	4.5	62.0	-8.8	62.0	-8.8		120.0	9.1	70.0	-12.5	70.0	-12.5	68.0	-12.8	**
			44	115.0	4.5	62.0	-8.8	62.0	-8.8		120.0	9.1	70.0	-12.5	70.0	-12.5	68.0	-12.8	**
			45	130.0	18.2	74.0	8.8	74.0	8.8		120.0	9.1	80.0	0.0	80.0	0.0	78.0	-4.8	**
			46	130.0	18.2	74.0	8.8	74.0	8.8		120.0	9.1	80.0	0.0	80.0	0.0	78.0	-4.8	**
			47	125.0	13.6	85.0	6.3	64.0	-5.9		120.0	9.1	80.0	0.0	80.0	0.0	66.0	-15.4	**
			48	125.0	13.6	85.0	6.3	64.0	-5.9		120.0	9.1	80.0	0.0	80.0	0.0	66.0	-15.4	**
			49	130.0	18.2	70.0	-12.5	70.0	2.9		110.0	0.0	70.0	-12.5	70.0	-12.5	72.0	-7.7	**
			50	130.0	18.2	70.0	-12.5	70.0	2.9		110.0	0.0	70.0	-12.5	70.0	-12.5	72.0	-7.7	**
			51	110.0	0.0	80.0	0.0	58.0	-44.7		115.0	4.5	75.0	-6.3	75.0	-6.3	62.0	-20.5	**
			52	110.0	0.0	80.0	0.0	58.0	-44.7		115.0	4.5	75.0	-6.3	75.0	-6.3	62.0	-20.5	**
			30	GMH	-1	1	120.0	0.0	80.0	12.5	120.0	33.3	120.0	-8.3	75.0	6.7	84.0	9.5	
2	120.0	0.0				90.0	-12.5	80.0	-33.3	120.0	-8.3	80.0	6.7	92.0	9.5				
3	100.0	-16.7				70.0	-12.5	92.0	-23.3	100.0	-16.7	75.0	0.0	100.0	19.0				
4	100.0	-16.7				70.0	-12.5	72.0	-60.0	100.0	-16.7	75.0	0.0	100.0	19.0				
5	120.0	0.0				80.0	0.0	88.0	-26.7	110.0	-8.3	70.0	0.0	80.0	-4.8				
6	120.0	0.0				80.0	0.0	88.0	-26.7	110.0	-8.3	70.0	0.0	80.0	-4.8				
7	120.0	0.0				80.0	0.0	88.0	-26.7	110.0	-8.3	70.0	0.0	80.0	-4.8				
8	120.0	0.0				80.0	0.0	88.0	-26.7	110.0	-8.3	70.0	0.0	80.0	-4.8				
9	120.0	0.0				80.0	0.0	88.0	-26.7	110.0	-8.3	70.0	0.0	80.0	-4.8				
10	125.0	4.2				85.0	6.3	64.0	-46.7	120.0	0.0	80.0	6.7	68.0	-19.0				
11	125.0	4.2				85.0	6.3	64.0	-46.7	120.0	0.0	80.0	6.7	68.0	-19.0				
12	130.0	8.3				80.0	0.0	62.0	-48.3	120.0	0.0	70.0	6.7	68.0	-19.0				

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 50 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	Initial	Visit	LYING				STANDING									
				S.B.P.	% diff	D.B.P.	% diff	H.R.	% diff	S.B.P.	% diff	D.B.P.	% diff	H.R.	% diff		
1	30	GHH	14	110.0	-8.3	70.0	-12.5	64.0	-46.7	110.0	-8.3	70.0	-6.7	72.0	-14.3		
			16	115.0	-4.2	75.0	-6.3	72.0	-40.0	110.0	-8.3	70.0	-6.7	76.0	-9.5		
			18	120.0	0.0	80.0	0.0	74.0	-38.3	110.0	-8.3	70.0	-6.7	76.0	-9.5		
			20	110.0	-8.3	70.0	-12.5	64.0	-46.7	100.0	-16.7	70.0	-6.7	68.0	-19.0		
			22	115.0	-4.2	80.0	0.0	60.0	-50.0	120.0	0.0	75.0	0.0	72.0	-14.3		
			24	105.0	-12.5	75.0	-6.3	80.0	-33.3	95.0	-20.8	80.0	-6.7	92.0	9.5		
			26	100.0	-16.7	75.0	-6.3	96.0	-20.0	100.0	-16.7	80.0	-6.7	96.0	14.3		
			28	100.0	-16.7	70.0	-12.5	80.0	-33.3	100.0	-16.7	70.0	-6.7	80.0	-4.8		
			30	100.0	-16.7	70.0	-12.5	80.0	-33.3	100.0	-16.7	70.0	-6.7	80.0	-4.8		
			32	100.0	-16.7	70.0	-12.5	80.0	-33.3	100.0	-16.7	70.0	-6.7	80.0	-4.8		
			34	90.0	-25.0	*	-12.5	80.0	-33.3	100.0	-16.7	80.0	-6.7	80.0	9.5		
			36	90.0	-25.0	*	-12.5	88.0	-26.7	100.0	-16.7	80.0	6.7	92.0	9.5		
			38	90.0	-25.0	*	-12.5	88.0	-26.7	100.0	-16.7	80.0	6.7	92.0	9.5		
			40	90.0	-25.0	*	-12.5	88.0	-26.7	100.0	-16.7	80.0	6.7	92.0	9.5		
			42	90.0	-25.0	*	-12.5	88.0	-26.7	100.0	-16.7	80.0	6.7	92.0	9.5		
			44	90.0	-25.0	*	-12.5	88.0	-26.7	100.0	-16.7	80.0	6.7	92.0	9.5		
			46	110.0	8.3	80.0	0.0	80.0	-33.3	105.0	-12.5	75.0	0.0	84.0	0.0		
			48	110.0	8.3	80.0	0.0	76.0	-36.7	105.0	-12.5	75.0	0.0	82.0	-2.4		
			50	110.0	8.3	80.0	0.0	80.0	-33.3	105.0	-12.5	75.0	0.0	84.0	0.0		
			52	110.0	8.3	80.0	0.0	80.0	-33.3	105.0	-12.5	75.0	0.0	84.0	0.0		
			121	FMA	-1	130.0	0.0	100.0	0.0	76.0	0.0	130.0	0.0	100.0	0.0	60.0	0.0
					0	130.0	0.0	100.0	0.0	76.0	0.0	130.0	0.0	100.0	0.0	60.0	0.0
					1	130.0	0.0	90.0	-10.0	88.0	15.8	130.0	0.0	100.0	0.0	88.0	46.7
					2	130.0	0.0	90.0	-10.0	94.0	23.7	140.0	0.0	90.0	-10.0	88.0	26.7
					3	130.0	0.0	90.0	-10.0	76.0	0.0	130.0	0.0	110.0	10.0	76.0	26.7
					4	130.0	0.0	100.0	0.0	88.0	15.8	130.0	0.0	105.0	5.0	100.0	66.7
5	140.0	7.7			95.0	-5.0	88.0	15.8	135.0	3.8	95.0	-5.0	92.0	53.3			
6	140.0	7.7			90.0	-10.0	88.0	15.8	135.0	3.8	95.0	-5.0	92.0	53.3			
8	140.0	7.7			95.0	-5.0	88.0	15.8	135.0	3.8	95.0	-5.0	92.0	53.3			
10	140.0	7.7			95.0	-5.0	88.0	15.8	135.0	3.8	95.0	-5.0	92.0	53.3			
12	140.0	7.7	95.0	-5.0	88.0	15.8	135.0	3.8	95.0	-5.0	92.0	53.3					
14	140.0	7.7	95.0	-5.0	88.0	15.8	135.0	3.8	95.0	-5.0	92.0	53.3					
16	140.0	7.7	95.0	-5.0	88.0	15.8	135.0	3.8	95.0	-5.0	92.0	53.3					
18	140.0	7.7	95.0	-5.0	88.0	15.8	135.0	3.8	95.0	-5.0	92.0	53.3					
20	140.0	7.7	95.0	-5.0	88.0	15.8	135.0	3.8	95.0	-5.0	92.0	53.3					
22	140.0	7.7	95.0	-5.0	88.0	15.8	135.0	3.8	95.0	-5.0	92.0	53.3					
24	125.0	-3.8	85.0	-15.0	74.0	-2.6	120.0	-7.7	80.0	-20.0	86.0	43.3					
26	120.0	-7.7	80.0	-20.0	62.0	-18.4	115.0	-11.5	70.0	-30.0	72.0	20.0					

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 beats/min
 H.R. values <= 50 beats/min

2372

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	Initial	Visit	LIVING				STANDING									
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	D.B.P.	% diff	H.R.	% diff		
1	123	ELF	-1	90.0	0.0	66.0	-9.1	100.0	0.0	70.0	0.0	80.0	0.0				
			0	90.0	0.0	60.0	0.0	100.0	0.0	70.0	0.0	80.0	0.0				
			1	95.0	5.6	65.0	8.3	92.0	39.4	80.0	-20.0	60.0	-14.3	100.0	25.0		
			2	100.0	11.1	80.0	33.3	80.0	21.2	100.0	0.0	80.0	14.3	96.0	20.0		
			3	100.0	11.1	70.0	16.7	80.0	21.2	95.0	-5.0	75.0	7.1	80.0	0.0		
			4	100.0	11.1	80.0	33.3	96.0	45.5	100.0	0.0	80.0	14.3	100.0	25.0		
			5	95.0	5.6	70.0	16.7	100.0	51.5	90.0	-10.0	70.0	0.0	104.0	30.0		
			6	95.0	5.6	70.0	16.7	100.0	51.5	90.0	-10.0	70.0	0.0	104.0	30.0		
			8	100.0	11.1	75.0	25.0	100.0	51.5	90.0	-10.0	75.0	7.1	108.0	35.0		
			10	100.0	11.1	75.0	25.0	100.0	51.5	90.0	-10.0	75.0	7.1	108.0	35.0		
			12	95.0	5.6	75.0	25.0	100.0	45.5	90.0	-10.0	70.0	0.0	104.0	30.0		
			14	100.0	11.1	75.0	25.0	108.0	63.6	90.0	-10.0	70.0	0.0	112.0	40.0		
			16	85.0	-5.6	60.0	0.0	96.0	45.5	95.0	-5.0	70.0	0.0	104.0	30.0		
			18	85.0	-5.6	60.0	0.0	96.0	45.5	95.0	-5.0	70.0	0.0	104.0	30.0		
			20	95.0	5.6	75.0	25.0	104.0	57.6	100.0	0.0	80.0	14.3	104.0	30.0		
			22	95.0	5.6	75.0	25.0	104.0	57.6	100.0	0.0	80.0	14.3	104.0	30.0		
			24	95.0	5.6	75.0	25.0	104.0	57.6	100.0	0.0	80.0	14.3	104.0	30.0		
			26	95.0	5.6	75.0	25.0	104.0	57.6	100.0	0.0	80.0	14.3	104.0	30.0		
			28	90.0	0.0	88.0	33.3	92.0	39.4	100.0	0.0	80.0	14.3	96.0	20.0		
			30	105.0	16.7	70.0	16.7	92.0	39.4	100.0	0.0	80.0	14.3	100.0	25.0		
			32	105.0	16.7	70.0	16.7	92.0	39.4	100.0	0.0	80.0	14.3	100.0	25.0		
			34	100.0	11.1	80.0	33.3	100.0	51.5	100.0	0.0	80.0	14.3	108.0	35.0		
			36	100.0	11.1	80.0	33.3	100.0	51.5	100.0	0.0	80.0	14.3	108.0	35.0		
			38	120.0	33.3	80.0	33.3	96.0	45.5	110.0	10.0	90.0	28.6	100.0	25.0		
			40	120.0	33.3	80.0	33.3	96.0	45.5	110.0	10.0	90.0	28.6	100.0	25.0		
			42	115.0	27.8	80.0	33.3	96.0	45.5	105.0	5.0	80.0	14.3	92.0	15.0		
			44	105.0	16.7	80.0	33.3	88.0	33.3	105.0	5.0	80.0	14.3	88.0	10.0		
			46	105.0	16.7	80.0	33.3	92.0	39.4	100.0	0.0	80.0	14.3	96.0	20.0		
			48	105.0	16.7	80.0	33.3	92.0	39.4	100.0	0.0	80.0	14.3	96.0	20.0		
			50	115.0	27.8	80.0	33.3	92.0	39.4	110.0	10.0	90.0	28.6	100.0	25.0		
			52	115.0	27.8	80.0	33.3	92.0	39.4	110.0	10.0	90.0	28.6	100.0	25.0		
			134	JSS	-1	105.0	0.0	76.0	0.0	105.0	0.0	70.0	0.0	76.0	0.0		
					0	105.0	0.0	70.0	0.0	105.0	0.0	70.0	0.0	76.0	0.0		
					1	100.0	-4.8	70.0	0.0	100.0	31.6	95.0	-9.5	75.0	7.1	92.0	21.1
					2	110.0	4.8	90.0	28.6	80.0	5.3	120.0	14.3	90.0	28.6	86.0	13.2
					3	115.0	9.5	80.0	14.3	92.0	21.1	100.0	-4.8	75.0	7.1	112.0	47.4
					4	115.0	9.5	80.0	14.3	84.0	10.5	100.0	-4.8	75.0	7.1	100.0	31.6
			5	105.0	0.0	80.0	14.3	84.0	10.5	95.0	-9.5	70.0	0.0	104.0	36.8		
			6	105.0	0.0	80.0	14.3	84.0	10.5	95.0	-9.5	70.0	0.0	104.0	36.8		

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 mm Hg
 H.R. values <= 50 beats/min

2373

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 ROXOMETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: ROXOMETINE

Centre	Patient	Initial Visit	LYING				STANDING								
			S.B.P. % diff	H.R. % diff	D.B.P. % diff	H.R. % diff	S.B.P. % diff	H.R. % diff	D.B.P. % diff	H.R. % diff					
1	134	JSS	8	120.0	14.3	80.0	14.3	76.0	0.0	115.0	9.5	80.0	14.3	82.0	7.9
	138	GMT	-1	135.0	-3.7	90.0	0.0	76.0	10.5	130.0	-7.7	85.0	5.9	80.0	15.0
			0	130.0	-7.4	85.0	-5.6	84.0	0.0	115.0	-11.5	90.0	-5.9	92.0	15.0
			2	130.0	-3.7	80.0	-11.1	74.0	-2.6	120.0	-7.7	80.0	-5.9	82.0	2.5
			3	135.0	0.0	85.0	-5.6	82.0	7.9	130.0	0.0	80.0	-5.9	90.0	12.5
			4	130.0	-3.7	90.0	0.0	74.0	-2.6	125.0	-3.8	80.0	-5.9	82.0	2.5
			5	120.0	-11.1	80.0	-11.1	82.0	7.9	110.0	-15.4	70.0	-17.6	90.0	12.5
			6	130.0	-3.7	80.0	-11.1	82.0	7.9	120.0	-7.7	80.0	-5.9	92.0	15.0
			8	120.0	-11.1	80.0	-11.1	78.0	2.6	115.0	-11.5	75.0	-11.8	84.0	5.0
			10	120.0	-11.1	80.0	-11.1	82.0	7.9	115.0	-11.5	75.0	-11.8	86.0	7.5
			12	125.0	-7.4	70.0	-11.1	76.0	0.0	125.0	-3.8	75.0	-11.8	78.0	-2.5
			14	125.0	-7.4	80.0	-11.1	68.0	-10.5	120.0	-7.7	70.0	-17.6	74.0	-7.5
			16	120.0	-11.1	80.0	-11.1	78.0	2.6	115.0	-11.5	80.0	-5.9	84.0	5.0
			18	115.0	-14.8	75.0	-16.7	82.0	7.9	120.0	-7.7	70.0	-17.6	82.0	2.5
			20	125.0	-7.4	80.0	-11.1	74.0	-2.6	120.0	-7.7	70.0	-17.6	82.0	2.5
			22	120.0	-11.1	80.0	-11.1	74.0	-2.6	115.0	-11.5	70.0	-17.6	84.0	5.0
			24	135.0	0.0	80.0	-11.1	78.0	2.6	110.0	-15.4	70.0	-17.6	84.0	5.0
			26	115.0	-14.8	70.0	-22.2	66.0	-13.2	110.0	-15.4	70.0	-17.6	74.0	-7.5
			28	120.0	-11.1	80.0	-11.1	76.0	0.0	110.0	-15.4	70.0	-17.6	82.0	2.5
			30	115.0	-14.8	75.0	-16.7	64.0	-15.8	120.0	-7.7	70.0	-17.6	72.0	-10.0
			32	110.0	-18.5	70.0	-22.2	76.0	0.0	100.0	-23.1	60.0	-29.4	82.0	2.5
			34	100.0	-25.9	70.0	-22.2	76.0	0.0	110.0	-15.4	70.0	-17.6	80.0	0.0
			36	115.0	-14.8	70.0	-22.2	72.0	0.0	110.0	-15.4	70.0	-17.6	80.0	0.0
			38	120.0	-11.1	70.0	-22.2	74.0	-2.6	110.0	-15.4	75.0	-11.8	74.0	-7.5
			40	120.0	-11.1	70.0	-22.2	82.0	7.9	110.0	-15.4	70.0	-17.6	78.0	-2.5
			42	120.0	-11.1	80.0	-11.1	84.0	10.5	115.0	-11.5	70.0	-17.6	86.0	7.5
			44	125.0	-7.4	80.0	-11.1	74.0	-2.6	115.0	-11.5	70.0	-17.6	86.0	7.5
			46	130.0	-3.7	70.0	-22.2	84.0	10.5	120.0	-7.7	70.0	-17.6	90.0	12.5
			48	120.0	-11.1	80.0	-11.1	78.0	2.6	115.0	-11.5	70.0	-17.6	84.0	5.0
			50	110.0	-18.5	70.0	-22.2	84.0	10.5	115.0	-11.5	70.0	-17.6	88.0	10.0
			52	125.0	-7.4	85.0	-5.6	82.0	7.9	120.0	-7.7	70.0	-17.6	86.0	7.5
139	SPH		-1	140.0	0.0	90.0	0.0	80.0	0.0	135.0	0.0	85.0	0.0	86.0	2.3
			1	140.0	0.0	90.0	0.0	76.0	-5.0	140.0	3.7	85.0	0.0	80.0	-7.0
			2	140.0	0.0	80.0	0.0	78.0	-2.5	135.0	0.0	80.0	-5.9	86.0	0.0
			3	140.0	0.0	80.0	-11.1	76.0	-5.0	140.0	3.7	85.0	0.0	80.0	-7.0
			4	150.0	7.1	90.0	0.0	86.0	7.5	140.0	3.7	90.0	5.9	92.0	7.0

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 mm Hg
 H.R. values <= 50 beats/min

2374

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXYTINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXYTINE

Centre	Patient	Initial	Visit	LYING			STANDING								
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	H.R.	% diff				
1	139	SPH	5	120.0	-14.3	85.0	-5.6	84.0	5.0	130.0	-3.7	85.0	0.0	86.0	0.0
			6	150.0	7.1	90.0	0.0	86.0	7.5	150.0	11.1	80.0	-5.9	92.0	7.0
			8	120.0	-14.3	85.0	-5.6	100.0	25.0	125.0	-7.4	80.0	-5.9	104.0	20.9
			10	120.0	-14.3	80.0	-11.1	94.0	17.5	110.0	-18.5	70.0	-17.6	98.0	14.0
			12	115.0	-17.9	80.0	-11.1	88.0	10.0	110.0	-18.5	80.0	-5.9	98.0	14.0
			14	130.0	-7.1	80.0	-11.1	104.0	30.0	110.0	-18.5	70.0	-17.6	104.0	20.9
			16	110.0	-21.4	80.0	-11.1	100.0	25.0	120.0	-11.1	75.0	-11.8	104.0	20.9
			18	130.0	-7.1	80.0	-11.1	96.0	20.0	125.0	-7.4	75.0	-11.8	104.0	14.0
			20	125.0	-10.7	80.0	-11.1	90.0	20.0	120.0	-11.1	85.0	0.0	104.0	20.9
			22	130.0	-7.1	80.0	-11.1	74.0	12.5	120.0	-11.1	80.0	-5.9	96.0	11.6
			24	130.0	-7.1	80.0	-11.1	74.0	12.5	120.0	-11.1	75.0	-11.8	80.0	-7.0
			26	120.0	-14.3	80.0	-11.1	76.0	-5.0	110.0	-18.5	70.0	-17.6	84.0	-2.3
			28	115.0	-17.9	80.0	-11.1	84.0	5.0	115.0	-18.5	70.0	-17.6	86.0	0.0
			30	120.0	-14.3	80.0	-11.1	84.0	5.0	110.0	-18.5	70.0	-17.6	86.0	0.0
			32	115.0	-17.9	80.0	-11.1	84.0	5.0	110.0	-18.5	70.0	-17.6	86.0	0.0
			34	130.0	-7.1	70.0	-22.2	68.0	-15.0	120.0	-11.1	75.0	-11.8	74.0	-14.0
			36	115.0	-17.9	80.0	-11.1	84.0	5.0	110.0	-18.5	70.0	-17.6	86.0	0.0
			38	120.0	-14.3	80.0	-11.1	84.0	5.0	105.0	-22.2	70.0	-17.6	86.0	0.0
			40	115.0	-17.9	80.0	-11.1	84.0	5.0	120.0	-11.1	70.0	-17.6	86.0	0.0
			42	120.0	-14.3	70.0	-22.2	64.0	-20.0	110.0	-18.5	60.0	-29.4	68.0	-20.9
			44	120.0	-14.3	80.0	-11.1	66.0	-17.5	115.0	-18.5	70.0	-17.6	72.0	-16.3
			46	120.0	-14.3	80.0	-11.1	64.0	-20.0	110.0	-18.5	70.0	-17.6	68.0	-20.9
			48	120.0	-14.3	80.0	-11.1	76.0	-5.0	110.0	-18.5	75.0	-11.8	78.0	-9.3
			50	115.0	-17.9	70.0	-22.2	64.0	-20.0	130.0	-3.7	70.0	-17.6	72.0	-16.3
			52	115.0	-17.9	75.0	-16.7	68.0	-15.0	120.0	-11.1	70.0	-17.6	72.0	-16.3
			-1	90.0	0.0	50.0	0.0	84.0	0.0	100.0	0.0	60.0	0.0	92.0	0.0
			1	100.0	11.1	50.0	0.0	88.0	4.8	105.0	5.0	45.0	-25.0	100.0	8.7
			2	95.0	5.6	55.0	10.0	120.0	42.9	85.0	-15.0	50.0	-16.7	140.0	52.2
			3	95.0	5.6	55.0	10.0	120.0	42.9	85.0	-15.0	50.0	-16.7	140.0	52.2
			4	110.0	22.2	70.0	40.0	98.0	16.7	110.0	10.0	70.0	16.7	105.0	14.1
			5	110.0	22.2	70.0	40.0	98.0	16.7	110.0	10.0	70.0	16.7	105.0	14.1
			6	110.0	22.2	70.0	40.0	98.0	16.7	110.0	10.0	70.0	16.7	105.0	14.1
			8	100.0	11.1	60.0	20.0	120.0	42.9	105.0	5.0	60.0	0.0	120.0	30.4
			10	95.0	5.6	65.0	30.0	104.0	23.8	95.0	-5.0	65.0	8.3	112.0	21.7
			12	100.0	11.1	65.0	30.0	100.0	19.0	105.0	5.0	65.0	8.3	100.0	8.7
			14	100.0	11.1	60.0	20.0	120.0	42.9	105.0	5.0	60.0	0.0	120.0	30.4
			16	95.0	5.6	65.0	30.0	104.0	23.8	95.0	-5.0	65.0	8.3	112.0	21.7
			18	95.0	5.6	65.0	30.0	104.0	23.8	95.0	-5.0	65.0	8.3	112.0	21.7

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 mm Hg
 H.R. values <= 50 beats/min

2
 13
 7
 CT 143

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REDOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: REDOXETINE

Centre	Patient	Initial	Visit	LYING				STANDING								
				S.B.P. % diff	H.R. % diff	D.B.P. % diff	S.B.P. % diff	H.R. % diff	D.B.P. % diff	H.R. % diff						
1	143	JLL	20	100.0	11.1	30.0	100.0	19.0	105.0	5.0	65.0	8.3	100.0	8.7		
			22	100.0	11.1	30.0	100.0	19.0	105.0	5.0	65.0	8.3	100.0	8.7		
			24	105.0	16.7	20.0	96.0	14.3	115.0	15.0	50.0	-16.7	50.0	4.3		
			26	100.0	11.1	30.0	64.0	-23.8	105.0	5.0	60.0	0.0	68.0	-26.1		
			28	100.0	11.1	30.0	88.0	4.8	100.0	0.0	65.0	8.3	108.0	17.4		
			30	100.0	11.1	30.0	88.0	4.8	100.0	0.0	65.0	8.3	108.0	17.4		
			32	105.0	16.7	40.0	84.0	0.0	105.0	5.0	65.0	8.3	92.0	0.0		
			34	105.0	16.7	20.0	68.0	-19.0	120.0	20.0	70.0	16.7	68.0	-26.1		
			36	115.0	27.8	20.0	108.0	28.6	115.0	15.0	60.0	0.0	120.0	30.4		
			38	100.0	11.1	20.0	104.0	23.8	110.0	10.0	70.0	16.7	108.0	17.4		
			40	100.0	11.1	40.0	84.0	0.0	105.0	5.0	70.0	16.7	104.0	13.0		
			42	105.0	16.7	20.0	100.0	19.0	115.0	15.0	70.0	16.7	96.0	4.3		
			44	110.0	22.2	40.0	114.0	38.1	105.0	5.0	65.0	8.3	108.0	17.4		
			46	100.0	11.1	20.0	104.0	23.8	105.0	5.0	70.0	16.7	108.0	17.4		
			48	90.0	0.0	30.0	92.0	9.5	110.0	10.0	70.0	16.7	100.0	8.7		
			50	110.0	22.2	40.0	104.0	23.8	105.0	5.0	60.0	0.0	132.0	43.5		
			52	105.0	16.7	20.0	96.0	14.3	110.0	10.0	80.0	33.3	96.0	4.3		
			149	IPL	-1	120.0	0.0	80.0	82.0	-7.3	110.0	0.0	70.0	0.0	86.0	-4.7
					0	120.0	0.0	0.0	76.0	-7.3	110.0	0.0	70.0	0.0	82.0	-4.7
					1	125.0	4.2	0.0	80.0	-9.8	115.0	4.5	70.0	0.0	78.0	-9.3
					2	110.0	-8.3	70.0	68.0	-17.1	115.0	4.5	75.0	7.1	76.0	-11.6
					3	110.0	-8.3	0.0	68.0	-17.1	110.0	0.0	70.0	0.0	76.0	-11.6
					4	110.0	-8.3	70.0	72.0	-12.2	110.0	0.0	75.0	7.1	78.0	-9.3
					5	110.0	-8.3	70.0	74.0	-9.8	105.0	-4.5	70.0	0.0	76.0	-11.6
					6	110.0	-8.3	80.0	74.0	-9.8	105.0	-4.5	75.0	7.1	78.0	-9.3
					8	125.0	4.2	0.0	76.0	-7.3	120.0	9.1	70.0	0.0	86.0	0.0
					10	120.0	0.0	70.0	92.0	12.2	125.0	13.6	70.0	0.0	98.0	14.0
					12	120.0	0.0	0.0	82.0	0.0	110.0	0.0	70.0	0.0	88.0	2.3
					14	130.0	8.3	0.0	76.0	-7.3	120.0	9.1	75.0	0.0	82.0	-4.7
					16	130.0	8.3	80.0	84.0	2.4	135.0	22.7	85.0	21.4	86.0	0.0
					18	120.0	0.0	0.0	88.0	7.3	110.0	0.0	70.0	0.0	96.0	0.0
			20	120.0	0.0	-12.5	80.0	-2.4	110.0	0.0	75.0	7.1	84.0	-2.3		
			22	125.0	4.2	75.0	78.0	-4.9	120.0	9.1	70.0	0.0	86.0	0.0		
			24	125.0	4.2	85.0	66.0	-19.5	115.0	4.5	80.0	14.3	70.0	-18.6		
26	125.0	4.2	62.0	-24.4	62.0	-24.4	80.0	14.3	80.0	14.3	64.0	-25.6				
28	130.0	8.3	70.0	60.0	-26.8	115.0	4.5	65.0	-7.1	64.0	-25.6					
30	125.0	4.2	80.0	72.0	-12.2	115.0	4.5	70.0	0.0	72.0	-16.3					
32	115.0	-4.2	75.0	76.0	-7.3	110.0	0.0	70.0	0.0	78.0	-9.3					
34	125.0	4.2	70.0	70.0	-14.6	115.0	4.5	60.0	-14.3	72.0	-16.3					

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 beats/min
 H.R. values <= 50 beats/min

23 376

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBONEXINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: REBONEXINE

Centre	Patient	Initial	Visit	LYING				STANDING							
				S.B.P.	% diff	D.B.P.	% diff	H.R.	% diff	S.B.P.	% diff	D.B.P.	% diff	H.R.	% diff
1	149	IPL	36	110.0	-8.3	70.0	-12.5	74.0	-9.8	120.0	9.1	80.0	14.3	76.0	-11.6
			38	120.0	0.0	80.0	0.0	62.0	-24.4	110.0	0.0	70.0	0.0	70.0	-18.6
			40	120.0	0.0	70.0	-12.5	72.0	-12.2	115.0	4.5	65.0	-7.1	76.0	-11.6
			42	120.0	0.0	70.0	-12.5	76.0	-7.3	110.0	0.0	70.0	0.0	78.0	-9.3
			44	115.0	-4.2	80.0	0.0	70.0	-14.6	110.0	0.0	70.0	0.0	72.0	-16.3
			46	115.0	-4.2	75.0	-6.3	70.0	-14.6	110.0	0.0	70.0	0.0	76.0	-11.6
			48	115.0	-4.2	60.0	-25.0	72.0	-12.2	110.0	0.0	65.0	-7.1	78.0	-9.3
			50	125.0	4.2	70.0	-12.5	82.0	0.0	115.0	4.5	65.0	-7.1	86.0	0.0
			52	120.0	0.0	80.0	0.0	84.0	2.4	110.0	0.0	70.0	0.0	88.0	2.3
301	ENP		-1	90.0		65.0		76.0		95.0		70.0		88.0	
			0	120.0	33.3	80.0	23.1	78.0	2.6	120.0	26.3	80.0	14.3	84.0	-4.5
			1	130.0	44.4	80.0	-13.2	66.0	-15.8	120.0	26.3	70.0	0.0	70.0	-20.5
			2	125.0	38.9	85.0	30.8	64.0	-15.8	120.0	26.3	80.0	14.3	70.0	-20.5
			3	130.0	44.4	80.0	23.1	72.0	-5.3	120.0	26.3	75.0	7.1	78.0	-11.4
			4	130.0	44.4	80.0	23.1	70.0	-7.3	120.0	26.3	80.0	14.3	82.0	-6.8
			5	130.0	44.4	80.0	23.1	66.0	-13.2	120.0	26.3	70.0	0.0	72.0	-18.2
			6	125.0	38.9	85.0	30.8	64.0	-15.8	120.0	26.3	75.0	7.1	72.0	-18.2
			8	90.0	0.0	70.0	7.7	80.0	5.3	90.0	0.0	70.0	0.0	80.0	-9.1
			10	110.0	22.2	75.0	15.4	82.0	21.1	95.0	0.0	65.0	-7.1	112.0	27.3
			12	118.0	22.2	80.0	23.1	88.0	15.8	95.0	0.0	75.0	7.1	104.0	18.2
			14	118.0	22.2	70.0	7.7	88.0	15.8	100.0	5.3	75.0	7.1	112.0	27.3
			16	100.0	11.1	70.0	0.0	70.0	0.0	100.0	5.3	75.0	7.1	104.0	18.2
			18	110.0	22.2	75.0	15.4	104.0	36.8	90.0	-5.3	75.0	7.1	116.0	31.8
			20	110.0	22.2	75.0	15.4	104.0	36.8	90.0	-5.3	75.0	7.1	116.0	31.8
			22	105.0	16.7	75.0	15.4	92.0	21.1	90.0	-5.3	75.0	7.1	108.0	22.7
			24	100.0	11.1	70.0	7.7	92.0	21.1	100.0	5.3	80.0	14.3	94.0	6.8
			26	100.0	11.1	70.0	7.7	92.0	21.1	100.0	5.3	80.0	14.3	94.0	6.8
			28	110.0	22.2	75.0	15.4	100.0	31.6	110.0	15.8	80.0	14.3	104.0	18.2
			30	110.0	22.2	75.0	15.4	100.0	31.6	110.0	15.8	80.0	14.3	104.0	18.2
			32	110.0	22.2	75.0	15.4	100.0	31.6	110.0	15.8	80.0	14.3	104.0	18.2
			34	105.0	16.7	75.0	15.4	100.0	31.6	100.0	5.3	80.0	14.3	112.0	27.3
			36	110.0	22.2	80.0	23.1	96.0	26.3	105.0	10.5	75.0	7.1	104.0	18.2
			38	110.0	22.2	80.0	23.1	96.0	26.3	105.0	10.5	75.0	7.1	104.0	18.2
			40	120.0	33.3	80.0	23.1	82.0	7.9	110.0	15.8	70.0	0.0	95.0	8.0
			42	120.0	33.3	80.0	23.1	82.0	7.9	110.0	15.8	70.0	0.0	95.0	8.0
			44	110.0	22.2	80.0	23.1	80.0	5.3	110.0	15.8	70.0	0.0	80.0	-9.1
			46	110.0	22.2	80.0	23.1	80.0	5.3	100.0	5.3	70.0	0.0	80.0	-9.1
			48	110.0	22.2	75.0	15.4	92.0	21.1	95.0	0.0	75.0	7.1	112.0	27.3
			50	110.0	22.2	75.0	15.4	92.0	21.1	95.0	0.0	75.0	7.1	112.0	27.3

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOMETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: REBOMETINE

Centre	Patient	Initial	Visit	LYING			STANDING								
				S.B.P. % diff	H.R. % diff	D.B.P. % diff	S.B.P. % diff	H.R. % diff	D.B.P. % diff						
1	301	EMP	52	110.0	22.2	75.0	15.4	72.0	-5.3	95.0	0.0	75.0	7.1	80.0	-9.1
	303	RF	-1	120.0		86.0		80.0		120.0		90.0		80.0	
			0	150.0	25.0	100.0	16.3	80.0	0.0	160.0	33.3 **	100.0	11.1	100.0	25.0 **
			1	160.0	33.3 **	95.0	10.5	100.0	25.0 **	170.0	41.7 **	100.0	11.1	104.0	30.0 **
			2	155.0	29.2	100.0	16.3	92.0	15.0	155.0	29.2	100.0	11.1	92.0	15.0
			3	145.0	20.8	90.0	4.7	100.0	25.0 **	150.0	25.0	100.0	11.1	88.0	10.0
			4	140.0	16.7	100.0	16.3	100.0	35.0 **	150.0	25.0	100.0	11.1	96.0	20.0 **
			5	160.0	33.3 **	100.0	16.3	108.0	35.0 **	155.0	29.2	105.0	16.7	112.0	40.0 **
			6	165.0	37.5 **	100.0	16.3	96.0	20.0	160.0	33.3 **	100.0	11.1	100.0	25.0 **
			8	140.0	16.7	95.0	10.5	96.0	20.0	150.0	25.0	95.0	5.6	96.0	20.0 **
			10	140.0	16.7	95.0	10.5	104.0	30.0 **	135.0	12.5	100.0	11.1	112.0	40.0 **
			12	145.0	20.8	100.0	16.3	100.0	25.0 **	145.0	20.8	100.0	11.1	100.0	25.0 **
			14	140.0	16.7	95.0	10.5	100.0	25.0 **	150.0	25.0	100.0	11.1	108.0	35.0 **
			16	135.0	12.5	100.0	16.3	92.0	15.0	160.0	33.3 **	110.0	22.2 **	92.0	15.0
			18	140.0	16.7	110.0	27.9 **	100.0	25.0 **	150.0	25.0	110.0	22.2 **	100.0	25.0 **
			20	140.0	16.7	110.0	27.9 **	100.0	25.0 **	150.0	25.0	110.0	22.2 **	100.0	25.0 **
			22	130.0	8.3	100.0	16.3	88.0	10.0	130.0	8.3	100.0	11.1	96.0	20.0
			24	130.0	8.3	100.0	16.3	88.0	10.0	130.0	8.3	100.0	11.1	96.0	20.0
			26	110.0	-8.3	80.0	-7.0	80.0	0.0	110.0	-8.3	85.0	-5.6	84.0	5.0
			28	110.0	-8.3	80.0	-7.0	80.0	0.0	110.0	-8.3	85.0	-5.6	84.0	5.0
			30	130.0	8.3	90.0	4.7	80.0	0.0	130.0	8.3	90.0	0.0	80.0	0.0
			32	130.0	8.3	90.0	4.7	88.0	10.0	130.0	8.3	90.0	0.0	88.0	10.0
			34	160.0	33.3 **	100.0	16.3	90.0	12.5	160.0	33.3 **	100.0	11.1	88.0	10.0
			36	155.0	29.2	110.0	27.9 **	80.0	0.0	150.0	25.0	100.0	11.1	94.0	17.5
			38	160.0	33.3 **	100.0	16.3	92.0	15.0	145.0	20.8	105.0	16.7	90.0	15.0
			40	160.0	33.3 **	100.0	16.3	92.0	15.0	145.0	20.8	105.0	16.7	90.0	15.0
			42	130.0	8.3	95.0	10.5	98.0	22.5	140.0	16.7	100.0	11.1	100.0	25.0 **
			44	140.0	16.7	100.0	16.3	100.0	25.0 **	140.0	16.7	100.0	11.1	100.0	25.0 **
			46	115.0	-4.2	80.0	-7.0	100.0	25.0 **	105.0	-12.5	85.0	-5.6	100.0	25.0 **
			48	110.0	-8.3	85.0	-1.2	102.0	27.5 **	130.0	8.3	95.0	5.6	104.0	30.0 **
			50	125.0	4.2	100.0	16.3	96.0	20.0	135.0	12.5	105.0	16.7	104.0	30.0 **
			52	130.0	8.3	90.0	4.7	92.0	15.0	129.0	7.5	95.0	5.6	100.0	25.0 **
305	ASS		-1	120.0		80.0		80.0		120.0		80.0		84.0	
			0	120.0	0.0	70.0	-12.5	76.0	-5.0	110.0	-8.3	70.0	-12.5	80.0	-4.8
			1	90.0	-25.0 *	50.0	-37.5 *	96.0	20.0	85.0	-29.2 *	50.0	-37.5 *	100.0	19.0
			2	120.0	0.0	80.0	0.0	88.0	10.0	120.0	0.0	70.0	-12.5	95.0	13.1
			3	100.0	-16.7	80.0	0.0	84.0	5.0	105.0	-12.5	80.0	0.0	88.0	4.8
			4	95.0	-20.8 *	65.0	-18.8	100.0	25.0 **	100.0	-16.7	70.0	-12.5	104.0	23.8 **

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 50 mm Hg
H.R. values <= 50 beats/min

2378

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXYTINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXYTINE

Centre	Patient	Initial	Visit	LYING				STANDING											
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff						
1	305	ASS	5	100.0	-16.7	70.0	-12.5	90.0	12.5	100.0	-16.7	70.0	-12.5	95.0	13.1				
			6	110.0	-8.3	70.0	-12.5	90.0	12.5	110.0	-8.3	70.0	-12.5	100.0	19.0				
			8	100.0	-16.7	70.0	-12.5	90.0	12.5	105.0	-12.5	70.0	-12.5	100.0	19.0				
			10	105.0	-12.5	85.0	6.3	102.0	27.5	**	110.0	-8.3	90.0	12.5	102.0	21.4			
			12	110.0	-8.3	70.0	-12.5	96.0	20.0	**	100.0	-16.7	70.0	-12.5	100.0	19.0			
			14	115.0	-4.2	85.0	6.3	108.0	35.0	**	110.0	-8.3	75.0	-6.3	108.0	28.6			
			16	100.0	-16.7	70.0	-12.5	96.0	20.0	**	90.0	-25.0	*	60.0	-25.0	96.0	14.3		
			18	120.0	0.0	80.0	0.0	104.0	30.0	**	125.0	4.2	85.0	6.3	108.0	28.6			
			20	130.0	8.3	90.0	12.5	92.0	15.0	**	130.0	8.3	90.0	12.5	92.0	9.5			
			22	130.0	8.3	90.0	-12.5	96.0	20.0	**	130.0	8.3	80.0	0.0	92.0	9.5			
			24	95.0	-20.8	70.0	-12.5	96.0	20.0	**	110.0	-8.3	80.0	0.0	96.0	14.3			
			26	95.0	-20.8	70.0	-12.5	96.0	20.0	**	110.0	-8.3	80.0	0.0	96.0	14.3			
			28	120.0	0.0	80.0	0.0	96.0	20.0	**	120.0	0.0	80.0	0.0	96.0	14.3			
			30	105.0	-12.5	80.0	0.0	106.0	32.5	**	110.0	-8.3	90.0	12.5	110.0	31.0			
			32	105.0	-12.5	80.0	0.0	106.0	32.5	**	110.0	-8.3	90.0	12.5	110.0	31.0			
			34	105.0	-12.5	80.0	0.0	106.0	32.5	**	110.0	-8.3	90.0	12.5	110.0	31.0			
			36	105.0	-12.5	80.0	0.0	106.0	32.5	**	110.0	-8.3	90.0	12.5	110.0	31.0			
			38	105.0	-12.5	75.0	-6.3	96.0	20.0	**	105.0	-12.5	75.0	-6.3	108.0	28.6			
			40	105.0	-12.5	75.0	-6.3	96.0	20.0	**	105.0	-12.5	75.0	-6.3	108.0	28.6			
			42	105.0	-12.5	75.0	-6.3	96.0	20.0	**	105.0	-12.5	75.0	-6.3	108.0	28.6			
			44	125.0	4.2	90.0	12.5	96.0	20.0	**	125.0	4.2	90.0	12.5	96.0	14.3			
			46	125.0	4.2	90.0	12.5	96.0	20.0	**	125.0	4.2	90.0	12.5	96.0	14.3			
			48	140.0	16.7	85.0	6.3	96.0	20.0	**	130.0	8.3	90.0	12.5	100.0	19.0			
			50	140.0	16.7	85.0	6.3	96.0	20.0	**	130.0	8.3	90.0	12.5	100.0	19.0			
			52	120.0	0.0	85.0	6.3	92.0	15.0	**	100.0	-16.7	70.0	-12.5	92.0	9.5			
			309	ARN		-1	120.0	-8.3	80.0	0.0	80.0	0.0	120.0	-8.3	80.0	0.0	90.0	11.1	
						1	110.0	0.0	80.0	0.0	96.0	20.0	**	110.0	-8.3	85.0	6.3	100.0	11.1
						2	115.0	-4.2	75.0	-6.3	92.0	15.0	**	110.0	-8.3	80.0	0.0	88.0	-2.2
						3	110.0	-8.3	70.0	-12.5	60.0	-25.0	**	110.0	-8.3	75.0	-6.3	100.0	11.1
						4	110.0	-8.3	80.0	0.0	84.0	5.0	**	105.0	-12.5	60.0	-25.0	66.0	-26.7
						5	100.0	-16.7	75.0	-6.3	108.0	25.0	**	100.0	-16.7	75.0	-6.3	104.0	15.6
						6	115.0	-4.2	85.0	6.3	102.0	27.5	**	100.0	-16.7	75.0	-6.3	104.0	15.6
						8	110.0	-8.3	80.0	0.0	116.0	45.0	**	130.0	8.3	90.0	12.5	120.0	33.3
						10	110.0	-8.3	80.0	0.0	92.0	15.0	**	110.0	-8.3	80.0	0.0	100.0	11.1
						12	120.0	0.0	90.0	12.5	120.0	50.0	**	120.0	0.0	90.0	12.5	128.0	42.2
						14	120.0	0.0	80.0	0.0	100.0	20.0	**	110.0	-8.3	80.0	0.0	108.0	17.8
						16	120.0	0.0	80.0	0.0	120.0	50.0	**	105.0	-12.5	80.0	0.0	124.0	37.8
						18	120.0	0.0	80.0	0.0	120.0	50.0	**	105.0	-12.5	80.0	0.0	124.0	37.8

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	Initial Visit	LYING				STANDING													
			S.B.P. % diff	D.B.P. % diff	H.R. % diff	S.B.P. % diff	D.B.P. % diff	H.R. % diff												
1	309	ARN	20	95.0	-20.8	*	75.0	-6.3	104.0	**	30.0	**	100.0	-16.7	80.0	0.0	124.0	**		
		22	95.0	-20.8	*	75.0	-6.3	104.0	**	30.0	**	100.0	-16.7	80.0	0.0	124.0	**			
		24	110.0	-8.3	*	80.0	0.0	120.0	**	50.0	**	110.0	-8.3	80.0	0.0	116.0	**			
		26	105.0	-12.5		80.0	0.0	120.0	**	50.0	**	110.0	-8.3	80.0	0.0	120.0	**			
		28	105.0	-12.5		80.0	0.0	120.0	**	50.0	**	110.0	-8.3	80.0	0.0	120.0	**			
		30	105.0	-12.5		80.0	0.0	120.0	**	50.0	**	110.0	-8.3	80.0	0.0	120.0	**			
		32	105.0	-12.5		80.0	0.0	120.0	**	50.0	**	110.0	-8.3	80.0	0.0	120.0	**			
		34	105.0	-12.5		80.0	0.0	120.0	**	50.0	**	110.0	-8.3	80.0	0.0	120.0	**			
		36	140.0	16.7		100.0	25.0	**	104.0	**	30.0	**	130.0	8.3	95.0	18.8	104.0	15.6		
		38	140.0	16.7		100.0	25.0	**	104.0	**	30.0	**	130.0	8.3	95.0	18.8	104.0	15.6		
		40	140.0	16.7		100.0	25.0	**	104.0	**	30.0	**	130.0	8.3	95.0	18.8	104.0	15.6		
		42	140.0	16.7		100.0	25.0	**	104.0	**	30.0	**	130.0	8.3	95.0	18.8	104.0	15.6		
		44	120.0	0.0		75.0	-6.3		103.0	**	35.0	**	130.0	8.3	90.0	12.5	120.0	33.3		
		46	105.0	-12.5		80.0	0.0		116.0	**	45.0	**	130.0	8.3	90.0	12.5	120.0	33.3		
		48	105.0	-12.5		80.0	0.0		116.0	**	45.0	**	130.0	8.3	90.0	12.5	120.0	33.3		
		50	105.0	-12.5		80.0	0.0		94.0	**	17.5	**	130.0	8.3	90.0	12.5	98.0	8.9		
		52	105.0	-12.5		80.0	0.0		90.0	0.0	12.5		130.0	8.3	90.0	12.5	98.0	8.9		
		310	DPS	-1	130.0			80.0		90.0		30.0		120.0		76.0		80.0		
				0	180.0	38.5	**	110.0	37.5	**	60.0	-33.3			160.0	33.3	**	105.0	38.2	**
				1	145.0	11.5		90.0	12.5		76.0	-15.6			130.0	0.0		90.0	18.4	
				2	120.0	-7.7		80.0	0.0		88.0	-2.2			115.0	-4.2		80.0	5.3	
				3	130.0	15.4		90.0	12.5		84.0	-6.7			130.0	8.3		90.0	18.4	
				4	140.0	7.7		90.0	12.5		84.0	-6.7			140.0	16.7		95.0	25.0	
				5	140.0	7.7		90.0	12.5		84.0	-6.7			140.0	16.7		90.0	18.4	
				6	120.0	-7.7		75.0	-6.3		88.0	-2.2			120.0	0.0		85.0	11.8	
				8	130.0	0.0		90.0	12.5		84.0	-6.7			110.0	-8.3		85.0	11.8	
				10	160.0	23.1	**	110.0	37.5	**	80.0	-11.1			150.0	25.0		105.0	38.2	**
				12	150.0	15.4		100.0	25.0	**	84.0	-6.7			170.0	41.7	**	110.0	44.7	**
				14	140.0	7.7		90.0	12.5	**	80.0	-11.1			140.0	16.7	**	90.0	18.4	**
				16	140.0	7.7		90.0	12.5	**	80.0	-11.1			140.0	16.7	**	90.0	18.4	**
				18	140.0	7.7		90.0	12.5	**	80.0	-11.1			140.0	16.7	**	90.0	18.4	**
				20	140.0	7.7		90.0	12.5	**	80.0	-11.1			140.0	16.7	**	90.0	18.4	**
				22	140.0	7.7		90.0	12.5	**	80.0	-11.1			140.0	16.7	**	90.0	18.4	**
				24	140.0	7.7		90.0	12.5	**	80.0	-11.1			140.0	16.7	**	90.0	18.4	**
				26	150.0	15.4		95.0	18.8		62.0	-31.1			145.0	20.8		100.0	31.6	**
				28	150.0	15.4		95.0	18.8		96.0	6.7			165.0	20.8		100.0	31.6	**
				30	125.0	-3.8		90.0	12.5		88.0	-2.2			110.0	0.0		85.0	11.8	
				32	125.0	-3.8		90.0	12.5		88.0	-2.2			110.0	0.0		85.0	11.8	
				34	110.0	-15.4		90.0	12.5		88.0	-2.2			100.0	-16.7		80.0	5.3	

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	Initial	LIVING				STANDING								
			S.B.P. % diff	D.B.P. % diff	H.R. % diff	S.B.P. % diff	D.B.P. % diff	H.R. % diff							
1	310	DPS	36	140.0	7.7	90.0	12.5	84.0	-6.7	125.0	4.2	90.0	18.4	84.0	5.0
			38	140.0	7.7	90.0	12.5	84.0	-6.7	125.0	4.2	90.0	18.4	84.0	5.0
			40	140.0	7.7	100.0	25.0	88.0	-2.2	130.0	8.3	100.0	31.6	94.0	17.5
			42	140.0	7.7	100.0	25.0	88.0	-2.2	130.0	8.3	100.0	31.6	94.0	17.5
			44	140.0	7.7	100.0	25.0	88.0	-2.2	130.0	8.3	100.0	31.6	94.0	17.5
			46	140.0	7.7	90.0	12.5	80.0	-11.1	140.0	16.7	90.0	18.4	88.0	10.0
			48	140.0	7.7	90.0	12.5	80.0	-11.1	140.0	16.7	90.0	18.4	88.0	10.0
			50	140.0	7.7	90.0	12.5	80.0	-11.1	140.0	16.7	90.0	18.4	88.0	10.0
			52	140.0	7.7	100.0	25.0	88.0	-2.2	130.0	8.3	85.0	11.8	84.0	5.0
	311	SP	-1	110.0	0.0	70.0	0.0	80.0	0.0	105.0	14.3	65.0	23.1	96.0	-22.9
			1	110.0	0.0	80.0	14.3	76.0	-5.0	120.0	14.3	80.0	7.7	74.0	-20.8
			2	110.0	0.0	85.0	21.4	76.0	-5.0	120.0	14.3	80.0	7.7	76.0	-22.9
			3	130.0	18.2	80.0	14.3	68.0	-15.0	115.0	9.5	70.0	7.7	72.0	-23.0
			4	120.0	9.1	80.0	14.3	68.0	-15.0	110.0	4.8	70.0	7.7	74.0	-23.0
			5	120.0	9.1	70.0	0.0	72.0	-10.0	110.0	4.8	70.0	7.7	80.0	-16.7
			6	110.0	0.0	80.0	14.3	70.0	-12.5	110.0	4.8	70.0	7.7	78.0	-18.8
			8	110.0	0.0	70.0	0.0	96.0	20.0	100.0	4.8	75.0	15.4	100.0	4.2
			10	110.0	0.0	70.0	0.0	96.0	20.0	100.0	4.8	75.0	15.4	100.0	4.2
			12	95.0	-13.6	65.0	-7.1	88.0	20.0	95.0	-9.5	65.0	0.0	112.0	16.7
			14	95.0	-13.6	70.0	0.0	88.0	20.0	100.0	-4.8	70.0	7.7	104.0	8.3
			16	95.0	-13.6	70.0	0.0	88.0	20.0	100.0	-4.8	70.0	7.7	104.0	8.3
			18	105.0	-4.5	65.0	-7.1	104.0	30.0	105.0	0.0	70.0	7.7	120.0	25.0
			20	105.0	-4.5	65.0	-7.1	100.0	25.0	105.0	0.0	70.0	7.7	100.0	4.2
			22	105.0	-4.5	65.0	-7.1	100.0	25.0	105.0	0.0	70.0	7.7	100.0	4.2
			24	105.0	-4.5	70.0	0.0	88.0	10.0	100.0	-4.8	75.0	15.4	88.0	-8.3
			26	105.0	-4.5	70.0	0.0	88.0	10.0	100.0	-4.8	75.0	15.4	88.0	-8.3
			28	105.0	-4.5	70.0	0.0	88.0	10.0	100.0	-4.8	75.0	15.4	88.0	-8.3
			30	110.0	0.0	75.0	0.0	96.0	20.0	105.0	0.0	70.0	7.7	100.0	4.2
			32	110.0	0.0	75.0	0.0	96.0	20.0	105.0	-4.8	70.0	7.7	100.0	4.2
			34	110.0	0.0	75.0	0.0	96.0	20.0	105.0	-4.8	70.0	7.7	100.0	4.2
			36	110.0	0.0	75.0	0.0	96.0	20.0	105.0	-4.8	70.0	7.7	100.0	4.2
			38	110.0	0.0	75.0	0.0	96.0	20.0	105.0	-4.8	70.0	7.7	100.0	4.2
			40	120.0	9.1	80.0	14.3	86.0	7.5	115.0	9.5	75.0	15.4	92.0	-4.2
			42	110.0	0.0	80.0	14.3	96.0	20.0	120.0	14.3	75.0	15.4	108.0	12.5
			44	120.0	9.1	80.0	14.3	102.0	27.5	115.0	9.5	70.0	7.7	104.0	8.3
			46	125.0	13.6	85.0	21.4	84.0	5.0	120.0	14.3	80.0	7.7	88.0	-8.3
			48	125.0	13.6	85.0	21.4	89.0	11.3	120.0	14.3	80.0	7.7	102.0	6.3
			50	125.0	13.6	70.0	0.0	102.0	27.5	115.0	9.5	70.0	7.7	106.0	10.4

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 40 mm Hg
 H.R. values <= 50 beats/min

N
 C
 C
 1-4

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: REBOMETINE

Centre	Patient	Initial	Visit	LIVING				STANDING								
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff			
1	311	SP	52	115.0	4.5	75.0	7.1	100.0	25.0	**	110.0	4.8	70.0	7.7	110.0	14.6
	313	SCN	-1	95.0	36.8	65.0	23.1	80.0	20.0		100.0	20.0	70.0	14.3	80.0	25.0
			0	130.0	47.4	90.0	38.5	96.0	7.5		120.0	30.0	80.0	14.3	100.0	7.5
			1	140.0	36.8	80.0	23.1	74.0	-7.5		130.0	25.0	80.0	0.0	86.0	2.5
			2	125.0	31.6	85.0	30.8	74.0	-7.5		125.0	20.0	80.0	14.3	82.0	2.5
			3	125.0	31.6	85.0	30.8	74.0	-7.5		120.0	20.0	80.0	14.3	82.0	10.0
			4	125.0	26.3	85.0	23.1	84.0	5.0		120.0	20.0	80.0	0.0	86.0	7.5
			5	120.0	31.6	85.0	30.8	74.0	-5.0		120.0	20.0	80.0	21.4	86.0	-2.5
			6	125.0	15.8	85.0	30.8	74.0	10.0		120.0	20.0	85.0	0.0	104.0	30.0
			8	110.0	31.6	90.0	38.5	96.0	25.0	**	115.0	15.0	75.0	28.5	100.0	25.0
			10	125.0	21.1	75.0	15.4	100.0	30.0	**	105.0	5.0	75.0	7.1	103.0	35.0
			12	115.0	26.3	80.0	23.1	104.0	10.0	**	110.0	10.0	80.0	14.3	103.0	35.0
			14	120.0	26.3	80.0	23.1	88.0	10.0		100.0	0.0	80.0	14.3	103.0	20.0
			16	110.0	26.3	80.0	23.1	92.0	15.0		105.0	5.0	70.0	0.0	100.0	20.0
			18	120.0	5.3	75.0	15.4	84.0	5.0		90.0	-10.0	65.0	-7.1	104.0	30.0
			20	100.0	26.3	80.0	23.1	88.0	10.0		120.0	20.0	80.0	14.3	100.0	25.0
			22	120.0	26.3	80.0	23.1	88.0	10.0		120.0	20.0	85.0	21.4	100.0	23.0
			24	120.0	26.3	80.0	23.1	88.0	10.0		120.0	20.0	85.0	21.4	100.0	25.0
			26	120.0	26.3	80.0	23.1	100.0	25.0	**	120.0	20.0	80.0	14.3	100.0	25.0
			28	105.0	10.5	80.0	23.1	76.0	-5.0		110.0	10.0	85.0	21.4	92.0	15.0
			30	120.0	26.3	80.0	23.1	72.0	-10.0		120.0	20.0	80.0	14.3	80.0	0.0
			32	100.0	5.3	80.0	23.1	88.0	10.0		100.0	0.0	80.0	14.3	108.0	35.0
			34	100.0	5.3	80.0	23.1	88.0	10.0		100.0	0.0	80.0	14.3	108.0	35.0
			36	120.0	26.3	80.0	23.1	72.0	-10.0		120.0	20.0	80.0	14.3	80.0	0.0
			38	140.0	47.4	85.0	30.8	86.0	7.5		130.0	30.0	80.0	14.3	88.0	10.0
			40	140.0	47.4	85.0	30.8	86.0	7.5		135.0	35.0	80.0	14.3	88.0	10.0
			42	125.0	31.6	80.0	23.1	86.0	7.5		120.0	20.0	80.0	14.3	94.0	17.5
			44	125.0	31.6	80.0	23.1	86.0	7.5		120.0	20.0	80.0	14.3	94.0	17.5
			46	125.0	31.6	80.0	23.1	86.0	7.5		120.0	20.0	80.0	14.3	94.0	17.5
			48	110.0	15.8	75.0	15.4	88.0	10.0		110.0	10.0	80.0	14.3	98.0	22.5
			50	115.0	21.1	75.0	15.4	80.0	0.0		100.0	0.0	80.0	14.3	88.0	10.0
			52	115.0	21.1	75.0	15.4	80.0	0.0		100.0	0.0	80.0	14.3	88.0	10.0
316	HTS		-1	130.0	0.0	90.0	0.0	88.0	-2.3		140.0	0.0	90.0	0.0	90.0	0.0
			1	130.0	0.0	90.0	0.0	69.0	-21.6		130.0	-7.1	90.0	0.0	79.0	-12.2
			2	130.0	0.0	85.0	-5.6	100.0	13.6		130.0	-7.1	95.0	5.6	108.0	20.0
			3	130.0	0.0	100.0	11.1	80.0	-9.1		130.0	-7.1	100.0	11.1	82.0	-8.9
			4	160.0	23.1	105.0	16.7	108.0	22.7	**	165.0	17.9	120.0	33.3	116.0	28.9

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 100 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CVS R&D
 REDOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: REDOXETINE

Centre	Patient	Initial	Visit	LYING			STANDING													
				S.B.P. % diff	D.B.P. % diff	H.R. % diff	S.B.P. % diff	D.B.P. % diff	H.R. % diff											
1	316	MTS	5	130.0	0.0	11.1	80.0	-9.1	140.0	0.0	100.0	11.1	82.0	-8.9						
			6	130.0	0.0	11.1	80.0	-9.1	140.0	0.0	110.0	22.2	**	80.0	-11.1					
			8	130.0	0.0	0.0	100.0	13.6	150.0	7.1	140.0	0.0	100.0	11.1	104.0	15.6				
			10	130.0	0.0	0.0	78.0	-11.4	140.0	0.0	80.0	0.0	80.0	22.2	100.0	0.0				
			12	160.0	23.1	**	11.1	84.0	-4.5	160.0	14.3	110.0	22.2	**	100.0	11.1				
			14	140.0	7.7	**	11.1	85.0	-3.4	140.0	0.0	110.0	22.2	**	95.0	5.6				
			16	140.0	7.7	**	11.1	90.0	2.3	140.0	0.0	110.0	22.2	**	100.0	11.1				
			18	140.0	7.7	**	11.1	110.0	22.2	**	140.0	0.0	110.0	22.2	**	100.0	11.1			
			20	155.0	19.2	**	12.0	104.0	18.2	155.0	10.7	130.0	44.4	**	100.0	11.1				
			22	160.0	23.1	**	12.0	104.0	18.2	150.0	7.1	115.0	27.8	**	108.0	20.0				
			24	160.0	23.1	**	12.0	104.0	18.2	150.0	7.1	115.0	27.8	**	108.0	20.0				
			26	160.0	23.1	**	12.0	104.0	18.2	150.0	7.1	115.0	27.8	**	108.0	20.0				
			28	150.0	15.4	**	11.0	22.2	**	80.0	-9.1	140.0	0.0	100.0	22.2	**				
			30	150.0	15.4	**	11.0	22.2	**	80.0	-9.1	140.0	0.0	100.0	22.2	**				
			32	130.0	0.0	**	10.0	11.1	100.0	13.6	140.0	0.0	100.0	11.1	100.0	11.1				
			34	130.0	0.0	**	10.0	11.1	100.0	13.6	140.0	0.0	100.0	11.1	100.0	11.1				
			36	130.0	0.0	**	10.0	11.1	100.0	13.6	140.0	0.0	100.0	11.1	100.0	11.1				
			38	130.0	0.0	**	10.0	11.1	100.0	13.6	140.0	0.0	100.0	11.1	100.0	11.1				
			40	100.0	-23.1	*	70.0	-22.2	*	74.0	-15.9	105.0	-25.0	*	70.0	-22.2				
			42	115.0	-11.5	*	85.0	-5.6	*	74.0	-15.9	105.0	-21.4	*	75.0	-16.7				
			44	115.0	-11.5	*	70.0	-22.2	*	70.0	-20.5	105.0	-25.0	*	65.0	-27.8				
			46	120.0	-7.7	*	80.0	-11.1	*	76.0	-13.6	110.0	-21.4	*	70.0	-22.2				
			48	115.0	-11.5	*	75.0	-16.7	*	80.0	-9.1	120.0	-14.3	*	70.0	-22.2				
			50	125.0	-3.8	*	70.0	-22.2	*	74.0	-15.9	115.0	-17.9	*	70.0	-22.2				
			52	120.0	-7.7	*	80.0	-11.1	*	74.0	-15.9	110.0	-21.4	*	70.0	-22.2				
			318	DHG		-1	130.0	0.0	70.0	68.0	0.0	130.0	0.0	70.0	0.0	76.0	0.0			
						1	130.0	0.0	0.0	68.0	0.0	130.0	0.0	70.0	0.0	76.0	0.0			
						2	120.0	-7.7	28.6	80.0	17.6	120.0	-7.7	120.0	-7.7	90.0	28.6	90.0		
						3	140.0	7.7	7.1	90.0	32.4	125.0	-3.8	80.0	0.0	80.0	14.3	100.0		
						4	140.0	7.7	7.1	84.0	23.5	130.0	0.0	80.0	0.0	80.0	14.3	96.0		
						5	150.0	15.4	*	80.0	29.4	155.0	19.2	85.0	0.0	85.0	21.4	96.0		
						6	105.0	-19.2	*	85.0	21.4	130.0	0.0	80.0	0.0	80.0	14.3	92.0		
						7	105.0	-19.2	*	85.0	21.4	130.0	0.0	80.0	0.0	80.0	14.3	92.0		
						8	130.0	0.0	28.6	80.0	17.6	160.0	23.1	**	100.0	42.9	**	88.0		
						10	130.0	0.0	28.6	80.0	17.6	160.0	23.1	**	100.0	42.9	**	88.0		
						12	130.0	0.0	28.6	80.0	17.6	160.0	23.1	**	100.0	42.9	**	88.0		
						14	130.0	0.0	28.6	80.0	17.6	160.0	23.1	**	100.0	42.9	**	88.0		
						320	ARM		-1	90.0	0.0	60.0	76.0	0.0	100.0	0.0	70.0	0.0	80.0	0.0

** S.B.P. values => 160 mm Hg
 D.B.P. values => 100 mm Hg
 H.R. values => 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	Initial	Visit	LYING			STANDING											
				S.B.P.	D.B.P.	H.R.	S.B.P.	D.B.P.	H.R.									
				% diff	% diff	% diff	% diff	% diff	% diff									
1	320	ARM	0	90.0	0.0	76.0	0.0	100.0	0.0	70.0	0.0	80.0	0.0					
			1	110.0	22.2	85.0	41.7	100.0	0.0	100.0	0.0	70.0	0.0	100.0	25.0			
			2	115.0	27.8	80.0	33.3	88.0	15.8	120.0	20.0	80.0	14.3	88.0	10.0			
			3	120.0	33.3	80.0	33.3	80.0	5.3	120.0	20.0	80.0	14.3	88.0	10.0			
			4	115.0	27.8	85.0	41.7	80.0	-10.5	100.0	0.0	80.0	14.3	88.0	10.0			
			5	105.0	16.7	75.0	25.0	72.0	-5.3	110.0	10.0	85.0	21.4	88.0	10.0			
			6	100.0	11.1	75.0	25.0	76.0	0.0	100.0	0.0	80.0	14.3	88.0	10.0			
			8	110.0	22.2	70.0	16.7	64.0	-15.8	105.0	5.0	75.0	7.1	70.0	-12.5			
			10	115.0	27.8	75.0	25.0	66.0	-13.2	110.0	10.0	70.0	0.0	72.0	-10.0			
			12	115.0	27.8	70.0	16.7	66.0	-13.2	105.0	5.0	60.0	-14.3	72.0	-10.0			
			14	110.0	22.2	70.0	16.7	70.0	-7.9	105.0	5.0	65.0	-7.1	74.0	-7.5			
			16	115.0	27.8	75.0	25.0	76.0	0.0	110.0	10.0	70.0	0.0	78.0	-2.5			
			2	323	RVC	-1	110.0	0.0	72.0	0.0	115.0	0.0	80.0	0.0	76.0	0.0		
						1	115.0	4.5	80.0	23.1	106.0	44.4	100.0	-13.0	80.0	0.0	76.0	0.0
						2	105.0	-4.5	70.0	7.7	88.0	22.2	90.0	-21.7	65.0	-18.8	96.0	26.3
						3	120.0	9.1	80.0	23.1	80.0	11.1	105.0	-8.7	75.0	-6.3	100.0	31.6
4	120.0	9.1				75.0	15.4	84.0	22.2	95.0	-17.4	65.0	-18.8	96.0	26.3			
5	110.0	0.0				75.0	15.4	84.0	16.7	100.0	-13.0	70.0	-12.5	100.0	31.6			
6	110.0	0.0				80.0	23.1	88.0	22.2	110.0	-4.3	90.0	12.5	100.0	31.6			
8	105.0	-4.5				75.0	15.4	76.0	5.6	110.0	-4.3	75.0	-6.3	84.0	10.5			
10	115.0	4.5				75.0	15.4	88.0	22.2	100.0	-13.0	70.0	-12.5	100.0	31.6			
12	115.0	4.5				75.0	15.4	88.0	22.2	100.0	-13.0	70.0	-12.5	100.0	31.6			
14	95.0	-13.6				70.0	7.7	96.0	33.3	110.0	-4.3	75.0	-6.3	104.0	36.8			
16	130.0	18.2				80.0	23.1	88.0	22.2	90.0	-21.7	70.0	-12.5	96.0	26.3			
20	115.0	4.5				75.0	15.4	86.0	19.4	110.0	-4.3	75.0	-6.3	104.0	36.8			
22	115.0	4.5				80.0	23.1	92.0	27.8	110.0	-4.3	85.0	6.3	104.0	36.8			
24	110.0	0.0				75.0	15.4	84.0	16.7	110.0	-4.3	85.0	6.3	104.0	36.8			
26	110.0	0.0				75.0	15.4	84.0	16.7	110.0	-4.3	85.0	6.3	104.0	36.8			
28	125.0	13.6	85.0	30.8	84.0	16.7	135.0	17.4	85.0	6.3	96.0	26.3						
30	125.0	13.6	85.0	30.8	84.0	16.7	135.0	17.4	85.0	6.3	96.0	26.3						
32	125.0	13.6	85.0	30.8	84.0	16.7	135.0	17.4	85.0	6.3	96.0	26.3						
34	125.0	13.6	85.0	30.8	84.0	16.7	135.0	17.4	85.0	6.3	96.0	26.3						
36	130.0	18.2	90.0	38.5	88.0	22.2	130.0	13.0	85.0	6.3	104.0	36.8						
38	130.0	18.2	80.0	23.1	96.0	33.3	135.0	17.4	85.0	6.3	96.0	26.3						
40	120.0	9.1	80.0	23.1	84.0	16.7	100.0	-13.0	60.0	-21.4	92.0	21.1						
42	115.0	4.5	70.0	7.7	92.0	27.8	110.0	-4.3	70.0	-12.5	100.0	31.6						
44	115.0	4.5	70.0	7.7	92.0	27.8	110.0	-4.3	70.0	-12.5	100.0	31.6						

** S.B.P. values => 160 mm Hg
D.B.P. values => 100 mm Hg
H.R. values => 100 beats/min
* S.B.P. values <= 100 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

2334

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 ROXOXYTINE - PROTOCOL 20124/013
 Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: ROXOXYTINE

Centre	Patient	Initial	Visit	LYING				STANDING					
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff
1	323	HVC	46	130.0	18.2	80.0	11.1	132.0	14.8	90.0	12.5	84.0	10.5
			48	105.0	-4.5	88.0	22.2	110.0	-4.3	80.0	0.0	104.0	36.8 **
			50	105.0	-4.5	88.0	22.2	110.0	-4.3	80.0	0.0	104.0	36.8 **
			52	105.0	-4.5	92.0	27.8	100.0	-13.0	70.0	-12.5	92.0	21.1
			-1	120.0	0.0	80.0	0.0	130.0	0.0	90.0	0.0	88.0	0.0
1	326	TCG	0	120.0	0.0	80.0	0.0	130.0	0.0	90.0	0.0	88.0	0.0
			1	110.0	-8.3	100.0	25.0 **	100.0	-23.1 *	80.0	-11.1	110.0	25.0 **
			2	110.0	-8.3	100.0	25.0 **	110.0	-15.4	80.0	-11.1	100.0	13.6
			3	120.0	0.0	92.0	15.0 **	110.0	-15.4	75.0	-16.7	104.0	18.2
			4	100.0	-16.7	100.0	25.0 **	100.0	-23.1 *	75.0	-16.7	100.0	13.6
			5	110.0	-8.3	112.0	40.0 **	120.0	-7.7	90.0	0.0	128.0	45.5 **
			6	100.0	-16.7	92.0	15.0 **	100.0	-23.1 *	80.0	-11.1	92.0	4.5
			8	130.0	8.3	82.0	2.5	120.0	-7.7	100.0	11.1	86.0	-2.3
			10	130.0	8.3	80.0	0.0	120.0	-7.7	100.0	11.1	84.0	-4.5
			12	120.0	0.0	88.0	10.0	110.0	-15.4	80.0	-11.1	100.0	13.6
			14	135.0	12.5	76.0	-5.0	125.0	-3.8	80.0	-11.1	92.0	4.5
			16	130.0	8.3	88.0	10.0	115.0	-11.5	85.0	-5.6	112.0	27.3 **
			18	130.0	8.3	88.0	10.0	115.0	-11.5	85.0	-5.6	112.0	27.3 **
			20	130.0	8.3	88.0	10.0	115.0	-11.5	85.0	-5.6	112.0	27.3 **
			22	130.0	8.3	88.0	10.0	115.0	-11.5	85.0	-5.6	112.0	27.3 **
			24	110.0	-8.3	120.0	50.0 **	110.0	-15.4	90.0	0.0	124.0	40.9 **
			26	135.0	12.5	84.0	5.0	115.0	-11.5	86.0	-2.3	108.0	22.7 **
			28	115.0	-4.2	96.0	20.0	110.0	-15.4	80.0	-11.1	104.0	18.2
			30	125.0	4.2	104.0	30.0 **	120.0	-7.7	95.0	5.6	104.0	18.2
			32	130.0	8.3	92.0	15.0	135.0	3.8	100.0	11.1	96.0	9.1
			34	115.0	-4.2	100.0	11.1	110.0	-15.4	90.0	0.0	100.0	13.6
			36	120.0	0.0	96.0	20.0	125.0	3.8	100.0	11.1	100.0	13.6
			38	110.0	-8.3	100.0	25.0 **	130.0	0.0	90.0	0.0	100.0	13.6
			40	120.0	0.0	96.0	20.0 **	130.0	0.0	90.0	0.0	100.0	13.6
			42	130.0	8.3	92.0	15.0	135.0	3.8	100.0	11.1	106.0	20.5 **
44	115.0	-4.2	116.0	45.0 **	130.0	0.0	85.0	-5.6	108.0	4.5			
46	120.0	0.0	80.0	0.0	140.0	-15.4	80.0	-11.1	108.0	22.7 **			
48	120.0	0.0	88.0	10.0	110.0	-15.4	80.0	-11.1	108.0	0.0			
50	115.0	-4.2	90.0	0.0	110.0	-15.4	80.0	-11.1	100.0	13.6			
52	130.0	8.3	78.0	-2.5	125.0	-3.8	95.0	5.6	80.0	-9.1			
329	ONY	-1	105.0	0.0	88.0	0.0	100.0	0.0	70.0	0.0	96.0	0.0	
		0	105.0	0.0	88.0	0.0	100.0	0.0	70.0	0.0	96.0	0.0	
		1	92.0	-12.4	88.0	0.0	100.0	0.0	75.0	7.1	92.0	-4.2	

** S.B.P. values > 160 mm Hg
 D.B.P. values > 100 mm Hg
 H.R. values > 100 beats/min
 * S.B.P. values <= 100 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	Initial	Visit	LYING				STANDING										
				S.B.P. % diff	D.B.P. % diff	H.R. % diff	S.B.P. % diff	D.B.P. % diff	H.R. % diff									
1	329	OHV	2	90.0	-14.3	-7.1	96.0	9.1	100.0	0.0	70.0	0.0	96.0	0.0				
			3	110.0	4.8	0.0	120.0	36.4	**	110.0	10.0	80.0	14.3	120.0	0.0			
			4	100.0	-4.8	0.0	88.0	0.0	0.0	100.0	0.0	70.0	0.0	80.0	-16.7			
			5	100.0	-4.8	14.3	96.0	9.1	0.0	100.0	0.0	80.0	14.3	104.0	8.3			
			6	100.0	-4.8	14.3	96.0	9.1	0.0	100.0	0.0	80.0	14.3	104.0	8.3			
			8	100.0	-4.8	14.3	96.0	9.1	0.0	100.0	0.0	80.0	14.3	104.0	8.3			
			10	100.0	-4.8	0.0	90.0	2.3	0.0	110.0	10.0	70.0	0.0	98.0	2.1			
			12	110.0	4.8	7.1	108.0	22.7	**	95.0	-5.0	75.0	7.1	120.0	25.0			
			14	100.0	-4.8	14.3	100.0	13.6	0.0	100.0	0.0	75.0	7.1	100.0	4.2			
			16	100.0	-4.8	14.3	100.0	13.6	0.0	100.0	0.0	75.0	7.1	100.0	4.2			
			18	105.0	0.0	7.1	108.0	22.7	**	105.0	5.0	80.0	14.3	112.0	16.7			
			20	105.0	0.0	7.1	108.0	22.7	**	105.0	5.0	80.0	14.3	112.0	16.7			
			22	105.0	0.0	7.1	108.0	22.7	**	105.0	5.0	80.0	14.3	112.0	16.7			
			24	110.0	4.8	0.0	104.0	18.2	0.0	100.0	0.0	80.0	14.3	112.0	16.7			
			26	110.0	4.8	0.0	104.0	18.2	0.0	100.0	0.0	80.0	14.3	112.0	16.7			
			28	95.0	-9.5	0.0	100.0	13.6	0.0	100.0	0.0	80.0	14.3	106.0	10.4			
			30	100.0	-4.8	14.3	112.0	27.3	**	110.0	10.0	70.0	0.0	104.0	8.3			
			32	95.0	-9.5	0.0	100.0	13.6	0.0	100.0	0.0	80.0	14.3	106.0	10.4			
			34	95.0	-9.5	0.0	100.0	13.6	0.0	100.0	0.0	80.0	14.3	106.0	10.4			
			36	120.0	14.3	14.3	104.0	18.2	0.0	120.0	20.0	80.0	14.3	112.0	16.7			
			38	120.0	14.3	14.3	104.0	18.2	0.0	120.0	20.0	80.0	14.3	112.0	16.7			
			40	110.0	4.8	7.1	102.0	15.9	0.0	105.0	5.0	80.0	14.3	112.0	16.7			
			42	100.0	-4.8	0.0	100.0	13.6	0.0	110.0	10.0	80.0	14.3	112.0	16.7			
			44	100.0	-4.8	0.0	100.0	13.6	0.0	110.0	10.0	80.0	14.3	112.0	16.7			
			46	105.0	0.0	0.0	96.0	9.1	0.0	110.0	10.0	75.0	7.1	110.0	14.6			
			48	110.0	4.8	0.0	92.0	4.5	0.0	110.0	10.0	75.0	7.1	108.0	12.5			
			50	110.0	4.8	0.0	92.0	4.5	0.0	110.0	10.0	75.0	7.1	108.0	12.5			
			52	110.0	4.8	0.0	92.0	4.5	0.0	110.0	10.0	75.0	7.1	100.0	4.2			
			394	MGA		-1	100.0	0.0	0.0	84.0	0.0	95.0	0.0	60.0	0.0	96.0	0.0	
						0	100.0	0.0	0.0	84.0	0.0	95.0	0.0	60.0	0.0	96.0	0.0	
						1	100.0	0.0	15.4	100.0	19.0	0.0	95.0	0.0	60.0	0.0	108.0	12.5
						2	90.0	-10.0	0.0	72.0	-14.3	0.0	95.0	0.0	65.0	8.3	60.0	-37.5
						3	90.0	-10.0	0.0	72.0	-14.3	**	95.0	0.0	65.0	8.3	60.0	-37.5
						4	110.0	10.0	7.7	70.0	-16.7	0.0	110.0	15.8	70.0	16.7	120.0	25.0
						5	110.0	10.0	7.7	70.0	-16.7	0.0	110.0	15.8	70.0	16.7	120.0	25.0
						6	90.0	-10.0	15.4	70.0	-16.7	0.0	90.0	-5.3	75.0	25.0	78.0	-18.8
						8	110.0	10.0	23.1	112.0	33.3	**	90.0	-5.3	75.0	25.0	78.0	-18.8
						10	115.0	15.0	108.0	28.6	**	105.0	10.5	75.0	25.0	112.0	16.7	
						12	100.0	0.0	15.4	100.0	19.0	0.0	100.0	5.3	80.0	33.3	104.0	8.3

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 mm Hg
 H.R. values <= 50 beats/min

23080

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	Initial	Visit	LYING				STANDING										
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff					
1	334	MGA	14	105.0	5.0	75.0	15.4	96.0	14.3	100.0	5.3	70.0	16.7	100.0	4.2			
			16	100.0	0.0	75.0	15.4	104.0	23.8	105.0	10.5	85.0	41.7	108.0	12.5			
			18	100.0	0.0	75.0	15.4	104.0	23.8	105.0	10.5	85.0	41.7	108.0	12.5			
			20	110.0	10.0	80.0	23.1	100.0	19.0	105.0	10.5	80.0	33.3	120.0	25.0			
			22	110.0	10.0	80.0	23.1	116.0	38.1	105.0	10.5	80.0	33.3	120.0	25.0			
			24	90.0	-10.0	65.0	0.0	104.0	23.8	95.0	0.0	70.0	16.7	112.0	16.7			
			26	90.0	-10.0	65.0	0.0	104.0	23.8	95.0	0.0	70.0	16.7	112.0	16.7			
			28	110.0	10.0	80.0	23.1	100.0	19.0	110.0	15.8	80.0	33.3	108.0	12.5			
			30	110.0	10.0	80.0	23.1	100.0	19.0	110.0	15.8	80.0	33.3	108.0	12.5			
			32	110.0	10.0	80.0	23.1	100.0	19.0	110.0	15.8	80.0	33.3	108.0	12.5			
			34	110.0	10.0	80.0	23.1	100.0	19.0	110.0	15.8	80.0	33.3	108.0	12.5			
			36	110.0	10.0	80.0	23.1	100.0	19.0	110.0	15.8	80.0	33.3	108.0	12.5			
			38	110.0	10.0	80.0	23.1	100.0	19.0	110.0	15.8	80.0	33.3	108.0	12.5			
			40	110.0	10.0	80.0	23.1	100.0	19.0	110.0	15.8	80.0	33.3	108.0	12.5			
			42	95.0	-5.0	65.0	0.0	92.0	9.5	115.0	21.1	80.0	33.3	92.0	-4.2			
			44	95.0	-5.0	65.0	0.0	88.0	4.8	90.0	-5.3	70.0	16.7	100.0	4.2			
			46	85.0	-15.0	55.0	-15.4	106.0	26.2	90.0	-5.3	60.0	0.0	112.0	16.7			
			48	85.0	-15.0	55.0	-15.4	106.0	26.2	90.0	-5.3	60.0	0.0	112.0	16.7			
			50	110.0	10.0	80.0	23.1	104.0	23.8	100.0	5.3	70.0	16.7	100.0	4.2			
			52	110.0	10.0	80.0	23.1	104.0	23.8	100.0	5.3	70.0	16.7	100.0	4.2			
			2	335	PSL	-1	150.0	0.0	110.0	0.0	96.0	0.0	150.0	0.0	110.0	0.0	100.0	0.0
						0	150.0	0.0	110.0	0.0	96.0	0.0	150.0	0.0	110.0	0.0	100.0	0.0
						1	115.0	-23.3	80.0	-27.3	108.0	12.5	100.0	-33.3	80.0	-27.3	116.0	16.0
						2	130.0	-13.3	100.0	-9.1	82.0	-14.6	120.0	-20.0	100.0	-20.0	100.0	-9.1
						3	130.0	-13.3	100.0	-9.1	104.0	8.3	120.0	-20.0	100.0	-20.0	100.0	-9.1
						4	130.0	-13.3	100.0	-9.1	104.0	8.3	120.0	-20.0	100.0	-20.0	100.0	-9.1
						5	130.0	-13.3	115.0	4.5	100.0	4.2	120.0	-20.0	100.0	-20.0	100.0	-9.1
						6	130.0	-13.3	115.0	4.5	100.0	4.2	120.0	-20.0	100.0	-20.0	100.0	-9.1
						8	170.0	13.3	115.0	4.5	96.0	0.0	155.0	3.3	100.0	0.0	100.0	0.0
						10	130.0	-13.3	95.0	-13.6	108.0	12.5	110.0	-26.7	95.0	-13.6	120.0	20.0
						12	130.0	-13.3	90.0	-18.2	90.0	-6.3	130.0	-13.3	90.0	-13.6	105.0	-5.0
						14	140.0	-6.7	110.0	0.0	100.0	4.2	140.0	-6.7	105.0	-4.5	100.0	0.0
						16	140.0	-6.7	110.0	0.0	92.0	4.2	130.0	-13.3	110.0	0.0	100.0	0.0
						18	145.0	-3.3	110.0	0.0	112.0	16.7	130.0	-13.3	105.0	-4.5	112.0	12.0
						20	130.0	-13.3	95.0	-13.6	100.0	4.2	135.0	-10.0	105.0	-4.5	104.0	4.0
						22	140.0	-6.7	95.0	-13.6	100.0	4.2	135.0	-10.0	105.0	-4.5	104.0	4.0
			24	140.0	-6.7	110.0	0.0	98.0	2.1	140.0	-6.7	105.0	-4.5	104.0	4.0			
			26	140.0	-6.7	100.0	-9.1	92.0	-4.2	130.0	-13.3	100.0	-9.1	96.0	-4.0			
			28	125.0	-16.7	90.0	-18.2	112.0	16.7	110.0	-26.7	90.0	-18.2	120.0	20.0			

** S.B.P. values => 160 mm Hg
D.B.P. values => 100 mm Hg
H.R. values => 100 beats/min
* S.B.P. values <= 100 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: REBOMETINE

Centre	Patient	Initial Visit	LYING				STANDING											
			S.B.P.	% diff	H.R.	% diff	S.B.P.	% diff	H.R.	% diff								
1	335	PSL	30	135.0	-10.0	100.0	-9.1	95.0	-1.0	130.0	-13.3	100.0	-9.1	108.0	8.0			
			32	150.0	0.0	110.0	0.0	88.0	-8.3	150.0	0.0	115.0	4.5	96.0	-4.0			
			34	135.0	-10.0	100.0	-9.1	94.0	-2.1	140.0	-6.7	105.0	-4.5	104.0	4.0			
			36	120.0	-20.0	90.0	-18.2	100.0	4.2	130.0	-13.3	100.0	0.0	112.0	12.0			
			38	130.0	-13.3	100.0	-9.1	100.0	4.2	135.0	-10.0	110.0	0.0	100.0	0.0			
			40	130.0	-13.3	100.0	-9.1	100.0	4.2	135.0	-10.0	110.0	0.0	100.0	0.0			
			42	140.0	-6.7	105.0	-4.5	92.0	-4.2	145.0	-3.3	110.0	0.0	100.0	0.0			
			44	140.0	-6.7	105.0	-4.5	92.0	-4.2	145.0	-3.3	110.0	0.0	100.0	0.0			
			46	145.0	-3.3	105.0	-4.5	94.0	-2.1	140.0	-6.7	110.0	0.0	104.0	4.0			
			48	150.0	0.0	110.0	0.0	98.0	2.1	140.0	-6.7	110.0	0.0	108.0	8.0			
			50	150.0	0.0	110.0	0.0	98.0	2.1	140.0	-6.7	110.0	0.0	108.0	8.0			
			52	125.0	-16.7	100.0	-9.1	96.0	0.0	140.0	-6.7	115.0	4.5	104.0	4.0			
			338	MLL		-1	140.0	0.0	60.0	16.7	86.0	2.3	135.0	3.7	60.0	8.3	86.0	7.0
						1	135.0	-3.6	65.0	8.3	70.0	-18.6	140.0	0.0	65.0	0.0	78.0	-9.3
						2	140.0	0.0	70.0	16.7	74.0	-14.0	140.0	0.0	70.0	0.0	82.0	-4.7
						3	135.0	-3.6	75.0	25.0	76.0	-11.6	130.0	-3.7	60.0	0.0	82.0	-4.7
						4	130.0	-7.1	80.0	33.3	82.0	-4.7	135.0	0.0	75.0	25.0	88.0	2.3
						5	130.0	-7.1	80.0	33.3	84.0	-2.3	140.0	3.7	90.0	50.0	86.0	0.0
						6	130.0	-7.1	80.0	33.3	86.0	0.0	130.0	-3.7	85.0	41.7	92.0	7.0
						8	120.0	-14.3	70.0	16.7	56.0	-34.9	110.0	-18.5	70.0	16.7	64.0	-25.6
						10	110.0	-21.4	70.0	16.7	56.0	-34.9	110.0	-18.5	65.0	8.3	62.0	-27.9
12	115.0	-17.9				75.0	25.0	54.0	-37.2	110.0	-18.5	75.0	25.0	62.0	-27.9			
14	115.0	-17.9				70.0	16.7	62.0	-27.9	110.0	-18.5	75.0	25.0	68.0	-20.9			
16	110.0	-21.4				70.0	16.7	64.0	-25.6	105.0	-22.2	70.0	16.7	68.0	-20.9			
18	115.0	-17.9				75.0	25.0	56.0	-34.9	110.0	-18.5	70.0	16.7	60.0	-30.2			
20	110.0	-21.4				70.0	16.7	58.0	-32.6	100.0	-25.9	60.0	0.0	66.0	-23.3			
22	105.0	-25.0				65.0	8.3	64.0	-30.2	100.0	-25.9	60.0	0.0	66.0	-23.3			
24	120.0	-14.3	80.0	33.3	60.0	-30.2	115.0	-14.8	75.0	25.0	68.0	-20.9						
26	120.0	-14.3	70.0	16.7	74.0	-14.0	125.0	-7.4	70.0	16.7	82.0	-4.7						
28	125.0	-10.7	70.0	16.7	64.0	-25.6	115.0	-14.8	70.0	16.7	66.0	-23.3						
30	120.0	-14.3	80.0	33.3	68.0	-20.9	115.0	-14.8	70.0	16.7	72.0	-16.3						
32	125.0	-10.7	80.0	33.3	72.0	-16.3	120.0	-11.1	70.0	16.7	74.0	-14.0						
34	130.0	-7.1	80.0	33.3	80.0	-7.0	125.0	-7.4	80.0	33.3	86.0	0.0						
36	130.0	-7.1	80.0	33.3	74.0	-14.0	115.0	-14.8	70.0	16.7	76.0	-11.6						
38	130.0	-7.1	70.0	16.7	72.0	-16.3	120.0	-11.1	70.0	16.7	74.0	-14.0						
40	110.0	-21.4	70.0	16.7	58.0	-32.6	100.0	-25.9	60.0	0.0	62.0	-27.9						
42	130.0	-7.1	80.0	33.3	58.0	-32.6	120.0	-11.1	60.0	33.3	62.0	-27.9						
44	120.0	-14.3	80.0	33.3	74.0	-14.0	115.0	-14.8	70.0	16.7	78.0	-9.3						

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 100 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

2 3 8 8

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013

Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	Initial	Visit	LYING			STANDING								
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	H.R.	% diff				
1	338	MLL	46	120.0	-14.3	70.0	16.7	64.0	-25.6	110.0	-18.5	70.0	16.7	68.0	-20.9
			48	120.0	-14.3	70.0	16.7	76.0	-11.6	110.0	-18.5	70.0	16.7	82.0	-4.7
			50	120.0	-14.3	70.0	16.7	68.0	-20.9	110.0	-18.5	70.0	16.7	72.0	-16.3
			52	125.0	-10.7	85.0	41.7	76.0	-11.6	120.0	-11.1	80.0	33.3	80.0	-7.0
			-1	125.0		75.0		86.0		120.0		70.0		70.0	
1	342	VPD	0	130.0	4.0	80.0	6.7	92.0	7.0	120.0	0.0	70.0	0.0	100.0	8.7
			1	135.0	8.0	80.0	6.7	84.0	-2.3	130.0	8.3	75.0	7.1	88.0	-4.3
			2	130.0	4.0	80.0	6.7	82.0	-4.7	120.0	0.0	70.0	0.0	92.0	0.0
			3	135.0	8.0	80.0	6.7	82.0	-4.7	130.0	8.3	70.0	0.0	88.0	-4.3
			4	130.0	4.0	80.0	6.7	76.0	-11.6	120.0	0.0	75.0	7.1	82.0	-10.9
			5	135.0	8.0	80.0	6.7	76.0	-14.0	130.0	8.3	80.0	14.3	78.0	-15.2
			6	130.0	4.0	80.0	6.7	78.0	-9.3	120.0	0.0	80.0	14.3	82.0	-10.9
			8	120.0	-4.0	85.0	13.3	84.0	9.3	120.0	0.0	80.0	14.3	100.0	8.7
			10	120.0	-4.0	75.0	0.0	82.0	7.0	110.0	-8.3	70.0	0.0	104.0	13.0
			12	125.0	0.0	85.0	13.3	84.0	9.3	120.0	0.0	75.0	7.1	108.0	17.4
			14	120.0	-4.0	75.0	0.0	90.0	4.7	120.0	0.0	70.0	0.0	106.0	15.2
			16	120.0	-4.0	75.0	0.0	102.0	16.6	115.0	-4.2	70.0	0.0	96.0	4.3
			18	125.0	0.0	80.0	6.7	88.0	2.3	120.0	0.0	70.0	0.0	96.0	4.3
			20	125.0	0.0	85.0	13.3	98.0	14.0	115.0	-4.2	80.0	14.3	102.0	10.3
			22	120.0	-4.0	80.0	6.7	98.0	14.0	115.0	-4.2	75.0	7.1	104.0	13.0
			24	125.0	0.0	80.0	6.7	82.0	-4.7	115.0	-4.2	70.0	0.0	90.0	-2.2
			26	120.0	-4.0	70.0	-6.7	86.0	0.0	125.0	4.2	75.0	7.1	88.0	-4.3
			28	130.0	4.0	75.0	0.0	84.0	-2.3	120.0	0.0	70.0	0.0	90.0	-2.2
			30	125.0	0.0	80.0	6.7	96.0	11.6	115.0	-4.2	70.0	0.0	100.0	8.7
			32	130.0	4.0	80.0	6.7	76.0	-11.6	120.0	0.0	70.0	0.0	78.0	-15.2
			34	125.0	0.0	75.0	0.0	92.0	7.0	120.0	0.0	80.0	14.3	94.0	2.2
			36	125.0	0.0	80.0	6.7	78.0	-9.3	125.0	4.2	80.0	14.3	80.0	-13.0
			38	115.0	-8.0	80.0	6.7	82.0	-4.7	120.0	0.0	70.0	0.0	84.0	-8.7
40	120.0	-4.0	70.0	-6.7	76.0	-11.6	115.0	-4.2	60.0	-14.3	80.0	-13.0			
42	100.0	-20.0	70.0	-6.7	72.0	-16.3	90.0	-25.0	*						
44	125.0	0.0	70.0	-6.7	72.0	-16.3	115.0	-4.2	70.0	0.0	82.0	-10.9			
46	110.0	-12.0	70.0	-6.7	74.0	-14.0	110.0	-8.3	60.0	-14.3	82.0	-10.9			
48	115.0	-8.0	75.0	0.0	80.0	-7.0	110.0	-8.3	70.0	0.0	84.0	-8.7			
50	120.0	-4.0	70.0	-6.7	78.0	-9.3	110.0	-8.3	70.0	0.0	84.0	-8.7			
52	120.0	-4.0	80.0	6.7	76.0	-11.6	110.0	-8.3	70.0	0.0	82.0	-10.9			
352	MCA	-1	130.0	7.7	90.0	96.0	135.0	0.0	90.0	0.0	102.0	100.0	100.0	-2.0	
		0	140.0	3.8	85.0	-5.6	94.0	-2.1	135.0	0.0	90.0	90.0	102.0	0.0	
		1	135.0				96.0	0.0	140.0	3.7	90.0	90.0	102.0	0.0	

2389

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 50 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	Initial	Visit	LYING				STANDING							
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff		
1	352	MCA	2	135.0	3.8	85.0	-5.6	98.0	2.1	130.0	-3.7	80.0	-11.1	108.0	5.9
			3	145.0	11.5	90.0	0.0	90.0	-6.3	140.0	3.7	90.0	0.0	96.0	-5.9
			4	145.0	11.5	85.0	-5.6	94.0	-2.1	145.0	7.4	90.0	0.0	104.0	2.0
			5	135.0	3.8	90.0	-11.1	94.0	-2.1	140.0	3.7	85.0	-5.6	96.0	-5.9
			6	140.0	7.7	80.0	0.0	94.0	-2.1	135.0	0.0	85.0	-5.6	98.0	-3.9
			8	130.0	0.0	80.0	-11.1	84.0	-12.5	115.0	-14.8	75.0	-16.7	85.0	-15.7
			10	125.0	-3.8	85.0	-5.6	76.0	-20.8	120.0	-14.8	75.0	-16.7	84.0	-17.6
			12	115.0	-11.5	75.0	-16.7	78.0	-18.8	110.0	-18.5	70.0	-22.2	86.0	-15.7
			14	115.0	-11.5	75.0	-16.7	78.0	-18.8	110.0	-18.5	70.0	-22.2	86.0	-15.7
			16	120.0	-7.7	80.0	-11.1	86.0	-10.4	110.0	-18.5	70.0	-22.2	88.0	-13.7
			18	125.0	-3.8	70.0	-22.2	84.0	-12.5	115.0	-14.8	70.0	-22.2	86.0	-15.7
			20	115.0	-11.5	70.0	-22.2	84.0	-18.8	110.0	-18.5	70.0	-22.2	86.0	-15.7
			22	115.0	-11.5	70.0	-22.2	84.0	-18.8	110.0	-18.5	70.0	-22.2	86.0	-15.7
			24	125.0	-3.8	85.0	-5.6	84.0	-12.5	105.0	-22.2	60.0	-35.3	88.0	-13.7
			26	125.0	-3.8	85.0	-5.6	84.0	-12.5	105.0	-22.2	60.0	-35.3	88.0	-13.7
			28	110.0	-15.4	70.0	-22.2	80.0	-25.0	115.0	-14.8	70.0	-22.2	78.0	-23.5
			30	130.0	0.0	70.0	-22.2	80.0	-16.7	100.0	-25.9	70.0	-22.2	82.0	-19.6
			32	120.0	-7.7	70.0	-22.2	76.0	-20.8	110.0	-14.8	75.0	-16.7	80.0	-21.6
			34	120.0	-7.7	70.0	-22.2	76.0	-20.8	110.0	-14.8	75.0	-16.7	80.0	-21.6
			36	125.0	-3.8	80.0	-11.1	84.0	-12.5	115.0	-14.8	70.0	-22.2	86.0	-15.7
			38	130.0	0.0	70.0	-22.2	84.0	-12.5	110.0	-14.8	70.0	-22.2	86.0	-15.7
			40	110.0	-15.4	60.0	-35.3	70.0	-27.1	100.0	-25.9	60.0	-35.3	76.0	-25.5
			42	120.0	-7.7	80.0	-11.1	84.0	-12.5	115.0	-14.8	75.0	-16.7	80.0	-21.6
			44	130.0	0.0	70.0	-22.2	84.0	-12.5	110.0	-14.8	70.0	-22.2	86.0	-15.7
			46	120.0	-7.7	70.0	-22.2	80.0	-20.8	115.0	-14.8	75.0	-16.7	80.0	-21.6
			48	115.0	-11.5	75.0	-16.7	82.0	-14.6	120.0	-11.1	70.0	-22.2	86.0	-15.7
			50	125.0	-3.8	75.0	-16.7	78.0	-18.8	115.0	-14.8	70.0	-22.2	84.0	-17.6
			52	110.0	-15.4	70.0	-22.2	74.0	-22.9	115.0	-14.8	60.0	-35.3	78.0	-23.5
356	ARF		-1	145.0		90.0		104.0		145.0		90.0		106.0	
			0	120.0	-17.2	80.0	-11.1	96.0	-7.7	120.0	-17.2	85.0	-5.6	100.0	-5.7
			1	120.0	-17.2	80.0	-11.1	96.0	-7.7	120.0	-17.2	85.0	-5.6	100.0	-5.7
			2	120.0	-17.2	85.0	-5.6	116.0	11.5	120.0	-17.2	80.0	-11.1	116.0	9.4
			3	115.0	-20.7	85.0	-5.6	80.0	-23.1	120.0	-17.2	80.0	-11.1	116.0	9.4
			4	110.0	-24.1	80.0	-11.1	100.0	-3.8	110.0	-24.1	80.0	-11.1	104.0	-1.9
			5	130.0	3.4	100.0	11.1	100.0	-3.8	130.0	10.3	95.0	5.6	100.0	-5.7
			6	110.0	-24.1	70.0	-22.2	84.0	-19.2	110.0	-24.1	80.0	-11.1	88.0	-17.0
			8	130.0	10.3	100.0	11.1	96.0	-7.7	130.0	10.3	100.0	11.1	96.0	-9.4
			10	130.0	10.3	80.0	-11.1	98.0	-5.8	120.0	-17.2	90.0	0.0	104.0	-1.9
			12	120.0	-17.2	80.0	-11.1	100.0	-3.8	120.0	-17.2	80.0	-11.1	100.0	-5.7

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

23 39 00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	Initial	Visit	LYING				STANDING										
				S.B.P.	Z diff	H.R.	Z diff	S.B.P.	Z diff	H.R.	Z diff							
1	356	ARF	14	120.0	-17.2	80.0	-11.1	100.0	-3.8	120.0	-17.2	80.0	-11.1	100.0	-5.7			
			16	130.0	-10.3	90.0	0.0	104.0	0.0	145.0	0.0	145.0	0.0	95.0	5.6			
			18	130.0	-10.3	90.0	0.0	104.0	0.0	145.0	0.0	145.0	0.0	95.0	5.6			
			20	140.0	-3.4	95.0	5.6	104.0	0.0	160.0	10.3	160.0	10.3	100.0	11.1			
			22	130.0	-10.3	95.0	5.6	112.0	7.7	130.0	0.0	130.0	0.0	100.0	11.1			
			24	146.0	0.7	100.0	11.1	146.0	0.0	164.0	13.1	164.0	13.1	100.0	11.1			
			26	135.0	-6.9	90.0	0.0	88.0	-15.4	150.0	3.4	150.0	3.4	90.0	0.0			
			28	130.0	-10.3	90.0	0.0	106.0	1.9	150.0	3.4	150.0	3.4	100.0	11.1			
			30	135.0	-6.9	90.0	0.0	106.0	1.9	150.0	3.4	150.0	3.4	100.0	11.1			
			32	140.0	-3.4	90.0	0.0	96.0	-7.7	145.0	0.0	145.0	0.0	90.0	0.0			
			34	140.0	-3.4	90.0	0.0	100.0	0.0	130.0	-10.3	130.0	-10.3	90.0	0.0			
			36	120.0	-17.2	80.0	-11.1	100.0	-3.8	120.0	-17.2	120.0	-17.2	85.0	-5.6			
			38	130.0	-10.3	80.0	-11.1	104.0	0.0	140.0	0.0	140.0	0.0	85.0	-5.6			
			358	LRM		-1	125.0		85.0		82.0		120.0		80.0		90.0	
						0	120.0	-4.0	80.0	-5.9	88.0	7.3	130.0	8.3	130.0	8.3	88.0	-2.2
						1	120.0	-4.0	80.0	-5.9	88.0	7.3	130.0	8.3	130.0	8.3	88.0	-2.2
						2	110.0	-12.0	90.0	5.3	100.0	22.0	120.0	0.0	120.0	0.0	95.0	48.8
						3	130.0	4.0	85.0	0.0	116.0	41.5	130.0	8.3	130.0	8.3	85.0	6.3
						4	120.0	-4.0	100.0	17.6	120.0	46.3	130.0	8.3	130.0	8.3	100.0	25.0
						5	120.0	-4.0	90.0	5.9	100.0	22.0	120.0	0.0	120.0	0.0	90.0	12.5
						6	115.0	-8.0	90.0	5.9	104.0	26.8	130.0	8.3	130.0	8.3	100.0	11.1
						8	130.0	4.0	90.0	5.9	100.0	22.0	140.0	16.7	140.0	16.7	90.0	25.0
						10	120.0	-4.0	80.0	-5.9	92.0	12.2	120.0	0.0	120.0	0.0	90.0	12.5
						12	130.0	4.0	90.0	5.9	112.0	36.6	145.0	20.8	145.0	20.8	95.0	18.8
						14	120.0	-4.0	80.0	-5.9	100.0	22.0	130.0	8.3	130.0	8.3	90.0	12.5
						16	120.0	-4.0	85.0	0.0	100.0	22.0	120.0	0.0	120.0	0.0	90.0	12.5
						18	120.0	-4.0	85.0	0.0	100.0	22.0	130.0	8.3	130.0	8.3	105.0	31.3
			20	125.0	0.0	95.0	11.8	96.0	17.1	135.0	12.5	135.0	12.5	110.0	37.5			
			22	130.0	4.0	90.0	5.9	80.0	-2.4	150.0	25.0	150.0	25.0	95.0	18.8			
			24	120.0	-4.0	80.0	-5.9	80.0	-2.4	120.0	0.0	120.0	0.0	90.0	12.5			
			26	120.0	-4.0	80.0	-5.9	80.0	-2.4	120.0	0.0	120.0	0.0	90.0	12.5			
			28	120.0	-4.0	80.0	-5.9	76.0	-7.3	150.0	25.0	150.0	25.0	100.0	25.0			
			30	120.0	-4.0	80.0	-5.9	76.0	-7.3	150.0	25.0	150.0	25.0	100.0	25.0			
			32	120.0	-4.0	90.0	5.9	100.0	22.0	120.0	0.0	120.0	0.0	95.0	18.8			
			34	110.0	-12.0	80.0	-5.9	100.0	22.0	130.0	8.3	130.0	8.3	105.0	31.3			
			36	115.0	-8.0	80.0	-5.9	96.0	17.1	115.0	-4.2	115.0	-4.2	85.0	6.3			
			38	110.0	-12.0	80.0	-5.9	100.0	22.0	130.0	8.3	130.0	8.3	105.0	31.3			
			40	120.0	-4.0	90.0	5.9	100.0	22.0	120.0	0.0	120.0	0.0	90.0	12.5			
42	120.0	-4.0	90.0	5.9	92.0	12.2	120.0	0.0	120.0	0.0	90.0	12.5						

** S.B.P. values => 160 mm Hg
 D.B.P. values => 100 mm Hg
 H.R. values => 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R8D
 REBOXYETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXYETINE

Centre	Patient	Initial	Visit	LYING				STANDING										
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff					
1	358	LRM	44	120.0	-4.0	90.0	5.9	92.0	12.2	120.0	0.0	90.0	12.5	112.0	24.4	**		
			46	125.0	0.0	90.0	5.9	90.0	9.8	125.0	4.2	95.0	18.8	96.0	6.7	**		
			48	135.0	8.0	95.0	11.8	100.0	22.0	**	130.0	8.3	100.0	25.0	**	112.0	24.4	**
			50	135.0	8.0	95.0	11.8	100.0	22.0	**	130.0	8.3	100.0	25.0	**	112.0	24.4	**
			52	135.0	8.0	100.0	17.6	98.0	19.5		140.0	16.7	105.0	31.3	**	108.0	20.0	**
3	71	GRI	-1	120.0		60.0		88.0		125.0		70.0		89.0				
			0	110.0	-8.3	80.0	33.3	64.0	-27.3	110.0	-12.0	70.0	14.3	68.0	-23.6			
			1	110.0	-8.3	60.0	0.0	65.0	-26.1	100.0	-20.0	70.0	0.0	65.0	-27.0			
			2	135.0	12.5	70.0	16.7	62.0	-29.5	120.0	-4.0	60.0	-14.3	64.0	-28.1			
			3	110.0	-8.3	70.0	16.7	63.0	-28.4	120.0	-4.0	70.0	0.0	66.0	-25.8			
			4	110.0	-8.3	70.0	16.7	72.0	-18.2	110.0	-20.0	80.0	14.3	80.0	-10.1			
			5	120.0	0.0	80.0	33.3	88.0	0.0	100.0	-20.0	70.0	0.0	72.0	-19.1			
			6	130.0	8.3	80.0	33.3	100.0	13.6	120.0	-4.0	80.0	14.3	100.0	12.4			
			8	160.0	33.3	90.0	50.0	72.0	-18.2	120.0	-4.0	80.0	14.3	104.0	12.4			
			10	150.0	25.0	80.0	33.3	76.0	-13.6	125.0	0.0	70.0	0.0	108.0	16.9	**		
9	259	NF	-1	140.0		90.0		72.0		140.0		80.0		76.0				
			0	130.0	-7.1	80.0	0.0	71.0	-1.4	130.0	-7.1	80.0	0.0	73.0	-3.9			
			1	140.0	0.0	80.0	-11.1	73.0	1.4	130.0	-7.1	80.0	0.0	74.0	-2.6			
			2	140.0	0.0	90.0	0.0	71.0	-1.4	130.0	-7.1	80.0	0.0	75.0	-1.3			
			3	130.0	-7.1	80.0	-11.1	75.0	4.2	120.0	-14.3	70.0	-12.5	80.0	5.3			
			4	140.0	0.0	90.0	0.0	71.0	-1.4	130.0	-7.1	80.0	0.0	73.0	-3.9			
			5	120.0	-14.3	80.0	-11.1	73.0	1.4	110.0	-21.4	70.0	-12.5	76.0	0.0			
			6	140.0	0.0	70.0	-22.2	73.0	1.4	130.0	-7.1	73.0	0.0	70.0	-12.5	-1.3		
			8	140.0	0.0	90.0	0.0	72.0	0.0	130.0	-7.1	80.0	0.0	74.0	-2.6			
			10	130.0	-7.1	80.0	-11.1	76.0	5.6	120.0	-14.3	80.0	0.0	78.0	2.6			
10	31	TK	-1	120.0		80.0		70.0		110.0		80.0		84.0				
			0	115.0	-4.2	70.0	-12.5	60.0	-14.3	110.0	0.0	60.0	-25.0	84.0	0.0			
			1	105.0	-12.5	60.0	-25.0	64.0	-8.6	110.0	0.0	70.0	-12.5	78.0	-7.1			
			2	110.0	-8.3	60.0	-25.0	68.0	-2.9	115.0	4.5	70.0	-12.5	80.0	-4.8			
			3	110.0	-8.3	60.0	-25.0	60.0	-14.3	115.0	4.5	70.0	-12.5	76.0	-9.5			
			4	125.0	4.2	60.0	-25.0	82.0	17.1	120.0	9.1	60.0	-25.0	96.0	14.3			
			5	110.0	-8.3	80.0	0.0	84.0	20.0	120.0	9.1	85.0	6.3	98.0	16.7			
			6	110.0	-8.3	80.0	0.0	92.0	31.4	130.0	18.2	100.0	25.0	100.0	19.0			
			8	115.0	-4.2	80.0	0.0	74.0	5.7	110.0	0.0	80.0	0.0	98.0	16.7			
			10	110.0	-8.3	80.0	0.0	66.0	-5.7	110.0	0.0	70.0	-12.5	74.0	-11.9			
			12	130.0	8.3	75.0	-6.3	80.0	14.3	120.0	9.1	85.0	6.3	110.0	31.0	**		
			14	125.0	4.2	70.0	-12.5	78.0	11.4	115.0	4.5	80.0	0.0	98.0	14.3			

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

2392

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	Initial Visit	LYING				STANDING							
			S.B.P. % diff	D.R.P. % diff	H.R. % diff	S.B.P. % diff	D.B.P. % diff	H.R. % diff						
10	TK	16	120.0	0.0	66.0	-5.7	115.0	4.5	85.0	6.3	98.0	16.7		
		-1	105.0	-4.8	84.0	-10.7	110.0	0.0	85.0	-17.6	98.0	-12.2		
	IM	0	100.0	2.9	75.0	-11.9	105.0	-4.5	70.0	-17.6	86.0	-10.2		
		1	108.0	-6.7	70.0	-14.3	100.0	-9.1	65.0	-23.5	88.0	-14.3		
		2	98.0	-1.0	65.0	-14.3	106.0	-3.6	66.0	-22.4	84.0	-18.4		
		3	104.0	4.8	66.0	-16.7	110.0	0.0	80.0	-5.9	72.0	-26.5		
		4	110.0	0.0	80.0	-8.8	120.0	9.1	80.0	-29.4	88.0	-10.2		
		5	105.0	0.0	80.0	-10.7	105.0	-4.5	70.0	-17.6	80.0	-18.4		
		6	105.0	4.8	70.0	-11.9	110.0	0.0	80.0	-5.9	98.0	0.0		
		8	110.0	4.8	80.0	11.9	110.0	-4.5	75.0	-11.8	90.0	-8.2		
		10	105.0	0.0	75.0	-6.3	105.0	9.1	105.0	23.5	98.0	0.0		
		12	115.0	9.5	85.0	7.1	120.0	4.5	100.0	47.6	98.0	0.0		
		14	110.0	4.8	100.0	2.4	115.0	4.5	100.0	47.6	98.0	0.0		
		16	105.0	0.0	85.0	6.3	130.0	18.2	95.0	11.8	98.0	0.0		
		37	LL	-1	110.0	0.0	72.0	2.8	120.0	0.0	70.0	-14.3	80.0	0.0
				0	110.0	0.0	74.0	2.8	120.0	0.0	60.0	-14.3	80.0	0.0
1	120.0		9.1	60.0	-5.6	125.0	4.2	65.0	-7.1	98.0	22.5			
2	125.0		13.6	75.0	-8.3	115.0	-4.2	70.0	0.0	86.0	7.5			
3	120.0		9.1	80.0	-16.7	110.0	-8.3	70.0	0.0	92.0	15.0			
4	110.0		0.0	70.0	2.8	110.0	-8.3	70.0	0.0	90.0	12.5			
5	100.0		-9.1	70.0	8.3	100.0	-16.7	70.0	0.0	104.0	30.0			
6	100.0		-9.1	80.0	16.7	110.0	-8.3	90.0	28.6	86.0	7.5			
8	105.0		-4.5	70.0	8.3	115.0	-4.2	70.0	0.0	98.0	22.5			
10	105.0		-4.5	75.0	-8.3	120.0	0.0	75.0	7.1	98.0	22.5			
12	110.0		0.0	68.0	-5.6	100.0	-16.7	75.0	7.1	90.0	12.5			
14	110.0		0.0	75.0	-2.8	105.0	-12.5	75.0	7.1	98.0	22.5			
16	110.0		0.0	80.0	0.0	105.0	-12.5	78.0	0.0	90.0	12.5			
40	VM		-1	120.0	0.0	72.0	0.0	110.0	0.0	85.0	0.0	74.0	0.0	
			0	120.0	0.0	80.0	0.0	110.0	0.0	85.0	0.0	74.0	0.0	
	1		115.0	-4.2	80.0	13.9	108.0	-1.8	80.0	-5.9	88.0	18.9		
	2	123.0	4.2	80.0	16.7	115.0	4.5	85.0	0.0	90.0	21.6			
	3	120.0	0.0	95.0	5.6	120.0	0.0	80.0	-5.9	80.0	8.1			
	4	115.0	-4.2	80.0	8.3	130.0	9.1	85.0	0.0	84.0	13.5			
	5	120.0	0.0	80.0	16.7	120.0	9.1	90.0	5.9	88.0	18.9			
	8	110.0	-8.3	70.0	-5.6	120.0	9.1	80.0	-5.9	78.0	5.4			
	8	125.0	4.2	70.0	-22.2	120.0	9.1	65.0	-23.5	80.0	8.1			
	10	135.0	12.5	80.0	11.1	140.0	27.3	80.0	-5.9	84.0	13.5			

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 100 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	Initial	Visit	LIVING				STANDING								
				S.B.P.	% diff	H.R.	% diff	D.R.P.	% diff	S.B.P.	% diff	H.R.	% diff			
10	40	VH	12	120.0	0.0	70.0	-22.2	*	88.0	22.2	118.0	7.3	74.0	-12.9	92.0	24.3
			14	120.0	0.0	75.0	-16.7		90.0	25.0	105.0	-4.5	85.0	0.0	120.0	62.2
			16	120.0	0.0	80.0	-11.1		78.0	8.3	110.0	0.0	90.0	5.9	98.0	32.4
			18	115.0	-4.2	75.0	-16.7		84.0	16.7	110.0	0.0	80.0	-5.9	96.0	29.7
			20	115.0	-4.2	80.0	-11.1		78.0	8.3	120.0	9.1	85.0	0.0	96.0	29.7
			22	115.0	-4.2	75.0	-16.7		84.0	16.7	120.0	9.1	80.0	-5.9	90.0	21.6
			24	115.0	-4.2	85.0	-5.6		84.0	16.7	115.0	4.5	85.0	0.0	102.0	37.8
			26	110.0	-8.3	70.0	-22.2	*	72.0	0.0	130.0	18.2	90.0	5.9	84.0	13.5
			28	120.0	0.0	90.0	0.0		78.0	8.3	115.0	4.5	90.0	5.9	102.0	37.8
			30	125.0	4.2	95.0	5.6		84.0	16.7	128.0	16.4	102.0	20.0	96.0	29.7
			32	120.0	0.0	80.0	-11.1		78.0	8.3	105.0	-4.5	90.0	5.9	96.0	29.7
			34	130.0	8.3	85.0	-5.6		78.0	8.3	135.0	22.7	90.0	5.9	90.0	21.6
			36	135.0	12.5	105.0	16.7		84.0	16.7	135.0	22.7	100.0	17.6	90.0	21.6
			38	165.0	37.5	105.0	16.7		84.0	16.7	140.0	27.3	100.0	17.6	96.0	29.7
			40	150.0	25.0	85.0	-5.6		96.0	33.3	145.0	31.8	100.0	17.6	96.0	29.7
			42	160.0	33.3	95.0	5.6		84.0	16.7	145.0	31.8	100.0	17.6	108.0	45.9
			44	150.0	25.0	90.0	0.0		78.0	8.3	140.0	27.3	95.0	11.8	96.0	29.7
			46	145.0	20.8	80.0	-11.1		78.0	8.3	130.0	18.2	90.0	5.9	90.0	21.6
			48	145.0	20.8	85.0	-5.6		66.0	-8.3	135.0	22.7	90.0	5.9	90.0	21.6
			50	150.0	25.0	95.0	5.6		78.0	8.3	140.0	27.3	100.0	17.6	96.0	29.7
			52	140.0	16.7	90.0	0.0		72.0	0.0	135.0	22.7	95.0	11.8	90.0	21.6
	42	VP	-1	150.0	0.0	90.0	0.0		68.0	0.0	120.0	0.0	80.0	0.0	84.0	0.0
	33		0	150.0	0.0	90.0	0.0		68.0	0.0	120.0	0.0	80.0	0.0	84.0	0.0
	39		1	150.0	0.0	90.0	0.0		70.0	2.9	120.0	0.0	80.0	0.0	86.0	2.4
	4		2	145.0	-3.3	90.0	0.0		70.0	2.9	125.0	4.2	85.0	6.3	81.0	-3.6
			3	150.0	0.0	90.0	0.0		70.0	2.9	125.0	4.2	85.0	6.3	81.0	-3.6
			4	145.0	-3.3	85.0	-5.6		72.0	5.9	120.0	0.0	80.0	0.0	88.0	4.8
			5	140.0	-6.7	80.0	-11.1		74.0	8.8	125.0	4.2	75.0	-6.3	80.0	-4.8
			6	140.0	-6.7	80.0	-11.1		80.0	17.6	120.0	0.0	70.0	-12.5	84.0	0.0
			8	145.0	-3.3	80.0	-11.1		72.0	5.9	130.0	8.3	75.0	-6.3	82.0	-2.4
			10	130.0	-13.3	80.0	-11.1		88.0	29.4	120.0	0.0	80.0	0.0	88.0	4.8
			12	130.0	-13.3	70.0	-22.2	*	80.0	17.6	134.0	11.7	70.0	-12.5	72.0	-14.3
			14	130.0	-13.3	75.0	-16.7		72.0	5.9	135.0	12.5	75.0	-6.3	72.0	-14.3
			16	130.0	-13.3	70.0	-22.2	*	74.0	8.8	130.0	8.3	70.0	-12.5	80.0	-4.8
			18	130.0	-13.3	70.0	-22.2	*	74.0	8.8	130.0	8.3	70.0	-12.5	80.0	-4.8
			20	145.0	3.3	85.0	-5.6		78.0	14.7	140.0	16.7	80.0	6.3	86.0	2.4
			22	140.0	-6.7	90.0	0.0		72.0	5.9	130.0	8.3	85.0	6.3	80.0	-4.8
			24	140.0	-6.7	80.0	-11.1		72.0	5.9	130.0	8.3	80.0	0.0	80.0	-4.8
			26	135.0	-10.0	85.0	-5.6		74.0	8.8	130.0	8.3	80.0	0.0	82.0	-2.4

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 100 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	Initial	Visit	LYING				STANDING							
				S.B.P.	% diff	D.B.P.	% diff	H.R.	% diff	S.B.P.	% diff	D.B.P.	% diff	H.R.	% diff
10	42	VP	28	140.0	-6.7	85.0	-5.6	78.0	14.7	135.0	12.5	85.0	6.3	90.0	7.1
			30	145.0	-3.3	85.0	-5.6	80.0	17.6	140.0	16.7	80.0	0.0	86.0	2.4
			32	130.0	-13.3	80.0	-11.1	82.0	20.6	130.0	8.3	75.0	-6.3	90.0	7.1
			34	140.0	-6.7	80.0	-11.1	76.0	11.8	135.0	12.5	75.0	-6.3	84.0	0.0
			36	145.0	-3.3	80.0	-11.1	75.0	11.8	140.0	16.7	75.0	-6.3	84.0	0.0
			38	145.0	-3.3	80.0	-11.1	74.0	8.8	140.0	16.7	75.0	-6.3	86.0	2.4
			40	140.0	-6.7	80.0	-11.1	76.0	11.8	135.0	12.5	80.0	0.0	86.0	2.4
			42	145.0	-3.3	80.0	-11.1	76.0	11.8	140.0	16.7	75.0	-6.3	82.0	-2.4
			44	140.0	-6.7	80.0	-11.1	76.0	11.8	140.0	16.7	80.0	0.0	86.0	2.4
			46	145.0	-3.3	85.0	-5.6	80.0	11.8	140.0	16.7	80.0	0.0	84.0	0.0
			48	140.0	-6.7	80.0	-11.1	74.0	8.8	135.0	12.5	75.0	-6.3	80.0	-4.8
			50	145.0	-3.3	80.0	-11.1	72.0	5.9	135.0	12.5	70.0	-12.5	80.0	-4.8
52	140.0	-6.7	80.0	-11.1	74.0	8.8	135.0	12.5	70.0	-12.5	82.0	-2.4			
43	VM	-1	110.0	0.0	75.0	0.0	64.0	0.0	100.0	0.0	70.0	0.0	80.0	0.0	
		0	110.0	0.0	75.0	0.0	64.0	25.0	100.0	0.0	70.0	0.0	80.0	0.0	
		1	110.0	0.0	75.0	-6.7	80.0	0.0	120.0	20.0	80.0	14.3	100.0	25.0	
		2	115.0	4.5	80.0	6.7	86.0	34.4	100.0	0.0	70.0	0.0	80.0	0.0	
		3	140.0	27.3	85.0	26.7	96.0	50.0	120.0	20.0	80.0	14.3	80.0	0.0	
		4	104.0	-5.5	80.0	-20.0	68.0	6.3	135.0	35.0	85.0	21.4	120.0	50.0	
		5	104.0	-5.5	80.0	-20.0	68.0	6.3	120.0	20.0	58.0	-17.1	72.0	-10.0	
		6	110.0	0.0	70.0	-6.7	80.0	25.0	115.0	15.0	70.0	0.0	89.0	11.3	
		8	120.0	7.1	64.0	-14.7	84.0	31.3	125.0	25.0	60.0	-14.3	80.0	0.0	
		10	118.0	7.3	64.0	-14.7	84.0	31.3	114.0	14.0	60.0	-14.3	100.0	25.0	
		12	120.0	9.1	65.0	-13.3	80.0	25.0	115.0	15.0	60.0	-14.3	88.0	10.0	
		14	115.0	4.5	65.0	-13.3	82.0	28.1	115.0	15.0	60.0	-14.3	90.0	12.5	
47	MA	16	110.0	0.0	60.0	-20.0	72.0	12.5	110.0	10.0	60.0	-14.3	80.0	0.0	
		18	110.0	0.0	60.0	-20.0	68.0	6.3	105.0	5.0	60.0	-14.3	80.0	0.0	
		20	120.0	9.1	70.0	-6.7	78.0	21.9	110.0	10.0	65.0	-7.1	88.0	10.0	
		22	120.0	9.1	70.0	-6.7	82.0	28.1	115.0	15.0	65.0	-7.1	92.0	15.0	
		24	110.0	0.0	70.0	-6.7	78.0	21.9	105.0	5.0	65.0	-7.1	86.0	7.5	
		26	120.0	9.1	70.0	-6.7	72.0	12.5	115.0	15.0	65.0	-7.1	80.0	0.0	
		28	110.0	0.0	70.0	-6.7	78.0	21.9	100.0	0.0	60.0	-14.3	82.0	2.5	
		-1	110.0	0.0	60.0	0.0	66.0	0.0	118.0	0.0	78.0	0.0	80.0	0.0	
		0	110.0	0.0	60.0	0.0	66.0	0.0	118.0	0.0	78.0	0.0	80.0	0.0	
		1	95.0	-13.6	60.0	0.0	60.0	-9.1	95.0	-19.5	60.0	0.0	68.0	-15.0	
		2	100.0	-9.1	70.0	16.7	72.0	9.1	100.0	-15.3	60.0	0.0	88.0	10.0	
		3	116.0	5.5	58.0	-3.3	72.0	9.1	120.0	1.7	58.0	-25.6	72.0	-10.0	
4	110.0	0.0	60.0	0.0	70.0	6.1	120.0	1.7	60.0	-25.1	72.0	-10.0			

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 ROXOXYTINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: ROXOXYTINE

Centre	Patient	Initial	Visit	LYING			STANDING										
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	H.R.	% diff						
10	47	MA	5	105.0	-4.5	0.0	68.0	3.0	110.0	-6.8	60.0	-23.1	*	72.0	-10.0		
			6	100.0	-9.1	0.0	68.0	3.0	100.0	-15.3	60.0	-23.1	*	72.0	-10.0		
			8	95.0	-13.6	0.0	70.0	6.1	95.0	-19.5	60.0	-23.1	*	72.0	-10.0		
			10	95.0	-13.6	-3.3	68.0	3.0	100.0	-11.0	60.0	-23.1	*	74.0	-7.5		
			12	100.0	-9.1	0.0	74.0	12.1	105.0	-11.0	70.0	-2.5	60.0	-23.1	*	78.0	-2.5
			14	110.0	0.0	16.7	70.0	9.1	115.0	-2.5	70.0	-6.8	70.0	-10.3	*	74.0	-7.5
			16	110.0	0.0	0.0	70.0	6.1	110.0	-6.8	60.0	-23.1	*	74.0	-7.5		
			18	110.0	0.0	16.7	68.0	3.0	105.0	-11.0	70.0	-6.8	70.0	-10.3	*	76.0	-5.0
			20	100.0	-9.1	0.0	70.0	5.1	100.0	-15.3	60.0	-23.1	*	76.0	-5.0		
			22	105.0	-4.5	0.0	68.0	3.0	110.0	-4.8	65.0	-16.7	60.0	-23.1	*	76.0	-5.0
			24	95.0	-13.6	0.0	72.0	3.1	102.0	-15.3	60.0	-23.1	*	80.0	0.0		
			26	100.0	-9.1	8.3	68.0	3.0	105.0	-11.0	65.0	-16.7	60.0	-23.1	*	78.0	-2.5
			28	100.0	-9.1	0.0	67.0	1.5	100.0	-15.3	65.0	-16.7	60.0	-23.1	*	74.0	-7.5
			30	105.0	-4.5	0.0	68.0	3.0	100.0	-6.8	65.0	-16.7	60.0	-23.1	*	74.0	-7.5
32	100.0	-9.1	0.0	68.0	3.0	105.0	-11.0	60.0	-23.1	*	74.0	-7.5					
34	100.0	-9.1	0.0	68.0	3.0	105.0	-11.0	65.0	-16.7	60.0	-23.1	*	76.0	-5.0			
50	JP		-1	120.0	4.2	0.0	80.0	-20.0	125.0	0.0	64.0	-6.3	88.0	-9.1			
			0	125.0	-18.3	-3.3	68.0	-15.0	104.0	-16.8	60.0	-6.3	76.0	-13.6			
			1	98.0	-25.0	*	80.0	0.0	90.0	-28.0	60.0	-6.3	88.0	0.0			
			2	90.0	-8.3	0.0	60.0	-25.0	110.0	-12.0	60.0	-6.3	60.0	-31.8			
			3	110.0	-8.3	0.0	60.0	-5.0	115.0	-8.0	60.0	-6.3	84.0	-4.5			
			4	115.0	-4.2	0.0	76.0	-5.0	120.0	-4.0	65.0	1.6	78.0	-11.4			
			5	115.0	-4.2	8.3	66.0	-17.5	110.0	-12.0	60.0	-6.3	78.0	-11.4			
			6	115.0	-4.2	0.0	66.0	-17.5	110.0	-12.0	60.0	-6.3	78.0	-11.4			
			8	110.0	-8.3	0.0	66.0	-17.5	110.0	-12.0	60.0	-6.3	78.0	-11.4			
			10	110.0	-8.3	0.0	72.0	-10.0	115.0	-8.0	65.0	1.6	84.0	-4.5			
53	TA		-1	98.0	6.1	66.0	66.0	100.0	10.0	66.0	33.3	66.0	-6.1				
			0	104.0	7.1	26.7	72.0	-6.1	110.0	10.0	80.0	33.3	90.0	36.4			
			1	105.0	2.0	25.0	72.0	9.1	110.0	10.0	80.0	33.3	96.0	45.5			
			2	100.0	2.0	16.7	72.0	9.1	110.0	10.0	75.0	25.0	96.0	45.5			
			3	100.0	2.0	33.3	84.0	27.3	110.0	10.0	80.0	33.3	96.0	45.5			
			4	104.0	6.1	50.0	86.0	30.3	110.0	10.0	90.0	50.0	120.0	81.8			
			5	110.0	12.2	0.0	84.0	27.3	110.0	10.0	80.0	33.3	96.0	45.5			
			6	120.0	22.4	33.3	90.0	36.4	122.0	22.0	84.0	40.0	92.0	39.4			
			8	115.0	17.5	25.0	78.0	18.2	115.0	15.0	75.0	25.0	90.0	36.4			
			10	110.0	12.2	30.0	80.0	21.2	110.0	10.0	76.0	26.7	92.0	39.4			
59	LS		-1	130.0		65.0	80.0	130.0		65.0		92.0					

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 100 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	Initial	Visit	LYING				STANDING								
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff			
10	59	LS	0	130.0	0.0	80.0	0.0	130.0	0.0	65.0	0.0	92.0	0.0			
			1	120.0	-7.7	70.0	-12.5	130.0	0.0	90.0	38.5	88.0	-4.3			
			2	120.0	-7.7	70.0	-12.5	110.0	-15.4	70.0	7.7	72.0	-21.7			
			3	120.0	-7.7	76.0	-5.0	110.0	-15.4	70.0	7.7	108.0	17.4			
			4	100.0	-23.1	84.0	0.0	110.0	-15.4	70.0	23.1	100.0	8.7			
			5	110.0	-15.4	80.0	0.0	100.0	-23.1	70.0	7.7	84.0	-8.7			
			6	100.0	-23.1	72.0	-10.0	110.0	-15.4	70.0	23.1	88.0	-4.3			
			8	115.0	-11.5	72.0	-10.0	110.0	-15.4	70.0	7.7	78.0	-15.2			
			10	110.0	-15.4	74.0	-7.5	105.0	-19.2	70.0	7.7	80.0	-13.0			
			12	120.0	-7.7	72.0	-10.0	115.0	-11.5	65.0	0.0	76.0	-17.4			
			14	115.0	-11.5	72.0	-10.0	110.0	-15.4	65.0	0.0	78.0	-15.2			
			16	120.0	-7.7	72.0	-10.0	115.0	-11.5	70.0	7.7	76.0	-17.4			
			18	115.0	-11.5	72.0	-10.0	110.0	-15.4	65.0	0.0	76.0	-17.4			
			20	120.0	-7.7	72.0	-10.0	110.0	-15.4	65.0	0.0	76.0	-17.4			
			22	120.0	-7.7	68.0	-15.0	115.0	-11.5	65.0	0.0	76.0	-17.4			
			24	120.0	-7.7	68.0	-15.0	115.0	-11.5	60.0	-7.7	74.0	-19.6			
			26	115.0	-11.5	72.0	-10.0	110.0	-15.4	60.0	-7.7	78.0	-15.2			
			28	120.0	-7.7	68.0	-15.0	115.0	-11.5	65.0	0.0	76.0	-17.4			
			30	120.0	-7.7	72.0	-10.0	115.0	-11.5	65.0	0.0	76.0	-17.4			
			32	115.0	-11.5	72.0	-10.0	115.0	-11.5	65.0	0.0	78.0	-15.2			
			34	120.0	-7.7	72.0	-10.0	110.0	-15.4	65.0	0.0	76.0	-17.4			
			36	115.0	-11.5	72.0	-10.0	110.0	-15.4	60.0	-7.7	80.0	-13.0			
			38	120.0	-7.7	68.0	-15.0	115.0	-11.5	65.0	0.0	76.0	-17.4			
			40	115.0	-11.5	72.0	-10.0	110.0	-15.4	65.0	0.0	80.0	-13.0			
			42	120.0	-7.7	74.0	-7.5	110.0	-15.4	60.0	-7.7	82.0	-10.9			
			44	115.0	-11.5	72.0	-10.0	105.0	-19.2	60.0	-7.7	80.0	-13.0			
			46	120.0	-7.7	74.0	-7.5	110.0	-15.4	60.0	-7.7	80.0	-13.0			
			48	120.0	-7.7	74.0	-7.5	110.0	-15.4	60.0	-7.7	80.0	-13.0			
			63	HV		-1	120.0	-8.3	72.0	0.0	130.0	0.0	90.0	0.0	80.0	-12.5
						0	110.0	12.5	68.0	-5.6	130.0	0.0	90.0	0.0	70.0	25.0
						1	135.0	21.7	100.0	38.9	140.0	7.7	100.0	11.1	100.0	35.0
						2	140.0	16.7	100.0	38.9	160.0	23.1	100.0	11.1	108.0	8.7
						3	146.0	21.7	84.0	5.0	124.0	-4.6	80.0	-11.1	80.0	0.0
						4	140.0	16.7	78.0	5.6	130.0	0.0	80.0	-11.1	86.0	7.5
						5	135.0	12.5	85.0	6.3	140.0	11.5	100.0	11.1	104.0	30.0
						6	140.0	16.7	95.0	18.8	132.0	9.2	100.0	11.1	106.0	32.5
						8	140.0	16.7	90.0	14.3	142.0	11.1	100.0	11.1	106.0	32.5
						10	140.0	16.7	95.0	18.8	165.0	26.9	120.0	33.3	93.0	16.2
						12	145.0	20.8	95.0	18.8	145.0	11.5	100.0	11.1	96.0	20.0
											160.0	23.1	105.0	16.7	90.0	12.5

** S.B.P. values => 160 mm Hg
D.B.P. values => 100 mm Hg
H.R. values => 100 beats/min
* S.B.P. values <= 100 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

2397

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	Initial	Visit	LYING			STANDING								
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	H.R.	% diff				
10	63	HV	14	135.0	12.5	92.0	27.8	130.0	0.0	100.0	11.1	100.0	25.0	**	
			16	140.0	16.7	90.0	25.0	130.0	0.0	105.0	0.0	105.0	16.7	96.0	20.0
	70	SV	-1	110.0	0.0	70.0	0.0	120.0	0.0	80.0	0.0	84.0	0.0	84.0	0.0
			1	105.0	-4.5	72.0	0.0	120.0	0.0	82.0	0.0	82.0	0.0	84.0	0.0
			2	110.0	0.0	75.0	7.1	110.0	-8.3	110.0	-8.3	83.0	6.3	90.0	7.1
			3	100.0	-9.1	60.0	-14.3	88.0	22.2	115.0	-4.2	70.0	-12.5	92.0	9.5
			4	105.0	-4.5	60.0	-14.3	88.0	22.2	115.0	-4.2	70.0	-12.5	92.0	9.5
			5	105.0	-4.5	60.0	-14.3	88.0	22.2	115.0	-4.2	70.0	-12.5	92.0	9.5
			6	100.0	-9.1	70.0	0.0	78.0	8.3	110.0	-8.3	85.0	6.3	90.0	14.3
			8	110.0	0.0	100.0	38.9	83.0	8.3	110.0	-8.3	85.0	6.3	90.0	14.3
10	110.0	0.0	75.0	7.1	78.0	8.3	110.0	-8.3	75.0	-6.3	90.0	7.1			
23	HI	12	110.0	0.0	75.0	7.1	66.0	-8.3	105.0	-12.5	80.0	0.0	84.0	0.0	
		14	115.0	4.5	85.0	21.4	78.0	8.3	110.0	-8.3	85.0	6.3	90.0	7.1	
		16	115.0	4.5	83.0	18.6	85.0	23.6	105.0	-12.5	85.0	6.3	96.0	14.3	
		18	110.0	0.0	80.0	16.7	84.0	16.7	105.0	-12.5	85.0	6.3	96.0	14.3	
		20	110.0	0.0	80.0	16.7	84.0	16.7	105.0	-12.5	85.0	6.3	90.0	7.1	
		22	115.0	4.5	80.0	14.3	78.0	8.3	100.0	-16.7	80.0	0.0	90.0	7.1	
		24	115.0	4.5	80.0	14.3	72.0	0.0	100.0	-16.7	85.0	6.3	84.0	0.0	
		26	115.0	4.5	85.0	21.4	78.0	8.3	108.0	-10.0	85.0	6.3	96.0	14.3	
		74	HI	-1	110.0	0.0	80.0	0.0	58.0	110.0	0.0	80.0	0.0	60.0	0.0
				1	130.0	18.2	90.0	12.5	64.0	10.3	120.0	9.1	90.0	12.5	76.0
2	120.0			9.1	85.0	6.3	66.0	13.8	120.0	9.1	85.0	6.3	84.0	46.0	
3	130.0			18.2	80.0	0.0	66.0	13.8	120.0	9.1	85.0	6.3	84.0	46.0	
4	130.0			18.2	85.0	6.3	72.0	24.1	120.0	9.1	80.0	0.0	80.0	50.0	
5	125.0			13.6	90.0	12.5	78.0	34.5	125.0	13.6	80.0	0.0	86.0	46.7	
6	125.0			13.6	85.0	6.3	72.0	24.1	115.0	4.5	85.0	12.5	96.0	60.0	
8	105.0			-4.5	65.0	-18.8	78.0	34.5	110.0	0.0	75.0	-6.3	84.0	40.0	
10	95.0			-13.6	70.0	-12.5	78.0	34.5	95.0	-13.6	70.0	-12.5	96.0	60.0	
12	95.0			-13.6	60.0	-25.0	78.0	34.5	100.0	-9.1	75.0	-6.3	90.0	50.0	
14	100.0	-9.1	60.0	-25.0	78.0	34.5	110.0	0.0	75.0	-6.3	84.0	40.0			
16	95.0	-13.6	70.0	-12.5	84.0	44.8	105.0	-4.5	80.0	0.0	96.0	60.0			
18	100.0	-9.1	70.0	-12.5	72.0	24.1	110.0	0.0	70.0	-12.5	90.0	50.0			
20	100.0	-9.1	70.0	-12.5	66.0	13.8	105.0	-4.5	75.0	-6.3	84.0	40.0			
22	95.0	-13.6	60.0	-25.0	66.0	13.8	100.0	-9.1	70.0	-12.5	78.0	30.0			
24	105.0	-4.5	60.0	-25.0	72.0	24.1	110.0	0.0	75.0	-6.3	96.0	60.0			
26	100.0	-9.1	70.0	-12.5	78.0	34.5	110.0	0.0	80.0	0.0	84.0	40.0			

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 100 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	Initial	Visit	LYING				STANDING							
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff		
10	74	HI	28	105.0	-4.5	70.0	-12.5	72.0	24.1	115.0	4.5	80.0	0.0	90.0	50.0
			30	100.0	-9.1	60.0	-25.0	66.0	13.8	110.0	0.0	80.0	0.0	78.0	30.0
	271	WK	-1	120.0		65.0		82.0		110.0		60.0		80.0	
			0	125.0	4.2	70.0	7.7	83.0	1.2	110.0	0.0	65.0	8.3	81.0	1.2
			1	120.0	0.0	86.0	32.3	64.0	-22.0	120.0	9.1	90.0	50.0	60.0	-25.0
			2	130.0	8.3	86.0	32.3	84.0	2.4	120.0	9.1	90.0	50.0	60.0	-25.0
			3	132.0	10.0	84.0	29.2	64.0	-22.0	112.0	1.8	90.0	50.0	70.0	-12.5
			4	150.0	25.0	100.0	53.8	73.0	-11.0	130.0	18.2	90.0	50.0	78.0	-2.5
			5	130.0	8.3	86.0	32.3	63.0	-23.2	120.0	9.1	90.0	50.0	68.0	-15.0
			6	140.0	16.7	90.0	38.5	68.0	-17.1	140.0	27.3	90.0	50.0	68.0	-15.0
			8	120.0	0.0	70.0	7.7	80.0	-2.4	130.0	18.2	80.0	33.3	80.0	0.0
			10	120.0	0.0	70.0	7.7	80.0	-2.4	130.0	18.2	80.0	33.3	80.0	0.0
			12	140.0	16.7	90.0	38.5	66.0	-19.5	145.0	31.8	90.0	50.0	90.0	12.5
			14	120.0	0.0	75.0	15.4	71.0	-13.4	130.0	18.2	80.0	33.3	78.0	-2.5
			16	120.0	0.0	80.0	23.1	63.0	-23.2	130.0	18.2	80.0	33.3	68.0	-15.0
			274	NP	-1	110.0		60.0		68.0		110.0		65.0	
1	100.0	-9.1			60.0	0.0	68.0	0.0	105.0	-4.5	65.0	0.0	72.0	0.0	
2	100.0	-9.1			50.0	-16.7	64.0	-5.9	110.0	0.0	60.0	-7.7	64.0	-11.1	
3	106.0	-3.6			78.0	16.7	88.0	29.4	120.0	9.1	60.0	-7.7	88.0	22.2	
4	120.0	9.1			70.0	16.7	80.0	17.6	110.0	0.0	80.0	23.1	120.0	66.7	
5	110.0	0.0			70.0	16.7	80.0	17.6	100.0	-9.1	70.0	7.7	116.0	61.1	
6	120.0	9.1			80.0	33.3	80.0	14.7	100.0	-9.1	70.0	7.7	86.0	19.4	
8	140.0	27.3			80.0	33.3	68.0	0.0	120.0	9.1	70.0	7.7	92.0	27.8	
-1	120.0				100.0		80.0		120.0		100.0		80.0		
0	180.0	50.0			100.0	0.0	70.0	-12.5	180.0	50.0	100.0	10.0	76.0	-5.0	
1	135.0	12.5			80.0	-20.0	83.0	3.8	130.0	8.3	80.0	-20.0	100.0	25.0	
2	120.0	0.0			80.0	-20.0	77.0	-3.8	120.0	0.0	80.0	-20.0	105.0	31.3	
3	150.0	25.0			90.0	-10.0	78.0	-2.5	140.0	16.7	100.0	0.0	80.0	0.0	
4	120.0	0.0			60.0	-40.0	66.0	-17.5	120.0	0.0	80.0	-20.0	68.0	-15.0	
5	120.0	0.0			65.0	-35.0	65.0	-18.8	120.0	0.0	85.0	-15.0	80.0	0.0	
6	130.0	8.3			85.0	-15.0	73.0	-8.8	130.0	8.3	85.0	-15.0	80.0	0.0	
8	140.0	16.7	90.0	-10.0	76.0	-5.0	142.0	18.3	92.0	-8.0	80.0	0.0			
275	AN	10	140.0	16.7	95.0	-5.0	72.0	-10.0	140.0	16.7	90.0	-10.0	76.0	-5.0	
		12	140.0	16.7	80.0	-20.0	68.0	-15.0	145.0	20.8	85.0	-15.0	74.0	-7.5	
		14	145.0	20.8	85.0	-15.0	72.0	-10.0	150.0	25.0	85.0	-15.0	76.0	-5.0	
		15	135.0	12.5	80.0	-20.0	70.0	-12.5	145.0	20.8	80.0	-20.0	82.0	2.5	

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	Initial	Visit	LYING				STANDING										
				S.B.P.	% diff	D.B.P.	% diff	H.R.	% diff	S.B.P.	% diff	D.B.P.	% diff	H.R.	% diff			
10	275	AN	18	140.0	16.7	75.0	-25.0	72.0	-10.0	145.0	20.8	80.0	-20.0	80.0	0.0			
			20	140.0	16.7	80.0	-20.0	70.0	-12.5	145.0	20.8	85.0	-15.0	78.0	-2.5			
			22	140.0	16.7	90.0	-10.0	72.0	-10.0	140.0	16.7	85.0	-15.0	80.0	0.0			
			24	140.0	16.7	80.0	-20.0	68.0	-15.0	145.0	20.8	80.0	-20.0	76.0	-5.0			
			26	140.0	16.7	80.0	-20.0	70.0	-12.5	145.0	20.8	85.0	-15.0	78.0	-2.5			
			28	140.0	16.7	80.0	-20.0	68.0	-15.0	150.0	25.0	90.0	-10.0	78.0	-2.5			
			30	140.0	16.7	80.0	-20.0	72.0	-10.0	145.0	20.8	85.0	-15.0	78.0	-2.5			
			32	145.0	20.8	80.0	-20.0	70.0	-12.5	150.0	25.0	85.0	-15.0	78.0	-2.5			
			34	140.0	16.7	75.0	-25.0	68.0	-15.0	145.0	20.8	85.0	-15.0	75.0	-6.3			
			36	135.0	12.5	75.0	-25.0	68.0	-15.0	145.0	20.8	85.0	-15.0	74.0	-7.5			
			38	140.0	16.7	70.0	-30.0	70.0	-12.5	145.0	20.8	80.0	-20.0	74.0	-7.5			
			40	140.0	16.7	75.0	-25.0	68.0	-15.0	145.0	20.8	80.0	-20.0	76.0	-5.0			
			42	135.0	12.5	70.0	-30.0	70.0	-12.5	145.0	20.8	75.0	-25.0	76.0	-5.0			
			44	140.0	16.7	70.0	-30.0	70.0	-12.5	145.0	20.8	80.0	-20.0	78.0	-2.5			
			46	140.0	16.7	75.0	-25.0	70.0	-12.5	145.0	20.8	80.0	-20.0	78.0	-2.5			
			48	160.0	16.7	75.0	-25.0	70.0	-12.5	145.0	20.8	100.0	0.0	74.0	-7.5			
			50	145.0	20.8	90.0	-10.0	68.0	-15.0	170.0	41.7	**	75.0	-25.0	76.0	-5.0		
			52	140.0	16.7	70.0	-30.0	70.0	-12.5	150.0	25.0	75.0	-25.0	86.0	7.5			
			277	EP		-1	90.0	0.0	60.0	0.0	72.0	0.0	90.0	0.0	80.0	0.0	76.0	0.0
						0	90.0	0.0	60.0	0.0	72.0	0.0	90.0	0.0	80.0	0.0	76.0	0.0
1	120.0	33.3				80.0	33.3	74.0	2.8	125.0	38.9	90.0	12.5	79.0	3.9			
2	140.0	55.6				100.0	66.7	72.0	0.0	140.0	55.6	100.0	25.0	84.0	10.5			
3	140.0	55.6				85.0	41.7	64.0	-11.1	110.0	22.2	80.0	0.0	66.0	-13.2			
4	140.0	55.6				100.0	66.7	62.0	-13.9	130.0	44.4	100.0	25.0	65.0	-14.5			
5	110.0	22.2				80.0	33.3	62.0	-13.9	110.0	22.2	80.0	0.0	68.0	-10.5			
6	120.0	33.3				80.0	33.3	68.0	-5.6	125.0	38.9	80.0	0.0	71.0	-6.6			
8	120.0	33.3				98.0	63.3	59.0	-18.1	108.0	20.0	100.0	25.0	62.0	-18.4			
-1	100.0	0.0				60.0	0.0	76.0	0.0	100.0	0.0	55.0	0.0	80.0	0.0			
0	100.0	0.0				60.0	0.0	88.0	15.8	95.0	-5.0	60.0	-9.1	80.0	0.0			
1	100.0	0.0				70.0	16.7	80.0	5.3	110.0	10.0	50.0	-9.1	120.0	50.0			
2	110.0	10.0	60.0	0.0	92.0	21.1	100.0	0.0	50.0	-9.1	100.0	25.0						
3	110.0	10.0	60.0	0.0	70.0	-5.3	122.0	22.0	70.0	27.3	92.0	15.0						
4	100.0	0.0	60.0	0.0	72.0	-5.3	110.0	10.0	70.0	27.3	86.0	7.5						
5	100.0	0.0	60.0	0.0	74.0	-2.6	105.0	5.0	60.0	9.1	90.0	12.5						
6	110.0	10.0	60.0	0.0	74.0	-2.6	105.0	5.0	55.0	0.0	86.0	7.5						
8	110.0	10.0	60.0	0.0	72.0	-5.3	100.0	0.0	55.0	0.0	86.0	7.5						
278	HU		-1	110.0	0.0	80.0	0.0	72.0	0.0	115.0	0.0	80.0	0.0	78.0	0.0			
			0	110.0	0.0	80.0	0.0	72.0	0.0	115.0	0.0	80.0	0.0	78.0	0.0			

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 50 beats/min
H.R. values <= 50 beats/min

2400

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	Initial	Visit	LYING			STANDING										
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	H.R.	% diff						
10	278	HU	1	120.0	9.1	80.0	0.0	64.0	-11.1	110.0	-4.3	80.0	0.0	68.0	-12.8		
			2	110.0	0.0	78.0	-2.5	66.0	-8.3	96.0	0.0	60.0	-16.5	60.0	-25.0	69.0	-11.5
			3	120.0	9.1	80.0	0.0	64.0	-11.1	110.0	0.0	90.0	-4.3	90.0	12.5	72.0	-7.7
			4	120.0	9.1	80.0	0.0	80.0	36.1	104.0	0.0	80.0	-9.6	80.0	12.5	105.0	34.6
			5	120.0	9.1	80.0	0.0	80.0	11.1	110.0	0.0	80.0	-4.3	80.0	12.5	96.0	10.3
			6	110.0	0.0	80.0	0.0	76.0	5.6	105.0	0.0	80.0	-8.7	80.0	12.5	79.0	1.3
			7	120.0	9.1	80.0	0.0	74.0	2.8	105.0	0.0	80.0	-8.7	80.0	12.5	80.0	2.6
			8	120.0	9.1	80.0	0.0	74.0	2.8	105.0	0.0	80.0	-8.7	80.0	12.5	80.0	2.6
280	HT		-1	120.0	0.0	70.0	0.0	68.0	0.0	132.0	0.0	80.0	0.0	60.0	0.0		
			1	120.0	0.0	70.0	0.0	68.0	0.0	132.0	0.0	80.0	0.0	60.0	0.0		
			2	120.0	0.0	80.0	14.3	70.0	2.3	140.0	0.0	90.0	6.1	90.0	12.5	82.0	36.7
			3	120.0	0.0	80.0	14.3	70.0	2.3	140.0	0.0	100.0	17.4	100.0	25.0	80.0	33.3
			4	120.0	-8.3	80.0	14.3	68.0	0.0	130.0	0.0	80.0	-1.5	80.0	0.0	61.0	1.7
			5	120.0	0.0	70.0	0.0	68.0	0.0	138.0	0.0	80.0	4.5	80.0	0.0	60.0	0.0
			6	130.0	8.3	80.0	14.3	65.0	-4.4	140.0	0.0	90.0	6.1	90.0	12.5	74.0	23.3
			7	120.0	0.0	80.0	14.3	68.0	-5.9	145.0	0.0	90.0	9.8	90.0	12.5	72.0	20.0
			8	120.0	0.0	80.0	14.3	66.0	-2.9	140.0	0.0	85.0	6.1	85.0	6.3	72.0	20.0
			10	120.0	0.0	80.0	14.3	68.0	0.0	125.0	0.0	85.0	-5.3	85.0	6.3	73.0	21.7
285	AN		10	110.0	-8.3	70.0	0.0	70.0	2.9	110.0	-16.7	65.0	-16.8	65.0	-16.8	78.0	30.0
			12	120.0	0.0	65.0	-7.1	68.0	0.0	110.0	0.0	60.0	-16.7	60.0	-25.0	74.0	23.3
			14	120.0	0.0	70.0	0.0	68.0	0.0	115.0	0.0	65.0	-12.9	65.0	-18.8	76.0	26.7
			16	115.0	-4.2	70.0	0.0	72.0	5.9	110.0	0.0	70.0	-16.7	70.0	-12.5	76.0	26.7
			18	110.0	-8.3	65.0	-7.1	72.0	5.9	110.0	0.0	60.0	-16.7	60.0	-25.0	78.0	30.0
			20	120.0	0.0	70.0	0.0	68.0	0.0	110.0	0.0	60.0	-16.7	60.0	-25.0	78.0	30.0
			22	110.0	-8.3	65.0	-7.1	68.0	0.0	105.0	0.0	60.0	-20.5	60.0	-25.0	76.0	26.7
			24	120.0	0.0	70.0	0.0	70.0	2.9	110.0	0.0	60.0	-16.7	60.0	-25.0	78.0	30.0
			26	115.0	-4.2	65.0	-7.1	72.0	5.9	110.0	0.0	60.0	-16.7	60.0	-25.0	78.0	30.0
			28	120.0	0.0	70.0	0.0	68.0	0.0	110.0	0.0	60.0	-16.7	60.0	-25.0	75.0	25.0
30	110.0	-8.3	65.0	-7.1	70.0	2.9	110.0	0.0	60.0	-16.7	60.0	-25.0	75.0	25.0			
32	120.0	0.0	70.0	0.0	68.0	0.0	110.0	0.0	60.0	-16.7	60.0	-25.0	75.0	25.0			
34	120.0	0.0	70.0	0.0	66.0	-2.9	110.0	0.0	60.0	-16.7	60.0	-25.0	72.0	20.0			
36	110.0	-8.3	65.0	-7.1	64.0	-5.9	105.0	0.0	60.0	-20.5	60.0	-25.0	70.0	16.7			
EJ			-1	115.0	0.0	55.0	0.0	72.0	0.0	115.0	0.0	70.0	0.0	78.0	0.0		
			0	120.0	4.3	60.0	9.1	70.0	-2.8	120.0	0.0	80.0	4.3	80.0	0.0		
			1	105.0	-8.7	70.0	27.3	74.0	2.8	98.0	0.0	75.0	-7.1	95.0	21.8		
			2	100.0	-13.0	72.0	30.9	72.0	0.0	92.0	0.0	70.0	-20.0	70.0	0.0		
			3	125.0	8.7	80.0	48.5	90.0	25.0	120.0	0.0	80.0	4.3	80.0	0.0		
4	120.0	4.3	80.0	48.5	80.0	11.1	125.0	0.0	70.0	0.0	70.0	0.0					
5	160.0	21.7	85.0	54.5	78.0	8.3	115.0	0.0	85.0	0.0	85.0	21.4	100.0	28.2			

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 50 beats/min
H.R. values <= 50 beats/min

2401

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 ROXETINE - PROTOCOL 20124/013
 Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: ROXETINE

Centre	Patient	Initial	Visit	LYING			STANDING											
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	H.R.	% diff							
10	285	EJ	6	130.0	13.0	80.0	45.5	79.0	9.7	120.0	4.3	75.0	7.1	89.0	6.4			
			8	140.0	21.7	85.0	54.5	84.0	16.7	110.0	-4.3	70.0	0.0	80.0	2.6			
			10	110.0	-4.3	65.0	18.2	68.0	-5.6	115.0	0.0	75.0	0.0	80.0	2.6			
			12	110.0	-4.3	70.0	27.3	84.0	16.7	100.0	-13.0	90.0	28.6	92.0	17.9			
			14	120.0	4.3	70.0	27.3	88.0	22.2	110.0	-4.3	75.0	7.1	88.0	12.8			
			16	105.0	-8.7	75.0	36.4	87.0	20.8	120.0	4.3	85.0	21.4	90.0	15.4			
			18	90.0	-21.7	50.0	-9.1	90.0	25.0	105.0	-8.7	98.0	25.6	98.0	25.6			
			20	110.0	-4.3	65.0	18.2	90.0	25.0	130.0	13.0	80.0	14.3	86.0	23.1			
			22	110.0	-4.3	60.0	9.1	72.0	0.0	120.0	4.3	80.0	14.3	86.0	23.1			
			24	95.0	-17.4	60.0	9.1	78.0	8.3	105.0	-8.7	75.0	7.1	92.0	17.9			
			26	100.0	-13.0	70.0	27.3	78.0	8.3	110.0	-4.3	80.0	14.3	80.0	17.9			
			28	95.0	-17.4	65.0	18.2	74.0	2.8	105.0	-8.7	80.0	14.3	88.0	12.8			
			286	AA	AA	-1	145.0	0.0	96.0	0.0	72.0	0.0	140.0	0.0	95.0	-11.6	84.0	13.1
						0	145.0	0.0	96.0	0.0	72.0	0.0	140.0	0.0	95.0	-11.6	84.0	13.1
						1	135.0	-6.9	90.0	-8.2	72.0	0.0	150.0	10.7	100.0	5.3	140.0	66.7
						2	140.0	-3.4	94.0	-4.1	100.0	38.9	130.0	-7.1	100.0	5.3	126.0	50.0
						3	146.0	0.7	98.0	0.0	72.0	0.0	140.0	0.0	100.0	5.3	126.0	50.0
						4	140.0	-3.4	80.0	-18.4	68.0	-5.6	125.0	-10.7	85.0	-10.5	88.0	4.8
						5	140.0	-3.4	75.0	-23.5	74.0	2.8	130.0	-7.1	85.0	-10.5	92.0	9.5
						6	150.0	3.4	100.0	2.0	76.0	5.6	140.0	-7.1	96.0	1.1	85.0	1.2
						8	165.0	13.8	110.0	12.2	76.0	5.6	140.0	0.0	100.0	5.3	100.0	19.0
						10	135.0	-6.9	95.0	-3.1	84.0	16.7	135.0	-3.6	95.0	0.0	110.0	31.0
						12	125.0	-13.8	90.0	-8.2	72.0	0.0	125.0	-10.7	105.0	10.5	85.0	1.2
						14	125.0	-13.8	90.0	-8.2	72.0	0.0	125.0	-10.7	105.0	10.5	85.0	1.2
						16	130.0	-10.3	105.0	7.1	84.0	16.7	125.0	-14.3	100.0	5.3	87.0	3.6
						18	160.0	10.3	110.0	12.2	90.0	25.0	140.0	14.3	110.0	10.5	108.0	28.6
						20	150.0	3.4	100.0	2.0	90.0	25.0	160.0	0.0	105.0	10.5	98.0	16.7
						22	160.0	3.4	110.0	12.2	90.0	25.0	150.0	7.1	105.0	10.5	98.0	16.7
24	140.0	-3.4				95.0	-3.1	86.0	19.4	140.0	0.0	100.0	5.3	98.0	16.7			
26	135.0	-6.9				90.0	-8.2	74.0	2.8	140.0	0.0	95.0	0.0	96.0	14.3			
28	135.0	-6.9				95.0	-3.1	72.0	0.0	135.0	-3.6	95.0	0.0	90.0	7.1			
30	140.0	-3.4				90.0	-8.2	78.0	8.3	125.0	-10.7	95.0	0.0	100.0	19.0			
32	160.0	10.3				105.0	7.1	76.0	5.6	150.0	7.1	110.0	15.8	98.0	16.7			
34	165.0	0.0				85.0	-13.3	78.0	8.3	130.0	-7.1	90.0	-5.3	96.0	14.3			
36	150.0	3.4				105.0	7.1	60.0	-16.7	135.0	-3.6	100.0	5.3	78.0	-7.1			
38	130.0	-10.3				90.0	-8.2	70.0	-2.8	120.0	-14.3	80.0	-15.8	96.0	14.3			
40	130.0	-10.3				85.0	-13.3	66.0	-8.3	130.0	-7.1	85.0	-10.5	78.0	-7.1			
42	125.0	-13.8				90.0	-8.2	72.0	0.0	120.0	-14.3	85.0	-10.5	80.0	7.1			
44	130.0	-10.3				90.0	-8.2	76.0	8.3	130.0	-7.1	90.0	-5.3	90.0	7.1			

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 mm Hg
 H.R. values <= 50 beats/min

2403

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	Initial	Visit	LYING				STANDING							
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff		
10	286	AA	46	125.0	-13.8	90.0	-8.2	78.0	8.3	125.0	-10.7	90.0	-5.3	96.0	14.3
			48	125.0	-13.8	90.0	-8.2	84.0	16.7	120.0	-14.3	90.0	-5.3	90.0	7.1
			50	130.0	-10.3	90.0	-8.2	78.0	8.3	125.0	-10.7	85.0	-10.5	90.0	7.1
			52	120.0	-17.2	85.0	-13.3	88.0	22.2	120.0	-14.3	85.0	-10.5	96.0	14.3
			-1	105.0	0.0	70.0	0.0	62.0	-12.9	100.0	0.0	80.0	0.0	78.0	-1.4
	287	LT	0	105.0	0.0	70.0	0.0	54.0	0.0	95.0	-5.0	80.0	0.0	72.0	0.0
			1	105.0	0.0	60.0	-14.3	78.0	25.8	98.0	-2.0	80.0	-25.0	100.0	37.0
			2	100.0	-4.8	60.0	-14.3	68.0	9.7	96.0	-4.0	80.0	-25.0	100.0	37.0
			3	100.0	-4.8	60.0	-14.3	76.0	22.6	100.0	0.0	80.0	0.0	122.0	67.1
			4	100.0	-4.8	70.0	0.0	82.0	0.0	100.0	0.0	70.0	-12.5	100.0	37.0
291	LL	5	104.0	-1.0	65.0	-7.1	74.0	19.4	105.0	5.0	70.0	-12.5	92.0	26.0	
		6	104.0	-1.0	66.0	-5.7	76.0	22.6	100.0	0.0	70.0	-12.5	100.0	37.0	
		8	103.0	-3.8	68.0	-2.9	76.0	22.6	100.0	0.0	60.0	-25.0	120.0	64.4	
		10	135.0	28.6	75.0	7.1	88.0	41.9	120.0	20.0	70.0	-12.5	96.0	31.5	
		12	105.0	0.0	65.0	-7.1	64.0	3.2	95.0	-5.0	85.0	6.3	90.0	23.3	
		14	105.0	0.0	65.0	-7.1	72.0	16.1	120.0	20.0	80.0	0.0	88.0	20.5	
		16	110.0	4.8	70.0	0.0	65.0	4.8	110.0	0.0	85.0	6.3	96.0	31.5	
		18	120.0	14.3	85.0	21.4	71.0	14.5	100.0	0.0	80.0	0.0	97.0	32.9	
		20	110.0	4.8	80.0	14.3	74.0	19.4	110.0	10.0	85.0	6.3	96.0	31.5	
		22	110.0	4.8	80.0	14.3	78.0	25.8	110.0	10.0	80.0	0.0	90.0	23.3	
24	105.0	0.0	65.0	-7.1	66.0	6.5	105.0	5.0	65.0	-18.8	78.0	6.8			
26	105.0	0.0	60.0	-14.3	66.0	6.5	115.0	15.0	70.0	-12.5	64.0	-12.3			
28	95.0	-9.5	60.0	-14.3	66.0	6.5	100.0	0.0	60.0	-25.0	66.0	-9.6			
30	100.0	-4.8	65.0	-7.1	68.0	9.7	110.0	10.0	70.0	-12.5	68.0	-6.8			
32	90.0	-14.3	55.0	-21.4	58.0	-6.5	100.0	0.0	60.0	-25.0	64.0	-12.3			
34	90.0	-14.3	60.0	-14.3	68.0	9.7	95.0	-5.0	70.0	-12.5	78.0	6.8			
36	90.0	-14.3	60.0	-14.3	72.0	16.1	100.0	0.0	70.0	-12.5	84.0	15.1			
38	90.0	-14.3	65.0	-7.1	66.0	6.5	100.0	0.0	70.0	-12.5	84.0	15.1			
40	95.0	-9.5	70.0	0.0	72.0	16.1	90.0	-10.0	65.0	-18.8	84.0	15.1			
42	105.0	0.0	70.0	0.0	66.0	6.5	90.0	-10.0	60.0	-25.0	84.0	15.1			
44	98.0	-6.7	70.0	0.0	78.0	25.8	95.0	-5.0	65.0	-18.8	90.0	23.3			
291	LL	-1	120.0	0.0	80.0	0.0	89.0	0.0	130.0	-3.8	90.0	0.0	70.0	0.0	
		0	125.0	4.2	80.0	0.0	72.0	-19.1	125.0	-11.5	90.0	0.0	90.0	28.6	
		1	140.0	16.7	90.0	12.5	70.0	-19.1	115.0	-11.5	90.0	0.0	84.0	20.0	
		2	115.0	-4.2	85.0	6.3	78.0	-12.4	105.0	-19.2	95.0	5.6	89.0	20.0	
		3	135.0	12.5	90.0	12.5	78.0	-12.4	123.0	-3.8	105.0	16.7	86.0	20.0	
4	145.0	20.8	95.0	18.8	70.0	-21.3	140.0	7.7	105.0	16.7	86.0	20.0			
5	125.0	4.2	85.0	6.3	68.0	-23.6	130.0	0.0	100.0	11.1	76.0	8.6			

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 100 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

2403

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	Initial	Visit	LYING				STANDING								
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	D.B.P.	% diff	H.R.	% diff	
10	291	LL	6	145.0	20.8	105.0	31.3 **	69.0	-22.5	140.0	7.7	105.0	16.7	95.0	35.7	
			8	135.0	12.5	95.0	18.8	74.0	-16.9	140.0	7.7	105.0	16.7	90.0	28.6	
			10	140.0	16.7	95.0	18.8	68.0	-23.6	135.0	3.8	100.0	11.1	100.0	81.0	15.7
			12	120.0	0.0	85.0	6.3	89.0	0.0	108.0	-16.9	95.0	5.6	104.0	48.6	**
			14	120.0	0.0	85.0	6.3	81.0	-9.0	110.0	-15.4	95.0	5.6	92.0	31.4	**
			16	150.0	25.0	115.0	43.8 **	72.0	-19.1	150.0	15.4	115.0	11.1	100.0	28.6	**
			18	130.0	8.3	95.0	18.8	76.0	-14.6	115.0	-11.5	100.0	11.1	90.0	28.6	**
			20	108.0	-10.0	80.0	0.0	72.0	-19.1	105.0	-3.8	85.0	-5.6	98.0	40.0	**
			22	145.0	20.8	105.0	31.3 **	72.0	-19.1	125.0	-3.8	100.0	11.1	100.0	20.0	**
			24	140.0	16.7	95.0	18.8	78.0	-12.4	140.0	7.7	105.0	16.7	84.0	20.0	**
			26	140.0	16.7	105.0	31.3 **	78.0	-12.4	140.0	7.7	100.0	11.1	98.0	40.0	**
			28	120.0	0.0	80.0	0.0	64.0	-5.6	120.0	-7.7	80.0	-11.1	100.0	42.9	**
			30	120.0	0.0	80.0	0.0	58.0	-4.5	110.0	-15.4	85.0	-5.6	96.0	37.1	**
			32	130.0	8.3	90.0	12.5	78.0	-12.4	120.0	-7.7	85.0	-5.6	96.0	20.0	**
			34	130.0	8.3	85.0	6.3	72.0	-19.1	125.0	-3.8	78.0	-13.3	80.0	28.6	**
			36	140.0	16.7	90.0	12.5	66.0	-25.8	130.0	0.0	85.0	-3.8	90.0	37.1	**
			38	130.0	8.3	80.0	0.0	72.0	-19.1	125.0	-3.8	80.0	-11.1	96.0	20.0	**
			40	110.0	-8.3	85.0	6.3	60.0	-32.6	120.0	-7.7	90.0	0.0	84.0	20.0	**
			42	110.0	-8.3	75.0	-6.3	78.0	-12.4	120.0	-7.7	80.0	-11.1	90.0	28.6	**
			44	140.0	16.7	90.0	12.5	78.0	-12.4	130.0	0.0	85.0	-5.6	84.0	20.0	**
			46	125.0	4.2	85.0	6.3	72.0	-19.1	115.0	-11.5	90.0	0.0	90.0	28.6	**
			48	115.0	-4.2	85.0	6.3	66.0	-25.8	110.0	-15.4	90.0	0.0	90.0	28.6	**
50	125.0	4.2	90.0	12.5	72.0	-19.1	130.0	0.0	90.0	0.0	96.0	37.1	**			
RK	297	RK	-1	110.0		65.0		66.0		120.0		75.0		78.0		
			0	140.0	27.3	80.0	23.1	70.0	6.1	135.0	12.5	100.0	33.3 **	92.0	17.9	
			1	125.0	13.6	70.0	7.7	66.0	0.0	140.0	16.7	75.0	0.0	78.0	0.0	
			2	120.0	9.1	65.0	0.0	62.0	-6.1	130.0	8.3	70.0	-6.7	68.0	-12.8	
			3	110.0	0.0	70.0	7.7	76.0	15.2	100.0	-16.7	65.0	-13.3	88.0	12.8	
			4	110.0	0.0	80.0	23.1	70.0	6.1	90.0	-25.0 *	75.0	0.0	98.0	25.6	
			5	110.0	0.0	85.0	30.8	78.0	18.2	100.0	-16.7	80.0	6.7	96.0	23.1	
			6	100.0	-9.1	80.0	23.1	84.0	27.3	100.0	-16.7	85.0	13.3	120.0	53.8 **	
			8	120.0	9.1	75.0	15.4	90.0	36.4	125.0	4.2	100.0	33.3 **	120.0	53.8 **	
			10	115.0	4.5	85.0	30.8	90.0	36.4	95.0	-20.8 *	85.0	13.3	120.0	53.8 **	
			12	120.0	9.1	85.0	30.8	72.0	9.1	105.0	-12.5	90.0	20.0	120.0	53.8 **	
			14	120.0	9.1	80.0	23.1	78.0	18.2	110.0	-8.3	90.0	20.0	116.0	48.7 **	
16	115.0	4.5	85.0	30.8	72.0	9.1	115.0	-4.2	85.0	13.3	102.0	30.8 **				
18	120.0	9.1	80.0	23.1	66.0	0.0	110.0	-8.3	90.0	20.0	102.0	30.8 **				
20	115.0	4.5	80.0	23.1	60.0	-9.1	105.0	-12.5	90.0	20.0	90.0	15.4				
22	120.0	9.1	90.0	36.5	72.0	9.1	120.0	0.0	90.0	20.0	96.0	23.1				

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 beats/min
 H.R. values <= 50 beats/min

2404

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	Initial	Visit	LYING			STANDING											
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	H.R.	% diff							
10	297	RK	24	115.0	4.5	38.5	66.0	0.0	125.0	4.2	95.0	26.7	90.0	15.4				
			26	110.0	0.0	38.5	66.0	0.0	120.0	0.0	95.0	26.7	120.0	30.8				
			28	110.0	0.0	46.2	78.0	18.2	115.0	0.0	95.0	26.7	120.0	30.8				
			30	115.0	4.5	100.0	53.8	**	80.0	21.2	125.0	4.2	100.0	33.3				
			32	120.0	9.1	90.0	38.5	78.0	18.2	125.0	4.2	95.0	26.7	90.0	15.4			
			34	120.0	9.1	90.0	38.5	78.0	18.2	125.0	4.2	100.0	33.3	90.0	15.4			
			36	130.0	18.2	85.0	30.8	78.0	18.2	130.0	8.3	110.0	46.7	90.0	15.4			
			38	125.0	13.6	95.0	46.2	9.1	72.0	9.1	120.0	0.0	90.0	20.0	15.4			
			40	120.0	9.1	90.0	38.5	78.0	18.2	120.0	0.0	90.0	20.0	102.0	30.8			
			42	120.0	9.1	90.0	38.5	78.0	18.2	120.0	0.0	95.0	26.7	96.0	23.1			
			44	115.0	4.5	85.0	30.8	72.0	9.1	125.0	4.2	90.0	20.0	96.0	23.1			
			46	120.0	9.1	90.0	38.5	78.0	18.2	160.0	16.7	100.0	33.3	80.0	15.4			
			48	125.0	13.6	90.0	38.5	66.0	0.0	125.0	4.2	90.0	20.0	84.0	7.7			
			50	120.0	9.1	85.0	30.8	78.0	18.2	125.0	4.2	95.0	26.7	90.0	15.4			
			52	120.0	9.1	80.0	23.1	66.0	0.0	130.0	8.3	90.0	20.0	78.0	0.0			
			299	LK		-1	115.0	-4.3	70.0	60.0	0.0	125.0	-16.0	75.0	20.0	66.0	39.4	
						0	110.0	-4.3	75.0	7.1	84.0	40.0	105.0	-12.0	90.0	6.7	96.0	45.5
						1	110.0	-4.3	80.0	14.3	64.0	6.7	110.0	-4.0	80.0	-13.3	80.0	21.2
						2	130.0	13.0	60.0	-14.3	68.0	13.3	120.0	0.0	65.0	-6.7	96.0	45.5
						3	130.0	13.0	60.0	-14.3	82.0	36.7	125.0	-4.0	70.0	0.0	92.0	39.4
						4	130.0	13.0	65.0	-7.1	78.0	30.0	120.0	-4.0	75.0	0.0	96.0	45.5
						5	110.0	-4.3	80.0	14.3	64.0	6.7	110.0	-12.0	80.0	6.7	96.0	45.5
						6	110.0	-4.3	80.0	14.3	68.0	13.3	120.0	-4.0	65.0	-13.3	80.0	21.2
						8	106.0	-7.8	72.0	2.9	80.0	33.3	100.0	-20.0	70.0	-6.7	120.0	81.8
						10	110.0	-4.3	80.0	14.3	72.0	20.0	100.0	-20.0	80.0	6.7	82.0	24.2
						12	105.0	-8.7	70.0	0.0	72.0	20.0	100.0	-20.0	70.0	-6.7	84.0	27.3
						14	110.0	-4.3	75.0	7.1	78.0	30.0	105.0	-16.0	70.0	-6.7	90.0	36.4
						16	100.0	-13.0	65.0	-7.1	78.0	30.0	103.0	-17.6	85.0	13.3	96.0	45.5
						18	102.0	-11.3	70.0	0.0	72.0	20.0	105.0	-16.0	80.0	6.7	90.0	36.4
						20	103.0	-10.4	65.0	-7.1	90.0	50.0	105.0	-16.0	70.0	-6.7	120.0	81.8
						22	105.0	-8.7	70.0	0.0	84.0	40.0	105.0	-16.0	70.0	-6.7	98.0	48.5
						24	110.0	-4.3	70.0	0.0	84.0	40.0	105.0	-16.0	65.0	-13.3	96.0	45.5
						26	115.0	0.0	70.0	0.0	84.0	40.0	110.0	-12.0	70.0	-6.7	90.0	36.4
						28	105.0	-8.7	75.0	7.1	78.0	30.0	105.0	-16.0	80.0	6.7	90.0	36.4
						30	110.0	-4.3	75.0	7.1	66.0	10.0	110.0	-12.0	75.0	0.0	96.0	45.5
32	107.0	-7.0				75.0	7.1	66.0	10.0	110.0	-12.0	80.0	6.7	90.0	36.4			
34	90.0	-21.7				65.0	-7.1	84.0	40.0	105.0	-16.0	85.0	13.3	96.0	45.5			
36	103.0	-10.4				63.0	-10.0	90.0	50.0	103.0	-17.6	80.0	6.7	86.0	45.5			
38	103.0	-10.4				75.0	7.1	84.0	40.0	105.0	-16.0	78.0	4.0	108.0	63.6			
																45.5		

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 mm Hg
 H.R. values <= 50 beats/min

2405

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	Initial	Visit	LIVING			STANDING										
				S.B.P.	% diff	H.R.	% diff	S.B.P.	% diff	H.R.	% diff						
10	299	LK	40	95.0	-17.4	75.0	7.1	86.0	43.3	100.0	-20.0	85.0	13.3	90.0	36.4		
			42	90.0	-21.7	70.0	0.0	84.0	40.0	105.0	-16.0	80.0	6.7	96.0	45.5		
			44	95.0	-17.4	65.0	-7.1	90.0	50.0	110.0	-12.0	85.0	13.3	108.0	53.6		
			46	95.0	-17.4	70.0	0.0	84.0	40.0	105.0	-16.0	80.0	6.7	98.0	36.4		
			48	100.0	-13.0	65.0	-7.1	84.0	40.0	110.0	-12.0	80.0	6.7	102.0	54.5		
			50	100.0	-13.0	70.0	0.0	78.0	30.0	100.0	-20.0	75.0	0.0	90.0	36.4		
			52	100.0	-13.0	70.0	0.0	84.0	40.0	110.0	-12.0	80.0	0.0	90.0	36.4		
			300	EK	-1	100.0	10.0	75.0	20.0	82.0	-14.6	105.0	0.0	70.0	21.4	66.0	31.8
			1	100.0	0.0	60.0	-20.0	70.0	0.0	60.0	-26.8	110.0	4.8	60.0	-16.3	78.0	18.2
			2	90.0	-10.0	65.0	-13.3	75.0	0.0	88.0	7.3	110.0	4.8	70.0	0.0	96.0	45.5
			3	100.0	0.0	80.0	6.7	88.0	6.7	86.0	4.9	115.0	9.5	80.0	14.3	92.0	39.4
			4	105.0	5.0	80.0	6.7	87.0	6.1	87.0	6.1	115.0	9.5	80.0	14.3	98.0	48.5
5	120.0	20.0	85.0	13.3	87.0	6.1	87.0	6.1	115.0	9.5	80.0	14.3	96.0	45.5			
6	115.0	15.0	85.0	13.3	84.0	2.4	84.0	2.4	105.0	0.0	85.0	21.4	96.0	45.5			
8	115.0	15.0	85.0	13.3	84.0	2.4	84.0	2.4	105.0	0.0	85.0	21.4	110.0	66.7			
10	95.0	-5.0	75.0	0.0	84.0	2.4	84.0	2.4	105.0	0.0	85.0	21.4	90.0	36.4			
12	115.0	15.0	70.0	-6.7	78.0	0.0	78.0	0.0	120.0	14.3	95.0	35.7	86.0	30.3			
14	115.0	15.0	70.0	-6.7	72.0	0.0	72.0	-12.2	120.0	14.3	85.0	21.4	84.0	27.3			
16	120.0	20.0	80.0	6.7	78.0	0.0	78.0	-4.9	125.0	19.0	85.0	21.4	90.0	36.4			
18	120.0	20.0	85.0	13.3	66.0	-19.5	66.0	-19.5	125.0	19.0	85.0	21.4	90.0	36.4			
11	361	NGX	-1	120.0	25.0	80.0	12.5	84.0	-9.5	130.0	15.4	80.0	12.5	88.0	-12.5		
			0	150.0	8.3	90.0	12.5	76.0	-9.5	140.0	7.7	80.0	0.0	77.0	0.0		
			1	130.0	8.3	90.0	0.0	76.0	-9.5	140.0	7.7	80.0	0.0	80.0	-9.1		
			2	130.0	8.3	80.0	0.0	88.0	4.8	110.0	-15.4	70.0	0.0	100.0	13.6		
			3	140.0	16.7	90.0	12.5	108.0	28.6	130.0	0.0	90.0	0.0	112.0	27.3		
			4	140.0	16.7	90.0	12.5	90.0	7.1	130.0	0.0	90.0	0.0	112.0	27.3		
			5	130.0	8.3	70.0	-12.5	84.0	0.0	130.0	0.0	90.0	0.0	92.0	4.5		
			6	120.0	0.0	90.0	12.5	80.0	-4.8	130.0	0.0	90.0	0.0	88.0	0.0		
			8	120.0	0.0	80.0	0.0	80.0	-4.8	130.0	0.0	90.0	0.0	90.0	2.3		
			10	110.0	-8.3	80.0	0.0	80.0	-4.8	130.0	0.0	90.0	0.0	86.0	-2.3		
			12	140.0	16.7	90.0	12.5	80.0	-4.8	130.0	-7.7	90.0	0.0	86.0	-2.3		
			14	140.0	16.7	90.0	12.5	90.0	7.1	130.0	15.4	100.0	25.0	82.0	-6.8		
16	120.0	0.0	80.0	0.0	82.0	-2.4	130.0	0.0	80.0	0.0	86.0	-2.3					
18	140.0	16.7	90.0	12.5	88.0	4.8	140.0	7.7	100.0	25.0	90.0	2.3					
20	140.0	16.7	90.0	12.5	72.0	-14.3	140.0	7.7	100.0	25.0	82.0	-6.8					
22	150.0	25.0	90.0	12.5	86.0	2.4	150.0	15.4	100.0	25.0	90.0	2.3					
24	140.0	16.7	90.0	12.5	92.0	9.5	140.0	7.7	100.0	25.0	98.0	11.4					

** S.B.P. values \geq 160 mm Hg
D.B.P. values \geq 100 mm Hg
H.R. values \geq 100 beats/min
* S.B.P. values \leq 70 mm Hg
D.B.P. values \leq 50 beats/min
H.R. values \leq 50 beats/min

2406

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 ROXOMETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: ROXOMETINE

Centre	Patient	Initial	Visit	LIVING				STANDING								
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff			
11	363	BJ	-1	130.0	-7.7	80.0	0.0	76.0	-2.6	120.0	0.0	90.0	80.0	-2.5		
			0	120.0	-7.7	80.0	0.0	74.0	0.0	120.0	0.0	90.0	82.0	2.5		
			1	120.0	0.0	12.5	12.5	76.0	0.0	110.0	-8.3	90.0	80.0	0.0		
			2	130.0	0.0	12.5	12.5	72.0	-5.3	130.0	8.3	90.0	73.0	-8.8		
			3	160.0	23.1	90.0	12.5	84.0	10.5	140.0	16.7	90.0	86.0	7.5		
			4	140.0	7.7	90.0	12.5	88.0	15.8	140.0	16.7	90.0	88.0	10.0		
			5	120.0	-7.7	90.0	12.5	86.0	13.2	110.0	-8.3	90.0	88.0	10.0		
			6	140.0	7.7	90.0	12.5	80.0	5.3	140.0	16.7	90.0	86.0	7.5		
			8	120.0	-7.7	90.0	12.5	70.0	-7.9	110.0	0.0	80.0	72.0	-10.0		
			10	120.0	-7.7	80.0	0.0	78.0	2.6	120.0	0.0	80.0	82.0	7.5		
			12	110.0	-15.4	70.0	-12.5	76.0	0.0	120.0	0.0	80.0	82.0	7.5		
			14	120.0	-7.7	80.0	0.0	78.0	2.6	130.0	8.3	90.0	82.0	2.5		
			16	130.0	0.0	90.0	12.5	80.0	5.3	130.0	8.3	90.0	76.0	-5.0		
			18	120.0	-7.7	80.0	0.0	78.0	2.6	130.0	8.3	90.0	84.0	5.0		
			20	120.0	-7.7	80.0	0.0	78.0	2.6	130.0	8.3	90.0	86.0	7.5		
			22	130.0	0.0	80.0	0.0	76.0	0.0	120.0	0.0	80.0	82.0	2.5		
			24	140.0	7.7	90.0	12.5	80.0	5.3	140.0	16.7	90.0	86.0	7.5		
			26	130.0	0.0	80.0	0.0	85.0	11.8	130.0	8.3	90.0	80.0	0.0		
			28	140.0	7.7	80.0	0.0	76.0	0.0	120.0	0.0	80.0	84.0	5.0		
			30	130.0	0.0	80.0	0.0	80.0	5.3	120.0	0.0	80.0	82.0	2.5		
			32	120.0	-7.7	70.0	-12.5	76.0	0.0	120.0	0.0	80.0	82.0	2.5		
			34	120.0	-7.7	70.0	-12.5	72.0	-5.3	110.0	-8.3	70.0	70.0	-12.5		
			36	120.0	-7.7	80.0	0.0	78.0	2.6	120.0	0.0	80.0	76.0	-5.0		
			38	130.0	0.0	80.0	0.0	70.0	-7.9	120.0	0.0	70.0	80.0	0.0		
			40	120.0	-7.7	80.0	0.0	72.0	-5.3	120.0	0.0	80.0	80.0	0.0		
			42	130.0	0.0	90.0	12.5	80.0	5.3	130.0	8.3	80.0	86.0	7.5		
			44	120.0	-7.7	80.0	0.0	78.0	2.6	110.0	-8.3	70.0	88.0	10.0		
			46	120.0	-7.7	80.0	0.0	68.0	-10.5	120.0	0.0	80.0	80.0	0.0		
			48	130.0	0.0	80.0	0.0	70.0	-7.9	120.0	0.0	80.0	80.0	0.0		
			50	120.0	-7.7	80.0	0.0	68.0	-10.5	130.0	8.3	80.0	76.0	-5.0		
			52	120.0	-7.7	70.0	-12.5	76.0	0.0	120.0	0.0	80.0	88.0	10.0		
			365	GK	-1	140.0	-14.3	100.0	0.0	76.0	-7.9	130.0	0.0	90.0	78.0	0.0
					0	120.0	-14.3	80.0	-20.0	70.0	-7.9	120.0	-7.7	80.0	80.0	0.0
					1	120.0	-14.3	80.0	-20.0	76.0	0.0	130.0	0.0	80.0	82.0	2.6
					2	120.0	-14.3	80.0	-20.0	76.0	0.0	130.0	0.0	80.0	80.0	0.0
					3	130.0	-7.1	80.0	-20.0	90.0	18.4	140.0	7.7	90.0	96.0	23.1
					4	130.0	-7.1	80.0	-20.0	82.0	7.9	130.0	0.0	90.0	86.0	10.3
			5	130.0	-7.1	80.0	-20.0	90.0	18.4	130.0	0.0	80.0	92.0	17.9		
			6	130.0	-7.1	80.0	-20.0	80.0	5.3	120.0	-7.7	80.0	78.0	0.0		

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 beats/min
 H.R. values <= 50 beats/min

2407

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	Initial	Visit	LYING			STANDING										
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	H.R.	% diff						
11	365	OK	8	120.0	-14.3	80.0	-20.0	88.0	15.8	130.0	0.0	80.0	-11.1	80.0	2.6		
			10	120.0	-14.3	80.0	-20.0	82.0	7.9	130.0	0.0	80.0	0.0	80.0	-11.1	90.0	15.4
			12	100.0	-28.6	70.0	-30.0	70.0	-7.9	120.0	-7.7	120.0	-7.7	80.0	-11.1	78.0	0.0
			14	110.0	-21.4	80.0	-30.0	66.0	-13.2	100.0	0.0	130.0	0.0	80.0	-22.2	74.0	-5.1
			16	140.0	0.0	80.0	-20.0	76.0	0.0	130.0	0.0	130.0	0.0	80.0	-11.1	75.0	-3.8
			18	130.0	-7.1	80.0	-20.0	78.0	2.6	130.0	0.0	130.0	0.0	80.0	-11.1	82.0	5.1
			20	130.0	-7.1	80.0	-20.0	80.0	5.3	120.0	-7.7	120.0	-7.7	80.0	-11.1	82.0	5.1
			-1	120.0	0.0	90.0	0.0	80.0	10.0	130.0	0.0	130.0	-7.7	90.0	0.0	82.0	12.2
			0	120.0	0.0	90.0	0.0	88.0	10.0	130.0	0.0	130.0	0.0	90.0	0.0	80.0	-2.4
			1	120.0	0.0	90.0	0.0	76.0	-5.0	130.0	-2.5	130.0	-7.7	80.0	-11.1	84.0	2.4
367	NA		3	110.0	-8.3	80.0	-11.1	78.0	-2.5	130.0	0.0	80.0	0.0	80.0	0.0	90.0	9.8
			4	130.0	8.3	90.0	-2.0	86.0	7.5	130.0	0.0	118.0	-15.4	80.0	-11.1	90.0	9.8
			5	100.0	-16.7	70.0	-22.2	80.0	0.0	120.0	-7.7	110.0	-15.4	80.0	-11.1	86.0	4.9
			6	100.0	-16.7	70.0	-22.2	80.0	0.0	120.0	-7.7	110.0	-15.4	80.0	-11.1	94.0	14.6
			8	110.0	-8.3	80.0	-11.1	80.0	0.0	120.0	-7.7	140.0	0.0	90.0	-11.1	98.0	9.8
			10	130.0	8.3	80.0	-11.1	86.0	7.5	140.0	0.0	140.0	0.0	90.0	-11.1	98.0	9.8
			12	130.0	8.3	80.0	-11.1	76.0	-5.0	120.0	-7.7	120.0	-7.7	80.0	-11.1	88.0	7.3
			14	140.0	16.7	100.0	11.1	92.0	15.0	120.0	-7.7	120.0	-7.7	90.0	0.0	90.0	9.8
			15	140.0	16.7	100.0	11.1	90.0	12.5	140.0	7.7	140.0	7.7	100.0	11.1	94.0	14.6
			16	130.0	8.3	80.0	-11.1	92.0	15.0	140.0	7.7	140.0	7.7	80.0	-11.1	98.0	14.6
368	UZ		-1	130.0	0.0	90.0	0.0	80.0	0.0	140.0	0.0	100.0	0.0	86.0	0.0		
			0	130.0	0.0	90.0	0.0	76.0	-5.0	140.0	0.0	140.0	0.0	90.0	-10.0	82.0	-4.7
			1	110.0	-15.4	70.0	-22.2	80.0	0.0	110.0	-21.4	110.0	-21.4	70.0	-30.0	82.0	-4.7
			2	120.0	-7.7	80.0	-11.1	90.0	12.5	110.0	-21.4	110.0	-21.4	80.0	-20.0	92.0	7.0
			3	110.0	-15.4	70.0	-22.2	80.0	0.0	120.0	-14.3	120.0	-14.3	80.0	-20.0	86.0	0.0
			4	120.0	-7.7	80.0	-11.1	86.0	7.5	130.0	-7.1	130.0	-7.1	80.0	-20.0	88.0	2.3
			5	120.0	-7.7	70.0	-22.2	80.0	0.0	120.0	-14.3	120.0	-14.3	80.0	-20.0	72.0	-16.3
			6	110.0	-15.4	90.0	0.0	80.0	0.0	110.0	-21.4	110.0	-21.4	80.0	-20.0	86.0	0.0
			8	120.0	-7.7	80.0	-11.1	76.0	-5.0	130.0	-7.1	130.0	-7.1	80.0	-20.0	88.0	2.3
			10	130.0	0.0	80.0	-11.1	70.0	-12.5	130.0	-7.1	130.0	-7.1	90.0	-10.0	75.0	-12.8
369	UZ		12	140.0	7.7	90.0	0.0	78.0	-2.5	130.0	-7.1	90.0	-10.0	88.0	2.3		
			14	110.0	-15.4	70.0	0.0	80.0	0.0	110.0	-21.4	110.0	-21.4	90.0	-10.0	78.0	-9.3
			16	140.0	7.7	90.0	0.0	68.0	-15.0	130.0	-7.1	130.0	-7.1	90.0	-10.0	70.0	-18.6
			18	130.0	0.0	80.0	-11.1	64.0	-20.0	130.0	-7.1	130.0	-7.1	80.0	-20.0	72.0	-16.3
			20	130.0	0.0	80.0	-11.1	62.0	-22.5	130.0	-7.1	130.0	-7.1	80.0	-20.0	66.0	-23.3
			22	130.0	0.0	80.0	-11.1	66.0	-17.5	110.0	-21.4	110.0	-21.4	70.0	-30.0	70.0	-18.6
			24	120.0	-7.7	80.0	-11.1	68.0	-15.0	120.0	-14.3	120.0	-14.3	80.0	-20.0	74.0	-14.0

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARRACIA CNS R&D
 ROXYMETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: ROXYMETINE

Centre	Patient	Initial	Visit	LYING				STANDING							
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff		
11	368	UZ	26	120.0	-7.7	80.0	-11.1	70.0	-12.5	120.0	-14.3	80.0	-20.0	74.0	-14.0
			28	130.0	0.0	80.0	-11.1	68.0	-15.0	120.0	-14.3	80.0	-20.0	76.0	-11.6
			30	120.0	-7.7	80.0	-11.1	66.0	-17.5	130.0	-7.1	80.0	-20.0	80.0	-7.0
			32	120.0	-7.7	80.0	-11.1	70.0	-12.5	120.0	-14.3	80.0	-20.0	74.0	-14.0
			34	110.0	-15.4	80.0	-22.2	70.0	-12.5	110.0	-21.4	70.0	-30.0	80.0	-7.0
			36	120.0	-7.7	80.0	-11.1	72.0	-10.0	110.0	-21.4	70.0	-30.0	84.0	-2.3
			38	130.0	0.0	80.0	-11.1	66.0	-17.5	120.0	-14.3	70.0	-30.0	78.0	-9.3
			40	120.0	-7.7	80.0	-22.2	70.0	-12.5	120.0	-14.3	80.0	-20.0	80.0	-7.0
			42	130.0	0.0	80.0	-11.1	76.0	-5.0	120.0	-14.3	80.0	-20.0	86.0	0.0
			44	130.0	0.0	80.0	-11.1	76.0	-5.0	110.0	-21.4	80.0	-20.0	89.0	3.5
			46	120.0	-7.7	80.0	-22.2	68.0	-15.0	120.0	-14.3	80.0	-20.0	74.0	-11.6
373	HB	1	130.0	-15.4	70.0	0.0	78.0	-2.6	115.0	4.3	90.0	-33.3	90.0	0.0	
		2	130.0	0.0	70.0	0.0	70.0	-10.3	120.0	30.4	80.0	-33.3	92.0	2.2	
		3	135.0	3.8	95.0	35.7	80.0	20.5	150.0	30.4	100.0	11.1	76.0	-15.6	
		4	140.0	7.7	100.0	42.9	94.0	20.5	150.0	30.4	100.0	11.1	90.0	0.0	
		5	160.0	23.1	90.0	28.6	88.0	12.8	160.0	39.1	90.0	0.0	100.0	11.1	
		6	160.0	15.4	100.0	42.9	88.0	12.8	150.0	30.4	90.0	0.0	90.0	0.0	
		8	140.0	7.7	100.0	42.9	72.0	-7.7	140.0	21.7	50.0	-44.4	88.0	-2.2	
		10	160.0	23.1	100.0	42.9	83.0	6.4	150.0	30.4	90.0	0.0	78.0	-13.3	
		12	150.0	15.4	100.0	42.9	88.0	12.8	150.0	30.4	100.0	11.1	86.0	-4.4	
		14	130.0	0.0	80.0	14.3	80.0	2.6	145.0	26.1	100.0	11.1	82.0	-8.9	
		16	140.0	7.7	90.0	28.6	76.0	-2.6	140.0	21.7	90.0	0.0	82.0	-8.9	
374	RF	1	150.0	15.4	90.0	28.6	80.0	2.6	150.0	30.4	100.0	11.1	86.0	-4.4	
		2	150.0	15.4	90.0	28.6	83.0	6.4	140.0	21.7	90.0	0.0	86.0	-4.4	
		4	160.0	23.1	100.0	42.9	90.0	15.4	150.0	30.4	90.0	0.0	75.0	-16.7	
		6	150.0	15.4	100.0	42.9	84.0	0.0	160.0	39.1	100.0	11.1	96.0	6.7	
		8	150.0	15.4	100.0	42.9	84.0	0.0	160.0	39.1	100.0	11.1	80.0	-11.1	
		10	150.0	15.4	100.0	42.9	84.0	0.0	150.0	30.4	100.0	11.1	94.0	4.4	
		12	150.0	15.4	100.0	42.9	82.0	5.1	140.0	21.7	100.0	11.1	85.0	-5.6	
		14	150.0	15.4	100.0	42.9	70.0	-10.3	150.0	30.4	100.0	11.1	76.0	-15.6	
		16	150.0	15.4	90.0	28.6	100.0	0.0	130.0	0.0	80.0	-20.0	102.0	2.0	
		18	120.0	-20.0	70.0	-22.2	96.0	-4.0	140.0	7.7	80.0	0.0	100.0	-2.0	
		20	150.0	0.0	90.0	0.0	88.0	-12.0	155.0	19.2	100.0	25.0	90.0	-11.8	

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 100 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

2409

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 ROXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: ROXETINE

Centre	Patient	Initial	Visit	LYING			STANDING											
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	H.R.	% diff							
11	374	RF	3	140.0	-6.7	90.0	0.0	88.0	-12.0	150.0	15.4	100.0	25.0	**	92.0	-9.8		
			4	150.0	0.0	90.0	0.0	92.0	-8.0	140.0	7.7	7.7	90.0	12.5	100.0	-2.0		
			5	140.0	-6.7	80.0	-11.1	84.0	-16.0	120.0	0.0	-7.7	80.0	0.0	90.0	-11.8		
			6	140.0	-6.7	70.0	-22.2	82.0	-18.0	130.0	0.0	0.0	70.0	-12.5	86.0	-15.7		
			8	150.0	0.0	80.0	-11.1	84.0	-16.0	140.0	7.7	7.7	70.0	-12.5	82.0	-19.6		
			10	140.0	-6.7	90.0	0.0	80.0	-20.0	140.0	7.7	7.7	90.0	12.5	82.0	-19.6		
			-1	110.0	-9.1	60.0	-16.7	78.0	2.6	100.0	0.0	-10.0	90.0	0.0	50.0	0.0	82.0	6.1
			1	130.0	18.2	60.0	0.0	64.0	-17.9	120.0	0.0	20.0	20.0	60.0	20.0	68.0	-17.1	
			2	130.0	18.2	70.0	16.7	66.0	-15.4	130.0	30.0	30.0	30.0	40.0	40.0	70.0	-14.6	
			3	145.0	31.8	90.0	50.0	82.0	5.1	145.0	65.0	65.0	65.0	100.0	100.0	88.0	7.3	
4	140.0	27.3	80.0	33.3	80.0	2.6	140.0	40.0	40.0	40.0	80.0	80.0	82.0	0.0				
5	130.0	18.2	90.0	50.0	92.0	17.3	130.0	30.0	30.0	30.0	80.0	80.0	90.0	9.8				
6	120.0	9.1	80.0	33.3	80.0	2.6	120.0	20.0	20.0	20.0	60.0	60.0	80.0	-2.4				
8	130.0	18.2	90.0	50.0	82.0	5.1	130.0	30.0	30.0	30.0	80.0	80.0	86.0	4.9				
10	130.0	18.2	90.0	50.0	80.0	2.6	120.0	20.0	20.0	20.0	60.0	60.0	82.0	0.0				
12	130.0	18.2	80.0	33.3	100.0	28.2	130.0	30.0	30.0	30.0	80.0	80.0	102.0	24.4				
14	130.0	18.2	80.0	33.3	82.0	5.1	120.0	20.0	20.0	20.0	70.0	40.0	90.0	9.8				
16	130.0	18.2	90.0	50.0	74.0	-5.1	150.0	50.0	50.0	50.0	90.0	80.0	96.0	17.1				
18	140.0	27.3	90.0	50.0	100.0	28.2	140.0	40.0	40.0	40.0	80.0	80.0	97.0	18.3				
20	125.0	13.6	80.0	33.3	96.0	23.1	115.0	15.0	15.0	15.0	80.0	60.0	84.0	2.4				
22	130.0	18.2	90.0	50.0	68.0	-12.8	120.0	20.0	20.0	20.0	80.0	60.0	84.0	2.4				
24	140.0	27.3	90.0	50.0	79.0	1.3	140.0	40.0	40.0	40.0	90.0	80.0	70.0	-14.6				
26	130.0	18.2	80.0	33.3	70.0	-10.3	120.0	20.0	20.0	20.0	80.0	60.0	80.0	-2.4				
28	130.0	18.2	90.0	50.0	72.0	-7.7	120.0	20.0	20.0	20.0	80.0	60.0	72.0	-12.2				
30	140.0	27.3	90.0	50.0	92.0	17.9	120.0	20.0	20.0	20.0	80.0	60.0	84.0	2.4				
32	140.0	27.3	90.0	50.0	92.0	17.9	130.0	30.0	30.0	30.0	90.0	80.0	90.0	9.8				
34	130.0	18.2	90.0	50.0	77.0	-1.3	140.0	40.0	40.0	40.0	90.0	80.0	82.0	0.0				
36	130.0	18.2	90.0	50.0	92.0	17.9	130.0	30.0	30.0	30.0	90.0	80.0	90.0	9.8				
38	130.0	18.2	80.0	33.3	89.0	14.1	130.0	30.0	30.0	30.0	90.0	80.0	87.0	6.1				
40	130.0	18.2	70.0	16.7	88.0	12.8	130.0	30.0	30.0	30.0	70.0	40.0	90.0	9.8				
42	140.0	27.3	90.0	50.0	85.0	9.0	130.0	20.0	20.0	20.0	100.0	100.0	84.0	2.4				
44	130.0	18.2	80.0	33.3	76.0	-2.6	120.0	20.0	20.0	20.0	90.0	80.0	76.0	-7.3				
46	140.0	27.3	80.0	33.3	82.0	5.1	130.0	30.0	30.0	30.0	80.0	60.0	84.0	2.4				
48	120.0	9.1	70.0	16.7	87.0	11.5	130.0	30.0	30.0	30.0	70.0	40.0	87.0	6.1				
50	110.0	0.0	70.0	16.7	88.0	12.8	120.0	20.0	20.0	20.0	70.0	40.0	84.0	2.4				
52	120.0	9.1	80.0	33.3	92.0	17.9	130.0	30.0	30.0	30.0	90.0	80.0	80.0	-2.4				
12	92	IB	-1	140.0		90.0		75.0		140.0		90.0		85.0				

** S.B.P. values => 160 mm Hg
 D.B.P. values => 100 mm Hg
 H.R. values => 100 beats/min
 * S.B.P. values <= 100 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBONETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: REBONETINE

Centre	Patient	Initial	LYING				STANDING								
			S.B.P.	% diff	H.R.	% diff	S.B.P.	% diff	H.R.	% diff					
12	92	IB	0	140.0	0.0	75.0	0.0	140.0	0.0	90.0	0.0	85.0	0.0		
			1	120.0	-14.3	104.0	38.7	130.0	0.0	90.0	0.0	110.0	29.4		
			2	140.0	0.0	80.0	6.7	140.0	0.0	90.0	0.0	86.0	1.2		
			3	150.0	7.1	100.0	6.7	140.0	0.0	90.0	0.0	90.0	5.9		
			4	150.0	7.1	110.0	22.2	160.0	14.3	115.0	27.8	110.0	29.4		
			5	150.0	7.1	90.0	20.0	160.0	14.3	95.0	5.6	94.0	10.6		
			6	150.0	7.1	90.0	22.7	160.0	14.3	120.0	33.3	106.0	24.7		
			8	130.0	-14.3	80.0	4.0	140.0	0.0	90.0	0.0	88.0	3.5		
			10	120.0	-14.3	80.0	6.7	140.0	0.0	80.0	0.0	92.0	8.2		
			12	150.0	7.1	96.0	28.0	150.0	7.1	100.0	11.1	126.0	48.2		
			14	150.0	7.1	100.0	11.1	144.0	52.0	100.0	11.1	100.0	17.6		
			16	170.0	21.4	100.0	33.3	170.0	0.0	110.0	22.2	104.0	22.4		
			18	140.0	0.0	88.0	17.3	165.0	17.9	130.0	44.4	92.0	8.2		
			20	160.0	14.3	88.0	22.7	165.0	17.9	120.0	33.3	120.0	41.2		
			22	170.0	21.4	100.0	33.3	160.0	14.3	120.0	33.3	120.0	41.2		
			24	160.0	0.0	90.0	20.0	150.0	7.1	90.0	0.0	96.0	12.9		
			26	130.0	-7.1	86.0	14.7	140.0	0.0	90.0	0.0	92.0	8.2		
			28	165.0	5.6	88.0	17.3	145.0	3.6	100.0	11.1	110.0	29.4		
			30	160.0	4.3	88.0	17.3	145.0	3.6	100.0	11.1	88.0	3.5		
			32	130.0	-7.1	80.0	6.7	160.0	14.3	100.0	0.0	78.0	-8.2		
			34	170.0	21.4	88.0	9.3	160.0	0.0	90.0	0.0	90.0	5.9		
			36	140.0	0.0	90.0	20.0	180.0	28.6	110.0	22.2	90.0	10.6		
			38	130.0	-7.1	82.0	6.7	160.0	14.3	90.0	0.0	94.0	10.6		
			40	140.0	0.0	82.0	9.3	150.0	7.1	90.0	0.0	85.0	0.0		
			42	190.0	35.7	88.0	22.7	150.0	0.0	80.0	-11.1	94.0	10.6		
			44	160.0	14.3	116.0	54.7	170.0	21.4	100.0	11.1	98.0	15.3		
			46	160.0	14.3	84.0	12.0	140.0	0.0	100.0	11.1	124.0	45.9		
			48	160.0	14.3	80.0	6.7	160.0	14.3	100.0	11.1	88.0	3.5		
			50	150.0	7.1	93.0	24.0	140.0	0.0	100.0	11.1	97.0	14.1		
			52	140.0	0.0	86.0	14.7	140.0	0.0	90.0	0.0	90.0	5.9		
			93	IF	-1	115.0	0.0	78.0	0.0	115.0	0.0	90.0	0.0	95.0	0.0
					0	115.0	0.0	78.0	0.0	115.0	0.0	90.0	0.0	95.0	0.0
					1	110.0	-4.3	70.0	2.6	115.0	0.0	80.0	-11.1	100.0	5.3
					2	130.0	13.0	91.0	16.7	100.0	-13.0	70.0	-22.2	116.0	22.1
					3	120.0	4.3	88.0	12.8	125.0	8.7	80.0	-11.1	96.0	1.1
					4	130.0	13.0	90.0	2.6	120.0	4.3	80.0	-11.1	88.0	-7.4
			5	120.0	4.3	80.0	5.1	130.0	13.0	80.0	-11.1	86.0	-9.5		
			6	140.0	21.7	100.0	30.8	130.0	13.0	90.0	0.0	72.0	-24.2		
			8	120.0	4.3	60.0	-23.1	130.0	13.0	80.0	-11.1	78.0	-17.9		

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 beats/min
 H.R. values <= 50 beats/min

2411

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

ROBOXYTINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: ROBOXYTINE

Centre	Patient	Initial	Visit	LYING				STANDING							
				S.B.P. % diff	D.B.P. % diff	H.R. % diff	S.B.P. % diff	D.B.P. % diff	H.R. % diff						
12	98	IF	10	120.0	4.3	80.0	0.0	66.0	-15.4	130.0	13.0	80.0	-11.1	84.0	-11.5
			12	140.0	21.7	100.0	25.0	72.0	-7.7	130.0	13.0	90.0	0.0	86.0	-3.5
			14	120.0	4.3	80.0	0.0	66.0	-15.4	130.0	13.0	80.0	-11.1	86.0	-7.9
			16	120.0	4.3	80.0	0.0	84.0	7.7	120.0	4.3	80.0	-11.1	82.0	-3.2
			18	130.0	13.0	80.0	0.0	64.0	-17.9	130.0	13.0	80.0	0.0	82.0	-24.2
			20	130.0	13.0	80.0	0.0	90.0	15.4	140.0	21.7	90.0	0.0	88.0	-7.4
			22	120.0	4.3	80.0	0.0	78.0	0.0	130.0	13.0	80.0	-11.1	90.0	-5.3
			24	125.0	8.7	70.0	-12.5	80.0	2.6	130.0	13.0	80.0	-11.1	88.0	-7.4
			26	135.0	17.4	90.0	12.5	78.0	0.0	140.0	21.7	90.0	0.0	84.0	-11.6
			28	140.0	21.7	100.0	25.0	80.0	2.6	140.0	21.7	90.0	0.0	80.0	-15.8
			30	130.0	13.0	80.0	0.0	78.0	0.0	140.0	21.7	90.0	0.0	94.0	-1.1
			32	125.0	8.7	80.0	0.0	82.0	5.1	135.0	17.4	80.0	-11.1	96.0	1.1
			34	110.0	-4.3	70.0	-12.5	88.0	12.8	120.0	4.3	70.0	-22.2	90.0	-5.3
			36	110.0	-4.3	70.0	-12.5	74.0	-5.1	120.0	4.3	70.0	-22.2	74.0	-22.1
			38	120.0	4.3	80.0	0.0	78.0	0.0	120.0	4.3	80.0	-11.1	80.0	-15.8
			40	130.0	13.0	80.0	0.0	68.0	-12.8	120.0	4.3	80.0	-11.1	74.0	-22.1
			42	130.0	13.0	80.0	0.0	90.0	12.5	120.0	4.3	80.0	-11.1	88.0	-7.4
			44	120.0	4.3	80.0	0.0	80.0	2.6	130.0	13.0	80.0	-11.1	86.0	-9.5
			46	110.0	-4.3	70.0	-12.5	74.0	-5.1	110.0	-4.3	80.0	-11.1	80.0	-15.8
			48	120.0	4.3	80.0	0.0	76.0	-2.6	120.0	4.3	80.0	-11.1	86.0	-9.5
50	120.0	4.3	80.0	0.0	82.0	5.1	130.0	13.0	80.0	-11.1	90.0	-5.3			
52	125.0	8.7	80.0	0.0	74.0	-5.1	135.0	17.4	90.0	0.0	88.0	-7.4			
99	EFC	-1	120.0	8.3	80.0	0.0	84.0	0.0	120.0	12.5	80.0	0.0	84.0	0.0	
		0	130.0	8.3	90.0	12.5	76.0	-9.5	135.0	12.5	90.0	12.5	85.0	1.2	
		1	130.0	8.3	80.0	0.0	74.0	-11.9	130.0	8.3	90.0	12.5	80.0	-4.8	
		2	130.0	8.3	90.0	12.5	76.0	-9.5	135.0	12.5	90.0	12.5	80.0	-4.8	
		3	130.0	8.3	90.0	12.5	80.0	-4.8	125.0	4.2	90.0	12.5	86.0	2.4	
		4	130.0	8.3	90.0	12.5	76.0	-9.5	135.0	12.5	90.0	12.5	82.0	-2.4	
		5	130.0	8.3	85.0	6.3	90.0	7.1	110.0	-8.3	70.0	-12.5	120.0	42.9	
		6	120.0	0.0	80.0	0.0	88.0	4.8	110.0	-8.3	70.0	-12.5	100.0	19.0	
		8	120.0	0.0	80.0	0.0	86.0	2.4	120.0	0.0	80.0	0.0	90.0	7.1	
		10	130.0	8.3	90.0	12.5	84.0	0.0	120.0	0.0	80.0	0.0	96.0	14.3	
12	130.0	8.3	80.0	0.0	92.0	9.5	120.0	0.0	80.0	0.0	104.0	23.8			
100	EG	-1	110.0	0.0	90.0	0.0	84.0	0.0	120.0	0.0	90.0	0.0	86.0	-7.0	
		0	110.0	0.0	90.0	0.0	82.0	-2.4	120.0	0.0	90.0	0.0	76.0	-11.6	
		1	110.0	0.0	90.0	0.0	80.0	-4.8	110.0	-8.3	90.0	0.0	78.0	-9.3	
2	110.0	0.0	90.0	0.0	80.0	-4.8	110.0	-8.3	90.0	0.0	76.0	-9.3			
3	110.0	0.0	80.0	-11.1	80.0	-4.8	110.0	-8.3	70.0	-22.2	80.0	-7.0			

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 50 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 15.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	Initial	Visit	LIVING				STANDING								
				S.B.P. % diff	D.B.P. % diff	H.R. % diff	S.B.P. % diff	D.B.P. % diff	H.R. % diff							
12	100	EG	4	110.0	0.0	93.0	10.7	130.0	8.3	100.0	11.1	100.0	16.3			
			5	115.0	4.5	68.0	-19.0	130.0	8.3	80.0	-11.1	74.0	-14.0			
			6	125.0	13.6	60.0	-19.0	130.0	8.3	110.0	22.2	74.0	-14.0			
			8	115.0	4.5	78.0	-7.1	110.0	-8.3	80.0	-11.1	76.0	-11.6			
			10	120.0	9.1	100.0	19.0	130.0	8.3	110.0	22.2	104.0	20.9			
			12	140.0	27.3	100.0	11.1	130.0	8.3	80.0	-11.1	66.0	-23.3			
			14	130.0	18.2	80.0	0.0	140.0	16.7	110.0	22.2	96.0	2.3			
			16	120.0	9.1	78.0	-7.1	125.0	4.2	80.0	-11.1	88.0	2.3			
			18	115.0	4.5	74.0	-11.2	120.0	0.0	80.0	-11.1	80.0	-7.0			
			20	120.0	9.1	82.0	-9.5	130.0	8.3	90.0	0.0	90.0	4.7			
			22	120.0	9.1	88.0	-2.4	130.0	8.3	90.0	0.0	90.0	0.0			
			24	120.0	9.1	88.0	0.0	140.0	16.7	90.0	0.0	100.0	16.3			
			26	140.0	27.3	95.0	13.1	140.0	16.7	80.0	0.0	90.0	4.7			
			28	150.0	36.4	86.0	2.4	140.0	16.7	80.0	-11.1	94.0	9.3			
			102	LK		-1	140.0	0.0	90.0	0.0	140.0	0.0	100.0	0.0	100.0	-2.0
						0	140.0	0.0	90.0	0.0	140.0	0.0	100.0	0.0	98.0	-2.0
						1	130.0	-7.1	80.0	0.0	110.0	-21.4	80.0	-20.0	98.0	-2.0
						2	130.0	-7.1	90.0	0.0	140.0	0.0	90.0	-10.0	96.0	-4.0
						3	130.0	-7.1	85.0	-2.2	140.0	0.0	75.0	-25.0	100.0	0.0
						4	140.0	0.0	96.0	6.7	135.0	-3.6	90.0	-10.0	100.0	0.0
						5	135.0	-3.6	85.0	-2.2	145.0	3.6	90.0	-10.0	94.0	-6.0
						6	125.0	-10.7	85.0	-15.0	140.0	0.0	90.0	-5.0	100.0	0.0
						8	150.0	7.1	100.0	0.0	140.0	0.0	100.0	0.0	100.0	0.0
						10	125.0	-10.7	75.0	-20.0	140.0	0.0	90.0	-10.0	80.0	-20.0
						12	130.0	-7.1	80.0	-2.2	140.0	0.0	90.0	-10.0	94.0	-6.0
						14	120.0	-14.3	80.0	-2.2	140.0	0.0	80.0	-20.0	100.0	0.0
						16	130.0	-7.1	80.0	-10.0	145.0	3.6	95.0	-5.0	94.0	-6.0
						18	120.0	-14.3	80.0	-10.0	140.0	-14.3	80.0	-20.0	88.0	-12.0
20	110.0	-21.4				80.0	-10.0	130.0	-7.1	70.0	-30.0	88.0	-12.0			
22	160.0	0.0				92.0	2.2	150.0	7.1	95.0	-5.0	98.0	-2.0			
24	160.0	14.3				101.0	12.2	130.0	-7.1	90.0	-10.0	98.0	-2.0			
26	130.0	-7.1				90.0	-10.0	140.0	0.0	95.0	-5.0	98.0	-2.0			
28	130.0	-7.1				100.0	0.0	140.0	0.0	100.0	0.0	96.0	-4.0			
104	GB					-1	140.0	0.0	88.0	0.0	130.0	0.0	100.0	-10.0	88.0	0.0
						0	140.0	0.0	88.0	0.0	130.0	0.0	100.0	0.0	80.0	0.0
						1	150.0	7.1	80.0	-9.1	150.0	16.4	100.0	0.0	80.0	-9.1
						2	150.0	7.1	88.0	0.0	120.0	-7.7	90.0	-10.0	80.0	-9.1
						3	130.0	-7.1	96.0	9.1	140.0	7.7	90.0	-10.0	96.0	9.1

24113

** S.B.P. values \Rightarrow 160 mm Hg
D.B.P. values \Rightarrow 100 mm Hg
H.R. values \Rightarrow 100 beats/min
* S.B.P. values \leq 100 mm Hg
D.B.P. values \leq 70 mm Hg
H.R. values \leq 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: REBOXETINE

Centre	Patient	Initial	Visit	LYING				STANDING							
				S.B.P.	% diff	D.B.P.	% diff	S.B.P.	% diff	D.B.P.	% diff				
12	104	GB	4	140.0	0.0	100.0	0.0	100.0	13.6	140.0	7.7	100.0	0.0	88.0	0.0
			5	140.0	0.0	90.0	-10.0	72.0	-18.2	125.0	-3.8	80.0	-20.0	80.0	-9.1
			6	150.0	7.1	90.0	-10.0	100.0	13.6	160.0	23.1	90.0	-10.0	100.0	13.6
			8	160.0	14.3	100.0	0.0	100.0	13.6	150.0	15.4	100.0	0.0	96.0	9.1
			10	150.0	7.1	100.0	0.0	100.0	13.6	150.0	15.4	100.0	0.0	88.0	0.0
			12	170.0	21.4	110.0	10.0	100.0	13.6	170.0	30.8	110.0	10.0	100.0	13.6
			14	140.0	0.0	100.0	0.0	100.0	13.6	130.0	0.0	100.0	0.0	100.0	13.6
			16	120.0	-14.3	90.0	-10.0	96.0	9.1	110.0	-15.4	90.0	-10.0	110.0	25.0
			18	120.0	-14.3	80.0	-20.0	80.0	-9.1	120.0	7.7	80.0	-20.0	80.0	-9.1
			20	140.0	0.0	100.0	0.0	84.0	-4.5	130.0	0.0	100.0	0.0	88.0	0.0
			22	130.0	-7.1	90.0	-10.0	84.0	-4.5	140.0	7.7	100.0	0.0	88.0	0.0
			24	130.0	-7.1	80.0	-20.0	84.0	-4.5	140.0	7.7	100.0	0.0	88.0	0.0
26	150.0	7.1	90.0	-10.0	96.0	9.1	160.0	23.1	90.0	-10.0	100.0	13.6			
105	FN		-1	110.0	0.0	70.0	0.0	96.0	120.0	8.3	80.0	0.0	108.0	3.7	
			0	110.0	0.0	80.0	14.3	100.0	4.2	130.0	8.3	80.0	0.0	120.0	14.8
			1	120.0	9.1	70.0	0.0	100.0	-16.7	130.0	8.3	80.0	0.0	92.0	-9.3
			2	110.0	0.0	80.0	14.3	100.0	4.2	120.0	0.0	80.0	0.0	98.0	-3.3
			3	130.0	18.2	90.0	28.6	74.0	-22.9	130.0	8.3	80.0	0.0	72.0	-22.2
			4	130.0	18.2	70.0	0.0	80.0	-16.7	130.0	8.3	80.0	0.0	84.0	-22.2
			5	130.0	18.2	70.0	0.0	88.0	-8.3	120.0	0.0	80.0	0.0	92.0	-14.8
			6	140.0	27.3	90.0	28.6	96.0	0.0	120.0	0.0	80.0	0.0	108.0	0.0
			8	110.0	0.0	70.0	0.0	96.0	2.1	110.0	-8.3	90.0	-12.5	120.0	11.1
			10	120.0	9.1	90.0	28.6	88.0	-8.3	115.0	-8.3	80.0	-12.5	94.0	-13.0
			12	120.0	9.1	80.0	14.3	76.0	-20.8	115.0	-4.2	80.0	0.0	92.0	-14.8
			14	110.0	0.0	80.0	14.3	98.0	2.1	100.0	-16.7	60.0	-25.0	120.0	11.1
16	110.0	0.0	70.0	0.0	88.0	-8.3	110.0	-8.3	70.0	-12.5	94.0	-13.0			
18	120.0	9.1	70.0	0.0	84.0	-12.5	120.0	0.0	75.0	-6.3	88.0	-18.5			
20	110.0	0.0	70.0	0.0	90.0	-6.3	100.0	-16.7	70.0	-12.5	88.0	-18.5			
22	120.0	9.1	80.0	14.3	84.0	-12.5	110.0	-8.3	80.0	0.0	104.0	-3.7			
24	120.0	9.1	70.0	0.0	84.0	-12.5	110.0	-8.3	70.0	-12.5	92.0	-14.8			
26	110.0	0.0	70.0	0.0	82.0	-14.6	120.0	0.0	70.0	-12.5	96.0	-11.1			
110	FL		-1	120.0	0.0	80.0	0.0	82.0	125.0	4.0	90.0	0.0	94.0	-6.4	
			0	120.0	0.0	80.0	0.0	90.0	9.8	130.0	4.0	80.0	0.0	88.0	-2.1
			1	120.0	0.0	80.0	0.0	80.0	-2.4	120.0	-4.0	80.0	-11.1	92.0	-2.1
			2	120.0	0.0	80.0	0.0	92.0	12.2	110.0	-12.0	80.0	-11.1	90.0	-4.3
			3	110.0	-8.3	70.0	-12.5	72.0	-12.2	110.0	-12.0	80.0	-11.1	98.0	4.3
			4	120.0	0.0	80.0	0.0	86.0	4.3	120.0	-4.0	80.0	-11.1	100.0	6.4
5	120.0	0.0	80.0	0.0	78.0	-4.3	120.0	-4.0	80.0	-11.1	88.0	-6.4			

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 mm Hg
 H.R. values <= 50 beats/min

2414

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXYETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: REBOXYETINE

Centre	Patient	Initial	Visit	LYING				STANDING												
				S.B.P.	% diff	H.R.	% diff	S.B.P.	% diff	H.R.	% diff									
12	FL		6	120.0	0.0	100.0	22.0	**	110.0	-12.0	70.0	-22.2	*	92.0	-2.1					
			8	120.0	0.0	82.0	0.0	82.0	4.0		90.0	0.0	90.0	0.0	94.0	0.0				
			10	130.0	8.3	80.0	12.5	80.0	4.0		130.0	4.0	90.0	0.0	90.0	-4.3				
			12	140.0	16.7	80.0	12.5	88.0	7.3		130.0	4.0	90.0	0.0	90.0	-4.3				
			14	110.0	-8.3	80.0	0.0	88.0	7.3		120.0	-4.0	90.0	0.0	100.0	6.4				
			16	130.0	8.3	80.0	0.0	84.0	2.4		123.0	0.0	70.0	-22.2	*	88.0	-6.4			
			18	100.0	-16.7	70.0	-12.5	92.0	12.2		100.0	-20.0	70.0	-22.2	*	86.0	-8.5			
			20	120.0	0.0	80.0	0.0	94.0	14.6		150.0	4.0	70.0	-11.1		93.0	-1.1			
			114	FS		-1	110.0	18.2	60.0	100.0		100.0	0.0	60.0			105.0	6.7		
						0	130.0	36.4	90.0	50.0	84.0	-16.0		100.0	0.0	90.0	50.0	112.0	3.8	
						1	150.0	54.5	90.0	50.0	84.0	-16.0		140.0	40.0	80.0	33.3	101.0	14.3	
						2	170.0	72.7	120.0	100.0	**	110.0	10.0	150.0	50.0	110.0	83.3	**	120.0	14.3
						3	160.0	27.3	90.0	50.0	82.0	-18.0		120.0	20.0	85.0	41.7	90.0	-14.3	
						4	160.0	27.3	90.0	50.0	80.0	-20.0		120.0	20.0	85.0	41.7	82.0	-21.9	
						5	120.0	9.1	80.0	33.3	90.0	-10.0		120.0	20.0	75.0	25.0	94.0	-10.5	
						6	130.0	18.2	90.0	50.0	80.0	-20.0		140.0	40.0	90.0	50.0	84.0	-20.0	
						8	130.0	18.2	90.0	50.0	78.0	-22.0		140.0	40.0	90.0	50.0	96.0	-8.6	
						10	120.0	9.1	80.0	33.3	82.0	-18.0		120.0	20.0	80.0	33.3	88.0	-10.5	
						12	130.0	18.2	90.0	50.0	84.0	-16.0		120.0	20.0	80.0	33.3	88.0	-16.2	
						14	130.0	18.2	90.0	50.0	78.0	-22.0		140.0	40.0	90.0	50.0	82.0	-21.9	
16	140.0	27.3				90.0	50.0	82.0	-18.0		130.0	30.0	80.0	33.3	88.0	-16.2				
18	130.0	18.2				90.0	50.0	74.0	-26.0		140.0	40.0	90.0	50.0	82.0	-21.9				
20	140.0	27.3				90.0	50.0	88.0	-12.0		140.0	40.0	90.0	50.0	82.0	-21.9				
22	180.0	63.6				130.0	116.7	**	80.0	-20.0	140.0	40.0	100.0	50.0	100.0	-4.8				
24	140.0	27.3				100.0	66.7	**	92.0	-8.0	130.0	30.0	90.0	50.0	96.0	-8.6				
26	130.0	18.2				100.0	66.7	**	84.0	-18.0	140.0	40.0	100.0	50.0	96.0	-8.6				
28	130.0	18.2				90.0	50.0	82.0	-16.0		140.0	40.0	100.0	50.0	96.0	-8.6				
30	130.0	18.2				90.0	50.0	76.0	-24.0		140.0	40.0	100.0	50.0	96.0	-8.6				
32	130.0	18.2	90.0	50.0	72.0	-28.0		140.0	40.0	100.0	50.0	96.0	-8.6							
34	170.0	54.5	110.0	83.3	**	96.0	-4.0	150.0	50.0	95.0	58.3	84.0	-20.0							
36	150.0	36.4	100.0	66.7	**	84.0	-16.0	150.0	50.0	100.0	66.7	**	86.0	-18.1						
38	140.0	27.3	100.0	66.7	**	86.0	-14.0	150.0	50.0	100.0	66.7	**	86.0	-18.1						
40	150.0	36.4	100.0	66.7	**	82.0	-18.0	150.0	50.0	100.0	66.7	**	86.0	-18.1						
42	130.0	18.2	90.0	50.0	72.0	-28.0		150.0	50.0	100.0	66.7	**	86.0	-18.1						
44	140.0	27.3	90.0	50.0	68.0	-32.0		150.0	50.0	100.0	66.7	**	86.0	-18.1						
46	150.0	36.4	90.0	50.0	68.0	-32.0		150.0	50.0	100.0	66.7	**	86.0	-18.1						
48	140.0	27.3	90.0	50.0	68.0	-32.0		150.0	50.0	100.0	66.7	**	86.0	-18.1						
50	140.0	27.3	85.0	41.7	**	78.0	-22.0	155.0	55.0	100.0	66.7	**	102.0	-2.9						
52	150.0	36.4	100.0	66.7	**	50.0	-20.0	160.0	60.0	100.0	66.7	**	82.0	-21.9						

** S.B.P. values => 160 mm Hg
D.B.P. values => 100 mm Hg
H.R. values => 100 beats/min
* S.B.P. values <= 100 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013

Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE-BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	Initial	Visit	LYING			STANDING									
				D.B.P. % diff	H.R. % diff	S.B.P. % diff	D.B.P. % diff	H.R. % diff	S.B.P. % diff							
12	115	VCS	-1	110.0	-9.1	80.0	80.0	110.0	0.0	88.0	0.0	88.0				
			0	100.0	-12.5	70.0	88.0	10.0	110.0	0.0	94.0	0.0	94.0			
			1	100.0	-9.1	70.0	88.0	10.0	110.0	0.0	100.0	-12.5	100.0			
			2	100.0	-9.1	70.0	110.0	37.5	110.0	0.0	110.0	-12.5	110.0			
			3	110.0	0.0	80.0	90.0	12.5	110.0	0.0	80.0	0.0	92.0			
			4	100.0	-9.1	70.0	88.0	10.0	110.0	0.0	80.0	-12.5	94.0			
			5	100.0	-9.1	70.0	95.0	18.8	120.0	0.0	80.0	0.0	100.0			
			6	120.0	9.1	60.0	104.0	30.0	110.0	0.0	70.0	-12.5	100.0			
			8	110.0	0.0	70.0	100.0	25.0	110.0	0.0	70.0	-12.5	100.0			
			10	100.0	-9.1	70.0	88.0	10.0	100.0	0.0	70.0	-12.5	92.0			
			12	100.0	-9.1	60.0	88.0	10.0	100.0	-9.1	70.0	-12.5	90.0			
			14	120.0	0.0	80.0	90.0	12.5	120.0	9.1	80.0	0.0	100.0			
			16	110.0	0.0	70.0	92.0	15.0	110.0	0.0	80.0	0.0	100.0			
			18	120.0	9.1	70.0	88.0	10.0	120.0	9.1	80.0	0.0	90.0			
			20	100.0	-9.1	60.0	80.0	0.0	100.0	-9.1	70.0	-12.5	88.0			
			22	120.0	9.1	80.0	84.0	5.0	110.0	0.0	80.0	0.0	88.0			
			24	110.0	0.0	70.0	74.0	7.5	120.0	9.1	80.0	0.0	80.0			
			26	120.0	9.1	80.0	108.0	35.0	120.0	9.1	80.0	0.0	110.0			
			28	120.0	9.1	80.0	76.0	-5.0	120.0	9.1	80.0	0.0	82.0			
			30	120.0	9.1	80.0	102.0	27.5	120.0	9.1	80.0	0.0	106.0			
			32	130.0	18.2	80.0	92.0	15.0	130.0	18.2	90.0	12.5	102.0			
			34	130.0	18.2	90.0	100.0	25.0	120.0	9.1	90.0	12.5	120.0			
			2	147	AK	-1	120.0	-8.3	80.0	88.0	120.0	0.0	96.0	0.0	96.0	
						0	110.0	0.0	80.0	80.0	-9.1	120.0	0.0	88.0	0.0	88.0
						1	130.0	8.3	80.0	92.0	4.5	130.0	8.3	90.0	12.5	96.0
						2	110.0	-8.3	70.0	84.0	-4.5	110.0	-8.3	70.0	-12.5	92.0
						3	100.0	-16.7	60.0	76.0	-13.6	110.0	-8.3	70.0	-12.5	82.0
						4	120.0	0.0	80.0	100.0	13.6	120.0	0.0	80.0	0.0	100.0
						5	120.0	0.0	80.0	98.0	11.4	120.0	0.0	80.0	0.0	100.0
						6	110.0	-8.3	80.0	88.0	0.0	120.0	0.0	70.0	-12.5	96.0
						8	110.0	16.7	80.0	84.0	-4.5	130.0	0.0	80.0	0.0	100.0
						10	140.0	16.7	80.0	82.0	-6.8	130.0	8.3	80.0	0.0	94.0
			14	146	G	12	125.0	0.0	70.0	88.0	0.0	125.0	4.2	90.0	12.5	90.0
						14	110.0	-8.3	70.0	82.0	-6.8	130.0	0.0	80.0	0.0	92.0
16	110.0	-8.3				70.0	84.0	-4.5	120.0	0.0	80.0	0.0	88.0			
18	110.0	0.0				70.0	74.0	-15.9	120.0	0.0	80.0	0.0	78.0			
20	120.0	0.0				80.0	88.0	0.0	110.0	-8.3	70.0	-12.5	84.0			
22	110.0	-8.3				80.0	88.0	-22.7	120.0	0.0	80.0	0.0	76.0			
24	110.0	-8.3	80.0	80.0	-9.1	120.0	0.0	80.0	0.0	82.0						

** S.B.P. values => 160 mm Hg
D.B.P. values => 100 mm Hg
H.R. values => 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	Initial	Visit	LYING				STANDING								
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff			
12	117	AK	26	140.0	16.7	80.0	0.0	88.0	0.0	140.0	16.7	90.0	12.5	92.0	-4.2	
			28	120.0	0.0	80.0	0.0	80.0	-9.1	125.0	4.2	80.0	0.0	94.0	-2.1	
			30	130.0	8.3	80.0	0.0	82.0	-6.8	140.0	16.7	90.0	12.5	96.0	0.0	
			32	115.0	-4.2	80.0	0.0	80.0	-9.1	120.0	0.0	85.0	6.3	92.0	-4.2	
			34	110.0	-8.3	70.0	-12.5	96.0	9.1	120.0	0.0	95.0	18.8	96.0	0.0	
			36	120.0	0.0	80.0	0.0	82.0	-6.8	125.0	4.2	85.0	6.3	90.0	-6.3	
			38	120.0	0.0	80.0	0.0	92.0	4.5	130.0	8.3	90.0	12.5	100.0	4.2	
			40	120.0	0.0	80.0	0.0	84.0	-4.5	130.0	8.3	80.0	0.0	92.0	-4.2	
			42	120.0	0.0	80.0	0.0	70.0	-20.5	140.0	16.7	80.0	0.0	72.0	-25.0	
			44	120.0	0.0	80.0	0.0	74.0	-15.9	130.0	8.3	80.0	0.0	78.0	-18.8	
			46	120.0	0.0	70.0	-12.5	68.0	-22.7	130.0	8.3	80.0	0.0	78.0	-18.8	
			48	120.0	0.0	80.0	0.0	86.0	-2.3	100.0	-16.7	70.0	-12.5	100.0	4.2	
50	120.0	0.0	70.0	-12.5	64.0	-27.3	130.0	8.3	80.0	0.0	78.0	-18.8				
52	120.0	0.0	80.0	0.0	80.0	0.0	140.0	16.7	80.0	0.0	94.0	-2.1				
385	FB		-1	130.0	7.7	80.0	0.0	78.0	0.0	130.0	0.0	80.0	0.0	92.0	-2.2	
			1	140.0	0.0	80.0	0.0	84.0	7.7	140.0	0.0	80.0	0.0	90.0	0.0	
			2	130.0	0.0	80.0	0.0	90.0	15.4	140.0	7.7	80.0	0.0	98.0	6.5	
			3	120.0	-7.7	80.0	0.0	92.0	17.9	120.0	-7.7	80.0	0.0	86.0	-6.5	
			4	120.0	-7.7	80.0	0.0	80.0	2.6	130.0	0.0	80.0	0.0	94.0	2.2	
			5	140.0	7.7	80.0	0.0	86.0	10.3	130.0	0.0	90.0	12.5	92.0	0.0	
			6	120.0	-7.7	80.0	0.0	92.0	17.9	140.0	7.7	90.0	12.5	90.0	-2.2	
			8	130.0	0.0	80.0	0.0	90.0	15.4	120.0	-7.7	80.0	0.0	87.0	-5.4	
			10	110.0	-15.4	80.0	0.0	100.0	28.2	130.0	0.0	100.0	25.0	104.0	13.0	
			12	125.0	-3.8	80.0	0.0	86.0	10.3	120.0	-7.7	80.0	0.0	92.0	0.0	
						12	125.0	-3.8	90.0	12.5	102.0	30.8	80.0	0.0	100.0	8.7
			388	IN		-1	180.0	-22.2	110.0	-18.2	68.0	0.0	160.0	-12.5	110.0	-18.2
1	140.0	-22.2				80.0	-27.3	87.0	27.9	140.0	-12.5	80.0	-27.3	85.0	31.3	
2	140.0	-22.2				80.0	-27.3	64.0	-5.9	140.0	-12.5	80.0	-27.3	84.0	31.3	
3	149.0	-17.2				90.0	-18.2	80.0	17.6	150.0	-6.3	100.0	-9.1	84.0	31.3	
4	130.0	-33.3				80.0	-27.3	84.0	23.5	140.0	-12.5	100.0	-9.1	76.0	18.8	
5	140.0	-27.8				80.0	-27.3	82.0	20.6	120.0	-25.0	80.0	-27.3	78.0	21.9	
6	140.0	-22.2				90.0	-18.2	80.0	17.6	150.0	-6.3	90.0	-18.2	88.0	37.5	
8	130.0	-27.8				80.0	-18.2	76.0	11.8	130.0	-18.8	80.0	-27.3	100.0	56.3	
10	120.0	-33.3				80.0	-18.2	88.0	29.4	130.0	-18.8	80.0	-27.3	80.0	25.0	
12	120.0	-33.3				80.0	-27.3	81.0	19.1	130.0	-18.8	90.0	-18.2	85.0	32.8	
14	120.0	-33.3				80.0	-27.3	80.0	17.6	120.0	-25.0	80.0	-18.2	78.0	21.9	
16	130.0	-33.3				80.0	-27.3	85.0	25.0	120.0	-25.0	80.0	-18.2	85.0	32.8	
			100.0	-9.1	85.0	25.0	130.0	-6.3	90.0	-18.2	85.0	29.7				

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 50 mm Hg
H.R. values <= 50 beats/min

2417

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	Initial	Visit	LIVING			STANDING								
				S.B.P. z diff	D.B.P. z diff	H.R. z diff	S.B.P. z diff	D.B.P. z diff	H.R. z diff						
12	388	LN	18	130.0	-27.8	90.0	-18.2	83.0	22.1	130.0	-18.8	95.0	-13.6	85.0	32.8
			20	120.0	-33.3	80.0	-27.3	80.0	17.6	125.0	-21.9	90.0	-18.2	85.0	32.8
			-1	115.0		80.0		80.0		120.0		90.0			
			0	120.0	4.3	70.0	-12.5	99.0	23.7	110.0	-8.3	80.0	-22.2	85.0	18.8
			1	115.0	0.0	70.0	-12.5	88.0	10.0	110.0	-8.3	80.0	-11.1	100.0	17.6
			2	110.0	-4.3	80.0	0.0	90.0	12.5	100.0	-16.7	70.0	-22.2	110.0	29.4
			3	115.0	0.0	70.0	-12.5	102.0	27.5	100.0	-16.7	65.0	-27.8	120.0	41.2
			4	130.0	13.0	90.0	-12.5	100.0	25.0	120.0	0.0	50.0	-11.1	128.0	50.6
			5	110.0	-4.3	70.0	-12.5	103.0	28.7	105.0	-12.5	70.0	-22.2	140.0	29.4
			6	110.0	-4.3	70.0	-12.5	72.0	-10.0	110.0	-8.3	75.0	-22.2	100.0	17.6
13	219	P2	8	100.0	-13.0	75.0	-6.3	78.0	-2.5	95.0	-8.3	70.0	-16.7	92.0	8.2
			10	100.0	-13.0	70.0	-12.5	100.0	25.0	100.0	0.0	80.0	-22.2	95.0	11.8
			12	120.0	4.3	70.0	-12.5	120.0	50.0	120.0	0.0	80.0	-11.1	130.0	52.9
			14	115.0	0.0	70.0	-12.5	110.0	37.5	115.0	-4.2	80.0	-11.1	120.0	41.2
			16	115.0	0.0	70.0	-12.5	88.0	10.0	90.0	-25.0	60.0	-33.3	126.0	48.2
			18	110.0	-4.3	70.0	-12.5	120.0	50.0	115.0	-4.2	80.0	-11.1	130.0	52.9
			20	110.0	-4.3	70.0	-12.5	120.0	50.0	110.0	-16.7	70.0	-22.2	132.0	55.3
			22	120.0	4.3	80.0	0.0	120.0	50.0	110.0	-8.3	70.0	-22.2	125.0	47.1
			24	115.0	0.0	70.0	-12.5	104.0	30.0	110.0	-8.3	60.0	-33.3	120.0	41.2
			26	115.0	0.0	70.0	-12.5	85.0	6.3	100.0	-16.7	80.0	-11.1	90.0	5.9
220	BL	BL	-1	110.0		70.0		80.0	0.0	100.0	-16.7	70.0	-22.2	85.0	0.0
			0	130.0	18.2	90.0	-12.5	96.0	20.0	115.0	-4.2	70.0	-22.2	108.0	27.1
			1	110.0	0.0	80.0	-12.5	80.0	0.0	115.0	-4.2	70.0	-22.2	100.0	17.6
			2	115.0	4.5	70.0	-12.5	76.0	-5.0	90.0	-25.0	80.0	-22.2	107.0	25.9
			3	120.0	9.1	80.0	-12.5	85.0	6.3	120.0	0.0	80.0	-22.2	105.0	23.5
			4	110.0	-4.3	60.0	-25.0	84.0	5.0	115.0	-4.2	70.0	-22.2	112.0	31.8
			6	100.0	-13.0	60.0	-25.0	82.0	2.5	100.0	-16.7	60.0	-33.3	110.0	29.4
			8	100.0	-13.0	60.0	-25.0	80.0	0.0	100.0	-16.7	60.0	-33.3	110.0	29.4
			10	100.0	-13.0	70.0	-12.5	70.0	-12.5	100.0	-16.7	60.0	-33.3	68.0	-20.0
			12	110.0	-4.3	80.0	0.0	80.0	0.0	100.0	-16.7	70.0	-22.2	75.0	-11.8
14	110.0	-4.3	80.0	0.0	80.0	0.0	100.0	-16.7	70.0	-22.2	98.0	15.3			
16	120.0	4.3	60.0	-25.0	84.0	5.0	110.0	-8.3	60.0	-33.3	85.0	0.0			
18	100.0	-13.0	60.0	-25.0	80.0	0.0	100.0	-8.3	60.0	-33.3	92.0	8.2			
20	100.0	-13.0	60.0	-25.0	80.0	0.0	100.0	-16.7	70.0	-22.2	90.0	5.9			

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 100 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

2418

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
 REXOXYLINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: REXOXYLINE

Centre	Patient	Initial	Visit	LYING			STANDING										
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	H.R.	% diff						
13	220	BL	4	130.0	18.2	90.0	-2.2	140.0	16.7	100.0	25.0	**	100.0	0.0			
			5	120.0	9.1	90.0	-2.2	110.0	-8.3	80.0	0.0	80.0	0.0	95.0	-5.0		
			6	120.0	9.1	80.0	14.3	110.0	8.7	90.0	0.0	90.0	12.5	105.0	5.0		
			8	115.0	4.5	80.0	14.3	96.0	4.3	110.0	-8.3	80.0	0.0	104.0	4.0		
			10	115.0	4.5	80.0	14.3	92.0	0.0	120.0	0.0	80.0	0.0	110.0	10.0		
			12	120.0	9.1	70.0	0.0	76.0	-17.4	115.0	-4.2	70.0	-12.5	92.0	-8.0		
			14	115.0	4.5	80.0	14.3	94.0	2.2	120.0	0.0	80.0	0.0	108.0	8.0		
			16	120.0	9.1	80.0	14.3	78.0	-15.2	115.0	-4.2	80.0	0.0	96.0	-4.0		
			18	120.0	9.1	70.0	0.0	92.0	0.0	115.0	-4.2	70.0	-12.5	104.0	4.0		
			20	120.0	9.1	80.0	14.3	76.0	-17.4	115.0	-4.2	70.0	-12.5	106.0	6.0		
			22	120.0	9.1	70.0	0.0	92.0	0.0	110.0	0.0	80.0	0.0	100.0	0.0		
			24	115.0	4.5	80.0	14.3	76.0	-17.4	110.0	0.0	80.0	0.0	85.0	-15.0		
			26	130.0	18.2	90.0	28.6	80.0	-13.0	120.0	0.0	75.0	-6.3	100.0	0.0		
			28	120.0	9.1	80.0	14.3	84.0	-8.7	115.0	-4.2	90.0	12.5	84.0	-16.0		
			30	135.0	22.7	85.0	21.4	68.0	-26.1	120.0	0.0	90.0	12.5	92.0	-8.0		
			32	120.0	9.1	80.0	14.3	72.0	-21.7	120.0	0.0	90.0	12.5	104.0	4.0		
			34	120.0	9.1	80.0	14.3	88.0	0.0	130.0	8.3	90.0	12.5	104.0	4.0		
			36	120.0	9.1	70.0	0.0	78.0	-15.2	123.0	4.2	85.0	6.3	96.0	-4.0		
			38	110.0	0.0	80.0	14.3	90.0	-2.2	120.0	0.0	100.0	25.0	100.0	0.0		
			40	120.0	9.1	70.0	0.0	76.0	-17.4	120.0	0.0	70.0	-12.5	84.0	-16.0		
			42	120.0	9.1	80.0	14.3	90.0	-2.2	120.0	0.0	70.0	-12.5	104.0	4.0		
			44	110.0	0.0	70.0	0.0	96.0	4.3	110.0	-8.3	60.0	-25.0	108.0	8.0		
			46	120.0	9.1	80.0	14.3	90.0	-2.2	110.0	-8.3	70.0	-12.5	100.0	0.0		
			48	110.0	0.0	80.0	14.3	90.0	-2.2	120.0	0.0	80.0	0.0	98.0	-2.0		
			50	110.0	0.0	70.0	0.0	86.0	-6.5	110.0	-8.3	80.0	0.0	98.0	-2.0		
			52	120.0	9.1	80.0	14.3	80.0	-13.0	120.0	0.0	80.0	0.0	72.0	-28.0		
			221	AL	-1	125.0		80.0		120.0		75.0				88.0	
					0	120.0	-4.0	80.0	0.0	115.0	-4.2	70.0	-6.7	82.0	-6.8	101.0	14.8
					1	100.0	-20.0	70.0	-12.5	110.0	7.5	70.0	-8.3	70.0	-6.7	98.0	11.4
					2	100.0	-20.0	70.0	-12.5	92.0	15.0	100.0	-16.7	70.0	-6.7	102.0	15.9
					3	110.0	-12.0	70.0	-12.5	104.0	30.0	110.0	-8.3	70.0	-6.7	102.0	15.9
					4	120.0	-4.0	80.0	0.0	104.0	30.0	110.0	-8.3	70.0	-6.7	102.0	15.9
					5	110.0	-12.0	70.0	-12.5	103.0	28.7	100.0	-16.7	70.0	-6.7	105.0	19.3
					6	105.0	-20.0	70.0	-12.5	70.0	-12.5	100.0	-16.7	70.0	-6.7	104.0	18.2
					8	115.0	-8.0	80.0	0.0	74.0	-7.5	110.0	-16.7	80.0	6.7	80.0	-9.1
					10	115.0	-8.0	70.0	-12.5	120.0	50.0	105.0	-12.5	70.0	-6.7	124.0	60.9
					12	110.0	-12.0	80.0	0.0	100.0	25.0	105.0	-12.5	70.0	-6.7	120.0	36.4
					14	100.0	-20.0	70.0	-12.5	120.0	50.0	105.0	-12.5	70.0	-6.7	148.0	68.2
					16	100.0	-20.0	70.0	-12.5	134.0	67.5	90.0	-25.0	60.0	-20.0	140.0	59.1

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

2419

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD
 REBONETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: REBONETINE

Centre	Patient	Initial	Visit	LYING			STANDING												
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	H.R.	% diff								
19	221	AI	18	115.0	-8.0	80.0	0.0	110.0	37.5 **	120.0	0.0	80.0	6.7	130.0	47.7 **				
			20	110.0	-12.0	70.0	-12.5	112.0	40.0 **	110.0	110.0	-8.3	80.0	6.7	135.0	53.4 **			
			22	120.0	-4.0	80.0	0.0	100.0	25.0 **	100.0	100.0	-16.7	70.0	-6.7	110.0	25.0 **			
			24	100.0	-20.0	90.0	12.5	120.0	50.0 **	80.0	80.0	-33.3 *	60.0	-20.0	125.0	42.0 **			
			26	115.0	-8.0	80.0	0.0	98.0	22.5	115.0	115.0	-4.2	80.0	6.7	110.0	25.0 **			
			28	110.0	-12.0	70.0	-12.5	100.0	25.0 **	100.0	100.0	-25.0 *	70.0	-6.7	110.0	25.0 **			
			30	115.0	-8.0	80.0	-25.0 *	76.0	5.0	100.0	100.0	-16.7	70.0	-6.7	100.0	13.6			
			32	110.0	-12.0	80.0	0.0	80.0	0.0	120.0	120.0	0.0	80.0	6.7	90.0	2.3			
			34	105.0	-16.0	70.0	-12.5	86.0	7.5	110.0	110.0	-8.3	70.0	-6.7	120.0	36.4 **			
			36	100.0	-20.0	80.0	0.0	100.0	50.0 **	110.0	110.0	-8.3	90.0	20.0	125.0	42.0 **			
			38	115.0	-8.0	80.0	0.0	100.0	25.0 **	115.0	115.0	-4.2	80.0	6.7	121.0	37.5 **			
			40	110.0	-12.0	70.0	-12.5	88.0	10.0	100.0	100.0	-16.7	80.0	6.7	100.0	13.6			
			42	110.0	-12.0	80.0	0.0	84.0	5.0	100.0	100.0	-16.7	70.0	-6.7	116.0	31.8 **			
			44	115.0	-8.0	80.0	0.0	100.0	25.0 **	100.0	100.0	-16.7	80.0	6.7	110.0	25.0 **			
			46	100.0	-20.0	70.0	-12.5	92.0	15.0	100.0	100.0	-16.7	70.0	-6.7	100.0	13.6			
			48	115.0	-8.0	70.0	-12.5	84.0	3.0	100.0	100.0	-16.7	60.0	-20.0	96.0	9.1			
			50	120.0	-4.0	80.0	0.0	92.0	15.0	130.0	130.0	8.3	80.0	6.7	104.0	18.2			
			52	100.0	-20.0	70.0	-12.5	94.0	17.5	90.0	90.0	-25.0 *	80.0	6.7	106.0	20.5 **			
			223	2420	RM	-1	160.0	-7.1	70.0	0.0	73.0	-15.1	120.0	16.7	70.0	14.3	74.0	-2.7	
						0	130.0	-7.1	80.0	14.3	62.0	-17.8	140.0	140.0	-16.7	80.0	14.3	72.0	8.1
						1	130.0	-14.3	80.0	14.3	60.0	-17.8	140.0	140.0	-16.7	60.0	14.3	80.0	8.1
						2	120.0	-14.3	80.0	14.3	60.0	-17.8	115.0	115.0	-4.2	80.0	14.3	75.0	1.4
						3	115.0	-17.9	80.0	14.3	80.0	9.6	100.0	100.0	-16.7	70.0	0.0	70.0	-5.4
						4	115.0	-17.9	70.0	0.0	70.0	-4.1	105.0	105.0	-12.5	70.0	0.0	80.0	8.1
						5	100.0	-28.6 *	80.0	14.3	70.0	-4.1	95.0	95.0	-20.8 *	70.0	0.0	65.0	-12.2
						6	115.0	-17.9	75.0	7.1	80.0	9.6	100.0	100.0	-16.7	80.0	14.3	90.0	21.6
						8	100.0	-28.6 *	70.0	0.0	76.0	4.1	100.0	100.0	-16.7	80.0	14.3	92.0	24.3
						10	100.0	-28.6 *	70.0	0.0	80.0	9.6	95.0	95.0	-20.8 *	70.0	0.0	85.0	14.9
						12	110.0	-21.4	70.0	0.0	80.0	9.6	100.0	100.0	-16.7	70.0	0.0	100.0	35.1 **
						14	120.0	-14.3	80.0	14.3	90.0	23.3	115.0	115.0	-4.2	70.0	0.0	100.0	35.1 **
						16	100.0	-28.6 *	60.0	-14.3	80.0	9.6	110.0	110.0	-8.3	70.0	0.0	85.0	14.9
						18	110.0	-17.9	80.0	14.3	84.0	15.1	100.0	100.0	-16.7	70.0	0.0	88.0	18.9
20	115.0	-17.9				80.0	14.3	82.0	12.3	110.0	110.0	-8.3	70.0	0.0	92.0	24.3			
22	120.0	-14.3				80.0	14.3	84.0	15.1	110.0	110.0	-8.3	80.0	14.3	100.0	35.1 **			
24	115.0	-17.9	70.0	0.0	77.0	5.5	110.0	110.0	-8.3	70.0	0.0	92.0	24.3						
26	110.0	-21.4	80.0	0.0	60.0	-17.8	90.0	90.0	-25.0 *	60.0	-14.3	75.0	1.4						
28	105.0	-25.0	70.0	-14.3	76.0	4.1	100.0	100.0	-16.7	60.0	-14.3	84.0	13.5						
30	120.0	-14.3	70.0	0.0	112.0	53.4 **	100.0	100.0	-16.7	70.0	0.0	104.0	40.5 **						
32	100.0	-28.6 *	70.0	0.0	70.0	-4.1	100.0	100.0	-16.7	70.0	0.0	80.0	8.1						

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 ROXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: ROXETINE

Centre	Patient	Initial	Visit	LYING				STANDING										
				S.B.P.	Z diff	H.R.	Z diff	D.B.P.	Z diff	S.B.P.	Z diff	H.R.	Z diff					
13	223	IH	34	115.0	-17.9	80.0	14.3	65.0	-11.0	115.0	-4.2	80.0	14.3	70.0	-5.4			
			36	115.0	-17.9	80.0	14.3	64.0	-12.3	100.0	-16.7	60.0	-14.3	84.0	13.5			
			38	115.0	-17.9	70.0	0.0	60.0	-17.8	90.0	-25.0	70.0	0.0	80.0	8.1			
			40	110.0	-21.4	70.0	0.0	76.0	4.1	100.0	-16.7	70.0	0.0	88.0	18.9			
			42	100.0	-28.6	60.0	-14.3	76.0	4.1	90.0	-25.0	70.0	0.0	84.0	13.5			
			44	115.0	-17.9	70.0	0.0	60.0	-17.8	90.0	-25.0	70.0	0.0	80.0	8.1			
			46	115.0	-17.9	70.0	0.0	60.0	-17.8	90.0	-25.0	70.0	0.0	84.0	13.5			
			48	100.0	-28.6	70.0	0.0	68.0	-6.8	90.0	-25.0	70.0	0.0	80.0	8.1			
			50	90.0	-35.7	60.0	-14.3	76.0	4.1	90.0	-25.0	70.0	0.0	84.0	13.5			
			52	100.0	-28.6	60.0	-14.3	80.0	9.6	90.0	-25.0	70.0	0.0	80.0	8.1			
			226	KE		-1	120.0	0.0	90.0	-16.7	88.0	0.0	130.0	-23.1	80.0	-12.5	97.0	7.2
						1	120.0	0.0	75.0	0.0	90.0	2.3	100.0	-23.1	70.0	-12.5	104.0	7.2
						2	120.0	0.0	80.0	-4.1	101.0	14.8	120.0	-7.7	80.0	0.0	103.0	6.2
						3	110.0	-8.3	70.0	0.0	110.0	25.0	110.0	-15.4	75.0	-6.3	120.0	23.7
						4	115.0	-4.2	80.0	-11.1	88.0	0.0	105.0	-19.2	70.0	-12.5	106.0	9.3
						5	120.0	0.0	80.0	-22.2	80.0	-9.1	115.0	-11.5	60.0	-25.0	70.0	-27.8
						6	120.0	0.0	70.0	0.0	112.0	27.3	115.0	-11.5	70.0	-12.5	118.0	21.6
8	115.0	-4.2				90.0	0.0	120.0	36.4	120.0	-7.7	90.0	-12.5	110.0	13.4			
10	120.0	0.0				70.0	-22.2	108.0	22.7	95.0	-26.9	80.0	0.0	112.0	15.5			
12	120.0	0.0				80.0	-11.1	110.0	25.0	120.0	-7.7	80.0	0.0	126.0	29.9			
14	120.0	0.0				80.0	-11.1	110.0	25.0	120.0	-7.7	80.0	0.0	120.0	23.7			
16	120.0	0.0				80.0	-11.1	100.0	13.6	100.0	-23.1	70.0	-12.5	128.0	32.0			
18	100.0	-16.7				70.0	-22.2	100.0	13.6	120.0	-7.7	80.0	0.0	105.0	8.2			
20	110.0	-8.3				70.0	-22.2	100.0	13.6	100.0	-23.1	60.0	-25.0	112.0	15.5			
22	120.0	0.0				80.0	-22.2	92.0	4.5	115.0	-11.5	70.0	-12.5	120.0	23.7			
24	120.0	0.0				80.0	-11.1	86.0	-2.3	120.0	-7.7	90.0	-12.5	126.0	29.9			
26	110.0	-8.3				70.0	-22.2	108.0	22.7	100.0	-23.1	70.0	-12.5	116.0	19.6			
28	120.0	0.0	70.0	-22.2	80.0	22.7	110.0	-15.4	60.0	-25.0	85.0	-12.4						
30	110.0	-8.3	70.0	-22.2	80.0	-9.1	110.0	-15.4	70.0	0.0	116.0	19.6						
32	120.0	0.0	70.0	-22.2	120.0	36.4	100.0	-23.1	70.0	-12.5	115.0	23.7						
34	110.0	-8.3	70.0	-22.2	120.0	36.4	110.0	-15.4	80.0	0.0	120.0	23.7						
36	110.0	-8.3	70.0	-22.2	120.0	36.4	110.0	-15.4	70.0	-12.5	115.0	18.6						
38	120.0	0.0	70.0	-22.2	100.0	13.6	110.0	-15.4	70.0	-12.5	100.0	3.1						
40	120.0	0.0	80.0	-11.1	110.0	25.0	120.0	-7.7	80.0	0.0	100.0	3.1						
42	110.0	-8.3	80.0	-11.1	96.0	9.1	100.0	-23.1	75.0	-6.3	116.0	19.6						
44	115.0	-4.2	80.0	-11.1	105.0	19.3	115.0	-11.5	80.0	0.0	110.0	13.4						
46	115.0	-4.2	70.0	-22.2	76.0	-13.6	115.0	-11.5	80.0	0.0	104.0	7.2						
48	120.0	0.0	90.0	0.0	100.0	13.6	100.0	-23.1	80.0	0.0	110.0	13.4						

** S.B.P. values => 160 mm Hg
 D.B.P. values => 100 mm Hg
 H.R. values => 100 beats/min
 * S.B.P. values <= 100 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

23 42 4

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CVS RD
 ROBOXYLINE - PROTOCOL 20124/013
 Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: ROBOXYLINE

Centre	Patient	Initial	Visit	LYING				STANDING							
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff		
13	226	RE	50	120.0	0.0	80.0	-11.1	112.0	27.3 **	110.0	-15.4	80.0	0.0	114.0	17.5
			52	120.0	0.0	80.0	-11.1	72.0	-18.2	120.0	-7.7	80.0	0.0	100.0	3.1
	227	VT	-1	120.0	0.0	80.0	0.0	66.0	-3.0	130.0	9.1	70.0	0.0	78.0	2.6
			1	90.0	-25.0 *	60.0	-25.0 *	80.0	21.2	90.0	-18.2	60.0	-14.3	80.0	28.2 **
			2	95.0	-20.8 *	70.0	-12.5	85.0	16.7	90.0	-18.2	60.0	-14.3	60.0	-23.1
			3	115.0	-4.2	80.0	0.0	65.0	11.5	110.0	0.0	80.0	-14.3	70.0	-10.3
			4	100.0	-16.7	90.0	12.5	80.0	21.2	90.0	-18.2	80.0	-14.3	80.0	2.6
			5	100.0	-16.7	70.0	-12.5	92.0	39.4	85.0	-22.7 *	70.0	0.0	112.0	43.6 **
			6	130.0	8.3	80.0	0.0	100.0	51.5 **	100.0	-9.1	80.0	14.3	102.0	30.8 **
			8	100.0	-16.7	70.0	-12.5	80.0	21.2	95.0	-13.6	70.0	0.0	106.0	28.2 **
			10	90.0	-25.0 *	60.0	-25.0 *	68.0	3.0	100.0	-9.1	70.0	0.0	70.0	-10.3
			12	115.0	-4.2	80.0	0.0	100.0	51.5 **	115.0	4.5	90.0	28.6	110.0	41.0 **
			14	110.0	-8.3	70.0	-12.5	92.0	39.4	100.0	-9.1	60.0	-14.3	112.0	43.6 **
			16	100.0	-16.7	80.0	0.0	108.0	63.6 **	100.0	-9.1	112.0	0.0	112.0	43.6 **
			18	100.0	-16.7	80.0	0.0	92.0	39.4	100.0	-9.1	112.0	0.0	112.0	43.6 **
			20	100.0	-16.7	80.0	0.0	96.0	45.5	100.0	-9.1	70.0	0.0	106.0	35.9 **
			22	120.0	0.0	90.0	12.5	80.0	21.2	115.0	4.5	70.0	0.0	85.0	9.0
			24	100.0	-16.7	80.0	0.0	92.0	36.4	95.0	-13.6	70.0	0.0	98.0	25.6
			26	100.0	-16.7	70.0	-12.5	90.0	36.4	100.0	-9.1	60.0	-14.3	70.0	0.0
			28	115.0	-4.2	70.0	-12.5	86.0	30.3	100.0	-9.1	70.0	0.0	107.0	37.2 **
			30	115.0	-4.2	70.0	-12.5	90.0	36.4	120.0	14.3	80.0	14.3	80.0	2.6
			32	90.0	-25.0 *	70.0	-12.5	95.0	43.9	100.0	-9.1	80.0	14.3	90.0	15.4
			34	90.0	-25.0 *	70.0	-12.5	95.0	43.9	100.0	-9.1	80.0	14.3	120.0	53.8 **
			36	115.0	-4.2	80.0	0.0	110.0	66.7 **	115.0	4.5	80.0	14.3	115.0	47.4 **
			38	100.0	-16.7	70.0	-12.5	72.0	9.1	90.0	-18.2	70.0	0.0	100.0	28.2 **
			40	120.0	0.0	80.0	0.0	90.0	36.4	110.0	0.0	80.0	14.3	100.0	28.2 **
			42	115.0	-4.2	70.0	-12.5	74.0	15.2	115.0	4.5	70.0	0.0	100.0	28.2 **
			44	120.0	0.0	80.0	0.0	96.0	45.5	120.0	9.1	90.0	28.6	120.0	53.8 **
			46	115.0	-4.2	80.0	0.0	80.0	21.2	120.0	9.1	80.0	14.3	98.0	15.4
			48	120.0	0.0	80.0	0.0	80.0	21.2	120.0	9.1	90.0	28.6	110.0	41.0 **
			50	120.0	0.0	80.0	0.0	84.0	27.3	100.0	-9.1	80.0	14.3	100.0	28.2 **
			52	110.0	-8.3	80.0	0.0	90.0	36.4	100.0	-9.1	80.0	14.3	100.0	28.2 **
	230	NL	-1	140.0	0.0	90.0	88.0	88.0	120.0	0.0	90.0	0.0	100.0	0.0	
			0	140.0	0.0	90.0	0.0	88.0	0.0	120.0	0.0	90.0	-11.1	100.0	0.0
			1	115.0	-17.9	80.0	-11.1	88.0	8.0	120.0	0.0	90.0	0.0	110.0	10.0

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 100 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

2422

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centres	Patient	Initial	Visit	LYING			STANDING										
				S.B.P.	H.R.	D.B.P.	S.B.P.	H.R.	D.B.P.								
13	230	NL	4	115.0	-17.9	70.0	-22.2	80.0	-9.1	110.0	-8.3	80.0	-11.1	100.0	0.0		
			5	110.0	-21.4	70.0	-22.2	84.0	-4.5	110.0	-4.5	120.0	-8.3	70.0	-22.2	92.0	-8.0
			6	120.0	-14.3	70.0	-22.2	84.0	-4.5	120.0	0.0	120.0	0.0	70.0	-22.2	88.0	-12.0
			8	115.0	-17.9	70.0	-22.2	80.0	-9.1	120.0	0.0	120.0	0.0	80.0	-11.1	100.0	0.0
			10	120.0	-14.3	80.0	-11.1	80.0	4.5	120.0	0.0	120.0	0.0	90.0	0.0	103.0	3.0
			12	120.0	-14.3	80.0	-11.1	80.0	-9.1	120.0	0.0	120.0	0.0	90.0	0.0	100.0	0.0
			14	120.0	-14.3	80.0	-11.1	80.0	-9.1	120.0	-4.2	120.0	-4.2	70.0	-22.2	88.0	-15.0
			16	115.0	-17.9	70.0	-22.2	80.0	-6.8	120.0	0.0	120.0	0.0	70.0	-22.2	88.0	-14.0
			18	120.0	-14.3	80.0	-11.1	80.0	-9.1	120.0	0.0	120.0	0.0	70.0	-22.2	88.0	-12.0
			20	120.0	-14.3	80.0	-11.1	80.0	-9.1	120.0	0.0	120.0	0.0	70.0	-22.2	88.0	-12.0
			22	115.0	-17.9	80.0	-11.1	88.0	-3.4	120.0	0.0	120.0	0.0	80.0	-11.1	90.0	-10.0
			24	120.0	-14.3	80.0	-11.1	88.0	0.0	120.0	0.0	120.0	0.0	80.0	0.0	92.0	-8.0
			26	115.0	-17.9	80.0	-11.1	88.0	0.0	120.0	0.0	120.0	0.0	80.0	0.0	92.0	-8.0
			28	120.0	-14.3	75.0	-16.7	80.0	-9.1	120.0	-16.7	100.0	-16.7	80.0	-11.1	90.0	-10.0
			30	120.0	-14.3	80.0	-11.1	88.0	0.0	120.0	0.0	120.0	0.0	80.0	-11.1	90.0	-10.0
			32	120.0	-14.3	80.0	-11.1	88.0	0.0	120.0	0.0	120.0	0.0	80.0	-11.1	90.0	-10.0
34	120.0	-14.3	80.0	-11.1	88.0	0.0	120.0	0.0	120.0	0.0	80.0	-11.1	90.0	-10.0			
36	120.0	-14.3	80.0	-11.1	88.0	0.0	120.0	0.0	120.0	0.0	80.0	-11.1	90.0	-10.0			
38	120.0	-14.3	80.0	-11.1	88.0	0.0	120.0	0.0	120.0	0.0	80.0	-11.1	90.0	-10.0			
40	120.0	-14.3	80.0	-11.1	88.0	0.0	120.0	0.0	120.0	0.0	80.0	-11.1	90.0	-10.0			
42	120.0	-14.3	80.0	-11.1	88.0	0.0	120.0	0.0	120.0	0.0	80.0	-11.1	90.0	-10.0			
44	115.0	-17.9	80.0	-11.1	88.0	0.0	120.0	0.0	120.0	0.0	80.0	-11.1	90.0	-10.0			
46	120.0	-14.3	80.0	-11.1	88.0	0.0	120.0	0.0	120.0	0.0	80.0	-11.1	90.0	-10.0			
48	120.0	-14.3	80.0	-11.1	88.0	0.0	120.0	0.0	120.0	0.0	80.0	-11.1	90.0	-10.0			
50	120.0	-14.3	80.0	-11.1	88.0	0.0	120.0	0.0	120.0	0.0	80.0	-11.1	90.0	-10.0			
52	130.0	-7.1	70.0	-22.2	84.0	-4.5	120.0	-16.7	100.0	-16.7	90.0	0.0	80.0	-20.0			
-1	110.0	9.1	80.0	0.0	65.0	56.9	120.0	0.0	120.0	0.0	90.0	-11.1	70.0	60.0			
0	120.0	9.1	80.0	0.0	102.0	29.2	120.0	0.0	120.0	0.0	80.0	-11.1	112.0	60.0			
1	120.0	9.1	80.0	0.0	84.0	35.4	120.0	0.0	120.0	0.0	70.0	-22.2	108.0	54.3			
2	100.0	-9.1	70.0	-12.5	88.0	41.5	100.0	-8.3	110.0	-8.3	70.0	-22.2	102.0	45.7			
3	110.0	0.0	70.0	-12.5	92.0	16.9	100.0	-16.7	100.0	-16.7	60.0	-33.3	126.0	71.4			
4	115.0	4.5	70.0	-12.5	76.0	23.1	100.0	-16.7	100.0	-16.7	70.0	-22.2	100.0	62.9			
5	120.0	9.1	80.0	0.0	80.0	10.8	120.0	0.0	120.0	0.0	80.0	-11.1	92.0	31.4			
6	115.0	4.5	80.0	0.0	72.0	29.2	115.0	-4.2	120.0	-4.2	80.0	-11.1	120.0	71.4			
8	120.0	9.1	80.0	0.0	84.0	41.5	120.0	0.0	120.0	0.0	80.0	-11.1	108.0	54.3			
10	120.0	9.1	80.0	0.0	92.0	16.9	120.0	-8.3	110.0	-8.3	70.0	-22.2	116.0	65.7			
12	120.0	9.1	80.0	0.0	76.0	20.0	120.0	0.0	120.0	0.0	90.0	0.0	104.0	48.6			
14	115.0	4.5	80.0	0.0	78.0	16.3	120.0	0.0	120.0	0.0	80.0	-11.1	100.0	42.9			
16	120.0	9.1	70.0	-12.5	80.0	23.1	120.0	0.0	120.0	0.0	80.0	-11.1	108.0	54.3			

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 40 mm Hg
H.R. values <= 50 beats/min

2420

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R8D

REBOXETINE - PROTOCOL 20124/013

Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: REBOXETINE

Centre	Patient	Initial	Visit	LIVING			STANDING													
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	H.R.	% diff									
13	231	CI	18	120.0	9.1	80.0	0.0	100.0	53.8	**	120.0	0.0	80.0	-11.1	105.0	50.0	**			
			20	120.0	9.1	90.0	12.5	92.0	41.5	**	120.0	0.0	90.0	0.0	104.0	48.6	**			
			22	120.0	9.1	80.0	0.0	90.0	38.5	**	120.0	0.0	90.0	0.0	108.0	54.3	**			
			24	100.0	-9.1	70.0	-12.5	96.0	47.7	**	110.0	-8.3	80.0	-11.1	104.0	48.6	**			
			26	115.0	4.5	80.0	0.0	80.0	23.1	**	110.0	-8.3	70.0	-22.2	100.0	42.9	**			
			28	120.0	9.1	80.0	0.0	84.0	29.2	**	100.0	-16.7	70.0	-22.2	96.0	37.1	**			
			30	140.0	27.3	80.0	0.0	80.0	23.1	**	140.0	16.7	80.0	-11.1	88.0	25.7	**			
			32	115.0	4.5	80.0	0.0	84.0	29.2	**	120.0	0.0	90.0	0.0	92.0	31.4	**			
			34	120.0	9.1	80.0	0.0	80.0	23.1	**	120.0	0.0	70.0	-22.2	84.0	20.0	**			
			36	140.0	27.3	80.0	12.5	88.0	35.4	**	130.0	8.3	100.0	11.1	92.0	31.4	**			
			38	130.0	18.2	80.0	0.0	86.0	32.3	**	120.0	0.0	80.0	-11.1	90.0	28.6	**			
			40	115.0	4.5	80.0	0.0	78.0	20.0	**	120.0	0.0	80.0	-11.1	88.0	25.7	**			
			42	120.0	9.1	80.0	0.0	80.0	23.1	**	120.0	0.0	80.0	-11.1	90.0	28.6	**			
			44	150.0	36.4	100.0	25.0	92.0	41.5	**	150.0	25.0	110.0	22.2	100.0	42.9	**			
			46	140.0	27.3	90.0	12.5	88.0	35.4	**	140.0	16.7	90.0	0.0	98.0	40.0	**			
			48	110.0	0.0	80.0	0.0	80.0	23.1	**	100.0	-16.7	80.0	-11.1	84.0	20.0	**			
			50	130.0	18.2	80.0	0.0	76.0	16.9	**	130.0	8.3	80.0	0.0	92.0	31.4	**			
			52	115.0	4.5	80.0	0.0	78.0	20.0	**	115.0	-4.2	80.0	0.0	80.0	14.3	**			
			232	NYH	CI	-1	110.0	0.0	70.0	0.0	72.0	5.6	**	100.0	0.0	70.0	0.0	92.0	8.7	**
						0	110.0	0.0	60.0	-14.3	76.0	16.7	**	100.0	0.0	60.0	-14.3	100.0	8.7	**
						1	115.0	4.5	60.0	-14.3	84.0	16.7	**	110.0	10.0	70.0	0.0	100.0	8.7	**
						2	115.0	4.5	70.0	0.0	80.0	11.1	**	115.0	15.0	70.0	0.0	100.0	8.7	**
						3	100.0	-9.1	80.0	14.3	90.0	25.0	**	115.0	15.0	80.0	14.3	95.0	3.3	**
						4	115.0	4.5	70.0	0.0	76.0	5.6	**	120.0	20.0	80.0	14.3	92.0	0.0	**
						5	100.0	-9.1	70.0	0.0	86.0	19.4	**	115.0	15.0	80.0	14.3	105.0	14.1	**
						6	100.0	-9.1	60.0	-14.3	72.0	0.0	**	100.0	0.0	60.0	-14.3	92.0	0.0	**
						8	110.0	0.0	70.0	0.0	80.0	11.1	**	100.0	0.0	70.0	0.0	85.0	-7.6	**
						10	120.0	9.1	80.0	14.3	100.0	38.9	**	110.0	10.0	80.0	14.3	104.0	13.0	**

2424

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 100 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING			STANDING									
				S.B.P.	D.B.P.	H.R.	S.B.P.	D.B.P.	H.R.							
1	1	MGA	-1	120.0	75.0	74.0	115.0	70.0	76.0							
			0	115.0	80.0	68.0	110.0	80.0	70.0	14.3	70.0	-7.9				
			1	110.0	75.0	82.0	110.0	70.0	82.0	0.0	82.0	7.9				
			2	115.0	80.0	74.0	110.0	75.0	72.0	0.0	72.0	-5.3				
			3	120.0	80.0	84.0	115.0	80.0	86.0	0.0	86.0	13.2				
			4	120.0	80.0	74.0	115.0	75.0	74.0	0.0	74.0	0.0				
			5	125.0	80.0	67.0	125.0	80.0	81.0	0.0	81.0	6.6				
			6	125.0	80.0	70.0	120.0	75.0	71.0	0.0	70.0	0.0				
			8	120.0	80.0	70.0	120.0	80.0	70.0	0.0	70.0	-7.9				
			10	100.0	70.0	116.0	100.0	80.0	116.0	0.0	116.0	52.6	**			
			12	110.0	65.0	96.0	110.0	80.0	104.0	0.0	104.0	36.8	**			
			14	110.0	70.0	95.0	110.0	80.0	100.0	0.0	100.0	31.6	**			
			16	110.0	60.0	95.0	110.0	80.0	98.0	0.0	98.0	28.9	**			
			18	110.0	75.0	96.0	110.0	70.0	100.0	0.0	100.0	31.6	**			
			5	5	CPM	-1	130.0	90.0	72.0	125.0	90.0	75.0				
						0	130.0	90.0	68.0	125.0	85.0	68.0	-5.6	68.0	-9.3	
						1	135.0	85.0	72.0	140.0	85.0	74.0	0.0	74.0	-1.3	
						2	140.0	80.0	76.0	135.0	80.0	78.0	0.0	78.0	4.0	
3	140.0	85.0				72.0	135.0	80.0	74.0	0.0	74.0	-1.3				
4	130.0	80.0				80.0	130.0	80.0	85.0	0.0	85.0	13.3	**			
5	140.0	80.0				88.0	140.0	80.0	100.0	0.0	100.0	33.3	**			
6	135.0	80.0				88.0	140.0	90.0	82.0	0.0	82.0	9.3	**			
8	130.0	80.0				74.0	140.0	90.0	100.0	0.0	100.0	33.3	**			
10	160.0	90.0				88.0	135.0	80.0	102.0	0.0	102.0	36.0	**			
12	130.0	85.0				94.0	150.0	90.0	104.0	0.0	104.0	38.7	**			
14	150.0	85.0				90.0	130.0	90.0	100.0	0.0	100.0	33.3	**			
16	140.0	100.0				100.0	150.0	95.0	100.0	0.0	100.0	33.3	**			
18	140.0	90.0				86.0	140.0	80.0	90.0	0.0	90.0	20.0				
6	6	MVB				-1	120.0	80.0	76.0	120.0	75.0	78.0				
						0	120.0	85.0	80.0	125.0	80.0	100.0	6.7	100.0	28.2	**
						1	120.0	80.0	120.0	120.0	75.0	132.0	0.0	132.0	69.2	**
						2	120.0	70.0	116.0	120.0	80.0	128.0	0.0	128.0	64.1	**
			3	100.0	70.0	120.0	110.0	80.0	132.0	0.0	132.0	69.2	**			
			4	120.0	80.0	110.0	110.0	70.0	124.0	0.0	124.0	59.0	**			
			5	110.0	70.0	104.0	115.0	80.0	116.0	0.0	116.0	48.7	**			
			6	110.0	75.0	110.0	110.0	75.0	123.0	0.0	123.0	63.4	**			
			8	120.0	80.0	86.0	110.0	80.0	100.0	0.0	100.0	28.2	**			
			10	110.0	80.0	96.0	105.0	80.0	112.0	0.0	112.0	43.6	**			

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 beats/min
 H.R. values <= 50 beats/min

2426

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING				STANDING												
				S.B.P.	D.B.P.	H.R.	% diff	S.B.P.	D.B.P.	H.R.	% diff									
1	6	MYB	12	110.0	-8.3	65.0	-18.8	102.0	34.2	**	105.0	-12.5	65.0	-13.3	110.0	41.0	**			
			14	100.0	-16.7	70.0	-12.5	84.0	10.5		105.0	-12.5	70.0	-6.7	82.0	5.1	**			
			16	120.0	0.0	70.0	-12.5	100.0	31.6	**	120.0	0.0	60.0	-20.0	100.0	28.2	**			
			18	110.0	-8.3	80.0	0.0	88.0	15.8		105.0	-12.5	75.0	0.0	100.0	28.2	**			
			20	105.0	-12.5	80.0	0.0	88.0	15.8		105.0	-12.5	70.0	-6.7	90.0	15.4	**			
			22	105.0	-12.5	70.0	-12.5	88.0	15.8		95.0	-20.8	*	65.0	-13.3	104.0	33.3	**		
			24	110.0	-8.3	75.0	-6.3	90.0	18.4		110.0	-8.3		70.0	-6.7	98.0	25.6	**		
			26	110.0	-8.3	70.0	-12.5	100.0	31.6	**	110.0	-8.3		75.0	0.0	102.0	30.8	**		
			9	VRT		-1	90.0	0.0	60.0	0.0	90.0	0.0		100.0	0.0	70.0	0.0	110.0	0.0	
						1	90.0	0.0	60.0	0.0	95.0	5.6		90.0	-10.0	60.0	-14.3	100.0	-9.1	
						2	90.0	0.0	65.0	8.3	76.0	-15.6		80.0	-20.0	60.0	-14.3	96.0	-12.7	
						3	90.0	0.0	60.0	0.0	74.0	-17.8		90.0	-10.0	65.0	-7.1	100.0	-9.1	
						4	90.0	0.0	60.0	0.0	104.0	15.6		80.0	-20.0	60.0	-14.3	124.0	12.7	
						5	95.0	5.6	60.0	0.0	88.0	-2.2		90.0	-10.0	60.0	-14.3	112.0	11.8	
						6	90.0	0.0	60.0	0.0	85.0	-5.6		90.0	-10.0	60.0	-14.3	88.0	-20.0	
						8	90.0	0.0	60.0	0.0	80.0	-11.1		90.0	-10.0	70.0	-14.3	88.0	-20.0	
						10	100.0	11.1	60.0	0.0	80.0	-11.1		100.0	0.0	60.0	-14.3	100.0	-9.1	
						12	90.0	0.0	55.0	-8.3	80.0	-11.1		90.0	-10.0	60.0	-14.3	92.0	-16.4	
						14	100.0	11.1	60.0	0.0	80.0	-11.1		95.0	-5.0	60.0	-7.1	92.0	-16.4	
						16	85.0	-5.6	55.0	-8.3	80.0	-11.1		95.0	-5.0	60.0	-14.3	92.0	-16.4	
						18	85.0	-5.6	55.0	-8.3	80.0	-11.1		95.0	-5.0	60.0	-14.3	92.0	-16.4	
						20	85.0	-5.6	44.0	-26.7	*			95.0	-5.0	60.0	-14.3	92.0	-16.4	
						22	85.0	-5.6	55.0	-8.3	80.0	-11.1		95.0	-5.0	60.0	-14.3	92.0	-16.4	
						24	100.0	11.1	65.0	8.3	72.0	-20.0		95.0	-5.0	65.0	-7.1	84.0	-23.6	
						26	100.0	11.1	65.0	8.3	72.0	-20.0		95.0	-5.0	55.0	-21.4	*		
						28	90.0	0.0	50.0	-16.7	80.0	-11.1		95.0	-5.0	60.0	-7.1	80.0	-18.2	
30	100.0	11.1	65.0	8.3	72.0	-20.0		100.0	0.0	65.0	-7.1	80.0	-27.3							
32	100.0	11.1	65.0	8.3	72.0	-20.0		95.0	-5.0	60.0	-14.3	90.0	-27.3							
34	100.0	11.1	60.0	0.0	80.0	-11.1		100.0	0.0	60.0	-14.3	90.0	-18.2							
36	100.0	11.1	60.0	0.0	80.0	-11.1		100.0	0.0	60.0	-14.3	90.0	-18.2							
10	SLT		-1	80.0	0.0	60.0	0.0	80.0	0.0		85.0	0.0	60.0	0.0	100.0	0.0				
			0	80.0	0.0	60.0	0.0	80.0	0.0		85.0	0.0	60.0	0.0	100.0	0.0				
			1	120.0	50.0	60.0	0.0	70.0	-12.5		100.0	17.6	60.0	0.0	120.0	20.0				
			2	85.0	6.3	60.0	0.0	96.0	20.0		85.0	0.0	60.0	0.0	106.0	6.0				
			3	85.0	6.3	60.0	0.0	96.0	20.0		85.0	0.0	60.0	0.0	106.0	6.0				
			4	90.0	12.5	60.0	0.0	106.0	32.5	**	90.0	5.9	60.0	0.0	116.0	14.0				
5	90.0	12.5	65.0	8.3	106.0	35.0	**	90.0	5.9	65.0	8.3	116.0	16.0							

** S.B.P. values => 160 mm Hg
 D.B.P. values => 100 mm Hg
 H.R. values => 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 beats/min
 H.R. values <= 50 beats/min

2426

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REMOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial Visit	LYING			STANDING				
			S.B.P.	H.R.	D.B.P.	S.B.P.	H.R.	D.B.P.		
		Visit	% diff	% diff	% diff	% diff	% diff	% diff		
1	10	SLT	100.0	100.0	25.0	110.0	11.8	60.0	108.0	8.0
	6		100.0	100.0	25.0	110.0	29.4	65.0	108.0	8.0
	8		90.0	80.0	0.0	85.0	0.0	50.0	88.0	-12.0
	10		100.0	80.0	0.0	95.0	11.8	65.0	100.0	0.0
	12		90.0	88.0	10.0	90.0	5.9	65.0	88.0	-12.0
	14		90.0	88.0	10.0	90.0	5.9	65.0	88.0	-12.0
	16		90.0	88.0	10.0	90.0	5.9	65.0	88.0	-12.0
	18		90.0	88.0	10.0	90.0	5.9	65.0	88.0	-12.0
	20		100.0	88.0	10.0	90.0	5.9	65.0	88.0	-12.0
	22		100.0	88.0	10.0	90.0	5.9	65.0	88.0	-12.0
	24		90.0	88.0	10.0	90.0	5.9	65.0	88.0	-12.0
	26		90.0	88.0	10.0	90.0	5.9	65.0	88.0	-12.0
	28		90.0	88.0	10.0	90.0	5.9	65.0	88.0	-12.0
	30		100.0	84.0	5.0	90.0	5.9	65.0	88.0	-16.0
	32		100.0	84.0	5.0	90.0	5.9	65.0	88.0	-16.0
	34		100.0	85.0	6.3	90.0	5.9	65.0	88.0	-16.0
	36		85.0	85.0	10.0	80.0	29.4	70.0	108.0	8.0
	38		100.0	88.0	10.0	80.0	29.4	70.0	108.0	8.0
	40		100.0	88.0	10.0	80.0	29.4	70.0	108.0	8.0
	42		100.0	75.0	-6.3	110.0	29.4	60.0	82.0	-18.0
	44		100.0	75.0	-6.3	110.0	29.4	60.0	82.0	-18.0
	46		90.0	75.0	-5.0	90.0	5.9	60.0	80.0	-20.0
	48		90.0	76.0	-5.0	90.0	5.9	60.0	80.0	-20.0
	50		90.0	76.0	-5.0	90.0	5.9	60.0	80.0	-20.0
	52		90.0	92.0	15.0	85.0	0.0	60.0	100.0	0.0
			90.0	92.0	15.0	85.0	0.0	60.0	100.0	0.0
12	MAO		130.0	60.0	0.0	130.0	0.0	80.0	60.0	0.0
	0		130.0	60.0	0.0	130.0	0.0	80.0	60.0	0.0
	1		110.0	84.0	40.0	110.0	-15.4	75.0	94.0	56.7
	2		120.0	84.0	40.0	110.0	-15.4	80.0	96.0	60.0
	3		120.0	84.0	40.0	110.0	-15.4	80.0	96.0	60.0
	4		110.0	80.0	33.3	105.0	-19.2	70.0	80.0	33.3
	5		120.0	84.0	40.0	110.0	-15.4	80.0	96.0	60.0
	6		110.0	80.0	33.3	105.0	-19.2	70.0	80.0	33.3
	7		140.0	80.0	33.3	160.0	7.7	90.0	87.0	45.0
	8		140.0	80.0	33.3	160.0	7.7	90.0	87.0	45.0
	10		120.0	88.0	66.7	120.0	-7.7	80.0	92.0	53.3
	12		130.0	80.0	33.3	130.0	0.0	85.0	88.0	46.7
	14		130.0	80.0	33.3	130.0	0.0	85.0	88.0	46.7
	16		110.0	80.0	33.3	120.0	-7.7	80.0	92.0	53.3
	18		120.0	88.0	66.7	110.0	-15.4	85.0	68.0	13.3
	20		130.0	80.0	33.3	130.0	0.0	85.0	74.0	23.3

2427

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING				STANDING									
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff				
1	12	MAO	22	110.0	-15.4	80.0	-5.9	84.0	40.0	115.0	-11.5	85.0	6.3	92.0	53.3		
			24	110.0	-15.4	65.0	-23.5	80.0	33.3	110.0	-15.4	70.0	-12.5	88.0	46.7		
			26	120.0	-7.7	80.0	-5.9	69.0	15.0	120.0	-7.7	80.0	0.0	80.0	33.3		
			28	120.0	-7.7	80.0	-5.9	64.0	6.7	120.0	-7.7	85.0	6.3	64.0	6.7		
			30	120.0	-7.7	80.0	-5.9	64.0	6.7	120.0	-7.7	85.0	6.3	64.0	6.7		
			32	120.0	-7.7	80.0	-5.9	64.0	6.7	120.0	-7.7	85.0	6.3	64.0	6.7		
			34	120.0	-7.7	80.0	-5.9	64.0	6.7	120.0	-7.7	85.0	6.3	64.0	6.7		
			36	120.0	-7.7	80.0	-5.9	64.0	6.7	120.0	-7.7	85.0	6.3	64.0	6.7		
			38	120.0	-7.7	80.0	-5.9	64.0	6.7	120.0	-7.7	85.0	6.3	64.0	6.7		
			40	120.0	-7.7	80.0	-5.9	64.0	6.7	120.0	-7.7	85.0	6.3	64.0	6.7		
			42	120.0	-7.7	80.0	-5.9	64.0	6.7	120.0	-7.7	85.0	6.3	64.0	6.7		
			44	120.0	-7.7	80.0	-5.9	64.0	6.7	120.0	-7.7	85.0	6.3	64.0	6.7		
			46	105.0	-19.2	75.0	-11.8	68.0	13.3	110.0	-15.4	80.0	0.0	76.0	26.7		
			48	105.0	-19.2	75.0	-11.8	68.0	13.3	110.0	-15.4	80.0	0.0	76.0	26.7		
			50	105.0	-19.2	75.0	-11.8	68.0	13.3	110.0	-15.4	80.0	0.0	76.0	26.7		
			52	115.0	-11.5	80.0	-5.9	68.0	13.3	120.0	-7.7	85.0	6.3	80.0	33.3		
			13	MHC	-1	115.0	0.0	65.0	0.0	72.0	0.0	110.0	0.0	65.0	0.0	84.0	0.0
					0	115.0	0.0	65.0	0.0	72.0	0.0	110.0	0.0	65.0	0.0	84.0	0.0
					1	100.0	-13.0	60.0	-7.7	86.0	19.4	100.0	-9.1	60.0	-7.7	96.0	14.3
					2	100.0	-13.0	60.0	-7.7	90.0	25.0	95.0	-13.6	70.0	7.7	100.0	19.0
					3	90.0	-21.7	60.0	-7.7	80.0	11.1	90.0	-18.2	65.0	0.0	96.0	14.3
					4	100.0	-13.0	60.0	-7.7	88.0	22.2	110.0	0.0	70.0	7.7	92.0	9.5
					5	110.0	-4.3	70.0	7.7	80.0	11.1	105.0	-4.5	65.0	0.0	92.0	9.5
					6	100.0	-13.0	70.0	7.7	88.0	22.2	100.0	-9.1	65.0	0.0	96.0	14.3
					8	120.0	4.3	80.0	23.1	68.0	-5.6	110.0	0.0	80.0	23.1	80.0	-4.8
					10	95.0	-17.4	70.0	7.7	88.0	22.2	100.0	-9.1	70.0	7.7	104.0	23.8
					12	115.0	0.0	75.0	15.4	84.0	16.7	125.0	13.6	75.0	15.4	88.0	4.8
					14	120.0	4.3	75.0	15.4	80.0	11.1	120.0	9.1	70.0	7.7	92.0	9.5
					16	120.0	4.3	75.0	15.4	80.0	11.1	120.0	9.1	70.0	7.7	92.0	9.5
					18	120.0	4.3	75.0	15.4	80.0	11.1	120.0	9.1	70.0	7.7	92.0	9.5
					20	140.0	21.7	90.0	38.5	88.0	22.2	140.0	27.3	90.0	38.5	100.0	19.0
					22	160.0	41.7	90.0	38.5	84.0	16.7	160.0	27.3	85.0	30.8	92.0	9.5
			24	125.0	6.7	70.0	7.7	78.0	8.3	130.0	18.2	75.0	15.4	80.0	-4.8		
			26	100.0	-13.0	80.0	23.1	72.0	0.0	120.0	9.1	80.0	23.1	84.0	0.0		
			28	110.0	-4.3	70.0	7.7	76.0	5.6	110.0	0.0	80.0	23.1	80.0	-4.8		
			30	110.0	-4.3	70.0	7.7	76.0	5.6	110.0	0.0	80.0	23.1	80.0	-4.8		
			32	110.0	-4.3	70.0	7.7	76.0	5.6	110.0	0.0	80.0	23.1	80.0	-4.8		
			34	110.0	-4.3	70.0	7.7	76.0	5.6	110.0	0.0	80.0	23.1	80.0	-4.8		
			36	115.0	0.0	70.0	7.7	84.0	16.7	120.0	9.1	80.0	23.1	88.0	4.8		

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 mm Hg
 H.R. values <= 50 beats/min

2423

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING				STANDING							
				S.B.P.	% diff	D.B.P.	% diff	H.R.	% diff	S.B.P.	% diff	D.B.P.	% diff	H.R.	% diff
1	13	MHC	38	115.0	0.0	70.0	7.7	84.0	16.7	120.0	9.1	80.0	23.1	88.0	4.8
			40	115.0	0.0	70.0	7.7	84.0	16.7	120.0	9.1	80.0	23.1	88.0	4.8
	16	SR	-1	90.0	0.0	65.0	0.0	80.0	0.0	90.0	0.0	65.0	-7.7	96.0	0.0
			0	90.0	5.6	65.0	0.0	80.0	0.0	90.0	-16.7	60.0	-7.7	60.0	-37.5
			1	95.0	0.0	60.0	-7.7	98.0	22.5	80.0	-11.1	65.0	0.0	100.0	4.2
			2	90.0	0.0	70.0	7.7	80.0	0.0	80.0	0.0	70.0	7.7	100.0	4.2
			3	90.0	0.0	70.0	7.7	80.0	0.0	80.0	0.0	70.0	7.7	100.0	4.2
			4	90.0	0.0	70.0	7.7	80.0	0.0	80.0	0.0	70.0	7.7	100.0	4.2
			5	100.0	11.1	70.0	7.7	100.0	25.0	85.0	-5.6	65.0	0.0	108.0	12.5
			6	100.0	11.1	70.0	7.7	100.0	25.0	85.0	-5.6	65.0	0.0	108.0	12.5
			8	100.0	11.1	65.0	0.0	88.0	10.0	100.0	11.1	70.0	7.7	100.0	4.2
			10	120.0	33.3	70.0	7.7	100.0	25.0	85.0	-11.1	60.0	0.0	120.0	25.0
			12	100.0	11.1	60.0	-7.7	88.0	10.0	100.0	11.1	70.0	7.7	120.0	25.0
			14	100.0	11.1	60.0	-7.7	88.0	10.0	100.0	11.1	70.0	7.7	120.0	25.0
16	130.0	44.4	70.0	7.7	80.0	0.0	90.0	0.0	70.0	7.7	88.0	-8.3			
18	90.0	0.0	70.0	7.7	80.0	0.0	90.0	0.0	70.0	7.7	88.0	-8.3			
20	95.0	5.6	65.0	0.0	108.0	35.0	85.0	-5.6	50.0	-23.1	120.0	23.0			
22	120.0	33.3	70.0	7.7	96.0	20.0	90.0	0.0	85.0	-5.6	50.0	-23.1			
24	110.0	22.2	70.0	7.7	90.0	12.5	100.0	11.1	70.0	7.7	100.0	4.2			
26	105.0	16.7	70.0	7.7	88.0	10.0	100.0	11.1	70.0	7.7	100.0	4.2			
28	80.0	-11.1	60.0	-7.7	80.0	0.0	80.0	0.0	95.0	5.6	65.0	0.0			
30	80.0	-11.1	60.0	-7.7	80.0	0.0	80.0	0.0	95.0	5.6	65.0	0.0			
32	80.0	-11.1	60.0	-7.7	80.0	0.0	80.0	0.0	95.0	5.6	65.0	0.0			
34	90.0	0.0	60.0	-7.7	90.0	12.5	100.0	11.1	80.0	-11.1	65.0	0.0			
36	110.0	22.2	60.0	-7.7	88.0	10.0	100.0	11.1	70.0	7.7	70.0	-7.7			
38	110.0	22.2	60.0	-7.7	88.0	10.0	100.0	11.1	70.0	7.7	70.0	-7.7			
18	VNC	-1	110.0	0.0	80.0	0.0	64.0	0.0	115.0	0.0	90.0	0.0	72.0	0.0	
		0	110.0	0.0	80.0	0.0	64.0	0.0	115.0	0.0	90.0	0.0	72.0	0.0	
		1	115.0	4.5	90.0	12.5	88.0	37.5	110.0	-4.3	90.0	0.0	96.0	33.3	
		2	110.0	0.0	90.0	12.5	50.0	-21.9	115.0	0.0	90.0	0.0	58.0	-19.4	
		3	120.0	9.1	90.0	12.5	80.0	25.0	120.0	4.3	90.0	0.0	84.0	16.7	
		4	110.0	0.0	85.0	6.3	52.0	-18.8	115.0	0.0	95.0	5.6	52.0	-27.8	
		5	125.0	13.6	90.0	12.5	84.0	31.3	120.0	4.3	90.0	0.0	88.0	22.2	
		6	125.0	13.6	85.0	6.3	50.0	-21.9	120.0	4.3	80.0	0.0	54.0	-25.0	
		8	125.0	13.6	85.0	6.3	72.0	12.5	130.0	13.0	90.0	0.0	80.0	11.1	
		10	130.0	18.2	90.0	12.5	80.0	25.0	140.0	21.7	100.0	11.1	92.0	27.8	
		12	90.0	-18.2	70.0	-12.5	80.0	25.0	90.0	-21.7	70.0	-22.2	80.0	11.1	
		14	100.0	-9.1	80.0	0.0	72.0	12.5	120.0	4.3	85.0	-5.6	68.0	-5.6	

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 beats/min
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LIVING			STANDING								
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	H.R.	% diff				
1	18	VNC	16	130.0	18.2	90.0	12.5	80.0	25.0	130.0	13.0	90.0	0.0	88.0	22.2
			18	120.0	9.1	80.0	12.5	76.0	18.8	120.0	4.3	90.0	0.0	80.0	11.1
			20	110.0	0.0	80.0	6.3	68.0	6.3	115.0	0.0	90.0	0.0	88.0	22.2
			22	130.0	18.2	90.0	12.5	80.0	6.3	115.0	0.0	95.0	5.6	72.0	0.0
			24	115.0	4.5	80.0	0.0	68.0	6.3	120.0	4.3	90.0	0.0	76.0	5.6
			26	115.0	4.5	80.0	0.0	68.0	6.3	120.0	4.3	90.0	0.0	76.0	5.6
			28	115.0	4.5	80.0	0.0	68.0	6.3	120.0	4.3	90.0	0.0	76.0	5.6
			30	120.0	9.1	85.0	6.3	72.0	12.5	115.0	0.0	90.0	0.0	84.0	16.7
			32	120.0	9.1	85.0	6.3	72.0	12.5	115.0	0.0	90.0	0.0	84.0	16.7
			34	120.0	9.1	85.0	6.3	72.0	12.5	115.0	0.0	90.0	0.0	84.0	16.7
			36	100.0	-9.1	80.0	0.0	88.0	37.5	120.0	4.3	85.0	-5.6	112.0	55.6
			38	100.0	-9.1	80.0	0.0	88.0	37.5	120.0	4.3	85.0	-5.6	112.0	55.6
			40	115.0	4.5	75.0	-6.3	78.0	21.9	110.0	-4.3	70.0	-22.2	76.0	5.6
			42	125.0	13.6	80.0	0.0	52.0	-18.8	120.0	4.3	80.0	-11.1	60.0	-16.7
			44	125.0	13.6	75.0	-6.3	54.0	-15.6	120.0	4.3	80.0	-11.1	58.0	-19.4
			46	120.0	9.1	80.0	-6.3	58.0	-9.4	125.0	8.7	80.0	-11.1	64.0	-11.1
			48	120.0	9.1	80.0	0.0	56.0	-12.5	110.0	-4.3	75.0	-16.7	60.0	-16.7
			50	125.0	13.6	80.0	0.0	60.0	-6.3	120.0	4.3	75.0	-16.7	64.0	-11.1
			52	120.0	9.1	80.0	0.0	54.0	-15.6	115.0	0.0	75.0	-16.7	58.0	-19.4
22	0C		-1	100.0	0.0	70.0	0.0	68.0	0.0	100.0	0.0	70.0	0.0	76.0	0.0
			1	100.0	0.0	65.0	-7.1	88.0	29.4	90.0	-10.0	60.0	-14.3	76.0	0.0
			2	85.0	-15.0	60.0	-14.3	88.0	29.4	85.0	-15.0	65.0	-7.1	104.0	36.8
			3	105.0	5.0	70.0	0.0	80.0	17.6	110.0	10.0	75.0	7.1	90.0	18.4
			4	100.0	0.0	65.0	-7.1	88.0	29.4	100.0	0.0	70.0	0.0	88.0	15.8
			5	105.0	5.0	70.0	0.0	80.0	17.6	100.0	0.0	75.0	7.1	96.0	26.3
			6	100.0	0.0	65.0	-7.1	88.0	29.4	100.0	0.0	70.0	0.0	88.0	15.8
			8	100.0	0.0	60.0	-14.3	80.0	17.6	100.0	0.0	70.0	0.0	96.0	26.3
			10	100.0	0.0	65.0	-7.1	72.0	5.9	95.0	-5.0	70.0	0.0	80.0	5.3
			12	85.0	-15.0	60.0	-14.3	68.0	0.0	100.0	0.0	65.0	-14.3	80.0	5.3
			14	105.0	5.0	60.0	-7.1	92.0	35.3	90.0	-10.0	60.0	-14.3	116.0	52.6
			16	100.0	0.0	65.0	-7.1	84.0	23.5	105.0	5.0	65.0	-7.1	92.0	21.1
			18	105.0	5.0	60.0	-7.1	80.0	17.6	95.0	-5.0	70.0	0.0	96.0	26.3
			20	105.0	5.0	65.0	-7.1	96.0	41.2	105.0	5.0	65.0	-7.1	108.0	42.1
			22	100.0	0.0	60.0	-14.3	84.0	23.5	100.0	0.0	60.0	-14.3	88.0	15.8
			24	100.0	0.0	60.0	-14.3	92.0	35.3	110.0	10.0	70.0	0.0	92.0	21.1
			26	100.0	0.0	60.0	-14.3	82.0	-8.8	110.0	10.0	70.0	0.0	62.0	-18.4
			28	100.0	0.0	65.0	-7.1	72.0	5.9	110.0	10.0	70.0	0.0	72.0	-5.3
			30	100.0	0.0	60.0	-14.3	72.0	5.9	100.0	0.0	65.0	-7.1	92.0	21.1

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 mm Hg
 H.R. values <= 50 beats/min

2430

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013

Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING				STANDING											
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff						
1	22	OC	32	90.0	-10.0	60.0	-14.3	72.0	5.9	90.0	-10.0	60.0	-14.3	88.0	15.8				
			34	100.0	0.0	70.0	0.0	68.0	0.0	100.0	0.0	75.0	7.1	84.0	10.5				
			36	100.0	0.0	70.0	0.0	68.0	0.0	100.0	0.0	75.0	7.1	84.0	10.5				
			38	90.0	-10.0	70.0	0.0	112.0	64.7	**	100.0	0.0	80.0	14.3	116.0	52.6			
			40	100.0	0.0	60.0	-14.3	76.0	11.8	**	105.0	5.0	75.0	7.1	92.0	21.1			
			42	90.0	-10.0	60.0	-14.3	92.0	35.3	**	90.0	-10.0	65.0	-7.1	108.0	42.1			
			44	90.0	-10.0	60.0	-14.3	92.0	35.3	**	90.0	-10.0	65.0	-7.1	108.0	42.1			
			46	110.0	10.0	70.0	0.0	80.0	17.6	**	100.0	0.0	70.0	0.0	88.0	15.8			
			48	110.0	10.0	70.0	0.0	80.0	17.6	**	100.0	0.0	70.0	0.0	88.0	15.8			
			50	110.0	10.0	70.0	0.0	80.0	17.6	**	100.0	0.0	70.0	0.0	88.0	15.8			
			52	110.0	10.0	70.0	0.0	72.0	5.9		100.0	0.0	75.0	7.1	72.0	-5.3			
			24	RMH		-1	130.0	0.0	80.0	0.0	76.0	0.0	140.0	0.0	90.0	0.0	80.0	0.0	
						0	130.0	0.0	80.0	0.0	76.0	0.0	140.0	0.0	90.0	0.0	80.0	0.0	
						1	125.0	-3.8	80.0	0.0	100.0	31.6	**	120.0	0.0	90.0	0.0	92.0	15.0
						2	130.0	0.0	90.0	12.5	80.0	5.3		120.0	-14.3	95.0	5.6	88.0	10.0
						3	130.0	0.0	85.0	6.3	92.0	21.1		130.0	-7.1	90.0	0.0	100.0	25.0
						4	130.0	0.0	85.0	6.3	80.0	5.3		140.0	0.0	105.0	16.7	84.0	5.0
5	130.0	0.0				80.0	0.0	88.0	15.8	**	130.0	-7.1	90.0	0.0	88.0	10.0			
6	125.0	-3.8				85.0	6.3	80.0	5.3		125.0	-10.7	90.0	0.0	88.0	10.0			
8	130.0	0.0				100.0	25.0	84.0	10.5	**	150.0	14.3	100.0	11.1	84.0	5.0			
10	160.0	23.1				100.0	25.0	84.0	10.5	**	160.0	14.3	100.0	11.1	88.0	10.0			
12	140.0	7.7				100.0	25.0	92.0	21.1	**	150.0	7.1	100.0	11.1	92.0	15.0			
14	130.0	0.0				90.0	12.5	100.0	31.6	**	145.0	3.6	100.0	11.1	100.0	25.0			
16	120.0	-7.7				80.0	0.0	100.0	31.6	**	130.0	-7.1	90.0	0.0	100.0	25.0			
18	140.0	7.7				90.0	12.5	80.0	5.3	**	150.0	7.1	100.0	11.1	84.0	5.0			
20	130.0	0.0				90.0	12.5	96.0	26.3	**	150.0	7.1	100.0	11.1	100.0	25.0			
22	120.0	-7.7				90.0	12.5	80.0	5.3	**	130.0	-7.1	100.0	11.1	112.0	40.0			
24	120.0	-7.7				80.0	0.0	84.0	10.5		120.0	-14.3	80.0	-11.1	92.0	15.0			
25	AFO		-1	120.0	0.0	80.0	0.0	68.0	0.0	120.0	0.0	80.0	0.0	70.0	8.6				
			0	120.0	0.0	90.0	12.5	80.0	17.6	**	115.0	-4.2	80.0	0.0	76.0	8.6			
			1	120.0	0.0	90.0	12.5	92.0	35.3	**	120.0	0.0	90.0	12.5	116.0	65.7			
			2	110.0	-8.3	85.0	6.3	80.0	29.4	*	95.0	-20.8	75.0	-6.3	108.0	54.3			
			3	120.0	0.0	85.0	6.3	60.0	-11.8	**	110.0	-8.3	80.0	0.0	60.0	-14.3			
			4	120.0	0.0	70.0	-12.5	64.0	-5.9	**	120.0	0.0	80.0	0.0	64.0	-8.6			
			5	115.0	-4.2	90.0	12.5	100.0	47.1	**	120.0	0.0	90.0	12.5	100.0	42.9			
			6	130.0	8.3	100.0	25.0	88.0	29.4	**	130.0	8.3	90.0	12.5	98.0	40.0			
			8	120.0	0.0	80.0	0.0	90.0	32.4	**	130.0	8.3	90.0	12.5	95.0	35.7			
			10	130.0	8.3	90.0	12.5	80.0	17.6	**	130.0	8.3	100.0	25.0	86.0	25.7			

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 100 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

2431

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING			STANDING										
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	H.R.	% diff						
1	25	AFD	12	130.0	8.3	90.0	12.5	88.0	29.4	120.0	0.0	90.0	12.5	80.0	14.3		
			14	110.0	-8.3	80.0	0.0	80.0	17.6	100.0	-16.7	70.0	-12.5	84.0	20.0		
			16	130.0	8.3	90.0	12.5	70.0	2.9	135.0	12.5	95.0	18.8	84.0	20.0		
			18	130.0	8.3	100.0	25.0	**	90.0	32.4	120.0	0.0	85.0	6.3	94.0	34.3	
			20	130.0	8.3	100.0	25.0	**	108.0	58.8	**	120.0	0.0	90.0	12.5	108.0	54.3
			22	125.0	4.2	95.0	18.8	**	100.0	47.1	**	125.0	4.2	90.0	12.5	104.0	48.6
			24	130.0	8.3	80.0	0.0	100.0	47.1	**	130.0	8.3	90.0	12.5	110.0	57.1	
			26	130.0	8.3	90.0	12.5	88.0	29.4	**	120.0	0.0	95.0	18.8	104.0	48.6	
			28	110.0	-8.3	80.0	0.0	60.0	-11.8	**	110.0	-8.3	80.0	0.0	60.0	-14.3	
			30	140.0	16.7	90.0	12.5	88.0	29.4	**	120.0	0.0	90.0	12.5	88.0	25.7	
			32	140.0	16.7	90.0	12.5	96.0	41.2	**	120.0	0.0	90.0	12.5	100.0	42.9	
			34	110.0	-8.3	80.0	0.0	60.0	-11.8	**	110.0	-8.3	80.0	0.0	68.0	-2.9	
			36	110.0	-8.3	80.0	0.0	60.0	-11.8	**	110.0	-8.3	80.0	0.0	68.0	-2.9	
			38	120.0	0.0	80.0	0.0	88.0	29.4	**	120.0	0.0	90.0	12.5	100.0	42.9	
			40	120.0	0.0	80.0	0.0	88.0	29.4	**	120.0	0.0	90.0	12.5	100.0	42.9	
			42	120.0	0.0	80.0	0.0	88.0	29.4	**	120.0	0.0	90.0	12.5	100.0	42.9	
44	120.0	0.0	80.0	0.0	88.0	29.4	**	120.0	0.0	90.0	12.5	100.0	42.9				
46	120.0	0.0	85.0	18.8	88.0	29.4	**	140.0	16.7	90.0	12.5	96.0	37.1				
48	120.0	0.0	85.0	18.8	88.0	29.4	**	140.0	16.7	90.0	12.5	96.0	37.1				
50	120.0	0.0	85.0	18.8	88.0	29.4	**	140.0	16.7	90.0	12.5	96.0	37.1				
52	120.0	0.0	95.0	18.8	88.0	29.4	**	140.0	16.7	90.0	12.5	96.0	37.1				
26	ERV		-1	130.0	0.0	90.0	18.8	88.0	29.4	125.0	0.0	80.0	12.5	80.0	0.0		
			0	120.0	-7.7	80.0	-11.1	80.0	5.3	120.0	-4.0	80.0	0.0	80.0	0.0		
			1	110.0	-15.4	80.0	-11.1	88.0	15.8	105.0	-16.0	75.0	-6.3	84.0	5.0		
			2	110.0	-15.4	70.0	-22.2	*	108.0	42.1	**	110.0	-12.0	80.0	0.0		
			3	120.0	-7.7	80.0	-11.1	88.0	15.8	100.0	-20.0	65.0	-18.8	96.0	20.0		
			4	130.0	0.0	85.0	-5.6	120.0	57.9	**	130.0	4.0	80.0	0.0	120.0	50.0	
			5	110.0	-15.4	75.0	-16.7	64.0	-15.8	**	110.0	0.0	80.0	0.0	60.0	-25.0	
			6	110.0	-15.4	80.0	-11.1	84.0	10.5	**	110.0	-12.0	80.0	0.0	100.0	25.0	
			8	110.0	-15.4	70.0	-22.2	*	70.0	-7.9	**	110.0	-12.0	80.0	0.0	85.0	6.3
			10	110.0	-15.4	75.0	-16.7	80.0	5.3	**	105.0	-16.0	80.0	0.0	90.0	12.5	
			12	110.0	-15.4	80.0	-11.1	84.0	10.5	**	100.0	-20.0	80.0	0.0	100.0	25.0	
			14	110.0	-15.4	70.0	-22.2	*	70.0	-7.9	**	110.0	-12.0	80.0	0.0	84.0	5.0
			16	110.0	-15.4	80.0	-11.1	84.0	10.5	**	105.0	-16.0	75.0	-6.3	92.0	15.0	
			29	OFC		-1	110.0	4.5	70.0	-14.3	100.0	38.9	**	110.0	0.0	65.0	0.0
						0	115.0	9.1	60.0	-14.3	100.0	38.9	**	115.0	4.5	65.0	0.0
						1	100.0	-9.1	55.0	-21.4	*	100.0	38.9	**	110.0	0.0	108.0
2	110.0	0.0	65.0	-7.1	120.0	66.7	**	105.0	-4.5	65.0	0.0	112.0	47.4				
														120.0	57.9		

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 100 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

2432

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOMETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING				STANDING									
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff				
1	29	OFC	3	105.0	-4.5	65.0	-7.1	108.0	50.0	**	95.0	-13.6	55.0	-15.4	116.0	52.6	**
			4	110.0	0.0	65.0	-7.1	120.0	66.7	**	105.0	-4.5	65.0	0.0	120.0	57.9	**
			5	110.0	0.0	70.0	0.0	100.0	38.9	**	120.0	9.1	70.0	7.7	105.0	38.2	**
			6	110.0	0.0	60.0	-14.3	120.0	66.7	**	115.0	4.5	65.0	0.0	128.0	68.4	**
			8	120.0	9.1	70.0	0.0	68.0	-5.6		120.0	9.1	70.0	7.7	75.0	-1.3	
			10	120.0	9.1	70.0	0.0	75.0	4.2		120.0	9.1	80.0	23.1	80.0	5.3	
			12	120.0	9.1	70.0	0.0	75.0	4.2		120.0	9.1	80.0	23.1	80.0	5.3	
	122	IVL	-1	120.0		80.0		88.0			115.0		75.0		100.0		
			0	90.0	-25.0	60.0	-25.0	88.0	0.0		95.0	-17.4	70.0	-6.7	88.0	-12.0	
			1	105.0	-12.5	70.0	-12.5	76.0	-13.6		95.0	-17.4	70.0	0.0	92.0	-8.0	
			2	90.0	-25.0	65.0	-18.8	80.0	-9.1		80.0	-30.4	60.0	-20.0	100.0	0.0	
			3	90.0	-25.0	70.0	-12.5	80.0	-9.1		90.0	-21.7	70.0	-6.7	90.0	-10.0	
			4	95.0	-20.8	65.0	-18.8	96.0	9.1		95.0	-17.4	75.0	0.0	108.0	8.0	
			5	95.0	-20.8	65.0	-18.8	96.0	9.1		95.0	-17.4	75.0	0.0	108.0	8.0	
			6	95.0	-20.8	65.0	-18.8	96.0	9.1		95.0	-17.4	75.0	0.0	108.0	8.0	
			8	95.0	-20.8	65.0	-18.8	96.0	9.1		95.0	-17.4	75.0	0.0	108.0	8.0	
			10	90.0	-25.0	70.0	-12.5	100.0	13.6		100.0	-13.0	70.0	-6.7	108.0	8.0	
			12	90.0	-25.0	70.0	-12.5	100.0	13.6		100.0	-13.0	70.0	-6.7	108.0	8.0	
			14	90.0	-25.0	60.0	-25.0	100.0	13.6		100.0	-13.0	70.0	-6.7	108.0	8.0	
			16	90.0	-25.0	60.0	-25.0	68.0	-22.7	*	80.0	-30.4	60.0	-20.0	80.0	-20.0	
			18	100.0	-16.7	65.0	-18.8	72.0	-18.2		100.0	-13.0	70.0	-6.7	84.0	-16.0	
			20	100.0	-16.7	65.0	-18.8	72.0	-18.2		100.0	-13.0	70.0	-6.7	84.0	-16.0	
			22	100.0	-16.7	75.0	-6.3	76.0	-13.6		100.0	-13.0	70.0	-6.7	84.0	-16.0	
			24	110.0	-8.3	80.0	0.0	84.0	-4.5		95.0	0.0	75.0	0.0	96.0	-4.0	
			26	110.0	-8.3	80.0	0.0	78.0	-11.4		90.0	-17.4	65.0	-13.3	84.0	-16.0	
			28	100.0	-16.7	70.0	-12.5	88.0	0.0		95.0	-17.4	70.0	-6.7	92.0	-8.0	
			30	100.0	-16.7	80.0	0.0	88.0	0.0		95.0	-17.4	70.0	-6.7	92.0	-8.0	
			32	115.0	-4.2	80.0	0.0	64.0	-27.3		105.0	-8.7	80.0	6.7	68.0	-32.0	
			34	115.0	-4.2	80.0	0.0	64.0	-27.3		105.0	-8.7	80.0	6.7	68.0	-32.0	
			36	95.0	-20.8	55.0	-31.3	84.0	-4.5	*	95.0	-17.4	70.0	-6.7	92.0	-8.0	
			38	95.0	-20.8	55.0	-31.3	84.0	-4.5	*	95.0	-17.4	70.0	-6.7	92.0	-8.0	
			40	105.0	-12.5	70.0	-12.5	80.0	-9.1		105.0	-8.7	85.0	13.3	74.0	-26.0	
			42	105.0	-12.5	70.0	-12.5	80.0	-9.1		105.0	-8.7	85.0	13.3	74.0	-26.0	
			44	110.0	-8.3	80.0	0.0	72.0	-18.2		100.0	-13.0	70.0	-6.7	76.0	-24.0	
			46	105.0	-12.5	80.0	-12.5	80.0	-9.1		110.0	-4.3	70.0	-6.7	84.0	-16.0	
			48	105.0	-12.5	65.0	-18.8	82.0	-6.8		110.0	-4.3	70.0	-6.7	84.0	-16.0	
			50	105.0	-12.5	80.0	-12.5	80.0	-9.1		110.0	-4.3	70.0	-6.7	84.0	-16.0	
			52	105.0	-12.5	75.0	-6.3	86.0	-4.5		100.0	-13.0	70.0	-6.7	88.0	-12.0	

2433

** S.B.P. values => 160 mm Hg
D.B.P. values => 100 mm Hg
H.R. values => 100 beats/min
* S.B.P. values <= 100 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3
VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	Initial Visit	LYING			STANDING								
			S.B.P. z diff	D.B.P. z diff	H.R. z diff	S.B.P. z diff	D.B.P. z diff	H.R. z diff						
1	126	JCM	-1	120.0	8.3	90.0	-11.1	82.0	130.0	-7.7	80.0	-12.5	90.0	-17.8
			0	130.0	8.3	80.0	-5.6	60.0	120.0	-7.7	70.0	-12.5	74.0	-6.7
			1	135.0	12.5	85.0	-5.6	72.0	120.0	-7.7	70.0	-6.3	84.0	-8.9
			2	130.0	8.3	85.0	-11.1	76.0	120.0	-7.7	80.0	0.0	82.0	0.0
			3	135.0	12.5	80.0	-11.1	84.0	120.0	-7.7	75.0	-6.3	90.0	0.0
			4	130.0	8.3	80.0	-11.1	76.0	120.0	-7.7	75.0	-6.3	82.0	-8.9
			5	130.0	8.3	75.0	-16.7	76.0	120.0	-7.7	70.0	-12.5	82.0	-8.9
			6	130.0	8.3	80.0	-11.1	68.0	120.0	-7.7	75.0	-6.3	78.0	-13.3
			8	130.0	8.3	80.0	-11.1	60.0	125.0	-3.8	75.0	-6.3	82.0	-31.1
			10	120.0	0.0	70.0	-22.2	54.0	110.0	-15.4	65.0	-18.8	60.0	-33.3
			12	110.0	-8.3	70.0	-22.2	56.0	105.0	-19.2	64.0	-28.9	64.0	-28.9
			14	110.0	-8.3	70.0	-22.2	54.0	110.0	-15.4	60.0	-25.0	58.0	-35.6
			16	105.0	-12.5	75.0	-16.7	54.0	105.0	-19.2	64.0	-28.9	64.0	-28.9
			18	110.0	-8.3	70.0	-22.2	54.0	105.0	-19.2	64.0	-28.9	64.0	-28.9
			20	110.0	-8.3	70.0	-22.2	54.0	105.0	-19.2	64.0	-28.9	64.0	-28.9
			22	105.0	-12.5	70.0	-22.2	58.0	105.0	-19.2	64.0	-28.9	64.0	-28.9
			24	120.0	0.0	80.0	-11.1	72.0	115.0	-11.5	75.0	-6.3	80.0	-11.1
			26	115.0	-4.2	75.0	-16.7	70.0	120.0	-7.7	70.0	-12.5	76.0	-15.6
			28	110.0	-8.3	70.0	-22.2	72.0	120.0	-7.7	70.0	-12.5	76.0	-15.6
			30	115.0	-4.2	80.0	-11.1	78.0	110.0	-15.4	70.0	-12.5	84.0	-6.7
			32	120.0	0.0	70.0	-22.2	82.0	120.0	-7.7	70.0	-12.5	86.0	-4.4
			34	125.0	4.2	85.0	-5.6	82.0	120.0	-7.7	70.0	-12.5	86.0	-4.4
			36	130.0	8.3	80.0	-11.1	78.0	125.0	-3.8	80.0	-12.5	88.0	-2.2
			38	125.0	4.2	75.0	-16.7	78.0	120.0	-7.7	80.0	0.0	82.0	-8.9
			40	115.0	-4.2	70.0	-22.2	88.0	110.0	-15.4	70.0	-12.5	88.0	-2.2
			42	120.0	0.0	70.0	-22.2	90.0	110.0	-15.4	70.0	-12.5	92.0	2.2
			44	130.0	8.3	70.0	-22.2	82.0	115.0	-11.5	70.0	-12.5	86.0	-4.4
			46	115.0	-4.2	78.0	-16.7	78.0	110.0	-15.4	70.0	-12.5	90.0	0.0
			48	120.0	0.0	80.0	-11.1	88.0	115.0	-11.5	75.0	-6.3	94.0	4.4
			50	120.0	0.0	70.0	-22.2	92.0	110.0	-15.4	70.0	-12.5	96.0	6.7
			52	130.0	8.3	70.0	-22.2	94.0	120.0	-7.7	70.0	-12.5	96.0	6.7
144	144	MTF	-1	110.0	0.0	70.0	0.0	72.0	100.0	10.0	60.0	0.0	82.0	-7.3
			0	110.0	0.0	70.0	0.0	76.0	100.0	0.0	60.0	0.0	76.0	-2.4
			1	105.0	-4.5	75.0	7.1	74.0	100.0	0.0	70.0	16.7	80.0	-4.9
			2	100.0	-9.1	70.0	0.0	74.0	90.0	-10.0	65.0	8.3	78.0	-4.9
			3	110.0	0.0	80.0	14.3	72.0	100.0	0.0	70.0	16.7	78.0	-4.9
			4	115.0	4.5	75.0	7.1	78.0	110.0	10.0	70.0	16.7	74.0	-9.8
			5	120.0	9.1	80.0	14.3	72.0	110.0	10.0	70.0	16.7	78.0	-4.9
			6	110.0	0.0	70.0	0.0	76.0	105.0	5.0	70.0	16.7	82.0	0.0

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 100 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

2434

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXYTINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LIVING			STANDING										
				S.B.P. % diff	D.R.P. % diff	H.R. % diff	S.B.P. % diff	D.B.P. % diff	H.R. % diff								
1	144	NTF	8	120.0	9.1	75.0	7.1	102.0	41.7	**	115.0	15.0	70.0	16.7	104.0	26.8	**
			10	130.0	18.2	80.0	14.3	88.0	22.2		120.0	20.0	75.0	25.0	98.0	19.5	
			12	120.0	9.1	80.0	14.3	74.0	2.8		115.0	15.0	70.0	16.7	84.0	2.4	**
			14	125.0	13.6	85.0	21.4	90.0	25.0		130.0	30.0	80.0	50.0	102.0	24.4	**
			16	120.0	9.1	80.0	14.3	92.0	27.8		120.0	20.0	85.0	41.7	98.0	19.5	
			18	125.0	13.6	85.0	21.4	84.0	16.7		120.0	20.0	80.0	33.3	92.0	12.2	
			20	130.0	18.2	90.0	28.6	96.0	39.3		125.0	25.0	85.0	41.7	104.0	26.8	**
			22	130.0	18.2	80.0	14.3	92.0	27.8		120.0	20.0	85.0	41.7	104.0	26.8	**
			24	120.0	9.1	70.0	0.0	74.0	2.8		125.0	25.0	75.0	25.0	78.0	-4.9	
			26	120.0	9.1	70.0	0.0	70.0	-2.8		125.0	25.0	80.0	33.3	72.0	-12.2	
			28	120.0	9.1	80.0	14.3	74.0	-2.8		110.0	10.0	70.0	16.7	76.0	-7.3	
			30	120.0	9.1	80.0	14.3	74.0	-2.8		110.0	10.0	70.0	16.7	76.0	-7.3	
			32	125.0	13.6	70.0	0.0	70.0	-2.8		115.0	15.0	70.0	16.7	72.0	-12.2	
			34	110.0	0.0	70.0	0.0	60.0	-16.7		100.0	0.0	70.0	16.7	64.0	-22.0	
			36	125.0	13.6	80.0	14.3	66.0	-8.3		110.0	10.0	70.0	16.7	72.0	-12.2	
			38	125.0	13.6	80.0	14.3	72.0	0.0		120.0	20.0	75.0	25.0	76.0	-7.3	
			40	125.0	13.6	80.0	14.3	68.0	-5.6		115.0	15.0	70.0	16.7	72.0	-12.2	
			42	120.0	9.1	70.0	0.0	68.0	-8.3		110.0	10.0	65.0	8.3	72.0	-12.2	
			44	115.0	4.5	75.0	7.1	68.0	-5.6		110.0	10.0	70.0	16.7	74.0	-9.8	
			46	120.0	9.1	70.0	0.0	66.0	-8.3		115.0	15.0	70.0	16.7	74.0	-9.8	
			48	130.0	18.2	70.0	0.0	66.0	-8.3		115.0	15.0	75.0	25.0	70.0	-14.6	
			50	120.0	9.1	70.0	0.0	64.0	-11.1		115.0	15.0	70.0	16.7	68.0	-17.1	
			52	120.0	9.1	75.0	7.1	74.0	2.8		115.0	15.0	70.0	16.7	80.0	-2.4	
		MRN	-1	125.0	4.0	90.0	0.0	84.0	-2.4		120.0	4.2	80.0	12.5	92.0	-2.2	
			0	130.0	8.0	85.0	-5.6	76.0	-9.5		130.0	8.3	90.0	12.5	82.0	-10.9	
			1	135.0	12.0	80.0	-11.1	70.0	-16.7		120.0	0.0	80.0	0.0	82.0	-10.9	
			2	130.0	4.0	80.0	-11.1	66.0	-21.4		110.0	-8.3	70.0	-12.5	76.0	-19.6	
			3	120.0	-4.0	80.0	-11.1	69.0	-17.9		130.0	8.3	80.0	0.0	76.0	-17.4	
			4	125.0	0.0	80.0	-11.1	69.0	-17.9		130.0	8.3	80.0	0.0	76.0	-17.4	
			5	130.0	4.0	90.0	0.0	78.0	-7.1		130.0	8.3	90.0	12.5	86.0	-6.5	
			6	125.0	0.0	85.0	-5.6	75.0	-9.5		130.0	8.3	90.0	12.5	86.0	-6.5	
			8	130.0	4.0	85.0	-11.1	68.0	-19.0		120.0	0.0	75.0	-6.3	82.0	-10.9	
			10	125.0	0.0	80.0	-5.6	70.0	-16.7		120.0	0.0	80.0	0.0	78.0	-15.2	
			12	130.0	4.0	90.0	0.0	80.0	7.1		125.0	4.2	90.0	12.5	92.0	0.0	
			14	120.0	-4.0	80.0	-11.1	84.0	0.5		115.0	-4.2	85.0	-6.3	86.0	-6.5	
			16	120.0	-4.0	75.0	-16.7	76.0	-9.5		130.0	8.3	80.0	0.0	82.0	-10.9	
			18	120.0	-4.0	80.0	-11.1	78.0	-7.1		125.0	4.2	85.0	-6.3	86.0	-6.5	
			20	120.0	-4.0	75.0	-16.7	84.0	0.0		125.0	4.2	80.0	0.0	86.0	-6.5	
			22	130.0	4.0	80.0	-11.1	84.0	0.0		120.0	0.0	75.0	-6.3	88.0	-4.3	

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 100 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	Initial Visit	LIVING				STANDING										
			S.B.P. z diff	D.R.P. z diff	H.R. z diff	S.B.P. z diff	D.R.P. z diff	H.R. z diff									
1	146	MRN	24	120.0	-4.0	-22.2	*	74.0	-11.9	110.0	-8.3	70.0	-12.5	78.0	-15.2		
		26	120.0	-4.0	-11.1	80.0	-31.0	58.0	-23.8	125.0	4.2	70.0	-12.5	64.0	-30.4		
		28	125.0	0.0	-11.1	80.0	-2.4	64.0	-11.9	115.0	-4.2	70.0	-12.5	68.0	-26.1		
		30	125.0	0.0	-11.1	80.0	-4.0	82.0	-31.0	115.0	-4.2	70.0	-12.5	84.0	-8.7		
		32	120.0	0.0	-11.1	80.0	-11.1	74.0	-11.9	115.0	-4.2	70.0	-12.5	78.0	-15.2		
		34	130.0	4.0	-11.1	80.0	-11.1	58.0	-31.0	115.0	-4.2	70.0	-12.5	66.0	-28.3		
		36	130.0	4.0	-11.1	80.0	-11.1	74.0	-11.9	120.0	0.0	70.0	-12.5	76.0	-17.4		
		38	125.0	0.0	-11.1	80.0	-11.1	74.0	-11.9	120.0	0.0	70.0	-12.5	78.0	-15.2		
		40	110.0	-12.0	-22.2	*	60.0	-28.6	115.0	-6.3	100.0	-6.3	75.0	-6.3	64.0	-30.4	
		42	110.0	-12.0	-16.7	*	56.0	-33.3	115.0	-16.7	100.0	-16.7	75.0	-25.0	62.0	-32.6	
		44	120.0	-4.0	-11.1	80.0	-22.2	60.0	-23.8	110.0	-8.3	70.0	-12.5	66.0	-28.3		
		46	120.0	-4.0	-11.1	80.0	-22.2	68.0	-19.0	105.0	-12.5	70.0	-12.5	72.0	-21.7		
		48	120.0	-4.0	-22.2	*	74.0	-19.0	120.0	0.0	60.0	-25.0	70.0	-12.5	76.0	-17.4	
		50	125.0	0.0	-22.2	*	56.0	-33.3	100.0	-16.7	100.0	-16.7	70.0	-12.5	58.0	-37.0	
		52	110.0	-12.0	-22.2	*	70.0	-30.0	100.0	-26.7	100.0	-26.7	70.0	-30.0	76.0	-13.6	
		302	LM		-1	150.0	0.0	0.0	68.0	0.0	150.0	0.0	100.0	0.0	100.0	88.0	0.0
0	150.0			0.0	-15.0	85.0	58.8	108.0	23.5	120.0	-20.0	90.0	-10.0	88.0	31.8		
1	130.0			-13.3	-20.0	80.0	92.0	84.0	23.5	115.0	-23.3	85.0	-15.0	116.0	13.6		
2	115.0			-10.0	-5.0	95.0	84.0	84.0	23.5	125.0	-16.7	90.0	-10.0	100.0	9.1		
3	135.0			-10.0	-5.0	95.0	84.0	84.0	23.5	125.0	-16.7	90.0	-10.0	80.0	-9.1		
4	135.0			-10.0	-5.0	95.0	84.0	84.0	23.5	125.0	-16.7	90.0	-10.0	80.0	-9.1		
5	100.0			-33.3	*	80.0	92.0	92.0	35.3	120.0	-20.0	80.0	-20.0	88.0	0.0		
6	100.0			-33.3	*	80.0	92.0	92.0	35.3	120.0	-20.0	80.0	-20.0	88.0	0.0		
8	120.0			-20.0	-20.0	80.0	72.0	72.0	5.9	110.0	-26.7	80.0	-20.0	80.0	-9.1		
10	125.0			-16.7	-15.0	85.0	84.0	84.0	8.8	120.0	-20.0	80.0	-20.0	80.0	-9.1		
12	130.0			-13.3	-20.0	80.0	72.0	72.0	5.9	120.0	-20.0	70.0	-30.0	80.0	-9.1		
14	120.0			-20.0	-25.0	75.0	84.0	84.0	8.8	125.0	-16.7	80.0	-20.0	76.0	-13.6		
16	120.0			-20.0	-30.0	70.0	72.0	72.0	5.9	110.0	-26.7	70.0	-30.0	76.0	-13.6		
304	DBF				-1	120.0	0.0	0.0	88.0	0.0	120.0	0.0	100.0	0.0	100.0	100.0	0.0
				0	120.0	0.0	0.0	88.0	0.0	120.0	0.0	120.0	0.0	90.0	0.0	120.0	20.0
				1	120.0	0.0	28.6	90.0	36.4	120.0	36.4	120.0	0.0	90.0	0.0	120.0	20.0
		2	125.0	4.2	28.6	90.0	36.4	120.0	36.4	120.0	0.0	90.0	0.0	116.0	16.0		
		3	120.0	0.0	28.6	90.0	36.4	120.0	36.4	120.0	0.0	90.0	0.0	108.0	8.0		
		4	140.0	16.7	28.6	90.0	31.8	116.0	31.8	150.0	25.0	90.0	0.0	120.0	20.0		
		5	115.0	-4.2	14.3	80.0	36.4	120.0	36.4	105.0	-12.5	85.0	-5.6	132.0	32.0		
		6	150.0	25.0	28.6	90.0	36.4	120.0	36.4	140.0	16.7	90.0	0.0	120.0	20.0		
		8	110.0	-8.3	14.3	80.0	36.4	120.0	36.4	120.0	0.0	85.0	-8.0	92.0	-8.0		
		10	140.0	16.7	28.6	90.0	25.0	110.0	25.0	140.0	16.7	90.0	0.0	110.0	10.0		

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 50 mm Hg
H.R. values <= 50 beats/min

2436

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS 88D

REBOXETINE - PROTOCOL 20124/013

Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	Initial	LYING			STANDING											
			Visit	S.B.P. % diff	H.R. % diff	D.B.P. % diff	S.B.P. % diff	H.R. % diff	D.B.P. % diff								
1	304	DBF	12	130.0	8.3	90.0	28.6	116.0	31.8	**	130.0	6.3	90.0	0.0	120.0	20.0	
			14	145.0	20.8	85.0	21.4	120.0	36.4	**	160.0	33.3	**	100.0	11.1	120.0	20.0
			16	150.0	25.0	90.0	28.6	92.0	4.5		140.0	16.7	100.0	11.1	100.0	0.0	
			18	120.0	0.0	80.0	14.3	136.0	54.5	**	105.0	-12.5	80.0	-11.1	140.0	40.0	
			20	140.0	16.7	90.0	28.6	116.0	31.8	**	150.0	25.0	100.0	11.1	100.0	0.0	
			22	160.0	33.3	**	100.0	42.9	**	155.0	29.2	110.0	22.2	**	100.0	0.0	
			24	160.0	33.3	**	100.0	42.9	**	155.0	29.2	100.0	11.1	120.0	20.0		
			26	160.0	33.3	**	100.0	42.9	**	155.0	29.2	100.0	11.1	120.0	20.0		
			28	140.0	16.7	85.0	21.4	112.0	27.3	**	125.0	4.2	85.0	-5.6	120.0	20.0	
			30	150.0	25.0	100.0	42.9	104.0	18.2	**	150.0	25.0	100.0	11.1	104.0	4.0	
			32	140.0	16.7	85.0	21.4	100.0	0.0		135.0	12.5	90.0	0.0	100.0	-12.0	
			34	140.0	16.7	85.0	21.4	100.0	13.6		140.0	16.7	85.0	0.0	100.0	0.0	
			36	125.0	4.2	95.0	35.7	88.0	0.0		115.0	-4.2	85.0	-5.6	100.0	0.0	
			38	165.0	37.5	**	110.0	57.1	**	100.0	13.6	150.0	25.0	105.0	16.7	104.0	4.0
			40	130.0	8.3	95.0	35.7	88.0	0.0		150.0	25.0	100.0	11.1	104.0	4.0	
			42	140.0	16.7	90.0	28.6	112.0	27.3	**	150.0	25.0	100.0	11.1	104.0	4.0	
			44	160.0	33.3	**	95.0	94.3	0.0		170.0	41.7	**	110.0	22.2	**	
			46	150.0	25.0	80.0	14.3	86.0	0.0		150.0	25.0	85.0	-5.6	92.0	-8.0	
			48	150.0	25.0	90.0	28.6	76.0	-13.6		140.0	16.7	80.0	-11.1	84.0	-16.0	
			50	155.0	23.2	95.0	35.7	88.0	0.0		145.0	20.8	90.0	0.0	96.0	-4.0	
			52	160.0	33.3	**	105.0	50.0	**	100.0	13.6	145.0	20.8	105.0	16.7	108.0	8.0
		EM	-1	130.0		80.0		60.0			125.0		80.0		60.0		
			0	100.0	-23.1	*	-12.5	80.0	33.3		100.0	-20.0	70.0	-12.5	84.0	40.0	
			1	100.0	-23.1	*	-25.0	*	33.3		105.0	-16.0	65.0	-18.8	92.0	53.3	
			2	105.0	-19.2	*	-18.8	76.0	26.7		90.0	-28.0	*	25.0	80.0	33.3	
			3	95.0	-26.9	*	-25.0	*	53.3		90.0	-28.0	*	25.0	108.0	80.0	
			4	90.0	-30.8	*	-25.0	*	46.7		100.0	-20.0	*	25.0	108.0	80.0	
			5	110.0	-15.4	*	-12.5	90.0	50.0		110.0	-12.0	70.0	-12.5	94.0	46.7	
			6	100.0	-23.1	*	-25.0	*	26.7		100.0	-20.0	70.0	-12.5	94.0	46.7	
			8	110.0	-15.4	*	-12.5	100.0	66.7	**	120.0	-4.0	80.0	0.0	100.0	66.7	
			10	100.0	-23.1	*	-25.0	*	46.7		105.0	-16.0	60.0	-25.0	108.0	80.0	
			12	100.0	-23.1	*	-25.0	*	66.7	**	100.0	-20.0	65.0	-18.8	108.0	80.0	
			14	110.0	-15.4	*	-12.5	100.0	66.7	**	110.0	-12.0	70.0	-12.5	100.0	66.7	
			16	90.0	-30.8	*	-25.0	*	46.7		95.0	-24.0	*	25.0	92.0	53.3	
			18	100.0	-23.1	*	-6.3	118.0	96.7	**	100.0	0.0	80.0	0.0	120.0	100.0	
			20	90.0	-30.8	*	-25.0	*	46.7		95.0	-24.0	*	25.0	92.0	53.3	
			22	90.0	-30.8	*	-25.0	*	53.3		90.0	-28.0	*	60.0	92.0	53.3	
			24	95.0	-26.9	*	-25.0	*	40.0		90.0	-28.0	*	65.0	96.0	60.0	
			26	110.0	-15.4	*	-18.8	92.0	55.3		110.0	-12.0	70.0	-12.5	100.0	66.7	

** S.B.P. values => 160 mm Hg
D.B.P. values => 100 mm Hg
H.R. values => 100 beats/min
* S.B.P. values <= 100 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

24537

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 RENDOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING				STANDING									
				S.B.P. % diff	D.B.P. % diff	H.R. % diff	S.R.P. % diff	S.B.P. % diff	D.B.P. % diff	H.R. % diff	S.R.P. % diff						
1	306	EM	28	110.0	-15.4	65.0	-18.8	92.0	53.3	110.0	-12.0	70.0	-12.5	100.0	66.7	**	
			30	110.0	-15.4	65.0	-18.8	92.0	53.3	110.0	-12.0	70.0	-12.5	100.0	66.7	**	
			32	110.0	-15.4	70.0	-12.5	100.0	66.7	**	100.0	-20.0	70.0	-12.5	100.0	66.7	**
			34	110.0	-15.4	70.0	-12.5	100.0	66.7	**	100.0	-20.0	70.0	-12.5	100.0	66.7	**
			36	100.0	-23.1	65.0	-18.8	88.0	46.7	**	90.0	-28.0	75.0	-6.3	100.0	66.7	**
			38	110.0	-15.4	85.0	6.3	88.0	46.7	**	120.0	-4.0	75.0	-6.3	88.0	46.7	**
			40	110.0	-15.4	85.0	6.3	88.0	46.7	**	120.0	-4.0	75.0	-6.3	88.0	46.7	**
			42	110.0	-15.4	85.0	6.3	88.0	46.7	**	120.0	-4.0	75.0	-6.3	88.0	46.7	**
			44	110.0	-15.4	85.0	6.3	88.0	46.7	**	120.0	-4.0	75.0	-6.3	88.0	46.7	**
			46	115.0	-11.5	75.0	-6.3	90.0	50.0	**	100.0	-4.0	75.0	-6.3	96.0	40.0	**
			48	115.0	-11.5	75.0	-6.3	78.0	26.7	**	100.0	-20.0	75.0	-6.3	84.0	40.0	**
			50	115.0	-11.5	75.0	-6.3	82.0	36.7	**	100.0	-20.0	75.0	-6.3	90.0	50.0	**
			52	115.0	-11.5	75.0	-6.3	82.0	36.7	**	100.0	-20.0	75.0	-6.3	90.0	50.0	**
			54	115.0	-11.5	75.0	-6.3	82.0	36.7	**	100.0	-20.0	75.0	-6.3	86.0	43.3	**
			56	130.0	0.0	90.0	0.0	76.0	0.0	**	125.0	4.0	90.0	0.0	80.0	12.5	**
			58	130.0	0.0	80.0	-11.1	88.0	15.8	**	130.0	4.0	85.0	-5.6	90.0	12.5	**
			60	120.0	-7.7	65.0	-27.8	80.0	5.3	**	100.0	-20.0	70.0	-22.2	92.0	15.0	**
			62	120.0	-7.7	70.0	-22.2	88.0	15.8	**	120.0	-4.0	80.0	-11.1	92.0	15.0	**
			64	120.0	-7.7	70.0	-22.2	88.0	15.8	**	120.0	-4.0	80.0	-11.1	92.0	15.0	**
			66	120.0	-7.7	70.0	-22.2	88.0	15.8	**	120.0	-4.0	80.0	-11.1	92.0	15.0	**
			68	120.0	-7.7	70.0	-22.2	88.0	15.8	**	120.0	-4.0	80.0	-11.1	92.0	15.0	**
70	120.0	-7.7	70.0	-22.2	88.0	15.8	**	120.0	-4.0	80.0	-11.1	92.0	15.0	**			
72	120.0	-7.7	70.0	-22.2	88.0	15.8	**	120.0	-4.0	80.0	-11.1	92.0	15.0	**			
74	120.0	-7.7	70.0	-22.2	88.0	15.8	**	120.0	-4.0	80.0	-11.1	92.0	15.0	**			
76	120.0	-7.7	70.0	-22.2	88.0	15.8	**	120.0	-4.0	80.0	-11.1	92.0	15.0	**			
78	120.0	-7.7	70.0	-22.2	88.0	15.8	**	120.0	-4.0	80.0	-11.1	92.0	15.0	**			
80	120.0	-7.7	70.0	-22.2	88.0	15.8	**	120.0	-4.0	80.0	-11.1	92.0	15.0	**			
82	120.0	-7.7	70.0	-22.2	88.0	15.8	**	120.0	-4.0	80.0	-11.1	92.0	15.0	**			
84	120.0	-7.7	70.0	-22.2	88.0	15.8	**	120.0	-4.0	80.0	-11.1	92.0	15.0	**			
86	120.0	-7.7	70.0	-22.2	88.0	15.8	**	120.0	-4.0	80.0	-11.1	92.0	15.0	**			
88	120.0	-7.7	70.0	-22.2	88.0	15.8	**	120.0	-4.0	80.0	-11.1	92.0	15.0	**			
90	120.0	-7.7	70.0	-22.2	88.0	15.8	**	120.0	-4.0	80.0	-11.1	92.0	15.0	**			
92	120.0	-7.7	70.0	-22.2	88.0	15.8	**	120.0	-4.0	80.0	-11.1	92.0	15.0	**			
94	120.0	-7.7	70.0	-22.2	88.0	15.8	**	120.0	-4.0	80.0	-11.1	92.0	15.0	**			
96	120.0	-7.7	70.0	-22.2	88.0	15.8	**	120.0	-4.0	80.0	-11.1	92.0	15.0	**			
98	120.0	-7.7	70.0	-22.2	88.0	15.8	**	120.0	-4.0	80.0	-11.1	92.0	15.0	**			
100	120.0	-7.7	70.0	-22.2	88.0	15.8	**	120.0	-4.0	80.0	-11.1	92.0	15.0	**			

** S.B.P. values => 160 mm Hg
 D.B.P. values => 100 mm Hg
 H.R. values => 100 beats/min
 * S.B.P. values <= 100 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

24 00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING			STANDING								
				S.B.P. % diff	H.R. % diff	D.B.P. % diff	S.B.P. % diff	H.R. % diff	D.B.P. % diff						
1	307	SFS	44	140.0	7.7	90.0	0.0	74.0	-2.6	135.0	8.0	90.0	0.0	82.0	2.5
	308	ICC	-1	130.0	0.0	80.0	12.5	76.0	5.3	120.0	8.3	70.0	28.6	84.0	9.5
			0	130.0	-7.7	90.0	0.0	80.0	21.1	130.0	-8.3	90.0	35.7	92.0	23.8
			1	120.0	-7.7	90.0	12.5	104.0	36.8	110.0	-8.3	85.0	21.4	104.0	33.3
			2	120.0	-7.7	90.0	12.5	94.0	26.3	110.0	-8.3	80.0	14.3	100.0	19.0
			3	120.0	0.0	85.0	6.3	100.0	31.6	110.0	-8.3	70.0	0.0	118.0	40.5
			4	120.0	-7.7	90.0	12.5	98.0	28.9	120.0	0.0	90.0	23.6	105.0	25.0
			5	125.0	-3.8	85.0	6.3	88.0	15.8	110.0	-8.3	80.0	14.3	100.0	19.0
			6	130.0	0.0	90.0	12.5	76.0	10.5	130.0	-16.7	92.0	0.0	92.0	9.5
			8	115.0	-11.5	80.0	0.0	84.0	10.5	100.0	-16.7	70.0	0.0	100.0	19.0
			10	115.0	-11.5	80.0	0.0	80.0	5.3	100.0	-16.7	70.0	0.0	84.0	0.0
			12	115.0	-11.5	80.0	0.0	80.0	5.3	100.0	-8.3	84.0	0.0	84.0	0.0
			14	105.0	-19.2	80.0	0.0	80.0	5.3	110.0	-8.3	85.0	21.4	84.0	0.0
			16	105.0	-19.2	80.0	0.0	80.0	5.3	110.0	-8.3	85.0	21.4	84.0	0.0
			18	105.0	-19.2	80.0	0.0	76.0	0.0	105.0	-12.5	75.0	7.1	88.0	4.8
			20	105.0	-19.2	80.0	0.0	76.0	0.0	105.0	-16.7	70.0	0.0	88.0	7.1
			22	130.0	0.0	90.0	12.5	82.0	7.9	115.0	-4.2	85.0	21.4	90.0	7.1
			24	130.0	0.0	90.0	12.5	82.0	7.9	115.0	-4.2	85.0	21.4	90.0	7.1
			26	140.0	7.7	90.0	12.5	80.0	5.3	120.0	0.0	90.0	28.6	80.0	-4.8
			28	140.0	7.7	90.0	12.5	80.0	5.3	120.0	0.0	90.0	28.6	80.0	-4.8
			30	110.0	-15.4	80.0	0.0	68.0	-10.5	100.0	-16.7	70.0	0.0	92.0	9.5
			32	110.0	-15.4	80.0	0.0	68.0	-10.5	100.0	-16.7	70.0	0.0	92.0	9.5
			34	110.0	-15.4	80.0	0.0	68.0	-10.5	100.0	-16.7	70.0	0.0	92.0	9.5
			36	110.0	-15.4	80.0	0.0	68.0	-10.5	100.0	-16.7	70.0	0.0	92.0	9.5
			38	110.0	-15.4	80.0	0.0	68.0	-10.5	100.0	-16.7	70.0	0.0	92.0	9.5
			40	110.0	-15.4	80.0	0.0	68.0	-10.5	100.0	-16.7	70.0	0.0	92.0	9.5
			42	120.0	-7.7	80.0	0.0	84.0	10.5	120.0	0.0	80.0	14.3	84.0	0.0
			44	120.0	-7.7	80.0	0.0	84.0	10.5	120.0	0.0	80.0	14.3	84.0	0.0
			46	120.0	-7.7	80.0	0.0	84.0	10.5	120.0	0.0	80.0	14.3	84.0	0.0
			48	120.0	-7.7	80.0	0.0	76.0	0.0	100.0	-16.7	80.0	14.3	88.0	4.8
			50	120.0	-7.7	80.0	0.0	76.0	0.0	100.0	-16.7	80.0	14.3	88.0	4.8
			52	105.0	-19.2	65.0	-18.8	76.0	0.0	95.0	-20.8	60.0	-14.3	76.0	-9.5
	312	MCS	-1	130.0	0.0	90.0	0.0	92.0	0.0	125.0	0.0	85.0	0.0	88.0	0.0
			0	130.0	0.0	90.0	0.0	92.0	0.0	125.0	0.0	85.0	0.0	88.0	0.0
			1	130.0	0.0	90.0	0.0	80.0	-13.0	130.0	4.0	90.0	5.9	90.0	2.3
			2	125.0	-3.8	85.0	-5.6	108.0	17.4	105.0	-16.0	70.0	-17.6	108.0	22.7
			3	110.0	-15.4	90.0	0.0	90.0	-2.2	120.0	-4.0	58.0	11.8	100.0	13.6
			4	115.0	-11.5	80.0	-11.1	100.0	8.7	105.0	-16.0	75.0	-11.8	108.0	22.7

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 50 mm Hg
H.R. values <= 50 beats/min

2439

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD
REBOXYTINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Centre	Patient	Initial	Visit	LYING			STANDING									
				S.B.P. x diff	H.R. x diff	D.B.P. x diff	S.B.P. x diff	H.R. x diff	D.B.P. x diff							
1	312	MCS	5	100.0	-23.1	*	80.0	-11.1	100.0	8.7	100.0	-20.0	80.0	-5.9	100.0	13.6
			6	130.0	0.0		85.0	-5.6	108.0	17.4	120.0	-4.0	85.0	0.0	108.0	22.7
			8	130.0	0.0		90.0	0.0	100.0	8.7	120.0	-4.0	95.0	0.0	100.0	13.6
			10	100.0	-23.1	*	75.0	-16.7	92.0	0.0	110.0	-12.0	80.0	-5.9	96.0	9.1
			12	120.0	-7.7		85.0	-5.6	96.0	4.3	130.0	4.0	90.0	5.9	84.0	-4.5
			14	110.0	-15.4		90.0	0.0	96.0	4.3	110.0	-12.0	90.0	5.9	88.0	0.0
			16	110.0	-15.4		90.0	0.0	96.0	4.3	110.0	-12.0	90.0	5.9	88.0	0.0
			18	125.0	-3.8		85.0	-5.6	88.0	-4.3	120.0	-4.0	85.0	0.0	96.0	9.1
			20	125.0	-3.8		85.0	-5.6	88.0	-4.3	120.0	-4.0	85.0	0.0	96.0	9.1
			22	105.0	-19.2		80.0	-11.1	80.0	-13.0	105.0	-16.0	80.0	-5.9	84.0	-4.5
			24	135.0	3.8		95.0	5.6	80.0	-13.0	130.0	4.0	90.0	5.9	84.0	-4.5
			26	135.0	3.8		95.0	5.6	80.0	-13.0	130.0	4.0	90.0	5.9	84.0	-4.5
			28	135.0	3.8		90.0	0.0	80.0	-13.0	130.0	4.0	95.0	11.8	84.0	-4.5
			30	135.0	3.8		95.0	5.6	80.0	-13.0	130.0	4.0	95.0	11.8	84.0	-4.5
			32	115.0	-11.5		80.0	-11.1	84.0	-8.7	115.0	-8.0	80.0	-5.9	80.0	-9.1
			34	115.0	-11.5		80.0	-11.1	84.0	-8.7	115.0	-8.0	80.0	-5.9	80.0	-9.1
			36	115.0	-11.5		80.0	-11.1	84.0	-8.7	115.0	-8.0	80.0	-5.9	80.0	-9.1
			38	115.0	-11.5		85.0	-5.6	80.0	-13.0	120.0	-4.0	80.0	-5.9	80.0	-9.1
			40	115.0	-11.5		85.0	-5.6	80.0	-13.0	120.0	-4.0	80.0	-5.9	80.0	-9.1
			42	115.0	-11.5		80.0	-11.1	80.0	-13.0	120.0	-4.0	80.0	-5.9	80.0	-6.8
			44	120.0	-7.7		80.0	-11.1	80.0	-13.0	120.0	-4.0	80.0	-5.9	84.0	-4.5
			46	120.0	-7.7		80.0	-11.1	80.0	-13.0	120.0	-4.0	80.0	-5.9	84.0	-4.5
			-1	110.0			60.0		100.0		100.0		60.0		104.0	
			0	110.0	0.0		60.0	0.0	100.0	0.0	100.0	0.0	60.0	0.0	104.0	0.0
			1	110.0	0.0		70.0	16.7	100.0	0.0	110.0	10.0	70.0	16.7	104.0	0.0
			2	110.0	0.0		65.0	8.3	116.0	16.0	105.0	5.0	60.0	0.0	132.0	1.0
			3	115.0	4.5		70.0	16.7	96.0	-4.0	115.0	15.0	65.0	8.3	132.0	26.9
			4	110.0	0.0		80.0	33.3	80.0	-20.0	110.0	10.0	80.0	5.9	104.0	3.8
			5	115.0	4.5		80.0	33.3	84.0	-16.0	110.0	10.0	80.0	5.9	104.0	0.0
			6	90.0	-18.2		70.0	16.7	116.0	16.0	95.0	-5.0	70.0	16.7	120.0	-3.8
			8	100.0	-9.1		60.0	0.0	90.0	-10.0	100.0	0.0	60.0	0.0	120.0	15.4
			10	120.0	9.1		75.0	25.0	68.0	-12.0	115.0	15.0	70.0	16.7	95.0	-8.7
			12	100.0	-9.1		80.0	33.3	116.0	16.0	100.0	0.0	80.0	33.3	120.0	-11.5
			14	110.0	0.0		70.0	16.7	100.0	0.0	100.0	0.0	70.0	16.7	120.0	15.4
			16	100.0	-9.1		60.0	0.0	100.0	0.0	100.0	0.0	60.0	0.0	120.0	15.4
			18	100.0	-9.1		80.0	0.0	100.0	0.0	100.0	0.0	70.0	16.7	110.0	5.8
			20	130.0	18.2		80.0	33.3	92.0	-8.0	115.0	15.0	80.0	33.3	108.0	3.8
			22	130.0	18.2		80.0	33.3	92.0	-8.0	115.0	15.0	80.0	33.3	108.0	3.8
			24	110.0	0.0		75.0	25.0	100.0	0.0	110.0	10.0	70.0	16.7	108.0	3.8

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 100 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

2440

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING				STANDING												
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff							
1	314	MFA	26	120.0	9.1	75.0	25.0	96.0	-4.0	115.0	15.0	80.0	33.3	104.0	0.0					
			28	115.0	4.5	75.0	25.0	98.0	-2.0	115.0	15.0	75.0	25.0	106.0	1.9					
			30	110.0	0.0	70.0	16.7	96.0	-4.0	115.0	15.0	75.0	25.0	100.0	-3.8					
			32	110.0	0.0	70.0	16.7	96.0	-4.0	115.0	15.0	75.0	25.0	100.0	-3.8					
			34	105.0	-4.5	70.0	16.7	96.0	-4.0	115.0	15.0	75.0	25.0	100.0	-3.8					
			36	105.0	-4.5	70.0	16.7	96.0	-4.0	115.0	15.0	75.0	25.0	100.0	-3.8					
			38	105.0	-4.5	70.0	16.7	96.0	-4.0	115.0	15.0	75.0	25.0	100.0	-3.8					
			40	120.0	9.1	70.0	16.7	96.0	-4.0	115.0	15.0	75.0	25.0	100.0	-3.8					
			42	120.0	9.1	70.0	16.7	96.0	-4.0	115.0	15.0	75.0	25.0	100.0	-3.8					
			44	130.0	18.2	80.0	33.3	72.0	-24.0	110.0	10.0	120.0	20.0	60.0	0.0	82.0	-21.2			
			46	125.0	13.6	85.0	41.7	82.0	-18.0	125.0	25.0	115.0	15.0	65.0	8.3	84.0	-19.2			
			48	125.0	13.6	80.0	33.3	80.0	-32.0	115.0	15.0	115.0	15.0	70.0	16.7	74.0	-28.8			
			50	130.0	18.2	80.0	33.3	84.0	-16.0	115.0	15.0	115.0	15.0	75.0	25.0	86.0	-17.3			
			52	120.0	9.1	80.0	33.3	72.0	-28.0	110.0	10.0	110.0	10.0	75.0	25.0	76.0	-26.9			
			315	ASA		-1	120.0	0.0	70.0	0.0	72.0	0.0	120.0	0.0	75.0	0.0	70.0	0.0		
						1	100.0	-16.7	60.0	-14.3	80.0	11.1	110.0	11.1	110.0	0.0	70.0	0.0		
						2	120.0	0.0	80.0	14.3	90.0	25.0	120.0	0.0	120.0	0.0	80.0	6.7	95.0	35.7
						3	120.0	0.0	80.0	14.3	106.0	47.2	120.0	0.0	120.0	0.0	80.0	6.7	102.0	45.7
						4	120.0	0.0	80.0	14.3	108.0	50.0	120.0	0.0	120.0	0.0	80.0	6.7	108.0	54.3
						5	115.0	-4.2	75.0	7.1	92.0	27.8	120.0	0.0	120.0	0.0	75.0	0.0	92.0	31.4
						6	115.0	-4.2	90.0	28.6	112.0	55.6	120.0	0.0	120.0	0.0	90.0	20.0	112.0	60.0
						8	125.0	4.2	80.0	14.3	80.0	11.1	110.0	11.1	125.0	4.2	85.0	13.3	92.0	31.4
						10	100.0	-16.7	70.0	0.0	80.0	11.1	110.0	11.1	110.0	0.0	80.0	6.7	84.0	20.0
						12	115.0	-4.2	65.0	-7.1	108.0	50.0	120.0	0.0	120.0	0.0	75.0	0.0	112.0	60.0
						14	130.0	8.3	80.0	14.3	100.0	38.9	120.0	0.0	120.0	0.0	90.0	20.0	108.0	54.3
						16	110.0	-8.3	70.0	0.0	120.0	66.7	110.0	0.0	120.0	0.0	70.0	0.0	116.0	65.7
						18	110.0	-8.3	70.0	0.0	102.0	41.7	110.0	0.0	110.0	0.0	70.0	0.0	120.0	71.4
						20	130.0	8.3	80.0	14.3	65.0	-9.7	130.0	8.3	130.0	8.3	82.0	6.7	72.0	2.9
						22	130.0	8.3	80.0	14.3	68.0	-5.6	130.0	8.3	130.0	8.3	82.0	6.7	72.0	2.9
						24	120.0	0.0	75.0	7.1	106.0	44.4	110.0	0.0	110.0	0.0	80.0	13.3	75.0	7.1
						26	105.0	-12.5	65.0	-7.1	108.0	50.0	110.0	0.0	110.0	0.0	70.0	0.0	108.0	54.3
						28	105.0	-12.5	65.0	-7.1	108.0	50.0	110.0	0.0	110.0	0.0	70.0	0.0	108.0	54.3
						30	105.0	-12.5	65.0	-7.1	108.0	50.0	110.0	0.0	110.0	0.0	70.0	0.0	108.0	54.3
						32	115.0	-4.2	70.0	0.0	100.0	38.9	125.0	4.2	125.0	4.2	80.0	6.7	104.0	48.6
						34	115.0	-4.2	70.0	0.0	100.0	38.9	125.0	4.2	125.0	4.2	80.0	6.7	104.0	48.6
						36	115.0	-4.2	70.0	0.0	100.0	38.9	125.0	4.2	125.0	4.2	80.0	6.7	104.0	48.6
						38	135.0	12.5	85.0	21.4	104.0	44.4	140.0	16.7	140.0	16.7	85.0	13.3	104.0	48.6
						40	130.0	8.3	85.0	21.4	108.0	50.0	130.0	8.3	130.0	8.3	90.0	20.0	114.0	62.9

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 100 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

2441

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING				STANDING										
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff					
1	315	ASA	42	120.0	0.0	80.0	14.3	108.0	50.0	110.0	-8.3	75.0	0.0	108.0	54.3	**		
			44	120.0	0.0	80.0	14.3	108.0	50.0	110.0	-8.3	75.0	0.0	108.0	54.3	**		
			46	124.0	3.3	76.0	8.6	96.0	33.3	128.0	6.7	74.0	-1.3	80.0	37.1	**		
			48	120.0	0.0	75.0	7.1	100.0	38.9	115.0	-4.2	80.0	6.7	100.0	42.9	**		
			50	120.0	0.0	80.0	14.3	102.0	41.7	120.0	0.0	85.0	13.3	102.0	45.7	**		
			52	120.0	0.0	85.0	21.4	104.0	44.4	130.0	8.3	90.0	20.0	104.0	48.6	**		
			317	JFT	-1	140.0	0.0	85.0	0.0	76.0	0.0	135.0	0.0	85.0	0.0	76.0	0.0	
					1	110.0	-21.4	80.0	-5.9	84.0	10.5	110.0	-18.5	75.0	-11.8	88.0	15.8	
					2	105.0	-25.0	70.0	-17.6	70.0	-7.9	115.0	-14.8	70.0	-11.8	70.0	-7.9	
					3	110.0	-21.4	70.0	-17.6	96.0	26.3	110.0	-18.5	75.0	-11.8	100.0	31.6	**
	4	110.0			-21.4	75.0	-11.8	96.0	26.3	100.0	-25.9	70.0	-17.6	80.0	5.3	**		
	5	110.0			-21.4	75.0	-11.8	96.0	26.3	105.0	-22.2	75.0	-11.8	104.0	36.8	**		
	6	100.0			-28.6	70.0	-17.6	92.0	21.1	100.0	-25.9	70.0	-17.6	92.0	21.1			
	8	120.0			-14.3	80.0	-5.9	68.0	-10.5	110.0	-18.5	70.0	-17.6	74.0	-2.6			
	10	115.0			-17.9	75.0	-11.8	68.0	-10.5	120.0	-11.1	80.0	-5.9	74.0	-2.6			
	12	125.0			-10.7	80.0	-5.9	68.0	-10.5	110.0	-18.5	70.0	-17.6	88.0	15.8			
	14	120.0			-14.3	80.0	-5.9	84.0	10.5	115.0	-14.8	75.0	-11.8	88.0	15.8			
	16	115.0			-17.9	70.0	-17.6	68.0	-10.5	120.0	-11.1	80.0	-5.9	70.0	-7.9			
	18	125.0	-10.7	80.0	-5.9	66.0	-13.2	120.0	-11.1	80.0	-5.9	70.0	-7.9					
	20	130.0	-7.1	80.0	-5.9	78.0	2.6	120.0	-11.1	70.0	-17.6	82.0	7.9					
	22	150.0	7.1	80.0	-5.9	68.0	-10.5	125.0	-7.4	75.0	-11.8	76.0	0.0					
	2	SPF	-1	100.0	0.0	60.0	0.0	80.0	0.0	105.0	0.0	60.0	0.0	88.0	0.0			
1			100.0	0.0	60.0	0.0	80.0	0.0	105.0	0.0	60.0	0.0	88.0	0.0				
2			100.0	-20.0	60.0	0.0	100.0	25.0	85.0	-19.0	65.0	8.3	116.0	31.8	**			
3			100.0	0.0	60.0	0.0	74.0	-7.5	100.0	-4.8	60.0	0.0	82.0	-6.8				
4			115.0	15.0	70.0	16.7	108.0	35.0	95.0	-9.5	70.0	16.7	100.0	13.6	**			
5			100.0	0.0	60.0	0.0	116.0	16.0	105.0	0.0	75.0	25.0	108.0	22.7	**			
6			90.0	-10.0	60.0	0.0	100.0	25.0	100.0	-4.8	70.0	16.7	108.0	22.7	**			
8			100.0	0.0	60.0	0.0	100.0	25.0	110.0	4.8	80.0	33.3	100.0	13.6	**			
10			100.0	0.0	60.0	0.0	100.0	25.0	100.0	-4.8	70.0	16.7	92.0	4.5				
12			100.0	0.0	60.0	0.0	100.0	25.0	100.0	-4.8	70.0	16.7	92.0	4.5				
14	95.0	-5.0	70.0	16.7	80.0	0.0	90.0	-14.3	70.0	16.7	92.0	4.5						
16	95.0	-5.0	70.0	16.7	80.0	0.0	90.0	-14.3	70.0	16.7	92.0	4.5						
18	95.0	-5.0	70.0	16.7	80.0	0.0	90.0	-14.3	70.0	16.7	92.0	4.5						
20	110.0	10.0	65.0	8.3	72.0	-10.0	105.0	0.0	70.0	16.7	92.0	4.5						
22	110.0	10.0	65.0	8.3	72.0	-10.0	105.0	0.0	70.0	16.7	92.0	4.5						

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 beats/min
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 2012A/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial Visit	LIVING				STANDING										
			S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	D.B.P.	% diff	H.R.	% diff			
1	321	SPF	24	115.0	15.0	25.0	74.0	-7.5	115.0	9.5	80.0	33.3	82.0	-6.8			
			26	120.0	20.0	16.7	78.0	-2.5	110.0	4.8	75.0	25.0	84.0	-4.5			
			28	125.0	25.0	41.7	76.0	-5.0	115.0	9.5	80.0	33.3	82.0	-6.8			
			30	125.0	25.0	41.7	76.0	-5.0	110.0	14.3	70.0	16.7	86.0	-2.3			
			32	115.0	15.0	25.0	82.0	2.5	110.0	4.8	70.0	0.0	86.0	-2.3			
			34	120.0	20.0	33.3	66.0	-17.5	125.0	19.0	70.0	16.7	74.0	-15.9			
			36	115.0	15.0	25.0	75.0	-5.0	120.0	14.3	80.0	33.3	82.0	-6.8			
			38	125.0	25.0	41.7	74.0	-7.5	110.0	4.8	70.0	16.7	80.0	-9.1			
			40	120.0	20.0	33.3	76.0	-5.0	110.0	4.8	70.0	16.7	80.0	-9.1			
			42	110.0	10.0	16.7	62.0	-22.5	120.0	14.3	60.0	0.0	72.0	-18.2			
			44	110.0	10.0	16.7	64.0	-20.0	110.0	4.8	70.0	16.7	68.0	-22.7			
			46	110.0	10.0	16.7	64.0	-20.0	100.0	-4.8	70.0	16.7	68.0	-22.7			
			48	120.0	20.0	33.3	66.0	-17.5	110.0	4.8	70.0	16.7	72.0	-18.2			
			50	110.0	10.0	16.7	68.0	-15.0	120.0	14.3	70.0	16.7	72.0	-18.2			
			52	120.0	20.0	33.3	60.0	-25.0	110.0	4.8	70.0	16.7	68.0	-22.7			
			322	EK		-1	120.0	0.0	80.0	116.0	0.0	120.0	0.0	80.0	0.0	120.0	0.0
						0	120.0	0.0	80.0	116.0	0.0	120.0	0.0	80.0	0.0	120.0	0.0
						1	130.0	8.3	80.0	110.0	-5.2	130.0	8.3	80.0	0.0	120.0	0.0
						2	120.0	0.0	80.0	116.0	0.0	120.0	0.0	85.0	6.3	120.0	0.0
						3	120.0	0.0	80.0	112.0	-3.4	115.0	-4.2	80.0	0.0	120.0	0.0
						4	120.0	0.0	80.0	112.0	-3.4	115.0	-4.2	80.0	0.0	120.0	0.0
						5	120.0	0.0	80.0	100.0	-13.8	115.0	-4.2	85.0	6.3	116.0	-3.3
						6	120.0	0.0	80.0	116.0	0.0	120.0	0.0	80.0	0.0	116.0	-3.3
						8	100.0	-16.7	80.0	98.0	-15.5	120.0	0.0	90.0	12.5	100.0	-16.7
						10	100.0	-16.7	80.0	98.0	-15.5	120.0	0.0	90.0	12.5	100.0	-16.7
						12	100.0	-16.7	80.0	98.0	-15.5	120.0	0.0	90.0	12.5	100.0	-16.7
						14	100.0	-16.7	80.0	98.0	-15.5	120.0	0.0	90.0	12.5	100.0	-16.7
						16	100.0	-16.7	80.0	98.0	-15.5	120.0	0.0	90.0	12.5	100.0	-16.7
						18	120.0	0.0	90.0	98.0	-15.5	135.0	12.5	95.0	18.8	98.0	-18.3
						20	120.0	0.0	90.0	98.0	-15.5	135.0	12.5	95.0	18.8	98.0	-18.3
						22	120.0	0.0	90.0	102.0	-12.1	125.0	4.2	85.0	6.3	114.0	-5.0
			24	115.0	-4.2	80.0	102.0	-12.1	125.0	4.2	85.0	6.3	114.0	-5.0			
26	115.0	-4.2	80.0	102.0	-12.1	125.0	4.2	85.0	6.3	114.0	-5.0						
28	110.0	-8.3	70.0	108.0	-6.9	110.0	-8.3	70.0	-12.5	120.0	0.0						
30	120.0	0.0	75.0	94.0	-19.0	115.0	0.0	70.0	-12.5	120.0	0.0						
32	120.0	0.0	75.0	94.0	-19.0	115.0	0.0	70.0	-12.5	120.0	0.0						
34	130.0	8.3	85.0	88.0	-24.1	120.0	0.0	75.0	-5.0	100.0	-16.7						
36	120.0	0.0	80.0	100.0	-13.8	126.0	5.0	76.0	-5.0	108.0	-10.0						
38	120.0	0.0	80.0	100.0	-13.8	126.0	5.0	76.0	-5.0	108.0	-10.0						

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 beats/min
 H.R. values <= 50 beats/min

2443

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING				STANDING									
				S.B.P.	% diff	H.R.	% diff	S.B.P.	% diff	H.R.	% diff						
1	322	EK	40	120.0	0.0	80.0	0.0	100.0	-13.8	126.0	5.0	76.0	-5.0	108.0	-10.0		
			42	120.0	0.0	78.0	-2.5	110.0	-5.2	120.0	0.0	80.0	0.0	115.0	-4.2		
			44	120.0	0.0	78.0	-2.5	110.0	-5.2	120.0	0.0	80.0	0.0	115.0	-4.2		
			46	120.0	0.0	85.0	6.3	104.0	-10.3	110.0	-8.3	80.0	0.0	106.0	-11.7		
			48	120.0	0.0	85.0	6.3	104.0	-10.3	110.0	-8.3	80.0	0.0	106.0	-11.7		
			50	100.0	-16.7	70.0	-12.5	92.0	-20.7	106.0	-11.7	60.0	-25.0	96.0	-20.0		
			52	100.0	-16.7	70.0	-12.5	92.0	-20.7	106.0	-11.7	60.0	-25.0	96.0	-20.0		
			324	REA	-1	130.0	0.0	80.0	0.0	80.0	0.0	130.0	0.0	80.0	0.0	88.0	0.0
					1	120.0	0.0	80.0	0.0	92.0	15.0	120.0	0.0	80.0	0.0	100.0	13.6
					2	140.0	7.7	80.0	0.0	88.0	10.0	130.0	0.0	90.0	12.5	100.0	13.6
					3	140.0	7.7	90.0	12.5	92.0	15.0	140.0	7.7	95.0	18.8	100.0	13.6
					4	150.0	15.4	90.0	12.5	95.0	18.8	150.0	15.4	90.0	12.5	100.0	13.6
					5	140.0	7.7	90.0	12.5	95.0	18.8	140.0	7.7	90.0	12.5	100.0	13.6
					6	110.0	-15.4	80.0	0.0	88.0	10.0	98.0	-26.9	70.0	-12.5	100.0	13.6
					8	165.0	11.5	80.0	0.0	80.0	0.0	145.0	11.5	85.0	6.3	88.0	0.0
					10	165.0	11.5	80.0	0.0	80.0	0.0	145.0	11.5	85.0	6.3	88.0	0.0
					12	150.0	15.4	100.0	25.0	80.0	0.0	150.0	15.4	90.0	12.5	88.0	0.0
					14	150.0	15.4	80.0	0.0	80.0	0.0	145.0	11.5	90.0	12.5	80.0	-9.1
					16	150.0	15.4	80.0	0.0	80.0	0.0	145.0	11.5	90.0	12.5	80.0	-9.1
					18	150.0	15.4	80.0	0.0	80.0	0.0	145.0	11.5	90.0	12.5	80.0	-9.1
					20	125.0	-3.8	80.0	0.0	84.0	5.0	140.0	7.7	100.0	25.0	84.0	-4.5
					22	125.0	-3.8	80.0	0.0	84.0	5.0	140.0	7.7	100.0	25.0	84.0	-4.5
					24	130.0	0.0	80.0	0.0	76.0	-5.0	140.0	7.7	70.0	-12.5	80.0	-9.1
					26	130.0	0.0	70.0	-12.5	60.0	-25.0	120.0	0.0	-7.7	-7.7	70.0	-25.0
					28	115.0	-11.5	75.0	-6.3	64.0	-20.0	110.0	-15.4	-15.4	-15.4	70.0	-18.2
					30	130.0	0.0	80.0	0.0	66.0	-17.5	120.0	0.0	-7.7	-7.7	75.0	-6.3
					32	135.0	3.8	85.0	6.3	76.0	-5.0	130.0	0.0	3.8	3.8	80.0	0.0
					34	130.0	0.0	90.0	12.5	62.0	-22.5	120.0	0.0	3.8	3.8	90.0	12.5
					36	130.0	0.0	80.0	0.0	82.0	2.5	120.0	0.0	-7.7	-7.7	70.0	-12.5
					38	125.0	-3.8	85.0	6.3	76.0	-5.0	130.0	0.0	0.0	0.0	80.0	-4.5
					40	140.0	7.7	80.0	0.0	84.0	5.0	150.0	15.4	0.0	0.0	80.0	-9.1
					42	140.0	7.7	80.0	0.0	84.0	5.0	150.0	15.4	0.0	0.0	80.0	-9.1
					44	140.0	7.7	70.0	-12.5	78.0	-2.5	130.0	0.0	0.0	0.0	70.0	-12.5
					46	135.0	3.8	85.0	6.3	82.0	2.5	140.0	7.7	0.0	0.0	90.0	-6.8
					48	135.0	3.8	85.0	6.3	82.0	2.5	140.0	7.7	0.0	0.0	90.0	-6.8
					50	140.0	7.7	75.0	-6.3	84.0	5.0	130.0	0.0	0.0	0.0	70.0	-12.5
					52	130.0	0.0	90.0	12.5	80.0	0.0	135.0	3.8	3.8	3.8	100.0	25.0

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 mm Hg
 H.R. values <= 50 beats/min

2444

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE-BLIND PHASE
 TREATMENT: PLACERO

Centre	Patient	Initial	Visit	LYING			STANDING				
				S.B.P.	D.B.P.	H.R.	S.B.P.	D.B.P.	H.R.		
				% diff	% diff	% diff	% diff	% diff	% diff	% diff	
1	325	ENF	-1	120.0	75.0	104.0	95.0	65.0	116.0	0.0	0.0
			0	120.0	75.0	104.0	95.0	65.0	116.0	0.0	0.0
			1	130.0	90.0	92.0	130.0	90.0	120.0	38.5	3.4
			2	120.0	80.0	124.0	100.0	75.0	124.0	15.4	6.9
			3	130.0	80.0	116.0	120.0	90.0	120.0	38.5	3.4
			4	110.0	80.0	64.0	110.0	80.0	104.0	23.1	-10.3
			5	110.0	90.0	94.0	110.0	90.0	96.0	0.0	-17.2
			6	110.0	70.0	116.0	100.0	65.0	128.0	10.3	10.3
			8	130.0	80.0	120.0	120.0	70.0	120.0	7.7	3.4
			10	100.0	60.0	110.0	100.0	70.0	116.0	0.0	0.0
			12	100.0	70.0	112.0	100.0	70.0	124.0	7.7	6.9
			14	100.0	70.0	124.0	90.0	70.0	128.0	7.7	10.3
			16	110.0	85.0	132.0	105.0	80.0	136.0	23.1	6.9
			18	120.0	90.0	132.0	110.0	75.0	136.0	15.4	17.2
			20	120.0	80.0	120.0	110.0	75.0	136.0	15.4	17.2
			22	120.0	80.0	120.0	110.0	75.0	136.0	15.4	3.4
			24	120.0	80.0	120.0	110.0	75.0	136.0	15.4	3.4
			26	120.0	80.0	112.0	120.0	80.0	128.0	23.1	10.3
			28	130.0	85.0	100.0	110.0	75.0	104.0	15.4	-10.3
			30	130.0	80.0	120.0	130.0	80.0	120.0	23.1	3.4
			32	130.0	80.0	128.0	130.0	80.0	124.0	15.4	6.9
			34	120.0	75.0	120.0	110.0	75.0	120.0	15.4	3.4
			36	135.0	80.0	116.0	120.0	75.0	116.0	15.4	0.0
			38	140.0	80.0	112.0	130.0	90.0	120.0	38.5	3.4
			40	130.0	75.0	114.0	130.0	75.0	132.0	15.4	13.8
			42	120.0	75.0	114.0	115.0	70.0	126.0	7.7	8.6
			44	110.0	75.0	116.0	100.0	65.0	120.0	0.0	3.4
			46	130.0	80.0	128.0	125.0	90.0	132.0	38.5	13.8
			48	140.0	80.0	124.0	130.0	90.0	124.0	6.9	6.9
			50	120.0	90.0	120.0	130.0	90.0	128.0	10.3	10.3
			52	130.0	80.0	124.0	140.0	90.0	128.0	38.5	10.3
327	MAA		-1	150.0	90.0	98.0	150.0	90.0	110.0	0.0	0.0
			0	150.0	90.0	98.0	150.0	90.0	110.0	0.0	0.0
			1	150.0	90.0	100.0	150.0	90.0	104.0	0.0	-5.5
			2	140.0	100.0	108.0	140.0	100.0	104.0	15.6	-5.5
			3	160.0	100.0	96.0	160.0	100.0	104.0	11.1	-5.5
			4	160.0	120.0	96.0	160.0	120.0	102.0	33.3	-7.3
			5	190.0	120.0	112.0	190.0	130.0	112.0	44.4	1.8
			6	150.0	100.0	95.0	150.0	100.0	105.0	11.1	-4.5

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 beats/min
 H.R. values <= 50 beats/min

2445

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXYETINE - PROTOCOL 20126/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING				STANDING							
				S.B.P.	% diff	H.R.	% diff	S.B.P.	% diff	H.R.	% diff				
1	327	MAA	8	150.0	0.0	95.0	-3.1	150.0	0.0	100.0	11.1	105.0	-4.5		
			10	150.0	0.0	95.0	-3.1	150.0	0.0	100.0	11.1	105.0	-4.5		
			12	165.0	10.0	110.0	22.2	170.0	13.3	120.0	33.3	116.0	5.5		
			14	140.0	-6.7	88.0	-10.2	140.0	-6.7	95.0	5.6	88.0	-20.0		
			16	140.0	-6.7	88.0	-10.2	140.0	-6.7	95.0	5.6	88.0	-20.0		
			18	140.0	-6.7	88.0	-10.2	140.0	-6.7	95.0	5.6	88.0	-20.0		
			20	140.0	-6.7	88.0	-10.2	140.0	-6.7	95.0	5.6	88.0	-20.0		
			22	140.0	-6.7	88.0	-10.2	140.0	-6.7	95.0	5.6	88.0	-20.0		
			24	140.0	-6.7	88.0	-10.2	140.0	-6.7	95.0	5.6	88.0	-20.0		
			26	145.0	-3.3	85.0	-5.6	140.0	-10.0	90.0	0.0	82.0	-25.5		
			328	MLM	-1	130.0		72.0		120.0		80.0		80.0	
					0	110.0	-15.4	72.0	0.0	115.0	-4.2	80.0	0.0	84.0	5.0
					1	110.0	-15.4	84.0	16.7	105.0	-12.5	80.0	0.0	96.0	20.0
					2	120.0	-7.7	75.0	-6.3	100.0	-16.7	80.0	0.0	100.0	25.0
					3	115.0	-11.5	80.0	0.0	100.0	-16.7	80.0	0.0	112.0	40.0
					4	120.0	-7.7	92.0	27.8	120.0	0.0	80.0	0.0	96.0	20.0
					5	130.0	0.0	80.0	11.1	120.0	0.0	85.0	6.3	80.0	0.0
					6	110.0	-15.4	88.0	22.2	125.0	4.2	90.0	12.5	100.0	25.0
					8	125.0	-3.8	76.0	5.6	120.0	0.0	85.0	6.3	78.0	-2.5
					10	130.0	0.0	60.0	-16.7	130.0	8.3	90.0	12.5	68.0	-15.0
					12	130.0	0.0	70.0	-12.5	120.0	0.0	70.0	-12.5	82.0	2.5
					14	130.0	0.0	72.0	0.0	125.0	4.2	85.0	6.3	74.0	-7.5
			16	135.0	3.8	70.0	-2.8	135.0	12.5	70.0	-12.5	78.0	-2.5		
			18	135.0	3.8	68.0	-5.6	130.0	8.3	70.0	-12.5	70.0	-12.5		
			20	130.0	0.0	64.0	-11.1	130.0	8.3	80.0	0.0	72.0	-10.0		
			22	135.0	3.8	74.0	2.8	130.0	8.3	70.0	-12.5	78.0	-2.5		
332	CLF	-1	80.0		92.0		80.0		50.0		104.0	0.0			
		0	80.0	0.0	92.0	0.0	80.0	0.0	50.0	0.0	104.0	0.0			
		1	90.0	12.5	92.0	0.0	85.0	6.3	50.0	0.0	96.0	-7.7			
		2	90.0	12.5	92.0	0.0	85.0	6.3	50.0	0.0	96.0	-7.7			
		3	90.0	12.5	80.0	-13.0	90.0	12.5	70.0	40.0	88.0	-15.4			
		4	90.0	12.5	80.0	-13.0	90.0	12.5	70.0	40.0	88.0	-15.4			
		5	90.0	12.5	80.0	-13.0	90.0	12.5	70.0	40.0	88.0	-15.4			
		6	80.0	0.0	112.0	21.7	80.0	0.0	50.0	0.0	112.0	7.7			
		8	90.0	12.5	91.0	-1.1	85.0	6.3	60.0	20.0	112.0	7.7			
		10	85.0	6.3	88.0	-4.3	80.0	0.0	60.0	20.0	104.0	0.0			
		12	90.0	12.5	72.0	-21.7	90.0	12.5	40.0	-20.0	84.0	-19.2			
		14	90.0	12.5	80.0	8.7	90.0	12.5	60.0	20.0	112.0	7.7			

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

2446

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING				STANDING							
				S.B.P.	% diff	D.B.P.	% diff	H.R.	% diff	S.B.P.	% diff	D.B.P.	% diff	H.R.	% diff
1	332	CIF	16	90.0	12.5	60.0	9.1	100.0	8.7	90.0	12.5	60.0	20.0	112.0	7.7
			18	90.0	12.5	60.0	9.1	100.0	8.7	90.0	12.5	60.0	20.0	112.0	7.7
			20	90.0	12.5	60.0	9.1	100.0	8.7	90.0	12.5	60.0	20.0	112.0	7.7
			22	90.0	12.5	60.0	9.1	100.0	8.7	90.0	12.5	60.0	20.0	112.0	7.7
			24	120.0	50.0	80.0	45.5	76.0	-17.4	115.0	43.8	80.0	60.0	82.0	-21.2
			26	120.0	50.0	70.0	27.3	80.0	-13.0	110.0	37.5	70.0	40.0	86.0	-17.3
			28	120.0	50.0	80.0	45.5	72.0	-21.7	115.0	43.8	70.0	40.0	84.0	-19.2
			30	125.0	56.3	80.0	45.5	74.0	-19.6	110.0	37.5	70.0	40.0	80.0	-23.1
			32	120.0	50.0	70.0	27.3	82.0	-10.9	110.0	37.5	70.0	40.0	84.0	-19.2
			34	120.0	50.0	80.0	45.5	82.0	-10.9	115.0	56.3	75.0	50.0	84.0	-19.2
			36	125.0	56.3	80.0	45.5	76.0	-17.4	125.0	56.3	70.0	40.0	84.0	-19.2
			38	130.0	62.5	80.0	45.5	82.0	-10.9	115.0	43.8	70.0	40.0	84.0	-19.2
			40	120.0	50.0	80.0	45.5	82.0	-10.9	115.0	43.8	70.0	40.0	84.0	-19.2
			42	130.0	62.5	70.0	27.3	84.0	-8.7	120.0	50.0	70.0	40.0	88.0	-15.4
			44	125.0	56.3	85.0	56.3	76.0	-17.4	120.0	50.0	65.0	70.0	78.0	-25.0
			46	130.0	62.5	70.0	27.3	86.0	-6.5	115.0	43.8	70.0	40.0	86.0	-15.4
			48	120.0	50.0	70.0	27.3	72.0	-21.7	125.0	56.3	80.0	60.0	78.0	-25.0
			50	120.0	50.0	70.0	27.3	72.0	-21.7	110.0	37.5	80.0	60.0	82.0	-25.0
			52	120.0	50.0	80.0	45.5	82.0	-10.9	125.0	56.3	75.0	50.0	86.0	-17.3
	333	EIS	-1	120.0	0.0	80.0	0.0	96.0	0.0	125.0	0.0	90.0	0.0	96.0	0.0
			1	120.0	0.0	80.0	0.0	96.0	0.0	120.0	-4.0	80.0	-11.1	104.0	8.3
			2	120.0	0.0	80.0	0.0	100.0	4.2	120.0	-4.0	80.0	-11.1	104.0	8.3
			3	120.0	0.0	80.0	0.0	100.0	4.2	120.0	-4.0	80.0	-11.1	104.0	8.3
			4	130.0	8.3	70.0	-12.5	80.0	-16.7	130.0	4.0	80.0	-11.1	86.0	-10.4
			5	130.0	8.3	70.0	-12.5	80.0	-16.7	130.0	4.0	80.0	-11.1	86.0	-10.4
			6	100.0	-16.7	70.0	-12.5	80.0	-16.7	120.0	-4.0	80.0	-11.1	86.0	-10.4
			8	120.0	0.0	90.0	12.5	100.0	4.2	120.0	-4.0	80.0	-11.1	100.0	4.2
			10	120.0	0.0	90.0	12.5	100.0	4.2	120.0	-4.0	80.0	-11.1	100.0	4.2
			12	110.0	-8.3	75.0	-6.3	88.0	-8.3	90.0	-23.0	60.0	-33.3	92.0	-4.2
			14	105.0	-12.5	70.0	-12.5	92.0	-4.2	90.0	-23.0	50.0	-44.4	96.0	0.0
			16	105.0	-12.5	70.0	-12.5	92.0	-4.2	90.0	-23.0	50.0	-44.4	96.0	0.0
			18	105.0	-12.5	70.0	-12.5	92.0	-4.2	90.0	-23.0	50.0	-44.4	96.0	0.0
			20	100.0	-16.7	70.0	-12.5	90.0	-6.3	105.0	-16.0	60.0	-33.3	92.0	-4.2
			22	100.0	-16.7	70.0	-12.5	90.0	-6.3	105.0	-16.0	60.0	-33.3	92.0	-4.2
			24	120.0	0.0	70.0	-12.5	84.0	-12.5	110.0	-12.0	70.0	-22.2	86.0	-10.4
			26	125.0	4.2	75.0	-6.3	72.0	-25.0	120.0	-4.0	70.0	-22.2	76.0	-20.8
			28	125.0	4.2	70.0	-12.5	84.0	-12.5	115.0	-8.0	60.0	-33.3	86.0	-10.4
			30	120.0	0.0	80.0	0.0	84.0	-12.5	115.0	-8.0	70.0	-22.2	86.0	-10.4

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 beats/min
 H.R. values <= 50 beats/min

2447

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING				STANDING											
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff						
1	333	ELS	32	120.0	0.0	70.0	-12.5	78.0	-18.8	110.0	-12.0	70.0	-22.2	*	82.0	-14.6			
			34	120.0	0.0	80.0	0.0	76.0	-20.8	110.0	-12.0	70.0	-22.2	*	82.0	-14.6			
			36	120.0	0.0	80.0	0.0	76.0	-20.8	76.0	-20.8	75.0	-16.7	*	80.0	-16.7			
			38	130.0	8.3	70.0	-12.5	72.0	-25.0	115.0	-8.0	70.0	-22.2	*	74.0	-22.9			
			40	120.0	0.0	80.0	0.0	68.0	-29.2	115.0	-8.0	70.0	-22.2	*	74.0	-22.9			
			42	125.0	4.2	80.0	0.0	78.0	-18.8	115.0	-8.0	75.0	-16.7	*	84.0	-12.5			
			44	120.0	0.0	70.0	-12.5	82.0	-14.6	110.0	-12.0	70.0	-22.2	*	84.0	-12.5			
			46	130.0	8.3	70.0	-12.5	86.0	-10.4	120.0	-4.0	70.0	-22.2	*	90.0	-6.3			
			48	120.0	0.0	70.0	-12.5	84.0	-12.5	110.0	-12.0	60.0	-33.3	*	86.0	-10.4			
			50	120.0	0.0	80.0	0.0	82.0	-14.6	130.0	4.0	75.0	-16.7	*	86.0	-10.4			
			52	130.0	8.3	80.0	0.0	84.0	-12.5	120.0	-4.0	70.0	-22.2	*	86.0	-10.4			
			337	HSS		-1	130.0	-3.8	80.0	6.3	86.0	-4.7	120.0	0.0	75.0	6.7		96.0	-4.2
						0	125.0	0.0	85.0	0.0	82.0	-11.6	120.0	0.0	75.0	0.0		78.0	-18.8
						1	130.0	0.0	80.0	0.0	82.0	-4.7	120.0	0.0	75.0	0.0		88.0	-8.3
						2	125.0	-3.8	75.0	-6.3	82.0	-4.7	120.0	0.0	75.0	-6.7		86.0	-10.4
						3	120.0	-7.7	80.0	0.0	82.0	-4.7	110.0	-8.3	75.0	0.0		90.0	6.3
						4	120.0	-3.8	85.0	6.3	74.0	-14.0	120.0	0.0	80.0	6.7		84.0	-12.5
						5	125.0	-7.7	75.0	-6.3	70.0	-18.6	115.0	-4.2	80.0	0.0		78.0	-18.8
						6	120.0	-7.7	70.0	-12.5	52.0	-39.5	95.0	-20.8	65.0	-19.3		58.0	-39.6
						8	100.0	-23.1	70.0	-12.5	54.0	-37.2	90.0	-25.0	60.0	-20.0		56.0	-41.7
						10	100.0	-23.1	65.0	-18.8	48.0	-44.2	90.0	-25.0	60.0	-20.0		58.0	-39.6
						12	100.0	-23.1	60.0	-25.0	50.0	-41.9	95.0	-20.8	65.0	-19.3		62.0	-35.4
						14	95.0	-26.9	60.0	-25.0	50.0	-41.9	95.0	-20.8	65.0	-19.3		56.0	-41.7
						16	105.0	-19.2	60.0	-25.0	48.0	-44.2	90.0	-25.0	60.0	-20.0		58.0	-39.6
						18	90.0	-30.8	60.0	-25.0	56.0	-34.9	100.0	-16.7	70.0	-20.0		58.0	-39.6
						20	115.0	-11.5	75.0	-6.3	54.0	-37.2	90.0	-25.0	60.0	-20.0		58.0	-39.6
						22	100.0	-23.1	70.0	-12.5	54.0	-37.2	90.0	-25.0	60.0	-20.0		58.0	-39.6
						24	130.0	0.0	80.0	0.0	84.0	-2.3	120.0	0.0	70.0	-22.2		86.0	-10.4
						26	120.0	-7.7	80.0	0.0	64.0	-25.6	110.0	-8.3	70.0	-22.2		68.0	-29.2
						28	120.0	-7.7	70.0	-12.5	68.0	-20.9	110.0	-8.3	75.0	0.0		74.0	-22.9
						30	125.0	-3.8	80.0	0.0	70.0	-18.6	115.0	-4.2	80.0	6.7		74.0	-22.9
						32	125.0	-3.8	80.0	0.0	64.0	-23.3	130.0	8.3	70.0	-22.2		68.0	-29.2
						34	125.0	6.3	85.0	6.3	66.0	-23.3	130.0	8.3	70.0	-22.2		72.0	-25.0
						36	120.0	-7.7	70.0	-12.5	70.0	-18.6	115.0	-4.2	70.0	-22.2		74.0	-22.9
						38	120.0	-7.7	80.0	0.0	82.0	-4.7	125.0	4.2	70.0	-22.2		84.0	-12.5
			40	120.0	-7.7	70.0	-12.5	74.0	-14.0	110.0	-4.2	70.0	-22.2		76.0	-20.8			
			42	125.0	-3.8	85.0	6.3	72.0	-16.3	120.0	0.0	80.0	6.7		80.0	-16.7			
			44	115.0	-11.5	70.0	-12.5	72.0	-16.3	110.0	-8.3	70.0	-22.2		80.0	-16.7			
			46	110.0	-15.4	70.0	-12.5	82.0	-4.7	115.0	-4.2	75.0	0.0		84.0	-12.5			

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 50 mm Hg
H.R. values <= 50 beats/min

2448

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING			STANDING												
				S.B.P. % diff	H.R. % diff	D.B.P. % diff	S.B.P. % diff	H.R. % diff	D.B.P. % diff										
1	337	HSS	48	120.0	-7.7	70.0	-12.5	82.0	-4.7	110.0	-8.3	75.0	0.0	84.0	-12.5				
			50	130.0	0.0	70.0	-12.5	72.0	-16.3	120.0	0.0	120.0	0.0	75.0	0.0	76.0	-20.8		
			52	120.0	-7.7	70.0	-12.5	96.0	11.6	125.0	4.2	125.0	4.2	75.0	0.0	100.0	4.2		
			344	MNS	-1	130.0		80.0		86.0		120.0		80.0		96.0			
					0	140.0	7.7	90.0	12.5	80.0	-7.0	130.0	8.3	130.0	8.3	100.0	37.5	100.0	4.2
					1	125.0	-3.8	90.0	12.5	104.0	20.9	150.0	25.0	150.0	25.0	90.0	12.5	120.0	25.0
					2	125.0	-3.8	90.0	12.5	104.0	20.9	150.0	25.0	150.0	25.0	90.0	12.5	120.0	25.0
					3	125.0	-3.8	90.0	12.5	104.0	20.9	150.0	25.0	150.0	25.0	90.0	12.5	120.0	25.0
					4	120.0	-7.7	80.0	0.0	108.0	25.6	130.0	8.3	130.0	8.3	90.0	12.5	120.0	25.0
					5	120.0	-7.7	80.0	0.0	108.0	25.6	130.0	8.3	130.0	8.3	90.0	12.5	120.0	25.0
					6	120.0	-7.7	80.0	0.0	108.0	25.6	130.0	8.3	130.0	8.3	90.0	12.5	120.0	25.0
					8	120.0	-7.7	90.0	12.5	116.0	34.9	125.0	4.2	125.0	4.2	100.0	25.0	132.0	37.5
					10	120.0	-7.7	90.0	12.5	116.0	34.9	125.0	4.2	125.0	4.2	100.0	25.0	132.0	37.5
					12	120.0	-7.7	85.0	6.3	100.0	16.3	125.0	4.2	125.0	4.2	100.0	25.0	132.0	37.5
					14	120.0	-7.7	85.0	6.3	92.0	7.0	125.0	4.2	125.0	4.2	85.0	6.3	108.0	12.5
					16	120.0	-7.7	85.0	6.3	100.0	16.3	125.0	4.2	125.0	4.2	85.0	6.3	108.0	12.5
					18	120.0	-7.7	85.0	6.3	100.0	16.3	125.0	4.2	125.0	4.2	85.0	6.3	108.0	12.5
			20	120.0	-7.7	85.0	6.3	90.0	4.7	125.0	4.2	125.0	4.2	85.0	6.3	98.0	2.1		
			22	120.0	-7.7	85.0	6.3	100.0	16.3	125.0	4.2	125.0	4.2	85.0	6.3	108.0	12.5		
			24	120.0	-7.7	70.0	-12.5	66.0	-23.3	125.0	4.2	125.0	4.2	75.0	-6.3	72.0	-25.0		
			26	130.0	0.0	70.0	-12.5	72.0	-16.3	110.0	-8.3	110.0	-8.3	70.0	-12.5	74.0	-22.9		
28	120.0	-7.7	80.0	0.0	74.0	-14.0	125.0	4.2	125.0	4.2	70.0	-12.5	76.0	-20.8					
30	125.0	-3.8	80.0	0.0	72.0	-16.3	115.0	-4.2	115.0	-4.2	70.0	-12.5	74.0	-22.9					
32	125.0	-3.8	80.0	0.0	64.0	-25.6	110.0	-8.3	110.0	-8.3	70.0	-12.5	70.0	-27.1					
34	120.0	-7.7	70.0	-12.5	72.0	-16.3	100.0	-16.7	100.0	-16.7	70.0	-12.5	80.0	-16.7					
36	120.0	-7.7	80.0	0.0	70.0	-18.6	115.0	-4.2	115.0	-4.2	70.0	-12.5	74.0	-22.9					
38	120.0	-7.7	80.0	0.0	74.0	-14.0	130.0	8.3	130.0	8.3	80.0	0.0	78.0	-18.8					
40	125.0	-3.8	85.0	6.3	70.0	-14.0	125.0	4.2	125.0	4.2	80.0	0.0	78.0	-18.8					
42	120.0	-7.7	80.0	0.0	70.0	-18.6	125.0	4.2	125.0	4.2	80.0	0.0	78.0	-18.8					
345	EGA	-1	120.0		70.0		86.0		115.0		65.0		90.0						
		0	100.0	-16.7	70.0	0.0	116.0	34.9	100.0	-17.4	100.0	-17.4	65.0	0.0					
		1	95.0	-20.8	70.0	0.0	116.0	34.9	100.0	-13.0	100.0	-13.0	65.0	0.0					
		2	95.0	-20.8	70.0	0.0	116.0	34.9	100.0	-13.0	100.0	-13.0	65.0	0.0					
		3	95.0	-20.8	70.0	0.0	116.0	34.9	100.0	-13.0	100.0	-13.0	65.0	0.0					
		4	100.0	-16.7	60.0	-14.3	106.0	20.9	100.0	-13.0	100.0	-13.0	60.0	-7.7					
		5	100.0	-16.7	60.0	-14.3	100.0	16.3	100.0	-13.0	100.0	-13.0	60.0	-7.7					
		6	90.0	-25.0	70.0	0.0	116.0	34.9	100.0	-21.7	100.0	-21.7	60.0	-7.7					
8	120.0	0.0	60.0	-14.3	64.0	-25.6	110.0	-4.3	110.0	-4.3	65.0	0.0							

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 50 mm Hg
H.R. values <= 50 beats/min

2449

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXYMETINE - PROTOCOL 20124/013
 Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACERO

Centre	Patient	Initial	Visit	LYING			STANDING										
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	H.R.	% diff						
1	345	EKG	10	115.0	-4.2	75.0	7.1	58.0	-32.6	105.0	-8.7	70.0	7.7	64.0	-28.9		
			12	110.0	-8.3	70.0	0.0	64.0	-25.6	100.0	-13.0	70.0	7.7	72.0	-20.0		
			14	110.0	-8.3	75.0	7.1	66.0	-23.3	100.0	-13.0	70.0	7.7	72.0	-20.0		
			16	110.0	-8.3	70.0	0.0	72.0	-16.3	100.0	-13.0	65.0	0.0	78.0	-13.3		
			18	105.0	-12.5	70.0	0.0	56.0	-34.9	100.0	-13.0	65.0	0.0	64.0	-28.9		
			20	105.0	-12.5	75.0	7.1	82.0	-4.7	100.0	-13.0	70.0	7.7	82.0	-8.9		
			22	110.0	-8.3	70.0	0.0	72.0	-16.3	100.0	-13.0	65.0	0.0	82.0	-8.9		
			-1	125.0		85.0		82.0		120.0		120.0		80.0		90.0	
			1	130.0	4.0	80.0	-5.9	82.0	0.0	120.0	0.0	120.0	0.0	75.0	-6.3	84.0	-6.7
			2	120.0	-4.0	80.0	-5.9	76.0	-4.9	110.0	-8.3	110.0	-8.3	70.0	-12.5	82.0	-8.9
			3	115.0	-8.0	75.0	-14.8	76.0	-7.3	115.0	-4.2	115.0	-4.2	75.0	-6.3	82.0	-8.9
			4	115.0	-8.0	80.0	-5.9	76.0	-4.9	105.0	-12.5	105.0	-12.5	75.0	-6.3	84.0	-6.7
			5	115.0	-8.0	75.0	-11.8	76.0	-7.3	110.0	-8.3	110.0	-8.3	70.0	-12.5	80.0	-11.1
			6	120.0	-4.0	70.0	-17.6	78.0	-4.9	110.0	-8.3	110.0	-8.3	75.0	-6.3	82.0	-8.9
			8	120.0	-4.0	75.0	-11.8	74.0	-9.8	115.0	-4.2	115.0	-4.2	78.0	-13.3	78.0	-13.3
			10	125.0	4.0	80.0	-5.9	80.0	-2.4	110.0	-8.3	110.0	-8.3	70.0	-12.5	86.0	-4.4
			12	125.0	4.0	80.0	-5.9	78.0	-4.9	115.0	-4.2	115.0	-4.2	75.0	-6.3	88.0	-2.2
			14	120.0	-4.0	80.0	-5.9	78.0	-4.9	115.0	-4.2	115.0	-4.2	75.0	-6.3	86.0	-4.4
			16	125.0	4.0	70.0	-17.6	84.0	2.4	110.0	-8.3	110.0	-8.3	70.0	-12.5	84.0	-6.7
			18	125.0	4.0	85.0	0.0	74.0	-9.8	120.0	0.0	120.0	0.0	80.0	0.0	78.0	-2.2
			20	120.0	-4.0	80.0	-5.9	82.0	0.0	115.0	-4.2	115.0	-4.2	70.0	-12.5	80.0	-6.7
			22	130.0	4.0	85.0	0.0	84.0	2.4	115.0	-4.2	115.0	-4.2	80.0	0.0	86.0	-4.4
24	125.0	4.0	80.0	-5.9	84.0	2.4	120.0	0.0	120.0	0.0	70.0	-12.5	86.0	-4.4			
26	120.0	-4.0	80.0	-5.9	76.0	-7.3	115.0	-4.2	115.0	-4.2	70.0	-12.5	82.0	-8.9			
28	120.0	-4.0	80.0	-5.9	82.0	0.0	110.0	-8.3	110.0	-8.3	70.0	-12.5	84.0	-6.7			
30	125.0	4.0	70.0	-17.6	86.0	4.9	110.0	-8.3	110.0	-8.3	65.0	-18.8	80.0	0.0			
32	120.0	-4.0	80.0	-5.9	74.0	-9.8	115.0	-4.2	115.0	-4.2	70.0	-12.5	74.0	-17.8			
34	125.0	4.0	70.0	-17.6	68.0	-17.1	105.0	-12.5	105.0	-12.5	70.0	-12.5	74.0	-17.8			
36	120.0	-4.0	80.0	-5.9	80.0	-2.4	120.0	0.0	120.0	0.0	70.0	-12.5	82.0	-8.9			
38	120.0	-4.0	70.0	-17.6	66.0	-19.5	110.0	-8.3	110.0	-8.3	70.0	-12.5	82.0	-8.9			
40	120.0	-4.0	80.0	-5.9	80.0	-2.4	110.0	-8.3	110.0	-8.3	70.0	-12.5	82.0	-8.9			
42	110.0	-12.0	70.0	-17.6	74.0	-9.8	115.0	-4.2	115.0	-4.2	60.0	-43.0	72.0	-20.0			
44	125.0	4.0	85.0	0.0	72.0	-12.0	115.0	-4.2	115.0	-4.2	70.0	-12.5	76.0	-15.6			
46	125.0	4.0	85.0	0.0	72.0	-12.0	115.0	-4.2	115.0	-4.2	70.0	-12.5	66.0	-26.7			
48	120.0	-4.0	80.0	-5.9	78.0	-4.9	110.0	-8.3	110.0	-8.3	80.0	0.0	78.0	-13.3			
50	130.0	4.0	80.0	-5.9	72.0	-12.0	120.0	0.0	120.0	0.0	70.0	-12.5	82.0	-8.9			
52	120.0	-4.0	70.0	-17.6	60.0	-26.6	125.0	4.2	125.0	4.2	65.0	-18.8	75.0	-15.6			

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 100 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

2450

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING			STANDING										
				S.B.P.	% diff	H.R.	% diff	S.B.P.	% diff	H.R.	% diff						
1	349	AVP	-1	130.0	-7.7	80.0	0.0	74.0	-5.4	120.0	0.0	70.0	7.1	84.0	-9.5		
			0	120.0	-3.8	80.0	0.0	74.0	0.0	115.0	-4.2	75.0	14.3	76.0	-7.1		
			1	125.0	-7.7	80.0	-6.3	74.0	10.8	110.0	-8.3	80.0	0.0	70.0	0.0	78.0	-2.4
			2	120.0	-3.8	85.0	0.0	78.0	5.4	115.0	-8.3	80.0	14.3	70.0	14.3	82.0	-2.4
			3	125.0	-7.7	80.0	6.3	76.0	2.7	110.0	-8.3	70.0	0.0	70.0	0.0	82.0	-2.4
			4	120.0	-3.8	85.0	0.0	78.0	5.4	120.0	-8.3	80.0	14.3	70.0	14.3	82.0	-2.4
			5	125.0	-7.7	80.0	6.3	78.0	5.4	110.0	-8.3	70.0	0.0	70.0	0.0	82.0	-2.4
			6	120.0	-3.8	85.0	0.0	82.0	10.8	120.0	-4.2	80.0	14.3	70.0	14.3	86.0	2.4
			8	135.0	-7.7	80.0	-12.5	84.0	13.5	115.0	-4.2	80.0	14.3	70.0	14.3	88.0	4.8
			10	125.0	-3.8	85.0	6.3	78.0	5.4	115.0	-4.2	80.0	14.3	70.0	14.3	86.0	2.4
			12	120.0	-7.7	80.0	-6.3	86.0	16.2	110.0	-8.3	75.0	0.0	70.0	0.0	90.0	7.1
			14	115.0	-11.5	85.0	0.0	88.0	18.9	115.0	-4.2	75.0	0.0	70.0	0.0	84.0	0.0
			16	120.0	-7.7	80.0	-6.3	84.0	13.5	110.0	-8.3	70.0	0.0	70.0	0.0	88.0	4.8
			18	115.0	-11.5	85.0	0.0	86.0	16.2	110.0	-4.2	75.0	0.0	70.0	0.0	88.0	4.8
			20	130.0	-7.7	80.0	-12.5	84.0	13.5	115.0	-4.2	70.0	0.0	70.0	0.0	92.0	9.5
			22	125.0	-3.8	80.0	0.0	86.0	16.2	110.0	-4.2	70.0	0.0	70.0	0.0	82.0	-2.4
			24	120.0	-7.7	80.0	-6.3	84.0	13.5	115.0	-4.2	70.0	0.0	70.0	0.0	86.0	2.4
			26	120.0	-7.7	80.0	-6.3	86.0	16.2	130.0	-8.3	70.0	0.0	70.0	0.0	88.0	4.8
			28	120.0	-7.7	80.0	-6.3	82.0	10.8	110.0	-4.2	70.0	0.0	70.0	0.0	86.0	2.4
			30	130.0	0.0	80.0	0.0	72.0	-2.7	110.0	-4.2	70.0	0.0	70.0	0.0	80.0	-4.8
			32	125.0	-3.8	80.0	0.0	84.0	13.5	115.0	-4.2	70.0	0.0	70.0	0.0	86.0	2.4
			34	125.0	-3.8	80.0	0.0	82.0	10.8	115.0	-4.2	70.0	0.0	70.0	0.0	92.0	9.5
			36	125.0	-3.8	80.0	0.0	80.0	8.1	120.0	0.0	80.0	14.3	70.0	14.3	84.0	0.0
			38	120.0	-7.7	80.0	-6.3	78.0	5.4	115.0	-4.2	70.0	0.0	70.0	0.0	84.0	0.0
			40	115.0	-11.5	75.0	-6.3	76.0	2.7	110.0	-4.2	70.0	0.0	70.0	0.0	82.0	-2.4
			42	110.0	-15.4	70.0	-12.5	74.0	0.0	100.0	-16.7	60.0	-14.3	60.0	-14.3	78.0	-7.1
			44	120.0	-7.7	70.0	-12.5	90.0	21.6	110.0	-8.3	75.0	7.1	94.0	11.9	96.0	11.9
			46	120.0	-7.7	70.0	-12.5	86.0	16.2	125.0	4.2	65.0	-7.1	92.0	9.5	92.0	9.5
			48	125.0	-3.8	85.0	6.3	88.0	18.9	115.0	-4.2	75.0	7.1	92.0	9.5	92.0	9.5
			50	125.0	-3.8	85.0	-6.3	88.0	18.9	120.0	0.0	70.0	0.0	70.0	0.0	94.0	11.9
			52	100.0	-23.1	70.0	-12.5	74.0	0.0	90.0	-25.0	70.0	0.0	70.0	0.0	80.0	-4.8
			350	LBV	-1	130.0	-7.7	80.0	0.0	82.0	-24.4	120.0	-4.2	75.0	0.0	94.0	-29.8
					0	120.0	-3.8	80.0	0.0	64.0	-22.0	115.0	-8.3	70.0	-6.7	66.0	-29.8
					1	125.0	-7.7	80.0	-12.5	74.0	-9.8	110.0	-8.3	70.0	-6.7	76.0	-19.1
					2	120.0	-3.8	75.0	-6.3	64.0	-22.0	110.0	-8.3	70.0	-6.7	66.0	-29.8
					3	115.0	-11.5	85.0	6.3	66.0	-19.5	120.0	0.0	80.0	6.7	70.0	-25.5
					4	125.0	-7.7	70.0	-12.5	78.0	-4.9	115.0	-4.2	60.0	-20.0	78.0	-17.0
			6	115.0	-11.5	75.0	-6.3	74.0	-9.8	110.0	-8.3	70.0	-6.7	72.0	-23.4		

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 50 beats/min
H.R. values <= 50 beats/min

2451

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING			STANDING								
				S.B.P. z diff	H.R. z diff	D.B.P. z diff	S.B.P. z diff	H.R. z diff	D.B.P. z diff						
1	350	LBV	8	115.0	-11.5	75.0	-6.3	64.0	-22.0	110.0	-8.3	70.0	-6.7	68.0	-27.7
			10	100.0	-23.1	70.0	-12.5	56.0	-31.7	100.0	-16.7	60.0	-20.0	58.0	-38.3
			12	115.0	-11.5	75.0	-6.3	60.0	-26.8	110.0	-8.3	70.0	-6.7	64.0	-31.9
			14	120.0	-7.7	70.0	-12.5	52.0	-36.6	110.0	-8.3	70.0	-6.7	58.0	-38.3
			16	120.0	-7.7	70.0	-12.5	58.0	-29.3	115.0	-4.2	75.0	0.0	64.0	-31.9
			18	115.0	-11.5	75.0	-6.3	52.0	-36.6	115.0	-4.2	70.0	-6.7	60.0	-36.2
			20	125.0	-3.8	80.0	0.0	58.0	-29.3	120.0	0.0	75.0	0.0	68.0	-27.7
			22	115.0	-11.5	75.0	-6.3	62.0	-24.4	110.0	-8.3	70.0	-6.7	66.0	-29.8
			24	125.0	-3.8	80.0	0.0	74.0	-9.8	120.0	0.0	70.0	-6.7	76.0	-19.1
			26	130.0	0.0	80.0	0.0	82.0	12.2	125.0	4.2	85.0	13.3	94.0	0.0
			28	125.0	-7.7	80.0	0.0	84.0	2.4	125.0	4.2	70.0	-6.7	90.0	-4.3
			30	125.0	-3.8	80.0	0.0	78.0	-7.3	115.0	-4.2	70.0	-6.7	80.0	-14.9
			32	130.0	0.0	80.0	0.0	78.0	-9.8	135.0	12.5	60.0	-20.0	82.0	-12.8
			34	120.0	-7.7	80.0	0.0	90.0	9.8	125.0	4.2	70.0	-6.7	92.0	-2.1
			36	120.0	-7.7	70.0	-12.5	82.0	0.0	125.0	4.2	65.0	-13.3	86.0	-8.5
			40	125.0	-3.8	80.0	0.0	84.0	2.4	125.0	4.2	70.0	-6.7	86.0	-8.5
			42	105.0	-19.2	65.0	-18.8	72.0	-12.2	115.0	-4.2	60.0	-20.0	72.0	-23.4
			44	115.0	-11.5	70.0	-14.6	68.0	-17.1	100.0	-16.7	70.0	-6.7	76.0	-19.1
			46	120.0	-7.7	70.0	-12.5	70.0	-14.6	105.0	-12.5	60.0	-20.0	76.0	-19.1
			48	120.0	-7.7	70.0	-12.5	86.0	4.9	105.0	-12.5	60.0	-20.0	90.0	-4.3
			50	130.0	0.0	70.0	-12.5	80.0	-2.4	100.0	-16.7	60.0	-20.0	82.0	-12.8
			52	110.0	-15.4	70.0	-12.5	72.0	-12.2	115.0	-4.2	70.0	-6.7	78.0	-17.0
			-1	125.0	-4.0	85.0	-5.9	86.0	-25.6	120.0	4.2	80.0	-12.5	90.0	-26.7
			1	120.0	-4.0	80.0	-5.9	64.0	-27.9	110.0	-8.3	70.0	-12.5	66.0	-28.9
			2	120.0	-4.0	70.0	-17.6	60.0	-30.2	110.0	-8.3	70.0	-12.5	64.0	-28.9
			3	115.0	-8.0	75.0	-11.8	68.0	-20.9	110.0	-8.3	70.0	-12.5	74.0	-17.8
			4	120.0	-4.0	70.0	-17.6	66.0	-23.3	110.0	-8.3	75.0	-6.3	70.0	-22.2
			5	115.0	-8.0	75.0	-11.8	60.0	-30.2	110.0	-8.3	70.0	-12.5	64.0	-28.9
			6	110.0	-12.0	70.0	-11.8	58.0	-32.6	110.0	-8.3	65.0	-18.8	64.0	-28.9
			8	115.0	-8.0	75.0	-11.8	74.0	-14.0	110.0	-8.3	75.0	-6.3	76.0	-15.6
			10	130.0	4.0	80.0	-5.9	76.0	-11.6	120.0	0.0	70.0	-12.5	78.0	-13.3
			12	120.0	-4.0	80.0	-5.9	72.0	-16.3	110.0	-8.3	70.0	-12.5	76.0	-15.6
			14	120.0	-4.0	80.0	-5.9	76.0	-11.6	110.0	-8.3	70.0	-12.5	80.0	-11.1
			16	110.0	-12.0	70.0	-17.6	74.0	-14.0	105.0	-12.5	60.0	-25.0	78.0	-13.3
			18	120.0	-4.0	70.0	-17.6	70.0	-18.6	105.0	-12.5	65.0	-18.8	74.0	-17.8
			20	125.0	0.0	85.0	0.0	74.0	-14.0	115.0	-4.2	75.0	-6.3	76.0	-15.6
			22	125.0	0.0	85.0	0.0	76.0	-11.6	120.0	0.0	80.0	-12.5	82.0	-8.9

** S.B.P. values => 160 mm Hg
 D.B.P. values => 100 mm Hg
 H.R. values => 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 beats/min
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING				STANDING								
				S.B.P.	% diff	H.R.	% diff	S.B.P.	% diff	H.R.	% diff					
1	353	AMG	24	115.0	-8.0	75.0	-11.8	62.0	-27.9	110.0	-8.3	70.0	-12.5	66.0	-26.7	
			26	110.0	-12.0	70.0	-17.6	60.0	-30.2	110.0	-8.3	65.0	-18.8	64.0	-28.9	
			28	120.0	-4.0	70.0	-14.0	74.0	-14.0	115.0	-4.2	60.0	-25.0	70.0	-22.2	
			30	110.0	-12.0	80.0	-5.9	62.0	-27.9	100.0	-16.7	65.0	-18.8	64.0	-28.9	
			32	120.0	-4.0	80.0	-5.9	56.0	-34.9	110.0	-8.3	70.0	-12.5	58.0	-35.6	
			34	125.0	0.0	80.0	-5.9	58.0	-32.6	110.0	-8.3	70.0	-12.5	62.0	-31.1	
	355	JEP	-1	120.0	-4.0	80.0	-5.9	62.0	-27.9	105.0	-12.5	70.0	-12.5	64.0	-28.9	
			0	120.0	0.0	70.0	90.0	-16.7	75.0	9.1	110.0	9.1	80.0	13.0	80.0	-13.0
			1	120.0	0.0	80.0	14.3	70.0	-22.2	120.0	9.1	80.0	14.3	75.0	-18.5	
			2	100.0	-16.7	70.0	0.0	90.0	0.0	110.0	0.0	80.0	14.3	94.0	2.2	
			3	100.0	-16.7	60.0	-14.3	96.0	6.7	100.0	-9.1	80.0	14.3	96.0	4.3	
			4	110.0	-8.3	80.0	14.3	96.0	6.7	105.0	-4.5	80.0	14.3	108.0	17.4	
2453	357	SLD	5	120.0	0.0	85.0	21.4	84.0	-6.7	110.0	0.0	80.0	0.0	108.0	-4.3	
			6	95.0	-20.8	80.0	-14.3	100.0	11.1	95.0	-15.6	70.0	0.0	108.0	17.4	
			8	120.0	0.0	75.0	7.1	80.0	-11.1	110.0	0.0	70.0	0.0	92.0	0.0	
			10	120.0	0.0	80.0	14.3	78.0	-13.3	115.0	4.5	80.0	14.3	86.0	-6.5	
			12	120.0	0.0	75.0	7.1	84.0	-6.7	115.0	4.5	75.0	7.1	90.0	-2.2	
			14	115.0	-4.2	75.0	7.1	74.0	-17.8	120.0	9.1	80.0	14.3	82.0	-10.9	
	16	130.0	8.3	80.0	14.3	78.0	-13.3	110.0	0.0	70.0	0.0	86.0	-6.5			
	18	130.0	8.3	80.0	14.3	74.0	-17.8	120.0	9.1	75.0	7.1	78.0	-15.2			
	20	125.0	4.2	85.0	21.4	76.0	-15.6	120.0	9.1	80.0	14.3	84.0	-8.7			
	357	SLD	-1	130.0	8.3	80.0	21.4	76.0	-15.6	120.0	9.1	80.0	14.3	84.0	-8.7	
			0	90.0	-30.8	65.0	-18.8	64.0	-27.3	120.0	9.1	70.0	0.0	94.0	0.0	
			1	90.0	-30.8	65.0	-18.8	64.0	-27.3	90.0	-25.0	70.0	0.0	70.0	-25.5	
2			90.0	-30.8	60.0	-25.0	84.0	-4.5	90.0	-25.0	60.0	-14.3	70.0	-25.5		
3			110.0	-15.4	80.0	0.0	84.0	-4.5	100.0	-16.7	80.0	14.3	100.0	6.4		
4			110.0	-15.4	80.0	0.0	84.0	-4.5	100.0	-16.7	80.0	14.3	100.0	6.4		
357	SLD	5	100.0	-23.1	75.0	-6.3	96.0	9.1	100.0	-16.7	80.0	14.3	100.0	6.4		
		6	110.0	-15.4	70.0	-12.5	96.0	9.1	100.0	-16.7	75.0	7.1	104.0	10.6		
		8	115.0	-11.5	70.0	-12.5	64.0	-27.3	90.0	-25.0	70.0	0.0	108.0	14.9		
		10	115.0	-11.5	70.0	-12.5	64.0	-27.3	90.0	-25.0	70.0	0.0	76.0	-19.1		
		12	90.0	-30.8	55.0	-31.3	72.0	-18.2	85.0	-29.2	60.0	-14.3	88.0	-6.4		
		14	90.0	-30.8	55.0	-31.3	72.0	-18.2	85.0	-29.2	60.0	-14.3	88.0	-6.4		
357	SLD	16	90.0	-30.8	65.0	-18.8	82.0	-6.8	100.0	-16.7	70.0	0.0	96.0	2.1		
		18	90.0	-30.8	65.0	-18.8	82.0	-6.8	100.0	-16.7	70.0	0.0	96.0	2.1		
		20	100.0	-23.1	65.0	-18.8	78.0	-11.4	95.0	-20.8	60.0	-14.3	96.0	2.1		
		22	100.0	-23.1	70.0	-12.5	84.0	-4.5	90.0	-25.0	60.0	-14.3	96.0	2.1		

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 beats/min
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	Initial Visit	LYING				STANDING											
			S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff						
1	357	SLD	24	105.0	-19.2	60.0	-25.0	80.0	-9.1	90.0	-25.0	60.0	-14.3	84.0	-10.6			
			26	110.0	-15.4	60.0	-25.0	80.0	-9.1	90.0	-25.0	60.0	-14.3	84.0	-10.6			
			28	80.0	-38.5	*	50.0	-37.5	*	68.0	-22.7	90.0	-25.0	55.0	-21.4	76.0	-19.1	
			30	100.0	-23.1	*	70.0	-12.5	80.0	-9.1	100.0	-16.7	65.0	-7.1	84.0	-10.6		
			32	100.0	-23.1	*	70.0	-12.5	80.0	-9.1	100.0	-16.7	80.0	14.3	88.0	-6.4		
			34	100.0	-23.1	*	70.0	-12.5	80.0	-9.1	100.0	-16.7	80.0	14.3	88.0	-6.4		
			36	100.0	-23.1	*	70.0	-12.5	80.0	-9.1	100.0	-16.7	80.0	14.3	88.0	-6.4		
			38	100.0	-23.1	*	70.0	-12.5	80.0	-9.1	100.0	-16.7	80.0	14.3	88.0	-6.4		
			40	110.0	-15.4	80.0	0.0	84.0	0.0	84.0	0.0	100.0	-16.7	80.0	14.3	88.0	-6.4	
			42	110.0	-15.4	80.0	0.0	84.0	0.0	84.0	0.0	100.0	-16.7	80.0	14.3	88.0	-6.4	
			44	105.0	-19.2	75.0	-6.3	80.0	-9.1	80.0	-9.1	100.0	-16.7	75.0	0.0	84.0	-10.6	
			46	100.0	-23.1	*	70.0	-12.5	80.0	-9.1	80.0	-9.1	100.0	-16.7	80.0	-14.9		
			48	110.0	-15.4	75.0	-6.3	80.0	-9.1	80.0	-9.1	100.0	-16.7	70.0	0.0	84.0	-14.9	
			50	120.0	-7.7	80.0	0.0	82.0	-6.8	82.0	-6.8	100.0	-8.3	70.0	0.0	86.0	-8.5	
			52	110.0	-15.4	80.0	0.0	64.0	-27.3	64.0	-27.3	100.0	-16.7	70.0	0.0	66.0	-29.8	
			3	72	TOR	-1	120.0	0.0	60.0	50.0	80.0	-22.5	120.0	-16.7	60.0	0.0	86.0	-16.3
						0	120.0	0.0	80.0	33.3	65.0	-18.8	100.0	-16.7	70.0	0.0	72.0	-18.6
						1	120.0	0.0	70.0	16.7	65.0	-18.8	100.0	-16.7	70.0	0.0	60.0	-30.2
						2	110.0	-8.3	80.0	16.7	68.0	-15.0	100.0	-16.7	70.0	0.0	72.0	-16.3
						3	110.0	-8.3	80.0	16.7	68.0	-15.0	100.0	-16.7	70.0	0.0	72.0	-16.3
4	110.0	-8.3				80.0	16.7	68.0	-15.0	100.0	-16.7	70.0	0.0	72.0	-16.3			
5	140.0	16.7				80.0	33.3	106.0	32.5	110.0	8.8	90.0	-25.0	80.0	33.3	105.0	22.1	
6	110.0	-8.3				80.0	16.7	68.0	-15.0	100.0	-16.7	70.0	0.0	72.0	-16.3			
8	120.0	0.0				90.0	50.0	92.0	15.0	92.0	15.0	110.0	-8.3	80.0	33.3	94.0	9.3	
10	100.0	-16.7				70.0	16.7	88.0	10.0	88.0	10.0	100.0	-16.7	80.0	33.3	90.0	4.7	
12	90.0	-25.0				*	60.0	0.0	64.0	-20.0	64.0	-20.0	110.0	-8.3	70.0	0.0	66.0	-23.3
14	110.0	-8.3				80.0	16.7	76.0	-5.0	76.0	-5.0	100.0	-16.7	50.0	-16.7	88.0	2.3	
16	110.0	-8.3				80.0	16.7	76.0	-5.0	76.0	-5.0	100.0	-16.7	50.0	-16.7	88.0	2.3	
18	105.0	-12.5				50.0	0.0	60.0	-25.0	60.0	-25.0	95.0	-20.8	60.0	0.0	82.0	-4.7	
20	110.0	-8.3				60.0	0.0	65.0	-18.8	65.0	-18.8	100.0	-16.7	55.0	-8.3	70.0	-18.6	
22	120.0	0.0				80.0	0.0	78.0	-2.6	78.0	-2.6	120.0	0.0	80.0	0.0	79.0	-2.5	
9	248	BP				-1	125.0	0.0	80.0	0.0	76.0	-7.7	120.0	0.0	80.0	0.0	77.0	-2.5
						0	125.0	0.0	80.0	0.0	76.0	-7.7	120.0	0.0	80.0	0.0	77.0	-2.5
						1	120.0	-4.0	80.0	0.0	72.0	-10.5	120.0	0.0	75.0	-6.3	74.0	-6.3
						2	120.0	-4.0	80.0	0.0	72.0	-10.5	120.0	0.0	75.0	-6.3	74.0	-6.3
						3	120.0	-4.0	80.0	0.0	72.0	-10.5	120.0	0.0	75.0	-6.3	74.0	-6.3
						4	120.0	-4.0	80.0	0.0	72.0	-10.5	120.0	0.0	75.0	-6.3	74.0	-6.3
5	120.0	-4.0	80.0	0.0	71.0	-9.0	120.0	0.0	80.0	0.0	76.0	-3.8						

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 100 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

2454

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBONEXINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial BP	LYING				STANDING										
			Visit	S.B.P. % diff	H.R. % diff	D.B.P. % diff	S.B.P. % diff	H.R. % diff	D.B.P. % diff	H.R. % diff							
9	248	BP	6	120.0	-4.0	70.0	-12.5	72.0	-7.7	110.0	-8.3	70.0	-12.5	75.0	-5.1		
			8	120.0	-4.0	80.0	0.0	70.0	-10.3	120.0	0.0	80.0	0.0	120.0	0.0	72.0	-8.9
			10	120.0	-4.0	80.0	0.0	72.0	-7.7	110.0	-8.3	70.0	-12.5	75.0	-5.1		
			12	120.0	-4.0	80.0	0.0	74.0	-5.1	110.0	-8.3	80.0	0.0	76.0	-3.8		
			14	130.0	4.0	80.0	0.0	72.0	-7.7	120.0	0.0	70.0	-12.5	74.0	-6.3		
			16	120.0	-4.0	80.0	0.0	70.0	-10.3	110.0	-8.3	70.0	-12.5	74.0	-6.3		
			18	120.0	-4.0	80.0	0.0	74.0	-5.1	110.0	-8.3	70.0	-12.5	76.0	-3.8		
			20	120.0	-4.0	80.0	0.0	70.0	-10.3	120.0	0.0	70.0	-12.5	73.0	-7.6		
			22	125.0	0.0	80.0	0.0	74.0	-5.1	120.0	0.0	70.0	-12.5	76.0	-3.8		
			24	120.0	-4.0	80.0	0.0	72.0	-7.7	110.0	-8.3	80.0	0.0	73.0	-7.6		
			26	120.0	-4.0	80.0	0.0	71.0	-9.0	115.0	-4.2	80.0	0.0	75.0	-7.6		
			28	120.0	-4.0	80.0	0.0	70.0	-10.3	120.0	0.0	80.0	0.0	72.0	-8.9		
			30	120.0	-4.0	80.0	0.0	71.0	-9.0	120.0	0.0	80.0	0.0	71.0	-10.1		
			32	130.0	4.0	80.0	0.0	70.0	-10.3	120.0	0.0	80.0	0.0	72.0	-8.9		
			34	120.0	-4.0	80.0	0.0	70.0	-10.3	120.0	0.0	70.0	-12.5	74.0	-6.3		
			36	130.0	4.0	80.0	0.0	71.0	-9.0	120.0	0.0	78.0	-1.3	74.0	-6.3		
			38	120.0	-4.0	80.0	0.0	69.0	-11.5	120.0	0.0	70.0	-12.5	74.0	-6.3		
			40	130.0	4.0	80.0	0.0	70.0	-12.5	120.0	0.0	60.0	-25.0	71.0	-10.1		
42	120.0	-4.0	80.0	0.0	71.0	-9.0	120.0	0.0	70.0	-12.5	72.0	-8.9					
44	120.0	-4.0	80.0	0.0	71.0	-9.0	110.0	-8.3	70.0	-12.5	72.0	-8.9					
46	130.0	4.0	80.0	0.0	76.0	-2.6	120.0	0.0	70.0	-12.5	75.0	-5.1					
48	120.0	-4.0	80.0	0.0	75.0	-3.8	120.0	0.0	70.0	-12.5	76.0	-3.8					
50	120.0	-4.0	80.0	0.0	72.0	-7.7	120.0	0.0	70.0	-12.5	74.0	-6.3					
52	120.0	-4.0	80.0	0.0	72.0	-7.7	110.0	-8.3	70.0	-12.5	75.0	-5.1					
251	RF		-1	140.0	-7.1	90.0	-11.1	74.0	-2.7	130.0	-7.7	90.0	77.0	-3.9			
			0	130.0	-4.3	80.0	-11.1	72.0	-5.4	120.0	-7.7	80.0	74.0	-6.5			
			1	120.0	-4.3	80.0	-11.1	70.0	-4.1	120.0	-11.1	80.0	72.0	-5.2			
			2	120.0	-4.3	80.0	-11.1	71.0	-5.4	115.0	-3.8	80.0	73.0	-5.2			
			3	130.0	-7.1	80.0	-11.1	70.0	-2.7	120.0	-7.7	80.0	73.0	-2.6			
			4	120.0	-4.3	80.0	-11.1	72.0	-2.7	120.0	-7.7	80.0	75.0	-2.6			
			5	130.0	-7.1	90.0	-11.1	72.0	-2.7	120.0	-7.7	80.0	75.0	-2.6			
			6	120.0	-4.3	80.0	-11.1	72.0	-2.7	120.0	-7.7	80.0	75.0	-2.6			
			8	120.0	-4.3	80.0	-11.1	72.0	-2.7	120.0	-7.7	80.0	75.0	-2.6			
			10	130.0	-7.1	90.0	-11.1	71.0	-4.1	120.0	-7.7	80.0	74.0	-3.9			
			12	120.0	-4.3	80.0	-11.1	68.0	-8.1	120.0	-7.7	70.0	74.0	-3.9			
			14	125.0	-10.7	90.0	-11.1	71.0	-4.1	120.0	-7.7	80.0	74.0	-3.9			
			16	130.0	-7.1	90.0	0.0	73.0	-1.4	120.0	-7.7	80.0	75.0	-2.6			
			18	120.0	-4.3	80.0	-11.1	71.0	-4.1	110.0	-15.4	70.0	76.0	-1.3			

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 mm Hg
 H.R. values <= 50 beats/min

2455

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING				STANDING									
				S.B.P.	% diff	H.R.	% diff	S.B.P.	% diff	H.R.	% diff						
9	253	LCY	-1	130.0	-7.7	80.0	0.0	90.0	-12.2	120.0	0.0	80.0	0.0	91.0			
			0	120.0	-7.7	80.0	0.0	79.0	-13.3	110.0	-8.3	80.0	0.0	80.0			
			1	120.0	-7.7	80.0	12.5	78.0	-13.3	110.0	-8.3	80.0	0.0	80.0			
			2	120.0	-7.7	80.0	0.0	72.0	-20.0	110.0	-8.3	80.0	-12.5	76.0			
			3	120.0	-7.7	80.0	0.0	71.0	-21.1	110.0	-8.3	80.0	-12.5	73.0			
			4	120.0	-7.7	80.0	0.0	70.0	-22.2	110.0	-8.3	80.0	-12.5	70.0			
			5	120.0	-7.7	80.0	0.0	72.0	-20.0	120.0	0.0	80.0	0.0	73.0			
			6	125.0	-3.8	80.0	0.0	72.0	-20.0	120.0	0.0	80.0	-12.5	75.0			
			8	120.0	-7.7	80.0	0.0	71.0	-21.1	120.0	0.0	80.0	-12.5	72.0			
			10	120.0	-7.7	80.0	0.0	73.0	-18.9	110.0	-8.3	80.0	-12.5	75.0			
			12	130.0	0.0	80.0	0.0	72.0	-20.0	120.0	0.0	80.0	-12.5	74.0			
			14	120.0	-7.7	80.0	-25.0	78.0	-13.3	110.0	-8.3	80.0	-25.0	80.0			
			16	120.0	-7.7	80.0	0.0	71.0	-21.1	120.0	0.0	80.0	-25.0	75.0			
			18	120.0	-7.7	80.0	-12.5	72.0	-20.0	100.0	-16.7	80.0	-25.0	73.0			
			20	120.0	-7.7	80.0	0.0	73.0	-18.9	110.0	-8.3	80.0	-12.5	75.0			
			254	PH		-1	150.0	0.0	90.0	0.0	78.0	-5.1	140.0	0.0	90.0	-11.1	80.0
						0	150.0	0.0	90.0	0.0	74.0	-7.7	140.0	-7.1	90.0	-11.1	77.0
						1	140.0	-6.7	80.0	-11.1	72.0	-7.7	130.0	-7.1	80.0	-22.2	71.0
						2	130.0	-13.3	80.0	-11.1	72.0	-7.7	130.0	-7.1	80.0	-22.2	70.0
						3	150.0	0.0	90.0	0.0	72.0	-7.7	140.0	0.0	90.0	-11.1	74.0
4	140.0	-6.7				90.0	0.0	70.0	-10.3	130.0	-7.1	80.0	-11.1	72.0			
5	140.0	-6.7				80.0	-11.1	73.0	-6.4	130.0	-7.1	80.0	-11.1	75.0			
6	130.0	-13.3				80.0	-11.1	70.0	-10.3	130.0	-7.1	80.0	-11.1	72.0			
8	140.0	-6.7				80.0	-11.1	72.0	-7.7	150.0	7.1	80.0	-11.1	76.0			
10	150.0	0.0				90.0	0.0	74.0	-5.1	140.0	0.0	90.0	-11.1	77.0			
12	130.0	-13.3				80.0	-11.1	72.0	-7.7	130.0	-7.1	80.0	-22.2	75.0			
14	140.0	-6.7				80.0	-11.1	73.0	-6.4	130.0	-7.1	80.0	-11.1	74.0			
16	150.0	0.0				90.0	0.0	70.0	-10.3	140.0	0.0	90.0	-11.1	72.0			
18	140.0	-6.7				90.0	0.0	73.0	-6.4	130.0	-7.1	80.0	-11.1	76.0			
20	150.0	0.0				90.0	0.0	78.0	0.0	140.0	0.0	90.0	-11.1	79.0			
22	140.0	-6.7				90.0	0.0	72.0	-7.7	120.0	-14.3	80.0	-11.1	74.0			
24	130.0	-13.3	80.0	-11.1	73.0	-6.4	120.0	-14.3	80.0	-22.2	74.0						
26	140.0	-6.7	80.0	-11.1	76.0	-2.6	130.0	-7.1	80.0	-22.2	75.0						
28	130.0	-13.3	80.0	-11.1	72.0	-7.7	130.0	-7.1	80.0	-22.2	75.0						
30	120.0	-20.0	80.0	-11.1	76.0	-2.6	120.0	-14.3	70.0	-22.2	79.0						
32	140.0	-6.7	90.0	0.0	76.0	-2.6	140.0	0.0	90.0	-11.1	77.0						
34	140.0	-6.7	80.0	-11.1	77.0	-1.9	130.0	-7.1	80.0	-11.1	79.0						
36	150.0	0.0	90.0	0.0	72.0	-7.7	140.0	0.0	90.0	-11.1	75.0						
38	130.0	-13.3	80.0	-11.1	71.0	-9.0	140.0	0.0	90.0	-11.1	75.0						

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 mm Hg
 H.R. values <= 50 beats/min

9
 12
 13
 14
 20

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING				STANDING											
				S.B.P.	% diff	H.R.	% diff	S.B.P.	% diff	H.R.	% diff								
9	254	PM	40	150.0	0.0	80.0	-11.1	86.0	10.3	140.0	0.0	70.0	-22.2	*	87.0	8.8			
			42	140.0	-6.7	80.0	-11.1	72.0	-7.7	130.0	-7.1	70.0	-22.2	*	76.0	-5.0			
			44	150.0	0.0	80.0	-11.1	78.0	0.0	140.0	0.0	80.0	-11.1		79.0	-1.2			
			46	140.0	-6.7	90.0	0.0	76.0	-2.6	140.0	0.0	80.0	-11.1		80.0	0.0			
			48	150.0	0.0	90.0	0.0	76.0	-2.6	140.0	0.0	80.0	-11.1		78.0	-2.5			
			50	160.0	6.7	90.0	0.0	80.0	0.0	140.0	0.0	80.0	-11.1		92.0	15.0			
			10	32	BK	-1	100.0	0.0	70.0	0.0	70.0	14.3	105.0	28.6	75.0	-6.7		78.0	7.7
						1	110.0	10.0	80.0	14.3	90.0	28.6	95.0	4.8	60.0	-20.0		100.0	28.2
						2	110.0	10.0	80.0	-14.3	90.0	14.3	110.0	0.0	60.0	-20.0		80.0	2.6
						3	140.0	40.0	70.0	0.0	88.0	25.7	130.0	23.8	70.0	-6.7		88.0	12.8
4	140.0	40.0				80.0	14.3	88.0	25.7	125.0	19.0	70.0	-6.7		96.0	23.1			
5	140.0	40.0				85.0	21.4	84.0	20.0	130.0	23.8	75.0	0.0		92.0	17.9			
6	140.0	40.0				70.0	0.0	98.0	40.0	130.0	23.8	80.0	6.7		98.0	25.6			
8	110.0	10.0				70.0	0.0	92.0	31.4	115.0	9.5	80.0	6.7		98.0	25.6			
10	150.0	50.0				70.0	0.0	78.0	11.4	165.0	57.1	80.0	6.7		98.0	23.6			
12	140.0	40.0				70.0	0.0	84.0	20.0	150.0	47.6	80.0	6.7		96.0	23.1			
10	33	AP	-1	110.0	0.0	70.0	0.0	76.0	0.0	115.0	0.0	75.0	0.0		76.0	0.0			
			1	110.0	0.0	70.0	0.0	76.0	0.0	115.0	0.0	75.0	0.0		76.0	0.0			
			1	105.0	-4.5	65.0	-7.1	84.0	10.5	100.0	-13.0	70.0	-6.7		98.0	28.9			
			2	150.0	36.4	70.0	0.0	90.0	18.4	100.0	0.0	80.0	6.7		110.0	44.7			
			3	110.0	0.0	75.0	7.1	82.0	7.9	115.0	0.0	80.0	6.7		88.0	15.8			
			4	100.0	-9.1	70.0	0.0	88.0	15.8	110.0	-4.3	75.0	0.0		98.0	28.9			
			5	100.0	-9.1	75.0	7.1	78.0	2.6	100.0	-13.0	80.0	6.7		92.0	21.1			
			6	110.0	0.0	70.0	0.0	100.0	31.6	105.0	-8.7	70.0	-6.7		80.0	5.3			
			8	115.0	4.5	75.0	7.1	78.0	2.6	105.0	-8.7	92.0	22.7		98.0	28.9			
			10	110.0	0.0	75.0	7.1	72.0	-5.3	110.0	-4.3	75.0	0.0		90.0	18.4			
10	33	AP	12	115.0	4.5	80.0	14.3	78.0	2.6	110.0	-4.3	85.0	13.3		96.0	26.3			
			14	120.0	9.1	75.0	7.1	78.0	2.6	105.0	-8.7	80.0	6.7		90.0	18.4			

** S.B.P. values => 160 mm Hg
 D.B.P. values => 100 mm Hg
 H.R. values => 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

2457

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	Initial Visit	LYING			STANDING										
			S.B.P. % diff	D.B.P. % diff	H.R. % diff	S.B.P. % diff	D.B.P. % diff	H.R. % diff								
10	34	KJ	-1	115.0	0.0	70.0	66.0	0.0	120.0	0.0	75.0	72.0				
			0	115.0	0.0	70.0	66.0	0.0	120.0	0.0	75.0	72.0	0.0			
			1	120.0	4.3	70.0	66.0	0.0	122.0	1.7	122.0	1.3	68.0	-5.6		
			2	90.0	-21.7	*	60.0	-14.3	0.0	122.0	0.0	60.0	-20.0	86.0	19.4	
			3	118.0	2.6	0.0	70.0	6.1	0.0	122.0	1.7	75.0	0.0	80.0	11.1	
			4	160.0	39.1	**	100.0	42.9	**	150.0	25.0	90.0	20.0	100.0	38.9	
			5	130.0	13.0	0.0	80.0	14.3	0.0	130.0	8.3	75.0	0.0	88.0	22.2	
			6	130.0	13.0	0.0	80.0	14.3	0.0	130.0	8.3	80.0	6.7	88.0	22.2	
			8	120.0	4.3	0.0	60.0	-14.3	0.0	125.0	5.0	70.0	-6.7	78.0	8.3	
			10	120.0	4.3	0.0	65.0	-7.1	0.0	125.0	4.2	75.0	0.0	86.0	19.4	
			12	115.0	0.0	0.0	65.0	-7.1	0.0	120.0	0.0	65.0	-13.3	80.0	11.1	
			14	120.0	4.3	0.0	65.0	-7.1	0.0	120.0	0.0	65.0	-13.3	78.0	8.3	
			16													
			38	TN		-1	135.0	0.0	80.0	60.0	0.0	145.0	0.0	80.0	66.0	66.0
						0	135.0	0.0	80.0	60.0	0.0	145.0	0.0	80.0	66.0	66.0
						1	150.0	11.1	100.0	25.0	**	145.0	0.0	95.0	18.8	86.0
2	145.0	7.4				80.0	0.0	0.0	140.0	-3.4	80.0	0.0	72.0	9.1		
3	140.0	3.7				80.0	0.0	0.0	145.0	0.0	85.0	6.3	80.0	21.2		
4	150.0	11.1				90.0	12.5	0.0	140.0	-3.4	95.0	18.8	70.0	18.2		
5	140.0	3.7				80.0	0.0	0.0	140.0	-3.4	80.0	0.0	84.0	27.3		
6	145.0	7.4				80.0	0.0	0.0	150.0	3.4	80.0	0.0	80.0	21.2		
CT39 CO	TM		-1	120.0	0.0	70.0	66.0	10.0	135.0	-6.9	75.0	74.0	74.0			
			0	120.0	0.0	70.0	66.0	10.0	135.0	-6.9	75.0	74.0	74.0			
			1	130.0	8.3	65.0	-7.1	0.0	130.0	18.2	70.0	0.0	78.0	0.0		
			2	118.0	-1.7	64.0	-8.6	0.0	124.0	12.7	60.0	-25.0	68.0	-12.8		
			3	120.0	0.0	70.0	0.0	0.0	125.0	13.6	80.0	0.0	84.0	7.7		
			4	130.0	8.3	65.0	-7.1	0.0	130.0	18.2	70.0	-12.5	68.0	-12.8		
			5	120.0	0.0	60.0	-14.3	0.0	125.0	13.6	60.0	-25.0	80.0	2.6		
			6	115.0	-4.2	65.0	-7.1	0.0	115.0	4.5	60.0	-25.0	80.0	2.6		
CT39 CO	TM		8	120.0	0.0	80.0	88.0	25.7	100.0	-9.1	70.0	-12.5	120.0	53.8		
			10	120.0	0.0	70.0	0.0	0.0	110.0	4.5	65.0	-18.8	82.0	5.1		
			12	115.0	-4.2	70.0	0.0	0.0	110.0	0.0	65.0	-18.8	82.0	5.1		
			14	115.0	-4.2	72.0	7.1	0.0	115.0	4.5	65.0	-18.8	80.0	2.6		
			16	120.0	0.0	70.0	0.0	0.0	115.0	4.5	70.0	-12.5	82.0	5.1		
			18	110.0	-8.3	75.0	7.1	0.0	100.0	-9.1	70.0	-12.5	88.0	12.8		
			20	120.0	0.0	70.0	0.0	0.0	140.0	0.0	65.0	-18.8	84.0	7.7		
			22	115.0	-4.2	70.0	0.0	0.0	110.0	0.0	65.0	-18.8	82.0	5.1		

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 50 beats/min
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	Initial Visit	LYING			STANDING									
			S.B.P. % diff	H.R. % diff	D.B.P. % diff	S.B.P. % diff	H.R. % diff	D.B.P. % diff							
10	39	TM	24	120.0	0.0	70.0	0.0	72.0	2.9	115.0	4.5	65.0	-18.8	78.0	0.0
			26	130.0	8.3	70.0	0.0	74.0	5.7	120.0	9.1	60.0	-25.0	80.0	2.6
			28	115.0	-4.2	65.0	-7.1	72.0	2.9	110.0	0.0	60.0	-25.0	82.0	5.1
			30	110.0	-8.3	60.0	-14.3	74.0	5.7	110.0	0.0	60.0	-25.0	78.0	0.0
			32	115.0	-4.2	60.0	-14.3	72.0	2.9	110.0	0.0	60.0	-25.0	80.0	2.6
			34	120.0	0.0	65.0	-7.1	68.0	0.0	115.0	4.5	60.0	-25.0	74.0	-5.1
			36	120.0	0.0	70.0	0.0	70.0	0.0	110.0	0.0	60.0	-25.0	78.0	0.0
			38	115.0	-4.2	70.0	0.0	72.0	2.9	110.0	0.0	60.0	-25.0	78.0	0.0
			40	115.0	-4.2	65.0	-7.1	68.0	0.0	110.0	0.0	60.0	-25.0	76.0	-2.6
			44	120.0	0.0	75.0	7.1	70.0	0.0	115.0	4.5	70.0	0.0	76.0	0.0
41	IP		1	120.0	0.0	75.0	0.0	64.0	0.0	110.0	0.0	70.0	0.0	74.0	0.0
			2	135.0	12.5	65.0	-13.3	72.0	12.5	140.0	27.3	70.0	0.0	96.0	29.7
			3	130.0	8.3	70.0	-6.7	80.0	25.0	120.0	9.1	68.0	-2.9	96.0	29.7
			4	120.0	0.0	65.0	-13.3	92.0	43.8	100.0	-9.1	60.0	-44.3	120.0	62.2
			5	120.0	0.0	70.0	-6.7	104.0	62.5	110.0	0.0	60.0	-44.3	102.0	37.8
			6	110.0	-8.3	70.0	-6.7	80.0	25.0	108.0	-1.8	60.0	-44.3	92.0	24.3
			8	110.0	-8.3	60.0	-20.0	80.0	25.0	118.0	7.3	70.0	0.0	96.0	29.7
			10	125.0	4.2	80.0	6.7	72.0	12.5	140.0	27.3	60.0	-14.3	96.0	29.7
			12	115.0	-4.2	65.0	-13.3	78.0	21.9	125.0	13.6	90.0	28.6	80.0	8.1
			14	120.0	0.0	65.0	-13.3	76.0	18.8	115.0	4.5	65.0	-7.1	82.0	10.8
44	EE		1	120.0	0.0	70.0	-6.7	72.0	12.5	120.0	9.1	70.0	0.0	80.0	8.1
			2	120.0	0.0	70.0	-6.7	78.0	21.9	120.0	9.1	70.0	0.0	86.0	16.2
			3	125.0	4.2	80.0	0.0	76.0	18.8	110.0	0.0	65.0	-7.1	86.0	16.2
			4	120.0	0.0	80.0	0.0	104.0	30.0	125.0	8.3	80.0	0.0	100.0	8.7
			5	120.0	0.0	80.0	0.0	100.0	25.0	130.0	8.3	80.0	0.0	100.0	8.7
			6	120.0	0.0	80.0	0.0	100.0	25.0	130.0	8.3	80.0	0.0	128.0	39.1

** S.B.P. values => 160 mm Hg
D.B.P. values => 100 mm Hg
H.R. values => 100 beats/min
* S.B.P. values <= 100 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING				STANDING										
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff					
10	44	EE	8	130.0	8.3	80.0	0.0	84.0	5.0	135.0	12.5	80.0	8.1	94.0	2.2			
			10	135.0	12.5	80.0	0.0	84.0	5.0	140.0	16.7	80.0	8.1	96.0	4.3			
			12	130.0	8.3	80.0	0.0	82.0	2.5	135.0	12.5	80.0	8.1	86.0	-6.5			
			14	135.0	12.5	80.0	0.0	80.0	0.0	135.0	0.0	85.0	14.9	92.0	0.0			
			16	125.0	4.2	70.0	-12.5	78.0	-2.5	130.0	8.3	80.0	8.1	82.0	-10.9			
			18	115.0	-4.2	70.0	-12.5	68.0	-15.0	115.0	-4.2	75.0	1.4	70.0	-23.9			
			20	120.0	0.0	70.0	-12.5	72.0	-10.0	125.0	4.2	75.0	1.4	80.0	-13.0			
			22	120.0	0.0	70.0	-12.5	74.0	-7.5	120.0	0.0	75.0	1.4	80.0	-13.0			
			24	125.0	4.2	70.0	-12.5	72.0	-10.0	130.0	8.3	75.0	1.4	80.0	-13.0			
			26	130.0	8.3	75.0	-6.3	74.0	-7.5	135.0	12.5	80.0	8.1	82.0	-10.9			
			28	130.0	8.3	70.0	-12.5	74.0	-7.5	140.0	16.7	80.0	8.1	86.0	-6.5			
			30	130.0	8.3	70.0	-12.5	72.0	-10.0	135.0	12.5	80.0	8.1	84.0	-8.7			
			32	130.0	8.3	70.0	-12.5	74.0	-7.5	140.0	16.7	80.0	8.1	80.0	-13.0			
			34	125.0	4.2	70.0	-12.5	70.0	-12.5	135.0	12.5	75.0	1.4	82.0	-10.9			
			36	125.0	4.2	70.0	-12.5	70.0	-12.5	135.0	12.5	75.0	1.4	82.0	-10.9			
			38	135.0	12.5	75.0	-6.3	72.0	-10.0	140.0	16.7	80.0	8.1	82.0	-10.9			
			40	130.0	8.3	75.0	-6.3	72.0	-10.0	140.0	16.7	80.0	8.1	82.0	-10.9			
			42	130.0	8.3	80.0	0.0	70.0	-12.5	125.0	4.2	85.0	14.9	78.0	-15.2			
			44	135.0	12.5	80.0	0.0	72.0	-10.0	135.0	12.5	80.0	8.1	80.0	-13.0			
			46	130.0	8.3	75.0	-6.3	70.0	-12.5	135.0	12.5	80.0	8.1	76.0	-17.4			
			48	135.0	12.5	75.0	-6.3	66.0	-17.5	140.0	16.7	80.0	8.1	72.0	-21.7			
			50	130.0	8.3	75.0	-6.3	68.0	-15.0	135.0	12.5	80.0	8.1	78.0	-15.2			
			52	135.0	12.5	75.0	-6.3	70.0	-12.5	140.0	16.7	80.0	8.1	78.0	-15.2			
			45	UL		-1	140.0	0.0	90.0	0.0	68.0	0.0	130.0	0.0	90.0	0.0	76.0	0.0
						0	140.0	0.0	90.0	0.0	68.0	0.0	130.0	0.0	90.0	0.0	76.0	0.0
						1	135.0	-3.6	90.0	0.0	76.0	11.8	125.0	-3.8	85.0	-5.6	80.0	5.3
						2	130.0	-7.1	85.0	-5.6	78.0	14.7	130.0	0.0	90.0	0.0	84.0	10.5
						3	135.0	-3.6	80.0	-11.1	80.0	17.6	130.0	0.0	100.0	11.1	108.0	42.1
						4	120.0	-14.3	86.0	-4.4	64.0	-5.9	120.0	-7.7	90.0	0.0	88.0	15.8
						5	118.0	-15.7	65.0	-27.8	76.0	11.8	120.0	-7.7	70.0	-22.2	80.0	5.3
						6	130.0	-7.1	80.0	-11.1	74.0	8.8	125.0	-3.8	80.0	-11.1	80.0	5.3
						8	120.0	-14.3	75.0	-16.7	72.0	5.9	120.0	-7.7	70.0	-22.2	78.0	2.6
						10	130.0	-7.1	80.0	-11.1	72.0	5.9	120.0	-7.7	70.0	-22.2	84.0	10.5
						12	125.0	-10.7	80.0	-11.1	72.0	5.9	120.0	-7.7	80.0	-11.1	82.0	7.9
						14	120.0	-14.3	80.0	-11.1	76.0	11.8	115.0	-11.5	80.0	-11.1	80.0	5.3
			16	130.0	-7.1	80.0	-11.1	74.0	8.8	120.0	-7.7	70.0	-22.2	80.0	5.3			
			18	120.0	-14.3	80.0	-11.1	72.0	5.9	120.0	-7.7	80.0	-11.1	80.0	5.3			
			20	115.0	-17.9	70.0	-22.2	74.0	8.8	120.0	-7.7	70.0	-22.2	84.0	10.5			
			22	120.0	-14.3	80.0	-11.1	72.0	5.9	120.0	-7.7	75.0	-16.7	78.0	2.6			

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 50 beats/min
H.R. values <= 50 beats/min

2460

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING				STANDING							
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff		
10	45	UL	24	125.0	-10.7	80.0	-11.1	72.0	5.9	115.0	-11.5	75.0	-16.7	80.0	5.3
			26	125.0	-10.7	75.0	-16.7	68.0	0.0	120.0	-7.7	75.0	-16.7	78.0	2.6
			28	120.0	-14.3	75.0	-16.7	70.0	2.9	115.0	-11.5	70.0	-22.2	78.0	2.6
			30	125.0	-10.7	75.0	-16.7	72.0	5.9	120.0	-7.7	70.0	-22.2	78.0	2.6
			32	120.0	-14.3	75.0	-16.7	70.0	2.9	115.0	-11.5	70.0	-22.2	78.0	2.6
			34	120.0	-14.3	75.0	-16.7	72.0	5.9	120.0	-7.7	70.0	-22.2	78.0	2.6
			36	120.0	-14.3	70.0	-22.2	72.0	2.9	115.0	-11.5	65.0	-27.8	74.0	-2.6
			38	120.0	-14.3	70.0	-22.2	68.0	0.0	120.0	-7.7	70.0	-22.2	74.0	0.0
			40	120.0	-14.3	70.0	-22.2	68.0	0.0	115.0	-11.5	65.0	-27.8	74.0	0.0
			42	120.0	-14.3	75.0	-16.7	72.0	5.9	110.0	-15.4	70.0	-22.2	78.0	2.6
			44	115.0	-17.9	70.0	-22.2	68.0	0.0	110.0	-15.4	60.0	-33.3	80.0	5.3
			46	120.0	-14.3	70.0	-22.2	72.0	5.9	110.0	-15.4	60.0	-33.3	78.0	2.6
			48	120.0	-14.3	70.0	-22.2	70.0	2.9	115.0	-11.5	60.0	-33.3	78.0	2.6
			50	120.0	-14.3	70.0	-22.2	66.0	-2.9	110.0	-15.4	60.0	-33.3	72.0	-5.3
			52	115.0	-17.9	70.0	-22.2	68.0	0.0	110.0	-15.4	65.0	-27.8	74.0	-2.6
46	JN		-1	105.0	0.0	80.0	0.0	78.0	0.0	105.0	0.0	75.0	0.0	82.0	0.0
			1	110.0	4.8	70.0	-12.5	74.0	0.0	105.0	0.0	70.0	-6.7	82.0	0.0
			2	115.0	9.5	80.0	0.0	70.0	-10.3	110.0	4.8	80.0	6.7	76.0	-7.3
			3	120.0	14.3	80.0	0.0	74.0	-5.1	114.0	8.6	80.0	6.7	94.0	14.6
			4	120.0	14.3	80.0	0.0	74.0	-5.1	120.0	14.3	80.0	6.7	80.0	-2.4
			5	120.0	14.3	80.0	0.0	72.0	-7.7	120.0	14.3	80.0	6.7	78.0	-4.9
			6	120.0	14.3	80.0	0.0	76.0	-2.6	115.0	9.5	80.0	6.7	84.0	2.4
			8	120.0	14.3	80.0	0.0	74.0	-5.1	115.0	9.5	75.0	0.0	80.0	-2.4
			10	115.0	9.5	80.0	0.0	72.0	-7.7	110.0	4.8	75.0	0.0	78.0	-4.9
			12	110.0	4.8	80.0	0.0	72.0	-7.7	110.0	4.8	80.0	6.7	80.0	-2.4
			14	110.0	4.8	70.0	-12.5	72.0	-7.7	105.0	0.0	70.0	-6.7	78.0	-4.9
			16	120.0	14.3	70.0	-12.5	74.0	-5.1	110.0	4.8	65.0	-13.3	80.0	-2.4
			18	110.0	4.8	65.0	-25.0	72.0	-7.7	110.0	4.8	65.0	-13.3	76.0	-7.3
			20	105.0	0.0	60.0	-33.3	68.0	-12.8	100.0	0.0	60.0	-20.0	76.0	-7.3
			22	110.0	4.8	65.0	-25.0	72.0	-7.7	105.0	0.0	60.0	-20.0	78.0	-4.9
			24	120.0	14.3	70.0	-12.5	70.0	-10.3	110.0	4.8	65.0	-13.3	78.0	-4.9
			26	115.0	9.5	65.0	-25.0	70.0	-7.7	110.0	4.8	60.0	-20.0	74.0	-9.8
			28	110.0	4.8	65.0	-25.0	72.0	-7.7	110.0	4.8	60.0	-20.0	78.0	-4.9
			30	110.0	4.8	65.0	-25.0	68.0	-12.8	110.0	4.8	60.0	-20.0	74.0	-9.8
			32	120.0	14.3	70.0	-12.5	70.0	-10.3	110.0	4.8	60.0	-20.0	76.0	-7.3
			34	115.0	9.5	70.0	-12.5	67.0	-14.1	110.0	4.8	65.0	-13.3	74.0	-9.8
			36	120.0	14.3	70.0	-12.5	70.0	-10.3	110.0	4.8	60.0	-20.0	76.0	-7.3
			38	110.0	4.8	65.0	-25.0	68.0	-12.8	105.0	0.0	60.0	-20.0	76.0	-7.3

** S.B.P. values => 160 mm Hg
D.B.P. values => 100 mm Hg
H.R. values => 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 50 mm Hg
H.R. values <= 50 beats/min

2461

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING			STANDING			H.R. % diff									
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff		H.R.	% diff							
10	46	JN	40	110.0	4.8	68.0	-12.8	105.0	0.0	60.0	-20.0	78.0	-4.9						
			42	115.0	9.5	70.0	-10.3	110.0	4.8	60.0	0.0	60.0	-20.0	78.0	-4.9				
			44	120.0	14.3	70.0	-7.7	110.0	4.8	60.0	4.8	60.0	-20.0	80.0	-2.4				
			46	115.0	9.5	70.0	-10.3	110.0	4.8	65.0	4.8	65.0	-13.3	78.0	-4.9				
			49	TP	-1	115.0	0.0	60.0	0.0	110.0	0.0	80.0	0.0	80.0	0.0	80.0	0.0		
					0	120.0	4.3	64.0	6.7	110.0	0.0	65.0	0.0	65.0	-18.8	75.0	-6.3		
					1	115.0	0.0	72.0	20.0	115.0	4.5	65.0	4.5	65.0	-18.8	84.0	5.0		
					2	120.0	4.3	70.0	0.0	115.0	4.5	70.0	4.5	70.0	-12.5	82.0	2.5		
					3	115.0	0.0	75.0	25.0	115.0	4.5	65.0	4.5	65.0	-18.8	86.0	7.5		
					4	120.0	4.3	70.0	0.0	110.0	0.0	65.0	0.0	65.0	-18.8	80.0	0.0		
					5	115.0	0.0	68.0	13.3	110.0	0.0	65.0	0.0	65.0	-18.8	70.0	-12.5		
					6	115.0	0.0	68.0	13.3	110.0	0.0	65.0	0.0	65.0	-18.8	72.0	-10.0		
					8	115.0	0.0	66.0	10.0	110.0	0.0	65.0	0.0	65.0	-18.8	72.0	-10.0		
					10	115.0	0.0	70.0	16.7	115.0	4.5	65.0	4.5	65.0	-25.0	78.0	-2.5		
					12	115.0	0.0	68.0	13.3	115.0	4.5	65.0	4.5	65.0	-18.8	78.0	-2.5		
					14	110.0	-4.3	68.0	13.3	105.0	-4.5	65.0	-4.5	65.0	-18.8	78.0	-2.5		
					16	115.0	0.0	70.0	16.7	115.0	4.5	65.0	4.5	65.0	-18.8	78.0	-2.5		
					18	120.0	4.3	70.0	0.0	110.0	0.0	65.0	0.0	65.0	-18.8	78.0	-2.5		
					20	120.0	4.3	70.0	0.0	110.0	0.0	65.0	0.0	65.0	-18.8	78.0	-2.5		
					22	110.0	-4.3	72.0	20.0	115.0	4.5	65.0	4.5	65.0	-18.8	78.0	-2.5		
					24	120.0	4.3	68.0	13.3	110.0	0.0	65.0	0.0	65.0	-18.8	74.0	-7.5		
					26	115.0	0.0	72.0	20.0	110.0	0.0	65.0	0.0	65.0	-18.8	76.0	-5.0		
					28	120.0	4.3	72.0	20.0	115.0	4.5	65.0	4.5	65.0	-25.0	78.0	-2.5		
					30	115.0	0.0	72.0	20.0	110.0	0.0	65.0	0.0	65.0	-18.8	78.0	-2.5		
					32	120.0	4.3	68.0	13.3	110.0	0.0	65.0	0.0	65.0	-18.8	78.0	-2.5		
					34	115.0	0.0	74.0	23.3	110.0	0.0	65.0	0.0	65.0	-18.8	78.0	-2.5		
					36	120.0	4.3	72.0	20.0	110.0	0.0	65.0	0.0	65.0	-25.0	78.0	-2.5		
					38	115.0	0.0	68.0	13.3	110.0	0.0	65.0	0.0	65.0	-18.8	74.0	-7.5		
					40	120.0	4.3	70.0	0.0	115.0	4.5	60.0	0.0	60.0	-25.0	78.0	-2.5		
					42	110.0	-4.3	68.0	13.3	105.0	-4.5	60.0	0.0	60.0	-25.0	72.0	-10.0		
					44	120.0	4.3	72.0	20.0	110.0	0.0	65.0	0.0	65.0	-25.0	74.0	-7.5		
					46	120.0	4.3	68.0	13.3	115.0	4.5	65.0	4.5	65.0	-18.8	74.0	-7.5		
					48	120.0	4.3	70.0	0.0	110.0	0.0	65.0	0.0	65.0	-25.0	74.0	-7.5		
					50	115.0	0.0	68.0	13.3	105.0	-4.5	60.0	0.0	60.0	-25.0	72.0	-10.0		
					52	120.0	4.3	60.0	0.0	100.0	0.0	65.0	0.0	65.0	-18.8	68.0	-15.0		
					52	KK	-1	90.0	0.0	60.0	0.0	100.0	0.0	60.0	0.0	60.0	0.0	64.0	0.0
							0	90.0	0.0	60.0	0.0	100.0	0.0	60.0	0.0	60.0	0.0	64.0	0.0
							1	120.0	33.3	88.0	46.7	120.0	20.0	60.0	0.0	60.0	0.0	100.0	56.3

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 100 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

2462

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REROMETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LIVING				STANDING										
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff					
10	52	KK	2	120.0	53.3	70.0	16.7	68.0	13.3	100.0	0.0	70.0	16.7	100.0	56.3	**		
			3	110.0	22.2	60.0	0.0	80.0	33.3	112.0	12.0	60.0	0.0	88.0	37.5			
			4	108.0	20.0	60.0	0.0	84.0	40.0	104.0	4.0	58.0	-3.3	88.0	37.5			
			5	105.0	16.7	75.0	25.0	60.0	0.0	110.0	10.0	80.0	33.3	88.0	37.5			
			6	100.0	11.1	75.0	25.0	78.0	30.0	110.0	10.0	80.0	33.3	88.0	37.5			
			8	100.0	11.1	68.0	13.3	48.0	-20.0	105.0	5.0	80.0	33.3	84.0	31.3			
			10	100.0	11.1	65.0	8.3	48.0	-20.0	105.0	5.0	80.0	33.3	84.0	31.3			
			12	100.0	11.1	70.0	16.7	60.0	0.0	110.0	10.0	75.0	25.0	78.0	21.9			
			14	100.0	11.1	65.0	8.3	54.0	-10.0	105.0	5.0	75.0	25.0	72.0	12.5			
			16	95.0	5.6	60.0	0.0	60.0	0.0	100.0	0.0	70.0	16.7	78.0	21.9			
			18	85.0	-5.6	65.0	8.3	54.0	-10.0	95.0	8.3	65.0	8.3	72.0	12.5			
			20	85.0	-5.6	55.0	-8.3	58.0	0.0	90.0	0.0	60.0	0.0	84.0	31.3			
			22	100.0	11.1	65.0	8.3	60.0	0.0	110.0	10.0	80.0	33.3	84.0	31.3			
			24	100.0	11.1	60.0	0.0	54.0	-10.0	105.0	5.0	75.0	25.0	84.0	31.3			
			26	95.0	5.6	60.0	0.0	54.0	-10.0	100.0	0.0	70.0	16.7	78.0	21.9			
			28	90.0	0.0	50.0	0.0	60.0	0.0	95.0	0.0	70.0	16.7	90.0	40.6			
			30	90.0	0.0	55.0	8.3	54.0	-10.0	100.0	0.0	70.0	16.7	84.0	31.3			
			32	90.0	0.0	60.0	0.0	60.0	0.0	100.0	0.0	70.0	16.7	84.0	31.3			
			34	100.0	11.1	60.0	0.0	60.0	0.0	110.0	10.0	75.0	25.0	90.0	40.6			
			36	100.0	11.1	65.0	8.3	60.0	0.0	105.0	5.0	80.0	33.3	84.0	31.3			
			38	90.0	0.0	60.0	0.0	60.0	0.0	105.0	5.0	75.0	25.0	90.0	40.6			
			40	100.0	11.1	70.0	16.7	54.0	-10.0	110.0	10.0	80.0	33.3	78.0	21.9			
			42	95.0	5.6	60.0	0.0	60.0	0.0	100.0	0.0	70.0	16.7	84.0	31.3			
			44	100.0	11.1	60.0	0.0	54.0	-10.0	105.0	5.0	75.0	25.0	78.0	21.9			
			46	100.0	11.1	60.0	0.0	60.0	0.0	105.0	5.0	75.0	25.0	78.0	21.9			
			48	95.0	5.6	60.0	0.0	54.0	-10.0	105.0	5.0	70.0	16.7	78.0	21.9			
			50	95.0	5.6	65.0	8.3	60.0	0.0	100.0	0.0	60.0	0.0	70.0	16.7	72.0	12.5	
			52	100.0	11.1	70.0	16.7	60.0	0.0	105.0	5.0	75.0	25.0	78.0	21.9			
			55	JT	-1	130.0	0.0	60.0	0.0	60.0	0.0	110.0	0.0	80.0	0.0	112.0	0.0	
					0	130.0	0.0	60.0	0.0	60.0	0.0	110.0	0.0	80.0	0.0	112.0	0.0	
					1	130.0	0.0	80.0	33.3	78.0	30.0	110.0	0.0	80.0	0.0	100.0	-10.7	
					2	130.0	0.0	68.0	13.3	84.0	40.0	110.0	0.0	64.0	-20.0	100.0	-10.7	
					3	130.0	0.0	80.0	33.3	80.0	33.3	132.0	20.0	80.0	0.0	88.0	-21.4	
					4	124.0	-4.6	65.0	8.3	96.0	60.0	124.0	12.7	68.0	-15.0	132.0	0.0	
					5	140.0	7.7	100.0	66.7	82.0	36.7	130.0	18.2	90.0	12.5	90.0	-19.6	
					6	130.0	0.0	80.0	33.3	74.0	23.3	110.0	0.0	70.0	-12.5	96.0	-14.3	
					8	130.0	0.0	80.0	33.3	75.0	25.0	120.0	9.1	70.0	-12.5	92.0	-17.3	
					10	130.0	0.0	80.0	33.3	78.0	30.0	120.0	9.1	75.0	-6.3	98.0	-19.6	
					12	130.0	0.0	70.0	16.7	74.0	23.3	125.0	13.6	70.0	-12.5	89.0	-20.5	

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING				STANDING					
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff
10	55	JT	14	130.0	0.0	72.0	0.0	120.0	9.1	70.0	-12.5	84.0	-25.0
			16	125.0	-3.8	72.0	0.0	120.0	9.1	75.0	-6.3	82.0	-26.8
	56	RK	18	120.0	-7.7	58.0	-3.3	115.0	4.5	70.0	-12.5	60.0	-46.4
			-1	140.0		72.0		140.0		100.0		96.0	
			0	140.0	0.0	72.0	0.0	140.0	0.0	100.0	0.0	96.0	0.0
			1	140.0	0.0	72.0	0.0	140.0	0.0	100.0	0.0	96.0	0.0
			2	140.0	0.0	72.0	0.0	140.0	0.0	100.0	0.0	96.0	0.0
			3	118.0	-15.7	72.0	*	145.0	3.6	75.0	-25.0	80.0	-16.7
			4	116.0	-17.1	72.0	*	128.0	-8.6	72.0	-28.0	84.0	-12.5
			5	120.0	-14.3	80.0	*	120.0	-14.3	65.0	-35.0	88.0	-8.3
6	110.0	-21.4	82.0	*	130.0	7.1	75.0	-25.0	90.0	-6.3			
8	130.0	-11.4	90.0		130.0	0.0	80.0	-20.0	92.0	-4.2			
10	125.0	-10.7	75.0	2.8	118.0	-15.7	80.0	-20.0	86.0	-10.4			
12	130.0	-7.1	80.0	0.0	130.0	0.0	80.0	-20.0	84.0	-12.5			
14	135.0	-3.6	75.0	2.8	125.0	-10.7	75.0	-25.0	88.0	-16.7			
16	130.0	-7.1	76.0	5.6	125.0	-10.7	80.0	-20.0	88.0	-8.3			
18	135.0	-3.6	76.0	5.6	130.0	0.0	80.0	-20.0	88.0	-8.3			
20	130.0	-14.3	75.0	2.8	130.0	0.0	80.0	-20.0	88.0	-8.3			
22	130.0	-7.1	72.0	0.0	115.0	-17.9	75.0	-25.0	82.0	-14.6			
24	130.0	-7.1	76.0	5.6	125.0	-10.7	80.0	-20.0	88.0	-16.7			
26	130.0	-7.1	76.0	5.6	125.0	-10.7	80.0	-20.0	88.0	-16.7			
28	130.0	-7.1	76.0	5.6	125.0	-10.7	80.0	-20.0	88.0	-16.7			
30	125.0	-10.7	76.0	5.6	130.0	0.0	75.0	-25.0	86.0	-10.4			
32	135.0	-3.6	75.0	5.6	125.0	-10.7	75.0	-25.0	86.0	-10.4			
73	LA	-1	100.0		60.0		100.0		70.0		84.0		
		0	100.0	0.0	60.0	0.0	100.0	0.0	70.0	0.0	84.0	0.0	
		1	120.0	20.0	60.0	0.0	100.0	0.0	70.0	0.0	80.0	-4.8	
		2	100.0	0.0	60.0	-14.3	100.0	0.0	70.0	0.0	108.0	28.6	
		3	110.0	10.0	78.0	30.0	100.0	0.0	65.0	-7.1	90.0	7.1	
		4	105.0	5.0	78.0	30.0	105.0	5.0	75.0	7.1	96.0	14.3	
		5	105.0	5.0	72.0	0.0	100.0	0.0	65.0	-7.1	90.0	7.1	
		6	115.0	15.0	78.0	30.0	105.0	5.0	70.0	0.0	84.0	0.0	
		8	100.0	0.0	66.0	10.0	100.0	0.0	65.0	-7.1	84.0	0.0	
		10	100.0	0.0	72.0	20.0	98.0	-2.0	60.0	-14.3	90.0	7.1	
12	110.0	10.0	66.0	*	115.0	15.0	65.0	-7.1	84.0	0.0			
14	95.0	-5.0	78.0	30.0	105.0	10.0	60.0	-14.3	96.0	14.3			
16	95.0	-5.0	60.0	0.0	105.0	10.0	70.0	0.0	78.0	-7.1			
18	100.0	0.0	54.0	-10.0	110.0	10.0	80.0	14.3	84.0	0.0			

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 100 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RBD

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	Initial Visit	LYING				STANDING												
			S.B.P. % diff	H.R. % diff	D.B.P. % diff	H.R. % diff	S.B.P. % diff	H.R. % diff	D.B.P. % diff	H.R. % diff									
10	73	LA	20	100.0	0.0	60.0	-14.3	60.0	0.0	105.0	5.0	70.0	0.0	78.0	-7.1				
			22	100.0	0.0	65.0	-7.1	72.0	20.0	110.0	10.0	10.0	75.0	7.1	84.0	0.0			
			24	110.0	10.0	70.0	0.0	66.0	10.0	110.0	0.0	10.0	70.0	0.0	78.0	-7.1			
			26	95.0	-5.0	60.0	-14.3	60.0	0.0	105.0	5.0	70.0	0.0	0.0	78.0	-7.1			
			28	95.0	-5.0	55.0	-21.4	60.0	0.0	100.0	0.0	0.0	70.0	0.0	72.0	-14.3			
			30	100.0	0.0	70.0	0.0	72.0	20.0	115.0	15.0	15.0	80.0	14.3	84.0	0.0			
			32	90.0	-10.0	55.0	-21.4	60.0	0.0	110.0	10.0	10.0	70.0	0.0	84.0	0.0			
			34	110.0	10.0	75.0	7.1	66.0	10.0	105.0	5.0	5.0	80.0	14.3	84.0	0.0			
			36	95.0	-5.0	60.0	-14.3	66.0	10.0	105.0	5.0	5.0	70.0	0.0	90.0	7.1			
			38	105.0	5.0	80.0	14.3	60.0	0.0	110.0	10.0	10.0	75.0	7.1	84.0	0.0			
			40	105.0	5.0	70.0	0.0	66.0	10.0	110.0	10.0	5.0	80.0	14.3	84.0	0.0			
			42	105.0	5.0	75.0	7.1	60.0	0.0	110.0	10.0	10.0	75.0	7.1	78.0	-7.1			
			44	95.0	-5.0	65.0	-7.1	66.0	10.0	105.0	5.0	5.0	75.0	7.1	78.0	-7.1			
			46	105.0	5.0	70.0	0.0	66.0	10.0	110.0	10.0	10.0	80.0	14.3	84.0	0.0			
			48	120.0	20.0	80.0	14.3	58.0	-3.3	105.0	5.0	5.0	75.0	7.1	78.0	-7.1			
			50	120.0	20.0	80.0	14.3	60.0	0.0	110.0	10.0	10.0	70.0	0.0	72.0	-14.3			
			52	95.0	-5.0	55.0	-21.4	60.0	0.0	110.0	10.0	10.0	75.0	7.1	78.0	-7.1			
			272	25D		-1	110.0	0.0	80.0	0.0	57.0	1.8	110.0	0.0	85.0	0.0	60.0	0.0	
						1	140.0	27.3	95.0	18.8	72.0	26.3	140.0	27.3	27.3	50.0	5.9	60.0	0.0
						2	160.0	45.5	80.0	0.0	65.0	14.0	145.0	31.8	50.0	50.0	5.9	72.0	20.0
3	130.0	18.2				80.0	0.0	68.0	19.3	145.0	31.8	31.8	85.0	0.0	71.0	18.3			
4	130.0	18.2				86.0	7.5	66.0	15.8	130.0	18.2	31.8	90.0	5.9	74.0	23.3			
5	136.0	23.6				70.0	-12.5	72.0	26.3	156.0	41.8	18.2	90.0	5.9	66.0	10.0			
6	136.0	23.6				70.0	-12.5	72.0	26.3	156.0	41.8	41.8	90.0	5.9	80.0	33.3			
8	125.0	13.6				85.0	6.3	60.0	5.3	140.0	27.3	5.9	90.0	5.9	80.0	0.0			
10	170.0	54.5				90.0	12.5	60.0	5.3	168.0	52.7	27.3	100.0	17.6	60.0	0.0			
12	180.0	63.6				105.0	31.3	60.0	5.3	180.0	63.6	52.7	100.0	17.6	68.0	13.3			
14	160.0	45.5				95.0	18.8	58.0	1.8	175.0	59.1	63.6	105.0	23.5	60.0	0.0			
16	185.0	68.2				105.0	31.3	62.0	8.8	200.0	81.8	59.1	90.0	5.9	58.0	-3.3			
18												81.8	105.0	23.5	66.0	10.0			
20																			
22	130.0	18.2				95.0	18.8	52.0	-8.8	160.0	45.5	45.5	110.0	29.4	60.0	0.0			
24	130.0	18.2				95.0	18.8	52.0	-8.8	160.0	45.5	45.5	110.0	29.4	60.0	0.0			
26	130.0	18.2	100.0	25.0	60.0	5.3	160.0	45.5	27.3	90.0	5.9	66.0	10.0						
28	160.0	45.5	100.0	25.0	60.0	5.3	190.0	72.7	72.7	105.0	23.5	66.0	10.0						
30	160.0	45.5	95.0	18.8	60.0	5.3	180.0	63.6	63.6	105.0	23.5	66.0	10.0						
273	AN		-1	90.0		70.0		58.0		110.0		65.0		59.0					

2465

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 50 beats/min
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBONETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	Initial Visit	LIVING			STANDING										
			S.B.P.	H.R.	D.B.P.	S.B.P.	H.R.	D.B.P.								
			% diff	% diff	% diff	% diff	% diff	% diff								
10	273	AN	0	86.0	-4.4	70.0	0.0	53.0	-8.6	108.0	-1.8	60.0	-7.7	53.0	-10.2	
		1	80.0	-11.1	66.0	-5.7	51.0	-12.1	110.0	0.0	110.0	0.0	60.0	-7.7	52.0	-11.9
		2	96.0	6.7	68.0	-2.9	66.0	13.8	90.0	-18.2	90.0	0.0	66.0	1.5	96.0	62.7
		3	110.0	22.2	70.0	0.0	66.0	13.8	116.0	5.5	116.0	0.0	70.0	7.7	72.0	22.0
		4	110.0	22.2	70.0	0.0	66.0	-3.4	100.0	-9.1	100.0	0.0	70.0	7.7	66.0	11.9
		5	105.0	16.7	75.0	7.1	56.0	-3.4	105.0	-4.5	105.0	0.0	80.0	23.1	60.0	1.7
		6	90.0	0.0	70.0	0.0	56.0	-3.4	96.0	-12.7	96.0	0.0	76.0	16.9	56.0	-5.1
		8	90.0	0.0	60.0	-14.3	60.0	3.4	86.0	-21.8	86.0	*	60.0	-7.7	86.0	45.8
		-1	105.0	0.0	60.0	0.0	88.0	0.0	118.0	0.0	118.0	0.0	60.0	0.0	84.0	0.0
		1	105.0	0.0	60.0	0.0	88.0	0.0	118.0	-6.8	118.0	-6.8	60.0	0.0	81.0	-3.6
		2	120.0	14.3	60.0	0.0	88.0	0.0	130.0	10.2	130.0	10.2	70.0	16.7	92.0	4.8
		3	125.0	19.0	70.0	16.7	88.0	0.0	138.0	16.9	138.0	16.9	70.0	16.7	94.0	11.9
		4	125.0	19.0	70.0	16.7	100.0	13.6	138.0	16.9	138.0	16.9	70.0	16.7	100.0	19.0
		5	110.0	4.8	70.0	16.7	100.0	13.6	120.0	1.7	120.0	1.7	70.0	16.7	110.0	31.0
		6	100.0	-4.8	60.0	0.0	116.0	31.8	104.0	-11.9	104.0	-11.9	60.0	0.0	120.0	62.9
		8	110.0	4.8	60.0	0.0	96.0	9.1	120.0	1.7	120.0	1.7	70.0	16.7	104.0	23.8
10	110.0	4.8	65.0	8.3	98.0	11.4	115.0	-2.5	115.0	-2.5	70.0	16.7	100.0	31.0		
12	115.0	9.5	65.0	8.3	92.0	4.5	125.0	5.9	125.0	5.9	70.0	16.7	100.0	19.0		
14	100.0	-4.8	60.0	0.0	94.0	6.8	105.0	-11.0	105.0	-11.0	60.0	0.0	102.0	21.4		
16	105.0	0.0	60.0	0.0	92.0	4.5	110.0	-6.8	110.0	-6.8	65.0	8.3	100.0	19.0		
24	G276	AN	-1	140.0	0.0	75.0	0.0	78.0	0.0	130.0	0.0	60.0	0.0	80.0	0.0	
		0	140.0	0.0	75.0	0.0	78.0	0.0	130.0	0.0	130.0	0.0	60.0	0.0	80.0	0.0
		1	130.0	-7.1	80.0	6.7	80.0	2.6	130.0	0.0	130.0	0.0	60.0	0.0	80.0	0.0
		2	134.0	-4.3	70.0	-6.7	80.0	2.6	134.0	3.1	134.0	3.1	70.0	16.7	68.0	-15.0
		3	120.0	-14.3	70.0	-6.7	78.0	0.0	134.0	3.1	134.0	3.1	75.0	25.0	88.0	10.0
		4	120.0	-14.3	75.0	0.0	78.0	0.0	134.0	0.0	134.0	0.0	75.0	25.0	88.0	10.0
		5	130.0	-7.1	80.0	6.7	80.0	2.6	130.0	0.0	130.0	0.0	60.0	0.0	88.0	10.0
		6	124.0	-11.4	64.0	-14.7	84.0	7.7	140.0	7.7	140.0	7.7	70.0	16.7	84.0	5.0
8	150.0	7.1	100.0	33.3	72.0	-7.7	135.0	3.8	135.0	3.8	80.0	33.3	78.0	-2.5		
NH	-1	110.0	0.0	70.0	0.0	70.0	0.0	110.0	0.0	110.0	0.0	50.0	0.0	70.0	-2.8	
	0	110.0	0.0	70.0	0.0	70.0	0.0	110.0	0.0	110.0	0.0	50.0	0.0	70.0	-2.8	
	1	120.0	9.1	80.0	14.3	70.0	0.0	116.0	5.5	116.0	5.5	84.0	68.0	72.0	0.0	
	2	120.0	9.1	80.0	14.3	64.0	-8.6	100.0	-9.1	100.0	-9.1	80.0	60.0	96.0	33.3	
	3	120.0	9.1	70.0	0.0	88.0	23.7	124.0	12.7	124.0	12.7	78.0	56.0	80.0	11.1	
	4	116.0	5.5	80.0	14.3	84.0	20.0	120.0	9.1	120.0	9.1	70.0	40.0	88.0	22.2	
5	120.0	9.1	70.0	0.0	85.0	21.4	125.0	13.6	125.0	13.6	80.0	60.0	80.0	11.1		
6	110.0	0.0	70.0	0.0	70.0	0.0	110.0	0.0	110.0	0.0	55.0	10.0	74.0	2.8		

** S.B.P. values => 160 mm Hg
D.B.P. values => 100 mm Hg
H.R. values => 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3
VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: PLACED

Centre	Patient	Initial	Visit	LYING			STANDING										
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	H.R.	% diff						
10	276	MH	8	122.0	10.9	85.0	21.4	68.0	-2.9	177.0	60.9	**	95.0	90.0	80.0	11.1	
			10	140.0	27.3	90.0	28.6	72.0	2.9	120.0	9.1	85.0	70.0	72.0	0.0		
	279	AA	-1	130.0	-7.7	90.0	-11.1	62.0	-1.6	150.0	-6.7	105.0	-4.8	68.0	0.0		
			0	120.0	-7.7	80.0	-22.2	61.0	3.2	100.0	-33.3	70.0	*	68.0	4.4		
			1	130.0	0.0	70.0	-11.1	68.0	9.7	180.0	20.0	110.0	4.8	71.0	4.4		
			2	120.0	-7.7	80.0	-11.1	61.0	-1.6	110.0	-26.7	98.0	-6.7	69.0	1.5		
			3	120.0	-7.7	90.0	0.0	62.0	48.4	130.0	-13.3	90.0	-14.3	96.0	41.2		
			4	120.0	-7.7	70.0	-22.2	59.0	11.3	110.0	-26.7	70.0	-33.3	73.0	7.4		
			5	120.0	-15.4	78.0	-15.6	62.0	48.4	140.0	-6.7	100.0	-4.8	120.0	76.5		
			6	110.0	-7.7	80.0	-11.1	60.0	-3.2	130.0	-13.3	90.0	-14.3	74.0	8.8		
			8	120.0	0.0	100.0	-11.1	64.0	3.2	100.0	-33.3	80.0	-23.3	88.0	29.4		
			10	130.0	0.0	85.0	-5.6	68.0	9.7	140.0	-6.7	95.0	-9.5	68.0	0.0		
			12	125.0	-3.8	85.0	-22.2	62.0	0.0	130.0	-13.3	90.0	-14.3	74.0	8.8		
			14	120.0	-7.7	70.0	-11.1	65.0	4.8	132.0	-12.0	95.0	-9.5	74.0	8.8		
			16	120.0	-7.7	80.0	-5.6	52.0	-16.1	110.0	-26.7	95.0	-9.5	62.0	-4.4		
			18	130.0	3.8	90.0	0.0	49.0	-21.0	105.0	-20.0	90.0	-14.3	77.0	13.2		
			20	135.0	0.0	80.0	-11.1	70.0	12.9	120.0	-16.7	95.0	-9.5	72.0	5.9		
			22	130.0	0.0	85.0	-5.6	62.0	0.0	125.0	-16.7	95.0	-9.5	71.0	4.4		
			24	130.0	0.0	90.0	0.0	58.0	-6.5	125.0	-16.7	95.0	-9.5	78.0	14.7		
			26	125.0	-3.8	75.0	-16.7	51.0	-17.7	130.0	-13.3	95.0	-9.5	78.0	14.7		
			28	120.0	-7.7	70.0	-22.2	58.0	-6.5	115.0	-23.3	80.0	-23.8	70.0	2.9		
			30	105.0	-19.2	70.0	-27.8	60.0	-3.2	110.0	-26.7	80.0	-23.8	78.0	14.7		
			32	110.0	-15.4	65.0	-22.2	66.0	6.5	115.0	-20.0	80.0	-23.8	84.0	23.5		
			34	110.0	-15.4	70.0	-22.2	60.0	-3.2	120.0	-16.7	80.0	-23.8	72.0	5.9		
			36	105.0	-19.2	65.0	-27.8	66.0	6.5	125.0	-16.7	80.0	-23.8	88.0	29.4		
			38	110.0	-15.4	70.0	-22.2	60.0	-3.2	130.0	-13.3	85.0	-19.0	84.0	23.5		
			40	115.0	-11.5	70.0	-22.2	66.0	6.5	120.0	-20.0	85.0	-19.0	78.0	14.7		
			42	115.0	-11.5	78.0	-13.3	66.0	-3.2	125.0	-16.7	85.0	-19.0	78.0	14.7		
			44	125.0	-3.8	85.0	-5.6	60.0	-3.2	120.0	-20.0	80.0	-23.8	72.0	5.9		
			46	115.0	-11.5	75.0	-16.7	66.0	6.5	100.0	-33.3	85.0	-19.0	78.0	14.7		
			48	95.0	-26.9	65.0	-27.8	66.0	6.5	105.0	-30.0	75.0	-28.6	78.0	14.7		
			50	100.0	-23.1	70.0	-23.2	66.0	6.5	110.0	-26.7	80.0	-23.8	68.0	0.0		
			52	100.0	-23.1	70.0	-22.2	60.0	-3.2	130.0	-13.3	80.0	-23.8	82.0	12.2		
			281	AJ	-1	120.0	1.7	70.0	0.0	75.0	-4.0	140.0	7.7	86.0	5.0	92.0	12.2
					0	122.0	-15.0	70.0	0.0	66.0	-12.0	110.0	-15.4	80.0	0.0	76.0	7.3
					1	102.0	0.0	80.0	14.3	72.0	-4.0	120.0	-7.7	75.0	-6.3	88.0	7.3
			3	110.0	-8.3	78.0	11.4	68.0	-9.3	118.0	-9.2	80.0	0.0	88.0	7.3		

2467

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 100 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 ROXOXYTINE - PROTOCOL 20124/013
 Listing No.: IS.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial Visit	LYING			STANDING										
			S.B.P. % diff	D.B.P. % diff	H.R. % diff	S.B.P. % diff	D.B.P. % diff	H.R. % diff								
10	281	AJ	4	110.0	-8.3	70.0	0.0	96.0	28.0	120.0	-7.7	70.0	-12.5	100.0	22.0	**
			5	100.0	-16.7	60.0	-14.3	69.0	-8.0	100.0	-23.1	* 72.0	-10.0	84.0	2.4	
			6	105.0	-12.5	65.0	-7.1	78.0	4.0	100.0	-23.1	* 75.0	-6.3	102.0	24.4	**
			8	100.0	-16.7	70.0	0.0	76.0	1.3	103.0	-16.9	* 80.0	0.0	98.0	19.5	
			10	90.0	-25.0	* 55.0	-21.4	80.0	6.0	105.0	-19.2	* 60.0	-25.0	*		
			12	110.0	-8.3	70.0	0.0	60.0	-20.0	110.0	-19.2	85.0	6.3	70.0	-14.6	
			14	105.0	-12.5	60.0	-14.3	59.0	-21.3	110.0	-15.4	80.0	0.0	70.0	-14.6	
			16	105.0	-12.5	60.0	-14.3	67.0	-10.7	115.0	-11.5	75.0	0.0	78.0	-4.9	
			18	85.0	-29.2	* 40.0	-42.9	58.0	-22.7	105.0	-19.2	* 85.0	-6.3	88.0	7.3	
			20	108.0	-10.0	70.0	0.0	64.0	-12.0	105.0	-19.2	80.0	0.0	90.0	9.8	
			22	105.0	-12.5	65.0	-7.1	61.0	-18.7	110.0	-15.4	80.0	0.0	78.0	-4.9	
			24	115.0	-4.2	80.0	14.3	70.0	-6.7	110.0	-15.4	85.0	6.3	89.0	8.5	
			26	110.0	-8.3	80.0	14.3	73.0	-2.7	110.0	-15.4	90.0	12.5	90.0	9.8	
			28	140.0	-8.3	75.0	7.1	66.0	-12.0	110.0	-15.4	70.0	-12.5	58.0	19.5	
			30	108.0	-10.0	70.0	0.0	60.0	-20.0	105.0	-19.2	85.0	6.3	88.0	7.3	
			32	105.0	-12.5	65.0	-7.1	62.0	-17.3	100.0	-23.1	* 70.0	-12.5	80.0	17.1	
			34	90.0	-25.0	* 65.0	-7.1	60.0	-20.0	100.0	-23.1	* 75.0	-6.3	96.0	17.1	
			36	95.0	-20.8	* 65.0	-7.1	66.0	-12.0	100.0	-23.1	* 75.0	-6.3	90.0	9.8	
			38	90.0	-25.0	* 65.0	-7.1	66.0	-12.0	100.0	-23.1	* 75.0	-6.3	96.0	17.1	
			40	100.0	-16.7	65.0	-7.1	64.0	-14.7	105.0	-19.2	80.0	0.0	84.0	2.4	
			42	105.0	-12.5	70.0	0.0	66.0	-12.0	110.0	-15.4	75.0	-6.3	78.0	-4.9	
			44	105.0	-12.5	70.0	0.0	60.0	-20.0	110.0	-15.4	80.0	0.0	68.0	-17.1	
			46	100.0	-16.7	75.0	7.1	60.0	-20.0	105.0	-19.2	80.0	0.0	72.0	-12.2	
			48	100.0	-16.7	65.0	-7.1	66.0	-12.0	110.0	-15.4	75.0	-6.3	78.0	-4.9	
			50	100.0	-16.7	70.0	0.0	72.0	-4.0	105.0	-19.2	75.0	-6.3	84.0	2.4	
			52	110.0	-8.3	75.0	7.1	54.0	-28.0	102.0	-21.5	75.0	-6.3	78.0	-4.9	
282	MX		-1	130.0	0.0	90.0	0.0	62.0	0.0	140.0	0.0	100.0	0.0	66.0	3.0	
			0	130.0	0.0	90.0	0.0	62.0	0.0	140.0	0.0	100.0	0.0	68.0	3.0	
			1	130.0	0.0	90.0	0.0	60.0	-3.2	160.0	14.3	110.0	10.0	64.0	-3.0	
			2	125.0	-3.8	85.0	-5.6	54.0	-12.9	150.0	7.1	100.0	0.0	68.0	3.0	
			3	130.0	0.0	80.0	-11.1	88.0	41.9	100.0	-28.6	80.0	-20.0	94.0	42.4	
			4	160.0	23.1	** 90.0	0.0	69.0	11.3	160.0	14.3	90.0	-10.0	64.0	-3.0	
			5	130.0	0.0	80.0	-11.1	88.0	41.9	110.0	-21.4	80.0	-20.0	90.0	36.4	
			6	110.0	-15.4	80.0	-11.1	92.0	48.4	130.0	-7.1	110.0	10.0	92.0	39.4	
			8	160.0	7.7	94.0	4.4	78.0	22.6	140.0	0.0	100.0	0.0	88.0	33.3	
			10	130.0	9.9	80.0	-11.1	68.0	9.7	160.0	0.0	90.0	-10.0	79.0	19.7	
			12	140.0	7.7	90.0	0.0	62.0	0.0	160.0	7.1	95.0	-5.0	90.0	36.4	
			14	170.0	30.8	** 100.0	11.1	62.0	0.0	165.0	17.9	100.0	0.0	72.0	9.1	
			16	145.0	11.5	95.0	5.6	66.0	6.5	140.0	0.0	105.0	5.0	82.0	24.2	

2463

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 beats/min
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Centre	Patient	Initial	Visit	LYING				STANDING											
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff						
10	282	MM	18	160.0	23.1	**	100.0	11.1	64.0	3.2	150.0	7.1	115.0	15.0	90.0	36.4			
			20	140.0	7.7		90.0	0.0	63.0	1.6	150.0	7.1	105.0	5.0	86.0	30.3			
			22	140.0	7.7		95.0	5.6	65.0	4.8	145.0	3.6	110.0	10.0	90.0	36.4			
			24	160.0	23.1	**	105.0	16.7	60.0	-3.2	135.0	-3.6	105.0	5.0	78.0	18.2			
			26	145.0	11.5		90.0	0.0	64.0	3.2	145.0	3.6	105.0	5.0	76.0	15.2			
			28	140.0	7.7		85.0	-5.6	55.0	-11.5	145.0	3.6	100.0	-5.0	66.0	0.0			
			30	135.0	3.8		80.0	-11.1	58.0	-8.5	150.0	7.1	95.0	-5.0	72.0	9.1			
			32	130.0	0.0		85.0	-5.6	60.0	-3.2	125.0	-10.7	105.0	5.0	90.0	36.4			
			34	125.0	-3.8		75.0	-16.7	72.0	16.1	140.0	0.0	95.0	-5.0	90.0	36.4			
			36	140.0	7.7		95.0	5.6	60.0	-3.2	140.0	0.0	100.0	0.0	72.0	9.1			
			38	130.0	0.0		85.0	-5.6	62.0	0.0	108.0	0.0	95.0	-5.0	70.0	6.1			
			40	130.0	0.0		85.0	-5.6	62.0	0.0	108.0	-22.9	95.0	-5.0	70.0	6.1			
			42	150.0	15.4		95.0	5.6	60.0	-3.2	120.0	-14.3	90.0	-10.0	72.0	9.1			
			44	150.0	15.4		95.0	5.6	72.0	16.1	140.0	0.0	100.0	0.0	78.0	18.2			
			46	130.0	0.0		90.0	0.0	66.0	6.5	135.0	-3.6	95.0	-5.0	78.0	18.2			
			48	135.0	3.8		90.0	0.0	60.0	-3.2	125.0	-10.7	95.0	-5.0	78.0	18.2			
			50	155.0	19.2		90.0	0.0	66.0	6.5	125.0	-10.7	95.0	-5.0	84.0	27.3			
			52	150.0	15.4		90.0	0.0	60.0	-3.2	140.0	0.0	100.0	0.0	84.0	27.3			
			-1	130.0	0.0		80.0	-11.1	60.0	-3.2	135.0	-3.6	95.0	-5.0	66.0	0.0			
			284	TN	MM	0	130.0	0.0		90.0	0.0	82.0	-14.6	130.0	-1.5	100.0	-5.0	77.0	24.7
						1	130.0	0.0		85.0	-5.6	77.0	-6.1	128.0	-7.7	85.0	-5.0	96.0	27.3
						2	115.0	-11.5		80.0	-6.7	88.0	7.3	110.0	-15.4	80.0	-20.0	98.0	27.3
						3	114.0	-12.3		84.0	-6.7	76.0	-7.3	108.0	-16.9	84.0	-16.0	112.0	45.5
						4	120.0	-7.7		80.0	-11.1	80.0	-2.4	110.0	-15.4	70.0	-30.0	100.0	29.9
						5	110.0	-15.4		80.0	0.0	72.0	-12.2	130.0	0.0	80.0	-20.0	74.0	-3.9
						6	160.0	23.1	**	70.0	-22.2	92.0	12.2	120.0	-7.7	90.0	-10.0	120.0	55.8
						8	115.0	-11.5		80.0	-11.1	70.0	-14.6	125.0	-3.6	80.0	-20.0	76.0	-1.3
						10	120.0	-7.7		80.0	-11.1	72.0	-12.2	120.0	-7.7	80.0	-20.0	76.0	-3.9
						12	125.0	-3.8		70.0	-22.2	95.0	15.9	125.0	-3.6	80.0	-20.0	85.0	5.2
						14	120.0	-7.7		80.0	-11.1	73.0	-11.0	135.0	3.8	85.0	-5.0	81.0	5.2
						16	120.0	-7.7		80.0	-11.1	60.0	-26.8	110.0	-15.4	70.0	-30.0	70.0	-9.1
						18	115.0	-11.5		80.0	-11.1	64.0	-23.0	120.0	-3.6	85.0	-15.0	73.0	-5.2
20	110.0	-15.4					90.0	0.0	74.0	-9.8	115.0	-11.5	85.0	-5.0	90.0	16.9			
22	115.0	-11.5					80.0	-11.1	81.0	-1.2	105.0	-19.2	75.0	-25.0	91.0	18.2			
24	120.0	-7.7					80.0	-11.1	68.0	-17.1	100.0	-23.1	75.0	-25.0	68.0	-11.7			
26	125.0	-3.8					85.0	-5.6	78.0	-4.9	105.0	-19.2	80.0	-20.0	84.0	9.1			
28	100.0	-23.1				*	65.0	-27.8	66.0	-17.1	105.0	-19.2	70.0	-30.0	76.0	-1.3			
30	105.0	-19.2					75.0	-16.7	72.0	-17.2	110.0	-15.4	80.0	-20.0	82.0	6.5			
32	105.0	-19.2					75.0	-16.7	84.0	2.4	105.0	-19.2	75.0	-25.0	84.0	9.1			

** S.B.P. values => 160 mm Hg
D.B.P. values => 100 mm Hg
H.R. values => 100 beats/min
* S.B.P. values <= 100 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

2469

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REDOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING			STANDING											
				S.B.P.	H.R.	D.B.P.	S.B.P.	H.R.	D.B.P.									
10	284	TN	34	120.0	-7.7	80.0	-11.1	68.0	-17.1	115.0	-11.5	80.0	-20.0	84.0	9.1			
			36	110.0	-15.4	80.0	-11.1	70.0	-14.6	115.0	-11.5	80.0	-20.0	84.0	9.1			
			38	120.0	-7.7	80.0	-11.1	66.0	-19.5	120.0	-7.7	80.0	-20.0	84.0	9.1			
			40	120.0	-7.7	80.0	-11.1	68.0	-17.1	110.0	-15.4	80.0	-20.0	84.0	9.1			
			42	120.0	-7.7	80.0	-11.1	68.0	-17.1	125.0	-3.8	90.0	-10.0	84.0	9.1			
			44	130.0	0.0	85.0	-5.6	66.0	-19.5	110.0	-15.4	80.0	-20.0	84.0	9.1			
			46	115.0	-11.5	85.0	-5.6	72.0	-12.2	110.0	-15.4	85.0	-15.0	84.0	9.1			
			48	120.0	-7.7	80.0	-11.1	78.0	-4.9	110.0	-15.4	85.0	-15.0	84.0	9.1			
			50	115.0	-11.5	80.0	-11.1	76.0	-7.3	110.0	-15.4	80.0	-10.0	84.0	9.1			
			52	120.0	-7.7	90.0	0.0	72.0	0.0	115.0	0.0	80.0	0.0	80.0	0.0			
			288	AK		-1	105.0	0.0	70.0	0.0	72.0	0.0	115.0	0.0	80.0	0.0	80.0	0.0
						1	90.0	-14.3	70.0	0.0	64.0	-11.1	100.0	-13.0	70.0	-12.5	98.0	22.5
						2	100.0	-4.8	80.0	14.3	76.0	5.6	120.0	4.3	80.0	0.0	92.0	13.0
						3	90.0	-14.3	86.0	19.4	86.0	19.4	96.0	16.5	60.0	-25.0	96.0	22.5
						4	90.0	-14.3	60.0	-14.3	84.0	16.7	100.0	-13.0	60.0	-25.0	96.0	20.0
						5	100.0	-4.8	65.0	-7.1	84.0	16.7	105.0	-8.7	70.0	-12.5	98.0	22.5
						6	120.0	14.3	80.0	14.3	78.0	8.3	125.0	8.7	80.0	0.0	84.0	5.0
						8	95.0	-9.5	70.0	0.0	80.0	11.1	110.0	-4.3	75.0	-6.3	92.0	15.0
						10	105.0	0.0	65.0	-7.1	76.0	5.6	95.0	-17.4	65.0	-18.8	84.0	5.0
						12	110.0	4.8	60.0	-14.3	68.0	-5.6	100.0	-13.0	65.0	-18.8	76.0	-5.0
						14	100.0	-4.8	60.0	-14.3	76.0	5.6	100.0	-13.0	55.0	-31.3	84.0	5.0
						16	100.0	-4.8	80.0	14.3	76.0	5.6	100.0	-13.0	74.0	-7.5	96.0	20.0
18	100.0	-4.8				60.0	-14.3	84.0	16.7	100.0	-13.0	60.0	-25.0	92.0	15.0			
20	110.0	4.8				70.0	0.0	70.0	-2.8	120.0	4.3	80.0	0.0	74.0	-7.5			
22	105.0	0.0	75.0	7.1	78.0	8.3	120.0	4.3	80.0	0.0	78.0	-2.5						
289	AL		-1	120.0	4.2	80.0	0.0	90.0	-6.7	130.0	15.4	90.0	11.1	98.0	-8.2			
			0	125.0	8.3	84.0	5.0	72.0	-20.0	124.0	-4.6	100.0	11.1	90.0	0.0			
			1	130.0	16.7	84.0	25.0	84.0	-6.7	120.0	-7.7	80.0	-11.1	98.0	0.0			
			2	140.0	3.3	70.0	-12.5	96.0	6.7	120.0	-7.7	70.0	-22.2	84.0	-14.3			
			3	124.0	4.2	75.0	-6.3	92.0	2.2	120.0	-7.7	75.0	-16.7	96.0	-2.0			
			4	125.0	8.3	80.0	0.0	98.0	8.9	130.0	0.0	80.0	-11.1	100.0	2.0			
			5	130.0	8.3	80.0	0.0	84.0	-6.7	130.0	0.0	80.0	-11.1	100.0	2.0			
			6	130.0	8.3	80.0	0.0	84.0	-6.7	130.0	0.0	80.0	-11.1	100.0	2.0			
			8	135.0	12.5	80.0	0.0	90.0	0.0	125.0	-3.8	80.0	-11.1	98.0	0.0			
			10	120.0	0.0	75.0	-6.3	84.0	-6.7	110.0	-16.4	80.0	-11.1	74.0	-24.5			
			12	130.0	8.3	70.0	-12.5	72.0	-20.0	124.0	-4.6	70.0	-22.2	72.0	-56.5			
			14	130.0	8.3	70.0	-12.5	72.0	-20.0	120.0	-7.7	70.0	-22.2	78.0	-20.4			

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 beats/min
 H.R. values <= 50 beats/min

2470

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING				STANDING							
				S.B.P.	% diff	H.R.	% diff	S.B.P.	% diff	H.R.	% diff				
10	289	AL	16	135.0	12.5	80.0	0.0	76.0	-15.6	130.0	0.0	80.0	-11.1	80.0	-18.4
			18	115.0	-4.2	80.0	0.0	72.0	-20.0	110.0	-15.4	90.0	0.0	92.0	-6.1
			20	130.0	8.3	80.0	0.0	78.0	-13.3	130.0	0.0	95.0	5.6	84.0	-14.3
			22	110.0	-8.3	75.0	-6.3	78.0	-13.3	130.0	0.0	95.0	5.6	84.0	-14.3
			24	125.0	4.2	85.0	6.3	74.0	-17.8	125.0	-3.8	85.0	-5.6	90.0	-8.2
			26	115.0	-4.2	85.0	6.3	78.0	-13.3	115.0	-11.5	85.0	-5.6	96.0	-2.0
			28	110.0	-8.3	75.0	-6.3	72.0	-20.0	115.0	-11.5	85.0	-5.6	84.0	-14.3
			30	120.0	0.0	80.0	0.0	76.0	-15.6	115.0	-11.5	90.0	0.0	78.0	-20.4
			32	125.0	4.2	80.0	0.0	72.0	-20.0	120.0	-7.7	85.0	-5.6	78.0	-20.4
			34	120.0	0.0	80.0	0.0	66.0	-26.7	115.0	-11.5	85.0	-5.6	74.0	-24.5
			36	125.0	4.2	90.0	12.5	68.0	-24.4	125.0	-3.8	90.0	0.0	98.0	0.0
			38	110.0	-8.3	70.0	-12.5	72.0	-20.0	115.0	-11.5	85.0	-5.6	80.0	-8.2
			40	105.0	-12.5	75.0	-6.3	72.0	-20.0	110.0	-15.4	85.0	-5.6	86.0	-2.0
			42	125.0	4.2	80.0	0.0	78.0	-13.3	115.0	-11.5	95.0	5.6	95.0	-3.1
			44	110.0	-8.3	70.0	-12.5	72.0	-20.0	110.0	-15.4	79.0	-16.7	84.0	-14.3
			46	115.0	-4.2	75.0	-6.3	66.0	-26.7	110.0	-15.4	79.0	-16.7	78.0	-20.4
			48	120.0	0.0	80.0	0.0	72.0	-20.0	115.0	-11.5	79.0	-16.7	78.0	-20.4
			50	125.0	4.2	85.0	6.3	78.0	-13.3	125.0	-3.8	95.0	5.6	90.0	-8.2
			52	115.0	-4.2	80.0	0.0	60.0	-33.3	120.0	-7.7	80.0	-11.1	72.0	-26.5
			293	JJ		-1	105.0	0.0	70.0	0.0	78.0	0.0	115.0	0.0	75.0
1	110.0	4.8				75.0	7.1	80.0	2.6	120.0	4.3	75.0	0.0	92.0	-4.2
2	120.0	14.3				80.0	14.3	68.0	-12.8	100.0	-13.0	78.0	4.0	120.0	25.0
3	115.0	9.5				80.0	14.3	74.0	-5.1	105.0	-8.7	80.0	6.7	96.0	0.0
4	115.0	9.5				80.0	14.3	74.0	-5.1	110.0	-4.3	80.0	6.7	90.0	-6.3
5	110.0	4.8				80.0	14.3	70.0	-10.3	115.0	0.0	70.0	-6.7	98.0	2.1
6	100.0	-4.8				80.0	14.3	84.0	7.7	110.0	-4.3	70.0	-6.7	96.0	0.0
8	90.0	-14.3				60.0	-14.3	60.0	-23.1	120.0	4.3	65.0	-13.3	72.0	-25.0
10	110.0	4.8				85.0	-7.1	82.0	5.1	100.0	-13.0	70.0	-6.7	98.0	2.1
12	118.0	12.4				70.0	0.0	96.0	23.1	110.0	-4.3	85.0	13.3	104.0	8.3
295	TT		0	110.0	0.0	80.0	0.0	84.0	0.0	120.0	0.0	70.0	0.0	92.0	0.0
			1	120.0	9.1	84.0	5.0	64.0	-23.8	106.0	-11.7	84.0	20.0	120.0	30.4
			2	120.0	9.1	60.0	-25.0	114.0	35.7	130.0	8.3	65.0	-7.1	120.0	30.4

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 40 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial Visit	LYING			STANDING												
			S.B.P. % diff	H.R. % diff	D.B.P. % diff	S.B.P. % diff	H.R. % diff	D.B.P. % diff										
10	295	TT	3	125.0	13.6	70.0	-12.5	72.0	-14.3	125.0	4.2	70.0	0.0	92.0	0.0			
			4	140.0	27.3	70.0	-12.5	72.0	-14.3	140.0	16.7	70.0	0.0	96.0	4.3			
			5	130.0	18.2	90.0	12.5	84.0	0.0	110.0	-8.3	80.0	14.3	90.0	-2.2			
			6	140.0	27.3	90.0	12.5	84.0	0.0	130.0	8.3	80.0	14.3	90.0	-2.2			
			8	130.0	18.2	80.0	0.0	76.0	-9.5	135.0	12.5	80.0	14.3	80.0	-13.0			
			10	130.0	18.2	80.0	0.0	72.0	-14.3	130.0	8.3	80.0	14.3	80.0	-13.0			
			12															
			298	AB		-1	115.0	0.0	65.0	0.0	64.0	0.0	110.0	0.0	65.0	0.0	72.0	0.0
						0	115.0	4.3	65.0	0.0	64.0	0.0	110.0	0.0	70.0	7.7	88.0	22.2
						1	120.0	8.7	60.0	-7.7	96.0	50.0	120.0	9.1	60.0	-7.7	108.0	50.0
						2	125.0	13.1	60.0	-7.7	96.0	50.0	120.0	9.1	60.0	-7.7	108.0	50.0
						3	125.0	13.1	60.0	-7.7	96.0	50.0	120.0	9.1	60.0	-7.7	108.0	50.0
4	120.0	4.3				70.0	7.7	88.0	22.2	120.0	9.1	90.0	38.5	92.0	27.8			
5	125.0	8.7				65.0	0.0	74.0	15.6	125.0	13.6	70.0	7.7	88.0	22.2			
6	120.0	4.3				65.0	0.0	72.0	12.5	125.0	13.6	70.0	7.7	88.0	22.2			
8	120.0	4.3				65.0	0.0	72.0	12.5	125.0	13.6	65.0	0.0	80.0	11.1			
10	120.0	4.3				70.0	7.7	72.0	12.5	120.0	9.1	65.0	0.0	86.0	19.4			
12	120.0	4.3				70.0	7.7	70.0	9.4	115.0	4.5	60.0	-7.7	80.0	11.1			
14	115.0	0.0				65.0	0.0	70.0	9.4	115.0	4.5	65.0	0.0	78.0	8.3			
16	120.0	4.3	70.0	7.7	72.0	12.5	115.0	4.5	65.0	0.0	80.0	11.1						
362	FI		-1	120.0	0.0	80.0	0.0	92.0	2.2	130.0	0.0	80.0	0.0	96.0	4.2			
			0	120.0	0.0	80.0	0.0	94.0	2.2	130.0	0.0	80.0	0.0	100.0	6.3			
			1	130.0	8.3	90.0	12.5	94.0	2.2	120.0	-7.7	90.0	12.5	102.0	6.3			
			2	120.0	0.0	70.0	-12.5	70.0	-23.9	120.0	-7.7	80.0	0.0	72.0	-25.0			
			3	160.0	33.3	100.0	25.0	79.0	-14.1	150.0	15.4	100.0	25.0	84.0	-12.5			
			4	130.0	8.3	80.0	0.0	102.0	10.9	130.0	0.0	80.0	0.0	100.0	4.2			
			5	140.0	16.7	100.0	25.0	88.0	-4.3	140.0	-15.4	80.0	0.0	84.0	-12.5			
			6	130.0	8.3	80.0	0.0	102.0	10.9	140.0	7.7	80.0	0.0	102.0	6.3			
			8	140.0	16.7	100.0	25.0	80.0	-13.0	130.0	0.0	100.0	25.0	88.0	-8.3			
			10	130.0	8.3	90.0	12.5	80.0	-13.0	140.0	7.7	90.0	12.5	90.0	-6.3			
			12	140.0	16.7	90.0	12.5	86.0	-6.5	150.0	15.4	90.0	12.5	92.0	-4.2			
			364	PJ		-1	150.0	0.0	100.0	-10.0	76.0	36.8	150.0	-13.3	90.0	-11.1	80.0	43.8
0	150.0	0.0				90.0	-10.0	104.0	36.8	130.0	-13.3	90.0	0.0	104.0	30.0			
1	140.0	-4.7				90.0	-10.0	98.0	28.9	130.0	-13.3	90.0	0.0	104.0	30.0			
2	130.0	-13.3				90.0	-10.0	86.0	13.2	130.0	-13.3	90.0	0.0	96.0	20.0			
3	120.0	-20.0	80.0	-20.0	80.0	18.4	130.0	-13.3	90.0	0.0	96.0	20.0						
4	120.0	-20.0	80.0	-20.0	90.0	18.4	120.0	-20.0	80.0	-11.1	96.0	20.0						

** S.B.P. values => 160 mm Hg
 D.B.P. values => 100 mm Hg
 H.R. values => 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 mm Hg
 H.R. values <= 50 beats/min

2472

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RD

REBOMETINE - PROTOCOL 20124/013
Listing No.: 13.5

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING				STANDING										
				S.B.P.	% diff	D.B.P.	% diff	H.R.	% diff	S.B.P.	% diff	D.B.P.	% diff	H.R.	% diff			
11	364	PJ	5	110.0	-26.7	90.0	-10.0	76.0	0.0	120.0	-20.0	90.0	0.0	82.0	2.5			
			6	120.0	-20.0	80.0	-20.0	80.0	5.3	130.0	-13.3	90.0	0.0	86.0	7.5			
			8	120.0	-20.0	80.0	-20.0	90.0	18.4	130.0	-13.3	90.0	0.0	96.0	20.0			
			10	140.0	-6.7	100.0	0.0	84.0	10.5	140.0	-6.7	100.0	11.1	90.0	12.5			
			12	130.0	-13.3	80.0	-20.0	76.0	0.0	120.0	-20.0	80.0	-11.1	80.0	0.0			
			14	110.0	-26.7	80.0	-20.0	92.0	21.1	120.0	-20.0	80.0	-11.1	100.0	25.0			
			16	110.0	-26.7	80.0	-20.0	94.0	23.7	120.0	-20.0	80.0	-11.1	100.0	25.0			
			18	130.0	-13.3	80.0	-20.0	90.0	18.4	120.0	-20.0	80.0	-11.1	96.0	20.0			
			20	140.0	-6.7	100.0	0.0	82.0	7.9	150.0	0.0	90.0	0.0	90.0	12.5			
			22	140.0	-6.7	90.0	-10.0	90.0	18.4	140.0	-6.7	100.0	11.1	92.0	15.0			
			24	145.0	-3.3	90.0	-10.0	86.0	13.2	130.0	-13.3	90.0	0.0	90.0	12.5			
			26	140.0	-6.7	90.0	-10.0	86.0	13.2	120.0	-20.0	80.0	-11.1	92.0	15.0			
			28	130.0	-13.3	80.0	-20.0	92.0	21.1	130.0	-13.3	70.0	-22.2	88.0	10.0			
			30	140.0	-6.7	90.0	-10.0	86.0	13.2	140.0	-6.7	90.0	0.0	88.0	10.0			
			32	130.0	-13.3	80.0	-20.0	80.0	5.3	130.0	-13.3	80.0	-11.1	78.0	-2.5			
			34	140.0	-6.7	90.0	-10.0	90.0	18.4	120.0	-20.0	80.0	-11.1	66.0	17.5			
			36	140.0	-6.7	90.0	-10.0	90.0	18.4	120.0	-20.0	80.0	-11.1	96.0	20.0			
			38	140.0	-6.7	90.0	-10.0	86.0	13.2	130.0	-13.3	80.0	-11.1	94.0	17.5			
			40	140.0	-6.7	90.0	-10.0	78.0	2.6	120.0	-20.0	80.0	-11.1	86.0	7.5			
			42	130.0	-13.3	70.0	-30.0	70.0	-7.9	110.0	-26.7	70.0	-22.2	76.0	-5.0			
			44	110.0	-26.7	70.0	-30.0	66.0	-13.2	120.0	-20.0	80.0	-11.1	70.0	-12.5			
			46	120.0	-20.0	80.0	-20.0	88.0	15.8	110.0	-26.7	80.0	-11.1	90.0	12.5			
			48	110.0	-26.7	70.0	-30.0	70.0	-7.9	110.0	-26.7	80.0	-11.1	76.0	-5.0			
			50	120.0	-20.0	80.0	-20.0	86.0	13.2	130.0	-13.3	80.0	-11.1	90.0	12.5			
			52	130.0	-13.3	80.0	-20.0	78.0	2.6	120.0	-20.0	80.0	-11.1	88.0	10.0			
			369	EI		-1	130.0	-7.7	90.0	-11.1	80.0	0.0	140.0	-7.1	100.0	0.0	86.0	7.0
						0	120.0	0.0	90.0	0.0	76.0	-5.0	130.0	-7.1	90.0	-10.0	78.0	-9.3
						1	130.0	0.0	90.0	-11.1	76.0	-5.0	120.0	-14.3	80.0	-20.0	80.0	-7.0
						2	110.0	-15.4	80.0	-11.1	80.0	0.0	120.0	-14.3	90.0	-10.0	86.0	0.0
						3	110.0	-15.4	80.0	-11.1	80.0	0.0	120.0	-14.3	80.0	-20.0	82.0	-4.7
						4	120.0	-7.7	80.0	-11.1	80.0	0.0	120.0	-14.3	90.0	-10.0	86.0	0.0
						5	120.0	-7.7	80.0	-11.1	86.0	7.5	140.0	0.0	90.0	-10.0	92.0	7.0
						6	130.0	0.0	80.0	-11.1	86.0	-2.5	120.0	-14.3	80.0	-20.0	88.0	2.3
						8	110.0	-15.4	70.0	-22.2	78.0	-2.5	120.0	-14.3	90.0	-10.0	86.0	0.0
						10	110.0	-15.4	80.0	-11.1	82.0	2.5	120.0	-14.3	80.0	-20.0	74.0	-14.0
						12	120.0	-7.7	80.0	-11.1	72.0	-10.0	140.0	0.0	95.0	-5.0	78.0	-9.3
						14	140.0	7.7	100.0	11.1	80.0	0.0	140.0	0.0	100.0	0.0	76.0	-11.6
						16	140.0	7.7	100.0	11.1	80.0	0.0	140.0	0.0	100.0	0.0	76.0	-11.6
						18	130.0	0.0	90.0	0.0	78.0	-2.5	140.0	0.0	100.0	0.0	86.0	0.0

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 50 mm Hg
H.R. values <= 50 beats/min

2473

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LIVING				STANDING											
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff						
11	369	EI	20	120.0	-7.7	70.0	-22.2	*	78.0	-2.5	130.0	-7.1	80.0	-20.0	76.0	-11.6			
			22	130.0	0.0	80.0	-11.1		82.0	2.5	110.0	-21.4	80.0	-20.0	86.0	0.0			
			24	130.0	0.0	80.0	-11.1		74.0	-7.5	120.0	-14.3	80.0	-20.0	86.0	0.0			
			26	120.0	-7.7	80.0	-11.1		72.0	-10.0	110.0	-21.4	80.0	-20.0	80.0	*			
			28	120.0	-7.7	80.0	-11.1		86.0	7.5	130.0	-7.1	80.0	-20.0	88.0	2.3			
			30	130.0	0.0	80.0	-11.1		76.0	-5.0	130.0	-7.1	80.0	-20.0	82.0	-4.7			
			32	140.0	7.7	80.0	-11.1		80.0	0.0	130.0	-7.1	80.0	-20.0	84.0	-2.3			
			34	120.0	-7.7	70.0	-22.2	*	70.0	-12.5	120.0	-14.3	80.0	-20.0	80.0	-7.0			
			36	130.0	0.0	80.0	-11.1		72.0	-10.0	110.0	-21.4	70.0	-30.0	84.0	-2.3			
			38	130.0	0.0	80.0	-11.1		78.0	-2.5	140.0	0.0	80.0	-20.0	86.0	0.0			
			40	130.0	0.0	80.0	-11.1		68.0	-17.5	120.0	-14.3	80.0	-20.0	78.0	-9.3			
			42	130.0	0.0	80.0	-11.1		66.0	-22.5	130.0	-7.1	80.0	-20.0	74.0	-14.0			
			44	130.0	0.0	80.0	-11.1		62.0	-27.5	140.0	0.0	80.0	-20.0	72.0	-16.3			
			46	130.0	0.0	80.0	-11.1		66.0	-22.5	130.0	-7.1	80.0	-20.0	68.0	-20.9			
48	140.0	7.7	80.0	-11.1		60.0	-25.0	130.0	-7.1	80.0	-20.0	70.0	-18.6						
50	130.0	0.0	80.0	-11.1		68.0	-15.0	130.0	-7.1	80.0	-20.0	76.0	-11.6						
52	140.0	7.7	95.0	5.6		80.0	0.0	130.0	-7.1	90.0	-10.0	88.0	-2.5						
371	LJ		-1	120.0	0.0	80.0	0.0		80.0	10.0	130.0	0.0	80.0	0.0	86.0	4.7			
			0	120.0	0.0	80.0	0.0		88.0	7.5	130.0	0.0	80.0	0.0	92.0	7.0			
			1	120.0	0.0	70.0	-12.5		86.0	7.5	120.0	-7.7	80.0	0.0	88.0	2.3			
			2	130.0	8.3	90.0	12.5		90.0	12.5	140.0	7.7	90.0	12.5	86.0	0.0			
			3	130.0	8.3	80.0	0.0		76.0	-5.0	130.0	0.0	80.0	0.0	82.0	-4.7			
			4	120.0	0.0	80.0	0.0		72.0	-10.0	140.0	7.7	90.0	12.5	86.0	0.0			
			5	130.0	8.3	80.0	0.0		82.0	2.5	140.0	7.7	100.0	25.0	86.0	0.0			
			6	130.0	8.3	90.0	12.5		72.0	-10.0	100.0	-23.1	70.0	-12.5	77.0	-10.5			
			8	110.0	-8.3	70.0	-12.5		82.0	2.5	110.0	-15.4	80.0	0.0	86.0	0.0			
			10	130.0	8.3	90.0	12.5		68.0	-15.0	120.0	-7.7	80.0	0.0	76.0	-11.6			
			12	130.0	8.3	80.0	0.0		72.0	-10.0	110.0	-15.4	80.0	0.0	76.0	-11.6			
			14	130.0	8.3	80.0	0.0		63.0	-20.0	120.0	-15.4	70.0	-12.5	68.0	-20.9			
			372	DF		-1	120.0	0.0	80.0	0.0		63.0	7.9	120.0	0.0	70.0	14.3	68.0	5.9
						0	120.0	0.0	80.0	0.0		68.0	7.9	120.0	0.0	80.0	14.3	72.0	7.0
1	130.0	8.3				80.0	0.0		87.0	38.1	120.0	0.0	80.0	0.0	87.0	27.9			
2	140.0	16.7				90.0	12.5		88.0	39.7	130.0	8.3	90.0	28.6	90.0	32.4			
3	140.0	16.7				80.0	0.0		86.0	36.5	120.0	0.0	80.0	0.0	90.0	32.4			
4	150.0	25.0				90.0	12.5		90.0	42.9	155.0	29.2	90.0	28.6	96.0	41.2			
5	170.0	41.7	100.0	37.5	**	88.0	39.7	150.0	25.0	100.0	42.9	92.0	35.3						
6	130.0	8.3	90.0	12.5	**	94.0	49.2	130.0	8.3	80.0	14.3	94.0	38.2						
8	120.0	0.0	80.0	0.0		76.0	20.6	120.0	0.0	90.0	28.6	82.0	20.6						

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 beats/min
 H.R. values <= 50 beats/min

2474

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING				STANDING												
				S.B.P.	% diff	D.B.P.	% diff	H.R.	% diff	S.B.P.	% diff	D.B.P.	% diff	H.R.	% diff					
11	372	DF	10	130.0	8.3	90.0	12.5	82.0	30.2	140.0	16.7	100.0	42.9	**	84.0	23.5				
			12	120.0	0.0	90.0	12.5	83.0	31.7	120.0	0.0	80.0	14.3	**	82.0	20.6				
			14	120.0	0.0	90.0	12.5	80.0	27.0	120.0	0.0	80.0	14.3	**	82.0	20.6				
			16	130.0	8.3	80.0	0.0	72.0	14.3	130.0	8.3	100.0	28.6	**	80.0	17.6				
			18	130.0	8.3	90.0	12.5	76.0	20.6	130.0	8.3	100.0	42.9	**	78.0	14.7				
			20	110.0	-8.3	90.0	12.5	76.0	20.6	110.0	0.0	70.0	0.0	**	80.0	17.6				
			22	120.0	0.0	90.0	12.5	84.0	33.3	130.0	8.3	90.0	28.6	**	100.0	47.1				
			24	130.0	8.3	80.0	0.0	84.0	33.3	130.0	8.3	90.0	28.6	**	100.0	47.1				
			26	130.0	8.3	90.0	12.5	72.0	14.3	130.0	8.3	80.0	14.3	**	80.0	32.4				
			28	130.0	8.3	90.0	12.5	73.0	15.9	130.0	8.3	90.0	28.6	**	78.0	14.7				
			30	115.0	-4.2	90.0	12.5	76.0	20.6	130.0	8.3	90.0	28.6	**	73.0	7.4				
			32	130.0	8.3	80.0	0.0	84.0	33.3	120.0	0.0	80.0	14.3	**	76.0	11.8				
			34	140.0	16.7	90.0	12.5	72.0	14.3	140.0	16.7	90.0	28.6	**	88.0	29.4				
			375	BA	-1	150.0	6.7	100.0	0.0	80.0	160.0	7.1	90.0	0.0	86.0	16.3				
					0	160.0	0.0	100.0	0.0	78.0	-2.5	150.0	0.0	90.0	0.0	100.0	0.0			
					1	150.0	0.0	100.0	0.0	90.0	12.5	130.0	0.0	90.0	0.0	96.0	11.6			
					2	130.0	-13.3	90.0	-10.0	100.0	25.0	130.0	**	90.0	0.0	102.0	18.6			
					3	160.0	6.7	100.0	0.0	96.0	20.0	150.0	0.0	100.0	11.1	92.0	7.0			
					4	150.0	0.0	100.0	0.0	92.0	15.0	150.0	0.0	100.0	11.1	98.0	14.0			
					5	150.0	0.0	90.0	-10.0	92.0	15.0	140.0	0.0	90.0	0.0	98.0	14.0			
					6	150.0	0.0	100.0	0.0	88.0	10.0	160.0	0.0	100.0	11.1	92.0	7.0			
					8	170.0	13.3	100.0	0.0	100.0	25.0	130.0	**	100.0	11.1	102.0	18.6			
					10	160.0	6.7	100.0	0.0	84.0	5.0	160.0	0.0	90.0	0.0	105.0	22.1			
					12	150.0	0.0	90.0	-10.0	80.0	0.0	160.0	14.3	100.0	11.1	102.0	18.6			
					14	150.0	0.0	80.0	-20.0	72.0	-10.0	160.0	14.3	100.0	11.1	86.0	0.0			
					16	140.0	-6.7	90.0	-10.0	80.0	0.0	145.0	3.6	90.0	0.0	86.0	0.0			
					18	140.0	-6.7	90.0	-10.0	72.0	-10.0	130.0	0.0	90.0	0.0	78.0	-9.3			
					20	140.0	-6.7	80.0	-10.0	80.0	0.0	150.0	0.0	100.0	11.1	90.0	4.7			
					22	150.0	0.0	90.0	-10.0	75.0	-6.3	150.0	0.0	100.0	11.1	82.0	-4.7			
					376	RX	-1	120.0	25.0	70.0	42.9	**	84.0	0.0	100.0	20.0	60.0	33.3	84.0	31.0
							0	150.0	16.7	100.0	42.9	**	84.0	0.0	120.0	20.0	80.0	50.0	100.0	19.0
							1	140.0	8.3	100.0	42.9	**	85.0	2.4	120.0	20.0	90.0	50.0	94.0	11.9
							2	130.0	8.3	90.0	28.6	**	84.0	0.0	120.0	20.0	80.0	50.0	92.0	9.5
							3	130.0	8.3	100.0	42.9	**	100.0	19.0	130.0	30.0	100.0	66.7	**	100.0
4	150.0	25.0					100.0	42.9	**	85.0	2.4	150.0	50.0	100.0	66.7	**	86.0	2.4		
5	160.0	33.3	80.0	14.3			**	86.0	2.4	130.0	20.0	90.0	50.0	86.0	2.4					
6	140.0	16.7	110.0	41.7			**	86.0	2.4	160.0	60.0	100.0	66.7	**	90.0	7.1				

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 beats/min
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXYETINE - PROTOCOL 20124/013
 Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING			STANDING													
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	H.R.	% diff									
11	376	KK	10	160.0	33.3	**	100.0	42.9	**	160.0	60.0	**	100.0	66.7	**	96.0	14.3			
			12	160.0	33.3	**	100.0	42.9	**	150.0	50.0	**	100.0	66.7	**	90.0	7.1			
			14	160.0	33.3	**	100.0	42.9	**	85.0	2.4		150.0	60.0	**	100.0	66.7	**	90.0	7.1
			16	150.0	25.0	0.0	90.0	28.6	0.0	84.0	0.0		150.0	50.0	0.0	100.0	66.7	**	76.0	-9.5
			18	130.0	8.3	0.0	70.0	0.0	80.0	-4.8	0.0		120.0	20.0	0.0	70.0	16.7	0.0	85.0	1.2
			20	120.0	0.0	0.0	70.0	0.0	80.0	-4.8	0.0		130.0	30.0	0.0	100.0	66.7	**	86.0	2.4
			22	140.0	16.7	0.0	90.0	28.6	0.0	78.0	-7.1		150.0	50.0	0.0	100.0	66.7	**	90.0	7.1
			24	140.0	16.7	0.0	100.0	42.9	**	80.0	-4.8		110.0	10.0	0.0	100.0	66.7	**	90.0	7.1
			26	140.0	16.7	0.0	100.0	42.9	**	80.0	-7.1		140.0	40.0	0.0	80.0	33.3	0.0	90.0	7.1
			28	150.0	25.0	0.0	100.0	42.9	**	80.0	-4.8		150.0	50.0	0.0	100.0	66.7	**	86.0	2.4
			30	150.0	25.0	0.0	100.0	42.9	**	76.0	-9.5		150.0	50.0	0.0	100.0	66.7	**	80.0	-4.8
32	150.0	25.0	0.0	100.0	42.9	**	76.0	-9.5		140.0	40.0	0.0	100.0	66.7	**	80.0	-4.8			
34	140.0	16.7	0.0	100.0	42.9	**	78.0	-7.1		140.0	40.0	0.0	100.0	66.7	**	86.0	2.4			
36	140.0	16.7	0.0	90.0	28.6	0.0	82.0	-2.4		140.0	40.0	0.0	100.0	66.7	**	94.0	11.9			
38	150.0	25.0	0.0	90.0	28.6	0.0	86.0	2.4		150.0	50.0	0.0	90.0	50.0	0.0	80.0	-4.8			
40	150.0	25.0	0.0	90.0	28.6	0.0	86.0	2.4		150.0	50.0	0.0	90.0	50.0	0.0	84.0	0.0			
42	150.0	25.0	0.0	100.0	42.9	**	78.0	-7.1		140.0	40.0	0.0	100.0	66.7	**	80.0	-4.8			
44	140.0	16.7	0.0	90.0	28.6	0.0	86.0	2.4		130.0	30.0	0.0	90.0	50.0	0.0	86.0	2.4			
46	150.0	25.0	0.0	100.0	42.9	**	82.0	-2.4		150.0	50.0	0.0	100.0	66.7	**	82.0	-2.4			
48	150.0	25.0	0.0	100.0	42.9	**	80.0	-4.8		150.0	50.0	0.0	100.0	66.7	**	86.0	2.4			
50	130.0	8.3	0.0	80.0	14.3	0.0	78.0	-7.1		140.0	40.0	0.0	80.0	33.3	0.0	86.0	2.4			
52	130.0	8.3	0.0	80.0	14.3	0.0	72.0	-14.3		130.0	30.0	0.0	80.0	33.3	0.0	80.0	-4.8			
12	94	ER	-1	110.0	0.0	0.0	80.0	0.0	80.0	0.0	110.0	0.0	0.0	80.0	0.0	88.0	0.0			
			1	110.0	0.0	0.0	80.0	0.0	74.0	-7.5	0.0	0.0	0.0	0.0	80.0	0.0	85.0	-3.4		
			2	110.0	0.0	0.0	60.0	-25.0	*	92.0	15.0	0.0	0.0	0.0	70.0	-12.5	82.0	-6.8		
			3	130.0	18.2	0.0	80.0	0.0	80.0	0.0	120.0	9.1	0.0	80.0	0.0	84.0	-4.5			
			4	110.0	0.0	0.0	70.0	-12.5	0.0	88.0	10.0	0.0	9.1	0.0	80.0	0.0	84.0	-4.5		
			5	120.0	9.1	0.0	80.0	0.0	82.0	2.5	120.0	9.1	0.0	80.0	0.0	85.0	-3.4			
			6	110.0	0.0	0.0	70.0	-12.5	0.0	92.0	15.0	0.0	9.1	0.0	80.0	0.0	100.0	13.6		
			8	130.0	18.2	0.0	80.0	0.0	80.0	0.0	130.0	18.2	0.0	80.0	0.0	86.0	-2.3			
			10	120.0	9.1	0.0	90.0	12.5	0.0	78.0	-2.5	0.0	9.1	0.0	80.0	0.0	80.0	-9.1		
			12	120.0	9.1	0.0	80.0	0.0	70.0	-12.5	120.0	9.1	0.0	70.0	-12.5	80.0	0.0	80.0	-9.1	
			95	25H	-1	110.0	0.0	0.0	80.0	0.0	88.0	0.0	100.0	0.0	0.0	80.0	0.0	96.0	0.0	
0	110.0	0.0			0.0	80.0	0.0	80.0	-9.1	100.0	0.0	0.0	80.0	0.0	88.0	-8.3				
1	120.0	9.1			0.0	80.0	0.0	80.0	-9.1	90.0	-10.0	0.0	60.0	-25.0	82.0	-14.6				
2	130.0	18.2	0.0	80.0	0.0	88.0	0.0	120.0	20.0	0.0	80.0	0.0	88.0	-8.3						
3	120.0	9.1	0.0	90.0	12.5	0.0	88.0	0.0	90.0	-10.0	0.0	60.0	-25.0	82.0	-14.6					

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

2476

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013

Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING				STANDING										
				S.B.P.	% diff	H.R.	% diff	S.B.P.	% diff	H.R.	% diff							
12	95	ZSH	4	130.0	18.2	80.0	0.0	88.0	0.0	120.0	20.0	80.0	0.0	96.0	0.0			
			5	140.0	27.3	90.0	12.5	88.0	0.0	120.0	20.0	80.0	12.5	80.0	-16.7			
			6	110.0	0.0	90.0	12.5	80.0	-9.1	110.0	10.0	90.0	12.5	80.0	-16.7			
			8	140.0	27.3	100.0	25.0	74.0	**	130.0	30.0	90.0	12.5	72.0	-25.0			
			10	130.0	18.2	90.0	12.5	100.0	13.6	130.0	30.0	90.0	12.5	100.0	4.2			
			12	150.0	36.4	100.0	25.0	100.0	**	140.0	40.0	100.0	25.0	100.0	4.2			
			14	130.0	18.2	70.0	-12.5	72.0	-18.2	100.0	0.0	70.0	-12.5	72.0	-25.0			
			16	120.0	9.1	80.0	0.0	80.0	-9.1	110.0	20.0	80.0	0.0	88.0	-8.3			
			18	120.0	9.1	80.0	0.0	88.0	0.0	110.0	10.0	80.0	0.0	80.0	-16.7			
			96	IP		-1	120.0	0.0	80.0	0.0	88.0	0.0	110.0	0.0	80.0	0.0	88.0	0.0
						1	120.0	0.0	80.0	0.0	80.0	-9.1	100.0	0.0	80.0	0.0	80.0	0.0
						2	130.0	8.3	90.0	12.5	88.0	0.0	140.0	27.3	90.0	12.5	88.0	0.0
						3	110.0	-8.3	80.0	0.0	80.0	-9.1	100.0	0.0	80.0	0.0	78.0	-11.4
						4	100.0	-16.7	80.0	0.0	80.0	-9.1	90.0	-18.2	60.0	-25.0	80.0	-9.1
						5	130.0	8.3	90.0	12.5	80.0	-9.1	110.0	0.0	80.0	0.0	80.0	-9.1
						6	120.0	0.0	90.0	12.5	80.0	-9.1	120.0	0.0	80.0	0.0	80.0	4.5
						8	130.0	8.3	90.0	12.5	78.0	-11.4	140.0	27.3	100.0	25.0	120.0	36.4
						10	120.0	0.0	80.0	0.0	80.0	-9.1	130.0	18.2	80.0	0.0	80.0	-9.1
12	130.0	8.3				90.0	12.5	88.0	0.0	130.0	18.2	90.0	12.5	88.0	0.0			
14	120.0	0.0				70.0	-12.5	80.0	-9.1	110.0	0.0	70.0	-12.5	80.0	-9.1			
16	130.0	8.3				90.0	12.5	92.0	4.5	120.0	9.1	90.0	12.5	96.0	9.1			
18	120.0	0.0				80.0	0.0	72.0	-18.2	120.0	9.1	80.0	0.0	72.0	-18.2			
20	120.0	0.0				80.0	0.0	80.0	-9.1	140.0	27.3	80.0	0.0	80.0	-9.1			
22	130.0	8.3				100.0	25.0	100.0	**	130.0	18.2	100.0	25.0	100.0	13.6			
24	130.0	8.3				90.0	12.5	88.0	0.0	130.0	18.2	90.0	12.5	100.0	13.6			
97	FS2					-1	120.0	0.0	80.0	0.0	86.0	0.0	130.0	0.0	90.0	0.0	90.0	22.2
						1	110.0	-8.3	80.0	0.0	97.0	12.8	130.0	0.0	80.0	-11.1	110.0	22.2
			2	120.0	0.0	80.0	0.0	95.0	10.5	140.0	7.7	80.0	-11.1	124.0	37.8			
			3	120.0	0.0	80.0	-0.0	102.0	18.6	130.0	0.0	80.0	-11.1	125.0	38.9			
			4	120.0	0.0	80.0	0.0	100.0	16.3	130.0	0.0	90.0	0.0	120.0	33.3			
			5	140.0	16.7	90.0	12.5	82.0	-4.7	130.0	0.0	80.0	-11.1	86.0	-4.4			
			6	120.0	0.0	80.0	0.0	88.0	2.3	130.0	0.0	80.0	-11.1	120.0	33.3			
			8	120.0	0.0	80.0	0.0	80.0	-7.0	130.0	0.0	90.0	0.0	92.0	2.2			
			10	120.0	0.0	80.0	0.0	78.0	-9.3	120.0	-7.7	80.0	-11.1	72.0	-20.0			
			-1	130.0	0.0	80.0	0.0	72.0	-16.3	130.0	0.0	80.0	-11.1	84.0	-6.7			
98	HK		-1	130.0	0.0	80.0	0.0	90.0	0.0	120.0	0.0	80.0	0.0	110.0	0.0			
			1	130.0	0.0	80.0	0.0	90.0	0.0	120.0	0.0	80.0	0.0	110.0	0.0			

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 50 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXTINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING				STANDING									
				S.B.P.	% diff	D.B.P.	% diff	H.R.	% diff	S.B.P.	% diff	D.B.P.	% diff	H.R.	% diff		
12	98	MK	0	110.0	-15.4	80.0	0.0	100.0	11.1	100.0	-16.7	80.0	0.0	110.0	0.0		
			1	130.0	0.0	90.0	12.5	78.0	-13.3	120.0	0.0	90.0	12.5	92.0	-16.4		
			2	90.0	-30.8	70.0	-12.5	92.0	2.2	90.0	-25.0	70.0	-12.5	110.0	0.0		
			3	90.0	-30.8	70.0	-12.5	100.0	11.1	90.0	-25.0	70.0	-12.5	120.0	0.0		
			4	120.0	-7.7	70.0	-12.5	88.0	-2.2	120.0	0.0	70.0	-12.5	92.0	-16.4		
			5	105.0	-19.2	70.0	-12.5	84.0	-6.7	90.0	-25.0	70.0	-12.5	88.0	-20.0		
			6	100.0	-23.1	70.0	-12.5	80.0	-11.1	100.0	-16.7	70.0	-12.5	86.0	-21.8		
			8	110.0	-15.4	80.0	0.0	72.0	-20.0	120.0	0.0	80.0	0.0	66.0	-40.0		
			10	110.0	-15.4	60.0	-25.0	100.0	11.1	110.0	-8.3	70.0	-12.5	90.0	-18.2		
			12	120.0	-7.7	90.0	12.5	82.0	-8.9	110.0	-8.3	70.0	-12.5	90.0	-18.2		
			14	100.0	-23.1	70.0	-12.5	64.0	-28.9	100.0	-16.7	70.0	-12.5	72.0	-34.5		
			16	120.0	-7.7	80.0	0.0	90.0	0.0	130.0	8.3	100.0	25.0	100.0	-9.1		
			18	100.0	-23.1	70.0	-12.5	90.0	0.0	110.0	-8.3	70.0	-12.5	96.0	-12.7		
			20	110.0	-15.4	70.0	-12.5	92.0	2.2	100.0	-16.7	70.0	-12.5	90.0	-18.2		
			22	110.0	-15.4	70.0	-12.5	100.0	11.1	110.0	-8.3	70.0	-12.5	100.0	-9.1		
			24	100.0	-23.1	70.0	-12.5	80.0	-11.1	100.0	-16.7	70.0	-12.5	88.0	-20.0		
			26	110.0	-15.4	70.0	-12.5	86.0	-4.4	110.0	-8.3	70.0	-12.5	100.0	-9.1		
			28	110.0	-15.4	70.0	-12.5	80.0	-11.1	100.0	-16.7	70.0	-12.5	88.0	-20.0		
			30	110.0	-15.4	70.0	-12.5	82.0	-8.9	100.0	-16.7	70.0	-12.5	90.0	-18.2		
			101	GS2	-1	150.0	0.0	105.0	0.0	120.0	-13.3	150.0	-6.7	105.0	0.0	130.0	-15.4
					0	150.0	0.0	100.0	-4.8	104.0	-13.3	140.0	-6.7	90.0	-14.3	110.0	-15.4
					1	120.0	-20.0	80.0	-23.8	92.0	-23.3	120.0	-20.0	80.0	-23.8	85.0	-34.6
					2	130.0	-13.3	90.0	-14.3	80.0	-33.3	120.0	-20.0	80.0	-23.8	82.0	-36.9
					3	100.0	-33.3	70.0	-33.3	102.0	-15.0	120.0	-20.0	95.0	-9.5	92.0	-29.2
					4	130.0	-13.3	95.0	-9.5	92.0	-23.3	120.0	-20.0	90.0	-14.3	106.0	-18.5
					5	130.0	-13.3	100.0	-4.8	88.0	-26.7	120.0	-20.0	90.0	-14.3	100.0	-23.1
					6	149.0	-0.7	100.0	-4.8	88.0	-26.7	130.0	-13.3	100.0	-4.8	92.0	-29.2
					8	150.0	0.0	100.0	-4.8	74.0	-38.3	160.0	6.7	110.0	4.8	80.0	-38.5
					10	150.0	0.0	100.0	-4.8	86.0	-28.3	140.0	-6.7	100.0	-4.8	92.0	-29.2
			107	KS2	-1	130.0	-7.7	80.0	0.0	84.0	-9.5	140.0	-14.3	80.0	0.0	98.0	-14.3
0	120.0	-7.7			80.0	0.0	84.0	0.0	130.0	-7.1	80.0	0.0	96.0	-2.0			
1	120.0	-7.7			80.0	0.0	86.0	2.4	120.0	-14.3	80.0	0.0	90.0	-8.2			
2	120.0	-7.7			80.0	0.0	80.0	-4.8	120.0	-14.3	80.0	0.0	82.0	-16.3			
3	120.0	-7.7			70.0	-12.5	88.0	4.8	125.0	-10.7	90.0	12.5	100.0	2.0			
4	120.0	-7.7			80.0	0.0	80.0	-4.8	130.0	-7.1	80.0	0.0	88.0	-10.2			
5	120.0	-7.7	80.0	0.0	80.0	-4.8	125.0	-10.7	80.0	0.0	88.0	-10.2					
6	120.0	-7.7	80.0	0.0	78.0	-7.1	120.0	-14.3	80.0	0.0	84.0	-14.3					

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 beats/min
 H.R. values <= 50 beats/min

2478

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	Initial Visit	LYING			STANDING									
			S.B.P. % diff	D.B.P. % diff	H.R. % diff	S.B.P. % diff	D.B.P. % diff	H.R. % diff							
12	107	KSZ	10	130.0	0.0	92.0	140.0	0.0	80.0	0.0	95.0	-3.1			
			12	130.0	0.0	82.0	140.0	0.0	80.0	0.0	94.0	-4.1			
			14	130.0	0.0	86.0	140.0	0.0	90.0	0.0	88.0	-10.2			
			16	140.0	7.7	60.0	140.0	0.0	90.0	12.5	60.0	-38.8			
			18	110.0	-15.4	72.0	110.0	-21.4	60.0	-25.0	72.0	-25.5			
			20	110.0	-15.4	72.0	130.0	0.0	80.0	0.0	68.0	-30.6			
			22	120.0	-7.7	76.0	130.0	-7.1	80.0	0.0	82.0	-16.3			
			24	130.0	0.0	78.0	140.0	0.0	80.0	0.0	82.0	-16.3			
			26	140.0	7.7	88.0	160.0	14.3	100.0	25.0	98.0	0.0			
			28	120.0	-7.7	80.0	140.0	0.0	90.0	12.5	94.0	-4.1			
			108	TK		-1	120.0	0.0	72.0	130.0	0.0	80.0	0.0	84.0	4.8
						0	120.0	0.0	72.0	130.0	0.0	80.0	0.0	88.0	4.8
						1	140.0	16.7	78.0	130.0	0.0	90.0	12.5	88.0	4.8
						2	120.0	0.0	72.0	130.0	0.0	90.0	12.5	88.0	4.8
						3	120.0	0.0	78.0	120.0	-7.7	90.0	12.5	88.0	4.8
						4	120.0	0.0	80.0	110.0	11.1	90.0	12.5	100.0	19.0
						5	100.0	-16.7	80.0	110.0	11.1	110.0	-15.4	90.0	7.1
						6	130.0	8.3	88.0	125.0	22.2	70.0	-12.5	96.0	14.3
						8	120.0	0.0	78.0	125.0	3.8	80.0	0.0	84.0	0.0
						10	130.0	8.3	72.0	130.0	0.0	90.0	0.0	88.0	4.8
						12	120.0	0.0	66.0	130.0	0.0	80.0	0.0	78.0	-7.1
						14	120.0	0.0	86.0	130.0	0.0	90.0	12.5	90.0	7.1
						16	120.0	0.0	80.0	125.0	-3.8	90.0	12.5	64.0	-23.8
						18	110.0	-8.3	74.0	120.0	6.3	85.0	6.3	86.0	2.4
						20	110.0	-8.3	62.0	120.0	-7.7	80.0	0.0	88.0	4.8
						22	120.0	0.0	72.0	125.0	-3.8	90.0	12.5	84.0	0.0
						24	120.0	0.0	64.0	120.0	-7.7	80.0	0.0	76.0	-9.5
						26	120.0	0.0	60.0	120.0	-7.7	70.0	-12.5	80.0	-4.8
28	120.0	0.0				58.0	125.0	-3.8	80.0	0.0	78.0	-7.1			
109	LS					-1	120.0	0.0	60.0	120.0	0.0	80.0	0.0	72.0	13.9
						0	120.0	0.0	58.0	120.0	0.0	80.0	0.0	84.0	16.7
						1	130.0	8.3	66.0	120.0	0.0	90.0	12.5	84.0	16.7
						2	120.0	0.0	64.0	110.0	0.0	80.0	0.0	62.0	-33.9
						3	110.0	-8.3	60.0	110.0	0.0	70.0	-12.5	80.0	11.1
						4	110.0	-8.3	62.0	110.0	0.0	80.0	0.0	80.0	11.1
						5	130.0	8.3	76.0	120.0	8.3	90.0	12.5	82.0	13.9
						6	110.0	-8.3	67.0	110.0	0.0	70.0	-12.5	82.0	13.9

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 100 mm Hg
D.B.P. values <= 70 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING				STANDING								
				S.B.P.	% diff	H.R.	% diff	S.B.P.	% diff	H.R.	% diff					
12	109	LS	10	120.0	0.0	74.0	23.3	120.0	0.0	80.0	0.0	82.0	13.9			
			12	130.0	8.3	84.0	-6.7	140.0	0.0	90.0	12.5	86.0	19.4			
			14	120.0	0.0	80.0	0.0	130.0	8.3	80.0	0.0	80.0	0.0			
			16	120.0	0.0	70.0	20.0	130.0	8.3	80.0	0.0	80.0	0.0			
			18	120.0	0.0	64.0	6.7	120.0	0.0	80.0	0.0	80.0	0.0			
			20	80.0	0.0	72.0	20.0	130.0	8.3	80.0	0.0	86.0	19.4			
			111	RV	RV	-1	130.0	0.0	90.0	0.0	140.0	0.0	80.0	0.0	92.0	4.3
						1	130.0	0.0	84.0	-6.7	140.0	0.0	90.0	12.5	96.0	4.3
						2	140.0	7.7	80.0	-11.1	140.0	0.0	90.0	12.5	88.0	-4.3
						3	145.0	11.5	88.0	-2.2	145.0	3.6	90.0	12.5	96.0	4.3
						4	130.0	-3.8	80.0	-11.1	140.0	0.0	90.0	12.5	88.0	-4.3
						5	130.0	0.0	80.0	-11.1	140.0	0.0	90.0	12.5	84.0	-8.7
						6	130.0	0.0	84.0	-6.7	140.0	0.0	90.0	12.5	96.0	4.3
						8	130.0	0.0	80.0	-11.1	140.0	0.0	90.0	12.5	88.0	-4.3
						10	140.0	7.7	86.0	-4.4	140.0	0.0	90.0	12.5	82.0	-10.9
						12	130.0	0.0	85.0	-5.6	140.0	0.0	90.0	12.5	88.0	-4.3
						14	140.0	7.7	92.0	2.2	130.0	-7.1	90.0	12.5	96.0	4.3
						16	140.0	7.7	90.0	0.0	140.0	0.0	90.0	12.5	94.0	2.2
						18	150.0	15.4	96.0	6.7	140.0	0.0	90.0	12.5	90.0	-2.2
						20	140.0	7.7	95.0	5.6	160.0	14.3	100.0	25.0	98.0	6.5
22	130.0	0.0				90.0	0.0	120.0	0.0	80.0	0.0	90.0	-2.2			
24	110.0	-15.4				76.0	-15.6	120.0	0.0	90.0	12.5	92.0	0.0			
26	130.0	0.0				88.0	-2.2	120.0	0.0	80.0	0.0	90.0	-13.0			
28	140.0	7.7				88.0	-2.2	110.0	-21.4	70.0	-12.5	80.0	-2.2			
30	130.0	0.0				80.0	-11.1	120.0	0.0	80.0	0.0	90.0	-2.2			
32	140.0	7.7				76.0	-24.4	140.0	0.0	90.0	12.5	88.0	-4.3			
34	140.0	7.7	76.0	-24.4	130.0	-7.1	90.0	12.5	88.0	-4.3						
36	140.0	7.7	100.0	11.1	160.0	14.3	90.0	12.5	60.0	-94.8						
38	130.0	0.0	85.0	-5.6	120.0	0.0	90.0	12.5	96.0	4.3						
40	135.0	3.8	80.0	-11.1	130.0	-4.4	90.0	12.5	84.0	0.0						
42	140.0	7.7	86.0	-4.4	150.0	11.1	100.0	25.0	84.0	-8.7						
44	150.0	15.4	68.0	-24.4	145.0	3.6	90.0	12.5	82.0	-10.9						
46	135.0	3.8	66.0	-26.7	140.0	0.0	90.0	12.5	64.0	-30.4						
48	140.0	7.7	68.0	-24.4	160.0	14.3	95.0	18.8	70.0	-23.9						
50	140.0	7.7	85.0	-5.6	150.0	7.1	95.0	18.8	82.0	-32.6						
52	140.0	7.7	68.0	-24.4	160.0	14.3	95.0	18.8	88.0	-4.3						
-1	EN		80.0	0.0	76.0	0.0	85.0	0.0	85.0	0.0	82.0	-23.9				

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

03480

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R8D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LIVING				STANDING										
				S.B.P.	z diff	H.R.	z diff	D.B.P.	z diff	S.B.P.	z diff	H.R.	z diff					
12	112	EN	0	140.0	0.0	80.0	0.0	82.0	7.9	140.0	0.0	80.0	-5.9	84.0	2.4			
			1	140.0	0.0	80.0	0.0	78.0	2.6	145.0	3.6	80.0	-5.9	92.0	12.2			
			2	130.0	-7.1	80.0	0.0	82.0	7.9	130.0	-7.1	90.0	5.9	96.0	17.1			
			3	120.0	-16.3	80.0	0.0	100.0	31.6	130.0	0.0	80.0	-5.9	98.0	17.1			
			4	120.0	-16.3	80.0	0.0	78.0	2.6	130.0	-7.1	80.0	-5.9	96.0	17.1			
			5	120.0	-16.3	80.0	0.0	100.0	31.6	110.0	-21.4	70.0	-17.6	100.0	22.0			
			6	110.0	-21.4	70.0	-12.5	98.0	28.9	140.0	0.0	70.0	-17.6	109.0	32.9			
			8	120.0	-16.3	80.0	0.0	84.0	10.5	120.0	-14.3	90.0	5.9	102.0	24.4			
			10	130.0	-7.1	80.0	0.0	86.0	13.2	130.0	-7.1	80.0	-5.9	98.0	19.5			
			12	120.0	-14.3	70.0	-12.5	74.0	-2.6	130.0	-7.1	80.0	-5.9	90.0	9.8			
			14	130.0	-7.1	80.0	0.0	82.0	7.9	140.0	0.0	80.0	-5.9	110.0	34.1			
			16	120.0	-14.3	80.0	0.0	80.0	5.3	130.0	-7.1	90.0	-5.9	120.0	26.8			
			18	125.0	-10.7	70.0	-12.5	96.0	26.3	110.0	-21.4	70.0	-17.6	104.0	19.5			
			20	120.0	-14.3	80.0	0.0	92.0	21.1	120.0	-21.4	70.0	-17.6	98.0	19.5			
			22	110.0	-21.4	80.0	0.0	84.0	10.5	120.0	-14.3	90.0	5.9	86.0	4.9			
			24	140.0	0.0	70.0	-12.5	94.0	23.7	120.0	-14.3	80.0	-5.9	92.0	12.2			
			26	130.0	-7.1	80.0	0.0	86.0	13.2	110.0	-21.4	70.0	-17.6	88.0	7.3			
			28	125.0	-10.7	80.0	0.0	90.0	16.4	125.0	-10.7	80.0	-5.9	94.0	14.6			
			116	IV		-1	110.0	-18.2	70.0	0.0	72.0	22.2	110.0	-18.2	70.0	0.0	80.0	20.0
						0	90.0	-18.2	70.0	0.0	88.0	22.2	100.0	-9.1	70.0	0.0	96.0	37.5
						1	90.0	-18.2	70.0	0.0	100.0	38.9	90.0	-18.2	80.0	0.0	110.0	37.5
						2	90.0	-18.2	70.0	0.0	100.0	38.9	90.0	-18.2	80.0	0.0	110.0	37.5
						3	100.0	-9.1	70.0	0.0	102.0	41.7	100.0	-9.1	70.0	0.0	105.0	31.3
						4	100.0	-9.1	70.0	0.0	88.0	22.2	100.0	-9.1	70.0	0.0	100.0	25.0
						5	90.0	-18.2	70.0	0.0	84.0	16.7	100.0	-9.1	70.0	0.0	96.0	20.0
						6	110.0	0.0	70.0	0.0	97.0	34.7	100.0	-9.1	70.0	0.0	104.0	30.0
						8	100.0	-9.1	70.0	0.0	84.0	16.7	100.0	-9.1	70.0	0.0	92.0	15.0
						10	90.0	-18.2	60.0	-14.3	80.0	11.1	100.0	-9.1	60.0	-14.3	82.0	2.5
12	100.0	-9.1				60.0	-14.3	87.0	20.8	90.0	-18.2	60.0	-14.3	86.0	7.5			
14	105.0	-6.5				70.0	0.0	96.0	33.3	105.0	-4.5	80.0	14.3	100.0	25.0			
16	120.0	9.1				80.0	14.3	88.0	22.2	130.0	18.2	80.0	14.3	96.0	20.0			
120	TGB					-1	130.0	7.7	90.0	-11.1	84.0	7.1	140.0	0.0	90.0	0.0	96.0	4.2
						0	140.0	-7.7	80.0	-11.1	88.0	4.8	140.0	0.0	90.0	0.0	100.0	-2.1
						1	120.0	-15.4	70.0	-22.2	72.0	-19.0	120.0	-14.3	70.0	-22.2	80.0	-16.7
			2	130.0	0.0	90.0	0.0	78.0	-14.3	130.0	-7.1	90.0	0.0	84.0	-12.5			
			4	120.0	-7.7	80.0	-11.1	76.0	-9.5	130.0	-7.1	80.0	-11.1	78.0	-18.8			
5	110.0	-15.4	70.0	-22.2	76.0	-9.5	120.0	-14.3	80.0	-11.1	88.0	-8.3						

** S.B.P. values => 160 mm Hg
 D.B.P. values => 100 mm Hg
 H.R. values => 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 70 mm Hg
 H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING				STANDING									
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff				
12	120	T68	6	100.0	-23.1	*	60.0	-33.3	*	78.0	-7.1	120.0	-14.3	80.0	-11.1	72.0	-25.0
			8	140.0	7.7		100.0	11.1		84.0	0.0	140.0	0.0	90.0	0.0	92.0	-4.2
			10	110.0	-15.4		80.0	-11.1		80.0	-4.8	120.0	-14.3	80.0	-11.1	88.0	-8.3
			12	130.0	0.0		80.0	-11.1		90.0	7.1	130.0	-7.1	80.0	-11.1	100.0	4.2
			14	120.0	-7.7		80.0	-11.1		80.0	-4.8	110.0	-21.4	70.0	-22.2	96.0	0.0
			16	120.0	-7.7		80.0	-11.1		80.0	-4.8	110.0	-21.4	70.0	-22.2	96.0	0.0
			18	120.0	-7.7		80.0	-11.1		76.0	-9.5	110.0	-21.4	70.0	-22.2	90.0	-6.3
			20	120.0	-7.7		80.0	-11.1		88.0	4.8	120.0	-14.3	80.0	-11.1	100.0	4.2
			22	120.0	-7.7		70.0	-22.2	*	72.0	-14.3	110.0	-21.4	80.0	-11.1	84.0	-12.5
			24	120.0	-7.7		80.0	-11.1		80.0	-4.8	120.0	-14.3	80.0	-11.1	84.0	-12.5
			26	115.0	-11.5		80.0	-11.1		80.0	-4.8	125.0	-10.7	95.0	5.6	95.0	-1.0
			28	130.0	7.7		80.0	-11.1		76.0	-9.5	130.0	-7.1	80.0	-11.1	84.0	-12.5
			30	140.0	7.7		80.0	-11.1		86.0	2.4	130.0	-14.3	95.0	5.6	92.0	-4.2
			32	140.0	7.7		80.0	0.0		82.0	-2.4	130.0	-7.1	80.0	-11.1	86.0	-10.4
			34	140.0	7.7		80.0	-11.1		72.0	-14.3	130.0	-7.1	85.0	-5.6	70.0	-27.1
			36	140.0	7.7		80.0	-11.1		82.0	-2.4	140.0	0.0	85.0	-5.6	84.0	-12.5
			38	130.0	0.0		80.0	-11.1		86.0	2.4	130.0	-7.1	80.0	-11.1	86.0	-10.4
			40	140.0	7.7		90.0	0.0		96.0	14.3	150.0	7.1	100.0	11.1	100.0	4.2
			42	140.0	7.7		100.0	11.1		80.0	-4.8	150.0	7.1	100.0	11.1	92.0	-4.2
			44	140.0	7.7		80.0	-11.1		78.0	-7.1	130.0	-7.1	80.0	-11.1	80.0	-16.7
			46	120.0	-7.7		100.0	11.1		84.0	0.0	140.0	0.0	100.0	11.1	110.0	14.6
			48	140.0	7.7		100.0	11.1		82.0	-2.4	150.0	7.1	110.0	22.2	96.0	0.0
50	140.0	7.7		100.0	11.1		78.0	-7.1	140.0	0.0	100.0	11.1	84.0	-12.5			
52	140.0	7.7		70.0	0.0		80.0	0.0	130.0	-11.5	70.0	-14.3	80.0	0.0			
13	217	DF	-1	140.0	-14.3		70.0	0.0	80.0	-2.5	115.0	-11.5	70.0	-15.6	76.0	-15.6	
			0	120.0	-14.3		80.0	14.3		82.0	2.5	115.0	-11.5	80.0	14.3	106.0	17.6
			1	120.0	-14.3		70.0	0.0		75.0	-6.3	100.0	-23.1	60.0	-33.3	60.0	-33.3
			2	120.0	-14.3		80.0	14.3		80.0	0.0	120.0	-7.7	80.0	14.3	90.0	0.0
			3	120.0	-14.3		80.0	14.3		84.0	5.0	115.0	-11.5	80.0	14.3	106.0	17.6
			4	125.0	-10.7		80.0	14.3		75.0	-6.3	120.0	-7.7	80.0	14.3	90.0	0.0
			5	120.0	-14.3		70.0	0.0		84.0	5.0	120.0	-7.7	90.0	14.3	108.0	20.0
			6	120.0	-14.3		70.0	0.0		80.0	0.0	130.0	0.0	90.0	28.6	108.0	20.0
			8	130.0	-7.1		80.0	28.6		80.0	0.0	120.0	-7.7	90.0	28.6	100.0	11.1
			10	115.0	-17.9		80.0	14.3		60.0	-25.0	115.0	-11.5	70.0	0.0	80.0	-11.1
			12	120.0	-14.3		80.0	14.3		80.0	0.0	130.0	0.0	80.0	14.3	85.0	0.0
			14	130.0	-7.1		80.0	14.3		80.0	0.0	130.0	0.0	80.0	14.3	90.0	0.0
			16	120.0	-14.3		80.0	28.6		64.0	-20.0	110.0	-15.4	70.0	0.0	72.0	-20.0
			18	130.0	-7.1		60.0	-14.3		76.0	-5.0	110.0	-15.4	70.0	0.0	84.0	-6.7
20	110.0	-21.4															

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 beats/min
 H.R. values <= 50 beats/min

2482

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING				STANDING										
				S.B.P.	% diff	D.B.P.	% diff	H.R.	% diff	S.B.P.	% diff	D.B.P.	% diff	H.R.	% diff			
13	217	DF	22	120.0	-14.3	80.0	14.3	95.0	18.8	120.0	-7.7	80.0	14.3	100.0	11.1			
			24	120.0	-14.3	70.0	0.0	110.0	37.5	115.0	-11.5	70.0	0.0	116.0	28.9			
			26	115.0	-17.9	80.0	14.3	76.0	-5.0	120.0	-7.7	80.0	14.3	80.0	-11.1			
			28	100.0	-28.6	80.0	0.0	84.0	5.0	100.0	-23.1	70.0	0.0	120.0	33.3			
			30	100.0	-28.6	60.0	-14.3	80.0	0.0	115.0	-11.5	70.0	0.0	90.0	0.0			
			32	100.0	-28.6	60.0	-14.3	80.0	0.0	115.0	-11.5	70.0	0.0	90.0	0.0			
			34	120.0	-14.3	80.0	14.3	80.0	0.0	120.0	-7.7	80.0	14.3	90.0	5.6			
			36	120.0	-14.3	70.0	0.0	84.0	5.0	110.0	-15.4	70.0	0.0	90.0	0.0			
			40	120.0	-14.3	80.0	14.3	80.0	0.0	100.0	-23.1	70.0	0.0	100.0	11.1			
			42	115.0	-17.9	80.0	14.3	64.0	-20.0	115.0	-11.5	70.0	0.0	92.0	2.2			
			44	120.0	-14.3	80.0	14.3	70.0	0.0	100.0	-23.1	70.0	0.0	75.0	-16.7			
			46	120.0	-14.3	80.0	14.3	90.0	12.5	110.0	-15.4	70.0	0.0	110.0	22.2			
			48	110.0	-21.4	80.0	0.0	84.0	5.0	90.0	-30.8	80.0	14.3	100.0	11.1			
			50	120.0	-14.3	70.0	0.0	86.0	7.5	110.0	-15.4	70.0	0.0	90.0	0.0			
			52	110.0	-21.4	60.0	-14.3	68.0	-15.0	100.0	-23.1	70.0	0.0	80.0	0.0			
			218	GSM		-1	140.0	0.0	90.0	0.0	100.0	0.0	130.0	0.0	90.0	0.0	100.0	0.0
						1	110.0	-21.4	70.0	-22.2	86.0	-14.0	120.0	-7.7	70.0	0.0	100.0	0.0
						2	120.0	-14.3	80.0	-11.1	86.0	-14.0	130.0	0.0	80.0	-22.2	100.0	0.0
						3	120.0	-14.3	80.0	-11.1	86.0	-14.0	130.0	0.0	80.0	-11.1	96.0	-4.0
						4	115.0	-17.9	70.0	-22.2	104.0	4.0	100.0	-23.1	70.0	-22.2	120.0	20.0
						5	130.0	-7.1	80.0	-11.1	120.0	20.0	130.0	0.0	70.0	-22.2	128.0	28.0
						6	115.0	-17.9	80.0	-11.1	84.0	-16.0	110.0	-15.4	70.0	-22.2	100.0	0.0
						8	140.0	0.0	80.0	-11.1	84.0	-16.0	120.0	-7.7	80.0	-11.1	89.0	-11.0
						10	110.0	-21.4	60.0	-33.3	80.0	-20.0	95.0	-26.9	60.0	-33.3	100.0	0.0
						14	110.0	-21.4	70.0	-22.2	98.0	-2.0	100.0	-7.7	80.0	-11.1	100.0	0.0
						16	100.0	-28.6	70.0	-22.2	84.0	-16.0	100.0	-23.1	70.0	-22.2	104.0	4.0
						18	110.0	-21.4	80.0	-11.1	84.0	-16.0	110.0	-15.4	70.0	-22.2	88.0	-12.0
						20	120.0	-14.3	70.0	-22.2	88.0	-12.0	90.0	-30.8	70.0	-22.2	100.0	0.0
						22	120.0	-14.3	70.0	-22.2	96.0	-4.0	100.0	-30.8	60.0	-33.3	120.0	20.0
			24	115.0	-17.9	70.0	-22.2	104.0	4.0	90.0	-23.1	70.0	-22.2	112.0	12.0			
			26	100.0	-28.6	80.0	-11.1	76.0	-24.0	100.0	-23.1	70.0	-22.2	80.0	-20.0			
			28	115.0	-17.9	80.0	-11.1	100.0	0.0	120.0	-7.7	80.0	-11.1	120.0	20.0			
30	110.0	-21.4	70.0	-22.2	68.0	-32.0	100.0	-23.1	70.0	-22.2	80.0	-20.0						
32	130.0	-7.1	90.0	0.0	80.0	-20.0	130.0	0.0	70.0	-22.2	85.0	-15.0						
34	130.0	-7.1	80.0	-11.1	64.0	-16.0	120.0	-7.7	80.0	-11.1	92.0	8.0						
36	120.0	-14.3	80.0	-11.1	76.0	-24.0	120.0	-7.7	80.0	-11.1	76.0	-24.0						

** S.B.P. values >= 160 mm Hg
 D.B.P. values >= 100 mm Hg
 H.R. values >= 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 beats/min
 H.R. values <= 50 beats/min

24000

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING			STANDING								
				S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	H.R.	% diff				
13	218	GSM	38	130.0	-7.1	80.0	-11.1	90.0	-10.0	115.0	-11.5	80.0	-11.1	95.0	-5.0
			40	120.0	-14.3	80.0	-11.1	84.0	-16.0	115.0	-11.5	70.0	-22.2	88.0	-12.0
			42	140.0	0.0	80.0	-11.1	88.0	-12.0	130.0	0.0	80.0	-11.1	96.0	-4.0
			44	120.0	-14.3	80.0	-11.1	120.0	20.0	130.0	0.0	90.0	0.0	125.0	25.0
			46	140.0	0.0	90.0	0.0	80.0	-20.0	130.0	0.0	90.0	0.0	85.0	-15.0
			48	150.0	7.1	80.0	-11.1	88.0	-12.0	150.0	15.4	90.0	0.0	100.0	0.0
			50	120.0	-14.3	80.0	-11.1	84.0	-16.0	120.0	-7.7	90.0	0.0	88.0	-12.0
			52	120.0	-14.3	80.0	-11.1	80.0	-20.0	100.0	-23.1	60.0	-33.3	88.0	-12.0
	222	RG	-1	120.0	16.7	80.0	12.5	92.0	-19.6	120.0	8.3	90.0	-11.1	92.0	0.0
			1	120.0	0.0	80.0	0.0	80.0	-13.0	120.0	0.0	80.0	0.0	98.0	6.5
			2	110.0	-8.3	70.0	-12.5	76.0	-17.4	120.0	0.0	80.0	-11.1	88.0	-4.3
			3	100.0	-16.7	70.0	-12.5	92.0	0.0	110.0	-8.3	70.0	-22.2	112.0	21.7
			4	115.0	-4.2	70.0	-12.5	70.0	-23.2	110.0	-8.3	70.0	-22.2	92.0	0.0
			5	115.0	-4.2	80.0	0.0	86.0	-6.5	115.0	-4.2	80.0	-11.1	90.0	-2.2
			6	130.0	8.3	70.0	-12.5	76.0	-17.4	110.0	-8.3	80.0	-11.1	92.0	0.0
			8	130.0	8.3	70.0	-12.5	76.0	-17.4	120.0	0.0	80.0	-11.1	92.0	0.0
			10	120.0	0.0	70.0	-12.5	72.0	-21.7	110.0	-8.3	70.0	-22.2	76.0	-17.4
			12	120.0	0.0	90.0	-12.5	72.0	-21.7	110.0	-8.3	80.0	-11.1	88.0	-4.3
			14	130.0	8.3	90.0	-12.5	70.0	-23.9	110.0	-8.3	80.0	-11.1	80.0	-13.0
			16	120.0	0.0	70.0	-12.5	72.0	-21.7	120.0	0.0	80.0	-11.1	80.0	-13.0
			18	120.0	0.0	90.0	-12.5	72.0	-21.7	110.0	-8.3	70.0	-22.2	80.0	-13.0
			20	130.0	8.3	80.0	0.0	76.0	-17.4	115.0	-4.2	80.0	-11.1	84.0	-8.7
			22	120.0	0.0	80.0	0.0	64.0	-30.4	100.0	-16.7	60.0	-33.3	80.0	-13.0
			24	110.0	-8.3	70.0	-12.5	88.0	-4.3	100.0	-16.7	60.0	-33.3	80.0	-13.0
			26	105.0	-4.2	60.0	-25.0	60.0	-34.8	115.0	-4.2	70.0	-22.2	68.0	-26.1
			28	115.0	-4.2	70.0	-12.5	60.0	-34.8	100.0	-16.7	60.0	-33.3	76.0	-17.4
			30	100.0	-16.7	60.0	-25.0	60.0	-30.4	90.0	-25.0	60.0	-33.3	68.0	-26.1
			32	90.0	-25.0	60.0	-25.0	64.0	-30.4	100.0	-16.7	70.0	-22.2	75.0	-18.5
			34	110.0	-8.3	70.0	-12.5	70.0	-23.9	100.0	-16.7	70.0	-22.2	80.0	-13.0
			36	100.0	-16.7	60.0	-25.0	60.0	-34.8	100.0	-16.7	60.0	-33.3	80.0	-13.0
			38	100.0	-16.7	80.0	0.0	60.0	-34.8	100.0	-16.7	60.0	-33.3	80.0	-13.0
			40	100.0	-16.7	80.0	0.0	64.0	-30.4	100.0	-16.7	60.0	-33.3	70.0	-23.9
			42	100.0	-16.7	70.0	-12.5	64.0	-30.4	100.0	-16.7	60.0	-33.3	72.0	-21.7
			44	120.0	0.0	80.0	0.0	60.0	-34.8	100.0	-16.7	70.0	-22.2	65.0	-29.3
			46	115.0	-4.2	80.0	0.0	60.0	-34.8	110.0	-8.3	80.0	-11.1	70.0	-23.9
			48	120.0	0.0	80.0	0.0	60.0	-34.8	115.0	-4.2	70.0	-22.2	100.0	8.7
			50	110.0	-8.3	80.0	0.0	84.0	-8.7	110.0	-8.3	70.0	-22.2	92.0	0.0
			52	120.0	0.0	80.0	0.0	74.0	-19.6	110.0	-8.3	70.0	-22.2	92.0	0.0

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 50 mm Hg
H.R. values <= 50 beats/min

2484

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 13.3
 VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
 DOUBLE BLIND PHASE
 TREATMENT: PLACEBO

Centre	Patient	Initial	Visit	LYING				STANDING									
				S.B.P.	% diff	D.B.P.	% diff	H.R.	% diff	S.B.P.	% diff	D.B.P.	% diff	H.R.	% diff		
13	224	TUS	-1	120.0	0.0	80.0	6.3	98.0	0.0	120.0	0.0	75.0	0.0	102.0	2.9		
			0	130.0	8.3	85.0	0.0	110.0	12.2	130.0	8.3	90.0	20.0	105.0	-2.0		
			1	115.0	-4.2	80.0	-18.8	106.0	8.2	95.0	-20.8	60.0	-20.0	116.0	13.7		
			2	120.0	0.0	70.0	-12.5	88.0	-10.2	115.0	-4.2	70.0	-6.7	98.0	-3.9		
			3	120.0	0.0	80.0	0.0	112.0	14.3	110.0	-8.3	70.0	-6.7	126.0	23.5		
			4	120.0	0.0	70.0	-12.5	106.0	8.2	100.0	-16.7	70.0	-6.7	116.0	13.7		
			5	115.0	-4.2	70.0	-12.5	110.0	12.2	100.0	-16.7	80.0	6.7	100.0	-2.0		
			6	120.0	0.0	70.0	-12.5	80.0	-18.4	100.0	-16.7	70.0	-6.7	90.0	-11.8		
			8	130.0	8.3	80.0	0.0	104.0	6.1	115.0	-4.2	80.0	6.7	120.0	17.8		
			10	115.0	-4.2	70.0	-12.5	100.0	2.0	115.0	-4.2	70.0	-6.7	112.0	5.8		
			12	120.0	0.0	80.0	0.0	98.0	0.0	115.0	-4.2	70.0	-6.7	104.0	2.0		
			14	120.0	0.0	70.0	-12.5	92.0	-6.1	115.0	-4.2	70.0	-6.7	108.0	5.9		
			16	115.0	-4.2	70.0	-12.5	80.0	-18.4	115.0	-4.2	70.0	-6.7	112.0	9.8		
			18	120.0	0.0	80.0	0.0	92.0	-6.1	115.0	-4.2	70.0	-6.7	108.0	5.9		
			20	120.0	0.0	70.0	-12.5	108.0	10.2	115.0	-4.2	70.0	-6.7	116.0	13.7		
			22	120.0	0.0	80.0	0.0	119.0	21.4	100.0	-16.7	70.0	-6.7	124.0	21.6		
			24	100.0	-16.7	70.0	-12.5	104.0	6.1	115.0	-4.2	70.0	-6.7	120.0	17.6		
			26	120.0	0.0	80.0	0.0	72.0	-26.5	100.0	-16.7	70.0	-6.7	80.0	-21.6		
			28	115.0	-4.2	70.0	-12.5	80.0	-18.4	100.0	-16.7	70.0	-6.7	92.0	-9.8		
			30	100.0	-16.7	70.0	-12.5	76.0	-22.4	100.0	-16.7	60.0	-20.0	75.0	-26.5		
			32	100.0	-16.7	70.0	-12.5	76.0	-22.4	100.0	-16.7	60.0	-20.0	84.0	-17.6		
			34	100.0	-16.7	70.0	-12.5	76.0	-22.4	100.0	-16.7	60.0	-20.0	80.0	-21.6		
			36	100.0	-16.7	70.0	-12.5	76.0	-22.4	100.0	-16.7	60.0	-20.0	72.0	-29.4		
			38	100.0	-16.7	70.0	-12.5	76.0	-22.4	100.0	-16.7	60.0	-20.0	80.0	-21.6		
			40	115.0	-4.2	70.0	-12.5	76.0	-22.4	100.0	-16.7	60.0	-20.0	78.0	-23.5		
			42	110.0	-8.3	70.0	-12.5	72.0	-26.5	100.0	-16.7	60.0	-20.0	80.0	-21.6		
			44	100.0	-16.7	70.0	-12.5	69.0	-29.6	100.0	-16.7	60.0	-20.0	65.0	-36.3		
			46	100.0	-16.7	70.0	-12.5	60.0	-38.8	90.0	-25.0	60.0	-20.0	75.0	-26.5		
			48	105.0	-12.5	60.0	-38.8	72.0	-26.5	90.0	-25.0	60.0	-20.0	88.0	-13.7		
			50	120.0	0.0	70.0	-12.5	80.0	-18.4	110.0	-8.3	70.0	-6.7	92.0	-9.8		
			52	110.0	-8.3	80.0	0.0	70.0	-28.6	100.0	-16.7	70.0	-6.7	78.0	-23.5		
			228	PK	-1	140.0	-3.6	80.0	12.5	92.0	-13.0	145.0	0.0	90.0	11.1	96.0	19.8
					0	135.0	-7.1	80.0	0.0	78.0	-15.2	110.0	-24.1	70.0	-22.2	96.0	0.0
					1	130.0	-14.3	70.0	-12.5	100.0	8.7	130.0	-10.3	90.0	0.0	108.0	12.5
					2	120.0	-14.3	80.0	0.0	80.0	-13.0	140.0	-17.2	90.0	0.0	90.0	-6.5
					3	140.0	0.0	80.0	0.0	80.0	-13.0	160.0	0.0	90.0	0.0	100.0	4.2
					4	130.0	-7.1	80.0	0.0	90.0	-2.2	115.0	-20.7	80.0	-11.1	100.0	4.2
			5	120.0	-14.3	80.0	0.0	80.0	-15.0	115.0	-20.7	90.0	0.0	110.0	14.6		

** S.B.P. values => 160 mm Hg
 D.B.P. values => 100 mm Hg
 H.R. values => 100 beats/min
 * S.B.P. values <= 70 mm Hg
 D.B.P. values <= 50 mm Hg
 H.R. values <= 50 beats/min

24 00 07

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 13.3

VITAL SIGNS CHANGES OF CLINICAL RELEVANCE
DOUBLE BLIND PHASE
TREATMENT: PLACERO

Centre	Patient	Initial Visit	LIVING				STANDING									
			S.B.P.	% diff	H.R.	% diff	D.B.P.	% diff	S.B.P.	% diff	H.R.	% diff				
13	228	PK	8	130.0	-7.1	80.0	-13.0	130.0	-10.3	90.0	0.0	90.0	-6.3			
			10	120.0	-14.3	80.0	-17.4	115.0	-20.7	90.0	0.0	104.0	8.3			
			12	130.0	-7.1	70.0	-26.1	120.0	-17.2	90.0	0.0	80.0	-16.7			
			14	110.0	-21.4	70.0	-15.2	100.0	-31.0	70.0	-22.2	89.0	-7.3			
			16	110.0	-21.4	80.0	-23.9	115.0	-20.7	90.0	0.0	75.0	-21.9			
			18	110.0	-21.4	80.0	-29.3	120.0	-17.2	90.0	0.0	80.0	-16.7			
			20	110.0	-21.4	70.0	-21.7	120.0	-17.2	90.0	0.0	100.0	4.2			
			22	100.0	-28.6	70.0	-4.3	115.0	-20.7	80.0	-11.1	110.0	14.6			
			24	130.0	-7.1	80.0	-4.3	120.0	-17.2	90.0	0.0	96.0	0.0			
			26	115.0	-17.9	70.0	-13.0	115.0	-20.7	70.0	-22.2	104.0	8.3			
			28	120.0	-14.3	80.0	4.3	120.0	-17.2	90.0	0.0	104.0	8.3			
			30	140.0	0.0	80.0	-13.0	115.0	-20.7	70.0	-22.2	98.0	2.1			
			229	SZS		-1	130.0	-7.7	82.0	2.4	135.0	0.0	90.0	0.0	88.0	9.1
						0	120.0	-7.7	80.0	-2.4	135.0	0.0	90.0	0.0	96.0	9.1
						1	120.0	-7.7	80.0	-2.4	110.0	-18.5	70.0	-22.2	104.0	18.2
						2	120.0	-7.7	80.0	-2.4	110.0	-18.5	70.0	-22.2	104.0	18.2
						3	120.0	-7.7	80.0	2.4	110.0	-18.5	70.0	-22.2	106.0	20.5
						4	120.0	-7.7	80.0	2.4	110.0	-18.5	70.0	-22.2	106.0	20.5
						5	120.0	-7.7	80.0	-2.4	100.0	-25.9	70.0	-22.2	100.0	13.6
						6	120.0	-7.7	80.0	-11.1	115.0	-14.8	70.0	-22.2	88.0	0.0
						8	130.0	0.0	80.0	-2.4	140.0	3.7	90.0	0.0	100.0	13.6
						10	120.0	-7.7	72.0	-12.2	140.0	3.7	90.0	0.0	80.0	-9.1
						12	140.0	7.7	76.0	-7.3	145.0	7.4	100.0	11.1	60.0	-31.8
						14	120.0	-7.7	66.0	-19.5	120.0	-11.1	60.0	-33.3	84.0	-4.5
			16	160.0	23.1	80.0	-2.4	180.0	33.3	100.0	11.1	100.0	13.6			
			18	140.0	7.7	84.0	2.4	140.0	3.7	90.0	0.0	96.0	9.1			
			20	130.0	0.0	80.0	-2.4	120.0	-11.1	80.0	-11.1	100.0	13.6			

2486

** S.B.P. values >= 160 mm Hg
D.B.P. values >= 100 mm Hg
H.R. values >= 100 beats/min
* S.B.P. values <= 70 mm Hg
D.B.P. values <= 50 mm Hg
H.R. values <= 50 beats/min

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 14.1
 ECG TRACINGS: PATIENTS ALWAYS NORMAL
 OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value
1	1	NGA	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	2	RAQ	Male	Screen weeks 0-2	Normal
				Screen weeks 0-2	Normal
	3	TA	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	4	DNC	Female	Screen weeks 0-2	Normal
Screen weeks 3-4				Normal	
Screen weeks 5-6				Normal	
5	DB	Female	Screen weeks 0-2	Normal	
			Screen weeks 3-4	Normal	
			Screen weeks 5-6	Normal	
6	CFM	Female	Screen weeks 0-2	Normal	
			Screen weeks 3-4	Normal	
			Screen weeks 5-6	Normal	
7	JSA	Male	Screen weeks 0-2	Normal	
			Screen weeks 0-2	Normal	
8	MYB	Male	Screen weeks 0-2	Normal	
			Screen weeks 3-4	Normal	
			Screen weeks 5-6	Normal	
9	CCR	Male	Screen weeks 0-2	Normal	
			Screen weeks 3-4	Normal	
			Screen weeks 5-6	Normal	

2487

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 14.1
 ECG TRACINGS: PATIENTS ALWAYS NORMAL
 OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value
1	10	LDL	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal Normal
	11	VRT	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal
	12	SLT	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal Normal
	13	JR	Female	Screen weeks 0-2	Normal Normal
	14	MLC	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal Normal
	15	MAO	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal Normal
	17	CEC	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal Normal
	18	ITH	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal Normal
	19	SR	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal Normal

2488

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 14.1
 ECG TRACINGS: PATIENTS ALWAYS NORMAL
 OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value
1	22	SK	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	23	AR	Female	Screen weeks 0-2	Normal
				Screen weeks 0-2	Normal
	25	AHR	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	26	OC	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	27	RK	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	29	AFO	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	30	ERV	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	31	MAN	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	32	DCM	Female	Screen weeks 0-2	Normal
				Screen weeks 0-2	Normal

2489

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value
1	32	DGM	Female	Screen weeks 3-4 Screen weeks 5-6	Normal Normal
	33	OFC	Male	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal
	34	CHR	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal
	35	EMP	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal
	36	LN	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal
	37	RF	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal
	38	DBF	Male	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal
	39	ASS	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal
	40	EM	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal

2490

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS R8D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value
1	41	SFS	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	42	ICC	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	43	ARN	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	44	MAL	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	45	DPS	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	46	SP	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	47	MCS	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	48	SCH	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal

2491

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 14.1
 ECG TRACINGS: PATIENTS ALWAYS NORMAL
 OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value
1	49	DAS	Female	Screen weeks 0-2	Normal Normal
	50	MFA	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal Normal
	51	ASA	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal Normal
	52	MTS	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal Normal
	53	JTF	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal Normal
	54	JD	Female	Screen weeks 0-2 Screen weeks 3-4	Normal Normal Normal
	55	DMG	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal Normal
	56	IAL	Male	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal Normal
	58	ARM	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal Normal

2492

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
OPEN PHASE

Centre	Patient	Initials	Sex	Time Interval	E. C. G. value
1	59	SPF	Female	Screen weeks 0-2	Normal
				weeks 3-4	Normal
				weeks 5-6	Normal
	60	EM	Male	Screen weeks 0-2	Normal
				weeks 3-4	Normal
				weeks 5-6	Normal
	61	HVC	Female	Screen weeks 0-2	Normal
				weeks 3-4	Normal
				weeks 5-6	Normal
	62	MEA	Female	Screen weeks 0-2	Normal
				weeks 3-4	Normal
				weeks 5-6	Normal
	63	JCL	Male	Screen weeks 0-2	Normal
					Normal
	64	EMF	Female	Screen weeks 0-2	Normal
				weeks 3-4	Normal
				weeks 5-6	Normal
	65	FS	Male	Screen weeks 0-2	Normal
				weeks 3-4	Normal
				weeks 5-6	Normal
	66	TCG	Female	Screen weeks 0-2	Normal
				weeks 3-4	Normal
				weeks 5-6	Normal
	67	WAA	Female	Screen weeks 0-2	Normal
					Normal

2482

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 14.1
 ECG TRACINGS: PATIENTS ALWAYS NORMAL
 OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value
1	67	MAA	Female	Screen weeks 3-4 Screen weeks 5-6	Normal Normal
	68	MGS	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal
	69	RFA	Male	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal
	70	MLM	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal
	71	ONV	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal
	72	RLJ	Male	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal
	73	FMA	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal
	74	IVL	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal
	75	SFA	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal

2494

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value
1	77	ACG	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	78	SD	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	79	JCM	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
80	MEL	Female	Screen weeks 0-2	Normal	
			Screen weeks 3-4	Normal	
			Screen weeks 5-6	Normal	
81	MFB	Female	Screen weeks 0-2	Normal	
			Screen weeks 3-4	Normal	
			Screen weeks 5-6	Normal	
82	NDS	Female	Screen weeks 0-2	Normal	
			Screen weeks 3-4	Normal	
			Screen weeks 5-6	Normal	
83	LPM	Female	Screen weeks 0-2	Normal	
			Screen weeks 3-4	Normal	
			Screen weeks 5-6	Normal	
84	IN	Male	Screen weeks 0-2	Normal	
			Screen weeks 3-4	Normal	
			Screen weeks 5-6	Normal	

2495

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
 Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
 OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value
1	85	MLP	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	86	MTF	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	87	MDO	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	88	VRL	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	89	NMV	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	90	JSS	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	91	MSC	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	92	PSS	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	93	AL	Female	Screen weeks 0-2	Normal
				Screen weeks 0-2	Normal

2496

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

EKG TRACINGS: PATIENTS ALWAYS NORMAL
OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value
1	93	AL	Female	Screen weeks 3-4 Screen weeks 5-6	Normal Normal
	94	RAB	Male	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal
	95	GHT	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal
	96	SPM	Male	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal
	97	MND	Male	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal
	98	YTT	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal
	99	LGD	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal
	100	JHA	Male	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal
	101	JLL	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal

2497

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXYTINE - PROTOCOL 20124/013
 Listing No.: 14.1
 ECC TRACINGS: PATIENTS ALWAYS NORMAL
 OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value
1	102	ESF	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	104	MIF	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	105	ABS	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	106	MRN	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	107	LAN	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	108	STB	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	109	IPL	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	110	TQO	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal

2498

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 14.1
 ECG TRACINGS: PATIENTS ALWAYS NORMAL
 OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value
1	111	JBF	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	112	PSA	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	113	LFS	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
114	CLF	Female	Screen weeks 0-2	Normal	
			Screen weeks 3-4	Normal	
			Screen weeks 5-6	Normal	
115	ELS	Female	Screen weeks 0-2	Normal	
			Screen weeks 3-4	Normal	
			Screen weeks 5-6	Normal	
116	MGA	Female	Screen weeks 0-2	Normal	
			Screen weeks 3-4	Normal	
			Screen weeks 5-6	Normal	
117	PSL	Female	Screen weeks 0-2	Normal	
			Screen weeks 3-4	Normal	
			Screen weeks 5-6	Normal	
118	MYH	Female	Screen weeks 0-2	Normal	
			Screen weeks 3-4	Normal	
			Screen weeks 5-6	Normal	
119	MYN	Female	Screen weeks 0-2	Normal	
			Screen weeks 3-4	Normal	
			Screen weeks 5-6	Normal	

2499

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value
1	119	MYM	Female	Screen weeks 5-6	Normal
	120	JLB	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	121	LAC	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	122	HSS	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	123	MLL	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	124	PPC	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	125	FDP	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	126	SHB	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	127	VPD	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal

2500

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value
1	128	LAM	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	129	MNS	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	130	EGA	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	132	MAT	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	133	JPH	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	134	LHS	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	135	MNS	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	136	AVP	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal

2501

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value
1	138	LBV	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	139	RA	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	140	MCA	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	141	AHG	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	142	SCC	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	143	JEP	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	144	ARF	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	145	SLD	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	146	LRH	Male	Screen weeks 0-2	Normal

2502

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value
1	146	LRM	Male	weeks 3-4	Normal
				weeks 5-6	Normal
	147	JGH	Female	Screen weeks 0-2	Normal
					Normal
	148	CAS	Male	Screen weeks 0-2	Normal
				weeks 3-4	Normal
weeks 5-6				Normal	
149	SC	Female	Screen weeks 0-2	Normal	
			weeks 3-4	Normal	
			weeks 5-6	Normal	
150	VA	Female	Screen weeks 0-2	Normal	
			weeks 3-4	Normal	
			weeks 5-6	Normal	
2	32	GE	Female	Screen weeks 0-2	Normal
					Normal
3	33	HS	Female	Screen weeks 0-2	Normal
					Normal
34	EH	Female	Screen weeks 0-2	Normal	
			weeks 3-4	Normal	
				Normal	
3	1	AMR	Female	Screen weeks 0-2	Normal
				weeks 3-4	Normal
2	FIL	Female	Screen weeks 0-2	Normal	
			weeks 3-4	Normal	
			weeks 5-6	Normal	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXETINE - PROTOCOL 20124/013
 Listing No.: 14.1
 ECG TRACINGS: PATIENTS ALWAYS NORMAL
 OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value
3	3	DUB	Male	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal Normal
	4	AUD	Female	Screen weeks 0-2 Screen weeks 3-4	Normal Normal Normal
	5	MMA	Female	Screen weeks 0-2	Normal Normal
	7	GRI	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal Normal
	9	DEN	Female	Screen weeks 0-2	Normal Normal
	10	TOR	Male	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal Normal
8	2	TE	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal Normal
	6	TL	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal Normal
	7	SZT	Female	Screen weeks 0-2	Normal Normal
9	1	US	Female	Screen weeks 0-2 Screen weeks 3-4	Normal Normal Normal Normal

2504

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD

BEXOMEFINE - PROTOCOL 20124/013
Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value
9	1	US	Female	Screen weeks 5-6	Normal
	2	VCF	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	3	SF	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	4	SA	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	5	MF	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	6	SD	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	7	PP	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	8	KTM	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	9	PL	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value
9	10	BG	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	11	KE	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	12	GVT	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	13	BP	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	15	BI	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	16	UGY	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	18	MBM	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	19	KF	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal

2506

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 14.1
 ECG TRACINGS: PATIENTS ALWAYS NORMAL
 OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value
9	21	TA	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	22	RKE	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	23	SZN	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
24	LGY	Male	Screen weeks 0-2	Normal	
			Screen weeks 3-4	Normal	
			Screen weeks 5-6	Normal	
26	CP	Female	Screen weeks 0-2	Normal	
			Screen weeks 3-4	Normal	
			Screen weeks 5-6	Normal	
28	HI	Male	Screen weeks 0-2	Normal	
			Screen weeks 3-4	Normal	
			Screen weeks 5-6	Normal	
29	SZF	Female	Screen weeks 0-2	Normal	
			Screen weeks 3-4	Normal	
			Screen weeks 5-6	Normal	
10	4	2SD	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
6	RS	Male	Screen weeks 0-2	Normal	
				Normal	
				Normal	

2507

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

EKG TRACINGS: PATIENTS ALWAYS NORMAL
OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E. C. G. value
10	6	RS	Male	weeks 3-4 weeks 5-6	Normal Normal
	7	RK	Male	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal
	9	RT	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal
	10	MH	Female	Screen weeks 0-2 Screen weeks 5-6	Normal Normal
	12	EP	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal
	13	HU	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal
	14	AA	Male	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal
	15	HT	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal
	16	AJ	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal

2508

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXETINE - PROTOCOL 20124/013
 Listing No.: 14.1
 ECG TRACINGS: PATIENTS ALWAYS NORMAL
 OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value
10	20	EJ	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	21	AK	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	23	LT	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	28	LL	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	29	JJ	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	33	EK	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	34	TK	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	42	TT	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal

2509

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 14.1
 ECG TRACINGS: PATIENTS ALWAYS NORMAL
 OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E. C. G. value
10	44	AB	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	46	TN	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	53	MA	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	54	UN	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	59	TA	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	60	JM	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	85	AK	Male	Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
				Screen weeks 0-2	Normal
	86	NP	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	87	AN	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	89	SK	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal

2510

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 BEROXETINE - PROTOCOL 20124/013
 Listing No.: 14.1
 ECG TRACINGS: PATIENTS ALWAYS NORMAL
 OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value
10	89	SK	Female	weeks 3-4	Normal
				weeks 5-6	Normal
	92	LA	Female	Screen weeks 0-2	Normal
				Screen weeks 5-6	Normal
11	1	DF	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
	4	BA	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
	5	ZM	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
	6	VP	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
	7	KK	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
	10	BJ	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
	11	NGY	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
				Screen weeks 5-6	Normal

2511

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value
11	12	PJ	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
13	GK	Female	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
14	BJ	Female	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
15	NF	Female	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
16	NA	Female	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
17	UZ	Female	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
18	EI	Female	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
19	FK	Female	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
20	LJ	Female	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXETINE - PROTOCOL 20124/013
 Listing No.: 14.1
 ECG TRACINGS: PATIENTS ALWAYS NORMAL
 OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value
11	20	LJ	Female	Screen weeks 5-6	Normal
12	2	EFC	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
3	IF	Female	Screen weeks 0-2	Normal	
			Screen weeks 3-4	Normal	
			Screen weeks 5-6	Normal	
7	LK	Male	Screen weeks 0-2	Normal	
			Screen weeks 3-4	Normal	
			Screen weeks 5-6	Normal	
8	FM	Female	Screen weeks 0-2	Normal	
			Screen weeks 3-4	Normal	
			Screen weeks 5-6	Normal	
9	KBP	Female	Screen weeks 0-2	Normal	
			Screen weeks 3-4	Normal	
			Screen weeks 5-6	Normal	
12	FSZ	Female	Screen weeks 0-2	Normal	
			Screen weeks 3-4	Normal	
			Screen weeks 5-6	Normal	
13	ISZ	Female	Screen weeks 0-2	Normal	
			Screen weeks 3-4	Normal	
			Screen weeks 5-6	Normal	
17	TK	Male	Screen weeks 0-2	Normal	
			Screen weeks 3-4	Normal	
			Screen weeks 5-6	Normal	

2513

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 14.1
 ECG TRACINGS: PATIENTS ALWAYS NORMAL
 OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value
12	18	LS	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
20	KSZ	Male	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
21	FL	Female	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
22	HV	Female	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
23	EN	Female	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
24	MF	Female	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
25	FS	Female	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
26	LB	Male	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
29	AK	Female	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal

2514

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value
12	29	AK	Female	Screen weeks 5-6	Normal
	30	FS	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
	31	FH	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	32	LM	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
	33	LN	Female	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
34	TGB	Female	Screen weeks 0-2	Normal	
			Screen weeks 3-4	Normal	
			Screen weeks 5-6	Normal	
37	EK	Female	Screen weeks 0-2	Normal	
			Screen weeks 3-4	Normal	
			Screen weeks 5-6	Normal	
13	4	SZJ	Male	Screen weeks 0-2	Normal
				Screen weeks 3-4	Normal
				Screen weeks 5-6	Normal
5	MF	Female	Screen weeks 0-2	Normal	
			Screen weeks 3-4	Normal	
9	S2S	Male	Screen weeks 0-2	Normal	
			Screen weeks 3-4	Normal	

2515

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
OPEN PHASE

Centre	Patient	Initials	Sex	Time Interval	E. C. G. value
13	9	SZS	Male	weeks 3-4	Normal
				weeks 5-6	Normal
11	HS	Female	Screen	Normal	
			weeks 0-2	Normal	
			weeks 3-4	Normal	
13	HM	Male	Screen	Normal	
			weeks 0-2	Normal	
			weeks 3-4	Normal	
16	SZL	Female	Screen	Normal	
			weeks 0-2	Normal	
			weeks 3-4	Normal	
18	VT	Female	Screen	Normal	
			weeks 0-2	Normal	
			weeks 3-4	Normal	
19	KK	Female	Screen	Normal	
			weeks 0-2	Normal	
			weeks 3-4	Normal	
20	NL	Female	Screen	Normal	
			weeks 0-2	Normal	
			weeks 3-4	Normal	
21	CL	Female	Screen	Normal	
			weeks 0-2	Normal	
			weeks 3-4	Normal	
23	BSB	Female	Screen	Normal	
			weeks 0-2	Normal	
			weeks 3-4	Normal	

2516

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
DOUBLE BLIND PHASE

Centre	Patient	Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value					
1	1	MGA	Placebo	Female	Run In	Screen	Normal					
					Run In	weeks 0-2	Normal					
					Run In	weeks 3-4	Normal					
					Run In	weeks 5-6	Normal					
					D. B.	weeks 7-10	Normal					
					D. B.	weeks 11-18	Normal					
					3	TA		Reboxetine	Female	Run In	Screen	Normal
										Run In	weeks 0-2	Normal
										Run In	weeks 3-4	Normal
										Run In	weeks 5-6	Normal
D. B.	weeks 7-10	Normal										
D. B.	weeks 11-18	Normal										
D. B.	weeks 19-26	Normal										
D. B.	weeks 27-34	Normal										
D. B.	weeks 35-42	Normal										
D. B.	weeks 43-52	Normal										
4	DNC		Reboxetine	Female	Run In	Screen	Normal					
					Run In	weeks 0-2	Normal					
					Run In	weeks 3-4	Normal					
					Run In	weeks 5-6	Normal					
					D. B.	weeks 7-10	Normal					
					D. B.	weeks 11-18	Normal					
					D. B.	weeks 19-26	Normal					
					D. B.	weeks 27-34	Normal					
					D. B.	weeks 35-42	Normal					
					D. B.	weeks 43-52	Normal					
5	DB		Reboxetine	Female	Run In	Screen	Normal					
					Run In	weeks 0-2	Normal					
					Run In	weeks 3-4	Normal					
					Run In	weeks 5-6	Normal					
					D. B.	weeks 7-10	Normal					
					D. B.	weeks 11-18	Normal					
					D. B.	weeks 19-26	Normal					
					D. B.	weeks 27-34	Normal					
					D. B.	weeks 35-42	Normal					
					D. B.	weeks 43-52	Normal					
6	CPH		Placebo	Female	Run In	Screen	Normal					
					Run In	weeks 0-2	Normal					
					Run In	weeks 3-4	Normal					
					Run In	weeks 5-6	Normal					
					D. B.	weeks 7-10	Normal					
					D. B.	weeks 11-18	Normal					

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACTA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 14.1
 ECG TRACINGS: PATIENTS ALWAYS NORMAL
 DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value
1	8 MVB	Placebo	Male	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
				D. B.	weeks 43-52	Normal
9	CCR	Reboxetine	Male	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
				D. B.	weeks 43-52	Normal
10	LDL	Reboxetine	Female	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
				D. B.	weeks 43-52	Normal
11	VRT	Placebo	Female	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
				D. B.	weeks 43-52	Normal
12	SLT	Placebo	Female	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
				D. B.	weeks 43-52	Normal

2513

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

ECC TRACINGS: PATIENTS ALWAYS NORMAL
DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value
1	12 SLT	Placebo	Female	D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
	14 MLC	Reboxetine	Female	Screen		Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
	15 MAO	Placebo	Female	Screen		Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
17 CEC	Reboxetine	Female	D. B.	weeks 7-10	Normal	
			D. B.	weeks 11-18	Normal	
			D. B.	weeks 19-26	Normal	
			D. B.	weeks 27-34	Normal	
	17 CEC	Reboxetine	Female	D. B.	weeks 35-42	Normal
				D. B.	weeks 43-52	Normal
				Screen		Normal
				Run In	weeks 0-2	Normal
	17 CEC	Reboxetine	Female	Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				Run In	weeks 7-10	Normal
				Run In	weeks 11-18	Normal
17 CEC	Reboxetine	Female	D. B.	weeks 19-26	Normal	
			D. B.	weeks 27-34	Normal	
			D. B.	weeks 35-42	Normal	
			D. B.	weeks 43-52	Normal	
18 TTM	Reboxetine	Female	Screen		Normal	
			Run In	weeks 0-2	Normal	
			Run In	weeks 3-4	Normal	
			Run In	weeks 5-6	Normal	
	18 TTM	Reboxetine	Female	D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
	18 TTM	Reboxetine	Female	Screen		Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
18 TTM	Reboxetine	Female	D. B.	weeks 7-10	Normal	
			D. B.	weeks 11-18	Normal	
			D. B.	weeks 19-26	Normal	
			D. B.	weeks 27-34	Normal	
19 SR	Placebo	Female	Screen		Normal	
			Run In	weeks 0-2	Normal	
			Run In	weeks 3-4	Normal	
			Run In	weeks 5-6	Normal	
	19 SR	Placebo	Female	D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
	19 SR	Placebo	Female	Screen		Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
19 SR	Placebo	Female	D. B.	weeks 7-10	Normal	
			D. B.	weeks 11-18	Normal	
			D. B.	weeks 19-26	Normal	
			D. B.	weeks 27-34	Normal	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 14.1
 ECG TRACINGS: PATIENTS ALWAYS NORMAL
 DOUBLE BLIND PHASE

Centre	Patient	Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value					
1	22	SK	Reboxetine	Female	Run In	Screen	Normal					
					Run In	weeks 0-2	Normal					
					Run In	weeks 3-4	Normal					
					Run In	weeks 5-6	Normal					
					D. B.	weeks 7-10	Normal					
					D. B.	weeks 11-18	Normal					
					D. B.	weeks 19-26	Normal					
					D. B.	weeks 27-34	Normal					
					D. B.	weeks 35-42	Normal					
					D. B.	weeks 43-52	Normal					
					25	AMR		Reboxetine	Female	Run In	Screen	Normal
										Run In	weeks 0-2	Normal
										Run In	weeks 3-4	Normal
										Run In	weeks 5-6	Normal
										D. B.	weeks 7-10	Normal
D. B.	weeks 11-18	Normal										
D. B.	weeks 19-26	Normal										
D. B.	weeks 27-34	Normal										
D. B.	weeks 35-42	Normal										
D. B.	weeks 43-52	Normal										
26	OC		Placebo	Female						Run In	Screen	Normal
										Run In	weeks 0-2	Normal
										Run In	weeks 3-4	Normal
										Run In	weeks 5-6	Normal
										D. B.	weeks 7-10	Normal
					D. B.	weeks 11-18	Normal					
					D. B.	weeks 19-26	Normal					
					D. B.	weeks 27-34	Normal					
					D. B.	weeks 35-42	Normal					
					D. B.	weeks 43-52	Normal					
					27	RK		Placebo	Male	Run In	Screen	Normal
										Run In	weeks 0-2	Normal
										Run In	weeks 3-4	Normal
										Run In	weeks 5-6	Normal
										D. B.	weeks 7-10	Normal
29	AFO		Placebo	Female						Run In	Screen	Normal
										Run In	weeks 0-2	Normal
										Run In	weeks 3-4	Normal
										Run In	weeks 5-6	Normal
										D. B.	weeks 7-10	Normal

2520

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 44.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value	
1	29	Placebo	Female	D. B.	weeks 11-18	Normal	
					weeks 19-26	Normal	
					weeks 27-34	Normal	
					weeks 35-42	Normal	
	30	Placebo	Male	D. B.	weeks 43-52	Normal	
					Screen	Normal	
					Run In weeks 0-2	Normal	
					Run In weeks 3-4	Normal	
	31	31	Reboxetine	Female	D. B.	weeks 5-6	Normal
						weeks 7-10	Normal
						weeks 11-18	Normal
						weeks 19-26	Normal
32		Reboxetine	Female	D. B.	weeks 27-34	Normal	
					weeks 35-42	Normal	
					weeks 43-52	Normal	
					Screen	Normal	
32		32	Reboxetine	Female	D. B.	weeks 0-2	Normal
						weeks 3-4	Normal
						weeks 5-6	Normal
						weeks 7-10	Normal
	33	Placebo	Male	D. B.	weeks 11-18	Normal	
					weeks 19-26	Normal	
					weeks 27-34	Normal	
					weeks 35-42	Normal	
	34	Reboxetine	Female	D. B.	weeks 43-52	Normal	
					Screen	Normal	
					Run In weeks 0-2	Normal	
					Run In weeks 3-4	Normal	
33	Placebo	Male	D. B.	weeks 5-6	Normal		
				weeks 7-10	Normal		
				Screen	Normal		
				Run In weeks 0-2	Normal		
34	Reboxetine	Female	D. B.	weeks 3-4	Normal		
				weeks 5-6	Normal		
				weeks 7-10	Normal		
				Screen	Normal		
34	Reboxetine	Female	D. B.	weeks 0-2	Normal		
				weeks 3-4	Normal		
				weeks 5-6	Normal		
				weeks 7-10	Normal		

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value
1	34	Reboxetine	Female	D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
	35	Reboxetine	Female	Screen		Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
36	36	Placebo	Female	Screen		Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
	37	Reboxetine	Female	Screen		Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
38	38	Placebo	Male	Screen		Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
	39	Reboxetine	Female	D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
				D. B.	weeks 43-52	Normal
				D. B.	weeks 43-52	Normal
				D. B.	weeks 43-52	Normal

2522

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RSD
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 14.1
 ECG TRAININGS: PATIENTS ALWAYS NORMAL
 DOUBLE BLIND PHASE

Centre	Patient	Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value
1	39	ASS	Reboxetine	Female	Run In	Screen	Normal
					Run In	weeks 0-2	Normal
					Run In	weeks 3-4	Normal
					Run In	weeks 5-6	Normal
					D. B.	weeks 7-10	Normal
					D. B.	weeks 11-18	Normal
					D. B.	weeks 19-26	Normal
					D. B.	weeks 27-34	Normal
					D. B.	weeks 35-42	Normal
					D. B.	weeks 43-52	Normal
					D. B.	Screen	Normal
					40	EM	
					Run In	weeks 0-2	Normal
					Run In	weeks 3-4	Normal
					Run In	weeks 5-6	Normal
					D. B.	weeks 7-10	Normal
					D. B.	weeks 11-18	Normal
					D. B.	weeks 19-26	Normal
					D. B.	weeks 27-34	Normal
					D. B.	weeks 35-42	Normal
					D. B.	weeks 43-52	Normal
41	SFS		Placebo	Male	Run In	Screen	Normal
					Run In	weeks 0-2	Normal
					Run In	weeks 3-4	Normal
					Run In	weeks 5-6	Normal
					D. B.	weeks 7-10	Normal
					D. B.	weeks 11-18	Normal
					D. B.	weeks 19-26	Normal
					D. B.	weeks 27-34	Normal
					D. B.	weeks 35-42	Normal
					D. B.	weeks 43-52	Normal
					D. B.	Screen	Normal
					43	ARN	
					Run In	weeks 0-2	Normal
					Run In	weeks 3-4	Normal
					Run In	weeks 5-6	Normal
					D. B.	weeks 7-10	Normal
					D. B.	weeks 11-18	Normal
					D. B.	weeks 19-26	Normal
					D. B.	weeks 27-34	Normal
					D. B.	weeks 35-42	Normal
					D. B.	weeks 43-52	Normal
45	DPS		Reboxetine	Female	Run In	Screen	Normal
					Run In	weeks 0-2	Normal
					Run In	weeks 3-4	Normal
					Run In	weeks 3-4	Normal

21 22 23

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value
1	45	DPS	Female	Reboxetine	Run In	Normal
				D. B.	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
	46	SP	Female	Reboxetine	Run In	Normal
				D. B.	Screen	Normal
				D. B.	weeks 0-2	Normal
				D. B.	weeks 3-4	Normal
				D. B.	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
47	MCS	Female	Placebo	Run In	Normal	
			D. B.	Screen	Normal	
			D. B.	weeks 0-2	Normal	
			D. B.	weeks 3-4	Normal	
			D. B.	weeks 5-6	Normal	
			D. B.	weeks 7-10	Normal	
	48	SCM	Female	Reboxetine	Run In	Normal
				D. B.	Screen	Normal
				D. B.	weeks 0-2	Normal
				D. B.	weeks 3-4	Normal
				D. B.	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
50	MFA	Female	Placebo	Run In	Normal	
			D. B.	Screen	Normal	
			D. B.	weeks 0-2	Normal	
			D. B.	weeks 3-4	Normal	
			D. B.	weeks 5-6	Normal	
			D. B.	weeks 7-10	Normal	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 14.1
 ECG TRACINGS: PATIENTS ALWAYS NORMAL
 DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value
1	50 MFA	Placebo	Female	D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
51	ASA	Placebo	Female	Screen		Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
				D. B.	weeks 43-52	Normal
				52	MTS	Reboxetine
Run In	weeks 0-2	Normal				
Run In	weeks 3-4	Normal				
Run In	weeks 5-6	Normal				
D. B.	weeks 7-10	Normal				
D. B.	weeks 11-18	Normal				
D. B.	weeks 19-26	Normal				
D. B.	weeks 27-34	Normal				
D. B.	weeks 35-42	Normal				
D. B.	weeks 43-52	Normal				
53	JFT	Placebo	Female			
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
55	DMG	Reboxetine	Female	Screen		Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
58	ARM	Reboxetine	Female	Screen		Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal

2
2
2
2

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

EKG TRACINGS: PATIENTS ALWAYS NORMAL
DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value				
1	59 SPF	Placebo	Female	Run In	Screen	Normal				
				Run In	weeks 0-2	Normal				
				Run In	weeks 3-4	Normal				
				Run In	weeks 5-6	Normal				
				D. B.	weeks 7-10	Normal				
				D. B.	weeks 11-18	Normal				
				D. B.	weeks 19-26	Normal				
				D. B.	weeks 27-34	Normal				
				D. B.	weeks 35-42	Normal				
				D. B.	weeks 43-52	Normal				
				60	EK	Placebo	Male	Run In	Screen	Normal
								Run In	weeks 0-2	Normal
Run In	weeks 3-4	Normal								
Run In	weeks 5-6	Normal								
D. B.	weeks 7-10	Normal								
D. B.	weeks 11-18	Normal								
D. B.	weeks 19-26	Normal								
D. B.	weeks 27-34	Normal								
D. B.	weeks 35-42	Normal								
D. B.	weeks 43-52	Normal								
61	HVC	Reboxetine	Female					Run In	Screen	Normal
								Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal				
				Run In	weeks 5-6	Normal				
				D. B.	weeks 7-10	Normal				
				D. B.	weeks 11-18	Normal				
				D. B.	weeks 19-26	Normal				
				D. B.	weeks 27-34	Normal				
				D. B.	weeks 35-42	Normal				
				D. B.	weeks 43-52	Normal				
				62	MEA	Placebo	Female	Run In	Screen	Normal
								Run In	weeks 0-2	Normal
Run In	weeks 3-4	Normal								
Run In	weeks 5-6	Normal								
D. B.	weeks 7-10	Normal								
D. B.	weeks 11-18	Normal								
D. B.	weeks 19-26	Normal								
D. B.	weeks 27-34	Normal								
D. B.	weeks 35-42	Normal								
D. B.	weeks 43-52	Normal								

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013

Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value				
1	64 EMF	Placebo	Female	Run In	Screen	Normal				
				Run In	weeks 0-2	Normal				
				Run In	weeks 3-4	Normal				
				Run In	weeks 5-6	Normal				
				D. B.	weeks 7-10	Normal				
				D. B.	weeks 11-18	Normal				
				D. B.	weeks 19-26	Normal				
				D. B.	weeks 27-34	Normal				
				D. B.	weeks 35-42	Normal				
				D. B.	weeks 43-52	Normal				
				66	TCG	Reboxetine	Female	Run In	Screen	Normal
								Run In	weeks 0-2	Normal
								Run In	weeks 3-4	Normal
								Run In	weeks 5-6	Normal
								D. B.	weeks 7-10	Normal
D. B.	weeks 11-18	Normal								
D. B.	weeks 19-26	Normal								
D. B.	weeks 27-34	Normal								
D. B.	weeks 35-42	Normal								
D. B.	weeks 43-52	Normal								
67	HAA	Placebo	Female					Run In	Screen	Normal
								Run In	weeks 0-2	Normal
								Run In	weeks 3-4	Normal
								Run In	weeks 5-6	Normal
								D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal				
				D. B.	weeks 19-26	Normal				
				D. B.	weeks 27-34	Normal				
				D. B.	weeks 35-42	Normal				
				D. B.	weeks 43-52	Normal				
				70	MLM	Placebo	Female	Run In	Screen	Normal
								Run In	weeks 0-2	Normal
								Run In	weeks 3-4	Normal
								Run In	weeks 5-6	Normal
								D. B.	weeks 7-10	Normal
D. B.	weeks 11-18	Normal								
D. B.	weeks 19-26	Normal								
71	OHV	Reboxetine	Female					Run In	Screen	Normal
								Run In	weeks 0-2	Normal
								Run In	weeks 3-4	Normal
								Run In	weeks 5-6	Normal
								D. B.	weeks 7-10	Normal
								D. B.	weeks 11-18	Normal
								D. B.	weeks 19-26	Normal
								D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

EKG TRACINGS: PATIENTS ALWAYS NORMAL
DOUBLE BLIND PHASE

Centre	Patient	Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value
1	71	OHV	Reboxetine	Female	D. B.	weeks 43-52	Normal
					Run In	Screen	Normal
					Run In	weeks 0-2	Normal
					Run In	weeks 3-4	Normal
	72	RLJ	Reboxetine	Male	Run In	weeks 0-2	Normal
					Run In	weeks 3-4	Normal
					Run In	weeks 5-6	Normal
					D. B.	weeks 7-10	Normal
	73	FMA	Reboxetine	Female	Run In	weeks 11-18	Normal
					Run In	Screen	Normal
					Run In	weeks 0-2	Normal
					Run In	weeks 3-4	Normal
74	IVL	Placebo	Female	Run In	weeks 5-6	Normal	
				Run In	weeks 7-10	Normal	
				Run In	weeks 11-18	Normal	
				D. B.	weeks 19-26	Normal	
				D. B.	weeks 27-34	Normal	
				D. B.	weeks 35-42	Normal	
				D. B.	weeks 43-52	Normal	
				Screen	weeks 0-2	Normal	
				Run In	weeks 3-4	Normal	
				Run In	weeks 5-6	Normal	
				Run In	weeks 7-10	Normal	
				D. B.	weeks 11-18	Normal	
D. B.	weeks 19-26	Normal					
D. B.	weeks 27-34	Normal					
D. B.	weeks 35-42	Normal					
D. B.	weeks 43-52	Normal					
76	SFA	Placebo	Female	Run In	weeks 0-2	Normal	
				Run In	weeks 3-4	Normal	
				Run In	weeks 5-6	Normal	
				D. B.	weeks 7-10	Normal	
				D. B.	weeks 11-18	Normal	
				D. B.	weeks 19-26	Normal	
				D. B.	weeks 27-34	Normal	
				D. B.	weeks 35-42	Normal	
				D. B.	weeks 43-52	Normal	
				Screen	weeks 0-2	Normal	
				Run In	weeks 3-4	Normal	
				Run In	weeks 5-6	Normal	
D. B.	weeks 7-10	Normal					
D. B.	weeks 11-18	Normal					
D. B.	weeks 19-26	Normal					
D. B.	weeks 27-34	Normal					
D. B.	weeks 35-42	Normal					
D. B.	weeks 43-52	Normal					
77	ACG	Reboxetine	Male	Run In	weeks 0-2	Normal	
				Run In	weeks 3-4	Normal	
				Run In	weeks 5-6	Normal	
				Run In	weeks 7-10	Normal	
				D. B.	weeks 11-18	Normal	
				Screen	weeks 19-26	Normal	
				Run In	weeks 27-34	Normal	
				Run In	weeks 35-42	Normal	
				Run In	weeks 43-52	Normal	
				Screen	weeks 0-2	Normal	
				Run In	weeks 3-4	Normal	
				Run In	weeks 5-6	Normal	
D. B.	weeks 7-10	Normal					
D. B.	weeks 11-18	Normal					

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013

Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value				
1	77	ACG	Male	Reboxetine	D. B.	weeks 19-26	Normal			
					D. B.	weeks 27-34	Normal			
					D. B.	weeks 35-42	Normal			
	79	JCM	Placebo	Male	Screen		Normal			
					Run In	weeks 0-2	Normal			
					Run In	weeks 3-4	Normal			
					Run In	weeks 5-6	Normal			
					D. B.	weeks 7-10	Normal			
					D. B.	weeks 11-18	Normal			
D. B.					weeks 19-26	Normal				
D. B.					weeks 27-34	Normal				
D. B.					weeks 35-42	Normal				
80	NEL	Placebo	Female	Screen		Normal				
				Run In	weeks 0-2	Normal				
				Run In	weeks 3-4	Normal				
				Run In	weeks 5-6	Normal				
				D. B.	weeks 7-10	Normal				
				81	MFB	Reboxetine	Female	Screen		Normal
								Run In	weeks 0-2	Normal
								Run In	weeks 3-4	Normal
								Run In	weeks 5-6	Normal
D. B.	weeks 7-10	Normal								
D. B.	weeks 11-18	Normal								
D. B.	weeks 19-26	Normal								
D. B.	weeks 27-34	Normal								
D. B.	weeks 35-42	Normal								
82	MDS	Reboxetine	Female	Screen		Normal				
				Run In	weeks 0-2	Normal				
				Run In	weeks 3-4	Normal				
				Run In	weeks 5-6	Normal				
				D. B.	weeks 7-10	Normal				
				D. B.	weeks 11-18	Normal				
				D. B.	weeks 19-26	Normal				
				D. B.	weeks 27-34	Normal				
				D. B.	weeks 35-42	Normal				
84	IN	Placebo	Male	Screen		Normal				
				Run In						
				Run In						

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
DOUBLE BLIND PHASE

Centre	Patient	Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value
1	84	IN	Placebo	Male	Run In	weeks 0-2	Normal
					Run In	weeks 3-4	Normal
					Run In	weeks 5-6	Normal
					D. B.	weeks 7-10	Normal
					D. B.	weeks 11-18	Normal
					D. B.	weeks 19-26	Normal
					D. B.	weeks 27-34	Normal
					D. B.	weeks 35-42	Normal
					D. B.	weeks 43-52	Normal
					Screen	weeks 0-2	Normal
					Run In	weeks 3-4	Normal
					Run In	weeks 5-6	Normal
					Run In	weeks 7-10	Normal
					D. B.	weeks 11-18	Normal
					D. B.	weeks 19-26	Normal
D. B.	weeks 27-34	Normal					
D. B.	weeks 35-42	Normal					
D. B.	weeks 43-52	Normal					
85	MLP		Placebo	Male	Run In	Screen	Normal
					Run In	weeks 0-2	Normal
					Run In	weeks 3-4	Normal
					Run In	weeks 5-6	Normal
					D. B.	weeks 7-10	Normal
					D. B.	weeks 11-18	Normal
					D. B.	weeks 19-26	Normal
					D. B.	weeks 27-34	Normal
					D. B.	weeks 35-42	Normal
					D. B.	weeks 43-52	Normal
					Screen	weeks 0-2	Normal
					Run In	weeks 3-4	Normal
					Run In	weeks 5-6	Normal
					Run In	weeks 7-10	Normal
					D. B.	weeks 11-18	Normal
D. B.	weeks 19-26	Normal					
D. B.	weeks 27-34	Normal					
D. B.	weeks 35-42	Normal					
D. B.	weeks 43-52	Normal					
87	MDO		Reboxetine	Female	Run In	Screen	Normal
					Run In	weeks 0-2	Normal
					Run In	weeks 3-4	Normal
					Run In	weeks 5-6	Normal
					D. B.	weeks 7-10	Normal
					D. B.	weeks 11-18	Normal
					D. B.	weeks 19-26	Normal
					D. B.	weeks 27-34	Normal
					D. B.	weeks 35-42	Normal
					D. B.	weeks 43-52	Normal
					Screen	weeks 0-2	Normal
					Run In	weeks 3-4	Normal
					Run In	weeks 5-6	Normal
					Run In	weeks 7-10	Normal
					D. B.	weeks 11-18	Normal
D. B.	weeks 19-26	Normal					
D. B.	weeks 27-34	Normal					
D. B.	weeks 35-42	Normal					
D. B.	weeks 43-52	Normal					
89	NNV		Reboxetine	Female	Run In	Screen	Normal
					Run In	weeks 0-2	Normal
					Run In	weeks 3-4	Normal
					Run In	weeks 5-6	Normal
					D. B.	weeks 7-10	Normal
					D. B.	weeks 11-18	Normal
					D. B.	weeks 19-26	Normal
					D. B.	weeks 27-34	Normal
					D. B.	weeks 35-42	Normal
					D. B.	weeks 43-52	Normal
					Screen	weeks 0-2	Normal
					Run In	weeks 3-4	Normal
					Run In	weeks 5-6	Normal
					Run In	weeks 7-10	Normal
					D. B.	weeks 11-18	Normal
D. B.	weeks 19-26	Normal					
D. B.	weeks 27-34	Normal					
D. B.	weeks 35-42	Normal					
D. B.	weeks 43-52	Normal					
91	MSC		Placebo	Female	Run In	Screen	Normal
					Run In	weeks 0-2	Normal
					Run In	weeks 3-4	Normal
					Run In	weeks 5-6	Normal
					D. B.	weeks 7-10	Normal
					D. B.	weeks 11-18	Normal
					D. B.	weeks 19-26	Normal
					D. B.	weeks 27-34	Normal
					D. B.	weeks 35-42	Normal
					D. B.	weeks 43-52	Normal
					Screen	weeks 0-2	Normal
					Run In	weeks 3-4	Normal
					Run In	weeks 5-6	Normal
					Run In	weeks 7-10	Normal
					D. B.	weeks 11-18	Normal
D. B.	weeks 19-26	Normal					
D. B.	weeks 27-34	Normal					
D. B.	weeks 35-42	Normal					
D. B.	weeks 43-52	Normal					

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 14.1
 ECG TRACINGS: PATIENTS ALWAYS NORMAL
 DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value
1	93 AL	Placebo	Female	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
				D. B.	weeks 43-52	Normal
				Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
D. B.	weeks 11-18	Normal				
D. B.	weeks 19-26	Normal				
D. B.	weeks 27-34	Normal				
D. B.	weeks 35-42	Normal				
D. B.	weeks 43-52	Normal				
95 GMT		Reboxetine	Female	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
				D. B.	weeks 43-52	Normal
				Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
D. B.	weeks 11-18	Normal				
D. B.	weeks 19-26	Normal				
D. B.	weeks 27-34	Normal				
D. B.	weeks 35-42	Normal				
D. B.	weeks 43-52	Normal				
96 SPH		Reboxetine	Male	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
				D. B.	weeks 43-52	Normal
				Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
D. B.	weeks 11-18	Normal				
D. B.	weeks 19-26	Normal				
D. B.	weeks 27-34	Normal				
D. B.	weeks 35-42	Normal				
D. B.	weeks 43-52	Normal				
97 MND		Placebo	Male	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	Screen	Normal

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 44.1
 ECG TRACINGS: PATIENTS ALWAYS NORMAL
 DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value
1	97 MND	Placebo	Male	Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
				D. B.	weeks 43-52	Normal
				Screen	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
98 IYT	98 IYT	Reboxetine	Female	Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
				D. B.	weeks 43-52	Normal
				Screen	weeks 0-2	Normal
100 JWA	100 JWA	Placebo	Male	Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
				D. B.	weeks 43-52	Normal
				Screen	weeks 0-2	Normal
101 JLL	101 JLL	Reboxetine	Female	Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
				D. B.	weeks 43-52	Normal
				Screen	weeks 0-2	Normal
104 MTF	104 MTF	Placebo	Female	Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				Screen	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

ECC TRACINGS: PATIENTS ALWAYS NORMAL
DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value
1	104 MTF	Placebo	Female	D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
				D. B.	weeks 43-52	Normal
	105 ABS	Placebo	Female	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
106 HRN	Placebo	Male	Run In	Screen	Normal	
			Run In	weeks 0-2	Normal	
			Run In	weeks 3-4	Normal	
			Run In	weeks 5-6	Normal	
			D. B.	weeks 7-10	Normal	
			D. B.	weeks 11-18	Normal	
	107 LAN	Reboxetine	Female	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
108 STB	Placebo	Female	Run In	Screen	Normal	
			Run In	weeks 0-2	Normal	
			Run In	weeks 3-4	Normal	
			Run In	weeks 5-6	Normal	
			D. B.	weeks 7-10	Normal	
			D. B.	weeks 11-18	Normal	

21 22 23

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

EKG TRACINGS: PATIENTS ALWAYS NORMAL
DOUBLE BLIND PHASE

Centre	Patient	Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value
1	108	STB	Placebo	Female	D. B.	weeks 19-26	Normal
					D. B.	weeks 27-34	Normal
					D. B.	weeks 35-42	Normal
	109	IPL	Reboxetine	Female	Run In	Screen	Normal
					Run In	weeks 0-2	Normal
					Run In	weeks 3-4	Normal
					Run In	weeks 5-6	Normal
					D. B.	weeks 7-10	Normal
					D. B.	weeks 11-18	Normal
D. B.	weeks 19-26	Normal					
110	TQO	Reboxetine	Female	Run In	Screen	Normal	
				Run In	weeks 0-2	Normal	
				Run In	weeks 3-4	Normal	
				Run In	weeks 5-6	Normal	
				D. B.	weeks 7-10	Normal	
				D. B.	weeks 11-18	Normal	
D. B.	weeks 19-26	Normal					
114	CLF	Placebo	Female	Run In	Screen	Normal	
				Run In	weeks 0-2	Normal	
				Run In	weeks 3-4	Normal	
				Run In	weeks 5-6	Normal	
				D. B.	weeks 7-10	Normal	
				D. B.	weeks 11-18	Normal	
D. B.	weeks 19-26	Normal					
115	ELS	Placebo	Female	Run In	Screen	Normal	
				Run In	weeks 0-2	Normal	
				Run In	weeks 3-4	Normal	
				Run In	weeks 5-6	Normal	
				D. B.	weeks 7-10	Normal	
				D. B.	weeks 11-18	Normal	
D. B.	weeks 19-26	Normal					
D. B.	weeks 27-34	Normal					
D. B.	weeks 35-42	Normal					
D. B.	weeks 43-52	Normal					

2534

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
DOUBLE BLIND PHASE

Centre	Patient	Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value
1	115	ELS	Placebo	Female	D. B. D. B.	weeks 35-42 weeks 43-52	Normal Normal
	116	NGA	Reboxetine	Female	Run In Run In Run In D. B. D. B. D. B. D. B. D. B. D. B.	Screen weeks 0-2 weeks 3-4 weeks 5-6 weeks 7-10 weeks 11-18 weeks 19-26 weeks 27-34 weeks 35-42 weeks 43-52	Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal
	117	PSL	Reboxetine	Female	Run In Run In Run In D. B. D. B. D. B. D. B. D. B. D. B.	Screen weeks 0-2 weeks 3-4 weeks 5-6 weeks 7-10 weeks 11-18 weeks 19-26 weeks 27-34 weeks 35-42 weeks 43-52	Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal
	121	LAC	Reboxetine	Female	Run In Run In Run In D. B. D. B. D. B. D. B. D. B.	Screen weeks 0-2 weeks 3-4 weeks 5-6 weeks 7-10 weeks 11-18 weeks 19-26 weeks 27-34 weeks 35-42 weeks 43-52	Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal
	124	PPC	Placebo	Male	Run In Run In Run In D. B. D. B. D. B. D. B. D. B.	Screen weeks 0-2 weeks 3-4 weeks 5-6 weeks 7-10 weeks 11-18 weeks 19-26 weeks 27-34 weeks 35-42 weeks 43-52	Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal

25335

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R2D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
DOUBLE BLIND PHASE

Centre	Patient	Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value					
1	125	FDP	Reboxetine	Female	Run In	Screen	Normal					
					Run In	weeks 0-2	Normal					
					Run In	weeks 3-4	Normal					
					Run In	weeks 5-6	Normal					
					D. B.	weeks 7-10	Normal					
					D. B.	weeks 11-18	Normal					
					D. B.	weeks 19-26	Normal					
					D. B.	weeks 27-34	Normal					
					D. B.	weeks 35-42	Normal					
					D. B.	weeks 43-52	Normal					
					126	SMB		Placebo	Female	Run In	Screen	Normal
										Run In	weeks 0-2	Normal
										Run In	weeks 3-4	Normal
										Run In	weeks 5-6	Normal
										D. B.	weeks 7-10	Normal
D. B.	weeks 11-18	Normal										
D. B.	weeks 19-26	Normal										
D. B.	weeks 27-34	Normal										
D. B.	weeks 35-42	Normal										
D. B.	weeks 43-52	Normal										
127	VPD		Reboxetine	Female						Run In	Screen	Normal
										Run In	weeks 0-2	Normal
										Run In	weeks 3-4	Normal
										Run In	weeks 5-6	Normal
										D. B.	weeks 7-10	Normal
					D. B.	weeks 11-18	Normal					
					D. B.	weeks 19-26	Normal					
					D. B.	weeks 27-34	Normal					
					D. B.	weeks 35-42	Normal					
					D. B.	weeks 43-52	Normal					
					128	LAM		Reboxetine	Male	Run In	Screen	Normal
										Run In	weeks 0-2	Normal
										Run In	weeks 3-4	Normal
										Run In	weeks 5-6	Normal
										D. B.	weeks 7-10	Normal
D. B.	weeks 11-18	Normal										
D. B.	weeks 19-26	Normal										
D. B.	weeks 27-34	Normal										
D. B.	weeks 35-42	Normal										
D. B.	weeks 43-52	Normal										

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value				
1	129 MNS	Placebo	Male	Run In	Screen	Normal				
				Run In	weeks 0-2	Normal				
				Run In	weeks 3-4	Normal				
				Run In	weeks 5-6	Normal				
				D. B.	weeks 7-10	Normal				
				D. B.	weeks 11-18	Normal				
				D. B.	weeks 19-26	Normal				
				D. B.	weeks 27-34	Normal				
				D. B.	weeks 35-42	Normal				
				D. B.	weeks 43-52	Normal				
				D. B.	Screen	Normal				
				D. B.	weeks 0-2	Normal				
130	EGA	Placebo	Female	Run In	Screen	Normal				
				Run In	weeks 0-2	Normal				
				Run In	weeks 3-4	Normal				
				Run In	weeks 5-6	Normal				
				D. B.	weeks 7-10	Normal				
				D. B.	weeks 11-18	Normal				
				133	JPM	Placebo	Male	Run In	Screen	Normal
								Run In	weeks 0-2	Normal
								Run In	weeks 3-4	Normal
								Run In	weeks 5-6	Normal
								D. B.	weeks 7-10	Normal
								D. B.	weeks 11-18	Normal
D. B.	weeks 19-26	Normal								
D. B.	weeks 27-34	Normal								
D. B.	weeks 35-42	Normal								
D. B.	weeks 43-52	Normal								
D. B.	Screen	Normal								
D. B.	weeks 0-2	Normal								
134	LMS	Reboxetine	Female	Run In	Screen	Normal				
				Run In	weeks 0-2	Normal				
				Run In	weeks 3-4	Normal				
				Run In	weeks 5-6	Normal				
				D. B.	weeks 7-10	Normal				
				D. B.	weeks 11-18	Normal				
				D. B.	weeks 19-26	Normal				
				D. B.	weeks 27-34	Normal				
				D. B.	weeks 35-42	Normal				
				D. B.	weeks 43-52	Normal				
				D. B.	Screen	Normal				
				D. B.	weeks 0-2	Normal				
135	MMS	Reboxetine	Female	Run In	Screen	Normal				
				Run In	weeks 0-2	Normal				
				Run In	weeks 3-4	Normal				
				Run In	weeks 5-6	Normal				
				D. B.	weeks 7-10	Normal				
				D. B.	weeks 11-18	Normal				
				D. B.	weeks 19-26	Normal				

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013

Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value		
1	135 MMS	Reboxetine	Female	D. B.	weeks 27-34	Normal		
				D. B.	weeks 35-42	Normal		
				D. B.	weeks 43-52	Normal		
				Run In	Screen	Normal		
				Run In	weeks 0-2	Normal		
				Run In	weeks 3-4	Normal		
	136 AVP	Placebo	Male	Run In	weeks 5-6	Normal		
				Run In	weeks 7-10	Normal		
				D. B.	weeks 11-18	Normal		
				D. B.	weeks 19-26	Normal		
				D. B.	weeks 27-34	Normal		
				D. B.	weeks 35-42	Normal		
139 RA	Reboxetine	Male	D. B.	weeks 43-52	Normal			
			Run In	Screen	Normal			
			Run In	weeks 0-2	Normal			
			Run In	weeks 3-4	Normal			
			Run In	weeks 5-6	Normal			
			D. B.	weeks 7-10	Normal			
			D. B.	weeks 11-18	Normal			
			D. B.	weeks 19-26	Normal			
			D. B.	weeks 27-34	Normal			
			D. B.	weeks 35-42	Normal			
			D. B.	weeks 43-52	Normal			
			140 NCA	Reboxetine	Female	Run In	Screen	Normal
Run In	weeks 0-2	Normal						
Run In	weeks 3-4	Normal						
Run In	weeks 5-6	Normal						
D. B.	weeks 7-10	Normal						
D. B.	weeks 11-18	Normal						
D. B.	weeks 19-26	Normal						
D. B.	weeks 27-34	Normal						
D. B.	weeks 35-42	Normal						
D. B.	weeks 43-52	Normal						
142 SCC	Reboxetine	Female				Run In	Screen	Normal
						Run In	weeks 0-2	Normal
			Run In	weeks 3-4	Normal			
			Run In	weeks 5-6	Normal			
			D. B.	weeks 7-10	Normal			
			D. B.	weeks 11-18	Normal			
			D. B.	weeks 19-26	Normal			
			D. B.	weeks 27-34	Normal			
			D. B.	weeks 35-42	Normal			
			D. B.	weeks 43-52	Normal			

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value
1	142 SCC	Reboxetine	Female	D. B.	weeks 43-52	Normal
	143 JEP	Placebo	Male	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
	144 ARF	Reboxetine	Male	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
				D. B.	weeks 43-52	Normal
	146 LRH	Reboxetine	Male	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
				D. B.	weeks 43-52	Normal
	148 CAS	Reboxetine	Male	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
				D. B.	weeks 43-52	Normal
	149 SC	Placebo	Female	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 14.1
 ECG TRACINGS: PATIENTS ALWAYS NORMAL
 DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value
1	149 SC	Placebo	Female	D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
150 VA	Placebo	Female	Run In	Screen	Normal	
			Run In	weeks 0-2	Normal	
			Run In	weeks 3-4	Normal	
			Run In	weeks 5-6	Normal	
3	2 FLL	Placebo	Female	D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
3	3 DUB	Placebo	Male	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
7	7 GRI	Reboxetine	Female	D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				Run In	Screen	Normal
				Run In	weeks 0-2	Normal
10	10 TOR	Placebo	Male	Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				Run In	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
DOUBLE BLIND PHASE

Centre	Patient	Initials	Assigned treatment	Sex	Phase	Time interval	E. C. G. value					
8	2	TE	Reboxetine	Female	Run In	Screen	Normal					
					Run In	weeks 0-2	Normal					
					Run In	weeks 3-4	Normal					
					Run In	weeks 5-6	Normal					
					D. B.	weeks 7-10	Normal					
					D. B.	weeks 11-18	Normal					
					D. B.	weeks 19-26	Normal					
					D. B.	weeks 27-34	Normal					
					D. B.	weeks 35-42	Normal					
					D. B.	weeks 43-52	Normal					
					6	TL		Reboxetine	Female	Run In	Screen	Normal
										Run In	weeks 0-2	Normal
										Run In	weeks 3-4	Normal
										Run In	weeks 5-6	Normal
										D. B.	weeks 7-10	Normal
D. B.	weeks 11-18	Normal										
D. B.	weeks 19-26	Normal										
D. B.	weeks 27-34	Normal										
D. B.	weeks 35-42	Normal										
D. B.	weeks 43-52	Normal										
9	2	VCF	Placebo	Female						Run In	Screen	Normal
										Run In	weeks 0-2	Normal
										Run In	weeks 3-4	Normal
										Run In	weeks 5-6	Normal
										D. B.	weeks 7-10	Normal
					D. B.	weeks 11-18	Normal					
					D. B.	weeks 19-26	Normal					
					D. B.	weeks 27-34	Normal					
					D. B.	weeks 35-42	Normal					
					D. B.	weeks 43-52	Normal					
					5	HF		Placebo	Female	Run In	Screen	Normal
										Run In	weeks 0-2	Normal
										Run In	weeks 3-4	Normal
										Run In	weeks 5-6	Normal
										D. B.	weeks 7-10	Normal
D. B.	weeks 11-18	Normal										
D. B.	weeks 19-26	Normal										
D. B.	weeks 27-34	Normal										
D. B.	weeks 35-42	Normal										
D. B.	weeks 43-52	Normal										
6	SD		Reboxetine	Female						Run In	Screen	Normal
										Run In	weeks 0-2	Normal
										Run In	weeks 3-4	Normal
										Run In	weeks 5-6	Normal
										D. B.	weeks 7-10	Normal
					D. B.	weeks 11-18	Normal					
					D. B.	weeks 19-26	Normal					
					D. B.	weeks 27-34	Normal					
					D. B.	weeks 35-42	Normal					
					D. B.	weeks 43-52	Normal					

2541

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013

Listing No.: 14.1

ECC TRACINGS: PATIENTS ALWAYS NORMAL
DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value	
9	6 SD	Reboxetine	Female	Run In	weeks 3-4	Normal	
				Run In	weeks 5-6	Normal	
				D. B.	weeks 7-10	Normal	
				D. B.	weeks 11-18	Normal	
				D. B.	weeks 19-26	Normal	
				D. B.	weeks 27-34	Normal	
	8 KTM	Placebo	Female	Screen	weeks 0-2	Normal	
				Run In	weeks 3-4	Normal	
				Run In	weeks 5-6	Normal	
				D. B.	weeks 7-10	Normal	
				D. B.	weeks 11-18	Normal	
				D. B.	weeks 19-26	Normal	
11	KE	Reboxetine	Female	Screen	weeks 0-2	Normal	
				Run In	weeks 3-4	Normal	
				Run In	weeks 5-6	Normal	
				D. B.	weeks 7-10	Normal	
				D. B.	weeks 11-18	Normal	
				D. B.	weeks 19-26	Normal	
	12	GYT	Placebo	Female	Screen	weeks 0-2	Normal
					Run In	weeks 3-4	Normal
					Run In	weeks 5-6	Normal
					D. B.	weeks 7-10	Normal
					D. B.	weeks 11-18	Normal
					D. B.	weeks 19-26	Normal
19	KF	Placebo	Female	Screen	weeks 0-2	Normal	
				Run In	weeks 3-4	Normal	
				Run In	weeks 5-6	Normal	
				D. B.	weeks 7-10	Normal	
				D. B.	weeks 11-18	Normal	
				D. B.	weeks 19-26	Normal	
	23	SZH	Reboxetine	Female	Screen	weeks 0-2	Normal
					Run In	weeks 3-4	Normal
					Run In	weeks 5-6	Normal
					Run In	weeks 7-10	Normal
					D. B.	weeks 11-18	Normal
					D. B.	weeks 19-26	Normal

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 14.1
 ECG TRACINGS: PATIENTS ALWAYS NORMAL
 DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value
9	23 SZN	Reboxetine	Female	D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
	24 L6Y	Placebo	Male	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
	28 HI	Placebo	Male	D. B.	weeks 7-10	Normal
				D. B.	weeks 19-26	Normal
				Run In	Screen	Normal
				Run In	weeks 0-2	Normal
10	29 SZF	Reboxetine	Female	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
	4 ZSD	Placebo	Female	D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				Run In	Screen	Normal
				Run In	weeks 0-2	Normal
	9 RT	Reboxetine	Female	Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
D. B.				weeks 7-10	Normal	
D. B.				weeks 19-26	Normal	
10 MH	Placebo	Female	Run In	Screen	Normal	
			Run In	weeks 0-2	Normal	
			Run In	weeks 3-4	Normal	
			Run In	weeks 5-6	Normal	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 14.1
 ECG TRACINGS: PATIENTS ALWAYS NORMAL
 DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value
10	12 EP	Reboxetine	Female	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				D. B.	weeks 5-6	Normal
14	AA	Placebo	Male	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				D. B.	weeks 5-6	Normal
				Run In	weeks 7-10	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 35-42	Normal
				D. B.	weeks 43-52	Normal
15	HT	Reboxetine	Female	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				D. B.	weeks 5-6	Normal
				Run In	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
				Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
				Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
				Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CHS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value
10	29 JJ	Placebo	Male	D. B.	weeks 19-26	Normal
	33 EK	Reboxetine	Male	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
	34 TK	Reboxetine	Male	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
	42 TT	Placebo	Male	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
	44 AB	Placebo	Male	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
	53 MA	Reboxetine	Female	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
	59 TA	Reboxetine	Female	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
	86 NP	Reboxetine	Female	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal

2545

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value
10	87 AN	Reboxetine	Female	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
				D. B.	weeks 43-52	Normal
11	1 DF	Placebo	Male	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
				D. B.	weeks 43-52	Normal
4	BA	Placebo	Male	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
				D. B.	weeks 43-52	Normal
6	VP	Reboxetine	Male	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
				D. B.	weeks 43-52	Normal
7	KX	Placebo	Female	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value
11	7 RK	Placebo	Female	D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
10	BJ	Reboxetine	Female	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
				D. B.	weeks 43-52	Normal
11	NGY	Reboxetine	Female	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
12	PJ	Placebo	Female	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
				D. B.	weeks 43-52	Normal
13	GX	Reboxetine	Female	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
15	NF	Placebo	Female	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

EKG TRACINGS: PATIENTS ALWAYS NORMAL
DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value
11	15 NF	Placebo	Female	Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
16 NA	Reboxetine	Female	Run In	Screen	Normal	
			Run In	weeks 0-2	Normal	
			Run In	weeks 3-4	Normal	
17 UZ	Reboxetine	Female	Run In	weeks 5-6	Normal	
			Run In	weeks 7-10	Normal	
			D. B.	weeks 11-18	Normal	
18 EI	Placebo	Female	Run In	weeks 19-26	Normal	
			Run In	weeks 27-34	Normal	
			D. B.	weeks 35-42	Normal	
19 FK	Reboxetine	Female	Run In	weeks 43-52	Normal	
			Run In	Screen	Normal	
			Run In	weeks 0-2	Normal	
			Run In	weeks 3-4	Normal	
			Run In	weeks 5-6	Normal	
			D. B.	weeks 7-10	Normal	
			Run In	weeks 11-18	Normal	
			Run In	weeks 19-26	Normal	
			D. B.	weeks 27-34	Normal	
			Run In	weeks 35-42	Normal	
			Run In	weeks 43-52	Normal	
			D. B.	Screen	Normal	
			Run In	weeks 0-2	Normal	
			Run In	weeks 3-4	Normal	
			Run In	weeks 5-6	Normal	
			Run In	weeks 7-10	Normal	
			Run In	weeks 11-18	Normal	
			D. B.	weeks 19-26	Normal	
			Run In	weeks 27-34	Normal	
			Run In	weeks 35-42	Normal	
			D. B.	weeks 43-52	Normal	
			Run In	Screen	Normal	
			Run In	weeks 0-2	Normal	
			Run In	weeks 3-4	Normal	
			Run In	weeks 5-6	Normal	
			Run In	weeks 7-10	Normal	
			D. B.	weeks 11-18	Normal	
			Run In	weeks 19-26	Normal	
			Run In	weeks 27-34	Normal	
			D. B.	weeks 35-42	Normal	
			Run In	weeks 43-52	Normal	
			Run In	Screen	Normal	
			Run In	weeks 0-2	Normal	
			Run In	weeks 3-4	Normal	
			Run In	weeks 5-6	Normal	
			D. B.	weeks 7-10	Normal	
			Run In	weeks 11-18	Normal	
			Run In	weeks 19-26	Normal	
			D. B.	weeks 27-34	Normal	
			Run In	weeks 35-42	Normal	
			Run In	weeks 43-52	Normal	
			D. B.	Screen	Normal	
			Run In	weeks 0-2	Normal	
			Run In	weeks 3-4	Normal	
			Run In	weeks 5-6	Normal	
			Run In	weeks 7-10	Normal	
			Run In	weeks 11-18	Normal	
			D. B.	weeks 19-26	Normal	
			Run In	weeks 27-34	Normal	
			Run In	weeks 35-42	Normal	
			D. B.	weeks 43-52	Normal	

2548

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
DOUBLE BLIND PHASE

Centre	Patient	Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value
11	20	LJ	Placebo	Female	Run In	Screen	Normal
					Run In	weeks 0-2	Normal
					Run In	weeks 3-4	Normal
					Run In	weeks 5-6	Normal
12	2	EFC	Reboxetine	Female	D. B.	weeks 7-10	Normal
					D. B.	weeks 11-18	Normal
					Run In	Screen	Normal
					Run In	weeks 0-2	Normal
12	2	EFC	Reboxetine	Female	Run In	weeks 3-4	Normal
					Run In	weeks 5-6	Normal
					Run In	weeks 7-10	Normal
					D. B.	weeks 11-18	Normal
13	152	IF	Reboxetine	Female	Run In	Screen	Normal
					Run In	weeks 0-2	Normal
					Run In	weeks 3-4	Normal
					Run In	weeks 5-6	Normal
					Run In	weeks 7-10	Normal
					D. B.	weeks 11-18	Normal
					D. B.	weeks 19-26	Normal
					Run In	Screen	Normal
					Run In	weeks 0-2	Normal
					Run In	weeks 3-4	Normal
					Run In	weeks 5-6	Normal
					Run In	weeks 7-10	Normal
7	LK	LK	Reboxetine	Male	Run In	Screen	Normal
					Run In	weeks 0-2	Normal
					Run In	weeks 3-4	Normal
					Run In	weeks 5-6	Normal
					D. B.	weeks 7-10	Normal
					D. B.	weeks 11-18	Normal
9	KBP	KBP	Reboxetine	Female	Run In	Screen	Normal
					Run In	weeks 0-2	Normal
					Run In	weeks 3-4	Normal
					Run In	weeks 5-6	Normal
					D. B.	weeks 7-10	Normal
					D. B.	weeks 11-18	Normal
13	152	152	Placebo	Female	Run In	Screen	Normal
					Run In	weeks 0-2	Normal
					Run In	weeks 3-4	Normal
					Run In	weeks 5-6	Normal
					Run In	weeks 7-10	Normal
					D. B.	weeks 11-18	Normal

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value
12	18 LS	Placebo	Male	Run In	Screen	Normal
				Run In	Weeks 0-2	Normal
				Run In	Weeks 3-4	Normal
				Run In	Weeks 5-6	Normal
				D. B.	Weeks 7-10	Normal
21	FL	Reboxetine	Female	Run In	Screen	Normal
				Run In	Weeks 0-2	Normal
				Run In	Weeks 3-4	Normal
				Run In	Weeks 5-6	Normal
				D. B.	Weeks 7-10	Normal
22	NV	Placebo	Female	Run In	Screen	Normal
				Run In	Weeks 0-2	Normal
				Run In	Weeks 3-4	Normal
				Run In	Weeks 5-6	Normal
				D. B.	Weeks 7-10	Normal
23	EN	Placebo	Female	Run In	Screen	Normal
				Run In	Weeks 0-2	Normal
				Run In	Weeks 3-4	Normal
				Run In	Weeks 5-6	Normal
				D. B.	Weeks 7-10	Normal
24	NF	Reboxetine	Female	Run In	Screen	Normal
				Run In	Weeks 0-2	Normal
				Run In	Weeks 3-4	Normal
				Run In	Weeks 5-6	Normal
				D. B.	Weeks 7-10	Normal
25	FS	Reboxetine	Female	Run In	Screen	Normal
				Run In	Weeks 0-2	Normal
				Run In	Weeks 3-4	Normal
				Run In	Weeks 5-6	Normal
				D. B.	Weeks 7-10	Normal

2550

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 14.1
 ECG TRACINGS: PATIENTS ALWAYS NORMAL
 DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value				
13	9 SZS	Placebo	Male	Run In	weeks 0-2	Normal				
				Run In	weeks 3-4	Normal				
				Run In	weeks 5-6	Normal				
11	HS	Placebo	Female	D. B.	weeks 7-10	Normal				
				D. B.	weeks 11-18	Normal				
				D. B.	weeks 19-26	Normal				
				D. B.	weeks 27-34	Normal				
				D. B.	weeks 35-42	Normal				
				D. B.	weeks 43-52	Normal				
13	HM	Reboxetine	Male	Screen	weeks 0-2	Normal				
				Run In	weeks 3-4	Normal				
				Run In	weeks 5-6	Normal				
				Run In	weeks 7-10	Normal				
				D. B.	weeks 11-18	Normal				
				D. B.	weeks 19-26	Normal				
				D. B.	weeks 27-34	Normal				
				D. B.	weeks 35-42	Normal				
				D. B.	weeks 43-52	Normal				
				18	VT	Reboxetine	Female	Screen	weeks 0-2	Normal
								Run In	weeks 3-4	Normal
								Run In	weeks 5-6	Normal
Run In	weeks 7-10	Normal								
D. B.	weeks 11-18	Normal								
D. B.	weeks 19-26	Normal								
D. B.	weeks 27-34	Normal								
D. B.	weeks 35-42	Normal								
D. B.	weeks 43-52	Normal								
20	NL	Reboxetine	Female					Screen	weeks 0-2	Normal
								Run In	weeks 3-4	Normal
								Run In	weeks 5-6	Normal
				Run In	weeks 7-10	Normal				
				D. B.	weeks 11-18	Normal				
				D. B.	weeks 19-26	Normal				

25 52 2

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.1

ECG TRACINGS: PATIENTS ALWAYS NORMAL
DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value
13	20 NL	Reboxetine	Female	D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
				D. B.	weeks 43-52	Normal
21 CL		Reboxetine	Female	Run In	Screen	Normal
				Run In	weeks 0-2	Normal
				Run In	weeks 3-4	Normal
				Run In	weeks 5-6	Normal
				D. B.	weeks 7-10	Normal
				D. B.	weeks 11-18	Normal
				D. B.	weeks 19-26	Normal
				D. B.	weeks 27-34	Normal
				D. B.	weeks 35-42	Normal
				D. B.	weeks 43-52	Normal

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.2

ECG TRACINGS: PATIENTS WITH AT LEAST ONE ABNORMALITY
OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value	Abnormality type	Abnormality group
1	16	MHC	Female	Screen weeks 0-2	Abnormal	A-V BLOCK 1ST DEGREE	Conduction disorders
				Screen weeks 3-4	Abnormal	A-V BLOCK 1ST DEGREE	
				Screen weeks 5-6	Normal	A-V BLOCK 1ST DEGREE	
	20	EFC	Female	Screen weeks 0-2	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
				Screen weeks 3-4	Abnormal	SINUS TACHYCARDIA (> 100)	
				Screen weeks 5-6	Normal	SINUS TACHYCARDIA (> 100)	
	21	VMC	Female	Screen weeks 0-2	Normal	SINUS BRADYCARDIA (< 60)	Rhythm disorders
				Screen weeks 3-4	Abnormal	SINUS BRADYCARDIA (< 60)	
				Screen weeks 5-6	Abnormal	SINUS BRADYCARDIA (< 60)	
23	24	LVF	Female	Screen weeks 0-2	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
				Screen weeks 3-4	Normal	SINUS TACHYCARDIA (> 100)	
				Screen weeks 5-6	Abnormal	SINUS TACHYCARDIA (> 100)	
24	28	RMN	Female	Screen weeks 0-2	Normal	VENTRICULAR ECTOPIC BEATS - OC	Rhythm disorders
				Screen weeks 3-4	Abnormal	VENTRICULAR ECTOPIC BEATS - OC	
				Screen weeks 5-6	Abnormal	VENTRICULAR ECTOPIC BEATS - OC	
57	57	SMC	Female	Screen weeks 0-2	Normal	A-V BLOCK 1ST DEGREE	Conduction disorders
				Screen weeks 0-2	Abnormal	A-V BLOCK 1ST DEGREE	
75	ELF	Female	Female	Screen weeks 0-2	Abnormal	RIGHT BUNDLE BRANCH BLOCK	Conduction disorders
				Screen weeks 3-4	Normal	RIGHT BUNDLE BRANCH BLOCK	
				Screen weeks 5-6	Normal	RIGHT BUNDLE BRANCH BLOCK	
103	JRA	Male	Male	Screen weeks 0-2	Normal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
				Screen weeks 0-2	Abnormal	SINUS TACHYCARDIA (> 100)	
131	RMR	Female	Female	Screen weeks 0-2	Normal	VENTRICULAR ECTOPIC BEATS - OC	Rhythm disorders
				Screen weeks 3-4	Abnormal	VENTRICULAR ECTOPIC BEATS - OC	
				Screen weeks 5-6	Abnormal	VENTRICULAR ECTOPIC BEATS - OC	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.2

ECG TRACINGS: PATIENTS WITH AT LEAST ONE ABNORMALITY
OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value	Abnormality type	Abnormality group
1	137	CME	Female	Screen weeks 0-2	Normal		
				Screen weeks 3-4	Abnormal	A-V BLOCK 1ST DEGREE LEFT BUNDLE BRANCH BLOCK	Conduction disorders
				Screen weeks 5-6	Abnormal	A-V BLOCK 1ST DEGREE LEFT BUNDLE BRANCH BLOCK	Conduction disorders
2	31	IK	Female	Screen weeks 0-2	Abnormal	RIGHT VENTRICULAR HYPERTROPHY	Other disorders
				Screen weeks 3-4	Normal		
8	1	HJ	Female	Screen weeks 0-2	Normal		
				Screen weeks 3-4	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
				Screen weeks 5-6	Normal		
3	JL	Male	Male	Screen weeks 0-2	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
				Screen weeks 3-4	Normal		
				Screen weeks 5-6	Normal		
4	BA	Female	Female	Screen weeks 0-2	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
				Screen weeks 3-4	Normal		
				Screen weeks 5-6	Normal		
5	SL	Male	Male	Screen weeks 0-2	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
				Screen weeks 3-4	Normal		
				Screen weeks 5-6	Normal		
9	14	SZF	Female	Screen weeks 0-2	Abnormal	MYOCARDIAL ISCHEMIA	Ischemic signs
				Screen weeks 3-4	Normal		
				Screen weeks 5-6	Normal		
20	GYE	Female	Female	Screen weeks 0-2	Abnormal	SINUS TACHYCARDIA (> 100) MYOCARDIAL ISCHEMIA	Rhythm disorders Ischemic signs
				Screen weeks 3-4	Normal		
				Screen weeks 5-6	Normal		

2
3
4

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.2

ECG TRACINGS: PATIENTS WITH AT LEAST ONE ABNORMALITY
OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value	Abnormality type	Abnormality group
9	25	PH	Female	Screen weeks 0-2	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
				weeks 3-4	Normal		
				weeks 5-6	Normal		
10	1	VK	Male	Screen weeks 0-2	Abnormal	OTHER CONDUCTION DISORDER	Other disorders Conduction disorders
				weeks 3-4	Normal		
				weeks 5-6	Normal		
10	30	MF	Female	Screen weeks 0-2	Normal		
				weeks 3-4	Abnormal	MYOCARDIAL ISCHEMIA	Ischemic signs
				weeks 5-6	Normal		
10	5	AN	Female	Screen weeks 0-2	Abnormal	LEFT VENTRICULAR HYPERTROPHY	Other disorders
				weeks 3-4	Abnormal	LEFT VENTRICULAR HYPERTROPHY	Other disorders
				weeks 5-6	Abnormal	LEFT VENTRICULAR HYPERTROPHY	Other disorders
10	8	VP	Female	Screen weeks 0-2	Abnormal	SINUS BRADYCARDIA (< 60)	Rhythm disorders
				weeks 3-4	Normal		
				weeks 5-6	Abnormal	RIPOLARIZATION DISTURBANCES SINUS BRADYCARDIA (< 60)	Ischemic signs Rhythm disorders
11	TM	Female	Screen weeks 0-2	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders	
				Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH NON SPECIFIC ST-T WAVE CHANGES	Conduction disorders Ischemic signs	
				Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH NON SPECIFIC ST-T WAVE CHANGES	Conduction disorders Ischemic signs	
17	MM	Female	Screen weeks 3-4	Abnormal	LEFT AXIAL DEVIATION	Conduction disorders	
				Abnormal	LEFT AXIAL DEVIATION	Conduction disorders	
				Abnormal	LEFT AXIAL DEVIATION	Conduction disorders	
18	SS	Female	Screen weeks 0-2	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs	
				Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs	

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.2

EKG TRACINGS: PATIENTS WITH AT LEAST ONE ABNORMALITY
OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value	Abnormality type	Abnormality group
10	18	SS	Female	Screen weeks 3-4	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs Ischemic signs
				Screen weeks 5-6	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	
	19	TN	Female	Screen weeks 0-2	Normal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
				Screen weeks 3-4	Normal		
				Screen weeks 5-6	Abnormal		
	22	AA	Male	Screen weeks 0-2	Normal	SINUS TACHYCARDIA (> 100) RIPOLARIZATION DISTURBANCES RIPOLARIZATION DISTURBANCES	Rhythm disorders Ischemic signs Ischemic signs
				Screen weeks 3-4	Abnormal		
	24	AL	Male	Screen weeks 0-2	Abnormal	RIGHT VENTRICULAR HYPERTROPHY RIGHT VENTRICULAR HYPERTROPHY SINUS TACHYCARDIA (> 100)	Other disorders Other disorders Rhythm disorders
				Screen weeks 3-4	Abnormal		
	25	ES	Male	Screen weeks 3-4	Abnormal	RIGHT VENTRICULAR HYPERTROPHY RIGHT VENTRICULAR HYPERTROPHY	Other disorders Other disorders
				Screen weeks 5-6	Abnormal		
	26	JIF	Female	Screen weeks 0-2	Normal	RIGHT INCOMPLETE BUNDLE BRANCH RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders Conduction disorders
				Screen weeks 3-4	Normal		
	27	MK	Female	Screen weeks 0-2	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
				Screen weeks 3-4	Normal		
	30	VK	Female	Screen weeks 0-2	Normal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
				Screen weeks 3-4	Normal		
	31	RK	Female	Screen weeks 0-2	Normal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
				Screen weeks 3-4	Abnormal		
	31	RK	Female	Screen weeks 3-4	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs Ischemic signs
				Screen weeks 5-6	Abnormal		
	31	RK	Female	Screen weeks 0-2	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs Ischemic signs
				Screen weeks 3-4	Abnormal		
	31	RK	Female	Screen weeks 3-4	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs Ischemic signs
				Screen weeks 5-6	Abnormal		

2557

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.2

ECG TRACINGS: PATIENTS WITH AT LEAST ONE ABNORMALITY
OPEN PHASE

Centre	Patient Initials	Sex	Time interval	E.C.G. value	Abnormality type	Abnormality group
10	32 LK	Female	Screen weeks 0-2	Abnormal	VENTRICULAR ECTOPIC BEATS - OC	Rhythm disorders Ischemic signs Ischemic signs
			Screen weeks 3-4	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	
			Screen weeks 5-6	Normal	NON SPECIFIC ST-T WAVE CHANGES	
	35 IK	Female	Screen weeks 0-2	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders Conduction disorders Conduction disorders
			Screen weeks 3-4	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH	
			Screen weeks 5-6	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH	
	36 AK	Female	Screen weeks 0-2	Normal		Rhythm disorders
			Screen weeks 3-4	Abnormal	SINUS BRADYCARDIA (< 60)	
			Screen weeks 5-6	Normal		
	37 HK	Female	Screen weeks 0-2	Abnormal	OTHER	Other disorders Other disorders Other disorders
Screen weeks 3-4			Abnormal	OTHER		
Screen weeks 5-6			Abnormal	OTHER		
38 LL	Female	Screen weeks 0-2	Normal		Conduction disorders Conduction disorders	
		Screen weeks 3-4	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH		
		Screen weeks 5-6	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH		
39 VM	Female	Screen weeks 0-2	Normal		Conduction disorders Conduction disorders	
		Screen weeks 3-4	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH		
		Screen weeks 5-6	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH		
40 AP	Female	Screen weeks 0-2	Normal		Rhythm disorders Ischemic signs	
		Screen weeks 3-4	Abnormal	SINUS TACHYCARDIA (> 100)		
		Screen weeks 5-6	Normal	NON SPECIFIC ST-T WAVE CHANGES		
41 VP	Female	Screen weeks 0-2	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders Ischemic signs Conduction disorders	
		Screen weeks 3-4	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH		
		Screen weeks 5-6	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH		

2
5
5
00

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.2

ECG TRACINGS: PATIENTS WITH AT LEAST ONE ABNORMALITY
OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value	Abnormality type	Abnormality group
10	41	VP	Female	Screen weeks 5-6	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders
	43	IK	Female	Screen weeks 0-2 weeks 3-4 weeks 5-6	Normal Abnormal Abnormal	NON SPECIFIC ST-T WAVE CHANGES NON SPECIFIC ST-T WAVE CHANGES NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs Ischemic signs Ischemic signs
	45	KJ	Female	Screen weeks 0-2 weeks 3-4 weeks 5-6	Abnormal Abnormal Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH RIGHT INCOMPLETE BUNDLE BRANCH RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders Conduction disorders Conduction disorders
	47	TM	Female	Screen weeks 0-2 weeks 3-4 weeks 5-6	Abnormal Abnormal Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH RIGHT INCOMPLETE BUNDLE BRANCH SINUS TACHYCARDIA (> 100)	Conduction disorders Conduction disorders Rhythm disorders Conduction disorders
	48	IP	Female	Screen weeks 0-2 weeks 3-4 weeks 5-6	Abnormal Abnormal Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH SINUS TACHYCARDIA (> 100) RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders Rhythm disorders Conduction disorders Conduction disorders
	49	VK	Female	Screen weeks 0-2 weeks 3-4 weeks 5-6	Abnormal Normal Normal	OTHER	Other disorders
	50	EE	Male	Screen weeks 0-2 weeks 3-4 weeks 5-6	Abnormal Abnormal Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH RIGHT INCOMPLETE BUNDLE BRANCH RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders Conduction disorders Conduction disorders
	51	UL	Female	Screen weeks 0-2 weeks 3-4 weeks 5-6	Abnormal Abnormal Abnormal	NON SPECIFIC ST-T WAVE CHANGES NON SPECIFIC ST-T WAVE CHANGES NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs Ischemic signs Ischemic signs
	52	HP	Male	Screen	Abnormal	SINUS TACHYCARDIA (> 100) RIGHT AXIAL DEVIATION RIGHT INCOMPLETE BUNDLE BRANCH	Rhythm disorders Other disorders Conduction disorders

22
21
20
19

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBEXETINE - PROTOCOL 20124/013
Listing No.: 14.2

ECG TRACINGS: PATIENTS WITH AT LEAST ONE ABNORMALITY
OPEN PHASE

Centre	Patient Initials	Sex	Time interval	E.C.G. value	Abnormality type	Abnormality group
10	52 MP	Male	weeks 0-2 weeks 3-4	Abnormal Abnormal	RIGHT AXIAL DEVIATION RIGHT INCOMPLETE BUNDLE BRANCH RIGHT AXIAL DEVIATION	Other disorders Conduction disorders Other disorders
	55 TP	Male	Screen weeks 0-2 weeks 3-4 weeks 5-6	Normal Abnormal Normal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
	56 JP	Male	Screen weeks 0-2 weeks 3-4 weeks 5-6	Abnormal Abnormal Abnormal	NON SPECIFIC ST-T WAVE CHANGES NON SPECIFIC ST-T WAVE CHANGES NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs Ischemic signs Ischemic signs
	57 AG	Female	Screen weeks 0-2 weeks 3-4 weeks 5-6	Abnormal Abnormal Normal	NON SPECIFIC ST-T WAVE CHANGES NON SPECIFIC ST-T WAVE CHANGES NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs Ischemic signs Ischemic signs
	58 KK	Female	Screen weeks 0-2 weeks 3-4 weeks 5-6	Normal Abnormal Abnormal Normal	OTHER NON SPECIFIC ST-T WAVE CHANGES NON SPECIFIC ST-T WAVE CHANGES	Other disorders Ischemic signs Ischemic signs
	61 JT	Male	Screen weeks 0-2 weeks 3-4 weeks 5-6	Abnormal Normal Abnormal Normal	NON SPECIFIC ST-T WAVE CHANGES NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs Ischemic signs
	62 RK	Male	Screen weeks 3-4 weeks 5-6	Abnormal Abnormal Normal	NON SPECIFIC ST-T WAVE CHANGES NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs Ischemic signs
	63 MS	Male	Screen weeks 0-2 weeks 3-4 weeks 5-6	Abnormal Abnormal Abnormal Abnormal	OTHER NON SPECIFIC ST-T WAVE CHANGES NON SPECIFIC ST-T WAVE CHANGES NON SPECIFIC ST-T WAVE CHANGES NON SPECIFIC ST-T WAVE CHANGES	Other disorders Ischemic signs Ischemic signs Other disorders Ischemic signs Other disorders Other disorders Ischemic signs

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REMOXETINE - PROTOCOL 20124/013
 Listing No.: 14.2
 ECG TRACINGS: PATIENTS WITH AT LEAST ONE ABNORMALITY
 OPEN PHASE

Centre	Patient Initials	Sex	Time interval	E.C.G. value	Abnormality type	Abnormality group
10	64 LT	Female	Screen	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders Ischemic signs Ischemic signs Conduction disorders Ischemic signs
			weeks 0-2	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	
			weeks 5-6	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH NON SPECIFIC ST-T WAVE CHANGES	
31	JN	Female	Screen	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
			weeks 0-2	Normal		
			weeks 3-4 weeks 5-6	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH	
82	LS	Male	Screen	Abnormal	MYOCARDIAL ISCHEMIA PREVIOUS MYOCARDIAL INFARCTION	Ischemic signs Other disorders Ischemic signs Other disorders Ischemic signs Other disorders Ischemic signs Other disorders
			weeks 0-2	Abnormal	MYOCARDIAL ISCHEMIA PREVIOUS MYOCARDIAL INFARCTION	
			weeks 3-4 weeks 5-6	Abnormal	MYOCARDIAL ISCHEMIA PREVIOUS MYOCARDIAL INFARCTION	
83	KL	Male	Screen	Normal	CONDUCTION DISORDER	Conduction disorders Ischemic signs
			weeks 0-2	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	
			weeks 3-4 weeks 5-6	Normal		
84	HV	Female	Screen	Normal	SINUS TACHYCARDIA (> 100)	Rhythm disorders Rhythm disorders Ischemic signs Rhythm disorders Ischemic signs
			weeks 0-2	Abnormal	SINUS TACHYCARDIA (> 100)	
			weeks 3-4 weeks 5-6	Abnormal	NON SPECIFIC ST-T WAVE CHANGES SINUS TACHYCARDIA (> 100) NON SPECIFIC ST-T WAVE CHANGES	
88	AH	Female	Screen	Normal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
			weeks 0-2	Normal		
			weeks 3-4 weeks 5-6	Abnormal		
90	SV	Female	Screen	Normal	RIPOLARIZATION DISTURBANCES	Ischemic signs
			weeks 0-2	Normal		
			weeks 3-4 weeks 5-6	Abnormal		

2561

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOXETINE - PROTOCOL 20124/013
 Listing No.: 14.2
 ECG TRACINGS: PATIENTS WITH AT LEAST ONE ABNORMALITY
 OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value	Abnormality type	Abnormality group
10	91	HI	Male	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Abnormal Abnormal Normal	A-V BLOCK 1ST DEGREE A-V BLOCK 1ST DEGREE	Conduction disorders Conduction disorders
93	AN		Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Abnormal Normal Abnormal	NON SPECIFIC ST-T WAVE CHANGES NON SPECIFIC ST-T WAVE CHANGES SINUS BRADYCARDIA (< 60) NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs Ischemic signs Rhythm disorders Ischemic signs
94	PV		Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
11	2	HB	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Abnormal Normal Normal	RIGHT VENTRICULAR HYPERTROPHY	Other disorders
3	RF		Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Abnormal Normal Normal	MYOCARDIAL ISCHEMIA	Ischemic signs
8	KF		Female	Screen weeks 0-2 Screen weeks 3-4	Normal Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
9	FI		Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
12	1	IB	Male	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Abnormal Normal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
4	EG		Female	Screen weeks 0-2	Normal Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders

2562

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REROMETINE - PROTOCOL 20124/013
 Listing No.: 14.2
 ECG TRACINGS: PATIENTS WITH AT LEAST ONE ABNORMALITY
 OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value	Abnormality type	Abnormality group
12	4	EG	Female	Screen weeks 3-4 Screen weeks 5-6	Normal Normal		
	5	ZSH	Male	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Abnormal Normal Abnormal	SINUS TACHYCARDIA (> 100) SINUS TACHYCARDIA (> 100)	Rhythm disorders Rhythm disorders
	6	MK	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Abnormal Normal Abnormal Abnormal	SINUS TACHYCARDIA (> 100) SINUS TACHYCARDIA (> 100) SINUS TACHYCARDIA (> 100)	Rhythm disorders Rhythm disorders Rhythm disorders
	10	IP	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Abnormal Normal Abnormal Normal	SINUS BRADYCARDIA (< 60) SINUS BRADYCARDIA (< 60)	Rhythm disorders Rhythm disorders
	11	ER	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Normal Normal Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
	14	G52	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Abnormal Normal Normal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
	15	GB	Male	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Normal Abnormal Normal Abnormal	SINUS TACHYCARDIA (> 100) SINUS TACHYCARDIA (> 100)	Rhythm disorders Rhythm disorders
	16	FN	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Abnormal Normal Normal Normal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
	19	SS2	Female	Screen weeks 0-2 Screen weeks 3-4 Screen weeks 5-6	Abnormal Normal Normal	SINUS BRADYCARDIA (< 60)	Rhythm disorders

2563

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 14.2
 ECG TRACINGS: PATIENTS WITH AT LEAST ONE ABNORMALITY
 OPEN PHASE

Centre	Patient	Initials	Sex	Time interval	E.C.G. value	Abnormality type	Abnormality group
12	27	VCS	Female	Screen weeks 0-2	Normal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
				Screen weeks 3-4	Normal		
				Screen weeks 5-6	Abnormal		
	28	IV	Female	Screen weeks 0-2	Normal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
				Screen weeks 3-4	Abnormal		
				Screen weeks 5-6	Normal		
	35	LP	Female	Screen weeks 0-2	Normal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
				Screen weeks 3-4	Abnormal		
				Screen weeks 5-6	Normal		
	36	FB	Female	Screen weeks 0-2	Normal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
				Screen weeks 3-4	Abnormal		
				Screen weeks 5-6	Normal		
	38	FG	Female	Screen weeks 0-2	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
				Screen weeks 3-4	Normal		
				Screen weeks 5-6	Normal		
13	1	PZ	Female	Screen weeks 0-2	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
				Screen weeks 3-4	Normal		
				Screen weeks 5-6	Normal		
	2	TCS	Female	Screen weeks 0-2	Normal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
				Screen weeks 3-4	Normal		
				Screen weeks 5-6	Abnormal		
	3	AI	Female	Screen weeks 0-2	Normal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
				Screen weeks 3-4	Normal		
				Screen weeks 5-6	Abnormal		

2564

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
 REBOMETINE - PROTOCOL 20124/013
 Listing No.: 14.2
 ECG TRACINGS: PATIENTS WITH AT LEAST ONE ABNORMALITY
 OPEN PHASE

Centre	Patient Initials	Sex	Time interval	E.C.G. value	Abnormality type	Abnormality group
13	6 KE	Female	Screen weeks 0-2	Normal		
			Screen weeks 3-4	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
			Screen weeks 5-6	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
7 BL	Female	Screen weeks 0-2	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders	
		Screen weeks 3-4	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders	
		Screen weeks 5-6	Normal			
8 PK	Female	Screen weeks 0-2	Normal			
		Screen weeks 3-4	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders	
		Screen weeks 5-6	Normal			
10 BK	Female	Screen weeks 0-2	Abnormal	SINUS TACHYCARDIA (> 100) LEFT POSTERIOR HEMIBLOCK	Rhythm disorders Conduction disorders	
		Screen weeks 3-4	Normal			
12 BF	Male	Screen weeks 0-2	Normal			
		Screen weeks 3-4	Abnormal	SINUS TACHYCARDIA (> 100) SINUS TACHYCARDIA (> 100)	Rhythm disorders Rhythm disorders	
14 DF	Female	Screen weeks 0-2	Abnormal	RIGHT BUNDLE BRANCH BLOCK	Conduction disorders	
		Screen weeks 3-4	Normal			
		Screen weeks 5-6	Normal			
15 KG	Female	Screen weeks 0-2	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders	
		Screen weeks 3-4	Normal			
		Screen weeks 5-6	Normal			
17 GSM	Female	Screen weeks 0-2	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders	
		Screen weeks 3-4	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders	
		Screen weeks 5-6	Normal			
22 NYM	Female	Screen weeks 0-2	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders	
		Screen weeks 3-4	Normal			
		Screen weeks 5-6	Normal			

22
27
31
31

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.2

ECG TRACINGS: PATIENTS WITH AT LEAST ONE ABNORMALITY
DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value	Abnormality type	Abnormality group
1	16 MHC	Placebo	Female	Run In	Screen	Abnormal	A-V BLOCK 1ST DEGREE	Conduction disorders Conduction disorders Conduction disorders Conduction disorders Conduction disorders Conduction disorders
				Run In	weeks 0-2	Abnormal	A-V BLOCK 1ST DEGREE	
				Run In	weeks 3-4	Abnormal	A-V BLOCK 1ST DEGREE	
				Run In	weeks 5-6	Normal		
				D. B.	weeks 7-10	Abnormal	LEFT BUNDLE BRANCH BLOCK	
				D. B.	weeks 11-18	Abnormal	LEFT BUNDLE BRANCH BLOCK	
				D. B.	weeks 19-26	Abnormal	A-V BLOCK 1ST DEGREE	
				D. B.	weeks 27-34	Abnormal	A-V BLOCK 1ST DEGREE	
				Run In	Screen	Normal		
				Run In	weeks 0-2	Abnormal	SINUS BRADYCARDIA (< 60)	
				Run In	weeks 3-4	Abnormal	SINUS BRADYCARDIA (< 60)	
				Run In	weeks 5-6	Abnormal	SINUS BRADYCARDIA (< 60)	
D. B.	weeks 7-10	Normal						
D. B.	weeks 11-18	Normal						
D. B.	weeks 19-26	Normal						
D. B.	weeks 27-34	Normal						
D. B.	weeks 35-42	Normal						
D. B.	weeks 43-52	Normal						
24	LVF	Reboxetine	Female	Run In	Screen	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders Rhythm disorders Rhythm disorders
				Run In	weeks 0-2	Normal		
				Run In	weeks 3-4	Abnormal	SINUS TACHYCARDIA (> 100)	
				Run In	weeks 5-6	Abnormal	SINUS TACHYCARDIA (> 100)	
				D. B.	weeks 7-10	Normal		
				D. B.	weeks 11-18	Normal		
				D. B.	weeks 19-26	Normal		
				D. B.	weeks 27-34	Normal		
				D. B.	weeks 35-42	Normal		
				D. B.	weeks 43-52	Normal		
				Run In	Screen	Normal		
				Run In	weeks 0-2	Abnormal	VENTRICULAR ECTOPIC BEATS - OC	
Run In	weeks 3-4	Abnormal	VENTRICULAR ECTOPIC BEATS - OC					
Run In	weeks 5-6	Abnormal	VENTRICULAR ECTOPIC BEATS - OC					
D. B.	weeks 7-10	Normal						
D. B.	weeks 11-18	Normal						
D. B.	weeks 19-26	Normal						
D. B.	weeks 27-34	Normal						
42	ICC	Placebo	Female	Run In	Screen	Normal		Ischemic signs
				Run In	weeks 0-2	Normal		
				Run In	weeks 3-4	Normal		
				Run In	weeks 5-6	Normal		
				D. B.	weeks 7-10	Normal		
				D. B.	weeks 11-18	Normal		
				D. B.	weeks 19-26	Normal		
				D. B.	weeks 27-34	Abnormal	RIPOLARIZATION DISTURBANCES	

25
51
06
03

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013

Listing No.: 14.2

ECG TRACINGS: PATIENTS WITH AT LEAST ONE ABNORMALITY
DOUBLE BLIND PHASE

Centre	Patient	Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value	Abnormality type	Abnormality group
1	42	ICC	Placebo	Female	D. B.	weeks 35-42	Normal		
					D. B.	weeks 43-52	Normal		
	75	ELF	Reboxetine	Female	Screen		Abnormal	RIGHT BUNDLE BRANCH BLOCK	Conduction disorders
					Run In	weeks 0-2	Normal		
					Run In	weeks 3-4	Normal		
					Run In	weeks 5-6	Normal		
					D. B.	weeks 7-10	Normal		
					D. B.	weeks 11-18	Normal		
					D. B.	weeks 19-26	Normal		
					D. B.	weeks 27-34	Normal		
D. B.	weeks 35-42	Normal							
D. B.	weeks 43-52	Normal							
111	JBF	Placebo	Male	Screen		Normal			
				Run In	weeks 0-2	Normal			
				Run In	weeks 3-4	Normal			
				Run In	weeks 5-6	Normal			
				D. B.	weeks 7-10	Normal			
				D. B.	weeks 11-18	Normal			
				D. B.	weeks 19-26	Abnormal	SINUS BRADYCARDIA (< 60)	Rhythm disorders	
				D. B.	weeks 27-34	Abnormal	SINUS BRADYCARDIA (< 60)	Rhythm disorders	
				D. B.	weeks 35-42	Normal			
				D. B.	weeks 43-52	Normal			
122	HSS	Placebo	Male	Screen		Normal			
				Run In	weeks 0-2	Normal			
				Run In	weeks 3-4	Normal			
				Run In	weeks 5-6	Normal			
				D. B.	weeks 7-10	Abnormal	SINUS BRADYCARDIA (< 60)	Rhythm disorders	
				D. B.	weeks 11-18	Abnormal	SINUS BRADYCARDIA (< 60)	Rhythm disorders	
				D. B.	weeks 19-26	Normal			
				D. B.	weeks 27-34	Normal			
				D. B.	weeks 35-42	Normal			
				D. B.	weeks 43-52	Normal			
123	MLL	Reboxetine	Female	Screen		Normal			
				Run In	weeks 0-2	Normal			
				Run In	weeks 3-4	Normal			
				Run In	weeks 5-6	Normal			
				D. B.	weeks 7-10	Abnormal	SINUS BRADYCARDIA (< 60)	Rhythm disorders	
				D. B.	weeks 11-18	Abnormal	SINUS BRADYCARDIA (< 60)	Rhythm disorders	
				D. B.	weeks 19-26	Normal			
				D. B.	weeks 27-34	Normal			
				D. B.	weeks 35-42	Normal			
				D. B.	weeks 43-52	Normal			

2567

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013

Listing No.: 14.2

ECG TRACINGS: PATIENTS WITH AT LEAST ONE ABNORMALITY
DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value	Abnormality type	Abnormality group				
1	138 LBV	Placebo	Female	Screen	Normal							
				Run In weeks 0-2	Normal							
				Run In weeks 3-4	Normal							
				Run In weeks 5-6	Normal							
				Run In weeks 7-10	Normal							
				D. B. weeks 11-18	Normal							
				D. B. weeks 19-26	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders					
				D. B. weeks 27-34	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders					
				D. B. weeks 35-42	Normal							
				D. B. weeks 43-52	Normal							
				27 37 50 50	141 AMG	Placebo	Female	Screen	Normal			
								Run In weeks 0-2	Normal			
								Run In weeks 3-4	Normal			
								Run In weeks 5-6	Normal			
Run In weeks 7-10	Normal											
D. B. weeks 11-18	Normal											
D. B. weeks 19-26	Abnormal	SINUS BRADYCARDIA (< 60)	Rhythm disorders									
D. B. weeks 27-34	Abnormal	SINUS BRADYCARDIA (< 60)	Rhythm disorders									
D. B. weeks 35-42	Normal											
D. B. weeks 43-52	Normal											
8	1 HJ	Placebo	Female					Screen	Normal			
								Run In weeks 0-2	Normal			
								Run In weeks 3-4	Normal			
								Run In weeks 5-6	Normal			
				Run In weeks 7-10	Normal							
				D. B. weeks 11-18	Normal							
				D. B. weeks 19-26	Abnormal	SINUS BRADYCARDIA (< 60)	Rhythm disorders					
				D. B. weeks 27-34	Abnormal	SINUS BRADYCARDIA (< 60)	Rhythm disorders					
				D. B. weeks 35-42	Normal							
				Screen	Normal							
				Run In weeks 0-2	Normal							
				Run In weeks 3-4	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders					
				Run In weeks 5-6	Normal							
				D. B. weeks 7-10	Normal							
D. B. weeks 11-18	Normal											
D. B. weeks 19-26	Normal											
D. B. weeks 27-34	Normal											
D. B. weeks 35-42	Normal											
3	JL	Reboxetine	Male	Screen	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders					
				Run In weeks 0-2	Normal							
				Run In weeks 3-4	Normal							
				Run In weeks 5-6	Normal							

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013

Listing No.: 14.2

ECG TRACINGS: PATIENTS WITH AT LEAST ONE ABNORMALITY
DOUBLE BLIND PHASE

Centre	Patient	Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value	Abnormality type	Abnormality group
8	3	JL	Reboxetine	Male	Run In	weeks 5-6	Normal		
					D. B.	weeks 7-10	Normal		
9	4	BA	Placebo	Female	Screen		Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
					Run In	weeks 0-2	Normal		
					Run In	weeks 3-4	Normal		
					Run In	weeks 5-6	Normal		
					Run In	weeks 7-10	Normal		
					D. B.	weeks 11-18	Normal		
					D. B.	weeks 19-26	Normal		
					D. B.	weeks 27-34	Normal		
					D. B.	weeks 35-42	Normal		
					D. B.	weeks 43-52	Normal		
					Screen		Normal		
					Run In	weeks 0-2	Normal		
Run In	weeks 3-4	Normal							
Run In	weeks 5-6	Normal							
Run In	weeks 7-10	Normal							
D. B.	weeks 11-18	Normal							
D. B.	weeks 19-26	Normal							
D. B.	weeks 27-34	Normal							
D. B.	weeks 35-42	Normal							
D. B.	weeks 43-52	Abnormal							
Screen		Normal							
Run In	weeks 0-2	Normal							
Run In	weeks 3-4	Normal							
Run In	weeks 5-6	Normal							
Run In	weeks 7-10	Normal							
D. B.	weeks 11-18	Normal							
D. B.	weeks 19-26	Normal							
D. B.	weeks 27-34	Normal							
D. B.	weeks 35-42	Normal							
D. B.	weeks 43-52	Abnormal							
Screen		Normal							
Run In	weeks 0-2	Normal							
Run In	weeks 3-4	Normal							
Run In	weeks 5-6	Normal							
Run In	weeks 7-10	Normal							
D. B.	weeks 11-18	Normal							
D. B.	weeks 19-26	Normal							
D. B.	weeks 27-34	Abnormal							
D. B.	weeks 35-42	Normal							
D. B.	weeks 43-52	Normal							
Screen		Normal							
Run In	weeks 0-2	Normal							
Run In	weeks 3-4	Normal							
Run In	weeks 5-6	Normal							
Run In	weeks 7-10	Normal							
D. B.	weeks 11-18	Normal							
D. B.	weeks 19-26	Normal							
D. B.	weeks 27-34	Normal							
D. B.	weeks 35-42	Abnormal							
D. B.	weeks 43-52	Normal							
Screen		Normal							
Run In	weeks 0-2	Normal							
Run In	weeks 3-4	Normal							
Run In	weeks 5-6	Normal							
Run In	weeks 7-10	Normal							
D. B.	weeks 11-18	Normal							
D. B.	weeks 19-26	Normal							
D. B.	weeks 27-34	Normal							
D. B.	weeks 35-42	Abnormal							
D. B.	weeks 43-52	Normal							
Screen		Normal							
Run In	weeks 0-2	Normal							
Run In	weeks 3-4	Normal							
Run In	weeks 5-6	Normal							
Run In	weeks 7-10	Normal							
D. B.	weeks 11-18	Normal							
D. B.	weeks 19-26	Normal							
D. B.	weeks 27-34	Normal							
D. B.	weeks 35-42	Abnormal							
D. B.	weeks 43-52	Normal							

2569

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013

Listing No.: 14.2

ECG TRACINGS: PATIENTS WITH AT LEAST ONE ABNORMALITY
DOUBLE BLIND PHASE

Centre	Patient	Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value	Abnormality type	Abnormality group							
9	16	UCY	Reboxetine	Female	Run In	Screen	Normal									
					Run In	weeks 0-2	Normal									
					Run In	weeks 3-4	Normal									
					Run In	weeks 5-6	Normal									
					D. B.	weeks 7-10	Normal									
					D. B.	weeks 11-18	Normal									
					D. B.	weeks 19-26	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders							
					D. B.	weeks 35-42	Abnormal	OTHER	Other disorders							
					D. B.	weeks 43-52	Normal	OTHER	Other disorders							
					20	GYE	Female	Reboxetine	Run In	Screen	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders			
									Run In	weeks 0-2	Normal	MYOCARDIAL ISCHEMIA	Ischemic signs			
									Run In	weeks 3-4	Normal					
									Run In	weeks 5-6	Normal					
									D. B.	weeks 7-10	Normal					
									D. B.	weeks 11-18	Normal					
25	PH	Female	Placebo	Run In					Screen	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders				
				Run In					weeks 0-2	Normal						
				Run In					weeks 3-4	Normal						
				Run In					weeks 5-6	Normal						
				D. B.					weeks 7-10	Normal						
				D. B.					weeks 19-26	Normal						
				D. B.					weeks 27-34	Normal						
				D. B.					weeks 35-42	Normal						
				26					CP	Female	Reboxetine	Run In	Screen	Normal		
					Run In	weeks 0-2	Normal									
					Run In	weeks 3-4	Normal									
					Run In	weeks 5-6	Normal									
					D. B.	weeks 7-10	Normal									
					D. B.	weeks 11-18	Abnormal	SINUS TACHYCARDIA (> 100)				Rhythm disorders				
					10	VK	Male	Reboxetine				Run In	Screen	Abnormal	LEFT VENTRICULAR HYPERTROPHY	Other disorders
Run In	weeks 0-2	Abnormal	LEFT VENTRICULAR HYPERTROPHY									Other disorders				
Run In	weeks 3-4	Abnormal	LEFT VENTRICULAR HYPERTROPHY									Other disorders				
Run In	weeks 5-6	Abnormal	LEFT VENTRICULAR HYPERTROPHY									Other disorders				
D. B.	weeks 7-10	Abnormal	LEFT VENTRICULAR HYPERTROPHY									Other disorders				
D. B.	weeks 11-18	Abnormal	LEFT VENTRICULAR HYPERTROPHY									Other disorders				
5	AN	Female	Placebo									Run In	Screen	Abnormal	SINUS BRADYCARDIA (< 60)	Rhythm disorders

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013

Listing No.: 14.2

ECG TRACINGS: PATIENTS WITH AT LEAST ONE ABNORMALITY
DOUBLE BLIND PHASE

Centre	Patient	Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value	Abnormality type	Abnormality group	
10	5	AN	Placebo	Female	Run In	weeks 0-2	Normal			
					Run In	weeks 3-4	Abnormal	RIPOLARIZATION DISTURBANCES	Ischemic signs	
	16	AJ	Placebo	Female	Run In	weeks 3-4	Normal			
					Run In	weeks 5-6	Abnormal	SINUS BRADYCARDIA (< 60)	Rhythm disorders	
						Run In	weeks 7-10	Abnormal	SINUS BRADYCARDIA (< 60)	Rhythm disorders
						Run In	weeks 11-18	Abnormal	CONDUCTION DISORDER	Conduction disorders
						Screen	weeks 11-18	Abnormal	SINUS BRADYCARDIA (< 60)	Rhythm disorders
						Run In	Screen	Normal		
						Run In	weeks 0-2	Normal		
						Run In	weeks 3-4	Normal		
17	MI		Placebo	Female	Run In	weeks 3-4	Abnormal	LEFT AXIAL DEVIATION	Conduction disorders	
					Run In	weeks 5-6	Abnormal	LEFT AXIAL DEVIATION	Conduction disorders	
						Run In	weeks 7-10	Abnormal	LEFT AXIAL DEVIATION	Conduction disorders
						Run In	weeks 11-18	Abnormal	LEFT AXIAL DEVIATION	Conduction disorders
						Run In	weeks 19-26	Abnormal	LEFT AXIAL DEVIATION	Conduction disorders
						Run In	weeks 27-34	Abnormal	LEFT AXIAL DEVIATION	Conduction disorders
						Run In	weeks 35-42	Abnormal	LEFT AXIAL DEVIATION	Conduction disorders
						Run In	weeks 43-52	Abnormal	LEFT AXIAL DEVIATION	Conduction disorders
	19	TN		Placebo	Female	Run In	Screen	Normal		
						Run In	weeks 0-2	Normal		
						Run In	weeks 3-4	Normal		
						Run In	weeks 5-6	Normal		
						Run In	weeks 7-10	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
						Run In	weeks 11-18	Normal		
						Run In	weeks 19-26	Normal		
						Run In	weeks 35-42	Normal		
						Run In	weeks 43-52	Normal		
						Screen	Normal			
20	EJ		Reboxetine	Female	Run In	Screen	Normal			
					Run In	weeks 0-2	Normal			
						Run In	weeks 3-4	Normal		
						Run In	weeks 5-6	Normal		
						Run In	weeks 7-10	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
						Run In	weeks 11-18	Abnormal	HYOCARDIAL ISCHEMIA	Ischemic signs
						Run In	weeks 11-18	Abnormal		
						Run In	weeks 27-34	Normal		

2571

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACTA CNS R&D

REBOXETINE - PROTOCOL 20124/013

Listing No.: 14.2

ECG TRACINGS: PATIENTS WITH AT LEAST ONE ABNORMALITY
DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value	Abnormality type	Abnormality group				
10	22 AA	Reboxetine	Male	Run In	Screen	Normal						
				Run In	weeks 0-2	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders				
				Run In	weeks 3-4	Abnormal	RIPOLARIZATION DISTURBANCES	Ischemic signs				
				Run In	weeks 5-6	Abnormal	RIPOLARIZATION DISTURBANCES	Ischemic signs				
				D. B.	weeks 7-10	Normal	RIPOLARIZATION DISTURBANCES	Ischemic signs				
				D. B.	weeks 11-18	Normal						
				D. B.	weeks 19-26	Normal						
				D. B.	weeks 27-34	Normal						
				D. B.	weeks 35-42	Normal						
				D. B.	weeks 43-52	Normal						
				23	IT	Reboxetine	Female	Run In	Screen	Normal		
								Run In	weeks 0-2	Normal		
								Run In	weeks 3-4	Normal		
								Run In	weeks 5-6	Normal		
								Run In	weeks 7-10	Abnormal	RIPOLARIZATION DISTURBANCES	Ischemic signs
D. B.	weeks 11-18	Normal										
D. B.	weeks 19-26	Normal										
D. B.	weeks 27-34	Normal										
D. B.	weeks 35-42	Abnormal	RIPOLARIZATION DISTURBANCES					Ischemic signs				
24	AL	Placebo	Male					Run In	Screen	Abnormal	RIGHT VENTRICULAR HYPERTROPHY	Other disorders
								Run In	weeks 0-2	Abnormal	RIGHT VENTRICULAR HYPERTROPHY	Other disorders
								Run In	weeks 3-4	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
								Run In	weeks 5-6	Abnormal	RIGHT VENTRICULAR HYPERTROPHY	Other disorders
								Run In	weeks 7-10	Normal	RIGHT VENTRICULAR HYPERTROPHY	Other disorders
								D. B.	weeks 11-18	Normal		
				D. B.	weeks 19-26	Abnormal	RIPOLARIZATION DISTURBANCES	Ischemic signs				
				D. B.	weeks 27-34	Abnormal	RIGHT VENTRICULAR HYPERTROPHY	Other disorders				
				D. B.	weeks 35-42	Abnormal	MYOCARDIAL ISCHEMIA	Ischemic signs				
				D. B.	weeks 43-52	Abnormal	RIPOLARIZATION DISTURBANCES	Ischemic signs				
				26	JIF	Reboxetine	Female	Run In	Screen	Normal		
								Run In	weeks 0-2	Normal		
								Run In	weeks 3-4	Normal		
								Run In	weeks 5-6	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
								D. B.	weeks 7-10	Normal		
27	MK	Reboxetine	Female					Run In	Screen	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
								Run In	weeks 0-2	Normal		
								Run In	weeks 3-4	Normal		
								Run In	weeks 5-6	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
								D. B.	weeks 7-10	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs

2572

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CMS RED

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.2

ECG TRACINGS: PATIENTS WITH AT LEAST ONE ABNORMALITY
DOUBLE BLIND PHASE

Centre	Patient	Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value	Abnormality type	Abnormality group
10	27	MK	Reboxetine	Female	D. B.	weeks 11-18	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
					D. B.	weeks 27-34	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
					D. B.	weeks 35-42	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
	30	VK	Placebo	Female	Screen	weeks 43-52	Normal		
					Run In	weeks 0-2	Normal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
					Run In	weeks 3-4	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
	31	RK	Reboxetine	Female	Run In	weeks 5-6	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
					Run In	weeks 7-10	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
					Run In	weeks 11-18	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
	32	LK	Reboxetine	Female	Run In	weeks 19-26	Normal		
					Run In	weeks 27-34	Normal		
					Run In	weeks 43-52	Normal		
	33	RK	Reboxetine	Female	Screen	weeks 0-2	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
					Run In	weeks 3-4	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
					Run In	weeks 5-6	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
	34	RK	Reboxetine	Female	Run In	weeks 7-10	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
					Run In	weeks 11-18	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
					Run In	weeks 27-34	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
	35	LH	Reboxetine	Female	Run In	weeks 35-42	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
					Run In	weeks 43-52	Normal		
					Screen	weeks 0-2	Abnormal	VENTRICULAR ECTOPIC BEATS - OC	Rhythm disorders
	36	LH	Reboxetine	Female	Run In	weeks 3-4	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
					Run In	weeks 5-6	Normal		
					Run In	weeks 7-10	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
	37	RH	Placebo	Female	Run In	weeks 27-34	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
					Run In	weeks 35-42	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
					Run In	weeks 43-52	Normal		
	38	RH	Placebo	Female	Screen	weeks 0-2	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders
					Run In	weeks 3-4	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders
					Run In	weeks 5-6	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders
	39	RH	Placebo	Female	Run In	weeks 7-10	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders
					Run In	weeks 11-18	Abnormal		
					Run In	weeks 19-26	Abnormal	OTHER	Other disorders
	40	RH	Placebo	Female	Run In	weeks 27-34	Abnormal	OTHER	Other disorders
					Run In	weeks 35-42	Abnormal	OTHER	Other disorders
					Run In	weeks 43-52	Abnormal	OTHER	Other disorders

2573

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013

Listing No.: 14.2

ECG TRACINGS: PATIENTS WITH AT LEAST ONE ABNORMALITY
DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value	Abnormality type	Abnormality group
10	37 MK	Placebo	Female	D. B.	weeks 19-26	Abnormal	OTHER	Other disorders
	38 LL	Reboxetine	Female	Run In	Screen	Normal		
				Run In	weeks 0-2	Normal		
				Run In	weeks 3-4	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders
				Run In	weeks 5-6	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders
				D. B.	weeks 7-10	Abnormal	OTHER	Other disorders
	39 VK	Reboxetine	Female	Run In	Screen	Normal		
				Run In	weeks 0-2	Normal		
				Run In	weeks 3-4	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders
				Run In	weeks 5-6	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders
				D. B.	weeks 7-10	Abnormal	NON SPECIFIC ST-T HAVE CHANGES	Ischemic signs
				D. B.	weeks 19-26	Normal		
				D. B.	weeks 27-34	Normal		
				D. B.	weeks 35-42	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders
				D. B.	weeks 43-52	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders
	40 AP	Placebo	Female	Run In	Screen	Normal		
				Run In	weeks 0-2	Normal		
				Run In	weeks 3-4	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
				Run In	weeks 5-6	Normal	NON SPECIFIC ST-T HAVE CHANGES	Ischemic signs
				D. B.	weeks 7-10	Normal		
	41 VP	Reboxetine	Female	Run In	Screen	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders
				Run In	weeks 0-2	Abnormal	NON SPECIFIC ST-T HAVE CHANGES	Ischemic signs
				Run In	weeks 3-4	Abnormal	NON SPECIFIC ST-T HAVE CHANGES	Ischemic signs
				Run In	weeks 5-6	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders
				D. B.	weeks 7-10	Abnormal	NON SPECIFIC ST-T HAVE CHANGES	Ischemic signs
				D. B.	weeks 11-18	Normal		
				D. B.	weeks 19-26	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders
				D. B.	weeks 27-34	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders
				D. B.	weeks 35-42	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders
				D. B.	weeks 43-52	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders
	43 IK	Placebo	Female	Run In	Screen	Normal		
				Run In	weeks 0-2	Abnormal	NON SPECIFIC ST-T HAVE CHANGES	Ischemic signs
				Run In	weeks 3-4	Abnormal	NON SPECIFIC ST-T HAVE CHANGES	Ischemic signs
				Run In	weeks 5-6	Abnormal	NON SPECIFIC ST-T HAVE CHANGES	Ischemic signs
				D. B.	weeks 7-10	Abnormal	NON SPECIFIC ST-T HAVE CHANGES	Ischemic signs

2574

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.2

ECG TRACINGS: PATIENTS WITH AT LEAST ONE ABNORMALITY
DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value	Abnormality type	Abnormality group
10	45 KJ	Placebo	Female	Run In Run In Run In D. B.	Screen weeks 0-2 weeks 3-4 weeks 5-6 weeks 7-10	Abnormal Abnormal Abnormal Normal	RIGHT INCOMPLETE BUNDLE BRANCH RIGHT INCOMPLETE BUNDLE BRANCH RIGHT INCOMPLETE BUNDLE BRANCH RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders Conduction disorders Conduction disorders Conduction disorders
47	TH	Placebo	Female	Run In Run In Run In D. B. D. B. D. B. D. B. D. B.	Screen weeks 0-2 weeks 3-4 weeks 5-6 weeks 7-10 weeks 11-18 weeks 19-26 weeks 27-34 weeks 35-42 weeks 43-52	Abnormal Abnormal Abnormal Abnormal Abnormal Abnormal Abnormal Abnormal Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH RIGHT INCOMPLETE BUNDLE BRANCH RIGHT INCOMPLETE BUNDLE BRANCH SINUS TACHYCARDIA (> 100) RIGHT INCOMPLETE BUNDLE BRANCH RIGHT AXIAL DEVIATION RIGHT INCOMPLETE BUNDLE BRANCH RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders Conduction disorders Conduction disorders Rhythm disorders Other disorders Conduction disorders Conduction disorders Conduction disorders Conduction disorders Conduction disorders Conduction disorders Conduction disorders
48	IP	Placebo	Female	Run In Run In Run In D. B.	Screen weeks 0-2 weeks 3-4 weeks 5-6 weeks 7-10	Abnormal Abnormal Abnormal Normal	RIGHT INCOMPLETE BUNDLE BRANCH SINUS TACHYCARDIA (> 100) RIGHT INCOMPLETE BUNDLE BRANCH RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders Rhythm disorders Conduction disorders Conduction disorders
49	VH	Reboxetine	Female	Run In Run In Run In D. B. D. B.	Screen weeks 0-2 weeks 3-4 weeks 5-6 weeks 7-10 weeks 11-18 weeks 19-26	Abnormal Normal Normal Normal Normal Normal	OTHER	Other disorders
50	EE	Placebo	Male	Run In Run In Run In Run In D. B. D. B. D. B. D. B.	Screen weeks 0-2 weeks 3-4 weeks 5-6 weeks 7-10 weeks 11-18 weeks 19-26 weeks 27-34 weeks 35-42 weeks 43-52	Abnormal Abnormal Abnormal Abnormal Abnormal Abnormal Abnormal Abnormal Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders Conduction disorders Conduction disorders Conduction disorders Conduction disorders Conduction disorders Conduction disorders Conduction disorders Conduction disorders

27
27
27

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROVOCOL 20124/013

Listing No.: 14.2

ECG TRACINGS: PATIENTS WITH AT LEAST ONE ABNORMALITY
DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value	Abnormality type	Abnormality group
10	51 UL	Placebo	Female	Run In	Screen	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
				Run In	weeks 0-2	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
				Run In	weeks 3-4	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
				Run In	weeks 5-6	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
				D. B.	weeks 7-10	Normal		
				D. B.	weeks 11-18	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
				D. B.	weeks 19-26	Normal		
				D. B.	weeks 27-34	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
				D. B.	weeks 35-42	Normal		
				D. B.	weeks 43-52	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
54 UN	Reboxetine	Female	Run In	Screen	Normal			
			Run In	weeks 0-2	Normal			
			Run In	weeks 3-4	Normal			
			Run In	weeks 5-6	Normal			
			D. B.	weeks 7-10	Normal			
			D. B.	weeks 11-18	Normal			
			D. B.	weeks 19-26	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders	
			D. B.	weeks 27-34	Normal			
			D. B.	weeks 35-42	Normal			
			D. B.	weeks 43-52	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders	
55 TP	Placebo	Male	Run In	Screen	Normal			
			Run In	weeks 0-2	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs	
			Run In	weeks 3-4	Normal			
			Run In	weeks 5-6	Normal			
			D. B.	weeks 7-10	Normal			
			D. B.	weeks 11-18	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders	
			D. B.	weeks 19-26	Normal			
			D. B.	weeks 27-34	Normal			
			D. B.	weeks 35-42	Normal			
			D. B.	weeks 43-52	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders	
57 AG	Reboxetine	Female	Run In	Screen	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs	
			Run In	weeks 0-2	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs	
			Run In	weeks 3-4	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs	
			Run In	weeks 5-6	Normal			
			D. B.	weeks 7-10	Normal			
			D. B.	weeks 11-18	Abnormal	RIPOLARIZATION DISTURBANCES	Ischemic signs	
			D. B.	weeks 19-26	Normal			
			D. B.	weeks 27-34	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs	
			D. B.	weeks 35-42	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs	
			D. B.	weeks 43-52	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs	
58 XK	Placebo	Female	Run In	Screen	Normal			
			Run In	weeks 0-2	Abnormal	OTHER NON SPECIFIC ST-T WAVE CHANGES	Other disorders Ischemic signs	

200706

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.2

EKG TRACINGS: PATIENTS WITH AT LEAST ONE ABNORMALITY
DOUBLE BLIND PHASE

Centre	Patient	Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value	Abnormality type	Abnormality group			
10	58	KK	Placebo	Female	Run In	weeks 3-4	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs			
					Run In	weeks 5-6	Normal					
					D. B.	weeks 7-10	Normal					
					D. B.	weeks 19-26	Normal					
61	JT	Placebo	Male	Run In	Screen	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs				
				Run In	weeks 0-2	Normal						
				Run In	weeks 3-4	Abnormal						
				Run In	weeks 5-6	Normal						
62	RK	Placebo	Male	Run In	Screen	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs				
				Run In	weeks 3-4	Abnormal						
				Run In	weeks 5-6	Normal						
				D. B.	weeks 7-10	Abnormal						
63	MS	Reboxetine	Male	Run In	Screen	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Other disorders				
				Run In	weeks 0-2	Abnormal						
				Run In	weeks 3-4	Abnormal						
				Run In	weeks 5-6	Abnormal						
				Run In	weeks 7-10	Abnormal						
				Run In	Screen	Abnormal			NON SPECIFIC ST-T WAVE CHANGES	Other disorders		
				Run In	weeks 0-2	Abnormal						
				Run In	weeks 3-4	Abnormal						
				Run In	weeks 5-6	Abnormal						
				Run In	weeks 7-10	Abnormal						
				D. B.	weeks 7-10	Normal					NON SPECIFIC ST-T WAVE CHANGES	Other disorders
				D. B.	weeks 11-18	Abnormal						
D. B.	weeks 19-26	Abnormal										
D. B.	weeks 27-34	Normal										
D. B.	weeks 35-42	Normal										
D. B.	weeks 43-52	Normal										
64	LT	Placebo	Female	Run In	Screen	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders				
				Run In	weeks 0-2	Abnormal						
				Run In	weeks 5-6	Abnormal						
				D. B.	weeks 7-10	Normal						
81	JN	Placebo	Female	Run In	Screen	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs				
				Run In	weeks 0-2	Normal						
				Run In	weeks 3-4	Normal						
				Run In	weeks 5-6	Abnormal						

2577

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013

Listing No.: 14.2

ECG TRACINGS: PATIENTS WITH AT LEAST ONE ABNORMALITY
DOUBLE BLIND PHASE

Centre	Patient	Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value	Abnormality type	Abnormality group					
10	81	JN	Placebo	Female	D. B.	weeks 7-10	Normal							
					D. B.	weeks 11-18	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders					
					D. B.	weeks 19-26	Abnormal	SINUS BRADYCARDIA (< 60)	Rhythm disorders					
					D. B.	weeks 27-34	Abnormal	RIGHT INCOMPLETE BUNDLE BRANCH	Conduction disorders					
			D. B.	weeks 35-42	Normal			Conduction disorders						
82	LS		Reboxetine	Male	Run In	Screen	Abnormal	MYOCARDIAL ISCHEMIA	Ischemic signs					
					Run In	weeks 0-2	Abnormal	PREVIOUS MYOCARDIAL INFARCTION	Other disorders					
					Run In	weeks 3-4	Abnormal	MYOCARDIAL ISCHEMIA	Ischemic signs					
					Run In	weeks 5-6	Abnormal	PREVIOUS MYOCARDIAL INFARCTION	Other disorders					
					Run In	weeks 7-10	Abnormal	MYOCARDIAL ISCHEMIA	Ischemic signs					
					D. B.	weeks 11-18	Abnormal	PREVIOUS MYOCARDIAL INFARCTION	Other disorders					
					D. B.	weeks 19-26	Abnormal	MYOCARDIAL ISCHEMIA	Ischemic signs					
					D. B.	weeks 27-34	Abnormal	PREVIOUS MYOCARDIAL INFARCTION	Other disorders					
					D. B.	weeks 35-42	Abnormal	MYOCARDIAL ISCHEMIA	Ischemic signs					
								Run In	Screen	Normal				
								Run In	weeks 0-2	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders		
								Run In	weeks 3-4	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders		
			Run In	weeks 5-6	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs							
			D. B.	weeks 7-10	Normal			Ischemic signs						
84	HV		Reboxetine	Female	Run In	Screen	Normal							
					Run In	weeks 0-2	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders					
					Run In	weeks 3-4	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders					
					Run In	weeks 5-6	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs					
					D. B.	weeks 7-10	Normal		Ischemic signs					
					88	AH		Placebo	Female	Run In	Screen	Normal		
										Run In	weeks 0-2	Normal		
										Run In	weeks 3-4	Abnormal	NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
										Run In	weeks 5-6	Normal		
										D. B.	weeks 7-10	Normal		
										D. B.	weeks 11-18	Normal		
								D. B.	weeks 19-26	Normal				
			D. B.	weeks 27-34	Normal									
			D. B.	weeks 35-42	Normal									
			D. B.	weeks 43-52	Normal									
90	SV		Reboxetine	Female	Run In	Screen	Normal							
					Run In	weeks 0-2	Normal							

2578

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.2

ECG TRACINGS: PATIENTS WITH AT LEAST ONE ABNORMALITY
DOUBLE BLIND PHASE

Centre	Patient	Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value	Abnormality type	Abnormality group		
10	90	SV	Reboxetine	Female	Run In	weeks 3-4	Normal	RIPOLARIZATION DISTURBANCES	Ischemic signs		
					Run In	weeks 5-6	Abnormal				
					D. B.	weeks 11-18	Normal				
91	HI	Reboxetine	Male	Run In	Screen	Normal	A-V BLOCK 1ST DEGREE A-V BLOCK 1ST DEGREE	Conduction disorders Conduction disorders			
				Run In	weeks 0-2	Abnormal					
				Run In	weeks 3-4	Abnormal					
				Run In	weeks 5-6	Normal					
				Run In	weeks 7-10	Normal					
				D. B.	weeks 7-10	Normal					
92	LA	Placebo	Female	Run In	Screen	Normal	CONDUCTION DISORDER	Conduction disorders			
				Run In	weeks 0-2	Normal					
				Run In	weeks 5-6	Normal					
				Run In	weeks 7-10	Normal					
				D. B.	weeks 11-18	Normal					
				D. B.	weeks 27-34	Normal					
				D. B.	weeks 35-42	Normal					
				D. B.	weeks 43-52	Abnormal					
				Run In	Screen	Abnormal			NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs	
				Run In	weeks 0-2	Normal					
93	AN	Reboxetine	Female	Run In	Screen	Abnormal	NON SPECIFIC ST-T WAVE CHANGES NON SPECIFIC ST-T WAVE CHANGES SINUS BRADYCARDIA (< 60) NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs Ischemic signs Rhythm disorders Ischemic signs			
				Run In	weeks 0-2	Normal					
				Run In	weeks 3-4	Abnormal					
				Run In	weeks 5-6	Abnormal					
				D. B.	weeks 7-10	Normal					
				D. B.	weeks 19-26	Normal					
94	PV	Placebo	Female	Run In	Screen	Normal	SINUS TACHYCARDIA (> 100)	Rhythm disorders			
				Run In	weeks 0-2	Normal					
				Run In	weeks 3-4	Normal					
				Run In	weeks 5-6	Abnormal					
				Run In	weeks 7-10	Normal					
				D. B.	weeks 7-10	Normal					
11	2	HB	Reboxetine	Female	Run In	Screen	Abnormal	RIGHT VENTRICULAR HYPERTROPHY	Other disorders		
					Run In	weeks 0-2	Normal				
					Run In	weeks 3-4	Normal				
					Run In	weeks 5-6	Normal				
					D. B.	weeks 7-10	Normal				
					D. B.	weeks 11-18	Normal				
					D. B.	weeks 19-26	Normal				
					D. B.	weeks 27-34	Normal				
					Run In	Screen	Abnormal			NON SPECIFIC ST-T WAVE CHANGES	Ischemic signs
					Run In	weeks 0-2	Normal				

21
57
70

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D
REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.2

EKG TRACINGS: PATIENTS WITH AT LEAST ONE ABNORMALITY
DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value	Abnormality type	Abnormality group
12	10 IP	Placebo	Female	Run In	Screen weeks 0-2	Abnormal	SINUS BRADYCARDIA (< 60)	Rhythm disorders
				Run In	weeks 3-4	Normal		
				Run In	weeks 5-6	Abnormal	SINUS BRADYCARDIA (< 60)	Rhythm disorders
				D. B.	weeks 7-10	Normal		
11	ER	Placebo	Female	Run In	Screen weeks 0-2	Normal		
				Run In	weeks 3-4	Normal		
				Run In	weeks 5-6	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
				D. B.	weeks 7-10	Normal		
14	GS2	Placebo	Female	Run In	Screen weeks 0-2	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
				Run In	weeks 3-4	Normal		
				Run In	weeks 5-6	Normal		
				D. B.	weeks 7-10	Normal		
15	GB	Reboxetine	Male	Run In	Screen weeks 0-2	Normal		
				Run In	weeks 3-4	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
				Run In	weeks 5-6	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
				D. B.	weeks 7-10	Normal		
16	FN	Reboxetine	Female	Run In	Screen weeks 0-2	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
				Run In	weeks 3-4	Normal		
				Run In	weeks 5-6	Normal		
				D. B.	weeks 7-10	Normal		
17	TK	Placebo	Male	Run In	Screen weeks 0-2	Normal		
				Run In	weeks 3-4	Normal		
				Run In	weeks 5-6	Normal		
				D. B.	weeks 7-10	Normal		
				Run In	Screen weeks 11-18	Normal		
				Run In	weeks 19-26	Abnormal	SINUS BRADYCARDIA (< 60)	Rhythm disorders
				D. B.	weeks 11-18	Normal		
				D. B.	weeks 19-26	Normal		

2581

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.2

ECG TRACINGS: PATIENTS WITH AT LEAST ONE ABNORMALITY
DOUBLE BLIND PHASE

Centre	Patient	Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value	Abnormality type	Abnormality group					
12	19	SSZ	Reboxetine	Female	Run In	Screen	Abnormal	SINUS BRADYCARDIA (< 60)	Rhythm disorders					
					Run In	weeks 0-2	Normal							
					Run In	weeks 3-4	Normal							
					Run In	weeks 5-6	Normal							
					D. B.	weeks 7-10	Normal							
20	KSZ		Placebo	Male	Run In	Screen	Normal		Rhythm disorders					
					Run In	weeks 0-2	Normal							
					Run In	weeks 3-4	Normal							
					Run In	weeks 5-6	Normal							
					Run In	weeks 7-10	Abnormal	SINUS TACHYCARDIA (> 100)						
					D. B.	weeks 11-18	Normal							
					D. B.	weeks 19-26	Normal							
27	VCS		Reboxetine	Female	Run In	Screen	Normal		Rhythm disorders					
					Run In	weeks 0-2	Normal							
					Run In	weeks 3-4	Normal							
					Run In	weeks 5-6	Abnormal	SINUS TACHYCARDIA (> 100)						
					Run In	weeks 7-10	Normal							
					D. B.	weeks 11-18	Normal							
					D. B.	weeks 19-26	Abnormal	SINUS TACHYCARDIA (> 100)						
					D. B.	weeks 27-34	Abnormal	SINUS TACHYCARDIA (> 100)						
													Normal	
													Normal	
													Abnormal	
													Normal	
28	IV		Placebo	Female	Run In	Screen	Normal		Rhythm disorders					
					Run In	weeks 0-2	Normal							
					Run In	weeks 3-4	Abnormal	SINUS TACHYCARDIA (> 100)						
					Run In	weeks 5-6	Normal							
					D. B.	weeks 7-10	Normal							
35	LP		Placebo	Female	Run In	Screen	Normal		Rhythm disorders					
					Run In	weeks 0-2	Normal							
					Run In	weeks 3-4	Abnormal	SINUS TACHYCARDIA (> 100)						
					Run In	weeks 5-6	Normal							
					Run In	weeks 7-10	Normal							
					D. B.	weeks 11-18	Normal							
							Normal							
36	FB		Reboxetine	Female	Run In	Screen	Normal		Rhythm disorders					
					Run In	weeks 0-2	Abnormal	SINUS TACHYCARDIA (> 100)						
					Run In	weeks 3-4	Normal							
					Run In	weeks 5-6	Normal							
					Run In	weeks 7-10	Normal							
					D. B.									

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.2

ECG TRACINGS: PATIENTS WITH AT LEAST ONE ABNORMALITY
DOUBLE BLIND PHASE

Centre	Patient	Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value	Abnormality type	Abnormality group
13	1	PZ	Reboxetine	Female	Run In	Screen	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
					Run In	weeks 0-2	Normal		
					Run In	weeks 3-4	Normal		
					Run In	weeks 5-6	Normal		
					D. B.	weeks 7-10	Abnormal		
					D. B.	weeks 11-18	Normal		
					D. B.	weeks 19-26	Normal		
					D. B.	weeks 27-34	Normal		
					D. B.	weeks 35-42	Normal		
					D. B.	weeks 43-52	Normal		
2	TCS		Placebo	Female	Run In	Screen	Normal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
					Run In	weeks 0-2	Normal		
					Run In	weeks 3-4	Normal		
					Run In	weeks 5-6	Abnormal		
					D. B.	weeks 7-10	Abnormal		
					D. B.	weeks 11-18	Normal		
					D. B.	weeks 19-26	Abnormal		
					D. B.	weeks 27-34	Normal		
					D. B.	weeks 35-42	Normal		
					D. B.	weeks 43-52	Normal		
3	AI		Reboxetine	Female	Run In	Screen	Normal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
					Run In	weeks 0-2	Normal		
					Run In	weeks 3-4	Normal		
					Run In	weeks 5-6	Abnormal		
					D. B.	weeks 7-10	Abnormal		
					D. B.	weeks 11-18	Abnormal		
					D. B.	weeks 19-26	Normal		
					D. B.	weeks 27-34	Abnormal		
					D. B.	weeks 35-42	Abnormal		
					D. B.	weeks 43-52	Normal		
6	KE		Reboxetine	Female	Run In	Screen	Normal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
					Run In	weeks 0-2	Abnormal		
					Run In	weeks 3-4	Normal		
					Run In	weeks 5-6	Abnormal		
					D. B.	weeks 7-10	Abnormal		
					D. B.	weeks 11-18	Normal		
					D. B.	weeks 19-26	Abnormal		
					D. B.	weeks 27-34	Abnormal		
					D. B.	weeks 35-42	Abnormal		
					D. B.	weeks 43-52	Normal		
7	BL		Reboxetine	Female	Run In	Screen	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
					Run In	weeks 0-2	Abnormal		
					Run In	weeks 3-4	Normal		
					Run In	weeks 5-6	Abnormal		
					D. B.	weeks 7-10	Abnormal		
					D. B.	weeks 11-18	Normal		
					D. B.	weeks 19-26	Abnormal		
					D. B.	weeks 27-34	Abnormal		
					D. B.	weeks 35-42	Abnormal		
					D. B.	weeks 43-52	Normal		

2503

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013
Listing No.: 14.2

ECG TRACINGS: PATIENTS WITH AT LEAST ONE ABNORMALITY
DOUBLE BLIND PHASE

Centre	Patient	Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value	Abnormality type	Abnormality group
13	7	BL	Reboxetine	Female	Run In	weeks 3-4	Normal		
					Run In	weeks 5-6	Normal		
					D. B.	weeks 7-10	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
					D. B.	weeks 11-18	Normal		
					D. B.	weeks 19-26	Normal		
					D. B.	weeks 27-34	Normal		
8	PK		Placebo	Female	Screen		Normal		
					Run In	weeks 0-2	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
					Run In	weeks 3-4	Normal		
					Run In	weeks 5-6	Normal		
					D. B.	weeks 7-10	Normal		
					D. B.	weeks 11-18	Normal		
20 21 28 4	14	DF	Placebo	Female	Screen		Abnormal	RIGHT BUNDLE BRANCH BLOCK	Conduction disorders
					Run In	weeks 0-2	Normal		
					Run In	weeks 3-4	Normal		
					Run In	weeks 5-6	Normal		
					Run In	weeks 7-10	Normal		
					D. B.	weeks 11-18	Normal		
					D. B.	weeks 19-26	Normal		
					D. B.	weeks 27-34	Normal		
					D. B.	weeks 35-42	Normal		
					D. B.	weeks 43-52	Normal		
					Screen		Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
					15	KG		Placebo	Female
Run In	weeks 0-2	Normal							
Run In	weeks 3-4	Normal							
Run In	weeks 5-6	Normal							
Run In	weeks 7-10	Normal							
D. B.	weeks 11-18	Normal							
D. B.	weeks 19-26	Normal							
D. B.	weeks 27-34	Normal							
D. B.	weeks 35-42	Normal							
D. B.	weeks 43-52	Normal							
Screen		Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders					
17	GSH		Placebo	Female					
					Run In	weeks 0-2	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
					Run In	weeks 3-4	Abnormal	SINUS TACHYCARDIA (> 100)	Rhythm disorders
					Run In	weeks 5-6	Normal		
					D. B.	weeks 7-10	Abnormal	SICK SINUS SYNDROME	Rhythm disorders
					D. B.	weeks 11-18	Normal		

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R&D

REBOXETINE - PROTOCOL 20124/013

Listing No.: 14.2

EKG TRACINGS: PATIENTS WITH AT LEAST ONE ABNORMALITY
DOUBLE BLIND PHASE

Centre	Patient Initials	Assigned treatment	Sex	Phase	Time interval	E.C.G. value	Abnormality type	Abnormality group
13	17	Placebo	Female	D. B.	weeks 19-26	Normal		
				D. B.	weeks 27-34	Normal		
				D. B.	weeks 35-42	Normal		
22	NYM	Reboxetine	Female	Screen	Abnormal		SINUS TACHYCARDIA (> 100)	Rhythm disorders
				Run In	Normal			
				Run In	Normal			
				D. B.	Normal			

2585

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R & D
REBOXETINE - PROTOCOL 20124 / 013
LISTING NO. 15 . OPHTHALMOLOGIC EXAMINATION AT BASELINE AND AT LAST ASSESSMENT
RANDOMIZED PATIENTS - TREATMENT REBOXETINE

CENTER	PAT. NO.	BASELINE				LAST ASSESSMENT			
		I.O.P (mmHg)		GLOBAL ASSESSMENT	I.O.P (mmHg)		GLOBAL ASSESSMENT		
		RIGHT	LEFT		RIGHT	LEFT			
1	3/2			ND		15	17	N	
1	4/3			ND		18	16	N	
1	5/4			ND		16	18	N	
1	9/7			ND		16	18	N	
1	10/8	15	18	N	18	18	16	N	
1	14/11	16	17	N	17	17	19	N	
1	17/14	18	16	N	17	17	19	N	
1	18/15	16	18	N	15	15	15	N	
1	20/17	15	16	N	15	15	15	N	
1	22/19	17	17	N	15	15	16	N	
1	24/20	18	16	N	17	16	16	N	
1	25/21	15	16	N	16	15	15	N	
1	31/27	15	16	N	17	17	15	N	
1	32/28	15	15	N	16	16	15	N	
1	34/30	16	17	N	17	17	17	N	
1	35/301	18	17	N	17	17	16	N	
1	37/303	16	16	N	15	15	15	N	
1	39/305	15	16	N	16	16	16	N	
1	43/309	16	15	N	16	16	15	N	
1	45/310	15	16	N	16	16	15	N	
1	46/311	16	16	N	17	17	16	N	
1	48/313	15	15	N	14	14	15	N	

2586

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

CENTER	PAT. NO.	BASELINE						LAST ASSESSMENT		
		I.O.P (mmHg)			GLOBAL ASSESSMENT			I.O.P (mmHg)		
		RIGHT	LEFT	GLOBAL ASSESSMENT	RIGHT	LEFT	GLOBAL ASSESSMENT	RIGHT	LEFT	GLOBAL ASSESSMENT
1	52/316	17	15	N			15	15	N	
1	55/318	15	16	N			17	15	N	
1	56/319	16	17	N			16	15	N	
1	58/320	17	16	N			15	15	N	
1	61/323	17	19	N			16	15	N	
1	66/326	15	16	N			16	15	N	
1	71/329	15	17	N			16	18	N	
1	72/330	16	17	N			18	18	N	
1	73/121	15	14	N			17	17	N	
1	75/123	16	17	N			18	19	N	
1	77/125	17	15	N			18	17	N	
1	81/128	16	16	N			20	20	N	
1	82/129	16	17	N			19	20	N	
1	87/132	14	13	N			14	16	N	
1	89/133	15	13	N			16	17	N	
1	90/134	13	14	N			14	16	N	
1	95/138	15	15	N			18	19	N	
1	96/139	15	16	N			19	18	N	
1	98/141	14	13	N			15	13	N	
1	101/143	15	14	N			16	18	N	
1	107/147	15	16	N			19	19	N	
1	109/149	16	17	N			18	20	N	
1	110/150	15	16	N			17	17	N	
1	116/334	13	14	N			15	15	N	
1	117/335	17	19	N			18	18	N	
1	121/336	16	17	N			18	19	N	
1	123/338	16	18	N			17	18	N	

2587

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

CENTER	PAT.NO.	BASELINE				LAST ASSESSMENT			
		I.O.P (mmHg)		GLOBAL ASSESSMENT	I.O.P (mmHg)		GLOBAL ASSESSMENT		
		RIGHT	LEFT		RIGHT	LEFT			
1	125/340	16	16	N	15	15	N		
1	127/342	15	17	N	17	17	N		
1	128/343	14	13	N	14	14	N		
1	134/347	17	15	N	18	17	N		
1	135/348	16	17	N	15	16	N		
1	139/351	19	20	N	18	19	N		
1	140/352	19	18	N	18	19	N		
1	142/354	18	15	N	17	16	N		
1	144/356	19	19	N	20	19	N		
1	146/358	17	18	N	16	17	N		
1	148/359	16	14	N	15	14	N		
3	7/71			ND			ND		
8	2/212	10	10	N	10	10	N		
8	3/213	12	12	N			ND		
8	6/216			ND	12	12	N		
9	6/245	18	17	N	17	17	N		
9	7/243	18	18	N	18	18	N		
9	11/246	18	18	N	16	16	N		
9	15/249	18	18	N	16	16	N		
9	16/250	18	18	Macular degeneration	17	17	No change		
				Cataract l.e.					
9	20/252	16	16	N	16	16	N		
9	23/256	18	18	N	17	17	N		
9	26/255	18	18	N	16	16	N		
9	29/258	16	17	Myopia l.e.	17	17	No change		
				Astigmatism					
				Bilateral amblyopia					

25
57
88

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

CENTER	PAT. NO.	BASELINE						LAST ASSESSMENT		
		I.O.P. (mmHg)			GLOBAL ASSESSMENT			I.O.P. (mmHg)		
		RIGHT	LEFT	GLOBAL ASSESSMENT	RIGHT	LEFT	GLOBAL ASSESSMENT	RIGHT	LEFT	GLOBAL ASSESSMENT
9	30/259	17	17	N		16	17	N		
9	1/271	18	17	N		19	18	N		
10	7/274	22	22	N		20	20	N		
10	9/275	18	20	N		17	18	N		
10	12/277	21.5	22.5	Visual field abn.		22	23	No change		
10	13/278	19	18	N				ND		
10	15/280	20	20	N				ND		
10	20/285	21	20	N				ND		
10	22/286	20	19	N		22	21	N		
10	23/287	22	21	N				ND		
10	26/290	20	20	N				ND		
10	27/292	19	18	N				ND		
10	28/291	18	18	N				ND		
10	31/297	20	20	N				ND		
10	32/299	19	20	N				ND		
10	33/300	23	22	N				ND		
10	34/31	22	22	N				ND		
10	35/35	20	20	N				ND		
10	36/36	18	19	N				ND		
10	38/37	19	18	N				ND		
10	39/40	22	22	N		24	24	N		
10	41/42	21	21	N				ND		
10	49/43	22	23	N		21	21	N		
10	53/47	19	20	N				ND		
10	54/48	20	20	N				ND		
10	56/50	21.5	18	N				ND		
10	57/51	20	21	N		21	21	N		

2589

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

CENTER	PAT. NO.	BASELINE				LAST ASSESSMENT			
		I.O.P. (mmHg)		GLOBAL ASSESSMENT		I.O.P. (mmHg)		GLOBAL ASSESSMENT	
		RIGHT	LEFT	GLOBAL ASSESSMENT	RIGHT	LEFT	GLOBAL ASSESSMENT	GLOBAL ASSESSMENT	
10	59/53	25	24	N				ND	
10	63/57	21.5	21.5	N				ND	
10	82/59	22	22	N				ND	
10	83/60	21	21	N				ND	
10	84/63	22	22	N				ND	
10	86/274	22	21	N				ND	
10	87/275	23	23	N	20	21	N	N	
10	89/277	20	19	N				ND	
10	90/70	21	20	N				ND	
10	91/74	18	19	N				ND	
10	93/285	20	21	N				ND	
11	2/373	20	20	N				ND	
11	3/374	20	20	N	18.5	20	N	N	
11	6/377	20	20	N	20	20	N	N	
11	10/363	17	16	N	16	16	N	N	
11	11/361	13	18.5	N	16	16	N	N	
11	13/365	16	16	N	18.5	18.5	N	N	
11	16/367	18.5	18.5	N	18.5	18.5	N	N	
11	17/368	16	18.5	N	16	18	N	N	
11	19/370			N	16	18	N	N	
11	1/92	13	16	N	15	14.5	N	N	
12	2/99	16	16	N				ND	
12	3/93	11	11	N	13	13	N	N	
12	4/100	18.5	17	N	17	17	N	N	
12	7/102	11	9	N	14	12	N	N	
12	9/91	11	11	N	14	14	N	N	
12	15/104	13	13	N	13	13	N	N	

2590

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

CENTER	PAT. NO.	BASELINE				LAST ASSESSMENT			
		I.O.P. (mmHg)		GLOBAL ASSESSMENT	I.O.P. (mmHg)		GLOBAL ASSESSMENT		
		RIGHT	LEFT		RIGHT	LEFT			
12	16/105	11	11	N	14	13.5	N		
12	19/106	18.5	18.5	N	17	17	N		
12	21/110	16	16.5	N	14	14	N		
12	24/113	13	11	N	16	16	N		
12	25/114	13	13	N	16	17	N		
12	27/115	11	11	N	15	16.5	N		
12	29/117	13	16	N	14	13.5	N		
12	33/388	13	12.5	N	16	16	N		
12	36/385	14	13.5	N	17	17	N		
12	1/219	14.5	14.5	N	16	14.5	N		
13	3/221	16	14.5	N	14.5	14.5	N		
13	6/226	16	16	N	16	14.5	N		
13	7/220	14.5	14.5	N	14.5	14.5	N		
13	13/223	14.5	14.5	N	16	14.5	N		
13	18/227	14.5	14.5	N	20.5	22	N		
13	20/230	16	16	N	16	16	N		
13	21/231	14.5	14.5	N	14.5	14.5	N		
13	22/232	18	19	N	18	19	N		
n	145	138	138		113	113			
MEAN		16.97	17.07		16.62	16.72			
ST DEV		2.95	2.94		2.11	2.35			
n*		107	107		107	107			
MEAN		16.08	16.28		16.69	16.73			
ST DEV		2.48	2.66		2.11	2.36			

N = NORMAL; ND = NOT DONE
 * patients with both baseline and on treatment evaluations

2591

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

PHARMACIA CNS R & D
REBOXETINE - PROTOCOL 20124 / 013
LISTING NO. 15. OPHTHALMOLOGIC EXAMINATION AT BASELINE AND AT LAST ASSESSMENT
RANDOMIZED PATIENTS-TREATMENT PLACEBO

CENTER	PAT. NO.	BASELINE						LAST ASSESSMENT		
		I.O.P. (mmHg)		GLOBAL ASSESSMENT	I.O.P. (mmHg)		GLOBAL ASSESSMENT	LEFT		GLOBAL ASSESSMENT
		RIGHT	LEFT		RIGHT	LEFT				
1	1/1			ND		16	17	N		
1	6/5			ND		15	16	N		
1	8/6			ND		15	15	N		
1	11/9	16	15	N		15	17	N		
1	12/10	16	17	N		16	17	N		
1	15/12	18	15	N		18	16	N		
1	16/13	18	17	N		17	18	N		
1	19/16	15	19	N		14	18	N		
1	21/18	17	15	N		17	15	N		
1	26/22	16	17	N		16	16	N		
1	27/23	17	16	N		16	15	N		
1	28/24	17	17	N		16	16	N		
1	29/25	17	18	N		16	15	N		
1	30/26	16	17	N		17	17	N		
1	33/29	16	14	N		16	14	N		
1	36/302	18	16	N		16	17	N		
1	38/304	16	15	N		17	16	N		
1	40/306	15	14	N		15	14	N		
1	41/307	17	17	N		17	18	N		
1	42/308	15	15	N		16	17	N		
1	47/312	16	16	N		16	15	N		
1	50/314	16	17	N		16	15	N		

2592

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

CENTER	PAT. NO.	BASELINE						LAST ASSESSMENT					
		I.O.P (mmHg)			GLOBAL ASSESSMENT			I.O.P (mmHg)			GLOBAL ASSESSMENT		
		RIGHT	LEFT	N	RIGHT	LEFT	N	RIGHT	LEFT	N	RIGHT	LEFT	N
1	51/315	15	16	N	16	16	N	16	16	N	16	16	N
1	53/317	15	15	N	15	15	N	15	15	N	15	15	N
1	59/321	15	16	N	16	16	N	16	16	N	16	17	N
1	60/322	15	16	N	16	16	N	16	17	N	17	17	N
1	62/324	16	17	N	17	17	N	16	16	N	17	17	N
1	64/325	16	16	N	16	16	N	16	17	N	16	16	N
1	67/327	16	16	N	16	16	N	15	15	N	15	16	N
1	70/328	18	18	N	18	18	N	18	17	N	17	17	N
1	74/122	15	15	N	15	15	N	15	15	N	15	15	N
1	76/124	15	16	N	16	16	N	17	17	N	15	15	N
1	79/126	16	15	N	15	15	N	16	16	N	15	15	N
1	80/127	15	15	N	15	15	N	17	17	N	18	18	N
1	84/130	14	15	N	15	15	N	14	14	N	14	14	N
1	85/131	15	14	N	14	14	N	15	15	N	13	13	N
1	91/135	16	15	N	15	15	N	15	15	N	14	14	N
1	93/136	15	14	N	14	14	N	14	14	N	13	13	N
1	94/137	15	16	N	16	16	N	15	15	N	13	13	N
1	97/140	15	16	N	16	16	N	14	14	N	14	14	N
1	100/142	16	14	N	14	14	N	15	15	N	14	14	N
1	104/144	15	15	N	15	15	N	17	17	N	18	18	N
1	105/145	16	14	N	14	14	N	15	15	N	16	16	N
1	106/146	15	16	N	16	16	N	17	17	N	16	16	N
1	108/148	16	15	N	15	15	N	15	15	N	14	14	N
1	111/331	15	14	N	14	14	N	18	18	N	18	18	N
1	114/332	16	16	N	16	16	N	18	18	N	16	16	N
1	115/333	16	17	N	17	17	N	16	16	N	15	15	N

2593

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

CENTER	PAT. NO.	BASELINE						LAST ASSESSMENT					
		I.O.P. (mmHg)			GLOBAL ASSESSMENT			I.O.P. (mmHg)			GLOBAL ASSESSMENT		
		RIGHT	LEFT		RIGHT	LEFT		RIGHT	LEFT		RIGHT	LEFT	
1	122/337	16	15	N	N		15	15	N	N			
1	124/339	16	16	N	N		16	16	N	N			
1	126/341	16	15	N	N		16	15	N	N			
1	129/344	16	15	N	N		16	16	N	N			
1	130/345	13	15	N	N		14	15	N	N			
1	133/346	18	18	N	N		18	18	N	N			
1	136/349	14	13	N	N		14	14	N	N			
1	138/350	17	19	N	N		16	19	N	N			
1	141/353	16	17	N	N		17	17	N	N			
1	143/355	16	17	N	N		17	16	N	N			
1	145/357	14	12	N	N		13	12	N	N			
1	149/360	14	13	N	N		13	12	N	N			
1	150/151	15	15	N	N		14	16	N	N			
3	2/61			ND	ND				ND	ND			
3	3/62			ND	ND				ND	ND			
3	10/72	12	12	N	N				ND	ND			
8	1/211	15	18	Cataract					ND	ND			
8	4/214			ND			12	12	N	N			
8	5/215	10	10	N	N		12	12	N	N			
9	2/241			ND			18	18	N	N			
9	5/242	16	17	N	N		16	16	N	N			
9	8/244	18	18	N	N		15	15	N	N			
9	12/247	18	18	N	N		18	18	N	N			
9	13/248	18	18	N	N		18	18	N	N			
9	19/251	14	16	N	N		17	17	N	N			
9	24/253	18	17	N	N		16	16	N	N			

2594

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

CENTER	PAT. NO.	BASELINE						LAST ASSESSMENT		
		I.O.P (mmHg)			GLOBAL ASSESSMENT			I.O.P (mmHg)		
		RIGHT	LEFT	GLOBAL ASSESSMENT	RIGHT	LEFT	GLOBAL ASSESSMENT	RIGHT	LEFT	GLOBAL ASSESSMENT
9	25/254			N			17	17.5	N	
9	28/257	18	18	N			17	17	N	
10	4/272	23	24	N			17	17	N	
10	5/273	23	21	N			19	18	N	
10	10/276	18	18	N					ND	
10	14/279	18	17	N			17	17	N	
10	16/281	20	20	N			22	21	N	
10	17/282	20	19	N			22	22	N	
10	18/283	20	21	N					ND	
10	19/284	20	20	N			20	19	N	
10	21/288	21	21	N					ND	
10	24/289	20	20	N			20	20	N	
10	29/293	18	18	N					ND	
10	30/294	20	19	N					ND	
10	37/32	20	20	N					ND	
10	40/33	18	18	N			23	23	N	
10	42/295	21	21	N			21	20	N	
10	43/296	19	19	N					ND	
10	44/298	21	22	N			24	22	Scotomas	
10	45/34	22	22	N			22	22	N	
10	46/38	20	20	N					ND	
10	47/39	22	21	N					ND	
10	48/41	22	22	N					ND	
10	50/44	24	23	N					ND	
10	51/45	21	21	N			24	24	N	
10	55/49	20	20	N					ND	

2595

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

CENTER	PAT. NO.	BASELINE						LAST ASSESSMENT					
		I.O.P. (mmHg)			GLOBAL ASSESSMENT			I.O.P. (mmHg)			GLOBAL ASSESSMENT		
		RIGHT	LEFT		RIGHT	LEFT		RIGHT	LEFT		RIGHT	LEFT	
10	58/52	20	21		N								ND
10	60/54	18	16		N								ND
10	61/55	19	19.5		N								ND
10	62/56	18	18		N								ND
10	64/58	21	20		N								ND
10	81/46	20	20		N								ND
10	85/272	20	21		N			19	19				N
10	88/276	22	22		N			19	18				N
10	92/73	20	21		N			18	18				N
10	94/273	21	21		N								ND
10	1/372	20	20		N			18.5	18.5				N
11	4/375	13	13		N			16	16				N
11	7/376	18.5	18.5		N			20	20				N
11	9/362	20	20		N			13	13				N
11	12/364	16	11		N			16	16				N
11	15/366	18.5	18.5		N			13	13				N
11	18/369	13	16		N			14	14				N
11	20/371				N			13	13				N
12	5/95	13	13		N			11	11				N
12	6/98	17	17		N			16	16				N
12	10/96	13	11		N			11	11				N
12	11/94	11	11		N			11	11				N
12	12/97	16	17		N			18.5	18.5				N
12	13/103	11	13		N			11	11				N
12	14/101	16	18.5		N			16	16				N
12	17/108	11	9		N			12	11				N

2596

9550077

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17

CENTER	PAT. NO.	BASELINE						LAST ASSESSMENT		
		I.O.P (mmHg)			GLOBAL ASSESSMENT	I.O.P (mmHg)			GLOBAL ASSESSMENT	
		RIGHT	LEFT	RIGHT		LEFT	RIGHT	LEFT		
12	18/109	11	11	N	18.5	18	N			
12	20/107	11	13	N	14	13.5	N			
12	22/111	13	13	N	17	14.5	N			
12	23/112	13	13	N	14	14	N			
12	28/116	11	13	N	16	16	N			
12	34/120	12	12.5	N	17	17	N			
12	35/119	12	12	N	16	16	N			
12	37/386	14	14.5	N	15	15	N			
13	2/224	14.5	14.5	N	16	16	N			
13	8/228	16	14.5	N	16	16	N			
13	9/229	16	16	N	16	14.5	N			
13	11/225	14.5	14.5	N	14.5	14.5	N			
13	14/217	16	14.5	N	16	14.5	N			
13	15/222	17	17	N	16	14.5	N			
13	17/218	16	16	N	16	16	N			
n	141	132	132		118	118				
MEAN		16.64	16.61		16.24	16.12				
ST DEV		2.88	2.95		2.45	2.47				
n*		111	111		111	111				
MEAN		16.11	16.09		16.31	16.16				
ST DEV		2.64	2.76		2.47	2.49				

N = NORMAL; ND = NOT DONE
n* = patients with both baseline and on treatment evaluations

2597

Pharmacia

Document 9550077

12.2.3 CRFs

Individual Patient CRFs are filed in the Study Master File.

090177e1803f2135\Approved\Approved On: 11-Nov-2002 19:17